id|nct_id|name
795433|NCT03190512|Periodontal disease
795434|NCT03190512|depression
795435|NCT03190512|body image
795436|NCT03190512|self-esteem
795437|NCT03190499|Cancer
795438|NCT03190499|Leukemia
795439|NCT03190486|Baby cries
795440|NCT03190486|pain
795441|NCT03190486|brain responses
795442|NCT03190486|neuroimaging
795443|NCT03190486|fMRI
795444|NCT03190395|Paroxysmal Atrial Fibrillation
795445|NCT03190395|Circumferential Pulmonary Vein Isolation(CPVI)
795446|NCT03190395|Leftatrium Roofline Ablation(LARA)
795447|NCT03190395|Longterm success rate
795448|NCT03190317|electronic medical record
795449|NCT03190317|personal health record
795450|NCT03190317|Veteran
795451|NCT03190317|self-management
795458|NCT03190265|cy
795459|NCT03190265|Cyclophosphamide
795460|NCT03190265|Pancreatic Vaccine
795461|NCT03190265|GVAX
795462|NCT03190265|Nivolumab
795463|NCT03190265|Vaccine
795464|NCT03190265|Ipilimumab
795465|NCT03190265|CRS-207
795466|NCT03190265|Immunotherapy
795467|NCT03190265|PD-1
795468|NCT03190265|Adenocarcinoma
795469|NCT03190265|Carcinoma
795470|NCT03190265|Neoplasms
795471|NCT03190252|Diving medicine
795472|NCT03190252|Inflammation
795473|NCT03190252|Central nervous system injury
795474|NCT03190252|Trimix
795475|NCT03190252|Decompression sickness
795476|NCT03190252|Venous gas emboli
795481|NCT03190213|Poorly differentiated
795482|NCT03190213|high grade
795483|NCT03190161|Schizophrenia
795484|NCT03190148|GLP-1
795485|NCT03190148|Ectopic Lipids
795486|NCT03190135|Overweight
795487|NCT03190135|Obesity
795488|NCT03190135|School
795489|NCT03190135|Physical Activity
795490|NCT03190109|bone age measurement
795491|NCT03190109|skeletal age measurement
795492|NCT03190109|ultrasound
795493|NCT03190109|x-Ray
795494|NCT03190083|mastectomy
795495|NCT03190083|lumpectomy
795496|NCT03190083|3-Dimensional Mammogram
795497|NCT03190083|digital breast tomosynthesis
795498|NCT03190070|Renal reserve, physiological study, diagnostic testing
795499|NCT03190057|BioFreedom
795500|NCT03190057|Drug Eluting Stent
795501|NCT03190057|Coronary Artery Disease
795502|NCT03190031|training
795503|NCT03190031|exercise
795504|NCT03190031|quality of life
795505|NCT03190005|PRU
795506|NCT03190005|P2Y12 receptor
795507|NCT03189979|community based participatory research
795508|NCT03189979|Childhood obesity
795509|NCT03189966|transversalis fascia plane block
795510|NCT03189966|quadratus lumborum block
795511|NCT03189966|ultrasound-guided
795512|NCT03189966|Developmental Dysplasia of the Hip
795513|NCT03189966|postoperative analgesia
795514|NCT03189914|pancreatic cancer
795515|NCT03189914|Abraxane
795516|NCT03189914|first line
795517|NCT03189875|Systemic Lupus Erythematosus Disease
795518|NCT03189849|Farming environment
795519|NCT03189836|CD20+
795520|NCT03189836|B cell
795521|NCT03189836|ACTR
795522|NCT03189836|ACTR707
795523|NCT03189836|relapsed
795524|NCT03189836|refractory
795525|NCT03189836|T cell
795526|NCT03189836|T cell product
795527|NCT03189836|adoptive T cells
795528|NCT03189836|gene therapy
795529|NCT03189810|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
795530|NCT03189810|Schizophrenia
795531|NCT03189810|Cannabis Use Disorder
795532|NCT03189810|Cognitive Function
795533|NCT03189758|chronic kidney disease
795534|NCT03189758|hemodialysis
795535|NCT03189758|sodium restriction
795536|NCT03189758|MRI
795537|NCT03189732|lipolysis
795538|NCT03189732|adipose tissue
795539|NCT03189732|exercise
795540|NCT03189719|PD1
795541|NCT03189719|PD-1
795542|NCT03189719|PDL1
795543|NCT03189719|PD-L1
795550|NCT03189680|sensorimotor training
795551|NCT03189680|exergaming
795552|NCT03189680|posture
795553|NCT03189680|quality of life
795559|NCT03189628|stromal vascular fraction
795560|NCT03189628|skin regeneration
795561|NCT03189628|skin texture
795562|NCT03189628|anti-aging
795563|NCT03189602|Takayasu Arteritis
795564|NCT03189602|Pulmonary artery hypertension
795572|NCT03189537|Profilaxis
795573|NCT03189537|Ingavirin
795574|NCT03189511|Brown Adipose Tissue
795575|NCT03189511|Brown Fat
795576|NCT03189511|Fluvastatin
795577|NCT03189511|Prospective Clinical Trial
795578|NCT03189446|Endometrial Cancer
795579|NCT03189446|Gynecologic Cancer
795583|NCT03189407|Moringa Oleifera tea
795584|NCT03189407|Type 2 Diabetes Mellitus
795585|NCT03189407|Metformin Steady state concentrations
795586|NCT03189407|Herb-drug interaction
795587|NCT03189394|HIV
795588|NCT03189394|gay couples
795589|NCT03189394|relationships
795590|NCT03189394|dyads
795591|NCT03189381|Whole Brain Radiation
795592|NCT03189381|Simultaneous Integrated Boost
795593|NCT03189368|Cardiac Resynchronization Therapy
795594|NCT03189368|Multi-site Pacing
795595|NCT03189368|Ventriculoarterial Coupling
795596|NCT03189368|Energy Efficiency
795597|NCT03189342|Balance
795598|NCT03189342|Dual-task interference
795599|NCT03189342|Falls
795600|NCT03189342|Gait
795601|NCT03189342|Older Adults
795602|NCT03189329|NIR spectroscopy, cognitive function, eye, nerve block
795603|NCT03189316|Peritoneal fluid
795604|NCT03189316|B cells
795605|NCT03189316|Regulatory B cells
795606|NCT03189316|Human
795607|NCT03189264|Percutaneous Nephrolithotomy
795608|NCT03189264|Postoperative Complications
795609|NCT03189264|Renal Stone
795610|NCT03189264|Surgical Success
795611|NCT03189264|Surgical Complications
795612|NCT03189264|Pneumatic Dilation
795613|NCT03189212|Telemedicine
795614|NCT03189186|Kidney Cancer
795615|NCT03189186|Immunotherapy
795616|NCT03189186|Renal Cell Carcinoma
795617|NCT03189186|Cryoablation
795618|NCT03189186|Metastatic Renal Cancer
795619|NCT03189173|Obstructive Sleep Apnea
795620|NCT03189173|Ventilatory Control Instability
795621|NCT03189173|Complex Sleep Apnea
795627|NCT03189108|Paracentesis
795628|NCT03189108|Thoracentesis
795629|NCT03189095|exercise
795630|NCT03189095|physical activity
795631|NCT03189095|SCI
795632|NCT03189095|spinal cord injury
795633|NCT03189095|online
795634|NCT03189056|chronic Chagas disease
795635|NCT03189056|bladder
795636|NCT03189056|lower urinary tract
795637|NCT03189056|urodynamic
795638|NCT03189030|metastatic
795639|NCT03189030|microsatellite stable (MSS)
795641|NCT03188965|First in human
795642|NCT03188965|Solid tumors
795643|NCT03188965|Lymphomas
795644|NCT03188965|Dose escalation
795645|NCT03188965|Dose expansion
795646|NCT03188913|Burns
795647|NCT03188913|Coagulation
795648|NCT03188913|Factor XIII
795649|NCT03188913|Glycocalix
795650|NCT03188913|Cicatrization
795654|NCT03188887|NIgA
795655|NCT03188887|Kidney biopsy
795656|NCT03188887|GFR
795657|NCT03188887|Corticotherapy
795658|NCT03188861|mental health conditions in ACSC patients
795659|NCT03188861|multimorbidity
795660|NCT03188861|health care utilization
795661|NCT03188809|Postoperative Pain
795662|NCT03188809|Functional Outcomes
795663|NCT03188809|Total Knee Arthroplasty
795664|NCT03188809|Adductor Canal Block
795665|NCT03188809|Femoral Nerve Block
795666|NCT03188796|vitamin D
795667|NCT03188796|critical care
795668|NCT03188770|Middle-income countries
795673|NCT03188731|ZIKA
795674|NCT03188731|Dengue
795675|NCT03188731|Chikungunya
795676|NCT03188731|Pregnant Women
795677|NCT03188731|Pregnant Woman
795678|NCT03188731|ZIKV
795679|NCT03188718|Polysomnogram
795680|NCT03188718|Sleep Disordered Breathing
795681|NCT03188705|pharmacogenetics
795682|NCT03188705|carboxylesterase
795683|NCT03188705|Personalized Medicine
795690|NCT03188679|CMV
795691|NCT03188679|neurological impairment
795692|NCT03188679|outcome prediction
795693|NCT03188679|amniotic fluid biomarkers
795694|NCT03188640|Bariatric surgery
795695|NCT03188640|Sex hormones
795696|NCT03188640|Women
795697|NCT03188640|Quality of life
795698|NCT03188614|shock
795699|NCT03188614|crystalloid
795700|NCT03188614|acute kidney injury
795701|NCT03188601|Graft vs Host Disease
795702|NCT03188601|Immune System Diseases
795703|NCT03188601|Protease Inhibitors
795704|NCT03188601|Alpha 1-Antitrypsin
795705|NCT03188601|Enzyme Inhibitors
795706|NCT03188601|Molecular Mechanisms of Pharmacological Action
795707|NCT03188601|Trypsin Inhibitors
795708|NCT03188601|Serine Proteinase Inhibitors
795709|NCT03188484|Atrial Fibrillation; Electrocardiography; Biological Markers; Risk Assessment
795710|NCT03188458|Infants
795711|NCT03188458|Cord blood sample
795712|NCT03188458|Acellular pertussis
795713|NCT03188458|Boostrix
795714|NCT03188458|Colombia
795715|NCT03188458|Pregnant women
795722|NCT03188380|nec
795723|NCT03188380|abdominal ultrasound
795724|NCT03188380|abdominal radiograph
795725|NCT03188380|preterm
795726|NCT03188367|dose-finding
795727|NCT03188367|extraintestinal symptoms
795728|NCT03188367|gluten
795729|NCT03188367|intestinal symptoms
795730|NCT03188367|placebo
795731|NCT03188354|Positron-Emission Tomography
795732|NCT03188354|Magnetic Resonance Imaging
795733|NCT03188341|vascular surgery
795734|NCT03188341|repolarization disturbances
795735|NCT03188341|cardiac complications
795736|NCT03188341|high risk patient
795737|NCT03188341|high risk procedure
795738|NCT03188302|Stool consistency
795739|NCT03188302|Texture Analyser
795740|NCT03188302|Bristol Stool Form Scale
795741|NCT03188289|chitosan
795742|NCT03188289|clorhexidine
795743|NCT03188289|suture
795744|NCT03188289|bacteria
795745|NCT03188289|wisdom
795746|NCT03188276|Chronic Hepatitis C
795747|NCT03188276|direct-acting antiviral agents
795748|NCT03188276|Myeloid-Derived Suppressor Cells
795749|NCT03188276|NK cells
795754|NCT03188224|Transition
795755|NCT03188224|Improved patient outcomes
795756|NCT03188224|RCT
795757|NCT03188224|Child health
795758|NCT03188224|Empower youth
795759|NCT03188185|Alkermes
795760|NCT03188185|Major Depressive Disorder
795761|NCT03188185|Treatment Refractory MDD
795762|NCT03188185|ALKS 5461
795763|NCT03188133|Schizophrenia
795764|NCT03188133|Visual Hallucination
795765|NCT03188133|False Perception
795766|NCT03188133|emotional priming
795767|NCT03188107|Risky Infant
795768|NCT03188107|Cerebral Palsy
795769|NCT03188107|Down Syndrome
795770|NCT03188107|Spina Bifida
795771|NCT03188107|Infant Motor Profile
795772|NCT03188068|Kaposiform Hemangioendothelioma
795773|NCT03188068|Kasabach Merritt Phenomenon
795774|NCT03188068|Sirolimus
795775|NCT03188068|Prednisolone
795776|NCT03188055|patient decision making
795777|NCT03188055|surgical decision making
795778|NCT03188055|shared decision making
795779|NCT03188055|decision support techniques
795780|NCT03188042|Transorbital Alternating Current Stimulation
795781|NCT03188042|Glaucoma
795782|NCT03188029|ethomidate adrenocortical insufficiency
795783|NCT03188016|"music therapy"
795784|NCT03188016|"Intensive Interaction"
795785|NCT03188016|"non-verbal communication"
795786|NCT03188016|"musical improvisation"
795787|NCT03188016|"feasibility study"
795788|NCT03188016|"randomised controlled trial"
795789|NCT03188003|Exercise Movement Techniques
795790|NCT03188003|Low Back Pain
795791|NCT03188003|Exercise
795792|NCT03187990|PSMA PET/MRI
795793|NCT03187990|Guided Biopsy
795794|NCT03187990|Prostate Cancer
795798|NCT03187964|People Living with HIV (PLHIV)
795799|NCT03187964|Xpert HIV-1 Viral Load (Xpert VL)
795800|NCT03187964|Xpert Ultra
795801|NCT03187964|Antiretroviral treatment (ART)
795802|NCT03187951|Other disorders of glucose regulation and pancreatic internal secretion
795803|NCT03187951|Pancreatic cancer
795804|NCT03187951|Questionnaires
795805|NCT03187951|Surveys
795806|NCT03187951|Nutritional Questionnaire
795807|NCT03187951|Nutritional Counseling
795808|NCT03187951|Booklet
795809|NCT03187951|Pamphlet
795810|NCT03187951|Educational materials
795811|NCT03187951|Aerobic Exercise
795812|NCT03187951|Strength Training Exercises
795813|NCT03187951|Physical Assessments
795814|NCT03187951|Walk Test
795821|NCT03187899|cervical plexus block
795822|NCT03187899|clavicle fracture
795823|NCT03187899|interscalene brachial plexus block
795824|NCT03187886|Cerebral amyloid angiopathy
795825|NCT03187886|CAA-RI
795826|NCT03187886|MRI
795827|NCT03187886|Intracerebral hemorrhage
795828|NCT03187873|community participation
795829|NCT03187873|Maternal and child health
795830|NCT03187873|Kenya
795831|NCT03187860|Bronchial epithelial cell
795832|NCT03187860|mucus
795833|NCT03187860|Air Liquid Interface
795834|NCT03187847|Physical Activity
795835|NCT03187847|Fatigue
795836|NCT03187834|infection
795837|NCT03187834|azithromycin
795838|NCT03187834|amoxicillin
795839|NCT03187834|co-trimoxazole
795840|NCT03187834|trachoma
795841|NCT03187834|mass treatment
795842|NCT03187808|Neck pain, Thoracic manipulation, special massage
795843|NCT03187795|Spinal Cord Injuries
795844|NCT03187795|Randomized Controlled Trial
795845|NCT03187795|Neurogenic Bladder
795846|NCT03187795|Rehabilitation
795847|NCT03187769|Alkermes
795848|NCT03187769|ALKS 3831
795849|NCT03187769|Olanzapine
795850|NCT03187769|Samidorphan
795851|NCT03187769|Schizophrenia
795852|NCT03187769|Schizophreniform
795853|NCT03187769|Bipolar I
795854|NCT03187756|Hematopoietic Malignancies
795855|NCT03187756|Nonmyeloablative Peripheral Blood Stem Cell Transplant
795856|NCT03187756|Posttransplantation
795857|NCT03187743|Lupus erythematosus
795858|NCT03187743|Systemic
795859|NCT03187743|Corticosteroid
795860|NCT03187743|Prednisone
795861|NCT03187743|Pharmacokinetics
795862|NCT03187730|Smoking Cassation
795863|NCT03187730|Immigrants
795864|NCT03187730|Economic Disparity
795865|NCT03187717|Postoperative pain
795866|NCT03187717|Recovery period
795867|NCT03187717|Total intravenous anesthesia
795868|NCT03187717|Inhalation anesthesia
795870|NCT03187678|switch
795871|NCT03187678|intravenous
795872|NCT03187678|selexipag
795873|NCT03187665|Pediatric
795874|NCT03187665|Pulse Oximeter
795875|NCT03187665|Wireless
795876|NCT03187665|Motion
795877|NCT03187665|False Alarm
795878|NCT03187639|Coronary artery disease
795879|NCT03187639|CT coronary angiography
795880|NCT03187639|FFRct
795881|NCT03187639|Rapid access chest pain clinic
795882|NCT03187639|Stable chest pain
795883|NCT03187639|Resource utilisation
795884|NCT03187639|Quality of life
795885|NCT03187626|Base-of-thumb osteoarthritis
795886|NCT03187626|Botulinum toxin A
795887|NCT03187626|Intra-articular therapy
795888|NCT03187626|Randomized trial
795893|NCT03187587|Hyperthermia, Induced
795894|NCT03187587|Laser Coagulation
795895|NCT03187587|Laser Therapy
795896|NCT03187574|vaginal prolapse, mesh kit, anatomic assessment, quality of life
795897|NCT03187561|Sleep
795898|NCT03187561|Parenting
795899|NCT03187561|Marital relationship
795900|NCT03187561|Parent-child relations
795901|NCT03187548|WSL
795902|NCT03187548|CPP-ACP
795903|NCT03187535|Transcutaneous Electrical Acupoint Stimulation
795904|NCT03187522|AAA
795905|NCT03187522|Abdominal Aortic Aneurysms
795906|NCT03187509|Torsemide, loop diuretics, weight-based
795907|NCT03187496|drug-drug interaction
795908|NCT03187444|Cardiovascular risk
795909|NCT03187444|Chronic inflammatory rheumatism
795910|NCT03187444|Rheumatoid arthritis
795911|NCT03187444|Spondyloarthritis
795912|NCT03187444|Inflammation
795913|NCT03187431|Stem cell
795914|NCT03187431|Therapy
795915|NCT03187431|IPF
795916|NCT03187418|Cyclophotocoagulation
795917|NCT03187418|Micropulse TSCPC
795918|NCT03187418|Laser ablation
795919|NCT03187418|Laser therapy
795920|NCT03187405|Subarachnoid Hemorrhage
795921|NCT03187405|Intracranial Aneurysm
795922|NCT03187405|Cerebral Ischemia
795923|NCT03187405|Ventriculostomy
795924|NCT03187405|Tissue Plasminogen Activator
795925|NCT03187353|Cognitive complaints
795926|NCT03187353|RRSO
795927|NCT03187353|Oophorectomy
795928|NCT03187353|Memory
795929|NCT03187353|Cognition
795930|NCT03187353|Early menopause
795931|NCT03187327|prophylactic salpingectomy
795932|NCT03187327|vaginal hysterectomy
795933|NCT03187327|p53 expression
795934|NCT03187327|ovarian cancers
795935|NCT03187314|Esophageal cancer
795936|NCT03187314|Radiation
795937|NCT03187314|Anti-PD-1 Antibody
795940|NCT03187275|Cancer Related Fatigue (CRF)
795941|NCT03187275|Prostate Cancer
795942|NCT03187275|Swedish Massage Therapy (SMT)
795943|NCT03187275|Cancer
795944|NCT03187275|Quality of Life (QOL)
795945|NCT03187262|Waldenström Macroglobulinemia
795946|NCT03187223|Multiple Myeloma
795947|NCT03187223|Bendamustine
795948|NCT03187223|Melphalan
795949|NCT03187223|ASCT
795950|NCT03187210|CD30+ Lymphoma
795951|NCT03187210|ASCT
795952|NCT03187210|Brentuximab Vedotin
795953|NCT03187171|Anterior Cervical Spine Fusion
795954|NCT03187132|virtual reality
795955|NCT03187132|transcutaneous electrical nerve stimulation
795956|NCT03187132|analgesia
795957|NCT03187119|Pediatric
795958|NCT03187119|Education
795959|NCT03187119|Technology-supported intervention
795960|NCT03187119|Asthma Action Plan
795961|NCT03187119|Health literacy
795962|NCT03187093|MDD
795963|NCT03187093|Vortioxetine
795964|NCT03187093|IGF-1
795965|NCT03187093|Cognitive dysfunction
795966|NCT03187067|pneumonia
795967|NCT03187067|diagnostic
795968|NCT03187067|ultrasound
795969|NCT03187067|Pakistan
795970|NCT03187067|Mozambique
795971|NCT03187041|blood draw tourniquets
795972|NCT03187041|skin surface pressure
795973|NCT03187041|blood draw band
795974|NCT03187041|elastic tourniquet
795975|NCT03187041|phlebotomy
795976|NCT03187041|tourniquet pressure
795977|NCT03187028|Cancer of Pancreas
795978|NCT03187028|Neoplasms, Pancreatic
795979|NCT03187028|Pancreas Cancer
795980|NCT03187028|Pancreas Neoplasms
795981|NCT03187028|Cancer of the Pancreas
795982|NCT03187028|Pancreatic Cancer
795983|NCT03187015|Healthy Volunteers
795984|NCT03187015|Entinostat
795985|NCT03187015|Histone Deacetylase Inhibitor
795986|NCT03187015|HDAC
795987|NCT03186989|Mild Alzheimer's Disease
795988|NCT03186989|ISIS 814907
795989|NCT03186976|Risk Factor Modification
795990|NCT03186976|Catheter ablation
795994|NCT03186898|hepatocellular carcinoma
795995|NCT03186898|HCC
795996|NCT03186898|Proton Therapy
795997|NCT03186898|Photon Therapy
795998|NCT03186898|Liver cancer
795999|NCT03186859|non-alcoholic fatty liver disease
796000|NCT03186859|bariatric surgery
796001|NCT03186846|cognitive decline
796002|NCT03186846|hemodynamic monitoring
796003|NCT03186846|LIDCO
796004|NCT03186846|INVOS
796005|NCT03186846|BIS
796006|NCT03186846|brain injury biomarkers
796010|NCT03186807|normogram
796011|NCT03186807|brain lumination
796012|NCT03186807|fetal cortex
796013|NCT03186807|ultrasound
796020|NCT03186742|Eplerenone
796021|NCT03186742|Concentric hypertrophy
796022|NCT03186729|Intracerebral hemorrhage
796023|NCT03186716|Colostrum
796024|NCT03186716|Enteral Nutrition
796025|NCT03186716|Intestinal Permeability
796026|NCT03186716|Intensive Care Unit
796027|NCT03186703|Cancer prevention
796028|NCT03186703|Knowledge translation
796029|NCT03186703|Physical activity
796030|NCT03186703|Diet
796031|NCT03186703|Alcohol
796032|NCT03186703|Smoking
796033|NCT03186690|vital pulp therapy
796034|NCT03186690|Biodentine
796035|NCT03186690|Mineral Trioxide Aggregate
796036|NCT03186677|ISU304
796037|NCT03186677|previously treated hemophilia B patients
796038|NCT03186677|FIX
796039|NCT03186677|Factor IX
796040|NCT03186651|Vaginal
796041|NCT03186651|Medical Device
796042|NCT03186651|Female Stress Urinary Incontinence
796043|NCT03186625|acute coronary syndrome
796044|NCT03186625|gut microbiota
796045|NCT03186625|Trimethylamine N-oxide
796046|NCT03186625|percutaneous coronary intervention
796047|NCT03186612|Video games; Virtual reality; Occupational therapy, Manual dexterity; Multiple sclerosis.
796048|NCT03186599|Medication Event Monitoring System
796049|NCT03186599|adherence
796050|NCT03186586|Heavy Menstrual Bleeding
796051|NCT03186586|Levonorgestrel relesing intrauterine system
796052|NCT03186560|Leg ulcers and use of geko device
796053|NCT03186508|obesity prevention
796054|NCT03186508|sleep
796055|NCT03186508|behavioral intervention
796056|NCT03186456|acute cerebral infarction
796057|NCT03186456|umbilical cord mesenchymal stem cells
796058|NCT03186443|herpetic neuralgia
796059|NCT03186443|post-herpetic neuralgia
796060|NCT03186443|pregabalin
796067|NCT03186417|Arthritis, Rheumatoid, Stem Cells, Mesenchymal, Autoimmune
796074|NCT03186339|QoL
796075|NCT03186339|TAVI
796076|NCT03186339|surgical aortic valve replacement
796077|NCT03186339|Aortic stenosis
796078|NCT03186326|immunotherapy
796079|NCT03186326|second line
796080|NCT03186313|HCV
796081|NCT03186313|Sofosbuvir
796082|NCT03186313|Ribavirin
796083|NCT03186300|bolus advisor
796084|NCT03186248|Achalasia cardia
796085|NCT03186248|myotomy
796086|NCT03186248|Per oral endoscopic myotomy
796087|NCT03186248|laparoscopic fundoplication
796093|NCT03186196|Folate
796094|NCT03186196|Polymorphism
796095|NCT03186196|Overweight and Obesity
796096|NCT03186196|Inflammatory markers
796097|NCT03186183|HIV prevention
796098|NCT03186183|Sexual health
796099|NCT03186183|Motivational interviewing
796100|NCT03186183|Information-Motivation-Behavioural skills model
796101|NCT03186183|Health promotion
796102|NCT03186157|trephined syndrome
796103|NCT03186157|sinking skin flap syndrome
796104|NCT03186157|craniectomy
796105|NCT03186157|decompressive craniectomy
796106|NCT03186157|neurosurgical complications
796114|NCT03186105|Appendicitis Acute
796115|NCT03186105|AMBULATORY
796125|NCT03186014|Malignant dysphagia
796126|NCT03186014|Stent
796127|NCT03186014|Esophageal neoplasms
796128|NCT03186014|Brachytherapy
796129|NCT03186001|frontalis
796130|NCT03186001|frontal line
796131|NCT03186001|glabellar line
796132|NCT03186001|botulinum toxin
796133|NCT03186001|abobotulinum
796134|NCT03185988|Human epidermal growth factor receptor 2
796135|NCT03185988|Biliary tract cancer
796136|NCT03185988|Esophageal squamous cell carcinoma
796137|NCT03185988|Targeted therapy
796138|NCT03185975|HIV
796139|NCT03185975|transgender
796140|NCT03185975|trans
796141|NCT03185975|youth
796142|NCT03185975|home testing
796143|NCT03185936|optic disc pit
796144|NCT03185936|retinal detachment
796145|NCT03185936|maculopathy
796146|NCT03185923|Community-Acquired Infections
796147|NCT03185923|Humans
796148|NCT03185923|Medicine, Chinese Traditional
796149|NCT03185871|Invasive breast carcinoma
796150|NCT03185871|breast carcinoma stage T1cN0 to N3N0
796151|NCT03185858|secondary prevention
796152|NCT03185858|primary healthcare
796153|NCT03185858|village doctors
796154|NCT03185858|rural China
796155|NCT03185858|medication adherence
796156|NCT03185858|physical activity
796157|NCT03185832|Hear failure
796158|NCT03185832|Sudden Cardiac Death
796159|NCT03185832|Arrhythmia
796160|NCT03185832|Implanted device
796161|NCT03185832|ICD
796162|NCT03185832|CRT
796163|NCT03185806|severe acute pancreatitis
796164|NCT03185806|sterile acute peripancreatic fluid collections
796165|NCT03185806|percutaneous catheter drainage
796167|NCT03185780|complementary/integrative medicine
796168|NCT03185780|glioblastoma
796169|NCT03185780|quality of life
796170|NCT03185780|adherence
796175|NCT03185728|Child Abuse
796176|NCT03185728|Mandated Reporting
796177|NCT03185728|Online Learning
796178|NCT03185728|Child Protection
796179|NCT03185728|GAMIFICATION
796180|NCT03185728|Early Childhood Education
796181|NCT03185715|oocyte donation
796182|NCT03185715|recipient counselling
796183|NCT03185715|single embryo transfer (SET)
796184|NCT03185715|double embryo transfer (DET)
796185|NCT03185715|decision-making
796186|NCT03185689|Glycemic control
796187|NCT03185689|Diabetes self-management education
796188|NCT03185650|Healthy Volunteers
796189|NCT03185637|Outcomes
796190|NCT03185637|Mortality
796191|NCT03185637|Complications
796192|NCT03185637|Neonatal surgery
796193|NCT03185637|Paediatric surgery
796194|NCT03185637|Childrens surgery
796195|NCT03185637|Sub-Saharan Africa
796196|NCT03185637|Research Collaboration
796197|NCT03185637|Gastroschisis
796198|NCT03185637|Anorectal malformation
796199|NCT03185637|Appendicitis
796200|NCT03185637|Intussuception
796201|NCT03185637|Inguinal hernia
796203|NCT03185520|Stroke
796204|NCT03185520|Ischemic Stroke
796205|NCT03185520|Cryptogenic Stroke
796206|NCT03185520|Embolic stroke of undetermined source
796207|NCT03185520|ESUS
796208|NCT03185520|Cerebrovascular Disease
796209|NCT03185481|Parkinson's Disease; Motor Fluctuations; D1 partial agonist;
796212|NCT03185455|Hypertension
796213|NCT03185455|Pregnancy
796214|NCT03185455|Text
796215|NCT03185442|fMRI
796216|NCT03185442|PRF
796217|NCT03185416|Quality of Life
796218|NCT03185416|Caregiver
796219|NCT03185416|Quality Improvement
796220|NCT03185403|hemodynamic effect
796221|NCT03185403|para vertebral block
796222|NCT03185390|periampullary lesions
796223|NCT03185351|midazolam
796224|NCT03185351|brachial plexus block
796225|NCT03185338|physical activity, promotion, school
796226|NCT03185299|Polyp detection rate
796227|NCT03185299|Adenoma detection rate
796228|NCT03185299|Boston Bowel Preparation Scale
796229|NCT03185286|3D printing, metal implant, bone defect
796230|NCT03185260|Cardio-Pulmonary Resuscitation
796231|NCT03185260|Cardiac Arrest
796232|NCT03185260|Training
796233|NCT03185247|Transdiagnostic
796234|NCT03185247|POTS (Postural Orthostatic Tachycardia Syndrome)
796235|NCT03185247|Therapy
796236|NCT03185234|tDCS
796237|NCT03185221|Stents Coronary Artery Disease
796238|NCT03185208|Lithium
796239|NCT03185208|Mild Cognitive Impairment
796240|NCT03185208|MCI
796241|NCT03185208|Dementia
796242|NCT03185208|Alzheimer
796243|NCT03185208|Alzheimer's Disease
796244|NCT03185208|Cognition
796245|NCT03185208|Memory
796246|NCT03185208|Thinking
796247|NCT03185208|Prevention
796248|NCT03185208|amyloid
796249|NCT03185208|imaging
796250|NCT03185208|MRI
796251|NCT03185208|PET
796252|NCT03185208|tau
796253|NCT03185208|plaques
796254|NCT03185208|tangles
796255|NCT03185182|Diagnosis
796256|NCT03185182|Imaging
796257|NCT03185169|breast cancer survivor
796258|NCT03185169|postmenopausal
796259|NCT03185169|dysuria
796260|NCT03185169|dyspareunia
796261|NCT03185169|vaginal dryness
796262|NCT03185169|urinary tract infections
796263|NCT03185169|urinary frequency
796264|NCT03185169|urinary urgency
796265|NCT03185169|genital burning
796266|NCT03185169|genital itching
796267|NCT03185169|genital dryness
796268|NCT03185156|nausea and vomiting
796269|NCT03185156|hemabate
796270|NCT03185156|propofol
796271|NCT03185130|Headache
796272|NCT03185130|Benign Headache
796273|NCT03185117|opioid consumption
796274|NCT03185117|postdischarge
796275|NCT03185117|major orthopedic surgery
796276|NCT03185104|removable partial denture
796277|NCT03185104|silver diamine fluoride
796278|NCT03185078|physical therapy
796279|NCT03185078|ESWT
796280|NCT03185026|Psychiatry
796281|NCT03185026|Suicide
796282|NCT03185026|Psychoeducation
796283|NCT03185026|Randomized controlled trial
796284|NCT03185026|current suicidal behavior disorder
796285|NCT03185026|DSM-5
796299|NCT03184935|Myelodysplastic Syndromes
796300|NCT03184935|mesenchymal stem cells
796301|NCT03184922|femoral suspensory loops
796306|NCT03184844|Thalidomide TI
796307|NCT03184831|sinus lift, injectable platelet rich fibrin, sticky bone, bovine bone
796308|NCT03184792|Spinal electrical stimulation
796309|NCT03184779|Ski
796310|NCT03184779|Snowboard
796311|NCT03184779|Snow Sport
796312|NCT03184779|Injury
796313|NCT03184779|Injury Prevention
796314|NCT03184779|Safety
796315|NCT03184779|Safety Video
796316|NCT03184779|Video Intervention
796317|NCT03184779|Youth
796318|NCT03184779|Children
796319|NCT03184779|Adolescent
796320|NCT03184779|Education
796321|NCT03184779|Knowledge
796322|NCT03184753|Autologous
796323|NCT03184753|IgT
796324|NCT03184753|Ovarian Cancer
796325|NCT03184701|Telehealth
796326|NCT03184701|Quality of Life
796327|NCT03184688|platelet rich plasma
796328|NCT03184688|Perineural injection therapy
796329|NCT03184688|hydrodissection
796330|NCT03184662|High-intensity physical activity
796331|NCT03184662|Diabetes
796332|NCT03184662|Renal function decline
796336|NCT03184610|Keratoconus
796337|NCT03184610|Optical Coherence Tomography
796338|NCT03184610|Corneal Epithelium Thickness Maps
796339|NCT03184597|HLA screening
796340|NCT03184597|SJS/TEN
796341|NCT03184597|MPE
796342|NCT03184597|AEDs
796343|NCT03184571|BGB324
796344|NCT03184571|NSCLC
796345|NCT03184571|pembrolizumab
796346|NCT03184571|Keytruda
796347|NCT03184558|BGB324
796348|NCT03184558|TNBC
796349|NCT03184558|pembrolizumab
796350|NCT03184558|Keytruda
796351|NCT03184545|anterior knee pain
796357|NCT03184467|GV1001
796358|NCT03184467|Alzheimer Disease
796359|NCT03184454|OCD
796360|NCT03184454|deep brain stimulation
796361|NCT03184454|treatment-resistant OCD
796362|NCT03184428|YAG-Laser Capsulotomy
796363|NCT03184389|Behavioral Counseling
796364|NCT03184389|Cigarette Smoking
796365|NCT03184389|Mobile Health
796366|NCT03184389|Heart Rate Variability Monitoring
796367|NCT03184389|Mindfulness-Based Exercises
796368|NCT03184389|Mobile Apps
796369|NCT03184389|Physiological Monitoring
796370|NCT03184389|Respiratory Pattern Monitoring
796371|NCT03184389|Stress-Management Interventions
796372|NCT03184389|Sensor-Triggered Stress Intervention
796373|NCT03184389|Smartphone Apps
796374|NCT03184389|Smoking Cessation
796375|NCT03184389|Wearable Sensors
796376|NCT03184389|Eating Behavior
796377|NCT03184389|Stress-Related Eating
796378|NCT03184376|Gut microbiota
796379|NCT03184376|Prebiotic
796380|NCT03184376|Liver biopsy
796381|NCT03184376|Oligofructose
796382|NCT03184350|cervical cancer
796383|NCT03184350|endometrial cancer
796384|NCT03184350|proton therapy
796392|NCT03184311|Iron deficiency
796393|NCT03184311|Therapy response prediction
796394|NCT03184311|Exercise tolerance
796395|NCT03184298|Military Personnel
796396|NCT03184298|Sexual Assault
796397|NCT03184298|Military Sexual Trauma
796398|NCT03184298|Alcohol and Substance Abuse
796399|NCT03184285|limitation in conventional monitoring
796400|NCT03184272|limitation in conventional monitoring
796401|NCT03184246|Videolaryngoscopy (GlideScope)
796402|NCT03184246|Direct laryngoscopy
796403|NCT03184220|Neck Pain
796404|NCT03184220|Physical Therapy Modalities
796405|NCT03184220|Fascia
796406|NCT03184220|Manual Therapy
796407|NCT03184220|Massage
796408|NCT03184194|daratumumab
796409|NCT03184194|nivolumab
796410|NCT03184194|lenalidomide
796411|NCT03184181|tendinopathy
796412|NCT03184181|electrolysis
796413|NCT03184181|exercise
796414|NCT03184181|dry needling
796415|NCT03184168|healthy volunteers, lorlatinib, PF-06463922, ADME, NSCLC, radiolabel, metabolism
796416|NCT03184155|Nicardipine
796417|NCT03184155|Percutaneous Coronary Intervention
796418|NCT03184155|Coronary Artery Disease
796419|NCT03184142|Intimidation
796420|NCT03184142|Simulation
796421|NCT03184142|Medical education
796422|NCT03184142|Surgical education
796423|NCT03184077|Postpartum dyspareunia
796424|NCT03184077|Obestric laceration
796425|NCT03184064|Blackcurrant
796426|NCT03184064|Citrus
796427|NCT03184064|Polyphenols
796428|NCT03184064|Glucose
796429|NCT03184064|Postprandial
796430|NCT03184064|Metabolism
796431|NCT03184051|Knee
796432|NCT03184051|Osteoarthritis
796433|NCT03184051|Ultrasonography evaluation/ultrasound
796434|NCT03184051|Articular cartilage
796559|NCT03183284|severe ITP
796435|NCT03184051|UltraSound Speed Of Sound (US-SOS)
796436|NCT03184051|UltraSound Time of Flight (US-TOF)
796437|NCT03184012|caries
796438|NCT03184012|full coverage
796439|NCT03184012|strip crown
796440|NCT03184012|Zirconia crown
796441|NCT03184012|primary anterior teeth
796442|NCT03184012|crown
796443|NCT03183960|Self-management
796444|NCT03183960|Quality of Life
796445|NCT03183960|Self-efficacy
796446|NCT03183960|Support
796447|NCT03183960|Stroke
796448|NCT03183960|Older adults
796449|NCT03183947|fMRI
796450|NCT03183947|neurofeedback
796451|NCT03183947|emotion regulation
796452|NCT03183947|schizophrenia
796453|NCT03183947|cognitive reappraisal
796454|NCT03183947|depression
796455|NCT03183934|Epidermolysis Bullosa
796456|NCT03183934|Stem cell
796457|NCT03183908|influenza vaccine
796458|NCT03183908|fever following vaccination
796459|NCT03183908|pain following vaccination
796460|NCT03183908|quality of life
796461|NCT03182049|GPA
796462|NCT03182049|Granulomatosis with polyangiitis
796463|NCT03182049|Wegener's granulomatosis
796464|NCT03182049|Subglottic Stenosis
796465|NCT03182049|Bronchial Stenosis
796466|NCT03182023|outcome,ECMO,Respiratory Failure,Circulatory Failure
796467|NCT03182010|Cesarean section scar, Barbed suture, Conventional suture
796468|NCT03181997|Aortic Valve Stenosis
796469|NCT03181997|Transcatheter Aortic Valve Implantation
796470|NCT03181997|Cancer
796471|NCT03181997|Malignancy
796472|NCT03181971|water
796473|NCT03181971|sugar-sweetened beverages
796474|NCT03181971|schools
796475|NCT03181958|nasal high frequency oscillation ventilation
796476|NCT03181958|mechanical ventilation
796477|NCT03181906|medication discrepancy
796478|NCT03181906|primary care
796479|NCT03181906|transition of care
796480|NCT03181880|ASTUTE
796481|NCT03181880|Chronic Obstructive Pulmonary Disease
796482|NCT03181880|Randomised
796483|NCT03181880|Pragmatic
796484|NCT03181880|Standard of Care
796485|NCT03181880|Aclidinium bromide/formoterol fumarate fixed-dose combination
796486|NCT03181880|Duaklir
796487|NCT03181880|Genuair
796488|NCT03183869|microbiome
796489|NCT03183869|multiple sclerosis
796490|NCT03183869|microbiota
796491|NCT03183869|gut
796492|NCT03183843|Atrial Fibrillation
796493|NCT03183843|Mitral Valve Stenosis
796494|NCT03183843|Mitral Valve Insufficiency
796495|NCT03183843|Dabigatran
796496|NCT03183843|Biological Prosthesis
796497|NCT03183843|Mitral Valve Replacement
796498|NCT03183843|Cox-Maze Procedure
796499|NCT03183830|Cardiovascular Disease
796500|NCT03183830|Inorganic nitrate
796501|NCT03183830|Nitric Oxide
796502|NCT03183830|Inflammation
796503|NCT03183817|Person-centred care
796504|NCT03183778|Chronic kidney disease, stages 3B-4
796505|NCT03183752|thyroid
796506|NCT03183752|insulin
796507|NCT03183752|thyroid nodule
796508|NCT03183752|insulin resistance
796509|NCT03183752|thyroid volume
796510|NCT03183752|metformin
796511|NCT03183739|ASP8062
796512|NCT03183739|Pharmacokinetics
796513|NCT03183739|Safety
796514|NCT03183700|Screening HPV
796515|NCT03183700|Self sampling
796516|NCT03183700|DNA Methylation
796517|NCT03183687|neurosurgery
796518|NCT03183687|resident wellness
796519|NCT03183687|health
796520|NCT03183687|mental health
796521|NCT03183687|physical activity
796522|NCT03183687|physician health
796523|NCT03183622|Deep Second-Degree Burn Wound
796524|NCT03183596|Deep Serratus Block
796525|NCT03183596|Reconstructive Breast Surgery
796526|NCT03183596|Superficial Serratus block
796527|NCT03183583|Tissue Adhesive
796528|NCT03183492|Israel
796529|NCT03183492|Universal Mass Vaccination
796530|NCT03183492|Havrix®
796531|NCT03183492|Hepatitis A
796532|NCT03183492|Healthy adults
796533|NCT03183492|Long term persistence
796534|NCT03183492|Toddlers
796535|NCT03183479|adolescent idiopathic scoliosis
796536|NCT03183479|fibrinogen concentrate
796537|NCT03183479|perioperative blood loss
796538|NCT03183479|transfusion
796539|NCT03183453|Confabulations
796540|NCT03183453|Neuropsychological rehabilitation
796541|NCT03183453|Memory
796542|NCT03183440|Atopic dermatitis
796543|NCT03183440|Prevention
796544|NCT03183440|Prebiotics
796545|NCT03183440|Pregnancy
796546|NCT03183414|cardiac surgery
796547|NCT03183414|transoesophageal echocardiography
796549|NCT03183388|psychotherapy
796550|NCT03183362|Barbed sutures,Cesarean Section, adhesions
796551|NCT03183323|hfpef
796552|NCT03183323|hfref
796553|NCT03183323|cardiorenal syndrome
796554|NCT03183323|exercise
796555|NCT03183323|telerehabilitation
796556|NCT03183323|rehabilitation
796557|NCT03183284|dexamethazone
796558|NCT03183284|prednislone
796560|NCT03183232|Immunotherapy, γδ T Cell, Lung Cancer
796561|NCT03183219|Immunotherapy, γδ T Cell, Liver Cancer
796562|NCT03183206|Immunotherapy, γδ T Cell, Breast Cancer
796563|NCT03183193|NAFLD
796564|NCT03183193|NASH
796565|NCT03183193|Obesity
796566|NCT03183193|AASLD
796567|NCT03183193|AHA
796568|NCT03183193|Energy-restricted diet
796569|NCT03183193|Lifestyle intervention
796570|NCT03183193|Mediterranean diet
796571|NCT03183193|Weight loss
796572|NCT03183193|Liver damage
796573|NCT03183193|Inflammation
796574|NCT03183193|Oxidative stress
796575|NCT03183193|Microbiota composition
796576|NCT03183193|Eating behaviour
796577|NCT03183193|Satiety
796578|NCT03183193|Physical activity
796579|NCT03183193|Sedentary behaviours
796580|NCT03183193|Sleep quality
796581|NCT03183193|Sleep duration
796582|NCT03183193|Psychological factors
796583|NCT03183193|Nutrigenomics
796584|NCT03183193|Nutrigenetics
796585|NCT03183193|Transcriptomics
796586|NCT03183193|Epigenetics
796587|NCT03183193|Metabolomics
796588|NCT03183193|miRNAs
796589|NCT03183193|Lipidomics
796590|NCT03183115|Early esophageal squamous cell neoplasm
796591|NCT03183115|Radiofrequency ablation
796592|NCT03183115|Endoscopic submucosal dissection
796593|NCT03183115|Esophageal cancer
796594|NCT03183115|Recurrence
796595|NCT03183115|Field cancerization
796596|NCT03183076|epilepsy
796597|NCT03183076|Diet, Carbohydrate-Restricted
796598|NCT03183076|Drug Resistance
796599|NCT03183037|Acupuncture
796600|NCT03183037|17-298
796601|NCT03183011|cardiac resynchronization therapy
796602|NCT03183011|implantable cardioverter defibrillator
796603|NCT03183011|heart failure
796604|NCT03183011|magnetic resonance imaging
796605|NCT03182972|medication reconciliation
796606|NCT03182972|implementation
796607|NCT03182972|pharmacists
796608|NCT03182972|southwestern Nigeria
796609|NCT03182959|Nrf2 pathway
796610|NCT03182959|Oral mucosa
796611|NCT03182959|HNSCC
796612|NCT03182959|Head and Neck Cancer
796613|NCT03182959|Head and Neck Squamous Cell Carcinoma
796614|NCT03182959|Avmacol
796615|NCT03182959|Tobacco-related Head and Neck Cancer
796616|NCT03182959|broccoli sprout powder
796617|NCT03182959|broccoli seed extract powder
796618|NCT03182933|10 meter walk test
796619|NCT03182933|Opioid consumption
796620|NCT03182894|chemo-refractory
796621|NCT03182894|pembrolizumab
796622|NCT03182894|epacadostat
796623|NCT03182894|azacitidine
796624|NCT03182894|recommended phase 2 dose (RP2D)
796625|NCT03182894|microsatellite-stable (MSS) Metastatic Colorectal Cancer
796626|NCT03182881|Myofascial-reléase
796627|NCT03182881|Fibromyalgia
796628|NCT03182881|Lymphatic drainage
796629|NCT03182881|Breast cancer
796634|NCT03182855|Acute Coronary Syndrome
796635|NCT03182855|STEMI
796636|NCT03182855|Platelet reactivity
796637|NCT03182855|Anti-thrombotic therapy
796638|NCT03182829|direct oral anticoagulants
796639|NCT03182829|apixaban
796640|NCT03182829|dabigatran
796641|NCT03182829|edoxaban
796642|NCT03182829|rivaroxaban
796643|NCT03182829|urine
796644|NCT03182829|LC-MS/MS
796645|NCT03182829|evaluation study
796646|NCT03182829|point of care test
796647|NCT03182816|epidermal growth factor receptor
796648|NCT03182816|CTLA-4
796649|NCT03182816|PD-1
796650|NCT03182816|chimeric antigen receptor T cells
796651|NCT03182816|solid tumor
796652|NCT03182803|mesothelin
796653|NCT03182803|CTLA-4
796654|NCT03182803|PD-1
796655|NCT03182803|chimeric antigen receptor T cells
796656|NCT03182803|solid tumor
796665|NCT03182777|arrhythmias, cardiac
796666|NCT03182777|channelopathies
796667|NCT03182777|death, sudden
796668|NCT03182777|genetic testing
796669|NCT03182777|electrocardiography, ambulatory
796670|NCT03182777|anesthesia, local
796671|NCT03182777|dentistry
796672|NCT03182738|HIV/AIDS Health Management App
796673|NCT03182738|HIV/AIDS symptoms
796677|NCT03182699|Secondary Hyperparathyroidism
796678|NCT03182699|Hemodialysis
796679|NCT03182699|Left Ventricular Hypertrophy
796680|NCT03182699|FGF 23
796681|NCT03182699|Etelcalcetide
796682|NCT03182699|Alfacalcidol
796688|NCT03182673|advanced solid tumor
796689|NCT03182673|Protein Kinase MEK inhibitor (MEKi)
796690|NCT03182673|Programmed Death 1(PD-1)
796691|NCT03182673|Safety
796692|NCT03182673|Pharmacokinetics
796693|NCT03182621|Physical Fitness
796694|NCT03182621|Body Composition
796695|NCT03182621|Executive Cognitive Function
796696|NCT03182582|Laser Debridement
796697|NCT03182582|Debridement
796698|NCT03182556|Dance Therapy
796699|NCT03182556|Exercise
796700|NCT03182556|Myofeedback
796701|NCT03182556|Fibromyalgia
796702|NCT03182543|Exercise
796703|NCT03182543|Oxidative stress
796704|NCT03182543|Antioxidant
796708|NCT03182478|skin picking
796709|NCT03182478|SPD
796710|NCT03182478|Cognitive-Behavioral Therapy
796711|NCT03182478|CBT
796712|NCT03182478|Group treatment
796713|NCT03182478|Rothbaum protocol
796714|NCT03182452|Alarms
796715|NCT03182452|Alarm Fatigue
796716|NCT03182452|Alarm Nuisance
796717|NCT03182452|Alarm Reduction
796718|NCT03182452|Patient Monitoring
796719|NCT03182452|Intensive Care
796720|NCT03182439|WEARABLE HEART RATE MONITORS, ACCURACY
796721|NCT03182413|modafinil
796722|NCT03182413|connexin
796723|NCT03182413|sleep deprivation
796724|NCT03182413|cognitive performance
796725|NCT03182387|Bronchoalveolar lavage
796726|NCT03182387|amylase assay
796727|NCT03182387|aspiration pneumonia
796728|NCT03182374|Autologous Protein Solution (APS)
796729|NCT03182374|Intra-articular Injection
796730|NCT03182374|Osteoarthritis
796731|NCT03182361|Auricular, nasal, orbital, extraoral prostheses, extraoral implants, peri-implant reactions, Holgers
796732|NCT03182348|Microvessels
796733|NCT03182348|Cardiovascular disease
796734|NCT03182348|OCT
796735|NCT03182322|Type 1 diabetes
796736|NCT03182322|T1D
796737|NCT03182322|diabetes mellitus
796738|NCT03182322|intranasal insulin
796739|NCT03182322|mucosal tolerance
796740|NCT03182322|autoantigen
796741|NCT03182322|self tolerance
796742|NCT03182322|prevention
796743|NCT03182322|at risk for developing type 1 diabetes
796744|NCT03182322|juvenile diabetes
796745|NCT03182296|beta cell mass
796746|NCT03182296|exendin
796747|NCT03182296|GLP-1 PET
796748|NCT03182283|Person-centered care
796749|NCT03182283|Psychosis care
796750|NCT03182283|Integrated care
796751|NCT03182257|TRK
796752|NCT03182257|TRKA
796753|NCT03182257|TRKB
796754|NCT03182257|TRKC
796755|NCT03182257|NTRK1
796756|NCT03182257|NTRK2
796757|NCT03182257|NTRK3
796758|NCT03182257|NTRK fusion positive
796759|NCT03182257|NTRK1 fusion
796760|NCT03182257|NTRK2 fusion
796761|NCT03182257|NTRK3 fusion
796762|NCT03182257|NTRK1 gene rearrangement
796763|NCT03182257|NTRK2 gene rearrangement
796764|NCT03182257|NTRK3 gene fusion
796765|NCT03182257|ETV6-NTRK3
796766|NCT03182257|fusion
796767|NCT03182257|tumors
796768|NCT03182257|solid tumors
796769|NCT03182257|CNS tumors
796770|NCT03182257|central nervous system tumors
796771|NCT03182257|TRK fusion
796772|NCT03182257|ETV6
796773|NCT03182257|ETV6 fusion
796774|NCT03182257|solid CNS tumor
796775|NCT03182257|advanced CNS tumor
796776|NCT03182257|primary CNS tumor
796777|NCT03182244|Acute Myeloid Leukemia (AML)
796778|NCT03182244|ASP2215
796779|NCT03182231|exendin
796780|NCT03182231|GLP1
796781|NCT03182231|beta cell mass
796782|NCT03182218|Periprocedural
796783|NCT03182218|Anticoagulation
796784|NCT03182218|Dabigatran
796785|NCT03182218|Rivaroxaban
796786|NCT03182218|Apixaban
796787|NCT03182218|Edoxaban
796788|NCT03182218|Direct oral anticoagulant
796789|NCT03182218|Surgery
796790|NCT03182218|Anaesthesia
796791|NCT03182218|Novel oral anticoagulant
796792|NCT03182218|Perioperative medicine
796793|NCT03182205|Breathing Exercises
796794|NCT03182205|Autonomic Nervous System
796795|NCT03182205|Hemodynamics
796796|NCT03182192|Betal cells
796797|NCT03182192|Roux- and Y gastic bypass
796798|NCT03182192|exendin
796799|NCT03182192|GLP1
796800|NCT03182166|golimumab
796801|NCT03182166|clinical response
796802|NCT03182166|mayo score
796803|NCT03182166|rectosigmoidoscopy
796804|NCT03182166|ulcerative colitis
796805|NCT03182140|long-acting contraception,
796806|NCT03182140|unintended pregnancy
796807|NCT03182140|satisfaction
796808|NCT03182140|bleeding profile
796809|NCT03182140|amenorrhea
796810|NCT03182075|Obsessive-Compulsive Disorder
796811|NCT03182075|OCD
796812|NCT03182075|Obsessive Personality Disorder
796813|NCT03182075|Compulsive Behavior
796814|NCT03182075|Personality Disorders
796815|NCT03182075|Mental Disorders
796816|NCT03182075|Anxiety Disorders
796817|NCT03182075|Impulsive Behavior
796818|NCT03182075|Cognition
796819|NCT03182075|Emotion
796820|NCT03182075|Emotional Regulation
796821|NCT03182062|one lung ventilation
796822|NCT03182062|postoperative pulmonary complication
796823|NCT03182062|perioperative lung protective ventilation
796824|NCT03181854|Integrated Early Palliative Care
796825|NCT03181828|CPSI deficiency
796826|NCT03181828|OTC Deficiency
796827|NCT03181828|AS Deficiency
796828|NCT03181828|AL Deficiency
796829|NCT03181815|CLADRIBINE
796830|NCT03181815|ACUTE MYELOID LEUKEMIA
796839|NCT03181763|MDMA
796840|NCT03181763|fear extinction
796841|NCT03181763|sleep
796842|NCT03181750|Palliative Care
796843|NCT03181750|Latino
796844|NCT03181750|Patient Navigation
796846|NCT03181711|Dental caries
796847|NCT03181711|Tooth, deciduous
796848|NCT03181711|Children
796849|NCT03181711|Radiography/bitewing
796850|NCT03181711|diagnostic imaging
796851|NCT03181685|Progesterone supplementation
796852|NCT03181685|IVF
796853|NCT03181685|Preference expressed by the patient
796854|NCT03181672|Stellate ganglion block Tourniquet reaction
796855|NCT03181659|Musculoskeletal Manipulations
796856|NCT03181659|Exercise
796857|NCT03181659|Patient Education
796858|NCT03181659|Low back pain
796859|NCT03181633|PNH
796860|NCT03181633|Paroxysmal
796861|NCT03181633|Hemoglobinuria
796862|NCT03181633|ACH-0144471
796863|NCT03181581|ultrasonography
796864|NCT03181581|ultrasonics
796865|NCT03181581|brain
796866|NCT03181581|surgery
796867|NCT03181555|Pregnant
796868|NCT03181555|Obese
796869|NCT03181555|Omic
796870|NCT03181490|Pulmonary Nodule
796871|NCT03181490|Solitary
796872|NCT03181477|Phase II
796873|NCT03181477|Radiotherapy with SIB-IMRT
796874|NCT03181477|Tomozolomide
796875|NCT03181438|Renal Transplantation
796876|NCT03181438|Acute pain
796877|NCT03181438|Regional Anesthesia
796878|NCT03181438|TAP Block
796879|NCT03181425|Knee cartilage
796880|NCT03181425|Early Osteoarthritis
796881|NCT03181425|MRI tractography
796882|NCT03181425|Diffusion Tensor Imaging
796883|NCT03181386|Dabigatran
796884|NCT03181386|Rivaroxaban
796885|NCT03181386|Apixaban
796886|NCT03181386|Warfarin
796887|NCT03181386|Tooth Extraction
796888|NCT03181373|Craniocerebral injury
796889|NCT03181373|Mild and severe brain traumatic injury
796890|NCT03181373|Neuropsychological abilities
796891|NCT03181373|Clinical assessment
796892|NCT03181373|Anatomical and functional imaging
796893|NCT03181360|ischemic stroke
796894|NCT03181360|wake-up
796895|NCT03181360|thrombolysis
796896|NCT03181360|tenecteplase
796897|NCT03181360|computed tomography
796898|NCT03181347|Bariatrics
796899|NCT03181347|Microbiology
796900|NCT03181334|colorectal
796901|NCT03181334|cancer
796902|NCT03181334|neoplasm
796903|NCT03181334|CRC screening
796904|NCT03181334|FIT
796905|NCT03181334|Fecal Immunochemical Test
796906|NCT03181321|nutrition
796907|NCT03181321|fitness
796908|NCT03181321|cardiovascular disease
796909|NCT03181321|firefighters
796910|NCT03181321|obesity
796911|NCT03181321|injury
796912|NCT03181295|Family Medicine
796913|NCT03181295|Primary Care
796914|NCT03181295|Exercise prescriptions
796915|NCT03181295|Technology
796916|NCT03181282|Deep brain stimulation
796917|NCT03181282|Balance
796918|NCT03181282|Gait
796919|NCT03181282|Physical Therapy
796920|NCT03181282|Parkinson disease
796921|NCT03181230|Turner syndrome
796922|NCT03181230|45,XO
796923|NCT03181230|body composition
796924|NCT03181230|cardiometabolism
796925|NCT03181230|quality of life
796926|NCT03181230|fitness
796927|NCT03181178|Complementary food supplement
796928|NCT03181178|Protein quality and linear growth
796929|NCT03181178|Intervention targeting complementary foods and growth
796930|NCT03181165|Low-carbohydrate
796931|NCT03181165|Low calorie
796932|NCT03181165|Energy restricted
796933|NCT03181139|Enhanced Recovery after Surgery (ERAS)
796934|NCT03181139|Fast-track surgery
796935|NCT03181139|Pec Blocks
796936|NCT03181139|Mastectomy
796937|NCT03181126|Relapsed of Refractory Acute Lymphoblastic Leukemia
796938|NCT03181126|Navitoclax
796939|NCT03181126|Cancer
796940|NCT03181126|Venetoclax
796941|NCT03181113|peginterferon alpha
796942|NCT03181113|HBeAg seroconversion
796943|NCT03181113|immune control
796971|NCT03181087|Mesenchyme Stem Cells
796972|NCT03181087|Cesarean Section
796973|NCT03181087|Uterine Scar
796974|NCT03181035|Oral Tongue Cancer
796975|NCT03181035|Tumor Hypoxia
796976|NCT03181022|Patient-Provider Communication
796977|NCT03181022|Motivational Interviewing
796978|NCT03181022|Medication Adherence
796979|NCT03181009|Oral Immunotherapy
796980|NCT03181009|Omalizumab
796981|NCT03181009|OIT
796982|NCT03181009|Xolair
796983|NCT03180996|FEVAR
796984|NCT03180996|Fenestrated
796985|NCT03180996|Endovascular
796986|NCT03180996|AAA
796987|NCT03180996|Custom device
796988|NCT03180957|Dupuytren
796989|NCT03180957|adalimumab
796990|NCT03180957|anti TNF
796991|NCT03180957|phase II clinical trial
796992|NCT03180957|randomized controlled trial
796993|NCT03180957|double-blind method
796994|NCT03180892|Iodine
796995|NCT03180892|thyroid peroxidase antibody
796996|NCT03180840|Enzyme-Replacement Therapy
796997|NCT03180840|pegunigalsidase alfa
796998|NCT03180840|Fabry Disease
796999|NCT03180801|broad
797000|NCT03180801|universal
797001|NCT03180801|vaccine
797002|NCT03180801|influenza
797003|NCT03180801|peptide
797004|NCT03180801|T cell
797005|NCT03180801|H1N1
797006|NCT03180801|human challenge
797007|NCT03180788|ESD
797008|NCT03180788|Traction assisted ESD
797009|NCT03180788|Polypectomy
797010|NCT03180788|Clip and thread ESD
797011|NCT03180775|Amino acids
797012|NCT03180775|Macrophage atherogenicity
797013|NCT03180775|Triglycerides
797014|NCT03180775|Cholesterol
797015|NCT03180775|Lipoproteins
797016|NCT03180697|Amide Proton Transfer
797017|NCT03180697|bevacizumab
797018|NCT03180697|recurrent malignant gliomas
797019|NCT03180697|efficacy
797020|NCT03180684|High-grade squamous intraepithelial lesions (HSIL)
797021|NCT03180684|Human papillomavirus (HPV)
797022|NCT03180684|HPV-16
797023|NCT03180684|HPV-18
797024|NCT03180684|Vulvar intraepithelial neoplasia (VIN)
797025|NCT03180671|anterior deprogrammer
797026|NCT03180671|muscle pain
797027|NCT03180671|centric relation
797028|NCT03180606|Elderly
797029|NCT03180606|Frail
797030|NCT03180606|Primary care
797031|NCT03180580|Childhood, Overweight, Obesity
797032|NCT03180554|Vagal nerve stimulation
797033|NCT03180554|diaphragmatic breathing
797034|NCT03180554|chronic widespread pain
797035|NCT03180554|parasympathetic nervous system
797036|NCT03180554|heart rate variability
797037|NCT03180463|Osteonecrosis of Femoral Head
797038|NCT03180463|umbilical cord mesenchymal stem cells
797039|NCT03180450|Heart Failure
797040|NCT03180450|Human Umbilical Cord Mesenchymal Stem Cells
797041|NCT03180437|Immunotherapy
797042|NCT03180437|γδ T Cell
797043|NCT03180437|Pancreatic Cancer
797044|NCT03180424|carnitine
797045|NCT03180424|elderly
797046|NCT03180424|functional status
797047|NCT03180411|Colorectal Cancer
797048|NCT03180411|CRC
797049|NCT03180411|Colorectal cancer surveillance
797050|NCT03180411|Decision support tool
797051|NCT03180411|Interviews
797052|NCT03180411|Questionnaire
797053|NCT03180411|Survey
797054|NCT03180385|NAVA
797055|NCT03180385|BiPAP
797056|NCT03180385|Pediatrics
797057|NCT03180385|Cardiac Surgery
797058|NCT03180359|solid transplant
797059|NCT03180359|grafted children
797060|NCT03180359|vaccine recommendation
797061|NCT03180359|immunization efficacy
797062|NCT03180359|solid grafted children
797063|NCT03180359|solid transplant candidate children
797064|NCT03180333|Chronic Hepatitis B
797065|NCT03180320|chronic heart failure
797315|NCT03178487|Upadacitinib
797066|NCT03180320|exercise-based cardiac rehabilitation
797067|NCT03180320|Baduanjin
797068|NCT03180203|INTELLiVENT-ASV
797069|NCT03180203|Fully closed-loop ventilation
797070|NCT03180203|Wean
797071|NCT03180177|Hyperthermic Intraperitoneal Chemotherapy
797072|NCT03180177|Neoadjuvant Chemotherapy
797073|NCT03180177|Interval Debulking Surgery
797074|NCT03180177|Advanced-Stage Epithelial Ovarian Cancer
797075|NCT03180177|Postoperative Chemotherapy
797076|NCT03180151|corticotomy
797077|NCT03180151|enmass retraction
797078|NCT03180151|mini implant
797079|NCT03180138|mobile phone
797080|NCT03180138|Children's Health
797081|NCT03180125|hydrodissection
797082|NCT03180125|sodium hyaluorinate
797083|NCT03180099|Lumbar Disk Hernia
797084|NCT03180099|Thoracolumbar Interfascial Plane Block
797085|NCT03180099|Lumbar Disk Surgery
797086|NCT03180086|Breast cancer risk
797087|NCT03180086|Primary Care
797088|NCT03180086|Women
797089|NCT03180060|Likelihood Ratio
797090|NCT03180060|Cardiovascular Magnetic Resonance
797091|NCT03180060|CMR
797092|NCT03180060|Myocardial Perfusion
797093|NCT03180060|Predictive Values
797094|NCT03180060|Computed Tomography Perfusion
797095|NCT03180060|CTP
797096|NCT03180060|SPECT
797097|NCT03180060|PET
797098|NCT03180060|Diagnostic Accuracy
797099|NCT03180060|Quantitative Coronary Angiography
797100|NCT03180060|Area Under the Curve
797101|NCT03180060|ROC Curve
797106|NCT03179995|Octreotide, Major Liver Resection
797107|NCT03179930|Entinostat
797108|NCT03179930|Pembrolizumab
797109|NCT03179930|17-073
797110|NCT03179917|Pembrolizumab
797111|NCT03179917|Radiation Therapy
797112|NCT03179917|17-054
797113|NCT03179891|Interictal Period A
797114|NCT03179891|Icta/peri-ictal Period B
797115|NCT03179839|Mindfulness-Based Cognitive Therapy
797116|NCT03179813|hydrocortisone
797117|NCT03179813|third molar
797118|NCT03179813|oral surgery
797119|NCT03179813|postoperative pain
797120|NCT03179813|edema
797121|NCT03179800|Hypertension
797122|NCT03179800|Resistant Hypertension
797123|NCT03179800|Baroreceptor
797124|NCT03179800|BAT
797125|NCT03179722|Aging
797126|NCT03179722|Drug-related problems
797127|NCT03179722|Medication review
797128|NCT03179722|Community pharmacist
797129|NCT03179722|Medication use
797130|NCT03179709|Acute Respiratory Distress Syndrome
797131|NCT03179709|Neuromuscular Blockade
797132|NCT03179709|Interviews
797133|NCT03179709|Implementation Science
797134|NCT03179696|Schizophrenia
797135|NCT03179696|CBSST
797136|NCT03179696|mobile CBT
797137|NCT03179696|negative symptoms
797138|NCT03179683|aluminum step-wedge
797139|NCT03179683|demineralized bone matrix
797140|NCT03179683|dental implant
797141|NCT03179683|digital densitometry
797142|NCT03179683|low level laser therapy
797143|NCT03179683|maxillary sinus augmentation.
797144|NCT03179657|Prospective Cohort study
797145|NCT03179657|Nutrition
797146|NCT03179657|Diet
797147|NCT03179657|Guangzhou
797148|NCT03179657|Chinese
797149|NCT03179631|Duchenne Muscular Dystrophy
797150|NCT03179631|Dystrophinopathy
797151|NCT03179631|Nonsense Mutation
797152|NCT03179631|Premature Stop Codon
797153|NCT03179631|Becker Muscular Dystrophy
797154|NCT03179631|DMD/BMD
797155|NCT03179631|PTC124
797156|NCT03179631|Ataluren
797157|NCT03179618|Unstable Angina
797158|NCT03179618|Xuefu Zhuyu Decoction
797159|NCT03179592|Computed Tomography
797160|NCT03179579|Gastric Cancer
797161|NCT03179579|Peritoneal Carcinomatosis
797162|NCT03179579|Hyperthermic Intraperitoneal Chemotherapy
797163|NCT03179579|Systemic Chemotherapy
797164|NCT03179579|Cytoreductive Surgery
797165|NCT03179566|drug disposal
797166|NCT03179540|Low Rectal Cancer
797167|NCT03179540|Complete Clinical Response
797168|NCT03179540|Non-operative Management
797169|NCT03179527|Unstable Angina
797170|NCT03179527|Shuanghe Decoction
797171|NCT03179514|Unstable Angina
797172|NCT03179514|Gualou Xiebai Banxia Decoction
797173|NCT03179514|Danshen Decoction
797174|NCT03179475|Spinal Cord Injury
797175|NCT03179475|Traumatic Spinal Cord Injury
797176|NCT03179475|Targin®
797177|NCT03179475|Opioids
797178|NCT03179475|Naloxone
797179|NCT03179475|Opioid Induced Constipation
797180|NCT03179475|Oxycodone-Naloxone
797181|NCT03179436|PD1
797182|NCT03179436|PD-1
797183|NCT03179436|PDL1
797184|NCT03179436|PD-L1
797185|NCT03179423|Diabetes Mellitus, Type 1
797186|NCT03179423|T1D
797187|NCT03179423|Monoclonal antibody
797188|NCT03179423|Multiple Sclerosis associated retrovirus MSRV
797316|NCT03178474|infant formula
797189|NCT03179423|Human Endogenous Retrovirus Type w (HERV-W)
797190|NCT03179423|GNbAC1
797191|NCT03179410|metastatic castrate-resistant prostate cancer (mCRPC)
797192|NCT03179410|neuroendocrine prostate cancer (NEPC)
797193|NCT03179345|Volunteer
797194|NCT03179345|Pharmacodynamics
797195|NCT03179345|Pharmacokinetics
797196|NCT03179319|PrEP
797197|NCT03179319|HIV testing
797198|NCT03179319|Sexually transmitted disease (STD) testing
797199|NCT03179319|Mobile app
797200|NCT03179319|Young men who have sex with men
797201|NCT03179319|Technology
797202|NCT03179306|Cervix
797203|NCT03179306|HPV
797204|NCT03179306|Imaging
797205|NCT03179306|Costa Rica
797206|NCT03179280|Type 1 diabetes
797207|NCT03179280|Dual-wave bolus
797208|NCT03179280|Postprandial euglycaemia
797209|NCT03179267|vital signs
797210|NCT03179267|monitoring
797211|NCT03179267|early warning score
797212|NCT03179202|Electrical Stimulation
797213|NCT03179202|Neurostimulation
797214|NCT03179202|Neuromodulation
797215|NCT03179202|Back Pain
797216|NCT03179202|Low Back Pain
797217|NCT03179163|Hypertension
797218|NCT03179163|Blood Pressure
797219|NCT03179163|Cardiovascular Disease
797220|NCT03179163|ACE Inhibitor
797221|NCT03179163|Diuretic
797222|NCT03179163|Nitric Oxide
797223|NCT03179163|Hydrogen Sulfide
797224|NCT03179163|Captopril
797225|NCT03179163|Enalapril
797226|NCT03179163|Hydrochlorothiazide
797227|NCT03179163|Microcirculation
797228|NCT03179163|Skin
797229|NCT03179150|computer-aided diagnosis
797230|NCT03179150|Web
797231|NCT03179150|Cloud computing
797232|NCT03179150|lung cancer
797233|NCT03179124|cerebral palsy
797234|NCT03179124|trunk control
797235|NCT03179124|upper extremity
797236|NCT03179098|Elbow
797237|NCT03179098|Stretching
797238|NCT03179098|Joint amplitude
797239|NCT03179098|Electromyography
797240|NCT03179098|Surface heat
797241|NCT03179098|Orthosis
797242|NCT03179098|Posttraumatic
797243|NCT03179085|Diabetes
797244|NCT03179085|American Indians
797245|NCT03179085|Disparity
797246|NCT03179085|microalbuminuria
797247|NCT03179085|Telemedicine
797248|NCT03179085|Community health representative (CHR)
797249|NCT03179085|Patient Activation Measure (PAM)
797250|NCT03179085|Home base kidney care
797251|NCT03179059|Reproductive Health
797252|NCT03179059|Family Planning
797253|NCT03179059|Randomization Trial
797254|NCT03179059|Uganda
797255|NCT03179033|LVAD
797256|NCT03179033|Passive leg raising
797257|NCT03179020|Intensive Care Units
797258|NCT03179020|Brain Death
797259|NCT03179020|Organ Donation
797260|NCT03179020|Family interview
797261|NCT03179007|MUC1
797262|NCT03179007|CTLA-4
797263|NCT03179007|PD-1
797264|NCT03179007|chimeric antigen receptor T cells
797265|NCT03179007|solid tumor
797266|NCT03178994|Post - adolescence acne
797267|NCT03178994|Topical 2% ketoconazole cream
797268|NCT03178877|IBS, Rome IV criteria, anxiety
797269|NCT03178864|cerebral venous thrombosis
797270|NCT03178864|anticoagulation
797276|NCT03178786|Art Therapy
797277|NCT03178773|mobile health
797278|NCT03178773|social support
797279|NCT03178773|health disparity
797280|NCT03178773|Latino
797281|NCT03178760|Optic nerve sheath diameter
797282|NCT03178760|average optic nerve sheath diameter for healthy children
797283|NCT03178747|Methylene blue
797284|NCT03178747|Giemsa
797285|NCT03178747|Tzanck smear
797298|NCT03178656|sorafenib, operation
797299|NCT03178578|Fluid therapy
797300|NCT03178565|Respiratory Failure
797301|NCT03178565|Mechanical Ventilation
797302|NCT03178565|Mechanical insufflation-exsufflation
797303|NCT03178565|Airway mucus clearance
797304|NCT03178539|tonsillectomy
797305|NCT03178539|post operative analgesia
797306|NCT03178539|diklofanic
797307|NCT03178539|ketorolac
797308|NCT03178500|clomiphene citrate
797309|NCT03178500|stair- step
797310|NCT03178500|poly cystic ovary
797311|NCT03178487|Efficacy
797312|NCT03178487|ABT-494
797313|NCT03178487|Safety
797314|NCT03178487|Ankylosing Spondylitis (AS)
797317|NCT03178474|Clinical trial
797318|NCT03178474|Chinese infant
797319|NCT03178474|body growth
797320|NCT03178474|gut microbiota
797321|NCT03178474|Stool characteristics
797322|NCT03178461|Caesarean Section
797323|NCT03178461|Delivery
797324|NCT03178435|risk score
797325|NCT03178435|Acute kidney injury
797326|NCT03178435|critical care
797327|NCT03178422|tobacco use cessation
797328|NCT03178422|smoking prevention
797329|NCT03178422|NRT
797330|NCT03178370|Gastroparesis
797331|NCT03178370|Nausea and Vomiting
797332|NCT03178370|Abdominal Pain
797333|NCT03178370|Gastric Emptying
797334|NCT03178370|Electrophysiology
797335|NCT03178370|Hormones
797336|NCT03178370|Inflammation
797337|NCT03178370|Enteric Nervous System
797338|NCT03178370|Autonomic Nervous System
797339|NCT03178331|School health services
797340|NCT03178331|Screening
797341|NCT03178331|Student
797342|NCT03178331|School doctor
797343|NCT03178331|Health check
797344|NCT03178331|Children
797345|NCT03178279|physical health
797346|NCT03178188|lupus erythematosus, Discoid
797347|NCT03178188|Pulsed-dye Laser
797348|NCT03178175|Scalp acupuncture
797349|NCT03178175|Parkinson's disease
797350|NCT03178175|Balance
797351|NCT03178162|limitation in conventional monitoring
797352|NCT03178149|Age-related Macular Degeneration
797353|NCT03178149|ASP7317
797354|NCT03178136|HR-HPV opportunistic screening
797355|NCT03178136|virus load
797356|NCT03178136|multi-site
797357|NCT03178123|anti-PD-1 monoclonal antibody
797358|NCT03178123|Mucosal Melanoma
797359|NCT03178123|Interferons
797360|NCT03178110|physical therapy
797361|NCT03178110|cancer rehabilitation
797362|NCT03178097|limitation in conventional monitoring
797363|NCT03178084|HIV
797364|NCT03178084|CD4/CD8 ratio
797365|NCT03178084|immune recovery
797366|NCT03178084|maraviroc
797367|NCT03178084|efavirenz
797368|NCT03178071|NSCLC
797369|NCT03178032|Diffuse intrinsic pontine gliomas
797370|NCT03178032|Oncolytic adenovirus
797371|NCT03177980|Term infants
797372|NCT03177980|Analgesia
797373|NCT03177980|fentanyl
797374|NCT03177980|clonidine
797375|NCT03177980|pharmacokinetics
797376|NCT03177980|sedation
797377|NCT03177980|pharmacodynamics
797378|NCT03177980|neurophysiology
797379|NCT03177980|pharmacogenetics
797380|NCT03177980|asphyxia
797381|NCT03177980|hypothermia
797382|NCT03177967|Insomnia
797383|NCT03177967|Cognitive behavioral treatment for insomnia (CBT-I)
797384|NCT03177941|Melanoma
797385|NCT03177941|Skin Self-Examination
797386|NCT03177941|First-degree Relative
797387|NCT03177941|Mobile Application
797388|NCT03177876|tenting Hydroxyapetite nano particles implant immediate
797389|NCT03177863|neoplasm
797390|NCT03177863|uterine cervix
797391|NCT03177850|sleep related breathing disturbances
797392|NCT03177850|respiratory polygraphy
797393|NCT03177850|airway disease
797394|NCT03177850|emphysema
797395|NCT03177850|acetazolamide
797396|NCT03177850|altitude
797397|NCT03177850|nocturnal pulse oxymetry
797398|NCT03177837|exercise performance
797399|NCT03177837|maximal spiroergometry
797400|NCT03177837|airway disease
797401|NCT03177837|emphysema
797402|NCT03177837|prevention
797403|NCT03177837|acetazolamide
797404|NCT03177837|altitude
797405|NCT03177811|postural control
797406|NCT03177811|balance performance
797407|NCT03177811|airway disease
797408|NCT03177811|altitude
797409|NCT03177811|prevention
797410|NCT03177811|acetazolamide
797411|NCT03177772|caregivers
797412|NCT03177772|grief
797413|NCT03177772|dementia
797414|NCT03177772|long-term care
797415|NCT03177772|psychotherapy group
797416|NCT03177733|breast surgery
797417|NCT03177733|acute pain
797418|NCT03177733|regional anesthesia
797419|NCT03177694|cough
797420|NCT03177694|exacerbation
797421|NCT03177694|connected device
797422|NCT03177681|Malignant neoplasms of independent (primary) multiple sites
797423|NCT03177681|Gastrointestinal symptoms
797424|NCT03177681|Probiotics
797425|NCT03177681|Yogurt
797426|NCT03177681|Stool sample
797427|NCT03177681|Questionnaires
797428|NCT03177681|Surveys
797429|NCT03177681|Holter monitor
797430|NCT03177629|Immune Thrombocytopenic Purpura
797431|NCT03177629|Helicobacter pylori
797440|NCT03177603|Pulmonary Arterial Hypertension
797441|NCT03177603|Dose-escalation
797442|NCT03177603|Safety
797443|NCT03177603|Tolerability
797444|NCT03177603|GSK2586881
797445|NCT03177590|autism
797446|NCT03177590|Pervasive Developmental Disorder
797447|NCT03177564|driving pressure
797448|NCT03177564|one-lung ventilation
797449|NCT03177551|Prostatic Neoplasms
797450|NCT03177551|Nomograms
797451|NCT03177551|Drug Resistance, Neoplasm
797452|NCT03177538|suboptimal response
797453|NCT03177538|Corifollitropin alfa
797454|NCT03177538|IVF
797455|NCT03177538|Ovarian stimulation
797456|NCT03177525|parent training
797457|NCT03177525|social skills
797458|NCT03177512|PrEP
797459|NCT03177512|HIV Testing
797460|NCT03177512|STI Testing
797461|NCT03177512|Mobile app
797462|NCT03177512|Technology
797463|NCT03177512|Young men who have sex with men
797464|NCT03177499|Portal pressure gradient
797465|NCT03177499|Transjugular intrahepatic portosystemic shunt
797466|NCT03177499|Virtual imaging-based portal pressure gradient
797467|NCT03177486|Syntax score
797468|NCT03177486|Frank sign
797469|NCT03177486|Coronary angiography
797470|NCT03177473|degenerative disc disease
797471|NCT03177473|CervicalStim devic
797472|NCT03177473|cervical
797473|NCT03177473|cervical fusion
797474|NCT03177460|Malignant neoplasms of male genital organs
797475|NCT03177460|Prostate Cancer
797476|NCT03177460|Adenocarcinoma of the Prostate
797477|NCT03177460|High-risk
797478|NCT03177460|Localized
797479|NCT03177460|Daratumumab
797480|NCT03177460|Prostatectomy
797481|NCT03177447|Cardiac Failure
797482|NCT03177447|Congestive Heart Failure
797483|NCT03177447|Heart Decompensation
797484|NCT03177447|Heart Failure, Congestive
797485|NCT03177434|constipation
797486|NCT03177434|children
797487|NCT03177434|polyethylene glycols (PEG)
797488|NCT03177434|lactulose
797489|NCT03177408|Diastolic Dysfunction
797490|NCT03177408|Hypertension
797491|NCT03177408|HMGB1
797492|NCT03177382|Total Neoadjuvant Treatment
797493|NCT03177382|Rectal Cancer
797494|NCT03177382|High Risk Factors
797495|NCT03177382|Chemoradiotherapy
797496|NCT03177369|Bone and joint infection
797497|NCT03177369|Staphylococcus aureus
797498|NCT03177369|Teicoplanin
797499|NCT03177369|Subcutaneous administration
797500|NCT03177356|Platelet rich fibrin,xenograft
797501|NCT03177343|Pristinamycin
797502|NCT03177343|Staphylococcus aureus
797503|NCT03177343|Bone and joint infection
797504|NCT03177304|Interpersonal Psychotherapy
797505|NCT03177304|Internet
797506|NCT03177304|Training
797507|NCT03177304|Depression
797508|NCT03177304|Dissemination
797509|NCT03177291|NSCLC
797510|NCT03177291|SCLC
797511|NCT03177265|nicotine dependence
797512|NCT03177265|tobacco cessation
797516|NCT03177161|PROM
797517|NCT03177161|Patient Reported Outcome Measure
797518|NCT03177161|PROMIS
797519|NCT03177161|PROMIS-10
797520|NCT03177161|PROMIS Global Health
797521|NCT03177161|RiksStroke
797522|NCT03177161|ICHOM
797523|NCT03177161|International Consortium for Health Outcomes Measurement
797524|NCT03177161|Wales
797525|NCT03177161|Administration
797526|NCT03177161|Method
797527|NCT03177161|Delivery
797528|NCT03177122|Polycystic Ovary Syndrome
797529|NCT03177122|Myo-Inositol
797530|NCT03177122|Assisted Reproductive Technology
797531|NCT03177122|oocyte performance
797532|NCT03177122|pregnancy
797533|NCT03177109|Dentine Hypersensitivity
797534|NCT03177109|Fluoride varnish
797535|NCT03177109|Desensitizing agents
797536|NCT03177096|Type 1 diabetes children,School,Childcare facilities,Sensor
797537|NCT03177070|Ureteric injury
797538|NCT03177070|Colorectal Surgery
797539|NCT03177044|Inflammatory bowel disease, pelvic floor exercise
797540|NCT03176992|ablation
797541|NCT03176992|surgicel
797542|NCT03176953|PTSD
797543|NCT03176953|alcohol use disorder
797544|NCT03176953|Veterans
797546|NCT03176927|magnetogastrogram
797547|NCT03176927|gastroparesis
797548|NCT03176927|electrogastrogram
797549|NCT03176927|gastric slow wave
797550|NCT03176914|Community mobilisation
797551|NCT03176901|urinary urge incontinence
797552|NCT03176901|urinary incontinence
797553|NCT03176901|older adult women
797554|NCT03176901|older adults
797555|NCT03176901|mindfulness-based stress reduction
797556|NCT03176901|health enhancement program
797557|NCT03176901|feasibility
797558|NCT03176901|randomized controlled trial
797559|NCT03176901|complementary
797560|NCT03176901|integrative
797561|NCT03176901|therapies
797562|NCT03176888|Exercise
797563|NCT03176888|Aerobic capacity
797564|NCT03176888|Rehabilitation
797565|NCT03176810|percutaneous coronary intervention
797566|NCT03176810|optical coherence tomography
797567|NCT03176797|Liver Fibrosis, multiparametric magnetic resonance imaging
797568|NCT03176784|Varenicline
797569|NCT03176784|Nicotine Patch
797570|NCT03176784|Quit Smoking
797571|NCT03176784|Tobacco
797572|NCT03176784|Cigarettes
797573|NCT03176732|Sleep Apnea
797574|NCT03176732|Hypertension
797575|NCT03176732|Positive Airway Pressure
797576|NCT03176732|Blood Pressure
797577|NCT03176680|Anesthesia,Esophagectomy,Esophageal cancer,Treatment outcome
797578|NCT03176667|regional, erector spinae block, lobectomy, video-assisted
797579|NCT03176641|Platelet-Rich Plasma
797580|NCT03176641|Meniscus
797581|NCT03176641|Knee Injuries
797582|NCT03176628|Pharmacokinetics
797583|NCT03176628|Pharmacodynamics
797584|NCT03176615|Gastric Bypass
797585|NCT03176602|Subjective Global Assessment
797586|NCT03176602|Nutrition Risk in Critically ill Score
797587|NCT03176602|Critical Illness
797588|NCT03176589|positive expiratory pressure
797589|NCT03176589|oxygen saturation
797590|NCT03176589|abdominal surgery
797591|NCT03176589|carbon dioxide
797592|NCT03176576|cancer among adolescents
797593|NCT03176576|cancer among young adults
797594|NCT03176576|adolescents and young adults (AYA)
797595|NCT03176576|quality of life
797596|NCT03176576|reduce stress
797597|NCT03176576|patient navigation
797598|NCT03176576|questionnaire
797599|NCT03176576|supportive care
797600|NCT03176576|distress levels
797601|NCT03176576|support resources
797602|NCT03176576|satisfaction survey
797603|NCT03176576|teen cancer
797604|NCT03176563|herbal treatment
797605|NCT03176563|antibiotics
797606|NCT03176563|uncomplicated urinary tract infection
797607|NCT03176511|older adults
797608|NCT03176511|dual task
797609|NCT03176511|A Matter of Balance
797610|NCT03176498|cerebral Infarction
797611|NCT03176498|umbilical cord mesenchymal stem cells
797612|NCT03176485|metastatic
797613|NCT03176485|melanoma
797614|NCT03176485|cancer
797615|NCT03176485|colon
797616|NCT03176485|thyroid
797617|NCT03176485|Differentiated
797618|NCT03176485|Hepatocellular Carcinoma
797619|NCT03176485|HCC
797620|NCT03176485|RCC
797621|NCT03176485|Renal Cell Carcinoma
797622|NCT03176472|Diabetic Neuropathic Pain
797623|NCT03176472|Neuropathic Pain
797624|NCT03176472|HDAC6
797625|NCT03176472|ricolinostat
797626|NCT03176459|bupvacaine
797627|NCT03176459|exparel
797628|NCT03176459|analgesic
797629|NCT03176459|TAP Block
797630|NCT03176407|sensor capsule
797631|NCT03176394|Foley, UTI, Biofilm, DNA
797632|NCT03176381|Prostatic Neoplasms
797633|NCT03176381|Abiraterone Acetate
797634|NCT03176381|FK506 binding protein 5
797635|NCT03176381|Neurotensin
797636|NCT03176381|yes-associated protein 1
797637|NCT03176381|AKR1C3 protein
797638|NCT03176381|Proliferating Cell Nuclear Antigen
797639|NCT03176368|dry mouth
797640|NCT03176368|coconut oil
797641|NCT03176368|radiation
797642|NCT03176342|Drug patch tests
797643|NCT03176329|Full closed-loop ventilation control
797644|NCT03176329|Critical care
797645|NCT03176316|ileus
797646|NCT03176316|fusion of spine
797647|NCT03176277|Leukemia
797648|NCT03176277|Leukemia, Myeloid
797649|NCT03176277|Leukemia, Myeloid, Acute
797650|NCT03176277|MER
797651|NCT03176277|MERTK
797652|NCT03176277|TYRO3
797653|NCT03176277|AXL
797654|NCT03176277|AML
797655|NCT03176277|de novo AML
797656|NCT03176277|Relapsed/ Refractory AML
797657|NCT03176277|TAM
797658|NCT03176264|PDR001
797659|NCT03176264|immunotherapy
797660|NCT03176264|bevacizumab
797661|NCT03176264|mFOLFOX6
797662|NCT03176264|CRC
797663|NCT03176264|MMS
797664|NCT03176264|CMS4
797665|NCT03176264|ElevatION;CRC-101
797666|NCT03176238|post menopausal
797667|NCT03176238|advanced breast cancer
797668|NCT03176238|metastatic breast cancer
797669|NCT03176238|everolimus
797670|NCT03176238|exemestane
797671|NCT03176238|mTor inhibitor
797672|NCT03176238|endocrine therapy
797673|NCT03176212|Gut permeability
797674|NCT03176212|Cytokine
797675|NCT03176212|Endotoxin
797676|NCT03176199|control-released oxycodone
797677|NCT03176199|immediate-released oxycodone
797678|NCT03176199|cancer pain
797679|NCT03176199|opioid-naive
797680|NCT03176186|ischemic-reperfusion injury
797681|NCT03176186|out of hospital cardiac arrest
797682|NCT03176160|LASR
797683|NCT03176160|Fecci
797684|NCT03176160|Pro00079623
797685|NCT03176160|Glioblastoma
797686|NCT03176160|Laser Interstitial Thermal Therapy
797687|NCT03176160|short-course radiation therapy
797688|NCT03176147|Anemia
797689|NCT03176147|Pregnancy
797690|NCT03176147|Hepcidine
797691|NCT03176147|Iron
797692|NCT03176121|Oxycodone
797693|NCT03176121|Cancer Pain
797694|NCT03176121|Long-term use
797695|NCT03176082|colorectal cancer screening
797696|NCT03176082|colorectal cancer
797697|NCT03176069|Vaginismus
797698|NCT03176069|Muscle Tone
797699|NCT03176069|Sexual dysfunctions
797700|NCT03176056|Type 2 Diabetes Mellitus
797701|NCT03176056|Low carbohydrate diet
797702|NCT03176017|Transurethral Incision Of The Prostate
797703|NCT03176017|Prostate
797704|NCT03176017|Holmium Laser
797705|NCT03176017|Ejaculatory Sparing
797706|NCT03175965|Heart arrest, hypothermia, SEP, prognosis
797707|NCT03175939|adjuvant chemotherapy
797708|NCT03175939|NPC
797709|NCT03175926|Asthma
797710|NCT03175926|inhaler device
797711|NCT03175926|handling
797712|NCT03175900|Migraine
797713|NCT03175900|Naoandiwan
797714|NCT03175900|Traditional Chinese Medicine
797715|NCT03175900|fMRI
797716|NCT03175900|Randomized Controlled trial
797717|NCT03175887|depression
797718|NCT03175887|trd
797719|NCT03175887|treatment-resistant depression
797720|NCT03175887|TMS
797721|NCT03175874|Osteoporosis
797722|NCT03175874|Alzheimer Disease
797723|NCT03175848|Cervical Cancer
797724|NCT03175848|Radiotherapy
797725|NCT03175848|Chemotherapy
797726|NCT03175848|stage IVB cervical cancer
797727|NCT03175835|Dyslipidemia
797728|NCT03175835|CKD-519
797729|NCT03175835|Rosuvastatin
797730|NCT03175835|Drug-Drug Interaction
797731|NCT03175809|Chronic pelvic pain
797732|NCT03175809|Pain
797733|NCT03175809|Dry needling
797734|NCT03175809|Biofeedback
797735|NCT03175809|Pelvic pain
797736|NCT03174912|EORTC
797737|NCT03174912|CUETO
797738|NCT03174912|bladder neoplasm
797739|NCT03174912|disease progression
797740|NCT03174912|recurrence
797741|NCT03174886|tau
797742|NCT03174886|neurofibrillary
797743|NCT03174886|degeneration
797744|NCT03174886|primary progressive aphasia
797745|NCT03174886|agrammatic
797746|NCT03174886|tauopathy
797747|NCT03174886|immunotherapy
797748|NCT03174886|immunization
797749|NCT03174860|Pulpitis, irreversible Pulpitis, Hot tooth
797750|NCT03174860|Cataflam, Diclofenac Potassium, Preoperative, Premedication, Analgesic
797751|NCT03174860|Local anesthesia, Articaine, Buccal infiltration
797752|NCT03174847|Primary aldosteronism
797753|NCT03174847|Blood pressure
797754|NCT03174847|Adrenalectomy
797755|NCT03174847|Mineralocorticoid-receptor Antagonists
797756|NCT03174847|Cardiovascular
797757|NCT03174847|Endothelial
797758|NCT03174847|Renal
797759|NCT03174834|Bladder Stimulation Technique
797760|NCT03174834|Clean Catch Urine
797761|NCT03174834|UTI in infants less than 6 months
797762|NCT03174821|Diabetic nephropathy
797763|NCT03174821|Insulin pump intensive therapy
797764|NCT03174808|cutaneous T-cell lymphoma
797765|NCT03174756|Hypochlorous Acid
797766|NCT03174756|Chlorhexidine
797767|NCT03174756|Antiplaque agents
797768|NCT03174756|Substantivity
797769|NCT03175718|Sarcoma
797770|NCT03175718|Wound
797771|NCT03175718|Therapy
797772|NCT03175627|Dental caries
797773|NCT03175627|Proximal surfaces
797774|NCT03175627|Posterior teeth
797775|NCT03175627|Carious lesions
797776|NCT03175627|Tooth diseases
797777|NCT03175627|Dental restorations
797778|NCT03175627|Composite resin
797779|NCT03175614|Physical activity
797780|NCT03175614|Food Habits
797781|NCT03175614|Information and communiation Technology
797782|NCT03175614|Health education
797783|NCT03175601|Sleep disturbances
797784|NCT03175601|Biomarkers
797785|NCT03175601|Prefrailty
797786|NCT03175601|Insulin resistance
797787|NCT03175601|Olfactory impairment
797788|NCT03175601|Multiplex array
797789|NCT03175601|Gait speed
797790|NCT03175536|high-deductible health plan
797791|NCT03175536|medication adherence
797792|NCT03175536|out-of-pocket costs
797793|NCT03175536|preventive drug list
797794|NCT03175536|value-based insurance design
797795|NCT03175523|BioResorbable Scaffold
797796|NCT03175523|Quantitative Coronary Angiography
797797|NCT03175523|Intravascular Imaging
797798|NCT03175510|validity, reliability, low back pain
797799|NCT03175497|Gastric Cancer, VEGFR inhibitor
797800|NCT03175484|High Fidelity Simulation
797801|NCT03175484|Cognitive Load
797802|NCT03175484|Simulation Training/methods*
797803|NCT03175484|Task Performance and Analysis*
797804|NCT03175484|Students, Medical
797805|NCT03175484|Prospective Studies
797806|NCT03175458|tenting
797807|NCT03175458|grafting
797808|NCT03175458|implant placement
797809|NCT03175432|Melanoma and other malignant neoplasms of skin
797810|NCT03175432|Untreated Melanoma Brain Metastases
797811|NCT03175432|Bevacizumab
797812|NCT03175432|rhuMA-VEGF
797813|NCT03175432|Avastin
797814|NCT03175432|ANTI-VEGF monoclonal antibody
797815|NCT03175432|Atezolizumab
797816|NCT03175432|MPDL3280A
797817|NCT03175432|Questionnaires
797818|NCT03175432|Surveys
797819|NCT03175432|Neurocognitive Exam
797820|NCT03175419|laparoscopic liver resection
797821|NCT03175341|breast cancer
797822|NCT03175341|ascorbic acid
797823|NCT03175341|vitamin C
797824|NCT03175341|vitamin supplementation
797825|NCT03175341|quality of life
797826|NCT03175315|psychoeducation
797827|NCT03175315|treatment and education programme
797828|NCT03175315|self-management
797829|NCT03175315|diabetes education
797830|NCT03175315|flash glucose monitoring
797831|NCT03175302|cognitive processes
797832|NCT03175302|perioperative cognition
797833|NCT03175302|neurocognitive impairment
797834|NCT03175276|Delirium
797835|NCT03175276|Cognitive decline
797836|NCT03175276|IQCODE
797837|NCT03175263|onabotulinumtoxinA, chronic migraine, myofascial pain
797838|NCT03175224|Advanced Solid Tumor
797839|NCT03175224|Relapsed Solid Tumor
797840|NCT03175224|Recurrent Solid Tumor
797841|NCT03175159|Risk Reduction
797842|NCT03175159|Crystal Methamphetamine
797843|NCT03175159|Cocaine
797844|NCT03175159|Stimulant Abuse
797845|NCT03175159|HIV
797846|NCT03175159|Behavioral Activation
797847|NCT03175133|rehabilitation
797848|NCT03175133|physical therapy
797849|NCT03175107|exergaming
797850|NCT03175107|physiotherapy
797851|NCT03175107|upper extremities
797852|NCT03175107|telerehabilitation
797853|NCT03175094|women
797854|NCT03175094|HIV prevention
797855|NCT03175094|criminal justice
797856|NCT03175081|Intraperitoneal local anesthetic
797857|NCT03175081|Ropivacaine
797858|NCT03175081|Postoperative pain
797859|NCT03175081|Bariatric surgery
797860|NCT03175068|Functional magnetic resonance imaging
797861|NCT03175068|Electroencephalography
797862|NCT03175068|Cognitive Behavioral Therapy
797863|NCT03175068|Supportive Therapy
797864|NCT03175029|Lower Urinary Tract Symptoms
797865|NCT03174990|aspirin
797866|NCT03174990|clopidogrel
797867|NCT03174990|peripheral arterial disease
797868|NCT03174990|genetics
797869|NCT03174964|Recurrent Implantation Failure
797870|NCT03174964|IVIg
797871|NCT03174964|Pregnancy Rate
797872|NCT03174951|Recurrent Pregnancy Loss
797873|NCT03174951|IVIg
797874|NCT03174951|Pregnancy Rate
797875|NCT03174938|Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test
797876|NCT03174730|smoking
797877|NCT03174730|smartphone
797878|NCT03174730|technology
797879|NCT03174730|addiction
797880|NCT03174678|Dexmedetomidine
797881|NCT03174678|child
797882|NCT03174678|premedication
797883|NCT03174678|emergence delirium
797884|NCT03174678|dental treatment
797885|NCT03174626|caregiver
797886|NCT03174626|stress management
797887|NCT03174600|Stroke
797888|NCT03174600|Lower urinary tract dysfunction
797889|NCT03174600|Functional status
797890|NCT03174600|Mini mental test
797891|NCT03174587|Systemic lupus erythematosus
797892|NCT03174587|HLA-haplo-matching
797893|NCT03174587|allogenic bone marrow derived mesenchymal stem cell
797894|NCT03174587|Phase 1 clinical trial
797895|NCT03174535|Ischemic Stroke
797896|NCT03174535|Secondary Prevention
797897|NCT03174535|Endpoint Events
797898|NCT03174535|Risk Assessment
797899|NCT03174535|Traditional Chinese Medicine
797900|NCT03174535|Registry Study
797901|NCT03174522|Autologous
797902|NCT03174522|Bone Marrow-derived Mononuclear Cells (BM-MNCs)
797903|NCT03174522|Advanced Therapy Medicinal Product (ATMP)
797904|NCT03174522|Tissue-engineered Medicinal Product
797905|NCT03174522|Revascularization
797906|NCT03174522|Angiogenesis
797907|NCT03174522|Vasculogenesis
797908|NCT03174522|Arteriogenesis
797909|NCT03174509|airway extubation
797910|NCT03174509|positive-pressure respiration
797911|NCT03174509|suction
797912|NCT03174509|ventilator weaning
797913|NCT03174457|Oesophageal Candidiasis
797914|NCT03174457|Paediatric
797915|NCT03174457|Invasive Candidiasis
797916|NCT03174457|Prophylaxis of Candida Infections
797917|NCT03174457|Candidemia
797918|NCT03174457|Aspergillosis
797919|NCT03174457|Micafungin
797920|NCT03174444|Chinese American
797921|NCT03174444|Asian American
797922|NCT03174444|Colorectal cancer screening
797923|NCT03174444|Print materials
797924|NCT03174418|Optical coherence tomography
797925|NCT03174418|Percutaneous coronary interventions
797926|NCT03174418|Coronary atherosclerosis in bifurcations
797927|NCT03174392|Exercise
797928|NCT03174392|Multimodal
797929|NCT03174392|Balance
797930|NCT03174392|Resistance
797931|NCT03174392|Mobility
797932|NCT03174314|Visual Impairment
797933|NCT03174275|squamous cell carcinoma of the head and neck (SCCHN)
797934|NCT03174275|durvalumab
797935|NCT03174275|neoadjuvant induction
797936|NCT03174275|post-operative treatment
797937|NCT03174262|Ergonomics
797938|NCT03174262|Computer Workstation
797939|NCT03174262|Habit
797940|NCT03174262|Self-efficacy
797941|NCT03174262|Knowledge
797942|NCT03174249|Behavioural therapy
797943|NCT03174249|Exposure in vivo
797944|NCT03174249|Cortical reorganisation
797945|NCT03174249|Mirror therapy
797946|NCT03174210|COPD
797947|NCT03174210|supplemental oxygen
797948|NCT03174210|oxygen concentrator
797961|NCT03174171|Everolimus, mTor inhibitor
797962|NCT03174158|text messaging
797963|NCT03174093|Mobile Health
797964|NCT03174080|Positron-Emission
797965|NCT03174080|PET Scan Tomography
797966|NCT03174067|buprenorphine
797967|NCT03174067|emergency department
797968|NCT03174054|Men aged 40 and over
797969|NCT03174054|multi parametric MRI
797970|NCT03174015|Sanitation
797971|NCT03174015|Demand
797972|NCT03174015|Peri-urban
797973|NCT03174015|Behavior Change
797974|NCT03174015|Lusaka
797975|NCT03174015|Zambia
797981|NCT03173989|osteoarthritis
797982|NCT03173989|hand deformities
797983|NCT03173989|hand strength
797984|NCT03173989|assistive technology
797985|NCT03173989|exercise
797986|NCT03173989|health education
797999|NCT03173924|Small Molecule
798000|NCT03173924|Radiolabeled
798001|NCT03173924|18F-NaF-PET
798002|NCT03173924|Imaging
798003|NCT03173924|PMSA
798004|NCT03173911|Balance
798005|NCT03173911|Postural control
798006|NCT03173911|Elastic Bandages
798007|NCT03173911|Force plate
798008|NCT03173898|PDL Injection; Infiltration; Anesthesia; Extraction
798009|NCT03173872|Reiki
798010|NCT03173872|Chronic Pain
798011|NCT03173872|Military
798012|NCT03173859|prostate cancer, abiraterone, apalutamide
798013|NCT03173846|neurofeedback
798014|NCT03173846|episodic memory
798015|NCT03173846|real-time functional MRI
798016|NCT03173833|cancer patients, quality of life
798017|NCT03173820|tacrolimus
798018|NCT03173820|transplantation
798019|NCT03173820|CYP3A5
798020|NCT03173820|genotype
798021|NCT03173768|intravenous antibiotics
798022|NCT03173768|appropriateness
798023|NCT03173768|outpatient antimicrobial therapy
798024|NCT03173716|DEFINITY contrast
798025|NCT03173677|Mononuclear cells
798026|NCT03173677|Whey proteins
798027|NCT03173677|Metabolically-Activated Macrophage
798028|NCT03173677|Macrophage Polarization
798029|NCT03173677|Macronutrients
798030|NCT03173638|acute non arteritic anterior ischemic optic neuropathy
798031|NCT03173638|mesenchymal stem cells
798032|NCT03173638|intravitreal injection
798033|NCT03173638|safety
798034|NCT03173599|Chronic Hepatitis B
798035|NCT03173586|Sugar sweetened beverage, biomarker
798036|NCT03173573|Cystic Fibrosis
798037|NCT03173560|Renal Cell Carcinoma
798038|NCT03173560|lenvatinib
798039|NCT03173560|everolimus
798040|NCT03173560|E7080
798041|NCT03173560|VEGF-targeted treatment
798042|NCT03173508|right ventricular function
798043|NCT03173508|echocardiography
798044|NCT03173508|obstructive airway disease
798045|NCT03173508|emphysema
798046|NCT03173508|acetazolamide
798047|NCT03173508|altitude
798048|NCT03173495|fat metabolism
798049|NCT03173495|fructose
798050|NCT03173495|exercise
798051|NCT03173456|acute pain
798052|NCT03173456|musculoskeletal pain
798053|NCT03173456|emergency medicine
798054|NCT03173456|Emergency Service, Hospital
798055|NCT03173456|analgesics
798056|NCT03173456|Acetaminophen
798057|NCT03173456|Ibuprofen
798058|NCT03173456|oxycodone
798059|NCT03173456|hydrocodone
798060|NCT03173456|codeine
798061|NCT03173456|adult
798062|NCT03173443|Fiberoptic intubation
798063|NCT03173443|double lumen tube
798064|NCT03173391|GKA
798065|NCT03173391|T2DM
798066|NCT03173391|HMS5552
798067|NCT03173391|mono therapy
798068|NCT03173365|Hand-foot Syndrome
798069|NCT03173365|Brimonidine
798070|NCT03173365|Mirvaso
798071|NCT03173365|palmar-plantar erythrodysesthesia syndrome
798072|NCT03173365|Brimonidine Tartrate
798073|NCT03173352|Hemangioma
798074|NCT03173339|intubation
798075|NCT03173339|pharyngitis
798076|NCT03173339|remifentanil
798077|NCT03173313|Hypothermia
798078|NCT03173313|Acute Myocardial Infarction
798079|NCT03173313|AMI
798080|NCT03173313|PCI
798081|NCT03173313|Therapeutic Hypothermia
798082|NCT03173300|PMM2-CDG
798083|NCT03173300|CDG-Ia
798084|NCT03173287|Hepatic fibrosis
798085|NCT03173287|IVIM
798086|NCT03173287|1.5T MRI
798092|NCT03173209|school
798093|NCT03173196|severe sepsis
798094|NCT03173196|encephalopathy
798095|NCT03173170|Drug Therapy
798096|NCT03173144|Life Style
798097|NCT03173144|Diet
798098|NCT03173144|Food
798099|NCT03173144|Exercise
798100|NCT03173144|Treatment Outcome
798101|NCT03173144|Biomarkers
798102|NCT03173144|Smoking
798103|NCT03173105|Visually Impaired Persons
798104|NCT03173105|Postural Balance
798105|NCT03173105|Rehabilitation
798106|NCT03173105|Transcranial Direct Current Stimulation
798108|NCT03173053|S. aureus
798109|NCT03173053|Home Parenteral Nutrition
798110|NCT03173053|Intestinal failure
798111|NCT03173053|Eradication
798112|NCT03173053|Decolonization
798113|NCT03173040|Traditional Chinese medicine
798114|NCT03173040|Niu Bang Zi pill
798115|NCT03173040|methotrexate
798116|NCT03173040|active rheumatoid arthritis
798117|NCT03173001|intestinal helminths; protozoan infections;
798118|NCT03173001|colorectal cancer; chemotherapy; cancer pathogenesis;
798124|NCT03172975|Controlled infection
798125|NCT03172975|Na-GST-1
798126|NCT03172975|Hookworm vaccine
798127|NCT03172936|injected lesion
798128|NCT03172936|distal lesion
798129|NCT03172936|abscopal activity
798130|NCT03172936|intratumoral
798131|NCT03172936|checkpoint inhibitor
798132|NCT03172936|cyclic dinucleotide
798133|NCT03172936|programmed cell death
798134|NCT03172910|PER977
798135|NCT03172910|Ciraparantag
798136|NCT03172910|Whole Blood Clotting Time (WBCT)
798137|NCT03172910|Rivaroxaban
798138|NCT03172897|Adult
798139|NCT03172897|Intensive care unit
798140|NCT03172897|Mechanical ventilation
798141|NCT03172897|Delirium
798142|NCT03172897|Dexmedetomidine
798143|NCT03172884|Renal Impairment
798144|NCT03172884|Pharmacokinetics
798145|NCT03172871|Schizophrenia
798146|NCT03172871|Aripiprazole Intramuscular Depot
798147|NCT03172871|Acute treatment
798148|NCT03172858|cervical ripening
798149|NCT03172858|term premature rupture of membrane
798150|NCT03172858|intracervical balloon catheter
798151|NCT03172845|coronary bifurcation lesion
798152|NCT03172845|optical coherence tomography
798153|NCT03172845|vulnerable plaque
798154|NCT03172793|telavancin
798155|NCT03172793|lipoglycopeptide
798156|NCT03172793|MRSA
798157|NCT03172793|pharmacokinetics
798158|NCT03172767|Preterm
798159|NCT03172767|Sensory processing
798160|NCT03172767|School Readiness
798161|NCT03172741|Cannabis
798162|NCT03172715|Open reduction internal fixation
798163|NCT03172715|Arthroplasty
798164|NCT03172715|Surgery
798165|NCT03172715|Randomized controlled trial
798166|NCT03172663|obesity
798167|NCT03172624|Nivolumab
798168|NCT03172624|Ipilimumab
798169|NCT03172624|17-219
798170|NCT03172572|minimally invasive surgical procedures
798171|NCT03172572|pancreas surgery
798172|NCT03172572|pancreatoduodenectomy
798173|NCT03172559|Stereotactic body radiotherapy
798174|NCT03172559|SBRT
798175|NCT03172559|Radiotherapy
798176|NCT03172559|Bridging therapy
798177|NCT03172559|Transplant
798178|NCT03172546|direct oral anticoagulant
798179|NCT03172546|hemorrhagic complication
798180|NCT03172546|thrombotic complication
798181|NCT03172546|genetic polymorphisms
798182|NCT03172533|anorexia nervosa
798183|NCT03172533|estrogen
798184|NCT03172533|psychotherapy
798185|NCT03172533|cortisol
798186|NCT03172533|appetite regulation
798187|NCT03172533|neurocognitive performance
798188|NCT03172533|eating disorder
798189|NCT03172533|sexual hormone
798190|NCT03172520|Parotidectomy
798191|NCT03172507|Hematopoietic Stem Cells
798195|NCT03172429|pulmonary hypertension
798196|NCT03172429|cerebral tissue oxygenation
798197|NCT03172429|disease progression
798198|NCT03172429|hypoxia
798199|NCT03172416|Gastric Cancer
798200|NCT03172416|Unresectable Peritoneal Carcinomatosis
798201|NCT03172416|Oxaliplatin
798202|NCT03172416|Pressurized intraperitoneal aerosol chemotherapy
798203|NCT03172403|Cachexia
798204|NCT03172403|Colon cancer
798205|NCT03172403|Myostatin
798206|NCT03172403|Skeletal muscle
798207|NCT03172390|Ascending aorta aneurysm
798208|NCT03172390|Aortic wall shear stress
798209|NCT03172390|4D phase contrast Cardiovascular Magnetic Resonance
798210|NCT03172390|Aortic dissection
798211|NCT03172377|adalimumab
798212|NCT03172377|anti-TNF
798213|NCT03172377|Humira
798214|NCT03172377|interval lengthening
798215|NCT03172377|dosing interval
798216|NCT03172377|inflammatory bowel disease
798217|NCT03172377|antidrug antibodies
798218|NCT03172377|trough levels
798219|NCT03172377|pharmacokinetics
798220|NCT03172377|immunogenicity
798221|NCT03172377|cost-effectiveness
798222|NCT03172377|dose reduction
798223|NCT03172312|Intraoperative Parathyroid Scores System
798224|NCT03172312|total thyroidectomy
798225|NCT03172312|thyroid cancer
798226|NCT03172312|hypoparathyroidism
798227|NCT03172312|prediction
798228|NCT03172273|Liver Cirrhosis
798229|NCT03172273|Transjugular Intrahepatic Portosystemic shunt
798230|NCT03172273|Refractory ascites
798231|NCT03172247|cardiology diabetes
798232|NCT03172234|β-endorphins,laryngoscopy and tracheal intubation
798233|NCT03172221|malaria
798234|NCT03172221|pregnancy
798235|NCT03172221|diagnosis
798236|NCT03172221|low-transmission
798237|NCT03172221|Plasmodium falciparum
798238|NCT03172221|rapid diagnostic test
798239|NCT03172195|ulcerative colitis
798240|NCT03172195|inflammation
798241|NCT03172195|immunosuppressive drugs
798242|NCT03172195|herpesvirus
798243|NCT03172195|qPCR
798244|NCT03172195|colonic mucosa
798245|NCT03172156|NSCLC
798246|NCT03172156|stage I
798247|NCT03172156|The next generation of high-throughput gene sequencing (NGS)
798248|NCT03172156|ctDNA
798249|NCT03172130|Obstructive Sleep Apnea
798250|NCT03172130|CPAP
798251|NCT03172091|Lung transplant
798252|NCT03172091|Acute resection
798253|NCT03172091|Volatile Organic Compounds
798254|NCT03172078|advanced endoscopic procedure
798255|NCT03172078|ERCP
798256|NCT03172078|EUS
798257|NCT03172078|target-controlled infusion
798258|NCT03172078|sedation
798259|NCT03172078|propofol
798260|NCT03172039|hemodialysis
798261|NCT03172039|antimicrobial stewardship
798262|NCT03172039|antimicrobial agents
798263|NCT03172039|bacterial infections
798264|NCT03172039|ambulatory care
798265|NCT03172026|Telerehabilitation
798266|NCT03172026|Maraviroc
798270|NCT03171974|breast capsular contructure
798271|NCT03171961|weight loss
798272|NCT03171961|Diet
798273|NCT03171961|online visit
798274|NCT03171961|clinic visit
798275|NCT03171948|almond
798276|NCT03171948|weight loss
798277|NCT03171948|Weight maintenance
798278|NCT03171948|hypoenergetic diet
798279|NCT03171922|weight loss
798280|NCT03171922|internet-based diet
798281|NCT03171922|online dietary coach
798282|NCT03171922|clinic visit approach
798283|NCT03171922|Diet
798284|NCT03171792|Musculoskeletal pain
798285|NCT03171792|Adolescent
798286|NCT03171792|Qualitative research
798287|NCT03171792|Attitude
798288|NCT03171792|Health professionals
798289|NCT03171740|Emergence Delirium
798290|NCT03171740|Emergence Agitation
798291|NCT03171740|premedication
798292|NCT03171740|dexmedetomidine
798293|NCT03171740|midazolam
798294|NCT03171714|Drainage Catheter
798295|NCT03171688|Postoperative Nausea and Vomiting
798296|NCT03171688|cesarean
798297|NCT03171688|risk factors
798298|NCT03171675|Chronic Periodontitis
798299|NCT03171675|Preterm Labor
798300|NCT03171675|Preterm Birth
798301|NCT03171675|Interleukin-17
798302|NCT03171675|IL-17
798303|NCT03171675|Periodontal Disease
798304|NCT03171675|Periodontitis
798305|NCT03171675|Periodontal risk factors
798306|NCT03171675|Medical risk factors
798307|NCT03171649|rehabilitation
798308|NCT03171649|exoskeleton
798309|NCT03171649|functional electrical stimulation
798310|NCT03171649|upper limb
798311|NCT03171649|sub-acute
798312|NCT03171649|motor re-learning
798313|NCT03171623|T2DM
798314|NCT03171623|Diabetes
798315|NCT03171623|GKA
798316|NCT03171610|laparoscopic nephrectomy
798317|NCT03171610|Patient-controlled analgesia (PCA)
798318|NCT03171610|sufentanil
798319|NCT03171610|fentanyl
798320|NCT03171597|Unstable Angina
798321|NCT03171597|Traditional Chinese Medicine
798322|NCT03171571|eating Behavior
798323|NCT03171571|Volunteers
798324|NCT03171545|Peer Mentoring
798325|NCT03171545|Team Training
798326|NCT03171545|Checklist
798327|NCT03171532|ACL
798328|NCT03171519|Physical activity
798329|NCT03171519|Disorders of onset and maintenance of sleep
798330|NCT03171519|non-pharmacological treatment
798331|NCT03171519|Acupuncture
798332|NCT03171506|ketogenic diet
798333|NCT03171506|carbohydrate-restricted diet
798334|NCT03171493|Bladder cancer, Radical cystectomy
798335|NCT03171480|Preeclampsia
798336|NCT03171480|Induction
798337|NCT03171454|hysteroscopic operation
798338|NCT03171454|intrauterine balloon
798339|NCT03171454|adhesions
798340|NCT03171415|Obesity
798341|NCT03171415|Overweight
798342|NCT03171415|Thermogenesis
798343|NCT03171415|Fat reduction
798344|NCT03171389|GIST
798345|NCT03171389|KIT secondary mutation
798346|NCT03171389|ponatinib
798347|NCT03171376|Root canal treatment
798348|NCT03171376|Coronal leakage
798349|NCT03171376|Intraorifice barrier
798350|NCT03171363|Attention bias modification treatment
798351|NCT03171363|Anxiety disorders
798352|NCT03171363|Attention training
798353|NCT03171337|Chronic tension-type headache
798354|NCT03171337|Acupuncture
798355|NCT03171337|Fu's subcutaneous needling(FSN)
798356|NCT03171337|fMRI
798357|NCT03171337|Regional homogeneity (ReHo)
798358|NCT03171246|dietary intervention
798359|NCT03171220|Neoantigen
798360|NCT03171220|Neoantigen Reactive T cells (NRTs)
798361|NCT03171220|PD-1 Inhibitor
798362|NCT03171220|Advanced Solid Tumor
798363|NCT03171220|Adoptive Cell Therapy(ACT)
798364|NCT03171220|PD-1 antibody
798365|NCT03171220|SHR1210
798366|NCT03171207|Gait Therapy
798367|NCT03171194|Lupus
798368|NCT03171194|Stem Cell
798369|NCT03171194|Systemic Lupus Erythematosus
798370|NCT03171181|Spatial cognition, vestibular system, motor control
798371|NCT03171168|Gait Analysis
798372|NCT03171168|WOMAC
798373|NCT03171168|SF-36
798374|NCT03171142|Heliox
798375|NCT03171129|Respiratory Distress
798376|NCT03171129|Nasal CPAP
798377|NCT03171129|high flow nasal canula
798378|NCT03171116|ghrelin
798379|NCT03171116|obestatin
798380|NCT03171116|children
798381|NCT03171064|Exercise
798382|NCT03171064|Cancer
798383|NCT03171064|Melanoma
798384|NCT03171064|Feasibility
798385|NCT03171064|PD-1 antibodies
798386|NCT03171064|Checkpoint inhibitors
798387|NCT03171064|Immune system
798388|NCT03171038|Telemonitoring
798389|NCT03171038|Chronic Heart Failure
798390|NCT03171038|eHealth
798391|NCT03171038|Mortality
798392|NCT03171025|Muscle Invasive
798393|NCT03171012|Muscle Stretching Exercises
798394|NCT03170999|China
798395|NCT03170999|Cognitive testing
798396|NCT03170999|COPD exacerbation
798397|NCT03170999|CERT
798398|NCT03170973|Obesity
798399|NCT03170973|Motor Activity
798400|NCT03170973|Fatty acids
798401|NCT03170973|Lipid
798402|NCT03170960|Kidney
798403|NCT03170960|Bladder
798404|NCT03170960|Renal pelvis
798405|NCT03170960|Ureter
798406|NCT03170960|Urethra
798407|NCT03170960|Cancer
798408|NCT03170947|Rheumatoid arthritis
798409|NCT03170947|Foot
798410|NCT03170947|Insoles
798411|NCT03170947|Quality of life
798412|NCT03170947|Physical Activity
798413|NCT03170895|FLT3-ITD (+) Acute Myeloid Leukemia (AML)
798414|NCT03170882|Drug therapy
798415|NCT03170778|Congenital Heart Disease
798416|NCT03170778|CHD
798417|NCT03170778|Fontan
798418|NCT03170752|RCT, Cardiovascular Risk Factors, Screening
798419|NCT03170739|dexmedetomidine
798420|NCT03170739|dopamine
798421|NCT03170739|surgery
798422|NCT03170726|Preemptive intravenous ibuprofen
798423|NCT03170726|Intraoperative analgesia
798424|NCT03170726|Third molar tooth surgery
798425|NCT03170713|Preemptive intravenous ibuprofen
798426|NCT03170713|trismus
798427|NCT03170713|edema
798428|NCT03170713|Third molar tooth extraction
798429|NCT03170713|Antiinflammatory effect
798430|NCT03170700|preschool
798431|NCT03170700|eating behaviors
798432|NCT03170700|family
798433|NCT03170648|Acupuncture
798434|NCT03170648|Breast Cancer
798435|NCT03170635|recess, occupational therapy
798436|NCT03170622|children
798437|NCT03170622|paediatrics
798438|NCT03170622|faecal volitile organic compounds
798439|NCT03170622|diagnosis
798440|NCT03170622|pathogenesis
798441|NCT03170583|bradycardia, pacemaker, MRI scan
798442|NCT03170570|recurrent cervical cancer
798443|NCT03170570|re-irradiation
798444|NCT03170570|intensity-modulated raditherapy
798445|NCT03170557|Persistent pain
798446|NCT03170557|Spinal cord injury
798447|NCT03170557|Acupuncture
798448|NCT03170557|Randomized Controlled Trial
798449|NCT03170557|RCT
798450|NCT03170531|MRI
798451|NCT03170531|MR imaging
798452|NCT03170531|17-267
798453|NCT03170505|cleft palate
798454|NCT03170466|Palliative care
798455|NCT03170453|Autism
798456|NCT03170453|Autism Spectrum Disorder
798457|NCT03170453|Asperger's Syndrome
798458|NCT03170453|Pervasive Developmental Disorder
798459|NCT03170453|Cognition
798460|NCT03170453|Social Cognition
798461|NCT03170453|Psychosocial Treatment
798462|NCT03170453|Cognitive Enhancement Therapy
798463|NCT03170453|Enriched Supportive Therapy
798464|NCT03170453|Therapy
798465|NCT03170453|Psychotherapy
798466|NCT03170440|Sleep
798467|NCT03170440|Vagal nerve stimulation
798468|NCT03170414|HIV
798469|NCT03170414|Kidney Transplant
798470|NCT03170414|Liver Transplant
798471|NCT03170414|Transplant
798472|NCT03170414|HOPE Act
798473|NCT03170375|obesity
798474|NCT03170375|sodium
798475|NCT03170375|DASH diet
798476|NCT03170375|hypertension
798477|NCT03170375|vascular stiffness
798478|NCT03170375|diastolic function
798479|NCT03170362|Treatment
798480|NCT03170362|Pharmacogenetics
798481|NCT03170362|Depression
798482|NCT03170271|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
798483|NCT03170271|Additional relevant MeSH terms:
798484|NCT03170271|Asthma
798485|NCT03170271|Inflammation
798486|NCT03170271|Bronchial Diseases
798487|NCT03170271|Respiratory Tract Diseases
798488|NCT03170271|Lung Diseases, Obstructive
798489|NCT03170271|Lung Diseases Respiratory Hypersensitivity
798490|NCT03170271|Hypersensitivity, Immediate
798491|NCT03170271|Hypersensitivity
798492|NCT03170271|Immune System Diseases
798493|NCT03170271|Pathologic Processes
798494|NCT03170258|real-time fMRI
798495|NCT03170258|reward
798496|NCT03170258|motivation
798497|NCT03170258|dopamine
798498|NCT03170232|HRQoL
798499|NCT03170232|Disease Progression
798500|NCT03170232|Danirixin
798501|NCT03170232|COPD
798502|NCT03170206|Lung Cancer
798503|NCT03170141|CAR T
798504|NCT03170141|EGFRviii
798505|NCT03170141|GBM
798506|NCT03170141|PDL1
798507|NCT03170141|PD1
798508|NCT03170115|Rectal Cancer
798509|NCT03170115|Total neoadjuvant therapy
798510|NCT03170115|Induction chemotherapy
798511|NCT03170115|Aspirin colorectal cancer
798512|NCT03170102|occupational therapy
798513|NCT03170089|oral-health-awareness, Diabetes
798514|NCT03170076|skin manifestations - hepatitis c virus
798515|NCT03170063|Parkinson's Disease
798516|NCT03170063|Alpha-Synuclein
798517|NCT03170063|Biomarker
798518|NCT03170011|Cardiac rehabilitation
798519|NCT03170011|Sit to Stand
798520|NCT03170011|Function
798521|NCT03169985|Rosuvastatin
798522|NCT03169985|Ezetimibe
798523|NCT03169985|Atherosclerotic plaque
798524|NCT03169985|Intravascular ultrasound
798525|NCT03169959|Anti-diabetic
798526|NCT03169959|Anti-hyperglycemic agents
798527|NCT03169959|Bioequivalence
798528|NCT03169959|Fixed-Combination Drug Product (FCDP) of saxagliptin / dapagliflozin / metformin extended-release (XR).
798529|NCT03169959|Fed-state bioequivalence (BE)
798530|NCT03169959|XIGDUO® XR
798531|NCT03169959|ONGLYZA®
798538|NCT03169907|Cardiac functions
798539|NCT03169907|Intrauterine fetal anemia
798540|NCT03169907|Intrauterine Fetal blood transfusion
798541|NCT03169907|Myocardial performance index
798542|NCT03169907|spatiotemporal imaging correlation
798543|NCT03169868|clinical decision support
798544|NCT03169868|drug levels in blood
798545|NCT03169868|therapeutic drug monitoring
798546|NCT03169868|medication adherence
798547|NCT03169868|medication therapy management
798548|NCT03169855|Traffic Ophthalmology
798549|NCT03169855|Glare
798550|NCT03169855|Cataract
798551|NCT03169855|Nighttime driving
798552|NCT03169855|contrast sensitivity
798553|NCT03169855|mesopic vision
798554|NCT03169829|Hemodialysis
798555|NCT03169829|Renal Disease
798556|NCT03169803|Electrical Stimulation Therapy
798557|NCT03169803|Electrodes
798558|NCT03169803|Parasympathetic Nervous System
798559|NCT03169803|Sympathetic Fibers
798560|NCT03169803|Post Ganglionic
798561|NCT03169803|Congestive Heart Failure
798562|NCT03169803|Heart Failure
798563|NCT03169673|Magnetic Resonance Imaging
798564|NCT03169673|Pulmonary Function
798565|NCT03169634|Failed knee replacement
798566|NCT03169634|loosening
798567|NCT03169634|wear
798568|NCT03169634|reoperation
798569|NCT03169621|Chronic Endometritis
798570|NCT03169621|Endometrial pathogens
798571|NCT03169621|Microbiological diagnosis
798572|NCT03169621|Next Generation Sequencing
798573|NCT03169621|Metagenomics
798574|NCT03169621|Endometrial receptivity
798575|NCT03169608|autonomic nervous system
798576|NCT03169608|atrial fibrillation
798577|NCT03169608|acute kidney injury
798578|NCT03169608|baroreflex sensitivity
798579|NCT03169608|microcirculation
798580|NCT03169608|coronary artery bypass graft
798581|NCT03169569|hemostatic powder
798582|NCT03169569|post-ESD bleeding
798583|NCT03169569|antithrombotic therapy
798584|NCT03169569|high risk of bleeding
798585|NCT03169569|endoscopic submucosal dissection
798586|NCT03169569|adverse event
798587|NCT03169556|Intubation
798588|NCT03169556|light wand
798589|NCT03169556|video laryngoscopy
798590|NCT03169556|cervical spine immobilization
798591|NCT03169530|cardiovascular, alcohol, diabetes
798592|NCT03169517|Peripheral nerve block
798593|NCT03169517|laser speckle contrast imaging
798594|NCT03169517|blood flow index
798595|NCT03169504|Pulmonary Disease, Chronic Obstructive
798596|NCT03169504|Acupuncture Therapy
798597|NCT03169504|Humans
798598|NCT03169491|Sleep Apnea, Obstructive
798599|NCT03169491|Child
798600|NCT03169491|Continuous Positive Airway Pressure
798601|NCT03169491|Perioperative management
798602|NCT03169491|Adenotonsillectomy
798603|NCT03169491|Acoustic pharyngometry
798604|NCT03169478|hysteroscopic myomectomy
798605|NCT03169478|balloon dilatation
798606|NCT03169478|adhesions
798607|NCT03169426|remote ischemic conditioning
798608|NCT03169426|beta-blocker
798609|NCT03169400|vascular calcification
798610|NCT03169400|haemodialysis
798611|NCT03169400|dialysis membrane
798612|NCT03169387|Virtual Reality Exposure Therapy
798613|NCT03169374|Virtual Reality
798614|NCT03169374|Mechanical Ventilation
798615|NCT03169374|Anxiety
798616|NCT03169309|complementary and alternative medicine
798617|NCT03169309|military
798618|NCT03169309|binaural beat technology
798619|NCT03169309|brain entrainment technology
798620|NCT03169309|sleep
798621|NCT03169296|Myelodysplastic syndrome
798622|NCT03169296|Mutations
798623|NCT03169296|Next-generation sequencing
798624|NCT03169270|Exercise training
798625|NCT03169270|Muscle dysfunction
798626|NCT03169270|COPD
798627|NCT03169257|paediatric obesity
798628|NCT03169257|cardiovascular dysfunction
798629|NCT03169257|metabolic syndrome
798630|NCT03169257|adipokines
798631|NCT03169257|inflammation
798632|NCT03169257|oxidative stress
798633|NCT03169218|Adult
798634|NCT03169218|Chronic pain
798635|NCT03169218|Entrapment neuropathy. Carpal tunnel
798636|NCT03169218|Exercise therapy
798637|NCT03169218|Humans
798638|NCT03169218|Neuronal plasticity
798639|NCT03169218|Mirror neurons
798640|NCT03169218|Pain/cognitive aspects
798641|NCT03169218|Physiotherapy
798642|NCT03169218|Somatosensory cortex
798643|NCT03169179|Physical activity
798644|NCT03169179|Mobile health
798645|NCT03169179|Wearable fitness technology
798646|NCT03169179|Organisational wellness
798647|NCT03169179|Occupational health
798648|NCT03169179|Police force
798649|NCT03169166|GnRH agonist
798650|NCT03169166|In Vitro fertilization
798651|NCT03169166|Assisted Reproductive Technology
798652|NCT03169166|Follicule Maturation
798653|NCT03169166|Pregnancy
798657|NCT03169140|pain management
798658|NCT03169140|topical analgesic
798659|NCT03169140|acute low back pain
798660|NCT03169140|kinesiology tape
798661|NCT03169127|Ibuprofen
798662|NCT03169127|Lower third molar
798663|NCT03169127|Oral Surgery
798664|NCT03169114|Appendicitis
798665|NCT03169114|Surgery
798666|NCT03169114|Antibiotic therapy
798667|NCT03169114|RIPASA Score
798668|NCT03169101|Smoking Cessation
798669|NCT03169101|HIV
798670|NCT03169101|Cognition
798671|NCT03169088|eating Behavior
798672|NCT03169088|Volunteers
798673|NCT03169075|Adapted physical ctivity
798674|NCT03169075|Oral targeted thérapy
798675|NCT03169075|Advanced cancer
798676|NCT03169075|Fatigue
798677|NCT03169075|Quality of life
798678|NCT03169075|Randomized Study
798679|NCT03169049|nerve conduction block
798680|NCT03169049|high frequency stimulation
798681|NCT03169049|handgrip
798682|NCT03169010|registry
798683|NCT03169010|pulmonary hypertension
798684|NCT03169010|survival
798685|NCT03169010|biomarker
798686|NCT03169010|whole genome sequencing
798687|NCT03168997|Alzheimer Disease Memantine
798688|NCT03168984|Healthy Japanese subjects
798689|NCT03168984|Healthy Caucasian subjects
798690|NCT03168984|UCB0942
798691|NCT03168971|Cancer
798692|NCT03168971|Anxiety
798693|NCT03168971|Cognitive behavior therapy
798694|NCT03168971|Elderly
798695|NCT03168971|Caregivers
798696|NCT03168945|Active Case Finding
798697|NCT03168906|Amyloidosis
798698|NCT03168906|NEOD001
798699|NCT03168906|RAIN
798700|NCT03168893|deep brain stimulation
798701|NCT03168867|insulin dependent diabetes mellitus
798702|NCT03168867|adolescents/young adults
798703|NCT03168867|e-health intervention
798704|NCT03168867|parental monitoring
798705|NCT03168854|Anopheles stephensi
798706|NCT03168854|GAP3KO
798707|NCT03168854|Malaria
798708|NCT03168854|Mosquitoes
798709|NCT03168854|Plasmodium falciparum
798710|NCT03168815|HFNC
798711|NCT03168815|Bronchoscopy
798712|NCT03168815|Hypoxia
798713|NCT03168815|Immunocompromised
798714|NCT03168815|Hematological malignancy
798719|NCT03168789|Breathing Awareness Meditation,
798720|NCT03168776|Drug-eluting stent
798721|NCT03168763|Malignant neoplasms of independent (primary) multiple sites
798722|NCT03168763|Advanced Cancer
798723|NCT03168763|Videos
798724|NCT03168763|Questionnaires
798725|NCT03168763|Surveys
798726|NCT03168737|Malignant neoplasms of independent (primary) multiple sites
798727|NCT03168737|Solid tumors
798728|NCT03168737|PET-CT
798729|NCT03168737|18F-fluoroazomycin arabinoside
798730|NCT03168737|18F-FAZA
798731|NCT03168724|Cognition
798732|NCT03168724|Intervention
798733|NCT03168724|Self-management
798734|NCT03168724|Rehabilitation
798735|NCT03168711|ALS
798736|NCT03168711|Inosine
798737|NCT03168711|Uric acid
798738|NCT03168711|Urate
798739|NCT03168711|Glutathione
798740|NCT03168711|Biomarker
798741|NCT03168711|Oxidative stress
798742|NCT03168711|Oxidative damage
798743|NCT03168698|pregnancy
798744|NCT03168698|postpartum hemorrhage
798745|NCT03168698|cesarean delivery
798746|NCT03168698|carbetocin
798747|NCT03168698|duratocin
798748|NCT03168698|oxytocin
798749|NCT03168685|smartphones
798750|NCT03168685|clinical trials
798751|NCT03168685|weight
798752|NCT03168685|actigraph
798753|NCT03168685|tracking
798754|NCT03168685|hemophilia
798755|NCT03168633|: Type 2 Diabetes Mellitus
798756|NCT03168633|Web-based intervention
798757|NCT03168633|medication adherence
798758|NCT03168633|lifestyle changes
798759|NCT03168607|ORR
798760|NCT03168607|OS
798761|NCT03168607|PFS
798762|NCT03168607|safety
798763|NCT03168594|chemotherapy
798764|NCT03168594|OS
798765|NCT03168594|ORR
798766|NCT03168594|PFS
798767|NCT03168594|safety
798768|NCT03168529|Acute Heart Failure
798769|NCT03168529|Observation
798770|NCT03168529|Ivabradine
798771|NCT03168516|Oxygen
798772|NCT03168516|closed-loop automatic control
798773|NCT03168516|Oxygen saturation
798774|NCT03168516|preterm infants
798775|NCT03168451|text messaging
798786|NCT03168412|Hepatitis E
798787|NCT03168399|Phenylketonuria
798788|NCT03168399|PKU
798789|NCT03168399|Metabolism
798790|NCT03168399|Metabolic
798791|NCT03168399|Control
798792|NCT03168399|Acceptability
798793|NCT03168347|Decision making
798794|NCT03168269|CCTA interpretation
798795|NCT03168269|technicians
798796|NCT03168269|experts
798797|NCT03168269|comparison
798799|NCT03168217|Periodontitis
798800|NCT03168217|classification
798801|NCT03168217|Cluster analysis
798802|NCT03168139|Metastatic colorectal cancer
798803|NCT03168139|Metastatic pancreatic cancer
798804|NCT03168139|NOX-A12
798805|NCT03168139|Olaptesed pegol
798806|NCT03168139|Spiegelmer
798807|NCT03168139|Pembrolizumab
798808|NCT03168139|PD-1 inhibitor
798809|NCT03168139|Stromal cell-derived factor-1 (SDF-1)
798810|NCT03168139|CXCL12
798811|NCT03168139|Tumor microenvironment
798812|NCT03168139|Immunotherapy
798813|NCT03168139|Checkpoint inhibition
798814|NCT03168113|skin barrier function
798815|NCT03168113|microbiome
798816|NCT03168113|transepidermal water loss (TEWL)
798817|NCT03168113|epidermal transcriptome
798818|NCT03168113|epidermal lipid composition
798819|NCT03168061|advanced solid tumor
798820|NCT03168061|unresectable soft tissue sarcoma
798821|NCT03168048|mobile application
798822|NCT03168048|radiotherapy
798823|NCT03168048|patient-care
798824|NCT03168048|mhealth
798825|NCT03168048|follow-up
798826|NCT03168048|patient satisfaction
798827|NCT03168048|quality of life
798828|NCT03168009|BAT
798829|NCT03168009|Bariatric Surgery
798830|NCT03168009|Energy Metabolism
798831|NCT03167996|South Asian
798832|NCT03167996|Cardiovascular Risk Reduction
798833|NCT03167996|Metabolic Disorders
798834|NCT03167996|Lifestyle modifications
798835|NCT03167957|fluconazole
798836|NCT03167957|fluconazole-resistant
798837|NCT03167944|Mastectomy
798838|NCT03167944|Seroma
798839|NCT03167931|non-invasive brain stimulation
798840|NCT03167931|neuromodulation
798841|NCT03167931|semantic tasks
798842|NCT03167918|calcium dobesilate
798843|NCT03167918|Xuefuzhuyu Decoction
798844|NCT03167918|pulmonary function
798845|NCT03167905|Anesthesia, Obstetrical
798846|NCT03167905|Epidural anesthesia
798847|NCT03167905|Postnatal depression
798848|NCT03167905|Persistent pain
798849|NCT03167879|family planning
798850|NCT03167879|safer conception
798851|NCT03167879|HIV
798852|NCT03167879|serodiscordant couples
798853|NCT03167879|Uganda
798854|NCT03167879|contraception
798855|NCT03167840|falls prevention, older adults, mild cognitive impairment
798856|NCT03167827|pelvic floor
798857|NCT03167827|climateric
798858|NCT03167827|exercise
798859|NCT03167827|Supplementation of Isoflavone
798860|NCT03167801|tetraplegia
798861|NCT03167801|spinal cord injury
798862|NCT03167801|melatonin
798863|NCT03167801|sleep quality
798864|NCT03167801|sleepiness
798865|NCT03167723|Chest tube size
798866|NCT03167723|Hemothorax
798867|NCT03167723|Empyema
798868|NCT03167697|Phenylketonuria
798869|NCT03167697|Hyperphenylalaninaemia
798870|NCT03167697|Inherited Metabolic Disorders
798871|NCT03167671|Oswestry
798872|NCT03167671|SF 36
798873|NCT03167671|Promis Pain and Function
798874|NCT03167671|Berg Balance
798875|NCT03167658|Wellness
798876|NCT03167658|Prevention
798877|NCT03167619|Mestastic
798878|NCT03167619|Platinum Sensitive
798879|NCT03167619|Advanced
798880|NCT03167619|PARP inhibitor
798881|NCT03167606|myPEEPS
798882|NCT03167606|Mobile Intervention
799017|NCT03166566|glaucoma surgery
798883|NCT03167606|Human Immunodeficiency Virus (HIV)
798884|NCT03167606|Men who have sex with men (MSM)
798885|NCT03167593|Lactobacillus coryniformis
798886|NCT03167593|Flu
798887|NCT03167593|Vaccine
798888|NCT03167528|Pain
798889|NCT03167528|Quality of life
798890|NCT03167476|miRNA
798891|NCT03167476|biomarker
798899|NCT03167424|In-stent restenosis
798900|NCT03167424|Bioresorbable vascular scaffold
798901|NCT03167424|Coronary angiography
798902|NCT03167398|fecal microbiota transplantation
798903|NCT03167398|carbapenem-resistant enterobacteriaceae
798904|NCT03167398|multidrug resistant bacteria
798905|NCT03167398|carrier
798906|NCT03167385|locally advanced differentiated thyroid carcinoma
798907|NCT03167385|radioiodine refractory thyroid carcinoma
798908|NCT03167372|Light Therapy
798909|NCT03167372|N-of-1
798910|NCT03167359|Psychiatry
798911|NCT03167359|Radiation Therapy
798912|NCT03167346|stroke
798913|NCT03167346|core symptoms
798914|NCT03167346|public awareness
798915|NCT03167346|FAST
798916|NCT03167307|omega-3 fatty acids
798917|NCT03167307|eicosapentaenoic acid
798918|NCT03167307|docosahexaenoic acid
798919|NCT03167307|antidepressants
798920|NCT03167307|suicidality
798921|NCT03167307|cognition
798922|NCT03167307|childhood depression
798923|NCT03167307|pediatric depression
798924|NCT03167281|Chest tube
798925|NCT03167281|Thoracostomy
798926|NCT03167281|Pleural Diseases
798927|NCT03167281|Lung Neoplasms
798928|NCT03167281|Pulmonary Embolism
798929|NCT03167281|Pneumothorax
798930|NCT03167281|Thoracic Surgery
798931|NCT03167281|Deoxyribonucleases
798932|NCT03167281|Fibrinolytic Agents
798933|NCT03167281|Drainage
798934|NCT03167281|Pleural Effusion
798935|NCT03167268|Lycopene
798936|NCT03167268|Anti EGFR therapy
798937|NCT03167229|Tenofovir
798938|NCT03167229|Hepatitis B
798939|NCT03167216|chronic pain
798940|NCT03167216|prostatitis
798941|NCT03167216|pelvic pain
798942|NCT03167203|hESC-RPE
798943|NCT03167203|Macular Degenerative Disease
798944|NCT03167190|Point of Care Ultrasound
798945|NCT03167151|Recurrent intermediate risk NMIBC
798946|NCT03167151|Intravesical Pembrolizumab
798947|NCT03167151|Intravenous Pembrolizumab
798948|NCT03167151|Phase I/II
798949|NCT03167151|Marker-lesion
798950|NCT03167151|Non-muscle invasive bladder cancer (NMIBC)
798951|NCT03167138|Shoulder pain
798952|NCT03167138|Rotator cuff disease
798953|NCT03167138|Spinal cord injuries
798954|NCT03167138|Mesenchymal stromal cells
798955|NCT03167138|Regenerative medicine
798956|NCT03167138|Rehabilitation
798957|NCT03167125|colorectal cancer screening
798958|NCT03167125|cancer screening
798959|NCT03167125|pragmatic trial
798960|NCT03167125|boot camp translation
798961|NCT03167112|Potentially Curable
798962|NCT03167112|Preoperative
798963|NCT03167112|FOLFIRINOX
798964|NCT03167073|smart-phone application
798965|NCT03167073|low-income women
798966|NCT03167073|breastfeeding
798967|NCT03167073|health education
798968|NCT03167073|health disparities
798969|NCT03167034|exercise
798970|NCT03167034|echocardiography
798971|NCT03167034|right ventricular function
798972|NCT03167034|obstructive airway disease
798973|NCT03167034|emphysema
798974|NCT03167034|acetazolamide
798975|NCT03167034|altitude
798976|NCT03167021|Cannabis
798977|NCT03167021|Community pharmacy
798978|NCT03167021|Prevention
798979|NCT03167021|Students
798980|NCT03166995|Fibromyalgia,postural exercises
798981|NCT03166982|Tubo-ovarian abscess
798982|NCT03166982|Transvaginal drainage
798983|NCT03166982|Laparoscopic treatment
798984|NCT03166956|Vitamin C
798985|NCT03166956|Glutamine
798986|NCT03166956|Interleukin-6
798987|NCT03166956|Clinical outcomes
798988|NCT03166930|Muscle Spasticity
798989|NCT03166930|Muscle Stretching Exercises
798990|NCT03166891|ovarian cancer, relapsed or refractory,chiauranib
798997|NCT03166865|osteoarthritis (OA)
798998|NCT03166865|mesenchymal stem cells(MSC)
798999|NCT03166839|maternal health
799000|NCT03166839|statistical analysis plan
799001|NCT03166813|remote ischaemic preconditioning
799002|NCT03166813|childhood cancer
799003|NCT03166813|cardio-oncology
799004|NCT03166813|anthracycline
799005|NCT03166813|myocardial reperfusion injury
799006|NCT03166800|mitoquinone
799007|NCT03166800|Fatigue
799008|NCT03166800|Multiple Sclerosis
799009|NCT03166748|Incomplete lower first molar
799010|NCT03166748|Immature permanent molar
799011|NCT03166748|Potassium nitrate in polycarboxylate
799012|NCT03166748|Mineral trioxide aggregate .Mineral trioxid
799013|NCT03166644|Analgesia Nociception Index (ANI)
799014|NCT03166644|Postoperative Analgesia
799015|NCT03166644|Postoperative Hypoxemia
799016|NCT03166566|glaucoma
799018|NCT03166566|glaucoma drainage device
799019|NCT03166566|glaucoma implant
799020|NCT03166566|blindness
799021|NCT03166540|coffee
799022|NCT03166540|cocoa
799023|NCT03166540|bioavailability
799024|NCT03166540|pharmacokinetics
799025|NCT03166540|cardiometabolic risk factors
799026|NCT03166540|caffeoylquinic acids
799027|NCT03166540|flavan-3-ol
799028|NCT03166540|caffeine
799029|NCT03166540|trigonelline
799030|NCT03166540|diterpene
799031|NCT03166449|Traumatic Brain injury
799032|NCT03166449|Immunonutrition
799033|NCT03166384|electrosurgical bipolar sealing devices, breast cancer
799034|NCT03166371|Endocrinology
799035|NCT03166371|Nutrition
799036|NCT03166371|Aging
799037|NCT03166332|Mindfulness
799038|NCT03166332|Mediterranean diet
799039|NCT03166332|Neurodevelopment
799040|NCT03166332|Epigenetics
799041|NCT03166332|Fetal growth restriction
799042|NCT03166306|pulmonary vascular disease
799043|NCT03166306|pulmonary vascular imaging
799044|NCT03166293|Cerebral Palsy
799045|NCT03166293|Physical Therapy
799046|NCT03166293|Rehabilitation
799047|NCT03166280|hepatitis C
799048|NCT03166280|vitamin D
799049|NCT03166280|iron
799050|NCT03166280|hepcidin
799052|NCT03166202|age-related macular degeneration
799053|NCT03166189|Repeated IVF failure
799054|NCT03166189|Stem cell
799055|NCT03166163|bleeding on brushing
799056|NCT03166150|Urinary Incontinence, pelvic floor muscle training
799057|NCT03166137|Warts,Laser,Cryotherapy
799058|NCT03166098|Psychotic Spectrum Disorders
799059|NCT03166085|HER2-Negative
799060|NCT03166085|PU-H71
799061|NCT03166085|Nab-paclitaxel (Abraxane)
799062|NCT03166085|17-093
799063|NCT03166072|Low-vision
799064|NCT03166072|health related quality of life
799065|NCT03166072|visual aids
799066|NCT03166072|randomized controlled trial
799067|NCT03166059|Catheter directed thrombolysis (CDT)
799068|NCT03166033|Carpal Tunnel Syndrome
799069|NCT03166033|etiology
799070|NCT03166033|risk factor
799071|NCT03166020|Serious Game
799072|NCT03166020|Stroke
799073|NCT03166020|Rehabilitation
799074|NCT03166020|Connected objects
799075|NCT03166007|Multiple Sclerosis
799076|NCT03166007|Neurogenic Bowel Dysfunction
799077|NCT03166007|Abdominal massage
799078|NCT03165994|esophagus
799079|NCT03165994|gastroesoophageal (GE) junction
799080|NCT03165994|T1-3N0-1
799081|NCT03165981|Influenza vaccine
799082|NCT03165981|fever following vaccination
799083|NCT03165981|PCV13 vaccine
799084|NCT03165981|DTaP vaccine
799085|NCT03165981|pneumococcal vaccine
799086|NCT03165955|breast cancer
799087|NCT03165955|paclitaxel
799088|NCT03165929|free gingival grafts
799089|NCT03165929|connective tissue grafts
799090|NCT03165929|flurbiprofen
799091|NCT03165890|cognition
799092|NCT03165890|visuomotor learning
799093|NCT03165890|airway disease
799094|NCT03165890|altitude
799095|NCT03165890|prevention
799096|NCT03165890|acetazolamide
799097|NCT03165877|GLYCEMIC INDEX
799098|NCT03165877|NAFLD
799099|NCT03165877|METABOLIC PARAMETERS
799100|NCT03165877|SATIETY
799101|NCT03165864|Thalassaemia, IONIS TMPRSS6-Lrx
799102|NCT03165838|postpartum
799103|NCT03165838|pregnancy
799104|NCT03165838|contraception
799105|NCT03165838|RROP
799106|NCT03165812|Sleeve Gastrectomy
799107|NCT03165812|Duodeno Jejunal Bypass
799108|NCT03165812|Single Anastomosis
799109|NCT03165812|Intensive Medical Therapy
799110|NCT03165812|Diabetes Mellitus
799111|NCT03165786|fear of hypoglycemia
799112|NCT03165786|self-management
799113|NCT03165786|glycemic control
799114|NCT03165786|glycemic variability
799115|NCT03165760|protective mechanical ventilation
799118|NCT03165734|myelofibrosis
799119|NCT03165734|pacritinib
799120|NCT03165734|Post-polycythemia Vera Myelofibrosis
799121|NCT03165734|Post-essential Thrombocythemia Myelofibrosis
799122|NCT03165734|Ruxolitinib
799123|NCT03165734|Bone Marrow Disease
799124|NCT03165734|Hematologic Diseases
799125|NCT03165734|Blood Platelet Disorders
799126|NCT03165734|Hemorrhagic Disorders
799127|NCT03165734|Splenomegaly
799128|NCT03165734|Anemia
799129|NCT03165734|Spleen volume
799130|NCT03165734|Spleen
799136|NCT03165708|Epidural technique
799137|NCT03165695|Delirium
799138|NCT03165695|Insomnia
799139|NCT03165695|Ramelteon
799140|NCT03165682|fatigue
799141|NCT03165682|depression
799142|NCT03165682|cortical excitability
799143|NCT03165669|education
799144|NCT03165669|sleep
799145|NCT03165669|pillow
799146|NCT03165669|neck
799147|NCT03165656|Echocardiography
799148|NCT03165656|right ventricular function
799149|NCT03165656|pulmonary hypertension
799150|NCT03165656|disease progression
799151|NCT03165656|hypoxia
799152|NCT03165617|Influenza vaccine
799153|NCT03165604|Physical fitness
799154|NCT03165604|Exercise
799155|NCT03165604|Childhood Obesity
799156|NCT03165604|Information
799157|NCT03165539|Postoperative
799158|NCT03165539|One-lung ventilation
799159|NCT03165539|Cerebral oximetry
799160|NCT03165539|Cerebral desaturation
799161|NCT03165513|Traditional healer
799162|NCT03165513|faith healer
799163|NCT03165513|depression
799164|NCT03165513|mhGAP
799165|NCT03165513|Kenya
799166|NCT03165500|Exodontia
799167|NCT03165500|Sedation
799168|NCT03165500|Nitrous Oxide
799169|NCT03165500|Benzodiazepines
799170|NCT03165487|Triple Negative Breast Cancer
799171|NCT03165487|microenvironment
799172|NCT03165487|IORT
799173|NCT03165487|Hormone Receptor Positive, HER 2 negative
799174|NCT03165474|childhood obesity
799175|NCT03165474|mhealth
799176|NCT03165474|digital health
799177|NCT03165474|nutrition
799178|NCT03165474|intervention
799179|NCT03165461|intubation to supraglottic devices
799180|NCT03165461|intubating laryngeal tube
799181|NCT03165448|oral surgery
799182|NCT03165448|psychology
799183|NCT03165448|fear
799184|NCT03165448|pain
799185|NCT03165448|dentistry
799186|NCT03165396|mild cognitive impairment
799187|NCT03165383|Transverse Abdominis Plane (TAP) Block
799188|NCT03165383|Patient Control Analgesia (PCA)
799189|NCT03165357|Crossfit
799190|NCT03165357|Sodium bicarbonate
799191|NCT03165357|Physical capacity
799192|NCT03165318|Pulsed electromagnetic field
799193|NCT03165318|Anterior cruciate ligament reconstruction
799194|NCT03165318|Muscle
799195|NCT03165253|Helicobacter pylori infection
799196|NCT03165253|Children
799197|NCT03165253|Synbiotic
799198|NCT03165253|Standard Triple Therapy
799199|NCT03165201|Liver transplantation and Biopsy
799200|NCT03165201|Liver transplantation and LiverMultiScan
799201|NCT03165175|prescription drug abuse
799202|NCT03165175|prescription drug misuse
799203|NCT03165175|risk reduction
799204|NCT03165175|education
799205|NCT03165175|military
799206|NCT03165175|mobile application
799207|NCT03165175|substance misuse
799208|NCT03165175|substance abuse
799209|NCT03165162|natural
799210|NCT03165162|Food Label Choices
799211|NCT03165136|Unexplained Recurrent Miscarriage
799212|NCT03165136|First trimester abortion
799213|NCT03165136|Hydroxychloroquine
799214|NCT03165136|Antiphospholipide antibody
799215|NCT03165097|tolerability
799216|NCT03165097|safety
799217|NCT03165084|Self-management
799218|NCT03165084|Primary Health Care
799219|NCT03165084|eHealth
799220|NCT03165032|exercise
799221|NCT03165032|echocardiography
799222|NCT03165032|right ventricular function
799223|NCT03165032|pulmonary hypertension
799224|NCT03165032|hypoxia
799225|NCT03165019|high altitude illness
799226|NCT03165019|pulmonary hypertension
799227|NCT03165019|sleep apnea
799228|NCT03165019|disease progression
799229|NCT03165019|hypoxia
799230|NCT03165006|Breast cancer, screening, survival
799231|NCT03164993|Neoplasms
799232|NCT03164980|Quality of life
799233|NCT03164980|ovarian cancer
799234|NCT03164980|platinum sensitive
799235|NCT03164980|recurrent
799236|NCT03164941|selective laser trabeculoplasty
799237|NCT03164941|practice
799238|NCT03164941|treatment
799239|NCT03164941|intraocular pressure
799240|NCT03164928|Denosumab
799241|NCT03164928|Pediatric GIOP
799242|NCT03164928|Glucocorticoid-induced
799243|NCT03164928|Osteoporosis
799244|NCT03164889|Chronic hepatitis B, antiviral treatment
799245|NCT03164863|Neoadjuvant Chemotherapy, Triple Negative Breast Cancer
799246|NCT03164824|Questionnaire
799247|NCT03164824|Functional Rating Index
799248|NCT03164824|Cross-cultural adaptation
799249|NCT03164824|Psychometric properties testing
799250|NCT03164772|mRNA Vaccine
799251|NCT03164772|Durvalumab
799252|NCT03164772|MEDI4736
799253|NCT03164772|anti-PD-L1
799254|NCT03164772|tremelimumab
799255|NCT03164772|anti-CTLA-4
799256|NCT03164772|BI 1361849
799257|NCT03164746|Autism
799258|NCT03164746|Therapeutic body wraps
799259|NCT03164681|sheerly
799260|NCT03164642|Depressive Symptoms
799261|NCT03164642|Developmental Disabilities
799262|NCT03164642|Early Intervention
799263|NCT03164642|Language Development
799264|NCT03164642|Communication
799265|NCT03164642|Maternal Empowerment
799266|NCT03164629|BPH
799267|NCT03164629|Lower Urinary Track Infection
799268|NCT03164629|Urine Retention
799269|NCT03164616|NSCLC
799270|NCT03164616|PD-L1
799271|NCT03164616|Durvalumab
799272|NCT03164616|Tremelimumab
799273|NCT03164616|PFS
799274|NCT03164551|GERI+
799275|NCT03164551|TICON
799276|NCT03164551|EEVA
799277|NCT03164551|Embryo culture
799278|NCT03164551|In Vitro Fertilization
799279|NCT03164551|Intracytoplasmic Sperm Injection
799280|NCT03164525|Thai version
799281|NCT03164525|validated
799282|NCT03164525|Critical Care Pain Observation Tool
799283|NCT03164525|Behavioral Pain Scale
799284|NCT03164525|adult ICU patients
799285|NCT03164499|Health education
799286|NCT03164499|Life style
799287|NCT03164499|Risk factors
799288|NCT03164499|Cardiovascular diseases
799289|NCT03164499|Cognitive performance
799290|NCT03164499|Quality of life
799291|NCT03164473|Eosinophilic granulomatosis with polyangiitis in remission
799292|NCT03164473|double-blind randomized controlled trial
799293|NCT03164473|maintenance therapy
799294|NCT03164473|rituximab versus azathioprine
799295|NCT03164473|vasculitis remission
799296|NCT03164473|asthma control
799297|NCT03164473|rhinosinusal manifestations control
799298|NCT03164473|glucocorticoid therapy reduction/withdrawal
799299|NCT03164473|steroid sparing effect
799300|NCT03164473|damage
799301|NCT03164460|Head and Neck Cancer
799302|NCT03164460|Stereotactic ablative radiotherapy
799303|NCT03164460|SBRT
799304|NCT03164460|Intensity modulated radiation therapy
799305|NCT03164460|IMRT
799306|NCT03164460|Intensity modulated proton therapy
799307|NCT03164460|IMPT
799308|NCT03164460|Questionnaires
799309|NCT03164460|Surveys
799310|NCT03164434|intracranial pressure
799311|NCT03164434|cerebrospinal fluid drainage
799312|NCT03164434|waveform analysis
799316|NCT03164369|epidural block, ultrasound
799317|NCT03164356|Limb Fluid Volume Management
799318|NCT03164356|Prosthetic Socket Modification
799319|NCT03164343|Pain Neuroscience Education
799320|NCT03164330|Health Care
799321|NCT03164330|Workplace Wellness
799322|NCT03164330|Preventative Health Care
799323|NCT03164330|Health Costs
799324|NCT03164317|Hypertension
799325|NCT03164317|High blood pressure
799326|NCT03164317|Task shifting
799327|NCT03164317|Decision support system
799328|NCT03164291|MAC and NTM
799334|NCT03164265|Regulatory Dendritic Cells
799335|NCT03164252|Third molar;
799336|NCT03164252|Third molar surgery;
799337|NCT03164252|Laser;
799338|NCT03164252|Tissue Repair.
799339|NCT03164226|endothelial function
799340|NCT03164226|acute coronary syndrome
799341|NCT03164213|tDCS
799342|NCT03164213|aphasia
799343|NCT03164161|Pain Sensitivity
799344|NCT03164161|Measurement
799345|NCT03164161|Cold Pressor
799346|NCT03164161|β-endorphins
799347|NCT03164161|saliva
799348|NCT03164161|oral surgery
799349|NCT03164109|Healthy Adult
799350|NCT03164109|Superoxide Dismutase
799351|NCT03164109|Free Radical Dismutase
799352|NCT03164109|Cardiodynamic Assessment
799353|NCT03164083|Joint Diseases
799354|NCT03164083|Musculoskeletal Diseases
799355|NCT03164083|Arthritis
799356|NCT03164070|Osteoarthritis
799357|NCT03164070|Flow cytometry
799358|NCT03164070|Synovial fluid
799361|NCT03164044|Allergy
799362|NCT03164044|Drug allergy
799363|NCT03164044|Basophil activation test
799364|NCT03164044|Flow cytometry
799365|NCT03164005|VEGF-B
799366|NCT03163979|locally advanced cervical cancer; radiotherapy
799367|NCT03163953|Physical Activity
799368|NCT03163953|Sedentary Lifestyle
799369|NCT03163953|Office Workers
799370|NCT03163940|Laughter Yoga
799371|NCT03163940|Major Depressive Disorder
799372|NCT03163940|Anxiety
799373|NCT03163940|Stress
799374|NCT03163940|Depression
799375|NCT03163940|Quality of Life
799376|NCT03163940|Mood Disorder
799377|NCT03163914|vasopressor
799378|NCT03163914|spinal anaesthesia
799379|NCT03163901|traumatic brain injury
799380|NCT03163875|erythema
799381|NCT03163875|wheal formation
799382|NCT03163875|vascular reaction of the skin
799383|NCT03163862|IVF
799384|NCT03163836|Double Valve Replacement
799385|NCT03163836|Atrial Fibrillation Ablation
799386|NCT03163797|Oropharyngeal cancer
799387|NCT03163797|integrated PET/MR
799388|NCT03163797|diffusion-weighted imaging
799389|NCT03163797|perfusion-weighted imaging
799390|NCT03163758|Ischemic stroke
799391|NCT03163758|Functional magnetic resonance imaging (fMRI)
799392|NCT03163758|Repetitive transcranial magnetic stimulation (rTMS)
799393|NCT03163758|Brain Reorganization
799397|NCT03163719|Seizure
799398|NCT03163719|Generalized convulsive seizure
799399|NCT03163719|Convulsions
799400|NCT03163719|Creatine Kinase
799401|NCT03163719|Lactate
799402|NCT03163719|Lactacidaemia
799403|NCT03163719|Diagnostic
799404|NCT03163719|Losing consciousness
799405|NCT03163719|Epilepsy
799406|NCT03163719|Epileptic generalized tonic-clonic seizure
799407|NCT03163706|Schizophrenia
799408|NCT03163706|Stroop effect
799409|NCT03163706|Semantic conflict
799410|NCT03163706|Response conflict
799411|NCT03163693|Dexmedetomidine
799412|NCT03163693|Cardiac Troponin I
799413|NCT03163693|Glycogen Phosphorylase Isoenzyme BB
799414|NCT03163680|Gastroduodenal Ulcer
799415|NCT03163680|Marginal Ulcer
799416|NCT03163680|Peptic Ulcer Hemorrhage
799417|NCT03163680|Peptic Ulcer
799418|NCT03163667|advanced, metastatic RCC
799419|NCT03163667|RCC
799420|NCT03163667|CB-839
799421|NCT03163667|Everolimus
799422|NCT03163667|CBE
799423|NCT03163667|Glutaminase Inhibitor
799424|NCT03163667|Glutaminase
799425|NCT03163667|Tumor Metabolism
799426|NCT03163667|Glutamine
799427|NCT03163654|multiple gingival recessions
799428|NCT03163654|collagen matrix
799429|NCT03163654|connective tissue graft
799430|NCT03163654|tunnel technique
799431|NCT03163628|severe bacterial infection
799432|NCT03163628|acute infection
799433|NCT03163628|infection viral
799434|NCT03163628|biomarker combination
799435|NCT03163628|diagnostic
799436|NCT03163628|child
799437|NCT03163602|Peri-Implantitis
799438|NCT03163602|Infection
799439|NCT03163602|Bone substitutes
799440|NCT03163524|family planning
799441|NCT03163524|reproductive health
799442|NCT03163524|m-health
799443|NCT03163498|Hypertension
799444|NCT03163498|Exercise
799445|NCT03163498|Sleep
799446|NCT03163485|epilepsy
799447|NCT03163485|multimodal neuromonitoring
799448|NCT03163485|depth EEG
799449|NCT03163485|microdialysis
799450|NCT03163485|brain injury
799451|NCT03163485|brain tissue at risk
799452|NCT03163485|NCSE
799453|NCT03163485|short time monitoring
799454|NCT03163485|neurologic ICU
799455|NCT03163459|mechanical thrombectomy
799456|NCT03163459|selective brain cooling
799460|NCT03163433|Patient activation measure
799461|NCT03163433|Self-efficacy
799462|NCT03163433|Patient participation in research
799463|NCT03163420|Anesthetic efficacy
799464|NCT03163420|Diclofenac
799465|NCT03163420|Irreversible pulpitis
799466|NCT03163381|first-line treatment failure
799467|NCT03163381|one measurable lesion
799468|NCT03163368|metastatic tumor
799469|NCT03163368|brain lesion
799470|NCT03163368|stereotactic radiosurgery
799471|NCT03163368|neoadjuvant
799472|NCT03163368|maximum tolerated dose
799473|NCT03163368|dose escalation
799474|NCT03163368|neurosurgical resection
799475|NCT03163355|pureed diet
799476|NCT03163355|dysphasia
799477|NCT03163342|Seasonal
799478|NCT03163303|Tobacco
799479|NCT03163303|Cigarettes
799480|NCT03163303|Alcohol
799481|NCT03163303|Cessation
799482|NCT03163303|Intervention
799483|NCT03163303|Young adults
799484|NCT03163303|Internet
799485|NCT03163303|Social media
799486|NCT03163264|obesity
799487|NCT03163264|weight loss
799488|NCT03163264|weight gain
799489|NCT03163264|weight management
799490|NCT03163264|primary care
799491|NCT03163264|health coach
799492|NCT03163251|READ-SG
799493|NCT03163251|Burnout
799494|NCT03163251|Professional identity
799495|NCT03163251|Empathy
799496|NCT03163251|Emotional intelligence
799497|NCT03163238|Dexmedetomidine
799498|NCT03163238|Congenital Heart Disease
799499|NCT03163238|Cardiopulmonary Bypass
799500|NCT03163238|Interleukin
799501|NCT03163225|outpatient care
799502|NCT03163225|emergency department visits
799503|NCT03163212|Lactoferrin/FOS Supplementation
799504|NCT03163173|Healthy Adult
799505|NCT03163173|Superoxide Dismutase
799506|NCT03163173|Absorption
799507|NCT03163173|Metabolism
799508|NCT03163173|Elimination
799509|NCT03163173|Mass Balance
799510|NCT03163173|Male Subjects
799511|NCT03163160|pelvic floor muscles
799512|NCT03163160|pelvic floor myalgia
799513|NCT03163160|manual therapy
799514|NCT03163160|electrolysis
799515|NCT03163160|galvanic
799516|NCT03163147|frequency
799517|NCT03163134|Lumbar Drain, CSF Leak
799518|NCT03163121|Plasmodium falciparum
799519|NCT03163121|PfSPZ Vaccine
799520|NCT03163121|PfSPZ-GA1 Vaccine
799521|NCT03163121|Controlled human malaria infection (CHMI)
799522|NCT03163121|Genetically attenuated sporozoites
799523|NCT03163121|Plasmodium falciparum sporozoites (PfSPZ)
799524|NCT03163108|controller
799525|NCT03163108|hyperoxia
799526|NCT03163108|hypoxia
799527|NCT03163108|ventilation
799528|NCT03163108|cerebral oxygenation
799529|NCT03163095|sepsis
799530|NCT03163095|abdominal infection
799531|NCT03163095|open abdomen management
799532|NCT03163095|Negative pressure peritoneal therapy
799533|NCT03163082|Coercion theory
799534|NCT03163082|Corrosive Couple Coercion
799535|NCT03163069|bleaching
799536|NCT03163056|Smoking cessation
799537|NCT03163056|Depression
799538|NCT03163056|Clinical trial
799539|NCT03163030|Heart Failure
799540|NCT03163030|Preserved Ejection Fraction
799541|NCT03163030|VNS
799542|NCT03163030|Vagus Nerve
799543|NCT03163030|Autonomic Regulation Therapy
799544|NCT03163017|3D Fluoroscopy
799545|NCT03163004|Sedentary behavior
799546|NCT03162978|Exercise
799547|NCT03162978|behavior economics
799548|NCT03162952|Chronic pain
799549|NCT03162913|Strawberry
799550|NCT03162913|Cognition
799551|NCT03162913|Gait
799552|NCT03162913|Posture
799553|NCT03162900|Glasdegib
799554|NCT03162900|PF-04449913
799555|NCT03162900|Pharmacokinetics
799556|NCT03162900|QTc
799557|NCT03162900|TQT
799558|NCT03162874|Levodopa-Induced Dyskinesia (LID)
799559|NCT03162874|Wearing-off
799560|NCT03162874|Foliglurax
799561|NCT03162874|Parkinson's Disease
799562|NCT03162874|mGluR4 PAM
799563|NCT03162835|Pain Neuroscience Education
799564|NCT03162822|caregiver-child coercion
799565|NCT03162822|Dental Caries
799566|NCT03162809|infertility
799567|NCT03162809|in vitro fertilization
799568|NCT03162809|Estradiol
799569|NCT03162809|Progesterone
799570|NCT03162783|Aldeyra
799571|NCT03162770|mindfulness meditation
799572|NCT03162770|hemodialysis
799573|NCT03162770|quality of life
799574|NCT03162770|stress
799575|NCT03162718|lung cancer
799576|NCT03162718|exercise
799577|NCT03162718|pre-operative exercise program
799578|NCT03162679|trauma treatment
799579|NCT03162679|Refugees
799580|NCT03162679|Emotion regulation
799581|NCT03162679|Group therapy
799582|NCT03162679|randomized controlled
799583|NCT03162679|PTSD
799584|NCT03162653|Allopurinol
799585|NCT03162653|hypothermia therapy
799586|NCT03162653|hypoxic-ischemic encephalopathy
799587|NCT03162653|neonatal oxygen deficiency
799588|NCT03162653|childbirth outcome
799589|NCT03162653|perinatal asphyxia
799590|NCT03162640|Early onset of cannabis use
799591|NCT03162640|Addiction
799592|NCT03162640|Time perception
799593|NCT03162627|Malignant neoplasm of breast
799594|NCT03162627|Malignant neoplasms of digestive organs
799595|NCT03162627|Malignant neoplasms of female genital organs
799596|NCT03162627|Malignant neoplasms of male genital organs
799597|NCT03162627|Malignant neoplasms of thyroid and other endocrine glands
799598|NCT03162627|Solid tumors
799599|NCT03162627|Ras Pathway Alterations
799600|NCT03162627|Ovarian Tumors with PARP Resistance
799601|NCT03162627|Selumetinib
799602|NCT03162627|AZD6244
799603|NCT03162627|Olaparib
799604|NCT03162627|Lynparza
799605|NCT03162614|healthy volunteers
799606|NCT03162614|Malaria
799607|NCT03162614|malaria vaccine
799608|NCT03162614|controlled human challenge
799609|NCT03162614|RTS,S/AS01
799620|NCT03162510|SOLAR regimen
799621|NCT03162471|Corneal astigmatism
799622|NCT03162471|Cataract surgery
799623|NCT03162471|Corneal hysteresis
799624|NCT03162471|Corneal resistance factor
799625|NCT03162471|Intraocular pressure
799626|NCT03162445|bone mineral density
799627|NCT03162445|Autism Spectrum Disorder
799628|NCT03162445|Autism
799629|NCT03162432|IBD
799630|NCT03162393|brachial plexus; avulsion injury
799631|NCT03162380|Bipolar Disorder
799632|NCT03162380|occupational stress
799633|NCT03162367|Burn
799634|NCT03162367|Epidermal cell suspension
799635|NCT03162341|Dual-Energy Computed Tomography
799636|NCT03162341|UltraSonography
799637|NCT03162341|Gout
799638|NCT03162341|Urate deposition
799639|NCT03161275|cerebral saturation
799640|NCT03161275|epidural anaesthesia
799641|NCT03161275|Near Infrared Spectroscopy (NIRS)
799642|NCT03161275|Regional cerebral oxygen saturation
799643|NCT03161262|Text-message reminder
799644|NCT03161262|Post-operative medication
799645|NCT03161262|Behavioral Research
799646|NCT03161262|Social Research
799647|NCT03161262|Short Message Service (SMS)
799648|NCT03161249|first psychotic episode, mobile app intervention
799649|NCT03161197|CKD, Dialysis, ESRD
799650|NCT03161197|Mindfulness-Based Stress Reduction (MBSR)
799651|NCT03161184|maternal health
799652|NCT03161184|community health
799653|NCT03161184|health services
799654|NCT03161184|Tanzania
799655|NCT03161184|evaluation
799656|NCT03161184|cluster randomized trial
799657|NCT03161158|Cardio-Renal Syndrome type 1
799658|NCT03161158|Acutely decompensated chronic heart failure
799659|NCT03161158|Ultrafiltration
799660|NCT03162302|MRI
799661|NCT03162302|magnetic resonance imaging
799662|NCT03162302|fat quantification
799663|NCT03162302|iron quantification
799664|NCT03162289|Fasting
799665|NCT03162289|Vegan
799666|NCT03162276|BRCA 1/2 Carriers
799667|NCT03162276|The Work
799668|NCT03162276|RCT
799669|NCT03162276|IBSR
799670|NCT03162263|Ekso
799671|NCT03162263|neuroplasticity
799672|NCT03162263|functional recovery
799673|NCT03162237|Type1 diabetes
799674|NCT03162237|porcine islets
799675|NCT03162237|treg cells
799676|NCT03162237|immunosuppress
799677|NCT03162237|xenotransplantation
799678|NCT03162224|Head and Neck Squamous Cell Carcinoma
799679|NCT03162224|Oropharyngeal Cancer
799680|NCT03162224|HPV
799681|NCT03162224|Human Papilloma Virus
799682|NCT03162224|Cancer Immunotherapy
799683|NCT03162224|Check point inhibitors
799684|NCT03162224|PD-L1 inhibitor
799685|NCT03162224|Recurrent or Metastatic Cancer
799686|NCT03162224|Durvalumab
799687|NCT03162224|MEDI0457
799688|NCT03162224|Antineoplastic agents
799689|NCT03162224|Neoplasms
799690|NCT03162185|Neuroplasticity
799691|NCT03162185|SSRI
799692|NCT03162185|Motor Learning
799693|NCT03162172|congenital adrenal hyperplasia
799694|NCT03162172|short stature
799695|NCT03162172|growth hormone treatment
799696|NCT03162133|Breast Cancer
799697|NCT03162133|Aromatase Inhibitor Therapy
799698|NCT03162133|Baduanjin Exercise
799699|NCT03162107|adherence
799700|NCT03162107|HIV
799701|NCT03162107|MDR/XDR TB
799702|NCT03162107|Health Care Worker
799703|NCT03162081|addiction
799704|NCT03162081|cognition
799705|NCT03162081|impulsivity
799706|NCT03162081|neuropsychology
799707|NCT03162081|prescription drug misuse
799708|NCT03162081|dependence
799709|NCT03162068|Cushing's syndrome
799710|NCT03162068|Osteoporosis
799711|NCT03162068|peripheral Quantitative Computed
799712|NCT03162068|volumetric Bone Mineral Density
799713|NCT03162068|Cortical and trabecular bone
799714|NCT03162068|Bone Strength
799715|NCT03162055|COPD
799716|NCT03162042|Activin A
799717|NCT03162042|Myostatin
799718|NCT03162042|Follistatin
799719|NCT03162042|Cachexia
799720|NCT03162042|Squamous cell carcinoma
799721|NCT03162029|CBCT
799722|NCT03162029|Bone quality
799723|NCT03162029|Renal failure
799724|NCT03161990|DAIR
799725|NCT03161990|Transgluteal approach
799726|NCT03161990|Posterior approach
799727|NCT03161964|Hypoglycemia
799728|NCT03161964|Impaired Awareness of Hypoglycemia
799729|NCT03161964|Propranolol
799730|NCT03161951|acute Infections, flow cytometry, cell activation
799742|NCT03161899|thalassemia - nutrition -growth
799743|NCT03161886|colon capsule endoscopy
799744|NCT03161860|Program evaluation
799745|NCT03161860|Cost-effectiveness
799746|NCT03161860|Community participation
799747|NCT03161860|empowerment
799748|NCT03161847|OPMD
799749|NCT03161834|DNA
799750|NCT03161834|Circulating tumor cells
799751|NCT03161795|Chemical coping
799752|NCT03161795|Adequacy consumption measure
799753|NCT03161795|Long-term opioids use
799754|NCT03161795|CAGE-Opioid
799755|NCT03161782|pain
799756|NCT03161782|exercise
799757|NCT03161782|proprioceptive neuromuscular facilitation stretching
799758|NCT03161782|static stretching
799759|NCT03161743|platelet-rich plasma
799760|NCT03161743|platelet
799761|NCT03161730|videolaryngoscope, novice
799762|NCT03161717|electrical stimulation
799763|NCT03161717|vaginal delivery
799764|NCT03161678|Pharmacogenetics
799765|NCT03161678|Carboxylesterase 1 (CES1)
799766|NCT03161678|Antiplatelet therapy
799767|NCT03161652|diabetic retinopathy
799768|NCT03161652|blindness
799769|NCT03161652|eye
799770|NCT03161652|macular edema
799771|NCT03161652|prolactin
799772|NCT03161652|dopamine antagonists
799773|NCT03161652|peptide hormones
799774|NCT03161639|Pulpectomy
799775|NCT03161639|Primary teeth
799776|NCT03161639|Working length
799777|NCT03161639|Apex locator
799785|NCT03161574|neochemotherapy
799786|NCT03161574|CRM
799787|NCT03161522|Malignant neoplasms of digestive organs
799788|NCT03161522|Esophageal Cancer
799789|NCT03161522|Gastric Cancer
799790|NCT03161522|Oligometastatic
799791|NCT03161522|Chemotherapy
799792|NCT03161522|Radiation therapy
799793|NCT03161522|Surgery
799794|NCT03161522|Questionnaires
799795|NCT03161522|Surveys
799796|NCT03161483|CC-220
799797|NCT03161483|Safety
799798|NCT03161483|Efficacy
799799|NCT03161483|Active Systemic Lupus Erythematosus
799800|NCT03161457|RA
799801|NCT03161457|Moderate RA
799802|NCT03161457|Moderate Rheumatoid Arthritis
799803|NCT03161457|Severe RA
799804|NCT03161457|Severe Rheumatoid Arthritis
799805|NCT03161457|Moderate to Severe RA
799806|NCT03161457|Moderate to Severe Rheumatoid Arthritis
799807|NCT03161431|Immunotherapy
799808|NCT03161431|Chemokine receptor blockade
799809|NCT03161431|Myeloid-derived suppressor cells
799810|NCT03161405|Drug Therapy
799811|NCT03161392|mammography
799812|NCT03161392|ductal ectasia
799813|NCT03161392|breast neoplasm/diagnostic imaging
799814|NCT03161392|mammary Glands, Human/pathology
799815|NCT03161392|female
799816|NCT03161379|Neoadjuvant therapy
799817|NCT03161379|immunotherapy
799818|NCT03161379|Cytoxan
799819|NCT03161379|Cyclophosphamide
799820|NCT03161379|Pancreatic Vaccine
799821|NCT03161379|SBRT
799822|NCT03161379|GVAX
799823|NCT03161379|Nivolumab
799824|NCT03161379|borderline resectable
799825|NCT03161379|Radioimmunotherapy
799826|NCT03161379|Vaccine
799827|NCT03161379|Antibody
799828|NCT03161379|Anti-PD-1
799829|NCT03161366|Ebola Zaire Outbreak
799830|NCT03161366|Safety of rVSVΔG-ZEBOV-GP vaccine
799831|NCT03161366|Effectiveness of rVSVΔG-ZEBOV-GP vaccine
799832|NCT03161340|Recurrent Implantation Failure
799833|NCT03161340|Rapamycin
799834|NCT03161340|Pregnancy Rate
799835|NCT03161327|ankle brachial index
799836|NCT03161327|peripheral arterial disease
799837|NCT03161314|Plantar Fasciitis
799838|NCT03161314|Plantar Heel Pain
799839|NCT03161314|Multisegment Foot Motion
799840|NCT03161314|EMG
799841|NCT03161314|Gait
799843|NCT03161054|Metronomic Chemotherapy
799844|NCT03161054|Elderly non-fit patients
799845|NCT03161054|Aggressive B-Cell lymphomas
799846|NCT03161041|Cytoreductive surgery, HIPEC, perioperative chemotherapy, peritoneal carcinomatosis, bevacizumab, colorectal surgery
799847|NCT03161028|multiple sclerosis
799848|NCT03161028|magnetic resonance imaging
799849|NCT03161028|gait
799850|NCT03161028|neuroprotective agents
799851|NCT03161028|thioctic acid
799852|NCT03161028|alpha-lipoic acid
799853|NCT03161028|mobility
799854|NCT03161028|chronic progressive multiple sclerosis
799855|NCT03160989|Blood pressure variability
799856|NCT03160989|Combined physical exercise
799857|NCT03160989|Hypertension
799858|NCT03160963|elderly
799859|NCT03160937|pain
799860|NCT03160924|Enhanced recovery after surgery
799861|NCT03160924|ERAS
799862|NCT03160924|Fast track recovery
799863|NCT03160924|Laparoscopic gastrectomy
799864|NCT03160924|Gastric Cancer
799865|NCT03160911|Over-the-scope clip
799866|NCT03160911|endoscopic haemostasis
799867|NCT03160898|Amyotrophic Lateral Sclerosis
799868|NCT03160898|ALS
799869|NCT03160898|CK-2127107
799870|NCT03160872|Donor sperm insemination
799871|NCT03160872|Anti Mullerian Hormone
799872|NCT03160872|Ovarian reserve
799873|NCT03160872|Antral follicle count
799878|NCT03160846|Inotrope
799879|NCT03160846|Milrinone
799880|NCT03160846|Dopamine
799881|NCT03160846|Dobutamine
799885|NCT03160794|Prostate cancer
799886|NCT03160794|stereotactic ablative radiotherpy
799887|NCT03160794|PET/MR
799888|NCT03160768|p16
799889|NCT03160768|T cell isolation
799890|NCT03160768|physiologic age
799891|NCT03160703|Dental stain, stannous fluoride, dentifrice
799892|NCT03160690|Choroidal thickness
799893|NCT03160690|Open Angle Glaucoma
799894|NCT03160690|Non penetrating deep sclerectomy
799895|NCT03160677|Acute Stroke
799896|NCT03160677|Blood Pressure
799897|NCT03160677|Cerebral Hemorrhage
799898|NCT03160664|magnetic seizure therapy
799899|NCT03160664|electroconvulsive therapy
799900|NCT03160664|bipolar mania
799901|NCT03160664|cognition
799902|NCT03160664|randomized controlled trial
799903|NCT03160651|alcoholic hepatitis
799904|NCT03160651|spontaneous improvement
799905|NCT03160651|corticosteroids
799906|NCT03160638|Azithromycin
799907|NCT03160638|Immunomodulation
799908|NCT03160638|Pharmacokinetics
799909|NCT03160638|Tissue degradation
799910|NCT03160638|Tissue remodelling
799911|NCT03160612|Wheelchair
799912|NCT03160612|Biomechanics
799913|NCT03160612|Transfer
799914|NCT03160612|Training
799915|NCT03160586|Stuttering
799916|NCT03160586|Anxiety
799917|NCT03160495|PET/MR
799918|NCT03160495|Squamous cell carcinoma
799919|NCT03160495|Heterogeneity
799920|NCT03160482|Thyroid Neoplasm
799921|NCT03160482|Papillary Carcinoma
799922|NCT03160482|Follicular Carcinoma
799923|NCT03160482|Colloid Nodule
799924|NCT03160482|Hyperplastic Nodule
799925|NCT03160482|Adenomatoid Nodule
799926|NCT03160482|Follicular Adenoma
799927|NCT03160482|Thyroid Cancer
799928|NCT03160482|Bethesda Classification
799929|NCT03160482|Biomarkers
799930|NCT03160482|Protein convertase
799931|NCT03160469|obesity
799938|NCT03160443|Anorexia nervosa
799939|NCT03160443|Bulimia
799940|NCT03160443|Binge eating disorders
799941|NCT03160443|Neuropsychology
799942|NCT03160443|Neurocognition
799943|NCT03160443|Daily functioning
799944|NCT03160430|Chronic Kidney Failure
799945|NCT03160430|ESRD
799946|NCT03160430|End-Stage Kidney Disease
799947|NCT03160430|End-Stage Renal Disease
799948|NCT03160430|Renal Disease, End-Stage
799949|NCT03160430|Renal Failure, Chronic
799950|NCT03160430|Renal Failure, End-Stage
799951|NCT03160404|Exercise
799952|NCT03160404|Zolpidem
799953|NCT03160404|Sleep
799954|NCT03160326|chronic kidney disease
799955|NCT03160326|ultrasound
799956|NCT03160326|muscle loss
799957|NCT03160313|Social engagement
799958|NCT03160313|Physical Activity
799959|NCT03160313|Sleep Quality
799960|NCT03160313|Traumatic Brain Injury
799961|NCT03160313|Veteran
799962|NCT03160287|mobile, sleep, physical activity, older adults
799963|NCT03160274|tumor suppressor gene
799964|NCT03160274|oncogene
799965|NCT03160274|mutation
799966|NCT03160274|susceptibility gene
799967|NCT03160222|reliability
799968|NCT03160222|bioelectrical impedance analysis
799969|NCT03160222|computed tomography
799970|NCT03160222|strength
799971|NCT03160222|mobility
799972|NCT03160209|risk factors
799973|NCT03160209|case-control study
799974|NCT03160196|Diabetes Mellitus, Type 2
799975|NCT03160196|Hemoglobin A, Glycosylated
799976|NCT03160183|initiating chemotherapy
799977|NCT03160183|prospective, open label, single arm, cohort
799978|NCT03160183|non randomized, non interventional
799979|NCT03160170|open lumbar spine surgery
799980|NCT03160170|operative time and efficiency
799981|NCT03160170|Suction-Integrated Surgical Tissue Elevator and Retractor
799982|NCT03160144|laparoscopic resection of colorectal cancer
799983|NCT03160144|open lung approach
799984|NCT03160131|Stroke
799985|NCT03160131|Visual impairment
799986|NCT03160131|Hemianopia
799987|NCT03160131|Neuro Vision Technology
799988|NCT03160131|Rehabilitation
799989|NCT03160079|blinatumomab
799990|NCT03160079|pembrolizumab
799991|NCT03160079|MK-3475
799992|NCT03160079|relapsed
799993|NCT03160079|refractory
799994|NCT03160079|B-lineage acute lymphoblastic leukemia
799995|NCT03160079|ALL
799996|NCT03160066|Psychobiotic
799997|NCT03160066|Brain-gut axis
799998|NCT03160066|Stress
799999|NCT03160066|Cognition
800000|NCT03160066|EEG
800001|NCT03160001|Niclosamide
800002|NCT03160001|Rheumatoid arthritis
800003|NCT03160001|diseases activity
800004|NCT03160001|Efficacy
800005|NCT03160001|Safety
800006|NCT03159975|Tuberculosis
800007|NCT03159975|DNA vaccine
800008|NCT03159975|Electroporation
800009|NCT03159975|GX-70
800010|NCT03159962|Rapid maxillary expansion
800011|NCT03159962|Mandibular response
800012|NCT03159962|Class II malocclusion
800013|NCT03159962|Growing subjects
800014|NCT03159949|VO2max, maximal oxygen uptake
800015|NCT03159910|Shoulder Pain
800016|NCT03159910|Occupational Exposure
800017|NCT03159910|Clinical Trial
800018|NCT03159897|advanced stage (IIB-IV)
800019|NCT03159897|ABVD DD-DI
800020|NCT03159897|PET
800021|NCT03159871|Cesarean section
800022|NCT03159871|C- section
800023|NCT03159871|Suture
800024|NCT03159858|Complex Abdominal Aortic Aneurysm
800025|NCT03159845|zinc
800026|NCT03159832|Efficacy
800027|NCT03159832|PK/PD study
800028|NCT03159832|Renal Insufficiency
800029|NCT03159832|Type 2 Diabetes
800030|NCT03159728|Ability Care
800031|NCT03159728|Caregiver overload
800032|NCT03159728|Family caregiver
800033|NCT03159715|Internet, Behavioral Activation, Positive Psychology
800034|NCT03159702|hematological malignancy
800035|NCT03159702|EVOMELA
800036|NCT03159702|Melphalan HCl
800037|NCT03159702|Total Body Irradiation
800038|NCT03159702|Reduced Intensity Conditioning
800039|NCT03159702|Haploidentical Transplantation
800040|NCT03159702|Fludarabine
800041|NCT03159702|Hematologic Diseases
800042|NCT03159702|Neoplasms, Plasma Cell
800043|NCT03159702|Neoplasms by Histologic Type
800044|NCT03159702|Lymphoproliferative Disorders
800045|NCT03159637|Pneumoperitoneum
800046|NCT03159637|Trendelenburg position
800047|NCT03159637|intra-abdominal pressure
800048|NCT03159624|nasoseptal flap
800049|NCT03159624|tissue repair
800050|NCT03159624|wound healing
800051|NCT03159624|remucosalization
800052|NCT03159624|upper airway
800053|NCT03159624|granulation tissue
800054|NCT03159624|tissue graft
800055|NCT03159598|A-BR
800056|NCT03159598|Abdominal-based breast reconstruction
800057|NCT03159598|Seroma
800058|NCT03159572|Ovarian cancer
800059|NCT03159572|Fallopian tube cancer
800184|NCT03158792|Anti-Xa levels
800060|NCT03159572|Primary peritoneal cancer
800061|NCT03159572|Germline Breast Cancer Susceptibility Gene (BRCA1/2 gene)
800062|NCT03159572|Homologous Recombination Deficiency (HRD)
800063|NCT03159520|Pain
800064|NCT03159507|Omega-3 Index
800065|NCT03159507|Cellular metabolism
800066|NCT03159507|EPA Monoglyceride
800067|NCT03159507|Quality of life
800079|NCT03159390|dietary supplements
800080|NCT03159377|pulmonary nodule, CT, low dose
800081|NCT03159364|Virus-CTL
800082|NCT03159364|EBV
800083|NCT03159364|CMV
800084|NCT03159364|ADV
800085|NCT03159364|BKV
800086|NCT03159325|internet
800087|NCT03159325|chronic disease management
800088|NCT03159325|technology
800089|NCT03159325|telehealth
800090|NCT03159325|application
800091|NCT03159312|obesity,bariatric surgery,physical activity
800092|NCT03159299|mHealth
800093|NCT03159299|Hispanic/Latinos
800094|NCT03159299|Diabetes Self-Management Education
800095|NCT03159273|Dietary nitrate supplementation
800096|NCT03159273|Cold symptoms
800097|NCT03159273|Stress
800098|NCT03159273|Immunity
800099|NCT03159273|Exhaled nitric oxide
800100|NCT03159273|Lung function
800101|NCT03159273|Cardiovascular activity
800102|NCT03159260|night-time leg cramps
800103|NCT03159260|topical
800104|NCT03159260|spasm
800105|NCT03159247|education
800106|NCT03159247|counseling
800107|NCT03159247|motivational interviewing
800108|NCT03159247|tailoring
800109|NCT03159221|type 2 diabetes in adolescents
800110|NCT03159221|obesity in adolescents
800111|NCT03159221|behavioral family systems therapy
800112|NCT03159208|Prognosis
800113|NCT03159208|Critical Illness
800114|NCT03159208|Ventilation, Mechanical
800115|NCT03159208|Disease Attributes
800116|NCT03159208|Socioeconomic Factors
800117|NCT03159208|Activities of Daily LIving
800118|NCT03159208|Cognition
800119|NCT03159195|metastatic breast cancer
800120|NCT03159195|advanced breast cancer
800121|NCT03159195|HR+/ HER2-
800122|NCT03159182|Hypertrophic scarring
800123|NCT03159182|Silicone Material
800124|NCT03159182|Pressure garments
800125|NCT03159169|Neck Pain
800126|NCT03159169|Upper Limb Pain
800127|NCT03159130|Pain pump catheters
800128|NCT03159130|bariatric surgery
800129|NCT03159130|OnQ pump
800130|NCT03159130|sleeve gastrectomy
800131|NCT03159130|continuous infusion catheter
800132|NCT03159117|GD3 ADC (Pfizer PF-06688992)
800133|NCT03159117|Stage III Melanoma
800134|NCT03159117|Stage IV Melanoma
800135|NCT03159117|17-165
800139|NCT03159026|Amish/Mennonite variant
800140|NCT03159013|Pyrethroids
800141|NCT03159013|Lambda-cyhalothrin
800142|NCT03159013|Biomarkers
800143|NCT03159013|Toxicokinetics
800144|NCT03158974|External Genital Warts
800145|NCT03158961|Thyroid
800146|NCT03158961|Thyroidectomy
800147|NCT03158961|Transoral
800148|NCT03158961|Endoscopic
800149|NCT03158961|Surgery
800150|NCT03158948|Sepsis
800151|NCT03158948|LR12
800152|NCT03158948|TREM1
800153|NCT03158948|TREM-1
800154|NCT03158935|adoptive cell therapy
800155|NCT03158935|melanoma
800156|NCT03158935|ovarian
800157|NCT03158935|cyclophosphamide
800158|NCT03158935|fludarabine
800159|NCT03158935|tumor-infiltrating lymphocytes (TILs)
800160|NCT03158935|pembrolizumab
800161|NCT03158935|interleukin-2
800162|NCT03158935|anti-PD-1
800163|NCT03158935|immune checkpoint
800164|NCT03158909|Eyemask
800165|NCT03158909|Earplugs
800166|NCT03158896|mesenchymal stem cell
800167|NCT03158896|hematopoietic stem cell transplant
800168|NCT03158896|Allogeneic hematopoietic stem cell transplant
800169|NCT03158896|Autologous hematopoietic stem cell transplant
800170|NCT03158896|Wharton's jelly
800171|NCT03158896|umbilical cord blood
800172|NCT03158896|steroid refractory graft versus host disease
800173|NCT03158883|Avelumab
800174|NCT03158883|NSCLC
800175|NCT03158883|Stereotactic ablative radiotherapy (SAR)
800176|NCT03158857|Myanmar
800177|NCT03158857|HIV
800178|NCT03158831|Drug Allergy
800179|NCT03158831|Penicillin Allergy
800180|NCT03158831|Antibiotic Allergy
800181|NCT03158831|Graded Drug Challenge
800182|NCT03158792|Anticoagulation
800183|NCT03158792|Thromboprophylaxis
800185|NCT03158792|Elderly
800186|NCT03158792|Prevention
800187|NCT03158792|Enoxaparin
800188|NCT03158792|Low molecular weight heparin
800189|NCT03158766|infection
800190|NCT03158766|intervertebral disc
800191|NCT03158766|Propionibacterium acnes
800192|NCT03158766|spine
800193|NCT03158727|intensive care
800194|NCT03158701|evaluation
800195|NCT03158675|fractional co2 laser, topical steroid,UVB narrow band
800196|NCT03158662|Epidermolysis Bullosa
800197|NCT03158662|Recessive Dystrophic
800198|NCT03158662|Simplex
800199|NCT03158662|Junctional Non-Herlitz
800200|NCT03158649|Pregnancy
800201|NCT03158649|Prenatal well-being
800202|NCT03158649|Mental maternal prenatal well-being
800203|NCT03158649|Positive Psychology
800204|NCT03158649|Positive Psychology Intervention
800205|NCT03158649|Web-based intervention
800206|NCT03158623|total joint arthroplasty
800207|NCT03158623|platelet-rich plasma
800208|NCT03158623|activated collagen
800209|NCT03158571|Gastric Cancer
800210|NCT03158571|gastric adenocarcinoma
800211|NCT03158571|cancer subtypes
800212|NCT03158571|prognosis
800213|NCT03158571|survival
800214|NCT03158571|molecular classification
800215|NCT03158571|chemotherapy
800216|NCT03158571|immunotherapy
800217|NCT03158519|Physical activity
800220|NCT03158441|MRI
800221|NCT03158441|Diffusion
800222|NCT03158441|DTI
800223|NCT03158415|mHealth
800224|NCT03158402|Inspiratory muscle training
800225|NCT03158402|Systemic Inflammatory Response Syndrome
800226|NCT03158389|MGMT methylation
800227|NCT03158389|targeted therapy
800228|NCT03158389|umbrella protocol
800229|NCT03158376|gabapentin
800230|NCT03158376|thoracotomy
800231|NCT03158376|chronic post-thoracotomy pain
800232|NCT03158376|acute post-thoracotomy pain
800233|NCT03158376|quality of life
800234|NCT03158376|neuropathic pain
800235|NCT03158363|immobilization
800236|NCT03158363|fasting
800237|NCT03158363|endotoxemia
800238|NCT03158363|LPS
800239|NCT03158363|metabolism
800240|NCT03158363|model of disease
800241|NCT03158337|Exercise
800242|NCT03158337|Physical Activity
800243|NCT03158337|Brain blood flow
800244|NCT03158337|Cognition
800245|NCT03158337|Fitness
800246|NCT03158259|IS
800247|NCT03158259|ICH
800248|NCT03158259|rtPa
800249|NCT03158259|Prehospital
800250|NCT03158259|MSU
800251|NCT03158246|zoledronic acid
800252|NCT03158246|Yigu
800253|NCT03158246|Aclasta
800254|NCT03158246|Osteoporosis
800255|NCT03158246|Postmenopausal
800256|NCT03158246|BMD
800257|NCT03158246|fracture
800258|NCT03158246|Biochemical markers
800259|NCT03158233|Zika virus disease
800260|NCT03158194|Anxiety
800261|NCT03158194|Stress
800262|NCT03158194|Asthma
800263|NCT03158181|Behavior; Operational block; Monitoring; Social Sciences ; New technologies
800264|NCT03158129|Non-Small Cell Lung Cancer
800265|NCT03158129|NSCLC
800266|NCT03158129|Nivolumab
800267|NCT03158129|BMS-936558
800268|NCT03158129|Opdivo
800269|NCT03158129|Ipilimumab
800270|NCT03158129|Yervoy
800271|NCT03158129|BMS-734016
800272|NCT03158129|MDX010
800273|NCT03158129|Amenable For Surgical Resection
800274|NCT03158116|tracheostomy tube
800275|NCT03158116|Pseudomonas aeruginosa
800276|NCT03158103|MEK162 (Binimetinib)
800277|NCT03158103|Pexidartinib
800278|NCT03158103|17-056
800279|NCT03158090|Acromegaly
800280|NCT03158064|17-160
800281|NCT03158064|durvalumab
800282|NCT03158064|tremelimumab
800283|NCT03158064|MEDI4736
800284|NCT03158051|Hypertension
800285|NCT03158051|Young Adult
800286|NCT03158051|Self-Management
800287|NCT03158051|Health coach
800288|NCT03158038|Trivalent
800289|NCT03158038|Influenza
800290|NCT03158038|FluMist Quadrivalent
800291|NCT03158038|Vaccine
800292|NCT03158038|Prevention
800293|NCT03158038|Healthy
800294|NCT03158038|Monovalent
800305|NCT03157986|COPD
800306|NCT03157986|Balance
800307|NCT03157986|Whole Body Vibration Training
800308|NCT03157986|pulmonary rehabilitation
800309|NCT03157986|exercise
800310|NCT03157973|Information Literacy
800311|NCT03157973|Nursing Care
800312|NCT03157973|Social Support
800313|NCT03157960|Fructose
800314|NCT03157960|Uric acid
800315|NCT03157960|Oxidised LDL
800316|NCT03157960|Interleukin 6
800317|NCT03157947|decision aid
800318|NCT03157947|focus group
800319|NCT03157934|stroke network
800320|NCT03157934|acute stroke care
800321|NCT03157934|emergency medical services
800322|NCT03157934|integrated care
800327|NCT03157895|Foster Families
800328|NCT03157882|pediatric
800329|NCT03157882|children
800330|NCT03157882|Faces Pain Scale Revised
800331|NCT03157882|Wong Baker FACES
800332|NCT03157882|pain scales
800333|NCT03157882|BRIGANCE
800334|NCT03157869|Learning, Automatism, Motor Activity, Electric Stimulation
800335|NCT03157856|Fluorescence imaging technique
800336|NCT03157856|Biopsies from resected prostate
800337|NCT03157856|Medical device
800338|NCT03157830|Multiple Sclerosis
800339|NCT03157830|MS
800340|NCT03157830|ocrelizumab
800341|NCT03157830|OCREVUS
800342|NCT03157830|Natalizumab
800343|NCT03157830|Tysabri
800344|NCT03157791|simethicone
800345|NCT03157778|pregnenolone
800346|NCT03157778|endocannabinoid
800347|NCT03157778|food intake
800348|NCT03157778|type-1 cannabinoid receptor
800349|NCT03157765|recurrent implantation failure
800350|NCT03157765|frozen embryo transfer
800351|NCT03157765|IVF
800352|NCT03157765|endometrial scratch
800353|NCT03157765|endometrial injury
800354|NCT03157739|Migraine
800359|NCT03157713|Obesity
800360|NCT03157713|Weight-loss
800361|NCT03157713|Financial Incentives
800362|NCT03157713|Behavioral Economics
800363|NCT03157648|Shivering temperature
800364|NCT03157622|Chronic Low Back Pain
800365|NCT03157622|Cognitive-Behavioural Therapy
800366|NCT03157622|Exposure
800367|NCT03157622|Therapeutic processes
800368|NCT03157622|Single-case study
800369|NCT03157609|Thermometry
800370|NCT03157609|SpotOn
800371|NCT03157596|disability
800372|NCT03157596|developmental disability
800373|NCT03157596|special healthcare needs
800374|NCT03157557|Treatment
800375|NCT03157557|Sheltered Housing
800376|NCT03157544|Chronic Neck Pain
800377|NCT03157544|Chronic Back Pain
800378|NCT03157544|non-pharmacological
800379|NCT03157544|pain relief
800380|NCT03157518|Asthma
800381|NCT03157518|obesity
800382|NCT03157518|micorbiome
800383|NCT03157518|probiotics
800384|NCT03157492|Adult
800385|NCT03157492|Post-lingual
800386|NCT03157492|Auditory training
800387|NCT03157492|Communication strategies
800388|NCT03157492|Speech tracking
800389|NCT03157492|Speech recognition
800390|NCT03157492|Quality of Life
800391|NCT03157479|Mechanical ventilation
800392|NCT03157453|Evaluation scale
800393|NCT03157453|Brain injury
800394|NCT03157453|Severity of Brain Injury
800395|NCT03157453|Initial Evaluation
800397|NCT03157388|inflammation
800398|NCT03157388|Macrophages
800399|NCT03157388|CD163
800400|NCT03157375|IOL, IOL Rotation, Axial Rotation
800401|NCT03157349|Biofreeze
800402|NCT03157349|Acute Neck Pain
800403|NCT03157349|Placebo
800404|NCT03157349|chiropractic
800405|NCT03157336|Cassava
800406|NCT03157336|Konzo
800407|NCT03157336|Cyanide
800408|NCT03157336|Cyanate
800409|NCT03157336|Thiocyanate
800410|NCT03157336|Carbamoylation
800411|NCT03157336|Isoprostanes
800412|NCT03157336|Oxidative Damage
800413|NCT03157323|Glycemic Index
800414|NCT03157323|Acute Lymphoblastic Leukemia
800415|NCT03157323|Dietary Change
800416|NCT03157323|Pediatric Oncology
800417|NCT03157284|Lactobacillus, Probiotics
800418|NCT03157219|Heart failure
800419|NCT03157219|Institutional level registry
800420|NCT03157219|Systolic heart failure
800421|NCT03157219|Acute heart failure
800422|NCT03157219|Heart failure India
800423|NCT03157193|Peri-Implantitis
800424|NCT03157193|Dental Implants
800425|NCT03157193|Hyaluronic Acid
800426|NCT03157193|Clinical Trial
800427|NCT03157167|Kaposi Sarcoma, HIV, Lymphedema
800433|NCT03157141|Ankle osteoarthritis
800434|NCT03157141|total ankle replacement
800435|NCT03157141|ankle arthrodesis
800436|NCT03157141|kinematics
800437|NCT03157141|kinetics
800438|NCT03157141|plantar pressure measurements
800439|NCT03157141|functional compensatory adaptations
800440|NCT03157128|LOXO-292
800441|NCT03157128|KIF5B-RET
800442|NCT03157128|M918T
800443|NCT03157128|CCDC6-RET
800444|NCT03157128|RET-PTC1
800445|NCT03157128|NCOA4-RET
800446|NCT03157128|RET-PTC
800447|NCT03157128|RET-PTC3
800448|NCT03157128|RET-PTC4
800449|NCT03157128|PRKAR1A-RET
800450|NCT03157128|RET-PTC2
800451|NCT03157128|GOLGA5-RET
800452|NCT03157128|RET-PTC5
800453|NCT03157128|ERC1-RET
800454|NCT03157128|KTN1-RET
800455|NCT03157128|RET-PTC8
800456|NCT03157128|HOOK3-RET
800457|NCT03157128|PCM1-RET
800458|NCT03157128|TRIM24-RET
800459|NCT03157128|RET-PTC6
800460|NCT03157128|TRIM27-RET
800461|NCT03157128|TRIM33-RET
800462|NCT03157128|RET-PTC7
800463|NCT03157128|AKAP13-RET
800464|NCT03157128|FKBP15-RET
800465|NCT03157128|SPECC1L-RET
800466|NCT03157128|TBL1XR1-RET
800467|NCT03157128|BCR-RET
800468|NCT03157128|FGRF1OP-RET
800469|NCT03157128|RFG8-RET
800470|NCT03157128|RET-PTC9
800471|NCT03157128|ACBD5-RET
800472|NCT03157128|MYH13-RET
800473|NCT03157128|CUX1-RET
800474|NCT03157128|KIAA1468-RET
800475|NCT03157128|FRMD4A-RET
800476|NCT03157128|SQSTM1-RET
800477|NCT03157128|AFAP1L2-RET
800478|NCT03157128|PPFIBP2-RET
800479|NCT03157128|EML4-RET
800480|NCT03157128|PARD3-RET
800481|NCT03157128|G533C
800482|NCT03157128|C609F
800483|NCT03157128|C609G
800484|NCT03157128|C609R
800485|NCT03157128|C609S
800486|NCT03157128|C609Y
800487|NCT03157128|C611F
800488|NCT03157128|C611G
800489|NCT03157128|C611S
800490|NCT03157128|C611Y
800491|NCT03157128|C611W
800492|NCT03157128|C618F
800493|NCT03157128|C618R
800494|NCT03157128|C618S
800495|NCT03157128|C620F
800496|NCT03157128|C620R
800497|NCT03157128|C620S
800498|NCT03157128|C630R
800499|NCT03157128|C630Y
800500|NCT03157128|D631Y
800501|NCT03157128|C634F
800502|NCT03157128|C634G
800503|NCT03157128|C634R
800504|NCT03157128|C634S
800505|NCT03157128|C634W
800506|NCT03157128|C634Y
800507|NCT03157128|K666E
800508|NCT03157128|E768D
800509|NCT03157128|L790F
800510|NCT03157128|V804L
800511|NCT03157128|V804M
800512|NCT03157128|A883F
800513|NCT03157128|S891A
800514|NCT03157128|R912P
800515|NCT03157128|CLIP1-RET
800516|NCT03157128|Y806C
800517|NCT03157128|RET fusion
800518|NCT03157128|RET alteration
800519|NCT03157128|RET mutation
800520|NCT03157128|RET rearrangement
800521|NCT03157128|RET translocation
800522|NCT03157128|Neoplasms by Site
800523|NCT03157128|Neoplasms
800524|NCT03157128|Non-Small Cell Lung Cancer
800525|NCT03157128|Lung Neoplasms
800526|NCT03157128|Carcinoma, Non-Small-Cell Lung
800527|NCT03157128|Cancer of Lung
800528|NCT03157128|Cancer of the Lung
800529|NCT03157128|Lung Cancer
800530|NCT03157128|Neoplasms, Lung
800531|NCT03157128|Neoplasms, Pulmonary
800532|NCT03157128|Pulmonary Cancer
800533|NCT03157128|Pulmonary Neoplasms
800534|NCT03157128|Respiratory Tract Neoplasms
800535|NCT03157128|Lung Diseases
800536|NCT03157128|Respiratory Tract Diseases
800537|NCT03157128|Carcinoma, Bronchogenic
800538|NCT03157128|Bronchial Neoplasms
800539|NCT03157128|Medullary Thyroid Cancer
800540|NCT03157128|Papillary Thyroid Cancer
800541|NCT03157128|Thyroid Diseases
800542|NCT03157128|Thyroid Neoplasms
800543|NCT03157128|Cancer of the Thyroid
800544|NCT03157128|Cancer of Thyroid
800545|NCT03157128|Neoplasms, Thyroid
800546|NCT03157128|Thyroid Ademona
800547|NCT03157128|Thyroid Cancer
800548|NCT03157128|Thyroid Carcinoma
800549|NCT03157128|Endocrine System Diseases
800550|NCT03157128|Endocrine Gland Neoplasms
800551|NCT03157128|Head and Neck Neoplasms
800552|NCT03157128|Thoracic Neoplasms
800553|NCT03157128|CNS tumor
800554|NCT03157128|Primary CNS tumor
800555|NCT03157128|Cancer of Colon
800556|NCT03157128|Cancer of the Colon
800557|NCT03157128|Colon Cancer
800558|NCT03157128|Colon Neoplasms
800559|NCT03157128|Colonic Cancer
800560|NCT03157128|Neoplasms, Colonic
800561|NCT03157128|Malignant tumor of Breast
800562|NCT03157128|Mammary Cancer
800563|NCT03157128|Mammary Carcinoma, Human
800564|NCT03157128|Mammary Neoplasm, Human
800565|NCT03157128|Neoplasms, Breast
800566|NCT03157128|Tumors, Breast
800567|NCT03157128|Human Mammary Carcinoma
800568|NCT03157128|Malignant Neoplasm of Breast
800569|NCT03157128|Breast Carcinoma
800570|NCT03157128|Breast Tumors
800571|NCT03157128|Cancer of the Breast
800572|NCT03157128|Breast Neoplasms
800573|NCT03157128|Breast Cancer
800574|NCT03157115|Kinocardiography
800575|NCT03157115|Cardiac contractility
800576|NCT03157115|Heart kinetic energy
800577|NCT03157102|children
800578|NCT03157102|status asthmaticus
800579|NCT03157102|HFNC
800580|NCT03157011|Primary Sjögren syndrome - Digestive symptoms
800593|NCT03156907|High dosage Buprenorphine (HDB)
800594|NCT03156907|Chronic pain
800595|NCT03156907|Analgesics opioids
800596|NCT03156907|Withdrawal symptoms
800597|NCT03156894|Graft Dysfunction
800598|NCT03156894|Primary Graft Dysfunction
800599|NCT03156894|heart transplant
800600|NCT03156894|heart failure
800601|NCT03156894|Hemodynamic parameters
800602|NCT03156894|Incidence of PDG
800603|NCT03156855|efficacy
800604|NCT03156855|safety
800605|NCT03156855|H. pylori eradication
800606|NCT03156842|Hypertension
800607|NCT03156842|Dyslipidemia
800608|NCT03156842|Fimasartan
800609|NCT03156842|Rosuvastatin
800610|NCT03156829|splinting
800611|NCT03156829|steroid
800612|NCT03156829|cortisone
800613|NCT03156829|trigger digit
800614|NCT03156816|Myocardial Infarction
800615|NCT03156816|STEMI
800616|NCT03156816|Inflammation
800617|NCT03156816|Left ventricular remodeling
800618|NCT03156816|Colchicine
800619|NCT03156816|CMR
800620|NCT03156790|recombinant L-Asparaginase
800621|NCT03156790|Spectrila®
800622|NCT03156790|Lymphoblastic Leukaemia
800623|NCT03156790|BRALL 2014
800624|NCT03156777|Gastric cancer; Circulating tumor cells; Prognosis
800625|NCT03156764|Qp/Qs ratio
800626|NCT03156764|Pediatric congenital heart disease
800627|NCT03156751|Syphilis screening
800628|NCT03156751|antenatal care
800629|NCT03156751|prenatal diagnosis
800630|NCT03156751|rapid diagnosis test
800631|NCT03156751|Burkina Faso
800632|NCT03156751|feasibility
800633|NCT03156725|Iron Bioavailability
800634|NCT03156725|hepcidin
800635|NCT03156725|ferritin
800636|NCT03156725|iron absorption
800637|NCT03156725|iron status
800638|NCT03156712|Anemia
800639|NCT03156712|Iron deficiency anemia
800640|NCT03156712|Iron fortification
800641|NCT03156712|ferrous sulfate
800642|NCT03156712|aspergillus oryzae
800643|NCT03156712|iron supplementation
800644|NCT03156712|AUC
800645|NCT03156686|Acute Heart Failure
800646|NCT03156686|Chronic Heart Failure
800647|NCT03156686|Home care services
800648|NCT03156686|Cost-Benefit Analysis
800649|NCT03156686|Quality of life
800650|NCT03156634|Patient education
800651|NCT03156634|Internet
800652|NCT03156608|External Fetal Heart Rate Monitor
800653|NCT03156608|Fetal Heart Rate Monitor
800654|NCT03156582|liver transplantation, hepatocellular carcinoma, alpha-foetoproteins, AFP
800655|NCT03156569|saliva , dental , oral health
800656|NCT03156530|Acupunture
800657|NCT03156530|Acupunture Therapy
800658|NCT03156530|Acupunture Points
800659|NCT03156530|Acupunture Ear
800660|NCT03156530|Postural Balance
800661|NCT03156517|Treatment
800662|NCT03156517|Deep Brain Stimulation
800663|NCT03156517|VIM Nucleus of the Thalamus
800664|NCT03156517|Posterior Subthalamic Area
800665|NCT03156517|Zona Incerta
800666|NCT03156517|Efficacy
800667|NCT03156517|Safety
800668|NCT03156491|recurrent miscarriages (RM)
800669|NCT03156491|recurrent pregnancy loss (RPL)
800670|NCT03156491|fetal-maternal interface
800671|NCT03156491|decidualization
800672|NCT03156491|co-culture
800673|NCT03156491|implantation
800674|NCT03156491|immune regulation
800675|NCT03156478|Prevention
800676|NCT03156478|Digital solutions
800677|NCT03156478|Type 2 diabetes
800678|NCT03156478|Life style modification
800679|NCT03156478|Physical activity
800680|NCT03156478|Healthy diet
800681|NCT03156478|Health economics
800682|NCT03156478|Environmental choice architecture
800683|NCT03156478|Socio-economic facilitators
800684|NCT03156478|Socio-economic barriers
800685|NCT03156478|Wellbeing
800686|NCT03156387|diode laser
800687|NCT03156387|scalpel surgery
800688|NCT03156387|frenectomy
800689|NCT03156387|postoperative complications
800690|NCT03156348|Pharmaceutical intervention
800691|NCT03156348|Older adult
800692|NCT03156348|Internal medicine
800693|NCT03156348|Adverse drug event
800694|NCT03156322|cesarean section
800695|NCT03156322|combined spinal epidural anesthesia
800696|NCT03156322|patient controlled epidural analgesia
800697|NCT03156322|postoperative pain
800698|NCT03156296|transversus abdominis plane block , Dexmedetomidine
800702|NCT03156270|nasal valve
800703|NCT03156270|nasal airway obstruction
800704|NCT03156257|Microgravity Effects on Vascular Cells
800706|NCT03156231|airway disease
800707|NCT03156231|bronchitis
800708|NCT03156231|emphysema
800709|NCT03156231|altitude
800710|NCT03156231|prevention
800711|NCT03156231|acetazolamide
800712|NCT03156218|PaO2/FiO2 ratio, hyperoxia, mechanical ventilation, ARDS
800713|NCT03156205|critically ill patients
800714|NCT03156205|music therapy
800715|NCT03156205|sleep
800716|NCT03156205|delirium
800717|NCT03156205|melatonin
800718|NCT03156205|elderly
800719|NCT03156192|Caregivers
800720|NCT03156192|Family-centered care
800721|NCT03156192|Music use
800722|NCT03156192|Psycho-social benefits of music
800723|NCT03156088|Predictors
800724|NCT03156088|Sacral neuromodulation
800725|NCT03156088|Outcomes
800726|NCT03156088|Overactive bladder
800727|NCT03156075|hip fracture, intervention, mortality, mobility
800728|NCT03156036|Temozolomide
800729|NCT03156036|Capecitabine
800730|NCT03156036|MGMT
800731|NCT03156010|oculomotor testing
800732|NCT03155997|early stage breast cancer
800733|NCT03155997|cyclin-dependent kinase (CDK)
800734|NCT03155971|Drug-Coated Balloon
800735|NCT03155971|Main Coronary Artery
800736|NCT03155971|De Novo Lesion
800737|NCT03155919|taurine
800738|NCT03155919|triathletes
800739|NCT03155919|oxidative stress
800740|NCT03155919|chocolate milk
800741|NCT03155906|Chronic hepatitis C
800742|NCT03155906|Opiate Substitution Treatment
800743|NCT03155906|Integrated Delivery of Health Care
800744|NCT03155906|Substance Abuse Treatment Centers
800750|NCT03155828|PCOS, OSA, CPAP
800751|NCT03155763|kidney transplantation
800752|NCT03155763|implantation biopsy
800753|NCT03155763|histology
800754|NCT03155763|allograft function
800755|NCT03155763|allograft survival
800756|NCT03155750|insomnia
800757|NCT03155737|Knee Osteoarthritis
800758|NCT03155685|antipsychotic
800759|NCT03155685|palliative care
800760|NCT03155659|Fish
800761|NCT03155659|Polyunsaturated fatty acids
800762|NCT03155659|Mortality
800763|NCT03155659|CHNS
800764|NCT03155659|NHANES
800765|NCT03155646|TAP block
800766|NCT03155646|Dexmedetomidine
800767|NCT03155646|Clonidine
800768|NCT03155633|Marathon, runners, biomarkers, recovery
800769|NCT03155594|Diabetes
800770|NCT03155594|Diabetes Mellitus
800771|NCT03155594|Diabetes Type 1
800772|NCT03155594|Diabetes Type 2
800773|NCT03155594|CGM
800774|NCT03155594|Continuous Glucose Monitoring
800775|NCT03155594|Inpatient
800776|NCT03155594|Outpatient
800777|NCT03155594|Transition of care
800778|NCT03155594|DM-1
800779|NCT03155594|DM-2
800780|NCT03155594|Freestyle Libre
800781|NCT03155555|Fluid Responsiveness
800782|NCT03155555|Pediatric surgery
800783|NCT03155555|General endotracheal anaesthesia
800784|NCT03155542|alcohol
800785|NCT03155542|gene polymorphisms
800786|NCT03155542|Colorectal cancer
800787|NCT03155529|cervical cancer
800788|NCT03155529|radical hysterectomy
800789|NCT03155529|Postoperative pelvic floor dysfunction
800790|NCT03155529|the injure of pelvic floor
800791|NCT03155529|Three-dimensional reconstruction
800792|NCT03155529|structural destruction of pelvic organs
800793|NCT03155529|structural destruction of pelvoic floor
800794|NCT03155516|Cancer pain
800795|NCT03155516|GPM
800796|NCT03155516|pain assessment
800797|NCT03155503|SUVN-911
800798|NCT03155503|Depression
800799|NCT03155503|single dose
800800|NCT03155503|multiple dose
800801|NCT03155503|alpha4 beta2 receptor
800802|NCT03155503|first in human
800803|NCT03155503|safety
800804|NCT03155503|pharmacokinetics
800805|NCT03155503|tolerability
800806|NCT03155490|Hospital medical emergency team
800807|NCT03155490|Leadership
800808|NCT03155490|Simulation training
800809|NCT03155477|SLE, vitamin D, SLEDAI, IL-6, TGF- β1
800810|NCT03155464|indocyanine-green
800811|NCT03155464|systemic scerlosis
800812|NCT03155438|Oxidative stress
800813|NCT03155438|Cumulus cell
800814|NCT03155438|Controlled ovarian hyperstimulation
800815|NCT03155438|In vitro fertilization
800816|NCT03155438|Low responder
800817|NCT03155412|Type 2 Diabetes
800818|NCT03155412|adipose tissue
800819|NCT03155412|preadipocytes
800820|NCT03155412|expandability
800821|NCT03155412|hypertrophy
800822|NCT03155412|hyperplasia
800823|NCT03155412|lipogenesis
800824|NCT03155412|adipogenesis
800825|NCT03155412|insulin sensitivity
800826|NCT03155399|Stroke
800827|NCT03155399|Neurorehabilitation
800828|NCT03155399|Proprioceptive Training
800829|NCT03155399|Bilateral Arm Training
800830|NCT03155399|Intracortical Inhibition
800831|NCT03155373|Cardiopulmonary exercise testing
800832|NCT03155360|Colics
800833|NCT03155360|infant colics
800834|NCT03155360|Migraine equivalent
800835|NCT03155360|Migraine
800836|NCT03155360|Episodic symptoms associated to migraine
800837|NCT03155360|Colic
800838|NCT03155334|Multiple Sclerosis; Patient Information Sheet; User Testing
800839|NCT03155256|EUS, cyanoacrylate, coils, gastric varices
800840|NCT03155243|Humira®
800841|NCT03155243|Ocular inflammation
800842|NCT03155243|Adalimumab
800843|NCT03155243|Active non-infectious intermediate, posterior and panuveitis
800844|NCT03155230|Inguinal hernia
800845|NCT03155217|melanoma
800846|NCT03155217|elderly
800847|NCT03155217|tolerance
800848|NCT03155217|adverse effects
800849|NCT03155217|targeted therapies
800850|NCT03155204|inhalation
800851|NCT03155204|LABA
800852|NCT03155204|corticosteroid
800867|NCT03155165|Colonoscopy, Retroview™ colonoscope, retrofex colonoscopy
800868|NCT03155139|prevalence
800869|NCT03155139|primary aldosteronism
800870|NCT03155139|hypertension
800871|NCT03155139|nationwide
800872|NCT03155126|shock
800873|NCT03155126|acute kidney injury
800874|NCT03155126|crystalloid
800875|NCT03155113|Chronic infection
800876|NCT03155113|HCV
800877|NCT03155113|DAA therapy
800878|NCT03155113|immune response
800879|NCT03155087|T2DM
800880|NCT03155087|genetic polymorphism
800881|NCT03155087|diabetic nephropathy
800882|NCT03155035|deworming
800883|NCT03155035|STH
800884|NCT03155022|ST-elevation myocardial infarction
800885|NCT03154996|Gliomas
800886|NCT03154996|Recurrent
800887|NCT03154996|Chronic Convection
800888|NCT03154996|High Grade Gliomas
800889|NCT03154983|Mesylate Apatinib
800890|NCT03154983|The First-line Treatment
800891|NCT03154983|Metastatic Gastric Cancer
800892|NCT03154970|Physical Therapy Specialty
800893|NCT03154931|PTSD
800894|NCT03154931|CBT
800895|NCT03154931|CFT
800896|NCT03154931|compassion
800897|NCT03154931|shame
800898|NCT03154931|guilty
800899|NCT03154931|self-criticism
800900|NCT03154879|Heart arrest
800901|NCT03154879|Hypothermia
800902|NCT03154879|EEG
800903|NCT03154879|Prognosis
800904|NCT03154866|Lactobacillus kefiri LKF01 DSM32079
800905|NCT03154866|Microbial Colonization
800906|NCT03154853|Electromyography,Excessive Foot Pronation,exercise,neurology,physical therapy
800907|NCT03154814|ulinastatin
800908|NCT03154814|cardiopulmonary bypass
800909|NCT03154814|cardiac surgery
800910|NCT03154788|Falls prevention
800911|NCT03154788|Community-Based Participatory Research
800912|NCT03154749|Neoadjuvant chemotherapy
800913|NCT03154749|Triple-Negative Breast Cancer
800914|NCT03154736|CVD
800915|NCT03154736|FDRCV
800916|NCT03154736|Developing countries
800917|NCT03154736|Rcih countries
800918|NCT03154710|Web-mediated follow up
800919|NCT03154710|Lymphoma
800920|NCT03154710|Personalized medicine
800921|NCT03154684|Autonomy
800922|NCT03154684|Rehabilitation
800923|NCT03154684|Falls
800924|NCT03154684|Quality of life
800925|NCT03154684|Senior
800926|NCT03154671|older adult;
800927|NCT03154671|comprehensive geriatric assessment
800928|NCT03154671|chemotherapy
800929|NCT03154671|integrated care
800930|NCT03154671|randomized controlled trial
800931|NCT03154632|Myofascial trigger point
800932|NCT03154632|Trapezius Muscle
800933|NCT03154632|Diathermy
800934|NCT03154632|Ultrasound
800935|NCT03154593|Prevalence
800936|NCT03154541|Chronic Rhinosinusitis (CRS), Cystic Fibrosis related CRS
800937|NCT03154515|Respiratory Tract Infections
800938|NCT03154515|Acute Respiratory Viral Infection
800939|NCT03154502|Sodium intake
800940|NCT03154502|Urinary sodium excretion
800941|NCT03154411|ABY-029
800942|NCT03154411|Affibody
800943|NCT03154411|molecular fluorescence-guided surgery
800944|NCT03154411|Epidermal Growth Factor Receptor (EGFR)
800945|NCT03154398|evaluation of thyroid function in diabetes patients
800946|NCT03154385|ITP
800947|NCT03154346|Baseline
800948|NCT03154346|Project Baseline
800949|NCT03154346|Baseline Study
800950|NCT03154346|Project Baseline Study
800951|NCT03154333|Epidermolysis
800952|NCT03154333|bullosa
800953|NCT03154333|simplex
800954|NCT03154333|blister
800955|NCT03154333|EBS
800956|NCT03154333|topical
800957|NCT03154333|ointment
800958|NCT03154333|lesion
800959|NCT03154281|Breast
800960|NCT03154281|Ovarian
800961|NCT03154268|Gestational weight gain
800962|NCT03154268|Chinese pregnant women
800963|NCT03154268|Retrospective longitudinal study
800964|NCT03154268|China
800965|NCT03154268|IOM guideline
800966|NCT03154268|Adverse outcome
800967|NCT03154268|Model
800968|NCT03154255|Obesity
800969|NCT03154255|Paediatric
800970|NCT03154255|Mediterranean diet
800971|NCT03154255|Gamification
800972|NCT03154255|Insulin-resistance
800973|NCT03154242|non small cell lung cancer
800974|NCT03154242|NSCLC
800975|NCT03154242|Platinum
800976|NCT03154151|PTSD
800977|NCT03154151|Post-Traumatic Stress Disorder
800978|NCT03154151|Post-Traumatic Stress Disorder symptoms
800979|NCT03154151|World Trade Center
800980|NCT03154151|9/11
800981|NCT03154151|first responder
800982|NCT03154151|rescue/recovery/clean-up worker
800983|NCT03154138|Stroke
800984|NCT03154138|hemiplegia
800985|NCT03154138|rehabilitation
800986|NCT03154138|prismatic adaptation
800987|NCT03154138|postural imbalance
800988|NCT03154138|posture
800989|NCT03154138|spatial cognition
800990|NCT03154099|CIRCI
800991|NCT03154086|REarranged during Transfection
800992|NCT03154073|Exercise
800993|NCT03154073|Physical activity
800994|NCT03154073|Blood glucose
800995|NCT03154073|Sleep
800996|NCT03154060|Flash glucose monitoring
800997|NCT03154060|Accuracy
800998|NCT03154060|Precision
800999|NCT03154034|Stress echocardiography
801000|NCT03154034|Cardiopulmonary exercise testing
801001|NCT03154034|ergospirometry
801002|NCT03154021|Gingival Index
801003|NCT03154021|Plaque Index
801004|NCT03154021|Bleeding
801005|NCT03154021|Pocket Depth
801006|NCT03154008|reward
801007|NCT03154008|emotion regulation
801008|NCT03154008|electroencephalogram
801009|NCT03154008|event-related potentials
801010|NCT03154008|cognitive behavior therapy
801011|NCT03153995|expander
801012|NCT03153982|HNSCC
801013|NCT03153956|AposTherapy® System
801014|NCT03153956|Osteoarthritis
801015|NCT03153956|Total knee arthroplasties
801016|NCT03153956|Degenerative joint disease
801017|NCT03153930|sedentary behavior
801018|NCT03153930|youth
801019|NCT03153930|moderating factors
801020|NCT03153930|metabolic outcomes
801024|NCT03153904|anxiety
801025|NCT03153904|depression
801026|NCT03153904|trauma
801027|NCT03153904|behavior problems
801028|NCT03153904|evidence-based treatments
801029|NCT03153904|manualized treatments
801030|NCT03153904|cognitive-behavioral therapy
801031|NCT03153904|youth
801032|NCT03153904|mental health
801033|NCT03153891|environment
801034|NCT03153891|nature
801035|NCT03153878|Unruptured Intracranial Aneurysm
801036|NCT03153878|Benefit-risk
801037|NCT03153878|Ischemic heart disease
801038|NCT03153878|Ischemic cerebrovascular disease
801039|NCT03153878|Antithrombotic
801040|NCT03153878|Anticoagulant
801041|NCT03153878|People's Republic of China
801042|NCT03153878|Multicenter Studies
801043|NCT03153839|Children
801044|NCT03153839|Babies
801045|NCT03153839|Infant
801046|NCT03153839|Swimming pool
801047|NCT03153839|Aquatic physical activity
801048|NCT03153839|Motor development
801049|NCT03153839|Neurodevelopment
801050|NCT03153826|COPD Exacerbation
801051|NCT03153826|Muscle atrophy
801052|NCT03153826|Inflammation
801053|NCT03153826|Oxidative stress
801054|NCT03153813|pain
801055|NCT03153813|knee osteoarthritis
801056|NCT03153813|obesity
801057|NCT03153813|capsaicin
801058|NCT03153787|implantation failure
801059|NCT03153787|fertility
801060|NCT03153787|microbiome
801061|NCT03153787|Assisted reproduction
801062|NCT03153774|Sarcopenia
801063|NCT03153774|Heart failure (HF)
801064|NCT03153774|The trans aortic valvular implantation (TAVI)
801065|NCT03153748|Treatment strategy
801066|NCT03153735|Hyaluronic acid
801067|NCT03153735|Small Penis
801068|NCT03153735|Penile Enhancement
801069|NCT03153722|pediatric
801070|NCT03153722|hospital discharge
801071|NCT03153722|quality improvement
801072|NCT03153722|transition of care
801073|NCT03153709|Pregnancy rates
801074|NCT03153709|pharmacokinetic interactions
801075|NCT03153709|Women on efavirenz
801076|NCT03153709|initiating the Levonorgestrel Implant
801077|NCT03153709|initiating the Depot Medroxyprogesterone Acetate Injectable
801078|NCT03153683|Acute, Ischemic, Stroke, Biomarkers, Proteins, Leukocyte, Inflammatory Cells; Acid/Base Balance
801079|NCT03153657|Tooth Bleaching
801080|NCT03153644|Qualitative Research
801081|NCT03153644|Medical conditions
801082|NCT03153644|Birth control methods
801083|NCT03153644|Intrauterine Devices
801084|NCT03153644|Physicians, Primary Care
801085|NCT03153644|Long-acting reversible contraceptives (LARC)
801086|NCT03153540|Aphasia
801087|NCT03153540|Agrammatism
801088|NCT03153540|Frontotemporal Dementia
801089|NCT03153540|Tauopathies
801090|NCT03153540|Neurodegenerative Diseases
801091|NCT03153540|Language Disorders
801092|NCT03153540|Frontotemporal Lobar Degeneration
801093|NCT03153514|CLL
801094|NCT03153488|ADHD
801095|NCT03153488|Methylphenidate
801096|NCT03153488|Amphetamine
801097|NCT03153488|Attention Deficit Hyperactivity Disorder
801098|NCT03153488|Treatment
801099|NCT03153475|Revision knee surgery, implant replacement
801100|NCT03153449|complex primary, deformity, ligamentous laxity
801101|NCT03153410|Pancreas vaccine
801102|NCT03153410|immunotherapy
801103|NCT03153410|antibody
801104|NCT03153410|PD-1
801105|NCT03153410|IMC-CS4
801106|NCT03153410|Pembrolizumab
801107|NCT03153410|GVAX
801108|NCT03153410|Borderline Resectable
801109|NCT03153397|trauma
801110|NCT03153397|brain
801111|NCT03153397|neurological
801112|NCT03153397|injury
801113|NCT03153397|enteral
801114|NCT03153397|tube
801115|NCT03153397|feeding
801116|NCT03153397|nutrition
801117|NCT03153384|Diagnosis
801118|NCT03153384|Blood Culture
801119|NCT03153371|Alzheimer's disease
801120|NCT03153371|Young-onset
801121|NCT03153371|variant
801122|NCT03153371|visuospatial
801123|NCT03153371|language
801124|NCT03153371|apraxia
801125|NCT03153371|control
801126|NCT03153371|dementia
801127|NCT03153371|memory
801128|NCT03153371|MRI
801129|NCT03153371|neurology
801130|NCT03153371|neuropsychology
801131|NCT03153371|brain
801132|NCT03153358|EGFR mutation icotinib SBRT
801133|NCT03153306|Albumin
801134|NCT03153293|Leber's Hereditary Optic Neuropathy,G11778A mutation, rAAV2-ND4，gene therapy
801135|NCT03153254|Upper extremity
801136|NCT03153254|Rehabilitation
801137|NCT03153254|Robot assisted therapy
801138|NCT03153254|Robotics
801139|NCT03153254|Devices
801140|NCT03153254|Orthosis
801141|NCT03153228|E-cigarettes
801142|NCT03153202|Ibrutinib
801143|NCT03153202|Pembrolizumab
801144|NCT03153202|Chronic Lymphocytic Leukemia
801145|NCT03153202|Mantle Cell Lymphoma
801146|NCT03153189|PA,menatal health,QOL
801147|NCT03153176|physical activity
801148|NCT03153176|physical fitness
801149|NCT03153176|eating habits
801150|NCT03153176|sedentary behavior
801151|NCT03153176|sleep quality
801152|NCT03153176|satisfaction personal
801153|NCT03153176|school health
801154|NCT03153176|adolescent
801155|NCT03153150|Oral anticoagulant
801156|NCT03153150|Factor Xa inhibitors
801157|NCT03153150|Direct thrombin inhibitor
801158|NCT03153150|Vitamin K antagonist
801159|NCT03153150|Antiplatelet drug
801160|NCT03153124|Respiratory muscle strength
801161|NCT03153124|Renal insufficiency
801162|NCT03153124|Respiratory muscle training
801163|NCT03153098|physical activity
801164|NCT03153098|intervention
801165|NCT03153098|behaviour change
801166|NCT03153098|inactive adults
801167|NCT03153098|behaviour change techniques
801168|NCT03153098|well-being
801169|NCT03153085|Unresectable melanoma
801170|NCT03153085|Metastatic melanoma
801171|NCT03153085|Recurrent Melanoma
801172|NCT03153085|TBI-1401(HF10)
801173|NCT03153085|HF10
801174|NCT03153085|HSV-1
801175|NCT03153085|Oncolytic virus
801176|NCT03153085|Oncolytic viral immunotherapy
801177|NCT03153085|Ipilimumab
801178|NCT03153085|Intratumoral administration
801179|NCT03153059|gut microbiota
801180|NCT03153059|stool frequency
801181|NCT03153046|prebiotics
801182|NCT03153046|cognitive impairment
801183|NCT03153046|weight gain
801184|NCT03153033|Wheelchair propulsion
801185|NCT03153033|Shoulder
801186|NCT03153033|Biomechanics
801187|NCT03152994|Chronic Obstructive Pulmonary Disease
801188|NCT03152994|Type 2 Diabetes Mellitus
801189|NCT03152994|neutrophil-lymphocyte ratio
801190|NCT03152994|platelet-lymphocyte ratio
801191|NCT03152994|lymphocyte-monocyte ratio
801192|NCT03152968|FMS
801193|NCT03152955|trigeminal neuralgia
801194|NCT03152955|nerve block
801195|NCT03152929|Surgery
801196|NCT03152929|Breast
801197|NCT03152929|Pectoral Never Block
801198|NCT03152929|Paravertebral Block
801199|NCT03152929|Analgesia
801200|NCT03152929|Mastectomy
801201|NCT03152916|subtalar joint
801202|NCT03152916|arthrodesis
801203|NCT03152916|3d printing
801204|NCT03152903|Recombinant BCG vaccine
801205|NCT03152903|Category 1 pulmonary tuberculosis
801206|NCT03152903|Recurrence
801207|NCT03152903|Efficacy
801208|NCT03152890|Insulin
801209|NCT03152890|Liver transplantation
801210|NCT03152890|Hyperglycemia
801211|NCT03152825|myocardial ischaemia
801212|NCT03152825|myocardial viability
801213|NCT03152825|coronary chronic total occlusions
801214|NCT03152825|cardiac magnetic resonance
801215|NCT03152825|stress CMR
801216|NCT03152799|remote ischaemic conditioning
801217|NCT03152799|remote ischemic conditioning
801218|NCT03152799|cerebral infarction
801219|NCT03152799|ischaemia reperfusion injury
801220|NCT03152799|ischemia reperfusion injury
801221|NCT03152799|anterior circulation stroke
801222|NCT03152799|mechanical thrombectomy
801229|NCT03152734|Elderly patients, Mortality, morbidity, post-intervention
801230|NCT03152721|accelerometry
801231|NCT03152721|home based
801232|NCT03152721|motor complications
801233|NCT03152721|Parkinson KinetiGraph
801234|NCT03152721|Registry
801235|NCT03152682|glucose
801236|NCT03152682|glucose homeostasis
801237|NCT03152669|asthma
801238|NCT03152669|Chronic obstructive pulmonary disease
801239|NCT03152669|Salford Lung Study
801240|NCT03152656|Familial hypercholesterolemia
801241|NCT03152656|total cholesterol
801242|NCT03152656|low-density lipoprotein cholesterol
801243|NCT03152656|tendon xanthomas
801244|NCT03152656|premature atherosclerosis
801245|NCT03152630|lncRNAs
801246|NCT03152630|Alzheimer's disease
801247|NCT03152630|vascular dementia
801248|NCT03152617|bariatric surgery
801249|NCT03152617|gastric bypass
801250|NCT03152617|malnutrition
801251|NCT03152617|bone disease
801252|NCT03152617|oral health
801253|NCT03152591|Polycystic ovary syndrome
801254|NCT03152591|PCOS
801255|NCT03152591|hyperandrogenism
801256|NCT03152591|insulin resistance
801257|NCT03152591|overweight
801258|NCT03152591|obesity
801259|NCT03152552|diabetes type 2
801260|NCT03152552|heart failure
801261|NCT03152500|IOL
801262|NCT03152500|Stability
801263|NCT03152500|FEMTIS IOL
801264|NCT03152500|Acrysof IOL
801265|NCT03152500|FLACS
801266|NCT03152500|Capsulotomy
801267|NCT03152487|endoscopic ultrasound
801268|NCT03152487|celiac plexus neurolysis
801269|NCT03152487|radiofrequency ablation
801270|NCT03152487|pancreatic cancer
801271|NCT03152461|Viscoelastic testing
801272|NCT03152461|Coagulation
801273|NCT03152461|Quantra
801274|NCT03152461|Hemostasis
801275|NCT03152448|Prolaris
801276|NCT03152448|Prostate Cancer
801277|NCT03152409|Aspirin
801278|NCT03152409|Treatment
801279|NCT03152409|Salicylic acid
801280|NCT03152409|anti-inflammatory
801281|NCT03152396|modifiable cardiovascular risk factors
801282|NCT03152396|cardiovascular risk factors
801283|NCT03152396|blood pressure
801284|NCT03152396|LDL-cholesterol
801285|NCT03152396|total-cholesterol
801286|NCT03152396|HDL-cholesterol
801287|NCT03152396|hemoglobin A1C
801288|NCT03152396|tobacco cessation
801289|NCT03152396|patient satisfaction
801290|NCT03152383|Autism Spectrum Disorder
801291|NCT03152383|Behavioral Research
801292|NCT03152383|Psychology
801293|NCT03152383|Cognitive Disorders
801294|NCT03152370|E7046
801295|NCT03152370|Radiotherapy/Chemoradiotherapy
801296|NCT03152370|Neoadjuvant therapy
801297|NCT03152370|Rectal cancer
801298|NCT03152357|osteoarthritis
801299|NCT03152357|total knee arthroplasty
801300|NCT03152357|TKA
801301|NCT03152357|TKR
801302|NCT03152357|patient specific
801303|NCT03152357|Conformis
801304|NCT03152344|Fall
801305|NCT03152344|Balance control
801306|NCT03152344|Screening test
801307|NCT03152344|Oxygen
801308|NCT03152344|Skeletal muscle mass
801309|NCT03152331|Neurofeedback
801310|NCT03152318|Malignant Glioma
801311|NCT03152305|Migraine
801312|NCT03152305|Intracranial pressure
801313|NCT03152305|Headache
801314|NCT03152253|Tobacco, Smoking, Text Message
801315|NCT03152240|Acute Coronary Syndrome
801316|NCT03152240|Primary Angioplasty
801317|NCT03152240|Gender
801318|NCT03152214|Transition out of military
801325|NCT03152175|Memory Reconsolidation
801326|NCT03152175|Propranolol
801327|NCT03152175|Police officers
801328|NCT03152175|911 operators
801329|NCT03152175|Efficacy
801330|NCT03152175|Cost-effectiveness
801331|NCT03152162|osteoarthritis
801332|NCT03152162|patient-specific
801333|NCT03152162|knee replacement
801334|NCT03152162|TKA
801335|NCT03152162|knee arthroplasty
801336|NCT03152162|total knee replacement
801337|NCT03152162|posterior stabilized
801338|NCT03152149|Chronic Obstructive Pulmonary Disease
801339|NCT03152110|High Intensity Interval Training
801340|NCT03152110|HIIT
801341|NCT03152110|Physical Activity
801342|NCT03152071|thoracoscopic surgery
801343|NCT03152071|RATS
801344|NCT03152071|VATS
801345|NCT03152071|Robot
801347|NCT03152032|employment service
801348|NCT03152032|vocational counseling
801349|NCT03152032|employment outcome
801350|NCT03152032|schizophrenia
801351|NCT03152032|bipolar
801352|NCT03152032|occupational therapy in mental health
801353|NCT03152019|Hemorrhagic Hereditary Telangiectasia (HHT)
801354|NCT03152019|Antiangiogenic therapy
801355|NCT03152019|Tacrolimus
801356|NCT03152006|Healthcare transition
801357|NCT03152006|Adolescents
801358|NCT03152006|Nigeria
801359|NCT03151993|Ischemic Stroke
801360|NCT03151993|Fibrinolysis
801361|NCT03151993|Fortelyzin
801362|NCT03151954|nasal epithelium stem cells
801363|NCT03151954|Hippo-YAP pathway
801364|NCT03151954|proliferation
801365|NCT03151954|differentiation
801366|NCT03151863|Dexmedetomidine
801367|NCT03151863|Opioids
801368|NCT03151863|Palliative Care
801369|NCT03151863|Elderly people
801370|NCT03151863|Nursing care
801371|NCT03151863|Analgesia
801372|NCT03151863|Sedation
801373|NCT03151863|Anxiolysis
801374|NCT03151863|Intranasal
801375|NCT03151850|fungal
801376|NCT03151850|mucosa
801377|NCT03151850|diversity
801378|NCT03151850|Basidiomycete
801379|NCT03151837|Diabetes
801380|NCT03151837|Bitter melon(Momordica charantia)
801381|NCT03151837|Insulin sensitivity
801382|NCT03151811|Refractory Multiple Myeloma
801383|NCT03151811|Relapsed Multiple Myeloma
801384|NCT03151811|Melflufen
801385|NCT03151811|Pomalidomide
801386|NCT03151811|Dexamethasone
801387|NCT03151798|Nonalcoholic fatty liver
801388|NCT03151798|Exercise
801389|NCT03151798|Weight loss diet
801390|NCT03151785|CPR
801391|NCT03151785|Schools
801392|NCT03151785|Education
801393|NCT03151785|Lifesaver
801394|NCT03151733|SILS
801395|NCT03151733|colorectal cancer
801396|NCT03151694|childhood obesity
801397|NCT03151694|body weight
801398|NCT03151694|nutritional risk
801399|NCT03151681|Reconsolidation
801400|NCT03151681|Propranolol
801401|NCT03151681|Infidelity
801402|NCT03151681|Attachment injury
801403|NCT03151681|Romantic relationships
801404|NCT03151603|Uva Ursi
801405|NCT03151603|fosfomycin
801406|NCT03151603|uncomplicated urinary tract infection of women
801407|NCT03151564|Diseases of liver
801408|NCT03151564|Colon carcinoma
801409|NCT03151564|Colorectal carcinoma
801410|NCT03151564|Liver metastases
801411|NCT03151564|Computed tomography
801412|NCT03151564|CT
801413|NCT03151564|Reduced radiation doses
801414|NCT03151538|Pedography
801415|NCT03151538|Exercise
801416|NCT03151538|Play Training
801417|NCT03151538|Pes Planus
801418|NCT03151538|Femoral Anteversion
801419|NCT03151512|MRI
801420|NCT03151512|distortion correction
801421|NCT03151512|Magnetic Resonance Imaging
801422|NCT03151512|prostheses
801423|NCT03151447|Breast Cancer
801424|NCT03151447|Anti-PD1 Antibody
801425|NCT03151447|Stereotactic Body Radiation Therapy
801426|NCT03151434|VATS
801427|NCT03151434|pain
801428|NCT03151421|air quality feedback
801429|NCT03151421|second-hand smoke
801430|NCT03151421|passive smoking
801431|NCT03151421|exposure to second-hand smoke
801432|NCT03151421|second-hand smoke exposure prevention
801433|NCT03151408|AML
801434|NCT03151395|COPD
801435|NCT03151395|AECOPD
801436|NCT03151395|GOLD (Global Initiative for Chronic Obstructive Lung Disease)
801437|NCT03151395|Asia Pacific
801438|NCT03151382|Alzheimer Disease
801439|NCT03151382|Cognitive Function
801440|NCT03151382|tandospirone
801441|NCT03151304|MDS
801442|NCT03151291|cancer cachexia
801443|NCT03151291|WB-EMS
801444|NCT03151291|skeletal muscle mass
801445|NCT03151291|exercise
801446|NCT03151291|nutrition
801447|NCT03151291|dietary supplements
801448|NCT03151278|Fluoroscopy
801449|NCT03151278|Ablation
801450|NCT03151278|Three dimensional
801451|NCT03151278|Atrial arrhythmia
801452|NCT03151278|Radiation
801453|NCT03151265|Functional Outcome Measures
801454|NCT03151265|Wearable Sensors
801455|NCT03151265|ViMove
801456|NCT03151265|Low Back Pain
801457|NCT03151265|Range of Movement
801458|NCT03151265|Muscle Activity
801459|NCT03151265|ThermaCare
801460|NCT03151226|obstructive sleep apnea screen negative
801461|NCT03151226|respiratory depression
801462|NCT03151226|cesarean section
801463|NCT03151200|Amblyopia treatment
801464|NCT03151161|chemotherapy
801465|NCT03151161|maintenance therapy
801466|NCT03151161|icotinib
801467|NCT03151148|allogeneic targeted microbiome transplant (TMT)
801468|NCT03151148|dysbiosis in AD
801469|NCT03151148|Staphylococcus aureus colonized skin
801470|NCT03151148|antimicrobial peptides (AMPs)
801471|NCT03151148|randomized trial
801472|NCT03151135|Energy metabolism
801473|NCT03151109|reverse total shoulder arthroplasty
801474|NCT03151109|glenoid bone loss
801475|NCT03151083|Health Technology
801476|NCT03151083|Internet-Based Psychotherapy
801477|NCT03151083|self-care
801478|NCT03151083|Primary Care
801479|NCT03151083|Mental Health
801480|NCT03151057|Idelalisib
801481|NCT03151057|Gilead
801482|NCT03151057|Gladstone
801483|NCT03151057|RIC allogeneic BMT
801484|NCT03151057|Phase 1
801485|NCT03151057|Hopkins
801486|NCT03151057|B cell malignancies
801487|NCT03151044|epirubicin
801488|NCT03151044|high-dose
801489|NCT03151044|Diffuse Large B-cell Lymphoma
801490|NCT03151044|medium/high-risk
801491|NCT03151031|balance
801492|NCT03151031|college students
801493|NCT03151031|star excursion balance test
801494|NCT03151018|coronary artery disease
801495|NCT03151018|percutaneous coronary intervention
801496|NCT03151018|zotarolimus-eluting stents
801497|NCT03151005|Polycystic Ovary Syndrome (PCOS)
801498|NCT03151005|Overweight
801499|NCT03151005|Obesity
801500|NCT03151005|GLP-1 Agonist
801501|NCT03151005|Oral contraceptives (OCs)
801502|NCT03151005|Metformin
801503|NCT03151005|Reproductive Disorders
801504|NCT03151005|Cardiovascular risk factor
801505|NCT03151005|Lipid Metabolism
801506|NCT03150992|Feasibility
801507|NCT03150992|Elemental Diet
801508|NCT03150992|Quality of life
801509|NCT03150992|Palliative
801510|NCT03150992|Nutrition
801511|NCT03150992|Ovarian
801512|NCT03150992|Peritoneal
801513|NCT03150992|Advanced
801514|NCT03150992|Metastatic
801515|NCT03150992|Bowel obstruction
801516|NCT03150992|Inoperable
801517|NCT03150979|Stroke
801518|NCT03150979|Assistive devices
801519|NCT03150979|Gait
801520|NCT03150979|Rehabilitation
801521|NCT03150979|Clinical trial
801522|NCT03150966|Multiple sclerosis
801523|NCT03150966|Nanocurcumin
801524|NCT03150966|MicroRNAs
801525|NCT03150966|Th17 cells
801526|NCT03150953|anesthesia
801527|NCT03150953|MRI
801528|NCT03150953|thermoregulation
801529|NCT03150862|Adult glioblastoma, adult gian cell glioblastoma, adult gliosarcoma, glioma neoplasms
801530|NCT03150862|recurrent adult brain tumor
801531|NCT03150862|neoplasms, central nervous system neoplasms, neoplasms by histologic type, neoplasms by site
801532|NCT03150862|astrocytoma
801533|NCT03150862|neuroepithelial
801534|NCT03150862|neuroectodermal tumors
801535|NCT03150862|germ cell and embryonal
801536|NCT03150862|antineoplastic agents
801537|NCT03150862|glandular and epithelial
801538|NCT03150862|nerve tissue, nervous system diseases
801539|NCT03150862|temozolomide
801540|NCT03150862|BGB-290
801541|NCT03150862|alkylating, alkylating agents
801542|NCT03150862|molecular mechanisms of pharmacological action
801543|NCT03150862|Poly(ADP-ribose) polymerase inhibitors
801544|NCT03150862|enzyme inhibitors
801545|NCT03150836|bladder cancer
801546|NCT03150836|urothelial
801547|NCT03150823|Direct current
801548|NCT03150823|Galvanic current
801549|NCT03150823|Handgrip Force
801550|NCT03150823|Palmar Grip
801551|NCT03150823|Dynamometry
801552|NCT03150823|Miofeedback
801553|NCT03150810|Ovarian cancer
801554|NCT03150810|Triple negative breast cancer
801555|NCT03150810|Small cell lung cancer
801556|NCT03150810|Prostate cancer,
801557|NCT03150810|Gastric cancer
801558|NCT03150810|neoplasms
801559|NCT03150810|temozolomide
801560|NCT03150810|BGB-290
801561|NCT03150810|antineoplastic agents
801562|NCT03150810|alkylating, alkylating agents,
801563|NCT03150810|Poly (ADP-ribose) polymerase inhibitors
801564|NCT03150810|enzyme inhibitors
801565|NCT03150797|UCSF
801566|NCT03150797|UCLA
801567|NCT03150797|melatonin
801568|NCT03150797|migraine
801569|NCT03150797|headache
801570|NCT03150784|Motor Learning
801571|NCT03150784|Coordination
801572|NCT03150784|Children
801573|NCT03150784|Motor Skills Disorders
801574|NCT03150784|Movement
801575|NCT03150758|Erectile Disfunction
801576|NCT03150758|Urinary Function
801577|NCT03150706|POLE mutation
801578|NCT03150706|mismatch repair deficient
801579|NCT03150706|Avelumab
801580|NCT03150680|SYNTAX score
801581|NCT03150680|SNPs
801582|NCT03150680|Genetics
801583|NCT03150680|Pharmacogenetics
801584|NCT03150680|Genetic Risk Score
801585|NCT03150680|Precision Medicine
801586|NCT03150654|macular pigment
801587|NCT03150654|macular pigment optical density
801588|NCT03150654|diabetic retinopathy
801589|NCT03150654|laser pan-retinal photocoagulation
801590|NCT03150641|Maternal blood loss
801591|NCT03150641|Cesarean delivery
801592|NCT03150641|Delayed cord clamping
801593|NCT03150641|Neonatal health
801594|NCT03150576|Triple negative breast cancer
801595|NCT03150576|germline BRCA
801596|NCT03150576|platinum and PARP inhibitor
801597|NCT03150576|neoadjuvant chemotherapy
801598|NCT03150576|olaparib
801599|NCT03150563|Stretching
801600|NCT03150563|Stretching sensation
801601|NCT03150563|Isokinetic dynamometry
801602|NCT03150563|Stretching load.
801603|NCT03150550|Mindfulness
801604|NCT03150550|Alcohol
801605|NCT03150550|Alcohol Use Disorder
801606|NCT03150550|Relapse
801607|NCT03150550|Relapse Prevention
801608|NCT03150550|Cognitive-behavioral therapy
801609|NCT03150537|jet injector
801610|NCT03150537|influenza vaccine
801611|NCT03150537|immune response
801612|NCT03150524|stroke
801613|NCT03150524|RCVS
801614|NCT03150498|Food Effect
801615|NCT03150498|Pharmacokinetics
801616|NCT03150472|Dental Instruments
801617|NCT03150472|Dental Technology
801618|NCT03150446|laparoscopy
801619|NCT03150446|ureteral catheterization
801620|NCT03150420|calciphylaxis
801621|NCT03150420|calcific uremic arteriolopathy, calcinosis
801622|NCT03150420|calcium metabolism disorders
801623|NCT03150420|metabolic diseases
801624|NCT03150420|sodium thiosulfate
801625|NCT03150342|CZT scanner
801626|NCT03150342|myocardial perfusion imaging
801627|NCT03150342|Hypertrophic Cardiomyopathy
801628|NCT03150303|Periprocedural period
801629|NCT03150303|Anticoagulant treatment
801630|NCT03150303|Thromboembolic events
801631|NCT03150303|Bleeding events
801632|NCT03150264|lung protective ventilation strategies
801633|NCT03150264|obesity
801634|NCT03150225|andropause
801635|NCT03150225|depressive symptoms
801636|NCT03150225|stress
801637|NCT03150225|abdominal Obesity
801638|NCT03150225|testosterone
801639|NCT03150225|erectile dysfunction
801640|NCT03150186|second hand smoke
801641|NCT03150186|passive smoking
801642|NCT03150186|airborne nicotine
801643|NCT03150186|private settings
801644|NCT03150186|outdoors
801645|NCT03150173|opioid use disorder, syringe exchange, HIV risk reduction
801646|NCT03150160|travoprost
801647|NCT03150160|brinzolamide 1% / brimonidine 0.2%
801648|NCT03150160|normal tension glaucoma
801649|NCT03150160|intraocular pressure
801650|NCT03150160|efficacy
801651|NCT03150160|safety
801652|NCT03150147|Organ preservation
801653|NCT03150147|Survival
801654|NCT03150147|Graft function
801655|NCT03150147|Reperfusion injury
801656|NCT03150147|Heart transplantation
801657|NCT03150134|Acute Myeloid Leukemia
801658|NCT03150134|transplantation
801659|NCT03150134|allogeneic transplantation
801660|NCT03150134|immunosuppressive agents
801661|NCT03150082|GR37547
801662|NCT03150082|Cross-over
801663|NCT03150082|Bioequivalence
801664|NCT03150082|Ciprofloxacin
801665|NCT03150069|Pregnancy
801666|NCT03150056|abiraterone
801667|NCT03150056|castrate-resistant prostate cancer
801668|NCT03150056|androgen receptor targeted therapy
801669|NCT03150056|RP2D
801670|NCT03150056|enzalutamide
801671|NCT03150056|GSK525762
801672|NCT03150043|Hemoglobin
801673|NCT03150043|Cesarean delivery
801674|NCT03150004|Acute myeloid leukemia
801675|NCT03150004|AML
801676|NCT03150004|salvage chemotherapy
801677|NCT03150004|CLAG-M
801678|NCT03150004|relapse acute myeloid leukemia
801679|NCT03150004|secondary acute myeloid leukemia
801680|NCT03150004|phase II
801681|NCT03150004|pharmacogenomics
801682|NCT03149991|treatment resistant
801683|NCT03149991|inadequate response
801684|NCT03149978|Neoadjuvant Chemoradiation
801685|NCT03149978|treatment effect prediction
801686|NCT03149978|metabonomics
801687|NCT03149913|below the knee artery
801688|NCT03149913|endovascular
801689|NCT03149913|drug coated balloon
801690|NCT03149913|critical limb ischemia
801691|NCT03149848|Tuberculosis
801692|NCT03149848|Human Immunodeficiency Virus
801693|NCT03149848|Rifabutin
801694|NCT03149848|Drug-drug interaction
801695|NCT03149848|Cabotegravir
801696|NCT03149809|Urinary incontinence
801697|NCT03149809|Parkinson disease
801698|NCT03149809|Overactive urinary bladder
801699|NCT03149809|Nocturia
801700|NCT03149757|Treatment Adherence
801701|NCT03149757|Alcohol or Drugs
801702|NCT03149757|Behavioral
801703|NCT03149757|Internet
801704|NCT03149757|Adolescents
801705|NCT03149757|Young Adults
801706|NCT03149757|Social Support
801707|NCT03149718|Pharmacy
801708|NCT03149718|Intervention
801709|NCT03149718|Medication Adherence
801710|NCT03149705|Ischemic stroke, stroke, bio-collection, Imaging markers, biomarkers, clinical outcomes
801711|NCT03149679|Cyclophosphamide
801712|NCT03149679|Colorectal Cancer Metastatic
801713|NCT03149679|TP53 Gene Mutation
801714|NCT03149653|lipid emulsion
801715|NCT03149653|olive oil
801716|NCT03149653|fish oil
801717|NCT03149653|intestinal failure
801718|NCT03149653|home parenteral nutrition
801719|NCT03149640|Prevention
801720|NCT03149640|inhaled amikacin
801721|NCT03149640|placebo
801722|NCT03149614|mobilization
801723|NCT03149614|resonant oscillation
801752|NCT03149549|cancer
801753|NCT03149549|solid tumor
801754|NCT03149549|PROCLAIM
801755|NCT03149549|CX-2009
801756|NCT03149549|PROBODY™ Therapeutic
801757|NCT03149549|Drug Conjugate
801758|NCT03149549|Antibody drug conjugate
801759|NCT03149549|CD166
801760|NCT03149536|pharmacogenetic
801761|NCT03149536|pharmacogenomic
801762|NCT03149536|polymorphism
801763|NCT03149536|individualized controlled ovarian stimulation
801764|NCT03149536|algorithm
801765|NCT03149536|assisted reproduction
801766|NCT03149523|exhaustive genetic and immunological analyses
801767|NCT03149523|targeted therapies
801768|NCT03149523|colon cancer
801769|NCT03149523|kidney cancer
801770|NCT03149523|liver cancer
801771|NCT03149523|immunological tumor microenvironment
801772|NCT03149523|tumor microenvironment heterogeneity
801773|NCT03149510|mobile application
801774|NCT03149510|mHealth
801775|NCT03149458|stroke
801776|NCT03149458|balance
801777|NCT03149458|dance
801778|NCT03149432|mirror therapy
801779|NCT03149432|amputation
801780|NCT03149432|phantom pain
801781|NCT03149419|postmenopause
801782|NCT03149419|paroxetine
801783|NCT03149419|endothelial dysfunction
801784|NCT03149419|blood pressure
801785|NCT03149419|heart rate variability
801786|NCT03149419|sleep quality
801787|NCT03149419|perceived stress
801788|NCT03149419|sleepiness
801789|NCT03149393|Functional Dyspepsia
801790|NCT03149393|Qizhi Weitong Granules
801791|NCT03149393|Traditional Chinese Medicine
801792|NCT03149328|Home Dialysis
801793|NCT03149328|Person-Centered Care
801794|NCT03149328|Patient-Reported Outcome Measures
801795|NCT03149328|Process Evaluation
801796|NCT03149328|Educational Support
801797|NCT03149328|Electronic Patient-Reported Outcome Measures
801798|NCT03149328|Patient-Reported Experience Measures
801799|NCT03149302|Manual therapy
801800|NCT03149302|Sensorimotor exercises
801801|NCT03149302|Balance exercises
801802|NCT03149302|Cervical mobilization
801803|NCT03149302|Specific neck muscle exercises
801804|NCT03149263|botulinum toxin
801805|NCT03149263|anxiety reduction
801806|NCT03149263|pain reduction
801807|NCT03149263|medical clowns
801808|NCT03149263|distraction
801809|NCT03149250|Aggregometry
801810|NCT03149237|Mozambique
801811|NCT03149237|Couples-based services
801812|NCT03149237|HIV/AIDS
801813|NCT03149237|Ante-natal Care
801814|NCT03149198|Fibromyalgia, pilates, exercises
801815|NCT03149185|prostate cancer
801816|NCT03149185|advanced prostate cancer
801817|NCT03149185|technology based
801818|NCT03149146|Clinical Decision Making
801819|NCT03149146|Myanmar Physical therapists
801820|NCT03149146|Educational workshop
801821|NCT03149133|Biomechanics
801822|NCT03149133|Strength training
801823|NCT03149133|Elastography
801824|NCT03149133|Ultrasound
801825|NCT03149120|Metastatic
801826|NCT03149120|Unresectable
801827|NCT03149120|anthracycline
801828|NCT03149120|chemotherapy
801829|NCT03149120|systemic therapy
801830|NCT03149107|Ultra-high-risk for psychosis, clinical high risk, prodrom, schizophrenia, psychotic disorder, prevention, N-acetylcysteine, therapy
801831|NCT03149094|Self-Management
801832|NCT03149094|mHealth
801833|NCT03149042|FFR
801834|NCT03149042|Fractional Flow Reserve
801835|NCT03149042|Atherosclerosis
801836|NCT03149042|Coronary
801837|NCT03149042|stenosis
801838|NCT03149029|Metastatic Melanoma
801839|NCT03149003|Glioblastoma
801840|NCT03149003|Wilms Tumor 1
801841|NCT03149003|Cancer Vaccines
801842|NCT03149003|Neoplasms
801843|NCT03148990|Double Viral Vaccine Measles and Rubella
801844|NCT03148990|Safety Efficacy Imunogenicity
801845|NCT03148977|Matrix Metalloproteinases
801846|NCT03148951|MPV
801847|NCT03148951|NLR
801848|NCT03148951|Postoperative pain
801849|NCT03148938|DAM
801850|NCT03148938|multiple sclerosis
801851|NCT03148938|MSFC
801852|NCT03148938|application
801853|NCT03148938|mobile
801854|NCT03148925|nicotine vaccine
801855|NCT03148925|smoking vaccine
801856|NCT03148925|smoking cessation
801857|NCT03148925|SELA-070
801858|NCT03148899|Sleep Apnea
801859|NCT03148899|Oxytocin Nasal Spray
801860|NCT03148886|Physical activity
801861|NCT03148860|Psoriatic Arthritis
801862|NCT03148860|Ustekinumab
801863|NCT03148860|Methotrexate
801864|NCT03148860|DAS28
801865|NCT03148834|Acute Myocardial Infarction Reperfusion Injury
801869|NCT03148769|Bloodstream infections, epidemiology
801870|NCT03148678|Emotional reactivity
801871|NCT03148678|Cognitive flexibility
801872|NCT03148665|Oral Cancer
801873|NCT03148665|Head and Neck Cancer
801874|NCT03148639|auditory hallucination
801875|NCT03148639|schizophrenia
801876|NCT03148639|treatment-resistant
801877|NCT03148639|psychotherapy
801878|NCT03148639|virtual reality
801879|NCT03148639|avatar
801881|NCT03148600|Ileoanal pouch, pelvic floor exercise
801882|NCT03148587|abortion
801883|NCT03148587|medical abortion
801884|NCT03148587|mifepristone
801885|NCT03148587|pregnancy test
801886|NCT03148548|VTE
801887|NCT03148548|thrombophilia screening
801888|NCT03148548|patients
801889|NCT03148548|risk factors
801890|NCT03148548|post-thrombotic syndrome
801891|NCT03148496|abdominal surgery
801892|NCT03148496|wound complication
801893|NCT03148483|Pregnancy outcome
801894|NCT03148483|Feasibility
801895|NCT03148483|Milk Fortification
801896|NCT03148483|Periodontitis
801897|NCT03148483|Pregnant women
801898|NCT03148483|Periodontal Therapy
801899|NCT03148470|theta burst stimulation
801900|NCT03148470|Language switching
801901|NCT03148470|dorsolateral prefrontal cortex
801902|NCT03148457|stroke
801903|NCT03148457|direct oral anticoagulation
801904|NCT03148457|Apixaban
801905|NCT03148457|Dabigatran
801906|NCT03148457|Rivaroxaban
801907|NCT03148457|Edoxaban
801908|NCT03148457|therapy initiation
801909|NCT03148457|major bleeding
801910|NCT03148457|atrial fibrillation
801911|NCT03148379|Total Knee Replacement
801912|NCT03148366|Self Efficacy
801913|NCT03148353|ultrasonography, corticosteroid, subacromial impingement syndrome, shoulder pain
801919|NCT03148223|Dysmenorrhea
801920|NCT03148223|acupuncture
801921|NCT03148223|auriculotherapy
801922|NCT03148197|Allogeneic hematopoietic stem cell transplantation
801923|NCT03148197|Graft-versus-host-disease
801924|NCT03148197|Acute Myeloid Leukemia
801925|NCT03148184|reverse total shoulder arthroplasty
801926|NCT03148184|60 years old or younger
801927|NCT03148184|outcomes
801928|NCT03148171|Pre-Exposure Prophylaxis (PrEP); Retention in PrEP Care
801929|NCT03148158|Bladder Cancer
801930|NCT03148158|Flexible cystoscopy
801931|NCT03148158|Diagnosis
801932|NCT03148132|Retinopathy of Prematurity
801933|NCT03148132|VEGF
801934|NCT03148132|Bevacizumab
801935|NCT03148132|Ranibizumab
801936|NCT03148093|Metastatic Colorectal Cancer
801937|NCT03148093|Registry
801938|NCT03148093|Patient Reported Outcomes
801939|NCT03148093|Treatment Patterns
801940|NCT03148093|Prescription Use
801941|NCT03148067|Risk Factors
801942|NCT03148067|Incidence
801943|NCT03148067|Epidemiology
801944|NCT03148054|Anastomosis
801945|NCT03148054|Colon
801946|NCT03148054|CT
801947|NCT03148054|Endoscopy
801948|NCT03148054|Enema
801949|NCT03148054|Detection leak
801950|NCT03148054|Anastomotic leak
801951|NCT03147989|MultiHance
801952|NCT03147989|MRI
801953|NCT03147989|CNS
801954|NCT03147989|Gadobenate Dimeglumine
801955|NCT03147963|therapy
801956|NCT03147963|breast cancer
801957|NCT03147963|docetaxel
801958|NCT03147963|metastasis
801959|NCT03147950|Prone-Flexed Position
801960|NCT03147950|Percutaneous Nephrolithotomy (PCNL)
801961|NCT03147950|Clavien-Dindo Classification Score
801962|NCT03147911|Stroke or systemic embolism
801963|NCT03147911|CHA2DS2-VASc score
802091|NCT03147313|nerve regeneration
801966|NCT03147807|Carbapenems de-escalation, rapid diagnostic test,
801967|NCT03147807|Carbapenem-antimicrobial de-escalation-rapid diagnostic test
801968|NCT03147781|auriculotherapy, human milk, breast feeding, lactogenesis
801969|NCT03147768|Laser Tissue Welding
801970|NCT03147768|Pancreatic Sealing
801971|NCT03147768|Hemostasis
801972|NCT03147768|Pancreatic Tumors
801973|NCT03147768|Pancreatic Resection
801974|NCT03147768|Pancreatic leakage
801975|NCT03147768|LTW
801976|NCT03147755|stroke
801977|NCT03147742|ruxolitinib
801978|NCT03147742|acute or chronic steroid-refractory GVHD
801979|NCT03147742|hematopoietic stem cell transplantation (allo-HSCT)
801980|NCT03147729|Radiofrequency
801981|NCT03147729|Anal incontinence
801982|NCT03147729|Fecal incontinence
801983|NCT03147729|Women sexual function
801984|NCT03147729|Sexuality
801985|NCT03147703|Microbiota
801986|NCT03147703|Food timing
801987|NCT03147703|Obesity
801988|NCT03147690|Solid Organ Injury
801989|NCT03147677|Type 2 diabetic nephropathy
801990|NCT03147677|Alfacalcidol
801991|NCT03147664|pompe disease
801992|NCT03147664|exercise capacity
801993|NCT03147664|cardiopulmonary exercise testing
801994|NCT03147651|Cystic fibrosis
801995|NCT03147651|exercise capacity
801996|NCT03147651|non-cystic fibrosis
801997|NCT03147651|bronchiectasis
801998|NCT03147625|Aged
801999|NCT03147625|Independent living
802000|NCT03147625|Health Promotion
802001|NCT03147625|Residence Characteristics
802002|NCT03147625|Elderly-only household
802003|NCT03147612|Acute Lymphoblastic Leukemia
802004|NCT03147612|ALL
802005|NCT03147612|Philadelphia Chromosome (Ph)-Positive
802006|NCT03147612|BCR-ABL Positive
802007|NCT03147612|Ponatinib
802008|NCT03147612|Iclusig
802009|NCT03147612|AP24534
802010|NCT03147612|Cyclophosphamide
802011|NCT03147612|Cytoxan
802012|NCT03147612|Neosar
802013|NCT03147612|Mesna
802014|NCT03147612|Mesnex
802015|NCT03147612|Rituximab
802016|NCT03147612|Rituxan
802017|NCT03147612|Vincristine
802018|NCT03147612|Dexamethasone
802019|NCT03147612|Decadron
802020|NCT03147612|G-CSF
802021|NCT03147612|Filgrastim
802022|NCT03147612|Neupogen
802023|NCT03147612|Methotrexate
802024|NCT03147612|Cytarabine
802025|NCT03147612|Ara-C
802026|NCT03147612|Cytosar
802027|NCT03147612|DepoCyt
802028|NCT03147612|Cytosine Arabinosine Hydrochloride
802029|NCT03147612|Prednisone
802030|NCT03147599|Mebeverine
802031|NCT03147599|Incontinence
802032|NCT03147599|Orthotopic Neobladder
802033|NCT03147586|Immune Nutrition
802034|NCT03147586|Morbidity
802035|NCT03147573|Hypertension
802036|NCT03147573|Blood pressure monitoring
802037|NCT03147560|Immunogenicity
802038|NCT03147560|Safety
802039|NCT03147560|Sabin IPV
802040|NCT03147560|bOPV
802041|NCT03147508|Diagnostics, clinical criteria, clincal reasoning, neck pain
802042|NCT03147456|bariatric
802043|NCT03147456|obesity
802044|NCT03147456|protein supplements
802045|NCT03147443|traditional Chinese medicine
802046|NCT03147443|Drugs, Chinese Herbal
802047|NCT03147443|N-of-1 trials
802048|NCT03147443|sputum
802049|NCT03147443|symptoms
802050|NCT03147443|individualized treatment
802051|NCT03147443|stable bronchiectasis
802052|NCT03147391|Atrial Fibrillation
802053|NCT03147391|Left Atrial Appendage Closure
802054|NCT03147391|LAmbre device
802055|NCT03147391|Stroke
802056|NCT03147352|Fasciitis
802057|NCT03147352|Gangrene
802058|NCT03147352|Fasciitis, Necrotizing
802059|NCT03147352|Soft Tissue Infections
802060|NCT03147352|Fournier's Gangrene
802061|NCT03147352|Streptococcal septic shock syndrome
802062|NCT03147352|Flesh eating bacteria
802063|NCT03147352|Meleneys ulcer
802064|NCT03147352|Wounds and Injuries
802065|NCT03147352|Streptococcus pyogenes
802066|NCT03147352|Staphylococcus aureus
802067|NCT03147352|Soft Tissue Infections/blood
802068|NCT03147352|Necrosis/blood
802069|NCT03147352|Necrosis/diagnosis
802070|NCT03147352|Necrosis/mortality
802071|NCT03147352|Necrosis/surgery
802072|NCT03147352|Prognosis
802073|NCT03147352|Risk Factors
802074|NCT03147352|Bacterial Infections
802075|NCT03147352|Infection
802076|NCT03147352|Skin Diseases, Bacterial
802077|NCT03147352|Observational study
802078|NCT03147352|Biological markers
802079|NCT03147352|Endothelium
802080|NCT03147352|suPAR
802081|NCT03147352|sTM
802082|NCT03147352|syndecan-1
802083|NCT03147352|sE-selectin
802084|NCT03147352|VE-cadherin
802085|NCT03147352|protein C
802086|NCT03147352|Hyperbaric oxygen therapy
802087|NCT03147352|HBOT
802088|NCT03147339|AGEs( Advanced glycation end products)
802089|NCT03147313|extracorporeal shock wave
802090|NCT03147313|microsurgical nerve coaptation
802092|NCT03147300|Low back pain
802093|NCT03147300|Model of care
802094|NCT03147300|Primary health care
802095|NCT03147300|Implementation
802096|NCT03147300|Patient-rated outcome
802097|NCT03147300|Clinician-rated outcome
802098|NCT03147300|Cost-effectiveness
802099|NCT03147287|Breast Cancer
802100|NCT03147274|Diabetes Mellitus, Type 1
802101|NCT03147274|Adolescence
802102|NCT03147222|hip fracture
802103|NCT03147222|dementia
802104|NCT03147222|intervention
802105|NCT03147157|tacrolimus
802106|NCT03147157|histocompatibility antigens
802107|NCT03147131|Total Hip Arthroplasty
802108|NCT03147131|Short Stem
802109|NCT03147131|DEXA
802110|NCT03147118|trapeziometacarpal arthritis
802111|NCT03147105|chronic progressive multiple sclerosis, mobility, arm ergometry, rehabilitation
802112|NCT03147079|obesity
802113|NCT03147079|pregnancy
802114|NCT03147079|lifestyle
802115|NCT03147079|gestational weight gain
802116|NCT03147079|weight of offspring
802117|NCT03147079|antenatal care
802118|NCT03147079|health behavior
802119|NCT03147079|physical activity
802120|NCT03147079|diet
802121|NCT03147079|programme evaluation
802122|NCT03147079|costs and costs analysis
802123|NCT03147066|Dezocine
802124|NCT03147066|CRBD
802125|NCT03147066|General anesthesia
802126|NCT03147066|Urinary catheter
802127|NCT03147040|Lobular
802128|NCT03147040|Metastatic or incurable locally advanced cancer
802129|NCT03147040|Disease progression on endocrine therapy in advanced setting
802130|NCT03147027|ischemic cardiomyopathy
802131|NCT03147027|prophylactic ablation
802132|NCT03147014|Echocardiography
802133|NCT03147014|Congenital Heart Disease
802134|NCT03147014|Maternal hyperoxygenation
802135|NCT03147001|Endurance exercise
802136|NCT03147001|Dietary protein
802137|NCT03146975|Beta-defensins
802138|NCT03146975|Chronic periodontitis
802139|NCT03146975|Diabetes mellitus
802140|NCT03146975|Non-surgical periodontal therapy
802141|NCT03146897|Food Aid, Malnutrition, RUSF, FBF, Supplementary Food
802142|NCT03146845|Diabetic Foot Ulcer
802143|NCT03146845|Pressure Ulcer
802144|NCT03146845|Leg Ulcer
802145|NCT03146819|osteoarthritis
802146|NCT03146819|osteoarthritis knee
802147|NCT03146819|total knee replacement
802148|NCT03146819|patient specific
802149|NCT03146819|total knee arthroplasty
802150|NCT03146819|orthopedics
802151|NCT03146806|Cancer pain
802152|NCT03146806|Anesthesiology
802153|NCT03146806|Opiates
802154|NCT03146806|Intranasal ketamine
802155|NCT03146793|Calciphylaxis/complications
802156|NCT03146793|Kidney Failure, Chronic/complications
802157|NCT03146793|Renal Dialysis
802158|NCT03146793|Thiosulfates/therapeutic use
802159|NCT03146793|Time Factors
802160|NCT03146741|Heart Failure
802161|NCT03146702|Quality of Life
802162|NCT03146689|osteoarthritis
802163|NCT03146689|n-of-1
802164|NCT03146689|ibuprofen
802165|NCT03146689|capsaicin
802166|NCT03146689|NSAID
802167|NCT03146689|topical
802168|NCT03146663|Platinum-resistant
802169|NCT03146663|ovarian neoplasm
802170|NCT03146663|antineoplastic agents
802171|NCT03146663|ovarian diseases
802172|NCT03146663|cancer of the ovary
802173|NCT03146637|PD-1 activated CIK
802174|NCT03146637|MUC1
802175|NCT03146637|Bispecfic antibody
802176|NCT03146637|liver cancer
802177|NCT03146598|Foot deformity
802178|NCT03146598|Orthopaedic management
802179|NCT03146598|prevention
802180|NCT03146598|side pole static ankle foot orthosis
802181|NCT03146585|Glycocalyx
802182|NCT03146559|Cross education
802183|NCT03146559|EMG
802184|NCT03146520|Syndecan 2
802185|NCT03146520|Methylation biomarker
802186|NCT03146520|Colorectal cancer
802187|NCT03146520|EarlyTect Colon Cancer test
802188|NCT03146481|Anesthetic efficacy, Irriversible pulpitis, Aceclofenac
802189|NCT03146455|Thrombelastograghy
802190|NCT03146455|reference ranges
802191|NCT03146455|racial
802192|NCT03146455|geographic
802193|NCT03146455|Blood Transfusion
802194|NCT03146442|increased dietary protein
802195|NCT03146442|breakfast
802196|NCT03146442|weight management
802197|NCT03146442|satiety
802198|NCT03146442|glucose control
802199|NCT03146442|fMRI
802200|NCT03146403|HSV
802201|NCT03146403|Herpes
802202|NCT03146403|Genital Herpes
802203|NCT03146403|Vaccine
802204|NCT03146390|biofilms
802205|NCT03146390|essential oils
802206|NCT03146390|microscopy, confocal
802207|NCT03146390|mouthwashes
802208|NCT03146364|Virtual Reality
802209|NCT03146351|preterm
802210|NCT03146351|infant
802211|NCT03146351|physiotherapy
802212|NCT03146338|Anti-EGFR
802213|NCT03146338|Hypomagnesemia
802214|NCT03146338|Magnesium-rich mineral water
802215|NCT03146338|Metastatic colorectal or head and neck cancers
802216|NCT03146325|H. pylori infection
802217|NCT03146312|gene expression
802218|NCT03146312|gene array
802219|NCT03146312|epigenetics
802220|NCT03146312|DNA methylation
802221|NCT03146260|Surgical microscope
802222|NCT03146260|Sperm retreival
802223|NCT03146260|Azoospermia
802224|NCT03146260|FSH
802225|NCT03146260|LH
802226|NCT03146208|Growth differentiation factor-15
802227|NCT03146208|Dipeptidyl-peptidase inhibitors (DPP4 -I)
802228|NCT03146208|Coronroy artery diseases
802229|NCT03146195|pelvic organ prolapse
802230|NCT03146195|dynamic magnetic resonance imaging
802231|NCT03146195|three-dimensional reconstruction
802232|NCT03146195|space coordinates
802233|NCT03146182|C-reactive protein
802234|NCT03146182|Procalcitonin
802235|NCT03146182|Community-acquired pneumonia
802236|NCT03146182|Antibiotic stewardship
802237|NCT03146156|obesity
802238|NCT03146156|overweight
802239|NCT03146156|lifestyle intervention
802240|NCT03146156|fetal growth/adiposity
802241|NCT03146156|Mediterranean diet
802242|NCT03146117|PET CT
802243|NCT03146091|Antibiotics
802244|NCT03146052|Colon cleansing
802245|NCT03146013|HTLV
802246|NCT03146013|Confirmatory
802247|NCT03146013|Supplemental
802248|NCT03146013|Blot
802249|NCT03146013|HTLV-I
802250|NCT03146013|HTLV-II
802251|NCT03145987|Cognitive functioning
802252|NCT03145987|Neuropsychological status
802253|NCT03145987|Vitis vinifera
802254|NCT03145974|respiratory failure
802255|NCT03145974|mechanical ventilation
802256|NCT03145961|Breast cancer early stage
802257|NCT03145961|circulating tumour DNA
802258|NCT03145961|pembrolizumab
802259|NCT03145961|targeted therapy
802260|NCT03145961|randomised clinical trial
802261|NCT03145961|phase II
802262|NCT03145961|mutation screening
802263|NCT03145961|intermediate endpoint
802269|NCT03145909|Prolactin Receptor (PRLR)
802270|NCT03145909|Chromophobe renal cell carcinoma
802271|NCT03145909|Adrenocortical carcinoma,
802272|NCT03145909|Colorectal cancer
802273|NCT03145909|Breast cancer
802274|NCT03145909|Cancer
802275|NCT03145909|Metastatic
802276|NCT03145909|Hepatocellular carcinoma
802277|NCT03145896|vitamin D
802278|NCT03145896|Anemia
802279|NCT03145896|IBD
802280|NCT03145857|Gallium-68
802281|NCT03145857|Positron Emission Tomography
802282|NCT03145844|DAA
802283|NCT03145844|Hepatitis
802284|NCT03145831|Pediatrics
802285|NCT03145818|dissemination
802286|NCT03145805|blood chemical analysis
802287|NCT03145805|bupivacaine
802288|NCT03145805|local anesthetic toxicity
802289|NCT03145805|Drug-Related Side Effects and Adverse Reactions
802291|NCT03145753|HIV testing program
802292|NCT03145753|HCV testing program
802293|NCT03145753|education
802294|NCT03145727|Chemotherapy
802295|NCT03145727|nausea
802296|NCT03145727|vomiting
802297|NCT03145727|transcutaneous electrical acupoint stimulation
802298|NCT03145714|POCD
802299|NCT03145714|Elderly
802300|NCT03145688|Behavioural
802301|NCT03145688|Family physical activity habit
802302|NCT03145675|Anticoagulation
802303|NCT03145675|Enoxaparin
802304|NCT03145675|Dose
802305|NCT03145649|Breast milk
802306|NCT03145649|Hormone
802307|NCT03145649|Infant growth
802308|NCT03145649|Gestational diabetes mellitus
802309|NCT03145636|Obesity
802310|NCT03145636|Bariatric surgery
802311|NCT03145636|Vagal blocking
802312|NCT03145636|vBloc therapy
802313|NCT03145636|Vagus Nerve
802314|NCT03145636|Percent excess weight loss
802315|NCT03145636|Percent total body weight loss
802316|NCT03145597|facings
802317|NCT03145597|veneers
802318|NCT03145597|laminates
802319|NCT03145597|existing
802320|NCT03145597|restorations
802321|NCT03145597|esthetics
802322|NCT03145597|dental
802323|NCT03145584|Total Knee Arthroplasty
802324|NCT03145584|Physiotherapy
802325|NCT03145558|Tirapazamine, embolization, TACE, Hepatocellular carcinoma
802326|NCT03145493|Drainage, Suction
802327|NCT03145493|tranexamic acid
802328|NCT03145480|leukemia
802329|NCT03145480|richter
802330|NCT03145467|Migraine
802331|NCT03145467|Paracetamol
802332|NCT03145467|Zolmitriptan
802333|NCT03145467|Emergency services
802334|NCT03145454|Pain
802335|NCT03145454|children
802336|NCT03145454|emergency
802337|NCT03145454|electroencephalography
802338|NCT03145454|heart rate
802339|NCT03145454|skin conductance
802340|NCT03145454|pupillary diameter
802341|NCT03145415|pudendal nerve block
802342|NCT03145415|hypospadias
802343|NCT03145415|caudal block
802344|NCT03145376|TAVI
802345|NCT03145376|MitraClip
802346|NCT03145376|geriatric assessment
802347|NCT03145376|heart rate variability
802348|NCT03145376|elderly
802349|NCT03145350|NAFLD
802350|NCT03145350|Fat intake
802351|NCT03145350|Sugar intake
802352|NCT03145311|Repetitive transcranial magnetic stimulation, Drug Induced Tardive Syndrome
802353|NCT03145298|HPAH (heritable)
802354|NCT03145298|IPAH (idiopathic)
802355|NCT03145298|PAH-CTD (connective tissue diseases)
802356|NCT03145298|PAH-HIV (human immunodeficiency virus)
802357|NCT03145285|Abiraterone Acetate
802358|NCT03145285|Cushing Syndrome
802359|NCT03145285|Adrenocortical Carcinoma
802360|NCT03145272|Pharmacogenomics
802361|NCT03145272|Pharmacokinetics
802362|NCT03145272|Oxycodone
802363|NCT03145246|intrabony defect
802364|NCT03145246|periodontal regeneration
802365|NCT03145233|physiotherapy
802366|NCT03145220|EA-230
802367|NCT03145220|Systemic Inflammatory Response Syndrome
802368|NCT03145220|Acute Kidney Injury
802369|NCT03145220|Interleukin-6
802370|NCT03145220|Safety
802371|NCT03145220|Tolerability
802372|NCT03145220|Phase II
802373|NCT03145220|Randomized clinical trial
802374|NCT03145155|continuum of care
802375|NCT03145155|maternal
802376|NCT03145155|newborn
802377|NCT03145155|child health
802378|NCT03145155|noncommunicable diseases
802379|NCT03145142|Near-Infrared Spectroscopy
802380|NCT03145129|Intraocular pressure
802381|NCT03145129|IOP
802382|NCT03145129|CPAP
802383|NCT03145090|bone scintigraphy
802384|NCT03145090|knee arthroplasty
802385|NCT03145090|spect-ct
802386|NCT03145090|quantification
802387|NCT03145077|Head and Neck Cancer
802388|NCT03145077|Osteoradionecrosis
802389|NCT03145077|ORN
802390|NCT03145077|Dynamic contrast-enhanced magnetic resonance imaging
802391|NCT03145077|DCE-MRI
802392|NCT03145077|Questionnaires
802393|NCT03145077|Surveys
802394|NCT03145064|relapsed/refractory non-GCB type
802395|NCT03145051|saline solution
802396|NCT03145051|minerals
802397|NCT03145051|cystic fibrosis
802398|NCT03145051|chronic rhinosinusitis
802399|NCT03145051|nasal irrigation
802400|NCT03145012|Cancer
802401|NCT03145012|Immunity
802402|NCT03145012|Peripheral Blood Mononuclear Cells
802403|NCT03145012|Ranitidine
802404|NCT03144999|Dry AMD
802405|NCT03144999|Dry Age-related Macular Degeneration
802406|NCT03144999|Gene Therapy
802407|NCT03144999|Complement
802408|NCT03144999|Intravitreal Injection
802409|NCT03144999|Geographic Atrophy
802410|NCT03144999|Drusen
802411|NCT03144999|Membrane Attack Complex
802412|NCT03144999|CD59
802413|NCT03144934|HPV
802419|NCT03144869|type 1 diabetes mellitus
802420|NCT03144869|physical activity
802421|NCT03144869|children
802422|NCT03144869|constant glucose monitoring
802423|NCT03144856|Biliary Tract Cancer
802424|NCT03144856|Second line thrapy
802425|NCT03144856|Apatinib
802426|NCT03144843|Gastric cancer
802427|NCT03144843|Peritoneal metastasis
802428|NCT03144843|Paclitaxol
802429|NCT03144843|Apatinib
802430|NCT03144843|Second-line chemotherapy
802431|NCT03144817|hemodialysis
802432|NCT03144817|fluid overload
802433|NCT03144817|dialysis disequilibrium
802434|NCT03144817|intra-dialytic hypotension
802435|NCT03144817|dialysate sodium lowering
802436|NCT03144804|Colorectal Cancer
802445|NCT03144765|taTME
802446|NCT03144765|Transanal
802447|NCT03144765|Rectal cancer
802448|NCT03144765|Colorectal
802449|NCT03144765|Total mesorectal excision
802450|NCT03144765|TME
802451|NCT03144687|Myelofibrosis
802452|NCT03144687|Janus kinase (JAK) inhibitor
802453|NCT03144687|itacitinib
802454|NCT03144687|ruxolitinib
802455|NCT03144674|Marginal zone lymphoma
802456|NCT03144674|phosphatidylinositol 3-kinase (PI3K)δ inhibitor
802457|NCT03144674|indolent (slow-growing) non-Hodgkin lymphoma B-cell lymphoma
802458|NCT03144661|hepatocellular carcinoma
802459|NCT03144661|cholangiocarcinoma
802460|NCT03144661|esophageal
802461|NCT03144661|nasopharyngeal
802462|NCT03144661|serous ovarian
802463|NCT03144661|solid tumors
802464|NCT03144661|fibroblast growth factor (FGF)
802465|NCT03144661|fibroblast growth factor receptor (FGFR)
802466|NCT03144635|Direct Acting Antivirals
802467|NCT03144635|Grazoprevir
802468|NCT03144635|Elbasvir
802469|NCT03144622|(4S)-4-(3-[18F]fluoropropyl-)-L-glutamate
802470|NCT03144622|18F-FSPG
802471|NCT03144622|PET/CT
802472|NCT03144622|system xC-transporter
802473|NCT03144609|mechanical ventilation, obesity, oral-surgical procedures
802475|NCT03144570|ICU, encephalitis, meningo-encephalitis, seizures
802476|NCT03144557|Education
802477|NCT03144557|COPD
802478|NCT03144557|Inhalation Devices
802479|NCT03144544|Similarity
802480|NCT03144544|Diversity
802481|NCT03144531|School-age child
802482|NCT03144518|Positive Affect
802483|NCT03144518|Positive Mood
802484|NCT03144518|Influenza Vaccination
802485|NCT03144518|Vaccination
802614|NCT03143777|seating
802486|NCT03144518|Randomised Controlled Trial
802487|NCT03144505|Type 2 Diabetes
802488|NCT03144505|Exercise
802489|NCT03144505|High Intensity Interval Training
802490|NCT03144505|Glycemic Control
802491|NCT03144492|Cell Culture
802492|NCT03144492|Microgravity co-culture
802493|NCT03144453|Curare
802494|NCT03144453|Robotic surgery
802495|NCT03144440|ZEPATIER
802496|NCT03144427|albumin
802497|NCT03144427|resuscitation
802498|NCT03144427|burns
802499|NCT03144427|shock
802500|NCT03144427|fluid creep
802501|NCT03144401|cesarean section
802502|NCT03144401|Misoprostol
802503|NCT03144401|sublingual
802504|NCT03144401|uterotonics
802505|NCT03144323|Intraoral elastics
802506|NCT03144258|congenital heart defects
802507|NCT03144258|systemic microcirculation
802508|NCT03144258|laser Doppler perfusion imaging
802509|NCT03144258|cardiac corrective surgery
802510|NCT03144245|AML
802511|NCT03144245|treatment
802512|NCT03144245|relapsed
802513|NCT03144245|refractory
802514|NCT03144245|phase 1
802515|NCT03144219|intracranial pressure
802516|NCT03144219|transcranial Doppler
802517|NCT03144219|jugular compression
802518|NCT03144219|cerebral compliance
802519|NCT03144193|topical treatment
802520|NCT03144193|wrinkles
802521|NCT03144193|extracellular matrix
802522|NCT03144180|pregnant
802523|NCT03144180|third trimester
802524|NCT03144180|umbilical cord blood collection
802525|NCT03144154|Cancer
802526|NCT03144154|Fatigue
802527|NCT03144154|Hypnosis
802528|NCT03144154|Self-hypnosis
802529|NCT03144154|Self-care
802530|NCT03144154|Emotional distress
802531|NCT03144154|Cancer survivors
802532|NCT03144128|vitamin D
802533|NCT03144128|muscle
802534|NCT03144128|metabolism
802535|NCT03144128|cancer cachexia
802536|NCT03144115|oxytocin
802537|NCT03144115|sex hormone
802538|NCT03144115|verbal reward
802539|NCT03144115|mate selection
802540|NCT03144115|metaphorical language
802541|NCT03144089|Morbid obesity
802542|NCT03144089|Obstructive sleep apnea
802543|NCT03144089|Mask ventilation
802544|NCT03144089|Upper airway obstruction
802545|NCT03144076|healthcare
802546|NCT03144076|India
802547|NCT03144076|health insurance
802548|NCT03144076|RSBY
802549|NCT03144076|free health insurance
802550|NCT03144076|inpatient insurance
802551|NCT03144076|wealth transfer
802552|NCT03144063|Disease Activity
802553|NCT03144063|SLEDAI-2K
802554|NCT03144024|Tricuspid Regurgitation
802555|NCT03144024|Insufficiency, Tricuspid Valve
802556|NCT03144024|Valvular Annuloplasty
802557|NCT03144024|Cardiac Valve Annulus Repair
802558|NCT03144011|acute kidney injury, cardiosurgery
802559|NCT03143985|TEW-7197
802560|NCT03143985|Pomalidomide
802561|NCT03143972|Dexmedetomidine
802562|NCT03143972|Remifentanil
802563|NCT03143972|Pharmacodynamics
802564|NCT03143972|Interaction
802565|NCT03143946|neuroendocrine tumor
802566|NCT03143946|vitamin
802567|NCT03143946|diet
802568|NCT03143933|propofol, BIS, general anesthesia
802569|NCT03143920|hyperbaric oxygen
802570|NCT03143920|inflammation
802571|NCT03143920|chronic disease
802572|NCT03143920|urinary bladder
802573|NCT03143920|urinary tract infection
802574|NCT03143920|recurrent urinary tract infection
802575|NCT03143920|painful bladder syndrome
802576|NCT03143920|chronic pain
802577|NCT03143920|hypoxia
802578|NCT03143920|bacterial infection
802579|NCT03143907|Mindfulness
802580|NCT03143907|Group Therapy
802581|NCT03143894|Breast Cancer
802582|NCT03143894|Cognition
802583|NCT03143894|Fatigue
802584|NCT03143894|Cancer-related Cognitive Impairment
802585|NCT03143894|Transcranial Direct Current Stimulation
802586|NCT03143868|acute exercise
802587|NCT03143868|resistance exercise
802588|NCT03143868|aerobic exercise
802589|NCT03143868|appetite
802590|NCT03143868|energy intake
802591|NCT03143855|oxycodone
802592|NCT03143855|lorcaserin
802593|NCT03143855|Belviq
802594|NCT03143842|VNS
802595|NCT03143842|accelerate learning
802596|NCT03143842|memory
802597|NCT03143829|gerontology
802598|NCT03143829|symptom self-management
802599|NCT03143829|Chemotherapy-induced Nausea and Vomiting
802600|NCT03143816|diabetes
802601|NCT03143816|time in range
802602|NCT03143816|inhaled insulin
802603|NCT03143816|continuous glucose monitoring
802604|NCT03143816|type 1 diabetes
802605|NCT03143816|hypoglycemia
802606|NCT03143816|post prandial hypergylcemia
802607|NCT03143790|Erectile Function
802608|NCT03143790|Prostatectomy
802609|NCT03143790|Extracorporeal Shock Wave Therapy
802610|NCT03143790|IIEF-5
802611|NCT03143777|physiotherapy
802612|NCT03143777|rehabilitation
802613|NCT03143777|critical care
802615|NCT03143738|regional anesthesia
802616|NCT03143738|knee replacement
802617|NCT03143738|pain treatment
802618|NCT03143738|rehabilitation
802619|NCT03143686|Severe symptomatic Aortic Stenosis
802620|NCT03143673|Severe Symptomatic Aortic Valve Stenosis
802621|NCT03143660|obesity
802622|NCT03143608|GERD
802623|NCT03143608|Hiatal hernia repair
802624|NCT03143608|Transoral Incision less fundoplication
802625|NCT03143595|Preexisting cognitive impairment
802626|NCT03143595|Elderly
802627|NCT03143595|Outcomes
802628|NCT03143556|renal transplant
802629|NCT03143556|magnetic ureteral stent
802630|NCT03143556|Black-Star®
802631|NCT03143543|cocaine disorder
802632|NCT03143543|opioid disorder
802633|NCT03143543|lorcaserin
802634|NCT03143543|MRI
802635|NCT03143543|fMRI
802636|NCT03143530|Ropivacaine
802637|NCT03143517|Inflammatory Bowel Diseases
802638|NCT03143517|Irritable Bowel Syndrome
802639|NCT03143517|Ulcerative Colitis
802640|NCT03143517|Crohn Disease
802641|NCT03143517|Indeterminate Colitis
802644|NCT03143413|Salivary glands ultrasonography
802645|NCT03143413|Systemic sclerosis
802646|NCT03143413|Gougerot Sjogren syndrome
802647|NCT03143413|Sicca syndrome
802648|NCT03143400|Probiotics
802649|NCT03143400|Galenic form
802650|NCT03143400|Digestive tract
802651|NCT03143400|Intestinal microbiota
802652|NCT03143400|Lactobacillus salivarius
802653|NCT03143361|aortic valve stenosis
802654|NCT03143361|heart valves
802655|NCT03143361|heart surgery
802656|NCT03143335|Breast; Reconstruction; BAD; Implant; ADM
802657|NCT03143322|Bone-only metastases
802658|NCT03143322|solid tumors
802659|NCT03143322|SBRT
802660|NCT03143283|suicide
802661|NCT03143283|lethal means
802662|NCT03143283|counseling
802663|NCT03143283|youth
802664|NCT03143283|parents
802665|NCT03143283|firearms
802666|NCT03143283|medication
802667|NCT03143283|suicidal
802668|NCT03143283|emergency department
802669|NCT03143270|nivolumab
802670|NCT03143270|deb-TACE
802671|NCT03143270|17-087
802672|NCT03143218|Malaria
802673|NCT03143218|Seasonal vaccination
802674|NCT03143218|Seasonal chemoprevention
802675|NCT03143192|DME, Micropulse Laser, Anti-VEGF
802676|NCT03143140|Ablation Techniques
802677|NCT03143101|FluMist Quadrivalent
802678|NCT03143101|Trivalent
802679|NCT03143101|Influenza
802680|NCT03143101|Vaccine
802681|NCT03143101|Prevention
802682|NCT03143088|Blood pressure
802683|NCT03143088|Medical clown
802684|NCT03143088|Pediatric
802685|NCT03143062|National Early Warning Score
802686|NCT03143062|Rapid response system
802687|NCT03143049|Pomalidomide
802688|NCT03143036|daratumumab
802689|NCT03142971|Shock waves
802690|NCT03142971|Greater trochanteric pain syndrome
802691|NCT03142932|smoking
802692|NCT03142919|Mood Disorder
802693|NCT03142919|MDD
802694|NCT03142919|Endotoxin
802695|NCT03142919|MRI
802696|NCT03142919|CRP
802697|NCT03142906|preoperative, perioperative, point-of-care ultrasound
802698|NCT03142893|testosterone
802699|NCT03142893|cortisol
802700|NCT03142880|marginally hyperbaric
802701|NCT03142880|ropivacaine
802702|NCT03142880|cesarean
802703|NCT03142867|Non-Alcoholic Fatty Liver Disease
802704|NCT03142867|Non Alcoholic Steatohepatitis
802705|NCT03142867|Prevalence
802706|NCT03142867|Coronary Artery Disease
802707|NCT03142867|PDFF
802708|NCT03142854|bowel preparation
802709|NCT03142854|colonoscopy
802710|NCT03142854|predictive model
802711|NCT03142841|Depression
802712|NCT03142841|Burden
802713|NCT03142841|Problem Solving Ability
802714|NCT03142841|Caregivers
802715|NCT03142841|Stroke
802716|NCT03142841|Veterans
802717|NCT03142828|chlorhexidine, dental implant, in-situ drug delivery,
802719|NCT03142802|Testicular cancer
802720|NCT03142802|low-dose CT
802721|NCT03142802|CT scan
802722|NCT03142789|Pain
802723|NCT03142789|Total knee arthroplasty
802724|NCT03142789|Regional anesthesia
802725|NCT03142776|clarithromycin
802726|NCT03142776|photodynamic therapy
802727|NCT03142776|Antimicrobial therapy
802728|NCT03142776|Periodontal pocket
802729|NCT03142724|HV
802730|NCT03142698|hepatic steatosis
802731|NCT03142698|MRImaging
802732|NCT03142685|NEC
802733|NCT03142685|Bowel Ultrasound
802734|NCT03142685|CHD
802735|NCT03142672|Postoperative pain
802736|NCT03142672|child
802737|NCT03142672|pulpotomy
802738|NCT03142672|general anesthesia
802739|NCT03142620|Drug resistant H.pylori infection
802740|NCT03142620|vitamin D
802741|NCT03142620|gastritis
802742|NCT03142529|Non dialysis
802743|NCT03142516|Clinical Trial, Phase II
802744|NCT03142516|Elderly
802745|NCT03142516|Aged
802746|NCT03142516|Disease-Free Survival
802747|NCT03142516|Safety
802748|NCT03142516|Tolerability
802749|NCT03142516|Chemotherapy regimen
802750|NCT03142516|Monoclonal antibody
802751|NCT03142516|FOLFIRI
802752|NCT03142516|Panitumumab
802753|NCT03142516|RAS/BRAF Wild-type
802754|NCT03142503|psoriatic arthritis
802755|NCT03142503|psoriasis
802756|NCT03142503|body composition
802757|NCT03142503|DXA measurements
802758|NCT03142503|spondyloarthritis
802759|NCT03142503|diet therapy
802760|NCT03142503|adipose tissue
802761|NCT03142490|Acupuncture
802762|NCT03142490|Infertility
802763|NCT03142490|In vitro fertilization
802764|NCT03142490|Quality of life
802765|NCT03142490|Stress
802766|NCT03142490|Anxiety
802767|NCT03142477|Therapeutic touch
802768|NCT03142477|Reiki
802769|NCT03142477|Laying-on-of-Hands
802770|NCT03142477|Spiritual Therapies
802771|NCT03142464|saline solution
802772|NCT03142464|laparoscopy
802773|NCT03142464|cholecystectomy
802774|NCT03142464|outcomes
802775|NCT03142412|Lupus
802776|NCT03142412|SLE
802777|NCT03142412|Systemic Lupus Erythematosus
802778|NCT03142399|heart failure
802779|NCT03142399|cardiac reabilitation
802780|NCT03142399|nutritional status
802781|NCT03142399|quality of life
802782|NCT03142399|milk protein
802783|NCT03142386|geriatric oncology
802784|NCT03142386|pain
802785|NCT03142386|osteopathic manipulative treatment
802786|NCT03142386|quality of life
802787|NCT03142373|heart rate variability
802788|NCT03142373|autonomic nervous system
802789|NCT03142373|osteopathic manipulative treatment
802790|NCT03142373|skin conductance
802791|NCT03142347|remote endarterectomy
802792|NCT03142347|DCB balloon
802793|NCT03142334|PD1
802794|NCT03142334|PD-1
802795|NCT03142334|PDL1
802796|NCT03142334|PD-L1
802797|NCT03142334|Adjuvant
802798|NCT03142308|Satisfaction
802799|NCT03142308|Training program
802800|NCT03142308|Egypt
802801|NCT03142308|Cross-sectional
802802|NCT03142308|Multi-center
802803|NCT03142295|Urine transfusion
802804|NCT03142295|Recurrent urinary tract infection
802805|NCT03142295|Urinary microbiota
802806|NCT03142282|maintenance treatment
802807|NCT03142243|Tennis
802808|NCT03142243|Asymmetry
802809|NCT03142243|Morphological
802810|NCT03142230|feeding tube
802811|NCT03142230|gastric
802812|NCT03142230|newborn infant
802813|NCT03142230|nursing
802814|NCT03142230|pain
802815|NCT03142191|Idiopathic Pulmonary Fibrosis
802816|NCT03142191|Pulmonary Fibrosis
802817|NCT03142191|CC-90001
802818|NCT03142191|Safety
802819|NCT03142191|Efficacy
802820|NCT03142178|neuralgia
802821|NCT03142178|pain
802822|NCT03142178|post herpetic
802823|NCT03142152|Functional Mitral Regurgitation
802824|NCT03142152|Percutaneous Mitral Valve Repair
802825|NCT03142152|Percutaneous Mitral Valve Annuloplasty
802826|NCT03142152|Coronary sinus Annuloplasty
802827|NCT03142152|Secondary Mitral Regurgitation
802828|NCT03142152|Functional MR
802829|NCT03142152|FMR
802830|NCT03142139|Observational study; DTaP-IPV-Hib; Atopic Dermatitis; AD; Heterologous immunity; Non-specific effects; Non-targeted effects; Immunization;
802831|NCT03142113|optimization
802832|NCT03142113|adalimumab
802833|NCT03142087|balance
802834|NCT03142087|brain tumor
802835|NCT03142087|virtual reality
802836|NCT03142074|Improve diagnosis
802837|NCT03142009|Community-Based Participatory Research
802838|NCT03141996|vibration
802839|NCT03141996|stroke
802840|NCT03141996|activities of daily living
802841|NCT03141983|ESRD
802842|NCT03141983|End-Stage Kidney Disease
802843|NCT03141970|Proteinuria Hypoproteinemia Edema Hypoalbuminemia Prednisone
802844|NCT03141957|Aging
802845|NCT03141957|Hypermetabolism
802846|NCT03141944|non motor symptoms
802847|NCT03141931|Nutraceutical supplement
802848|NCT03141905|patient safety
802849|NCT03141905|self-management
802850|NCT03141905|remote monitoring
802851|NCT03141879|Frailty
802852|NCT03141879|Physical Activity
802853|NCT03141879|Resistance training
802854|NCT03141853|Randomized Controlled Trial
802855|NCT03141853|Intervention Study
802856|NCT03141827|Lipoprotein
802857|NCT03141827|Apolipoprotein
802858|NCT03141827|Pancreatic clamp
802859|NCT03141827|Insulin
802860|NCT03141827|Nasal
802861|NCT03141801|ACL
802862|NCT03141801|Knee
802863|NCT03141801|Muscle
802864|NCT03141788|Aligners
802865|NCT03141775|Clostridium difficile associated diarrhea (CDAD)
802866|NCT03141762|Falls
802867|NCT03141762|Intensive care
802868|NCT03141736|Infant
802869|NCT03141736|Newborn
802870|NCT03141736|Preterm
802871|NCT03141736|Hypothermia
802872|NCT03141736|Kangaroo
802873|NCT03141736|Plastic
802874|NCT03141736|Bag
802875|NCT03141723|Infant
802876|NCT03141723|Newborn
802877|NCT03141723|Preterm
802878|NCT03141723|Hypothermia
802879|NCT03141723|Kangaroo
802880|NCT03141723|Plastic
802881|NCT03141723|Bag
802882|NCT03141697|Carbon Dioxide
802883|NCT03141697|Coloboscopy
802884|NCT03141684|PD-L1
802885|NCT03141684|Immunotherapy
802886|NCT03141684|Pharmacodynamics
802887|NCT03141684|Pediatric
802888|NCT03141684|Checkpoint Inhibitor
802889|NCT03141671|Prostate Cancer
802890|NCT03141658|TS-134
802891|NCT03141658|ketamine
802892|NCT03141658|fMRI
802893|NCT03141619|cerebral oximetry
802894|NCT03141619|near-infrared spectroscopy
802895|NCT03141619|neurocognitive
802896|NCT03141619|post-ICU syndrome
802897|NCT03141593|adherence to medication
802898|NCT03141593|electronic monitoring
802899|NCT03141567|Lymphangiogenesis
802900|NCT03141567|Heart Failure
802901|NCT03141541|low back pain
802902|NCT03141541|cognitive behavioural therapy
802903|NCT03141541|randomised controlled trial
802904|NCT03141528|Self-learning
802905|NCT03141528|Instructor-led learning
802906|NCT03141528|Long-term retention
802907|NCT03141515|lung ultrasound
802908|NCT03141515|recruitment maneuver
802909|NCT03141515|atelectasis
802910|NCT03141515|children
802911|NCT03141502|tension wound
802912|NCT03141502|skin stretching device
802913|NCT03141502|skin grafting
802914|NCT03141476|Surgery
802915|NCT03141476|Obesity
802916|NCT03141476|Drug
802917|NCT03141476|Antibiotics
802918|NCT03141476|Cefuroxime
802919|NCT03141463|Therapeutic vaccination
802920|NCT03141437|Malignant Neoplasm of Breast
802921|NCT03141437|Malignant Neoplasm of Female Genital Organs
802922|NCT03141437|Lymphoma
802923|NCT03141437|Myeloma
802924|NCT03141437|Decision Aid Website
802925|NCT03141437|DA
802926|NCT03141437|Fertility preservation support
802927|NCT03141437|Questionnaires
802928|NCT03141437|Surveys
802929|NCT03141437|Educational materials
802930|NCT03141372|Total Laparoscopic Hysterectomy
802931|NCT03141372|Urinary Retention
802932|NCT03141372|Backfill Void Trial
802933|NCT03141372|Autofill Void Trial
802934|NCT03141307|Neonatal screening
802935|NCT03141307|Biobank
802936|NCT03141307|Broad Consent
802937|NCT03141294|tracheostomy，fascia，force gauge
802938|NCT03141281|aging
802939|NCT03141281|cognitive ability
802940|NCT03141281|IADL
802941|NCT03141281|driving
802942|NCT03141281|financial fraud
802943|NCT03141281|perception
802944|NCT03141281|attention
802945|NCT03141281|memory
802946|NCT03141255|Therapeutic Hypothermia (TH)
802947|NCT03141242|Advance Care Planning
802948|NCT03141242|Group Medial Visit
802949|NCT03141242|Shared Medical Appointment
802950|NCT03141229|MBSR
802951|NCT03141229|Children
802952|NCT03141229|Teacher
802953|NCT03141229|School
802954|NCT03141229|Burnout
802955|NCT03141229|Classroom behavior
802956|NCT03141125|Erythrocyte sedimentation rate
802957|NCT03141125|Modified Rodnan Skin Score
802958|NCT03141125|B-cell Activating Factor
802959|NCT03141125|soluble-CD40Ligand
802960|NCT03141125|Procollagen Type-1 N-terminal Propeptide
802961|NCT03141125|Scleroderma
802962|NCT03141099|OHCA
802963|NCT03141099|Hemodynamic
802964|NCT03141099|TTM
802965|NCT03141099|post-rescusitation care
802966|NCT03141099|Blood pressure targets
802967|NCT03141099|Oxygenation targets
802968|NCT03141086|shift work disorder
802969|NCT03141073|GKA
802970|NCT03141073|T2DM
802971|NCT03141073|HMS5552
802972|NCT03141073|Add on therapy
802973|NCT03141073|Metformin
802974|NCT03141047|Sexual trauma, Lifespan Integration
802978|NCT03140995|Exercise
802979|NCT03140995|Sleep
802980|NCT03140982|propofol
802981|NCT03140982|pharmacology
802982|NCT03140982|anesthesic induction
802983|NCT03140982|drug titration
802984|NCT03140969|CEP290
802985|NCT03140969|p.Cys998X
802986|NCT03140969|c.2991+1655A>G
802987|NCT03140969|RNA therapy
802988|NCT03140969|Antisense oligonucleotide
802989|NCT03140969|Leber's congenital amaurosis
802990|NCT03140943|carfilzomib
802991|NCT03140917|Liver function
802992|NCT03140917|Future liver remnant
802993|NCT03140917|Chemotherapy
802994|NCT03140891|preterm infant
802995|NCT03140891|respiratory distress syndrome
802996|NCT03140891|high frequence oscillation
802997|NCT03140865|Alzheimer's
802998|NCT03140865|observational
802999|NCT03140865|prediabetes
803000|NCT03140865|mild cognitive impairment
803001|NCT03140774|Ebola vaccine
803002|NCT03140774|immunogenicity
803003|NCT03140774|persistence
803004|NCT03140722|anemia
803005|NCT03140722|kidney
803006|NCT03140722|dialysis-dependent chronic kidney disease
803007|NCT03140722|CKD
803008|NCT03140722|DD-CKD
803009|NCT03140722|renal
803010|NCT03140722|vadadustat
803011|NCT03140722|AKB-6548
803012|NCT03140722|hypoxia-inducible factor
803013|NCT03140722|HIF
803014|NCT03140722|hypoxia-inducible factor prolyl-hydroxylase inhibitor
803015|NCT03140722|HIF-PHI
803016|NCT03140722|hyporesponder
803017|NCT03140722|hyporesponsive
803018|NCT03140722|epoetin alfa
803019|NCT03140722|hemoglobin
803020|NCT03140722|erythropoiesis stimulating agent
803021|NCT03140722|ESA
803022|NCT03140709|Salivary
803023|NCT03140709|Oxytocin
803024|NCT03140709|Induction
803025|NCT03140709|Labor
803026|NCT03140657|Ankylosing spondylitis, Nanocurcumin, MicroRNA, Th17 cells
803027|NCT03140644|thoracic sarcoidosis
803028|NCT03140644|ultra-low dose computed tomography
803029|NCT03140644|Magnetic resonance imaging using Ultrashort echo time
803030|NCT03140631|atrial fibrillation
803031|NCT03140631|catheter ablation
803032|NCT03140631|protamine sulfate
803033|NCT03140631|anticoagulation reversal
803034|NCT03140618|single-system-design
803035|NCT03140618|mixed methods
803036|NCT03140618|psychiatric inpatient care
803037|NCT03140618|work environment
803038|NCT03140618|rebuilding
803039|NCT03140579|recruitment
803040|NCT03140579|lung homogeneity
803041|NCT03140579|airway pressure release ventilation
803042|NCT03140566|heart failure
803043|NCT03140566|acute decompensated heart failure
803044|NCT03140566|congestion
803045|NCT03140566|inferior vena cava
803046|NCT03140553|Neoadjuvant Treatment
803047|NCT03140553|HER2-Positive Breast Cancer
803048|NCT03140540|Fluid management
803049|NCT03140540|goal-directed therapy
803050|NCT03140540|transesophageal echocardiography
803052|NCT03140488|Induction of labor
803053|NCT03140488|Pitocin
803054|NCT03140488|BMI
803055|NCT03140475|Metacognition
803056|NCT03140475|Mousetracking
803057|NCT03140475|EEG
803058|NCT03140475|Event related potentials
803059|NCT03140475|Frequency analysis
803060|NCT03140475|Depression
803061|NCT03140462|Tacrolimus
803062|NCT03140462|Pharmacokinetics
803063|NCT03140462|Genetic polymorphisms
803064|NCT03140449|Tuberous sclerosis complex
803065|NCT03140449|facial angiofibroma
803066|NCT03140449|rapamycin
803067|NCT03140449|calcitriol
803068|NCT03140436|stain removal efficacy, air polishing powder
803069|NCT03140423|MRSA
803070|NCT03140423|healthcare-associated infections
803071|NCT03140423|mupirocin
803072|NCT03140423|iodophor
803073|NCT03140423|resistance
803074|NCT03140410|Staphylococci
803075|NCT03140410|Blood-stream infections
803076|NCT03140410|Linezolid
803077|NCT03140397|Bioavailability
803078|NCT03140397|Pharmacokinetics
803079|NCT03140397|8-prenylnaringenin
803080|NCT03140397|6-prenylnaringenin
803081|NCT03140397|Prenylflavonoids
803082|NCT03140397|PBMC
803083|NCT03140371|Enteral feeding
803084|NCT03140371|Oral nutritional supplements
803085|NCT03140371|Peptide-based feed
803086|NCT03140371|Hydrolysed feed
803087|NCT03140371|Semi-elemental feed
803088|NCT03140345|Hemodialysis
803089|NCT03140345|Microcirculation
803090|NCT03140345|Traditional Chinese Medicine
803091|NCT03140345|Hemodialysis vascular access
803092|NCT03140319|Fibroblast
803093|NCT03140319|Cell transplantation
803094|NCT03140306|Computed tomography
803095|NCT03140306|Model based iterative reconstruction
803096|NCT03140306|Low dose CT
803097|NCT03140293|Chorionic villus sampling
803098|NCT03140293|Pain
803099|NCT03140293|Anxiety
803100|NCT03140280|Black raspberries
803101|NCT03140280|MDS
803102|NCT03140280|Myelodysplastic Syndromes
803103|NCT03140280|hypomethylating effects
803104|NCT03140280|chemopreventive agent
803105|NCT03140280|BRB
803106|NCT03140280|pharmokinetics
803107|NCT03140267|Ventilated induced diaphragmatic dysfunction
803108|NCT03140267|Weaning
803109|NCT03140267|Inspiratory muscle training
803110|NCT03140215|Baska
803111|NCT03140215|seal pressure
803112|NCT03140215|I-Gel
803113|NCT03140215|Supraglottic airway device
803114|NCT03140189|Esophageal cancer
803115|NCT03140189|Robotic
803116|NCT03140189|Ivor-Lewis esophagectomy
803117|NCT03140176|Sunitinib
803118|NCT03140176|Metastatic Renal Cell Carcinoma
803119|NCT03140176|Africa Middle East
803120|NCT03140098|Collagen membrane
803121|NCT03140098|Cardiac surgery
803122|NCT03140098|Postoperative complication
803124|NCT03140059|surgical procedure
803125|NCT03140059|residual pockets
803126|NCT03140059|agressive periodontitis
803127|NCT03140059|antimicrobial photodynamic therapy
803128|NCT03140020|aneurysm
803129|NCT03140020|cognition
803130|NCT03140020|functional connectivity
803131|NCT03140020|frontal lobe function
803132|NCT03140020|neuropsychological testing
803133|NCT03140020|coiling
803134|NCT03140020|clipping
803135|NCT03140007|ERCP
803136|NCT03140007|cholangioscopy
803137|NCT03139994|occlusion
803138|NCT03139994|pain
803139|NCT03139981|eczema
803140|NCT03139955|Feasibility Study
803141|NCT03139955|Pre/Post-Operative Patient Monitoring
803142|NCT03139955|Continuous Patient Monitoring
803143|NCT03139955|Patient Deterioration Identification
803144|NCT03139955|Bodytrak
803145|NCT03139955|National Early Warning System
803146|NCT03139955|Patient Safety
803147|NCT03139942|Endoscopy
803148|NCT03139942|Colonoscopy
803149|NCT03139942|Hyperspectral imaging
803150|NCT03139942|Tissue classification
803151|NCT03139942|Tissue autofluorescence
803152|NCT03139942|Advanced imaging techniques
803153|NCT03139916|Glioblastoma
803154|NCT03139903|Seckel Syndrome
803155|NCT03139903|Microcephalic Osteodysplastic Primordial Dwarfism Type II
803156|NCT03139864|Type 1 diabetes
803157|NCT03139864|Control
803158|NCT03139864|Physical activity
803159|NCT03139864|Substrate utilization
803160|NCT03139864|Hormonal regulation
803166|NCT03139838|Palliative Care
803167|NCT03139838|Pragmatic Clinical Trial
803168|NCT03139838|Electronic Health Records
803169|NCT03139838|Economics, Behavioral
803170|NCT03139812|continuous contact lens wear
803171|NCT03139812|silicone hydrogel contact lenses
803172|NCT03139812|irrigation
803173|NCT03139812|corneal epithelial permeability
803174|NCT03139812|contact lens-related adverse events
803175|NCT03139734|Sacral Nerve Modulation
803176|NCT03139708|Mydriasis
803177|NCT03139708|Cycloplegics
803178|NCT03139630|HIV, Dyslipidemia
803179|NCT03139630|Dyslipidemia
803180|NCT03139630|Protease Inhibitor
803181|NCT03139630|Ritonavir
803182|NCT03139630|PCSK9
803183|NCT03139630|Observational
803184|NCT03139617|Fascia Iliaca Block
803185|NCT03139617|Femoral 3-in-1 block
803186|NCT03139617|Fracture femur
803187|NCT03139617|Spinal anesthesia
803193|NCT03139565|Influenza
803194|NCT03139565|Solid Organ Transplant
803195|NCT03139565|Infection
803196|NCT03139565|Vaccine
803197|NCT03139565|Immunogenicity
803198|NCT03139552|Taste Test
803199|NCT03139552|Spices
803200|NCT03139552|Reduced sugar
803201|NCT03139552|Food liking
803202|NCT03139526|Craniopharyngioma
803203|NCT03139526|Children
803204|NCT03139526|Social participation
803205|NCT03139526|Life-H questionnaire
803206|NCT03139487|Anticoagulant Adverse Reaction
803207|NCT03139487|Cancer-associated Thrombosis
803208|NCT03139487|Low molecular weight heparin
803209|NCT03139487|Direct oral anticoagulant
803210|NCT03139461|Physical Therapy
803211|NCT03139461|Capacity Building
803212|NCT03139461|Clinical-Community Linkages
803213|NCT03139396|inlay bridge, tub shaped design
803214|NCT03139383|postoperative nausea
803215|NCT03139383|postoperative vomiting
803216|NCT03139383|gynecologic laparoscopic surgery
803217|NCT03139344|metabolism
803218|NCT03139344|exercise
803219|NCT03139344|glucose
803220|NCT03139344|secondary health conditions
803221|NCT03139344|quality of life
803222|NCT03139305|glucagon
803223|NCT03139266|cystic fibrosis
803224|NCT03139266|mindfulness
803225|NCT03139266|cognitive behavioral therapy
803226|NCT03139266|UPLIFT
803227|NCT03139266|anxiety
803228|NCT03139266|depression
803229|NCT03139266|web based intervention
803230|NCT03139253|Helicobacter Pylori Infection
803231|NCT03139253|Antimicrobial susceptibility testing (AST)
803232|NCT03139253|Triple Therapy
803233|NCT03139201|silicone hydrogel soft contact lens
803234|NCT03139188|Cancer
803235|NCT03139188|incurable pathologies
803236|NCT03139188|palliative care
803237|NCT03139162|Home Care Services
803238|NCT03139162|Aging
803239|NCT03139162|Frailty
803240|NCT03139162|Complexity
803241|NCT03139162|Nursing
803242|NCT03139149|conservative treatment
803243|NCT03139149|laparoscopic adhesiolysis
803244|NCT03139149|strangulation
803245|NCT03139071|coffee consumption
803246|NCT03139071|cardiovascular diseases
803247|NCT03139071|coronary artery calcium
803248|NCT03139071|subclinical atherosclerosis
803249|NCT03139019|Diabetes prevention
803250|NCT03139019|Weight loss
803251|NCT03139019|Lifestyle change
803252|NCT03138967|Malignant neoplasms of urinary tract
803253|NCT03138967|Bladder cancer
803254|NCT03138967|Outpatient bladder procedures
803255|NCT03138967|Outpatient cystoscopy procedure
803256|NCT03138967|Transurethral resection of the bladder
803257|NCT03138967|TURB
803258|NCT03138967|Rocuronium
803259|NCT03138967|Rocuronium Bromide
803260|NCT03138967|Zemuron
803261|NCT03138967|Sugammadex
803262|NCT03138967|Neostigmine
803263|NCT03138967|Glycopyrrolate
803264|NCT03138928|glaucoma
803265|NCT03138928|trabeculectomy
803266|NCT03138928|minimally invasive glaucoma surgery
803267|NCT03138928|XEN45 gel stent
803268|NCT03138915|clinically significant portal hypertension
803269|NCT03138915|hepatic venous pressure gradient
803270|NCT03138915|radiomics
803276|NCT03138850|intravenous sedation
803277|NCT03138850|esophagogastroduodenalscopy
803278|NCT03138850|upper airway
803279|NCT03138850|mandibular advancement device
803280|NCT03138850|high flow nasal cannula
803281|NCT03138837|Bladder cancer
803282|NCT03138837|Magnetic Resonance Imaging
803283|NCT03138837|Bladder Cancer Superficial
803284|NCT03138824|Bladder Urothelial Carcinoma
803285|NCT03138824|TURBT
803286|NCT03138824|Recurrence
803287|NCT03138824|Progression
803295|NCT03138798|Labor
803296|NCT03138798|Second stage
803297|NCT03138798|Dental device
803298|NCT03138746|hyperbaric oxygenation
803299|NCT03138746|insulin sensitivity
803300|NCT03138746|human
803301|NCT03138746|inflammation
803303|NCT03138642|mucosal melanoma
803304|NCT03138642|radiotherapy
803305|NCT03138616|Gestational diabetes mellitus
803306|NCT03138616|vitamin D
803307|NCT03138616|postpartum
803308|NCT03138603|surgery
803309|NCT03138603|heart disease
803310|NCT03138603|metoprolol
803311|NCT03138603|myocardial injury
803312|NCT03138590|transcranial Direct Current Stimulation (tDCS)
803313|NCT03138590|accelerate learning
803314|NCT03138590|memory
803319|NCT03138551|Sensory Food Aversions
803320|NCT03138538|Advanced Solid Tumors
803321|NCT03138538|M8891
803322|NCT03138538|Methionine Aminopeptidase 2 Inhibitor
803323|NCT03138512|localized
803324|NCT03138512|resected
803325|NCT03138512|adjuvant
803326|NCT03138473|SYNTAX Score
803327|NCT03138473|residual SYNTAX score
803328|NCT03138473|SYNTAX Revascularization Index
803329|NCT03138447|insulin
803330|NCT03138447|basal
803331|NCT03138447|titration
803332|NCT03138447|digital health
803333|NCT03138434|Abdominal Aortic Aneurysm
803334|NCT03138434|4D flow MRI
803335|NCT03138434|DCE-MRI
803336|NCT03138434|T1 and T2 mapping
803337|NCT03138408|Ovarian cancer
803338|NCT03138408|SC-004
803339|NCT03138408|Solid tumor cancers
803340|NCT03138408|Maximum tolerated dose (MTD)
803341|NCT03138408|Endometrial cancer
803342|NCT03138408|Cancer
803343|NCT03138395|acute myeloid leukemia
803344|NCT03138395|myelodysplastic syndrome
803345|NCT03138395|relapse
803346|NCT03138395|PCR
803347|NCT03138395|droplet digital
803348|NCT03138395|polymerase chain reaction
803349|NCT03138382|obesity
803350|NCT03138382|metabolic syndrome
803351|NCT03138382|weight loss
803359|NCT03138356|Type 2 diabetes mellitus, saxagliptin, dapagliflozin, metformin XR, fixed-dose combination, healthy subjects, crossover, cohorts.
803360|NCT03138304|decision making
803361|NCT03138304|heuristics
803362|NCT03138226|uterus, transplantation, infertility, twin
803363|NCT03138213|pancreaticoduodenectomy
803364|NCT03138213|surgical outcome
803365|NCT03138200|Transfusion
803366|NCT03138200|ScvO2
803367|NCT03138200|Hemoglobin
803372|NCT03138148|intensive care
803373|NCT03138135|PrEP
803374|NCT03138135|HIV prevention
803375|NCT03138135|Risk reduction
803376|NCT03138135|STI prevention
803377|NCT03138135|Home HIV testing
803378|NCT03138135|HIV testing
803379|NCT03138135|STI testing
803380|NCT03138109|non-cardiac surgery
803381|NCT03138109|major adverse cardiac event
803382|NCT03138083|Mesenchymal-epithelial transition factor (MET) inhibitor
803383|NCT03138044|Hepatocellular Carcinoma
803384|NCT03138044|Ipsilateral Liver Lobe Devascularization
803385|NCT03138044|Alcohol Treatment
803386|NCT03138044|CILDAT
803387|NCT03138031|Percutaneuos Ethanol alcohol injection
803388|NCT03138005|Emergency Care, Prehospital
803389|NCT03138005|Resuscitation
803390|NCT03138005|Oxygen
803391|NCT03138005|Cardiac Arrest
803392|NCT03138005|Heart Arrest
803393|NCT03137992|COPD
803394|NCT03137979|Periodontitis
803395|NCT03137979|Gingiva mesenchymal stem cells
803396|NCT03137966|Diabetes mellitus, foot ulcer, deferoxamine
803397|NCT03137940|Unilateral Cerebral Palsy
803398|NCT03137940|tDCS
803399|NCT03137940|Safety
803400|NCT03137940|Upper Limb functions
803401|NCT03137927|bordetella pertussis
803402|NCT03137927|vaccine
803403|NCT03137927|Immunologic Factors
803404|NCT03137927|whooping cough
803405|NCT03137914|orthognathic surgery
803406|NCT03137914|TMJ
803407|NCT03137914|osteoarthritis
803408|NCT03137875|Tuberculosis
803409|NCT03137875|TB
803410|NCT03137875|MDR-TB
803411|NCT03137875|LIPA
803412|NCT03137875|filter paper
803413|NCT03137875|slides
803414|NCT03137875|MTBDR Plus
803415|NCT03137849|Yoga
803416|NCT03137849|Hypertension
803417|NCT03137849|Post-Menopausal Women
803418|NCT03137849|Heart Rate Variability
803419|NCT03137823|diagnosis, tonsillitis, streptococcus, GABHS
803420|NCT03137784|asthma,
803421|NCT03137784|NVA237,
803422|NCT03137784|glycopyrronium bromide
803423|NCT03137784|allergic asthma,
803424|NCT03137784|allergy triggered asthma,
803425|NCT03137784|reactive asthma,
803426|NCT03137784|asthma attack,
803427|NCT03137784|difficulty breathing
803428|NCT03137745|Thromboelastography, chemotherapy,hyperthermic
803429|NCT03137693|histologically proven
803430|NCT03137693|invasive adenocarcinoma of breast
803431|NCT03137693|node negative (N0)
803432|NCT03137693|breast-conserving surgery
803433|NCT03137693|negative for Her-2 amplification
803434|NCT03137693|estrogen receptor (ER) positive
803435|NCT03137693|progesterone receptor (PR) positive
803436|NCT03137680|Arteriovenous Fistula
803437|NCT03137680|Pre-operative Exercise
803438|NCT03137680|Fistula Maturation
803439|NCT03137667|Influenza Vaccination Rates
803440|NCT03137654|Cognitive Training
803441|NCT03137654|Emotion Processing
803442|NCT03137641|occupational exposure
803443|NCT03137641|antineoplastic drugs
803444|NCT03137641|biomonitoring
803445|NCT03137628|general anesthesia,mechanical ventilation,colectomy
803446|NCT03137589|Telemedicine
803447|NCT03137576|Awake Thoracic Surgery, Serratus block
803448|NCT03137563|Women
803449|NCT03137563|25-65 years
803450|NCT03137537|Lymphoma
803451|NCT03137537|Abnormal resting heart rate
803452|NCT03137537|Autonomic imbalance
803453|NCT03137537|Cancer survivorship
803454|NCT03137524|Fan or Air Therapy
803455|NCT03137511|Public Health
803456|NCT03137511|General Medicine
803457|NCT03137511|Dermatology
803458|NCT03137498|renal colic
803459|NCT03137498|lidocaine
803460|NCT03137498|ketorolac
803461|NCT03137498|acute pain
803462|NCT03137472|TMS, CRPS, Sham
803463|NCT03137459|Transtheoretical Model (TTM)
803464|NCT03137446|Intravenous fluid resuscitation
803465|NCT03137446|Septic shock
803466|NCT03137446|Severe sepsis
803467|NCT03137446|Fluid restriction
803468|NCT03137433|Weight loss
803469|NCT03137433|Cardiometabolic
803470|NCT03137433|Meal-replacement therapy
803471|NCT03137407|heel pain
803472|NCT03137394|spinal cord injury
803473|NCT03137394|shoulder pain
803474|NCT03137394|psychosocial
803480|NCT03137355|Leigh Syndrome
803481|NCT03137355|Leigh Disease
803482|NCT03137355|Leigh's Necrotizing Encephalopathy
803483|NCT03137355|Subacute Necrotizing Encephalomyelopathy
803484|NCT03137355|Subacute Necrotizing Encephalomyopathy
803485|NCT03137342|PrEP
803486|NCT03137342|Adherence
803487|NCT03137342|Risk Reduction
803488|NCT03137342|Stimulant Use
803489|NCT03137290|Paediatric general anaesthesia
803490|NCT03137290|Rocuronium
803491|NCT03137290|Neostigmine
803492|NCT03137290|Sugammadex
803493|NCT03137277|Colonoscopy
803494|NCT03137277|ADR
803495|NCT03137277|Adenoma detection rate
803496|NCT03137277|colonoscopic imaging feature improvement
803497|NCT03137277|Olympus colonoscopes
803498|NCT03137264|T790M mutation
803499|NCT03137264|EGFR epidermal growth factor receptor
803500|NCT03137264|non-invasive testing
803501|NCT03137264|lung cancer
803502|NCT03137251|Transcutaneous electrical nerve stimulation
803503|NCT03137251|TENS
803504|NCT03137251|Analgesia
803505|NCT03137251|Labour pain
803506|NCT03137251|Physical therapy modality
803507|NCT03137238|Self-motion perception
803508|NCT03137238|Optic flow
803509|NCT03137238|Vestibular system
803510|NCT03137238|Multisensory integration
803511|NCT03137238|Parkinson's disease
803512|NCT03137212|Percutaneous Coronary Intervention
803513|NCT03137212|STEMI
803514|NCT03137212|Thrombosis
803515|NCT03137199|stem cell
803516|NCT03137199|mesenchymal stem cell
803517|NCT03137199|lung
803518|NCT03137199|asthma
803519|NCT03137186|Metformin, prostate cancer
803520|NCT03137147|pediatric
803521|NCT03137147|children
803522|NCT03137147|adolescent
803523|NCT03137147|sleep
803524|NCT03137147|pain
803525|NCT03137147|cognitive-behavioral therapy
803529|NCT03137082|Alcohol Use Disorder
803530|NCT03137082|Guanfacine
803531|NCT03137082|Stress
803532|NCT03137082|Craving
803533|NCT03137082|Gender
803534|NCT03137082|Relapse
803535|NCT03137056|Hemodialysis
803536|NCT03137056|Membrane
803537|NCT03137056|Albumin
803538|NCT03137056|Proteomics
803539|NCT03137043|GINA guidelines
803540|NCT03137043|Prevalence
803541|NCT03137043|Mepolizumab
803542|NCT03137043|severe asthma
803543|NCT03137043|Spain
803544|NCT03137030|Abuse deterrent formulation
803545|NCT03137030|Hydrocodone
803546|NCT03137030|Analgesics, Opioid
803547|NCT03137030|Narcotics
803548|NCT03137017|Abuse deterrent formulation
803549|NCT03137017|Hydrocodone
803550|NCT03137017|Analgesics, Opioid
803551|NCT03137017|Narcotics
803552|NCT03136991|Oral myeloperoxidase inhibitor
803553|NCT03136978|Macrophages
803554|NCT03136978|Macrophages, Peritoneal
803555|NCT03136978|Endometriosis
803556|NCT03136952|NIRS
803557|NCT03136952|Monitoring
803558|NCT03136952|Pediatric
803559|NCT03136874|donors
803560|NCT03136874|gametes
803561|NCT03136874|motivation
803562|NCT03136874|psychological
803563|NCT03136861|axial spondyloarthritis
803564|NCT03136861|ankylosing spondylitis
803565|NCT03136861|non-radiographic axial spondyloarthritis
803566|NCT03136861|inflammatory back pain
803567|NCT03136861|spinal pain
803568|NCT03136861|secukinumab
803569|NCT03136861|AIN457
803570|NCT03136848|perfusion
803571|NCT03136822|Diabetic Foot
803572|NCT03136744|Sedentary behaviour
803573|NCT03136744|Co-morbidity
803574|NCT03136744|Intervention
803575|NCT03136731|Celiac disease, Gluten, Microbiome, Genetic
803576|NCT03136718|mHealth
803577|NCT03136718|Hearing aids
803578|NCT03136718|Auditory rehabilitation
803579|NCT03136718|Adult
803580|NCT03136718|Reusable Learning Object
803581|NCT03136718|Education
803582|NCT03136718|Personalised
803583|NCT03136718|Telehealth
803584|NCT03136718|Teleaudiology
803585|NCT03136705|Phosphorus Homeostasis
803586|NCT03136705|FGF23
803587|NCT03136705|Vitamin D
803588|NCT03136692|app
803589|NCT03136692|weight loss
803590|NCT03136692|diet
803591|NCT03136692|behavior
803592|NCT03136653|DARPin
803593|NCT03136653|MP0250
803594|NCT03136653|VEGF
803595|NCT03136653|HGF
803596|NCT03136653|RRMM
803597|NCT03136627|RCC, Tivozanib, Nivolumab, Metastatic Renal Cell Cancer
803598|NCT03136588|Information and Communication Technology
803599|NCT03136588|Adherence
803600|NCT03136588|Kidney transplantation
803601|NCT03136523|NSCLC
803602|NCT03136523|SCLC
803603|NCT03136523|MOLECULAR BIOMARKERS
803604|NCT03136523|EGFR
803605|NCT03136523|PD-L1
803606|NCT03136523|ALK
803607|NCT03136523|KRAS
803608|NCT03136458|contrast media
803609|NCT03136458|nephropathy
803610|NCT03136458|ischemic preconditioning
803611|NCT03136445|Tranexamic acid
803612|NCT03136445|Platelet transfusion
803613|NCT03136432|Cerebral Palsy
803614|NCT03136432|Functional Exercise Capacity
803615|NCT03136432|Quality of Life
803616|NCT03136419|microbiota
803617|NCT03136419|innate immunity
803618|NCT03136393|nutrition
803619|NCT03136393|pregnancy
803620|NCT03136393|birth weight
803621|NCT03136380|healthy Japanese subjects
803622|NCT03136380|CXCR2 inhibitor
803623|NCT03136380|Danirixin
803624|NCT03136367|encounter decision aids
803625|NCT03136367|shared decision making
803626|NCT03136367|socioeconomic status
803627|NCT03136367|disparities
803628|NCT03136367|decision quality
803629|NCT03136341|Upper Limb
803630|NCT03136341|Tremor
803631|NCT03136341|task-dependent
803632|NCT03136315|Renal failure
803633|NCT03136315|athlete
803634|NCT03136315|ultra endurance
803635|NCT03136263|Attention
803636|NCT03136263|Attention deficit/hyperactivity disorder
803637|NCT03136263|Cognitive control
803638|NCT03136263|Executive control
803639|NCT03136263|Executive functions
803640|NCT03136263|Impulse control
803641|NCT03136263|Impulsivity
803642|NCT03136263|Oxytocin
803643|NCT03136250|Muscle Energy Techniques
803644|NCT03136250|Autogenic Inhibition
803645|NCT03136250|Reciprocal Inhibition
803646|NCT03136250|Stretching
803647|NCT03136250|Range of Motion
803648|NCT03136250|Muscle Strength
803649|NCT03136250|VAS
803650|NCT03136250|Neck Disability Index
803651|NCT03136250|NDI
803652|NCT03136224|circumcision
803653|NCT03136224|Thermocautery
803654|NCT03136224|Clamp
803655|NCT03136224|Surgical Circumcision
803656|NCT03136198|Heart Failure
803657|NCT03136198|Acute Heart Failure
803658|NCT03136198|Pulmonary Edema
803659|NCT03136198|Lung ultrasound
803660|NCT03136198|Extra vascular lung water
803661|NCT03136198|B-lines
803662|NCT03136159|pregnancy
803663|NCT03136159|delivery
803664|NCT03136159|cesarean section
803665|NCT03136159|wound healing
803666|NCT03136159|silver-containing dressing
803667|NCT03136146|Hematopoietic/Lymphoid Cancer
803668|NCT03136146|Acute Lymphoblastic Leukemia
803669|NCT03136146|ALL
803670|NCT03136146|Lymphoblastic Lymphoma
803671|NCT03136146|LL
803672|NCT03136146|Relapsed/Refractory
803673|NCT03136146|Clofarabine
803674|NCT03136146|Clofarex
803675|NCT03136146|Clolar
803676|NCT03136146|Etoposide
803677|NCT03136146|VePesid
803678|NCT03136146|Cyclophosphamide
803679|NCT03136146|Cytoxan
803680|NCT03136146|Neosar
803681|NCT03136146|Liposomal Vincristine
803682|NCT03136146|Vincristine Sulfate Liposomes Injection
803683|NCT03136146|VSLI
803684|NCT03136146|Marqibo
803685|NCT03136146|Bortezomib
803686|NCT03136146|Velcade
803687|NCT03136146|LDP-341
803688|NCT03136146|MLN341
803689|NCT03136146|PS-341
803690|NCT03136146|Ofatumumab
803691|NCT03136146|Arzerra
803692|NCT03136146|Rituximab
803693|NCT03136146|Rituxan
803694|NCT03136146|Pegfilgrastim
803695|NCT03136146|Neulasta
803696|NCT03136146|PEG-G-CSF
803703|NCT03136094|American Indian
803704|NCT03136094|Alaska Native
803705|NCT03136094|Youth and Young Adult
803706|NCT03136094|SBIRT
803707|NCT03136081|Septic shock
803708|NCT03136081|Candidiasis
803709|NCT03136081|Candidemia
803710|NCT03136081|Bacteremia
803711|NCT03136081|Immunoparalysis
803712|NCT03136055|NEC
803713|NCT03136029|HFrEF
803714|NCT03136029|Exercise Intolerance
803715|NCT03136029|Nitric Oxide
803716|NCT03135990|Virtual Reality
803717|NCT03135990|Exposure Therapy
803718|NCT03135990|Cognitive Behavioral Therapy
803719|NCT03135990|Extinction Learning
803720|NCT03135964|NPWT
803721|NCT03135964|foam
803722|NCT03135964|gauze
803723|NCT03135951|Breast Cancer
803724|NCT03135951|Pharmacokinetics
803725|NCT03135951|Long-acting Myeloid Growth Factor
803726|NCT03135951|Early Stage Breast Cancer
803727|NCT03135951|Docetaxel + Cyclophosphamide (TC) Chemotherapy
803728|NCT03135912|Tinea Pedis
803729|NCT03135912|Athlete's Foot
803730|NCT03135886|HIV
803731|NCT03135886|HIV Testing
803732|NCT03135886|Hepatitis C Virus Testing
803733|NCT03135886|Opioid Use Disorder Treatment
803734|NCT03135886|Substance Use Disorders Treatment
803735|NCT03135886|Hepatitis C Virus
803736|NCT03135886|Practice Coaching
803737|NCT03135860|Inhaled Nitric Oxide
803738|NCT03135860|COPD
803739|NCT03135860|Chronic Obstructive Pulmonary Disease
803740|NCT03135860|Idopathic Pulmonary Fibrosis
803741|NCT03135860|Long Term Oxygen Therapy (LTOT)
803742|NCT03135808|MRI
803743|NCT03135808|Imaging,
803744|NCT03135808|Anatomy
803745|NCT03135808|Tissue
803746|NCT03135808|Colorectal
803747|NCT03135808|Sigmoid
803748|NCT03135808|Colon
803749|NCT03135808|Pathology
803750|NCT03135795|sufentanil
803751|NCT03135795|DNA methylation
803752|NCT03135769|avelumab
803753|NCT03135769|PDL1
803754|NCT03135769|Gestational Trophoblastic Neoplasias
803755|NCT03135769|GTN
803756|NCT03135769|Hydatiform mole
803757|NCT03135769|hCG
803758|NCT03135717|Chronic kidney disease
803759|NCT03135717|Enteral nutrition
803760|NCT03135717|Oral nutritional supplements
803761|NCT03135717|Parenteral nutrition
803762|NCT03135717|Refeeding
803763|NCT03135717|Wasting
803767|NCT03135639|tACS
803768|NCT03135639|transcranial alternating current stimulation
803769|NCT03135639|stimulation
803770|NCT03135639|healthy control
803771|NCT03135639|alpha oscillations
803772|NCT03135639|heart rate variability
803773|NCT03135626|Pulpotomy
803774|NCT03135626|Primary molars
803775|NCT03135613|Knee tumor
803776|NCT03135613|Microwave
803777|NCT03135613|Gait
803778|NCT03135600|Knee
803779|NCT03135600|ACL Injury
803780|NCT03135600|Kinematics
803781|NCT03135587|Knee
803782|NCT03135587|Loading
803783|NCT03135587|Kinematics
803784|NCT03135522|Chronic cough
803785|NCT03135522|Refractory cough
803786|NCT03135522|Chronic refractory cough
803787|NCT03135522|Zinc
803788|NCT03135522|Zinc acetate
803793|NCT03135470|pain
803794|NCT03135470|ambulatory surgery
803795|NCT03135470|oxycodone
803796|NCT03135470|adverse effect
803797|NCT03135444|Screening
803798|NCT03135444|Shared Decision Making
803799|NCT03135418|Virtual Reality
803800|NCT03135392|Breast Cancer
803801|NCT03135392|sensation recovery
803802|NCT03135392|Neurotization
803803|NCT03135366|Tuberculosis
803804|NCT03135366|TB
803805|NCT03135366|Adherence
803806|NCT03135366|Mobile Health
803807|NCT03135366|mHealth
803808|NCT03135366|Behavior change
803809|NCT03135366|Social and Behavior Change Communication (SBCC)
803810|NCT03135366|Drug-Resistance
803811|NCT03135366|Keheala
803812|NCT03135275|ST-elevation Myocardial Infarction
803813|NCT03135275|Multivessel coronary disease
803814|NCT03135275|Immediate complete coronary revascularization
803815|NCT03135275|Staged complete coronary revascularization
803816|NCT03135275|Percutaneous coronary intervention
803817|NCT03135275|Biodegradable-polymer everolimus-eluting stent
803818|NCT03135236|Parent training
803819|NCT03135236|Family education
803820|NCT03135236|Young adults
803821|NCT03135236|Down syndrome
803822|NCT03135236|sexuality
803823|NCT03135223|Physical activity
803824|NCT03135145|Single Event Multilevel Lower Extremity Orthopedic Surgery (SEMLS)
803825|NCT03135145|Physical Therapy
803826|NCT03135145|Gait Training
803827|NCT03135145|Functional Walking
803828|NCT03135145|Selective Dorsal Rhizotomy (SDR)
803829|NCT03135132|High visceral fat
803830|NCT03135132|Low calorie diet
803831|NCT03135132|Mild weight loss
803832|NCT03135132|Metabolomics
803833|NCT03135132|Metabolites
803834|NCT03135132|Acylcarnitines
803835|NCT03135093|synergies
803836|NCT03135093|upper limb
803837|NCT03135093|vision
803838|NCT03135067|HIV self-testing
803839|NCT03135067|female sex workers
803840|NCT03135067|partner testing
803841|NCT03135067|couples testing
803842|NCT03135067|transactional sex
803843|NCT03135054|FLT3-ITD (+) AML; Quizartinib (AC220), Omacetaxine mepesuccinate
803844|NCT03135041|Prebiotics
803845|NCT03135041|Microbiome
803846|NCT03135041|Glucose metabolism
803847|NCT03133000|Recurrent abdominal wall hernia
803848|NCT03133000|Incisional hernia
803849|NCT03132987|quadriceps strength
803850|NCT03132987|quadriceps voluntary activation
803851|NCT03132987|progressive strength program
803852|NCT03134976|Salvage surgery
803853|NCT03134976|Head and neck cancer
803854|NCT03134976|Wound healing
803855|NCT03134976|Hypothyroidism
803856|NCT03134976|Levothyroxine
803857|NCT03134937|Gastric Ultrasound
803858|NCT03134937|Gastric Distension
803859|NCT03134937|Gastric Volume
803860|NCT03134937|Gastric Fluid Volume
803861|NCT03134937|High-flow oxygen therapy
803862|NCT03134937|HFNO
803863|NCT03134924|Bacterial Vaginosis
803864|NCT03134885|suicide
803865|NCT03134885|suicidal conducts
803866|NCT03134885|post discharge monitoring system
803867|NCT03134872|PD-1
803868|NCT03134872|PD-L1
803869|NCT03134872|SHR-1210
803870|NCT03134872|Carboplatin
803871|NCT03134872|Pemetrexed
803872|NCT03134859|motor development
803873|NCT03134846|Intraoperative fluorescence imaging
803874|NCT03134846|Cetuximab-IRDye800CW
803875|NCT03134846|Molecular imaging
803876|NCT03134833|HIV
803877|NCT03134833|STI
803878|NCT03134833|Mental Health
803879|NCT03134833|Substance Use
803880|NCT03134833|Peer Support
803881|NCT03134820|Low molecular weight heparins
803882|NCT03134820|Procoagulants
803883|NCT03134820|Phospholipid-dependent Microparticles
803884|NCT03134794|neuroeconomics
803885|NCT03134794|multiple sclerosis
803886|NCT03134794|educational intervention
803887|NCT03134794|traffic light system
803888|NCT03134794|aversion to ambiguity
803889|NCT03134794|risk
803890|NCT03134794|outcomes
803891|NCT03134794|knowledge
803892|NCT03134794|action
803893|NCT03134794|gaps
803894|NCT03134794|disease modifying agents
803895|NCT03134755|Asthma
803896|NCT03134755|Children
803897|NCT03134755|Stress
803898|NCT03134755|Puerto Rican
803899|NCT03134755|Health disparities
803900|NCT03134755|Treatment response
803901|NCT03134742|soft tissue sarcoma extremities
803902|NCT03134729|Serratus Block, Pain Management, lung lobectomy
803903|NCT03134690|Poor ovarian response gonadotropins antagonist
803904|NCT03134677|Spinal anesthesia
803905|NCT03134677|General anesthesia
803906|NCT03134677|P wave dispersion
803907|NCT03134651|Anxiety
803908|NCT03134651|Oocyte retrieval
803909|NCT03134651|Monitoring of brain function
803910|NCT03134625|metabolomics
803911|NCT03134625|biomarker
803912|NCT03134625|acute rejection
803913|NCT03134612|lidocain
803914|NCT03134612|ondansetron
803915|NCT03134612|pain
803916|NCT03134612|propofol
803917|NCT03134586|Capsule endoscopy
803918|NCT03134586|Crohn's disease
803919|NCT03134586|Magnetic resonance enterography
803920|NCT03134586|Ileocolonoscopy
803921|NCT03134586|Bowel Ultrasound
803922|NCT03134586|diagnostic imaging
803926|NCT03134560|vein display instrument
803927|NCT03134560|pediatric
803928|NCT03134560|vein access
803929|NCT03134560|vein cannulation
803930|NCT03134547|emergence agitation
803931|NCT03134547|sevoflurane
803932|NCT03134547|children
803933|NCT03134534|lobectomy
803934|NCT03134534|robot-assisted thoracoscopic surgery
803935|NCT03134534|lung cancer
803936|NCT03134521|bone and joint infection
803937|NCT03134521|daptomycin
803938|NCT03134521|population pharmacokinetics
803939|NCT03134521|Glycoprotein-P (PgP)
803940|NCT03134482|in vitro maturation (IVM)
803941|NCT03134482|polycystic ovarian syndrome (PCOS)
803942|NCT03134482|ovarian hyperstimulation syndrome (OHSS)
803943|NCT03134482|assisted reproductive technology (ART)
803944|NCT03134430|Regional nerve block
803945|NCT03134430|cancer recurrence
803946|NCT03134404|RAMP
803947|NCT03134404|Rapid Access
803948|NCT03134404|Metastasis to Bone
803949|NCT03134404|Cancer
803950|NCT03134378|Helicobacter pylori
803951|NCT03134378|triple therapy
803952|NCT03134378|eradication
803953|NCT03134365|meal ingestion
803954|NCT03134365|palatability
803955|NCT03134365|postprandial responses
803956|NCT03134365|hedonic response
803958|NCT03134339|nicotine, smoking
803959|NCT03134209|Monocryl
803960|NCT03134209|Dermabond
803961|NCT03134209|Polyester mesh
803962|NCT03134209|Joint Disease
803963|NCT03134209|Arthropathy
803964|NCT03134209|Joint Replacement
803965|NCT03134196|Herpes Zoster Ophthalmicus
803966|NCT03134196|Zoster Eye Disease Study
803967|NCT03134196|Varicella Zoster Virus
803968|NCT03134196|Zoster
803969|NCT03134196|Shingles
803976|NCT03134170|pharmacist
803977|NCT03134170|diabetes
803978|NCT03134170|Preventative Care
803979|NCT03134170|Quality of Life
803980|NCT03134157|Leiomyoma simvastatin infertility
803981|NCT03134144|Exoskeleton
803982|NCT03134144|Manual materials handling
803983|NCT03134144|Musculoskeletal disorders
803984|NCT03134144|Posture
803985|NCT03134144|Standing work
803986|NCT03134144|Muscle activity
803987|NCT03134118|Thymoma
803988|NCT03134118|Phase II
803989|NCT03134118|nivolumab
803990|NCT03134118|Thymic carcinoma
803991|NCT03134079|Taste Testing
803992|NCT03134079|Spices
803993|NCT03134079|Reduced sugar
803994|NCT03134079|Food liking
803995|NCT03134053|hypertrophy scar
803996|NCT03134053|burn
803997|NCT03134040|Incentives
803998|NCT03134040|Motivation
803999|NCT03132961|Vestibular evoked myogenic potentials
804000|NCT03132961|Electrocochleography
804001|NCT03132961|Infrasound
804002|NCT03132948|ALL Cancer Patients
804003|NCT03132948|Quality of Life
804004|NCT03132948|Fitness
804005|NCT03133975|high dose vitamin D
804006|NCT03133975|dyslipidemia
804007|NCT03133975|premenopausal women
804008|NCT03133923|Attenuated Mumps Vaccine(F-genotype，Human Diploid Cell, KMB-17), safety, immunogenecity
804009|NCT03133910|Pharmacokinetics
804010|NCT03133910|Ceftazidime
804011|NCT03133897|dexamethasone
804012|NCT03133897|prednisone
804013|NCT03133897|inpatient
804014|NCT03133897|paediatrics
804015|NCT03133884|chronic tension-type headache
804016|NCT03133884|acupuncture
804017|NCT03133884|Deqi
804018|NCT03133845|delirium
804019|NCT03133845|elderly
804020|NCT03133845|lumbar
804021|NCT03133845|surgery
804022|NCT03133832|Schistosomiasis haematobium
804023|NCT03133832|Praziquantel
804024|NCT03133832|A randomized controlled trial
804025|NCT03133806|Percutaneous Occlusion
804026|NCT03133793|heart failure with preserved ejection fraction
804027|NCT03133767|Normal saline
804028|NCT03133767|Lactated ringers
804029|NCT03133767|Emergency department
804030|NCT03133741|GIP
804031|NCT03133741|GIP receptor antagonist
804037|NCT03133715|robot-assisted
804038|NCT03133689|Alcohol
804039|NCT03133689|Coronary heart disease
804040|NCT03133689|Ischemic heart disease
804041|NCT03133689|Cardiovascular health
804042|NCT03133689|Individual participant data meta-analysis
804043|NCT03133689|Longitudinal
804044|NCT03133676|Osteoarthritis
804045|NCT03133676|Arthritis
804046|NCT03133676|Joint Disease
804047|NCT03133676|Osteoarthritis, Knee
804048|NCT03133663|electrocardiogram
804049|NCT03133663|premature
804050|NCT03133663|resuscitation
804053|NCT03133624|unruptured intracranial aneurysms
804054|NCT03133624|rupture risk
804055|NCT03133624|computational fluid dynamic
804056|NCT03133624|high resolution magnetic resonance images
804057|NCT03133624|gene
804058|NCT03133624|multi dimensional prediction model
804059|NCT03133624|clinical features
804060|NCT03133624|risk factors
804061|NCT03133624|registry study
804062|NCT03133624|china
804063|NCT03133624|biomarkers
804064|NCT03133611|Speech disorder
804065|NCT03133611|Acoustic analysis
804066|NCT03133611|Dysarthria
804067|NCT03133598|Un-ruptured intracranial aneurysm
804068|NCT03133598|Interventional therapy and craniotomy
804069|NCT03133598|Prospective cohort study
804070|NCT03133598|China
804071|NCT03133546|NSCLC
804072|NCT03133546|EGFR
804073|NCT03133546|TKI
804074|NCT03133546|EGFRm
804075|NCT03133546|T790M
804076|NCT03133533|robot-assisted
804077|NCT03133520|Respiratory failure
804078|NCT03133520|immuncompromise patients
804079|NCT03133520|high flow oxygen
804080|NCT03133507|cancer
804081|NCT03133507|salivary alpha amylase
804082|NCT03133507|pain
804083|NCT03133507|positive affect
804084|NCT03133507|emotion regulation strategies
804085|NCT03133481|Adductor Canal Block
804086|NCT03133481|Femoral Canal Block
804087|NCT03133468|AJM347
804088|NCT03133468|pharmacokinetics
804089|NCT03133468|food effect study
804090|NCT03133468|pharmacodynamics
804091|NCT03133455|Rumination
804092|NCT03133429|carotid artery
804093|NCT03133429|stroke
804094|NCT03133429|stent
804095|NCT03133416|rotator cuff tendinopathy
804096|NCT03133416|rotator cuff tear
804097|NCT03133416|platelet-rich plasma
804098|NCT03133416|physiotherapy
804099|NCT03133416|exercise
804100|NCT03133377|Early activity and mobilization, rehabilitation, intensive care
804101|NCT03133325|Hyaluronic Acid, Lidocaine
804102|NCT03133286|Anal Cancer
804103|NCT03133286|Bladder
804104|NCT03133286|Cervical
804105|NCT03133286|Colorectal
804106|NCT03133286|Esophageal
804107|NCT03133286|Gallbladder
804108|NCT03133286|Liver
804109|NCT03133286|Ovarian
804110|NCT03133286|Pancreas
804111|NCT03133286|Pancreatic
804112|NCT03133286|Prostate
804113|NCT03133286|Rectal
804114|NCT03133286|Renal
804115|NCT03133286|Kidney
804116|NCT03133286|Stomach
804117|NCT03133286|Testicular
804118|NCT03133286|Uterine
804119|NCT03133286|Cancer
804120|NCT03133286|Radiation Therapy
804121|NCT03133286|Radiation Treatment
804122|NCT03133273|Colorectal Cancer Metastatic
804123|NCT03133273|Chemosensitivity
804124|NCT03133221|NHL
804125|NCT03133221|indolent NHL
804126|NCT03133221|Zydelig
804127|NCT03133221|Idelalisib
804128|NCT03133221|B-cell NHL
804129|NCT03133221|Non-Hodgkin Lymphoma
804130|NCT03133221|Maintenance
804131|NCT03133221|Transformed B-cell Non-Hodgkin's lymphoma
804132|NCT03133221|Autologous Stem Cell Transplantation
804133|NCT03133208|sepsis
804134|NCT03133208|sepsis associated encephalopathy
804135|NCT03133208|sepsis associated delirium
804136|NCT03133208|altered mental status
804137|NCT03133195|Terriparatide, bone fracture healing, PFNA
804138|NCT03133169|Thalassemia
804139|NCT03133169|Glutamine/glutamate ratio
804140|NCT03133169|Pulmonary hypertension
804141|NCT03133156|Exercise
804142|NCT03133156|Training
804143|NCT03133156|Type 2 Diabetes
804144|NCT03133156|Mellitus
804145|NCT03133143|Cognitive Function
804146|NCT03133143|Schizophrenia and Disorders with Psychotic Features
804147|NCT03133143|Computers, Digital
804148|NCT03133130|Scar
804149|NCT03133130|Scar prevention
804150|NCT03133130|siRNA
804151|NCT03133091|PIEB
804152|NCT03133091|PCEA
804153|NCT03133091|LEVOBUPIVACAINE
804154|NCT03133078|Side Hop
804155|NCT03133078|Forward Hop
804156|NCT03133078|Step test
804157|NCT03133078|Vertical Jump
804158|NCT03133052|cognitive control training
804159|NCT03133052|aMCI
804160|NCT03133052|MRI
804161|NCT03133052|RCT
804162|NCT03133026|obstructive Jaundice
804163|NCT03133026|Self Expandable Metal Stents (SEMS)
804164|NCT03133026|Cholangitis
804165|NCT03132935|Non-STEMI Acute Coronary Syndrome
804166|NCT03132935|ST-segment elevation myocardial infarction
804167|NCT03132935|Telemedicine
804179|NCT03132818|Procreation with donation
804180|NCT03132792|Alpha-fetoprotein
804181|NCT03132792|Cell Therapy
804182|NCT03132792|T Cell Therapy
804183|NCT03132792|SPEAR T Cell
804184|NCT03132792|Immuno-oncology
804185|NCT03132792|Metastatic
804186|NCT03132792|Previously treated
804187|NCT03132792|T Cell Receptor
804188|NCT03132779|Intralipid
804189|NCT03132779|NK cells
804190|NCT03132779|Recurrent miscarriage
804191|NCT03132740|Hepatic Carcinoma,Three-dimensional Visualization
804192|NCT03132714|Full-mouth ultrasonic debridement
804193|NCT03132714|Clarithromycin
804194|NCT03132714|Amoxicillin
804195|NCT03132714|Metronidazole
804196|NCT03132714|Antimicrobial therapy
804197|NCT03132714|Photodynamic therapy
804198|NCT03132714|Low-level laser therapy
804199|NCT03132675|Melanoma
804200|NCT03132675|pIL-12
804201|NCT03132675|pembrolizumab
804202|NCT03132649|Three dimensional visualization
804203|NCT03132649|Operation strategy
804204|NCT03132597|stress
804205|NCT03132597|anxiety
804206|NCT03132597|depression
804207|NCT03132597|quality of life
804208|NCT03132597|Mindfulness
804213|NCT03132519|Cough
804214|NCT03132519|Hypertension
804215|NCT03132519|Remifentanil
804216|NCT03132519|Sevoflurane
804217|NCT03132519|Desflurane
804218|NCT03132467|Breast Cancer
804219|NCT03132467|Hormone Receptor Positive, HER2 Negative Breast Cancer
804220|NCT03132467|Tremelimumab
804221|NCT03132467|Ticilimumab
804222|NCT03132467|CP-675,206
804223|NCT03132467|Durvalumab
804224|NCT03132467|MEDI4736
804225|NCT03132454|Hematopoietic/Lymphoid Cancer
804226|NCT03132454|Acute myeloid leukemia
804227|NCT03132454|AML
804228|NCT03132454|Acute lymphoblastic leukemia
804229|NCT03132454|ALL
804230|NCT03132454|Relapsed or refractory
804231|NCT03132454|R/R
804232|NCT03132454|Palbociclib
804233|NCT03132454|PD-0332991
804234|NCT03132454|Ibrance
804235|NCT03132454|Sorafenib
804236|NCT03132454|Nexavar
804237|NCT03132454|BAY 43-9006
804238|NCT03132454|Decitabine
804239|NCT03132454|Dacogen
804240|NCT03132454|Dexamethasone
804241|NCT03132454|Decadron
804242|NCT03132441|advanced heart failure
804243|NCT03132441|NYHA Class III-IV
804244|NCT03132441|frailty
804245|NCT03132441|cardiac rehabilitation
804246|NCT03132415|Prevention & Control
804247|NCT03132415|Internet
804248|NCT03132415|Adolescents
804249|NCT03132415|Young adults
804250|NCT03132402|Elisa
804251|NCT03132402|Plasmodium Falciparum
804252|NCT03132389|Sexual assault
804253|NCT03132389|Sexually transmitted diseases
804254|NCT03132389|Chlamydia trachomatis
804255|NCT03132389|Mycoplasma genitalium
804256|NCT03132389|Neisseria gonorrhoeae
804257|NCT03132389|Hepatitis B and C
804258|NCT03132389|HIV
804259|NCT03132389|Syphilis
804260|NCT03132389|Follow up visits after sexual assault
804261|NCT03132324|Sickle cell disease (SCD)
804262|NCT03132324|sickle cell SS
804263|NCT03132324|lysine demethylase 1 (LSD1) inhibition
804264|NCT03132311|yellow fever vaccine
804265|NCT03132311|hiv
804266|NCT03132272|ADAsorb apheresis
804267|NCT03132272|Globaffin adsorber
804268|NCT03132272|Agonistic Autoantibodies
804269|NCT03132272|Immunoadsorption
804270|NCT03132272|Alzheimer Dementia
804271|NCT03132259|Dexmedethomidine
804272|NCT03132246|Methicillin-resistant Staphylococcus aureus (MRSA)
804273|NCT03132246|Infection
804274|NCT03132246|Biofilm Assay
804275|NCT03132233|Migraine
804276|NCT03132233|Prevention
804277|NCT03132233|Prophylaxis
804278|NCT03132233|Ketone bodies
804279|NCT03132233|Beta-hydroxybutyrate
804280|NCT03132233|Double-blind
804281|NCT03132233|Randomised
804282|NCT03132233|Placebo controlled
804283|NCT03132233|Mitochondrial functioning
804284|NCT03132233|Energy metabolism
804285|NCT03132233|Intervention
804286|NCT03132233|Dietary Supplement
804287|NCT03132220|critical care nurses
804288|NCT03132220|mindfulness-based cognitive therapy
804289|NCT03132220|Burn-out Syndrome
804290|NCT03132220|Post-traumatic Stress Disorder
804291|NCT03132220|Cognitive Behavioral Therapy
804292|NCT03132207|Oral Health
804293|NCT03132207|Pregnancy
804294|NCT03132207|Prevention
804295|NCT03132207|adverse pregnancy outcomes
804296|NCT03132181|Empagliflozin
804297|NCT03132181|Diabetes
804298|NCT03132181|Systemic vascular resistance
804299|NCT03132181|Cardiac output
804300|NCT03132181|Blood pressure
804301|NCT03132168|cystectomy
804302|NCT03132168|urology
804303|NCT03132168|surgery
804304|NCT03132129|Type 2 diabetes
804305|NCT03132129|Diabetic cardiomyopathy
804306|NCT03132129|Cardiovascular magnetic resonance
804307|NCT03132116|Cat Scratch Disease's lymphadenitis
804308|NCT03132116|Infectious Diseases
804309|NCT03132103|Vitamin D deficiency
804310|NCT03132103|Simulated sunlight radiation
804311|NCT03132103|Oral vitamin D3
804312|NCT03132051|carpal tunnel syndrome
804313|NCT03132025|Metastatic Colorectal Cancer
804314|NCT03132025|Apatinib
804315|NCT03132025|Capecitabine
804316|NCT03131999|VEGF-D
804317|NCT03131999|Imatinib mesylate
804318|NCT03131999|Sirolimus
804319|NCT03131921|Energy expenditure
804320|NCT03131921|Nutrition
804321|NCT03131921|Colorectal cancer
804322|NCT03131921|Dietary needs
804323|NCT03131908|Melanoma and other malignant neoplasms of skin
804324|NCT03131908|Metastatic Melanoma
804325|NCT03131908|GSK2633771
804326|NCT03131908|Pembrolizumab
804327|NCT03131908|Keytruda
804328|NCT03131908|MK-3475
804329|NCT03131908|SCH-900475
804330|NCT03131895|Drug therapy
804331|NCT03131882|trigger finger
804332|NCT03131882|trigger thumb
804333|NCT03131882|ultrasound guided
804334|NCT03131882|hyaluronic acid
804335|NCT03131856|Geriatrics
804336|NCT03131856|Nutritional risk
804337|NCT03131856|Multi-disciplinary intervention
804338|NCT03131856|Randomized Controlled Trial
804339|NCT03131843|skin infection
804340|NCT03131843|vaccination
804341|NCT03131843|children
804342|NCT03131843|alcohol swab
804343|NCT03131843|skin preparation
804344|NCT03131804|Aerobic
804345|NCT03131804|Intradialytic
804346|NCT03131804|Cardio-metabolic markers
804347|NCT03131804|Dialysis Adequacy
804348|NCT03131804|Quality of Life
804349|NCT03131804|Cost Effectiveness
804350|NCT03131791|Extracorporeal Shock Wave
804351|NCT03131791|Spasticity in stokes
804352|NCT03131791|Botulinum toxin
804353|NCT03131752|chronic obstructive pulmonary disease
804354|NCT03131752|muscle strength
804355|NCT03131752|physical activity
804356|NCT03131739|Resilience
804357|NCT03131739|Alaska Native
804358|NCT03131739|Community Based Participatory Research
804359|NCT03131739|Culture and Community Factors
804360|NCT03131739|Protective Factors
804361|NCT03131739|Risk Factors
804362|NCT03131726|simvastatin
804363|NCT03131726|diclofenac
804364|NCT03131713|Mohs micrographic surgery
804365|NCT03131713|pain
804366|NCT03131713|functional status
804367|NCT03131700|RPH101
804368|NCT03131700|RPH-101
804369|NCT03131700|Biosimilar
804370|NCT03131700|Bevacizumab
804371|NCT03131700|Safety
804372|NCT03131674|Somatic tinnitus
804374|NCT03131596|intrauterine balloon
804375|NCT03131596|hysteroscopy
804376|NCT03131583|SHR4640 Febuxostat Colchicine pharmacodynamics
804377|NCT03131570|Psoriasis
804378|NCT03131570|Chronic Plaque Psoriasis
804379|NCT03131570|Secukinumab
804380|NCT03131544|BPH
804381|NCT03131544|Benign Prostatic Hypertrophy
804382|NCT03131544|MRI
804383|NCT03131544|Prostate
804384|NCT03131544|Lower Urinary Tract Symptoms
804385|NCT03131544|Nocturia
804386|NCT03131544|Incomplete bladder emptying
804387|NCT03131479|renal function
804388|NCT03131479|sodium-glucose co-transporter
804389|NCT03131479|pharmacokinetics
804390|NCT03131479|decreased renal function
804391|NCT03131479|decreased kidney function
804392|NCT03131479|kidney disease
804393|NCT03131479|urinary glucose excretion
804394|NCT03131479|UGE
804395|NCT03131466|Trigeminal Neuralgia
804396|NCT03131466|Pulsed Radiofrequency
804397|NCT03131466|Gasserian Ganglion
804398|NCT03131453|Placebo controlled,
804399|NCT03131453|APOE4 carriers,
804400|NCT03131453|Homozygotes,
804401|NCT03131453|Heterozygotes,
804402|NCT03131453|Brain Amyloid,
804403|NCT03131453|Preclinical Alzheimer's Disease (AD),
804404|NCT03131453|Aβ lowering,
804405|NCT03131453|BACE-1 inhibitor
804406|NCT03131427|Wilson's Disease
804407|NCT03131427|Hereditary Hemochromatosis
804408|NCT03131427|Hereditary Hyperbilirubinemias
804409|NCT03131427|Inherited Cholestatic Liver Disease
804410|NCT03131427|Genetic Testing
804411|NCT03131375|dexmedetomidine
804412|NCT03131375|emergence delirium
804413|NCT03131375|anesthesia
804414|NCT03131375|propofol
804415|NCT03131375|children
804417|NCT03131323|delineate the prevalence of abnormal nasal finding in wheezy child
804418|NCT03131297|anal fistulas
804419|NCT03131297|evaluation of radiofrequency
804420|NCT03131271|Percutaneous coronary intervention
804421|NCT03131271|Femoral arterial catheter
804422|NCT03131271|Pain
804423|NCT03131271|Cold application
804424|NCT03131271|Nursing
804425|NCT03131206|Non-small cell lung cancer
804426|NCT03131206|NSCLC
804427|NCT03131206|ALK
804428|NCT03131206|RET
804429|NCT03131206|alectinib
804430|NCT03131206|Thyroid cancer
804431|NCT03131128|Mindfulness-based intervention
804432|NCT03131128|Weight loss
804433|NCT03131128|Workplace health promotion
804434|NCT03131128|Obesity
804435|NCT03131063|Extracorporeal Membrane Oxygenation
804436|NCT03131063|Sepsis
804437|NCT03131063|Antibiotics
804438|NCT03131063|Pharmacokinetic
804439|NCT03131063|Intensive Care Unit
804440|NCT03131050|Scopolamine
804441|NCT03131037|immunotherapy
804442|NCT03131037|immuno-oncology
804443|NCT03131037|tumor vaccine
804444|NCT03131024|anthracyclines
804445|NCT03130998|smoking cessation
804446|NCT03130998|depression
804447|NCT03130998|mental health
804448|NCT03130998|mood management
804449|NCT03130998|primary care
804450|NCT03130998|screening
804451|NCT03130998|brief intervention
804452|NCT03130998|referral to treatment
804453|NCT03130985|microRNA
804454|NCT03130985|biomarker
804455|NCT03130946|breast neoplasms
804456|NCT03130946|Ultrasonography, Interventional
804457|NCT03130946|Biopsy, Large-Core Needle
804458|NCT03130946|Biopsy, Fine-Needle
804459|NCT03130933|third molar
804460|NCT03130933|oral surgical procedures
804461|NCT03130933|antibiotic prophylaxis
804462|NCT03130933|placebo effect
804463|NCT03130920|preconditioning, resection
804464|NCT03130894|trimethylamine-N-oxide
804465|NCT03130894|type2 Diabetes
804466|NCT03130894|enzyme flavin monooxygenase 3 polymorphisms
804467|NCT03130855|pediatric patients
804468|NCT03130855|articaine local anesthesia
804469|NCT03130829|NSCLC
804470|NCT03130829|QoL
804471|NCT03130829|Fucoidan
804472|NCT03130816|Umbilical cord blood transplantation
804473|NCT03130816|Cytokine changes
804474|NCT03130764|Non-small Cell Lung Cancer
804475|NCT03130712|immunotherapy
804476|NCT03130712|GPC3-CART
804477|NCT03130712|HCC
804478|NCT03130699|Diabetes
804479|NCT03130699|mHealth
804480|NCT03130699|Medical Assistant
804481|NCT03130699|Automated
804482|NCT03130699|Adaptive Feedback
804483|NCT03130699|Self-Management Support
804484|NCT03130699|Hispanics
804485|NCT03130699|HbA1c
804486|NCT03130699|Cyberinfrastructure
804487|NCT03130699|Federally-Qualified Health Centers
804488|NCT03130699|Cost-Effectiveness
804489|NCT03130699|T2DM
804490|NCT03130699|Pay-for-Performance
804491|NCT03130699|Medication Adherence
804492|NCT03130699|LDL-C
804493|NCT03130699|Systolic Blood Pressure
804494|NCT03130699|Text Messaging
804495|NCT03130673|hip fracture
804496|NCT03130673|trochanteric fracure
804497|NCT03130673|subtrocantheric fracture
804498|NCT03130673|femoral head fracture
804499|NCT03130673|epidemiology
804500|NCT03130660|central line
804501|NCT03130660|Central Line Complication
804502|NCT03130634|CPT-11(irinotecan)
804503|NCT03130634|silymarin
804504|NCT03130634|GI toxicity
804505|NCT03130608|liver disease
804506|NCT03130608|transplant
804507|NCT03130608|muscle wasting
804508|NCT03130608|breathing exercise
804509|NCT03130595|accelerometry
804510|NCT03130595|Parkinson Kinetigraph
804511|NCT03130582|high-dose etoposide,autologous peripheral blood stem cell transplantation
804512|NCT03130569|Risk Assessment
804513|NCT03130569|Personal Genomic Testing
804514|NCT03130569|Skin Cancer
804515|NCT03130569|Primary Care
804516|NCT03130556|Glasdegib
804517|NCT03130556|PF-04449913
804518|NCT03130556|Pharmacokinetics
804519|NCT03130556|Bioavailability
804520|NCT03130543|Brief resolved unexplained event
804521|NCT03130530|robotic
804522|NCT03130530|colorectal
804523|NCT03130530|surgery
804525|NCT03130478|long-acting injectable antipsychotic
804526|NCT03130478|persistence
804527|NCT03130465|adherence
804528|NCT03130465|long-acting injectable antipsychotic
804529|NCT03130465|all-cause treatment discontinuation
804530|NCT03130465|recent-onset schizophrenia
804531|NCT03130465|daily oral atypical antipsychotic
804532|NCT03130439|Breast Cancer
804533|NCT03130426|Diabetes
804534|NCT03130426|iGlarLixi
804535|NCT03130426|Metformin
804536|NCT03130426|Insulin
804537|NCT03130426|Diet
804538|NCT03130426|Exercise
804539|NCT03130426|Lifestyle
804540|NCT03130413|Ambu Aura Gain
804541|NCT03130413|Air-Q intubating laryngeal airway
804542|NCT03130413|Paediatric surgery
804543|NCT03130400|Knee
804544|NCT03130400|Gait
804545|NCT03130400|Injuries
804546|NCT03130400|Arthritis
804547|NCT03130387|Hytsteroscopy
804548|NCT03130374|mesenchymal stem cells
804549|NCT03130374|Tracheal Stenosis
804550|NCT03130374|Laryngeal Stenosis
804551|NCT03130374|cell therapy
804552|NCT03130309|Knee
804553|NCT03130309|Replacement
804554|NCT03130309|Mobile-bearing
804555|NCT03130309|unicompartmental prosthesis
804556|NCT03130296|HIV infection
804557|NCT03130296|Fc receptor polymorphism (FcR)
804558|NCT03130283|Acute patients
804559|NCT03130283|Exacerbated chronic patients
804560|NCT03130270|nasopharyngeal carcinoma
804561|NCT03130270|disease-free survival
804562|NCT03130270|adverse reaction
804564|NCT03130231|Delirium β2-microspheres
804566|NCT03130166|Postoperative pain
804567|NCT03130166|Postoperative recovery
804568|NCT03130166|Intracorporeal anastomosis
804569|NCT03130166|Robotic right colectomy
804570|NCT03130114|Mortality
804571|NCT03130114|Infant
804572|NCT03130114|Antibiotics
804573|NCT03130114|Linear Growth
804574|NCT03130101|Type 1 Diabetes
804575|NCT03130101|Exercise
804576|NCT03130101|Basal insulin
804577|NCT03130101|CSII
804578|NCT03130101|OmniPod
804579|NCT03130101|CGM
804580|NCT03130088|Out-Of-Hospital Cardiac Arrest
804581|NCT03130088|Resuscitation Registry
804582|NCT03130088|EuReCa TWO
804583|NCT03130062|Resistance Exercise
804584|NCT03130062|Functional Fitness
804585|NCT03130062|Actigraphy
804586|NCT03130062|Primary Sjögren Syndrome
804587|NCT03130049|Peripheral nerve block
804588|NCT03130049|Ultrasound
804589|NCT03130036|Memory
804590|NCT03130036|Cognitive
804591|NCT03129984|mandibular movements
804592|NCT03129958|NECK PAIN, OFFICE WORKERS
804593|NCT03129945|Obstetric Labor, Premature
804594|NCT03129945|Tocolytic Agents
804595|NCT03129932|gluten
804596|NCT03129932|adipokine
804597|NCT03129932|obesity
804598|NCT03129932|diet
804599|NCT03129906|Fibromyalgia; non-celiac gluten sensitivity
804600|NCT03129880|Voice disorder
804601|NCT03129880|Hoarseness
804602|NCT03129880|Phonation Disorders
804603|NCT03129880|Speech Disorders
804604|NCT03129854|prostate cancer
804605|NCT03129854|metastatic
804606|NCT03129854|cryotherapy
804607|NCT03129854|ADT
804608|NCT03129841|weight loss
804609|NCT03129841|dietary pattern
804610|NCT03129841|late dinner
804611|NCT03129841|early dinner
804612|NCT03129828|Diffuse Large B Cell Lymphoma
804613|NCT03129828|Ibrutinib
804614|NCT03129828|Bortezomib
804615|NCT03129815|extubation
804616|NCT03129815|pediatric resuscitation
804617|NCT03129815|reintubation
804618|NCT03129815|failures of extubation.
804619|NCT03129802|extubation
804620|NCT03129802|pediatric resuscitation
804621|NCT03129802|reintubation
804622|NCT03129802|failures of extubation.
804623|NCT03129802|Respiratory Insufficiency
804624|NCT03129763|SPY-ICG Angiography
804625|NCT03129763|Tissue Expander
804626|NCT03129763|Capsule Pressure
804627|NCT03129763|Blood Supply
804628|NCT03129724|Kidney Neoplasms
804629|NCT03129724|Kidney
804630|NCT03129724|Neoplasms
804631|NCT03129724|TKI
804632|NCT03129724|Axitinib
804633|NCT03129724|VEGF
804634|NCT03129724|mTORi
804635|NCT03129685|Hepatocellular carcinoma
804636|NCT03129685|Devascularization
804637|NCT03129672|allograft
804638|NCT03129672|distal tibia sarcoma
804639|NCT03129659|Coronary CT Angiography
804640|NCT03129659|High-sensitivity Troponin
804641|NCT03129659|Diagnosis
804642|NCT03129620|Ampicillin
804643|NCT03129607|POPF
804644|NCT03129607|Classification system
804645|NCT03129581|obesity, diet, sleep activity
804646|NCT03129555|Non-vitamin K antagonist oral anticoagulation
804647|NCT03129555|Non-vitamin K Antagonist Oral Anticoagulants
804648|NCT03129555|Direct-acting Oral Anticoagulants
804649|NCT03129555|Novel oral anticoagulant drugs
804650|NCT03129516|imaginary
804651|NCT03129516|Turkish version
804652|NCT03129516|motor imagery
804653|NCT03129516|reliability
804654|NCT03129503|Optical coherence tomography (OCT)
804655|NCT03129490|Atrial Fibrillation
804656|NCT03129490|Non-vitamin K antagonist oral anticoagulation
804657|NCT03129490|Direct-acting oral anticoagulants
804658|NCT03129490|Novel oral anticoagulant drugs
804659|NCT03129490|Non-vitamin K antagonist oral anticoagulants
804660|NCT03129477|Non invasive ventilation in COPD
804661|NCT03129477|Noninvasive ventilation
804662|NCT03129477|Tele-monitoring
804663|NCT03129438|continuous EEG
804664|NCT03129438|routine EEG
804665|NCT03129438|prognosis
804666|NCT03129425|Patient
804667|NCT03129425|Caregiver
804668|NCT03129425|Coping
804669|NCT03129425|Psychosocial adaptation
804670|NCT03129399|anesthesia
804671|NCT03129399|King Vision
804672|NCT03129399|videolaryngoscope
804673|NCT03129399|nasotracheal
804674|NCT03129360|Early Psychosis
804675|NCT03129360|Levetiracetam
804676|NCT03129308|HIV
804677|NCT03129308|Cutaneous Autoantibodies
804678|NCT03129308|Indirect Immunofluorescence
804679|NCT03129269|Cognitive decline
804680|NCT03129269|frailty
804681|NCT03129269|mild cognitive impairment
804682|NCT03129269|Positron Emission Tomography, PET
804683|NCT03129269|Alzheimer disease
804684|NCT03129269|amyloid load
804685|NCT03129269|Magnetic resonance imaging, MRI
804686|NCT03129256|non-small cell lung cancer
804687|NCT03129256|Apatinib
804688|NCT03129256|S1
804689|NCT03129217|Diaphragm function
804690|NCT03129217|Acute respiratory failure
804691|NCT03129217|Weaning
804692|NCT03129204|intensive care unit
804693|NCT03129204|critical care
804694|NCT03129204|family
804695|NCT03129204|caregiver
804696|NCT03129204|actigraphy
804700|NCT03129165|Cardiovascular diseases
804701|NCT03129165|Public Health
804702|NCT03129165|Hypertension
804703|NCT03129165|Smoking
804704|NCT03129165|Hypercholesterolemia
804705|NCT03129165|Food Habits
804706|NCT03129165|Exercise
804707|NCT03129165|Anxiety
804708|NCT03129165|Depression
804709|NCT03129165|Obesity
804710|NCT03129165|Diabetes
804711|NCT03129139|Metastatic
804712|NCT03128996|Bone marrow transplant
804713|NCT03128996|Transplant
804714|NCT03128996|Transplantation
804715|NCT03128996|Reduced Intensity
804716|NCT03128996|Familial HLA mismatched
804717|NCT03128905|Colchicine
804718|NCT03128905|Corticoids
804719|NCT03128905|Prednisone
804720|NCT03128905|CPPD
804721|NCT03128905|Calcium Pyrophosphate Deposition Disease
804722|NCT03126682|Wellbutrin
804723|NCT03126682|Electroconvulsive therapy
804724|NCT03126682|Right Unilateral Ultra Brief
804725|NCT03126669|Hyperbaric oxygen
804726|NCT03126669|multitasking performance
804727|NCT03126669|cognitive funcitons
804728|NCT03126656|testosterone
804729|NCT03126656|chronic heart failure
804730|NCT03128879|Primary lymphoid haematopoietic neoplasms
804731|NCT03128879|Chronic lymphocytic leukemia
804732|NCT03128879|CLL
804733|NCT03128879|Small lymphocytic lymphoma
804734|NCT03128879|SLL
804735|NCT03128879|High risk
804736|NCT03128879|Venetoclax
804737|NCT03128879|ABT-199
804738|NCT03128879|GDC-0199
804739|NCT03128879|Ibrutinib
804740|NCT03128879|PCI-32765
804741|NCT03128879|Imbruvica
804742|NCT03128879|Allopurinol
804743|NCT03128879|Lopurin
804744|NCT03128879|Zurinol
804745|NCT03128879|Zyloprim
804746|NCT03128866|Malignant neoplasms of bone and articular cartilage
804747|NCT03128866|Pelvic Tumor
804748|NCT03128866|Tranexamic acid
804749|NCT03128814|Tennis
804750|NCT03128814|Asymmetry
804751|NCT03128814|Structural
804752|NCT03128814|Functional
804753|NCT03128801|Low Back Pain
804754|NCT03128801|Back Pain
804755|NCT03128801|Muscle Stretching Exercises
804756|NCT03128801|Stabilization Exercise
804757|NCT03128801|Exercise Therapy
804758|NCT03128801|Exercise Movement
804759|NCT03128801|Exercise Movement Tecniques
804760|NCT03128801|Pain
804761|NCT03128801|Disability
804762|NCT03128788|epidurography epidural pressure patient posture
804763|NCT03128749|Obsessive-Compulsive Disorder
804764|NCT03128749|Mindfulness Based Intervention
804765|NCT03128749|Cognitive-Behavioral Therapy
804766|NCT03128749|Functional Magnetic Resonance Imaging
804767|NCT03128749|Neuropsychology
804768|NCT03128749|Childhood Maltreatment
804770|NCT03128710|Survey
804771|NCT03128710|Focus Group
804772|NCT03128710|Treatment Preferences
804773|NCT03128697|Obesity
804774|NCT03128697|Satiety quotient
804775|NCT03128697|Appetite control
804776|NCT03128697|Weight loss
804777|NCT03128697|Satiety phenotype
804778|NCT03128697|Functional food
804779|NCT03128684|lentils
804780|NCT03128684|satiety
804781|NCT03128684|appetite
804782|NCT03128684|food intake
804783|NCT03128684|24-hour energy intake
804784|NCT03128671|intensive care unit
804785|NCT03128671|critical care
804786|NCT03128671|mechanical ventilation
804787|NCT03128671|confusion
804788|NCT03128671|polysomnography
804789|NCT03128671|delirium
804790|NCT03128671|adult
804791|NCT03128658|Trauma induced coagulopathy
804792|NCT03126552|hookworm
804793|NCT03126552|controlled human infection model
804794|NCT03126539|aging
804795|NCT03126539|ultraviolet exposure
804796|NCT03126539|skin fragility
804797|NCT03126539|sulforaphane
804798|NCT03126513|G-POEM
804799|NCT03126513|Safety
804800|NCT03126513|Efficacy
804801|NCT03126500|Malnutrition
804802|NCT03126500|Disease-related malnutrition
804803|NCT03126500|Frailty
804804|NCT03126500|Sarcopenia
804805|NCT03126500|Hospital discharge
804806|NCT03126500|Geriatrics
804807|NCT03126461|metastatic melanoma
804808|NCT03128554|Not Ready to Quit
804809|NCT03128554|Primary Care
804810|NCT03128554|Tobacco
804811|NCT03128554|Reduce to Quit
804812|NCT03128554|Smoking Reduction
804813|NCT03128528|SGLT-2 inhibitor, Chronic heart failure, tissue sodium,
804814|NCT03128515|Hydroxyurea
804815|NCT03128502|saliva
804816|NCT03128502|GCF
804817|NCT03128502|pentraxin-3
804818|NCT03128489|Safety
804819|NCT03128489|Infanrix™-IPV/Hib
804820|NCT03128489|Immunogenicity
804821|NCT03128489|Indian infants
804822|NCT03128489|Combined vaccine
804823|NCT03128463|Age-Related Macular Degeneration
804824|NCT03128463|Polypoidal Choroidal Vasculopathy
804825|NCT03128463|Pathological Myopia
804826|NCT03128463|Conbercept
804827|NCT03128450|Parkinson Disease
804828|NCT03128450|Neural stem cell
804829|NCT03128450|Nasal delivery
804830|NCT03128437|Anxiety
804831|NCT03128437|Young Adults
804832|NCT03128437|Health Behaviors
804833|NCT03128411|Leukemia, Chronic Myelogenous
804834|NCT03128398|Gastroparesis
804835|NCT03128385|Upper limb neurorehabilitation
804836|NCT03128385|Neurological rehabilitation
804837|NCT03128385|Upper extremity
804838|NCT03128281|Malignant Neoplasms of Female Genital Organs
804839|NCT03128281|Laparoscopic gynecologic surgery
804840|NCT03128281|Robotic gynecologic surgery
804841|NCT03128281|AirSeal® Insufflation System
804842|NCT03128281|AIS
804843|NCT03128281|Conventional Insufflation System
804844|NCT03128281|CIS
804845|NCT03128281|Questionnaires
804846|NCT03128281|Surveys
804847|NCT03128255|Fusion
804848|NCT03128255|Hybrid Imaging
804849|NCT03128255|Mapping
804850|NCT03128255|Iodine
804851|NCT03128255|Ultrasound
804852|NCT03128242|oxytocin
804853|NCT03128242|attention bias
804854|NCT03128242|attention training
804855|NCT03128242|eye-tracking
804856|NCT03128203|Oxytocin
804857|NCT03128203|Resting-state
804858|NCT03128203|Functional connectivity
804859|NCT03128203|BOLD
804860|NCT03128190|high-risk surgery
804861|NCT03128190|pulse-pressure variation
804862|NCT03128190|monitoring
804863|NCT03128190|Postoperative Complications
804864|NCT03128177|nocturnal hypertension
804865|NCT03128177|non-dipping blood pressure
804866|NCT03128177|obstructive sleep apnea
804867|NCT03128151|NMB (Neuromuscular Blockade)
804868|NCT03128151|Anesthesia
804869|NCT03128151|Curarization
804870|NCT03128151|TOFr (train of four)
804871|NCT03128151|PACU (postanesthesia care unit)
804872|NCT03128151|Monitorization
804873|NCT03128112|Parental perception, obesity, overweight
804874|NCT03128099|Social Skills
804875|NCT03128099|Social attention
804876|NCT03128099|Virtual reality
804877|NCT03128099|Eye tracking
804878|NCT03128073|Heart failure, Cardio-Renal Syndrome
804879|NCT03128047|pediatric cancer
804880|NCT03128047|brain tumor
804881|NCT03128047|glioblastoma
804882|NCT03128047|high grade brain tumor
804883|NCT03128047|malignant brain tumor
804884|NCT03128021|Depression
804885|NCT03128021|fMRI
804886|NCT03128021|Escitalopram
804887|NCT03128021|Lexapro
804888|NCT03128021|Placebo
804889|NCT03128021|Randomized Clinical Trial
804890|NCT03127995|Breast Cancer pT1-3, pN0-N3, M0
804891|NCT03127995|Lymph Node Irradiation
804892|NCT03127982|Anxiety Depression Emotion PTSD Randomized Clinical Trial
804893|NCT03127969|Rheumatoid hand
804894|NCT03127969|Fluidotherapy
804895|NCT03127969|Rehabilitation
804896|NCT03127943|lidocaine, mandible
804897|NCT03127930|Cognitive Impairment
804898|NCT03127930|Memory loss
804899|NCT03127930|Caregivers
804900|NCT03127930|Medication adherence
804901|NCT03127930|Medication compliance
804902|NCT03127930|Medication management
804903|NCT03127930|Problem solving
804904|NCT03127930|Quality of Life
804905|NCT03127930|Health resource utilization
804906|NCT03127930|Community dwelling
804907|NCT03127917|Gait Speed
804908|NCT03127917|Cognitive Function
804909|NCT03127904|Varicose ulcer
804910|NCT03127904|Compressive therapy
804911|NCT03127904|Venous ulcer
804912|NCT03127904|Chronic venous disease
804913|NCT03127891|pranayama yoga
804914|NCT03127878|Exercise
804915|NCT03127878|Pulmonary Disease, Chronic Obstructive
804916|NCT03127878|Activities of Daily Living
804917|NCT03127878|Upper Extremity
804918|NCT03127878|Motor Activity
804919|NCT03127839|Exercise
804920|NCT03127839|Pain Neuroscience Education
804921|NCT03127839|Physical Therapy
804922|NCT03127839|Subacromial Pain
804923|NCT03127839|Rotator Cuff
804924|NCT03127826|Low Back Pain
804925|NCT03127826|Risk-Stratified Care
804926|NCT03127813|glaucoma
804927|NCT03127813|OSA
804928|NCT03127813|apnoea
804929|NCT03127813|intraocular
804930|NCT03127813|CPAP
804931|NCT03127813|airway
804932|NCT03127813|pressure
804933|NCT03127813|blindness
804934|NCT03127800|Obstructive Sleep Apnoea
804935|NCT03127800|Morphine sulphate
804936|NCT03127800|Sleep Disordered Breathing
804937|NCT03127800|Central Sleep Apnoea
804938|NCT03127800|Hypoxaemia
804939|NCT03127800|Hypercapnia
804940|NCT03127800|Cheyne-Stokes Respiration
804941|NCT03127800|Analgesia
804942|NCT03127800|Respiration
804943|NCT03127800|Apnoea-Hypopnea Index
804944|NCT03127800|Oxygen Desaturation Index
804945|NCT03127800|Oximetry
804946|NCT03127800|Respiratory Polygraphy
804947|NCT03127800|Polysomnography
804948|NCT03127761|Multiple Myeloma
804949|NCT03127748|ventricular septal defect,transcatheter closure
804954|NCT03127709|17-199
804955|NCT03127709|histiocytosis
804956|NCT03127696|Fecal Microbiota Transplant
804957|NCT03127631|Androgen Deprivation Therapy
804958|NCT03126448|Infection
804959|NCT03126448|Nonunion
804960|NCT03126448|Fracture healing
804961|NCT03126435|FOLFIRINOX
804962|NCT03126435|5-Fluorouracil
804963|NCT03126435|folinic acid
804964|NCT03126435|irinotecan
804965|NCT03126435|oxaliplatin
804966|NCT03126435|Gemcitabine
804967|NCT03127553|salt intake
804968|NCT03127553|functional food
804969|NCT03127553|low-salt bread
804970|NCT03127553|blood pressure
804977|NCT03126409|coronary artery disease
804978|NCT03126409|coronary artery bypass graft
804979|NCT03126344|King Vision
804980|NCT03127475|Parkinson's disease
804981|NCT03127475|freezing of gait
804982|NCT03127475|electrophysiology
804983|NCT03127475|magnetic resonance image
804984|NCT03127475|direct current stimulation
804985|NCT03127423|Hybrid ablation
804986|NCT03127423|Thoracoscope
804987|NCT03127397|antiretroviral therapy
804988|NCT03127397|HIV/AIDS
804989|NCT03127397|ART adherence
804990|NCT03127371|Nitrous Oxide
804991|NCT03127371|Abscess
804992|NCT03127371|Incision and drainage
804993|NCT03127358|Addiction
804994|NCT03127358|Sustained Viral Response
804995|NCT03127358|Adherence
804996|NCT03127358|Adverse Effects
804997|NCT03127358|Direct Acting Antiviral Agent
804998|NCT03127358|Chronic Hepatitis C
804999|NCT03127358|Resistance Development
805000|NCT03127358|Methadone Clinic
805001|NCT03127358|Primary Care
805002|NCT03127358|Directly Observed Therapy
805003|NCT03127358|Randomized Controlled Trial
805004|NCT03127358|Resistance
805005|NCT03127358|Reinfection
805006|NCT03127358|Treatment Outcome
805007|NCT03127358|Patient Navigation
805008|NCT03127358|Multi-Site
805009|NCT03127358|Liver Disease
805010|NCT03127358|Intervention
805011|NCT03127332|Treatment care planning
805012|NCT03127306|Pain
805013|NCT03127306|Behavioural Pain Scale
805014|NCT03127306|BPS
805015|NCT03127306|NRS
805016|NCT03127306|Delirium
805017|NCT03127306|CAM-ICU
805018|NCT03127280|urinary tract infections
805019|NCT03127280|postoperative voiding dysfunction
805020|NCT03127280|foley removal
805021|NCT03127280|patient satisfaction
805022|NCT03127254|Video Narrative
805023|NCT03127241|Assistive devices
805024|NCT03127241|Randomized controlled trial (RCT)
805025|NCT03127241|Upper limbs
805026|NCT03127241|Robotic devices
805028|NCT03127202|Cardiac Resynchronization Therapy
805029|NCT03127150|Chylous leakage
805030|NCT03127150|Diagnostic criteria
805031|NCT03127150|Pancreas surgery
805032|NCT03127150|Therapy
805033|NCT03127098|locally advanced or metastatic
805034|NCT03127098|carcinoembryonic antigen (CEA)-expressing
805035|NCT03127098|CEA
805036|NCT03127098|carcinoembryonic antigen
805037|NCT03127072|colorectal cancer
805038|NCT03127072|liver metastasis
805039|NCT03127072|Radiofrequency Ablation
805040|NCT03127072|chemotherapy
805041|NCT03127072|target therapy
805046|NCT03127007|immunotherapy
805047|NCT03127007|anti-PD-L1
805048|NCT03126955|microvascular decompression, Xth nerve
805049|NCT03126942|Aged patients
805050|NCT03126942|Cost Estimates
805051|NCT03126942|Complete Denture
805052|NCT03126942|Dental Economics
805053|NCT03126942|Dental Implants
805054|NCT03126942|Dental Prosthesis, Implant-Supported
805055|NCT03126942|Denture Retention
805056|NCT03126942|Minimally Invasive Surgical Procedures
805057|NCT03126942|Oral Health-Related Quality of Life
805058|NCT03126942|Overdenture
805059|NCT03126942|Patient Acceptance of Health Care
805060|NCT03126942|Quality of Healthcare
805061|NCT03126942|Quality of Life
805062|NCT03126942|Patient Satisfaction
805063|NCT03126942|Single implant overdenture
805064|NCT03126929|disorders of consciousness
805065|NCT03126929|Vegetative state
805066|NCT03126929|Minimally conscious state
805067|NCT03126929|Emergence from MCS
805068|NCT03126929|Coma Recovery Scale-Revised
805069|NCT03126890|Pharmacokinetics,adverse events
805070|NCT03126890|Linezolid
805071|NCT03126890|Therapeutic drug monitoring
805072|NCT03126890|Myelosuppression
805073|NCT03126890|Lactic acidosis
805074|NCT03126890|Peripheral neuropathy
805075|NCT03126864|Hematopoietic/Lymphoid Cancer
805076|NCT03126864|Acute Myeloid Leukemia
805077|NCT03126864|AML
805198|NCT03125889|robotics
805078|NCT03126864|Relapsed or Refractory CD33-Positive
805079|NCT03126864|CD33-CAR-T cells
805080|NCT03126864|Fludarabine
805081|NCT03126864|Fludarabine phosphate
805082|NCT03126864|Fludara
805083|NCT03126864|Cyclophosphamide
805084|NCT03126864|Cytoxan
805085|NCT03126864|Neosar
805086|NCT03126838|diaphragm
805087|NCT03126838|ultrasound
805088|NCT03126838|dysfunction
805089|NCT03126838|cardiac surgery
805090|NCT03126838|weaning
805091|NCT03126812|Primary stage 4
805092|NCT03126812|Neo adjuvant
805107|NCT03126734|Down Syndrome
805108|NCT03126734|Acceptance
805109|NCT03126734|Commitment
805110|NCT03126734|Concience of influence
805111|NCT03126721|drug interaction
805112|NCT03126721|PF-06751979
805113|NCT03126721|oral midazolam
805119|NCT03126331|Kidney Cancer
805120|NCT03126331|Metastatic
805121|NCT03126331|Nivolumab
805122|NCT03126305|exposure
805123|NCT03126305|response prevention
805124|NCT03126305|web-based application
805125|NCT03126292|Medical home
805126|NCT03126292|Primary care
805127|NCT03126292|Children
805128|NCT03126292|Development
805129|NCT03126279|Osteoarthritis
805130|NCT03126279|Pain
805131|NCT03126279|Postoperative Pain
805132|NCT03126253|childhood anemia, socioeconomic status
805133|NCT03126227|AR101
805134|NCT03126227|Characterized Peanut Allergen
805135|NCT03126227|CPNA (Characterized Peanut Allergen)
805136|NCT03126227|OIT (oral immunotherapy)
805137|NCT03126227|Peanut Allergy
805138|NCT03126227|Peanut-Allergic Children
805139|NCT03126227|Desensitization
805140|NCT03126227|ARC007
805141|NCT03126227|Characterized Oral Desensitization Immunotherapy (CODIT™)
805142|NCT03126214|atrial fibrillation
805143|NCT03126214|stroke
805144|NCT03126214|oral anticoagulation therapy
805145|NCT03126214|pharmacist case management
805146|NCT03126201|focal segmental glomerulosclerosis
805147|NCT03126201|disease progression
805148|NCT03126162|minimally invasive gynecologic surgery
805149|NCT03126162|same-day discharge
805150|NCT03126162|bladder testing
805154|NCT03126123|Anal condylomatosis
805155|NCT03126123|surgery
805156|NCT03126123|acetic acid
805157|NCT03126123|dysplastic areas
805158|NCT03126110|cervical cancer
805159|NCT03126110|endometrial cancer
805160|NCT03126110|gastric cancer (stomach, esophageal, and gastroesophageal junction [GEJ])
805161|NCT03126110|hepatocellular carcinoma (HCC)
805162|NCT03126110|melanoma
805163|NCT03126110|Merkel cell carcinoma
805164|NCT03126110|mesothelioma
805165|NCT03126110|microsatellite instability-high (MSI-H) colorectal cancer (CRC)
805166|NCT03126110|non-small cell lung cancer (NSCLC)
805167|NCT03126110|ovarian cancer
805168|NCT03126110|squamous cell carcinoma of the head and neck (SCCHN)
805169|NCT03126110|small cell lung cancer (SCLC)
805170|NCT03126110|renal cell carcinoma (RCC)
805171|NCT03126110|triple-negative breast cancer (TNBC)
805172|NCT03126110|urothelial carcinoma
805173|NCT03126110|glucocorticoid-induced tumor necrosis factor receptor (GITR)
805174|NCT03126058|enhanced recovery after surgery
805175|NCT03126058|colorectal cancer
805176|NCT03126045|Lumbar puncture
805177|NCT03126045|Post lumbar puncture headache
805178|NCT03126045|Atraumatic needle
805179|NCT03126045|Haematology
805180|NCT03126032|Sepsis
805181|NCT03126032|SIRS
805182|NCT03126032|Glycocalyx
805183|NCT03126032|Glycocheck™-System
805184|NCT03126032|Infection
805185|NCT03126019|Follicular lymphoma
805186|NCT03126019|non-Hodgkin lymphoma (NHL)
805187|NCT03126019|phosphatidylinositol 3-kinase (PI3K) δ inhibitor
805188|NCT03125993|obesity; brisk walking
805189|NCT03125928|Atezolizumab
805190|NCT03125928|PD-L1
805191|NCT03125915|couples HIV testing; drug intervention; communication skills
805192|NCT03125889|image-guided
805193|NCT03125889|BPH
805194|NCT03125889|Aquablation
805195|NCT03125889|AQUABEAM
805196|NCT03125889|lower urinary tract symptoms
805197|NCT03125889|prostate tissue resection
805199|NCT03125863|minimally invasive
805200|NCT03125863|image-guided
805201|NCT03125863|bph
805202|NCT03125863|aquablation
805203|NCT03125863|AquaBeam
805204|NCT03125863|lower urinary tract symptoms
805205|NCT03125863|tissue resection
805206|NCT03125863|robotics
805207|NCT03125850|day-ward
805208|NCT03125850|inpatient
805209|NCT03125811|Isopropyl alcohol
805210|NCT03125811|Zofran
805211|NCT03125811|antiemetics
805212|NCT03125798|video-assisted thoracic surgery
805213|NCT03125798|LigaSure
805214|NCT03125798|mediastinal lymph node dissection
805215|NCT03125785|congenital cataract, contact lens
805216|NCT03125772|coronary artery disease
805217|NCT03125772|diabetes mellitus
805218|NCT03125772|everolimus
805219|NCT03125772|paclitaxel stents
805220|NCT03125759|Ischemic Stroke
805221|NCT03125759|Omentin
805226|NCT03125720|cardiac resynchronization therapy
805227|NCT03125720|chronic heart failure
805228|NCT03125720|image fusion-guided implantation
805229|NCT03125720|SPECT
805230|NCT03125720|venogram
805231|NCT03125681|remote ischemic conditioning
805232|NCT03125681|off-pump coronary artery bypass surgery
805234|NCT03125642|Lymphoblastic Lymphoma
805235|NCT03125642|Mature B-cell Lymphomas
805236|NCT03125642|Follicular Lymphoma
805237|NCT03125642|Diffuse Large B-Cell Lymphoma
805238|NCT03125642|Mantle Cell Lymphoma
805239|NCT03125642|Burkitt's/Burkitt's like
805240|NCT03125642|Mature T-Cell Lymphoma
805241|NCT03125616|Prematurity
805242|NCT03125616|Vaccination
805243|NCT03125603|Immunotherapy
805244|NCT03125603|Anti-PD-(L)-1
805245|NCT03125603|Anti-CTLA-4
805246|NCT03125590|Osteoporosis, osteopenia, test-retest, validity, PEQ, questionnaire, facilitators, barriers, exercise, physical activity
805247|NCT03125577|4S CAR-T
805248|NCT03125577|CD19
805249|NCT03125577|CD20
805250|NCT03125577|CD22
805251|NCT03125577|CD38
805252|NCT03125577|CD123
805253|NCT03125577|B cell leukemia
805254|NCT03125577|B-ALL
805255|NCT03125551|Dietary supplements
805256|NCT03125551|Bleeding tendency
805257|NCT03125538|Motor Imagery
805258|NCT03125538|Amputation
805259|NCT03125538|Functional rehabilitation
805260|NCT03125538|Locomotion
805261|NCT03125538|Phantom-limb pain
805262|NCT03125525|migraine
805263|NCT03125525|transcutaneous
805264|NCT03125525|supraorbital
805265|NCT03125525|nerve
805266|NCT03125525|stimulation
805267|NCT03125512|Sleep Apnea Syndromes
805268|NCT03125512|Positional sleep apnea
805269|NCT03125512|CPAP
805270|NCT03125512|Night Shift
805271|NCT03125486|SC Belimumab
805272|NCT03125486|Individual Patient Compassionate Use
805273|NCT03125486|SLE
805274|NCT03125486|GSK1550188
805275|NCT03125447|Prematurely born children
805276|NCT03125447|Attention function
805277|NCT03125447|Posture
805278|NCT03125447|Mobility
805279|NCT03125356|diet soda
805280|NCT03125356|low-calorie sweeteners
805281|NCT03125356|obesity
805282|NCT03125343|radiotherapy
805283|NCT03125343|chemotherapy
805284|NCT03125343|complete response
805285|NCT03125330|Coaching
805286|NCT03125330|Professional coaching
805287|NCT03125330|Emergency physicians
805288|NCT03125330|Emergency medicine
805289|NCT03125330|Goal attainment
805290|NCT03125330|Leadership strengths
805291|NCT03125330|Well-being
805292|NCT03125330|Burnout
805293|NCT03125330|Adult level of development
805294|NCT03125330|Group coaching
805295|NCT03125330|Instructor
805296|NCT03125330|Assistant professor
805297|NCT03125330|Academic faculty
805298|NCT03125330|Subject-Object Interview
805299|NCT03125304|Endometriosis
805300|NCT03125304|acupuncture
805301|NCT03125304|pain
805302|NCT03125304|dysmenorrhea
805303|NCT03125291|Substance Use and Abuse
805304|NCT03125291|Risky Sexual Behavior
805305|NCT03125291|Behavior Problems
805306|NCT03125291|Academic Achievement
805307|NCT03125265|nutrition
805308|NCT03125265|hemodialysis
805309|NCT03125265|mortality
805310|NCT03125265|omega 3
805311|NCT03125252|Delirium
805312|NCT03125252|Reanimation
805313|NCT03125252|Conversational hypnosis
805314|NCT03125239|Refractory Adult Acute Myeloid Leukemia
805315|NCT03125239|Relapsed Adult Acute Myeloid Leukemia
805316|NCT03125187|Sodium Heparin
805317|NCT03125187|Intravenous administration
805318|NCT03125187|Pharmacokinetics
805319|NCT03125187|Coagulation factor
805320|NCT03125174|sputum
805321|NCT03125174|bronchiectasis
805322|NCT03125174|lung disease
805323|NCT03125161|colorectal cancer
805324|NCT03125161|liver metastasis
805325|NCT03125161|hepatic arterial infusion
805326|NCT03125161|chemotherapy
805327|NCT03125161|target therapy
805328|NCT03125161|conversional resection rates
805329|NCT03124004|direct oral anticoagulant
805330|NCT03124004|oral anticoagulant therapy
805331|NCT03124004|periodontal disease
805332|NCT03124004|periodontal debridement
805333|NCT03124004|ultrasonic periodontal debridement
805334|NCT03124004|ultrasonic scaling
805335|NCT03124004|periodontal scaling
805336|NCT03124004|subgingival scaling
805337|NCT03123978|castration resistant prostate cancer
805338|NCT03125083|Skin restricted lupus
805339|NCT03125083|Psychiatric disorders
805340|NCT03125083|Inflammation
805341|NCT03125083|Kynurenine pathway
805342|NCT03122535|Femtosecond LASIK (FS--LASIK)
805343|NCT03122535|Visual acuity
805344|NCT03122535|Refractive errors
805345|NCT03122535|Side-cut angles
805351|NCT03122509|Durvalumab
805352|NCT03122509|Tremelimumab
805353|NCT03122509|Radiation Therapy
805354|NCT03122509|Ablation
805355|NCT03122509|17-139
805356|NCT03124667|adherence
805357|NCT03124667|cognition
805358|NCT03124667|exercise
805359|NCT03124667|aging
805360|NCT03124667|brain training
805361|NCT03124667|cognitive training
805362|NCT03124667|executive function
805363|NCT03124641|Hypothermic oxygenated machine perfusion
805364|NCT03124641|Orthotopic liver transplantation
805365|NCT03124641|Extended criteria donation
805366|NCT03124641|Donation after brain death
805367|NCT03124641|HOPE
805368|NCT03124563|Exercise
805369|NCT03124563|Health Behavior
805370|NCT03124563|Aging
805371|NCT03124550|Caregivers
805372|NCT03124550|Exercise
805373|NCT03124550|Behavior Change
805374|NCT03124537|Physical Exercise
805375|NCT03124537|Behavior Change
805376|NCT03124524|estradiol valerate/dienogest
805377|NCT03124524|ethinylestradiol/ drospirenone
805378|NCT03124524|pelvic pain
805379|NCT03124524|primary dysmenorrhea
805380|NCT03124524|uterine artery doppler indices
805381|NCT03124498|Hepatocellular Carcinoma, Autologous Cytokine-Induced Killer
805382|NCT03124459|CMT1 / CMTX
805383|NCT03124446|mindfulness
805384|NCT03124433|prostate cancer
805385|NCT03124433|prostatectomy, retropubic
805386|NCT03124433|Androgen Receptor Antagonists
805387|NCT03124420|Helicobacter Infection
805388|NCT03124420|Eradication therapy
805389|NCT03124420|Antibiotics
805390|NCT03122496|Durvalumab (Medi4736)
805391|NCT03122496|Tremelimumab
805392|NCT03122496|Image Guided Stereotactic Body Radiotherapy (SBRT)
805393|NCT03122496|17-108
805394|NCT03124355|vagal stimulation
805395|NCT03124355|POTS
805396|NCT03124355|galantamine
805397|NCT03124355|pyridostigmine
805398|NCT03124238|massage
805399|NCT03124212|mutation carrier
805400|NCT03124212|blood relative
805401|NCT03124212|genetic testing
805402|NCT03124212|family-based cohort
805403|NCT03124199|Eradication
805404|NCT03124199|Helicobacter pylori
805405|NCT03124199|rifaximin
805406|NCT03124199|therapy
805407|NCT03124199|standard triple therapy
805408|NCT03124186|motor recovery
805409|NCT03124186|neuroplasticity
805410|NCT03124186|subacute
805411|NCT03124186|human
805412|NCT03124186|sensory
805413|NCT03124186|nerve stimulation
805414|NCT03124173|fMRI
805415|NCT03124173|cingulate cortex
805416|NCT03124173|adaptation
805417|NCT03124173|frontal cortex
805421|NCT03124147|motor recovery
805422|NCT03124147|neuroplasticity
805423|NCT03124147|chronic
805424|NCT03124147|human
805425|NCT03124147|noninvasive brain stimulation
805426|NCT03124147|neuromodulation
805427|NCT03124108|Elafibranor
805428|NCT03124108|Primary Biliary Cholangitis
805429|NCT03124108|Alkaline phosphatase
805430|NCT03124095|physical exercise
805431|NCT03124095|combined training
805432|NCT03124095|physical activity
805433|NCT03124095|physical fitness
805434|NCT03124056|Extracorporeal photopheresis
805435|NCT03124056|Biomarker of response
805436|NCT03124056|Steroid resistant
805437|NCT03124030|direct oral anticoagulant
805438|NCT03124030|oral anticoagulant therapy
805439|NCT03124030|dental extraction
805440|NCT03124030|bleeding complication
805441|NCT03124030|atrial fibrillation
805442|NCT03124030|deep venous thrombosis
805443|NCT03123965|Special Access Scheme
805444|NCT03123965|Expanded Access
805445|NCT03123965|Pre-approval Access
805446|NCT03123965|Compassionate Use
805447|NCT03123965|Special Access Program
805448|NCT03123965|Named Patient Basis
805449|NCT03123952|Expanded Access
805450|NCT03123952|Pre-approval Access
805451|NCT03123952|Compassionate Use
805452|NCT03123952|Special Access Program
805453|NCT03123952|Named Patient Basis
805454|NCT03123952|Special Access Scheme
805455|NCT03123939|ALL
805456|NCT03123926|spontaneous preterm birth
805457|NCT03123926|lipids
805458|NCT03123926|biomarkers
805459|NCT03123874|human milk
805460|NCT03123874|breast milk
805461|NCT03123874|expressed human milk
805462|NCT03123874|bacterial communities
805463|NCT03123874|microbiome
805464|NCT03123874|breast pump
805465|NCT03123874|bacterial growth
805469|NCT03123835|Achalasia
805470|NCT03123835|Fistula
805471|NCT03123835|Obesity
805472|NCT03123835|POEM
805473|NCT03123835|GERD
805474|NCT03123835|endoscopic
805475|NCT03123835|treatments
805476|NCT03123835|post bariatric surger weight gain
805477|NCT03123835|endoluminal
805478|NCT03123835|Bariatric Surgery
805479|NCT03123835|Barretts
805480|NCT03123809|Diabetes
805481|NCT03123809|gastroparesis
805482|NCT03123809|gastric electrical stimulation
805483|NCT03123809|pyloroplasty
805484|NCT03123796|chronic rejection
805485|NCT03123796|transplant outcome
805486|NCT03123783|CD40
805487|NCT03123783|Immunotherapy
805488|NCT03123783|Nivolumab
805489|NCT03123783|APX005M
805490|NCT03123783|PD-1
805491|NCT03123770|Breast cancer
805492|NCT03123770|Neoadjuvant Chemotherapy
805493|NCT03123770|Pegylated liposomal doxorubicin
805494|NCT03123770|PLD
805495|NCT03123744|Palbociclib
805496|NCT03123744|Cyclin Pathway
805497|NCT03123744|kinase inhibitor
805498|NCT03123731|physical activity
805499|NCT03123731|diet
805500|NCT03123731|mHealth
805501|NCT03123731|Fitbit
805502|NCT03123731|neurocognition
805503|NCT03123731|text messaging
805504|NCT03123718|methotrexate
805505|NCT03123640|Medication reconciliation
805506|NCT03123640|Medication review
805507|NCT03123640|Drug related admission
805508|NCT03123627|Cytomegalovirus, Seropositive
805509|NCT03123614|Photorefractive keratectomy
805510|NCT03123601|Nursing home
805511|NCT03123601|Falls
805512|NCT03123601|Dysphasia
805513|NCT03123601|Choking
805514|NCT03123601|Dehydration
805515|NCT03123588|Essential thrombocythemia
805516|NCT03123588|hydroxyurea-resistant
805517|NCT03123588|hydroxyurea-intolerant
805518|NCT03123588|ruxolitinib
805519|NCT03123588|anagrelide
805520|NCT03123562|Cerebral palsy
805521|NCT03123562|Stem cell
805522|NCT03123562|Jaundice
805523|NCT03123536|high risk
805524|NCT03123536|complication
805525|NCT03123536|Ultrasonography
805526|NCT03123510|probiotics
805527|NCT03123510|prebiotics
805528|NCT03123510|synbiotics
805529|NCT03123510|obesity
805530|NCT03123497|Idiopathic Thrombocytopenic Purpura
805531|NCT03123484|beta-elemene
805532|NCT03123471|Plaque Psoriasis
805533|NCT03123471|Scalp
805534|NCT03123471|Double-Blind
805535|NCT03123471|Efficacy
805536|NCT03123471|Safety
805537|NCT03123471|CC-10004
805538|NCT03123471|Apremilast
805539|NCT03123471|Otezla
805540|NCT03123471|Itch
805541|NCT03123471|Head
805542|NCT03123458|MSC
805543|NCT03123458|GVHDs
805544|NCT03123458|transplantation
805545|NCT03123445|endostar
805546|NCT03123432|immunomodulating nutrients
805547|NCT03123406|cinacalcet
805548|NCT03123406|secondary hyperparathyroidism
805549|NCT03123406|calcimimetics
805550|NCT03123406|CKD-MBD
805551|NCT03123393|Drug therapy
805552|NCT03122470|TRUS biopsy
805553|NCT03122470|Pelvic MRI
805554|NCT03122457|Actinic Keratosis
805555|NCT03121573|near infrared spectroscopy, NIRS, duloxetine
805556|NCT03121560|Hysteroscopy
805557|NCT03121560|Saline infusion hysterosonography
805558|NCT03121534|Hematopoietic/Lymphoid Cancer
805559|NCT03121534|Richter's transformation
805560|NCT03121534|RT
805561|NCT03121534|Blinatumomab
805562|NCT03121534|Dexamethasone
805563|NCT03121534|Decadron
805564|NCT03123315|hysterectomy
805565|NCT03123315|ureter
805566|NCT03123302|MRI scan, sedation, epilepsia
805567|NCT03123289|PET/CT
805568|NCT03123289|68Gallium Citrate
805569|NCT03123289|Orthopedic Hardware infection
805570|NCT03123250|Lower Urinary Tract Symptoms (LUTS)
805571|NCT03123250|AQUABEAM
805572|NCT03123250|Aquablation
805573|NCT03123250|Benign Prostatic Hyperplasia (BPH)
805574|NCT03123224|Caregiver
805575|NCT03123224|Caregiving
805576|NCT03123224|TBI
805577|NCT03123224|dementia
805578|NCT03123224|Alzheimer's disease
805579|NCT03123224|physical exercise
805580|NCT03123224|physical activity
805581|NCT03123224|psychosocial
805582|NCT03123224|caregiver skills training
805583|NCT03123211|Expanded Access
805584|NCT03123211|Pre-approval Access
805585|NCT03123211|Compassionate Use
805586|NCT03123211|Special Access Program
805587|NCT03123211|Named Patient Basis
805588|NCT03123211|Special Access Scheme
805589|NCT03123198|borderline personality disorder, dialectical behavior therapy, suicidal behaviors
805590|NCT03123172|co2 gap
805591|NCT03123172|PPV
805592|NCT03123172|resuscitation
805593|NCT03123172|liver transplantation
805594|NCT03123146|Cognitive Behavioral Therapy
805595|NCT03123107|Vitamin C
805596|NCT03123107|Postoperative atrial fibrillation
805597|NCT03123107|coronary artery bypass graft
805598|NCT03123107|ascorbic acid
805599|NCT03123055|Urothelial Cell Carcinoma
805600|NCT03123055|UCC
805601|NCT03123055|bladder cancer
805602|NCT03123055|B-701
805603|NCT03123055|FGFR3
805604|NCT03123055|invasive bladder cancer
805605|NCT03123055|Transitional Cell Carcinoma
805606|NCT03123055|TCC
805607|NCT03123055|second line therapy
805608|NCT03123055|monoclonal antibody
805609|NCT03123055|combination therapy
805610|NCT03123055|Phase 1
805611|NCT03123055|atezolizumab
805612|NCT03123042|Sentinel lymph node
805613|NCT03123042|Early gastric cancer
805614|NCT03123042|Non-curative endoscopic resection
805615|NCT03123029|Expanded Access
805616|NCT03123029|Pre-approval Access
805617|NCT03123029|Compassionate Use
805618|NCT03123029|Special Access Program
805619|NCT03123029|Named Patient Basis
805620|NCT03123029|Special Access Scheme
805621|NCT03123016|Vitiligo
805622|NCT03123003|Bone age,
805623|NCT03123003|Height prediction
805624|NCT03123003|Growth
805625|NCT03122938|lactoferrin
805626|NCT03122938|Iron Metabolism
805627|NCT03122938|iron-deficiency anemia
805628|NCT03122938|pregnant women
805629|NCT03122938|fetal development
805636|NCT03122860|SM04690
805637|NCT03122860|Wnt pathway inhibitor
805638|NCT03122860|osteoarthritis
805639|NCT03122860|Samumed
805640|NCT03122834|Heart Failure
805641|NCT03122834|Genetic Polymorphism
805642|NCT03122834|RAAS
805643|NCT03122834|Cardiac Fibrosis
805644|NCT03122834|Remodeling
805645|NCT03122808|Tachysystole
805646|NCT03122808|Excessive Uterine Activity
805647|NCT03122769|Metformin
805648|NCT03122769|Heart Failure
805649|NCT03122769|Organic cation transporter
805650|NCT03122769|Pharmacogenetics
805651|NCT03122769|Pharmacokinetics
805652|NCT03122769|Positron Emission Tomography
805653|NCT03122756|Intravenous Dexamethasone
805654|NCT03122756|Spinal Anesthesia
805655|NCT03122756|Post-cesarean Section Pain
805656|NCT03122730|Cardiac surgery
805657|NCT03122730|Cardiopulmonary bypass
805658|NCT03122730|Epoprostenol
805659|NCT03122717|Non-Small Cell Lung Cancer
805660|NCT03122665|Nefopam
805661|NCT03122665|Pharmacokinetics
805662|NCT03122665|Shivering,
805663|NCT03122665|Thermoregulation
805664|NCT03122665|Anesthesia
805665|NCT03122626|stroke
805666|NCT03122626|community-based exercise program
805667|NCT03122626|task-oriented exercise
805668|NCT03122626|group exercise program
805669|NCT03122626|healthcare-recreation partnership
805670|NCT03122626|randomized controlled pilot trial
805671|NCT03122626|mixed methods
805672|NCT03122587|tACS
805673|NCT03122587|Brain Stimulation
805674|NCT03122587|Transcranial Alternating Current Stimulation
805675|NCT03122587|Substance Use
805676|NCT03122574|aromatherapy
805677|NCT03122574|pediatric
805678|NCT03122574|venipuncture
805679|NCT03122574|lavender
805680|NCT03122574|pain management
805681|NCT03122366|single nucleotide polymorphisms
805682|NCT03122366|Toll-like receptor-4
805683|NCT03122340|Acute Coronary Syndrome
805684|NCT03122340|Polyprenols
805685|NCT03122340|Cholesterol
805686|NCT03122314|paracetamol
805687|NCT03122314|dexketoprofen
805688|NCT03122314|emergency department
805689|NCT03122314|musculoskeletal pain
805690|NCT03122275|Adherence
805691|NCT03122275|Directive Counseling
805692|NCT03122262|Antiretroviral Agents, first-line antiretroviral therapy
805693|NCT03122262|dolutegravir
805694|NCT03122262|Tenofovir alafenamide
805695|NCT03122249|Palliative care
805696|NCT03122249|Symptom management
805697|NCT03122249|Self-management
805698|NCT03122249|Rural area
805699|NCT03122249|eHealth
805700|NCT03122249|telehealth
805701|NCT03122223|HIV
805702|NCT03122158|major depressive disorder
805703|NCT03122158|anxiety disorders
805704|NCT03122158|adolescent
805705|NCT03122158|child
805706|NCT03122145|healthy
805707|NCT03122145|volunteer
805708|NCT03122132|Hepatitis C Infection
805709|NCT03122132|Ombitasvir/Paritaprevir/Ritonavir+dasabuvir
805710|NCT03122119|Sacroiliac
805711|NCT03122119|Joint Injection
805712|NCT03122119|Platelet Rich Plasma
805713|NCT03122119|Ultrasound
805714|NCT03122119|Low Back Pain
805715|NCT03122119|Corticosteroid
805716|NCT03122093|pediatric
805717|NCT03122093|dietary treatment
805718|NCT03122093|celiac disease
805719|NCT03122093|T1D
805720|NCT03122080|acupuncture
805721|NCT03122080|insomnia
805722|NCT03122080|depression
805723|NCT03122080|antidepressants
805724|NCT03122067|oxytocin
805725|NCT03122067|social cognition
805726|NCT03122067|fMRI
805727|NCT03122067|empathy
805728|NCT03122054|Laparoscopic Cholecystectomy, Delayed Cholecystectomy
805729|NCT03122041|metformin intolerance
805730|NCT03122041|PCOS
805731|NCT03122041|Sitagliptin
805732|NCT03122041|beta cell function
805733|NCT03122028|LAmbre
805734|NCT03122002|Ischemic Stroke
805735|NCT03122002|Cerebral Infarction
805736|NCT03122002|Cerebrovascular Disorders
805737|NCT03121950|dementia
805738|NCT03121924|oocyte denudation
805739|NCT03121924|preincubation
805740|NCT03121924|icsi
805741|NCT03121924|oocyte donation
805742|NCT03121911|Recent Myocardial Infarction
805743|NCT03121911|Interval Physical Training
805744|NCT03121911|Inspiratory Muscle Training
805745|NCT03121911|Expiratory Flow Limitation
805746|NCT03121911|Ventilatory Efficiency
805747|NCT03121911|Inflammatory Markers
805748|NCT03121911|Heart Rate Variability
805749|NCT03121859|TENS
805750|NCT03121859|interferential current therapy
805751|NCT03121859|Chronic neck pain
805752|NCT03121846|Apatinib
805753|NCT03121846|Soft Tissue Sarcoma
805754|NCT03121833|Endostar
805755|NCT03121833|Soft Tissue Sarcoma
805756|NCT03121833|Chemotherapy
805757|NCT03121807|home parenteral nutrition
805758|NCT03121794|ultrasonography
805759|NCT03121794|Intraosseous Vascular access
805760|NCT03121794|humerus
805761|NCT03121794|anatomic landmark
805762|NCT03121768|Prognostic Model
805763|NCT03121768|Bladder Cancer
805764|NCT03121768|Superficial Bladder Cancer
805765|NCT03121768|Recurrence
805766|NCT03121768|Progression
805767|NCT03121768|BCG
805768|NCT03121742|Suicide
805769|NCT03121729|enhanced recovery after surgery
805770|NCT03121729|gastric cancer
805772|NCT03121651|Mobile technology
805773|NCT03121651|Reinforcement-learning
805774|NCT03121651|Medication management
805775|NCT03121638|Varicella Vaccine
805776|NCT03121638|Herpes Zoster Vaccine
805777|NCT03121612|RDS
805778|NCT03121521|statins liver enzymes melatonin
805779|NCT03121430|peripheral arterial disease
805780|NCT03121430|Drug eluting peripheral vascular stent system
805781|NCT03121430|primary patency
805782|NCT03121378|Hip Joint Alloplasty
805783|NCT03121378|Bone Cements
805784|NCT03121378|Impedance Aggregometry
805785|NCT03121378|Platelet Activation
805786|NCT03121365|Digital literacy
805787|NCT03121365|Reading
805788|NCT03121352|Carboplatin
805789|NCT03121352|Nab-Paclitaxel
805790|NCT03121352|Pembrolizumab
805791|NCT03121326|Sarcopenia
805792|NCT03121326|Aging
805793|NCT03121326|Biomarkers
805794|NCT03121326|Metabolomics
805795|NCT03121313|Tegafur-uracil
805796|NCT03121313|distant metastasis
805797|NCT03121313|oral cavity cancer
805798|NCT03121261|levobupivacaine
805799|NCT03121261|nerve fibers
805800|NCT03121261|clonidine
805801|NCT03121248|Accelerated radiotherapy
805802|NCT03121248|Older women
805803|NCT03121248|Hypo-fractonation
805804|NCT03121235|aspergillosis
805805|NCT03121235|mycosis
805806|NCT03121235|neutropenia
805807|NCT03121235|hematologic diseases
805808|NCT03121235|AsperGenius PCR
805809|NCT03121235|Ambisome
805810|NCT03121235|Voriconazole
805811|NCT03121196|Social deprivation
805812|NCT03121196|Adverse perinatal outcomes
805813|NCT03121183|Cardiology
805814|NCT03121183|Device Removal
805815|NCT03121183|Pacemaker
805816|NCT03121183|Defibrillators
805817|NCT03121183|Catheterization
805818|NCT03121183|Laser Therapy
805819|NCT03121183|Cost-Benefit Analysis
805820|NCT03121170|primary dysmenorrhea
805821|NCT03121170|extracorporeal shock wave therapy
805822|NCT03121170|traditional Chinese medicine
805823|NCT03121157|African Americans
805824|NCT03121157|Emerging adults
805825|NCT03121157|Medication adherence
805826|NCT03121157|eHealth
805827|NCT03121118|Mild Cognitive Impairment
805828|NCT03121118|Amyvid
805829|NCT03121118|Amyloid Imaging
805830|NCT03121118|PET Brain Scan
805831|NCT03121118|Amyloid Plaque
805832|NCT03121118|Ethics
805833|NCT03121118|Results disclosure
805834|NCT03121105|Idiopathic Inflammatory demyelinating disorders of the central nervous system
805835|NCT03121105|Multiple Sclerosis
805836|NCT03121105|Neuromyelitis Optica
805837|NCT03121105|MRI
805838|NCT03121105|pahtological
805839|NCT03121079|Interferon-alpha
805840|NCT03121079|Relapse
805841|NCT03121079|prevention
805842|NCT03121079|hematopietic stem cell transplantation
805843|NCT03121079|acute myeloid leukemia
805844|NCT03121066|Transcranial Magnetic Stimulation
805845|NCT03121066|Non invasive brain stimulation
805846|NCT03121066|Theta Burst Protocol
805847|NCT03121066|Brain connectivity
805848|NCT03121066|Dorsolateral prefrontal cortex
805849|NCT03121066|Parietal cortex
805850|NCT03121053|transcatheter aortic valve implantation
805851|NCT03121053|transcatheter aortic valve replacement
805852|NCT03121040|Vespa amino acid mixture (VAAM®)
805853|NCT03121040|Young athletes
805854|NCT03121040|Nutrition
805855|NCT03121040|lactic acid accumulation
805856|NCT03121040|Anaerobic metabolism
805857|NCT03121040|ATP
805858|NCT03121040|Sports damage
805859|NCT03121027|Anemia
805860|NCT03121027|Ever married women
805861|NCT03121027|Economic inequality
805862|NCT03121027|Diabetes
805863|NCT03121027|Maternity
805864|NCT03121027|BMI
805865|NCT03120988|Knee OA
805866|NCT03120988|lavage
805867|NCT03120988|Platelet Poor Plasma (PPP)
805868|NCT03120975|Anti-Infective Agents
805869|NCT03120975|Decision Support Systems, Clinical
805870|NCT03120975|Quality Improvement
805871|NCT03120949|Rheumatoid Arthritis
805872|NCT03120949|moderate
805873|NCT03120949|severe
805874|NCT03120949|subcutaneous
805875|NCT03120949|Olokizumab
805876|NCT03120949|open-label
805877|NCT03120936|Adherence
805878|NCT03120936|Transgender
805879|NCT03120936|PrEP
805880|NCT03120936|HIV Prevention
805881|NCT03120936|Truvada
805882|NCT03120936|HIV Risk Reduction
805883|NCT03120923|subacromial injection
805884|NCT03120065|adherence
805885|NCT03120013|Transcranial direct current stimulation
805886|NCT03120013|Transcranial magnetic stimulation
805887|NCT03120013|Spinocerebellar ataxia
805888|NCT03120013|Cerebellar ataxia
805889|NCT03120000|DLBCL
805890|NCT03119987|Red cell Distribution Width
805891|NCT03119987|Risk
805892|NCT03119987|Mortality
805893|NCT03119987|Hemorrhage
805894|NCT03119974|ITP
805895|NCT03119974|TPO-RAS
805896|NCT03119974|Thrombopoietin-receptor agonists
805897|NCT03119961|Amyloid Amyloid Plaque
805898|NCT03119961|Tau Protein
805899|NCT03119961|Sonication
805900|NCT03119948|Muscle spasticity
805901|NCT03119948|Botulinum toxin
805902|NCT03119935|ambu bag, ventilation, tidal volume
805903|NCT03119922|major sickle cell disease (SCD)
805904|NCT03119922|children
805905|NCT03119922|pneumococcal preventive measures
805906|NCT03119909|fMRI
805907|NCT03119909|cingulate cortex
805908|NCT03119909|adaptation
805909|NCT03119909|frontal cortex
805910|NCT03119896|chronic pain
805911|NCT03119896|self-management
805912|NCT03119896|pain management
805913|NCT03119896|doctor patient communication
805914|NCT03119896|primary care
805919|NCT03120845|Pain,
805920|NCT03120845|one-visit
805921|NCT03120845|two visits
805922|NCT03120819|exercise
805923|NCT03120819|fatigue
805924|NCT03120819|physical activity
805925|NCT03120754|ERAS
805926|NCT03120754|Peritoneal drainage
805927|NCT03120754|Primary Closure
805928|NCT03120741|Healthcare Quality
805929|NCT03120728|Emergency contraception
805930|NCT03120728|Contraceptive vaginal ring
805931|NCT03120728|NuvaRing
805932|NCT03120728|Contraception
805933|NCT03120715|low molecular weight heparin (LMWH)
805934|NCT03120715|frozen embryo transfer (FET)
805935|NCT03120715|pregnancy
805936|NCT03120689|VITOM
805937|NCT03120689|Adult learners
805938|NCT03120689|Medical students
805939|NCT03120689|Residents
805940|NCT03120689|Vaginal surgery
805941|NCT03120689|Medical education
805942|NCT03120676|Relapsed
805943|NCT03120676|Refractory
805944|NCT03120676|Atezolizumab
805945|NCT03120676|17-191
805946|NCT03120663|antimicrobials
805947|NCT03120663|pharmacokinetics
805948|NCT03120663|augmented renal clearance
805949|NCT03120663|non critically ill
805950|NCT03120637|Methylene Blue
805951|NCT03120637|Septic Shock
805952|NCT03120637|Vasoplegia
805953|NCT03120637|Cirrhosis
805954|NCT03120611|Exercise
805955|NCT03120611|Hemodialysis
805956|NCT03120611|Virtual Reality
805957|NCT03120598|preparation strategies
805958|NCT03120598|implementation strategies
805959|NCT03120598|sustainment strategies
805960|NCT03120585|Respiratory Distress Syndrome, Newborn
805961|NCT03120585|fluid restriction
805962|NCT03120572|Respiratory muscle strength
805963|NCT03120572|Diaphragmatic surface electromyography
805964|NCT03120572|Functional capacity
805965|NCT03120559|Gingivitis
805966|NCT03120559|SMS
805967|NCT03120559|Dental floss
805968|NCT03120559|behavior change
805969|NCT03120559|HAPA
805970|NCT03120546|cervical spine motion
805971|NCT03120546|video laryngoscope
805972|NCT03120546|rigid video stylet
805973|NCT03120533|iontophoresis
805974|NCT03120533|treprostinil
805975|NCT03120507|in-hospital cardiac arrest
805976|NCT03120507|IHCA
805977|NCT03120507|quality of life
805978|NCT03120507|QoL
805979|NCT03120507|patient-reported outcomes
805980|NCT03120494|HIV prevention, high risk MSM, sero-discordant couples, PrEP
805981|NCT03120468|alcohol, alcohol dependence, addiction, alcohol use disorder
805982|NCT03120455|weight loss
805983|NCT03120455|Almond
805984|NCT03120455|Pistachio
805985|NCT03120455|hypoenergetic diet
805986|NCT03120455|Nut
805987|NCT03120442|postoperative delirium
805988|NCT03120442|total knee arthroplasty
805989|NCT03120442|propofol
805990|NCT03120442|dexmedetomidine
805991|NCT03120442|fentanyl
805992|NCT03120442|inflammatory response
805993|NCT03120442|interleukins
805994|NCT03120442|CAM-ICU
805995|NCT03120429|lean fish
805996|NCT03120429|weight loss
805997|NCT03120429|Diet
805998|NCT03120364|Herpes Zoster Vaccine
805999|NCT03120364|Prevention of Herpes Zoster
806000|NCT03120338|Child and Adolescent
806001|NCT03120338|Randomised Controlled Trial
806002|NCT03120338|Paediatrics
806003|NCT03120338|DAWBA
806004|NCT03120338|eHealth Services
806005|NCT03120312|outcome
806006|NCT03120286|OBESITY
806007|NCT03120286|In Vitro Fertilization (IVF)
806008|NCT03120286|Polycystic ovary syndrome (PCOS)
806009|NCT03120260|Caloric Restriction
806010|NCT03120260|weight loss
806011|NCT03120260|sleep
806012|NCT03120221|Pregnancy
806013|NCT03120221|Iodine deficiency
806014|NCT03120221|Thyroid
806015|NCT03120208|Postpartum psychological disorders
806016|NCT03120208|immediate postpartum hemorrhage.
806017|NCT03120182|aspirin
806018|NCT03120182|bleeding risk
806019|NCT03120182|intracranial bleeding
806020|NCT03120182|burr-hole drainage
806021|NCT03120182|chronic subdural hematoma
806022|NCT03120182|anticoagulation
806023|NCT03120169|COPD
806024|NCT03120169|exercise
806025|NCT03120169|training
806026|NCT03120169|cycling
806027|NCT03120169|treadmill
806028|NCT03120169|walking
806029|NCT03120169|pulmonary rehabilitation
806030|NCT03120156|sensomotoric insoles
806031|NCT03120156|postural control
806032|NCT03120156|proprioceptive insoles
806033|NCT03120156|insoles
806034|NCT03120143|Small-sided ball games
806035|NCT03120143|Aging
806036|NCT03120143|Muscle mass
806037|NCT03120143|Health
806038|NCT03120143|Training
806039|NCT03120143|Protein intake
806040|NCT03120143|Physical function
806041|NCT03120143|Physiological adaptations
806043|NCT03120117|Midurethral Slings
806044|NCT03119883|Myeloma
806045|NCT03119883|Metabolism
806046|NCT03119883|Glutamine
806047|NCT03119870|fMRI
806048|NCT03119870|EEG
806049|NCT03119870|behavior
806050|NCT03119870|cingulate cortex
806051|NCT03119857|Non-metastatic Prostate Cancer
806052|NCT03119831|chlorhexidine
806053|NCT03119831|alcohol
806054|NCT03119831|C31G
806055|NCT03119831|Mouthrinses
806056|NCT03119831|Early postsurgical wound healing
806057|NCT03119818|ESRD
806058|NCT03119818|hemodialysis
806059|NCT03119818|phosphate
806060|NCT03119818|ATP
806061|NCT03119818|magnetic resonance spectroscopy
806062|NCT03119805|composite scores
806063|NCT03119805|patient reported outcomes
806064|NCT03119805|patient perpective
806065|NCT03119805|physician perspective
806066|NCT03119805|cut-off values
806067|NCT03119805|flare
806068|NCT03119805|remission
806069|NCT03119805|minimal disease activity
806070|NCT03119805|low disease activity
806071|NCT03119792|Behavioral Modification
806072|NCT03119792|Health Community
806073|NCT03119792|Community Intervention
806074|NCT03119792|Prevention
806075|NCT03119792|Cardiovascular Health
806076|NCT03119792|Education Intervention
806077|NCT03119792|Colombia
806078|NCT03119779|pulpotomy
806079|NCT03119779|deep caries
806080|NCT03119779|permanent molars
806081|NCT03119779|MTA
806082|NCT03119753|Rapid Prototyping technique
806083|NCT03119753|complete denture
806084|NCT03119714|bronchoprovocation
806085|NCT03119714|early-late asthmatic reaction
806086|NCT03119714|mast cell stabilizer
806087|NCT03119714|mast cell mediators
806088|NCT03119714|sputum eosinophils
806089|NCT03119701|Patients Surviving Open Surgery
806090|NCT03119701|Ruptured Abdominal Aortic Aneurysm
806091|NCT03119675|Myopia
806092|NCT03119675|Hyperopia
806093|NCT03119675|Anisometropia
806094|NCT03119675|Amblyopia Risk Factors
806095|NCT03119675|Risk Factors
806096|NCT03119675|Smartphone Application (App)
806097|NCT03119675|Photoscreening
806098|NCT03119675|Vision Screening
806099|NCT03119675|Mobile Vision Screening
806100|NCT03119662|Acute kidney injury (AKI)
806101|NCT03119662|Acute kidney injury network (AKIN)
806102|NCT03119662|Chronic kidney disease (CKD)
806103|NCT03119662|Contrast-enhanced computed tomography (CECT)
806104|NCT03119662|Endovascular Aneurysm Repair (EVAR)
806105|NCT03119662|Iodixanol
806106|NCT03119662|Non-enhanced computed tomography (NECT)
806107|NCT03119662|Serum creatinine (SCr)
806108|NCT03119623|Heart Failure
806109|NCT03119623|Endothelial function
806110|NCT03119623|Brachial Artery Reactivity Test
806111|NCT03119623|Sacubitril/Valsartan
806112|NCT03119623|Enalapril
806113|NCT03119623|HFREF
806114|NCT03119597|low mood, depression
806115|NCT03119584|chronic constipation, diabetes
806116|NCT03119571|Cardiac arrest
806117|NCT03119571|Ventricular fibrillation
806118|NCT03119571|coronary artery disease
806119|NCT03119545|intervention
806120|NCT03119545|support program
806121|NCT03119545|family centered
806122|NCT03119545|parental death
806123|NCT03119519|NSCLC
806124|NCT03119519|Oligometastases
806125|NCT03119519|radiotherapy
806126|NCT03119493|Metabolic syndrome X
806127|NCT03119493|Autonomic nervous system
806128|NCT03119493|Aerobic exercise
806129|NCT03119493|Exercise
806130|NCT03119493|Heart rate
806131|NCT03119480|Acute Kidney Injury
806132|NCT03119480|Electronic alerts
806139|NCT03119389|Hand Hygiene
806140|NCT03119389|Non-sterile glove use
806141|NCT03119376|peer review
806142|NCT03119376|online tool
806143|NCT03119376|Randomized Controlled Trial
806144|NCT03119363|cancer-related fatigue
806145|NCT03119363|circadian rhythms
806146|NCT03119363|light therapy
806147|NCT03119363|systematic light exposure
806148|NCT03119363|cancer survivors
806149|NCT03119363|oncology
806150|NCT03119363|Multiple Myeloma
806151|NCT03119363|Hematopoietic stem cell transplantation
806152|NCT03119363|Autologous stem cell transplantation
806153|NCT03119337|male circumcision, text-based follow-up, Zimbabwe,
806154|NCT03119324|Biomodulation
806155|NCT03119324|LLLT
806156|NCT03119324|Temporomandibular Joint Disorders
806157|NCT03119324|Pain management
806158|NCT03119285|ovarian cancer
806159|NCT03119285|BRCA1
806160|NCT03119285|BRCA2
806161|NCT03119285|BROCA
806162|NCT03119246|beta testing
806163|NCT03119246|assessment battery
806164|NCT03119246|HD
806165|NCT03119207|ICU
806166|NCT03119168|screening
806167|NCT03119168|adenoma detection rate
806168|NCT03119168|simethicone
806169|NCT03119155|Congenital Heart Disease
806170|NCT03119155|Echocardiography
806171|NCT03119155|Diagnosis
806172|NCT03119129|prevention
806173|NCT03119129|health disparities
806174|NCT03119129|Native Hawaiians and other Pacific Islanders
806175|NCT03119116|Stroke Prevention in NVAF patients
806176|NCT03119103|respiratory pattern
806177|NCT03119103|sensor data
806178|NCT03119103|bed sheet
806179|NCT03119103|pressure
806180|NCT03119103|respiration rate
806181|NCT03119090|biomarkers
806182|NCT03119090|Fontan operation
806183|NCT03119090|Single ventricle
806184|NCT03119090|congenital heart disease
806186|NCT03119051|mild cognitive impairment
806187|NCT03119038|total hip
806188|NCT03119038|degenerative joint disease
806189|NCT03119038|osteoarthritis
806190|NCT03119025|Dendritic Cells
806191|NCT03119025|DC-based Vaccines
806192|NCT03119025|Chronic HCV Infection
806193|NCT03119025|Antigen-Specific T cell response
806194|NCT03119025|Recombinant HCV-Core antigen
806195|NCT03119025|Recombinant HCV-NS3 antigen
806196|NCT03119012|Bioresorbable scaffold
806197|NCT03119012|Dual antiplatelet therapy
806198|NCT03119012|P2Y12 receptor inhibitor
806199|NCT03119012|Coronary artery disease
806200|NCT03118986|olanzapine
806201|NCT03118986|vomiting
806202|NCT03118986|children
806203|NCT03118986|adolescents
806204|NCT03118986|bone marrow transplant
806205|NCT03118986|supportive care
806209|NCT03118908|Succinate
806210|NCT03118908|B complex vitamins
806211|NCT03118908|menopause
806212|NCT03118882|Breast cancer screening
806213|NCT03118882|Colorectal Cancer screening
806214|NCT03118882|Primary prevention
806215|NCT03118882|Lifestyles
806216|NCT03118882|Teachable moment
806217|NCT03118869|Asthma
806218|NCT03118869|B2 adrenergic receptors
806219|NCT03118869|Polymorphism
806220|NCT03118804|Weaning
806221|NCT03118804|Mechanical ventilation
806222|NCT03118804|Electrical impedance tomography
806223|NCT03118804|Tidal distribution
806225|NCT03118726|LARC
806226|NCT03118726|New Mexico
806227|NCT03118726|Contraception
806228|NCT03118713|Glimepride
806229|NCT03118713|Metformin
806230|NCT03118713|Ipragliflozin
806231|NCT03118713|Type 2 Diabetes Mellitus
806232|NCT03118713|ASP1941
806233|NCT03118687|Immune system
806234|NCT03118674|Interventional, Open-label, PCT, Hepatitis C
806238|NCT03118635|Summer
806239|NCT03118635|Diet
806240|NCT03118635|Physical Activity
806241|NCT03118635|Sedentary behavior
806242|NCT03118635|Low-income
806243|NCT03118609|Caregivers
806244|NCT03118609|Chronic Pain
806245|NCT03118596|intubation
806246|NCT03118596|tracheal
806247|NCT03118596|airway device
806248|NCT03118596|supra-glottic airway device
806249|NCT03118596|fibreoptic scope
806252|NCT03118557|pelvic floor strengthening, stress urinary incontinence
806258|NCT03118531|Long Lesion
806259|NCT03118531|In-stent Late Lumen Loss (LLL)
806260|NCT03118531|Major Adverse Cardiac Events (MACE)
806261|NCT03118531|MYOCARDIAL INFARCTION (MI)
806262|NCT03118531|TARGET VESSEL REVASCULARIZATION (TVR)
806263|NCT03118531|TARGET LESION REVASCULARIZATION (TLR)
806264|NCT03118531|Target Vessel Failure (TVF)
806265|NCT03118531|Target Lesion Failure (TLF)
806266|NCT03118531|Stent Thrombosis (ST)
806267|NCT03118479|IHH
806268|NCT03118479|KS
806269|NCT03118479|Idiopathic hypogonadotropic hypogonadism
806270|NCT03118479|GnRH deficiency
806271|NCT03118466|AML
806272|NCT03118453|Musculoskeletal pain/*therapy
806273|NCT03118453|Behavioral medicine
806274|NCT03118453|Physical therapy
806275|NCT03118453|Cost-benefit analyses
806276|NCT03118453|Treatment outcome
806277|NCT03118453|Adults
806278|NCT03118440|Fluoroscopy
806279|NCT03118440|Pacemaker
806280|NCT03118440|Three dimensional
806281|NCT03118440|Radiation
806282|NCT03118440|Imaging
806283|NCT03118427|Fluoroscopy
806284|NCT03118427|Pacemaker
806285|NCT03118427|Three dimensional
806286|NCT03118427|Radiation
806287|NCT03118427|Imaging
806288|NCT03118414|Balance
806289|NCT03118414|Cognition
806290|NCT03118414|Exercise
806294|NCT03118349|CA19-9 Positive Malignancies
806299|NCT03118310|Reduction of liver fat
806300|NCT03118297|Etonogestrel Implant
806301|NCT03118284|Foley catheter
806302|NCT03118271|lumbar disc herniation
806303|NCT03118271|lumbar traction
806304|NCT03118271|spinal manipulation
806305|NCT03118271|lumbar surgery
806306|NCT03118258|Vaginal HPV self-sampling
806307|NCT03118258|Pap test smear
806308|NCT03118258|cervical cancer screening
806309|NCT03118258|deprivation
806310|NCT03118258|sexual and reproductive health
806311|NCT03118258|Precariousness
806312|NCT03118232|Nursing Homes
806313|NCT03118232|Health Facilities
806314|NCT03118232|Infections
806315|NCT03118232|Readmissions
806316|NCT03118232|Multi-Drug resistance
806317|NCT03118232|Antibiotic Use
806318|NCT03118219|assisted reproductive technology
806319|NCT03118219|embryo transfer
806320|NCT03118219|online intervention
806321|NCT03118219|rct
806322|NCT03118206|Lumbar spinal stenosis
806323|NCT03118206|spinal manipulation
806324|NCT03118206|physical therapy
806325|NCT03118206|surgery
806329|NCT03118167|Acrylamide
806330|NCT03118167|Tea polyphenols
806331|NCT03118167|Water-soluble antioxidant of bamboo leaves
806332|NCT03118154|endometriosis
806333|NCT03118154|pelvic pain
806334|NCT03118154|dysmenorrhea
806335|NCT03118141|preimplantation genetic screening
806336|NCT03118141|single embryo transfer
806337|NCT03118141|frozen embryo transfer
806338|NCT03118141|cumulative live birth rate
806339|NCT03118128|Acute Lymphoblastic Leukemia (ALL), ABCB1, Metformin
806340|NCT03118115|bioimpedance
806341|NCT03118115|thrombosis
806342|NCT03118115|free flap
806343|NCT03118115|microsurgerie
806344|NCT03118115|breast reconstruction
806345|NCT03118089|Oral nutritional supplements
806346|NCT03118037|Radiofrequency Ablation
806347|NCT03118024|deep inferior epigastric perforator flap
806348|NCT03118024|fluid restriction
806349|NCT03118024|catecholamine restriction
806350|NCT03118011|Tobacco use, withdrawal symptoms
806351|NCT03117985|HIV reservoirs
806352|NCT03117985|HIV persistence
806353|NCT03117985|Viral rebound
806354|NCT03117972|Metastatic colorectal cancer
806355|NCT03117972|Biomarker
806356|NCT03117972|Chemotherapy intensification
806357|NCT03117972|Syndecan1
806358|NCT03117972|LDH
806359|NCT03117972|CD138
806360|NCT03117946|immunomonitoring
806361|NCT03117946|immune checkpoint
806362|NCT03117946|chemoradiation
806363|NCT03117946|T cells
806364|NCT03117933|BRCA1/2 mutation
806365|NCT03117933|Platinum resistance
806366|NCT03117920|Refractory pancreatic cancer
806367|NCT03117920|Minnelide
806368|NCT03117920|Minnelide002
806369|NCT03117920|2017-000126-36
806370|NCT03117881|Multiple Sclerosis
806371|NCT03117881|Yoga
806372|NCT03117881|Pilates
806373|NCT03117881|Telerehabilitation
806374|NCT03117881|Physical activity
806375|NCT03117842|Female entertainment workers
806376|NCT03117842|mHealth
806377|NCT03117842|HIV testing
806378|NCT03117842|Cambodia
806379|NCT03117816|deep molecular remission of MR4 or better
806380|NCT03117803|Aneurysm, Intracranial
806381|NCT03117803|Registries
806382|NCT03117803|Multicenter Studies
806383|NCT03117803|People's Republic of China
806384|NCT03117790|elderly
806385|NCT03117790|surgery
806386|NCT03117790|analgesia
806387|NCT03117790|dexmedetomidine
806388|NCT03117790|sleep quality
806389|NCT03117751|Leukemia
806390|NCT03117751|Lymphoma
806391|NCT03117751|Pediatric
806392|NCT03117751|B-Cell
806393|NCT03117751|T-Cell
806394|NCT03117725|oxidative stress
806395|NCT03117725|antioxidants
806396|NCT03117725|diminished ovarian reserve
806397|NCT03117712|cerebral blood supply
806398|NCT03117712|cardiopulmonary bypass
806399|NCT03117712|open-heart cardiac surgery
806400|NCT03117699|Hemiplegia
806401|NCT03117699|transport device
806402|NCT03117673|right ventricular systolic pressure (RVSP)
806403|NCT03117673|Transesophageal echocardiography
806404|NCT03117634|anti vegf
806405|NCT03117634|aflibercept
806406|NCT03117634|treat and extend
806407|NCT03117621|Blincyto
806408|NCT03117608|OA
806409|NCT03117608|aMAT
806410|NCT03117608|PRP
806411|NCT03117595|Single Shot Spinal
806412|NCT03117595|Intrathecal narcotics
806413|NCT03117595|Morphine
806414|NCT03117595|Fentanyl
806415|NCT03117595|Labour Analgesia
806416|NCT03117582|C. diff
806417|NCT03117582|CDI
806418|NCT03117582|Clostridium Difficile Infection
806419|NCT03117582|Diarrhea
806420|NCT03117582|Fecal microbiota transplantation
806421|NCT03117582|FMT
806422|NCT03117543|Screening
806423|NCT03117530|minocycline
806424|NCT03117530|brain inflammation
806425|NCT03117530|microglia
806426|NCT03117530|cognition
806427|NCT03117517|PCOS
806428|NCT03117504|Stress urinary incontinence
806429|NCT03117504|SUI
806430|NCT03117491|Gow-Gates nerve block
806431|NCT03117491|Inferior alveolar nerve block
806432|NCT03117491|local anesthesia
806433|NCT03117491|molar
806434|NCT03117491|pulpitis
806435|NCT03117452|schizophrenia
806436|NCT03117452|visual processing
806437|NCT03117452|cognitive training
806438|NCT03117452|visual training
806439|NCT03117426|Symfony Extended Range of Vision IOL
806440|NCT03117426|AT LISA tri 839MP IOL
806441|NCT03117426|Trifocal IOL
806442|NCT03117426|Extended depth of focus IOLs
806443|NCT03117413|Cochlear implantation
806444|NCT03117413|Deafness
806445|NCT03117413|Auditory cortex
806446|NCT03117413|Auditory plasticity
806447|NCT03117413|Tinnitus
806448|NCT03117361|multiple myeloma
806449|NCT03117361|plitidepsin
806450|NCT03117361|Aplidin
806451|NCT03117348|Enteral Nutrition
806452|NCT03117348|Digestive System Neoplasms
806453|NCT03117348|Randomized Controlled Trial
806454|NCT03117348|Clinical Outcomes
806455|NCT03117335|Non-small Cell Lung Cancer
806456|NCT03117335|Sulijia
806457|NCT03117335|Recombinant endostatin
806458|NCT03117335|Vinorelbine
806459|NCT03117335|Cisplatin
806460|NCT03117322|cerebral palsy
806461|NCT03117322|children
806462|NCT03117322|chronic constipation
806463|NCT03117322|synbiotic
806464|NCT03117322|prebiotics
806465|NCT03117322|probiotics
806466|NCT03117322|agave inulin
806467|NCT03117322|microbiota
806468|NCT03117309|Nivolumab
806469|NCT03117309|Ipilimumab
806470|NCT03117309|OPDIVO
806471|NCT03117309|IgG1 kappa immunoglobulin
806472|NCT03117296|physical therapy
806473|NCT03117296|occupational therapy
806474|NCT03117296|tAVR
806475|NCT03117283|Laparoscopic surgery
806476|NCT03117283|Radical total gastrectomy
806477|NCT03117283|Bursectomy
806478|NCT03117283|Advanced posterior gastric wall cancer
806479|NCT03117257|Lobaplatin
806480|NCT03117257|head and neck cancer
806481|NCT03117257|chronic-chemotherapy
806482|NCT03117231|osteoarthritis
806483|NCT03117231|elderly
806484|NCT03117231|musculoskeletal pain
806485|NCT03117231|transcranial direct current stimulation
806486|NCT03117192|zinc supplementation
806487|NCT03117192|immunity
806488|NCT03117192|thalassemia
806489|NCT03117166|lidocaine implantation ICD
806490|NCT03117140|Brachial Plexus Block
806491|NCT03117140|Clonidine
806492|NCT03117140|Dexamethasone
806493|NCT03117140|Buprenorphine
806494|NCT03117114|colonoscopy
806495|NCT03117114|polyp
806496|NCT03117114|resection
806497|NCT03117101|Tolerability Pharmacokinetics
806498|NCT03117088|Standardized handover
806499|NCT03117088|Online-based
806500|NCT03117088|SOFA-Score
806501|NCT03117088|ICU
806502|NCT03117088|ISBAR3
806503|NCT03117075|cancer pain, wearable device
806504|NCT03117036|lymphoma
806505|NCT03117036|cohort
806506|NCT03117036|serum
806507|NCT03117036|cell-free DNA
806508|NCT03117023|dexmedetomidine
806509|NCT03117023|sleep deprivation
806510|NCT03117023|gastric cancer
806511|NCT03117023|middle-aged and elderly patient
806512|NCT03117010|Hemophagocytic lymphohistiocytosis
806513|NCT03116997|neuromuscular blockade
806514|NCT03116997|sugammadex
806515|NCT03116997|SUG
806516|NCT03116997|neostigmine
806517|NCT03116997|NEO/GLYCO
806518|NCT03116997|17-207
806519|NCT03116984|Hepatocellular Carcinoma
806520|NCT03116984|external- beam radiotherapy (EBRT)
806521|NCT03116984|transarterial chemoembolization (TACE)
806522|NCT03116971|M3814, Small Cell Lung Cancer (SCLC), Deoxyribonucleic acid-dependent protein kinase inhibitor, Chemotherapy
806523|NCT03116958|CPAP compliance
806524|NCT03116958|Telemedicine integrated platform
806525|NCT03116958|Standard management
806526|NCT03116958|Cost-effectiveness
806527|NCT03116945|PET/CT
806528|NCT03116945|68Gallium Citrate
806529|NCT03116945|Hepatocellular carcinoma
806530|NCT03116932|HIV prevention, high risk MSM, PrEP
806531|NCT03116919|nutrition
806532|NCT03116919|Potatoes
806533|NCT03116919|endothelial function
806534|NCT03116919|feeding trial
806535|NCT03116880|Aorta, Abdominal/surgery
806536|NCT03116880|Endovascular Procedures
806537|NCT03116854|Acute Coronary Syndrome
806538|NCT03116854|Beta Blockers
806539|NCT03116854|Prognosis
806540|NCT03116828|epilepsy
806541|NCT03116828|seizures
806542|NCT03116828|partial on-set seizures
806543|NCT03116815|blood pressure
806544|NCT03116815|monitoring
806545|NCT03116815|hypertension
806546|NCT03116815|patient reported outcomes
806547|NCT03116776|walnut shell glasses moxibustion
806548|NCT03116776|dry eye
806549|NCT03116776|randomized controlled trial
806550|NCT03116750|mechanical thrombectomy
806551|NCT03116737|AOM
806552|NCT03116724|catheterization, central venous
806553|NCT03116724|jugular veins
806554|NCT03116724|echocardiography, transesophageal
806555|NCT03116672|pain
806556|NCT03116672|Diclofenac
806557|NCT03116672|NSAID
806558|NCT03116672|Ketorolac
806559|NCT03116646|mastication
806560|NCT03116646|cerebral palsy
806561|NCT03116646|family
806562|NCT03116633|lung cancer
806563|NCT03116633|biopsy
806564|NCT03116620|mastication
806565|NCT03116620|children with neuromuscular disorders
806566|NCT03116607|User satisfaction
806567|NCT03116607|Readmission
806568|NCT03116607|Emergency department
806569|NCT03116607|Pharmaceutical intervention
806570|NCT03116594|Herpes Zoster Vaccine
806571|NCT03116594|Prevention of Herpes Zoster
806572|NCT03116581|Perceptual Decision
806573|NCT03116581|Social Cognition
806574|NCT03116581|Motivation
806575|NCT03116568|IBD
806576|NCT03116568|Meconium
806577|NCT03116568|Pregnancy
806578|NCT03116568|Microbiota
806579|NCT03116568|Newborn
806580|NCT03116555|Apatinib
806581|NCT03116555|Irinotecan
806582|NCT03116555|Second-line
806583|NCT03116555|Metastatic Gastric Adenocarcinoma
806598|NCT03116503|Suicide
806599|NCT03116490|morbidity
806600|NCT03116490|mortality
806601|NCT03116490|hip fracture
806602|NCT03116490|anesthesia type
806603|NCT03116490|POSSUM
806604|NCT03116451|foot health
806605|NCT03116451|nurses
806606|NCT03116451|work well-being
806607|NCT03116438|Coronary Artery Disease
806608|NCT03116438|Nuclear Stress Test
806609|NCT03116438|CT Angiography
806610|NCT03116438|Angiography
806611|NCT03116425|Precision Medicine
806612|NCT03116425|Functional Neuroimaging
806613|NCT03116425|Transcranial Magnetic Stimulation, Repetitive
806614|NCT03116425|Transcranial Direct Current Stimulation
806615|NCT03116425|Monocentric
806616|NCT03116425|Comparative balanced, randomized
806617|NCT03116425|double-blind cross-over 3 Arms Study
806618|NCT03116412|Malignant melanoma
806619|NCT03116412|Follow up
806620|NCT03116412|Radiology
806621|NCT03116412|Survival
806622|NCT03116399|Older adults
806623|NCT03116399|Social Support
806624|NCT03116399|Technology uptake
806625|NCT03116373|Posture
806626|NCT03116373|Physiology
806627|NCT03116373|Head
806628|NCT03116373|Intubation
806629|NCT03116373|Intratracheal methods
806630|NCT03116334|Obesity
806631|NCT03116334|BMI
806632|NCT03116334|executive functioning
806633|NCT03116334|general cognitive ability
806634|NCT03116334|twin study
806635|NCT03116334|heritability
806636|NCT03116334|cognition
806637|NCT03116334|GCTA
806638|NCT03116243|migrant and seasonal head start
806639|NCT03116243|early childhood education
806640|NCT03116243|head start
806641|NCT03116230|Knee pathology
806642|NCT03116217|renal function
806643|NCT03116217|post natal
806644|NCT03116217|peptidome
806645|NCT03116204|Dependency
806646|NCT03116204|FRC department
806647|NCT03116204|scale validation
806648|NCT03116204|validity
806649|NCT03116204|reliability
806650|NCT03116178|Fluid therapy
806651|NCT03116178|oximetry
806652|NCT03116178|thromboelastography
806653|NCT03116178|intraoperative/method
806654|NCT03116178|monitoring
806655|NCT03116139|Computed tomography scan
806656|NCT03116139|Ventilation-perfusion lung scan
806657|NCT03116139|Acute kidney injury
806658|NCT03116139|Pulmonary embolism
806659|NCT03116139|Contrast-induced nephropathy
806660|NCT03116087|Postmenopausal women
806661|NCT03116061|Multimorbidity
806662|NCT03116061|Family Medicine
806663|NCT03116061|decompensation
806664|NCT03116061|predictive value
806665|NCT03116022|menopause
806666|NCT03116022|sexual dysfunction
806667|NCT03116022|coital pain
806668|NCT03116022|vagina
806669|NCT03116009|Obesity
806670|NCT03116009|Pregnancy
806671|NCT03116009|Diabetes Mellitus
806672|NCT03116009|Perinatal Outcomes
806673|NCT03115957|Parenteral Nutrition
806674|NCT03115957|Digestive System Neoplasms
806675|NCT03115957|Randomized Controlled Trials
806676|NCT03115957|Clinical Outcomes
806677|NCT03115957|Postoperative Period
806678|NCT03115905|Aneurysmal Subarachnoid Hemorrhage
806679|NCT03115905|Emergency Medical Services
806680|NCT03115905|Registry Study
806681|NCT03115905|China
806682|NCT03115866|Healthy Diet
806683|NCT03115866|Fruits and Vegetables
806684|NCT03115866|Metabolome
806685|NCT03115866|Microbiome
806686|NCT03115866|Young Adults
806687|NCT03115788|Thermal
806688|NCT03115762|ASKB1202
806689|NCT03115749|Crohn's disease
806690|NCT03115749|ulcerative colitis
806691|NCT03115749|mesenchymal stem cells
806692|NCT03115749|intestinal inflammation
806693|NCT03115736|HIV
806694|NCT03115736|Hepatitis B
806695|NCT03115736|Renal dysfunction
806696|NCT03115736|tenofovir alafenamide
806697|NCT03115723|Hospitalization
806698|NCT03115723|Health Care Economics and Organizations
806699|NCT03115710|Keratoconus
806700|NCT03115710|Prevalence
806701|NCT03115671|Phosphatidylserine
806702|NCT03115671|Omega-3
806703|NCT03115606|videolaryngoscope
806704|NCT03115606|Fastrach LMA
806705|NCT03115606|cervical motion
806706|NCT03115593|hysteroscopy
806707|NCT03115593|pipette
806708|NCT03115593|biopsy
806709|NCT03115593|endometrial cancer
806710|NCT03115541|venous thromboembolism prophylaxis
806711|NCT03115541|deep vein thrombosis
806712|NCT03115541|pulmonary embolus
806713|NCT03115541|esophageal resection
806714|NCT03115541|incidence
806715|NCT03115528|Malignant neoplasms of independent (primary) multiple sites
806716|NCT03115528|Medical oncologists
806717|NCT03115528|Palliative care physicians
806718|NCT03115528|Questionnaire
806719|NCT03115528|Survey
806720|NCT03115515|Thyroid Stimulating Hormone
806721|NCT03115489|seizure
806722|NCT03115489|glutamate activation
806723|NCT03115489|N-Methyl D-Aspartate
806724|NCT03115489|GABA receptor
806725|NCT03115489|Ketamine
806726|NCT03115463|Neonatal Resuscitation
806727|NCT03115463|Prematurity
806728|NCT03115463|Oxygen
806729|NCT03115450|External ventricular drain (EVD)
806730|NCT03115450|Placement of Bolt
806731|NCT03115437|Body mass
806732|NCT03115437|Running-related injury
806733|NCT03115437|Sports injury prevention
806734|NCT03115437|Impact forces
806735|NCT03115437|Epidemiology
806736|NCT03115437|Running biomechanics
806737|NCT03115437|Sports footwear
806738|NCT03115437|Shoe cushioning
806739|NCT03115424|Weight Loss
806740|NCT03115424|Bariatric Surgery
806741|NCT03115398|Fitness Tracker
806742|NCT03115398|Activity Monitoring
806743|NCT03115398|Chemotherapy
806744|NCT03115398|Radiation Therapy
806745|NCT03115398|Chemoradiotherapy
806746|NCT03115359|Chronic Low Back Pain
806747|NCT03115359|Opioid Therapy
806748|NCT03115359|Chronic Pain
806749|NCT03115359|Mindfulness Meditation
806750|NCT03115359|Cognitive Behavioral Therapy
806751|NCT03115359|Opioid-treated Chronic Low Back Pain
806752|NCT03115359|CLBP
806753|NCT03115307|Insemination
806754|NCT03115307|Luteal phase support
806755|NCT03115307|Gonadotropin-releasing hormone agonist
806756|NCT03115307|Triptoreline
806757|NCT03115268|social support
806758|NCT03115255|retinopathy of prematurity
806759|NCT03115255|ranibizumab
806760|NCT03115255|vascular endothelial growth factor
806761|NCT03115229|Obesity
806762|NCT03115229|Overweight
806763|NCT03115229|Physical Activity
806764|NCT03115229|Nutrition
806765|NCT03115229|Nursing
806766|NCT03115203|muscle skin
806767|NCT03115203|IRM 3 tesla
806768|NCT03115138|Biopsy
806769|NCT03115125|B lymphocyte
806777|NCT03115073|Vulvovaginal candidiasis
806778|NCT03115073|Candiplus
806779|NCT03115073|Clotrimazole
806780|NCT03115073|Safety
806781|NCT03115073|Tolerability
806782|NCT03115073|Clinical efficacy
806783|NCT03115034|carotid stenosis
806784|NCT03115034|melatonin
806785|NCT03115034|vascular injury
806786|NCT03115034|ischemia reperfusion
806787|NCT03114995|Tirofiban
806788|NCT03114995|Resistance to antiplatelet agents
806789|NCT03114982|Prevention of varicella
806790|NCT03114982|Varicella-zoster vaccine
806797|NCT03114943|prevention of varicella
806798|NCT03114943|Varicella-zoster vaccine
806799|NCT03114917|Suicide
806800|NCT03114917|Self-harm
806801|NCT03114917|Psychosis
806802|NCT03114917|Community
806803|NCT03114917|Suicide Prevention
806804|NCT03114917|CBT
806805|NCT03114917|CARMS
806806|NCT03114917|Randomised controlled trial
806809|NCT03114865|bone marrow
806810|NCT03114865|bone marrow transplant
806811|NCT03114865|allogeneic
806812|NCT03114865|tacrolimus
806813|NCT03114865|cyclophosphamide
806814|NCT03114865|Blinatumomab
806818|NCT03114761|Roux-en-Y Gastric Bypass
806819|NCT03114761|Internal Herniation
806820|NCT03114761|Computed Tomography
806821|NCT03114748|deep brain stimulation
806822|NCT03114748|EEG
806823|NCT03114709|Mindfulness
806824|NCT03114709|Exercise
806825|NCT03114709|Physical activity
806826|NCT03114709|Behavior change
806827|NCT03114709|Aging
806828|NCT03114709|Randomized controlled trial
806829|NCT03114709|Pilot
806830|NCT03114670|Leukemia
806831|NCT03114670|Leukemia, Myeloid
806832|NCT03114670|Recurrence
806833|NCT03114670|Neoplasms by Histologic Type
806834|NCT03114670|Disease Attributes
806835|NCT03114670|Cyclophosphamide
806836|NCT03114670|Fludarabine
806837|NCT03114670|CD123
806838|NCT03114670|Chimeric Antigen Receptor modified T-cells
806839|NCT03114631|dendritic cells, pancreatic cancer, immunotherapy
806840|NCT03114566|transplant donor
806841|NCT03114566|HLA typed
806842|NCT03114566|17-211
806843|NCT03114553|family health history
806844|NCT03114553|prevention
806845|NCT03114553|genetic risk
806846|NCT03114553|clinical decision support
806847|NCT03114527|Dedifferentiated liposarcoma
806848|NCT03114527|DDL
806849|NCT03114527|Leiomyosarcoma
806850|NCT03114527|LMS
806851|NCT03114527|Ribociclib
806852|NCT03114501|Malignant neoplasms of lip oral cavity and pharynx
806853|NCT03114501|Head and Neck Cancer
806854|NCT03114501|Yoga
806855|NCT03114501|Questionnaires
806856|NCT03114501|Surveys
806857|NCT03114462|Malignant neoplasms of respiratory and intrathoracic organs
806858|NCT03114462|Squamous cell carcinoma of the larynx
806859|NCT03114462|Stereotactic hypofractionated radioablation
806860|NCT03114462|HYDRA
806861|NCT03114462|Questionnaires
806862|NCT03114462|Surveys
806863|NCT03114423|EMDR
806864|NCT03114423|Psychotherapy
806865|NCT03114423|Substance Use Disorders
806866|NCT03114423|Eye Movement Desensitization and Reprocessing
806867|NCT03114371|Prader-Willi syndrome
806868|NCT03114371|Oxytocin
806869|NCT03114371|Behavioural troubles
806870|NCT03114358|De-escalation
806871|NCT03114358|Carbapenems
806872|NCT03114358|Antimicrobial stewardship
806873|NCT03114345|Pressure ulcer
806874|NCT03114345|Interface pressure
806875|NCT03114345|Pressure mapping device
806876|NCT03114345|Monitoring
806877|NCT03114345|Microvascularization
806878|NCT03114319|TNO155
806879|NCT03114319|SHP2
806880|NCT03114319|advanced solid tumor
806881|NCT03114319|NSCLC
806882|NCT03114319|HNSCC
806883|NCT03114319|EGFR
806884|NCT03114319|GIST
806885|NCT03114319|PTPN11
806886|NCT03114319|cancers with a mass
806887|NCT03114319|bulky tumor
806888|NCT03114319|nodule
806889|NCT03114319|lump
806890|NCT03114319|advanced solid malignancies
806891|NCT03114306|ERAS
806892|NCT03114306|pain
806893|NCT03114306|knee arthroplasty
806894|NCT03114306|joint pain
806895|NCT03114306|regional anaesthesia
806896|NCT03114293|Physical activity
806897|NCT03114293|Mobility
806898|NCT03114254|Recurrent
806899|NCT03114254|Locally advanced
806900|NCT03114254|Metastatic
806901|NCT03114241|COPD
806902|NCT03114241|Physical activity
806903|NCT03114241|Endothelial function
806904|NCT03114228|myeloid
806905|NCT03114228|leukemia
806906|NCT03114228|FLT3-mutated
806907|NCT03114228|PKC412
806908|NCT03114228|midostaurin
806909|NCT03114228|adult
806910|NCT03114228|AML
806911|NCT03114228|ETP
806912|NCT03114228|FMS-like tyrosine kinase receptor
806913|NCT03114228|Acute myeloid leukemia
806914|NCT03114215|Biotin
806915|NCT03114215|MD1003
806916|NCT03114215|ALSFRS-R
806917|NCT03114189|Sleep disturbance
806918|NCT03114189|footbath
806919|NCT03114189|Kneipp
806920|NCT03114189|care of sleep
806921|NCT03114189|sleep
806922|NCT03114150|physical activity
806923|NCT03114150|aging
806924|NCT03114150|learning and memory
806925|NCT03114150|exercise
806926|NCT03114150|brain
806927|NCT03114137|Sub-Saharan Africa
806928|NCT03114137|Sickle Cell Disease
806929|NCT03114137|Vasculopathy
806930|NCT03114137|Nephropathy
806931|NCT03114137|Pulmonary hypertension
806932|NCT03114137|cardiac disease
806933|NCT03114137|hemolysis
806934|NCT03114137|pulse wave velocity
806935|NCT03114137|blood viscosity
806936|NCT03114124|ablation
806937|NCT03114124|atrioventricular node
806938|NCT03114124|microfidelity
806939|NCT03114098|Drug Resistance
806940|NCT03114098|CYP2D6
806941|NCT03114098|cytochrom P450
806942|NCT03114072|Pregnancy
806943|NCT03114072|Blue-blockers
806944|NCT03114072|Sleep quality
806945|NCT03114072|Melatonin
806946|NCT03114059|Late Effects of Surgery
806947|NCT03114033|Cardiac Arrest
806948|NCT03114033|Intensive Care Unit
806949|NCT03114033|Therapeutic Mild Hypercapnia
806950|NCT03114033|Normocapnia
806951|NCT03114033|Mortality
806952|NCT03114033|Neurological function
806953|NCT03114020|Emphysema
806954|NCT03114020|COPD
806955|NCT03114020|Alpha-1 Antitrypsin Deficiency
806956|NCT03114007|Mental health problems
806957|NCT03114007|Substance misuse
806958|NCT03114007|Psychosocial difficulties
806959|NCT03114007|Youth
806960|NCT03113994|Spinal Cord Injury
806961|NCT03113994|Osteoporosis
806962|NCT03113994|Cardiometabolic Syndrome
806963|NCT03113916|Culturally-tailored
806964|NCT03113916|Weight Loss
806965|NCT03113916|Diabetes
806966|NCT03113916|Women
806967|NCT03113916|Hispanic
806968|NCT03113916|Obesity
806969|NCT03113903|Pain
806970|NCT03113903|psychophysics
806971|NCT03113903|Nociception
806972|NCT03113903|Sensitivity
806973|NCT03113903|Senses
806974|NCT03113903|Phenotyping
806975|NCT03113903|Questionnaire
806976|NCT03113903|Anxiety
806977|NCT03113903|Depression
806978|NCT03113903|Catastrophizing
806986|NCT03113864|Vision
806987|NCT03113864|Eye Health
806988|NCT03113864|Lutein
806989|NCT03113864|Carotenoids
806990|NCT03113838|Drug-Induced Liver Injury
806991|NCT03113825|breast carcinoma
806992|NCT03113825|DCIS
806993|NCT03113786|Discectomy
806994|NCT03113786|Lumbar discectomy
806995|NCT03113786|Protruding disc
806996|NCT03113747|Allogeneic adipose-derived stem cells
806997|NCT03113747|burn wounds
806998|NCT03113747|wound healing
806999|NCT03113747|regeneration
807000|NCT03113747|repair
807001|NCT03113747|skin tissue engineering
807002|NCT03113708|heparin
807003|NCT03113708|heparin antagonists
807004|NCT03113708|cardiac surgery
807005|NCT03113708|active clotting time
807006|NCT03113695|Richter's Syndrome
807007|NCT03113695|CLL
807008|NCT03113695|Chronic Lumphocytic Leukemia
807009|NCT03113695|obinutuzumab
807010|NCT03113695|HDMP
807011|NCT03113695|lenalidomide
807012|NCT03113695|cancer
807013|NCT03113695|methylprednisolone
807016|NCT03113630|Amyotrophic Lateral Sclerosis
807017|NCT03113630|Virtual Reality Exposure Therapy
807018|NCT03113630|User-Computer Interface
807019|NCT03113630|Rehabilitation
807020|NCT03113630|Motor Activity
807021|NCT03113591|total hip arthroplasty
807022|NCT03113591|minimal invasive
807023|NCT03113578|Balloon enteroscopy
807024|NCT03113578|colonoscopy
807025|NCT03113578|polyps
807026|NCT03113461|cognitive impairment
807027|NCT03113461|sleep apnea
807028|NCT03113461|positive airway pressure therapy
807029|NCT03113448|capsaicin
807030|NCT03113448|neuropathic pain
807031|NCT03113448|diabetic neuropathy
807032|NCT03113448|topical lotion
807033|NCT03113435|CO2 gap
807034|NCT03113435|oxygen consumption
807035|NCT03113435|Stroke volume optimization
807036|NCT03113422|High Tumor Burden Follicular Lymphoma
807037|NCT03113422|Venetoclax
807038|NCT03113422|Obinutuzumab
807039|NCT03113422|Bendamustine
807040|NCT03113422|Bcl-2 Family Protein Inhibitor
807041|NCT03113422|Monoclonal Antibody
807042|NCT03113409|Outpatient detoxification
807043|NCT03113409|Opioid dependence
807044|NCT03113409|Naltrexone
807045|NCT03113409|Vivitrol
807046|NCT03113409|Buprenorphine
807047|NCT03113370|n-3 polyunsaturated fatty acids
807048|NCT03113370|tobacco use
807049|NCT03113370|postpartum
807050|NCT03113357|myofascial release
807051|NCT03113357|cervicogenic headache
807052|NCT03113357|pain intensity
807053|NCT03113357|exercise therapy
807054|NCT03113357|pressure pain threshold
807055|NCT03113331|Intrauterine growth restriction
807056|NCT03113331|Preterm birth
807057|NCT03113331|Birth defect
807058|NCT03113331|Infant growth
807059|NCT03113331|Neurodevelopmental outcomes
807060|NCT03113318|Pulmonary neoplasm
807061|NCT03113318|Metastasis
807062|NCT03113318|colorectal neoplasm
807063|NCT03113305|Gastric bypass
807064|NCT03113305|Morbid obesity
807065|NCT03113305|Food choice
807066|NCT03113305|Ingestive behaviour
807067|NCT03113292|physical therapy
807068|NCT03113292|therapeutic exercises
807069|NCT03113292|low back pain
807070|NCT03113266|anti-PD-1 monoclonal antibody
807071|NCT03113266|Metastatic
807072|NCT03113266|Advanced
807073|NCT03113266|Bladder Urothelial Carcinoma
807074|NCT03113253|Tranexamic Acid
807075|NCT03113253|Burn
807076|NCT03113253|Surgery
807077|NCT03113253|Excision
807078|NCT03113240|Glutamin
807079|NCT03113240|Enteral Nutrition
807080|NCT03113240|Intensive Care Unit
807081|NCT03113240|Intestinal Permeability
807082|NCT03113227|induction of labor
807083|NCT03113227|Bishop score
807084|NCT03113227|posterior cervical angle
807085|NCT03113227|cervical length
807086|NCT03113201|Depression
807087|NCT03113201|Collaborative care
807088|NCT03113201|Care manager
807089|NCT03113201|Anxiety
807090|NCT03113201|Psychiatry
807091|NCT03113201|Consultation-liaison
807092|NCT03113201|General practitioner
807093|NCT03113175|Anxiety
807094|NCT03113175|Collaborative care
807095|NCT03113175|Consultation-liaison
807096|NCT03113175|General practitioner
807097|NCT03113175|Psychiatry
807098|NCT03113162|multiple sclerosis
807099|NCT03113162|HSCT
807100|NCT03113149|Physical Therapy Modalities
807101|NCT03113149|Recovery of Function
807102|NCT03113149|Predictive Value of Tests
807103|NCT03113149|Cohort Studies
807104|NCT03113123|Adherence
807105|NCT03113123|Prevention
807106|NCT03113123|Tenofovir
807107|NCT03113123|Emtricitabine
807108|NCT03113123|Antiretroviral
807109|NCT03113123|Prophylaxis
807110|NCT03113123|Men who have sex with men
807111|NCT03113110|Empagliflozin
807112|NCT03113110|SGLT-2 Inhibition
807113|NCT03113110|Glucose Metabolism
807114|NCT03113084|Sodium Heparin
807115|NCT03113084|Pharmacokinetics
807116|NCT03113084|Coagulation factor
807117|NCT03113058|HBV infection,γδT cells,Adoptive treatment
807118|NCT03113032|total knee replacement
807119|NCT03113032|sensorimotor training
807120|NCT03113032|pre-surgery exercise
807121|NCT03113032|sensorimotor function
807122|NCT03113032|neuromuscular
807123|NCT03113019|dendritic cell, IL-12, IL-18, сytotoxicity
807124|NCT03112993|spine surgery
807125|NCT03112993|neuromuscular blockade
807126|NCT03112993|sugammadex
807127|NCT03112993|elderly
807128|NCT03112993|reversal
807129|NCT03112993|neostigmine
807130|NCT03112993|recovery
807131|NCT03112980|Aortic Valve Stenosis
807132|NCT03112980|Transcatheter Aortic Valve Replacement
807133|NCT03112980|Surgical aortic valve replacement
807134|NCT03112980|Intermediate operative risk
807135|NCT03112915|postoperative pain
807136|NCT03112915|Laparoscopic cholecystectomy
807137|NCT03112915|Quadratus lumborum block
807138|NCT03112915|transversus abdominis plan block
807139|NCT03112889|McArdle Disease
807140|NCT03112889|McArdle's Disease
807141|NCT03112889|Glycogen Storage Disease Type V
807142|NCT03112889|GSDV
807143|NCT03112889|Sodium Valproate
807144|NCT03112889|Valproic Acid
807145|NCT03112889|Myophosphorylase Deficiency
807146|NCT03112889|Muscle Phosphorylase Deficiency
807147|NCT03112889|Glycogenosis
807148|NCT03112889|Glycogen Storage Disorder
807149|NCT03112876|younger age
807150|NCT03112876|older age
807151|NCT03112876|atopic dermatitis
807152|NCT03112876|acne
807153|NCT03112876|smoker
807154|NCT03112850|Crossover design
807155|NCT03112850|Randomized controlled trial
807156|NCT03112850|Aural rehabilitation intervention
807157|NCT03112798|tracheal intubation
807158|NCT03112798|Macintosh blade
807159|NCT03112798|Miller blade
807160|NCT03112785|Hip
807161|NCT03112785|Arthroplasty
807162|NCT03112785|Stem
807163|NCT03112785|Outcome
807164|NCT03112746|child
807165|NCT03112746|goal
807166|NCT03112746|intervention
807167|NCT03112746|motor skills disorder
807168|NCT03112746|occupational therapy
807169|NCT03112655|diagnosis
807170|NCT03112655|sensitivity
807171|NCT03112655|specificity
807172|NCT03112655|therapeutic outcome
807173|NCT03112655|cerebrospinal fluid
807174|NCT03112629|Quality of Care
807175|NCT03112629|aortic stenosis
807176|NCT03112629|transcatheter aortic valve implantation
807177|NCT03112629|surgical aortic valve replacement
807178|NCT03112629|facilitated data relay
807184|NCT03112590|Histologically confirmed HER2 positive breast cancer
807185|NCT03112590|Unresectable breast cancer
807186|NCT03112590|Locally advanced breast cancer
807187|NCT03112590|Metastatic breast cancer
807188|NCT03112590|Clinical stage 2-3 early stage breast cancer
807189|NCT03112564|Endotracheal intubation
807190|NCT03112564|muscle relaxants
807191|NCT03112564|inhalational anesthesia
807192|NCT03112538|insulin pump
807193|NCT03112538|basal bolus insulin
807194|NCT03112525|rivaroxaban
807195|NCT03112525|apixaban
807196|NCT03112525|cytochrome
807197|NCT03112525|anticoagulant
807198|NCT03112525|transporter
807199|NCT03112525|polymorphism
807200|NCT03112525|genotyping
807201|NCT03112525|phenotyping
807202|NCT03112512|optimal positive end-expiratory pressure determination
807203|NCT03112512|Electrical impedance tomography
807204|NCT03112499|Acute Kidney Injury
807205|NCT03112499|PCNL
807206|NCT03112499|mini-PCNL
807207|NCT03112499|RIRS
807208|NCT03112499|urine biomarkers
807209|NCT03112486|out-of-hospital cardiac arrrest
807210|NCT03112486|neurological outcome
807211|NCT03112486|prognostication
807212|NCT03112486|cerebral performance category
807213|NCT03112486|hypoxic-ischemic brain injury
807214|NCT03112486|biomarkers
807215|NCT03112460|Cardiopulmonary Resuscitation
807216|NCT03112447|medial epicondyle humerus
807217|NCT03112447|absorbable cartilage nail
807218|NCT03112421|IVD
807219|NCT03112408|cerebellar lesion
807220|NCT03112408|saccadic adaptation
807221|NCT03112408|spatial localization
807222|NCT03112408|visuo spatial perception
807223|NCT03112408|eye movements
807224|NCT03112369|American Indian / Alaska Native
807225|NCT03112369|HIV Prevention
807226|NCT03112369|Sexual Risk Behavior
807227|NCT03112369|Trauma
807228|NCT03112369|Substance Use
807233|NCT03112343|ICT based clinical trial
807234|NCT03112343|Contract research organization (CRO)
807235|NCT03112343|eCRF
807236|NCT03112343|Joint Electronic-institutional review board (eIRB)
807237|NCT03112343|Centralized monitoring
807238|NCT03112330|atrophic rhinitis
807239|NCT03112317|Surgery
807240|NCT03112317|Hypothermia
807241|NCT03112317|Prevention
807242|NCT03112317|Surgical Site Infection
807243|NCT03112317|Bleeding
807244|NCT03112304|children
807245|NCT03112304|youth
807246|NCT03112304|adolescents
807247|NCT03112304|anxiety
807248|NCT03112304|depression
807249|NCT03112304|trauma
807250|NCT03112304|behavior problems
807251|NCT03112304|evidence-based treatments
807252|NCT03112304|manualized
807253|NCT03112304|cognitive-behavioral therapy
807254|NCT03112304|mental health
807255|NCT03112291|anti-microbial agents
807256|NCT03112291|apexification
807257|NCT03112291|dental pulp
807258|NCT03112291|endodontics
807259|NCT03112291|root canal therapy
807260|NCT03112291|dental trauma
807261|NCT03112278|tooth erosion
807262|NCT03112278|Computer-Aided Design
807263|NCT03112278|occlusal veneers
807264|NCT03112278|dental veneers
807265|NCT03112265|anxiety
807266|NCT03112265|depression
807267|NCT03112265|trauma
807268|NCT03112265|behavior problems
807269|NCT03112265|evidence-based treatments
807270|NCT03112265|manualized treatments
807271|NCT03112265|cognitive-behavioral therapy
807272|NCT03112265|youth
807273|NCT03112265|mental health
807274|NCT03112265|self-regulation
807275|NCT03112265|neuroimaging
807276|NCT03112252|Immunotherapy
807277|NCT03112239|Asthma
807278|NCT03112239|Photobiomodulation
807279|NCT03112239|Resistance Training
807280|NCT03112226|cognitive impairment
807281|NCT03112226|menopause
807282|NCT03112226|estrogen
807283|NCT03112226|functional MRI
807284|NCT03112226|executive function
807285|NCT03112226|endothelial function
807286|NCT03112226|arterial stiffness
807287|NCT03112200|Subchondroplasty
807288|NCT03112200|Arthroscopy
807289|NCT03112200|Bone Substitute Material
807290|NCT03112200|Subchondral Bone Defect
807291|NCT03112200|AccuFill
807292|NCT03112200|Bone Marrow Lesion
807293|NCT03112187|IDA
807294|NCT03112187|iron deficiency anemia
807295|NCT03112187|iron supplements
807296|NCT03112187|Pakistan
807297|NCT03112187|Liposomal iron
807298|NCT03112174|PCYC
807299|NCT03112174|MCL
807300|NCT03112174|Non-Hodgkin's Lymphoma
807301|NCT03112174|NHL
807302|NCT03112174|ibrutinib
807303|NCT03112174|venetoclax
807304|NCT03112174|Pharmacyclics
807305|NCT03112122|Bone Marrow Edema
807306|NCT03112122|Mesenchymal Stem Cells
807307|NCT03112096|Tau
807308|NCT03112096|neurodegeneration
807309|NCT03112096|positron emission tomography
807310|NCT03112083|krill powder
807311|NCT03112083|krill oil
807312|NCT03112083|safety
807313|NCT03112083|tolerability
807314|NCT03112083|adverse event
807315|NCT03112083|omega-3 fatty acids
807316|NCT03112083|eicosapentaenoic acid
807317|NCT03112083|docosahexaenoic acid
807318|NCT03112044|Lung
807319|NCT03112044|Transplant
807320|NCT03112044|Hepatitis C
807321|NCT03112044|DAAs
807322|NCT03112044|Epclusa
807323|NCT03112031|Tamoxifen
807324|NCT03112031|Cryptococcal meningitis
807325|NCT03112031|Cryptococcus neoformans
807326|NCT03112031|Human immunodeficiency virus
807327|NCT03112018|premature birth
807328|NCT03112018|neonatal mortality
807329|NCT03112018|premature infant
807330|NCT03112005|Diabetic Eye Disease
807331|NCT03111992|Myeloma,
807332|NCT03111992|Multiple Myeloma,
807333|NCT03111992|Hematologic Diseases,
807334|NCT03111992|Myeloma, Multiple,
807335|NCT03111992|Myeloma-Multiple,
807336|NCT03111992|Programmed Cell Death 1 Receptor
807337|NCT03111979|beta-alanine
807338|NCT03111979|Carnosine
807339|NCT03111979|Neuromuscular
807340|NCT03111979|Stimulation
807341|NCT03111979|Skeletal muscle
807342|NCT03111966|Hepatitis C
807343|NCT03111953|Bariatric Surgery
807344|NCT03111953|Roux-en-Y gastric bypass
807345|NCT03111953|Biliopancreatic Diversion
807346|NCT03111927|Nutrition, Brain Development, Cognition, Heathy Infants
807347|NCT03111901|pembrolizumab
807348|NCT03111901|IL-2
807349|NCT03111901|interleukin-2
807350|NCT03111901|MK-3475
807351|NCT03111875|Hypothermia
807352|NCT03111875|Intraoperative warming
807353|NCT03111875|non-cardiac surgery
807354|NCT03111875|myocardial injury
807355|NCT03111849|COPD
807356|NCT03111849|Sarcopenia
807357|NCT03111849|Prevalence
807358|NCT03111849|Mortality
807359|NCT03111849|Malnutrition
807360|NCT03111849|Nutritional assessment
807361|NCT03111849|Body composition
807362|NCT03111849|Pulmonary cachexia
807363|NCT03111810|Corticosteroids
807364|NCT03111810|Prednisolone
807365|NCT03111810|11 beta-Hydroxysteroid dehydrogenase1 inhibitor
807366|NCT03111810|Iatrogenic Cushing's disease
807367|NCT03111810|AZD4017
807368|NCT03111784|Fish Consumption, Fatty acid composition, Lipid Profile, Tocopherol, Sociodemographics
807369|NCT03111771|Cancer
807370|NCT03111771|Cachexia
807371|NCT03111771|Myosteatosis
807372|NCT03111771|Mitochondrial activity
807373|NCT03111771|Upper aerodigestive pathways
807374|NCT03111771|Lipotoxicity
807378|NCT03111732|Immune-Based Strategies
807379|NCT03111732|Anti-PD1 Therapy
807380|NCT03111732|Chronic Inflammation
807381|NCT03111732|Combination Chemotherapy
807382|NCT03111693|Epicardial fat
807383|NCT03111693|Obesity
807384|NCT03111693|Cardiovascular risks markers
807385|NCT03111693|Metabolic syndrome
807386|NCT03111693|Low dose computed tomography
807387|NCT03111667|Marijuana
807388|NCT03111667|Motivational Enhancement Therapy
807389|NCT03111667|Adolescents
807390|NCT03111615|Aromatase inhibitors
807514|NCT03111043|Clinical outcome
807391|NCT03111615|Luminal Breast Cancer neoadjuvant hormone therapy
807392|NCT03111602|polyphenols
807393|NCT03111602|pregnant
807394|NCT03111602|fetal ductal constriction
807395|NCT03111602|prostaglandin E2
807396|NCT03111589|Sickle Cell Disease
807397|NCT03111589|Heme oxidase-1 (HO-1)
807398|NCT03111537|cigarette
807399|NCT03111537|smoking
807400|NCT03111537|snus
807401|NCT03111537|e-cigarette
807402|NCT03111537|nicotine replacement therapy
807403|NCT03111537|nrt
807404|NCT03111537|tobacco
807405|NCT03111524|stuttering
807406|NCT03111524|children who stutter
807407|NCT03111524|peer attitudes
807408|NCT03111524|classroom-based intervention
807409|NCT03111524|teasing
807410|NCT03111524|bullying
807411|NCT03111498|Vacuum assisted delivery
807412|NCT03111498|technical skills
807413|NCT03111498|training
807414|NCT03111459|endograft repair,
807415|NCT03111433|Type 1 Diabetes mellitus
807416|NCT03111433|Coenzyme Q10
807417|NCT03111433|endothelial dysfunction
807418|NCT03111433|pediatric patients
807419|NCT03111407|primary total knee arthroplasty
807420|NCT03111394|MS
807421|NCT03111394|23andMe
807422|NCT03111394|MRI
807423|NCT03111394|Genome-wide association studies
807424|NCT03111368|eus-fna
807425|NCT03111368|pancreatic neoplasm
807426|NCT03111368|slow-pull
807427|NCT03111368|negative pressure
807428|NCT03111355|nuts
807429|NCT03111355|micronutrients
807430|NCT03111355|nutrigenomics
807431|NCT03111355|nutrigenetics
807432|NCT03111342|Intrauterine contraception
807433|NCT03111342|Pain
807434|NCT03111342|Anesthesia
807435|NCT03111342|LNG-IUD
807436|NCT03111342|nulligravida
807437|NCT03111329|Gastric residuals assessment
807438|NCT03111329|Prematurity
807439|NCT03111329|Necrotizing Enterocolitis of Newborn
807440|NCT03111329|Sepsis Newborn
807441|NCT03111329|Nutrition of newborn
807442|NCT03111329|feeding tolerance of newborn
807443|NCT03111316|Cervical Ripening
807444|NCT03111316|Induction of Labor
807445|NCT03111290|Facial recognition
807446|NCT03111277|neuropathic pain
807447|NCT03111264|Overweight
807448|NCT03111264|Obesity
807449|NCT03111264|Prevention
807450|NCT03111264|Children
807451|NCT03111264|Childcare
807452|NCT03111264|Physical Activity
807453|NCT03111264|Nutrition
807454|NCT03111264|Wellness
807455|NCT03111264|Environment
807456|NCT03111264|Intervention
807457|NCT03111264|Feeding
807458|NCT03111238|Autologous
807459|NCT03111238|Bone Marrow-derived Mononuclear Cells (BM-MNCs)
807460|NCT03111238|Advanced Therapy Medicinal Product (ATMP)
807461|NCT03111238|Tissue-engineered Medicinal Product
807462|NCT03111238|Revascularization
807463|NCT03111238|Angiogenesis
807464|NCT03111238|Vasculogenesis
807465|NCT03111238|Arteriogenesis
807466|NCT03111212|Acute respiratory distress syndrome
807467|NCT03111199|Low back pain
807468|NCT03111199|Analgesia
807469|NCT03111199|Physical therapy
807470|NCT03111186|oxycodone
807471|NCT03111186|ibuprofen
807472|NCT03111186|acetaminophen
807473|NCT03111186|soft-tissue hand surgery
807474|NCT03111186|carpal tunnel release
807475|NCT03111186|Dupuytren contracture release
807476|NCT03111186|Trigger digit release
807477|NCT03111186|Ganglion cyst removal
807478|NCT03111186|De Quervain's release
807479|NCT03111173|ECG
807480|NCT03111173|Fetus
807481|NCT03111173|R peak extraction
807482|NCT03111160|Small-incision lenticule extraction
807483|NCT03111160|femtosecond laser
807484|NCT03111160|lower laser energy level
807485|NCT03111160|early visual recovery
807486|NCT03111134|abdominal wound closure techniques
807487|NCT03111134|layered closure
807488|NCT03111134|component separation technique
807489|NCT03111121|deeply anesthetized
807490|NCT03111121|ideal surgical exposure
807491|NCT03111121|muscle relaxation
807492|NCT03111121|Adults
807493|NCT03111069|Malignant neoplasms of mesothelial and soft tissue
807494|NCT03111069|Pelvic and Abdominal Rhabdomyosarcoma
807495|NCT03111069|Undifferentiated Sarcomas
807496|NCT03111069|Unresectable or Refractory
807497|NCT03111069|Abdominal tumors
807498|NCT03111069|Hyperthermic intra-peritoneal chemotherapy
807499|NCT03111069|HIPEC
807500|NCT03111069|Abdominal surgery
807501|NCT03111069|Doxorubicin
807502|NCT03111069|Doxorubicin Hydrochloride
807503|NCT03111069|Adriamycin PFS
807504|NCT03111069|Adriamycin RDF
807505|NCT03111069|Adriamycin
807506|NCT03111069|Rubex
807507|NCT03111069|Intra-operative radiation
807508|NCT03111069|IORT
807509|NCT03111069|Brachytherapy
807510|NCT03111043|computed tomography
807511|NCT03111043|Sudden cardiac arrest
807512|NCT03111043|Cardiac computed tomography
807513|NCT03111043|Diagnostic accuracy
807515|NCT03111017|muscle sympathetic nerve activity
807516|NCT03111017|exercise tolerance
807517|NCT03111017|exercise training
807518|NCT03111017|peak oxygen uptake
807519|NCT03111004|information technology
807520|NCT03111004|telemedicine
807521|NCT03111004|integrated care
807522|NCT03111004|MAST framework
807523|NCT03111004|organizational change
807524|NCT03111004|social care
807525|NCT03111004|elderly patients
807526|NCT03110991|Depression
807527|NCT03110991|Depressive symptoms
807528|NCT03110991|Prevention
807529|NCT03110991|Non-professional caregivers
807530|NCT03110991|App
807544|NCT03110913|Healthy
807545|NCT03110913|Men
807546|NCT03110913|Adults
807547|NCT03110913|Methionine
807548|NCT03110887|Dynamic prediction model
807549|NCT03110822|Ruxolitinib
807550|NCT03110822|Steroids
807551|NCT03110822|Lenalidomide
807552|NCT03110822|Relapsed/Refractory Multiple Myeloma
807553|NCT03110809|obesity
807554|NCT03110809|brown
807555|NCT03110809|fat
807556|NCT03110809|weight
807557|NCT03110809|loss
807558|NCT03110783|Bioseal as an Adjunct to Sutured Dural Repair
807559|NCT03110783|elective posterior fossa
807560|NCT03110783|supratentorial procedure
807567|NCT03110757|GLA-AF
807568|NCT03110757|healthy adults
807569|NCT03110757|Immunogenicity
807570|NCT03110757|Phase Ib
807571|NCT03110757|Reactogenicity
807572|NCT03110757|Safety
807573|NCT03110757|Schistosomiasis
807574|NCT03110757|Sm-TSP-2/Alhydrogel®
807575|NCT03110718|robotic rehabilitation
807576|NCT03110718|muscle vibration
807577|NCT03110718|combined approach
807578|NCT03110679|osteoarthritis
807579|NCT03110679|autologous bone marrow concentrate
807580|NCT03110666|knee osteoarthritis ,
807581|NCT03110666|bone marrow aspirate
807582|NCT03110666|injections
807583|NCT03110627|Single-chamber ICD (implantable cardioverter-defibrillator)
807584|NCT03110627|Cardiac Arrhythmias
807585|NCT03110627|Atrial fibrillation
807586|NCT03110627|Atrial flutter
807587|NCT03110627|Stroke
807588|NCT03110614|COPD
807589|NCT03110614|acute
807590|NCT03110614|exacerbation
807591|NCT03110614|lung ultrasound
807595|NCT03110575|TNX-102 SL
807596|NCT03110575|Bedtime
807597|NCT03110575|Sublingual
807598|NCT03110575|3-month
807599|NCT03110575|Safety
807600|NCT03110575|Efficacy
807601|NCT03110575|PTSD
807602|NCT03110562|Relapsed or Refractory Multiple Myeloma
807603|NCT03110562|RRMM
807604|NCT03110562|Bortezomib
807605|NCT03110562|Dexamethasone
807606|NCT03110536|Burnout syndrome
807607|NCT03110536|Triage
807608|NCT03110536|Nurse
807609|NCT03110536|Emergency Department
807610|NCT03110536|Romania
807611|NCT03110497|Cervical cancer
807612|NCT03110497|Image guided Brachytherapy
807613|NCT03110497|single application
807614|NCT03110471|Cognitive impairment
807615|NCT03110471|antipsychotics
807616|NCT03110471|antidepressants
807618|NCT03110419|Elderly
807619|NCT03110419|Frailty
807620|NCT03110419|Multicomponent training
807621|NCT03110419|Physical exercise
807622|NCT03110419|Functional capacity
807623|NCT03110419|Complexity
807624|NCT03110419|Physical Therapy
807625|NCT03110406|renal transplant recipients
807626|NCT03110406|exercise
807627|NCT03110406|heart rate variability
807628|NCT03110406|Cardiovascular mortality
807629|NCT03110393|Obese
807630|NCT03110393|Laryngeal Mask Airway
807631|NCT03110393|Anaesthesia
807632|NCT03110354|AML
807633|NCT03110354|ALL
807634|NCT03110315|Multiple Sclerosis
807635|NCT03110315|Fatigue
807636|NCT03110315|Insomnia
807637|NCT03110315|Suvorexant
807638|NCT03110315|Belsomra
807639|NCT03110315|Sleep disorder
807640|NCT03110315|Sleep
807641|NCT03110302|Posttraumatic Stress Disorder
807642|NCT03110302|Telehealth
807643|NCT03110302|Video teleconferencing
807644|NCT03110302|In home therapy
807645|NCT03110302|Prolonged Exposure
807646|NCT03110289|Fecal microbiota transplantation
807647|NCT03110250|Familial Hypercholesterolemia
807648|NCT03110250|registry
807649|NCT03110250|Turkey
807650|NCT03110250|Lipid lowering therapy
807651|NCT03110224|Subchondroplasty
807652|NCT03110224|Bone Marrow Lesion
807653|NCT03110224|Arthroscopy
807654|NCT03110224|Bone Substitute Material
807655|NCT03110224|AccuFill
807656|NCT03110224|Subchondral Bone Defect
807657|NCT03110198|Mesalazine
807658|NCT03110198|Ulcerative Colitis(UC)
807659|NCT03110198|Enema
807660|NCT03110172|Osteoarthritis
807661|NCT03110172|Depression
807662|NCT03110172|Pain
807663|NCT03110159|Photodynamic therapy
807664|NCT03110159|Prevention
807665|NCT03110159|Actinic Keratosis
807666|NCT03110159|Skin Cancer
807667|NCT03110159|Non-melanoma Skin Cancer
807668|NCT03110159|Sun Damaged Skin
807669|NCT03110159|Solid Organ Transplant
807670|NCT03110159|PDT
807677|NCT03110068|microvascular invasion
807678|NCT03110068|serum biomarker
807679|NCT03110068|radiological feature
807680|NCT03110068|pathological differentiation
807681|NCT03110003|Neuraxial epidural techniques
807682|NCT03110003|Combined spinal epidural
807683|NCT03110003|Epidural volume extension
807684|NCT03110003|Transient Neurologic Symptoms (TNS)
807685|NCT03109977|17-059
807686|NCT03109977|Zr-DFO-pertuzumab
807687|NCT03109951|Type 2 diabetes
807688|NCT03109951|colonoscopy
807689|NCT03109951|hypoglycemia
807690|NCT03109951|hyperglycemia
807691|NCT03109951|polyethylene glycol
807692|NCT03109925|PAE
807693|NCT03109925|embolization
807694|NCT03109925|non-surgical
807695|NCT03109925|prostate artery embolization
807696|NCT03109925|radio-opaque embolic
807697|NCT03109899|mHealth
807698|NCT03109899|HIV Prevention
807699|NCT03109886|Unresectable Hepatocellular Carcinoma
807700|NCT03109886|Metastatic Hepatocellular Carcinoma
807701|NCT03109886|Child-Pugh Class A
807702|NCT03109860|Chronic neuropathic pain
807703|NCT03109834|Weight Management Programs
807704|NCT03109834|Weight loss stabilization
807705|NCT03109834|Cardiometabolic risk
807708|NCT03109782|Spinal Cord Injury
807709|NCT03109782|Spine Surgery
807710|NCT03109782|Patient Registry
807711|NCT03109782|Trauma
807712|NCT03109743|HIV treatment
807713|NCT03109743|Adherence Group Treatment
807714|NCT03109717|Treatment Resistant Depression
807715|NCT03109704|scapular kinematics
807716|NCT03109704|thoracic spine
807717|NCT03109704|thrust manipulation
807718|NCT03109652|total knee replacement arthroplasty
807719|NCT03109652|total knee arthroplasty
807720|NCT03109652|tranexamic acid
807721|NCT03109652|oral tranexamic acid
807722|NCT03109652|transfusion
807723|NCT03109652|blood loss
807724|NCT03109639|EUS
807725|NCT03109639|FNA
807726|NCT03109639|FNB
807727|NCT03109639|Core Histology
807728|NCT03109626|DHA, replacement, treatment, brain PET-FDG, ataxia
807729|NCT03109613|Positive end-expiratory pressure
807730|NCT03109613|PEEP
807731|NCT03109613|Bronchopulmonary Dysplasia
807732|NCT03109613|Ventilator Induced Lung Injury
807733|NCT03109613|V/Q mismatch
807734|NCT03109522|axillary reverse mapping (ARM)
807735|NCT03109522|sentinel lymph node biopsy (SLNB)
807736|NCT03109522|axillary lymph node dissection (ALND)
807737|NCT03109522|lymphedema
807738|NCT03109522|breast cancer
807739|NCT03109522|surgery
807740|NCT03109496|OME
807741|NCT03109496|Otitis Media with Effusion
807742|NCT03109496|Microbiota
807743|NCT03109496|Microbiome
807744|NCT03109496|URT
807745|NCT03109496|Upper Respiratory Tract
807746|NCT03109496|Healthy URT microbiota
807747|NCT03109483|geriatric patients
807748|NCT03109483|elderly
807749|NCT03109483|multicomponent physical therapy
807750|NCT03109470|Tocilizumab
807751|NCT03109470|Early Rheumatoid Arthritis
807752|NCT03109470|Observational
807753|NCT03109470|Canadian
807754|NCT03109457|Hepatitis C Virus
807755|NCT03109457|Oral squamous cell carcinoma
807756|NCT03109444|Hip Growth Chart
807757|NCT03109431|HIV Treatment Continuum
807758|NCT03109431|HIV Disease Progression
807759|NCT03109431|Mental Health
807760|NCT03109431|Substance Use
807761|NCT03109431|ARV Adherence
807762|NCT03109431|Retention in Care
807763|NCT03109431|STI
807764|NCT03109418|Ketamine
807765|NCT03109418|Postoperative morbidity
807766|NCT03109353|Photopheresis
807767|NCT03109353|5-aminolevulinic acid
807768|NCT03109353|Extracorporeal Circulation
807769|NCT03109340|abdominal obesity
807770|NCT03109340|walking
807771|NCT03109340|aerobic exercise
807772|NCT03109314|amblyopia
807773|NCT03109314|donepezil
807774|NCT03109314|perceptual learning
807775|NCT03109314|crowding
807776|NCT03109314|contrast sensitivity
807777|NCT03109314|visual acuity
807785|NCT03109184|Dating violence prevention
807786|NCT03109184|Adolescent boys
807787|NCT03109184|Middle school
807788|NCT03109184|Web-based prevention
807789|NCT03109171|Endoscopy
807790|NCT03109171|Lasers
807791|NCT03109171|Fiber Optic Technology
807792|NCT03109171|Bronchoscopy
807793|NCT03109171|Esthesiometer
807794|NCT03109171|Mechanoreceptors
807795|NCT03109171|Diagnosis
807796|NCT03109171|Reflex
807797|NCT03109171|Reproducibility of Results
807798|NCT03109171|Reliability of Results
807799|NCT03109171|Validity of Results
807800|NCT03109171|Sensory Thresholds
807801|NCT03109158|squamous cell carcinoma
807802|NCT03109158|head
807803|NCT03109158|neck
807804|NCT03109145|Shared decision making
807805|NCT03109145|Knowledge
807806|NCT03109145|Patient portal
807807|NCT03109145|Secure messaging
807808|NCT03109119|genomic instability
807809|NCT03109119|Sevoflurane
807810|NCT03109119|General anaesthesia
807811|NCT03109106|MICU
807812|NCT03109106|CICU
807813|NCT03109106|PCT - Procalcitonin
807814|NCT03109106|B·R·A·H·M·S PCT sensitive Kryptor®
807815|NCT03109106|Antibiotic initiation
807816|NCT03109106|Antibiotic de-escalation
807822|NCT03109067|Cholesterol, HDL, Postprandial Period, Polymorphism, Genetic
807823|NCT03109054|Melatonin
807824|NCT03109054|Anxiety
807825|NCT03109015|metastatic renal cell carcinoma
807826|NCT03109015|sunitinib
807827|NCT03109015|Sutent
807828|NCT03109015|cardiopulmonary function
807829|NCT03108976|Autism
807830|NCT03108976|Sensori-motor learning
807831|NCT03108976|Development
807832|NCT03108976|Neuroimaging
807833|NCT03108872|Anticoagulants
807834|NCT03108872|Atrial Appendage
807835|NCT03108872|Stroke
807836|NCT03108846|Alzheimer's Disease
807837|NCT03108846|Agitation
807838|NCT03108807|Emergency Department
807839|NCT03108807|Medical patients
807840|NCT03108807|D-dimer
807841|NCT03108807|National Early Warning Score
807842|NCT03108807|NEWS
807843|NCT03108807|30-days mortality
807844|NCT03108807|Mortality
807845|NCT03108794|hepatitis B，registry,cirrhosis, HCC
807846|NCT03108781|Dementia
807847|NCT03108781|Behavioral Psychiatric symptoms
807848|NCT03108781|Treatment
807849|NCT03108755|ASP7713
807852|NCT03108703|RCC
807853|NCT03108703|Stereotactic Body Radiotherapy
807854|NCT03108703|SBRT
807855|NCT03108703|Stereotactic Ablative Radiotherapy
807856|NCT03108703|SABR
807857|NCT03108690|Therapeutic drug monitoring
807858|NCT03108690|Continuous infusion
807859|NCT03108690|Beta-lactam
807860|NCT03108690|Antibiotics
807861|NCT03108690|Bacteraemia
807862|NCT03108677|RNA profiling
807863|NCT03108677|Exosome
807864|NCT03108677|Lung Metastases
807865|NCT03108677|Osteosarcoma
807868|NCT03108625|children
807869|NCT03108625|adolescent
807870|NCT03108612|diagnostic accuracy
807871|NCT03108612|upper limb
807872|NCT03108599|Health Promotion
807873|NCT03108599|Injury Prevention
807874|NCT03108599|Safety
807875|NCT03108599|Wellbeing
807876|NCT03108599|Physical Activity
807877|NCT03108599|Sleep
807878|NCT03108599|Whole Body Vibration
807879|NCT03108599|Self-Monitoring
807880|NCT03108586|restorations
807881|NCT03108586|diagnosis
807882|NCT03108586|secondary caries
807883|NCT03108586|treatment decision
807884|NCT03108560|sublobar resection
807885|NCT03108560|lobectomy
807886|NCT03108547|Sarcoidosis
807887|NCT03108547|Scalp hair cortisol and testosterone
807888|NCT03108547|Fatigue
807889|NCT03108547|Biomarker
807890|NCT03108547|Psychological distress
807891|NCT03108521|DPP - 4; GLP1R ; gene polymorphism research; diabetes
807892|NCT03108495|LN-145
807893|NCT03108495|Cell Therapy
807894|NCT03108495|Autologous Adoptive Cell Transfer
807895|NCT03108495|Autologous Adoptive Cell Therapy
807896|NCT03108495|Cellular Immuno-therapy
807897|NCT03108495|Tumor Infiltrating Lymphocytes
807898|NCT03108495|TIL
807899|NCT03108495|IL-2
807900|NCT03108482|Acute Pain
807901|NCT03108482|Post-surgical Pain
807902|NCT03108482|Bunionectomy
807903|NCT03108482|Co-crystal
807904|NCT03108482|Tramadol
807905|NCT03108482|Celecoxib
807906|NCT03108469|migraine
807907|NCT03108456|atherectomy
807908|NCT03108456|CAD
807909|NCT03108456|severe calcium
807910|NCT03108456|orbital atherectomy
807911|NCT03108456|minimum stent area
807912|NCT03108404|predictive score
807913|NCT03108378|Gadolinium
807914|NCT03108378|Bone
807915|NCT03108378|Skin
807916|NCT03108300|efficacy
807917|NCT03108300|propranolol hydrochloride
807918|NCT03108300|sts
807919|NCT03108274|Midazolam
807920|NCT03108274|Fexofenadine
807921|NCT03108274|Mycophenolate Mofetil
807922|NCT03108248|transarterial chemoembolization
807923|NCT03108248|stent
807924|NCT03108248|irradiation
807925|NCT03108248|survival
807926|NCT03108248|decompensation
807927|NCT03108248|tumor response
807928|NCT03108222|chronic kidney disease
807929|NCT03108222|CKD
807930|NCT03108222|renal failure
807931|NCT03108222|phosphorus
807932|NCT03108222|phosphate
807933|NCT03108222|intestinal absorption
807934|NCT03108196|bladder cancer， neobladder, detaenial sigmoid, ileal
807935|NCT03108157|IVF
807936|NCT03108157|DONOR EGGS
807937|NCT03108157|ENDOMETRIAL SCRATCH
807938|NCT03108157|PIPELLE
807939|NCT03108157|ONGOING PREGNANCY
807940|NCT03108144|smoking cessation
807941|NCT03108144|alcohol
807942|NCT03108144|primary care
807943|NCT03108144|screening
807944|NCT03108144|brief intervention
807945|NCT03108144|referral to treatment
807946|NCT03108144|cancer risk
807947|NCT03108131|Malignant Neoplasms of Digestive Organs
807948|NCT03108131|Melanoma and Other Malignant Neoplasms of Skin
807949|NCT03108131|Appendiceal Adenocarcinoma
807950|NCT03108131|Cutaneous Squamous Cell Carcinoma
807951|NCT03108131|Small Bowel Adenocarcinoma
807952|NCT03108131|Advanced rare tumors
807953|NCT03108131|Cobimetinib
807954|NCT03108131|Atezolizumab
807955|NCT03108131|MPDL3280A
807956|NCT03108118|Diaphragm dysfunction
807957|NCT03108118|Acute respiratory failure
807958|NCT03108118|Weaning
807959|NCT03108092|Drug Utilization Review
807960|NCT03108092|Older people
807961|NCT03108092|Health economics
807962|NCT03108079|Urologic Injuries
807963|NCT03108079|Urologic Diseases
807964|NCT03108079|Bladder Infection
807965|NCT03108079|Urinary Tract Infections
807966|NCT03108079|Mucosal Inflammation
807967|NCT03108079|Mucosal Infection
807968|NCT03108079|Bladder Injury
807969|NCT03108079|Catheter Related Infections
807970|NCT03108079|Catheter Complications
807971|NCT03108079|Catheter Infection
807972|NCT03108079|Indwelling Catheter
807973|NCT03108079|Pelvic Floor Disorders
807974|NCT03108079|Urinary Incontinence
807975|NCT03108053|urinary stones
807976|NCT03108053|semirigid ureteroscopy
807977|NCT03108053|guidewire
807978|NCT03108027|QVM149,
807979|NCT03108027|asthma,
807980|NCT03108027|allergic asthma,
807981|NCT03108027|allergy triggered asthma,
807982|NCT03108027|reactive asthma,
807983|NCT03108027|asthma attack,
807984|NCT03108027|difficulty breathing
807985|NCT03107962|NK/T cell lymphoma
807986|NCT03107962|immunotherapy
807987|NCT03107962|clinical trial
807988|NCT03107962|RR
807989|NCT03107962|PFS
807990|NCT03107962|OS
807991|NCT03107949|Diaphragm atrophy
807992|NCT03107949|VIDD
807993|NCT03107949|weaning failure
807994|NCT03107949|SBT
807995|NCT03107923|Myocardial fibrosis
807996|NCT03107923|Aortic Valve Stenosis
807997|NCT03107923|TAVI
807998|NCT03107923|Outcome
807999|NCT03107897|TAVR
808000|NCT03107897|elevated frailty score
808001|NCT03107897|Transcatheter Valve Replacement
808002|NCT03107871|valganciclovir
808003|NCT03107845|CBT
808004|NCT03107845|Psychometric Feedback
808005|NCT03107845|Clinical Support Tools
808006|NCT03107819|Plasma metabolomics
808007|NCT03107819|Urinary metabolomics
808008|NCT03107819|Metabonomics
808009|NCT03107819|Biomarker discovery
808010|NCT03107806|acute coronary syndromes
808011|NCT03107806|hyperglycemia
808012|NCT03107806|hypoglycemia
808013|NCT03107806|continuous glucose monitoring
808014|NCT03107741|Metabolic Syndrome
808015|NCT03107741|Waist circumference
808016|NCT03107741|Blood pressure
808017|NCT03107741|Triglyceride
808018|NCT03107741|HDL cholesterol
808025|NCT03107715|exclusive breastfeeding
808026|NCT03107715|health disparity
808027|NCT03107715|prenatal intervention
808028|NCT03107689|ILE
808029|NCT03107689|lipid
808030|NCT03107689|overdose
808031|NCT03107689|resuscitation
808032|NCT03107676|trunk extensors; endurance, peak torque, power, work
808033|NCT03107663|PET/CT
808034|NCT03107663|Imaging
808035|NCT03107663|89Zr-Df-IAB22M2C
808036|NCT03107663|CD8 + T Cells
808037|NCT03107663|Standard of Care
808038|NCT03107663|Check Point Inhibitor
808039|NCT03107637|Embolic Stroke of Undetermined Source
808040|NCT03107637|transesophageal echocardiography
808041|NCT03107637|cardiac source of embolism
808042|NCT03107637|ischemic stroke
808043|NCT03107598|spinal anesthesia
808044|NCT03107598|neonatal outcome
808045|NCT03107598|Caesarean Section
808046|NCT03107585|cervical plexus block
808047|NCT03107585|thyroidectomy
808048|NCT03107585|opioid consumption
808049|NCT03107559|perfüsion index
808050|NCT03107559|epidural analgesia
808051|NCT03107559|labor
808052|NCT03107546|Syndactyly
808053|NCT03107546|Syndactyly release surgery
808054|NCT03107546|Full thickness skin graft
808055|NCT03107546|Hyalomatrix
808056|NCT03107546|Scar formation
808057|NCT03107520|contrast-enhanced ultrasound
808058|NCT03107520|Lumason
808059|NCT03107520|developmental dysplasia of the hip (DDH)
808060|NCT03107520|avascular necrosis
808061|NCT03107507|EEG with Periodic Abnormalities
808062|NCT03107507|Levetiracetam
808063|NCT03107507|Phenobarbitone
808064|NCT03107507|neonatal seizures
808065|NCT03107507|Neurodevelopmental Abnormality
808066|NCT03107481|Acetaminophen
808067|NCT03107481|Hydromorphone
808068|NCT03107481|Emergency Department
808069|NCT03107481|Narcotics
808070|NCT03107481|Analgesics, Opioid
808071|NCT03107481|Analgesics, Non-Narcotic
808072|NCT03107468|Non-surgical treatment
808073|NCT03107468|Acupuncture
808074|NCT03107468|Chuna
808075|NCT03107468|Physiotherapy
808076|NCT03107468|Epidural steroid injection
808077|NCT03107455|MitraClip
808078|NCT03107455|Acute mitral regurgitation
808079|NCT03107455|Acute myocardial infarction
808080|NCT03107442|Arterial stiffness
808081|NCT03107442|Markers of Inflammation
808082|NCT03107442|Exercise
808083|NCT03107442|Physical fitness
808084|NCT03107442|Cardiovascular risk
808085|NCT03107442|Autoimmune diseases
808086|NCT03107429|Trendelenburg
808212|NCT03106584|WOMAC
808087|NCT03107429|Laparoscopic colorectal surgery
808088|NCT03107429|POVL
808089|NCT03107416|Bumetanide
808090|NCT03107416|Diuretic
808091|NCT03107416|Transarterial Embolization (TAE)
808092|NCT03107416|17-141
808093|NCT03107403|dreams bereavement
808094|NCT03107403|emotional
808095|NCT03107403|regulation
808096|NCT03107403|bereavement
808097|NCT03107338|Pre-emptive analgesia; Dexketoprofen trometamol
808098|NCT03107208|DKA
808099|NCT03107208|type 1 diabetes
808100|NCT03107208|children
808101|NCT03107208|continuous glucose monitoring
808102|NCT03107182|HPV- positive HNSCC
808103|NCT03107182|head and neck squamous cell carcinoma
808104|NCT03107156|Treatment care planning
808105|NCT03107143|Pressure ulcer prevention
808106|NCT03107143|Pressure injury
808107|NCT03107091|Terlipressin
808108|NCT03107091|Terlipressin acetate
808109|NCT03107065|Sweating
808110|NCT03107026|Binge eating Disorder
808111|NCT03107026|dasotraline
808121|NCT03106935|recurrent pregnancy loss
808122|NCT03106935|Clinical hypothyroidism
808123|NCT03106935|Subclinical hypothyroidism
808124|NCT03106935|thyroid stimulating hormone
808125|NCT03106935|thyroid peroxidase antibody
808126|NCT03106935|Levothyroxine
808127|NCT03106922|Polyethylene glycol
808128|NCT03106922|Bowel cleansing
808129|NCT03106922|Colonoscopy
808130|NCT03106909|stroke
808131|NCT03106909|pneumonia
808132|NCT03106909|biomarkers
808133|NCT03106909|pulmonary CT
808134|NCT03106883|Attention bias modification
808135|NCT03106883|Cognitive bias modification
808136|NCT03106883|Eye-tracking
808137|NCT03106883|Treatment
808138|NCT03106844|FMT
808139|NCT03106844|IBD
808140|NCT03106805|intrauterine device
808141|NCT03106779|Phase 3
808142|NCT03106779|Chronic Myelogenous Leukemia
808143|NCT03106779|CML
808144|NCT03106779|bosutinib
808145|NCT03106779|ABL001
808146|NCT03106779|tyrosine kinase inhibitor
808147|NCT03106779|Chronic myelogenous leukemia (CML)
808148|NCT03106779|chronic myeloid leukemia (CML)
808149|NCT03106779|chronic myelocytic leukemia (CML)
808150|NCT03106779|chronic granulocytic leukemia (CGL)
808151|NCT03106779|cancer of the white blood cells
808152|NCT03106779|clonal bone marrow stem cell disorder
808153|NCT03106779|proliferation of mature granulocytes
808154|NCT03106753|External Cephalic Version
808155|NCT03106753|neuraxial analgesia
808156|NCT03106740|Microglia
808157|NCT03106740|Minocycline
808158|NCT03106740|Magnetic Resonance Imaging
808159|NCT03106740|Positron Emission Tomography
808160|NCT03106740|Pain
808161|NCT03106740|Astrocytes
808162|NCT03106740|Glia
808163|NCT03106740|Human
808164|NCT03106740|Back Pain
808165|NCT03106727|Community Health Workers
808166|NCT03106727|Maternal and Child Health
808167|NCT03106727|Integrated Care
808168|NCT03106727|Malawi
808169|NCT03106727|NCD
808170|NCT03106714|persistence
808171|NCT03106714|body fluids
808172|NCT03106688|PET imaging
808173|NCT03106688|Cannabinoid receptor
808174|NCT03106688|Opioid receptor
808175|NCT03106688|Addiction
808176|NCT03106688|fMRI imaging
808177|NCT03106675|HIFU
808178|NCT03106675|MR-HIFU
808179|NCT03106675|MRgFUs
808180|NCT03106675|MRI-intervention
808181|NCT03106675|Palliation
808182|NCT03106662|Mesenchymal stem cell
808183|NCT03106662|haploidentical hematopoietic stem cell transplantation
808184|NCT03106662|graft-versus-host disease
808185|NCT03106662|engraftment
808186|NCT03106636|Preschool-aged
808187|NCT03106636|Foster children
808188|NCT03106636|child welfare
808189|NCT03106636|Fostercare
808190|NCT03106636|Parent training
808191|NCT03106636|early adversity
808192|NCT03106636|curriculum based
808193|NCT03106636|early intervention
808194|NCT03106636|preschool
808195|NCT03106636|foster placement disruptions
808196|NCT03106636|manualized intervention
808197|NCT03106636|group based intervention
808198|NCT03106636|high-risk children
808199|NCT03106610|Bladder cancer
808200|NCT03106610|Cancer of urothelium
808201|NCT03106610|Transitional cell carcinoma
808202|NCT03106610|Carcinoma in situ
808203|NCT03106610|Nivolumab
808204|NCT03106610|BMS-936558
808205|NCT03106610|Opdivo
808206|NCT03106610|Questionnaires
808207|NCT03106610|Surveys
808208|NCT03106597|Peripheral Edema
808209|NCT03106597|Bioimpedance Analysis
808210|NCT03106584|Knee pain
808211|NCT03106584|Glucosamine
808213|NCT03106584|Osteoarthritis
808214|NCT03106571|Phase 1 clinical trial
808215|NCT03106506|Implants
808216|NCT03106506|Conjunctive tissue graft
808217|NCT03106506|Prospective study
808218|NCT03106480|Pre-diabetes
808219|NCT03106480|Diabetes Mellitus
808220|NCT03106480|HIV
808221|NCT03106480|ART
808222|NCT03106480|Body composition
808223|NCT03106480|Inflammation
808224|NCT03106480|Insulin resistance
808225|NCT03106480|Beta-cell function
808226|NCT03106480|Pre-Hypertension
808227|NCT03106480|Hypertension
808228|NCT03106467|appendectomy
808229|NCT03106467|laparoscopic
808230|NCT03106467|single port
808231|NCT03106467|randomized
808232|NCT03106389|misoprostol
808233|NCT03106389|transcervical balloon catheter
808234|NCT03106389|second trimester
808235|NCT03106389|induced abortion
808236|NCT03106337|Thyroid
808237|NCT03106337|Follicular Neoplasms
808238|NCT03106337|Bethesda System
808239|NCT03106337|Elastography
808240|NCT03106337|Doppler ultrasound
808241|NCT03106337|Thyroidectomy
808242|NCT03106324|Multiple Myeloma
808243|NCT03106324|Non transplant eligible
808244|NCT03106324|Revlimid
808245|NCT03106324|PASS
808246|NCT03106324|Non-interventional
808247|NCT03106324|Lenalidomide
808248|NCT03106298|Iron Deficiency
808249|NCT03106298|Fibroblast Growth Factor 23
808250|NCT03106298|Phosphate
808251|NCT03106259|FURESTEM-RA
808252|NCT03106246|Extracellular vesicles
808253|NCT03106246|Autoimmunity
808254|NCT03106246|Beta-cell injury
808255|NCT03106233|Breast reconstruction
808256|NCT03106233|Perforator flap
808257|NCT03106233|Microsurgery
808258|NCT03106168|Extraction
808259|NCT03106168|Local Anesthetic
808260|NCT03106168|Mepivacaine
808261|NCT03106168|Mandibular Molar
808262|NCT03106142|intervention, improvement strategy
808263|NCT03106116|Coronary Heart Disease
808264|NCT03106116|Ventricular Function
808265|NCT03106116|Vascular Endothelium
808266|NCT03106116|Counterpulsation, External
808267|NCT03106103|urodynamics
808268|NCT03106103|cystitis
808269|NCT03106103|prophylactic antibiotics
808270|NCT03106103|bacteriuria
808271|NCT03106090|survivorship care plan
808272|NCT03106090|head and neck cancer
808273|NCT03106090|survivorship
808281|NCT03106051|Arthritis
808282|NCT03106051|Psoriatic
808283|NCT03106051|Observational
808284|NCT03106051|Apremilast
808285|NCT03106038|contrast agent
808286|NCT03106038|ureter imaging
808287|NCT03106038|intraoperative monitoring
808288|NCT03106038|intraoperative procedures
808289|NCT03106038|near infrared fluorescence
808290|NCT03106038|minimally invasive
808291|NCT03105973|jail
808292|NCT03105973|prison
808293|NCT03105973|technology
808294|NCT03105973|depression
808295|NCT03105973|CBT
808296|NCT03105947|lipids
808297|NCT03105947|dietary fats
808298|NCT03105921|Locally advanced pancreatic carcinoma
808299|NCT03105921|Irreversible electroporation
808300|NCT03105921|Interventional radiology
808301|NCT03105895|Incisional hernia
808302|NCT03105895|Mesh prevention
808303|NCT03105895|Mesh augmentation
808304|NCT03105882|Spinal Cord Injury
808305|NCT03105882|SCI
808306|NCT03105882|Complete (AIS A) Traumatic Acute Spinal Cord Injury
808307|NCT03105869|repeatability
808308|NCT03105869|positron emission tomography (PET) with fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium
808309|NCT03105856|Mass screening
808310|NCT03105856|Vaccination
808311|NCT03105856|Mexico
808312|NCT03105843|Asthma
808313|NCT03105843|Cough
808314|NCT03105843|Eucapneic Voluntary Hyperventilation
808315|NCT03105843|Hypertonic Saline
808316|NCT03105817|Asymmetric cellulose triacetate
808317|NCT03105817|Biocompatibility
808318|NCT03105817|Hemodiafiltration on-line
808319|NCT03105817|Convective volume
808320|NCT03105817|Adequacy
808321|NCT03105778|BNP
808322|NCT03105778|IVD
808323|NCT03105765|Neuropathic Pain
808324|NCT03105765|Chronic Pain
808325|NCT03105765|Posterolateral thoracotomy
808326|NCT03105752|Outcome Assessments (Health Care)
808327|NCT03105752|Volunteers
808328|NCT03105752|Informed consent
808329|NCT03105752|Comprehension
808330|NCT03105752|Language tests
808331|NCT03105726|End Stage Heart Failure
808332|NCT03105726|New York Heart Association functional class III or IV
808333|NCT03105726|Heart transplantation
808334|NCT03105726|Ventricular assisted devices
808335|NCT03105726|Cardiogenic shock
808336|NCT03105713|Checklist
808337|NCT03105713|Patient Checklist
808338|NCT03105713|Surgery
808339|NCT03105713|Safety
808340|NCT03105713|Patient Involvement
808341|NCT03105700|epilepsy
808342|NCT03105700|depression
808343|NCT03105700|refractory
808344|NCT03105700|temporal lobe
808345|NCT03105700|TMS
808346|NCT03105700|biomarker
808347|NCT03105687|mHealth
808348|NCT03105687|SMS reminders
808349|NCT03105687|adherence
808350|NCT03105687|antihypertensive drugs
808351|NCT03105687|pharmacists
808352|NCT03105687|cost-effectiveness
808353|NCT03105674|analgesia
808354|NCT03105674|peri-anal procedure
808355|NCT03105674|peri-anal block
808356|NCT03105674|anal surgery
808357|NCT03105635|Community Resources
808358|NCT03105635|Health Navigator
808359|NCT03105622|Exercise
808360|NCT03105622|Screen
808361|NCT03105622|Music
808362|NCT03105622|Energy compensation
808363|NCT03105622|Adolescents
808364|NCT03105622|Running+screen
808365|NCT03105622|Running+music
808366|NCT03105622|Running without stimulus (control condition)
808367|NCT03105609|hyperspectral imaging, Ranibizumab
808368|NCT03105583|Medication beliefs
808369|NCT03105583|Information desire
808370|NCT03105583|Vitamin deficiencies
808371|NCT03105570|breast neoplasms
808372|NCT03105570|Mastectomy, Subcutaneous
808373|NCT03105570|Areola
808374|NCT03105557|Prematurely born newborns
808375|NCT03105557|Urine
808376|NCT03105557|Collecting device
808377|NCT03105544|simulation-based training
808378|NCT03105544|obstetric ultrasound
808379|NCT03105544|intrauterine growth restriction
808380|NCT03105544|ultrasound simulation
808381|NCT03105531|primary aldosteronism
808382|NCT03105531|hypertension
808383|NCT03105531|screening
808384|NCT03105531|secondary hypertension
808385|NCT03105518|assisted reproduction
808386|NCT03105518|postoperative pain
808387|NCT03105518|opioid
808390|NCT03105479|vancomycin
808391|NCT03105479|children
808392|NCT03105479|cadazolid
808393|NCT03105479|clostridium difficile associated diarrhea
808394|NCT03105466|Corneal Transplantation
808395|NCT03105466|Xenotransplantation
808396|NCT03105466|Bioegineered cornea
808397|NCT03105453|Assisted reproductive technologies
808398|NCT03105453|Microbiome
808399|NCT03105440|breast cancer
808400|NCT03105440|lymphedema
808401|NCT03105440|pain
808402|NCT03105440|range of motion
808403|NCT03105440|technologic innovation
808404|NCT03105440|rehabilitation
808405|NCT03105414|Mechanical ventilation
808406|NCT03105414|Pediatrics
808407|NCT03105414|Cross infection
808408|NCT03105414|Intensive care
808409|NCT03105414|Diagnosis
808410|NCT03105375|Potassium competitive acid blocker
808411|NCT03105375|X842
808412|NCT03105375|Gastroesophageal reflux disease
808413|NCT03105375|Esophagitis
808414|NCT03105375|Intragastric pH
808415|NCT03105375|Acid inhibition
808417|NCT03105310|Hepatitis D
808418|NCT03105310|Ezetimibe
808419|NCT03105310|Pegylated interferon
808420|NCT03105297|Nasal dilator strip
808421|NCT03105297|Sleep disordered breathing
808422|NCT03105284|stem cell
808423|NCT03105284|liposuction
808424|NCT03105284|regenerative medicine
808425|NCT03105245|electroconvulsive therapy
808426|NCT03105245|anaesthesia
808427|NCT03105206|lowl pole renal calculus
808428|NCT03105206|anatomical parameters
808429|NCT03105206|flexible ureteroscopy
808430|NCT03105193|Colon surgery
808431|NCT03105193|Lignocaine
808432|NCT03105193|Lidocaine
808433|NCT03105193|Analgesia
808434|NCT03105193|Local anaesthetic
808435|NCT03105167|CBT
808436|NCT03105167|RCT
808437|NCT03105167|TLIF
808438|NCT03105141|Intracranial atherosclerotic stenosis
808439|NCT03105141|Remote ischemic conditioning
808440|NCT03105141|Stroke
808443|NCT03105102|ABBV-066
808444|NCT03105102|risankizumab
808445|NCT03105102|BI 655066
808446|NCT03105050|access
808447|NCT03105050|policy
808448|NCT03105024|specific phobia
808449|NCT03105024|height phobia
808450|NCT03105024|exposure
808451|NCT03105024|virtual reality
808452|NCT03105024|extinction
808453|NCT03105024|self-efficacy
808454|NCT03105011|Type 2 diabetes
808455|NCT03104998|Idiopathic
808456|NCT03104998|Infertility
808457|NCT03104998|coenzyme q10
808458|NCT03104998|Pakistan
808459|NCT03104985|Trophic ulcer; low level laser therapy; Chronic Venous Insufficiency
808460|NCT03104972|ADHD
808461|NCT03104972|TRANS CRANIAL ELECTRIC STIMULATION
808462|NCT03104959|hangovers
808463|NCT03104959|N-acetyl cysteine
808464|NCT03104959|alcohol
808465|NCT03104933|Proadrenomedullin
808466|NCT03104933|Copeptin
808467|NCT03104933|Vasopressors
808468|NCT03104933|Septic Shock
808469|NCT03104920|ERAS
808470|NCT03104920|Time to ready for discharge
808471|NCT03104907|IPSS
808472|NCT03104907|Quality of Life
808473|NCT03104907|DAN-PSS
808474|NCT03104907|Complications
808475|NCT03104907|Prostate cancer
808476|NCT03104881|stroke
808477|NCT03104855|cystic fibrosis
808478|NCT03104855|vitamin d catabolism
808479|NCT03104816|Acetaminophen po
808480|NCT03104816|Acetaminophen IV
808481|NCT03104816|Pain management
808482|NCT03104816|minimally invasive lumbar fusions
808483|NCT03104816|Ofirmev
808484|NCT03104816|Analgesics
808485|NCT03104816|Opioid
808486|NCT03104816|Pain
808487|NCT03104816|Postoperative
808488|NCT03104816|Spinal
808489|NCT03104764|labial frenulum
808490|NCT03104764|surgery
808491|NCT03104764|scalpel technique
808492|NCT03104764|Er:YAG laser
808493|NCT03104751|Complex Congenital Heart Defect
808494|NCT03104751|Infants
808499|NCT03104712|glycemic index
808500|NCT03104699|Antibodies
808501|NCT03104699|Immunologic effects
808502|NCT03104699|Physiological Effects of Drugs
808503|NCT03104673|Molecular signature
808504|NCT03104673|Thailand-Myanmar border
808505|NCT03104621|preservative-free, tafluprost
808506|NCT03104595|EC-18, febrile neutropenia, breast cancer, chemotherapy
808507|NCT03104582|ERCP
808508|NCT03104582|PTBD
808509|NCT03104582|EBD
808510|NCT03104582|Cholangitis
808511|NCT03104582|Complication
808512|NCT03104582|Klatskin tumor
808513|NCT03104569|ERCP
808514|NCT03104569|Contrast agent
808515|NCT03104569|Hilar cholangiocarcinoma
808516|NCT03104569|Cholangitis
808517|NCT03104569|Nonionic
808518|NCT03104543|survivor
808519|NCT03104543|undertreatment
808520|NCT03104543|adherence
808521|NCT03104543|self-efficacy
808522|NCT03104530|Crab
808523|NCT03104530|Brown meat
808524|NCT03104530|Cadmium body burden
808525|NCT03104530|Ferritin
808526|NCT03104530|Zinc
808527|NCT03104530|Selenium
808528|NCT03104530|Creatinine
808529|NCT03104530|B2-Microglobulin
808530|NCT03104517|Urinary Incontinence
808531|NCT03104517|Urinary Stress Incontinence
808532|NCT03104517|Lower Urinary Tract Symptoms
808533|NCT03104517|Urinary Bladder
808534|NCT03104517|Urinary Tract Diseases
808535|NCT03104517|Bladder
808536|NCT03104517|Urinary Leak
808537|NCT03104517|Urine Leak
808538|NCT03104517|Bladder Leak
808539|NCT03104517|Urethra
808540|NCT03104517|Urethral Sphincter
808541|NCT03104504|Suicide Screening
808542|NCT03104504|Safety Planning
808543|NCT03104491|allogeneic hematopoietic stem cell transplantation
808544|NCT03104491|donor chimerism
808545|NCT03104478|DLBCL
808546|NCT03104478|Real time molecular characterization
808547|NCT03104465|Chronic Pain
808548|NCT03104465|Mindfulness
808549|NCT03104465|Behavioral Health
808550|NCT03104465|Quality of Life
808551|NCT03104439|Pancreatic Cancer
808552|NCT03104439|Microsatellite Stable Colorectal Cancer
808553|NCT03104426|Hemolytic disease of the fetus and newborn
808554|NCT03104426|HDFN
808555|NCT03104426|Red blood cell alloimmunization
808556|NCT03104413|BI 655066
808557|NCT03104413|ABBV-066
808577|NCT03104361|intersitial cystitis
808578|NCT03104361|Bladder pain syndrome
808579|NCT03104361|Intravesical treatment
808580|NCT03104348|COPD
808581|NCT03104348|Primary care
808582|NCT03104335|soft tissue sarcoma
808583|NCT03104335|advanced
808584|NCT03104335|apatinib
808585|NCT03104335|tyrosine-kinase inhibitors
808586|NCT03104322|digital health
808587|NCT03104322|home spirometry
808588|NCT03104322|patient reported outcome measure
808589|NCT03104322|e-health
808590|NCT03104322|pirfenidone
808591|NCT03104322|nintedanib
808592|NCT03104322|FVC
808593|NCT03104322|antifibrotic
808594|NCT03104296|NIRS
808595|NCT03104296|Griffiths Mental Development Scales
808596|NCT03104296|prematurity
808597|NCT03104283|apatinib
808598|NCT03104283|gastric cancer
808599|NCT03104283|elderly patients
808600|NCT03104270|Elotuzumab, Multiple Myeloma, Phase 2
808601|NCT03104257|Healthy Control, Cannabis, Dependence
808602|NCT03104244|concussion
808603|NCT03104244|subconcussive impacts
808604|NCT03104244|brain function
808605|NCT03104244|football
808606|NCT03104231|atrial fibrillation
808607|NCT03104231|oral anticoagulantion
808608|NCT03104231|stroke prevention
808609|NCT03104231|education
808610|NCT03104231|e-medicine
808623|NCT03104127|Lower-limb robotic device
808624|NCT03104127|Gait
808625|NCT03104127|Balance
808626|NCT03104127|Pressure
808627|NCT03104127|Chronic stroke
808628|NCT03104127|Blood pressure
808629|NCT03104127|Blood velocity
808630|NCT03104127|Aerobic fitness
808631|NCT03104127|Strength
808632|NCT03104101|PTNS
808633|NCT03104101|Neuromodulation
808634|NCT03104101|TPTNS
808635|NCT03104101|Trospium chloride
808636|NCT03104075|Genomics
808637|NCT03104075|Epigenomics
808638|NCT03104075|Pneumococcal vaccine
808639|NCT03104075|Elderly
808640|NCT03104049|Parkinson's Disease
808641|NCT03104049|Neuromuscular taping
808642|NCT03104049|Trunk
808643|NCT03104049|Posture
808644|NCT03104049|Kinematic
808645|NCT03104049|rehabilitation
808646|NCT03104036|Feacal bacterial transplantation
808647|NCT03104036|Left-sided ulcerative colitis
808648|NCT03103997|Liver
808649|NCT03103997|EUS
808650|NCT03103997|Biopsy
808651|NCT03103997|Heparin
808652|NCT03103984|Obesity
808653|NCT03103984|Liver transplantation
808654|NCT03103984|weight loss diet
808655|NCT03103984|immunosuppression
808656|NCT03103958|probiotic
808657|NCT03103958|metagenomic
808658|NCT03103958|constipation
808659|NCT03103945|Atrial Fibrillation
808660|NCT03103945|Atrial Arrhythmia
808661|NCT03103945|Arrhythmias, Cardiac
808662|NCT03103945|Cardiac Diseases
808663|NCT03103945|Electrophysiologic Techniques, Cardiac
808664|NCT03103945|Electrophysiology
808665|NCT03103945|Remote Magnetic Navigation
808666|NCT03103945|Contact Detection System
808670|NCT03103919|Parkinson´s Disease
808671|NCT03103919|Kinesia-360™
808672|NCT03103919|Kinesia-ONE™
808673|NCT03103919|Biosensor
808674|NCT03103880|Patient Adherence
808675|NCT03103880|Mobile Applications
808676|NCT03103880|Mobile Health
808677|NCT03103854|Exercise
808678|NCT03103854|Secondary Prevention
808679|NCT03103854|Diabetes
808680|NCT03103854|Rehabilitation
808681|NCT03103841|Children
808682|NCT03103815|Amyotrophic lateral sclerosis, survival, adverse event
808683|NCT03103763|Elderly
808684|NCT03103763|Anticoagulation
808685|NCT03103763|Risk Assessment
808687|NCT03103737|Well-being
808688|NCT03103737|Information and communication technologies
808689|NCT03103737|Hospital
808690|NCT03103711|Virtual reality
808691|NCT03103711|Well-being
808692|NCT03103711|Hospital
808693|NCT03103698|analgesia per-operative
808694|NCT03103685|Dual antiplatelet therapy
808695|NCT03103685|Dental procedure
808696|NCT03103672|quality of anesthesia
808697|NCT03103672|reduce recovery time
808698|NCT03103633|oxygen dynamics
808699|NCT03103633|Prognosis
808700|NCT03103555|Anti-interferon gamma autoantibody
808701|NCT03103542|ITI
808702|NCT03103542|rFVIIIFc
808703|NCT03103542|Immune Tolerance Induction
808704|NCT03103490|PET/MR
808705|NCT03103425|New onset seizures
808706|NCT03103412|Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
808707|NCT03103386|fermented rye bran
808708|NCT03103386|H. pylori infections
808709|NCT03103386|non-communicable diseases
808710|NCT03103373|Echocardiography
808711|NCT03103373|anesthesia
808712|NCT03103373|general surgery
808713|NCT03103347|EEG
808714|NCT03103347|Parkinson Disease
808715|NCT03103347|Beta Oscillations
808716|NCT03103308|Cancer
808717|NCT03103308|Exercise
808718|NCT03103308|Physical Function
808719|NCT03103295|tissue engineering,
808720|NCT03103295|regeneration,
808721|NCT03103295|repair,
808722|NCT03103295|traumatic bone defects,
808723|NCT03103295|regenerative therapy
808724|NCT03103269|Overweight
808725|NCT03103269|Obesity
808726|NCT03103269|Prevention
808727|NCT03103269|Diet
808728|NCT03103269|Physical activity
808729|NCT03103269|Depression
808730|NCT03103269|Anxiety
808731|NCT03103269|Stages of change
808732|NCT03103269|Barriers
808733|NCT03103269|Perceptions
808734|NCT03103269|Environment
808735|NCT03103269|Eating Disorder
808736|NCT03103269|Self efficacy
808737|NCT03103243|Lupus
808738|NCT03103243|SLE
808739|NCT03103243|Erythematosus
808740|NCT03103230|Motor evoked potentials
808741|NCT03103230|aphasia
808742|NCT03103230|prognosis
808743|NCT03103230|stroke
808744|NCT03103204|Obesity
808745|NCT03103204|Periodontitis
808746|NCT03103204|Therapeutics
808747|NCT03103204|Chlorhexidine
808748|NCT03103152|Prostate Cancer
808749|NCT03103152|Active Surveillance
808750|NCT03103152|Chemo-prevention
808751|NCT03103126|pedometer-determined walking
808752|NCT03103126|resistance exercise
808753|NCT03103100|Local anesthetic
808754|NCT03103100|Labor epidural
808755|NCT03103074|botulinum toxin
808756|NCT03103061|Computed Tomography
808757|NCT03102996|Alkali
808758|NCT03102996|Graft
808759|NCT03102996|Acid base
808760|NCT03102996|Metabolic acidosis
808761|NCT03102996|Chronic kidney disease
808762|NCT03102983|MRI, Functional
808763|NCT03102970|COPD, Pain, Exacerbation
808764|NCT03102918|Cannabidiol
808765|NCT03102879|mesenchymal stem cells
808766|NCT03102879|regenerative procedures
808767|NCT03102879|tissue engineering
808768|NCT03102879|regenerative endodontic
808769|NCT03102879|scaffold
808770|NCT03102879|cell encapsulation
808771|NCT03102879|dental pulp
808772|NCT03102879|pulp regeneration
808773|NCT03102879|plasma-derived biomaterial
808774|NCT03102879|allogenic stem cells
808775|NCT03102879|mesenchymal stromal cells
808776|NCT03102879|adult stem cells
808777|NCT03102879|umbilical cord stem cells
808778|NCT03102840|Carriage
808779|NCT03102840|Immunogenicity
808780|NCT03102840|Pneumococcal conjugate vaccine 13 (PCV 13)
808781|NCT03102840|Children
808782|NCT03102840|Pneumococcus
808783|NCT03102775|poverty
808784|NCT03102775|unemployment
808785|NCT03102775|cluster-randomized
808786|NCT03102775|family-project
808787|NCT03102762|Erectile dysfunction
808788|NCT03102762|Botulinum toxin A
808789|NCT03102762|Botox
808790|NCT03102749|Airways
808791|NCT03102749|asthma
808792|NCT03102749|overweight
808793|NCT03102736|depression
808794|NCT03102736|ketamine
808795|NCT03102736|nitroprusside
808796|NCT03102723|STEMI
808797|NCT03102723|primary percutaneous coronary intervention (PPCI)
808798|NCT03102723|cangrelor
808799|NCT03102723|reperfusion
808800|NCT03102697|Intragastric balloon
808801|NCT03102697|obesity
808802|NCT03102697|metabolic syndrome
808803|NCT03102697|bariatric surgery
808804|NCT03102684|e-cigarette
808805|NCT03102684|electronic cigarette
808806|NCT03102684|passive exposure
808807|NCT03102684|secondhand exposure
808808|NCT03102684|smoking
808809|NCT03102684|respiratory system
808810|NCT03102619|Wireless monitoring
808811|NCT03102619|Postoperative complications
808812|NCT03102619|Vital parameters
808813|NCT03102619|Continuous monitoring
808814|NCT03102606|Plinabulin
808815|NCT03102606|Pegfilgrastim
808816|NCT03102606|Duration of Severe Neutropenia
808817|NCT03102606|Bone Pain
808818|NCT03102580|Shared Decision Making
808819|NCT03102554|Exome Sequencing
808820|NCT03102502|Coronary Heart Disease
808821|NCT03102502|Atherosclerosis
808822|NCT03102502|Vascular Endothelium
808823|NCT03102502|Counterpulsation, External
808824|NCT03102463|Insulin sensitivity
808825|NCT03102463|Obesity
808826|NCT03102463|Insulin resistance
808827|NCT03102463|Milk derived hydrolysate
808828|NCT03102463|Hyperinsulinemic-euglycaemic clamp
808829|NCT03102437|Cardiac Contractility Modulation
808830|NCT03102437|CCM
808831|NCT03102385|blood donation
808832|NCT03102385|motivation
808833|NCT03102385|donor retention
808834|NCT03102372|FFM
808835|NCT03102372|VLCD
808836|NCT03102372|exercise
808837|NCT03102372|Protein
808838|NCT03102372|Obesity
808839|NCT03102346|cardiorespiratory fitness
808840|NCT03102346|coronary artery disease
808841|NCT03102346|cardiac rehabilitation
808842|NCT03102346|remote control
808843|NCT03102346|major adverse cardiac and cerebrovascular events
808850|NCT03102307|Targeted axillary dissection
808851|NCT03102307|Sentinel node biopsy
808852|NCT03102307|Neoadjuvant chemotherapy
808853|NCT03102255|Nasotracheal intubation
808854|NCT03102229|Activity Monitoring
808855|NCT03102229|Chemotherapy
808856|NCT03102229|Radiotherapy
808857|NCT03102164|heart failure
808858|NCT03102164|decompensation
808859|NCT03102125|heart transplant, acute graft rejection, chronic graft rejection
808860|NCT03102112|Glioma APT MRI
808861|NCT03102073|Reading speed
808862|NCT03102047|microsatellite stable
808863|NCT03102047|MSS
808864|NCT03102047|durvalumab
808865|NCT03102047|NSABP
808866|NCT03102008|Transdiagnostic Treatment
808867|NCT03102008|Emotional Disorders
808868|NCT03102008|Adolescence
808869|NCT03102008|Psychotherapy
808870|NCT03101995|Treatment
808871|NCT03101995|Locally advanced cervical cancer
808872|NCT03101995|Renal failure
808873|NCT03101995|Gemcitabine
808874|NCT03101969|language
808875|NCT03101969|scheduled
808876|NCT03101969|appointment
808877|NCT03101956|Spine Manipulation
808878|NCT03101943|Sugar
808879|NCT03101943|Sweetened
808880|NCT03101943|Beverages
808881|NCT03101891|Amnioinfusion
808882|NCT03101891|Fetal therapy
808883|NCT03101878|Hypertension, ISIS 757456
808884|NCT03101865|Type 1 diabetes
808885|NCT03101865|Artificial Pancreas
808886|NCT03101865|Closed-loop glucose control
808887|NCT03101865|Very young children
808888|NCT03101865|Continuous subcutaneous insulin infusion
808889|NCT03101865|Continuous glucose monitoring
808890|NCT03101852|severe acute malnutrition
808891|NCT03101852|moderate acute malnutrition
808892|NCT03101852|HIV-infection
808893|NCT03101852|adolescents
808894|NCT03101852|antiretroviral
808895|NCT03101852|Africa
808896|NCT03101852|ready-to-use food
808897|NCT03101852|outpatient care
808898|NCT03101826|Polyvagal Theory
808899|NCT03101826|Respiratory Sinus Arrhythmia
808900|NCT03101826|Heart rate
808901|NCT03101826|Social Behavior
808902|NCT03101826|Arginine Vasopressin
808903|NCT03101826|Dichotic Listening Tests
808904|NCT03101826|Oxytocin
808905|NCT03101826|Hyperacusis
808906|NCT03101826|Affect
808907|NCT03101826|Auditory perception
808908|NCT03101826|Sound spectrography
808909|NCT03101800|Azathioprine
808910|NCT03101800|Allopurinol
808911|NCT03101800|Antimetabolites
808912|NCT03101800|Ulcerative Colitis
808913|NCT03101787|ECPR
808914|NCT03101787|Extracorporeal CardioPulmonary Resuscitation
808915|NCT03101787|OHCA
808916|NCT03101787|Out-of-Hospital Cardiac Arrest
808917|NCT03101787|CPR
808918|NCT03101787|CardioPulmonary Resuscitation
808919|NCT03101787|ECMO
808920|NCT03101787|ExtraCorporeal Membrane Oxygenation
808921|NCT03101787|Refractory Cardiac Arrest
808922|NCT03101774|inspiratory muscle training
808948|NCT03101722|presbycusis
808949|NCT03101722|tinnitus
808950|NCT03101722|cognitive impairment
808951|NCT03101722|Huperzine A
808952|NCT03101722|hearing aid
808953|NCT03101722|age-related hearing impairment
808954|NCT03101696|coronary angiography
808955|NCT03101696|coronary conductance
808956|NCT03101696|hyperemia
808957|NCT03101696|regadenoson
808958|NCT03101696|fractional flow reserve
808959|NCT03101696|coronary flow reserve
808960|NCT03101696|index of microcirculatory resistance
808961|NCT03101631|Elderly population with cancer
808962|NCT03101631|Toxicity risk
808963|NCT03101631|Mortality risk
808964|NCT03101631|Frailty conditions in elderly population
808965|NCT03101631|Chemotherapy in elderly population
808966|NCT03101618|allergen
808967|NCT03101618|allergy
808968|NCT03101618|pet
808969|NCT03101592|antiretroviral therapy
808970|NCT03101592|retention
808971|NCT03101592|ART
808972|NCT03101592|cost-effectiveness
808973|NCT03101592|virologic suppression
808974|NCT03101579|Leptomeningeal metastasis
808975|NCT03101579|Recurrence
808976|NCT03101579|Intrathecal chemotherapy
808977|NCT03101579|Pemetrexed
808978|NCT03101540|Major Depressive Disorder,
808979|NCT03101540|omega-3 polyunsaturated fatty acid
808980|NCT03101540|PUFA
808981|NCT03101540|Pregnancy
808982|NCT03101540|eicosapentaenoic acid (EPA) supplementation
808983|NCT03101540|cytokine
808984|NCT03101540|docosahexaenoic acid (DHA)
808985|NCT03101527|Major Depressive Disorder
808986|NCT03101527|omega-3 polyunsaturated fatty acid
808987|NCT03101527|PUFA
808988|NCT03101527|Pregnancy
808989|NCT03101527|eicosapentaenoic acid (EPA) supplementation
808990|NCT03101514|head and neck
808991|NCT03101514|tumor
808992|NCT03101514|radiotherapy
808993|NCT03101514|mucositis
808994|NCT03101514|toxicity
808995|NCT03101514|Kanglaite injection
808996|NCT03101488|KN035
808997|NCT03101488|phase 1
808998|NCT03101475|Colorectal Cancer
808999|NCT03101475|Liver Metastases
809000|NCT03101475|Durvalumab
809001|NCT03101475|Tremelimumab
809002|NCT03101436|Insulin Resistance
809003|NCT03101436|Extra Virgin Olive Oil
809004|NCT03101436|Red Wine
809005|NCT03101436|Diet
809006|NCT03101436|Microbiota
809007|NCT03101423|thalassemia
809008|NCT03101423|transplantation
809009|NCT03101423|chimerism
809010|NCT03101423|donor ymphocytes
809011|NCT03101410|Gluten
809012|NCT03101410|sport performance
809013|NCT03101397|serum KL-6
809014|NCT03101397|pulmonary function test
809015|NCT03101397|CT score
809016|NCT03101397|evaluation
809017|NCT03101306|cervix, radiotherapy, magnetic resonance imaging
809018|NCT03101293|Drug therapy
809019|NCT03101267|Cedar pollinosis
809020|NCT03101267|ASP4070
809021|NCT03101267|DNA plasmid vaccine
809022|NCT03101254|Melanoma
809023|NCT03101241|Essential Tremor
809024|NCT03101241|Movement Disorders
809025|NCT03101241|thalamocortical dysrhythmias
809026|NCT03101228|Physical Activity
809027|NCT03101228|Metabolic Syndrome
809028|NCT03101228|Insulin Sensitivity
809029|NCT03101228|Cardiovascular Risk Factor
809030|NCT03101228|Sedentary Lifestyle
809031|NCT03101228|Accelerometry
809032|NCT03101189|safety
809033|NCT03101189|Japanese
809034|NCT03101189|pharmacokinetics
809035|NCT03101176|multiparametric ultrasound
809036|NCT03101176|prostate cancer
809037|NCT03101176|contrast ultrasound
809038|NCT03101176|CEUS
809039|NCT03101176|radical prostatectomy
809040|NCT03101150|Maternal vitamin D
809041|NCT03101150|Deficiency
809042|NCT03101150|Insufficiency
809043|NCT03101150|Pregnancy
809044|NCT03101150|Pre-eclampsia
809045|NCT03101150|IUGR
809046|NCT03101124|Hemostasis, Surgical
809047|NCT03101124|Tranexamic Acid
809048|NCT03101124|Antifibrinolytic Agents
809049|NCT03101124|Administration, Cutaneous
809050|NCT03101124|Administration, Intravenous
809051|NCT03101124|Administration, Topical
809052|NCT03101072|Gram-negative bacteremia
809053|NCT03101072|antibiotic durations
809054|NCT03101072|point-of-care randomization
809055|NCT03101059|Tracheal
809056|NCT03101059|Bronchial
809057|NCT03101059|Tracheobronchiomegaly
809058|NCT03101059|Collapse
809059|NCT03101059|obstructive sleep apnea syndrome
809060|NCT03101059|Computer Tomography
809061|NCT03101059|Impedance Tomography
809062|NCT03101046|Docetaxel
809063|NCT03101046|Cabazitaxel
809064|NCT03101033|Herniated lumbar disc
809065|NCT03101033|Epidural neuroplasty
809066|NCT03101033|Epidural injection
809067|NCT03101020|Visceral Manipulation
809068|NCT03101007|Comparative study
809069|NCT03101007|Knee Prosthesis
809070|NCT03101007|Prosthesis Design
809071|NCT03101007|Treatment Outcome
809072|NCT03101007|Follow-up studies
809073|NCT03101007|Arthroplast, Replacement, Knee/methods
809074|NCT03100981|Mindfulness-Based Cognitive Therapy
809075|NCT03100981|Internet-delivered
809076|NCT03100981|Breast cancer
809077|NCT03100981|Prostate cancer
809078|NCT03100981|Survivors
809079|NCT03100981|Depression
809080|NCT03100981|Anxiety
809081|NCT03100981|Stress
809082|NCT03100838|Proton Pump Inhibitor
809083|NCT03100838|Bioequivalence
809084|NCT03100838|Drug-Drug Interaction
809085|NCT03100838|Modified Release
809086|NCT03100838|Nifedipine
809087|NCT03100825|QVM149,
809088|NCT03100825|Asthma,
809089|NCT03100825|Japanese,
809090|NCT03100825|Allergic asthma,
809091|NCT03100825|Allergy triggered asthma,
809092|NCT03100825|Reactive asthma,
809093|NCT03100825|Asthma attack,
809094|NCT03100825|Difficulty breathing
809095|NCT03100812|Hypertensive
809096|NCT03100812|Hypertension
809097|NCT03100812|Filipino
809098|NCT03100799|Osteoarthritis
809099|NCT03100799|Senescence
809100|NCT03100799|Magnetic resonance imaging
809101|NCT03100799|Arthroscopy
809102|NCT03100799|Arthrocentesis
809103|NCT03100799|Biomarker
809104|NCT03100786|Tuberculosis
809105|NCT03100786|tuberculous meningitis
809106|NCT03100786|drug induced liver injury
809107|NCT03100786|dexamethasone
809108|NCT03100786|LTA4H
809109|NCT03100786|host genotype
809110|NCT03100786|personalized medicine
809111|NCT03100773|alpha-amylases
809112|NCT03100773|child
809113|NCT03100773|cortisol
809114|NCT03100773|dental anxiety
809115|NCT03100773|dental atraumatic restorative treatment
809116|NCT03100773|health education
809117|NCT03100773|microbiota
809118|NCT03100773|oral hygiene
809119|NCT03100773|quality of life
809120|NCT03100773|saliva
809121|NCT03099707|Treatment
809122|NCT03099707|ART
809123|NCT03099707|South Africa
809124|NCT03099694|NRDS
809125|NCT03099694|nHFOV
809126|NCT03099694|nCPAP
809127|NCT03099694|preterm infants
809128|NCT03099655|Heart Failure
809129|NCT03099655|Cardiac Pacing
809130|NCT03099655|Cardiac Resynchronization Therapy
809131|NCT03099655|Left Ventricular Lead
809132|NCT03099642|lumbar puncture
809133|NCT03099642|Point of care ultrasound
809134|NCT03099642|children
809135|NCT03099629|Inspiratory muscle training
809136|NCT03099629|Diaphragmatic surface electromyography
809137|NCT03099629|Respiratory muscle strength
809138|NCT03099629|Functional capacity
809139|NCT03099616|propofol
809140|NCT03099616|CLADS
809141|NCT03099616|Desflurane
809142|NCT03099616|Obesity
809143|NCT03099564|Pembrolizumab
809144|NCT03099564|Y90 Radioembolization
809145|NCT03099564|KEYTRUDA®
809146|NCT03099564|TheraSphere®
809147|NCT03099564|PD-1
809148|NCT03099564|IgG4/kappa isotype
809149|NCT03099551|Plaque
809150|NCT03099551|oral hygiene
809151|NCT03099551|gingivitis
809152|NCT03099551|sonic toothbrush
809153|NCT03099551|manual toothbrush
809154|NCT03099538|Ixekizumab
809155|NCT03099538|Bullous Pemphigoid
809156|NCT03099538|Pemphigoid
809157|NCT03099538|IL17
809158|NCT03099538|IL-17
809159|NCT03099538|Interleukin 17
809160|NCT03100734|Biosimilar
809161|NCT03100734|etanercept
809162|NCT03100734|Benepali
809163|NCT03100734|Enbrel
809164|NCT03100721|Chronic pain
809165|NCT03100721|Musculoskeletal diseases
809166|NCT03100721|Pain Neuroscience Education
809167|NCT03100721|Physiotherapy
809168|NCT03100656|psychopathology
809169|NCT03100656|treatment
809170|NCT03100656|epoxide hydrolases
809171|NCT03100656|polyunsaturated fatty acids
809172|NCT03100656|eicosanoids
809173|NCT03100643|HIV/AIDS, mHealth, intervention development, African American men
809174|NCT03100617|Family caregiver
809175|NCT03100604|middle ear pressure
809176|NCT03100604|sevoflurane
809177|NCT03100604|desflurane
809178|NCT03100578|PANCREAS
809179|NCT03100578|ENDOSCOPIC INTERVENTION
809180|NCT03100578|PLASTIC STENT
809181|NCT03100578|SELF EXPANDING METALLIC STENT
809182|NCT03100578|ENDOSCOPIC TRANSMURAL DRAINAGE
809183|NCT03100578|WALLED OFF PANCREATIC NECROSIS
809188|NCT03100552|Colonoscopy
809189|NCT03100552|Endoscopic resection
809190|NCT03100552|Sessile serrated adenoma
809191|NCT03100539|Massage
809192|NCT03100539|Caregiver
809193|NCT03100539|Fascia
809194|NCT03100526|High-Risk Patients
809195|NCT03100500|QVM149,
809196|NCT03100500|Asthma,
809197|NCT03100500|Japanese,
809198|NCT03100500|Allergic asthma,
809199|NCT03100500|Allergy triggered asthma,
809200|NCT03100500|Reactive asthma,
809201|NCT03100500|Asthma attack,
809202|NCT03100500|Difficulty breathing
809203|NCT03100474|tremor
809204|NCT03100474|Parkinson's
809205|NCT03100474|movement
809206|NCT03100474|neuropathic
809207|NCT03100474|pain
809208|NCT03100461|Cancer Screening
809209|NCT03100461|Colon Cancer
809210|NCT03100461|Colon Cancer Screening
809211|NCT03100409|Cervical cancer
809212|NCT03100383|gestational diabetes
809213|NCT03100383|Type2 Diabetes
809214|NCT03100331|neuropsychological outcomes
809215|NCT03100331|HIV/AIDS
809216|NCT03100331|international adoption
809217|NCT03100331|perinatal infection
809218|NCT03100292|primary bariatric surgery
809219|NCT03100292|morbid obesity
809220|NCT03100292|South Korea
809221|NCT03100292|sleeve gastrectomy
809222|NCT03100292|Roux-en Y gastric bypass
809223|NCT03100279|cognitive behavioral therapy
809224|NCT03100279|treatment mediators
809225|NCT03100279|trajectories of change
809226|NCT03100253|Rheumatoid Arthritis
809227|NCT03100253|Tocilizumab
809228|NCT03100253|anti-TNF treatment
809229|NCT03100201|robotic-assisted rehabilitation
809230|NCT03100201|humeral fracture
809231|NCT03100201|randomised controlled study
809232|NCT03100188|peritoneal dialysis
809233|NCT03100188|incremental peritoneal dialysis
809234|NCT03100188|quality of life
809235|NCT03100188|end stage renal disease
809236|NCT03100188|adequacy
809237|NCT03100162|probiotics
809238|NCT03100162|metabolic syndrome
809239|NCT03100162|obesity
809240|NCT03100162|microbiome
809241|NCT03100136|PET
809242|NCT03100136|[11C]PF-06809247
809243|NCT03100136|Reliability
809244|NCT03100136|Scan, Safety
809245|NCT03100110|Brain-Computer Interface
809246|NCT03100110|Brain-Machine Interface
809247|NCT03100110|Prefrontal Cortex
809248|NCT03100084|Preeclampsia
809249|NCT03100084|Diabetes in Pregnancy
809250|NCT03100084|Fetal Growth Restriction
809251|NCT03100084|Reduced Fetal Movements
809252|NCT03100058|Obesity
809253|NCT03100058|Overweight
809254|NCT03100045|HPV
809255|NCT03100045|suppository
809256|NCT03100045|Artesunate
809257|NCT03100045|artemisinin
809258|NCT03100045|anal dysplasia
809259|NCT03100045|treatment
809260|NCT03100045|alternative treatment
809261|NCT03100045|anal precancer
809262|NCT03100045|Johns Hopkins
809263|NCT03100045|Sandy Fang
809264|NCT03100045|Frantz Viral Therapeutics
809265|NCT03100032|Spinal Fusion
809266|NCT03100032|Lumbar Interbody Fusion
809267|NCT03100032|Autologous Stem Cell Therapy
809268|NCT03100032|Bone Graft
809269|NCT03100032|Demineralized Bone Matrix
809270|NCT03100032|Polyetheretherketone (PEEK) cage
809271|NCT03100019|Resveratrol
809272|NCT03100019|Cerebral blood flow
809273|NCT03100019|Cognition
809274|NCT03099993|Unilateral cerebral palsy
809275|NCT03099993|kinematics
809276|NCT03099993|electromyography
809277|NCT03099993|constraint-induced therapy
809278|NCT03099993|muscle activation
809279|NCT03099993|upper limb
809280|NCT03099993|child
809281|NCT03099941|Low Back Pain, Mechanical, Biofeedback, Pain, Chronic
809282|NCT03099902|Asthma
809283|NCT03099902|Wheezing
809284|NCT03099902|GSTP1
809285|NCT03099902|TNFa
809286|NCT03099902|Secondhand smoking
809287|NCT03099902|Passive smoking
809288|NCT03099902|Intrauterine smoking
809289|NCT03099850|Chronic Pancreatitis
809290|NCT03099850|Data management
809291|NCT03099850|Regulatory compliance
809292|NCT03099850|Protocol monitoring
809300|NCT03099772|Cognitive-Behavioral Therapy
809303|NCT03099746|chronically critically ill
809304|NCT03099746|surrogate decision maker
809305|NCT03099512|Patellofemoral pain
809306|NCT03099512|foot deformity
809307|NCT03099512|foot pronation
809308|NCT03099512|short foot exercise
809309|NCT03099473|electroacupuncture
809310|NCT03099473|trochlear nerve palsy
809311|NCT03099473|eyeball movement
809312|NCT03099473|diplopia
809313|NCT03099473|ocular motility disorder
809314|NCT03099460|electroacupuncture
809315|NCT03099460|abducens nerve palsy
809316|NCT03099460|eyeball movement
809317|NCT03099460|diplopia
809318|NCT03099460|ocular motility disorder
809319|NCT03099447|electroacupuncture
809320|NCT03099447|oculomotor nerve palsy
809321|NCT03099447|rehabilitation
809322|NCT03099447|diplopia
809323|NCT03099447|ocular motility disorder
809324|NCT03099434|Live Donor Transplant, Social Media, Education, Advocacy, Live Donor
809325|NCT03099421|Benign prostatic obstruction
809326|NCT03099421|benign prostatic enlargement
809327|NCT03099421|benign prostatic hyperplasia
809328|NCT03099421|prostatic artery embolization
809329|NCT03099421|Quality of Life
809330|NCT03099421|IPSS
809331|NCT03099421|DAN-PSS
809332|NCT03099421|Complications
809333|NCT03099408|Recurrence
809334|NCT03099408|Lactobacillus Vaginal Suppositories
809335|NCT03099395|myocardial infarction
809336|NCT03099369|Peripheral Artery Disease
809337|NCT03099369|Peripheral Arterial Disease
809338|NCT03099369|Exercise
809339|NCT03099369|Step Count
809340|NCT03099369|Fitness Monitor
809341|NCT03099369|Mobile Health
809342|NCT03099369|Walking Ability
809343|NCT03099369|Quality of Life
809344|NCT03099343|sodium
809345|NCT03099343|salt
809346|NCT03099343|diet
809347|NCT03099343|tailored messaging
809348|NCT03099343|mobile application
809349|NCT03099317|Knee Osteoarthritis
809350|NCT03099317|Sinew Acupuncture
809351|NCT03099317|Pain
809352|NCT03099304|Vitiligo
809353|NCT03099304|depigmenting disorder
809354|NCT03099304|topical JAK inhibitor
809355|NCT03099278|hepatitis D
809356|NCT03099278|Ezetimibe
809357|NCT03099278|HDV RNA
809367|NCT03099096|SB240563
809368|NCT03099096|Mepolizumab
809369|NCT03099096|self-administration
809370|NCT03099096|eosinophilic asthma
809371|NCT03099096|autoinjector
809372|NCT03099083|Adalimumab
809373|NCT03099083|Psoriasis
809374|NCT03099083|Humira
809375|NCT03099083|Korea
809376|NCT03099070|Stress
809377|NCT03099070|Fasting
809378|NCT03099070|Migraine
809379|NCT03099031|Ottawa score
809380|NCT03099031|tinzaparin
809381|NCT03099031|low-molecular weight heparin
809382|NCT03099031|anticoagulants
809383|NCT03099031|venous thrombosis
809384|NCT03099031|thromboembolism
809385|NCT03099031|hemostatic disorders
809386|NCT03099031|vascular disease
809387|NCT03099031|neoplasms
809388|NCT03099031|breast neoplasms
809389|NCT03099031|lung neoplasms
809390|NCT03099031|prostatic neoplasms
809391|NCT03099031|colorectal neoplasms
809392|NCT03099031|genital neoplasms
809393|NCT03099031|urogenital neoplasms
809394|NCT03099031|intestinal neoplasms
809395|NCT03099031|digestive system neoplasms
809396|NCT03099031|lymphoma
809397|NCT03099031|leukemia
809398|NCT03099031|multiple myeloma
809399|NCT03099031|lymphoproliferative disorders
809400|NCT03099031|myeloproliferative disorders
809401|NCT03099031|lymphatic disease
809402|NCT03099018|GAS
809403|NCT03099018|pharyngitis
809404|NCT03099018|children
809405|NCT03099018|RADT
809406|NCT03099005|neuropathic pain
809407|NCT03099005|human immunovirus
809408|NCT03099005|vaporized cannabis
809409|NCT03098979|Chronic Heart Failure
809410|NCT03098979|Heart Failure with Preserved Ejection Fraction
809411|NCT03098953|Ocular Installation
809412|NCT03098927|Motor Imagery
809413|NCT03098927|Spinal Cord Injury
809414|NCT03098927|Motor Function Improvement
809415|NCT03098914|Pathogen
809416|NCT03098914|Mortality
809417|NCT03098914|Community-acquired Pneumonia
809418|NCT03098914|Risk factors
809419|NCT03098901|TTR Amyloidosis
809420|NCT03098901|Heart Failure with Preserved Ejection Fraction
809421|NCT03098901|Ventricular arrhythmia
809422|NCT03098901|Cardiac Conduction Disturbances
809423|NCT03098888|side effects
809424|NCT03098888|decision making
809425|NCT03098888|indications
809426|NCT03098888|risk factors
809432|NCT03098849|Buteyko-based breathing technique training
809433|NCT03098836|metastatic
809434|NCT03098836|castrate resistant
809435|NCT03098797|Barth Syndrome
809436|NCT03098797|elamipretide
809437|NCT03098797|MTP-131
809438|NCT03098797|Stealth
809439|NCT03098797|Stealth BT
809440|NCT03098797|BTHS
809441|NCT03098784|airport environment
809442|NCT03098784|Air France
809443|NCT03098784|flightline employees
809444|NCT03098784|administrative employees
809445|NCT03098758|Polymerase Chain Reaction
809446|NCT03098758|gastric cancer
809447|NCT03098758|citology
809448|NCT03098758|peritoneal washing
809449|NCT03098758|CK20
809450|NCT03098758|CEA
809451|NCT03098758|BER-EP4
809452|NCT03098732|Stroke
809453|NCT03098732|Ischemic
809454|NCT03098732|Tissue Plasminogen Activator
809455|NCT03098732|Thrombolysis
809456|NCT03098732|Vascular Diseases
809457|NCT03098732|Cerebrovascular Disorders
809458|NCT03098732|Fibrinolytic Agents
809459|NCT03098732|Plasminogen
809460|NCT03098693|Serodiscordant
809461|NCT03098693|Pre-exposure Prophylaxis
809462|NCT03098693|Self-testing
809463|NCT03098693|Tanzania
809464|NCT03098680|Adverse reactions
809465|NCT03098680|Cardiovascular
809466|NCT03098680|Translation
809467|NCT03098680|Modelling
809468|NCT03098680|Pharmacokinetics
809469|NCT03098680|Pharmacodynamics
809470|NCT03098654|Human Immunodeficiency Virus
809471|NCT03098654|Community Health Services
809472|NCT03098654|Chronic Disease
809473|NCT03098654|Integrated Delivery of Health Care
809474|NCT03098654|Tanzania
809475|NCT03098589|Adult T-cell Leukemia Lymphoma
809476|NCT03098589|Teratogenicity
809477|NCT03098589|Myelosuppression
809478|NCT03098589|Haemorrhage
809479|NCT03098589|Infection
809480|NCT03098589|Thromboembolism
809481|NCT03098589|Hypersensitivity
809482|NCT03098589|Tumor lysis syndrome
809483|NCT03098589|Peripheral neuropathy
809484|NCT03098589|Ischaemic heart disease
809485|NCT03098589|Cardiac failure
809486|NCT03098589|Arrhythmia
809487|NCT03098589|Renal failure
809488|NCT03098589|Interstitial lung disease
809489|NCT03098589|Hepatic disorder
809490|NCT03098589|Hypothyroidism
809491|NCT03098589|Gastrointestinal perforation
809492|NCT03098589|Orthostatic hypotension
809493|NCT03098589|Convulsion
809494|NCT03098589|Somnolence
809495|NCT03098589|Confusion
809496|NCT03098589|Fatigue
809497|NCT03098589|Dizziness
809498|NCT03098589|Blurred vision
809499|NCT03098589|Second primary cancer
809500|NCT03098589|Cataract
809501|NCT03098589|Revlimid capsules
809502|NCT03098576|advanced
809503|NCT03098576|metastatic solid tumors
809504|NCT03098563|Clinical Trial
809505|NCT03098563|Phase II
809506|NCT03098550|Non-small cell lung cancer (NSCLC)
809507|NCT03098550|Triple Negative Breast Cancer (TNBC)
809508|NCT03098550|Pancreatic Cancer (PAC)
809509|NCT03098524|Cardiac surgery
809510|NCT03098524|Mechanical ventilation
809511|NCT03098524|Cardiopulmonary bypass
809512|NCT03098524|Pneumonia
809513|NCT03098524|Atelectasis
809514|NCT03098511|Neurological Determination of Death
809515|NCT03098511|Determination of Death
809516|NCT03098511|CT-Perfusion scan
809517|NCT03098511|Ancillary Test
809518|NCT03098511|Organ Donation
809519|NCT03098498|periodontitis
809520|NCT03098498|scaling
809521|NCT03098498|attachment gain
809522|NCT03098498|air polishing
809523|NCT03098498|periodontal lesion
809524|NCT03098394|Rapid turnaround test
809525|NCT03098394|RTAT
809526|NCT03098394|Gonorrhea
809527|NCT03098394|Chlamydia
809528|NCT03098394|STI
809529|NCT03098368|Parkinson's disease
809530|NCT03098368|Rotigotine transdermal patch
809531|NCT03098368|Nocturnal hypokinesia
809532|NCT03098355|CART
809533|NCT03098355|CD19
809534|NCT03098355|CD22
809535|NCT03098355|Interleukin-2
809536|NCT03098342|Onychomycosis
809537|NCT03098342|photodynamic therapy
809538|NCT03098342|methylene blue
809539|NCT03098342|amorolfine, nail lacquer
809540|NCT03098342|Asians
809541|NCT03098329|Screening
809542|NCT03098329|men
809543|NCT03098329|expedited treatment
809544|NCT03098316|Cross sectional studies
809545|NCT03098316|Metabolomics
809546|NCT03098316|Glaucoma
809547|NCT03098316|Low tension glaucoma
809548|NCT03098316|Ophthalmologic surgical procedures
809549|NCT03098290|GermanVasc
809550|NCT03098290|Peripheral Arterial Disease
809551|NCT03098290|IDOMENEO
809552|NCT03098290|Routine Data
809553|NCT03098290|Registry Data
809554|NCT03098290|Data Validity
809555|NCT03098199|Antimullerian Hormone
809556|NCT03098199|In vitro fertilization
809557|NCT03098199|Medications
809558|NCT03098199|Dosing
809559|NCT03098186|Medication adherence
809560|NCT03098186|mHealth
809561|NCT03098173|Early colonoscopy
809562|NCT03098173|Stigmata of recent hemorrhage
809563|NCT03098173|Rebleeding
809564|NCT03098160|Immunotherapy
809565|NCT03098160|Hypoxia
809566|NCT03098160|Evofosfamide
809567|NCT03098160|Ipilimumab
809568|NCT03098160|TH-302
809569|NCT03098069|Kangaroo Mother Care
809570|NCT03098069|Low Birth Weight
809571|NCT03098069|Implementation research
809572|NCT03098043|Hypothermic machine perfusion
809573|NCT03098043|Donation after circulatory death
809574|NCT03098043|Extended criteria liver grafts
809578|NCT03097991|Coparenting Unmarried African-American Prenatal
809579|NCT03097913|nasotracheal intubation
809580|NCT03097913|video-stylet
809581|NCT03097913|nasal cavity injury
809582|NCT03097900|Postoperative Ileus
809583|NCT03097900|Caffeine Citrate
809584|NCT03097887|Omega Loop Gastric Bypass
809585|NCT03097887|Reflux
809586|NCT03097887|Mini Gastric Bypass
809587|NCT03097874|anorexia
809588|NCT03097874|anorexia nervosa
809589|NCT03097874|eating disorder
809590|NCT03097874|weight
809591|NCT03097874|eating
809592|NCT03097874|weight loss
809593|NCT03097874|family based treatment
809594|NCT03097874|FBT
809595|NCT03097874|family treatment
809596|NCT03097874|therapy
809597|NCT03097874|Maudsley method
809598|NCT03097783|hyaluronic acid, midface
809599|NCT03097757|Ultrasound
809600|NCT03097757|Forearm Fracture Reduction
809601|NCT03097757|Pediatric Emergency Department
809602|NCT03097744|Lateral Meniscus Tear
809603|NCT03097744|Medial Meniscus Tear
809604|NCT03097731|interleukin-10
809605|NCT03097731|inflammatory bowel disease
809606|NCT03097692|cardiac preconditioning
809607|NCT03097692|open heart surgery
809608|NCT03097653|breast cancer screening
809609|NCT03097653|mammography
809610|NCT03097653|decision-aid
809611|NCT03097653|informed choice
809612|NCT03097653|National Cancer Screening Program
809613|NCT03097627|Indocyanine Green
809614|NCT03097627|Near-infrared imaging
809615|NCT03097575|Lung lesions
809616|NCT03097575|Navigational bronchoscopy
809617|NCT03097575|Near infrared imaging
809618|NCT03097575|Lymphadenectomy
809619|NCT03097562|Cataract
809620|NCT03097562|Femtosecond laser
809621|NCT03097562|Cornea
809622|NCT03097562|Anatomy
809623|NCT03097562|FSL
809624|NCT03097562|surgery
809625|NCT03097549|urinary incontinence
809626|NCT03097549|urgency urinary incontinence
809627|NCT03097549|mixed urinary incontinence
809628|NCT03097549|smartphone application
809629|NCT03097549|ehealth
809630|NCT03097549|mhealth
809631|NCT03097549|randomized controlled trial
809632|NCT03097549|self management
809633|NCT03097549|treatment
809634|NCT03097536|Blood Sugar
809635|NCT03097523|NSBRI
809636|NCT03097510|Perceived stress
809637|NCT03097510|Leadership
809638|NCT03097510|Transcendental Meditation
809639|NCT03097497|Chronic Non-specific Low-Back Pain
809640|NCT03097497|Chronic Low-Back Pain
809641|NCT03097497|Physiotherapy
809642|NCT03097497|Therapeutic Exercise
809643|NCT03097497|Primary Care
809644|NCT03097497|Transverse Abdominal Muscle
809645|NCT03097458|Counselling for Families
809646|NCT03097458|Parental cancer
809647|NCT03097458|Psychological distress and adjustment
809648|NCT03097445|Smoking
809649|NCT03097445|Nicotine
809650|NCT03097445|Nicotine Replacement Therapy
809651|NCT03097445|Nicotine Patch
809652|NCT03097445|Mass Distribution
809653|NCT03097445|Tobacco Control
809654|NCT03097445|Cancer Prevention
809655|NCT03097445|Randomized Controlled Trial
809656|NCT03097419|non-ST segment elevation myocardial infarction
809657|NCT03097419|myocardial infarction
809658|NCT03097419|remote ischemic conditioning
809659|NCT03097419|ischemic conditioning
809660|NCT03097419|sphygmomanometer
809661|NCT03097419|metabolomics
809663|NCT03097367|laparoscopic radical prostatectomy
809664|NCT03097367|urinary incontinence
809665|NCT03097367|prostate cancer
809666|NCT03097367|bladder neck level
809667|NCT03097367|urodynamics
809668|NCT03097354|alcohol use
809669|NCT03097354|consumption measure
809670|NCT03097354|Composite International Diagnostic Interview (CIDI)
809671|NCT03097354|internet survey
809672|NCT03097354|standardized assessment
809673|NCT03097328|Renal Cell Carcinoma
809687|NCT03097302|laser-assisted keratotomy
809688|NCT03097302|anterior astigmatism
809689|NCT03097302|posterior astigmatism
809690|NCT03097302|total corneal refractive power
809691|NCT03097302|nomogram
809692|NCT03097289|Healthy Adults
809693|NCT03097250|PKU
809694|NCT03097250|Neuropsychology
809695|NCT03097250|MRI
809696|NCT03097198|Juvenile
809697|NCT03097198|Traditional Chinese Medicine
809698|NCT03097198|Plum-blossom needle
809699|NCT03097185|pancreatitis
809700|NCT03097185|islet cell
809701|NCT03097172|Percutaneous Coronary Intervention (PCI)
809702|NCT03097172|Chronic Total Occlusion (CTO)
809703|NCT03097172|Cardiac MRI
809704|NCT03097172|Fractional Flow Reserve (FFR)
809705|NCT03097172|Doppler Flow Velocity
809706|NCT03097172|Cardiovascular Disease
809707|NCT03097172|Atherosclerosis
809708|NCT03097172|Hydrostatic Pressure
809709|NCT03097159|costoclavicular block
809710|NCT03097146|Stroke
809711|NCT03097146|Aftercare
809712|NCT03097146|Comprehensive Care
809713|NCT03097107|hypertriglyceridemia
809714|NCT03097107|dyslipidemia
809715|NCT03097107|saroglitazar magnesium
809716|NCT03097107|lipid disorder
809717|NCT03097094|Dog allergy
809718|NCT03097094|Can f 5
809719|NCT03097094|Male dog
809720|NCT03097094|Female dog
809721|NCT03097094|Allergen components
809722|NCT03097055|Stroke
809723|NCT03097055|Acupuncture
809724|NCT03097055|antiinflammatory
809725|NCT03097055|NIHSS
809726|NCT03097029|pancreatic enzymes
809727|NCT03097016|Renal Impairment
809728|NCT03097016|Pharmacokinetics
809729|NCT03097016|CC-122
809730|NCT03097016|Mild
809731|NCT03097016|Moderate
809732|NCT03097016|Severe
809733|NCT03097003|Proriasis
809734|NCT03097003|Real-life management
809735|NCT03097003|Observational
809736|NCT03097003|Otezla
809737|NCT03097003|CC-10004
809738|NCT03097003|Apremilast
809739|NCT03097003|Belgium
809740|NCT03097003|OTELO
809741|NCT03096990|Psoriatic Arthritis
809742|NCT03096990|Observational
809743|NCT03096990|Otezla
809744|NCT03096990|Apremilast
809745|NCT03096990|Real-Life management
809746|NCT03096990|Belgium
809747|NCT03096990|APOLO
809748|NCT03096990|CC-10004
809749|NCT03096977|Hand dexterity
809750|NCT03096977|Multiple sclerosis
809751|NCT03096977|Nine Holes Peg
809752|NCT03096964|Elderly training
809753|NCT03096964|Pole walking
809754|NCT03096964|Locomotor Rehabilitation Index
809755|NCT03096964|Self-selected speed of walking
809756|NCT03096964|Recovery
809757|NCT03096938|cell-free DNA
809758|NCT03096938|methylation
809759|NCT03096938|markers
809760|NCT03096938|cancer
809761|NCT03096938|screening
809762|NCT03096925|non-cardiac chest pain
809763|NCT03096925|anxiety
809764|NCT03096912|CDK4 inhibitor
809765|NCT03096912|LEE011
809766|NCT03096912|ribociclib
809767|NCT03096912|liposarcoma dedifferentiated
809768|NCT03096912|liposarcoma well differentiated
809769|NCT03096886|Cognitive Behavioral Therapy
809770|NCT03096886|Computer-Assisted Cognitive Behavioral Therapy
809771|NCT03096886|Computer-Augmented Cognitive Behavioral Therapy
809772|NCT03096886|CBT
809773|NCT03096886|Computer-Assisted CBT
809774|NCT03096886|Computer-Augmented CBT
809775|NCT03096847|ribociclib
809776|NCT03096847|LEE011
809777|NCT03096847|RIBECCA
809778|NCT03096847|breast cancer
809779|NCT03096847|breast carcinoma
809780|NCT03096847|HR-positive
809781|NCT03096847|HER2-negative
809782|NCT03096847|advanced breast cancer
809783|NCT03096847|Letrozole
809784|NCT03096847|CDK4/6
809793|NCT03096808|adaptive radiotherapy
809794|NCT03096808|ART
809795|NCT03096808|intensity modulated radiation therapy
809796|NCT03096808|IMRT
809797|NCT03096795|MEDI3506
809798|NCT03096795|Safety
809799|NCT03096795|Tolerability
809800|NCT03096795|Pharmacokinetics
809801|NCT03096795|Immunogenicity
809802|NCT03096782|Acute Myelogenous Leukemia
809803|NCT03096782|AML
809804|NCT03096782|Myelodysplastic Syndrome
809805|NCT03096782|MDS
809806|NCT03096782|Acute Lymphoblastic Leukemia
809807|NCT03096782|ALL
809808|NCT03096782|Non-Hodgkin's Lymphoma
809809|NCT03096782|NHL
809810|NCT03096782|Small Lymphocytic Lymphoma
809811|NCT03096782|SLL
809812|NCT03096782|Chronic Lymphocytic Leukemia
809813|NCT03096782|CLL
809814|NCT03096782|Hodgkin's Disease
809815|NCT03096782|HD
809816|NCT03096782|Busulfan
809817|NCT03096782|Busulfex
809818|NCT03096782|Myleran
809819|NCT03096782|Rituximab
809820|NCT03096782|Rituxan
809821|NCT03096782|ATG
809822|NCT03096782|ATG(rabbit)
809823|NCT03096782|Rabbit Antithymocyte Globulin
809824|NCT03096782|Rabbit Antilymphocyte Globulin
809825|NCT03096782|Rabbit ATG
809826|NCT03096782|rATg
809827|NCT03096782|Thymoglobulin
809828|NCT03096782|Fludarabine
809829|NCT03096782|Fludarabine Phosphate
809830|NCT03096782|Fludara
809831|NCT03096782|Clofarabine
809832|NCT03096782|Clofarex
809833|NCT03096782|Clolar
809834|NCT03096782|Total Body Irradiation
809835|NCT03096782|TBI
809836|NCT03096782|XRT
809837|NCT03096782|External Beam Radiotherapy
809838|NCT03096782|Mycophenolate Mofetil
809839|NCT03096782|MMF
809840|NCT03096782|CellCept
809841|NCT03096782|Tacrolimus
809842|NCT03096782|Prograf
809843|NCT03096782|G-CSF
809844|NCT03096782|Filgrastim
809845|NCT03096782|Neupogen
809846|NCT03096782|Melphalan
809847|NCT03096782|Alkeran
809848|NCT03096782|Cyclophosphamide
809849|NCT03096782|Cytoxan
809850|NCT03096782|Neosar
809851|NCT03096782|Mesna
809852|NCT03096782|Mesnex
809853|NCT03096782|Cord Blood Transplantation
809854|NCT03096782|Stem Cell Transplant
809855|NCT03096756|Oral Formulation
809856|NCT03096756|Food Effect
809857|NCT03096756|Superoxide Dismutase
809858|NCT03096756|Single Ascending Dose
809859|NCT03096756|GC4702
809860|NCT03096756|Bioavailability
809861|NCT03096756|Pharmacokinetics
809862|NCT03096756|Active Comparator
809863|NCT03096730|Remifentanil
809864|NCT03096730|Opioid-induced hyperalgesia
809865|NCT03096730|Postoperative pain
809866|NCT03096730|pain intensity
809867|NCT03096691|cervical pessary
809868|NCT03096691|preterm labor
809869|NCT03096691|Cervical insufficiency
809870|NCT03096678|Left Bundle Branch Block
809871|NCT03096678|Regional/Globle cardiac function
809872|NCT03096678|Mechanical asynchrony
809873|NCT03096678|Cardiovascular Magnetic Resonance
809874|NCT03096678|Outcome
809875|NCT03096678|Cardiovascular events
809876|NCT03096665|venous blood
809877|NCT03096665|arterial blood
809878|NCT03096665|capillary blood
809879|NCT03096652|gynecologic cancer - panniculectomy
809880|NCT03096639|Diaphragm atrophy
809881|NCT03096639|VIDD
809882|NCT03096639|Weaning failure
809883|NCT03096626|Depression
809884|NCT03096613|heart failure
809885|NCT03096613|Subclinical Hyperthyroidism
809886|NCT03096613|levothyroxine
809887|NCT03096613|6-minute walk test
809888|NCT03096600|spine
809889|NCT03096587|XP Endo Finisher
809890|NCT03096587|ultrasonic activated irrigation
809891|NCT03096587|postoperative pain
809892|NCT03096574|Respiratory Syncytial Virus (RSV)
809893|NCT03096574|Maternal vaccination
809894|NCT03096574|Attitudes
809895|NCT03096574|Pregnancy
809896|NCT03096548|Skin Cancer
809897|NCT03096548|Tattoo
809898|NCT03096496|Quality of life
809899|NCT03096496|acute promyelocytic leukemia
809900|NCT03096496|ATO
809901|NCT03096457|leishmaniasis
809902|NCT03096457|L.braziliensis
809903|NCT03096457|paromomycin cream
809904|NCT03096457|intralesional pentamidine
809905|NCT03096457|leishmaniasis local therapy
809906|NCT03096431|whole-brain radiation therapy
809907|NCT03096431|sterotactic radiosurgery
809908|NCT03096431|cognitive rehabilitation
809909|NCT03096431|physical activity
809910|NCT03096379|TB
809911|NCT03096379|CD
809912|NCT03096379|MRE
809913|NCT03096379|ileocecal
809914|NCT03096366|anterior cruciate ligament reconstruction
809918|NCT03096340|SN-38
809919|NCT03096340|irinotecan
809920|NCT03096327|Quality of Life
809921|NCT03096327|Asthma control test
809922|NCT03096327|Montelukast
809923|NCT03096327|Asthma
809924|NCT03096314|ARDS
809925|NCT03096314|Vitamin D
809926|NCT03096301|temporomandibular disorder
809927|NCT03096301|photobiomodulation
809928|NCT03096301|pain
809929|NCT03096275|Mycophenolate mofetil
809930|NCT03096275|Methotrexate
809931|NCT03096275|cyclophosphamide
809932|NCT03096262|cognitive skills
809933|NCT03096262|technical
809934|NCT03096262|internet platform
809935|NCT03096262|Stroke
809936|NCT03096262|Hemiparesis
809937|NCT03096249|oxytocin
809938|NCT03096249|emotion recognition
809939|NCT03096249|emotion processing
809940|NCT03096249|social salience
809941|NCT03096249|face processing
809942|NCT03096249|Electroencephalography (EEG)
809943|NCT03096210|Maxillar sinus
809944|NCT03096210|Titanium-Prepared Platelet Rich Fibrin
809945|NCT03096210|Allograft
809946|NCT03096210|implant
809947|NCT03096197|Spinal Cord injury (SCI)
809948|NCT03096197|Transcutaneous lumbosacral stimulation (TLS)
809949|NCT03096197|Exoskeleton-Assisted Walking (EAW)
809950|NCT03096184|head and neck cancer
809951|NCT03096184|Apatinib
809952|NCT03096184|Tegafur Gimeracil Oteracil
809953|NCT03096171|Stress
809954|NCT03096171|Well-being
809955|NCT03096171|Positive Psychology
809956|NCT03096158|Coronary artery bypass grafting
809957|NCT03096158|Cardiorespiratory rehabilitation
809958|NCT03096158|Functional electrical stimulation
809959|NCT03096158|Inspiratory muscle training
809960|NCT03096158|Aerobic training
809961|NCT03096158|Isometric handgrip training
809962|NCT03096158|Functional capacity
809963|NCT03096158|Endothelial function
809964|NCT03096158|Cardiac function
809965|NCT03096145|tobacco
809966|NCT03096145|quitlines
809967|NCT03096145|social support
809968|NCT03096145|mobile support
809969|NCT03096132|Obesity
809970|NCT03096132|Overweight
809971|NCT03096132|Overeating
809972|NCT03096132|Body Mass Index
809973|NCT03096132|Treatment
809974|NCT03096132|Intervention
809975|NCT03096132|Family Based Therapy
809976|NCT03096132|Weight
809977|NCT03096132|Children
809978|NCT03096119|blood pressure monitoring, home
809979|NCT03096119|Asia
809990|NCT03096041|auriculotherapy
809991|NCT03096041|aromatase inhibitors
809992|NCT03096041|adjuvant treatment
809993|NCT03096028|maternal nutrition
809994|NCT03096028|neurocognitive development
809995|NCT03096028|brain volume
809996|NCT03096002|PreDiabetes, Lifestyle intervention, Exercise Behavior, Adherence
809997|NCT03095989|mindfulness
809998|NCT03095976|Guided Tissue Regeneration,
809999|NCT03095976|Amnion-Chorion,
810000|NCT03095976|Intrabony defects,
810001|NCT03095976|furcation
810002|NCT03095950|Spin
810003|NCT03095950|Misleading reporting
810004|NCT03095950|Misleading interpretation
810005|NCT03095950|Misleading extrapolation
810006|NCT03095950|Randomized controlled trials
810007|NCT03095950|Patients
810008|NCT03095924|Spin
810009|NCT03095924|Misleading reporting
810010|NCT03095924|Misleading interpretation
810011|NCT03095924|Misleading extrapolation
810012|NCT03095924|Randomized controlled trials
810013|NCT03095924|Patients
810014|NCT03095911|Spin
810015|NCT03095911|Misleading reporting
810016|NCT03095911|Misleading interpretation
810017|NCT03095911|Misleading extrapolation
810018|NCT03095911|Randomized controlled trials
810019|NCT03095911|Patients
810020|NCT03095898|Colonoscopy
810021|NCT03095898|Acupuncture
810022|NCT03095885|Urine Oxalate
810023|NCT03095885|Nephrolithiasis
810024|NCT03095885|Kidney Stones
810025|NCT03095885|Hyperoxaluria
810026|NCT03095885|Enteric Hyperoxaluria
810027|NCT03095885|urological Diseases
810028|NCT03095885|Kidney Diseases
810029|NCT03095885|Dietary Oxalate
810030|NCT03095885|Idiopathic Hyperoxaluria
810031|NCT03095885|Oxalate Absorption
810032|NCT03095872|photodamaged skin
810033|NCT03095872|wound healing
810034|NCT03095872|CO2 laser
810035|NCT03095820|Community
810036|NCT03095820|Depressive Symptoms
810037|NCT03095820|Mental Health Program
810038|NCT03095820|Older adults
810039|NCT03095768|Lifestyle
810040|NCT03095768|Nutrition
810041|NCT03095768|Cooking
810042|NCT03095742|Microdialysis
810043|NCT03095742|Cerebral metabolism
810044|NCT03095742|Cardiac arrest
810045|NCT03095742|Intravenous
810046|NCT03095742|Neurological prognosis
810047|NCT03095716|Carbon dioxide pneumoperitoneum
810048|NCT03095716|Intraperitoneal pressure
810049|NCT03095716|Post-operative recovery
810050|NCT03095716|Laparoscopic Humidification System
810051|NCT03095703|Sirolimus
810052|NCT03095703|Intestinal adenomas
810053|NCT03095690|Osteoporosis
810054|NCT03095690|Parkinson
810055|NCT03095690|HR-pQCT
810056|NCT03095690|bone microstructure
810057|NCT03095690|fracture risk
810058|NCT03095677|dynamic apnea
810059|NCT03095677|muscle oxygenation
810060|NCT03095677|physical performance
810061|NCT03095664|lifestyle intervention
810062|NCT03095664|endometrial cancer
810063|NCT03095664|survival
810064|NCT03095638|Dispersible tablets
810065|NCT03095638|Bioavailability
810066|NCT03095638|Dolutegravir
810067|NCT03095638|Healthy
810068|NCT03095638|Conventional tablets
810069|NCT03095625|Sepsis
810070|NCT03095625|Bleeding disorder
810071|NCT03095625|Viscoelastic tests
810072|NCT03095599|Influenza
810073|NCT03095599|Vaccine
810074|NCT03095586|Spin
810075|NCT03095586|Misleading reporting
810076|NCT03095586|Misleading interpretation
810077|NCT03095586|Misleading extrapolation
810078|NCT03095586|Randomized controlled trials
810079|NCT03095586|Patients
810080|NCT03095573|Celiac disease
810081|NCT03095573|Enteropathy associated T cell lymphoma
810082|NCT03095573|Refractory celiac disease
810083|NCT03095573|Small bowel adenocarcinoma
810084|NCT03095534|Occupational Therapy
810085|NCT03095534|Aging in place
810086|NCT03095534|Activities of daily living
810087|NCT03095534|Community program
810088|NCT03095521|Angal
810089|NCT03095521|ANTI-ANGIN® FORMULA
810090|NCT03095521|sore throat
810091|NCT03095521|no less therapeutic efficacy
810092|NCT03095508|Angal S
810093|NCT03095508|ANTI-ANGIN FORMULA
810094|NCT03095508|Sore Throat
810095|NCT03095508|no less therapeutic efficacy
810096|NCT03095495|Heated Humidified High Flow Nasal Cannula (HHHFNC)
810097|NCT03095495|Low Flow Nasal Cannula
810098|NCT03095495|Bronchiolitis
810099|NCT03095495|Respiratory Syncytial Virus (RSV)
810100|NCT03095495|Respiratory Failure
810101|NCT03095495|High Flow Nasal Cannula (HFNC)
810102|NCT03095495|Lung Diseases, Obstructive
810103|NCT03095482|Arachnophobia (fear of spiders)
810104|NCT03095482|Ophidophobia (fear of snakes)
810105|NCT03095482|Claustrophobia (fear of tightly enclosed spaces)
810106|NCT03095482|Germaphobia (fear of germs, dirtiness, and contamination)
810107|NCT03095456|Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate
810108|NCT03095443|Delirium
810109|NCT03095443|Critical Illness
810110|NCT03095443|Music Therapy
810111|NCT03095430|Trauma
810112|NCT03095430|General Anesthesia
810113|NCT03095430|Surgical Pleth Index
810114|NCT03095430|Entropy
810115|NCT03095417|Delirium
810116|NCT03095417|Alzheimer's Disease
810117|NCT03095417|Aging
810118|NCT03095417|Exercise Therapy
810119|NCT03095417|Cognitive Training
810120|NCT03095378|gingival recession
810121|NCT03095339|Burkina Faso
810122|NCT03095339|Community-based randomized controlled trial
810123|NCT03095339|Cysticercosis
810124|NCT03095339|Implementation Research
810125|NCT03095339|Effectiveness
810126|NCT03095313|Transcatheter Aortic Valve Replacement (TAVR).
810127|NCT03095313|Surgical bioprosthetic aortic valve replacement
810128|NCT03095300|Prone Position
810129|NCT03095300|High-flow oxygen therapy
810138|NCT03095261|Cardiovascular Disease
810139|NCT03095261|Cardiac Rehabilitation
810140|NCT03095261|Financial Incentives
810141|NCT03095261|Outpatient (Phase II) Cardiac Rehabilitation Exercise Adherence
810142|NCT03095235|keratoconus
810143|NCT03095235|cornea ectasia
810144|NCT03095183|Posterior oropharynx exam
810145|NCT03095183|Pediatric
810146|NCT03095183|Tongue Depressor
810147|NCT03095183|Flavored Tongue Depressor
810148|NCT03095144|pyloromyotomy
810149|NCT03095144|spinal anaesthesia
810150|NCT03095144|surgical outcomes
810151|NCT03095144|general anaesthesia
810152|NCT03095144|infants
810153|NCT03095131|Heart Spectrum Blood Pressure MonitorHeart Spectrum
810154|NCT03095079|endostar
810155|NCT03095079|dacarbazine
810156|NCT03095079|cisplatin
810157|NCT03095066|aggression
810158|NCT03095066|agitation
810159|NCT03095066|irritability
810160|NCT03095066|non-penetrating brain injury
810161|NCT03095066|traumatic brain injury
810162|NCT03095066|AVP-786
810163|NCT03095053|blastocyst
810164|NCT03095053|comprehensive chromosome screening
810165|NCT03095053|euploidy
810166|NCT03095053|frozen embryo transfer
810167|NCT03093987|Shock
810168|NCT03093987|Critical Care Ultrasound
810169|NCT03093987|Lactate
810170|NCT03093987|Mortality
810171|NCT03093987|Prognosis
810172|NCT03093935|Post-Stroke
810173|NCT03093935|Neuromodulation
810174|NCT03093935|Axillary nerve
810175|NCT03093935|Peripheral Nerve Stimulation
810176|NCT03093922|Gemcitabine
810177|NCT03093922|Atezolizumab
810178|NCT03093922|Cisplatin
810179|NCT03093922|16-1621
810180|NCT03093909|Solid Tumors and Pulmonary Metastases
810181|NCT03093909|aerosol gemcitabine
810182|NCT03093909|aerosol GCB
810183|NCT03093909|Lung metastases
810184|NCT03093909|osteosarcoma
810185|NCT03093896|almonds
810186|NCT03093896|cereal snack
810187|NCT03095001|bevacizumab
810188|NCT03095001|Intraperitoneal administration
810189|NCT03095001|Ovarian Cancer
810190|NCT03095001|Peritoneal Adhesion
810191|NCT03094962|Kinematics
810192|NCT03094962|MRI Scans
810193|NCT03094962|CT Scan, Single-Photon Emission
810194|NCT03094962|finger interphalangeal joint
810195|NCT03094949|microwave ablation
810196|NCT03094949|partial nephrectomy
810197|NCT03094910|Raynaud Phenomenon
810198|NCT03094910|Hand and Arm Vibration Syndrome
810199|NCT03094910|Autonomic Imbalance
810200|NCT03094910|Thermography
810201|NCT03094897|Breast Neoplasms,Prostatic Neoplasms
810202|NCT03094858|Smartphone, sedentary behavior, smartphone intervention
810203|NCT03094832|ARQ 092
810204|NCT03094832|ArQule
810205|NCT03094832|AKT
810206|NCT03094832|PIK3CA
810207|NCT03094832|Overgrowth
810208|NCT03094832|Congenital malformations
810209|NCT03094793|abnormal EEGs (AIC)
810210|NCT03094767|Type 2 Diabetes Mellitus
810211|NCT03094767|Heart Rate Variability
810212|NCT03094767|Rehabilitation
810213|NCT03094767|Hemoglobin Glycated
810214|NCT03094715|Mechanical thrombectomy
810215|NCT03094715|Endovascular thrombectomy
810216|NCT03094689|Physical activity
810217|NCT03094689|Muscle pain
810218|NCT03094689|Cryotherapy
810219|NCT03094676|Massage
810220|NCT03094676|Autonomic nervous system
810221|NCT03094676|Recovery of Physiological Function
810222|NCT03094676|Heart Rate
810223|NCT03094663|IPACK
810224|NCT03094663|PAI
810225|NCT03094650|stroke
810226|NCT03094650|neurorehabilitation
810227|NCT03094650|virtual reality
810228|NCT03094650|rehabilitation dose
810229|NCT03094650|motor rehabilitation
810230|NCT03094637|Hematopoietic/Lymphoid Cancer
810231|NCT03094637|Myelodysplastic Syndrome
810232|NCT03094637|MDS
810233|NCT03094637|Higher risk
810234|NCT03094637|Azacitidine
810235|NCT03094637|5-azacytidine
810236|NCT03094637|5-aza
810237|NCT03094637|Vidaza
810238|NCT03094637|5-AZC
810239|NCT03094637|AZA-CR
810240|NCT03094637|Ladakamycin
810241|NCT03094637|NSC-102816
810242|NCT03094637|Azacytidine
810243|NCT03094637|Pembrolizumab
810244|NCT03094637|Keytruda
810245|NCT03094637|MK-3475
810246|NCT03094637|SCH-900475
810247|NCT03094624|Amusia
810248|NCT03094624|Audition
810249|NCT03094624|Short-term memory
810250|NCT03094624|Emotions
810251|NCT03094624|EEG
810252|NCT03094624|MEG
810253|NCT03094624|MRI
810254|NCT03094611|Acute lymphocytic leukemia
810255|NCT03094611|ALL
810256|NCT03094611|CD22-positive
810257|NCT03094611|Inotuzumab Ozogamicin
810258|NCT03094611|CMC-544
810259|NCT03094585|Healthy nurses
810260|NCT03094572|spinal cord circuitry
810261|NCT03094572|hemiplegia
810262|NCT03094572|rhythmic task
810263|NCT03094559|peripheral arterial disease
810264|NCT03094546|subjective cognitive decline
810265|NCT03094546|Alzheimer's disease, dementia
810266|NCT03094546|dietary supplement
810267|NCT03094546|polyamine
810268|NCT03094546|prevention
810269|NCT03094546|treatment
810270|NCT03094546|lifestyle
810271|NCT03094546|memory
810272|NCT03094546|autophagy
810273|NCT03094533|Anesthesia, intravenous
810274|NCT03094533|Anesthesia, inhalation
810275|NCT03094533|propofol
810276|NCT03094533|sevoflurane
810277|NCT03094533|glucose
810278|NCT03094468|terbinafine nail solution
810279|NCT03094468|nail fungal infection
810280|NCT03094468|topical antifungal drug
810281|NCT03094455|Tele-rehabilitation
810282|NCT03094455|Action Observation
810283|NCT03094455|Mirror neurons
810284|NCT03094455|ICT
810285|NCT03094442|Quality of Recovery
810286|NCT03094442|Minimally Invasive Sacrocolpopexy
810287|NCT03094442|Dexamethasone
810288|NCT03094377|Multisensory stimulation; motor recovery
810289|NCT03094364|Constraint-induced movement therapy
810290|NCT03094364|gaming
810291|NCT03094364|virtual reality
810292|NCT03094364|upper extremity
810293|NCT03094364|CI therapy
810294|NCT03094364|rehabilitation
810295|NCT03094364|hemiparesis
810296|NCT03094364|MS
810297|NCT03094364|therapy
810298|NCT03094351|robot assisted esophagectomy
810299|NCT03094351|minimally invasive esophagectomy
810300|NCT03094351|esophageal cancer
810301|NCT03094338|Psychology, Educational [F02.784.629]
810302|NCT03094325|Septal Myectomy
810307|NCT03094286|HIV
810308|NCT03094286|HIV with cancer patient
810309|NCT03094286|D006678
810310|NCT03094273|Melanocytic neoplasm
810311|NCT03094273|Biopsy
810312|NCT03094273|Saucerization biopsy
810313|NCT03094273|Skin lesion
810314|NCT03094247|Malnutrition
810315|NCT03094247|Micronutrients
810316|NCT03094247|Polyunsaturated fatty acids
810317|NCT03094247|Ready-to-use therapeutic foods
810318|NCT03094247|Omega-3 fatty acids
810319|NCT03094247|Peanuts
810320|NCT03094195|post-herpetic neuralgia
810321|NCT03094195|neuropathic pain
810322|NCT03094195|angiotensin II type 2 receptor antagonist
810323|NCT03094195|dose ranging
810324|NCT03094130|Spin
810325|NCT03094130|Misleading reporting
810326|NCT03094130|Misleading interpretation
810327|NCT03094130|Misleading extrapolation
810328|NCT03094130|phase I/II trials
810329|NCT03094130|non-randomized trials
810330|NCT03094130|Patients
810331|NCT03094117|Spin
810332|NCT03094117|Misleading reporting
810333|NCT03094117|Misleading interpretation
810334|NCT03094117|Misleading extrapolation
810335|NCT03094117|phase I/II trials
810336|NCT03094117|non-randomized trials
810337|NCT03094117|Patients
810338|NCT03094104|Spin
810339|NCT03094104|Misleading reporting
810340|NCT03094104|Misleading interpretation
810341|NCT03094104|Misleading extrapolation
810342|NCT03094104|phase I/II trials
810343|NCT03094104|non-randomized trials
810344|NCT03094104|Patients
810345|NCT03094091|Spin
810346|NCT03094091|Misleading reporting
810347|NCT03094091|Misleading interpretation
810348|NCT03094091|Misleading extrapolation
810349|NCT03094091|phase I/II trials
810350|NCT03094091|non-randomized trials
810351|NCT03094091|Patients
810352|NCT03094078|Spin
810353|NCT03094078|Misleading reporting
810354|NCT03094078|Misleading interpretation
810355|NCT03094078|Misleading extrapolation
810356|NCT03094078|Animal studies
810357|NCT03094078|Cell culture studies
810358|NCT03094078|Pre-clinical studies
810359|NCT03094065|Spin
810360|NCT03094065|Misleading reporting
810361|NCT03094065|Misleading interpretation
810362|NCT03094065|Misleading extrapolation
810363|NCT03094065|Animal studies
810364|NCT03094065|Cell culture studies
810365|NCT03094065|Pre-clinical studies
810366|NCT03094052|neratinib
810367|NCT03094052|trastuzumab
810368|NCT03094052|crofelemer
810369|NCT03094026|Hematologic cancers
810370|NCT03094026|Hematopoietic cell transplantation
810371|NCT03094026|cognitive training
810372|NCT03094026|genetic knowledge
810373|NCT03094026|genetic attitude
810374|NCT03094026|adult cancer survivors
810375|NCT03094013|psycho-social factors, psychological symptoms
810376|NCT03094000|Bulimia Nervosa
810377|NCT03094000|Binge-Eating
810378|NCT03094000|Self monitoring
810379|NCT03094000|Cognitive Behavioral Therapy (CBT)
810380|NCT03094000|Mindfulness
810381|NCT03093870|Neoplasms
810382|NCT03093870|Biliary Tract Neoplasms
810383|NCT03093870|Bile Duct Neoplasms
810384|NCT03093870|Gallbladder Neoplasms
810385|NCT03093844|Stem Cell Transplant
810386|NCT03093844|Umbilical Cord Blood Transplant
810387|NCT03093844|Haploidentical CD34+ Selected Cells
810388|NCT03093805|Hematopoietic Stem Cell Transplant
810389|NCT03093805|Graft Versus Host Disease
810390|NCT03093779|Hearing Loss
810391|NCT03093779|Deaf
810392|NCT03093779|Health Literacy
810393|NCT03093779|Health Information
810394|NCT03093779|Visual Learning
810395|NCT03093766|Aetiology
810396|NCT03093740|hemodialysis
810397|NCT03093740|renal failure
810398|NCT03093740|kidney transplant
810399|NCT03093714|Cystic Fibrosis
810400|NCT03093636|Type 1 Diabetes Mellitus (T1DM)
810401|NCT03093636|Continuous Glucose Monitor (CGM)
810402|NCT03093636|Multiple Daily Injections (MDI)
810403|NCT03093636|Insulin Pen
810404|NCT03093636|inControl Advice
810405|NCT03093636|Decision Support System (DSS)
810406|NCT03093623|physical activity
810407|NCT03093623|abstain from smoking
810408|NCT03093623|human papillomavirus (HPV)
810409|NCT03093623|cervical intraepithelial neoplasia (CIN)
810410|NCT03093558|adherence
810411|NCT03093558|quality of life
810412|NCT03093558|health literacy
810413|NCT03093545|rabies
810414|NCT03093545|obese
810415|NCT03093545|immunoglobulin
810416|NCT03093545|rabies vaccine
810417|NCT03093545|post-exposure
810418|NCT03093545|immunogenicity
810419|NCT03093532|emergency department
810420|NCT03093532|stage 2 hypertension
810421|NCT03093532|minorities
810422|NCT03093506|Erythropoietin
810423|NCT03093506|Randomized controlled trial
810424|NCT03093506|Human volunteers
810425|NCT03093506|Mitochondrial function
810426|NCT03093506|Cognitive performance
810427|NCT03093467|Internet
810428|NCT03093467|Mental Health
810429|NCT03093441|High-intensity interval training
810430|NCT03093441|cardiometabolic
810431|NCT03093441|physical performance
810432|NCT03093441|psychosocial adaptation
810434|NCT03093415|Hepatitis C
810435|NCT03093415|HCV
810436|NCT03093415|People Who Inject Drugs
810437|NCT03093415|PWID
810438|NCT03093415|Medication Assisted Therapy
810439|NCT03093415|MAT
810440|NCT03093415|Needle Exchange Program
810441|NCT03093402|JBT-101
810442|NCT03093402|SLE
810443|NCT03093402|efficacy
810444|NCT03093402|musculoskeletal disease
810445|NCT03093402|randomized trial
810446|NCT03093376|Anxiety
810447|NCT03093376|Effortful Control
810448|NCT03093376|Preschool
810449|NCT03093376|ERN
810450|NCT03093350|Breast Cancer
810451|NCT03093350|Tumor Associated Antigen Specific T cells
810452|NCT03093337|Neuromotor sequelae
810453|NCT03093337|Cognitive disorders
810454|NCT03093337|Cerebral development
810455|NCT03093337|Psychomotoricity
810456|NCT03093337|Postural management
810457|NCT03093337|Motor coordination
810458|NCT03093337|Parenthood
810459|NCT03093324|Relapsing Remitting Multiple Sclerosis
810460|NCT03093324|RRMS
810461|NCT03093324|Multiple Sclerosis
810462|NCT03093324|MS
810463|NCT03093324|Alkermes
810464|NCT03093324|ALKS 8700
810465|NCT03093324|Dimethyl Fumarate
810466|NCT03093324|DMF
810467|NCT03093324|Tecfidera
810468|NCT03093311|Near-Infrared Spectroscopy
810469|NCT03093311|Neurosurgical Procedures
810470|NCT03093311|Cognitive Dysfunction
810475|NCT03093246|Full-mouth ultrasonic debridement
810476|NCT03093246|Aspirin
810477|NCT03093246|Omega-3 polyunsaturated fatty acids
810478|NCT03093246|Non-surgical therapy
810479|NCT03093207|Aggressive periodontitis
810480|NCT03093207|Aspirin
810481|NCT03093207|Omega-3 polyunsaturated fatty acids
810482|NCT03093207|Surgical therapy
810483|NCT03093142|transcranial direct current stimulation (tDCs)
810484|NCT03093142|neurofeedback
810485|NCT03093116|ALK Gene Rearrangement
810486|NCT03093116|ROS1 Gene Rearrangement
810487|NCT03093116|NTRK 1/2/3 Gene Rearrangement
810488|NCT03093103|empagliflozin
810489|NCT03093103|kidney
810490|NCT03093103|BOLD-MRI
810492|NCT03093051|Termination
810493|NCT03093051|Unpinning
810494|NCT03093051|Therapy
810495|NCT03093025|Major Depressive Disorder
810496|NCT03093025|Adjunctive Treatment
810497|NCT03092999|Pharmacokinetics
810500|NCT03092934|Small Cell Lung Carcinoma
810501|NCT03092908|calcium oxalate
810502|NCT03092908|nephrolithiasis
810503|NCT03092908|Mature vinegar
810504|NCT03092908|prophylaxis
810505|NCT03092869|Feet
810506|NCT03092869|Ankle
810507|NCT03092869|Balance
810508|NCT03092869|Manual Therapy
810509|NCT03092869|Older Adult
810510|NCT03092830|SCC
810511|NCT03092830|BCC
810512|NCT03092830|DNA
810513|NCT03092830|RNA
810514|NCT03092830|HEDGE HOG
810515|NCT03092830|epidermal growth factor receptor
810516|NCT03092817|Tuberculosis
810517|NCT03092817|tuberculous meningitis
810518|NCT03092817|drug induced liver injury
810519|NCT03092817|HIV
810520|NCT03092817|IRIS
810521|NCT03092817|randomized controlled trial
810522|NCT03092817|dexamethasone
810523|NCT03092804|Shunting
810524|NCT03092804|Brain constructure
810525|NCT03092804|Neural network
810526|NCT03092791|Drug Therapy
810527|NCT03092778|Cryoablation
810528|NCT03092778|Radiology
810529|NCT03092765|E6011
810530|NCT03092765|Ursodeoxycholic acid
810531|NCT03092765|Japan
810532|NCT03092726|ASP8062
810533|NCT03092726|Fibromyalgia
810534|NCT03092713|Cognitive Rehabilitation
810535|NCT03092713|Supported employment
810536|NCT03092713|Mild and moderate TBI
810537|NCT03092713|Return to work
810538|NCT03092713|Randomized Controlled Trial
810542|NCT03092661|Oxygen saturation
810543|NCT03092661|Pulse oximetry
810544|NCT03092661|Neonate
810545|NCT03092661|Infant
810546|NCT03092622|Exercise Therapy
810547|NCT03092609|Attentional Bias to Threat
810548|NCT03092596|HIV infection
810549|NCT03092596|drug abuse
810550|NCT03092596|substance use
810551|NCT03092596|alcohol abuse
810552|NCT03092596|screening
810553|NCT03092596|treatment
810554|NCT03092596|primary care
810555|NCT03092596|motivational interviewing
810556|NCT03092570|Motor learning
810557|NCT03092570|stroke
810558|NCT03092570|tDCS
810559|NCT03092570|upper limb
810560|NCT03092531|HIV
810561|NCT03092531|ART Adherence
810562|NCT03092531|Adolescents
810573|NCT03092466|femoral nerve block
810574|NCT03092466|elderly patient
810575|NCT03092466|cognitive impairment
810576|NCT03092466|hip fracture
810577|NCT03092466|regional anesthesia
810578|NCT03092440|Medical Education
810579|NCT03092440|simulation
810580|NCT03092440|serious game
810581|NCT03092440|validity
810582|NCT03092401|Liver transplantation
810583|NCT03092401|Hepatopulmonary Syndrome
810584|NCT03092401|Liver Cirrhosis
810585|NCT03092388|Sleep-Disordered Breathing
810586|NCT03092388|Heart Failure
810587|NCT03092388|Leg Fluid Shift
810588|NCT03092375|HCV
810589|NCT03092375|Previously treated
810590|NCT03092362|persistent atrial fibrillation
810591|NCT03092362|Heart rate variability
810592|NCT03092362|quality of life
810593|NCT03092336|Peripheral Arterial Disease, training
810594|NCT03092310|Artificial Pancreas
810595|NCT03092271|suicide
810596|NCT03092271|suicide attempt
810597|NCT03092271|self harm
810598|NCT03092271|depression
810599|NCT03092193|Naproxen
810600|NCT03092193|Association of naproxen-esomeprazole
810601|NCT03092193|High pressure liquid chromatography
810602|NCT03092193|Cytochrome P450
810603|NCT03092180|Dermatomyositis
810604|NCT03092180|Immunomodulation
810605|NCT03092180|Immunosuppressive agents
810606|NCT03092180|Myositis
810607|NCT03092180|Polymyositis
810608|NCT03092180|Necrotizing myopathies
810609|NCT03092180|Antisynthetase syndrome
810610|NCT03092128|Gastrointestinal stromal tumor (GIST)
810611|NCT03092128|Imatinib
810612|NCT03092128|Pharmacogenetics
810613|NCT03092128|Pharmacokinetics
810614|NCT03092128|Precision medicine
810615|NCT03092128|Somatic and germ-line mutations
810616|NCT03092115|Men who have sex with men (MSM)
810617|NCT03092115|mHealth
810618|NCT03092115|antiretroviral therapy (ART)
810619|NCT03092115|native android app
810620|NCT03092089|Sonothrombolysis, STEMI, PPCI, Microbubbles
810621|NCT03092076|pharmacokinetics
810622|NCT03092076|antiplatelet effects
810623|NCT03092076|single nucleotide polymorphism (SNP)
810624|NCT03092024|Systemic Sclerosis
810625|NCT03092024|Scleroderma
810626|NCT03092024|Hand
810627|NCT03092024|Intervention
810628|NCT03092024|Exercise
810629|NCT03091985|Breastshield
810630|NCT03091985|Breastpump
810631|NCT03091985|Breastfeeding
810632|NCT03091972|Persistent Atrial Fibrillation
810633|NCT03091972|Linear ablation
810634|NCT03091972|Catheter ablation
810635|NCT03091972|Contact force
810636|NCT03091946|Oatmeal; Post-prandial glycemic response ; Post-prandial insulin response; Post-prandial hunger
810637|NCT03091933|AML, ALL, MDS
810638|NCT03091933|relapsed hematopoietic malignancy
810639|NCT03091933|Stem cell transplantation
810640|NCT03091933|minor histocompatibilty antigen (MiHA)
810641|NCT03091907|Necrotizing enterocolitis
810642|NCT03091907|Followup
810643|NCT03091907|Neurodevelopmental impairments
810644|NCT03091907|Growth impairments
810645|NCT03091907|Gut function
810646|NCT03091907|Behavioural impairments
810647|NCT03091894|dexmedetomidine,propofol,sleep endoscopy,sedation
810648|NCT03091881|Granisetron
810649|NCT03091881|Spinal induced hypotension
810650|NCT03091790|ventral hernia
810651|NCT03091790|mesh
810652|NCT03091777|bacterial vaginosis
810653|NCT03091777|vaginal infection
810654|NCT03091777|BV
810655|NCT03091764|NMIBC
810656|NCT03091764|non-muscle invasive bladder cancer
810657|NCT03091764|Patient reported outcome
810658|NCT03091764|Symptom burden
810659|NCT03091764|Questionnaire
810660|NCT03091751|Factor IX (FIX)
810661|NCT03091738|sleep
810662|NCT03091725|Obesity
810663|NCT03091725|Roux-en-Y gastric bypass (RYGB)
810664|NCT03091725|Very low calorie diet
810665|NCT03091725|Fibroblast growth factor 21 (FGF21)
810666|NCT03091712|Degludec
810667|NCT03091712|MIDS
810668|NCT03091712|Mobile Insulin Dosing System
810669|NCT03091712|Glooko
810670|NCT03091712|Tresiba
810671|NCT03091712|Tresiba® U-200 FlexTouch®
810672|NCT03091699|Smoking
810673|NCT03091699|Nicotine
810674|NCT03091699|Exercise
810675|NCT03091699|Cognition
810676|NCT03091686|Sedentary Behaviour
810677|NCT03091686|Health Behaviour Change
810678|NCT03091686|Health Action Process Approach
810679|NCT03091686|Intervention
810680|NCT03091686|Prolonged Sitting
810681|NCT03091686|Light Intensity Physical Activity
810682|NCT03091686|Motivational Factors
810683|NCT03091686|Intentions
810684|NCT03091686|Diabetes
810685|NCT03091686|Self-Efficacy
810686|NCT03091686|Risk Perception
810687|NCT03091686|Outcome Expectancies
810688|NCT03091647|Chinese women
810689|NCT03091647|Cancer-related fatigue
810690|NCT03091647|Acupressure
810691|NCT03091634|Xu-Fu-Zhu-Yu Capsule
810692|NCT03091634|Qi Stagnation and Blood Stasis syndrome
810693|NCT03091634|National Center for Complementary and Integrative Health
810694|NCT03091621|Deep Vein Thrombosis
810695|NCT03091621|pulmonary embolism
810696|NCT03091608|Drug-Induced Liver Injury
810697|NCT03091582|Psychological Therapy
810698|NCT03091556|Drug-Induced Liver Injury
810699|NCT03091530|Throwing
810700|NCT03091530|Sleeper Stretch
810701|NCT03091530|Balloon Blow
810702|NCT03091530|GIRD (Glenohumeral internal rotation deficit)
810703|NCT03091517|Online lifestyle modification
810704|NCT03091517|Self-management
810705|NCT03091517|HbA1c
810706|NCT03091439|Osteomyelitis
810707|NCT03091439|dalbavancin
810708|NCT03091439|antibiotic
810709|NCT03091400|Memory Disorders
810710|NCT03091400|Multiple Sclerosis
810711|NCT03091400|Atomoxetine Hydrochloride
810712|NCT03091387|neonates, extubation
810713|NCT03091361|Bacterial imaging
810714|NCT03091361|PPV
810715|NCT03091361|Chronic wounds
810716|NCT03091309|Inflammatory Bowel Diseases
810717|NCT03091309|Medication Adherence
810718|NCT03091309|Crohn Disease
810719|NCT03091309|Ulcerative Colitis
810720|NCT03091309|Pregnancy
810721|NCT03091309|Counselling
810722|NCT03091309|Patient Education
810723|NCT03091283|time management, anaesthesia training program
810724|NCT03091270|gliomas
810725|NCT03091270|motor functional cortex
810726|NCT03091270|ZOOMit-fMRI
810727|NCT03091270|BOLD-fMRI
810728|NCT03091257|Multiple Myeloma
810729|NCT03091244|Drug-Induced Liver Injury
810730|NCT03091218|Drug-Induced Liver Injury
810731|NCT03091192|Papillary Renal Cell Cancer
810732|NCT03091192|AZD6094
810733|NCT03091192|Savolitinib
810734|NCT03091179|airway management
810735|NCT03091179|high flow nasal oxygen
810736|NCT03091179|high flow nasal cannula
810737|NCT03091179|THRIVE
810738|NCT03091140|Parathyroidectomy
810739|NCT03091140|Muscular Functional Characteristics
810740|NCT03091140|Parathyroid Glands
810741|NCT03091114|fractures, risk prediction
810742|NCT03091101|keratoconus
810743|NCT03091101|corneal innervation
810744|NCT03091101|scleral contact lenses
810745|NCT03091075|Rotator Cuff Tear
810746|NCT03091075|Rotator Cuff
810747|NCT03091075|Anabolic Steroid
810748|NCT03091075|Testosterone
810749|NCT03091075|Oxandrolone
810750|NCT03091049|coronary
810751|NCT03091049|catheterization
810752|NCT03091049|transradial
810753|NCT03091049|anesthesia
810754|NCT03091036|Chronic
810755|NCT03091036|Complex
810756|NCT03091023|Endometrial receptivity
810757|NCT03091023|Transcriptomic
810758|NCT03091023|Single cell
810759|NCT03091023|Endometrial fluid
810760|NCT03090997|resveratrol, vitamin C, antioxidant therapy, antioxidant capacity
810761|NCT03090984|Hemodialysis
810762|NCT03090984|Coagulation activation
810763|NCT03090958|technology
810764|NCT03090958|app
810765|NCT03090958|YMSM
810766|NCT03090958|HIV
810767|NCT03090945|Endoscopy
810768|NCT03090945|GI Bleeding
810769|NCT03090945|Pediatrics
810770|NCT03090945|Upper Gastrointestinal Bleeding
810771|NCT03090945|Gastro Intestinal Bleeding
810772|NCT03090906|volume gain
810773|NCT03090906|soft tissue augmentation
810774|NCT03090906|dental implants
810775|NCT03090906|histology
810776|NCT03090880|Low-molecular-weight Heparin
810777|NCT03090880|Tinzaparin
810778|NCT03090867|Clinical Practice Guideline
810779|NCT03090867|Critical care
810780|NCT03090867|Family-centered care
810781|NCT03090867|Professional-family relations
810782|NCT03090867|Family nursing
810783|NCT03090867|Anxiety
810784|NCT03090867|Depression
810785|NCT03090867|Participation in care
810786|NCT03090854|Alzheimer's Disease
810787|NCT03090854|Cognition
810788|NCT03090854|Cholinergic target
810789|NCT03090841|Cytomegalovirus Congenital
810790|NCT03090841|Non-invasive diagnosis
810791|NCT03090841|Omics
810792|NCT03090841|Biomarkers
810793|NCT03090828|economic evaluation
810794|NCT03090828|e health
810795|NCT03090815|Circulating Tumor DNA
810796|NCT03090815|Prognostic
810797|NCT03090815|Molecular tests
810798|NCT03090802|Human Immunodeficiency Virus
810799|NCT03090802|resilience
810800|NCT03090802|adolescent mothers
810801|NCT03090802|Sub-Saharan Africa
810802|NCT03090802|intimate partner violence
810803|NCT03090802|postpartum period
810804|NCT03090789|Friedreich Ataxia
810805|NCT03090789|Neuro-degenerative disease
810806|NCT03090698|osteoarthritis
810807|NCT03090698|knee
810808|NCT03090698|treatment
810809|NCT03090685|Chikungunya Fever
810810|NCT03090685|Pain
810811|NCT03090685|Mobility Limitation
810812|NCT03090685|Auriculotherapy
810813|NCT03090685|Complementary Therapies
810814|NCT03090685|Physical Therapy
810815|NCT03090672|Arthritis
810816|NCT03090672|Degenerative
810817|NCT03090672|Tendinosis
810818|NCT03090672|Jont disease
810819|NCT03090672|Low back pain
810820|NCT03090659|multiple myeloma
810821|NCT03090659|BCMA
810822|NCT03090659|CAR-T
810823|NCT03090646|social behavioral
810824|NCT03090646|living donor kidney transplant
810825|NCT03090646|follow-up
810826|NCT03090646|health utilization
810827|NCT03090646|incentives
810828|NCT03090633|Fetoscopy
810829|NCT03090633|Fetal surgery
810830|NCT03090633|Fetal spina bifida
810831|NCT03090594|Cryoprobe
810832|NCT03090594|Bronchoscopy
810833|NCT03090594|Acute cellular rejection
810834|NCT03090581|Graft Rejection/diagnosis
810835|NCT03090581|Lung Transplantation
810836|NCT03090581|Cryoprobe
810837|NCT03090555|adhesive capsulitis
810838|NCT03090555|clinical trial
810839|NCT03090555|manipulation
810840|NCT03090529|Exercise training
810841|NCT03090529|Ambulatory blood pressure
810842|NCT03090529|Resistant Hypertension
810843|NCT03090529|Nitric Oxide
810844|NCT03090516|Ginkgo biloba dispersible tablets
810845|NCT03090516|Alzheimer's
810846|NCT03090503|Antipsychotic agents
810847|NCT03090503|Treatment
810848|NCT03090503|Effectiveness
810849|NCT03090503|Aripiprazole
810850|NCT03090503|Risperidone
810851|NCT03090490|Treatment
810852|NCT03090490|Maintenance
810853|NCT03090464|Type 2 diabetes mellitus
810854|NCT03090464|Digital disease management
810855|NCT03090464|T2DM
810856|NCT03090464|Hyperglycemia
810857|NCT03090464|Diabetes mellitus
810858|NCT03090451|Insulin
810859|NCT03090451|Glucose Clamp
810860|NCT03090451|Glucose Tracer
810861|NCT03090451|Artificial Pancreas
810862|NCT03090451|Exercise
810863|NCT03090451|Aerobic
810864|NCT03090399|Goal Directed Fluid Therapy
810865|NCT03090373|Catheter
810866|NCT03090373|UTI's
810867|NCT03090360|Healthy babies
810868|NCT03090360|Infant formula
810869|NCT03090360|Growth
810870|NCT03090334|beta-d-glucan
810871|NCT03090334|abdominal candidiasis
810872|NCT03090321|fitness
810873|NCT03090321|health
810874|NCT03090321|activity
810875|NCT03090321|heart risk
810876|NCT03090321|wellness
810877|NCT03090282|mechanical treatment
810878|NCT03090282|implant
810886|NCT03090243|Glaucoma
810887|NCT03090243|Intraocular pressure
810888|NCT03090243|Colonoscopy
810889|NCT03090243|Virtual Colonoscopy
810890|NCT03090243|Valsalva
810891|NCT03090230|Descending Thoracic Aorta
810892|NCT03090230|DTA
810893|NCT03090230|Transection
810894|NCT03090230|Traumatic Injury of the Descending Thoracic Aorta
810895|NCT03090217|Radiotherapy
810896|NCT03090217|Brachytherapy
810897|NCT03090217|Physiotherapy
810898|NCT03090217|Vaginal dilators
810899|NCT03090217|Pelvic floor exercises
810900|NCT03090217|Vaginal Stenosis
810901|NCT03090204|strain
810902|NCT03090204|myocarditic deformation imaging
810903|NCT03090204|right ventricle (RV)
810904|NCT03090204|systolic RV function
810905|NCT03090204|preload dependence
810906|NCT03090204|contractility
810907|NCT03090204|intermittent hemodialysis (HDI)
810908|NCT03090165|Triple Negative Breast Neoplasms
810909|NCT03090165|ribociclib
810910|NCT03090165|LEE011
810911|NCT03090165|CDK 4/6 inhibitor
810912|NCT03090165|bicalutamide
810913|NCT03090152|Total Hip Replacement
810914|NCT03090152|Total Hip Arthroplasty
810915|NCT03090139|Drug therapy
810916|NCT03090113|Stroke
810917|NCT03090113|Embolic Stroke
810918|NCT03090113|Shuxuetong
810919|NCT03090113|Recurrence
810920|NCT03090113|Symptomatic New Cerebral Infarction
810921|NCT03090113|Asymptomatic New Cerebral Infarction
810922|NCT03090087|Diameter of retinal arteries
810923|NCT03090087|Adenosine
810924|NCT03090087|Hypoxia
810925|NCT03090035|HCV genotype 2, HCV genotype 3, IL-28B, PEG-INF.
810926|NCT03090009|Peri-implant Mucositis
810927|NCT03090009|NSAID
810928|NCT03090009|Microbiome
810929|NCT03090009|16s Ribosomal Pyro-sequencing
810930|NCT03089996|piezocision
810931|NCT03089996|corticotomy
810932|NCT03089996|Gingival Crevicular Fluid
810933|NCT03089983|prison
810934|NCT03089957|Acute Respiratory Distress Syndrome
810935|NCT03089957|Critical Illness
810936|NCT03089957|Randomized Controlled Trial
810937|NCT03089957|Ulinastatin
810957|NCT03089866|Central nervous System
810958|NCT03089866|Memory functions
810959|NCT03089866|Executive functions
810960|NCT03089866|Cognitive impairment
810961|NCT03089853|COPD
810962|NCT03089853|pulmonary rehabilitation
810963|NCT03089853|telehealth
810964|NCT03089853|smart
810965|NCT03089853|technology
810966|NCT03089853|NEMS
810967|NCT03089853|acute exacerbation
810968|NCT03089840|normothermic perfusion
810969|NCT03089840|liver transplantation
810970|NCT03089827|Memory
810971|NCT03089814|tissue oxygen saturation, ischemic conditioning
810972|NCT03089801|health care access
810973|NCT03089801|eHealth
810974|NCT03089801|telehealth
810975|NCT03089775|Contact
810976|NCT03089775|Treatment
810977|NCT03089775|Prevention
810978|NCT03089775|BBI-2000
810979|NCT03089775|Dermatitis
810980|NCT03089775|Allergic
810981|NCT03089736|Pain
810982|NCT03089736|Head and neck cancer
810983|NCT03089736|depression
810984|NCT03089736|anxiety
810985|NCT03089736|health
810986|NCT03089736|catastrophizing
810987|NCT03089723|carpometacarpal joint ostearthritis
810988|NCT03089723|hyaluronic acid
810989|NCT03089723|Rhizarthrosis
810990|NCT03089697|N-Rephasin SAL200
810991|NCT03089697|Methicillin-Sensitive Staphylococcus aureus
810992|NCT03089697|Methicillin Resistant Staphylococcus Aureus
810993|NCT03089684|NHANES
810994|NCT03089684|Folate
810995|NCT03089684|Folic Acid
810996|NCT03089671|Vitamin B
810997|NCT03089671|5% Dextrose in Water
810998|NCT03089671|Cystoscopy
810999|NCT03089671|Ureter
811000|NCT03089658|Metastatic Merkel Cell Carcinoma
811001|NCT03089658|Expanded Access Program
811002|NCT03089658|Temporary Authorisation for Use
811003|NCT03089658|Avelumab
811004|NCT03089632|gluten-free diet
811005|NCT03089632|gluten sensitivity
811006|NCT03089632|dyspepsia
811007|NCT03089632|diabetes mellitus, type 1
811008|NCT03089632|gastroparesis
811009|NCT03089632|motility
811010|NCT03089619|Alveolar bone
811011|NCT03089619|Bone resorption
811012|NCT03089619|dental implants
811016|NCT03089567|Silver diamine Fluoride
811017|NCT03089567|Streptococcus mutans
811018|NCT03089567|Caries prevention
811019|NCT03089567|Fluoride
811020|NCT03089528|Direct laryngoscopy
811021|NCT03089528|Videolaryngoscopy
811022|NCT03089528|Diabetes Mellitus
811023|NCT03089528|Intubation
811024|NCT03089528|Anesthesia
811025|NCT03089515|World Trade Center
811026|NCT03089515|World Trade Center Survivors
811027|NCT03089502|Exercise
811028|NCT03089502|Cardiac Rehabilitation
811029|NCT03089502|Breast Caner
811030|NCT03089502|Left Ventricular Dysfunction
811031|NCT03089502|Trastuzumab
811032|NCT03089502|Anthracyclines
811033|NCT03089489|Primary graft dysfunction
811034|NCT03089489|Lung transplantation
811035|NCT03089489|Surfactant Protein
811036|NCT03089489|inflammation
811038|NCT03089463|Diabetes
811039|NCT03089463|Diabetic Foot
811040|NCT03089463|Biomechanics
811041|NCT03089463|Stratification
811042|NCT03089463|Diabetes Complications
811043|NCT03089463|Diabetes; Neuropathic (Manifestation)
811044|NCT03089463|Risk Factors
811045|NCT03089463|Prospective Studies
811046|NCT03089424|low back pain, photobiomodulation therapy, LLLT
811047|NCT03089411|myeloma multiple
811048|NCT03089411|newly diagnosed
811049|NCT03089398|Hybrid Coronary Revascularization
811050|NCT03089398|Coronary Artery Bypass Grafting
811051|NCT03089398|Percutaneous Coronary Intervention
811052|NCT03089372|Erectile Dysfunction
811053|NCT03089372|Low intensity extracorporeal shock wave treatment
811054|NCT03089359|Unspecific symptoms
811429|NCT03086720|Sodium hypochlorite
811055|NCT03089359|Soluvent urokinase plasminogen activator receptor
811056|NCT03089359|Lactate
811057|NCT03089359|Emergency Medical Services
811058|NCT03089346|Imaging
811059|NCT03089346|Bronchial Remodeling
811060|NCT03089320|HIV, Heavy drinking, Alcohol Abuse, AIDS
811061|NCT03089307|Erectile Dysfunction
811062|NCT03089307|Low intensity extracorporeal shock wave treatment
811063|NCT03089294|Erectile Dysfunction
811064|NCT03089294|Low intensity extracorporeal shock wave treatment
811065|NCT03089268|sessile serrated polyp
811066|NCT03089268|prevalence
811067|NCT03089268|colorectal cancer
811068|NCT03089268|molecular biology
811069|NCT03089255|Thrombophylaxis
811070|NCT03089255|Deep Venous Thrombosis
811071|NCT03089255|Pulmonary Embolism
811072|NCT03089255|Lower Leg Trauma
811073|NCT03089229|Topical Cream
811074|NCT03089229|Novel
811075|NCT03089190|Appetite
811076|NCT03089190|Satiety
811077|NCT03089190|Energy intake
811078|NCT03089190|Hunger
811079|NCT03089190|Peptide
811080|NCT03089190|Encapsulation
811081|NCT03089177|Randomized Controlled Trial
811082|NCT03089177|Community Gardening
811083|NCT03089177|Health Behavior Change
811084|NCT03089177|Physical Activity
811085|NCT03089177|Diet
811086|NCT03089177|Obesity
811087|NCT03089177|Cancer Prevention
811088|NCT03089177|Neighborhood
811089|NCT03089151|Pilot Randomized Controlled Trial
811090|NCT03089151|Community Garden
811091|NCT03089151|Health Behavior Change
811092|NCT03089151|Physical Activity
811093|NCT03089151|Diet
811094|NCT03089151|Obesity
811095|NCT03089151|Neighborhood
811096|NCT03089151|Microbiome
811097|NCT03089151|Inflammatory biomarkers
811098|NCT03089125|Lung Cancer
811099|NCT03089099|Metastatic Castration-Resistant Prostate Cancer
811100|NCT03089099|circulating tumor cells
811101|NCT03089099|Prognosis
811102|NCT03089099|Liquid biopsy
811103|NCT03089086|meningococcal B vaccine
811104|NCT03089086|herd immunity
811105|NCT03089086|adolescents
811106|NCT03089086|young adults
811107|NCT03089086|south australia
811108|NCT03089060|Fingertip Amputation
811109|NCT03089060|Fingertip Regeneration
811110|NCT03089060|Infection
811111|NCT03089060|Occlusive Dressings
811112|NCT03089060|Pediatric Surgery
811113|NCT03089060|Silicone Finger Cap
811114|NCT03089021|neck pain,
811115|NCT03088982|Family Medicine
811116|NCT03088982|multimorbidity
811117|NCT03088982|prevention
811118|NCT03088969|Chronic Low Back Pain
811119|NCT03088969|Function
811120|NCT03088969|Self-efficacy
811121|NCT03088969|Return to work
811122|NCT03088969|Questionnaire
811123|NCT03088956|longitudinal
811124|NCT03088956|caregiver
811125|NCT03088956|cognitive assessments
811126|NCT03088904|Inactivated, quadrivalent influenza vaccine
811127|NCT03088904|Live, attenuated quadrivalent influenza vaccine
811128|NCT03088904|Monozygotic twins
811129|NCT03088904|Dizygotic twins
811130|NCT03088904|Adults
811131|NCT03088904|Adolescents
811132|NCT03088891|altitude training
811133|NCT03088891|antioxidants
811134|NCT03088891|oxidative stress
811135|NCT03088891|elite athletes
811136|NCT03088891|inflammation
811137|NCT03088891|diet
811138|NCT03088878|Chronic lymphocytic leukemia
811139|NCT03088878|Small lymphocytic lymphoma
811140|NCT03088878|Mantle cell lymphoma
811141|NCT03088878|Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)
811142|NCT03088878|Bruton Tyrosine Kinase (BTK)
811143|NCT03088774|Low back pain
811144|NCT03088761|tracheal tube
811145|NCT03088761|cuff pressure
811146|NCT03088748|total knee arthroplasty
811147|NCT03088722|Contraceptive implant
811148|NCT03088722|Task sharing
811149|NCT03088722|Nigeria
811150|NCT03088709|NHL
811151|NCT03088709|Non-Hodgkin Lymphoma
811152|NCT03088709|Haploidentical
811153|NCT03088709|Bone Marrow Transplant
811154|NCT03088709|Stem Cell Transplant
811155|NCT03088709|Acute Myeloid Leukemia
811156|NCT03088709|Acute Lymphocytic Leukemia
811157|NCT03088709|Myelodysplastic Syndrome
811158|NCT03088709|Chronic Lymphocytic Leukemia
811159|NCT03088709|GVHD
811160|NCT03088696|laparoscopic
811161|NCT03088696|acupuncture
811162|NCT03088683|sleeve gastrectomy
811163|NCT03088683|liver retractor
811164|NCT03088683|nathanson
811165|NCT03088683|reveel
811166|NCT03088683|liver trauma
811167|NCT03088657|Cohort study
811168|NCT03088657|early-onset mood disorders
811169|NCT03088618|Nasal obstruction
811170|NCT03088618|Septal deformity
811171|NCT03088618|Septoplasty
811172|NCT03088618|TnR Mesh
811173|NCT03088618|polycaprolactone
811174|NCT03088592|Deep Brain Stimulation
811175|NCT03088579|radiation shielding
811176|NCT03088553|Ganciclovir
811177|NCT03088553|trough concentrations
811178|NCT03088553|CMV viral load
811179|NCT03088553|safety
811180|NCT03088553|Solid organ transplantation (heart, kidney or liver)
811181|NCT03088514|Hypertension
811182|NCT03088514|Left Ventricular Hypertrophy
811183|NCT03088514|Endothelial Dysfunction
811184|NCT03088514|Nitrate
811185|NCT03088501|Birth cohort, follow-up, IVRS
811186|NCT03088488|25-OH vitamin D
811187|NCT03088488|RANKL
811188|NCT03088488|Osteoprotogerin
811189|NCT03088488|TNF-α
811190|NCT03088462|Bipolar Disorder
811191|NCT03088462|Smartphone
811192|NCT03088462|Behavior Therapy
811193|NCT03088449|Crohns disease
811194|NCT03088449|primary non response
811195|NCT03088449|lose of response
811196|NCT03088449|personalising anti-TNF therapy
811197|NCT03088449|Anti-TNF
811198|NCT03088449|PANTS
811199|NCT03088449|Biosimilars
811200|NCT03088436|MRI
811201|NCT03088436|Breast
811202|NCT03088423|MRI
811203|NCT03088423|Stereotactic body radiation therapy
811204|NCT03088384|Post Traumatic Stress Disorder
811205|NCT03088384|PTSD
811206|NCT03088384|Combat Trauma
811207|NCT03088371|Total knee replacement
811208|NCT03088371|Psoas Sciatic block
811209|NCT03088371|Epidural anaesthesia
811210|NCT03088345|Fontan Palliation Surgery
811211|NCT03088345|Post-Operative Care
811212|NCT03088319|postnatal depression stress mindfulness allostatic load
811213|NCT03088293|idiopathic refractory scleritis
811214|NCT03088293|infliximab
811215|NCT03088293|cyclophosphamide
811216|NCT03088241|randomized clinical trial
811217|NCT03088241|low level viremia
811218|NCT03088241|lesotho
811219|NCT03088241|resource-limited setting
811220|NCT03088241|ART first-line failure
811221|NCT03088215|Trigger Point Pain, Myofascial
811222|NCT03088215|shock-waves
811223|NCT03088215|extracorporeal shock-wave treatment (ESWT)
811224|NCT03088215|pain
811225|NCT03088215|trigger point
811226|NCT03088215|referred pain
811233|NCT03088189|maternal nutrition
811234|NCT03088189|periconceptional
811235|NCT03088189|neurocognitive development
811236|NCT03088176|Melanoma
811237|NCT03088176|BRAF inhibitor
811238|NCT03088176|Intratumoral injection
811239|NCT03088176|Talimogene laherparepvec
811240|NCT03088176|MEK inhibitor
811241|NCT03088176|dabrafenib
811242|NCT03088176|trametinib
811243|NCT03088150|Hepatic resection
811244|NCT03088150|Liver surgery
811245|NCT03088150|Thermal ablation
811246|NCT03088150|Radiofrequency ablation
811247|NCT03088150|Microwave ablation
811248|NCT03088150|RFA
811249|NCT03088150|MWA
811250|NCT03088137|in vitro fertilization
811251|NCT03088111|Anthim®
811252|NCT03088111|Obiltoxaximab
811253|NCT03088111|anthrax
811254|NCT03088111|anti-toxin
811255|NCT03088098|left atrial appendage occlusion
811256|NCT03088098|transcatheter aortic valve implantation
811257|NCT03088098|atrial fibrillation
811258|NCT03088072|Edoxaban
811259|NCT03088072|WATCHMAN device
811260|NCT03087201|Chronic tic disorders
811261|NCT03087201|Tourette syndrome
811262|NCT03088020|CCHS
811263|NCT03088020|PHOX2B
811264|NCT03088020|Paired-like Homeobox gene PHOX2B
811265|NCT03088020|autonomic nervous system dysregulation
811266|NCT03088020|control of breathing
811267|NCT03088020|Hirschsprung disease
811268|NCT03088020|neural crest tumors
811269|NCT03088020|neuroblastoma
811270|NCT03088020|ganglioneuroma
811271|NCT03088020|ganglioneuroblastoma
811272|NCT03088020|artificial ventilation
811273|NCT03088020|diaphragm pacing
811274|NCT03088007|Intellectual Deficiency
811275|NCT03088007|cognitive, adaptive
811276|NCT03088007|behavioral and academic profile
811277|NCT03088007|regular and special schools
811278|NCT03087942|end stage renal disase ESRD
811279|NCT03087942|dialysis effect on pharmacokinetics PK
811280|NCT03087942|renal impairment
811281|NCT03087903|Prostate Specific Antigen (PSA)
811282|NCT03087903|Non-Metastatic Prostate Cancer
811283|NCT03087890|Trimethoprim, Sulfamethoxazole Drug Combination
811287|NCT03087851|Denosumab
811288|NCT03087851|Bone Turnover markers
811289|NCT03087851|Drug Holiday
811290|NCT03087812|Microbiological burden
811291|NCT03087812|kidney
811292|NCT03087812|stone
811293|NCT03087812|durability of flexible endoscopes
811294|NCT03087734|Prostheses and Implants
811295|NCT03087721|Metabolic Syndrome
811296|NCT03087721|Exercise Training
811297|NCT03087721|Interval Training
811298|NCT03087721|Skeletal Muscle
811299|NCT03087721|Risk Factors
811300|NCT03087721|Insulin Resistance
811301|NCT03087695|Nasopharyngeal carcinoma
811302|NCT03087695|EBV DNA
811303|NCT03087695|Chemoradiotherapy
811304|NCT03087669|Left Ventricular Assist Device
811305|NCT03087669|Hemodynamic monitoring
811306|NCT03087656|levofloxacin
811307|NCT03087656|Ceftriaxone
811308|NCT03087656|Cholangitis
811309|NCT03087656|ERCP
811310|NCT03087643|Flow-mediated dilation
811311|NCT03087643|Passive limb movement
811312|NCT03087604|epidural catheter placement
811313|NCT03087578|overactive bladder, acupuncture
811314|NCT03087526|Non Invasive Prenatal Diagnosis (NIPD)
811315|NCT03087526|Circulating Fetal Trophoblastic Cells (CFTC)
811316|NCT03087526|Triplet repeat diseases
811317|NCT03087526|Huntington Disease - Myotonic Dystrophy Type 1 - Spinocerebellar Ataxia 1, 2 and 3
811318|NCT03087500|Down Syndrome
811319|NCT03087500|Typically Developing Participants
811320|NCT03087500|Children
811321|NCT03087500|Adolescents
811322|NCT03087500|Adults
811323|NCT03087448|ALK rearranged
811324|NCT03087448|Stage IIIB NSCLC
811325|NCT03087448|Stage IV NSCLC
811326|NCT03087448|ROS-1 rearranged NSCLC
811327|NCT03087396|bone marrow defect
811328|NCT03087396|bone marrow lesion
811329|NCT03087396|stress fracture
811330|NCT03087396|calcium phosphate
811331|NCT03087396|bone substitute material
811332|NCT03087370|CXCR4 Mutation
811333|NCT03087370|Primary immunodeficiency disorder
811334|NCT03087370|Warts
811335|NCT03087370|Hypogammaglobulinemia
811336|NCT03087370|Infections
811337|NCT03087370|Myelokathexis
811338|NCT03087370|Human papillomavirus (HPV)
811339|NCT03087370|Neutropenia
811340|NCT03087370|Herpes
811341|NCT03087344|Postprandial liver and spleen stiffness measurements
811342|NCT03087344|Transient elastography
811343|NCT03087344|Cirrhosis
811344|NCT03087344|Acoustic radiation force impulse
811345|NCT03087318|Obstructive sleep apnea (OSA)
811346|NCT03087318|Overweight and moderate obesity
811347|NCT03087318|Sport prescription
811348|NCT03087318|Physical activity
811349|NCT03087305|Interventional Pulmonary
811350|NCT03087305|EBUS-TBNA
811351|NCT03087305|Lung cancer staging
811352|NCT03087292|blood flow restriction
811353|NCT03087292|resistance training
811354|NCT03087292|coronary heart disease
811355|NCT03087240|Disease Activity Score 28 (DAS28)
811356|NCT03087240|Health Assessment Questionnaire (HAQ)
811357|NCT03087240|Dental Scaling
811358|NCT03087240|Dental Polishing
811359|NCT03087240|Oral Health
811360|NCT03087240|Gingival Crevicular Fluid
811361|NCT03087240|Inflammatory Cytokine Profile
811362|NCT03087240|Biofilm
811363|NCT03087240|Oral Microbiome
811364|NCT03087240|Intestinal Microbiome
811365|NCT03087227|mHealth
811366|NCT03087227|febrile neutropenia
811367|NCT03087227|neutropenia/chemically induced/*complications
811368|NCT03087227|antineoplastic agents/*adverse events
811369|NCT03087227|Patient readmission
811370|NCT03087227|disease management
811371|NCT03087149|vitamin D
811372|NCT03087149|supplementation
811373|NCT03087149|hydroxyvitamin D
811374|NCT03087149|pretrem infants
811375|NCT03087149|osteopenia
811376|NCT03087136|multiple sclerosis
811377|NCT03087136|pediatric
811378|NCT03087123|single-case design
811379|NCT03087123|children
811380|NCT03087123|health equity
811381|NCT03087123|mobile health
811382|NCT03087071|Colorectal cancer
811383|NCT03087071|Colorectal adenocarcinoma
811384|NCT03087071|EGFR S492R or other ectodomain mutations in circulating free tumor DNA
811385|NCT03087071|Detectable KRAS or NRAS mutations in exons 2, 3, or 4; or BRAF codon 600 mutations in circulating free tumor DNA
811386|NCT03087071|No detectable mutations in circulating free tumor DNA
811387|NCT03087071|Panitumumab
811388|NCT03087071|Vectibix
811389|NCT03087071|Trametinib
811390|NCT03087071|GSK1120212
811391|NCT03087058|Treatment of Hyperkalemia
811392|NCT03087058|Hyperkalemia
811393|NCT03087058|Potassium
811394|NCT03087058|Chronic Kidney Disease
811395|NCT03087032|Liraglutide
811396|NCT03087032|Insulin Glargine
811397|NCT03087032|Prandial Insulin
811399|NCT03086980|health related quality of life
811400|NCT03086980|utility
811401|NCT03086980|regression
811402|NCT03086967|cervical ripening
811403|NCT03086967|double lumen catheter
811404|NCT03086954|CD19 positive lymphoma
811405|NCT03086915|neuromuscular blockade
811406|NCT03086915|muscle relaxation
811407|NCT03086915|muscle relaxant
811408|NCT03086902|Ablation; Cryo Energy; Radofrequency Ablation
811409|NCT03086863|electroacupuncture
811410|NCT03086863|randomized controlled trial
811411|NCT03086824|Bone Metastasis
811412|NCT03086811|feeding interaction, infant eating habits, hunger satiety cues, childhood obesity
811413|NCT03086798|Magill forceps
811414|NCT03086798|cuff inflation
811415|NCT03086798|Nasotracheal Intubation
811416|NCT03086746|Remodeling
811417|NCT03086733|Lung Cancer
811418|NCT03086733|Non small cell lung cancer
811419|NCT03086733|Metformin
811420|NCT03086733|Pre-operative treatment
811421|NCT03086733|Neoadjuvant treatments
811422|NCT03086733|Cancer
811423|NCT03086733|Phase II
811424|NCT03086720|Adhesive system
811425|NCT03086720|Controlled clinical trial
811426|NCT03086720|Dental restoration
811427|NCT03086720|Noncarious cervical lesions
811428|NCT03086720|Dental restoration failure
811432|NCT03086694|oromaxillofacial surgery
811433|NCT03086694|nasotracheal intubation
811434|NCT03086694|stroke volume variation
811435|NCT03086681|Cervical carcinoma
811436|NCT03086681|endostar
811437|NCT03086681|concurrent chemoradiotherapy
811438|NCT03086668|Nasotracheal Intubation
811439|NCT03086668|jaw thrust
811440|NCT03086668|hook-finger
811441|NCT03086655|biological markers
811442|NCT03086655|monitoring device
811443|NCT03086655|wireless technology
811444|NCT03086642|locally advanced pancreatic cancer
811445|NCT03086642|locally advanced pancreas cancer
811446|NCT03086642|metastatic pancreatic cancer
811447|NCT03086642|metastatic pancreas cancer
811448|NCT03086642|refractory
811449|NCT03086642|refractory pancreatic cancer
811450|NCT03086642|refractory pancreas cancer
811451|NCT03086642|T-Vec
811452|NCT03086642|T Vec
811453|NCT03086616|DIPG
811454|NCT03086616|CED
811455|NCT03086616|glioma
811456|NCT03086590|Body composition
811457|NCT03086590|Ultrasound
811458|NCT03086590|Chronic Pulmonary Obstructive Disease
811459|NCT03086590|Respiratory muscles
811460|NCT03086564|HCC
811461|NCT03086564|ADCC
811462|NCT03086564|TACE
811463|NCT03086564|immuno therapy
811464|NCT03086551|Transcranial Magnetic Stimulation
811465|NCT03086551|Motor Impairment
811466|NCT03086551|Rehabilitation
811467|NCT03086551|Motor Learning
811468|NCT03086525|Chronic pain
811469|NCT03086525|Psychological factors
811470|NCT03086525|Musculoskeletal pain
811471|NCT03086525|Prognosis
811472|NCT03086499|pectus excavatum
811473|NCT03086486|Tuberculosis
811474|NCT03086486|Multi Drug-Resistant Tuberculosis
811475|NCT03086486|Extensively Drug-Resistant Tuberculosis
811476|NCT03086486|Drug-Resistant Tuberculosis
811477|NCT03086486|Pretomanid
811478|NCT03086486|PA-824
811479|NCT03086486|Bedaquiline
811480|NCT03086486|Linezolid
811481|NCT03086486|NC-007
811482|NCT03086486|TB Alliance
811483|NCT03086486|pre-XDR-TB
811484|NCT03086473|caffeine
811485|NCT03086473|intubation
811486|NCT03086473|hemodynamics
811487|NCT03086473|mechanical ventilation
811488|NCT03086473|cardiac output
811489|NCT03086473|near infrared spectroscopy
811490|NCT03086473|functional echocardiography
811491|NCT03086434|Culturally tailored intervention
811492|NCT03086434|American Indian early adolescents
811493|NCT03086434|Prevention of substance use
811494|NCT03086421|Childhood cancer
811495|NCT03086421|Social functioning
811496|NCT03086421|Social development
811497|NCT03086408|airway management
811498|NCT03086408|high flow nasal oxygen
811499|NCT03086408|high flow nasal cannula
811500|NCT03086408|THRIVE
811501|NCT03086395|relapsed
811502|NCT03086395|refractory
811503|NCT03086382|Lacosamide
811504|NCT03086382|Syrup
811505|NCT03086382|Bioequivalence
811506|NCT03086382|Tablet
811512|NCT03086317|Pulmonary Medicine
811513|NCT03086317|Therapy Evaluation
811514|NCT03086304|postoperative intestinal obstruction;TEAS
811515|NCT03086265|airway management
811516|NCT03086265|high flow nasal oxygen high flow nasal cannula THRIVE
811517|NCT03086265|high flow nasal cannula THRIVE
811518|NCT03086265|THRIVE
811523|NCT03086226|Mycetoma Fosravuconazole Itraconazole Surgery Sudan
811524|NCT03086213|nonintubated uniport thoracoscopic surgery
811525|NCT03086213|paravertebral nerve block
811526|NCT03086213|intercostal nerve block
811527|NCT03086213|peripheral solitary pulmonary nodule
811528|NCT03086200|PrEP
811529|NCT03086200|Pre-exposure Prophylaxis
811530|NCT03086200|Text messaging
811531|NCT03086200|Truvada
811532|NCT03086200|Motivational interviewing
811533|NCT03086200|Transgender
811534|NCT03086200|Gender Non-conforming
811535|NCT03086187|weight bearing
811536|NCT03086187|muscle unloading
811537|NCT03086187|bone loss
811538|NCT03086187|arterial adaptation
811539|NCT03086187|muscular adaptation
811540|NCT03086174|anti-PD-1 monoclonal antibody
811541|NCT03086174|advanced
811542|NCT03086174|melanoma
811543|NCT03086174|kidney cancer
811544|NCT03086122|OSA
811545|NCT03086122|Erectile Dysfunction
811546|NCT03086122|CPAP treatment
811547|NCT03086122|Endothelial Dysfunction
811548|NCT03086122|Cardiovascular risk
811549|NCT03086109|prevalence
811550|NCT03086109|Bone Degenerative Disease
811551|NCT03086083|Traumatic memories
811552|NCT03086083|comparative study
811553|NCT03086083|single session
811554|NCT03086083|EMDR
811555|NCT03086083|Beck inventory
811556|NCT03086070|omeprazole
811557|NCT03086070|placebo
811558|NCT03086070|treatment
811559|NCT03086070|adults
811560|NCT03086057|PrEP
811561|NCT03086057|Prevention
811562|NCT03086057|Male Sex Workers (MSW)
811563|NCT03086031|Traumatic brain injury, Vocational rehabilitation, Caregiver intervention,
811564|NCT03086005|Metformin
811565|NCT03085992|rectal cancer
811566|NCT03085992|FOLFOXIRI
811567|NCT03085992|bevacizumab
811568|NCT03085992|trust
811569|NCT03085966|central memory T cell
811570|NCT03085966|metastatic castration-resistant prostate cancer
811571|NCT03085953|Psychological health
811572|NCT03085953|Well-being
811573|NCT03085953|Employee
811574|NCT03085927|music therapy
811575|NCT03085927|neoplasms
811576|NCT03085927|play
811577|NCT03085927|children
811578|NCT03085927|parents
811579|NCT03085914|solid tumors
811580|NCT03085914|colorectal cancer
811581|NCT03085914|pancreatic ductal adenocarcinoma
811582|NCT03085914|non-small cell lung cancer
811583|NCT03085914|PD-1
811584|NCT03085914|PD-L1
811585|NCT03085914|epacadostat
811586|NCT03085914|IDO inhibitor
811587|NCT03085888|Cancer Screening
811588|NCT03085888|Next Generation Sequencing
811589|NCT03085888|Circulating cell-free nucleic acid
811590|NCT03085888|Circulating cell-free tumor DNA
811591|NCT03085888|Deep sequencing
811592|NCT03085875|Weight Change
811593|NCT03085875|Healthy Pregnancy
811594|NCT03085875|Physiologic Sensors
811595|NCT03085862|Ultrasonography
811596|NCT03085862|Extravascular lung water
811597|NCT03085862|PaO2/FiO2 ratio
811598|NCT03085836|Drug Therapy
811605|NCT03085758|Early Septic Shock
811606|NCT03085745|Writer's cramp
811607|NCT03085745|Sensorimotor plasticity
811608|NCT03085745|TMS
811609|NCT03085745|Afferent inhibition
811610|NCT03085745|Motor mapping
811611|NCT03085745|Sensory mapping
811612|NCT03085745|adaptive sensorimotor synergies
811613|NCT03085745|fine motor control
811614|NCT03085732|saline irrigation
811615|NCT03085732|abdominal hysterectomy
811616|NCT03085732|postoperative infectious morbidities
811617|NCT03085732|gastrointestinal disturbances
811618|NCT03085719|Head and Neck Cancer
811619|NCT03085680|Curcumin, physical function, cognitive function
811620|NCT03085667|Left atrial appendage occluder
811621|NCT03085667|Watchman device
811622|NCT03085667|Atrial fibrillation
811623|NCT03085667|atrial natriureitc peptide
811624|NCT03085667|brain natriuretic peptide
811625|NCT03085654|multiple doses
811626|NCT03085654|oxytocin
811627|NCT03085654|trait anxiety
811628|NCT03085641|High flow oxygen therapy
811629|NCT03085628|social sharing
811630|NCT03085628|social reward
811631|NCT03085628|functional magnetic resonance imaging
811632|NCT03085628|reward circuit
811638|NCT03085576|Atrial Fibrillation
811639|NCT03085576|Anticoagulation
811640|NCT03085576|Stroke
811641|NCT03085576|Vitamin K antagonist
811642|NCT03085576|Cardioversion
811643|NCT03085576|INR (International Normalized Ratio)
811644|NCT03085550|diabetic foot ulcer
811645|NCT03085550|diabetes mellitus
811646|NCT03085550|fat grafting
811647|NCT03085550|platelet rich plasma
811648|NCT03085550|wound healing
811649|NCT03085537|home monitoring
811650|NCT03085537|Non-invasive mechanical ventilation
811651|NCT03085511|Egg breakfast
811652|NCT03085511|Weight loss
811653|NCT03085511|Satiety
811654|NCT03085511|Insulin
811655|NCT03085511|Glucagon-Like Peptide 1
811656|NCT03085511|PYY (3-36) peptide
811657|NCT03085511|Ghrelin
811658|NCT03085511|Glucose
811659|NCT03085511|Protein quality
811660|NCT03085498|retinal vessels
811661|NCT03085498|physical activity
811662|NCT03085498|children
811663|NCT03085498|psychosocial health
811664|NCT03085485|COPD
811665|NCT03085485|CFTR
811666|NCT03085485|ivacaftor
811667|NCT03085485|topic trial
811668|NCT03085472|intracerebral hemrrohage
811669|NCT03085472|stroke
811670|NCT03085472|China
811671|NCT03085472|hematoma
811672|NCT03085472|CT
811673|NCT03085472|predictor
811674|NCT03085472|prognosis
811675|NCT03085472|outcome
811676|NCT03085420|Burns
811677|NCT03085420|Pediatrics
811678|NCT03085420|Cardiac Arrhythmia
811679|NCT03085394|Morbid Obesity
811680|NCT03085394|Sleeve gastrectomy
811681|NCT03085368|breast cancer
811682|NCT03085368|her-2 positive
811683|NCT03085368|lapatinib
811684|NCT03085368|herceptin
811685|NCT03085355|neck pain
811686|NCT03085342|liver
811687|NCT03085342|fibrosis
811688|NCT03085342|MRI
811689|NCT03085329|bubble nasal continuous positive airway pressure
811690|NCT03085329|respiratory support
811691|NCT03085290|dry eye syndrome
811692|NCT03085290|serum eye drops
811693|NCT03085277|Bovine colostrum
811694|NCT03085277|Preterm formula
811695|NCT03085277|Very preterm infants
811696|NCT03085277|Enteral feeding
811697|NCT03085225|Advanced tumor
811698|NCT03085225|Pretreated tumor
811699|NCT03085225|Soft Tissue Sarcomas
811700|NCT03085225|Ovarian Carcinomas
811701|NCT03085225|Phase Ib
811702|NCT03085225|Circulating DNA
811703|NCT03085199|gastric cancer
811704|NCT03085199|laparoscopic gastrectomy
811705|NCT03085199|laparoscopic reinforcement suture (LARS)
811706|NCT03085173|CAR T Cells Targeting CD19
811707|NCT03085173|EGFRt/19-28z/4-1BBL
811708|NCT03085173|16-1570
811709|NCT03085147|Tongue
811710|NCT03085147|Mouth
811711|NCT03085147|Fluorescent PARP1 Binding Imaging Agent
811712|NCT03085147|PARPi-FL
811713|NCT03085147|15-336
811714|NCT03085121|extramedullary
811715|NCT03085121|intramedullary
811716|NCT03085121|total knee arthroplasty (TKA)
811717|NCT03085069|PD-1
811718|NCT03085069|PD-L1
811719|NCT03085069|shr-1210
811720|NCT03085056|Trametinib
811721|NCT03085056|Paclitaxel
811722|NCT03085056|15-055
811723|NCT03085043|Prostate Cancer
811724|NCT03085043|Whole body MRI
811725|NCT03085043|MRI of the pelvis
811726|NCT03085043|Magnetic resonance imaging
811727|NCT03085043|Bone scan
811728|NCT03085043|Computed tomography scan of abdomen and pelvis
811729|NCT03085043|CT
811730|NCT03085030|infertility
811731|NCT03085030|IVF
811732|NCT03085030|ICSI
811733|NCT03085030|poor responders in IVF/ICSI cycles
811734|NCT03085030|antioxidant
811735|NCT03085004|Pancreatic cyst
811736|NCT03085004|Cyst Ablation
811737|NCT03085004|Eus-FNA (fine-needle aspiration )
811738|NCT03085004|Chemotherapy
811739|NCT03084952|safety
811740|NCT03084952|pharmacokynetics
811741|NCT03084952|leishmaniasis treatment
811742|NCT03084913|dietary treatment
811743|NCT03084887|Tissue Expansion Devices
811744|NCT03084887|Tissue Expansion
811745|NCT03084887|common complications
811746|NCT03084887|intervention study
811747|NCT03084874|COPD
811748|NCT03084874|Physical Activity
811749|NCT03084874|Sedentary behaviour
811750|NCT03084874|Hospitalization
811751|NCT03084848|brain/cognitive measures
811752|NCT03084848|condition
811753|NCT03084848|inhibitor control
811754|NCT03084848|training at adolescence
811755|NCT03084835|tobacco
811756|NCT03084835|smoking
811757|NCT03084835|low dose computed tomography
811758|NCT03084835|lung screening
811759|NCT03084835|text messaging
811760|NCT03084783|dexamethasone
811761|NCT03084783|HSV encephalitis
811762|NCT03084770|NF-PNEN
811763|NCT03084731|Microbiota
811764|NCT03084731|Complementary Food
811765|NCT03084692|caregiver
811766|NCT03084692|lung cancer
811767|NCT03084692|yoga
811768|NCT03084692|resistance exercise
811769|NCT03084679|Heart Failure
811770|NCT03084679|Hypertrophy
811771|NCT03084679|Fibrosis
811772|NCT03084679|Magnetic Resonance
811773|NCT03084653|Trocar entery
811774|NCT03084653|Surgery, Laparoscopic
811775|NCT03084627|tailored dietary advice
811776|NCT03084627|nutrient adequacy
811777|NCT03084627|dietary modifications
811778|NCT03084614|Infectious Diseases
811779|NCT03084614|Dendritic Cells
811780|NCT03084614|Pathogens
811781|NCT03084614|Passive Cellular Immunity
811782|NCT03084614|Immune-Modulating
811783|NCT03084575|neuroaxial rhizolysis -selective rhizolysis-thermal radiofrequency
811784|NCT03084510|High risk for surgical valve replacement
811785|NCT03084510|transcatheter aortic valve replacement
811786|NCT03084497|Massage
811787|NCT03084497|Development
811788|NCT03084471|Programmed death ligand 1 (PD-L1)
811789|NCT03084471|Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
811790|NCT03084471|Durvalumab in combination with tremelimumab
811791|NCT03084458|Increasing daily physical activity
811792|NCT03084445|Brominated Flame Retardants (BFRs)
811793|NCT03084445|Phthalates
811794|NCT03084445|pregnant women
811795|NCT03084445|newborn
811796|NCT03084445|Heavy Metals
811797|NCT03084445|Volatile Organic Compounds
811798|NCT03084432|caffeine
811799|NCT03084432|bone mineral content
811800|NCT03084419|Rheumatoid Arthritis
811801|NCT03084419|Interstitial Lung Disease
811802|NCT03084419|RA-ILD
811803|NCT03084419|Abatacept
811804|NCT03084406|Substance Abuse
811805|NCT03084406|Implementation Science
811806|NCT03084406|Evidence-based Practices
811807|NCT03084393|non-cardiac surgery
811808|NCT03084393|Postoperative Cognitive Dysfunction
811809|NCT03084354|pelvic floor
811810|NCT03084354|women's experiences
811811|NCT03084354|bladder care
811812|NCT03084354|pregnancy
811813|NCT03084354|labour
811814|NCT03084354|postpartum
811815|NCT03084341|Elasticity
811816|NCT03084341|Electric Stimulation
811817|NCT03084341|Muscle Stretching Exercises
811818|NCT03084315|smoking
811819|NCT03084315|electronic cigarettes
811820|NCT03084315|nicotine
811821|NCT03084302|sedentary behavior
811822|NCT03084302|physical activity
811823|NCT03084276|meal ingestion
811824|NCT03084276|meal composition
811825|NCT03084276|postprandial responses
811826|NCT03084276|hedonic sensations
811827|NCT03084276|homeostatic sensations
811828|NCT03084276|new composition
811832|NCT03084198|Bioartificial Liver
811833|NCT03084198|Acute Liver Failure
811834|NCT03084185|decompensation
811835|NCT03084185|deficit
811836|NCT03084185|metabolomics
811837|NCT03084185|portal hypertension
811838|NCT03084133|Therapeutic education strategy
811842|NCT03084094|Fibromyalgia
811843|NCT03084094|tDCS
811844|NCT03084081|Human Papilloma Virus (HPV)
811845|NCT03084081|Cryotherapy
811846|NCT03084081|Thermoablation
811847|NCT03084081|Thermocoagulation
811848|NCT03084081|Low and Middle Income Countries (LMICs)
811849|NCT03084042|emotional impairments
811850|NCT03084042|cognitive impairments
811851|NCT03084029|oxytocin
811852|NCT03084029|fMRI
811853|NCT03084029|empathy
811854|NCT03083964|Middle aged women
811855|NCT03083964|35-64yrs
811856|NCT03083964|BMI= >30
811857|NCT03083951|Complete mesocolon excision
811858|NCT03083951|Sigmoid cancer
811859|NCT03083951|Colorectal cancer
811860|NCT03083938|Pancreatoduodenectomy
811861|NCT03083938|Omentum
811862|NCT03083938|Wrapping
811863|NCT03083938|Roll-up
811864|NCT03083938|Whipple
811865|NCT03083912|Malnutrition
811866|NCT03083912|Disability
811867|NCT03083912|Oral Nutritional Supplementation
811868|NCT03083899|Diabetes
811869|NCT03083899|Organization
811870|NCT03083899|Out-patient control
811871|NCT03083873|LN-145
811872|NCT03083873|Cell Therapy
811873|NCT03083873|Autologous Adoptive Cell Transfer
811874|NCT03083873|Autologous Adoptive Cell Therapy
811875|NCT03083873|Cellular Immuno-therapy
811876|NCT03083873|Tumor Infiltrating Lymphocytes
811877|NCT03083873|TIL
811878|NCT03083873|IL-2
811879|NCT03083847|Malaria
811880|NCT03083847|Parasitemia
811881|NCT03083847|Immune
811882|NCT03083847|Responses
811883|NCT03083847|Sporozoites
811884|NCT03083834|cosyntropin
811885|NCT03083834|salivary free cortisol
811886|NCT03083834|mitotane
811887|NCT03083808|PD-1
811888|NCT03083808|PD-L1 Inhibitor
811889|NCT03083808|Pembrolizumab
811890|NCT03083808|Docetaxel
811891|NCT03083808|Pemetrexed
811892|NCT03083808|Gemcitabine
811893|NCT03083795|Social relationships
811894|NCT03083795|Vulnerable connections
811895|NCT03083795|Diabetes Distress
811896|NCT03083795|Support group
811897|NCT03083782|Apixaban
811898|NCT03083782|Cyclosporine
811899|NCT03083782|Tacrolimus
811900|NCT03083782|Cytochrome P450 CYP3A4
811901|NCT03083782|Permeability Glycoprotein P-gp
811902|NCT03083782|Breast cancer resistance protein BCRP
811903|NCT03083782|Factor Xa Inhibitors
811904|NCT03083782|Anticoagulants
811905|NCT03083782|Enzyme Inhibitors
811906|NCT03083769|tacrolimus
811907|NCT03083769|genetic variants
811908|NCT03083769|side effects
811909|NCT03083743|Carcinoma, Non-Small-Cell Lung
811910|NCT03083743|Carcinoma, Bronchogenic
811911|NCT03083743|Bronchial Neoplasms
811912|NCT03083743|Lung Neoplasms
811913|NCT03083743|Thoracic Neoplasms
811914|NCT03083743|Neoplasms
811915|NCT03083743|Lung Diseases
811916|NCT03083743|Antineoplastic Agents, Cytokines
811917|NCT03083743|Antineoplastic Agents
811918|NCT03083743|Biological activity factor
811919|NCT03083743|Genetic Engineering
811920|NCT03083743|Molecular Mechanisms of Pharmacological Action
811921|NCT03083743|Physiological Effects of Drugs
811922|NCT03083730|Atopic Dermatitis
811923|NCT03083730|Eczema
811924|NCT03083730|Systemic Inflammation
811925|NCT03083730|UVB Phototherapy
811926|NCT03083691|Nivolumab
811927|NCT03083691|Ipilimumab
811928|NCT03083678|EGFR
811929|NCT03083678|Afatinib
811930|NCT03083665|Epilepsy
811931|NCT03083665|Partial seizures with or without secondary generalization
811932|NCT03083665|Brivaracetam
811933|NCT03083665|Asian subjects
811934|NCT03083652|physiotherapy
811935|NCT03083652|neuromuscular electrical stimulation
811936|NCT03083652|exercise capacity
811937|NCT03083639|Drug Therapy
811938|NCT03083626|Chronic pain
811939|NCT03083626|Narcotic abuse
811940|NCT03083626|Opioid related disorders
811941|NCT03083626|Opiate substitution treatment
811942|NCT03083626|Buprenorphine
811943|NCT03083626|Pregabalin
811944|NCT03083626|Methadone
811945|NCT03083613|Raltitrexed
811946|NCT03083613|Paclitaxel
811947|NCT03083613|chemotherapy
811948|NCT03083613|Gastric cancer
811949|NCT03083613|Gastroesophageal Junction Adenocarcinoma
811953|NCT03083574|Hematology
811954|NCT03083574|Chronic graft versus host disease (cGVHD)
811955|NCT03083574|Extracorporeal photopheresis
811956|NCT03083574|Hematopoietic stem cell transplantation
811957|NCT03083574|Donor lymphocyte infusion
811958|NCT03083522|Cold Hypersensitivity
811959|NCT03083522|Korean medicine
811960|NCT03083522|Ojeok-san
811961|NCT03083522|Cold intolerance
811962|NCT03083418|AECOPD
811963|NCT03083418|EDP
811964|NCT03083418|Neural Respiratory Drive
811965|NCT03083418|Surface EMGdi
811966|NCT03083392|DIVA
811967|NCT03083392|sinusitis
811968|NCT03083392|maxillary
811969|NCT03083379|Incentive spirometry
811970|NCT03083379|EzPAP
811971|NCT03083379|Electrical impedance tomography
811972|NCT03083366|spinal cord injury
811973|NCT03083366|Neurogenic
811974|NCT03083366|bladder
811975|NCT03083366|electrical stimulation
811976|NCT03083366|neuromodulation
811977|NCT03083301|Cardiac resynchronisation
811978|NCT03083223|patient positioning
811979|NCT03083223|lung diseases
811980|NCT03083223|oxygenation
811981|NCT03083223|hemodynamic parameters
811982|NCT03083223|vital signs
811983|NCT03083197|Scrub Typhus
811984|NCT03083197|Antibiotic Resistance
811985|NCT03083184|Hemodialysis
811986|NCT03083184|hemodiafiltration
811987|NCT03083184|tunnelled dialysis catheter
811988|NCT03083184|interdialytic lock solution
811989|NCT03083184|preventing tunnelled catheter infection
811990|NCT03083171|Adrecizumab
811991|NCT03083171|Adrenomedullin
811992|NCT03083171|Healthy volunteers
811993|NCT03083171|LPS
811994|NCT03083171|Monoclonal recombinant antibody
811995|NCT03083132|freezing of gait
811996|NCT03083067|AECOPD
811997|NCT03083067|air pollution
811998|NCT03083067|COPD
811999|NCT03083067|salvational Intervention
812000|NCT03083041|SHR-1210
812001|NCT03083041|Apatinib
812002|NCT03083041|NSCLC
812003|NCT03083028|Ankle Fracture
812004|NCT03083015|regeneration, MTA apexification and TAP
812005|NCT03083015|revascularization
812006|NCT03082963|atrial fibrillation
812007|NCT03082963|ablation
812008|NCT03082950|hpv prevalence
812009|NCT03082950|recurrence rate
812010|NCT03082950|survival
812011|NCT03082924|surface EMGdi
812012|NCT03082924|pulmonary rehabilitation
812013|NCT03082924|inspiratory muscle training
812014|NCT03082924|exercise training
812015|NCT03082911|screening
812016|NCT03082911|early detection
812017|NCT03082911|participation
812018|NCT03082872|Reduction, Fracture
812019|NCT03082859|Exercise
812020|NCT03082859|Interval Training
812021|NCT03082859|Glycaemic Control
812022|NCT03082859|Type 2 Diabetes
812023|NCT03082846|malignant glioma
812024|NCT03082846|intensity modulated radiation therapy
812025|NCT03082846|simultaneous integrated boost
812026|NCT03082846|hypofractionation
812027|NCT03082846|temozolomide
812028|NCT03082846|maximum tolerated dose
812029|NCT03082807|Caloric Restriction
812030|NCT03082807|Diet
812031|NCT03082807|Exercise
812032|NCT03082807|Obesity
812033|NCT03082807|Overweight
812034|NCT03082807|Sedentary lifestyle
812035|NCT03082807|weight loss
812036|NCT03082807|Men
812037|NCT03082794|Dietary Formulations
812038|NCT03082794|Lifestyle
812039|NCT03082794|Obesity
812040|NCT03082794|Overweight
812041|NCT03082794|weight loss
812042|NCT03082781|Diet
812043|NCT03082781|Exercise
812044|NCT03082781|Obesity
812045|NCT03082781|Overweight
812046|NCT03082781|Weight loss
812047|NCT03082768|HV
812048|NCT03082742|diuretics
812049|NCT03082742|furosemide
812050|NCT03082742|hydrochlorothiazide
812051|NCT03082742|CKD-MBD
812052|NCT03082742|peripheral micro-CT
812053|NCT03082742|parathyroid hormone
812054|NCT03082716|cardioplegia
812055|NCT03082716|myocardial protection
812056|NCT03082716|custodiol
812057|NCT03082716|htk
812058|NCT03082677|Ixazomib
812059|NCT03082677|Graft-versus-Host Disease
812060|NCT03082677|Allogeneic Hematopoietic Stem Cell Transplantation
812061|NCT03082677|16-076
812062|NCT03082651|Running injuries, footwear, alternating load
812063|NCT03082612|Behavioral research
812064|NCT03082612|Social research
812065|NCT03082612|Spirituality
812066|NCT03082612|Late stage cancer
812067|NCT03082547|Headache
812068|NCT03082547|Neuropsychological tests
812069|NCT03082547|Myofascial trigger points
812070|NCT03082547|electrophysiology
812071|NCT03082534|Head and Neck Cancer
812072|NCT03082534|Pembrolizumab
812073|NCT03082534|Keytruda®
812074|NCT03082534|Cetuximab
812075|NCT03082534|Erbitux®
812076|NCT03082534|Recurrent
812077|NCT03082534|Metastatic
812078|NCT03082534|PD-1
812079|NCT03082534|PD-L1
812080|NCT03082534|non-EBV related Nasopharynx
812081|NCT03082521|After hours care; Primary care; Antibiotics; Action Research
812082|NCT03082508|Algisyl
812083|NCT03082508|Heart Failure
812084|NCT03082508|Dilated Cardiomyopathy
812085|NCT03082508|Alginate Hydrogel
812086|NCT03082508|Heart Failure with Reduced Ejection Fraction
812087|NCT03082508|Congestive Heart Failure
812088|NCT03082495|Exercise
812089|NCT03082495|Cancer
812090|NCT03082495|Symptom management
812091|NCT03082495|Quality of life
812092|NCT03082495|presurgical
812093|NCT03082495|chemoradiotherapy
812094|NCT03082495|Physical Fitness
812095|NCT03082482|Smoking Cessation
812096|NCT03082482|HIV
812097|NCT03082482|AIDS
812098|NCT03082469|Severe acute pancreatitis
812099|NCT03082469|Haemodynamic monitoring
812100|NCT03082469|Cytokine removal
812101|NCT03082469|Vasopressor dependency index
812102|NCT03082456|molecuiar breast imaging
812103|NCT03082456|MBI
812104|NCT03082456|breast cancer
812105|NCT03082456|mammography
812106|NCT03082456|sonography
812107|NCT03082456|recall rate
812108|NCT03082456|diagnostic accuracy
812109|NCT03082456|breast echo
812110|NCT03082456|female population
812111|NCT03082443|Cardiac rehabilitation
812112|NCT03082443|psychology
812113|NCT03082443|nutrition
812114|NCT03082443|stress
812115|NCT03082443|quality of life
812116|NCT03082417|Bone Fracture
812117|NCT03082417|75 years old
812118|NCT03082417|Elderly
812119|NCT03082417|Older adults
812120|NCT03082417|Pain scale
812121|NCT03082417|Pain documentation
812122|NCT03082417|Analgesics
812123|NCT03082417|Acetaminophen
812124|NCT03082417|Opioid
812125|NCT03082417|Nonsteroidal anti-inflammatory drugs
812126|NCT03082417|Emergency Department
812127|NCT03082404|Chronic kidney disease
812128|NCT03082404|Inspiratory muscle training
812129|NCT03082391|Ventral Hernia Repair
812130|NCT03082391|Heavyweight Mesh
812131|NCT03082391|Mediumweight Mesh
812132|NCT03082365|oral findings or oral manifestations
812133|NCT03082365|pre-dialysis or end stage renal disease
812134|NCT03082326|shock
812135|NCT03082326|critical care ultrasound
812136|NCT03082326|hemodynamics
812137|NCT03082326|lung pathology
812138|NCT03082326|epidemic
812139|NCT03082326|prognosis
812140|NCT03082313|infant
812141|NCT03082313|leg movement
812142|NCT03082313|wearable sensors
812143|NCT03082313|early intervention
812144|NCT03082300|ASP8273
812145|NCT03082300|Epidermal growth factor receptor (EGFR) mutations
812146|NCT03082300|Non-small cell lung cancer (NSCLC)
812147|NCT03082300|Bioequivalence
812148|NCT03082261|Failed Back Surgery Syndrome
812149|NCT03082261|Radiculopathy
812150|NCT03082261|Post Laminectomy Syndrome
812151|NCT03082248|Low Back Pain
812152|NCT03082248|Surgery
812153|NCT03082248|Lumbar Spine
812154|NCT03082248|Physical Therapy Modalities
812155|NCT03082248|Rehabilitation
812156|NCT03082235|Healthy participants
812157|NCT03082235|E6742
812158|NCT03082235|pharmacokinetics
812159|NCT03082222|partial onset seizures
812160|NCT03082222|secondary generalization
812167|NCT03082196|sodium fluoride
812168|NCT03082196|povidone iodine
812169|NCT03082196|varnish
812170|NCT03082170|sleep apnea
812171|NCT03082170|robotic surgery for base of tongue
812172|NCT03082170|soft palate surgery
812173|NCT03082170|post operative swallowing evaluation
812174|NCT03082170|dysphagia
812179|NCT03082092|Knee
812180|NCT03082092|Pain
812181|NCT03082092|Recovery
812182|NCT03082092|Steroid
812183|NCT03082092|Replacement
812184|NCT03082092|Arthroplasty
812185|NCT03082079|GIST
812186|NCT03082079|ESD
812187|NCT03082066|bone access
812188|NCT03082066|intraosseus needle
812189|NCT03082066|resuscitation
812190|NCT03082066|infusion
812191|NCT03082066|volume therapy
812192|NCT03082066|emergency
812193|NCT03082027|ultrasonography
812194|NCT03082027|carpal tunnel syndrome
812195|NCT03082014|Hypertension
812196|NCT03082014|Cerebrovascular Reactivity
812197|NCT03082014|Blood Pressure Variability
812198|NCT03082001|Neonate
812199|NCT03082001|Pain
812200|NCT03082001|ELBW
812201|NCT03081988|Esophageal Cancer
812202|NCT03081988|chemoradiotherapy response
812203|NCT03081988|molecular factors
812204|NCT03081975|adenoma detection rate
812205|NCT03081975|narrow band imaging
812206|NCT03081949|peripartum cardiomyopathy
812207|NCT03081949|Ventricular remodelling
812208|NCT03081949|Survival
812209|NCT03081949|Selenium
812210|NCT03081949|Oxidative stress
812211|NCT03081949|Nigeria
812212|NCT03081923|Immunotherapy
812213|NCT03081923|Durvalumab
812214|NCT03081923|Tremelimumab
812215|NCT03081923|Combination therapy
812216|NCT03081923|Testicular cancer
812217|NCT03081910|Autologous CAR T cells
812218|NCT03081910|T-cell acute lymphoblastic lymphoma
812219|NCT03081910|T-non-Hodgkin Lymphoma
812220|NCT03081910|T-cell Acute Lymphoblastic Leukemia
812221|NCT03081884|Prostate cancer
812222|NCT03081884|Metastatic cancer
812223|NCT03081884|Urogenital disorders
812224|NCT03081884|Oncology
812225|NCT03081884|Radiology
812226|NCT03081858|NMIBC
812227|NCT03081858|Paclitaxel
812228|NCT03081858|Antineoplastic Agents
812229|NCT03081832|Prader-Willi
812230|NCT03081832|Oxytocin
812231|NCT03081832|Communication skills
812232|NCT03081832|Oral skills
812233|NCT03081832|Brain activity
812234|NCT03081832|Hormonal disease
812235|NCT03081806|Phase 3
812236|NCT03081806|Efficacy
812237|NCT03081806|Safety
812238|NCT03081806|Osteoarthritis, Knee
812239|NCT03081793|postoperative monitoring
812240|NCT03081793|plethysmography
812241|NCT03081793|monitoring
812242|NCT03081780|AML
812243|NCT03081767|PET/CT
812244|NCT03081767|digital PET/CT
812245|NCT03081715|esophageal cancer
812246|NCT03081715|immune checkpoint
812247|NCT03081715|PD-1
812248|NCT03081715|CRISPER
812249|NCT03081715|autologous cell infusion
812250|NCT03081676|Maturity-Onset Diabetes of the Young, Type 3
812251|NCT03081676|Glucose-dependent insulinotropic peptide
812252|NCT03081676|Glucagon-like-peptide 1
812253|NCT03081676|Dipeptidyl peptidase 4
812254|NCT03081676|Glimepiride
812255|NCT03081676|Sulphonylurea
812256|NCT03081676|Glucose clamp
812257|NCT03081676|Hepatocyte nuclear factor 1 alpha
812258|NCT03081663|total knee arthroplasty
812259|NCT03081663|quadriceps sparing mid-vastus
812260|NCT03081663|medial para-patellar
812261|NCT03081624|preterm
812262|NCT03081624|neurological status
812263|NCT03081624|School Readiness
812264|NCT03081585|fmri
812265|NCT03081585|neuronal reward processing
812266|NCT03081585|hormonal satiety signalling
812267|NCT03081585|fasting
812268|NCT03081559|transgender
812269|NCT03081559|women
812270|NCT03081533|Circular dance
812271|NCT03081533|Older caregiver
812272|NCT03081533|Dance Therapy
812273|NCT03081507|Muslim Americans
812274|NCT03081507|Patient Navigation
812275|NCT03081507|Breast Cancer
812276|NCT03081507|Cervical Cancer
812284|NCT03081481|Intraprostatic
812285|NCT03081481|MRI lesion
812286|NCT03081481|Prostate biopsies
812287|NCT03081468|Optical coherence tomography
812288|NCT03081468|Pupillometry
812289|NCT03081468|Automated
812290|NCT03081468|Binocular
812291|NCT03081455|Screening
812292|NCT03081455|Hereditary Cancer
812293|NCT03081403|Sensitive skin
812294|NCT03081403|Quantitative Sensory Testing
812295|NCT03081364|Cardiac Implanted Device
812296|NCT03081351|Extended retroperitoneal lymphadenectomy, Nerve plexus clearance, Survival benefit
812297|NCT03081338|ALS, MND, Care, Patient journey
812298|NCT03081325|URSA
812299|NCT03081312|Family Cancer Caregivers,
812300|NCT03081312|Needs
812301|NCT03081312|Burden of Care
812302|NCT03081312|Quality of Life
812303|NCT03081273|Antimicrobial susceptibility
812304|NCT03081273|Biofilm formation
812305|NCT03081273|Bone and joint infection
812306|NCT03081273|Corynebacterium spp
812307|NCT03081273|Osteoblast
812308|NCT03081273|Outcome
812309|NCT03081273|Prosthetic joint infection
812310|NCT03081260|Total Knee Arthroplasty
812311|NCT03081260|Patella
812312|NCT03081260|Resurfacing
812313|NCT03081260|IKS score
812314|NCT03081234|Hormone receptor-positive
812315|NCT03081234|Estrogen and/or progesterone receptor-positive
812316|NCT03081234|HER2-negative
812317|NCT03081234|Intermediate risk early breast cancer
812318|NCT03081234|Adjuvant
812319|NCT03081234|Ribociclib
812320|NCT03081234|LEE011
812321|NCT03081234|CDK4/6 inhibitor
812322|NCT03081234|Endocrine therapy
812323|NCT03081234|Phase III
812324|NCT03081234|breast carcinoma
812325|NCT03081234|breast cancer
812326|NCT03081208|IVF
812327|NCT03081208|ICSI
812328|NCT03081195|child behavior
812329|NCT03081195|intervention
812330|NCT03081195|multiple family group
812331|NCT03081195|Sub Saharan Africa
812332|NCT03081195|caregivers
812333|NCT03081182|Pediatric Chronic Pancreatitis
812334|NCT03081182|Data management
812335|NCT03081182|Regulatory compliance
812336|NCT03081182|Protocol monitoring
812337|NCT03081156|chronic obstructive pulmonary disease (COPD)
812338|NCT03081156|exercise intolerance
812339|NCT03081156|dynamic hyperinflation
812340|NCT03081117|HIV-Associated Neurocognitive Disorder (HAND)
812341|NCT03081117|Intranasal
812342|NCT03081052|Heart and Lung transplantation surgery
812343|NCT03081052|Pulmonary vasodilation therapy
812344|NCT03081039|cholangiocarcinoma
812345|NCT03081039|gemcitabine
812346|NCT03081039|carboplatin
812347|NCT03081039|cisplatin
812348|NCT03081026|surgery
812349|NCT03081026|ages 6-16
812350|NCT03081013|adolescents
812351|NCT03081013|social norms
812352|NCT03080974|irreversible electroporation
812353|NCT03080974|Nivolumab
812354|NCT03080961|Barrier cream
812355|NCT03080922|Acute Myeloid Leukemia
812356|NCT03080922|Relapsed
812357|NCT03080922|Refractory
812358|NCT03080922|hematopoietic stem cell
812366|NCT03080870|Art intervention
812367|NCT03080870|Quality of Life
812368|NCT03080870|Well-being
812369|NCT03080870|Physical performance
812370|NCT03080870|Family caregivers
812371|NCT03080870|Older adults
812372|NCT03080831|Maintenance Fluid Therapy
812373|NCT03080818|Probiotic, Cognitive Function, Mood
812374|NCT03080792|stem cell transplantation
812375|NCT03080792|exercise
812376|NCT03080792|high intensity interval training
812377|NCT03080792|resistance training
812378|NCT03080792|physical fitness
812379|NCT03080792|cancer
812380|NCT03080753|Sphinkeeper
812381|NCT03080753|Intersphincteric implants
812382|NCT03080753|Gatekeeper
812383|NCT03080714|no known ocular pathology
812384|NCT03080714|Glaucoma
812385|NCT03080714|Retinal Disease
812387|NCT03080675|Aging population
812388|NCT03080649|dental caries, Er:YAG laser, rotary bur
812389|NCT03080636|Post-exercise hypotension
812390|NCT03080636|Aerobic Exercise
812391|NCT03080636|Resistance Exercise
812392|NCT03080636|Autonomic Stress
812393|NCT03080636|Heart Rate Variability
812394|NCT03080636|Sex difference
812395|NCT03080610|Post-Dural Puncture Headache [C10.228.140.546.699.124]
812396|NCT03080610|Blood Patch, Epidural [E02.319.267.530.580.300.145]
812397|NCT03080584|acupuncture
812398|NCT03080584|IVF
812399|NCT03080584|AMH
812400|NCT03080584|ovarian reserve
812401|NCT03080558|Indocyanine green fluorescence
812402|NCT03080558|Rectal vascularisation
812403|NCT03080558|Vaginal vascularisation
812404|NCT03080558|Laparoscopic surgery
812405|NCT03080558|Rectal shaving
812406|NCT03080558|Recto vaginal node
812407|NCT03080558|Deep Endometriosis
812408|NCT03080532|Microbiome
812409|NCT03080532|Mediterranean diet
812410|NCT03080519|renal artery stenosis
812411|NCT03080519|balloon angioplasty
812412|NCT03080519|stents
812413|NCT03080493|Abortion
812414|NCT03080493|Osmotic dilators
812415|NCT03080493|Gabapentin
812416|NCT03080493|Text message
812417|NCT03080480|Chronic Granulomatous Disease
812418|NCT03080480|Severe Infection
812419|NCT03080480|PPARγ
812420|NCT03080480|Pioglitazone
812421|NCT03080480|phagocytes
812422|NCT03080467|Trauma
812423|NCT03080467|Laceration
812424|NCT03080467|Suture
812425|NCT03080467|Cosmesis
812426|NCT03080467|Ethyl-2-Cyanoacrylate
812427|NCT03080467|Tissue adhesive
812428|NCT03080467|Lip lacerations
812429|NCT03080467|Skalp lacerations
812430|NCT03080467|Facial injuries
812431|NCT03080454|stroke
812432|NCT03080454|CVA
812433|NCT03080454|Spasticity
812434|NCT03080454|hemiparesis
812435|NCT03080454|rehabilitation
812436|NCT03080454|tsDCS
812437|NCT03080454|non-invasive stimulation
812438|NCT03080428|Breast cancer
812439|NCT03080428|ER-positive
812440|NCT03080428|Her-2 negative
812441|NCT03080428|genomic test
812442|NCT03080402|Anterior Cruciate Ligament
812443|NCT03080402|ACL injury
812444|NCT03080402|Injury prevention
812445|NCT03080402|Perturbation training
812446|NCT03080402|Risk factors
812447|NCT03080389|overactive bladder
812448|NCT03080389|overactive detrusor
812449|NCT03080389|urgency-frequency
812450|NCT03080389|urinary tract infection
812451|NCT03080376|Exercise
812452|NCT03080376|Web-based intervention
812453|NCT03080363|Extracorporeal Shockwave Lithotripsy
812454|NCT03080363|Quadratus Lumborum Block
812455|NCT03080363|bupivacaine
812456|NCT03080363|lidocaine
812457|NCT03080350|Fentanyl
812458|NCT03080350|Transmucosal administration
812459|NCT03080350|Endovenous administration
812460|NCT03080350|Pain therapy
812461|NCT03080350|Mountain emergency medicine
812462|NCT03080324|Fentanyl
812463|NCT03080324|Transmucosal administration
812464|NCT03080324|Endovenous administration
812465|NCT03080324|Pain therapy
812467|NCT03080272|individual patient
812468|NCT03080259|ADHD
812469|NCT03080259|Stimulant Misuse
812470|NCT03080259|Stimulant Diversion
812471|NCT03080233|stroke
812472|NCT03080233|Validation
812473|NCT03080233|Clinical decision support tool
812474|NCT03080207|Lower Extremity Lymphedema
812475|NCT03080207|Physiotherapy
812476|NCT03080207|Complex Decongestive Physiotherapy
812477|NCT03080207|Low Level Laser
812478|NCT03080207|Platelet rich plasma
812479|NCT03080194|schizophrenia
812480|NCT03080194|violence risk
812481|NCT03080194|long-acting antipsychotics
812482|NCT03080194|community-based
812483|NCT03080168|suicidal ideation
812484|NCT03080168|suicidal behavior
812485|NCT03080168|Veterans
812486|NCT03080168|inpatients
812487|NCT03080168|Actigraphy
812488|NCT03080168|implicit associations
812489|NCT03080168|risk factors
812490|NCT03080129|Liver cirrhosis
812491|NCT03080129|Sarcopenia
812492|NCT03080129|Microbiome
812493|NCT03080116|Randomized
812494|NCT03080116|Placebo-controlled
812495|NCT03080116|Neoadjuvant
812496|NCT03080116|Androgen deprivation
812497|NCT03080116|Antiandrogen
812498|NCT03080116|Radical Prostatectomy
812499|NCT03080103|Acute Appendicitis
812500|NCT03080103|Uncomplicated Acute Appendicitis
812501|NCT03080103|Appendectomy
812502|NCT03080103|Conservative Treatment
812503|NCT03080103|Antibiotic-first Treatment
812504|NCT03080103|Recurrent Appendicitis
812505|NCT03080103|Prospective Study
812506|NCT03080051|PSP
812507|NCT03080051|AD
812508|NCT03080051|HV
812509|NCT03080038|Sepsis
812510|NCT03080038|Shock
812511|NCT03080038|Septic Shock
812512|NCT03080038|Fluid Therapy
812513|NCT03080038|Resuscitation
812514|NCT03080038|Pediatrics
812515|NCT03080038|Emergency Medicine
812516|NCT03080038|Critical Care
812517|NCT03080025|CBCT® (Cognitively Based Compassion-Training)
812518|NCT03080025|Psychobiological Evaluation
812519|NCT03080025|Real Time Social Interaction
812520|NCT03080025|Eye-Tracking
812521|NCT03080025|Heart Rate Variability
812522|NCT03080025|IL-6
812523|NCT03080025|IL-1b
812524|NCT03080025|Cortisol
812525|NCT03080025|Alpha-Amylase
812526|NCT03080025|Randomised Controlled Trial
812527|NCT03080025|Compassion
812528|NCT03080025|Empathy
812529|NCT03080025|Relationship Quality
812530|NCT03080025|Interpersonal Relations
812531|NCT03080025|Stress
812532|NCT03079986|Pancreatic surgery
812533|NCT03079986|Chylous ascites
812534|NCT03079973|Calcipotriene
812535|NCT03079960|Parkinson
812536|NCT03079960|DBS
812537|NCT03079960|Deep Brain Stimulation
812538|NCT03079960|LFP
812539|NCT03079960|Local Field Potentials
812540|NCT03079960|EEG
812541|NCT03079960|Electroencephalogram
812542|NCT03079947|Circulating DNA
812543|NCT03079947|Diffuse Large B Cell Lymphoma
812544|NCT03079947|Peripheral T-Cell Lymphoma
812545|NCT03079947|prognosis
812546|NCT03079934|Bioresorbable vascular scaffold
812547|NCT03079934|Optical coherence tomography
812548|NCT03079934|strut coverage
812549|NCT03079934|acute coronary syndrome
812550|NCT03079921|Islet Graft Function
812551|NCT03079921|Islet Cell transplantation
812552|NCT03079921|Auto-islet transplantation
812553|NCT03079921|Intra-hepatic islets
812554|NCT03079921|Extra-hepatic islets
812562|NCT03079895|Depression
812563|NCT03079895|internet
812564|NCT03079895|Cognitive Behavioral Therapy
812565|NCT03079895|CBT
812566|NCT03079895|computer
812567|NCT03079895|Primary Care
812568|NCT03079895|Psychiatry
812569|NCT03079895|treatment
812570|NCT03079895|self-help
812571|NCT03079895|managed care
812572|NCT03079882|Ultrasound
812573|NCT03079882|Viscoelasticity
812574|NCT03079882|Viscoelastic Response (VisR) Ultrasound
812575|NCT03079856|Emerging adults
812576|NCT03079856|Drugs
812577|NCT03079856|HIV
812578|NCT03079856|Risky Sex Behaviors
812579|NCT03079830|aortic valve surgery
812580|NCT03079830|postoperative pain
812581|NCT03079791|OCT
812582|NCT03079791|cardiac allograft vasculopathy
812583|NCT03079791|CAV
812584|NCT03079791|intravascular imaging
812585|NCT03079765|Telehealth
812586|NCT03079765|Functional behavior assessment
812587|NCT03079713|pain
812588|NCT03079713|anesthesia
812589|NCT03079713|vibrator
812590|NCT03079713|intravitreal
812591|NCT03079713|injection
812592|NCT03079687|Ovarian cancer
812593|NCT03079687|gynaecological cancer
812594|NCT03079687|platinum-sensitive disease
812595|NCT03079687|platinum-sensitive relapsed
812596|NCT03079687|Olaparib
812597|NCT03079687|Ovarian Neoplasms
812598|NCT03079687|Neoplasms
812599|NCT03079687|Ovarian Disease
812600|NCT03079687|fallopean tube cancer
812601|NCT03079687|primary peritoneal cancer
812602|NCT03079687|epithelial ovarian cancer
812603|NCT03079687|PARP inhibitors
812604|NCT03079687|Poly (ADP-ribose) polymerase inhibitors.
812605|NCT03079674|transient Ischemic Attack
812606|NCT03079674|minor Stroke
812607|NCT03079674|non-disabling ischemic cerebrovascular events
812608|NCT03079674|biomarker
812609|NCT03079674|epidemiology
812610|NCT03079674|prognosis
812611|NCT03079661|pollution
812612|NCT03079661|ozone
812613|NCT03079661|Copd
812614|NCT03079661|particles
812615|NCT03079648|Angelica gigas N. extract
812616|NCT03079648|Hyperlipidemia
812617|NCT03079648|Clinical Trial
812618|NCT03079596|gastric cancer
812619|NCT03079596|ERAS (early recovery after surgery)
812620|NCT03079596|laparoscopic total gastrectomy
812621|NCT03079557|Adolescent
812622|NCT03079557|Injections, intraperitoneal
812623|NCT03079557|Endoscopy
812624|NCT03079557|Botulinum Toxins, Type A
812625|NCT03079557|OnabotulinumtoxinA
812626|NCT03079518|iron deficiency
812627|NCT03079518|HFREF
812628|NCT03079518|FGF23
812629|NCT03079518|ferric carboxymaltose
812630|NCT03079479|Arthoplasty
812631|NCT03079479|Gait
812632|NCT03079479|muscle strenght
812633|NCT03079479|Quality of life
812634|NCT03079466|Sleep apnea
812635|NCT03079466|Elderly
812636|NCT03079466|CPAP
812637|NCT03079453|Dexamethasone
812638|NCT03079453|Tonsillectomy
812639|NCT03079453|Uvula
812640|NCT03079453|Edema
812641|NCT03079453|Uvula edema
812642|NCT03079453|Post-tonsillectomy
812643|NCT03079440|Neuroendocrine tumors
812644|NCT03079440|Neuroendocrine Carcinoma
812645|NCT03079440|Capecitabine
812646|NCT03079440|Temozolomide
812647|NCT03079427|Cholangiocarcinoma
812648|NCT03079427|Adjuvant chemotherapy
812649|NCT03079414|Sudden Cardiac Death
812650|NCT03079414|Cardiac Arrhythmia
812651|NCT03079414|Electrophysiology Study
812652|NCT03079414|Genetics
812653|NCT03079401|biventricular conversion
812654|NCT03079375|cross sectional
812655|NCT03079375|medication review
812656|NCT03079375|readmissions
812657|NCT03079375|follow-up
812658|NCT03079336|Randomized controlled design development
812659|NCT03079336|Translational Research
812660|NCT03079336|Psychological Interventions
812661|NCT03079336|Contextual Model of Psychotherapy
812662|NCT03079323|External beam radiotherapy
812663|NCT03079323|Prostate cancer
812664|NCT03079323|Elective para-aortic radiation therapy
812665|NCT03079323|PART
812666|NCT03079310|spinal cord stimulation
812667|NCT03079310|gait analysis
812668|NCT03079310|whole-body kinematics
812669|NCT03079310|Parkinson's disease
812670|NCT03079310|Neuromodulation
812671|NCT03079310|Feature extraction
812672|NCT03079297|Antidepressant
812673|NCT03079297|Inflammation
812674|NCT03079297|Biomarker
812675|NCT03079297|Depression
812676|NCT03079297|Treatment Resistant Depression
812677|NCT03079297|Leucine
812678|NCT03079258|vascular structure
812679|NCT03079258|vascular function
812680|NCT03079258|cerebrovascular reactivity
812681|NCT03079258|physical activity
812682|NCT03079258|sedentary behaviour
812683|NCT03079258|offspring health
812684|NCT03079258|maternal health
812685|NCT03079245|Neonatal ICU
812686|NCT03079245|antimicrobial stewardship
812687|NCT03079232|Optical biopsy
812688|NCT03079232|Skin cancer
812689|NCT03079232|Diagnostic performance
812690|NCT03079206|hazelnut
812691|NCT03079206|allergens
812692|NCT03079206|basophile-activation-test
812693|NCT03079206|food
812694|NCT03079206|allergy
812695|NCT03079193|post thyroidectomy
812696|NCT03079193|laryngeoscopic examination
812697|NCT03079180|Tendon
812698|NCT03079180|Ageing
812699|NCT03079180|Training
812700|NCT03079180|Achilles tendon
812701|NCT03079180|Patella tendon
812702|NCT03079180|Skeletal muscle
812703|NCT03079180|Adaptation
812704|NCT03079180|Triceps Surae
812705|NCT03079180|Quadriceps
812706|NCT03079115|Atorvastatin
812710|NCT03079076|Postoperative Analgesia
812711|NCT03079076|Ultrasound guided thoracolumbar interfascial plane block
812712|NCT03079011|ESR1 mutation detection, ctDNA
812713|NCT03078998|Juvenile Idiopathic Arthritis
812714|NCT03078998|Cerebral Palsy
812715|NCT03078998|Obstetric Brachial Plexus Palsy
812716|NCT03078998|Human Computer Interaction
812717|NCT03078998|Leap Motion
812718|NCT03078998|Video Game Based Rehabilitation
812719|NCT03078985|real-time MRI
812720|NCT03078985|electrophysiology study
812721|NCT03078985|atrial flutter ablation
812722|NCT03078985|active tracking
812723|NCT03078946|Cardiac surgery
812724|NCT03078946|delirium
812725|NCT03078946|dexmedetomidine
812726|NCT03078946|morphine
812727|NCT03078946|midazolam
812728|NCT03078933|DFU
812729|NCT03078907|daily life
812730|NCT03078907|physical activity
812731|NCT03078907|actigraphy
812732|NCT03078907|PAH-SYMPACT
812733|NCT03078894|Zika
812734|NCT03078894|Dengue
812735|NCT03078894|Chikagunya
812736|NCT03078894|Peru
812737|NCT03078829|gender identity
812738|NCT03078829|trans female
812739|NCT03078829|GnRH agonists
812740|NCT03078829|QTc interval
812741|NCT03078803|fecal transplant
812742|NCT03078803|inflammatory bowel disease
812743|NCT03078777|Pharmacokinetics
812744|NCT03078764|Mobile health (mHealth)
812757|NCT03078738|OMT-28
812758|NCT03078738|Atrial Fibrillation
812759|NCT03078738|SAD
812760|NCT03078738|MAD
812761|NCT03078738|First-in-Man
812762|NCT03078738|Cardiovascular
812763|NCT03078725|gestational diabetes
812764|NCT03078725|glyburide
812765|NCT03078725|metformin
812766|NCT03078725|failure rate
812767|NCT03078712|Septic Shock
812768|NCT03078712|Lactate
812769|NCT03078712|Capillary Refill Time
812770|NCT03078712|Fluid Responsiveness
812771|NCT03078712|Mortality
812772|NCT03078699|Thymoma
812773|NCT03078699|Thymic tumor
812774|NCT03078699|Stereotactic body radiotherapy
812775|NCT03078686|Stem Cells,PRP, tSVF,cSVF,Alopecia Areata,Scarring Alopecia
812776|NCT03078673|Cross country poling, motor skill, strength training
812777|NCT03078634|Irritable bowel syndrome
812778|NCT03078634|Constipation
812779|NCT03078634|Functional dyspepsia
812780|NCT03078634|Multi-disciplinary treatment
812781|NCT03078621|stem cells
812782|NCT03078608|anxiety
812783|NCT03078608|quality of life
812784|NCT03078608|mindfulness
812785|NCT03078608|meditation
812786|NCT03078608|depression
812787|NCT03078595|periodontal disease
812788|NCT03078595|plaque-induced gingivitis
812789|NCT03078595|bleeding on probing
812790|NCT03078595|von willebrand disease
812791|NCT03078595|gingival bleeding
812792|NCT03078582|PNH
812793|NCT03078569|Poor responders
812794|NCT03078556|FDC
812795|NCT03078556|Lamivudine
812796|NCT03078556|Bio-equivalence
812797|NCT03078556|Dolutegravir
812798|NCT03078556|HIV
812799|NCT03078530|GWI
812800|NCT03078530|IBS
812801|NCT03078530|Irritable Bowel Syndrome
812802|NCT03078530|Gulf War Illness
812803|NCT03078530|Probiotics
812804|NCT03078517|I-gel
812805|NCT03078517|Laryngeal mask airway protector
812806|NCT03078491|type 1 diabetes
812807|NCT03078491|geriatrics
812808|NCT03078491|older adults
812809|NCT03078491|technology
812810|NCT03078491|CGM
812811|NCT03078491|clinical decision support
812812|NCT03078491|hypoglycemia
812813|NCT03078439|very preterm birth
812814|NCT03078439|developmental disorders
812815|NCT03078439|health problems
812816|NCT03078439|prospective population-based cohort
812817|NCT03078426|Lung
812818|NCT03078426|MRI
812819|NCT03078426|CT
812820|NCT03078426|Usual interstitial pneumonia
812821|NCT03078426|Ultra-short echo time
812822|NCT03078413|Mustard Procedure
812824|NCT03078361|cancer screening
812825|NCT03078361|colon
812826|NCT03078348|cancer screening
812832|NCT03078309|retinitis pigmentosa
812833|NCT03078309|retinal degeneration
812834|NCT03078309|cannabis
812835|NCT03078309|THC
812836|NCT03078309|CBD
812837|NCT03078309|electrophysiology
812838|NCT03078309|visual functions
812839|NCT03078309|eye
812840|NCT03078309|retina
812841|NCT03078270|social anxiety
812842|NCT03078270|botulinum toxin
812843|NCT03078270|botox
812844|NCT03078257|Platelet Activities
812845|NCT03078257|light aggregometry
812846|NCT03078257|VerifyNow P2Y12-assay
812847|NCT03078257|peripheral vein
812848|NCT03078257|peripheral artery
812849|NCT03078257|intracoronary artery
812850|NCT03078257|tirofiban
812851|NCT03078257|antiplatelet thrombolysin
812852|NCT03078218|Pulse oximetry
812853|NCT03078218|Asymptomatic newborns
812854|NCT03078205|TCM multi-channel therapy
812855|NCT03078205|ART failure
812856|NCT03078179|Probiotic
812857|NCT03078179|Child
812858|NCT03078179|Care, dental
812859|NCT03078166|Cardiac Failure
812860|NCT03078166|Congestive Heart Failure
812861|NCT03078166|Heart Decompensation
812862|NCT03078166|Heart Failure, Congestive
812863|NCT03078166|Heart Failure, Left-Sided
812864|NCT03078166|Heart Failure, Right-Sided
812865|NCT03078166|Left-Sided Heart Failure
812866|NCT03078166|Myocardial Failure
812867|NCT03078166|Right-Sided Heart Failure
812868|NCT03078166|Outcomes
812869|NCT03078166|Co-morbidities
812870|NCT03078166|Biomarkers
812871|NCT03078101|Empagliflozin
812872|NCT03078101|SGLT-2 Inhibiton and RAS in CKD
812878|NCT03078062|Spinal anesthesia
812879|NCT03078062|Motor block
812880|NCT03078062|Sensory block
812881|NCT03078062|Dexamethasone
812882|NCT03078036|HER2-ve metastatic breast cancer
812883|NCT03078036|gBRCA, sBRCA and HRR gene mutations
812884|NCT03078023|EoE
812885|NCT03078010|Antibiotic
812886|NCT03078010|piperacillin-tazobactam
812887|NCT03078010|cefepime
812888|NCT03078010|aztreonam
812889|NCT03078010|17-097
812890|NCT03077997|Diabetes
812891|NCT03077997|Diabetes distress
812892|NCT03077971|Carers of People with Multiple Sclerosis
812893|NCT03077971|Carer Strain
812894|NCT03077971|Acceptance and Commitment Therapy
812895|NCT03077945|biofeedback
812896|NCT03077945|heart rate variability
812897|NCT03077945|HRV
812898|NCT03077945|psychophysiology
812899|NCT03077945|reappraisal
812900|NCT03077945|cognitive reappraisal
812901|NCT03077945|arousal reappraisal
812902|NCT03077945|woman
812903|NCT03077945|women
812904|NCT03077945|female
812905|NCT03077945|smoker
812906|NCT03077945|relapse
812907|NCT03077945|cigarette
812908|NCT03077945|craving
812909|NCT03077945|self regulation
812910|NCT03077945|emotion regulation
812911|NCT03077945|stress response
812912|NCT03077945|cognitive behavioral intervention
812913|NCT03077945|respiratory sinus arrhythmia
812914|NCT03077945|smoking cessation intervention
812915|NCT03077919|Posttraumatic Stress Disorder
812916|NCT03077919|Generalized Anxiety Disorder
812917|NCT03077919|Depression
812918|NCT03077919|Distress
812919|NCT03077919|Alcohol Use
812920|NCT03077919|Pain
812921|NCT03077906|Gastroœsophageal Reflux
812922|NCT03077906|Sleeve Gastrectomy
812923|NCT03077880|implant insertion
812924|NCT03077880|bone resorption
812925|NCT03077880|soft tissue
812926|NCT03077867|sinus lift
812927|NCT03077867|synthetic hydroxyapatite
812928|NCT03077867|bone graft
812929|NCT03077854|Lung Cancer
812930|NCT03077854|Radiotherapy
812931|NCT03077854|Biomarkers
812932|NCT03077854|Radiation Lung Injury
812933|NCT03077854|Quality of Life
812934|NCT03077841|Malignant neoplasm of breast
812935|NCT03077841|Breast cancer
812936|NCT03077841|Radiation therapy
812937|NCT03077841|XRT
812938|NCT03077841|External beam radiation therapy
812939|NCT03077841|Shorter course
812940|NCT03077841|Questionnaires
812941|NCT03077841|Surveys
812942|NCT03077802|Seldinger technique
812943|NCT03077802|Modified Seldinger technique
812944|NCT03077802|Complication
812945|NCT03077802|Success rate
812946|NCT03077789|visual acuity
812947|NCT03077789|prognosis epidemiology
812948|NCT03077763|nitrite
812949|NCT03077763|haemoglobin
812950|NCT03077763|normoxia
812951|NCT03077763|hypoxia
812952|NCT03077763|vasodilatation
812953|NCT03077763|blood
812954|NCT03077750|viral skin disease
812955|NCT03077737|Treatment access
812956|NCT03077737|Treatment utilization
812957|NCT03077737|Smoking cessation
812958|NCT03077737|Low income
812959|NCT03077737|Electronic health record system
812960|NCT03077737|Electronic referral
812961|NCT03077724|n-3 polyunsaturated fatty acids
812962|NCT03077724|tobacco use
812963|NCT03077724|pregnancy
812964|NCT03077698|Endometrial cancer
812965|NCT03077698|Recurrent or persistent endometrial carcinoma
812966|NCT03077698|Progesterone Receptor Negative
812967|NCT03077698|Sodium Cridanimod
812968|NCT03077672|Mitochondrial DNA
812969|NCT03077672|Lactate
812970|NCT03077672|Mortality
812971|NCT03077672|Emergency Department
812972|NCT03077672|Intensive Care Unit
812973|NCT03077672|Triage
812974|NCT03077672|Organ Dysfunction
812975|NCT03077672|Biomarker
812976|NCT03077672|Prognosis
812977|NCT03077646|firearm
812978|NCT03077646|gun
812979|NCT03077646|safety
812980|NCT03077646|pediatric
812981|NCT03077646|inpatient
812982|NCT03077633|Cerclage
812983|NCT03077633|Cervical shortening
812984|NCT03077633|Twins
812985|NCT03077633|Progesterone
812986|NCT03077568|internet
812987|NCT03077568|web-based
812988|NCT03077568|behavior change
812989|NCT03077568|stress-management
812990|NCT03077555|quick starting contraception
812991|NCT03077542|Peripheral Blood Stem Cells
812992|NCT03077542|Host-Donor Chimerism
812993|NCT03077542|Graft Versus Host Disease
812994|NCT03077542|Haploidentical
812995|NCT03077542|Donor Apheresis
812996|NCT03077503|Hemodynamic response
812997|NCT03077503|Skull pins application
812998|NCT03077503|Dexmedetomidine
812999|NCT03077503|Fentanyl
813000|NCT03077490|Pelvic organ prolapse
813001|NCT03077490|transvaginal mesh
813002|NCT03077490|complications
813003|NCT03077464|nutrition education
813004|NCT03077464|Vegetables
813005|NCT03077464|Fruit
813010|NCT03077399|lateropulsion
813011|NCT03077399|stroke
813012|NCT03077399|Pusher syndrome
813013|NCT03077386|patient navigator
813014|NCT03077386|multi-morbidity
813015|NCT03077386|vulnerable populations
813016|NCT03077373|systolic blood pressure
813017|NCT03077373|physical activity
813018|NCT03077373|sedentary time
813019|NCT03077373|smoking
813020|NCT03077347|Schizophrenia
813021|NCT03077347|Transcranial Direct Current Stimulation
813022|NCT03077347|tDCS
813023|NCT03077347|Cognitive Control
813024|NCT03077347|fMRI
813025|NCT03077347|Dorsolateral Prefrontal Cortex
813026|NCT03077308|Auditory ERP, Visual ERP, EEG
813027|NCT03077282|Prasaprohyai extract, Healthy volunteers
813028|NCT03077269|burn
813029|NCT03077269|coagulation
813030|NCT03077269|inflammation
813031|NCT03077256|Ankle Arthrodesis
813032|NCT03077256|Cellular Allograft
813033|NCT03077243|Human Papillomavirus
813034|NCT03077243|Oropharynx
813035|NCT03077243|Oropharyngeal Squamous Cell Carcinoma
813036|NCT03077243|Squamous Cell Carcinoma
813037|NCT03077243|Radiation Therapy
813038|NCT03077243|Chemotherapy
813039|NCT03077243|p16
813040|NCT03077217|covert hepatic encephalopathy
813041|NCT03077217|low-dose rifaximin
813042|NCT03077204|Total cervical vertebrectomy
813043|NCT03077204|Partial cervical vertebrectomy
813044|NCT03077204|Failed previous fusion
813045|NCT03077204|Spinal stenosis
813046|NCT03077204|Tumor
813047|NCT03077204|Decompression of the spinal cord
813048|NCT03077204|Pseudoarthrosis
813049|NCT03077204|Curvatures
813050|NCT03077204|Deformities
813051|NCT03077191|hypofractionated whole breast radiotherapy
813052|NCT03077191|breast cancer
813053|NCT03077191|conservative treatment
813054|NCT03077191|quality of life
813055|NCT03077178|Soft Tissue Sarcoma
813056|NCT03077178|Surgery
813057|NCT03077178|Functional Impact
813058|NCT03077178|Elderly Patient
813059|NCT03077178|Geriatrics
813060|NCT03077152|copd, aecopd, antibiotic use
813061|NCT03077126|elastography
813062|NCT03077126|ultrasound
813063|NCT03077126|prostate
813064|NCT03077126|cancer screening
813065|NCT03077113|lung cancer
813066|NCT03077113|radiation therapy
813067|NCT03077048|CKD
813068|NCT03077048|Ketosteril
813069|NCT03077048|keto-acids
813070|NCT03077048|ketoanalogues
813071|NCT03077048|Chronic kidney disease
813072|NCT03077035|ICDAS
813073|NCT03077035|DIAGNOdent
813074|NCT03077035|glass ionomer sealant
813075|NCT03077035|resin-based sealant
813076|NCT03077035|pit and fissure sealants
813077|NCT03077035|effectiveness of preventing caries
813080|NCT03076931|Voice
813081|NCT03076931|Biomarker
813082|NCT03076931|Airway Reconstruction
813083|NCT03076918|PDT, Methyl Aminolevulinate, Light Emitting Textile
813084|NCT03076892|PDT
813085|NCT03076892|Methyl Aminolevulinate
813086|NCT03076892|light emitting textile
813093|NCT03076840|hamstring tightness
813094|NCT03076801|Choral Singing
813095|NCT03076801|Music
813096|NCT03076801|Quality of Life
813097|NCT03076801|Psychosocial Stress
813098|NCT03076801|Cardiac Rehabilitation
813099|NCT03076788|echocardiography
813100|NCT03076788|intraventricular pressure gradients
813101|NCT03076788|cardiac remodeling
813102|NCT03076788|athletes
813103|NCT03076775|Betamethasone
813104|NCT03076775|Late preterm
813105|NCT03076775|Steroids
813106|NCT03076762|interstitial cystitis
813107|NCT03076762|pain
813108|NCT03076762|intravesical injection
813109|NCT03076762|therapy
813110|NCT03076762|bladder
813111|NCT03076749|Betalactam
813112|NCT03076749|Decision tree
813113|NCT03076749|Drug hypersensitivity
813114|NCT03076749|Logistic regression
813115|NCT03076749|Predictive modelling
813121|NCT03076697|fundus photography
813122|NCT03076697|smartphone-based photography
813123|NCT03076671|Palliative Care
813124|NCT03076671|Supportive Care
813125|NCT03076671|Movement Disorders
813126|NCT03076671|Brain Disease
813127|NCT03076671|Neurodegeneration
813128|NCT03076671|Parkinson's Disease
813129|NCT03076632|transcranial magnetic stimulation
813130|NCT03076632|neurostimulation
813131|NCT03076632|non-invasive stimulation
813132|NCT03076632|closed-loop stimulation
813133|NCT03076619|pregnancy induced hypertension
813134|NCT03076619|ophthalmoscopy
813135|NCT03076593|geriatric
813136|NCT03076567|Epidemiology
813137|NCT03076567|Cancer
813138|NCT03076567|Methylation
813139|NCT03076567|Genetics
813140|NCT03076567|Screening
813141|NCT03076554|Programmed Death 1 (PD-1)
813142|NCT03076554|Immune Checkpoint Blockade
813143|NCT03076541|Restless legs syndrome
813144|NCT03076541|Periodic leg movements
813145|NCT03076541|Heart rate
813146|NCT03076541|Heart rate variability
813147|NCT03076541|Microarousals
813148|NCT03076541|Autonomic nervous system activity
813149|NCT03076528|exercise
813150|NCT03076528|exergame
813151|NCT03076528|hemodialysis
813152|NCT03076528|balance
813153|NCT03076502|ctDNA
813154|NCT03076502|Gastrointestinal Cancer
813155|NCT03076502|ROS
813156|NCT03076502|Hepatobiliary Pancreatic Cancer
813157|NCT03076476|Coronary Stent
813158|NCT03076476|PCI
813159|NCT03076476|BVS
813160|NCT03076476|Index of microcirculatory resistance
813161|NCT03076463|Polyphenols
813162|NCT03076463|Metabolic syndrome
813163|NCT03076463|Cardiometabolic risk
813164|NCT03076463|Grape pomace
813165|NCT03076463|Postprandial glucose
813166|NCT03076463|Insulin resistance
813167|NCT03076463|Obesity
813168|NCT03076450|Acute respiratory distress syndrome, ARDS
813169|NCT03076450|Point-of-care lung ultrasound,POC-LUS
813170|NCT03076450|Pressure-volume curve, PVC
813293|NCT03075735|DNA-repair
813171|NCT03076450|Positive end-expiratory pressure, PEEP
813172|NCT03076450|Ultrasound re-aeration score, US-RAS
813173|NCT03076411|Dyspepsia
813174|NCT03076411|Observational trial
813175|NCT03076411|Enzyme therapy
813176|NCT03076411|Pepsin
813177|NCT03076385|VAL-506440
813178|NCT03076385|H10N8 antigen mRNA
813179|NCT03076385|Influenza vaccine
813180|NCT03076372|Cancer
813181|NCT03076372|Oncology
813182|NCT03076372|Phase I
813183|NCT03076372|Gemcitabine
813184|NCT03076372|Carboplatin
813185|NCT03076372|MM-310
813186|NCT03076372|EphA2
813187|NCT03076372|Ephrin A2
813188|NCT03076372|Solid tumors
813189|NCT03076372|urothelial carcinoma
813190|NCT03076372|gastric carcinoma
813191|NCT03076372|squamous cell carcinoma of the head and neck
813192|NCT03076372|ovarian cancer
813193|NCT03076372|pancreatic ductal adenocarcinoma
813194|NCT03076372|prostate adenocarcinoma
813195|NCT03076372|non-small cell lung cancer
813196|NCT03076372|small cell lung cancer
813197|NCT03076372|triple negative breast cancer
813198|NCT03076372|endometrial carcinoma
813199|NCT03076372|soft tissue sarcoma
813200|NCT03076372|Merrimack
813201|NCT03076320|Modified diallyl disulfide oxide (M-DDO)
813202|NCT03076320|Pirfenidone (PFD)
813203|NCT03076320|Adapalene + Benzoyl peroxide (A-BPO)
813204|NCT03076294|knee ostearthritis
813205|NCT03076294|transcranial magnetic stimulation
813206|NCT03076294|repetitive transcranial magnetic stimulation
813207|NCT03076294|chronic pain
813208|NCT03076294|musculoskeletal manipulations
813209|NCT03076216|Pancreatic Cancer
813210|NCT03076216|Pancreas
813211|NCT03076216|metastases
813212|NCT03076216|pancreatic tumour
813213|NCT03076216|unresectable
813214|NCT03076216|locally advanced
813215|NCT03076216|implantable
813216|NCT03076216|radiographic
813217|NCT03076216|device
813218|NCT03076216|Phosphorous-32 (P32)
813219|NCT03076216|OncoSil™
813220|NCT03076216|brachytherapy
813221|NCT03076216|gemcitabine
813222|NCT03076216|nab-paclitaxel
813223|NCT03076216|Abraxane
813224|NCT03076190|psychology
813225|NCT03076190|pain
813226|NCT03076190|surgery
813227|NCT03076190|treatment
813228|NCT03076190|catastrophizing
813229|NCT03076190|cancer
813230|NCT03076177|knee osteoarthritis, kinesio taping, knee function, pain
813231|NCT03076164|erlotinib
813232|NCT03076164|trametinib
813233|NCT03076164|15-098
813234|NCT03076151|Transplantation
813235|NCT03076151|Kidney
813236|NCT03076151|pharmacokinetic
813237|NCT03076151|bayesian estimators
813238|NCT03076138|Gene-activated matrix
813239|NCT03076138|Bone substitute
813240|NCT03076138|Bone grafting
813241|NCT03076138|Dental implantation
813242|NCT03076138|gene therapy
813243|NCT03076138|plasmid DNA
813244|NCT03076138|VEGF gene
813245|NCT03076138|octacalcium phosphate
813246|NCT03076125|Primary Stroke Prevention, Risk Factors for Stroke
813247|NCT03076112|Ipragliflozin
813248|NCT03076112|Sitagliptin
813249|NCT03076099|Dexmedetomidine
813250|NCT03076099|brain arteriovenous malformation
813251|NCT03076099|embolization
813252|NCT03076099|post-operative hypertension
813253|NCT03076073|Ultrasound
813254|NCT03076073|Achilles tendon
813255|NCT03076073|Patellar tendon
813256|NCT03076073|obesity
813257|NCT03076060|Ketogenic Diet
813258|NCT03076060|Very low calories diet
813259|NCT03076060|ketone bodies
813260|NCT03075995|lapatinib
813261|NCT03075995|steady state plasma concentration
813262|NCT03075995|high-fat breakfast
813263|NCT03075969|Chronic myeloid leukemia; quality of life
813264|NCT03075930|Atrial fibrillation
813265|NCT03075930|ECG
813266|NCT03075930|Body surface potential map
813267|NCT03075930|Recurrence of AF
813268|NCT03075917|Allergic rhinitis
813269|NCT03075865|intermaxillary fixation
813270|NCT03075865|maxillo-mandibular fixation
813271|NCT03075852|Heads-up display, NGENUITY, Vitreoretinal surgery
813272|NCT03075800|Assertive Community Treatment (ACT) Only
813273|NCT03075800|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)
813274|NCT03075787|Obstructive sleep apnea
813275|NCT03075787|Heart rate
813276|NCT03075787|Heart rate variability
813277|NCT03075787|Microarousals
813278|NCT03075787|Autonomic nervous system activity
813279|NCT03075761|Venous thromboembolism
813280|NCT03075761|Deep Vein Thrombosis
813281|NCT03075761|Lower Extremity
813282|NCT03075761|Blood clot
813283|NCT03075761|Anticoagulation
813284|NCT03075761|Physical Activity
813285|NCT03075761|Fitbit
813286|NCT03075761|Post-thrombotic syndrome
813287|NCT03075761|Post-phlebitic syndrome
813288|NCT03075761|Thrombosis
813289|NCT03075748|Vascular
813290|NCT03075748|Stent
813291|NCT03075748|Graft
813292|NCT03075735|Castration-Resistant Prostate Cancer
813294|NCT03075735|BRCA1
813295|NCT03075735|BRCA2
813296|NCT03075735|ATM
813297|NCT03075735|PALB2
813298|NCT03075709|Clinical Pathway
813299|NCT03075709|CPW
813300|NCT03075709|Chronic Obstructive Pulmonary Disease
813301|NCT03075709|COPD
813302|NCT03075709|Protocol
813303|NCT03075709|Adherence
813304|NCT03075709|Readmission
813305|NCT03075709|Length of Stay
813306|NCT03075709|Cost
813307|NCT03075683|Cognitive behavioural therapy
813308|NCT03075683|Non-pharmacological treatment
813309|NCT03075683|Internet mediated
813310|NCT03075579|ADHD, cortisol, α-amylase, actometer
813311|NCT03075566|coronary artery disease
813312|NCT03075566|risk factors
813313|NCT03075566|inflammation
813314|NCT03075566|biomarkers
813315|NCT03075566|atherosclerosis
813316|NCT03075540|Latinas
813317|NCT03075527|Mesothelioma
813318|NCT03075514|ketogenic
813319|NCT03075501|drug cues
813320|NCT03075475|Child
813321|NCT03075475|Adolescent
813322|NCT03075475|Mental Health
813323|NCT03075475|Randomized Controlled Trial
813324|NCT03075462|PARP inhibitor
813325|NCT03075462|VEGFR inhibitor
813326|NCT03075462|Combination therapy
813327|NCT03075462|Ovarian Cancer
813328|NCT03075462|Triple Negative Breast Cancer
813329|NCT03075436|Sanitation
813330|NCT03075436|Hygiene
813331|NCT03075436|Public Health
813332|NCT03075436|Behavior change
813333|NCT03075436|Neglected tropical diseases
813334|NCT03075436|Demand-side sanitation and hygiene
813335|NCT03075436|Mental well-being
813336|NCT03075436|Water insecurity
813337|NCT03075436|Sanitation insecurity
813338|NCT03075436|Collective efficacy
813339|NCT03075410|ascending dose
813340|NCT03075410|Pharmacokinetics
813341|NCT03075410|GSK3036656
813342|NCT03075410|FTIH
813343|NCT03075410|Safety
813344|NCT03075397|HIV-1
813345|NCT03075397|Colo-rectal transmission
813346|NCT03075397|seminal plasma
813347|NCT03075384|computer-assisted navigation system
813348|NCT03075332|Detraining
813349|NCT03075332|Physical aptitude
813350|NCT03075332|HIV
813351|NCT03075280|ERCP
813352|NCT03075280|ERAS
813353|NCT03075280|complication
813354|NCT03075280|fatigue
813355|NCT03075280|high carbohydrate diet
813356|NCT03075254|Pain
813357|NCT03075241|Sleep Disturbances
813358|NCT03075241|Alzheimer Disease
813359|NCT03075241|Insomnia
813360|NCT03075241|Z-Drugs
813361|NCT03075241|Treatment
813362|NCT03075228|microbiota
813363|NCT03075228|small intestine
813364|NCT03075228|metabolic disease
813365|NCT03075202|Schizophrenia
813366|NCT03075202|Smoking
813367|NCT03075202|E-cigarette
813368|NCT03075189|Frailty
813369|NCT03075189|geriatric
813370|NCT03075189|hospitalized
813371|NCT03075189|enrichment
813372|NCT03075189|whey protein
813373|NCT03075189|protein intake
813374|NCT03075189|sarcopenia
813375|NCT03075189|dietary counseling
813376|NCT03075176|Photorefractive keratectomy
813377|NCT03075176|Laser-assisted in situ keratomileusis
813378|NCT03075163|PONV
813379|NCT03075163|Nausea
813380|NCT03075163|Vomiting
813381|NCT03075163|Acupressure
813382|NCT03075150|PVI
813383|NCT03075150|Dynamic Cardiac Monitors
813384|NCT03075150|SVV
813385|NCT03075150|PPV
813386|NCT03075137|ischemic stroke
813387|NCT03075137|external counter pulsation
813388|NCT03075137|mRS
813389|NCT03075124|Coronary Artery Disease
813390|NCT03075124|external counter pulsation
813391|NCT03075124|major adverse cardiovascular events
813392|NCT03075098|Colposcopy
813393|NCT03075098|oral epithelial dysplasia
813394|NCT03075098|diagnostic accuracy
813395|NCT03075072|Brain metastases
813396|NCT03075072|Brain metastasis
813397|NCT03075072|Lung cancer
813398|NCT03075072|Melanoma
813399|NCT03075072|Breast cancer
813400|NCT03075072|Kidney cancer
813401|NCT03075072|Renal cell carcinoma
813402|NCT03075072|Stereotactic radiation
813403|NCT03075072|Stereotactic radiosurgery
813404|NCT03075072|SRS
813405|NCT03075072|Stereotactic
813406|NCT03075072|Whole brain radiation
813407|NCT03075072|WBRT
813408|NCT03075072|Hippocampal avoidance
813409|NCT03075072|Hippocampal sparing
813410|NCT03075072|Hippocampal
813411|NCT03075072|Hippocampus
813412|NCT03075072|Radiation
813413|NCT03075072|Quality of Life
813414|NCT03075072|Neurocognitive
813415|NCT03075072|Neurocognition
813416|NCT03075072|Survival
813417|NCT03075072|Salvage
813418|NCT03075072|MDASI
813419|NCT03075072|Chemotherapy
813420|NCT03075072|Recurrence
813421|NCT03075046|Blue Light Emitting Diode
813422|NCT03075046|Women
813546|NCT03074214|myocardial infarct size
813547|NCT03074214|prognosis
813423|NCT03075033|Shikani optical stylet, rigid optical stylets, awake, fiber-optic intubation, and cervical spine injury.
813424|NCT03075007|Alzheimer Disease
813425|NCT03075007|Aging
813426|NCT03075007|Dementia
813427|NCT03075007|PET
813428|NCT03074994|Tranexamic acid
813429|NCT03074994|Peri-articular injection
813430|NCT03074994|Intraarticular injection
813431|NCT03074994|Total knee arthroplasty
813432|NCT03074994|Blood loss
813433|NCT03074955|Hypotension
813434|NCT03074955|Propofol
813435|NCT03074955|Trendelenburg
813436|NCT03074955|leg wrapping
813437|NCT03074929|risk communication
813438|NCT03074903|intrauterine device
813439|NCT03074903|bleeding
813440|NCT03074877|Substance Use
813441|NCT03074864|Activating mutations,lung cancer,radiotherapy
813442|NCT03074851|low sodium salt
813443|NCT03074851|blood pressure
813444|NCT03074851|reporter
813445|NCT03074838|Cardiac surgery
813446|NCT03074838|TAVI
813447|NCT03074825|Non-Hodgkin's lymphoma
813448|NCT03074825|Relapsed/Refractory
813449|NCT03074825|Aurora kinase B
813450|NCT03074734|secondhand smoke
813451|NCT03074734|passive smoking
813452|NCT03074734|respiratory diseases
813453|NCT03074734|COPD
813454|NCT03074734|asthma
813455|NCT03074734|SHS health effect
813456|NCT03074708|Three-Dimensional Image
813457|NCT03074708|Three Dimensional Printing
813458|NCT03074682|Resuscitation
813459|NCT03074669|Anxiety symptoms/disorders (OCD, PTSD, GAD, SAD, Panic)
813460|NCT03074656|infliximab
813461|NCT03074656|therapeutic drug monitoring
813462|NCT03074656|anti drug antibodies
813463|NCT03074604|Brain Injuries
813464|NCT03074604|Neurological Injury
813465|NCT03074604|Stroke
813466|NCT03074604|Postoperative Cognitive Dysfunction
813467|NCT03074604|Postoperative Delirium
813468|NCT03074604|Coronary Artery Disease
813469|NCT03074604|Coronary Artery Bypass Grafting
813470|NCT03074604|Coronary Artery Bypass Surgery
813471|NCT03074604|Bypass surgery
813472|NCT03074604|Beating Heart Coronary Artery Bypass
813473|NCT03074604|Off-Pump Coronary Artery Bypass
813474|NCT03074591|Iron deficiency
813475|NCT03074591|Heart failure
813476|NCT03074578|sleep
813477|NCT03074578|verbal abuse
813478|NCT03074578|polysomnography
813479|NCT03074578|perception
813480|NCT03074578|neuropsychological tests
813481|NCT03074565|Sanative Therapy
813482|NCT03074565|Ultrasonic Therapy
813483|NCT03074565|Deep Scaling
813484|NCT03074565|Hand Scaling
813485|NCT03074552|probiotics
813486|NCT03074552|VAP
813487|NCT03074552|microbiome
813488|NCT03074552|trauma
813489|NCT03074552|infections
813490|NCT03074513|Malignant neoplasms of digestive organs
813491|NCT03074513|Malignant neoplasms of lip oral cavity and pharynx
813492|NCT03074513|Malignant neoplasms of mesothelial and soft tissue
813493|NCT03074513|Malignant neoplasms of respiratory and intrathoracic organs
813494|NCT03074513|Rare Solid Tumors
813495|NCT03074513|Atezolizumab
813496|NCT03074513|MPDL3280A
813497|NCT03074513|Bevacizumab
813498|NCT03074513|Avastin
813499|NCT03074513|Anti-VEGF monoclonal antibody
813500|NCT03074513|rhuMAb-VEGF
813501|NCT03074513|Phone call
813502|NCT03074500|Kinesio taping
813503|NCT03074500|lateral epicondylitis
813504|NCT03074500|tennis elbow
813505|NCT03074500|treatment
813506|NCT03074487|Spinal cord ischemia
813507|NCT03074487|Postoperative
813508|NCT03074487|Thoracoabdominal Aneurysm
813509|NCT03074487|Monitoring
813510|NCT03074474|use of mesh
813511|NCT03074461|Rectal Cancer
813512|NCT03074461|Low Anterior Resection
813513|NCT03074461|Coloplasty Pouch
813514|NCT03074461|Side-to-end Anastomosis
813515|NCT03074461|Continence
813516|NCT03074461|Quality of Life
813517|NCT03074448|Colonoscopy
813518|NCT03074448|Intestinal Cleaning
813519|NCT03074448|Picoprep
813520|NCT03074448|Aquanet
813521|NCT03074422|Functional neurosurgery
813522|NCT03074422|Pain management
813523|NCT03074422|Hypnosis
813524|NCT03074422|Stereotaxy
813525|NCT03074422|Parkinson disease
813526|NCT03074422|Essential tremor
813527|NCT03074422|Dystonia
813528|NCT03074422|Invasive monitoring of epilepsy
813529|NCT03074409|Oxytocin
813530|NCT03074344|Dry Eye Syndrome
813531|NCT03074344|artificial tear
813532|NCT03074344|CoQ10
813533|NCT03074344|Hyaluronic acid
813534|NCT03074305|In-bioresorbable vascular scaffold restenosis
813535|NCT03074305|drug-eluting stent
813536|NCT03074305|drug-eluting balloon
813537|NCT03074305|bioresorbable scaffold
813538|NCT03074279|Epilepsy
813539|NCT03074279|SUDEP
813540|NCT03074279|case-control study
813541|NCT03074279|risks factors
813542|NCT03074240|Truncal block
813543|NCT03074240|Surgical anesthesia
813544|NCT03074240|Postoperative pain control
813545|NCT03074214|copeptin
813548|NCT03074214|ST-elevation myocardial infarction
813549|NCT03074214|percutaneous coronary intervention
813550|NCT03074201|ERCP, choledocholithiasis, cholangioscopy
813551|NCT03074188|oral findings or oral manifestation
813552|NCT03074188|pre-dialysis stage or end stage renal disease
813553|NCT03074136|photodynamic therapy
813554|NCT03074136|diode laser
813555|NCT03074136|immature permanent teeth
813556|NCT03074136|endodontic therapy
813557|NCT03074123|cosyntropin stimulation test
813558|NCT03074123|low-dose
813559|NCT03074110|Inhalation Anaesthetics, Sevoflurane
813560|NCT03074110|Carbon Dioxide
813561|NCT03074110|Hyperventilation
813562|NCT03074110|Anaesthesia Recovery Period
813563|NCT03074110|Ventilators
813564|NCT03074084|abdominal pain
813565|NCT03074084|adult
813566|NCT03074084|emergency department
813567|NCT03074084|electronic nose
813568|NCT03074084|celiac disease
813569|NCT03074071|Disambiguation, Depression, Burnout
813570|NCT03074045|Intrauterine
813571|NCT03074045|Birth control
813572|NCT03073993|nasogastric
813573|NCT03073993|orogastric
813574|NCT03073993|nutrition
813575|NCT03073993|preterm
813576|NCT03073993|feeding tube
813577|NCT03073993|insertion
813578|NCT03073993|episodes
813579|NCT03073993|bradycardia
813580|NCT03073993|desaturation
813581|NCT03073980|in vitro fertilization
813582|NCT03073980|oocyte retrieval
813583|NCT03073980|acetaminophen
813584|NCT03073980|postoperative pain control
813585|NCT03073954|Health Behavior
813586|NCT03073954|Executive function
813587|NCT03073954|Working-memory training
813588|NCT03073954|Feasibility
813589|NCT03073954|Impulsivity
813590|NCT03073941|Knee arthroplasty
813591|NCT03073941|Knee function
813592|NCT03073941|Total knee replacement
813593|NCT03073941|Persona total knee system
813594|NCT03073941|NexGen total knee system
813595|NCT03073928|Nerve block
813596|NCT03073928|Diaphragm function
813597|NCT03073889|Aneurysm Clipping
813598|NCT03073889|Scalp nerve block
813599|NCT03073889|Scalp infiltration
813600|NCT03073889|Ropivacaine
813601|NCT03073876|Alzheimer Disease
813602|NCT03073876|Attention
813603|NCT03073876|Donepezil hydrochloride
813604|NCT03073863|LDL Cholesterol
813605|NCT03073863|Statin intensity
813606|NCT03073863|post hoc analysis
813607|NCT03073863|Achieved LDL Cholesterol level
813608|NCT03073811|protein supplementation
813609|NCT03073811|older adults
813610|NCT03073811|nutrition perihabilitation
813611|NCT03073811|perioperative optimization
813612|NCT03073798|Lung Disease
813613|NCT03073798|Breathing Difficulty
813614|NCT03073798|Smoking
813615|NCT03073798|Mucociliary
813616|NCT03073746|Google
813617|NCT03073746|Knowledge Panels
813618|NCT03073746|Health Search
813619|NCT03073746|Online
813620|NCT03073746|Internet
813621|NCT03073746|Smartphone
813622|NCT03073746|Tablet
813623|NCT03073746|Digital
813624|NCT03073746|Mobile
813625|NCT03073746|Symptoms
813626|NCT03073746|Differential diagnosis
813627|NCT03073746|Diagnosis
813628|NCT03073746|Anxiety
813629|NCT03073707|Non-Typhoid Salmonella
813630|NCT03073707|Invasive blood stream infections
813631|NCT03073707|Reservoir
813632|NCT03073707|Household environment
813633|NCT03073707|Children
813634|NCT03073694|Peritoneal Surface Disease
813635|NCT03073694|mitomycin-c
813636|NCT03073694|melphalan
813637|NCT03073694|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC)
813638|NCT03073694|Peritoneal Carcinomatosis
813639|NCT03073681|cataract
813640|NCT03073655|shoulder pain
813641|NCT03073655|shoulder function
813642|NCT03073642|Hydrotherapy
813643|NCT03073642|Pain education
813644|NCT03073577|Type 1 Diabetes Mellitus
813645|NCT03073577|Islet Transplantation
813646|NCT03073577|Diabetes
813647|NCT03073577|Diabetes Treatment
813648|NCT03073564|Dyspnea
813649|NCT03073564|Cardiopulmonary Exercise Test
813650|NCT03073564|Positive-Pressure Respiration
813657|NCT03073447|Myocardial infarction
813658|NCT03073447|Women
813659|NCT03073447|Young
813660|NCT03073447|Primary PCI
813661|NCT03073447|Hormone
813662|NCT03073408|Propofol
813663|NCT03073408|Bispectral index (BIS)
813664|NCT03073408|Closed loop
813665|NCT03073356|Myocardial metabolism
813666|NCT03073356|Positron emission tomography
813667|NCT03073356|Echocardiography
813668|NCT03073356|Right sided heart catheterization
813669|NCT03073317|Preterm Infants
813670|NCT03073317|Premature Birth
813671|NCT03073317|Placenta growth factor
813672|NCT03073317|Prenatal Care
813673|NCT03073317|PERINATAL MORTALITY
813674|NCT03073317|Pre-Eclampsia
813675|NCT03073304|isolated limb perfusion
813676|NCT03073291|cannabis
813677|NCT03073291|commerce
813678|NCT03073265|DOAC
813679|NCT03073265|apixaban
813680|NCT03073265|IVD
813681|NCT03073239|Amyotrophic Lateral Sclerosis
813682|NCT03073239|Bulbar disfunction
813683|NCT03073239|Rik factors ALS
813687|NCT03073187|Asthma
813688|NCT03073187|Sleep
813689|NCT03073187|Adolescents
813690|NCT03073187|Urban
813691|NCT03073187|Intervention
813692|NCT03073187|High school
813693|NCT03073174|dietary intake
813694|NCT03073174|nutritional supplements
813695|NCT03073174|sanative therapy
813696|NCT03073174|healing
813697|NCT03073174|flavonoids
813698|NCT03073174|tea
813699|NCT03073161|flavonoids
813700|NCT03073161|tea
813701|NCT03073161|dietary intake
813702|NCT03073161|nutritional supplements
813703|NCT03073161|periodontal disease
813704|NCT03073161|healing
813705|NCT03073161|sanative therapy
813706|NCT03073096|axillary nodal dissection
813707|NCT03073096|groin nodal dissection
813708|NCT03073083|autograft
813709|NCT03073070|diabetic children
813710|NCT03073070|RBC lifespan
813711|NCT03073044|Quality of life
813712|NCT03073044|psychosocial and psychological problems
813713|NCT03073005|ventricular assist device (VAD)
813714|NCT03073005|heart failure
813715|NCT03073005|simulation
813716|NCT03072966|Distress
813717|NCT03072966|Exercise
813718|NCT03072966|Wearable device
813719|NCT03072966|Smartphone
813720|NCT03072927|Lumbar Spinal Stenosis
813721|NCT03072927|Interspinous process decompression
813722|NCT03072927|MILD
813723|NCT03072927|Medicare
813724|NCT03072888|acute pain
813725|NCT03072888|Transcutaneous Electric Nerve Stimulation
813726|NCT03072888|Anesthesia Recovery Period
813727|NCT03072875|Suicidality
813728|NCT03072875|Collaborative Assessment and Management of Suicidality
813729|NCT03072875|Technology
813730|NCT03072875|Suicide Prevention
813731|NCT03072875|Suicide Intervention
813732|NCT03072862|Cochlear implant treatment, aging adults
813733|NCT03072849|Pediatrics
813734|NCT03072849|Airflow obstruction
813735|NCT03072849|Chronic graft-vs-host disease
813736|NCT03072849|Bronchiolitis obliterans syndrome
813737|NCT03072823|CVDs
813738|NCT03072823|cardiovascular diseases
813739|NCT03072823|n-3 polyunsaturated fatty acids
813740|NCT03072823|depression
813741|NCT03072810|Positive psychology
813742|NCT03072810|Wellbeing
813743|NCT03072810|Chronic pain
813744|NCT03072810|Mindfulness
813745|NCT03072797|Atherosclerosis
813746|NCT03072797|Longitudinal
813747|NCT03072797|Biomarker
813748|NCT03072797|Coronary angiography
813749|NCT03072797|Follow-up
813750|NCT03072797|Metabolomics
813751|NCT03072797|Risk factor
813752|NCT03072758|Male partner involvement
813753|NCT03072745|Cognitive Impairment
813754|NCT03072706|hip replacement
813755|NCT03072706|acetabulum
813756|NCT03072706|anteversion
813757|NCT03072706|position
813758|NCT03072706|guide
813759|NCT03072667|prematurity
813760|NCT03072667|bowel atresia
813761|NCT03072667|necrotizing entercolitis
813762|NCT03072667|parenteral nutrition associated liver disease (PNALD)
813763|NCT03072667|intestinal failure
813764|NCT03072667|parenteral nutrition associated cholestasis
813765|NCT03072667|fish oil
813766|NCT03072641|Probiotics
813767|NCT03072641|Epigenetics
813768|NCT03072641|Microbiota
813769|NCT03072628|nicotine
813770|NCT03072628|sympathetic nerve activity
813771|NCT03072628|oxidative stress
813772|NCT03072602|Racial differences
813773|NCT03072576|Diagnosis
813774|NCT03072576|Xpert MTB/RIF
813775|NCT03072576|Ultra Xpert MTB/RIF
813776|NCT03072550|fungal nail
813777|NCT03072550|toenail fungus
813778|NCT03072537|growth, BMI, obesity, overweight, weight, height, childhood, adolescence, development
813779|NCT03072524|pre-hospital stroke scale test
813780|NCT03072524|severe hemiparesis
813781|NCT03072524|large vessel occlusion
813782|NCT03072524|mechanical thrombectomy
813783|NCT03072485|aging
813784|NCT03072472|Colorectal Cancer
813785|NCT03072472|Endoscopy
813786|NCT03072472|Screening
813787|NCT03072472|Colonic Adenoma
813788|NCT03072472|Adenoma Detection Rate
813789|NCT03072472|Endocuff
813790|NCT03072472|Endocuff Vision
813791|NCT03072446|Uterine Fibroid
813792|NCT03072446|Embolization
813793|NCT03072446|symptoms
813794|NCT03072446|Gel-Beads
813795|NCT03072433|child malnutrition
813796|NCT03072433|child development
813797|NCT03072433|counseling
813798|NCT03072420|MRI, fingers compression
813799|NCT03072381|CLE
813800|NCT03072381|epicondylosis
813801|NCT03072381|platelet rich plasma
813802|NCT03072381|PRP
813803|NCT03072381|ultrasound
813804|NCT03072381|shear wave ultrasound
813805|NCT03072381|tendinopathy
813806|NCT03072381|elbow
813807|NCT03072381|tenis elbow
813808|NCT03072381|plasma
813809|NCT03072381|plasma injection
813810|NCT03072381|tendinosis
813811|NCT03072381|tendinitis
813812|NCT03072355|fatigue
813813|NCT03072355|resistance test
813814|NCT03072316|breast cancer
813815|NCT03072316|mastectomy
813816|NCT03072316|deep inferior perforator flap reconstruction
813817|NCT03072316|post mastectomy radiotherapy
813825|NCT03072277|DHA
813826|NCT03072277|Docosa Hexaenoic Acid
813827|NCT03072277|Omega 3 fatty acid
813828|NCT03072277|Newborn Outcome
813829|NCT03072277|Birth Size
813830|NCT03072277|Gestational Age
813831|NCT03072277|DASII
813832|NCT03072277|Prenatal Supplementation
813833|NCT03072277|Randomized Controlled Trial
813834|NCT03072277|Neurodevelopment
813835|NCT03072264|Generalized Anxiety Disorder, GAD, mindfulness, anxiety
813836|NCT03072238|Metastatic Castrate-Resistant Prostate Cancer
813837|NCT03072225|herbal medicine
813838|NCT03072225|stroke
813839|NCT03072225|vulnerable plaques of carotid artery
813840|NCT03072212|HIV
813841|NCT03072212|Stroke
813842|NCT03072212|Cerebral vascular accident
813843|NCT03072212|Uganda
813844|NCT03072199|Rituximab
813845|NCT03072199|B cells
813846|NCT03071055|Macular Degeneration
813847|NCT03071055|AMD
813848|NCT03071055|Wet AMD
813849|NCT03071055|Lucentis
813850|NCT03071029|family planning
813851|NCT03071029|reproductive health
813852|NCT03071029|abortion
813853|NCT03071029|health providers
813854|NCT03071016|T2D,
813855|NCT03071016|Type 2 Diabetes,
813856|NCT03071016|T2DM
813857|NCT03071003|Pharmacokinetics
813858|NCT03071003|Healthy Volunteer Study
813859|NCT03070990|Enfortumab vedotin
813860|NCT03070990|ASG-22CE
813861|NCT03070990|ASG-22ME
813862|NCT03070990|Metastatic Urothelial Cancer
813863|NCT03070977|Interprofessional education
813864|NCT03070977|study unit
813865|NCT03070977|Psychiatry
813866|NCT03070951|Uterine Fibroid
813867|NCT03070951|Leiomyomata
813868|NCT03070951|Heavy Menstrual Bleeding
813869|NCT03070951|HMB
813870|NCT03070951|Heavy Uterine Bleeding
813871|NCT03070951|Menorrhagia
813872|NCT03070951|OBE2109 + Add-back
813873|NCT03070938|Chronic wounds
813874|NCT03070938|Acute Wounds
813875|NCT03070938|PHMB
813876|NCT03070938|Wound Management
813877|NCT03070938|Bioburden
813878|NCT03070938|Collagen
813882|NCT03072134|Glioma
813883|NCT03072134|Glioblastoma
813884|NCT03072134|Astrocytoma
813885|NCT03072134|Brain Cancer
813886|NCT03072134|New Diagnosed Glioma
813887|NCT03072134|Temozolomide
813888|NCT03072134|Radiation
813889|NCT03072134|Neural Stem Cells
813890|NCT03072134|Virotherapy
813891|NCT03072134|Adenovirus
813892|NCT03072134|Oncolytic virotherapy
813893|NCT03072121|coronary artery disease
813894|NCT03072121|revascularization
813895|NCT03072121|Shexiang Baoxin Pill
813896|NCT03072095|Colorectal Neoplasms
813897|NCT03072095|Colonic Neoplasms
813898|NCT03072095|Gastrointestinal Neoplasms
813899|NCT03072095|Digestive System Neoplasms
813900|NCT03072095|Neoplasms
813901|NCT03072095|Digestive System Diseases
813902|NCT03072095|Gastrointestinal Diseases
813903|NCT03072095|Colonic Diseases
813904|NCT03072095|Rectal Diseases
813905|NCT03072082|coronary artery disease
813906|NCT03072082|revascularization
813907|NCT03072082|Danlou Tablet
813908|NCT03072043|myelodysplastic syndrome (MDS)
813909|NCT03072043|TP53 mutant myelodysplastic syndrome
813910|NCT03072043|MDS/myeloproliferative neoplasm (MPN)
813911|NCT03072043|chronic myelomonocytic leukemia (CMML)
813912|NCT03072043|acute myeloid leukemia (AML)
813918|NCT03072004|Leprosy
813919|NCT03072004|Neuropathy
813920|NCT03072004|LLLT
813921|NCT03071991|preinsicional bupivacain
813922|NCT03071991|laparoscopic bariatric surgery
813923|NCT03071991|postoperative pain
813924|NCT03071978|Heart Failure
813925|NCT03071978|LV-fusion pacing
813926|NCT03071978|Cardiac Resynchronization Therapy
813927|NCT03071952|Heart Failure
813928|NCT03071952|Chronotropic Incompetence
813929|NCT03071952|Rate Response
813930|NCT03071952|Exercise Test
813931|NCT03071874|Meningioma
813932|NCT03071861|darbepoetin
813933|NCT03071861|Brain Diseases
813934|NCT03071835|Stem Cells
813935|NCT03071835|Cardiovascular
813936|NCT03071835|Quality of Life
813937|NCT03071835|Cardiomyopathy
813938|NCT03071822|PTCLs
813945|NCT03071770|Healthy Volunteers
813946|NCT03071770|Japanese
813947|NCT03071770|Caucasian
813962|NCT03071731|Glittre
813963|NCT03071731|COPD
813964|NCT03071731|sit-to-stand
813965|NCT03071731|responsiveness
813966|NCT03071731|bronchodilation
813967|NCT03071718|cardiovascular diseases
813968|NCT03071718|gut microbiota
813969|NCT03071718|Mediterranean diet
813970|NCT03071705|NSCLC
813971|NCT03071705|metformin
813972|NCT03071705|metformin plus TKI
813973|NCT03071705|EGFR positive status
813974|NCT03071666|Nepal
813975|NCT03071666|South Asia
813976|NCT03071666|Nutrition
813977|NCT03071666|Pregnancy
813978|NCT03071666|Neurodevelopment
813979|NCT03071666|Growth
813980|NCT03071653|Cardiomyopathy
813981|NCT03071653|Left Cardiac Sympathetic Denervation
813982|NCT03071640|old
813983|NCT03071640|elderly
813984|NCT03071640|radiotherapy
813985|NCT03071640|geriatric assessment
813986|NCT03071627|Spin
813987|NCT03071627|Misleading reporting
813988|NCT03071627|Misleading interpretation
813989|NCT03071627|Misleading extrapolation
813990|NCT03071627|Animal studies
813991|NCT03071627|Cell culture studies
813992|NCT03071627|Pre-clinical studies
813993|NCT03071614|Spin, misleading reporting, misleading interpretation, misleading extrapolation, animal studies, cell culture studies, pre-clinical studies
813994|NCT03071614|Misleading reporting
813995|NCT03071614|Misleading interpretation
813996|NCT03071614|Misleading extrapolation
813997|NCT03071614|Animal studies
813998|NCT03071614|Cell culture studies
813999|NCT03071614|Pre-clinical studies
814000|NCT03071601|Laceration
814001|NCT03071601|Suture
814002|NCT03071601|Topical anesthesia
814003|NCT03071601|Lidocaine
814004|NCT03071575|measles
814005|NCT03071575|rubella
814006|NCT03071575|immunogenicity
814007|NCT03071575|congenital rubella syndrome
814008|NCT03071575|measles-rubella vaccine
814009|NCT03071562|HIV
814010|NCT03071562|Cognitive impairment
814011|NCT03071562|Aging
814012|NCT03071562|Physical Activity
814013|NCT03071562|Exercise
814014|NCT03071562|Yoga
814015|NCT03071562|Neuroplasticity
814016|NCT03071549|Acne vulgaris
814017|NCT03071549|Chemical peeling
814018|NCT03071549|Dermoscopy
814019|NCT03071536|furosemide stress test
814020|NCT03071536|kidney transplantation
814021|NCT03071536|urine output
814022|NCT03071536|perioperation
814023|NCT03071536|delayed graft function
814024|NCT03071497|Iron-deficiency
814025|NCT03071497|Anemia
814026|NCT03071497|Iron-deficiency Anemia
814027|NCT03071497|Zinc protoporphyrin
814028|NCT03071484|Early Stages of Psychosis
814029|NCT03071484|Schizophrenia
814030|NCT03071484|Transcranial Direct Current Stimulation
814031|NCT03071484|Cognitive Symptomatology
814032|NCT03071484|Double-blind Randomized Controlled Trial
814033|NCT03071419|fathers
814034|NCT03071406|Merkel cell carcinoma (MCC)
814035|NCT03071406|Metastatic
814036|NCT03071406|Metastasis
814037|NCT03071406|Stereotactic body radiation therapy (SBRT)
814038|NCT03071406|Immunology
814039|NCT03071406|Antibody
814040|NCT03071406|Nivolumab
814041|NCT03071406|Ipilimumab
814042|NCT03071406|Metastatic skin cancer
814043|NCT03071406|Cutaneous
814044|NCT03071393|acute intermittent hypoxia
814045|NCT03071393|walking
814046|NCT03071393|breathing
814047|NCT03071393|standing
814048|NCT03071393|sitting
814049|NCT03071393|spinal cord injury
814050|NCT03071367|Airway Management
814051|NCT03071367|Medical students
814052|NCT03071367|Intratracheal intubation
814053|NCT03071367|Educational Technology
814054|NCT03071354|ICU-acquired weakness
814055|NCT03071341|MPS I; Hurler Syndrome
814056|NCT03071315|Economic evaluation
814057|NCT03071315|Heroin dependence
814058|NCT03071315|Compulsory treatment
814059|NCT03071315|Methadone treatment
814060|NCT03071315|Vietnam
814061|NCT03071315|East and Southeast Asia
814062|NCT03071315|Cost-effectiveness
814063|NCT03071302|Keratoconus,Corneal Dystrophies, corneal Tomography, topography
814064|NCT03071263|Treatment of Hyperkalemia
814065|NCT03071263|Hyperkalemia
814066|NCT03071263|Potassium
814067|NCT03071263|Chronic Kidney Disease
814068|NCT03071263|Hypertension
814069|NCT03071263|Resistant Hypertension
814070|NCT03071263|Spironolactone
814071|NCT03071237|infrapyloric artery
814072|NCT03071237|gastric cancer
814073|NCT03071224|AD
814074|NCT03071224|HV
814075|NCT03071211|pelvic organ prolapse
814076|NCT03071211|urinary catheters
814077|NCT03071198|Neoadjuvant Chemotherapy
814078|NCT03071185|free flap
814079|NCT03071185|nerve block
814080|NCT03071185|elective reconstructive surgery
814081|NCT03071185|free fibular
814082|NCT03071185|anterolateral thigh flaps
814083|NCT03071159|Flash Glucose Monitoring
814084|NCT03071159|Usability
814085|NCT03071159|Metabolic control
814086|NCT03070925|Antimicrobial
814087|NCT03070925|Collagen
814088|NCT03070925|Bioburden
814089|NCT03070925|Biofilm
814090|NCT03070925|PHMB
814091|NCT03070925|Chronic wounds
814092|NCT03070925|Acute wounds
814093|NCT03070912|mechanical circulatory support
814094|NCT03070912|bleeding, acquired von willebrand disease
814095|NCT03070912|acquired von willebrand disease
814103|NCT03070873|Quality of life
814104|NCT03070873|Vaginal mesh
814105|NCT03070873|Mesh complications
814106|NCT03070860|Low Grade Chronic vascular and skin Inflammation
814107|NCT03070860|Molecular vascular and skin Calcification
814108|NCT03070860|Calcium Score
814109|NCT03070847|tranexamic acid
814110|NCT03070847|rhinoplasty
814111|NCT03070847|bleeding reduction
814112|NCT03070821|neurofeedback
814113|NCT03070821|real-time functional MRI
814114|NCT03070821|parahippocampus
814115|NCT03070808|obesity
814116|NCT03070808|voice
814117|NCT03070795|post-operative ileus
814118|NCT03070795|early feeding
814119|NCT03070795|delayed feeding
814120|NCT03070782|IONIS-APO(a)-LRx
814121|NCT03070782|AKCEA-APO(a)-LRx
814122|NCT03070782|Dyslipidemia
814123|NCT03070782|Dyslipoproteinemia
814124|NCT03070782|Hyperlipidemia
814125|NCT03070782|Hyperlipoproteinemia
814126|NCT03070782|Hyperlipoproteinemia(a)
814127|NCT03070782|Hyperlipoproteinemia a
814128|NCT03070782|Lipoprotein
814129|NCT03070782|Lipoprotein(a)
814130|NCT03070782|Lipoprotein a
814131|NCT03070782|Lp(a)
814132|NCT03070782|Lp a
814133|NCT03070756|auto-CPAP
814134|NCT03070756|forced oscillation technique
814135|NCT03070756|obstructive sleep apnea
814136|NCT03070743|basilar invagination
814137|NCT03070743|atlantoaxial dislocation
814138|NCT03070743|surgery
814139|NCT03070743|restoration technique
814140|NCT03070730|Tachycardia
814141|NCT03070730|orthostatic symptoms
814142|NCT03070730|autonomic reflex
814143|NCT03070717|High myopia, shortsightedness, retinal changes
814144|NCT03070691|Basal cell carcinoma
814145|NCT03070691|Nevoid Basal Cell Carcinoma Syndrome
814146|NCT03070691|NBCCS, Gorlin syndrome
814147|NCT03070691|Gorlin-Goltz Syndrome
814148|NCT03070691|Basal Cell Nevus Syndrome
814149|NCT03070691|BCNS, Hedgehog pathway inhibitor
814150|NCT03070691|topical
814151|NCT03070691|Smoothened
814152|NCT03070665|endoscopic submucosal dissection
814153|NCT03070665|postoperation bleeding
814154|NCT03070652|attachment
814155|NCT03070652|bonding psychological
814156|NCT03070626|General Surgery
814157|NCT03070626|Carbohydrates
814158|NCT03070626|Perioperative
814159|NCT03070613|Colonoscopy
814160|NCT03070613|Fluorescence guided surgery
814161|NCT03070600|PrEP
814162|NCT03070574|Lynch Syndrome
814163|NCT03070574|Chemoprevention
814164|NCT03070574|Mesalazine
814165|NCT03070535|APOE E4; cognition; metabolic markers; beta-amyloid
814166|NCT03070496|Myocardial infarction
814167|NCT03070496|bio-collection
814168|NCT03070496|Imaging markers
814169|NCT03070496|biomarkers
814170|NCT03070496|STEMI
814171|NCT03070496|clinical outcomes
814172|NCT03070457|bariatric surgery
814173|NCT03070457|sleeve gastrectomy
814174|NCT03070457|eras
814175|NCT03070444|Essix retainer
814176|NCT03070444|Cuspid-to-cuspid retainer
814177|NCT03070431|spinal cord compression, radiotherapy
814178|NCT03070418|DHS
814179|NCT03070418|DCS
814180|NCT03070418|Boyd and Griffin Classification
814181|NCT03070405|Tenofovir Disoproxil Fumarate
814182|NCT03070405|4-Aminosalicylic Acid
814183|NCT03070405|Tuberculosis
814184|NCT03070405|HIV
814185|NCT03070392|Melanoma
814186|NCT03070392|Uveal Cancer
814187|NCT03070392|IMCgp100
814188|NCT03070392|Immunotherapy
814189|NCT03070366|Oligometastasis
814190|NCT03070366|stereotactic irradiation
814191|NCT03070353|Cirrhosis
814192|NCT03070353|AKI
814193|NCT03070353|Albumin
814194|NCT03070353|Dextran
814195|NCT03070340|mastectomy
814196|NCT03070340|breast MRI
814197|NCT03070340|contrast enhanced mammography
814198|NCT03070340|CEDM
814199|NCT03070340|17-045
814200|NCT03070327|B-cell Maturation Antigen (BCMA)
814201|NCT03070327|Targeted EGFRt/BCMA-41BBz
814202|NCT03070327|Chimeric antigen receptor (CAR)
814203|NCT03070327|17-025
814204|NCT03070314|Echinacea
814205|NCT03070314|bioavailability
814206|NCT03070314|children
814207|NCT03070301|LEE011
814208|NCT03070301|Everolimus
814209|NCT03070301|16-1535
814210|NCT03070288|RGB
814211|NCT03070288|red-green-blue
814212|NCT03070288|rhinitis
814213|NCT03070288|allergic rhinitis
814214|NCT03070288|nasal mucosa
814215|NCT03070275|surgical implant placement
814216|NCT03070275|crestal bone
814217|NCT03070275|mucosa thickness
814218|NCT03070275|stem cells
814219|NCT03070275|fibrin glue
814220|NCT03070275|collagen fleece
814221|NCT03070262|esophageal cancer
814222|NCT03070262|caffeic acid
814223|NCT03070249|Emergency Department
814224|NCT03070236|Breast Cancer
814225|NCT03070184|Racial differences
814226|NCT03070158|Premature Infant
814227|NCT03070158|Mother-Infant Interaction
814228|NCT03070158|Acoustic stimulation/methods
814229|NCT03070158|Touch
814230|NCT03070158|Visual Stimulation
814231|NCT03070158|Vestibule, Labyrinth/physiology
814238|NCT03070015|Weight Loss
814239|NCT03070015|Obesity
814240|NCT03070015|Overweight
814248|NCT03069950|Hepatic Arterial Infusion
814249|NCT03069950|Floxuridine (FUDR)
814250|NCT03069950|Irinotecan (CPT-11)
814251|NCT03069950|FLUOROURACIL
814252|NCT03069950|PANITUMUMAB
814253|NCT03069950|16-1341
814254|NCT03069911|Parkinson Disease
814255|NCT03069911|Parkinsonism
814256|NCT03069911|Depression
814257|NCT03069911|OnabotulinumtoxinA
814258|NCT03069911|BOTOX
814259|NCT03069898|Marital relationship
814260|NCT03069872|Transvaginal ultrasound
814261|NCT03069872|General practice
814262|NCT03069872|Early diagnosis
814263|NCT03069872|Symptoms
814264|NCT03069859|Post partum hemorrhage
814265|NCT03069859|Tranexamic acid
814266|NCT03069859|Spontaneous vaginal delivery
814267|NCT03069859|C-section
814268|NCT03069846|skin cancer
814269|NCT03069846|laser spectroscopy
814270|NCT03069846|non-invasive diagnostics
814271|NCT03069781|estrogen
814272|NCT03069768|Nicotine addiction
814273|NCT03069768|Cigarette smoking
814274|NCT03069768|Smoking cessation
814275|NCT03069768|Quit smoking
814276|NCT03069755|India
814277|NCT03069755|Perioperative mortality
814278|NCT03069755|Trauma
814279|NCT03069755|Surgery
814280|NCT03069742|Breast Cancer Prevention
814281|NCT03069742|Risk Assessment
814282|NCT03069742|Chemoprevention
814283|NCT03069742|Decision Making
814284|NCT03069729|screen
814285|NCT03069716|Pulmonary Arterial Hypertension
814286|NCT03069703|Vaccine
814287|NCT03069703|ANCA- associated vasculitides
814288|NCT03069703|pneumo 23
814289|NCT03069703|prevenar
814290|NCT03069703|pneumovas
814291|NCT03069677|midazolam
814292|NCT03069664|Pancreatic Cancer
814293|NCT03069664|Pancreatic Duct Stricture
814294|NCT03069664|Endoscopic treatment
814295|NCT03069638|sedation
814296|NCT03069638|pediatrics
814297|NCT03069638|intranasal sedation
814298|NCT03069638|dexmedetomidine
814299|NCT03069638|dinitrous oxide
814300|NCT03069638|intra-articular joint injection
814301|NCT03069625|Cystic Fibrosis
814302|NCT03069625|Exercise Testing
814303|NCT03069625|Muscular strength
814304|NCT03069625|Pediatrics
814305|NCT03069625|Quality of life
814306|NCT03069612|repetitive transcranial magnetic stimulation
814307|NCT03069612|working memory
814308|NCT03069612|gamma oscillations
814309|NCT03069612|dorsolateral prefrontal cortex
814310|NCT03069573|Eosinophilic Esophagitis
814311|NCT03069573|Gastroesophageal Reflux
814312|NCT03069573|Diagnose
814313|NCT03069573|Biomarker
814314|NCT03069560|suicide attempt
814315|NCT03069560|SMS monitoring
814316|NCT03069560|Phone
814317|NCT03069560|Prevention control
814318|NCT03069560|tertiary healthcare
814319|NCT03069534|MDR-TB
814320|NCT03069534|rhIL-2
814321|NCT03069534|immunotherapy
814322|NCT03069495|Allergy
814323|NCT03069495|Asthma
814324|NCT03069495|Urticaria
814325|NCT03069482|Smoking
814326|NCT03069482|mHealth
814327|NCT03069482|Serious Mental Illness
814328|NCT03069482|Acceptance and Commitment Therapy
814329|NCT03069482|US DHHS Clinical Practice Guidelines
814330|NCT03069469|CSF1R
814331|NCT03069469|ALL
814332|NCT03069469|CML
814333|NCT03069469|AML
814334|NCT03069469|MDS
814335|NCT03069456|sevoflurane
814336|NCT03069456|Bistpectral index
814337|NCT03069456|Anesthetic Depth Monitoring System
814338|NCT03069456|population pharmacodynamics
814343|NCT03069417|HIV
814344|NCT03069417|Medication adherence
814345|NCT03069417|PMTCT
814346|NCT03069417|Depression
814347|NCT03069391|exercise
814348|NCT03069391|exergame
814349|NCT03069378|Metastatic
814350|NCT03069378|Locally Advanced
814351|NCT03069378|Talimogene Laherparepvec (T-VEC)
814352|NCT03069378|Pembrolizumab
814353|NCT03069378|16-1534
814371|NCT03069326|Ruxolitinib
814372|NCT03069326|Thalidomide
814373|NCT03069326|16-1498
814374|NCT03069313|Aromatase Inhibitor
814375|NCT03069313|Breast Cancer
814376|NCT03069313|Arthralgia
814377|NCT03069313|Musculoskeletal symptoms
814378|NCT03069313|Joint pain
814379|NCT03069261|Breast reconstruction
814380|NCT03069261|Autologous tissue flaps
814381|NCT03069261|Indocyanine green angiography
814382|NCT03069261|Breast cancer
814383|NCT03069235|HIV
814384|NCT03069235|Breast Feeding
814385|NCT03069222|diffusion tensor imaging
814386|NCT03069196|Prevalence
814387|NCT03069196|Incidence
814388|NCT03069196|Type 1 diabetes and its Micro-vascular complications
814389|NCT03069196|Type 1 diabetes and its Macro-vascular complications
814390|NCT03069196|Type 1 Diabetes and its complications in India
814391|NCT03069183|Fascia Iliaca Block
814392|NCT03069183|Total Hip Arthroplasty
814393|NCT03069183|Total Hip Replacement
814394|NCT03069183|Ultrasound
814395|NCT03069144|Psoriasis
814396|NCT03069144|Topical
814397|NCT03069131|primary prophylaxis
814398|NCT03069131|rifaximin
814399|NCT03069118|Telemedicine
814400|NCT03069118|Online Treatment
814401|NCT03069118|Digital Intervention
814402|NCT03069079|primary immunodeficiency
814403|NCT03069079|dental health
814404|NCT03069079|neutrophil defect
814405|NCT03069079|periodontitis
814406|NCT03069066|In-stent restenosis
814407|NCT03069066|Bioresorbable vascular scaffold
814408|NCT03069066|Stent
814409|NCT03069066|Drug-eluting stent
814410|NCT03069066|Coronary angiography
814411|NCT03069066|Scoring balloon
814412|NCT03069040|cervical cancer
814413|NCT03069040|NSRH
814414|NCT03069040|RH
814415|NCT03069040|urine flow mechanics
814416|NCT03069040|anorectal dynamics
814417|NCT03069027|Nasal surgery
814418|NCT03069027|external nasal nerve block
814419|NCT03069027|postoperative agitation
814420|NCT03069001|HCV treatment
814421|NCT03068988|bone marrow stem cells
814422|NCT03068988|rotator cuff lesion
814423|NCT03068936|Nasopharyngeal Carcinoma
814424|NCT03068936|Intensity modulated radiotherapy
814425|NCT03068936|Cisplatin
814426|NCT03068923|Blood clot
814427|NCT03068923|Deep Vein Thrombosis
814428|NCT03068923|Pulmonary Embolism
814429|NCT03068923|Lower Extremity
814430|NCT03068923|Upper Extremity
814431|NCT03068923|Cerebral sinus
814432|NCT03068923|Renal vein
814433|NCT03068923|Portal vein
814434|NCT03068923|thrombin
814435|NCT03068923|fibrinolysis
814436|NCT03068923|coagulation
814437|NCT03068923|anticoagulation
814438|NCT03068923|Post trombotic syndrome
814439|NCT03068923|Post pulmonary embolism syndrome
814440|NCT03068923|Chronic thromboembolic pulmonary hypertension
814441|NCT03068910|PCOS
814442|NCT03068845|non-maturing arteriovenous fistula
814443|NCT03068845|stenosis of arteriovenous fistula
814444|NCT03068845|drug-eluting balloon
814445|NCT03068767|HBV DNA, qHBsAg
814446|NCT03068754|ALS
814447|NCT03068728|bilateral chronic rhino sinusitis
814448|NCT03068715|transcranial magnetic stimulation
814449|NCT03068715|theta burst
814450|NCT03068689|Partial nephrectomy, RIPC, Reperfusion Injury
814451|NCT03068676|Depression
814452|NCT03068676|Anxiety
814453|NCT03068676|Internet-delivered
814454|NCT03068676|CBT
814455|NCT03068676|Primary Care
814456|NCT03068663|lung cancer
814457|NCT03068663|intestinal microbiota
814458|NCT03068663|lung microbiota
814459|NCT03068663|surgery
814460|NCT03068663|chemotherapy
814461|NCT03068624|Melanoma and Other Malignant Neoplasms of Skin
814462|NCT03068624|Metastatic uveal melanoma
814463|NCT03068624|Autologous CD8+ T cells
814464|NCT03068624|Cyclophosphamide
814465|NCT03068624|Cytoxan
814466|NCT03068624|Neosar
814467|NCT03068624|Interleukin-2
814468|NCT03068624|IL-2
814469|NCT03068624|Aldesleukin
814470|NCT03068624|Proleukin
814471|NCT03068624|Ipilimumab
814472|NCT03068624|Yervoy
814473|NCT03068624|BMS-734016
814474|NCT03068624|MDX010
814475|NCT03068585|PAD
814476|NCT03068585|CLI
814477|NCT03068585|stage 2a-3 of Pokrovsky-Fonteine
814478|NCT03068572|minimal change esophageal reflux disease diagnosis
814479|NCT03068572|Linked Color imaging
814480|NCT03068572|non-erosive reflux disease
814610|NCT03067896|intrathecally
814482|NCT03068533|DH, dentin hypersensitivity, chronic periodontitis
814483|NCT03068520|PET
814484|NCT03068520|MRI
814485|NCT03068520|BRAIN METASTASIS
814486|NCT03068520|BRAIN PRIMARY TUMOR
814487|NCT03068520|RESPONSE TO TREATMENT
814488|NCT03068507|Perioperative
814489|NCT03068507|functional capability
814490|NCT03068507|Prehabilitation
814491|NCT03068507|thoracoscopic lobectomy
814492|NCT03068507|Lung Cancer
814493|NCT03068494|Coronary Bifurcation Lesion
814494|NCT03068494|2md generation drug-eluting stent
814495|NCT03068442|Carotid artery
814496|NCT03068442|MRI
814497|NCT03068442|PET
814498|NCT03068442|Intraplaque hemorrhage
814499|NCT03068429|obsessive-compulsive disorder
814500|NCT03068429|fear conditioning
814501|NCT03068429|functional neuroimaging
814502|NCT03068429|sertraline
814503|NCT03068403|CEUS Perfusion
814504|NCT03068403|Rectal Cancer
814505|NCT03068403|Tumor Perfusion
814506|NCT03068403|Radiochemotherapy
814507|NCT03068377|lycopene
814508|NCT03068377|eye
814509|NCT03068364|Mortality
814510|NCT03068364|Hypertension
814511|NCT03068364|Left ventricular hypertrophy
814512|NCT03068364|NT-proBNP
814513|NCT03068364|ECG
814514|NCT03068364|Transthoracic echocardiography
814515|NCT03068299|Prevention
814516|NCT03068299|Cognition
814517|NCT03068299|Aged care
814518|NCT03068299|Caregivers
814519|NCT03068299|Frail elderly
814520|NCT03068299|Dancing therapy
814521|NCT03068299|Rural population
814522|NCT03068273|Hospitalization
814523|NCT03068260|caesarean section
814524|NCT03068260|postoperative pain
814525|NCT03068260|transmuscular quadratus lumborum block
814526|NCT03068260|reduction of opioid consumption
814527|NCT03068208|Methylene blue
814528|NCT03068208|photodynamic therapy
814529|NCT03068208|primary cutaneous localized amyloidosis
814530|NCT03068208|lichen amyloidosis
814531|NCT03068195|laparoscopy
814532|NCT03068195|microwave
814533|NCT03068195|ablation technique
814534|NCT03068182|Exercise ,Autonomic cardiac function ,Adult subjects
814535|NCT03068169|remote ECG
814536|NCT03068169|atrial fibrillation
814537|NCT03068169|cardiac rehabilitation
814538|NCT03068169|cardiac resynchronization therapy
814539|NCT03068169|supraventricular tachycardia
814540|NCT03068156|308-nm excimer laser
814541|NCT03068156|primary localized cutaneous amyloidosis
814542|NCT03068156|lichen amyloidosis
814543|NCT03068156|Asians
814544|NCT03068130|Pulmonary Arterial Hypertension
814545|NCT03068130|Pulmonary Hypertension
814546|NCT03068130|PH
814547|NCT03068130|PAH
814548|NCT03068130|Bardoxolone methyl
814549|NCT03068130|6-minute walk distance
814550|NCT03068130|CDDO-ME
814551|NCT03068130|RTA 402
814552|NCT03068130|LARIAT
814553|NCT03068130|CATALYST
814554|NCT03068130|RANGER
814555|NCT03068117|Specialist Palliative Care
814556|NCT03068117|Symptom Control
814557|NCT03068117|Early Referral
814558|NCT03068117|Quality of Life
814559|NCT03068117|Malignant Pleural Mesothelioma
814560|NCT03068117|Mesothelioma
814561|NCT03068104|Trauma
814562|NCT03068104|Haemorrhage
814563|NCT03068104|Massive transfusion
814564|NCT03068104|India
814565|NCT03068091|Interstitial Lung Disease
814566|NCT03068091|Idiopathic Pulmonary Fibrosis
814567|NCT03068065|Liraglutide
814568|NCT03068065|Metformin
814569|NCT03068065|Gliclazide
814570|NCT03068039|MRI
814571|NCT03068039|blood glucose
814572|NCT03068039|porridge
814573|NCT03068039|breakfast
814574|NCT03068039|satiety
814575|NCT03068039|plasma peptides
814576|NCT03068026|Chronic Obstructive Pulmonary Disease
814577|NCT03068026|Non-invasive ventilation
814578|NCT03068013|CALM
814579|NCT03068013|Depression
814580|NCT03068013|Demoralization
814581|NCT03068013|Cancer
814582|NCT03068013|Spirituality
814583|NCT03068013|Psychotherapy
814584|NCT03068013|Quality of Life
814585|NCT03068013|Anxiety
814586|NCT03068013|Post-Traumatic Growth
814587|NCT03068000|Martial arts
814588|NCT03068000|Judo
814589|NCT03068000|Motor skills
814590|NCT03068000|Physical fitness
814591|NCT03068000|Cardiovascular parameters
814592|NCT03068000|Quality of life
814593|NCT03068000|Physical Activity
814594|NCT03067974|ketamine
814595|NCT03067974|pediatric
814596|NCT03067974|procedural sedation
814597|NCT03067961|Enteric fever
814598|NCT03067961|Typhoid
814599|NCT03067961|Salmonella Typhi
814600|NCT03067961|Challenge study
814601|NCT03067961|Human model of infection
814602|NCT03067961|Typhoid toxin
814603|NCT03067922|Mastectomy
814604|NCT03067922|Pain
814605|NCT03067922|Severity
814606|NCT03067922|Life quality
814607|NCT03067896|spinal block
814608|NCT03067896|stress response
814609|NCT03067896|dexmedetomidine
814611|NCT03067870|Stem cells
814612|NCT03067870|Rheumatoid arthritis
814613|NCT03067831|stem cells
814614|NCT03067818|arm
814615|NCT03067818|rehabilitation
814616|NCT03067818|non-invasive brain stimulation
814617|NCT03067818|transcranial magnetic stimulation
814618|NCT03067818|upper extremity
814619|NCT03067805|Oxytocin effect
814620|NCT03067805|romantic jealousy
814621|NCT03067805|Arousal Rating
814622|NCT03067805|Jealousy Rating
814623|NCT03067792|inoperable gastric cancer
814624|NCT03067792|palliative chemotherapy
814625|NCT03067740|appendicectomy
814626|NCT03067740|children
814627|NCT03067740|local anesthetics
814628|NCT03067740|laparoscopy
814629|NCT03067740|peritoneum
814630|NCT03067675|no known ocular pathology
814631|NCT03067623|Thin endometrium
814632|NCT03067623|Endometrial thickness
814633|NCT03067584|Familial cancer
814634|NCT03067584|Genetic predisposition
814635|NCT03067584|Heritable disease
814636|NCT03067584|Cancer risk
814637|NCT03067584|Genome analysis
814638|NCT03067584|Genetic modifiers
814639|NCT03067584|Next generation sequencing (NGS)
814640|NCT03067584|Genetic counseling
814641|NCT03067584|DNA
814648|NCT03067558|Pneumonia
814649|NCT03067558|Diagnostics
814650|NCT03067558|Childhood
814651|NCT03067558|Respiratory rate
814652|NCT03067558|Ethiopia
814654|NCT03067454|early mobilisation
814655|NCT03067454|metacarpal fracture
814656|NCT03067454|operation
814657|NCT03067441|hyperlipidemia
814658|NCT03067441|cholesterol
814659|NCT03067441|heterozygous familial hypercholesterolemia
814660|NCT03067441|atherosclerotic cardiovascular disease
814661|NCT03067441|ASCVD
814662|NCT03067441|HeFH
814663|NCT03067441|LDL
814664|NCT03067428|Fructose
814665|NCT03067428|Diet
814666|NCT03067415|Glaucoma, Primary Open Angle
814667|NCT03067415|Ocular hypertension
814668|NCT03067415|CKD-351
814669|NCT03067402|Myocardial Infarction
814670|NCT03067402|Physiological Stress Test
814671|NCT03067402|Nuclear Image Perfusion
814672|NCT03067402|Angioplasty
814673|NCT03067402|Coronary Artery Bypass Graft
814674|NCT03067402|Percutaneous Coronary Intervention
814675|NCT03067402|Angina
814676|NCT03067402|Ischemia
814677|NCT03067376|ADME
814678|NCT03067376|Metabolism
814679|NCT03067376|Metabolite Profiling
814680|NCT03067376|Excretion
814681|NCT03067350|voriconazole
814682|NCT03067350|pharmacogenetics
814683|NCT03067350|pharmacokinetics
814684|NCT03067350|therapeutic drug monitoring
814685|NCT03067337|Stainless Steel Crowns
814686|NCT03067337|Zirconia Crowns
814687|NCT03067337|Aesthetic restorations
814688|NCT03067324|Islet Transplantation
814689|NCT03067298|pregnancy
814690|NCT03067298|screening
814691|NCT03067298|doppler
814692|NCT03067298|markers
814693|NCT03067298|PlGF
814694|NCT03067298|sFlt-1
814695|NCT03067298|placenta
814696|NCT03067272|Permanent contraception
814697|NCT03067272|Birth control
814698|NCT03067259|eldery patients
814699|NCT03067259|cognitive impairment
814700|NCT03067246|Supraglottic device
814701|NCT03067246|Fibre optic scope
814702|NCT03067246|Endotracheal intubation
814703|NCT03067220|outpatients
814704|NCT03067220|general surgery
814705|NCT03067220|virtual clinic
814706|NCT03067220|patient satisfaction
814707|NCT03067207|mindfulness meditation
814708|NCT03067207|Adolescent
814709|NCT03067207|eHealth
814710|NCT03067207|randomized trial
814711|NCT03067194|Osteoarthritis Hand
814712|NCT03067155|allogeneic stem cell transplantation
814713|NCT03067155|CMV reactivation
814726|NCT03067116|balance, postural
814727|NCT03067116|fall risk
814728|NCT03067116|anthropometrics
814729|NCT03067116|blood pressure
814730|NCT03067116|SpO2
814731|NCT03067116|heart rate
814732|NCT03067116|heart rate variability
814733|NCT03067116|stance width
814734|NCT03067103|Adenotonsillectomy
814735|NCT03067103|pain
814736|NCT03067103|topic analgesia
814737|NCT03067103|child
814738|NCT03067077|SMILE
814739|NCT03067077|LASIK
814740|NCT03067077|Myopia
814741|NCT03067077|Wavefront-guided
814742|NCT03067012|Oncometabolic surgery
814743|NCT03067012|Long limb uncut Roux-en-Y gastrojejunostomy
814744|NCT03067012|Obesity
814745|NCT03067012|Diabetes
814746|NCT03067012|Early gastric cancer
814747|NCT03066986|Venom anaphylaxis
814748|NCT03066986|Myrmecia piluosa
814749|NCT03066986|Immunological adjuvant
814750|NCT03066986|Immunotherapy
814751|NCT03066986|Jack jumper ant
814752|NCT03066973|breath exercises
814753|NCT03066973|labor pain
814754|NCT03066973|labor duration
814755|NCT03066973|VAS
814756|NCT03066934|Noninvasive Positive Pressure Ventilation
814757|NCT03066934|Nasal high flow
814758|NCT03066934|Respiratory Failure
814759|NCT03066934|Childhood
814760|NCT03066921|Lactic acid bacteria
814761|NCT03066921|dyslipidemia uremic toxins
814762|NCT03066921|Hemodialysis
814764|NCT03066882|Caloric Restriction
814765|NCT03066882|Diet
814766|NCT03066882|Obesity
814767|NCT03066882|Overweight
814768|NCT03066882|Sedentary Lifestyle
814769|NCT03066882|Weight loss
814770|NCT03066882|Women
814771|NCT03066856|BRCA genes
814772|NCT03066856|Mutation carriers
814773|NCT03066856|IGF-I
814774|NCT03066856|Diet
814775|NCT03066817|Vitamin D
814776|NCT03066817|Deficiency
814777|NCT03066817|Insufficiency
814778|NCT03066817|Bone turnover
814779|NCT03066817|Bone healing
814780|NCT03066817|Polytrauma
814781|NCT03066804|Cardiovascular Diseases
814782|NCT03066804|Heart Failure
814783|NCT03066804|Heart failure with Preserved Ejection Fraction
814784|NCT03066804|NT-proBNP
814785|NCT03066804|KCCQ
814786|NCT03066804|6 MWT
814787|NCT03066804|SF-36
814788|NCT03066804|NYHA Class
814789|NCT03066804|LCZ696
814790|NCT03066804|Enalapril
814791|NCT03066804|Valsartan
814792|NCT03066804|Angiotensin-Converting Enzyme Inhibitors (ACEi)
814793|NCT03066804|Angiotensin II Type 1 Receptor Blockers (ARB)
814794|NCT03066804|Renin Angiotensin System Inhibitors (RASi)
814800|NCT03066726|Biophysical profile
814801|NCT03066726|Cesarean section
814802|NCT03066726|Estimated fetal weight
814803|NCT03066726|Middle cerebral artery
814804|NCT03066726|Umbilical artery
814805|NCT03066726|Fetal growth restriction
814806|NCT03066726|Pulsatility index
814807|NCT03066726|Estimated gestational age
814808|NCT03066726|Doppler
814809|NCT03066648|Acute Myeloid Leukemia
814810|NCT03066648|Myelodysplastic syndromes
814811|NCT03066635|Nerve block
814812|NCT03066635|Ganglia, Parasympathetic
814813|NCT03066635|Botulinum Toxins, Type A
814814|NCT03066635|Injection
814815|NCT03066609|Plaque psoriasis, Secukinumab, Skin condition, skin disease, itching, psoriasis vulgaris, immune-mediated systemic disease, skin lesions, scaly patches, papules
814816|NCT03066583|meniscus repair
814817|NCT03066583|platelet rich plasma
814818|NCT03066570|Graded Exposure
814819|NCT03066570|Quality of Life
814820|NCT03066570|Physical Activity
814821|NCT03066570|Anxiety
814822|NCT03066557|Hepatocellular Carcinoma
814823|NCT03066557|Apatinib
814824|NCT03066544|migraine
814825|NCT03066544|responder
814826|NCT03066544|non-responder
814827|NCT03066544|treatment
814828|NCT03066531|ACT
814829|NCT03066531|CBT obesity
814830|NCT03066531|Eating disorders
814831|NCT03066531|Health psychology
814832|NCT03066518|melatonin
814833|NCT03066518|sleep
814834|NCT03066518|dementia
814835|NCT03066518|cognition
814840|NCT03066466|Acute Myeloid Leukemia
814841|NCT03066466|Acute Lymphocytic Leukemia
814842|NCT03066466|Myelodysplastic Syndrome
814843|NCT03066466|BMT
814844|NCT03066466|Matched unrelated donor transplant
814845|NCT03066466|Graft versus Host Disease
814846|NCT03066466|GVHD
814847|NCT03066453|cystic fibrosis, tobramycin, antibiotic courses, FEV1
814848|NCT03066440|diabetic ketoacidosis
814849|NCT03066440|fluid management
814850|NCT03066440|hyperchloremia
814853|NCT03066414|hemochromatosis
814854|NCT03066414|blood withdrawal
814855|NCT03066414|respiratory variations
814856|NCT03066414|inferior vena cava
814857|NCT03066414|internal jugular vein
814858|NCT03066414|ultrasound
814859|NCT03066414|ultrasonography
814860|NCT03066414|echography
814861|NCT03066401|hyperferritinemia
814862|NCT03066401|dysmetabolic hyperferritinemia
814863|NCT03066401|obese
814864|NCT03066401|blood withdrawal
814865|NCT03066401|respiratory variations
814866|NCT03066401|inferior vena cava
814867|NCT03066401|internal jugular vein
814868|NCT03066401|ultrasound
814869|NCT03066401|ultrasonography
814870|NCT03066401|echography
814871|NCT03066388|fluid
814872|NCT03066388|fluid responsiveness
814873|NCT03066388|pulse pressure
814874|NCT03066388|noninvasive monitoring
814875|NCT03066388|pulse pressure variations
814876|NCT03066388|volume expansion
814877|NCT03066388|SIRS
814878|NCT03066388|systemic inflammatory response syndrome
814879|NCT03066375|vena cava
814880|NCT03066375|fluid
814881|NCT03066375|sepsis
814882|NCT03066375|echocardiography
814883|NCT03066375|ultrasound
814884|NCT03066375|ultrasonography
814885|NCT03066375|collapsibility index
814886|NCT03066375|circulatory failure
814887|NCT03066375|irregular cardiac rhythm
814888|NCT03066375|fluid responsiveness
814889|NCT03066375|Spontaneous breathing
814890|NCT03066362|Spontaneous ventilation
814891|NCT03066323|Blood glucose
814892|NCT03066310|Bladder cancer
814893|NCT03066310|Urine
814894|NCT03066310|DNA biomarker
814895|NCT03066310|Diagnosis
814896|NCT03066297|Clinical stage IA non-small cell lung cancer
814897|NCT03066297|Lobectomy
814898|NCT03066297|Segmentectomy
814899|NCT03066297|Wedge resection
814900|NCT03066297|Sublobar resection
814901|NCT03066297|Limited resection
814902|NCT03066284|Children
814903|NCT03066284|Adolescents
814904|NCT03066284|Parents
814905|NCT03066284|Insulin Pump Therapy
814906|NCT03066271|Aerobic exercise
814907|NCT03066271|Lung Cancer
814908|NCT03066258|nAMD
814909|NCT03066258|wet AMD
814910|NCT03066258|gene therapy
814911|NCT03066245|Aneurysmal bone cysts
814912|NCT03066245|PLGA
814913|NCT03066245|Platelet Lysate
814914|NCT03066245|Bone marrow
814915|NCT03066245|Mesenchymal stem cells
814916|NCT03066232|Delirium
814917|NCT03066232|Dementia
814918|NCT03066232|Physical function
814919|NCT03066206|Malignant Neoplasm of Respiratory and Intrathoracic Organ
814920|NCT03066206|Non-Small Cell Lung Cancer
814921|NCT03066206|NSCLC
814922|NCT03066206|Advanced
814923|NCT03066206|EGFR exon 20 mutation
814924|NCT03066206|EGFR-positive
814925|NCT03066206|Poziotinib
814926|NCT03066193|Motor tics
814927|NCT03066193|Vocal tics
814928|NCT03066193|Cannabinoids
814929|NCT03066193|Dronabinol
814930|NCT03066193|PEA
814931|NCT03066193|Palmitoylethanolamide
814932|NCT03066193|Tourettes
814933|NCT03066193|TS
814934|NCT03066167|Cancer of the gastro-esophageal junction
814935|NCT03066167|Watson score
814936|NCT03066167|Ogilvie score
814937|NCT03066167|Goldschmid score
814938|NCT03066167|Validation
814939|NCT03066167|Quality of Life
814940|NCT03066154|High risk prostate cancer
814941|NCT03066154|>T2cN+M0
814942|NCT03066128|Task shifting
814943|NCT03066128|HIV care
814944|NCT03066115|Cerebral blood flow
814945|NCT03066115|Cyclooxygenase
814946|NCT03066115|Nitric oxide synthase
814947|NCT03066115|Reactive Oxygen Species
814948|NCT03066102|sensorimotor system
814949|NCT03066102|scapular joint position sense
814950|NCT03066102|fatigue
814951|NCT03066089|FBS,HbA1C, PPBS
814952|NCT03066050|Ischemic Mitral Regurgitation
814953|NCT03066050|Mitral Valve Disease
814954|NCT03066050|Moderate Mitral Regurgitation
814955|NCT03066050|Severe Mitral Regurgitation
814956|NCT03066037|regional-anaesthesiological infiltration
814957|NCT03066037|block series
814958|NCT03066037|invasive pain treatment
814959|NCT03066011|mold-active triazoles
814960|NCT03065972|kidney disease
814961|NCT03065972|vascular access
814962|NCT03065972|graft
814963|NCT03065972|fistula
814964|NCT03065972|hemodialysis
814965|NCT03065972|dialysis
814966|NCT03065959|CK-2127107
814967|NCT03065959|Mobility Limitation
814968|NCT03065959|Phase 1b
814969|NCT03065959|skeletal muscle fatigue
814970|NCT03065946|Therapeutic hypothermia
814971|NCT03065946|Electroencephalogram
814972|NCT03065946|Neuron-Specific Enolase
814973|NCT03065946|Return of Spontaneous Circulation
814974|NCT03065946|S-100B
814975|NCT03065933|mania
814976|NCT03065933|clonidine
814977|NCT03065933|bipolar disorder
814978|NCT03065894|stratified care
814979|NCT03065894|psychologically informed practice
814980|NCT03065894|matched care
814981|NCT03065868|gastric polyp
814982|NCT03065868|Helicobacter pylori eradication
814983|NCT03065855|laparoscopic mesorectal excision
814984|NCT03065855|rectal cancer
814985|NCT03065855|urinary distention
814986|NCT03065842|Stigma
814987|NCT03065842|Pregnancy
814988|NCT03065842|Abortion
814989|NCT03065842|Contraception
814990|NCT03065842|Adolescence
814991|NCT03065829|caregiver
814992|NCT03065829|chronically critically ill
814993|NCT03065777|single file.
814994|NCT03065777|ONE ENDO.
814995|NCT03065777|F6 SkyTaper.
814996|NCT03065777|ProTaper Universal.
814997|NCT03065777|irreversible pulpitis.
814998|NCT03065777|postoperative pain.
814999|NCT03065764|Pembrolizumab
815000|NCT03065764|89Zirconium
815001|NCT03065738|reduction osteotomy
815002|NCT03065738|knee arthroplasty
815003|NCT03065712|Breast Cancer
815004|NCT03065712|PET/CT
815005|NCT03065712|FES
815006|NCT03065712|18F Fluoroestradiol
815007|NCT03065712|Breast
815008|NCT03065699|Medical device
815009|NCT03065699|Liver dialysis
815010|NCT03065699|Haemofilter
815011|NCT03065699|ACLF
815012|NCT03065686|Cleft Lip and Palate
815013|NCT03065686|CL/P
815014|NCT03065686|WES
815015|NCT03065673|Tooth bleaching
815016|NCT03065673|Tooth sensitivity
815017|NCT03065660|Missed miscarriage
815018|NCT03065660|Mifepristone
815019|NCT03065660|Misoprostol
815020|NCT03065660|Medical management
815021|NCT03065647|Out-of-hospital cardiac arrest
815022|NCT03065647|Cardiac Arrest
815023|NCT03065647|Heart Arrest
815024|NCT03065647|Sudden Cardiac Arrest
815025|NCT03065647|Cardiopulmonary Resuscitation
815026|NCT03065647|Extracorporeal Cardiopulmonary Resuscitation
815027|NCT03065647|Extracorporeal Membrane Oxygenation
815028|NCT03065647|CPR
815029|NCT03065647|ECPR
815030|NCT03065647|ECMO
815031|NCT03065647|Emergency Medical Services
815032|NCT03065647|EMS
815033|NCT03065647|OHCA
815034|NCT03065621|Breast
815035|NCT03065595|Ophiocephalus striatus
815036|NCT03065595|IGF-1
815037|NCT03065595|hypoalbuminemia
815038|NCT03065595|MNA score
815039|NCT03065595|elderly
815040|NCT03065543|Hyperlipidemias
815041|NCT03065543|Secondary prevention
815042|NCT03065543|high risk patients
815043|NCT03065543|very high risk patients
815044|NCT03065530|Dexmedetomidine
815045|NCT03065530|Butorphanol tartrate
815046|NCT03065530|Analgesia
815047|NCT03065530|Breastfeeding
815048|NCT03065530|Relative infant dose
815049|NCT03065517|Criminal Justice
815050|NCT03065517|Juvenile Delinquency
815051|NCT03065491|Red yeast rice
815052|NCT03065491|Phytosterols
815053|NCT03065491|L-Tyrosol
815054|NCT03065491|Lipids
815055|NCT03065491|LDL-cholesterol
815056|NCT03065491|Endothelial function
815057|NCT03065478|Peripheral Neuropathy
815058|NCT03065478|Chemotherapy induced
815059|NCT03065478|CIPN
815060|NCT03065465|Upper GI hemorrhage
815061|NCT03065465|Stigmata of recent hemorrhage
815062|NCT03065465|Diverticular Hemorrhage
815063|NCT03065465|Ulcers
815064|NCT03065400|Myelofibrosis
815065|NCT03065400|Acute Leukemia
815066|NCT03065387|Metastatic solid tumors
815067|NCT03065387|Genetic mutation
815068|NCT03065387|Biomarkers
815069|NCT03065387|Neratinib
815070|NCT03065387|Everolimus
815071|NCT03065387|Afinitor
815072|NCT03065387|Zortress
815073|NCT03065387|RAD001
815074|NCT03065387|Palbociclib
815075|NCT03065387|PD-0332991
815076|NCT03065387|Ibrance
815077|NCT03065387|Trametinib
815078|NCT03065361|Chronic Kidney Disease
815079|NCT03065361|Handgrip Strength
815080|NCT03065361|Fine Motor Skills
815081|NCT03065361|Sensitivity
815082|NCT03065348|prehabilitation
815083|NCT03065348|nutrition
815084|NCT03065348|hydration
815085|NCT03065348|cystectomy and urinary diversion
815086|NCT03065348|regional anesthesia
815087|NCT03065348|cognition
815088|NCT03065335|Magnetic Resonance Imaging
815089|NCT03065335|Magnetoencephalography
815090|NCT03065335|Major Depressive Disorder
815091|NCT03065335|Ketamine
815092|NCT03065335|NEUROPHARMACOLOGY
815093|NCT03065322|PCOS
815094|NCT03065322|OSA
815095|NCT03065296|Behavior
815096|NCT03065296|education
815097|NCT03065296|medical residents
815098|NCT03065296|knowledge
815099|NCT03065296|confidence
815100|NCT03065296|skills assessment
815101|NCT03065257|EMR
815102|NCT03065257|ESD
815103|NCT03065257|Resection
815104|NCT03065257|STER
815105|NCT03065257|EFTR
815106|NCT03065257|Submucosal dissection
815107|NCT03065257|Endoscopic resection
815108|NCT03065244|Kawasaki disease
815109|NCT03065218|Thyroid
815110|NCT03065218|sestamibi
815111|NCT03065192|Gene Therapy
815112|NCT03065192|PD
815113|NCT03065192|Parkinson's Disease
815114|NCT03065192|Aromatic L- Amino Acid Decarboxylase
815115|NCT03065192|AADC
815116|NCT03065192|AAV2-AADC
815117|NCT03065192|AAV2
815118|NCT03065192|Viral Vector
815119|NCT03065192|Gene Transfer
815120|NCT03065192|MRI
815121|NCT03065192|PET
815122|NCT03065192|VY-AADC01
815123|NCT03065153|Torso
815124|NCT03065153|Trunk
815125|NCT03065088|Exercise
815126|NCT03065088|Feasibility Studies
815127|NCT03065088|Healthy Lifestyle
815128|NCT03065088|Health Promotion
815129|NCT03065088|Health Behavior
815130|NCT03065088|Aging
815131|NCT03065088|Activities of Daily Living
815132|NCT03065088|Mobile Applications
815133|NCT03065062|Lung Cancer Squamous Cell
815134|NCT03065062|Head & Neck Cancer
815135|NCT03065062|Neoplasms
815136|NCT03065062|Endometrial Cancer
815137|NCT03065049|Physical Activity
815138|NCT03065049|Peer-facilitation
815139|NCT03065049|Methadone Maintenance Therapy
815140|NCT03065036|Primary Open Angle Glaucoma
815141|NCT03065036|POAG
815142|NCT03065023|advanced tumor
815143|NCT03065023|intratumoral injection
815144|NCT03065023|intralesional injection
815145|NCT03064997|prebiotic
815146|NCT03064997|pediatric patients
815147|NCT03064997|health status
815148|NCT03064997|intestine permeability
815149|NCT03064971|Quitline
815150|NCT03064971|culturally specific
815151|NCT03064958|glucose regulation
815152|NCT03064958|lipids
815153|NCT03064958|Immune markers
815154|NCT03064958|Endothelium, Vascular
815155|NCT03064945|Livia TENS
815156|NCT03064945|safety and efficacy
815157|NCT03064945|menstruating women
815158|NCT03064919|hunger and fullness
815159|NCT03064919|regulation of energy intake
815160|NCT03064919|energy compensation
815161|NCT03064919|nutrition knowledge
815162|NCT03064906|T1D, Omnipod
815163|NCT03064880|Thoracic surgery
815164|NCT03064880|Fluid responsiveness
815165|NCT03064880|Hemodynamics
815166|NCT03064880|Oxidative stress
815167|NCT03064880|Goal-directed fluid therapy
815168|NCT03064867|venetoclax
815169|NCT03064867|rituximab
815170|NCT03064867|ifosfamide
815171|NCT03064867|carboplatin
815172|NCT03064867|etoposide
815173|NCT03064854|PDR001
815174|NCT03064854|immunotherapy
815175|NCT03064854|Non-small cell lung cancer
815176|NCT03064854|lung
815177|NCT03064854|NSCLC
815178|NCT03064802|BioBurst
815179|NCT03064802|Spinal Fusion
815180|NCT03064802|Cellular Allograft
815181|NCT03064789|Candidiases
815182|NCT03064789|Vaginal Infections
815183|NCT03064776|telemedicine
815185|NCT03064750|Exercise Therapy
815186|NCT03064750|Pelvic Floor
815187|NCT03064750|Preoperative Care
815188|NCT03064724|smoking
815189|NCT03064724|tobacco use
815190|NCT03064724|Asian
815191|NCT03064724|patients
815192|NCT03064724|provider advice
815193|NCT03064724|digital health intervention
815194|NCT03064685|Pyogenic Liver abscess
815195|NCT03064685|Liver transplantation
815196|NCT03064685|Biliary disease
815197|NCT03064659|Postoperative pulmonary complications
815198|NCT03064659|Driving Pressure
815199|NCT03064659|Limitation of Expiratory Flow
815200|NCT03064659|Cardiac Surgery
815201|NCT03064659|Cardio-pulmonary bypass
815202|NCT03064646|ORGAN PRESERVATION
815203|NCT03064646|WATCH AND WAIT
815204|NCT03064646|TRANSANAL ENDOSCOPIC MICROSURGERY
815205|NCT03064633|Dexamethasone
815206|NCT03064633|Dexmedetomidine
815207|NCT03064633|Transversus abdominis plane block
815208|NCT03064633|Local anesthetic adjuvants
815209|NCT03064633|postoperative pain
815210|NCT03064620|PCV effects
815211|NCT03064620|S. pneumoniae carriage
815212|NCT03064620|S. aureus carriage
815213|NCT03064620|Indirect vaccination effects
815214|NCT03064620|Palestinian-Israeli Collaborative Research (PICR)
815215|NCT03064607|Neonates
815216|NCT03064607|biomarkers
815217|NCT03064607|EXIT procedure
815218|NCT03064607|Cesarean Section
815219|NCT03064581|Cervical Cancer
815220|NCT03064581|Screening
815221|NCT03064581|Pap Test
815222|NCT03064581|Pacific Islander Americans
815223|NCT03064568|Myomectomy, Misoprostol, Vasopressin, Blood loss
815224|NCT03064555|Renal
815225|NCT03064555|Acute
815226|NCT03064555|Exercise
815227|NCT03064555|Dialysis
815228|NCT03064555|Hemodialysis
815229|NCT03064555|End stage renal disease
815230|NCT03064555|Aerobic
815231|NCT03064503|myocardial fibrosis
815232|NCT03064503|cardiac function
815233|NCT03064503|ageing
815234|NCT03064477|Unified Protocol
815235|NCT03064477|Transdiagnostic approach
815236|NCT03064477|Public health
815237|NCT03064464|methicillin-resistant Staphylococcus aureus
815239|NCT03064373|S. aureus
815240|NCT03064373|carriage
815241|NCT03064373|mother-neonatal transmission
815242|NCT03064373|microbiome
815243|NCT03064347|Diabetes Mellitus, Type 2
815244|NCT03064347|Obesity
815245|NCT03064347|Nutrient
815246|NCT03064321|cognitive behavioral treatment
815269|NCT03064269|CNS B cell acute lymphocytic leukemia
815270|NCT03064256|Exercisy therapy
815271|NCT03064256|Hypertension
815272|NCT03064256|Physiopathology
815273|NCT03064256|Heart rate
815274|NCT03064256|Nonlinear dynamics
815275|NCT03064217|Clinical crown lengthening
815276|NCT03064217|intraoral imaging
815277|NCT03064217|Emax crown
815278|NCT03064191|intra-canal medications
815279|NCT03064178|periodontal therapy
815280|NCT03064178|anticipated pain
815281|NCT03064178|experienced pain
815282|NCT03064178|pain medication use
815283|NCT03064139|physical activity
815284|NCT03064139|gait
815285|NCT03064139|biomechanics
815286|NCT03064126|Artery
815287|NCT03064126|Atherosclerosis
815288|NCT03064126|Arterial
815289|NCT03064126|Peripheral
815290|NCT03064126|Plaque
815291|NCT03064126|Angioplasty
815292|NCT03064126|PTA
815293|NCT03064113|Chronic Obstructive Pulmonary Disease, COPD
815294|NCT03064087|Self-Sampling
815295|NCT03064087|HPV Testing
815296|NCT03064087|Diagnostic Test Accuracy
815297|NCT03064087|Cervical Intraepithelial Neoplasia
815298|NCT03064087|Urine
815299|NCT03064087|Cervical Cancer Screening
815300|NCT03064048|Argininosuccinate Lyase Deficiency
815301|NCT03064048|Urea Cycle Disorder
815302|NCT03064022|weight gain
815303|NCT03064022|head circumference
815304|NCT03064022|length
815305|NCT03064022|neurodevelopment
815306|NCT03063983|osteosarcoma
815307|NCT03063983|metastatic
815308|NCT03063983|metronomic therapy
815309|NCT03063970|Upper extremity
815310|NCT03063970|Rehabilitation
815311|NCT03063931|Breast cancer
815312|NCT03063931|Mastectomy
815313|NCT03063931|Pain
815314|NCT03063931|Anxiety and Depression
815315|NCT03063931|Cognition
815316|NCT03063931|Quality of life
815317|NCT03063905|Opioid related disorders
815318|NCT03063905|Narcotic abuse
815319|NCT03063879|hepatitis C
815320|NCT03063879|renal failure
815321|NCT03063879|sofosbuvir
815322|NCT03063879|daclatasvir
815323|NCT03063840|hepatocellular carcinoma
815324|NCT03063840|microwave ablation
815325|NCT03063840|liver cancer
815326|NCT03063801|Congenital Heart Disease
815327|NCT03063801|Blood products transfusion
815328|NCT03063762|Renal Cell Carcinoma
815329|NCT03063762|RO6874281
815330|NCT03063762|Obinutuzumab
815331|NCT03063762|Atezolizumab
815332|NCT03063762|Bevacizumab
815333|NCT03063723|Chronic Hepatitis C
815334|NCT03063723|Monocytes
815335|NCT03063723|Nk cells
815336|NCT03063723|direct-acting antiviral agents
815337|NCT03063697|Carvedilol SR Cap
815338|NCT03063697|Essential hypertension
815339|NCT03063697|Chronic stable angina
815340|NCT03063697|Congestive heart failure
815341|NCT03063671|postmastectomy pain
815342|NCT03063658|Ibuprofen
815343|NCT03063658|Paracetamol
815344|NCT03063658|Laparoscopic cholecystectomy
815345|NCT03063658|Morphine
815346|NCT03063658|Visual analog scale
815352|NCT03063554|Endoscopy
815353|NCT03063554|Pancreatic Cancer
815354|NCT03063554|Bile duct
815355|NCT03063554|Periampullary
815356|NCT03063554|ERCP
815357|NCT03063554|Biliary drainage
815358|NCT03063554|Biliary obstruction
815359|NCT03063554|EUSBD
815360|NCT03063554|TEUS
815361|NCT03063554|EUS
815362|NCT03063554|Endoscopic Ultrasound
815363|NCT03063528|Pregnancy
815364|NCT03063528|Weight
815365|NCT03063528|Gestational weight gain
815366|NCT03063528|Stress reduction
815367|NCT03063528|Exercise
815368|NCT03063515|Insulin secretion
815376|NCT03063437|vancomycin resistant enterococcus
815377|NCT03063437|VRE
815378|NCT03063437|decolonization
815379|NCT03063437|VRE colonization
815380|NCT03063437|fecal microbiota transplantation
815381|NCT03063437|FMT
815382|NCT03063437|FMT capsule
815383|NCT03063437|capsule
815384|NCT03063437|antimicrobial resistance
815385|NCT03063437|antibiotic resistance
815386|NCT03063437|MDRO
815387|NCT03063437|multidrug-resistant organism
815388|NCT03063437|OpenBiome
815389|NCT03063424|isocapnic voluntary hyperventilation
815390|NCT03063424|eucapnic voluntary hyperventilation
815391|NCT03063424|exercise induced bronchoconstriction
815392|NCT03063424|exercise challenge cycle ergometer
815393|NCT03063411|Maths reasoning
815394|NCT03063411|Working memory
815395|NCT03063411|Executive Functions
815396|NCT03063411|Cognitive Control
815397|NCT03063411|Academic Skills
815398|NCT03063411|Randomised Control Trial
815399|NCT03063385|Adolescents
815400|NCT03063385|Parents
815401|NCT03063385|Web-based
815402|NCT03063385|Puerto Rico
815403|NCT03063385|Latino
815404|NCT03063385|Sexual communication
815405|NCT03063385|Stigma
815406|NCT03063385|Randomized controlled trial
815407|NCT03063385|STD
815408|NCT03063385|Intercourse
815409|NCT03063385|Sexual behavior
815410|NCT03063385|HIV/AIDS
815411|NCT03063372|Pomegranate
815412|NCT03063372|Burnout
815413|NCT03063372|Psychological Distress
815414|NCT03063372|Antioxidant
815415|NCT03063359|traumatic pain
815416|NCT03063359|children
815417|NCT03063359|fentanyl
815418|NCT03063359|intranasal use
815419|NCT03063333|spinal cord injury
815420|NCT03063333|hypnosis
815421|NCT03063333|pain
815422|NCT03063333|pain catastrophizing
815423|NCT03063333|coping
815424|NCT03063307|Tooth, Deciduous
815425|NCT03063307|Dental Caries
815426|NCT03063307|Glass Ionomer Cements
815427|NCT03063307|Dental Atraumatic Restorative Treatment
815428|NCT03063307|Cariostatic Agents
815429|NCT03063307|Fluorides
815430|NCT03063294|Coordination, Administrative
815431|NCT03063294|Coaching
815432|NCT03063294|Primary Care
815433|NCT03063294|Quality Improvement
815434|NCT03063281|ficolin-2
815435|NCT03063281|anti-ficolin-2 antibodies
815436|NCT03063281|lupus nephritis
815437|NCT03063281|Lupus Erythematosus, Systemic
815438|NCT03063281|biomarker
815439|NCT03063281|ficolin-3
815440|NCT03063281|anti-ficolin-3 antibodies
815441|NCT03063268|Electronic Consent
815442|NCT03063268|Human Behavior
815443|NCT03063268|Bioethics
815444|NCT03063268|Research Ethics
815445|NCT03063268|Electronic Medical Records (EMR)
815446|NCT03063268|Electronic Health Records (EHR)
815447|NCT03063268|Informed Consent Form
815448|NCT03063268|Interactive Consent
815449|NCT03063268|Health Record Data
815450|NCT03063242|Sargramostim
815451|NCT03063229|Insulin Pump Therapy
815452|NCT03063229|Islet Cell Transplant
815453|NCT03063229|Energy Expenditure
815454|NCT03063177|chronic thoracic pain
815455|NCT03063177|spine stiffness
815456|NCT03063177|spinal manipulation
815457|NCT03063177|spinal manipulative therapy
815458|NCT03063164|Femtosecond laser
815459|NCT03063164|Visumax
815460|NCT03063164|Intralase IFS150
815461|NCT03063164|LASIK
815462|NCT03063138|Diabetic foot ulcer
815463|NCT03063138|Measurement
815464|NCT03063138|Wound healing
815465|NCT03063138|Measurement device
815466|NCT03063138|Three-dimensional measurements
815467|NCT03063125|radical cystectomy
815468|NCT03063125|hypogonadism
815469|NCT03063008|Lumbar spine; Fusion; Titanium; PEEK
815470|NCT03062930|stroke
815471|NCT03062930|hemiparesis
815472|NCT03062930|lesion hemisphere
815473|NCT03062930|ipsilesional deficits
815474|NCT03062930|contralesional deficits
815475|NCT03062930|rehabilitation
815476|NCT03062930|remediation
815477|NCT03062930|paretic arm
815478|NCT03062904|healthy
815479|NCT03062904|respiratory system
815480|NCT03062904|ventilation
815481|NCT03062904|paradoxical effect
815482|NCT03062904|methacholine
815483|NCT03062904|bronchodilator
815484|NCT03062904|NEP
815485|NCT03062904|EFL
815486|NCT03062865|Rheumatoid arthritis (RA)
815487|NCT03062865|TNF-alpha inhibitors
815488|NCT03062852|Medication Errors/prevention & control
815489|NCT03062852|Nursing Staff, Hospital/organization & administration
815490|NCT03062852|Drug Therapy/nursing
815491|NCT03062852|Safety Management
815492|NCT03062852|Medication Systems, Hospital/organization & administration
815493|NCT03062826|OCT
815494|NCT03062826|STEMI
815495|NCT03062813|Hepatitis B virus, tacrolimus,membranous nephropathy
815496|NCT03062800|thalidomide
815497|NCT03062800|pemetrexed
815498|NCT03062800|nsclc
815499|NCT03062800|maintenance treatment
815500|NCT03062722|microsurgical treatment
815501|NCT03062722|pain
815502|NCT03062722|dexterity
815503|NCT03062722|Phalen sign
815504|NCT03062722|functional status
815505|NCT03062709|tobacco cessation
815506|NCT03062709|bronchiolitis
815507|NCT03062709|pneumonia
815508|NCT03062709|pediatric
815509|NCT03062709|environmental tobacco smoke
815510|NCT03062709|secondhand tobacco smoke
815511|NCT03062709|thirdhand tobacco smoke
815512|NCT03062709|tobacco smoke
815513|NCT03062709|asthma
815514|NCT03062709|reactive airway disease
815515|NCT03062709|bronchopulmonary dysplasia
815516|NCT03062683|lactate
815517|NCT03062683|syncope
815518|NCT03062644|Open Total or Subtotal Abdominal Hysterectomy
815519|NCT03062631|Congenital Myasthenic Syndrome
815520|NCT03062631|Lambert-Eaton Myasthenic Syndrome
815521|NCT03062631|3,4 DAP
815522|NCT03062631|3,4 Diaminopyridine
815523|NCT03062592|incretin
815524|NCT03062592|insulin
815525|NCT03062592|glucose
815526|NCT03062566|biomarkers
815527|NCT03062566|point-of-care analysis
815528|NCT03062540|PTSD
815529|NCT03062540|Military-related PTSD
815530|NCT03062527|Nutrition
815531|NCT03062527|Training support
815532|NCT03062527|Low Glycemic Index
815533|NCT03062527|Moderate Glycemic Index
815534|NCT03062527|Endurance
815535|NCT03062527|Running
815536|NCT03062449|L-Serine, Alzheimer's Disease, AD, Memory,
815537|NCT03062436|CML, treatment free remission
815538|NCT03062410|Health Related Quality of Life
815539|NCT03062410|Routine clinical practice
815540|NCT03062410|Electronic Patient Reported Outcome
815541|NCT03062410|EORTC QLQ-C30
815542|NCT03062410|Pazopanib
815543|NCT03062410|Sunitinib
815544|NCT03062410|Tyrosine Kinase Inhibitor anti-VEGF
815545|NCT03062410|Patient Reported Outcome
815546|NCT03062410|Supportive Care
815547|NCT03062410|Quality of Life
815548|NCT03062384|brain
815549|NCT03062384|health
815558|NCT03062345|Stroke
815559|NCT03062345|Virtual Reality Therapy
815560|NCT03062345|Rehabilitation
815561|NCT03062345|Upper Extremity
815562|NCT03062345|Arm
815563|NCT03062345|Telerehabilitation
815564|NCT03062319|anticoagulant
815565|NCT03062319|antiplatelet
815566|NCT03062306|Cerebral Oxygenation
815567|NCT03062306|Cardiopulmonary Resuscitation
815568|NCT03062306|Chest Compression
815569|NCT03062293|Lumbo-pelvic muscles
815570|NCT03062293|Rehabilitation
815571|NCT03062293|Exercise
815572|NCT03062293|Low back pain
815573|NCT03062293|Functional Re-adaptive Exercise Device
815574|NCT03062280|Extension study
815575|NCT03062267|mhealth
815576|NCT03062267|texting intervention
815577|NCT03062267|mobile health
815578|NCT03062267|mobile mental health
815579|NCT03062254|PSMA
815580|NCT03062241|cryoablation
815581|NCT03062241|conventional treatment of heart failure
815582|NCT03062228|stillbirth
815583|NCT03062228|sleep
815584|NCT03062228|low birth weight
815585|NCT03062228|pregnancy
815586|NCT03062228|supine
815587|NCT03062228|small for gestational age
815588|NCT03062215|Culturally adapted psychotherapy
815589|NCT03062215|Internet-delivered treatment
815590|NCT03062215|Depression
815591|NCT03062215|Latin America
815592|NCT03062202|Depression
815593|NCT03062202|Anxiety
815594|NCT03062202|Online interventions
815595|NCT03062202|CBT
815596|NCT03062202|IAPT
815597|NCT03062176|Heart failure
815598|NCT03062176|End-stage renal disease
815599|NCT03062176|Interleukin-1
815600|NCT03062176|Interleukin-1 receptor antagonist
815601|NCT03062176|Metabolomics
815602|NCT03062176|Lipidomics
815603|NCT03062137|bronchoscopy
815604|NCT03062137|saturation
815605|NCT03062124|SpyGlass
815606|NCT03062124|Pancreatoscopy
815607|NCT03062072|normoglycemia
815608|NCT03062072|cancer
815609|NCT03062072|chemotherapy
815610|NCT03062072|Hyperglycemia Drug Induced
815612|NCT03062020|Preterm Birth
815613|NCT03062020|Asymptomatic high-risk women
815614|NCT03062020|QUIPP
815615|NCT03062020|Quantitative fetal fibronectin
815616|NCT03062020|Cervical length
815617|NCT03061968|acupressure
815618|NCT03061968|very-low- birth-weight premature
815619|NCT03061968|body weight
815620|NCT03061968|behavioral state
815621|NCT03061968|developmental status
815622|NCT03061903|total hip arthroplasty
815623|NCT03061903|direct anterior approach
815624|NCT03061903|wound complication
815634|NCT03061877|Rheumatoid arthritis
815635|NCT03061877|Anxiety
815636|NCT03061877|Depression
815637|NCT03061825|Aneurysm
815638|NCT03061825|Aortic Aneurysm
815639|NCT03061825|Aortic Aneurysm, Abdominal
815640|NCT03061825|Iliac Aneurysm
815641|NCT03061825|Vascular Diseases
815642|NCT03061825|Cardiovascular Diseases
815643|NCT03061825|Aortic Diseases
815649|NCT03061760|Prostate cancer
815650|NCT03061760|Incontinence
815651|NCT03061760|Radical prostatectomy
815652|NCT03061760|Urge urinary incontinence
815657|NCT03061721|NASH
815658|NCT03061721|NAFLD
815659|NCT03061721|Saroglitazar
815660|NCT03061669|heart failure
815661|NCT03061669|pulmonary hypertension
815662|NCT03061669|right heart catheterization
815663|NCT03061591|Turmeric
815664|NCT03061591|Curcumin
815665|NCT03061591|colorectal polyps
815666|NCT03061591|colorectal neoplasia
815667|NCT03061591|mutyh mutation
815668|NCT03061591|apc mutation
815669|NCT03061578|Tear Film
815670|NCT03061578|Hyperspectral imaging
815671|NCT03061578|Low Humidity Environmental Exposure Chamber
815672|NCT03061565|erythropoietin
815673|NCT03061565|traumatic brain injury
815674|NCT03061539|Immunogenic signature
815675|NCT03061513|Parkinson Disease
815676|NCT03061513|ubiquinol
815677|NCT03061513|CoQ10
815678|NCT03061513|magnetic resonance spectroscopy
815679|NCT03061513|lactate
815680|NCT03061513|glutathione
815681|NCT03061500|Proadrenomedullin
815682|NCT03061500|Sepsis
815683|NCT03061500|Intraabdominal Infections
815684|NCT03061500|prognosis
815685|NCT03061474|Mild Cognitive Impairment
815686|NCT03061474|Alzheimer's Disease
815687|NCT03061474|Nicotinamide
815688|NCT03061474|Niacinamide
815689|NCT03061474|Niacin
815690|NCT03061474|Nicotinic Acids
815691|NCT03061474|Vitamin
815692|NCT03061474|Neurodegenerative Diseases
815693|NCT03061474|Tauopathies
815694|NCT03061474|Dementia
815695|NCT03061461|Extracorporeal shock wave therapy
815696|NCT03061461|ESWT
815697|NCT03061461|Radial extracorporeal shock wave therapy
815698|NCT03061461|rESWT
815699|NCT03061461|Diabetes
815700|NCT03061435|Vulvar Cancer
815701|NCT03061435|Cervical Cancer
815702|NCT03061435|Vulvar Dysplasia
815703|NCT03061435|Cervical Dysplasia
815704|NCT03061435|Anal Cancer
815705|NCT03061435|Anal Dysplasia
815706|NCT03061435|HPV
815707|NCT03061357|activity tracker
815708|NCT03061357|behavior change
815709|NCT03061318|Fine Needle Aspiration, Genetic Classifier
815710|NCT03061279|Medial Malleolus fractures
815711|NCT03061279|headless screws
815712|NCT03061279|headed screws
815713|NCT03061266|type 2 diabetes mellitus, application, e-health education
815714|NCT03061253|Electronic Cigarettes
815715|NCT03061253|Laser Doppler Flowmetry
815716|NCT03061253|Ultrasound
815717|NCT03061253|Nicotine Replacement Therapy
815718|NCT03061240|Internet of Things
815719|NCT03061136|Cognition
815720|NCT03061136|Gamma oscillations
815721|NCT03061136|EEG
815722|NCT03061136|Executive function
815723|NCT03061136|Benzodiazepine
815724|NCT03061136|GABA
815725|NCT03061097|Autologous Fecal Microbiota Transplantation
815726|NCT03061084|Spina Bifida,Neurogenic bladder, Myelomeningocele, Meningocele
815727|NCT03061071|Positional Sleep Apnea
815728|NCT03061071|Positional Obstructive Sleep Apnea
815729|NCT03061071|POSA
815730|NCT03061071|OSA
815731|NCT03061071|Obstructive Sleep Apnea
815732|NCT03061071|Sleep Apnea
815733|NCT03061019|child
815734|NCT03061019|myofunctional therapy
815735|NCT03061019|adenotonsillectomy
815736|NCT03061019|randomized controlled trial
815737|NCT03060993|Cannabis
815738|NCT03060993|Marijuana
815739|NCT03060967|motivation, instrumental tasks, food-related stimuli, size/time discrimination, major depression
815740|NCT03060954|Visual Disorder
815741|NCT03060928|Rotator Cuff Tear
815742|NCT03060928|Artelon®
815743|NCT03060915|Actigraphy
815744|NCT03060915|Polysomnography
815745|NCT03060915|Obstructive Sleep Apnea
815746|NCT03060889|Cesarean section
815747|NCT03060889|placenta previa
815748|NCT03060889|Tranexamic acid
815749|NCT03060876|shoulder fractures
815750|NCT03060876|humeral fractures
815751|NCT03060876|operative therapy
815752|NCT03060876|conservative therapy
815753|NCT03060876|range of motion, articular
815754|NCT03060876|quality of life
815755|NCT03060876|proximal
815756|NCT03060863|children
815757|NCT03060837|RIRS
815758|NCT03060837|Kidney Stone
815759|NCT03060837|Single lung ventilation
815760|NCT03060837|Simultaneous normal ventilation
815761|NCT03060824|Osmolality
815762|NCT03060824|Sodium
815763|NCT03060824|CABG
815764|NCT03060824|Cardiovascular Diseases
815765|NCT03060824|Cardiopulmonary bypass
815771|NCT03060759|Multiple Sclerosis
815772|NCT03060759|Relapsing-Remitting Multiple Sclerosis
815773|NCT03060759|Fatigue
815774|NCT03060759|Light Therapy
815775|NCT03060720|Pancreatic Cancer
815776|NCT03060694|Non-alcoholic Fatty Liver Disease
815777|NCT03060694|Diabetes Mellitus, Type 2
815778|NCT03060668|Critical Illness
815779|NCT03060668|Indirect Calorimetry
815780|NCT03060668|Dietary Proteins
815781|NCT03060655|PLGA-Mg
815782|NCT03060655|fracture
815783|NCT03060655|fixation
815784|NCT03060655|union
815785|NCT03060642|Microenvironment
815786|NCT03060642|Microbiome
815787|NCT03060642|Screening
815788|NCT03060642|Barrett Esophagus
815789|NCT03060642|Esophageal Adenocarcinoma
815790|NCT03060603|Erythropoietin
815791|NCT03060603|Endometrium
815792|NCT03060603|Doppler Ultrasonography
815793|NCT03060590|sarcopenia, uremic toxins
815794|NCT03060564|shoulder
815795|NCT03060564|orthopaedics
815796|NCT03060525|Deaf
815797|NCT03060525|American Sign Language
815798|NCT03060525|Overweight
815799|NCT03060525|Obese
815800|NCT03060512|Opioid Induced constipation,
815801|NCT03060512|constipation,
815802|NCT03060512|laxative,
815803|NCT03060512|bowel movement,
815804|NCT03060512|Movantik,
815805|NCT03060512|Naloxegol
815806|NCT03060499|Thyroidectomy
815807|NCT03060499|Myocardial Function
815808|NCT03060499|Thyroid gland
815809|NCT03060499|Heart
815810|NCT03060473|PPROM
815811|NCT03060473|Azithromycin
815812|NCT03060473|Erythromycin
815813|NCT03060434|pentoxifylline
815814|NCT03060434|Disc hernia
815815|NCT03060434|sciatica
815816|NCT03060434|lumbar radiculopathy
815817|NCT03060408|Fluid Therapy
815818|NCT03060408|Laparoscopy
815819|NCT03060369|Tissue Perfusion
815820|NCT03060369|Noninvasive Monitoring
815821|NCT03060369|Near-infrared spectroscopy
815822|NCT03060369|CareGuide
815823|NCT03060317|Disorders of consciousness
815824|NCT03060317|validation studies
815825|NCT03060317|coma
815826|NCT03060317|vegetative state
815827|NCT03060304|tamoxifen
815828|NCT03060304|thin endometrium
815829|NCT03060304|frozen embryo transfer
815830|NCT03060304|pregnancy rate
815831|NCT03060291|Family Check-up
815832|NCT03060278|smoking cessation, food pantry
815833|NCT03060265|multimodal analgesia
815834|NCT03060265|paracetamol
815835|NCT03060265|cesarean section
815836|NCT03060252|Drug-Induced Liver Injury
815837|NCT03060239|Parkinson Disease
815838|NCT03060239|Near infrared Spectroscopy
815839|NCT03060239|REM sleep behaviour disorder
815840|NCT03060239|Supplementary motor area
815841|NCT03060213|Well-Being
815842|NCT03060213|e-Health
815843|NCT03060213|Randomized Controlled Trial
815844|NCT03060213|Self-Efficacy
815845|NCT03060213|Interpersonal well-being
815846|NCT03060213|Community well-being
815847|NCT03060213|Occupational well-being
815848|NCT03060213|Physical well-being
815849|NCT03060213|Psychological well-being
815850|NCT03060213|Economic well-being
815851|NCT03060200|depression
815852|NCT03060200|treatment
815853|NCT03060200|CBT
815854|NCT03060200|online
815855|NCT03060200|app
815856|NCT03060161|Health promotion
815857|NCT03060161|Healthy Diet
815858|NCT03060161|Exercise
815859|NCT03060148|Heart failure
815860|NCT03060148|Spinal cord stimulation
815861|NCT03060109|Traumatic brain injury
815862|NCT03060109|Head injury
815863|NCT03060031|Oxytocin
815864|NCT03060005|Sjögren's syndrome
815865|NCT03060005|meibomian gland dysfunction
815866|NCT03060005|dry eye disease
815867|NCT03059940|Smoking Cessation
815868|NCT03059940|Low Dose computed tomography
815869|NCT03059940|LDCT
815870|NCT03059940|Quitline
815871|NCT03059940|Questionnaires
815872|NCT03059940|Surveys
815873|NCT03059940|Counseling
815874|NCT03059940|Smoking cessation drugs
815875|NCT03059940|Anti-Smoking Drug
815876|NCT03059940|Nicotine replacement therapy
815877|NCT03059940|NRT
815878|NCT03059940|Nicotine Patch
815879|NCT03059927|Cruciate retaining
815880|NCT03059927|Anterior stabilized
815881|NCT03059927|Posterior stabilized
815882|NCT03059927|Posterior cruciate ligament
815883|NCT03059927|Degenerative knee joint disease
815884|NCT03059927|Knee injury and Osteoarthritis Outcome Score
815885|NCT03059927|Kinematic radiostereometry
815886|NCT03059901|Physical Activity
815887|NCT03059901|Latina Women
815888|NCT03059901|Minority Health
815889|NCT03059901|Mobile Technology
815890|NCT03059901|Social Support
815891|NCT03059875|Breastcancer
815892|NCT03059875|Standardized Geriatric Evaluation
815893|NCT03059875|Onco-Geriatric Filter
815894|NCT03059862|immunity
815895|NCT03059862|Aryl-hydrocarbon receptor
815896|NCT03059862|immune homeostasis
815897|NCT03059862|microbiota
815898|NCT03059862|tryptophan
815899|NCT03059836|n3 PUFA
815900|NCT03059823|Solid tumors
815901|NCT03059823|Metastatic cancer
815904|NCT03059732|Gastric cancer
815905|NCT03059732|Thailand
815906|NCT03059732|Japan
815907|NCT03059719|safety
815908|NCT03059719|pharmacokinetics
815909|NCT03059719|pharmacodynamics
815910|NCT03059693|Eczema
815911|NCT03059693|Topical
815912|NCT03059680|Potassium
815913|NCT03059680|Nutrition
815914|NCT03059667|Small Cell Lun cancer
815915|NCT03059667|IFCT
815916|NCT03059667|immune therapy
815917|NCT03059654|Percutaneous tracheostomy
815918|NCT03059654|surgical tracheostomy
815919|NCT03059654|airway ultrasound
815920|NCT03059654|intensive care
815921|NCT03059641|Next Generation Sequencing (NGS)
815922|NCT03059641|Tyrosine Kinase Inhibitor (TKI)
815923|NCT03059641|liquid biopsy
815924|NCT03059641|EGFR Gene mutation
815925|NCT03059589|food anaphylaxis
815926|NCT03059589|peanut anaphylaxis
815927|NCT03059589|food oral immunotherapy
815928|NCT03059589|food allergy
815929|NCT03059589|food allergy treatment
815930|NCT03059576|Chronobiology
815931|NCT03059576|Circadian rhythms
815932|NCT03059576|Heritability
815933|NCT03059576|Twins
815934|NCT03059563|Varenicline
815935|NCT03059563|Positron Emission Tomography
815936|NCT03059563|Functional Magnetic Resonance Imaging
815937|NCT03059563|Methamphetamine Abuse
815938|NCT03059550|cardiac rehabilitation
815939|NCT03059550|prediabetes
815940|NCT03059524|microRNA
815941|NCT03059498|PECS I and II
815942|NCT03059498|PECS blocks
815943|NCT03059485|Leukemia
815944|NCT03059472|physical activity
815945|NCT03059472|nutrition
815946|NCT03059472|social network
815947|NCT03059472|civic engagement
815948|NCT03059459|Lung Diseases, Obstructive
815949|NCT03059459|Air Pollution
815950|NCT03059459|Particulate Matter
815951|NCT03059433|Substance use
815952|NCT03059433|adolescent
815953|NCT03059433|health
815954|NCT03059433|social network
815955|NCT03059420|CFEOM (Congenital Fibrosis of Extraocular Muscles)
815956|NCT03059420|CCDD (Congenital Cranial Dysinnervation Disorders)
815957|NCT03059420|DRS (Duane Retraction Syndrome)
815958|NCT03059420|DRRS (Duane Radial Ray Syndrome)
815959|NCT03059420|Strabismus
815960|NCT03059420|MGJWS (Marcus Gunn Jaw Winking Syndrome)
815961|NCT03059420|HGP (Horizontal Gaze Palsy)
815962|NCT03059420|HGPPS (Horizontal Gaze Palsy with Progressive Scoliosis)
815963|NCT03059420|Moebius
815964|NCT03059394|reliability
815965|NCT03059394|validity
815966|NCT03059394|measurement error
815967|NCT03059381|adolescent epilepsy participants
815968|NCT03059381|partial seizures
815969|NCT03059381|primary generalized Tonic-clonic seizures
815970|NCT03059342|spastic diplegic CP
815971|NCT03059342|self-care
815972|NCT03059342|functional mobility
815973|NCT03059342|multilevel surgery
815974|NCT03059329|adult epilepsy participants
815975|NCT03059329|partial seizures
815976|NCT03059329|primary generalized Tonic-clonic seizures
815977|NCT03059316|controlled hypotension, perfusion
815978|NCT03059290|post operative pain
815979|NCT03059290|Post operative flare ups
815980|NCT03059290|Post endodontic pain
815981|NCT03059290|Post endodontic flare ups
815982|NCT03059290|Necrotic teeth
815983|NCT03059290|Non vital teeth
815984|NCT03059290|Neolix file
815985|NCT03059290|Single rotating file
815986|NCT03059290|Protaper next file
815987|NCT03059290|Multiple rotating file
815988|NCT03059290|Single visit
815989|NCT03059277|Diabetic Macular Edema
815990|NCT03059277|Diabetes
815991|NCT03059277|reduced treatment frequency
815992|NCT03059251|CLL, obinutuzumab, treatment
815993|NCT03059238|Pain control
815994|NCT03059238|TACE
815995|NCT03059238|Opioids
815996|NCT03059238|NSAIDs
815997|NCT03059225|Stroke
815998|NCT03059225|Aphasia
815999|NCT03059225|rTMS
816000|NCT03059225|Functional MRI
816001|NCT03059225|Speech training
816002|NCT03059212|working memory
816003|NCT03059212|parkinson's disease
816004|NCT03059199|Prospective/Retrospective
816005|NCT03059173|Polycystic ovary syndrome
816006|NCT03059173|Reproductive medicine
816007|NCT03059160|Rett syndrome, Triheptanoic acid, Walking, EEG
816008|NCT03059134|Overactive bladder
816009|NCT03059134|Pharmacotherapy
816010|NCT03059134|Adverse event
816011|NCT03059121|HIV
816012|NCT03059121|Lipodystrophy
816015|NCT03059030|Thrombocytopenia
816016|NCT03059030|cirrhosis
816017|NCT03059030|Therasphere®
816018|NCT03059030|Y90
816019|NCT03059030|Radioembolization
816020|NCT03059004|physical therapy
816021|NCT03058965|AD
816022|NCT03058965|HV
816023|NCT03058965|PSP
816028|NCT03058939|Breast Cancer
816029|NCT03058939|Breast Cancer Stage II
816030|NCT03058939|Breast Cancer Stage III
816031|NCT03058939|Paclitaxel
816032|NCT03058939|Taxol
816033|NCT03058926|Chronic Pancreatitis
816034|NCT03058926|Diabetes
816035|NCT03058926|Pancreatic Cancer
816036|NCT03058926|Data Management
816037|NCT03058926|Protocol compliance
816038|NCT03058926|Regulatory compliance
816039|NCT03058926|Consortium studies
816040|NCT03058900|Fecal Microbiota Transplantation
816041|NCT03058900|FMT
816042|NCT03058900|Randomized Controlled Trial
816043|NCT03058900|Intestinal microbiome
816044|NCT03058900|RCT
816045|NCT03058887|High Intensity Interval Training
816046|NCT03058887|Exercise
816047|NCT03058887|Microcirculation
816048|NCT03058874|Chronic Kidney Disease
816049|NCT03058874|Hemodialysis
816050|NCT03058874|Hypertension
816051|NCT03058874|Arterial Stifness
816052|NCT03058874|Ambulatory Blood Pressure Monitoring
816059|NCT03058835|HIV
816060|NCT03058835|Truvada
816061|NCT03058796|stroke
816062|NCT03058796|rehabilitation
816063|NCT03058796|Hemipelegia
816064|NCT03058770|chronic stroke, sensorimotor retraining
816065|NCT03058692|Immunogenicity
816066|NCT03058692|Influenza A/H7N9 Vaccine
816067|NCT03058692|M-001 vaccine
816068|NCT03058692|MF59 Adjuvant
816069|NCT03058692|Reactogenicity
816070|NCT03058692|Safety
816071|NCT03058679|diet
816072|NCT03058679|specific carbohydrate diet
816073|NCT03058679|Mediterranean style diet
816074|NCT03058679|randomized controlled trial
816075|NCT03058666|Aerosol
816076|NCT03058666|surfactant
816077|NCT03058666|calfactant
816078|NCT03058666|Infasurf
816079|NCT03058666|Respiratory Distress Syndrome
816080|NCT03058666|RDS
816081|NCT03058666|Premature
816082|NCT03058666|Neonates
816083|NCT03058614|Contrast-enhanced ultrasound
816084|NCT03058614|Percutaneous nephrolithotomy
816085|NCT03058575|Microbiome
816086|NCT03058575|Gut
816087|NCT03058575|Skin
816088|NCT03058575|Fiber
816089|NCT03058575|Starch
816090|NCT03058549|Expectant parents
816091|NCT03058549|Relationship education
816092|NCT03058536|twin short cervix pessary progesterone preterm birth
816093|NCT03058523|Flavour
816094|NCT03058523|Infants
816095|NCT03058523|Taste
816096|NCT03058523|Pregnancy
816097|NCT03058523|Programming
816098|NCT03058523|Fruit
816099|NCT03058523|Vegetables
816100|NCT03058523|Bitter profile
816101|NCT03058523|Food preferences
816102|NCT03058510|bifurcation lesion
816103|NCT03058510|atherectomy
816104|NCT03058510|calcification
816105|NCT03058510|stent
816106|NCT03058445|Central venous catheter
816107|NCT03058445|MMode echocardiography
816111|NCT03058341|postoperative pain
816112|NCT03058341|propofol
816113|NCT03058341|TIVA
816114|NCT03058328|Inflammation/physiopathology, Immune System/immunology,
816115|NCT03058328|Neuroimmunomodulation/physiology, General Surgery
816116|NCT03058328|Heart Rate/physiology*Vagus Nerve/physiology*
816117|NCT03058315|Physical activity
816118|NCT03058315|Disease perception
816119|NCT03058315|Pain beliefs
816120|NCT03058315|Disability
816121|NCT03058315|Advice
816122|NCT03058289|Neoplasm
816123|NCT03058289|Malignancy
816124|NCT03058289|Intratumoral
816125|NCT03058289|Intralesional
816126|NCT03058289|anti-PD-1 antibodies
816127|NCT03058289|Immuno therapy
816128|NCT03058289|Dose escalation
816129|NCT03058289|Platinum
816130|NCT03058289|Intensity Therapeutics
816131|NCT03058289|INT230-6
816132|NCT03058289|cisplatin
816133|NCT03058289|vinblastine
816134|NCT03058289|PD-1
816135|NCT03058276|rTMS
816136|NCT03058276|AAT
816137|NCT03058276|Alcohol-Dependence
816138|NCT03058276|Relapses
816139|NCT03058224|Pain, Symptom Severity
816140|NCT03058224|Immunoglobulin IgY
816141|NCT03058224|Fibromyalgia
816142|NCT03058224|Widespread Pain Index
816143|NCT03058224|Eggyolk
816144|NCT03058224|FIQ-R
816145|NCT03058224|SF-36v2TM
816146|NCT03058224|MOS-SS
816147|NCT03058224|FSS
816148|NCT03058224|PGIC
816149|NCT03058224|Quality of life
816150|NCT03058211|Pneumococcal pneumonia
816151|NCT03058211|Acute cardiovascular events
816152|NCT03058198|Glioma
816153|NCT03058198|PET
816154|NCT03058198|EGFR vIII
816155|NCT03058198|Multimodal neuronavigation
816156|NCT03058198|Molecular pathology
816157|NCT03058198|PET-CT
816158|NCT03058198|Neuronavigation
816159|NCT03058185|Lamin A/C
816160|NCT03058185|Emerin
816161|NCT03058146|Exercise
816162|NCT03058146|Fitness
816163|NCT03058146|Physical Activity
816164|NCT03058146|Cognitive Aging
816165|NCT03058146|Cerebral Blood Flow
816166|NCT03058146|Brain Imaging
816167|NCT03058146|Unsupervised Intervention
816168|NCT03058146|Mobile Health
816169|NCT03058146|Free-living exercise intervention
816170|NCT03058133|fMRI, perception, face-voice processing
816171|NCT03058107|Nutrition Therapy
816172|NCT03058081|COPD
816173|NCT03058081|Exercise
816174|NCT03058081|High Flow Nasal
816175|NCT03058081|Muscle Oxygenation
816176|NCT03058081|Pulmonary Rehabilitation
816180|NCT03058003|balance, postural
816181|NCT03058003|postural equilibrium
816182|NCT03058003|chronic pain
816183|NCT03058003|Chronic nonspecific low back pain
816184|NCT03058003|Fibromyalgia
816185|NCT03058003|Cervicogenic headache
816186|NCT03058003|Chronic tension type headache
816187|NCT03058003|Irritable bowel syndrome
816188|NCT03058003|Whiplash associated disorder
816189|NCT03058003|Temporomandibular disorder
816190|NCT03057990|Pyrimethamine
816191|NCT03057990|Myelodysplastic Syndromes (MDS)
816192|NCT03057990|Refractory
816193|NCT03057990|Relapsed
816194|NCT03057938|Alzheimer
816195|NCT03057938|Subjective Cognitive Decline
816196|NCT03057938|Florbetaben
816197|NCT03057925|thyroid nodule
816198|NCT03057925|microwave ablation
816199|NCT03057912|Cervical intraepithelial neoplasiaⅠ
816200|NCT03057912|TALEN
816201|NCT03057912|CRISPR/Cas9
816202|NCT03057899|Herbal medicine
816203|NCT03057899|phytotherapy
816204|NCT03057899|testosterone
816205|NCT03057873|protein
816206|NCT03057873|fiber
816207|NCT03057873|weight loss
816208|NCT03057873|fat loss
816209|NCT03057821|hydrogen peroxide
816210|NCT03057821|Propionibacterium Acnes
816211|NCT03057821|shoulder arthroplasty
816212|NCT03057808|Pregnancy
816213|NCT03057808|Postpartum
816214|NCT03057782|Pain
816215|NCT03057782|Sedation
816216|NCT03057782|Surgery
816217|NCT03057769|ERCP, post-ERCP pancreatitis, indomethacin, epinephrine
816218|NCT03057756|Multi-drug Resistant Tuberculosis
816219|NCT03057756|short course regimen protocol
816220|NCT03057730|acellular dermal matrix
816221|NCT03057704|Propofol
816222|NCT03057704|lidocaine
816223|NCT03057704|pain
816224|NCT03057691|Acute Coronary Syndrome
816225|NCT03057691|Major Depressive Disorder
816226|NCT03057691|Generalized Anxiety Disorder
816227|NCT03057691|Percutaneous Coronary Intervention
816228|NCT03057691|Major Adverse Cardiovascular Events
816229|NCT03057613|radiation
816230|NCT03057613|resected
816231|NCT03057600|African ancestry
816232|NCT03057600|African American
816233|NCT03057600|CB-839
816234|NCT03057600|Glutaminase Inhibitor
816235|NCT03057600|Glutaminase
816236|NCT03057600|TNBC
816237|NCT03057600|Tumor Metabolism
816238|NCT03057600|Glutamine
816239|NCT03057561|CAD
816240|NCT03057548|Atrial Fibrillation
816241|NCT03057548|Long-Standing Atrial Fibrillation
816242|NCT03057548|Posterior Left Atrial Wall Ablation
816243|NCT03057535|Exercise
816244|NCT03057535|Sodium Bicarbonate
816245|NCT03057535|Ventilatory equivalent for carbon dioxide
816246|NCT03057522|Run
816247|NCT03057522|Cadence
816248|NCT03057522|Home exercise
816249|NCT03057509|Carcinoid Tumors
816250|NCT03057470|Diabetes
816251|NCT03057470|Exercise
816252|NCT03057470|Insulin
816253|NCT03057444|resistant starch type III
816254|NCT03057444|butyrate-producing gut bacteria
816255|NCT03057444|diabetes mellitus type 2
816256|NCT03057444|prediabetes
816257|NCT03057431|kidney stones
816258|NCT03057431|hydrochlorothiazide
816259|NCT03057405|intra-operative navigation
816260|NCT03057405|3D virtual planning
816261|NCT03057405|intra-operative cone beam computed tomography (CBCT)
816262|NCT03057392|immersion
816263|NCT03057392|ultrafiltration
816264|NCT03057392|dialysis
816265|NCT03057379|HPV vaccine
816266|NCT03057379|Immunization registry
816267|NCT03057379|Reminder recall
816268|NCT03057366|Drug therapy
816269|NCT03057340|Advanced non-small cell lung cancer
816270|NCT03057340|Dribbles
816271|NCT03057275|Threatened Premature Labor
816272|NCT03057275|Abdominal Fetal ECG
816273|NCT03057262|temporomandibular joint disorders
816274|NCT03057262|disc displacement with reduction
816275|NCT03057262|anterior repositioning splint
816276|NCT03057249|Surgery
816277|NCT03057249|Thermography
816278|NCT03057249|Perfusion
816279|NCT03057249|Imaging
816280|NCT03057236|psychological, behavioral, psychosocial, antiviral, liver
816281|NCT03057223|3D printing
816282|NCT03057223|patient-specific titanium plate
816283|NCT03057223|mandibular malignancy
816284|NCT03057223|dento-maxillofacial deformity
816285|NCT03057223|orthognathic surgery
816286|NCT03057223|mandibular reconstruction
816287|NCT03057210|Exercise
816288|NCT03057210|Massage
816289|NCT03057210|Post-exercise recovery
816290|NCT03057210|Athletic performance
816291|NCT03057184|Adult Day Care Center
816292|NCT03057184|behavioral problems
816293|NCT03057184|caregivers
816294|NCT03057171|Helicobacter pylori
816295|NCT03057171|long non-coding RNA
816296|NCT03057171|THRIL
816297|NCT03057171|PACER
816298|NCT03057171|cagA
816299|NCT03057158|OAB
816300|NCT03057158|Insulin resistance
816301|NCT03057158|diabetes
816302|NCT03057158|pre-diabetes
816303|NCT03057145|Solid Tumor
816304|NCT03057093|NSTEMI, ECG
816305|NCT03057067|Embolization, Therapeutic
816306|NCT03057067|Pelvis
816307|NCT03056976|Overdenture
816308|NCT03056976|Dental implant
816309|NCT03056976|Complete denture
816310|NCT03056976|Cost analysis
816311|NCT03056963|Guided Imagery
816312|NCT03056950|Blood Flow Restriciton
816313|NCT03056950|Occlusion training
816314|NCT03056950|Distal radius fracture
816315|NCT03056911|ozone therapy
816316|NCT03056911|percutaneous treatment
816317|NCT03056911|Oswestry Disability Index (ODI)
816318|NCT03056911|Visual analog Scale (VAS)
816319|NCT03056911|Neuropathic Pain Questionnaire (DN-4)
816320|NCT03056911|cervical
816321|NCT03056898|eicosapentaenoic acid
816322|NCT03056898|EPA
816323|NCT03056898|docosahexaenoic acid
816324|NCT03056898|DHA
816325|NCT03056898|omega-3 index
816326|NCT03056885|one-lung ventilation
816327|NCT03056885|broncho-alveolar lavage
816328|NCT03056885|protective ventilation
816329|NCT03056885|cytokines
816330|NCT03056885|thoracic surgery
816331|NCT03056859|Operator satisfaction with device
816332|NCT03056846|probiotic
816333|NCT03056846|gastrointestinal
816334|NCT03056846|stress
816335|NCT03056846|student
816336|NCT03056820|tracheal intubation
816337|NCT03056807|tolerable apneic time
816338|NCT03056807|bariatric surgery
816339|NCT03056807|gastric band surgery
816340|NCT03056807|intubation
816341|NCT03056794|pyruvate
816342|NCT03056794|pyruvate dehydrogenase
816343|NCT03056794|PDC
816344|NCT03056794|PDCD
816353|NCT03056716|thoracic surgery
816354|NCT03056716|silastic drains
816355|NCT03056716|conventional drains
816358|NCT03056677|Whey protein
816359|NCT03056677|Dietary supplementation
816360|NCT03056677|Glucose
816361|NCT03056677|GLP-1
816362|NCT03056677|Satiety
816363|NCT03056651|heart failure
816364|NCT03056651|day care
816365|NCT03056651|prognosis
816366|NCT03056638|Androgen Deprivation Therapy
816367|NCT03056638|Ultra-Hypofractionated SBRT
816368|NCT03056638|16-1686
816369|NCT03056625|fortified rice
816370|NCT03056625|lactating women
816371|NCT03056625|13C2-retinol isotope dilution
816372|NCT03056625|vitamin A liver store
816373|NCT03056599|in vivo drug sensitivity
816374|NCT03056599|personalized medicine
816375|NCT03056599|precision oncology
816376|NCT03056599|in vivo oncology
816377|NCT03056599|soft tissue sarcoma
816378|NCT03056599|chemotherapy
816379|NCT03056599|microinjection
816380|NCT03056599|microdosing
816381|NCT03056573|TAVI
816382|NCT03056573|Valvular heart disease
816383|NCT03056573|Transcatheter aortic valve implantation
816384|NCT03056534|Primary Total Hip Arthroplasty
816385|NCT03056534|Non-Inflammatory Arthritis
816386|NCT03056534|Degenerative Joint Disease
816387|NCT03056534|R3 Delta Ceramic Acetabular Insert
816388|NCT03056508|diet
816389|NCT03056508|nutrition
816390|NCT03056508|aerobic exercise
816391|NCT03056508|cognition
816392|NCT03056508|grey matter
816393|NCT03056508|cerebral blood flow
816394|NCT03056508|neural activity
816395|NCT03056508|resting state connectivity
816396|NCT03056482|cannabis
816397|NCT03056482|haloperidol
816398|NCT03056482|ondansetron
816399|NCT03056482|hyperemesis
816400|NCT03056482|cyclic vomiting syndrome
816401|NCT03056469|patient-reported outcomes
816402|NCT03056469|supportive care
816403|NCT03056469|clinical practice
816404|NCT03056469|hematological cancer
816405|NCT03056430|MRI, Neuroplasticity, Balance, Spatial orientation, Hippocampus, Slacklining
816406|NCT03056417|chronic pain
816407|NCT03056417|telomere
816408|NCT03056417|telomerase
816409|NCT03056417|life style
816410|NCT03056391|knowlesi malaria
816411|NCT03056391|paracetamol
816412|NCT03056391|renal function
816413|NCT03056391|haemolysis
816414|NCT03056391|oxidative stress
816415|NCT03056365|Detoxification
816416|NCT03056365|Outpatient
816417|NCT03056365|Advanced Nursing
816418|NCT03056365|Health Services
816438|NCT03056313|Delivery, Obstetric
816439|NCT03056313|Uterine Contraction
816440|NCT03056313|Cervix Uteri
816441|NCT03056274|Metformin
816442|NCT03056274|Ursodeoxycholic acid
816443|NCT03056274|Outcomes
816444|NCT03056261|Combined general-epidural anesthesia intestinal recovery
816445|NCT03056235|Atrophic acne scar
816446|NCT03056209|Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
816447|NCT03056157|Moral Injury
816448|NCT03056157|Post-traumatic Stress Disorder
816449|NCT03056157|Traumatic Loss
816450|NCT03056157|Adaptive Disclosure
816451|NCT03056157|Veterans
816452|NCT03056144|spinal muscular atrophy
816453|NCT03056144|total body vibration
816454|NCT03056144|children
816455|NCT03056118|OPTIMA-C
816456|NCT03056105|Well-being, affiliation, inflammation
816457|NCT03056092|ranibizumab
816458|NCT03056092|aqueous cytokine
816459|NCT03056092|age related macular degeneration
816460|NCT03056092|diabetic macular edema
816461|NCT03056092|retinal vein occlusion
816462|NCT03056079|neovascular age related macular degeneration
816463|NCT03056079|diabetic macular edema
816464|NCT03056079|retinal vein occlusion
816465|NCT03056079|aflibercept
816466|NCT03056079|aqueous humor cytokine
816467|NCT03056053|insomnia
816468|NCT03055975|Bacteria
816469|NCT03055975|Root canal treatment
816470|NCT03055975|Endodontics
816471|NCT03055962|Healthy Participants
816472|NCT03055962|E2609
816473|NCT03055962|Pharmacokinetics
816474|NCT03055962|Japan
816475|NCT03055949|early rehabilitation
816476|NCT03055949|early mobilization
816477|NCT03055949|surgical intensive care unit
816478|NCT03055884|transcranial Direct Current Stimulation (tDCS)
816479|NCT03055884|accelerated learning
816480|NCT03055884|memory
816481|NCT03055871|Behavioural: Family physical activity habit
816482|NCT03055858|PDA, ADO II AS
816483|NCT03055819|Brow Lift
816484|NCT03055819|Brow Ptosis
816485|NCT03055806|Sex
816486|NCT03055806|Sexual Dysfunction
816487|NCT03055806|IX-01
816488|NCT03055741|Alzheimer's disease
816489|NCT03055728|streptococcal infections
816490|NCT03055728|rapid strep testing
816491|NCT03055728|rapid antigen detection test
816492|NCT03055715|NSCLC
816493|NCT03055715|Radiotherapy
816494|NCT03055715|young DEGRO
816495|NCT03055715|tumor volume
816496|NCT03055715|lung cancer
816497|NCT03055715|radiochemotherapy
816498|NCT03055715|prognostic factors
816499|NCT03055702|Short Message Service
816500|NCT03055702|appointment reminder
816501|NCT03055702|Attendance rate
816502|NCT03055689|Colonoscopy
816503|NCT03055689|Educational intervention
816504|NCT03055676|Pancreaticoduodenectomy
816505|NCT03055676|Time of drain removal
816506|NCT03055624|prostate artery embolization (PAE)
816507|NCT03055624|benign prostatic hyperplasia (BPH)
816508|NCT03055624|lower urinary tract symptoms (LUTS)
816509|NCT03055611|Blood Coagulation Disorder
816510|NCT03055611|Hematologic Diseases
816511|NCT03055611|Coagulation Protein Disorder
816512|NCT03055611|Hemorrhagic Disorder
816513|NCT03055611|Genetic Diseases, Inborn
816514|NCT03055585|Wolbachia; Aedes aegypti; Indonesia; Dengue; Cluster-randomised trial
816515|NCT03055572|Rhinitis
816516|NCT03055572|Chronic Rhinosinusitis
816517|NCT03055572|Olfactory Training
816518|NCT03055559|Iron, Hemoglobin, Feritin, erytrocyty. transferin
816519|NCT03055546|oxytocin
816520|NCT03055546|emotion regulation
816521|NCT03055533|Behavioral
816522|NCT03055533|Social
816523|NCT03055533|Headsprout reading program
816524|NCT03055520|schizophrenia
816525|NCT03055520|cognition
816526|NCT03055520|arithmetic training
816527|NCT03055520|Kumon method
816528|NCT03055481|neonatal jaundice
816529|NCT03055481|phototherapy
816530|NCT03055481|neonate
816531|NCT03055429|Prisoners
816532|NCT03055429|End-of-life care
816533|NCT03055429|Geriatric care
816534|NCT03055429|Palliative care
816535|NCT03055429|Hospice care
816536|NCT03055416|Overweight
816537|NCT03055416|Obesity
816538|NCT03055416|Physical Activity
816539|NCT03055416|African-American Men
816540|NCT03055416|mHealth
816541|NCT03055416|Mobile Health
816542|NCT03055390|hyoscine butylbromide
816543|NCT03055390|progress of labor
816544|NCT03055390|duration of labor
816545|NCT03055377|cannabis
816546|NCT03055377|marijuana
816547|NCT03055377|youth
816548|NCT03055377|adolescent
816549|NCT03055377|pharmacotherapy
816550|NCT03055377|medication
816551|NCT03055377|n-acetylcysteine
816552|NCT03055377|trial
816553|NCT03055351|Exercise motivation
816554|NCT03055351|Psychological well-being
816555|NCT03055351|Healthy living
816556|NCT03055351|Physical activity
816557|NCT03055351|Autonomy support
816558|NCT03055351|Self-determination theory
816559|NCT03055338|Schizophrenia, acute episode
816560|NCT03055338|Schizophrenia Spectrum and Other Psychotic Disorders
816561|NCT03055338|Mental Disorders
816562|NCT03055247|Chronic granulomatous disease X-linked
816563|NCT03055247|Ibuprofen
816564|NCT03055247|Mobilization regimen
816565|NCT03055247|Gene Therapy
816566|NCT03055234|Oral treprostinil
816567|NCT03055234|6-Minute Walk Distance
816568|NCT03055234|PH
816569|NCT03055234|sickle cell
816570|NCT03055221|Remodulin
816571|NCT03055221|6-Minute Walk Test
816572|NCT03055208|Glioblastoma
816573|NCT03055208|Radiosurgery
816574|NCT03055208|Gamma Knife
816580|NCT03055182|Isokinetic
816581|NCT03055182|oxygenation
816582|NCT03055182|deoxygenation
816583|NCT03055182|aerobic metabolism
816584|NCT03055169|hyperglycemia
816585|NCT03055169|Multiple Organ Failure
816586|NCT03055169|biobank
816587|NCT03055169|diabetes
816588|NCT03055156|Sleep Apnea
816589|NCT03055156|Insomnia
816590|NCT03055156|sleep disorders
816591|NCT03055156|sleep environment
816592|NCT03055156|core body temperature
816593|NCT03055117|Shoulder pain
816594|NCT03055117|Physiotherapy
816595|NCT03055117|Rehabilitation
816596|NCT03055117|Exercise
816597|NCT03055104|severe malnutrition
816598|NCT03055104|Critically Ill
816599|NCT03055104|refeeding syndrome
816600|NCT03055104|guideline
816601|NCT03055065|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
816607|NCT03054974|Stroke
816608|NCT03054974|Traditional Chinese Medicine
816609|NCT03054974|Rehabilitation
816610|NCT03054961|epilepsy
816611|NCT03054961|cytochrome oxidase redox state
816612|NCT03054961|childhood epilepsy
816613|NCT03054961|partial epilepsy
816614|NCT03054961|NIRS
816615|NCT03054961|near-infrared spectroscopy
816616|NCT03054961|regional cerebral oxygen saturation
816617|NCT03054935|Energy Expenditure
816618|NCT03054935|Body Composition
816619|NCT03054935|Food Intake
816620|NCT03054896|Richter Syndrome
816621|NCT03054883|Mantle Cell Lymphoma
816622|NCT03054883|minimal residual disease
816623|NCT03054883|cytosine arabinoside
816624|NCT03054870|pulmonary ventilation
816625|NCT03054870|ventilation scintigraphy
816626|NCT03054844|Intranasal
816627|NCT03054844|Pain
816628|NCT03054844|Lidocaine
816629|NCT03054844|Midazolam
816630|NCT03054844|Emergency department
816631|NCT03054766|Laser Photocoagulation
816632|NCT03054766|Ranibizumab
816633|NCT03054766|Branch Retinal Vein Occlusion
816634|NCT03054766|Vascular Endothecial Growth Factor
816635|NCT03054753|Abduction brace
816636|NCT03054753|Compliance
816637|NCT03054753|Rotator cuff tear
816638|NCT03054753|Rotator cuff repair
816640|NCT03054727|Post Thrombotic Syndrome
816641|NCT03054727|Venous Thromboembolism
816642|NCT03054727|Incidence
816643|NCT03054727|Risk factors
816644|NCT03054727|Venous ulcer
816645|NCT03054701|Patellofemoral pain
816646|NCT03054701|PFP
816647|NCT03054701|PFPS
816648|NCT03054675|lung resection
816649|NCT03054675|lung function
816650|NCT03054675|VATS
816651|NCT03054675|Thoracotomy
816652|NCT03054662|Haemophilia
816653|NCT03054610|plantar fascitis
816654|NCT03054610|Botulinum toxin A
816655|NCT03054610|Betamethason Sodium Phosphate
816656|NCT03054610|infiltration
816657|NCT03054610|plantar fascia
816658|NCT03054558|Junctional zone
816659|NCT03054558|recurrent pregnancy loss
816660|NCT03054558|3D power Doppler
816661|NCT03054480|Fractional Micro-Needle Radiofrequency
816662|NCT03054480|Intradermal Botulinum Toxin A
816663|NCT03054441|Upper limb
816664|NCT03054441|Inertial sensors
816665|NCT03054415|neuronal-glial-epithelial unit, anorectal function
816666|NCT03054376|Immobilization
816667|NCT03054376|Angiogenesis
816668|NCT03054376|Skeletal muscle
816669|NCT03054376|Exercise training
816670|NCT03054376|Vascular function
816671|NCT03054363|Metastatic Breast Cancer
816672|NCT03054363|Tucatinib
816673|NCT03054363|Palbociclib
816674|NCT03054363|Letrozole
816675|NCT03054363|HR-positive
816676|NCT03054363|HER2-positive
816677|NCT03054363|ER-positive
816678|NCT03054363|PR-positive
816679|NCT03054363|HER2-targeted therapy
816680|NCT03054363|CDK4/6 inhibitor
816681|NCT03054363|ONT-380
816682|NCT03054363|Ibrance
816683|NCT03054350|Anemia
816684|NCT03054350|kidney
816685|NCT03054350|dialysis-dependent chronic kidney disease
816686|NCT03054350|CKD
816687|NCT03054350|DD-CKD
816688|NCT03054350|renal
816689|NCT03054350|vadadustat
816690|NCT03054350|AKB-6548
816691|NCT03054350|hypoxia-inducible factor
816692|NCT03054350|HIF
816693|NCT03054350|hypoxia-inducible factor prolyl-hydroxylase inhibitor
816694|NCT03054350|HIF-PHI
816695|NCT03054350|Japan
816696|NCT03054350|Japanese
816697|NCT03054337|Anemia
816698|NCT03054337|kidney
816699|NCT03054337|non-dialysis dependent chronic kidney disease
816700|NCT03054337|CKD
816701|NCT03054337|NDD-CKD
816702|NCT03054337|renal
816703|NCT03054337|vadadustat
816704|NCT03054337|AKB-6548
816705|NCT03054337|hypoxia-inducible factor
816706|NCT03054337|HIF
816707|NCT03054337|hypoxia-inducible factor prolyl-hydroxylase inhibitor
816708|NCT03054337|HIF-PHI
816709|NCT03054337|Japan
816710|NCT03054337|Japanese
816711|NCT03054324|Cardiovascular Diseases
816712|NCT03054324|Fractional Flow Reserve
816713|NCT03054324|Ischemic Heart Disease
816714|NCT03054324|CT Angiogram
816715|NCT03054285|Seizures
816716|NCT03054285|Traumatic Brain Injury
816717|NCT03054285|Prophylaxis
816718|NCT03054285|Levetiracetam
816719|NCT03054272|High-fidelity simulation
816720|NCT03054272|Eye-tracking
816721|NCT03054272|Difficult intubation
816722|NCT03054233|spinal anesthesia
816723|NCT03054233|spinal-bone contact
816724|NCT03054233|caesarian section
816725|NCT03054233|crossed leg sitting position
816726|NCT03054194|Healthy participants
816727|NCT03054194|E2730
816728|NCT03054194|Pharmacokinetics
816729|NCT03054181|Observational
816730|NCT03054181|Infection
816731|NCT03054181|Utilisation
816732|NCT03054181|Safety
816733|NCT03054181|Tolerability
816734|NCT03054181|Infusion
816735|NCT03054181|chronic
816736|NCT03054168|Protein Synthesis
816737|NCT03054168|Hypertrophy
816738|NCT03054168|Testosterone
816739|NCT03054155|hidradenitis suppurativa
816740|NCT03054155|hidradenitis
816741|NCT03054155|laser
816742|NCT03054103|ketamine
816743|NCT03054103|midazolam
816744|NCT03054103|sedation
816745|NCT03054090|Cardiovascular Diseases
816746|NCT03054090|Primary Care
816747|NCT03054077|pre-procedural anxiety
816748|NCT03054077|children
816749|NCT03054077|pediatric sedation
816750|NCT03054051|HIV prevention
816751|NCT03054051|Preadolescence
816752|NCT03054051|Mobile phone game
816753|NCT03054051|Feasibility
816754|NCT03054012|CAD-CAM software
816755|NCT03054012|accuracy
816756|NCT03054012|head and neck region
816757|NCT03054012|mandibular reconstruction
816758|NCT03053999|Multiple Endocrine Neoplasia
816759|NCT03053999|Pancreatic Neuroendocrine Tumors
816760|NCT03053999|Hyperparathyroidism
816761|NCT03053999|HPTH
816762|NCT03053999|PNET
816763|NCT03053999|Biomarkers
816764|NCT03053999|Parathyroidectomy
816765|NCT03053999|Genome sequencing
816766|NCT03053999|Data review
816767|NCT03053973|COPD
816768|NCT03053973|airway inflammation
816769|NCT03053973|airway remodeling
816770|NCT03053973|health-related auality of life
816771|NCT03053973|forced expiratory volume 1 second
816772|NCT03053947|Intranasal Ketamine
816773|NCT03053947|Pain Management
816775|NCT03053921|gingival recession
816776|NCT03053921|Zuchellis technique,
816777|NCT03053921|placental membrane
816778|NCT03053908|Orexin
816779|NCT03053908|Cognitive Behavioral Therapy (CBT)
816780|NCT03053882|mouth wash , green tea , peppermint , bad breath
816781|NCT03053856|stage IIIA non-small cell lung cancer
816782|NCT03053856|Adjuvant pembrolizumab
816783|NCT03053843|Atrial fibrillation
816784|NCT03053843|Mediterranean Diet
816785|NCT03053843|Extra Virgin Olive Oil
816786|NCT03053843|Ablation
816787|NCT03053830|Ketamine
816788|NCT03053830|Major Depressive Disorder
816789|NCT03053804|MR/PET
816790|NCT03053804|Non-small cell lung cancer (NSCLC)
816791|NCT03053791|Deep brain stimulation
816792|NCT03053791|DBS
816793|NCT03053791|Spinal cord injury
816794|NCT03053791|SCI
816795|NCT03053791|Paraplegia
816796|NCT03053791|Mesencephalic locomotor region
816797|NCT03053791|MLR
816798|NCT03053791|Pedunculopontine nucleus
816799|NCT03053791|PPN
816800|NCT03053778|Readmission
816801|NCT03053778|Early follow-up
816802|NCT03053778|Heart valves
816803|NCT03053778|Heart valve surgery
816804|NCT03053739|Systemic sclerosis, Associated Pulmonary Arterial Hypertension
816805|NCT03053726|Variable Frequency Stimulation
816806|NCT03053713|Mediterranean diet pattern
816807|NCT03053713|nutrition
816808|NCT03053713|diet intervention
816809|NCT03053713|disease activity
816810|NCT03053713|intestinal microbiome
816811|NCT03053713|inflammatory bowel disease
816812|NCT03053700|Rosacea, Bromonidine, intensed pulse light
816813|NCT03053661|Head and Neck Squamous Cell Carcinoma
816814|NCT03053661|cancer-specific immunity
816815|NCT03053661|cancer immunology
816816|NCT03053661|cancer-testis antigens
816817|NCT03053661|human papilloma virus
816818|NCT03053661|immune modulatory cells
816819|NCT03053648|Insomnia
816820|NCT03053648|Randomized controlled trial
816821|NCT03053648|Acupressure
816822|NCT03053648|Self-help
816823|NCT03053635|Photodynamic Therapy
816824|NCT03053635|Non-muscle invasive bladder cancer (NMIBC)
816825|NCT03053635|Urothelial carcinoma
816826|NCT03053635|Ta bladder cancer
816827|NCT03053635|T1 bladder cancer
816828|NCT03053635|Refractory to BCG
816829|NCT03053609|gastroesophageal reflux
816830|NCT03053609|apnea
816831|NCT03053609|bradycardia
816832|NCT03053609|desaturation
816833|NCT03053609|impedance
816834|NCT03053596|HCC
816835|NCT03053596|LifePearl
816836|NCT03053583|larynx, laryngoscopy
816837|NCT03053583|vocal cords, laryngoscopy
816838|NCT03053583|airway
816839|NCT03053583|pediatric
816840|NCT03053570|Cryoballoon
816841|NCT03053570|Contact Force
816842|NCT03053570|Persistent Atrial Fibrillation
816843|NCT03053557|mental health consumers
816844|NCT03053544|rectal cancer
816845|NCT03053544|adenocarcinoma of the rectum
816846|NCT03053544|node positive rectal tumors
816847|NCT03053544|metformin
816848|NCT03053544|neoadjuvant chemoradiation
816849|NCT03053518|Type 2 Diabetes
816850|NCT03053518|Hyperglycemia
816851|NCT03053518|Personal Nutrition Project
816852|NCT03053505|fecal microbiota transplantation (FMT)
816853|NCT03053505|Clostridium difficile infection
816854|NCT03053505|gut flora
816855|NCT03053505|human microbiome
816856|NCT03053505|colitis
816857|NCT03053492|Video Games
816858|NCT03053479|surgery
816859|NCT03053479|native tissue prolapse repair
816860|NCT03053479|laparoscopic sacrocolpopexy
816861|NCT03053479|vaginal mesh
816862|NCT03053466|Advanced Solid Tumor
816863|NCT03053466|Relapsed Solid Tumor
816864|NCT03053466|Recurrent Solid Tumor
816865|NCT03053453|Total Knee Replacement Arthroplasty
816866|NCT03053427|Restless Legs Syndrome
816867|NCT03053427|Gabapentin enacarbil
816868|NCT03053401|Quadriceps muscle strength
816869|NCT03053401|Anterior cruciate ligament repair
816870|NCT03053401|Femoral nerve block
816871|NCT03053401|Adductor Canal block
816872|NCT03053401|Saphenous nerve block in the Adductor Canal
816873|NCT03053401|Pediatrics
816874|NCT03053401|Postoperative analgesia
816875|NCT03053401|Ultrasound guided nerve block
816876|NCT03053323|Preconception
816877|NCT03053323|Pregnancy
816878|NCT03053323|Lifestyle
816879|NCT03053310|surgery
816880|NCT03053310|curative intent
816881|NCT03053310|geriatric assessment
816882|NCT03053310|30-day postoperative morbidity
816911|NCT03053271|Endogenous Cushing's Syndrome
816912|NCT03053271|ATR-101
816913|NCT03053271|CS
816914|NCT03053245|Collaborative Care Model
816915|NCT03053245|Intensive Care Unit
816920|NCT03053180|Ombitasvir
816921|NCT03053180|Dasabuvir
816922|NCT03053180|Hepatitis
816923|NCT03053180|Chronic Hepatitis C genotype 1b (GT1b)
816924|NCT03053180|Paritaprevir
816925|NCT03053180|Cirrhosis
816926|NCT03053180|Compensated liver cirrhosis
816927|NCT03053180|Ribavirin free
816928|NCT03053180|Ritonavir
816929|NCT03053167|Raltitrexed
816930|NCT03053167|Irinotecan
816931|NCT03053167|Second-line Treatment
816932|NCT03053167|Advanced Colorectal Cancer(ACC)
816933|NCT03053154|Pelvic Inclination
816934|NCT03053154|Sit to Stand
816935|NCT03053154|Stroke
816936|NCT03053154|Anterior pelvic tilt
816937|NCT03053154|Posterior pelvic tilt
816938|NCT03053128|cardiac ischemia
816939|NCT03053102|PNH
816940|NCT03053102|Paroxysmal
816941|NCT03053102|Hemoglobinuria
816942|NCT03053089|MPS I; Hurler Syndrome
816943|NCT03053076|cord blood mononuclear cells
816944|NCT03053076|safety
816945|NCT03053076|effect
816946|NCT03053076|neonates
816947|NCT03053037|apical size
816948|NCT03053037|root canal treatment success
816949|NCT03053037|micro biome analysis
816950|NCT03053037|pulp necrosis
816951|NCT03052985|medical devices (meshes)
816952|NCT03052985|surgery
816953|NCT03052946|fecal incontinence, anorectal manometry, bulking agents
816954|NCT03052933|copanlisib
816955|NCT03052933|gemcitabine
816956|NCT03052933|peripheral T-cell lymphoma
816957|NCT03052933|extranodal NK/T-cell lymphoma
816958|NCT03052920|cochlear implant
816959|NCT03052920|asymmetric hearing loss
816963|NCT03052855|Psychiatry
816964|NCT03052855|Suicidal behaviour
816965|NCT03052855|Cerebral metabolites
816966|NCT03052855|MRI
816967|NCT03052855|Inflammatory markers
816970|NCT03052738|central nervous system (brain or spinal) tumor
816971|NCT03052712|Disorders of socio-emotional
816972|NCT03052712|Alzheimer
816973|NCT03052712|frontal temporal dementia
816974|NCT03052712|Parkinson
816975|NCT03052712|Huntington
816976|NCT03052712|traumatic brain injury
816977|NCT03052712|stroke
816978|NCT03052712|focal lesions
816979|NCT03052699|Complications; Cesarean Section
816980|NCT03052686|Uterine rupture
816981|NCT03052673|ketamine
816982|NCT03052673|fentanyl
816983|NCT03052673|postoperative pain
816984|NCT03052660|Midazolam
816985|NCT03052660|Anxiety
816986|NCT03052660|Clinical trial
816987|NCT03052660|Patient Satisfaction
816988|NCT03052647|dermaclip
816989|NCT03052647|subcuticular
816990|NCT03052647|cesarean section
816991|NCT03052647|staples
816992|NCT03052647|adhesive latch
816993|NCT03052647|rousseau
816994|NCT03052608|ALK; anaplastic lymphoma kinase; Non-Small-Cell Lung cancer; NSCLC
816995|NCT03051581|Lymphoma, T-Cell, Peripheral
816996|NCT03051581|Positron-Emission Tomography
816997|NCT03051581|Prognosis
816998|NCT03051568|Lymphoma, T-Cell, Peripheral
816999|NCT03051568|Positron-Emission Tomography
817000|NCT03051568|Prognosis
817001|NCT03051555|Lymphoma, Extranodal NK-T-Cell
817002|NCT03051555|Positron-Emission Tomography
817003|NCT03051555|Prognosis
817004|NCT03051542|Lymphoma, Extranodal NK-T-Cell
817005|NCT03051542|Positron-Emission Tomography
817006|NCT03051542|Prognosis
817007|NCT03051451|Hydrochloride of Metformin / Fluoxetine
817008|NCT03051451|Placebo
817009|NCT03051451|Obesity
817010|NCT03051425|Probiotics
817011|NCT03051425|Immune function
817012|NCT03051425|Natural killer cell activity
817013|NCT03051425|Interleukin-12
817014|NCT03051425|Interferon-gamma
817015|NCT03051425|Immunoglobulin
817016|NCT03051399|Constipation
817017|NCT03051399|Gastrointestinal symptoms of discomfort
817018|NCT03051399|Quality of life
817019|NCT03051399|Saccharomyces cerevisiae
817020|NCT03051399|Gut microbiome
817021|NCT03052556|cystic Fibrosis
817022|NCT03052556|cervical cancer
817023|NCT03052556|screening
817024|NCT03052556|human papilloma virus (HPV)
817025|NCT03052556|pap smear test
817026|NCT03052517|Asthma, QAW039
817027|NCT03052465|Motility
817028|NCT03052413|thinning hair
817029|NCT03052413|female pattern hair loss
817030|NCT03052400|type 2 diabetes mellitus
817031|NCT03052400|insulin resistance
817032|NCT03052400|mifepristone
817033|NCT03052400|glucocorticoids
817034|NCT03052374|Video-Feedback Interaction Guidance
817035|NCT03052374|Depressed Mothers and their Infants
817036|NCT03052361|Children
817037|NCT03052361|emergency department
817038|NCT03052361|ondansetron
817039|NCT03052348|Topical Antibiotics
817040|NCT03052348|Supiroban
817041|NCT03052348|Atopic Dermatitis
817042|NCT03052348|Eczema
817043|NCT03052335|colorectal cancer
817044|NCT03052335|screening
817045|NCT03052335|colon capsule
817046|NCT03052335|colonoscopy
817047|NCT03052283|Cystic fibrosis
817048|NCT03052283|Abdomen
817049|NCT03052283|Pancreas
817050|NCT03052283|Liver
817051|NCT03052283|Gut
817052|NCT03052283|Symptom Score
817053|NCT03052283|Patient reported outcome measure (PROM)
817054|NCT03052257|Glaucoma
817055|NCT03052257|Disease management
817056|NCT03052257|Smart bottle
817057|NCT03052244|tDCS (trans cranial direct current stimulation)
817058|NCT03052244|Visual illusion
817059|NCT03052244|Neuropathic pain
817060|NCT03052244|Spinal cord Injury
817061|NCT03052231|adherence
817062|NCT03052231|cystic fibrosis
817063|NCT03052218|children
817064|NCT03052218|pain
817065|NCT03052218|Cytochrome P450 CYP2D6 genotype
817066|NCT03052218|Cytochrome P450 CYP2D6 phenotype
817067|NCT03052218|Pupillometry
817068|NCT03052127|Uveal melanoma
817069|NCT03052127|Eye cancer
817070|NCT03052127|Ocular melanoma
817071|NCT03052127|Choroidal melanoma
817072|NCT03052114|Electrical Impedance Tomography
817073|NCT03052114|EIT
817074|NCT03052114|Stroke
817075|NCT03052114|Craniocerebral Injury
817076|NCT03052114|Head Injury
817077|NCT03052101|PLCH
817078|NCT03052101|Air travel
817079|NCT03052101|pneumothorax
817080|NCT03052101|pleurodesis
817081|NCT03052075|Primary Hyperparathyroidism
817082|NCT03052075|Parathyroidectomy
817083|NCT03052075|Bone mineral density
817084|NCT03052075|BMD
817085|NCT03052075|Data Review
817086|NCT03052049|Prostate Artery Embolization
817087|NCT03052036|Acute Coronory Syndrome
817088|NCT03052023|dual approach
817089|NCT03052023|laparoscopic hernioplasty
817090|NCT03052010|HIV-1 serodiscordant couples
817091|NCT03052010|PrEP as Bridge to ART
817092|NCT03051919|Laparoscopic sleeve gastrectomy
817093|NCT03051919|reinforcement
817094|NCT03051919|leak
817095|NCT03051906|Carcinoma, squamous cell
817096|NCT03051906|Head and Neck Neoplasms
817097|NCT03051906|Radiotherapy
817098|NCT03051906|Immunotherapy
817099|NCT03051880|Epidermal Growth Factor
817100|NCT03051854|Violence
817101|NCT03051854|Children
817102|NCT03051854|Prevalence
817103|NCT03051854|Abuse
817104|NCT03051854|Prevention
817105|NCT03051828|fencing, cancer
817106|NCT03051815|obstructive sleep apnea
817107|NCT03051802|Endoscopy
817108|NCT03051802|HDR Brachytherapy
817109|NCT03051802|navigation
817110|NCT03051789|Menstrual hygiene management
817111|NCT03051789|Sexual and Reproductive Health
817112|NCT03051789|Adolescent schoolgirls
817113|NCT03051789|School dropoout
817114|NCT03051789|sub-Saharan Africa
817115|NCT03051789|Kenya
817116|NCT03051776|Compression garments
817117|NCT03051776|Kinesio Taping
817118|NCT03051776|Breast Cancer-Related Lymphedema
817119|NCT03051763|pulmonary hypertension
817120|NCT03051763|commercial air travel
817121|NCT03051750|Breast Cancer-Related Lymphedema
817122|NCT03051750|Complex Physical Therapy
817123|NCT03051750|Pressotherapy
817124|NCT03051750|Kinesio Taping
817125|NCT03051750|Physiotherapy
817126|NCT03051750|Manual Lymph Drainage
817127|NCT03051750|Multilayer Bandage
817128|NCT03051750|TTDL questionnaire
817129|NCT03051737|Multi-scale
817130|NCT03051737|Prediction
817131|NCT03051737|Patient Flow
817132|NCT03051737|Emergency Department
817133|NCT03051737|Hospitalization
817134|NCT03051737|Ile-de-France
817135|NCT03051724|OSA
817136|NCT03051724|CPAP management
817137|NCT03051724|Telemedicine
817138|NCT03051698|C1-inhibitor
817139|NCT03051698|house dust mite
817140|NCT03051698|complement system
817141|NCT03051672|Breast Cancer
817142|NCT03051659|Breast Cancer
817143|NCT03051646|Exercise
817144|NCT03051646|Time to Exhaustion
817148|NCT03051607|Motor Fluctuations
817149|NCT03051607|Off time
817150|NCT03051607|On time
817151|NCT03051607|Dyskinesia
817152|NCT03051360|aortic valve stenosis
817153|NCT03051360|PCSK9 inhibitor
817154|NCT03051308|Parathyroid cell viability
817155|NCT03051308|Ischemia
817156|NCT03051308|Parathyroid allotransplantation
817157|NCT03051308|Vitamin D Receptor
817158|NCT03051308|Calcium Sensing Receptor
817159|NCT03051295|Communication Barriers
817160|NCT03051295|Persuasive Communication
817161|NCT03051295|Risk
817162|NCT03051269|Electroporation
817163|NCT03051269|Calcium
817164|NCT03051269|Head and Neck cancer
817165|NCT03051256|REL-1017
817166|NCT03051256|d-Methadone
817167|NCT03051256|Methadone
817168|NCT03051256|Depression
817169|NCT03051256|Refractory Depression
817170|NCT03051256|Antidepressant
817171|NCT03051256|Adjunctive Treatment
817172|NCT03051256|NMDA Receptor Antagonist
817173|NCT03051256|Excitatory Amino Acid Antagonist
817174|NCT03051256|Glutamate Antagonist
817175|NCT03051230|Blood Coagulation Disorders
817176|NCT03051230|Cell-Derived Microparticles
817177|NCT03051230|Superovulation
817178|NCT03051230|Fertilization in Vitro
817179|NCT03051230|Biomarkers
817180|NCT03051217|Psoriasis
817181|NCT03051217|PSO
817182|NCT03051217|Chronic plaque psoriasis
817183|NCT03051217|Certolizumb Pegol
817184|NCT03051217|Cimzia
817185|NCT03051217|Generalized pustular psoriasis and erythrodermic psoriasis
817186|NCT03051191|atherosclerotic cardiovascular diseases
817187|NCT03051191|nonischemic heart failure
817188|NCT03051191|cancer
817189|NCT03051165|Cardiovascular Disease
817190|NCT03051165|Pulmonary Medicine
817191|NCT03051165|Hypoglossal Nerve Stimulation
817192|NCT03051139|Implementation Science
817193|NCT03051139|Low Tidal Volume Ventilation (LTVV)
817194|NCT03051126|Parathyroid disease
817195|NCT03051126|Parathyroid Tissue Bank
817196|NCT03051126|Database
817197|NCT03051126|Blood samples
817198|NCT03051100|hyperlididemia
817199|NCT03051100|LDL
817200|NCT03051100|cholesterol
817203|NCT03051061|Atrial Fibrillation
817204|NCT03051061|Coronary Heart Disease
817205|NCT03051061|antithrombotic treatment
817206|NCT03051061|clinical prognosis
817207|NCT03051048|Acute Myocardial Infarction
817208|NCT03051035|non-hematological malignancies
817209|NCT03051035|non-squamous
817210|NCT03051035|squamous
817211|NCT03051035|BRAF
817212|NCT03051035|KRAS
817213|NCT03051035|NRAS
817214|NCT03051022|Bupivacaine
817215|NCT03051022|adjuvant
817216|NCT03051022|regional anesthesia
817217|NCT03051022|dexamethasone
817218|NCT03051022|morphine
817219|NCT03050983|Respiratory Compromise
817220|NCT03050970|minor head trauma
817221|NCT03050970|child
817222|NCT03050970|age less than 2 years
817223|NCT03050970|Clinically-important traumatic brain injury (ciTBI)
817224|NCT03050970|Computed tomography scan
817225|NCT03050970|Radiation exposure from CT scans
817226|NCT03050944|Fertility
817227|NCT03050944|Infertility
817228|NCT03050944|Dietary Patterns
817229|NCT03050944|Mediterranean diet
817230|NCT03050944|Adiponectin
817231|NCT03050944|Follistatin
817232|NCT03050944|Assisted Reproduction
817233|NCT03050944|In Vitro Fertilization
817234|NCT03050944|Semen quality
817235|NCT03050944|Diet
817236|NCT03050944|IVF
817237|NCT03050931|Electrical Impedance Tomography
817238|NCT03050931|EIT
817239|NCT03050931|Epilepsy
817240|NCT03050879|Stomach Neoplasms
817241|NCT03050879|Indocyanine Green Tracer
817242|NCT03050879|Laparoscopic Gastrectomy
817243|NCT03050879|Lymph Node Dissection
817244|NCT03050866|Androgen Receptor
817245|NCT03050866|AR-V7
817246|NCT03050866|Predictive Factor
817247|NCT03050814|Anti-PDL1 Antibody
817248|NCT03050814|Therapeutic Cancer Vaccine
817249|NCT03050814|Mismatch Repair Deficiency
817250|NCT03050814|Progression Free Survival
817251|NCT03050814|Adenovirus Based, CEA-Targeting Vaccine
817252|NCT03050801|Explicit Memory
817253|NCT03050801|Implicit Memory
817254|NCT03050801|Memory Disorder
817255|NCT03050788|Smartphone confocal microscopy
817256|NCT03050788|Kaposi Sarcoma
817257|NCT03050788|Point of care diagnosis
817258|NCT03050762|Endocrine Disease
817259|NCT03050762|Thyroid disease
817260|NCT03050762|Parathyroid disease
817261|NCT03050762|Adrenal disease
817262|NCT03050762|Data Review
817263|NCT03050762|Database
817264|NCT03050736|Glioma
817265|NCT03050736|Glioblastoma
817266|NCT03050736|Glioblastoma multiforme
817267|NCT03050736|GBM
817268|NCT03050736|brain tumor
817269|NCT03050736|brain cancer
817270|NCT03050632|working memory
817271|NCT03050632|adherence
817272|NCT03050606|Exercise Therapy
817273|NCT03050606|Exercise Movement Techniques
817274|NCT03050606|Pilates-Based Exercises
817275|NCT03050606|Cost-effectiveness
817276|NCT03050593|HFpEF
817277|NCT03050593|HFrEF
817278|NCT03050580|Abused women
817279|NCT03050580|treatment group
817280|NCT03050580|family violence
817281|NCT03050567|Microemboli
817282|NCT03050554|cancer
817283|NCT03050554|Non-Small Cell Lung Cancer
817284|NCT03050554|SBRT
817285|NCT03050554|Avelumab
817286|NCT03050554|Stereotactic Body Radiation Therapy
817287|NCT03050554|radiation
817288|NCT03050554|NSCLC
817289|NCT03050554|PD-1
817290|NCT03050554|PD-L1
817291|NCT03050554|Immunotherapy
817292|NCT03050554|Lung
817293|NCT03050541|MDMA
817294|NCT03050541|adult
817295|NCT03050528|Acceptance and Commitment Therapy
817296|NCT03050528|Exercise
817297|NCT03050528|Psychology
817298|NCT03050528|Psychological therapy
817299|NCT03050528|Physiotherapy
817300|NCT03050528|Physical therapy
817301|NCT03050502|Hemothorax
817302|NCT03050502|Management
817303|NCT03050489|CABG
817304|NCT03050489|Off-Pump CABG
817305|NCT03050489|On-Pump CABG
817306|NCT03050489|ischemic-reperfusion injury during CABG
817307|NCT03050489|comparison of On- and Off- Pump CABG
817308|NCT03050489|Ischemic Heart Disease
817309|NCT03050489|Myocardial ischemia-reperfusion and myeloperoxidase
817310|NCT03050489|Myocardial ischemia-reperfusion biomarkers
817311|NCT03050476|side-effects
817312|NCT03050476|heart-lung machine
817313|NCT03050476|alkaline phosphatase
817314|NCT03050437|Failed in First Line EGFR-TKI
817315|NCT03050437|EGFR Activating Mutation
817316|NCT03050437|Pemetrexed
817317|NCT03050424|COPD
817318|NCT03050424|Iron
817319|NCT03050424|Exercise Capacity
817320|NCT03050424|Non-anaemic iron deficiency
817321|NCT03050411|Non Small Cell Lung Cancer
817322|NCT03050411|EGFR-TKI resistance
817323|NCT03050411|Apatinib
817324|NCT03050411|anti-angiogenesis drugs
817325|NCT03050398|HR-positive
817326|NCT03050398|HER2-negative
817327|NCT03050398|Advanced breast cancer
817328|NCT03050398|LEE011
817329|NCT03050398|ribociclib
817330|NCT03050398|letrozole
817331|NCT03050398|femara
817332|NCT03050398|CDK
817333|NCT03050398|CDK4
817334|NCT03050398|CDK6
817335|NCT03050398|CDK4/6
817336|NCT03050398|CDK4/6 inhibitor
817337|NCT03050398|Phase III
817338|NCT03050398|Phase IIIb
817339|NCT03050398|ER-positive
817340|NCT03050398|PR-positive
817341|NCT03050398|Postmenopausal
817342|NCT03050398|Premenopausal
817343|NCT03050398|Men
817344|NCT03050385|cognitive rehabilitation
817345|NCT03050359|Drug therapy
817346|NCT03050359|Gastrointestinal Diseases
817347|NCT03050359|Digestive System Diseases
817348|NCT03050359|Lansoprazole
817349|NCT03050359|Anti-Ulcer Agents
817350|NCT03050359|Gastrointestinal Agents
817351|NCT03050359|Proton Pump Inhibitors
817352|NCT03050359|Enzyme Inhibitors
817353|NCT03050359|Molecular Mechanisms of Pharmacological Action
817361|NCT03050320|Resilience
817362|NCT03050320|Exercise in the workplace
817363|NCT03050307|Drug therapy
817364|NCT03050268|Familial cancer
817365|NCT03050268|Genetic predisposition
817366|NCT03050268|Heritable disease
817367|NCT03050268|Cancer risk
817368|NCT03050268|Genome analysis
817369|NCT03050268|Genetic modifiers
817370|NCT03050268|Next generation sequencing (NGS)
817371|NCT03050268|Genetic counseling
817372|NCT03050268|DNA
817373|NCT03050255|supplemental oxygen
817374|NCT03050255|walking capacity
817375|NCT03050255|exercise capacity
817376|NCT03050255|endurance shuttle walk test
817377|NCT03050190|4s CAR-T
817378|NCT03050190|CD19
817379|NCT03050190|B cell leukemia
817380|NCT03050190|B-ALL
817381|NCT03050177|Bioequivalence Study
817382|NCT03050138|Postthrombotic Syndrome
817383|NCT03050138|Venous Thrombosis
817384|NCT03050138|Quality of Life
817385|NCT03050138|Hemorrhage
817386|NCT03050138|Recurrence
817387|NCT03050112|MacNew questionnaire
817388|NCT03050112|Quality of life
817389|NCT03050034|Wireless monitoring system
817390|NCT03050034|Acute Medicine
817391|NCT03050034|Poly-pathological patients
817392|NCT03050034|Internal Medicine core competencies
817393|NCT03050034|Acute Complex Care Model
817394|NCT03050021|Delirium
817395|NCT03050021|Intensive care unit
817396|NCT03050008|Cataract Surgery
817397|NCT03049995|effectiveness; imaging; prognosis; stress echocardiography
817398|NCT03049982|Oral appliance therapy
817399|NCT03049969|Working Memory
817400|NCT03049969|Cognitive Training
817401|NCT03049969|Transcranial Magnetic Stimulation
817402|NCT03049956|Ocular Vestibular Evoked Myogenic Potentials
817403|NCT03049943|low level laser therapy
817404|NCT03049943|hyposalivation
817405|NCT03049930|Burns
817406|NCT03049930|Ketamine
817407|NCT03049930|Anesthesia
817408|NCT03049917|financial incentive
817409|NCT03049917|pediatric HIV testing
817410|NCT03049904|Indian, North America
817411|NCT03049904|Male, Two-Spirit
817412|NCT03049904|HIV Prevention
817413|NCT03049904|MSM
817414|NCT03049891|Antiretroviral Therapy
817415|NCT03049891|Retention
817416|NCT03049891|Loss to Follow Up
817417|NCT03049878|postoperative pain
817418|NCT03049878|paracetamol
817419|NCT03049878|codeine
817420|NCT03049878|tooth extractions
817421|NCT03049878|analgesia
817422|NCT03049878|premedication
817423|NCT03049826|nutrient
817428|NCT03049787|physical therapy
817429|NCT03049787|home exercise
817430|NCT03049787|adhesive capsulitis
817431|NCT03049748|Heart-Assist Devices, Self-care, Quality of Life
817432|NCT03049709|central blood pressure
817433|NCT03049709|measurement
817434|NCT03049709|oscillometric radial pulse wave analysis
817435|NCT03049696|Roux-En-Y Gastric Bypass
817436|NCT03049696|Bariatric Surgery
817437|NCT03049696|Pre-Operative Physical Activity and Education Program
817438|NCT03049696|Obesity
817439|NCT03049696|Exercise
817440|NCT03049696|Behaviour Modification
817441|NCT03049696|Surgical Outcomes
817442|NCT03049696|Quality of Life
817443|NCT03049683|Vestibular evoked myogenic potentials
817444|NCT03049670|Safety Issue
817445|NCT03049644|chronic lower back pain
817446|NCT03049644|Manual Therapy
817447|NCT03049644|Mechanical Diagnosis and Treatment
817448|NCT03049631|Pre-diabetes
817449|NCT03049631|red raspberry
817450|NCT03049631|fructooligosaccharide
817451|NCT03049631|metagenomics
817452|NCT03049631|polyphenol bioavailability
817453|NCT03049631|glycemic response
817454|NCT03049631|insulin response
817455|NCT03049605|Neuropathies laser and magnetic therapy
817456|NCT03049592|Diabetes
817457|NCT03049592|Contraception
817458|NCT03049592|Prenatal Counseling
817459|NCT03049566|Bleeding
817460|NCT03049566|Adverse Cardiac Events
817461|NCT03049566|Adherence, Medication
817462|NCT03049566|Aspirin
817463|NCT03049566|Acetylsalicylic acid
817464|NCT03049553|Cervical screening
817465|NCT03049553|Human papillomavirus (HPV)
817466|NCT03049553|Cytology
817467|NCT03049553|HPV-test
817468|NCT03049553|Cervical intraepithelial neoplasia (CIN)
817469|NCT03049527|Chronic Kidney Disease
817470|NCT03049527|Unknown Origin
817471|NCT03049514|Thrombolysis
817472|NCT03049514|Recanalization
817473|NCT03049514|Dynamic retinal angiography
817474|NCT03049501|Alzheimer's caregivers
817475|NCT03049501|Technology-based intervention
817476|NCT03049501|Culturally-tailored intervention
817477|NCT03049488|Immune Response
817478|NCT03049488|Respiratory Syncytial Virus
817479|NCT03049488|Vaccine-Mediated Protection
817480|NCT03049488|Neutralizing Antibody
817481|NCT03049488|Antibody Response
817482|NCT03049475|Pain
817483|NCT03049475|Cell Free DNA
817484|NCT03049475|Inflammatory Markers
817485|NCT03049475|Microparticles
817486|NCT03049475|NETosis
817487|NCT03049462|Brown Adipose Tissue
817488|NCT03049462|Energy Expenditure
817489|NCT03049462|Energy Metabolism
817490|NCT03049462|Obesity
817496|NCT03049436|Physical activity
817497|NCT03049436|cancer
817498|NCT03049436|chemotherapy
817499|NCT03049436|daily care unit
817500|NCT03049410|Cystectomy
817501|NCT03049332|Quality of Life
817502|NCT03049306|Obstructive sleep apnea
817503|NCT03049306|CPAP
817504|NCT03049306|Propranolol
817505|NCT03049306|Metabolism
817506|NCT03049293|COPD,IVF
817507|NCT03048240|Glioblastoma
817508|NCT03048227|TIDM
817509|NCT03048227|Type1diabetes
817510|NCT03048227|Implantable Pump
817511|NCT03048227|CGM
817512|NCT03048214|Nerve block; Infraclavicular; Acute pain
817513|NCT03048201|Physica KR
817514|NCT03048201|Physica CR
817515|NCT03048201|Physica PS
817516|NCT03048201|Kinematic Retaining
817517|NCT03048201|Cruciate Retaining
817518|NCT03048201|Posterior Stabilized
817519|NCT03048201|Physica System
817520|NCT03048175|C-reactive protein
817521|NCT03048175|Systemic inflammation
817522|NCT03048175|Third molar
817523|NCT03048175|Wisdom tooth
817524|NCT03048149|hazelnut allergy
817525|NCT03048123|Hepatic arterial infusion chemotherapy
817526|NCT03048123|Transarterial Chemoembolization
817527|NCT03048123|Large and unresectable HCC
817528|NCT03048071|Contegra
817529|NCT03048071|Homograft
817530|NCT03049267|acne inversa
817531|NCT03049241|Children
817532|NCT03049241|Neuromuscular fatigue
817533|NCT03049241|Muscle group
817534|NCT03049241|Magnetic Nerve stimulation
817535|NCT03049241|Muscle length
817536|NCT03049241|Stiffness
817537|NCT03049241|prepubertal children
817538|NCT03049241|adults
817539|NCT03049228|Spectrum Analysis
817540|NCT03049228|Mitochondria
817541|NCT03049228|Peroxisome Proliferator-Activated Receptors
817542|NCT03049228|Respirometry
817543|NCT03049228|Human
817544|NCT03049228|Heart
817545|NCT03049189|non-functional and functional P-NET
817546|NCT03049189|non-functional GE-NET
817547|NCT03049176|HIV-discordant couple
817548|NCT03049176|ART
817549|NCT03049176|PrEP
817550|NCT03049176|semen washing
817551|NCT03049176|artificial vaginal insemination
817552|NCT03049176|safer conception
817553|NCT03049176|pregnancy
817554|NCT03049150|Urine
817555|NCT03049150|Mass Spectometry
817556|NCT03049150|Observational
817557|NCT03049124|Exercise
817558|NCT03049124|Feasibility trial
817559|NCT03049124|Cancer
817560|NCT03049124|Chemoradiation
817562|NCT03049098|Eye-tracking
817563|NCT03049098|High Fidelity Simulation Training
817564|NCT03049098|Visual Perception
817565|NCT03049085|OPCAB
817566|NCT03049085|ASA
817567|NCT03049085|Aspirin
817568|NCT03049020|pelvic organ prolapse
817569|NCT03049020|sacrocolpopexy
817570|NCT03049020|pelvic floor ultrasound
817571|NCT03049007|bereavement
817572|NCT03049007|natural grief
817573|NCT03049007|prolonged grief
817574|NCT03049007|complicated grief
817575|NCT03048994|Glutamine
817576|NCT03048994|Severe sepsis
817577|NCT03048981|Thrombocyte aggregation
817578|NCT03048981|Fish oil
817579|NCT03048981|Alternative medicine
817580|NCT03048981|Point of care testing
817581|NCT03048981|Coagulation monitoring
817582|NCT03048968|Exoskeleton Device
817583|NCT03048968|elderly
817584|NCT03048968|stroke
817585|NCT03048942|Breast cancer
817586|NCT03048942|HER2 negative
817587|NCT03048942|Cabazitaxel
817588|NCT03048942|Paclitaxel
817589|NCT03048942|Chemotherapy
817590|NCT03048916|dysphagia
817591|NCT03048916|stroke
817592|NCT03048916|magnetic resonance imaging
817593|NCT03048916|videofluoroscopy
817594|NCT03048903|Gastrointestinal dysfunction
817595|NCT03048903|sepsis
817596|NCT03048903|trauma
817597|NCT03048890|PAD
817598|NCT03048877|Radioactive iodine-refractory
817599|NCT03048877|differentiated thyroid cancer
817600|NCT03048877|Apatinib
817601|NCT03048877|anti-angiogenesis drugs
817602|NCT03048864|Metabolic Screening
817603|NCT03048864|24 hour urine
817604|NCT03048851|Cerebral palsy
817605|NCT03048851|sensory electrical stimulation
817606|NCT03048851|virtual reality constraint-induced therapy
817607|NCT03048812|Dental implant
817608|NCT03048812|Mandibular overdenture
817609|NCT03048812|Cross-over study
817610|NCT03048786|Peer mentoring
817611|NCT03048786|social support
817612|NCT03048786|text messaging
817613|NCT03048786|smoking cessation
817614|NCT03048773|shockwave therapy
817615|NCT03048773|knee osteoarthritis
817616|NCT03048760|MRI scan
817617|NCT03048760|Organs at Risk
817618|NCT03048708|Bariatric surgery
817619|NCT03048708|Leptin
817620|NCT03048708|Thyroid function tests
817621|NCT03048617|Primary Mitochondrial Disease
817622|NCT03048617|Stealth
817623|NCT03048617|Myopathy
817624|NCT03048617|exercise intolerance
817625|NCT03048617|muscle pain
817626|NCT03048617|Mitochondrial Myopathy
817627|NCT03048617|Primary Mitochondrial Myopathy
817628|NCT03048578|Roux-en-Y gastric bypass (RYGB)
817629|NCT03048565|mindfulness
817630|NCT03048565|caregivers
817631|NCT03048552|drug use
817632|NCT03048552|drug addiction
817633|NCT03048552|drug habituation
817634|NCT03048552|drug use disorders
817635|NCT03048552|organic mental disorders
817636|NCT03048552|substance-induced
817637|NCT03048552|substance abuse
817638|NCT03048552|substance addiction
817639|NCT03048552|substance dependence
817640|NCT03048552|substance use disorders
817641|NCT03048539|Endoscopic surgery
817642|NCT03048539|Thyroidectomy
817643|NCT03048539|Quality of life
817644|NCT03048513|Melioidosis
817645|NCT03048513|Head and Neck
817646|NCT03048513|Clinical
817647|NCT03048474|progressive disease after at least 1 course of chemotherapy
817648|NCT03048448|Hepatic impairment,
817649|NCT03048448|Fevipiprant,
817650|NCT03048448|adults,
817651|NCT03048448|pharmacokinetics
817657|NCT03048383|Facial paralysis
817658|NCT03048383|Facial synkinesis
817659|NCT03048383|Botulinum toxin
817663|NCT03048331|Functional Electrical Stimulation
817664|NCT03048331|Tetraplegia
817665|NCT03048331|Reconstructive Hand Surgery
817666|NCT03048292|Embolectomy
817667|NCT03048292|Embolus
817668|NCT03048292|Thrombectomy
817669|NCT03048292|Thrombolysis
817670|NCT03048292|Thrombus
817671|NCT03048292|Mobile
817672|NCT03048292|Interventional
817673|NCT03048292|Neurointervention
817674|NCT03048292|Stroke
817675|NCT03048292|Ischemic
817676|NCT03048292|Acute
817677|NCT03048292|Endovascular
817678|NCT03048292|Cerebrovascular
817679|NCT03048292|Clot
817680|NCT03048292|Stent Retriever
817681|NCT03048292|Tissue Plasminogen Activator
817682|NCT03048292|Drip and Ship
817683|NCT03048292|Mothership
817684|NCT03048292|Trip and Treat
817685|NCT03048279|Multiple Endocrine Neoplasia Syndromes
817686|NCT03048279|MEN1
817687|NCT03048279|MEN2
817688|NCT03048279|Relatives
817689|NCT03048279|Database
817690|NCT03048279|Questionnaires
817691|NCT03048279|Surveys
817692|NCT03048266|Multiple endocrine neoplasia
817693|NCT03048266|MEN1
817694|NCT03048266|Aggressive pancreatic neuroendocrine tumors
817695|NCT03048266|PNET
817696|NCT03048266|Non-aggressive pancreatic neuroendocrine tumors
817697|NCT03048266|Metabolomics
817698|NCT03048266|Genetics
817699|NCT03048266|Biomarkers
817700|NCT03048045|chronic periodontitis
817701|NCT03048045|aggressive periodontitis
817702|NCT03048045|supportive periodontal treatment
817703|NCT03048032|acute heart failure
817704|NCT03048032|right ventricular failure
817705|NCT03048032|cardiac biomarkers
817706|NCT03048032|echocardiography
817707|NCT03048032|diagnosis
817708|NCT03048032|prognosis
817709|NCT03047993|Myelodysplastic syndrome
817710|NCT03047993|MDS
817711|NCT03047993|Other diseases of blood and blood-forming organs
817712|NCT03047993|CB-839
817713|NCT03047993|Azacitidine
817714|NCT03047993|5-azacytidine
817715|NCT03047993|5-aza
817716|NCT03047993|Vidaza
817717|NCT03047993|5-AZC
817718|NCT03047993|AZA-CR
817719|NCT03047993|Ladakamycin
817720|NCT03047993|NSC-102816
817721|NCT03047993|Azacytidine
817722|NCT03047993|Pharmacokinetic testing
817723|NCT03047993|Pharmacodynamic testing
817724|NCT03047980|SWS
817725|NCT03047980|Cognitive impairment
817726|NCT03047980|sirolimus
817727|NCT03047915|Anxiety
817728|NCT03047915|Music intervention
817729|NCT03047915|Emergency department (ED)
817730|NCT03047902|Adolescent Smoking Cessation Asthma Carbon Monoxide.
817731|NCT03047876|cardiac
817732|NCT03047876|aortic arch surgery
817733|NCT03047876|Brain vascular reactivity
817734|NCT03047876|neonates
817735|NCT03047876|infants
817736|NCT03047863|Epidermal Growth Factor
817737|NCT03047850|Sternotomy
817738|NCT03047837|Colorectal cancer
817739|NCT03047837|aspirin
817740|NCT03047837|metformin
817741|NCT03047837|chemoprevention
817742|NCT03047798|centella asiatica
817743|NCT03047798|bamboo salt
817744|NCT03047798|magnolia bark
817745|NCT03047798|gingivitis
817746|NCT03047798|dental plaque
817747|NCT03047798|mouthrinse
817748|NCT03047785|Myocardial Infarction
817749|NCT03047785|Highly sensitive troponin
817750|NCT03047785|Hospital population
817751|NCT03047785|99th percentile
817752|NCT03047785|Upper limit of normal
817753|NCT03047733|Vitiligo
817754|NCT03047733|308 nm excimer laser
817755|NCT03047720|bedwetting
817756|NCT03047707|ultrasound elastography
817757|NCT03047707|S-Shearwave
817758|NCT03047707|liver
817759|NCT03047707|fibrosis
817760|NCT03047694|Lexico-semantic stimulation
817761|NCT03047694|tactile tablet
817762|NCT03047681|TAVR
817763|NCT03047681|tryptse
817764|NCT03047681|mast
817765|NCT03047642|biomarker
817766|NCT03047642|low and middle income countries
817767|NCT03047642|fever
817768|NCT03047642|antimicrobial resistance
817769|NCT03047642|diagnostic
817771|NCT03047603|Hepatocellular carcinoma
817772|NCT03047603|Protein induced by vitamin K absence or antagonist-II
817773|NCT03047603|Differential diagnosis
817774|NCT03047603|Des-γ-carboxy prothrombin
817775|NCT03047603|Alpha-fetoprotein
817776|NCT03047603|Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein-fetoprotein
817777|NCT03047590|exercise behavior
817778|NCT03047590|exercise prescription
817779|NCT03047590|affect-based exercise
817780|NCT03047590|affect-guided exercise
817781|NCT03047590|self-paced exercise
817782|NCT03047590|self-selected exercise
817783|NCT03047577|Brief intervention
817784|NCT03047577|Alcohol
817785|NCT03047577|Alcohol use disorder
817786|NCT03047577|Intensive care unit
817787|NCT03047577|Critically ill
817788|NCT03047577|Audit
817789|NCT03047564|Total Knee Arthroplasty
817790|NCT03047564|Total Knee Replacement
817791|NCT03047564|Outcome
817792|NCT03047564|Metal ion concentration
817793|NCT03047564|Results
817794|NCT03047551|Abortion, induced
817795|NCT03047551|Ultrasonography
817796|NCT03047551|Health Services accessibility
817797|NCT03047551|Pragmatic Clinical Trial
817798|NCT03047551|Randomized controlled trial as topic
817799|NCT03047538|Arterial hypertension
817800|NCT03047538|Dyslipidemia
817801|NCT03047538|Blood pressure control
817802|NCT03047538|Fixed combination
817803|NCT03047525|cytokine-induced killer cell
817804|NCT03047525|dendritic and cytokine-induced killer cells
817805|NCT03047512|Depression in adolescents
817806|NCT03047512|Mental Health
817807|NCT03047512|E-mental health
817808|NCT03047512|Prevention and Early intervention
817809|NCT03047486|insulin pump
817810|NCT03047486|continuous glucose monitoring sensor
817811|NCT03047486|predictive low glucose suspend
817812|NCT03047473|newly diagnosed
817813|NCT03047460|motor evoked potential
817814|NCT03047460|somatosensory evoked potentials
817815|NCT03047460|biomarker
817816|NCT03047408|REM Sleep Behavior Disorder
817817|NCT03047408|Parkinson's Disease
817818|NCT03047408|REM sleep without Atonia
817821|NCT03047369|leukodystrophy
817822|NCT03047369|white matter disease
817823|NCT03047369|leukoencephalopathy
817824|NCT03047369|myelin
817825|NCT03047369|demyelinating
817826|NCT03047369|mdbp
817827|NCT03047343|pulmonary artery strapping
817828|NCT03047330|menopause
817829|NCT03047330|sleep fragmentation
817830|NCT03047330|leuprolide
817831|NCT03047330|adipokine
817832|NCT03047330|weight gain
817833|NCT03047330|leptin
817835|NCT03047291|mucositis, periimplantitis, probiotic
817836|NCT03047226|Lynch Syndrome
817837|NCT03047226|mismatch repair
817838|NCT03047226|microsatellite instability
817839|NCT03047226|next-generation sequencing
817840|NCT03047226|immunohistochemistry
817841|NCT03047200|Diabetes Mellitus
817842|NCT03047200|Hypoglycemia
817843|NCT03047200|Hyperglycemia
817844|NCT03047200|Type 1 Diabetes
817845|NCT03047200|Islet Cell Transplantation
817846|NCT03047174|Head and Neck Neoplasms, Radio(chemo)therapy
817847|NCT03047161|magnetocardiography
817848|NCT03047135|high-risk biochemically-recurrent
817849|NCT03047122|Breast
817850|NCT03047122|ultrasonography
817851|NCT03047109|Ephedrine
817852|NCT03047109|Phenylephrine
817853|NCT03047109|Spinal Hypotension
817854|NCT03047109|Cesarean Section
817855|NCT03047109|Maternal Cardiodynamics
817856|NCT03047083|Retrospective
817857|NCT03047083|Non-interventional Study
817858|NCT03047083|FMS-like tyrosine kinase-3 (FLT3) mutations
817859|NCT03047044|lumbar fusion surgery
817860|NCT03047044|Patient Controlled Analgesia
817861|NCT03047044|Optimizing Basal Infusion Mode
817862|NCT03047018|Nutrition
817863|NCT03046992|EGFR
817864|NCT03046992|Non-Small Cell Lung Cancer
817865|NCT03046992|T790M
817866|NCT03046992|Brain Metastasis
817867|NCT03046979|apatinib
817868|NCT03046979|advanced hepatocellular carcinoma
817869|NCT03046953|Lymphoma
817870|NCT03046927|Type 1 diabetes
817871|NCT03046927|vitamin D
817872|NCT03046927|honeymoon phase
817873|NCT03046901|Vancomycin
817874|NCT03046901|Primary Sclerosing cholangitis
817875|NCT03046901|Post-liver transplantation
817876|NCT03046849|Lynch Syndrome
817877|NCT03046849|next-generation sequencing
817878|NCT03046849|germline mutation
817879|NCT03046836|Couples
817880|NCT03046836|Oxytocin
817881|NCT03046836|Aggression
817882|NCT03046836|Alcohol
817883|NCT03046771|falls
817884|NCT03046771|readmissions
817885|NCT03046771|emergency department visits
817886|NCT03046771|transitions of care
817887|NCT03046745|Gastric cancer, endoscopy, pepsinogen, TFF3, biomarker
817888|NCT03046732|Kidney Transplant Education
817889|NCT03046732|Transplant Readiness
817890|NCT03046732|Living Donor Kidney Transplant
817891|NCT03046732|Chronic Kidney Disease
817892|NCT03046732|End Stage Kidney Disease
817893|NCT03046732|Renal Replacement Therapy
817894|NCT03046719|bupivacaine
817895|NCT03046719|intravitreal
817896|NCT03046719|analgesia
817897|NCT03046719|silicone oil removal
817898|NCT03046719|retinal detachment
817899|NCT03046719|subconjunctival
817900|NCT03046706|voice rest
817901|NCT03046706|laryngeal surgery
817902|NCT03046706|glottic polyp
817903|NCT03046706|glottic cyst
817904|NCT03046693|Non-arteritic anterior ischemic optic neuropathy
817905|NCT03046693|pattern electroretinography
817906|NCT03046693|citicoline
817907|NCT03046693|retinal ganglion cell
817908|NCT03046693|visual field
817909|NCT03046667|Beta glucans
817910|NCT03046667|Barley
817911|NCT03046667|SCFA
817912|NCT03046667|Calprotectin
817913|NCT03046667|Microbiota
817914|NCT03046667|Hydrogene
817915|NCT03046667|Methane
817916|NCT03046667|Metabolomics
817917|NCT03046667|Stool volume
817918|NCT03046667|Stool frequency
817919|NCT03046641|Caloric Restriction
817920|NCT03046641|Dietary Formulations
817921|NCT03046641|Exercise
817922|NCT03046641|Men
817923|NCT03046615|EEG electrodes
817924|NCT03046563|acupressure
817925|NCT03046563|abdominal massage
817926|NCT03046563|constipation
817927|NCT03046563|stroke patients
817928|NCT03046563|Traditional Chinese medicine
817929|NCT03046524|Parathyroid Carcinoma
817930|NCT03046524|Parathyroid Neoplasm
817931|NCT03046524|Chart Review
817932|NCT03046485|AMD
817933|NCT03046485|vision loss
817934|NCT03046485|self-management strategies
817935|NCT03046485|low-vision rehabilitation
817936|NCT03046485|IVI
817937|NCT03046472|thorax curve angle
817941|NCT03046446|Osteoarthritis
817942|NCT03046446|Knee
817943|NCT03046446|Pain
817944|NCT03046446|Steroid
817945|NCT03046446|Intra-articular
817946|NCT03046446|Injection
817947|NCT03046433|children
817948|NCT03046433|asthma
817949|NCT03046433|China
817950|NCT03046394|prosthetic feet
817951|NCT03046394|gait pattern
817952|NCT03046394|one leg standing
817953|NCT03046394|walking speed
817954|NCT03046342|Gastroenteritis, Polymerase chain reaction
817955|NCT03046329|patient care planning
817956|NCT03046316|Therapeutics
817957|NCT03046303|ERAS,gastric cancer
817958|NCT03046264|central blood pressure
817959|NCT03046264|measurement
817960|NCT03046264|oscillometric radial pulse wave analysis
817961|NCT03046186|Gastric sleeve
817962|NCT03046186|Gastric bypass
817963|NCT03046160|PPT
817964|NCT03046160|Scapula
817965|NCT03046160|Intervention
817966|NCT03046160|Manual therapy
817967|NCT03046160|mobilization
817968|NCT03046121|dementia
817969|NCT03046121|acute care
817970|NCT03046121|post-acute recovery
817971|NCT03046121|family caregivers
817972|NCT03046095|Muscle Hypertrophy
817973|NCT03046095|Muscle Atrophy
817974|NCT03046095|Resistance Training
817975|NCT03046095|Immobilization
817976|NCT03046069|Triple therapy
817977|NCT03046069|COPD
817978|NCT03046069|DCE
817979|NCT03046069|Qualitative
817980|NCT03046004|breast cancer
817981|NCT03046004|screening
817982|NCT03046004|decision aid
817983|NCT03046004|informed choice
817984|NCT03046004|decisional conflict
817985|NCT03045965|Salpingectomy
817986|NCT03045965|Hysterectomy
817987|NCT03045965|Ovarian cancer
817988|NCT03045952|Multicenter study
817989|NCT03045952|microwave
817990|NCT03045939|cervical ripening
817991|NCT03045939|labor induction
817992|NCT03045939|double balloon device
817993|NCT03045939|cervical ripening device
817994|NCT03045939|unfavorable cervix
817995|NCT03045913|Observational registry
817996|NCT03045913|All-comers open label registry
817997|NCT03045913|Genoss DES
817998|NCT03045913|Multicenter
817999|NCT03045913|Stenting
818000|NCT03045913|Coronary Artery Disease
818001|NCT03045913|Coronary revascularization
818002|NCT03045913|Percutaneous Coronary Intervention
818003|NCT03045887|repeat dose
818004|NCT03045887|GSK2292767
818005|NCT03045887|smoke
818006|NCT03045887|tolerability
818007|NCT03045887|safety
818008|NCT03045887|dry powder inhalation
818009|NCT03045887|pharmacokinetics
818010|NCT03045887|single dose
818011|NCT03045848|Observational registry
818012|NCT03045848|All-comers open label registry
818013|NCT03045848|Drug coated stent
818014|NCT03045848|Multicenter
818015|NCT03045848|Stenting
818016|NCT03045848|Coronary Artery Disease
818017|NCT03045848|Coronary revascularization
818018|NCT03045848|Percutaneous Coronary Intervention
818019|NCT03045835|laparoscopic surgery BASKA mask ambulatory care
818020|NCT03045822|Bioimpedance analysis
818021|NCT03045822|implantable cardioverter-defibrillators
818022|NCT03045822|pacemakers
818023|NCT03045809|Syndromic management
818024|NCT03045809|Point of care testing
818025|NCT03045783|gastric varices
818026|NCT03045783|endoscopic injection of tissue adhesive
818027|NCT03045731|kidney transplantation
818028|NCT03045731|ultrasound
818029|NCT03045731|mathematical model
818030|NCT03045718|Horticultural Therapy
818031|NCT03045718|Dementia
818032|NCT03045718|Randomized Controlled Trial
818033|NCT03045718|Elderly
818034|NCT03045718|Prevention
818035|NCT03045692|drug dosing, eGFR, CCr
818036|NCT03045679|Roux-en Y gastric bypass
818037|NCT03045679|One-anastomosis gastric bypass
818038|NCT03045679|Mini-gastric bypass
818039|NCT03045679|metabolic surgery
818040|NCT03045653|Breast Cancer
818041|NCT03045653|high dose Tamoxifen
818042|NCT03045653|endocrine therapy
818043|NCT03045653|Hormone Receptor Positive Malignant Neoplasm of Breast
818044|NCT03045653|Tamoxifen
818045|NCT03045653|Breast Cancer Metastatic
818046|NCT03045640|ECD
818047|NCT03045640|parenting program
818048|NCT03045640|home visiting
818049|NCT03045627|Acute Myeloid Leukemia
818050|NCT03045627|PEG-G-CSF
818051|NCT03045601|Diagnostic Techniques, Cardiovascular
818052|NCT03045601|Coronary Angiography
818053|NCT03045601|Fractional Flow Reserve, Myocardial
818054|NCT03045601|Echocardiography, Stress
818055|NCT03045510|Decitabine Myelodysplastic syndrome
818056|NCT03045484|nasopharyngeal carcinoma
818057|NCT03045484|Oral Mucositis Pain
818058|NCT03045484|Oxycodone
818059|NCT03045458|one stage dental implant
818060|NCT03045458|two stage dental implant
818061|NCT03045458|Interleukin-1β
818062|NCT03045445|CT
818063|NCT03045445|dual energy
818064|NCT03045445|low dose
818065|NCT03045432|Stroke
818066|NCT03045432|Hemiplegia
818067|NCT03045432|Rotator Cuff Injury
818068|NCT03045419|MRI
818069|NCT03045419|gadoxetic acid
818070|NCT03045419|CT
818071|NCT03045393|Neoadjuvant
818072|NCT03045393|Breast Cancer
818073|NCT03045393|Folate Receptor Alpha
818074|NCT03045393|FRa
818075|NCT03045393|TNBC
818076|NCT03045393|Triple Negative Breast Cancer
818077|NCT03045393|Preoperative
818078|NCT03045393|Presurgery
818079|NCT03045393|Mirvetuximab Soravtansine
818080|NCT03045393|IMGN853
818081|NCT03045367|Metamorphopsia
818082|NCT03045367|Epiretinal membrane
818083|NCT03045367|Vitrectomy
818084|NCT03045354|children
818085|NCT03045354|dietary carbohydrates
818086|NCT03045354|satiety
818087|NCT03045354|appetite
818088|NCT03045354|blood glucose
818089|NCT03045354|solanum tuberosum
818090|NCT03045354|obesity
818091|NCT03045354|breakfast
818092|NCT03045276|Spina Bifida
818093|NCT03045276|Kidney Transplant
818094|NCT03045263|ASD
818095|NCT03045237|Pregnancy
818096|NCT03045237|Physical activity
818097|NCT03045237|Newborn
818098|NCT03045237|Depressive Symptoms
818099|NCT03045237|Dietary habits
818100|NCT03045237|Healthy lifestyles
818101|NCT03045224|PAD, PTA, mortality, morbidity, amputation rate, quality of life
818102|NCT03045224|Percutaneous transluminal angioplasty (PTA), Stenting, balloon angioplasty
818103|NCT03045198|cystic fibrosis
818104|NCT03045185|Non Vital teeth
818105|NCT03045185|Traumatised teeth
818106|NCT03045185|Immature teeth
818107|NCT03045185|Regenerative Endodontics
818108|NCT03045172|Lichen Sclerosus
818109|NCT03045172|Platelet Rich Plasma
818110|NCT03045172|Vulvar
818111|NCT03045172|Vulva
818112|NCT03045159|deployment cycle
818113|NCT03045159|military family
818114|NCT03045159|prevention
818115|NCT03045159|stress
818116|NCT03045159|military child
818117|NCT03045159|parenting
818118|NCT03045159|coparenting
818119|NCT03045146|Acute Ischemic Stroke, Thrombectomy
818120|NCT03045133|Postoperative pain
818121|NCT03045133|Postoperative nausea and vomiting
818122|NCT03045133|Quality of recovery
818123|NCT03045133|QoR-40
818124|NCT03045133|Total intravenous anesthesia
818125|NCT03045107|right colon
818126|NCT03045107|laparoscopic right colectomy
818127|NCT03045107|intracorporeal anastomosis
818128|NCT03045107|extracorporeal anastomosis
818129|NCT03045107|hospital stay
818130|NCT03045107|quality of life
818131|NCT03045107|costs
818132|NCT03045094|pediatric
818133|NCT03045094|intubation
818134|NCT03045094|neck movement
818135|NCT03045055|Acute ischemic stroke
818136|NCT03045055|Endovascular treatment
818137|NCT03045055|Remote ischemic conditioning
818138|NCT03045042|Pompe
818139|NCT03045042|microRNA
818140|NCT03045042|biomarker
818141|NCT03045042|muscle MRI
818142|NCT03045042|glycogenosis
818143|NCT03045029|PAH
818144|NCT03045029|Oral Treprostiinil
818145|NCT03045029|Orenitram
818146|NCT03045016|Acute stress Disorder
818147|NCT03045016|Post Traumatic Stress Disorder
818148|NCT03045016|Prevention
818149|NCT03045016|trauma
818150|NCT03045016|prazosin
818151|NCT03045003|Resilience, Supportive Care, Psychosocial Care, Nursing
818152|NCT03044990|Acute coronary syndrome
818153|NCT03044990|renal insufficiency
818154|NCT03044990|mortality
818155|NCT03044977|3-Iodobenzylguanidine
818156|NCT03044977|dose-response relationship, radiation
818157|NCT03044977|theranostic
818158|NCT03044977|radionuclide
818159|NCT03044977|MIBG
818160|NCT03044977|DOTA
818161|NCT03044964|Angina, Chest Pain
818162|NCT03044951|atrial fibrillation
818163|NCT03044951|cryoablation
818164|NCT03044951|irrigated radiofrequency ablation
818165|NCT03044951|pulmonary vein isolation
818166|NCT03044938|Asthma
818167|NCT03044938|Salbutamol
818168|NCT03044938|Exercise
818169|NCT03044938|Heart Rate
818170|NCT03044938|Blood pressure
818171|NCT03044925|persistent atrial fibrillation
818172|NCT03044925|remote magnetic navigation
818173|NCT03044925|cryoablation
818174|NCT03044899|Surgery
818175|NCT03044899|Complications
818176|NCT03044899|Mortality
818177|NCT03044886|Vitamin D
818178|NCT03044821|Neural Tube Defect
818179|NCT03044795|homologous recombination deficiency
818180|NCT03044795|veliparib
818181|NCT03044795|PARP inhibitor
818182|NCT03044795|biomarker
818183|NCT03044769|Congenital Lung Anomalies
818184|NCT03044756|GnRH antagonist
818185|NCT03044756|Pituitary downregulation
818186|NCT03044756|IVF
818187|NCT03044756|ICSI
818188|NCT03044743|PD-1
818189|NCT03044743|CRISPR Cas9
818190|NCT03044743|EBV
818191|NCT03044743|advanced stage malignancies
818192|NCT03044717|Nutrition Education
818193|NCT03044717|Cardiology Fellows
818194|NCT03044652|Vulvovaginal Dryness
818195|NCT03044626|Nivolumab
818196|NCT03044626|Radiotherapy
818197|NCT03044600|Parathyroid disease
818198|NCT03044600|Hyperparathyroidism
818199|NCT03044600|Chart review
818200|NCT03044600|MEN1-negative
818201|NCT03044600|HRPT2 mutations
818202|NCT03044587|Biliary Tract Cancer
818203|NCT03044587|NaI-IRI
818204|NCT03044574|venous thromboembolism
818205|NCT03044574|deep vein thrombosis
818206|NCT03044574|pulmonary embolism
818207|NCT03044574|prevention
818208|NCT03044574|intermittent pneumatic compression
818209|NCT03044574|sequential pneumatic compression
818210|NCT03044574|surgery
818211|NCT03044574|elastic compression
818212|NCT03044574|low-molecular weight heparin
818213|NCT03044574|prophylaxis
818214|NCT03044535|quality of life
818215|NCT03044535|mechanical circulatory support
818216|NCT03044509|Immunodiagnostics tests
818217|NCT03044509|TB exposure
818218|NCT03044509|Latent TB
818219|NCT03044509|TB disease
818220|NCT03044509|Biomarkers
818221|NCT03044496|NIR Spectroscopy
818222|NCT03044496|Nerve Blockade
818223|NCT03044496|Surgical Arteriovenous Shunt
818224|NCT03044483|Sepsis
818225|NCT03044483|Microcirculatory function
818226|NCT03044444|performance
818227|NCT03044444|polyphenols
818228|NCT03044444|nutrition
818229|NCT03044444|sports
818230|NCT03044431|Shortness of breath
818231|NCT03044431|Breathlessness
818232|NCT03044431|Stem cells
818233|NCT03044431|Platelet rich plasma
818234|NCT03044431|Quality of life
818235|NCT03044431|Pulmonary Function
818236|NCT03044418|laser
818237|NCT03044418|endotracheal tube
818238|NCT03044418|total intravenous anesthesia
818239|NCT03044418|side effect
818240|NCT03044418|endolaryngeal surgery
818241|NCT03044405|fluid responsiveness
818242|NCT03044405|focused echocardiography
818243|NCT03044405|major surgery
818244|NCT03044353|echocardiography (ECHO)
818245|NCT03044353|skin biopsy
818246|NCT03044353|monoclonal anti-serum amyloid p component antibody (anti-SAP mAb)
818247|NCT03044353|Amyloidosis
818248|NCT03044353|cardiac magnetic resonance imaging (CMR)
818249|NCT03044353|biomarkers
818250|NCT03044353|cardiac functional measures
818251|NCT03044353|left ventricular mass
818252|NCT03044314|pulmonary hypertension
818253|NCT03044314|vasodilator challenge
818254|NCT03044314|echocardiography
818255|NCT03044314|outcomes
818256|NCT03044314|iloprost
818257|NCT03044314|inhaled nitric oxide
818258|NCT03044249|Psychotic Disorders
818259|NCT03044223|pseudomonas aeruginosa
818260|NCT03044223|critically ill patient
818261|NCT03044223|sepsis
818262|NCT03044223|monocyte
818263|NCT03044223|macrophage
818264|NCT03044223|cytokine
818265|NCT03044223|severity of disease
818266|NCT03044210|Rest energetic cost measured by indirect calorimetry
818267|NCT03044210|Hormonal axis
818268|NCT03044210|Mitochondrial oxidative phosphorylation
818269|NCT03044210|Basal metabolism
818270|NCT03044197|prostate cancer
818271|NCT03044197|magnetic resonance imaging
818272|NCT03044197|transperineal biopsy
818273|NCT03044197|target lesion
818274|NCT03044197|fusion biopsy
818275|NCT03044184|Tranexamic Acid
818276|NCT03044184|Antifibrinolytic
818277|NCT03044158|tuberculosis
818278|NCT03044158|implementation science
818279|NCT03044158|point-of-care
818280|NCT03044158|diagnostics
818281|NCT03044158|GeneXpert
818282|NCT03044158|Uganda
818283|NCT03044145|Cultural Competence
818284|NCT03044145|Patient-Clinician communication
818285|NCT03044132|Diabetic Foot Ulcer
818286|NCT03044132|DFU
818287|NCT03044132|Lower Extremity Wound
818288|NCT03044132|Skin Substitute
818289|NCT03044106|hamstrings
818290|NCT03044106|flexibility
818291|NCT03044106|strength
818292|NCT03044106|pain pressure threshold
818293|NCT03044106|lllt
818294|NCT03044106|photobiomodulation
818295|NCT03044106|cranial reflex
818296|NCT03044106|cranial laser reflex technique
818297|NCT03044106|CLRT
818298|NCT03044080|Walking Disorder
818299|NCT03044080|Stroke
818300|NCT03044080|Botulinum Toxin
818301|NCT03044080|Spasticity
818302|NCT03044067|Chronic pain
818303|NCT03044067|Fibromyalgia
818304|NCT03044067|Pain neuroscience education
818305|NCT03044067|Exercise
818306|NCT03044054|HIFU
818307|NCT03044041|Blood loss
818308|NCT03044041|Tranexamic acid
818309|NCT03044041|Total knee arthroplasty
818310|NCT03044041|Topical administration
818311|NCT03043989|docetaxel
818312|NCT03043989|cabazitaxel
818313|NCT03043989|phase 1b
818314|NCT03043989|castration-resistant
818315|NCT03043989|bone metastasis
818316|NCT03043976|Physical activity
818317|NCT03043976|Steps count
818318|NCT03043950|mCRC
818319|NCT03043950|First line
818320|NCT03043950|Panitumumab
818321|NCT03043950|mCCS Prognostic Score
818322|NCT03043950|Prognosis
818323|NCT03043950|Ras wild type
818324|NCT03043924|hypothalamus
818325|NCT03043924|Diffusion Magnetic Resonance Imaging
818326|NCT03043924|Magnetic Resonance Spectroscopy
818327|NCT03043911|early detection
818328|NCT03043911|respiratory events
818329|NCT03043911|sepsis
818335|NCT03043846|Treat to Target approach
818336|NCT03043820|raloxifene
818337|NCT03043820|selective estrogen receptor modulator (SERM)
818338|NCT03043820|schizophrenia
818339|NCT03043820|psychosis
818340|NCT03043820|cognition
818341|NCT03043820|negative symptoms
818342|NCT03043807|prostatectomy
818343|NCT03043807|androgen deprivation
818344|NCT03043807|chemotherapy
818345|NCT03043807|radiation
818346|NCT03043794|early stage
818347|NCT03043794|low risk
818348|NCT03043768|Parkinson's disease
818349|NCT03043768|Autonomic
818350|NCT03043768|Diagnosis
818351|NCT03043768|Pilomotor
818352|NCT03043768|Alpha-synuclein
818353|NCT03043768|Axon-reflex
818354|NCT03043768|Peripheral nerve fibers
818355|NCT03043729|neoadjuvant
818356|NCT03043729|MRI-defined T3
818357|NCT03043729|mFOLFOX6
818358|NCT03043729|Aflibercept
818359|NCT03043690|menopause
818360|NCT03043690|ammonium succinate
818361|NCT03043664|GEP-NET
818362|NCT03043664|Pembrolizumab
818363|NCT03043664|Lanreotide depot
818364|NCT03043664|PD-1
818369|NCT03043638|multiple adjacent gingival recessions
818370|NCT03043638|platelet rich plasma
818371|NCT03043638|acellular dermal matrix
818372|NCT03043638|coronally advanced flap
818373|NCT03043638|gingival recession
818374|NCT03043638|root coverage
818375|NCT03043638|clinical attachment level
818376|NCT03043625|Neck pain
818377|NCT03043625|visceral manipulation
818378|NCT03043625|functional dyspepsia
818379|NCT03043625|electromyography
818380|NCT03043625|pain
818381|NCT03043612|Ureteroscopy for urolithiasis
818382|NCT03043599|Thoracic
818383|NCT03043599|Radiotherapy
818384|NCT03043599|Platinum Based Chemotherapy
818385|NCT03043599|Immunotherapy
818386|NCT03043599|Ipilimumab
818387|NCT03043599|Nivolumab
818388|NCT03043599|Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
818389|NCT03043586|Acromegaly
818390|NCT03043560|depression
818391|NCT03043560|anhedonia
818392|NCT03043560|reward
818393|NCT03043547|nal-IRI
818394|NCT03043547|5-Fluorouracil
818395|NCT03043508|Genetic mutation
818396|NCT03043508|MEN1
818397|NCT03043508|Pancreatic neuroendocrine tumor
818398|NCT03043508|PNET
818399|NCT03043508|Chart review
818400|NCT03043508|Questionnaire
818401|NCT03043508|Survey
818402|NCT03043495|dexamethasone
818403|NCT03043495|supraclavicular brachial plexus block
818404|NCT03043495|ultrasound
818405|NCT03043482|VS-105
818406|NCT03043482|Renal Insufficiency, Chronic
818407|NCT03043482|Secondary hyperparathyroidism
818408|NCT03043469|dysfunctional breathing
818409|NCT03043443|sleep
818410|NCT03043443|Alcohol dependence
818411|NCT03043443|Melatonin
818412|NCT03043417|Stigma
818413|NCT03043417|Primary Health Care
818414|NCT03043417|Recovery
818415|NCT03043391|Pediatric Malignant Glioma
818416|NCT03043391|PVSRIPO
818417|NCT03043391|Pro00071228
818418|NCT03043391|Eric Thompson
818419|NCT03043391|Darell Bigner
818420|NCT03043391|Oncolytic Poliovirus
818421|NCT03043378|Malignant Neoplasms of Independent (Primary) Multiple Sites
818422|NCT03043378|Non-malignant pain
818423|NCT03043378|Supportive care
818424|NCT03043378|Questionnaires
818425|NCT03043378|Surveys
818426|NCT03043378|Chronic non-malignant pain
818427|NCT03043365|Fish Oils
818428|NCT03043365|Long Chain Monounsaturated Fatty Acids
818429|NCT03043365|Lipoproteins
818430|NCT03043365|Cardiovascular Disease
818431|NCT03043352|SAM
818432|NCT03043352|Malnutrition
818433|NCT03043352|LHW
818434|NCT03043352|CMAM
818435|NCT03043339|Microbiota composition
818436|NCT03043339|Kidney transplant recipient
818437|NCT03043339|Kidney transplant donor
818438|NCT03043339|Antibiotics
818439|NCT03043339|Drug resistance
818440|NCT03043339|Transplantation surgery
818441|NCT03043326|Pre-exposure Prophylaxis
818442|NCT03043326|MSM and transgender women
818443|NCT03043300|Travelers' diarrhea
818444|NCT03043300|Intestinal microbiota
818445|NCT03043300|Antibiotic resistance
818446|NCT03043300|Antibiotics
818447|NCT03043300|Gastrointestinal disorders
818448|NCT03043300|Infectious diseases
818449|NCT03043300|International Travel
818450|NCT03043300|Travel Medicine
818451|NCT03043300|Resistome
818452|NCT03043300|Microbiome
818453|NCT03043261|CHF
818454|NCT03043248|TRK-700
818455|NCT03043248|PK
818456|NCT03043248|Digoxin
818457|NCT03043248|Midazolam
818458|NCT03043248|Drug-Drug interaction
818459|NCT03043248|P-glycoprotein
818460|NCT03043248|CYP3A4
818461|NCT03043248|MDR1
818462|NCT03043248|pharmacokinetics
818463|NCT03043248|multidrug resistance 1
818470|NCT03043183|gastric cancer
818471|NCT03043183|Enhanced recovery after surgery
818472|NCT03043170|Adults
818473|NCT03043170|Emergency Department
818474|NCT03043170|Haemodynamics
818475|NCT03043170|Resuscitation
818476|NCT03043170|Shock
818477|NCT03043170|Uscom
818478|NCT03043131|Cardiopulmonary bypass prime
818479|NCT03043131|Plasma Lyte - A
818480|NCT03043131|Ringer;s lactate
818481|NCT03043131|Acidosis
818482|NCT03043118|Eating Behaviors
818483|NCT03043118|Preschool
818484|NCT03043118|Vegetable Intake
818485|NCT03043105|Multicentric Castleman's Disease
818486|NCT03043105|Thalidomide, cyclophosphamide and prednisone (TCP regimen)
818487|NCT03043105|Efficacy
818488|NCT03043105|Safety
818489|NCT03043092|ultrasound, transcranial Doppler, arterial diseases
818490|NCT03043066|Chronic Periodontitis
818491|NCT03043066|TRAP-5b
818492|NCT03043066|Non-surgical periodontal therapy
818493|NCT03043066|Systemic antibiotics
818494|NCT03043053|weight loss
818495|NCT03043053|body mass index
818496|NCT03043053|oxytocin
818497|NCT03043053|magnetic resonance imaging
818498|NCT03043040|suicide, attempted
818499|NCT03043040|prevention
818500|NCT03043040|telemedicine
818501|NCT03042988|supine hypertension
818502|NCT03042988|autonomic failure
818503|NCT03042988|heat stress
818504|NCT03042988|orthostatic hypotension
818505|NCT03042975|spasmodic dysphonia
818506|NCT03042975|dystonia
818507|NCT03042975|laryngeal dystonia
818508|NCT03042975|imaging
818509|NCT03042975|genetics
818510|NCT03042962|dystonia
818511|NCT03042962|imaging
818512|NCT03042962|genetics
818513|NCT03042962|neuropathology
818514|NCT03042936|Children
818515|NCT03042936|Teens
818516|NCT03042936|Adolescents
818517|NCT03042936|Type 2 diabetes
818518|NCT03042936|Impaired glucose tolerance
818519|NCT03042936|Exercise
818520|NCT03042936|Nutrition
818521|NCT03042936|Education
818522|NCT03042884|Benign Neoplasms
818523|NCT03042884|In Situ Neoplasms
818524|NCT03042884|Malignant Neoplasms of Independent (Primary) Multiple Sites
818525|NCT03042884|Wearable exercise trackers
818526|NCT03042884|Questionnaires
818527|NCT03042884|Surveys
818528|NCT03042871|PM-CNV ,Ranibizumab, Dosing Strategy
818529|NCT03042858|PPV
818530|NCT03042858|patent processus vaginalis
818531|NCT03042858|inguinal hernia
818532|NCT03042832|Leadership
818533|NCT03042832|Organizational Climate
818534|NCT03042832|Implementation
818535|NCT03042832|Implementation Climate
818536|NCT03042832|Motivational Interviewing
818537|NCT03042832|Fidelity
818538|NCT03042806|Physical Activity
818539|NCT03042806|Questionnaire
818540|NCT03042793|myeloma
818541|NCT03042793|vaccination
818542|NCT03042793|PD-L1
818543|NCT03042793|peptide vaccine
818544|NCT03042793|cancer vaccine
818545|NCT03042793|immunotherapy
818546|NCT03042780|Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)
818547|NCT03042780|Metastatic
818548|NCT03042780|High grade
818549|NCT03042780|Pancreas
818550|NCT03042780|Neuroendocrine carcinoma of gastrointestinal tract
818551|NCT03042754|LAM
818552|NCT03042754|XpertMTB/RIF
818553|NCT03042754|treatment outcome
818554|NCT03042754|Microbacterial tuberculosis
818555|NCT03042715|Supportive Care
818556|NCT03042689|AML
818557|NCT03042676|anti-T lymphocytic globulin (ATG)
818558|NCT03042676|allogeneic stem cell transplant
818559|NCT03042676|prophylaxis of GVHD
818564|NCT03042611|Gastric Cancer
818565|NCT03042611|Gastric Adenocarcinoma
818566|NCT03042611|Gastro-esophageal Cancer
818567|NCT03042611|Gastro-esophageal junction Cancer
818568|NCT03042611|Stomach Cancer
818569|NCT03042611|Tumor
818570|NCT03042611|Oncology
818571|NCT03042611|Antiangiogenesis
818572|NCT03042611|Metastatic
818573|NCT03042598|Safe Apneic Period
818574|NCT03042598|Emergency Intubation
818575|NCT03042598|Biphasic Cuirass Ventilation (BCV)
818576|NCT03042598|Non-invasive ventilation
818577|NCT03042598|Peri-intubation Hemodynamic instability
818578|NCT03042598|desaturation
818579|NCT03042598|waveform capnography
818580|NCT03042598|Patient safety
818581|NCT03042585|BMT
818582|NCT03042585|NHL
818583|NCT03042585|Non-Hodgkin Lymphoma
818584|NCT03042585|Relapsed Non-Hodgkin Lymphoma
818585|NCT03042585|Refractory Non-Hodgkin Lymphoma
818586|NCT03042585|autologous stem cell transplantation
818587|NCT03042572|Critical Limb Ischemia (CLI)
818588|NCT03042572|Severe Limb Ischemia (SLI)
818589|NCT03042572|Peripheral Artery Disease (PAD)
818590|NCT03042572|Peripheral Artery Occlusive Disease (PAOD)
818591|NCT03042572|Cardiovascular disease
818592|NCT03042572|Mesenchymal stromal cell (MSC)
818593|NCT03042572|Mesenchymal stem cell (MSC)
818594|NCT03042494|Prebiotic
818595|NCT03042494|Gut microbiota
818596|NCT03042494|Dietary fiber
818597|NCT03042494|Gastrointestinal tolerance
818598|NCT03042481|chronic hepatitis B
818599|NCT03042481|entecavir
818600|NCT03042481|tenofovir
818601|NCT03042481|off-therapy
818602|NCT03042481|relapse
818603|NCT03042442|pancreatic cancer
818604|NCT03042442|cachexia
818605|NCT03042442|perineural invasion
818606|NCT03042442|pain
818607|NCT03042442|diabetes
818608|NCT03042429|neuroblastoma
818609|NCT03042429|chemotherapy
818610|NCT03042429|autologous stem cell transplantation
818611|NCT03042429|radiotherapy
818612|NCT03042429|mIBG
818613|NCT03042429|tumor resection
818614|NCT03042416|18F-DOPA PET/CT
818615|NCT03042403|hemodynamics
818616|NCT03042403|physiotherapy
818617|NCT03042403|breath stacking
818618|NCT03042377|Endodontics
818619|NCT03042377|Retreatment
818620|NCT03042377|Postoperative Pain
818621|NCT03042377|Visual Analogue Pain Scale
818622|NCT03042364|Endometrium, Cytokines, Endometrial secretion, Implantation, Endometrial scratching
818623|NCT03042351|Urinary Incontinence
818624|NCT03042351|Pelvic Floor
818626|NCT03042286|statin
818627|NCT03042286|myalgia
818628|NCT03042286|myopathy
818629|NCT03042286|adverse drug reactions (ADRs)
818630|NCT03042286|pharmacokinetics and pharmacogenetics
818631|NCT03042273|recurrent
818632|NCT03042260|trimethoprim, sulfamethoxazole drug combination
818633|NCT03042260|Infection
818634|NCT03042260|Prophylaxis
818635|NCT03042234|Obesity
818636|NCT03042234|Exercise
818637|NCT03042234|Fat oxidation
818638|NCT03042234|Adolescent
818639|NCT03042234|Insulin resistance
818640|NCT03042195|Supplementary Parenteral Nutrition
818641|NCT03042195|Postoperative Nutrition
818642|NCT03042195|Postoperative complications
818643|NCT03042169|Stage IV gastric cancer
818644|NCT03042169|palliative surgery
818645|NCT03042169|chemotherapy
818646|NCT03042169|survival
818647|NCT03042169|quality of life
818648|NCT03042143|Acute respiratory distress syndrome
818649|NCT03042143|Human umbilical cord-derived mesenchymal stem cells
818650|NCT03042104|Stenosis
818651|NCT03042104|Heart Disease
818652|NCT03042104|Valve
818653|NCT03042104|Tricuspid
818654|NCT03042104|Aortic Valve
818655|NCT03042104|Asymptomatic
818656|NCT03042078|Fluoroscopy
818657|NCT03042078|Ablation
818658|NCT03042078|Three dimensional
818659|NCT03042078|Paroxysmal supraventricular tachycardia
818660|NCT03042078|Radiation
818661|NCT03042065|pediatrics
818662|NCT03042065|asthma
818663|NCT03042065|nebulization
818664|NCT03042065|vibrating mesh
818665|NCT03042065|salbutamol
818666|NCT03042065|Efficiency
818667|NCT03042013|ASP8273
818668|NCT03042013|Non-Small-Cell Lung Cancer
818669|NCT03042013|EGFR mutations
818670|NCT03042013|Oncology
818671|NCT03042000|rectal cancer
818672|NCT03042000|neoadjuvant chemoradiation
818673|NCT03042000|circulating tumor DNA
818674|NCT03042000|local recurrence
818675|NCT03042000|long-term survival
818676|NCT03041987|Cohort studies
818677|NCT03041987|Prognosis
818678|NCT03041974|Red Blood Cell Transfusion
818679|NCT03041974|Cell-Derived Microparticles
818680|NCT03041961|Vascular function
818681|NCT03041961|Endothelial function
818682|NCT03041961|(Poly)phenols
818683|NCT03041948|Inguinal hernia
818684|NCT03041948|Caudal nerve block
818685|NCT03041948|Ilioinguinal nerve block
818686|NCT03041948|Pain
818687|NCT03041935|Testicle
818688|NCT03041935|Pain
818689|NCT03041935|Orchiopexy
818690|NCT03041935|Caudal nerve block
818691|NCT03041935|Ilioinguinal nerve block
818692|NCT03041922|Elastography
818693|NCT03041922|Buttocks
818694|NCT03041922|Ultrasound
818695|NCT03041922|Soft tissue
818696|NCT03041870|PET-fMRI
818697|NCT03041870|dominance
818698|NCT03041870|5HT transporter
818699|NCT03041857|Videofluoroscopy
818700|NCT03041857|GMK Sphere
818701|NCT03041857|GMK PS Fixed Bearing
818702|NCT03041857|GMK UC Mobile Bearing
818703|NCT03041844|therapeutic ultrasound
818704|NCT03041844|quality of life
818710|NCT03041818|cerebral palsy
818711|NCT03041818|horseback riding
818712|NCT03041805|venous thromboembolism
818713|NCT03041805|deep vein thrombosis
818714|NCT03041805|pulmonary embolism
818715|NCT03041805|varicose veins
818716|NCT03041805|surgery
818717|NCT03041805|endovenous laser treatment
818718|NCT03041805|radiofrequency ablation
818719|NCT03041805|ultrasound-guided foam sclerotherapy
818720|NCT03041805|register
818721|NCT03041805|anticoagulation
818722|NCT03041766|Schistosomiasis
818723|NCT03041766|Recombinant vaccine
818724|NCT03041766|rSm14
818725|NCT03041766|GLA-SE
818726|NCT03041766|Fatty acid-binding protein (FABP)
818727|NCT03041766|Phase II Clinical Trial
818728|NCT03041766|Senegal
818729|NCT03041753|stroke
818730|NCT03041753|thrombolysis
818731|NCT03041753|metalloproteinases
818732|NCT03041753|blood brain barrier
818733|NCT03041740|Bronchopulmonary Dysplasia
818734|NCT03041740|Neonates
818735|NCT03041714|Essential Tremor
818736|NCT03041714|Cervical Dystonia
818737|NCT03041714|Hand Dystonia
818738|NCT03041714|Neurophysiology
818739|NCT03041714|Dystonic Tremor
818745|NCT03041675|Lacer Acupuncture
818746|NCT03041675|Paralytic ileus
818747|NCT03041649|Gastroesophageal Reflux
818748|NCT03041649|Feeding Disorder
818749|NCT03041649|Gastrostomy tube
818750|NCT03041649|Family Satisfaction
818751|NCT03041649|GT button
818752|NCT03041649|Enteral nutrition
818753|NCT03041649|Gastrostomy button
818754|NCT03041636|Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
818755|NCT03041636|Other Diseases of Blood and Blood-Forming Organs
818756|NCT03041636|Chronic Lymphocytic Leukemia
818757|NCT03041636|CLL
818758|NCT03041636|Ruxolitinib
818759|NCT03041636|Jakafi
818760|NCT03041636|INCB018424
818761|NCT03041623|IIPs
818762|NCT03041558|healthy relationships
818763|NCT03041558|interpersonal relations
818764|NCT03041558|domestic violence
818765|NCT03041532|retroflexion proximal
818766|NCT03041532|colorectal cancer screening programme
818767|NCT03041532|adenoma detection rate
818768|NCT03041532|right colon
818769|NCT03041519|Fluoroscopy
818770|NCT03041519|Ablation
818771|NCT03041519|Three dimensional
818772|NCT03041519|Ventricular arrhythmias
818773|NCT03041519|Radiation
818774|NCT03041506|Shoulder dislocation reduction
818775|NCT03041506|Ultrasound guided interscalene block (ISCB)
818776|NCT03041506|Sedation
818779|NCT03041480|chronic periodontitis
818780|NCT03041480|lipids
818781|NCT03041480|Lp-PLA2
818782|NCT03041402|non-invasive ventilation
818783|NCT03041402|Pressure Support Ventilation
819055|NCT03039296|Endoscopic rhizotomy
818784|NCT03041402|Neurally Adjusted Ventilatory Assist
818785|NCT03041402|patient-ventilator interaction
818786|NCT03041402|ventilator performance
818787|NCT03041402|asynchrony
818788|NCT03041389|Computerized Cognitive Behavioral Therapy
818789|NCT03041350|Emergency Medical Services
818790|NCT03041350|Smartphone
818791|NCT03041350|Survival
818795|NCT03041246|pelvic floor
818796|NCT03041207|ventilator associated infection
818797|NCT03041207|ventilator associated pneumonia
818798|NCT03041207|ventilator associated tracheitis
818799|NCT03041207|Lower respiratory infection
818800|NCT03041181|Nivolumab
818801|NCT03041181|BMS-936558-01
818802|NCT03041181|Anti-PD-1 Antibody
818803|NCT03041181|Docetaxel
818804|NCT03041142|Obesity
818805|NCT03041142|Cardiovascular risk factors
818806|NCT03041142|Interdisciplinary intervention
818808|NCT03041116|PKAN
818809|NCT03041090|infiltration
818810|NCT03041090|extravasation
818811|NCT03041090|PET/CT
818812|NCT03041090|PET
818813|NCT03041090|PET-CT
818814|NCT03041025|Systemic Sclerosis
818815|NCT03041025|Repeat-dose
818816|NCT03041025|Phase IIA
818817|NCT03041025|GSK2330811
818818|NCT03041025|Pharmacodynamics
818819|NCT03041025|Pharmacokinetics
818820|NCT03041025|Proof of mechanism study
818821|NCT03041012|HIV-1
818822|NCT03041012|Latency Reversal Agent
818823|NCT03041012|Immunotherapy
818833|NCT03040973|capmatinib
818834|NCT03040973|cMET
818835|NCT03040973|advanced solid tumor
818836|NCT03040973|cancer
818837|NCT03040960|infection
818838|NCT03040960|wound infection
818839|NCT03040960|surgical wound infection
818840|NCT03040960|Staphylococcal infections
818841|NCT03040960|wound and injuries
818842|NCT03040960|postoperative complications
818843|NCT03040960|Gram-positive bacterial infections
818844|NCT03040960|bacterial infections
818845|NCT03040895|Parenting practices
818846|NCT03040856|Omega 3
818847|NCT03040856|Supplements
818848|NCT03040856|Alpha Linolenic Acid
818849|NCT03040843|documentation
818850|NCT03040843|altered mental status
818851|NCT03040843|definition
818852|NCT03040843|clinically
818853|NCT03040804|hidradenitis suppurativa
818854|NCT03040804|HS
818855|NCT03040804|radiotherapy
818856|NCT03040791|prostate cancer
818857|NCT03040778|MRONJ
818858|NCT03040778|BRONJ
818859|NCT03040765|Osteoporosis
818860|NCT03040765|Beta-Thalassemia Major
818861|NCT03040765|Denosumab
818862|NCT03040765|Zoledronic Acid
818863|NCT03040739|O'ARM
818864|NCT03040726|In situ neoplasm
818865|NCT03040726|Malignant neoplasms of independent (primary) multiple sites
819115|NCT03038945|Suture Techniques
818866|NCT03040726|Symptoms and signs involving the digestive system and abdomen
818867|NCT03040726|Chronic nausea and vomiting
818868|NCT03040726|Netupitant/Palonosetron
818869|NCT03040726|NEPA
818870|NCT03040726|Placebo
818871|NCT03040726|Sugar pill
818872|NCT03040726|Symptom questionnaires
818873|NCT03040726|Surveys
818874|NCT03040726|Pill diary
818875|NCT03040726|Akynzeo
818876|NCT03040700|coronary artery disease
818877|NCT03040700|surgery
818878|NCT03040700|angina
818879|NCT03040700|myocardial ischemia
818880|NCT03040700|non-invasive testing
818881|NCT03040687|ETEC
818882|NCT03040687|Escherichia coli
818883|NCT03040687|enteritis
818884|NCT03040687|challenge
818885|NCT03040687|CS6
818886|NCT03040687|B7A
818887|NCT03040674|Shortness of breath
818888|NCT03040674|Breathlessness
818889|NCT03040674|Stem cells
818890|NCT03040674|Platelet rich plasma
818891|NCT03040674|Quality of life
818892|NCT03040674|Pulmonary function
818893|NCT03040622|WATCHMAN
818894|NCT03040622|Left Atrial Appendage Closure
818895|NCT03040622|Thrombosis
818896|NCT03040622|Platelet Function
818897|NCT03040609|Profound Multiple Intellectual Disabilities
818898|NCT03040609|Visual-Behavioral Scale
818899|NCT03040596|vocal fold nodules
818900|NCT03040596|inhaled steroid
818901|NCT03040596|steroid
818902|NCT03040596|children
818903|NCT03040596|nodules
818904|NCT03040583|Primary Sjögren's syndrome (PSS)
818905|NCT03040583|auto-immune diseases
818906|NCT03040557|plantar fasciitis
818907|NCT03040557|shoes
818908|NCT03040557|insoles
818909|NCT03040557|pain
818910|NCT03040557|foot
818911|NCT03040544|minimally invasive surgery
818912|NCT03040544|video-based trainer
818913|NCT03040531|glucocorticoid
818914|NCT03040531|genistein
818915|NCT03040531|alendronate
818916|NCT03040518|Behaviour change
818917|NCT03040518|Male obesity
818918|NCT03040518|SMS
818919|NCT03040518|Financial Incentive
818920|NCT03040518|Endowment incentive
818921|NCT03040466|ureteroscopy
818922|NCT03040466|flexible ureteroscope
818923|NCT03040466|randomized controlled trial
818924|NCT03040453|Irreversible electroporation
818925|NCT03040453|Microwave ablation
818926|NCT03040427|F-18 florbetapir
818927|NCT03040427|Amyvid
818928|NCT03040427|PET scan
818929|NCT03040427|Early detection
818930|NCT03040414|Hybrid closed loop
818931|NCT03040414|Closed loop
818932|NCT03040414|Artificial pancreas
818933|NCT03040401|CMML
818934|NCT03040401|Ceplene
818935|NCT03040401|Interleukin-2
818936|NCT03040388|Electroconvulsive therapy
818937|NCT03040388|Depressive Disorder
818938|NCT03040388|Magnetic Resonance Imaging
818939|NCT03040388|Hippocampus
818940|NCT03040388|Brain-Derived Neurotrophic Factor
818941|NCT03040388|Vascular Endothelial Growth Factor
818942|NCT03040388|Blood-Brain Barrier
818943|NCT03040349|primary care
818944|NCT03040349|greece
818945|NCT03040349|cyprus
818946|NCT03040349|tobacco use treatment
818947|NCT03040349|evidence-based guidelines
818948|NCT03040336|surgery
818949|NCT03040336|prehabilitation
818950|NCT03040336|exercise therapy
818951|NCT03040336|nutrition support
818952|NCT03040297|Weaning from mechanical ventilation
818953|NCT03040297|tracheostomized patients
818954|NCT03040297|Tracheal gas insufflation
818955|NCT03040284|noninvasive monitoring
818956|NCT03040284|intracranial pressure
818957|NCT03040284|cochlear electrophysiology
818958|NCT03040284|aneurysmal subarachnoid haemorrhage
818959|NCT03040284|cerebrovascular disorders
818960|NCT03040284|brain diseases
818961|NCT03040271|School-based intervention
818962|NCT03040258|School-based intervention
818963|NCT03040245|Emergency physician
818964|NCT03040245|Whiplash Book
818965|NCT03040245|Whiplash trauma
818966|NCT03040245|Fears
818967|NCT03040245|Beliefs
818969|NCT03040180|Neoplasms
818970|NCT03040180|Neoplasms, primary
818971|NCT03040180|Cancer
818972|NCT03040180|Colorectal cancer
818973|NCT03040180|rectal cancer
818974|NCT03040180|rectal cancer, locally advanced
818975|NCT03040180|Electrochemotherapy
818976|NCT03040180|Electroporation
818977|NCT03040180|Neoadjuvant therapy
818978|NCT03040180|Antineoplastic, antibodies
818979|NCT03040180|Bleomycin
818980|NCT03040180|Pathologic processes
818981|NCT03040180|Neoplastic processes
818982|NCT03040154|Filipino
818983|NCT03040102|Advanced Cancer
818984|NCT03040063|aneurysm, poplietl artery, acute limb ischemia
818985|NCT03040024|Anesthesiology
818986|NCT03040011|Vaginal Surgery
818987|NCT03040011|Pelvic Organ Prolapse
818988|NCT03040011|Postoperative Pain
818989|NCT03039959|Chronic Kidney Disease
818990|NCT03039946|Fluid therapy
818991|NCT03039946|Hemodynamic flow monitoring
818992|NCT03039946|Closed-loop system
818993|NCT03039946|Goal-directed fluid therapy
818994|NCT03039946|Anesthesiology
818995|NCT03039907|Knee
818996|NCT03039907|Replacement
818997|NCT03039894|school-based, evaluation, interrupted time series
818998|NCT03039881|Minute ventilation, ExSpiron monitor
819007|NCT03039842|dextromethorphan; memantine; treatment response
819008|NCT03039790|Immunogenicity, Norovirus vaccination
819009|NCT03039686|muscular dystrophy
819010|NCT03039686|Duchenne's Muscular Dystrophy
819011|NCT03039686|DMD
819014|NCT03039608|esophageal stricture
819015|NCT03039608|endoscopic submucosal dissection
819016|NCT03039608|prevention
819017|NCT03039595|Early rectal cancer
819018|NCT03039595|Ploidy
819019|NCT03039595|Tumour:stroma ratio
819020|NCT03039582|perineal tear
819021|NCT03039582|bidigital palpation
819022|NCT03039582|perineal ultrasound
819023|NCT03039582|post partum diagnostics
819024|NCT03039569|Type 2 diabetes patients
819025|NCT03039569|Diabetes self-management
819026|NCT03039569|Cardiovascular diseases awareness
819027|NCT03039569|Home food environment
819028|NCT03039569|Text message
819029|NCT03039530|Postpartum Depression
819030|NCT03039530|Cognitive Behavioral Therapy
819031|NCT03039530|Public Health
819032|NCT03039530|Mother
819033|NCT03039530|Infant
819034|NCT03039530|Emotion
819035|NCT03039517|Adaptive Compression Therapy Delivery System
819036|NCT03039504|Succinates
819037|NCT03039504|Dietary supplement
819038|NCT03039491|pneumococcal vaccination
819039|NCT03039465|Indwelling Trachea-oesophageal Prosthesis
819040|NCT03039465|Voice Rehabilitation
819041|NCT03039465|Total Laryngectomy
819042|NCT03039439|Immunohistochemical profiling of tumors
819043|NCT03039439|Biomarkers
819044|NCT03039374|OASI
819045|NCT03039374|Faecal incontinence
819046|NCT03039374|Obstetric anal sphincter injury
819047|NCT03039374|MRI
819048|NCT03039348|Breast Cancer Female
819049|NCT03039348|Mastectomy
819050|NCT03039348|Breast Reconstruction
819051|NCT03039348|questionnaire
819052|NCT03039309|Endoscopic Submucosal Dissection
819053|NCT03039296|Low back pain
819054|NCT03039296|Facet joints
819056|NCT03039283|Moderate to profound sensorineural hearing loss
819057|NCT03039270|Tooth Sensitivity
819058|NCT03039270|Tooth Bleaching
819059|NCT03039270|Desensitizing agent
819060|NCT03039270|Sonic vibration
819061|NCT03039257|hematopoietic stem cell transplant
819062|NCT03039257|vitamin a
819063|NCT03039244|Photochemotherapy
819064|NCT03039244|Photosensitizing agents
819065|NCT03039244|Smokers
819066|NCT03039231|PTSD
819067|NCT03039218|erectile dysfunction
819068|NCT03039218|shockwave
819069|NCT03039218|Dornier
819070|NCT03039205|Platelet aggregation
819071|NCT03039205|Adenosine
819072|NCT03039205|Coronary artery disease
819073|NCT03039205|Kidney dysfunction
819074|NCT03039205|Ticagrelor
819075|NCT03039205|Clopidogrel
819076|NCT03039127|Hyperthermia
819077|NCT03039127|Laser Coagulation
819078|NCT03039127|Laser Therapy
819079|NCT03039127|Induced
819080|NCT03039114|Follicular lymphoma
819081|NCT03039114|relapsed
819082|NCT03039114|refractory
819083|NCT03039114|non-Hodgkin lymphoma
819084|NCT03039114|phosphatidylinositol 3-kinase (PI3K)
819085|NCT03039101|allergen
819086|NCT03039101|neutrophils
819087|NCT03039101|allergy
819088|NCT03039062|Serum miR-122
819089|NCT03039062|drug-induced liver injury by chemotherapy
819090|NCT03039062|malignant tumor patients
819091|NCT03039049|GnRH agonist trigger
819092|NCT03039049|IVF
819093|NCT03039049|Luteal phase support
819094|NCT03039049|Mid-luteal GnRH agonist
819095|NCT03039036|Labor Induction
819096|NCT03039036|Early Amniotomy
819097|NCT03039036|Foley catheter
819098|NCT03039023|TMAO
819099|NCT03039023|choline
819100|NCT03039023|eggs
819101|NCT03039023|gastrointestinal microbiome
819102|NCT03039023|healthy volunteers
819103|NCT03038984|IBD
819104|NCT03038984|Telemedicine
819105|NCT03038984|At-home monitoring
819106|NCT03038984|Disease activity
819107|NCT03038984|fecal calprotectin
819108|NCT03038984|Total inflammation burden
819109|NCT03038984|11 years follow up
819110|NCT03038958|Local Anaesthetic
819111|NCT03038958|spinal anesthesia
819112|NCT03038958|Knee arthroscopy
819113|NCT03038945|Laparoscopy
819114|NCT03038945|Hysterectomy
819116|NCT03038932|whole genome sequencing (WGS)
819117|NCT03038919|prolonged mechanical ventilation
819118|NCT03038919|critically ill patients
819119|NCT03038919|anabolic steroid
819120|NCT03038893|Ultrasonography
819121|NCT03038893|Point-of-care systems
819122|NCT03038893|Deep venous thrombosis
819123|NCT03038893|Hospitalization
819124|NCT03038776|vaccine
819125|NCT03038750|Healthy Volunteers
819126|NCT03038750|Genetic Risk Markers for Cardiovascular Disease
819127|NCT03038750|Non-Alcoholic Fatty Liver Disease
819128|NCT03038750|Coronary Disease
819129|NCT03038750|Hypertension
819130|NCT03038750|Venous Thromboses
819131|NCT03038750|Venous Thromboembolism
819132|NCT03038750|Coronary Heart Disease
819133|NCT03038750|Coronary Artery Disease
819134|NCT03038737|nylon
819135|NCT03038737|polyamide
819136|NCT03038737|PEEK
819137|NCT03038737|partial denture
819138|NCT03038724|HIV testing
819139|NCT03038698|spirometry
819140|NCT03038698|normative values
819141|NCT03038698|health
819142|NCT03038698|south africa
819143|NCT03038698|children
819144|NCT03038685|Secondary prevention
819145|NCT03038685|Web-based intervention
819146|NCT03038685|Strokecoach
819147|NCT03038646|Pharmacokinetics
819148|NCT03038646|Food Effect
819149|NCT03038620|Obesity
819150|NCT03038620|Visceral
819151|NCT03038620|Cardiovascular Disease
819152|NCT03038620|Fat
819153|NCT03038594|Burns
819154|NCT03038594|Growth Hormone
819155|NCT03038594|Lean Body Mass
819156|NCT03038594|Strength
819157|NCT03038594|Exercise Endurance
819158|NCT03038581|Deep wrist injury
819159|NCT03038581|Self inflicted
819160|NCT03038581|Traumatic wrist injury
819161|NCT03038568|colorectal liver metastases
819162|NCT03038568|CT scan
819163|NCT03038568|17-010
819164|NCT03038555|Medical staff
819165|NCT03038555|preeclampsia
819166|NCT03038555|cohort study
819167|NCT03038555|further effect
819168|NCT03038529|low back pain , Ozone
819169|NCT03038503|refractory septic shock
819170|NCT03038503|catecholamine resistance septic shock
819171|NCT03038503|terlipressin
819172|NCT03038503|methylene blue
819173|NCT03038477|Borderline Resectable Pancreatic Ductal Adenocarcinoma
819174|NCT03038477|Durvalumab
819175|NCT03038399|Duchenne muscular dystrophy
819176|NCT03038399|vamorolone
819177|NCT03038347|cross-cultural competencies
819178|NCT03038347|internet-based training
819179|NCT03038347|cognitive-behavioural therapy (CBT)
819180|NCT03038347|psychotherapy training
819181|NCT03038347|competence training
819182|NCT03038321|BCG Cystitis
819183|NCT03038321|Bladder Cancer
819184|NCT03038321|Levofloxacin
819185|NCT03038321|Solifenacin
819186|NCT03038321|Lornoxicam
819187|NCT03038308|ropinirole
819188|NCT03038308|hyperprolactinemia
819189|NCT03038308|prolactin
819190|NCT03038295|Retinopathy of Prematurity
819191|NCT03038295|propranolol
819192|NCT03038295|ROP
819193|NCT03038269|Robotics
819194|NCT03038269|Upper Extremity
819195|NCT03038256|High Risk Rectal Cancer
819196|NCT03038256|Neoadjuvant chemotherapy
819197|NCT03038256|Delayed total mesorectal excision
819198|NCT03038243|Shigella
819199|NCT03038243|vaccine
819200|NCT03038243|shigellosis
819201|NCT03038243|dysentery
819202|NCT03038243|whole cell
819203|NCT03038230|human bispecific full length IgG antibody, CLEC12A, CD3
819204|NCT03038230|MCLA-117
819205|NCT03038230|First in Human
819206|NCT03038230|Antibodies, Bispecific
819207|NCT03038230|Immunologic Factors
819208|NCT03038230|relapsed, refractory patient
819209|NCT03038230|AML, minimal residual disease (MRD)
819210|NCT03038230|Acute Myelogenous Leukemia
819211|NCT03038230|Acute Myeloid Leukemia
819212|NCT03038230|CD34+CD38
819213|NCT03038230|T-cell recruiting
819214|NCT03038217|rectal cancer
819215|NCT03038217|neoajuvant chemoradiation
819216|NCT03038217|circulating tumor DNA
819217|NCT03038204|Papillary muscles approximation
819218|NCT03038178|Mycobacterium Infections, Nontuberculous
819219|NCT03038178|Mycobacteria, Atypical
819220|NCT03038178|Amikacin
819221|NCT03038178|Inhalation
819222|NCT03038165|Hemodialysis
819223|NCT03038165|Intradialytic hypertension
819224|NCT03038165|Hemodynamics changes
819225|NCT03038152|Disorder of breast
819226|NCT03038152|Breast Cancer
819227|NCT03038152|Lymph node metastasis
819228|NCT03038152|Magseed marker
819229|NCT03038152|Lymph node removal
819230|NCT03038139|forward head posture
819231|NCT03038139|postural correction
819232|NCT03038139|spinal muscles
819233|NCT03038126|chronic kidney disease
819234|NCT03038126|patient safety
819235|NCT03038126|home telehealth
819236|NCT03038061|Diaphragm
819237|NCT03038061|Capnoperitoneum
819238|NCT03038061|EIT
819239|NCT03038061|Laparoscopy
819240|NCT03038009|Coronary Artery Bypass Graft
819241|NCT03038009|Dual Antiplatelet Therapy
819242|NCT03038009|Gastrointestinal
819243|NCT03038009|Mucosal Injury
819244|NCT03038009|Proton Pump Inhibitor
819245|NCT03037996|anesthesia
819246|NCT03037996|satisfaction
819247|NCT03037983|Schizophrenia
819248|NCT03037983|Transcranial magnetic stimulation
819249|NCT03037983|Electroencephalography
819250|NCT03037944|Adenomyosis
819251|NCT03037944|Contraceptive pills
819252|NCT03037944|Levonorgestrel-releasing Intrauterine System
819253|NCT03037918|Gut Microbiota
819254|NCT03037918|High Fat Diets
819255|NCT03037918|Probiotics
819256|NCT03037918|Glycaemic Control
819257|NCT03037853|Atlas
819258|NCT03037853|Full human Body
819259|NCT03037853|MRI
819260|NCT03037840|RF EMF
819261|NCT03037840|In Vivo
819262|NCT03037840|tumor specific frequencies
819263|NCT03037827|endovenous laser ablation
819264|NCT03037827|radial fiber
819265|NCT03037827|linear endovenous energy density
819266|NCT03037827|1470 nm
819267|NCT03037827|occlusion rate
819268|NCT03037814|restorative materials
819269|NCT03037814|primary teeth
819270|NCT03037814|children
819271|NCT03037788|Excessive sweating
819272|NCT03037775|tobacco
819273|NCT03037775|cardiovascular system
819274|NCT03037775|sympathetic nervous system
819275|NCT03037684|neuropathic pain
819276|NCT03037684|chronic postoperative pain
819277|NCT03037671|Malglycemia
819278|NCT03037658|physical activity
819279|NCT03037658|walking
819280|NCT03037658|incentive
819281|NCT03037658|step count
819299|NCT03037593|Pregnancy
819300|NCT03037593|Gestational Diabetes
819305|NCT03037554|Skin Temperature
819306|NCT03037554|Hot Flashes
819307|NCT03037554|Sleep Disturbance
819308|NCT03037541|Wake Forest
819309|NCT03037541|Actinic Keratosis
819310|NCT03037541|Cryosurgery
819311|NCT03037541|Cream
819312|NCT03037502|Men's Health
819313|NCT03037502|weight loss
819314|NCT03037502|African American men
819315|NCT03037502|Latino men
819316|NCT03037437|Hepatocellular Cancer
819317|NCT03037437|Sorafenib
819318|NCT03037437|Hydroxychloroquine
819319|NCT03037424|Cyroprecipitate
819320|NCT03037424|Fibrinogen
819321|NCT03037424|Cardiac Surgery
819322|NCT03037411|Atherosclerosis
819323|NCT03037411|Superficial Femoral Artery (SFA)
819324|NCT03037411|Proximal Popliteal Artery (PPA)
819325|NCT03037411|Stenting
819326|NCT03037411|Paclitaxel
819327|NCT03037411|Health Economics
819328|NCT03037385|medullary thyroid cancer
819329|NCT03037385|non-small cell lung cancer
819330|NCT03037385|papillary thyroid cancer
819331|NCT03037372|adults
819332|NCT03037372|antiretroviral therapy
819333|NCT03037359|PID
819334|NCT03037346|Malignant neoplasms of female genital organs
819335|NCT03037346|Invasive gynecologic malignancy
819336|NCT03037346|Medical Power of Attorney Documents
819337|NCT03037346|MPOAD
819338|NCT03037346|Questionnaires
819339|NCT03037346|Surveys
819340|NCT03037333|echocardiogram
819341|NCT03037333|Electrocardiogram: Electrical Alternans
819342|NCT03037333|fluoroscopy
819343|NCT03037229|Myocardial Infarction
819344|NCT03037229|Ischemia
819345|NCT03037229|Myocardial Ischemia
819346|NCT03037229|Heart Diseases
819347|NCT03037229|Cardiovascular Diseases
819348|NCT03037229|Vascular Diseases
819349|NCT03037216|Exercise
819350|NCT03037164|INTERCEPT
819351|NCT03037164|Red Blood Cells
819352|NCT03037164|RBC
819353|NCT03037164|Pathogen Inactivation
819354|NCT03037164|Zika
819355|NCT03037164|Cerus
819356|NCT03037164|Pathogen Reduction
819357|NCT03037151|Safety
819358|NCT03037151|Efficacy
819359|NCT03037151|grazoprevir
819360|NCT03037151|elbasvir
819361|NCT03037151|compensated cirrhosis
819362|NCT03037151|genotype 1 (GT1)
819363|NCT03037151|genotype 6 (GT6)
819364|NCT03037151|hepatitis virus C (HCV)
819365|NCT03037151|human immunodeficiency virus (HIV)
819366|NCT03037138|postdialysis washed-out
819367|NCT03037099|Glycemic index
819368|NCT03037099|dietary intakes
819369|NCT03037086|NSCLC
819370|NCT03037073|Duloxetine
819371|NCT03037073|Succinylcholine
819372|NCT03037073|Postoperative Myalgia
819373|NCT03037073|Microlaryngoscopy
819374|NCT03037060|Alcohol use, problem
819375|NCT03037021|Sickle Cell Disease
819376|NCT03037021|Needs Assessment
819377|NCT03037021|Barriers to care
819378|NCT03037021|Access to care
819379|NCT03037021|Primary care
819380|NCT03037008|perineal sonography
819381|NCT03037008|male sling
819382|NCT03037008|post prostatectomy incontinence
819383|NCT03037008|ultrasonography
819384|NCT03036956|subclinical hypothyroidism in pregnancy
819385|NCT03036904|venetoclax
819386|NCT03036904|dose-adjusted EPOCH-R
819387|NCT03036904|aggressive B-Cell lymphoma
819388|NCT03036904|Lymphoma
819389|NCT03036904|Non-Hodgkin lymphoma
819390|NCT03036904|Diffuse large B-cell lymphoma
819391|NCT03036904|Double hit lymphoma
819392|NCT03036891|Gastroparesis
819393|NCT03036891|Opioid-Induced
819394|NCT03036891|Delayed Gastric Emptying
819395|NCT03036878|Osteochondral
819396|NCT03036878|Marrow Stimulation
819397|NCT03036878|ReNu
819398|NCT03036865|Healthy participants
819399|NCT03036865|BOS161721
819400|NCT03036865|Pharmacokinetics
819401|NCT03036865|Pharmacodynamics
819402|NCT03036826|renal replacement therapy
819403|NCT03036787|Premature Baby
819404|NCT03036787|motor development
819405|NCT03036787|cognitive development
819406|NCT03036774|Gastric contents
819407|NCT03036774|Ultrasound
819408|NCT03036774|Diabetes
819409|NCT03036761|Auriculotherapy
819410|NCT03036696|Retention
819411|NCT03036696|Lactation
819412|NCT03036696|Human milk
819413|NCT03036696|Pregnancy
819414|NCT03036696|Clinical Research Studies
819415|NCT03036696|BEACH
819416|NCT03036657|Acupuncture
819417|NCT03036657|Electroacupuncture
819418|NCT03036657|Nerve Conduction Studies
819419|NCT03036657|Quantitative Sensory Testing
819420|NCT03036644|electronic cigarette
819421|NCT03036644|e-cigarette
819422|NCT03036644|oxidative stress
819423|NCT03036644|tobacco smoking
819424|NCT03036618|BMI
819425|NCT03036618|Blood Cholesterol
819426|NCT03036618|Glucose
819427|NCT03036618|Insulin
819428|NCT03036618|Gut health
819429|NCT03036605|dexamethasone
819430|NCT03036605|bupivacaine
819431|NCT03036605|nasal surgery
819432|NCT03036605|nasal packing
819433|NCT03036592|Glucose tolerance test, MTNR1B, nutrigenomics, food timing
819434|NCT03036579|CAD/CAM
819435|NCT03036579|Ceramic
819436|NCT03036579|Crown
819437|NCT03036553|Chronic pain
819438|NCT03036553|Psychological factors
819439|NCT03036553|Musculoskeletal pain
819440|NCT03036553|Prognosis
819441|NCT03036540|upper limb thrombosis, midline catheter
819442|NCT03036527|Bladder
819443|NCT03036527|Sexual Function
819444|NCT03036514|numeric rating scale
819445|NCT03036514|opioid side effects
819455|NCT03036449|Medication errors
819456|NCT03036449|Patient safety
819457|NCT03036436|Cancer
819458|NCT03036436|EHealth
819459|NCT03036436|Cancer Survivor
819460|NCT03036436|Rehabilitation
819461|NCT03036410|Hearing Aid Usage (monaural, binaural)
819462|NCT03036410|Cochlear Implant Usage (monaural, binaural)
819731|NCT03034967|Danirixin
819463|NCT03036410|Hearing Aid and Cochlear Implant Usage (monaural)
819464|NCT03036397|Anxiety
819465|NCT03036397|Vasopressin
819466|NCT03036397|Fear-Potentiated Startle
819467|NCT03036397|Shock Threat
819468|NCT03036397|Emotion Recognition
819469|NCT03036384|scheduled cesarean delivery
819470|NCT03036384|spinal anesthesia
819471|NCT03036384|local anesthesia
819472|NCT03036371|Neurogenesis
819473|NCT03036371|Memory
819474|NCT03036371|Spatial Processing
819475|NCT03036371|Hippocampus
819476|NCT03036371|Cognition
819477|NCT03036371|Aerobic Exercise
819478|NCT03036332|aerobic interval training
819479|NCT03036332|biomarkers
819480|NCT03036306|scar
819481|NCT03036306|nefopam
819482|NCT03036306|cicatrix
819483|NCT03036280|E2609
819484|NCT03036280|elenbecestat
819485|NCT03036280|Alzheimer's Disease
819486|NCT03036280|Early Alzheimer's Disease
819487|NCT03036280|Prodromal Alzheimer's Disease
819488|NCT03036280|Dementia
819489|NCT03036280|Dementia, Alzheimer's type
819490|NCT03036280|mild cognitive impairment
819491|NCT03036280|MissionAD2
819492|NCT03036267|health disparity
819493|NCT03036267|motivational interviewing
819494|NCT03036267|African American adults
819495|NCT03036267|Federally Qualified Health Centers
819496|NCT03036267|adherence
819497|NCT03036267|health beliefs
819498|NCT03036267|self-management
819499|NCT03036267|asthma control
819500|NCT03036254|Diabetes Mellitus
819501|NCT03036254|Cognition
819505|NCT03036228|Solid tumours
819506|NCT03036202|epinephrine
819507|NCT03036163|Tuberculosis
819508|NCT03036150|Chronic Kidney Disease (CKD)
819509|NCT03036150|Cardiovascular Events (CV)
819510|NCT03036150|Phase III outcome trial
819511|NCT03036137|Tinnitus
819512|NCT03036137|Electroencephalogram
819513|NCT03036137|Transcranial Direct Current Stimulation
819514|NCT03036124|HFrEF
819515|NCT03036124|Heart Failure (HF)
819516|NCT03036124|Cardiovascular Events (CV)
819517|NCT03036124|Phase III outcome trial
819518|NCT03036085|postoperative pain
819519|NCT03036085|video-assisted thoracoscopic surgery (VATS)
819520|NCT03036085|opioids
819521|NCT03036085|bupivacaine
819522|NCT03036085|liposomal bupivacaine
819523|NCT03036085|analgesia
819524|NCT03036085|local anesthetics
819525|NCT03036072|Therapeutic Hypothermia
819526|NCT03036059|Twice a year treatment
819527|NCT03036059|Biannual treatment
819528|NCT03036059|Wuchereria bancrofti
819530|NCT03035968|Vojta therapy
819531|NCT03035968|reflex locomotion
819532|NCT03035968|stroke rehabilitation
819533|NCT03035968|stroke
819534|NCT03035968|physiotherapy
819535|NCT03035955|Rosacea
819536|NCT03035955|Wake Forest
819537|NCT03035955|Demodex
819538|NCT03035955|Finacea Gel
819539|NCT03035942|Intrathecal morphine
819540|NCT03035942|Nausea and vomiting
819541|NCT03035942|Quality of recovery
819542|NCT03035942|Patient satisfaction
819543|NCT03035942|Pruritus
819544|NCT03035942|Postoperative pain
819545|NCT03035916|transversus abdominal plane block
819546|NCT03035916|epidural anesthesia
819547|NCT03035916|stress response
819548|NCT03035916|anesthetic recovery
819549|NCT03035890|NSCLC
819550|NCT03035890|Lung Cancer
819551|NCT03035890|Non Small Cell Lung Cancer
819552|NCT03035877|Antisocial Behavior
819553|NCT03035877|Alcohol Abuse
819554|NCT03035877|Drug Abuse
819555|NCT03035877|Young Adults
819556|NCT03035864|Ocular discomfort after cataract and refractive surgery
819557|NCT03035864|cataract surgery
819558|NCT03035864|refractive surgery
819559|NCT03035851|Alzheimer Disease
819560|NCT03035851|Dementia
819561|NCT03035851|Exercise
819562|NCT03035851|Physical Activity
819563|NCT03035851|Brain blood flow
819564|NCT03035851|Cognition
819565|NCT03035851|Fitness
819566|NCT03035812|Bicarbonate
819567|NCT03035773|Cancer
819568|NCT03035773|Oncology
819569|NCT03035773|Survivorship
819570|NCT03035760|Helminths
819571|NCT03035760|Oxfendazole
819572|NCT03035760|Pharmacokinetics
819573|NCT03035760|Safety
819574|NCT03035747|registry
819575|NCT03035747|varicose veins
819576|NCT03035747|conventional surgery
819577|NCT03035747|thermal ablation
819578|NCT03035747|radiofrequency
819579|NCT03035747|laser
819580|NCT03035747|sclerotherapy
819586|NCT03035695|Trauma
819587|NCT03035695|Scalp injuries
819588|NCT03035695|Profused Bleeding
819589|NCT03035695|Accident
819590|NCT03035656|Pain
819591|NCT03035656|analgesic
819592|NCT03035656|spinal fusion
819593|NCT03035630|Avelumab
819594|NCT03035630|Sunitinib
819595|NCT03035630|MSB0010718C
819596|NCT03035630|Sutent
819597|NCT03035630|IgG1 antibody
819598|NCT03035630|Anti-PD-L1
819599|NCT03035630|Tyrosine kinase inhibitor
819600|NCT03035617|Bupivacaine
819601|NCT03035604|Malnutrition
819602|NCT03035604|Nutritional status
819603|NCT03035604|Mini Nutritional Assessment
819604|NCT03035604|MNA
819605|NCT03035604|Weight loss
819606|NCT03035604|Body Mass Index
819607|NCT03035604|BMI
819608|NCT03035604|Lean muscle mas
819609|NCT03035604|American Society for Parenteral and Enteral Nutrition
819610|NCT03035604|ASPEN
819611|NCT03035578|Pharmacokinetics
819612|NCT03035578|Pharmacodynamics
819613|NCT03035578|Morphine
819614|NCT03035578|Neonatal
819615|NCT03035565|Heart Failure
819616|NCT03035565|Cognition in Heart Failure
819617|NCT03035552|Congenital heart disease (CCHD)
819618|NCT03035552|Non-Nutritive Suck
819619|NCT03035539|Rehabilitation
819620|NCT03035513|Continuous spikes
819621|NCT03035513|Epilepsy
819622|NCT03035513|Nervous system disease
819623|NCT03035513|Neuronal plasticity
819624|NCT03035513|Diffusion MRI
819625|NCT03035513|Functional MRI
819626|NCT03035513|waves during slow sleep (CSWS)
819629|NCT03035461|diagnosis annoucement
819630|NCT03035461|patient's feelings
819631|NCT03035448|Malignant neoplasms of independent (primary) multiple sites
819632|NCT03035448|Advanced cancer
819633|NCT03035448|Recurrent cancer
819634|NCT03035448|Metastatic disease
819635|NCT03035448|Palliative care
819636|NCT03035448|Videos
819637|NCT03035448|Questionnaires
819638|NCT03035448|Surveys
819639|NCT03035435|fast-track rehabilitation
819640|NCT03035435|fast-track surgery
819641|NCT03035422|Allogenic cell stem transplant, Sequential chemotherapy Haploidentical transplant
819642|NCT03035409|Malignant neoplasms of independent (primary) multiple sites
819643|NCT03035409|Advanced Cancer
819644|NCT03035409|Metastatic or recurrent incurable solid tumors
819645|NCT03035409|Anamorelin
819646|NCT03035409|Physical activity
819647|NCT03035409|Questionnaires
819648|NCT03035409|Surveys
819649|NCT03035409|Dietary Counseling
819650|NCT03035409|Exercise Counseling
819651|NCT03035383|Large thyroid
819652|NCT03035383|purse string suture
819653|NCT03035383|thyroidectomy
819654|NCT03035370|Pertussis
819655|NCT03035370|Epicutaneous ImmunoTherapy (EPIT)
819656|NCT03035370|Vaccine
819657|NCT03035370|Viaskin PT
819658|NCT03035357|Malignant neoplasms of male genital organs
819659|NCT03035357|Prostate cancer
819660|NCT03035357|Adenocarcinoma of the prostate
819661|NCT03035357|Daratumumab
819662|NCT03035357|Biomarker response
819663|NCT03034720|Concussion
819664|NCT03034720|persistent post-concussive symptoms
819665|NCT03034720|CBT
819666|NCT03034720|collaborative care
819667|NCT03034720|Depression
819668|NCT03034720|Anxiety
819669|NCT03034707|biotin pharmacokinetic
819670|NCT03034707|biotinylated assay
819671|NCT03034707|hormone measurement
819672|NCT03034707|thyroid
819673|NCT03034707|parathyroid
819674|NCT03034707|prolactin
819675|NCT03035305|Seasonal malaria chemoprevention
819676|NCT03035305|Lipid-based nutrient supplement
819677|NCT03035305|Children
819678|NCT03035305|Mali
819685|NCT03035266|blood flow restriction
819686|NCT03035266|strength
819687|NCT03035266|muscle atrophy
819688|NCT03035266|post-operative therapy
819689|NCT03035266|knee
819690|NCT03035201|Memory
819691|NCT03035201|Mild Cognitive Impairment
819692|NCT03035201|Alzheimer's Disease
819693|NCT03035201|Cognition
819694|NCT03035188|resectable
819695|NCT03035175|Residences
819696|NCT03035175|Video Laryngoscopy
819697|NCT03035175|Intubations
819698|NCT03035175|Neonatal
819699|NCT03035175|NICU
819700|NCT03035175|neonates
819701|NCT03035175|Medical Education
819702|NCT03035162|dual tDCS
819703|NCT03035162|physical rehabilitation
819704|NCT03035162|lower limb functions
819705|NCT03035149|Obesity
819706|NCT03035149|Metabolic Syndrome
819707|NCT03035149|Dyspnea
819708|NCT03035149|Pulmonary Function
819709|NCT03035149|Exercise Capacity
819710|NCT03035136|polyps
819711|NCT03035123|Heart Failure
819712|NCT03035123|Therapeutic education
819713|NCT03035123|Quality of life
819714|NCT03035071|Minimal-invasive esophagectomy
819715|NCT03035071|Esophageal resection
819716|NCT03035071|Hybrid esophagectomy
819717|NCT03035058|Drug therapy
819718|NCT03035032|Leuprolide acetate
819719|NCT03035032|Prostate cancer
819720|NCT03035019|anxiety
819721|NCT03035019|behavioral app
819722|NCT03035006|Hepatocellular carcinoma
819723|NCT03035006|Portal vein tumor thrombosis
819724|NCT03035006|TLC388
819725|NCT03035006|Chemoradiotherapy
819726|NCT03035006|Lipotecan
819727|NCT03034967|HCRU exacerbations
819728|NCT03034967|SGRQ
819729|NCT03034967|CXCR2 antagonist
819730|NCT03034967|GSK1325756
819732|NCT03034967|COPD
819733|NCT03034941|Obesity
819734|NCT03034941|PCOS
819735|NCT03034941|Infertility
819736|NCT03034941|Liraglutide
819737|NCT03034941|Metformin
819738|NCT03034941|IVF
819744|NCT03034889|Anesthesia
819745|NCT03034889|Children
819746|NCT03034889|General Anesthesia
819747|NCT03034889|Neurocognitive Outcome
819748|NCT03034876|"Acute Kidney Injury, diagnosis, children, shock"
819749|NCT03034863|Family Caregivers
819750|NCT03034863|Spouse Caregivers
819751|NCT03034863|Veterans
819752|NCT03034863|Suicide
819753|NCT03034863|Clinical Trial
819754|NCT03034863|Military Families
819755|NCT03034863|Military Psychology
819756|NCT03034850|cytoreductive surgery
819757|NCT03034850|hyperthermic intraperitoneal peroperative chemotherapy
819758|NCT03034850|platelet function
819759|NCT03034850|thrombin generation
819760|NCT03034850|thromboelastometry
819761|NCT03034824|diode laser
819762|NCT03034824|Er,Cr:YSGG laser
819763|NCT03034824|Aggressive Periodontitis
819764|NCT03034824|Clinical periodontal parameters
819765|NCT03034824|Gingival crevicular fluid cytokines levels
819766|NCT03034811|Noninflammatory degenerative joint disease
819767|NCT03034811|Osteoarthritis
819768|NCT03034811|Avascular necrosis
819769|NCT03034811|Traumatic arthritis
819770|NCT03034811|Partial knee arthroplasty
819771|NCT03034811|Unicompartmental knee arthroplasty
819772|NCT03034772|neovascular
819773|NCT03034772|wet
819774|NCT03034772|age-related
819775|NCT03034772|macular degeneration
819776|NCT03034772|dorzolamide
819777|NCT03034772|timolol
819778|NCT03034759|continuous glucose monitoring
819779|NCT03034746|alzheimer's disease, physical activity, cognitive training
819780|NCT03034733|Arthroplasty
819781|NCT03034733|Knee Replacement
819782|NCT03034733|Pain, Postoperative
819783|NCT03034733|Glucocorticoids
819784|NCT03034733|Dexamethasone
819785|NCT03034668|Botanical Supplement
819786|NCT03034668|Performance-Enhancing Supplement
819787|NCT03034655|Vestibular rehabilitation
819788|NCT03034655|Falls in elderly
819789|NCT03034655|Computerized dynamic posturography
819790|NCT03034655|Mobile posturography
819791|NCT03034642|Apoptosis
819792|NCT03034642|Bronchoscopy
819793|NCT03034642|Human
819794|NCT03034642|Mice, inbred strains
819795|NCT03034642|Macrophages, Alveolar
819796|NCT03034642|MicroRNAs
819797|NCT03034642|Streptococcus pneumoniae
819798|NCT03034642|Fluticasone
819799|NCT03034616|Primary ovarian insufficiency
819800|NCT03034616|In-vivo activation
819801|NCT03034551|Adherence
819802|NCT03034551|Financial Incentives
819803|NCT03034551|Remote Monitoring
819804|NCT03034551|Self-Weighing
819805|NCT03034551|Behavioral Economics
819806|NCT03034551|Telehealth
819807|NCT03034551|mobile health (mHealth)
819808|NCT03034551|Smartphone App
819809|NCT03034551|Wellth App
819810|NCT03034486|Glaucoma
819811|NCT03034473|locally advanced rectal cancer
819812|NCT03034473|translational research
819813|NCT03034473|Biomarker
819814|NCT03034447|Asthma
819815|NCT03034447|Obstructive Sleep Apnea
819816|NCT03034447|Children
819817|NCT03034447|Teenagers
819818|NCT03034408|Impulsivity
819819|NCT03034408|Nalmefene
819820|NCT03034408|Baclofen
819821|NCT03034395|Melanoma
819822|NCT03034395|cT2N0M0
819823|NCT03034382|morphine
819824|NCT03034382|nalbuphine
819825|NCT03034382|arthroscopic rotator cuff repair
819826|NCT03034382|ultrasound guided interscalene block
819827|NCT03034369|Integration
819828|NCT03034369|Primary Care
819829|NCT03034369|Behavioral Health
819830|NCT03034369|Health Care Reform
819831|NCT03034369|Medical Home
819832|NCT03034369|Accountable Care Organization
819833|NCT03034356|Schizophrenia
819834|NCT03034343|Mindfulness
819835|NCT03034343|Internet program
819836|NCT03034343|Depression
819837|NCT03034343|Cost-effectiveness
819838|NCT03034330|informal care
819839|NCT03034330|empowerment
819840|NCT03034330|family-focused intervention
819841|NCT03034330|stroke rehabilitation
819842|NCT03034317|Diaphragm Pacing
819843|NCT03034304|MASCT-I，DC，T cell
819844|NCT03034304|Advanced solid tumors
819845|NCT03034304|Bladder Cancer
819846|NCT03034304|Soft Tissue Sarcoma
819847|NCT03034291|Cocoa
819848|NCT03034291|obesity
819849|NCT03034291|HOMA-IR
819850|NCT03034291|BMI
819851|NCT03034291|Quality of life
819852|NCT03034278|opioid use
819854|NCT03034226|Hypoglycemia-Associated Autonomic Failure (HAAF)
819855|NCT03034213|mesh
819856|NCT03034200|Pheochromocytoma-paraganglioma
819857|NCT03034200|ONC201
819858|NCT03034187|Acute toxicity
819859|NCT03034187|Late toxicity
819860|NCT03034187|Quality of Life since 2011(set-up SFP-prostate)
819861|NCT03034174|tigecycline
819862|NCT03034174|pharmacokinetics
819863|NCT03034148|Coronary artery disease
819864|NCT03034148|Atherothrombosis
819865|NCT03034148|Thrombin generation
819866|NCT03034148|Platelet Acetyl Coenzyme A carboxylase phosphorylation
819867|NCT03034109|Transcranial Direct Current Stimulation
819868|NCT03034109|Stroke
819869|NCT03034109|Electric Stimulation Therapy
819870|NCT03034109|Prefrontal Cortex
819871|NCT03034109|Electroencephalography
819872|NCT03034109|Cognition
819873|NCT03034109|Neurological Rehabilitation
819874|NCT03034109|Memory
819875|NCT03034109|Working Memory
819876|NCT03034109|Attention
819877|NCT03034109|Concentration
819878|NCT03034109|Short-Term Memory
819879|NCT03034109|Planning
819880|NCT03034109|Executive Function
819881|NCT03034109|Cerebrovascular disease
819882|NCT03034083|healthy marriage
819883|NCT03034083|healthy relationships
819884|NCT03034083|parenting
819885|NCT03034083|healthy marriage and relationship education
819886|NCT03034070|MRI
819887|NCT03034070|MRI sequences
819888|NCT03034070|prostate cancer
819889|NCT03034070|cancer
819890|NCT03034070|staging
819891|NCT03034070|bone metastasis
819892|NCT03034070|node metastasis
819893|NCT03034031|Traumatic Brain Injury
819894|NCT03034031|Children
819895|NCT03034031|Pediatric
819896|NCT03034031|MRI
819897|NCT03034031|fMRI
819898|NCT03034031|Cognition
819899|NCT03034031|DTI
819900|NCT03034031|Longitudinal
819901|NCT03034031|Connectivity
819902|NCT03034031|DAI
819903|NCT03034031|Neuropsychology
819904|NCT03034031|Rehabilitation
819905|NCT03034018|insomnia
819906|NCT03034018|hot flashes
819907|NCT03034018|menopause
819908|NCT03034018|suvorexant
819909|NCT03034018|belsomra
819910|NCT03034005|Inhaled corticosteroids
819911|NCT03034005|Airway hyper-responsiveness
819912|NCT03034005|Airway smooth muscle
819913|NCT03034005|sodium-potassium pump
819914|NCT03033966|Cerebral Oximetry
819915|NCT03033966|Cerebral Venous Thrombosis
819916|NCT03033966|Decompressive Craniectomy
819917|NCT03033927|Stage IV Pancreatic Cancer
819918|NCT03033927|FOLFIRINOX
819919|NCT03033927|gem/nab-P chemotherapy
819920|NCT03033927|17-042
819930|NCT03033836|transgender women
819931|NCT03033823|Alcoholism
819932|NCT03033823|Delirium
819933|NCT03033823|Magnesium Deficiency
819934|NCT03033797|assitive technology
819935|NCT03033797|virtual reality games
819936|NCT03033797|intellectual disability
819937|NCT03033797|augmentative and alternative communication
819938|NCT03033784|Neuroscience
819939|NCT03033758|comorbidities
819940|NCT03033732|opioid agonist treatment
819941|NCT03033732|pragmatic
819942|NCT03033732|prescription opioid use
819943|NCT03033732|patient engagement
819944|NCT03033719|Colorectal Surgery
819945|NCT03033719|Geriatrics
819946|NCT03033719|Digestive Oncology
819947|NCT03033719|Colon cancer
819948|NCT03033719|Elderly patients
819949|NCT03033719|Laparoscopy
819950|NCT03033719|Laparotomy
819951|NCT03033719|Morbidity
819952|NCT03033667|perioperative fasting
819953|NCT03033667|free fatty acids
819954|NCT03033667|coronary bypass grfting
819955|NCT03033589|Pain control
819956|NCT03033589|Anterior Cruciate Ligament (ACL_ Reconstruction)
819957|NCT03033589|Regional Anesthesia
819963|NCT03033485|Picolinamide
819964|NCT03033485|PET/CT
819965|NCT03033485|Diagnosis
819966|NCT03033485|Melanoma
819967|NCT03033459|breast feeding
819968|NCT03033459|motivational interviewing
819969|NCT03033420|Unipolar disorder
819970|NCT03033420|Bipolar disorder
819971|NCT03033420|Randomized controlled trial
819972|NCT03033420|Smartphone
819973|NCT03033420|Re-admission
819974|NCT03033420|CBT
819975|NCT03033381|Children
819976|NCT03033381|Inguinal hernia
819977|NCT03033381|Testis
819978|NCT03033381|Doppler ultrasonography
819979|NCT03033368|immunological outcome
819980|NCT03033368|virologic outcomes
819981|NCT03033368|HIV-1 infected adolescents
819982|NCT03033368|EFV switch to RPV
819983|NCT03033368|Rilpivirine pharmacokinetic
819984|NCT03033368|neuropsychiatric adverse events
819985|NCT03033355|Neurogenic Bladder, Detrusor Overactivity, Botox, fMRI, neurogenic detrusor overactivity
819986|NCT03033342|Phase 1
819987|NCT03033316|Multiple Myeloma
819988|NCT03033316|Liposomal Dexamethasone
819989|NCT03033316|Targeted Drug Delivery
819990|NCT03033303|Hu3F8
819991|NCT03033303|GM-CSF
819992|NCT03033303|Isotretinoin
819993|NCT03033303|16-1643
819994|NCT03033290|Qi-tonifying regimen
819995|NCT03033290|immune-modulation
819996|NCT03033290|gut microbiota
819997|NCT03033251|COPD exacerbation
819998|NCT03033251|Work of breathing
819999|NCT03033251|Non invasive ventilation
820000|NCT03033251|High Flow Oxygen Cannula
820001|NCT03033225|Pancrease
820002|NCT03033225|Cancer
820003|NCT03033225|Photodynamic Therapy
820004|NCT03033225|Pancreatic
820005|NCT03033225|Tumor
820006|NCT03033225|unresectable
820007|NCT03033199|Gut microbiota
820008|NCT03033199|Immune thrombocytopenia
820009|NCT03033186|Everolimus
820010|NCT03033186|Long term site effects
820011|NCT03033186|Dried Blood Spot
820012|NCT03033186|Therapeutic Drug Monitoring
820013|NCT03033160|Estrogen
820014|NCT03033160|Hematuria
820015|NCT03033121|growth hormone
820016|NCT03033121|children
820017|NCT03033121|metabolism
820018|NCT03033095|TNF inhibitor
820019|NCT03033095|Etanercept
820020|NCT03033095|Spondyloarthritis
820021|NCT03033095|Biomarkers analysis
820022|NCT03033095|Personnalized medicine
820023|NCT03033056|fear-conditioning
820024|NCT03033056|behavioral avoidance
820025|NCT03033056|anxiety disorders
820026|NCT03033056|fMRI
820027|NCT03033043|aortic
820028|NCT03033043|dissection
820029|NCT03033043|type B
820030|NCT03033043|thoracic
820031|NCT03033030|Ultrasound
820032|NCT03033030|Digital Breast Tomosynthesis
820033|NCT03033030|Cancer Detection rate
820034|NCT03033030|Sensitivity
820035|NCT03033030|Specificity
820036|NCT03033030|Breast density
820037|NCT03033017|HIV
820038|NCT03032991|Gestational diabetes
820039|NCT03032991|Neurodevelopment
820040|NCT03032991|Placenta
820041|NCT03032991|Gut microbiota
820042|NCT03032991|Protectins
820043|NCT03032991|MFSD2a
820044|NCT03032991|AdipoRon
820045|NCT03032965|atrial fibrillation
820046|NCT03032965|ablation
820047|NCT03032965|adenosine
820048|NCT03032952|RCT
820049|NCT03032952|Computerised interventions
820050|NCT03032952|Mobile applications
820051|NCT03032952|Stress, Psychological
820052|NCT03032952|Depressive symptoms
820053|NCT03032952|Anxious symptoms
820054|NCT03032952|Students
820055|NCT03032952|Mental health
820056|NCT03032926|Anxiety
820057|NCT03032913|Pancreas
820058|NCT03032913|Pancreatic
820059|NCT03032913|Cancer
820060|NCT03032913|Circulating tumor cell (CTC)
820061|NCT03032913|Adenocarcinoma
820062|NCT03032913|Ductal
820063|NCT03032913|Exosome
820064|NCT03032900|Major lung resection
820065|NCT03032900|Right Ventricular Dysfunction
820066|NCT03032900|2D Strain
820067|NCT03032887|hygiene
820068|NCT03032887|prenatal care
820069|NCT03032887|postnatal care
820070|NCT03032874|Colorectal cancer
820071|NCT03032874|Polyps
820072|NCT03032874|Colonoscopy
820073|NCT03032874|Rectal bleeding
820074|NCT03032874|Nigeria
820075|NCT03032861|Orange juice
820076|NCT03032861|Microbiota
820077|NCT03032861|Prebiotic
820078|NCT03032861|Flavanones
820079|NCT03032861|Bioavailability
820080|NCT03032835|Calciphylaxis
820081|NCT03032835|Warfarin
820082|NCT03032835|Dialysis
820083|NCT03032822|Opioid consumption
820084|NCT03032822|postdischarge
820085|NCT03032822|cystectomy
820086|NCT03032744|Pediatric
820087|NCT03032744|School Based Health Center
820088|NCT03032731|Physical activity
820089|NCT03032731|Diet
820090|NCT03032731|Health Behavior
820091|NCT03032705|Restorations
820092|NCT03032705|Composite
820093|NCT03032679|pain, acute, chronic, knee arthroplasty
820094|NCT03032666|Thalassemia
820095|NCT03032666|HCV
820096|NCT03032666|Sofosbuvir
820097|NCT03032666|Ledipasvir
820098|NCT03032653|ankle, fracture, rehabilitation, weightbearing, early, late
820099|NCT03032640|Glucose
820100|NCT03032640|Sweet taste receptors
820101|NCT03032640|Artificial sweeteners
820102|NCT03032601|MS (Multiple Sclerosis)
820103|NCT03032601|Acute Fulminating
820104|NCT03032601|Sclerosis
820105|NCT03032601|FDG
820106|NCT03032601|18F Fluorodeoxyglucose
820107|NCT03032601|18F-FDG
820108|NCT03032601|18FDG
820109|NCT03032601|2-Fluoro-2-deoxy-D-glucose
820110|NCT03032601|2-Fluoro-2-deoxyglucose
820111|NCT03032601|Fludeoxyglucose F 18
820112|NCT03032601|Fluorine-18-fluorodeoxyglucose
820113|NCT03032601|Fluorodeoxyglucose F 18
820114|NCT03032601|PET Scan
820115|NCT03032601|Tomography, Positron-Emission
820116|NCT03032601|Magnetic Resonance Imaging, Functional
820117|NCT03032601|fMRI
820118|NCT03032601|PET-MRI
820119|NCT03032601|Acetylcysteine
820120|NCT03032601|N-acetyl cysteine
820121|NCT03032601|NAC
820122|NCT03032601|Oral supplements
820123|NCT03032575|HIV
820124|NCT03032562|respiratory muscle strength
820125|NCT03032562|sleep-disordered breathing
820126|NCT03032562|neuromuscular disease
820127|NCT03032562|chronic-obstructive pulmonary disease
820128|NCT03032497|Brain Computer Interface
820129|NCT03032497|Electroencephalogram (EEG)
820130|NCT03032497|Chronic Pain
820131|NCT03032471|Subarachnoid Hemorrhage
820132|NCT03032471|Delayed cerebral ischemia
820133|NCT03032471|Cognitive Impairment
820134|NCT03032471|Montreal Cognitive Assessment
820135|NCT03032471|MoCA
820136|NCT03032471|Cognitive Deterioration
820137|NCT03032458|Shock Wave Lithotripsy
820138|NCT03032458|Ketorolac
820139|NCT03032458|Xylocaine Gel
820140|NCT03032458|Pethidine
820141|NCT03032445|Body Water/physiology
820142|NCT03032445|Hyponatremia/etiology
820143|NCT03032445|Physical Exertion/physiology
820144|NCT03032445|Running/physiology
820145|NCT03032445|Sodium/blood
820146|NCT03032445|Ethanol
820147|NCT03032380|Hospital-acquired pneumonia (HAP)
820148|NCT03032380|S-649266
820149|NCT03032380|linezolid
820150|NCT03032380|meropenem
820151|NCT03032380|Healthcare-associated pneumonia (HCAP)
820152|NCT03032380|nosocomial pneumonia
820153|NCT03032380|Ventilator-associated pneumonia (VAP)
820154|NCT03032380|Gram-negative pathogens
820155|NCT03032380|pneumonia
820156|NCT03032380|cefiderocol
820157|NCT03032354|probiotics
820158|NCT03032354|children
820159|NCT03032354|remission
820160|NCT03032341|mobility assessment tool
820161|NCT03032302|TBI
820162|NCT03032289|active transport
820163|NCT03032289|cycling
820164|NCT03032289|walking
820165|NCT03032276|Safe motherhood
820166|NCT03032276|Newborn survival
820167|NCT03032276|Community
820168|NCT03032276|Cluster Randomized Trial
820169|NCT03032237|Protein intake
820170|NCT03032237|Older adults
820171|NCT03032237|Protein-rich
820172|NCT03032237|Acceptance
820173|NCT03032237|Liking
820174|NCT03032237|Readymade meals
820175|NCT03032224|Body composition
820176|NCT03032224|sarcopenia
820177|NCT03032224|Dysphagia
820178|NCT03032224|Surgery
820179|NCT03032224|Quality of Life
820180|NCT03032224|Morbidity
820181|NCT03032185|menopause
820182|NCT03032185|post-menopause
820183|NCT03032185|transcutaneous electrical nerve stimulation
820184|NCT03032185|electrical stimulation therapy
820185|NCT03032185|women's health
820186|NCT03032133|Total Knee Arthroplasty
820187|NCT03032133|Total Knee Replacement
820188|NCT03032133|Outcome
820189|NCT03032133|Results
820190|NCT03032133|Pain
820191|NCT03032107|Breast Cancer
820192|NCT03032094|Gingival Recession
820193|NCT03032055|sickle cell desease
820194|NCT03032055|vaso occlusive crisis
820195|NCT03032055|acute chest syndrome
820196|NCT03032055|Validation of predictif score of acute chest syndrome
820197|NCT03032042|intestinal microbiome
820198|NCT03032042|soil-transmitted helminths
820199|NCT03032042|mass drug administration
820200|NCT03032016|VOD
820201|NCT03032016|Defibrotide
820202|NCT03032016|Defitelio
820203|NCT03032016|Registry
820204|NCT03032016|SOS
820205|NCT03031990|Yoga
820206|NCT03031990|Oocyte cryopreservation
820207|NCT03031990|In-vitro fertilization
820208|NCT03031951|Former athletes
820209|NCT03031951|Body composition
820210|NCT03031951|Adaptive thermogenesis
820211|NCT03031951|Physical activity
820212|NCT03031951|Energy expenditure
820213|NCT03031951|Sedentary behavior
820214|NCT03031951|Fat mass
820215|NCT03031951|Abdominal fat mass
820216|NCT03031951|Nutrition
820217|NCT03031951|Behavior modification
820218|NCT03031938|Exposure in utero in tanezumab program
820219|NCT03031925|Annexin A2
820220|NCT03031925|biomarker
820221|NCT03031821|Prostate Cancer
820222|NCT03031821|ADT
820223|NCT03031821|iADT
820224|NCT03031821|Metabolic Syndrome
820225|NCT03031821|Androgen Deprivation Therapy
820226|NCT03031821|Phase III
820227|NCT03031821|Phase 3
820228|NCT03031821|Randomized
820229|NCT03031821|Intermittent Androgen Deprivation Therapy
820230|NCT03031795|intrauterine device
820231|NCT03031782|JIA, JPsA, ERA, Secukinumab, ILAR
820232|NCT03031756|Air polishing
820233|NCT03031743|rotavirus vaccine
820234|NCT03031743|human microbiome
820235|NCT03031743|fecal microbiome
820236|NCT03031743|vaccine immunogenicity
820237|NCT03031743|Rotarix
820238|NCT03031743|immune response, mucosal
820239|NCT03031665|GABA
820240|NCT03031665|Depression
820241|NCT03031665|Stress
820242|NCT03031665|Androgens
820243|NCT03031652|pain
820244|NCT03031652|axial length
820245|NCT03031652|anterior chamber depth
820246|NCT03031652|intraocular pressure
820247|NCT03031639|endoscopic
820248|NCT03031639|thyroidectomy
820249|NCT03031613|intraocular pressure
820250|NCT03031613|intracerebral pressure
820251|NCT03031587|Thermometric MRI
820252|NCT03031587|Myocardium
820253|NCT03031574|Serotonin 4 (5-HT4) receptor
820254|NCT03031574|Phase 1
820255|NCT03031509|Nonunion Fracture of limb
820256|NCT03031496|Cross-over
820257|NCT03031496|Hydrochlorothiazide
820258|NCT03031496|Amiloride hydrochloride
820259|NCT03031496|Phase I
820260|NCT03031496|GSK3542503
820261|NCT03031496|Bioequivalence
820262|NCT03031496|FTIH
820263|NCT03031470|Liver Transplant
820264|NCT03031470|Ischemia-reperfusion injury
820265|NCT03031470|Early allograft dysfunction
820266|NCT03031444|colorectal liver metastasis
820267|NCT03031444|preoperative
820268|NCT03031444|chemotherapy
820269|NCT03031444|targeted therapy
820270|NCT03031431|Hypothermia
820271|NCT03031431|Infant Warmer
820272|NCT03031340|Spinal fusion
820273|NCT03031340|pregabalin
820274|NCT03031340|Spinal fusion surgeries
820275|NCT03031340|two or more vertebrae
820276|NCT03031327|Ocular Discomfort Following Refractive Surgery
820277|NCT03031327|Refractive Surgery
820278|NCT03031314|Joint Replacement
820279|NCT03031314|Knee Replacement
820280|NCT03031314|Wound Healing
820281|NCT03031314|Hip Replacement
820282|NCT03031288|gastroesophageal reflux
820283|NCT03031288|swallow
820284|NCT03031288|feeding bottle
820285|NCT03031288|cardiorespiratory
820286|NCT03031288|apnoea
820287|NCT03031288|preterm
820288|NCT03031288|impedance-pH-metry
820289|NCT03031275|extracorporeal circulation
820290|NCT03031275|critical care outcomes
820291|NCT03031236|Early Childhood Development (ECD)
820292|NCT03031236|Psychosocial stimulation
820293|NCT03031236|Cognition
820294|NCT03031236|Parenting
820295|NCT03031236|Malnutrition
820296|NCT03031236|Bangladesh
820297|NCT03031236|Childhood Maltreatment
820298|NCT03031223|Spinal cord injuries
820299|NCT03031223|low-level laser therapy
820300|NCT03031210|Non-severe community-acquired pneumonia
820301|NCT03031210|Amoxicillin treatment
820302|NCT03031210|Twice daily antibiotic regimen
820303|NCT03031197|adherence
820304|NCT03031197|adolescent
820305|NCT03031197|HIV/AIDS
820306|NCT03031197|Vietnam
820307|NCT03031184|Agitation
820308|NCT03031184|Agitated behaviours
820309|NCT03031184|Alzheimer's Disease
820310|NCT03031171|community engagement, navigation, cancer screening
820311|NCT03031132|Protein-rich breakfast
820312|NCT03031132|Breakfast Skipping
820313|NCT03031132|Young Adults
820314|NCT03031132|Breakfast
820315|NCT03031132|Food form
820316|NCT03031132|fMRI
820317|NCT03031132|Ghrelin
820318|NCT03031132|PYY
820319|NCT03031132|Sleep
820321|NCT03031106|Patient-reported outcomes, Health-related QoL, Internet-based tool
820322|NCT03031093|aerosol therapy
820323|NCT03031093|pulmonary scintigraphy
820324|NCT03031093|upper airways anatomy
820325|NCT03031080|Collagenase, Night-splinting, Dupuytrens, Contracture
820326|NCT03031067|Donors and donation
820327|NCT03031067|Extended criteria donor
820328|NCT03031067|Organ perfusion and preservation
820329|NCT03031067|Liver transplantation
820330|NCT03031067|Kidney transplantation
820331|NCT03031067|Preservation injury
820332|NCT03031067|Ischemia reperfusion injury
820333|NCT03031054|Hydrodissection
820334|NCT03031054|hyaluronic acid
820335|NCT03031041|Hydrodissection
820336|NCT03031041|short-axis
820337|NCT03031041|long-axis
820338|NCT03031028|refractory epilepsy,
820339|NCT03031028|ketogenic diet
820340|NCT03031028|classic ketogenic diet
820341|NCT03031028|seizure rate
820342|NCT03031028|efficacy
820343|NCT03031028|epilepsy
820344|NCT03031015|Reduction, Fracture
820345|NCT03031002|exposure
820346|NCT03031002|spider phobia
820347|NCT03031002|generalization
820348|NCT03031002|extinction
820349|NCT03030976|CD19
820350|NCT03030976|CAR-T
820351|NCT03030976|SLE
820352|NCT03030963|Equal ratio ventilation(ERV)
820353|NCT03030963|Peak inspiratory pressure(PIP)
820354|NCT03030963|Blood loss
820355|NCT03030963|Posterior lumbar interbody fusion(PLIF)
820356|NCT03030963|Prone position
820358|NCT03030885|Radiopharmaceutical (131I-MIP-1095)
820359|NCT03030885|16-1110
820360|NCT03030846|pregnancy
820361|NCT03030846|pelvic floor muscles
820362|NCT03030846|Lumbo-pelvic pain
820363|NCT03030846|Stabilization exercises
820364|NCT03030846|abdominal muscles thickness
820365|NCT03030846|Multifidus muscles thickness
820366|NCT03030846|Multifidus muscles cross section area
820367|NCT03030820|cirrhosis
820368|NCT03030820|Periodontitis
820369|NCT03030794|Gulf War Illness
820370|NCT03030794|Headache
820371|NCT03030794|Muscle Pain
820372|NCT03030794|Joint Pain
820373|NCT03030794|TMS
820374|NCT03030768|Pre-Exposure Prophylaxis
820375|NCT03030768|Fertility
820376|NCT03030768|mHealth
820377|NCT03030768|Pregnancy
820378|NCT03030716|antinutrients
820379|NCT03030716|tannins
820380|NCT03030716|proanthocyanidins
820381|NCT03030716|salivary proline-rich proteins
820382|NCT03030703|Phytic acid
820383|NCT03030703|Cystatin
820384|NCT03030703|Salivary proline-rich protein
820385|NCT03030703|antinutrient
820386|NCT03030690|Proximal Dental Caries
820387|NCT03030690|Glass Carbomer
820388|NCT03030690|Hydroxyapatite Enhanced Glass Ionomer
820389|NCT03030690|Primary Teeth
820390|NCT03030677|pecs block
820391|NCT03030677|breast surgery
820392|NCT03030677|ultrasound guidence
820393|NCT03030664|constipation
820394|NCT03030664|Lactobacillus reuteri
820395|NCT03030664|probiotics
820396|NCT03030651|Breastfeeding
820397|NCT03030651|Education and support
820398|NCT03030651|Ethiopia
820399|NCT03030651|Timely initiation of breastfeeding
820400|NCT03030625|Prostate Cancer
820401|NCT03030625|VMAT
820402|NCT03030625|Dominant Intraprostatic Lesion
820403|NCT03030625|Intensity modulated radiotherapy
820404|NCT03030586|Blood cell biomarkers, peripheral circulating biomarkers
820405|NCT03030573|Bile duct injury
820406|NCT03030573|Bile duct defect
820407|NCT03030573|Round ligament
820408|NCT03030573|Reconstruction
820409|NCT03030508|biomarks
820410|NCT03030508|colorectal cancer
820411|NCT03030508|capecitabine
820412|NCT03030508|gene polymorphism
820413|NCT03030495|Ischemic Heart Disease
820414|NCT03030495|Stable angina
820415|NCT03030495|Fractional flow reserve
820416|NCT03030495|Index of Microcirculatory Resistance
820417|NCT03030495|Coronary Flow Reserve
820418|NCT03030495|Intravascular Imaging
820419|NCT03030482|Anxiety
820420|NCT03030482|intensive care
820421|NCT03030482|mechanical ventilation
820422|NCT03030482|touch massage
820423|NCT03030456|whole body vibration
820424|NCT03030456|Oxidative Stress
820425|NCT03030456|Aged
820426|NCT03030456|Biochemical profile
820427|NCT03030456|muscle strength
820428|NCT03030456|flexibility
820429|NCT03030443|Pain management
820430|NCT03030443|Nitrous
820431|NCT03030417|Topoisomerase 1 Inhibitor
820432|NCT03030417|Epithelial-Mesenchymal Transition
820433|NCT03030417|Pharmacodynamics
820434|NCT03030417|DNA Damage
820435|NCT03030417|Pharmacokinetics
820436|NCT03030404|Genetics
820437|NCT03030404|Familial Background
820438|NCT03030404|Inherited Cancer Syndrome
820439|NCT03030404|Germline Mutation in the CDH1 Gene
820440|NCT03030404|Genetic Testing
820441|NCT03030391|Camp
820442|NCT03030391|Radiation Absorbed Dose
820443|NCT03030391|Compartmental Analysis
820444|NCT03030365|Orientation, Disorientation.
820445|NCT03030352|Child Mental Health
820446|NCT03030352|Parenting
820447|NCT03030352|Autonomy Support
820448|NCT03030352|How-to Parenting Program
820449|NCT03030352|Randomized Controlled Trial
820450|NCT03030352|Primary Prevention
820451|NCT03030352|Parental Mental Health
820452|NCT03030352|Child Well-Being
820453|NCT03030339|Vitamin A status
820454|NCT03030339|infant
820455|NCT03030339|dietary assessment
820456|NCT03030339|retinol isotope dilution
820457|NCT03030339|breast milk intake
820458|NCT03030300|type 2 diabetes
820459|NCT03030300|remission
820460|NCT03030300|short-term intensive insulin therapy
820461|NCT03030235|diabetes
820462|NCT03030235|heart failure
820463|NCT03030235|dapagliflozin
820464|NCT03030235|SGLT-2 inhibitors
820465|NCT03030222|diabetes
820466|NCT03030222|heart failure
820467|NCT03030222|empagliflozin
820468|NCT03030222|SGLT-2 inhibitors
820469|NCT03030209|pancreatectomy
820470|NCT03030209|diabetes mellitus
820471|NCT03030183|PNH
820472|NCT03030157|urothelial cancer
820473|NCT03030157|bladder cancer
820474|NCT03030157|nephroureterectomy
820475|NCT03030131|IFCT
820476|NCT03030131|neodjuvant
820477|NCT03030131|immune therapy
820478|NCT03030131|Non small cell lung cancer
820479|NCT03030118|hydroxychloroquine
820480|NCT03030105|Cognition
820481|NCT03030105|Dementia
820482|NCT03030105|Phosphodiesterase Type 4D
820483|NCT03030105|PDE4D
820484|NCT03030105|Scopolamine
820485|NCT03030105|Donepezil
820486|NCT03030066|DS-1001b
820487|NCT03030066|IDH1 mutation
820488|NCT03030066|Developmental Phase I
820489|NCT03030066|Glioma
820490|NCT03030053|Flavanols
820491|NCT03030053|Flavonoids
820492|NCT03030053|Polyphenols
820493|NCT03030053|Cognition
820494|NCT03030053|Aging
820745|NCT03028480|NUCALA
820495|NCT03030040|mindfulness-based cognitive therapy
820496|NCT03030040|self-help
820497|NCT03030040|healthcare staff
820498|NCT03030027|Intergeneration
820499|NCT03030027|Reappraisal
820500|NCT03030027|Caregiving
820501|NCT03030001|mesothelin
820502|NCT03030001|PD-1
820503|NCT03030001|CAR T
820504|NCT03030001|solid tumor
820639|NCT03029130|urinary catheter
820505|NCT03029988|adenocarcinoma, Colorectal Carcinoma, liver metastases
820506|NCT03029975|beef
820507|NCT03029975|protein
820508|NCT03029975|resistance training
820509|NCT03029975|strength
820510|NCT03029975|performance
820511|NCT03029962|Teenage Pregnancy Prevention
820512|NCT03029962|LGB Girls
820513|NCT03029962|Text-Messaging
820514|NCT03029962|Information-Motivation-Behavioral Skills(IMB)Model
820515|NCT03029949|chronic dizziness
820516|NCT03029949|persistent postural-perceptual dizziness
820517|NCT03029949|acceptance and commitment therapy
820518|NCT03029949|behavior therapy
820519|NCT03029949|vestibular rehabilitation
820520|NCT03029936|obesity
820521|NCT03029936|asthma
820522|NCT03029936|diaphragm excursion
820523|NCT03029936|pulmonary function test
820524|NCT03029923|smoking
820525|NCT03029923|depression
820526|NCT03029923|Behavioral Activation
820527|NCT03029910|Eccentric exercise
820528|NCT03029910|Whole body vibration
820529|NCT03029910|Cryotherapy
820530|NCT03029871|lung cancer
820531|NCT03029871|adenovirus
820532|NCT03029871|gene therapy
820533|NCT03029871|SBRT
820534|NCT03029793|Esophageal Cancer
820535|NCT03029793|Prediction
820536|NCT03029793|Biomarker
820537|NCT03029793|MRI-DWI
820538|NCT03029793|PET-CT
820539|NCT03029767|Hypertension
820540|NCT03029767|Anthropometry
820541|NCT03029767|Aerobic exercise
820542|NCT03029767|Resistance exercise
820545|NCT03029715|Sleeve gastrectomy
820546|NCT03029715|TIVA
820547|NCT03029702|Gestational diabetes
820548|NCT03029702|Diabetes in pregnancy
820549|NCT03029702|Insulin resistance
820550|NCT03029702|Insulin secretion deficiency
820551|NCT03029689|HIV infection
820552|NCT03029689|Gut microbiome
820553|NCT03029689|Raltegravir
820554|NCT03029689|Raltegravir intensification
820555|NCT03029689|Bacterial richness
820556|NCT03029676|spinal anesthesia, TURBT, POCD, premedication
820557|NCT03029663|bladder cancer
820558|NCT03029663|postoperative complications
820559|NCT03029650|Peer Review
820560|NCT03029650|Research
820561|NCT03029637|Resin bonded bridges
820562|NCT03029637|Randomized controlled trial
820563|NCT03029559|Inspiratory threshold loading
820564|NCT03029520|Endodontic Postoperative Pain
820565|NCT03029520|iRoot SP Sealer
820566|NCT03029520|Randomized Clinical Trial
820567|NCT03029520|Herofill carrier-based obturation
820568|NCT03029507|Obesity
820569|NCT03029507|Military
820570|NCT03029507|Acceptance and Commitment Therapy
820571|NCT03029507|Overweight
820572|NCT03029507|Weight-management
820573|NCT03029507|Navy Personnel
820574|NCT03029507|Fitness
820575|NCT03029494|oxidative stress
820576|NCT03029494|saliva
820577|NCT03029442|Spinal Cord Injury
820578|NCT03029442|Denosumab
820579|NCT03029442|Osteoporosis
820580|NCT03029442|Dual Energy X-ray Absorptiometry
820581|NCT03029429|pseudohypoparathyroidism
820582|NCT03029429|AHO
820583|NCT03029429|Albright Hereditary Osteodystrophy
820584|NCT03029390|Prediabetes
820585|NCT03029390|hyperglycemia
820586|NCT03029390|Impaired Fasting Glucose
820587|NCT03029390|Metformin
820588|NCT03029390|Berberine
820589|NCT03029390|glucose intolerance
820590|NCT03029377|CFS
820591|NCT03029377|Stress
820592|NCT03029377|Norepinephrine Transporter (NET)
820593|NCT03029377|Norepinephrine (NE)
820594|NCT03029377|Healthy Controls
820595|NCT03029377|Fatigue
820596|NCT03029364|Maximal Fat Oxidation
820597|NCT03029364|Exercise
820598|NCT03029364|Within-subject Variability
820599|NCT03029364|Determinants
820600|NCT03029351|albuminuria
820601|NCT03029351|GLP-1 Receptor Agonist
820602|NCT03029351|Type 2 Diabetes
820603|NCT03029338|lymphoma
820604|NCT03029338|non-hodgkin
820605|NCT03029338|B-cell
820606|NCT03029338|CD19 CAR T cells
820607|NCT03029338|refractory
820608|NCT03029338|relapse
820609|NCT03029312|whole body vibration
820610|NCT03029312|Muscle function
820611|NCT03029312|Physical activity
820612|NCT03029312|bone density
820613|NCT03029286|Breast Cancer
820614|NCT03029286|Breast Density
820621|NCT03029195|cleft lip and palate
820622|NCT03029195|nasoalveolar molding
820623|NCT03029195|Egyptian infants
820624|NCT03029195|quantitative analysis
820625|NCT03029182|Exercise
820626|NCT03029182|Cancer
820627|NCT03029182|Obesity
820628|NCT03029169|Supraventricular Arrhythmia
820629|NCT03029169|Septic shock
820630|NCT03029169|Propafenone
820631|NCT03029169|Amiodarone
820632|NCT03029169|Intensive Care
820633|NCT03029156|Asthma
820634|NCT03029156|Aeroneb
820635|NCT03029156|Aerogen
820636|NCT03029156|Bronchodilator
820637|NCT03029143|Drug Therapy
820638|NCT03029130|vesicovaginal fistula
820640|NCT03029130|catheter extension
820641|NCT03029117|rheumatic pregnancy
820642|NCT03029104|Keratoconus
820643|NCT03029104|Forme fruste keratoconus
820644|NCT03029104|Post-LASIK ectasia
820645|NCT03029104|Pellucid marginal degeneration
820646|NCT03029104|Forme fruste pellucid marginal degeneration
820647|NCT03029104|Diurnal fluctuation post-radial keratotomy
820648|NCT03029104|Terrien's marginal degeneration
820649|NCT03029078|XDR
820650|NCT03029078|fecal microbiota transplant
820651|NCT03029078|eradicate
820652|NCT03029078|colonization
820653|NCT03029078|CRE
820654|NCT03029078|GRE
820655|NCT03029078|bacteria
820656|NCT03029065|lung Adenocarcinoma with brain (meningeal) metastasis
820657|NCT03029039|Platelet
820658|NCT03029039|severe sepsis
820659|NCT03029039|inflammation
820660|NCT03029039|S. aureus
820661|NCT03029039|biomarkers
820662|NCT03029026|Cardiac amyloidosis
820663|NCT03029026|Aortic stenosis
820664|NCT03029026|DPD scintigraphy
820665|NCT03028987|Quadrivalent, inactivated influenza vaccine
820666|NCT03028987|Quadrivalent, live, attenuated influenza vaccine
820667|NCT03028987|Identical twin adults
820668|NCT03028974|Inactivated influenza vaccine
820669|NCT03028974|Live, attenuated influenza vaccine
820670|NCT03028974|Young children
820671|NCT03028974|Adults
820672|NCT03028922|creos xenogain
820673|NCT03028909|Influenza A
820674|NCT03028909|MEDI8852
820675|NCT03028896|LMA Flexible
820679|NCT03028844|Neonate
820680|NCT03028844|preterm
820681|NCT03028844|pain
820682|NCT03028844|music
820683|NCT03028844|EEG
820684|NCT03028844|venepuncture
820685|NCT03028805|Informatics
820686|NCT03028805|COPD
820687|NCT03028805|quality improvement
820688|NCT03028792|attention training, youth, latino
820689|NCT03028779|Outpatient,fast-track, arthroplasty, Total knee arthroplasty (TKA), Total hip Arthroplasty (THA)
820690|NCT03028714|University
820691|NCT03028714|College
820692|NCT03028714|University students
820693|NCT03028714|Health education
820694|NCT03028714|Educational techonology
820695|NCT03028714|Internet
820696|NCT03028714|Nutrition knowledge
820697|NCT03028714|Eating behaviour
820698|NCT03028714|Diet
820699|NCT03028714|Physical Activity
820700|NCT03028714|Weight gain prevention
820701|NCT03028701|Formoterol
820702|NCT03028701|Budesonide
820703|NCT03028701|Dry powder inhalation
820704|NCT03028701|Discair
820705|NCT03028701|COPD
820706|NCT03028662|Alcohol Dependence
820707|NCT03028662|Brain Connectivity
820708|NCT03028662|Inhibition
820709|NCT03028649|β-hydroxy-β-methylbutyric acid
820710|NCT03028649|Sport supplements
820711|NCT03028649|Training support
820712|NCT03028649|Adaptation
820713|NCT03028636|fecal incontinence
820714|NCT03028636|bowel control
820715|NCT03028636|accidental bowel leakage
820716|NCT03028636|medical device
820717|NCT03028636|women's health
820718|NCT03028636|vaginal insert
820719|NCT03028636|pessary
820720|NCT03028636|incontinence
820721|NCT03028636|bowel continence
820722|NCT03028636|pump
820723|NCT03028597|Hypertension
820724|NCT03028597|Medication Adherence
820725|NCT03028597|Values Affirmation
820726|NCT03028597|African Americans
820727|NCT03028584|BrCa
820728|NCT03028584|PrCa
820729|NCT03028584|CRCa
820730|NCT03028558|Electronic Cigarettes
820731|NCT03028558|Healthy Volunteers
820732|NCT03028558|E-Cigarettes Smokers
820733|NCT03028558|E-Cigarettes
820734|NCT03028545|schizophrenia
820735|NCT03028545|anorexia
820736|NCT03028545|bipolar disorders
820737|NCT03028545|personality disorders
820738|NCT03028532|Healthy Volunteers
820739|NCT03028532|Sports Medicine
820740|NCT03028532|Anti-doping
820741|NCT03028532|Athletes
820742|NCT03028532|Men's Health
820743|NCT03028480|Exacerbation
820744|NCT03028480|Mepolizumab
820755|NCT03028441|Chikungunya
820756|NCT03028441|Immunogenicity
820757|NCT03028441|Measles
820758|NCT03028441|Vaccine
820759|NCT03028428|Osteoarthritis
820760|NCT03028428|Stem Cell
820761|NCT03028428|Knee
820762|NCT03028428|Mesenchymal Stem Cell
820763|NCT03028389|elderly patients
820764|NCT03028389|non-cardiac surgery
820765|NCT03028389|ischemic preconditioning
820766|NCT03028389|delirium
820767|NCT03028376|biomarker
820768|NCT03028376|point-of-care analysis
820769|NCT03028337|Malignant neoplasms of eye brain and other parts of central nervous system
820770|NCT03028337|Solid tumor malignancy
820771|NCT03028337|Radiographic evidence of spine metastasis
820772|NCT03028337|Spine radiosurgery
820773|NCT03028337|Radiation therapy
820774|NCT03028337|Radiotherapy
820775|NCT03028337|Questionnaires
820776|NCT03028337|Surveys
820777|NCT03028337|XRT
820778|NCT03028311|Malignant neoplasms of digestive organs
820779|NCT03028311|Metastatic liver tumors
820780|NCT03028311|SIR-Spheres treatment
820781|NCT03028311|90Y-radioembolization
820782|NCT03028285|succinate
820783|NCT03028285|arginine
820784|NCT03028285|vasodilation
820785|NCT03028285|peripheral vascular disease
820786|NCT03028272|tympanic membrane perforation
820787|NCT03028233|physical activity
820788|NCT03028233|healthy eating
820789|NCT03028233|weight
820790|NCT03028233|families
820791|NCT03028233|Community Health Worker
820792|NCT03028233|childhood obesity
820793|NCT03028233|built environment
820794|NCT03028207|EPI-Scan-II Study
820795|NCT03028207|COPD
820796|NCT03028207|Epidemiology
820797|NCT03028207|Spain
820798|NCT03028207|Chronic Obstructive Pulmonary Disease
820799|NCT03028207|Prevalence
820800|NCT03028207|Cross-sectional
820801|NCT03028194|Pre-eclampsia
820802|NCT03028194|Eclampsia
820803|NCT03028194|Postpartum uterine curettage
820804|NCT03028181|smoke
820805|NCT03028181|acute pancreatitis
820806|NCT03028181|pro/antioxidant status
820807|NCT03028181|pro-inflammatory factors
820808|NCT03028181|lipid profile
820809|NCT03028181|exocrine functions of pancreas
820810|NCT03028168|Yôga
820811|NCT03028168|Breathing Techniques
820812|NCT03028168|Heart Failure and Preserved Ejection Fraction
820813|NCT03028129|Tuberculosis
820814|NCT03028129|Primary prevention
820815|NCT03028129|Prisoners
820816|NCT03028129|Controlled Clinical Trial
820817|NCT03028129|Isoniazid
820818|NCT03028116|vaccine
820819|NCT03028116|1 phase
820820|NCT03028116|safety
820821|NCT03028077|ultrafiltered red ginseng
820822|NCT03028077|hydrolyzed ginseng
820823|NCT03028077|acute respiratory illness
820824|NCT03028077|clinical trial
820825|NCT03028038|Platelet-rich plasma
820826|NCT03028038|Rapid maxillary expansion
820827|NCT03028038|Buccal bone thickness
820828|NCT03028038|Alveolar bone loss
820829|NCT03028038|Alveolar bone resorption
820830|NCT03028025|radial artery occlusion
820831|NCT03028025|time to hemostasis
820832|NCT03028025|radial artery
820833|NCT03028025|transradial catheterization
820834|NCT03028025|TR band
820835|NCT03028025|Statseal
820836|NCT03028025|hemostasis band
820837|NCT03028025|potassium ferrate
820838|NCT03028025|percutaneous coronary intervention
820842|NCT03027999|Rituximab
820843|NCT03027999|tight monitoring
820845|NCT03027947|Phantom Limb Pain
820846|NCT03027947|Lower-Limb Amputation
820847|NCT03027947|Electrodes
820848|NCT03027947|Stimulation
820849|NCT03027947|Pain
820850|NCT03027947|Sensation
820851|NCT03027882|Reliability
820852|NCT03027882|Validity
820853|NCT03027882|Functional Testing
820854|NCT03027856|Percutaneous intervention (PCI)
820855|NCT03027856|Optical coherence tomography (OCT)
820856|NCT03027856|Bifurcation lesion
820857|NCT03027856|Bioresorbable stents (BRS)
820858|NCT03027843|low ovarian reserve
820859|NCT03027843|growth hormone
820860|NCT03027843|embryo quality
820861|NCT03027843|live birth
820862|NCT03027843|clinical pregnancy
820863|NCT03027830|Provisional side-branch intervention strategy
820864|NCT03027830|iFR
820865|NCT03027830|Pilot study
820866|NCT03027817|Prone positioning
820867|NCT03027817|Non-invasive Cardiac Output Monitoring
820868|NCT03027791|Biosensors
820869|NCT03027791|Virtual Reality
820870|NCT03027791|Dietary Sodium
820871|NCT03027778|arterial stiffness
820872|NCT03027778|hemodialysis
820873|NCT03027778|intradialytic pedalling exercise
820874|NCT03027778|carotid-femoral pulse wave velocity
820875|NCT03027778|chronic kidney disease
820876|NCT03027778|hemodynamics
820877|NCT03027778|augmentation index
820878|NCT03027752|carotid endaretectomy
820879|NCT03027713|NAVA: neurally adjusted ventilatory assist
820880|NCT03027713|Diaphragm electromyographic activity
820881|NCT03027713|Weaning
820882|NCT03027687|Smoking
820883|NCT03027687|EMA
820884|NCT03027687|ERPs
820885|NCT03027687|tDCS
820886|NCT03027687|Cigarette consumption
820887|NCT03027687|Inhibitory control
820888|NCT03027687|Reward processing
820889|NCT03027674|Raynaud Phenomena
820890|NCT03027674|System; Sclerosis
820891|NCT03027674|Lupus Erythematosus, Systemic
820892|NCT03027674|Ultrasound
820893|NCT03027674|sildenafil
820894|NCT03027674|Nifedipine
820895|NCT03027661|para-cervical block
820896|NCT03027661|laparoscopic hysterectomy
820897|NCT03027648|levonorgestrel-releasing intrauterine system
820898|NCT03027648|adenomyosis
820899|NCT03027635|diuretic resistant ascites
820900|NCT03027635|Paracentesis
820901|NCT03027635|PleurX
820902|NCT03027635|Peritoneal tunnelated catheter
820903|NCT03027622|quality of life
820904|NCT03027622|pericoronitis
820905|NCT03027622|third molar
820906|NCT03027609|Pseudomonas aeruginosa
820907|NCT03027609|pneumonia
820908|NCT03027570|Exergame
820909|NCT03027570|Cellular apps
820910|NCT03027570|Smartphone
820911|NCT03027570|Overweight
820912|NCT03027570|Obesity
820913|NCT03027570|Children
820914|NCT03027570|Physical activity
820915|NCT03027570|Fitness
820916|NCT03027570|Motivation
820917|NCT03027570|BMI
820926|NCT03027544|multiple brain metastases
820927|NCT03027544|large brain metastases
820928|NCT03027544|meningeal metastases
820929|NCT03027544|tomotherapy
820930|NCT03027531|reproductive health, condoms, sexually transmitted diseases, contraception
820931|NCT03027505|MUAC
820932|NCT03027505|Acute malnutrition
820933|NCT03027505|RUTF
820934|NCT03027505|Children
820935|NCT03027505|Burkina Faso
820936|NCT03027492|Non-celiac Wheat Sensitivity
820937|NCT03027492|gynaecological disorders
820938|NCT03027492|gluten-free diet
820939|NCT03027479|weight loss
820940|NCT03027479|ovarian cancer
820941|NCT03027479|endometrial cancer
820942|NCT03027479|energy metabolism
820943|NCT03027479|Body mass index
820944|NCT03027479|obesity
820945|NCT03027479|muscle energy
820946|NCT03027466|Quitting Smoking
820947|NCT03027466|Phone Application
820948|NCT03027440|Stress Response
820949|NCT03027440|Neurodevelopment
820950|NCT03027440|Biomarkers
820951|NCT03027440|Cohort Study
820952|NCT03027427|Screening
820953|NCT03027427|Heritable Gastric Malignancy
820954|NCT03027427|Molecular Profiling
820955|NCT03027427|Molecular Alterations
820956|NCT03027414|Anxiety
820957|NCT03027414|Startle
820958|NCT03027414|Dorsolateral Prefrontal Cortex
820959|NCT03027414|Transcranial Magnetic Stimulation (TMS)
820960|NCT03027414|Working Memory
820961|NCT03027401|Genetic Testing
820962|NCT03027401|Tumor Profiling
820963|NCT03027401|Biorepository
820964|NCT03027388|Brain Tumor
820965|NCT03027388|Blood Brain Barrier
820966|NCT03027388|Pharmacokinetics
820967|NCT03027388|Pharmacodynamics
820968|NCT03027375|chronic heart failure
820969|NCT03027375|traditional Chinese medicine
820970|NCT03027375|Qishen granules
820971|NCT03027336|dyslipidemia
820972|NCT03027336|dietary supplement
820973|NCT03027323|undifferentiated hypotension
820974|NCT03027323|central venous cannulation
820975|NCT03027310|Dystonic Tremor
820976|NCT03027310|Essential Tremor
820977|NCT03027310|Tremor
820978|NCT03027310|Voice Tremor
820979|NCT03027310|Parkinson's Disease
820980|NCT03027284|Neoplasm
820981|NCT03027258|Mobile health technology
820982|NCT03027245|locally advanced or metastatic breast cancer
820983|NCT03027245|peripheral neuropathy
820984|NCT03027245|chemotherapy-induced peripheral neuropathy
820985|NCT03027245|eribulin
820986|NCT03027232|infection
820987|NCT03027154|diagnostic test
820988|NCT03027154|children
820989|NCT03027154|diagnosis of tuberculosis
820990|NCT03027141|Face Transplant
820991|NCT03027128|Phase 1
820992|NCT03027128|Metastatic
820993|NCT03027128|Locally Advanced
820994|NCT03027128|Cancer
820995|NCT03027128|Cell Therapy
820996|NCT03027102|allogenic double negative T cells
820997|NCT03027102|DNT cells
820998|NCT03027089|Aspergillus-specific IgG
820999|NCT03027076|prostatitis
821000|NCT03027076|chronic prostatitis
821001|NCT03027076|chronic pelvic pain syndrome
821002|NCT03027076|interstitial cystitis
821003|NCT03027076|painful bladder syndrome
821004|NCT03027076|bladder pain syndrome
821005|NCT03027076|biomarkers
821006|NCT03027076|biological markers
821007|NCT03027076|bacteria
821008|NCT03027076|microbiome
821009|NCT03027076|inflammation
821010|NCT03027063|Speckle tracking echocardiography
821011|NCT03027050|periodontitis
821012|NCT03027050|Growth factors
821013|NCT03027050|Periodontal healing
821014|NCT03027024|Intraocular Lens
821015|NCT03027024|trifocal
821016|NCT03027024|cataract
821017|NCT03027024|PhysIOL
821018|NCT03026998|hereditary retinoblastoma,
821019|NCT03026998|External beam radiation therapy (EBRT)
821020|NCT03026985|Extracorporeal Membrane Oxygenation
821021|NCT03026985|Ultrasonography
821022|NCT03026985|Intensive Care Units
821023|NCT03026972|Safety
821024|NCT03026972|Tolerance
821025|NCT03026946|Alitretinoin
821026|NCT03026946|Cyclosporine A
821027|NCT03026946|Hand eczema
821028|NCT03026920|Fracture
821029|NCT03026920|outcome
821030|NCT03026920|pelvic
821031|NCT03026920|acetabular
821032|NCT03026907|Alitretinoin
821033|NCT03026907|Azathioprine
821034|NCT03026907|Hand eczema
821035|NCT03026881|PARP inhibitor
821036|NCT03026881|VEGFR inhibitor
821037|NCT03026881|Combination therapy
821038|NCT03026881|Gastric cancer
821041|NCT03026855|Autologous PRP
821042|NCT03026855|Non-healing ulcer
821043|NCT03026855|Point-of-care
821046|NCT03026816|epidural stimulation
821047|NCT03026816|spinal cord stimulation
821048|NCT03026790|Opioid analgesics
821049|NCT03026790|Opioid partial agonists
821050|NCT03026790|Health care delivery
821051|NCT03026790|Back pain
821052|NCT03026790|Osteoarthritis
821053|NCT03026790|Veterans health
821054|NCT03026764|cost
821055|NCT03026764|total hip replacement
821056|NCT03026764|outpatient Surgery
821057|NCT03026764|satisfaction
821058|NCT03026764|arthroplasty
821059|NCT03026725|tooth sensitivity
821060|NCT03026725|tri calcium phosphate
821061|NCT03026725|at-home whitening
821062|NCT03026712|Robotic therapy
821063|NCT03026712|tDCS
821064|NCT03026712|non invasive electrical stimulation
821065|NCT03026712|ArmeoPower
821066|NCT03026712|interhemispheric balance
821067|NCT03026699|Brain
821068|NCT03026699|Nervous system
821069|NCT03026699|Neuro-oncology
821070|NCT03026699|Caregivers
821071|NCT03026699|Cancer patient
821072|NCT03026699|Family caregivers
821073|NCT03026699|Brain tumors
821074|NCT03026699|Quality of life
821075|NCT03026699|Stress
821076|NCT03026699|Social support
821077|NCT03026699|Feasibility
821078|NCT03026699|Electronic Social Network Assessment Program (eSNAP)
821079|NCT03026660|Moringa Oleifera
821080|NCT03026634|Sleep-Disordered Breathing
821081|NCT03026634|Heart Failure
821082|NCT03026634|Heart Transplantation
821083|NCT03026569|orange juice
821084|NCT03026569|chronic hepatitis C
821085|NCT03026569|biochemical markers
821086|NCT03026569|oxidative stress
821087|NCT03026569|nutritional status
821088|NCT03026569|antioxidants
821089|NCT03026517|Phenformin
821090|NCT03026517|Dabrafenib
821091|NCT03026517|Trametinib
821092|NCT03026517|BRAF
821093|NCT03026517|15-318
821094|NCT03026478|oral lichen planus
821095|NCT03026478|betamethasone
821096|NCT03026478|clobetasol
821097|NCT03026478|orabase
821098|NCT03026439|mild COPD
821099|NCT03026439|early COPD
821100|NCT03026439|six-min walk test
821101|NCT03026439|computed tomography
821102|NCT03026439|emphysema
821103|NCT03026439|airway disease
821104|NCT03026439|peripheral muscle mass
821105|NCT03026439|Saint George's Respiratory Questionnaire
821106|NCT03026426|Depression
821107|NCT03026426|Chronic diseases
821108|NCT03026426|Mobile technology
821109|NCT03026426|Clinical trial
821114|NCT03026387|Suicidal behavior
821115|NCT03026387|Suicide attempt
821116|NCT03026387|Emergency department
821117|NCT03026387|Psychometrics
821118|NCT03026387|Neuropsychological tests
821119|NCT03026387|Suicidal ideation
821120|NCT03026374|psychosocial support
821121|NCT03026374|resilience
821122|NCT03026374|metastatic breast cancer
821123|NCT03026374|survival
821124|NCT03026374|Quality of Life
821125|NCT03026348|RSV
821126|NCT03026335|Positive Youth Development
821127|NCT03026296|Physical Fitness
821128|NCT03026296|Health Status
821129|NCT03026296|Exercise
821130|NCT03026296|Tobacco Use Cessation
821131|NCT03026296|Quality of Life
821132|NCT03026296|Healthy Diet
821133|NCT03026296|Health Promotion
821134|NCT03026296|Patient Education as Topic
821135|NCT03026296|Counseling
821136|NCT03026270|Physiotherapy
821137|NCT03026270|Paraffin
821138|NCT03026270|Burn
821139|NCT03026270|Contracture
821140|NCT03026244|Immunity
821141|NCT03026244|Elderly
821142|NCT03026244|Inflammation
821143|NCT03026244|Milk protein
821144|NCT03026244|Prebiotics
821145|NCT03026231|Fecal microbiota transplantation
821151|NCT03026140|MSI tumors
821152|NCT03026140|MSS tumors
821153|NCT03026140|short-term immunotherapy
821154|NCT03026140|surgical resection
821155|NCT03026140|nivolumab
821156|NCT03026140|ipilimumab
821157|NCT03026127|Suicide
821158|NCT03026127|Middle-aged and Older Adults
821159|NCT03026127|Cognitive Reappraisal
821160|NCT03026127|Emotion Regulation
821161|NCT03026088|Chronic Heart Failure
821162|NCT03026088|Bisoprolol
821163|NCT03026088|Heart rate control
821164|NCT03026062|Recurrent Platinum-Resistant Epithelial Ovarian Cancer
821165|NCT03026062|Ovarian Cancer
821166|NCT03026062|epithelial ovarian cancer
821167|NCT03026036|Depression
821168|NCT03026036|MRI
821169|NCT03026036|PET
821170|NCT03026036|Reward
821171|NCT03026023|Heart Transplant
821172|NCT03026023|Cardiac Transplant
821173|NCT03026023|Hepatitis C
821174|NCT03026023|Zepatier
821175|NCT03025971|Severe Aortic Stenosis and/or severe aortic regurgitation
821176|NCT03025919|Advanced glycation end-product
821177|NCT03025919|Glycosuria
821178|NCT03025893|Sunitinib
821179|NCT03025893|Lomustine
821180|NCT03025893|High-dose
821181|NCT03025893|Intermittent
821182|NCT03025880|Advanced Breast Cancer
821183|NCT03025880|Pembrolizumab
821184|NCT03025880|HER2-negative
821185|NCT03025828|Membranous nephropathy
821186|NCT03025828|adrenocorticotropic hormone
821187|NCT03025828|ACTH
821188|NCT03025828|proteinuria
821189|NCT03025828|glomerulonephritis
821190|NCT03025815|Infant, Premature
821191|NCT03025802|Molecular diagnosis
821192|NCT03025802|Pathogen identification
821193|NCT03025802|Sepsis
821194|NCT03025802|Bacteremia
821195|NCT03025802|Rapid diagnostics
821196|NCT03025789|T.b gambiense
821197|NCT03025789|HAT
821198|NCT03025789|outpatients
821199|NCT03025763|Craniosynostosis
821200|NCT03025763|Bone
821201|NCT03025763|Birth Defect
821202|NCT03025763|Congenital Anomaly
821203|NCT03025763|Malformation
821204|NCT03025763|Genetics
821205|NCT03025763|Genomics
821206|NCT03025763|Skull
821207|NCT03025763|Human
821208|NCT03025763|Mouse
821209|NCT03025763|Imaging
821210|NCT03025763|Cell Biology
821211|NCT03025763|Induced Pluripotent Stem Cells
821212|NCT03025763|System Biology
821213|NCT03025737|Hypertrophy, Left Ventricular
821214|NCT03025737|Ventricular Remodeling
821215|NCT03025711|Advanced HER2+ breast cancer
821216|NCT03025711|Pertuzumab
821217|NCT03025711|Trastuzumab emtansine
821218|NCT03025711|Compassionate use
821219|NCT03025711|Early access program
821220|NCT03025711|Effectiveness
821221|NCT03025711|Safety
821222|NCT03025698|Eltrombopag
821223|NCT03025698|hATG
821224|NCT03025698|CsA
821225|NCT03025698|previously untreated or relapsed severe aplastic anemia
821226|NCT03025698|recurrent aplastic anemia
821227|NCT03025698|Severe aplastic anemia
821228|NCT03025698|Pharmacokinetics
821229|NCT03025698|Immunosuppressive therapy
821230|NCT03025698|ETB115
821231|NCT03025685|Percutaneous Coronary Intervention
821232|NCT03025685|Coronary Artery Disease
821233|NCT03025685|Wire
821234|NCT03025685|Coronary stenting
821235|NCT03025659|pediatric
821236|NCT03025659|congenital heart disease
821237|NCT03025646|Maternal depression
821238|NCT03025646|ASD
821239|NCT03025646|Home based training program
821240|NCT03025633|PEARL
821241|NCT03025620|Alphalinolenic acid
821242|NCT03025620|Lipid cardiovascular risk factors
821243|NCT03025620|Inflammation
821244|NCT03025607|Prevention
821245|NCT03025607|Mobile health
821246|NCT03025607|Autonomous motivation
821247|NCT03025594|Paralytic sellfish toxins
821248|NCT03025594|Gonyautoxin
821249|NCT03025594|Post surgery pain management
821250|NCT03025594|total knee arthroplasty
821251|NCT03025568|nylon
821252|NCT03025568|polyamide
821253|NCT03025568|denture base
821254|NCT03025555|nylon
821255|NCT03025555|polyamide
821256|NCT03025555|PEEK
821257|NCT03025555|partial denture
821258|NCT03025542|Psoriasis
821259|NCT03025542|Chronic Plaque Psoriasis
821260|NCT03025542|Bimekizumab
821261|NCT03025490|Capnography
821262|NCT03025490|Electrophysiology
821263|NCT03025477|Intraperitoneal
821264|NCT03025477|Intravenous
821265|NCT03025477|Completeness of cytoreduction score
821266|NCT03025477|Carboplatin
821267|NCT03025477|Epirubicin
821268|NCT03025477|Paclitaxel
821269|NCT03025477|Cisplatin
821270|NCT03025451|nutrition
821271|NCT03025451|exercise
821272|NCT03025451|stress
821273|NCT03025451|gender
821274|NCT03025451|age
821275|NCT03025451|community support
821276|NCT03025451|cardiovascular disease
821277|NCT03025451|diabetes
821278|NCT03025451|hypertension
821279|NCT03025451|dyslipidemia
821280|NCT03025451|cholesterol
821281|NCT03025451|overweight
821282|NCT03025451|obesity
821283|NCT03025451|lifestyle
821284|NCT03025438|angiosarcoma
821285|NCT03025438|Cytology
821286|NCT03025438|liver
821287|NCT03025438|cancer
821288|NCT03025412|Achilles Tendon
821289|NCT03025412|Endoscopy
821290|NCT03025412|Minimally Invasive Surgical Procedures
821291|NCT03025412|Exercise therapy
821292|NCT03025399|tang wang prescription
821293|NCT03024593|Cyberchondria
821294|NCT03024593|health-related internet use
821295|NCT03024593|pathological health anxiety
821296|NCT03024580|Megestrol Acetate
821297|NCT03024580|Steroid, Receptors
821298|NCT03024567|Calorimetry
821299|NCT03024567|Blood pressure
821300|NCT03024567|Immunophenotyping
821301|NCT03024567|Gut microbial composition
821302|NCT03024554|aortic aneurysm involving iliac arteries
821303|NCT03024554|abdominal aortic aneurysm
821304|NCT03024554|MFM
821305|NCT03024554|Multilayer Flow Modulator
821306|NCT03024554|Multilayer Stent
821307|NCT03024528|Pain
821308|NCT03024528|CPOT
821309|NCT03024528|ICU Delirium
821310|NCT03024528|Critical Care Pain Observation Tool
821311|NCT03024528|NRS
821312|NCT03024528|Behaviour
821313|NCT03024528|Critical care
821314|NCT03024528|Intensive Care
821315|NCT03024502|vulvovaginal candidiasis
821316|NCT03024502|EPPAF mucoadhesive gel
821317|NCT03024502|clotrimazol
821318|NCT03024489|Phase I/II
821319|NCT03024476|behavioral intervention
821320|NCT03024476|prespecified medication algorithm
821321|NCT03024476|bluetooth-equipped sphygmomanometer
821322|NCT03024450|Gastric cancer
821323|NCT03024450|HER2
821324|NCT03024450|trastuzumab
821325|NCT03024450|prognosis
821326|NCT03024437|PD-L1 inhibitor
821327|NCT03025321|Cocaine
821328|NCT03025321|tDCS
821329|NCT03025321|EMA
821330|NCT03025321|Inhibitory control
821331|NCT03025321|Reward processing
821332|NCT03025321|Addiction
821333|NCT03025321|dlPFC
821334|NCT03025321|craving
821335|NCT03025321|cognitive control
821336|NCT03025256|Melanoma and other malignant neoplasms of skin
821337|NCT03025256|Leptomeningeal disease
821338|NCT03025256|LMD
821339|NCT03025256|Nivolumab
821340|NCT03025256|BMS-936558
821341|NCT03025256|Opdivo
821342|NCT03025243|computer aided design , dental implants , accuracy
821343|NCT03025204|Regeneration Procedures
821344|NCT03025204|Intrabony Defects
821345|NCT03025204|Cronic Periodontitis
821346|NCT03025191|incarceration
821347|NCT03025191|HIV
821348|NCT03025152|Hou Gu Mi Xi
821349|NCT03025152|Shen Ling Bai Zhu San
821350|NCT03025152|radical gastrectomy
821351|NCT03025152|gastric cancer
821352|NCT03025152|traditional Chinese medicine
821353|NCT03025152|randomized controlled trial
821354|NCT03025139|breast cancer
821355|NCT03025139|younger women
821356|NCT03025139|education
821357|NCT03025139|mindfulness meditation
821358|NCT03025139|depression
821359|NCT03025139|cancer survivor
821360|NCT03025074|Liver Disease
821361|NCT03025074|Obesity
821362|NCT03025074|Hepatitis
821363|NCT03025074|HIV
821364|NCT03025074|Hepatology
821365|NCT03025061|Breath pattern
821366|NCT03025061|Children
821367|NCT03025061|Repeatability
821368|NCT03025035|BRCA-mutation
821369|NCT03025035|Immune checkpoint inhibition
821370|NCT03025035|Immunotherapy
821371|NCT03025035|Advanced BRCA-mutated breast cancer
821372|NCT03024957|morphine
821373|NCT03024957|dexmedetomidine
821374|NCT03024957|immune system
821375|NCT03024944|Diabetes Mellitus
821376|NCT03024944|Alzheimer's Disease
821377|NCT03024944|Dementia
821378|NCT03024944|THK
821379|NCT03024918|monochorionic
821380|NCT03024918|placental sharing
821381|NCT03024892|Fluorenscent image guided surgery
821382|NCT03024892|indocyanide green
821383|NCT03024892|laparoscopic cholecystectomy
821384|NCT03024892|common bile duct injury
821385|NCT03024879|Motilin
821386|NCT03024879|Erythromycin
821387|NCT03024879|Food intake
821388|NCT03024853|Best Possible Self
821389|NCT03024853|Positive Intervention
821390|NCT03024853|Optimism
821391|NCT03024840|Propofol
821392|NCT03024840|Neurocognitive Disorders
821393|NCT03024840|Liver transplantation
821394|NCT03024840|Pediatrics
821395|NCT03024840|Brain Injuries
821396|NCT03024827|Infantile Spasms
821397|NCT03024827|Lennox Gastaut Syndrome
821398|NCT03024827|Doose Syndrome
821399|NCT03024827|Continuous Spike Wave in Sleep
821400|NCT03024827|Landau-Kleffner Syndrome
821401|NCT03024827|Dravet Syndrome
821402|NCT03024827|Malignant Migrating Partial Seizures of Infancy (MMPSI)
821403|NCT03024788|Glycosylated haemoglobin
821404|NCT03024788|advanced glycation end products
821405|NCT03024775|Non-celiac Wheat Sensitivity
821406|NCT03024775|ancient wheats
821407|NCT03024775|modern wheats
821408|NCT03024775|ATIs
821409|NCT03024749|Spinal Arteriovenous Malformation
821410|NCT03024749|Spinal Arteriovenous Fistula
821411|NCT03024723|Obese patient
821412|NCT03024723|nasal CPAP
821413|NCT03024710|Stunting
821414|NCT03024710|complementary feeding Index
821415|NCT03024710|Bangladesh
821416|NCT03024697|Breast surgery
821417|NCT03024697|Pectoral plane block
821418|NCT03024697|PECs
821419|NCT03024697|Local anaesthesia infusion
821420|NCT03024697|Analgesia
821421|NCT03024684|Hepatocellular carcinoma
821422|NCT03024684|statin
821423|NCT03024684|curative ablation
821424|NCT03024658|Pulmonary artery systolic pressure
821425|NCT03024658|Positive end expiratory pressure
821426|NCT03024658|morbidly obese
821427|NCT03024658|laparoscopic bariatric surgery
821428|NCT03024645|Postpartum Depression
821429|NCT03024645|Cognitive-Behavioral Therapy
821430|NCT03024645|Prevention
821431|NCT03024645|Web-Based Psychological Intervention
821432|NCT03024359|Obesity
821433|NCT03024359|Brown adipose tissue
821434|NCT03024359|Monounsaturated fatty acids
821435|NCT03024359|Hypothalamic inflammation
821436|NCT03024333|Dysphagia
821437|NCT03024333|Swallowing Sound
821438|NCT03024333|Acoustic Analysis
821439|NCT03024307|Pharmaceutical Care
821440|NCT03024307|Medication Adherence
821441|NCT03024307|Direct Costs
821442|NCT03024281|Aspergillus
821443|NCT03024281|Antifungal susceptibility
821444|NCT03024281|Azole resistance
821445|NCT03024255|sweat gland disease
821446|NCT03024255|sweating
821447|NCT03024255|underarm
821448|NCT03024190|stroke
821449|NCT03024190|spasticity
821450|NCT03024190|Kinesiotaping
821451|NCT03024190|sonography
821452|NCT03024190|exercise
821453|NCT03024177|Human rhinovirus
821454|NCT03024177|HRV
821455|NCT03024177|Hematopoietic Stem Cell Transplant
821456|NCT03024177|HSCT
821457|NCT03024177|Antiviral
821458|NCT03024177|vapendavir
821459|NCT03024177|Allogeneic
821460|NCT03024177|Autologous
821461|NCT03024164|youth ischemic stroke; etiology; prognosis
821462|NCT03024125|lean mass
821463|NCT03024125|postmenopausal
821464|NCT03024125|protein
821465|NCT03024099|hippotherapy Gross Motor Function Functional performance.
821466|NCT03024060|Actinic Keratosis
821467|NCT03024021|therapeutic hypothermia
821468|NCT03024021|targeted temperature management
821469|NCT03024021|neurological outcome
821470|NCT03024021|post-cardiac arrest syndrome
821471|NCT03024008|Critical Gap
821472|NCT03024008|Comminuted Fracture
821473|NCT03024008|Extra-Articular
821474|NCT03023930|Opioid Use Disorder
821475|NCT03023917|jaundice,complication
821476|NCT03023891|glucocorticoids
821477|NCT03023891|efficacy
821478|NCT03023891|metabolic toxicity
821479|NCT03023865|Long gap esophageal atresia
821480|NCT03023839|Delirium
821481|NCT03023839|Trauma
821482|NCT03023839|Injury
821483|NCT03023839|restraints
821484|NCT03023761|Endodontic retreatments
821485|NCT03023761|Low level laser
821486|NCT03023761|Pain
821487|NCT03023748|activated vitamin D treatment
821488|NCT03023709|Quadrivalent inactivated influenza vaccine
821489|NCT03023709|Quadrivalent live, attenuated influenza vaccine
821490|NCT03023709|Adults with obstructive sleep apnea
821491|NCT03023696|C5 Palsy
821492|NCT03023683|Live, attenuated influenza vaccine
821493|NCT03023683|Children and young adults
821494|NCT03023670|Lung
821495|NCT03023670|Cardiopulmonary Bypass
821496|NCT03023670|Pediatric
821497|NCT03023670|Cardiac surgery
821502|NCT03023644|Congenital Heart Disease
821503|NCT03023644|Neurodevelopmental Disorders
821504|NCT03023644|Children
821505|NCT03023644|Executive Function
821506|NCT03023644|Working Memory
821507|NCT03023644|Cognitive interventions
821508|NCT03023644|Infant Open Heart Surgery
821509|NCT03023631|GARDASIL 9
821510|NCT03023631|Post allogeneic stem cell transplantation
821511|NCT03023631|HPV infection prevention
821512|NCT03023618|[G09.330.380]
821513|NCT03023605|Pulmonary embolism
821514|NCT03023605|Adherence to practice guidelines
821515|NCT03023605|Age-adjusted D-dimer
821516|NCT03023605|Clinical prediction rules
821517|NCT03023605|Elderly patients
821518|NCT03023592|Sjogren's Syndrome
821519|NCT03023592|Iguratimod
821520|NCT03023566|Dotarem
821521|NCT03023566|MRI
821522|NCT03023566|pediatric
821523|NCT03023566|safety
821524|NCT03023566|efficacy
821525|NCT03023553|Trivalent, inactivated influenza vaccine
821526|NCT03023553|Live, attenuated influenza vaccine
821527|NCT03023553|Nasopharyngeal swabs
821528|NCT03023553|Young adults
821529|NCT03023540|Charcot Marie Tooth Type 1A
821530|NCT03023540|Peripheral neuropathy
821531|NCT03023540|PXT3003
821532|NCT03023527|Refractory
821533|NCT03023527|Relapsed
821534|NCT03023527|Nivolumab
821535|NCT03023514|Oocyte donation
821536|NCT03023514|IVF
821537|NCT03023514|Lipoic acid
821538|NCT03023514|Implantation rate
821539|NCT03023514|Endometrial receptivity
821540|NCT03023488|flexible ureteroscopy
821541|NCT03023488|blood flow
821542|NCT03023436|Stomach Neoplasms
821543|NCT03023436|Cytoreduction Surgical Procedures
821544|NCT03023410|Revision TKA
821545|NCT03023410|Instability
821546|NCT03023410|Stiffness
821547|NCT03023410|Aseptic Loosening
821548|NCT03023410|Polyethylene Wear
821549|NCT03023410|Malrotation
821550|NCT03023410|Soft Tissue Imbalance
821551|NCT03023397|E-cig smokers
821552|NCT03023384|Acute Myeloid Leukemia
821553|NCT03023384|Chemotherapy
821554|NCT03023384|Autologous Stem Cell Transplantation
821555|NCT03023384|Developing country
821556|NCT03023384|Clinical network
821557|NCT03023371|Registry; cohort study; IgG4-related disease
821558|NCT03023358|peripheral T cell lymphoma
821559|NCT03023345|cancer
821560|NCT03023345|prostate
821561|NCT03023345|PSA
821562|NCT03023345|biopsies
821563|NCT03023345|microwave trans rectal focal treatment
821564|NCT03023332|Caregiver
821565|NCT03023332|Biofeedback
821566|NCT03023332|Resourcefulness
821567|NCT03023332|Self-Management
821568|NCT03023293|n-3 polyunsaturated fatty acids
821569|NCT03023293|irisin
821570|NCT03023241|BPS/IC
821571|NCT03023241|OAB
821572|NCT03023228|Diabetes mellitus
821573|NCT03023228|Hyperglycemia
821574|NCT03023228|Inpatient
821575|NCT03023228|self-management education
821576|NCT03023215|Meditation
821577|NCT03023215|Breast Biopsy
821578|NCT03023215|Stereotactic Breast Biopsy
821579|NCT03023215|SBB
821580|NCT03023215|Guided meditation
821581|NCT03023215|Focused breathing
821582|NCT03023215|Electroencephalogram
821583|NCT03023215|EEG
821584|NCT03023215|Heart rate
821585|NCT03023215|HR
821586|NCT03023215|Questionnaires
821587|NCT03023215|Surveys
821588|NCT03023189|Upper digestive bleeding
821589|NCT03023189|Haemorrhage
821590|NCT03023189|Cirrhosis
821591|NCT03023189|Portal hypertension
821592|NCT03023189|Antifibrinolytic
821593|NCT03023189|Tranexamic acid
821594|NCT03023189|Emergency
821595|NCT03023176|Trivalent, inactivated influenza vaccine
821596|NCT03023176|Child identical twins
821597|NCT03023176|Child fraternal twins
821598|NCT03023163|autonomic dysreflexia
821599|NCT03023163|baroreceptor integrity
821600|NCT03023163|sympathetic integrity
821601|NCT03023163|vagal integrity
821602|NCT03023163|autonomic integrity
821603|NCT03023163|arterial stiffness
821604|NCT03023163|cognitive function
821605|NCT03023163|traumatic brain injury
821606|NCT03023163|cerebral blood flow
821607|NCT03023163|white matter hyperintensities
821608|NCT03023163|cerebral vascular resistance index
821609|NCT03023137|prevention
821610|NCT03023137|carbohydrate
821611|NCT03023137|exercise
821612|NCT03023137|neonatal hypoglycemia
821613|NCT03023111|Cutaneous leishmaniasis
821614|NCT03023111|miltefosine
821615|NCT03023111|cytokines
821616|NCT03023111|treatment
821617|NCT03023098|Restenosis
821618|NCT03023098|Drug-eluting balloon
821619|NCT03023098|Vein graft
821620|NCT03023059|L-DOPA
821621|NCT03023059|GPR143
821622|NCT03023059|PEDF
821623|NCT03023059|VEGF
821624|NCT03023033|PMTCT
821625|NCT03023033|MNCH
821626|NCT03023020|Dual Antiplatelet Therapy
821627|NCT03022994|Non-celiac wheat sensitivity
821628|NCT03022994|eosinophils
821629|NCT03022994|lymphocytes
821630|NCT03022994|duodenal biopsies
821631|NCT03022994|rectal biopsies
821632|NCT03022825|BCG
821633|NCT03022825|bladder cancer
821634|NCT03022825|immunotherapy
821635|NCT03022825|interleukin-15
821636|NCT03022825|intravesical
821637|NCT03022825|non-muscle invasive
821638|NCT03022812|Neck pain
821639|NCT03022812|Rehabilitation
821640|NCT03022812|Exercise Therapy
821641|NCT03022812|Internet
821642|NCT03022799|FAF1
821643|NCT03022799|Fas (TNFRSF6)-associated factor 1
821644|NCT03022799|FAF1 inhibitor
821645|NCT03022799|KM-819
821646|NCT03022786|Dermatitis
821647|NCT03022760|Exhaustion Disorder
821648|NCT03022682|ethnicity
821649|NCT03022682|inflammation
821650|NCT03022669|mobile health
821651|NCT03022669|veterans
821652|NCT03022669|cardiovascular disease
821653|NCT03022669|medication adherence
821654|NCT03022656|Orthotic treatment, Ultrasound Imaging
821655|NCT03022630|palliative care
821656|NCT03022630|cirrhosis
821657|NCT03022630|liver disease
821658|NCT03022630|hepatology
821659|NCT03022630|end of life care
821660|NCT03022630|supportive care
821661|NCT03022578|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
821662|NCT03022578|Glioblastoma
821663|NCT03022578|Anaplastic Astrocytoma
821664|NCT03022578|AA
821665|NCT03022578|Laser interstitial thermal therapy
821666|NCT03022578|LITT
821667|NCT03022578|Lomustine
821668|NCT03022578|CeeNU
821669|NCT03022578|CCNU
821670|NCT03022565|Uveal Melanoma
821671|NCT03022552|Myocardial Infarction
821672|NCT03022552|Women
821673|NCT03022552|Platelets
821674|NCT03022552|Blood Collection
821675|NCT03022552|Genomics
821676|NCT03022526|Pregnant
821677|NCT03022526|Analgesia
821678|NCT03022526|Labor analgesia
821679|NCT03022526|Epidural
821680|NCT03022526|Combined spinal epidural
821681|NCT03022513|Non-celiac Wheat Sensitivity
821682|NCT03022513|fibromyalgia
821683|NCT03022513|synovitis
821684|NCT03022487|Sudden Cardiac Death (SCD)
821685|NCT03022487|implantable cardioverter defibrillator
821686|NCT03022487|electrophysiological
821687|NCT03022487|EP
821688|NCT03022487|Ischaemic cardiomyopathy
821689|NCT03022487|Ventricular Arrhythmia
821690|NCT03022487|ICD
821691|NCT03022474|Childhood obesity
821692|NCT03022461|Heart Failure
821693|NCT03022461|Ventricular Dysfunction
821694|NCT03022461|Cardiomyopathies
821695|NCT03022461|Heart Disease
821696|NCT03022461|Cardiovascular Disease
821697|NCT03022461|Heart-assist Devices
821698|NCT03022461|Thoratec Corporation
821699|NCT03022448|soft tissue sarcomas (STS)
821700|NCT03022448|trabectedin
821701|NCT03022448|metastatic STS patients
821702|NCT03022448|overall survival
821703|NCT03022435|Inactivated influenza vaccine
821704|NCT03022435|Live, attenuated influenza vaccine
821705|NCT03022435|Adult and elderly identical twins
821706|NCT03022435|Adult fraternal twins
821707|NCT03022422|Trivalent, inactivated influenza vaccine
821708|NCT03022422|High-Dose trivalent, inactivated influenza vaccine
821709|NCT03022422|Adult and elderly identical twins
821710|NCT03022422|Adult fraternal twins
821711|NCT03022409|Treatment naïve
821712|NCT03022409|Head and Neck Squamous Cell Carcinoma (HNSCC)
821713|NCT03022409|DNA Damage Repair (DDR)
821714|NCT03022396|Influenza vaccine
821715|NCT03022396|Identical twins
821716|NCT03022396|Fraternal twins
821717|NCT03022396|High-dose influenza vaccine
821718|NCT03022396|Elderly twins
821719|NCT03022396|Child twins
821720|NCT03022383|no known ocular pathology
821721|NCT03022370|informal settlements
821722|NCT03022370|poverty
821723|NCT03022344|DD2 plaque study
821724|NCT03022344|Coronary plaque
821725|NCT03022344|Type-2 diabetes mellitus
821726|NCT03022331|Idiopathic aortitis
821727|NCT03022331|Isolated aortitis
821728|NCT03022331|Vasculitis
821729|NCT03022318|GPR143
821730|NCT03022318|PEDF
821731|NCT03022318|VEGF
821732|NCT03022318|LDOPA
821733|NCT03022305|Hip alignment
821734|NCT03022305|Hip misalignment
821735|NCT03022305|Shoulder function
821736|NCT03022305|Shoulder rotation
821737|NCT03022305|Athletic shoulder injuries
821738|NCT03022305|Athletic hip alignment
821739|NCT03022305|Hip and shoulder alignment
821740|NCT03022305|Hip joint
821741|NCT03022305|Hip joint alignment
821742|NCT03022305|Hip joint misalignment
821743|NCT03022279|Pediatric
821744|NCT03022279|post-operative pain prevention
821745|NCT03022279|Anesthesia, Infiltration
821746|NCT03022279|Nerve Blockade
821747|NCT03022266|Adherence
821748|NCT03022266|CleverCap® Lite BLE C035
821749|NCT03022266|Smartphone App
821750|NCT03022266|Telehealth
821751|NCT03022266|Digital Health
821752|NCT03022266|Mobile Phone App
821753|NCT03022266|Behavioral Economics
821754|NCT03022266|Aspirin
821755|NCT03022266|Wellth App
821756|NCT03022253|PDA
821757|NCT03022253|Platelets
821758|NCT03022214|Dietary supplementation
821759|NCT03022214|Exercise
821760|NCT03022214|Increase Resilience
821761|NCT03022214|Oxidative Stress
821762|NCT03022214|Efficacy
821763|NCT03022201|Motilitone
821764|NCT03022188|pancreatic incidentaloma
821765|NCT03022188|pancreatic neuroendocrine tumor
821766|NCT03022188|EUS-guided fine-needle aspiration
821767|NCT03022188|contrast-enhanced endoscopic ultrasound
821768|NCT03022175|Safety
821769|NCT03022175|Tolerability
821770|NCT03022175|Pharmacokinetics
821771|NCT03022162|Neuropathic Pain, Paclitaxel, CIPN
821772|NCT03022136|epidural block
821773|NCT03022136|dermatome
821774|NCT03022136|human
821775|NCT03022136|spinal nerve
821776|NCT03022136|thoracic
821777|NCT03022071|Cognitive behavior therapy
821778|NCT03022071|Psychodynamic therapy
821779|NCT03022071|Mediators
821780|NCT03022071|Moderators
821785|NCT03022032|Gynecologic cancer
821786|NCT03022019|autologous cell suspension grafting
821787|NCT03022019|vitiligo
821788|NCT03022019|non-segmental
821789|NCT03022019|ReNovaCell
821790|NCT03021967|incurable pathologies
821791|NCT03021967|palliative care
821792|NCT03021954|platelet rich plasma
821793|NCT03021954|pelvic floor disorders
821794|NCT03021954|primipara
821795|NCT03021941|Gaucher Disease
821796|NCT03021941|Enzyme Replacement Therapy
821801|NCT03021889|HIV / AIDS
821802|NCT03021889|Dyslipidemia
821803|NCT03021889|Adolescents
821804|NCT03021889|Nutritional Therapy
821805|NCT03021863|Dissemination
821806|NCT03021863|Tone
821807|NCT03021863|Survey reminders
821808|NCT03021863|Questionnaires
821809|NCT03021850|Pliability
821810|NCT03021850|Cryotherapy
821811|NCT03021850|Hot temperature
821812|NCT03021850|Hyperthermia, induced
821813|NCT03021850|Randomized Controlled Trial
821814|NCT03021850|Hamstring muscles
821946|NCT03021122|Drugs
821815|NCT03021850|Muscle stretching exercises
821816|NCT03021824|Acute Respiratory Distress Syndrome
821817|NCT03021824|ARDS
821818|NCT03021824|Acute Lung Injury
821819|NCT03021824|ALI
821820|NCT03021824|Mechanical Ventilation
821821|NCT03021824|Extracorporeal Membrane Oxygenation
821822|NCT03021824|Neuromuscular Blockade
821823|NCT03021824|Vasodilator Agents
821824|NCT03021824|Prone Position
821825|NCT03021824|ECMO
821826|NCT03021824|Acute Respiratory Failure
821827|NCT03021798|Sarcopenia
821828|NCT03021798|Sarcopenic Obesity
821829|NCT03021798|observational study
821830|NCT03021798|6-minute walking distance
821831|NCT03021798|400 meters walking test
821832|NCT03021798|Patient Reported Outcomes
821833|NCT03021785|Neovascular Age-Related Macular Degeneration
821834|NCT03021785|Anti-VEGF
821835|NCT03021785|CNV
821836|NCT03021785|TK001
821837|NCT03021772|Neostigmine
821838|NCT03021772|Dexamethasone
821839|NCT03021772|Intravenous Local Anesthesia
821840|NCT03021746|African-American
821841|NCT03021720|Uterine fibroid embolization
821842|NCT03021720|Uterine artery embolization
821843|NCT03021720|Arterial access
821844|NCT03021720|Radial access
821845|NCT03021720|Interventional radiology
821846|NCT03021720|Quality of life
821847|NCT03021720|Patient Satisfaction
821848|NCT03021720|Patient centered care
821849|NCT03021720|Uterine fibroid
821850|NCT03021655|Youth
821851|NCT03021655|Randomized controlled trial
821852|NCT03021655|Adventure-based training
821853|NCT03021655|WhatsApp
821854|NCT03021642|healthy volunteer
821855|NCT03021642|Tepotinib
821856|NCT03021642|Mesenchymal-epithelial transition factor
821857|NCT03021642|Translocated promoter region
821858|NCT03021616|energy drink
821859|NCT03021616|qtc interval
821860|NCT03021616|clotting time
821861|NCT03021616|thorough qt study
821862|NCT03021603|Hope
821863|NCT03021603|psychotherapy
821864|NCT03021603|palliative
821865|NCT03021603|low-intensity intervention
821866|NCT03021590|Helicobacter pylori
821867|NCT03021590|Helicobacter Infections
821868|NCT03021590|Proton Pump Inhibitors
821869|NCT03021590|sequential therapy
821870|NCT03021590|Clarithromycin
821871|NCT03021590|Tinidazole
821872|NCT03021577|orbital atherectomy system
821873|NCT03021577|rotational atherectomy
821874|NCT03021577|Fractional flow reserve
821875|NCT03021577|coronary flow reserve
821876|NCT03021577|index of microcirculatory resistance (IMR)
821877|NCT03021551|oxygen
821878|NCT03021551|desaturation
821879|NCT03021551|obesity
821880|NCT03021538|Cardiopulmonary Bypass
821881|NCT03021538|Extracorporeal Membrane Oxygenation
821882|NCT03021538|Primary Graft Dysfunction
821883|NCT03021538|Hemorrhage
821884|NCT03021538|Mechanical Ventilator
821885|NCT03021525|Goal-directed therapy
821886|NCT03021525|postoperative morbidity
821887|NCT03021525|haemodynamic optimisation
821888|NCT03021525|individualised medicine
821889|NCT03021525|Pulse pressure variation
821890|NCT03021525|Cardiac output
821891|NCT03021499|lupus nephritis
821892|NCT03021499|calcineurin inhibitors
821893|NCT03021499|voclosporin
821894|NCT03021486|Malignant neoplasms of independent (primary) multiple sites
821895|NCT03021486|Haloperidol
821896|NCT03021486|Chlorpromazine
821897|NCT03021486|Chlorpromazine hydrochloride
821898|NCT03021486|Thorazine
821899|NCT03021486|Symptom questionnaire
821900|NCT03021486|Survey
821901|NCT03021486|Delirium
821902|NCT03021486|Acute palliative care unit
821903|NCT03021486|APCU
821904|NCT03021473|oxygen reserve index
821905|NCT03021473|desaturation
821906|NCT03021473|safety
821916|NCT03021421|Total knee arthroplasty
821917|NCT03021421|unilateral spinal anaesthesia
821918|NCT03021421|psoas compartment block
821919|NCT03021421|sciatic nerve block
821920|NCT03021421|haemodynamic effects
821921|NCT03021343|Atrial fibrillation
821922|NCT03021343|Colchicine
821923|NCT03021343|Cardiac surgery
821924|NCT03021304|SB240563
821925|NCT03021304|self-administration
821926|NCT03021304|Mepolizumab
821927|NCT03021304|safety syringe
821928|NCT03021304|Eosinophilic asthma
821929|NCT03021278|Tactile acuity
821930|NCT03021278|Chronic pain
821931|NCT03021278|Two-point discrimination
821932|NCT03021278|Point-to-point test
821933|NCT03021278|Two-point estimation
821934|NCT03021278|Body image
821935|NCT03021239|Ramp Test
821936|NCT03021239|Continuous Flow -Left Ventricular Assist Device (CF-LVAD)
821937|NCT03021239|LVAD Hemodynamics
821938|NCT03021226|Health Behavior
821939|NCT03021174|CIPN
821940|NCT03021174|Chemotherapy-induced peripheral neuropathy
821941|NCT03021161|probiotic
821942|NCT03021148|Non-celiac wheat sensitivity
821943|NCT03021148|self-reported
821944|NCT03021122|Medication errors
821945|NCT03021122|Resuscitation
821947|NCT03021122|Pediatrics
821948|NCT03021122|Biomedical technology
821949|NCT03021109|ultrasound
821950|NCT03021109|pediatrics
821951|NCT03021109|gastroenteritis
821952|NCT03021083|Lumbar multi-level fusions
821953|NCT03021083|Patient Controlled Analgesia
821954|NCT03021083|Fentanyl
821955|NCT03021083|Opioid Analgesia
821956|NCT03021070|Ante natal visit
821957|NCT03021070|Facility delivery
821958|NCT03021070|Post natal visit
821959|NCT03021070|Continuum of care
821960|NCT03021070|Conditional cash transfer
821961|NCT03021070|Maternal and child health
821962|NCT03021070|Cluster randomized trial
821963|NCT03021031|Parkinson's Disease
821964|NCT03021018|Epilepsy
821965|NCT03021018|Brivaracetam
821966|NCT03021018|Epilepsy Monitoring Unit
821967|NCT03021018|Increased seizure activity
821968|NCT03020992|Axial Spondyloarthritis
821969|NCT03020992|axSpA
821970|NCT03020992|Anterior Uveitis
821971|NCT03020992|Certolizumab Pegol
821972|NCT03020992|Cimzia
821973|NCT03020875|Acetaminophen
821974|NCT03020875|Pain management
821975|NCT03020862|Dietary nitrate
821976|NCT03020862|Physical performance
821977|NCT03020862|Blood pressure
821978|NCT03020862|Nitrite
821979|NCT03020862|Exercise
821980|NCT03020849|hypofibrinogenemia
821981|NCT03020849|prediction score
821982|NCT03020849|severe trauma
821983|NCT03020823|SCB01A
821984|NCT03020823|squamous cell carcinoma of head and neck
821985|NCT03020784|acute neuroinflammatory
821986|NCT03020771|Crimean-congo hemorrhagic fever
821987|NCT03020771|vaccine
821988|NCT03020771|human
821989|NCT03020771|phase I
821990|NCT03020745|Pharmacokinetics
821991|NCT03020745|Safety
821992|NCT03020745|Pharmacodynamics
821993|NCT03020745|Efficacy
821994|NCT03020745|Chronic Hepatitis B
821995|NCT03020745|GSK3389404
821996|NCT03020732|growth factor
821997|NCT03020732|mucogingival surgery
821998|NCT03020732|gingival recession
821999|NCT03020719|Growth Parameters
822000|NCT03020719|Cystic Fibrosis
822001|NCT03020706|magnesium sulphate
822002|NCT03020706|neostigmine
822003|NCT03020693|electrostimulation
822004|NCT03020693|exercise program
822005|NCT03020667|Conventional cigarette
822006|NCT03020667|iQOS
822007|NCT03020667|Never smoker
822008|NCT03020667|THS
822009|NCT03020641|low pressure pneumoperitoneum
822010|NCT03020641|standard pressure pneumoperitoneum
822011|NCT03020641|laparoscopy cholecystectomy
822012|NCT03020628|Influenza Vaccines
822013|NCT03020628|Vaccines, Inactivated
822014|NCT03020628|Cell Culture-Derived
822015|NCT03020615|Sickle cell
822016|NCT03020615|Hydroxyurea
822017|NCT03020615|Infants
822018|NCT03020589|Renal Transplant
822019|NCT03020589|Tacrolimus
822020|NCT03020589|UNC
822021|NCT03020589|Phase IV
822022|NCT03020550|GERD
822023|NCT03020550|Galvanic Skin Response
822024|NCT03020550|Heart Rate Variability
822025|NCT03020537|Trivalent inactivated influenza vaccine
822026|NCT03020537|Young children
822027|NCT03020537|Young adults
822028|NCT03020511|Modern grains
822029|NCT03020511|ancient grains
822030|NCT03020511|immunologic response
822031|NCT03020511|microbiota
822032|NCT03020498|Inactivated influenza vaccine
822033|NCT03020498|Live, attenuated influenza vaccine
822034|NCT03020498|Child identical twins and non-twins
822035|NCT03020498|Young and elderly non-twin adults
822036|NCT03020472|Live, attenuated influenza vaccine
822037|NCT03020472|Children
822038|NCT03020459|macular holes
822039|NCT03020433|Stroke
822040|NCT03020433|rehab
822041|NCT03020433|rehabilitation
822042|NCT03020433|paresis
822043|NCT03020433|paralysis
822044|NCT03020433|stroke therapy
822045|NCT03020433|CVA
822046|NCT03020433|cerebrovascular accident
822047|NCT03020433|brain diseases
822048|NCT03020433|TMS
822049|NCT03020433|transcranial magnetic stimulation
822050|NCT03020433|CIMT
822051|NCT03020433|constraint induced movement therapy
822052|NCT03020433|MRI
822053|NCT03020407|Septic Shock
822054|NCT03020407|Inferior vene cava diameter
822055|NCT03020407|Resuscitation
822056|NCT03020407|Mortality
822057|NCT03020394|COPD Exacerbation
822058|NCT03020394|Noninvasive Positive Ventilation
822059|NCT03020394|Invasive Positive Ventilation
822060|NCT03020394|severe
822061|NCT03020342|HCC
822062|NCT03020342|chimera DNA
822063|NCT03020342|circulating DNA
822064|NCT03020342|biomarker
822065|NCT03020329|Induction Chemotherapy
822066|NCT03020329|Nasopharyngeal carcinoma
822067|NCT03020329|Chemoradiotherapy
822068|NCT03020290|femoropopliteal artery
822069|NCT03020290|interwoven nitinol stent
822070|NCT03020290|self-expanding-endovascular
822071|NCT03020290|TASC C and TASC D
822072|NCT03020290|Peripheral Arterial Disease
822073|NCT03020264|Type 2 Diabetes
822074|NCT03020264|Hypoglycemia
822075|NCT03020264|Elderly
822076|NCT03020264|Insulinotherapy
822077|NCT03020251|preoperative rehabilitation program
822078|NCT03020251|chest physiotherapy
822079|NCT03020251|lung cancer resection
822080|NCT03020212|Chronic obstructive pulmonary disease
822081|NCT03020212|High altitude
822082|NCT03020212|Oxygen
822083|NCT03020212|long-term oxygen therapy
822084|NCT03020212|pulmonary hypertension
822085|NCT03020212|chronic hypoxemia
822086|NCT03020199|Psoriasis
822087|NCT03020134|pharmacokinetics
822088|NCT03020134|Danoprevir/r
822089|NCT03020134|Ravidasvir
822090|NCT03020095|Ravidasvir
822091|NCT03020095|HCV GT1
822092|NCT03020095|SVR12
822093|NCT03020095|Danoprevir/r
822094|NCT03020082|Danoprevir
822095|NCT03020082|non-cirrhotic
822096|NCT03020082|Chinese HCV G1
822097|NCT03020082|SVR12
822098|NCT03020069|Type 1 Diabetes
822099|NCT03020069|Adolescents
822100|NCT03020069|Glucose Monitoring
822101|NCT03020056|cataract surgery
822102|NCT03020056|economy
822103|NCT03020056|quality of life
822104|NCT03020056|rural area
822105|NCT03020030|acute lymphoblastic leukemia
822106|NCT03020004|Danoprevir
822107|NCT03020004|SVR12
822108|NCT03020004|Chinese HCV G1
822109|NCT03020004|non-cirrhotic
822110|NCT03019991|pharmacokinetics,Danoprevir
822111|NCT03019939|Acute Myeloid Leukemia
822112|NCT03019939|AML
822113|NCT03019939|Myelodysplastic Syndrome
822114|NCT03019939|MDS
822115|NCT03019939|Neutropenia
822116|NCT03019939|Invasive fungal infection
822117|NCT03019939|IFI
822118|NCT03019939|Isavuconazole
822119|NCT03019939|BAL8557
822120|NCT03019926|systemic lupus erythematosus
822121|NCT03019926|observance
822122|NCT03019926|hydroxychloroquine dosage
822123|NCT03019926|risk factors of non-observance
822124|NCT03019926|SLICC score
822125|NCT03019926|SLEDAI score
822126|NCT03019913|Skeletal muscle
822127|NCT03019861|Ayurveda
822128|NCT03019861|IBS
822129|NCT03019861|Complementary medicine
822130|NCT03019861|nutritional counseling
822131|NCT03019848|Redox and pro-inflammatory status
822132|NCT03019835|mivacurium
822133|NCT03019835|neostigmine
822134|NCT03019835|antagonism
822135|NCT03019783|Endothelial function
822136|NCT03019770|Pre-Exposure Prophylaxis
822137|NCT03019770|HIV
822138|NCT03019770|Decision Aid
822139|NCT03019770|Shared Decision Making
822140|NCT03019744|Functional Electrical Stimulation
822141|NCT03019744|Cerebrovascular accident
822142|NCT03019744|Stroke
822143|NCT03019744|Electromyography
822144|NCT03019731|Tics
822145|NCT03019731|Behavioral therapy
822146|NCT03019731|Neurologic Examination
822147|NCT03019718|Inpatient rehabilitation
822148|NCT03019718|Internet-based intervention
822149|NCT03019718|Aftercare
822150|NCT03019718|Return to work
822151|NCT03019718|Psychodynamic
822152|NCT03019705|Cyberchondria
822153|NCT03019705|health-related internet use
822154|NCT03019705|pathological health anxiety
822155|NCT03019705|ambulatory assessment
822156|NCT03019666|MM
822157|NCT03019666|NHL
822158|NCT03019640|B-Cell Non-Hodgkin Lymphoma
822159|NCT03019640|Relapsed follicular lymphoma
822160|NCT03019640|Indolent B-cell histology
822161|NCT03019640|Natural killer cells
822162|NCT03019640|NK
822163|NCT03019640|Stem cell transplant
822164|NCT03019640|Rituximab
822165|NCT03019640|Rituxan
822166|NCT03019640|Carmustine
822167|NCT03019640|BCNU
822168|NCT03019640|BiCNU
822169|NCT03019640|Etoposide
822170|NCT03019640|VePesid
822171|NCT03019640|Cytarabine
822172|NCT03019640|Ara-C
822173|NCT03019640|Cytosar
822174|NCT03019640|DepoCyt
822175|NCT03019640|Cytosine arabinosine hydrochloride
822176|NCT03019640|Melphalan
822177|NCT03019640|Alkeran
822178|NCT03019640|Lenalidomide
822179|NCT03019640|CC-5013
822180|NCT03019640|Revlimid
822181|NCT03019640|G-CSF
822182|NCT03019640|Filgrastim
822183|NCT03019640|Neupogen
822184|NCT03019601|HIV
822185|NCT03019601|PMTCT
822190|NCT03019562|postoperative pain
822191|NCT03019523|caffeine
822192|NCT03019523|mental performance
822193|NCT03019523|reaction time
822194|NCT03019523|focus
822195|NCT03019497|PTSD
822196|NCT03019497|Related Problems
822197|NCT03019497|Therapy
822198|NCT03019497|Traumatic Event
822199|NCT03019497|Quality of Life
822200|NCT03019497|Cognitive Behavioral Therapy (CBT)
822201|NCT03019497|Major depression
822202|NCT03019497|Sleep disorders
822203|NCT03019497|Pain
822204|NCT03019497|Stressors
822205|NCT03019497|Social support
822206|NCT03019497|Substance use disorder
822207|NCT03019497|Anxiety disorder
822208|NCT03019484|Self-efficacy
822209|NCT03019484|Self Efficacy
822210|NCT03019484|Nurses's Role
822211|NCT03019484|Professional Role
822212|NCT03019484|Clinical Trial
822213|NCT03019484|Breast Feeding
822215|NCT03019419|sporadic ALS
822216|NCT03019419|perampanel
822217|NCT03019393|non-transferrin bound iron (NTBI)
822218|NCT03019393|Red meat
822219|NCT03019393|Non-transferrin bound iron (NTBI) in serum
822220|NCT03019367|Premature infants
822221|NCT03019367|Umbilical cord milking
822222|NCT03019367|Delayed cord clamping
822223|NCT03019367|Intraventricular Hemorrhage
822224|NCT03019367|Death
822225|NCT03019354|high flow oxygen
822226|NCT03019354|pulmonary atelectasis
822227|NCT03019354|intravenous general anesthesia
822228|NCT03019341|Nausea
822229|NCT03019341|Vomiting
822230|NCT03019341|Non-ionic contrast media
822231|NCT03019341|Side effect
822232|NCT03019328|peanut allergy
822233|NCT03019328|food allergens
822234|NCT03019328|atopic dermatitis
822235|NCT03019328|eczema
822236|NCT03019328|infant food allergy testing
822237|NCT03019328|skin prick testing
822238|NCT03019328|peanut IgE
822239|NCT03019328|early peanut introduction
822240|NCT03019328|food allergy prevention
822241|NCT03019315|Ovarian Cancer
822242|NCT03019315|Chemotherapy
822243|NCT03019315|Response Rate
822244|NCT03019315|Survival
822245|NCT03019250|Colostrum
822246|NCT03019250|Critical Care Outcomes
822247|NCT03019250|Intensive Care Unit
822248|NCT03019250|Inflammation
822249|NCT03019250|Infection
822250|NCT03019250|mortality
822251|NCT03019224|Tooth whitening
822252|NCT03019224|Dentifrice
822253|NCT03019224|Sensitivity
822254|NCT03019211|Physical Therapy Modalities
822255|NCT03019211|Accidental Fall
822256|NCT03019211|Elderly
822257|NCT03019211|Hydrotherapy
822258|NCT03019211|Nursing Home
822259|NCT03019198|Tranexamic Acid
822260|NCT03019198|Blood loss
822261|NCT03019198|Tranfusion
822262|NCT03019185|Alport Syndrome
822263|NCT03019185|Bardoxolone methyl
822264|NCT03019185|CDDO-ME
822265|NCT03019185|RTA 402
822266|NCT03019146|Prehabilitation
822267|NCT03019133|Heart rate
822268|NCT03019133|Blood pressure variability
822269|NCT03019094|overactive bladder
822270|NCT03019094|urge urinary incontinence
822271|NCT03019094|urgency frequency
822272|NCT03019068|recruitment potential
822273|NCT03019068|prediction
822274|NCT03019068|databases
822275|NCT03019068|Clinical Trial Recruitment Support Systems (CTRSS)
822281|NCT03019029|Peripheral Nerve Amyloidosis
822282|NCT03019003|Head and Neck Cancer
822283|NCT03018964|Single incision
822284|NCT03018964|Solo surgery
822285|NCT03018951|frailty, assessement
822286|NCT03018938|mid mixture insulin analog
822287|NCT03018938|basal insulin analog
822288|NCT03018912|Subjective Sleep Vital Sign (VS)
822289|NCT03018912|Primary Care
822290|NCT03018912|Sleep Medicine
822291|NCT03018912|Cognitive Behavioral Therapy (CBT)
822292|NCT03018912|Obstructive Sleep Apnea (OSA)
822293|NCT03018912|Insomnia
822294|NCT03018912|Complex Sleep Disorders
822295|NCT03018912|Predictive Analytics
822296|NCT03018912|Screening
822297|NCT03018912|Therapy Outcomes
822298|NCT03018899|paravertebral block
822299|NCT03018899|ultrasound
822300|NCT03018899|percutaneous nephrolithotomy
822301|NCT03018899|postoperative pain
822302|NCT03018873|remote ischemic preconditioning
822303|NCT03018873|acute myocardial infarction
822304|NCT03018860|Active second stage
822305|NCT03018860|Neonatal morbidity
822306|NCT03018860|Operative delivery
822307|NCT03018860|Labor
822308|NCT03018834|Acute Myocarditis
822309|NCT03018834|ANAKINRA
822310|NCT03018808|Eosinophilia
822311|NCT03018808|COPD prevalence
822312|NCT03018808|Primary care subjects
822313|NCT03018795|peri-implantitis
822314|NCT03018795|Surgical regenerative treatment
822315|NCT03018795|ozone therapy
822316|NCT03018704|alcoholism
822317|NCT03018704|treatment
822318|NCT03018652|COPD
822319|NCT03018652|Ig
822320|NCT03018652|IPRAC
822321|NCT03018652|outpatient
822322|NCT03018626|Non-germinal b-cell-like
822323|NCT03018626|R-ACVBP
822324|NCT03018626|DA-EPOCH-R
822325|NCT03018613|Chronic Functional Constipation
822326|NCT03018613|Intestinal Bacteria Flora Disturbance
822327|NCT03018613|Fecal Microbiota Transplantation
822328|NCT03018600|prednisone, autoimmune disease
822329|NCT03018509|JTE-451
822330|NCT03018509|psoriasis
822331|NCT03018470|COPD
822332|NCT03018470|Non invasive ventilation
822333|NCT03018470|NIV
822334|NCT03018470|Acute exacerbation COPD
822335|NCT03018470|AECOPD
822336|NCT03018470|Telemonitoring
822337|NCT03018457|Trabecular microarchitecture
822338|NCT03018457|alveolar bone
822339|NCT03018457|osseointegration
822340|NCT03018457|dental implant
822341|NCT03018431|Lung ultrasonography
822342|NCT03018431|Chest CT scan
822343|NCT03018431|ventilator-associated pneumonia
822344|NCT03018431|ventilator-associated tracheobronchitis
822345|NCT03018431|antibiotic stewardship
822346|NCT03018418|Anal Cancer
822347|NCT03018379|Obesity
822348|NCT03018379|Body composition
822349|NCT03018379|energy expenditure
822350|NCT03018379|sedentarity
822351|NCT03018379|dietary behaviors
822352|NCT03018366|estrogen
822353|NCT03018366|premenopause
822354|NCT03018366|menopause
822355|NCT03018366|amenorrhea
822356|NCT03018353|Hepatitis C, Chronic
822357|NCT03018353|Jail
822358|NCT03018353|Patient Navigation
822359|NCT03018353|Incarcerated Population
822360|NCT03018353|HCV
822361|NCT03018353|Sofosbuvir/Velpatasvir
822362|NCT03018353|Hepatitis C
822363|NCT03018288|Malignant Gliomas
822364|NCT03018288|Immunotherapy
822365|NCT03018275|Lyophilized Biotherapeutic, Microbiome, Probiotic
822366|NCT03018275|Commensal Gram-negative Bacteria
822367|NCT03018275|Staphylococcus Aureus
822368|NCT03018275|Transepidermal Water Loss
822369|NCT03018275|Allergic Diseases
822370|NCT03018262|Surround Inhibition
822371|NCT03018262|Motor Control
822372|NCT03018262|Transcranial Magnetic Stimulation (TMS)
822373|NCT03018262|TMS-Evoked Potential
822374|NCT03018236|cocaine
822375|NCT03018236|alcohol
822376|NCT03018236|substance use disorders
822377|NCT03018236|addiction
822378|NCT03018236|N-acetylcysteine
822379|NCT03018236|randomized controlled trial
822380|NCT03018223|Acute leukemia in CR
822381|NCT03018223|Chronic myeloid leukemia
822382|NCT03018223|Non-Hodgkin lymphoma in high risk
822383|NCT03018223|Graft vs. Host Disease
822384|NCT03018223|GVHD
822385|NCT03018223|Hematopoietic cell transplant (HCT)
822386|NCT03018197|Personal Health Record
822387|NCT03018197|Medication Knowledge
822388|NCT03018197|Anticoagulants
822389|NCT03018197|Patient Engagement
822390|NCT03018184|MRI
822391|NCT03018184|CCSA
822392|NCT03018184|Contractile Cross Sectional Area
822393|NCT03018184|Strength
822394|NCT03018171|clonidine, spinal injections
822395|NCT03018132|perinatal mental health
822396|NCT03018106|Female sexual disorder
822397|NCT03018106|Aging
822398|NCT03018106|Menopause
822399|NCT03018106|Obstetrics/Gynecology
822400|NCT03018106|Female urogenital disorder
822401|NCT03018093|Relapsed or refractory acute lymphoblastic leukemia
822402|NCT03018093|Anti-CD19 chimeric antigen receptor T-cell
822403|NCT03018054|moderate active ulcerative colitis
822404|NCT03018054|Japanese
822405|NCT03018041|Kidney transplantation
822406|NCT03018041|Renal transplantation
822407|NCT03018041|Omega-3 fatty acids
822408|NCT03018041|Marine n-3 fatty acids
822409|NCT03018041|Fatty acids
822410|NCT03018041|Inflammation
822411|NCT03018041|Interstitial fibrosis
822412|NCT03018041|Glomerular filtration rate
822413|NCT03018041|Renal function
822414|NCT03018041|Allograft function
822415|NCT03018041|Proteinuria
822416|NCT03018041|Blood pressure
822417|NCT03018041|Heart rate variability
822418|NCT03018041|Lipids
822419|NCT03018041|Blood glucose
822420|NCT03018041|Body mass index
822421|NCT03018041|Fatty acid composition
822422|NCT03018041|Gas chromatography
822423|NCT03018041|Interventional study
822424|NCT03018041|Allograft biopsy
822425|NCT03018041|Kidney biopsy
822426|NCT03018015|Bioequivalence
822427|NCT03018015|Healthy
822428|NCT03018015|Bioavailability
822429|NCT03018015|Ibuprofen
822430|NCT03018002|HIV, PMTCT
822431|NCT03017989|Near Infrared Fluorescence Imaging
822432|NCT03017989|Indocyanine green (ICG)
822433|NCT03017963|acute coronary syndrome
822434|NCT03017963|sodium thiosulfate
822435|NCT03017963|maximum tolerable dose
822436|NCT03017963|dose-limiting toxicity
822437|NCT03017911|PICC Line
822438|NCT03017911|Complications
822439|NCT03017911|Thrombosis
822440|NCT03017911|Infection
822441|NCT03017898|FiLaC
822442|NCT03017898|Fistula Laser Closure
822443|NCT03017898|Laser Coagulation
822444|NCT03017872|HIV, second-line
822445|NCT03017833|Solid Tumors
822446|NCT03017833|Advanced Cancer
822447|NCT03017833|Metformin
822448|NCT03017833|Metformin ER
822449|NCT03017833|TAK-228
822450|NCT03017833|MLN0128
822451|NCT03017833|TAK228
822452|NCT03017794|Radiotherapy
822453|NCT03017794|Chromogranin A
822454|NCT03017794|Neuroendocrine differentiation
822455|NCT03017781|Bipolar
822456|NCT03017781|High-Risk Off-Spring
822457|NCT03017781|Psychosocial Functioning
822459|NCT03017716|Inflammatory back pain
822460|NCT03017716|gluten-free diet
822461|NCT03017716|celiac disease
822462|NCT03017716|non-celiac wheat sensitivity
822463|NCT03017703|Endothelial dysfunction
822464|NCT03017703|Insulin resistance
822465|NCT03017703|Type 2 diabetes
822466|NCT03017703|Mineralocorticoid blocker
822467|NCT03017625|COPD
822468|NCT03017625|Cardiovascular Disease
822469|NCT03017625|Platelets
822470|NCT03017625|Inflammation
822471|NCT03017612|Presbyopia
822472|NCT03017573|Immunological biomarkers
822473|NCT03017573|molecular profil
822474|NCT03017573|Circulating tumor DNA (ctDNA)
822475|NCT03017560|Breast Cancer
822476|NCT03017560|Chemotherapy
822477|NCT03017560|Verbal Memory
822478|NCT03017560|Processing Speed
822479|NCT03017534|Patient-Therapist Interaction
822480|NCT03017534|Non-Specific Effects
822481|NCT03017534|Manual Therapy
822482|NCT03017534|Neurodynamics
822483|NCT03017534|Sham
822484|NCT03017521|Refractory solid tumors
822485|NCT03017521|AKT inhibitor
822486|NCT03017508|Cross-over study
822487|NCT03017508|Riluzole
822488|NCT03017508|Double-blind study
822489|NCT03017508|Speech task
822490|NCT03017508|Social Anxiety Disorder
822491|NCT03017495|food-drug interaction
822492|NCT03017495|drug-drug interaction
822493|NCT03017495|pharmacokinetics
822494|NCT03017469|Resilience
822495|NCT03017469|Workplace Stress
822496|NCT03017469|Occupational Fatigue
822497|NCT03017469|Compassion Fatigue
822498|NCT03017469|Peer Support
822499|NCT03017469|Self-Care
822500|NCT03017469|Employee Assistance
822501|NCT03017456|Survivorship
822502|NCT03017456|Prostate Cancer
822503|NCT03017456|Survivorship Care Plan
822504|NCT03017443|Weight Loss
822505|NCT03017443|Obesity
822506|NCT03017443|Overweight
822507|NCT03017391|palliative care
822508|NCT03017391|palliative medicine
822509|NCT03017391|palliative
822510|NCT03017378|influenza vector
822511|NCT03017378|tuberculosis
822512|NCT03017378|vaccine
822513|NCT03017365|Motor Control
822514|NCT03017365|Balance
822515|NCT03017352|Diabetes Mellitus, Type 1
822516|NCT03017352|Exenatide
822517|NCT03017352|Incretins
822518|NCT03017352|GLP-1
822519|NCT03017352|Insulin
822520|NCT03017339|Low Lever Laser Therapy
822521|NCT03017339|Exercise Therapy
822522|NCT03017339|Chronic Pain
822523|NCT03017287|Glucose blood measurements, glucometer, BGM, Diabetes App
822524|NCT03017274|Non-celiac wheat sensitivity
822525|NCT03017274|celiac disease
822526|NCT03017274|abdominal ultrasonography;
822527|NCT03017261|Osteoarthritis
822528|NCT03017261|Arthroplasty
822529|NCT03017261|Robotic Surgery
822530|NCT03017261|Knee
822531|NCT03017248|pain
822532|NCT03017248|ketamine
822533|NCT03017248|morphine
822534|NCT03017248|analgesia
822535|NCT03017248|emergency
822536|NCT03017144|non-technical skills (NTS)
822537|NCT03017144|human factors
822538|NCT03017144|team work
822539|NCT03017144|Crew Resource Management / Crisis Resource Management (CRM)
822540|NCT03017144|technical skills (TS)
822541|NCT03017144|Cardiopulmonary resuscitation
822542|NCT03017144|Advanced cardiac life support
822543|NCT03017079|Semi-solidification
822544|NCT03017079|caloric debt
822545|NCT03017079|enteral nutrition
822546|NCT03017079|critical illness
822547|NCT03017066|Ultrasonography
822548|NCT03017066|Child
822549|NCT03017066|Preoperative period
822550|NCT03017053|Neck dissection
822551|NCT03017053|Survival
822552|NCT03017053|Early oral cancer
822553|NCT03017053|Early oral cavity squamous cancer with node negative neck
822554|NCT03017027|human-animal interaction
822555|NCT03017014|Humira®
822556|NCT03017014|Adalimumab
822557|NCT03017014|Crohn's Disease
822558|NCT03016988|Mantle cell lymphoma
822559|NCT03016988|Bortezomib
822560|NCT03016988|Fludarabine
822561|NCT03016988|Cytarabine
822562|NCT03016936|Metabolic equivalents (METs)
822563|NCT03016936|European Society of Anaesthesiology (ESA)
822564|NCT03016936|Noncardiac surgery
822565|NCT03016936|Cardiovascular Mortality
822566|NCT03016923|cerebral palsy
822567|NCT03016923|hemiplegia
822568|NCT03016923|fes
822569|NCT03016923|grasping
822570|NCT03016897|ALS
822571|NCT03016897|neurodegenerative
822572|NCT03016884|Herpes Zoster
822573|NCT03016884|anti TNF alpha
822574|NCT03016884|tofacitinib
822575|NCT03016884|Rheumatoid Arthritis
822576|NCT03016845|ciprofloxacin
822577|NCT03016845|pharmacokinetics
822578|NCT03016845|Intensive Care Unit
822579|NCT03016845|Cystatin C
822580|NCT03016845|CKD-EPI
822581|NCT03016845|renal function
822582|NCT03016780|Ulcerative Colitis
822583|NCT03016780|Intestinal Bacteria Flora Disturbance
822584|NCT03016780|Fecal Microbiota Transplantation
822585|NCT03016780|Intestinal Mucosal Immunity
822586|NCT03016767|oral feeding
822587|NCT03016767|oral stimulation
822588|NCT03016767|physiotherapy intervention
822589|NCT03016754|sudden cardiac death
822590|NCT03016754|SCD
822591|NCT03016754|sudden cardiac arrest
822592|NCT03016754|SCA
822593|NCT03016754|heart failure
822594|NCT03016754|HF
822595|NCT03016741|cognitive function
822596|NCT03016741|hormonal therapy
822597|NCT03016741|cancer survivorship
822598|NCT03016741|dementia
822599|NCT03016741|cognitive dysfunction
822600|NCT03016741|mild cognitive impairment
822601|NCT03016728|exercise
822602|NCT03016728|physical activity
822603|NCT03016728|pilot study
822604|NCT03016728|randomized controlled trial
822605|NCT03016728|cancer
822606|NCT03016728|adolescent and young adult
822607|NCT03016728|AYA
822608|NCT03016715|Epidermolysis bullosa simplex
822609|NCT03016676|Spinal Manipulation
822610|NCT03016676|Postural Instability
822611|NCT03016676|Quality of Life
822612|NCT03016650|Acetaminophen
822613|NCT03016650|Ibuprofen
822614|NCT03016637|endoscopic ultrasonography
822615|NCT03016637|EUS-FNA
822616|NCT03016598|oxytocin
822617|NCT03016598|substance-related disorders
822618|NCT03016598|Motivational Interviewing
822619|NCT03016598|Psychophysiology
822620|NCT03016598|Psychotherapeutic processes
822621|NCT03016572|Suicide
822622|NCT03016572|Adolescent
822623|NCT03016572|Intervention
822624|NCT03016572|Crisis
822625|NCT03016572|Follow-Up
822626|NCT03016559|releasing muscle, quadratus lumborum, hip angle
822627|NCT03016546|Pregnancy
822628|NCT03016533|Dolutegravir
822629|NCT03016533|Continued access study
822630|NCT03016533|HIV-1
822631|NCT03016533|GSK1349572
822632|NCT03016533|Pediatric
822633|NCT03016507|intraocular pressure
822634|NCT03016507|phacoemulsification
822635|NCT03016507|cataract
822636|NCT03016468|Oral Treprostinil
822637|NCT03016468|Remodulin
822638|NCT03016468|Selexipag
822639|NCT03016468|6 Minute Walk Test
822640|NCT03016455|Kidney Transplant
822641|NCT03016455|Immunology
822642|NCT03016442|Double balloon catheter
822643|NCT03016442|Dinoprostone
822644|NCT03016442|Labor induction
822645|NCT03016429|pacemaker
822646|NCT03016429|defibrillator
822647|NCT03016429|magnetic resonance imaging
822648|NCT03016429|cardiac implantable electronic device
822649|NCT03016390|Cardiac Implantable Electronic Device
822650|NCT03016390|Pacemaker
822651|NCT03016390|Automatic Implantable Cardioverter-Defibrillator (AICD)
822652|NCT03016390|Electromagnetic interference (EMI)
822653|NCT03016390|Keyless access system
822654|NCT03016390|Keyless entry system
822655|NCT03016377|CAR T cells
822656|NCT03016377|CD19
822657|NCT03016377|Leukemia
822658|NCT03016377|T Lymphocytes
822659|NCT03016377|AP1903
822660|NCT03016377|Cytokine Release Syndrome
822661|NCT03016351|Hypertension
822662|NCT03016351|Exercise
822663|NCT03016351|African Americans
822664|NCT03016351|Arterial Function
822665|NCT03016351|Arterial Stiffness
822666|NCT03016286|Whole body vibration
822667|NCT03016286|Bone myoregulation reflex
822668|NCT03016286|H-reflex
822669|NCT03016260|Rheumatoid Arthritis
822670|NCT03016260|Anti TNF
822671|NCT03016260|Infliximab
822672|NCT03016260|Adalimumab
822673|NCT03016260|Etanercept
822674|NCT03016260|Golimumab
822675|NCT03016260|Certolizumab Pegol
822676|NCT03016260|Infliximab biosimilar
822677|NCT03016260|Etanercept biosimilar
822678|NCT03016260|Methotrexate
822679|NCT03016247|magnetic resonance imaging, trust, reward
822680|NCT03016234|intraocular pressure
822681|NCT03016234|trendelenburg position
822682|NCT03016234|pneumoperitoneum
822683|NCT03016221|local skin responses
822684|NCT03016221|hyperemia
822685|NCT03016221|thermal sensation
822686|NCT03016221|topical warming ointments
822687|NCT03016221|topical cooling ointments
822688|NCT03016221|skin perfusion
822689|NCT03016221|subjective thermal sensation
822690|NCT03016221|muscle tissue oxygenation
822691|NCT03016221|skin temperature
822692|NCT03016221|skin redness
822693|NCT03016221|erythema
822694|NCT03016143|phase II
822695|NCT03016143|split
822696|NCT03016143|vaccine
822697|NCT03016130|leukemia
822698|NCT03016130|myelodysplastic
822699|NCT03016130|myeloid
822700|NCT03016130|lymphoblastic
822701|NCT03016130|diet
822702|NCT03016130|infection
822703|NCT03016130|hematopoietic
822704|NCT03016130|stem cell
822705|NCT03016130|transplant
822706|NCT03016104|magnetic seizure therapy
822707|NCT03016104|electroconvulsive therapy
822708|NCT03016104|bipolar mania
822709|NCT03016104|cognition
822710|NCT03016104|controlled trial
822711|NCT03016052|ABMT
822712|NCT03016052|social anxiety
822713|NCT03016052|generalized anxiety
822714|NCT03016026|ERAS,Laparoscopy,Distal Gastrectomy,Safety,Effectiveness
822715|NCT03016000|diffuse large B-cell lymphoma
822716|NCT03016000|Thalidomide
822717|NCT03016000|Maintenance
822718|NCT03015987|Diode laser
822719|NCT03015987|asymptomatic pulp
822720|NCT03015987|Laser activated irrigation
822721|NCT03015987|continuous ultrasonic activation
822722|NCT03015987|post obturation pain
822723|NCT03015935|Obesity, Morbid
822724|NCT03015883|Squamous Cell Carcinoma
822725|NCT03015883|Alpha emitting radiation
822726|NCT03015870|vocal dysfunction
822727|NCT03015870|voice
822728|NCT03015870|vocal folds
822729|NCT03015870|vocal aging
822730|NCT03015844|MIBG
822731|NCT03015844|131I-MIBG
822732|NCT03015844|relapsed
822733|NCT03015844|neuroblastoma
822734|NCT03015844|pheochromocytoma
822735|NCT03015831|Atrial fibrillation
822736|NCT03015831|Cardiac surgery
822737|NCT03015831|Colchicine
822738|NCT03015766|insomnia
822739|NCT03015766|hemodialysis
822740|NCT03015766|auricular acupressure
822741|NCT03015766|randomized controlled trial
822742|NCT03015753|Migraine
822743|NCT03015753|Tai Chi
822744|NCT03015753|Prophylaxis
822745|NCT03015753|Randomized controlled trial
822746|NCT03015740|Malignant neoplasms of urinary tract
822747|NCT03015740|Other disorders of kidney and ureter
822748|NCT03015740|Renal cell carcinoma
822749|NCT03015740|RCC
822750|NCT03015740|Metastatic
822751|NCT03015740|MGCD516
822752|NCT03015740|Nivolumab
822753|NCT03015740|BMS-936558
822754|NCT03015740|Opdivo
822755|NCT03015727|nasopharyngeal carcinoma
822756|NCT03015727|Induction chemotherapy
822757|NCT03015727|radiotherapy
822758|NCT03015727|chemoradiotherapy
822759|NCT03015701|Unresectable
822760|NCT03015688|Biomarkers
822766|NCT03015649|breast cancer, surgical guidance system
822767|NCT03015636|Cognitive Behaviour Therapy
822768|NCT03015636|Psychological Intervention
822769|NCT03015623|Mesenchymal stromal cells
822770|NCT03015623|MSC
822771|NCT03015623|Stem cells
822772|NCT03015623|Mesenchymal stem cells
822773|NCT03015610|Personalized Medicine
822774|NCT03015610|CYP2C19
822775|NCT03015610|Lansoprazole
822776|NCT03015610|Pharmacokinetics
822777|NCT03015597|Smoking
822778|NCT03015597|Tobacco Smoking
822779|NCT03015597|Smoking, Tobacco
822780|NCT03015597|Smoking Cessation
822781|NCT03015597|Opiate Addiction
822782|NCT03015597|Opiate Dependence
822783|NCT03015597|Contingency Management
822784|NCT03015571|heterotopic gastric mucosa
822785|NCT03015571|cervical inlet patch
822786|NCT03015571|narrow band imaging
822787|NCT03015571|endoscopy
822788|NCT03015558|Drug Resistance
822789|NCT03015558|Neuropathic Pain
822790|NCT03015558|opercular-insular cortex
822791|NCT03015558|Transcranial Direct Current Stimulation
822792|NCT03015545|Muscle Stiffness
822793|NCT03015545|Ultrasound elastography
822794|NCT03015545|H-reflex
822795|NCT03015545|Whole body vibration
822802|NCT03015493|Neck pain
822803|NCT03015493|Neurodynamics
822804|NCT03015493|Spinal manipulative therapy
822805|NCT03015480|Mobile Application
822806|NCT03015480|Chronic Kidney Disease
822807|NCT03015480|Diabetes Mellitus
822808|NCT03015480|Albuminuria
822809|NCT03015480|Diet
822810|NCT03015467|acute pancreatitis
822811|NCT03015467|intestinal mucosal barrier
822812|NCT03015467|Fecal Microbiota Transplantation
822813|NCT03015454|InSight
822814|NCT03015454|Dascena
822815|NCT03015441|Healthy subjects
822816|NCT03015441|Probiotics
822817|NCT03015441|Breath test
822818|NCT03015441|Dihydrogen
822819|NCT03015441|Methane
822820|NCT03015441|Intestinal gas production
822821|NCT03015441|Gut microbiota
822822|NCT03015428|Family caregivers
822823|NCT03015428|training programme
822824|NCT03015428|dementia
822825|NCT03015415|elbow
822826|NCT03015415|posttraumatic stiffness
822827|NCT03015415|elbow contractures
822828|NCT03015415|stiff elbow
822829|NCT03015415|dynamic orthoses
822830|NCT03015415|Dynamic splint
822831|NCT03015415|Rehabilitation
822832|NCT03015415|Splint
822833|NCT03015415|Effectiveness of bracing
822834|NCT03015376|epithelial ovarian cancer
822835|NCT03015376|Hereditary Breast and Ovarian Cancer Syndrome
822836|NCT03015376|next-generation sequencing
822837|NCT03015376|High-Throughput Nucleotide Sequencing
822838|NCT03015363|Hypertension
822839|NCT03015363|Telemonitoring
822840|NCT03015363|Vital signs
822841|NCT03015350|blood sevoflurane concentration
822842|NCT03015350|blood desflurane concentration
822843|NCT03015350|one lung ventilation
822844|NCT03015311|Blood pressure control
822845|NCT03015298|gastric cancer
822846|NCT03015298|Simultaneous PET/MRI
822847|NCT03015298|PET/CT
822848|NCT03015272|minimally-verbal
822849|NCT03015272|children
822850|NCT03015272|intervention
822851|NCT03015272|singing
822852|NCT03015272|music
822853|NCT03015233|Lactate
822854|NCT03015233|Acute Abdominal Pain
822855|NCT03015233|Acute Abdomen
822856|NCT03015233|Strong Ion Gap
822857|NCT03015233|Renal Colic
822858|NCT03015233|Emergency Department
822859|NCT03015233|Emergency
822860|NCT03015233|Surgery
822861|NCT03015233|Stewart
822862|NCT03015194|LVOT (left ventricular outflow tract, obstruction)
822863|NCT03015194|Transcatheter Mitral Valve Implantation
822864|NCT03015194|Transcatheter Heart Valve
822865|NCT03015194|Mitral Valve Regurgitation
822866|NCT03015194|Mitral Valve Stenosis
822867|NCT03015181|Broadly Neutralizing
822868|NCT03015181|HIV Prevention
822869|NCT03015181|Anti-Drug Antibody
822870|NCT03015181|HIV-1
822871|NCT03015181|Immune Response
822872|NCT03015129|Durvalumab
822873|NCT03015129|MEDI4736
822874|NCT03015129|Tremelimumab
822875|NCT03015129|anti-PD-L1 Antibody
822876|NCT03015129|anti-CTLA-4 antibody
822877|NCT03015129|16-1491
822878|NCT03015116|photobiomodulation
822879|NCT03015116|plantar fasciitis
822880|NCT03015090|COPD
822881|NCT03015090|CYP1A2
822882|NCT03015090|Theophylline
822883|NCT03015077|Glutamine
822884|NCT03015051|Bronchiolitis
822885|NCT03015051|High flow nasal cannula
822886|NCT03015051|Oxygen therapy
822887|NCT03015025|Acenocoumarol
822888|NCT03015025|Cytochrome P450
822889|NCT03015025|Pharmacogenetics
822890|NCT03015025|Algorithm
822891|NCT03015025|CYP2C9
822892|NCT03015025|VKORC1
822893|NCT03015025|CYP4F2
822894|NCT03015025|P450 oxidoreductase (POR)
822895|NCT03015012|Nutrigenomics
822896|NCT03015012|Genetics
822897|NCT03015012|Overweight
822898|NCT03015012|Obesity
822899|NCT03015012|Transplantation
822900|NCT03015012|Nutrition
822901|NCT03015012|Dietetics
822902|NCT03015012|BMI
822903|NCT03015012|Body Composition
822904|NCT03014999|Transcranial Magnetic Stimulation
822905|NCT03014999|Spinal Cord Injury
822906|NCT03014999|Humans
822907|NCT03014986|HCV
822908|NCT03014947|MSB11022
822909|NCT03014947|Humira®
822910|NCT03014934|Aspergillosis
822911|NCT03014934|IA
822912|NCT03014908|Type 1 diabetes
822913|NCT03014908|1H-NMR spectroscopy
822914|NCT03014908|Metabolomics
822915|NCT03014908|Pediatrics
822916|NCT03014895|E3112
822917|NCT03014895|Pharmacokinetics
822918|NCT03014895|Japanese
822919|NCT03014869|COPD Exacerbation
822920|NCT03014869|High Flow Oxygen
822921|NCT03014869|Noninvasive Positive Ventilation
822922|NCT03014869|moderate
822923|NCT03014856|Metabolic syndrome
822924|NCT03014856|Metabolomics
822925|NCT03014856|NMR spectroscopy
822926|NCT03014843|Esophagal sensitivity, GERD, endogenous opiods
822927|NCT03014791|Epidemiology
822928|NCT03014791|Ethnicity
822929|NCT03014791|Age
822930|NCT03014791|Weight
822931|NCT03014791|Hypertensive
822932|NCT03014791|Cardiac Output
822933|NCT03014791|Peripheral Vascular Resistance
822934|NCT03014791|Arterial Stiffness
822935|NCT03014791|Healthy Volunteers
822936|NCT03014791|Endothelial function
822937|NCT03014791|Arterial Structure
822938|NCT03014791|Left ventricular mass/function
822939|NCT03014765|endothelial dysfunction
822940|NCT03014765|perioperative stress
822941|NCT03014765|cardiovascular complications
822942|NCT03014765|inflammatory markers
822943|NCT03014739|Elastography
822944|NCT03014739|Musculoskeletal System
822945|NCT03014726|reduced urine flow rate
822946|NCT03014726|low peak flow rate
822947|NCT03014726|urinary tract infections
822948|NCT03014713|Dexmedetomidine
822949|NCT03014713|Dezocine
822950|NCT03014713|Flubiprofen
822951|NCT03014713|Analgesia
822952|NCT03014713|Colorectal Surgery
822953|NCT03014687|transsphenoidal surgery
822954|NCT03014674|SB-240563
822955|NCT03014674|subcutaneous
822956|NCT03014674|lyophilized drug product
822957|NCT03014674|Mepolizumab
822958|NCT03014674|liquid drug product
822959|NCT03014674|safety syringe
822960|NCT03014674|auto injector
822961|NCT03014661|pollinosis, quality of life, specific immunotherapy
822962|NCT03014635|glabellar lines, frown lines
822963|NCT03014622|glabellar lines, frown lines
822964|NCT03014609|chronic obstructive pulmonary disease
822965|NCT03014609|cardiovascular risk
822966|NCT03014609|inflammation
822967|NCT03014609|oxidative stress
822968|NCT03014609|peripheral muscle function
822969|NCT03014570|behavior,
822970|NCT03014570|apathy
822971|NCT03014570|mood
822972|NCT03014570|function
822973|NCT03014570|cognition
822974|NCT03014557|atrial fibrillation
822975|NCT03014557|left atrial appendage closure
822976|NCT03014557|WATCHMAN
822977|NCT03014518|Adolescent
822978|NCT03014518|Biological Markers
822979|NCT03014518|Biomarkers
822980|NCT03014518|Biomarkers for suicidality
822981|NCT03014518|Blood brain barrier
822982|NCT03014518|Clinical predictors
822983|NCT03014518|Cytokine
822984|NCT03014518|Feeling suicidal
822985|NCT03014518|Inflammation
822986|NCT03014518|Inflammatory marker
822987|NCT03014518|Inpatient discharge
822988|NCT03014518|Interleukin-1 beta
822989|NCT03014518|IL-1ß
822990|NCT03014518|Interleukin-6
822991|NCT03014518|IL-6
822992|NCT03014518|Kynurenic acid
822993|NCT03014518|Kynurenine pathway
822994|NCT03014518|Neuroinflammation
822995|NCT03014518|Novel marker
822996|NCT03014518|Peripheral blood biomarkers
822997|NCT03014518|Picolinic acid
822998|NCT03014518|Plasma biomarker
822999|NCT03014518|Psychiatric inpatient
823000|NCT03014518|S100B
823001|NCT03014518|Serum biomarker
823002|NCT03014518|Stress
823003|NCT03014518|Suicide
823004|NCT03014518|Suicidal behavior
823005|NCT03014518|Suicidal risk
823006|NCT03014518|Tumor necrosis factor alpha
823007|NCT03014518|TNF-α
823008|NCT03014505|Cirrhosis
823009|NCT03014505|Fecal Microbiota Transplantation
823010|NCT03014505|Intestinal flora
823011|NCT03014505|Intestinal mucosal barrier
823012|NCT03014505|Intestinal Bacteria Flora Disturbance
823013|NCT03014401|stem cell
823014|NCT03014401|knee pain
823015|NCT03014401|osteoarthritis
823016|NCT03014401|arthritis
823017|NCT03014401|ADSC
823018|NCT03014401|fat stem cell
823019|NCT03014349|Glaucoma
823020|NCT03014349|Ocular hypertension
823021|NCT03014336|co2 removal, anesthesia
823022|NCT03014323|insulin sensitivity
823023|NCT03014323|African American
823024|NCT03014323|obese
823025|NCT03014310|A/H5N8
823026|NCT03014310|Adjuvants
823027|NCT03014310|AS03
823028|NCT03014310|Inactivated
823029|NCT03014310|Influenza
823030|NCT03014310|MF59
823031|NCT03014310|Monovalent
823032|NCT03014284|Tissue collection
823033|NCT03014284|colonoscopic surgical procedures
823034|NCT03014258|Biology
823035|NCT03014258|falciparum
823036|NCT03014258|Immunity
823037|NCT03014258|Infections
823038|NCT03014258|Malaria
823039|NCT03014258|Pf
823040|NCT03014258|Plasmodium
823041|NCT03014258|Systems
823042|NCT03014232|sustained low-efficiency diafiltration (SLED-f)
823043|NCT03014232|high cut-off dialyzer
823044|NCT03014232|cytokines
823045|NCT03014180|Heart failure, CRT
823046|NCT03014167|transmission interruption
823047|NCT03014167|intestinal nematodes
823048|NCT03014167|soil-transmitted helminths
823049|NCT03014167|mass drug administration
823050|NCT03014167|Benin
823051|NCT03014167|India
823052|NCT03014167|Malawi
823053|NCT03014154|video games
823054|NCT03014154|asthma
823055|NCT03014154|physical exercise
823056|NCT03014128|musculoskeletal disorders
823057|NCT03014128|upper extremity
823058|NCT03014128|work
823059|NCT03014128|surgical instruments
823060|NCT03014115|arachidonic
823061|NCT03014115|docosahexaenoic acid
823062|NCT03014115|infant formula
823063|NCT03014089|mRNA-1325
823064|NCT03014089|Zika vaccine
823065|NCT03014063|sepsis
823066|NCT03014063|septic shock
823067|NCT03014063|vasopressin
823068|NCT03014063|AVP
823078|NCT03014037|Orthopedics
823079|NCT03014024|Distal Radius Fracture
823080|NCT03014024|Low Level Laser Therapy
823081|NCT03013985|Blood glucose
823082|NCT03013972|ColoRectal Cancer
823083|NCT03013972|Adjuvant Chemotherapy
823084|NCT03013972|Cancer-related Fatigue
823085|NCT03013972|Brief fatigue inventory (BFI)
823086|NCT03013972|Functional Assessment of Cancer Therapy-General 7 (FACT-G7)
823087|NCT03013920|upper urinary tract cancer
823088|NCT03013920|confocal laser endomicroscopy
823089|NCT03013920|urothelial carcinoma
823090|NCT03013907|Hypertension
823091|NCT03013907|Coping
823092|NCT03013907|Relaxing
823093|NCT03013894|bladder neoplasm
823094|NCT03013894|urothelium carcinoma
823095|NCT03013894|confocal laser endomicroscopy
823096|NCT03013881|UB-921
823097|NCT03013881|anti-HER2 monoclonal antibody
823098|NCT03013881|breast neoplasm
823099|NCT03013881|breast cancer
823100|NCT03013881|Herceptin
823101|NCT03013881|Trastuzumab
823102|NCT03013881|HER2
823103|NCT03013842|pregnancy
823104|NCT03013842|fetal monitoring
823105|NCT03013842|fetal oximetry
823106|NCT03013842|fetal heart rate
823107|NCT03013842|pulse oximetry
823108|NCT03013842|near infrared spectroscopy
823109|NCT03013829|Kidney Paired Donation
823110|NCT03013777|Familial dysautonomia
823111|NCT03013699|diet
823112|NCT03013699|nutrition
823113|NCT03013699|survival
823114|NCT03013699|recurrence
823115|NCT03013699|cruciferous
823116|NCT03013699|dark leafy greens
823117|NCT03013673|leishmaniasis, visceral, neglected, HIV, co-infection, asymptomatic, Ethiopia
823118|NCT03013647|actinic keratosis
823119|NCT03013647|field cancerization
823120|NCT03013647|photodynamic therapy
823121|NCT03013647|daylight photodynamic therapy
823122|NCT03013634|dexmedetomidine
823123|NCT03013621|Renal Failure
823124|NCT03013621|Renal Insufficiency
823125|NCT03013621|Acute Renal Failure
823126|NCT03013621|Acute Renal Injury
823127|NCT03013621|Kidney Failure
823128|NCT03013621|Kidney Insufficiency
823129|NCT03013621|Acute Kidney Failure
823130|NCT03013621|Acute Kidney Injury
823131|NCT03013621|Ventricular dysfunction
823132|NCT03013621|Venous congestion
823133|NCT03013621|Renal function
823134|NCT03013621|Kidney function
823135|NCT03013621|Venous heart failure
823136|NCT03013608|Nail bed injury
823137|NCT03013608|Nail bed injuries
823138|NCT03013608|Nail
823139|NCT03013608|Children
823140|NCT03013608|Fingertip injury
823141|NCT03013595|Mental health
823142|NCT03013595|Youth mental health
823143|NCT03013595|Adolescent
823144|NCT03013595|Health services
823145|NCT03013595|Transition
823146|NCT03013595|Longitudinal cohort study
823147|NCT03013595|Cluster randomised controlled trial
823148|NCT03013595|Young adult
823149|NCT03013556|HBeAg positive
823150|NCT03013543|POMC deficiency obesity
823151|NCT03013543|LepR deficiency obesity
823152|NCT03013543|Bardet-Biedl syndrome
823153|NCT03013543|Alström Syndrome
823154|NCT03013530|Intensive care unit
823155|NCT03013530|Triage and Therapy.
823156|NCT03013530|Advance Directives (AD).
823157|NCT03013530|Simulation model of real situations. (hypothetical scenario)
823158|NCT03013530|Intensivist physician.
823159|NCT03013517|Allergy
823160|NCT03013517|food allergy
823161|NCT03013517|viaskin
823162|NCT03013517|peanut
823163|NCT03013517|epicutaneous
823164|NCT03013504|randomized
823165|NCT03013504|double-blind
823166|NCT03013504|parallel group
823167|NCT03013504|equivalence
823168|NCT03013504|multicentre
823169|NCT03013504|phase III
823170|NCT03013504|efficacy
823171|NCT03013504|safety
823172|NCT03013504|pharmacokinetics
823173|NCT03013504|HD201
823174|NCT03013504|docetaxel
823175|NCT03013504|Herceptin
823176|NCT03013504|HER2 positive
823177|NCT03013504|metastatic breast cancer
823178|NCT03013504|breast cancer
823179|NCT03013491|cancer
823180|NCT03013491|checkpoint inhibitor
823181|NCT03013491|monotherapy
823182|NCT03013491|combination
823183|NCT03013491|PD-L1
823184|NCT03013491|CTLA-4
823185|NCT03013491|solid tumor
823186|NCT03013491|lymphoma
823187|NCT03013491|BRAF
823188|NCT03013491|PROCLAIM
823189|NCT03013491|CX-072
823190|NCT03013491|PROCLAIM-CX-072
823191|NCT03013374|protein accretion
823192|NCT03013374|body composition
823193|NCT03013361|ropivacaine, bupivacaine
823194|NCT03013335|Clear-cell
823195|NCT03013335|Nivolumab
823196|NCT03013335|Renal cell carcinoma
823197|NCT03013335|Immunotherapy
823198|NCT03013309|Hybrid
823199|NCT03013309|Implementation
823200|NCT03013309|Effectiveness
823201|NCT03013309|Parent training
823202|NCT03013309|Fidelity
823203|NCT03013309|Cost-Effectiveness
823204|NCT03013309|Primary Care
823205|NCT03013296|GIP
823206|NCT03013296|GIP receptor antagonist
823207|NCT03013270|Rehabilitation
823208|NCT03013270|Exercise
823209|NCT03013270|Training
823210|NCT03013257|Relapsed Graves' disease
823211|NCT03013257|High Intensity Focused Ultrasound
823212|NCT03013257|RAI
823213|NCT03013244|prevention
823214|NCT03013244|eating disorder
823215|NCT03013244|men
823216|NCT03013244|intervention
823217|NCT03013244|muscle dysmorphia
823218|NCT03013244|peer-led
823219|NCT03013231|ACL Reconstruction
823220|NCT03013231|Return to Sport
823221|NCT03013231|Resilience
823222|NCT03013218|Neoplasms
823223|NCT03013218|CD47
823224|NCT03013218|SIRPα
823225|NCT03013218|ALX148
823226|NCT03013205|adhesive capsulitis
823227|NCT03013153|Rectal Cancer
823228|NCT03013153|Inferior Mesenteric Artery
823229|NCT03013153|Ligation
823230|NCT03013153|Apical Lymph Nodes
823231|NCT03013153|Laparoscopy
823232|NCT03013153|IMA Types
823233|NCT03013140|Anesthesia, Obstetric
823234|NCT03013140|fluid therapy
823235|NCT03013140|cesarean section
823236|NCT03013140|spinal anesthesia
823237|NCT03013127|Osteogenic Sarcoma
823238|NCT03013127|Osteosarcoma
823239|NCT03013127|Sarcoma, Osteogenic
823240|NCT03013127|Pembrolizumab
823241|NCT03013127|Immunotherapy
823242|NCT03013114|Bortezomib Immune thrombocytopenia
823243|NCT03013101|anti-PD-1 monoclonal antibody
823244|NCT03013101|advanced
823245|NCT03013101|metastatic
823246|NCT03013101|melanoma
823247|NCT03013088|Chronic
823248|NCT03013088|Occlusion
823249|NCT03013088|CTO
823250|NCT03013023|Behavioral and Transaction Interventions
823251|NCT03013023|Parents' Biopsychosocial Well-being
823252|NCT03013023|Preterm Infants
823253|NCT03013023|Sleep
823254|NCT03013023|Salivary cortisol
823255|NCT03013010|Randomized
823256|NCT03013010|Open Label
823257|NCT03013010|Multicenter
823258|NCT03012984|elderly
823259|NCT03012984|surgery
823260|NCT03012984|analgesia
823261|NCT03012984|dexmedetomidine
823262|NCT03012984|delirium
823263|NCT03012971|Elderly
823264|NCT03012971|Surgery
823265|NCT03012971|Analgesia
823266|NCT03012971|Dexmedetomidine
823267|NCT03012971|Long-term outcome
823268|NCT03012945|Elderly
823269|NCT03012945|Cancer surgery
823270|NCT03012945|Epidural anesthesia and analgesia
823271|NCT03012945|Long-term survival
823272|NCT03012945|Quality of life
823273|NCT03012919|active decision support system
823274|NCT03012919|goal directed therapy
823275|NCT03012919|Lidco
823276|NCT03012919|vascular surgery
823277|NCT03012919|hemodynamic optimization
823278|NCT03012893|ultrasonography to identify C7 spinous process
823279|NCT03012867|criticall illness
823280|NCT03012867|enteral nutrition
823281|NCT03012854|Esophageal achalasia
823282|NCT03012854|Peroral endoscopic myotomy
823283|NCT03012854|POEM
823284|NCT03012815|gabapentin
823285|NCT03012815|Alcohol Withdrawal Syndrome
823286|NCT03012815|benzodiazepine
823287|NCT03012815|symptom-triggered
823288|NCT03012724|TMS
823289|NCT03012724|Deep Transcranial Magnetic Stimulation
823290|NCT03012724|MDD
823291|NCT03012724|Major Depressive Disorder
823292|NCT03012659|contraceptive counseling
823293|NCT03012659|cluster randomized trial
823294|NCT03012659|provider counseling training
823295|NCT03012646|Treprostinil
823296|NCT03012646|PH
823297|NCT03012646|COPD
823298|NCT03012646|6 Minute Walk Test
823299|NCT03012633|hyperfibrinolysis, Lysis Timer
823300|NCT03012607|PrEP
823301|NCT03012594|Small bowel motility disorder
823302|NCT03012594|Slow intestinal motility
823303|NCT03012594|Small bowel bacterial overgrowth
823304|NCT03012555|Sickle Cell Disease
823305|NCT03012555|Vitamin D
823306|NCT03012529|Rifampin
823307|NCT03012529|Double-blind
823308|NCT03012529|Clinical Trial
823309|NCT03012529|Veterans
823310|NCT03012529|Diabetes
823311|NCT03012516|Physical Therapy Specialty
823312|NCT03012516|Exercise Test
823313|NCT03012516|Prescriptions
823314|NCT03012516|Counseling
823315|NCT03012516|Primary Health Care
823316|NCT03012516|Exercise
823317|NCT03012490|Remote monitoring
823318|NCT03012477|Triple-negative metastatic breast cancer
823319|NCT03012451|Stress
823320|NCT03012451|Insecurity
823321|NCT03012451|Mental Health
823322|NCT03012438|Near infrared fluorescence
823323|NCT03012438|ICG
823324|NCT03012438|Parathyroid gland
823325|NCT03012425|Cognitive Behavioral Therapy
823326|NCT03012425|Acupuncture
823327|NCT03012425|17-001
823328|NCT03012399|Malignant Neoplasm of Breast
823329|NCT03012399|Breast Cancer
823330|NCT03012399|Hypnosedation
823331|NCT03012399|Hypnotherapist
823332|NCT03012399|Questionnaires
823333|NCT03012399|Surveys
823334|NCT03012386|CD36
823335|NCT03012386|Endothelial dysfunction
823336|NCT03012386|African Americans
823337|NCT03012373|methadone
823338|NCT03012373|heroin
823339|NCT03012373|acupuncture
823340|NCT03012360|Infectiology
823341|NCT03012360|Biology of infectious agents
823342|NCT03012360|Hygiene
823343|NCT03012360|Pneumology
823344|NCT03012360|Critical Care
823345|NCT03012308|Myocardial Dysfunction
823346|NCT03012308|left ventricular
823347|NCT03012308|mitral valve doppler
823348|NCT03012308|mitral ring doppler
823349|NCT03012308|ultrasound signs
823350|NCT03012308|lung edema
823351|NCT03012295|Genetic Testing
823352|NCT03012295|Chinese Population
823353|NCT03012256|Cardio-Respiratory Disease Management
823354|NCT03012256|Chronic Disease Management
823355|NCT03012256|Cluster-randomized Trial
823356|NCT03012256|Multi-component Intervention
823357|NCT03012256|DIVERT Scale
823358|NCT03012256|Frail Elderly
823359|NCT03012256|Interprofessional Care
823360|NCT03012256|Pragmatic Trial
823361|NCT03012256|Targeted Intervention
823362|NCT03012256|Home Care
823363|NCT03012204|Cerebrovascular Disease
823762|NCT03009656|Emergency
823364|NCT03012204|Repetitive Transcranial Magnetic Stimulation
823365|NCT03012178|Mitral Regurgitation
823366|NCT03012178|Mitral valve Surgery
823367|NCT03012178|MRI
823368|NCT03012165|ADX-102
823369|NCT03012165|Allergic Conjunctivitis
823370|NCT03012152|Oncoplastic surgery
823371|NCT03012152|Standard conservative surgery
823372|NCT03012152|Patient satisfaction
823373|NCT03012152|Margin Status
823374|NCT03012113|Adipose tissue
823375|NCT03012113|Type 2 Diabetes
823376|NCT03012061|Respiratory
823377|NCT03012061|Efficacy
823378|NCT03012061|Umeclidinium bromide
823379|NCT03012061|Parallel
823380|NCT03012061|Asthma
823381|NCT03012061|Dry powder inhaler
823382|NCT03012048|water treatment
823383|NCT03012035|psychotherapy
823384|NCT03012035|exposition
823385|NCT03012035|spider fear
823386|NCT03012035|expectation
823387|NCT03012022|Healthy Volunteers
823388|NCT03012022|Congestive Heart Failure
823389|NCT03012022|Cardiomyopathies
823390|NCT03012022|Heart Failure
823391|NCT03012022|Risk Factors
823392|NCT03012009|Bowen's Disease
823393|NCT03012009|Superficial Basal Cel Carcinoma
823394|NCT03012009|Non melanoma skin cancer
823395|NCT03012009|Photodynamic therapy
823396|NCT03012009|PDT
823397|NCT03012009|CO2 laser
823398|NCT03012009|Laser assisted drug delivery
823399|NCT03012009|Carbon dioxide laser
823400|NCT03012009|Laser assisted photodynamic therapy
823401|NCT03011983|Magnetoencephalography (MEG)
823402|NCT03011983|Magnetic resonance imaging (MRI)
823403|NCT03011892|Atopic dermatitis
823404|NCT03011892|eczema
823405|NCT03011892|pruritus
823406|NCT03011892|Janus kinase (JAK) inhibitors
823407|NCT03011840|Patient education handout
823408|NCT03011840|Patient satisfaction
823409|NCT03011775|Pioglitazone, Insulin Resistance
823410|NCT03011775|Atherosclerosis, Coronary Heart Disease
823411|NCT03011749|Radium-223 therapy
823412|NCT03011710|e-cigarette
823413|NCT03011710|blood flow
823414|NCT03011710|oral effects
823415|NCT03011710|oral pH
823416|NCT03011684|Fertility Preservation
823417|NCT03011684|Breast Cancer
823418|NCT03011671|Malignant Glioma of Brain
823419|NCT03011671|Acetazolamide
823420|NCT03011671|Temozolomide
823421|NCT03011619|Depression
823422|NCT03011619|Cognitive Behavioral Therapy (CBT)
823423|NCT03011606|prostate
823424|NCT03011606|ablation
823425|NCT03011606|focal
823426|NCT03011606|cancer
823427|NCT03011580|Vitamin D
823428|NCT03011567|Postpartum
823429|NCT03011541|Stem Cells
823430|NCT03011541|Bone Marrow Derived Stem Cells
823431|NCT03011541|BMSC
823432|NCT03011541|Mesenchymal Stem Cells
823433|NCT03011541|MSC
823434|NCT03011541|Eye Disease
823435|NCT03011541|Ophthalmology
823436|NCT03011541|Ophthalmic Disease
823437|NCT03011541|Retina
823438|NCT03011541|Retinal Disease
823439|NCT03011541|Macular Degeneration
823440|NCT03011541|Age Related Macular Degeneration
823441|NCT03011541|Myopic Macular Degeneration
823442|NCT03011541|Geographic Atrophy
823443|NCT03011541|Dry Macular Degeneration
823444|NCT03011541|Wet Macular Degeneration
823445|NCT03011541|Retinal Atrophy
823446|NCT03011541|Retinal Dystrophy
823447|NCT03011541|Hereditary Retinal Dystrophy
823448|NCT03011541|Malattia Leventinese
823449|NCT03011541|Retinitis Pigmentosa
823450|NCT03011541|Stargardt Disease
823451|NCT03011541|Cone Dystrophy
823452|NCT03011541|Rod-Cone Dystrophy
823453|NCT03011541|Cone-Rod Dystrophy
823454|NCT03011541|Maculopathy
823455|NCT03011541|Optic Nerve Disease
823456|NCT03011541|Optic Atrophy
823457|NCT03011541|Optic Neuropathy
823458|NCT03011541|Ischemic Optic Neuropathy
823459|NCT03011541|Optic Nerve Damage
823460|NCT03011541|Optic Nerve Compression
823461|NCT03011541|Compressive Optic Neuropathy
823462|NCT03011541|Devics Syndrome
823463|NCT03011541|Ushers Syndrome
823464|NCT03011541|Neuromyelitis Optica
823465|NCT03011541|Dominant Optic Atrophy
823466|NCT03011541|Kjers Optic Atrophy
823467|NCT03011541|Leber Hereditary Optic Neuropathy
823468|NCT03011437|linked color imaging
823469|NCT03011437|Helicobacter Pylori
823470|NCT03011424|Liver resection
823471|NCT03011424|post hepatectomy liver failure
823472|NCT03011424|liver dialysis
823473|NCT03011424|encephalopathy
823474|NCT03011424|mortality
823475|NCT03011411|methods, qualitative research
823476|NCT03011372|Myeloid neoplasm
823477|NCT03011372|fibroblast growth factor receptor inhibitor
823478|NCT03011372|FGFR1 rearrangement
823479|NCT03011372|8p11
823480|NCT03011372|eosinophilia
823481|NCT03011372|eosinophilic syndrome
823482|NCT03011372|Lymphoid neoplasm
823483|NCT03011359|Colon resection
823484|NCT03011359|Patient Controlled Analgesia
823485|NCT03011359|Optimizing Basal Infusion Mode
823486|NCT03011346|Aortic valve stenosis
823487|NCT03011346|Transcatheter aortic valve implantation
823488|NCT03011346|Transcatheter aortic valve replacement
823489|NCT03011346|Randomized controlled trial
823490|NCT03011320|ovarian cancer
823491|NCT03011320|specimen collection
823492|NCT03011268|Tumor Necrosis Factor-alpha/antagonists & inhibitors
823493|NCT03011268|Infliximab
823494|NCT03011268|Adalimumab
823495|NCT03011268|Golimumab
823496|NCT03011268|Recurrence
823497|NCT03011255|Esophageal cancer
823498|NCT03011255|Peptide specific CTL
823499|NCT03011255|Radiation
823500|NCT03011242|Psoriatic Arthritis
823501|NCT03011242|PDUS
823502|NCT03011203|glycogen storage disease type IIIa
823503|NCT03011203|exercise
823504|NCT03011203|ketone esters
823505|NCT03011203|magnetic resonance spectroscopy
823506|NCT03011190|Terapia Iconica
823507|NCT03011190|BPD
823508|NCT03011190|adolescence
823509|NCT03011190|suicide
823510|NCT03011164|Running
823511|NCT03011164|Gait velocity
823512|NCT03011164|Kinematics
823520|NCT03011138|knee
823521|NCT03011138|gait velocity
823522|NCT03011138|kinematic parameters
823523|NCT03011112|Osteoarthritis, Knee
823524|NCT03011112|WOMAC
823525|NCT03011112|gait
823526|NCT03011112|kinematics
823527|NCT03011086|Autoantibodies, Oral Submucous Fibrosis
823528|NCT03011060|neo-adjuvant chemotherapy
823529|NCT03011060|pathological complete response
823530|NCT03011060|Neoadjuvant Therapy
823531|NCT03011060|Capecitabine
823532|NCT03011060|Chemotherapy, Adjuvant
823533|NCT03011047|endoscopic, trans-antral, subciliary
823534|NCT03011021|Autoimmune Diabetes
823535|NCT03011021|Umbilical Cord Blood Regulatory T Lymphocyte
823536|NCT03011021|Liraglutide
823537|NCT03010995|electronic cigarette
823538|NCT03010995|endothelial function
823539|NCT03010969|Endothelial dysfunction
823540|NCT03010969|Surgery
823541|NCT03010969|Pulmonary function
823542|NCT03010969|Blood glucose level
823543|NCT03010969|Patient-related outcomes
823544|NCT03010956|Arterial stiffness
823545|NCT03010956|Endothelial glycocalyx
823546|NCT03010956|Coronary flow reserve
823547|NCT03010943|virtual reality
823548|NCT03010943|glioma surgery
823549|NCT03010943|awake craniotomy
823550|NCT03010943|brain tumor
823551|NCT03010943|glioma
823552|NCT03010943|neurosurgery
823553|NCT03010917|Alcohol Dependence
823554|NCT03010917|Fish Oil
823555|NCT03010891|Preterm infant
823556|NCT03010891|Stress
823557|NCT03010891|Salivary DHEA
823558|NCT03010891|Salivary cortisol
823559|NCT03010891|Actigraphy
823560|NCT03010878|yoga
823561|NCT03010878|chronic pain
823562|NCT03010878|occupational therapy
823563|NCT03010878|self-management
823564|NCT03010865|HDAC inhibitors
823565|NCT03010865|Inflammation
823566|NCT03010852|Bariatric Surgery
823567|NCT03010852|Spirometry Monitoring
823568|NCT03010761|addiction
823569|NCT03010761|betel-quid
823570|NCT03010761|drug therapy
823571|NCT03010761|clinical trial
823572|NCT03010748|corneal morphology
823573|NCT03010748|Chinese population
823574|NCT03010748|corneal curvature
823575|NCT03010748|corneal thickness
823576|NCT03010748|higher order aberrations
823577|NCT03010735|Kidney Failure, Chronic
823578|NCT03010735|Probiotics
823579|NCT03010735|Uremic toxins
823580|NCT03010735|Gastrointestinal Microbiome
823581|NCT03010709|Aneurysmal Subarachnoid Haemorrhage
823582|NCT03010709|Delayed Ischaemic Neurological Deficit
823583|NCT03010709|Induced Hypertension
823584|NCT03010709|Partial Brain Tissue Oxygen Tension
823585|NCT03010709|Cerebral Microdialysis
823586|NCT03010696|Kidney Failure, Chronic
823587|NCT03010696|Uremic toxins
823588|NCT03010696|Gastrointestinal Microbiome
823589|NCT03010696|Metabolomics
823590|NCT03010683|Arterial stiffness
823591|NCT03010683|Endothelial glycocalyx
823592|NCT03010683|Coronary flow reserve
823593|NCT03010670|Oxytocin
823594|NCT03010670|Gaze processing
823595|NCT03010670|Interpersonal motor resonance
823596|NCT03010618|hall technique
823597|NCT03010618|stainless steel crowns
823598|NCT03010618|temporomandibular joint
823599|NCT03010618|dental caries
823600|NCT03010618|occlusion
823601|NCT03010605|physical therapy post total knee replacement
823602|NCT03010605|range of motion
823603|NCT03010605|goniometry
823604|NCT03010592|Lung volume reduction treatment
823605|NCT03010592|Endobronchial cryotherapy
823606|NCT03010592|Microvesicles
823607|NCT03010579|Anemia
823608|NCT03010579|Lymphoma
823609|NCT03010579|Hematopoietic stem cell transplantation
823610|NCT03010579|Erythropoietin
823611|NCT03010566|Lung volume reduction coil
823612|NCT03010566|Lung Microbiome
823616|NCT03010488|Chronotherapy
823617|NCT03010488|Light Therapy
823618|NCT03010462|Stroke
823619|NCT03010462|rTMS
823620|NCT03010462|Motor rehabilitation
823621|NCT03010449|Lung volume reduction treatment
823622|NCT03010449|Autologous blood instillation
823623|NCT03010449|Intra-bronchial valve (IBV)
823624|NCT03010449|Endobronchial valve
823627|NCT03010371|positive psychotherapy, online, breast cancer, survivors
823628|NCT03010332|Cytomegalovirus
823629|NCT03010332|Cytomegalovirus Viremia
823630|NCT03010332|Cytomegalovirus Infection
823631|NCT03010332|CMV Infection
823632|NCT03010332|Hematopoietic Cell Transplant
823633|NCT03010332|Solid Organ Transplant
823634|NCT03010332|Human Immunodeficiency Virus
823635|NCT03010332|Cytomegalovirus Disease
823636|NCT03010332|Hematopoietic Stem Cell Transplant
823637|NCT03010332|CMV
823638|NCT03010332|CMV syndrome
823639|NCT03010332|Cytomegalovirus syndrome
823640|NCT03010332|CMV disease
823641|NCT03010332|CMV viremia
823642|NCT03010332|allogeneic
823643|NCT03010332|third-party
823644|NCT03010293|Antimicrobial therapy
823645|NCT03010293|Debridement
823646|NCT03010293|Osteomyelitis
823647|NCT03010293|Muscular flap
823648|NCT03010293|Pressure ulcer
823649|NCT03010293|Treatment failure
823650|NCT03010293|Vacuum-assisted closure therapy
823651|NCT03010267|DP-R213
823652|NCT03009214|solid epithelial cancer
823653|NCT03009214|CD44v6
823654|NCT03009214|c-Met
823655|NCT03009214|VEGFR-2
823656|NCT03009214|RON
823657|NCT03009214|receptor tyrosine kinase
823658|NCT03009188|Axenfeld-Rieger syndrom, genetic findings
823659|NCT03009136|Perennial Allergic Rhinitis
823660|NCT03009136|Herbal Medicine
823661|NCT03009136|Korean Medicine
823662|NCT03009136|So-Cheong-Ryong-Tang
823663|NCT03010241|Diabetes Distal Symmetric Polyneuropathy
823664|NCT03010241|Chinese medicine
823665|NCT03010228|VLA15
823666|NCT03010228|Lyme Borreliosis
823667|NCT03010228|Multivalent Recombinant OspA Vaccine
823668|NCT03010215|Minimally Invasive Surgery
823669|NCT03010215|Percutaneous distal osteotomy
823670|NCT03010215|Distal Metatarsal Minimally-invasive Osteotomy (DMMO)
823671|NCT03010215|Percutaneous Tenotomy
823672|NCT03010215|Forefoot
823673|NCT03010215|Metatarsal bones
823674|NCT03010202|immune thrombocytopenia
823675|NCT03010202|rituximab
823676|NCT03010202|thrombocytopenia
823677|NCT03010189|Cluster headache
823678|NCT03010189|Actigraphy
823679|NCT03010189|Pupillometry
823695|NCT03010111|Latent Tuberculosis
823696|NCT03010111|Interferons
823697|NCT03010111|Tuberculosis
823698|NCT03010111|Healthcare
823699|NCT03010098|POCD
823700|NCT03010098|narcotrend
823701|NCT03010098|closed-loop of target controlled infusion
823702|NCT03010033|pulmonary rehabilitation
823703|NCT03010033|lobectomy
823704|NCT03010033|smoker
823705|NCT03010020|HIV Prevention
823706|NCT03010020|MSM
823707|NCT03010020|Rectal Gonorrhea
823708|NCT03010020|Rectal Chlamydia
823709|NCT03010020|Personalized Cognitive Counseling
823710|NCT03010007|Influenza
823711|NCT03010007|High-Throughput Nucleotide Sequencing
823712|NCT03010007|Viral Transmission
823713|NCT03009981|PSA
823714|NCT03009981|Degarelix
823715|NCT03009981|Apalutamide
823716|NCT03009981|Abiraterone Acetate
823717|NCT03009981|Radical Prostatectomy
823718|NCT03009942|nitric oxide
823719|NCT03009942|arginase
823720|NCT03009942|loading
823721|NCT03009890|elderly
823722|NCT03009890|intra articular
823723|NCT03009890|RCT
823724|NCT03009864|Diabetic Kidney Disease
823725|NCT03009864|TCM
823726|NCT03009864|RCT
823727|NCT03009825|Trauma exposure
823728|NCT03009825|Psychological distress
823729|NCT03009825|Emotion regulation
823730|NCT03009825|Mindfulness
823731|NCT03009825|Eating pathology
823732|NCT03009799|adenoviral conjunctivis
823733|NCT03009799|iota-carrageenan
823734|NCT03009773|subacute stroke
823735|NCT03009773|multitasking rehabilitation
823736|NCT03009773|walking
823737|NCT03009747|rectal cancer
823738|NCT03009747|anterior resection syndrome
823739|NCT03009747|sphincter-preserving surgery
823740|NCT03009708|Allograft
823741|NCT03009708|Cytomegalovirus
823742|NCT03009708|Platelets
823743|NCT03009708|Hematopoietic stem cells
823744|NCT03009708|Graft Versus Host Disease (GVH)
823745|NCT03009708|Hemostasis
823746|NCT03009708|Adaptive immunity
823747|NCT03009708|Innate immunity
823748|NCT03009708|Post graft follow up
823749|NCT03009695|Transcranial Magnetic Stimulation
823750|NCT03009695|Obesity
823751|NCT03009695|Food Craving
823752|NCT03009695|Appetite/Satiety Hormones
823753|NCT03009695|fMRI
823754|NCT03009695|Intestinal microbiota
823755|NCT03009695|Physical activity
823756|NCT03009669|pleth variability index
823757|NCT03009669|stroke volume variation
823758|NCT03009669|perfusion Index
823759|NCT03009669|intraoperative
823760|NCT03009669|intestinal tumor
823761|NCT03009656|Stroke
823763|NCT03009656|Focal Neurological Deficits
823764|NCT03009656|Diagnostic
823765|NCT03009643|Nitric Oxide
823766|NCT03009643|hypoxemia
823767|NCT03009643|aortic surgery
823768|NCT03009630|Electromagnetic navigation bronchoscopy(ENB)
823769|NCT03009630|Radiofrequency ablation(RFA)
823770|NCT03009630|Peripheral lung cancer
823771|NCT03009617|adolescents
823772|NCT03009617|web-based health education
823773|NCT03009617|eHealth literacy
823774|NCT03009591|Hemophilia
823775|NCT03009591|Elbow
823776|NCT03009591|Arthropathy
823777|NCT03009591|Joint pain
823778|NCT03009591|Range of motion
823779|NCT03009591|Myofascial techniques
823780|NCT03009591|Safety patients
823781|NCT03009591|Quality of life
823782|NCT03009591|Functionality
823783|NCT03009565|coronary artery disease
823784|NCT03009565|human gut microbiota
823785|NCT03009565|microbiome
823786|NCT03009552|speckle tracking echocardiography
823787|NCT03009552|strain
823788|NCT03009552|strain rate
823789|NCT03009552|torsion
823790|NCT03009539|Prevention with Hispanic youth
823791|NCT03009539|eHealth preventive intervention in primary care
823792|NCT03009539|Hispanic adolescent
823793|NCT03009539|Familias Unidas
823794|NCT03009539|eHealth Familias Unidas
823795|NCT03009539|effectiveness trial
823796|NCT03009539|sexually transmitted disease
823797|NCT03009539|parent-centered
823798|NCT03009539|Hispanic
823799|NCT03009539|sexual risk behavior
823800|NCT03009526|Malaria
823801|NCT03009526|Pregnancy
823802|NCT03009526|Malawi
823803|NCT03009526|Intermittent preventive treatment
823804|NCT03009526|dihydroartemisinin-piperaquine
823805|NCT03009526|sulfadoxine-pyrimethamine
823810|NCT03009396|Crohn's Disease,
823811|NCT03009396|moderate to severe
823812|NCT03009396|remission
823813|NCT03009396|Mycobacterium avium paratuberculosis
823814|NCT03009396|antibiotic
823815|NCT03009370|Ovarian reserve, pregnancy loss
823816|NCT03009357|wearable activity tracker
823817|NCT03009357|thyrotoxicosis
823818|NCT03009344|relapsed or refractory B-cell non-Hodgkin's lymphoma
823819|NCT03009344|tazemetostat
823820|NCT03009344|Japan
823821|NCT03009331|Postoperative pulmonary dysfunction
823822|NCT03009331|Postoperative pulmonary complication
823823|NCT03009331|Recruitment manouver
823824|NCT03009331|Prone position
823825|NCT03009318|Glioma
823826|NCT03009318|Magnetic resonance spectroscopy
823827|NCT03009318|Methionine
823828|NCT03009318|PET/CT
823829|NCT03009292|solid tumor
823830|NCT03009292|Lenvatinib
823831|NCT03009292|pharmacokinetics
823832|NCT03009279|blood pressure
823833|NCT03009279|fasting plasma glucose
823834|NCT03009279|thyroid stimulating hormone
823835|NCT03009253|Neoadjuvant therapy
823836|NCT03009253|Pancreatic Cancer
823837|NCT03009227|colon cancer
823838|NCT03009227|lymph node dissection
823839|NCT03009227|D3 lymph node dissection
823840|NCT03009123|cohort study
823841|NCT03009123|prostate cancer
823842|NCT03009123|population-based study
823843|NCT03009123|benign prostatic hypertrophy
823844|NCT03009097|Chronic periodontitis
823845|NCT03009097|atorvastatin
823846|NCT03009097|intrabony defect
823847|NCT03009071|Neck Pain
823848|NCT03009071|Disability Evaluation
823849|NCT03009071|Costs and Cost Analysis
823850|NCT03009071|Doin Exercise Therapy
823851|NCT03009071|Acupuncture
823852|NCT03009058|Unresectable cancer
823853|NCT03009058|pancreatic
823854|NCT03009058|melanoma
823855|NCT03009058|breast
823856|NCT03009058|lung
823857|NCT03009058|colorectal
823858|NCT03009058|cholangio
823859|NCT03009058|sarcoma
823860|NCT03009045|bone and joint infection
823861|NCT03009045|osteomyelitis
823862|NCT03009045|tedizolid
823863|NCT03009032|HIV
823864|NCT03009032|immunologic recovery
823865|NCT03009032|microbiota
823866|NCT03009032|prebiotics
823867|NCT03009032|probiotics
823868|NCT03009032|synbiotics
823869|NCT03009006|Calcium hydroxide intracanal medication
823870|NCT03009006|Ca(OH)2 intracanal medication
823871|NCT03009006|Chlorhexidene gel
823872|NCT03009006|CHX gel
823873|NCT03009006|Root canal treatment
823874|NCT03008967|Total Knee Arthroplasty
823875|NCT03008967|Total Hip Arthroplasty
823876|NCT03008967|Rehabilitation
823877|NCT03008941|HIV
823878|NCT03008941|microbiota
823879|NCT03008941|inflammation
823880|NCT03008941|fecal microbiota restoration
823881|NCT03008915|alpha-1 antitrypsin deficiency
823882|NCT03008915|Emphysema
823883|NCT03008915|chronic obstructive pulmonary disease
823886|NCT03008876|neonate
823887|NCT03008876|acetaminophen
823888|NCT03008850|Shivering
823889|NCT03008850|Intrathecal
823890|NCT03008850|Magnesium Sulfate
823891|NCT03008811|Atrial Fibrillation
823892|NCT03008811|Catheter Ablation
823893|NCT03008798|Intracranial Artery
823894|NCT03008798|in-stent restenosis
823895|NCT03008798|Herbal Medicine
823896|NCT03008785|isoflavone
823897|NCT03008785|blood pressure
823898|NCT03008785|climateric symptoms
823899|NCT03008785|exercise
823900|NCT03008759|Fluoride
823901|NCT03008759|Dental caries
823902|NCT03008759|Dentifrice
823903|NCT03008720|functional electrical simulation
823904|NCT03008707|Laparoscopic peritoneal lavage
823905|NCT03008707|laparoscopic sigmoidectomy
823906|NCT03008707|complicated acute diverticulitis
823907|NCT03008707|D004238
823908|NCT03008694|PET/CT
823909|NCT03008642|Polycythemia
823910|NCT03008642|CO-Rebreathing
823911|NCT03008642|red cell mass determination
823912|NCT03008642|myeloproliferative neoplasms
823913|NCT03008603|CT-guided minimally invasive procedures
823914|NCT03008603|Robot
823915|NCT03008590|Pain management
823916|NCT03008590|Naltrexone
823917|NCT03008590|Controlled clinical trials, randomized
823918|NCT03008512|Liver Neoplasms
823919|NCT03008512|Antineoplastic Agents
823920|NCT03008512|Carcinoma, Hepatocellular
823921|NCT03008512|Genexol-PM
823922|NCT03008512|Neoplasms by Site
823923|NCT03008512|Sorafenib
823924|NCT03008512|Liver Diseases
823925|NCT03008512|Digestive System Neoplasms
823926|NCT03008499|Metastatic colorectal cancer
823927|NCT03008499|High-activity natural killer
823928|NCT03008447|E2006
823929|NCT03008447|postural stability
823930|NCT03008447|auditory awakening threshold
823931|NCT03008447|cognitive performance
823932|NCT03008447|healthy participants
823933|NCT03008434|yoga
823934|NCT03008434|Traumatic Brain Injury
823935|NCT03008408|Malignant neoplasms of female genital organs
823936|NCT03008408|Endometrial carcinoma
823937|NCT03008408|Advanced or Recurrent
823938|NCT03008408|Endometrioid and mixed endometrioid tumors
823939|NCT03008408|Ribociclib
823940|NCT03008408|LEE011
823941|NCT03008408|Everolimus
823942|NCT03008408|Afinitor
823943|NCT03008408|Zortress
823944|NCT03008408|RAD001
823945|NCT03008408|Letrozole
823946|NCT03008408|Femara
823947|NCT03008382|Interstitial Cystitis
823948|NCT03008382|Pelvic Pain
823949|NCT03008343|Irreversible Electroporation
823950|NCT03008343|NK Immunotherapy
823951|NCT03008343|Recurrent Liver Carcinoma
823952|NCT03008330|Metastatic tongue cancer
823953|NCT03008330|High-activity natural killer
823954|NCT03008304|Metastatic pancreatic cancer
823955|NCT03008304|High-activity natural killer Immunotherapy
823956|NCT03008265|Fascial dehiscence
823957|NCT03008265|Mortality
823958|NCT03008252|Non-celiac wheat sensitivity
823959|NCT03008252|lactose intolerance
823960|NCT03008252|cow's milk protein allergy
823961|NCT03008187|AML
823962|NCT03008174|tracheostomy
823963|NCT03008174|quality of life
823964|NCT03008174|speaking valve
823965|NCT03008174|speech
823966|NCT03008174|mechanically ventilated patients
823967|NCT03008161|GAIM
823968|NCT03008161|amyloid
823969|NCT03008161|anti-aBeta
823970|NCT03008161|anti-tau
823971|NCT03008122|Flavivirus
823972|NCT03008122|Inactivated
823973|NCT03008122|Phase I
823974|NCT03008122|Vaccine
823975|NCT03008122|ZIKA
823976|NCT03008122|ZPIV
823977|NCT03008109|EGFR-TKI
823978|NCT03008109|Recombinant human endostatin
823979|NCT03008070|Non-Alcoholic Steatohepatitis
823980|NCT03008070|NASH
823981|NCT03008070|peroxisome proliferator-activated receptor (PPAR)
823982|NCT03008070|Liver Diseases
823983|NCT03008070|Fibrosis
823984|NCT03008070|Fatty Liver
823985|NCT03008070|Non-alcoholic Fatty Liver Disease
823986|NCT03008070|Digestive System Diseases
823987|NCT03008070|IVA337
823988|NCT03008057|vitamin D
823989|NCT03008057|YKL40
823990|NCT03008057|PAI-1
823991|NCT03008057|RAGE
823992|NCT03008057|AGEs
823993|NCT03008057|glyoxalase enzyme
823994|NCT03008057|TNF-alpha
823995|NCT03008057|IL-6
823996|NCT03008057|Diabetes
823997|NCT03007992|Breast cancer
823998|NCT03007992|Vinorelbine
823999|NCT03007992|Metronomic chemotherapy
824000|NCT03007953|Palliative Care
824001|NCT03007953|Supportive Care
824002|NCT03007940|Implementation Strategies
824003|NCT03007940|Sustainability
824004|NCT03007940|Integrated Services
824005|NCT03007927|pain
824006|NCT03007927|hernia repair
824007|NCT03007927|Dexamethasone
824008|NCT03007914|Pulmonary Disease, Chronic Obstructive
824009|NCT03007914|Medicine, Chinese Traditional
824010|NCT03007914|Humans
824011|NCT03007914|Treatment Outcome
824012|NCT03007888|IPX203 (carbidopa-levodopa) Extended-Release capsules
824013|NCT03007875|Metastatic lung cancer
824014|NCT03007875|High-activity natural killer
824015|NCT03007836|Metastatic Nasopharyngeal Cancer
824016|NCT03007836|High-activity natural killer
824017|NCT03007823|Metastatic Melanoma
824018|NCT03007823|High-activity natural killer
824019|NCT03007784|Consciousness
824020|NCT03007784|Disorder of consciousness
824021|NCT03007784|Minimally conscious state
824022|NCT03007784|Vegetative state
824023|NCT03007784|Exit-MCS
824024|NCT03007784|Transcranial direct current stimulation (tDCS)
824025|NCT03007784|CRS-R
824026|NCT03007784|EEG
824027|NCT03007784|Cognitive ERPs
824028|NCT03007758|Hernia repair
824029|NCT03007758|Robotic hernia repair
824030|NCT03007758|Open hernia repair
824031|NCT03007758|Incisional hernia
824032|NCT03007745|Continuous positive airway pressure
824033|NCT03007628|magnetic seizure therapy
824034|NCT03007628|electroconvulsive therapy
824035|NCT03007628|controlled trial
824036|NCT03007602|Hematopoietic stem cell transplantation
824037|NCT03007602|Aerobic exercise
824038|NCT03007602|Quality of Life
824039|NCT03007602|Muscle Strength
824040|NCT03007602|Depression
824041|NCT03007602|exercise capacity
824042|NCT03007602|dyspnea
824043|NCT03007602|anxiety
824044|NCT03007602|fatigue
824045|NCT03007602|pulmonary functions
824046|NCT03007589|erythema
824047|NCT03007589|persistent pigment darkening
824048|NCT03007589|sunburn
824049|NCT03007589|suntan
824050|NCT03007563|Diagnosis
824051|NCT03007563|Cell Phones
824052|NCT03007563|Infant, Newborn
824053|NCT03007550|Gastric cancer
824054|NCT03007550|Laparoscopic total gastrectomy
824055|NCT03007550|Open total gastrectomy
824056|NCT03007537|Erythropoietin
824057|NCT03007537|Cardiac Surgery Associated-acute Kidney Injury
824058|NCT03007524|rosuvastatin
824059|NCT03007524|optical coherence tomography
824060|NCT03007524|acute coronary syndrome
824061|NCT03007511|Percutaneous Endoscopic Gastrostomy
824062|NCT03007511|Feeding tube
824063|NCT03007511|Enteral nutrition
824064|NCT03007511|Endoscopy
824065|NCT03007511|Gastrointestinal
824066|NCT03007459|Body composition
824067|NCT03007459|Bone mineral density
824068|NCT03007459|Binge Eating
824069|NCT03007459|Eating Disorder
824070|NCT03007459|Exercise Dependency
824071|NCT03007459|Depression
824072|NCT03007459|Perfectionism
824073|NCT03007459|Body building
824074|NCT03007459|Drive for Muscularity
824075|NCT03007459|Drive for leanness
824076|NCT03007446|Apatinib
824077|NCT03007446|SOX
824078|NCT03007446|Conversion Surgery
824079|NCT03007446|unresectable gastric cancer
824080|NCT03007433|gastric emptying
824081|NCT03007433|functional dyspepsia
824082|NCT03007433|non invasive imaging
824083|NCT03007433|MRI
824084|NCT03007433|gamma scintigraphy
824085|NCT03007433|gastroparesis
824086|NCT03007407|microsatellite stable
824087|NCT03007407|MSS
824088|NCT03007407|durvalumab
824089|NCT03007407|tremelimumab
824090|NCT03007407|mCRC
824091|NCT03007407|NSABP
824093|NCT03007342|Amoxicillin
824094|NCT03007342|clavulanic acid
824095|NCT03007342|Periapical periodontitis
824096|NCT03007342|Post-operative pain
824097|NCT03007329|SGLT2 inhibitor
824098|NCT03007329|GLP1 agonist
824099|NCT03007329|type 2 Diabetes
824100|NCT03007329|steatosis of the liver
824101|NCT03007329|ectopic lipids
824102|NCT03007329|combined therapy
824103|NCT03007264|cold atmospheric plasma
824104|NCT03007264|pain
824105|NCT03007264|bacteria
824106|NCT03007264|skin parameters
824107|NCT03007186|Blood glucose monitoring
824108|NCT03007186|Glucose tolerance
824109|NCT03007186|HbA1C
824110|NCT03007186|Insulin
824111|NCT03007186|Betamethasone
824112|NCT03007173|umbilical pilonidal sinus
824113|NCT03007082|endovascular treatment
824114|NCT03007082|mechanical thrombectomy
824115|NCT03007082|stent retriever
824116|NCT03007082|human
824117|NCT03007056|high flow nasal cannula
824118|NCT03007056|nasal continuous positive airway pressure
824119|NCT03007056|noninvasive ventilatory support
824120|NCT03007056|newborn developmental care
824121|NCT03007056|bronchopulmonary dysplasia
824122|NCT03007056|weaning
824123|NCT03007056|pain
824124|NCT03007056|length of stay
824125|NCT03007030|Lung Diseases Due to External Agents
824126|NCT03007030|Mesothelioma
824127|NCT03007030|Unresectable malignant pleural mesothelioma
824128|NCT03007030|MPM
824129|NCT03007030|CD30+
824130|NCT03007030|Brentuximab vedotin
824131|NCT03007030|SGN-35
824132|NCT03007030|Adcetris
824133|NCT03007004|Systemic aclerosis
824134|NCT03007004|digital ulcer
824135|NCT03007004|botulinum toxin
824136|NCT03006991|methotrexate, Juvenile Idiopathic Arthritis
824137|NCT03006965|hemophilia
824138|NCT03006965|Hemophilia A
824139|NCT03006965|Factor VIII
824140|NCT03006965|Advate
824141|NCT03006965|Antithrombotic factor
824142|NCT03006965|Pharmacokinetic dosing
824143|NCT03006965|hemarthrosis
824144|NCT03006965|myPKFiT
824145|NCT03006926|hepatocellular carcinoma
824146|NCT03006926|E7080
824147|NCT03006926|lenvatinib
824148|NCT03006926|pembrolizumab
824149|NCT03006926|Japan
824150|NCT03006913|Genetic counseling modes
824151|NCT03006887|solid tumors
824152|NCT03006887|non-small cell lung cancer
824153|NCT03006887|predominantly clear cell renal cell carcinoma
824154|NCT03006887|endometrial carcinoma
824155|NCT03006887|urothelial carcinoma
824156|NCT03006887|squamous cell carcinoma of the head and neck
824157|NCT03006887|non-uveal melanoma
824158|NCT03006887|E7080
824159|NCT03006887|lenvatinib
824160|NCT03006887|pembrolizumab
824161|NCT03006887|Japan
824162|NCT03006835|Clopidogrel; Platelet Inhibition Ratio
824163|NCT03006822|Myofascial Trigger Points
824164|NCT03006822|Liberation for Pression
824165|NCT03006822|Therapy Soft Tissue
824166|NCT03006809|Ulcerative colitis
824167|NCT03006809|FMT
824168|NCT03006809|fecal transplant
824169|NCT03006796|Obesity
824170|NCT03006705|ONO-4538,BMS-936558,Nivolumab,gastric,adjuvant,S-1,CapeOX
824171|NCT03006614|Breast Cancer Model
824172|NCT03006614|Effects of Chemotherapy
824173|NCT03006614|breast cancer
824174|NCT03006588|FNA,EUS,retropharyngeal lymph node (RPLN),NPC
824175|NCT03006575|Non-small cell lung cancer
824176|NCT03006575|Split-course Chemoradiotherapy
824177|NCT03006575|Locoregional recurrence
824178|NCT03006575|Postoperative recurrence
824179|NCT03006575|Consolidation chemotherapy
824180|NCT03006549|Emergency Manual
824181|NCT03006549|Crisis Checklist
824182|NCT03006523|donor intrauterine insemination
824183|NCT03006523|insemination volume
824184|NCT03006523|Live Birth Rates
824185|NCT03006523|donor sperm
824186|NCT03006510|inpatient diabetes
824187|NCT03006510|hypoglycemia
824188|NCT03006497|neck
824189|NCT03006497|motor control
824190|NCT03006497|motor learning
824191|NCT03006484|Cardiac arrest
824192|NCT03006484|Inhospital Cardiac Arrest
824193|NCT03006484|Cardiopulmonary Resuscitation
824194|NCT03006471|Prediabetes
824195|NCT03006471|Prehypertension
824196|NCT03006471|Variability of blood pressure
824197|NCT03006471|ABPM
824198|NCT03006471|Dapagliflozin
824199|NCT03006471|SGLT2
824200|NCT03006432|OESOPHAGO-GASTRIC CARCINOMA
824201|NCT03006419|kidney transplantation
824202|NCT03006419|induction
824203|NCT03006419|thymoglobulin
824204|NCT03006419|basiliximab
824205|NCT03006419|acute rejection
824206|NCT03006419|graft loss
824207|NCT03006406|endometriosis
824208|NCT03006406|long term GnRH-a
824209|NCT03006393|Neuroscience
824210|NCT03006393|Behavioral
824211|NCT03006393|Social
824212|NCT03006354|high frequency oscillatory ventilation
824213|NCT03006354|newborn
824214|NCT03006354|noninvasive ventilation
824215|NCT03006354|transient tachypnea of the newborn
824216|NCT03006328|weight gain
824217|NCT03006328|weight loss
824218|NCT03006315|multiple myeloma
824219|NCT03006315|garmin vivofit
824220|NCT03006302|pancreatic cancer
824221|NCT03006302|vaccine
824222|NCT03006302|immunotherapy
824223|NCT03006302|MK-3475
824224|NCT03006302|PD-1
824225|NCT03006302|IDO
824226|NCT03006289|Metabolic Syndrome
824227|NCT03006289|fasting plasma glucose
824228|NCT03006263|Stomach Neoplasms
824229|NCT03006263|Totally Laparoscopic Total Gastrectomy
824230|NCT03006263|Laparoscopy Assisted Total Gastrectomy
824231|NCT03006250|Desflurane
824232|NCT03006250|Sevoflurane
824233|NCT03006250|Respiratory Complications
824234|NCT03006224|secondary smoking
824235|NCT03006224|one lung ventilation
824236|NCT03006224|arterial oxygen tension
824237|NCT03006224|lobectomy
824238|NCT03006211|nitrogen protoxide
824239|NCT03006211|oxygen
824240|NCT03006211|corneal endothelial
824241|NCT03006211|pediatric
824242|NCT03006107|Irreversible pulpitis
824243|NCT03006107|Post endodontic pain
824244|NCT03006107|Symptomatic pulpitis pain
824245|NCT03006107|Single visit RCT pain
824246|NCT03006107|Root canal treatment flare up
824247|NCT03006107|Single dose piroxicam
824248|NCT03006107|Intraligamentary piroxicam
824249|NCT03006107|Intraligamentary mepecaine
824250|NCT03006094|questionnaire
824251|NCT03006094|hip
824252|NCT03006094|pain
824253|NCT03006081|Retinal nonperfusion
824254|NCT03006081|Aflibercept
824255|NCT03006068|Ulcerative Colitis (UC)
824256|NCT03006068|Safety
824257|NCT03006068|Open-Label Extension (OLE)
824258|NCT03006068|Efficacy
824259|NCT03006068|ABT-494
824260|NCT03006042|bupivacaine
824261|NCT03006042|local anaesthetics
824262|NCT03006042|cesarean section
824263|NCT03006042|transversus abdominis plane block
824264|NCT03006042|toxicity
824265|NCT03006042|ultrasound guidance
824266|NCT03006042|QTc interval
824267|NCT03006003|Osteoporosis
824268|NCT03006003|Raloxifene
824269|NCT03006003|Central nervous disorders
824270|NCT03005990|Sleep disturbance
824271|NCT03005990|Body composition
824272|NCT03005990|Energy metabolism
824273|NCT03005990|Exercise training
824274|NCT03005990|Community-dwelling elderly
824275|NCT03005977|Urodynamics
824276|NCT03005977|Pyridium pad test
824277|NCT03005977|Cough stress test
824278|NCT03005977|Pelvic organ prolapse
824279|NCT03005938|Cerebral Palsy
824280|NCT03005938|Spinal Manipulation
824281|NCT03005938|Muscle Spasticity
824282|NCT03005938|Manual Dexterity
824283|NCT03005912|Speech Comprehension
824284|NCT03005912|Telephony
824285|NCT03005912|VoIP
824286|NCT03005886|Periodontitis
824287|NCT03005886|Periodontal-systemic disease
824288|NCT03005886|Cardiovascular diseases
824289|NCT03005886|Gingival crevicular fluid
824290|NCT03005886|Acute myocardial infarction
824291|NCT03005886|Neopterin
824292|NCT03005886|Vascular cell adhesion molecule-1
824293|NCT03005873|osteoarthritis of the knee
824294|NCT03005873|TLC599
824295|NCT03005873|Dexamethasone
824296|NCT03005873|DSP
824297|NCT03005834|Atherosclerotic cardiovascular diseases, cancers
824298|NCT03005821|pediatric massage
824299|NCT03005821|Tuina therapy
824300|NCT03005821|acute diarrhea
824301|NCT03005808|appendectomy, pediatrics, nerve block, abdominal wall
824302|NCT03005795|cervical dysplasia
824303|NCT03005795|colposcopy
824304|NCT03005795|anxiety
824305|NCT03005795|music
824306|NCT03005795|mozart
824307|NCT03005795|randomized controlled trial
824308|NCT03005769|persistence
824309|NCT03005769|long-acting injectable antipsychotic
824310|NCT03005769|adherence
824311|NCT03005743|Cervical cancer
824312|NCT03005743|Brachytherapy
824313|NCT03005743|Conventional planning
824314|NCT03005743|MR based Brachytherapy
824315|NCT03005717|submental
824316|NCT03005717|Salmeterol Xinafoate
824317|NCT03005717|LIPO-202
824318|NCT03005717|bulge
824319|NCT03005704|Ticagrelor
824320|NCT03005704|Acetylsalicylic acid
824321|NCT03005704|Platelet transfusion
824322|NCT03005704|Reversal
824323|NCT03005691|metabolite
824324|NCT03005691|central sensitization
824325|NCT03005691|whiplash
824326|NCT03005678|glucocorticoids, steroids, osteoporosis
824327|NCT03005665|optic nerve sheath diameter
824328|NCT03005665|acetazolamide
824329|NCT03005652|Subjective Cognitive Decline
824330|NCT03005652|Mental Health
824331|NCT03005652|Meditation
824332|NCT03005652|Health Education
824333|NCT03005613|Pelvic organ prolapse
824334|NCT03005613|Sacrospinous ligament fixation
824335|NCT03005613|Ischial spine fascia fixation
824336|NCT03005613|Clinical outcome
824337|NCT03005600|Screening, diagnosis, risk stratification, ethnic
824338|NCT03005574|Severe Mental Illness
824339|NCT03005574|Cognitive Remediation
824340|NCT03005574|Employment
824341|NCT03005548|Transcranial Direct Current Stimulation
824342|NCT03005548|Pain Postoperative
824343|NCT03005548|Thoracotomy
824344|NCT03005509|Quality improvement
824345|NCT03005509|Injury
824346|NCT03005509|Injuries
824347|NCT03005483|GABAPENTIN POSTOPERATIVE PAIN CHILD
824348|NCT03005470|Prehypertension
824349|NCT03005470|Hypertension
824350|NCT03005470|Blood pressure
824351|NCT03005470|Intervention
824352|NCT03005470|Lifestyle
824353|NCT03005470|Blood pressure monitoring
824354|NCT03005470|Ambulatory Blood Pressure Monitoring
824355|NCT03005470|Text Messages
824356|NCT03005444|liver cirrhosis
824357|NCT03005444|Transjugular Intrahepatic Portosystemic Stent Shunt
824358|NCT03005444|Anticoagulation
824359|NCT03005444|Survival
824360|NCT03005444|Additional decompensation
824361|NCT03005431|Parenting
824362|NCT03005431|Training
824363|NCT03005431|Support
824364|NCT03005431|On-line
824365|NCT03005431|Stress
824366|NCT03005405|Dental Caries
824367|NCT03005405|Primary tooth
824368|NCT03005405|Ionomer Sealants
824369|NCT03005405|Glass Ionomer Restoration
824370|NCT03005392|Cancer
824371|NCT03005392|Physical therapy
824372|NCT03005392|Cardiorespiratory fitness
824373|NCT03005379|FMT
824374|NCT03005379|recurrent c. difficile
824375|NCT03005379|infectious disease
824376|NCT03005379|intestine
824377|NCT03005379|clinical trial
824378|NCT03005379|gastrointestinal
824379|NCT03005379|prevention
824380|NCT03005379|randomized
824381|NCT03005379|diarrhea
824382|NCT03005379|fecal microbiota therapy
824383|NCT03005366|Atrial fibrillation
824384|NCT03005366|vernakalant
824385|NCT03005366|flecainide
824386|NCT03005366|cardioversion
824387|NCT03005301|electroacupuncture instrument
824388|NCT03005288|type 2 diabetes
824389|NCT03005288|obesity
824390|NCT03005288|DXA
824391|NCT03005288|MRI
824392|NCT03005236|Kidney transplant
824393|NCT03005236|Tacrolimus
824394|NCT03005236|Envarsus
824395|NCT03005236|Older adult
824396|NCT03005236|Elderly
824397|NCT03005158|High-sensitivity cardiac troponin I
824398|NCT03005158|Myocardial infarction
824399|NCT03005158|Acute coronary syndrome
824400|NCT03005158|Cluster-randomized trial
824401|NCT03005132|GBM; Integrative Analysis; WES
824402|NCT03004989|Qualitative study
824403|NCT03004989|Musculoskeletal Disorders
824404|NCT03004989|Return to Work Programme
824405|NCT03004976|hematopoietic stem cells
824406|NCT03004976|umbilical cord blood
824407|NCT03004976|stroke
824408|NCT03004976|ischemic stroke
824409|NCT03004963|Peritoneal Dialysis
824410|NCT03004963|Volume Status
824411|NCT03004963|Body Composition Monitor
824412|NCT03004911|fibromyalgia
824413|NCT03004911|mobile application
824414|NCT03004911|self-care
824415|NCT03004911|quality of life
824416|NCT03004872|birth experience
824417|NCT03004872|postpartum depression
824418|NCT03004872|PTSD
824419|NCT03004872|pain during labor
824420|NCT03004872|pain during cesarean delivery
824421|NCT03004872|non-elective induction of labor
824422|NCT03004872|unplanned surgery for urgent/emergent cesarean delivery
824423|NCT03004872|postpartum hemorrhage
824424|NCT03004859|atrial fibrillation
824425|NCT03004859|screening
824426|NCT03004859|electrocardiogram
824427|NCT03004859|community pharmacy
824428|NCT03004859|Germany
824429|NCT03004846|Vehicle- controlled
824430|NCT03004846|GSK2981278
824431|NCT03004846|Plaque psoriasis
824432|NCT03004820|Minor Ischemic Stroke
824433|NCT03004820|Transient Ischemic Attack
824434|NCT03004820|Remote Ischemic Conditioning
824435|NCT03004807|Nutrition
824436|NCT03004807|Aging
824437|NCT03004807|Multivitamin
824438|NCT03004781|parenting intervention
824439|NCT03004781|externalizing behavior
824440|NCT03004781|emotion coaching practices
824441|NCT03004781|self-efficacy beliefs
824442|NCT03004742|polyphenols
824443|NCT03004742|metabolomics
824444|NCT03004742|oxidative stress
824445|NCT03004729|Allergy
824446|NCT03004729|Atopic Dermatitis
824447|NCT03004729|Immunoglobulin E (IgE)
824448|NCT03004729|CMPA
824454|NCT03004690|biosafety
824455|NCT03004690|outbreaks
824456|NCT03004690|clinic
824457|NCT03004690|personal protective equipment
824458|NCT03004690|ergonomics
824459|NCT03004690|error rates
824460|NCT03004664|Latinos
824461|NCT03004664|Low Income
824462|NCT03004664|Self Management
824463|NCT03004664|Education
824464|NCT03004664|Cultural Competence
824465|NCT03004638|Atherosclerosis
824466|NCT03004638|Cardiovascular Disease
824467|NCT03004638|CAD
824468|NCT03004638|Atherosclerotic Cardiovascular Disease
824469|NCT03004612|prediabetes
824470|NCT03004599|Valvular Heart Disease
824471|NCT03004599|Critical Aortic Stenosis
824472|NCT03004599|Severe Aortic Stenosis
824473|NCT03004599|High Risk
824474|NCT03004599|Aortic Valve Replacement
824475|NCT03004599|Cardiovascular Disease
824476|NCT03004599|Aortic Stenosis
824477|NCT03004599|Heart Valve Therapy
824478|NCT03004599|Transcatheter
824479|NCT03004599|Transfemoral
824480|NCT03004599|TAVI
824481|NCT03004599|TAVR
824482|NCT03004599|ACURATE neo™ Aortic Bioprosthesis
824483|NCT03004599|ACURATE TF™ Transfemoral Delivery System
824484|NCT03004586|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
824485|NCT03004586|Lung cancer
824486|NCT03004586|Ultrasound-guided transbronchial needle aspiration
824487|NCT03004586|EBUS-TBNA
824488|NCT03004586|25-gauge needle
824489|NCT03004586|22-gauge needle
824490|NCT03004573|Parkinson Disease
824491|NCT03004573|emotional recognition
824492|NCT03004573|Deep Brain Stimulation
824493|NCT03004560|Bariatric
824494|NCT03004560|standard laparoscopic surgery
824495|NCT03004560|minimally invasive
824496|NCT03004560|scars
824497|NCT03004560|psychology
824502|NCT03004521|Lithium
824503|NCT03004521|Quetiapine
824504|NCT03004521|Augmentation
824505|NCT03004508|Ginkgo Biloba Extract
824506|NCT03004508|Safety
824507|NCT03004508|Genomic Stability
824508|NCT03004508|DNA cell maintenance
824509|NCT03004482|NICU
824510|NCT03004482|Recorded video images
824511|NCT03004482|physiological disorders
824512|NCT03004456|Phlebotomy
824513|NCT03004456|Pain
824514|NCT03004456|Distress
824515|NCT03004443|Psychiatry
824516|NCT03004430|Mantra
824517|NCT03004430|Meditation
824518|NCT03004391|Shared decision making
824519|NCT03004391|Follow-up
824520|NCT03004378|obesity
824521|NCT03004378|adolescent
824522|NCT03004378|tracking device
824523|NCT03004378|fitbit
824524|NCT03004326|DIV
824525|NCT03004326|CSS
824526|NCT03004326|EGPA
824527|NCT03004326|HSP
824528|NCT03004326|GPA
824529|NCT03004326|MPA
824530|NCT03004326|PAN
824531|NCT03004326|Wegeners
824532|NCT03004313|migraine
824536|NCT03004261|cytomegalovirus infection
824537|NCT03004261|cytotoxic T lymphocyte
824538|NCT03004261|hematopoietic stem cell transplantation
824539|NCT03004248|glabellar lines, frown lines
824540|NCT03004209|Erythropoietin
824541|NCT03004209|Autoimmune encephalitis
824542|NCT03004196|White Spot Lesion
824543|NCT03004196|Probiotics
824544|NCT03004196|Chlorhexidine
824545|NCT03004196|Streptococcus Mutans
824546|NCT03004196|Fixed Orthodontic Treatment
824547|NCT03004170|HIV
824548|NCT03004170|Motivational Interviewing
824549|NCT03004170|Telephone
824550|NCT03004170|Telehealth
824551|NCT03004170|Risky Sex
824552|NCT03004170|Unprotected Sex
824553|NCT03004170|Condoms
824554|NCT03004170|Older Adults
824555|NCT03004157|infant
824556|NCT03004157|cardiopulmonary resuscitation
824557|NCT03004157|hemodynamics
824558|NCT03004157|chest compressions
824559|NCT03004105|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
824560|NCT03004105|Advanced Lung Cancer
824561|NCT03004105|Recurrent Nonsmall Cell Lung Cancer
824562|NCT03004105|Selumetinib
824563|NCT03004105|AZD6244
824564|NCT03004105|Durvalumab
824565|NCT03004105|MEDI4736
824566|NCT03004092|bis(methylthio)gliotoxin
824567|NCT03004092|lateral flow device
824568|NCT03004092|JF5
824569|NCT03004092|Galactomannan
824570|NCT03004092|Invasive aspergillosis
824574|NCT03004027|health behaviour change
824575|NCT03004027|implementation intention
824576|NCT03004027|if then plan
824577|NCT03004027|skin condition
824578|NCT03004027|visible difference
824579|NCT03004027|self help
824580|NCT03004014|sleep endoscopy
824581|NCT03004014|sedation
824582|NCT03004001|Severe proteinuria
824583|NCT03004001|Dyslipidemia
824584|NCT03003975|Ablation
824585|NCT03003975|Cryoballoon
824586|NCT03003975|Achieve
824587|NCT03003962|NSCLC
824588|NCT03003962|PD-L1
824589|NCT03003962|Durvalumab
824590|NCT03003962|MEDI4736
824591|NCT03003962|PFS
824592|NCT03003962|OS
824593|NCT03003949|perimenopause
824594|NCT03003949|menopause transition
824595|NCT03003949|estrogen
824596|NCT03003949|stress
824597|NCT03003949|mood
824598|NCT03003936|Glucose tolerance
824599|NCT03003936|MTNR1B
824600|NCT03003936|nutrigenomics
824601|NCT03003936|Food timing
824602|NCT03003923|Vegetable intake
824603|NCT03003923|Taste exposures
824604|NCT03003923|Educational intervention
824605|NCT03003923|Preschool children
824606|NCT03003923|Healthy eating intervention
824607|NCT03003910|Best Possible Self
824608|NCT03003897|Dietary Fiber
824609|NCT03003897|Soluble Fiber
824610|NCT03003897|Body Mass Index
824611|NCT03003897|Body Weight
824612|NCT03003897|Blood Glucose
824613|NCT03003897|Insulin
824614|NCT03003871|stroke
824615|NCT03003871|randomized controled clinical trial
824616|NCT03003871|oral health promotion
824617|NCT03003858|gingivitis
824618|NCT03003858|hyaluronic acid
824619|NCT03003858|pediatrics
824620|NCT03003858|medical devices
824621|NCT03003806|Insulin pump treatment
824622|NCT03003806|Type 1 diabetes
824623|NCT03003806|Pump setting advisor
824624|NCT03002727|Colorectal cancer
824625|NCT03002727|Microsatellite
824626|NCT03002727|Colorectal cancer stem cells
824627|NCT03003689|Scaling and Root Planing
824628|NCT03003689|Er:YAG
824638|NCT03003650|Severe Symptomatic Aortic Valve Stenosis
824639|NCT03003624|Incisions
824640|NCT03003624|microdissection needle
824641|NCT03003598|Intraocular pressure
824642|NCT03003598|videolaryngoscope
824643|NCT03003598|direct laryngoscope
824644|NCT03003585|intraocular pressure
824645|NCT03003585|direct laryngoscopy
824646|NCT03003585|fiberoptic bronchoscopy
824647|NCT03003572|Sjögren's syndrome
824648|NCT03003572|Immunoglobulin E
824649|NCT03003572|Anti-Ro/SSA
824650|NCT03003572|Autoimmune disease
824651|NCT03003572|Biomarker
824652|NCT03003559|COPD Exacerbation
824653|NCT03003559|High Flow Oxygen
824654|NCT03003559|Nasal Cannula
824655|NCT03003559|mild
824656|NCT03003533|Adeno-Associated Virus (AAV)
824657|NCT03003533|Blood Coagulation Disorders
824658|NCT03003533|Blood Coagulation Disorders, Inherited
824659|NCT03003533|Coagulation Protein Disorders
824660|NCT03003533|Factor VIII (FVIII)
824661|NCT03003533|Factor VIII (FVIII) Deficiency
824662|NCT03003533|Factor VIII (FVIII) Gene
824663|NCT03003533|Factor VIII (FVIII) Protein
824664|NCT03003533|Genetic Diseases, Inborn
824665|NCT03003533|Genetic Diseases, X-Linked
824666|NCT03003533|Gene Therapy
824667|NCT03003533|Gene Transfer
824668|NCT03003533|Hematologic Diseases
824669|NCT03003533|Hemorrhagic Disorders
824670|NCT03003533|Recombinant
824671|NCT03003533|Vector
824684|NCT03003507|Hyperglycemia
824685|NCT03003507|Fructose
824686|NCT03003507|Diabetes mellitus
824687|NCT03003507|Enteral Nutrition
824688|NCT03003507|Glycemic Variability
824689|NCT03003468|Anti-PD-1
824690|NCT03003468|Pembrolizumab
824691|NCT03003468|Imprime PGG
824692|NCT03003468|MK-3475
824693|NCT03003455|Nasotracheal Intubation
824694|NCT03003442|Multivitamin/mineral
824695|NCT03003442|Exercise
824696|NCT03003442|Fatigue
824697|NCT03003442|Stress
824698|NCT03003442|Arousal
824699|NCT03003442|Energy expenditure
824700|NCT03003442|Recovery biomarkers
824701|NCT03003442|Cognition
824702|NCT03003429|Heart rate variability
824703|NCT03003429|anxiety
824704|NCT03003429|Autonomic dysfunction
824705|NCT03003403|mHealth
824706|NCT03003403|Digital Health
824707|NCT03003403|Primary Care
824708|NCT03003403|Pragmatic Clinical Trial
824709|NCT03003403|Behavior Change
824710|NCT03003403|Weight Management
824711|NCT03003390|child
824712|NCT03003390|critical illness
824713|NCT03003390|venous thromboembolism
824714|NCT03003390|enoxaparin
824715|NCT03003390|thrombin generation
824716|NCT03003377|Sevoflurane
824717|NCT03003377|Remifentanil
824718|NCT03003377|Laryngeal mask supreme
824719|NCT03003377|laryngeal mask proseal
824720|NCT03003351|Fistula
824721|NCT03003351|Cohort Study
824722|NCT03003338|chronic HCV Genotype 1b infection
824723|NCT03003338|HCV RNA
824724|NCT03003338|OBV/PTV/r in combination with DSV
824725|NCT03003338|neuropsychiatric manifestations
824726|NCT03003325|low risk of thrombosis
824727|NCT03003325|Interferon
824728|NCT03003312|Urolithiasis
824729|NCT03003312|Uyghur
824730|NCT03003312|Prevalence
824731|NCT03003312|Associated factors
824732|NCT03003312|Children
824733|NCT03003299|Sapien 3
824734|NCT03003299|Partner 3
824735|NCT03003299|cardiovascular disease
824736|NCT03003299|heart disease
824737|NCT03003299|aortic stenosis
824738|NCT03003299|SAVR
824739|NCT03003299|TAVR
824740|NCT03003299|failing surgical valve
824741|NCT03003299|failing bioprosthetic valve
824742|NCT03003299|failing valve
824743|NCT03003286|Contingency Behavior Management
824744|NCT03003286|Flexible
824745|NCT03003286|Unstuck
824746|NCT03003286|Low Income
824747|NCT03003286|Behavior
824748|NCT03003286|Coping
824749|NCT03003286|Disparity
824750|NCT03003286|Problem Solving
824751|NCT03003286|Self-Control
824752|NCT03003286|impulsive
824753|NCT03003286|intervention
824754|NCT03003221|Parent training
824755|NCT03003221|Dental care
824756|NCT03003169|surgery
824757|NCT03003169|breast cancer
824758|NCT03003169|quality of life
824759|NCT03003156|magnetic seizure therapy
824760|NCT03003156|schizophrenia
824761|NCT03003156|controlled trial
824762|NCT03003156|cognition
824763|NCT03003130|Hyaluronic acid
824764|NCT03003130|Comparative study
824765|NCT03003130|NLF
824766|NCT03003117|Infant
824767|NCT03003117|Diet
824768|NCT03003117|Growth
824769|NCT03003117|Breastfeeding
824770|NCT03003117|Complementary feeding
824771|NCT03003117|Pregnancy
824772|NCT03003117|Body mass index
824773|NCT03003117|Social disadvantage
824774|NCT03003117|Randomized controlled trial
824775|NCT03003117|Education
824776|NCT03003117|Food vouchers
824777|NCT03003104|Skin diseases
824778|NCT03003104|rosacea
824779|NCT03003078|Pancreatic cancer
824780|NCT03003078|Pancreas
824781|NCT03003078|metastases
824782|NCT03003078|pancreatic tumour
824783|NCT03003078|unresectable
824784|NCT03003078|locally advanced
824785|NCT03003078|implantable
824786|NCT03003078|radiographic
824787|NCT03003078|device
824788|NCT03003078|Phosphorous-32
824789|NCT03003078|OncoSil™
824790|NCT03003078|brachytherapy
824791|NCT03003078|FOLFIRINOX
824792|NCT03003078|gemcitabine
824793|NCT03003078|nab-paclitaxel
824794|NCT03003078|Abraxane
824795|NCT03003065|Inoperable cholangiocarcinoma
824796|NCT03003065|Photodynamic therapy
824797|NCT03003065|Endoscopic retrograde cholangiopancreatography
824798|NCT03003052|dental implants
824799|NCT03003052|edentulous
824800|NCT03003052|dental hygiene
824801|NCT03003052|evidence-based dentistry
824802|NCT03003039|GB241
824803|NCT03003039|Rituximab
824804|NCT03003039|B-cell Lymphoma
824805|NCT03003026|motor learning
824806|NCT03003026|participation
824807|NCT03003013|Odontogenic cysts
824808|NCT03003013|Bone substitutes materials
824809|NCT03003013|SYMBIOS®
824810|NCT03003013|Platelets rich fibrin (PRF)
824811|NCT03003013|Bone regeneration
824812|NCT03002974|Gout
824813|NCT03002974|Interleukin 1 receptor antagonist
824814|NCT03002974|IL-1 receptor antagonist
824815|NCT03002896|Cancer
824816|NCT03002896|Caregivers
824817|NCT03002896|Pep-pal
824818|NCT03002896|Pep-Pal + Treatment as Usual
824819|NCT03002896|Treatment as Usual
824820|NCT03002857|Laryngeal Mask Airway
824821|NCT03002857|Urologic Surgical Procedure
824822|NCT03002831|CIK
824823|NCT03002831|Chemotherapy
824824|NCT03002831|Pancreatic Cancer
824825|NCT03002818|Ritonavir
824826|NCT03002818|Chronic Hepatitis C (HCV)
824827|NCT03002818|Dasabuvir
824828|NCT03002818|Paritaprevir
824829|NCT03002818|Sustained Virological Response
824830|NCT03002818|Ombitasivir
824831|NCT03002818|Genotype 1
824836|NCT03002792|anesthesia
824837|NCT03002792|neurodevelopment
824838|NCT03002792|dental caries
824839|NCT03002753|OCD
824840|NCT03002753|obsessive-compulsive disorder
824841|NCT03002753|cognitive therapy
824842|NCT03002753|metacognitive therapy
824843|NCT03002753|cognitive restructuring
824844|NCT03002753|detached mindfulness
824845|NCT03002753|comparison
824846|NCT03002753|Germany
824847|NCT03002753|Muenster
824848|NCT03002753|Christoph-Dornier-Stiftung
824849|NCT03002753|metacognition
824850|NCT03002714|Resistance Training
824851|NCT03002714|Psychological Stress
824852|NCT03002714|Aging
824853|NCT03002714|Hypertension
824854|NCT03002714|Autonomic Nervous System
824855|NCT03002701|Prevention
824856|NCT03002701|Critical care
824857|NCT03002701|Delirium
824858|NCT03002701|Nurse
824859|NCT03002701|RCT
824860|NCT03002675|Adipose tissue
824861|NCT03002675|Type 2 diabetes
824862|NCT03002649|Dermatomyositis
824863|NCT03002649|Tofacitinib
824864|NCT03002649|Refractory dermatomyositis
824865|NCT03002636|Obesity
824866|NCT03002636|Anesthesia Complications
824867|NCT03002636|Body Mass Index (BMI)
824868|NCT03002623|Dual Inhibitor of HDAC and P13K Signaling
824869|NCT03002623|HDSC2
824870|NCT03002623|EGFR/RAS/RAF/MEK/ERK Signaling Pathway Inhibition
824871|NCT03002584|IBS, population
824872|NCT03002558|Hypertension
824873|NCT03002558|Continuous Positive Airway Pressure
824874|NCT03002558|Obstructive Sleep Apnea
824875|NCT03002558|Cardiovascular Diseases
824876|NCT03002545|Magnesium
824877|NCT03002545|Type II diabetes
824878|NCT03002545|magnesium-sensitive genes
824879|NCT03002532|Breast cancer
824880|NCT03002532|Brain metastasis
824881|NCT03002532|Whole brain radiotherapy
824882|NCT03002532|Hippocampal avoidance
824883|NCT03002532|Neurocognitive function
824884|NCT03002532|intracranial failure
824885|NCT03002506|ceftolozane
824886|NCT03002506|tazobactam
824887|NCT03002493|Rifampicin
824888|NCT03002493|Pharmacokinetics
824889|NCT03002493|Eribulin Mesylate
824890|NCT03002493|E7389
824891|NCT03002493|Advanced Solid Tumors
824892|NCT03002493|Tumors
824893|NCT03002454|99mTc Pertechnetate
824894|NCT03002454|Sodium Pertechnetate
824895|NCT03002454|Technetium
824896|NCT03002454|Molybdenum
824897|NCT03002454|MDP
824898|NCT03002454|neutron activation
824899|NCT03002402|asthma
824900|NCT03002402|insomnia
824901|NCT03002402|cognitive-behavioral treatment
824902|NCT03002389|chronic obstructive pulmonary disease
824903|NCT03002389|COPD
824904|NCT03002389|emphysema
824905|NCT03002389|MRI
824906|NCT03002389|hyper polarized gas MRI
824907|NCT03002363|autism
824908|NCT03002363|audiology
824909|NCT03002363|video modeling
824910|NCT03002363|testing compliance
824911|NCT03002350|Circulating tumor cells (CTCs)
824912|NCT03002350|Optically induced dielectrophoresis (ODEP)
824913|NCT03002350|Cell sorting
824914|NCT03002350|Next-generation sequencing (NGS)
824915|NCT03002350|disruptive mutation
824916|NCT03002337|aromatherapy massage, yoga
824917|NCT03002324|Vaccines
824918|NCT03002324|Childhood Vaccination
824919|NCT03002324|Decision Making
824920|NCT03002324|Health Belief Model
824921|NCT03002311|Bioinformatics
824922|NCT03002311|Electronic pharmacology
824923|NCT03002311|Mobile health
824924|NCT03002311|Electronic health
824925|NCT03002311|Adherence
824926|NCT03002311|Digital health
824927|NCT03002311|Health information technology
824928|NCT03002311|mHealth
824929|NCT03002311|eHealth
824930|NCT03002259|cardiac surgery
824931|NCT03002233|TRK-820
824932|NCT03002233|Hemodialysis
824933|NCT03002233|Uremic Pruritus
824934|NCT03002194|rhytides
824935|NCT03002194|wrinkle
824936|NCT03002142|Alzheimer
824937|NCT03002142|Hearing loss
824938|NCT03002142|Cognition
824939|NCT03002142|Quality of life
824940|NCT03002142|Hearing aids
824941|NCT03002090|iron deficiency
824942|NCT03002090|anemia
824943|NCT03002090|exercise training
824944|NCT03002090|aerobic
824945|NCT03002090|performance
824946|NCT03002090|Chinese medicine
824947|NCT03002090|BaZhen KeLi
824948|NCT03002064|Esophagus squamous carcinoma
824949|NCT03002064|First-line chemotherapy
824950|NCT03002064|Docetaxel
824951|NCT03002064|Cisplatin
824952|NCT03002064|5-fluorouracil
824953|NCT03002038|neuromyelitis optica spectrum disorder
824954|NCT03002038|azathioprine
824955|NCT03002038|rituximab
824956|NCT03002038|clinical trial
824957|NCT03002038|annual relapse rate
824958|NCT03002038|expanded disability status scale
824959|NCT03002012|cryptococcal antigen
824960|NCT03002012|preemptive treatment
824961|NCT03002012|CRAG+
824962|NCT03002012|sertraline
824963|NCT03002012|fluconazole
824964|NCT03002012|randomized clinical trial
824965|NCT03002012|HIV
824966|NCT03001999|Diabetes
824967|NCT03001999|Positive Psychology
824968|NCT03001999|Physical Activity
824969|NCT03001986|safety
824970|NCT03001986|efficacy
824971|NCT03001986|hand, foot and mouth disease (HFMD)
824972|NCT03001973|Lupus nephritis
824973|NCT03001973|Patient survival
824974|NCT03001973|Renal survival
824975|NCT03001947|IgA nephropathy
824976|NCT03001947|All-cause mortality
824977|NCT03001947|Cardiovascular mortality
824978|NCT03001947|A composite renal outcome
824979|NCT03001934|Nephrotic syndrome
824980|NCT03001934|Treatment response
824981|NCT03001934|Renal function
824982|NCT03001921|Hemodialysis
824983|NCT03001921|Patient survival
824984|NCT03001921|Quality of life
824985|NCT03001921|Hemodialysis access
824986|NCT03001908|shoulder
824987|NCT03001908|mobilization
824988|NCT03001908|electromyography
824989|NCT03001908|imaging ultrasound
824990|NCT03001804|Multiple Myeloma
824991|NCT03001804|Revlimid
824992|NCT03001804|Lenalidomide
824993|NCT03001804|Non-transplantable
824994|NCT03001791|CO2 laser
824995|NCT03001791|thermal damage zone
824996|NCT03001791|Er:YAG laser
824997|NCT03001778|Physical Activity
824998|NCT03001778|Older Adults
824999|NCT03001778|Independent Living Facilities
825000|NCT03001778|Multimedia technology
825001|NCT03001752|post-extraction dental implant
825002|NCT03001752|immediate dental implant
825003|NCT03001752|open flap
825004|NCT03001752|flapless
825005|NCT03001752|bone grafting
825006|NCT03001752|CT Cone Beam
825007|NCT03001687|hepcidin
825008|NCT03001687|sepsis
825009|NCT03001687|surgery
825010|NCT03001687|vitamin D
825011|NCT03001661|Propess
825012|NCT03001661|Dilapan-S
825013|NCT03001661|Dinoprostone
825014|NCT03001661|Labour
825015|NCT03001661|Induction
825016|NCT03001661|Child birth
825017|NCT03001596|Neoadjuvant Chemoradiotherapy
825018|NCT03001596|Neoadjuvant Chemotherapy
825019|NCT03001596|Minimally Invasive Esophagectomy
825020|NCT03001596|Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0）
825021|NCT03001583|Mediterranean diet
825022|NCT03001583|weight loss
825023|NCT03001583|type 2 diabetes
825024|NCT03001583|education program
825025|NCT03001583|cooking
825026|NCT03001557|Mild to Moderate Alzheimer's Disease Dementia
825027|NCT03001557|sleep
825028|NCT03001557|circadian rhythms
825029|NCT03001531|Complete paraplegia
825030|NCT03001466|Cataract
825031|NCT03001466|Urea-loaded NPs
825032|NCT03001466|TEM examination
825033|NCT03001453|Exparel
825034|NCT03001453|total hip replacement
825035|NCT03001453|bupivacaine
825036|NCT03001440|REMS
825037|NCT03001440|Smoking cessation
825038|NCT03001440|WELLBUTRIN
825039|NCT03001440|ZYBAN
825040|NCT03001440|Neuropsychiatric adverse events
825041|NCT03001388|Cystic Fibrosis Liver Disease
825042|NCT03001388|Pancreatic insufficiency
825043|NCT03001388|Cystic Fibrosis
825044|NCT03001388|Transient Elastography
825045|NCT03001375|Laparoscopic colectomy.
825046|NCT03001375|Splenic flexure mobilization.
825047|NCT03001375|Anastomotic leakage.
825048|NCT03001349|Malignant neoplasms of digestive organs
825049|NCT03001349|Neuroendocrine Tumors
825050|NCT03001349|NET
825051|NCT03001349|Malignant neoplasms of eye brain and other parts of central nervous system
825052|NCT03001349|PET/CT scan
825053|NCT03001349|68Ga-DOTATOC
825054|NCT03001336|Thyroid
825055|NCT03001336|Diabetes Mellitus
825056|NCT03001297|atherosclerosis; acute coronary syndrome; MEDI5884
825057|NCT03001271|Angiotensin-(1-7)
825058|NCT03001271|Renin-angiotensin System
825059|NCT03001271|Autonomic Nervous System
825060|NCT03001245|adolescents
825061|NCT03001245|depression
825062|NCT03001245|psychotherapy
825063|NCT03001245|interpersonal therapy
825064|NCT03001232|Movement-oriented Dementia Care
825065|NCT03001232|QoL
825066|NCT03001232|ADL
825067|NCT03001232|Nursing Home
825068|NCT03001193|Primary slow progress
825069|NCT03001193|Prolonged latent phase
825070|NCT03001193|Labor arrest
825071|NCT03001180|Generalized Lymphatic Anomaly
825072|NCT03001180|Vascular Anomaly
825073|NCT03001180|Kaposiform Hemangioendothelioma
825074|NCT03001180|Kaposiform Lymphangiomatosis
825075|NCT03001180|Vascular Endothelial Growth Factor
825076|NCT03001180|Biomarkers
825077|NCT03001180|GLA
825078|NCT03001180|KLA
825079|NCT03001180|KHE
825080|NCT03001180|GSD
825081|NCT03001167|Microbiome
825082|NCT03001167|Antibiotics
825083|NCT03001167|Growth
825084|NCT03001141|MultiPoint Pacing
825085|NCT03001141|Heart Failure
825086|NCT03001141|Cardiac Resynchronization Therapy
825087|NCT03001141|Quadripolar pacing
825088|NCT03001115|Korean participants
825089|NCT03001115|Hidradenitis Suppurativa
825090|NCT03001115|Safety
825091|NCT03001115|Adalimumab
825092|NCT03001102|Preoperative Care
825093|NCT03001102|Baths
825094|NCT03001102|Chlorhexidine
825095|NCT03001102|Soaps
825096|NCT03001102|Povidone-Iodine
825097|NCT03001102|Arthroplasty, Replacement, Hip
825098|NCT03001102|Surgical Wound Infection
825099|NCT03001089|Neonatology
825100|NCT03001089|Endocrinology
825101|NCT03001076|hyperlididemia
825102|NCT03001076|LDL
825103|NCT03001076|cholesterol
825104|NCT03001076|statin intolerance
825105|NCT03001037|Functional Outcome Measures
825106|NCT03001037|Wearable Sensors
825107|NCT03001037|ViMove
825108|NCT03001037|Low Back Pain
825109|NCT03001037|Range of Movement
825110|NCT03001037|Muscle Activity
825111|NCT03000998|HPV
825112|NCT03000998|Cancer
825113|NCT03000985|schizophrenia
825114|NCT03000985|psychoeducation program
825115|NCT03000985|family caregiver
825116|NCT03000985|relapse
825117|NCT03000985|medication adherence
825118|NCT03000985|burden
825119|NCT03000972|Augmentation
825120|NCT03000972|PET-CT
825121|NCT03000972|Positron Emission Tomography
825122|NCT03000972|Fluorine-18
825123|NCT03000946|Pancreatectomy
825124|NCT03000946|Somatostatin analogue
825125|NCT03000946|Octreotide
825126|NCT03000946|Pancreatic fistula
825127|NCT03000920|short message service (SMS)
825128|NCT03000920|screening
825129|NCT03000920|cost-effectiveness
825130|NCT03000907|prevention
825131|NCT03000907|frailty
825132|NCT03000907|obese
825133|NCT03000907|elderly
825134|NCT03000907|physical exercise
825135|NCT03000894|cognitive-behavioral therapy for insomnia
825136|NCT03000894|insomnia
825137|NCT03000894|mood disorder
825138|NCT03000868|Colonic Polyps
825139|NCT03000868|Endoscopic Mucosal Resection
825140|NCT03000868|Colonoscopy
825141|NCT03000855|Malignant biliary obstruction
825142|NCT03000855|EUS - guided choledocho-duodenostomy
825143|NCT03000855|ERCP with covered metallic stents
825144|NCT03000842|autonomic control
825145|NCT03000842|transcutaneous vagal nerve stimulation
825146|NCT03000842|transauricular vagal nerve stimulation
825155|NCT03000790|Anterior disc displacement
825156|NCT03000790|TMD therapy
825157|NCT03000790|internal derangement
825158|NCT03000790|Lingual Ring
825159|NCT03000777|melatonin
825160|NCT03000777|zinc
825161|NCT03000777|Myalgic Encephalomyelitis
825162|NCT03000777|Chronic Fatigue Syndrome
825163|NCT03000777|sleep
825164|NCT03000777|pain
825165|NCT03000764|Skin biopsy
825166|NCT03000764|Radiotherapy
825167|NCT03000764|RNA biomarker
825168|NCT03000764|HSP biomarker
825169|NCT03000764|Exon junction array
825170|NCT03000764|Gene expression
825171|NCT03000764|Radiosensitivity prediction
825172|NCT03000751|CT scan
825173|NCT03000751|CT exam
825174|NCT03000751|ionizing radiation
825175|NCT03000751|medical imaging
825176|NCT03000751|cat scan
825177|NCT03000751|radiation
825178|NCT03000738|CD16- monocyte/CD16+ monocyte ratio
825179|NCT03000738|CytoDiff flow cytometric system
825180|NCT03000738|Diffuse Large B Cell Lymphoma
825181|NCT03000738|Peripheral T-Cell Lymphoma
825182|NCT03000738|prognosis
825183|NCT03000712|adipose tissue derived mesenchymal stem cell
825184|NCT03000712|osteoarthritis
825185|NCT03000712|degenerative arthritis
825186|NCT03000712|kyung hee university hospital
825187|NCT03000712|biostar
825188|NCT03000712|Rbio
825189|NCT03000712|Osteoarthritis, Knee
825190|NCT03000712|High tibial osteotomy
825191|NCT03000712|Joint Diseases
825192|NCT03000699|cognitive bias modification
825193|NCT03000699|interpretation bias
825194|NCT03000699|suicidal ideation
825195|NCT03000699|depression
825197|NCT03000660|Amyloidosis
825198|NCT03000660|AL Amyloidosis
825199|NCT03000660|Amyloid Light Chain Amylodosis
825200|NCT03000660|ABT-199
825201|NCT03000660|Venetoclax
825202|NCT03000647|Pelvic floor muscle exercise
825203|NCT03000647|Supervision
825204|NCT03000647|Physiotherapy
825205|NCT03000621|MicroRNA
825206|NCT03000621|miR-122
825207|NCT03000621|Diagnosis
825208|NCT03000621|Prognosis
825209|NCT03000595|eczema
825210|NCT03000569|Parkinson
825211|NCT03000543|Infants
825212|NCT03000543|Children
825213|NCT03000543|Adequate or high vitamin A store
825214|NCT03000530|Depression
825215|NCT03000517|levofloxacin
825216|NCT03000517|multi-drug resistant TB
825217|NCT03000517|pharmacokinetics
825218|NCT03000465|pneumoperitoneum pressure
825219|NCT03000465|laparoscopic pressure
825220|NCT03000465|intra-abdominal insufflation
825221|NCT03000465|intra-abdominal pressures
825222|NCT03000465|abdominal compliance
825223|NCT03000452|Multiple Myeloma
825224|NCT03000452|Daratumumab
825225|NCT03000452|Durvalumab
825226|NCT03000452|Relapsed and Refractory Multiple Myeloma
825227|NCT03000439|systemic Juvenile Idiopathic Arthritis
825228|NCT03000439|Xeljanz
825229|NCT03000439|Tofacitinib
825230|NCT03000439|sJIA
825231|NCT03000439|CP-690 550
825232|NCT03000426|Low level laser therapy
825233|NCT03000387|Nicotine Replacement Therapy
825234|NCT03000387|Smoking Cessation
825235|NCT03000387|Randomized Clinical Trial
825236|NCT03000387|Nicotine Patch
825237|NCT03000387|Abstinence
825238|NCT03000387|Placebo
825239|NCT03000387|Double blind
825240|NCT03000361|Colonoscopy
825241|NCT03000361|motorized spiral endoscopy
825242|NCT03000361|adenoma detection rate
825243|NCT03000348|Exacerbation
825244|NCT03000348|CF
825245|NCT03000348|Lung disease
825246|NCT03000348|Lung infection
825247|NCT03000348|Gram negative
825248|NCT03000348|Bacterial Infection
825249|NCT03000348|pneumonia
825250|NCT03000348|bronchitis
825251|NCT03000335|microRNA
825252|NCT03000335|relapse
825253|NCT03000335|blood
825254|NCT03000335|in vitro diagnostics
825255|NCT03000335|prediction
825256|NCT03000335|lab test
825257|NCT03000296|autologous
825258|NCT03000296|lymphoablation
825259|NCT03000296|hematopoetic stem cell transplant
825260|NCT03000296|immune system
825261|NCT03000296|Bone marrow transplant
825262|NCT03000283|Conivaptan
825269|NCT03000257|Non-small cell lung cancer (NSCLC)
825270|NCT03000257|Gastric cancer
825271|NCT03000257|Merkel cell carcinoma
825272|NCT03000257|Cholangiocarcinoma
825273|NCT03000257|Advanced Solid Tumors
825274|NCT03000257|Ovarian cancer
825275|NCT03000257|Triple negative breast cancer
825276|NCT03000257|Hepatocellular carcinoma
825277|NCT03000257|Small cell lung cancer
825278|NCT03000257|Mesothelioma,
825279|NCT03000257|Cancer
825280|NCT03000244|Natural History
825281|NCT03000244|HCT
825282|NCT03000205|Dextrose prolotherapy
825283|NCT03000205|patients
825284|NCT03000192|Survivorship
825285|NCT03000192|Cancer
825286|NCT03000192|Recovery
825287|NCT03000192|Self-management
825288|NCT03000192|Cohort
825289|NCT03000127|testosterone
825290|NCT03000127|multiple sclerosis
825291|NCT03000127|fatigue
825292|NCT03000114|Collagenase injection
825293|NCT03000114|percutaneous needle aponeurotomy
825294|NCT03000101|Biomarkers
825295|NCT03000101|Colitis
825296|NCT03000101|Colitis, Ulcerative
825297|NCT03000101|Colonic Diseases
825298|NCT03000101|Crohn Disease
825299|NCT03000101|Digestive System Diseases
825300|NCT03000101|Fruit
825301|NCT03000101|Fruit and Vegetable Juices
825302|NCT03000101|Gastroenteritis
825303|NCT03000101|Gastrointestinal Diseases
825304|NCT03000101|Humans
825305|NCT03000101|Hydrolysable Tannins
825306|NCT03000101|Inflammation
825307|NCT03000101|Inflammatory Bowel Diseases
825308|NCT03000101|Intestinal Diseases
825309|NCT03000101|Punicaceae
825310|NCT03000075|BI 655066
825311|NCT03000075|ABBV-066
825312|NCT03000075|risankizumab
825313|NCT03000062|overweight, general practice
825314|NCT03000049|sepsis
825315|NCT03000049|septic shock
825316|NCT03000049|blood cultures
825317|NCT03000049|anti-infective therapy
825318|NCT03000036|Breast cancer
825319|NCT03000036|Doxorubicin
825320|NCT03000036|Cardiovascular Magnetic Resonance
825321|NCT03000036|T1 mapping
825322|NCT03000023|Hepatitis C
825323|NCT03000023|Patient-Reported Outcomes
825324|NCT03000023|DAA Treatment
825325|NCT03000023|Qualitative
825326|NCT03000023|Mixed methods
825327|NCT03000010|Wound Vac
825328|NCT03000010|Neuromuscular Scoliosis
825329|NCT03000010|Posterior Spinal Fusion
825330|NCT02999997|Physical therapy modalities
825331|NCT02999997|Dual-task performance
825332|NCT02999997|Parkinson's disease
825333|NCT02999997|Active music therapy
825334|NCT02999997|Physical activity
825335|NCT02999971|circuit class therapy
825336|NCT02999971|ICF model
825337|NCT02999971|aquatic therapy
825338|NCT02999971|neuro-rehabilitation
825339|NCT02999945|preterm infants
825340|NCT02999945|SGA infants
825341|NCT02999945|IUGR infants
825342|NCT02999945|growth
825343|NCT02999945|body composition
825344|NCT02999945|metabolomics
825345|NCT02999945|microbiome
825346|NCT02999945|adiposity markers
825347|NCT02999945|metabolic programming
825348|NCT02999945|neurodevelopmental outcome
825349|NCT02999906|PAH
825350|NCT02999906|Oral Treprostinil
825351|NCT02999906|dual therapy
825352|NCT02999906|6 Minute Walk Test
825353|NCT02999854|Haploidentical stem cell transplantation
825354|NCT02999854|Graft-versus-host disease
825355|NCT02999854|Immune reconstitution
825356|NCT02999854|Alloreactive T-cells
825357|NCT02999854|Photodynamic treatment
825358|NCT02999854|Hematologic malignancy
825359|NCT02999854|Transplant-related mortality
825360|NCT02999854|Overall survival
825361|NCT02999854|GRFS
825362|NCT02999854|GVHD
825363|NCT02999841|Visceral fat
825364|NCT02999828|safety
825365|NCT02999828|immune persistence
825366|NCT02999815|Tetanus
825367|NCT02999802|Nutrient Sensing
825368|NCT02999802|Exercise
825369|NCT02999802|Elderly
825370|NCT02999776|Plaques Psoriasis
825371|NCT02999776|Topical
825372|NCT02999776|Laser microporation
825373|NCT02999763|lipolysis
825374|NCT02999763|fat reduction
825375|NCT02999763|circumference reduction
825376|NCT02999737|Platelet Rich Plasma
825377|NCT02999737|PRP
825378|NCT02999737|Hair loss
825379|NCT02999737|Alopecia
825380|NCT02999737|Hypotrichosis
825381|NCT02999737|Hair diseases
825382|NCT02999698|Psoriasis
825383|NCT02999698|Hidradenitis
825384|NCT02999698|Psychological impact
825385|NCT02999698|Quality of life
825386|NCT02999659|pupillometry
825387|NCT02999659|autonomous nerve system
825393|NCT02999607|Transcranial direct current stimulation
825394|NCT02999607|Positron emission tomography
825395|NCT02999529|Chemotherapy
825396|NCT02999529|Oncology
825397|NCT02999503|adhd treatment
825398|NCT02999503|nutrition
825399|NCT02999477|Breast Cancer
825400|NCT02999464|stroke
825401|NCT02999464|qigong
825402|NCT02999464|randomized controlled trial
825403|NCT02999464|body-mind exercise
825404|NCT02999464|balance
825405|NCT02999464|quality of life
825406|NCT02999464|wellbeing
825407|NCT02999412|Integrated Healthcare System
825408|NCT02999412|Inappropriate Prescribing
825409|NCT02999412|Pragmatic Clinical Trial
825410|NCT02999412|Crossover Design
825411|NCT02999412|Randomised Controlled Trial
825412|NCT02999399|Smoker
825413|NCT02999399|Former smoker
825414|NCT02999386|stress, hyperglycemia, inflammatory markers, trauma, HbA1c
825415|NCT02999386|interleukin-6
825416|NCT02999373|prevention, infection, preterm, cord blood mononuclear cells
825417|NCT02999360|Aphasia
825418|NCT02999360|Speech Therapy
825419|NCT02999360|Aerobic Exercise (AE)
825420|NCT02999347|Treatment Outcome
825421|NCT02999347|Mid-urethral slings
825422|NCT02999347|Gynecologic Surgery Procedures
825423|NCT02999334|Group healthcare models
825424|NCT02999334|Antenatal care
825425|NCT02999334|Prenatal care
825426|NCT02999334|Perinatal health
825427|NCT02999334|CenteringPregnancy
825428|NCT02999334|sub-Saharan Africa
825429|NCT02999334|Malawi
825430|NCT02999334|Tanzania
825431|NCT02999334|Pregnancy
825432|NCT02999308|haemophilia
825433|NCT02999308|prophylaxis
825434|NCT02999308|children
825435|NCT02999282|TMS
825436|NCT02999282|tDCS
825437|NCT02999282|Rehabilitation
825438|NCT02999269|electroconvulsive therapy
825439|NCT02999269|MRI
825440|NCT02999269|major depressive disorder
825441|NCT02999256|Tart Cherry Juice
825442|NCT02999256|Fat Oxidation
825443|NCT02999256|Lipid Profile
825444|NCT02999256|Anthocyanins
825445|NCT02999256|Exercise
825446|NCT02999256|Calorie Restrictive Mimetic
825447|NCT02999230|Cavities
825448|NCT02999217|iron isomaltoside
825449|NCT02999217|plasma ferritin
825450|NCT02999217|haemoglobin
825451|NCT02999217|colorectal cancer
825452|NCT02999165|Breastfeeding
825453|NCT02999165|CPAP
825454|NCT02999165|Humidified High Flow Nasal Cannula Oxygen
825455|NCT02999165|preterm neonate
825456|NCT02999152|Bio-markers
825457|NCT02999152|Radiation
825458|NCT02999152|Appropriate therapeutic strategy
825459|NCT02999152|Total Body Irradiation
825460|NCT02999152|Partial Body Irradiation
825461|NCT02999139|Injury
825462|NCT02999139|Prevention
825463|NCT02999126|Total Intravenous Anesthesia
825464|NCT02999126|Titration
825465|NCT02999126|Target Controlled Infusion
825466|NCT02999126|Propofol
825467|NCT02999126|Bispectral index
825475|NCT02999087|Head and Neck cancer
825476|NCT02999087|Immunotherapy
825477|NCT02999074|exercise
825478|NCT02999074|resistance training
825479|NCT02999074|aerobic training
825480|NCT02999074|breast cancer
825481|NCT02999074|neoadjuvant chemotherapy
825482|NCT02999074|fatigue
825483|NCT02999074|quality of life
825484|NCT02999074|tumor response
825485|NCT02999061|pre-term children
825486|NCT02999048|panax notoginseng saponins
825487|NCT02999048|hypertensive intracerebral hemorrhage
825488|NCT02999048|hematoma
825489|NCT02999048|neurological function
825490|NCT02999035|ocular surface sensitivity
825491|NCT02999022|bone fractures
825492|NCT02999022|bony callus
825493|NCT02999022|fractures, bone
825494|NCT02999022|lithium
825495|NCT02999022|lithium carbonate
825496|NCT02999022|osteogenesis
825497|NCT02999022|bone development
825498|NCT02999022|fracture healing
825499|NCT02999022|fracture repair
825500|NCT02998970|Cardiovascular Disease
825501|NCT02998970|Type 2 Diabetes
825502|NCT02998970|Cardiac Magnetic Resonance Imaging
825503|NCT02998957|Acupuncture
825504|NCT02998957|TENS
825505|NCT02998957|Physiotherapy
825506|NCT02998931|Glutamin
825507|NCT02998931|Enteral Nutrition
825508|NCT02998931|Intensive Care Unit
825509|NCT02998931|Critical Care Outcomes
825510|NCT02998931|inflammatory
825511|NCT02998931|Immune System
825512|NCT02998918|Inflammation
825513|NCT02998918|HDL
825514|NCT02998918|Anti-inflammatory
825515|NCT02998918|Supplementation
825516|NCT02998918|Curcumin
825517|NCT02998918|polyphenol
825518|NCT02998918|V-cam
825519|NCT02998918|I-cam
825520|NCT02998918|atherosclerosis
825521|NCT02998918|cardiovascular disease
825522|NCT02998918|atherogenesis
825523|NCT02998918|antioxidant
825524|NCT02998918|resveratrol
825525|NCT02998918|quercetin
825526|NCT02998892|Sedentary Behavior
825527|NCT02998866|Cryoballoon Pulmonary Vein Isolation
825528|NCT02998866|Esophageal Effects
825529|NCT02998853|Non culprit
825530|NCT02998853|STEMI PCI
825531|NCT02998853|angio QFR
825532|NCT02998853|FFR
825533|NCT02998853|Staged procedure
825535|NCT02998814|fissure sealant
825536|NCT02998814|etch and rinse
825537|NCT02998814|self etch
825538|NCT02998788|heart failure
825539|NCT02998788|risk factor
825540|NCT02998788|cardiovascular disease
825541|NCT02998788|lifestyle behavior
825542|NCT02998775|in vitro protein binding
825543|NCT02998775|hepatic impairment
825544|NCT02998775|renal impairment
825545|NCT02998762|major depression
825546|NCT02998762|major depressive disorder
825547|NCT02998762|biomarkers
825548|NCT02998762|MDD
825549|NCT02998762|long term follow up
825550|NCT02998736|Colon
825551|NCT02998723|Basic Life Support
825552|NCT02998723|Education, Medical
825553|NCT02998723|Cardiopulmonary Resuscitation
825554|NCT02998723|Learning
825555|NCT02998697|Systolic Heart Failure
825556|NCT02998697|Anemia
825557|NCT02998697|Iron Deficiency
825558|NCT02998684|Autism
825559|NCT02998684|Adolescent
825560|NCT02998684|Social skills
825561|NCT02998671|Acne, inflammatory acne, efficacy, safety, PK
825562|NCT02998658|Laparoscopy
825563|NCT02998658|Barbed sutures
825564|NCT02998658|Hysterectomy
825565|NCT02998645|severe acquired aplastic anemia
825566|NCT02998645|SAA
825567|NCT02998645|first line
825568|NCT02998645|eltrombopag
825569|NCT02998645|cyclosporine
825570|NCT02998645|h-ATG
825571|NCT02998645|severe aplastic anemia
825572|NCT02998645|aplastic anemia
825573|NCT02998593|Semen parameters Male infertility oligospermia Traditional Medicine
825574|NCT02998580|late-life depression
825575|NCT02998580|treatment resistance
825576|NCT02998515|supplemental oxygen
825577|NCT02998515|concentrator
825578|NCT02998515|endurance shuttle walk test
825579|NCT02998502|Obsessive Compulsive Disorder (OCD)
825580|NCT02998502|Anxiety
825581|NCT02998502|Pediatrics
825582|NCT02998489|enteral nutrition
825583|NCT02998489|infant,premature
825584|NCT02998489|feeding method
825585|NCT02998476|Diffuse large B-cell lymphoma
825586|NCT02998476|relapsed
825587|NCT02998476|refractory
825588|NCT02998476|non-Hodgkin lymphoma
825589|NCT02998476|phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor
825590|NCT02998476|Bruton's tyrosine kinase (BTK)
825591|NCT02998463|Skin-to-skin
825592|NCT02998463|Kangaroo Care
825593|NCT02998463|Kangaroo Mother Care
825594|NCT02998450|Sickle Cell Disease
825595|NCT02998450|Sickle Beta 0 Thalassemia
825596|NCT02998424|propofol
825597|NCT02998424|pupillary diameter
825598|NCT02998411|anti-infectives
825599|NCT02998411|adults
825600|NCT02998411|pharmacokinetic
825601|NCT02998411|pharmacodynamic end-points
825602|NCT02998411|clinical cure
825603|NCT02998398|Biosimilar
825604|NCT02998385|salivary glands
825605|NCT02998385|sinus carcinoma
825606|NCT02998385|radiochemotherapy concomitant
825607|NCT02998385|cisplatin
825608|NCT02998346|Nutrition
825609|NCT02998346|CRRT
825610|NCT02998346|CVVH
825611|NCT02998346|citrate
825612|NCT02998346|anticoagulation
825613|NCT02998346|caloric uptake
825614|NCT02998333|Instability
825615|NCT02998333|Ankle
825616|NCT02998333|Surgical stabilization
825617|NCT02998281|cerebral palsy
825618|NCT02998281|inspiratory muscle training
825619|NCT02998255|PEG
825620|NCT02998255|Bowel preparation
825621|NCT02998255|Colonoscopy
825622|NCT02998203|organic diet
825623|NCT02998203|health
825624|NCT02998203|pesticides
825625|NCT02998203|inflammation biomarkers
825626|NCT02998203|oxidative stress biomarkers
825627|NCT02998177|Postoperative pain
825628|NCT02998177|Rebound pain
825629|NCT02998177|Gut microbiome
825630|NCT02998177|Gut microbiota
825631|NCT02998177|Peripheral nerve block
825632|NCT02998177|Axillary brachial plexus block
825633|NCT02998138|Chronic Pain
825634|NCT02998138|Pain, Postoperative
825635|NCT02998112|fecal microbiota transplantation
825636|NCT02998112|Ulcerative colitis
825637|NCT02998099|Healthy Volunteers
825638|NCT02998099|Rivipansel
825639|NCT02998060|Robot
825640|NCT02998060|Spinal Fusion
825641|NCT02998060|Spine
825642|NCT02998060|Navigation
825643|NCT02998060|Freehand
825644|NCT02998008|Exercise Therapy
825645|NCT02998008|Heart Function Tests
825646|NCT02998008|Heart/physiology
825647|NCT02998008|Echocardiography
825648|NCT02997995|T2-T4 Breast cancer
825649|NCT02997995|Estrogen Receptor Positive Tumor
825650|NCT02997995|PD-1
825651|NCT02997995|Neoadjuvant
825652|NCT02997995|Immune-attractants
825653|NCT02997995|lymphocytes activation
825654|NCT02997982|Alzheimer's Disease
825655|NCT02997982|Herpes Simplex Virus
825656|NCT02997982|HSV
825657|NCT02997982|Antiviral Drugs
825658|NCT02997969|HIV
825659|NCT02997943|Obesity
825660|NCT02997943|Weight Loss
825661|NCT02997943|Diet
825662|NCT02997943|Physical Activity
825663|NCT02997943|Mobile Health
825664|NCT02996864|college students
825665|NCT02996864|physical activity
825666|NCT02996864|sleep behaviors
825667|NCT02996864|diet
825668|NCT02997891|cognition
825669|NCT02997891|hip replacement
825670|NCT02997891|physical activity
825671|NCT02997891|quality of life
825672|NCT02997891|psychological distress
825673|NCT02997878|autoimmune
825674|NCT02997878|AiH
825675|NCT02997878|PSC
825676|NCT02997878|liver disease
825677|NCT02997878|cholangitis
825678|NCT02997865|heart failure
825679|NCT02997865|depressive disorder, major
825680|NCT02997865|cognitive therapy
825681|NCT02997865|antidepressive agents
825682|NCT02997865|self-care
825683|NCT02997852|human-animal interaction
825684|NCT02997787|adenomyosis
825685|NCT02997787|leiomyoma
825686|NCT02997787|neutrophil to lymphocyte ratio
825687|NCT02997787|platelet to lymphocyte ratio
825688|NCT02997748|acute kidney injury
825689|NCT02997748|cardiac surgery
825690|NCT02997748|Remote ischemic preconditioning
825691|NCT02997748|[TIMP-2]*[IGFBP7]
825692|NCT02997735|Secondhand Smoke
825693|NCT02997735|Nicotine Replacement Therapy
825694|NCT02997735|Clinical Decision Support
825695|NCT02997735|Tobacco quitline
825696|NCT02997722|ketamine
825697|NCT02997722|suicide
825698|NCT02997709|Prostate Cancer
825699|NCT02997709|Circulating Tumor Cells
825700|NCT02997709|CTCs
825701|NCT02997709|Androgen Deprivation Therapy
825702|NCT02997709|ADT
825703|NCT02997670|Cardiac resynchronization pacing therapy
825704|NCT02997644|patient education
825705|NCT02997644|orthopaedic surgery
825706|NCT02997644|post-surgical pain
825707|NCT02997644|chronic opioid use
825708|NCT02997631|Pain Management
825709|NCT02997631|Distraction Therapy
825710|NCT02997631|Robot Based Distraction
825711|NCT02997631|MEDi
825712|NCT02997605|low disease activity
825713|NCT02997605|remission
825714|NCT02997566|Autonomic Nervous System
825715|NCT02997566|Sympathetic Nervous System
825716|NCT02997566|Heart Rate
825717|NCT02997553|Indocyanine green (ICG)
825718|NCT02997553|Sentinel lymph node biopsy
825719|NCT02997553|Technetium99
825720|NCT02997553|Tumors
825721|NCT02997553|Optonuclear probe
825722|NCT02997553|Surgery
825723|NCT02997540|female breast lesion
825724|NCT02997540|ultrasound examination
825725|NCT02997514|Solution focused coaching
825726|NCT02997514|Self determination
825727|NCT02997488|videolaryngoscope
825728|NCT02997475|Bulimia Nervosa
825729|NCT02997475|Bulimia
825730|NCT02997475|fMRI
825731|NCT02997475|Emotion Regulation
825732|NCT02997475|Response Inhibition
825733|NCT02997462|Monocyte
825734|NCT02997462|Oxidative Stress
825735|NCT02997462|Endothelial Function
825736|NCT02997462|Congestive Heart Failure
825737|NCT02997449|Non-Small Cell Lung Cancer (NSCLC)
825738|NCT02997449|Stereotactic ablative radiotherapy (SABR)
825739|NCT02997449|Intrathoracic nodal staging
825740|NCT02997423|Glioblastoma Multiforme
825741|NCT02997423|Biomarker
825742|NCT02997423|Cytochrome C Oxidase
825743|NCT02997423|Newly diagnosed
825744|NCT02997410|Ozone
825745|NCT02997371|Traumatic brain injury
825746|NCT02997371|Microdialysis
825747|NCT02997371|Interleukin-1 receptor antagonist
825748|NCT02997371|Magnetic Resonance Imaging
825749|NCT02997371|Positron Emission Tomography
825750|NCT02997345|PPROM
825751|NCT02997319|Diabetes Mellitus, Type 2
825752|NCT02997319|Insulin Resistance
825753|NCT02997319|Shift Work
825754|NCT02997319|Circadian Rhythms
825755|NCT02997319|MTNR1B
825756|NCT02997306|Moh's Surgery
825757|NCT02997306|Erythema
825758|NCT02997306|Face
825759|NCT02997306|Simple Interrupted Sutures
825760|NCT02997306|Running Sutures
825761|NCT02997306|Image Processing
825762|NCT02997280|acute graft-versus-host disease
825763|NCT02997280|chronic graft-versus-host disease
825764|NCT02997280|Steroid-refractory GVHD
825765|NCT02997280|ruxolitinib
825766|NCT02997280|JAK inhibitors
825767|NCT02997254|atrial fibrillation
825768|NCT02997254|ablation
825769|NCT02997254|abnormal heart rhythm
825770|NCT02997241|Colonic Neoplasms
825771|NCT02997241|recurrence
825772|NCT02997215|intravenous lidocaine
825773|NCT02997215|postoperative pain management
825778|NCT02997150|Idiopathic nephrotic syndrome-child-steroid dependant-IL2
825779|NCT02997150|Safety
825780|NCT02997150|Efficacy
825781|NCT02997137|Chronic psychological distress
825782|NCT02997137|Chronic exhaustion conditions
825783|NCT02997137|Perceived Stress Questionnaire 30 (PSQ30)
825784|NCT02997137|Stress management
825785|NCT02997137|Dietary supplement
825786|NCT02997124|Alveolar bone grafting
825787|NCT02997124|delirium
825788|NCT02997124|early ambulation
825789|NCT02997098|Hepatectomy
825790|NCT02997085|Pain
825791|NCT02997085|Virtual Reality
825792|NCT02997085|Opioid
825793|NCT02997085|Prescription pain reliever
825794|NCT02997085|Treatment
825795|NCT02997072|electrical impedance tomography
825796|NCT02997072|high frequency jet ventilation
825797|NCT02997072|drive pressure
825798|NCT02997059|Crohn disease
825799|NCT02997059|Candida
825800|NCT02997059|ASCA
825801|NCT02997046|Ferumoxytol
825802|NCT02997046|MRI
825803|NCT02997046|fistula
825804|NCT02997046|graft
825805|NCT02997046|kidney transplant
825806|NCT02997046|angiography
825807|NCT02997046|arteriovenous
825808|NCT02997033|Bone
825809|NCT02997033|Sex steroids
825810|NCT02997033|Body composition
825811|NCT02997033|Men
825812|NCT02997007|tDCS
825813|NCT02997007|Mild Cognitive Impairment
825814|NCT02997007|fMRI
825815|NCT02997007|Healthy ageing
825816|NCT02996955|Low Back Pain
825817|NCT02996955|Social Support
825818|NCT02996955|Illness Perceptions
825819|NCT02996955|Activity Advice
825820|NCT02996942|haemophilia, joint disease, quality of life
825821|NCT02996903|Cardiac Computed Tomography (CT) Angiography (CCTA)
825822|NCT02996903|coronary artery disease
825823|NCT02996903|malignancy induction
825824|NCT02996903|radiation dose
825825|NCT02996903|dose saving techniques
825826|NCT02996903|effective dose
825827|NCT02996851|Fibrinolytic Agents
825828|NCT02996851|Adverse effects
825829|NCT02996851|Norway
825830|NCT02996851|Registries
825831|NCT02996812|Post-bariatric hypoglycemia
825832|NCT02996812|Non-insulinoma pancreatogenous hypoglycemia syndrome
825833|NCT02996812|Late dumping syndrome
825834|NCT02996773|high-risk malignancies
825835|NCT02996773|Lymphoma
825836|NCT02996773|Haploidentical
825837|NCT02996773|Bone Marrow Transplant (BMT)
825838|NCT02996773|Post-transplant
825839|NCT02996773|myeloablative (MAC)
825840|NCT02996773|reduced intensity conditioning (RIC)
825841|NCT02996773|haploidentical hematopoietic cell transplantation (HHCT)
825842|NCT02996773|Leukemia
825843|NCT02996747|bone tumors
825844|NCT02996747|chondroma
825845|NCT02996747|chondrosarcoma
825846|NCT02996734|bone tumors
825847|NCT02996734|giant cell tumor
825848|NCT02996734|treatment
825849|NCT02996708|Telemedicine
825850|NCT02996708|Health economics
825851|NCT02996695|Chemoprophylaxis
825852|NCT02996695|Chloroquine
825853|NCT02996695|Cryopreserved
825854|NCT02996695|Malaria
825855|NCT02996695|Plasmodium
825856|NCT02996695|Sporozoites
825857|NCT02996682|Communicable Diseases
825858|NCT02996682|Hepatitis
825859|NCT02996682|Hepatitis C
825860|NCT02996682|Virus Diseases
825861|NCT02996682|Liver Diseases
825862|NCT02996682|Digestive System Diseases
825863|NCT02996682|Hepatitis, Viral, Human
825864|NCT02996682|Velpatasvir
825865|NCT02996682|Flaviviridae Infections
825866|NCT02996682|RNA Virus Infections
825867|NCT02996682|Ribavirin
825868|NCT02996682|Sofosbuvir
825869|NCT02996682|Antiviral Agents
825870|NCT02996682|Antimetabolites
825871|NCT02996682|Molecular Mechanisms of Pharmacological Action
825872|NCT02996682|Anti-Infective Agents
825873|NCT02996682|Decompensated Cirrhosis
825874|NCT02996643|Adolescent Idiopathic Scoliosis
825875|NCT02996643|Brace Treatment
825876|NCT02996643|Ultrasound Imaging
825877|NCT02996630|LVOTO
825878|NCT02996630|Fallot
825879|NCT02996630|Great Arteries Transposition
825880|NCT02996617|Lymphomas Non-Hodgkin's B-Cell
825881|NCT02996617|Lymphomas Non-Hodgkin's T-Cell
825882|NCT02996617|PEG-rhG-CSF
825883|NCT02996617|Neutropenia
825884|NCT02996604|acupuncture
825885|NCT02996604|functional dyspepsia
825886|NCT02996604|functional magnetic resonance imaging (fMRI)
825887|NCT02996591|Nerve Block
825888|NCT02996591|General Anesthesia
825889|NCT02996591|Spinal Anesthesia
825890|NCT02996591|Pain
825891|NCT02996591|Postoperative Nausea and Vomiting
825892|NCT02996578|Cognition
825893|NCT02996578|Cacao
825894|NCT02996578|Flavan-3-ols
825895|NCT02996578|Blood Pressure
825896|NCT02996578|hemoglobin A1c protein, human
825897|NCT02996578|Memory
825898|NCT02996565|Clinic care
825899|NCT02996565|Team-based care
825900|NCT02996565|Medication Therapy Management (MTM)
825901|NCT02996565|Telehealth
825902|NCT02996565|Cluster-randomized
825903|NCT02996565|Home blood pressure monitoring
825904|NCT02996565|Pharmacist
825905|NCT02996552|Tricuspid annulus dilation
825906|NCT02996552|mitral valve regurgitation
825907|NCT02996526|vocal cord palsy dysfunction thoracic surgery complication
825908|NCT02996513|Vitamin A status
825909|NCT02996513|Retinol Isotope Dilution
825910|NCT02996513|Nigeria
825911|NCT02996513|Preschool children
825912|NCT02996513|Malaria
825913|NCT02996513|Inflammation
825917|NCT02996461|Zika Infection
825918|NCT02996461|Immune Response
825919|NCT02996461|Flavivirus
825920|NCT02996461|Arthropod-Borne Virus
825921|NCT02996448|AD-HIES
825922|NCT02996448|Anti-rAls3 Antibody
825923|NCT02996448|Staphylococcus Aureus
825924|NCT02996448|Candida Albicans
825925|NCT02996448|RNA Transcriptome
825926|NCT02996396|AAA, Aortoiliac Aneurysm
825927|NCT02996383|arthroplasty
825928|NCT02996370|esthetic
825929|NCT02996370|inter-implant papilla
825930|NCT02996370|soft tissue tickness
825931|NCT02996370|crestal bone loss
825932|NCT02996370|second stage surgery
825933|NCT02996357|Incontinence-associated dermatitis
825934|NCT02996357|Risk factor
825935|NCT02996357|Intensive care unit
825936|NCT02996357|Prevention
825937|NCT02996292|Crowding
825938|NCT02996292|Self ligating
825939|NCT02996292|CBCT
825940|NCT02996292|RCT
825941|NCT02996279|Neonate
825942|NCT02996279|Chorioamnionitis
825943|NCT02996279|S100A12
825944|NCT02996266|Targeted Temperature Management
825945|NCT02996175|Behavior
825946|NCT02996175|Sleep
825947|NCT02996175|Problems
825948|NCT02996175|Intervention
825949|NCT02996162|Bronchopulmonary Dysplasia
825950|NCT02996162|Chronic Lung Disease
825951|NCT02996162|Prematurity
825952|NCT02996084|Imaging research
825953|NCT02995980|breast cancer screening
825954|NCT02995980|dense breasts
825955|NCT02995980|dual-energy contrast-enhanced digital mammography
825956|NCT02995954|Combination therapy
825957|NCT02995954|ACE inhibitor Calcium Antagonist
825958|NCT02995941|reliability
825959|NCT02995941|validity
825960|NCT02995941|classification
825961|NCT02995941|irritability
825962|NCT02995941|symptom
825963|NCT02995941|intensity
825964|NCT02995941|intervention
825965|NCT02995928|Subarachnoid Hemorrhage
825966|NCT02995928|Decompressive Craniectomy
825967|NCT02995928|Cerebral Aneurysm
825968|NCT02995837|Obstructive Sleep Apnea Syndrome
825969|NCT02995837|Cerebral Blood Flow
825970|NCT02995837|Neurocognition
825971|NCT02995824|Liver transplantation
825972|NCT02995824|HIV infection
825973|NCT02995824|Antiretroviral therapy
825974|NCT02995824|Raltegravir
825975|NCT02995785|Simulation
825976|NCT02995707|Thalidomide NTDT
825977|NCT02995681|COPD
825978|NCT02995681|Falls
825979|NCT02995681|Balance training
825980|NCT02995642|Aortic Aneurysm, Abdominal
825981|NCT02995642|Carotid Stenosis
825982|NCT02995642|Atherosclerosis
825983|NCT02995642|Angiogenesis
825984|NCT02995642|Inflammation
825985|NCT02995642|Macrophages
825986|NCT02995642|Positron-Emission Tomography
825987|NCT02995642|Computerized tomography
825988|NCT02995642|Magnetic Resonance Imaging
825989|NCT02995642|(18F)FPP(RGD)2
825990|NCT02995616|Robot-Assisted Gait Training
825991|NCT02995616|Guidance force
825992|NCT02995616|Stroke
825993|NCT02995616|Energy Consumption
825994|NCT02995616|Cardiorespiratory Load
825995|NCT02995564|Social Skills
825996|NCT02995564|Asperger's
825997|NCT02995564|High-functioning autism
825998|NCT02995564|Young adults
825999|NCT02995551|Menisci, Tibial
826000|NCT02995551|Knee Injuries
826001|NCT02995551|Arthroscopy
826002|NCT02995551|Exercise
826003|NCT02995551|Young adults
826004|NCT02995551|Treatment Outcome
826005|NCT02995551|Humans
826006|NCT02995512|myocardial infarction
826007|NCT02995512|colchicine
826008|NCT02995512|anti-inflammatory
826009|NCT02995499|ASA-PS classification
826010|NCT02995499|inter-rater reliability
826011|NCT02995499|general surgery
826012|NCT02995473|Psoriasis
826013|NCT02995460|Exercise Therapy
826014|NCT02995447|propofol
826015|NCT02995447|electroencephalogram
826016|NCT02995434|Virtual Reality
826017|NCT02995434|Cancer Survivorship
826018|NCT02995434|Pain Management
826019|NCT02995434|Cancer Pain Management
826020|NCT02995434|Chronic Pain Management
826021|NCT02995434|Adjunctive Pain Management
826022|NCT02995408|resiliency training
826023|NCT02995408|parenting
826024|NCT02995408|Autism Spectrum Disorders
826025|NCT02995369|Sealants
826026|NCT02995369|Dryshield
826027|NCT02995369|Cotton roll
826028|NCT02995369|Isolation
826029|NCT02995369|Efficiency
826030|NCT02995369|Preference
826031|NCT02995356|Ectopic pregnancy
826032|NCT02995356|Axonemal Dynein Heavy Chain 5
826033|NCT02995356|Creatine Kinase
826034|NCT02995356|Cervical fluid
826035|NCT02995330|Metastatic Castration-Resistant Prostate Cancer
826036|NCT02995330|Bone Marrow Transplantation
826037|NCT02995317|Aged
826038|NCT02995317|Gait
826039|NCT02995317|Postural Balance
826040|NCT02995317|Accelerometry
826041|NCT02995317|Physical Activity
826042|NCT02995265|Exoskeleton
826043|NCT02995265|Stroke
826044|NCT02995265|Walking
826045|NCT02995265|Rehabilitation
826046|NCT02995187|Apatinib
826047|NCT02995187|Third-line and Later Therapy
826048|NCT02995187|Small Cell Lung Cancer
826049|NCT02995174|amblyopia
826050|NCT02995174|fixation stability
826051|NCT02995174|perceptual learning
826052|NCT02995083|osteoarthritis
826053|NCT02995057|Microneedles
826054|NCT02995057|Biocompatibility
826055|NCT02995057|Allergy
826056|NCT02995057|Metal
826057|NCT02995057|Nickel
826058|NCT02995057|Contact dermatitis
826059|NCT02995005|mother to child transmission
826060|NCT02995005|hepatitis B
826061|NCT02995005|tenofovir
826062|NCT02994953|Avelumab
826063|NCT02994953|M9241
826064|NCT02994953|NHS-IL12
826065|NCT02994953|Advanced Solid Tumors
826066|NCT02994927|ANCA-associated vasculitis
826067|NCT02994927|complement
826068|NCT02994927|vasculitis
826069|NCT02994927|C5aR
826070|NCT02994927|avacopan
826071|NCT02994927|CCX168
826072|NCT02994914|Breast Cancer
826073|NCT02994914|Onco Geriatric Evaluation
826074|NCT02994914|Radiotherapy
826075|NCT02994914|Hypo fractionated radiotherapy
826076|NCT02994914|Normo fractionated radiotherapy
826077|NCT02994914|Large hypo fractionated radiotherapy
826078|NCT02994901|Sarcopenia
826079|NCT02994901|Geriatrics
826080|NCT02994901|Biomarker
826081|NCT02994836|Crohn's Disease
826082|NCT02994836|Inflammatory bowel disease
826083|NCT02994836|Anti-TNF discontinuation
826084|NCT02994836|Ulcerative colitis
826085|NCT02994810|Breastfeeding
826086|NCT02994810|Orientation
826087|NCT02994797|salivary glands
826088|NCT02994797|ultrasonography
826089|NCT02994797|elastometry
826090|NCT02994797|elastography
826091|NCT02994771|Lymphedema, Breast cancer
826092|NCT02994758|Prostate
826093|NCT02994758|bladder
826094|NCT02994758|renal
826095|NCT02994758|NGS
826096|NCT02994758|DSRT
826097|NCT02994758|drug screening
826098|NCT02994758|sequencing
826099|NCT02994758|personalised medicine
826106|NCT02994641|critical care
826107|NCT02994641|patient discharge
826108|NCT02994641|costs and cost analysis
826109|NCT02994641|length of stay
826110|NCT02994641|hospital mortality
826111|NCT02994628|oxidative stress
826112|NCT02994628|immune function
826113|NCT02994628|muscle damage
826114|NCT02994628|carbohydrate
826115|NCT02994628|polyphenols
826116|NCT02994628|cycling
826117|NCT02994615|Index of Microvascular Resistance
826118|NCT02994615|Microvascular dysfunction
826119|NCT02994602|Healthy Men
826120|NCT02994602|Male Contraception
826121|NCT02994602|Healthy Women
826122|NCT02994602|Transfer
826123|NCT02994602|Transference
826124|NCT02994602|Gel
826125|NCT02994602|Nestorone
826126|NCT02994602|Testosterone
826127|NCT02994550|FSH
826128|NCT02994550|LH
826129|NCT02994550|IVF
826130|NCT02994511|Circulating tumour DNA
826131|NCT02994511|ctDNA
826132|NCT02994420|Obesity
826133|NCT02994420|Menstrual Cycle
826134|NCT02994420|Gonadal Steroid Hormones
826135|NCT02994420|Satiety Response
826136|NCT02994420|Glucagon-Like Peptide 1
826137|NCT02994420|Cholecystokinin
826138|NCT02994420|Magnetic Resonance Imaging
826139|NCT02994381|Healthy Male Adults
826140|NCT02994381|14C
826141|NCT02994381|RPC1063
826142|NCT02994368|retinal degeneration
826143|NCT02994368|eye
826144|NCT02994368|REP-1 gene
826145|NCT02994355|Family planning clinics
826146|NCT02994355|Implementation Science
826147|NCT02994355|Systems Analysis and Improvement Approach (SAIA)
826152|NCT02994329|HIV testing
826153|NCT02994329|Linkage to care
826154|NCT02994303|Fabry disease
826155|NCT02994303|Fabry nephropathy
826156|NCT02994303|end-stage renal disease
826157|NCT02994277|"Artificial Pancreas"
826158|NCT02994277|"control System"
826159|NCT02994277|"Closed loop"
826160|NCT02994277|diabetes
826161|NCT02994277|"T1DM"
826162|NCT02994277|"pump"
826163|NCT02994277|algorithm
826164|NCT02994277|CGM
826165|NCT02994199|Active video gaming
826166|NCT02994199|Energy expenditure
826167|NCT02994186|cognitive function
826168|NCT02994186|obesity
826169|NCT02994186|bariatric surgery
826170|NCT02994186|metabolic surgery
826171|NCT02994160|peripheral nerve
826172|NCT02994160|intraneural electrode
826173|NCT02994160|hand amputation
826174|NCT02994108|Human Papillomavirus
826175|NCT02994108|Men Who Have Sex with Men
826176|NCT02994082|Rural health
826177|NCT02994082|Veterans
826178|NCT02994082|Smokeless tobacco cessation
826179|NCT02994069|Cisplatin
826180|NCT02994069|Squamous Cell
826181|NCT02994069|Carcinoma
826182|NCT02994030|neuromuscular disorder
826183|NCT02994017|cystic fibrosis
826184|NCT02994017|Cardiopulmonary exercise testing
826185|NCT02994017|prognostic
826186|NCT02994004|Hospital, medical decision-making, role conflict, f-MRI
826187|NCT02993978|Pediatric radiotherapy
826188|NCT02993926|Drug Therapy
826189|NCT02993887|Caregiver
826190|NCT02993887|Technology Dependent Children
826191|NCT02993887|Resourcefulness
826192|NCT02993887|Mindfulness
826196|NCT02993848|Scapula
826197|NCT02993848|Fracture
826198|NCT02993796|Krabbe disease
826199|NCT02993796|globoid cell leukodystrophy
826200|NCT02993796|galactosylceramide lipidosis
826201|NCT02993796|sphingolipidosis
826202|NCT02993783|Drug Therapy
826209|NCT02993744|preterm birth
826210|NCT02993744|corticosteroids
826211|NCT02993744|inflammatory parameters
826212|NCT02993744|betamethasone
826213|NCT02993744|leukocytes
826214|NCT02993731|Neoplasms
826215|NCT02993731|Neoplasms by Site
826216|NCT02993731|Digestive System Neoplasms
826217|NCT02993731|Endocrine Gland Neoplasms
826218|NCT02993731|Pancreatic Neoplasms
826219|NCT02993731|Adenocarcinoma
826220|NCT02993731|Neoplasms, Glandular and Epithelial
826221|NCT02993731|Neoplasms by Histologic Type
826222|NCT02993731|Digestive System Diseases
826223|NCT02993731|Pancreatic Diseases
826224|NCT02993731|Endocrine System Diseases
826225|NCT02993731|Albumin-Bound Paclitaxel
826226|NCT02993731|Gemcitabine
826227|NCT02993692|direct laryngoscopy
826228|NCT02993692|fiberopitc bronchoscopy
826229|NCT02993692|nasotracheal intubation
826230|NCT02993640|vasopressin
826231|NCT02993640|nitroglycerine
826232|NCT02993640|portal pressure
826233|NCT02993640|portal flow
826234|NCT02993627|obesity
826235|NCT02993627|BMI
826236|NCT02993627|body weight
826237|NCT02993601|Heart Failure
826238|NCT02993601|Edema
826239|NCT02993601|Oedema
826240|NCT02993601|Decompensated Heartfailure
826241|NCT02993588|Melatonin
826242|NCT02993588|IVF/ICSI
826243|NCT02993588|Poor ovarian response
826244|NCT02993575|Pharmacokinetics
826245|NCT02993575|Flucloxacillin
826246|NCT02993575|Continuous infusion
826247|NCT02993575|Intensive Care Unit
826248|NCT02993562|Food intake
826249|NCT02993562|Resting Energy Expenditure
826250|NCT02993562|Gall Bladder emptying
826251|NCT02993562|Insulin response
826252|NCT02993562|Body Composition
826257|NCT02993510|microfracture
826258|NCT02993510|enhanced marrow stimulation
826259|NCT02993510|articular cartilage
826260|NCT02993510|Autologous Matrix-Induced Chondrogenesis
826261|NCT02993510|Chondro-Gide®
826262|NCT02993510|knee surgery
826263|NCT02993510|AMIC
826264|NCT02993458|dietary patterns
826265|NCT02993458|blood pressure
826266|NCT02993458|adolescents
826267|NCT02993458|dietary sodium
826268|NCT02993393|Simulation Training [I02.903.847]
826269|NCT02993393|Problem-Based Learning [F02.463.425.720]
826270|NCT02993380|Olive oil
826271|NCT02993380|Erythrocyte membrane fatty acid contents
826272|NCT02993380|Oleic acid
826273|NCT02993367|Butylphthalide Soft Capsules
826274|NCT02993367|VCIND
826275|NCT02993367|fMRI
826276|NCT02993302|vitamin D
826277|NCT02993302|graves' disease
826278|NCT02993302|dendritic cells
826279|NCT02993224|thalassemia
826280|NCT02993224|TDT
826281|NCT02993224|transfusion-dependent
826282|NCT02993224|non-transfusion-dependent
826283|NCT02993224|NTDT
826284|NCT02993211|Bladder cancer
826285|NCT02993211|Transurethral resection
826286|NCT02993211|En bloc resection
826287|NCT02993211|TURBT
826288|NCT02993185|pregnancy
826289|NCT02993185|adolescents
826290|NCT02993185|sexually transmitted diseases
826291|NCT02993185|decision making
826292|NCT02993185|prevention education
826293|NCT02993107|AR101
826294|NCT02993107|Characterized Peanut Allergen
826295|NCT02993107|CPNA (Characterized Peanut Allergen)
826296|NCT02993107|OIT (oral immunotherapy)
826297|NCT02993107|Peanut Allergy
826298|NCT02993107|Allergy
826299|NCT02993107|Peanut-Allergic Children
826300|NCT02993107|Peanut-Allergic Adults
826301|NCT02993107|Desensitization
826302|NCT02993107|PALISADE
826303|NCT02993094|breast cancer
826304|NCT02993094|advanced triple negative
826305|NCT02993094|ixazomib
826306|NCT02993094|carboplatin
826307|NCT02993094|CARIXA
826308|NCT02993094|Study Group of Medical Tumor Therapy (AGMT)
826309|NCT02993081|YAG laser
826310|NCT02993068|Genetic testing
826311|NCT02993068|Genetic educational video
826312|NCT02993068|Genetic counseling
826313|NCT02993068|Online genetic test results
826314|NCT02993068|Telephone genetic counseling
826315|NCT02993068|Saliva test
826316|NCT02993068|Questionnaires
826317|NCT02993068|Surveys
826318|NCT02993042|Rehabilitation
826319|NCT02993042|Robot-assisted gait training
826320|NCT02993029|99Tc-MDP
826321|NCT02993029|osteoarthritis
826322|NCT02993029|celecoxib
826323|NCT02992977|Vaccine, neoantigen
826324|NCT02992951|Infection
826325|NCT02992951|Surgical Site Infection
826326|NCT02992951|Dialkylcarbamoylchloride
826327|NCT02992938|Opioid hyperalgesia
826328|NCT02992938|Acetazolamide
826329|NCT02992938|Remifentanil
826330|NCT02992925|Haemophilus influenza type b
826331|NCT02992925|Adsorbed Diphteria-purified Pertussis-Tetanus-Inactivate poliovirus combined vaccine
826332|NCT02992925|Hib
826333|NCT02992925|DPT-IPV
826334|NCT02992899|stress disorders, post-traumatic
826335|NCT02992899|posttraumatic stress disorder
826336|NCT02992899|PTSD
826337|NCT02992899|vagal nerve
826338|NCT02992886|elderly patients
826339|NCT02992886|rectal cancer
826340|NCT02992886|preoperative chemoradiotherapy
826341|NCT02992886|comprehensive geriatric assessment
826342|NCT02992860|Myelodysplastic Syndrome (MDS)
826343|NCT02992860|Acute Myeloid Leukemia (AML)
826344|NCT02992860|hypomethylating agent (HMA) treatment
826345|NCT02992860|leukemic stem cell
826346|NCT02992860|CD123
826347|NCT02992860|immunotherapy
826348|NCT02992847|Multiple sclerosis
826349|NCT02992847|Gadolinium based contrast agent
826350|NCT02992847|MRI
826351|NCT02992847|Dentate nucleus
826352|NCT02992821|Hand-held
826353|NCT02992821|Ultrasound
826354|NCT02992821|Diagnosis
826355|NCT02992821|Carotid artery stenosis
826356|NCT02992808|IVF
826357|NCT02992808|Ovarian stimulation
826358|NCT02992808|Androgenic profile
826359|NCT02992808|Follicular fluid
826360|NCT02992808|Recombinant gonadotropins
826361|NCT02992808|human menopausal gonadotropin
826362|NCT02992769|Breast Cancer
826363|NCT02992769|Nomogram
826364|NCT02992769|Ultrasound
826365|NCT02992769|Axillary Metastases
826366|NCT02992743|Sarcoma
826367|NCT02992743|Cell Therapy
826368|NCT02992743|T Cell Therapy
826369|NCT02992743|NY-ESO-1
826370|NCT02992743|Immuno-oncology
826371|NCT02992743|Metastatic
826372|NCT02992743|Previously treated
826373|NCT02992743|T Cell Receptor
826374|NCT02992730|Medication Adherence
826375|NCT02992665|Calcium ionophore
826376|NCT02992665|Fertilization
826377|NCT02992665|Sperm
826378|NCT02992665|Oocyte
826379|NCT02992665|ICSI
826380|NCT02992639|High visceral fat
826381|NCT02992639|Liver enzymes
826382|NCT02992639|Aminotransferase
826383|NCT02992639|Mild calorie restriction
826384|NCT02992600|non-cardiac surgery
826385|NCT02992600|Postoperative Cognitive Dysfunction
826386|NCT02992574|Post-Mastectomy Radiation
826387|NCT02992574|Node Negative
826388|NCT02992574|Early breast Cancer
826389|NCT02992561|Aggression
826390|NCT02992561|Violence
826391|NCT02992561|Post-conflict reconstruction
826392|NCT02992561|Demobilization
826393|NCT02992561|Traumatized offenders
826394|NCT02992548|chronic kidney disease
826395|NCT02992548|pravastatin
826396|NCT02992548|erythrocyte membrane fatty acid
826397|NCT02992483|multiple myeloma
826398|NCT02992483|lymphoma
826399|NCT02992483|dlbcl
826400|NCT02992431|patient care planning
826401|NCT02992431|primary health care
826402|NCT02992431|comorbidity
826407|NCT02992392|Tear film
826408|NCT02992392|Lipid layer
826409|NCT02992392|Liposic
826410|NCT02992392|Tears Naturale Forte
826411|NCT02992379|Anterior disc displacement
826412|NCT02992379|Stabilizing splint
826413|NCT02992366|socket shield
826414|NCT02992366|volumetric tissue alteration
826415|NCT02992366|immediate implant
826416|NCT02992353|VATS
826417|NCT02992353|NSCLC
826418|NCT02992353|recurrence rate
826419|NCT02992288|Chronic Heart Failure
826420|NCT02992288|Heart Failure with Reduced Ejection Fraction
826421|NCT02992275|Hip
826422|NCT02992275|Muscle
826423|NCT02992275|Skeletal/physiopathology
826424|NCT02992223|Aggressive B-cell non-Hodgkin Lymphoma
826425|NCT02992223|Relapsed
826426|NCT02992223|Refractory
826427|NCT02992223|Zevalin
826428|NCT02992223|Y90 Ibritumomab Tiuxetan
826429|NCT02992223|Autologous stem cell transplant
826430|NCT02992223|BEAM
826431|NCT02992223|Recurrent
826432|NCT02992210|CAR
826433|NCT02992210|chimeric antigen receptor
826434|NCT02992210|adoptive T cell transfer
826439|NCT02992184|HCV
826440|NCT02992184|Genedrive
826441|NCT02992184|Point of Care
826442|NCT02992119|safety
826443|NCT02992119|immunogenicity
826444|NCT02992106|Maternal Obesity
826445|NCT02992106|Endothelial Dysfunction
826446|NCT02992106|Childhood Obesity
826447|NCT02992093|Polycystic ovary syndrome
826448|NCT02992093|Metabonomics
826449|NCT02992093|Traditional Chinese medicine syndromes
826450|NCT02992080|Patient with Cystic Fibrosis
826451|NCT02992080|Patient without Cystic fibrosis
826452|NCT02992067|lymph node metastasis
826453|NCT02992067|breast cancer
826454|NCT02992067|CK19
826455|NCT02992067|contrast-enhanced ultrasonography
826456|NCT02992028|Rotator cuff repair
826457|NCT02992028|Vitamin C
826458|NCT02992028|postoperative pain
826459|NCT02991989|Home-based exercise
826460|NCT02991989|Exercise snacking
826461|NCT02991989|Protein
826462|NCT02991989|Yogurt
826463|NCT02991976|Normobaric hyperoxia
826464|NCT02991976|Cerebral oxygenation
826465|NCT02991976|Near-infrared spectroscopy
826466|NCT02991976|Carotid endarterectomy
826467|NCT02991976|TIVA
826468|NCT02991924|endobronchial ultrasound
826469|NCT02991924|EBUS-TBNA
826470|NCT02991924|lung cancer
826471|NCT02991924|staging
826472|NCT02991911|metastatic, prostate cancer
826473|NCT02991898|CML
826474|NCT02991898|MDS
826475|NCT02991898|CLL
826476|NCT02991872|Persistence
826477|NCT02991872|Purified chicken-embryo cell rabies vaccine
826478|NCT02991872|Rabies Virus Neutralizing Antibody (RVNA)
826479|NCT02991872|Immunogenicity
826480|NCT02991872|Post-Exposure Prophylaxis (PEP)
826481|NCT02991872|Rabipur
826482|NCT02991859|Dose-response
826483|NCT02991859|AMP challenge
826484|NCT02991859|cortisol suppression
826485|NCT02991859|dose escalation
826486|NCT02991859|therapeutic index
826487|NCT02991846|chronic graft-versus-host disease cGVHD
826488|NCT02991846|Hematopoietic stem cell transplantation HSCT
826489|NCT02991846|NIH consensus criteria
826490|NCT02991846|GITMO
826491|NCT02991833|urinary incontinence
826492|NCT02991833|care product
826493|NCT02991833|bowel incontinence
826494|NCT02991807|PTEN
826495|NCT02991807|PTEN Gene Mutation
826496|NCT02991807|PTEN Hamartoma Tumor Syndrome
826497|NCT02991807|Autism
826498|NCT02991807|Intellectual Disability
826499|NCT02991807|Neurocognition
826500|NCT02991807|Afinitor
826501|NCT02991807|Everolimus
826502|NCT02991807|RAD001
826508|NCT02991742|nephropathy
826509|NCT02991742|catheterization
826510|NCT02991742|contrast media
826511|NCT02991742|ioxaglate
826512|NCT02991742|iodixanol
826513|NCT02991742|high risk
826514|NCT02991742|prevention
826515|NCT02991729|Decision aid
826516|NCT02991703|Arterial stiffness
826517|NCT02991703|pulse wave velocity
826518|NCT02991703|Sphygmocor
826519|NCT02991703|applanation tonometry
826520|NCT02991703|pOpmètre
826521|NCT02991703|children
826522|NCT02991703|EPIPAGE cohort
826526|NCT02991677|exercise
826527|NCT02991677|neuropathy
826528|NCT02991664|glass ionomer cement
826529|NCT02991664|composite resin
826530|NCT02991651|RXR agonist IRX4204 erlotinib
826531|NCT02991599|Hepatitis B, Vaccine
826532|NCT02991599|Immunogenicity
826533|NCT02991599|methadone maintenance treatment
826534|NCT02991599|Randomized Controlled Trial
826535|NCT02991586|Emotional Instability
826536|NCT02991586|Family Therapy
826537|NCT02991586|BPD
826538|NCT02991586|DBT
826539|NCT02991560|physiotherapy
826540|NCT02991560|taping
826541|NCT02991560|conservative treatment
826542|NCT02991534|Patient Participation [N05.300.150.600.620]
826543|NCT02991534|Health Behavior [F01.145.488]
826544|NCT02991534|Women [M01.975]
826545|NCT02991534|Patient Satisfaction [N05.715.360.600]
826546|NCT02991534|Physicians, Primary Care [M01.526.485.810.800]
826547|NCT02991534|Physicians, Women [M01.526.485.810.820]
826548|NCT02991534|Health Educators [M01.526.485.410]
826549|NCT02991534|Cardiovascular Diseases [C14]
826550|NCT02991534|Hypertension [C14.907.489]
826551|NCT02991534|Hyperlipidemias [C18.452.584.500.500]
826552|NCT02991534|Dyslipidemias [C18.452.584.500]
826553|NCT02991534|Obesity [C18.654.726.500]
826554|NCT02991534|Diabetes Mellitus [C18.452.394.750]
826555|NCT02991534|Tobacco Use Disorder [C25.775.912]
826556|NCT02991534|Overweight [C23.888.144.699]
826557|NCT02991508|Adrecizumab
826558|NCT02991508|Phase 1 clinical trial
826559|NCT02991508|Adrenomedullin
826560|NCT02991508|Healthy volunteers
826561|NCT02991508|Monoclonal recombinant antibody
826562|NCT02991495|epidemic response
826563|NCT02991482|MPM
826564|NCT02991456|malignant glioma
826565|NCT02991456|temozolomide
826566|NCT02991456|temodar
826567|NCT02991456|radiation
826568|NCT02991456|emesis
826569|NCT02991456|nausea
826570|NCT02991456|vomiting
826571|NCT02991456|chemotherapy
826572|NCT02991456|Affronti
826573|NCT02991456|Peters
826574|NCT02991456|00076418
826575|NCT02991378|preschool children
826576|NCT02991378|emotional disorders/problems
826577|NCT02991378|stress related disorders/problems
826578|NCT02991378|early intervention
826579|NCT02991352|Vascular Malformations
826580|NCT02991352|Image Guidance
826581|NCT02991339|Dexamethasone
826582|NCT02991339|Liver Dysfunction
826583|NCT02991339|Hepatectomy
826584|NCT02991339|Bilirubinaemia
826585|NCT02991339|Jaundice
826586|NCT02991326|Osteopathic Manipulative Treatment
826587|NCT02991326|Temporomandibular Disorder
826588|NCT02991300|focal defect
826589|NCT02991300|focal lesion
826590|NCT02991300|chondral lesion
826591|NCT02991300|osteochondral lesion
826595|NCT02991196|Advanced colorectal cancer
826596|NCT02991196|DNA mismatch repair (MMR)
826597|NCT02991196|MMR-proficient Subjects
826598|NCT02991196|TRAIL-R2 (DR5) Antibody
826599|NCT02991183|Caregivers
826600|NCT02991183|Acceptance and Commitment Therapy
826601|NCT02991170|myocardial infarction
826602|NCT02991170|ventricular arrhythmia
826603|NCT02991170|radiofrequency ablation
826604|NCT02991170|Coronary Artery Bypass Grafts
826605|NCT02991157|cerebral vasospasm
826606|NCT02991157|nimodipine
826610|NCT02991131|Acute bacterial skin infection
826611|NCT02991131|Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
826612|NCT02991131|Abscess
826613|NCT02991131|Cellulitis
826614|NCT02991131|Erysipelas
826615|NCT02991131|Wound infection
826616|NCT02991131|Methicillin resistant Staphylococcus aureus (MRSA)
826617|NCT02991118|hyperlipidemia
826618|NCT02991118|cholesterol
826619|NCT02991118|familial hypercholesterolemia
826620|NCT02991118|atherosclerotic cardiovascular disease
826621|NCT02991118|ASCVD
826622|NCT02991118|HeFH
826623|NCT02991118|LDL
826624|NCT02991105|Malignancy
826625|NCT02991105|Cancer
826626|NCT02991105|Organ Transplantation
826627|NCT02991092|colon carcinoma
826628|NCT02991092|liquid treatment
826629|NCT02991092|fast-track surgery
826630|NCT02991079|Food Habits
826631|NCT02991079|Health education
826632|NCT02991079|Physical activity
826633|NCT02991079|Information and Communication Technologies
826634|NCT02991066|Acute promyelocytic leukemia
826635|NCT02991066|Coagulopathy
826636|NCT02991066|Microparticles
826637|NCT02991066|Mechanism
826638|NCT02991053|Intra-operative anesthesia
826639|NCT02991053|Pediatric patient
826640|NCT02991053|Transversus Abdominis Plane Block
826641|NCT02991053|ilioinguinal / iliohypogastric nerve block
826642|NCT02991027|no known ocular pathology
826643|NCT02991014|music intervention
826644|NCT02991014|heart rate variability
826645|NCT02991014|frequency modulation
826646|NCT02991014|pain perception
826647|NCT02991014|cold pressor test (CPT)
826648|NCT02991001|Hydrodissection
826649|NCT02990988|Blood donation
826650|NCT02990988|Iron repletion
826651|NCT02990988|Transfusion
826652|NCT02990975|Intra-operative anesthesia
826653|NCT02990975|Pediatric patient
826654|NCT02990975|Transversus Abdominis Plane Block
826655|NCT02990962|perineural injection
826656|NCT02990962|ultrasound-guided
826657|NCT02990962|dextrose
826658|NCT02990962|steroid
826659|NCT02990936|Oropharynx squamous cell carcinoma
826660|NCT02990936|tumor growth
826661|NCT02990936|predictive markers
826662|NCT02990936|tumoral kinetics
826663|NCT02990910|respiratory morbidity
826664|NCT02990910|obstructive sleep apnea syndrome
826665|NCT02990897|Medical informatics
826666|NCT02990897|Quality of care
826667|NCT02990897|Referral
826668|NCT02990884|Intra-operative anesthesia and analgesia
826669|NCT02990884|ilioinguinal / iliohyogogastric nerve block
826670|NCT02990884|Pediatric patient
826671|NCT02990819|Immunodeficiencies
826672|NCT02990819|Immune dysregulation syndromes
826673|NCT02990793|PTSD
826674|NCT02990793|Concussion
826675|NCT02990793|TBI
826676|NCT02990793|TMS
826677|NCT02990741|atrial fibrillation
826678|NCT02990741|automated ECG system
826679|NCT02990728|Endometrial Cancer.Mirena®
826680|NCT02990715|average risk CRC screening
826681|NCT02990715|Non compliant patients for CRC screening
826682|NCT02990715|Counterindicated patients for colonoscopy
826683|NCT02990702|Infraclavicular block
826684|NCT02990702|Retroclavicular block
826685|NCT02990702|Ultrasound
826686|NCT02990676|Cognition
826687|NCT02990676|Computerised cognitive training
826688|NCT02990676|Feasibility study
826689|NCT02990676|Huntington's disease
826690|NCT02990676|Translational
826691|NCT02990663|Pragmatic
826692|NCT02990663|Primary Care
826693|NCT02990663|Chronotherapy
826694|NCT02990663|Administrative Data
826695|NCT02990663|Stroke
826696|NCT02990663|Myocardial Infarction
826697|NCT02990663|Congestive Heart Failure
826698|NCT02990663|Glaucoma
826699|NCT02990663|Dementia
826700|NCT02990663|Hip Fracture
826701|NCT02990637|Olive leaf extract
826702|NCT02990637|Cardiovascular health
826703|NCT02990637|Cholesterol
826704|NCT02990624|psoriasis
826705|NCT02990624|photochemotherapy
826706|NCT02990624|atherosclerosis
826707|NCT02990624|metabolic syndrome
826708|NCT02990624|cardiovascular risk
826709|NCT02990598|Hydroxyurea
826710|NCT02990572|Amish
826711|NCT02990572|Mennonite
826712|NCT02990559|Iron repletion
826713|NCT02990559|Blood donation
826714|NCT02990559|Transfusion
826715|NCT02990507|mobility impairment
826716|NCT02990507|virtual environment
826717|NCT02990507|exercise
826718|NCT02990507|physical activity
826719|NCT02990468|Mucositis
826720|NCT02990468|Xerostomia
826721|NCT02990455|alcohol
826722|NCT02990455|drinking
826723|NCT02990455|smoking
826724|NCT02990455|cigarette
826725|NCT02990455|nicotine
826726|NCT02990442|rTMS
826727|NCT02990442|Repetitive Transcranial Magnetic Stimulation
826728|NCT02990442|Brain Stimulation
826729|NCT02990429|hypothermia
826730|NCT02990429|Shivering
826731|NCT02990429|Gynecologic laparoscopic surgery
826732|NCT02990429|Warming
826733|NCT02990429|General anesthesia
826734|NCT02990377|Opioid Analgesics
826735|NCT02990377|Opioid Safety
826736|NCT02990377|Emergency Department
826737|NCT02990377|Motivational Enhancement
826738|NCT02990377|Interactive Voice Response
826739|NCT02990377|Reinforcement Learning
826740|NCT02990377|mHealth
826745|NCT02990299|Diabetes Mellitus, Type 2
826746|NCT02990299|Medication Adherence
826747|NCT02990299|Telemedicine
826748|NCT02990299|Community Health Workers
826749|NCT02990299|Pharmacists
826750|NCT02990299|Mobile Health
826751|NCT02990286|Non specific intertitial pneumonia
826752|NCT02990286|interstitial pneumonia with autoimmune feature
826753|NCT02990286|connective tissue disease
826754|NCT02990286|rituximab
826755|NCT02990286|Mycophenolate Mofetil
826756|NCT02990286|pulmonary fibrosis
826757|NCT02990247|Asthma
826758|NCT02990247|Exacerbations
826759|NCT02990247|Telemonitoring
826760|NCT02990247|Biomarkers
826761|NCT02990234|Capsular Repair
826762|NCT02990234|FAI
826763|NCT02990234|Hip
826764|NCT02990221|Field Cancerization
826765|NCT02990208|Diaphragmatic Breathing
826766|NCT02990208|Virtual Reality Exposure Therapy
826767|NCT02990182|Yellow Fever Vaccine
826768|NCT02990182|Immunity, Humoral
826769|NCT02990182|Immunity, Cellular
826770|NCT02990182|children
826771|NCT02990156|Coils
826772|NCT02990091|TBI
826773|NCT02990091|DHA
826774|NCT02990091|omega-3 highly unsaturated fatty acids
826775|NCT02990091|synaptamide
826776|NCT02990078|TBI
826777|NCT02990078|CVR
826778|NCT02990078|Hypercapnia
826779|NCT02990078|fNIRS
826780|NCT02990065|PROTEIN SUPPLEMENTATION
826781|NCT02990065|NUTRITIONAL STATUS
826782|NCT02990039|physical activity
826783|NCT02990039|sedentary time
826784|NCT02990039|feasibility study
826785|NCT02990039|accelerometer
826786|NCT02989987|PTSD
826787|NCT02989987|Shame
826788|NCT02989987|Narrative Exposure Therapy
826789|NCT02989987|Sexual and gender based violence (SGBV)
826790|NCT02989987|DR Congo
826791|NCT02989974|Survivorship Care
826792|NCT02989974|Caregiving
826793|NCT02989948|Endovascular
826794|NCT02989935|respiratory muscle
826795|NCT02989935|bronchodilator
826796|NCT02989896|Perfusion index
826797|NCT02989896|Peripheral nerve block success
826798|NCT02989896|older age
826799|NCT02989883|achalasia
826800|NCT02989883|POEM
826801|NCT02989883|outcome
826802|NCT02989870|Liver Disease
826803|NCT02989870|Child-Pugh Class A
826804|NCT02989870|Child-Pugh Class B7
826806|NCT02989831|diabetic neuropathy
826807|NCT02989831|foot ulcers
826808|NCT02989831|random vibration
826809|NCT02989831|vibration perception threshold
826810|NCT02989831|mechanical noise
826811|NCT02989805|Emergency Medicine
826812|NCT02989805|Psychiatry
826813|NCT02989805|Health Promotion
826814|NCT02989805|Public Health
826815|NCT02989792|pain
826816|NCT02989753|Prevention
826817|NCT02989740|Diabetes Mellitus
826818|NCT02989740|Thincap fibroatheroma
826819|NCT02989740|Optical Coherence Tomography
826820|NCT02989740|Fractional Flow Reserve
826821|NCT02989701|Plerixafor
826822|NCT02989675|pediatric
826823|NCT02989675|critical illness
826824|NCT02989675|Malawi
826825|NCT02989649|Drug Therapy
826826|NCT02989584|bladder cancer
826827|NCT02989584|metastatic bladder cancer
826828|NCT02989584|atezolizumab
826829|NCT02989584|urothelial carcinoma
826830|NCT02989519|preterm labor
826831|NCT02989519|progesterone efficacy
826832|NCT02989519|threatened preterm labor
826833|NCT02989493|Alcoholism
826834|NCT02989493|Stress
826835|NCT02989493|Norepinephrine
826836|NCT02989493|Doxazosin
826837|NCT02989493|Anxiety
826838|NCT02989493|Startle Potentiation
826839|NCT02989493|Relapse
826840|NCT02989493|Adrenergic Antagonists
826841|NCT02989493|Surrogate Endpoint
826842|NCT02989480|Cardiomyopathy
826843|NCT02989441|Perfusion Index
826844|NCT02989441|Hemodynamics
826845|NCT02989441|Anesthesia
826846|NCT02989441|Stroke Volume
826847|NCT02989415|Anesthesia
826848|NCT02989415|Mechanical Ventilation
826849|NCT02989415|Robotic Surgery
826850|NCT02989415|Postoperative Pulmonary Complications
826851|NCT02989402|Alzheimer, Rivastigmine
826852|NCT02989363|deep brain surgery and complex back surgery
826853|NCT02989337|Hyperemesis Gravidarum
826854|NCT02989337|Inflammatory adhesion molecules
826855|NCT02989337|Dehydration
826856|NCT02989311|Iron absorption
826857|NCT02989311|Iron deficiency
826858|NCT02989311|Hepcidin
826859|NCT02989311|Stable isotopes
826860|NCT02989311|Anemia
826861|NCT02989311|Infants
826862|NCT02989298|Peritoneal Dialysis (PD)
826863|NCT02989298|Residual renal function
826864|NCT02989298|Peritoneum function
826865|NCT02989298|Peritonitis rate
826866|NCT02989298|Technical survival
826867|NCT02989298|Patient survival
826868|NCT02989285|HIV
826869|NCT02989285|HIV-associated neurocognitive disorder (HAND)
826870|NCT02989285|Neurology
826871|NCT02989285|Latent HIV
826872|NCT02989285|HIV Reservoirs
826873|NCT02989259|apatinib
826874|NCT02989259|advanced head and neck cancer
826875|NCT02989259|non-squamous
826876|NCT02989246|pediatrics
826877|NCT02989246|ventilator weaning
826878|NCT02989220|Miscarriage
826879|NCT02989207|Glaucoma
826880|NCT02989207|Trabeculectomy
826881|NCT02989207|Glaucoma drainage implant
826882|NCT02989207|Africa and Africa-Caribbean
826883|NCT02989168|Idiopathic pulmonary fibrosis
826884|NCT02989168|hypoxemia
826885|NCT02989168|oxygen
826886|NCT02989142|interpregnancy
826887|NCT02989142|pregnancy-induced hypertension
826888|NCT02989142|gestational diabetes mellitus
826889|NCT02989142|caesarean section
826890|NCT02989142|large-for-gestational-age
826891|NCT02989129|Polyneuropathies and Other Disorders of the Peripheral Nervous System
826892|NCT02989129|Chemotherapy Induced Neuropathic Pain
826893|NCT02989129|CINP
826894|NCT02989129|Quercetin
826895|NCT02989129|Questionnaires
826896|NCT02989129|Surveys
826897|NCT02989116|Learning
826898|NCT02989116|Executive functions
826899|NCT02989116|Cognitive control
826900|NCT02989116|Prefrontal Cortex
826901|NCT02989116|Typically developing children
826902|NCT02989116|Genotype
827041|NCT02988440|liver cancer
826903|NCT02989116|Functional Magnetic Resonance Imaging
826904|NCT02989116|Structural Magnetic Resonance Imaging
826905|NCT02989116|Inhibition
826906|NCT02989116|Working Memory
826907|NCT02989116|Metacognition
826908|NCT02989116|Mindfulness
826909|NCT02989116|Preterm children
826910|NCT02989116|Developmental Psychology
826911|NCT02989116|Developmental cognitive neuroscience
826912|NCT02989116|Touch screen tablet
826913|NCT02989116|Adaptive training
826914|NCT02989103|Hyperthyroidism
826915|NCT02989103|Radiation
826916|NCT02989103|Mortality
826917|NCT02989090|Patient Engagement
826918|NCT02989090|Defibrillators
826919|NCT02989090|Health Records, Personal
826920|NCT02989090|Patient Portal
826921|NCT02989077|combined coronary and cerebral ischemia
826931|NCT02989038|smoker
826932|NCT02989038|young adult
826933|NCT02988999|D-allulose or erythritol
826934|NCT02988986|mTOR
826935|NCT02988986|Tamoxifen
826936|NCT02988986|Breast Cancer
826937|NCT02988973|Roxadustat
826938|NCT02988973|Anemia
826939|NCT02988973|Non-dialysis chronic kidney disease
826940|NCT02988973|ASP1517
826948|NCT02988947|Knee Arthroplasty
826949|NCT02988947|Hypnosis
826950|NCT02988947|Pain Neuroscience Education
826951|NCT02988947|Pain
826952|NCT02988947|Catastrophizing
826953|NCT02988947|Optimism
826954|NCT02988947|Distress
826955|NCT02988947|Hope
826956|NCT02988947|Self-Efficacy
826957|NCT02988895|Brachytherapy
826958|NCT02988895|Wet AMD
826959|NCT02988869|COPD
826960|NCT02988869|Tiotropium
826961|NCT02988869|Formoterol
826962|NCT02988843|GCT
826963|NCT02988830|Subcutaneous stimulation
826964|NCT02988804|endoscopic endonasal transsphenoidal surgery
826965|NCT02988804|laryngeal mask
826966|NCT02988765|vulvar cancer
826967|NCT02988765|inguinal lymph node
826968|NCT02988765|lymph node status
826969|NCT02988765|cytology
826970|NCT02988765|core biopsy
826971|NCT02988726|Neurofibroma
826972|NCT02988726|Schwannoma
826973|NCT02988713|stimulation
826974|NCT02988713|chronic pain
826975|NCT02988713|back pain
826976|NCT02988713|leg pain
826977|NCT02988687|fatigue
826978|NCT02988687|quality of life
826979|NCT02988687|depression
826980|NCT02988687|cognitive function
826981|NCT02988687|growth hormone
826982|NCT02988687|traumatic brain injury
826983|NCT02988674|Ankylosing spondylitis
826984|NCT02988674|Humira®
826985|NCT02988674|Adalimumab
826986|NCT02988674|Spondylarthritis
826987|NCT02988674|Psoriatic arthritis
826988|NCT02988661|Autoimmunity
826989|NCT02988661|Immune System Disorders
826990|NCT02988648|Metastatic Breast Cancer
826991|NCT02988635|Early Palliative Care
826992|NCT02988635|Simultaneous Care
826993|NCT02988635|Chemotherapy
826994|NCT02988635|Quality of Life
826995|NCT02988596|Concussion
826996|NCT02988596|Rehabilitation
826997|NCT02988583|silicone oil
826998|NCT02988583|emulsification
826999|NCT02988583|retinal detachment surgery
827000|NCT02988557|cerebral palsy
827001|NCT02988557|gait
827002|NCT02988557|slope
827003|NCT02988557|electromyography
827004|NCT02988531|PET
827005|NCT02988531|MRI
827006|NCT02988531|Attenuation
827007|NCT02988531|Correction
827008|NCT02988531|Cardiovascular
827009|NCT02988531|coronary
827010|NCT02988531|disease
827011|NCT02988518|Psychiatry
827012|NCT02988518|Bipolar disorder
827013|NCT02988518|Memory complaints
827014|NCT02988518|Global functioning
827015|NCT02988518|Cognitive remediation
827016|NCT02988518|Working memory
827017|NCT02988466|Acute Leukemias
827018|NCT02988466|Acute myeloid leukemia (AML)
827019|NCT02988466|Acute lymphoblastic leukemia (ALL)/lymphoma
827020|NCT02988466|Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
827021|NCT02988466|Myelodysplastic syndrome
827022|NCT02988466|Chronic myelogenous leukemia
827023|NCT02988466|Minimal Residual Disease (MRD) positive leukemia
827024|NCT02988466|Leukemia or Myelodysplastic Syndromes (MDS) in aplasia
827025|NCT02988466|Myeloproliferative neoplasms/myelofibrosis
827026|NCT02988466|Relapsed large-cell lymphoma, mantle-cell lymphoma and Hodgkin lymphoma
827027|NCT02988466|Burkitt's lymphoma
827028|NCT02988466|Relapsed T-cell lymphoma
827029|NCT02988466|Natural Killer cell malignancies
827030|NCT02988466|Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma
827031|NCT02988466|Lymphoplasmacytic lymphoma
827032|NCT02988466|Relapsed multiple myeloma
827033|NCT02988466|Bone marrow failure syndromes
827034|NCT02988453|mentalization-based treatment
827035|NCT02988453|conduct disorder
827036|NCT02988453|adolescents
827037|NCT02988440|HCC
827038|NCT02988440|Hepatocellular carcinoma
827039|NCT02988440|Hepatocellular carcinoma (HCC)
827040|NCT02988440|PDR001
827042|NCT02988440|immunotherapy liver
827043|NCT02988440|malignant hepatoma
827044|NCT02988440|Hepatocellular cancer
827045|NCT02988440|advanced hepatocellular carcinoma (HCC)
827046|NCT02988440|advanced liver cancer
827047|NCT02988440|liver cancer progression
827048|NCT02988440|sorafenib
827049|NCT02988440|anti-PD1
827050|NCT02988440|first line
827051|NCT02988414|Sepsis
827052|NCT02988414|Infection
827053|NCT02988414|Culture
827054|NCT02988414|Sequencing
827055|NCT02988414|Non-invasive
827056|NCT02988414|NGS
827057|NCT02988375|insomnia
827058|NCT02988375|depression
827059|NCT02988375|digital CBTI
827060|NCT02988375|online CBTI
827061|NCT02988336|difficult intubation
827062|NCT02988336|thyromental height
827063|NCT02988323|sport concussion
827064|NCT02988323|cervical spine
827065|NCT02988323|vestibular rehabilitation
827066|NCT02988323|exercise
827067|NCT02988323|rehabilitation
827068|NCT02988323|children
827069|NCT02988323|youth
827070|NCT02988310|Limb Loss
827071|NCT02988310|Gait Characteristics
827072|NCT02988284|Gait variability
827073|NCT02988271|Meditation
827074|NCT02988271|Anxiety
827075|NCT02988271|Psychosocial distress
827076|NCT02988271|Depression
827077|NCT02988271|Questionnaires
827078|NCT02988271|Surveys
827079|NCT02988271|Meditation Video
827080|NCT02988271|Meditation app
827081|NCT02988258|Ex vivo gene therapy
827082|NCT02988258|T cell receptor transduction
827083|NCT02988258|Immunotherapy
827084|NCT02988258|Allogeneic Haematopoietic Stem Cell Transplantation
827085|NCT02988258|CMV
827086|NCT02988232|Work Related Chronic Low Back Pain
827087|NCT02988232|Korean Medicine
827088|NCT02988232|Sogyeonghwalhyeol-tang
827089|NCT02988219|cardiac arrhythmia
827090|NCT02988219|epidural anesthesia
827091|NCT02988219|combined anesthesia
827092|NCT02988219|general anesthesia
827093|NCT02988219|NSS
827094|NCT02988219|radical nephrectomy
827095|NCT02988219|extraperitoneal
827096|NCT02988193|clinical reasoning artificial intelligence
827097|NCT02988193|poorly controlled hypertension
827098|NCT02988167|Spontaneous Breathing Trial (SBT)
827099|NCT02988167|Extubation Decision Support Tool
827100|NCT02988167|Extubation
827101|NCT02988167|Extubation Readiness
827102|NCT02988154|Medical education
827103|NCT02988154|simulation
827104|NCT02988154|neurosurgical education
827105|NCT02988154|Simulation laboratory
827106|NCT02988154|Ventricular drain
827107|NCT02988128|Embolization Device
827108|NCT02988128|Flow Diverter
827109|NCT02988128|Intra saccular device
827110|NCT02988128|Vascular Reconstruction Device
827111|NCT02988128|Ruptured Intracranial Aneurysm
827112|NCT02988128|Unruptured Intracranial Aneurysm
827113|NCT02988115|hyperlipidemia
827114|NCT02988115|cholesterol
827115|NCT02988115|familial hypercholesterolemia
827116|NCT02988115|atherosclerotic cardiovascular disease
827117|NCT02988115|ASCVD
827118|NCT02988115|HeFH
827119|NCT02988115|LDL
827120|NCT02988115|statin intolerence
827121|NCT02988102|S100B, NSE
827122|NCT02988102|moderate brain trauma
827123|NCT02988102|mild brain trauma
827124|NCT02988089|Helicobacter Pylori Infection
827125|NCT02988089|Antimicrobial susceptibility testing (AST)
827126|NCT02988063|Varithena
827127|NCT02988063|Polidocanol Endovenous Microfoam
827128|NCT02988050|Epilepsy Surgery
827129|NCT02988050|Conscious sedation
827130|NCT02988011|type 2 diabetes
827131|NCT02988011|gastric by-pass surgery
827132|NCT02988011|low calorie diet
827133|NCT02988011|glucose metabolism
827134|NCT02987998|Pembrolizumab
827135|NCT02987998|Chemoradiation
827136|NCT02987985|Opioid-sparing
827137|NCT02987985|Opioid-free
827138|NCT02987959|TAK-228
827139|NCT02987959|MLN0128
827140|NCT02987959|mTOR
827141|NCT02987933|Chronic Pain
827142|NCT02987933|fMRI
827143|NCT02987933|DTI
827144|NCT02987894|TAVI
827145|NCT02987894|Transcatheter Aortic Valve Replacement
827146|NCT02987894|Transcatheter Aortic Valve Implant
827147|NCT02987894|Transfemoral access
827148|NCT02987894|Aortic valve regurgitation
827149|NCT02987868|Somatostatin
827150|NCT02987868|Thyroid Hormone
827151|NCT02987868|Growth Hormone
827152|NCT02987842|Mild cognitive impairment
827153|NCT02987842|Alzhiemer's disease
827154|NCT02987842|Neurofeedback
827155|NCT02987842|EEG
827164|NCT02987764|Premature
827165|NCT02987764|Birth weight
827166|NCT02987725|Adolescence
827167|NCT02987725|Autonomic Nervous System
827168|NCT02987725|Hypnosis
827169|NCT02987725|Pain
827170|NCT02987725|Sickle Cell Disease
827171|NCT02987712|Thromboelastography
827172|NCT02987699|Hepatocellular Carcinoma
827173|NCT02987699|Hepatic arterial infusion chemotherapy
827174|NCT02987699|optimal dose
827175|NCT02987686|Topical Infliximab
827176|NCT02987686|Cornea
827177|NCT02987686|Keratolysis
827178|NCT02987673|Mini/One anastomosis gastric bypass
827179|NCT02987673|Sleeve Gastrectomy
827180|NCT02987673|Gastro-esophageal sphincter function
827181|NCT02987634|gingivitis
827182|NCT02987634|dental implant
827183|NCT02987634|mouthwash
827184|NCT02987595|intervention
827185|NCT02987595|lignans
827186|NCT02987595|whole-grain
827187|NCT02987582|mental health
827188|NCT02987582|mindfulness
827189|NCT02987582|shame
827190|NCT02987569|Home Parenteral Nutrition
827191|NCT02987569|HPN
827192|NCT02987569|Total Parenteral Nutrition
827193|NCT02987569|TPN
827194|NCT02987569|mConnect
827195|NCT02987569|SBS
827196|NCT02987569|short bowel disorder
827197|NCT02987569|telehealth
827198|NCT02987569|telemedicine
827199|NCT02987543|metastatic castration-resistant prostate cancer (mCRPC)
827200|NCT02987543|homologous recombination repair (HRR)
827201|NCT02987530|primary infection
827202|NCT02987517|running
827203|NCT02987517|vertical load rates
827204|NCT02987517|cadence
827205|NCT02987517|footstrike
827206|NCT02987504|Cancer
827207|NCT02987504|Solid tumor
827208|NCT02987504|Phase 1
827209|NCT02987491|exercise
827210|NCT02987478|Vitamin D following intra cytoplasmic sperm injection
827211|NCT02987452|exercise
827212|NCT02987452|resistant hypertension
827213|NCT02987452|blood pressure
827214|NCT02987439|COPD
827215|NCT02987439|Exacerbation
827216|NCT02987439|Rehabilitation
827217|NCT02987413|Amyotrophic Lateral Sclerosis
827218|NCT02987400|DLBCL
827219|NCT02987400|GA-101
827220|NCT02987400|ABT-199
827221|NCT02987400|relapsed DLBCL
827222|NCT02987400|refractory DLBCL
827223|NCT02987400|AGMT
827224|NCT02987400|Diffuse large B-cell lymphoma
827225|NCT02987400|window of opportunity
827226|NCT02987387|Tetralogy of Fallot
827227|NCT02987387|Aortic Valve Defect/Disease Resulting in Ross Procedure
827228|NCT02987387|Transcatheter pulmonary valve implantation
827229|NCT02987387|Transcatheter pulmonary valve replacement
827230|NCT02987387|Pulmonary Atresia
827231|NCT02987387|Pulmonary Stenosis
827232|NCT02987374|Influenza Vaccine
827233|NCT02987348|type 2 diabetes
827234|NCT02987309|indirect calorimetry
827235|NCT02987309|method comparison
827236|NCT02987296|Colorectal Cancer
827237|NCT02987296|Surgery
827238|NCT02987296|Arginine depletion
827239|NCT02987296|Immune system dysfunction
827240|NCT02987296|Arginine Supplementation
827241|NCT02987270|mass screen and treat
827242|NCT02987270|malaria
827243|NCT02987270|asymptomatic infections
827244|NCT02987270|transmission reduction
827245|NCT02987270|infectious reservoir
827246|NCT02987270|kenya
827247|NCT02987257|Therapeutics
827248|NCT02987257|Management
827249|NCT02987257|Cyclosporine
827250|NCT02987257|Etanercept
827251|NCT02987257|Supportive Care
827252|NCT02987257|Immunopathogenesis
827253|NCT02987257|Genetics
827254|NCT02987257|Adverse Drug Reaction
827255|NCT02987244|Chidamide, T Cell Non-Hodgkin's Lymphoma
827256|NCT02987218|POCD
827257|NCT02987218|subarachnoid hemorrhage
827258|NCT02987218|Propofol
827259|NCT02987218|Desflurane
827260|NCT02987192|spinal anesthesia
827261|NCT02987192|anticoagulation
827262|NCT02987192|minimally invasive
827263|NCT02987192|Cesarean Section
827264|NCT02987192|Maternal
827265|NCT02987166|immunotherapy
827266|NCT02987166|pembrolizumab
827267|NCT02987166|MK-3475
827268|NCT02987166|High-dose conformal radiation therapy
827269|NCT02987166|HDCRT
827270|NCT02987166|advanced solid tumor
827271|NCT02987153|Kyphoplasty
827272|NCT02987153|Spinal metastases
827273|NCT02987153|IORT
827274|NCT02987153|Intraoperative radiation therapy
827275|NCT02987153|Pain management
827276|NCT02987140|Parkinson's disease
827277|NCT02987140|freezing of gait
827278|NCT02987140|context-dependency
827279|NCT02987140|transcranial magnetic stimulation
827280|NCT02987140|visual cues
827281|NCT02987062|Atrial Fibrillation
827282|NCT02987062|Non-vitamin K Oral Anticoagulants
827283|NCT02987062|Vitamin K Antagonists
827284|NCT02987062|ROCKET-AF
827285|NCT02987062|RE-LY
827286|NCT02987062|ARISTOTLE
827287|NCT02987049|heart disease, cardiac rehabilitation
827288|NCT02987036|nebulizer technologies, lung mechanics, beta-agonistic drug
827289|NCT02987023|infertility, uterus, transplantation
827290|NCT02986997|epidural anesthesia
827291|NCT02986997|prone position
827292|NCT02986997|percutaneous nephrolithotomy
827293|NCT02986984|Diabetes
827294|NCT02986984|Chronic kidney disease
827295|NCT02986984|Progression
827296|NCT02986984|Genomics
827297|NCT02986984|Transcriptomics
827298|NCT02986971|Contraceptive implant
827299|NCT02986945|Depressive symptoms
827300|NCT02986945|resiliency
827301|NCT02986945|Health Promotion
827302|NCT02986945|minority health
827303|NCT02986945|text-messaging app
827304|NCT02986945|participatory technology development
827305|NCT02986932|Blood-Brain Barrier
827306|NCT02986906|ulnar neuropathy at elbow
827307|NCT02986906|Dextrose
827308|NCT02986906|perineural injection
827309|NCT02986893|Multiple Sclerosis
827310|NCT02986893|Diet
827311|NCT02986893|Clinical Trial
827312|NCT02986854|Meningococcal disease
827313|NCT02986854|Booster vaccination
827314|NCT02986854|Meningitis
827315|NCT02986854|Antibody persistence
827316|NCT02986828|platelet rich plasma
827317|NCT02986828|Hydrodissection
827318|NCT02986737|TAVI
827319|NCT02986737|Aortic Stenosis
827320|NCT02986737|Transcatether Aortic Valve Implantation
827321|NCT02986724|Drug therapy
827322|NCT02986698|intrauterine transfusion
827323|NCT02986698|in utero human stem cell transplantation
827324|NCT02986685|Refractory reflux esophagitis
827325|NCT02986685|Rabeprazole
827326|NCT02986685|trimebutine maleate
827327|NCT02986672|ADHD
827328|NCT02986672|omega 3
827329|NCT02986672|children
827330|NCT02986672|nutrition
827331|NCT02986672|MUFA
827332|NCT02986672|ADD
827333|NCT02986672|PUFA
827334|NCT02986672|Calanus
827335|NCT02986672|learning difficulties
827336|NCT02986633|Cardiac Resynchronization Therapy
827337|NCT02986633|Echocardiography
827338|NCT02986633|Biventricular Pacing
827339|NCT02986568|Ontogenetic surgery
827340|NCT02986568|TMMR
827341|NCT02986568|PMMR
827342|NCT02986568|LEER
827343|NCT02986555|Stress
827344|NCT02986555|Virtual Reality
827345|NCT02986555|Motion sickness
827346|NCT02986555|Visual Fatigue
827347|NCT02986555|Biofeedback
827348|NCT02986542|newborns,femoral artery, catheterization
827349|NCT02986490|Mental disorders
827350|NCT02986490|Antipsychotic agents
827351|NCT02986490|Magnesium
827352|NCT02986490|Cardiovascular risk factor
827353|NCT02986490|Metabolic syndrome
827354|NCT02986464|Virtual reality
827355|NCT02986464|Immersive distraction
827356|NCT02986464|Virtual world
827357|NCT02986464|Virtual environment
827358|NCT02986464|Procedural pain
827359|NCT02986464|Acute pain
827360|NCT02986464|Pain Management
827361|NCT02986464|Children, Child
827362|NCT02986464|Kid, Kids
827363|NCT02986464|Pediatric, Pediatrics
827364|NCT02986464|Young children
827365|NCT02986464|Burns
827366|NCT02986464|Burn injuries
827367|NCT02986464|Burn unit
827368|NCT02986464|Hydrotherapy
827369|NCT02986464|Burn dressing
827370|NCT02986464|Non-pharmacological
827371|NCT02986464|Clinical Research
827372|NCT02986464|Nursing Practice
827373|NCT02986438|Cocaine
827374|NCT02986438|Addiction
827375|NCT02986438|rTMS
827376|NCT02986438|fMRI
827377|NCT02986425|Drug Utilization Review
827378|NCT02986425|Older people
827379|NCT02986399|fast track
827380|NCT02986386|Dental Occlusion
827381|NCT02986386|Oral Health
827382|NCT02986386|Mastication
827383|NCT02986386|Dementia
827384|NCT02986386|Psychological health
827385|NCT02986373|ABBV-066
827386|NCT02986373|BI655066
827387|NCT02986373|risankizumab
827388|NCT02986334|chronic
827389|NCT02986334|low back
827390|NCT02986334|back
827391|NCT02986334|pain
827392|NCT02986334|brain
827393|NCT02986334|MRI
827394|NCT02986321|anti-inflammatory respiratory drug
827395|NCT02986321|PDE4 inhibitor
827396|NCT02986308|Metabolomics
827397|NCT02986308|Intestinal Polyps
827398|NCT02986308|TCM Syndromes
827399|NCT02986308|TCM Constitution Types
827400|NCT02986295|BioMime, Ultimaster, Ischemic heart disease, DES
827401|NCT02986282|ankle - brachial index
827402|NCT02986269|Respiratory Function
827403|NCT02986269|Patient Positioning
827404|NCT02986269|anesthesia
827405|NCT02986256|telemedicine
827406|NCT02986230|Cancer prevention
827407|NCT02986230|Clinical Decision Support
827408|NCT02986230|Rural Health
827409|NCT02986230|Shared Decision Making
827410|NCT02986204|implant removal
827411|NCT02986204|Nexplanon
827412|NCT02986204|Implanon
827413|NCT02986204|contraception
827414|NCT02986204|ENG
827415|NCT02986191|gingival graft
827416|NCT02986191|free gingival graft
827417|NCT02986191|coronally advanced flap
827418|NCT02986191|reduced keratinized gingiva
827419|NCT02986178|Glioblastoma
827420|NCT02986178|Glioma
827421|NCT02986178|PVSRIPO
827422|NCT02986178|Duke
827423|NCT02986178|Pro00077024
827424|NCT02986178|Peters
827425|NCT02986178|Brain tumor
827426|NCT02986178|Bigner
827427|NCT02986165|Platelet Aggregation
827428|NCT02986152|PTSD
827429|NCT02986152|anxiety
827430|NCT02986152|depression
827431|NCT02986152|distress
827432|NCT02986152|fear
827433|NCT02986152|coping
827434|NCT02986152|support
827435|NCT02986152|caregiver
827436|NCT02986152|oncology
827437|NCT02986152|app
827438|NCT02986152|mobile app
827439|NCT02986126|Depression
827440|NCT02986126|Resilience
827441|NCT02986126|Minority health
827442|NCT02986126|Community-based participatory research
827443|NCT02986126|Lesbian, gay, bisexual, transgender, and intersex (LGBTI) health
827444|NCT02986126|Racial / ethnic health disparities
827445|NCT02986126|Patient-centered outcomes research
827446|NCT02986126|Comparative-effectiveness research
827447|NCT02986100|rucaparib
827448|NCT02986100|CO-338
827449|NCT02986100|Clovis
827450|NCT02986100|Clovis Oncology
827451|NCT02986100|PARP inhibitor
827452|NCT02986100|Absorption
827453|NCT02986100|Metabolism
827454|NCT02986100|Excretion
827455|NCT02986048|proton beam
827456|NCT02986048|registry
827457|NCT02986048|radiation
827458|NCT02986048|cancer
827459|NCT02986022|Self-efficacy
827460|NCT02986022|optimism
827461|NCT02986022|altruism
827462|NCT02986022|goal setting
827463|NCT02986009|emotion management
827464|NCT02986009|positive and negative affect
827465|NCT02986009|satisfaction with parent-child relationship
827466|NCT02986009|subjective happiness
827467|NCT02986009|family harmony
827468|NCT02985996|Preventative Medicine
827469|NCT02985996|Infectious Diseases
827470|NCT02985996|Sexually Transmitted Diseases
827471|NCT02985983|Brodalumab
827472|NCT02985983|KHK4827
827473|NCT02985983|Axial Spondyloarthritis
827474|NCT02985970|crush induction, RSI
827475|NCT02985944|colorectal cancer
827476|NCT02985944|Colon polyp
827477|NCT02985944|Colonoscopy
827478|NCT02985944|Adenoma detection rate
827479|NCT02985905|Zinc supplementation
827480|NCT02985905|Thiol
827481|NCT02985905|Glutathione peroxidase
827482|NCT02985905|Sulfhydryl oxidase
827483|NCT02985892|Physical therapy
827484|NCT02985892|Muscle Stretching Exercises
827485|NCT02985892|Low Back pain
827486|NCT02985879|tauopathy
827487|NCT02985879|PSP
827488|NCT02985879|Steele-Richardson-Olszewski syndrome
827489|NCT02985866|Artificial Pancreas
827490|NCT02985866|Closed Loop Control
827491|NCT02985866|Continuous Glucose Monitor (CGM)
827492|NCT02985840|ondansetron
827493|NCT02985840|dexamethasone
827494|NCT02985814|COPD Asthma Overlap
827495|NCT02985775|CMV-specific T cell
827496|NCT02985775|haploidentical stem cell transplantation
827497|NCT02985775|immunologic response
827498|NCT02985775|acute GVHD
827499|NCT02985762|bupivacaine
827500|NCT02985762|exparel
827501|NCT02985762|analgesic
827502|NCT02985762|lumbar spine
827503|NCT02985749|Autism Spectrum Disorders
827504|NCT02985749|Pervasive Developmental Disorder
827505|NCT02985749|ASD
827506|NCT02985749|PDD
827507|NCT02985749|Oxytocin
827508|NCT02985749|Syntocinon
827509|NCT02985749|Social Impairment
827510|NCT02985749|Treatment
827511|NCT02985671|Postural Low Back Pain
827512|NCT02985671|Mechanical Low Back Pain
827513|NCT02985671|Low Back Pain
827514|NCT02985671|acetaminophen
827515|NCT02985671|caffeine
827516|NCT02985671|orphenadrine
827517|NCT02985671|diclofenac sodium
827518|NCT02985645|CGF
827519|NCT02985645|sinus augmentation
827520|NCT02985645|DIVA
827521|NCT02985645|Platelet-Rich Plasma
827522|NCT02985554|hematologic malignancies
827523|NCT02985554|allogeneic stem cell transplantation (allo-SCT)
827524|NCT02985541|Birth Control
827525|NCT02985541|Heavy menstrual bleeding
827526|NCT02985515|Anosmia
827527|NCT02985515|Olfactory Neuroplasticity
827528|NCT02985515|Intranasal Steroid Irrigation
827529|NCT02985502|Quality of Life
827530|NCT02985502|Diabetes Mellitus
827531|NCT02985502|Pancreatectomy
827532|NCT02985476|Electronic health records
827533|NCT02985476|Health records personal
827534|NCT02985437|wound healing
827535|NCT02985437|Bovine Lung Surfactant
827536|NCT02985437|SATOSU
827537|NCT02985385|Congenital Lethal Malformations
827538|NCT02985359|Program impact evaluation
827539|NCT02985359|Malawi
827540|NCT02985359|Lipid-based nutrient supplements
827541|NCT02985359|Social behavior change communication
827542|NCT02985359|Childhood stunting
827543|NCT02985346|Idiopathic pulmonary hemosiderosis
827544|NCT02985346|Bone marrow mesenchymal stem cells
827545|NCT02985333|paclitaxe,cyclophosphamide,dexamethasone, Multiple Myeloma
827546|NCT02985320|Sabin strain
827547|NCT02985320|Inactivated poliovirus vaccine
827548|NCT02985320|poliomyelitis
827549|NCT02985320|safety
827550|NCT02985320|immunogenicity
827551|NCT02985320|infant
827552|NCT02985294|Neuropathic pain
827553|NCT02985294|Quantitative Sensory Testing
827554|NCT02985294|Multiple Excitability Measures
827555|NCT02985294|Threshold Tracking
827556|NCT02985281|direct acting antiviral drugs, chronic hepatitis C virus infection
827557|NCT02985268|MitraClip
827558|NCT02985268|Cardiovascular resynchronization therapy
827559|NCT02985268|Six minute walk test
827560|NCT02985268|Mitral regurgitation
827561|NCT02985268|CRT-D
827562|NCT02985255|Neoadjuvant Chemotherapy
827563|NCT02985255|Tongue Malignancy
827564|NCT02985255|Squamous Cell Carcinoma
827565|NCT02985203|lung cancer
827566|NCT02985203|vinorelbine
827567|NCT02985203|metronomic chemotherapy
827568|NCT02985190|Azacitidine
827569|NCT02985190|MDS
827570|NCT02985190|Systemic auto-immune and inflammatory disorders
827571|NCT02985177|Children
827572|NCT02985177|Musculoskeletal injury
827573|NCT02985177|Emergency department
827574|NCT02985177|Analgesia
827575|NCT02985177|Opioids
827576|NCT02985164|Anesthesiology( H02.403.066 )
827577|NCT02985164|Radiation Protection( N06.850.810.425)
827578|NCT02985164|Cholangiopancreatography, Endoscopic Retrograde(D002760 )
827579|NCT02985151|Scar
827580|NCT02985151|Carbon Dioxide Laser
827581|NCT02985151|Laser Ablation
827582|NCT02985125|Pancreas
827583|NCT02985125|5-FU
827584|NCT02985125|Gemcitabine
827585|NCT02985125|LEE011
827586|NCT02985125|Everolimus
827587|NCT02985125|Refractory
827588|NCT02985125|Chemotherapy
827589|NCT02985086|term premature rupture of membranes, antibiotic prophylaxis, chorioamnionitis, endometritis, neonatal infection
827590|NCT02985060|Therapeutic hypothermia
827595|NCT02985034|HCC
827596|NCT02985034|RFA
827597|NCT02985034|Liver tumor
827598|NCT02985008|Shock, IVBP, ECMO, In hospital death
827599|NCT02984995|FLT3-ITD
827600|NCT02984995|Positive refractory or relapsed acute myeloid leukemia
827601|NCT02984995|Hematology malignancy
827602|NCT02984995|Developmental Phase II
827603|NCT02984956|Hypotension
827604|NCT02984956|Pleth variability index
827605|NCT02984956|Hip Fracture
827606|NCT02984956|Spinal anesthesia
827607|NCT02984943|Rheumatoid Arthritis
827608|NCT02984943|Hyperbaric Oxygen
827609|NCT02984917|anterior transversalis fascia repair; preperitoneal repair
827610|NCT02984904|Fusarium Infection
827611|NCT02984904|Corneal ulcer
827612|NCT02984904|Spain
827613|NCT02984904|Epidemiology
827614|NCT02984891|Intravascular ultrasound
827615|NCT02984891|Optical coherence tomography
827616|NCT02984865|transversus plane block
827617|NCT02984865|opioid
827618|NCT02984865|nalbuphine
827619|NCT02984865|gastrointestinal surgery
827620|NCT02984865|elderly patient
827621|NCT02984839|intra-abdominal surgery
827622|NCT02984839|neuromuscular blocking agent
827623|NCT02984839|post-anesthesia care unit
827624|NCT02984787|Gastric Cancer
827625|NCT02984787|3D
827626|NCT02984787|2D
827627|NCT02984774|Endometriosis
827628|NCT02984774|Infertility
827629|NCT02984774|Telomerase activity
827630|NCT02984761|Carcinoma, Non-Small Cell Lung
827631|NCT02984761|Respiratory Tract Neoplasms
827632|NCT02984761|Thoracic Neoplasms
827633|NCT02984761|Neoplasms by Site
827634|NCT02984761|Neoplasms
827635|NCT02984761|Lung Diseases
827636|NCT02984761|Respiratory Tract Diseases
827637|NCT02984761|Carcinoma, Bronchogenic
827638|NCT02984761|Bronchial Neoplasms
827639|NCT02984761|Radiosurgery
827640|NCT02984761|Radiotherapy
827641|NCT02984761|Radiotherapy, Image-Guided
827642|NCT02984761|Lung Neoplasms
827643|NCT02984748|cochlear implants
827644|NCT02984748|hearing loss
827645|NCT02984735|chewing
827646|NCT02984735|cerebral palsy
827647|NCT02984735|chewing disorders
827648|NCT02984735|gross motor function
827649|NCT02984722|PCOS
827650|NCT02984722|metformin
827651|NCT02984670|Cognitive therapy
827652|NCT02984670|Behavior therapy
827653|NCT02984670|Moderation
827654|NCT02984670|Mediation
827655|NCT02984657|Hypoxemia
827656|NCT02984657|Reverse Trendelenburg
827657|NCT02984592|premature ejaculation
827658|NCT02984592|intravaginal ejaculatory latency time
827659|NCT02984592|premature ejaculation diagnostic tools
827660|NCT02984566|Primary liver cancer
827661|NCT02984566|Secondary liver cancer
827662|NCT02984566|Kilovoltage Intrafraction Monitoring
827663|NCT02984566|Stereotactic Ablative Body Radiation
827664|NCT02984553|accelerometry
827665|NCT02984553|aerobic fitness
827666|NCT02984553|metabolic thresholds
827667|NCT02984553|moderate to vigorous physical activity
827668|NCT02984501|radiochemotherapy
827669|NCT02984501|neoadjuvant therapy
827670|NCT02984488|necrotic teeth
827671|NCT02984488|single visit
827672|NCT02984488|multiple visits
827673|NCT02984488|protaper next
827674|NCT02984475|Beta Thalassemia
827675|NCT02984475|Metformin
827676|NCT02984475|Oxidative stress
827677|NCT02984475|Iron overload
827678|NCT02984475|Liver function
827679|NCT02984462|percutaneous
827680|NCT02984462|non-fixed
827681|NCT02984462|Akin ;
827682|NCT02984462|osteotomy
827683|NCT02984449|cardiac rehabilitation
827684|NCT02984449|surgical complications
827685|NCT02984449|quality of life
827686|NCT02984449|preoperative
827687|NCT02984449|cardiac surgery
827688|NCT02984423|Ovarian Cancer
827689|NCT02984423|BRCA mutations
827690|NCT02984410|T1-T2, N0 oropharyngeal carcinoma
827691|NCT02984397|pain
827692|NCT02984397|ketotifen
827693|NCT02984397|pediatric
827694|NCT02984397|mast cell
827695|NCT02984384|Trauma
827696|NCT02984384|Blood clot
827697|NCT02984384|Venous Thromboembolism
827698|NCT02984384|Pulmonary Embolism
827699|NCT02984384|Deep Vein Thrombosis
827700|NCT02984384|Thromboprophylaxis
827701|NCT02984384|Blood clot prevention
827702|NCT02984384|trauma patients
827703|NCT02984371|atrial fibrillation
827704|NCT02984371|ganglionated plexi
827705|NCT02984371|ischemic heart disease
827706|NCT02984293|Atorvastatin
827707|NCT02984293|LILRB5
827708|NCT02984293|Statin intolerance
827709|NCT02984254|knee
827710|NCT02984254|knee osteoarthritis
827711|NCT02984254|Bracing
827712|NCT02984254|patellofemoral osteoarthritis
827713|NCT02984189|Physical Exercise
827714|NCT02984189|Physical Therapy
827715|NCT02984189|Physical Performance
827716|NCT02984189|Critical Power
827717|NCT02984189|Respiratory Muscle
827718|NCT02984176|Simethicone
827719|NCT02984176|Laparoscopies
827720|NCT02984176|Pain
827721|NCT02984163|cancer
827722|NCT02984163|exercise
827723|NCT02984137|Lewy body disease
827724|NCT02984137|REM Sleep Behavior Disorder
827725|NCT02984137|Parkinson disease
827726|NCT02984137|Imaging
827727|NCT02984137|Bio-markers
827728|NCT02984137|Prospective cohort
827729|NCT02984111|Coronary Artery Bypass Graft Surgery
827730|NCT02984111|Erythropoietin
827731|NCT02984111|Cardioprotective
827732|NCT02984098|procedural pain, 40% Dextrose, heel lance
827733|NCT02984085|RDEB
827734|NCT02984085|Stem cells
827735|NCT02984085|Gene therapy
827736|NCT02984046|Acute bronchiolitis
827737|NCT02984046|RSV
827738|NCT02984046|CC16
827739|NCT02984046|SP-D
827740|NCT02984046|sRAGE
827741|NCT02984046|Severity
827742|NCT02984046|Biomarkers
827743|NCT02983994|asthma, devices
827744|NCT02983968|Oncology
827745|NCT02983968|Hepatology
827746|NCT02983968|Public Health
827747|NCT02983968|Liver
827748|NCT02983942|ketogenic diet
827749|NCT02983942|Primary Central Nervous System Lymphoma
827750|NCT02983942|chemotherapy
827751|NCT02983916|Adhesions
827752|NCT02983916|Adhesiolysis
827753|NCT02983916|chronic pain
827754|NCT02983916|post-operative complications
827755|NCT02983916|anti-adhesion barrier
827756|NCT02983916|cine-MRI
827757|NCT02983916|shared decision making
827758|NCT02983851|Noninvasive mechanical ventilation
827759|NCT02983851|Invasive mechanical ventilation
827760|NCT02983838|Amyloid
827761|NCT02983838|BDNF
827762|NCT02983838|major depressive disorder
827763|NCT02983838|cognitive decline
827768|NCT02983799|BRCA, ovarian, platinum, chemotherapy
827769|NCT02983760|Pulmonary embolism
827770|NCT02983747|Platelet Rich Plasma
827771|NCT02983747|Intervertebral Disk Injection Therapy
827772|NCT02983747|Low Back Pain
827773|NCT02983747|Ultrasound Guided
827774|NCT02983747|Degenerative Spinal Disease
827775|NCT02983734|Gulf War
827776|NCT02983734|D-cycloserine
827777|NCT02983734|Neuroinflammation
827778|NCT02983734|Cognition
827779|NCT02983734|Memory
827780|NCT02983708|Neuroregeneration
827781|NCT02983708|G-CSF
827782|NCT02983708|Peripheral blood mononuclear cells
827783|NCT02983708|Cerebral palsy
827784|NCT02983682|Anesthetics, Local
827785|NCT02983682|Lidocaine
827786|NCT02983682|Pediatrics
827787|NCT02983682|Children
827788|NCT02983682|Adolescents
827789|NCT02983669|Thymus Plant
827790|NCT02983669|Multiflotriol [Supplementary Concept]
827791|NCT02983669|Zataria multiflora
827792|NCT02983669|Complementary Therapies
827793|NCT02983669|Herbal Medicine
827794|NCT02983669|Medicine, traditional
827795|NCT02983656|Vaccine Safety
827796|NCT02983643|Skeletal Muscle Index
827797|NCT02983643|Visceral Adipose Tissue
827798|NCT02983643|Metabolic Syndrome
827806|NCT02983578|Pancreatic cancer
827807|NCT02983578|Mismatch deficient colorectal cancer
827808|NCT02983578|Non-small cell lung cancer
827809|NCT02983578|NSCLC
827810|NCT02983578|AZD9150
827811|NCT02983578|MEDI4736
827812|NCT02983578|Durvalumab
827813|NCT02983565|Long-term oxygen therapy
827814|NCT02983565|Intelligent oxygen therapy system
827815|NCT02983565|Auto-titrating oxygen system
827816|NCT02983552|Amblyopia
827817|NCT02983539|sarcomas
827818|NCT02983539|immunocytochemistry
827819|NCT02983539|circulating tumor cells
827820|NCT02983526|short stem
827821|NCT02983513|Early intervention
827822|NCT02983513|Brain Development
827823|NCT02983513|Neurodevelopment
827824|NCT02983500|Patient Reported Outcome (PRO)
827825|NCT02983487|Bordetella Pertussis
827826|NCT02983487|Whooping Cough
827827|NCT02983487|vaccine
827828|NCT02983461|urinary incontinence
827829|NCT02983461|pelvic floor dysfunction
827830|NCT02983435|Osteopathic Treatment
827831|NCT02983435|Postural control
827832|NCT02983435|Neuromuscular activation
827833|NCT02983435|Physiotherapy
827834|NCT02983409|computerized tomography
827835|NCT02983409|Urinary Calculi
827836|NCT02983409|Patient admission
827837|NCT02983409|Pain
827838|NCT02983396|RELF method
827839|NCT02983396|Medical device
827840|NCT02983396|Admission delay
827841|NCT02983383|Varicocele
827842|NCT02983383|TAP block
827843|NCT02983383|spinal anesthesia
827844|NCT02983357|Shoulder Arthroplasty
827845|NCT02983357|glenohumeral arthritis
827846|NCT02983344|fascia iliaca compartment block
827847|NCT02983344|fentanyl
827848|NCT02983266|Hyperadrenergia
827849|NCT02983266|Inflammatory stress
827850|NCT02983214|Cilostazol
827851|NCT02983214|Clopidogrel
827852|NCT02983214|Peripheral Artery Disease
827853|NCT02983201|Orthopedic Pain Syndromes
827854|NCT02983201|Thumbtack Intra-dermal Needle
827855|NCT02983201|Filiform needle
827856|NCT02983201|Acupuncture
827857|NCT02983188|Schizophrenia
827858|NCT02983188|Berberine
827859|NCT02983188|Metabolic Syndrome
827860|NCT02983188|Chinese medicine
827861|NCT02983188|Herbal medicine
827862|NCT02983175|ultrasonogaphy
827863|NCT02983175|full stomach
827864|NCT02983175|pulmonary aspiration
827865|NCT02983175|anaesthesia
827866|NCT02983136|Hand Hygiene
827867|NCT02983136|Implementation
827868|NCT02983136|Partnership
827869|NCT02983136|Surgery
827870|NCT02983123|Acute MI
827871|NCT02983123|Acute myocardial infarction cardiac troponin
827872|NCT02983123|High-sensitivity cardiac troponin T
827873|NCT02983123|0/1-hour algorithm
827874|NCT02983123|Outpatient clinic
827875|NCT02983123|Cardiac troponin
827876|NCT02983123|Chest pain
827877|NCT02983110|Hormones, Transgender
827878|NCT02983097|lymphoma
827879|NCT02983097|relapse
827880|NCT02983097|recurrence
827881|NCT02983097|progress
827882|NCT02983097|progressive
827883|NCT02983097|b-cell lymphoma
827884|NCT02983097|chemotherapy
827885|NCT02983097|immunotherapy
827886|NCT02983097|IMiD
827887|NCT02983097|Salvage chemotherapy
827888|NCT02983097|peripheral stem cell mobilization
827889|NCT02983097|lenalidomide
827890|NCT02983097|Rituximab
827891|NCT02983097|CD20
827892|NCT02983097|Cytarabine
827893|NCT02983097|Ara-C
827894|NCT02983097|platinum-based chemotherapy
827895|NCT02983097|Cisplatin
827896|NCT02983097|Carboplatin
827897|NCT02983097|Cisplatinum
827898|NCT02983097|Carboplatinum
827899|NCT02983097|Dexamethasone
827900|NCT02983084|Orthodontic wires
827901|NCT02983084|Root resorption
827902|NCT02983071|Breast Cancer
827903|NCT02983071|CDK 4/6 Inhibitor
827904|NCT02983071|HER2-Negative
827905|NCT02983071|HR-Positive
827906|NCT02983071|HR+
827907|NCT02983071|HER2-
827908|NCT02983071|HER2 -ve
827909|NCT02983071|HER2 +ve
827910|NCT02983032|Caregivers
827911|NCT02983032|Insomnia
827912|NCT02983019|influenza
827913|NCT02983019|flu
827914|NCT02983019|acute respiratory viral infection
827915|NCT02983019|ARVI
827916|NCT02983019|acute upper respiratory infection
827917|NCT02983019|AURI
827918|NCT02983006|TRAIL-DR5
827919|NCT02983006|DS-8273a
827920|NCT02983006|Immunoglobulin gamma-1 (IgG1)
827921|NCT02983006|Cell mediated cytotoxicity (ADCC)
827922|NCT02983006|Complement dependent cytotoxicity (CDC)
827923|NCT02983006|DR5
827924|NCT02983006|Immunoglobulin G4 (IgG4)
827925|NCT02983006|Monoclonal antibody
827926|NCT02983006|Programmed Cell Death 1 (PD-1)
827927|NCT02982993|hepatitis C virus
827928|NCT02982993|linkage-to-care
827929|NCT02982993|World Trade Center Health Program cohort
827930|NCT02982993|Baby Boomer
827931|NCT02982993|risk factors for hepatitis C virus infection
827932|NCT02982967|child
827933|NCT02982967|physical activity
827934|NCT02982967|irisin
827935|NCT02982967|EPCs
827943|NCT02982928|Obesity
827944|NCT02982928|Bariatrics
827945|NCT02982928|Acetaminophen
827946|NCT02982928|robot-assisted or laparoscopic bariatric surgery
827947|NCT02982928|Pharmacokinetics
827948|NCT02982902|Immunotherapy
827949|NCT02982902|T-Cell Therapy
827950|NCT02982902|Lymphoproliferative Disorder
827951|NCT02982889|Analytical, Diagnostic,Therapeutic Technique and Equipment
827952|NCT02982889|Anesthesia and Analgesia
827953|NCT02982876|Silicone Airway stent
827954|NCT02982876|Metallic Airway stent
827955|NCT02982850|Atrial Fibrillation
827956|NCT02982850|Valvular Insufficiency
827957|NCT02982850|Valvular Stenosis
827958|NCT02982824|Children
827959|NCT02982824|IQ
827960|NCT02982824|Idiopathic epilepsy
827961|NCT02982824|Magnesium supplementation
827962|NCT02982824|Seizure control
827963|NCT02982824|Chalfont score
827964|NCT02982811|Activity-based
827965|NCT02982811|Client-centred
827966|NCT02982811|Rehabilitation
827967|NCT02982811|Quality of life
827968|NCT02982772|Nicotine Replacement
827969|NCT02982772|Smoking
827970|NCT02982772|HIV
827971|NCT02982746|Head and neck cancer
827972|NCT02982746|Person Centred Care
827973|NCT02982746|Health related quality of life
827974|NCT02982746|EORTC QLQ-C30
827975|NCT02982746|EORTC QLQ-C35
827981|NCT02982694|MSI
827982|NCT02982694|colorectal
827983|NCT02982694|chemotherapy
827984|NCT02982694|Bevacizumab
827985|NCT02982694|Atezolizumab
827986|NCT02982681|Periodontal disease
827987|NCT02982681|Platelet rich fibrin
827988|NCT02982668|severe stroke
827989|NCT02982668|Acute Stroke
827990|NCT02982668|Enteral Feeding
827991|NCT02982668|Mortality
827992|NCT02982668|Disability
827993|NCT02982668|Clinical trial
827994|NCT02982655|Severe Stroke
827995|NCT02982655|Acute Stroke
827996|NCT02982655|Antihypertension
827997|NCT02982655|mortality
827998|NCT02982655|disability
827999|NCT02982655|clinical trial
828000|NCT02982629|Glaucoma
828001|NCT02982629|Eye Care
828002|NCT02982629|Community Outreach
828003|NCT02982577|Xerostomia
828004|NCT02982577|Pilocarpine
828005|NCT02982577|Quality of life
828006|NCT02982564|Exercise
828007|NCT02982564|Physical Functioning
828008|NCT02982564|Hispanic
828009|NCT02982538|posttraumatic stress symptoms
828010|NCT02982538|implementation
828011|NCT02982538|dissemination
828012|NCT02982538|PTSD
828013|NCT02982525|Mussels
828014|NCT02982525|Dietary Intervention
828015|NCT02982525|Long-term intervention
828016|NCT02982525|Vitamin D status
828017|NCT02982525|Selenium
828018|NCT02982525|Iodine
828019|NCT02982525|Vitamin B12
828020|NCT02982525|Omega-3 index
828021|NCT02982512|Potential local fields
828022|NCT02982512|Subthalamic neuronal activity
828023|NCT02982499|glaucoma
828024|NCT02982499|Leber optic neuropathy
828025|NCT02982499|anterior ischemic optic neuropathy
828026|NCT02982486|nivolumab
828027|NCT02982486|ipilimumab
828028|NCT02982486|immunotherapy
828029|NCT02982486|PD-1 inhibitor
828030|NCT02982486|sarcoma
828031|NCT02982460|Rotator cuff tendinopathy
828032|NCT02982460|Eccentric exercise
828033|NCT02982460|Isoinertial training
828034|NCT02982447|blue laser imaging,detection,randomized trial
828035|NCT02982434|atrial fibrillation
828036|NCT02982434|botulinum toxin
828037|NCT02982434|ischemic heart disease
828038|NCT02982395|Nanoxel M
828039|NCT02982395|Docetaxel PM
828040|NCT02982395|Docetaxel
828041|NCT02982395|Mitomycin C
828042|NCT02982395|BCG
828043|NCT02982395|BCG refractory
828044|NCT02982395|Non muscle invasive bladder cancer
828045|NCT02982395|intravesical
828046|NCT02982395|superficial bladder cancer
828047|NCT02982395|Urothelial carcinoma
828048|NCT02982395|Transitional cell carcinoma
828049|NCT02982382|Low Back Pain
828050|NCT02982382|Musculoskeletal Manipulations
828051|NCT02982382|Neurophysiology
828052|NCT02982382|Education
828056|NCT02982252|Power mobility
828057|NCT02982252|Wheelchair skills training
828058|NCT02982252|Older adults
828059|NCT02982226|Plantar Fasciitis
828060|NCT02982226|Jogger's Heel
828061|NCT02982226|ReNu
828062|NCT02982213|Newest Vital Sign
828063|NCT02982213|Anxiety
828064|NCT02982213|Health literacy
828065|NCT02982213|Neuraxial Analgesia
828066|NCT02982213|Epidural catheter placement
828067|NCT02982213|Pregnancy
828068|NCT02982213|Parturients
828069|NCT02982213|Pain Catastrophizing Scale
828070|NCT02982213|STAI questionnaire
828071|NCT02982213|Companion
828072|NCT02982200|Embolization Device
828073|NCT02982200|Medina
828074|NCT02982200|Rupture Intracranial Aneurysm
828075|NCT02982200|Unrupture Intracranial Aneurysm
828083|NCT02982174|no known ocular pathology
828084|NCT02982161|Third Molar Tooth Extraction
828085|NCT02982148|sentinel lymph node biopsy
828086|NCT02982148|methylene blue
828087|NCT02982148|intradermal injection
828088|NCT02982148|subcutaneous injection
828089|NCT02982135|hemorrhagic moyamoya disease
828090|NCT02982135|bypass
828091|NCT02982135|indirect bypass
828092|NCT02982083|Rheumatoid arthritis
828093|NCT02982083|Raloxifene
828094|NCT02982083|Disease activity
828095|NCT02982070|psychological well-being, academic success
828096|NCT02982044|blood flow
828097|NCT02982044|endothelial function
828098|NCT02982044|shear stress
828099|NCT02982031|Ultrasound-guided lumbar plexus blockade
828100|NCT02982031|Shamrock technique
828101|NCT02982031|Paramedian transverse scan
828102|NCT02982031|USG LPB
828103|NCT02982031|USGRA
828104|NCT02982005|KHK4827 (brodalumab)
828105|NCT02981979|Takayasu Arteritis
828106|NCT02981979|Leflunomide
828107|NCT02981953|Valtech Cardio
828108|NCT02981953|Cardioband
828109|NCT02981953|Tricuspid
828111|NCT02981914|Classical Hodgkin Lymphoma
828112|NCT02981914|B-cell Non-Hodgkin Lymphoma
828113|NCT02981914|Acute Myeloid Leukemia
828114|NCT02981914|Myelodysplastic Syndromes
828115|NCT02981914|pembrolizumab
828116|NCT02981875|reading eye movement
828117|NCT02981862|HPV infection
828118|NCT02981862|Blood sample
828119|NCT02981862|Biopsy
828120|NCT02981836|live attenuated varicella vaccine
828121|NCT02981836|protective effect
828122|NCT02981836|safety
828123|NCT02981836|immunogenicity
828124|NCT02981836|child
828125|NCT02981810|TONSILLAR COBLATION
828126|NCT02981797|symptomatic bone metastasis
828127|NCT02981797|metastatic
828128|NCT02981797|castration resistant
828129|NCT02981784|chronic myeloid leukemia (CML)
828130|NCT02981784|Philadelphia-positive (Ph+)
828131|NCT02981784|Acute Lymphoblastic Leukemia (ALL)
828132|NCT02981732|Osteoporosis
828133|NCT02981732|kidney yin deficiency syndrome
828134|NCT02981732|liuwei dihuang pill
828135|NCT02981706|Arteriovenous Fistula (AVF)
828136|NCT02981706|Arteriovenous Graft (AVG)
828137|NCT02981680|remote ischemic preconditioning; transient limb ischemia; acute kidney injury; coronary artery bypass graft surgery
828138|NCT02981641|Pancreatic cancer
828139|NCT02981641|Intraoperative radiotherapy (IORT)
828140|NCT02981641|Concurrent Chemoradiotherapy (CCRT)
828141|NCT02981602|Hepatitis
828142|NCT02981602|Chronic
828143|NCT02981602|HBV
828144|NCT02981576|Spinal Cord Injury
828145|NCT02981576|Mesenchymal Stem Cells
828146|NCT02981563|engagement
828147|NCT02981563|psychiatric in-patient care
828148|NCT02981563|mental health nursing
828149|NCT02981563|quality interactions
828150|NCT02981550|Infection
828151|NCT02981524|Colorectal Neoplasms
828152|NCT02981524|Gastrointestinal Neoplasms
828153|NCT02981524|Digestive System Neoplasms
828154|NCT02981524|Neoplasms by Site
828155|NCT02981524|Neoplasms
828156|NCT02981524|Digestive System Diseases
828157|NCT02981524|Gastrointestinal Diseases
828158|NCT02981524|Intestinal Diseases
828159|NCT02981524|Rectal Diseases
828160|NCT02981524|Colonic Diseases
828161|NCT02981498|Hepatic arterial infusion chemotherapy
828162|NCT02981498|Sorafenib
828163|NCT02981485|Fat Grafting, Breast Cancer Lymphedema
828164|NCT02981459|bladder pain
828165|NCT02981459|urinary frequency
828166|NCT02981459|urinary urgency
828167|NCT02981459|mirabegron
828168|NCT02981407|Red Blood Cell Transfusion
828169|NCT02981407|Anemia
828170|NCT02981407|Heart Disease
828171|NCT02981407|Cardiovascular Disease
828172|NCT02981381|sTMS
828173|NCT02981381|NeoSync
828174|NCT02981381|NEST
828175|NCT02981381|synchronous
828176|NCT02981381|non-invasive neuromodulation
828177|NCT02981381|TMS
828178|NCT02981381|Transcranial Magnetic Stimulation
828179|NCT02981381|PTSD
828180|NCT02981381|EEG
828181|NCT02981381|Depression
828182|NCT02981368|Diagnostic
828183|NCT02981368|Imaging
828184|NCT02981368|2301
828185|NCT02981368|PET/CT
828186|NCT02981368|PyL
828187|NCT02981368|PSMA
828188|NCT02981368|radical prostatectomy
828189|NCT02981368|metastatic prostate cancer
828190|NCT02981368|recurrent prostate cancer
828191|NCT02981355|BST-CarGel
828192|NCT02981355|Microfracture
828193|NCT02981355|Cartilage Lesion, Chondral Lesion
828194|NCT02981355|Femoral condyle
828195|NCT02981355|Bone Marrow Stimulation
828196|NCT02981355|Cartilage Repair
828197|NCT02981355|Tear of Articular Cartilage of Knee, Current
828198|NCT02981342|pancreatic cancer
828199|NCT02981329|Metformin
828200|NCT02981329|Sickle Cell Anemia
828201|NCT02981329|Sickle Cell Disease
828202|NCT02981329|Hemoglobinopathies
828203|NCT02981329|Hemoglobin Disorder
828204|NCT02981329|Blood Disease
828205|NCT02981329|Hemoglobin Disease; Sickle-Cell, Thalassemia
828206|NCT02981329|Hemoglobin Disease
828207|NCT02981277|Bronchoscopy
828208|NCT02981277|Lignocaine
828209|NCT02981264|Bronchoscopy
828210|NCT02981264|Lignocaine
828211|NCT02981264|Endobronchial Ultrasound
828212|NCT02981251|Hypertension
828213|NCT02981251|Uncontrolled blood pressure
828214|NCT02981251|Health education
828215|NCT02981251|Community based
828216|NCT02981199|microtransplantation
828217|NCT02981199|multiple myeloma
828218|NCT02981186|Intraocular Lens
828219|NCT02981186|trifocal
828220|NCT02981186|cataract
828221|NCT02981186|PhysIOL
828222|NCT02981147|cough
828223|NCT02981147|thyme
828224|NCT02981147|Cisti
828225|NCT02981147|Ivy Leaves
828226|NCT02981134|bioabsorbable scaffold
828227|NCT02981134|computed tomography
828228|NCT02981121|Diabetes Prevention
828229|NCT02981082|Systemic Sclerosis, Scleroderma, PAH, Pulmonary Hypertension
828230|NCT02981056|Skincare regimens
828231|NCT02981056|Skin moisturization
828232|NCT02981056|Skin barrier
828233|NCT02981056|Skin development
828234|NCT02981017|Chronic sinusitis
828235|NCT02981017|Frontal sinusitis
828236|NCT02981017|Skull base neoplasm
828237|NCT02981004|Aortic valve disease, patient prosthesis mismatch
828238|NCT02980965|breast cancer
828239|NCT02980965|neoadjuvant chemotherapy
828240|NCT02980965|endocrine therapy
828241|NCT02980965|concurrent
828242|NCT02980887|Pulmonary arterial hypertension
828254|NCT02980861|Gastric Cancer
828255|NCT02980861|Splenic Hilum Lymph Nodes Dissection
828256|NCT02980861|Gastrectomy
828257|NCT02980848|digital mammography
828258|NCT02980848|digital breast tomosynthesis
828259|NCT02980848|breast magnetic resonance imaging
828260|NCT02980848|screening
828261|NCT02980848|breast density
828262|NCT02980848|breast imaging
828263|NCT02980848|pre-operative magnetic resonance imaging
828264|NCT02980796|Brain
828265|NCT02980796|MRI
828266|NCT02980796|Exercise
828267|NCT02980796|Rehabilitation
828268|NCT02980796|TMS
828269|NCT02980770|Obstructive Sleep Apnea
828270|NCT02980770|Obesity Hypoventilation Syndrome
828271|NCT02980770|Hypercapnia
828272|NCT02980770|Post-Op Complication
828273|NCT02980770|Acid-Base Imbalance
828274|NCT02980744|Stroke
828275|NCT02980744|Sedentary behaviour
828276|NCT02980744|Intervention
828277|NCT02980731|Duration of overall response (Dor)
828278|NCT02980731|Complete remission rate (CR + CRi)
828279|NCT02980731|B-Cell receptor inhibitor (BCRi)
828280|NCT02980731|TP53 gene
828281|NCT02980731|Progression-free survival (PFS)
828282|NCT02980731|European Organization of Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
828283|NCT02980731|Refractory CLL
828284|NCT02980731|Overall response rate (ORR)
828285|NCT02980731|Overall survival (OS)
828286|NCT02980731|Relapsed CLL
828287|NCT02980731|17p deletion
828288|NCT02980718|Olfaction training
828289|NCT02980718|Smell
828290|NCT02980653|Phase II study
828291|NCT02980653|Critical body weight loss
828292|NCT02980653|Concurrent chemoradiotherapy
828293|NCT02980653|Megestrol acetate
828294|NCT02980653|Head and neck cancer
828295|NCT02980640|Multiple Sclerosis
828296|NCT02980640|Treatment
828297|NCT02980640|Quality of Life
828298|NCT02980640|Symptoms
828299|NCT02980627|Eating Disorders
828300|NCT02980627|Diabulimia
828301|NCT02980627|ED-T1DM
828302|NCT02980627|Type 1 Diabetes
828303|NCT02980627|Mobile Technology
828304|NCT02980627|Acceptance and Commitment Therapy
828305|NCT02980614|phase-contrast MRI
828306|NCT02980614|blood flow
828307|NCT02980614|velocity mapping
828308|NCT02980614|Quantitative MRI
828309|NCT02980614|Cardiac imaging
828310|NCT02980614|Tetralogy of Fallot
828311|NCT02980601|Traumatic Defect
828312|NCT02980601|Chronic Wounds
828313|NCT02980575|COPD
828314|NCT02980575|Music
828315|NCT02980575|Exercise
828316|NCT02980562|Bowel preparation
828317|NCT02980562|Ascorbic acid
828318|NCT02980562|Bisacodyl
828319|NCT02980562|Polyethylene glycol
828320|NCT02980536|NSCLC
828321|NCT02980536|TKI
828322|NCT02980536|Mutation
828323|NCT02980536|Liquid Biopsy
828324|NCT02980497|mouthrinse
828325|NCT02980497|plaque
828326|NCT02980497|gingivitis
828327|NCT02980497|gum bleeding
828328|NCT02980484|rTMS
828329|NCT02980458|Healthy
828330|NCT02980458|Bioequivalence
828331|NCT02980458|Deferiprone
828332|NCT02980445|Myopia
828333|NCT02980445|Outdoor time
828334|NCT02980445|Children
828335|NCT02980445|Intervention
828336|NCT02980445|Prevention
828337|NCT02980432|vestibular
828338|NCT02980432|spatial orientation
828339|NCT02980432|vision
828340|NCT02980432|optokinetic
828341|NCT02980406|FODMAP
828342|NCT02980406|Irritable bowel syndrome
828343|NCT02980406|Gastric accommodation
828344|NCT02980406|Gastric motility
828345|NCT02980406|brain-gut axis
828346|NCT02980393|congenital heart disease
828347|NCT02980393|smart mobile technology
828348|NCT02980393|children
828349|NCT02980393|adolescents
828350|NCT02980393|lifestyle counselling
828351|NCT02980393|nutrition
828352|NCT02980393|physical activity
828353|NCT02980380|non-invasive brain computer interface
828354|NCT02980380|communication
828355|NCT02980380|amyotrophic lateral sclerosis
828356|NCT02980380|complete locked-in state
828357|NCT02980367|Anterior Cruciate Ligament
828358|NCT02980367|ACL
828359|NCT02980367|Anterior Cruciate Ligament deficiency
828360|NCT02980367|ACL deficiency
828361|NCT02980367|ACLD
828362|NCT02980367|Anterior Cruciate Ligament reconstruction
828363|NCT02980367|ACL reconstruction
828364|NCT02980367|Anterior Cruciate Ligament physiotherapy
828365|NCT02980367|Anterior Cruciate Ligament rehabilitation
828366|NCT02980367|ACL physiotherapy
828367|NCT02980367|ACL rehabilitation
828368|NCT02980367|Anterior Cruciate Ligament management
828369|NCT02980367|ACL management
828370|NCT02980354|endothelial progenitor cells, ischaemic stroke, aging
828371|NCT02980341|Oncology
828372|NCT02980341|HER3
828373|NCT02980341|Antibody drug conjugate
828374|NCT02980341|Developmental Phase I/II
828375|NCT02980328|Overactive bladder
828376|NCT02980328|Urinary incontinence
828377|NCT02980328|Low-level light therapy
828378|NCT02980315|nasopharyngeal carcinoma
828379|NCT02980315|EBV related cancers
828380|NCT02980302|Mental retardation MR
828381|NCT02980302|IQ
828382|NCT02980302|Mutation
828383|NCT02980302|Gene MYT1L
828384|NCT02980276|Gestational Diabetes
828385|NCT02980276|Diabetes
828386|NCT02980276|Pregnancy
828387|NCT02980263|Kawasaki disease
828388|NCT02980263|Coronary artery aneurysm
828389|NCT02980263|mucocutaneous lymph node syndrome
828390|NCT02980263|lymph node syndrome
828391|NCT02980263|canakinumab
828392|NCT02980263|intravenous immunoglobulin naïve (IVIG-naïve)
828393|NCT02980263|intravenous immunoglobulin refractory (IVIG-refractory)
828394|NCT02980263|pediatric
828395|NCT02980250|feeding intolerance
828396|NCT02980250|premature infant
828397|NCT02980250|domperidone
828398|NCT02980237|Office workers
828399|NCT02980237|Quality of life
828400|NCT02980237|e-Learning
828401|NCT02980237|Occupational health
828402|NCT02980211|Alveolar Bone
828403|NCT02980211|Alveolar Ridge
828404|NCT02980211|Bone Resorption
828405|NCT02980211|Bone Grafting
828406|NCT02980211|Barrier Membrane
828407|NCT02980172|triage
828408|NCT02980120|Eating Disorders
828409|NCT02980120|Anorexia Nervosa
828410|NCT02980120|Bulimia Nervosa
828411|NCT02980094|aging
828412|NCT02980094|nutrients
828413|NCT02980094|milk
828414|NCT02980094|dietary supplementation
828415|NCT02980055|connective tissue graft
828416|NCT02980055|transplantation
828417|NCT02980055|collagen
828418|NCT02980055|autologous
828419|NCT02980055|gingiva
828420|NCT02980003|contrast media
828421|NCT02980003|contrast-induced acute kidney injury (AKI)
828422|NCT02980003|contrast-induced nephropathy (CIN)
828423|NCT02979990|infertility
828424|NCT02979990|education
828425|NCT02979951|Observational Study
828426|NCT02979951|Non-Interventional Study
828427|NCT02979951|Registries
828428|NCT02979951|Prospective
828429|NCT02979951|Monitored
828430|NCT02979951|Multicentric
828431|NCT02979951|International
828432|NCT02979951|Fosfomycin
828433|NCT02979951|Infectofos
828434|NCT02979951|Fomicyt
828435|NCT02979951|Bacterial Infections
828436|NCT02979951|Gram-Negative Bacterial Infections
828437|NCT02979951|Gram-Positive Bacterial Infections
828438|NCT02979951|Bone Diseases, Infectious
828439|NCT02979951|Osteomyelitis
828440|NCT02979951|Central Nervous System Bacterial Infections
828441|NCT02979951|Meningitis, Bacterial
828442|NCT02979951|Encephalitis
828443|NCT02979951|Brain Abscess
828444|NCT02979951|Urinary Tract Infections
828445|NCT02979951|Respiratory Tract Infections
828446|NCT02979951|Pneumonia, Bacterial
828447|NCT02979951|Skin Diseases, Bacterial
828448|NCT02979951|Soft Tissue Infections
828449|NCT02979951|Intraabdominal Infections
828450|NCT02979951|Sepsis
828451|NCT02979951|Bacteremia
828452|NCT02979951|Endocarditis, Bacterial
828453|NCT02979951|Treatment Outcome
828454|NCT02979951|Clinical Efficacy
828455|NCT02979951|Microbiological Efficacy
828456|NCT02979951|Safety
828457|NCT02979925|neuropathic pain
828458|NCT02979925|TMS
828459|NCT02979925|nerve injury
828460|NCT02979925|transcutaneous magnetic stimulation
828461|NCT02979912|Persistent corneal epithelial defect
828462|NCT02979912|Platelet Lysate
828463|NCT02979899|angiosarcoma
828596|NCT02978872|Cardiac surgery
828464|NCT02979886|single nucleotide polymorphism,GnRH receptor, IVF
828465|NCT02979873|Rapamycin
828466|NCT02979873|Relapse Prevention
828467|NCT02979873|Immune Tolerance
828468|NCT02979847|persistent atrial fibrillation
828469|NCT02979847|catheter ablation
828470|NCT02979847|hybrid
828471|NCT02979834|fetal movement
828472|NCT02979834|placenta site
828473|NCT02979834|body mass index
828474|NCT02979834|maternal education
828475|NCT02979821|pan-HER inhibitor
828476|NCT02979782|cardiac surgery
828477|NCT02979782|neurological outcome
828478|NCT02979782|minimal invasive coronary artery bypass graft (Endo-CABG)
828479|NCT02979769|Open-label extension study
828480|NCT02979769|Clinical trial Phase 2
828481|NCT02979769|Efficacy and safety
828482|NCT02979769|Heterotopic ossification
828483|NCT02979769|Flare-up
828484|NCT02979769|Palovarotene
828485|NCT02979769|Retinoic acide receptor agonist
828486|NCT02979769|Retinoic acide receptor gamma agonist
828487|NCT02979769|Clementia
828488|NCT02979769|Myositis Ossificans
828489|NCT02979769|Munchmeyer's Disease
828490|NCT02979769|FOP
828491|NCT02979717|satiety
828492|NCT02979717|protein
828493|NCT02979717|fiber
828494|NCT02979678|Breast cancer, quality of life
828495|NCT02979639|Herpes Zoster
828496|NCT02979639|Reactogenicity
828497|NCT02979639|Quality of life
828498|NCT02979639|Shingles
828499|NCT02979626|hospitalization
828500|NCT02979626|intensive care unit
828501|NCT02979626|school absenteeism
828502|NCT02979626|work absenteeism
828503|NCT02979600|Oral immunotherapy
828504|NCT02979600|Oral tolerance induction
828505|NCT02979574|acupuncture
828506|NCT02979574|pain
828507|NCT02979574|chronic pain
828508|NCT02979574|pain management
828509|NCT02979574|16-1579
828510|NCT02979561|Dabigatran etexilate
828511|NCT02979561|Recurrence of DVT
828512|NCT02979561|Pulmonary Embolism
828513|NCT02979561|Warfarin
828514|NCT02979548|Aprepitant
828521|NCT02979522|Drug therapy, pediatric Hodgkin disease, frontline Hodgkin disease, advanced stage Hodgkin disease, pediatric lymphoma
828522|NCT02979496|immune
828523|NCT02979496|citrus
828524|NCT02979470|advanced colon cancer
828525|NCT02979470|advanced rectum cancer
828526|NCT02979470|circulating tumor cells
828527|NCT02979470|immune response
828528|NCT02979470|mutations
828529|NCT02979457|telephone consultation, patient involvement
828530|NCT02979418|Water insecurity
828531|NCT02979340|Cystic Fibrosis Liver Disease
828532|NCT02979340|Pancreatic Insufficiency
828533|NCT02979275|acute kidney injury
828534|NCT02979275|cardiopulmonary bypass
828535|NCT02979275|neutrophil gelatinase-associated lipocalin
828536|NCT02979275|tissue hypoxia
828537|NCT02979249|Interventional
828538|NCT02979249|open-label
828539|NCT02979249|EPP
828540|NCT02979249|XLP
828541|NCT02979249|porphyria
828542|NCT02979197|High blood pressure
828543|NCT02979197|Systolic blood pressure
828544|NCT02979197|Diastolic blood pressure
828545|NCT02979197|Antihypertensive
828546|NCT02979184|Lymphedema, Obstructive Sleep Apnea , Intensive Decongestive Physiotherapy
828547|NCT02979119|Hemophilia
828548|NCT02979119|Children, ,
828549|NCT02979119|Inhibitors,
828550|NCT02979119|Prophylaxis
828551|NCT02979119|Long-term outcome
828552|NCT02979119|Congenital
828553|NCT02979093|maternal drug addiction
828554|NCT02979093|mother-infant attachment
828555|NCT02979093|intranasal oxytocin
828556|NCT02979093|unresolved trauma
828557|NCT02979093|maternal brain responses
828558|NCT02979093|mother-infant synchrony
828559|NCT02979067|Apnoea time, preoxygenation, difficult airway, emergency
828560|NCT02979041|neck pain
828561|NCT02979041|Virtual reality
828562|NCT02979041|Range of motion
828563|NCT02979041|physiotherapy
828564|NCT02979041|Air force
828565|NCT02979041|kinematics
828566|NCT02979028|TEAS
828567|NCT02979028|complication
828568|NCT02978989|Laparoscopic cholecystectomy
828569|NCT02978989|Solo surgery
828570|NCT02978989|Camera holder
828571|NCT02978989|Cholecystitis
828572|NCT02978976|RDS
828573|NCT02978976|Doppler on fetal pulmonary artery
828578|NCT02978950|duplex ultrasound
828579|NCT02978950|trauma
828580|NCT02978950|venous thromboembolism
828581|NCT02978950|prevention
828582|NCT02978924|spinal cord
828583|NCT02978924|tsDCS
828584|NCT02978924|3D motion capture
828585|NCT02978924|EMG
828586|NCT02978911|RMI
828587|NCT02978898|Follicular Lymphoma
828588|NCT02978898|flow cytometry
828589|NCT02978898|CD180
828590|NCT02978898|Toll-like receptor
828591|NCT02978898|lymphoproliferative disease
828592|NCT02978885|Acute lung injury
828593|NCT02978885|Chronic obstructive pulmonary disease (COPD)
828594|NCT02978885|Whipple procedures
828595|NCT02978885|pancreatico-duodenectomies
828597|NCT02978872|Quantra
828598|NCT02978872|Viscoelastic testing
828599|NCT02978872|Coagulation
828600|NCT02978859|MGCD516
828601|NCT02978859|Sarcoma
828602|NCT02978859|liposarcoma
828603|NCT02978859|Unresectable Liposarcoma
828604|NCT02978859|Metastatic Liposarcoma
828605|NCT02978833|Gluteus Medius Tendinosis
828606|NCT02978820|scientific exercise approach to scoliosis
828607|NCT02978820|core stabilization training
828608|NCT02978820|bracing
828609|NCT02978820|adolescent idiopathic scoliosis
828610|NCT02978794|stroke, clinical pathway, medical care
828612|NCT02978768|dementia
828613|NCT02978768|Tai Chi
828614|NCT02978768|mental training
828615|NCT02978768|cognitive rehabilitation
828616|NCT02978742|Eating Disorders
828617|NCT02978742|Bulimia Nervosa
828618|NCT02978742|Binge Eating Disorder
828619|NCT02978742|App
828620|NCT02978742|Smartphone
828621|NCT02978742|Self-Help
828622|NCT02978742|Coaching
828623|NCT02978742|Recovery Record
828624|NCT02978742|Mobile Phone
828625|NCT02978742|Cognitive Behavioral Therapy
828626|NCT02978729|Telemedicine
828627|NCT02978729|Counseling, Genetic
828628|NCT02978716|Breast Cancer
828629|NCT02978716|CDK 4/6 Inhibitor
828630|NCT02978716|Triple Negative Breast Cancer
828634|NCT02978664|colonoscopy
828635|NCT02978664|water exchange
828636|NCT02978664|adenoma detection rate
828637|NCT02978664|distraction
828638|NCT02978651|EDS
828639|NCT02978651|OSA
828640|NCT02978638|Spinal cord injury
828641|NCT02978638|Bladder capacity
828642|NCT02978638|Electrical stimulation
828643|NCT02978638|Continence
828644|NCT02978638|Urodynamics
828645|NCT02978612|Colorectal Neoplasms
828646|NCT02978586|PSMA
828647|NCT02978586|PET/MRI
828648|NCT02978573|First MTP Joint
828649|NCT02978573|Hallux Rigidus
828650|NCT02978573|Hallux Limitus
828651|NCT02978573|Cartilage Replacement
828652|NCT02978573|Osteoarthritis
828653|NCT02978573|First MTP Joint Osteoarthritis
828654|NCT02978573|Big Toe Pain
828655|NCT02978547|Resectable pancreatic ductal adenocarcinoma
828656|NCT02978547|PDAC
828657|NCT02978547|Metformin
828658|NCT02978534|pregnant
828659|NCT02978534|quetiapine
828660|NCT02978534|bipolar
828661|NCT02978534|women
828662|NCT02978534|female
828663|NCT02978534|postpartum
828664|NCT02978534|seroquel
828665|NCT02978534|perinatal
828666|NCT02978534|manic-depressive
828667|NCT02978469|Habitual Physical Activity (HPA); Sedentary Behavior;
828668|NCT02978456|IVUS guided PCI
828669|NCT02978456|QCA guided PCI
828670|NCT02978443|Melanoma
828671|NCT02978443|Mucosal
828672|NCT02978443|Acral Lentiginous
828673|NCT02978443|Ipilimumab
828674|NCT02978443|Nivolumab
828675|NCT02978443|Anti-tumor
828676|NCT02978443|Potential Predictors
828677|NCT02978443|Opdivo
828678|NCT02978443|Yervoy
828679|NCT02978430|Fluid therapy
828680|NCT02978430|Anesthesiology
828681|NCT02978430|Major surgery
828682|NCT02978430|Goal-directed fluid therapy
828683|NCT02978430|Fluid responsiveness
828684|NCT02978430|Closed-loop system
828685|NCT02978417|Medication-assisted treatment
828686|NCT02978417|Drug Court
828687|NCT02978417|Pilot study
828688|NCT02978417|Opioid dependence
828689|NCT02978417|Criminal justice
828690|NCT02978404|radiosurgery
828691|NCT02978404|PD-1
828692|NCT02978404|Nivolumab
828693|NCT02978326|Postpartum Care
828694|NCT02978287|Calcium sensing receptor
828695|NCT02978287|Parathyroid cell viability
828696|NCT02978287|Parathyroid allotransplantation
828697|NCT02978287|Transporting solution
828698|NCT02978235|Multiple Myeloma
828699|NCT02978235|Relapsed/Refractory
828700|NCT02978235|Lymphoma
828701|NCT02978235|Non-Hodgkin Lymphoma
828702|NCT02978235|Diffuse Large B-Cell Lymphoma
828703|NCT02978235|DLBCL
828704|NCT02978235|Mantle Cell Lymphoma
828705|NCT02978235|MCL
828706|NCT02978235|Peripheral T-Cell Lymphoma
828707|NCT02978235|PTCL
828708|NCT02978235|TAS4464
828709|NCT02978235|NEDD8
828710|NCT02978235|NAE inhibitor
828711|NCT02978235|Neoplasms
828712|NCT02978235|Hematologic Diseases
828713|NCT02978235|Myeloma
828714|NCT02978170|Bronchoscopy
828715|NCT02978170|Lung lesions
828716|NCT02978170|Cone Beam Computed Tomography
828717|NCT02978170|CBCT
828718|NCT02978170|Cone Beam CT
828719|NCT02978157|Helicobacter pylori
828720|NCT02978157|Eradication rate
828721|NCT02978157|Rescue treatment
828722|NCT02978144|Chronic Obstructive Pulmonary Disease (COPD)
828723|NCT02978131|TUBERCULOSIS
828724|NCT02978131|Sensitivity and Specificity
828725|NCT02978131|Polymerase Chain Reaction
828726|NCT02978131|Immunohistochemistry
828727|NCT02978131|Histochemistry
828858|NCT02977585|helmet
828728|NCT02978131|Paraformaldehyde and paraffin embedded tissues
828729|NCT02978053|Bright light
828730|NCT02978053|Sleepiness
828731|NCT02978053|Sleep
828732|NCT02978053|Psychomotor vigilance
828733|NCT02978040|Antiplatelet therapy
828734|NCT02978040|Cangrelor
828735|NCT02978040|Tirofiban
828736|NCT02978040|Prasugrel
828737|NCT02978040|Acute Myocardial Infarction
828738|NCT02978040|Primary Percutaneous Coronary Intervention
828739|NCT02978040|Pharmacokinetic/Pharmacodynamic
828740|NCT02978027|motivational interviewing
828741|NCT02978027|brief alcohol intervention in primary care
828742|NCT02978014|Prostate
828743|NCT02978014|Radiotherapy
828744|NCT02978014|Obturator
828745|NCT02978014|Toxicity
828746|NCT02978014|Bowel
828747|NCT02978014|Urinary
828748|NCT02978014|Sexual
828749|NCT02978014|PROM
828750|NCT02978014|EPIC
828751|NCT02977988|Mindfulness
828752|NCT02977988|Women
828753|NCT02977988|Relapse prevention
828754|NCT02977988|Clinical trial
828755|NCT02977988|Substance use disorder
828756|NCT02977988|Ethnically diverse
828757|NCT02977988|Underserved
828758|NCT02977988|Health disparities
828759|NCT02977988|Stress
828760|NCT02977988|Addiction
828761|NCT02977988|Latina/Hispanic
828762|NCT02977988|African American
828763|NCT02977988|Treatment retention
828764|NCT02977988|Residential treatment
828765|NCT02977988|Brain Imaging
828766|NCT02977975|Irritable bowel syndrome
828767|NCT02977975|The human microbiome
828768|NCT02977975|Microbiota
828769|NCT02977975|Gut microbiota
828770|NCT02977975|Probiotics
828771|NCT02977975|Sauerkraut
828772|NCT02977949|SERM
828773|NCT02977949|Season
828774|NCT02977949|Variation
828775|NCT02977949|Vitamin D
828776|NCT02977923|Virtual reality
828777|NCT02977923|Immersive distraction
828778|NCT02977923|Oculus rift
828779|NCT02977923|Virtual world
828780|NCT02977923|Virtual environment
828781|NCT02977923|Procedural pain
828782|NCT02977923|Procedural anxiety
828783|NCT02977923|Acute pain
828784|NCT02977923|Pain management
828785|NCT02977923|Anxiety
828786|NCT02977923|Children, Child
828787|NCT02977923|Kid, Kids
828788|NCT02977923|Pediatric, Pediatrics
828789|NCT02977923|Young children
828790|NCT02977923|Burns
828791|NCT02977923|Burn injuries
828792|NCT02977923|Burn unit
828793|NCT02977923|Physiotherapy
828794|NCT02977923|Physical therapy
828795|NCT02977923|Burn dressing
828796|NCT02977923|Dressing change
828797|NCT02977923|Non-pharmacological, nonpharmacological
828798|NCT02977923|Clinical Research
828799|NCT02977923|Nursing Practice
828800|NCT02977897|Diarrhea
828801|NCT02977897|Immunosuppression
828802|NCT02977897|Post-transplantation
828803|NCT02977897|Octreotide
828804|NCT02977897|Mycophenolate Mofetil
828805|NCT02977897|Fecal Calprotectin
828806|NCT02977884|nutrition
828807|NCT02977884|exercise
828808|NCT02977884|stress
828809|NCT02977884|cardiovascular disease
828810|NCT02977884|diabetes
828811|NCT02977884|hypertension
828812|NCT02977884|dyslipidemia
828813|NCT02977884|cholesterol
828814|NCT02977884|overweight
828815|NCT02977884|obesity
828816|NCT02977884|lifestyle
828817|NCT02977871|Cesarean section
828818|NCT02977871|operating time
828819|NCT02977871|bladder
828820|NCT02977871|urinary retention
828821|NCT02977845|dypsnea
828822|NCT02977845|fatigue
828823|NCT02977845|anxiety
828824|NCT02977845|Qigong
828825|NCT02977845|Lung cancer
828826|NCT02977832|LUTS
828827|NCT02977832|Iresine celosia
828828|NCT02977832|Odyliresin
828829|NCT02977832|medical therapy
828830|NCT02977780|Glioblastoma
828831|NCT02977728|MTBI
828832|NCT02977728|olfaction
828833|NCT02977728|acute
828834|NCT02977715|Democratic Republic of the Congo
828835|NCT02977715|IMVAMUNE
828836|NCT02977715|Modified Vaccinia Ankara (MVA)
828837|NCT02977715|Monkeypox
828838|NCT02977715|Orthopoxvirus
828839|NCT02977715|Vaccine
828840|NCT02977715|Vaccinia virus
828841|NCT02977689|Isocitrate dehydrogenase (IDH)
828842|NCT02977689|R-2-Hydroxyglutarate (2-HG)
828843|NCT02977689|Gene encoding UDP-glucuronosyltransferase (UGT1A1)
828844|NCT02977689|Glioblastoma (GBM)
828845|NCT02977689|IDH305
828846|NCT02977689|IDHR132 mutations
828847|NCT02977689|Astrocytoma
828848|NCT02977689|Oligodendroglioma
828849|NCT02977689|Oligoastrocytoma
828850|NCT02977689|IDH1 R132H
828851|NCT02977689|IDH1
828852|NCT02977637|hht
828853|NCT02977637|hereditary
828854|NCT02977637|hemorrhagic
828855|NCT02977637|telangiectasia
828856|NCT02977637|feraheme
828857|NCT02977585|continous positive airway pressure
828859|NCT02977585|non invasive
828860|NCT02977585|positive end expiratory pressure
828861|NCT02977585|severe bronchiolitis
828862|NCT02977585|pediatric intensive care unit
828863|NCT02977572|Non-invasive ventilation,
828864|NCT02977572|continuous positive airway pressure
828865|NCT02977572|cardiogenic pulmonary oedema,
828866|NCT02977572|acute respiratory failure
828867|NCT02977559|Laryngeal Tube Suction Ambu AuraGain Leak Pressure
828868|NCT02977546|Hemodynamics
828869|NCT02977546|Noninvasive
828870|NCT02977546|Pulse contour analysis
828871|NCT02977546|Heart failure
828872|NCT02977546|Swan Ganz Catheterization
828873|NCT02977546|Pulmonary artery Catheter
828874|NCT02977468|triple negative breast cancer
828875|NCT02977468|Pembrolizumab
828876|NCT02977468|IORT
828877|NCT02977468|tumor microenvironment
828878|NCT02977442|Mitochondrial Dynamics
828879|NCT02977442|Insulin Resistance
828880|NCT02977442|Exercise and Diabetes
828881|NCT02977429|Tumor
828882|NCT02977429|Abdominal infection
828883|NCT02977429|Hemodynamics
828884|NCT02977429|Pcv-aCO2
828885|NCT02977429|Early Goal-directed Therapy (EGDT)
828886|NCT02977416|Juvenile idiopathic arthritis
828887|NCT02977416|fat oxidation
828888|NCT02977416|exercise
828889|NCT02977403|Binge Eating
828890|NCT02977403|Eating Behavior
828891|NCT02977403|Children
828892|NCT02977403|Magnetoencephalography
828893|NCT02977403|Loss of Control
828894|NCT02977351|Periodontopathogenic microorganisms
828895|NCT02977351|Non-surgical periodontal treatment
828896|NCT02977325|Physical activity level
828897|NCT02977325|Personal efficacy
828898|NCT02977325|Knee osteoarthritis
828899|NCT02977325|Self-management
828900|NCT02977325|Self-care
828901|NCT02977325|Education and exercise in knee osteoarthritis
828902|NCT02977273|Meal size
828903|NCT02977260|Meal size
828904|NCT02977247|SoftVue
828905|NCT02977247|Dense Breast Tissue
828906|NCT02977247|Breast Screening
828907|NCT02977247|Abnormal Breast
828908|NCT02977247|Normal Breast
828909|NCT02977247|Breast Imaging
828910|NCT02977247|Breast Biopsy
828911|NCT02977247|Mammography
828912|NCT02977247|Tomosynthesis
828913|NCT02977247|Automated Breast Ultrasound
828914|NCT02977247|Breast Cancer
828915|NCT02977247|Breast Carcinoma
828916|NCT02977247|Breast Tumors
828917|NCT02977247|Mammary Carcinoma
828918|NCT02977247|Malignant Breast Tumor
828919|NCT02977247|Mammary Neoplasm
828920|NCT02977247|Mammary Cancer
828921|NCT02977247|ABUS
828922|NCT02977247|AWBUS
828923|NCT02977247|Breast Tomography
828924|NCT02977247|ATUS
828925|NCT02977247|ABTUS
828926|NCT02977247|Mammogram
828927|NCT02977247|3D Mammogram
828928|NCT02977247|3D ABUS
828929|NCT02977247|3D Breast Ultrasound
828930|NCT02977247|DBT
828931|NCT02977247|FFDM
828932|NCT02977247|Digital Mammography
828933|NCT02977247|Breast Ultrasound
828934|NCT02977247|Dense Breasts
828935|NCT02977247|Breast Density
828936|NCT02977247|Dense Parenchyma
828937|NCT02977247|Asymptomatic
828938|NCT02977247|Delphinus
828939|NCT02977247|Delphinus Medical Technologies
828940|NCT02977247|Diagnostic Breast Imaging
828941|NCT02977221|corticotomy
828942|NCT02977221|piezocision
828943|NCT02977221|piezosurgery
828944|NCT02977221|acceleration of tooth movement
828945|NCT02977221|crowded anterior teeth
828946|NCT02977208|Gabapentin
828947|NCT02977208|OCT2
828948|NCT02977208|OCTN1
828949|NCT02977208|Pharmacogenetics
828950|NCT02977208|Pharmacokinetics
828951|NCT02977208|Polymorphisms
828952|NCT02977195|First in Human
828953|NCT02977195|monoclonal antibody
828954|NCT02977195|Netrin-1
828955|NCT02977156|Injectable lesion
828956|NCT02977156|Intra-tumoral injection
828957|NCT02977143|fluid responsiveness
828958|NCT02977143|central venous pressure
828959|NCT02977143|positive end-expiratory pressure
828960|NCT02977143|robot surgery
828961|NCT02977117|magnesium
828962|NCT02977117|ectopic calcification
828963|NCT02977117|chronic kidney disease - mineral and bone disorder
828964|NCT02977117|serum calcification propensity
828965|NCT02977091|short stature
828966|NCT02977091|fitness
828967|NCT02977091|children
828968|NCT02977078|Inhaler
828969|NCT02977065|Dyslipidemia
828970|NCT02977065|CETP Inhibitors
828971|NCT02977065|Hyperlipidemia
828976|NCT02976987|Colvir
828977|NCT02976987|high grade squamous intraepithelial lesions
828978|NCT02976987|cervix
828979|NCT02976974|chronic pain
828980|NCT02976974|central sensitization
828981|NCT02976974|function
828982|NCT02976974|force
828983|NCT02976974|ultrasonography
828984|NCT02976961|Information
828985|NCT02976961|Empowerment
828986|NCT02976922|RAS
828987|NCT02976922|microbiome
828988|NCT02976922|probiotics
828989|NCT02976883|Hypoxia
828990|NCT02976883|HX4
828991|NCT02976883|PET CT
828992|NCT02976883|Radiotherapy
828993|NCT02976870|Hydronephrosis
828994|NCT02976870|Anterior Lumbar Interbody Fusion
828995|NCT02976857|refractory diffuse large B-cell lymphoma
828996|NCT02976857|anti-CD19 chimeric antigen receptor T-cell
828997|NCT02976844|optimal balloon volume
828998|NCT02976844|positive end-expiratory pressure
828999|NCT02976831|Plaque psoriasis vulgaris
829000|NCT02976792|Transcatheter aortic valve implantation
829001|NCT02976792|Acute Kidney Injury
829002|NCT02976792|early acute kidney injury detection
829003|NCT02976792|Nephrocheck™
829004|NCT02976792|Renal Resistive Index
829005|NCT02976766|Neuroprotection
829006|NCT02976766|Clinical trial
829007|NCT02976766|Traditional Chinese medicine
829008|NCT02976766|Axonal loss
829009|NCT02976766|Jiaogulan
829010|NCT02976766|Gynostemma pentaphyllum
829011|NCT02976766|Optical coherence tomography
829012|NCT02976753|Blood Coagulation Disorders
829013|NCT02976753|Hematologic Diseases
829014|NCT02976753|Coagulation Protein Disorders
829015|NCT02976753|Hemorrhagic Disorders
829016|NCT02976753|Genetic Diseases, Inborn
829017|NCT02976740|lung cancer
829018|NCT02976740|SBRT
829019|NCT02976740|rhGM-CSF
829020|NCT02976740|Thymosin Alpha 1
829021|NCT02976727|Vitamin D
829022|NCT02976727|Calcipotriol
829023|NCT02976727|Ablative fractional laser
829024|NCT02976727|Actinic keratosis
829025|NCT02976727|Photodynamic therapy
829026|NCT02976714|Cystic Fibrosis
829027|NCT02976714|Lung disease
829028|NCT02976714|DNA methylation
829029|NCT02976714|Predictive biomarkers
829030|NCT02976701|STEMI
829031|NCT02976701|acute coronary syndrome
829032|NCT02976701|DLBS1033
829033|NCT02976701|microvascular resistance index
829034|NCT02976701|Left ventricular function
829035|NCT02976688|Endstage renal Disease
829036|NCT02976688|Hemodialysis
829037|NCT02976649|Morbid obesity
829038|NCT02976649|Bariatric surgery
829039|NCT02976649|Multi-dimensional score
829040|NCT02976636|Obesity treatment
829041|NCT02976636|Parenting training
829042|NCT02976636|Parenting style
829043|NCT02976636|Family-based behavioral therapy
829044|NCT02976623|metrics
829045|NCT02976623|feedback
829046|NCT02976623|ultrasound-guided
829047|NCT02976623|procedural skills
829048|NCT02976610|hemolysis
829050|NCT02976584|EEG
829051|NCT02976584|Cardiac Surgery
829052|NCT02976584|Seizure
829053|NCT02976584|Tranexamic acid
829054|NCT02976558|CAM
829055|NCT02976558|allogenic Stem Cell Transplantation
829056|NCT02976558|Graft-Versus-Host Disease
829057|NCT02976558|Depression
829058|NCT02976558|Quality of Life
829059|NCT02976558|Acupuncture
829060|NCT02976558|Traditional chinese Medicine
829061|NCT02976558|Integrative medicine
829062|NCT02976558|Complementary and Alternative Medicine
829063|NCT02976558|Music therapy TaKeTiNa
829064|NCT02976558|Clown theatrical performance
829065|NCT02976558|Humour
829066|NCT02976558|Chemotherapy side effects
829067|NCT02976558|Psycho neuro immune system
829068|NCT02976558|GvHD
829069|NCT02976558|PNEIS
829070|NCT02976558|CMV
829071|NCT02976558|EBV
829072|NCT02976558|holistic medicine
829073|NCT02976532|Electromagnetic tracking
829074|NCT02976532|Internal rotation gait
829075|NCT02976532|Femoral derotation osteotomy
829076|NCT02976480|Irrigation
829077|NCT02976454|Obesity treatment
829078|NCT02976454|Primary care
829079|NCT02976454|Guided Self-Help
829080|NCT02976428|knee soft tissue balancing
829081|NCT02976428|sensor-guided
829082|NCT02976428|range of motion
829083|NCT02976415|Cardiac Surgery
829084|NCT02976415|Physiotherapy
829085|NCT02976415|In-Bed Cycling
829086|NCT02976415|Mechanical Ventilation
829087|NCT02976415|Cycle Ergometry
829088|NCT02976415|Early Mobilization
829089|NCT02976415|Rehabilitation
829090|NCT02976415|Critical Care
829091|NCT02976415|Intensive Care Unit
829092|NCT02976389|Supplemental Nutrition Assistance Program
829093|NCT02976389|Food insecurity
829094|NCT02976389|fruit and vegetable
829095|NCT02976389|healthy diet
829096|NCT02976376|Myocardial infarction
829097|NCT02976376|e-Health
829098|NCT02976376|mHealth
829099|NCT02976376|mobile phones
829100|NCT02976376|smartphone
829101|NCT02976376|follow-up
829102|NCT02976363|Radiotherapy
829103|NCT02976363|Respiratory muscles
829104|NCT02976363|Neoplasms
829105|NCT02976363|Breast
829106|NCT02976350|Heart failure
829107|NCT02976350|Heart failure with preserved ejection fraction
829108|NCT02976350|GH deficiency
829109|NCT02976350|Testosterone deficiency
829110|NCT02976350|Low- T3 syndrome
829111|NCT02976350|Multiple Hormone Deficiencies
829112|NCT02976337|Central sensitization
829113|NCT02976337|Endogenous opioids
829114|NCT02976337|Humans
829115|NCT02976337|Latent sensitization
829116|NCT02976337|Mandibular third molar extraction
829117|NCT02976337|Naloxone
829118|NCT02976337|Pain
829119|NCT02976337|Pressure algometry
829120|NCT02976337|Randomized controlled trial
829121|NCT02976337|Secondary hyperalgesia
829122|NCT02976337|Target controlled infusion
829123|NCT02976311|inflammatory reaction
829124|NCT02976311|IL-6
829125|NCT02976311|TNF
829126|NCT02976311|Misgav Ladach technique
829127|NCT02976311|Pfannenstiel-Kerr technique
829128|NCT02976311|cesarean delivery
829129|NCT02976311|cesarean technique
829130|NCT02976298|cerebellum
829131|NCT02976298|supplementary motor area
829132|NCT02976285|arthroscopic rotator cuff repair
829133|NCT02976285|patch augmentation
829134|NCT02976272|Bortezomib regimen
829135|NCT02976272|patients with multiple myeloma
829136|NCT02976233|Acute Respiratory Failure
829137|NCT02976233|Non Invasive Ventilation
829138|NCT02976233|Ultrasound
829139|NCT02976233|Diaphragm Thickening
829140|NCT02976168|Cognitive functioning
829141|NCT02976168|Brain tissue oxygenation
829142|NCT02976168|cerebral perfusion
829143|NCT02976168|head down tilt
829144|NCT02976155|critically ill, intensive care, enteral nutrition
829145|NCT02976142|gastric cancer, metastatic
829146|NCT02976142|positive wash cytology
829147|NCT02976142|neoadjuvant intraperitoneal immunotherapy
829148|NCT02976116|Fruquintinib
829149|NCT02976116|NSCLC
829150|NCT02976116|1st line
829151|NCT02976103|recovery
829152|NCT02976103|pain
829153|NCT02976103|surgical drains
829154|NCT02976077|social cognition
829155|NCT02976077|cognitive remediation
829156|NCT02976077|emotions
829157|NCT02976077|theory of mind
829158|NCT02976077|attributions
829159|NCT02976077|social perception
829160|NCT02976064|physical activity
829161|NCT02976064|lifestyle
829162|NCT02976064|adaptive case management
829163|NCT02976064|telemedicine
829164|NCT02976064|integrated care
829165|NCT02976064|collaborative self-management
829166|NCT02976038|Primary Mitochondrial Disease
829167|NCT02976038|Stealth
829168|NCT02976038|elamipretide
829169|NCT02976012|Proliferative Diabetic Retinopathy
829170|NCT02976012|Aflibercept
829171|NCT02976012|Vitreous Hemorrhage
829172|NCT02975986|acidic, urine, nephrolithiasis, free fatty acid.
829173|NCT02975973|tDCS
829174|NCT02975973|cognitive control
829175|NCT02975973|EEG
829176|NCT02975973|gamma oscillations
829177|NCT02975960|systemic sclerosis
829178|NCT02975960|adipose derived stem cell
829179|NCT02975960|stromal vascular fraction
829180|NCT02975960|digital ulcer
829181|NCT02975960|gangrene
829182|NCT02975934|CRPC
829183|NCT02975934|PARP inhibitor
829184|NCT02975934|PARPi
829185|NCT02975934|BRCA
829186|NCT02975934|ATM
829187|NCT02975934|HRD
829188|NCT02975934|TRITON
829189|NCT02975934|homologous recombination
829190|NCT02975934|DNA repair
829191|NCT02975934|DNA defect
829192|NCT02975934|DNA anomaly
829193|NCT02975934|germline
829194|NCT02975934|somatic
829199|NCT02975908|Acute Respiratory Distress Syndrome
829200|NCT02975908|epidemiology
829201|NCT02975908|clinical features
829202|NCT02975908|management
829203|NCT02975908|prognosis
829204|NCT02975869|Leukemia
829205|NCT02975869|Acute Myeloid Leukemia
829206|NCT02975856|Anthocyanins
829207|NCT02975856|Bioavailability
829208|NCT02975856|Flavonoids
829209|NCT02975856|Port wine
829210|NCT02975856|Red wine
829211|NCT02975817|pediatric, intraoperative, neurosurgery, inadvertent
829212|NCT02975804|cerebral palsy
829213|NCT02975804|video games
829214|NCT02975804|postural control
829215|NCT02975804|balance
829216|NCT02975804|children
829217|NCT02975791|Airway Obstruction
829218|NCT02975778|80 years old
829219|NCT02975765|corticotomy
829220|NCT02975765|minimally invasive
829221|NCT02975765|piezosurgery
829222|NCT02975765|piezocision
829223|NCT02975765|pain
829224|NCT02975765|discomfort
829225|NCT02975739|Intratumoral
829226|NCT02975739|Tongue
829227|NCT02975739|Microspheres
829228|NCT02975726|Liver Cirrhosis
829229|NCT02975726|Refractory ascites
829230|NCT02975726|PD catheter
829231|NCT02975713|P4,ART,IVF,FSH,LH,AMH
829232|NCT02975700|PLX3397
829233|NCT02975700|Kit-mutant Melanoma
829234|NCT02975687|Acute
829235|NCT02975687|Leukemia
829236|NCT02975687|Lymphoid
829237|NCT02975687|CD19
829238|NCT02975687|Refractory
829239|NCT02975635|Patients' Preferences
829240|NCT02975596|educational intervention
829241|NCT02975583|Atherosclerosis
829242|NCT02975557|Brimonidine
829243|NCT02975557|Dry Eye
829244|NCT02975557|oGVHD
829245|NCT02975557|MGD
829246|NCT02975544|social and emotional competence
829247|NCT02975544|healthy lifestyles
829248|NCT02975544|children
829249|NCT02975544|educational programme
829250|NCT02975531|Pompage
829251|NCT02975479|Hay fever
829252|NCT02975479|Pollen allergy
829253|NCT02975479|Allergic rhinitis
829254|NCT02975440|Vilaprisan
829255|NCT02975440|PK
829256|NCT02975440|rifampicin
829257|NCT02975440|midazolam,
829258|NCT02975440|CYP3A4 induction
829259|NCT02975440|drug-drug interaction
829260|NCT02975427|Diet
829261|NCT02975427|Abdominal bioelectrical impedance analysis
829262|NCT02975427|Anthropometry
829263|NCT02975427|Insulin resistance
829276|NCT02975323|hepatic venous pressure gradient
829277|NCT02975323|liver disease
829278|NCT02975323|US Doppler waveform
829279|NCT02975323|Cirrhosis
829280|NCT02975297|smoking
829281|NCT02975297|pre-diabetes
829282|NCT02975297|overweight
829283|NCT02975297|exenatide
829284|NCT02975297|GLP-1 agonists
829285|NCT02975284|bronchial thermoplasty
829286|NCT02975284|long term
829287|NCT02975284|interventional bronchoscopy
829288|NCT02975258|HIV
829289|NCT02975258|Asthma
829290|NCT02975258|Adiposity
829291|NCT02975258|Lung disease
829292|NCT02975258|Weight
829293|NCT02975258|Fat
829294|NCT02975258|Obese
829295|NCT02975245|Male infertility
829296|NCT02975245|Germ cells
829297|NCT02975245|Chemotherapy
829298|NCT02975245|Sperm
829299|NCT02975232|nutrition disparities
829300|NCT02975232|SNAP population
829301|NCT02975232|behavioral economics
829302|NCT02975232|retail setting
829303|NCT02975232|point of purchase education
829304|NCT02975232|pediatric obesity
829305|NCT02975232|rural population
829306|NCT02975232|fruit and vegetable purchases
829307|NCT02975232|fruit and vegetable consumption
829308|NCT02975193|Parkinsons Disease
829309|NCT02975193|Cognition
829310|NCT02975167|Induction of labor
829311|NCT02975167|mechanical cervical ripening
829312|NCT02975167|patient satisfaction
829313|NCT02975167|outpatient
829314|NCT02975167|cost savings
829315|NCT02975154|osteoarthritis
829316|NCT02975154|microcurrent
829317|NCT02975154|knee
829318|NCT02975154|electrotherapy
829319|NCT02975141|Palliative Chemotherapy
829320|NCT02975141|Afatinib
829321|NCT02975141|Gemcitabine
829322|NCT02975141|nab-paclitaxel
829323|NCT02975141|pancreatic cancer
829324|NCT02975128|Minimal invasive
829325|NCT02975128|Biopsy
829326|NCT02975089|Frailty
829327|NCT02975089|nutrition education
829328|NCT02975089|designed dishware
829329|NCT02975089|balanced diet
829330|NCT02975089|multiple dietary components
829331|NCT02975076|Sanchitongshu
829332|NCT02975076|Acute Minor Stroke
829333|NCT02975076|Transient Ischemic Attack
829334|NCT02975063|Exclusive breastfeeding
829335|NCT02975024|mandibular vestibuloplasty
829336|NCT02975024|wound healing
829337|NCT02975024|microcirculation
829338|NCT02975024|Laser Speckle Contrast Imager
829339|NCT02975024|Mucograft
829340|NCT02975024|strip gingival graft
829341|NCT02975011|Magnetic Resonance Imaging
829342|NCT02975011|Patient Satisfaction
829343|NCT02975011|Numeric Rating Scale
829344|NCT02974998|Human Immunodeficiency Virus (HIV)
829345|NCT02974998|HIV Testing and Counseling (HTC)
829346|NCT02974998|Sexually Transmitted Infections (STIs)
829347|NCT02974998|Substance Abuse
829348|NCT02974998|Gender Based Violence
829349|NCT02974998|Gang Violence
829350|NCT02974998|Victimization
829351|NCT02974998|Linkage to Care
829352|NCT02974998|Sexual Risk
829353|NCT02974998|Out-of-school Adolescents
829354|NCT02974998|Young Women
829355|NCT02974985|Facelift
829356|NCT02974985|HA Filler
829357|NCT02974985|Hyaluronic acid
829358|NCT02974985|Facial Rejuvenation
829359|NCT02974985|Aging Face
829360|NCT02974985|WIZDOM
829361|NCT02974985|Midface lift
829362|NCT02974985|Midface augmentation
829363|NCT02974933|apatinib
829364|NCT02974933|pemetrexed
829365|NCT02974933|NSCLC
829366|NCT02974907|Dry Eye Syndrome
829367|NCT02974907|Dry Eye
829368|NCT02974907|DES
829369|NCT02974868|Phase 2
829370|NCT02974868|randomized
829371|NCT02974868|double-blind
829372|NCT02974868|placebo
829373|NCT02974868|alopecia areata
829374|NCT02974868|safety
829375|NCT02974868|efficacy
829376|NCT02974868|JAK
829377|NCT02974868|janus kinase
829378|NCT02974868|moderate
829379|NCT02974868|severe
829380|NCT02974855|hemophilia
829381|NCT02974829|Chronic Hepatitis B
829390|NCT02974790|echocardiography
829391|NCT02974790|training
829392|NCT02974790|emergency department
829393|NCT02974790|circulatory failure
829409|NCT02974712|Arterial blood gases
829410|NCT02974712|MAP
829411|NCT02974712|HR
829412|NCT02974673|Spinal Cord Injury
829413|NCT02974673|Genito sexuals disorders
829414|NCT02974673|Ejaculatory test
829415|NCT02974647|Ruxolitinib
829416|NCT02974647|T or NK Cell
829417|NCT02974647|Relapsed
829418|NCT02974647|Refractory
829419|NCT02974634|Ileostomy
829420|NCT02974608|Placental
829421|NCT02974608|Fetal Loss
829422|NCT02974608|Observational
829423|NCT02974608|Antenatal
829424|NCT02974608|Infection
829425|NCT02974608|Malaria
829426|NCT02974595|Autoinflammation
829427|NCT02974595|Pediatric Syndromes
829428|NCT02974595|Immune Dysregulation
829429|NCT02974595|IL-1 Mediated Diseases
829430|NCT02974595|Interferonopathies
829436|NCT02974569|adolescents
829437|NCT02974569|young adults
829438|NCT02974543|tinnitus
829439|NCT02974517|time-lapes
829440|NCT02974517|IVF/ICSI
829441|NCT02974517|pregnancy outcome
829442|NCT02974491|hemodialysis
829443|NCT02974491|diabetes mellitus
829444|NCT02974491|apple juice
829445|NCT02974491|potassium
829446|NCT02974478|orange juice consumption
829447|NCT02974478|glucose homeostasis
829448|NCT02974478|antioxidative status
829449|NCT02974465|Brain injuries
829450|NCT02974465|upper extremity
829451|NCT02974465|biofeedback
829452|NCT02974465|electromyography
829453|NCT02974465|recovery of function
829454|NCT02974400|internet-based intervention
829455|NCT02974400|e-mental health
829456|NCT02974400|cognitive behavioural intervention
829457|NCT02974322|Crohn's Disease
829458|NCT02974322|GED-0301
829459|NCT02974322|Mongersen
829460|NCT02974322|Adolescent
829461|NCT02974322|Pediatric
829462|NCT02974322|Children
829463|NCT02974309|Youth
829464|NCT02974309|Diabetes Management
829465|NCT02974309|Sleep
829466|NCT02974283|Normobaric hyperoxia
829467|NCT02974283|r-tPA thrombolytic therapy
829468|NCT02974257|cardiac arrest
829469|NCT02974257|thiamine
829470|NCT02974257|oxygen consumption
829471|NCT02974257|lactate
829472|NCT02974257|shock
829473|NCT02974244|Type 2 diabetes
829474|NCT02974192|Ischemic stroke
829475|NCT02974192|Soluble CD40 Ligand
829476|NCT02974192|Neopetrin
829477|NCT02974192|stroke risk factors
829478|NCT02974192|functional outcome
829479|NCT02974166|Temporomandibular Disorder
829480|NCT02974166|Osteopathic Manipulative Treatment
829481|NCT02974166|Rigid Splint
829482|NCT02974166|Speech Therapy
829483|NCT02974127|intracranial benign meningioma
829484|NCT02974127|radiosurgery
829485|NCT02974127|large meningioma
829486|NCT02974127|critical site
829487|NCT02974127|multisession radiosurgery
829488|NCT02974101|Spinal cord stimulation
829489|NCT02974101|AdaptiveStim
829490|NCT02974062|Position sense
829491|NCT02974062|Lumbar stabilization exercise
829492|NCT02974049|Ivermectin
829493|NCT02974049|Albendazole
829494|NCT02974049|Diethylcarbamazine
829495|NCT02974036|Patient education
829496|NCT02974036|Osteoarthritis
829497|NCT02974036|Primary health care
829498|NCT02974010|d-cycloserine
829499|NCT02974010|lurasidone
829500|NCT02974010|ketamine
829501|NCT02974010|randomized controlled trial
829502|NCT02973984|Anticoagulant Treatments
829503|NCT02973984|Multidimensional Prognostic Index (MPI)
829504|NCT02973984|Comprehensive Geriatric Assessment (CGA)
829505|NCT02973984|Frailty
829506|NCT02973984|Elderly
829507|NCT02973984|Atrial Fibrillation
829508|NCT02973971|Blood cell biomarkers, peripheral circulating biomarkers
829509|NCT02973958|Penis
829510|NCT02973958|Pain
829511|NCT02973958|Ketorolac
829512|NCT02973958|Circumcision
829513|NCT02973945|Pulmonary Rehabilitation
829514|NCT02973945|High Flow Nasal Cannula
829515|NCT02973945|The Venturi Mask
829516|NCT02973945|Exercise capacity
829517|NCT02973945|Aerobic capacity
829518|NCT02973945|HFNC
829519|NCT02973932|cognitive-behavioral psychotherapy
829520|NCT02973932|obsessive-compulsive disorder
829521|NCT02973932|internet-based
829523|NCT02973880|Steroid/antibiotic associated treatment
829524|NCT02973880|Phaco-emulsification
829525|NCT02973880|Cataract extraction
829526|NCT02973867|Bone mineral density
829527|NCT02973867|Myokines
829528|NCT02973867|Adipokines
829529|NCT02973815|family meals
829530|NCT02973815|home food availability
829531|NCT02973802|Graves Disease
829532|NCT02973802|Phase 1
829533|NCT02973789|Non-Small Cell Lung Cancer
829534|NCT02973789|NSCLC
829535|NCT02973789|Treatment
829536|NCT02973789|Minimal Toxicity
829537|NCT02973789|TTFields
829538|NCT02973789|TTF
829539|NCT02973789|Tumor Treating Fields
829540|NCT02973789|Novocure
829541|NCT02973789|Docetaxel
829542|NCT02973789|PD-1 inhibitor
829543|NCT02973750|high-grade serous cancer
829544|NCT02973750|stage III cancer
829545|NCT02973750|stage IV cancer
829546|NCT02973724|Extubation
829547|NCT02973724|Remifentanil
829548|NCT02973724|Laryngomicrosurgery
829549|NCT02973685|Hepatic arterial infusion chemotherapy
829550|NCT02973685|Transarterial Chemoembolization
829551|NCT02973685|BCLC A/B
829552|NCT02973672|Fluorescence
829553|NCT02973672|Surgery
829554|NCT02973672|Cancer
829555|NCT02973672|SGM-101
829556|NCT02973672|Near Infrared
829557|NCT02973672|Immunophotodetection
829558|NCT02973646|chronic hepatitis b
829559|NCT02973646|peginterferon alfa-2b
829560|NCT02973646|interferon gene mutation
829561|NCT02973646|interferon receptor
829562|NCT02973633|Heart Failure
829563|NCT02973633|Remodeling
829564|NCT02973633|Myocardial Infarction
829565|NCT02973633|Left Ventricular Hypertrophy
829566|NCT02973633|Diffusion Tensor MRI
829567|NCT02973594|left ventricular reverse remodeling
829568|NCT02973594|beta-1 adrenergic receptor signaling
829569|NCT02973594|idiopathic dilated cardiomyopathy
829570|NCT02973594|HCN4 inhibition
829571|NCT02973594|beta-1 adrenergic receptor blocker
829572|NCT02973594|gene expression
829573|NCT02973581|Surgical Pleth Index (SPI)
829574|NCT02973581|General Anaesthesia (GA),
829575|NCT02973581|Numerical Rating Scale (NRS)
829576|NCT02973581|Adequacy of Anaesthesia (AoA)
829577|NCT02973581|Peribulbar Block (PBB)
829578|NCT02973581|Topical Analgesia (TA)
829579|NCT02973581|Oculocardiac reflex (OCR)
829580|NCT02973581|Postoperative nausea nad vomitting (PONV)
829581|NCT02973542|IBS
829582|NCT02973542|Ethosuximide
829583|NCT02973542|Pain
829584|NCT02973529|Percutaneous intervention (PCI)
829585|NCT02973529|Optical coherence tomography (OCT)
829586|NCT02973529|Bifurcation lesion
829587|NCT02973529|Bioresorbable stents (BRS)
829588|NCT02973503|Hepatitis C
829589|NCT02973503|Genotype 1B
829590|NCT02973503|Non Severe Fibrosis
829591|NCT02973503|Treatment Naïve
829592|NCT02973503|8 Weeks of Treatment
829593|NCT02973503|Elbasvir/Grazoprevir Combination
829594|NCT02973490|ESD;Transanal Tube Drainage;Colorectal Tumor
829595|NCT02973438|Spinal Cord Injuries
829596|NCT02973438|Obesity
829597|NCT02973438|Insulin Resistance
829598|NCT02973438|Intermittent hypoxia
829599|NCT02973425|mHealth, Smoking cessation,
829600|NCT02973399|CLL
829601|NCT02973399|Leukemia, Chronic Lymphocytic
829602|NCT02973399|Hsp90
829603|NCT02973399|Ibrutinib
829604|NCT02973386|Local advanced
829605|NCT02973386|High Risk
829606|NCT02973386|Nasopharyngeal Carcinoma
829607|NCT02973373|MRI
829608|NCT02973373|Chest
829609|NCT02973373|Apnea
829610|NCT02973347|Enteral Feeding
829611|NCT02973347|Ventilator-Associated Pneumonia
829612|NCT02973347|Mechanical Ventilation
829613|NCT02973347|Pediatric Intensive Care Unit
829614|NCT02973347|Critical Illness
829615|NCT02973334|sweeteners
829616|NCT02973334|sugar
829617|NCT02973334|stress response
829618|NCT02973295|NAFLD;
829619|NCT02973295|Fibroscan
829620|NCT02973295|Silymarin
829621|NCT02973256|Meningioma grade II
829622|NCT02973256|Meningioma grade III
829623|NCT02973243|early warning scoring
829624|NCT02973243|respiration rate
829625|NCT02973243|acute care teams
829626|NCT02973243|NEWS
829627|NCT02973243|CREWS
829628|NCT02973230|Pregnancy, Ectopic
829629|NCT02973230|Vascular Endothelial Growth Factor A
829630|NCT02973230|Pregnancy, Tubal
829631|NCT02973217|Hyperthermia, Induced
829632|NCT02973217|Laser Coagulation
829633|NCT02973217|Laser Therapy
829634|NCT02973204|tumor DNA
829635|NCT02973204|circulating tumor cells
829636|NCT02973204|biopsy
829637|NCT02973191|Leukemia
829638|NCT02973191|B-Cell Acute Lymphoblastic Leukemia
829639|NCT02973191|JCAR015
829640|NCT02973152|Type I Thyroplasty
829641|NCT02973152|Reinnervation
829642|NCT02973113|Nivolumab
829643|NCT02973113|Hodgkin Lymphoma
829644|NCT02973113|Non-Hodgkin Lymphoma
829645|NCT02973113|Lymphoproliferative Disorders
829646|NCT02973113|EBV-specific T Cells
829647|NCT02973074|iron deficiency
829648|NCT02973074|patient blood management
829649|NCT02973074|anemia
829650|NCT02973048|Cesarean delivery
829651|NCT02973048|Spinal anesthesia
829652|NCT02973048|Local anesthetics
829653|NCT02973009|The Sleeve Gastrectomy (SG)
829654|NCT02973009|bariatric surgery
829655|NCT02973009|laparoscopy
829656|NCT02973009|systematic closure of the epigastric
829660|NCT02972957|intranasal
829661|NCT02972957|flu vaccine
829662|NCT02972957|Gambian children
829663|NCT02972931|HIV infection
829664|NCT02972931|low HIV reservoir
829665|NCT02972931|functional cure
829666|NCT02972905|pharmacokinetics
829667|NCT02972905|GSK2269557
829668|NCT02972905|Dry powder Inhaler (DPI)
829669|NCT02972905|tolerability
829670|NCT02972905|safety
829671|NCT02972905|ELLIPTA
829672|NCT02972879|trigger finger
829673|NCT02972879|Therapeutic Modalities
829674|NCT02972879|Corticosteroid Injection
829675|NCT02972840|Bruton tyrosine kinase inhibitor
829676|NCT02972840|Btk
829677|NCT02972840|ACP-196
829678|NCT02972840|Mantle Cell Lymphoma
829679|NCT02972840|acalabrutinib
829680|NCT02972840|ACE-LY-308
829681|NCT02972840|Treatment naive
829682|NCT02972840|Lymphoma
829683|NCT02972840|non-Hodgkins
829684|NCT02972814|Troponin
829685|NCT02972814|Point of care test
829686|NCT02972814|myocardial infarction
829687|NCT02972801|Spermatogonial stem cells
829688|NCT02972801|Testis
829689|NCT02972801|Fertility
829690|NCT02972801|Infertility
829691|NCT02972801|Oncofertility
829692|NCT02972762|depth of anesthesia\postoperation delirium
829693|NCT02972736|Radiation dose
829694|NCT02972736|percutaneous coronary intervention
829695|NCT02972736|Coronary
829696|NCT02972736|Interventional radiology
829697|NCT02972736|Electrophysiology
829698|NCT02972723|Metformin Therapy in HCV
829699|NCT02972684|Cardiopulmonary Bypass
829700|NCT02972684|Hemorrhage
829701|NCT02972684|blood transfusion
829702|NCT02972684|Point-of-care test
829703|NCT02972684|health economics
829704|NCT02972671|MiStent
829716|NCT02972632|Drug Therapy
829717|NCT02972619|Blood Pressure
829718|NCT02972619|Lipids
829719|NCT02972619|Cardiovascular
829720|NCT02972619|Health Services
829721|NCT02972619|Hypertension
829722|NCT02972606|HIV
829723|NCT02972606|Peripheral Neuropathy
829724|NCT02972606|Chronic Pain
829725|NCT02972606|Qualitative Research
829726|NCT02972567|probiotics
829727|NCT02972567|metabolic syndrome
829728|NCT02972567|non-alcoholic fatty liver disease
829729|NCT02972528|DFU
829730|NCT02972528|Diabetic Foot Ulcer
829731|NCT02972528|Diabetes
829732|NCT02972528|Platelet Rich Plasma
829733|NCT02972515|Smoking
829734|NCT02972515|Smoking cessation
829735|NCT02972515|Multiple behaviors
829736|NCT02972515|mHealth
829737|NCT02972515|Mobile Application
829738|NCT02972502|Metoclopramide (Reglan)
829739|NCT02972502|Haloperidol (Haldol)
829740|NCT02972476|Chronic Obstructive Pulmonary Disease
829741|NCT02972463|Gastrointestinal
829742|NCT02972463|Microbiome
829743|NCT02972463|Inflammation
829744|NCT02972437|GAS in oral cavity
829745|NCT02972424|pelvic fracture
829746|NCT02972424|healing
829747|NCT02972424|teriparatide
829748|NCT02972398|treatment resistant depression
829749|NCT02972398|N-Acetyl Cysteine
829750|NCT02972398|inflammation mediators
829751|NCT02972398|oxidative stress
829752|NCT02972398|brain imaging
829753|NCT02972385|warfarin
829754|NCT02972385|blood clotting
829755|NCT02972372|esophageal cancer
829756|NCT02972372|chemoradiation
829757|NCT02972372|esophagectomy
829762|NCT02972294|iron isomaltoside
829763|NCT02972294|tranexamic acid
829764|NCT02972203|Mindfulness
829765|NCT02972203|primary care
829766|NCT02972203|self-control
829767|NCT02972203|self-regulation
829768|NCT02972203|adherence
829769|NCT02972177|Lung cancer
829770|NCT02972177|Transbronchial ablation
829771|NCT02972177|Radiofrequency ablation
829772|NCT02972177|Microwave ablation
829773|NCT02972164|Childhood obesity
829774|NCT02972164|Lifestyle
829775|NCT02972164|Prevention
829776|NCT02972164|Intervention
829777|NCT02972164|Behavioural psychology
829778|NCT02972138|Sickle-cells Disease
829779|NCT02972138|bisphosphonates
829780|NCT02972138|Vitamine D
829781|NCT02972125|Lacosamide
829782|NCT02972125|Bioequivalence
829783|NCT02972125|Dry Syrup
829784|NCT02972073|Low back pain
829785|NCT02972073|Neuromuscular control
829786|NCT02972060|Hormone Naive Prostate Cancer
829787|NCT02972047|Reflux
829788|NCT02972021|respiratory insufficiency
829789|NCT02972021|High-flow nasal cannula
829790|NCT02972008|Aortic stenosis
829791|NCT02972008|Transaortic valve replacement
829792|NCT02972008|stroke
829793|NCT02972008|Epigenetic
829794|NCT02971969|gene therapy
829795|NCT02971969|Hemophilia B
829796|NCT02971956|Esophageal Cancer
829797|NCT02971917|Chest radiography
829798|NCT02971917|Image improvements
829799|NCT02971917|Image Reconstruction
829800|NCT02971917|Preprocessing
829801|NCT02971917|MTF
829802|NCT02971904|newborn
829803|NCT02971904|prematurity
829804|NCT02971904|preterm
829805|NCT02971904|human milk
829806|NCT02971904|human milk analyzer
829807|NCT02971904|neonatology
829808|NCT02971904|neonatal intensive care unit
829809|NCT02971904|low birth weight
829810|NCT02971865|Cognitive Behavior Therapy
829811|NCT02971865|Chiropractic
829812|NCT02971865|Diabetes Mellitus, Type 2
829813|NCT02971865|Primary care shared visit
829814|NCT02971852|Hypnosis
829815|NCT02971852|Anesthesia
829816|NCT02971852|Suggestion
829817|NCT02971852|Thermography
829818|NCT02971826|Stroke
829819|NCT02971826|thrombectomy
829820|NCT02971826|REVIVETM SE
829821|NCT02971826|MRI
829822|NCT02971826|Computed Tomography
829823|NCT02971813|cardiac rehabilitation
829824|NCT02971813|social media
829825|NCT02971813|adherence
829826|NCT02971813|motivation
829827|NCT02971800|sodium fluorescein
829828|NCT02971800|ureteral efflux
829829|NCT02971800|laparoscopic hysterectomy
829830|NCT02971774|stroke
829831|NCT02971774|botulinum toxin injection
829832|NCT02971774|daily life
829833|NCT02971748|hormone receptor-positive localized inflammatory breast cancer
829834|NCT02971748|Hormonal therapy
829835|NCT02971748|IBC
829836|NCT02971748|standard adjuvant hormonal therapy
829837|NCT02971748|maintenance therapy
829838|NCT02971748|immune related biomarkers
829839|NCT02971748|PD-L1 expression
829840|NCT02971748|HR positive
829841|NCT02971748|HR-positive localized IBC
829842|NCT02971735|cognitive style
829843|NCT02971735|e-learning
829844|NCT02971735|mobile technology
829845|NCT02971735|randomized controlled trial
829846|NCT02971735|otolaryngology-head and neck surgery
829847|NCT02971722|GLP-1 receptor agonist
829848|NCT02971657|Staphylococcus aureus phenotypic characterization
829849|NCT02971657|Antibiotic resistance
829850|NCT02971657|Orthopedic device related infections
829851|NCT02971657|Phenotypic characterization
829852|NCT02971631|Dumping syndrome
829853|NCT02971631|Gastrectomy
829854|NCT02971631|GLP-1
829855|NCT02971631|Insulin
829856|NCT02971618|dapagliflozin,
829857|NCT02971618|Russia,
829858|NCT02971618|retrospective study,
829859|NCT02971618|diabetes mellitus type 2
829860|NCT02971579|ERCP
829861|NCT02971579|biliary diseases
829862|NCT02971579|Pancreatic diseases
829863|NCT02971579|outcome
829864|NCT02971579|Quality
829865|NCT02971579|Training
829866|NCT02971566|feeding intolerance
829867|NCT02971566|preterm infants
829868|NCT02971566|near infrared spectroscopy
829869|NCT02971566|abnormal antenatal Doppler
829870|NCT02971540|Surgical Pleth Index (SPI)
829871|NCT02971540|General Anaesthesia (GA),
829872|NCT02971540|Numerical Rating Scale (NRS)
829873|NCT02971540|Adequacy of Anaesthesia (AoA
829874|NCT02971540|Spectral Entropy (SE)
829875|NCT02971540|Local Anesthetic (LA)
829876|NCT02971488|Hepatitis C
829877|NCT02971488|PWID
829878|NCT02971488|Linkage-to-care
829879|NCT02971475|Extracorporeal Shock Wave lithotripsy(ESWL)
829880|NCT02971475|Endoscopic Retrograde Cholangiopancreatography(ERCP)
829881|NCT02971475|chronic pancreatitis
829882|NCT02971475|pain relief
829883|NCT02971462|stroke
829884|NCT02971462|Vertebrobasilar atherosclerosis
829885|NCT02971462|remote ischemic conditioning
829886|NCT02971449|Village Healthcare Team
829887|NCT02971449|mHealth
829888|NCT02971449|Telemedicine
829889|NCT02971423|infection
829890|NCT02971423|gram-negative bacterium
829891|NCT02971345|Hepatocellular carcinoma
829892|NCT02971345|main portal vein tumor thrombus
829893|NCT02971345|endovascular brachytherapy
829894|NCT02971345|stent
829895|NCT02971345|chemoembolization
829896|NCT02971306|alcoholic hepatitis
829897|NCT02971306|alcoholic liver disease
829898|NCT02971306|jaundice
829899|NCT02971306|ascites
829900|NCT02971306|regeneration
829901|NCT02971293|AZD8871
829902|NCT02971293|long-acting muscarinic antagonist (LAMA)
829903|NCT02971293|long-acting β2-agonist (LABA)
829904|NCT02971293|inhaled long-acting bronchodilator
829905|NCT02971293|pharmacokinetics
829906|NCT02971293|safety
829907|NCT02971293|tolerability
829908|NCT02971293|efficacy
829909|NCT02971293|Phase IIa
829910|NCT02971293|Muscarinic receptor antagonist β2 adrenoceptor agonist (MABA)
829911|NCT02971267|heart failure
829912|NCT02971267|cardiomyopathy
829913|NCT02971267|myocarditis
829914|NCT02971254|cognitive functions
829915|NCT02971254|anaesthesia recovery
829916|NCT02971254|sevoflurane
829917|NCT02971254|desflurane
829918|NCT02971241|Integeneration
829919|NCT02971241|Mobile technology
829920|NCT02971241|Chronic disease management
829921|NCT02971241|Diabetes self-management
829931|NCT02971202|o-glcnacylation
829932|NCT02971202|hexosamine
829933|NCT02971163|Syncope
829934|NCT02971163|Shared Decision-Making
829935|NCT02971163|Emergency Medicine
829936|NCT02971163|Decision Aid
829937|NCT02971137|Smoking
829938|NCT02971137|Cigarette Smoking
829939|NCT02971137|Veterans
829940|NCT02971137|Tobacco Use
829941|NCT02971137|Pain
829942|NCT02971124|Cognitive Performance
829943|NCT02971124|Meaningful Play
829944|NCT02971124|Screening test
829945|NCT02971124|Dementia
829946|NCT02971085|low-risk prostate cancer
829947|NCT02971085|active surveillance
829948|NCT02971085|pathologic reclassification
829949|NCT02971072|address
829950|NCT02971072|atrophic
829951|NCT02971072|base
829952|NCT02971072|clinical
829953|NCT02971072|cost
829954|NCT02971072|data
829955|NCT02971072|disability
829956|NCT02971072|effectiveness
829957|NCT02971072|attention
829958|NCT02971072|biofeedback
829959|NCT02971072|electrical stimulation
829960|NCT02971072|electromyography
829961|NCT02971072|exercise
829962|NCT02971072|exertion
829963|NCT02971072|health care service utilization
829964|NCT02971072|improved
829965|NCT02971072|injection of therapeutic agent
829966|NCT02971072|innovation
829967|NCT02971072|intervention
829968|NCT02971072|knowledge
829969|NCT02971072|local anesthetics
829970|NCT02971072|measures
829971|NCT02971072|modeling
829972|NCT02971072|motor
829973|NCT02971072|motor control
829974|NCT02971072|muscle
829975|NCT02971072|neuroadaptation
829976|NCT02971072|neurophysiology
829977|NCT02971072|novel
829978|NCT02971072|outcome
829979|NCT02971072|outcome measure
829980|NCT02971072|pain inhibition
829981|NCT02971072|patients
829982|NCT02971072|pattern
829983|NCT02971072|programs
829984|NCT02971072|public health relevance
829985|NCT02971072|rehabilitation strategy
829986|NCT02971072|relating to nervous system
829987|NCT02971072|reporting
829988|NCT02971072|research
829989|NCT02971072|rotator cuff
829990|NCT02971072|shoulder
829991|NCT02971072|staging
829992|NCT02971072|strength training
829993|NCT02971072|success
829994|NCT02971072|systematic review
829995|NCT02971072|techniques
829996|NCT02971072|testing
829997|NCT02971072|time
829998|NCT02971072|training
829999|NCT02971072|treatment strategy
830000|NCT02971072|United States
830001|NCT02971072|work
830002|NCT02971059|Elderly
830003|NCT02971059|Phenylalanine
830004|NCT02971059|Healthy
830005|NCT02971046|healthy children
830006|NCT02971046|protein
830007|NCT02971046|glutathione
830008|NCT02971046|protein requirement
830009|NCT02971033|hepatitis C virus
830010|NCT02971033|antiviral treatment
830011|NCT02971033|viral entry inhibitor
830012|NCT02971033|mathematical modeling
830013|NCT02970994|Linear growth and neurodevelopment outcome
830014|NCT02970994|< 34 weeks
830015|NCT02970981|Monoclonal antibody
830016|NCT02970981|Programmed Death-1 (PD-1)
830017|NCT02970981|Programmed Death-Ligand 1 (PD-L1)
830018|NCT02970981|Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
830019|NCT02970981|Antigen
830020|NCT02970929|Schizophrenia
830021|NCT02970916|metastatic colorectal cancer
830022|NCT02970916|FOLFIRI
830023|NCT02970916|aflibercept
830024|NCT02970916|oxaliplatin
830025|NCT02970916|ACE polymorphisms
830026|NCT02970890|Total Hip Arthroplasty (THA)
830027|NCT02970890|Phototherapy
830028|NCT02970890|Low-level laser therapy
830029|NCT02970890|Light-emitting diodes
830030|NCT02970877|Fecal microbiota transplant
830031|NCT02970877|Intestinal microbiome
830032|NCT02970877|Oral microbiome
830033|NCT02970877|Mucosa associated microbiome
830034|NCT02970877|Appetite
830035|NCT02970877|Metabolome
830036|NCT02970877|Depression
830037|NCT02970877|Anxiety
830038|NCT02970864|Nerve regeneration
830039|NCT02970864|Peripheral nerve injury
830040|NCT02970864|Nerve conduits
830041|NCT02970864|Sensory nerve transection
830042|NCT02970851|Endothelin receptor antagonist (ERA)
830043|NCT02970851|pulmonary artery hypertension (PAH),
830044|NCT02970851|18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT)
830045|NCT02970851|Rubidium-82 (82Rb) PET/CT
830046|NCT02970838|Formula diet
830047|NCT02970825|exercise medicine
830048|NCT02970825|youth
830049|NCT02970825|adolescents
830050|NCT02970825|students
830051|NCT02970695|insomnia
830052|NCT02970695|older people
830053|NCT02970695|auriculotherapy
830054|NCT02970669|Heart failure with reduced left ventricular ejection fraction (LVEF)
830055|NCT02970669|Cardiac dysfunction
830056|NCT02970669|Heart muscle dysfunction
830057|NCT02970669|Left ventricular (LV) dilation
830058|NCT02970669|Left ventricular hypertrophy
830059|NCT02970669|HF
830060|NCT02970669|AHF
830061|NCT02970669|CHF
830062|NCT02970669|acute heart failure
830063|NCT02970669|chronic heart failure
830064|NCT02970669|congestive heart failure
830065|NCT02970669|congestive cardiac failure
830066|NCT02970669|Heart failure
830067|NCT02970669|HReEF
830068|NCT02970669|Physical Activity
830069|NCT02970669|Actigraphy
830070|NCT02970669|Home sleep test
830071|NCT02970669|wake
830072|NCT02970643|Olanzapine
830073|NCT02970643|Chemotherapy-Induced Nausea and Vomiting
830074|NCT02970643|Moderate risk
830075|NCT02970630|prophylaxis
830076|NCT02970591|FODMAPS
830077|NCT02970591|carbohydrates
830078|NCT02970591|metabolomics
830079|NCT02970591|microbiota
830080|NCT02970565|Family Nurture Intervention
830081|NCT02970565|Martha G. Welch MD
830082|NCT02970565|Randomized Control Trial
830083|NCT02970565|Pre-school Intervention
830084|NCT02970565|Preschool Intervention
830085|NCT02970565|Multiple Family Group Intervention
830086|NCT02970565|Emotional Connection
830087|NCT02970565|Co-regulation
830088|NCT02970552|PreTerm Birth
830089|NCT02970552|HIV
830090|NCT02970552|Vaginal Progesterone
830091|NCT02970552|ART
830092|NCT02970526|Colorectal cancer survivors
830093|NCT02970513|Escherichia coli
830094|NCT02970513|Microbiota
830095|NCT02970513|Colorectal cancer
830096|NCT02970513|Psychiatric disorders
830097|NCT02970513|Personality traits
830098|NCT02970500|Cognitive impairment
830099|NCT02970500|Methylphenidate
830100|NCT02970500|Cancer-related cognitive impairment
830101|NCT02970500|Mixed method
830102|NCT02970500|Phase II study
830103|NCT02970500|Breast cancer
830104|NCT02970487|cataract
830105|NCT02970461|personal health record
830106|NCT02970461|gamification
830107|NCT02970461|chronic patient care
830108|NCT02970448|LITT
830109|NCT02970448|Brain Tumor
830110|NCT02970448|Temozolomide
830111|NCT02970435|surgery
830112|NCT02970435|video discharge instructions
830113|NCT02970422|Survey
830114|NCT02970422|Priorities
830115|NCT02970422|Activities
830116|NCT02970422|Participation
830117|NCT02970357|Evaluation
830118|NCT02970357|Therapeutic education
830119|NCT02970357|Type 1 Diabetes
830120|NCT02970357|Children
830121|NCT02970344|Coping Skills Training
830122|NCT02970344|Diabetes Education
830123|NCT02970318|CLL
830124|NCT02970318|BTK
830125|NCT02970318|Bruton Tyrosine Kinase
830126|NCT02970318|acalabrutinib
830127|NCT02970318|ACP-196
830128|NCT02970279|Behavioural activation
830129|NCT02970279|Psychotherapy, group
830130|NCT02970279|Depression
830131|NCT02970279|Depressive disorder
830132|NCT02970266|Leber Congenital Amaurosis
830133|NCT02970266|Genetic Decryption
830134|NCT02970266|The genotype-phenotype correlations
830135|NCT02970266|Ethnicity families
830136|NCT02970240|cardiopulmonary exercise testing
830137|NCT02970240|inflammation
830138|NCT02970240|oxidative status
830139|NCT02970227|heart failure
830140|NCT02970227|cardiomyopathies
830141|NCT02970227|myocarditis
830142|NCT02970214|heart failure
830143|NCT02970214|heart disease
830144|NCT02970214|cardiovascular disease
830145|NCT02970214|metabolic risk
830146|NCT02970214|comorbidities
830147|NCT02970201|eHealth
830148|NCT02970201|mHealth
830149|NCT02970201|Hemodialysis
830150|NCT02970201|Adherence
830151|NCT02970201|Electronic intervention
830152|NCT02970201|ESRD
830153|NCT02970201|Nephrology
830154|NCT02970188|time restricted feeding
830155|NCT02970188|endothelial function
830156|NCT02970188|arterial stiffness
830157|NCT02970188|intermittent fasting
830158|NCT02970175|Terlipressin
830159|NCT02970162|LEMS
830160|NCT02970136|Increased Screening Uptake
830161|NCT02970136|Community Health Worker
830162|NCT02970136|Medically Underserved
830163|NCT02970097|infraclavicular brachial plexus block
830164|NCT02970097|wrist arthroscopy
830165|NCT02970097|quality of recovery score
830166|NCT02970097|pain score
830167|NCT02970097|modified sleep quality assessment
830168|NCT02970071|Spatio-Temporal Image Correlation
830169|NCT02970071|Complicated congenital heart disease
830170|NCT02970071|Echocardiography
830171|NCT02970006|spinal cord stimulation
830172|NCT02970006|virtual reality
830173|NCT02970006|full body illusion
830174|NCT02969980|MDS
830175|NCT02969980|AML progressed from MDS
830176|NCT02969980|CMML
830177|NCT02969967|rehabilitation
830178|NCT02969967|upper extremity
830179|NCT02969967|orthosis
830180|NCT02969967|SaeboFlex
830181|NCT02969941|Parkinson Disease
830182|NCT02969941|Functional Magnetic Resonance Imaging
830183|NCT02969941|Transcranial Magnetic Stimulation
830184|NCT02969928|Full-mouth ultrasonic debridement
830185|NCT02969928|Clarithromycin
830186|NCT02969928|Amoxicillin
830187|NCT02969928|Metronidazole
830188|NCT02969915|people who inject drugs
830189|NCT02969915|men who have sex with men
830190|NCT02969915|HIV
830191|NCT02969915|India
830192|NCT02969902|Procedural pain
830193|NCT02969902|Phlebotomy
830194|NCT02969902|Distraction
830195|NCT02969902|Hand-held computer
830196|NCT02969902|Children
830197|NCT02969889|Airtraq
830198|NCT02969889|Intubating laryngeal mask airway
830199|NCT02969889|BMI>35
830201|NCT02969850|vitamin D supplementation
830202|NCT02969850|calcium supplementation
830203|NCT02969837|Multiple Myeloma
830204|NCT02969837|Elotuzumab
830205|NCT02969837|Carfilzomib (Kyprolis)
830206|NCT02969837|Lenalidomide (Revlimid)
830207|NCT02969837|Dexamethasone (E-KRd)
830208|NCT02969824|Sport Injury
830209|NCT02969824|Concussion
830210|NCT02969824|Active Recovery
830211|NCT02969785|Postural control
830212|NCT02969785|Physiotherapy
830213|NCT02969785|Sports injuries
830214|NCT02969785|Low back pain
830215|NCT02969785|training
830216|NCT02969759|Bioenergetics
830217|NCT02969759|Protein Metabolism
830218|NCT02969759|Sporadic Amyotrophic Lateral Sclerosis
830219|NCT02969746|activated charcoal, direct oral anticoagulant
830220|NCT02969733|postoperative analgesia
830221|NCT02969733|PainMatcher
830222|NCT02969707|repetitive Transcranial Magnetic Stimulation
830223|NCT02969707|functional MRI
830224|NCT02969707|Fibromyalgia
830225|NCT02969707|Hypnosis
830226|NCT02969707|Pain Assessment
830227|NCT02969694|addiction
830228|NCT02969694|hypersexuality
830229|NCT02969694|psychostimulants
830230|NCT02969668|opioid substitution treatment
830231|NCT02969668|interferon-free direct acting antivirals
830232|NCT02969668|hepatitis c therapy
830233|NCT02969655|Safety
830234|NCT02969655|Efficacy
830235|NCT02969655|Daprodustat
830236|NCT02969655|Chronic kidney disease
830237|NCT02969616|lumbar, fusion, DDD, Trinity Elite
830238|NCT02969603|PET/MRI
830239|NCT02969603|muscular activity
830240|NCT02969603|11C-acetate
830241|NCT02969590|Contraception
830242|NCT02969590|Mucus
830243|NCT02969590|Cervix
830244|NCT02969590|progestin
830245|NCT02969590|hormones
830246|NCT02969577|Androgen deprivation therapy
830247|NCT02969577|ADT
830248|NCT02969564|prostate cancer
830249|NCT02969564|bone metastases
830250|NCT02969564|PET/MRI
830254|NCT02969512|Patient education
830255|NCT02969512|Advanced hip osteoarthritis
830256|NCT02969512|Online education
830257|NCT02969512|Computer-assisted instruction
830258|NCT02969512|e-learning
830259|NCT02969512|Older adult
830260|NCT02969499|Electroconvulsive Therapy
830261|NCT02969499|Dementia
830262|NCT02969473|esophageal squamous cell carcinoma
830263|NCT02969473|concurrent chemoradiotherapy
830264|NCT02969473|docetaxel
830265|NCT02969473|cisplatin
830266|NCT02969473|5-fluorouracil
830267|NCT02969447|Retained Placenta
830268|NCT02969447|Second trimester medical termination
830269|NCT02969447|Third stage labor
830270|NCT02969447|Oxytocin
830271|NCT02969395|3T
830272|NCT02969395|Magnetic Resonance Imaging (MRI)
830273|NCT02969395|Implantable Cardioverter Defibrillator (ICD)
830274|NCT02969395|Implantable Pulse Generator (IPG)
830275|NCT02969395|Cardiac Resynchronization Therapy (CRT)
830276|NCT02969395|Cardiac Implantable Electronic Device (CIED)
830277|NCT02969382|Schizophrenia
830278|NCT02969369|Parkinson's Disease Psychosis
830279|NCT02969304|Tecfidera
830280|NCT02969304|Off-label
830281|NCT02969304|Utilization
830282|NCT02969278|vulvar cancer
830283|NCT02969278|sentinel node biopsy
830284|NCT02969278|inguino-femoral lymphadenectomy
830285|NCT02969278|18F FDG- PET/TC
830286|NCT02969278|guidelines
830287|NCT02969278|preoperative imaging
830288|NCT02969265|Drug therapy
830289|NCT02969226|mechanical ventilation
830290|NCT02969226|weaning
830291|NCT02969226|critically ill
830292|NCT02969226|spontaneous breathing trial
830293|NCT02969226|screening
830294|NCT02969226|invasive ventilation
830295|NCT02969226|SBT technique
830296|NCT02969213|Electronic management of epilepsy
830297|NCT02969213|biological etiology
830298|NCT02969213|Chinese children
830299|NCT02969200|Fabry Disease
830300|NCT02969200|Nephropathy
830301|NCT02969200|Measured GFR
830302|NCT02969200|Enzyme replacement therapy
830303|NCT02969161|PMTCT (Prevention of Mother-to-Child Transmission)
830304|NCT02969161|HIV (Human Immunodeficiency Virus)
830305|NCT02969161|Loss to follow-up (LTF)
830306|NCT02969161|Option B+ (B+)
830307|NCT02969161|ART (antiretroviral therapy)
830308|NCT02969148|Laparoscopic
830309|NCT02969148|Bursectomy
830310|NCT02969148|D2 lymphadenectomy
830311|NCT02969148|Gastric Cancer
830312|NCT02969122|gastric cancer
830313|NCT02969122|peritoneal cytology
830314|NCT02969083|UTUC
830315|NCT02969083|Upper Tract Urothelial Carcinoma
830316|NCT02969083|Neoadjuvant chemotherapy
830317|NCT02969083|Adjuvant chemotherapy
830318|NCT02969083|Radical nephroureterectomy
830319|NCT02969057|Lipidemic Response
830320|NCT02969031|communication
830321|NCT02969018|plaque psoriasis
830322|NCT02969005|radiopaque localizer grid
830323|NCT02969005|methylene blue
830324|NCT02969005|reduce radiation exposure
830325|NCT02968979|cachexia
830326|NCT02968979|Non-Small Cell Lung cancer
830327|NCT02968979|anorexia
830328|NCT02968979|malnutrition
830329|NCT02968940|Programmed cell death protein 1 (PD-1)
830330|NCT02968940|Programmed death-ligand 1 (PD-L1)
830331|NCT02968940|Immunotherapy
830332|NCT02968940|Hypofractionated Radiotherapy (HFRT)
830333|NCT02968940|Isocitrate dehydrogenase (IDH)
830334|NCT02968940|Glioma
830335|NCT02968914|Asthma
830336|NCT02968914|Chronic Obstructive pulmonary Disease
830337|NCT02968914|Pharmacokinetics
830338|NCT02968914|Healthy volunteers
830339|NCT02968875|endurance training
830340|NCT02968875|BDNF analysis
830341|NCT02968875|cognitive function
830342|NCT02968875|physiological abilities
830343|NCT02968849|HIV
830344|NCT02968823|Postoperative Pain
830345|NCT02968823|Anesthesia
830346|NCT02968823|Oral Surgery
830347|NCT02968784|Prostate Cancer
830348|NCT02968784|MRgFUS
830349|NCT02968784|ExAblate
830350|NCT02968784|Focused Ultrasound
830351|NCT02968771|Coronary artery disease
830352|NCT02968771|Cardiac perfusion SPECT
830353|NCT02968771|Metabolomics
830354|NCT02968745|Rheumatoid arthritis
830355|NCT02968745|human activity
830356|NCT02968745|Canadian Occupational Performance Measure
830357|NCT02968706|High Flow Nasal Cannula
830358|NCT02968706|Colonoscopy
830359|NCT02968706|Obesity
830360|NCT02968654|Blood Transfusion
830361|NCT02968654|Brain Injury
830362|NCT02968654|Outcome
830363|NCT02968654|Hemoglobin
830364|NCT02968615|fiber
830365|NCT02968615|lean protein
830366|NCT02968615|loss weight
830367|NCT02968589|Tele-rehabilitation
830368|NCT02968589|Function
830369|NCT02968589|Quality of life
830370|NCT02968589|Exercise
830371|NCT02968589|Occupational Therapy
830372|NCT02968589|Physiotherapy
830373|NCT02968589|Caregiver burden
830374|NCT02968576|healthy volunteers
830375|NCT02968576|pharmacokinetics
830376|NCT02968537|Alcohol use disorders
830377|NCT02968537|inhibition
830378|NCT02968537|EEG
830379|NCT02968537|cortisol
830380|NCT02968537|Training
830381|NCT02968537|clinical outcome measures
830382|NCT02968498|Blood glucose level
830383|NCT02968498|Oral intake
830384|NCT02968498|Lactulose
830385|NCT02968498|Healthy volunteers
830386|NCT02968485|advanced solid tumor
830387|NCT02968485|Protein Kinase MEK inhibitor (MEKi)
830388|NCT02968485|Safety
830389|NCT02968485|Pharmacokinetics
830390|NCT02968472|4s CAR-T19
830391|NCT02968472|B cell leukemia
830392|NCT02968472|B-ALL
830393|NCT02968459|Mesenchyme Stem Cells
830394|NCT02968459|Cesarean Section
830395|NCT02968459|Uterine Scar
830396|NCT02968446|Valchlor
830397|NCT02968446|Vitamin D
830398|NCT02968446|Healthy Volunteer
830399|NCT02968433|Young Male Plasma
830400|NCT02968381|tobacco
830401|NCT02968381|smoking
830402|NCT02968381|imagery
830403|NCT02968342|Hypoactive sexual desire disorder
830404|NCT02968212|Mycobacterium avium Complex
830405|NCT02968212|Clofazimine
830409|NCT02968173|Bronchopulmonary dysplasia (BPD)
830410|NCT02968173|RSV hospitalization
830411|NCT02968173|Palivizumab
830412|NCT02968173|Immunoprophylaxis
830413|NCT02968173|Chronic lung disease (CLD) of prematurity
830414|NCT02968147|atrial fibrillation
830415|NCT02968147|catheter ablation
830416|NCT02968147|general anaesthesia
830417|NCT02968082|MVD
830418|NCT02968082|Scopolamine
830419|NCT02968082|Microvascular Decompression
830420|NCT02968056|atrial fibrillation
830421|NCT02968056|radiofrequency ablation
830422|NCT02968043|physiotherapeutic scoliosis specific exercise
830423|NCT02968030|Aged
830424|NCT02968030|Postural balance
830425|NCT02968030|Muscle strength
830426|NCT02967991|EUS
830427|NCT02967991|Biopsy
830428|NCT02967991|Liver
830429|NCT02967991|FNA
830430|NCT02967991|FNB
830431|NCT02967978|risk factors
830432|NCT02967978|Calcium isotopes
830433|NCT02967978|calcium turnover
830434|NCT02967978|DXA
830435|NCT02967965|clinical confounders
830436|NCT02967965|myocardial infarction size
830437|NCT02967965|determinants of myocardial infarct injury
830438|NCT02967952|out-of-hospital cardiac arrest (OHCA)
830439|NCT02967952|supraglottic airway (SGA)
830440|NCT02967952|endotracheal intubation (ETI)
830441|NCT02967952|emergency medical system (EMS)
830442|NCT02967952|Supraglottic Airway Versus Endotracheal tube (SAVE)
830443|NCT02967926|common bile duct stone
830444|NCT02967926|cholangioscopy
830445|NCT02967926|SpyGlass
830446|NCT02967926|non-fluoroscopic
830447|NCT02967913|Cesarean delivery
830448|NCT02967913|Obstetrical delivery
830449|NCT02967913|PFDI-20
830450|NCT02967913|UDI-6
830451|NCT02967913|Bladder flap
830452|NCT02967874|Adipose -Derived Stromal Vascular Fraction Cells
830453|NCT02967874|Knee Osteoarthritis
830454|NCT02967874|Intra-articular Administration
830455|NCT02967874|Liposuction
830456|NCT02967861|chronic periodontitis
830457|NCT02967861|Nuclear factor-kappa B
830458|NCT02967861|Pranayama
830459|NCT02967861|Peroxisome proliferator - activated receptor gamma
830460|NCT02967861|Red complex microorganisms
830461|NCT02967848|Radiotherapy
830462|NCT02967848|Mebrofenin
830463|NCT02967848|Liver
830464|NCT02967848|Cancer
830465|NCT02967848|SPECT
830466|NCT02967770|Metastatic
830467|NCT02967770|Pancreas
830468|NCT02967770|Cancer
830484|NCT02967679|Neuropathy
830485|NCT02967679|Demyelinating polyradiculoneuropathy
830486|NCT02967640|Ketamine
830487|NCT02967640|Analgesics
830488|NCT02967640|Excitatory Amino Acid Antagonists
830489|NCT02967640|Receptors, Glutamate
830490|NCT02967640|Shoulder
830491|NCT02967601|shivering, cesarean section, anxiety, STAI
830492|NCT02967588|Medication adherence
830493|NCT02967588|Behavioural intervention
830494|NCT02967588|Acute coronary syndrome
830495|NCT02967588|Medication beliefs
830496|NCT02967588|Implementation intentions
830497|NCT02967575|cervical total disc replacement (cTDR)
830498|NCT02967536|cognitive function
830499|NCT02967536|microglia
830500|NCT02967536|neuroinflammation
830501|NCT02967523|Hepatocellular carcinoma
830502|NCT02967523|DEB-TACE
830503|NCT02967497|Chemotherapy
830504|NCT02967497|Herbal medicine
830505|NCT02967497|Lung cancer
830512|NCT02967471|ARDS
830513|NCT02967458|prostate cancer
830514|NCT02967458|prostate ultrasound
830515|NCT02967458|subharmonic imaging
830516|NCT02967458|prostate biopsy
830517|NCT02967432|Staphylococcus aureus
830518|NCT02967432|Staphylococcal colonization
830519|NCT02967432|Staphylococcal infection
830520|NCT02967432|Mupirocin
830521|NCT02967432|Mupirocin-resistance
830522|NCT02967419|Repeated Implantation Failure; TWEAK;Fn14;JAK/STAT3;Indoleamine 2,3-dioxygenase
830523|NCT02967406|Lifestyle modification
830524|NCT02967406|Primary prevention
830525|NCT02967406|Community-based intervention
830526|NCT02967406|Randomized control trial
830527|NCT02967328|Reticulated Platelets
830528|NCT02967328|Immune Thrombocytopenia
830529|NCT02967302|knee arthritis, morphine, local injection, pain
830530|NCT02967289|colon
830531|NCT02967289|cancer
830532|NCT02967289|stage 3
830533|NCT02967289|high-risk
830534|NCT02967289|mFolfirinox
830535|NCT02967289|mFolfox6
830536|NCT02967289|adjuvant
830537|NCT02967276|Metformin
830538|NCT02967276|Dexamethasone
830539|NCT02967276|Multiple Myeloma
830540|NCT02967263|Acute Kidney Injury
830541|NCT02967263|Proteinosis
830542|NCT02967263|Epidemiology
830543|NCT02967263|Risk factors
830544|NCT02967198|Fusion
830545|NCT02967198|Ablation
830546|NCT02967198|Percutaneous biopsy
830547|NCT02967198|Shear wave elastography
830548|NCT02967159|chronic obstructive pulmonary disease (COPD)
830549|NCT02967159|asthma
830550|NCT02967107|adenoma
830551|NCT02967107|colorectal cancer
830552|NCT02967107|polypectomy
830553|NCT02967107|colonoscopy
830554|NCT02967081|Pulpitis
830555|NCT02967081|Biomarker
830556|NCT02967081|Diagnostic
830557|NCT02967081|Dentinal fluid
830558|NCT02967068|CSS
830559|NCT02967068|EGPA
830560|NCT02967068|GCA
830561|NCT02967068|GPA
830562|NCT02967068|MPA
830563|NCT02967068|PAN
830564|NCT02967068|TAK
830565|NCT02967068|HSP
830566|NCT02966951|osteoarthrosis
830567|NCT02966951|knee
830568|NCT02966951|adipose tissue
830569|NCT02966951|stem cells
830570|NCT02966951|cell therapy
830571|NCT02966925|Vulvovaginal dryness
830572|NCT02966886|Surgical Management
830573|NCT02966873|Post Traumatic Stress Disorder (PTSD)
830574|NCT02966873|Addiction
830575|NCT02966873|Alcohol Use Disorder
830576|NCT02966873|Cognitive Behavioral Therapy
830577|NCT02966873|N-acetylcysteine (NAC)
830578|NCT02966847|Video assisted thoracoscopy
830579|NCT02966847|Cone beam computed tomography
830586|NCT02966821|Sulfatinib
830587|NCT02966821|Biliary Tract Cancer
830588|NCT02966821|Second-line
830604|NCT02966756|Relapsed chronic lymphocytic leukemia (CLL)
830605|NCT02966756|Leukemia
830606|NCT02966756|17p deletion
830607|NCT02966756|Refractory chronic lymphocytic leukemia (CLL)
830608|NCT02966756|Lymphoproliferative Disorders
830609|NCT02966756|venetoclax
830610|NCT02966730|follicular lymphoma
830611|NCT02966730|Ibrutinib
830612|NCT02966730|FLIPP
830613|NCT02966730|16-396
830614|NCT02966717|Rituximab
830615|NCT02966717|Mesenchymal stem cells
830616|NCT02966717|primary nephrotic syndrome
830617|NCT02966717|chronic kidney disease
830619|NCT02966652|Male
830620|NCT02966652|Hypogonadism
830621|NCT02966652|Primary
830622|NCT02966652|Secondary
830623|NCT02966652|Androgen deficiency
830624|NCT02966626|Pragmatic, Sodium-Glucose Transporter 2 inhibitor, Malaysia
830625|NCT02966574|Whole body MRI
830626|NCT02966574|Breastcancer
830627|NCT02966561|Pulmonary Rehabilitation
830628|NCT02966561|Physical Activity
830629|NCT02966561|Behaviour Change
830630|NCT02966561|Pedometer
830631|NCT02966522|Thalidoide
830632|NCT02966483|Rectal cancer
830633|NCT02966483|Laparoscopic surgery
830634|NCT02966483|Total mesorectal excision
830635|NCT02966483|Transanal
830636|NCT02966483|Multicentre randomised clinical trial
830637|NCT02966470|surgical outcomes
830639|NCT02966418|Cerebrovascular Disease
830640|NCT02966418|Mild Hypoxia preconditioning
830641|NCT02966418|Ischemia, Brain
830642|NCT02966418|Brain Injury, Acute
830643|NCT02966392|Cuff pressure
830644|NCT02966392|Ventilator associated pneumonia
830645|NCT02966392|Respiratory tract infections
830646|NCT02966379|Electroacoustic stimulation
830647|NCT02966353|Ruxolitinib
830648|NCT02966353|anemia
830649|NCT02966353|Primary Myelofibrosis
830650|NCT02966353|PMF
830651|NCT02966353|Post-Polycythemia Vera-Myelofibrosis
830652|NCT02966353|PPV-MF
830653|NCT02966353|Post-Essential Thrombocythemia Myelofibrosis
830654|NCT02966353|PET-MF
830655|NCT02966340|Alcoholism
830656|NCT02966340|Prazosin
830657|NCT02966340|Startle Potentiation
830658|NCT02966340|Norepinephrine
830659|NCT02966340|Anxiety
830660|NCT02966340|Fear
830661|NCT02966340|Stress
830665|NCT02966301|c GvHD
830666|NCT02966301|Arsenic Trioxyde
830667|NCT02966301|Hematology
830675|NCT02966249|dexmetomidine, intrathecally, intavenously,anesthesia
830676|NCT02966236|percutaneous nephrolithotomy
830677|NCT02966171|Advanced Solid Malignancies
830678|NCT02966158|Aerobic Interval Training
830679|NCT02966158|Fitness
830680|NCT02966158|Endothelial Function
830681|NCT02966158|Cognition
830682|NCT02966145|CBD
830683|NCT02966145|CBS
830684|NCT02966145|CBGD
830685|NCT02966145|PSP
830686|NCT02966145|nfvPPA
830687|NCT02966145|oPSP
830688|NCT02966145|vPSP
830689|NCT02966145|o/vPSP
830690|NCT02966145|Corticobasal Degeneration
830691|NCT02966145|Corticobasal Syndrome
830692|NCT02966145|Cortocal-basal Ganglionic Degeneration
830693|NCT02966145|Progressive Supranuclear Palsy
830694|NCT02966145|Nonfluent Variant Primary Progressive Aphasia
830695|NCT02966145|Oligosymptomatic Progressive Supranuclear Palsy
830696|NCT02966145|Variant Progressive Supranuclear Palsy
830697|NCT02966145|Biomarker
830698|NCT02966145|Neuroimaging
830699|NCT02966145|MRI
830700|NCT02966145|PET
830701|NCT02966145|Tau
830702|NCT02966145|Oculomotor
830703|NCT02966145|Retinal Imaging
830704|NCT02966132|Asian American
830705|NCT02966132|Immigrant Health
830706|NCT02966132|Digital Health Intervention
830707|NCT02966132|Federally Qualified Health Centers
830708|NCT02966119|stroke
830709|NCT02966119|intracranial hemorrhage
830710|NCT02966119|intracerebral hemorrhage
830711|NCT02966119|antithrombotic drugs
830712|NCT02966119|brain microbleeds
830713|NCT02966093|Differentiated thyroid cancer
830714|NCT02966093|Chinese participants
830715|NCT02966093|Phase 3
830716|NCT02966093|Lenvatinib
830717|NCT02966093|E7080
830718|NCT02966080|extracorporeal membrane oxygenation
830719|NCT02966080|intravenous heparin
830720|NCT02966067|Microneedles
830721|NCT02966067|Dental Anaesthesia
830722|NCT02966041|Postoperative Nausea and Vomiting
830723|NCT02966041|PONV
830724|NCT02966041|CSICU
830725|NCT02966041|post-cardiac surgery
830726|NCT02966041|cardiac intensive care unit
830736|NCT02965989|nursery care
830737|NCT02965989|nursery infection
830738|NCT02965989|online learning
830739|NCT02965950|breast cancer
830740|NCT02965950|TP53
830741|NCT02965950|cyclophosphamide
830742|NCT02965937|Attentively embracing story
830743|NCT02965937|story-centred care
830744|NCT02965937|heart rate variability
830745|NCT02965937|cognitive function
830746|NCT02965911|UDCA, Fenofibrate
830747|NCT02965898|chronic pancreatitis
830748|NCT02965898|vitamin d
830749|NCT02965898|pancreatitis
830750|NCT02965898|Pancreatic stellate cell
830751|NCT02965898|rct
830752|NCT02965885|Phase I
830753|NCT02965885|Solid Tumors
830754|NCT02965885|Pharmacokinetics
830755|NCT02965885|Pharmacodynamics
830756|NCT02965885|MTD
830757|NCT02965885|TAS116
830758|NCT02965885|HSP90 Inhibitor
830759|NCT02965885|Neoplasms
830760|NCT02965885|HER2 positive MBC
830761|NCT02965885|NSCLC EGFR T790M Positive
830762|NCT02965885|NSCLC EGFR T790M Negative
830763|NCT02965872|Postural Balance
830764|NCT02965859|Chronic Hepatitis B
830767|NCT02965833|Contact lens induced dryness
830768|NCT02965820|Contact lens induced dryness
830769|NCT02965807|Bronchial Thermoplasty
830770|NCT02965807|moderate asthma
830771|NCT02965807|China
830772|NCT02965794|surgery
830773|NCT02965794|bowel
830774|NCT02965794|rectum
830775|NCT02965794|cancer
830776|NCT02965794|nutrition
830777|NCT02965755|Metastatic Breast Cancer
830778|NCT02965755|Breast Cancer
830779|NCT02965755|Molecular profiling
830780|NCT02965755|Personalized medicine
830781|NCT02965742|DXA
830782|NCT02965742|DMS
830783|NCT02965742|STRATOS
830784|NCT02965729|behavior goals
830785|NCT02965729|self-monitoring
830786|NCT02965729|pedometer
830787|NCT02965729|physical activity
830788|NCT02965690|Total Knee Arthroplasty (TKA)
830789|NCT02965690|TKR
830790|NCT02965690|Knee kinematics
830791|NCT02965690|Dynamic RSA
830792|NCT02965690|Fluoroscopy
830793|NCT02965690|Roentgen Fluoroscopic Stereophotogrammetric Analysis
830794|NCT02965677|drug eluting balloon
830795|NCT02965677|Femoral Popliteal Artery
830796|NCT02965651|embodied conversational agent
830797|NCT02965651|virtual patient agent
830798|NCT02965651|meditation
830799|NCT02965651|mindfulness based stress reduction
830800|NCT02965651|nutrition
830801|NCT02965638|LHH
830802|NCT02965612|Grass Allergy
830803|NCT02965612|Allergic Rhinitis
830804|NCT02965612|Allergic Asthma
830805|NCT02965612|Paediatric
830806|NCT02965599|pharmacodynamics
830807|NCT02965599|tolerability
830808|NCT02965599|GSK3117391
830809|NCT02965599|safety
830810|NCT02965599|efficacy
830811|NCT02965599|rheumatoid arthritis
830812|NCT02965599|pharmacokinetics
830813|NCT02965547|Ischemic Preconditioning
830814|NCT02965547|dynamic cerebral autoregulation
830815|NCT02965534|night vision
830816|NCT02965534|mesopic visual acuity
830817|NCT02965534|aberrometry
830818|NCT02965534|mesopic spectacle correction
830819|NCT02965534|night myopia
830820|NCT02965508|Home-bound
830821|NCT02965508|home-based primary care
830822|NCT02965495|Osteoarthritis
830823|NCT02965482|methacholine, airway hyperresponsiveness
830824|NCT02965417|Resistance to anti-EGFR monoclonal antibodies
830825|NCT02965417|Mutation of ECD-EGFR
830826|NCT02965404|live attenuated varicella vaccine
830827|NCT02965404|safety
830828|NCT02965404|adult
830829|NCT02965404|adolescent
830830|NCT02965404|child
830831|NCT02965391|Circulating Tumor DNA
830832|NCT02965391|Half time
830833|NCT02965391|Lung cancer
830834|NCT02965391|Surgery
830835|NCT02965391|Surveillance
830836|NCT02965339|Vasoplegia
830837|NCT02965339|endothelial dysfunction
830838|NCT02965339|extracorporeal circulation
830839|NCT02965339|cardiac surgery
830840|NCT02965300|Pulmonary lesion
830841|NCT02965300|Volatile Organic Compositions(VOCs)
830842|NCT02965248|Locally advanced colorectal cancer
830843|NCT02965248|Hyperthermic intraperitoneal chemotherapy
830844|NCT02965222|blastocyst
830845|NCT02965222|pregnancy rate
830846|NCT02965209|endoscopy
830847|NCT02965209|small bowel endoscopy
830848|NCT02965209|motorized spiral endoscopy
830849|NCT02965209|spiral endoscopy
830850|NCT02965144|long-term survivors, high-grade glioma
830851|NCT02965079|extracorporeal CO2 removal
830852|NCT02965079|registry
830853|NCT02965079|COPD and ARDS
830854|NCT02965079|CEDIT on behalf of APHP
830862|NCT02965027|Chronic Headache
830863|NCT02965027|Post-Traumatic Stress Disorder
830864|NCT02965027|Iraq/Afghanistan Veteran
830865|NCT02965014|Human Immunodeficiency Virus (HIV)
830866|NCT02965014|Sexually transmitted infections (STI)
830867|NCT02965014|mHealth
830868|NCT02965014|Substance abuse
830869|NCT02965014|Violence
830870|NCT02965014|Victimization
830871|NCT02965014|Linkage to care
830872|NCT02965014|Sexual Risk
830873|NCT02965001|Molecular Imaging
830874|NCT02965001|uPAR-PET/CT
830875|NCT02965001|Head and neck cancer
830876|NCT02965001|curative intended radiotherapy
830877|NCT02964949|Nonvalvular Atrial Fibrillation
830878|NCT02964949|High Creatinine Clearance
830879|NCT02964949|Developmental Phase III
830880|NCT02964949|Anticoagulant Naïve
830881|NCT02964936|Anemia
830882|NCT02964936|Non-dialysis chronic kidney disease
830883|NCT02964936|Roxadustat
830884|NCT02964936|ASP1517
830885|NCT02964923|Genetic polymorphism
830886|NCT02964923|Metabolic side effects of drugs
830887|NCT02964923|schizophrenia
830888|NCT02964923|Second-Generation Antipsychotic
830889|NCT02964923|Cannabinoid Receptor Type 1
830890|NCT02964910|Hepatitis E
830891|NCT02964897|justice involvement
830892|NCT02964897|Homeless
830893|NCT02964897|Vulnerable Populations
830894|NCT02964897|Linkage to care
830895|NCT02964897|Veterans
830896|NCT02964871|Long-term care facility
830897|NCT02964871|Elderly
830898|NCT02964858|Radiation Dose
830899|NCT02964858|Optimization
830900|NCT02964858|NHL
830901|NCT02964858|DLBCL
830902|NCT02964858|R-CHOP
830903|NCT02964832|Basic Cardiac Life Support, Education, Feedback
830904|NCT02964793|Fetal Growth Restriction
830905|NCT02964793|Customised Fetal Weight Reference
830906|NCT02964793|Estimated fetal Weight
830907|NCT02964793|Symphysis Fundal Height
830908|NCT02964767|HIV
830909|NCT02964767|HIV-Tb co infection
830910|NCT02964767|CD4 Cell
830911|NCT02964741|Episodic Migraine
830912|NCT02964741|Headache
830913|NCT02964741|Opioid
830914|NCT02964689|Advanced non-small cell lung cancer
830915|NCT02964689|KRAS mutations
830916|NCT02964689|Binimetinib
830917|NCT02964689|Pemetrexed
830918|NCT02964689|Cisplatin
830919|NCT02964689|Phase IB trial
830920|NCT02964624|Osteoarthritis
830921|NCT02964624|biomarkers
830922|NCT02964624|HMGB1
830923|NCT02964624|knee
830924|NCT02964598|Adolescent
830925|NCT02964598|Population-based
830926|NCT02964598|Social jetlag
830927|NCT02964598|Intervention
830928|NCT02964598|Bright light
830929|NCT02964598|Motivation
830930|NCT02964598|Circadian regulation
830931|NCT02964598|Behavioral change
830932|NCT02964585|Type 2 Diabetes Mellitus
830933|NCT02964585|Chronic Kidney Disease
830934|NCT02964585|Endothelial Cells
830935|NCT02964585|Cellular Biomarker
830936|NCT02964585|Endothelial Dysfunction
830937|NCT02964585|CD34+
830938|NCT02964585|Impaired renal function
830939|NCT02964546|direct oral anticoagulants
830940|NCT02964546|atrial fibrillation
830941|NCT02964546|renal function
830942|NCT02964546|ckd-epi
830943|NCT02964546|plasmatic concentration
830944|NCT02964520|trait anxiety
830945|NCT02964520|A/T neurofeedback
830946|NCT02964520|EEG biofeedback
830947|NCT02964520|randomized
830951|NCT02964481|malignant
830952|NCT02964481|genetics
830953|NCT02964481|RYR1
830954|NCT02964481|CAC-NA1S
830955|NCT02964481|hyperthermia
830956|NCT02964468|Rectal Cancer
830957|NCT02964468|IMRT
830958|NCT02964468|Radiation Dose Escalation
830959|NCT02964455|Esophageal squamous cell carcinoma
830960|NCT02964455|Chemoradiotherapy
830961|NCT02964455|Docetaxel
830962|NCT02964455|Nedaplatin
830963|NCT02964455|Twice weekly
830964|NCT02964416|supratentorial craniotomy
830965|NCT02964416|extubation response
830966|NCT02964416|emergence
830967|NCT02964416|tramadol
830968|NCT02964403|COX-2
830969|NCT02964403|ERCP
830970|NCT02964403|Pancreatitis
830971|NCT02964390|CTEPH
830972|NCT02964390|balloon pulmonary angioplasty
830973|NCT02964377|Pediatric
830974|NCT02964377|muscle disease
830975|NCT02964377|Duchenne muscular dystrophy
830976|NCT02964377|cardiomyopathy
830977|NCT02964364|TAKAYASU ARTERITIS
830978|NCT02964351|MicroRNA
830979|NCT02964351|Prostate Carcinoma
830980|NCT02964351|PET-MR
830981|NCT02964325|hypoproliferative thrombocytopenia
830982|NCT02964325|hematologic malignancies
830983|NCT02964325|thrombocytopenia
830984|NCT02964325|platelet therapy
830985|NCT02964325|apheresis
830986|NCT02964325|pathogen reduction therapy
830987|NCT02964299|Gastrointestinal endoscopy
830988|NCT02964299|Moderate sedation
830989|NCT02964299|Airway management
830990|NCT02964286|Cancer
830991|NCT02964286|Acupressure
830992|NCT02964286|Hematopoietic Cell Growth Factors
830993|NCT02964273|Autosomal Dominant Polycystic Kidney Disease
830994|NCT02964273|ADPKD
830995|NCT02964273|Tolvaptan
830996|NCT02964273|Renal cysts
830997|NCT02964273|Chronic Kidney Disease
830998|NCT02964273|Genetic Kidney Disease
830999|NCT02964260|Hepatocellular Carcinoma; Embolization; Ablation; simultaneously; sequentially
831000|NCT02964234|Mammography Screening
831001|NCT02964234|Latinas
831002|NCT02964234|Breast cancer disparities
831003|NCT02964208|Atrial Fibrillation
831004|NCT02964208|Thromboembolism
831005|NCT02964208|Stroke
831006|NCT02964208|ACP
831007|NCT02964208|Left Atrial Appendage
831008|NCT02964208|Cardiac Plug
831009|NCT02964182|Mental and Behavioral Disorders Due to Use of Tobacco
831010|NCT02964182|Carbon monoxide Testing
831011|NCT02964182|CO
831012|NCT02964182|Questionnaires
831013|NCT02964182|Surveys
831014|NCT02964182|Smartphone assessments
831015|NCT02964182|Electronic assessments
831016|NCT02964182|Usual brand cigarettes
831017|NCT02964182|UB
831018|NCT02964182|Very Low Nicotine Content Cigarettes
831019|NCT02964182|VLNCC
831020|NCT02964182|E-cigarettes
831021|NCT02964182|ECIG
831022|NCT02964156|RA
831023|NCT02964156|Insole
831024|NCT02964156|Forefoot
831025|NCT02964156|Walking Ability
831026|NCT02964156|Pain
831027|NCT02964117|Chronic Obstructive Pulmonary Disease
831028|NCT02964091|Hepatitis C Virus
831029|NCT02964091|sofosbuvir/ledipasvir
831030|NCT02964091|Efficacy
831031|NCT02964078|Kidney Disease
831032|NCT02964078|Metastatic
831033|NCT02964078|Antibody
831034|NCT02964065|Influenza Vaccines
831035|NCT02964065|LAIV
831036|NCT02964039|stroke
831037|NCT02964039|rehabilitation
831038|NCT02964039|gait
831039|NCT02964026|pulmonary artery catheter
831040|NCT02964026|Swan-Ganz catheter
831041|NCT02964013|Programmed Cell Death Receptor 1 (PD-1)
831042|NCT02964013|Programmed Cell Death Receptor Ligand 1 (PD-L1)
831043|NCT02964013|Programmed Cell Death Receptor Ligand 2 (PD-L2)
831044|NCT02964013|PD-1
831045|NCT02964013|PDL1
831046|NCT02964013|PD-L1
831047|NCT02964013|PD-L2
831048|NCT02964000|Pain
831049|NCT02964000|Low level laser therapy
831050|NCT02964000|Sham
831051|NCT02964000|Chronic Pain
831052|NCT02964000|Opioid
831053|NCT02964000|Physical activity
831054|NCT02964000|Quality of sleep
831055|NCT02963974|cochlear implant
831056|NCT02963961|Delirium
831057|NCT02963961|Cognition
831058|NCT02963961|Prehabilitation
831059|NCT02963961|Neuroplasticity
831060|NCT02963909|Adjuvant
831061|NCT02963909|Alum
831062|NCT02963909|Inactivated
831063|NCT02963909|Purified
831064|NCT02963909|Vaccine
831065|NCT02963909|Virus
831066|NCT02963909|Zika
831067|NCT02963896|vestibular rehabilitation
831068|NCT02963883|ScVO2
831069|NCT02963883|Post operative red cell transfusion
831070|NCT02963870|Cognitive behavioral
831071|NCT02963870|security plan
831072|NCT02963870|suicidal Recidivism in adolescents
831073|NCT02963857|breast surgery
831074|NCT02963857|acute pain
831075|NCT02963857|regional anesthesia
831076|NCT02963831|Oncos-102
831077|NCT02963831|Durvalumab
831078|NCT02963831|Peritoneal
831079|NCT02963831|Cyclophosphamide
831080|NCT02963818|Brief intervention
831081|NCT02963818|Harm reduction
831082|NCT02963818|Young adult
831083|NCT02963818|College Student
831084|NCT02963805|Children
831085|NCT02963805|Physical activity
831086|NCT02963805|Physical competence
831087|NCT02963805|Obesity
831088|NCT02963805|School
831089|NCT02963805|Health
831090|NCT02963805|Fundamental movement skills
831091|NCT02963792|Professionalism
831092|NCT02963792|Burnout prevention
831093|NCT02963792|Resiliency
831094|NCT02963792|Student education
831096|NCT02963753|Hyperemesis gravidarum
831097|NCT02963753|gestational diabetes mellitus
831098|NCT02963753|oral glucose tolerance test
831099|NCT02963740|breast cancer survivor
831100|NCT02963740|weight loss program
831101|NCT02963727|osteoarthrosis
831102|NCT02963727|Knee
831103|NCT02963727|Wharton Jelly
831104|NCT02963714|Hepatitis B, Vaccine
831105|NCT02963714|Randomized Controlled Trial
831106|NCT02963714|Hemodialysis
831107|NCT02963714|Immunogenicity
831108|NCT02963662|obesity
831109|NCT02963662|bariatric surgery
831110|NCT02963662|gut hormones
831111|NCT02963662|inflammatory adipokine
831112|NCT02963649|Drug-eluting angioplasty balloon, Drug coated angioplasty balloon, Experimental, percutaneous transluminal angioplasty (PTA)
831113|NCT02963636|family medicine group
831114|NCT02963636|pharmacists
831115|NCT02963636|primary health care
831116|NCT02963636|pharmaceutical services
831117|NCT02963636|interprofessional relations
831118|NCT02963623|fibtem
831119|NCT02963623|total knee replacement
831120|NCT02963584|chronic total occlusion
831121|NCT02963584|decision aid
831125|NCT02963493|relapsed refractory multiple myeloma
831126|NCT02963467|multiple inert gas elimination technique
831127|NCT02963467|smoking
831128|NCT02963467|pulmonary disorder
831129|NCT02963441|Diabetic Retinopathy
831130|NCT02963441|Macular Edema
831131|NCT02963415|Subjective memory complaint
831132|NCT02963363|Breast cancer
831133|NCT02963363|HER2+
831134|NCT02963363|Adapted physical activity
831135|NCT02963363|Neoadjuvant chemotherapy
831136|NCT02963337|remifentanil
831137|NCT02963337|combined spinal-epidural analgesia
831138|NCT02963337|multiparous
831139|NCT02963272|Heart failure
831140|NCT02963272|ST2
831141|NCT02963272|fibrosis
831142|NCT02963246|mindfulness
831143|NCT02963246|quality of life
831144|NCT02963246|Bowel Disease
831145|NCT02963207|colorectal polyp
831146|NCT02963207|colorectal lesion
831147|NCT02963207|Modified Sano's Classification
831148|NCT02963207|NICE classification
831149|NCT02963207|NBI
831150|NCT02963207|PIVI guidelines
831151|NCT02963207|SSA/P
831152|NCT02963207|sessile serrated adenoma
831153|NCT02963207|sessile serrated polyp
831154|NCT02963194|self-processing
831155|NCT02963194|endowment effect
831156|NCT02963194|neuroimage
831157|NCT02963181|Melatonin
831158|NCT02963181|Yohimbine
831159|NCT02963181|Anti-hypertensive agents
831160|NCT02963155|prostate, metastatic
831161|NCT02963142|Intensive care
831162|NCT02963142|Extra-corporeal membrane oxygenation (ECMO)
831163|NCT02963142|Severe Respiratory Infections
831164|NCT02963142|Sequencing
831165|NCT02963142|Metagenome
831166|NCT02963142|Diagnosis
831167|NCT02963129|Hereditary Hemorrhagic Telangiectasia
831168|NCT02963129|Epistaxis
831169|NCT02963116|Pharmacokinetics (PK)
831170|NCT02963116|Bioavailability (BA)
831171|NCT02963116|Safety
831172|NCT02963116|Tolerability
831173|NCT02963116|Healthy Volunteers
831174|NCT02963103|Tacrolimus
831175|NCT02963103|Kidney transplantation
831176|NCT02963090|SCLC
831177|NCT02963090|small cell lung cancer
831178|NCT02963090|lung cancer
831179|NCT02963090|topotecan
831180|NCT02963090|pembrolizumab
831181|NCT02963064|Immunodeficiency
831182|NCT02963064|Pediatric
831183|NCT02963064|SCID
831184|NCT02963064|Bone Marrow Transplantation
831185|NCT02963064|GVHD
831186|NCT02963064|Stem Cells
831187|NCT02963064|Chimerism
831188|NCT02963064|Transplant
831189|NCT02963064|BMT
831190|NCT02963051|metastatic castrate-resistant prostate cancer (mCRPC)
831191|NCT02963051|neuroendocrine prostate cancer (NEPC)
831192|NCT02963051|adenocarcinoma castrate-resistant prostate cancer (CRPC)
831193|NCT02963051|Copper
831194|NCT02963051|Disulfiram
831195|NCT02962999|Ketamine
831196|NCT02962999|One lung ventilation
831197|NCT02962999|Chronic obstructive pulmonary disease
831198|NCT02962986|vasopressor
831199|NCT02962986|blood pressure
831200|NCT02962986|cesarean section
831201|NCT02962986|spinal anesthesia
831202|NCT02962973|Advanced heart failure
831203|NCT02962973|Total artificial heart
831204|NCT02962947|Melanoma
831205|NCT02962947|Propanolol
831206|NCT02962947|Betablockers
831207|NCT02962908|broad
831208|NCT02962908|universal
831209|NCT02962908|vaccine
831210|NCT02962908|influenza
831211|NCT02962908|peptide
831212|NCT02962908|Tcell
831213|NCT02962908|UNISEC
831214|NCT02962843|Behavior Problem
831215|NCT02962843|Social Competence
831216|NCT02962843|Student
831217|NCT02962843|Children
831218|NCT02962830|fetal pain
831219|NCT02962830|fetal analgesia
831220|NCT02962804|kidney
831221|NCT02962804|renal cell
831222|NCT02962804|cancer
831223|NCT02962804|metastatic
831224|NCT02962804|recurrent
831225|NCT02962791|symptomatic heart failure
831226|NCT02962778|treatment-resistant
831227|NCT02962739|healthy volunteers
831228|NCT02962726|Anorexia
831229|NCT02962726|Depression
831230|NCT02962726|Microbiome
831231|NCT02962713|Atraumatic Restorative Treatment
831232|NCT02962713|glass ionomer cement
831233|NCT02962713|primary teeth
831234|NCT02962713|dental caries.
831235|NCT02962700|continuous haemofiltration
831236|NCT02962700|intermittent haemodialysis
831237|NCT02962687|Veterans
831238|NCT02962687|Cognitive impairments
831239|NCT02962687|Nursing care management
831240|NCT02962687|Videoconferencing
831241|NCT02962674|BPH
831242|NCT02962661|Other forms of heart disease
831243|NCT02962661|Left ventricular dysfunction
831244|NCT02962661|LV
831245|NCT02962661|Heart failure secondary to chemotherapy with anthracyclines
831246|NCT02962661|Human mesenchymal stem cells
831247|NCT02962661|hMSCs
831248|NCT02962661|Mesenchymal Stromal Cells
831249|NCT02962661|MSCs
831250|NCT02962661|Intravenous infusion
831251|NCT02962661|Transendocardial injection
831252|NCT02962661|Standard of care drugs for heart failure
831253|NCT02962648|IDA
831254|NCT02962622|Neurocognition
831255|NCT02962622|Exercise
831256|NCT02962622|Metabolism
831257|NCT02962622|Hispanic women
831258|NCT02962609|Feeding
831259|NCT02962609|preterm infant
831260|NCT02962609|physiological characteristics
831261|NCT02962609|position
831262|NCT02962609|ESL
831263|NCT02962609|ESU
831264|NCT02962557|ventilatory depression
831265|NCT02962544|Femtosecond
831266|NCT02962544|Small incision lenticule extraction
831267|NCT02962544|Lenticule extraction
831268|NCT02962544|LASIK
831269|NCT02962544|Myopia
831270|NCT02962518|Pressure Device
831271|NCT02962518|Clip
831272|NCT02962518|Triamcinolone
831273|NCT02962518|Fillet Technique
831274|NCT02962492|Dapagliflozin
831275|NCT02962492|Ketogenesis
831276|NCT02962492|Type 1 Diabetes
831277|NCT02962492|DKA
831278|NCT02962492|ketones
831279|NCT02962492|exenatide/Bydureon
831280|NCT02962414|Everolimus
831281|NCT02962414|Tuberous sclerosis complex
831282|NCT02962414|TSC
831283|NCT02962414|Refractory seizure
831284|NCT02962414|Roll over study
831285|NCT02962414|Long term safety
831286|NCT02962414|PASS
831287|NCT02962388|efficacy
831288|NCT02962388|safety
831289|NCT02962375|orange pomace fiber
831290|NCT02962375|glycemic response
831292|NCT02962271|Musculoskeletal Ultrasound
831293|NCT02962271|Psoriatic Arthritis
831294|NCT02962271|Enthesopathy
831295|NCT02962245|Ulcerative Colitis
831296|NCT02962245|Berberine
831297|NCT02962232|drug eluting balloon
831298|NCT02962232|arterial vasculature below the knee
831299|NCT02962219|oesophagectomy
831300|NCT02962193|ADL
831301|NCT02962193|Bariatric surgery
831302|NCT02962193|Daily participation
831303|NCT02962180|derma-rolling system, vitiligo
831304|NCT02962167|measles virus
831305|NCT02962167|recurrent medulloblastoma
831306|NCT02962167|recurrent ATRT
831307|NCT02962154|Invasive Coronary Angiography
831308|NCT02962154|Myocardial Infarction
831309|NCT02962154|Major Depressive Disorder
831310|NCT02962154|Bipolar I Disorder
831311|NCT02962154|Bipolar II Disorder
831312|NCT02962154|Mental Stress
831313|NCT02962141|drug eluting balloon, Arteriovenous Fistulae
831314|NCT02962089|Protein-energy wasting
831315|NCT02962089|Hemodialysis patients
831316|NCT02962089|Microbiota
831317|NCT02962089|Branched chain amino acids
831318|NCT02962089|Undernutrition
831319|NCT02962089|Malnutrition
831320|NCT02962089|Renal failure
831321|NCT02962089|Dialysis
831322|NCT02962089|Protein
831323|NCT02962089|Appetite
831324|NCT02962089|Body composition
831325|NCT02962089|Energy expenditure
831326|NCT02962063|Durvalumab
831327|NCT02962063|Anti-PD-L1 Antibody
831328|NCT02962063|16-1405
831329|NCT02962011|Cesarean, incision, suture,
831330|NCT02961998|hepatocellular carcinoma
831331|NCT02961998|sorafenib
831332|NCT02961998|celecoxib
831333|NCT02961972|vegetarianism
831334|NCT02961972|Hyperhomocysteinemia
831335|NCT02961972|vegan vegetarian
831339|NCT02961907|periconceptional habits
831340|NCT02961907|Pregnancy
831341|NCT02961907|Infertility
831342|NCT02961868|Renal Artery Obstruction
831343|NCT02961868|Carotid Artery Diseases
831344|NCT02961868|Genetic Association Studies
831345|NCT02961829|Dendritic Cell vaccination using
831346|NCT02961829|antiretroviral intensification
831347|NCT02961829|Auranofin
831348|NCT02961829|Histone Deacetylase Inhibitor
831349|NCT02961829|residual viral replication
831350|NCT02961829|HIV sanctuaries
831351|NCT02961829|HIV latency
831352|NCT02961816|Lymphoma
831353|NCT02961816|Refractory/Relapsed Lymphoma
831354|NCT02961816|Diffuse large B-cell lymphoma
831355|NCT02961816|Hodgkin's lymphoma
831356|NCT02961816|T-cell Lymphoma
831357|NCT02961816|Palifermin
831358|NCT02961816|Kepivance
831359|NCT02961816|Panobinostat
831360|NCT02961816|LBH589B
831361|NCT02961816|Gemcitabine
831362|NCT02961816|Gemcitabine Hydrochloride
831363|NCT02961816|Gemzar
831364|NCT02961816|Busulfan
831365|NCT02961816|Busulfex
831366|NCT02961816|Myleran
831367|NCT02961816|Melphalan
831368|NCT02961816|Alkeran
831369|NCT02961816|Rituximab
831370|NCT02961816|Rituxan
831371|NCT02961816|Dexamethasone
831372|NCT02961816|Decadron
831373|NCT02961816|Caphosol
831374|NCT02961816|Glutamine
831375|NCT02961816|Enterex
831376|NCT02961816|Glutapak-10
831377|NCT02961816|NutreStore
831378|NCT02961816|Resource
831379|NCT02961816|GlutaSolve
831380|NCT02961816|Sympt-X G.I.
831381|NCT02961816|Sympt-X
831382|NCT02961816|Pyridoxine
831383|NCT02961816|G-CSF
831384|NCT02961816|Filgrastim
831385|NCT02961816|Neupogen
831386|NCT02961816|Stem cell transplant
831387|NCT02961803|AMN
831388|NCT02961803|MD1003
831389|NCT02961803|Adrenomyeloneuropathy
831390|NCT02961803|ALD
831391|NCT02961803|Adrenoleukodystrophy
831392|NCT02961803|Biotin
831393|NCT02961803|2MWT
831394|NCT02961803|Two-minute walk test
831395|NCT02961803|TW25
831396|NCT02961803|Timed 25-Foot Walk
831397|NCT02961764|Critical Pathways
831398|NCT02961764|Health Facilities
831399|NCT02961764|Clinical Protocols
831400|NCT02961764|Patient Satisfaction
831401|NCT02961764|Absenteeism
831402|NCT02961764|Anti-Bacterial Agents
831403|NCT02961764|Quality of Life
831404|NCT02961764|Economics, Medical
831405|NCT02961764|Health Resources
831406|NCT02961764|Health resource utilization
831407|NCT02961764|Acute bacterial skin and skin structure infection (ABSSSI)
831408|NCT02961751|Ciprofloxacin-susceptibility
831409|NCT02961751|Gyrase A Assay
831410|NCT02961751|Neisseria gonorrhoeae
831411|NCT02961647|Hemodynamic stress test
831412|NCT02961647|Surgical intervention
831413|NCT02961634|onychomycosis
831414|NCT02961634|nail
831415|NCT02961595|Oral polio vaccine
831416|NCT02961595|Inactivated polio vaccine
831417|NCT02961595|Enterovirus
831418|NCT02961595|Type 1 diabetes
831419|NCT02961595|Autoantibody
831420|NCT02961582|Sacral neuromodulation
831421|NCT02961582|Constipation
831422|NCT02961582|Slow-transit constipation
831423|NCT02961582|Surgery
831424|NCT02961582|Colorectal surgery
831425|NCT02961582|Cost-effectiveness
831426|NCT02961582|Quality of life
831427|NCT02961556|AJG555
831428|NCT02961556|Constipation
831429|NCT02961556|Phase 3
831430|NCT02961556|Pediatric participants
831431|NCT02961491|MIBG
831432|NCT02961491|Azedra
831433|NCT02961491|Rare neuroendocrine tumors
831434|NCT02961491|Iobenguane I 131
831435|NCT02961491|Progenics
831436|NCT02961465|Sacral neuromodulation
831437|NCT02961465|Constipation
831438|NCT02961465|Slow-transit constipation
831439|NCT02961465|Surgery
831440|NCT02961465|Colorectal surgery
831441|NCT02961465|Cost-effectiveness
831442|NCT02961465|Quality of life
831443|NCT02961387|Tracheal stenosis, Hydrogen generator, Hydrogen-oxygen, Dyspnea.
831444|NCT02961361|dexmedetomidine
831445|NCT02961361|coracoid
831446|NCT02961361|brachial plexus block
831447|NCT02961348|Oral anticoagulants (NOAC)
831448|NCT02961309|THC
831449|NCT02961309|marijuana
831450|NCT02961309|tobacco cigarette
831451|NCT02961309|smoking
831452|NCT02961296|Helicobacter Pylori
831453|NCT02961283|BRAF Kinases
831454|NCT02961283|PIK3CA protein, human
831455|NCT02961244|Surgical Site Infection
831456|NCT02961244|normothermia
831457|NCT02961244|hypothermia
831458|NCT02961244|prewarming
831459|NCT02961231|Pneumococcal conjugate vaccine
831460|NCT02961231|Herd immunity
831461|NCT02961231|Reduced dosing schedule
831462|NCT02961218|Sickle cell disease
831463|NCT02961218|hemoglobinopathy
831464|NCT02961218|pediatric
831465|NCT02961166|IVIG
831466|NCT02961166|ARDS
831467|NCT02961166|ECMO
831468|NCT02961140|Outcome
831469|NCT02961127|tissue factor pathway inhibitor
831470|NCT02961114|Prostatitis, Chronic
831471|NCT02961114|Nocturia
831472|NCT02961114|BPH With Urinary Obstruction
831473|NCT02961101|relapsed or refractory
831474|NCT02961101|malignancies
831475|NCT02961101|decitabine
831476|NCT02961101|anti-PD-1 antibody
831477|NCT02961088|Systematic review and meta-analysis
831478|NCT02961088|Evidence-based medicine (EBM)
831479|NCT02961088|Evidence-based nutrition (EBN)
831480|NCT02961088|Clinical practice guidelines
831481|NCT02961088|Glycemic index
831482|NCT02961088|Pasta
831483|NCT02961088|Glycemic load
831484|NCT02961088|Body weight
831485|NCT02961088|Cardiovascular risk factors
831486|NCT02961088|Cardiovascular disease
831487|NCT02961062|ocular pain
831488|NCT02961062|photorefractive keratectomy (PRK)
831489|NCT02961062|SAF312
831490|NCT02961062|corneal epithelial defect
831491|NCT02961036|Surveys and Questionnaires
831492|NCT02961010|school based prevention, child sexual and domestic abuse
831493|NCT02960997|epidermolysis bullosa simplex
831494|NCT02960958|Rheumatoid arthritis
831495|NCT02960958|Metabolomics
831496|NCT02960958|urine
831497|NCT02960932|Hemiplegic
831498|NCT02960932|Child
831499|NCT02960932|Elastography
831500|NCT02960932|paralysis
831501|NCT02960893|Ataxia
831502|NCT02960893|SCA
831503|NCT02960893|Spinocerebellar Ataxia
831504|NCT02960880|Rivaroxaban, Phenprocoumon, retrospective cohort study, Non-Valvular Atrial fibrillation, NVAF
831505|NCT02960867|paediatric
831506|NCT02960867|kidney
831507|NCT02960815|influenza vaccine
831508|NCT02960815|Transplantation
831509|NCT02960815|imiquimod
831510|NCT02960815|HIV infection
831511|NCT02960815|immunogenicity
831512|NCT02960802|kidney transplant
831513|NCT02960802|renal blood flow
831514|NCT02960789|Dehydration
831515|NCT02960789|Children
831516|NCT02960789|Measurement
831517|NCT02960776|Body Weight
831518|NCT02960776|Habitual sleep
831519|NCT02960763|Comparative Effectiveness Research
831520|NCT02960763|Pragmatic Clinical Trials
831521|NCT02960763|Patient-Centered Outcomes Research
831522|NCT02960750|workplace
831523|NCT02960750|sedentary behavior
831524|NCT02960750|physical activity
831525|NCT02960750|physical risk factors
831526|NCT02960750|mental well-being
831527|NCT02960750|presenteeism
831528|NCT02960750|work productivity
831529|NCT02960750|activity-related energy expenditures
831530|NCT02960737|Dysphagia
831531|NCT02960737|Stroke
831532|NCT02960737|Intervention
831533|NCT02960737|Oral screen
831534|NCT02960737|Incidence
831535|NCT02960724|Uroplasminogen Plasminogen Activator Receptor
831536|NCT02960724|Oropharyngeal cancer
831537|NCT02960724|oral cancer
831538|NCT02960724|Positron Emission Tomography
831539|NCT02960698|cognitive impulsivity
831540|NCT02960698|IRM
831541|NCT02960698|Tourette Syndrome
831542|NCT02960672|KL-6
831543|NCT02960672|disease progression
831544|NCT02960672|predict
831545|NCT02960672|biomarkers
831546|NCT02960672|MMP-7
831549|NCT02960646|Leukemia
831550|NCT02960646|Blood And Marrow Transplantation
831551|NCT02960646|Acute lymphocytic leukemia
831552|NCT02960646|ALL
831553|NCT02960646|Acute myeloid leukemia
831554|NCT02960646|AML
831555|NCT02960646|Chronic lymphocytic leukemia
831556|NCT02960646|CLL
831557|NCT02960646|Chronic myeloid leukemia
831558|NCT02960646|CML
831559|NCT02960646|Hodgkin's disease
831560|NCT02960646|Non-Hodgkin's lymphoma
831561|NCT02960646|NHL
831562|NCT02960646|Small lymphocytic lymphoma
831563|NCT02960646|SLL
831564|NCT02960646|Myelodysplastic syndrome (MDS
831565|NCT02960646|MDS
831566|NCT02960646|Aplastic anemia
831567|NCT02960646|Modified (CD45RA depleted) peripheral blood (PB) stem cell infusion
831568|NCT02960646|T cells
831569|NCT02960646|Haploidentical transplantation
831570|NCT02960646|Rituximab
831571|NCT02960646|Rituxan
831572|NCT02960646|Melphalan
831573|NCT02960646|Alkeran
831574|NCT02960646|Fludarabine
831575|NCT02960646|Fludarabine Phosphate
831576|NCT02960646|Fludara
831577|NCT02960646|Cyclophosphamide
831578|NCT02960646|Cytoxan
831579|NCT02960646|Neosar
831580|NCT02960646|G-CSF
831581|NCT02960646|Filgrastim
831582|NCT02960646|Neupogen
831583|NCT02960620|Humanitarian Device Exemption
831584|NCT02960620|Liver Disease
831585|NCT02960620|HDE #980006
831586|NCT02960594|Immunotherapy
831587|NCT02960594|Human Telomerase Reverse Transcriptase (hTERT)
831588|NCT02960594|Breast Neoplasms
831589|NCT02960594|Lung Neoplasms
831590|NCT02960594|Pancreatic Neoplasms
831591|NCT02960594|High Risk of Relapse
831592|NCT02960594|Post Definitive Surgery
831593|NCT02960594|Post Adjuvant Therapy
831594|NCT02960594|No Evidence of Disease
831595|NCT02960568|primaquine
831596|NCT02960568|metabolism
831597|NCT02960568|malaria
831598|NCT02960568|hypnozoite
831599|NCT02960568|vivax
831600|NCT02960568|CYP2D6
831617|NCT02960503|sickle cell disease
831618|NCT02960503|pulmonary complications
831619|NCT02960503|reduced FEV1
831620|NCT02960503|azithromycin
831621|NCT02960503|lung function
831624|NCT02960477|Shoulder pain
831625|NCT02960477|Shoulder surgery
831626|NCT02960477|Pain neuroscience education
831627|NCT02960477|Chronic pain
831628|NCT02960464|Parkinson Disease
831629|NCT02960464|Depression
831630|NCT02960464|Transcranial Direct Current Stimulation
831631|NCT02960464|Neuromodulation
831632|NCT02960451|prodrome
831633|NCT02960451|cognitive behavioral therapy
831634|NCT02960451|family focused therapy
831637|NCT02960373|Dried fruit
831638|NCT02960373|Glycemic Index
831639|NCT02960373|Catalytic dose
831640|NCT02960373|Glycemic response
831641|NCT02960373|Fructose
831642|NCT02960373|Postprandial
831643|NCT02960373|Randomized clinical trial
831644|NCT02960373|Carbohydrate metabolism
831645|NCT02960334|Screening
831646|NCT02960334|Silent Atrial Fibrillation
831647|NCT02960334|Undertreated Atrial Fibrillation
831648|NCT02960334|Actionable Atrial Fibrillation
831649|NCT02960334|MyDiagnostick
831650|NCT02960334|Opportunistic Screening
831651|NCT02960334|Preoperative Consultation
831652|NCT02960334|OAC
831653|NCT02960334|VKA
831654|NCT02960334|NOAC
831655|NCT02960321|myocardial injury
831656|NCT02960321|high-sensitivity troponin I
831657|NCT02960321|periprocedural myocardial infarction
831658|NCT02960269|rural health
831659|NCT02960269|telehealth
831660|NCT02960269|physiotherapy
831661|NCT02960269|interprofessional
831662|NCT02960243|Deep Brain Stimulation
831663|NCT02960243|Laryngeal Motor Cortex
831664|NCT02960243|Essential Voice Tremor
831665|NCT02960243|Essential Tremor
831666|NCT02960230|peptide vaccine
831667|NCT02960230|immunotherapy
831668|NCT02960230|DIPG
831669|NCT02960230|vaccine
831670|NCT02960204|cirrhosis
831671|NCT02960204|Portal Hypertension
831672|NCT02960204|Non-alcoholic Steatohepatitis
831673|NCT02960204|Liver cirrhosis
831674|NCT02960152|periodontitis
831675|NCT02960113|cesarean section
831676|NCT02960113|acupressure point p6
831677|NCT02960113|scopolamine patch
831678|NCT02960100|Cancer prevention
831679|NCT02960100|HPV
831680|NCT02960100|Human papillomavirus vaccine
831681|NCT02960074|Allergy, Peanut
831682|NCT02960074|Hypersensitivity Peanut
831683|NCT02960074|Peanut Allergy
831684|NCT02960074|Donor Feces Infusion
831685|NCT02960074|Fecal Transplant
831686|NCT02960074|Fecal Transplantation
831687|NCT02960074|Intestinal Microbiota Transfer
831688|NCT02960074|Fecal Microbiota Transplantation
831689|NCT02960074|Food allergy
831690|NCT02960061|Intraperitoneal chemotherapy
831691|NCT02960061|gastric cancer
831692|NCT02960061|Neo-adjuvant chemotherapy
831693|NCT02960048|Anterior disc displacement
831694|NCT02960048|TMD therapy
831695|NCT02960048|internal derangement
831696|NCT02960048|occlusal splint
831697|NCT02960048|anterior repositioning splint
831698|NCT02960035|Mardird sonographic enthesis index
831699|NCT02960035|Spondyloarthropathy
831700|NCT02960035|Ultrasonics
831701|NCT02960035|Etanercept
831708|NCT02959944|chronic graft versus host disease
831709|NCT02959944|PCYC1140
831710|NCT02959944|PCYC1140IM
831711|NCT02959944|1140
831712|NCT02959944|Ibrutinib
831713|NCT02959944|GVHD
831714|NCT02959944|Steroid dependent
831715|NCT02959944|refractory
831716|NCT02959944|chronic
831717|NCT02959944|PCI32765
831718|NCT02959944|IMBRUVICA
831719|NCT02959944|Pharmacyclics
831720|NCT02959944|PCYC
831721|NCT02959944|graft versus host disease
831722|NCT02959944|immunology
831723|NCT02959944|new onset graft versus host disease
831724|NCT02959944|INTEGRATE
831725|NCT02959944|Corticosteroids
831726|NCT02959944|prednisone
831727|NCT02959931|Dietary Potassium
831728|NCT02959892|Drug therapy
831729|NCT02959879|FOLFOX
831730|NCT02959879|FOLFIRINOX
831731|NCT02959853|Hypogonadism
831732|NCT02959853|Severe obesity
831738|NCT02959814|Fractional Flow Reserve
831739|NCT02959814|Quantitative Coronary Analysis
831740|NCT02959814|Stable coronary artery disease
831741|NCT02959814|Angina pectoris
831742|NCT02959801|Deep Venous Thrombosis
831743|NCT02959801|Percutaneous Mechanical Thrombectomy
831744|NCT02959788|Heart rate variability
831745|NCT02959775|Hepatitis B vaccination
831746|NCT02959775|Immunogenicity
831747|NCT02959775|Randomized controlled trial
831748|NCT02959775|Drug abuse
831770|NCT02959749|Osimertinib
831771|NCT02959749|EGFR T790M Resistant Mutation
831772|NCT02959749|Docetaxel
831773|NCT02959749|Bevacizumab
831774|NCT02959749|Non Small Cell Lung
831775|NCT02959736|Vegetative State
831776|NCT02959736|Minimally Conscious State
831777|NCT02959736|Brain Injuries
831778|NCT02959723|Pulmonary Arterial Hypertension
831779|NCT02959723|BMPR2
831780|NCT02959723|Inflammation
831781|NCT02959710|Healthy volunteers
831782|NCT02959710|AC-1202
831783|NCT02959710|AC-1204
831784|NCT02959710|Pharmacokinetic
831785|NCT02959710|ketone body
831786|NCT02959697|Blepharoptosis
831787|NCT02959697|Ptosis
831788|NCT02959697|Surgery
831789|NCT02959697|Pain Reduction
831790|NCT02959697|Anesthetic
831791|NCT02959697|Local Anesthetic
831792|NCT02959697|Subconjunctival
831793|NCT02959593|Primary open-angle glaucoma
831794|NCT02959593|retinal capillary blood flow
831795|NCT02959593|visual stimulation
831796|NCT02959580|Granulomatous
831797|NCT02959580|Mastitis
831798|NCT02959580|topical steroids
831799|NCT02959567|cervix
831800|NCT02959567|cervical dilation
831801|NCT02959567|balloon catheter
831802|NCT02959554|Advanced
831803|NCT02959554|Metastatic
831804|NCT02959554|RCC
831805|NCT02959541|Leukovorin
831806|NCT02959476|Postoperative pain
831807|NCT02959476|Postsurgical pain
831808|NCT02959463|Malignant pleural mesothelioma
831809|NCT02959463|MPM
831810|NCT02959463|Non-metastatic
831811|NCT02959463|Pembrolizumab
831812|NCT02959463|Keytruda
831813|NCT02959463|MK-3475
831814|NCT02959463|SCH-900475
831815|NCT02959463|Radiation therapy
831816|NCT02959463|Radiation treatment
831817|NCT02959463|XRT
831818|NCT02959463|Intensity modulated radiation therapy
831819|NCT02959463|IMRT
831820|NCT02959463|Proton beam therapy
831821|NCT02959463|PBT
831822|NCT02959463|3D conformal therapy
831823|NCT02959450|Nutritional Intervention in Oropharyngeal Dysphagia
831824|NCT02959437|Solid tumors
831825|NCT02959437|NSCLC
831826|NCT02959437|CRC
831827|NCT02959359|Chronic hepatitis C
831828|NCT02959359|Hepatocellular Carcinoma
831829|NCT02959359|Direct-acting antiviral (DAA)
831830|NCT02959359|Recurrence
831831|NCT02959346|Minimal invasive thoracoscopic surgery
831832|NCT02959346|Pain control
831833|NCT02959346|Acupuncture
831834|NCT02959346|Randomized controlled trial
831835|NCT02959307|Depression
831836|NCT02959307|Major Depressive Disorder
831837|NCT02959307|Major Depressive Episode
831838|NCT02959294|TBI
831839|NCT02959294|mTBI
831840|NCT02959294|Concussion, Brain
831841|NCT02959294|Loss Consciousness, Traumatic
831842|NCT02959294|Headaches
831843|NCT02959242|glaucoma, follow-up intervals, treatment efficiency
831844|NCT02959229|Late onset sepsis
831845|NCT02959229|Bovine Lactoferrin
831846|NCT02959203|Central Venous Catheter
831847|NCT02959203|Ultrasound
831848|NCT02959203|Chest X-ray
831849|NCT02959203|Pneumothorax
831850|NCT02959190|prevention
831851|NCT02959190|prophylaxis
831852|NCT02959190|headache
831853|NCT02959177|prevention
831854|NCT02959177|prophylaxis
831855|NCT02959177|headache
831856|NCT02959112|pancreatitis after ERCP
831857|NCT02959112|epinephrine
831858|NCT02959112|papilla
831859|NCT02959112|rectal indomethacin
831860|NCT02959099|Acute myocardial infarction
831861|NCT02959099|ST elevation myocardial infarction
831862|NCT02959099|Non ST elevation myocardial infarction
831863|NCT02959099|Unstable angina
831864|NCT02959099|Coronary computed tomography angiography
831865|NCT02959086|Epidemiology
831866|NCT02959086|Shanghai
831867|NCT02959086|Cancer
831868|NCT02959086|Adolescents
831869|NCT02959086|Children
831870|NCT02959073|Symptom recording
831871|NCT02959047|MRI
831872|NCT02959047|PCSK9 inhibition
831873|NCT02959047|LDL cholesterol
831874|NCT02959021|weight loss
831875|NCT02959021|behavioral
831876|NCT02959021|primary care
831877|NCT02959021|lifestyle
831878|NCT02958995|Drug Therapy
831879|NCT02958982|RP3128
831880|NCT02958982|Phase 1
831881|NCT02958982|Healthy volunteers
831882|NCT02958969|venous thromboembolism
831883|NCT02958969|multiple myeloma
831884|NCT02958969|anticoagulation
831885|NCT02958956|Drug Therapy
831886|NCT02958943|atrial fibrillation
831887|NCT02958943|stroke
831888|NCT02958943|computerized decision support
831889|NCT02958904|Sexuality
831890|NCT02958904|Spinal cord injuries
831891|NCT02958904|Erectile dysfunction
831892|NCT02958904|depression
831894|NCT02958852|Breast Cancer
831895|NCT02958852|Endocrine Treatment
831896|NCT02958852|Atorvastatin
831897|NCT02958852|Mechanisms of Resistance
831898|NCT02958852|Statins
831899|NCT02958852|Fulvestrant
831900|NCT02958852|Circulating Tumor Cells
831901|NCT02958852|Statins and Endocrine Treatment
831902|NCT02958852|Tumor Marker Expression
831903|NCT02958852|ER+ Metastatic Breast Cancer
831904|NCT02958852|Circulating Tumor DNA
831905|NCT02958852|Cholesterol
831906|NCT02958839|Atrial fibrillation
831907|NCT02958839|Fibroblast Growth factor 23
831908|NCT02958800|Deprescribing
831909|NCT02958800|Single patient open label trial
831910|NCT02958800|Long-term care
831911|NCT02958761|knee arthrosis
831912|NCT02958761|platelet-derived growth factors
831913|NCT02958735|exercise
831914|NCT02958735|cognition
831915|NCT02958735|brain-derived neurotrophic factor
831916|NCT02958735|insulin-like growth factor 1
831917|NCT02958735|cortisol
831918|NCT02958683|Optoelectronic plethysmography
831919|NCT02958683|Structure light plethysmography
831920|NCT02958683|Respiratory Function Tests
831921|NCT02958657|Platelet function
831922|NCT02958657|Autonomic Nervous System
831923|NCT02958657|Multiplate® (Multiple Electrode Aggregometry - MEA)
831924|NCT02958657|VerifyNow®
831925|NCT02958644|prebiotic
831926|NCT02958644|obesity
831927|NCT02958644|body mass index
831928|NCT02958644|microbiota
831929|NCT02958605|Children
831930|NCT02958605|resuscitation
831931|NCT02958605|smartphone
831932|NCT02958592|shear-wave elastography
831933|NCT02958592|hepatic fibrosis
831934|NCT02958592|liver tumor
831935|NCT02958566|Pain control
831936|NCT02958566|Post-operative pain
831937|NCT02958566|Narcotic
831938|NCT02958566|Non-narcotic
831939|NCT02958566|Side effect
831940|NCT02958566|Toxicity
831941|NCT02958553|Lower Extremity Limb Loss
831942|NCT02958553|Prosthesis Use
831943|NCT02958540|Prophylaxis
831947|NCT02958514|IPL
831948|NCT02958514|MGD
831949|NCT02958501|Vitamin D
831950|NCT02958501|Inflammatory Bowel Diseases
831951|NCT02958488|34 to 36 Weeks Preterm Neonates
831952|NCT02958488|Respiratory Distress Syndrom
831953|NCT02958488|High Flow Nasal Cannula
831954|NCT02958436|Safety
831955|NCT02958436|Tolerability
831956|NCT02958436|Pharmacokinetics
831957|NCT02958436|REGN3500
831958|NCT02958410|CD30
831959|NCT02958410|CAR-T
831960|NCT02958397|Myeloid Malignancies
831961|NCT02958397|CAR-T
831962|NCT02958397|CD33
831963|NCT02958384|Myeloid Malignancies
831964|NCT02958384|CAR-T
831965|NCT02958384|LeY
831966|NCT02958371|Functional magnetic resonance imaging
831967|NCT02958371|Taste
831968|NCT02958371|Feeding behavior
831969|NCT02958371|Choice behavior
831970|NCT02958358|pulmonary hypertension
831971|NCT02958358|ambrisentan
831972|NCT02958358|PET imaging
831973|NCT02958358|CT/PET
831974|NCT02958332|video games
831975|NCT02958306|cleft lip repair
831976|NCT02958306|cheiloplasty
831977|NCT02958306|PRP
831978|NCT02958306|platelet rich plasma
831979|NCT02958280|Exercise
831980|NCT02958280|Smartphone
831981|NCT02958267|knee osteoarthritis
831982|NCT02958267|regenerative medicine
831983|NCT02958267|orthobiologics
831984|NCT02958267|cellular therapy
831985|NCT02958254|hamstring
831986|NCT02958254|ultrasonography
831987|NCT02958254|validation
831988|NCT02958254|magnetic resonance imaging
831989|NCT02958254|muscle thickness
831990|NCT02958241|spondylolisthesis
831991|NCT02958241|Lumbar spine
831992|NCT02958241|MRI
831993|NCT02958228|Positive Affect
831994|NCT02958228|Mental Imagery
831995|NCT02958228|Cognitive Bias Modification
831996|NCT02958228|Cognitive Control Training
831997|NCT02958215|Orthostatic
831998|NCT02958215|Cesarean section
831999|NCT02958215|Pregnant
832000|NCT02958215|Phenyephrine
832001|NCT02958215|Hypotension
832002|NCT02958202|Duchenne Muscular Dystrophy
832003|NCT02958202|DMD
832004|NCT02958202|Dystrophin
832005|NCT02958202|BMN 044
832006|NCT02958202|PRO044
832007|NCT02958202|BioMarin
832008|NCT02958189|Twitter
832009|NCT02958189|social support
832010|NCT02958189|internet intervention
832011|NCT02958189|sedentary lifestyle
832012|NCT02958189|walking
832013|NCT02958189|behavior change
832014|NCT02958163|Hepatocellular cancer
832015|NCT02958163|Stereotactic Body Radiotherapy
832016|NCT02958163|Chemoembolization, Therapeutic
832017|NCT02958111|Nasopharyngeal Carcinoma
832018|NCT02958111|Adjuvant chemotherapy
832019|NCT02958111|Capecitabine
832020|NCT02958098|myocardial infarction
832021|NCT02958098|stroke
832022|NCT02958098|dilated cardiomyopathy
832023|NCT02958098|systolic heart failure
832024|NCT02958098|atrial fibrillation
832025|NCT02958098|aortic dissection
832026|NCT02958098|wearable devices
832027|NCT02958098|genomic sequencing
832028|NCT02958072|Malleoli ulcers
832029|NCT02958072|Diabetes
832030|NCT02958072|Healing
832031|NCT02958072|Dressing
832032|NCT02958072|LeucoPatch
832033|NCT02958059|ERCP
832034|NCT02958059|prophylaxis
832035|NCT02958059|antibiotics
832036|NCT02958059|infection
832037|NCT02958059|cholangitis
832038|NCT02958020|cohort, osteoporosis, bone mineral density, Chinese
832039|NCT02957981|BRCA1
832040|NCT02957981|BRCA2
832041|NCT02957981|Men
832042|NCT02957981|Hereditary Cancer
832043|NCT02957981|Prostate Cancer
832044|NCT02957981|Male Breast Cancer
832045|NCT02957968|Breast Cancer
832046|NCT02957968|Invasive adenocarcinoma
832047|NCT02957968|HER2-negative
832048|NCT02957955|Heart failure
832049|NCT02957942|Repetitive transcranial magnetic stimulation (rTMS)
832050|NCT02957942|Spasmodic dysphonia
832051|NCT02957942|Dystonia
832052|NCT02957877|Anticoagulation
832053|NCT02957877|Anti-Xa activity
832054|NCT02957877|Low-molecular weight heparin
832055|NCT02957877|Unfractionated heparin
832056|NCT02957838|Transferrin Receptor
832057|NCT02957838|Type 2 Diabetes
832058|NCT02957838|Stearic Acid (C18:0)
832059|NCT02957838|Mitochondrial Morphology
832060|NCT02957838|Crossover Study
832061|NCT02957812|Gait
832062|NCT02957812|Balance Control
832063|NCT02957812|Orthotics
832064|NCT02957799|Pregnancy
832065|NCT02957799|Home Healthcare Visits
832066|NCT02957799|Community Health Workers
832067|NCT02957799|Infants
832068|NCT02957786|cytisine
832069|NCT02957786|varenicline
832070|NCT02957786|smoking cessation
832071|NCT02957786|indigenous
832072|NCT02957747|Women Veterans
832073|NCT02957747|Sexual Trauma
832074|NCT02957734|Vertical dimension of occlusion
832075|NCT02957734|Direct composite restorations
832076|NCT02957734|Indirect composite restorations
832077|NCT02957734|Tooth wear
832078|NCT02957734|Failure
832079|NCT02957734|Quality of Life
832080|NCT02957695|frontal brain lesions
832081|NCT02957695|neurofeedback
832082|NCT02957695|cognitive functions
832083|NCT02957682|Hyperlipidemias
832084|NCT02957682|Dyslipidemias
832085|NCT02957682|Lipid Metabolism Disorders
832086|NCT02957630|Estetrol (E4)
832087|NCT02957630|Drospirenone (DRSP)
832088|NCT02957630|Ethinylestradiol (EE)
832089|NCT02957630|Levonorgestrel (LNG)
832090|NCT02957630|Oral contraceptive
832091|NCT02957630|Prevention of pregnancy
832092|NCT02957630|Hemostasis
832093|NCT02957630|Metabolism
832356|NCT02956213|indoor air quality
832094|NCT02957617|Neuropathic Pain From Lumbosacral Radiculopathy, PLSR
832095|NCT02957604|Pregnancy; Cardiovascular Diseases; High serum cholesterol
832096|NCT02957591|Depression
832097|NCT02957591|probiotic supplementation
832098|NCT02957591|Adjuvant Therapy
832099|NCT02957591|Gut microbiome
832100|NCT02957591|Psychological functioning
832101|NCT02957591|Brain imaging
832102|NCT02957591|Brain-Gut interactions
832103|NCT02957591|Sleep
832104|NCT02957578|Tympanostomy Tube
832105|NCT02957578|Ventilation Tube
832106|NCT02957578|Grommet
832107|NCT02957578|Otitis Media
832108|NCT02957578|Middle Ear Effusion
832109|NCT02957565|Malignant neoplasms of independent (primary) multiple sites
832110|NCT02957565|Questionnaires
832111|NCT02957565|Surveys
832112|NCT02957565|Videos
832113|NCT02957565|Advanced Cancer
832114|NCT02957539|motivation
832115|NCT02957539|patient incentives
832116|NCT02957513|Diabetes
832117|NCT02957513|Uncontrolled
832118|NCT02957513|Chronic Disease
832119|NCT02957513|Chronic Conditions
832120|NCT02957513|Medically Underserved Areas
832121|NCT02957513|African Americans
832122|NCT02957513|Health Coaching
832123|NCT02957513|Health Education
832124|NCT02957513|Text Messaging
832125|NCT02957513|Text Messages
832126|NCT02957513|Mobile Health
832127|NCT02957474|Healthy Volunteers
832128|NCT02957474|Pharmacokinetics
832129|NCT02957474|Food Effect
832130|NCT02957474|Proton Pump
832131|NCT02957474|GED-0301
832132|NCT02957474|Mongersen
832133|NCT02957422|neurodegeneration
832134|NCT02957422|cognitive decline
832135|NCT02957422|cognition
832136|NCT02957422|age-related disease
832137|NCT02957422|dairy
832138|NCT02957422|dairy intake
832139|NCT02957409|Heart failure
832140|NCT02957409|Heart Failure with Reduced Ejection Fraction
832141|NCT02957409|HFrEF
832142|NCT02957383|Sleep, Melatonin
832143|NCT02957383|Circadian Rhythm
832144|NCT02957383|Temperature
832145|NCT02957383|screen illumination
832146|NCT02957344|health communication
832147|NCT02957344|Zika virus
832148|NCT02957344|legislation
832149|NCT02957344|vaccination
832150|NCT02957344|Child Care
832151|NCT02957305|misoprostol
832152|NCT02957305|miscarriage
832153|NCT02957279|sepsis
832154|NCT02957279|exosomes
832155|NCT02957279|dendritic cell
832156|NCT02957266|cervical cancer
832157|NCT02957266|interstitial brachytherapy
832158|NCT02957266|gemcitabine
832159|NCT02957266|volumetric arc therapy
832160|NCT02957253|Quality of care
832161|NCT02957253|Health related quality of life
832162|NCT02957253|Nurse-led clinic
832163|NCT02957253|Health economics
832164|NCT02957240|Forearm [A01.378.800.585]
832165|NCT02957240|Radius [A02.835.232.087.090.700]
832166|NCT02957240|Motor Skills [F02.808.260]
832167|NCT02957240|Task Performance and Analysis [F02.808.600]
832168|NCT02957240|Casts, Surgical [E07.858.442.660.430.500]
832169|NCT02957240|Splints [E07.858.690.725.430.750]
832170|NCT02957240|motor representation techniques
832171|NCT02957240|mirror therapy
832172|NCT02957240|Women [M01.975]
832173|NCT02957227|Alzheimer's disease
832174|NCT02957227|Frontotemporal Dementia
832175|NCT02957227|Lewy Body Dementia
832176|NCT02957227|Diagnosis
832177|NCT02957188|Eicosapentaenoic acid
832178|NCT02957188|Arachidonic acid
832179|NCT02957188|Metabolism
832180|NCT02957188|Healthy aging
832181|NCT02957175|Immunophenotyping
832182|NCT02957175|Perioperative Care
832183|NCT02957175|Innate Immunity
832184|NCT02957175|Cardiac Surgical Procedures
832185|NCT02957136|Respiratory Tract Infections
832186|NCT02957136|Influenza, Human
832187|NCT02957136|Common Cold
832188|NCT02957136|Viral Infection
832189|NCT02957136|Pathology, Molecular
832190|NCT02957136|Molecular Diagnostics
832191|NCT02957136|Diagnostic Testing
832192|NCT02957136|Clinical Microbiology
832193|NCT02957136|Polymerase Chain Reaction
832194|NCT02957136|Antibiotic Stewardship
832195|NCT02957136|Antimicrobial Use
832196|NCT02957136|Emergency Department
832197|NCT02957136|Emergency Room
832198|NCT02957123|macrophages M2 type
832199|NCT02957123|cytokines
832200|NCT02957123|intranasal administration
832201|NCT02957123|neuroprotection
832202|NCT02957123|neuroregeneration
832203|NCT02957123|organic brain syndrome
832204|NCT02957123|neurocognitive disorders
832205|NCT02957097|Gabapentin
832206|NCT02957097|acute pain
832207|NCT02957084|difficult laryngoscopy
832208|NCT02957084|neck circumference
832209|NCT02957084|sternomental distance
832210|NCT02957084|thyromental distance
832211|NCT02957084|hyomental distance
832212|NCT02957084|thyrosternal distance
832213|NCT02957058|Colonoscopy
832214|NCT02957058|Endoscopic Mucosal Resection
832215|NCT02957058|Adenoma Recurrence
832216|NCT02957058|EMR defect thermal ablation
832217|NCT02956993|peripheral artery disease
832218|NCT02956993|PAD
832219|NCT02956993|vonapanitase
832220|NCT02956993|critical limb ischemia
832221|NCT02956993|CLI
832222|NCT02956993|tibial artery
832223|NCT02956993|stenosis
832224|NCT02956993|distal popliteal artery
832225|NCT02956993|peroneal artery
832226|NCT02956993|below the knee
832227|NCT02956993|BTK
832228|NCT02956993|elastase
832229|NCT02956993|chymotrypsin-like elastase 1
832230|NCT02956993|CELA1
832231|NCT02956993|PRT-201
832232|NCT02956980|type 1 interferons
832233|NCT02956980|children
832234|NCT02956980|gender
832235|NCT02956980|pubertal status
832236|NCT02956980|sex difference
832237|NCT02956967|Non-Interventional Study
832238|NCT02956954|Enzyme replacement therapy
832239|NCT02956941|Academic performance
832240|NCT02956941|Behaviour change communication
832241|NCT02956941|Nutritional status
832242|NCT02956941|School children
832243|NCT02956941|Ethiopia
832244|NCT02956915|Transcatheter aortic valve implantation
832245|NCT02956889|Carcinoma, Basal Cell
832246|NCT02956889|Vismodegib
832247|NCT02956889|Radiotherapy
832248|NCT02956837|Vaccines
832249|NCT02956837|Respiratory Syncytial Viruses
832250|NCT02956837|Safety
832251|NCT02956837|Reactogenicity
832252|NCT02956837|Ranking of Formulations
832253|NCT02956837|Immunogenicity
832254|NCT02956824|Magnetic Resonance Imaging (MRI)
832255|NCT02956824|Sacro-iliac joints
832256|NCT02956824|Pelvis
832257|NCT02956824|Erosion
832258|NCT02956824|Fat deposit
832259|NCT02956824|Subchondral sclerosis
832260|NCT02956824|Bone marrow edema
832261|NCT02956824|Axial spondyloarthritis
832262|NCT02956811|Type 2 Diabetes
832263|NCT02956811|Left Ventricular Hypertrophy
832264|NCT02956811|Dapagliflozin
832265|NCT02956785|Propess
832266|NCT02956759|diabetic retinopathy
832267|NCT02956759|Pan-retinal photocoagulation
832268|NCT02956759|proliferative
832269|NCT02956759|non-proliferative
832270|NCT02956733|inexpensive, fasciotomy
832271|NCT02956707|neonates
832272|NCT02956707|cardiopulmonary bypass
832273|NCT02956707|adrenal insufficiency
832274|NCT02956707|congenital heart disease
832275|NCT02956694|Aged
832276|NCT02956694|Cognitive impairment
832277|NCT02956694|Neurocognitive Disorders
832278|NCT02956694|Shared decision making
832279|NCT02956694|Distance learning
832280|NCT02956694|Primary care
832281|NCT02956694|Decision support tool
832282|NCT02956694|Patient decision aid
832283|NCT02956668|tDCS
832284|NCT02956668|Visual field
832285|NCT02956668|Stroke
832286|NCT02956616|Enhanced Recovery
832287|NCT02956590|dyslipidemia
832288|NCT02956590|obesity
832289|NCT02956590|pitavastatin
832290|NCT02956590|lipids
832291|NCT02956577|Global Longitudinal Strain (GLS)
832292|NCT02956577|Coronary Flow Velocity Reserve (CFVR)
832293|NCT02956577|Cardiac dysfunction
832294|NCT02956577|Microcirculation
832295|NCT02956577|Coronary Computed Tomography Angiography (CCTA)
832296|NCT02956577|Type 1 Diabetes
832297|NCT02956577|Type 2 Diabetes
832298|NCT02956551|advanced non-small cell lung cancer
832299|NCT02956551|cell based therapy
832300|NCT02956551|safety
832301|NCT02956551|clinical efficacy
832302|NCT02956486|elenbecestat
832303|NCT02956486|E2609
832304|NCT02956486|Alzheimer's Disease
832305|NCT02956486|Early Alzheimer's Disease
832306|NCT02956486|Prodromal Alzheimer's Disease
832307|NCT02956486|Dementia
832308|NCT02956486|Dementia, Alzheimer's type
832309|NCT02956486|mild cognitive impairment
832310|NCT02956486|MissionAD1
832311|NCT02956473|Breast Cancer
832312|NCT02956447|Kisspeptin
832313|NCT02956447|Hyperprolactinemia
832314|NCT02956408|Obesity
832315|NCT02956408|Pediatrics
832316|NCT02956408|Vitamin D deficiency
832317|NCT02956395|adaptive case management approach
832318|NCT02956395|Transitional Care
832319|NCT02956395|multimorbidity
832320|NCT02956382|Ibrutinib
832321|NCT02956382|Venetoclax
832322|NCT02956382|Follicular
832323|NCT02956382|Refractory
832324|NCT02956382|Relapsed
832325|NCT02956382|Lymphoma
832340|NCT02956291|glioma
832341|NCT02956291|brain tumor
832342|NCT02956291|brain metastasis
832343|NCT02956278|allopurinol
832344|NCT02956252|cholecystectomy, laparoscopic
832345|NCT02956252|spinal anesthesia
832346|NCT02956252|general anesthesia
832347|NCT02956252|cholecystectomy
832348|NCT02956239|cervical precancer
832349|NCT02956239|screening
832350|NCT02956239|treatment
832351|NCT02956239|thermo-coagulation
832352|NCT02956239|thermal ablation
832353|NCT02956239|Reducing overtreatment
832354|NCT02956213|COPD
832355|NCT02956213|air filter
832357|NCT02956213|respiratory symptoms
832358|NCT02956213|emphysema
832359|NCT02956213|chronic obstructive pulmonary disease
832360|NCT02956213|tobacco use
832361|NCT02956200|Fingolimod Hydrochloride
832362|NCT02956200|Intravenous thrombolysis
832363|NCT02956200|Mechanical thrombectomy
832364|NCT02956200|Acute ischemic stroke
832365|NCT02956161|Sleep
832366|NCT02956161|Auditory stimulations
832367|NCT02956161|Slow oscillations
832368|NCT02956096|tDCS
832369|NCT02956096|Stroke
832370|NCT02956096|Autonomic Modulation
832371|NCT02956070|dental bleaching
832372|NCT02956070|antiinflammatory
832373|NCT02956070|tooth sensitivity
832374|NCT02956031|cancer prevention
832375|NCT02956031|cervical screening
832376|NCT02956031|cervical cancer
832377|NCT02956031|cervical disease
832378|NCT02956031|cervical neoplasm
832379|NCT02956031|HPV testing
832380|NCT02956031|immunocytochemistry
832381|NCT02956031|triage techniques
832382|NCT02956018|children
832383|NCT02955979|acute renal insufficiency
832384|NCT02955979|Iodinated Contrast Agents
832385|NCT02955979|pediatric
832386|NCT02955966|Aspergillosis
832387|NCT02955966|Haematological malignancy
832388|NCT02955966|18F-FDG PET/CT
832389|NCT02955966|Biomarkers
832390|NCT02955940|Solid tumors
832391|NCT02955940|ruxolitinib
832392|NCT02955940|regorafenib
832393|NCT02955940|capecitabine
832394|NCT02955927|Myopia control,ortho-k, atropine eye drops, children
832395|NCT02955914|Optimism
832396|NCT02955914|Pessimism
832397|NCT02955914|Recovery
832398|NCT02955914|Elective Cardiac surgery
832399|NCT02955901|Randomized controlled trial
832400|NCT02955901|Colonoscopy
832401|NCT02955901|Colon Disease
832402|NCT02955901|Low residue diet
832403|NCT02955901|Colon preparation
832404|NCT02955875|Diabetes Mellitus, Type 2
832405|NCT02955875|Pharmaceutical Services
832406|NCT02955862|Cryptococcal antigenemia
832407|NCT02955862|Cryptococcal meningitis
832408|NCT02955862|HIV/AIDS
832409|NCT02955849|glaucoma
832410|NCT02955849|rural
832411|NCT02955849|China
832412|NCT02955849|SLT
832413|NCT02955836|Patient Safety
832414|NCT02955836|Quality indicator
832415|NCT02955836|Information system
832416|NCT02955836|Nursing
832417|NCT02955836|Healthcare Quality
832418|NCT02955836|Quality measurement
832419|NCT02955823|B cell Lymphoma
832420|NCT02955823|non-Hodgkin Lymphoma
832421|NCT02955823|Elderly patients
832422|NCT02955810|Newly Diagnosed
832423|NCT02955810|Treatment Naiive
832429|NCT02955771|photodynamic therapy(PDT)
832430|NCT02955771|stenting
832431|NCT02955771|Hilar Cholangiocarcinoma
832432|NCT02955771|Deuteporfin
832433|NCT02955719|Collaborative Care
832434|NCT02955719|Depression
832435|NCT02955719|Anxiety
832436|NCT02955719|Mild Cognitive Impairment
832437|NCT02955719|Integrated Care Pathway
832438|NCT02955693|Pharmacokinetics
832439|NCT02955693|Healthy volunteers
832440|NCT02955693|Monomethylfumarate
832441|NCT02955693|Dimethyl fumarate
832442|NCT02955693|Fumaderm®
832443|NCT02955693|Ethyl fumarate
832444|NCT02955680|emergence delirium
832445|NCT02955680|emergence time
832446|NCT02955680|bispectral index
832447|NCT02955667|invivo microscopy
832448|NCT02955667|colposcopy
832449|NCT02955667|cervical precancer and cancer
832450|NCT02955641|Laser peripheral iridotomy
832451|NCT02955641|topical anti-inflammatory drops
832452|NCT02955602|PBC
832453|NCT02955602|Primary Biliary Cholangitis (PBC)
832454|NCT02955576|Psoriasis
832455|NCT02955563|decision making for incapacitated patients
832456|NCT02955563|intensive care
832457|NCT02955563|surrogate decision making
832458|NCT02955563|patient centered care
832459|NCT02955563|Palliative Care
832460|NCT02955563|End of Life
832461|NCT02955563|Quality of Communication
832462|NCT02955550|Multiple Myeloma
832463|NCT02955550|Plasma Cell Myeloma
832464|NCT02955550|Plasma Cell Neoplasm
832465|NCT02955550|Relapsed/refractory Myeloma
832466|NCT02955550|PNK-007
832467|NCT02955550|Recombinant Human IL-2 (RHIL-2)
832468|NCT02955550|Human IL-2
832469|NCT02955550|Bone Marrow Transplant
832472|NCT02955485|Ankle
832473|NCT02955485|Instability
832474|NCT02955485|Prediction
832475|NCT02955472|Neuralgia, Postherpetic
832476|NCT02955472|Postherpetic Neuralgia
832477|NCT02955472|Diabetic Neuropathies
832478|NCT02955472|Diabetic Neuralgia
832479|NCT02955472|Diabetic Polyneuropathy
832480|NCT02955472|Diabetic Neuropathy, Painful
832481|NCT02955472|Neuralgia
832482|NCT02955472|Neuropathic Pain
832483|NCT02955472|Pregabalin
832484|NCT02955472|Pharmacokinetics
832485|NCT02955472|Bioequivalent
832486|NCT02955459|Healthy volunteers
832487|NCT02955459|Pharmacokinetics
832488|NCT02955446|Refractory Tumors
832489|NCT02955446|Advanced Solid Tumors
832490|NCT02955433|Rideshare
832491|NCT02955433|Digital transportation network
832492|NCT02955433|Missed appointment
832493|NCT02955420|Autoantibodies
832494|NCT02955420|Heart Failure
832495|NCT02955420|Fatigue Syndrome, Chronic
832496|NCT02955420|Idiopathic Pulmonary Hypertension
832497|NCT02955420|Cardiomyopathies
832498|NCT02955394|ER+/Her2 - breast cancer
832499|NCT02955394|Preoperative Fulvestrant
832500|NCT02955394|Enzalutamide
832501|NCT02955368|DP-R212
832502|NCT02955303|Cognitive training
832503|NCT02955303|Tablet computers
832504|NCT02955277|Cognitive training
832505|NCT02955277|Tablet computers
832506|NCT02955264|Glycosylation
832507|NCT02955264|Glucose Metabolic Disorder
832508|NCT02955264|Galactose
832509|NCT02955251|Non-squamous NSCLC
832510|NCT02955251|Advanced solid tumor
832511|NCT02955251|Ovarian cancer
832512|NCT02955251|Non-small cell lung cancer (NSCLC)
832513|NCT02955251|Cancer
832514|NCT02955251|Neoplasm
832515|NCT02955251|Nivolumab
832516|NCT02955238|Intervention
832517|NCT02955238|Cardiovascular Disease
832518|NCT02955238|CVD
832519|NCT02955238|Diabetes
832520|NCT02955238|Latinos
832521|NCT02955238|CIMT
832522|NCT02955238|Medication Adherence
832523|NCT02955238|Risk Factors
832524|NCT02955238|T2D
832525|NCT02955225|Knee loads
832526|NCT02955225|Knee adduction moment
832527|NCT02955225|Biomechanical intervention
832528|NCT02955225|Insole
832529|NCT02955225|Shoe
832530|NCT02955212|Rheumatoid Arthritis
832531|NCT02955212|Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
832532|NCT02955212|ABT-494
832533|NCT02955134|central blinded histological assessment
832534|NCT02955134|traditional Chinese medicine intervention
832535|NCT02955134|long-term follow-up study
832536|NCT02955134|biological specimen banks
832537|NCT02955121|Cytochrome P-450 CYP2C19
832538|NCT02955121|Pharmacogenetics
832539|NCT02955121|Platelet Aggregation Inhibitors
832540|NCT02955121|Percutaneous Coronary Intervention
832541|NCT02955069|Advanced or metastatic
832542|NCT02955069|NET
832543|NCT02955069|pNET
832544|NCT02955069|GI NET
832545|NCT02955069|thoracic NET
832546|NCT02955069|GEP-NEC
832547|NCT02955056|Weber B
832548|NCT02955043|Hematopoietic Stem Cell Transplantation (HSCT)
832549|NCT02955043|Fatigue
832550|NCT02955043|Insomnia
832551|NCT02955043|Depression
832552|NCT02955043|Behavioral Intervention
832553|NCT02955017|obesity
832554|NCT02955017|children
832555|NCT02955017|adolescents
832556|NCT02955017|new technology
832557|NCT02955017|mobile health
832558|NCT02955017|chronic disease
832559|NCT02955004|silent brain embolism
832560|NCT02955004|atrial fibrillation
832561|NCT02955004|cardioversion
832562|NCT02954965|graduate student
832563|NCT02954965|burnout
832564|NCT02954965|stress
832565|NCT02954965|mood
832566|NCT02954939|lupus nephritis
832567|NCT02954939|lymphocyte subsets
832568|NCT02954939|cytokines
832569|NCT02954939|mycophenolate mofetil
832570|NCT02954939|cyclophosphamide
832571|NCT02954900|Breast Cancer Prevention
832572|NCT02954900|Risk Assessment
832573|NCT02954900|Chemoprevention
832574|NCT02954900|Decision Making
832575|NCT02954887|GWP42003-P
832576|NCT02954887|Cannabidiol
832577|NCT02954809|fatigue
832578|NCT02954809|sleep disturbances
832579|NCT02954809|circadian activity rhythms
832580|NCT02954783|Prostate cancer
832581|NCT02954783|Localized
832582|NCT02954783|Exercise
832583|NCT02954783|Physical activity
832584|NCT02954783|Natural killer cells
832585|NCT02954783|Immune cells
832586|NCT02954757|uterine adenomyosis
832587|NCT02954744|uterine fibroid
832588|NCT02954731|Cognitive Behavior Therapy
832589|NCT02954731|Negative Affect
832590|NCT02954731|Unified Protocol
832591|NCT02954731|Session Tracking
832592|NCT02954731|Mechanisms of Change in Psychotherapy
832593|NCT02954718|activity performance
832594|NCT02954718|juvenile idiopathic arthritis
832595|NCT02954718|virtual reality
832596|NCT02954679|Psychoactive Substances Consumption
832597|NCT02954679|Substance-related Disorder
832598|NCT02954679|Off label-use
832599|NCT02954679|Cognitive Enhancement
832600|NCT02954679|Students
832601|NCT02954679|Doping
832602|NCT02954679|Stimulants
832603|NCT02954679|Drug abuse
832604|NCT02954679|Methylphenidate
832605|NCT02954679|Addictovigilance
832606|NCT02954679|CEIP
832607|NCT02954666|cardio-neuromodulation
832608|NCT02954666|cardio-neuroablation
832609|NCT02954666|ablation
832610|NCT02954666|ganglionated plexi
832611|NCT02954666|anterior right ganglionated plexus
832612|NCT02954666|syncope
832613|NCT02954653|relapsed
832614|NCT02954653|refractory
832615|NCT02954653|acute myeloid leukemia
832616|NCT02954653|AML
832617|NCT02954627|Osteoarthritis
832618|NCT02954627|Obesity
832619|NCT02954627|Liraglutide 3 mg
832620|NCT02954627|Liraglutide
832621|NCT02954627|Ultrasound
832622|NCT02954601|Oral Insulin
832623|NCT02954601|DM T2 (Diabetes Mellitus Type 2)
832624|NCT02954562|anxiety
832625|NCT02954562|fMRI
832626|NCT02954562|emotion regulation
832627|NCT02954549|vitamin D deficiency, genomics, vitamin D supplementation
832628|NCT02954536|pembrolizumab
832629|NCT02954536|trastuzumab
832630|NCT02954536|capecitabine
832631|NCT02954536|cisplatin
832632|NCT02954536|Stage IV
832633|NCT02954536|HER2-positive
832634|NCT02954536|esophagogastric cancer
832635|NCT02954536|16-937
832636|NCT02954536|Oxaliplatin
832637|NCT02954536|5-Fluorouracil (5-FU)
832638|NCT02954523|NSCLC
832639|NCT02954523|Non-small cell
832640|NCT02954523|Lung Cancer
832641|NCT02954523|Dasatinib
832642|NCT02954523|Osimertinib
832643|NCT02954523|AZD9291
832644|NCT02954523|EGFR Mutations
832645|NCT02954523|Epidermal growth factor receptor (EGFR)
832646|NCT02954445|BCMA
832647|NCT02954445|CAR-T
832648|NCT02954432|transcranial Direct Current Stimulation
832649|NCT02954432|Transcranial Ultrasound
832650|NCT02954432|non-invasive brain stimulation
832651|NCT02954419|IgA Nephropathy
832652|NCT02954419|Biomarker
832653|NCT02954406|Drug Therapy
832654|NCT02954393|Periodontal disease
832655|NCT02954393|Metronidazole
832656|NCT02954393|Amoxicillin
832657|NCT02954393|Scaling and root planing
832658|NCT02954393|Healing phase
832659|NCT02954354|Flu
832660|NCT02954354|S-033188
832661|NCT02954354|Oseltamivir
832662|NCT02954354|Tamiflu®
832663|NCT02954302|Delayed gastric emptying
832664|NCT02954302|pancreaticoduodenectomy
832665|NCT02954289|modifiable risk factors
832666|NCT02954289|lifestyle
832667|NCT02954289|nutrition
832668|NCT02954289|weight control
832669|NCT02954289|dietary intervention
832670|NCT02954289|health promotion
832671|NCT02954289|patient-partner outcomes
832672|NCT02954289|survivorship
832673|NCT02954289|prostate cancer outcomes
832674|NCT02954276|safety
832675|NCT02954263|Multiple ascending dose (MAD)
832676|NCT02954237|Non-valvular atrial fibrillation (NVAF)
832677|NCT02954237|Anticoagulant
832678|NCT02954237|Warfarin
832679|NCT02954237|Stroke
832680|NCT02954224|sleep apnea, delirium
832681|NCT02954211|rTMS
832682|NCT02954211|noninvasive brain stimulation
832683|NCT02954211|physical therapy
832684|NCT02954185|Shoulder Pain
832685|NCT02954146|Veterans
832686|NCT02954146|Posttraumatic Stress Disorder
832687|NCT02954146|Anger
832688|NCT02954146|Behavioral Health
832689|NCT02954146|Mobile Health Technology
832690|NCT02954133|Alignment phase
832691|NCT02954133|Photobiomodulation
832692|NCT02954133|Orthodontic treatment
832693|NCT02954133|Malocclusion
832694|NCT02954133|OrthoPulse™
832695|NCT02954133|Invisalign
832696|NCT02954120|8- hydroxy -2´- deoxyguanosine
832697|NCT02954120|Malondialdehyde
832698|NCT02954120|Total antioxidant status
832699|NCT02954120|Oxidative stres
832700|NCT02954068|Oxytocin
832701|NCT02954055|locally advanced
832702|NCT02954055|metastatic
832703|NCT02954055|breast cancer
832704|NCT02954055|ER-positive
832705|NCT02954055|HER2-negative
832706|NCT02954055|Stage IV
832707|NCT02954042|Incontinence
832708|NCT02954016|Obesity
832709|NCT02954016|Weight Loss
832710|NCT02954016|Hypertension
832711|NCT02954016|Type 2 Diabetes Mellitus
832712|NCT02954016|Hyperlipidemia
832713|NCT02954003|Obesity
832714|NCT02954003|Weight Loss
832715|NCT02953990|Pregnancy
832716|NCT02953990|Self-Management
832717|NCT02953990|Yoga
832718|NCT02953951|blood transfusion
832719|NCT02953951|free hemoglobin
832720|NCT02953951|nitric oxide
832721|NCT02953951|endothelium-dependent vasodilatation
832722|NCT02953951|peripheral artery tonometry
832723|NCT02953951|cardiac surgery.
832724|NCT02953938|Ranibizumab
832725|NCT02953938|Grid&Direct short pulse laser photocoagulation
832726|NCT02953938|Macular edema,
832727|NCT02953938|Branch retinal vein occlusion (BRVO)
832728|NCT02953938|BCVA
832729|NCT02953938|CSFT
832730|NCT02953938|pro re nata
832731|NCT02953925|primary health care
832732|NCT02953925|village doctor
832733|NCT02953925|township hospital
832734|NCT02953925|community health center
832735|NCT02953912|Rotation
832736|NCT02953912|Reciprocation
832737|NCT02953912|single file
832738|NCT02953912|postoperative pain
832739|NCT02953912|Reciproc
832740|NCT02953912|One Shape
832741|NCT02953912|Symptomatic irreversible pulpitis
832742|NCT02953899|Internet
832743|NCT02953899|Contingency Management
832744|NCT02953899|Gambling Disorder
832745|NCT02953899|Rural
832746|NCT02953886|Caries
832747|NCT02953886|Cavity
832748|NCT02953886|Silver Diamine Fluoride (SDF)
832749|NCT02953886|HOMINGS
832750|NCT02953860|Advanced Breast Cancer
832751|NCT02953860|ER+/Her2 Advanced Breast Cancer
832752|NCT02953834|insulin regulation in pregnancy
832753|NCT02953834|kisspeptin
832754|NCT02953808|GSK2315698
832755|NCT02953808|Dose-ascending
832756|NCT02953808|Systemic amyloidosis
832757|NCT02953782|Colorectal Neoplasms, Hu5F9-G4, CD47, cetuximab
832758|NCT02953756|Brain metastases
832759|NCT02953756|Cognition
832760|NCT02953756|Radiosurgery
832761|NCT02953756|Stereotactic radiosurgery
832762|NCT02953756|Gamma Knife Radiosurgery
832763|NCT02953756|Quality of Life
832764|NCT02953756|Fatigue
832765|NCT02953756|Anxiety
832766|NCT02953756|Depression
832767|NCT02953743|E7080
832768|NCT02953743|Lenvatinib
832769|NCT02953743|Pharmacokinetic study
832770|NCT02953743|Chinese participants
832771|NCT02953743|Unresectable Hepatocellular Carcinoma
832772|NCT02953717|Brain metastases
832773|NCT02953717|Cognition
832774|NCT02953717|Radiosurgery
832775|NCT02953717|Gamma Knife Radiosurgery
832776|NCT02953717|Stereotactic radiosurgery
832777|NCT02953717|Whole Brain Radiation Therapy
832778|NCT02953717|Quality of Life
832779|NCT02953717|Fatigue
832780|NCT02953717|Anxiety
832781|NCT02953717|Depression
832782|NCT02953704|Myelofibrosis
832783|NCT02953704|essential thrombocythemia
832784|NCT02953704|clinical characteristics
832785|NCT02953704|disease burden
832786|NCT02953704|patient-reported outcomes
832787|NCT02953691|perioperative
832788|NCT02953691|surgery
832789|NCT02953691|pain
832790|NCT02953691|anxiety
832791|NCT02953691|post operative cognitive dysfunction
832792|NCT02953691|cognition
832793|NCT02953678|Graft-versus-host disease (GVHD)
832794|NCT02953678|acute GVHD
832795|NCT02953678|steroid-refractory
832796|NCT02953678|ruxolitinib
832797|NCT02953678|Janus kinase inhibitor
832798|NCT02953665|Parkinson's Disease, Liraglutide
832799|NCT02953665|Antidiabetic agents
832800|NCT02953665|GLP-1 agonists
832801|NCT02953665|Insulin resistance
832802|NCT02953626|pilot RCT
832803|NCT02953626|waitlist-controlled RCT
832804|NCT02953626|postpartum depression
832805|NCT02953613|Cardiac Catheterization
832806|NCT02953613|Cardiac intervention
832807|NCT02953613|coronary angiogram
832808|NCT02953613|coronary artery disease
832809|NCT02953613|atherosclerosis
832810|NCT02953587|Obesity
832811|NCT02953587|Bariatric Surgery
832812|NCT02953574|geriatric nursing
832813|NCT02953561|Relapsed Acute Myeloid Leukemia
832814|NCT02953561|Refractory Acute Myeloid Leukemia
832815|NCT02953561|Acute Myeloid Leukemia
832816|NCT02953561|AML
832817|NCT02953561|Avelumab
832818|NCT02953561|antiPDL1
832819|NCT02953561|5-azacytidine
832820|NCT02953561|Azacitidine
832821|NCT02953561|5-aza
832822|NCT02953561|Vidaza
832823|NCT02953561|5-AZC
832824|NCT02953561|AZA-CR
832825|NCT02953561|Ladakamycin
832826|NCT02953561|NSC-102816
832827|NCT02953561|Azacytidine
832828|NCT02953548|GWP42003-P
832829|NCT02953548|Cannabidiol
832830|NCT02953522|Polymorphism
832831|NCT02953522|Folate
832832|NCT02953522|Oxidative stress
832833|NCT02953522|Overweight and Obesity
832834|NCT02953509|non-Hodgkin's lymphoma
832835|NCT02953509|diffuse large B-cell lymphoma
832836|NCT02953509|indolent lymphoma
832837|NCT02953509|Hu5F9-G4
832838|NCT02953509|CD47
832839|NCT02953496|peripheral artery disease
832840|NCT02953496|PAD
832841|NCT02953496|vonapanitase
832842|NCT02953496|claudication
832843|NCT02953496|superficial femoral artery
832844|NCT02953496|SFA
832845|NCT02953496|popliteal artery
832846|NCT02953496|stenosis
832847|NCT02953496|elastase
832848|NCT02953496|chymotrypsin-like elastase 1
832849|NCT02953496|CELA1
832850|NCT02953496|PRT-201
832851|NCT02953483|Ex Vivo lung perfusion
832852|NCT02953470|chronic pain
832853|NCT02953470|community-dwelling
832854|NCT02953470|older adults
832855|NCT02953470|physical activity
832856|NCT02953470|physiotherapy
832857|NCT02953470|behavioural medicine
832858|NCT02953470|biopsychosocial
832859|NCT02953470|exercise
832860|NCT02953470|independency
832861|NCT02953470|everyday activities
832862|NCT02953470|self-efficacy
832863|NCT02953470|quality of life
832864|NCT02953470|pain-related beliefs
832865|NCT02953470|pain-related disability
832866|NCT02953431|Asthma
832867|NCT02953431|Obesity
832868|NCT02953353|Obesity
832869|NCT02953353|Feeding behavior
832870|NCT02953353|Transcranial direct current stimulation
832871|NCT02953353|Weight loss
832872|NCT02953340|Neutropenia
832873|NCT02953340|Breast Cancer
832874|NCT02953340|Long-acting Myeloid Growth Factor
832875|NCT02953340|Early Stage Breast Cancer
832876|NCT02953340|Docetaxel + Cyclophosphamide (TC) chemotherapy
832877|NCT02953327|Non-Specific Effect of Vaccine
832878|NCT02953327|Middle aged
832879|NCT02953327|Immunity, heterologous
832880|NCT02953301|Cutaneous T-Cell Lymphoma (CTLC)
832881|NCT02953301|Maintenance
832882|NCT02953301|resminostat
832883|NCT02953301|4SC
832884|NCT02953301|HDAC
832885|NCT02953301|Mycosis Fungoides
832886|NCT02953301|Sézary Syndrome
832887|NCT02953262|Diabetes Mellitus
832888|NCT02953262|Personal Health Records
832889|NCT02953262|Patient Outcome Assessment
832890|NCT02953262|Mental Health
832891|NCT02953184|neoadjuvant chemotherapy
832892|NCT02953184|Pegylated liposomal doxorubicin
832893|NCT02953184|breast cancer
832894|NCT02953171|Irritable Bowel Syndrome
832895|NCT02953171|The human microbiome
832896|NCT02953171|Microbiota
832897|NCT02953171|Gut microbiota
832898|NCT02953171|Probiotics
832899|NCT02953171|Sauerkraut
832900|NCT02953106|Asthma
832901|NCT02953106|Rhinitis
832902|NCT02953106|Dymista
832903|NCT02953106|allergy
832904|NCT02953093|acarbose
832905|NCT02953093|aging
832906|NCT02953054|Pain
832907|NCT02953054|Bunionectomy
832908|NCT02953054|Dexmedetomidine
832909|NCT02953054|Transdermal
832910|NCT02953054|Patch
832911|NCT02953054|Postoperative
832912|NCT02953054|DMTS
832913|NCT02953028|Continuous Positive Airway Pressure
832914|NCT02953028|Mandibular Advancing Splint
832915|NCT02953028|Efficacy
832916|NCT02953028|Compliance
832917|NCT02953028|Health related quality of life
832918|NCT02953028|Randomized Controlled Trial
832919|NCT02953028|Snoring
832920|NCT02953028|Mandibular Advancing Appliance
832921|NCT02953028|Mandibular Advancing Device
832922|NCT02953028|Humans
832923|NCT02953028|Quality of Life
832924|NCT02953028|Sleep Apnea, Obstructive
832925|NCT02953015|Chronic Migraine
832926|NCT02953015|Manipulative treatments
832927|NCT02953015|Transcutaneous Electrical Nerve Stimulation
832928|NCT02952976|open abdomen
832929|NCT02952976|Damage control
832930|NCT02952976|Abdominal Compartment Syndrome
832931|NCT02952950|Intra Oral Vacuum
832932|NCT02952950|protein content breastmilk
832933|NCT02952937|Neuralgia, Postherpetic
832934|NCT02952937|Postherpetic Neuralgia
832935|NCT02952937|Diabetic Neuropathies
832936|NCT02952937|Diabetic Neuralgia
832937|NCT02952937|Diabetic Polyneuropathy
832938|NCT02952937|Diabetic Neuropathy, Painful
832939|NCT02952937|Neuralgia
832940|NCT02952937|Neuropathic Pain
832941|NCT02952937|Pregabalin
832942|NCT02952937|Pharmacokinetics
832943|NCT02952937|Bioequivalent
832944|NCT02952898|solar keratoses
832945|NCT02952872|Computerized Brief Intervention
832946|NCT02952833|Inactivated
832947|NCT02952833|Phase I
832948|NCT02952833|placebo-controlled
832949|NCT02952833|Vaccine
832950|NCT02952833|ZIKA
832951|NCT02952820|insomnia
832952|NCT02952794|endoscopic submucosal dissection (ESD)
832953|NCT02952794|endoscopic mucosal band ligation (EMBL)
832954|NCT02952781|ECG Monitoring
832955|NCT02952781|Palpitations
832956|NCT02952716|carbon monoxide poisoning
832957|NCT02952716|delayed encephalopathy
832958|NCT02952638|Lipids
832959|NCT02952638|lysophosphatidic acid
832960|NCT02952638|Lysophospholipids
832961|NCT02952638|phosphatidylcholine
832962|NCT02952638|lysophosphatidylcholine
832963|NCT02952638|autotaxin
832964|NCT02952638|dietary
832965|NCT02952625|PET/MRI
832966|NCT02952599|Non-interventional Study
832967|NCT02952599|Real World Evidence
832968|NCT02952599|Patients with Acute VTE treated with Edoxaban
832969|NCT02952599|Efficacy/Safety
832970|NCT02952560|Ultrasound
832971|NCT02952560|Computed Tomography
832972|NCT02952560|Oral cavity size
832973|NCT02952560|The Mallampati classification
832974|NCT02952534|CRPC
832975|NCT02952534|PARP inhibitor
832976|NCT02952534|PARPi
832977|NCT02952534|BRCA
832978|NCT02952534|ATM
832979|NCT02952534|HRD
832980|NCT02952534|TRITON
832981|NCT02952534|homologous recombination
832982|NCT02952534|DNA repair
832983|NCT02952534|DNA defect
832984|NCT02952534|DNA anomaly
832985|NCT02952534|BARD1
832986|NCT02952534|BRIP1
832987|NCT02952534|CDK12
832988|NCT02952534|CHEK2
832989|NCT02952534|FANCA
832990|NCT02952534|NBN
832991|NCT02952534|PALB2
832992|NCT02952534|RAD51
832993|NCT02952534|RAD51B
832994|NCT02952534|RAD51C
832995|NCT02952534|RAD51D
832996|NCT02952534|RAD54L
832997|NCT02952534|germline
832998|NCT02952534|somatic
832999|NCT02952495|Alcohol Consumption
833000|NCT02952495|Older Adults
833001|NCT02952482|adrenoleukodystrophy
833002|NCT02952482|C26:0-lyso-PC
833003|NCT02952469|Positron-Emission Tomography
833004|NCT02952469|(68Ga)Glu-urea-Lys(Ahx)-HBED-CC
833005|NCT02952469|(68Ga)PSMA-HBED-CC
833006|NCT02952456|SUDEP
833007|NCT02952456|Epilepsy
833008|NCT02952456|Qualitative research
833009|NCT02952456|Risks associated with epilepsy
833010|NCT02952456|Epilepsy-related deaths
833011|NCT02952391|cognition
833012|NCT02952391|cholinergic system
833013|NCT02952365|LASIK, Ingrowth, Tissue sealant
833014|NCT02952300|irreversible pulpitis
833015|NCT02952300|reciprocation
833016|NCT02952300|rotation
833017|NCT02952300|single file
833018|NCT02952300|wave one
833019|NCT02952300|neolix
833020|NCT02952209|Alveolar Ridge Preservation
833021|NCT02952209|Xenograft bone graft
833022|NCT02952209|Collagen membrane
833023|NCT02952196|Amphetamine
833024|NCT02952196|Stress
833025|NCT02952196|Craving
833026|NCT02952196|CBD
833027|NCT02952183|Autonomic nerve monitoring
833028|NCT02952183|Nerve-sparing surgery
833029|NCT02952131|IBD,Crohn's,Ulcerative Bowel; Diverticulitis;IBS;UC
833030|NCT02952105|cardiac arrest
833031|NCT02952105|identify of electrocardiac rhythm
833032|NCT02952105|ventricuar fibrillation
833033|NCT02952105|defibrillation
833034|NCT02952092|ASP1517
833035|NCT02952092|Renal anemia
833036|NCT02952092|Hemodialysis
833037|NCT02952092|Roxadustat
833038|NCT02952053|Myofascial Trigger Points
833039|NCT02952053|Dry needling
833040|NCT02952053|Myotonometry
833041|NCT02952040|ASP1517
833042|NCT02952040|Pharmacokinetics
833043|NCT02952040|Drug-drug interaction
833057|NCT02951949|atherosclerosis, endogenous estrogens, age
833058|NCT02951897|circulating tumor cells
833059|NCT02951897|lung adenocarcinoma
833060|NCT02951897|treatment
833061|NCT02951897|early diagnosis
833062|NCT02951871|Follicular lymphoma; death, rituximab, treatment related toxicity
833063|NCT02951858|Alcohol,Smoking,and Substance Use Involvement Screening Test
833064|NCT02951858|Brief Intervention
833065|NCT02951858|Substance Use
833066|NCT02951858|Primary Medical and Health Care Institution
833067|NCT02951793|intensive care unit
833068|NCT02951793|delirium
833069|NCT02951793|substance withdrawal
833070|NCT02951767|anti-PD-L1
833071|NCT02951767|PD-L1
833072|NCT02951767|MPDL3280A
833073|NCT02951767|PD-1
833074|NCT02951767|bladder cancer
833075|NCT02951767|atezolizumab
833076|NCT02951767|Tecentriq
833077|NCT02951754|ADHD
833078|NCT02951754|Adults
833079|NCT02951754|treatment
833080|NCT02951754|Methylphenidate
833081|NCT02951650|vagus nerve stimulation
833082|NCT02951637|Adenocarcinoma, EGFR, Gefitinib, Pemetrexed, Carboplatin
833083|NCT02951624|Exercise
833084|NCT02951624|Breaking prolonged sitting
833085|NCT02951624|physical activity
833086|NCT02951572|Noninvasive Ventilation
833087|NCT02951572|Physical activity
833088|NCT02951520|Patients
833089|NCT02951481|Clostridium difficile.
833090|NCT02951481|Antimicrobial Stewardship.
833091|NCT02951481|Enterocolitis, Pseudomembranous
833092|NCT02951442|Arterial stiffness
833093|NCT02951442|Klotho-FGF23
833094|NCT02951403|elbow arthroscopy
833095|NCT02951403|DASH
833096|NCT02951403|elbow locking
833097|NCT02951403|elbow osteoarthritis
833098|NCT02951390|Surveillance
833099|NCT02951390|Colorectal cancer
833100|NCT02951390|Colonoscopy
833101|NCT02951390|Adenoma
833102|NCT02951390|Chromoendoscopy
833103|NCT02951377|mechanical diagnosis therapy (MDT)
833104|NCT02951377|physical therapy
833105|NCT02951377|steroid injection
833106|NCT02951377|exercise
833108|NCT02951338|Physical activity
833109|NCT02951338|Exercise
833110|NCT02951338|Behaviour change
833111|NCT02951338|Rehabilitation
833112|NCT02951338|Self-management
833113|NCT02951338|Education
833114|NCT02951325|adjuvant RT
833115|NCT02951312|Emphysema
833116|NCT02951312|Chronic bronchitis
833117|NCT02951312|COPD
833118|NCT02951312|Chronic Obstructive Pulmonary Disease
833119|NCT02951286|Skeletal openbite
833120|NCT02951286|Molar intrusion
833121|NCT02951286|high pull headgear
833122|NCT02951273|abdominal surgery
833123|NCT02951273|blood pressure
833124|NCT02951273|cardiac output
833125|NCT02951273|cerebral blood flow
833126|NCT02951273|cerebral oxygenation
833127|NCT02951273|CO2 reactivity
833128|NCT02951273|duplex ultrasound
833129|NCT02951273|general anaesthesia
833130|NCT02951273|mesenteric traction syndrome
833131|NCT02951273|near-infrared spectroscopy
833132|NCT02951273|upper gastrointestinal cancer surgery
833133|NCT02951234|coronary artery lesions
833134|NCT02951234|intravenous immunoglobulin
833135|NCT02951234|Kawasaki disease
833136|NCT02951234|randomized clinical trial
833137|NCT02951234|aspirin
833138|NCT02951130|CDH
833139|NCT02951130|PPHN
833140|NCT02951130|HRF
833141|NCT02951117|lymphoid malignancies
833142|NCT02951117|Next generation sequencing
833143|NCT02951117|Refractory Multiple Myeloma
833144|NCT02951117|Relapsed Multiple Myeloma
833145|NCT02951052|Long-acting cabotegravir
833146|NCT02951052|Virologic failure
833147|NCT02951052|long-acting rilpivirine
833148|NCT02951052|Antiretroviral
833149|NCT02951039|Non valvular Atrial Fibrillation
833150|NCT02951039|Non-interventional Study
833151|NCT02951039|Efficacy/Safety
833152|NCT02951039|Real World Evidence
833153|NCT02951026|knee
833154|NCT02951026|osteoarthritis
833155|NCT02951026|intra-articular injection
833156|NCT02951026|SM04690
833157|NCT02951000|thyroidectomy
833158|NCT02951000|postoperative pain
833159|NCT02951000|wound healing
833160|NCT02950987|Li-Fraumeni Syndrome (LFS)
833161|NCT02950987|Cancer Predisposition Syndromes
833162|NCT02950987|LFS
833163|NCT02950974|sterofundin
833164|NCT02950974|resuscitation
833165|NCT02950974|normal saline
833166|NCT02950974|chloride
833167|NCT02950974|fluid
833168|NCT02950974|SID
833169|NCT02950974|pH
833170|NCT02950974|osmolality
833171|NCT02950974|urine
833172|NCT02950961|Anxiety [F01.470.132]
833173|NCT02950961|Depression [F01.145.126.350]
833174|NCT02950961|Stress Disorders, Post-Traumatic [F03.950.750.500]
833175|NCT02950961|Primary Health Care [N04.590.233.727]
833176|NCT02950961|Mental Health [F02.418]
833177|NCT02950961|Patient Participation [N05.300.150.600.620]
833178|NCT02950961|Patient Satisfaction [N05.300.150.600.630]
833179|NCT02950961|Patient Preference [N05.300.150.600.630.500]
833180|NCT02950961|Physicians, Primary Care [M01.526.485.810.800]
833181|NCT02950961|Physicians, Women [M01.526.485.810.820]
833182|NCT02950961|Health Behavior [F01.145.488]
833186|NCT02950883|Cystic Fibrosis
833187|NCT02950883|Hypertonic Saline
833188|NCT02950883|Inhaled Saline
833189|NCT02950883|Digestive System Diseases
833190|NCT02950883|Genetic Diseases, Inborn
833191|NCT02950883|Lung Diseases
833192|NCT02950883|Pancreatic Diseases
833193|NCT02950883|Pathologic Processes
833194|NCT02950883|Respiratory Tract Diseases
833195|NCT02950883|Computed Tomography (CT)
833196|NCT02950844|Atrial fibrillation
833197|NCT02950844|Electrogram
833198|NCT02950844|Ablation
833199|NCT02950844|Drivers
833200|NCT02950831|Chronic Pain
833201|NCT02950831|BurstDR
833202|NCT02950831|spinal cord stimulation
833203|NCT02950831|Accelerometry
833204|NCT02950818|self-care
833205|NCT02950818|health education
833206|NCT02950818|chronic disease
833207|NCT02950818|heart diseases
833208|NCT02950818|risk factors for heart disease
833209|NCT02950805|AZD5634
833210|NCT02950805|Mucociliary Clearance
833211|NCT02950805|Safety
833212|NCT02950805|Tolerability
833213|NCT02950805|Pharmacokinetic
833214|NCT02950805|Cystic Fibrosis
833215|NCT02950805|Cross-Over Study
833216|NCT02950792|Non-Small Cell Lung Cancer
833217|NCT02950792|NSCLC
833218|NCT02950766|Kidney Cancer
833219|NCT02950753|Elevated Serum Lactate
833220|NCT02950753|Serum lactate
833221|NCT02950753|Ringer's Lactate
833222|NCT02950753|Lactated Ringer's
833223|NCT02950753|Hyperlactatemia
833224|NCT02950740|malnutrition
833225|NCT02950727|orthognathic surgery
833226|NCT02950727|bicortical screws
833227|NCT02950727|monocortical plates
833228|NCT02950675|Burn patient
833229|NCT02950675|Developmental Disabilities
833230|NCT02950675|Body function
833231|NCT02950675|Participation
833232|NCT02950675|Quality of Life
833233|NCT02950675|longitudinal study
833234|NCT02950636|Epilepsy
833235|NCT02950610|Electronic nose
833236|NCT02950610|Non invasive diagnosis of NAFLD
833237|NCT02950610|NAFLD
833238|NCT02950610|exhaled breath analysis
833239|NCT02950610|Volatile organic compounds
833240|NCT02950545|astigmatism, contact lens, driving
833241|NCT02950532|Posterior ligamentous complex
833242|NCT02950532|Thoracolumbar fractures
833243|NCT02950532|Interspinous distance
833244|NCT02950532|Local kyphosis
833245|NCT02950506|Interictal
833246|NCT02950506|Cognitive
833247|NCT02950506|Dysfunction
833248|NCT02950506|tDCS
833249|NCT02950506|transcranial direct current stimulation
833250|NCT02950480|Mastectomy
833251|NCT02950467|HIV/AIDS
833252|NCT02950467|Demoralization
833253|NCT02950467|Psilocybin
833254|NCT02950467|Group therapy
833255|NCT02950454|Progressive Multiple Sclerosis
833256|NCT02950454|Rehabilitation
833257|NCT02950454|Exercise
833258|NCT02950441|Nicotinamide Riboside
833259|NCT02950441|Nicotinamide Adenine Dinucleotide
833260|NCT02950441|Skeletal muscle
833261|NCT02950441|Metabolism
833262|NCT02950428|TAVI
833263|NCT02950428|Aortic Stenosis
833264|NCT02950428|transcatether Aortic Valve Implantation
833265|NCT02950389|PMMA
833266|NCT02950389|on-line HFR
833267|NCT02950389|free light chains
833268|NCT02950389|toxins
833269|NCT02950389|removal
833270|NCT02950389|hemodialysis
833271|NCT02950376|synthetic drugs
833272|NCT02950376|virtual reality
833273|NCT02950376|addiction evaluation
833274|NCT02950376|physiological data
833275|NCT02950376|eye movement index
833276|NCT02950363|Depression
833277|NCT02950363|Suicide
833278|NCT02950363|Anxiety disorder
833279|NCT02950363|Burn out
833280|NCT02950363|Sleep quality
833281|NCT02950363|Stress
833282|NCT02950350|Cervical cancer
833283|NCT02950350|Precision medicine
833284|NCT02950350|Individualized treatment
833285|NCT02950350|Surgical staging
833286|NCT02950337|Unbiopsied Early Stage Non Small Cell Lung Cancer
833287|NCT02950324|Prehabilitation
833288|NCT02950324|Oesophago-gastric
833289|NCT02950324|Cancer
833290|NCT02950324|Neo-adjuvant
833291|NCT02950324|Exercise
833292|NCT02950324|Cardiopulmonary exercise test
833293|NCT02950324|Insulin resistance
833294|NCT02950298|Pompe
833295|NCT02950298|Glycogen Storage Disease II
833296|NCT02950298|Telemedicine
833297|NCT02950298|Duke University Medical Center
833298|NCT02950259|Breast Cancer
833299|NCT02950259|Early Stage Breast Cancer
833300|NCT02950259|Male breast cancer
833301|NCT02950259|IRX-2
833302|NCT02950259|Immunotherapy
833303|NCT02950233|postoperative pain
833304|NCT02950233|VATS
833305|NCT02950233|activities of daily living
833306|NCT02950233|quality of life
833307|NCT02950194|mesh
833308|NCT02950194|rectus diastasis
833309|NCT02950194|panniculectomy
833310|NCT02950194|abdominoplasty
833311|NCT02950168|Diagnostic procedures
833312|NCT02950168|Interventional procedures
833313|NCT02950168|Planned or unplanned
833314|NCT02950168|Edoxaban-treated population
833315|NCT02950142|order sets
833316|NCT02950142|decision support
833317|NCT02950142|laboratory test
833318|NCT02950142|primary care
833319|NCT02950129|pelvic girdle dysfunction
833320|NCT02950103|solid tumor
833321|NCT02950103|phase II
833322|NCT02950103|phosphoethanolamine
833323|NCT02950090|Knee symptoms
833324|NCT02950090|physical activity
833325|NCT02950090|Fitbit
833326|NCT02950090|Accelerometer
833327|NCT02950090|remote coaching
833328|NCT02950064|BRCA
833329|NCT02950064|BRCA1
833330|NCT02950064|BRCA2
833331|NCT02950064|Pancreatic cancer
833332|NCT02950064|Ovarian cancer
833333|NCT02950064|Castrate resistant prostate cancer
833334|NCT02950064|Triple negative breast cancer
833335|NCT02950064|Breast cancer
833336|NCT02950064|DNA repair mutation-positive solid tumors
833337|NCT02950051|CLL
833338|NCT02950038|Lung Cancer, Nonsmall Cell
833339|NCT02950038|Advanced non-small cell lung cancer
833340|NCT02950038|NSCLC
833341|NCT02950038|Stage IV non-small cell lung cancer
833342|NCT02950038|Recurrent non-small cell lung cancer
833343|NCT02950038|Ibrutinib
833344|NCT02950038|PCI-32765
833345|NCT02950038|Imbruvica
833346|NCT02950038|Nivolumab
833347|NCT02950038|BMS-936558
833348|NCT02950038|Opdivo
833349|NCT02950012|Healthy
833350|NCT02950012|Bloating
833351|NCT02950012|Abdominal Discomfort
833352|NCT02950012|Gas
833353|NCT02950012|Probiotic
833354|NCT02950012|Bacillus Subtillis
833355|NCT02949999|Calcineurin inhibitor
833356|NCT02949999|Voclosporin
833357|NCT02949973|lupus nephritis
833358|NCT02949973|calcineurin inhibitors
833359|NCT02949973|voclosporin
833360|NCT02949960|Eczema
833361|NCT02949960|Dermatitis
833362|NCT02949960|Skin Diseases
833363|NCT02949960|Skin Diseases, Genetic
833364|NCT02949960|Dermatitis, Atopic
833365|NCT02949960|Skin Diseases, Eczematous
833366|NCT02949960|Hypersensitivity
833367|NCT02949960|Immune System Diseases
833368|NCT02949947|Malignant Neoplasms of Mesothelial and Soft Tissue
833369|NCT02949947|Gastrointestinal Stromal Tumor
833370|NCT02949947|GIST
833371|NCT02949947|Iron-deficiency anemia
833372|NCT02949947|Ferric Carboxymaltose
833373|NCT02949947|Injectafer
833374|NCT02949947|Iron supplement
833375|NCT02949947|Health Questionnaire
833376|NCT02949947|Survey
833377|NCT02949908|Relapsing Remitting Multiple Sclerosis
833378|NCT02949908|Rebif
833379|NCT02949908|Treatment Satisfaction Questionnaire for Medication Version II
833380|NCT02949908|Multiple Sclerosis International Quality of Life Questionnaire
833381|NCT02949882|Diarrhea
833382|NCT02949882|Constipation
833383|NCT02949882|Elderly
833384|NCT02949882|Nursing Homes
833385|NCT02949882|Probiotics
833386|NCT02949882|Bowel Habits
833387|NCT02949830|RNAi therapeutic
833388|NCT02949830|Porphyria
833389|NCT02949830|AIP
833390|NCT02949830|Heme/Haem Arginate
833391|NCT02949791|cisplatin
833392|NCT02949791|HIPEC
833393|NCT02949791|Intra abdominal pressure
833394|NCT02949791|tissue drug concentration
833395|NCT02949713|HIV
833396|NCT02949713|infant feeding
833397|NCT02949713|mHealth
833398|NCT02949713|behavioural intervention
833399|NCT02949700|metformin
833400|NCT02949700|head and neck cancer
833401|NCT02949687|ileal interposition
833402|NCT02949687|metabolic surgery
833403|NCT02949687|diabetes
833404|NCT02949687|intra abdominal selective denervation
833405|NCT02949648|Electronic cigarette
833406|NCT02949635|Aged
833407|NCT02949635|Patient readmission
833408|NCT02949635|Geriatric Assessment
833409|NCT02949635|Mortality
833415|NCT02949609|stroke
833416|NCT02949609|mirror therapy
833417|NCT02949609|neurorehabilitation
833418|NCT02949596|quality of sexual life
833419|NCT02949596|intensity-modulated radiotherapy
833420|NCT02949596|concurrent chemoradiotherapy
833421|NCT02949583|DENTAL PLAQUE
833422|NCT02949583|MEDICINAL PLANTS
833423|NCT02949583|GINGIVITIS
833424|NCT02949505|Prehabilitation
833425|NCT02949505|liver transplant
833426|NCT02949505|functional capacity
833427|NCT02949505|exercise
833428|NCT02949492|Liver
833429|NCT02949492|Transplant
833430|NCT02949492|Immunosuppression
833431|NCT02949479|sex offenses
833432|NCT02949466|knee osteoarthritis
833433|NCT02949466|triamcinolone
833434|NCT02949466|therapeutic effects
833435|NCT02949453|suicide
833436|NCT02949453|prevention
833437|NCT02949440|Laparoscopic right Hemicolectomy
833438|NCT02949440|Caudal-to-cranial Approach
833444|NCT02949414|Malacia
833445|NCT02949414|Stenosis
833446|NCT02949414|Trachea
833447|NCT02949414|Transplant
833448|NCT02948582|Chronic Obstructive Pulmonary Disease
833449|NCT02948582|COPD
833450|NCT02948582|Emphysema
833451|NCT02948582|Chronic bronchitis
833452|NCT02948569|Obesity
833453|NCT02948569|Hyperlipidemia
833454|NCT02948569|Impaired fasting glucose
833455|NCT02948569|Insulin resistance
833456|NCT02948569|Hypertension
833457|NCT02949349|Systemic Lupus Erythematosus
833458|NCT02949349|Lupus Nephritis
833459|NCT02949349|Mycophenolate Mofetil
833460|NCT02949349|Azathioprine
833461|NCT02949349|Maintenance Therapy
833462|NCT02949349|Prednisolone
833463|NCT02949349|Serum albumin
833464|NCT02949349|Serum creatinine
833465|NCT02949349|Spot urine protein/creatinine ratio
833466|NCT02949323|children
833467|NCT02949323|renal stone
833468|NCT02949323|metabolic evaluation
833469|NCT02949323|Mutational analysis
833470|NCT02949297|abdominal
833471|NCT02949297|aortic
833472|NCT02949297|aneurysm
833473|NCT02949271|epidural analgesia
833474|NCT02949258|gastric cancer
833475|NCT02949258|Borrmann type 4
833476|NCT02949258|Neoadjuvant chemotherapy
833477|NCT02949258|Intra-arterial administration
833478|NCT02949245|Spine
833479|NCT02949245|Surgery
833480|NCT02949245|Prospective Studies
833481|NCT02949245|Deformity
833482|NCT02949245|Neurologic deficit
833487|NCT02949167|Nurse-led follow-up after breast cancer
833488|NCT02949115|Red beetroot
833489|NCT02949115|Dietary Nitrate
833490|NCT02949115|Polyphenols
833491|NCT02949115|Endothelial Function
833492|NCT02949115|High-Fat Meal
833493|NCT02949115|Overweight
833494|NCT02949115|Obesity
833495|NCT02949115|Aging
833496|NCT02949115|Cardiometabolic
833497|NCT02949089|safety
833498|NCT02949089|tolerability
833499|NCT02949089|rising multiple doses
833500|NCT02949089|ACH04
833501|NCT02949089|adult
833502|NCT02949089|male
833503|NCT02949063|school lunch
833504|NCT02949063|occupational therapy
833505|NCT02949024|Diabetes mellitus
833506|NCT02949024|Diabetic retinopathy
833507|NCT02949024|Microneedle
833508|NCT02949024|Microinjection
833509|NCT02949024|Triamcinolone
833510|NCT02949024|Choroid
833511|NCT02949024|Choroid Injection
833512|NCT02949024|Aflibercept
833513|NCT02949024|Suprachoroidal
833514|NCT02949011|Tamiflu®
833515|NCT02949011|Influenza
833516|NCT02949011|Oseltamivir
833517|NCT02949011|Flu
833518|NCT02949011|S-033188
833519|NCT02948985|Metastatic colorectal cancer
833520|NCT02948985|Cetuximab
833521|NCT02948985|CTCs
833522|NCT02948985|ct DNA
833523|NCT02948972|deep infiltrating endometriosis
833524|NCT02948972|endometriosis surgery
833525|NCT02948972|In vitro fertilization
833526|NCT02948946|lung cancer
833527|NCT02948946|pancreatic cancer
833531|NCT02948920|ephedrine
833532|NCT02948920|core temperature
833533|NCT02948920|tympanic temperature
833534|NCT02948920|heat loss
833535|NCT02948920|spinal anesthesia
833536|NCT02948920|neuraxial
833537|NCT02948920|hypothermia
833538|NCT02948920|shivering
833539|NCT02948881|Osteoporosis
833540|NCT02948881|bisphosphonates
833541|NCT02948881|bone
833542|NCT02948868|Methamphetamine
833543|NCT02948868|MRI
833544|NCT02948868|South Africa
833545|NCT02948868|Contingency Management
833546|NCT02948855|Long non-coding RNA（LncRNA）
833547|NCT02948855|Thymoma
833548|NCT02948855|Autoimmune disease
833549|NCT02948855|Notch2 Signaling pathway
833550|NCT02948855|Regulatory B cell（Breg）
833551|NCT02948829|Drug therapy
833552|NCT02948803|intervention
833553|NCT02948803|mHealth
833554|NCT02948803|physical activity
833555|NCT02948803|active transport
833556|NCT02948803|smartphone
833557|NCT02948803|application
833558|NCT02948764|breast cancer
833559|NCT02948764|vacuum-assisted biopsy
833560|NCT02948764|pathological complete response
833561|NCT02948712|distress
833562|NCT02948712|survivorship
833563|NCT02948712|transition period
833564|NCT02948699|nasopharyngeal carcinoma
833565|NCT02948699|intensity-modulated radiotherapy
833566|NCT02948699|nutrition support
833567|NCT02948699|nutrition assessment
833568|NCT02948686|dentin bonding agents
833569|NCT02948686|tooth sensitivity
833570|NCT02948686|composite resin restoration
833571|NCT02948673|type 2 diabetes
833572|NCT02948673|mitochondrial reactive oxygen species production
833573|NCT02948673|oxidative stress
833574|NCT02948673|antioxidant treatment
833575|NCT02948673|glutathione supplementation
833576|NCT02948621|Endoscopic sleeve gastroplasty
833577|NCT02948621|Excess weight loss
833578|NCT02948621|Quality of life
833579|NCT02948608|spondyloarthropathy
833580|NCT02948608|ankylosing spondylitis
833581|NCT02948608|spinal diseases
833582|NCT02948608|spondylitis
833583|NCT02948608|spondylarthritis
833584|NCT02948608|psoriasis
833585|NCT02948608|uveitis
833586|NCT02948608|joint diseases
833587|NCT02948504|Unruptured Intracranial Aneurysm
833588|NCT02948504|Small aneurysms
833589|NCT02948504|Risk of rupture
833590|NCT02948504|Natural history
833591|NCT02948504|Endovascular Coiling
833592|NCT02948504|Surgical clipping
833593|NCT02948491|Complementary Therapies
833594|NCT02948491|Neonate Intensive Care Units (NICU)
833595|NCT02948491|Child Development
833596|NCT02948491|Infants Premature
833597|NCT02948478|precariousness
833598|NCT02948478|care pathways
833599|NCT02948465|Neutrophil Extracellular Traps
833600|NCT02948452|anorexia nervosa
833601|NCT02948452|anxiety
833602|NCT02948452|reward
833603|NCT02948452|recurrence
833604|NCT02948452|magnetic resonance imaging
833605|NCT02948439|pregnancy
833606|NCT02948439|cardiovascular
833607|NCT02948439|nervous system
833608|NCT02948439|exercise
833609|NCT02948426|Immunotherapy
833610|NCT02948426|Adoptive Cell Therapy
833611|NCT02948426|Carcinomatosis
833612|NCT02948426|CA125
833616|NCT02948335|Microbial communities
833617|NCT02948335|Hospital environment
833618|NCT02948335|Disinfection
833619|NCT02948335|Adenosine triphosphate measures
833620|NCT02948335|Bioburden
833621|NCT02948322|Acromegaly,
833622|NCT02948322|water retention
833623|NCT02948322|myocardial fibrosis
833624|NCT02948322|left ventricular hypertrophy
833625|NCT02948322|left ventricular dysfunction
833626|NCT02948309|Primary diagnosis
833627|NCT02948309|Relapse
833628|NCT02948257|Vessel closure
833629|NCT02948257|Antegrade access
833630|NCT02948257|Femoral arteriotomy
833631|NCT02948257|Peripheral endovascular interventions
833632|NCT02948244|fshd
833633|NCT02948244|creatine monohydrate
833634|NCT02948244|children
833635|NCT02948244|pediatrics
833636|NCT02948244|Facio-Scapulo-Humeral Dystrophy
833637|NCT02948205|Infertility, TU-LESS, 3D laparoscopy
833638|NCT02948192|Preterm Delivery
833639|NCT02948192|Preterm Birth
833640|NCT02948192|Vaginal Microbiome
833641|NCT02948192|Microbiome
833642|NCT02948192|Gut Microbiome
833643|NCT02948192|African American
833644|NCT02948192|Metabolomics
833645|NCT02948192|Pregnancy
833646|NCT02948166|remote endarterectomy
833647|NCT02948166|Angioplasty with stenting of the superficial femoral artery
833648|NCT02948140|Subdiaphragmatic infarction
833649|NCT02948101|Malignant Neoplasm of Female Genital Organs
833650|NCT02948101|Epithelial ovarian cancer
833651|NCT02948101|Fallopian tube cancer
833652|NCT02948101|Primary peritoneal cancer
833653|NCT02948101|PD 0360324
833654|NCT02948101|Cyclophosphamide
833655|NCT02948101|Cytoxan
833656|NCT02948101|Neosar
833657|NCT02948101|Pharmacokinetic testing
833658|NCT02948101|PK
833659|NCT02948101|Pharmacodynamic testing
833660|NCT02948101|PD
833661|NCT02948088|Tenosynovial Giant Cell Tumors
833662|NCT02948088|Disease registry
833663|NCT02948088|Routine clinical practice
833664|NCT02948088|Real World Evidence
833665|NCT02948062|ALD
833666|NCT02948062|Newborn Screening
833667|NCT02948049|Accelerometer
833668|NCT02948049|Spinal Cord Stimulator
833669|NCT02948049|Peripheral Nerve Stimulator
833670|NCT02948049|Physical Function
833671|NCT02947997|Healthy Volunteers
833672|NCT02947984|sphenoid region
833673|NCT02947984|parasellar area
833674|NCT02947984|photon radiation therapy
833675|NCT02947984|proton radiation therapy
833676|NCT02947958|teleconsultation
833677|NCT02947958|urology
833678|NCT02947958|primary care
833679|NCT02947958|tertiary care
833680|NCT02947932|acute pancreatitis
833681|NCT02947932|post-ERCP
833682|NCT02947932|endoscopy
833683|NCT02947919|Perioperative Period
833684|NCT02947919|Music
833685|NCT02947906|Gait
833686|NCT02947906|Loading
833687|NCT02947906|Multiple Sclerosis
833688|NCT02947906|Plantar Pressure
833689|NCT02947893|Nilotinib in Alzheimer's disease
833690|NCT02947880|autism, Bumetanide
833691|NCT02947854|Vaccine
833692|NCT02947854|Photochemical Internalisation
833693|NCT02947854|Immune Response
833694|NCT02947854|Peptide vaccine
833695|NCT02947854|Anti cancer vaccine
833696|NCT02947828|Diabetes Mellitus, Type 2
833697|NCT02947828|Polyneuropathies, Diabetic
833698|NCT02947750|Hypertension
833699|NCT02947750|Kidney Disorder
833700|NCT02947750|Nephrology
833701|NCT02947750|Physiology
833702|NCT02947737|Skin graft
833703|NCT02947724|chocolate cyst
833704|NCT02947724|laparoscopy
833705|NCT02947724|surgicel
833706|NCT02947711|E2027
833707|NCT02947711|Healthy participants
833708|NCT02947711|Pharmacokinetics
833709|NCT02947698|acute kidney injury
833710|NCT02947698|weekend admission
833711|NCT02947698|mortality
833712|NCT02947685|breast cancer
833713|NCT02947685|malignant tumor of the breast
833714|NCT02947685|HER2+
833715|NCT02947685|HR+
833716|NCT02947685|metastatic breast cancer
833717|NCT02947659|Body mass index
833718|NCT02947659|Academic stress
833719|NCT02947659|Musculoskeletal disorders
833720|NCT02947607|Human gut microbiome
833721|NCT02947607|Colorectal cancer
833722|NCT02947607|Colorectal adenoma
833723|NCT02947607|Gut bacteria
833724|NCT02947607|Metagenomics
833725|NCT02947607|Metatranscriptomics
833726|NCT02947581|subarachnoid neurocysticercosis
833727|NCT02947581|albendazole
833728|NCT02947581|praziquantel
833729|NCT02947568|Non-alcoholic Fatty Liver Disease
833730|NCT02947568|Chronic Kidney Disease
833731|NCT02947568|Diabetes Mellitus
833732|NCT02947568|Cross-sectional
833733|NCT02947555|diabetes mellitus
833734|NCT02947555|atherosclerosis
833735|NCT02947555|AGE
833736|NCT02947555|lens autofluorescence
833737|NCT02947529|Hemiarthroplasty
833738|NCT02947529|Intramedullary nail
833739|NCT02947529|Tranexamic acid
833740|NCT02947529|Transfusion
833741|NCT02947516|Endoscopic Ultrasound-Guided Fine Needle Aspiration
833742|NCT02947516|liver
833743|NCT02947516|biopsy
833744|NCT02947516|pain
833745|NCT02947503|Gestational Diabetes
833746|NCT02947503|Insulin Resistance
833747|NCT02947503|Metformin
833748|NCT02947503|Hyperinsulinaemia
833749|NCT02947503|Prevention of Complications
833750|NCT02947503|Long Term Study
833751|NCT02947503|Mother and Child
833752|NCT02947503|Health Benefits
833753|NCT02947490|Blood pressure monitoring
833754|NCT02947490|self BP monitoring
833755|NCT02947490|self BP management
833756|NCT02947438|Renal anemia
833757|NCT02947438|Haemodialysis
833758|NCT02947438|Maintenance phase
833759|NCT02947412|sleeve gastrectomy
833760|NCT02947412|long-term follow-up
833761|NCT02947412|gastroesophageal reflux disease after sleeve
833762|NCT02947412|revisional surgery
833763|NCT02947399|Thyroid
833764|NCT02947399|I-124
833765|NCT02947399|Thyroid hormone Withdrawal
833766|NCT02947373|brain tumor
833767|NCT02947373|children
833768|NCT02947321|Radiofrequency ablation
833769|NCT02947308|Anxiety
833770|NCT02947308|Depression
833771|NCT02947243|Virtual reality
833772|NCT02947243|Immersive distraction
833773|NCT02947243|Oculus rift
833774|NCT02947243|Virtual world
833775|NCT02947243|Virtual environment
833776|NCT02947243|Procedural pain
833777|NCT02947243|Procedural anxiety
833778|NCT02947243|Acute pain
833779|NCT02947243|Pain management
833780|NCT02947243|Anxiety
833781|NCT02947243|Children, Child
833782|NCT02947243|Kid, Kids
833783|NCT02947243|Pediatric, Pediatrics
833784|NCT02947243|Young children
833785|NCT02947243|Burns
833786|NCT02947243|Burn injuries
833787|NCT02947243|Burn unit
833788|NCT02947243|Physiotherapy
833789|NCT02947243|Physical therapy
833790|NCT02947243|Burn dressing
833791|NCT02947243|Dressing change
833792|NCT02947243|Non-pharmacological, nonpharmacological
833793|NCT02947243|Clinical Research
833794|NCT02947243|Nursing Practice
833795|NCT02947230|Mobility
833796|NCT02947230|Aging
833797|NCT02947230|Knowledge Translation
833798|NCT02947230|Physical Activity
833799|NCT02947217|Immunology
833800|NCT02947217|Pregnancy
833801|NCT02947217|Implantation Rate
833802|NCT02947217|Fertilization in Vitro
833803|NCT02947204|Bronchiolitis
833804|NCT02947204|Length of Hospital Stay
833805|NCT02947204|Clinical Trial
833806|NCT02947204|Oxygen Saturation Monitoring
833814|NCT02947126|cystic fibrosis
833815|NCT02947126|mucociliary clearance
833816|NCT02947126|CFTR
833817|NCT02947113|cancer
833818|NCT02947100|Sickle Cell Disease
833819|NCT02947100|omega-3 fatty acids
833820|NCT02947100|Docosahexaenoic Acid (DHA)
833821|NCT02947100|Eicosapentaenoic Acid (EPA)
833822|NCT02947087|Islet autotransplantation
833823|NCT02947087|Alpha1 anti trypsin
833824|NCT02947074|Yoga
833825|NCT02947074|Meditation
833826|NCT02947074|Glutathione
833827|NCT02947074|Catecholamine
833828|NCT02947074|polysomnography
833829|NCT02947061|Advanced Breast Cancer,first treatment, S1, Capecitabine
833830|NCT02947035|thyroid cancer
833831|NCT02947035|thyroid nodule
833832|NCT02947035|thyroidectomy
833833|NCT02947035|personalized medicine
833834|NCT02947022|gadolinium
833835|NCT02947022|deposition
833836|NCT02947022|GBCA
833837|NCT02947022|Extremity Pain
833838|NCT02947022|Skin Pain
833839|NCT02947022|Chest Wall Pain
833840|NCT02946944|Pulmonary Embolism
833841|NCT02946944|sildenafil
833842|NCT02946944|oral anticoagulation therapy
833843|NCT02946918|levothyroxine
833844|NCT02946853|Atrial Fibrillation
833845|NCT02946853|CRT
833846|NCT02946853|AV Junction Ablation
833847|NCT02946853|LVESV
833848|NCT02946827|FODMAPs diet
833849|NCT02946827|micro-macro nutrients intake
833850|NCT02946827|IBS (Irritable Bowel Syndrome)
833851|NCT02946814|essential oils
833852|NCT02946814|microscope, colfocal
833853|NCT02946814|dental plaque
833854|NCT02946801|Biofilms
833855|NCT02946801|essential oils
833856|NCT02946801|alcohol
833857|NCT02946801|microscopy, confocal
833858|NCT02946801|mouthwashes
833859|NCT02946775|septicemia
833860|NCT02946775|bacteremia
833861|NCT02946775|pneumonia
833862|NCT02946775|meningitis
833863|NCT02946762|HIV
833864|NCT02946762|TB
833865|NCT02946762|Antiretroviral Treatment
833866|NCT02946762|Anti-tuberculosis Treatment
833867|NCT02946762|HIV Counselling and Testing
833868|NCT02946762|Treatment as Prevention
833869|NCT02946749|Scar pregnancy
833870|NCT02946749|Placenta planting abnormal disease
833871|NCT02946749|Early diagnosis
833872|NCT02946749|Individualized treatment
833873|NCT02946736|Sleep
833874|NCT02946736|Physical Health
833875|NCT02946736|Psychological Health
833876|NCT02946736|Well-Being
833877|NCT02946736|Employee
833878|NCT02946736|Actigraphy
833879|NCT02946710|Alzheimer disease
833880|NCT02946710|Alzheimer's disease, biomarkers
833881|NCT02946710|p75NTR-ECD
833882|NCT02946697|Chinese
833883|NCT02946697|cancer survivors
833884|NCT02946697|Quality of Life
833885|NCT02946697|Social Support
833886|NCT02946658|COPD, Emphysema
833887|NCT02946619|Chinese breast cancer survivors
833888|NCT02946619|expressive writing
833889|NCT02946554|Acute-On-Chronic Liver Failure
833890|NCT02946554|ACLF
833891|NCT02946541|DA-1229
833892|NCT02946541|evogliptin
833893|NCT02946541|DPP-IV inhibitor
833894|NCT02946541|Suganon
833895|NCT02946541|DPP-4 inhibitor
833896|NCT02946515|Pediatrics
833897|NCT02946489|cannabis
833898|NCT02946489|mindfulness based relapse prevention
833899|NCT02946489|motivational enhancement therapy
833900|NCT02946437|severe SAH
833901|NCT02946437|prevention of vasospasm and/ or brain oedema
833902|NCT02946437|Sevoflurane
833903|NCT02946437|Postconditioning
833904|NCT02946411|Hyperglycemia
833905|NCT02946385|meningococcal disease
833906|NCT02946385|meningitis
833907|NCT02946385|booster
833908|NCT02946385|antibody persistence
833909|NCT02946372|retina surgery
833910|NCT02946372|macula
833911|NCT02946372|macular hole
833912|NCT02946372|internal limiting membrane (ILM)
833913|NCT02946372|vitrectomy
833914|NCT02946372|autologous transplantation
833915|NCT02946346|Human papillomaviruses
833916|NCT02946346|Clearance
833917|NCT02946346|Kinetics
833918|NCT02946346|Ecology
833919|NCT02946346|Bacterial vaginosis
833920|NCT02946346|Immune response
833921|NCT02946346|Microbiota
833922|NCT02946333|Multiple Myeloma
833923|NCT02946333|autologous stem cell transplant (ASCT)
833924|NCT02946333|QoLMMBuS
833925|NCT02946333|healthcare costs
833926|NCT02946320|PCI, bioabsorbable scaffold
833927|NCT02946281|self-management
833928|NCT02946281|health behavior
833929|NCT02946281|cardiac disease
833930|NCT02946281|habits
833931|NCT02946281|lifestyle
833932|NCT02946255|Psychosis
833933|NCT02946255|Psychosis NOS
833934|NCT02946255|Schizophrenia
833935|NCT02946255|Hospital discharge
833936|NCT02946255|Inpatient psychiatry
833937|NCT02946190|Acellular pertussis vaccines Genetically-detoxified pertussis toxin Adolescents
833938|NCT02946177|Immunology
833939|NCT02946177|Pregnancy
833940|NCT02946177|Implantation Rate
833941|NCT02946177|Fertilization in Vitro
833942|NCT02946177|Oocyte donor egg recipient
833943|NCT02946151|Epilepsy
833944|NCT02946151|Seizure monitoring
833945|NCT02946151|Electroencephalography
833946|NCT02946138|Hepatocellular Carcinoma
833947|NCT02946138|carbon-ion radiotherapy
833948|NCT02946138|GM-CSF
833949|NCT02946138|immunotherapy
833950|NCT02946086|motor skill learning, visuo-spatial attention
833951|NCT02946047|HIV
833952|NCT02946047|ART
833953|NCT02946047|Antiretroviral
833954|NCT02946047|Therapy
833955|NCT02946047|Resevoir
833956|NCT02946047|Cure
833957|NCT02946034|CKD
833958|NCT02946034|HCV
833959|NCT02946021|Lymphedema
833960|NCT02946021|Cancer
833961|NCT02946021|Head Cancer
833962|NCT02946021|Neck Cancer
833963|NCT02945982|Portal Hypertension
833964|NCT02945982|Fuzheng Huayu
833965|NCT02945982|Hepatitis B
833966|NCT02945969|dietary sodium
833967|NCT02945969|albuminuria
833968|NCT02945969|chronic kidney disease
833969|NCT02945956|Portal Hypertension
833970|NCT02945956|Fuzheng Huayu
833971|NCT02945956|Hepatitis B
833972|NCT02945930|Enbucrilate
833973|NCT02945930|Esophageal and Gastric Varices
833974|NCT02945930|Endoscopy
833975|NCT02945930|Safety
833976|NCT02945930|Efficacy
833977|NCT02945891|mass screening
833978|NCT02945891|coverage
833979|NCT02945891|self-sampling
833980|NCT02945891|clinical validity
833982|NCT02945839|Migraine
833983|NCT02945839|emergency department
833984|NCT02945826|urokinase plasminogen activator receptor
833985|NCT02945826|positron emission tomography
833986|NCT02945826|glioblastoma multiforme
833987|NCT02945813|Prostate Cancer
833988|NCT02945813|Prostate Cancer after Prostatectomy
833989|NCT02945813|Phase II Trial
833990|NCT02945813|Salvage Radiotherapy
833991|NCT02945813|Metformin
833992|NCT02945800|relapsed
833993|NCT02945800|refractory
833994|NCT02945800|soft tissue
833995|NCT02945800|bones and joints
833996|NCT02945800|non-rhabdomyosarcoma soft tissue sarcoma
833997|NCT02945800|pediatric
833998|NCT02945787|Spanish speaking
833999|NCT02945787|self-help
834000|NCT02945787|tobacco abstinence
834001|NCT02945787|public health
834002|NCT02945787|Forever Free
834003|NCT02945787|Stop Smoking for Good
834004|NCT02945774|PET
834005|NCT02945774|MRI
834006|NCT02945774|Inflammation
834007|NCT02945774|Microglia
834008|NCT02945774|FEPPA
834009|NCT02945748|pediatric
834010|NCT02945748|cardiac output
834011|NCT02945748|fluid responsiveness
834012|NCT02945748|critically ill
834013|NCT02945748|hemodynamic monitoring
834014|NCT02945735|depression
834015|NCT02945735|cognitive bias modification
834016|NCT02945735|MDD
834017|NCT02945735|major depressive disorder
834018|NCT02945735|attention bias modification treatment
834019|NCT02945722|Hemodialysis
834020|NCT02945722|S. Aureus
834021|NCT02945722|Decolonization
834022|NCT02945722|Persistent carriage
834023|NCT02945709|PTSD
834024|NCT02945709|attention training
834025|NCT02945709|cognitive bias modification
834026|NCT02945696|nerve block
834027|NCT02945696|laparoscopy
834028|NCT02945696|anesthesia
834029|NCT02945683|atopic dermatitis, probiotics, vitamin D3, L. reuteri
834030|NCT02945644|obstructive sleep apnea
834031|NCT02945644|trazodone
834032|NCT02945644|positive airway pressure
834033|NCT02945644|adherence
834034|NCT02945631|HPV
834035|NCT02945631|Induction Chemotherapy
834036|NCT02945631|De-Intensified Chemoradiotherapy
834037|NCT02945631|Oropharynx Cancer
834038|NCT02945618|cryotherapy
834039|NCT02945618|physical therapy
834040|NCT02945592|Hemispatial Neglect
834041|NCT02945592|cueing
834042|NCT02945592|egocentric-allocentric
834043|NCT02945592|early rehabilitation
834044|NCT02945592|parietal tDCS
834045|NCT02945579|Breast Cancer
834046|NCT02945579|Surveillance
834047|NCT02945579|Breast biopsy
834048|NCT02945579|Questionnaires
834049|NCT02945579|Surveys
834050|NCT02945540|Gestational diabetes
834051|NCT02945540|Patient education
834052|NCT02945540|Patient Satisfaction
834053|NCT02945514|Healthy
834054|NCT02945514|Diet
834055|NCT02945514|Microbiome
834056|NCT02945514|Personalized
834057|NCT02945514|Custom
834058|NCT02945475|functional magnetic resonance imaging
834059|NCT02945475|eating behavior
834060|NCT02945475|sugar
834061|NCT02945475|fructose
834062|NCT02945449|Wharton jelly mesenchymal stem cells
834063|NCT02945449|Erectile Dysfunction
834064|NCT02945449|Diabetes
834065|NCT02945397|Return to work
834066|NCT02945397|Work rehabilitation
834067|NCT02945397|Sick-leave
834068|NCT02945384|family well-being
834069|NCT02945332|exercise
834070|NCT02945332|activity
834071|NCT02945332|behavior
834072|NCT02945306|Sleep Disordered Breathing
834073|NCT02945306|Adenotonsillectomy
834074|NCT02945306|Child
834075|NCT02945293|Pain
834076|NCT02945293|Elderly
834077|NCT02945293|Aged
834078|NCT02945293|Opioid
834079|NCT02945293|Cognition
834080|NCT02945293|Side-effects
834081|NCT02945293|Alcohol
834082|NCT02945293|Alcohol Use Disorder (AUD)
834083|NCT02945293|Older
834084|NCT02945280|apixaban
834085|NCT02945280|factor Xa inhibitors
834086|NCT02945280|antithrombotic agent
834087|NCT02945280|deep vein thrombosis
834088|NCT02945280|upper extremity
834089|NCT02945267|Pancreatic Cancer
834090|NCT02945267|Unresectable
834091|NCT02945267|Maintenance Treatment
834092|NCT02945254|sleep onset latency
834093|NCT02945254|sleep quality
834094|NCT02945254|insomnia
834095|NCT02945228|Paritaprevir
834096|NCT02945228|Genotype 2
834097|NCT02945228|Hepatitis C Virus (HCV)
834098|NCT02945228|ombitasvir
834099|NCT02945228|Ritonavir
834100|NCT02945189|Pregnancy
834101|NCT02945176|Boston Keratoprosthesis
834102|NCT02945150|hemodialysis
834103|NCT02945150|peritoneal dialysis
834104|NCT02945150|renal failure
834105|NCT02945150|kidney transplant
834106|NCT02945085|older adults
834107|NCT02945085|family caregivers
834108|NCT02945085|Medicare Advantage beneficiaries
834109|NCT02945072|Child Behavior
834110|NCT02945072|Problem Behavior
834111|NCT02945072|postoperative behaviour problems
834112|NCT02945059|Liver regeneration
834113|NCT02945059|portal vein embolization
834114|NCT02945059|gelatin powder
834115|NCT02945059|liver surgery
834116|NCT02945059|hepatectomy
834117|NCT02945033|Pi3k mutation
834118|NCT02945033|Aspirin
834122|NCT02944929|Spastic hemiparesis
834123|NCT02944929|Stroke
834124|NCT02944929|Self-rehabilitation
834125|NCT02944929|Botulinum Toxin Injections
834126|NCT02944903|audit
834127|NCT02944903|Lung cancer
834128|NCT02944903|screening practice
834129|NCT02944903|Egypt
834130|NCT02944851|Blood donors
834131|NCT02944851|blood donation
834132|NCT02944851|traumatic blood loss
834133|NCT02944851|Trauma
834134|NCT02944838|older adults
834135|NCT02944838|physical activity
834136|NCT02944838|built environment
834137|NCT02944825|Urolithiasis
834138|NCT02944825|UTI
834139|NCT02944786|Chronic pain
834140|NCT02944786|Adolescents
834141|NCT02944786|School nurse
834142|NCT02944773|newborn
834143|NCT02944773|facilitated tucking
834144|NCT02944773|position
834145|NCT02944773|weight
834146|NCT02944773|stress
834147|NCT02944747|Gestational age, Preterm birth, LMP, Bangladesh
834148|NCT02944734|Candesartan
834149|NCT02944734|Amlodipine
834150|NCT02944734|Hypertension
834151|NCT02944734|Vascular Diseases
834152|NCT02944734|Cardiovascular Diseases
834153|NCT02944734|Antihypertensive Agents
834154|NCT02944734|Vasodilator Agents
834155|NCT02944734|Angiotensin II Type 1 Receptor Blockers
834156|NCT02944734|Angiotensin Receptor Antagonists
834157|NCT02944734|Calcium Channel Blockers
834158|NCT02944721|Neuropathic Pain
834159|NCT02944708|maintenance chemotherapy
834160|NCT02944695|audit
834161|NCT02944695|infection control
834162|NCT02944695|bronchoscopy unit
834163|NCT02944695|Egypt
834164|NCT02944682|Obstetrics
834165|NCT02944682|Pregnancy Outcomes
834166|NCT02944682|Pediatrics
834167|NCT02944682|Atherosclerosis
834168|NCT02944682|Cancer
834169|NCT02944682|Cardiovascular Disease
834170|NCT02944682|Public Health
834171|NCT02944682|Environmental Air Pollutants
834172|NCT02944656|Perioperative pain
834173|NCT02944656|Outpatient surgery
834174|NCT02944656|Obstetrics/gynecology
834175|NCT02944656|Pain management
834176|NCT02944630|quality of life
834177|NCT02944630|psychotherapy
834178|NCT02944630|psoriasis
834179|NCT02944630|treatments
834180|NCT02944578|Cancer
834181|NCT02944578|HIV
834182|NCT02944578|Oncology
834183|NCT02944578|Infectious Diseases
834184|NCT02944578|HPV
834185|NCT02944578|Preventive Medicine
834186|NCT02944539|Mitochondrial DNA copy number
834187|NCT02944539|Gastric cancer
834188|NCT02944526|suprascapular nerve
834189|NCT02944500|Brain
834190|NCT02944500|Liraglutide
834191|NCT02944500|MRI
834192|NCT02944487|safety
834193|NCT02944487|pharmacokinetics
834194|NCT02944474|Pharmacokinetics
834195|NCT02944474|Safety
834196|NCT02944448|Osteoarthritis
834197|NCT02944448|Hip
834198|NCT02944448|Knee
834199|NCT02944448|CR485
834200|NCT02944448|Analgesic
834201|NCT02944448|Kappa opioid
834202|NCT02944435|Glutaminase Inhibitor
834203|NCT02944435|Glutaminase
834204|NCT02944435|CB-839
834205|NCT02944396|Poly (ADP) ribose polymerase (PARP)
834206|NCT02944396|paclitaxel
834207|NCT02944396|nivolumab
834208|NCT02944396|metastatic
834209|NCT02944396|pemetrexed
834210|NCT02944396|Eastern Cooperative Oncology Group (ECOG)
834211|NCT02944396|carboplatin
834212|NCT02944396|Common Terminology Criteria for Adverse Events (CTCAE)
834213|NCT02944396|Immuno Oncology
834214|NCT02944396|veliparib
834215|NCT02944396|non-small cell lung cancer
834216|NCT02944396|Platinum Doublet Chemotherapy
834217|NCT02944396|Response Evaluation Criteria In Solid Tumors (RECIST)
834218|NCT02944383|Hypertriglycerides
834219|NCT02944344|breast cancer
834220|NCT02944344|stage 4
834221|NCT02944344|metastatic
834222|NCT02944344|hospice
834223|NCT02944344|palliative care
834224|NCT02944344|end of life
834225|NCT02944344|advance directive
834226|NCT02944344|oncology
834227|NCT02944344|caregiver
834228|NCT02944344|provider
834229|NCT02944344|coping
834230|NCT02944344|support
834231|NCT02944344|online
834232|NCT02944331|Steam ablation
834233|NCT02944331|Endothermal ablation
834234|NCT02944331|Varicose vein treatment
834235|NCT02944331|Venous insufficiency
834236|NCT02944331|Saphenous vein reflux
834237|NCT02944331|Recurrent varicosity
834238|NCT02944318|Physical Activity
834239|NCT02944318|Healthy Lifestyle
834240|NCT02944318|Academic performance
834241|NCT02944292|Intra-abdominal pressure
834242|NCT02944292|Intra-abdominal hypertension
834243|NCT02944266|post general anaesthesia induced
834244|NCT02944253|Diet, Reducing
834245|NCT02944253|Hunger
834246|NCT02944253|Appetite Regulation
834247|NCT02944253|Ketogenic Diet
834248|NCT02944253|Caloric Restriction
834249|NCT02944253|Weight Loss
834250|NCT02944253|Ketosis
834251|NCT02944214|Hyperuricemia
834252|NCT02944214|Renal Function
834253|NCT02944214|Chronic kidney disease
834254|NCT02944214|Febuxostat
834255|NCT02944214|Benzbromarone
834256|NCT02944201|carvedilol
834257|NCT02944201|biomarkers
834258|NCT02944201|autonomic nerves
834259|NCT02944188|enhanced recovery after surgery
834260|NCT02944188|right hemicolectomy
834261|NCT02944162|AML
834262|NCT02944162|CD33
834263|NCT02944162|CAR-NK
834264|NCT02944136|cancer
834265|NCT02944136|stepped collaborative care intervention
834266|NCT02944136|depression
834267|NCT02944136|quality of life
834268|NCT02944136|stress
834269|NCT02944136|dyadic function
834270|NCT02944136|spousal or intimate caregiver
834271|NCT02944123|Half dose
834272|NCT02944123|Newer oral P2Y12 receptor inhibitors
834273|NCT02944123|Acute coronary syndrome
834274|NCT02944097|Bioavailability
834275|NCT02944097|Pharmacokinetics
834276|NCT02944097|trans-resveratrol
834277|NCT02944097|trans-epsilon-viniferin
834278|NCT02944097|Vineatrol 30
834279|NCT02944084|Bioavailability
834280|NCT02944084|Pharmacokinetics
834281|NCT02944084|Rice bran extract
834282|NCT02944084|Vitamin E
834283|NCT02944084|Gamma-oryzanol
834284|NCT02944084|Ferulic acid
834285|NCT02944071|femoropopliteal artery lesions
834286|NCT02944071|Percutaneous Transluminal Angioplasty
834287|NCT02944071|Peripheral Artery Disease
834288|NCT02944071|Drug-coated Balloon
834289|NCT02944058|Multiloc
834290|NCT02944058|Philos
834291|NCT02944058|Locking plate
834292|NCT02944058|Straight nail
834293|NCT02944058|Randomized controlled trial
834294|NCT02944058|3 and 4 part fractures
834295|NCT02944019|Nonvalvular Atrial Fibrillation
834296|NCT02944019|Post Authorisation Safety Study
834297|NCT02944019|Safety
834298|NCT02944019|Real World Evidence
834299|NCT02944006|MRI
834300|NCT02943993|Post-Authorisation Safety Study
834301|NCT02943993|Real World Evidence
834302|NCT02943993|Edoxaban
834303|NCT02943993|Efficacy/Safety
834305|NCT02943967|Refractive Surgical Procedures
834306|NCT02943967|Photorefractive Keratectomy
834307|NCT02943967|Aberrometry
834308|NCT02943954|Fractional Flow Reserve
834309|NCT02943915|Spinal Cord
834310|NCT02943915|Injury
834311|NCT02943915|Exoskeleton
834312|NCT02943915|Ekso
834313|NCT02943915|Rehabilitation
834314|NCT02943902|immunogenicity
834315|NCT02943889|Mesenchymal stem cells
834316|NCT02943889|Liver cirrhosis
834317|NCT02943889|Stem cell therapy
834318|NCT02943876|risk prediction
834319|NCT02943876|risk score
834320|NCT02943876|accuracy of risk perception
834321|NCT02943876|self-help
834322|NCT02943876|psychological distress
834323|NCT02943850|stem cells
834324|NCT02943850|growth factor
834325|NCT02943850|ALS
834326|NCT02943824|brachytherapy
834327|NCT02943824|machine learning
834328|NCT02943824|treatment planning
834329|NCT02943824|Low-Dose-Rate brachytherapy
834330|NCT02943811|endometrial cancer
834331|NCT02943811|survival
834332|NCT02943811|uterine manipulator
834333|NCT02943798|Pulmonary Large Cell Neuroendocrine Carcinoma,chemotherapy
834334|NCT02943785|Transcatheter Aortic Valve Implantation -- TAVI
834335|NCT02943785|Anticoagulation
834336|NCT02943785|Atrial Fibrillation
834337|NCT02943785|ENVISAGE-TAVI-AF
834348|NCT02943733|Pancreatic neuroendocrine tumors (pNETs)
834349|NCT02943733|Pancreatic neuroendocrine tumors
834350|NCT02943733|pNETs
834351|NCT02943733|NETs
834352|NCT02943707|liver diseases
834353|NCT02943707|Bone Marrow Cell Transplantation
834354|NCT02943694|TaTME
834355|NCT02943694|Complications
834356|NCT02943694|Instrument
834357|NCT02943642|MF
834358|NCT02943642|CTCL
834359|NCT02943642|Cutaneous T Cell Lymphoma
834360|NCT02943616|Absorb GT1 BVS
834361|NCT02943616|BVS
834362|NCT02943616|Bioabsorbable
834363|NCT02943616|Myocardial ischemia
834364|NCT02943616|Stent thrombosis
834365|NCT02943616|Stents
834366|NCT02943603|mFOLFOX6
834367|NCT02943603|pembrolizumab
834368|NCT02943590|Cancer Treatment Related to Heart Failure
834369|NCT02943551|Pediatrics
834370|NCT02943551|Respiratory disease
834371|NCT02943551|antibiotic use
834372|NCT02943538|Crohn's Disease
834373|NCT02943538|Colitis, Ulcerative
834374|NCT02943538|Telemedicine
834375|NCT02943525|vaginal packing
834376|NCT02943525|pelvic organ prolapse
834377|NCT02943525|pain and satisfaction
834378|NCT02943486|Mesenchymal stromal cells
834379|NCT02943486|Fitostimoline
834380|NCT02943486|MSC derivatives
834381|NCT02943486|Diabetes
834386|NCT02943408|Veterans
834387|NCT02943408|mental health
834388|NCT02943408|Patient-Centered Care
834389|NCT02943382|MGD
834390|NCT02943382|Autologous Serum
834391|NCT02943382|Meibomian gland dysfunction
834392|NCT02943382|Dry eye disease
834393|NCT02943382|FAB
834394|NCT02943382|Fingerprick autologous blood
834395|NCT02943369|cangrelor
834396|NCT02943369|ticagrelor
834397|NCT02943369|P2Y12 receptor antagonist
834398|NCT02943369|acute myocardial infarction
834399|NCT02943330|Depression
834400|NCT02943330|Cytokines
834401|NCT02943330|Hemodialysis
834402|NCT02943330|Interferon treatment
834403|NCT02943330|Hepatitis C
834404|NCT02943304|Pregnancy
834405|NCT02943304|Fetal Development
834406|NCT02943304|Child Development
834407|NCT02943304|Developmental Disabilities
834408|NCT02943304|Zika Virus Infection
834409|NCT02943291|Exercise therapy
834410|NCT02943291|Adipose tissue
834411|NCT02943291|Mitochondria
834412|NCT02943291|Oxidative Phosphorylation
834413|NCT02943265|Care Coordination
834414|NCT02943252|apatinib
834415|NCT02943252|S1
834416|NCT02943252|advanced head and neck cancer
834417|NCT02943252|non-squamous
834418|NCT02943213|Chlorpromazine
834419|NCT02943213|Hydrochloride
834420|NCT02943213|Chlorpromazine Hydrochloride
834421|NCT02943213|Bioavailability
834422|NCT02943213|Variability
834423|NCT02943213|Variable
834424|NCT02943213|Absorption
834425|NCT02943213|USL Pharma
834426|NCT02943213|USL
834427|NCT02943213|Healthy
834428|NCT02943213|South Africa
834429|NCT02943213|Cycle
834430|NCT02943213|Anti-Psychotic
834431|NCT02943161|Obesity
834432|NCT02943161|L-citrulline
834433|NCT02943109|patient portal
834434|NCT02943109|Health Information Technology
834435|NCT02943109|Electronic Health Records
834436|NCT02943109|Inpatient Care
834437|NCT02943109|Outpatient Care
834438|NCT02943109|Patient Engagement
834439|NCT02943070|Rezum
834440|NCT02943070|Water Vapor Ablation
834441|NCT02943031|bile duct tumor
834442|NCT02943031|individualized precise treatment programs
834443|NCT02943018|ultrasound anovaginal distance, observer variation
834444|NCT02942979|Facilitation
834445|NCT02942979|Implementation
834446|NCT02942979|Homelessness
834447|NCT02942979|Substance Use Disorder
834448|NCT02942979|Mental Illness
834449|NCT02942979|Co-Occurring Disorders
834450|NCT02942979|Veterans
834451|NCT02942979|Primary Care
834458|NCT02942953|Pacemaker, Artificial
834459|NCT02942953|Diaphragmatic pacing
834460|NCT02942927|Polypharmacy
834461|NCT02942927|Multimorbidity
834462|NCT02942927|Randomized Control Trial
834463|NCT02942927|Drug Discontinuation
834464|NCT02942927|Patient Preference
834465|NCT02942927|eHealth
834466|NCT02942901|PET-CT
834467|NCT02942901|pulmonary metstasectomy
834468|NCT02942888|Mild Cognitive Impairment
834469|NCT02942888|MCI
834470|NCT02942888|NAD
834471|NCT02942888|nicotinamide riboside
834472|NCT02942888|aging
834473|NCT02942875|upper limb
834474|NCT02942875|mirror therapy
834475|NCT02942875|rehabilitation
834476|NCT02942875|subacute
834477|NCT02942849|Bemfola
834478|NCT02942849|r-hFSH
834479|NCT02942849|Oocytes
834480|NCT02942849|Pregnancy
834481|NCT02942849|OHSS
834482|NCT02942836|Respiration Rate Detection
834483|NCT02942823|obesity
834484|NCT02942823|child
834485|NCT02942823|primary prevention
834486|NCT02942823|serious game
834487|NCT02942823|nutrition
834488|NCT02942823|physical activity
834489|NCT02942823|psychosocial
834490|NCT02942823|stress
834491|NCT02942823|knowledge
834492|NCT02942823|diet
834493|NCT02942823|energy density
834494|NCT02942823|beverages
834495|NCT02942823|food pyramide
834496|NCT02942732|Vitamin D
834497|NCT02942732|Glucose
834498|NCT02942732|HbA1C
834499|NCT02942732|Insulin resistance
834500|NCT02942732|Blood lipids
834501|NCT02942693|Apatinib
834502|NCT02942693|Particle therapy
834503|NCT02942680|coronary artery bypass grafting
834504|NCT02942641|Urethral catheter
834505|NCT02942641|clean intermittent catheterization
834506|NCT02942641|UTI
834507|NCT02942641|pain
834508|NCT02942641|quality of life
834509|NCT02942641|hematuria
834510|NCT02942641|cloudy urine
834511|NCT02942589|Portion Size
834512|NCT02942498|behavior, cognitive
834513|NCT02942472|clinical pregnancy rate after embryo transfer
834514|NCT02942459|music therapy
834515|NCT02942459|double-blinded
834516|NCT02942459|Randomized Controlled study (RCT)
834517|NCT02942459|Schizophrenia, negative symptoms
834518|NCT02942407|Renal dialysis
834519|NCT02942329|humanized anti-PD-1 monoclonal antibody
834520|NCT02942329|apatinib
834521|NCT02942329|Gastric Neoplasms
834522|NCT02942329|Gastric Cancer
834523|NCT02942329|Cancer of Stomach
834524|NCT02942329|Hepatocellular Carcinoma
834525|NCT02942329|Liver Cancer, Adult
834526|NCT02942329|Liver Cell Carcinoma
834527|NCT02942316|Heart Rate
834528|NCT02942316|Reflex, Pupillary
834529|NCT02942316|Monitoring, Intraoperative
834530|NCT02942303|Botulinum Toxin, Rejuvenation, Brow lift, Eyebrow.
834531|NCT02942290|Myelodysplastic Syndromes (MDS)
834532|NCT02942290|Azacitidine
834533|NCT02942290|Higher-Risk (HR) Myelodysplastic Syndromes (MDS)
834534|NCT02942290|Venetoclax
834535|NCT02942290|Acute Myelogenous Leukemia
834536|NCT02942290|Pharmacokinetic
834537|NCT02942277|Malaria
834538|NCT02942277|Reactogenicity
834539|NCT02942277|Antibody
834540|NCT02942277|Direct Skin Feed
834541|NCT02942277|Mosquito
834542|NCT02942264|Brain Tumor
834543|NCT02942264|Glioblastoma
834544|NCT02942264|Relapse
834545|NCT02942264|Randomized
834546|NCT02942264|temodar
834547|NCT02942251|MDD
834548|NCT02942251|big data analytics
834549|NCT02942238|CME
834550|NCT02942238|Right hemi Colon cancer
834551|NCT02942238|D3
834552|NCT02942238|laparoscopy
834553|NCT02942225|Attention-deficit/hyperactivity disorder
834554|NCT02942225|metabolomics
834555|NCT02942225|neuropsychological deficits
834556|NCT02942225|pathway analysis
834557|NCT02942212|Smoking Cessation
834558|NCT02942212|Nicotine patch
834559|NCT02942212|Nicoderm Committed Quitters
834560|NCT02942212|CQ
834561|NCT02942212|Nicoderm CQ
834562|NCT02942212|Questionnaires
834563|NCT02942212|Surveys
834564|NCT02942212|Interviews
834565|NCT02942212|Breath tests
834566|NCT02942173|CD45RA-depletion
834567|NCT02942173|TCR-alpha/beta depletion
834568|NCT02942173|Hematopoietic Stem Cell Transplantation
834569|NCT02942121|surgery education
834570|NCT02942121|radical cystectomy
834571|NCT02942121|cystectomy
834572|NCT02942121|muscle-invasive bladder cancer
834573|NCT02942108|piezolectric surgery
834574|NCT02942108|conventional surgery
834575|NCT02942108|lower third molars
834585|NCT02942043|Malignant pleural effusion
834586|NCT02942043|Bevacizumab
834587|NCT02941991|Stargardt's Macular Dystrophy
834588|NCT02941991|Retinal Diseases
834589|NCT02941991|Macular Degeneration
834590|NCT02941991|fundus flavimaculatus
834591|NCT02941991|hESC-RPE
834592|NCT02941991|juvenile macular dystrophy
834593|NCT02941991|SMD
834594|NCT02941939|high intensity interval training
834595|NCT02941939|hyperbaric oxygen
834596|NCT02941926|HR-positive HER2-negative
834597|NCT02941926|advanced breast cancer
834598|NCT02941926|LEE011
834599|NCT02941926|ribociclib
834600|NCT02941926|letrozole
834601|NCT02941926|goserelin
834602|NCT02941926|CDK
834603|NCT02941926|CDK4
834604|NCT02941926|CDK6
834605|NCT02941926|CDK4/6
834606|NCT02941926|Phase IIIb
834607|NCT02941926|ER-positive
834608|NCT02941926|PR-positive
834609|NCT02941926|premenopausal
834610|NCT02941926|postmenopausal
834611|NCT02941926|men with advanced breast cancer
834612|NCT02941900|Genetic Testing
834613|NCT02941900|16-1243
834614|NCT02941887|Social behavior
834615|NCT02941887|Gingivitis
834616|NCT02941887|Periodontitis
834617|NCT02941887|Down's Syndrome
834618|NCT02941874|IRAP
834619|NCT02941874|Insulin Regulated Amino Peptidase
834620|NCT02941874|Diagnostic biomarker
834621|NCT02941874|Type 2 diabetes
834622|NCT02941861|Hepatocellular carcinoma
834623|NCT02941861|Cholangiocarcinoma
834624|NCT02941861|Recurrence
834625|NCT02941835|pre-operative radiotherapy
834626|NCT02941783|Kovaltry
834627|NCT02941783|hemophilia A
834628|NCT02941783|Japan
834629|NCT02941783|Post-marketing surveillance
834630|NCT02941770|Adolescents
834631|NCT02941770|Overweight
834632|NCT02941770|Obesity
834633|NCT02941770|Weight Loss
834634|NCT02941770|Physical activity consultation
834635|NCT02941770|Cardiorespiratory fitness
834636|NCT02941770|Endothelial structure
834637|NCT02941770|Endothelial function
834638|NCT02941757|Mediterranean Diet
834639|NCT02941757|Firefighters
834640|NCT02941757|workplace
834641|NCT02941757|Intervention
834642|NCT02941757|obesity
834643|NCT02941757|Randomized Control Trial
834644|NCT02941744|nivolumab
834645|NCT02941744|ipilimumab
834646|NCT02941744|low fixed dose
834647|NCT02941744|adjuvant therapy
834648|NCT02941744|Melanoma
834649|NCT02941718|Smoking
834650|NCT02941718|Smoking cessation
834651|NCT02941718|Nicotine
834652|NCT02941705|stem cell research
834653|NCT02941640|Laparoscopic appendectomy
834654|NCT02941640|Endoloop
834655|NCT02941640|Stapler
834656|NCT02941640|Hem-o-lok clip
834657|NCT02941640|DS clip
834658|NCT02941601|Thoracic Neoplasms
834659|NCT02941601|Lung Diseases
834660|NCT02941601|Lung Cancer
834661|NCT02941601|Respiratory Tract Diseases
834662|NCT02941601|Respiratory Tract Neoplasms
834663|NCT02941601|Antineoplastic Agents
834664|NCT02941601|Monoclonal Antibodies
834665|NCT02941562|rectal cancer, radiotherapy
834666|NCT02941536|Circulating Tumor Cells
834667|NCT02941536|Stereotactic Radiosurgery
834668|NCT02941497|Stress, Psychological
834669|NCT02941497|Obesity
834670|NCT02941497|Physical Activity
834671|NCT02941497|Fruit
834672|NCT02941497|Vegetables
834673|NCT02941497|Social Marketing
834674|NCT02941497|Peer Influence
834675|NCT02941497|Community-Based Participatory Research
834676|NCT02941471|Constipation
834677|NCT02941471|Neuromodulation
834678|NCT02941471|Interferential
834679|NCT02941471|Transabdominal
834680|NCT02941445|DPP4-inhibitors
834681|NCT02941419|Platelet lysate
834682|NCT02941419|Critical limb ischemia
834683|NCT02941419|Peripheral arterial disease
834684|NCT02941406|Retina
834685|NCT02941406|Perimetry
834686|NCT02941393|internal tocodynamometry, external tocodynamometry, cesarean section, labor, newborn, vacuum extraction, dystocia
834687|NCT02941380|coronary artery bypass grafting
834688|NCT02941380|cardiopulmonary bypass
834689|NCT02941380|Cerebral oxidative stress
834690|NCT02941380|Cerebral inflammatory stress
834691|NCT02941380|Cerebral hemodynamics
834692|NCT02941380|Postoperative cognitive dysfunction
834693|NCT02941341|Bemfola
834694|NCT02941341|r-hFSH
834695|NCT02941341|ART
834696|NCT02941341|Oocytes
834697|NCT02941341|OHSS
834698|NCT02941341|Pregnancy
834699|NCT02941328|SMA, SMN1, Kugelberg-Welander
834700|NCT02941315|Cardiomyopathy
834701|NCT02941315|Heart Failure
834702|NCT02941315|Cardiac Magnetic Resonance
834703|NCT02941302|gliomas
834704|NCT02941302|biological boundary
834705|NCT02941302|imaging border
834706|NCT02941302|operation
834707|NCT02941263|AMD
834708|NCT02941263|Georgraphic Atrophy
834709|NCT02941263|Macular Degeneration
834710|NCT02941237|Pulse oximetry
834711|NCT02941237|Children
834712|NCT02941211|cervix
834713|NCT02941211|cervical dilation
834714|NCT02941211|balloon catheter
834715|NCT02941172|Brown adipose tissue
834716|NCT02941172|Cannabinoid receptor
834717|NCT02941172|PET imaging
834718|NCT02941172|Metabolism
834719|NCT02941120|Cartilage defect
834720|NCT02941120|Knee
834721|NCT02941120|ACT (Autologous chondrocyte implantation)
834722|NCT02941120|NOVOCART® Inject
834723|NCT02941107|Aboriginal
834724|NCT02941107|Rotavirus
834725|NCT02941107|Vaccine
834726|NCT02941107|Diarrhoea
834728|NCT02941068|severe sepsis
834729|NCT02941068|intra-abdominal perforation
834730|NCT02941068|surgical intensive care unit
834731|NCT02941068|fungal infection
834732|NCT02941068|prophylactic anti-fungal treatment
834733|NCT02941055|Diet
834734|NCT02941055|Inflammation
834735|NCT02941055|Metabolomics
834738|NCT02941003|Early stage lung adenocarcinoma
834739|NCT02941003|Intraoperative frozen section
834740|NCT02941003|Diagnostic criteria
834741|NCT02940977|Circulating tumor cell
834742|NCT02940977|Epithelial to mesenchymal transition
834743|NCT02940977|Prostate specific antigen (PSA)
834744|NCT02940977|Partin table
834745|NCT02940925|Nasopharyngeal carcinoma
834746|NCT02940925|induction chemotherapy
834747|NCT02940912|Parkinson disease
834748|NCT02940912|Insomnia
834749|NCT02940912|Sleep disorders
834750|NCT02940912|Polysomnography
834751|NCT02940912|Apomorphine
834752|NCT02940912|Multiple sleep latency test
834753|NCT02940912|Parkinson Disease Sleep Scale 2 (PDSS-2)
834754|NCT02940873|severe hypoglycemia
834755|NCT02940873|impaired awareness of hypoglycemia
834756|NCT02940873|type 1 diabetes mellitus
834757|NCT02940873|cognitive behavioral therapy
834758|NCT02940873|structured education
834759|NCT02940847|ultrasound-guided technique
834760|NCT02940847|blind technique
834761|NCT02940847|medial brachial cutaneous nerve block
834762|NCT02940847|intercostobrachial nerve block
834763|NCT02940821|Tooth Whitening
834764|NCT02940808|Caffeine
834765|NCT02940808|EEG
834766|NCT02940808|Theta/beta ratio
834767|NCT02940808|Eye-blink rates
834768|NCT02940808|Cognitive control
834769|NCT02940808|Emotional Stroop
834770|NCT02940808|Global/local congruency
834771|NCT02940808|N-Back
834772|NCT02940808|Prefrontal Cortex
834773|NCT02940795|breast feeding
834774|NCT02940795|fructose
834775|NCT02940769|depression, insomnia. light, cortisol, melatonin
834776|NCT02940756|Malaria, efficacy, safety, ACT, DR Congo
834777|NCT02940743|Hemodialysis
834778|NCT02940704|Reciproc
834779|NCT02940704|One Shape
834780|NCT02940704|reciprocation
834781|NCT02940704|continuous rotation
834782|NCT02940704|irreversible pulpitis
834783|NCT02940704|postoperative pain
834784|NCT02940678|Trauma
834785|NCT02940678|Clinical prediction models
834786|NCT02940678|Transferability studies
834787|NCT02940678|Sweden
834789|NCT02940626|Pneumonia
834790|NCT02940626|S. aureus
834791|NCT02940626|Mechanically ventilated
834792|NCT02940613|Rapid response
834793|NCT02940613|Eating Disorders
834794|NCT02940613|Cognitive Behavior Therapy
834795|NCT02940613|Bulimia Nervosa
834796|NCT02940613|Binge Eating Disorder
834797|NCT02940613|Purging Disorder
834798|NCT02940600|normothermic perfusion
834799|NCT02940600|old donors
834800|NCT02940600|extended criteria grafts
834801|NCT02940600|reconditioning
834802|NCT02940587|Non Healing Wound
834803|NCT02940574|Oxytocin
834804|NCT02940574|Autism Spectrum Disorders
834805|NCT02940548|non-dipper hypertension
834806|NCT02940548|young
834807|NCT02940548|middle-aged
834808|NCT02940548|ambulatory blood pressure monitoring
834809|NCT02940548|arterial stiffness
834810|NCT02940548|nifedipine gastrointestinal therapeutic system (GITS)
834811|NCT02940496|Malignant neoplasms of digestive organs
834812|NCT02940496|Advanced liver cancer
834813|NCT02940496|Advanced hepatocellular carcinoma
834814|NCT02940496|Pembrolizumab
834815|NCT02940496|Keytruda
834816|NCT02940496|MK-3475
834817|NCT02940496|SCH-900475
834818|NCT02940496|Biomarkers
834819|NCT02940483|Ependymoma
834820|NCT02940457|tDCS
834821|NCT02940457|MCI
834822|NCT02940457|Working Memory
834823|NCT02940457|fNIRS
834824|NCT02940418|Diabetes Mellitus
834825|NCT02940418|Type 1
834826|NCT02940418|Adipose derived mesenchymal stem cells
834827|NCT02940405|Ketorolac Premedication
834828|NCT02940405|Anesthetic Efficiency
834829|NCT02940405|Post-Endodontic Pain
834830|NCT02940405|Post-operative pain
834831|NCT02940405|Irreversible Pulpitis
834832|NCT02940405|Oral premedication
834833|NCT02940392|Rezum
834834|NCT02940340|infective endocarditis
834835|NCT02940340|systemic microcirculation
834836|NCT02940327|ECMO
834837|NCT02940327|PPHN
834838|NCT02940327|Pulmonary Hypertension of the Newborn
834839|NCT02940327|Markers of inflammation
834840|NCT02940327|Mi-Ecmo
834841|NCT02940249|Polyphenol
834842|NCT02940249|Apple
834843|NCT02940249|Fruit
834844|NCT02940249|Hyperglycaemia
834845|NCT02940249|Metabolic
834846|NCT02940223|Malignant neoplasms of independent (primary) multiple sites
834847|NCT02940223|Advanced Colorectal Cancer
834848|NCT02940223|Metastatic colorectal cancer
834849|NCT02940223|mCRC
834850|NCT02940223|Cancer-related fatigue
834851|NCT02940223|Regorafenib
834852|NCT02940223|Stivarga
834853|NCT02940223|Fish oil
834854|NCT02940223|Icosapent ethyl
834855|NCT02940223|Quality of life questionnaire
834856|NCT02940223|Symptom questionnaire
834857|NCT02940223|Walk test
834858|NCT02940223|Chair/stand test
834859|NCT02940223|Placebo
834860|NCT02940223|Resistance exercises
834861|NCT02940223|Walking program
834862|NCT02940223|Resistance training
834863|NCT02940223|Stretching exercises
834864|NCT02940197|overweight
834865|NCT02940197|Caloric Restriction
834866|NCT02940184|Physiology
834867|NCT02940171|burns
834868|NCT02940171|critically ill
834869|NCT02940171|surgery outcome
834870|NCT02940171|mortality
834871|NCT02940158|lentils
834872|NCT02940158|diabetes
834873|NCT02940158|glycemia
834874|NCT02940158|insulin
834875|NCT02940158|glucose
834881|NCT02940106|oocyte cryopreservation
834882|NCT02940106|closed vitrification
834883|NCT02940106|open vitrification
834884|NCT02940067|prehabilitation
834885|NCT02940067|pancreatectomy
834886|NCT02940067|nutrition
834887|NCT02940067|exercise
834888|NCT02940054|Early diagnosis
834889|NCT02940041|Diagnosis
834890|NCT02940041|Sonography
834891|NCT02940041|Magnetic Ressonance
834892|NCT02940015|Quality Control
834893|NCT02940015|Urine
834894|NCT02940015|Tissue
834895|NCT02940015|Normal
834896|NCT02940002|Plaque form psoriasis vulgaris
834897|NCT02939989|Virologic failure
834898|NCT02939989|Compensated Cirrhosis
834899|NCT02939989|HCV Genotype 3 (HCV GT3)
834900|NCT02939989|HCV Genotype 5 (HCV GT5)
834901|NCT02939989|Chronic Hepatitis C (HCV)
834902|NCT02939989|HCV Genotype 4 (HCV GT4)
834903|NCT02939989|HCV Genotype 2 (HCV GT2)
834904|NCT02939989|HCV Genotype 1 (HCV GT1)
834905|NCT02939989|HCV Genotype 6 (HCV GT6)
834906|NCT02939989|Non-cirrhotics
834907|NCT02939976|ST-Elevation Myocardial Infarction
834908|NCT02939963|weaning
834909|NCT02939963|mechanical ventilation
834910|NCT02939963|work of breathing
834911|NCT02939963|automatic tube compensation
834912|NCT02939963|pressure support ventilation
834913|NCT02939911|Residual neuromuscular blockade
834914|NCT02939872|DAPT
834915|NCT02939872|BVS
834916|NCT02939872|Bioresorbable Vascular Scaffold
834917|NCT02939872|Dual Antiplatelet Therapy
834922|NCT02939846|Safety
834923|NCT02939846|Solid tumor
834924|NCT02939846|Trametinib
834925|NCT02939846|Pharmacokinetics
834926|NCT02939820|RNAi therapeutic
834927|NCT02939820|FAP
834928|NCT02939820|Familial Amyloid Polyneuropathies
834929|NCT02939820|TTR
834930|NCT02939820|Transthyretin
834931|NCT02939820|Amyloidosis
834932|NCT02939807|Yeliva™
834933|NCT02939807|hepatocellular carcinoma
834934|NCT02939807|ABC294640
834935|NCT02939807|hepatic neoplasms
834936|NCT02939807|liver neoplasms
834937|NCT02939807|hepatic cancer
834938|NCT02939794|cardiac surgery
834939|NCT02939794|hemoglobin
834940|NCT02939794|iron
834941|NCT02939755|Collaborative care intervention
834942|NCT02939755|Cancer
834943|NCT02939755|Depression
834944|NCT02939755|Palliative care
834945|NCT02939755|Quality of life
834946|NCT02939755|Fatigue
834947|NCT02939755|Pain
834948|NCT02939742|preterm premature rupture of membranes
834949|NCT02939742|complications of prematurity
834950|NCT02939742|neonatal morbidity
834951|NCT02939742|respiratory distress syndrome
834952|NCT02939742|antenatal corticosteroids
834953|NCT02939742|betamethasone
834954|NCT02939729|prehabilitation
834955|NCT02939729|physiotherapy
834956|NCT02939729|cardiac
834957|NCT02939729|thoracic
834958|NCT02939729|preoperative
834959|NCT02939716|small bowel
834960|NCT02939716|bloating
834961|NCT02939716|flow
834962|NCT02939703|Adipose tissue
834963|NCT02939703|calorimetry
834964|NCT02939703|energy expenditure
834965|NCT02939703|microbiome
834966|NCT02939690|Catheter
834967|NCT02939690|Umbilical vein
834968|NCT02939690|Neonate
834969|NCT02939664|banded gastric bypass
834970|NCT02939664|weight loss
834971|NCT02939651|Metastatic
834972|NCT02939651|High grade
834973|NCT02939638|Plant-based diet
834974|NCT02939638|Obesity
834975|NCT02939638|Insulin sensitivity
834976|NCT02939638|Intracellular lipid
834977|NCT02939638|Postprandial metabolism
834978|NCT02939638|Vegan diet
834979|NCT02939612|Stress management
834980|NCT02939612|App
834981|NCT02939599|Pulmonary hypertension (PH),
834982|NCT02939599|Increase blood pressure in the pulmonary artery
834983|NCT02939599|Increased blood pressure in the pulmonary vein
834984|NCT02939599|Increased blood pressure in the lung vasculature
834985|NCT02939599|Shortness of breath
834986|NCT02939599|Dizziness
834987|NCT02939599|Fainting
834988|NCT02939599|Leg swelling
834989|NCT02939599|Cough
834990|NCT02939599|Angina pector
834991|NCT02939586|Sleep, Sleep apnoea, Haemodialysis, Haemodiafiltration, end stage kidney disease
834992|NCT02939560|Autism Spectrum Disorder
834993|NCT02939560|Autism
834994|NCT02939560|Depressive
834995|NCT02939560|Depression
834996|NCT02939547|intravenous
834997|NCT02939547|cyclodextrin
834998|NCT02939547|compassionate
834999|NCT02939547|Trappsol
835000|NCT02939534|Parkinson's disease
835001|NCT02939534|autoimmunity
835002|NCT02939521|Pincer Nail
835003|NCT02939521|Surgery
835004|NCT02939508|Acute lower gastrointestinal dysfunction
835005|NCT02939508|Colon-originated lesions
835006|NCT02939508|Critical patient
835007|NCT02939508|Colonoscopic decompression
835008|NCT02939508|Anticholinergic drugs
835009|NCT02939495|Premature Ejaculation
835010|NCT02939495|Erectile Dysfunction
835011|NCT02939495|DAP-SPEED
835012|NCT02939495|Dapoxetine
835013|NCT02939495|Sildenafil
835014|NCT02939469|Sympathetic Nerve Activity
835015|NCT02939469|Skin Sympathetic Nerve Activity
835016|NCT02939456|prostate
835017|NCT02939456|cancer
835018|NCT02939456|MRI
835019|NCT02939417|Laminate veneers
835020|NCT02939417|Grape seed extract
835021|NCT02939417|Emax
835022|NCT02939417|collagen cross-linking agent
835023|NCT02939404|Energy Intake
835024|NCT02939404|Energy Expenditure
835025|NCT02939404|Eating Behavior
835026|NCT02939404|Cold Exposure
835027|NCT02939378|ketogenic diet
835028|NCT02939378|recurrent glioblastoma
835029|NCT02939378|chemotherapy
835030|NCT02939352|Transcranial Magnetic Stimulation
835031|NCT02939352|Magnetic Resonance Imaging
835032|NCT02939352|MRI, Functional
835033|NCT02939339|Transcranial Magnetic Stimulation
835034|NCT02939313|alcohol
835035|NCT02939313|addiction
835036|NCT02939313|cTBS
835037|NCT02939300|Melanoma
835038|NCT02939300|Leptomeningeal Metastases
835039|NCT02939287|autologous
835040|NCT02939287|myeloma
835041|NCT02939287|transplant
835042|NCT02939209|Rotator cuff repair
835043|NCT02939209|Interscalene block
835044|NCT02939209|Hydromorphone
835045|NCT02939209|Pain
835046|NCT02939209|Rebound pain
835047|NCT02939183|Multiple Myeloma
835048|NCT02939157|Diagnostic Ultrasound
835049|NCT02939157|Primary Care
835050|NCT02939131|Cognitive Behavioral Therapy
835051|NCT02939131|Medication Management
835052|NCT02938351|Intervention
835053|NCT02938351|dialysis
835054|NCT02938325|Electroencephalogram
835055|NCT02938325|awareness
835056|NCT02938286|Fractional laser
835057|NCT02938286|Topical anesthesia
835058|NCT02938286|Drug delivery
835059|NCT02938286|CO2 laser
835060|NCT02938286|Er:YAG laser
835061|NCT02938247|Malnutrition
835062|NCT02938247|Geriatric subjects
835063|NCT02938247|Nursing home
835064|NCT02938234|Malnutrition
835065|NCT02938234|Geriatric subjects
835066|NCT02938234|Nursing home
835067|NCT02938221|TeleStroke
835068|NCT02938221|HINTS
835069|NCT02938221|Diagnosis
835070|NCT02938221|Telemedicine
835071|NCT02938221|Acute Vestibular Syndrome
835072|NCT02939092|Gingival Bleeding on probing
835073|NCT02939079|Multiple Sclerosis
835074|NCT02939079|Fingolimod
835075|NCT02939079|Fish Oil
835076|NCT02939053|Bioimpedance spectroscopy
835077|NCT02939040|positive activities intervention
835078|NCT02939040|peri-operative
835079|NCT02939014|Drug therapy
835080|NCT02938988|Periodontal Diseases
835081|NCT02938988|Down Syndrome
835082|NCT02938975|malaria
835083|NCT02938975|personal protection
835084|NCT02938975|permethrin treated clothing
835085|NCT02938975|insect repellents
835086|NCT02938975|army personnel
835087|NCT02938975|cluster randomised trial
835088|NCT02938949|Myocardial Infarction
835089|NCT02938949|Low Density Lipoprotein Cholesterol
835090|NCT02938949|proprotein convertase subtilisin kexin 9, human
835091|NCT02938949|alirocumab
835092|NCT02938910|Primary hyperaldosteronism
835093|NCT02938910|Secondary hyperaldosteronism
835094|NCT02938910|Cardiac fibrosis
835095|NCT02938910|magnetic resonance imaging
835096|NCT02938897|Telehealth
835097|NCT02938897|Weight loss
835098|NCT02938897|Diet quality
835099|NCT02938897|Behavioral counseling
835100|NCT02938871|synbiotic
835101|NCT02938871|infections
835102|NCT02938871|probiotics
835103|NCT02938871|liver transplantation
835104|NCT02938832|cardiovascular disease, diet, diabetes
835105|NCT02938819|upper limbs
835106|NCT02938819|physiotherapy
835107|NCT02938793|cancer, malignancy
835108|NCT02938780|Behavioral economics
835109|NCT02938780|Breast cancer survivors
835110|NCT02938780|nutrition
835111|NCT02938780|physical activity
835112|NCT02938767|peritoneal dialysis
835113|NCT02938767|carotid intima-media thickness
835114|NCT02938767|coronary flow reserve
835115|NCT02938767|cardiovascular mortality
835116|NCT02938754|Hemiparesis
835117|NCT02938754|Functional independence
835118|NCT02938754|Virtual Rehabilitation
835119|NCT02938741|Acute Lymphoblastic Leukemia
835120|NCT02938741|lymphoblastic lymphoma
835121|NCT02938741|stem-cell transplant
835122|NCT02938741|T-cell lymphoma
835123|NCT02938741|ATG
835124|NCT02938728|AntiPD1
835125|NCT02938702|Active surveillance
835126|NCT02938650|nitrolipid
835127|NCT02938650|microbiome
835128|NCT02938650|inflammation
835129|NCT02938650|cytokine
835130|NCT02938598|maternal depression
835131|NCT02938598|pediatric-based maternal depression screening
835132|NCT02938598|maternal health services
835133|NCT02938546|Non-small-cell lung cancer
835134|NCT02938546|18F-FDG PET/CT
835135|NCT02938546|treatment response assessment
835136|NCT02938520|Antiretroviral agent
835137|NCT02938520|Maintenance
835138|NCT02938520|rilpivirine
835139|NCT02938520|dolutegravir
835140|NCT02938520|TMC278
835141|NCT02938520|Triumeq
835142|NCT02938520|non-nucleoside reverse transcriptase inhibitor
835143|NCT02938520|once monthly, every 4 weeks, once daily
835144|NCT02938520|GSK1265744
835145|NCT02938520|CAB
835146|NCT02938520|Tivicay
835147|NCT02938520|Long-Acting Intramuscular rilpivirine
835148|NCT02938520|lamivudine
835149|NCT02938520|integrase inhibitor
835150|NCT02938520|Long-Acting Intramuscular Cabotegravir
835151|NCT02938520|ART naïve
835152|NCT02938520|cabotegravir
835153|NCT02938520|abacavir
835154|NCT02938507|Overactive bladder, Incontinence
835155|NCT02938481|colon cancer, lymph node, extent of bowel resection
835156|NCT02938455|Hyperalgesia
835157|NCT02938455|Opioids
835158|NCT02938455|Postoperative pain
835159|NCT02938455|DNA methylation
835160|NCT02938429|congenital
835161|NCT02938390|Nipple Sparing Mastectomy
835162|NCT02938390|Ultrasound
835163|NCT02938169|low back pain
835164|NCT02938169|surface EMG
835165|NCT02938169|exercise
835166|NCT02938156|Hemophilia
835167|NCT02938143|Jumpers knee
835168|NCT02938143|Patellar Tendinopathy
835169|NCT02938143|Jumping Athletes
835170|NCT02938143|UTE MRI
835171|NCT02938143|Exercise Therapy
835172|NCT02938143|NBA
835173|NCT02938117|obesity
835174|NCT02938117|eccentric exercise
835175|NCT02938117|body composition
835176|NCT02938117|training program
835177|NCT02938091|Hispanics
835178|NCT02938091|Single nucleotide polymorphism
835179|NCT02938091|Hepatic lipase
835180|NCT02938052|Heart Failure
835181|NCT02938052|Positive Psychology
835182|NCT02938052|Adherence to Health Behaviors
835183|NCT02938039|laryngeal airways
835184|NCT02938039|infants
835185|NCT02938039|neonates
835186|NCT02938039|children
835187|NCT02938039|anesthetized
835188|NCT02938000|aerobic training
835189|NCT02938000|stroke
835190|NCT02938000|exercise
835191|NCT02938000|stroke recovery
835192|NCT02937974|Pulmonary Disease, Chronic Obstructive
835193|NCT02937974|Xuebijing
835194|NCT02937948|Locally advanced
835195|NCT02937922|Exercise
835196|NCT02937922|Endothelium
835197|NCT02937922|Hypertension
835198|NCT02937922|Endothelial progenitor cell
835199|NCT02937922|Endothelial microparticle
835200|NCT02937909|woundcare community nursing competence
835201|NCT02937883|Daily Activities
835202|NCT02937818|Platinum Refractory Extensive-Stage Carcinoma, Small Cell Lung
835203|NCT02937818|Platinum Refractory Extensive-Stage Oat Cell Carcinoma of Lung
835204|NCT02937818|Platinum Refractory Extensive-Stage Oat Cell Lung Cancer
835205|NCT02937818|Platinum Refractory Extensive-Stage Small Cell Cancer Of The Lung
835206|NCT02937818|Platinum Refractory Extensive-Stage Small Cell Lung Cancer
835207|NCT02937740|Hypogonadism
835208|NCT02937714|Teachers
835209|NCT02937714|mental health literacy
835210|NCT02937714|school mental health promotion
835211|NCT02937688|Parkinson's disease
835212|NCT02937688|Deep Brain Stimulation
835213|NCT02937675|small molecule inhibitor of protein translation
835214|NCT02937675|immunomodulator
835215|NCT02937675|phase 1 dose escalation
835216|NCT02937649|Obesity
835217|NCT02937649|Bariatric surgery
835218|NCT02937649|Sleeve gastrectomy
835219|NCT02937649|Staple-line Leak
835220|NCT02937649|Bougie
835221|NCT02937649|Calibration
835222|NCT02937597|proficiency based progression
835223|NCT02937597|feedback
835224|NCT02937597|computer based assessment
835225|NCT02937597|non technical skills
835226|NCT02937597|deteriorating patient
835227|NCT02937597|ISBAR
835228|NCT02937571|Carfilzomib
835229|NCT02937571|Lenalidomide
835230|NCT02937571|Dexamethasone
835231|NCT02937571|15-326
835232|NCT02937558|hypoglycemia
835233|NCT02937532|Fear of falling
835234|NCT02937532|Fear avoidance behavior
835235|NCT02937532|cognitive behavioral therapy
835236|NCT02937532|Rehabilitation
835237|NCT02937519|Chronomodulated Chemotherapy
835238|NCT02937519|Intensity Modulated Radiation Therapy
835239|NCT02937519|Advanced Nasopharyngeal Cancer
835240|NCT02937506|propofol
835241|NCT02937506|colonoscopy
835242|NCT02937506|patient satisfaction
835243|NCT02937480|stroke
835244|NCT02937480|physical activity
835245|NCT02937480|task performance
835246|NCT02937480|clinical protocol
835247|NCT02937467|SWE
835248|NCT02937467|diagnosis
835251|NCT02937441|C10.228.140.187
835252|NCT02937428|vaccination
835253|NCT02937428|pain
835254|NCT02937428|fear
835255|NCT02937428|psychological intervention
835256|NCT02937415|carbon monoxide
835257|NCT02937415|oxidative stress
835258|NCT02937415|waterpipe smoking
835259|NCT02937415|cigarette smoking
835260|NCT02937415|pulmonary function test
835261|NCT02937350|chronic kidney disease
835262|NCT02937350|vitamin d catabolism
835263|NCT02937311|Taping, stroke
835264|NCT02937311|rehabilitation
835265|NCT02937311|shoulder pain
835266|NCT02937311|electrical stimulation
835267|NCT02937298|Diet Induced Thermogenesis
835268|NCT02937298|Obesity
835269|NCT02937298|Energy balance
835270|NCT02937298|Energy expenditure
835271|NCT02937298|berries
835272|NCT02937298|Sea Buckthorn
835273|NCT02937298|Wild garlic
835275|NCT02937233|Zika
835276|NCT02937233|Vaccine
835277|NCT02937233|ZPIV
835278|NCT02937207|Bronchial Asthma
835279|NCT02937207|Traditional Chinese Medicine
835280|NCT02937194|Early childhood caries (ECC)
835281|NCT02937194|Oral health promotion
835282|NCT02937194|Randomized controlled trial
835283|NCT02937142|Behavior Therapy
835284|NCT02937142|Cognitive Therapy
835285|NCT02937142|Adolescents
835286|NCT02937142|Psychotherapy, Group
835287|NCT02937129|Infrared tympanic thermometer
835288|NCT02937129|Axillary thermometer
835289|NCT02937129|Mercury glass thermometer
835290|NCT02937129|Adult emergency department
835291|NCT02937103|Leukemia
835292|NCT02937103|Myeloid
835293|NCT02937103|CD123
835294|NCT02937103|CAR-T
835295|NCT02937090|Polycystic Ovary Syndrome
835296|NCT02937090|Intestinal Microbiota
835297|NCT02937077|etiology
835298|NCT02937038|Urine Biomarkers
835299|NCT02937038|Child Nutrition
835300|NCT02937038|Hydration
835301|NCT02937038|Parent Nutrition Habits
835302|NCT02937025|Nonvalvular atrial fibrillation
835303|NCT02937025|Stroke
835304|NCT02937025|Left Atrial Appendage Closure
835305|NCT02937025|Intervention
835306|NCT02937012|Primary Biliary Cirrhosis
835307|NCT02937012|Primary Biliary Cholangitis
835308|NCT02937012|Bezafibrate
835309|NCT02937012|Ursodeoxycholic acid
835310|NCT02936973|simple obesity
835311|NCT02936973|catgut implantation
835312|NCT02936934|Adverse Drug Reaction
835313|NCT02936934|Morphine
835314|NCT02936934|Oxycodone
835315|NCT02936934|Abdominal hysterectomy
835316|NCT02936921|Toxoplasma gondii
835317|NCT02936921|Toxoplasmosis
835318|NCT02936921|congenital
835319|NCT02936921|prenatal
835320|NCT02936921|screening
835321|NCT02936921|treatment
835322|NCT02936921|diagnosis
835323|NCT02936908|Neuromuscular Diseases
835324|NCT02936908|Muscular dystrophy
835325|NCT02936908|Amyotrophic Lateral Sclerosis
835326|NCT02936908|Acute respiratory failure
835327|NCT02936908|respiratory care
835328|NCT02936908|mechanical ventilation
835329|NCT02936908|weaning
835330|NCT02936908|Intensive Care Unit
835331|NCT02936908|Critical Care
835332|NCT02936908|Survival
835333|NCT02936882|ultrasonography
835334|NCT02936882|aspiration
835335|NCT02936882|emergency
835336|NCT02936882|children
835337|NCT02936882|antrum
835338|NCT02936843|Pain
835339|NCT02936843|Inflammation
835340|NCT02936843|Diabetes Mellitus
835341|NCT02936843|Adult
835342|NCT02936843|Neuropathy
835343|NCT02936817|HRCT
835344|NCT02936817|High Resolution Computed Tomography scans
835345|NCT02936817|Functional Respiratory Imaging
835346|NCT02936817|CT scan
835347|NCT02936817|Computed Tomography
835348|NCT02936817|COPD
835349|NCT02936817|sputum producing COPD patients
835350|NCT02936817|Aerobika® device
835351|NCT02936804|early stage lung cancer
835352|NCT02936804|LDCT screening
835353|NCT02936804|lung resection
835354|NCT02936804|electromagnetic navigation bronchoscopy
835355|NCT02936804|peripheral biomarker
835356|NCT02936791|autosomal dominant polycystic kidney disease
835357|NCT02936791|ADPKD
835358|NCT02936791|PKD biomarkers
835359|NCT02936791|Kidney Institute
835360|NCT02936791|University of Kansas Medical Center
835361|NCT02936778|Short-term medical and psychosocial functioning
835362|NCT02936713|flatulence
835363|NCT02936713|gas
835364|NCT02936713|probiotics
835365|NCT02936713|fermented milk
835366|NCT02936713|diet
835367|NCT02936713|functional gastrointestinal disorders
835368|NCT02936700|Psychiatry
835369|NCT02936700|Suicide
835370|NCT02936700|Randomized controlled trial
835371|NCT02936700|ACT
835372|NCT02936700|fMRI
835373|NCT02936687|blood flow
835374|NCT02936687|magnetic resonance imaging
835375|NCT02936687|insulin
835376|NCT02936687|vasodilation
835377|NCT02936661|postpartum hemorrhage， cesarean section， tranexamic acid
835378|NCT02936648|Hepatitis C
835379|NCT02936635|Amyotrophic Lateral Sclerosis
835380|NCT02936635|ALS
835381|NCT02936635|tirasemtiv
835382|NCT02936609|healthcare access
835383|NCT02936609|healthcare utilization
835384|NCT02936609|preventive services
835385|NCT02936609|cancer survivors
835386|NCT02936531|evoked response potential
835387|NCT02936531|ERP
835388|NCT02936531|Brain Network Activation
835389|NCT02936531|BNA
835390|NCT02936531|Biomarker
835391|NCT02936518|ankyloglossia
835392|NCT02936518|breastfeeding
835393|NCT02936518|lip tie
835394|NCT02936505|chronic lung allograft dysfunction
835395|NCT02936505|cyclosporin
835396|NCT02936505|tacrolimus
835397|NCT02936505|Bronchiolitis Obliterans Syndrome
835398|NCT02936505|Restrictive Allograft Syndrome
835399|NCT02936505|CLAD
835400|NCT02936492|Phase I
835401|NCT02936492|Healthy volunteers
835402|NCT02936466|Psychiatry
835403|NCT02936466|Randomized controlled trial
835404|NCT02936466|Bipolar disorder
835405|NCT02936466|Serious game
835406|NCT02936466|Compliance
835407|NCT02936466|Psychoeducation
835408|NCT02936453|Spinal Cord Injury
835409|NCT02936453|Epidural Electrical Stimulation
835410|NCT02936453|Robot-assisted
835411|NCT02936440|acute kidney injury
835412|NCT02936440|intensive care unit
835413|NCT02936440|bioelectrical impedance analysis
835414|NCT02936414|Berberine
835415|NCT02936414|Cytokine
835416|NCT02936414|CRP
835417|NCT02936414|Metabolism
835418|NCT02936414|Schizophrenia
835419|NCT02936388|uveal melanoma
835420|NCT02936388|liver metastasis
835421|NCT02936388|chemoembolisation
835422|NCT02936388|radioembolisation
835423|NCT02936375|lupus
835424|NCT02936375|nephritis
835425|NCT02936375|iguratimod
835426|NCT02936362|Bread
835427|NCT02936362|Microbiome
835428|NCT02936362|Blood tests
835429|NCT02936362|Sourdough bread
835430|NCT02936362|Dietary intervention
835431|NCT02936349|Hereditary Hemorrhagic Telangiectasia (HHT)
835432|NCT02936349|Pulmonary Arteriovenous Malformation (PAVM)
835433|NCT02936349|Transthoracic Contrast Echocardiogram (TTCE)
835435|NCT02936310|stress
835436|NCT02936310|mindfulness
835437|NCT02936310|Mindful Living With Stress Intervention
835438|NCT02936310|nurse
835439|NCT02936310|HIV/AIDS
835440|NCT02936271|Radiofrequency Ablation
835441|NCT02936271|Sclerotherapy
835442|NCT02936271|Vasculera
835443|NCT02936219|complementary feeding
835444|NCT02936219|breast milk
835445|NCT02936219|formula feeding
835446|NCT02936219|combined feeding
835447|NCT02936219|preterm infants
835448|NCT02936219|body composition
835449|NCT02936206|proliferation Index
835450|NCT02936206|Tamoxifen
835451|NCT02936206|Fulvestrant
835452|NCT02936206|cyclinD1
835453|NCT02936206|Breast cancer
835454|NCT02936180|Rheumatoid arthritis
835455|NCT02936180|Flu vaccine
835456|NCT02936180|Influenza
835457|NCT02936167|Ringer Lactate
835458|NCT02936167|Plasmalyte
835459|NCT02936167|Perioperative Period
835460|NCT02936141|homeless, mental disorders, attendance
835461|NCT02936102|Phase I
835462|NCT02936102|FAZ053
835463|NCT02936102|PDR001
835464|NCT02936102|Checkpoint inhibitor
835465|NCT02936102|PD-L1
835466|NCT02936102|PD-1
835467|NCT02936063|Head and neck surgery
835468|NCT02936063|Scar cosmesis
835469|NCT02936063|Surgical staples
835470|NCT02936063|Sutures
835471|NCT02936063|Patient satisfaction
835472|NCT02936050|Echocardiography
835473|NCT02936050|Telemedicine
835474|NCT02936050|Nurses
835475|NCT02936050|Decision support
835476|NCT02936050|eHealth
835477|NCT02936037|progressive multiple sclerosis
835478|NCT02936037|MS
835479|NCT02936037|EDSS
835480|NCT02936037|TW25
835481|NCT02936037|multiple sclerosis
835482|NCT02935998|schizophrenia
835483|NCT02935998|agitation
835484|NCT02935998|ziprasidone
835485|NCT02935985|spontaneous intracerebral hemorrhage
835486|NCT02935985|point-of-care bio-markers
835487|NCT02935985|multicenter
835488|NCT02935985|Emergency Department
835489|NCT02935985|Romania
835490|NCT02935972|prostate biopsy, analgesia, anesthesia, pain, prostate cancer
835491|NCT02935946|pharyngeal swallow, NICU, intervention, thickening
835492|NCT02935920|PRO, follow up
835493|NCT02935894|oxygenated lipids
835494|NCT02935894|metabolic profiling
835495|NCT02935894|sphingoid bases
835496|NCT02935894|ceramides
835497|NCT02935894|endocannabinoids
835498|NCT02935894|non-invasive sampling
835499|NCT02935868|Saliva
835500|NCT02935855|Diabetic patients
835501|NCT02935855|nondiabetic patients
835502|NCT02935842|Parkinson's Disease
835503|NCT02935842|Word Retrieval
835504|NCT02935842|Apraxia Symptoms
835505|NCT02935842|Dysarthria
835506|NCT02935829|energy intake
835507|NCT02935829|blood glucose
835508|NCT02935829|carob flour
835509|NCT02935790|unresectable
835510|NCT02935790|melanoma
835511|NCT02935777|Pomegranate extract
835512|NCT02935777|cognitive function
835513|NCT02935777|cognition
835514|NCT02935777|polyphenols
835515|NCT02935777|memory
835516|NCT02935738|prednisolone
835517|NCT02935738|anti-sperm antibodies
835518|NCT02935738|sperm penetration assay
835519|NCT02935712|Safety
835520|NCT02935712|Tolerability
835521|NCT02935712|AZD8601
835522|NCT02935712|Type II Diabetes
835528|NCT02935569|Alopecia
835529|NCT02935569|Radiotherapy
835530|NCT02935556|Post Partum Pre-eclampsia
835539|NCT02935504|Depression
835540|NCT02935504|Pregnancy
835541|NCT02935504|Postpartum
835542|NCT02935491|TAVI
835543|NCT02935491|Aortic stenosis
835544|NCT02935491|aortic stiffness
835545|NCT02935491|calcifications
835546|NCT02935491|CT-scan
835547|NCT02935491|Vascular impedance
835548|NCT02935478|bariatric surgery
835549|NCT02935478|minimally invasive
835550|NCT02935478|Embolization
835551|NCT02935478|ghrelin
835552|NCT02935478|gastric artery embolization
835553|NCT02935452|Self-management
835554|NCT02935452|Supportive self-management
835555|NCT02935452|Normalisation process theory
835556|NCT02935452|Social networks
835557|NCT02935439|Mobile Phone
835558|NCT02935439|Self-efficacy
835559|NCT02935439|Quality of Life
835560|NCT02935439|Knowledge
835561|NCT02935439|Feasibility
835562|NCT02935426|cyanoacrylate
835563|NCT02935426|sutures
835564|NCT02935400|porphyria
835565|NCT02935400|biomarkers
835566|NCT02935387|Very early rheumatoid arthritis
835567|NCT02935374|children
835568|NCT02935374|intestinal microbiome
835569|NCT02935374|microbiota
835570|NCT02935374|antimicrobial course
835571|NCT02935374|amoxicillin
835572|NCT02935374|amoxicillin-clavulanate
835573|NCT02935374|macrolide
835574|NCT02935322|Prevention
835575|NCT02935309|rectum
835576|NCT02935309|transrectal
835577|NCT02935309|carcinoma
835578|NCT02935270|Stroke
835579|NCT02935270|Neglect
835580|NCT02935270|Rehabilitation
835581|NCT02935244|Epidemiology
835582|NCT02935231|minimal cessation advice
835583|NCT02935231|proactive
835584|NCT02935231|nicotine replacement therapy
835585|NCT02935231|smoking hotspots
835586|NCT02935192|seasonal influenza
835587|NCT02935192|vaccine
835588|NCT02935153|CD22
835589|NCT02935153|CAR-T
835590|NCT02935153|Leukemia
835591|NCT02935153|Lymphoma
835592|NCT02935127|absorbable sutures
835593|NCT02935114|Tooth Bleaching
835594|NCT02935114|Tooth Bleaching Agents
835595|NCT02935114|Tooth Whitening
835596|NCT02935114|Hydrogen Peroxide
835597|NCT02935114|Carbamide Peroxide
835598|NCT02935101|glucocorticoids
835599|NCT02935101|craving
835600|NCT02935101|Heroin
835601|NCT02935101|Cocaine
835602|NCT02935101|dependency
835603|NCT02935088|FFR
835604|NCT02935088|Percutaneous coronary intervention
835605|NCT02935062|Speech
835606|NCT02935062|Speech Therapy
835607|NCT02935062|Speech Sound Disorders
835608|NCT02935062|Phonological Disorders
835609|NCT02935062|Auditory Perception
835610|NCT02935010|Helicobacter pylori
835611|NCT02935010|Bismuth quadruple therapy
835612|NCT02935010|Tailored therapy
835613|NCT02935010|Empiric therapy
835614|NCT02935010|clarithromycin susceptibility
835615|NCT02934997|sepsis
835616|NCT02934997|septic shock
835617|NCT02934997|cholesterol
835618|NCT02934997|high density lipoprotein
835619|NCT02934984|Pancreatic Cancer
835620|NCT02934984|recurrence
835621|NCT02934984|DNA
835622|NCT02934958|Colon Cancer Screening
835623|NCT02934945|Budesonide/formoterol
835624|NCT02934945|Typical asthma
835625|NCT02934945|Cough variant asthma
835626|NCT02934919|Nalmefene
835627|NCT02934919|Impulse control disorders
835628|NCT02934919|Parkinson's disease
835629|NCT02934919|Tolerance
835630|NCT02934919|Efficacy
835631|NCT02934906|Neonatal Alloimmune Thrombocytopenia
835632|NCT02934906|pregnancy
835633|NCT02934906|human platelet allogantigen
835634|NCT02934906|asian
835635|NCT02934906|Chinese
835636|NCT02934880|adapted physical activity, cognitive functions
835637|NCT02934854|GAMT deficiency
835638|NCT02934854|GAMT and AGAT deficiencies
835639|NCT02934854|Creatine Transporter Deficiency
835640|NCT02934854|Brain Creatine Transporter Deficiency
835641|NCT02934815|psychological intervention
835642|NCT02934815|breast cancer
835643|NCT02934815|supportive-expressive group therapy
835644|NCT02934815|emotion regulation
835645|NCT02934815|social support
835646|NCT02934815|attachment
835647|NCT02934815|quality of life
835651|NCT02934776|DTI
835652|NCT02934776|prostate cancer
835653|NCT02934776|MRI
835654|NCT02934750|pursed lip breathing
835655|NCT02934750|interstitial lund disease
835656|NCT02934750|exercise physiology
835657|NCT02934737|Obesity
835658|NCT02934737|Diabetes Mellitus
835659|NCT02934724|HPV vaccines
835660|NCT02934724|HPV-6
835661|NCT02934724|HPV-11
835662|NCT02934724|HPV-16
835663|NCT02934724|HPV-18
835664|NCT02934724|Gardasil
835665|NCT02934711|Multimorbidity
835666|NCT02934711|Exercise coordinated groups (GECO)
835667|NCT02934711|Caregivers
835668|NCT02934685|Prostatic Neoplasms
835669|NCT02934685|radiotherapy
835670|NCT02934646|Robotics
835671|NCT02934646|Upper Extremity
835672|NCT02934633|injury
835673|NCT02934633|child
835674|NCT02934633|cars
835675|NCT02934633|pedestrians
835676|NCT02934633|child safety
835677|NCT02934633|interactive
835678|NCT02934633|computer
835679|NCT02934633|prevention
835680|NCT02934633|internet
835681|NCT02934633|CD-ROM
835682|NCT02934620|pregnancy
835683|NCT02934620|condom
835684|NCT02934620|HIV
835685|NCT02934620|sexually transmitted infections
835686|NCT02934607|Asthma
835687|NCT02934607|Chronic obstructive pulmonary disease
835688|NCT02934607|Spacer device
835689|NCT02934607|Symbicort
835690|NCT02934607|Pressurized metered-dose inhaler
835691|NCT02934607|Relative bioavailability
835692|NCT02934607|Crossover
835693|NCT02934607|AstraZeneca
835694|NCT02934607|Safety
835695|NCT02934607|Activated charcoal
835696|NCT02934607|AeroChamber Plus Flow-Vu spacer device
835697|NCT02934568|Ribociclib
835698|NCT02934568|LEE011
835699|NCT02934542|Laparoscope holder
835700|NCT02934542|Colon resection
835701|NCT02934542|Right hemicolectomy
835702|NCT02934542|Left hemicolectomy
835703|NCT02934542|Sigmoid resection
835704|NCT02934542|Anti-reflux
835705|NCT02934542|Hiatal hernia
835706|NCT02934516|Obstructed labor
835707|NCT02934516|C section. push method
835708|NCT02934516|reverse breech
835709|NCT02934503|Chemotherapy
835710|NCT02934503|PD-L1
835711|NCT02934503|Thoracic radiotherapy
835712|NCT02934503|PD-1
835713|NCT02934503|MK-3475
835714|NCT02934477|Myelofibrosis
835715|NCT02934477|Hematopoietic Stem Cell Transplant
835716|NCT02934477|Medicare
835717|NCT02934438|nitric oxide
835718|NCT02934438|Neo40 supplement,
835719|NCT02934438|exercise tolerance
835720|NCT02934425|Pork
835721|NCT02934425|Refined carbohydrates
835722|NCT02934425|Satiety
835723|NCT02934425|Glucose
835724|NCT02934425|Insulin
835725|NCT02934425|Breakfast
835726|NCT02934425|Lipoprotein lipids
835727|NCT02934399|dynamic hormone diagnostics
835728|NCT02934399|adrenal insufficiency
835729|NCT02934399|congenital adrenal hyperplasia
835730|NCT02934399|primary hyperaldosteronism
835731|NCT02934399|cushing syndrome
835732|NCT02934399|growth hormone deficiency
835733|NCT02934399|acromegaly
835734|NCT02934360|Lung Cancer
835735|NCT02934360|Breast Cancer
835736|NCT02934360|cell free DNA
835737|NCT02934360|biomarker
835738|NCT02934347|Intubation, Back-up position; Glottis, View
835739|NCT02934334|major depression
835740|NCT02934334|major depressive episode
835741|NCT02934334|biomarkers
835742|NCT02934334|relapse
835743|NCT02934334|near term relapse
835744|NCT02934334|m-health
835745|NCT02934321|Erythritol
835746|NCT02934321|Satiety Response
835747|NCT02934321|Ghrelin
835748|NCT02934295|Rubeola
835749|NCT02934269|Healthy subjects
835750|NCT02934269|Safety
835751|NCT02934269|CC-90006
835752|NCT02934269|Phase 1
835753|NCT02934269|Tolerability
835754|NCT02934256|Neurofibromatosis Type 2
835755|NCT02934256|Vestibular Schwannoma
835756|NCT02934256|Other NF2-related tumors
835757|NCT02934243|Laryngeal Masks
835758|NCT02934243|Ventilation
835759|NCT02934243|Risk factors
835760|NCT02934204|PCNSL
835761|NCT02934204|DLBCL
835762|NCT02934204|methotrexate
835763|NCT02934204|temozolomide
835764|NCT02934191|Tonsillectomy
835765|NCT02934191|Post-operative complications
835766|NCT02934191|Post-operative pain
835767|NCT02934178|shigellosis
835768|NCT02934178|Enterobacteriaceae Infections
835769|NCT02934178|Gram-Negative Bacterial Infections
835770|NCT02934178|Bacterial Infections
835771|NCT02934178|Gastroenteritis
835772|NCT02934178|Gastrointestinal Diseases
835773|NCT02934178|Digestive System Diseases
835774|NCT02934178|Intestinal Diseases
835775|NCT02934165|child safety
835776|NCT02934165|injury
835777|NCT02934165|computer
835778|NCT02934165|prevention
835779|NCT02934165|internet
835780|NCT02934152|Gastroesophageal reflux disease
835781|NCT02934152|Helicobacter pylori
835782|NCT02934139|N91115
835783|NCT02934139|Cavosonstat
835784|NCT02934139|Healthy Volunteer
835785|NCT02934113|weight loss
835786|NCT02934113|text messaging
835787|NCT02934113|workplace
835788|NCT02934113|participatory approach
835789|NCT02934113|health care workers
835790|NCT02934100|Calcaneal spur
835791|NCT02934100|Heel spur
835792|NCT02934100|ESWT
835793|NCT02934100|Extracorporeal shock wave therapy
835794|NCT02934100|ultrasound therapy
835795|NCT02934100|electric field diathermy
835796|NCT02934100|skanlab 25 bodywave
835797|NCT02934100|sham laser therapy
835798|NCT02934087|snare technique
835799|NCT02934087|cannulation of contralateral gate
835800|NCT02934087|endovascular
835801|NCT02934087|aneurysm
835802|NCT02934087|AAA
835803|NCT02934087|Abdominal Aortic Aneurysm
835804|NCT02934074|Limb Loss
835805|NCT02934074|Gait Variability
835806|NCT02934074|Phantom Sensation
835807|NCT02934074|Phantom Pain
835808|NCT02934074|Peripheral Sensation
835809|NCT02934061|Acute low back pain
835810|NCT02934022|Maraviroc
835811|NCT02934022|HAART regimen
835812|NCT02934022|Immunologic response
835813|NCT02933996|immunosuppression
835814|NCT02933996|cardiac sugery
835815|NCT02933996|Transcutaneous electrical acupoint stimulation
835816|NCT02933996|postoperative
835817|NCT02933957|Vascular Evaluation
835818|NCT02933957|influencing factor
835819|NCT02933957|She Minority population
835820|NCT02933944|locally recurrent
835821|NCT02933918|Probiotics
835822|NCT02933918|Nasal Irrigation
835823|NCT02933918|Healthy Volunteers
835824|NCT02933801|metastatic castration resistant prostate cancer (mCRPC)
835825|NCT02933801|Prostate Cancer
835826|NCT02933801|phase II trial
835827|NCT02933801|ODM-201
835828|NCT02933801|maintenance therapy
835829|NCT02933788|cardiovascular disease
835830|NCT02933788|atherosclerosis
835831|NCT02933723|influenza vaccine
835832|NCT02933723|nursing home
835833|NCT02933723|influenza
835834|NCT02933723|vaccination
835835|NCT02933723|immunity
835836|NCT02933723|cell-mediated immunity
835837|NCT02933723|humoral immunity
835841|NCT02933697|Atrial Fibrillation
835842|NCT02933697|Kidney disease
835843|NCT02933697|Anticoagulation
835844|NCT02933671|suprainguinal fascia iliaca (SIFI)
835845|NCT02933671|nerve block
835846|NCT02933645|Insulin
835847|NCT02933645|Intranasal
835848|NCT02933645|Glucose/metabolism
835849|NCT02933645|Glucose homeostasis
835850|NCT02933632|Osteoarthritis
835851|NCT02933632|Physiotherapy
835852|NCT02933632|Rehabilitation
835853|NCT02933632|Clinical Trials
835854|NCT02933632|Accelerated rehabilitation
835855|NCT02933632|Hip Replacement Arthroplasty
835856|NCT02933554|bariatric surgery
835857|NCT02933554|minimally invasive
835858|NCT02933554|Embolization
835859|NCT02933554|NASH
835860|NCT02933554|ghrelin
835861|NCT02933554|gastric artery embolization
835862|NCT02933515|yoga
835863|NCT02933515|occupational therapy
835864|NCT02933515|stroke
835865|NCT02933463|children with high caries risk
835866|NCT02933437|Brugada syndrome
835867|NCT02933437|SCN5A
835868|NCT02933437|SCN10A
835869|NCT02933437|Ajmaline
835870|NCT02933411|Bleeding Disorders
835871|NCT02933411|Heavy Menstrual Bleeding
835872|NCT02933359|cranial vault
835873|NCT02933359|calvarial trauma
835874|NCT02933359|calvarial reconstruction
835875|NCT02933320|Indolent B-cell Lymphoma
835876|NCT02933320|Chronic Lymphocytic Leukaemia
835877|NCT02933320|Waldenström Macroglobulinaemia
835878|NCT02933320|BI-1206
835879|NCT02933320|CD32b
835880|NCT02933294|uniportal
835881|NCT02933294|lung cancer
835882|NCT02933294|VATS
835883|NCT02933268|Autosomal Dominant Polycystic Kidney Disease
835884|NCT02933268|Polycystic Kidney Disease
835885|NCT02933268|ADPKD
835886|NCT02933268|Water
835887|NCT02933268|Vasopressin
835888|NCT02933268|Dietary
835889|NCT02933255|Safety
835890|NCT02933255|Neoadjuvant
835891|NCT02933255|Prostatectomy
835892|NCT02933255|Immunotherapy
835893|NCT02933255|Vaccine
835894|NCT02933242|Cancer
835895|NCT02933216|Cesarean Scar Diverticula
835896|NCT02933177|Dementia
835897|NCT02933177|Alzheimer disease
835898|NCT02933177|Behavioral and Psychological Symptoms of Dementia
835899|NCT02933177|non-drug intervention
835900|NCT02933138|Lipoprotein Lipase
835901|NCT02933138|Hypertriglyceridemia
835902|NCT02933138|Triglycerides
835903|NCT02933138|Lipolysis
835904|NCT02933138|Multifactorial Chylomicronemia
835905|NCT02933125|substance abuse
835906|NCT02933125|group psychotherapy
835907|NCT02933125|family therapy
835908|NCT02933125|longitudinal study
835909|NCT02933125|child and adolescent
835911|NCT02933086|Pregnant
835912|NCT02933086|Low Back Pain
835913|NCT02933086|Postural Control
835914|NCT02933060|intravenous fluid
835915|NCT02933060|headache
835916|NCT02933047|Hysterectomy
835917|NCT02933047|Patient satisfaction
835918|NCT02933047|Rehabilitation
835919|NCT02933047|Laparoscopy
835920|NCT02933047|Return to work
835921|NCT02933047|Exercise
835922|NCT02933034|ISCHEMIC OR CORONARY HEART DISEASE
835923|NCT02933034|MYOCARDIAL INFARCTION
835924|NCT02933034|MAGNETIC RESONANCE IMAGING
835925|NCT02933034|DELAYED GADOLINIUM ENHANCEMENT MRI
835926|NCT02933034|MANGANESE-ENHANCED MRI
835927|NCT02933034|INFARCT VOLUME/SIZE
835928|NCT02933034|ALL CAUSE MORTALITY
835929|NCT02933034|VENTRICULAR ARRHYTHMIAS
835931|NCT02933008|ACL
835932|NCT02933008|biofeedback
835933|NCT02933008|injury prevention
835934|NCT02933008|virtual reality
835935|NCT02932995|Optical Coherence Tomography
835936|NCT02932995|Drug-Eluting Stent
835937|NCT02932982|primary care
835938|NCT02932982|chest pain
835939|NCT02932982|dyspnea
835940|NCT02932956|GPC3-Positive Solid Tumors
835941|NCT02932956|GPC3-CAR T cells
835942|NCT02932956|GPC3
835943|NCT02932956|Glypican
835944|NCT02932930|QLB
835945|NCT02932930|Abdominoplasty
835946|NCT02932930|Quadratus lumborum block
835947|NCT02932904|Drug therapy
835948|NCT02932865|azoospermia
835949|NCT02932865|male fertility
835950|NCT02932865|MD-TESE
835951|NCT02932865|miRNA
835952|NCT02932865|piRNA
835953|NCT02932865|male infertility
835954|NCT02932852|stem cell
835955|NCT02932852|mesenchymal
835956|NCT02932852|ADASc
835957|NCT02932852|transplantation
835958|NCT02932852|cornea
835959|NCT02932852|corneal defects
835960|NCT02932852|keratoconus
835961|NCT02932852|scaffold
835962|NCT02932852|lamina
835963|NCT02932839|Epilepsy surgery
835964|NCT02932839|Micro-electrode arrays
835965|NCT02932839|Single-neuron recordings
835966|NCT02932839|Electrocorticography
835967|NCT02932826|Autoimmune Diabetes
835968|NCT02932826|Umbilical Cord Blood Cell
835969|NCT02932826|Regulatory T Lymphocyte
835970|NCT02932826|Cell Therapy
835971|NCT02932800|Catheters
835972|NCT02932800|Vascular Access Devices
835973|NCT02932800|Suture Techniques
835974|NCT02932800|microbiota
835975|NCT02932800|Blood Circulation
835976|NCT02932774|SAR
835977|NCT02932774|seasonal allergic rhinitis
835978|NCT02932774|hay fever
835979|NCT02932774|seasonal allergic rhinoconjunctivitis
835980|NCT02932761|cesarean scar diverticula
835981|NCT02932761|vaginal repair
835982|NCT02932761|GnRHa
835983|NCT02932722|Propofol
835984|NCT02932722|Sevoflurane
835985|NCT02932722|Preconditioning
835986|NCT02932709|Emergency
835987|NCT02932709|follow-up
835988|NCT02932709|nurse
835989|NCT02932709|phone
835990|NCT02932709|suicide attempts
835991|NCT02932683|Resuscitation
835992|NCT02932683|Neonatal
835993|NCT02932683|Education
835994|NCT02932644|Rheumatoid Arthritis
835995|NCT02932644|Cardiovascular event
835996|NCT02932644|Cardiovascular mortality
835997|NCT02932644|Vitamin D
835998|NCT02932631|hemiparesis
835999|NCT02932631|STROKE
836000|NCT02932631|neural plasticity
836001|NCT02932631|PHYSICAL THERAPY
836002|NCT02932605|Schizophrenia
836003|NCT02932605|Cannabidiol
836004|NCT02932605|Positron Emission Tomography (PET)
836005|NCT02932605|Microglia
836006|NCT02932566|Heart failure
836007|NCT02932566|Heart failure with preserved ejection fraction (HFpEF)
836008|NCT02932566|Myocardial fibrosis
836009|NCT02932566|Extracellular volume fraction (ECV)
836010|NCT02932566|Interstitial fibrosis
836011|NCT02932553|bioresorbable vascular scaffold
836012|NCT02932553|variant angina
836013|NCT02932553|moderate coronary artery disease
836014|NCT02932553|vasospastic angina
836015|NCT02932527|cannabis
836016|NCT02932501|Bisphosphonate
836017|NCT02932501|Jaw
836018|NCT02932501|Osteonecrosis
836019|NCT02932501|Antiresorptive drugs
836020|NCT02932501|Denosumab
836021|NCT02932488|PET-MR
836022|NCT02932488|5-HT1B receptor
836023|NCT02932488|Sumatriptan
836024|NCT02932488|phMRI
836025|NCT02932488|[11C]AZ10419369
836026|NCT02932436|empagliflozin
836027|NCT02932436|diastolic function
836028|NCT02932436|poorly controlled type 2 diabetes mellitus
836029|NCT02932423|Sugar-sweetened beverage
836030|NCT02932423|Overweight
836031|NCT02932423|Obese
836032|NCT02932423|Sugar
836033|NCT02932423|Water
836034|NCT02932397|Ambulatory surgery
836035|NCT02932397|Perioperative outcomes
836036|NCT02932397|General anesthesia under desflurane
836037|NCT02932397|Prevention of coughing
836038|NCT02932397|Propofol
836039|NCT02932384|HIV
836040|NCT02932384|Black/African American
836041|NCT02932384|Men
836042|NCT02932384|Gay/bisexual
836043|NCT02932384|Los Angeles
836044|NCT02932371|Cardiac output
836045|NCT02932358|Intensive care units
836046|NCT02932358|Delirium
836047|NCT02932358|Cross infection
836048|NCT02932358|Mortality
836049|NCT02932358|Length of stay
836050|NCT02932358|Burnout, Professional
836051|NCT02932358|Depression
836052|NCT02932358|Anxiety
836053|NCT02932345|EGFR mutation; non-small-cell lung cancer;
836054|NCT02932332|shortness of breath
836055|NCT02932332|oxygen
836056|NCT02932332|breathing therapies
836057|NCT02932319|induction of labour
836058|NCT02932319|nulliparous
836059|NCT02932319|prolonged pregnancy
836060|NCT02932319|foley catheter
836061|NCT02932319|vaginal birth
836062|NCT02932280|Recurrent
836063|NCT02932280|Refractory Disease
836064|NCT02932280|Neratinib
836065|NCT02932280|16-878
836066|NCT02932267|Acne
836067|NCT02932267|Dark skin
836068|NCT02932254|Physiological Effects of Drugs
836069|NCT02932254|Rocuronium
836070|NCT02932254|Sugammadex sodium
836071|NCT02932254|Magnesium
836072|NCT02932254|Neuromuscular block, antagonism
836073|NCT02932215|mobile health device
836074|NCT02932215|substance abuse treatment
836075|NCT02932215|quality of life
836076|NCT02932215|lorcaserin
836077|NCT02932202|Obesity
836078|NCT02932202|Pregnancy
836079|NCT02932202|Weight Gain
836080|NCT02932189|Mechanical Ventilator Weaning
836081|NCT02932189|Respiratory Muscle Training
836082|NCT02932189|Mortality Rate
836083|NCT02932176|Arteries
836084|NCT02932163|Chronic low back pain
836085|NCT02932163|disability
836086|NCT02932163|endurance
836089|NCT02932137|SLE,IL-2
836090|NCT02932124|German Resuscitation Registry
836091|NCT02932124|out-of-hospital cardiac arrest
836092|NCT02932124|cardiopulmonary resuscitation
836093|NCT02932124|mechanical chest compression devices
836094|NCT02932111|IBS
836095|NCT02932111|Osteopathic manipulative treatment
836096|NCT02932111|pain
836097|NCT02932085|Transcranial magnetic stimulation
836098|NCT02932085|Magnetic resonance imaging
836099|NCT02932085|Magnetic resonance spectroscopy
836100|NCT02932059|Metamemory
836101|NCT02932059|Schizophrenia
836102|NCT02932059|Aging
836103|NCT02932059|Learning
836104|NCT02932059|Judgement of learning
836105|NCT02932059|Sentence construction strategy
836106|NCT02932046|eating disorders
836107|NCT02932046|anorexia nervosa
836108|NCT02932046|appetite
836109|NCT02932020|disc herniation
836110|NCT02932020|spinal stenosis
836111|NCT02932007|persistent
836112|NCT02932007|longstanding persistent
836113|NCT02931994|dental floss
836114|NCT02931994|gingival embrasure
836115|NCT02931994|oral hygiene
836116|NCT02931981|DKK4
836117|NCT02931981|Gastrointestinal Stromal Tumor
836118|NCT02931981|Biomarker
836119|NCT02931968|Monolithic Zirconia
836120|NCT02931968|Implant supported prosthesis
836121|NCT02931968|Fixed partial denture
836122|NCT02931955|allergy
836123|NCT02931955|insect venom
836124|NCT02931955|pollen
836125|NCT02931955|systems biology
836126|NCT02931942|AA
836127|NCT02931916|smart-phone
836128|NCT02931916|assessment
836129|NCT02931916|chronic ankle instability
836130|NCT02931903|implant supported restorations
836131|NCT02931903|IPS Emax (lithium disilicate glass-ceramic)
836132|NCT02931903|Vita Enamic (hybrid dental ceramic)
836133|NCT02931903|implant survival
836134|NCT02931903|peri-implant tissue response
836135|NCT02931890|gastric cancer
836136|NCT02931890|radiotherapy
836137|NCT02931890|chemoradiotherapy
836138|NCT02931877|Sevoflurane
836139|NCT02931877|Propofol
836140|NCT02931877|Cardiac valvular surgery
836141|NCT02931877|Cardiopulmonary bypass
836142|NCT02931877|Postoperative cognitive dysfunction
836143|NCT02931825|high risk
836144|NCT02931825|surveillance
836145|NCT02931825|screening
836146|NCT02931825|colonoscopy
836147|NCT02931812|cirrhosis
836148|NCT02931812|reward system
836149|NCT02931812|taste sensitivity
836150|NCT02931812|chronic renal failure
836151|NCT02931799|Colitis, Ulcerative
836152|NCT02931799|Crohn Disease
836153|NCT02931799|Inflammatory Bowel Diseases
836154|NCT02931799|Gastroenterology
836155|NCT02931799|Quality Improvement
836156|NCT02931799|Post-Discharge
836157|NCT02931786|core body temperature
836158|NCT02931786|magnetic resonance imaging
836159|NCT02931786|propofol
836160|NCT02931786|ketofol
836161|NCT02931773|Diabetes Autonomic Cardiovascular
836162|NCT02931747|Bacopa Monnieri
836163|NCT02931747|Working memory
836164|NCT02931747|Cognitive processing
836165|NCT02931747|Student
836166|NCT02931721|Azospermia
836167|NCT02931721|Micro Dissection Testicular Sperm Extraction
836168|NCT02931721|Male infertility
836169|NCT02931721|Testis
836170|NCT02931721|MRI
836171|NCT02931708|Heart Failure
836172|NCT02931708|Diaphragm
836173|NCT02931708|Electrical Stimulation
836174|NCT02931695|post partum
836175|NCT02931682|Creatine transporter
836176|NCT02931682|developmental delay
836177|NCT02931682|intellectual disability
836178|NCT02931682|X-linked
836179|NCT02931682|language
836180|NCT02931682|seizure
836181|NCT02931682|observational
836182|NCT02931682|brain spectroscopy
836183|NCT02931656|Gestational Diabetes
836184|NCT02931643|Spices
836185|NCT02931643|Functional food
836186|NCT02931643|Cardiometabolic risk
836187|NCT02931643|Metabolic syndrome
836188|NCT02931643|Inflammation
836189|NCT02931643|Peripheral blood mononuclear cell
836190|NCT02931643|Acute
836191|NCT02931643|miRNA
836192|NCT02931630|Whey protein
836193|NCT02931630|Dietary fibers
836194|NCT02931630|Wheat bran
836195|NCT02931630|Arabinoxylan
836196|NCT02931630|Postprandial lipaemia
836197|NCT02931630|Body composition
836198|NCT02931630|Blood pressure
836199|NCT02931630|Metabolic rate
836200|NCT02931630|Insulin sensitivity
836201|NCT02931630|Metabolic syndrome
836202|NCT02931604|sinus wash
836203|NCT02931604|sinus lavage
836204|NCT02931604|Sinusitis
836205|NCT02931591|Small for gestational age
836206|NCT02931591|insulin sensitivity
836207|NCT02931591|IGF-1 response
836208|NCT02931591|growth hormone treatment
836209|NCT02931578|glycemic index
836210|NCT02931552|Breast cancer
836211|NCT02931552|Latinas
836212|NCT02931552|Peer support counselor
836213|NCT02931552|Spanish speaking
836214|NCT02931552|Community based
836215|NCT02931552|Rural
836216|NCT02931526|Tigecycline
836217|NCT02931526|Continuous Renal Replacement Therapy
836218|NCT02931526|Pharmacokinetics
836221|NCT02931474|Growth Hormone
836222|NCT02931474|Traumatic Brain Injury
836223|NCT02931474|Insomnia
836224|NCT02931474|Polysomnography
836225|NCT02931474|NREM Sleep
836226|NCT02931461|endobronchial transbronchial needle aspiration lung cancer procore
836227|NCT02931448|Device assessment
836228|NCT02931435|Genicular Radiofrequency Ablation
836229|NCT02931435|Knee Arthroplasty, Total
836230|NCT02931422|HIV
836231|NCT02931422|financial incentive
836232|NCT02931422|pediatric HIV testing
836233|NCT02931409|Positive end-expiratory pressure
836234|NCT02931409|Static pulmonary compliance
836235|NCT02931409|Lung Protective Ventilation
836236|NCT02931409|Radical cystectomy and urinary diversion
836237|NCT02931409|Postoperative pulmonary complications
836238|NCT02931409|Procalcitonin
836239|NCT02931383|Liraglutide
836240|NCT02931383|Liraglutide 3 mg
836241|NCT02931383|Osteoarthritis
836242|NCT02931383|Obesity
836243|NCT02931383|Ultrasound
836244|NCT02931370|Osteoarthritis
836245|NCT02931370|Obesity
836246|NCT02931370|Ultrasound
836247|NCT02931370|Liraglutide
836248|NCT02931370|Liraglutide 3mg
836249|NCT02931357|Treatment of teething in infants
836250|NCT02931344|Osteoarthrtis
836251|NCT02931344|Obesity
836252|NCT02931344|Liraglutide 3 mg
836253|NCT02931344|Liraglutide
836254|NCT02931344|Biomarkers
836255|NCT02931318|Organ donation
836256|NCT02931318|brain death
836257|NCT02931318|public opinion
836258|NCT02931305|Epimedium prenylflavonoids
836259|NCT02931305|Osteoporosis
836260|NCT02931305|Cardiovascular diseases
836261|NCT02931305|Phase 1
836262|NCT02931305|safety
836263|NCT02931305|tolerability
836264|NCT02931292|sleeve gastrectomy
836265|NCT02931292|laparoscopy
836266|NCT02931292|bariatric surgery
836267|NCT02931292|obesity surgery
836268|NCT02931292|metabolic surgery
836269|NCT02931214|Healthy Subjects
836270|NCT02931214|Pharmacokinetics
836271|NCT02931214|Pharmacodynamics
836272|NCT02931201|Positron-Emission Tomography
836273|NCT02931201|Prognosis
836274|NCT02931188|Vascular Diseases
836275|NCT02931188|Lipids
836276|NCT02931188|Cholesteryl Ester Transfer Protein (CETP) Inhibition
836277|NCT02931188|Anacetrapib
836278|NCT02931188|Cardiovascular Disease
836279|NCT02931188|Cholesterol
836280|NCT02931175|ACTH gel
836281|NCT02931175|Non-Infectious Uveitis
836282|NCT02931175|ACTHAR
836283|NCT02931175|Posterior Uveitis
836284|NCT02931175|Intermediate Uveitis
836285|NCT02931175|Pan Uveitis
836286|NCT02931175|Uveitis
836287|NCT02931149|platelet-rich plasma
836288|NCT02931149|endoscopic mucosal resection
836289|NCT02931149|endoscopic submucosal dissection
836290|NCT02931110|Diffuse large B-cell lymphoma (DLBCL)
836291|NCT02931110|follicular lymphoma (FL)
836292|NCT02931110|mantle cell lymphoma (MCL)
836293|NCT02931110|Hodgkin lymphoma (HL)
836294|NCT02931097|Parkinson's disease
836295|NCT02931097|Deep brain stimulation
836296|NCT02931097|Mesencephalic locomotor region
836297|NCT02931058|Knee-extension exercise
836298|NCT02931058|Quadriceps exercise
836299|NCT02931058|Knee osteoarthritis
836300|NCT02931058|Exercise adherence
836301|NCT02931058|Dose-response relationship
836302|NCT02931058|Prehabilitation
836303|NCT02931045|extracellular vesicles
836304|NCT02931045|inflammation
836305|NCT02931045|thrombosis
836306|NCT02931045|antiplatelet drugs
836307|NCT02931032|nano receptor
836308|NCT02931032|oral microbiology
836309|NCT02931032|dental caries
836310|NCT02931032|periodontal disease
836311|NCT02931019|fiberoptic
836312|NCT02931019|intubation
836313|NCT02931019|posture
836314|NCT02930954|NSCLC, EGFR, Bim, mutation abundance
836315|NCT02930941|tranexamic acid
836316|NCT02930941|epistaxis
836317|NCT02930941|emergency medicine
836318|NCT02930941|intranasal
836319|NCT02930941|TXA
836320|NCT02930928|Anaesthesia
836321|NCT02930928|Anthropometry
836322|NCT02930928|Body weight and measures
836323|NCT02930928|Development
836324|NCT02930928|Emergency treatment
836325|NCT02930928|Patient safety
836326|NCT02930915|Head and Neck Cancer
836327|NCT02930915|Radiotherapy
836328|NCT02930902|Pancreatic Cancer
836329|NCT02930902|Pembrolizumab
836330|NCT02930902|MK3475
836331|NCT02930902|Paricalcitol
836332|NCT02930902|Zemplar
836333|NCT02930902|Gemcitabine
836334|NCT02930902|Hydrochloride Gemzar
836335|NCT02930902|Nab-paclitaxel
836336|NCT02930902|Paclitaxel
836337|NCT02930902|Abraxane
836338|NCT02930902|ABI-007
836339|NCT02930902|Resectable Pancreatic Cancer
836340|NCT02930889|Therapeutic Embolization
836341|NCT02930889|Prostatic Artery Embolization
836342|NCT02930876|sarcopenia
836343|NCT02930876|cancer
836344|NCT02930876|chemotherapy
836345|NCT02930876|palliative care
836346|NCT02930876|resistance training
836347|NCT02929797|pancreatic cancer
836348|NCT02929784|Hemiplegic Shoulder Pain
836349|NCT02929784|transcranial Direct Current Stimulation
836350|NCT02929784|Stroke
836351|NCT02929771|Virtual Reality
836352|NCT02929771|Subcutaneous Port Sampling
836353|NCT02929771|Pain
836354|NCT02929771|Children
836355|NCT02929745|immunology, genetics
836356|NCT02929667|Fluoxetine
836357|NCT02929641|Optical Enhancement technology
836358|NCT02929641|coloractal polyp prediction
836359|NCT02930733|Postoperative Analgesia
836360|NCT02930733|Ultrasound guided serratus plane block
836361|NCT02930720|TAUS
836362|NCT02930720|breathing protocols and cough
836363|NCT02930720|pelvic floor displacement
836364|NCT02930720|women
836365|NCT02930720|SUI
836366|NCT02930707|magnesium sulfate
836367|NCT02930707|postoperative pain
836368|NCT02930707|TAP block
836369|NCT02930707|total abdominal hysterectomy
836370|NCT02930655|Fabry disease
836371|NCT02930655|lucerastat
836372|NCT02930642|Mindfulness
836373|NCT02930642|Obesity
836374|NCT02930642|Food insecurity
836375|NCT02930642|Delay discounting
836376|NCT02930629|Recovery Period, Anesthesia
836377|NCT02930629|Neuromuscular Monitoring
836378|NCT02930603|Developmental Disabilities
836379|NCT02930603|Body function and body structure
836380|NCT02930603|Participation
836381|NCT02930603|Life activities
836382|NCT02930603|Quality of Life
836383|NCT02930577|treatment adherence
836384|NCT02930577|outpatient treatment
836385|NCT02930577|drug dependence
836386|NCT02930525|apnea
836387|NCT02930525|children
836388|NCT02930525|hypercarbia
836389|NCT02930525|procedural sedation
836390|NCT02930525|HFNC
836391|NCT02930512|Bone mineral density
836392|NCT02930512|Osteoporosis
836393|NCT02930512|Parkinson's disease
836394|NCT02930512|Bone turnover markers
836395|NCT02930486|Syndesmosis
836396|NCT02930486|Injury
836397|NCT02930486|Ankle
836398|NCT02930486|Fracture
836399|NCT02930486|Weber C
836400|NCT02930473|Psychotherapy
836401|NCT02930473|Nursing
836402|NCT02930473|Nursing Care
836403|NCT02930473|Nursing Model
836404|NCT02930473|Randomised Controlled Trial
836405|NCT02930434|Vitamin D
836406|NCT02930434|cholecalciferol
836407|NCT02930434|Antarctica
836408|NCT02930434|Chile
836409|NCT02930434|cathelicidin
836410|NCT02930434|bone metabolism
836411|NCT02930434|cardiovascular risk
836412|NCT02930421|mild COPD
836413|NCT02930421|Exercise training
836414|NCT02930421|Six minute walking distance
836415|NCT02930421|Quality of life
836416|NCT02930421|Saint George Respiratory Questionnaire (SGRQ)
836417|NCT02930395|Concussion
836418|NCT02930395|Professional rugby players
836419|NCT02930395|S100B
836420|NCT02930330|Exercise
836421|NCT02930330|Interval training
836422|NCT02930330|Blood platelets
836423|NCT02930330|Platelet function tests
836424|NCT02930330|Physical fitness
836425|NCT02930330|Rehabilitation
836426|NCT02930304|tennis elbow
836427|NCT02930304|pain
836428|NCT02930304|shock wave
836429|NCT02930304|kinesio taping
836430|NCT02930252|Self-expandable metal stent
836431|NCT02930252|strictures
836432|NCT02930252|biliary
836433|NCT02930239|ACL-reconstruction
836434|NCT02930239|Gait rehabilitation
836435|NCT02930239|Anti Gravity treadmill
836436|NCT02930239|ACL-rehabilitation
836437|NCT02930213|unresponsive wakefulness syndrome
836438|NCT02930213|minimally conscious state
836439|NCT02930213|circadian rhythms
836440|NCT02930213|free-running period
836441|NCT02930200|Smoking Cessation
836442|NCT02930200|Smartphone Based Smoking Cessation
836443|NCT02930187|Rheumatoid arthritis, remission, ultrasound
836444|NCT02930161|Nonalcoholic Fatty Liver Disease
836445|NCT02930161|Nonalcoholic Steatohepatitis
836446|NCT02930161|Methionine
836447|NCT02930161|Succinic acid
836448|NCT02930148|mHealth
836449|NCT02930148|adolescents
836450|NCT02930148|quasi-experimental study
836451|NCT02930148|apps
836452|NCT02930148|lifestyles
836453|NCT02930148|lifestyles knowledge
836454|NCT02930148|dietary behaviour
836455|NCT02930148|physical activity
836456|NCT02930148|sleeping behaviour
836457|NCT02930135|Indirect Pulp Capping, Young Permanent Molars
836458|NCT02930070|sepsis
836459|NCT02930070|qSOFA
836460|NCT02930070|SOFA
836461|NCT02930070|diagnostic accuracy
836462|NCT02930057|lumbar dorsal root ganglion
836463|NCT02930057|transforaminal epidural steroid injection
836464|NCT02930057|chronic lumbosacral radicular pain
836465|NCT02930057|pulsed radiofrequency treatment
836466|NCT02930057|betamethasone
836467|NCT02930057|dorsal root ganglion
836468|NCT02930044|Emergency department
836469|NCT02930044|Insulin
836470|NCT02930044|Adult
836471|NCT02930031|muscle injury
836472|NCT02930031|exercise
836473|NCT02930031|redox status
836474|NCT02930031|immune cells
836475|NCT02930018|Acute Ischemic Stroke
836476|NCT02930018|Endovascular Thrombectomy
836477|NCT02930018|Neuroprotection
836478|NCT02930018|Tat-NR2B9c
836479|NCT02930018|NA-1
836480|NCT02930005|Psychotic
836481|NCT02930005|Schizophrenia
836482|NCT02930005|Schizoaffective
836483|NCT02930005|Bipolar
836484|NCT02929979|PTSD
836485|NCT02929979|Alcohol Use Disorder
836486|NCT02929979|Cognitive Training
836487|NCT02929979|Veterans
836488|NCT02929953|premature birth
836489|NCT02929953|risk factor
836490|NCT02929953|type 1 diabetes mellitus
836491|NCT02929953|seasonality
836492|NCT02929953|prevalence
836493|NCT02929953|enteral feeding
836494|NCT02929953|immunomodulating medications
836495|NCT02929953|early onset
836496|NCT02929927|PDT
836497|NCT02929914|Carious dentin
836498|NCT02929914|Photodynamic Therapy
836499|NCT02929888|ST-segment elevacion myocardial infarction, platelets
836500|NCT02929836|Ablation Linear Lesions
836501|NCT02929602|prescribing
836502|NCT02929602|effectiveness
836503|NCT02929602|dental
836504|NCT02929602|opioid
836505|NCT02929602|analgesic
836506|NCT02929576|metastatic
836507|NCT02929576|triple negative
836508|NCT02929550|Cardiovascular disease
836509|NCT02929550|Costs
836510|NCT02929550|Guidelines
836511|NCT02929550|Lipids
836512|NCT02929550|Myocardial infarction
836513|NCT02929537|Pulmonary Disease, Chronic Obstructive
836514|NCT02929537|registration research
836515|NCT02929537|Medicine, Chinese Traditional
836516|NCT02929524|Ketamine
836517|NCT02929524|Intranasal administration
836518|NCT02929524|Pediatric nursing
836519|NCT02929498|GSK2879552
836520|NCT02929498|Revised International Prognostic Scoring System (IPSS-R)
836521|NCT02929498|azacitidine
836522|NCT02929498|hypomethylating agents
836523|NCT02929498|myelodysplastic syndrome
836524|NCT02929472|Physical Activity
836525|NCT02929472|Physical Fitness
836526|NCT02929472|Intervention
836527|NCT02929472|Children and Adolescents
836528|NCT02929459|Gut Microbiota
836529|NCT02929459|Riboflavin
836530|NCT02929459|Vitamin B2
836531|NCT02929459|oGTT
836532|NCT02929459|Faecalibacterium prausnitzii
836533|NCT02929446|mobilisation
836534|NCT02929446|physiotherapy
836535|NCT02929433|disability
836536|NCT02929433|pain
836537|NCT02929433|Rotator Cuff Tear
836538|NCT02929433|rehabilitation
836539|NCT02929433|range of motion (ROM)
836540|NCT02929420|Multicenter
836541|NCT02929420|randomized
836542|NCT02929420|open
836543|NCT02929420|parallel controlled
836544|NCT02929394|Histologically proven locally advanced or metastatic high grade STS (excluding histologies insensitive to chemotherapy such as ASPS, PECOMA subtypes)
836545|NCT02929381|Narrow Band Imaging
836546|NCT02929381|Colorectal Cancer Screening
836547|NCT02929381|Colonoscopy
836548|NCT02929381|Responsive Insertion Technology
836549|NCT02929381|Near Focus
836550|NCT02929368|PICC-Line
836551|NCT02929355|Carotid atherosclerosis
836552|NCT02929355|duplex ultrasonography
836553|NCT02929355|diabetes
836554|NCT02929355|vascular events
836555|NCT02929277|farm children
836556|NCT02929277|non-farm children
836557|NCT02929264|Healthy volunteer
836558|NCT02929264|Experimental hyperalgesia
836559|NCT02929264|fMRI
836560|NCT02929225|bacterial translocation;micro-inflammation;hemodialysis
836561|NCT02929212|Gastric Bypass
836562|NCT02929212|Meal Texture
836563|NCT02929212|Meal Number
836564|NCT02929212|GLP-1
836565|NCT02929212|Glucose
836566|NCT02929134|Lymphedema
836567|NCT02929134|Lymphatic Filariasis
836568|NCT02929134|Filariasis
836569|NCT02929134|Doxycycline
836570|NCT02929121|Lymphedema
836571|NCT02929121|Lymphatic Filariasis
836572|NCT02929121|Filariasis
836573|NCT02929121|Doxycycline
836574|NCT02929108|hospice
836575|NCT02929108|caregiver
836576|NCT02929082|magnetic resonance force
836577|NCT02929069|Minority Stress
836578|NCT02929017|Idiopathic Pulmonary Fibrosis
836579|NCT02929017|Fibrosis
836580|NCT02929017|IPF
836581|NCT02929017|Caregivers
836582|NCT02929017|Pulmonary
836583|NCT02929017|Palliative
836584|NCT02929017|end of life
836585|NCT02929017|Idiopathic
836586|NCT02929004|Anterior Cruciate Ligament Reconstruction
836587|NCT02929004|Local vibration training
836588|NCT02929004|Ligamentoplasty
836589|NCT02929004|Anterior cruciate ligament
836590|NCT02929004|Corticospinal excitability
836591|NCT02929004|Elastography
836592|NCT02929004|Knee extensor muscles
836593|NCT02929004|Readaptation
836594|NCT02928991|Acquired aplastic anemia
836595|NCT02928991|Inherited bone marrow failure
836596|NCT02928978|Premalignant Breast Disease
836597|NCT02928978|ALH
836598|NCT02928978|ADH
836599|NCT02928978|DCIS
836600|NCT02928978|LCIS
836601|NCT02928978|Breast Cancer Prevention
836602|NCT02928978|Ruxolitinib
836603|NCT02928965|psychosis
836604|NCT02928965|schizophrenia
836605|NCT02928965|negative symptoms
836606|NCT02928965|minocycline
836607|NCT02928952|Mindfulness
836608|NCT02928939|multimorbidity
836609|NCT02928939|multiple chronic conditions
836610|NCT02928939|drug-drug interactions
836611|NCT02928939|drug-disease interactions
836612|NCT02928939|polypharmacy
836613|NCT02928939|Oral anticoagulants
836614|NCT02928939|Steroids
836615|NCT02928913|sedentary
836616|NCT02928913|non-sedentary
836617|NCT02928913|populations
836618|NCT02928900|Adolescents
836619|NCT02928900|Clinical training
836620|NCT02928900|HIV care and treatment
836621|NCT02928900|Africa
836622|NCT02928861|Positron-Emission Tomography
836623|NCT02928861|Prognosis
836624|NCT02928835|Total knee arthroplasty
836625|NCT02928835|Knee flexion
836626|NCT02928835|Dynamic orthosis
836627|NCT02928822|stroke
836628|NCT02928822|broca's aphasia
836629|NCT02928822|priming
836630|NCT02928822|Intensive language-action therapy
836631|NCT02928822|Rehabilitation gaming system
836632|NCT02928809|temporomandibular joint
836633|NCT02928809|temporomandibular disorder
836634|NCT02928809|muscle fatigue
836635|NCT02928809|low-level laser therapy
836636|NCT02928796|Attentional capacity
836637|NCT02928796|Working memory
836638|NCT02928796|Simulation-based training
836639|NCT02928796|Eye-tracking
836640|NCT02928796|Visual attention
836641|NCT02928796|Psychophysiological measurement
836642|NCT02928796|Surgical simulation
836643|NCT02928796|Computer-based simulation
836644|NCT02928783|Home-based cardiac rehabilitation
836645|NCT02928783|Quality of Medical Care
836646|NCT02928783|Heart Failure
836647|NCT02928757|Care coordination
836648|NCT02928757|Complex care kids Ontario
836649|NCT02928757|Technology-dependent
836650|NCT02928757|Quality of life
836651|NCT02928744|Resistance
836652|NCT02928744|Forced oscillations
836653|NCT02928744|Dyspnea
836654|NCT02928731|Cancer
836655|NCT02928731|Quality of life
836656|NCT02928731|Child
836657|NCT02928718|Post-ERCP pancreatitis
836658|NCT02928718|Genetic variation
836659|NCT02928705|analgesia
836660|NCT02928705|prehospital
836661|NCT02928705|telemedicine
836662|NCT02928705|ambulance
836663|NCT02928705|opioids
836664|NCT02928705|teleconsultation
836665|NCT02928705|tele-emergency medical services
836666|NCT02928705|adverse events
836667|NCT02928705|prehospital emergency medical service physician
836668|NCT02928692|Minocycline
836669|NCT02928692|Postoperative cognitive dysfunction
836670|NCT02928692|Postoperative delirium
836671|NCT02928679|Magnetic resonance imaging
836672|NCT02928679|Dynamic contrast enhanced MRI
836673|NCT02928679|Liraglutide 3 mg
836674|NCT02928679|Liraglutide
836675|NCT02928679|Obesity
836676|NCT02928679|Osteoarthritis
836677|NCT02928666|decision-support
836678|NCT02928666|ontology
836679|NCT02928666|computer-interpretable guidelines
836680|NCT02928666|comorbidities
836681|NCT02928653|energy intake
836682|NCT02928653|energy expenditure
836683|NCT02928653|appetite
836684|NCT02928614|Osteoarthritis
836685|NCT02928614|Obesity
836686|NCT02928614|Liraglutide 3 mg
836687|NCT02928614|Liraglutide
836688|NCT02928614|Biomarkers
836689|NCT02928575|Glioblastoma
836690|NCT02928575|Sunitinib
836691|NCT02928575|Temozolomide
836692|NCT02928575|Radiation Therapy,
836693|NCT02928575|MGMT
836694|NCT02928575|Biomarkers
836695|NCT02928549|interviews
836696|NCT02928549|16-1378
836697|NCT02928523|Autologous Fecal Microbiota Transplantation
836698|NCT02928497|Non-valvular atrial fibrillation
836699|NCT02928497|Left atrial appendage
836700|NCT02928484|Functional dyspepsia
836701|NCT02928484|Abdominal pain
836702|NCT02928484|Flatulence
836703|NCT02928484|Probiotics
836704|NCT02928484|Bifidobacterium
836705|NCT02928484|Lactobacillus
836706|NCT02928471|Liraglutide
836707|NCT02928471|Liraglutide 3 mg
836708|NCT02928471|Osteoarthritis
836709|NCT02928471|Obesity
836710|NCT02928471|Magnetic resonance imaging
836711|NCT02928471|Computed tomography
836712|NCT02928471|Dynamic contrast enhanced MRI
836713|NCT02928445|Dementia with Lewy bodies
836714|NCT02928445|dementia
836715|NCT02928445|RVT-101
836716|NCT02928445|intepirdine
836717|NCT02928445|Lewy bodies
836718|NCT02928432|Castration-Resistant Prostate Cancer
836719|NCT02928432|Abiraterone acetate
836720|NCT02928432|Steroids Switch
836721|NCT02928354|Asthma
836722|NCT02928354|Chronic obstructive pulmonary disease (COPD)
836723|NCT02928354|Healthy volunteers
836724|NCT02928354|Pharmacokinetics (PK)
836725|NCT02928354|Bioavailability
836726|NCT02928354|AZD7594
836727|NCT02928354|Safety
836728|NCT02928354|Tolerability
836729|NCT02928328|craniofacial pain
836730|NCT02928328|masticatory muscle
836731|NCT02928328|burning mouth syndrome
836732|NCT02928328|temporomandibular disorders
836733|NCT02928276|Rheumakit
836734|NCT02928276|Rheumatoid Arthritis
836735|NCT02928276|anti-TNF
836736|NCT02928237|tDCS
836737|NCT02928237|cancer liver
836738|NCT02928237|chronic abdominal pain
836739|NCT02928237|VAS
836740|NCT02928237|VDS
836741|NCT02928237|HAM-D
836742|NCT02928237|BPI
836743|NCT02928237|analgesia
836744|NCT02928224|Colorectal cancer
836745|NCT02928224|BRAF
836746|NCT02928224|BRAFV600E
836747|NCT02928198|Tomography, Optical Coherence
836748|NCT02928198|Percutaneous Coronary Intervention
836749|NCT02928198|Cardiac Catheterization
836750|NCT02928198|Coronary Biovascular Scaffold
836751|NCT02928185|training manuals
836752|NCT02928185|patients and caregivers
836753|NCT02928185|16-1334
836754|NCT02928172|q-CON
836755|NCT02928172|q-NOX
836756|NCT02928172|BIS
836757|NCT02928172|Electroencephalograms (EEG)
836758|NCT02928172|Laryngeal Mask Airway (LMA)
836759|NCT02928172|Sedation
836760|NCT02928172|General Anesthesia
836761|NCT02928159|Low Pulse Amplitude Seizure Therapy
836762|NCT02928159|Electroconvulsive Therapy
836763|NCT02928159|Low Pulse Amplitude Electroconvulsive Therapy
836764|NCT02928159|Low Pulse Amplitude ECT
836765|NCT02928159|LAP
836766|NCT02928159|LAP-ST
836767|NCT02928159|ECT
836768|NCT02928159|Mood disorders
836769|NCT02928159|Psychotic disorders
836770|NCT02928146|TAPP
836771|NCT02928146|TEP
836772|NCT02928146|Lichtenstein
836773|NCT02928146|syntethic mesh
836774|NCT02928146|hernioplasty
836775|NCT02928133|Non-vitamin K antagonist oral anticoagulant (NOAC)
836776|NCT02928133|Congenital heart disease
836777|NCT02928133|Atrial fibrillation
836778|NCT02928133|Atrial tachyarrhythmia
836779|NCT02928133|Thromboembolism
836780|NCT02928094|refractory angina
836781|NCT02928094|myocardial ischemia
836782|NCT02928094|angiogenesis
836783|NCT02928068|telehealth
836784|NCT02928055|Stroke
836785|NCT02928055|Shoulder Pain
836786|NCT02928055|Electrical stimulation
836787|NCT02928055|Neuromuscular stimulation
836788|NCT02928055|Intramuscular stimulation
836789|NCT02928029|Radium-223 dichloride
836790|NCT02928029|bortezomib
836791|NCT02928029|dexamethasone
836792|NCT02928029|early relapsed multiple myeloma
836793|NCT02928029|combination therapy multiple myeloma
836794|NCT02928016|carbohydrate counting method
836795|NCT02928016|protein
836796|NCT02928016|fat
836797|NCT02928016|glucose
836798|NCT02928016|type 1 diabetes
836799|NCT02928003|Lung surgery
836800|NCT02927977|dry needling
836801|NCT02927977|exercise
836802|NCT02927977|manual therapy
836803|NCT02927951|Diabetes Mellitus
836804|NCT02927951|Peripheral Neuropathy
836805|NCT02927951|Diabetic Pain
836806|NCT02927899|Tomato-Soy-Arugula
836807|NCT02927873|Safety
836808|NCT02927873|Respiratory syncytial virus (RSV)
836809|NCT02927873|Immunogenicity
836810|NCT02927873|Reactogenicity
836811|NCT02927873|Infants
836812|NCT02927873|Vaccine
836813|NCT02927860|sleep
836814|NCT02927860|exercise
836815|NCT02927860|activity
836816|NCT02927821|Adult Day Care Centers
836817|NCT02927821|Caregivers
836818|NCT02927808|Motivational Interviewing
836819|NCT02927808|LDL-C
836820|NCT02927808|LDL target
836821|NCT02927808|Medication adherence
836822|NCT02927782|Cerebrospinal Fluid Leak
836823|NCT02927782|Lumbar
836824|NCT02927756|Non-Hodgkin Lymphoma Transformed Recurrent
836825|NCT02927756|Discordant Lymphomas
836826|NCT02927756|Composite Lymphomas
836827|NCT02927756|Follicular Lymphoma
836828|NCT02927756|Aggressive Lymphoma
836829|NCT02927730|Retained placenta, surgical hysteroscopy, residua
836830|NCT02927717|Grade 3b Follicular Lymphoma
836831|NCT02927717|2016 WHO Criteria
836832|NCT02927717|Front-line treatment
836833|NCT02927717|Rituximab
836834|NCT02927704|Aggressive Periodontitis
836835|NCT02927704|monocyte chemoattractant protein-1
836836|NCT02927704|gingival crevicular fluid
836837|NCT02927704|enzyme-linked immunosorbent assay
836838|NCT02927691|Rehabilitation
836839|NCT02927691|Parkinson's disease
836840|NCT02927691|Swallowing
836841|NCT02927691|Cough
836842|NCT02927691|Dysphagia
836843|NCT02927691|Dystussia
836844|NCT02927678|Diabetic foot
836845|NCT02927678|Osteomyelitis
836846|NCT02927678|Antibiotic treatment
836847|NCT02927678|White Blood Cell SPECT/CT
836849|NCT02927613|Home mechanical ventilation
836850|NCT02927613|Mortality
836851|NCT02927613|Complications
836852|NCT02927613|Developing country
836853|NCT02927600|Glycemic response
836854|NCT02927600|Glycemic index
836855|NCT02927600|Meal intervention
836856|NCT02927600|Chinese population
836857|NCT02927587|TCI
836858|NCT02927587|fiberoptic bronchoscopy
836859|NCT02927587|sedation
836860|NCT02927574|drug-coated balloon angioplasty
836861|NCT02927574|angioplasty
836862|NCT02927574|plain old balloon angioplasty
836863|NCT02927574|peripheral arterial disease
836864|NCT02927574|intermittent claudication
836865|NCT02927574|systematic review
836866|NCT02927574|meta-analysis
836867|NCT02927574|Paclitaxel
836868|NCT02927522|Postoperative Cognitive Dysfunction
836869|NCT02927522|Donepezil
836870|NCT02927522|Hip replacement
836871|NCT02927522|Knee replacement
836872|NCT02927496|Lymphedema
836873|NCT02927496|Lymphatic Filariasis
836874|NCT02927496|Filariasis
836875|NCT02927496|Doxycycline
836876|NCT02927483|Venous Insufficiency
836877|NCT02927470|Transcranial Magnetic Stimulation
836886|NCT02927405|gabapentin
836887|NCT02927405|TAP block
836888|NCT02927366|Pulmonary hypertension (PH),
836889|NCT02927366|Increase blood pressure in the pulmonary artery
836890|NCT02927366|Increased blood pressure in the pulmonary vein
836891|NCT02927366|Increased blood pressure in the lung vasculature
836892|NCT02927366|Shortness of breath
836893|NCT02927366|Dizziness
836894|NCT02927366|Fainting
836895|NCT02927366|Leg swelling
836896|NCT02927366|Cough
836897|NCT02927366|Angina pector
836898|NCT02927353|Bioequivalence, Biosimilarity, Pharmacokinetics, adalimumab
836899|NCT02927340|Lung Cancer
836900|NCT02927288|PTSD, mTBI
836906|NCT02927236|Non-Invasive Brain Stimulation
836907|NCT02927236|Functional Magnetic Resonance Imaging (fMRI)
836908|NCT02927210|Healthy Men
836909|NCT02927210|Male Contraception
836910|NCT02927210|Androgen
836911|NCT02927210|Dimethandrolone
836912|NCT02927171|Skilled Nursing Facility
836913|NCT02927171|Post-Acute Care
836914|NCT02927171|Older Adults
836915|NCT02927171|Physical Function
836916|NCT02927171|Rehabilitation
836917|NCT02927132|Drinking, Alcohol
836918|NCT02927119|thyroglobulin
836919|NCT02927119|iodine
836920|NCT02927119|pregnancy
836921|NCT02927106|leukemia
836922|NCT02927106|myeloid
836923|NCT02927106|genomics
836924|NCT02927080|FSHD
836925|NCT02927041|hemodynamic transesophageal echocardiography
836926|NCT02927028|energy availability
836927|NCT02927028|walnuts
836928|NCT02926989|Isotonic
836929|NCT02926989|Hypotonic
836930|NCT02926989|Intravenous fluids
836931|NCT02926976|Schizophrenia
836932|NCT02926963|Chronic Granulomatous Disease, Nox2, p22phox, iPS cells
836933|NCT02926911|Ductal Carcinoma
836934|NCT02926898|seizure
836935|NCT02926898|tonic clonic
836936|NCT02926898|epilepsy
836937|NCT02926898|myoclonic
836938|NCT02926898|encephalopathy
836939|NCT02926885|liver
836940|NCT02926885|laparoscopy
836941|NCT02926885|Bariatric Surgery
836942|NCT02926885|Esophagogastric Junction
836943|NCT02926885|obesity
836944|NCT02926872|Screening
836945|NCT02926872|Hepatic Injury
836946|NCT02926872|Pediatric Patients
836947|NCT02926846|Peritoneal dialysis
836948|NCT02926846|Lavage
836949|NCT02926820|Huntington disease
836950|NCT02926820|cognitive rehabilitation
836951|NCT02926820|cognitive dysfunction
836952|NCT02926807|Atopic Dermatitis
836953|NCT02926807|Vascular Inflammation
836954|NCT02926807|Coronary Atherosclerosis
836955|NCT02926807|Ascending aorta
836956|NCT02926807|Pet scan
836957|NCT02926768|Cancer
836958|NCT02926768|Non Small Cell Lung Cancer
836959|NCT02926768|EGFR sensitivity mutation
836960|NCT02926768|T790M
836961|NCT02926768|NSCLC
836962|NCT02926768|epidermal growth factor receptor
836963|NCT02926768|EGFR
836964|NCT02926768|EGFR inhibitor
836965|NCT02926768|Solid Tumors
836966|NCT02926755|Intra Venous Ultrasound (IVUS)
836967|NCT02926755|Fractional Flow Reserve (FFR)
836968|NCT02926755|Optical Coherence Tomography (OCT)
836969|NCT02926755|Acute Myocardial Infarction
836970|NCT02926755|Coronary Artery Disease (CAD)
836971|NCT02926755|Angiography
836972|NCT02926742|Thrombolysis
836973|NCT02926742|Ultrasound Thrombolysis
836974|NCT02926742|Pulmonary Embolism
836975|NCT02926742|Saddle PE
836976|NCT02926742|Submassive PE
836977|NCT02926742|Massive PE
836978|NCT02926742|Bilateral PE
836979|NCT02926729|Breast Cancer
836980|NCT02926716|Stomach neoplasm
836981|NCT02926716|Endoscopy
836982|NCT02926716|Narrow band imaging
836983|NCT02926703|seizure
836984|NCT02926703|lactate
836985|NCT02926703|creatine kinase
836986|NCT02926677|PTSD
836987|NCT02926677|Child Trauma
836988|NCT02926677|Cue-Centered Treatment
836989|NCT02926677|Trauma-Focused Cognitive-Behavioral Therapy
836990|NCT02926677|fNIRs
836991|NCT02926677|CCT
836992|NCT02926677|TF-CBT
836993|NCT02926677|Posttraumatic stress
836994|NCT02926677|NIRX
836995|NCT02926625|Unspecific fever
836996|NCT02926625|Ethiopia
836997|NCT02926625|iCCM
836998|NCT02926625|CHW
836999|NCT02926625|HEW
837000|NCT02926599|High Fidelity Simulation
837001|NCT02926586|RUNX1-RUNX1T1
837002|NCT02926586|CBFβ-MYH11
837003|NCT02926586|fludarabine
837004|NCT02926586|cytarabine
837005|NCT02926573|oral cavity
837006|NCT02926573|oropharynx
837007|NCT02926573|hypopharynx and larynx
837008|NCT02926560|Chronic inflammatory rheumatism
837009|NCT02926547|proteomics
837010|NCT02926534|chronic obstructive pulmonary disease
837011|NCT02926534|smoking
837012|NCT02926534|prevalence
837013|NCT02926534|cross-sectional study
837014|NCT02926534|Kazakhstan
837015|NCT02926521|nerve block catheter
837016|NCT02926521|catheter fixation
837017|NCT02926521|catheter dressing
837018|NCT02926508|Reading
837019|NCT02926508|Learning
837020|NCT02926508|Cognition
837021|NCT02926482|Evidence-based practice implementation
837022|NCT02926482|Buprenorphine
837023|NCT02926482|Addiction treatment
837024|NCT02926469|Virtual Reality
837025|NCT02926469|Analgesia
837026|NCT02926469|Immersive Virtual Reality
837027|NCT02926469|VR
837028|NCT02926469|Labor
837029|NCT02926469|Pain
837030|NCT02926443|Shoulder
837031|NCT02926443|Motor control
837032|NCT02926443|Proprioception
837033|NCT02926443|Usual physiotherapy care
837034|NCT02926443|Supervised exercise program
837035|NCT02926404|Sagittal alignment
837036|NCT02926404|Surgical planning
837037|NCT02926404|Patient-specific
837038|NCT02926404|Adult Spinal Deformity
837039|NCT02926352|LLLT
837040|NCT02926352|LLLS
837041|NCT02926352|Low-Level Laser Stimulation
837042|NCT02926352|Low-Level Laser Therapy
837043|NCT02926352|Low-Level Light Therapy
837044|NCT02926352|Transcranial infrared light stimulation
837045|NCT02926352|Near-infrared light
837046|NCT02926352|Photobiomodulation
837047|NCT02926352|Fear Extinction
837048|NCT02926352|Exposure Therapy
837049|NCT02926352|Claustrophobia
837050|NCT02926352|Fear of enclosed spaces
837051|NCT02926352|Fear of contamination
837052|NCT02926352|Fear of public speaking
837053|NCT02926352|Anxiety sensitivity
837054|NCT02926352|Cytochrome oxidase
837055|NCT02926352|Memory consolidation
837056|NCT02926352|Cognitive enhancer
837057|NCT02926326|Healthy Male volunteers
837058|NCT02926313|RCT
837059|NCT02926313|Specialized seating
837060|NCT02926313|Pressure ulcers
837061|NCT02926300|crohn's disease
837062|NCT02926300|stem cell therapy
837063|NCT02926300|inflammatory bowel disease
837064|NCT02926300|hUCB-MSC
837065|NCT02926300|UCB-MSC
837066|NCT02926300|Umbilical cord Blood
837067|NCT02926287|prolapse surgery
837068|NCT02926287|ambulatory surgery
837069|NCT02926274|whole blood
837070|NCT02926274|trauma
837071|NCT02926274|transfusion
837072|NCT02926274|coagulopathy
837073|NCT02926248|Arthrofibrosis
837074|NCT02926235|Total Knee Arthroplasty
837075|NCT02926209|colonoscopy
837076|NCT02926209|adenoma
837077|NCT02926209|polyp
837078|NCT02926209|crc screening
837082|NCT02926144|Intratracheal intubation
837083|NCT02926144|videolaryngoscope
837084|NCT02926144|McGrath MAC
837085|NCT02926131|stick test
837086|NCT02926118|Glucose
837087|NCT02926118|Continuous glucose monitor
837088|NCT02926118|Glycemic load
837089|NCT02926118|Dietary intervention
837090|NCT02926066|Aromatic L-amino acid decarboxylase (AADC)
837091|NCT02926014|Dysphagia
837092|NCT02926014|Lingual Tonsil Hypertrophy
837093|NCT02926014|Lingual Tonsil Enlargement
837094|NCT02926001|Taxes
837095|NCT02926001|Beverages/economics
837096|NCT02926001|Carbonated Beverages/economics
837097|NCT02926001|Diet, Food and Nutrition/economics
837098|NCT02926001|Economics
837099|NCT02926001|Energy Intake
837100|NCT02926001|Risk Factors
837101|NCT02925988|Critically ill
837102|NCT02925988|High risk neonates
837103|NCT02925949|Treatment
837104|NCT02925949|Adherence
837105|NCT02925949|Intervention
837106|NCT02925949|MSM Couples
837107|NCT02925936|Radiography
837108|NCT02925936|Radiation
837109|NCT02925936|Diagnostic imaging
837110|NCT02925871|stroke
837111|NCT02925871|rehabilitation
837112|NCT02925871|interdisciplinary health team
837113|NCT02925871|patient-centered care
837114|NCT02925871|care transition
837115|NCT02925858|Ketamine
837116|NCT02925858|Cardiac surgery
837117|NCT02925858|Pain
837118|NCT02925832|Deep topical fornix nerve block Anesthesia
837119|NCT02925832|Ropivacaine
837120|NCT02925832|Bupivacaine
837121|NCT02925832|Anaesthesia
837122|NCT02925832|Eye surgery blocks
837123|NCT02925832|Phacoemulsification
837124|NCT02925819|Mitral regurgitation
837125|NCT02925819|Mitral stenosis
837126|NCT02925819|Mitral valve repair deterioration
837127|NCT02925819|Bioprosthesis degeneration
837128|NCT02925780|Enamel defects
837129|NCT02925780|Fluorosis
837130|NCT02925741|bed linens
837131|NCT02925728|Finger-Food
837132|NCT02925663|executive functioning
837133|NCT02925650|Alzheimer's Disease
837134|NCT02925650|SILK™
837135|NCT02925650|Pharmacodynamics
837136|NCT02925650|Safety
837137|NCT02925650|Pharmacokinetics
837138|NCT02925624|ablation index
837139|NCT02925624|pulmonary vein isolation
837140|NCT02925624|implantable loop recorder
837141|NCT02925611|Postoperative delirium
837142|NCT02925611|spine surgery
837143|NCT02925611|isoflurane
837144|NCT02925611|desflurane
837145|NCT02925598|Laringeal masks
837146|NCT02925598|Cholecystectomy, Laparascopic
837147|NCT02925598|Intubation, intratracheal
837148|NCT02925572|pediatric obesity
837149|NCT02925572|eccentric exercise
837150|NCT02925572|body composition
837151|NCT02925572|training program
837152|NCT02925559|Diabetes Mellitus, Type 2
837153|NCT02925559|Glycemic Variability
837154|NCT02925559|Dapagliflozin
837155|NCT02925559|Gliclazide MR
837156|NCT02925559|Continuous Glucose Monitoring
837157|NCT02925559|Mean Amplitude of Glycemic Excursions
837158|NCT02925559|MAGE
837159|NCT02925546|Healthy
837160|NCT02925546|Pharmacokinetics
837161|NCT02925546|Phase I
837162|NCT02925546|GSK2798745
837163|NCT02925546|Tablet
837166|NCT02925520|Cholestasis
837167|NCT02925494|Elagolix
837168|NCT02925494|Elagolix plus Norethindrone Acetate
837169|NCT02925494|Uterine Fibroids
837170|NCT02925494|Elagolix Sodium
837171|NCT02925494|Heavy Menstrual Bleeding
837172|NCT02925481|Yoga
837173|NCT02925481|PTSD
837174|NCT02925481|mental health
837175|NCT02925481|stillbirth
837176|NCT02925468|orthodontics
837177|NCT02925455|Hemiplegia
837421|NCT02924090|Electroencephalography
837178|NCT02925455|Functional Electrical Stimulation
837179|NCT02925455|Video Games
837180|NCT02925455|Occupational Therapy
837181|NCT02925442|Unilateral Knee Arthroplasty
837182|NCT02925442|Radiofrequency Ablation
837183|NCT02925442|Genicular
837184|NCT02925442|RFA
837185|NCT02925442|C-RFA
837186|NCT02925442|t-RFA
837187|NCT02925442|total knee replacement
837188|NCT02925364|magnetic resonance imaging
837189|NCT02925364|central pain processing
837190|NCT02925364|anatomical MRI
837191|NCT02925364|fMRI
837192|NCT02925325|Major depressive disorder
837193|NCT02925325|Music therapy
837194|NCT02925325|Residual symptoms
837195|NCT02925286|gambling prevention
837196|NCT02925286|workplace policy
837197|NCT02925273|dementia
837198|NCT02925234|Molecular tumor profile
837199|NCT02925234|Multidisciplinary tumor board
837200|NCT02925234|Antitumor drugs
837201|NCT02925234|Molecular Targeted Therapy
837202|NCT02925234|Drug Repositioning
837203|NCT02925234|Off-Label Use
837204|NCT02925234|Sequence Analysis, DNA
837205|NCT02925221|Kidney Disease
837206|NCT02925221|ADPKD-Related Outcome
837207|NCT02925221|Quality of Life
837208|NCT02925195|Vitamin D
837209|NCT02925195|cardiovascular disease
837210|NCT02925195|MESA
837211|NCT02925195|genetics
837212|NCT02925195|pharmacogenetics
837213|NCT02925195|blood pressure
837214|NCT02925195|biomarkers
837215|NCT02925169|Subglottis, cricoid, airway shape, CT imaging
837216|NCT02925156|Activity Energy Expenditure
837217|NCT02925156|Doubly Labeled Water
837218|NCT02925156|Physical Activity
837219|NCT02925156|Obesity
837220|NCT02925156|Diabetes
837221|NCT02925156|Cardiovascular Disease
837222|NCT02925156|Adiponectin
837223|NCT02925156|Leptin
837224|NCT02925156|Ghrelin
837225|NCT02925143|Residual nerve blockade
837226|NCT02925143|Neuromuscular monitoring
837227|NCT02925143|Residual curarization
837228|NCT02925143|Neuromuscular blocking agents
837229|NCT02925143|E-learning
837230|NCT02925143|Web based learning
837233|NCT02925104|cMET, INC280, food,
837234|NCT02925065|Parkinson's
837235|NCT02925065|Non-traditional guitar instruction
837236|NCT02925065|Guitar therapy
837237|NCT02925065|Upper extremity motor function
837238|NCT02925065|Hand dexterity
837239|NCT02925039|Rehabilitation
837240|NCT02925039|Geriatric
837241|NCT02925013|Omega 3
837242|NCT02925013|Lipids
837243|NCT02925013|Pregnancy
837244|NCT02925000|Advanced Malignancy
837245|NCT02925000|lymphoma
837246|NCT02925000|TLC178
837247|NCT02924948|Endoscopic ultrasonography
837248|NCT02924922|renal cell carcinoma
837249|NCT02924922|laparoscopic partial nephrectomy
837250|NCT02924922|robot-assisted partial nephrectomy
837251|NCT02924922|nephron sparing surgery
837252|NCT02924922|warm ischemia time
837253|NCT02924922|renal function loss
837254|NCT02924870|health education
837255|NCT02924792|Intraosseous access
837256|NCT02924740|stress urinary incontinence
837257|NCT02924740|quality of life
837258|NCT02924740|pelvic floor muscle training
837259|NCT02924740|pelvic floor muscle exercises
837260|NCT02924740|vaginal tampon training
837261|NCT02924727|Spontaneous AMI
837262|NCT02924727|HF hospitalization
837263|NCT02924727|outpatient HF
837264|NCT02924727|LV systolic dysfunction
837265|NCT02924727|pulmonary congestion
837266|NCT02924727|STEMI
837267|NCT02924727|NSTEMI
837268|NCT02924727|randomized clinical trial
837269|NCT02924727|LCZ696
837270|NCT02924727|ramipril
837271|NCT02924714|GIST
837272|NCT02924701|prognosis
837281|NCT02924675|neuropathic pain, ent cancer, pregabalin
837282|NCT02924649|Brain injury
837283|NCT02924649|Early mobilisation
837284|NCT02924649|Consciousness
837285|NCT02924649|Cerebral blood flow
837286|NCT02924649|Blood pressure
837287|NCT02924636|C-section
837288|NCT02924636|Instrumental delivery
837289|NCT02924636|Pregnancy complications
837290|NCT02924636|Macrosomia
837291|NCT02924636|Neonatal complications
837292|NCT02924584|hormonal receptor positive, human epidermal growth factor receptor 2 negative, breast cancer, aromatse inhibitor, overall survival, prevalence
837293|NCT02924558|Egg
837294|NCT02924558|Protein
837295|NCT02924558|Unsaturated fatty acids
837296|NCT02924558|Triglycerides
837297|NCT02924558|Insulin sensitivity
837298|NCT02924558|Lipid triad
837299|NCT02924506|cervical arthroplasty
837300|NCT02924493|Endometriosis
837301|NCT02924493|IBS
837302|NCT02924493|Irritable bowel syndrome
837303|NCT02924493|low FODMAP diet
837304|NCT02924493|FODMAPs
837305|NCT02924493|visceral syndrome
837306|NCT02924493|fermentable carbohydrates
837307|NCT02924493|visceral hypersensitivity
837308|NCT02924493|cross organ effect
837309|NCT02924480|invasive bladder cancer
837310|NCT02924480|cystectomy
837311|NCT02924480|high grade bladder cancer
837312|NCT02924467|reminder systems
837313|NCT02924467|Influenza vaccines
837314|NCT02924454|metoprolol
837315|NCT02924454|lipid emulsion
837316|NCT02924454|pharmacodynamics
837317|NCT02924454|pharmacokinetics
837318|NCT02924441|Mammogram
837319|NCT02924441|Pain Management
837320|NCT02924441|Lidocaine
837321|NCT02924428|Acne
837322|NCT02924402|NHL
837323|NCT02924402|B-cell Prolymphocytic Leukemia
837324|NCT02924402|Transformed Lymphoma
837325|NCT02924402|Burkitt's Lymphoma
837326|NCT02924402|Mantle Cell Lymphoma
837327|NCT02924402|Hairy Cell Leukemia
837328|NCT02924402|Splenic Marginal Zone Lymphoma
837329|NCT02924402|Waldenstrom's Macroglobulinemia
837330|NCT02924402|Variant Hairy Cell Leukemia
837331|NCT02924402|Splenic B-cell Lymphoma/Leukemia
837332|NCT02924402|Lymphoplasmacytic Lymphoma
837333|NCT02924402|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT)
837334|NCT02924402|MALT Lymphoma
837335|NCT02924402|Nodal Marginal Zone Lymphoma
837336|NCT02924402|Follicular Lymphoma
837337|NCT02924402|In Situ Follicular Neoplasia
837338|NCT02924402|Duodenal-type Follicular Lymphoma
837339|NCT02924402|Large B-cell Lymphoma with IRF4 rearrangement
837340|NCT02924402|Primary Cutaneous Follicle Center Lymphoma
837341|NCT02924402|Diffuse Large B-cell Lymphoma
837342|NCT02924402|DLBCL
837343|NCT02924402|T-cell/Histiocyte-Rich Large B-cell Lymphoma
837344|NCT02924402|Primary Cutaneous DLBCL, leg type
837345|NCT02924402|EBV-positive DLBCL, NOS
837346|NCT02924402|EBV-positive Mucocutaneous Ulcer
837347|NCT02924402|DLBCL Associated with Chronic Inflammation
837348|NCT02924402|Lymphomatoid Granulomatosis
837349|NCT02924402|Primary Mediastinal (Thymic) Large B-cell Lymphoma
837350|NCT02924402|Intravascular Large B-cell Lymphoma
837351|NCT02924402|ALK+ Large B-cell Lymphoma
837352|NCT02924402|Plasmablastic Lymphoma
837353|NCT02924402|Primary Effusion Lymphoma
837354|NCT02924402|HHV8+ DLBCL
837355|NCT02924402|Burkitt-like Lymphoma with 11q Aberration
837356|NCT02924402|High-grade B-cell Lymphoma
837357|NCT02924402|B-cell Lymphoma, unclassifiable
837358|NCT02924402|Post-transplant Lymphoproliferative Disorder
837359|NCT02924402|PTLD
837360|NCT02924402|CLL
837361|NCT02924402|SLL
837362|NCT02924402|High-grade Lymphoma
837363|NCT02924376|Cholangiocarcinoma
837364|NCT02924376|fibroblast growth factor (FGF)
837365|NCT02924376|fibroblast growth factor receptor (FGFR)
837366|NCT02924376|FGF/FGFR alterations
837367|NCT02924363|Cardiac Magnetic Resonance
837368|NCT02924363|Mitra Clip
837369|NCT02924363|Mitral Valve
837370|NCT02924337|QT/QTC interval
837371|NCT02924337|Hypoglycemic Agents
837372|NCT02924337|Imeglimin
837373|NCT02924337|Healthy Volunteers
837374|NCT02924324|local Injection
837375|NCT02924324|pain Medication
837376|NCT02924324|propofol
837377|NCT02924324|ropivacaine
837378|NCT02924324|16-1417
837379|NCT02924311|Diabetic Macular Edema
837380|NCT02924272|Drug Therapy
837381|NCT02924259|muscle soreness
837382|NCT02924259|pain
837383|NCT02924259|myofascial release
837384|NCT02924246|immunity
837385|NCT02924246|vaccination
837386|NCT02924246|milk
837387|NCT02924233|Squamous
837388|NCT02924233|Non-Small Cell Lung Cancer
837389|NCT02924233|NSCLC
837390|NCT02924207|diabetes mellitus
837391|NCT02924181|pulmonary vein isolation
837392|NCT02924181|contact force sensing catheter
837393|NCT02924142|Kennedy classification for edentulous ridge
837394|NCT02924129|Chronic Pain
837395|NCT02924129|Back Pain
837396|NCT02924129|Leg Pain
837397|NCT02924129|Pain
837398|NCT02924129|Neurologic Manifestations
837399|NCT02924129|Nervous System Diseases
837400|NCT02924129|Signs and Symptoms
837401|NCT02924129|SCS
837402|NCT02924129|Closed Loop
837403|NCT02924116|insomnia
837404|NCT02924116|sleep
837405|NCT02924116|Bioboosti
837406|NCT02924116|Biomobie
837407|NCT02924116|device
837408|NCT02924103|acute rhinosinusitis
837409|NCT02924103|staphylococcus aureus
837410|NCT02924103|nasal vestibule
837411|NCT02924103|contamination
837412|NCT02924090|Major depressive disorder
837413|NCT02924090|Etomidate
837414|NCT02924090|Ketamine
837415|NCT02924090|Hyperventilation
837416|NCT02924090|Electroconvulsive therapy
837417|NCT02924090|Depression
837418|NCT02924090|Anesthesia
837419|NCT02924090|Nervous System Diseases
837420|NCT02924090|Mental Disorders
837422|NCT02924090|Cerebral Metabolism
837423|NCT02924038|low-grade glioma
837424|NCT02924038|glioma
837425|NCT02924038|immunotherapy
837426|NCT02924038|vaccine
837427|NCT02924038|WHO grade II
837428|NCT02924012|post exercise hypotension
837429|NCT02924012|exercise
837430|NCT02924012|video games
837431|NCT02923999|HIV
837432|NCT02923999|MAB
837433|NCT02923999|PLANT
837434|NCT02923986|Liposomal Grb-2 treatment of Ph+ CML
837435|NCT02923986|Liposomal Grb-2 with Das for Ph+ CML
837436|NCT02923947|Pharmacokinetics,
837437|NCT02923947|Renal impairment,
837438|NCT02923947|Safety assessments,
837439|NCT02923947|Solid tumours,
837440|NCT02923947|EGFRm+
837441|NCT02923947|EGFRm+/T790M+ inhibitor
837442|NCT02923908|Palatability
837443|NCT02923908|Pediatrics
837444|NCT02923908|Facial Recognition
837445|NCT02923908|Taste
837446|NCT02923908|Facial Expressions
837447|NCT02923882|Low-birth-weight
837448|NCT02923882|Model kitchen
837449|NCT02923882|Improved cookstove
837450|NCT02923869|Levobupivacaine
837451|NCT02923869|Bupivacaine
837452|NCT02923869|Nerve Block
837453|NCT02923869|Cleft Palate
837454|NCT02923856|Helicobacter pylori
837455|NCT02923856|Antibiotic resistance
837456|NCT02923856|Sequencing
837457|NCT02923843|frailty
837458|NCT02923843|comprehensive geriatric assessment
837459|NCT02923817|spinal cord injury
837460|NCT02923817|autologous transplants
837461|NCT02923817|bone marrow derived mononuclear cells
837462|NCT02923804|steatosis
837463|NCT02923804|NAFL
837464|NCT02923804|NAFLD
837465|NCT02923804|Polyunsaturated fatty acids
837466|NCT02923804|omega-3
837467|NCT02923804|EPA
837468|NCT02923804|DHA
837469|NCT02923804|fish oil
837470|NCT02923739|Malignant neoplasms of female genital organs
837471|NCT02923739|Ovarian Cancer
837472|NCT02923739|Fallopian Tube Cancer
837473|NCT02923739|Primary Peritoneal Cancer
837474|NCT02923739|relapsed/refractory
837475|NCT02923739|Platinum-resistant disease
837476|NCT02923739|Paclitaxel
837477|NCT02923739|Taxol
837478|NCT02923739|Bevacizumab
837479|NCT02923739|Avastin
837480|NCT02923739|rhuMAb-VEGF
837481|NCT02923739|Anti-VEGF monoclonal antibody
837482|NCT02923739|Emactuzumab
837483|NCT02923739|RO5509554
837487|NCT02923700|platelet rich plasma
837488|NCT02923700|intra-articular injection
837489|NCT02923700|leukocytes
837490|NCT02923687|Ketorolac
837491|NCT02923687|Root canal treatment
837492|NCT02923687|Pain
837493|NCT02923687|Premedication
837494|NCT02923661|single implant
837495|NCT02923635|Oncoplastic breast surgery
837496|NCT02923635|Standard Wide Local Excision
837497|NCT02923596|Keloid
837498|NCT02923570|proton-beam radiation therapy (PBRT)
837499|NCT02923570|intensity-modulated radiation therapy (IMRT)
837500|NCT02923570|16-1416
837501|NCT02923544|Uterine Manipulator
837502|NCT02923544|Yukio's Uterine Manipulating Instrument (YUMI)
837503|NCT02923544|16-1397
837504|NCT02923518|Heart Screening
837505|NCT02923518|Master Athletes
837506|NCT02923518|Cardiovascular Disease
837507|NCT02923479|Rehabilitation
837508|NCT02923479|Robotics
837509|NCT02923466|refractory solid tumor
837510|NCT02923427|laryngeal mask Supreme
837511|NCT02923427|i-gel
837512|NCT02923427|laparoscopic gynecological surgery
837513|NCT02923414|Cardioversion
837514|NCT02923401|Exercise
837515|NCT02923401|Biomarkers
837516|NCT02923401|Breast cancer high risk
837517|NCT02923401|Treadmill
837518|NCT02923401|Stationary bicycle
837519|NCT02923401|Questionnaires
837520|NCT02923401|Surveys
837521|NCT02923401|Motivational sessions
837522|NCT02923401|Phone calls
837523|NCT02923401|Printed materials
837524|NCT02923362|GERD
837525|NCT02923362|Reflux
837526|NCT02923362|Acid Reflux
837527|NCT02923362|Heartburn
837528|NCT02923362|Regurgitation
837529|NCT02923362|Laryngopharyngeal Reflux
837530|NCT02923362|Hiatal Hernia
837531|NCT02923362|LPR
837532|NCT02923362|LINX
837533|NCT02923362|Magnetic Sphincter Augmentation
837534|NCT02923362|Antireflux Surgery
837535|NCT02923362|Nissen
837536|NCT02923349|Solid tumor
837537|NCT02923349|adenocarcinoma of the endometrium
837538|NCT02923349|ovarian cancer
837539|NCT02923349|renal cell carcinoma
837540|NCT02923349|melanoma
837541|NCT02923349|non-small cell lung cancer
837542|NCT02923349|OX40
837543|NCT02923349|immunoglobulin G monoclonal antibody
837544|NCT02923336|liver cirrhosis
837545|NCT02923336|variceal bleeding
837546|NCT02923336|non selective beta blockers
837547|NCT02923323|Neurocognitive Function
837548|NCT02923323|MRI
837549|NCT02923323|Diffusion Tensor Imaging (DTI)
837550|NCT02923323|Sleep
837551|NCT02923297|parkinson
837552|NCT02923297|alpha-synuclein
837553|NCT02923297|GALIG
837554|NCT02923297|quantitative PCR (polymerase chain reaction)
837555|NCT02923271|Driving
837556|NCT02923271|Teens
837557|NCT02923271|Texting
837558|NCT02923271|Cellphone
837559|NCT02923271|DriveID
837560|NCT02923271|Motor vehicle accident
837561|NCT02923258|head and neck squamous cell carcinoma
837562|NCT02923258|concurrent chemotherapy
837563|NCT02923258|High-Risk
837564|NCT02923232|Contact lens; Accommodation; Visual performance
837565|NCT02923219|Facial Rejuvenation
837566|NCT02923219|Adipose-Derived Stem Cells
837567|NCT02923206|apheresis
837568|NCT02923206|pregnancy
837569|NCT02923206|pre-eclampsia
837570|NCT02923206|PE
837571|NCT02923206|sFlt-1
837572|NCT02923206|Pre-term
837573|NCT02923167|CP
837574|NCT02923167|Cerebral Palsy
837575|NCT02923167|Robotic
837576|NCT02923167|Hand
837577|NCT02923154|NASH
837578|NCT02923141|substance use
837579|NCT02923141|trauma
837580|NCT02923141|HIV
837581|NCT02923141|viral load
837582|NCT02923141|women
837583|NCT02923115|Venous thromboembolism
837584|NCT02923115|VTE
837585|NCT02923115|Pulmonary embolism
837586|NCT02923115|PE
837587|NCT02923115|Acute Submassive Pulmonary Embolism
837588|NCT02923102|Recovery
837589|NCT02923102|Muscle soreness
837590|NCT02923102|Lemon Verbena
837591|NCT02923089|Diabetes
837592|NCT02923089|Lentils
837593|NCT02923089|Pulses
837594|NCT02923089|Postprandial glycemia
837595|NCT02923076|Allogeneic Hematopoietic Cell Transplantation
837596|NCT02923063|Chronic Kidney Disease
837597|NCT02923063|Mitochondrial Metabolism
837598|NCT02923063|Physical Performance
837599|NCT02923063|Exercise Intolerance
837600|NCT02923063|Muscle Fatigue
837601|NCT02922998|CD64 antigens
837602|NCT02922998|Biomarkers
837603|NCT02922998|Granulocyte Colony-Stimulating Factor
837604|NCT02922998|Interleukin-4
837605|NCT02922998|Interferon-gamma
837606|NCT02922998|C-reactive protein
837607|NCT02922998|lipopolysaccharide-binding protein
837608|NCT02922998|procalcitonin
837609|NCT02922998|Cytokines
837610|NCT02922998|Patients
837611|NCT02922998|Human
837612|NCT02922998|Systemic Inflammatory Response Syndrome
837613|NCT02922998|Sepsis
837614|NCT02922998|Infection
837615|NCT02922998|Antibiotics
837616|NCT02922998|Intensive Care Units
837617|NCT02922998|Point-of-Care Systems
837618|NCT02922998|Bedside Testing
837619|NCT02922985|Cesarean delivery
837620|NCT02922985|Multimodal pain management
837621|NCT02922972|Keloid scar
837622|NCT02922972|Wound healing
837623|NCT02922972|Platelet-Rich Plasma
837624|NCT02922972|RegenLab
837625|NCT02922959|Opioid Substitution Treatment
837626|NCT02922959|Telephone intervention
837627|NCT02922959|secondary prevention
837628|NCT02922959|naloxone
837629|NCT02922946|entinostat
837630|NCT02922946|Histone Deacetylase Inhibitor
837631|NCT02922946|HDAC
837632|NCT02922933|entinostat
837633|NCT02922933|Histone Deacetylase Inhibitor
837634|NCT02922933|HDAC
837635|NCT02922868|Cystoscopy
837636|NCT02922868|EndoSheath
837637|NCT02922868|Infection Control
837638|NCT02922868|Bacteriuria
837639|NCT02922842|transcutaneous electrical nerve stimulation
837640|NCT02922829|Food Insecurity
837641|NCT02922829|Nutrition
837642|NCT02922816|Carbapenem-resistant Enterobacteriaceae (CRE)
837643|NCT02922816|Vancomycin-resistant Enterococcus (VRE)
837644|NCT02922816|Multidrug Resistant Organism (MDRO)
837645|NCT02922816|Fecal Microbiota Transplant (FMT)
837646|NCT02922816|Renal Transplant
837647|NCT02922816|Colonization
837648|NCT02922816|Infection
837649|NCT02922816|Antibiotic Resistance
837650|NCT02922816|Resistome
837651|NCT02922816|Multidrug Resistant (MDR) Pseudomonas
837652|NCT02922790|smoker
837653|NCT02922790|smoking
837654|NCT02922790|cigarette
837655|NCT02922790|cessation
837656|NCT02922790|DNA
837657|NCT02922790|DNA damage
837658|NCT02922790|blood draw
837659|NCT02922790|feedback
837660|NCT02922790|cellular
837661|NCT02922790|tobacco
837662|NCT02922790|tobacco smoke
837663|NCT02922764|Solid malignancy
837664|NCT02922764|Lymphoma
837665|NCT02922764|Solid tumor
837666|NCT02922764|Melanoma
837667|NCT02922764|Non-small cell lung cancer
837668|NCT02922764|Epithelial ovarian carcinoma
837669|NCT02922764|Breast cancer
837670|NCT02922764|NSCLC
837671|NCT02922764|EOC
837672|NCT02922764|BC
837673|NCT02922764|LXR
837674|NCT02922764|ApoE
837675|NCT02922764|mBC
837676|NCT02922751|transient elastography
837677|NCT02922751|pediatric liver disease
837678|NCT02922751|biliary atresia
837679|NCT02922751|Alagille Syndrome
837680|NCT02922751|Alpha1 Anti-Trypsin Deficiency
837681|NCT02922751|liver fibrosis
837682|NCT02922751|cholestasis
837683|NCT02922738|Clinical Knowledge Systems, Decision support, Dermatology
837684|NCT02922738|Technology Assessment
837685|NCT02922673|human endotoxemia
837686|NCT02922673|LPS
837687|NCT02922673|acetylsalicylic acid
837688|NCT02922673|placebo
837689|NCT02922673|endotoxin tolerance
837690|NCT02922660|Ambulatory surgery
837691|NCT02922660|Ophthalmic
837692|NCT02922660|Inhalation anesthesia
837693|NCT02922660|Desflurane
837694|NCT02922660|Total intravenous anesthesia
837695|NCT02922634|postoperative health outcomes
837696|NCT02922634|older surgical patients
837697|NCT02921581|Dose painting
837698|NCT02921581|18F-FDG
837699|NCT02921581|Positron emission tomography
837700|NCT02921581|Radiotherapy
837701|NCT02921555|RCT (randomized controlled trial)
837702|NCT02922608|Education, Medical
837703|NCT02922543|Multiple Myeloma
837704|NCT02922543|Teratogenicity
837705|NCT02922543|Thrombocytopenia and haemorrhage
837706|NCT02922543|Neutropenia and infection
837707|NCT02922543|Venous thromboembolism
837708|NCT02922543|Allergic reactions
837709|NCT02922543|Diarrhoea or constipation
837710|NCT02922543|Peripheral neuropathy
837711|NCT02922543|Cardiac failure
837712|NCT02922543|Arrhythmia
837713|NCT02922543|Renal failure
837714|NCT02922543|Myocardial infarction
837715|NCT02922543|Interstitial lung disease
837716|NCT02922543|Tumour lysis syndrome
837717|NCT02922517|biomarkers
837718|NCT02922517|echocardiography
837719|NCT02922517|MRI imaging
837720|NCT02922517|nuclear medicine
837721|NCT02922504|First trimester abortion
837722|NCT02922504|Surgical abortion
837723|NCT02922504|Music intervention
837724|NCT02922504|Local anesthesia
837725|NCT02922504|Pain
837726|NCT02922439|chronic disease
837727|NCT02922439|multimorbidity
837728|NCT02922439|chronic disease self-management
837729|NCT02922439|tailored information
837730|NCT02922439|mobile applications
837731|NCT02922426|ALKS 3831
837732|NCT02922426|Samidorphan
837733|NCT02922426|Olanzapine
837734|NCT02922413|Porphyria
837735|NCT02922413|Heme
837736|NCT02922400|Autism
837737|NCT02922400|Traumatic Brain Injury
837738|NCT02922400|Schizophrenia
837739|NCT02922400|Virtual-Reality Social Cognition Training
837740|NCT02922387|varenicline
837741|NCT02922387|COPD
837742|NCT02922387|asthma
837743|NCT02922387|pneumonia
837744|NCT02922387|smoking cessation
837745|NCT02922374|acute severe colitis
837746|NCT02922374|corticosteroids
837747|NCT02922374|UCEIS
837748|NCT02922374|fecal calprotectin
837749|NCT02922348|premature ovarian failure
837750|NCT02922348|hormone replacement
837751|NCT02922335|Antisocial Behavior
837752|NCT02922335|Mental Illness
837753|NCT02922335|Emerging Adulthood
837754|NCT02922335|Criminal Behavior
837755|NCT02922335|Serious Mental Illness
837756|NCT02922322|Mat Pilates
837757|NCT02922322|Chronic Nonspecific low back pain
837758|NCT02922322|Quality of life
837759|NCT02922322|Disability
837760|NCT02922322|transverse abdominal muscle
837761|NCT02922283|T cell response
837762|NCT02922283|Interleukin 2
837763|NCT02922283|PET scan
837764|NCT02922283|Ipilimumab
837765|NCT02922283|Pembrolizumab
837766|NCT02922283|Nivolumab
837767|NCT02922270|peritoneal dialysis: outcome
837768|NCT02922270|peritoneal dialysis: complications
837769|NCT02922270|peritoneal dialysis: technique
837770|NCT02922270|peritoneal dialysis: peritonitis
837771|NCT02922244|herbal products
837772|NCT02922244|reduction of radiation-induced dermatitis
837773|NCT02922244|breast cancer
837774|NCT02922244|radiotherapy
837775|NCT02922192|Anti-inflammatory
837776|NCT02922192|Biologics
837777|NCT02922192|Biologic and Biosimilars Collective Intelligence Consortium
837778|NCT02922192|BBCIC
837779|NCT02922179|Insulin
837780|NCT02922179|Diabetes
837781|NCT02922179|Biologic and Biosimilars Collective Intelligence Consortium
837782|NCT02922179|BBCIC
837783|NCT02922179|Descriptive analysis
837788|NCT02922140|pharmaceutical care service, clinical pharmacist
837789|NCT02922140|Cardiac rehabilitation unit
837790|NCT02922140|Acute coronary syndrome
837791|NCT02922140|patient education and counselling
837792|NCT02922127|Ulipristal Acetate (UPA)
837793|NCT02922127|Breast Cancer
837794|NCT02922127|Combined Oral Contraceptive (COC)
837795|NCT02922114|Ultrasonography
837796|NCT02922114|Clinical assesment
837797|NCT02922114|joint abnormalities
837798|NCT02922088|Vein Graft Failure
837799|NCT02922088|Coronary Artery Bypass Graft Surgery
837800|NCT02922088|Vascular Grafts
837801|NCT02922088|Saphenous Vein Grafts
837802|NCT02922088|Vein Graft Disease
837803|NCT02922088|Vein Graft Treatment
837804|NCT02922088|Vein Graft Handling
837805|NCT02922075|gingival recession
837806|NCT02922075|immediate implant and provisional placement
837807|NCT02922075|bone graft
837808|NCT02922075|connective tissue graft
837809|NCT02922075|collagen matrix
837810|NCT02922062|lipids
837811|NCT02922062|saturated fat
837812|NCT02922062|palm oil
837813|NCT02922049|Probe Based Confocal Laser Endomicroscopy (pCLE)
837814|NCT02922049|Barrett's esophagus
837815|NCT02922049|BORN
837816|NCT02922049|Intestinal metaplasia
837817|NCT02921997|A/H5N1
837818|NCT02921997|A/H7N9
837819|NCT02921997|ASO3 Adjuvant
837820|NCT02921997|influenza
837821|NCT02921997|monovalent
837822|NCT02921997|pH1N1
837823|NCT02921997|vaccines
837824|NCT02921984|Salivary Gland Tumors
837825|NCT02921984|Head and Neck Cancer
837826|NCT02921984|concurrent chemotherapy
837827|NCT02921984|genetic testing
837828|NCT02921958|Parents of children with disabilities
837829|NCT02921932|Physiotherapy
837830|NCT02921932|Inspiratory Muscle Training
837831|NCT02921932|Perioperative Medicine
837832|NCT02921932|Postoperative outcomes
837833|NCT02921932|Preoperative nutrition
837834|NCT02921932|Elderly, frail
837835|NCT02921906|Insulin
837836|NCT02921906|Glucose
837837|NCT02921906|Incretin
837838|NCT02921906|GLP-1
837839|NCT02921906|Food
837840|NCT02921867|ultrasound
837841|NCT02921867|radiology
837842|NCT02921867|simulation
837843|NCT02921867|abdominal ultrasound
837844|NCT02921867|medical education
837845|NCT02921841|Adolescents
837846|NCT02921841|HIV prevention
837847|NCT02921841|computerized intervention
837848|NCT02921841|mental health treatment
837849|NCT02921828|Pomalyst
837850|NCT02921828|Teratogenicity
837851|NCT02921828|bone marrow suppression
837852|NCT02921828|thromboembolism
837853|NCT02921828|peripheral neuropathy
837854|NCT02921828|infection
837855|NCT02921828|tumour lysis syndrome
837856|NCT02921828|somnolence
837857|NCT02921828|depressed level of consciousness
837858|NCT02921828|confusion
837859|NCT02921828|fatigue
837860|NCT02921828|dizziness
837861|NCT02921828|acute renal failure
837862|NCT02921828|heart failure
837863|NCT02921828|arrhythmia
837864|NCT02921828|interstitial pneumonia
837865|NCT02921828|hypersensitivity
837866|NCT02921828|hepatic function disorder
837867|NCT02921828|jaundice
837868|NCT02921815|Leukemia
837869|NCT02921815|Acute Myeloid Leukemia
837870|NCT02921815|Revlimid
837871|NCT02921802|Teratogenicity
837872|NCT02921802|Thrombocytopenia and haemorrhage
837873|NCT02921802|Neutropenia and infection
837874|NCT02921802|Venous thromboembolism
837875|NCT02921802|Allergic reactions
837876|NCT02921802|Diarrhoea or constipation
837877|NCT02921802|Peripheral neuropathy
837878|NCT02921802|Cardiac failure
837879|NCT02921802|Arrhythmia
837880|NCT02921802|Renal failure
837881|NCT02921802|Myocardial infarction
837882|NCT02921802|Interstitial lung disease
837883|NCT02921802|Tumour lysis syndrome
837884|NCT02921802|Transformation from myelodysplastic syndrome to acute myeloid leukemia
837888|NCT02921776|Vidatalk
837889|NCT02921776|App
837890|NCT02921776|Augmentative and Alternative Communication
837891|NCT02921776|iPad
837892|NCT02921776|Android
837893|NCT02921776|Mechanical ventilation
837894|NCT02921776|Patient Communication
837895|NCT02921776|Critical Illness
837896|NCT02921750|wound reduction wound healing, venous ulcers
837897|NCT02921737|metastatic
837898|NCT02921737|pancreatic
837899|NCT02921737|adenocarcinoma
837900|NCT02921724|cancer
837901|NCT02921724|oral drug
837902|NCT02921724|sunitinib
837903|NCT02921724|capecitabine
837904|NCT02921724|mobile app
837905|NCT02921659|nicotinamide riboside
837906|NCT02921659|aging
837907|NCT02921659|arterial stiffness
837908|NCT02921659|endothelial dysfunction
837909|NCT02921646|energetic expenditure
837910|NCT02921633|Immunization
837911|NCT02921633|Behavioural insights
837912|NCT02921633|Children
837913|NCT02921620|Gastrointestinal symptoms
837914|NCT02921620|Diarrhea
837915|NCT02921620|Abdominal pain
837916|NCT02921529|Postoperative recovery
837917|NCT02921529|colon surgery
837918|NCT02921516|Adolescence
837919|NCT02921516|Adherence
837920|NCT02921438|Cardiovascular Diseases
837921|NCT02921438|Heart Diseases
837922|NCT02921438|Myocardial Ischemia
837923|NCT02921438|NSTE ACS
837924|NCT02921438|NSTEMI
837925|NCT02921438|Unstable Angina Pectoris
837926|NCT02921438|Coronary Artery Disease
837927|NCT02921425|lifestyle
837928|NCT02921425|patient health record
837929|NCT02921425|Veterans
837930|NCT02921425|prediabetes
837931|NCT02921373|perfluorocarbon imaging
837932|NCT02921373|peripheral blood mononuclear cells
837933|NCT02921373|cancer immunotherapy
837934|NCT02921373|prostate cancer
837935|NCT02921373|MRI
837936|NCT02921360|thrombolytic therapy
837937|NCT02921360|tissue plasminogen activator
837938|NCT02921360|aspirin
837939|NCT02921321|MRI
837940|NCT02921321|Muscular Dystrophy
837941|NCT02921321|Cardiac
837942|NCT02921321|Late gadolinium enhancement
837943|NCT02921308|Prematurity
837944|NCT02921308|Bronchopulmonary dysplasia
837945|NCT02921308|MRI
837946|NCT02921308|PFT
837947|NCT02921308|Emphysema
837948|NCT02921282|genes
837949|NCT02921282|cues
837950|NCT02921282|reward
837951|NCT02921282|smoking
837952|NCT02921230|atherosclerosis
837953|NCT02921230|Superficial Femoral Artery (SFA)
837954|NCT02921230|Proximal Popliteal Artery (PPA)
837955|NCT02921230|stenting
837956|NCT02921230|paclitaxel
837957|NCT02921217|Cardiovascular diseases
837958|NCT02921217|abdominal visceral fat
837959|NCT02921217|subcutaneous body fat
837960|NCT02921217|body weight
837961|NCT02921217|waist circumference
837962|NCT02921217|lipid profile
837963|NCT02921217|insulin resistance
837964|NCT02921217|glucose metabolism
837965|NCT02921217|blood pressure
837966|NCT02921217|inflammation
837967|NCT02921217|adiponectin
837968|NCT02921217|leptin
837969|NCT02921217|metabolomics
837970|NCT02921217|cardiovascular risk factor
837971|NCT02921204|Vitamin D
837972|NCT02921204|Calcium
837973|NCT02921204|Phytic Acid
837974|NCT02921204|body weight
837975|NCT02921191|recombinant human granulocyte colony-stimulating factors
837976|NCT02921191|G-CSFs
837977|NCT02921191|biosimilar
837978|NCT02921191|biologics
837979|NCT02921191|High Neutropenia Risk Chemotherapy
837980|NCT02921191|Biologic and Biosimilars Collective Intelligence Consortium
837981|NCT02921191|bbcic
837982|NCT02921165|tooth extraction
837983|NCT02921165|tooth socket healing
837984|NCT02921165|hypertension
837985|NCT02921165|rinses
837986|NCT02921139|Hepatocellular Carcinoma
837987|NCT02921139|Transcatheter Arterial Chemoembolization (TACE)
837988|NCT02921139|Stereotactic ablative radiotherapy (SABR)
837989|NCT02921113|suPAR
837990|NCT02921113|Acute Kidney Injury
837991|NCT02921113|On-Pump Cardiac Surgery
837992|NCT02921113|Biomarker
837993|NCT02921048|Eicosapentaenoic Acid
837994|NCT02921048|Docosahexaenoic Acid
837995|NCT02921048|Ambient Air Pollution
837996|NCT02921035|Relapsing Multiple Sclerosis
837997|NCT02921035|Interferon beta-1a
837998|NCT02921035|Rebif®
837999|NCT02921035|Morisky Medication Adherence Scale
838000|NCT02921022|Gemcitabine
838001|NCT02921022|Nab-paclitaxel
838002|NCT02921022|PEGPH20
838003|NCT02921022|Rivaroxaban
838004|NCT02921022|thromboembolic event (TE)
838005|NCT02921022|16-1066
838006|NCT02920996|NSCLC
838007|NCT02920996|MET
838008|NCT02920996|Non-small cell lung cancer
838009|NCT02920996|MET mutation
838010|NCT02920996|NTRK rearrangement
838011|NCT02920996|NTRK
838012|NCT02920996|targeted therapy
838013|NCT02920996|MET exon 14
838014|NCT02920996|NTRK1
838015|NCT02920996|NTRK2
838016|NCT02920996|NTRK3
838017|NCT02920996|merestinib
838018|NCT02920996|LY2801653
838019|NCT02920918|Systolic Heart Failure
838020|NCT02920918|Canagliflozin
838021|NCT02920918|Sitagliptin Phosphate
838022|NCT02920918|Type 2 Diabetes
838023|NCT02920918|SGLT2 inhibitor
838024|NCT02920918|DPPIV inhibitor
838025|NCT02920866|Functional strength integration
838026|NCT02920866|Rehabilitation
838027|NCT02920866|Hip arthroplasty
838028|NCT02920866|Physical function
838029|NCT02920866|Muscle performance
838030|NCT02920866|Movement compensations
838031|NCT02920853|chronic pain
838032|NCT02920827|HIV Infections
838033|NCT02920827|HIV seronegativity
838034|NCT02920801|saxagliptin
838035|NCT02920801|endothelial progenitor cell
838036|NCT02920801|flow-mediated dilation
838037|NCT02920788|Rehabilitation
838038|NCT02920788|Functional Magnetic Resonance Imaging
838039|NCT02920749|anaesthesia
838040|NCT02920749|costs
838041|NCT02920749|recovery profiles
838042|NCT02920723|Sleep Apnea Syndromes
838043|NCT02920723|Sleep Apnea, Obstructives
838044|NCT02920723|Training
838045|NCT02920684|Early rehabilitation
838046|NCT02920684|Mechanical ventilation
838047|NCT02920684|Physiotherapy
838048|NCT02920658|NAVS Naphthalan
838049|NCT02920658|Betamethasone dipropionate
838050|NCT02920658|Topical treatment
838051|NCT02920645|ICH
838052|NCT02920645|AVM
838053|NCT02920645|intracerebral hemorrhage
838054|NCT02920645|arterio-venous malformation
838055|NCT02920645|AVICH
838056|NCT02920632|Parkinson
838057|NCT02920632|Cognitive training
838058|NCT02920632|Cognitive rehabilitation
838059|NCT02920632|Brain networks
838060|NCT02920619|ultrasound
838061|NCT02920619|muscle
838062|NCT02920606|pulpotomy
838063|NCT02920606|pulpitis
838064|NCT02920606|mature tooth
838065|NCT02920606|tricalcium silicate
838066|NCT02920593|Vitamin D; hypertensive disorders of pregnancy
838067|NCT02920580|Subarachnoid hemorrhage
838068|NCT02920580|Spontaneous intracerebral hemorrhage
838069|NCT02920580|Global cerebral anoxia/cardiac arrest
838070|NCT02920580|Meningitis/Encephalitis/Cerebral abscess
838071|NCT02920580|Seizure
838072|NCT02920580|Traumatic Brain Injury (TBI)
838073|NCT02920580|Ischemic Stroke
838074|NCT02920580|Brain tumor
838075|NCT02920554|gallbladder cancer
838076|NCT02920554|bisegmentectomy
838077|NCT02920515|epidemiology
838078|NCT02920515|treatment
838079|NCT02920515|molecular pathological mechanism
838080|NCT02920515|environmental disrupting chemicals
838081|NCT02920489|severity of labor pain
838082|NCT02920489|individualized administration
838083|NCT02920489|neuraxial labor analgesia
838084|NCT02920476|lung
838085|NCT02920476|metastatic
838086|NCT02920476|carcinoma
838087|NCT02920463|Anti-Infective agents
838088|NCT02920463|Antimicrobial stewardship
838089|NCT02920463|Empirical antibiotic therapy
838090|NCT02920463|De-escalation
838091|NCT02920463|Critical care
838092|NCT02920450|lung
838093|NCT02920450|carcinoma
838094|NCT02920437|dietary salt
838095|NCT02920437|24 hour urinary sodium excretion
838096|NCT02920437|blood pressure
838097|NCT02920437|hypertension
838098|NCT02920346|Neonatal Systemic lupus erythematosus
838099|NCT02920346|Sjogren's syndrome
838100|NCT02920346|Fetal Atrioventricular Block
838101|NCT02920346|Fetal Heart Block
838102|NCT02920333|stroke
838103|NCT02920333|transcraniel direct current stimulation
838104|NCT02920333|repetitive transcraniel magnetic stimulation
838105|NCT02920333|rehabilitation
838106|NCT02920333|lower extremeties
838107|NCT02920307|laparoscopic inguinal hernia repair
838108|NCT02920307|total extraperitoneoscopic hernia repair
838109|NCT02920307|transabdominal preperitoneal hernia repair
838110|NCT02920307|inguinal hernia
838111|NCT02920307|laparoscopy
838112|NCT02920307|hernia repair
838113|NCT02920307|herniorraphy
838114|NCT02920307|laparoscopic surgery
838115|NCT02920294|probiotics, microbiota, ileostoma
838116|NCT02920268|dance-intervention
838117|NCT02920268|yoga
838118|NCT02920268|adolescents
838119|NCT02920268|recurrent abdominal pain
838120|NCT02920242|Travelers
838121|NCT02920242|diarrhea
838122|NCT02920242|rifaximin
838123|NCT02920242|equivalence
838124|NCT02920229|68Ga-PSMA
838125|NCT02920229|HBED-PET/CT
838126|NCT02920229|biochemical relapse
838127|NCT02920229|prostate cancer
838128|NCT02920229|radically treated
838129|NCT02920216|Head and Neck Neoplasms
838130|NCT02920216|Recurrence
838131|NCT02920216|Indocyanine Green
838132|NCT02920216|Salvage surgery
838133|NCT02920203|Sudden unexpected death
838134|NCT02920203|young subjects
838135|NCT02920203|molecular genetic autopsy
838136|NCT02920203|sequencing
838137|NCT02920138|Obesity
838138|NCT02920138|intraabdominal pressure
838139|NCT02920138|cerebral oxymeter
838140|NCT02920138|sleeve gastrectomy
838141|NCT02920138|laparoscopy
838142|NCT02920125|Vascular disease
838143|NCT02920112|Obesity
838144|NCT02920112|Bariatric Surgery
838145|NCT02920112|Bariatrics
838146|NCT02920112|Cognitive Therapy
838147|NCT02920112|Binge eating
838148|NCT02920099|Nutrition literacy
838149|NCT02920073|Microbiota
838150|NCT02920073|anorexia nervosa
838151|NCT02920073|under nutrition
838152|NCT02920073|inpatients
838153|NCT02920073|enteral nutrition
838154|NCT02920060|RSE
838155|NCT02920047|Fimasartan
838157|NCT02919982|Anticoagulant
838158|NCT02919982|Nonvalvular atrial fibrillation
838159|NCT02919982|Registries
838160|NCT02919969|Anal Cancer
838161|NCT02919956|Single Ventricle
838162|NCT02919956|Fontan
838163|NCT02919904|prostate cancer
838164|NCT02919904|sleep
838165|NCT02919904|androgen deprivation therapy
838166|NCT02919891|intra-epidermal nerve fibre density
838167|NCT02919891|IENFD
838168|NCT02919891|Chronic Pain
838169|NCT02919891|Post-mastectomy
838170|NCT02919891|Post-mastectomy pain syndrome
838171|NCT02919891|PMPS
838172|NCT02919891|Chronic Post-Surgical Pain
838173|NCT02919891|CPSP
838174|NCT02919891|Mastectomy
838175|NCT02919813|mindfulness group therapy
838176|NCT02919813|vulvodynia
838177|NCT02919813|vulvar pain
838178|NCT02919787|Neoadjuvant treatment
838179|NCT02919761|persistant disease activity
838180|NCT02919748|dementia
838181|NCT02919748|cognitive decline
838182|NCT02919748|choral singing
838183|NCT02919748|health education program
838184|NCT02919748|randomized controlled trial
838185|NCT02919735|Alopecia
838186|NCT02919735|Hair
838187|NCT02919735|Chemotherapy
838188|NCT02919735|Cancer
838189|NCT02919722|Music therapy
838190|NCT02919722|sensorimotor cortex
838191|NCT02919722|brain injury
838192|NCT02919696|CDK4/6 Inhibitor
838193|NCT02919683|Head and Neck Cancer
838194|NCT02919670|Stem Cell Transplant
838195|NCT02919644|vaccination
838196|NCT02919644|autologous dendritic cells
838197|NCT02919644|autologous tumour homogenate
838198|NCT02919644|curative resection
838199|NCT02919644|stage IV colorectal cancer
838200|NCT02919618|Ventricular Tachycardia
838201|NCT02919618|Ablation
838202|NCT02919618|Noninvasive
838203|NCT02919605|Cutaneous Leishmaniasis
838204|NCT02919605|pentamidine isothionate
838205|NCT02919605|treatment
838206|NCT02919553|endoscopic ultrasound
838207|NCT02919553|wet-suction technique
838208|NCT02919553|capillary technique
838209|NCT02919553|fine needle aspiration
838210|NCT02919553|fine needle biopsy
838211|NCT02919514|fall prevention
838212|NCT02919514|Aging
838213|NCT02919514|surfaces
838214|NCT02919475|JTE-051
838215|NCT02919475|Active Rheumatoid Arthritis
838216|NCT02919475|Efficacy
838217|NCT02919475|Safety
838218|NCT02919475|Tolerability
838219|NCT02919475|Rheumatoid Arthritis
838220|NCT02919462|Carcinoma, Non-Small-Cell Lung
838221|NCT02919462|advanced stage IIIB
838222|NCT02919462|high Thymidylate Synthase expression
838223|NCT02919462|Treatment
838224|NCT02919462|Chemotherapy Naïve Patients
838225|NCT02919462|stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
838226|NCT02919462|Cisplatin and Pemetrexed
838227|NCT02919462|Cisplatin and Oral Vinorelbine
838228|NCT02919449|Lung Cancer Measles Nivolumab Opdivo
838229|NCT02918656|Cochrane
838230|NCT02918656|Abstract
838231|NCT02918656|Infographics
838232|NCT02918656|Understanding
838233|NCT02918643|Elderly
838234|NCT02918643|Potentially Inappropriate Medications
838235|NCT02918630|E-cigarettes
838236|NCT02918630|Schizophrenia
838237|NCT02918617|dentin hypersensitivity
838238|NCT02918617|nanohydroxyapatite
838239|NCT02918617|calcium sodium phosphosilicate
838240|NCT02918617|toothpaste
838241|NCT02918617|tooth cream
838242|NCT02918604|peripheral vein access
838243|NCT02918604|infrared
838244|NCT02918604|pediatric
838245|NCT02918578|Physical Inactivity
838246|NCT02918578|Behavior Change
838247|NCT02918526|Laryngeal masks
838248|NCT02918513|Wellness
838249|NCT02918513|Mental Wellness
838250|NCT02918513|Well-Being
838251|NCT02918500|Coronary Artery Bypass Surgery (CABG)
838252|NCT02918500|Nicotine Replacement Therapy (NRT)
838253|NCT02919384|Embryonic development
838254|NCT02919384|blastocyst stage
838255|NCT02919345|Dapagliflozin
838256|NCT02919345|Glibenclamide
838257|NCT02919345|Endothelial Function
838258|NCT02919345|Vascular Endothelial Cells
838259|NCT02919345|Flow Mediated Dilation
838260|NCT02919267|One lung ventilation
838261|NCT02919267|Lung collapse
838262|NCT02919267|Bronchial blocker
838263|NCT02919267|Double lumen tube
838264|NCT02919267|video assisted thoracoscopic surgery
838265|NCT02919267|VATS
838266|NCT02919267|DLT
838267|NCT02919267|Thoracic surgery
838268|NCT02919267|Video-assisted
838269|NCT02919241|dental anxiety
838270|NCT02919241|cognitive therapy
838271|NCT02919228|cerebral oxygen metabolism
838272|NCT02919228|functional near-infrared spectroscopy
838273|NCT02919228|partial pressure of carbon dioxide
838274|NCT02919228|heart rate variability
838275|NCT02919228|blood pressure
838276|NCT02919228|affect
838277|NCT02919228|mood
838278|NCT02919228|respiration
838279|NCT02919228|systematic randomized cross-over study
838280|NCT02919228|systemic physiology
838281|NCT02919228|electro-dermal activity
838282|NCT02919228|pulse-respiratory quotient
838283|NCT02919189|cerebral oxygen metabolism
838284|NCT02919189|functional near-infrared spectroscopy
838285|NCT02919189|partial pressure of carbon dioxide
838286|NCT02919189|heart rate variability
838287|NCT02919189|blood pressure
838288|NCT02919189|affect
838289|NCT02919189|mood
838290|NCT02919189|respiration
838291|NCT02919189|systematic randomized cross-over study
838292|NCT02919189|systemic physiology
838293|NCT02919189|electro-dermal activity
838294|NCT02919189|pulse-respiratory quotient
838295|NCT02919163|cerebral oxygen metabolism
838296|NCT02919163|functional near-infrared spectroscopy
838297|NCT02919163|partial pressure of carbon dioxide
838298|NCT02919163|heart rate variability
838299|NCT02919163|blood pressure
838300|NCT02919163|affect
838301|NCT02919163|mood
838302|NCT02919163|respiration
838303|NCT02919163|systematic randomized cross-over study
838304|NCT02919163|systemic physiology
838305|NCT02919163|electro-dermal activity
838306|NCT02919163|pulse-respiratory quotient
838307|NCT02919150|Myofascial Trigger Points
838308|NCT02919150|Myotonometry
838309|NCT02919150|Isokinetic Dynamometry
838310|NCT02919150|Assessment
838311|NCT02919150|Reliability
838312|NCT02919137|cerebral oxygen metabolism
838313|NCT02919137|functional near-infrared spectroscopy
838314|NCT02919137|partial pressure of carbon dioxide
838315|NCT02919137|heart rate variability
838316|NCT02919137|blood pressure
838317|NCT02919137|affect
838318|NCT02919137|mood
838319|NCT02919137|respiration
838320|NCT02919137|systematic randomized cross-over study
838321|NCT02919137|systemic physiology
838322|NCT02919137|electro-dermal activity
838323|NCT02919137|pulse-respiratory quotient
838324|NCT02919124|Coronary artery bypass grafting
838325|NCT02919124|Anastomosis
838326|NCT02919124|Ultrasonography
838327|NCT02919059|Diabetes Mellitus, Type 2
838328|NCT02919059|DM
838329|NCT02919046|neuroblastoma
838330|NCT02919046|CAR-T
838331|NCT02919033|randomized controlled trial
838332|NCT02919033|telemedicine
838333|NCT02919033|hypertension
838334|NCT02919033|primary care
838335|NCT02919033|medication adherence
838336|NCT02919020|Proprioceptive Neuromuscular Facilitation (PNF )
838337|NCT02919020|resistance exercise
838338|NCT02918968|enzalutamide
838339|NCT02918968|Xtandi
838340|NCT02918968|Prostate Cancer
838341|NCT02918955|head and neck cancer
838342|NCT02918955|radiotherapy
838343|NCT02918955|chemotherapy
838344|NCT02918955|neck dissection
838345|NCT02918955|surgery
838346|NCT02918955|quality of life
838347|NCT02918955|toxicity
838348|NCT02918955|oropharyngeal cancer
838349|NCT02918955|laryngeal cancer
838350|NCT02918955|hypopharyngeal cancer
838351|NCT02918929|First-in-human
838352|NCT02918929|Single Ascending Dose
838353|NCT02918929|Multiple Ascending Dose
838354|NCT02918890|Pediatric
838355|NCT02918890|HABIT
838356|NCT02918890|CIMT
838357|NCT02918890|Cerebral Palsy
838358|NCT02918890|Hemiplegia
838359|NCT02918890|Children
838360|NCT02918890|Therapy
838361|NCT02918877|Volatile Anesthetics
838362|NCT02918877|Intravenous Anesthetics
838363|NCT02918877|Inflammatory Lung Injury
838364|NCT02918877|Postoperative Pulmonary Complications
838365|NCT02918877|Cardiac Surgery
838366|NCT02918877|Cardiopulmonary Bypass
838367|NCT02918864|Autism Spectrum Disorder
838368|NCT02918864|Oxytocin
838369|NCT02918864|Social Skills
838370|NCT02918864|Social cognitive skills
838371|NCT02918864|Cognitive Behavioral Intervention
838372|NCT02918864|Combination treatment
838373|NCT02918864|Syntocinon
838374|NCT02918864|NETT (Nonverbal communication, Emotion recognition, Theory of mind Training)
838375|NCT02918864|emotion recognition
838376|NCT02918864|theory of mind
838377|NCT02918838|HIV
838378|NCT02918838|Antiretroviral (ARV)
838379|NCT02918838|co-trimoxazole
838380|NCT02918838|SMS
838381|NCT02918838|Lottery incentive
838382|NCT02918838|mobile health
838383|NCT02918838|Uganda
838384|NCT02918838|Youth
838385|NCT02918825|schizophrenia
838386|NCT02918825|clinical trial
838387|NCT02918825|olanzapine
838388|NCT02918825|paliperidone
838389|NCT02918812|Hysterosalpingography
838390|NCT02918812|Pain relief
838391|NCT02918812|Infertility
838392|NCT02918812|Intracervical block
838393|NCT02918812|Diclofenac
838394|NCT02918786|oxygen therapy
838395|NCT02918786|continuous positive airway pressure
838396|NCT02918786|extubation
838397|NCT02918773|Pediatrics
838398|NCT02918773|Emergency Medicine
838399|NCT02918773|Ear infection
838400|NCT02918760|Gabapentin, chronic pelvic pain.
838401|NCT02918734|Anterior Cruciate Ligament
838402|NCT02918734|Bone-Patellar Tendon-Bone Grafting
838403|NCT02918721|Hyaluronic Acid, Nasolabial Fold, Lidocaine
838404|NCT02918708|vaccination
838405|NCT02918708|immunisation
838406|NCT02918708|pneumococcal
838407|NCT02918708|conjugate
838408|NCT02918695|Geriatric assessment
838409|NCT02918695|Fit and frail elderly
838410|NCT02918695|Geriatric oncology
838411|NCT02918474|Contralateral prophylactic breast cancer
838412|NCT02918474|CPM
838413|NCT02918474|Breast cancer surgery
838414|NCT02918474|Breast Cancer
838415|NCT02918474|Questionnaire
838416|NCT02918474|Survey
838417|NCT02918474|Decision tool
838418|NCT02918474|Contralateral Prophylactic Mastectomy
838419|NCT02918422|Diet Intervention
838420|NCT02918422|Metabolic Syndrome
838421|NCT02918422|Feeding Study
838422|NCT02918422|Prediabetes
838423|NCT02918396|Atrial Fibrillation
838424|NCT02918396|Atrial Fibrosis
838425|NCT02918396|Late Gadolinium Enhancement Magnetic Resonance Imaging
838426|NCT02918396|Computational Modeling
838427|NCT02918396|Rotor Anchor Sites
838428|NCT02918370|Alcohol Use Disorder
838429|NCT02918370|Bipolar Disorder
838430|NCT02918370|Mood
838431|NCT02918370|Alcohol Craving
838432|NCT02918370|Aripiprazole
838433|NCT02918344|calcium phosphate paste
838434|NCT02918305|denervation
838435|NCT02918305|resistant hypertension
838436|NCT02918292|Unrelated Cord Blood (UCB)
838437|NCT02918292|Haploidentical Bone Marrow
838438|NCT02918292|Hematopoietic Stem Cell Transplant (HSCT)
838439|NCT02918292|Severe Aplastic Anemia (SAA)
838440|NCT02918292|Antithymocyte Globulin (ATG)
838441|NCT02918266|Drug Therapy
838442|NCT02918253|High dose-rate brachytherapy
838443|NCT02918227|Ejaculation
838444|NCT02918227|Benign Prostatic Hyperplasia
838445|NCT02918227|Prostate
838446|NCT02918214|Septic Shock
838447|NCT02918214|echocardiography
838448|NCT02918214|diastolic dysfunction
838449|NCT02918214|Transthoracic
838450|NCT02918214|Transesophageal
838451|NCT02918214|hyperkinesia
838452|NCT02918214|prognosis
838453|NCT02918201|Administration, topical
838454|NCT02918201|Tranexamic Acid
838455|NCT02918201|Postoperative Care
838456|NCT02918201|Bandages
838457|NCT02918201|Occlusive Dressings
838458|NCT02918175|mHealth
838459|NCT02918162|pembrolizumab
838460|NCT02918162|adenocarcinoma
838461|NCT02918162|gastric cancer
838462|NCT02918162|Locoregional gastric adenocarcinoma
838463|NCT02918162|Locoregional GE junction adenocarcinoma
838464|NCT02918149|Ultrasonography
838465|NCT02918149|Infant
838466|NCT02918149|Newborn
838467|NCT02918149|Lumbar puncture
838468|NCT02918149|Spinal puncture
838469|NCT02918149|Cerebrospinal fluid
838470|NCT02918123|Psoriasis
838471|NCT02918123|Plaque psoriasis
838472|NCT02918123|Stem cell
838473|NCT02918123|Cell therapy
838474|NCT02918123|Furestem
838475|NCT02918123|Mesenchymal stem cell
838476|NCT02918123|MSC
838477|NCT02918123|Umbilical cord blood
838478|NCT02918123|hUCB-MSC
838479|NCT02918123|UCB-MSC
838480|NCT02918097|Cost effectiveness
838481|NCT02918097|Bipolar disorder
838482|NCT02918097|Depressive episodes
838483|NCT02918097|Quality of Life
838484|NCT02918084|sequential administration chemiotherapy
838485|NCT02918084|early breast cancer
838486|NCT02918084|breast cancer
838487|NCT02918084|aromatase inhibitor
838488|NCT02918084|adjuvant
838489|NCT02918084|post menopausal
838490|NCT02918071|Asthma,
838491|NCT02918071|Bronchial Diseases,
838492|NCT02918071|Respiratory Tract Diseases,
838493|NCT02918071|Lung Diseases,
838494|NCT02918071|Obstructive Lung Diseases,
838495|NCT02918071|Benralizumab
838496|NCT02918058|Frailty
838497|NCT02918058|Deprescription
838498|NCT02918045|Tooth Extraction
838499|NCT02918045|Surgical Hemostasis
838500|NCT02918045|Platelet Aggregation Inhibitors
838501|NCT02918045|Chitosan
838502|NCT02918032|Jordans anomaly
838503|NCT02918032|neutral lipid storage disease
838504|NCT02918032|triglyceride deposit cardiovasculopathy
838505|NCT02918032|ATGL gene
838506|NCT02918032|CGI-58 gene
838507|NCT02918032|primary triglyceride deposit cardiomyovasculopathy (TGCV)
838508|NCT02918032|neutral lipid storage disease with myopathy (NLSD-M)
838509|NCT02917993|non-small cell lung cancer
838510|NCT02917993|locally advanced
838511|NCT02917993|metastatic
838512|NCT02917993|epidermal growth factor receptor (EGFR) inhibition
838513|NCT02917993|Janus kinase inhibition
838514|NCT02917980|structural Heart Diseases
838515|NCT02917980|surgical treatment
838516|NCT02917980|interventional treatment
838517|NCT02917980|hybrid treatment
838518|NCT02917954|eHealth/mHealth solutions
838519|NCT02917954|complex care needs
838520|NCT02917954|seniors
838521|NCT02917954|patient-centred care
838522|NCT02917954|goal-oriented care
838523|NCT02917954|primary health care
838524|NCT02917954|implementation
838525|NCT02917954|pragmatic trial
838526|NCT02917954|health outcomes
838527|NCT02917954|cost-effectiveness analysis
838528|NCT02917928|carnosine, type 2 diabetes, cardiovascular factors
838529|NCT02917915|COPD
838530|NCT02917915|Emphysema
838531|NCT02917915|Chronic Bronchitis
838532|NCT02917915|Pulmonary rehabilitation
838533|NCT02917915|Lung Diseases, Obstructive
838534|NCT02917902|student-run free clinic
838535|NCT02917902|food supply
838536|NCT02917902|food insecure
838537|NCT02917902|medically uninsured
838538|NCT02917902|medically underserved
838539|NCT02917889|Caffeine
838540|NCT02917889|Autonomic Nervous System
838541|NCT02917889|Recovery
838542|NCT02917889|Aerobic exercise
838543|NCT02917876|Obstructive Sleep Apnea
838544|NCT02917876|Pregnancy
838545|NCT02917876|Obesity
838546|NCT02917876|Fluid shifts
838547|NCT02917876|Body composition
838548|NCT02917876|Sleep
838549|NCT02917863|Hypothyroidism
838550|NCT02917863|Microbiota
838551|NCT02917863|Thyroid hormone
838552|NCT02917863|L-Thyroxine
838553|NCT02917863|Celiac disease
838554|NCT02917850|stroke
838555|NCT02917850|gait
838556|NCT02917850|hip flexors
838557|NCT02917850|paresis
838558|NCT02917850|hemiplegia
838559|NCT02917798|Genetic Testing
838560|NCT02917798|16-919
838561|NCT02917772|tailored immuno therapy
838562|NCT02917772|Nivolumab
838563|NCT02917772|Ipilimumab
838564|NCT02917772|boost
838565|NCT02917759|liver cancer
838566|NCT02917759|biliary tract cancer
838567|NCT02917759|cholangiocarcinoma
838568|NCT02917759|hepatocellular carcinoma
838569|NCT02917759|liver tumor
838570|NCT02917759|biliary tumor
838571|NCT02917759|hepatoma
838572|NCT02917759|liver mass
838573|NCT02917746|Cervical intraepithelial neoplasia
838574|NCT02917746|Imiquimod
838575|NCT02917746|Treatment
838576|NCT02917746|Predictive biomarkers
838577|NCT02917720|TKI discontinuation
838578|NCT02917707|CRC
838579|NCT02917707|liver metastasis
838580|NCT02917681|ALS
838581|NCT02917681|mesenchymal stem cells
838582|NCT02917681|intrathecal
838583|NCT02917668|Obesity
838584|NCT02917668|Hyperoxia
838585|NCT02917668|Hypercapnia
838586|NCT02917668|Postoperative complications
838587|NCT02917668|Cardiac surgical procedures
838588|NCT02917655|Education
838589|NCT02917655|Quality of Life
838590|NCT02917655|Osteoarthritis
838591|NCT02917655|Metabolic Syndrome
838592|NCT02917642|bacterial infection
838593|NCT02917642|endotoxin
838594|NCT02917642|passive ultrasonic irrigation
838595|NCT02917642|root canal treatment
838596|NCT02917590|Spinal cord injury
838597|NCT02917590|dual-task obstacle crossing
838598|NCT02917564|Choroidal effusions
838599|NCT02917564|Trabeculectomy
838600|NCT02917551|Bacteremia, duration, non-critically ill, non-ICU
838601|NCT02917525|Calcium metabolism
838602|NCT02917525|Matrix Gla Protein
838603|NCT02917525|Vitamin K2
838604|NCT02917486|ExtraCorporeal Membrane Oxygenation
838605|NCT02917486|patient in intensive care
838606|NCT02917486|pharmacokinetic modeling
838607|NCT02917473|Medical skin examination
838608|NCT02917473|Skin Self Examination
838609|NCT02917473|Sun protection
838610|NCT02917460|Rady
838611|NCT02917460|Pediatric
838612|NCT02917460|Genomic
838613|NCT02917460|Precision medicine
838614|NCT02917460|Biorepository
838615|NCT02917447|PTSD
838616|NCT02917447|Women Veterans
838617|NCT02917447|Online intervention
838618|NCT02917434|Obesity
838619|NCT02917434|Psoriatic arthritis
838620|NCT02917434|Psoriasis
838621|NCT02917434|Metabolic syndrome
838622|NCT02917434|Cardiovascular disease
838623|NCT02917395|hypertrophic cardiomyopathy, disopyramide,
838624|NCT02917369|LCLC; Integrative Analysis; Metastasis
838625|NCT02917356|Healing touch
838626|NCT02917356|Faith Healing
838627|NCT02917356|Pain
838628|NCT02917356|Joint stiffness
838629|NCT02917356|Functional status
838630|NCT02917356|Mental health
838631|NCT02917356|Osteoarthritis
838632|NCT02917304|Quadrivalent Influenza Vaccines
838633|NCT02917291|Trauma Spinal Cord
838634|NCT02917291|Thoracic Acute Spinal Cord Injury
838635|NCT02917291|Neurosurgery
838636|NCT02917291|Cell Therapy
838637|NCT02917291|ATMP
838638|NCT02917291|HC016 adipose mesenchymal stem cell
838639|NCT02917291|SPINE
838640|NCT02916641|Fuzhenghuayu
838641|NCT02917213|acute myocardial infarction
838642|NCT02917213|cardiac embolism
838643|NCT02917213|intracardiac fluid dynamics
838644|NCT02917213|silent brain infarct
838645|NCT02917213|intracardiac blood stasis
838646|NCT02917174|asthma
838647|NCT02917174|m-health
838648|NCT02917174|asthma control
838649|NCT02917174|self-management
838650|NCT02917161|Prostate
838651|NCT02917161|Prostatic Neoplams
838652|NCT02917161|Therapeutic Embolization
838653|NCT02917161|Prostatectomy
838654|NCT02917122|Parkinson disease
838655|NCT02917122|transcranial direct current stimulation
838656|NCT02917122|depression
838657|NCT02917122|dopamine transporter
838658|NCT02917122|single photon emission computerized tomography
838659|NCT02917083|chimeric antigen receptors
838660|NCT02917083|immunotherapy
838661|NCT02917083|CAR T-cells
838662|NCT02917083|lymphoma
838663|NCT02917083|Cyclophosphamide
838664|NCT02917083|fludarabine
838665|NCT02917070|Consanguinity-associated kidney diseases
838666|NCT02917070|Turkey population
838667|NCT02917031|Type 2 Diabetes Mellitus
838668|NCT02917031|Heart Failure
838669|NCT02917031|Saxagliptin
838670|NCT02917031|Sitagliptin
838671|NCT02917018|Dexmedetomidine
838672|NCT02917018|Stress response
838673|NCT02917018|Emergence agitation
838674|NCT02917005|breast cancer
838675|NCT02917005|hormone receptor positive, HER2 negative
838676|NCT02917005|palbociclib
838677|NCT02917005|premenopausal
838678|NCT02916992|spontaneous pneumothorax
838679|NCT02916992|familial pneumothorax
838680|NCT02916992|Birt-Hogg-Dube syndrome
838681|NCT02916992|prevalence
838682|NCT02916992|FLCN mutation
838683|NCT02916992|Lung cysts
838684|NCT02916992|BHD
838685|NCT02916992|inherited disease
838686|NCT02916992|genetic disease
838687|NCT02916992|primary pneumothorax
838688|NCT02916992|CAT scan
838689|NCT02916992|CT scan
838690|NCT02916940|sprains of the proximal interphalangeal joints of the long fingers
838691|NCT02916940|Diprophos
838692|NCT02916927|ketamine
838693|NCT02916927|emergency department
838694|NCT02916914|preterm
838695|NCT02916914|feeding
838696|NCT02916914|oral transition
838697|NCT02916901|Dyslipidemia
838698|NCT02916901|CKD-519
838699|NCT02916901|CETP inhibitor
838700|NCT02916901|ABPM
838701|NCT02916888|Atopic dermatitis
838702|NCT02916888|Topical corticosteroid
838703|NCT02916888|Pediatric
838704|NCT02916888|Eczema
838705|NCT02916888|Quality of life
838706|NCT02916875|Shared decision Making
838707|NCT02916875|Follow-up
838708|NCT02916862|fiber
838709|NCT02916862|calcium absorption
838710|NCT02916862|bone mass
838711|NCT02916862|adolescents
838712|NCT02916849|Accidental Falls
838713|NCT02916849|Prevention & Control
838714|NCT02916849|Exercise
838715|NCT02916849|Exercise therapy/methods*
838716|NCT02916849|Aged
838717|NCT02916849|Aged 80 and over
838718|NCT02916849|Smartphone
838719|NCT02916849|Computers
838720|NCT02916849|Computers handheld
838721|NCT02916849|Motivation
838722|NCT02916849|Postural balance
838723|NCT02916849|Health behaviour
838724|NCT02916849|mHealth
838725|NCT02916849|eHealth
838726|NCT02916810|transcranial magnetic stimulation
838727|NCT02916810|schizophrenia
838728|NCT02916810|MRI
838729|NCT02916797|Feedback
838730|NCT02916797|Physical Therapy
838731|NCT02916784|Sit-to-stand
838732|NCT02916784|Walking devices
838733|NCT02916771|Smoldering Multiple Myeloma
838734|NCT02916758|older adults
838735|NCT02916758|community mobility
838736|NCT02916758|wellness
838737|NCT02916758|isolation
838742|NCT02916732|asymptomatics
838743|NCT02916732|microcephaly
838744|NCT02916732|abnormalities
838745|NCT02916719|neo-adjuvant radiotherapy
838746|NCT02916719|breast cancer
838747|NCT02916719|MRI
838748|NCT02916693|Mirabegron
838749|NCT02916693|Overactive Bladder
838750|NCT02916693|Erectile Dysfunction
838751|NCT02916693|Beta 3 agonist
838752|NCT02916680|Pancreatic islet transplantation
838753|NCT02916628|smoking cessation
838754|NCT02916628|group counseling
838755|NCT02916628|acupressure
838756|NCT02916628|serotonin
838757|NCT02916628|depressive symptoms
838758|NCT02916628|resilience
838759|NCT02916537|prostate cancer
838760|NCT02916537|prostate specific membrane antigen
838761|NCT02916537|prostate neoplasms
838762|NCT02916537|metastatic prostate cancer
838763|NCT02916537|prostatic hyperplasia
838764|NCT02916524|Aphasia
838765|NCT02916524|Bilingualism
838766|NCT02916524|Language therapy
838767|NCT02916524|Rehabilitation of speech and language disorders
838768|NCT02916524|Speech-language pathology
838769|NCT02916498|chronic neuropathic pain in the low back and legs
838770|NCT02916498|subperception spinal cord stimulation
838771|NCT02916485|bioresorbable scaffold
838772|NCT02916485|vascular restoration therapy
838773|NCT02916472|AYA
838774|NCT02916472|exercise
838775|NCT02916472|cancer
838776|NCT02916472|cybercycling
838777|NCT02916407|Anesthesia
838778|NCT02916407|Agitation
838779|NCT02916407|Extubation
838780|NCT02916316|Lymphoma
838781|NCT02916316|Large B-Cell
838782|NCT02916316|Cardiotoxicity
838783|NCT02916303|Schizophrenia
838784|NCT02916303|Psychosis
838785|NCT02916303|Effectiveness
838786|NCT02916290|Fuzhenghuayu
838787|NCT02916264|scalp block, surgical peth index
838788|NCT02916160|Chronic Heart failure
838789|NCT02916160|Sleep Apnea Syndrome
838790|NCT02916160|Continuous Positive Airways Pressure
838791|NCT02916160|SACUBITRIL - VALSARTAN
838792|NCT02916108|Concussion
838793|NCT02916108|Mild traumatic brain injury
838794|NCT02916108|EEG
838795|NCT02916082|Cervical length
838796|NCT02916082|Prolonged pregnancy
838797|NCT02916082|Vaginal birth
838798|NCT02916069|Spectroscopy
838799|NCT02916069|Transcranial Doppler
838800|NCT02916069|Bispectral index
838801|NCT02916069|Cardiac surgery
838802|NCT02916056|Alzheimer's disease
838803|NCT02916056|RAGE
838804|NCT02916056|ADAS-cog
838805|NCT02916056|CDR-sb
838806|NCT02916043|acute kidney injury
838807|NCT02916043|cardiovascular surgery
838808|NCT02916043|mortality
838809|NCT02916030|Vitamin D
838810|NCT02916030|Stroke
838811|NCT02916030|Parathormone
838812|NCT02916017|Non-infectious Intermediate-, Posterior-, or Pan-uveitis
838813|NCT02916017|Adalimumab
838814|NCT02916017|Humira
838815|NCT02916004|Analgesia
838816|NCT02916004|Pain measurement
838817|NCT02916004|Nociception
838818|NCT02916004|Electromyography
838819|NCT02916004|Electrical stimulation
838820|NCT02916004|Pupillometry
838821|NCT02916004|Critical care
838822|NCT02916004|Sedation
838823|NCT02915991|Coronary catheterization
838824|NCT02915991|Instantaneous wave free ratio (iFR)
838825|NCT02915991|Fractional Flow Reserve (FFR)
838826|NCT02915991|automated co-registration
838827|NCT02915939|Family caregiving
838828|NCT02915939|Institutionalization
838829|NCT02915939|Residential long-term care
838830|NCT02915939|Placement
838831|NCT02915939|Psychosocial support
838832|NCT02915939|Dementia
838833|NCT02915939|Caregivers
838834|NCT02915939|Nursing homes
838835|NCT02915939|Assisted Living Facilities
838836|NCT02915939|Long-Term Care
838837|NCT02915939|Intervention Study
838838|NCT02915939|Psychosocial Support Systems
838839|NCT02915939|Social Support
838840|NCT02915939|Coping
838841|NCT02915900|In vitro fertilization
838842|NCT02915887|neck pain
838843|NCT02915887|chronic
838844|NCT02915887|taping
838845|NCT02915887|kinematics
838846|NCT02915887|motion analysis
838847|NCT02915887|physiotherapy
838848|NCT02915861|immune responses
838849|NCT02915861|vaccines
838850|NCT02915848|deep brain stimulation
838851|NCT02915848|local field potential
838852|NCT02915848|kinematic analysis
838853|NCT02915835|Scleroderma
838854|NCT02915835|Digital Ulcer
838855|NCT02915809|Influenza Vaccines
838856|NCT02915796|Endothelial progenitor cell
838857|NCT02915796|Percutaneous transluminal angioplasty
838858|NCT02915783|unresectable advanced
838859|NCT02915783|metastatic
838860|NCT02915770|Moderate dilatation of common bile duct
838861|NCT02915757|Depression
838862|NCT02915757|EDOR test
838863|NCT02915757|Electrodermal hyporeactivity
838864|NCT02915744|Breast Cancer Brain Metastases (BCBM)
838865|NCT02915744|Carcinoma
838866|NCT02915731|Vitamin A stores
838867|NCT02915731|Stable isotope dilution
838868|NCT02915731|Multiple vitamin A interventions
838869|NCT02915718|dilated cardiomyopathy
838870|NCT02915718|immunoadsorption
838871|NCT02915692|Foley
838872|NCT02915692|CAUTI
838873|NCT02915692|ERASE CAUTI
838874|NCT02915679|Suicidal behavior
838875|NCT02915679|psychological and social pain
838876|NCT02915679|physical pain
838877|NCT02915679|pain perception
838878|NCT02915666|Melanoma, skin
838879|NCT02915627|Antishock Garment
838880|NCT02915614|alpha-1 antitrypsin deficiency
838881|NCT02915614|pulmonary rehabilitation
838882|NCT02915614|exercise training
838883|NCT02915614|skeletal muscle biopsy
838884|NCT02915562|rehabilitation
838885|NCT02915562|exercise
838886|NCT02915562|outcome measurement
838887|NCT02915549|premature infant
838888|NCT02915549|early progressive feeding
838889|NCT02915536|iodine excess
838890|NCT02915536|thyroid disease
838891|NCT02915536|children
838892|NCT02915536|tolerable upper intake level
838893|NCT02915523|Ovarian Cancer
838894|NCT02915523|Histone Deacetylase Inhibitors
838895|NCT02915523|Entinostat
838896|NCT02915523|Solid tumor
838897|NCT02915523|Avelumab
838898|NCT02915523|SNDX-275
838899|NCT02915523|Ovarian Neoplasms
838900|NCT02915523|Ovarian Diseases
838901|NCT02915523|Fallopian Tube Cancer
838902|NCT02915523|Peritoneal Cancer
838903|NCT02915497|Prolonged Exposure Therapy
838904|NCT02915484|Transcranial Direct Current Stimulation
838905|NCT02915484|Apathy
838906|NCT02915484|Stroke
838907|NCT02915484|Empathy
838908|NCT02915484|Electric Stimulation Therapy
838909|NCT02915484|Depression
838910|NCT02915484|Anhedonia
838911|NCT02915484|Prefrontal Cortex
838912|NCT02915484|Electroencephalography
838913|NCT02915484|Cognition
838914|NCT02915484|Emotions
838915|NCT02915484|Neurological Rehabilitation
838916|NCT02915484|Brain Diseases
838917|NCT02915484|Cerebrovascular Disorders
838918|NCT02915471|Adolescent
838919|NCT02915471|Online Peer Support
838920|NCT02915471|Managing Cancer
838921|NCT02915471|Mentor
838922|NCT02915458|Weaning
838923|NCT02915458|Mechanical ventilation
838924|NCT02915458|synchrosqueezing transform
838925|NCT02915445|EpCAM CAR-T, solid tumors, cancer immunotherapy
838926|NCT02915432|Anti PD-1
838927|NCT02915432|JS001
838928|NCT02915432|Gastric Adenocarcinoma
838929|NCT02915432|Esophageal Squamous Cell Carcinoma
838930|NCT02915432|Nasopharyngeal Carcinoma
838931|NCT02915432|Head and Neck Squamous Cell Carcinoma
838932|NCT02915432|Simon's Two Stage
838933|NCT02915432|ORR
838934|NCT02915393|Chronic Gastritis
838935|NCT02915393|Qi Deficiency Constitution
838936|NCT02915393|Next Generation Sequencing
838937|NCT02915393|Proteomics
838938|NCT02915393|Metabonomics
838939|NCT02915367|HIV/AIDS
838940|NCT02915367|adherence
838941|NCT02915367|women
838942|NCT02915367|real time monitoring
838943|NCT02915367|risk
838944|NCT02915367|SMS
838945|NCT02915367|mHealth
838946|NCT02915315|blood pressure
838947|NCT02915315|Hypertrophy
838948|NCT02915315|Left Ventricular
838949|NCT02915315|arterial Stiffness
838950|NCT02915315|Proteinuria
838951|NCT02915315|baPWV
838952|NCT02915315|ambulatory Blood Pressure
838953|NCT02915302|Influenza
838954|NCT02915302|Influenza virus vaccine
838955|NCT02915302|Fluzone® Quadrivalent Influenza Vaccine (No Preservative)
838956|NCT02915289|Caesarean section
838957|NCT02915289|Chlorhexidine gluconate
838958|NCT02915276|Blastocyst
838959|NCT02915276|Human
838960|NCT02915276|DNA
838961|NCT02915276|Blastocentesis
838962|NCT02915263|Diabetes Complications
838963|NCT02915263|Diabetes Mellitus
838964|NCT02915263|Diabetic Neuropathies
838965|NCT02915263|IGIV-C
838966|NCT02915263|Immune Globulin Injection (Human), 10% Caprylate/Chromatography
838967|NCT02915263|Gamunex-C
838968|NCT02915237|Veterans
838969|NCT02915237|Gulf War Illness
838970|NCT02915237|Gulf War Veterans's Illness
838971|NCT02915237|Gulf War Veterans' Medically Unexplained Illnesses
838972|NCT02915211|Epilepsy
838973|NCT02915211|Glut
838974|NCT02915211|Ketogenic
838975|NCT02915211|Glucose
838976|NCT02915198|Metformin
838977|NCT02915198|Atherosclerosis
838978|NCT02915198|Prediabetic State
838979|NCT02915198|Hemoglobin A, Glycosylated
838980|NCT02915198|Coronary Artery Disease
838981|NCT02915198|Peripheral Arterial Disease
838982|NCT02915198|Cerebrovascular Disorders
838983|NCT02915185|exercise
838984|NCT02915185|rehabilitation
838985|NCT02915185|recovery of function
838986|NCT02915185|transcranial magnetic stimulation
838987|NCT02915185|transcranial direct-current stimulation
838988|NCT02915172|Advanced Cancer
838989|NCT02915172|Malignant neoplasm of breast
838990|NCT02915172|Malignant neoplasms of bone and articular cartilage
838991|NCT02915172|Malignant neoplasms of digestive organs
838992|NCT02915172|Malignant neoplasms of eye brain and other parts of central nervous system
838993|NCT02915172|Malignant neoplasms of female genital organs
838994|NCT02915172|Malignant neoplasms of ill-defined secondary and unspecified sites
838995|NCT02915172|Malignant neoplasms of independent (primary) multiple sites
838996|NCT02915172|Malignant neoplasms of lip oral cavity and pharynx
838997|NCT02915172|Malignant neoplasms of male genital organs
838998|NCT02915172|Malignant neoplasms of mesothelial and soft tissue
838999|NCT02915172|Malignant neoplasms of respiratory and intrathoracic organs
839000|NCT02915172|Malignant neoplasms of thyroid and other endocrine glands
839001|NCT02915172|Malignant neoplasms of urinary tract
839002|NCT02915172|Lenvatinib
839003|NCT02915172|E7080
839004|NCT02915172|Lenvima
839005|NCT02915172|Capecitabine
839006|NCT02915172|Xeloda
839007|NCT02915146|eczema
839008|NCT02915146|phototherapy
839009|NCT02915146|uva1
839010|NCT02915146|uvb
839011|NCT02915146|adults
839012|NCT02915146|children
839013|NCT02915133|high myopia
839014|NCT02915133|myopia foveoschisis
839015|NCT02915133|macular buckling
839016|NCT02915120|Knee pain
839017|NCT02915120|osteoarthritis
839018|NCT02915120|genicular nerve
839019|NCT02915120|ultrasonography
839020|NCT02915120|pulsed radiofrequency
839021|NCT02915107|drug eluting stents
839022|NCT02915107|coronary vascular healing
839023|NCT02915068|patient-provider communication
839024|NCT02915068|Electronic Health Records
839025|NCT02915068|Provider education
839026|NCT02915055|Analgesic efficacy
839027|NCT02915055|knee arthroplasty
839028|NCT02915055|Opioid consumption
839029|NCT02915055|Pain Medicine
839030|NCT02915055|Narcotics
839031|NCT02915055|Multimodal Analgesia
839032|NCT02915042|Pain
839033|NCT02915042|dexmedetomidine
839034|NCT02915042|postoperative
839035|NCT02915029|Native American
839036|NCT02915029|Community Health Representative
839037|NCT02915029|Home base
839038|NCT02915029|Diabetes
839039|NCT02915029|Point of care testing
839040|NCT02915029|Patient Activation Measure
839041|NCT02915029|Patient preferences
839042|NCT02915003|health care navigation
839043|NCT02915003|health literacy
839044|NCT02915003|Affordable Care Act
839045|NCT02914977|Relapsed
839046|NCT02914977|Refractory
839047|NCT02914964|Fatigue
839048|NCT02914964|Quality of Life
839049|NCT02914964|Diet
839050|NCT02914951|Autism
839051|NCT02914951|Irritability
839052|NCT02914951|Disruptive Behavior
839053|NCT02914951|Aggression
839054|NCT02914951|Behavior Therapy
839055|NCT02914951|Cognitive Behavioral Therapy
839056|NCT02914951|Intellectual Disability
839057|NCT02914951|Cognitive Impairment
839058|NCT02914925|CIT
839059|NCT02914925|ArmeoSpring
839060|NCT02914925|TMS
839061|NCT02914899|Chinese Taxi Drivers
839062|NCT02914899|16-949
839063|NCT02914886|Diabetes
839064|NCT02914886|Lipoatrophy
839065|NCT02914886|children
839066|NCT02914886|adolescents
839067|NCT02914886|adults
839068|NCT02914886|insulin therapy
839069|NCT02914873|prostate cancer
839070|NCT02914873|active surveillance
839071|NCT02914873|standardised treatment triggers
839072|NCT02914873|MRI
839073|NCT02914873|randomized
839074|NCT02914821|consumption
839075|NCT02914821|decision making
839076|NCT02914821|policy
839077|NCT02914821|sweetened beverages
839078|NCT02914821|taxes
839079|NCT02914821|Diet, Food, and Nutrition
839080|NCT02914769|Depression
839081|NCT02914769|Ayahuasca
839082|NCT02914769|Psychedelics
839083|NCT02914743|Oral health
839084|NCT02914743|Diabetes
839085|NCT02914743|Interprofessionalism
839086|NCT02914743|Periodontal disease
839087|NCT02914730|diabetes
839088|NCT02914730|insulin
839089|NCT02914730|medication adherence
839090|NCT02914717|golimumab
839091|NCT02914691|Type 2 diabetes
839092|NCT02914691|Diabetic Nephropathy
839093|NCT02914691|Proteomics
839094|NCT02914691|Albuminuria
839095|NCT02914691|SGLT2 inhibitor
839096|NCT02914678|Emergency Medical Services
839097|NCT02914678|Analgesics
839098|NCT02914665|Heart failure
839099|NCT02914665|diuresis
839100|NCT02914665|dropsy
839101|NCT02914665|congestion
839102|NCT02914665|elamipretide
839103|NCT02914665|MTP-131
839104|NCT02914665|Bendavia™
839105|NCT02914652|Congenital Heart Disease
839106|NCT02914652|Ventricular Septal Defect
839107|NCT02914652|Beta-2-agonists
839108|NCT02914652|Surgery
839109|NCT02914652|Follow-up
839110|NCT02914626|Glaucoma, Neovascular
839111|NCT02914626|Ranibizumab
839112|NCT02914626|Intraocular pressure
839113|NCT02914626|anti-VEGF
839114|NCT02914626|intravitreal injection
839115|NCT02914483|Myocardial Infarction
839116|NCT02914483|Women
839117|NCT02914483|Stress Management
839118|NCT02914470|advanced
839119|NCT02914431|Personalized Titanium Plate
839120|NCT02914431|Orthognathic Surgery
839121|NCT02914431|Maxilla Repositioning
839122|NCT02914431|Accuracy
839123|NCT02914431|Computer-aided Design and Manufacturing
839124|NCT02914418|transcranial magnetic stimulation
839125|NCT02914418|Spinal Cord Injuries
839126|NCT02914418|Muscle Spasticity
839127|NCT02914418|Pain
839128|NCT02914418|Spinal Cord
839129|NCT02914418|Spinal Cord Diseases
839130|NCT02914405|131-I-mIBG therapy
839131|NCT02914405|ch14.18/CHO
839132|NCT02914405|Nivolumab
839133|NCT02914392|case control study
839134|NCT02914392|Environmental Factors
839135|NCT02914392|Fetal Congenital Heart Disease
839136|NCT02914366|Ambroxol
839137|NCT02914366|Dementia
839138|NCT02914366|Parkinson's disease
839139|NCT02914366|Disease modifying treatment
839140|NCT02914366|Pharmacological Chaperone
839141|NCT02914366|GBA1
839142|NCT02914353|Factor X!a
839143|NCT02914353|anticoagulant
839144|NCT02914353|thromboembolism
839145|NCT02914353|venous thromboembolism
839146|NCT02914353|embolism and thrombosis
839147|NCT02914353|enzyme inhibitors
839148|NCT02914353|hematologic agent
839149|NCT02914327|CLL
839150|NCT02914327|Leukemia, Chronic Lymphocytic
839151|NCT02914327|Hsp90
839152|NCT02914327|BTK
839153|NCT02914327|Ibrutinib
839154|NCT02914314|epilepsy
839155|NCT02914314|refractory partial seizures
839156|NCT02914249|Orange juice
839157|NCT02914249|Low-calorie diet
839158|NCT02914249|Body composition
839159|NCT02914249|Weight-loss
839160|NCT02914249|Metabolic biomarkers
839161|NCT02914249|Obese
839162|NCT02914236|Nasal valve
839163|NCT02914236|Nasal airway obstruction
839164|NCT02914210|TKR
839165|NCT02914210|TKA
839166|NCT02914210|Knee
839167|NCT02914210|Surgery
839168|NCT02914210|Replacement
839169|NCT02914210|Rehabilitation
839170|NCT02914210|Virtual
839171|NCT02914210|Physical Therapy
839172|NCT02914210|Telerehabilitation
839173|NCT02914197|Decision
839174|NCT02914197|Mammography
839175|NCT02914197|Informed Choice
839176|NCT02914197|Full Information
839177|NCT02914197|Decision Aid
839178|NCT02914197|Self-efficacy
839179|NCT02914197|Shared decision making
839180|NCT02914197|Over-detection
839181|NCT02914197|Over-diagnosis
839182|NCT02914184|Safety
839183|NCT02914184|Healthy infants
839184|NCT02914184|Immunogenicity
839185|NCT02914184|Human Rotavirus (HRV)
839186|NCT02914171|Myopathic right ventricle
839187|NCT02914158|breast cancer
839188|NCT02914158|ovarian function suppression (OFS)
839189|NCT02914158|aromatase inhibitors（AIs）
839190|NCT02914158|tamoxifen（TAM）
839191|NCT02914119|Residual nerve blockade
839192|NCT02914119|Neuromuscular monitoring
839193|NCT02914119|Residual curarization
839194|NCT02914119|Neuromuscular blocking agents
839195|NCT02914106|Neuroactive steroids
839196|NCT02914106|Acute Ischemic Stroke
839197|NCT02914106|Patients
839198|NCT02914093|Hypercapnia
839199|NCT02914093|Physiotherapy
839200|NCT02914093|Inspiratory Muscle Training
839201|NCT02914067|Pediatric brain tumors
839202|NCT02914067|Cognitive deficits
839203|NCT02914067|Resting state functional connectivity
839204|NCT02914067|NIH toolbox
839205|NCT02914054|ITP
839206|NCT02914041|Kyphosis
839207|NCT02914041|Kyphosis wall distance
839208|NCT02914041|elderly
839209|NCT02914028|TAP block
839210|NCT02914028|subacute pain
839211|NCT02914028|inguinal herniography
839212|NCT02913937|ultrasonic irrigation
839213|NCT02913937|pain
839214|NCT02913937|healing
839215|NCT02913937|apical periodontitis
839216|NCT02913924|Marijuana
839217|NCT02913924|Treatment
839218|NCT02913911|feedback
839219|NCT02913898|learning
839220|NCT02913872|Spirometry
839221|NCT02913872|Exhaled Nitric Oxide
839222|NCT02913872|Primary Care
839223|NCT02913859|prostate cancer
839224|NCT02913859|hormone-sensitive
839225|NCT02913859|metastasis
839226|NCT02913846|denutrition
839227|NCT02913846|hospital length of stay
839228|NCT02913846|patient's autonomy
839229|NCT02913833|Pain
839230|NCT02913833|Hospital length of stay
839231|NCT02913833|Revalidation unit
839232|NCT02913781|Polar body removal
839233|NCT02913781|ICSI
839234|NCT02913781|Fertilization failure
839235|NCT02913742|Intraoperative Neurophysiological Monitoring
839236|NCT02913729|breast cancer
839238|NCT02913690|Hemodialysis
839239|NCT02913690|Tocotrienol
839240|NCT02913690|Vitamin E
839241|NCT02913677|feeding intolerance
839242|NCT02913677|minimal enteral nutrition
839243|NCT02913677|very low birth weight
839244|NCT02913677|preterm infant
839245|NCT02913664|Dementia
839246|NCT02913664|Alzheimer's Disease
839247|NCT02913664|Cognitive Function
839248|NCT02913664|Blood Pressure
839249|NCT02913664|Cholesterol
839250|NCT02913664|Physical Activity
839251|NCT02913664|Exercise
839252|NCT02913664|Magnetic Resonance Imaging
839253|NCT02913651|Idiopathic hypersomnia
839254|NCT02913651|heart rate variability
839255|NCT02913651|parasympathetic activity
839256|NCT02913651|autonomic arousal response
839257|NCT02913625|Brachial plexus
839258|NCT02913625|Regional anesthesia
839259|NCT02913625|Infraclavicular
839260|NCT02913625|Retroclavicular
839261|NCT02913625|Parasagittal
839262|NCT02913625|Upper limb surgery
839263|NCT02913625|Ultrasound guided block
839264|NCT02913625|Coracoid
839265|NCT02913612|Hemangioma
839266|NCT02913612|Infantile Hemangioma
839267|NCT02913612|Pharmacokinetics
839268|NCT02913508|Drug therapy
839269|NCT02913495|Progesterone
839270|NCT02913495|Prevention of preterm birth
839271|NCT02913469|Morphine，Ticagrelor，STEMI，PCI
839272|NCT02913417|uveal melanoma
839273|NCT02913417|liver metastases
839274|NCT02913391|noninvasive ventilation
839275|NCT02913391|myocardial revascularization
839276|NCT02913391|pulmonary atelectasis
839277|NCT02913391|anoxia
839278|NCT02913391|hypoxia
839279|NCT02913391|positive end expiratory pressure
839280|NCT02913365|Haemoptysis
839281|NCT02913365|Hemoptysis
839282|NCT02913365|Airway bleeding
839283|NCT02913365|Pulmonary hemorrhage
839284|NCT02913339|screening
839285|NCT02913339|telemedicine
839286|NCT02913339|risk assessment
839287|NCT02913339|prevention
839288|NCT02913300|Lignocaine
839289|NCT02913261|GvHD (Graft versus Host Disease)
839290|NCT02913261|INC424
839291|NCT02913261|ruxolitinib
839421|NCT02912247|pharmacokinetics
839292|NCT02913261|best available therapy (BAT)
839293|NCT02913261|corticosteroid-refractory acute graft vs. host disease
839294|NCT02913261|allogeneic stem cell transplantation
839295|NCT02913261|steroid refractory acute graft vs. host disease
839296|NCT02913261|Janus Kinase (JAK) inhibitor
839297|NCT02913248|periodontitis
839298|NCT02913248|saliva
839299|NCT02913248|bacteria
839300|NCT02913235|biofilm
839301|NCT02913235|saliva
839302|NCT02913235|bacteria
839303|NCT02913235|oral hygiene
839304|NCT02913222|femoroacetabular impingement
839305|NCT02913222|labral tear
839306|NCT02913222|rehabilitation
839307|NCT02913183|acute stroke
839308|NCT02913183|young health plasma
839309|NCT02913183|efficacy
839310|NCT02913183|safety
839314|NCT02913014|Antiarrhythmic Agents
839315|NCT02913014|Catheter Ablation, electric
839316|NCT02913014|Cardiac Arrhythmias
839317|NCT02913014|Anti-Arrhythmia Drugs
839318|NCT02913001|Diet
839319|NCT02913001|glycemic index
839320|NCT02913001|glycemic load
839321|NCT02913001|Acne Vulgaris
839322|NCT02912988|Subfertility
839323|NCT02912988|In-vitro fertilization
839324|NCT02912988|Letrozole
839325|NCT02912949|Bispecific Antibody IgG1, HER2, HER3
839326|NCT02912949|First-in-human
839327|NCT02912949|MCLA-128
839328|NCT02912949|Antibodies, Bispecific
839329|NCT02912949|Immunologic Factors
839330|NCT02912949|Cytokines
839331|NCT02912936|medium chain triglyceride
839332|NCT02912936|MCT
839333|NCT02912936|coconut oil
839334|NCT02912936|MRI
839335|NCT02912936|PET
839336|NCT02912936|ketones
839337|NCT02912923|Stroke
839338|NCT02912923|Rehabilitation Robotics
839339|NCT02912923|Bimanual
839340|NCT02912923|Compensatory Movements
839341|NCT02912923|Hemiplegia
839342|NCT02912923|Kinematics
839343|NCT02912923|Reaching
839344|NCT02912923|Trunk
839345|NCT02912897|EBV-CTL
839346|NCT02912897|Multiple sclerosis
839347|NCT02912897|cellular therapy
839348|NCT02912897|clinically isolated syndrome
839349|NCT02912871|subthalamotomy
839350|NCT02912871|motor features
839351|NCT02912871|deep brain stimulation
839352|NCT02912832|Diagnosis
839353|NCT02912806|Knee Arthroplasty
839354|NCT02912806|Total knee replacement
839355|NCT02912806|Knee osteoarthritis
839356|NCT02912806|Patient-Outcomes Measurement Program
839357|NCT02912806|Surgical Registries
839358|NCT02912806|Shared Decision Making
839359|NCT02912806|Patient Reported Outcomes
839360|NCT02912806|Patient Experience
839361|NCT02912806|Cohort Studies
839362|NCT02912767|lower-extremity lymphedema
839363|NCT02912767|16-1001
839364|NCT02912702|Pegaspargase
839365|NCT02912702|hemophagocytic lymphohistiocytosis
839366|NCT02912702|Epstein Barr virus
839367|NCT02912702|initial treatment
839368|NCT02912689|COPD
839369|NCT02912689|Non-invasive ventilation
839370|NCT02912689|NAVA
839371|NCT02912676|Cancer
839372|NCT02912676|Thioguanine
839373|NCT02912676|Acute Lymphoblastic Leukemia
839374|NCT02912676|6 Mercaptopurine
839375|NCT02912676|Maintenance Therapy of Leukemia
839376|NCT02912676|Denmark
839377|NCT02912676|Lymphoblastic Lymphoma
839378|NCT02912650|ibuprofen
839379|NCT02912650|acetaminophen
839380|NCT02912650|pain
839381|NCT02912650|molar extraction
839382|NCT02912624|Physical Examination
839383|NCT02912624|Diagnostic Imaging
839384|NCT02912624|Ultrasonography
839385|NCT02912624|Hemodynamics
839386|NCT02912624|Patient Outcome Assessment
839387|NCT02912624|Mortality
839388|NCT02912585|colostrum
839389|NCT02912572|Endometrial Cancer
839390|NCT02912546|Stroke, Acute
839391|NCT02912455|Post-Bariatric Surgery
839392|NCT02912455|hemoglobin A1c protein, human
839393|NCT02912442|thyroid
839394|NCT02912442|infertility
839395|NCT02912442|autoimmunity
839396|NCT02912442|pregnancy loss
839397|NCT02912442|autoantibodies
839398|NCT02912364|Eslicarbazepine
839399|NCT02912364|Carbamazepine
839400|NCT02912364|cognition
839401|NCT02912351|Total Knee Arthroplasty
839402|NCT02912351|Total Knee Replacement
839403|NCT02912351|Revision Knee Arthroplasty
839404|NCT02912338|Sarcopenic obesity
839405|NCT02912338|Body composition
839406|NCT02912338|Physical function
839407|NCT02912338|quality of life
839408|NCT02912338|long term care
839409|NCT02912312|Malignant neoplasm of breast
839410|NCT02912312|Lymphedema
839411|NCT02912312|Standard regional nodal irradiation
839412|NCT02912312|RNI
839413|NCT02912312|Shortened regional nodal irradiation
839414|NCT02912312|Radiation therapy
839415|NCT02912312|XRT
839416|NCT02912312|Arm swelling
839417|NCT02912312|Questionnaires
839418|NCT02912312|Surveys
839419|NCT02912273|Geriatric assessment
839420|NCT02912247|tumor necrosis factor-a blocker
839422|NCT02912247|safety
839423|NCT02912169|Alzheimer's Disease
839424|NCT02912169|Alzheimer's
839425|NCT02912169|Stem cell
839426|NCT02912169|Adipose-derived stem cells
839427|NCT02912169|ASC
839428|NCT02912169|ADSC
839429|NCT02912156|Pharmacokinetic
839430|NCT02912130|Exercise
839431|NCT02912130|Nutrition
839432|NCT02912130|Sarcopenia
839433|NCT02912130|Healthy Ageing
839434|NCT02912130|Elderly
839435|NCT02912130|Muscular Hypertrophy
839436|NCT02912104|primary ovarian insufficiency
839437|NCT02912104|premature ovarian failure
839438|NCT02912104|Infertility
839439|NCT02912104|human amniotic epithelial cells transplantation
839440|NCT02912052|Perioperative Chemotherapy
839441|NCT02912052|Postoperative Chemotherapy
839442|NCT02912052|Colon Cancer
839443|NCT02912052|Resectable Liver Metastasis
839444|NCT02912000|Dental Health Services
839445|NCT02912000|Sugar-Sweetened Beverages
839446|NCT02912000|Tobacco control
839447|NCT02912000|Pediatrics
839448|NCT02912000|Parents
839449|NCT02911974|fine needle biopsy
839450|NCT02911974|EUS
839451|NCT02911974|solid pancreatic mass
839452|NCT02911896|physical function
839453|NCT02911896|critical care
839454|NCT02911857|Canakinumab,
839455|NCT02911857|interleukin-1
839456|NCT02911857|Periodic Fevers Syndrome
839457|NCT02911857|TRAPS
839458|NCT02911857|HIDS
839459|NCT02911857|crFMF
839460|NCT02911857|auto-inflammatory diseases
839461|NCT02911857|extension study
839462|NCT02911805|Exercise
839463|NCT02911805|Retinal Degeneration
839464|NCT02911805|Neuropharmacology
839465|NCT02911805|Brain-Derived Neurotrophic Factor
839466|NCT02911805|Biometry
839467|NCT02911805|Immunochemistry
839468|NCT02911805|Molecular Biology
839469|NCT02911805|Neurosciences
839470|NCT02911805|Ophthalmology
839471|NCT02911792|hyperfiltering
839472|NCT02911792|Type 2 Diabetes Mellitus
839473|NCT02911766|Periodontal Index
839474|NCT02911727|Cesarean section
839475|NCT02911727|Postnatal Care
839476|NCT02911714|Kidney Transplantation
839477|NCT02911714|Delayed Graft Function
839478|NCT02911714|Acute Allograft Rejection
839479|NCT02911714|Acute Kidney Injury
839480|NCT02911597|Ketamine
839481|NCT02911597|Naltrexone
839482|NCT02911597|Treatment-Resistant
839483|NCT02911597|TRD
839484|NCT02910804|GBM
839485|NCT02910804|GRPR
839486|NCT02910804|IRDye800
839487|NCT02910804|NIRF
839488|NCT02910804|surgery
839489|NCT02910726|indocyanine green fluorescent dye
839490|NCT02910726|Technetium lymphoscintigraphy
839491|NCT02910726|sentinel lymph node biopsy
839492|NCT02910726|16-1003
839493|NCT02908854|Spices
839494|NCT02908854|Herbs
839495|NCT02908854|Vegetables
839496|NCT02908854|National School Lunch Program
839497|NCT02908854|High school
839498|NCT02908828|Biological Products/therapeutic use
839499|NCT02908828|Copepoda
839500|NCT02908828|Dietary Supplements
839501|NCT02908828|Fish Oils
839502|NCT02908828|Fatty Acids, Omega-3
839503|NCT02908828|Oxygen Consumption
839504|NCT02908828|Calanus
839505|NCT02908828|Maximal oxygen uptake
839506|NCT02908828|Zooplankton
839507|NCT02908789|Photochemotherapy
839508|NCT02908763|Chronic Hepatitis B
839509|NCT02908763|Peginterferon Alpha
839510|NCT02908750|oncology
839511|NCT02908750|cancer
839512|NCT02908750|non small cell lung cancer
839513|NCT02908750|anticancer drug
839514|NCT02908750|lung neoplasms
839515|NCT02908750|pharmacokinetics
839516|NCT02908750|AZD9291
839517|NCT02908750|osimertinib
839518|NCT02908750|fexofenadine
839519|NCT02908750|TAGRISSO™
839520|NCT02908750|EGFR genes
839521|NCT02911545|Atrial fibrillation
839522|NCT02911545|Anticoagulation
839523|NCT02911545|Cardioversion
839524|NCT02911532|pterygium
839525|NCT02911532|tissue engineering
839526|NCT02911532|atretoblepharia
839527|NCT02911519|Schizophrenia
839528|NCT02911519|Patient Education
839529|NCT02911493|sedentary time
839530|NCT02911493|number of steps/day
839531|NCT02911493|mobility
839532|NCT02911493|disability
839533|NCT02911428|Ebola
839534|NCT02911428|Ebola Virus Vaccines
839535|NCT02911428|Haemorrhagic Fever
839536|NCT02911428|Ebola Infection
839537|NCT02911428|GP protein, Ebola virus
839538|NCT02911415|Ebola
839539|NCT02911415|Ebola Virus Vaccines
839540|NCT02911415|Haemorrhagic Fever
839541|NCT02911415|Ebola Infection
839542|NCT02911415|GP protein, Ebola virus
839543|NCT02911311|conbercept
839544|NCT02911311|anti-VEGF agent
839545|NCT02911311|panretinal photocoagulation
839546|NCT02911285|Alcohol
839547|NCT02911285|PTSD
839548|NCT02911285|Trauma
839549|NCT02911285|Veteran
839550|NCT02911272|Partograph
839551|NCT02911272|Best action line
839552|NCT02911272|Prolonged labour prevention
839553|NCT02911207|chronic ill patients
839554|NCT02911207|Emotion management skill
839555|NCT02911207|Quality of Life
839556|NCT02911181|BIVA measurement
839557|NCT02911181|SNAQ score
839558|NCT02911168|NERVE BLOCK
839559|NCT02911168|ANESTHESIA RECOVERY PERIOD
839560|NCT02911168|PAIN MANAGEMENT
839561|NCT02911155|Cohort Study
839562|NCT02911155|Radiation
839563|NCT02911155|Occupation
839564|NCT02911142|Treatment Naive
839565|NCT02911142|Immune Modulatory
839566|NCT02911142|Chemotherapy
839567|NCT02911142|AIDS-Related Lymphoma
839568|NCT02911142|PEL
839569|NCT02911129|Chronic Stroke
839570|NCT02911129|Neglect
839571|NCT02911129|Transcranial Magnetic Stimulation
839572|NCT02911129|Visual and Motor Integration
839573|NCT02911129|Visual Fields
839574|NCT02911116|Panuveitis
839575|NCT02911116|Intermediate Uveitis
839576|NCT02911116|Uveitis
839577|NCT02911103|Electrophysiology
839578|NCT02911103|Neurosurgery
839579|NCT02911103|Dystonia
839580|NCT02911103|Deep Brain Stimulation
839581|NCT02911090|Endometriosis
839582|NCT02911090|Chronic pelvic pain
839583|NCT02911090|Dyspareunia
839593|NCT02911025|epilepsy
839594|NCT02911025|sleep
839595|NCT02911025|antiepileptic drugs
839596|NCT02910986|Mammography
839597|NCT02910986|Breast Density
839598|NCT02910986|Hispanic
839599|NCT02910973|Inflammation, Vagus Nerve Stimulation
839600|NCT02910960|fine needle biopsy
839601|NCT02910960|EUS
839602|NCT02910960|solid pancreatic mass
839603|NCT02910934|Indoor Residual Spray
839604|NCT02910934|IRS
839605|NCT02910934|Insecticide Treated Net
839606|NCT02910934|LLIN
839607|NCT02910934|ITN
839608|NCT02910921|Migraine
839609|NCT02910921|Prediction
839610|NCT02910921|Forecast
839611|NCT02910921|App
839612|NCT02910921|Fitbit
839613|NCT02910921|Individual
839614|NCT02910921|Algorithm
839615|NCT02910921|Machine Learning
839616|NCT02910921|Mayo Clinic
839617|NCT02910921|Allergan
839618|NCT02910921|Second Opinion
839619|NCT02910908|Elderly
839620|NCT02910908|ESRD prognosis
839621|NCT02910908|help decision making dialysis therapeutic project
839622|NCT02910882|Pancreas Cancer
839623|NCT02910882|Unresectable
839624|NCT02910882|Chemoradiation
839625|NCT02910882|PEGPH20
839626|NCT02910843|rectal cancer
839627|NCT02910843|Neoadjuvant treatment
839628|NCT02910843|Regorafenib
839629|NCT02910843|Capecitabine
839630|NCT02910843|locally advanced rectal cancer
839631|NCT02910843|Phase Ib trial
839632|NCT02910700|Melanoma
839633|NCT02910700|Metastatic Melanoma
839634|NCT02910700|BRAF- mutated metastatic melanoma
839635|NCT02910700|BRAF-wild type metastatic melanoma
839636|NCT02910700|Nivolumab
839637|NCT02910700|BMS-936558
839638|NCT02910700|Opdivo
839639|NCT02910700|Dabrafenib
839640|NCT02910700|Tafinlar
839641|NCT02910700|GSK2118436
839642|NCT02910700|Trametinib
839643|NCT02910700|GSK1120212
839644|NCT02910687|Non ST Elevation Myocardial Infarction (NSTEMI)
839645|NCT02910687|Elderly
839646|NCT02910687|Frailty
839647|NCT02910687|Prognostic value
839648|NCT02910661|Kidney Transplantation
839649|NCT02910648|healthy
839650|NCT02910648|BMI
839651|NCT02910648|weight loss
839652|NCT02910648|sleep
839653|NCT02910648|healthy sleeper
839654|NCT02910648|overweight
839655|NCT02910648|obese
839656|NCT02910635|Thorough QTc, Therapeutic dose, supra therapeutic dose
839657|NCT02910622|breast
839658|NCT02910622|ovarian
839659|NCT02910622|cancer
839660|NCT02910609|preterm
839661|NCT02910609|patent ductus arterioles
839662|NCT02910609|treatment
839663|NCT02910557|CTCAE - Common Terminology Criteria for Adverse Events
839664|NCT02910557|eCRF - electronic case report form
839665|NCT02910557|ECOG - Eastern Cooperative Oncology Group
839666|NCT02910557|EDC - electronic data capture
839667|NCT02910557|GM-CSF - human granulocyte macrophage colony-stimulating factor
839668|NCT02910557|HCP - health care provider
839669|NCT02910557|HSV-1 - herpes simplex virus type 1
839670|NCT02910557|ICF - informed consent form
839671|NCT02910557|ICP - infected cell protein
839672|NCT02910557|IEC - Independent Ethics Committee
839673|NCT02910557|IRB - Institutional Review Board
839674|NCT02910557|MedDRA - Medical Dictionary for Regulatory Activities
839675|NCT02910557|PFU - plaque-forming unit
839676|NCT02910557|qPCR - quantitative polymerase chain reaction
839677|NCT02910557|SmPC - Summary of Product Characteristics
839678|NCT02910557|USPI - United States Prescribing Information
839679|NCT02910531|Cystinuria
839680|NCT02910531|Kidney stone
839681|NCT02910531|Alpha lipoic acid
839682|NCT02910479|Body Temperature
839683|NCT02910479|Thermometers
839684|NCT02910453|Pulmonary lobectomy
839685|NCT02910453|Video-Assisted Thoracic Surgery
839686|NCT02910453|Opto-electronic plethysmography
839687|NCT02910453|Posterolateral thoracotomy
839688|NCT02910427|stroke
839689|NCT02910427|potassium and magnesium-enriched salt
839690|NCT02910427|neurological performance
839691|NCT02910388|conization
839692|NCT02910388|LLETZ
839693|NCT02910388|loop excision
839694|NCT02910388|randomized controlled trial
839695|NCT02910388|colposcopy
839696|NCT02910388|direct colposcopic vision
839697|NCT02910388|intraoperative colposcopy
839698|NCT02910375|golimumab
839699|NCT02910375|drug monitoring
839700|NCT02910375|home based care
839701|NCT02910349|valvular hear disease
839702|NCT02910349|echocardiography
839703|NCT02910349|magnetic resonance
839704|NCT02910349|global longitudinal strain
839705|NCT02910349|T1 relaxation time
839706|NCT02910310|Uterine Balloon Tamponade
839707|NCT02910297|cannabidiol
839708|NCT02910297|Dravet Syndrome
839709|NCT02910297|Lennox Gastaut Syndrome
839710|NCT02910284|HSV
839711|NCT02910284|Herpes
839712|NCT02910284|Genital Herpes
839713|NCT02910258|myelofibrosis
839714|NCT02910258|pegylated interferon
839715|NCT02910245|Therapeutic Drug Monitoring
839716|NCT02910245|Mercaptopurine (6-MP)
839717|NCT02910245|Thiopurine
839718|NCT02910245|Efficacy
839719|NCT02910232|Rice starch
839720|NCT02910232|Porous composite
839721|NCT02910232|Biomaterial
839722|NCT02910232|Bone regeneration
839723|NCT02910232|Clinical trial
839724|NCT02910232|Hydroxyapatite
839725|NCT02910219|HER2
839726|NCT02910219|pertuzumab
839727|NCT02910219|trastuzumab
839728|NCT02910219|docetaxel
839729|NCT02910219|paclitaxel
839730|NCT02910219|carboplatin
839731|NCT02910219|crofelemer
839732|NCT02910219|chemotherapy induced diarrhea
839733|NCT02910206|etomidate
839734|NCT02910206|propofol
839735|NCT02910193|alcoholism
839736|NCT02910193|genetics
839737|NCT02910193|functional MRI
839738|NCT02910193|structural MRI
839739|NCT02910193|first-degree relatives
839740|NCT02910180|Tissue Repository
839741|NCT02910180|Cerebrovascular Diseases
839742|NCT02910180|Stroke
839743|NCT02910180|Aneurysm
839744|NCT02910180|Arteriovenous malformation
839745|NCT02910180|Fistula
839746|NCT02910180|Intracranial Stenosis
839747|NCT02910180|Treatment
839748|NCT02910180|Registry
839749|NCT02910180|Outcomes
839750|NCT02910141|Type 2 diabetes
839751|NCT02910141|Continuous subcutaneous insulin infusion
839752|NCT02910141|Meta-analysis
839753|NCT02910141|Insulin pump therapy
839754|NCT02910141|Multiple daily insulin injections
839755|NCT02910102|RVT-101
839756|NCT02910102|intepirdine
839757|NCT02910102|Alzheimer's disease
839758|NCT02910102|Dementia with Lewy bodies
839759|NCT02910102|Lewy body dementia
839760|NCT02910102|Parkinson's Disease Dementia
839761|NCT02910089|Diabetes Mellitus Type 2
839769|NCT02910050|androgen receptor
839770|NCT02910050|bicalutamide
839771|NCT02910050|aromatase inhibitors
839772|NCT02910050|advanced breast cancer
839773|NCT02910050|letrozole
839774|NCT02910050|anastrozole
839775|NCT02910050|exemestane
839776|NCT02908984|unilateral headache
839777|NCT02908984|cervical pain
839778|NCT02908984|neck pain
839779|NCT02908984|voxel based morphometry
839780|NCT02908984|diffusion tensor imaging
839781|NCT02908984|structural brain changes
839782|NCT02908984|rehabilitation
839783|NCT02908971|soy based formula
839784|NCT02908971|overweight
839785|NCT02908971|adrenarche,
839786|NCT02908971|gonadarache
839792|NCT02908919|Colonoscopy
839793|NCT02908919|Picosulfate sodium
839794|NCT02908919|Polyethylene glycol
839795|NCT02908919|Magnesium citrate
839796|NCT02908919|Ascorbic acid
839797|NCT02908919|SPMC (solution picosulfate + magnesium citrate)
839798|NCT02908919|PEGA (Polyethylene glycol + ascorbic acid)
839799|NCT02908880|MANTA, arterial closure device, large bore closure device
839800|NCT02908867|Sexuality
839801|NCT02908867|Spinal cord injuries
839802|NCT02908867|Complementary Therapies
839803|NCT02908867|Medicinal plants
839804|NCT02909998|Biomarkers
839805|NCT02909998|Genetic
839806|NCT02909998|Chronic arthritis
839807|NCT02909998|Treatment
839808|NCT02909985|Infrared
839809|NCT02909985|Dark Adaptation
839810|NCT02909985|Vision
839811|NCT02909985|Scotopic Threshold Response
839812|NCT02909985|Transient Receptor Potential (TRP) Channels
839813|NCT02909985|Human
839814|NCT02909959|sulforaphane
839815|NCT02909959|glucoraphanin
839816|NCT02909959|physiologic effects of drugs
839817|NCT02909946|multidrug-resistant organisms
839818|NCT02909946|nursing home
839819|NCT02909946|post-acute care
839820|NCT02909946|long-term care
839821|NCT02909946|infection control
839822|NCT02909920|Telerehabilitation
839823|NCT02909920|Physiotherapy
839824|NCT02909920|Surgery
839825|NCT02909920|Telemedicine
839826|NCT02909894|Sedentary behaviour
839827|NCT02909894|Postprandial glycaemic response
839828|NCT02909881|polysaccharide
839829|NCT02909881|oxidation
839830|NCT02909881|endurance exercise
839831|NCT02909855|children
839832|NCT02909855|psychological predictors
839833|NCT02909855|side-effects
839834|NCT02909855|vaccination
839835|NCT02909842|influenza
839836|NCT02909842|vaccine
839837|NCT02909842|probiotic
839838|NCT02909842|immune response
839839|NCT02909829|Diabetes Mellitus, Type 1
839840|NCT02909829|Artificial Pancreas
839841|NCT02909829|Closed-Loop Delivery
839842|NCT02909829|Insulin
839843|NCT02909829|Adolescent
839844|NCT02909829|Missed Bolus
839845|NCT02909803|glucose
839846|NCT02909803|glycemic index
839847|NCT02909803|lentil
839848|NCT02909803|polyphenols
839849|NCT02909803|metabolites
839850|NCT02909803|bioavailability
839855|NCT02909764|Salty taste
839856|NCT02909764|Psychophysics
839857|NCT02909764|Genetics
839858|NCT02909764|Diet
839859|NCT02909764|Age
839860|NCT02909725|Physical activity
839861|NCT02909725|Sedentary time
839862|NCT02909725|Pregnancy
839863|NCT02909725|Pregnant women
839864|NCT02909725|Weight gain
839865|NCT02909712|sub-Saharan
839866|NCT02909712|dihydroartemisinin
839867|NCT02909712|piperaquine
839868|NCT02909712|sulphadoxine-pyrimethamine
839869|NCT02909712|antimalarials
839870|NCT02909686|Gulf War Syndrome
839871|NCT02909686|Chronic Multisymptom Illnesses
839872|NCT02909686|Medically Unexplained Illnesses
839873|NCT02909673|adolescent behavior
839874|NCT02909673|intimate partner violence
839875|NCT02909673|youth risk behavior
839876|NCT02909673|violence prevention
839877|NCT02909673|teen dating violence
839878|NCT02909621|OsteoArthritis; FLEXOFYTOL®; Curcuma; biomarkers
839879|NCT02909556|Transcatheter Aortic Valve Replacement
839880|NCT02909556|TAVI
839881|NCT02909556|Transcatheter Aortic Valve Implant
839882|NCT02909556|Transfemoral access
839883|NCT02909530|Endoscopic ultrasound-guided fine needle biopsy
839884|NCT02909530|Olympus EZ Shot 3Plus
839885|NCT02909530|Olympus EZ Shot 2
839886|NCT02909452|entinostat
839887|NCT02909452|pembrolizumab
839888|NCT02909452|solid tumor
839889|NCT02909452|Histone Deacetylase Inhibitor
839890|NCT02909426|Screening
839891|NCT02909426|Digital mammography
839892|NCT02909426|Ultrasonography
839893|NCT02909426|Sensitivity
839894|NCT02909426|Specificity
839895|NCT02909413|desflurane
839896|NCT02909413|sevoflurane
839897|NCT02909400|mitochondrial
839898|NCT02909400|oxidative phosphorylation (oxphos)
839899|NCT02909400|MELAS
839900|NCT02909400|MIDD
839901|NCT02909400|KH176
839902|NCT02909400|Proof of Concept
839903|NCT02909387|Epilepsy
839904|NCT02909387|Seizure Disorder
839905|NCT02909374|Implementation
839906|NCT02909374|fall prevention
839907|NCT02909374|balance training
839908|NCT02909348|Neoplasms
839909|NCT02909348|Melanoma
839910|NCT02909348|Immunotherapy
839911|NCT02909348|Biomarkers
839912|NCT02909309|Propofol
839913|NCT02909309|Deep Sedation
839914|NCT02909309|Anoxia
839915|NCT02909309|Hypercapnia
839916|NCT02909231|Patient Outcome Assessment
839917|NCT02909218|HIV/AIDS, Swaziland
839918|NCT02909205|child
839919|NCT02909205|gastrostomy
839920|NCT02909205|supportive care
839921|NCT02909205|educational program
839922|NCT02909192|Parkinson's Disease
839923|NCT02909192|Excessive Daytime Sleepiness
839924|NCT02909192|Circadian Rhythms
839925|NCT02909192|Light Therapy
839926|NCT02909179|Community Health Workers, mHealth, mobile phones, ANC, PNC, essential newborn care
839927|NCT02909153|Triferic
839928|NCT02909153|ferric pyrophosphate citrate
839929|NCT02909153|peritoneal dialysis
839930|NCT02909153|anemia
839931|NCT02909153|chronic kidney disease
839932|NCT02909153|FPC
839933|NCT02909127|deglutition
839934|NCT02909127|deglutition disorders
839935|NCT02909127|pediatric dysphagia
839936|NCT02909127|swallowing
839937|NCT02909114|stereotactic boday radiotherapy, oligometastases
839938|NCT02909101|Working memory
839939|NCT02909101|cognitive training
839940|NCT02909101|HIV
839941|NCT02909101|substance abuse
839942|NCT02909088|stuttering
839943|NCT02909088|childhood onset fluency disorder
839944|NCT02909088|ecopipam
839945|NCT02909075|PET/CT
839946|NCT02909075|MRI
839947|NCT02909075|Assess Thymic Function
839948|NCT02909075|16-1244
839949|NCT02909062|Electronic Activity Monitoring (EAM)
839950|NCT02909062|16-493
839951|NCT02909049|Prostate Biopsy
839952|NCT02909049|Local Anesthesia
839953|NCT02909049|Pain
839954|NCT02909049|Biopsy of prostate
839955|NCT02909036|Melphalan
839956|NCT02909036|Autologous Hematopoietic Progenitor Cell Transplant
839957|NCT02909036|High Dose Therapy
839958|NCT02909036|16-875
839959|NCT02909023|Hepatitis B Virus
839960|NCT02909023|Elispot test
839961|NCT02909023|T cellular immune response
839962|NCT02908724|Familial cardiomyopathies
839963|NCT02908724|Hypertrophic cardiomyopathy
839964|NCT02908724|Left ventricular hypertrophy
839965|NCT02908659|intensive care unit
839966|NCT02908659|patient's monitoring
839967|NCT02908659|respiratory rate
839968|NCT02908633|open angle glaucoma
839969|NCT02908633|canaloplasty
839970|NCT02908633|migs
839971|NCT02908633|abic
839972|NCT02908594|Nursing
839973|NCT02908594|ESRD
839974|NCT02908594|hemodialysis
839975|NCT02908594|intradialytic exercise
839976|NCT02908594|depression
839977|NCT02908594|fatigue
839978|NCT02908594|Quality Of Life
839979|NCT02908594|self-efficacy
839980|NCT02908594|resilience
839981|NCT02908568|mandibular stretching, trigeminocardiac reflex
839982|NCT02908555|type 1 diabetes
839983|NCT02908555|adolescents
839984|NCT02908555|sleep
839987|NCT02908464|Cardiac Surgery
839988|NCT02908464|Delirium
839989|NCT02908464|Postoperative Cognitive Dysfunction
839990|NCT02908451|Cancer
839991|NCT02908451|Antibody Drug Conjugate
839992|NCT02908451|AbGn-107
839993|NCT02908451|Adenocarcinoma
839994|NCT02908451|Gastric
839995|NCT02908451|Colorectal
839996|NCT02908451|Pancreatic
839997|NCT02908412|Nerve Block
839998|NCT02908412|Spectrophotometry
839999|NCT02908412|Bupivacaine
840000|NCT02908412|Spinal Surgery
840001|NCT02908412|Blood Loss, Surgical
840002|NCT02908386|Head and neck tumors
840003|NCT02908386|Proton
840004|NCT02908386|Photon
840005|NCT02908386|replanning timing
840006|NCT02908373|risk management
840007|NCT02908373|nursing home
840008|NCT02908373|elderly
840009|NCT02908373|care
840010|NCT02908360|Double positive lymphocyte T F prausnitzii
840011|NCT02908347|Plaque psoriasis
840012|NCT02908347|chronic
840013|NCT02908347|moderate
840014|NCT02908347|severe
840015|NCT02908347|Plaque
840016|NCT02908308|Induced hypothermia
840017|NCT02908308|Mild induced hypothermia
840018|NCT02908308|Therapeutic hypothermia
840019|NCT02908308|Cardiac arrest
840020|NCT02908308|Out-of-hospital cardiac arrest
840021|NCT02908308|Mortality
840022|NCT02908308|Neurological function
840023|NCT02908308|Randomised clinical trial
840024|NCT02908282|tear film
840025|NCT02908282|omega-3 fatty acids
840026|NCT02908282|eye drops
840030|NCT02908256|PVI
840031|NCT02908256|delta PP
840032|NCT02908256|vascular filling
840033|NCT02908243|Hemophilia
840034|NCT02908243|Primary prophylaxis
840035|NCT02908243|Pettersson Score
840036|NCT02908243|Joint function study
840037|NCT02908243|Comorbidity
840038|NCT02908217|Polymyalgia Rheumatica
840039|NCT02908217|Tocilizumab
840040|NCT02908217|Glucocorticoid
840041|NCT02908204|superficial esophageal squamous cell carcinoma
840042|NCT02908204|efficacy
840043|NCT02908204|survival
840044|NCT02908178|ductal carcinoma in situ (DCIS)
840170|NCT02907385|LifeSeal
840045|NCT02908178|sentinel lymph node biopsy (SLNB)
840046|NCT02908087|Diabetes Type 1
840047|NCT02908087|Diabetes, Insulin-Dependent
840048|NCT02908087|Liraglutide
840049|NCT02908087|GLP-1 Analogue
840050|NCT02908087|Early diagnosis
840054|NCT02908061|Mesh Placement
840055|NCT02908061|Radical Cystectomy
840056|NCT02908061|16-1285
840057|NCT02908048|liver cancer
840058|NCT02908048|cholangiocarcinoma (CCA)
840059|NCT02908048|cirrhosis
840060|NCT02908048|hepatitis
840061|NCT02908048|bile duct cancer
840062|NCT02908048|hepatocellular carcinoma (HCC)
840063|NCT02908048|hepatobiliary carcinoma
840064|NCT02908048|hepatoma
840065|NCT02908048|liver mass
840066|NCT02907983|Menopause
840067|NCT02907983|Post-menopausal
840068|NCT02907970|Cervical cancer
840069|NCT02907970|Screening
840070|NCT02907970|Barriers
840071|NCT02907931|hemodynamics
840072|NCT02907931|ultrasonography
840073|NCT02907879|Subarachnoid Hemorrhage
840074|NCT02907879|Ultrasound perfusion imaging
840075|NCT02907879|cerebral hypoperfusion
840076|NCT02907879|vasospasm
840077|NCT02907879|DIND
840078|NCT02907879|infarction
840079|NCT02907827|complete remission
840080|NCT02907827|cfDNA
840081|NCT02907827|DW-MRI
840082|NCT02907827|surveillance
840083|NCT02907814|Uveitis
840084|NCT02907814|Optical Coherence Tomography
840085|NCT02907801|congenital muscular torticollis
840086|NCT02907801|infants
840087|NCT02907801|perception-action approach
840088|NCT02907788|Cystic fibrosis
840089|NCT02907788|Neutrophils
840090|NCT02907788|PMN
840091|NCT02907788|Inflammation
840092|NCT02907788|Lung disease
840093|NCT02907788|PRAGMA
840094|NCT02907762|Endovascular
840095|NCT02907762|EVAR
840096|NCT02907762|Neck Angulation
840097|NCT02907710|Nasopharyngeal carcinoma
840098|NCT02907710|endostar
840099|NCT02907710|chemoradiotherapy
840100|NCT02907697|HIV/AIDS
840101|NCT02907697|adherence
840102|NCT02907697|substance use
840103|NCT02907697|HIV care continuum
840104|NCT02907684|Cardiovascular disease
840105|NCT02907684|Non alcoholic fatty liver
840106|NCT02907684|Diabetes
840107|NCT02907684|Almonds
840108|NCT02907684|Endothelium-dependent vasodilation
840109|NCT02907684|Fecal short chain fatty acids (SCFAs)
840110|NCT02907684|Snacking
840111|NCT02907671|carpal tunnel injection
840112|NCT02907671|corticosteroid
840113|NCT02907671|ultrasound-guided
840114|NCT02907671|musculoskeletal ultrasound
840115|NCT02907658|Internet Use Disorder
840116|NCT02907658|Internet Gaming Disorder
840117|NCT02907658|Cognitive-Behavioral Intervention
840118|NCT02907658|Indicated Prevention
840119|NCT02907658|Adolescents
840120|NCT02907658|Internet Addiction
840121|NCT02907632|Metoclopramide
840122|NCT02907632|Pro kinetic
840123|NCT02907632|Gastroesophageal Reflux
840124|NCT02907632|Premature Infant
840125|NCT02907632|Low Birth Weight
840126|NCT02907632|Kangaroo Mother Care Method
840127|NCT02907619|Duchenne muscular dystrophy, myostatin, open-label
840128|NCT02907606|Non-small-cell Lung Cancer
840129|NCT02907606|circulating tumor DNA
840130|NCT02907606|urine
840131|NCT02907593|Bronchopulmonary dysplasia
840132|NCT02907593|Pulmonary
840133|NCT02907593|Surfactant
840134|NCT02907593|Steroids
840135|NCT02907593|Extremely low gestational age
840136|NCT02907580|influenza
840137|NCT02907580|vaccination
840138|NCT02907554|Preconditioning
840139|NCT02907554|Tissue and organ procurement
840140|NCT02907554|Cyclosporine A
840141|NCT02907554|Kidney transplantation
840142|NCT02907554|Delayed graft function
840143|NCT02907541|eLearning
840144|NCT02907541|Quality Improvement Methods
840145|NCT02907541|Knowledge Transfer
840146|NCT02907541|Impact of learning
840147|NCT02907515|single implant retained mandibular overdenture
840148|NCT02907489|post operative pain
840149|NCT02907489|triple antibiotic paste
840150|NCT02907489|intracanal medication
840151|NCT02907463|Aortic Valve Replacement
840152|NCT02907463|Aortic Stenosis
840153|NCT02907463|EDWARDS INTUITY Elite
840154|NCT02907463|Rapid deployment valves
840155|NCT02907437|Minocycline
840156|NCT02907437|Negative symptoms
840157|NCT02907437|Cognitive symptoms
840158|NCT02907437|Inflammation
840159|NCT02907411|Quadrivas
840160|NCT02907411|Veins
840161|NCT02907411|Lipedema
840162|NCT02907411|Lymphedema
840163|NCT02907398|Neurostimulation
840164|NCT02907398|Hypoglossal nerve
840165|NCT02907398|Tongue
840166|NCT02907398|Upper airway stimulation
840167|NCT02907398|Surgery
840168|NCT02907385|Rectal Cancer
840169|NCT02907385|Low Anterior Resection
840171|NCT02907385|Surgical Sealant
840172|NCT02907372|cognitive dysfunctions
840173|NCT02907372|cognitive complaints
840174|NCT02907372|metastatic prostate cancer
840175|NCT02907372|new generations of hormone-therapy
840176|NCT02907333|Condom use
840177|NCT02907333|Human Papillomavirus
840178|NCT02907333|Conization
840179|NCT02907307|LactiSal
840180|NCT02907307|Vaginal therapy
840181|NCT02907294|PDE10 inhibitor
840182|NCT02907294|phosphodiesterase 10 inhibitor
840183|NCT02907294|Huntington's disease
840184|NCT02907294|psychiatric disorders
840185|NCT02907281|Multiple sclerosis
840186|NCT02907281|MS
840187|NCT02907281|Optical coherence tomography
840188|NCT02907281|OCT
840189|NCT02907281|RRMS
840190|NCT02907268|botulinum toxin type A, intradermal
840191|NCT02907255|Pulse oximetry
840192|NCT02907255|vital signs monitoring
840193|NCT02907255|wireless notification of clinicians
840194|NCT02907255|respiratory monitoring system
840195|NCT02907242|stillbirth
840196|NCT02907242|cerebroplacental ratio
840197|NCT02907242|fetal growth restriction
840198|NCT02907216|Healthy Japanese infants
840199|NCT02907216|Safety
840200|NCT02907216|Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) vaccine
840201|NCT02907216|Vaccination
840202|NCT02907216|Oral HRV liquid vaccine
840203|NCT02907216|Immunogenicity
840204|NCT02907190|pulses
840205|NCT02907190|beans
840206|NCT02907190|blood glucose
840207|NCT02907190|insulin
840208|NCT02907112|meat intake
840209|NCT02907112|meat analogues
840210|NCT02907112|LDL Cholesterol
840211|NCT02907112|HDL Cholesterol
840212|NCT02907099|Malignant neoplasms of digestive organs
840213|NCT02907099|Metastatic Pancreatic Cancer
840214|NCT02907099|Pancreatic adenocarcinoma
840215|NCT02907099|BL-8040
840216|NCT02907099|Pembrolizumab
840217|NCT02907099|Keytruda
840218|NCT02907099|MK-3475
840219|NCT02907099|SCH-900475
840220|NCT02907099|Phone call
840221|NCT02907060|prolonged pregnancy
840222|NCT02907060|mechanical cervical ripening
840223|NCT02906995|pharmacokinetics
840224|NCT02906995|nicotine absorption
840225|NCT02906982|Periodontal diseases
840226|NCT02906982|Periodontitis
840227|NCT02906982|Gingivitis
840228|NCT02906982|Teeth Whitening
840229|NCT02906982|Dental Plaque Index
840230|NCT02906982|Periodontal Index
840231|NCT02906982|Teeth Whitening Agents
840232|NCT02906982|Tooth Discoloration
840233|NCT02906982|Mean Probing Depth
840234|NCT02906982|Pocket Depth
840235|NCT02906943|Molecular Profiling
840236|NCT02906943|Advanced Cancer
840237|NCT02906943|Advanced Solid Tumors
840238|NCT02906943|Phase I Clinical Trial Candidates
840239|NCT02906943|Next Generation Sequencing
840240|NCT02906878|Intensive Care
840241|NCT02906878|Haematology
840242|NCT02906878|Platelets prophylactic transfusion
840243|NCT02906839|cardiovascular risk
840244|NCT02906839|risk of atrial fibrillation recurrence
840245|NCT02906839|sleep apnea syndrome
840246|NCT02906839|atrial fibrillation
840247|NCT02906826|Airway clearance technique
840248|NCT02906826|Positive expiratory pressure technique
840249|NCT02906826|Adherence
840250|NCT02906813|Drug Therapy
840251|NCT02906800|cisplatin
840252|NCT02906800|head and neck cancer
840253|NCT02906800|digoxin
840254|NCT02906787|Smoking Cessation
840255|NCT02906787|Weight Loss
840256|NCT02906761|asthma, aspirin
840257|NCT02906748|parathyroid autografting
840258|NCT02906748|thyroidectomy
840259|NCT02906748|survival rate
840260|NCT02906748|hypoparathyroidism
840261|NCT02906722|Nebulized colistin
840262|NCT02906722|Intravenous colistin
840263|NCT02906722|ventilator-associated pneumonia
840264|NCT02906722|multidrug resistance
840265|NCT02906722|Gram-negative bacteria
840266|NCT02906696|Chronic myelogenous leukemia
840267|NCT02906696|CML
840268|NCT02906696|Chronic phase post frontline TKI failure
840269|NCT02906696|Tyrosine kinase inhibitor
840270|NCT02906696|TKI
840271|NCT02906696|Bosutinib
840272|NCT02906696|SKI-606
840273|NCT02906696|Phone calls
840274|NCT02906696|Questionnaires
840275|NCT02906696|Surveys
840276|NCT02906683|Urinary Incontinence
840277|NCT02906683|Urinary Incontinence, Stress
840278|NCT02906683|Lower Urinary Tract Symptoms
840279|NCT02906670|Epithelial malignancies
840280|NCT02906657|Medication Reconciliation
840281|NCT02906657|Adverse Drug Event
840282|NCT02906657|Elderly
840283|NCT02906657|patient pharmaceutical record
840284|NCT02906644|Nicotine addiction
840285|NCT02906644|Cigarette smoking
840286|NCT02906644|Smoking cessation
840287|NCT02906644|lorcaserin
840288|NCT02906644|Belviq
840289|NCT02906644|Nicotine patches
840290|NCT02906631|encephalitis,
840291|NCT02906631|neurologic outcomes of all-cause encephalitis in intensive care unit
840292|NCT02906631|outcome, intensive care unit
840293|NCT02906553|Nitric Oxide
840294|NCT02906553|Cognition
840295|NCT02906527|Cardiology
840296|NCT02906527|Oral anticoagulants
840297|NCT02906527|Risk and Benefit analysis
840298|NCT02906527|Health insurance databases
840299|NCT02906527|Safety
840300|NCT02906527|Elderly
840301|NCT02906514|Hydroxyethyl Starch
840302|NCT02906514|Cardiac surgery
840303|NCT02906514|Priming of cardiopulmonary bypass
840304|NCT02906501|Risperidone
840305|NCT02906501|ADHD
840306|NCT02906501|DBD
840307|NCT02906501|IGT
840308|NCT02906501|CNP
840309|NCT02906501|Executive functions
840310|NCT02906488|Quality of life
840311|NCT02906475|Dermatitis, atopic
840312|NCT02906475|prevention and control
840313|NCT02906475|Infant
840314|NCT02906475|Skin care
840315|NCT02906475|randomized controlled trial
840316|NCT02906462|Leonetti French law
840317|NCT02906462|Palliative care
840318|NCT02906449|concussion, mild head injury, mindfulness
840319|NCT02906436|Lung transplantation
840320|NCT02906436|ExVivo reconditionning
840321|NCT02906423|Quality of Life
840322|NCT02906423|Patient-Centered Care
840323|NCT02906423|Patient Outcome Assessment
840324|NCT02906384|hippocampus avoidance
840325|NCT02906384|volumetric modulated arc therapy
840326|NCT02906384|functional MRI
840327|NCT02906384|hopkins Verbal Learning Test
840328|NCT02906384|prophylactic cranial irradiation
840329|NCT02906345|Septic shock
840330|NCT02906345|Fresh frozen plasma
840331|NCT02906306|Older adults
840332|NCT02906306|Occupational Therapy
840333|NCT02906306|Self-Efficacy
840334|NCT02906306|Psychological Well-being
840335|NCT02906280|EBUS-TBNA
840336|NCT02906241|African Americans
840337|NCT02906241|prostate cancer
840338|NCT02906241|Minority
840339|NCT02906241|Racial /Ethnic disparity
840340|NCT02906241|Cancer care
840341|NCT02906241|patient-physician communication
840342|NCT02906241|cancer clinical trial accrual
840343|NCT02906228|non-ionizing radiation
840344|NCT02906215|mHealth
840345|NCT02906215|implementation
840346|NCT02906163|EGFR mutation positive
840347|NCT02906163|Thymosin Alpha 1
840348|NCT02906163|Tyrosine Kinase inhibitor
840349|NCT02906163|Thymalfasin
840350|NCT02906163|Non Small Cell Lung Cancer
840351|NCT02906150|EGFR Wild Type
840352|NCT02906150|Thymosin Alpha 1
840353|NCT02906150|Non-Small Cell Lung Cancer
840354|NCT02906150|Thymalfasin
840358|NCT02906111|Estriol
840359|NCT02906111|Prolapse
840360|NCT02906111|Quality of life
840361|NCT02906111|Vaginal health
840362|NCT02906111|Vaginal surgery
840363|NCT02906098|Gingivitis
840364|NCT02906098|Adolescents
840365|NCT02906098|Oral hygiene
840366|NCT02906098|Oral health behavior
840367|NCT02906098|Periodontal infection control
840368|NCT02906085|[C10.228.140.546.399.750.250]
840369|NCT02906072|Obesity
840370|NCT02906072|Body fat
840371|NCT02906072|Plant-based diet
840372|NCT02906072|Plant-based meal replacement
840373|NCT02906059|RAS
840374|NCT02906059|KRAS
840375|NCT02906059|NRAS
840376|NCT02906059|BRAF
840377|NCT02906059|Mutated
840378|NCT02906059|Wee1 inhibitor
840379|NCT02906046|SCA 3
840380|NCT02906046|Ataxic Gait
840381|NCT02906033|Surgical Procedures, Operative
840382|NCT02906033|Operating Rooms
840383|NCT02906033|Quality of Life
840384|NCT02906033|Surgery-related anxiety
840385|NCT02905994|Leukemia
840386|NCT02905981|IRIDA
840387|NCT02905981|Triferic
840388|NCT02905981|soluble ferric pyrophosphate
840389|NCT02905981|Shohl's solution
840390|NCT02905968|Anastomotic leak
840391|NCT02905968|Low rectal cancer
840392|NCT02905929|sedentary behavior
840393|NCT02905929|standing
840394|NCT02905929|sitting
840395|NCT02905929|inclinometer
840396|NCT02905864|Liraglutide
840397|NCT02905864|Liraglutide 3 mg
840398|NCT02905864|Osteoarthritis
840399|NCT02905864|Obesity
840400|NCT02905799|Osteoarthritis
840401|NCT02905799|Knee
840402|NCT02905799|Resveratrol
840403|NCT02905799|Oral Treatment
840404|NCT02905799|Pain
840405|NCT02905799|Trial
840406|NCT02905786|General Practice
840407|NCT02905786|Nurse practitioner
840408|NCT02905786|Natriuretic peptides
840409|NCT02905786|Clinical audit
840410|NCT02905773|Intensity
840411|NCT02905760|Acute Myocardial Infarction
840412|NCT02905760|Right ventricular infarction
840413|NCT02905760|Diuretic
840414|NCT02905760|Fluid Expansion
840415|NCT02905747|Exercise Therapy
840416|NCT02905747|Musculoskeletal Pain
840417|NCT02905747|Knee osteoarthritis
840418|NCT02905747|Physical Therapy Modalities
840419|NCT02905734|Nicotine replacement therapy
840420|NCT02905734|Tobacco
840421|NCT02905708|normothermia
840422|NCT02905708|hypothermia
840423|NCT02905695|Post-partum Perineal pain
840424|NCT02905695|Episiotomy
840425|NCT02905695|First-degree tear
840426|NCT02905669|distensibility
840427|NCT02905669|impedance planimetry
840428|NCT02905669|esophagus
840429|NCT02905669|esophago-gastric junction
840430|NCT02905669|pylorus
840431|NCT02905656|quitline
840432|NCT02905656|nicotine replacement therapy
840433|NCT02905656|tobacco intervention
840434|NCT02905656|smokers not ready to quit
840435|NCT02905643|Pseudoprogression
840436|NCT02905643|Brain Cancer
840437|NCT02905630|coronary flow reserve
840438|NCT02905630|angina
840439|NCT02905630|exercise training
840440|NCT02905617|Breast Augmentation
840441|NCT02905617|Breast Revision-Augmentation
840442|NCT02905604|rTMS
840443|NCT02905604|negative symptoms
840444|NCT02905604|intermittent theta burst
840445|NCT02905604|iTBS
840446|NCT02905604|repetitive transcranial magnetic stimulation
840447|NCT02905604|dorsomedial prefrontal cortex
840448|NCT02905604|dmPFC
840449|NCT02905604|NIRS
840450|NCT02905591|pharmacological ascorbate
840451|NCT02905591|ascorbic acid
840452|NCT02905591|radiation
840453|NCT02905591|chemotherapy
840454|NCT02905591|carboplatin
840455|NCT02905591|paclitaxel
840456|NCT02905565|Multicenter
840457|NCT02905565|Randomized
840458|NCT02905565|Double-Blind
840459|NCT02905565|Placebo-Controlled
840460|NCT02905565|Add-On to Standard-of-Care
840461|NCT02905565|Safety
840462|NCT02905565|Efficacy
840463|NCT02905552|Myelodysplastic syndrome (myelodysplasia)
840464|NCT02905552|Infection
840465|NCT02905552|Risk Factors
840466|NCT02905539|Iron
840467|NCT02905539|anemia
840468|NCT02905539|phosphorus
840469|NCT02905539|FGF-23
840470|NCT02905526|Reproductive health
840471|NCT02905513|Reproductive health
840472|NCT02905500|Disability-Adjusted Life Years
840473|NCT02905500|Epidemiology
840474|NCT02905500|Public Health
840475|NCT02905487|Gestational Diabetes Mellitus
840476|NCT02905487|Obesity
840477|NCT02905487|Adipocytokin
840478|NCT02905474|chronic kidney disease, mobile applications, mHealth, medication reconciliation, self-management
840479|NCT02905461|Reproductive health
840480|NCT02905448|Obesity
840481|NCT02905448|Body composition
840482|NCT02905448|Atherosclerosis
840483|NCT02905448|Insulin resistance
840484|NCT02905448|Hyperuricemia
840485|NCT02905435|burns
840486|NCT02905435|autografts
840487|NCT02905435|humans
840488|NCT02905435|biodegradable polyurethane
840489|NCT02905435|dermal matrix
840490|NCT02905435|synthetic
840491|NCT02905422|physical activity
840492|NCT02905422|sleep
840493|NCT02905422|nutrition
840494|NCT02905422|Soldier
840495|NCT02905422|prevention
840496|NCT02905422|remote monitoring
840497|NCT02905422|mobile technology
840498|NCT02905396|small fiber neuropathy
840499|NCT02905396|spinal cord stimulation
840500|NCT02905396|treatment
840501|NCT02905396|pain
840502|NCT02905370|Home Health
840503|NCT02905370|Rehabilitation
840504|NCT02905370|High Intensity
840505|NCT02905370|Hospital Associated Deconditioning
840506|NCT02905370|Functional Mobility
840507|NCT02905370|Physical Function
840508|NCT02905357|Myocardial Infarction
840509|NCT02905357|Women
840510|NCT02905357|Imaging
840511|NCT02905305|cochlear implants
840512|NCT02905305|Dexamethasone
840513|NCT02905305|combined device
840514|NCT02905279|spider phobia
840515|NCT02905279|animal phobia
840516|NCT02905279|exposure therapy
840517|NCT02905279|biofeedback
840518|NCT02905279|relaxation training
840519|NCT02905240|Autologous Protein Solution
840520|NCT02905240|APS
840521|NCT02905240|intra-articular injection
840522|NCT02905240|osteoarthritis
840523|NCT02905227|Adult smokers
840524|NCT02905227|Asthma
840525|NCT02905227|Healthy volunteers
840526|NCT02905188|hepatocellular carcinoma
840527|NCT02905188|GPC3-CAR T cells
840528|NCT02905188|GPC3-positive hepatocellular carcinoma
840529|NCT02905175|rheumatoid arthritis
840530|NCT02905175|Porphyromonas gingivalis
840531|NCT02905149|Oncological
840532|NCT02905149|Surgery
840533|NCT02905149|Breast
840534|NCT02905149|Reconstruction
840535|NCT02905136|autoantibodies
840536|NCT02905136|neuronal synaptic receptors
840537|NCT02905136|autoimmune encephalitis
840538|NCT02905110|Malignant Neoplasms, Brain
840539|NCT02905097|Knee arthroplasty, Total
840540|NCT02905097|Knee replacement, Total
840541|NCT02905097|Survival rate
840542|NCT02905097|Osseointegration
840543|NCT02905097|Gait
840544|NCT02905071|mental health
840545|NCT02905071|well-being at work
840546|NCT02905071|screening
840547|NCT02905071|psychosocial risk
840548|NCT02905071|psychometrics
840549|NCT02905071|questionnaire
840550|NCT02905071|job stress
840551|NCT02905032|Afib
840552|NCT02905032|Atrial fib
840553|NCT02905032|Shared
840554|NCT02905032|Decision
840555|NCT02905032|Making
840556|NCT02905032|Aid
840557|NCT02905032|AF
840561|NCT02904980|Quiet eye training
840562|NCT02904980|Visual Attention
840563|NCT02904954|Lung neoplasms
840564|NCT02904954|Bronchial Neoplasms
840565|NCT02904954|Carcinoma, bronchogenic
840566|NCT02904954|Neoplasms
840567|NCT02904954|Neoplasms by site
840568|NCT02904954|Respiratory Tract Diseases
840569|NCT02904954|Respiratory Tract Neoplasms
840570|NCT02904954|Thoracic Neoplasms
840571|NCT02904941|Children
840572|NCT02904941|Skin Transplantation
840573|NCT02904941|Amniotic Membrane
840574|NCT02904902|adalimumab
840575|NCT02904902|japanese participants
840576|NCT02904902|efficacy
840577|NCT02904902|safety
840578|NCT02904850|Non-small cell lung cancer
840579|NCT02904850|locally advanced or metastatic
840580|NCT02904850|erlotinib monotherapy
840581|NCT02904837|Randomized clinical trial
840582|NCT02904837|Parkinson's disease
840583|NCT02904837|Mental practice
840584|NCT02904837|Gait
840585|NCT02904824|adipose tissue
840586|NCT02904824|adult stem cells
840587|NCT02904824|vocal cord paralysis
840588|NCT02904811|Chlamydia trachomatis
840589|NCT02904811|Pelvic inflammatory disease
840590|NCT02904798|sunscreen
840591|NCT02904798|photoprotection
840592|NCT02904798|visible light
840593|NCT02904746|follow-up
840594|NCT02904746|mental health appointment
840595|NCT02904720|Vitamin D; Pregnancy
840596|NCT02904707|Skin Graft
840597|NCT02904668|chronic pain
840598|NCT02904642|SMS reminder
840599|NCT02904642|incentive
840600|NCT02904642|mobile phone
840601|NCT02904642|Immunization
840602|NCT02904590|IBD
840603|NCT02904590|Infection
840604|NCT02904577|Indolent B-Cell Lymphomas
840605|NCT02904577|prospective collection
840606|NCT02904564|drug delivery
840607|NCT02904564|Idiopathic Guttate Hypomelanosis
840608|NCT02904551|prospective study
840609|NCT02904551|free gingival graft
840610|NCT02904551|keratinized gingiva
840611|NCT02904551|dental implant
840612|NCT02904538|Dexamethasone
840613|NCT02904538|Regional anesthesia
840614|NCT02904538|Front foot surgery
840615|NCT02904538|Metacarpal osteotomy
840616|NCT02904525|newly diagnosed
840617|NCT02904525|MRI
840618|NCT02904499|Atrial Fibrillation
840619|NCT02904499|Anticoagulants
840620|NCT02904499|Pharmacoepidemiology
840621|NCT02904447|hemicap
840622|NCT02904447|hallux rigidus
840623|NCT02904434|voriconazole
840624|NCT02904434|absorption
840625|NCT02904434|pharmacokinetic
840626|NCT02904434|grapefruit juice
840627|NCT02904434|bioavailability
840628|NCT02904434|intestinal first-pass metabolism
840629|NCT02904434|pharmacokinetics
840630|NCT02904434|intestinal
840631|NCT02904421|scoliosis
840632|NCT02904421|spinal deformity
840633|NCT02904421|vitamin D
840634|NCT02904421|bone health
840635|NCT02904408|quality of life
840636|NCT02904408|psychotherapy
840637|NCT02904408|hidradenitis
840638|NCT02904408|treatments
840639|NCT02904356|OCD
840640|NCT02904356|TMS
840641|NCT02904356|Neuromodulation
840642|NCT02904356|Obsessive-Compulsive Disorder
840643|NCT02904356|Transcranial Magnetic Stimulation
840644|NCT02904356|Imaging
840645|NCT02904343|hemodialysis machine
840646|NCT02904343|quality
840647|NCT02904343|safety
840648|NCT02904343|domestic
840649|NCT02904304|Flu
840650|NCT02904304|Treatment
840651|NCT02904291|Bariatric surgery
840652|NCT02904291|Gastrointestinal tract
840653|NCT02904291|Biological availability
840654|NCT02904291|Pharmacokinetics
840655|NCT02904278|Pediatric Heart Transplant Recipient
840656|NCT02904278|Medication Adherence
840657|NCT02904265|continuous spike wave in sleep
840658|NCT02904265|Landau-Kleffner syndrome
840659|NCT02904265|acetazolamide
840660|NCT02904265|diazepam
840661|NCT02904252|Transient elastography
840662|NCT02904252|Fibrotest
840663|NCT02904239|Contrast Media
840664|NCT02904239|Multidetector Computed Tomography
840665|NCT02904239|Individualized Medicine
840666|NCT02904239|Radiation Dosage
840667|NCT02904239|Incidental cardiac findings
840668|NCT02904239|Thoracic high-pitch Computed Tomography
840669|NCT02904226|ICOS
840670|NCT02904226|ICOS agonist monoclonal antibody
840671|NCT02904226|JTX-2011
840672|NCT02904226|Anti-PD-1
840673|NCT02904226|Nivolumab
840674|NCT02904226|ICONIC
840675|NCT02904226|Immunotherapy
840676|NCT02904226|Immuno-oncology
840677|NCT02904226|Cancer
840678|NCT02904226|Solid Tumor
840679|NCT02904226|Dose Escalation
840680|NCT02904226|Dose Expansion
840681|NCT02904213|vaccine
840682|NCT02904213|ComBe Five
840683|NCT02904213|Vietnam
840684|NCT02904213|pentavalent
840685|NCT02904135|Circulating Tumor Cells
840686|NCT02904070|Threat of
840687|NCT02904044|School
840688|NCT02904044|Sport
840689|NCT02904044|Injuries
840690|NCT02904005|Suicide
840691|NCT02904005|Prediction
840692|NCT02904005|Prospective study
840693|NCT02904005|Suicide attempt
840694|NCT02904005|Risk management
840695|NCT02903992|Frail Elderly
840696|NCT02903992|sarcopenia
840704|NCT02903914|Immuno-Oncology
840705|NCT02903914|Checkpoint Inhibitors
840706|NCT02903914|Tumor Metabolism
840707|NCT02903914|PD-1 inhibitor
840708|NCT02903914|PD-L1 inhibitor
840709|NCT02903914|Solid Tumors
840710|NCT02903914|RCC
840711|NCT02903914|MEL
840712|NCT02903914|NSCLC
840713|NCT02903914|Arginase
840714|NCT02903914|Arginase Inhibitor
840715|NCT02903914|CB-1158
840716|NCT02903914|SCCHN
840717|NCT02903914|GEJ
840718|NCT02903901|Delirium
840719|NCT02903862|Caregivers
840720|NCT02903862|Case Management
840721|NCT02903862|Alzheimer's Disease
840722|NCT02903862|Cognition
840723|NCT02903862|Caregiver Burden
840724|NCT02903862|Depression
840725|NCT02903823|spinal cord injury
840726|NCT02903823|cerebral palsy
840727|NCT02903823|stroke
840728|NCT02903797|Endometrial hyperplasia
840729|NCT02903797|Irisin
840730|NCT02903797|fibronectin type III domain containing 5
840731|NCT02903797|FNDC5 (fibronectin type III domain containing )
840734|NCT02903719|Phrenic
840735|NCT02903719|Nerve block
840736|NCT02903719|Postoperative shoulder pain
840737|NCT02903719|Liver resection
840738|NCT02903706|gold miners
840739|NCT02903706|plasmodium carriers
840740|NCT02903706|artemisinine resistance
840741|NCT02903680|Relapse Prevention
840742|NCT02903680|Children
840743|NCT02903667|bone grafting
840744|NCT02903667|implantology
840745|NCT02903667|oral surgery
840746|NCT02903628|myopia
840747|NCT02903615|glucose
840748|NCT02903615|inflammation
840749|NCT02903602|sharing histories
840750|NCT02903602|autobiographical memory
840751|NCT02903602|health behavior
840752|NCT02903602|narrative communication
840753|NCT02903602|community health workers
840754|NCT02903602|global health
840755|NCT02903602|maternal and child health
840756|NCT02903602|stunting
840757|NCT02903537|Multiple Sclerosis
840758|NCT02903537|Dendritic Cells
840759|NCT02903537|Immune Tolerance
840760|NCT02903537|Myelin Proteins
840761|NCT02903537|Tolerogenic dendritic cells
840762|NCT02903511|Metformin
840763|NCT02903511|total kidney volume
840764|NCT02903511|glomerular filtration rate
840765|NCT02903498|disease control survival
840766|NCT02903472|SCI
840767|NCT02903472|microbiome
840768|NCT02903472|metabolome
840769|NCT02903472|GI
840770|NCT02903472|UTI
840771|NCT02903472|DNA
840772|NCT02903472|genomics
840773|NCT02903472|infections
840774|NCT02903472|tetraplegic
840775|NCT02903472|paraplegic
840776|NCT02903459|Central Fat
840777|NCT02903459|Subcutaneous Fat
840778|NCT02903459|Lumbar Lordosis Degree
840779|NCT02903459|Cellulite
840780|NCT02903433|Avocado
840781|NCT02903433|Cardiovascular disease
840782|NCT02903407|Ventilators, Mechanical
840783|NCT02903407|Intensive Care Units
840784|NCT02903407|Deep Sedation
840785|NCT02903381|Smoldering Multiple Myeloma
840786|NCT02903368|Prostate Cancer
840787|NCT02903342|Fever
840788|NCT02903342|Febrile illness
840789|NCT02903342|Children
840790|NCT02903316|Fluid responsiveness
840791|NCT02903316|Perioperative
840792|NCT02903316|Extra systoles
840793|NCT02903316|Coronary artery bypass
840794|NCT02903316|Systolic arterial pressure
840795|NCT02903264|Gestational Diabetes Mellitus
840796|NCT02903264|Obesity
840797|NCT02903264|Periodontal Disease
840798|NCT02903251|Oxytocin
840799|NCT02903251|Administration, Intranasal
840800|NCT02903251|Ethanol
840801|NCT02903238|placebo
840802|NCT02903238|pain
840803|NCT02903238|osteoarthritis
840804|NCT02903225|Heart rate variability
840805|NCT02903225|Systolic heart failure
840806|NCT02903225|Physical exercise
840807|NCT02903225|Parasympathetic indexes
840808|NCT02903212|Apoptotic cells
840809|NCT02903199|Whey Protein
840810|NCT02903199|Postprandial Glycaemia
840811|NCT02903199|Appetite Response
840812|NCT02903186|infants
840813|NCT02903186|minorities
840814|NCT02903186|overfeeding
840815|NCT02903186|WIC program
840816|NCT02903186|feeding practices
840817|NCT02903186|breastfeeding
840818|NCT02903173|respiratory depression
840819|NCT02903173|postpartum
840820|NCT02903173|neuraxial morphine
840821|NCT02903173|cesarean delivery
840822|NCT02903160|Castration resistant
840823|NCT02903160|Prostate cancer
840824|NCT02903160|Metastatic
840825|NCT02903160|First-line
840826|NCT02903160|Treatment naive
840827|NCT02903160|Rapidly cycling
840828|NCT02903160|Non-cross resistant
840829|NCT02903147|IVDR; driving behavior patterns; Meta-Cognitive Intervention
840830|NCT02903121|Unscheduled bleeding
840831|NCT02903121|Long acting contraception
840832|NCT02903095|Single ascending dose
840833|NCT02903082|Myeloid-Derivated suppressive cell
840834|NCT02903082|Sepsis
840835|NCT02903082|Inflammatory Response Syndrome, Systemic
840836|NCT02903069|newly diagnosed
840837|NCT02903069|malignant glioma
840838|NCT02903069|WHO Grade 4
840839|NCT02903069|WHO Grade IV
840840|NCT02903069|Marizomib
840841|NCT02903069|MRZ
840842|NCT02903069|TMZ
840843|NCT02903069|RT
840844|NCT02903069|brain cancer
840845|NCT02903069|proteasome inhibitor
840846|NCT02903069|radiation
840847|NCT02903069|temozolomide
840848|NCT02903069|temodar
840849|NCT02903069|chemotherapy
840850|NCT02903069|concurrent
840851|NCT02903069|adjuvant
840852|NCT02903056|functional Magnetic Resonance Imaging
840853|NCT02903056|Diffusion Spectrum Imaging
840854|NCT02903056|Susceptibility weighted imaging
840855|NCT02903056|Magnetic Resonance Imaging
840856|NCT02903043|MicroRNAs
840857|NCT02903043|Angiogenesis
840858|NCT02903043|Skeletal muscle
840859|NCT02903043|COPD
840860|NCT02903030|Gastrointestinal Microbiome
840861|NCT02902991|liquid biopsy, breast cancer,circulating tumor biomarker
840866|NCT02902965|Bruton's Tyrosine Kinase
840867|NCT02902965|Bortezomib
840868|NCT02902965|Dexamethasone
840869|NCT02902965|Ibrutinib
840870|NCT02902939|Immune Suppression, Inflammatory Response, Cardiac Surgery
840871|NCT02902913|platelet reactivity
840872|NCT02902913|phenolic
840873|NCT02902913|extra virgin olive oil
840874|NCT02902913|cyclooxygenase
840875|NCT02902913|oleocanthal
840876|NCT02902913|oxylipin
840877|NCT02902900|Multiple Myeloma
840878|NCT02902900|Pomalidomide
840879|NCT02902900|Efficacy
840880|NCT02902835|Buprenorphine treatment
840881|NCT02902835|Incarceration
840882|NCT02902835|Linkage Intervention
840883|NCT02902835|Opioid use disorder
840884|NCT02902822|melanoma
840885|NCT02902822|non-melanoma skin cancer
840886|NCT02902822|mole
840887|NCT02902822|app
840888|NCT02902822|cliccailneo
840896|NCT02902770|Pain
840897|NCT02902770|Lidocaine
840898|NCT02902770|Ketorolac
840899|NCT02902757|FDG
840900|NCT02902757|PET/CT very early response (48 hrs)
840901|NCT02902705|White adipose tissue
840902|NCT02902705|chronic kidney disease
840903|NCT02902705|uremia
840904|NCT02902705|adipocytes
840905|NCT02902692|brief
840906|NCT02902692|mindfulness
840907|NCT02902666|Bioequivalence
840908|NCT02902666|Paracetamol 1000 mg/codeine 30 mg
840909|NCT02902666|Co-efferalgan 500 mg/30 mg
840910|NCT02902653|misoprostol
840911|NCT02902653|dinoprostonal
840912|NCT02902653|induction
840913|NCT02902614|embryo biopsy
840914|NCT02902614|preimplantation genetic testing
840915|NCT02902614|animal pole
840916|NCT02902614|vegetal pole
840917|NCT02902614|day 3 embryo biopsy
840918|NCT02902614|embryo implantation
840919|NCT02902614|Blastomeres
840920|NCT02902588|Blood-Brain Barrier
840921|NCT02902588|Magnetic Resonance Imaging
840922|NCT02902588|Spectroscopy, Near-Infrared
840923|NCT02902588|Indocyanine green
840924|NCT02902575|Stomach Neoplasms
840925|NCT02902575|Laparoscopy
840926|NCT02902575|Advanced Gastric Cancer
840927|NCT02902575|Neoadjuvant Chemotherapy
840928|NCT02902549|Optical Coherence Tomography
840929|NCT02902549|Fluorescence Imaging
840930|NCT02902549|Sidestream Darkfield Microscopy
840931|NCT02902549|Laser Speckle Contrast Imaging
840932|NCT02902536|Myasthenia Gravis
840933|NCT02902510|yoga
840934|NCT02902510|function
840935|NCT02902510|Parkinson's disease
840936|NCT02902510|gait
840937|NCT02902510|balance
840938|NCT02902458|implantable cardioverter defibrillator
840939|NCT02902458|primary prevention
840940|NCT02902458|psychological follow-up
840941|NCT02902458|anxiety
840942|NCT02902458|depression
840943|NCT02902458|quality of life
840944|NCT02902445|Vaccine
840945|NCT02902445|Polymorphism
840946|NCT02902432|endostar
840947|NCT02902432|cisplatin
840948|NCT02902393|Fibrinolysis
840949|NCT02902393|tPA
840950|NCT02902367|mobility
840951|NCT02902367|exercise
840952|NCT02902367|walking capacity
840953|NCT02902367|fat mass
840954|NCT02902367|muscles
840955|NCT02902341|Nutrition Therapy
840956|NCT02902315|Muscle soreness
840957|NCT02902315|Free radicals
840958|NCT02902315|Ascorbic acid
840959|NCT02902315|Alpha-Tocopherol
840960|NCT02902315|Cryotherapy
840961|NCT02902315|Exercise tolerance
840962|NCT02902315|Resistance training
840963|NCT02902302|Bioequivalence
840964|NCT02902302|Ibuprofen 400 mg/5 ml
840965|NCT02902302|Moment 400 mg coated tablet
840966|NCT02902302|Oral Suspension
840967|NCT02902289|Bioequivalence
840968|NCT02902289|Ibuprofen 200 mg/5 ml
840969|NCT02902289|Moment 200 mg coated tablet
840970|NCT02902289|Oral Suspension
840971|NCT02902276|plasma citrulline
840972|NCT02902276|lipopolysaccharide
840973|NCT02902276|critically ill
840974|NCT02902276|Hospitalization in an Intensive Care Unit
840975|NCT02902263|Telemedecine
840976|NCT02902263|Thrombolysis
840977|NCT02902211|ankle foot orthosis
840978|NCT02902211|biomechanics
840979|NCT02902211|mobility
840980|NCT02902185|Chidamide
840981|NCT02902185|Histone Deacetylase Inhibitor
840982|NCT02902185|HIV-1 Reservoir
840983|NCT02902185|Chronic HIV infections
840984|NCT02902185|HIV Eradication
840985|NCT02902185|Antiretroviral Therapy
840986|NCT02902159|Stress
840987|NCT02902159|Low Mood
840988|NCT02902159|Mental Health
840989|NCT02902159|Peer Support
840990|NCT02902159|Online
840991|NCT02902133|cerebrospinal fluid leak
840992|NCT02902107|Low Dose Rate Brachytherapy
840993|NCT02902107|CivaSheet
840994|NCT02902107|16-605
840995|NCT02902042|Unresectable or metastatic BRAF V600 mutant melanoma
840996|NCT02902042|Encorafenib, binimetinib, pembrolizumab
840997|NCT02902029|unresectable stage IIIB, IIIC, IV melanoma
840998|NCT02902016|PPARgamma
840999|NCT02902016|Lactose intolerance
841000|NCT02902016|Lactase
841001|NCT02901990|mumps
841002|NCT02901990|immunity
841003|NCT02901990|cohort study
841004|NCT02901990|children
841005|NCT02901990|vaccine
841006|NCT02901977|Hypertension
841007|NCT02901977|Blood pressure
841008|NCT02901977|Hemostasis
841009|NCT02901977|Endothelial function
841010|NCT02901951|adult subjects
841011|NCT02901951|Hepatitis B antibody
841012|NCT02901951|Hepatitis B
841013|NCT02901951|HBV
841014|NCT02901925|ABY-029
841015|NCT02901925|Affibody
841016|NCT02901925|Molecular Fluorescence-Guided Surgery
841017|NCT02901925|Epidermal Growth Factor Receptor (EGFR)
841018|NCT02901912|physical activity
841019|NCT02901912|sedentarism
841020|NCT02901912|fecal enzymatic activity
841021|NCT02901886|Rheumatoid Arthritis
841022|NCT02901886|Smoking Cessation
841023|NCT02901886|Disease Activity
841024|NCT02901886|Clinical Prevention
841025|NCT02901808|NOMI
841026|NCT02901808|Angiography
841027|NCT02901808|Digital Subtraction Angiography (DSA)
841028|NCT02901782|Knee
841029|NCT02901782|Titanium Plate
841030|NCT02901730|laser peripheral iridoplasty
841031|NCT02901730|treatment
841032|NCT02901678|skelatal open bite, posterior intrusion
841033|NCT02901626|Short cervix
841034|NCT02901626|Preterm delivery
841035|NCT02901626|Singletons
841036|NCT02901626|Pregnancy
841037|NCT02901626|Pessary
841038|NCT02901600|DMBT1 expression
841039|NCT02901600|Colorectal cancer
841040|NCT02901548|BCG refractory CIS
841041|NCT02901548|Urothelial CIS of bladder
841042|NCT02901548|Carcinoma in situ (CIS)
841043|NCT02901548|Bacillus Calmette-Guérin (BCG)
841044|NCT02901548|Medi4736
841045|NCT02901548|Durvalumab
841046|NCT02901548|CIS of the bladder
841047|NCT02901548|Bladder cancer
841048|NCT02901548|BCG Vaccine
841049|NCT02901548|Bladder diseases
841050|NCT02901548|Urothelial diseases
841051|NCT02901535|telemedicine
841052|NCT02901535|chronic obstructive pulmonary disease
841053|NCT02901535|Primary Health care
841054|NCT02901535|spirometry
841055|NCT02901522|telemedicine
841056|NCT02901522|asthma control test
841057|NCT02901522|Primary Health care
841058|NCT02901522|spirometry
841059|NCT02901509|Chikungunya
841060|NCT02901509|Quality of Life
841062|NCT02901457|Body Image
841063|NCT02901418|chronic hepatitis B
841064|NCT02901418|mother to child transmission
841065|NCT02901418|interruption
841066|NCT02901418|hepatitis B immunoglobulin
841067|NCT02901418|pregnancy
841068|NCT02901418|HBsAg
841069|NCT02901418|newborns
841070|NCT02901405|sarcoma
841071|NCT02901405|infection
841072|NCT02901405|negative pressure
841073|NCT02901392|Male Urethral Slings
841074|NCT02901392|Artificial Urinary Sphincter
841075|NCT02901392|Prostatectomy
841076|NCT02901392|Radiotherapy
841077|NCT02901379|atorvastatin
841078|NCT02901379|myocardial edema
841079|NCT02901379|Follistatin-like 1
841080|NCT02901379|FSTL1
841081|NCT02901379|atorvastatin 80mg
841082|NCT02901379|coronary artery bypass surgery
841083|NCT02901366|Mass balance
841084|NCT02901340|Borderline idiopathic isolated oligohydramnios
841085|NCT02901340|Fetal renal artery doppler indices
841086|NCT02901340|neonatal outcomes
841087|NCT02901340|Maternal hydration
841088|NCT02901327|Lumbar Stabilisation Exercise
841089|NCT02901327|Treadmill Walk
841090|NCT02901327|Multifidus Muscle Activation
841091|NCT02901327|Pain Intensity
841092|NCT02901327|Functional Disability
841093|NCT02901288|pulmonary tuberculosis
841094|NCT02901288|shortened regimen
841095|NCT02901288|clinical trial
841096|NCT02901275|Clinical Trial, Phase II
841097|NCT02901275|Analgesia
841098|NCT02901262|continuous EEG
841099|NCT02901249|Cost effectiveness
841100|NCT02901249|Unipolar Depression
841101|NCT02901249|Major Depression Disorder
841102|NCT02901249|Quality of life disorder
841103|NCT02901236|trabeculectomy
841104|NCT02901236|glaucoma
841105|NCT02901236|filtration surgery
841106|NCT02901236|wound healing
841107|NCT02901236|angiogenesis
841108|NCT02901236|mitomycin
841109|NCT02901236|vascular endothelial growth factor inhibition
841110|NCT02901223|Oncoplastic breast surgery
841111|NCT02901223|oncological safety
841112|NCT02901223|patient satisfaction
841113|NCT02901210|Recta prolapse
841114|NCT02901210|Intraoperative bleeding
841115|NCT02901210|mucosal cauterization
841116|NCT02901197|capnography
841117|NCT02901171|Smoking cessation
841118|NCT02901171|Acceptance and Commitment Therapy
841119|NCT02901171|Smartphone
841120|NCT02901158|esophageal pressure
841121|NCT02901158|chest wall elastance
841122|NCT02901158|lung elastance
841123|NCT02901158|transpulmonary pressure
841124|NCT02901145|immunotherapy,solid tumor,pediatric
841125|NCT02901106|Multiple Sclerosis, Relapsing-Remitting
841126|NCT02901106|Dimethyl fumarate
841127|NCT02901093|Stapes surgery
841128|NCT02901093|Sensorineural complications
841129|NCT02901093|Inner ear
841130|NCT02901093|Imaging
841131|NCT02901093|Cone Beam CT
841132|NCT02901067|Fibrinolysis
841133|NCT02901015|schizophrenia
841134|NCT02901002|Complex Regional Pain Syndromes
841135|NCT02901002|Pain
841136|NCT02901002|Spontaneous sensations
841137|NCT02901002|interoception
841138|NCT02900989|Psychiatry
841139|NCT02900989|Pediatrics
841140|NCT02900989|Suicide
841141|NCT02900976|Organ Transplantation
841142|NCT02900963|Nutrition
841143|NCT02900963|Head and Neck Cancer
841144|NCT02900950|cancer
841145|NCT02900950|resection margin
841146|NCT02900950|pathology
841147|NCT02900950|pancreas
841148|NCT02900937|Stents
841149|NCT02900937|Angioplasty
841150|NCT02900937|Coronary Vessels
841151|NCT02900937|Coronary Artery Disease
841152|NCT02900937|Angina Pectoris
841153|NCT02900937|Myocardial Ischemia
841154|NCT02900937|Myocardial Infarction
841155|NCT02900937|Myocardial Revascularization
841156|NCT02900924|PAD
841157|NCT02900924|PVD
841158|NCT02900924|SFA stent
841159|NCT02900911|head and neck cancer
841160|NCT02900911|dysphagia
841161|NCT02900911|rehabilitation
841162|NCT02900911|radiation therapy
841163|NCT02900820|Anti-Bacterial Agents
841164|NCT02900820|Primary Health Care
841165|NCT02900820|Drug Resistance, Microbial
841166|NCT02900820|Respiratory Tract Infections
841167|NCT02900781|Arthroplasty
841168|NCT02900781|Physical Therapy
841169|NCT02900768|Bone Marrow Transplantation
841170|NCT02900768|Exercise
841171|NCT02900768|Rehabilitation
841172|NCT02900768|Cancer
841173|NCT02900755|Electroencephalography
841174|NCT02900755|Perampanel
841175|NCT02900742|lung cancer
841176|NCT02900742|traditional Chinese medicine
841177|NCT02900742|maintenance therapy
841178|NCT02900742|chemotherapy
841179|NCT02900677|Pancreatic Cancer
841180|NCT02900677|Fatigue
841181|NCT02900677|Nutrition
841182|NCT02900677|Quality of Life
841191|NCT02900651|MAK683, advanced malignancies, DLBCL, EED - Embryonic ectoderm development, EZH2 - Enhancer of zeste homolog 2
841192|NCT02900638|mentoring
841193|NCT02900638|children
841194|NCT02900638|cardiovascular health
841195|NCT02900612|dyslipidemias,
841196|NCT02900612|aging
841197|NCT02900612|water aerobics training
841198|NCT02900612|resistance aquatic training
841199|NCT02900612|lipid profile
841200|NCT02900599|HIV
841201|NCT02900599|Behavior
841202|NCT02900547|Systolic Heart Failure
841203|NCT02900547|medical algorithm decision support system
841204|NCT02900534|grief
841205|NCT02900534|depression
841206|NCT02900534|bereavement
841207|NCT02900534|divorce
841208|NCT02900534|online self-help
841209|NCT02900495|Nocturnal Enuresis
841210|NCT02900495|Bedwetting
841211|NCT02900495|TENS
841212|NCT02900469|RANK
841213|NCT02900469|RANKL
841214|NCT02900456|Intra-aortic Balloon Pumps
841215|NCT02900456|Registry
841216|NCT02900417|type 2 diabetes
841217|NCT02900417|gut microbiota
841218|NCT02900417|sitagliptin
841219|NCT02900378|physical activity
841220|NCT02900378|actigraphy
841221|NCT02900378|sleep
841222|NCT02900378|sacubitril/valsartan
841223|NCT02900378|enalapril
841224|NCT02900378|heart failure
841225|NCT02900378|reduced ejection fraction
841226|NCT02900378|randomized controlled trial
841227|NCT02900378|accelerometry
841228|NCT02900365|trauma
841229|NCT02900365|cataract
841230|NCT02900365|lensectomy
841231|NCT02900365|time
841232|NCT02900365|early
841233|NCT02900365|late
841234|NCT02900352|Alcohol Use Disorder
841235|NCT02900352|Alcoholism
841236|NCT02900352|Alcohol Dependence
841237|NCT02900352|Zonisamide
841238|NCT02900352|Alcohol Intoxication
841239|NCT02900352|Drinking Behaviors
841240|NCT02900352|Anticonvulsants
841241|NCT02900339|MRI
841242|NCT02900339|Sequence optimization
841243|NCT02900339|Healthy volunteers
841244|NCT02900326|Exercise capacity
841245|NCT02900326|Mindfulness
841246|NCT02900326|Quality of life
841247|NCT02900313|acute kidney injury
841248|NCT02900313|cardiac surgery
841249|NCT02900313|cardiac surgery associated acute kidney injury
841250|NCT02900313|renal replacement therapy
841251|NCT02900313|renal recovery
841252|NCT02900313|serum hyperphosphatemia
841253|NCT02900287|Survival
841254|NCT02900287|Cancer
841255|NCT02900248|Biomarkers
841256|NCT02900248|High-Throughput Nucleotide Sequencing
841257|NCT02900248|Neoplasms
841258|NCT02900248|Myelodysplastic Syndromes
841259|NCT02900235|Healthy
841260|NCT02900209|Influenza
841261|NCT02900209|Exacerbations
841262|NCT02900196|Probiotics
841263|NCT02900196|Antibiotic Associated Diarrhea
841264|NCT02900196|Gastro-Intestinal disorders
841265|NCT02900196|Helicobacter pylori
841266|NCT02900170|Rivaroxaban, Acute Kidney Injury
841267|NCT02900157|Advanced Solid Tumor
841268|NCT02900157|Immunotherapy
841269|NCT02900157|MEDI9090
841270|NCT02900157|MEDI4736
841271|NCT02900157|Durvalumab
841272|NCT02900118|Bone metastasis
841273|NCT02900118|PET-CT
841274|NCT02900118|whole-body MRI
841275|NCT02900092|postmenopausal
841276|NCT02900092|women
841277|NCT02900092|depression
841278|NCT02900079|malaria
841279|NCT02900079|rapid diagnostic test
841280|NCT02900079|travel
841281|NCT02900079|fever
841282|NCT02900079|self care
841283|NCT02900066|fever
841284|NCT02900066|traveler
841285|NCT02900066|arbovirus
841286|NCT02900066|rickettsia
841287|NCT02900066|malaria
841288|NCT02900066|filter paper
841289|NCT02900066|diagnosis
841290|NCT02900001|myocardial infarction
841291|NCT02900001|invasive strategy
841292|NCT02900001|elderly
841293|NCT02900001|delayed
841294|NCT02899988|IL-23
841295|NCT02899988|dermatology
841296|NCT02899975|Validation
841297|NCT02899975|Information and Fitness Software
841298|NCT02899975|Elderly
841299|NCT02899975|WeTakeCare
841300|NCT02899949|dapagliflozin
841301|NCT02899949|type 2 diabetes
841302|NCT02899949|real-world data
841303|NCT02899936|Mass drug administration
841304|NCT02899936|Safety Data
841305|NCT02899897|echocardiography
841306|NCT02899884|Drug Therapy
841307|NCT02899871|joint pain
841434|NCT02898701|Overtraining
841308|NCT02899858|Thoracic spinal cord injury
841309|NCT02899858|Paralysis
841310|NCT02899858|ASIA A
841311|NCT02899858|Device
841312|NCT02899832|children
841313|NCT02899832|spasms
841314|NCT02899819|pesticides
841315|NCT02899819|exposure
841316|NCT02899819|in utero
841317|NCT02899806|Video Information
841318|NCT02899806|Satisfaction
841319|NCT02899806|Anxiety
841320|NCT02899806|Epidural Analgesia
841321|NCT02899806|Comprehension
841322|NCT02899806|delivery
841323|NCT02899767|transfusion dependency
841324|NCT02899767|transfusion intensity
841325|NCT02899767|prognosis
841326|NCT02899767|chemotherapy
841327|NCT02899754|lung cancer
841328|NCT02899754|decision support
841329|NCT02899754|implementation
841330|NCT02899741|Medically intractable epilepsy, Omega-3
841331|NCT02899689|Labor
841332|NCT02899689|Foley
841333|NCT02899689|Dilapan
841334|NCT02899689|Cervical Dilators
841335|NCT02899689|Induction
841336|NCT02899650|Delayed Onset Muscle Soreness
841337|NCT02899650|Eccentric exercise
841338|NCT02899650|Masters athlete
841339|NCT02899637|Incomplete Spinal Cord Injury
841340|NCT02899637|Rehabilitation
841341|NCT02899637|Non-invasive brain stimulation
841342|NCT02899637|Transcranial Magnetic Stimulation
841343|NCT02899611|Epilepsy
841344|NCT02899585|Palliative care
841345|NCT02899546|Peripherally Inserted Central Catheter
841346|NCT02899546|Infections
841347|NCT02899546|Radiology
841348|NCT02899533|PAH
841349|NCT02899533|Pulmonary hypertension
841350|NCT02899507|Out-of-hospital cardiac arrest
841351|NCT02899507|Prophylactic antibiotics
841352|NCT02899468|TBI
841353|NCT02899468|Virtual Reality
841354|NCT02899455|Hypertension
841355|NCT02899455|Hyperlipidemia
841356|NCT02899442|cardiovascular risk
841357|NCT02899442|Occupational Health
841358|NCT02899442|night work
841359|NCT02899442|Public Health
841360|NCT02899442|Preventive Health Services
841361|NCT02899416|cardiovascular risk
841362|NCT02899416|young adulthood
841363|NCT02899403|Cognitive Tasks
841364|NCT02899403|Mild Cognitive Impairment
841365|NCT02899403|Neurophysiological Correlates
841366|NCT02899403|Healthy Volunteers
841367|NCT02899377|PET/CT
841368|NCT02899377|Primary Sjögren's Syndrome
841369|NCT02899377|Magnetic resonance imaging
841370|NCT02899377|11^C-MET
841371|NCT02899377|18^F-FDG
841372|NCT02899364|Sodium thiosulfate
841373|NCT02899364|STEMI
841374|NCT02899364|Infarct size
841375|NCT02899364|Cardiac magnetic resonance imaging
841376|NCT02899364|Hydrogen sulfide
841377|NCT02899286|Acute myeloid leukemia
841378|NCT02899286|AML
841379|NCT02899286|pegylated recombinant human arginase
841380|NCT02899286|PEG-BCT-100
841381|NCT02899273|Early Childhood Caries
841382|NCT02899273|eye-tracking
841383|NCT02899273|children
841384|NCT02899273|dentistry
841385|NCT02899273|face perception
841386|NCT02899247|composite resin
841387|NCT02899247|surface sealant
841388|NCT02899234|Nicotine
841389|NCT02899234|Electronic Cigarette
841390|NCT02899195|Unresectable Mesothelioma
841391|NCT02899195|Durvalumab
841392|NCT02899195|Anti-Programmed Death-Ligand 1 Antibody
841393|NCT02899169|Acute promyelocytic leukemia
841394|NCT02899169|Realgar-Indigo Naturalis Formula
841395|NCT02899169|All-trans Retinoic Acid
841396|NCT02899091|Alzheimer's disease
841397|NCT02899091|Mesenchymal Stem cells
841401|NCT02899026|Glucocorticosteroids
841402|NCT02899026|Sirukumab
841403|NCT02899026|Prednisone
841404|NCT02899026|Polymyalgia Rheumatica
841405|NCT02899013|Perianal Lesions
841406|NCT02898987|HIV
841407|NCT02898987|Hepatitis C
841408|NCT02898987|Comorbidities
841409|NCT02898987|AIDS
841410|NCT02898948|procalcitonin
841411|NCT02898948|bacterial infection
841412|NCT02898909|femtosecond laser-assisted cataract surgery
841413|NCT02898909|nuclear lens fragmentation
841414|NCT02898844|dieting
841415|NCT02898844|dyads
841416|NCT02898844|psychological well-being
841417|NCT02898844|weight loss
841418|NCT02898844|cortisol
841419|NCT02898792|sensitivity, opioid
841420|NCT02898753|GSD-II
841421|NCT02898753|Pompe Disease
841422|NCT02898753|Glycogen Storage Diseases
841423|NCT02898753|GAA
841424|NCT02898740|Parkinson's disease
841425|NCT02898740|exercise therapy
841426|NCT02898740|quality of life
841427|NCT02898701|Motor Learning
841428|NCT02898701|Dose of Motor Practice
841429|NCT02898701|Postural Control
841430|NCT02898701|Serial Reaction Time Task
841431|NCT02898701|Retention
841432|NCT02898701|Transfer
841433|NCT02898701|Overpractice
841435|NCT02898701|Overlearning
841436|NCT02898688|Influenza vaccine
841437|NCT02898688|Pertussis vaccine
841438|NCT02898688|Perinatal vaccination
841439|NCT02898688|Infant vaccination
841444|NCT02898532|Children, ADHD, target shooting sport
841445|NCT02898506|Diabetes Type 1
841446|NCT02898506|Diabetes, Insulin-Dependent
841447|NCT02898506|Liraglutide
841448|NCT02898506|Preclinical Type 1 Diabetes
841449|NCT02898506|GLP-1 Analogue
841450|NCT02898506|Dysglycemia
841451|NCT02898506|Prevention
841452|NCT02898493|Validation of questionnaire
841453|NCT02898493|Quality of life
841454|NCT02898441|lung cancer screening
841455|NCT02898441|low-dose CT
841456|NCT02898441|high-risk population
841457|NCT02898415|HCC
841458|NCT02898415|Liver Transplantation
841459|NCT02898415|AFP
841460|NCT02898415|Mortality
841461|NCT02898415|Competing risk
841462|NCT02898415|Selection criteria
841463|NCT02898415|Recurrence
841464|NCT02898376|spa care
841465|NCT02898376|randomised controlled trial
841466|NCT02898376|pentoxifylline/tocopherol combination
841467|NCT02898376|late sequelae
841468|NCT02898376|radiotherapy
841469|NCT02898363|Care of disabled population
841470|NCT02898363|Mental retardation
841471|NCT02898363|Cancer screening
841472|NCT02898363|Cancer prevention
841473|NCT02898324|Bullying
841474|NCT02898324|KiVa program
841475|NCT02898324|Primary school students
841476|NCT02898311|CAD-CAM
841477|NCT02898311|composite dental resin
841478|NCT02898311|Immediate dental implant loading
841479|NCT02898259|Lenalidomide
841480|NCT02898259|Ixazomib
841481|NCT02898259|Rituximab
841482|NCT02898246|heart failure
841483|NCT02898246|fear of physical activity
841484|NCT02898246|motor activity
841485|NCT02898233|depression
841486|NCT02898233|internet-based
841487|NCT02898233|treatment
841488|NCT02898233|low-level light therapy
841489|NCT02898233|LLLT
841490|NCT02898233|deprexis
841491|NCT02898194|Surrogate Decision-making
841492|NCT02898194|Health Care
841493|NCT02898194|Medical Decisions
841494|NCT02898194|End of Life Care
841495|NCT02898168|stroke
841496|NCT02898168|Rehabilitation
841497|NCT02898168|WalkAide (WA)
841498|NCT02898168|Functional Electrical Stimulation (FES)
841499|NCT02898155|Avoidable hospitalizations
841500|NCT02898155|primary care
841501|NCT02898155|geographicvariation
841502|NCT02898142|Postprandial test
841503|NCT02898142|Metabolic syndrime
841504|NCT02898142|HTG
841505|NCT02898129|chronic respiratory diseases
841506|NCT02898129|housing
841507|NCT02898129|lung function test
841508|NCT02898116|ALK-rearranged
841509|NCT02898116|ALK-positive
841510|NCT02898116|ALK Inhibitor
841511|NCT02898116|Ensartinib
841512|NCT02898116|X-396
841513|NCT02898116|anti-PD-L1
841514|NCT02898116|Durvalumab
841515|NCT02898116|MEDI4736
841516|NCT02898116|ALK
841517|NCT02898090|Quality indicators
841518|NCT02898090|Appropriateness
841519|NCT02898090|Oral anticoagulant prescriptions
841520|NCT02898090|Development and validation
841521|NCT02898090|Hospital information system
841522|NCT02898090|Information Storage and Retrieval
841523|NCT02898090|Natural Language Processing
841524|NCT02898077|Second line
841525|NCT02898077|Angiogenesis
841526|NCT02898077|Vascular endothelial growth factor receptor 2
841527|NCT02898051|heparin low-molecular-weight;pharmacokinetics
841528|NCT02898012|Glioblastoma Multiforme
841529|NCT02898012|temozolomide
841530|NCT02898012|bevacizumab
841531|NCT02897973|Spinal loads
841532|NCT02897973|Trunk muscle force
841533|NCT02897973|Computational modeling
841534|NCT02897973|Unilateral lower limb amputation
841535|NCT02897960|wheezing
841536|NCT02897960|bronchiolitis
841537|NCT02897960|respiratory sound algorithm
841538|NCT02897947|Lumbosacral Region
841539|NCT02897947|Surgery
841540|NCT02897947|Registries
841541|NCT02897895|Lung transplantation in end-stage lung diseases
841542|NCT02897843|Electroconvulsive Therapy
841543|NCT02897843|Transcranial Direct Current Stimulation
841544|NCT02897843|cognition
841545|NCT02897817|Methotrexate
841546|NCT02897817|Treatment adherence
841547|NCT02897804|multiphase optimization strategy
841548|NCT02897804|college students
841549|NCT02897778|entinostat
841550|NCT02897778|solid tumor
841551|NCT02897778|Histone Deacetylase Inhibitors
841552|NCT02897765|Checkpoint Inhibitor
841553|NCT02897765|Immunotherapy
841554|NCT02897765|Personalized Vaccine
841555|NCT02897765|Neoantigen
841556|NCT02897765|Poly-ICLC
841557|NCT02897765|Peptide
841558|NCT02897752|stroke
841559|NCT02897752|Rehabilitation
841560|NCT02897752|WalkAide (WA)
841561|NCT02897752|Functional Electrical Stimulation (FES)
841562|NCT02897713|mechanical ventilation
841563|NCT02897713|enteral nutrition
841564|NCT02897713|feeding intolerance
841565|NCT02897700|Chemotherapy
841566|NCT02897700|Safety
841567|NCT02897700|Tolerability
841568|NCT02897700|Efficacy
841569|NCT02897687|Autism Spectrum Disorder
841570|NCT02897687|Social Skills
841571|NCT02897687|Social Media
841572|NCT02897661|fecal microbiota transplantation
841573|NCT02897661|enteral nutrition
841574|NCT02897622|Eating disorders
841575|NCT02897622|severe and enduring
841576|NCT02897622|quality of life
841577|NCT02897622|case management
841578|NCT02897609|Beta-lactamine
841579|NCT02897609|β-lactamine
841580|NCT02897570|ghrelin
841581|NCT02897570|breakfast meal
841582|NCT02897570|P-300
841583|NCT02897531|Ileocolic, stapled, laparoscopy, right hemicolectomy
841584|NCT02897518|Videolaryngoscopes
841585|NCT02897518|Intubation
841586|NCT02897505|post traumatic stress disorder (PTSD)
841587|NCT02897466|ventilator-associated pneumonia
841588|NCT02897466|Multidrug-resistant bacteria
841589|NCT02897440|Femoral Neck Fracture
841590|NCT02897440|Hip Arthroplasty
841591|NCT02897440|Repairing of soft tissue
841592|NCT02897427|Oropharyngeal cancer
841593|NCT02897427|Anal cancer
841594|NCT02897427|Penile cancer
841595|NCT02897427|Human papillomavirus
841596|NCT02897427|HPV
841597|NCT02897427|HPV 16 E antigens
841598|NCT02897427|Oropharyngeal cancer screening
841599|NCT02897427|Dysplasia
841600|NCT02897427|Ultrasound scans of throat and the lymph nodes in neck
841601|NCT02897427|Anal cancer screening
841602|NCT02897427|Anal pap test
841603|NCT02897427|High-resolution anoscopy
841604|NCT02897427|HRA
841605|NCT02897427|Penile cancer screening
841606|NCT02897401|urinary N'Nitrosonornicotine
841607|NCT02897401|nicotine
841608|NCT02897401|electronic cigarette
841609|NCT02897401|nicotine remplacement treatment
841610|NCT02897362|ADHD
841611|NCT02897362|Sleep
841612|NCT02897362|Adolescents
841613|NCT02897362|Neurocognition
841614|NCT02897362|Polysomnography
841615|NCT02897310|critically ill patients
841616|NCT02897310|acute kidney injury
841617|NCT02897310|renal replacement therapy
841618|NCT02897310|long term outcome
841619|NCT02897284|Mindfulness-based
841620|NCT02897284|Self-care
841621|NCT02897284|Health workers
841622|NCT02897284|Epigenetics
841623|NCT02897271|Eosinophilic Gastrointestinal Disorders
841624|NCT02897258|Dialysis
841625|NCT02897258|Thrombosis
841626|NCT02897258|Haemorrhage
841627|NCT02897245|Myelogenous
841628|NCT02897245|Chronic
841629|NCT02897245|BCR-ABL Positive
841630|NCT02897232|Human Papillomavirus Vaccine
841631|NCT02897232|HPV
841632|NCT02897232|Patient Acceptance
841633|NCT02897232|Physician Comfort
841634|NCT02897232|Male Vaccination
841635|NCT02897232|HPV Associated Cancers
841645|NCT02897180|tuberculosis
841646|NCT02897180|latent tuberculosis infection
841647|NCT02897180|Food supplement
841648|NCT02897180|Mycobacterium manresensis
841649|NCT02897180|Nyaditum resae
841650|NCT02897180|Efficacy trial
841651|NCT02897167|Psychosis
841652|NCT02897167|Antipsychotic Agents
841653|NCT02897167|Immunology
841654|NCT02897167|Schizophrenia Spectrum and Other Psychotic Disorders
841655|NCT02897141|HIV
841656|NCT02897141|Health Management App
841657|NCT02897141|HIV symptoms
841658|NCT02897128|Sarcoma
841659|NCT02897128|Radiation
841660|NCT02897128|Wound healing
841661|NCT02897115|Humira
841662|NCT02897115|Axial Spondyloarthritis
841663|NCT02897089|universal adhesive
841664|NCT02897089|fissure sealants
841665|NCT02897089|retention
841666|NCT02897063|midodrine
841667|NCT02897063|droxidopa
841668|NCT02897063|splanchnic circulation
841669|NCT02897037|Bivalirudin
841670|NCT02897037|Acute myocardial infarction
841671|NCT02897037|percutaneous transluminal coronary angioplasty
841672|NCT02897024|Cerebral Palsy
841673|NCT02897024|Motor Impairments
841674|NCT02896985|C-Reactive Protein (CRP)
841675|NCT02896985|Anti-Adalimumab Antibody (AAA)
841676|NCT02896985|Therapeutic Drug Monitoring (TDM)
841677|NCT02896985|Patient Reported Outcome 2 (PRO 2)
841678|NCT02896985|Adalimumab
841679|NCT02896985|Harvey Bradshaw Index (HBI)
841680|NCT02896972|vitrectomy
841681|NCT02896972|macular hole retinal detachment
841682|NCT02896972|high myopia
841683|NCT02896920|Humira®
841684|NCT02896920|Hidradenitis Suppurativa (HS)
841685|NCT02896920|Canada
841686|NCT02896816|Parkinson's
841687|NCT02896803|Pancreatic Cancer
841688|NCT02896803|Chemotherapy
841689|NCT02896790|Cancer
841690|NCT02896790|Oral Therapy
841691|NCT02896790|Compliance
841692|NCT02896790|Anthropology
841693|NCT02896790|Psychology
841694|NCT02896777|pH
841695|NCT02896777|IVF
841696|NCT02896777|live birth rate
841697|NCT02896751|CPAP
841698|NCT02896751|Noninvasive Ventilation Mask
841699|NCT02896725|Venous leg ulcer
841700|NCT02896725|Acellular skin substitutes
841701|NCT02896725|Keratin dressings
841702|NCT02896699|Pre-exposure prophylaxis (PrEP)
841703|NCT02896699|diffusion of innovation
841704|NCT02896699|men who have sex with men
841705|NCT02896699|LGBT
841706|NCT02896699|African American
841707|NCT02896699|Black
841708|NCT02896699|HIV
841709|NCT02896699|network analysis
841710|NCT02896699|network intervention
841711|NCT02896686|Ileostomy closure
841712|NCT02896686|Polypropylene Mesh
841713|NCT02896686|Incisional hernia
841714|NCT02896673|positive expiratory pressure (PEP)
841715|NCT02896673|Acute Respiratory Distress Syndrome (ARDS)
841716|NCT02896673|electrical impedance tomography (EIT)
841717|NCT02896673|tidal volume (TV)
841718|NCT02896673|transpulmonary pressure (TPP)
841719|NCT02896621|Sleep Apnea
841720|NCT02896621|Hypertension
841721|NCT02896621|Chlortalidone
841722|NCT02896621|Diastolic function
841723|NCT02896569|resurfacing
841724|NCT02896569|ablation
841725|NCT02896556|image analysis
841726|NCT02896543|dendritic cells
841727|NCT02896543|P-selectin
841728|NCT02896504|Chemobrain
841729|NCT02896504|Chemotherapy
841730|NCT02896504|Hormonal Therapy
841731|NCT02896504|Neuroimaging
841732|NCT02896465|Children
841733|NCT02896465|Diarrhea
841734|NCT02896465|Human milk oligosaccharides
841735|NCT02896439|Traumatic
841736|NCT02896439|Acetabular
841737|NCT02896426|Parent training
841738|NCT02896426|Preschoolers
841739|NCT02896426|Behavior problems
841740|NCT02896426|Oppositional Defiant Disorder
841741|NCT02896426|ODD
841742|NCT02896426|Conduct Disorder
841743|NCT02896426|CD
841744|NCT02896426|Children
841745|NCT02896426|Parenting
841746|NCT02896426|Collaborative Problem Solving
841747|NCT02896426|CPS
841748|NCT02896426|Disruptive behavior
841749|NCT02896348|Hemiparesis
841750|NCT02896348|Stroke
841751|NCT02896348|Rehabilitation
841752|NCT02896348|Home-based
841753|NCT02896335|Recurrent Brain metastases
841754|NCT02896283|wound healing
841755|NCT02896283|low-level laser therapy
841756|NCT02896283|gingival recession
841757|NCT02896270|idiopathic podocytopathies
841758|NCT02896270|Neprology
841759|NCT02896257|Quality Improvement
841760|NCT02896257|Quality Enhancement Research Initiatives
841761|NCT02896257|QuERI
841762|NCT02896257|Interventional
841763|NCT02896257|Multicenter
841764|NCT02896257|Inhaled corticosteroids
841765|NCT02896257|Pneumonia
841766|NCT02896257|Safety
841767|NCT02896257|De-implementation
841768|NCT02896257|Respiratory Tract Diseases
841769|NCT02896257|Lung Diseases
841770|NCT02896257|Lung Diseases, Obstructive
841771|NCT02896257|Pulmonary Diseases, Chronic Obstructive COPD
841772|NCT02896244|Clostridium difficile
841773|NCT02896244|Clostridium difficile infection
841774|NCT02896244|antibiotics
841775|NCT02896244|antibiotics associated diarrhea
841776|NCT02896244|microbiome
841777|NCT02896244|microbiota
841778|NCT02896218|Vancomycin
841779|NCT02896218|Critically Ill
841780|NCT02896218|Pharmacist
841781|NCT02896218|Population Pharmacokinetic
841782|NCT02896218|Bayesian Methods
841783|NCT02896192|POMC deficiency obesity
841784|NCT02896192|PCSK1 deficiency obesity
841785|NCT02896179|Multiple sclerosis
841786|NCT02896179|Gait rehabilitation
841787|NCT02896179|Quality of life
841788|NCT02896179|Virtual reality
841789|NCT02896179|Cognitive deficit
841790|NCT02896179|Robot assisted gait training
841791|NCT02896166|nsclc and stage I and microwave ablation
841792|NCT02896140|Type 2 diabetes
841793|NCT02896140|Obesity
841794|NCT02896140|Nutrition
841795|NCT02896140|Dairy
841796|NCT02896127|Ankylosing Spondyloarthritis
841797|NCT02896127|Axial spondyloarthritis
841799|NCT02896075|delayed onset muscle soreness
841800|NCT02896075|laughter
841801|NCT02896049|neoplasms
841802|NCT02896049|hyperthermia
841803|NCT02896036|Laparoscopic Entry
841804|NCT02896036|Veress Needle
841805|NCT02896036|Intraperitoneal insufflation
841806|NCT02896036|Time
841807|NCT02896036|Complications
841808|NCT02896023|predictors
841809|NCT02896023|ovarian reserve
841810|NCT02896023|infertile women
841811|NCT02896010|Mobile Health
841812|NCT02895997|mental fatigue
841813|NCT02895997|critical care
841814|NCT02895984|Social network analysis
841815|NCT02895984|Brief Motivational Interviewing
841816|NCT02895984|College Students
841817|NCT02895971|Venous Thromboembolism
841818|NCT02895971|professional Practices
841819|NCT02895906|22q11.2 DS
841820|NCT02895880|Communication Tool
841821|NCT02895880|Cancer Survivors
841822|NCT02895880|Increase Statin
841823|NCT02895880|16-1128
841824|NCT02895854|Low risk prostate cancer
841825|NCT02895854|Intermediate risk prostate cancer
841826|NCT02895854|Low dose-rate brachytherapy
841827|NCT02895854|Hypofractionated
841828|NCT02895854|Robotic external beam radiation
841829|NCT02895854|Quality of life
841833|NCT02895334|CHD
841834|NCT02895334|Congenital Heart Disease
841835|NCT02895321|nano-hydroxyapatite
841836|NCT02895321|potassium nitrate
841837|NCT02895308|compliance
841838|NCT02895295|Medicare Part D
841839|NCT02895295|decision support
841840|NCT02895295|prescription drugs
841841|NCT02895295|expert recommendation
841842|NCT02895295|health insurance choice
841843|NCT02895282|Obesity
841844|NCT02895282|Chronobiology
841845|NCT02895282|Circadian
841846|NCT02895269|Complementary Alternative Providers
841847|NCT02895269|Collaborative Shared Care
841848|NCT02895269|Primary Health Care Providers
841849|NCT02895269|Psychosis
841850|NCT02895802|down syndrome
841851|NCT02895789|spinal muscular atrophy
841852|NCT02895789|oxidative capacity
841853|NCT02895789|exercise tolerance
841854|NCT02895789|mitochondrial myopathy
841855|NCT02895789|SMA
841856|NCT02895789|six minute walk test
841857|NCT02895789|neuromuscular disease
841858|NCT02895789|ambulation
841859|NCT02895789|exercise
841860|NCT02895789|mitochondria
841861|NCT02895789|cycle ergometry
841862|NCT02895789|near infrared spectroscopy
841863|NCT02895763|QUALITY OF LIFE
841864|NCT02895763|NEUROMUSCULAR DISEASES
841865|NCT02895750|diabetes type 2
841866|NCT02895750|Metformin
841867|NCT02895750|chronic kidney disease
841868|NCT02895750|CKD
841869|NCT02895737|aortic stenosis, transcatheter aortic valve replacement, stroke, ischemic infarction, cerebral embolic protection device
841870|NCT02895724|Hyperbaric oxygen therapy
841871|NCT02895724|secondary lymphedema
841872|NCT02895698|Cupping
841873|NCT02895698|Dry cupping
841874|NCT02895698|Myofascial trigger points
841875|NCT02895685|Simulation
841876|NCT02895685|Self-regulated training
841877|NCT02895685|Education
841878|NCT02895685|Open surgery
841879|NCT02895685|Dyad training
841880|NCT02895659|fluid management
841881|NCT02895659|critical illness
841882|NCT02895659|hemodynamics
841883|NCT02895659|buffered infusates
841884|NCT02895633|MR imaging
841885|NCT02895633|Diffusion weighted imaging
841886|NCT02895633|MR proton spectroscopy
841887|NCT02895633|CT perfusion
841888|NCT02895633|Contrast enhanced ultrasound
841889|NCT02895568|Antimalarial drug
841890|NCT02895568|Resistance
841891|NCT02895568|Republic of Chard
841892|NCT02895555|ODI
841893|NCT02895503|Stage IA Non-Small Cell Lung Carcinoma
841894|NCT02895503|Stage IB Non-Small Cell Lung Carcinoma
841895|NCT02895503|Stage IIA Non-Small Cell Lung Carcinoma
841896|NCT02895503|Stage IIB Non-Small Cell Lung Carcinoma
841897|NCT02895503|Stage IIIA Non-Small Cell Lung Cancer
841898|NCT02895503|Stage IIIB Non-Small Cell Lung Cancer
841899|NCT02895503|Stage IV Non-Small Cell Lung Cancer
841900|NCT02895451|Exercise-based cardiac rehabilitation
841901|NCT02895451|Physical capacity
841902|NCT02895451|Adherence
841903|NCT02895451|Behavioral medicine
841904|NCT02895438|Gluten-Sensitive
841905|NCT02895438|Diet, Gluten-Free
841906|NCT02895438|Irritable Bowel Syndrome
841907|NCT02895438|non Coeliac Gluten sensitivity
841908|NCT02895438|children
841909|NCT02895425|Renal Transplant
841910|NCT02895386|Hypertension
841911|NCT02895386|High Blood Pressure
841912|NCT02895386|Systolic Blood Pressure
841913|NCT02895373|platelet inhibition
841914|NCT02895373|alprostadil
841915|NCT02895373|extracorporeal membrane oxygenation
841916|NCT02895373|bleeding
841917|NCT02895373|thromboembolic
841918|NCT02895230|Androgen-deprivation therapy
841919|NCT02895230|Prostate cancer
841920|NCT02895230|Nationwide population-based cohort
841921|NCT02895230|Myocardial infarction
841922|NCT02895230|Ischemic stroke
841923|NCT02895217|Energy expenditure
841924|NCT02895217|Food intake
841925|NCT02895217|Women
841926|NCT02895217|aquacycling
841927|NCT02895204|Fermented Maillard reacted whey protein
841928|NCT02895204|Natural killer cell activity
841929|NCT02895204|Immune function
841930|NCT02895204|Pre-albumin
841931|NCT02895204|Interleukin-12
841932|NCT02895178|Breast cancer
841933|NCT02895178|Survivors
841934|NCT02895178|Exercise
841935|NCT02895165|breast neoplasms
841936|NCT02895165|fertility preservation
841937|NCT02895165|pregnancy
841938|NCT02895152|COPD
841939|NCT02895152|Chronic Obstructive Pulmonary Disease
841940|NCT02895152|Pulmonary Rehabilitation
841941|NCT02895152|Activity Monitors
841942|NCT02895152|Fitbit
841943|NCT02895152|Fitness Tracker
841944|NCT02895139|Additive Manufacture
841945|NCT02895139|Orthotic Insole
841946|NCT02895113|Aspirin
841947|NCT02895113|Diabetes
841948|NCT02895113|Renal function
841949|NCT02895113|Thromboxane
841950|NCT02895100|ulcerative colitis
841951|NCT02895100|inflammatory bowel disease
841952|NCT02895087|diurnal variation
841953|NCT02895087|stress
841954|NCT02895074|femtosecond laser-assisted cataract surgery (FLACS)
841955|NCT02895074|subfoveal choroidal thickness (SFCT)
841956|NCT02895074|conventional phacoemulsification surgery (CPS)
841957|NCT02895009|Coronary Disease
841958|NCT02895009|Radial artery occlusion
841959|NCT02895009|transradial coronary intervention
841960|NCT02894996|pediatric
841961|NCT02894996|anesthesia
841962|NCT02894996|fluid responsiveness
841963|NCT02894996|hemodynamic
841964|NCT02894983|wrist fracture
841965|NCT02894983|colles fracture
841966|NCT02894983|non-operative
841967|NCT02894983|rehabilitation
841968|NCT02894944|Pancreatic cancer
841969|NCT02894944|Adenovirus
841970|NCT02894944|Gene therapy
841971|NCT02894931|macrophage atherogenicity
841972|NCT02894931|dietary interventions
841973|NCT02894931|sugars
841974|NCT02894931|amino acids
841975|NCT02894931|artificial sweeteners
841976|NCT02894931|atherosclerosis
841977|NCT02894892|Electron Microscopy
841978|NCT02894892|Helicobacter pylori
841979|NCT02894892|Bismuth
841980|NCT02894879|Postoperative pulmonary complications
841981|NCT02894866|hypoxic-ischemic encephalopathy
841982|NCT02894866|hyperbaric oxygen therapy
841983|NCT02894840|GPO Tri Fluvac Vaccine
841984|NCT02894840|Tri Fluvac Vaccine
841985|NCT02894814|Self administration
841986|NCT02894814|Medication
841987|NCT02894814|Inpatient
841988|NCT02894814|Self-care
841989|NCT02894814|Self-management
841990|NCT02894814|Medical patients
841991|NCT02894749|hybrid rooms
841992|NCT02894749|cone-beam computed tomography
841993|NCT02894723|Hypertension,
841994|NCT02894723|Nitric Oxide
841995|NCT02894723|L-Arginine
841996|NCT02894723|Arterial Stiffness
841997|NCT02894723|Ambulatory blood pressure measurement
841998|NCT02894710|postoperative pain
841999|NCT02894710|intravenous lidocaine
842000|NCT02894710|chronic post-surgical pain
842001|NCT02894710|remifentanil
842002|NCT02894710|patient controlled analgesia
842003|NCT02894710|morphine consumption
842004|NCT02894710|ENT surgery
842005|NCT02894632|MRI
842006|NCT02894632|Motion
842007|NCT02894632|Respiratory movement
842008|NCT02894632|Artifacts correction
842009|NCT02894619|urinary incontinence
842010|NCT02894619|anal incontinence
842011|NCT02894619|sexuality
842012|NCT02894619|quality of life
842013|NCT02894606|Kidney Transplant
842014|NCT02894606|Immunology
842015|NCT02894593|Antiplaque agents
842016|NCT02894593|chemical plaque control
842017|NCT02894593|oral hygiene
842018|NCT02894593|essential oils
842019|NCT02894593|alcohol
842020|NCT02894593|mouthwash
842021|NCT02894541|Dyslipidemia
842022|NCT02894541|CKD-519
842023|NCT02894541|CETP inhibitor
842024|NCT02894541|Food Drug Interaction
842025|NCT02894528|Alveolar ridge
842026|NCT02894528|guided bone regeneration
842027|NCT02894528|bone grafts
842028|NCT02894502|Self-care
842029|NCT02894502|Motivational interviewing
842030|NCT02894502|Heart failure
842031|NCT02894502|Caregivers
842032|NCT02894476|satisfaction with care
842033|NCT02894476|outpatient care
842034|NCT02894476|self-reported health status
842035|NCT02894476|alcohol dependence
842036|NCT02894476|opioid dependence
842037|NCT02894463|dental care
842038|NCT02894463|emeno
842039|NCT02894463|abuse
842040|NCT02894450|Atrial fibrillation
842041|NCT02894450|oral anticoagulant
842042|NCT02894450|bioassay
842043|NCT02894450|elderly subject
842044|NCT02894437|prevention
842045|NCT02894437|organization
842046|NCT02894437|pressure ulcers
842047|NCT02894424|Inner limiting membrane
842048|NCT02894424|Microperimetry
842049|NCT02894424|surgical's dye
842050|NCT02894411|MRI
842051|NCT02894411|Excyclotorsion
842059|NCT02894372|Oral spray
842060|NCT02894372|Topical sprays
842061|NCT02894372|Faringomoss
842062|NCT02894372|Local phytotherapy
842063|NCT02894359|Cervical spine
842064|NCT02894359|Musculoskeletal imagery
842065|NCT02894359|computer modelling of cervical spine
842066|NCT02894359|ConeBeam.
842067|NCT02894346|Motivation
842068|NCT02894346|Teachers
842069|NCT02894346|Physical activity
842070|NCT02894346|School
842071|NCT02894333|Parkinson's disease
842072|NCT02894333|Action-effect prediction
842073|NCT02894333|Sensory attenuation
842074|NCT02894333|Voluntary action
842075|NCT02894320|Parkinson's disease
842076|NCT02894320|Voluntary action
842077|NCT02894320|Action-effect preactivation
842078|NCT02894320|Action-effect prediction
842079|NCT02894307|MEchanical valves
842080|NCT02894307|Rivaroxaban
842081|NCT02894294|malaria
842082|NCT02894294|chemoprevention
842083|NCT02894294|season
842084|NCT02894294|anemia
842085|NCT02894294|impact
842086|NCT02894294|coverage
842087|NCT02894294|children
842088|NCT02894281|Pupillary light reflex
842089|NCT02894281|Multiple sclerosis
842090|NCT02894190|Non Invasive Ventilation (NIV)
842091|NCT02894190|Adherence
842092|NCT02894190|Beliefs
842093|NCT02894190|Development
842094|NCT02894190|Validation
842095|NCT02894177|E02.880.820.950
842096|NCT02894125|Chronic Low Back Pain
842097|NCT02894125|Old subject
842098|NCT02894125|SPA Therapy
842099|NCT02894125|Pain
842100|NCT02894125|Function
842101|NCT02894125|Expectations
842102|NCT02894125|Fears
842103|NCT02894112|endothelial dependent vasodilation
842104|NCT02894112|blood flow
842105|NCT02894112|blood glucose
842106|NCT02894112|triglycerides
842107|NCT02894112|non-fat milk
842108|NCT02894112|dairy
842109|NCT02894099|Aged
842110|NCT02894099|Sedentary Behaviour
842111|NCT02894099|Blood Glucose
842112|NCT02894099|Insulin
842113|NCT02894099|Inflammatory markers
842114|NCT02894086|acute appendicitis
842115|NCT02894086|ambulatory appendicectomy
842116|NCT02894073|obese patients
842117|NCT02894073|peripheral venous catheter
842118|NCT02894060|Cardiovascular events
842119|NCT02894047|calcium-sensitive receptor
842120|NCT02894034|optic nerve sheath
842121|NCT02894034|meningeal hemorrhage
842122|NCT02894034|early phase
842123|NCT02894034|prognostic
842124|NCT02894021|padding
842125|NCT02894021|lymphoceles
842126|NCT02894021|prevention
842127|NCT02893995|PAH
842128|NCT02893995|Subcutaneous Treprostinil
842129|NCT02893995|Remodulin
842130|NCT02893995|6 Minute Walk Test
842131|NCT02893969|Physical Activity
842132|NCT02893969|Rest
842133|NCT02893956|Echocardiography
842134|NCT02893956|postural support
842135|NCT02893956|preterm neonate
842136|NCT02893904|Propofol
842137|NCT02893904|Sevoflurane
842138|NCT02893904|Bispectral Index
842139|NCT02893904|Children
842140|NCT02893904|Electroencephalographic signs
842141|NCT02893891|Obesity
842142|NCT02893891|Bariatric medicine
842143|NCT02893891|Sleeve gastric resection
842144|NCT02893891|Gastric plication
842145|NCT02893891|Intragastric ballon
842146|NCT02893891|Body composition
842147|NCT02893891|Adipokines
842148|NCT02893891|Ghrelin
842149|NCT02893891|Bone mineral density
842150|NCT02893891|Quality of life
842151|NCT02893878|Seasonal influenza vaccines
842152|NCT02893878|Passive Enhanced Safety surveillance
842153|NCT02893878|England
842154|NCT02893878|Pilot study
842155|NCT02893865|Apnea syndrome
842156|NCT02893865|Coronary artery disease
842157|NCT02893865|Oxidative stress
842158|NCT02893865|Continuous positive airway pressure
842159|NCT02893865|Endothelial dysfunction
842160|NCT02893839|Allergy
842161|NCT02893839|cross-reactivity
842162|NCT02893839|oral allergy syndrome
842163|NCT02893839|potato
842164|NCT02893839|sensitization
842165|NCT02893826|Aneurysm
842166|NCT02893826|Ruptured
842167|NCT02893826|nimodipine
842168|NCT02893826|subarachnoid hemorrhage
842169|NCT02893800|assistive technology
842170|NCT02893800|dementia care
842171|NCT02893800|tracking technology
842172|NCT02893800|locating systems
842173|NCT02893800|user experience
842174|NCT02893787|Speckle Tracking
842175|NCT02893787|Anthracyclines
842176|NCT02893787|Chilhood cancers
842177|NCT02893787|Myocardial function
842178|NCT02893787|Echocardiography
842179|NCT02893761|breast cancer
842180|NCT02893761|survival
842181|NCT02893761|prognosis factors
842182|NCT02893748|colon
842183|NCT02893748|polyps
842184|NCT02893748|cancer
842185|NCT02893748|screening
842186|NCT02893735|Clinical Trial
842187|NCT02893735|Composite resin
842188|NCT02893722|ivf ,atosiban,repeated implantation failure,RCT
842189|NCT02893683|Paris Visual Learning Test
842190|NCT02893683|visual memory
842191|NCT02893683|criterion validity
842192|NCT02893657|MELD score
842193|NCT02893657|hemodynamics
842194|NCT02893657|liver abnormalities
842195|NCT02893566|overweight
842196|NCT02893566|body mass index
842197|NCT02893566|university students
842198|NCT02893566|physical activity
842199|NCT02893566|sedentary behavior
842200|NCT02893566|body composition
842201|NCT02893566|Mi Band
842202|NCT02893514|Drug Use
842203|NCT02893488|dolutegravir
842204|NCT02893488|abacavir
842205|NCT02893488|relative bioavailability
842206|NCT02893488|palatability
842207|NCT02893488|GSK2619619
842208|NCT02893488|palatability questionnaire
842209|NCT02893488|lamivudine
842210|NCT02893488|pediatric
842211|NCT02893488|calcium
842212|NCT02893488|dispersible tablet
842213|NCT02893462|data warehousing
842214|NCT02893462|data aggregation
842215|NCT02893462|data mining
842216|NCT02893449|Parkinson
842217|NCT02893449|SAS-SR
842218|NCT02893449|Social adaptation
842219|NCT02893449|Patients suffering from Parkinson's disease
842220|NCT02893423|Ropivacaine
842221|NCT02893423|C-Section Analgesia
842222|NCT02893423|Tap Block
842223|NCT02893358|Allisartan Isoproxil
842224|NCT02893358|left ventricular hypertrophy
842225|NCT02893358|large arterial stiffness
842226|NCT02893358|microalbuminuria
842227|NCT02893345|Self Care (Rehabilitation)
842228|NCT02893345|Community Participation
842229|NCT02893345|Patient-Centered Outcomes Research
842230|NCT02893345|Informatics, Clinical
842231|NCT02893319|Infant Feeding
842232|NCT02893319|Infant Growth
842233|NCT02893306|Type1 Diabetes Mellitus
842234|NCT02893306|Multipotent stromal cell
842235|NCT02893306|Mesenchymal stem cell
842236|NCT02893306|Insulin
842237|NCT02893306|Pancreatic reserve
842238|NCT02893306|Disease progression
842239|NCT02893267|Stroke
842240|NCT02893267|Shoulder Pain
842241|NCT02893267|Electrical stimulation
842242|NCT02893267|Neuromuscular stimulation
842243|NCT02893267|Intramuscular stimulation
842244|NCT02893267|Physical Therapy
842245|NCT02893254|ankylosing spondylitis, tumor necrosis factor-α inhibitors
842246|NCT02893228|forced expiratory volume in 1 second
842247|NCT02893228|forced vital capacity
842248|NCT02893228|peak expiratory flow rate
842249|NCT02893228|interscalene block
842250|NCT02893228|diaphragmatic paresis
842251|NCT02893202|PTSD
842252|NCT02893202|Equine assisted activities
842253|NCT02893202|quality of life
842254|NCT02893189|CD19+
842255|NCT02893189|allogeneic transplant
842256|NCT02893189|relapse
842257|NCT02893176|Lung Transplant
842258|NCT02893176|Macitentan
842259|NCT02893176|CLAD
842260|NCT02893176|BOS
842261|NCT02893176|bronchiolitis obliterans
842262|NCT02893176|chronic lung allograft dysfunction
842263|NCT02893176|Organ Rejection
842264|NCT02893163|Metabolic Syndrome
842265|NCT02893163|Cancer Risk
842266|NCT02893163|Lifestyle Interventions
842267|NCT02893163|Primary Care
842268|NCT02893163|Behavioural Change
842269|NCT02893150|Mindful Eating
842270|NCT02893150|Overweight
842271|NCT02893150|Primary Care
842272|NCT02893150|Randomized Clinical Trial
842273|NCT02893137|Tumour treating fields
842274|NCT02893137|Optune
842275|NCT02893137|Craniectomy
842276|NCT02893137|TTFields
842277|NCT02893124|chronic hepatitis B
842278|NCT02893111|neuromyelitis optica spectrum disorders
842279|NCT02893111|Bortezomib
842280|NCT02893111|Velcade
842281|NCT02893111|Proteasome inhibitor
842282|NCT02893072|Diabetes, Gestational
842283|NCT02893072|Nutrition Therapy
842284|NCT02893046|care pathway
842285|NCT02893046|hospital- private network
842286|NCT02893046|early consultation
842290|NCT02893020|Emotional experience and burnout in physicians
842291|NCT02892994|therapeutic ultrasound
842292|NCT02892968|Regional Anesthesia Ultrasound guided
842293|NCT02892968|Emergency Department
842294|NCT02892968|Knowledge to Practice Intervention
842295|NCT02892955|Heart Failure
842296|NCT02892955|LVAS
842297|NCT02892955|Ventricular Dysfunction
842298|NCT02892955|Cardiomyopathy
842299|NCT02892955|Heart Disease
842300|NCT02892955|Cardiovascular Disease
842301|NCT02892955|Heart-assist devices
842302|NCT02892955|Thoratec Corporation
842303|NCT02892942|Controlled ovarian hyperstimulation
842304|NCT02892942|Estradiol
842305|NCT02892942|Embryo implantation
842306|NCT02892942|Endometrial receptivity
842307|NCT02892942|Fertility preservation
842308|NCT02892929|Motivational Interviewing
842309|NCT02892929|Hypertension
842310|NCT02892929|Nursing
842311|NCT02892929|Randomized Controlled Trial
842312|NCT02892929|Life Style
842313|NCT02892916|Delirium
842314|NCT02892916|Ketamine
842315|NCT02892916|Elective orthopaedic surgery
842316|NCT02892903|Fractional flow reserve (FFR)
842317|NCT02892903|Pressure wire (PW)
842318|NCT02892903|Coronary angiography
842319|NCT02892877|Complete Hydatidiform mole
842320|NCT02892877|Partial Hydatidiform mole
842321|NCT02892877|Invasive mole
842322|NCT02892877|Choriocarcinoma
842323|NCT02892877|Post-molar neoplasia
842324|NCT02892877|Placental Site Trophoblastic Tumor (PSTT)
842325|NCT02892877|Epithelioid Trophoblastic Tumor (ETT)
842326|NCT02892877|hCG follow-up
842329|NCT02892851|STN-DBS
842330|NCT02892851|Craving
842331|NCT02892851|Cocaine addiction
842332|NCT02892838|mobile bearing knee prosthesis
842333|NCT02892825|Music
842334|NCT02892825|cataract surgery
842335|NCT02892825|topical anaesthesia
842336|NCT02892825|anxiety
842337|NCT02892825|hypertension
842338|NCT02892786|circulating tumor cell
842339|NCT02892786|CellSearch™ method
842340|NCT02892786|RT-PCR
842341|NCT02892773|electrical impedance tomography
842342|NCT02892773|incentive spirometry
842343|NCT02892773|EzPAP
842344|NCT02892773|lung volume
842345|NCT02892773|atelectasis
842346|NCT02892773|positive airway pressure
842347|NCT02892773|pulmonary complication
842348|NCT02892773|abdominal surgery
842349|NCT02892773|end-expiratory lung volume
842350|NCT02892747|Chronic Heart Failure (CHF)
842351|NCT02892747|Dietetics education
842352|NCT02892747|Malnutrition
842353|NCT02892721|CT Colonography
842354|NCT02892721|Virtual colonoscopy
842355|NCT02892721|Colorectal cancer
842356|NCT02892721|Colon cancer
842357|NCT02892721|Training
842358|NCT02892708|supratentorial gliomas
842359|NCT02892708|surgery
842360|NCT02892708|magnetic resonance spectroscopy
842361|NCT02892708|elderly
842362|NCT02892630|Immune Thrombocytopenia
842363|NCT02892630|Pregnancy
842364|NCT02892617|Modic 1
842365|NCT02892617|low back pain
842366|NCT02892604|Type 1 diabetes
842367|NCT02892604|artificial pancreas
842368|NCT02892604|closed-loop insulin infusion
842369|NCT02892565|systemic lupus erythematosus
842370|NCT02892565|antiphospholipid syndrome
842371|NCT02892565|antiphospholipid antibodies
842372|NCT02892513|Colorectal Surgery
842373|NCT02892513|transcutaneous electric nerve stimulation
842374|NCT02892487|Quality of life
842375|NCT02892487|Radiotherapy
842376|NCT02892487|Dysphagia
842377|NCT02892487|Oral cavity
842378|NCT02892487|Oropharynx
842379|NCT02892487|Hypopharynx
842380|NCT02892487|Larynx
842381|NCT02892487|Swallowing rehabilitation
842382|NCT02892487|Toxicity
842383|NCT02892474|Coronary Arteriosclerosis
842384|NCT02892474|Hybrid Coronary Revascularization
842385|NCT02892474|Coronary Artery Bypass Grafting
842386|NCT02892461|Anemia, Iron-Deficiency
842387|NCT02892461|Cesarean Section
842388|NCT02892461|Umbilical Cord Milking
842389|NCT02892461|Randomized Controlled Trial
842390|NCT02892409|Drug Therapy
842391|NCT02892344|Phase III, blinded, QMF149, Mometasone furoate (MF), mild asthma, Adolescent, adult
842392|NCT02892331|exercise
842393|NCT02892331|insulin resistance
842394|NCT02892331|mitochondrial function
842395|NCT02892331|arterial stiffness
842396|NCT02892331|exercise intensity
842397|NCT02892331|fitness
842398|NCT02892305|Pancreaticoduodenectomy
842399|NCT02892305|Hepatectomy
842400|NCT02892305|Liver ablation
842401|NCT02892279|Microneurography
842402|NCT02892279|Air pollution
842403|NCT02892266|Transplant recipients
842404|NCT02892266|Adolescents
842405|NCT02892266|Post-Traumatic Stress Symptoms (PTSS)
842406|NCT02892266|Transplant Recipient and Family Impact(s)
842533|NCT02891577|critically ill
842407|NCT02892253|postoperative hypocalcemia
842408|NCT02892253|near infrared imaging
842409|NCT02892253|parathyroid autofluorescence
842410|NCT02892227|bedside echography
842411|NCT02892162|atrial fibrillation
842412|NCT02892162|catheter ablation
842413|NCT02892149|AKB-6548
842414|NCT02892149|Chronic kidney disease
842415|NCT02892149|anemia
842416|NCT02892149|CKD
842417|NCT02892149|chronic renal insufficiency
842418|NCT02892149|renal impairment
842419|NCT02892149|erythropoietin
842420|NCT02892149|kidney
842421|NCT02892149|renal
842422|NCT02892149|oral anemia treatment
842423|NCT02892149|hemoglobin
842424|NCT02892149|hypoxia-inducible factor
842425|NCT02892149|HIF
842426|NCT02892149|hypoxia-inducible factor prolyl-hydroxylase inhibitor
842427|NCT02892149|HIF-PHI
842428|NCT02892149|efficacy
842429|NCT02892149|safety
842430|NCT02892149|Phase 3
842431|NCT02892149|cardiovascular
842432|NCT02892149|DD-CKD
842433|NCT02892123|HER2
842434|NCT02892123|bispecific antibody
842435|NCT02892123|biparatopic antibody
842436|NCT02892123|breast cancer
842437|NCT02892123|gastric cancer
842438|NCT02892123|gastroesophageal cancer
842439|NCT02892123|ovarian cancer
842440|NCT02892123|non-small cell lung cancer
842441|NCT02892110|Marijuana use
842442|NCT02892110|Varenicline/Chantix
842443|NCT02892110|Motivational enhancement therapy
842444|NCT02892097|tDCS
842445|NCT02892097|neglect
842446|NCT02892097|paresis
842447|NCT02892097|transcranial direct current stimulation
842448|NCT02892097|rehabilitation
842449|NCT02892084|Chronic Stroke ( > 6 months)
842450|NCT02892084|non-invasive brain stimulation
842451|NCT02892084|rehabilitation
842452|NCT02892084|walking
842453|NCT02892084|kinetics
842454|NCT02892045|neuromuscular block
842455|NCT02892045|monitoring
842456|NCT02892019|indacaterol acetate, asthma, GINA 2015, pediatrics
842457|NCT02891993|Cancer Care
842458|NCT02891980|Ad26
842459|NCT02891980|Ebola
842460|NCT02891980|immunogenicity response
842461|NCT02891980|MVA-Multi Filo
842462|NCT02891980|Omics
842463|NCT02891980|Zaire
842464|NCT02891954|Glucosuria
842465|NCT02891954|SGLT2 inhibitors
842466|NCT02891954|Canagliflozin
842467|NCT02891954|FGF23
842468|NCT02891954|Parathyroid hormone
842469|NCT02891954|1,25-Dihydroxyvitamin D
842470|NCT02891954|Glucagon
842471|NCT02891954|Ketone bodies
842472|NCT02891954|Uric acid
842473|NCT02891954|Pharmacogenomics
842474|NCT02891928|Type 2 diabetes
842475|NCT02891928|Diabetic neuropathy
842476|NCT02891928|Disorders of equilibrium
842477|NCT02891928|"Rocker sole shoes"
842478|NCT02891928|Walking
842479|NCT02891915|Antimicrobial
842480|NCT02891915|Beta-Lactam
842481|NCT02891915|Pneumonia
842482|NCT02891915|Short Course
842483|NCT02891915|Standard Course
842484|NCT02891915|Therapy
842485|NCT02891876|direct pulp capping, biodentine
842486|NCT02891863|Implantable Cardioverter-Defibrillator
842487|NCT02891837|L-citrulline
842488|NCT02891837|pediatric
842489|NCT02891837|Lung Injury
842490|NCT02891837|Bypass
842491|NCT02891837|Heart Defects
842492|NCT02891837|Clinical Sequelae
842493|NCT02891824|PD-L1
842494|NCT02891824|Atezolizumab
842495|NCT02891824|Randomized, double blinded
842496|NCT02891824|first or second late relapse
842497|NCT02891824|progressive non-mucinous epithelial ovarian cancer, primary peritoneal adenocarcinoma and / or fallopian-tube adenocarcinoma
842498|NCT02891824|progression-free survival
842499|NCT02891811|newly diagnosed multiple myeloma
842500|NCT02891811|carfilzomib
842501|NCT02891811|thalidomide
842502|NCT02891811|lenalidomide
842503|NCT02891811|dexamethasone
842504|NCT02891811|transplant ineligible
842505|NCT02891811|induction therapy
842506|NCT02891811|maintenance
842507|NCT02891811|Study Group of Medical Tumour Therapy (AGMT)
842508|NCT02891798|analgesia,
842509|NCT02891798|buprenorphine
842510|NCT02891798|clonidine
842511|NCT02891798|dexamethasone
842512|NCT02891798|bupivacaine
842513|NCT02891798|nerve block
842514|NCT02891733|Expression of the Neurotensin
842515|NCT02891733|Neurotensin
842516|NCT02891668|Basal Metabolic rate
842517|NCT02891668|Quality of life
842518|NCT02891668|Resting energy expenditure
842519|NCT02891668|Insulin resistance
842520|NCT02891668|Cognitive Function
842521|NCT02891668|Body Composition
842522|NCT02891642|malignancy
842523|NCT02891642|Pleural Effusion
842524|NCT02891642|Pleural Neoplasms
842525|NCT02891642|Ascites
842526|NCT02891616|Melanoma
842527|NCT02891616|18F-FLT
842528|NCT02891616|18F-FDG
842529|NCT02891616|PET/CT
842530|NCT02891616|PET/MR
842531|NCT02891577|intra abdominal hypertension
842532|NCT02891577|shock
842534|NCT02891564|therapeutic video games, mobile interventions
842535|NCT02891551|Leukemia
842536|NCT02891551|Chronic
842537|NCT02891551|Acute
842538|NCT02891551|Observational
842539|NCT02891551|Non-interventional
842540|NCT02891551|OCEAN
842541|NCT02891551|Netherlands
842542|NCT02891551|azacitidine
842543|NCT02891538|EGCG
842544|NCT02891538|Green Tea
842545|NCT02891538|Colon Cancer
842546|NCT02891512|Magnetic Fields
842547|NCT02891512|Pain
842548|NCT02891512|Paresthesia
842549|NCT02891512|Visual Analogue Scale
842550|NCT02891499|Miniscrews
842551|NCT02891499|Mini-implants
842552|NCT02891499|Temporal anchorage devices
842553|NCT02891499|Bone screws
842554|NCT02891499|Stability
842555|NCT02891499|Displacement
842556|NCT02891499|Low-level laser therapy
842557|NCT02891499|Cone-beam computed tomography
842558|NCT02891499|Resonance frequency analysis
842559|NCT02891499|Orthodontic
842560|NCT02891499|Orthodontic miniscrew implant
842561|NCT02891486|spinal surgery, surgical site infection
842562|NCT02891473|Posture
842563|NCT02891473|Pain
842564|NCT02891473|Muscle stretching
842565|NCT02891473|Mézières method
842566|NCT02891473|Camptocormia
842567|NCT02891473|Trunk control
842568|NCT02891460|Mitomycin C
842569|NCT02891460|MMC
842570|NCT02891460|NMIBC
842571|NCT02891460|Non Muscle Invasive Bladder Cancer
842572|NCT02891460|Hydrogel Reverse thermal gelation
842573|NCT02891460|Drug retention
842574|NCT02891460|Urinary Bladder Neoplasms
842575|NCT02891460|Urologic Neoplasms
842576|NCT02891460|Urinary Bladder Diseases
842577|NCT02891460|Urologic Diseases
842578|NCT02891434|Duchenne muscular dystrophy
842579|NCT02891434|motor learning
842580|NCT02891434|motor abilities
842581|NCT02891395|allogeneic stem cell transplantation
842582|NCT02891395|imatinib Mesylate
842583|NCT02891395|Nilotinib
842584|NCT02891382|Diabetes Mellitus, Type 2
842585|NCT02891382|Weight Loss
842586|NCT02891382|Financial Incentives
842587|NCT02891382|Hemoglobin A, Glycosylated
842588|NCT02891356|Adiponectin
842589|NCT02891356|Bone remodelling markers
842590|NCT02891343|Cognitive Function
842591|NCT02891343|Hypoxia
842592|NCT02891343|Neurophysiological Function
842593|NCT02891343|Effect of Alzheimer Disease symptomatic drugs
842594|NCT02891343|Healthy Subjects
842595|NCT02891330|Roux-en-Y Gastric ByPass
842596|NCT02891304|esophagogastroduodenoscopy
842597|NCT02891291|optical coherence tomography
842598|NCT02891278|leukemia
842599|NCT02891239|laser treatment
842603|NCT02891187|Postoperative Care
842604|NCT02891187|Telephone follow-up
842605|NCT02891187|Healthcare Value
842606|NCT02891174|ibuprofen
842607|NCT02891174|acetaminophen
842608|NCT02891174|blood pressure
842609|NCT02891174|post-partum
842610|NCT02891174|pain control
842611|NCT02891174|pre-eclampsia
842612|NCT02891174|gestational hypertension
842613|NCT02891161|durvalumab
842614|NCT02891161|MEDI4736
842615|NCT02891161|anti-PD-L1
842616|NCT02891096|respiratory complications
842617|NCT02891096|respiratory muscle strength
842618|NCT02891096|discriminator
842619|NCT02891083|adjuvant chemotherapy
842620|NCT02891083|adjuvant radiotherapy
842621|NCT02891083|lymph node metastasis
842622|NCT02891083|surgery
842623|NCT02891083|squamous cell carcinoma
842627|NCT02891031|Rhus
842628|NCT02891031|Medicine, Traditional
842629|NCT02891031|Herbal medicine
842630|NCT02891031|Uric acid
842631|NCT02890966|SHR4640 pharmacokinetics pharmacodynamics
842632|NCT02890927|Geriatric Nursing
842633|NCT02890927|Geriatric co-management
842634|NCT02890927|Geriatric team
842635|NCT02890901|Escherichia coli
842636|NCT02890901|Bloodstream infections
842637|NCT02890901|Severity
842638|NCT02890901|Score
842639|NCT02890901|Host factors
842640|NCT02890901|Microbiology
842641|NCT02890888|small vessel disease of the brain
842642|NCT02890888|hyperbaric oxygen
842643|NCT02890888|functional connectivity MRI
842644|NCT02890875|ethanol lock
842645|NCT02890875|parenteral nutrition
842646|NCT02890862|Kinematics
842647|NCT02890862|Activity of Daily living
842648|NCT02890862|3D motion analysis
842649|NCT02890836|Blood pressure
842650|NCT02890836|Hypertension
842651|NCT02890836|White coat hypertension
842652|NCT02890836|Preeclampsia
842653|NCT02890836|Anti-hypertensiva
842654|NCT02890823|Antiepileptic Drugs
842655|NCT02890823|Vitamin D Deficiency
842656|NCT02890823|Asian
842657|NCT02890810|Acupuncture
842658|NCT02890810|Back Pain
842659|NCT02890810|Chronic Pain
842660|NCT02890797|Child
842661|NCT02890771|Turmeric
842662|NCT02890771|Chronic periodontitis
842663|NCT02890758|Natural Killer Cell
842664|NCT02890758|ALT-803
842665|NCT02890745|Empagliflozin
842666|NCT02890745|Oxidative stress
842667|NCT02890745|Oxidative nucleic acid modifications
842668|NCT02890745|8-oxo-7,8-dihydro-2'-deoxyguanosine
842669|NCT02890745|8-oxo-7,8-dihydroguanosine
842670|NCT02890706|Pulmonary embolism (PE)
842671|NCT02890706|Dual-Energy CT (DECT)
842672|NCT02890706|Subtraction imaging
842673|NCT02890693|gestational diabetes mellitus
842674|NCT02890693|randomized controlled trial
842675|NCT02890693|lifestyle intervention
842676|NCT02890693|cardiovascular
842677|NCT02890693|metabolic
842678|NCT02890693|mental health
842679|NCT02890693|depression
842680|NCT02890693|physical activity
842681|NCT02890693|dietary intervention
842682|NCT02890680|platelet-rich fibrin
842683|NCT02890680|third molar
842684|NCT02890680|bone regeneration
842685|NCT02890667|Cancer
842686|NCT02890667|incidence
842687|NCT02890667|health insurance data
842688|NCT02890667|algorithms
842689|NCT02890654|Teenagers
842690|NCT02890654|Multidisciplinary approach
842691|NCT02890654|Pain
842692|NCT02890654|Surgery
842693|NCT02890628|Thai-Myanmar border
842694|NCT02890615|Survivors
842695|NCT02890615|Self Care
842696|NCT02890589|Acute coronary syndrome
842697|NCT02890589|ST (Software Test) -elevation
842698|NCT02890576|cochlear implant
842699|NCT02890576|telemedicine
842700|NCT02890576|new organization of patient monitoring
842701|NCT02890563|Varicose veins
842702|NCT02890563|Compression stockings
842703|NCT02890563|Sclerotherapy
842704|NCT02890563|Radiofrequency ablation
842705|NCT02890550|Ciliopathy
842706|NCT02890550|Retinitis pigmentosa
842707|NCT02890550|ALMS1 gene
842708|NCT02890537|Osteonecrosis
842709|NCT02890537|Femoral Head
842710|NCT02890537|Hip
842711|NCT02890537|Orthopedics
842712|NCT02890537|Bone
842713|NCT02890537|Musculoskeletal Disorders
842714|NCT02890524|aphthous stomatitis
842715|NCT02890524|night guard
842716|NCT02890524|inflammatory cytokine
842717|NCT02890459|HIV
842718|NCT02890459|incentives
842719|NCT02890459|behavioral economics
842720|NCT02890446|attentional focus
842721|NCT02890446|upper extremity
842722|NCT02890446|hemiparesis
842723|NCT02890446|stroke
842724|NCT02890394|Neck Pain
842725|NCT02890394|Suboccipital inhibition
842726|NCT02890394|Physical Therapy
842727|NCT02890368|CD47
842728|NCT02890368|SIRPa
842729|NCT02890368|Immunotherapy
842730|NCT02890368|Checkpoint inhibitor
842731|NCT02890342|Propionic Acidemia
842732|NCT02890342|Inborn Error of Metabolism
842733|NCT02890342|Genetics
842734|NCT02890342|Pccb
842735|NCT02890342|Pcca
842736|NCT02890290|Frail Elderly
842737|NCT02890290|Diet, Food, and Nutrition
842738|NCT02890290|physical function
842739|NCT02890290|marine protein hydrolysates
842740|NCT02890290|protein intake
842741|NCT02890290|seafood intake
842742|NCT02890290|municipal home care service
842743|NCT02890290|ageing
842744|NCT02890290|old
842745|NCT02890290|nutrition
842746|NCT02890290|frail
842747|NCT02890264|End stage renal disease
842748|NCT02890264|Dialysis
842749|NCT02890251|Infant
842750|NCT02890251|Premature
842751|NCT02890251|Diseases
842752|NCT02890238|Sildenafil Citrate
842753|NCT02890238|Induction of Ovulation
842754|NCT02890238|Pregnancy Rate
842755|NCT02890225|renal residual stones
842756|NCT02890225|external physical vibration lithecbole
842757|NCT02890225|stone free rate
842758|NCT02890225|complications
842759|NCT02890212|Major depression, selenium, placebo, sertraline
842760|NCT02890186|narcotrend
842761|NCT02890186|propofol
842762|NCT02890186|remifentanil
842763|NCT02890186|closed-loop of target controlled infusion
842764|NCT02890173|Essential hypertension
842765|NCT02890173|Mineralocorticoid receptor antagonist
842766|NCT02890173|Esaxerenone
842767|NCT02890173|Ambulatory blood pressure monitoring
842768|NCT02890160|Bioresorbable Vascular Scaffold
842769|NCT02890147|SADs
842770|NCT02890147|Healthy Volunteers
842771|NCT02890147|Molecular profiles
842772|NCT02890147|Omics Techniques
842773|NCT02890134|SADs
842774|NCT02890134|Molecular Reclassification
842775|NCT02890121|SADs
842776|NCT02890121|Molecular Reclassification
842777|NCT02890108|High-Intensity Sweeteners
842778|NCT02890108|Non-Nutritive Sweeteners
842779|NCT02890108|Artificial sweeteners
842780|NCT02890108|Glucose intolerance
842781|NCT02890082|Breast cancer
842782|NCT02890082|fertility
842783|NCT02890082|chemotherapy
842791|NCT02890056|sugar-sweetened beverage consumption
842792|NCT02890056|water consumption
842793|NCT02890056|dietary behaviors
842794|NCT02890056|youth
842795|NCT02890043|spine
842796|NCT02890043|robot-assisted surgery
842797|NCT02890043|pedicle screw
842798|NCT02890030|Cisplatin-based therapy
842799|NCT02890030|Ototoxicity
842800|NCT02890030|Neurotoxicity
842801|NCT02890017|outpatient surgery
842802|NCT02890017|urology medico-economic
842803|NCT02890017|hotel
842804|NCT02890004|Subarachnoid Hemorrhage
842805|NCT02890004|Neurointensive care
842806|NCT02890004|Observational registry
842807|NCT02889991|Myofascial pain.
842808|NCT02889991|Myofascial trigger point.
842809|NCT02889991|Infraspinatus muscle.
842810|NCT02889991|Deep dry needling.
842811|NCT02889991|Local twitch response.
842812|NCT02889991|Fascial mechanotransduction.
842813|NCT02889991|Needle grasp.
842814|NCT02889991|Myofascial fibrosis.
842815|NCT02889991|Elastography.
842816|NCT02889978|Cancer Screening
842817|NCT02889978|High-Throughput Nucleotide Sequencing
842818|NCT02889978|Deep Sequencing
842819|NCT02889978|Circulating cell-free tumor DNA
842820|NCT02889965|Multiple sclerosis
842821|NCT02889965|Pharmacoepidemiology
842822|NCT02889965|Disease modifying drugs
842823|NCT02889965|Neuro-myelitis optica
842824|NCT02889952|postoperative hypocalcemia
842825|NCT02889952|near infrared imaging
842826|NCT02889952|parathyroid autofluorescence
842827|NCT02889939|rehabilitation
842828|NCT02889939|recovery of function
842829|NCT02889939|environment
842830|NCT02889900|ovarian cancer
842831|NCT02889887|Preterm
842832|NCT02889887|Sensory Processing
842833|NCT02889887|Motor Development
842834|NCT02889874|Radiation therapy
842835|NCT02889874|omission
842836|NCT02889874|non-inferiority
842837|NCT02889874|breast cancer
842838|NCT02889861|Uveal melanoma
842839|NCT02889861|Cutaneous melanoma
842840|NCT02889835|Class II
842841|NCT02889835|molar and premolar
842842|NCT02889835|resin composite
842843|NCT02889835|adult
842844|NCT02889835|restoration
842845|NCT02889809|Growth Velocity
842846|NCT02889809|Prepubertal
842847|NCT02889809|Asthma
842848|NCT02889809|Paediatric
842849|NCT02889783|urodynamics
842850|NCT02889783|urethral sensation
842851|NCT02889783|urethral pain
842852|NCT02889757|tuberculosis
842853|NCT02889757|acetylcysteine
842854|NCT02889757|hepatotoxicity
842855|NCT02889744|Temperature
842856|NCT02889744|Hypothermia
842857|NCT02889744|Brain
842858|NCT02889744|Oxygen
842859|NCT02889744|Prognosis
842860|NCT02889731|Suicide
842861|NCT02889731|Heights
842862|NCT02889731|Suicide hot spots
842863|NCT02889731|Bridges
842864|NCT02889705|Ultrasonography
842865|NCT02889705|echotexture
842866|NCT02889705|K value
842867|NCT02889705|SCM muscles
842868|NCT02889705|CMT infants
842869|NCT02889692|lung cancer
842870|NCT02889692|traditional Chinese medicine
842871|NCT02889692|maintenance therapy
842872|NCT02889692|targeted therapy
842873|NCT02889679|Colonoscopy
842874|NCT02889679|Polypectomy
842875|NCT02889666|relapsed
842876|NCT02889666|non-small cell lung cancer
842877|NCT02889666|cisplatin
842878|NCT02889666|carboplatin
842879|NCT02889666|oxaliplatin
842880|NCT02889666|docetaxel
842881|NCT02889666|gemcitabine
842882|NCT02889627|Fecal Microbiota Transplantation
842883|NCT02889627|Gut microbiota
842884|NCT02889627|Brain-gut axis
842885|NCT02889627|Epilepsy
842886|NCT02889588|Refractive Surgery
842887|NCT02889588|higher order aberrations
842893|NCT02889536|parastomal hernia
842894|NCT02889536|ostomy
842895|NCT02889536|qualitative
842896|NCT02889536|phenomenological-hermeneutic research
842897|NCT02889536|symptoms
842898|NCT02889536|parastomal bulging
842899|NCT02889523|Front line therapy
842900|NCT02889523|Age-adjusted International Prognostic Index (aa-IPI) >1
842901|NCT02889523|60 to 80 years
842902|NCT02889510|diabetes
842903|NCT02889510|liraglutide
842904|NCT02889510|lung function
842905|NCT02889497|vaccine
842906|NCT02889497|safety
842907|NCT02889497|immunogenicity
842908|NCT02889458|Chinese
842909|NCT02889458|Breast Cancer
842910|NCT02889458|Women
842911|NCT02889419|Multiple Sclerosis
842912|NCT02889419|Disability
842913|NCT02889419|Underwear
842914|NCT02889419|Urinary catheter
842915|NCT02889419|Self-catheterisation
842916|NCT02889380|Infertility
842917|NCT02889380|Cetrotide
842918|NCT02889380|Assisted reproductive technology (ART)
842919|NCT02889341|Docosahexanoic Acid,
842920|NCT02889341|DNA fragmentation
842921|NCT02889341|male fertility
842922|NCT02889341|Sperm parameters improvements
842923|NCT02889315|PAH
842924|NCT02889315|treprostinil
842925|NCT02889315|LenusPro
842926|NCT02889315|implantable device
842927|NCT02889315|quality of life
842928|NCT02889289|traumatic brain injury
842929|NCT02889289|virtual reality
842930|NCT02889289|Xbox kinect
842931|NCT02889289|balance
842932|NCT02889250|geriatric
842933|NCT02889250|depression
842934|NCT02889250|deep brain stimulation
842935|NCT02889250|subcallosal cingulate
842936|NCT02889237|Fracture healing
842937|NCT02889237|Calcium supplementation
842938|NCT02889237|Vitamin D supplementation
842939|NCT02889237|HR-pQCT
842940|NCT02889224|Obesity
842941|NCT02889224|Cortisol
842942|NCT02889224|Hydrocortisone
842943|NCT02889224|Endocannabinoïds
842944|NCT02889198|web-based tool
842945|NCT02889198|child, preschool
842946|NCT02889198|nutrition
842947|NCT02889198|implementation
842948|NCT02889198|child care
842949|NCT02889185|Optical Coherence Tomography
842950|NCT02889185|Retinal camera
842951|NCT02889159|photoaging
842952|NCT02889146|Intensive Care Units
842953|NCT02889146|Physical Therapy Specialty
842954|NCT02889146|Critical illness
842955|NCT02889146|Muscle weakness
842956|NCT02889146|Bed rest
842957|NCT02889133|Iron deficiency
842958|NCT02889133|Transfusion
842959|NCT02889133|Blood donation
842960|NCT02889120|Drug advice by phone
842961|NCT02889120|Teleprescription
842962|NCT02889120|Medical call centre
842963|NCT02889120|Out of hours call
842964|NCT02889081|birth cohort
842965|NCT02889081|prenatal
842966|NCT02889081|skin barrier
842967|NCT02889081|atopic dermatitis
842968|NCT02889081|key nutritional factors
842969|NCT02889016|PANS
842970|NCT02889016|PANDAS
842971|NCT02888951|Diabetes
842972|NCT02888951|Diabetes Mellitus
842973|NCT02888951|Gastric Ultrasound
842974|NCT02888951|Preoperative fasting
842975|NCT02888951|Empty Stomach
842976|NCT02888951|Gastric Diabetes
842977|NCT02888912|glass ionomer cement
842978|NCT02888912|composite resin
842979|NCT02888886|systemic inflammation
842980|NCT02888873|composite resin
842981|NCT02888873|Clinical trial
842982|NCT02888873|FDI (World Dental Federation) criteria
842983|NCT02888860|genetic susceptibility
842984|NCT02888860|candida infection
842985|NCT02888860|colonization
842986|NCT02888847|post bleaching teeth sensitivity
842987|NCT02888834|elderly
842988|NCT02888834|adverse drug reactions
842989|NCT02888834|hospitalized subjects
842990|NCT02888834|community-dwelling
842991|NCT02888808|gastroesophageal reflux disease
842992|NCT02888808|women
842993|NCT02888808|Nigeria
842994|NCT02888808|obesity
842995|NCT02888795|hypertonic dextrose prolotherapy
842996|NCT02888795|osteoarthritis
842997|NCT02888769|Coronary artery disease
842998|NCT02888769|Text messages
842999|NCT02888769|Blood pressure
843000|NCT02888769|Lifestyle
843001|NCT02888769|Risk factors
843002|NCT02888756|Immunotherapy
843003|NCT02888756|mRNA
843004|NCT02888756|Lentivirus infection
843005|NCT02888756|Virus disease
843006|NCT02888756|Sexually transmitted disease
843007|NCT02888756|Immunodeficiency syndrome
843008|NCT02888730|cystic fibrosis
843009|NCT02888730|chronic rhinosinusitis
843010|NCT02888730|Lung Diseases
843011|NCT02888730|tobramycin
843012|NCT02888730|nebulized sonic aerosol therapy
843013|NCT02888704|Atopic dermatitis
843014|NCT02888704|Mesenchymal stem cells
843015|NCT02888678|ASPIRES
843016|NCT02888652|Coronary Heart Disease
843017|NCT02888652|PCI
843018|NCT02888652|Anti-Platelet Agents
843019|NCT02888613|mini-lumbotomy
843020|NCT02888613|mini-laparotomy
843021|NCT02888613|retroperitoneal approach
843022|NCT02888613|transperitoneal approach
843023|NCT02888613|abdominal aortic surgery
843024|NCT02888535|primary immunodeficiency
843025|NCT02888535|secondary immunodeficiency
843026|NCT02888535|intensive care unit
843027|NCT02888535|infection
843028|NCT02888535|adult
843029|NCT02888509|depression
843030|NCT02888509|anxiety disorder
843031|NCT02888509|bipolar disorder
843032|NCT02888509|Magnetic Resonance Imaging
843033|NCT02888483|physical activity
843034|NCT02888483|energy expenditure
843035|NCT02888457|nasopharyngeal carriage
843036|NCT02888457|Streptococcus pneumoniae
843037|NCT02888457|acute otitis media
843038|NCT02888457|day-care centers
843039|NCT02888431|pH
843040|NCT02888431|base deficit
843041|NCT02888431|lactate values
843042|NCT02888431|venous blood samples
843043|NCT02888431|arterial blood samples
843044|NCT02888418|vaccine
843045|NCT02888418|safety
843046|NCT02888418|immunogenicity
843047|NCT02888405|Body Composition
843048|NCT02888366|breast cancer
843049|NCT02888366|breath test
843050|NCT02888366|Menssana
843051|NCT02888366|Ancillary
843052|NCT02888366|Mammography
843053|NCT02888366|Rapid Point-of-care
843054|NCT02888366|Inflatable Bag
843055|NCT02888353|Magnetic Resonance Imaging and Pacemakers ICD
843056|NCT02888340|Acupuncture
843057|NCT02888340|Emergency Department
843058|NCT02888340|Pain
843059|NCT02888314|mHealth
843060|NCT02888314|Pokemon Go
843061|NCT02888288|adolescent
843062|NCT02888288|adolescence
843063|NCT02888288|HIV/AIDS
843064|NCT02888288|mental health
843065|NCT02888288|cognitive behavioral therapy
843066|NCT02888262|Bipolar disorder
843067|NCT02888262|Blood
843068|NCT02888262|Smartphone
843069|NCT02888262|Brain imaging
843070|NCT02888262|Cognition
843071|NCT02888262|Neuropsychology
843072|NCT02888249|Tobacco withdrawal
843073|NCT02888249|Autonomic Agents
843074|NCT02888236|Psoriasis
843091|NCT02888067|Neuromuscular Blockade
843092|NCT02888041|Cervical ripening
843093|NCT02888041|Pregnancy
843094|NCT02888041|Vaginal Administration
843095|NCT02888028|Remote ICD follow-up
843096|NCT02888028|HRQoL
843097|NCT02888028|Health related Quality of Life
843098|NCT02888028|Depression
843099|NCT02888028|anxiety
843100|NCT02888028|device acceptance
843101|NCT02888028|telemedicine
843102|NCT02888028|telemonitoring
843103|NCT02887989|Virtual Reality
843104|NCT02887989|Non-Opioid Pain Management
843105|NCT02887976|Prostate Cancer
843106|NCT02887976|Castrate Resistant Prostate Cancer (CRPC)
843107|NCT02887976|metastatic
843108|NCT02887976|castrate resistant
843109|NCT02887963|Iron Deficiency
843110|NCT02887963|Iron Deficiency Anemia
843111|NCT02887963|Pregnant Women
843112|NCT02887963|Gestation
843113|NCT02887963|China
843114|NCT02887963|Epidemiology
843115|NCT02887872|stroke
843116|NCT02887872|upper extremity function
843117|NCT02887872|rehabilitation
843118|NCT02887820|ECMO
843119|NCT02887820|TEG
843120|NCT02887807|Cardiac arrest
843121|NCT02887807|Shockable
843122|NCT02887807|Cyclosporine
843123|NCT02887794|pitch discrimination
843124|NCT02887794|auditory processing disorders
843125|NCT02887794|auditory perception
843126|NCT02887794|auditory-verbal hallucinations
843127|NCT02887794|theory of mind
843128|NCT02887729|Polycystic disease
843129|NCT02887703|ataxia
843130|NCT02887703|balance training
843131|NCT02887703|vibrotactile biofeedback
843132|NCT02887703|sensory augmentation
843133|NCT02887703|cerebellar ataxia
843134|NCT02887690|MPL
843135|NCT02887690|prosthetic limb
843136|NCT02887690|upper extremity
843137|NCT02887690|prosthesis
843138|NCT02887677|Dapagliflozin
843139|NCT02887677|Arterial Stiffness
843140|NCT02887677|Aortic Pressure
843141|NCT02887651|cerebrale metastases
843142|NCT02887651|radiotherapy
843143|NCT02887651|surgery
843144|NCT02887651|complete surgical resection
843145|NCT02887651|resection
843146|NCT02887651|cavity boost radiation therapy
843147|NCT02887651|observation
843148|NCT02887586|Auricular Needling
843149|NCT02887586|Mechanism Study
843150|NCT02887586|Anorexia
843151|NCT02887586|Cancer
843152|NCT02887573|Bowel preparation
843153|NCT02887573|Colorectal polyps
843154|NCT02887573|Colon capsule endoscopy
843155|NCT02887560|Right ventricle
843156|NCT02887560|Pulmonary transplantation
843157|NCT02887560|Strain
843158|NCT02887560|isovolumic acceleration (IVA)
843159|NCT02887495|scleroderma
843160|NCT02887495|biorepository
843161|NCT02887482|DNA
843162|NCT02887482|Vaccine
843163|NCT02887469|Hyponatremia
843164|NCT02887469|Hypertonic saline
843165|NCT02887469|Treatment
843166|NCT02887469|Osmotic demyelination syndrome
843167|NCT02887430|foot reflexology
843168|NCT02887430|pain intensity
843169|NCT02887430|health-related quality of life
843170|NCT02887417|platelet activation
843171|NCT02887391|hemodialysis
843172|NCT02887391|nutritional status
843173|NCT02887378|bronchial biopsy
843174|NCT02887365|colon cancer
843175|NCT02887365|MSI-L
843176|NCT02887365|MSS
843177|NCT02887365|Tegafur-Uracil
843178|NCT02887365|Low-Level Microsatellite-Instability
843179|NCT02887339|Informed Consent
843180|NCT02887339|Research donation request
843181|NCT02887339|Effective Communication
843182|NCT02887313|Rectal cancer
843183|NCT02887313|Neoadjuvant chemoradiation therapy
843184|NCT02887300|Quality of Health Care
843185|NCT02887300|Psychological Stress
843186|NCT02887300|Burnout
843187|NCT02887300|Health Care Professional
843188|NCT02887300|Mantra Meditation
843189|NCT02887300|Health Care Economics
843190|NCT02887274|Systemic Inflammatory Response Syndrome (SIRS)
843191|NCT02887274|Sepsis
843192|NCT02887274|Severe Sepsis
843193|NCT02887274|Septic shock
843194|NCT02887274|Multiple organ failure
843195|NCT02887261|Power Port
843196|NCT02887248|nab-paclitaxel
843197|NCT02887248|gemcitabine
843198|NCT02887222|Epidural
843199|NCT02887222|Labor analgesia
843200|NCT02887222|Programmed intermittent epidural bolus
843201|NCT02887196|Breast Cancer
843202|NCT02887183|Heart failure
843203|NCT02887183|Reduced left ventricular ejection fraction
843204|NCT02887183|HFrEF
843205|NCT02887183|NT-proBNP
843206|NCT02887183|Cardiac remodeling
843207|NCT02887170|Adolescent
843208|NCT02887170|Lost to contact
843209|NCT02887170|Recurrence
843210|NCT02887170|Long-term outcome
843211|NCT02887131|Subtalar arthritis
843212|NCT02887131|Subtalar instability
843213|NCT02887118|Erythrocytes
843214|NCT02887118|Sickle Cell Disease
843215|NCT02887092|health determinants
843216|NCT02887092|epidemiology
843217|NCT02887092|maintaining autonomy
843218|NCT02887092|psychology
843219|NCT02887092|osteoarthritis
843220|NCT02887092|perceived health
843221|NCT02887053|MRI
843222|NCT02887053|Healthy subjects
843223|NCT02887040|Diffuse, intrinsic brain stem glioma
843224|NCT02887040|Antineoplaston therapy
843225|NCT02887040|Radiation
843226|NCT02887014|bowel preparation
843227|NCT02887014|colonoscopy
843228|NCT02887014|inpatients
843229|NCT02887014|cathartics
843230|NCT02887001|cost study
843231|NCT02887001|clinical pharmacist
843232|NCT02886988|Botulinum toxin type A, scar
843233|NCT02886975|Renal Insufficiency, Chronic
843234|NCT02886975|Diet, Protein-Restricted
843235|NCT02886936|transtibial amputees
843236|NCT02885870|biomarker
843237|NCT02885870|spinal cord disease
843238|NCT02885870|resonance imaging
843239|NCT02885870|electrophysiology
843240|NCT02885831|Abduction splint
843241|NCT02885831|Pubo-femoral distance
843242|NCT02885792|Schizophrenia
843243|NCT02885792|Cardiovascular disease
843244|NCT02885792|Premature mortality
843245|NCT02885792|Arteriosclerosis
843246|NCT02885792|Risk factor
843247|NCT02885792|Intervention
843248|NCT02885792|Treatment
843249|NCT02885792|Somatic morbidity
843250|NCT02885766|CML
843251|NCT02885766|Myeloid leukaemia chronic
843252|NCT02885766|CML progression
843253|NCT02885766|Chronic phase chronic myeloid leukemia
843254|NCT02885766|PF-114
843255|NCT02885766|Cytogenetic response CCyR
843256|NCT02885766|Major molecular response MMR
843257|NCT02885766|Complete molecular response CMR
843258|NCT02885766|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
843259|NCT02885766|2-nd generation Bcr-Abl inhibitors resistant
843260|NCT02885753|colorectal
843261|NCT02885753|cancer
843262|NCT02885753|metastasis
843263|NCT02885753|hepatic
843264|NCT02885701|postoperative dressing
843265|NCT02885701|postoperative splint
843266|NCT02885701|mini-open carpal tunnel release
843267|NCT02885688|Septic Shock
843268|NCT02885688|Sepsis
843269|NCT02885688|Standard of care
843270|NCT02885688|Liquid nutrition
843271|NCT02885688|Metabolic support
843272|NCT02885688|Enteral nutrition
843273|NCT02885688|Insulin Drip
843274|NCT02885688|Glucose Drip
843275|NCT02885662|Primary aldosteronism
843276|NCT02885662|Hypertension
843277|NCT02885662|mineralocorticoid receptor antagonist
843278|NCT02885662|Developmental Phase III
843279|NCT02886910|Chorioamnionitis
843280|NCT02886910|Early onset neonatal sepsis
843281|NCT02886910|Antibiotics
843282|NCT02886910|Clinical observation
843283|NCT02886897|Refractory solid tumors
843284|NCT02886897|Dendritic and Cytokine-induced killer cell
843285|NCT02886897|Anti-PD-1 antibody
843286|NCT02886897|Combination immunotherapy
843287|NCT02886884|Diabetes
843288|NCT02886884|Endothelial dysfunction
843289|NCT02886884|Stem cells
843290|NCT02886858|Depression
843291|NCT02886858|Moods disorders
843292|NCT02886858|electroconvulsive therapy
843293|NCT02886845|SNP,Breast Neoplasms
843294|NCT02886832|Prostate Health
843295|NCT02886819|Whole body vibration
843296|NCT02886819|Tonic vibration reflex
843297|NCT02886819|Bone myoregulation reflex
843298|NCT02886806|closed loop
843299|NCT02886806|remifentanil
843300|NCT02886806|propofol
843301|NCT02886767|skin to skin contact
843308|NCT02886741|campaign
843309|NCT02886741|surgical site infection
843310|NCT02886741|orthopedic surgery
843311|NCT02886741|quality improvement
843312|NCT02886741|infection control
843313|NCT02886650|Paediatrics
843314|NCT02886650|epilepsy surgery
843315|NCT02886650|genetic mutation
843316|NCT02886650|focal seizures
843317|NCT02886637|A baumannii infection
843318|NCT02886637|Immunosuppression
843319|NCT02886637|prognosis
843320|NCT02886637|immune function
843321|NCT02886585|Brain Metastases
843322|NCT02886559|demethylating agent
843323|NCT02886559|chidamide
843324|NCT02886533|Major haemorrhage
843325|NCT02886533|Oral anticoagulation
843326|NCT02886533|Antiplatelet drugs
843327|NCT02886533|Gastrointestinal bleeding
843328|NCT02886533|Intracranial haemorrhage
843329|NCT02886520|Urinary incontinence
843330|NCT02886520|Materials
843331|NCT02886520|Surgery
843332|NCT02886520|Transobturator tape
843333|NCT02886520|Polyvinylidene fluoride
843334|NCT02886520|Polypropylene
843335|NCT02886481|thyroidectomy
843336|NCT02886481|Electrophysiologic
843337|NCT02886481|vocal cord movement
843338|NCT02886429|dexmedetomidine
843339|NCT02886429|bupivacaine
843340|NCT02886429|Ultrasound guided paravertebral block
843341|NCT02886429|pain
843342|NCT02886429|post-thoracotomy
843343|NCT02886416|HIV infection
843344|NCT02886390|remote ischemic conditioning
843345|NCT02886390|r-tPA thrombolytic therapy
843346|NCT02886351|Moderate Sedation
843347|NCT02886351|Pediatric Dentistry
843348|NCT02886351|Anxiety
843349|NCT02886325|Receipt of Preventive Cancer Screening
843350|NCT02886299|Fibrates
843351|NCT02886299|Statins
843352|NCT02886299|Hemodialysis
843353|NCT02886299|Dyslipidemia
843354|NCT02886299|Improved Oxidative Stress
843355|NCT02886299|Egypt
843356|NCT02886273|Sudden Cardiac Arrest
843357|NCT02886273|Out-of-hospital
843358|NCT02886273|Ventricular fibrillation
843359|NCT02886273|Classification
843360|NCT02886273|Mechanisms
843361|NCT02886273|Biomarkers
843362|NCT02886234|HIV
843363|NCT02886234|Mindfulness
843364|NCT02886234|Adherence behaviors
843365|NCT02886234|Stress
843366|NCT02886234|Depression
843367|NCT02886221|Hallux Valgus
843368|NCT02886221|Reverdin-Isham Osteotomy
843369|NCT02886221|Minimally Invasive Surgery
843370|NCT02886221|Percutaneous Distal Osteotomy
843371|NCT02886221|First Ray
843372|NCT02886221|Forefoot
843373|NCT02886182|chronic hepatitis B
843374|NCT02886182|pregnancy
843375|NCT02886182|Cellular immune response
843376|NCT02886182|Clinical implications
843377|NCT02886169|Sacha Inchi
843378|NCT02886169|High-fat meal
843379|NCT02886169|Postprandial inflammatory responses
843380|NCT02886156|OSA
843381|NCT02886156|CPAP
843382|NCT02886156|cognitive function
843383|NCT02886156|gut microbiota
843384|NCT02886156|metabolomics
843385|NCT02886130|Alpha-GPC
843386|NCT02886130|Volleyball
843387|NCT02886130|Athletes
843388|NCT02886130|Executive functions
843389|NCT02886130|Vertical jump
843390|NCT02886130|Peak power
843391|NCT02886104|synchronous
843392|NCT02886104|metachronous
843393|NCT02886104|colorectal liver metastasis
843394|NCT02886104|resection
843395|NCT02886104|ablation
843396|NCT02886091|Keloids
843397|NCT02886091|Shaving
843398|NCT02886091|Ears
843399|NCT02886091|Cryosurgery
843400|NCT02886091|Hypertrophic scars
843401|NCT02886065|Myeloma
843402|NCT02886052|Cognitive behavior therapy
843403|NCT02886052|Internet treatment
843404|NCT02886052|Self-help treatment
843405|NCT02886052|Insomnia
843406|NCT02886052|ICBT
843407|NCT02886052|CBT-i
843408|NCT02886052|Bereavement
843409|NCT02886039|Cardiorespiratory arrest
843410|NCT02886039|Neurologic outcome
843411|NCT02886039|Electroencephalogram
843412|NCT02886039|Somatosensory evoked potential
843413|NCT02886039|Synek classification
843414|NCT02886039|Cerebral performance category
843415|NCT02886039|Hypothermia
843416|NCT02886026|Laser
843417|NCT02886026|Bladder cancer
843418|NCT02886026|Treatment
843419|NCT02886026|Outpatient
843420|NCT02886026|TUR-BT
843421|NCT02886013|prevalence
843422|NCT02885974|Celecoxib
843423|NCT02885974|Bladder Cancer
843424|NCT02885909|type 2 diabetes
843425|NCT02885909|inpatient
843426|NCT02885909|glucose control
843427|NCT02885909|continue glucose monitor
843428|NCT02885896|Call center
843429|NCT02885896|nurses
843430|NCT02885896|pediatrics
843431|NCT02885896|standardized messages
843432|NCT02885896|family counseling
843433|NCT02885636|Heart Failure with Preserved Ejection Fraction
843434|NCT02885636|Pulmonary Hypertension
843435|NCT02885597|Juanbi Pill
843436|NCT02885597|Methotrexate
843437|NCT02885597|Active
843438|NCT02885597|Rheumatoid Arthritis
843439|NCT02885584|Mechanical ventilation
843440|NCT02885558|Receptors, Calcium Channel Blocker
843441|NCT02885532|alcohol
843442|NCT02885519|Vocational Rehabilitation
843443|NCT02885519|Common Mental Disorders
843444|NCT02885519|Return to Work
843445|NCT02885519|Mental Health Services
843446|NCT02885519|Psychological Stress
843447|NCT02885519|Adjustment Disorder
843448|NCT02885519|Burnout
843449|NCT02885519|Integration
843450|NCT02885519|Cognitive Behavior Therapy
843451|NCT02885493|Parkinson march
843452|NCT02885467|Total Knee Arthroplasty
843453|NCT02885441|Inflammation
843454|NCT02885389|Infantile spasms
843455|NCT02885389|West syndrome
843456|NCT02885389|variant
843457|NCT02885389|mutation
843458|NCT02885389|CNV
843459|NCT02885389|sequencing
843460|NCT02885376|Mucositis
843461|NCT02885337|Frail Elderly
843462|NCT02885337|Arthroplasty
843463|NCT02885337|Frailty
843464|NCT02885324|High Grade Glioma
843465|NCT02885324|Cabozantinib
843466|NCT02885324|GBM
843467|NCT02885324|Children
843468|NCT02885324|AA
843469|NCT02885311|Drinking
843470|NCT02885311|Excessive drinking
843471|NCT02885311|Alcohol use disorders
843472|NCT02885311|Primary Care
843473|NCT02885285|Parkinson's disease
843474|NCT02885285|fatigue
843475|NCT02885285|anxiety
843476|NCT02885285|depression
843477|NCT02885285|exercise
843483|NCT02885246|Panama
843484|NCT02885246|Influenza B
843485|NCT02885246|Influenza A
843486|NCT02885246|Strain circulation
843487|NCT02885246|Database
843488|NCT02885233|Fall Prevention
843489|NCT02885233|Multiple Sclerosis
843490|NCT02885233|Web-based education
843491|NCT02885233|Self-efficacy
843492|NCT02885207|Limbic encephalitis
843493|NCT02885207|anti-neuronal antibodies
843494|NCT02885194|Parkinson Disease
843495|NCT02885194|Pain
843496|NCT02885194|Deep Brain Stimulation
843497|NCT02885194|Laser-Evoked Potentials
843498|NCT02885168|vasoreactivity
843499|NCT02885168|recombinant activated protein C
843500|NCT02885116|NHF
843501|NCT02885116|pulmonary hypertension
843502|NCT02885103|NHF
843503|NCT02885103|nasal highflow
843504|NCT02885038|Platelet Transfusion
843505|NCT02885025|hypersensitivity
843506|NCT02885025|antioxidants
843507|NCT02884999|trauma
843508|NCT02884999|bleeding
843509|NCT02884999|coagulopathy
843510|NCT02884999|guidelines compliance
843511|NCT02884999|recommendation
843512|NCT02884999|transfusion
843513|NCT02884986|Etoricoxib
843514|NCT02884986|Spinal anaesthesia
843515|NCT02884986|Postoperative pain
843516|NCT02884973|congenital heart
843517|NCT02884973|NIRS
843518|NCT02884960|Uterine Fibroids
843519|NCT02884960|Embolization
843520|NCT02884947|Brain Neoplasms
843521|NCT02884947|Magnetic Resonance Imaging
843522|NCT02884947|Neurosurgery
843523|NCT02884934|venous thromboembolism
843524|NCT02884934|recurrent venous thromboembolism
843525|NCT02884934|anticoagulant-related bleeding
843526|NCT02884921|Postoperative pain
843527|NCT02884921|Dental treatment
843528|NCT02884921|Paracetamol
843529|NCT02884895|Intubating Laryngeal Tube Suction
843530|NCT02884895|Blind intubation
843531|NCT02884882|Stroke Basal Ganglia
843532|NCT02884882|Emotional change
843533|NCT02884869|Blind intubation,
843534|NCT02884869|Laryngeal Mask Airway
843535|NCT02884856|color
843536|NCT02884856|dentistry
843537|NCT02884856|gender
843538|NCT02884843|Laryngeal Tube
843539|NCT02884843|blind intubation
843540|NCT02884843|fiberoptic
843541|NCT02884804|Postpartum Hemorrhage
843542|NCT02884804|Immature platelet
843543|NCT02884791|FGF21
843544|NCT02884791|Fibroblast growth factor
843545|NCT02884791|fructose
843546|NCT02884778|pain
843547|NCT02884778|monitoring
843548|NCT02884778|anesthesia
843549|NCT02884765|mandibular condyle
843550|NCT02884765|subcondylar
843551|NCT02884765|mandible
843552|NCT02884765|fracture
843553|NCT02884700|Legionella
843554|NCT02884700|Legionnaires' disease
843555|NCT02884700|Diagnosis
843556|NCT02884700|Prognosis
843557|NCT02884674|Obsessive-Compulsive Disorder
843558|NCT02884674|Transcranial Magnetic Stimulation
843559|NCT02884648|Malignant neoplasms of female genital organs
843560|NCT02884648|Ovarian Cancer
843561|NCT02884648|Fallopian tube cancer
843562|NCT02884648|Primary peritoneal cancer
843563|NCT02884648|Bevacizumab
843564|NCT02884648|Avastin
843565|NCT02884648|Anti-VEGF monoclonal antibody
843566|NCT02884648|rhuMab-VEGF
843567|NCT02884635|Methotrexate
843568|NCT02884635|ASP1707
843569|NCT02884635|Rheumatoid arthritis
843570|NCT02884622|Lung disease
843571|NCT02884622|Epigenetics
843572|NCT02884622|DNA methylation
843573|NCT02884622|Modifier genes
843574|NCT02884596|Inferior alveolar nerve block
843575|NCT02884596|irreversible pulpitis
843576|NCT02884596|selective serotonin reuptake inhibitor antidepressants
843577|NCT02884583|Food allergy
843578|NCT02884583|asthma
843579|NCT02884583|Predictive factor
843580|NCT02884583|Exacerbation
843581|NCT02884583|Prevalence
843582|NCT02884570|Tracheotomy
843583|NCT02884570|Anxiety
843584|NCT02884570|Depression
843585|NCT02884570|Back Home
843586|NCT02884518|dopamine receptor occupancy
843587|NCT02884518|antipsychotics
843588|NCT02884518|positron emission tomography
843589|NCT02884492|inflammation
843590|NCT02884492|aging
843591|NCT02884492|mild cognitive impairment
843592|NCT02884453|gastrooesophageal carcinoma
843593|NCT02884427|Direct current
843594|NCT02884427|Dynamometry
843595|NCT02884427|Hand strength
843596|NCT02884427|Electrotherapy
843597|NCT02884427|Transcutaneous Electric Nerve Stimulation
843598|NCT02884414|Knee Pathology
843599|NCT02884375|Elderly
843600|NCT02884375|Cancer
843601|NCT02884375|Geriatric assessment
843602|NCT02884375|Treatment
843603|NCT02884375|Epidemiology
843604|NCT02884362|melanoma clinical biological database
843605|NCT02884349|Computer aided orthopaedic surgery
843606|NCT02884349|Implant orientation
843607|NCT02884349|Range of motion
843608|NCT02884310|Remifentanil
843609|NCT02884310|Heart Rate Variability
843610|NCT02884310|Pupil dilation
843611|NCT02884310|SPI
843612|NCT02884284|breast cancer
843613|NCT02884284|database
843614|NCT02884271|CPR
843615|NCT02884271|cardiac arrest
843616|NCT02884271|operating room
843617|NCT02884258|Assisted Reproductive Technology
843618|NCT02884258|Obesity
843619|NCT02884258|Bariatric Surgery
843620|NCT02884258|Infertility
843621|NCT02884258|Fertility Preservation
843622|NCT02884245|Fertility
843623|NCT02884245|Reproductive processes
843624|NCT02884245|In vitro fertilization
843625|NCT02884245|Intracytoplasmic sperm injection
843626|NCT02884245|Estrogens
843627|NCT02884245|Follicule Stimulating Hormon
843628|NCT02884219|Early treatment
843629|NCT02884219|Expectative treatment
843630|NCT02884219|Patent ductus arteriosus
843631|NCT02884219|Preterm
843632|NCT02884206|heart failure
843633|NCT02884206|cognition
843634|NCT02884206|positron emission tomography
843635|NCT02884206|magnetic resonance imaging
843636|NCT02884206|LCZ696
843637|NCT02884206|valsartan
843638|NCT02884193|Cooling
843639|NCT02884193|Cryotherapy
843640|NCT02884193|isometric Force
843641|NCT02884193|Palmar Grip
843642|NCT02884193|Dynamometry
843643|NCT02884180|Dexamethasone
843644|NCT02884180|Arthroplasty, Replacement, Knee
843645|NCT02884180|Revision
843646|NCT02884154|Endoscopic ultrasonography
843647|NCT02884154|Biopsy
843648|NCT02884154|Gastrointestinal tract
843649|NCT02884154|Subepithelial tumor
843650|NCT02884141|Renal Artery Obstruction
843651|NCT02884141|Carotid Artery Diseases
843652|NCT02884141|Genetic Association Studies
843653|NCT02884102|genetic sequencing
843654|NCT02884102|relapsed
843655|NCT02884076|Hemorrhoids
843656|NCT02884076|Sodergren score
843657|NCT02884076|Validation
843658|NCT02884063|PGS
843659|NCT02884063|PGD
843660|NCT02884063|free embryo DNA
843661|NCT02884063|NGS
843662|NCT02884037|NAFLD
843663|NCT02884037|Rifaximin
843664|NCT02884037|Endotoxin and Homeostatic Model Assessment
843665|NCT02884024|obesity
843666|NCT02884024|inflammation
843667|NCT02884024|cancer risk
843668|NCT02884011|Chronic antihypertensives
843669|NCT02884011|Septic shock
843670|NCT02884011|Vasopressor
843671|NCT02884011|Vasopressor dosing
843672|NCT02883998|home-based physical therapy
843673|NCT02883998|outpatient physical therapy
843674|NCT02883998|unicompartmental knee arthroplasty
843675|NCT02883998|PT (Physical Therapy)
843676|NCT02883998|osteoarthritis
843677|NCT02883972|Immunization
843678|NCT02883972|Behavioural insights
843679|NCT02883972|Children
843680|NCT02883959|critically ill
843681|NCT02883959|mechanical ventilation
843682|NCT02883959|pain
843683|NCT02883959|nursing
843684|NCT02883959|music
843685|NCT02883842|Coronary artery disease
843686|NCT02883842|Diabetes
843687|NCT02883842|Text messages
843688|NCT02883777|Kidney Transplantation
843689|NCT02883777|Low Glycemic Index
843690|NCT02883777|High Protein
843691|NCT02883764|eicosapentaenoic acid
843692|NCT02883764|EPA
843693|NCT02883764|docosahexaenoic acid
843694|NCT02883764|DHA
843695|NCT02883764|omega-3 index
843696|NCT02883751|diabetes mellitus
843697|NCT02883751|amputation stumps
843698|NCT02883751|diabetic foot
843699|NCT02883751|phototherapy
843700|NCT02883751|clinical trial
843701|NCT02883725|Esophageal atresia
843702|NCT02883712|epilepsy
843703|NCT02883712|pharmacoresistant
843704|NCT02883712|antiepileptic drug
843705|NCT02883712|pharmacokinetic
843706|NCT02883712|pharmacodynamic
843707|NCT02883712|pharmacogenetic
843708|NCT02883699|Breast cancer
843709|NCT02883699|Prostate cancer
843710|NCT02883699|Exercise prescription
843711|NCT02883699|High intensity interval training
843712|NCT02883699|Daily undulating periodization training
843713|NCT02883699|Aerobic training
843714|NCT02883699|Resistance training
843715|NCT02883699|Physical fitness
843716|NCT02883699|Exercise
843717|NCT02883686|depression
843718|NCT02883686|pregnancy
843719|NCT02883686|behavioral activation
843720|NCT02883686|peer delivery
843721|NCT02883686|effectiveness
843722|NCT02883673|Postpartum Hemorrhage
843723|NCT02883660|genetics
843724|NCT02883660|Antidepressants
843725|NCT02883647|chronic hepatitis b, nucleos(t)ide analog
843726|NCT02883634|Back pain
843727|NCT02883634|spinal manipulation
843728|NCT02883621|upper endoscopy
843729|NCT02883621|cap assisted endoscopy
843730|NCT02883621|esophagus
843731|NCT02883608|Papilla
843732|NCT02883608|major duodenal papilla
843733|NCT02883608|ampulla of vater
843734|NCT02883595|thymosin alpha 1; sepsis; monocyte; pharmacokinetics
843735|NCT02883582|asthma ,hydrogen
843736|NCT02883569|Low back pain
843737|NCT02883569|Intervertebral Disc Degeneration
843738|NCT02883569|Spinal stenosis
843739|NCT02883569|Comparative Effectiveness Research
843740|NCT02883569|Cost-Benefit Analysis
843741|NCT02883556|Carcinoma
843742|NCT02883556|Squamous Cell
843743|NCT02883556|Skin
843744|NCT02883556|pembrolizumab
843745|NCT02883556|Programmed Cell Death 1 Ligand 1
843746|NCT02883517|cell-free circulating DNA;
843747|NCT02883517|digital PCR
843748|NCT02883517|liquid biopsy
843749|NCT02883504|E/e' ratio
843750|NCT02883504|Doppler echocardiography, filling pressure
843751|NCT02883504|Left Ventricular end-Diastolic Pressure
843752|NCT02883465|diaphragmatic dysfunction
843753|NCT02883465|mechanical ventilation weaning
843754|NCT02883465|failure extubation rate
843755|NCT02883439|MP29-02
843756|NCT02883426|H3N2v Influenza Viruses
843757|NCT02883413|Adolescents
843758|NCT02883413|Cognitive Flexibility
843759|NCT02883413|Behavioral Flexibility
843760|NCT02883387|DIEP flap
843761|NCT02883387|Deep inferior epigastric artery perforator flap
843762|NCT02883374|cephalic and cervical adenocystic Carcinoma
843763|NCT02883374|Chidamide
843764|NCT02883309|Hemodialysis
843765|NCT02883309|Skeletal muscle
843766|NCT02883309|Exercise
843767|NCT02883309|Rehabilitation
843768|NCT02883309|Disability Evaluation
843769|NCT02883257|Major Depression
843770|NCT02883257|Major Depressive Disorder
843771|NCT02883257|Persistent Depressive Disorder
843772|NCT02883257|Cognitive Behavioral Therapy
843773|NCT02883257|Biomarkers
843774|NCT02883218|immunosuppression
843775|NCT02883218|community-acquired sepsis
843776|NCT02883218|mortality
843777|NCT02883192|Cesarean section
843778|NCT02883192|spinal anesthesia
843779|NCT02883192|hypotension
843780|NCT02883192|ondansetron
843781|NCT02883153|Zirconium-89
843782|NCT02883153|PET/CT
843783|NCT02883153|imaging
843784|NCT02883153|girentuximab
843785|NCT02883140|Sialography
843786|NCT02883140|Cone-beam CT
843787|NCT02883140|MRI sialography
843788|NCT02883140|non tumor salivary symptoms
843789|NCT02883127|Motivational Interviewing
843790|NCT02883127|Diet
843791|NCT02883127|Carbohydrates
843792|NCT02883127|Psychosocial factors
843793|NCT02883114|PF-06648671
843794|NCT02883114|GSM
843795|NCT02883114|CYP3A
843796|NCT02883114|drug interaction
843797|NCT02883088|Optical coherence tomograhpy
843798|NCT02883088|registry
843799|NCT02883088|Coronary artery disease
843800|NCT02883036|tigecycline
843801|NCT02883036|treatment
843802|NCT02883036|mitochondrial biogenesis
843803|NCT02883036|metabolic characteristics
843806|NCT02883010|Surgical incision
843807|NCT02883010|surgical complication
843808|NCT02883010|NPWT
843809|NCT02883010|negative pressure
843810|NCT02883010|colorectal surgery
843811|NCT02883010|dehisced
843812|NCT02882971|chronic pain
843813|NCT02882971|rating scale
843814|NCT02882958|Radiology
843815|NCT02882932|peritonitis
843816|NCT02882932|solutions
843817|NCT02882932|normal saline
843818|NCT02882932|infection
843819|NCT02882932|peritoneal lavage
843820|NCT02882906|Stroke
843821|NCT02882906|Pain
843822|NCT02882906|Shoulder
843823|NCT02882867|Prospective
843824|NCT02882867|Epidemiology
843825|NCT02882867|Track and Field
843826|NCT02882841|AIEC (Adherent and Invasive Escherichia Coli)
843827|NCT02882841|Mucosal Healing
843828|NCT02882841|Non-invasive biomarkers
843829|NCT02882815|IrisFIT PFO
843830|NCT02882802|anger
843831|NCT02882802|aggression
843832|NCT02882763|Early intervention
843833|NCT02882763|ECCE
843834|NCT02882763|Intervention study
843835|NCT02882763|Child development
843836|NCT02882763|At-risk families
843837|NCT02882763|Psychosocial stress
843838|NCT02882763|Prevention
843839|NCT02882763|Educational opportunities
843840|NCT02882763|Randomized controlled trial
843841|NCT02882763|Evaluation
843842|NCT02882763|Parenting
843843|NCT02882763|Parent-child interaction
843844|NCT02882750|Lung Cancer
843845|NCT02882750|Quality of Life
843846|NCT02882750|VATS
843847|NCT02882750|SABR
843848|NCT02882698|Down syndrome
843849|NCT02882698|motor skills
843850|NCT02882698|physiotherapy
843851|NCT02882698|mobile telephone
843852|NCT02882698|exposure to virtual reality therapy
843853|NCT02882685|Roux-en-Y gastric bypass
843854|NCT02882685|Mini-gastric bypass
843855|NCT02882685|Single anastomosis gastric bypass
843856|NCT02882659|Clinical Trial, Phase I
843857|NCT02882646|stroke
843858|NCT02882646|cerebral palsy
843859|NCT02882646|rehabilitation
843860|NCT02882646|robotics
843861|NCT02882646|therapy
843862|NCT02882646|bilateral
843863|NCT02882633|lumbar plexus block
843864|NCT02882633|fascia iliac block
843865|NCT02882633|quality of recovery score
843866|NCT02882633|pain score
843867|NCT02882620|Colorectal neoplasm
843868|NCT02882620|Screening
843869|NCT02882620|Patient navigation
843870|NCT02882620|Randomized controlled trial
843871|NCT02882620|Cost-benefit analysis
843872|NCT02882620|Health behavior
843873|NCT02882620|Health equity
843874|NCT02882620|American Indians
843875|NCT02882620|Community-based participatory research
843876|NCT02882620|Fecal occult blood test
843877|NCT02882607|HIV
843878|NCT02882607|Prevention
843879|NCT02882607|unintended pregnancy
843880|NCT02882607|Malawi
843881|NCT02882607|adolescent women
843882|NCT02882607|community
843883|NCT02882607|rural
843884|NCT02882581|Metformin
843885|NCT02882581|Pharmacokinetics
843886|NCT02882581|Organic cation transporter
843887|NCT02882581|Multidrug and toxin extrusion
843888|NCT02882581|Pharmacogenetics
843889|NCT02882581|positron emission tomography
843890|NCT02882542|cerebral oxygen metabolism
843891|NCT02882542|functional near-infrared spectroscopy
843892|NCT02882542|partial pressure of carbon dioxide
843893|NCT02882542|heart rate variability
843894|NCT02882542|blood pressure
843895|NCT02882542|affect
843896|NCT02882542|mood
843897|NCT02882542|respiration
843898|NCT02882542|systematic randomized cross-over study
843899|NCT02882542|systemic physiology
843900|NCT02882542|electro-dermal activity
843901|NCT02882542|pulse-respiratory quotient
843902|NCT02882529|cerebral oxygen metabolism
843903|NCT02882529|functional near-infrared spectroscopy
843904|NCT02882529|partial pressure of carbon dioxide
843905|NCT02882529|heart rate variability
843906|NCT02882529|blood pressure
843907|NCT02882529|affect
843908|NCT02882529|mood
843909|NCT02882529|respiration
843910|NCT02882529|systematic randomized cross-over study
843911|NCT02882529|systemic physiology
843912|NCT02882529|electro-dermal activity
843913|NCT02882529|pulse-respiratory quotient
843914|NCT02882516|cerebral oxygen metabolism
843915|NCT02882516|functional near-infrared spectroscopy
843916|NCT02882516|partial pressure of carbon dioxide
843917|NCT02882516|heart rate variability
843918|NCT02882516|blood pressure
843919|NCT02882516|affect
843920|NCT02882516|mood
843921|NCT02882516|respiration
843922|NCT02882516|systematic randomized cross-over study
843923|NCT02882516|systemic physiology
843924|NCT02882516|electro-dermal activity
843925|NCT02882516|pulse-respiratory quotient
843926|NCT02882503|Endoscopic ultrasound
843927|NCT02882503|Radiofrequency ablation
843928|NCT02882503|Pancreas
843929|NCT02882490|Tourette syndrome
843930|NCT02882464|gingival recession
843931|NCT02882464|mucogingival surgery
843932|NCT02882451|bile duct
843933|NCT02882451|endoscopic retrograde cholangiopancreatography
843934|NCT02882451|pinaverium bromide
843935|NCT02882425|selexipag
843936|NCT02882425|bioavailability
843937|NCT02882412|effectiveness
843938|NCT02882412|buprenorphine/naloxone
843939|NCT02882412|iatrogenic opioid dependence
843940|NCT02882399|athletes
843941|NCT02882373|Hypertensive diseases
843942|NCT02882373|Renal failure
843943|NCT02882373|High blood pressure
843944|NCT02882373|Proteinuria
843945|NCT02882373|L-Arginine
843946|NCT02882373|Placebo
843947|NCT02882373|Phone call
843948|NCT02882334|Focal Dystonia
843949|NCT02882334|Writer's cramp
843950|NCT02882321|Malignant Tumor of Lymphoid Hemopoietic and Related Tissue
843951|NCT02882321|Acute myeloid leukemia
843952|NCT02882321|AML
843953|NCT02882321|Relapsed/Refractory
843954|NCT02882321|IACS-010759
843955|NCT02882321|Phone Call follow up
843956|NCT02882282|Diseases of oral cavity salivary glands and jaws
843957|NCT02882282|High risk oral intra-epithelial neoplasias
843958|NCT02882282|IEN
843959|NCT02882282|Oral pre-malignant lesion(s)
843960|NCT02882282|History of invasive oral cancer
843961|NCT02882282|Pembrolizumab
843962|NCT02882282|Keytruda
843963|NCT02882282|MK-3475
843964|NCT02882282|SCH-900475
843965|NCT02882282|Observation only
843966|NCT02882269|locally advanced colon cancer
843967|NCT02882269|neoadjuvant chemotherapy
843968|NCT02882256|laceration
843969|NCT02882256|urinary tract infection
843970|NCT02882256|minor head injury
843971|NCT02882256|concussion
843972|NCT02882217|Double-blind
843973|NCT02882217|Randomized
843974|NCT02882217|Dose-escalating
843975|NCT02882217|Placebo-controlled
843976|NCT02882217|Phase I
843977|NCT02882217|Healthy volunteers
843978|NCT02882217|Bronchial asthma
843979|NCT02882217|Histamine glutarimide
843980|NCT02882217|EURRUS
843981|NCT02882191|contraception
843982|NCT02882178|Prostate cancer
843983|NCT02882178|cabazitaxel
843984|NCT02882178|consensus
843985|NCT02882178|conformity
843986|NCT02882178|prescription
843987|NCT02882178|conditions of use
843988|NCT02882165|COPD
843989|NCT02882165|Early Intervention
843990|NCT02882165|Risk
843991|NCT02882165|Stratification
843992|NCT02882152|Analgesia
843993|NCT02882152|Nerve Block
843994|NCT02882152|Pain, Postoperative
843995|NCT02882139|Electrical storm
843996|NCT02882126|PAH
843997|NCT02882126|Subcutaneous Treprostinil
843998|NCT02882126|Remodulin
843999|NCT02882126|6 Minute Walk Test
844000|NCT02882100|influenza
844001|NCT02882100|vaccine
844002|NCT02882100|vaccination
844003|NCT02882100|nursing home
844004|NCT02882100|cluster randomized trial
844005|NCT02882100|respiratory-related hospitalization
844006|NCT02882061|neck pain
844007|NCT02882061|physical examination
844008|NCT02882061|thoracic manipulation
844009|NCT02882048|Opioid addiction
844010|NCT02882048|Opioid weaning
844011|NCT02882035|pain
844012|NCT02882035|patient comfort
844013|NCT02882022|Eustachian tube dysfunction
844014|NCT02882022|Audiometry
844015|NCT02881996|appendicitis
844016|NCT02881996|pain
844017|NCT02881996|perforation
844018|NCT02881983|alcohol use disorder
844019|NCT02881983|emotion processing
844020|NCT02881983|abstinence
844021|NCT02881983|sympathetic system
844022|NCT02881983|parasympathetic system
844023|NCT02881957|critical illness
844024|NCT02881957|craniocerebral trauma
844025|NCT02881957|intracranial aneurysm
844026|NCT02881957|spinal cord injuries
844027|NCT02881957|seizures
844028|NCT02881957|meningitis
844029|NCT02881957|stroke
844030|NCT02881957|vitamin d deficiency
844031|NCT02881957|cholecalciferol
844032|NCT02881957|intracranial hemorrhages
844033|NCT02881944|Gulf War Illness
844034|NCT02881944|Diet
844035|NCT02881944|IBS
844036|NCT02881944|FODMAP
844037|NCT02881931|Huntington's disease
844038|NCT02881931|functional rating scale
844039|NCT02881931|cognitive pre-testing
844040|NCT02881931|patient reported outcome (PRO)
844041|NCT02881931|HDGEC participant at Pre-Manifest stage
844042|NCT02881931|HDGEC participant at Early-Manifest stage
844043|NCT02881931|Corresponding HDGEC participant companion
844044|NCT02881892|CAPD
844045|NCT02881892|Peritoneal solute transport rate
844046|NCT02881892|Dialysis adequacy
844047|NCT02881866|Air hunger
844048|NCT02881866|Work/effort
844049|NCT02881866|Aerosolized
844050|NCT02881866|Hypercapnia
844051|NCT02881866|Resistive load
844052|NCT02881866|Nebulised
844053|NCT02881853|healthy
844054|NCT02881853|atopic
844055|NCT02881827|Saliva
844056|NCT02881827|Low-level laser therapy
844057|NCT02881827|Masseter muscle
844058|NCT02881827|Salivary glands
844059|NCT02881814|Lung ultrasound
844060|NCT02881814|Chest physiotherapy
844061|NCT02881814|Decision-making process
844062|NCT02881814|Diagnostic
844063|NCT02881801|accelerometry
844064|NCT02881775|TMS
844065|NCT02881775|rTMS
844066|NCT02881775|corticospinal
844067|NCT02881775|quadriceps
844071|NCT02881671|genetic
844072|NCT02881671|congenital atrioventricular block
844073|NCT02881671|progressive Cardiac Conduction Disease
844074|NCT02881658|Plant sterols
844075|NCT02881658|Low-Density Lipoprotein Cholesterol
844076|NCT02881658|Phytosterols
844077|NCT02881658|Soya Beverage
844078|NCT02881645|Intensive care units
844079|NCT02881645|Nursing Care
844080|NCT02881645|Critical incidents
844081|NCT02881645|Best practices
844082|NCT02881619|Tooth bleaching
844083|NCT02881593|Operating in Minimally Invasive
844084|NCT02881567|Multiple Sclerosis
844085|NCT02881567|Daclizumab
844086|NCT02881567|Tysabri-Switch
844087|NCT02881528|Type 1 Diabetes
844088|NCT02881528|Juvenile Diabetes
844089|NCT02881502|granulocyte activation
844090|NCT02881502|HDAC2
844091|NCT02881502|severe asthma
844092|NCT02881437|Primary Immunodeficiency
844093|NCT02881437|SubCutaneous Immunoglobulins
844094|NCT02881424|Familiarity
844095|NCT02881424|Recollection
844096|NCT02881424|Face Recognition
844097|NCT02881424|Alcohol dependence
844098|NCT02881424|Social cognition
844099|NCT02881411|self-soft tissue therapy
844100|NCT02881411|trigger points
844101|NCT02881411|feasibility study
844102|NCT02881398|Mobile Health
844103|NCT02881398|Telemedicine
844104|NCT02881398|Pocket-Echocardiography
844105|NCT02881385|Synchrony
844106|NCT02881385|Pressure Support Ventilation
844107|NCT02881372|oral food desensitization
844108|NCT02881372|food elimination
844109|NCT02881372|food reintroduction
844110|NCT02881346|Psoriasis vulgaris
844111|NCT02881346|Plaque
844112|NCT02881346|Topical
844113|NCT02881346|Calcipotriol
844114|NCT02881346|Foam
844115|NCT02881346|Spray
844116|NCT02881307|Rheumatoid Arthritis (RA)
844117|NCT02881307|Musculoskeletal Ultrasound (MSUS)
844118|NCT02881255|implantable cardioverter defibrillator
844119|NCT02881255|subcutaneous ICD
844120|NCT02881255|transvenous ICD
844121|NCT02881255|inherited arrhythmia syndrome
844122|NCT02881203|breast cancer
844123|NCT02881203|radiation
844124|NCT02881203|DIBH
844125|NCT02881203|cardiac toxicity
844131|NCT02881164|Glycemia
844132|NCT02881164|Satiety
844133|NCT02881164|Insulin
844134|NCT02881164|Breakfast
844135|NCT02881164|Low glycemic index
844136|NCT02881164|High glycemic index
844137|NCT02881151|Deep brain stimulation
844138|NCT02881151|DBS
844139|NCT02881151|Central thalamus
844140|NCT02881151|TBI
844141|NCT02881151|Traumatic brain injury
844142|NCT02881086|Acute lymphoblastic leukemia
844143|NCT02881086|Lymphoblastic lymphoma
844144|NCT02881086|Nelarabine
844145|NCT02881086|BCR-ABL
844146|NCT02881086|MRD
844147|NCT02881086|PEG-Asparaginase
844148|NCT02881086|Rituximab
844149|NCT02881073|Placental Growth Factor
844150|NCT02881073|Maternal Morbidity
844151|NCT02881073|Neonatal Morbidity
844152|NCT02881073|Pre-eclampsia
844153|NCT02881073|Heath Economics
844154|NCT02881060|Glucagon
844155|NCT02881060|Ethanol
844156|NCT02881034|Anemia
844157|NCT02881034|Antiviral Agents
844158|NCT02881034|Glomerular Filtration Rate
844159|NCT02881034|Hepatitis C
844160|NCT02881034|Ribavirin
844161|NCT02881034|Telaprevir
844162|NCT02881021|elastic tape
844163|NCT02881021|kinesiology taping
844164|NCT02881021|physiotherapy
844165|NCT02881021|rotator cuff
844166|NCT02881021|shoulder pain
844167|NCT02881021|tendon injuries
844168|NCT02880995|dopamine receptor occupancy
844169|NCT02880995|antipsychotics
844170|NCT02880995|positron emission tomography
844171|NCT02880956|Tau
844172|NCT02880956|Nervous system diseases
844173|NCT02880956|Memory loss
844174|NCT02880956|Mild Alzheimer's Disease (AD)
844175|NCT02880956|Early Alzheimer's Disease
844176|NCT02880956|Early dementia
844177|NCT02880956|Mild Cognitive Impairment (MCI)
844178|NCT02880956|AD
844179|NCT02880956|Tauopathies
844180|NCT02880956|Neurodegenerative diseases
844181|NCT02880930|vitamin D
844182|NCT02880917|Attention
844183|NCT02880917|Memory (short and long-term)
844184|NCT02880917|Conflict monitoring tasks
844185|NCT02880917|Verbal fluency
844186|NCT02880878|Subcortical Intracerebral Hemorrhage
844187|NCT02880878|Intracerebral Hemorrhage
844188|NCT02880878|Intracranial Hemorrhages
844189|NCT02880878|ICH
844190|NCT02880878|Hemorrhage
844191|NCT02880878|Cerebrovascular Disorders
844192|NCT02880878|Brain Diseases
844193|NCT02880878|Central Nervous System Diseases
844194|NCT02880878|Nervous System Diseases
844195|NCT02880878|Vascular Diseases
844196|NCT02880878|Cardiovascular Diseases
844197|NCT02880878|Pathologic Processes
844198|NCT02880878|MIPS
844199|NCT02880878|Minimally Invasive Parafascicular Surgery
844200|NCT02880878|Neurosurgery
844201|NCT02880878|Medical Economic
844202|NCT02880878|Hospital Economics
844203|NCT02880865|vaccine
844204|NCT02880852|Systemic Lupus Erythematosus
844205|NCT02880852|Belimumab
844206|NCT02880852|Pharmacodynamics
844207|NCT02880852|safety tolerability
844208|NCT02880852|Pharmacokinetics
844209|NCT02880852|Chinese subjects
844210|NCT02880800|Analgesia, Patient-Controlled
844211|NCT02880800|Analgesics, Opioid
844212|NCT02880800|Drug-Related Side Effects and Adverse Reactions
844213|NCT02880774|Temporomandibular Joint Disorders
844214|NCT02880774|Mandibular Movement
844215|NCT02880774|Músculoesqueléticas Manipulations
844216|NCT02880774|Modalities of Physiotherapy.
844217|NCT02880761|hemodialysis
844218|NCT02880761|chronic renal failure
844219|NCT02880761|arteriovenous fistulae
844220|NCT02880748|Water exchange colonoscopy
844221|NCT02880748|Adenoma miss rate
844222|NCT02880748|Polyps
844223|NCT02880735|Myotonic Dystrophy
844224|NCT02880735|Noninvasive Ventilation
844225|NCT02880735|Respiratory Failure
844226|NCT02880722|Irritable Bowel Syndrome (IBS)
844227|NCT02880722|Experience Sampling Method (ESM)
844228|NCT02880722|Ecological Momentary Assessment (EMA)
844229|NCT02880722|Abdominal pain
844230|NCT02880696|Time Perception
844231|NCT02880696|Tactile Perception
844232|NCT02880696|Spectroscopy, Near-Infrared
844233|NCT02880683|Electrical Stimulation Therapy
844234|NCT02880683|Parasympathetic Nervous System
844235|NCT02880683|Sympathetic Fibers
844236|NCT02880683|Post Ganglionic
844237|NCT02880683|Congestive Heart Failure
844238|NCT02880683|Heart Failure
844239|NCT02880670|Rheumatoid
844240|NCT02880657|superoxide dismutase
844241|NCT02880657|melon concentrate
844242|NCT02880657|oxidative stress
844243|NCT02880657|physical training
844244|NCT02880644|Central retinal vein occlusion
844245|NCT02880644|OCT-A
844246|NCT02880644|CRVO
844247|NCT02880618|Heart Failure
844248|NCT02880618|Reduced ejection fraction
844249|NCT02880540|Adolescent
844250|NCT02880540|Bariatric
844251|NCT02880540|Obesity
844252|NCT02880540|Pain
844253|NCT02880540|Opiate-sparing
844254|NCT02880475|Moderate to severe chronic non-malignant pain
844255|NCT02880462|schizophrenia
844256|NCT02880462|sulforaphane
844257|NCT02880423|salpingectomy
844258|NCT02880423|cesarean section
844259|NCT02880423|tubal ligation
844260|NCT02880423|morbidity
844261|NCT02880410|Glioblastoma
844262|NCT02880410|NeuroBlate
844263|NCT02880410|LITT
844264|NCT02880410|Quality of Life
844265|NCT02880397|Anti-inflammatory agents, antimicrobials, Periodontitis
844269|NCT02880332|Chronic pain
844270|NCT02880332|Endogenous Pain Processing
844271|NCT02880332|Central sensitization
844272|NCT02880332|Pain neuroscience education
844273|NCT02880319|Bone Cancer
844277|NCT02880254|body mass index change
844278|NCT02880254|weight loss
844279|NCT02880254|patient compliance
844280|NCT02880202|Massage Therapy
844281|NCT02880202|Hospice
844282|NCT02880202|Integrative Medicine
844283|NCT02880202|Palliative Care
844284|NCT02880202|Caregivers
844285|NCT02880189|Obesity NOS
844286|NCT02880189|NASH
844287|NCT02880189|NASH with Fibrosis
844288|NCT02880189|Intragastric Balloon
844289|NCT02880189|ORBERA
844290|NCT02880189|ORBERA Intragastric Balloon
844291|NCT02880176|Behavioral Economics
844292|NCT02880176|Financial Incentives
844293|NCT02880176|Bladder Cancer
844294|NCT02880176|Ambulation
844295|NCT02880176|Surgical Co-Morbidity
844296|NCT02880176|Fitbit
844297|NCT02880176|Mobile Health
844298|NCT02880176|Radical Cystectomy
844299|NCT02880150|elite climbers
844300|NCT02880150|near infrared spectroscopy
844301|NCT02880124|Isotope Labeling, Stable
844302|NCT02880124|Exercise, Physical
844303|NCT02880124|Calorimetry, Indirect
844304|NCT02880124|Athletic Performance
844305|NCT02880124|Sugar Maple
844306|NCT02880111|Malignant Brain Tumor
844307|NCT02880111|patient sputum
844308|NCT02880098|Neonatology
844309|NCT02880098|Troponin T
844310|NCT02880098|Standards
844311|NCT02880059|Sleep Apnea, Aneurysm, Subarachnoid Hemorrhage, Blood Pressure.
844312|NCT02880046|immune response
844313|NCT02880046|T lymphocyte
844314|NCT02880046|PD-1/PDL-1 pathway
844315|NCT02880033|Parkinson's disease
844316|NCT02880033|Amyotrophic lateral sclerosis
844317|NCT02880033|Peripheral blood mononuclear cells
844318|NCT02880033|ex vivo model for oxidative stress
844319|NCT02880033|iron metabolism and chelation
844320|NCT02880007|Pulsed dose-rate brachytherapy
844321|NCT02880007|3D dosimetry
844322|NCT02880007|Prospective Studies
844323|NCT02880007|Radiotherapy Dosage
844324|NCT02880007|Uterine Cervical Neoplasms/radiotherapy
844325|NCT02880007|Brachytherapy/methods
844326|NCT02879968|serum squamous cell carcinoma antigen
844327|NCT02879968|tumor volume
844328|NCT02879968|Head and Neck Cancer
844329|NCT02879955|Glucagon-Like Peptide 1
844330|NCT02879955|Carbohydrates
844331|NCT02879955|Gastric bypass
844332|NCT02879955|Bariatric Surgery
844333|NCT02879955|Overweight
844334|NCT02879942|Placental volume
844335|NCT02879942|First-trimester screening
844336|NCT02879942|Ultrasound
844337|NCT02879942|Preeclampsia
844338|NCT02879942|Intrauterine growth restriction
844339|NCT02879942|Biochemical markers
844340|NCT02879942|Uterine artery doppler
844341|NCT02879929|chronic nasal dysfunction
844342|NCT02879929|Quality of life
844343|NCT02879929|measurement
844344|NCT02879929|self-reporting questionnaire
844345|NCT02879929|development
844346|NCT02879929|validation
844347|NCT02879903|Porphyromonas gingivalis
844348|NCT02879903|Periodontal treatment
844349|NCT02879903|Smokers
844350|NCT02879877|First in human
844351|NCT02879877|subjects
844352|NCT02879864|fatigue
844353|NCT02879864|tiredness
844354|NCT02879864|luxo therapy
844355|NCT02879864|therapy by light
844356|NCT02879851|ultrasound
844357|NCT02879851|Koelis system
844358|NCT02879851|MRI
844359|NCT02879851|gold grain
844360|NCT02879825|Ventricular Premature Complexes
844361|NCT02879812|Transplantation Surgery
844362|NCT02879812|Nephrology
844363|NCT02879812|Organ and Tissue Transplantation
844364|NCT02879799|Family-centered care
844365|NCT02879799|Family-integrated care
844366|NCT02879799|Neonatal intensive care unit
844367|NCT02879799|Premature
844368|NCT02879799|Infant
844369|NCT02879773|Respiratory Function Tests
844370|NCT02879773|Computed tomography
844371|NCT02879773|Thoracic surgical procedures
844372|NCT02879773|Diagnosis
844373|NCT02879760|Lung
844374|NCT02879760|Cancer
844375|NCT02879760|Chemotherapy
844376|NCT02879760|Oncolytic virus
844377|NCT02879760|Immunotherapy
844378|NCT02879760|Pembrolizumab
844379|NCT02879760|Keytruda
844380|NCT02879747|treatment
844381|NCT02879747|growth hormone
844382|NCT02879747|childhood
844383|NCT02879747|short stature
844384|NCT02879734|peritoneal dialysis
844385|NCT02879734|laparoscopy
844386|NCT02879734|omentum
844387|NCT02879721|Gastrointestinal
844388|NCT02879708|Social Accountability
844389|NCT02879708|Healthcare Quality
844390|NCT02879708|Health System Strengthening
844391|NCT02879708|Child Health
844392|NCT02879708|Childhood pneumonia
844393|NCT02879708|Childhood diarrhea
844394|NCT02879682|glioma
844395|NCT02879682|brain metastases
844396|NCT02879682|nTMS
844397|NCT02879630|pharmacokinetics
844398|NCT02879630|acyclovir
844399|NCT02879552|Upper blepharoplasty
844400|NCT02879552|brassiere sutures
844401|NCT02879552|tarsal platform show
844402|NCT02879552|eyeshadow space
844403|NCT02879552|brow fat span
844404|NCT02879539|cochlear implants, power consumption,
844405|NCT02879526|Relapse/Refratory Peripheral T Cell Lymphoma
844406|NCT02879526|Chidamide
844407|NCT02879526|Cyclophosphamide、Prednisone、Thalidomide(CPT)
844408|NCT02879500|Systematic review and meta-analysis
844409|NCT02879500|Evidence-based medicine (EBM)
844410|NCT02879500|Evidence-based nutrition (EBN)
844411|NCT02879500|Clinical practice guidelines
844412|NCT02879500|Randomized controlled trials
844413|NCT02879500|Prospective cohort studies
844414|NCT02879500|Body weight
844415|NCT02879500|Body mass index
844416|NCT02879500|Adiposity
844417|NCT02879500|Overweight
844418|NCT02879500|Obesity
844419|NCT02879461|SURGERY
844420|NCT02879461|REHABILITATION
844421|NCT02879448|Non-valvular atrial fibrillation
844422|NCT02879448|Left Atrial Appendage
844423|NCT02879409|HbA1c variability
844424|NCT02879409|Diabetes Mellitus Type 2
844425|NCT02879409|Diabetes microvascular complications
844426|NCT02879409|Diabetes macrovascular complications
844427|NCT02879396|Older adults
844428|NCT02879396|Avoidable admissions
844429|NCT02879396|Assisted living home
844430|NCT02879396|Emergency service calls
844560|NCT02878382|calcipotriol
844431|NCT02879396|Heading Assisted Living Facilities
844432|NCT02879383|Type 2 Diabetes
844433|NCT02879370|Anastomotic Leak
844434|NCT02879370|Rectal cancer
844435|NCT02879370|Double stapling technique
844436|NCT02879357|Care management
844437|NCT02879357|end of life
844438|NCT02879357|advanced care planning
844439|NCT02879357|palliative care
844440|NCT02879331|pulmonary emphysema
844441|NCT02879331|coils
844442|NCT02879331|cycloergometry
844443|NCT02879331|lung volume reduction
844451|NCT02879292|Pyloric stenosis spinal anesthesia postoperative pain
844452|NCT02879279|Stroke
844453|NCT02879279|Upper limb
844454|NCT02879279|Robotic rehabilitation
844455|NCT02879266|Dengue Vaccine
844456|NCT02879188|degenerative joint disease
844457|NCT02879188|total knee arthroplasty
844458|NCT02879188|physical therapy
844459|NCT02879188|arthroplasty, replacement, knee
844460|NCT02879149|Ankle Fusions
844461|NCT02879149|AUGMENT® Bone Graft
844462|NCT02879149|Autologous Bone Graft
844463|NCT02879149|arthritis
844464|NCT02879149|ankle pain
844465|NCT02879149|foot pain
844466|NCT02879149|hindfoot fracture
844467|NCT02879149|ankle fracture
844468|NCT02879136|Gait
844469|NCT02879136|Balance
844470|NCT02879136|PD
844471|NCT02879110|Sulforaphane
844472|NCT02879110|clinic trial
844473|NCT02879110|Autism Spectrum Disorder
844474|NCT02879110|Efficacy
844475|NCT02879110|Safety
844476|NCT02879110|Mechanism
844477|NCT02879032|Treadmill Scores
844478|NCT02879032|Coronary Angiogram
844479|NCT02879032|Coronary Artery Disease
844480|NCT02879006|Chinese herbal therapy
844481|NCT02879006|Oral immunotherapy
844482|NCT02879006|Food allergy
844483|NCT02879006|Omalizumab
844484|NCT02878928|Pharmacogenetic testing
844485|NCT02878928|PGx
844486|NCT02878928|Depression
844487|NCT02878928|Neuropsychiatric diseases
844488|NCT02878928|IDgenetix
844489|NCT02878928|AltheaDx
844490|NCT02878902|emergency
844491|NCT02878902|coordination
844492|NCT02878902|dialysis
844493|NCT02878824|Neurophysiology
844494|NCT02878824|Autonomic
844495|NCT02878824|Sensory
844496|NCT02878824|Child
844497|NCT02878824|Ethnicity
844498|NCT02878824|Environment
844499|NCT02878811|heart failure
844500|NCT02878811|prospective
844501|NCT02878811|cohort
844502|NCT02878785|AML
844503|NCT02878746|Mirror therapy
844504|NCT02878746|Proprioception
844505|NCT02878746|Rehabilitation
844506|NCT02878746|Stroke
844507|NCT02878746|Hemiplegia
844508|NCT02878720|ischemic stroke
844509|NCT02878720|hemorrhagic chronic
844510|NCT02878720|non-invasive vagus nerve stimulation
844511|NCT02878720|robot-assisted rehabilitation
844512|NCT02878681|Diabetic Macular Edema.
844513|NCT02878668|procalcitonin
844514|NCT02878668|post-operative
844515|NCT02878668|complication
844516|NCT02878668|CRP
844517|NCT02878655|N0 clinical and radiological
844518|NCT02878655|dissection IIb sector
844519|NCT02878564|Schistosomiasis mansoni
844520|NCT02878564|HIV susceptibility
844521|NCT02878564|Genital immunology
844522|NCT02878564|Mucosal immunology
844523|NCT02878564|HIV entry assay
844524|NCT02878564|Adult women
844525|NCT02878512|Segmental Epidural
844526|NCT02878512|Regional Anesthesia for PCNL
844527|NCT02878499|autism
844528|NCT02878499|autism spectrum disorder
844529|NCT02878499|ASD
844530|NCT02878499|sleep
844531|NCT02878499|Circadian
844532|NCT02878499|Biological rhythms
844533|NCT02878499|melatonin
844534|NCT02878499|Cognition
844535|NCT02878499|Behavior
844536|NCT02878499|Longitudinal
844537|NCT02878499|Longitudinal accelerated design
844538|NCT02878486|Physical activity
844539|NCT02878486|Alzheimer's disease
844540|NCT02878486|cognitive impairment
844541|NCT02878486|sedentary behavior
844542|NCT02878486|insulin sensitivity
844543|NCT02878447|Haemoptysis
844544|NCT02878447|Radiotherapy
844545|NCT02878447|Tuberculosis
844546|NCT02878447|Aspergilloma
844547|NCT02878447|Bronchiectasis
844548|NCT02878434|Cancer
844549|NCT02878434|Fertility
844550|NCT02878434|Pregnancy
844551|NCT02878434|Chemotherapy
844552|NCT02878434|Radiotherapy
844553|NCT02878434|Long term
844554|NCT02878434|Follow up
844555|NCT02878395|genomics
844556|NCT02878395|epigenomics
844557|NCT02878395|recurrence
844558|NCT02878382|PDT
844559|NCT02878382|skin cancer
844561|NCT02878369|fluid replacement
844562|NCT02878356|Motivational Interviewing, Clinical supervision, Education
844563|NCT02878330|Respiratory Syncytial Virus, RSV
844564|NCT02878330|Preterm Infants
844565|NCT02878330|Lower Respiratory Tract Infection
844566|NCT02878317|Glycosylation End Products, Advanced
844567|NCT02878317|Skin autofluorescence
844568|NCT02878317|Renal Dialysis
844569|NCT02878304|Prognosis
844570|NCT02878304|Hand function
844571|NCT02878304|Rehabilitation
844572|NCT02878304|Spasticity
844573|NCT02878304|MRI
844574|NCT02878278|Chidamide
844575|NCT02878278|Administration method
844576|NCT02878265|malaria
844577|NCT02878265|vitamin A
844578|NCT02878265|Zinc
844579|NCT02878265|Multivitamin
844580|NCT02878252|COPD, Asthma, ACOS
844581|NCT02878239|knee osteoarthritis
844582|NCT02878239|gait
844583|NCT02878239|Kellgren-Lawrence Scores
844584|NCT02878161|rheumatoid arthritis
844585|NCT02878161|tumor necrosis factor α inhibitor
844586|NCT02878161|predictive
844587|NCT02878161|iTRAQ
844588|NCT02878161|signal pathway
844589|NCT02878148|Nephrolithiasis
844590|NCT02878148|Ureteral stone
844591|NCT02878148|Acute renal colic
844592|NCT02878148|Ultrasonography
844593|NCT02878148|Computed tomography
844594|NCT02878148|Diagnosis
844595|NCT02878122|ovarian cancer
844596|NCT02878122|chemo resistance
844597|NCT02878122|predictive factors
844598|NCT02878122|cohort study
844599|NCT02878122|bio bank
844600|NCT02878109|Magnetic resonance imaging (MRI)
844601|NCT02878109|Transarterial chemoembolization (TACE)
844602|NCT02878096|nocturnal polyuria
844603|NCT02878083|vedolizumab,
844604|NCT02878083|confocal endomicroscopy
844605|NCT02878083|biomarker
844606|NCT02878083|ULCERATIVE COLITIS
844607|NCT02878070|Spinal Cord Injuries
844608|NCT02878070|Telemedicine
844609|NCT02878070|Health Behaviors
844610|NCT02878057|Apatinib
844611|NCT02878057|HER-2 Negative
844612|NCT02878057|Chest wall Metastasis
844613|NCT02878057|Multicenter Phase II Study
844614|NCT02878057|Breast cancer
844615|NCT02878044|Shared Decision Making, Decision Aid
844616|NCT02878031|Integrated Community Case Management
844617|NCT02878031|Community Health Worker
844618|NCT02878031|Nigeria
844619|NCT02878018|Cohort Study
844620|NCT02878018|Children
844621|NCT02878018|Henoch-Schonlein Purpura Nephritis
844622|NCT02878018|Diagnosis and Treatment of Traditional Chinese Medicine
844623|NCT02878005|Intubating Laryngeal Tube
844624|NCT02878005|blind intubation
844625|NCT02878005|fiberoptic
844626|NCT02877992|Infertility
844627|NCT02877992|Tachykinin
844628|NCT02877992|Kisspeptin
844629|NCT02877940|ProSeal LMA
844630|NCT02877940|LTS-D
844631|NCT02877940|i-gel
844632|NCT02877914|heart failure, retrospective
844633|NCT02877888|cost effectiveness
844634|NCT02877888|fluoride varnish
844635|NCT02877888|dental caries
844636|NCT02877875|anxiety
844637|NCT02877875|depression
844638|NCT02877875|trauma
844639|NCT02877875|behavior problems
844640|NCT02877875|evidence-based treatments
844641|NCT02877875|manualized treatments
844642|NCT02877875|cognitive-behavioral therapy
844643|NCT02877875|youth
844644|NCT02877875|mental health
844645|NCT02877849|fMRI
844646|NCT02877849|brain networks
844647|NCT02877849|biomarker
844648|NCT02877849|relapse
844649|NCT02877849|alcohol
844650|NCT02877836|Dystonia
844651|NCT02877836|fMRI
844652|NCT02877836|DTI
844653|NCT02877836|DBS
844654|NCT02877823|Pediatric Antipsychotic Treatment
844655|NCT02877823|Pediatric healthy lifestyle intervention
844656|NCT02877823|Parent peer support
844657|NCT02877784|screening
844658|NCT02877784|OPMD
844659|NCT02877784|dysphagia
844660|NCT02877784|dysarthria
844661|NCT02877758|cutaneous aging
844662|NCT02877758|skin rejuvenation
844663|NCT02877758|wrinkles
844664|NCT02877732|Concussion
844665|NCT02877732|Athletes
844666|NCT02877732|Eye-tracking
844667|NCT02877732|Vision
844668|NCT02877706|Register
844669|NCT02877693|ICD
844670|NCT02877693|Thoracic MRI Scan
844671|NCT02877693|tachycardia
844672|NCT02877680|Strengths-based
844673|NCT02877680|Mobile Health (mHealth)
844674|NCT02877680|Adolescence
844675|NCT02877680|Resilience
844676|NCT02877680|Family
844677|NCT02877667|tattoo
844678|NCT02877667|laser
844679|NCT02877654|Plasmatic zonulin
844680|NCT02877654|Irritable Bowel Syndrome
844681|NCT02877654|Intestinal permeability
844682|NCT02877641|Current Smoker
844683|NCT02877641|Former Smoker
844684|NCT02877628|pharmacokinetic
844685|NCT02877628|pharmacodynamic
844686|NCT02877628|tacrolimus
844687|NCT02877628|CYP3A5
844688|NCT02877628|liver transplantation
844689|NCT02877563|peripheral artery disease
844690|NCT02877563|contrast enhanced ultrasound
844691|NCT02877550|untreated Follicular lymphoma
844692|NCT02877550|non-Hodgkin lymphoma
844693|NCT02877550|Obinutuzumab
844694|NCT02877550|Gazyva
844695|NCT02877550|Gazyvaro
844696|NCT02877550|Venetoclax
844697|NCT02877550|Venclexta
844698|NCT02877446|Left ventricular assist device (LVAD)
844699|NCT02877446|Terminal heart failure
844700|NCT02877446|Ventricular assist device (VAD)
844701|NCT02877433|Small diameter implant
844702|NCT02877433|Cross-arch prostheses
844703|NCT02877420|Endoscopy
844704|NCT02877420|Simulation Training
844705|NCT02877420|Non-technical Skills
844706|NCT02877381|Tranexamic Acid
844707|NCT02877381|Blood Transfusion
844708|NCT02877342|Injury
844709|NCT02877342|Injuries
844710|NCT02877342|Triage
844711|NCT02877329|psychological effects
844769|NCT02877290|COPD
844770|NCT02877290|NIRS
844771|NCT02877290|NIV
844772|NCT02877290|Exercise
844773|NCT02877264|Vapendavir
844774|NCT02877264|Bioavailability
844775|NCT02877264|Biological Availability
844776|NCT02877264|Volunteers
844777|NCT02877251|Venous Thromboembolism
844778|NCT02877251|Venous Thrombosis
844779|NCT02877251|Pulmonary Thromboembolism
844780|NCT02877251|National Registry
844781|NCT02877251|Mexico
844782|NCT02877251|Major Adverse Cardiovascular Events
844783|NCT02877238|remote ischemic preconditioning
844784|NCT02877238|sevoflurane
844785|NCT02877238|total intravenous anesthetic
844786|NCT02877212|ITP
844787|NCT02877212|Eltrombopag
844788|NCT02877212|Steroid refractory
844789|NCT02877212|Fc Receptor
844790|NCT02877199|Hepatitis C
844791|NCT02877199|anti-E1E2 antibodies
844792|NCT02877199|cirrhosis
844793|NCT02877199|triple therapy
844794|NCT02877173|Arteriosclerosis Obliterans
844795|NCT02877173|Atherosclerotic Occlusive Disease of the Lower Extremities
844796|NCT02877173|Intermittent Claudication
844797|NCT02877121|interstitial lung disease
844798|NCT02877121|Respiratory Muscle Function
844799|NCT02877121|Neural Respiratory Drive
844800|NCT02877056|Colorectal adenocarcinoma
844801|NCT02877056|Neoadjuvant therapy
844802|NCT02877056|Endoscopy
844803|NCT02877056|Endoscopic biopsy
844804|NCT02877056|Biomarkers
844805|NCT02877056|Genes
844806|NCT02876991|choline positron emission tomography
844807|NCT02876991|occult recurrence
844808|NCT02876991|prostatic adenocarcinoma
844809|NCT02876991|sodium fluoride positron emission tomography
844812|NCT02876939|Hereditary Sensory Neuropathy
844813|NCT02876939|Autonomic Neuropathy
844814|NCT02876939|Familial Dysautonomia
844815|NCT02876939|proprioception
844816|NCT02876939|motor control
844817|NCT02876939|sensory nervous system.
844818|NCT02876939|HSAN III
844819|NCT02876939|IKBKAP gene mutation
844820|NCT02876926|HIV testing
844821|NCT02876926|Self-testing
844822|NCT02876926|Counseling
844823|NCT02876926|Referral
844824|NCT02876874|Rheumatoid Arthritis
844825|NCT02876874|lymph nodes morphology
844826|NCT02876874|drainage of lymphatic vessels
844827|NCT02876848|Administrative Claims, Healthcare
844828|NCT02876848|Aromatase Inhibitors
844829|NCT02876848|Breast Neoplasms
844830|NCT02876848|Health Services for the Aged
844831|NCT02876848|Medical Informatics Applications
844832|NCT02876848|Medication Adherence
844833|NCT02876848|Outcome and Process Assessment (Health Care)
844834|NCT02876848|Selective Estrogen Receptor Modulators
844835|NCT02876848|Telemedicine
844843|NCT02876809|centenarians
844844|NCT02876809|geriatric
844845|NCT02876809|telomere length
844846|NCT02876809|progerin
844847|NCT02876809|metagenome
844848|NCT02876809|metabolome
844849|NCT02876796|fractional de novo lipogenesis
844850|NCT02876796|DNL
844851|NCT02876796|pharmacodynamic
844852|NCT02876796|pharmacokinetic
844853|NCT02876705|Patterns
844854|NCT02876705|Pain
844855|NCT02876705|Cycling
844856|NCT02876705|Running
844857|NCT02876705|Exhaustion
844858|NCT02876679|Hematopoietic Stem Cell
844859|NCT02876679|Transplantation
844860|NCT02876679|Graft vs Host Disease
844861|NCT02876679|Cyclophosphamide
844862|NCT02876679|Anti-Thymocyte Globulin
844863|NCT02876679|GVHD prophylaxis
844864|NCT02876666|Spinal Cord Injuries
844865|NCT02876666|Health Behavior
844866|NCT02876653|Obstructive sleep apnea
844867|NCT02876653|Aging
844868|NCT02876653|Telomere length
844869|NCT02876614|radionuclide cisternography
844870|NCT02876614|CSF leak
844871|NCT02876614|imaging
844872|NCT02876601|Coagulation
844873|NCT02876601|Inflammation
844874|NCT02876601|Defibrotide
844875|NCT02876601|Fibrinolysis
844876|NCT02876588|Wrong-Patient Errors
844877|NCT02876588|Retract-and-Reorder Tool
844878|NCT02876562|Gingival Recession Coverage
844879|NCT02876549|G6PD
844880|NCT02876549|Primaquine
844881|NCT02876510|Ovarian Cancer
844882|NCT02876510|Esophageal Cancer
844883|NCT02876510|Head and neck squamous cell carcinoma
844884|NCT02876510|Squamous non-small cell lung cancer
844885|NCT02876458|Coronary angiogram
844886|NCT02876458|Survival rate
844887|NCT02876458|Neurological sequel
844888|NCT02876445|Huntington's disease
844889|NCT02876445|Caregiver
844890|NCT02876445|ZARIT burden scale
844891|NCT02876419|nucleic acid polymer REP 2139 HBsAg hepatitis B hepatitis D
844892|NCT02876367|Epidemiology
844893|NCT02876354|Hemodialysis
844894|NCT02876354|Vitamin k2
844895|NCT02876354|Vascular calcifications
844896|NCT02876341|Chronic antihypertensives
844897|NCT02876341|New onset atrial fibrillation
844898|NCT02876341|Septic shock
844899|NCT02876328|Ebola Vaccine
844900|NCT02876315|innate immunity
844901|NCT02876315|elderly adults
844902|NCT02876315|multivitamin supplement
844903|NCT02876315|vitamin D
844904|NCT02876315|vitamin C
844905|NCT02876315|zinc
844906|NCT02876302|Inflammatory Breast Cancer
844907|NCT02876302|Breast Cancer
844908|NCT02876302|Triple Negative Breast Cancer
844909|NCT02876263|aortic diseases
844910|NCT02876263|aortic aneurysm
844911|NCT02876263|electroencephalography
844912|NCT02876263|Near-Infrared spectroscopy
844913|NCT02876263|Transcranial Doppler ultrasonography
844914|NCT02876263|Cardiopulmonary arrest
844915|NCT02876263|Hypothermia, Induced
844916|NCT02876250|Lung transplantation
844917|NCT02876250|Cyclosporine
844918|NCT02876250|Postconditioning
844919|NCT02876211|Renal disease
844920|NCT02876211|Erythropoiesis
844921|NCT02876211|Erythropoietin stimulating agent
844922|NCT02876211|Iron
844923|NCT02876211|Klotho
844924|NCT02876211|Selective vitamin D receptor activation
844925|NCT02876198|Retinal neovascularization
844926|NCT02876198|Anti-VEGF
844927|NCT02876198|Retinal Nerve Fiber Layer (RNFL)
844930|NCT02876172|PTSD
844931|NCT02876172|psychotherapy
844932|NCT02876172|MDMA
844933|NCT02876172|dyad
844934|NCT02876172|cognitive behavioral therapy
844935|NCT02876159|Vaccination
844936|NCT02876146|Albendazole
844937|NCT02876146|Benzimidazole
844938|NCT02876146|Echinococcus multilocularis
844939|NCT02876146|Alveolar echinococcosis
844940|NCT02876146|Liver Diseases
844965|NCT02876055|Nerve Block/methods
844966|NCT02876055|Pain, Postoperative/prevention & control
844967|NCT02876055|Anesthetics, Local/administration & dosage
844968|NCT02876055|Brachial Plexus/ultrasonography
844969|NCT02876055|Shoulder Pain/prevention & control
844970|NCT02876042|Heart Failure
844971|NCT02876042|Preserved Ejection Fraction
844972|NCT02875938|left middle cerebral artery
844973|NCT02875938|cerebrovascular accident (CVA)
844974|NCT02875938|stroke
844975|NCT02875925|blood coagulation
844976|NCT02875912|Family
844977|NCT02875912|Care Rituals
844978|NCT02875912|End of Life
844979|NCT02875912|Discordance of care
844980|NCT02875860|CDH
844981|NCT02875860|Congenital Diaphragmatic Hernia
844982|NCT02875860|Fetal Tracheal Occlusion
844983|NCT02875860|FETO
844984|NCT02875860|plug-unplug
844985|NCT02875860|GoldBal2
844986|NCT02875860|Balloon
844987|NCT02875860|Goldvalve Balloon
844988|NCT02875860|TOTAL
844989|NCT02875795|linguistic
844990|NCT02875795|quality of life
844991|NCT02875782|Smoking Cessation
844992|NCT02875769|cetylpyridinium chloride
844993|NCT02875769|chlorhexidine
844994|NCT02875769|oral aerosol
844995|NCT02875769|oral splatter
844996|NCT02875769|mouthwash
844997|NCT02875769|microbiology
844998|NCT02875704|DR
844999|NCT02875704|AMD
845000|NCT02875691|disease activity
845001|NCT02875652|circulation tumor DNA
845002|NCT02875652|choroidal melanoma
845003|NCT02875639|Ischemic Heart Failure
845004|NCT02875639|coronary artery disease
845005|NCT02875639|qi deficiency and blood stasis
845006|NCT02875613|Nasopharyngeal
845007|NCT02875613|PD-L1
845008|NCT02875613|monoclonal antibody
845009|NCT02875613|Epstein-barr virus
845010|NCT02875600|chronic gastro-intestinal ischemia
845011|NCT02875600|oxygen deficiency of the gastro-intestinal tract
845012|NCT02875587|OHSS
845013|NCT02875587|Infertility
845014|NCT02875587|Cabergoline
845015|NCT02875587|Calcium gluconate
845016|NCT02875587|IVF-ET
845017|NCT02875574|Isoniazid
845018|NCT02875574|Drug Resistance
845019|NCT02875535|Evidence-based
845020|NCT02875535|lesbian, gay, bisexual, transgender, intersex, and queer
845021|NCT02875535|adolescent
845022|NCT02875535|Suicide prevention
845023|NCT02875535|Implementation study
845024|NCT02875522|COPD
845025|NCT02875522|Exercise Training
845026|NCT02875522|Flow-Mediated Dilation
845027|NCT02875522|Arterial Stiffness
845028|NCT02875522|Echocardiography
845029|NCT02875522|Cerebrovascular Physiology
845030|NCT02875470|non-surgical periodontal debridement
845031|NCT02875470|root planing/instrumentation
845032|NCT02875470|cytokine(s)
845033|NCT02875470|dental plaque
845034|NCT02875470|microscopy, electron, scanning
845035|NCT02875457|small cell lung cancer; apatinib; etoposide; cisplatin
845036|NCT02875405|postoperative
845037|NCT02875405|pericardiotomy
845038|NCT02875405|prevention
845039|NCT02875405|cardiac surgery
845040|NCT02875405|left
845041|NCT02875405|posterior
845042|NCT02875379|Noninvasive Ventilation
845043|NCT02875379|Mechanical Ventilation
845044|NCT02875353|Post-Polypectomy
845045|NCT02875353|Colon bleeding
845046|NCT02875353|Stigmata of recent hemorrhage
845047|NCT02875327|SEER
845048|NCT02875327|Medicaid
845049|NCT02875327|Cancer
845050|NCT02875327|Health Services Research
845051|NCT02875327|Epidemiology
845052|NCT02875301|Exercise
845053|NCT02875301|Brain Health
845054|NCT02875301|Dose Response
845055|NCT02875301|Cognition
845056|NCT02875262|intracranial aneurysm
845057|NCT02875262|subarachnoid hemorrhage
845058|NCT02875262|stroke
845059|NCT02875262|chelator
845060|NCT02875249|post-antibiotic diarrhea
845061|NCT02875249|intestinal microbiome
845062|NCT02875223|Safety
845063|NCT02875223|CC-90011
845064|NCT02875223|Relapsed and/or Refractory Solid Tumors
845065|NCT02875223|Non-Hodgkin's Lymphomas
845066|NCT02875210|Anterior Cruciate Ligament
845067|NCT02875210|A02.835.583.512.100
845068|NCT02875197|Kinetics
845069|NCT02875197|Biomechanics
845070|NCT02875197|Amputation
845071|NCT02875197|Prosthesis
845072|NCT02875197|Transtibial
845073|NCT02875184|Psoriatic Arthritis
845074|NCT02875184|Apremilast
845075|NCT02875184|CC-10004
845076|NCT02875171|Anthracyclines; Cardiotoxicity; 2-D Echocardiography
845077|NCT02875145|Corneal Transplantation
845078|NCT02875145|Graft Survival
845079|NCT02875106|Sinus rhythm
845080|NCT02875041|rehabilitation
845081|NCT02875041|balance
845082|NCT02875028|Coagulations
845083|NCT02875028|Platelets
845084|NCT02875028|Inflammation
845085|NCT02875028|endotoxemia
845086|NCT02875028|vorapaxar
845087|NCT02875015|Anesthetics
845088|NCT02875015|Anesthetic Effects
845089|NCT02875015|Mid-urethral sling
845090|NCT02874976|sedentary lifestyle
845091|NCT02874963|Diabetes
845092|NCT02874963|Oral Hygiene
845093|NCT02874963|Periodontal Surgery
845094|NCT02874963|Periodontal Medicine
845095|NCT02874950|Exercise
845096|NCT02874937|Syncope
845097|NCT02874937|Vasovagal
845098|NCT02874937|Atomoxetine
845099|NCT02874924|Geriatrics
845100|NCT02874911|Exergaming
845101|NCT02874911|Neurodegenerative diseases
845102|NCT02874911|Rare disease
845103|NCT02874911|Motor exercises
845104|NCT02874911|Training
845105|NCT02874911|Spinocerebellar ataxia
845106|NCT02874885|Locally-advanced rectal cancer
845107|NCT02874885|LARC
845108|NCT02874885|Colorectal cancer
845109|NCT02874885|CRC
845110|NCT02874885|Rectosigmoid cancer
845111|NCT02874885|No known diagnosis of colorectal cancer
845112|NCT02874885|Blood draws
845113|NCT02874885|Blood samples
845114|NCT02874885|Circulating tumor cells (CTC)
845115|NCT02874885|CTC
845116|NCT02874872|Nursing homes
845117|NCT02874872|Antibiotic Stewardship
845118|NCT02874872|Antibiotic Resistance
845119|NCT02874859|DIABETIC RETINOPATHY
845120|NCT02874859|Intravitreal aflibercept
845121|NCT02874833|Depression
845122|NCT02874833|Unipolar depression
845123|NCT02874833|Bipolar affective disorder
845124|NCT02874833|Exercise
845125|NCT02874833|Internet-based intervention
845126|NCT02874820|Imidazoline Receptor 2
845127|NCT02874820|(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole
845128|NCT02874820|BU99008
845129|NCT02874820|[11C]-BU99008
845130|NCT02874820|Radionuclide Imaging
845131|NCT02874820|Molecular Imaging
845132|NCT02874807|Hyponatremia
845133|NCT02874807|SGLT2 inhibitor
845134|NCT02874794|Heart Failure
845135|NCT02874794|Reduced Ejection Fraction
845136|NCT02874794|Central Aortic Stiffness
845137|NCT02874794|Vascular
845138|NCT02874794|Echocardiogram
845139|NCT02874755|Quality of Care
845140|NCT02874755|Standardized Patients
845141|NCT02874729|Biomarkers, Tumor
845142|NCT02874729|Biological Assay
845143|NCT02874716|Quality of Care
845144|NCT02874716|Standardized Patients
845145|NCT02874677|Multiple sclerosis
845146|NCT02874677|Ventilatory threshold
845147|NCT02874677|Effort Reeducation
845148|NCT02874651|Nasopharyngeal Carcinoma
845149|NCT02874651|EB Virus
845150|NCT02874651|DNA
845151|NCT02874651|vascular endothecial growth factor receptor inhibitor
845152|NCT02874651|Apatinib
845153|NCT02874612|Young Adults
845154|NCT02874612|Psychosocial Functioning
845157|NCT02874560|CNS
845158|NCT02874560|Antipsychotic
845159|NCT02874560|Functional remission
845160|NCT02874560|Observational study
845161|NCT02874560|FROGS
845162|NCT02874560|PSP
845163|NCT02874560|Functioning
845164|NCT02874560|Schizophrenia
845165|NCT02874508|leukocyte subpopulations
845166|NCT02874508|perioperative myocardial infarction
845167|NCT02874508|non-cardiac surgery
845168|NCT02874508|perioperative cardiovascular risk
845169|NCT02874495|Crohn's disease
845170|NCT02874495|Rectal Distension
845171|NCT02874495|Remission
845172|NCT02874495|Anticipation
845173|NCT02874495|Painful
845174|NCT02874482|Schizophrenia
845175|NCT02874482|Change blindness
845176|NCT02874482|Eye tracking
845177|NCT02874482|Implicit response
845178|NCT02874469|sudden death
845179|NCT02874469|post-traumatic stress disorder
845180|NCT02874469|psychological distress
845181|NCT02874469|diary
845182|NCT02874469|resuscitation
845183|NCT02874456|Zyca virus
845184|NCT02874352|intensive care
845185|NCT02874352|tracheostomy
845186|NCT02874339|Acute cardiogenic pulmonary
845187|NCT02874339|Respiratory failure
845188|NCT02874339|Hypercapnia
845189|NCT02874339|High flow nasal oxygen
845190|NCT02874339|Non invasive ventilation
845191|NCT02874339|Emergency department
845192|NCT02874326|Sandostatin LAR
845193|NCT02874326|Somatostatin
845194|NCT02874326|Octreotide
845195|NCT02874313|CPAP
845196|NCT02874313|Sleep apnea
845197|NCT02874313|Diabetes
845198|NCT02874313|Diabetic retinopathy
845199|NCT02874287|Coronary Artery Disease
845200|NCT02874287|Hydroxychloroquine
845201|NCT02874287|Cross-Over Study
845208|NCT02874222|aromatase inhibitors
845209|NCT02874183|Heart Failure
845210|NCT02874183|HF
845211|NCT02874183|CHF
845212|NCT02874183|RCT
845213|NCT02874183|Self-efficacy
845214|NCT02874183|Pharmacy
845215|NCT02874183|Pharmacist
845216|NCT02874183|Transition of Care
845217|NCT02874183|Readmission
845218|NCT02874131|Posttraumatic Stress Disorder
845219|NCT02874131|Major Depressive Disorder
845220|NCT02874131|Behavioral Activation
845221|NCT02874131|Cognitive Processing Therapy
845222|NCT02874131|Comorbidity
845223|NCT02874131|Military
845224|NCT02874105|Medical treatment
845225|NCT02874105|physiotherapy
845226|NCT02874092|Methotrexate (MTX)
845227|NCT02874092|Ticagrelor
845228|NCT02874066|Hepatitis C virus
845229|NCT02874066|Hemodialysis
845230|NCT02874066|Direct acting antiviral agents
845231|NCT02874053|Risk Perceptions
845232|NCT02874053|Medical Tradeoffs
845233|NCT02874053|Regulatory Focus
845234|NCT02874053|Integral Affect
845235|NCT02874027|gut microbiota
845236|NCT02874027|depression
845237|NCT02874027|gut-brain axis
845238|NCT02874027|circadian rhythm
845239|NCT02874027|Traumatic Brain Injury
845240|NCT02874001|psychology
845241|NCT02874001|caregiver support time
845242|NCT02873975|Advanced Cancers
845243|NCT02873975|Solid tumors
845244|NCT02873975|MYC amplification
845245|NCT02873975|CCNE1 amplification
845246|NCT02873975|Rb loss
845247|NCT02873975|FBXW7 mutation
845248|NCT02873975|BRCA1 mutation
845249|NCT02873975|BRCA2 mutation
845250|NCT02873975|PALB2 mutation
845251|NCT02873975|RAD51C mutation
845252|NCT02873975|RAD51D mutation
845253|NCT02873975|ATR mutation
845254|NCT02873975|ATM mutation
845255|NCT02873975|CHK2 mutation
845256|NCT02873975|Fanconi anemia
845257|NCT02873962|Relapsed Ovarian Cancer
845258|NCT02873949|immunology factors
845259|NCT02873949|TREM
845260|NCT02873949|stress
845261|NCT02873923|clinical trial
845262|NCT02873923|surrogate endpoints
845263|NCT02873923|meta analysis
845264|NCT02873897|elderly
845265|NCT02873858|elderly
845266|NCT02873780|Pulmonary rehabilitation
845267|NCT02873780|COPD
845268|NCT02873780|Evaluation
845269|NCT02873780|oxygen desaturation
845270|NCT02873780|exercise capacity
845271|NCT02873767|First in human
845272|NCT02873767|Healthy volunteers
845273|NCT02873741|Sexually Transmitted Diseases (STDs)
845274|NCT02873741|Cancer
845275|NCT02873741|AIDS
845276|NCT02873728|chronic ulcer
845277|NCT02873728|diabetic ulcer
845278|NCT02873728|venous ulcer
845279|NCT02873728|remote ischemic conditioning
845280|NCT02873715|Childhood weight control
845281|NCT02873702|Drug therapy
845282|NCT02873689|Drug therapy
845283|NCT02873676|prevalence; lifestyle modification; clinical outcomes
845284|NCT02873650|Hepatic impairment
845285|NCT02873650|Healthy volunteers
845286|NCT02873650|Clinical pharmacology study
845287|NCT02873650|DRB436
845288|NCT02873650|dabrafenib
845289|NCT02873650|normal hepatic function
845290|NCT02873650|impaired hepatic function
845291|NCT02873637|total knee replacement
845292|NCT02873637|anesthesia
845293|NCT02873637|catheter
845294|NCT02873624|Acute Kidney Injury , Laparoscopic Cholecystectomy
845295|NCT02873598|Induction Chemotherapy
845296|NCT02873598|Stereotactic Body Radiotherapy (SBRT)
845297|NCT02873598|Dose Escalation
845298|NCT02873598|Locally Advanced Pancreatic Cancer (LAPC)
845299|NCT02873598|Maximum Tolerated Dose (MTD)
845300|NCT02873572|Online poker
845301|NCT02873572|Casino
845302|NCT02873572|Massively Multiplayer Online Role-Playing Game (MMORPG)
845303|NCT02873572|Iowa Gambling Task (IGT)
845304|NCT02873572|High Resolution Electroencephalography (HR-EEG)
845305|NCT02873559|older
845306|NCT02873559|frail
845307|NCT02873559|men
845308|NCT02873559|progressive muscle training
845309|NCT02873559|muscle training
845310|NCT02873559|exercise
845311|NCT02873559|testosterone
845312|NCT02873520|Precision Cell Immunotherapy
845313|NCT02873520|Chemotherapy
845314|NCT02873520|Advanced Gastric Cancer
845315|NCT02873507|transplantation, liver
845316|NCT02873494|Hemodynamic monitoring
845317|NCT02873494|cardiac output
845318|NCT02873494|Transthoracic echocardiography
845319|NCT02873494|Impedance cardiography
845320|NCT02873494|Child
845321|NCT02873494|Physioflow
845322|NCT02873494|pediatric intensive care unit
845323|NCT02873442|Precision Cell Immunotherapy
845324|NCT02873442|Transcatheter Arterial Chemoembolization
845325|NCT02873442|Advanced Liver Cancer
845326|NCT02873416|Precision Cell Immunotherapy
845327|NCT02873416|Chemotherapy
845328|NCT02873416|Advanced Lung Cancer
845329|NCT02873390|PD-1 Antibody
845330|NCT02873390|CAR-T Cells
845331|NCT02873390|EGFR family
845332|NCT02873390|Advanced Malignancies
845333|NCT02873377|Hispanics
845334|NCT02873377|Construction workers
845335|NCT02873377|Tobacco Quitline
845336|NCT02873377|Nicotine replacement therapy
845337|NCT02873351|L-DOPA
845338|NCT02873351|GPR143
845339|NCT02873351|PEDF
845340|NCT02873351|VEGF
845341|NCT02873325|ADV
845342|NCT02873325|CMV
845343|NCT02873325|HSCT
845344|NCT02873299|PTSD, Post Traumatic Stress Disorder
845345|NCT02873286|RSV Vaccines
845346|NCT02873286|Respiratory Syncytial Virus Vaccines
845347|NCT02873260|Dengue Vaccine
845348|NCT02873234|Telemedicine
845349|NCT02873234|Chinese Medicine syndrome differentiation
845350|NCT02873234|Long-term study
845351|NCT02873234|Relapse rate
845352|NCT02873234|Suicide rate
845353|NCT02873234|Antidepressants
845354|NCT02873208|Alkermes
845355|NCT02873208|ALKS 3831
845356|NCT02873208|Samidorphan
845357|NCT02873208|Schizophrenia
845358|NCT02873208|Safety
845359|NCT02873182|Intraoperative monitoring
845360|NCT02873182|Intraoperative neuromonitoring
845361|NCT02873182|Autonomic nervous system
845362|NCT02873182|Spine surgery
845363|NCT02873182|Pelvic surgery
845364|NCT02873182|Sexual function
845365|NCT02873182|Bowel function
845366|NCT02873182|Bladder function
845367|NCT02873169|Left ventricular assist device
845368|NCT02873169|Ventricular Arrhythmias
845369|NCT02873169|Implantable Cardioverter-defibrillator
845370|NCT02873156|E2027
845371|NCT02873156|Healthy participants
845372|NCT02873156|Pharmacokinetics
845373|NCT02873156|Pharmacodynamics
845374|NCT02873117|Benign prostate hyperplasia
845375|NCT02873117|5 alpha reductase inhibitor
845376|NCT02873117|prostate cancer
845377|NCT02873117|Symptomatic
845378|NCT02873117|treated
845379|NCT02873013|prostate cancer
845380|NCT02873013|observational study
845381|NCT02873000|incentive spirometry
845382|NCT02873000|outcome
845383|NCT02873000|length of stay,
845384|NCT02873000|hospital complication
845385|NCT02873000|general internal medicine
845386|NCT02873000|hospital medicine
845387|NCT02873000|non-critically-ill
845388|NCT02872974|Cardiovascular diseases
845389|NCT02872974|Gestational diabetes mellitus
845390|NCT02872974|Pediatrics
845391|NCT02872974|Fetal programming
845392|NCT02872974|Cohort study
845393|NCT02872948|Non invasive prenatal testing
845394|NCT02872948|Down Syndrome
845395|NCT02872948|Digital PCR
845396|NCT02872922|Endothelial function
845397|NCT02872922|Ultrasonic Therapy
845398|NCT02872922|Vascular endothelium
845399|NCT02872922|Nitric oxide
845400|NCT02872922|Ultrasound
845401|NCT02872883|Prelabour rupture of membranes
845402|NCT02872883|term pregnancy
845403|NCT02872883|management
845404|NCT02872883|vaginal examination
845405|NCT02872883|induction of labour
845406|NCT02872883|expectant management
845407|NCT02872870|language disorders
845408|NCT02872870|developmental disorders of oral and written language
845409|NCT02872831|Fine needle aspiration
845410|NCT02872818|Apoptotic signal pathway
845411|NCT02872818|Survivin
845412|NCT02872818|Bcl-2
845413|NCT02872818|Bax
845414|NCT02872818|c-Myc
845415|NCT02872818|Caspase-9
845416|NCT02872818|endometrial hyperplasia
845417|NCT02872818|endometrium cancer
845418|NCT02872792|cycloergometer
845419|NCT02872753|Platelet Rich Plasma
845420|NCT02872753|meniscectomy
845421|NCT02872753|randomized controlled trial
845422|NCT02872753|intra-op injection
845423|NCT02872714|Urothelial carcinoma
845424|NCT02872714|fibroblast growth factor (FGF)
845425|NCT02872714|fibroblast growth factor receptor (FGFR)
845426|NCT02872714|FGF/FGFR alterations
845427|NCT02872675|Asthma
845428|NCT02872675|Exercise-Induced Asthma
845429|NCT02872675|Gut Bacteria
845430|NCT02872675|Bimuno® Galactooligosaccharide
845431|NCT02872675|Pulmonary Function
845432|NCT02872675|Prebiotics
845433|NCT02872675|Exercise-Induced Bronchoconstriction
845434|NCT02872675|Gut Microbiota
845435|NCT02872675|Nutritional Intervention
845565|NCT02871830|Adolescent girls
845436|NCT02872675|Eucapnic Voluntary Hyperpnoea
845437|NCT02872675|Systemic Inflammation
845438|NCT02872675|Systemic Immune Function
845439|NCT02872675|Regulatory T Cells
845440|NCT02872675|TH1 Cells
845441|NCT02872675|TH2 Cells
845442|NCT02872675|Short-Chain Fatty Acids
845443|NCT02872675|Acetate
845444|NCT02872675|Propionate
845445|NCT02872675|Butyrate
845446|NCT02872675|Metagenomics
845447|NCT02872675|Metabolomics
845448|NCT02872675|Airway Inflammation
845449|NCT02872610|suicidal thoughts
845450|NCT02872610|suicidal ideation
845451|NCT02872610|Internet intervention
845452|NCT02872610|self-help
845453|NCT02872571|islet of Langerhans
845454|NCT02872571|transplantation
845455|NCT02872571|muscle
845456|NCT02872506|Quality of life
845457|NCT02872506|Crohn's disease
845458|NCT02872506|Ileocecal resection
845459|NCT02872506|Anti TNF
845460|NCT02872493|obesity
845461|NCT02872493|bariatric surgery
845462|NCT02872493|bowel length
845463|NCT02872480|Concussion
845464|NCT02872480|Exercise
845465|NCT02872467|Cocaine
845466|NCT02872467|Mothers
845467|NCT02872467|Pregnant women
845468|NCT02872467|Postpartum women
845469|NCT02872467|Oxytocin
845470|NCT02872467|Substance use disorders
845471|NCT02872467|Substance abuse
845472|NCT02872467|Prenatal substance use
845473|NCT02872467|stress
845474|NCT02872454|Major Depression
845475|NCT02872454|Text Messaging
845476|NCT02872454|Guided Self-Help
845477|NCT02872402|gestational diabetes
845478|NCT02872402|dietary modification
845479|NCT02872402|weight loss
845480|NCT02872402|physical activity
845481|NCT02872402|breastfeeding
845482|NCT02872376|Anemia
845483|NCT02872376|Crohn's disease
845484|NCT02872376|Ulcerative colitis
845485|NCT02872363|breast screening
845486|NCT02872363|breast cancer
845487|NCT02872363|mammogram
845488|NCT02872363|uptake
845489|NCT02872363|reminder
845490|NCT02872363|text message
845491|NCT02872363|SMS
845492|NCT02872311|Vaccine
845493|NCT02872311|Influenza
845494|NCT02872311|High Dose
845495|NCT02872311|Adjuvanted
845496|NCT02872298|Severe
845497|NCT02872298|Refractory
845498|NCT02872259|metastatic melanoma
845499|NCT02872259|advanced Non-resectable melanoma
845500|NCT02872181|Maternal Position
845501|NCT02872181|Tilt
845502|NCT02872181|Left Uterine Displacement
845503|NCT02872181|Cesarean Delivery
845504|NCT02872181|Cesarean Section
845505|NCT02872155|contrast-induced nephropathy
845506|NCT02872155|renal insufficiency
845507|NCT02872155|computed tomography
845508|NCT02872129|Fibromyalgia
845509|NCT02872129|chronic widespread pain
845510|NCT02872129|follow-up
845511|NCT02872129|pain
845512|NCT02872129|fatigue
845513|NCT02872129|symptoms
845514|NCT02872129|workability
845515|NCT02872129|physical function
845516|NCT02872090|COPD
845517|NCT02872090|bronchodilatators
845518|NCT02872090|autonomic nervous system
845519|NCT02872090|cardiovascular system
845520|NCT02872077|AA for NAS
845521|NCT02872064|Early breast cancer
845522|NCT02872064|Photodynamic therapy
845523|NCT02872064|PDT
845524|NCT02872064|Visudyne
845525|NCT02872064|Verteporfin
845526|NCT02872051|Vocational Rehabilitation
845527|NCT02872051|Anxiety
845528|NCT02872051|Depression
845529|NCT02872051|Common Mental Disorders
845530|NCT02872051|Cognitive Behavior Therapy
845531|NCT02872051|Return to Work
845532|NCT02872051|Mental Health Services
845533|NCT02872051|Integration
845534|NCT02871999|Acupuncture Therapy
845535|NCT02871999|Pain degree after surgery
845536|NCT02871973|parenting
845537|NCT02871973|child development
845538|NCT02871973|language
845539|NCT02871947|severe asthma
845540|NCT02871934|Pharmacogenetics
845541|NCT02871934|SLCO1B1 protein, human
845542|NCT02871934|OATP1B1 protein, human
845543|NCT02871934|Simvastatin
845544|NCT02871934|Cardiovascular disease
845545|NCT02871934|Cholesterol
845546|NCT02871934|Statin-related myotoxicity
845547|NCT02871934|Veterans
845548|NCT02871934|Point-of-care
845549|NCT02871921|Behavioral prevention
845550|NCT02871921|social interaction
845551|NCT02871921|dementia
845552|NCT02871921|MRI
845553|NCT02871895|sepsis
845554|NCT02871895|severe sepsis
845555|NCT02871895|septic shock
845556|NCT02871895|multiple organ failure
845557|NCT02871869|Cinobufacini Tablets
845558|NCT02871869|CHOP protocol
845559|NCT02871856|Screening
845560|NCT02871856|Computed tomography
845561|NCT02871856|Lung cancer
845562|NCT02871830|Physical activity
845563|NCT02871830|Walking
845564|NCT02871830|Intervention
845566|NCT02871830|Randomised trial
845567|NCT02871817|Near Corrected Visual Acuity
845568|NCT02871817|Early Treatment Diabetes Retinopathy Study
845569|NCT02871817|Amsler Grid
845570|NCT02871817|Home Monitoring
845571|NCT02871791|Her2-negative metastatic breast cancer
845572|NCT02871791|Hormone receptor (HR)-positive breast cancer
845573|NCT02871765|Patient education
845574|NCT02871765|Knowledge
845575|NCT02871765|Life distress
845576|NCT02871765|Quality of life
845577|NCT02871752|prostate cancer
845578|NCT02871752|active surveillance
845579|NCT02871752|MBSR
845580|NCT02871752|couples
845581|NCT02871752|health promotion
845582|NCT02871752|quality of life
845583|NCT02871739|Communication skills training
845584|NCT02871739|Shared Decision Making
845585|NCT02871739|Decision making
845586|NCT02871739|Decision Aids
845587|NCT02871739|lung cancer screening
845588|NCT02871726|Prostate Cancer Detection
845589|NCT02871726|Prostate Biopsy
845590|NCT02871726|Prostate Cancer
845591|NCT02871726|Transrectal Ultrasound
845593|NCT02871700|stroke
845594|NCT02871700|translational rehabilitation
845595|NCT02871700|mirror neuron system
845596|NCT02871700|action observation
845597|NCT02871700|mirror therapy
845598|NCT02871700|MEG
845599|NCT02871674|Behavioural interventions
845600|NCT02871674|Sleep difficulties
845601|NCT02871674|Children
845602|NCT02871674|Attention Deficit Hyperactivity Disorder
845603|NCT02871674|Randomised controlled trial
845604|NCT02871674|Saudi Arabia
845605|NCT02871674|Behavioural Insomnia
845606|NCT02871661|vulvodynia
845607|NCT02871661|pelvic floor muscles
845608|NCT02871661|kinesiotherapy
845609|NCT02871661|electrical therapy
845610|NCT02871661|physical therapy
845611|NCT02871661|amitriptyline
845612|NCT02871661|female sexual dysfunction.
845613|NCT02871648|Healthy
845614|NCT02871609|Biofilm
845615|NCT02871609|Morbidity
845616|NCT02871609|Ureteral Catheterization
845617|NCT02871570|Hepatic Impairment
845618|NCT02871570|Rivipansel
845619|NCT02871544|BNP
845620|NCT02871544|NGAL
845621|NCT02871544|Sepsis
845622|NCT02871544|Mortality
845623|NCT02871531|retinal detachment
845624|NCT02871531|pneumatic retinopexy
845625|NCT02871531|vitrectomy
845626|NCT02871479|Atopic Dermatitis
845627|NCT02871479|Eczema
845628|NCT02871453|Ischemic Stroke
845629|NCT02871453|Motor Dysfunction
845630|NCT02871453|Scalp Acupuncture
845631|NCT02871427|Lewy body dementia
845632|NCT02871427|Dementia with Lewy bodies
845633|NCT02871427|Parkinson's disease dementia
845634|NCT02871427|Visual hallucinations
845635|NCT02871427|REM sleep behavior disorder
845636|NCT02871401|IPF
845637|NCT02871401|Herpesvirus
845638|NCT02871401|Valganciclovir
845639|NCT02871388|Physical activity; diet; nutrition; breast cancer prevention; mammography screening
845640|NCT02871375|myopia
845641|NCT02871375|presbyopia
845642|NCT02871349|Autism
845643|NCT02871349|ASD
845644|NCT02871336|Cata collection
845645|NCT02871336|Pancreatic cancer surgery
845646|NCT02871323|Myelofibrosis Transformation in Essential Thrombocythemia
845647|NCT02871297|adolescent
845648|NCT02871297|children
845649|NCT02871284|cancer
845650|NCT02871284|anticancer treatment
845651|NCT02871284|exercise
845652|NCT02871284|physical activity
845653|NCT02871284|sensorimotor training
845654|NCT02871284|chemotherapy-induced polyneuropathy
845655|NCT02871245|Acupuncture Therapy
845656|NCT02871245|Laparoscopic Surgery
845657|NCT02871245|Gastrointestinal Tract Recovery of Function
845658|NCT02871219|Follicular lymphoma
845659|NCT02871219|Obinutuzumab
845660|NCT02871219|GA101
845661|NCT02871219|Gazyva
845662|NCT02871219|Lenalidomide
845663|NCT02871219|CC-5013
845664|NCT02871219|Revlimid
845665|NCT02871193|paravertebral block
845666|NCT02871193|patient controlled analgesia
845667|NCT02871193|ropivacaine
845668|NCT02871193|dexamethasone
845669|NCT02871180|Hypoglycemia
845670|NCT02871180|Type 1 diabetes
845671|NCT02871167|oocyte/embryo cryopreservation
845672|NCT02871128|Hemoglobin
845673|NCT02871128|serum iron
845674|NCT02871128|serum ferritin
845675|NCT02871128|Hematocrit
845676|NCT02871128|antioxidant
845677|NCT02871115|Cancer Care
845678|NCT02871102|mechanical ventilation
845679|NCT02871102|respiratory mechanics
845680|NCT02871102|acute respiratory distress syndrome
845681|NCT02871102|positive end-expiratory pressure
845682|NCT02871102|tidal volume
845683|NCT02871089|Type 1 Diabetes
845684|NCT02871089|Closed-loop glucose control
845685|NCT02871089|Artificial Pancreas
845686|NCT02871089|Continuous subcutaneous insulin infusion
845687|NCT02871089|Multiple daily injection therapy
845688|NCT02871089|New onset type 1 diabetes
845689|NCT02871089|Residual C-Peptide secretion
845690|NCT02871089|Beta-cell function preservation
845691|NCT02871089|Continuous glucose monitoring
845692|NCT02871050|Biobank
845693|NCT02871050|biorepository
845694|NCT02871050|Castlebank
845695|NCT02871050|Castleman Disease
845696|NCT02871050|CD
845697|NCT02871050|MCD
845698|NCT02871050|iMCD
845699|NCT02871050|Castleman
845700|NCT02871050|Castleman's Disease
845701|NCT02871050|multicentric Castleman's disease
845702|NCT02871050|multicentric Castleman disease
845703|NCT02871050|Angiofollicular Lymph Hyperplasia
845704|NCT02871024|Polymyxin B
845705|NCT02871024|Pneumonia
845706|NCT02871024|Sepsis
845707|NCT02871024|Urinary tract infection
845708|NCT02871011|Tinea Bronchodilator Agents
845709|NCT02871011|Tinea Pedis
845710|NCT02871011|Nitric Oxide
845711|NCT02871011|Dermatomycoses
845712|NCT02871011|Endothelium-Dependent Relaxing Factors
845713|NCT02871011|Infectious
845714|NCT02871011|Infection
845715|NCT02871011|Mycoses
845716|NCT02871011|Skin Diseases
845717|NCT02871011|Foot Dermatoses
845718|NCT02871011|Foot Diseases
845719|NCT02871011|Pruritus
845720|NCT02871011|Skin Manifestations Signs and Symptoms
845721|NCT02870946|Extracorporeal Membrane Oxygenation
845722|NCT02870946|Cardiogenic Shock
845723|NCT02870946|Renal Replacement Therapy
845724|NCT02870933|CD 133+
845725|NCT02870933|Transepicardial with Transseptal Implantation
845726|NCT02870933|CABG
845727|NCT02870907|primary enucleation
845728|NCT02870907|retinoblastoma
845729|NCT02870868|slow breathing
845730|NCT02870868|yoga
845731|NCT02870868|mind-body practicers
845732|NCT02870842|ultrasonography
845733|NCT02870842|child
845734|NCT02870842|perioperative period
845735|NCT02870842|general anesthesia
845736|NCT02870842|lung
845737|NCT02870777|MRD
845738|NCT02870777|Acute myeloid leukemia
845739|NCT02870764|Danshenduofensuanyan
845740|NCT02870764|Lp-PLA2
845741|NCT02870764|coronary artery disease
845742|NCT02870764|Salvia miltiorrhiza
845743|NCT02870751|ETEC
845744|NCT02870751|human challenge study
845745|NCT02870751|heat stable toxin
845746|NCT02870751|tourist diarrhea
845747|NCT02870751|diarrhea
845748|NCT02870751|enterotoxigenic
845749|NCT02870725|chronic headaches, migraines, depression
845750|NCT02870712|perineal tear of first degree
845751|NCT02870712|suture
845752|NCT02870699|chemotherapy neoadjuvant
845753|NCT02870686|ERCP
845754|NCT02870686|EUS guided ERCP without fluoroscopy
845755|NCT02870673|acupuncture
845756|NCT02870673|electrical stimulation
845757|NCT02870673|carpal tunnel syndrome
845758|NCT02870608|Elastography
845759|NCT02870556|cervical epidural, laryngectomy, pharyngocutaneous fistula
845760|NCT02870543|Bruxism
845761|NCT02870543|Sleep bruxism
845762|NCT02870543|Sleep related bruxism
845763|NCT02870543|Homeopathy
845764|NCT02870504|laser peripheral iridoplasty
845765|NCT02870504|treatment
845766|NCT02870491|Child Diarrhea
845767|NCT02870491|Cluster Randomized Controlled Trial
845768|NCT02870491|Oral Rehydration
845769|NCT02870491|ORS
845770|NCT02870491|Zinc
845771|NCT02870491|Brac
845772|NCT02870491|Community Health Workers
845773|NCT02870491|Uganda
845774|NCT02870465|outpatient versus operating room
845775|NCT02870465|k wire infection
845776|NCT02870465|closed reduction internal fixation
845777|NCT02870452|Haemophilia
845778|NCT02870452|RCT
845779|NCT02870452|Pain
845780|NCT02870452|Hemarthrosis
845781|NCT02870452|Hypnosis
845782|NCT02870452|Cognitive-Behavioral Therapy
845783|NCT02870452|Quality of Life
845784|NCT02870452|Distress
845785|NCT02870452|Cytokines
845786|NCT02870426|Olfactory ensheathing cells
845787|NCT02870413|telehealth
845788|NCT02870387|chronic illness
845789|NCT02870387|children
845790|NCT02870387|children with medical complexity
845791|NCT02870387|medical home
845792|NCT02870387|inpatient consultation
845793|NCT02870335|low back
845794|NCT02870335|manual therapy
845795|NCT02870335|stretching
845796|NCT02870322|overweight
845797|NCT02870322|obesity
845798|NCT02870322|lifestyle prescription
845799|NCT02870322|prevention
845800|NCT02870322|physical activity
845801|NCT02870322|healthy eating
845802|NCT02870283|Cost effectiveness
845803|NCT02870283|Bipolar disorder
845804|NCT02870283|Mixed episodes
845805|NCT02870283|Quality of life
845806|NCT02870270|saliva
845807|NCT02870270|microflora
845808|NCT02870270|diet
845809|NCT02870270|quality of life
845810|NCT02870270|oral cancer
845811|NCT02870244|Melanoma
845812|NCT02870244|Gene Therapy
845813|NCT02870244|Adoptive T-Cell Transfer
845814|NCT02870244|IL-2
845815|NCT02870192|Rectal Prolapse
845816|NCT02870179|Pulse Oximetry
845817|NCT02870179|Temperature
845818|NCT02870179|Respiratory Rate
845819|NCT02870179|Respiratory Gases
845820|NCT02870179|This study determines the measurement accuracy of the physiological parameters
845821|NCT02870140|CAD
845822|NCT02870140|ACS
845823|NCT02870140|All comers
845824|NCT02870140|PCI
845825|NCT02870114|Haemophilia
845826|NCT02870114|Quality of Life
845827|NCT02870114|Distress
845828|NCT02870114|Hemarthrosis
845829|NCT02870114|Pain
845830|NCT02870101|Nucleic acid amplification tests
845831|NCT02870101|Neisseria gonorrhoeae infection
845832|NCT02870101|Chlamydia trachomatis infection
845833|NCT02870101|Sexually transmitted diseases
845834|NCT02870101|Pharynx
845835|NCT02870101|Rectum
845836|NCT02870101|Gram-Negative Bacterial Infections
845837|NCT02870101|Bacterial Infections
845838|NCT02870101|Genital Diseases, Male
845839|NCT02870101|Genital Diseases, Female
845840|NCT02870062|Chlorhexidine baths
845841|NCT02870062|Critical patient
845842|NCT02870062|Healthcare associated infections
845843|NCT02870062|Critical care environment
845844|NCT02870062|Patient colonization
845845|NCT02870049|early detection
845846|NCT02869971|Prostatic artery embolization
845847|NCT02869971|Combined Therapy
845848|NCT02869971|IPSS
845849|NCT02869958|Asthma
845850|NCT02869958|Exacerbation
845851|NCT02869958|Treatment
845852|NCT02869958|Internet
845853|NCT02869958|Emergency care
845854|NCT02869945|de novo untreated Parkinson Disease
845855|NCT02869945|genetic
845856|NCT02869945|COMT Polymorphism
845857|NCT02869945|gene
845858|NCT02869945|brain MRI
845859|NCT02869945|brain MPET
845860|NCT02869841|laparotomy
845861|NCT02869841|pain
845862|NCT02869841|rectus sheath block
845863|NCT02869815|Methylene blue
845864|NCT02869815|Indocyanine green
845865|NCT02869815|Neoadjuvant Therapy
845866|NCT02869815|Sentinel Lymph Node Biopsy
845867|NCT02869815|Breast Neoplasms
845868|NCT02869802|Cancer
845869|NCT02869802|Pancreatic Cancer
845870|NCT02869802|Advanced Pancreatic Ductal Adenocarcinoma
845871|NCT02869802|PDAC
845872|NCT02869802|Genomic Analysis
845873|NCT02869802|Molecular subtyping
845874|NCT02869763|Ethanol
845875|NCT02869763|Steroid profile
845876|NCT02869763|Pharmacokinetics
845877|NCT02869737|Point of Care Device; post traumatic coagulopathy
845878|NCT02869724|IMV : voluntary drug intoxications
845879|NCT02869724|Drug
845880|NCT02869724|Divided prescription
845881|NCT02869672|safety
845882|NCT02869672|immunogenicity
845883|NCT02869672|vaccine
845884|NCT02869659|obesity
845885|NCT02869659|pre-diabetes
845886|NCT02869659|overweight
845887|NCT02869659|lifestyle change
845888|NCT02869659|glucose
845889|NCT02869646|PTSD
845890|NCT02869646|acupuncture
845891|NCT02869646|integrative medicine
845892|NCT02869464|Aneurysm
845893|NCT02869464|Intracranial Aneurysm
845894|NCT02869464|Abdominal Aortic Aneurysm
845896|NCT02869399|head and neck cancer, nutritional intervention
845897|NCT02869386|stroke
845898|NCT02869386|prehospital
845899|NCT02869386|telemedicine
845900|NCT02869386|thrombolysis
845901|NCT02869386|thrombectomy
845902|NCT02869386|endovascular treatment
845903|NCT02869386|functional outcome
845904|NCT02869347|recombinant C1 esterase inhibitor
845905|NCT02869347|acute kidney injury
845906|NCT02869347|coronary angiography
845907|NCT02869347|contrast media
845908|NCT02869347|Conestat alfa
845909|NCT02869347|inflammation
845910|NCT02869308|Cardiomyopathy
845911|NCT02869308|Chemotherapy
845912|NCT02869308|Left ventricular ejection fraction
845913|NCT02869295|Metastatic Solid Tumors
845914|NCT02869295|Locally Advanced Solid Tumors
845915|NCT02869256|chronic myeloid leukemia
845916|NCT02869256|practices evaluation
845917|NCT02869243|A malignant growing astrocytoma of central nervous system
845918|NCT02869230|Breast cancer
845919|NCT02869230|Non palpable breast lesions
845920|NCT02869230|radioguided occult lesion localization
845921|NCT02869217|NY-ESO-1 expressing solid tumors in HLA-A2 positive patients
845922|NCT02869165|Postmenopausal
845923|NCT02869152|sentinel lymph node
845924|NCT02869152|lymphatic mapping
845925|NCT02869152|rectal tumor
845926|NCT02869152|rectal cancer
845927|NCT02869152|early stage
845928|NCT02869139|Thirst
845929|NCT02869139|Ice
845930|NCT02869139|Menthol
845931|NCT02869139|Perioperative Nursing.
845932|NCT02869139|Recovery Room
845933|NCT02869126|99mTc-Sestamibi
845934|NCT02869126|thallium-201
845935|NCT02869126|semiconductor camera
845936|NCT02869100|magnetic resonance imaging
845937|NCT02869100|sodium fluoride positron emission tomography
845938|NCT02869074|von Willebrand disease (VWD)
845939|NCT02869074|von Willebrand factor (VWF)
845940|NCT02869074|von Willebrand factor gene
845941|NCT02869074|next generation sequencing
845942|NCT02869074|diagnosis
845943|NCT02869074|VWD Spanish Cohort
845944|NCT02869061|Bladder neck obstruction
845945|NCT02869061|Bladder outlet obstruction
845946|NCT02869061|Benign prostatic hyperplasia
845947|NCT02869061|Urinary bladder neck obstruction
845948|NCT02869061|Bladder neck contracture
845949|NCT02869061|Bladder neck stricture
845950|NCT02869061|Bladder neck stenosis
845951|NCT02869061|Transurethral resection of the prostate
845952|NCT02869061|Prostatectomy
845953|NCT02869061|Stromal vascular fraction (SVF)
845954|NCT02869061|Adipose-derived regenerative cells (ADRC)
845955|NCT02869061|Adipose tissue
845956|NCT02869061|Stem cells
845957|NCT02869048|Biological Specimen Banks
845958|NCT02869048|Innate Immunity
845959|NCT02869048|Clinical Study
845960|NCT02869048|Complement system proteins
845961|NCT02869048|Amyotrophic lateral sclerosis
845962|NCT02869048|Neurodegenerative disease
845963|NCT02869048|Motor neuron disease
845964|NCT02869035|PET
845965|NCT02869035|Serotonin
845966|NCT02869035|5-HT4R
845967|NCT02869035|MRI
845968|NCT02869035|fMRI
845969|NCT02869035|EEG
845970|NCT02869035|Cortisol awakening response
845971|NCT02869035|Oxidative stress
845972|NCT02869035|Mental health
845973|NCT02869035|Prediction of treatment response
845974|NCT02869035|Inflammation
845975|NCT02869035|5-HTTLPR
845976|NCT02869035|Brain imaging
845977|NCT02869035|Early life stress
845978|NCT02869035|Selective Serotonin Reuptake Inhibitor
845979|NCT02869035|Escitalopram
845980|NCT02869035|Psychometrics
845981|NCT02869035|Moderate depression
845982|NCT02869035|Severe depression
845983|NCT02869035|ERP
845984|NCT02869035|rsfMRI
845985|NCT02869035|11C-SB207145
845986|NCT02869035|Sexual function
845987|NCT02869035|MDD
845988|NCT02869035|Affective cognition
845989|NCT02869035|Cold cognition
845990|NCT02869035|Social cognition
845991|NCT02869035|Anxiety
845992|NCT02869009|stroke
845993|NCT02869009|clopidogrel
845994|NCT02869009|antiplatelets
845995|NCT02868957|CAD
845996|NCT02868957|Digital imaging
845997|NCT02868957|Prosthetic Dentistry
845998|NCT02868931|self-management
845999|NCT02868931|empowerment
846000|NCT02868931|treatment and education program
846001|NCT02868931|insulin pump
846002|NCT02868931|diabetes education
846003|NCT02868866|physical activity
846004|NCT02868866|nutrition
846005|NCT02868866|fruits and vegetables
846006|NCT02868866|faith-based
846007|NCT02868866|churches
846008|NCT02868853|diet
846009|NCT02868853|weight loss
846010|NCT02868853|tracking
846011|NCT02868853|mobile
846012|NCT02868853|calories
846013|NCT02868840|stroke
846014|NCT02868840|Tai ji
846015|NCT02868840|postural balance
846016|NCT02868840|cognition
846017|NCT02868827|cholecalciferol and critical illness
846018|NCT02868827|Mortality and cholecalciferol supplementation
846019|NCT02868801|Pregabalin
846020|NCT02868788|inflammation
846021|NCT02868788|insulin resistance
846022|NCT02868788|type 2 diabetes
846023|NCT02868788|obesity
846024|NCT02868762|neck pain, voice disorder
846025|NCT02868749|Hyaluronic Acid
846026|NCT02868749|histology
846027|NCT02868749|ultrasound
846028|NCT02868749|subcutaneous
846029|NCT02868749|adipose tissue
846030|NCT02868723|cerebrovascular disease
846031|NCT02868723|patient management
846032|NCT02868723|stroke management
846033|NCT02868723|prognosis
846034|NCT02868723|3D Carotid Doppler Imaging
846035|NCT02868723|Randomization
846036|NCT02868710|primary prevention
846037|NCT02868671|mild TBI
846038|NCT02868671|Post-traumatic Stress Disorders
846039|NCT02868671|Acupuncture
846040|NCT02868658|Influenza
846041|NCT02868658|health care workers
846042|NCT02868658|nosocomial
846043|NCT02868658|asymptomatic
846044|NCT02868658|France
846045|NCT02868632|Unresectable
846046|NCT02868632|Locally Advanced
846047|NCT02868632|Non-Metastatic
846048|NCT02868619|fMRI
846049|NCT02868619|Deep brain stimulation
846050|NCT02868619|Food
846051|NCT02868619|Eating
846052|NCT02868619|Reward
846053|NCT02868580|ALS
846054|NCT02868580|Antiretroviral Therapy, Triumeq
846055|NCT02868541|microorganisms
846056|NCT02868541|pilgrim
846057|NCT02868541|hajj
846058|NCT02868528|advanced age women
846059|NCT02868528|blastocyst culture
846060|NCT02868528|PGS
846061|NCT02868528|live birth rate
846062|NCT02868502|Glaucoma
846063|NCT02868502|Open Angle Glaucoma
846064|NCT02868502|Intra Ocular Pressure
846065|NCT02868502|Ocular Hypotensive Drops
846066|NCT02868502|Trabeculectomy
846067|NCT02868502|Cyclophotocoagulation
846068|NCT02868502|Glaucoma Drainage Device
846070|NCT02868463|oxygen tension
846071|NCT02868463|Female Urinary Microbiome
846072|NCT02868463|Urinary Tract Symptoms
846073|NCT02868463|Urine Oxygen Level
846074|NCT02868398|Ulcerative Colitis
846075|NCT02868398|Golimumab
846076|NCT02868398|Deep and prolonged remission
846077|NCT02868385|Schistosomiasis
846078|NCT02868385|Schistosoma mansoni
846079|NCT02868385|Bilharzia
846080|NCT02868372|Cesarean section
846081|NCT02868372|Betadine
846082|NCT02868372|Wound infection
846083|NCT02868320|SMS
846084|NCT02868320|text messaging
846085|NCT02868320|diabetes self management
846086|NCT02868320|glycemic control
846087|NCT02868320|mHealth
846088|NCT02868320|mobile health
846089|NCT02868320|diabetes education
846095|NCT02868268|Neuroblastoma
846096|NCT02868255|Biobank analyses
846097|NCT02868255|Effect evaluation of the drug
846098|NCT02868255|patient-derived cells
846099|NCT02868255|SIRPα/CD47 expression
846100|NCT02868242|HCV genotype 1 or 4 (GT-1 or GT-4)
846101|NCT02868242|Direct Acting Antiviral
846102|NCT02868242|Combination Therapy
846103|NCT02868242|Hepatitis C, Chronic
846104|NCT02868242|Liver Diseases
846105|NCT02868242|Virus Diseases
846106|NCT02868177|Prevention
846107|NCT02868151|Oral mucositis, chemo radiotherapy, vitamin c,
846108|NCT02868138|Sickle cell disease
846109|NCT02868138|Hydroxyurea
846110|NCT02868138|Compliance
846111|NCT02868125|pertrochanteric
846112|NCT02868125|radiography
846113|NCT02868112|Cancer Care
846114|NCT02868112|Palliative Care
846115|NCT02868112|Geriatrics
846116|NCT02868112|Quality of Life
846117|NCT02868086|Age-related macular degeneration
846118|NCT02868086|Optical coherence tomography angiography
846119|NCT02868047|chronic pancreatitis
846120|NCT02868047|endoscopic ultrasound
846121|NCT02868034|Low Back Pain
846122|NCT02868034|Spinal Manipulation
846123|NCT02868034|Exercise
846124|NCT02868021|Elderly
846125|NCT02868021|Exercise
846126|NCT02868008|multimodal imaging
846127|NCT02868008|surgical risk
846128|NCT02868008|arteriovenous malformations
846129|NCT02867982|platform switching
846130|NCT02867982|crestal bone remodeling
846131|NCT02867982|soft tissue thickness
846132|NCT02867982|dental implant
846133|NCT02867969|Spinocerebellar ataxia
846134|NCT02867969|Exergaming
846135|NCT02867969|Neurodegenerative diseases
846136|NCT02867969|Rare disease
846137|NCT02867969|Motor exercises
846138|NCT02867969|Premanifest stage
846139|NCT02867969|Training
846140|NCT02867956|Ovarian cancer
846141|NCT02867956|Apatinib
846142|NCT02867956|Etoposide
846143|NCT02867956|Chemotherapy
846144|NCT02867943|sepsis, shock,Lactate,volume controlled ventilation
846145|NCT02867930|Echocardiography
846146|NCT02867930|Transesophageal
846147|NCT02867930|Dexmedetomidine
846148|NCT02867930|Ketamine
846149|NCT02867930|Propofol
846150|NCT02867917|Fibers
846151|NCT02867917|Constipation
846152|NCT02867891|FLT3-ITD
846153|NCT02867891|AML
846154|NCT02867891|allo-HSCT
846155|NCT02867839|Gastric cancer
846156|NCT02867839|Adjuvant chemotherapy
846157|NCT02867839|S1
846158|NCT02867839|Oxaliplatin
846159|NCT02867826|Endoscopy
846160|NCT02867826|Ampulla of Vater
846161|NCT02867826|Duodenoscopy
846162|NCT02867813|High Cholesterol
846163|NCT02867813|Treatment for high cholesterol
846164|NCT02867813|Lowering cholesterol
846165|NCT02867813|Lowering high cholesterol
846166|NCT02867813|Hypercholesterolemia
846167|NCT02867800|Sickle Cell Disease
846168|NCT02867800|Graft Versus Host Disease
846169|NCT02867800|Abatacept
846170|NCT02867800|Hematopoietic Stem Cell Transplantation
846171|NCT02867787|Shoulder Joint
846172|NCT02867787|A02.835.583.748
846173|NCT02867774|chronic pelvic pain
846174|NCT02867774|central pain amplification
846175|NCT02867774|exercise
846176|NCT02867774|physical activity
846177|NCT02867761|COPD
846178|NCT02867761|Chronic Obstructive Pulmonary Disease
846179|NCT02867761|Pulmonary Function Tests
846180|NCT02867761|Current Smoker
846181|NCT02867761|Former Smoker
846182|NCT02867761|Chronic Obstructive Airway Disease
846183|NCT02867761|Respiratory Symptoms
846184|NCT02867748|tvt abbrevo , Serasis
846185|NCT02867735|Macular Edema
846186|NCT02867735|Diabetic Macular Edema (DME)
846311|NCT02866643|contraceptive implant
846187|NCT02867735|Neovascular age-related Macular Degeneration(AMD)
846188|NCT02867735|Retinal Vein Occlusions(RVO)
846189|NCT02867696|Bariatric Surgery
846190|NCT02867696|Physical Activity
846191|NCT02867696|Weight Management
846192|NCT02867696|Weight Loss
846193|NCT02867683|vibrotactile feedback
846194|NCT02867683|vestibular rehabilitation
846195|NCT02867683|balance
846196|NCT02867670|Transcranial Magnetic Stimulation (TMS)
846197|NCT02867644|conversational hypnosis
846198|NCT02867644|imaging
846199|NCT02867644|care
846200|NCT02867644|breast neoplasia
846201|NCT02867644|anxiety
846202|NCT02867644|pain
846203|NCT02867631|Intervention study
846204|NCT02867631|Maternal obesity
846205|NCT02867631|Nutrition
846206|NCT02867631|Maternal child health
846207|NCT02867514|tobacco
846208|NCT02867514|craving
846209|NCT02867514|tDCS
846210|NCT02867514|attentional tasks
846211|NCT02867501|venous distension
846212|NCT02867501|venous reflux
846213|NCT02867488|carotenoids
846214|NCT02867488|phylloquinone
846215|NCT02867488|tocopherols
846216|NCT02867488|vitamin A
846217|NCT02867384|Graft vs. Host Disease
846218|NCT02867358|acute uncomplicated influenza
846219|NCT02867319|safety
846220|NCT02867319|vaccine
846221|NCT02867306|methotrexate (MTX)
846222|NCT02867306|Pharmacokinetics
846223|NCT02867306|ASP1707
846224|NCT02867306|Rheumatoid Arthritis (RA)
846225|NCT02867280|Sorafenib
846226|NCT02867280|Microvascular invasion
846227|NCT02867280|adjuvant therapy
846228|NCT02867280|hepatocellular carcinoma
846229|NCT02867267|thymosin alpha 1; thymalfasin; sepsis; immunodepression
846230|NCT02867254|candida
846231|NCT02867254|endodontic lesion
846232|NCT02867254|diabetes
846233|NCT02867202|intrauterine balloon
846234|NCT02867202|intrauterine contraceptive device
846235|NCT02867202|Asherman Syndrome
846236|NCT02867189|anterior chamber flare
846237|NCT02867189|cataract
846238|NCT02867189|intraocular pressure
846239|NCT02867189|micro-instrument
846240|NCT02867189|photograph-based atlas
846241|NCT02867189|visual
846242|NCT02867189|training nurse
846243|NCT02867111|sperm selection
846244|NCT02867111|ICSI
846245|NCT02867111|Assisted Reproductive Techniques
846246|NCT02867098|healthy
846247|NCT02867098|volunteer
846248|NCT02867085|MDS
846249|NCT02867085|Myelodysplastic Syndromes
846250|NCT02867033|desmoid tumour
846251|NCT02867020|apalutamide
846252|NCT02867020|abiraterone
846253|NCT02867020|prostate cancer
846254|NCT02867007|KW-0761
846255|NCT02867007|KHK2455
846256|NCT02867007|Metastatic Solid Tumors
846257|NCT02867007|Locally Advanced Solid Tumors
846258|NCT02867007|Mogamulizumab
846259|NCT02867007|Oncology
846260|NCT02867007|Anti-Tumor
846261|NCT02866994|Women
846262|NCT02866981|Brain Metastases
846263|NCT02866955|aromatase inhibitors
846264|NCT02866955|Metastases
846265|NCT02866929|orthodontics
846266|NCT02866929|periodontics
846267|NCT02866929|piezosurgery
846268|NCT02866929|accelerated orthodontics
846269|NCT02866929|Surgically Accelerated Orthodontic Treatment
846270|NCT02866903|Peritoneal carcinosis
846271|NCT02866903|intraperitoneal (IP) OXAliplatin
846272|NCT02866903|Phase I/II dose escalation trial
846273|NCT02866903|FOLFIRI Bevacizumab chemotherapy
846274|NCT02866890|Laryngeal Tube Suction
846275|NCT02866890|seal pressure
846276|NCT02866890|mechanical ventilation
846277|NCT02866877|augmented renal clearance
846278|NCT02866864|Allergen
846279|NCT02866864|Veterinary
846280|NCT02866864|Allergy
846281|NCT02866864|Animals
846282|NCT02866838|Tranexamic acid
846283|NCT02866838|NOAC
846284|NCT02866838|Direct Oral Anticoagulant (DOAC)
846285|NCT02866838|Direct oral anticoagulants
846286|NCT02866838|Non-Vitamin K antagonist oral anticoagulants
846287|NCT02866825|Inflammation
846288|NCT02866825|Systemic Inflammatory Response Syndrome
846289|NCT02866825|Pathologic Processes
846290|NCT02866825|Organ Dysfunction
846291|NCT02866799|Multimorbidity
846292|NCT02866799|Primary Health Care
846293|NCT02866799|Polypharmacy
846294|NCT02866799|Comorbidity
846295|NCT02866799|Medication Adherence
846296|NCT02866799|Medication Appropriateness Index
846297|NCT02866799|Patient-Centered Care
846298|NCT02866773|Family
846299|NCT02866773|well-being
846300|NCT02866773|Physical activity
846301|NCT02866773|Diet
846302|NCT02866760|Smoking Cessation
846303|NCT02866734|Diabetic Retinopathy
846304|NCT02866734|Screening
846305|NCT02866734|Fee for screening
846306|NCT02866734|Private practice
846307|NCT02866721|Human Mesenchymal Stem Cells
846308|NCT02866695|Actinic Keratosis
846309|NCT02866695|lung transplant
846310|NCT02866695|kidney transplant
846312|NCT02866643|postpartum contraception
846313|NCT02866643|breastfeeding and contraception
846314|NCT02866630|Sevoflurane
846315|NCT02866630|Desflurane
846316|NCT02866630|Coronary Sinus
846317|NCT02866630|Oxygenator Exhaust
846318|NCT02866630|Lactate
846319|NCT02866630|Cardiopulmonary bypass
846320|NCT02866617|Quality of Life
846321|NCT02866617|Vacuum formed thermoplastic retainer
846322|NCT02866617|Orthodontic study model
846323|NCT02866617|3D reconstructed study model
846324|NCT02866604|Traumatic brain injury
846325|NCT02866604|isotonic balanced fluid
846326|NCT02866591|mammography
846327|NCT02866591|pain
846328|NCT02866591|quality of life
846329|NCT02866591|screening
846330|NCT02866591|image quality
846331|NCT02866591|radiology
846332|NCT02866526|adolescents
846333|NCT02866526|young adults
846334|NCT02866448|Cardiovascular disease
846335|NCT02866448|Flavonoid
846336|NCT02866448|Isoquercetin
846337|NCT02866448|Aspirin
846338|NCT02866448|Platelet function
846339|NCT02866448|Vascular function
846340|NCT02866448|Blood pressure
846341|NCT02866435|MRI
846342|NCT02866422|OCD
846343|NCT02866409|dexmedetomidine
846344|NCT02866409|nerve block
846345|NCT02866409|anesthesia infiltration
846346|NCT02866396|chronic pain
846347|NCT02866396|oxycodone
846348|NCT02866396|pregabalin
846349|NCT02866396|lumbar spine surgery
846350|NCT02866396|multimodal analgesia
846351|NCT02866344|Microwave ablation
846352|NCT02866344|Ablation techniques
846353|NCT02866344|Operative surgical procedures
846354|NCT02866344|Hepatic resection
846355|NCT02866344|Surgery
846356|NCT02866344|Outcomes assessment
846357|NCT02866305|primary spontaneous pneumothorax
846358|NCT02866305|epidemiology
846359|NCT02866305|genetics
846360|NCT02866305|risk factors
846361|NCT02866292|Pelvic Floor
846362|NCT02866292|Pregnancy
846363|NCT02866292|Physical Therapy Specialty
846364|NCT02866253|Dehydroepiandrosterone（DHEA）
846365|NCT02866253|DOR（Diminished Ovarian Reserve)
846366|NCT02866253|IVF(In vitro fertilization)
846367|NCT02866253|BMP-15(Bone Morphogenetic Protein 15)
846368|NCT02866227|Bacterial
846369|NCT02866227|Candidiasis
846370|NCT02866227|Gel
846371|NCT02866227|Insert
846372|NCT02866227|TOL-463
846373|NCT02866227|Vaginal
846374|NCT02866227|Vaginitis
846375|NCT02866227|Vaginoses
846376|NCT02866227|Vulvovaginal
846377|NCT02866201|Turista
846378|NCT02866175|percutaneous intervention
846379|NCT02866175|vitamin K antagonist
846380|NCT02866149|Cancer
846381|NCT02866149|circulating tumor biomarkers
846382|NCT02866149|circulating tumor DNA
846383|NCT02866149|Circulating tumor Cell (CTC)
846384|NCT02866097|integrated community case management
846385|NCT02866097|Mobile Health (mHealth)
846386|NCT02866097|rapid diagnostic test
846387|NCT02866097|artemether-lumefantrine
846388|NCT02866097|amoxicillin
846389|NCT02866097|zinc
846390|NCT02866097|oral rehydration solution (ORS)
846391|NCT02866097|District Health Information System 2 (DHIS2)
846392|NCT02866097|iCCM-DHIS2
846393|NCT02866097|ZCAHRD
846394|NCT02866084|vestibular migraines
846395|NCT02866084|dizziness
846396|NCT02866084|migraine headache
846397|NCT02866045|Subepithelial lesions
846398|NCT02866045|Endoscopic Ultrasound-Guided Fine Needle Aspiration
846399|NCT02866006|HPV
846400|NCT02866006|Type 16, 18
846401|NCT02866006|E6E7
846402|NCT02866006|Immune therapeutic vaccine
846403|NCT02865993|cesarean section
846404|NCT02865993|cesarean section complications
846405|NCT02865993|betadine irrigation
846406|NCT02865980|inflammation, infection
846407|NCT02865967|Decision Support Techniques
846408|NCT02865967|Delayed Diagnosis
846409|NCT02865967|Natural Language Processing
846410|NCT02865967|Geographic Information Systems
846411|NCT02865941|Target Fortification
846412|NCT02865941|Breast milk analysis
846413|NCT02865941|Nutrition
846414|NCT02865941|Macronutrient intake
846415|NCT02865941|Protein accretion
846420|NCT02865902|Low level laser therapy
846421|NCT02865902|wound healing
846422|NCT02865902|periodontology
846423|NCT02865889|laparoscopic surgery
846424|NCT02865889|Uterine Neoplasms
846425|NCT02865876|Infectious keratitis
846426|NCT02865876|Cross-linking
846427|NCT02865863|Multivitamin
846428|NCT02865863|Eurycomalongifoliawater extract
846429|NCT02865863|Quality of Life
846430|NCT02865863|Mood
846431|NCT02865850|vadadustat
846432|NCT02865850|AKB-6548
846433|NCT02865850|anemia
846434|NCT02865850|chronic kidney disease
846435|NCT02865850|CKD
846436|NCT02865850|chronic renal insufficiency
846437|NCT02865850|renal impairment
846438|NCT02865850|erythropoietin
846439|NCT02865850|kidney
846440|NCT02865850|renal
846441|NCT02865850|oral anemia treatment
846442|NCT02865850|hemoglobin
846443|NCT02865850|hypoxia-inducible factor
846444|NCT02865850|HIF
846445|NCT02865850|efficacy
846446|NCT02865850|safety
846447|NCT02865850|phase 3
846448|NCT02865850|cardiovascular
846449|NCT02865837|Brachytherapy
846450|NCT02865837|Organs at Risk
846451|NCT02865837|Bladder volume
846452|NCT02865837|Cervical cancer
846453|NCT02865824|Colonoscopy
846455|NCT02865798|Heart Valve Diseases
846456|NCT02865798|Cardiovascular Diseases
846457|NCT02865798|Heart Disease
846458|NCT02865798|Valvular Heart Diseases
846459|NCT02865785|recurrent implantation failure
846460|NCT02865785|intralipid
846461|NCT02865785|uterine natural killer cells
846462|NCT02865746|Steroids
846463|NCT02865746|Pain measurement
846464|NCT02865733|Remodulin®
846465|NCT02865733|pulmonary vascular resistance
846466|NCT02865733|univentricular physiology
846467|NCT02865707|ulcerative colitis
846468|NCT02865707|prebiotics
846469|NCT02865707|b-fructans
846470|NCT02865707|inulin
846471|NCT02865707|oligofructose
846472|NCT02865707|intestinal microbiota
846473|NCT02865681|Infertility
846474|NCT02865681|Gonadotropins
846475|NCT02865681|Menopur
846476|NCT02865681|Ovarian stimulation
846477|NCT02865642|Stroke
846478|NCT02865642|Serotonin
846479|NCT02865642|Hand Paresis
846480|NCT02865616|CDI
846481|NCT02865616|recurrent infection
846482|NCT02865616|MET-1
846483|NCT02865616|C. difficile
846484|NCT02865590|Maxillary Sinus/surgery
846485|NCT02865590|Bone Substitutes
846486|NCT02865590|Radiography, Panoramic
846487|NCT02865564|Probiotics
846488|NCT02865564|Anti-Bacterial Agents
846489|NCT02865564|Infant, Newborn
846490|NCT02865564|Gastrointestinal Microbiome
846491|NCT02865564|Colic
846492|NCT02865564|Gastrointestinal Diseases
846493|NCT02865564|Body Composition
846494|NCT02865564|Bone Density
846495|NCT02865564|Randomized Controlled Trial
846496|NCT02865564|Lactobacillus reuteri
846497|NCT02865564|Pediatrics
846498|NCT02865564|Feces
846499|NCT02865564|ultrasonography
846500|NCT02865564|High-Throughput Nucleotide Sequencing
846501|NCT02865564|Electric Impedance
846502|NCT02865564|Surveys and Questionnaires
846505|NCT02865525|Surveys and Questionnaires
846506|NCT02865525|Patient Education as Topic
846507|NCT02865525|Medication Adherence
846508|NCT02865525|Pulmonary Disease, Chronic Obstructive
846509|NCT02865525|Diabetes Mellitus, Type 2
846510|NCT02865525|Heart failure
846511|NCT02865512|thoracic epidural injection
846512|NCT02865512|patient position
846513|NCT02865486|Gastric emptying
846514|NCT02865486|MRI
846515|NCT02865486|lipid emulsions
846516|NCT02865486|breath test
846517|NCT02865486|GI peptide hormones
846518|NCT02865473|Schlemm's canal lumen area
846519|NCT02865473|PEX
846520|NCT02865460|Chronic Pain
846521|NCT02865460|Cognitive Disorders
846522|NCT02865460|Inflammation
846523|NCT02865460|Neurologic manifestations
846524|NCT02865460|Dementia
846525|NCT02865460|Mental Disorders
846526|NCT02865460|Ubiquinol/ubiquinone
846527|NCT02865460|Pathologic Processes
846528|NCT02865460|Nervous System Diseases
846529|NCT02865460|Hormones, Hormone Substitutes, and Hormone Antagon
846530|NCT02865460|Anti-Inflammatory Agents
846531|NCT02865460|Pharmacologic Actions
846532|NCT02865460|Therapeutic Uses
846533|NCT02865460|Physiological Effects of Drugs
846534|NCT02865460|Gulf war illness
846535|NCT02865460|Chronic fatigue
846536|NCT02865447|dual energy x-ray absorptiometry
846537|NCT02865447|DEXA
846538|NCT02865447|DXA
846539|NCT02865447|total hip arthroplasty
846540|NCT02865447|PROFEMUR
846541|NCT02865447|PRESERVE
846542|NCT02865447|bone mineral density
846543|NCT02865447|BMD
846544|NCT02865447|osteoarthritis
846545|NCT02865447|THA
846546|NCT02865447|musculoskeletal disease
846547|NCT02865408|Amino acids
846548|NCT02865408|critically-ill
846549|NCT02865408|catabolic
846550|NCT02865408|nutrition
846551|NCT02865408|anabolic
846552|NCT02865395|Belladonna and Opium Suppositories
846553|NCT02865382|Adenoma detection rate
846554|NCT02865382|Optical Enhancement Technonogy
846555|NCT02865382|Colonoscopy
846556|NCT02865369|chronic hepatitis C
846557|NCT02865369|Daclatasvir
846558|NCT02865369|Asunaprevir
846559|NCT02865369|fibrosis
846560|NCT02865369|transient elastography
846561|NCT02865356|atopic dermatitis
846562|NCT02865356|eczema
846563|NCT02865356|children
846564|NCT02865356|skin
846565|NCT02865356|topical
846566|NCT02865356|cyclosporine
846567|NCT02865343|Functional Electrical Stimulation (FES)-Rowing
846568|NCT02865330|Intermediate Risk Prostate Cancer
846569|NCT02865330|Low Risk Prostate Cancer
846570|NCT02865330|Active Surveillance
846571|NCT02865304|metastatic breast cancer
846572|NCT02865304|HER-2-negative
846573|NCT02865304|endostar
846574|NCT02865252|manual therapy
846575|NCT02865252|mobilization with movement
846576|NCT02865239|Imaging, Three-Dimensional
846577|NCT02865239|Magnetic Resonance Imaging/methods*
846578|NCT02865239|Breast Neoplasms/diagnosis*
846579|NCT02865239|Prone Position
846580|NCT02865239|Prospective Studies
846581|NCT02865226|thoracic surgery
846582|NCT02865226|thoracotomy
846583|NCT02865213|Open bite
846584|NCT02865213|Molar intrusion
846585|NCT02865213|Temporary anchorage devices
846586|NCT02865200|Nutrition
846587|NCT02865200|Public Health
846588|NCT02865187|Vitamin D
846589|NCT02865187|polycystic ovary syndrome
846590|NCT02865187|polycystic ovarian syndrome
846591|NCT02865187|PCOS
846592|NCT02865187|sexual dysfunction
846593|NCT02865187|female sexual dysfunction
846594|NCT02865187|low libido
846595|NCT02865174|Thrombin-gelatin matrix
846596|NCT02865174|Floseal
846597|NCT02865174|Tranexamic Acid
846598|NCT02865174|Total Knee Arthroplasty
846599|NCT02865135|HPV Related Head and Neck
846600|NCT02865135|Cervical
846601|NCT02865135|Anal Cancer
846602|NCT02865109|Spinal Muscular Atrophy
846603|NCT02865109|SMA
846604|NCT02865109|SMN
846605|NCT02865109|SMNRx
846606|NCT02865109|ISIS-SMNRx
846607|NCT02865109|ISIS-SMN Rx
846608|NCT02865109|ISIS 396443
846609|NCT02865109|ISIS-396443
846610|NCT02865109|ENDEAR
846611|NCT02865109|IONIS-SMNRx
846612|NCT02865109|IONIS-SMN Rx
846613|NCT02865109|EMBRACE
846614|NCT02865109|NURTURE
846615|NCT02865109|IONIS
846616|NCT02865109|BIOGEN
846617|NCT02865109|SHINE
846618|NCT02865109|Nusinersen
846619|NCT02865070|premature
846620|NCT02865070|wireless vitals
846621|NCT02865070|vitals monitor
846622|NCT02865044|Fatty Acids
846623|NCT02865044|Fish Oil
846624|NCT02865044|Marine Copepod
846625|NCT02865044|Fatty Acid Absorption
846626|NCT02865018|Neuromyelitis Optica
846627|NCT02865018|Cetirizine
846628|NCT02864992|lung
846629|NCT02864992|neoplasm
846630|NCT02864992|cancer
846631|NCT02864992|tumor
846632|NCT02864992|adenocarcinoma
846633|NCT02864992|MET exon 14
846634|NCT02864992|METex14
846635|NCT02864992|pulmonary
846636|NCT02864992|stage III
846637|NCT02864992|stage IV
846638|NCT02864992|c-Met
846639|NCT02864992|cMET
846640|NCT02864992|NSCLC
846641|NCT02864992|advanced non-small cell lung cancer
846642|NCT02864966|Safety study
846643|NCT02864966|new product
846644|NCT02864966|normal healthy skin.
846645|NCT02864940|Memory
846646|NCT02864940|aneurysm
846647|NCT02864940|deficits
846648|NCT02864940|trouble
846649|NCT02864940|forgetful
846650|NCT02864940|ruptured
846651|NCT02864940|subarachnoid
846652|NCT02864940|hemorrhage
846658|NCT02864888|Diffuse, intrinsic brain stem glioma
846659|NCT02864888|QT/QTc interval
846660|NCT02864888|Radiation
846661|NCT02864888|Antineoplaston therapy
846662|NCT02864875|Fibrinogen
846663|NCT02864875|Tromboelastography
846664|NCT02864849|Rectal cancer
846665|NCT02864849|neoadjuvant
846666|NCT02864849|radiotherapy
846667|NCT02864849|chemotherapy
846668|NCT02864849|toxicity
846669|NCT02864836|Copper
846670|NCT02864836|isotopic distribution
846671|NCT02864836|cancer
846672|NCT02864823|Scleromalacia perforans
846673|NCT02864823|Necrotizing Scleritis
846674|NCT02864823|Perichondrium
846675|NCT02864797|Health related quality of life
846676|NCT02864797|patient reported outcomes
846677|NCT02864797|cohort
846678|NCT02864797|e-health
846679|NCT02864771|Ventricular Arrhythmias
846680|NCT02864771|ICD
846681|NCT02864771|Biological markers
846682|NCT02864745|early rehabilitation
846683|NCT02864745|critically ill
846684|NCT02864745|muscle weakness
846685|NCT02864745|neuromuscular stimulation
846686|NCT02864745|functional electrical stimulation-assisted cycle ergometry
846687|NCT02864745|ICUAW
846688|NCT02864732|Low back pain
846689|NCT02864732|stabilization exercises
846690|NCT02864732|neuromuscular electrical stimulation
846691|NCT02864719|Heart arrest
846692|NCT02864719|Cardiac arrest
846693|NCT02864719|Fatigue
846694|NCT02864693|Microprocessor Controlled Ankle
846695|NCT02864693|Transtibial Amputee
846696|NCT02864693|Pacifica LP
846697|NCT02864693|Kinnex
846698|NCT02864680|cannabis
846699|NCT02864680|magnocellular pathway
846700|NCT02864654|Critical lower limb ischemia
846701|NCT02864654|Atherosclerosis obliterans
846702|NCT02864654|Diabetic angiopathies
846703|NCT02864654|Thromboangiitis obliterans
846704|NCT02864654|Ischemic ulcers
846705|NCT02864654|Peripheral arterial disease
846706|NCT02864654|Indirect revascularisation
846707|NCT02864654|Intramuscular injection
846708|NCT02864654|Ankle-brachial index
846709|NCT02864654|Transcutaneous oxygen tension
846710|NCT02864654|Stromal vascular fraction (SVF)
846711|NCT02864654|Adipose-derived regenerative cells (ADRC)
846712|NCT02864654|Adipose tissue
846713|NCT02864654|Stem cells
846714|NCT02864641|chronic kidney disease
846715|NCT02864641|adolescents
846716|NCT02864641|renal disease
846717|NCT02864641|CKD
846718|NCT02864628|RSV Vaccines
846719|NCT02864628|Respiratory Syncytial Virus Vaccines
846720|NCT02864615|renal cell carcinoma
846721|NCT02864615|metastasis
846722|NCT02864615|stereotactic body radiation therapy
846723|NCT02864615|targted therapy
846724|NCT02864615|immune checkpoint inhibitors
846725|NCT02864602|Regional anesthesia
846726|NCT02864602|Adjuvant
846727|NCT02864602|Dexamethasone
846728|NCT02864589|Tourette, Tic, Tics
846729|NCT02864550|Men who have sex with men
846730|NCT02864550|Human immunodeficiency virus
846731|NCT02864550|Doxycycline
846732|NCT02864550|Tetracycline
846733|NCT02864537|warfarin
846734|NCT02864537|self-management
846735|NCT02864537|Conventional management
846736|NCT02864537|Training
846737|NCT02864537|TTR
846738|NCT02864537|Complications
846739|NCT02864537|Quality of life
846743|NCT02864485|Live donor liver transplantation
846744|NCT02864459|Ultrasonography
846745|NCT02864459|Weaning
846746|NCT02864433|cholera
846747|NCT02864433|oral cholera vaccine
846748|NCT02864433|diarrhea
846749|NCT02864420|home hospital
846750|NCT02864420|acute care home
846751|NCT02864420|care redesign
846752|NCT02864420|delivery innovation
846753|NCT02864420|heart failure
846754|NCT02864420|pneumonia
846755|NCT02864420|cellulitis
846756|NCT02864420|urinary tract infections
846757|NCT02864342|chronic obstructive pulmonary disease
846758|NCT02864342|COPD
846759|NCT02864342|Respiratory
846760|NCT02864342|adherence
846761|NCT02864342|medication reminders
846762|NCT02864329|Male Infertility
846763|NCT02864329|micro RNAs
846764|NCT02864329|small interfering RNAs
846765|NCT02864329|miRNA
846766|NCT02864329|siRNA
846767|NCT02864316|radiation-induced solid tumors
846768|NCT02864316|Nivolumab
846769|NCT02864316|Phase 2 study
846770|NCT02864303|Alzheimer's disease
846771|NCT02864303|Mild Cognitive Impairment
846772|NCT02864303|Saliva
846773|NCT02864303|Amyloid peptides
846774|NCT02864303|Diagnosis
846775|NCT02864290|Pharmacokinetics of AGS62P1
846776|NCT02864290|AGS62P1
846777|NCT02864290|AML
846778|NCT02864290|Acute Myeloid Leukemia
846779|NCT02864277|Gynecology
846780|NCT02864277|Cancer
846781|NCT02864277|General Surgery
846782|NCT02864277|Recovery Quality
846783|NCT02864277|Length of hospital stay
846784|NCT02864238|electronic milestone pathway
846785|NCT02864238|cardiac valve surgery
846786|NCT02864186|Pain
846787|NCT02864186|Quality of life
846788|NCT02864186|wound healing
846789|NCT02864173|Postoperative cognitive dysfunction
846790|NCT02864173|Postoperative cognitive decline
846791|NCT02864173|Postoperative delirium
846792|NCT02864173|Cognitive outcome
846793|NCT02864173|Neuropsychology
846794|NCT02864173|Genetics
846795|NCT02864160|Language Concordance
846796|NCT02864160|Diabetes Self-Management
846797|NCT02864160|Health Coaching
846798|NCT02864160|Latinos
846799|NCT02864134|Optic neuritis
846800|NCT02864134|ganglion cell layer
846801|NCT02864121|High-risk human papillomavirus
846802|NCT02864121|Integration of HR-HPV DNA
846803|NCT02864121|biomarker of severity
846804|NCT02864121|biomarker of evolution
846805|NCT02864095|Arthroplasty, Replacement, Hip
846806|NCT02864095|Epinephrine
846807|NCT02864095|Tranexamic acid
846808|NCT02864082|X-linked, lamellar
846809|NCT02864043|Barrett's Esophagus
846810|NCT02864043|Barrett's
846811|NCT02864043|OCT
846812|NCT02864043|VLE
846813|NCT02864030|Eribulin mesylate
846814|NCT02864030|Halaven
846815|NCT02864030|Polymorphisms
846816|NCT02864030|Tolerability
846817|NCT02864004|Parkinson disease
846818|NCT02864004|Quality of Life
846819|NCT02864004|Apomorphine infusion
846820|NCT02863978|Sepsis
846821|NCT02863978|Neonates
846822|NCT02863978|Cardio-respiratory maturation
846823|NCT02863978|Neurobehavioral maturation
846824|NCT02863926|BKA
846825|NCT02863926|amputation
846826|NCT02863926|MarrowStim
846827|NCT02863926|below knee amputation
846828|NCT02863926|wound complication
846829|NCT02863926|vascular disease
846830|NCT02863926|critical limb ischemia
846831|NCT02863926|peripheral artery disease
846832|NCT02863926|AKA
846833|NCT02863926|stem cells
846834|NCT02863926|bone marrow
846835|NCT02863887|Weight Loss
846836|NCT02863887|African American
846837|NCT02863887|Community Based
846838|NCT02863887|Mobile technology
846839|NCT02863887|Translational science
846840|NCT02863874|Perineal tear
846841|NCT02863874|Labor
846842|NCT02863874|Triclosan
846843|NCT02863861|Sedation
846844|NCT02863861|Pediatric Patients
846845|NCT02863822|Functional Dyspepsia
846846|NCT02863822|Low FODMAP
846847|NCT02863822|Dietary Modification
846848|NCT02863809|Keratolysis
846849|NCT02863809|Corneal Melting
846850|NCT02863809|Boston KPro
846851|NCT02863809|Keratoprosthesis
846852|NCT02863770|endosonography
846853|NCT02863744|mmp-8
846854|NCT02863744|early stages of wound healing
846855|NCT02863744|wound healing marker
846856|NCT02863731|postural changes
846857|NCT02863731|alternating postures
846858|NCT02863731|Cognitive performance
846859|NCT02863731|Height-adjustable desk
846860|NCT02863731|Worksite
846861|NCT02863718|CLL
846862|NCT02863692|CLL
846863|NCT02863692|B-PLL
846864|NCT02863692|T-PLL
846865|NCT02863692|SLL
846866|NCT02863692|T-NK-LGL
846867|NCT02863692|HCL
846868|NCT02863692|Richter´s Transformation
846869|NCT02863679|tetracaine hydrochloride gel
846870|NCT02863679|analgesia
846871|NCT02863679|intrauterine balloon
846872|NCT02863679|hysteroscope operation
846873|NCT02863666|Cariopulmonary, cardiac arrest
846874|NCT02863653|social participation
846875|NCT02863653|International Classification of Functioning
846876|NCT02863640|Senile macular degeneration
846877|NCT02863640|Parkinson's disease
846878|NCT02863627|Emergencies
846879|NCT02863627|newborn
846880|NCT02863627|care
846881|NCT02863601|Buprenorphine
846882|NCT02863601|Opiate Substitution Treatment
846887|NCT02863536|Recurrence of Bacterial Vaginosis
846888|NCT02863510|Carbon dioxide angiography
846889|NCT02863510|Renal sympathetic denervation
846890|NCT02863510|Uncontrolled hypertension
846891|NCT02863510|Chronic kidney disease
846892|NCT02863471|Pancreas
846893|NCT02863471|Adenocarcinoma
846894|NCT02863471|Hyperthermic intraperitoneal chemotherapy
846895|NCT02863471|HIPEC
846896|NCT02863471|Pancreatic surgery
846897|NCT02863471|Gemcitabine
846898|NCT02863458|MDS
846899|NCT02863458|AML
846900|NCT02863458|hypomethylating agents (HMA)
846901|NCT02863458|Surveillance Epidemiology and End Results (SEER)
846902|NCT02863445|Obesity
846903|NCT02863445|Body weight
846904|NCT02863445|Emergency contraception
846905|NCT02863445|Levonogestrel
846906|NCT02863445|Ulipristal acetate
846907|NCT02862392|Scoliosis
846908|NCT02862392|Adolescent
846909|NCT02862392|Idiopathic scoliosis
846910|NCT02862392|Predictive factors
846911|NCT02862366|myeloproliferative neoplasms
846912|NCT02862366|Circulating Procoagulants Microparticles
846913|NCT02862353|Validation new test
846914|NCT02862327|anaesthetic techniques
846915|NCT02862327|regional anesthesia
846916|NCT02862327|brachial plexus block
846917|NCT02862327|Local Anesthetic
846918|NCT02862327|ropivacaine
846919|NCT02862327|analgesia
846920|NCT02862327|steroid
846921|NCT02862327|dexamethasone
846922|NCT02862327|placebo
846923|NCT02862327|adjuvant
846924|NCT02862327|ultrasound guided
846925|NCT02862314|Procalcitonin
846926|NCT02862301|Histone Deacetylases
846927|NCT02862301|Histone Acetyltransferases
846928|NCT02862223|Coagulation
846929|NCT02862223|Circulatory Function
846930|NCT02862223|Blood Pressure
846931|NCT02862223|Inflammatory response
846932|NCT02862223|Blood Glucose
846933|NCT02862223|Healthy vascular function
846934|NCT02862210|Lithium
846935|NCT02862210|Lithium Carbonate
846936|NCT02863406|Dust rate
846937|NCT02863406|Microscopic analysis
846938|NCT02863380|Individualized Medicine
846939|NCT02863380|Transcranial Magnetic Stimulation, Repetitive
846940|NCT02863380|Transcranial Direct Current Stimulation Monocentric
846941|NCT02863380|Compariative Cross-Over 3 Arms Study Randomized, Single-Blind Method
846942|NCT02863380|Functional Neuroimaging
846943|NCT02863302|Acute Myeloid Leukemia, Reflexology
846944|NCT02863263|foam dressing
846945|NCT02863263|MedifoamⓇ
846946|NCT02863263|BetafoamⓇ
846947|NCT02863263|povidone iodine
846948|NCT02863237|brain injury
846949|NCT02863237|mechanical ventilation
846950|NCT02863237|weaning
846951|NCT02863198|unexplained infertility
846952|NCT02863198|endometrial injury
846953|NCT02863198|pregnancy
846954|NCT02863185|chronic kidney disease
846955|NCT02863185|pitavastatin
846956|NCT02863185|erythrocyte membrane fatty acid
846957|NCT02863172|Hereditary colorectal cancer syndrome
846958|NCT02863172|Questionnaires
846959|NCT02863172|Surveys
846960|NCT02863172|Blood sample
846961|NCT02863172|Saliva sample
846962|NCT02863146|locally advanced breast cancer
846963|NCT02863146|alopecia
846964|NCT02863146|eribulin
846965|NCT02863120|Bupivacaine
846966|NCT02863120|Osteoarthritis
846967|NCT02863120|Arthritis
846968|NCT02863120|Joint Diseases
846969|NCT02863120|Ropivacaine
846970|NCT02863120|Anesthetics, Local
846971|NCT02863120|Anesthetics
846972|NCT02863107|Colon Cancer
846973|NCT02863107|Rectal Cancer
846974|NCT02863107|Questionnaires
846975|NCT02863107|Surveys
846976|NCT02863107|Blood draw
846977|NCT02863094|schizophrenia
846978|NCT02863094|auditory hallucinations
846979|NCT02863094|functional magnetic resonance imaging
846980|NCT02863094|transcranial magnetic stimulation
846981|NCT02863068|Sickle cell disease
846982|NCT02863068|sodium nitrite
846983|NCT02863068|wound healing
846984|NCT02863068|Ulcer
846985|NCT02863055|MPM
846986|NCT02863055|Unresectable
846987|NCT02863055|Phase II
846988|NCT02863055|Randomized
846989|NCT02863055|Maintenance
846990|NCT02863029|Intestinal stem cells
846991|NCT02863016|dialysis
846992|NCT02863016|hemodiafiltration
846993|NCT02862990|Breast cancer
846994|NCT02862990|Fertility
846995|NCT02862964|back pain
846996|NCT02862951|pregnancy
846997|NCT02862925|fetal monitoring
846998|NCT02862925|cesarean delivery
846999|NCT02862925|obstetrics
847000|NCT02862925|midwifery
847001|NCT02862925|developing countries
847002|NCT02862912|Chloroprocaine
847003|NCT02862912|cervical cerclage
847004|NCT02862912|spinal anesthesia
847005|NCT02862912|Bupivacaine
847006|NCT02862873|Spinal anaesthesia
847007|NCT02862821|biomarkers of psychiatric disorder
847008|NCT02862821|gambling addiction
847009|NCT02862821|high resolution-ElectroEncephaloGraphy (HR-EEG)
847010|NCT02862808|Whole exome sequencing
847011|NCT02862808|Molecular diagnostic
847012|NCT02862808|Genetic counselling
847013|NCT02862795|colonoscopy
847014|NCT02862730|diabetes
847015|NCT02862730|closed-loop
847016|NCT02862730|dual hormone
847017|NCT02862730|exercise
847018|NCT02862717|Cost effectiveness
847019|NCT02862717|cost utility
847020|NCT02862717|ESRD
847021|NCT02862717|hemodialysis
847022|NCT02862717|ICER
847023|NCT02862717|Markov model
847024|NCT02862717|peritoneal dialysis
847025|NCT02862691|toothache
847026|NCT02862626|Diabetic children
847027|NCT02862626|Mothers
847028|NCT02862613|Precision Cells
847029|NCT02862613|Transcatheter Arterial Chemoembolization
847030|NCT02862613|Advanced Liver Cancer
847031|NCT02862600|hypertrophic cardiomyopathy
847032|NCT02862600|hypertrophic
847033|NCT02862600|cardiomyopathy
847034|NCT02862600|familial hypertrophic cardiomyopathy
847035|NCT02862600|heart failure
847036|NCT02862600|cardiopulmonary exercise testing
847037|NCT02862600|6 minute walk test
847038|NCT02862600|perhexiline
847039|NCT02862600|carnitine palmitoyltransferase
847040|NCT02862600|carbohydrate utilization
847041|NCT02862600|coronary ischemia
847042|NCT02862600|angina
847043|NCT02862600|mixed ion channel effects
847044|NCT02862600|late sodium current inhibitor
847045|NCT02862600|calcium channel inhibition
847046|NCT02862587|Precision Cells
847047|NCT02862587|Chemotherapy
847048|NCT02862587|Advanced Lung Cancer
847049|NCT02862574|Rheumatoid Arthritis
847050|NCT02862574|Tumor Necrosis Factor Inhibitor
847051|NCT02862574|TNF-IR
847052|NCT02862574|Methotrexate
847053|NCT02862561|Precision Cell Immunotherapy
847054|NCT02862561|Chemotherapy
847055|NCT02862561|Advanced Malignancies
847056|NCT02862522|uric acid
847057|NCT02862522|microvascular dysfunction
847058|NCT02862522|inflammation
847059|NCT02862509|Post-frontal sinus operation chronic rhinosinusitis patients
847060|NCT02862509|Budesonide nasal instillation
847061|NCT02862509|Vertex to floor position
847062|NCT02862496|Hyperemesis Gravidarum
847063|NCT02862496|Bone Health
847064|NCT02862496|Urine N-telopeptide
847065|NCT02862496|Serum calcium
847066|NCT02862496|Serum parathormone
847067|NCT02862496|Serum vit D
847068|NCT02862470|Lovastatin
847069|NCT02862470|Vildagliptin
847070|NCT02862470|Exosome
847071|NCT02862470|Anaplastic thyroid cancer
847072|NCT02862470|Proteomics
847073|NCT02862470|Urine
847074|NCT02862470|Biological marker
847075|NCT02862457|Advanced Solid Tumors
847076|NCT02862418|MRI
847077|NCT02862418|UTE MRI
847078|NCT02862418|Pulmonary
847079|NCT02862405|Vision loss
847080|NCT02862405|Object recognition
847081|NCT02862405|Space recognition
847082|NCT02862145|Biosy accessible melanoma
847083|NCT02862132|VDZ: Vedolizumab
847084|NCT02862132|UC: Ulcerative colitis
847085|NCT02862132|CD: Crohn's disease
847086|NCT02862132|TDM: Therapeutic drug monitoring
847087|NCT02862119|percutaneous coronary intervention
847088|NCT02862119|fractional flow reserve
847089|NCT02862119|all cause mortality
847090|NCT02862119|myocardial infarction
847091|NCT02862119|registry-based randomized clinical trial
847092|NCT02862106|Chronic Hepatitis B
847093|NCT02862106|HBeAg positive
847094|NCT02862106|Therapeutic HBV Vaccine
847095|NCT02862106|HBV-specific Cytotoxic T Lymphocyte
847096|NCT02862067|SGLT2
847097|NCT02862067|type 2 diabetes mellitus
847098|NCT02862067|systolic heart failure
847099|NCT02862067|heart failure with reduced ejection fraction
847100|NCT02862054|haemophagocytic lymphohistiocytosis
847101|NCT02862054|splenectomy
847102|NCT02862054|unknown etiology
847103|NCT02862028|PD-1 antibody
847104|NCT02862028|CAR-T cells
847105|NCT02862028|EGFR family
847106|NCT02862028|advanced solid tumor
847107|NCT02862002|opioid therapy
847108|NCT02862002|medical oncology.
847109|NCT02861989|osteoporosis
847110|NCT02861989|prevention
847111|NCT02861989|care management
847112|NCT02861989|focus groups
847113|NCT02861963|Femoral Allogenic Vein Valve Conduit
847114|NCT02861963|Rehabilitation of native pulmonary arteries
847115|NCT02861950|hypospadias
847116|NCT02861950|caudal
847117|NCT02861950|urethrocutaneous fistula
847118|NCT02861950|penile nerve block
847119|NCT02861911|Muscle function
847120|NCT02861911|Oxidative stress
847121|NCT02861911|Quality of life
847122|NCT02861911|Physical activities
847123|NCT02861898|EGFR
847124|NCT02861898|Epidermal Growth Factor Receptor
847125|NCT02861898|EGFRvIII
847126|NCT02861885|Colonoscopy
847127|NCT02861885|sessile serrated lesions
847128|NCT02861885|chromoendoscopy
847129|NCT02861885|narrow band imaging
847130|NCT02861885|Indigo Carmin®
847131|NCT02861885|Pit pattern
847132|NCT02861885|Kudo classification
847133|NCT02861885|NICE classification
847134|NCT02861885|neoplasms by histologic type
847135|NCT02861872|Ovarian
847136|NCT02861872|Ovarian cancer
847137|NCT02861872|Chemotherapy
847138|NCT02861872|Intraperitoneal chemotherapy
847139|NCT02861872|pharmacokinetics
847140|NCT02861859|Breast cancer
847141|NCT02861859|Breast Carcinoma
847142|NCT02861859|Breast Tumors
847143|NCT02861859|Chemotherapy
847144|NCT02861859|Antiemetic effects
847145|NCT02861859|Antiemetic drugs
847146|NCT02861859|Drug Therapy
847147|NCT02861846|epilepsy
847148|NCT02861846|Alzheimer
847149|NCT02861846|biomarkers
847150|NCT02861846|predictive value
847151|NCT02861820|fMRI
847152|NCT02861820|brain networks
847153|NCT02861820|biomarker
847154|NCT02861820|relapse
847155|NCT02861820|stimulants
847156|NCT02861794|Total Knee Arthroplasty (TKA)
847157|NCT02861794|Total Knee Replacement (TKR)
847158|NCT02861794|Kinematics
847159|NCT02861794|RSA
847160|NCT02861794|Knee arthroplasty
847161|NCT02861794|Implant stability
847162|NCT02861781|Bariatric surgery
847163|NCT02861755|Depression
847164|NCT02861755|Depressive Disorder
847165|NCT02861755|Psychological Stress
847166|NCT02861755|Behavioral Symptoms
847167|NCT02861755|Mental Disorders
847168|NCT02861755|Mood Disorders
847169|NCT02861729|Partial coverage restoration
847170|NCT02861729|Crown
847171|NCT02861729|Posterior teeth
847172|NCT02861729|All ceramic
847173|NCT02861729|Zirconia reinforced lithium silicate
847174|NCT02861729|Lithium disilicate
847175|NCT02861729|CAD/CAM
847176|NCT02861690|Esophageal Cancer
847177|NCT02861690|nedaplatin
847178|NCT02861690|Liposomal Paclitaxel
847179|NCT02861638|Total hip replacement
847180|NCT02861638|Action observation treatment
847181|NCT02861638|Rehabilitation
847182|NCT02861638|Arthroplasty
847183|NCT02861612|peripheral nerves
847184|NCT02861612|quadriplegia
847185|NCT02861612|nerve transfer
847186|NCT02861612|surgical procedures, operative
847187|NCT02861612|hand
847188|NCT02861612|upper extremity
847189|NCT02861612|quality of life
847190|NCT02861586|Chikungunya, infectious disease
847197|NCT02861508|Ultrasonography
847198|NCT02861495|upper extremity fracture
847199|NCT02861482|PPH, Bakri Ballon
847200|NCT02861469|qualitative study, end of life, ethics, palliative care
847201|NCT02861456|Adolescent
847202|NCT02861456|Low Back Pain
847203|NCT02861456|Athlete
847204|NCT02861430|colon cancer
847205|NCT02861430|sentinel node
847206|NCT02861417|Other diseases of blood and blood-forming organs
847207|NCT02861417|Acute myeloid leukemia
847208|NCT02861417|AML
847209|NCT02861417|Acute lymphocytic leukemia
847210|NCT02861417|ALL
847211|NCT02861417|Chronic myeloid leukemia
847212|NCT02861417|CML
847213|NCT02861417|Chronic lymphocytic leukemia
847214|NCT02861417|CLL
847215|NCT02861417|Myelodysplastic syndrome
847216|NCT02861417|MDS
847217|NCT02861417|Myeloproliferative syndrome
847218|NCT02861417|Non-Hodgkins lymphoma
847219|NCT02861417|NHL
847220|NCT02861417|Hodgkins lymphoma
847221|NCT02861417|HL
847222|NCT02861417|Multiple myeloma
847223|NCT02861417|MM
847224|NCT02861417|Stem cell infusion
847225|NCT02861417|Stem cell transplant
847226|NCT02861417|Haploidentical donor
847227|NCT02861417|Matched donor
847228|NCT02861417|Thiotepa
847229|NCT02861417|Mycophenolate Mofetil
847230|NCT02861417|MMF
847231|NCT02861417|CellCept
847232|NCT02861417|Busulfan
847233|NCT02861417|Busulfex
847234|NCT02861417|Myleran
847235|NCT02861417|Fludarabine
847236|NCT02861417|Fludarabine phosphate
847237|NCT02861417|Fludara
847238|NCT02861417|Mesna
847239|NCT02861417|Mesnex
847240|NCT02861417|Cyclophosphamide
847241|NCT02861417|Cytoxan
847242|NCT02861417|Neosar
847243|NCT02861417|Tacrolimus
847244|NCT02861417|Prograf
847245|NCT02861417|G-CSF
847246|NCT02861417|Filgrastim
847247|NCT02861417|Neupogen
847248|NCT02861404|HPV
847249|NCT02861378|anaesthesia, dental
847250|NCT02861378|lidocaine
847251|NCT02861352|Zinc
847252|NCT02861352|DNA Integrity
847253|NCT02861352|Gene Expression
847254|NCT02861352|diet zinc
847255|NCT02861352|nutrition requirements
847256|NCT02861326|chronic periodontitis, dental scaling, periodontal pockets
847257|NCT02861300|CB-839
847258|NCT02861300|PIK3CA
847259|NCT02861300|capecitabine
847260|NCT02861248|Burn Scar
847261|NCT02861248|Micro-plasma Radiofrequency Therapy
847262|NCT02861183|sodium hyaluronate
847263|NCT02861183|OVT
847264|NCT02861183|hyaluronic acid
847265|NCT02861170|Mindfulness
847266|NCT02861170|Chronic Pain
847267|NCT02861170|Chronic Hip Pain
847268|NCT02861170|Total Hip Arthroplasty
847269|NCT02861170|Disability
847270|NCT02861170|Quality of Life
847271|NCT02861157|Type 1 Diabetes
847272|NCT02861157|Adolescents
847273|NCT02861157|T1D
847274|NCT02861131|Sugammadex
847275|NCT02861131|Neuromuscular Blockade
847276|NCT02861118|Drug Therapy
847277|NCT02861092|Serious adverse event
847278|NCT02861092|bone and joint infection
847279|NCT02861092|obesity
847280|NCT02861092|dose adjustment
847281|NCT02861066|Mindfulness-based Intervention
847282|NCT02861066|Wellbeing
847283|NCT02861066|Treatment
847284|NCT02861027|Osteoarthritis
847285|NCT02861027|Total hip arthroplasty
847286|NCT02861027|Physiotherapy
847287|NCT02861027|Functional Electrical Stimulation
847288|NCT02861001|tracheotomy
847289|NCT02861001|bronchoscopy
847290|NCT02861001|critical care
847291|NCT02860975|Prolonged Hypoxia
847292|NCT02860975|Safety
847293|NCT02860975|Mitochondrial function
847294|NCT02860949|Local anesthetic infiltration
847295|NCT02860949|Posterior capsular infiltration
847296|NCT02860949|Multimodal anesthesia
847297|NCT02860949|Knee arthroplasty
847298|NCT02860949|Pain control
847299|NCT02860949|Osteoarthritis, Knee
847300|NCT02860923|glucagon-like peptide-1
847301|NCT02860923|exenatide
847302|NCT02860923|placebo
847303|NCT02860923|multicenter trial
847304|NCT02860910|hot flashes
847305|NCT02860910|postmenopause
847306|NCT02860910|perimenopause
847307|NCT02860832|Cyberbullying
847308|NCT02860832|Traditional bullying
847309|NCT02860832|Depression
847310|NCT02860819|Multiple relapsed/refractory testicular germ cell tumors
847311|NCT02860819|PARP inhibition
847312|NCT02860819|Chemotherapy
847313|NCT02860819|Gemcitabine
847314|NCT02860819|Carboplatin
847315|NCT02860793|PTK7
847316|NCT02860793|Acute Myeloid Leukemia
847317|NCT02860767|Prosthesis-Related Infections
847318|NCT02860767|Antibiotic dosing
847319|NCT02860767|Reimplantation
847320|NCT02860767|Knee-prothesis
847321|NCT02860767|Hip-prothesis
847322|NCT02860741|Sub-Clinical Depression
847323|NCT02860728|COPD
847324|NCT02860728|Resistance Training
847325|NCT02860728|Exercise Training
847326|NCT02860728|Dyspnea
847327|NCT02860715|Safety
847328|NCT02860715|Pharmacodynamics
847329|NCT02860715|Dose-Limiting Toxicity (DLT)
847330|NCT02860715|Immunogenicity
847331|NCT02860715|Pharmacokinetics
847332|NCT02860702|Single Ventricle
847333|NCT02860702|Congenital Heart Defect
847334|NCT02860689|Sexuality
847335|NCT02860689|Spinal cord injuries
847336|NCT02860689|Penile erection
847337|NCT02860689|erectile dysfunction
847338|NCT02860689|Psychological Sexual Dysfunctions
847339|NCT02860676|CLL
847340|NCT02860676|cancer
847341|NCT02860676|UC-961
847342|NCT02860676|cirmtuzumab
847343|NCT02860637|Sexuality
847344|NCT02860637|Spinal cord injuries
847345|NCT02860637|Penile erection
847346|NCT02860637|erectile dysfunction
847347|NCT02860624|GERD
847348|NCT02860611|Type 1 diabetes
847349|NCT02860611|Type 2 diabetes
847350|NCT02860611|T helper 1 cytokines
847351|NCT02860598|ESAs
847352|NCT02860598|erythropoietin
847353|NCT02860598|AML
847354|NCT02860598|HSCT
847355|NCT02860585|Metastatic breast cancer
847356|NCT02860585|high-dose chemotherapy
847357|NCT02860585|autologous haematopoietic progenitor cell transplantation
847358|NCT02860572|fluid therapy
847359|NCT02860572|oliguria
847360|NCT02860572|endothelial injury
847361|NCT02860559|Hematopoietic Stem Cell Transplantation
847362|NCT02860559|Severe Combined Immunodeficiency
847363|NCT02860546|Refractory
847364|NCT02860546|Metastatic
847365|NCT02860546|Colorectal cancer
847366|NCT02860546|TAS-102
847367|NCT02860546|Nivolumab
847368|NCT02860546|Microsatellite Stable
847369|NCT02860546|Programmed cell death protein1 (PD 1)
847370|NCT02860533|Blood pressure
847371|NCT02860533|smartphone App
847372|NCT02860533|Hypertension
847373|NCT02860533|Stress testing
847374|NCT02860533|Prevention
847375|NCT02860533|Cardiovascular risk factors
847376|NCT02860520|Retinitis pigmentosa:
847377|NCT02860494|Tuberous sclerosis complex (TSC)
847378|NCT02860494|topical everolimus
847379|NCT02860494|seamless design
847380|NCT02860494|dose-escalation study
847381|NCT02860494|m-TOR inhibitor
847382|NCT02860455|CO poisoning
847383|NCT02860455|CO-oximetry
847384|NCT02860455|Pulse oximetry
847385|NCT02860455|Carbon monoxide saturation (SpCO)
847386|NCT02860455|Emergency Department
847387|NCT02860455|Sensitivity
847388|NCT02860455|Specificity
847389|NCT02860442|Alcohol misuse
847390|NCT02860442|Smartphone app
847391|NCT02860442|Screening, Brief Intervention, Referral to Treatment (SBIRT)
847392|NCT02860416|Neurology
847393|NCT02860403|Cervical spinal cord injury
847394|NCT02860403|Motor imagery
847395|NCT02860403|Magnetoencephalography
847396|NCT02860377|emergence agitation
847397|NCT02860377|emergence time
847398|NCT02860377|pediatric
847399|NCT02860351|subclavian vein
847400|NCT02860338|Psuedobulbar affect, PBA
847401|NCT02860299|patients
847402|NCT02860273|Pulmonary Rehabilitation
847403|NCT02860273|COPD
847404|NCT02860273|High Flow Nasal Cannula
847405|NCT02860273|HFNC
847406|NCT02860273|Aerobic capacity
847407|NCT02860260|BDNF
847408|NCT02860247|antibiotic
847409|NCT02860247|MALDI-TOF MS
847410|NCT02860247|susceptibility testing
847411|NCT02860234|Rectal cancer
847412|NCT02860234|neoadjuvant
847413|NCT02860234|radiotherapy
847414|NCT02860234|chemotherapy
847415|NCT02860234|organ preservation
847416|NCT02860221|Arthroplasty, Replacement, Knee
847417|NCT02860221|Epinephrine
847418|NCT02860221|Tranexamic acid
847419|NCT02860208|Peri-Implantitis
847420|NCT02860208|Surgical therapy
847421|NCT02860208|Follow-up
847422|NCT02860208|Supportive peri-implant therapy
847423|NCT02860130|Regional Citrate Anticoagulation (RCA)
847424|NCT02860130|Continuous Renal Replacement Therapy (CRRT)
847425|NCT02860130|Acute Kidney Injury
847426|NCT02860117|ketamine
847427|NCT02860117|continuous infusion
847428|NCT02860117|severe burned patients
847429|NCT02860104|microwave ablation
847430|NCT02860104|breast
847431|NCT02860104|multicenter
847432|NCT02860091|ropivacaine infusion
847433|NCT02860091|regional anesthesia
847434|NCT02860091|paravertebral block
847435|NCT02860078|pain
847436|NCT02860078|epidural
847437|NCT02860078|ultrasound
847438|NCT02860013|Telemedicine
847439|NCT02860013|Effectiveness
847440|NCT02860013|Cost-effectiveness
847441|NCT02859987|US
847442|NCT02859987|Nursing Services
847443|NCT02859974|Paradoxical vocal fold motion disorder (PVFMD)
847444|NCT02859974|vocal cord dysfunction (VCD)
847445|NCT02859974|Respiratory retraining
847446|NCT02859974|Respiratory disorders
847447|NCT02859948|AML
847448|NCT02859935|HIV
847449|NCT02859935|drug abuse
847450|NCT02859935|MSM
847451|NCT02859935|Risk behavior
847452|NCT02859935|Sexually transmitted diseases
847453|NCT02859935|Sexually transmitted infections
847454|NCT02859922|Laryngeal Tube Supreme Spontaneous Ventilation
847455|NCT02859857|Glioblastoma Multiforme, Solid Tumors
847456|NCT02859727|APDS; PASLI; PI3Kdelta; p110delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency; Activated PI3Kdelta Syndrome;
847457|NCT02859662|abdominal compartment syndrome
847458|NCT02859662|abdominal aortic aneurysm
847459|NCT02859662|ruptured aneurysm
847460|NCT02859649|working memory
847461|NCT02859649|short term memory
847462|NCT02859649|gesture
847463|NCT02859584|Acute hepatitis
847464|NCT02859584|acute liver failure
847465|NCT02859584|adrenal dysfunction
847466|NCT02859584|salivary cortisol
847467|NCT02859584|serum free cortisol
847468|NCT02859545|chronic pain
847469|NCT02859545|pain
847470|NCT02859545|validation
847471|NCT02859545|couples
847472|NCT02859545|romantic relationships
847473|NCT02859545|emotional validation
847474|NCT02859532|blood coagulation
847475|NCT02859532|Endogenous Thrombin Potential
847476|NCT02859532|rotational thromboelastometry
847477|NCT02859480|Rosuvastatin Calcium
847478|NCT02859480|Percutaneous Coronary Intervention
847479|NCT02859480|Drug-Eluting Stents
847480|NCT02859480|Patient Outcome Assessment
847481|NCT02859480|Biomarkers
847482|NCT02859480|Hyperlipidemias
847483|NCT02859480|Dyslipidemias
847484|NCT02859480|Atherosclerosis
847485|NCT02859480|Hydroxymethylglutaryl-CoA Reductase Inhibitors
847486|NCT02859480|Anticholesteremic Agents
847487|NCT02859480|Hypolipidemic Agents
847488|NCT02859480|Lipid Regulating Agents
847493|NCT02859454|PD-L1 Expression
847494|NCT02859454|Human Papilloma Virus (HPV)
847495|NCT02859454|Juvenile-onset Disease
847496|NCT02859454|Papillomatous Lesions
847497|NCT02859454|Monoclonal Antibody
847498|NCT02859441|Intravitreal Injection
847499|NCT02859441|Retinal Capillary Hemangioma
847500|NCT02859428|Hereditary Spastic Paraplegia
847501|NCT02859415|Metastatic Colorectal Cancer
847502|NCT02859415|Metastatic Renal Cell Cancer
847503|NCT02859415|Sarcoma
847504|NCT02859415|ABCB4 Liver Toxicity
847505|NCT02859415|ABCB11 Heptatoxicity
847506|NCT02859402|T-cell Non-Hodgkin Lymphoma
847507|NCT02859402|NK/T-cell Non-Hodgkin Lymphoma
847508|NCT02859402|Relapsed, refractory
847509|NCT02859402|Conditioning
847510|NCT02859402|Allogeneic stem cell transplantation
847511|NCT02859389|Leukemia
847512|NCT02859389|Down Syndrome
847513|NCT02859389|Neurocognitive
847514|NCT02859389|Survivorship
847515|NCT02859389|Attention
847516|NCT02859389|Executive function
847517|NCT02859389|Late effects
847518|NCT02859376|Preterm infants
847519|NCT02859376|Pain
847520|NCT02859376|Sucrose
847521|NCT02859350|Plasmodium falciparum
847522|NCT02859350|PfSPZ Vaccine
847523|NCT02859350|PfSPZ Challenge (NF54)
847524|NCT02859350|CHMI
847525|NCT02859350|Chloroquine
847526|NCT02859350|Chemoprophylaxis
847527|NCT02859350|PfSPZ-CVac
847528|NCT02859337|obesity
847529|NCT02859337|body weight
847530|NCT02859337|BMI
847531|NCT02859337|emergency contraception
847532|NCT02859337|levonorgestrel
847533|NCT02859337|ulipristal acetate
847534|NCT02859324|CC-122
847535|NCT02859324|Nivolumab
847536|NCT02859324|Hepatocellular Carcinoma
847537|NCT02859324|Phase 1/2
847538|NCT02859324|Safety
847539|NCT02859311|Recovery
847540|NCT02859298|Premature Delivery
847541|NCT02859298|Polarimetric Imaging
847542|NCT02859298|Polarimetric colposcope
847543|NCT02859298|Diagnostic tool
847544|NCT02859285|Arousal
847545|NCT02859285|Orgasm
847546|NCT02859285|Clitoral
847547|NCT02859285|Estradiol
847548|NCT02859285|Post Menopausal
847549|NCT02859272|Suspension, benign hysterectomy, post operative prolapse
847550|NCT02859233|Spinal Puncture
847551|NCT02859233|Dural puncture
847552|NCT02859233|Nursing
847553|NCT02859220|hemodialysis
847554|NCT02859220|PTH
847555|NCT02859207|Early Alzheimer's disease
847556|NCT02859207|E2609
847557|NCT02859207|Mild and Moderate Hepatic Impairment
847558|NCT02859181|Increased Metabolic Requirement
847559|NCT02859168|Neck
847560|NCT02859168|Shoulder
847561|NCT02859168|Manual Therapies
847562|NCT02859142|Varenicline
847563|NCT02859129|Epanova
847564|NCT02859129|omega-3 carboxylic acids
847565|NCT02859129|Vascepa
847566|NCT02859129|Eicosapentaenoic acid ethyl ester
847567|NCT02859129|Crestor
847568|NCT02859129|rosuvastatin
847569|NCT02859116|Metabolic diseases
847570|NCT02859077|NSCLC
847571|NCT02859077|BIM
847572|NCT02859077|EGFR mutation
847573|NCT02859064|radioembolization
847574|NCT02859064|somatostatin analogs
847575|NCT02859064|carcinoid
847576|NCT02859064|neuroendocrine
847577|NCT02859064|liver-directed therapy
847578|NCT02859051|Cognitive Behavioral Support provided by Robot
847579|NCT02859025|Alveolar cleft
847580|NCT02859025|Osteoplasty
847581|NCT02859025|Tissue engineering
847582|NCT02859025|Stem cells
847583|NCT02859025|Regenerative medicine
847584|NCT02859025|Bone
847585|NCT02859025|Lateral ramus
847586|NCT02858999|primary plasma cell leukaemia
847587|NCT02858999|treatment
847588|NCT02858960|High Flow Nasal Cannula
847589|NCT02858960|COPD
847590|NCT02858960|Pulmonary rehabilitation
847591|NCT02858960|HFNC
847592|NCT02858960|Oxygen
847593|NCT02858947|composite resin
847594|NCT02858947|bulk-fill
847595|NCT02858947|teeth endodontically-treated
847596|NCT02858934|Short preoperative tomotherapy
847597|NCT02858934|Radiotherapy
847598|NCT02858921|Neoadjuvant Therapy
847599|NCT02858921|Pembrolizumab
847600|NCT02858921|Dabrafenib
847601|NCT02858921|Trametinib
847602|NCT02858921|Pathological response
847603|NCT02858921|RECIST
847604|NCT02858921|Immune response
847605|NCT02858921|BRAF
847606|NCT02858921|Randomised
847607|NCT02858921|Stage IIIB/C
847608|NCT02858921|Biomarkers, Tumour
847609|NCT02858921|Biomarkers, Drug response
847610|NCT02858921|Metabolic Response
847624|NCT02858843|genetics
847625|NCT02858830|FPL
847626|NCT02858830|adipose tissue
847627|NCT02858830|diabetes
847628|NCT02858830|dyslipidemia
847629|NCT02858830|metabolic
847630|NCT02858830|hyperinsulinemia
847631|NCT02858804|mantle cell lymphoma
847632|NCT02858804|EDOCH
847633|NCT02858804|DHAP
847634|NCT02858804|maintenance therapy
847635|NCT02858778|Palliative Care
847636|NCT02858778|Emergency Department
847637|NCT02858752|Attention
847638|NCT02858752|Short-term memory
847639|NCT02858752|Aural Memory
847640|NCT02858752|Visual Memory
847641|NCT02858752|Child
847642|NCT02858752|EEG
847643|NCT02858726|Hemodialysis
847644|NCT02858726|CR845
847645|NCT02858726|Kappa opioid
847646|NCT02858726|Anti-itch
847647|NCT02858713|psoriasis
847648|NCT02858700|neonatal bacterial infection
847649|NCT02858700|procalcitonin
847650|NCT02858635|Suicidal behaviour
847651|NCT02858635|Impulsivity
847652|NCT02858635|Genetics
847653|NCT02858635|Serotonin
847654|NCT02858622|pediatric
847655|NCT02858622|renal transplant
847656|NCT02858622|pain
847657|NCT02858622|dual TAB
847658|NCT02858570|Meningococcal Vaccines
847659|NCT02858570|Immunogenicity, Reactogenicity and Safety of Vaccine
847660|NCT02858544|Mild traumatic brain injury
847661|NCT02858518|anticoagulant
847662|NCT02858492|efficacy
847663|NCT02858492|safety
847664|NCT02858492|pharmacokinetics
847665|NCT02858492|pharmacodynamics
847666|NCT02858492|Rheumatoid Arthritis
847667|NCT02858492|autoimmune
847668|NCT02858453|Interstitial cystitis
847669|NCT02858453|Bladder pain syndrome
847670|NCT02858453|Painful bladder syndrome
847671|NCT02858453|Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
847672|NCT02858453|AQX-1125
847673|NCT02858453|SHIP1
847674|NCT02858453|Chronic interstitial cystitis
847675|NCT02858440|Primary dose
847676|NCT02858440|Reactogenicity
847677|NCT02858440|Immunogenicity
847678|NCT02858440|Booster dose
847679|NCT02858440|Combined vaccine
847680|NCT02858440|Russian Infants
847681|NCT02858440|Infanrix®-IPV/Hib
847682|NCT02858427|cognitive inhibition
847683|NCT02858427|elderly
847684|NCT02858427|suicide attempt
847685|NCT02858427|depression
847686|NCT02858388|Otitis Media with Effusion
847687|NCT02858388|Exudative otitis media
847688|NCT02858375|quality of life
847689|NCT02858375|botulinum toxin
847690|NCT02858375|provoked vulvodynia
847691|NCT02858362|DMD
847692|NCT02858362|Muscular Dystrophy
847693|NCT02858362|Utrophin
847694|NCT02858362|Duchenne
847695|NCT02858362|PhaseOut DMD
847705|NCT02858310|HPV-16
847706|NCT02858310|E7 TCR
847707|NCT02858310|Pembrolizumab
847708|NCT02858310|Immunotherapy
847709|NCT02858310|Reproductive Cancers
847710|NCT02858297|Oral lichen planus
847711|NCT02858297|Glucosamine
847712|NCT02858297|IL-8
847713|NCT02858258|MCL
847714|NCT02858245|MitraClip
847715|NCT02858245|Structural Heart Failure
847716|NCT02858245|Degenerative Mitral Regurgitation (DMR)
847717|NCT02858245|Actigraphy
847718|NCT02858232|MASCT-I
847719|NCT02858232|Solid Tumors
847720|NCT02858219|Botulinum toxin
847721|NCT02858219|Pain improvement
847722|NCT02858206|Locally advanced esophageal cancer
847723|NCT02858206|Radiotherapy and nimotuzumab
847724|NCT02858206|Concurrent chemoradiotherapy
847725|NCT02858154|OSA
847726|NCT02858154|obstructive sleep apnea
847727|NCT02858154|infants
847728|NCT02858154|high flow nasal cannula
847729|NCT02858154|HFNC
847730|NCT02858141|oncogeriatric evaluation
847731|NCT02858141|pancreatic cancer
847732|NCT02858141|Database
847733|NCT02858102|Schizophrenia
847734|NCT02858102|Psychosis
847735|NCT02858102|Obesity
847736|NCT02858102|Neurocognition
847737|NCT02858102|Depression
847738|NCT02858102|Bipolar disorder
847739|NCT02858102|Metabolomics
847740|NCT02858102|Biomarkers
847741|NCT02858102|Hypertension
847742|NCT02858102|Dyslipidemia
847743|NCT02858102|Hyperglycemia
847744|NCT02858102|Hypertriglyceridemia
847745|NCT02858076|Anti-VEGF
847746|NCT02858076|Vitrectomy
847747|NCT02858063|Breast cancer
847748|NCT02858063|Quality Of Life
847749|NCT02858063|Women
847750|NCT02858063|Partner
847751|NCT02858011|behavior change communication
847752|NCT02858011|cash transfer
847753|NCT02858011|household welfare
847754|NCT02858011|child nutrition status
847755|NCT02857985|Myocardial Infarction
847756|NCT02857985|MRI
847757|NCT02857985|rotational angiography
847758|NCT02857972|Menstruation, Female Barrier, Sanitary pads
847759|NCT02857933|cerebral palsy
847760|NCT02857933|motor impairments
847761|NCT02857920|Vascular Endothelial Growth Factor (VEGF) antibody
847762|NCT02857920|solid tumor
847763|NCT02857920|NK Immunotherapy
847764|NCT02857907|Kidney transplantation
847765|NCT02857907|Immunosuppressive treatment
847766|NCT02857894|Polypoidal choroidal vasculopathy
847767|NCT02857881|keratoconus
847768|NCT02857881|photokeratectomy
847769|NCT02857881|de-epithelization
847770|NCT02857868|Hepatic Impairment
847771|NCT02857868|ABL001
847772|NCT02857868|Child-Pugh
847773|NCT02857868|healthy subjects with normal hepatic function
847774|NCT02857855|liver transplantation
847775|NCT02857855|postoperative infection
847776|NCT02857855|biliary complications
847777|NCT02857855|patient survival
847778|NCT02857855|graft survival
847779|NCT02857855|supplemental oxygen
847780|NCT02857829|Cognition
847781|NCT02857829|working memory
847782|NCT02857829|nootropic
847783|NCT02857829|reaction time
847784|NCT02857829|healthy individuals
847785|NCT02857829|cognitive enhancement
847786|NCT02857803|Virtual Reality
847787|NCT02857803|Cognitive Rehabilitation
847788|NCT02857803|Motor Rehabilitation
847789|NCT02857803|Ecological validity
847790|NCT02857803|Personalisation
847791|NCT02857790|Rotablation
847792|NCT02857790|High speed rotational atherectomy
847793|NCT02857790|Type IV myocardial infarction
847794|NCT02857790|Cardiac magnetic resonance imaging
847795|NCT02857790|CMR
847796|NCT02857790|Percutaneous Coronary Intervention
847797|NCT02857751|depression
847798|NCT02857751|PTSD
847799|NCT02857751|anxiety
847800|NCT02857751|surf therapy
847801|NCT02857699|Quality of life
847802|NCT02857699|Phase I trials
847803|NCT02857673|Children with Special Health Care Needs
847804|NCT02857673|Violence Prevention
847805|NCT02857660|Sarcopenia
847806|NCT02857660|Obesity
847807|NCT02857660|Whole-Body Electromyostimulation
847808|NCT02857660|Protein Supplementation
847809|NCT02857660|community dwelling men
847810|NCT02857647|Bariatric surgery
847811|NCT02857647|Anxiety
847812|NCT02857647|Nutrition knowledge
847813|NCT02857647|Weight loss expectations
847814|NCT02857634|Urinary Bladder cancer
847815|NCT02857634|diagnosis
847816|NCT02857634|Cellvizio Dual Band
847817|NCT02857582|Antibiotic-induced diarrhea
847818|NCT02857582|Clostridium-difficile toxin
847819|NCT02857582|Pseudomembranous colitis
847820|NCT02857504|double lumen tube
847821|NCT02857504|hook
847822|NCT02857439|Trauma of the shoulder
847823|NCT02857413|Xerostomia
847824|NCT02857413|Radiotherapy
847825|NCT02857348|decision making
847826|NCT02857348|heuristics
847827|NCT02857283|Air pollution
847828|NCT02857283|Air pollutant exposure
847829|NCT02857283|Ozone
847830|NCT02857270|MAPK
847831|NCT02857270|RAS
847832|NCT02857270|BRAF
847833|NCT02857257|IBS
847834|NCT02857257|Microbiota
847835|NCT02857244|Freezing of Gait
847836|NCT02857231|Bioimpedance spectroscopy
847837|NCT02857205|Hirschsprung Associated EnteroColitis (HAEC)
847838|NCT02857179|bariatric surgery
847839|NCT02857179|follow-up
847840|NCT02857179|weight loss
847841|NCT02857179|complications
847842|NCT02857179|comorbidities evolution
847843|NCT02857166|JS001
847844|NCT02857166|solid tumors
847845|NCT02857153|MAP
847846|NCT02857153|Blood loss
847847|NCT02857153|Postoperative delirium
847848|NCT02857153|Elderly patients
847849|NCT02857153|Noncardiothoracic surgery
847850|NCT02857127|Low income population
847851|NCT02857127|Motor Activity
847852|NCT02857127|Primary Health Care
847853|NCT02857088|depression
847854|NCT02857088|emotional reactivity
847855|NCT02857036|rhythm
847856|NCT02857036|depression
847857|NCT02857036|antidepressant treatment
847858|NCT02857023|Neurocognitive
847859|NCT02857023|Working memory
847860|NCT02857023|Cogmed
847861|NCT02857023|Cognitive training
847862|NCT02856984|Pregnancy
847863|NCT02856984|Infant
847864|NCT02856971|Hinge Knee Prosthesis
847865|NCT02856971|TKA infection
847866|NCT02856971|rotating hinge prosthesis
847867|NCT02856971|hinge knee arthroplasty
847868|NCT02856945|fracture
847869|NCT02856945|children
847870|NCT02856945|knee
847871|NCT02856945|clinical criteria
847872|NCT02856945|decision making
847873|NCT02856906|Orofacial Pain
847874|NCT02856906|Electromyography
847875|NCT02856906|dental occlusion
847876|NCT02856893|AZD9291
847877|NCT02856893|Osimertinib
847878|NCT02856893|Gefitinib
847879|NCT02856893|NSCLC
847880|NCT02856841|epithelial ovarian cancer
847881|NCT02856841|optimum cytoreduction
847882|NCT02856815|Immuncell-LC
847883|NCT02856815|Transarterial Chemoembolization
847884|NCT02856789|Fibrin structure
847885|NCT02856789|Thromboelastography
847886|NCT02856789|Fibrin formation
847887|NCT02856789|Fibrinolysis
847888|NCT02856789|TEG 5000
847889|NCT02856789|TEG 6S
847890|NCT02856789|Coagulo-lytic balance
847891|NCT02856789|Normal range
847896|NCT02856711|Group Prenatal Visits,CenteringPregnancy
847897|NCT02856698|Acute heart failure
847898|NCT02856698|morphine
847899|NCT02856698|midazolam
847900|NCT02856698|in-hospital mortality
847901|NCT02856672|Laryngeal Tube Supreme Laryngeal Mask Airway Leak Pressure
847902|NCT02856620|cardiac mechanics
847903|NCT02856620|circulating biomarkers
847904|NCT02856620|frailty
847905|NCT02856542|Psoriasis vulgaris, scalp, topical, applicator, device
847906|NCT02856503|DCIS
847907|NCT02856503|IBC
847908|NCT02856503|Breast Cancer
847909|NCT02856503|Invasive Breast Carcinoma
847910|NCT02856503|High Grade Ductal Carcinoma in-situ
847911|NCT02855424|stroke
847912|NCT02855424|exercise capacity
847913|NCT02855385|Rectal bleeding, , ,
847914|NCT02855385|Attitude
847915|NCT02855385|Health seeking behaviour
847916|NCT02855385|Nigeria
847917|NCT02855385|Screening
847918|NCT02855385|high risk patients
847919|NCT02855359|Antibodies, Monoclonal
847920|NCT02855359|SGN-19A
847921|NCT02855359|Denintuzumab Mafodotin
847922|NCT02855359|DLBCL
847923|NCT02855359|Antibody-Drug Conjugate
847924|NCT02855359|Antigens, CD19
847925|NCT02855359|Hematologic Diseases
847926|NCT02855359|Immune System Diseases
847927|NCT02855359|Immunoproliferative Disorders
847928|NCT02855359|Immunotherapy
847929|NCT02855359|Lymphatic Diseases
847930|NCT02855359|Lymphoma
847931|NCT02855359|Lymphoma, B-Cell
847932|NCT02855359|Lymphoma, Large B-Cell, Diffuse
847933|NCT02855359|Lymphoma, Non-Hodgkin
847934|NCT02855359|Monomethyl auristatin F
847935|NCT02855359|Neoplasms
847936|NCT02855359|Neoplasms by Histologic Type
847937|NCT02855359|Transformed Lymphoma / DLBCL
847938|NCT02855359|Cyclophosphamide
847939|NCT02855359|Doxorubicin
847940|NCT02855359|Liposomal doxorubicin
847941|NCT02855359|Prednisone
847942|NCT02855359|Rituximab
847943|NCT02855359|Vincristine
847944|NCT02855359|Alkylating Agents
847945|NCT02855359|Anti-Inflammatory Agents
847946|NCT02855359|Antibiotic, Antineoplastic
847947|NCT02855359|Antimitotic Agents
847948|NCT02855359|Antineoplastic Agents, Alkylating
847949|NCT02855359|Antineoplastic Agents
847950|NCT02855359|Phytogenic Antirheumatic Agents
847951|NCT02855359|Glucocorticoids
847952|NCT02855359|Drug Therapy
847953|NCT02855359|Follicular Lymphoma Grade 3b
847954|NCT02855359|immunosuppressive agents
847955|NCT02855333|Merendino procedure
847956|NCT02855333|Feasibility, Safety and QoL of the Merendino procedure
847957|NCT02855320|Biologics safety
847958|NCT02855320|Rheumatoid arthritis
847959|NCT02855320|Spondyloarthritis
847960|NCT02855320|patient education
847961|NCT02855320|self-management
847962|NCT02855307|Closed-loop system
847963|NCT02855307|Artificial pancreas
847964|NCT02855307|Exercise
847965|NCT02855307|Hypoglycemia
847966|NCT02855307|Insulin
847967|NCT02855307|Glucagon
847968|NCT02855307|Type 1 diabetes
847969|NCT02855294|oral contraceptive pills
847970|NCT02855294|Joint stability
847971|NCT02855268|Kidney disease, nephritis
847972|NCT02856412|Stress Disorders, Post-Traumatic
847973|NCT02856412|Exercise
847974|NCT02856412|Mindfulness
847975|NCT02856399|methadone
847976|NCT02856399|cancer pain
847977|NCT02856399|long term effect
847978|NCT02856373|Denervation
847979|NCT02856373|Renal Artery
847980|NCT02856360|Football
847981|NCT02856360|Cleats
847982|NCT02856360|Stiffness
847983|NCT02856347|Medullary Thyroid Cancer
847984|NCT02856347|PET F-DOPA
847985|NCT02856347|18-FDOPA
847986|NCT02856334|chronic pelvic pain
847987|NCT02856334|vulvodynia
847988|NCT02856334|pelvic pain
847989|NCT02856334|psychosocial factors
847990|NCT02856334|central sensitization
847991|NCT02856295|postpartum venous thromboembolism
847992|NCT02856295|prophylactic dose of low molecular weight heparin
847993|NCT02856295|anti 10a
847994|NCT02856269|Zinc
847995|NCT02856256|Energy drink
847996|NCT02856256|Choroid
847997|NCT02856230|Critical limb ischemia
847998|NCT02856230|bellow-the-knee angioplasty
847999|NCT02856230|drug-eluting balloon
848000|NCT02856165|infant
848001|NCT02856165|oxygen therapy
848002|NCT02856165|High flow nasal canula oxygen therapy
848003|NCT02856165|Bronchiolitis
848004|NCT02856152|Healthy Volunteer
848005|NCT02856139|ultra-widefield fluorescein angiography
848006|NCT02856139|peripheral retina
848007|NCT02856139|normal eyes
848008|NCT02856126|Hepatic arterial infusion chemotherapy
848009|NCT02856126|Transarterial Chemoembolization
848010|NCT02856113|Drug therapy
848011|NCT02856087|acute pain
848012|NCT02856087|postoperative
848013|NCT02856087|surgery
848014|NCT02856048|GnRH agonist
848015|NCT02856048|Ovarian reserve
848016|NCT02856048|Fertility Preservation
848017|NCT02856048|Alkylating Agents
848018|NCT02856035|chronic stroke
848019|NCT02856035|functional MRI
848020|NCT02856035|functional NIRS
848021|NCT02856035|motor learning
848022|NCT02856035|FES
848023|NCT02856035|upper extremity
848024|NCT02856035|neural feedback
848025|NCT02856035|arm/hand functional training
848026|NCT02856022|electrical ilioinguinal nerve stimulation
848027|NCT02856022|bladder pain syndrome
848028|NCT02856022|intravesical irrigation
848029|NCT02855996|fatherhood
848030|NCT02855996|father involvement
848031|NCT02855996|economic stability
848032|NCT02855996|co-parenting
848033|NCT02855996|healthy relationships
848034|NCT02855996|father-child engagement
848035|NCT02855957|Alpha-Hemoglobin Stabilizing Protein
848036|NCT02855957|alpha-Hb pool
848037|NCT02855957|thalassemias
848038|NCT02855957|diagnostic method
848039|NCT02855957|biomarker
848040|NCT02855944|ovarian cancer
848041|NCT02855944|fallopian tube cancer
848042|NCT02855944|primary peritoneal cancer
848043|NCT02855944|peritoneal cancer
848044|NCT02855944|platinum sensitive
848045|NCT02855944|relapsed disease
848046|NCT02855944|PARP Inhibitor
848047|NCT02855944|PARP
848048|NCT02855944|rucaparib
848049|NCT02855944|ruca
848050|NCT02855944|homologous recombination
848051|NCT02855944|homologous recombination deficiency
848052|NCT02855944|genomic scarring
848053|NCT02855944|loss of heterozygosity
848054|NCT02855944|CO-338
848055|NCT02855944|PF-01367338
848056|NCT02855944|PF 01367338
848057|NCT02855944|CO-338-043
848058|NCT02855944|platinum sensitive ovarian cancer
848059|NCT02855944|platinum sensitive fallopian tube cancer
848060|NCT02855944|platinum sensitive primary peritoneal cancer
848061|NCT02855944|platinum sensitive peritoneal cancer
848062|NCT02855944|gynecological cancer
848063|NCT02855944|Clovis
848064|NCT02855944|Clovis oncology
848065|NCT02855944|ARIEL2
848066|NCT02855944|ARIEL 2
848067|NCT02855944|ARIEL-2
848068|NCT02855944|ARIEL-3
848069|NCT02855944|ARIEL 3
848070|NCT02855944|ARIEL3
848071|NCT02855944|ARIEL4
848072|NCT02855944|ARIEL-4
848073|NCT02855944|ARIEL 4
848074|NCT02855944|A4
848075|NCT02855944|advanced OC
848076|NCT02855944|platinum resistant ovarian cancer
848077|NCT02855944|platinum resistant primary ovarian cancer
848078|NCT02855944|Rubraca
848079|NCT02855918|Psychiatry
848080|NCT02855918|Depressive disorder
848081|NCT02855918|Suicidal behavior
848082|NCT02855918|Genetics
848083|NCT02855905|Exercise
848084|NCT02855905|Cold Temperature
848085|NCT02855892|GV1001
848086|NCT02855892|BPH
848087|NCT02855892|Benign prostatic hyperplasia
848088|NCT02855788|gastric cancer
848089|NCT02855788|gastroesophageal cancer
848090|NCT02855788|metastatic
848091|NCT02855788|advanced
848092|NCT02855736|Suicidal inpatients
848093|NCT02855736|Positive Psychology
848094|NCT02855736|Gratitude
848095|NCT02855736|Psychological pain
848096|NCT02855723|Squamous carcinoma of oral cavity and oropharynx
848097|NCT02855723|Sentinel lymph node
848098|NCT02855723|Lymph node dissection
848099|NCT02855723|Equivalence
848100|NCT02855671|microcirculation
848101|NCT02855671|thermal
848102|NCT02855671|temperature
848103|NCT02855658|Sjögren's syndrome
848104|NCT02855658|Gan-Lu-Yin
848105|NCT02855658|Sang-Ju-Yin
848106|NCT02855658|Xuefu-Zhuyu-Decoction
848107|NCT02855658|Oxidative stress
848108|NCT02855658|Immune regulation
848109|NCT02855658|Gene modulation
848110|NCT02855658|SS-1
848111|NCT02855645|Trichosanthes root
848112|NCT02855645|Traditional Chinese Medicine
848113|NCT02855645|Clinical trial
848114|NCT02855632|G-CSF
848115|NCT02855632|adhesion reformation
848116|NCT02855632|Asherman syndrome
848117|NCT02855619|inspiratory muscles training programs
848118|NCT02855619|Ventilator-induced diaphragmatic dysfunction
848119|NCT02855619|Weaning
848120|NCT02855619|Intensive care unit
848121|NCT02855606|Oral PrEP
848122|NCT02855606|TGW
848123|NCT02855606|Thai MSM
848124|NCT02855593|acupuncture
848125|NCT02855580|Pharmacogenomic
848126|NCT02855580|child
848127|NCT02855580|psychiatry
848128|NCT02855580|Obsessive Compulsive Disorder
848129|NCT02855580|Depression
848130|NCT02855580|Anxiety
848131|NCT02855580|CYP2D6
848132|NCT02855580|CYP2C19
848133|NCT02855580|Selective serotonin reuptake inhibitor
848134|NCT02855580|SSRI
848135|NCT02855567|surgery
848136|NCT02855567|acupuncture
848137|NCT02855567|gynecology
848138|NCT02855567|pain
848139|NCT02855567|narcotics
848140|NCT02855554|myocardial tissue characterization
848141|NCT02855541|Blood Glucose
848142|NCT02855541|Physical Fitness
848143|NCT02855541|Body Composition
848144|NCT02855541|Lipids
848145|NCT02855528|Tin Filter
848146|NCT02855528|Coronary Artery Calcium Scoring
848147|NCT02855528|Radiation dose reduction
848148|NCT02855515|drug-induced sleep endoscopy
848149|NCT02855515|obstructive sleep apnoea
848150|NCT02855515|VOTE classification
848151|NCT02855515|AHI
848152|NCT02855515|BMI
848153|NCT02855489|Condom Use
848154|NCT02855489|HIV/STD
848155|NCT02855489|Intervention
848156|NCT02855489|Theory of Planned Behavior
848157|NCT02855489|Dismantling Study Design
848158|NCT02855463|Giant virus
848159|NCT02855463|Amoeba
848160|NCT02855229|Translational
848161|NCT02855229|Electrophysiology
848162|NCT02855216|Physiotherapy
848163|NCT02855216|Range of motion
848164|NCT02855216|Inhibition sub-occipital techniques
848165|NCT02855190|Ga68-citrate
848166|NCT02855190|FDG
848167|NCT02855190|PET/MR and PET/CT
848168|NCT02855190|Periprosthetic joint infection
848169|NCT02855177|Hyperlipidemia
848170|NCT02855164|LJN452
848171|NCT02855164|non-alcoholic steatohepatitis
848172|NCT02855164|NASH
848173|NCT02855164|phase 2
848174|NCT02855164|adaptive design
848175|NCT02855164|randomized
848176|NCT02855151|EUS
848177|NCT02855138|isotretinoin
848178|NCT02855138|PCOS
848179|NCT02855138|acne vulgaris
848180|NCT02855125|NSCLC
848181|NCT02855125|phase 2 study
848182|NCT02855125|TAS-114
848183|NCT02855125|S-1
848184|NCT02855073|adipose-derived mesenchymal progenitor cells
848185|NCT02855073|Artz
848186|NCT02855034|child and infant
848187|NCT02855034|Blood samples
848188|NCT02855021|Dementia
848189|NCT02855021|Cerebral metabolism
848190|NCT02855021|PET scan
848191|NCT02855008|Social Problem-Solving
848192|NCT02855008|Intellectual Disability
848193|NCT02855008|Problem Behaviors
848194|NCT02855008|Community based intervention
848195|NCT02855008|Prevention
848196|NCT02854956|phenotype
848197|NCT02854956|X-linked mental retardation
848198|NCT02854956|neuronal networks
848199|NCT02854956|cognitive processes
848200|NCT02854930|Clinical death
848201|NCT02854930|state of consciousness
848202|NCT02854904|Immunomodulatory
848203|NCT02854904|dexmedetomidine
848204|NCT02854904|anesthesia
848205|NCT02854904|alpha-2 agonist
848206|NCT02854904|arthrodesis
848207|NCT02854904|spinal fusion
848208|NCT02854904|Immune effect
848209|NCT02854904|double randomized clinical trials
848210|NCT02854891|Effects
848211|NCT02854891|Heat
848212|NCT02854891|Light
848213|NCT02854826|Frail Older Adults, Interprofessional Team
848214|NCT02854813|overactive bladder
848215|NCT02854813|coronary artery disease
848216|NCT02854813|gensini score
848217|NCT02854800|varenicline
848218|NCT02854800|buprenorphine
848219|NCT02854787|Spinal anesthesia
848220|NCT02854787|cesarean
848221|NCT02854787|blood pressure
848222|NCT02854787|Norepinephrine
848223|NCT02854787|Phenylephrine
848224|NCT02854735|Head and Neck Neoplasms
848225|NCT02854735|Total body composition
848226|NCT02854735|Dual-Energy X-Ray Absorptiometry
848227|NCT02854735|Malnutrition
848228|NCT02854735|Muscle quantification
848229|NCT02854722|deferasirox
848230|NCT02854722|iron accumulation
848231|NCT02854696|Islet cell Transplantation
848232|NCT02854696|cost-effectiveness analysis
848233|NCT02854696|Cost-utility analysis
848234|NCT02854696|Type 1 Diabetes
848235|NCT02854683|Chronic Fatigue Syndrome (CFS)
848236|NCT02854683|Myalgic Encephalomyelitis (ME)
848237|NCT02854683|Postural Tachycardia Syndrome (POTS)
848238|NCT02854683|Neurally Mediated Syncope (NMS)
848239|NCT02854683|Systemic Exertion Intolerance Disease (SEID)
848240|NCT02854683|Orthostatic Intolerance (OI)
848241|NCT02854683|Oral Rehydration Solution (ORS)
848242|NCT02854683|Lower Body Negative Pressure (LBNP)
848243|NCT02854670|capsaicin
848244|NCT02854670|pain improvement
848245|NCT02854670|provoked vulvodynia
848246|NCT02854657|melanoma
848247|NCT02854657|skin self-examination
848251|NCT02854605|Non-alcoholic fatty liver disease (NAFLD)
848252|NCT02854605|Fibrosis
848253|NCT02854605|GS-9674
848254|NCT02854592|rtPA
848255|NCT02854592|urokinase
848256|NCT02854579|Hypoxic-Ischemic Encephalopathy
848257|NCT02854579|progenitor cell
848258|NCT02854579|paracrine factor
848259|NCT02854579|adipose mesenchymal stem cell
848260|NCT02854579|neonate
848261|NCT02854566|periprosthetic fracture of the femur
848262|NCT02854566|hip prosthesis
848263|NCT02854540|hyperhidrosis
848264|NCT02854540|palmar
848265|NCT02854540|sweating
848266|NCT02854540|iontophoresis
848267|NCT02854540|sweat gland diseases
848268|NCT02854540|skin diseases
848269|NCT02854514|endometrial -cytokines
848270|NCT02854501|Homocysteine
848271|NCT02854501|Preeclampsia
848272|NCT02854501|poor placentation
848273|NCT02854475|skin parameters
848274|NCT02854475|cholesterol
848275|NCT02854475|Raman spectroscopy
848276|NCT02854462|Language Development
848277|NCT02854462|Shared Picture Book reading
848278|NCT02854462|Preschoolers
848279|NCT02854462|Inference making
848280|NCT02854449|Immune Marker
848281|NCT02854449|Immunologic Marker
848282|NCT02854449|Radiotherapy
848283|NCT02854449|Dose Hypofractionation
848284|NCT02854436|Prostate cancer
848285|NCT02854436|CRPC
848286|NCT02854436|Metastatic castrate-resistant prostate cancer
848287|NCT02854436|Prostate neoplasm
848288|NCT02854436|Galahad
848289|NCT02854436|Niraparib
848290|NCT02854436|DNA anomalies
848291|NCT02854436|DNA defect
848292|NCT02854436|PARP inhibitor
848293|NCT02854436|PARPi
848294|NCT02854410|dietary sodium nitrate
848295|NCT02854410|radiotherapy
848296|NCT02854410|nasopharyngeal carcinoma
848297|NCT02854384|Epilepsy
848298|NCT02854384|Mobile phone
848299|NCT02854371|gadoxetic acid
848300|NCT02854371|T1 map
848301|NCT02854371|MRI
848302|NCT02854345|CZT camera
848303|NCT02854345|pinhole
848304|NCT02854332|Pain
848305|NCT02854332|Analgesic
848306|NCT02854332|Stimulation
848307|NCT02854332|Motor Cortex
848308|NCT02854306|Bariatric surgery
848309|NCT02854306|Mindfulness
848310|NCT02854306|Obese
848311|NCT02854293|palliative care
848312|NCT02854293|cancer
848313|NCT02854293|quality of life
848314|NCT02854280|Hypoxia
848315|NCT02854280|Brain
848316|NCT02854280|Effort
848317|NCT02854267|organ procurement
848318|NCT02854267|brain death
848319|NCT02854267|organ donation
848320|NCT02854267|next of kins
848321|NCT02854254|phlebitis
848322|NCT02854254|catheter
848323|NCT02854254|congestive heart failure
848324|NCT02854254|dobutamine
848325|NCT02854241|MRI
848326|NCT02854241|HCC
848327|NCT02854241|surveillance
848328|NCT02854228|Pituitary tumor
848329|NCT02854228|pituitary carcinoma
848330|NCT02854228|acromegaly
848331|NCT02854228|cushing
848332|NCT02854228|prolactinoma
848333|NCT02854163|Secukinumab
848334|NCT02854163|Neutrophils
848335|NCT02854163|Vitamin D
848336|NCT02854124|Melanoma
848337|NCT02854124|Dissemination
848338|NCT02854124|Initiating stem cells
848339|NCT02854098|BHJS, constipation
848340|NCT02854085|Prevention of Cognitive Decline
848341|NCT02854085|Art Therapy
848342|NCT02854085|Music Reminiscence Activity
848343|NCT02854085|Elderly
848344|NCT02854072|GV1001
848345|NCT02854059|Asymptomatic antibody-mediated TTP
848346|NCT02854046|calcific uremic arteriolopathy
848347|NCT02854046|case-control study
848348|NCT02854046|cohort study
848349|NCT02854033|amyloid
848350|NCT02854033|plaques
848351|NCT02854033|neuroimaging
848352|NCT02854033|biomarkers
848353|NCT02854033|cognition disorder
848354|NCT02854033|early detection
848355|NCT02854033|pre-dementia
848356|NCT02854033|dementia
848357|NCT02854033|Alzheimer's disease
848358|NCT02854033|tau
848359|NCT02854020|Aircraft
848360|NCT02854020|Emergency
848361|NCT02854020|First aid
848362|NCT02854020|Cabin crew
848363|NCT02854020|Burn
848364|NCT02854020|Cardiac arrest
848365|NCT02854007|Coronary artery disease
848366|NCT02854007|Angioplasty
848367|NCT02854007|Bioresorbable coronary device
848368|NCT02854007|QALY (Quality-Adjusted Life Years)
848369|NCT02853994|DCB
848370|NCT02853994|DEB
848371|NCT02853994|Sirolimus
848372|NCT02853994|PCI
848373|NCT02853994|ISR
848374|NCT02853994|SVD
848375|NCT02853994|Restenosis
848376|NCT02853994|Bifurcation
848377|NCT02853994|CAD
848378|NCT02853994|Coronary artery
848389|NCT02853929|Pertussis
848390|NCT02853929|Immunogenicity
848391|NCT02853929|Poliomyelitis
848392|NCT02853929|Tetanus
848393|NCT02853929|Hepatitis B
848394|NCT02853929|Diptheria
848395|NCT02853903|solid tumor
848396|NCT02853903|NK immunotherapy
848397|NCT02853890|Birth
848398|NCT02853890|obstetric analgesia
848399|NCT02853890|obstetric anesthesia
848400|NCT02853864|Gender
848401|NCT02853864|Propofol
848402|NCT02853864|Dexmedetomidine
848403|NCT02853864|Interaction
848404|NCT02853851|Stress factors,
848405|NCT02853851|intensive care units,
848406|NCT02853851|scale,
848407|NCT02853851|quality of care
848408|NCT02853838|acute viral bronchiolitis
848409|NCT02853838|respiratory syncytial virus
848410|NCT02853838|chest physiotherapy
848411|NCT02853812|tinnitus
848412|NCT02853812|residual inhibition
848413|NCT02853786|cochlear implant
848414|NCT02853786|language environment
848415|NCT02853786|speech therapy assessment
848416|NCT02853786|LENA technology
848417|NCT02853773|sweeteners
848418|NCT02853773|sugar
848419|NCT02853773|EEG
848420|NCT02853773|food viewing
848421|NCT02853773|food intake
848422|NCT02853747|arterial stiffness
848423|NCT02853747|retinal vessels
848424|NCT02853747|physical activity
848425|NCT02853747|children
848426|NCT02853708|E. coli
848427|NCT02853708|extended-spectrum beta-lactamase
848428|NCT02853708|molecular epidemiology
848429|NCT02853708|risk factors
848430|NCT02853695|Hysteroscopy
848431|NCT02853695|Diffusion
848432|NCT02853695|Implementation
848433|NCT02853695|Diagnostic hysteroscopy
848434|NCT02853695|Operative hysteroscopy
848435|NCT02853682|glycocalyx
848436|NCT02853682|capillary leak syndrome
848437|NCT02853656|preterm birth
848438|NCT02853656|gestation
848439|NCT02853617|S. pneumoniae
848440|NCT02853617|N. meningitidis
848441|NCT02853617|H. influenza
848442|NCT02853617|B. pertussis
848443|NCT02853617|C. tetani
848444|NCT02853617|MRSA
848445|NCT02853591|laparoscopy
848446|NCT02853591|hysterectomy
848447|NCT02853500|Liver Cancer
848448|NCT02853487|Cluster headache
848449|NCT02853487|actigraphy
848450|NCT02853487|circadian rhythm
848451|NCT02853461|biofilm
848452|NCT02853461|periprosthetic joint infection
848453|NCT02853461|hip
848454|NCT02853461|endoprothesis
848455|NCT02853461|ceramic
848456|NCT02853461|bearing components
848457|NCT02853461|sonication
848458|NCT02853461|low grade infection
848459|NCT02853461|joint aspiration
848460|NCT02853448|Plasma
848461|NCT02853448|Serum
848462|NCT02853448|Effective Blood Draws
848463|NCT02853435|Cross-over
848464|NCT02853435|Gepotidacin
848465|NCT02853435|Pharmacokinetics
848466|NCT02853435|Relative Bioavailability
848467|NCT02853435|non-compartmental PK analysis
848468|NCT02853435|High shear wet granulation
848469|NCT02853396|internalised stigma
848470|NCT02853396|self stigma
848471|NCT02853396|inpatients
848472|NCT02853396|CBT
848473|NCT02853396|Cognitive therapy
848474|NCT02853383|Chronic Obstructive Pulmonary Diseases, COPD
848475|NCT02853357|Thoracic manipulation
848476|NCT02853357|Low back pain
848477|NCT02853357|Core strengthening
848478|NCT02853357|Thoracic spine thrust manipulation
848479|NCT02853344|PD1
848480|NCT02853344|PD-1
848481|NCT02853344|PDL1
848482|NCT02853344|PD-L1
848483|NCT02853331|PD1
848484|NCT02853331|PD-1
848485|NCT02853331|PDL1
848486|NCT02853331|PD-L1
848487|NCT02853331|VEGFR TKI
848492|NCT02853266|Kawasaki disease
848493|NCT02853266|non-cruzi-related antibody (NCRA)
848494|NCT02853253|Preterm neonates
848495|NCT02853240|Cerebral palsy
848496|NCT02853240|children
848497|NCT02853240|muscle spasticity
848498|NCT02853240|botulinum toxin injection
848499|NCT02853227|Telemark score, reliability
848500|NCT02853214|Dysglobulinemia
848501|NCT02853214|Multiple Myeloma
848502|NCT02853214|MGUS
848503|NCT02853214|Waldenström
848504|NCT02853214|genetic factors
848505|NCT02853214|Sequencing
848506|NCT02853201|Extubation
848507|NCT02853201|Intercostal Muscles
848508|NCT02853201|Diaphragm
848509|NCT02853201|Sternocleidomastoid Muscle
848510|NCT02853162|Stereotactic body radiotherapy
848511|NCT02853162|MRI
848512|NCT02853162|Renal cell carcinoma
848513|NCT02853149|Spinal Cord Injury
848514|NCT02853149|disability
848515|NCT02853149|obesity
848516|NCT02853149|cardiometabolic
848517|NCT02853149|Caregiver
848518|NCT02853110|MRI, stereotactic body radiotherapy, hypofractionation
848519|NCT02853084|Auto-inflammatory diseases
848520|NCT02853084|IL-1 inhibitors
848521|NCT02853084|HL2351
848522|NCT02853084|Cryopyrin‑Associated Periodic Syndromes (CAPS)
848523|NCT02853084|Neonatal Onset Multisystem Inflammatory Disease (NOMID)
848524|NCT02853084|Muckle-Wells Syndrome (MWS)
848525|NCT02853084|Familial Cold Autoinflammatory Syndrome (FCAS)
848526|NCT02853058|stillbirth
848527|NCT02853058|hemorrhage
848528|NCT02853019|Emotion
848529|NCT02853019|motivation
848530|NCT02853019|cognition
848531|NCT02853019|schizophrenia
848532|NCT02853006|Cancer lung
848533|NCT02853006|Fluids
848534|NCT02853006|LungCancerTest
848535|NCT02853006|radiological anomalies
848536|NCT02853006|non-cancerous
848537|NCT02853006|carriers
848538|NCT02853006|Patient reference
848539|NCT02852993|Erythrocyte Transfusion
848540|NCT02852993|Survival
848541|NCT02852967|Skin Diseases
848542|NCT02852967|Auto-Immune Diseases
848543|NCT02852967|Plaque
848544|NCT02852967|Dermatology
848545|NCT02852954|Progesterone Induced Blocking Factor
848546|NCT02852954|Endometrial Cancer
848547|NCT02852941|Impedance
848548|NCT02852941|Kidney Transplantation
848549|NCT02852928|ILD; chILD
848550|NCT02852915|Colonic Neoplasms
848551|NCT02852915|Laparoscopic Surgery
848552|NCT02852915|T4
848553|NCT02852902|Bloodstream infections caused by MDR Enterobacteriaceae
848554|NCT02852902|Extended-spectrum β-lactamase-producers
848555|NCT02852902|Carbapenemase-producing organisms
848556|NCT02852902|Solid Organ Transplantation
848557|NCT02852902|Multidrug-resistant Enterobacteriaceae
848558|NCT02852902|Anti-Infective Agents
848559|NCT02852889|internal jugular vein distensibility,haemodynamics
848560|NCT02852876|Safety of ASP2151
848561|NCT02852876|Phase 1
848562|NCT02852876|Pharmacokinetics
848563|NCT02852876|Healthy male subjects
848564|NCT02852876|Tolerability
848565|NCT02852876|Food effect of ASP2151
848566|NCT02852811|Climacteric
848567|NCT02852811|Education
848568|NCT02852811|Mental health
848569|NCT02852811|Menopause
848570|NCT02852772|Cognitive impairment
848571|NCT02852772|HIV
848572|NCT02852772|Microalbuminuria
848573|NCT02852772|Chronic kidney disease
848574|NCT02852720|Pharmacokinetics
848575|NCT02852720|levobupivacaine
848576|NCT02852720|Pregnancy
848577|NCT02852720|Cesarean section
848578|NCT02852720|Electrocardiography
848579|NCT02852668|elderly
848580|NCT02852668|strength training
848581|NCT02852668|power training
848582|NCT02852668|functional capacity
848583|NCT02852668|gait biomechanics
848585|NCT02852642|power training
848586|NCT02852642|plyometric training
848587|NCT02852642|functional capacity
848588|NCT02852629|decision-support sheet
848589|NCT02852616|Course
848590|NCT02852616|Posttraumatic Stress Disorder
848591|NCT02852616|Narrative Exposure Therapy
848592|NCT02852603|dissection
848593|NCT02852603|aneurysm
848594|NCT02852603|thoracic aorta
848595|NCT02852590|Observational
848596|NCT02852590|Pediatric
848597|NCT02852590|Off-Label Use
848598|NCT02852590|Unlicensed drug use
848599|NCT02852590|Adverse Drug Reaction
848600|NCT02852590|Hospitalized Children
848601|NCT02852590|Pediatric inpatients
848602|NCT02852577|panic disorder
848603|NCT02852577|agoraphobia
848604|NCT02852577|clonazepam
848605|NCT02852577|paroxetine
848606|NCT02852564|Non-Muscle
848607|NCT02852564|Invasive
848608|NCT02852564|Bladder
848609|NCT02852564|Cancer
848610|NCT02852564|Muscle
848611|NCT02852564|Surgery
848612|NCT02852564|Transurethral
848613|NCT02852564|Resection
848614|NCT02852564|Tumor
848615|NCT02852564|Ethacrynic
848616|NCT02852564|Acid
848617|NCT02852564|Mitomycin
848618|NCT02852564|Urine
848619|NCT02852564|NMIBC
848620|NCT02852512|Laparoscopic Sacrocolpopexy
848621|NCT02852512|Robotic Assisted Sacrocolpopexy
848622|NCT02852512|Pelvic Organ Prolapse
848623|NCT02852499|environmental epidemiology
848624|NCT02852499|cohort
848625|NCT02852499|atmospheric pollutant
848626|NCT02852499|chemical pollutant
848627|NCT02852499|growth, neuro-development, respiratory health
848628|NCT02852499|big data
848629|NCT02852499|biological samples (RNA, DNA, urines ...)
848630|NCT02852499|e-dohad and exposome
848631|NCT02852486|BCR-ABL Positive
848632|NCT02852486|Leukemia, Chronic Myeloid
848633|NCT02852486|Imatinib
848634|NCT02852486|Pioglitazone
848635|NCT02852473|Continuous Positive Airway Pressure
848636|NCT02852473|Radiotherapy
848637|NCT02852473|Proton Therapy
848638|NCT02852382|scalp block
848639|NCT02852382|local infiltration
848640|NCT02852330|Voltage tomography
848641|NCT02852304|liver
848642|NCT02852304|transplant
848643|NCT02852304|Lysosomal Acid Lipase
848644|NCT02852278|Amyotrophic Lateral Sclerosis
848645|NCT02852278|ALS
848646|NCT02852278|motor neuron diseases
848647|NCT02852278|Progressive Muscular Atrophy
848648|NCT02852278|Primary Lateral Sclerosis
848649|NCT02852278|Hereditary Spastic Paraplegia
848650|NCT02852265|oral contraceptive
848651|NCT02852265|contraceptive implant
848652|NCT02852265|contraception
848653|NCT02852265|adherence
848654|NCT02852265|adverse event
848655|NCT02852239|Renal impairment
848656|NCT02852239|Healthy volunteers
848657|NCT02852239|Clinical pharmacology study
848658|NCT02852239|DRB436
848659|NCT02852239|dabrafenib
848660|NCT02852239|normal renal function
848661|NCT02852239|impaired renal function
848662|NCT02852213|AADC
848663|NCT02852213|gene therapy
848664|NCT02852187|Intervertebral Disc Degeneration
848665|NCT02852187|Lumbar Spinal Disease
848666|NCT02852148|Wound
848667|NCT02852148|Pressure Ulcer
848668|NCT02852148|Diabetic Foot Ulcer
848669|NCT02852148|Venous Leg Ulcer
848670|NCT02852148|Burn
848671|NCT02852148|Quality of Life
848672|NCT02852135|Laryngeal Mask Airway
848673|NCT02852135|lateral position
848674|NCT02852135|laparoscopic surgery
848675|NCT02852122|prostate cancer
848676|NCT02852122|C11 Choline PET/MR
848677|NCT02852122|staging
848678|NCT02852122|biochemical failure
848679|NCT02852096|gastric cancer
848680|NCT02852096|Her2/neu
848681|NCT02852096|dual paraffin blocks
848682|NCT02852096|trastuzumab
848683|NCT02852070|bronchoalveolar lavage
848684|NCT02852070|lower respiratory tract infections
848685|NCT02851979|premature newborns
848686|NCT02851979|apneas prevention
848687|NCT02851979|olfactory stimulation
848688|NCT02851979|latin square design
848689|NCT02851966|Non-obstructive Azoospermia
848690|NCT02851966|Sperm Retrieval
848691|NCT02851966|Infertility, Male
848692|NCT02851966|Semen
848693|NCT02851966|Biomarkers
848694|NCT02851966|Proteomics
848695|NCT02851966|Enzyme-Linked Immunosorbent Assay
848696|NCT02851953|cervix, cervical dilation, balloon catheter
848697|NCT02851940|Pain
848698|NCT02851940|Bleeding
848699|NCT02851940|Hemorrhoids
848700|NCT02851940|Band Ligation
848701|NCT02851940|hypertonic saline sclerotherapy
848702|NCT02851836|attachment
848703|NCT02851836|adolescent
848704|NCT02851836|picture
848705|NCT02851823|Er-YAG lasers
848706|NCT02851823|Nd-YAG lasers
848707|NCT02851823|chronic periodontitis
848708|NCT02851823|nonsurgical periodontal debridement
848709|NCT02851810|attachment
848710|NCT02851810|oculomotor marker
848711|NCT02851810|emotion regulation
848712|NCT02851784|hepatocellular carcinoma
848713|NCT02851784|ablation
848714|NCT02851784|immunotherapy
848715|NCT02851784|cytokine induced kill cell
848716|NCT02851732|Quality Improvement
848717|NCT02851732|Cluster Analysis
848718|NCT02851719|Urinary Incontinence, Stress
848719|NCT02851719|Pelvic Floor
848720|NCT02851719|Exercise
848721|NCT02851719|Patient Compliance
848722|NCT02851706|Brain Tumor
848723|NCT02851706|Glioma
848724|NCT02851706|Astrocytoma
848725|NCT02851706|Brain Cancer
848726|NCT02851706|Spine Cander
848727|NCT02851615|Anemia, Sickle Cell
848728|NCT02851615|Self Care
848729|NCT02851615|Adolescent
848730|NCT02851615|Young Adult
848731|NCT02851615|Disease Management
848732|NCT02851615|Behavioral Activation
848733|NCT02851615|Peer Communication
848734|NCT02851576|Adenovirus
848735|NCT02851550|liver
848736|NCT02851550|transplant
848737|NCT02851550|Lysosomal Acid Lipase
848738|NCT02851472|TRAGI (transfusion related acute gut injury)
848739|NCT02851472|inhaled nitric oxide (iNO)
848740|NCT02851472|prematurity
848741|NCT02851472|PRBC transfusion
848742|NCT02851472|NEC (necrotizing enterocolitis)
848743|NCT02851472|NIRS (near infrared spectroscopy)
848744|NCT02851472|ELGAN (extremely low gestational age neonate)
848745|NCT02851459|Vaccines
848746|NCT02851407|stem cell transplant
848747|NCT02851407|hematopoietic stem cell transplant (HSCT)
848748|NCT02851407|veno-occlusive disease (VOD)
848749|NCT02851407|sinosoidial obstruction syndrome (SOS)
848750|NCT02851368|Indocyanine Green
848751|NCT02851368|Fluorescence Imaging
848752|NCT02851342|Cognition
848753|NCT02851342|MEG
848754|NCT02851329|stage IV EGFR-mutant
848755|NCT02851329|EGFR TKIs
848756|NCT02851329|progression-free survival
848757|NCT02851329|prognosis
848758|NCT02851329|computed tomography
848759|NCT02851290|Hypospadias
848760|NCT02851290|Caudal block
848761|NCT02851290|Dorsal penile nerve block
848762|NCT02851290|Anesthesia
848763|NCT02851290|Urethrocutaneous fistula
848764|NCT02851290|Urethral stricture
848765|NCT02851290|Meatal stenosis
848766|NCT02851290|Glanular dehiscence
848767|NCT02851277|Peanut Allergy
848768|NCT02851277|ASP0892
848769|NCT02851264|Early Esophageal Squamous Neoplasia
848770|NCT02851264|optical enhancement technology
848771|NCT02851264|virtual chromoendoscopy
848772|NCT02851251|eye disease
848773|NCT02851251|neonatal eye disease
848774|NCT02851251|newborn
848775|NCT02851251|screening
848776|NCT02851251|multicenter
848777|NCT02851134|genetic
848778|NCT02851121|Neurophysiological
848779|NCT02851121|Perception-action
848780|NCT02851121|Link
848781|NCT02851108|falciparum malaria
848782|NCT02851108|sub saharan
848783|NCT02851108|africa
848784|NCT02851108|elimination disorder
848785|NCT02851082|Training Program
848786|NCT02851082|Endurance
848787|NCT02851082|Von Willebrand factor
848788|NCT02851069|Observational Study
848789|NCT02851069|Chronic Hepatitis C genotype 1
848790|NCT02851069|Paritaprevir/r - Ombitasvir, ± Dasabuvir
848791|NCT02851069|Chronic Hepatitis C
848792|NCT02851069|Sustained Virological Response
848793|NCT02851056|Myeloma
848794|NCT02851056|Vaccine
848795|NCT02851056|Dendritic cell
848796|NCT02851056|autologous hematopoietic cell transplant
848797|NCT02851056|HCT
848798|NCT02851030|Child, Preschool
848799|NCT02851030|Child Care
848800|NCT02850991|Esophageal cancer, radiation, chemotherapy
848801|NCT02850939|Breast cancer
848802|NCT02850939|Endocrine hormonal therapy
848803|NCT02850939|mHealth
848804|NCT02850926|Concussion
848805|NCT02850926|Soccer
848806|NCT02850926|Adolescent
848807|NCT02850874|hyperthermic intraperitoneal chemotherapy
848808|NCT02850874|perioperative systemic chemotherapy
848809|NCT02850874|peritoneal disease
848810|NCT02850848|Pharmacokinetic
848811|NCT02850835|Decision Aid
848812|NCT02850835|Pelvic Organ Prolapse (POP)
848813|NCT02850822|decitabine
848814|NCT02850822|chemotherapy
848815|NCT02850809|radiofrequency ablation
848816|NCT02850809|complications
848817|NCT02850796|Mindfulness
848818|NCT02850796|self-compassion
848819|NCT02850796|Acceptance and Commitment Therapy
848820|NCT02850796|weight self-stigma
848821|NCT02850796|quality-of-life
848822|NCT02850783|colon cancer
848823|NCT02850757|Modified William's airway
848824|NCT02850757|fiberoptic bronchoscope
848825|NCT02850757|U shape Guedls airway
848826|NCT02850757|oral airways
848827|NCT02850757|efficacy and safety
848828|NCT02850705|Neuromyelitis Optica
848829|NCT02850705|Myelitis
848830|NCT02850705|Optic Neuritis
848831|NCT02850705|autoantibody
848832|NCT02850705|demyelination
848833|NCT02850679|Atrial Fibrillation
848834|NCT02850679|Cardioversion
848835|NCT02850666|social skills
848836|NCT02850666|child
848837|NCT02850666|theory of mind
848838|NCT02850666|drama
848839|NCT02850666|occupational therapy
848840|NCT02850666|Speech-language pathology
848841|NCT02850653|Acute Endophthalmitis.
848842|NCT02850653|PCR
848843|NCT02850653|Ocular sampling
848844|NCT02850627|acute coronary syndrome
848845|NCT02850627|Tongguan capsule
848846|NCT02850627|miRNAs
848847|NCT02850601|Oral lichen planus
848848|NCT02850601|Dexamethasone solution
848849|NCT02850562|body composition,
848850|NCT02850562|Dual-Energy X-Ray Absorptiometry
848851|NCT02850562|sarcopenia
848852|NCT02850562|peripheral quantitative computed tomography
848853|NCT02850562|muscle density
848854|NCT02850562|elderly
848855|NCT02850549|neck pain
848856|NCT02850549|cervical
848857|NCT02850549|classification
848858|NCT02850549|outcomes
848859|NCT02850549|physical therapy
848860|NCT02850536|Colorectal Cancer
848861|NCT02850536|Liver Metastases
848862|NCT02850536|Breast Cancer
848863|NCT02850536|Gastric Cancer
848864|NCT02850536|Pancreas Cancer
848865|NCT02850536|Carcinoembryonic antigen
848866|NCT02850536|CAR-T
848867|NCT02850536|Immunotherapy
848868|NCT02850510|Harsh discipline
848869|NCT02850510|parental competence
848870|NCT02850510|positive parenting
848871|NCT02850497|optical coherence tomography
848872|NCT02850497|malapposition
848873|NCT02850497|endothelization
848874|NCT02850471|Postoperative pulmonary complications
848875|NCT02850471|Transcutaneous electric acupoint stimulation
848876|NCT02850471|pulmonary protection
848877|NCT02850432|Magnetic resonance imaging
848878|NCT02850432|Extracellular volume matrix fraction
848879|NCT02850432|Peripheral artery disease
848880|NCT02850432|Blood-oxygen level dependent
848881|NCT02850432|Cardiac function
848882|NCT02850393|suppression mnemonic
848883|NCT02850393|emotional response
848884|NCT02850393|inhibitory control of failures
848885|NCT02850393|neurological alterations
848886|NCT02850341|Physical Activity
848887|NCT02850341|Mental Health
848888|NCT02850341|Health Behavior
848889|NCT02850341|Walking
848890|NCT02850341|Physical Exercise
848891|NCT02850341|Mental disorder
848892|NCT02850315|optimal coherence tomography
848893|NCT02850315|myocardial reperfusion
848894|NCT02850276|HIV disease
848895|NCT02850276|gastrointestinal problems
848896|NCT02850263|Diabetic Retinopathy
848897|NCT02850263|Diabetic Macular Oedema
848898|NCT02850263|Diabetic Macular Edema
848899|NCT02850263|Aflibercept
848900|NCT02850250|Observational
848901|NCT02850250|pharmacokinetic
848902|NCT02850250|cardiac
848903|NCT02850250|Cefuroxime
848904|NCT02850250|Paediatric
848905|NCT02850237|cerebral saturation
848906|NCT02850237|capnography
848907|NCT02850237|pre-hospital
848908|NCT02850198|ischemic stroke
848909|NCT02850185|COPD
848910|NCT02850185|hydrogen
848911|NCT02850172|nutrition
848912|NCT02850172|exercise
848913|NCT02850172|inspiratory muscle training
848914|NCT02850146|tau
848915|NCT02850146|cognition
848916|NCT02850146|longitudinal
848917|NCT02850146|cognitive decline
848918|NCT02850146|observational
848919|NCT02850146|imaging
848920|NCT02850120|surgical mesh
848921|NCT02850120|observational study
848922|NCT02850120|intraoperative complications
848923|NCT02850120|postoperative complications
848924|NCT02850107|Atherectomy, Drug-Coated Balloon
848925|NCT02850094|Physical activity
848926|NCT02850094|Exercise
848927|NCT02850094|Financial Incentives
848928|NCT02850081|Carotid endarterectomy
848929|NCT02850081|CEA
848930|NCT02850081|stroke
848931|NCT02850081|asymptomatic stenosis
848932|NCT02850055|physiotherapy, Temporomandibular Joint Disorder, tinnitus.
848933|NCT02850042|motor recovery
848934|NCT02850042|human
849058|NCT02849444|renal function
848935|NCT02850042|occupation-based practice
848936|NCT02850042|motor training
848937|NCT02850042|transcranial magnetic stimulation
848938|NCT02850029|antimicrobial
848939|NCT02850029|intensive care units
848940|NCT02850016|Romidepsin
848941|NCT02850016|3BNC117
848942|NCT02850016|Broadly neutralizing antibody
848943|NCT02849977|POMC
848944|NCT02849977|PCSK1
848945|NCT02849977|Pro-opiomelanocortin
848946|NCT02849964|Incidence
848947|NCT02849964|Renal Replacement Therapy
848948|NCT02849964|Socioeconomic Factors
848949|NCT02849964|Clinical Practice Pattern
848950|NCT02849951|Colitis
848951|NCT02849951|Colitis, Ulcerative
848952|NCT02849951|Ulcer
848953|NCT02849951|Colonic Diseases
848954|NCT02849951|Digestive System Diseases
848955|NCT02849951|Gastroenteritis
848956|NCT02849951|Gastrointestinal Diseases
848957|NCT02849951|Inflammatory Bowel Diseases
848958|NCT02849951|Intestinal Diseases
848959|NCT02849951|Pathologic Processes
848960|NCT02849951|Mesalamine
848961|NCT02849938|children with medical complexity
848962|NCT02849938|Telemedicine
848963|NCT02849938|Tracheostomy
848964|NCT02849925|Pit and Fissure Sealants
848965|NCT02849925|Caries
848966|NCT02849925|Glass ionomer
848967|NCT02849925|Resin
848968|NCT02849886|GvHD
848969|NCT02849886|Suicide gene
848970|NCT02849886|Dimerizer drug AP1903
848971|NCT02849886|Hematological stem cell transplantation
848972|NCT02849834|Neuropathic Pain
848973|NCT02849834|Stimulation of the Motor Cortex (SCM)
848974|NCT02849834|Pharmacoresistant
848975|NCT02849834|rTMS
848976|NCT02849808|Corneal Transplantation
848977|NCT02849795|Obesity, Abdominal
848978|NCT02849795|Adipokines
848979|NCT02849795|Risk of cardiovascular diseases
848980|NCT02849782|Gait analysis
848981|NCT02849782|Fampridine
848982|NCT02849782|Fatigue
848983|NCT02849782|Daily activity
848984|NCT02849782|Cognition
848985|NCT02849756|Intensive care
848986|NCT02849756|elderly
848987|NCT02849756|autonomy
848988|NCT02849756|Future
848989|NCT02849756|older patients
848990|NCT02849756|intensive care unit
848991|NCT02849743|oxytocin
848992|NCT02849743|hypothalamic obesity
848993|NCT02849743|craniopharyngioma
848994|NCT02849743|metabolism
848995|NCT02849730|Epi-PCA
848996|NCT02849730|Patient controlled analgesia
848997|NCT02849730|Epidural patient controlled analgesia
848998|NCT02849730|Elderly patient
848999|NCT02849730|Side effect
849000|NCT02849730|Postoperative pain
849001|NCT02849704|Chronic Pancreatitis
849002|NCT02849704|Pancreatic Function
849003|NCT02849704|Reduced Exocrine Pancreatic Function
849004|NCT02849704|Pancreatic Insufficiency
849005|NCT02849678|Postoperative Pain
849006|NCT02849678|Bowel Surgery
849007|NCT02849678|Regional Anesthesia
849008|NCT02849665|Kangaroo-Mother Care Method; child development
849009|NCT02849652|Smoking cessation
849010|NCT02849652|Nicotine dependence
849011|NCT02849652|Organizational change
849012|NCT02849652|Mental Healthcare
849013|NCT02849626|Partial-Onset Seizures
849014|NCT02849626|Primary Generalized Tonic-Clonic Seizures
849015|NCT02849626|Adjunctive Therapy
849016|NCT02849626|Epilepsy
849017|NCT02849613|cell therapy
849018|NCT02849613|stem cell
849019|NCT02849613|transplantation
849020|NCT02849613|graft
849021|NCT02849613|recovery
849022|NCT02849613|repair
849023|NCT02849613|stroke
849024|NCT02849613|mesenchymal stem cell
849025|NCT02849613|regenerative
849026|NCT02849600|Vital pulp therapy,Young permanent tooth,Treatment outcome
849027|NCT02849587|Driving Under the Influence
849028|NCT02849587|Memory Impairment
849029|NCT02849587|Reaction Time
849030|NCT02849587|Time Perception
849031|NCT02849561|Pupillary light reflex
849032|NCT02849561|Cardio respiratory arrest
849033|NCT02849535|Oral chemotherapy
849034|NCT02849535|Relative dose intensity
849035|NCT02849535|Health related program
849036|NCT02849535|Secured drug intake
849037|NCT02849522|Lower Urinary Tract Symptoms caused by Benign Prostatic Enlargement (LUTS BPE)
849038|NCT02849522|Prostate Artery Embolisation (PAE)
849039|NCT02849522|Transurethral Resection of the Prostate (TURP)
849040|NCT02849522|Open prostatectomy
849041|NCT02849522|Laser enucleation or ablation of the prostate (Green Light, KTP, HoLEP)
849042|NCT02849522|IPSS Score
849043|NCT02849522|IIEF Score
849044|NCT02849522|Complications
849045|NCT02849522|Quality of Life
849046|NCT02849483|PONV
849047|NCT02849483|digestive signs and symptoms
849048|NCT02849483|vomiting
849049|NCT02849483|antiemetics
849050|NCT02849483|nausea
849051|NCT02849483|ramosetron
849052|NCT02849470|Adipose Stem/Stromal Cells
849053|NCT02849470|PRP
849054|NCT02849470|SVF
849055|NCT02849470|Cell Therapy
849056|NCT02849470|Alopecia
849057|NCT02849470|GF
849059|NCT02849444|Relapsed Multiple myeloma
849060|NCT02849444|anti-MM therapy
849061|NCT02849431|mindfulness
849062|NCT02849418|Botulinum toxin type A
849063|NCT02849418|Urinary Incontinence
849064|NCT02849418|Neurogenic Detrusor Overactivity
849065|NCT02849392|Pistachio
849066|NCT02849392|Body composition
849067|NCT02849392|Erythrocyte membrane incorporation of fatty acids
849068|NCT02849392|Dietary quality/micronutrient quality
849069|NCT02849392|Blood lipids
849070|NCT02849392|Inflammatory markers
849071|NCT02849392|Bone density
849072|NCT02849392|Bone turnover markers
849073|NCT02849392|Satiety
849074|NCT02849379|tongue cancer
849075|NCT02849379|cryosurgery
849076|NCT02849379|NK immunotherapy
849077|NCT02849366|Sarcoma
849078|NCT02849366|Cryosurgery
849079|NCT02849366|NK Immunotherapy
849080|NCT02849353|Ovarian Cancer
849081|NCT02849353|cryosurgery
849082|NCT02849353|NK immunotherapy
849083|NCT02849340|Cervical Cancer
849084|NCT02849340|cryosurgery
849085|NCT02849340|NK immunotherapy
849086|NCT02849327|Pharyngeal cancer
849087|NCT02849327|Cryosurgery
849088|NCT02849327|NK immunotherapy
849089|NCT02849314|laryngeal cancer
849090|NCT02849314|cryosurgery
849091|NCT02849314|NK immunotherapy
849092|NCT02849249|allergy
849093|NCT02849249|Immunotherapy
849094|NCT02849249|SCIT
849095|NCT02849236|PECS block,
849096|NCT02849236|pectoral block,
849097|NCT02849236|breast augmentation
849098|NCT02849223|Mild Traumatic Brain Injury
849099|NCT02849223|Transcranial Direct Current Stimulation
849100|NCT02849223|Working Memory
849101|NCT02849197|pilonidal sinus
849102|NCT02849197|complication
849103|NCT02849197|recurrence
849104|NCT02849171|18F-fluorocholine (18F-FCH) PET
849105|NCT02849171|16-676
849106|NCT02849171|High-grade Gliomas
849107|NCT02849158|Rectoscopy
849108|NCT02849158|Proctectomy
849109|NCT02849158|Fibroblasts
849110|NCT02849145|Circulating tumor DNA
849111|NCT02849119|Robot; Laparoscopic
849112|NCT02849119|Partial nephrectomy
849113|NCT02849119|Transperitoneal
849114|NCT02849119|Retroperitoneal
849115|NCT02849119|Laparoscopic Surgery
849116|NCT02849119|Surgical Procedures, Robotic
849117|NCT02849119|Nephrectomy
849118|NCT02849106|3D culture
849119|NCT02849106|chemogram
849120|NCT02849106|FOLFOX
849121|NCT02849106|FOLFIRI
849122|NCT02849093|Optical coherence tomography
849123|NCT02849093|imaging of ocular structures
849124|NCT02849067|ischaemic heart disease
849125|NCT02849067|comedy session
849126|NCT02849067|laughter therapy
849127|NCT02849041|Circulating Tumor Cells
849128|NCT02849041|Lung
849129|NCT02849028|gut microbiota
849130|NCT02849028|sleep disorder
849131|NCT02849028|gut-brain axis
849132|NCT02849028|circadian rhythm
849133|NCT02849028|Traumatic Brain Injury
849134|NCT02849015|liver tumor
849135|NCT02849015|cryosurgery
849136|NCT02849015|NK immunotherapy
849137|NCT02849002|Concussion
849138|NCT02848989|Breast Cancer Surgery Pain
849139|NCT02848989|Breast Cancer
849140|NCT02848950|Metformin
849141|NCT02848950|fecundability
849142|NCT02848950|uterine doppler
849143|NCT02848937|calcium balance
849144|NCT02848937|dialysis
849145|NCT02848937|concentrate with citrate
849146|NCT02848924|prevalence
849147|NCT02848924|surgery
849148|NCT02848924|Treatments
849149|NCT02848911|acute lymphoblastic leukemia
849150|NCT02848898|Focal Vibrations
849151|NCT02848898|Neurorehabilitation
849152|NCT02848898|Spasticity
849153|NCT02848898|Multiple Sclerosis
849154|NCT02848885|Magnetic resonance imaging
849155|NCT02848885|Anosognosia
849156|NCT02848885|Electrical stimulation of the brain
849157|NCT02848872|Tumor-infiltrating lymphocytes (TILs)
849158|NCT02848859|cognitive behavioral therapy for insomnia
849159|NCT02848859|randomized controlled trial
849160|NCT02848846|Amputees
849161|NCT02848820|Appendicitis
849162|NCT02848820|Appendectomy
849163|NCT02848820|Antibiotics
849164|NCT02848781|Sudden Cardiac Death
849165|NCT02848781|ICD Therapy
849166|NCT02848781|VT Ablation
849167|NCT02848690|Sodium restriction
849168|NCT02848690|Dietary sodium restriction questionnaire (DSRQ)
849169|NCT02848690|Low-sodium diet
849170|NCT02848690|Adherence
849171|NCT02848690|Educational intervention
849172|NCT02848677|advanced glycation end-products
849173|NCT02848677|Cardiovascular disease
849174|NCT02848677|Low Sodium Diet
849175|NCT02848677|vascular inflammation
849176|NCT02848638|PET, Yttrium-90
849177|NCT02848625|Idiopathic Pulmonary Fibrosis
849178|NCT02848625|Yoga
849179|NCT02848625|Quality of life
849180|NCT02848612|anticoagulation
849181|NCT02848612|aneurysmal subarachnoid haemorrhage
849182|NCT02848612|interventional neuroradiology
849183|NCT02848612|coil embolization
849184|NCT02848599|postoperative analgesia
849185|NCT02848599|postoperative cognitive disfunction
849186|NCT02848586|HIV
849187|NCT02848586|ECIGS
849188|NCT02848586|e-cigarettes
849189|NCT02848586|lung inflammation
849190|NCT02848560|Cystic Fibrosis
849191|NCT02848560|orkambi
849192|NCT02848560|129Xe MRI
849193|NCT02848560|hyperpolarized xenon
849194|NCT02848560|LCI
849195|NCT02848560|CFTR modulator therapy
849196|NCT02848534|fever
849197|NCT02848534|hyperthermia
849198|NCT02848534|inflammatory syndrome
849199|NCT02848521|ADPKD
849200|NCT02848521|CKD
849201|NCT02848521|Rapid progressor
849202|NCT02848521|quality of life
849203|NCT02848521|DCE
849204|NCT02848508|Metformin
849205|NCT02848508|moderate renal failure
849206|NCT02848508|severe renal failure
849207|NCT02848508|chronic kidney disease
849208|NCT02848508|hyperlactatemia
849209|NCT02848508|lactic acidosis
849210|NCT02848495|Aneurysm
849211|NCT02848495|Biocollection
849212|NCT02848495|Familial Form
849213|NCT02848482|Photodynamic therapy
849214|NCT02848456|Manipulation, Spinal
849215|NCT02848456|H-Reflex
849216|NCT02848456|Muscle Contraction
849217|NCT02848456|Muscle Strength Dynamometer
849218|NCT02848443|metastatic
849219|NCT02848443|colorectal
849220|NCT02848443|cancer
849221|NCT02848443|oxaliplatin
849222|NCT02848443|dose-escalation
849223|NCT02848443|Lonsurf
849224|NCT02848443|nivolumab
849225|NCT02848443|bevacizumab
849226|NCT02848430|Humulus lupulus
849227|NCT02848404|Mild cognitive impairment
849228|NCT02848404|Cognitive rehabilitation
849229|NCT02848404|Cognitive therapy
849230|NCT02848404|Alzheimer's disease
849231|NCT02848404|Memory enhancement
849232|NCT02848404|Categorical language fluency
849233|NCT02848378|Advanced Oxidation Protein Products
849234|NCT02848378|Gingival crevicular fluid
849235|NCT02848378|Monocyte chemoattractant protein-1
849236|NCT02848378|Periodontal Disease
849237|NCT02848365|Measurement
849244|NCT02848235|Prevention of Mother to Child Transmission
849245|NCT02848235|Antenatal Care for HIV positive women
849246|NCT02848235|Kenya
849247|NCT02848222|contact lens discomfort
849248|NCT02848222|dry eye disease
849249|NCT02848222|meibomian gland dysfunction
849250|NCT02848222|Bruder mask
849251|NCT02848209|Peeling
849252|NCT02848209|Histological skin changes
849253|NCT02848209|Trichloroacetic acid peel
849254|NCT02848209|phenol/croton oil peel
849255|NCT02848170|essential hypertension
849256|NCT02848170|mineralocorticoid receptor antagonist
849257|NCT02848170|Developmental Phase III
849258|NCT02848157|dexmedetomidine
849259|NCT02848157|pudendal block
849260|NCT02848157|hypospadias
849261|NCT02848144|Immunoparalysis
849262|NCT02848144|immune response
849263|NCT02848144|sepsis
849264|NCT02848144|toxic shock syndrome
849265|NCT02848118|Hypoventilation
849266|NCT02848118|capnography
849267|NCT02848118|bronchoscopy
849268|NCT02848105|aGVHD
849269|NCT02848105|valproic acid
849270|NCT02848092|Visual Attention
849271|NCT02848092|Automobile Driving
849272|NCT02848001|CC-90009
849273|NCT02848001|Hematologic Cancers
849274|NCT02848001|Leukemia
849275|NCT02848001|Acute Myeloid Leukemia
849276|NCT02847988|muscle strength
849277|NCT02847988|muscle function
849278|NCT02847988|functional status
849279|NCT02847975|Becker
849280|NCT02847975|dystrophy
849281|NCT02847975|sympatholysis
849282|NCT02847962|Fortified-blended foods
849283|NCT02847962|Extrusion
849284|NCT02847962|Sorghum
849285|NCT02847962|Cowpea
849286|NCT02847962|Vitamin A
849287|NCT02847962|Iron
849288|NCT02847962|Protein
849289|NCT02847962|Food Aid
849290|NCT02847962|Anemia, Iron-Deficiency
849291|NCT02847962|Deficiency, Vitamin A
849292|NCT02847962|Growth Velocity
849293|NCT02847962|Stunting
849294|NCT02847962|Wasting
849295|NCT02847962|Protein-Energy Malnutrition
849296|NCT02847962|Complementary Feeding
849297|NCT02847962|Corn
849298|NCT02847962|Soy
849299|NCT02847962|Fortified Foods
849300|NCT02847962|Food assistance
849301|NCT02847936|triclosan
849302|NCT02847936|sutures
849303|NCT02847936|infection
849304|NCT02847923|Mobile Devices
849305|NCT02847923|Augmentative and Alternative Communication
849306|NCT02847923|Cerebral Palsy
849307|NCT02847910|tissue suction tube
849308|NCT02847910|disposable instrument
849309|NCT02847910|induced abortion
849310|NCT02847884|IBD
849311|NCT02847884|Crohn's disease
849312|NCT02847884|Remicade
849313|NCT02847884|Infliximab
849314|NCT02847884|Level
849315|NCT02847884|Drug Level
849316|NCT02847884|Children
849317|NCT02847871|mobility
849318|NCT02847871|exercise
849319|NCT02847871|nutrition
849320|NCT02847871|primary care
849321|NCT02847871|prevention
849322|NCT02847871|care pathway
849323|NCT02847871|elderly patient
849324|NCT02847858|unsafe sex
849325|NCT02847858|unprotected sex
849326|NCT02847858|adolescents
849327|NCT02847858|Latinas
849328|NCT02847858|Hispanic
849329|NCT02847858|mobile health applications
849330|NCT02847858|unintended pregnancy
849331|NCT02847858|teen pregnancy prevention
849332|NCT02847858|school-based health centers
849333|NCT02847845|chronic fatigue syndrome
849334|NCT02847845|idiopathic chronic fatigue
849335|NCT02847845|red ginseng
849336|NCT02847845|cortisol
849337|NCT02847845|anti-oxidant
849338|NCT02847832|Adnexal Diseases
849339|NCT02847832|Ovary
849340|NCT02847832|Ovarian Neoplasms
849341|NCT02847832|Ovarian Cysts
849342|NCT02847832|Ovarian Diseases
849343|NCT02847832|Ultrasonography
849344|NCT02847832|Ultrasonography, Doppler
849345|NCT02847832|Diagnosis
849346|NCT02847832|Early Diagnosis
849347|NCT02847832|Early Detection of Cancer
849348|NCT02847832|Genital Neoplasms, Female
849349|NCT02847832|Genital Diseases, Female
849350|NCT02847832|Urogenital Neoplasms
849351|NCT02847832|Cysts
849352|NCT02847832|Endocrine System Diseases
849353|NCT02847832|Gonadal Disorders
849354|NCT02847832|Neoplasms
849355|NCT02847832|Endocrine Gland Neoplasms
849356|NCT02847832|International Ovarian Tumor Analysis
849357|NCT02847832|Simple Rules
849358|NCT02847832|Preoperative evaluation
849359|NCT02847832|Prediction Models
849360|NCT02847832|Logistic Regression Models
849361|NCT02847832|Mathematical Models
849362|NCT02847832|Adnexal Masses
849363|NCT02847832|Ovarian Tumors
849364|NCT02847832|Risk of Malignancy
849365|NCT02847793|Attentional Bias Modification (ABM)
849366|NCT02847793|Cognitive Bias Modification (CBM)
849367|NCT02847793|Depression
849368|NCT02847793|Dysphoria
849369|NCT02847793|Gaze patterns
849370|NCT02847793|Eye-tracking
849371|NCT02847767|Liver Perfusion
849372|NCT02847767|Hepatocellular Carcinoma
849373|NCT02847767|Dynamic Contrast-Enhanced Computed Tomography
849374|NCT02847754|bony metastases
849375|NCT02847754|physical exercise
849376|NCT02847741|Depression
849377|NCT02847741|Cholesterol
849378|NCT02847741|Suicidal behavior
849379|NCT02847741|Predictive factor
849380|NCT02847715|PRO
849381|NCT02847715|PROM
849382|NCT02847715|Adverse event
849383|NCT02847715|QTool
849384|NCT02847715|Aftercare
849385|NCT02847702|Osteoarthritis
849386|NCT02847702|Pain
849387|NCT02847702|Osteoarthritis, knee
849388|NCT02847689|Premature Birth
849389|NCT02847689|Obstetric Labor, Premature
849390|NCT02847689|Obstetric Labor Complications
849391|NCT02847689|Pregnancy Complications
849392|NCT02847676|Peritoneal adhesions
849393|NCT02847676|Stem cells
849394|NCT02847676|MSC
849395|NCT02847663|Cold
849396|NCT02847663|recovery
849399|NCT02847637|Hemophilia A
849400|NCT02847637|Emicizumab
849401|NCT02847611|Dynamometer mechanic
849402|NCT02847611|Strength of prehension
849403|NCT02847611|Comparison
849404|NCT02847611|Device
849405|NCT02847611|Diagnosis
849406|NCT02847611|Healthy Volunteers
849407|NCT02847598|CLE, SLE, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Lupus
849408|NCT02847585|water-soluble ubiquinol supplementation
849409|NCT02847585|pediatric cardiomyopathy
849410|NCT02847585|antioxidant
849411|NCT02847585|inflammation
849412|NCT02847585|complementary therapy
849413|NCT02847533|resistant depression
849414|NCT02847533|inflammation
849415|NCT02847520|Disorders related to gaming and gambling; poker
849416|NCT02847507|HIV
849417|NCT02847507|Hepatitis E
849418|NCT02847481|Fecal Microbiota Transplantation
849419|NCT02847455|Ilaprazole
849420|NCT02847455|Proton pump inhibitor
849421|NCT02847455|Duodenal ulcer
849422|NCT02847455|Acid suppression
849423|NCT02847455|Randomized trial
849424|NCT02847442|Ongentys
849425|NCT02847403|dysglycemia
849426|NCT02847403|MCI
849427|NCT02847403|exenatide LAR
849428|NCT02847403|GLP-1
849429|NCT02847390|diabetes mellitus
849430|NCT02847390|physician education
849431|NCT02847390|nursing education
849432|NCT02847390|hyperglycemia
849433|NCT02847390|hypoglycemia
849434|NCT02847390|inpatient
849435|NCT02847390|hospital
849436|NCT02847390|glycemic control
849437|NCT02847364|chewing gum
849438|NCT02847364|prevention
849439|NCT02847351|arabinoxylan, HOMA index, glycemic control, obesity.
849440|NCT02847338|Hypertension
849441|NCT02847312|Oat
849442|NCT02847312|Phenolic acid
849443|NCT02847312|Avenanthramide
849444|NCT02847312|FMD
849445|NCT02847312|LDI
849446|NCT02847312|Gut microbiota
849447|NCT02847312|Blood Pressure
849448|NCT02847312|Renin Angiotensin
849449|NCT02847312|Nitric Oxide
849450|NCT02847299|cough help
849451|NCT02847299|mechanical insufflation
849452|NCT02847299|mechanical ventilation
849453|NCT02847299|neuromuscular diseases
849454|NCT02847299|peak cough flow
849455|NCT02847273|NIRS
849456|NCT02847273|Regional oxygen saturation
849457|NCT02847273|cardiac surgery with bypass
849458|NCT02847247|healthy
849459|NCT02847234|Cervical necrotizing fasciitis
849460|NCT02847234|mediastinitis
849461|NCT02847221|cough peak flow
849462|NCT02847221|scheduled weaning trial
849463|NCT02847221|scheduled extubation
849464|NCT02847221|prognosis
849465|NCT02847208|cystic fibrosis
849466|NCT02847208|contraception
849467|NCT02847208|gynaecological follow-up
849468|NCT02847208|screening
849469|NCT02847208|Pap smear
849470|NCT02847208|counselling
849471|NCT02847195|pediatric intensive care
849472|NCT02847195|pain assessment
849473|NCT02847195|tracheal aspiration
849474|NCT02847195|sedation
849475|NCT02847195|pupillometer
849476|NCT02847156|cystic fibrosis
849477|NCT02847156|viruses
849478|NCT02847156|respiratory viral infection
849479|NCT02847156|children
849480|NCT02847143|Attachement
849481|NCT02847143|Oxytocin
849482|NCT02847143|fMRI
849483|NCT02847117|Natural Mastiha, Bioavailability
849484|NCT02847091|Ipragliflozin
849485|NCT02847091|SGLT2 inhibitor
849486|NCT02847091|Type 2 diabetes mellitus
849487|NCT02847091|ASP1941
849488|NCT02847078|Coronary Disease
849489|NCT02847078|percutaneous coronary intervention
849490|NCT02847078|secondary prevention
849491|NCT02847078|smart phone app
849492|NCT02847026|inactivated poliovirus vaccine
849493|NCT02847026|fractional inactivated poliovirus vaccine
849494|NCT02847026|Rotavirus
849495|NCT02847026|Rotarix
849496|NCT02847026|RotaTeq
849497|NCT02847026|fIPV
849498|NCT02847026|IPV
849499|NCT02847013|Postcesarean Section
849500|NCT02847013|Postoperative
849501|NCT02847000|Decitabine
849502|NCT02847000|Tetrahydrouridine
849503|NCT02847000|Epigenetic Therapy
849504|NCT02846987|Abemaciclib i
849505|NCT02846987|LY2835219
849506|NCT02846987|16-376
849507|NCT02846974|Pulse Oximetry
849508|NCT02846974|Free and Open Source
849509|NCT02846961|inflammatory bowel disease
849510|NCT02846961|biosimilar
849511|NCT02846961|anti-drug antibody
849512|NCT02846961|trough drug concentration
849513|NCT02846948|sepsis
849514|NCT02846948|echocardiography
849515|NCT02846948|urgent
849516|NCT02846948|abdominal surgery
849517|NCT02846935|p16/CDKN2A
849518|NCT02846935|TP53
849519|NCT02846935|THU
849520|NCT02846935|Decitabine
849521|NCT02846935|Tetrahydrouridine
849522|NCT02846935|DEC
849523|NCT02846883|aneurysms
849524|NCT02846857|Closed-loop system
849525|NCT02846857|Artificial pancreas
849526|NCT02846857|Type 1 diabetes
849527|NCT02846857|Hypoglycemia
849528|NCT02846857|Insulin
849529|NCT02846857|Glucagon
849530|NCT02846831|Type 1 diabetes
849531|NCT02846831|Artificial pancreas
849532|NCT02846831|Closed-loop system
849533|NCT02846831|Hypoglycemia
849534|NCT02846831|Glucagon
849535|NCT02846831|Insulin
849536|NCT02846818|Microdialysis
849537|NCT02846818|Cardiac surgery
849538|NCT02846818|Lactate to pyruvate ratio
849539|NCT02846818|Cardiopulmonary bypass
849540|NCT02846818|Neurological complications
849541|NCT02846779|Insulin persistence
849542|NCT02846779|Telepharmacy
849543|NCT02846766|advanced cancer
849544|NCT02846766|FGF
849545|NCT02846766|FGFR
849546|NCT02846766|Fibroblast Growth Factor Receptor
849547|NCT02846740|cranial electric stimulation
849548|NCT02846740|suicide
849549|NCT02846740|psychiatric inpatients
849550|NCT02846727|Hypoperfusion
849551|NCT02846727|Sepsis
849552|NCT02846714|Education
849553|NCT02846714|Prevention and Control
849554|NCT02846714|Behavioral Research
849555|NCT02846701|Neuropathic pain
849556|NCT02846701|Antidepressant
849557|NCT02846701|Duloxetine
849558|NCT02846701|Liquid Chromatography
849559|NCT02846701|Mass Spectrometry
849560|NCT02846675|SVF
849561|NCT02846675|Stromal Vascular Fraction
849562|NCT02846675|osteoarthritis(OA)
849563|NCT02846675|knee
849564|NCT02846675|adipose
849565|NCT02846662|depression
849566|NCT02846662|mobile technology
849567|NCT02846662|community trial
849568|NCT02846623|Chronic Lymphocytic Leukemia
849569|NCT02846623|CLL
849570|NCT02846623|Relapsed, Refractory
849571|NCT02846623|High-risk Untreated
849572|NCT02846623|High-risk molecular features
849573|NCT02846623|Genetic mutation
849574|NCT02846623|17p/TP53 deletion
849575|NCT02846623|Obinutuzumab
849576|NCT02846623|GA101
849577|NCT02846623|Gazyva
849578|NCT02846623|Atezolizumab
849579|NCT02846623|MPDL3280A
849580|NCT02846623|Tencentriq
849581|NCT02846623|Small Lymphocytic Lymphoma
849582|NCT02846623|SLL
849583|NCT02846610|anesthesia
849584|NCT02846610|continuous regional anesthesia
849585|NCT02846610|complications
849586|NCT02846610|epidural analgesia
849587|NCT02846610|antibiotics
849588|NCT02846597|Respiratory distress syndrome
849589|NCT02846597|Sustained lung inflation
849590|NCT02846597|Delivery room
849591|NCT02846584|CAR T
849592|NCT02846584|HSCT
849593|NCT02846571|Islet Transplantation
849594|NCT02846571|Type 1 Diabetes
849595|NCT02846571|Immune Tolerance Induction
849596|NCT02846571|Diabetes Complications
849597|NCT02846571|Intraocular Transplantation
849598|NCT02846571|Eye Anterior Chamber
849599|NCT02846571|Kidney Transplantation
849600|NCT02846571|Immunosuppression
849601|NCT02846571|Type 2 Diabetes
849602|NCT02846558|calorie restriction
849603|NCT02846558|weight loss
849604|NCT02846532|Thromboembolism
849605|NCT02846532|Fontan Procedure
849606|NCT02846532|Children
849607|NCT02846493|Ovarian hyperstimulation syndrome
849608|NCT02846493|Dexamethasone
849609|NCT02846467|Informed consent
849610|NCT02846467|Patient Education
849611|NCT02846467|Mobile applications
849612|NCT02846441|posthepatectomy liver failure
849613|NCT02846441|ALPPS
849614|NCT02846441|hepatobiliary scintigraphy
849615|NCT02846441|SPECT
849616|NCT02846441|mebrofenin
849617|NCT02846415|Dementia
849618|NCT02846415|Play and Playthings
849619|NCT02846415|Cognition
849620|NCT02846415|Memory
849621|NCT02846402|HIV testing
849622|NCT02846402|Female sex workers
849623|NCT02846402|HIV self-testing
849624|NCT02846389|Radiation therapy for Breast Cancer
849625|NCT02846363|stroke
849626|NCT02846363|public awareness campaign
849627|NCT02846363|call to EMS
849628|NCT02846337|cardio-renal syndrome
849629|NCT02846337|hemodialysis
849630|NCT02846337|peritoneal dialysis
849631|NCT02846337|hemofiltration
849632|NCT02846337|composite endpoint
849633|NCT02846311|test
849634|NCT02846311|winter
849635|NCT02846311|season
849636|NCT02846298|Drug Monitoring
849637|NCT02846298|ICU
849638|NCT02846298|Pharmacokinetic
849639|NCT02846298|Pharmacodynamic
849640|NCT02846298|antibiotic
849641|NCT02846298|Glycopeptides
849642|NCT02846298|β-lactam-aminoglycoside
849643|NCT02846285|Bleeding
849644|NCT02846259|intracranial aneurysm
849645|NCT02846259|cerebral ischemia
849646|NCT02846259|aspirin
849647|NCT02846246|aged care
849648|NCT02846246|health
849649|NCT02846246|home care services
849650|NCT02846246|person-centred care
849651|NCT02846220|Medication Adherence
849652|NCT02846220|Middle Aged 45-64
849653|NCT02846220|Aged 65-79
849654|NCT02846220|Aged, 80 and over
849655|NCT02846207|cerebral infarction
849656|NCT02846207|syndrome of qi deficiency and blood stasis
849657|NCT02846207|Buyanghuanwu decoction
849658|NCT02846207|clinical effects and mechanisms
849659|NCT02846194|Fibromyalgia
849660|NCT02846194|Guided Imagery
849661|NCT02846194|chronic pain
849662|NCT02846155|preparation
849663|NCT02846155|capsule endoscopy
849664|NCT02846129|multiple gestation
849665|NCT02846129|complications
849666|NCT02846129|cesarean delivery
849667|NCT02846116|all ceramic crown
849668|NCT02846116|Lithium disilicate
849669|NCT02846116|e-max
849670|NCT02846116|vita suprinity
849671|NCT02846077|sleep
849672|NCT02846077|social networks
849673|NCT02846077|undergraduates
849674|NCT02846077|mood
849675|NCT02846077|circadian rhythms
849676|NCT02846051|varicose vein
849677|NCT02846051|physical activity
849678|NCT02846038|Pediatric cancer
849679|NCT02846038|Childhood cancer
849680|NCT02846038|High-risk disease
849681|NCT02846038|Prognosis
849682|NCT02846038|Communication
849683|NCT02846038|Bad news
849684|NCT02846038|Pediatric oncologist
849685|NCT02846038|Parent
849686|NCT02846038|Relapse
849687|NCT02846038|Progression
849688|NCT02845999|natural killer cells
849689|NCT02845999|adoptive transfer
849690|NCT02845999|allogenic immunotherapy
849691|NCT02845999|gastrointestinal cancer EGFR+
849692|NCT02845986|Stomach Neoplasms
849693|NCT02845986|Laparoscopy
849694|NCT02845986|Spleen-Preserving
849695|NCT02845986|No.10 Lymph Node Dissection
849696|NCT02845973|gut microbiota
849697|NCT02845921|Propofol
849698|NCT02845921|Hypotension
849699|NCT02845921|Induction of anaesthesia
849700|NCT02845921|Leg elevation
849701|NCT02845921|Leg wrapping
849702|NCT02845895|Screening for nutritional disorder
849703|NCT02845895|Comparison of two organizations
849704|NCT02845895|Indicator IPAQSS
849705|NCT02845856|recurrent lung cancer
849706|NCT02845856|EGFR mutation
849707|NCT02845856|Cetuximab
849708|NCT02845856|NK immunotherapy
849709|NCT02845843|Middle East Respiratory Syndrome Coronavirus
849710|NCT02845843|MERS-CoV
849711|NCT02845843|Clinical trial
849712|NCT02845843|Lopinavir
849713|NCT02845843|Ritonavir
849714|NCT02845843|Interferon beta
849715|NCT02845830|dementia
849716|NCT02845830|elderly
849717|NCT02845830|quality of life
849718|NCT02845830|assessment
849719|NCT02845830|factor
849720|NCT02845830|trajectory
849721|NCT02845830|change
849722|NCT02845830|early stage
849723|NCT02845804|coronary artery disease
849724|NCT02845804|percutaneous coronary intervention
849725|NCT02845804|everolimus-eluting stents
849726|NCT02845778|melatonin
849727|NCT02845778|pharmacokinetics
849728|NCT02845765|Erectile Dysfunction
849729|NCT02845765|ED
849730|NCT02845765|Fundus Oculi
849731|NCT02845765|Retinal Vascularization
849732|NCT02845765|International Index of Erectile Function Questionnaire
849733|NCT02845765|IIEF
849734|NCT02845765|Dynamic Vessel Analyzer
849735|NCT02845765|DVA
849736|NCT02845765|Phosphodiesterase type 5 Inhibitor
849737|NCT02845765|PDE5Is
849738|NCT02845739|kidney transplantation
849739|NCT02845739|human papillomavirus
849740|NCT02845687|nicotine addiction
849741|NCT02845687|cigarette smoking
849742|NCT02845661|Narcotrend index
849743|NCT02845661|OAA/S scale
849744|NCT02845661|Dexmedetomidine
849745|NCT02845661|Sedation
849746|NCT02845648|anticholinergics
849747|NCT02845648|awakener
849748|NCT02845622|Hazelnut
849749|NCT02845622|Cocoa
849750|NCT02845622|Flavonoid
849751|NCT02845622|Lipids
849752|NCT02845622|Vascular Reactivity
849753|NCT02845609|Congenital macrothrombocytopenia
849754|NCT02845609|Sialic acid
849755|NCT02845609|Bleeding
849756|NCT02845583|Nursing
849757|NCT02845583|Diagnosis Related Group
849758|NCT02845583|Activity based costing
849759|NCT02845557|Youth
849760|NCT02845557|Type 2 Diabetes
849761|NCT02845557|glucose homeostasis
849762|NCT02845557|incretin effect
849763|NCT02845544|Postural Balance
849764|NCT02845531|Variant angina
849765|NCT02845531|Aborted sudden cardiac death
849766|NCT02845531|Implantable Cardioverter Defibrillator
849767|NCT02845531|Optimal Medical Therapy
849768|NCT02845531|ICD
849771|NCT02845492|Exercise
849772|NCT02845492|Qigong
849773|NCT02845492|Mind-Body
849774|NCT02845492|Fatigue
849775|NCT02845492|Cancer
849776|NCT02845492|EEG
849777|NCT02845492|HRV
849778|NCT02845466|Venous Leg Ulcer
849779|NCT02845466|Diabetic Foot Ulcer
849780|NCT02845466|Wound Healing
849781|NCT02845466|Growth Factor
849782|NCT02845466|Protease Inhibitor
849783|NCT02845453|youth
849784|NCT02845453|adolescent
849785|NCT02845453|young adult
849786|NCT02845453|substance use disorder
849787|NCT02845453|bipolar disorder
849788|NCT02845453|quetiapine
849789|NCT02845440|Pragmatic Trial
849790|NCT02845440|Community Health Workers
849791|NCT02845440|Academic Detailing
849792|NCT02845427|Closed Suction Drain
849793|NCT02845427|Wound Hematoma
849794|NCT02845388|IVF
849795|NCT02845362|Neuromuscular
849796|NCT02845362|dysphagia
849797|NCT02845362|Swallowing disorders
849798|NCT02845362|Questionnaire
849799|NCT02845362|Assessment
849800|NCT02845284|adolescent
849801|NCT02845284|reproductive health
849805|NCT02845232|Acute myeloid leukemia
849806|NCT02845232|Therapy
849807|NCT02845232|Blood transfusion
849808|NCT02845232|Cost-effectiveness
849809|NCT02845232|Prognosis
849810|NCT02845206|Total Knee Replacement
849811|NCT02845206|Patient Specific Instrumentation
849812|NCT02845180|lipectomy
849813|NCT02845180|panniculectomy
849814|NCT02845154|Ischemia reperfusion
849815|NCT02845154|post-reperfusion syndrome
849816|NCT02845154|living donor liver transplantation
849817|NCT02845154|patient outcome
849818|NCT02845141|ACL
849819|NCT02845141|Revision surgery
849820|NCT02845141|tunnel enlargement
849821|NCT02845141|bone substitute material
849822|NCT02845141|bone graft
849823|NCT02845115|Middle Ear Implant
849824|NCT02845115|laser velocimetry
849825|NCT02845102|Chronic Illness
849826|NCT02845102|Chronic Pain
849827|NCT02845102|Depression
849828|NCT02845102|Comorbid Depression
849829|NCT02845102|Cognitive Behavioral Therapy
849830|NCT02845102|Relational Agent Technology
849831|NCT02845102|CBT
849832|NCT02845102|Virtual Counselor
849833|NCT02845076|Noninvasive ventilation
849834|NCT02845076|Respiratory insufficiency
849835|NCT02845076|Hypercapnia
849836|NCT02845076|ventilator weaning
849837|NCT02845063|muscle plasticity
849838|NCT02845063|exercise
849839|NCT02845063|rehabilitation
849840|NCT02845063|perfusion
849841|NCT02845063|ACE
849842|NCT02845063|genotype
849843|NCT02845063|hypertension
849844|NCT02845063|molecular biology
849845|NCT02845050|neo-adjuvant
849846|NCT02845050|vinflunine
849847|NCT02845050|cisplatin
849848|NCT02845050|radical cystectomy
849849|NCT02845050|muscle-invasive bladder cancer
849850|NCT02845050|JaNEO
849851|NCT02845011|Cardio first angle
849852|NCT02845011|CPR
849853|NCT02845011|Cardiopulmonary Arrest
849854|NCT02845011|Clinical trial
849855|NCT02844998|intravaginal ejaculatory latency time
849856|NCT02844998|international physical activity questionnaire
849857|NCT02844998|premature ejaculation diagnostic tool
849858|NCT02844985|Sexual Addiction
849859|NCT02844985|Genomics
849860|NCT02844985|Personality
849861|NCT02844985|Polymorphism
849862|NCT02844972|arrest or limitation of active treatment
849863|NCT02844972|emergency treatment
849864|NCT02844959|Atrial Fibrillation
849865|NCT02844959|Biomarkers
849866|NCT02844959|Inflammatory Response
849867|NCT02844959|C-reactive protein
849868|NCT02844959|FGF2
849869|NCT02844959|MMP8
849870|NCT02844959|troponin I
849871|NCT02844959|body temperature
849872|NCT02844946|Acceptance and Commitment Therapy
849873|NCT02844946|mild Traumatic Brain Injury
849874|NCT02844946|Veterans
849875|NCT02844946|Post Traumatic Stress Disorder
849876|NCT02844907|Incretins
849877|NCT02844907|GLP-1
849878|NCT02844894|intubation, ischemia modified albumine, dexmedetomidine, esmolol
849879|NCT02844868|stroke
849880|NCT02844868|hemiplegia
849881|NCT02844868|transcranial direct current stimulation (tDCS)
849882|NCT02844868|rehabilitation
849883|NCT02844868|lower extremity
849884|NCT02844868|gait training
849885|NCT02844855|Alzheimer
849886|NCT02844855|Parkinson
849887|NCT02844855|Action memory
849888|NCT02844842|mild or moderate
849889|NCT02844829|Prostate Cancer
849890|NCT02844829|Magnetic Resonance Imaging
849891|NCT02844777|topical ointment
849892|NCT02844777|skin
849893|NCT02844777|hexokinase
849894|NCT02844777|precancerous conditions
849895|NCT02844777|carcinoma, squamous cell
849896|NCT02844712|Drug hypersensitivity
849897|NCT02844712|Betalactam
849898|NCT02844712|Drug provocation test
849899|NCT02844699|prostate cancer
849900|NCT02844699|adenovirus
849901|NCT02844699|TLR5
849902|NCT02844699|immunotherapy
849903|NCT02844699|Ad5
849904|NCT02844686|Myocardial perfusion imaging
849905|NCT02844686|Single-Photon Emission Computer-Assisted Tomography
849906|NCT02844673|Sickle cell disease
849907|NCT02844673|Hydroxyurea
849908|NCT02844673|Adherence
849909|NCT02844673|randomized trial
849910|NCT02844673|medication possession ratio
849911|NCT02844660|Diabetes Mellitus
849912|NCT02844660|Foot Diseases
849913|NCT02844660|Foot Ulcer
849914|NCT02844634|pre-exposure prophylaxis
849915|NCT02844634|men who have sex with men
849916|NCT02844634|HIV prevention
849917|NCT02844634|sexually transmitted infection
849918|NCT02844634|syphilis
849919|NCT02844608|Health-related quality of life
849920|NCT02844608|Oncology clinical practice
849921|NCT02844608|Electronic collection
849922|NCT02844595|Smoking, psychological treatment, depression
849923|NCT02844569|Dental Implants
849924|NCT02844569|Bone Grafting
849925|NCT02844556|SMILE surgery
849926|NCT02844556|FS-LASIK surgery
849927|NCT02844556|multicenter
849928|NCT02844543|concussion, eye-tracking, athletes, vision
849929|NCT02844530|adults
849930|NCT02844517|Artificial Pancreas
849931|NCT02844517|Closed Loop Control
849932|NCT02844517|Continuous Glucose Monitor (CGM)
849933|NCT02844504|Fatigue
849934|NCT02844504|Breast cancer
849935|NCT02844504|Force
849936|NCT02844504|Motor imagery
849937|NCT02844504|Cancer Treatment
849938|NCT02844478|Caregiving
849939|NCT02844478|Family caregiving
849940|NCT02844478|Stress
849941|NCT02844478|dementia caregiving
849942|NCT02844478|Hispanics
849943|NCT02844478|Spanish
849944|NCT02844478|Telomere
849945|NCT02844465|epilepsy
849946|NCT02844465|laser ablation
849947|NCT02844465|Visualase
849948|NCT02844465|laser interstitial thermal therapy
849949|NCT02844452|Atopic Dermatitis
849950|NCT02844452|acupuncture
849951|NCT02844452|visit frequency
849952|NCT02844452|adult patient with AD
849953|NCT02844426|synbiotic
849954|NCT02844426|soluble dietary fiber
849955|NCT02844426|slow transit constipation
849956|NCT02844426|microbiota
849957|NCT02844387|cancer
849958|NCT02844387|brain
849959|NCT02844387|arginine
849960|NCT02844387|radiation
849961|NCT02844374|Epilepsy
849962|NCT02844374|Surgery candidate
849963|NCT02844374|EEG's Signal
849964|NCT02844361|high-risk
849965|NCT02844361|ASCT
849966|NCT02844348|Pain
849967|NCT02844348|Hypnosis
849968|NCT02844348|Chronic Dialysis
849969|NCT02844348|Arterial Disease
849970|NCT02844335|Breast Cancer
849971|NCT02844335|Cryosurgery
849972|NCT02844335|NK Immunotherapy
849973|NCT02844296|short-bout exercise
849974|NCT02844296|craving
849975|NCT02844296|handgrip
849976|NCT02844296|smoking cessation
849977|NCT02844296|RCT
849978|NCT02844283|HGF,myocardial infarction
849979|NCT02844257|Acute myeloid leukaemia
849980|NCT02844257|Transfusion dependency
849981|NCT02844257|Transfusion intensity
849982|NCT02844257|Prognosis
849983|NCT02844257|Chemotherapy
849984|NCT02844244|family well-being
849985|NCT02844244|positive psychology
849986|NCT02844218|Acute myeloid leukemia
849987|NCT02844218|Chemotherapy
849988|NCT02844218|Low-intensity therapy
849989|NCT02844218|Older patients
849990|NCT02844218|Prognosis
849991|NCT02844218|Supportive care
849992|NCT02844205|nursing care
849993|NCT02844205|observational scale
849994|NCT02844205|neonate
849995|NCT02844205|premature infant
849996|NCT02844205|developmental care
849997|NCT02844192|Vancomycin
849998|NCT02844192|under dosage
849999|NCT02844192|intensive care unit
850000|NCT02844192|pharmacokinetics
850001|NCT02844153|Metformin
850002|NCT02844153|type 2 diabetes
850003|NCT02844153|chronic kidney disease
850004|NCT02844153|antidiabetic medications
850005|NCT02844153|lactic acidosis
850006|NCT02844114|Ganoderma Lucidum Spore
850007|NCT02844114|Carcinoma, Non-Small-Cell Lung
850008|NCT02844114|Chemotherapy
850009|NCT02844114|Gemcitabine
850010|NCT02844114|Cisplatin
850011|NCT02844088|meningococcus C
850012|NCT02844075|Esophageal Squamous Cell Carcinoma
850013|NCT02844075|pembrolizumab
850014|NCT02844075|PD-1
850015|NCT02844075|neoadjuvant
850016|NCT02844075|chemoradiation
850017|NCT02844049|Deep Brain Stimulation
850018|NCT02844049|Quality of Life
850019|NCT02844036|Distal Lesions
850020|NCT02844036|Post-embolic HTP
850021|NCT02844036|Angioplasty
850022|NCT02844023|Arteritis
850023|NCT02844023|Biomarker
850024|NCT02844023|Horton disease
850025|NCT02843997|Bipolar disorder
850026|NCT02843997|Endophenotype
850027|NCT02843997|Family
850028|NCT02843997|Autosomal dominant expression
850029|NCT02843997|Sequencing
850030|NCT02843997|Heritability
850031|NCT02843984|Amniocentesis
850032|NCT02843971|Water Drinking Test
850033|NCT02843971|Intraocular Pressure
850034|NCT02843971|Sensimed Triggerfish
850035|NCT02843958|Medical device
850036|NCT02843958|Hemoptic
850037|NCT02843958|Vitamin K antagonist
850038|NCT02843958|Diagnostic in vitro
850039|NCT02843932|Somatoform
850040|NCT02843932|Psychogenic
850041|NCT02843919|Electrocardiography
850042|NCT02843919|Electroencephalography
850043|NCT02843919|Neural Correlates
850044|NCT02843919|Mental Workload
850045|NCT02843906|alzheimer disease
850046|NCT02843906|bipolar disorders
850047|NCT02843906|mild cognitive impairement
850048|NCT02843893|Pupillary
850049|NCT02843893|Reflexes
850050|NCT02843893|Analgesia
850051|NCT02843893|Sedation
850052|NCT02843880|CMV reactivation
850053|NCT02843880|CMV disease
850054|NCT02843880|Predictive factors
850055|NCT02843880|Critically ill patients
850056|NCT02843880|Septic shock
850057|NCT02843867|Transplantation
850058|NCT02843867|Immunology
850059|NCT02843867|Atherosclerosis
850060|NCT02843828|Exoskeleton Device
850061|NCT02843828|elderly
850062|NCT02843828|stroke
850063|NCT02843828|gait rehabilitation
850064|NCT02843815|Non-small cell lung cancer
850065|NCT02843815|Cryosurgery
850066|NCT02843815|NK Immunotherapy
850067|NCT02843802|Metastatic liver cancer
850068|NCT02843802|Cryosurgery
850069|NCT02843802|NK Immunotherapy
850070|NCT02843789|Adipokines
850071|NCT02843789|Tocilizumab
850072|NCT02843776|Palliative Care
850073|NCT02843776|Euthanasia
850074|NCT02843776|Epidemiologic Studies
850075|NCT02843750|Rehabilitation
850076|NCT02843750|Inspiratory Muscle Training
850077|NCT02843724|Uncontrolled Type 2 Diabetes
850078|NCT02843724|HbA1c >7.0%
850079|NCT02843711|Lungcarta Panel
850080|NCT02843711|lung adenocarcinoma
850081|NCT02843672|metatarsalgia
850082|NCT02843672|surgery
850083|NCT02843672|weil
850084|NCT02843672|MIS
850085|NCT02843672|percutaneous
850086|NCT02843672|DMMO
850087|NCT02843646|gait training
850088|NCT02843646|stepping
850093|NCT02843620|Native Collagen
850094|NCT02843620|Joint
850095|NCT02843620|Joint Discomfort
850096|NCT02843607|Kidney Cancer
850097|NCT02843607|Cryosurgery
850098|NCT02843607|NK Immunotherapy
850099|NCT02843581|Esophageal Cancer
850100|NCT02843581|NK immunotherapy
850101|NCT02843581|Safety
850102|NCT02843581|Efficacy
850103|NCT02843555|Leukodystrophy
850104|NCT02843555|Myelin Gene
850105|NCT02843555|Myelin Protein
850106|NCT02843555|Sural Nerve Biopsy
850107|NCT02843555|Undiagnosed Disease
850108|NCT02843555|Schwann Cell
850109|NCT02843555|White Matter Pathology
850110|NCT02843555|Motor Delay
850111|NCT02843555|Cognitive Regression
850112|NCT02843555|Motor Deterioration
850113|NCT02843555|Unknown Disease
850114|NCT02843542|Positron emission tomography-magnetic resonance imaging (PET-MR)
850115|NCT02843542|Hyperthyroidism
850116|NCT02843542|Positron emission tomography-computed tomography (PET-CT)
850117|NCT02843529|biomarkers
850118|NCT02843529|CSF
850119|NCT02843529|EEG
850120|NCT02843529|MRI
850121|NCT02843490|neovascular age-related macular edema
850122|NCT02843490|biomarker
850123|NCT02843490|ranibizumab
850124|NCT02843490|lucentis
850125|NCT02843438|Toxoplasmosis
850126|NCT02843438|Uveitis
850127|NCT02843438|Chorioretinitis
850128|NCT02843438|Infection
850135|NCT02843412|Gastric cancer
850136|NCT02843412|Her2/neu
850137|NCT02843412|Dual paraffin blocks
850138|NCT02843412|Trastuzumab
850139|NCT02843412|Clinical Prospective Multicenter Cohort Study
850140|NCT02843399|Diabetes Mellitus Type 2
850141|NCT02843386|Uveal melanoma
850142|NCT02843386|High risk of metastasis
850143|NCT02843386|Genomic high risk signature
850144|NCT02843386|Adjuvant chemotherapy
850145|NCT02843360|public health
850146|NCT02843347|Biorepository
850147|NCT02843347|Genetics
850148|NCT02843334|Fabry disease
850149|NCT02843334|End Stage Renal Disease
850150|NCT02843334|chronic dialysis
850151|NCT02843334|alpha galactosidase A
850152|NCT02843334|Lyso-GB3
850153|NCT02843334|GLA mutation
850154|NCT02843334|Prevalence
850155|NCT02843321|infection
850156|NCT02843308|hoarding disorder
850157|NCT02843308|hoarding
850158|NCT02843308|clutter
850159|NCT02843295|renal transplantation
850160|NCT02843295|immunology
850161|NCT02843295|rejection
850162|NCT02843269|RCT
850163|NCT02843269|Multi-component intervention
850164|NCT02843269|Health personnel
850165|NCT02843269|Physical exercise training
850166|NCT02843230|Brain Tumor
850167|NCT02843204|solid tumor
850168|NCT02843204|anti-PD-L1
850169|NCT02843204|NK immunotherapy
850170|NCT02843191|Rectal Cancer
850171|NCT02843191|Consolidation Chemotherapy
850172|NCT02843178|nutrition
850173|NCT02843178|food security
850174|NCT02843178|behavioral economics
850175|NCT02843165|stereotactic body radiation therapy
850176|NCT02843165|checkpoint blockade immunotherapy
850177|NCT02843139|Circulating microRNA
850178|NCT02843139|Childhood obesity
850179|NCT02843139|Adulthood diabetes
850180|NCT02843126|recurrent breast cancer
850181|NCT02843126|Her-2 positive
850182|NCT02843126|Trastuzumab
850183|NCT02843126|NK immunotherapy
850184|NCT02843113|single father
850185|NCT02843113|parenting behavior
850186|NCT02843100|Crohn's Disease
850187|NCT02843100|Pediatric
850188|NCT02843100|Exclusive Enteral Nutrition
850189|NCT02843100|Diet
850190|NCT02843100|Microbiome
850191|NCT02843087|Breastfeeding
850192|NCT02843087|Microbiome
850193|NCT02843087|BEACH
850194|NCT02843087|Human milk
850195|NCT02843087|Pediatric Obesity
850196|NCT02843074|B-cell tumors
850197|NCT02843074|autologous stem cell transplantation
850198|NCT02843074|blood cancers
850199|NCT02843061|B lymphoma
850200|NCT02843061|Rituximab
850201|NCT02843061|NK immunotherapy
850202|NCT02843048|Osteoporosis
850203|NCT02843048|Bariatric Surgery
850204|NCT02843048|Physical exercise
850205|NCT02843048|Obesity
850206|NCT02843022|postpartum
850207|NCT02843022|nursing
850208|NCT02843022|follow-up
850209|NCT02842983|Esmolol
850210|NCT02842983|Hypotension
850211|NCT02842983|Shock, Septic
850212|NCT02842983|Sepsis
850213|NCT02842983|Systemic Inflammatory Response Syndrome
850214|NCT02842983|Adrenergic beta-1 Receptor Antagonists
850215|NCT02842983|Adrenergic Antagonists
850216|NCT02842983|Pharmacologic Actions
850217|NCT02842983|Physiological Effects of Drugs
850218|NCT02842931|DLBCL, R-DA-EPOCH-21, R-mNHL-BFM-90, auto-SCT
850219|NCT02842918|Thoracic Spine Manipulation
850220|NCT02842918|Neurodynamics
850221|NCT02842918|Sham
850222|NCT02842866|Meningitis
850223|NCT02842866|Meningococcal Meningitis
850224|NCT02842866|Meningococcal Infections
850225|NCT02842866|MenACYW conjugate vaccine
850226|NCT02842866|Menomune® - A/C/Y/W-135
850236|NCT02842788|prone position
850237|NCT02842788|acute respiratory distress syndrome (ARDS)
850238|NCT02842788|mechanical ventilation
850239|NCT02842788|ICU
850240|NCT02842788|prevalence
850241|NCT02842775|rehabilitation
850242|NCT02842762|Echocardiography, Three-dimensional
850243|NCT02842762|Cardiac Surgical Procedures
850244|NCT02842762|Cardiac Pacing, Artificial
850245|NCT02842762|Anesthesia
850246|NCT02842736|heavy menstrual bleeding
850247|NCT02842736|endometrial ablation
850248|NCT02842723|craniopharyngioma
850249|NCT02842723|protontherapy
850250|NCT02842697|clinically significant portal hypertension
850251|NCT02842697|hepatic venous pressure gradient
850252|NCT02842697|computed tomographic angiography
850253|NCT02842671|autism
850254|NCT02842671|ambassador
850255|NCT02842658|Chemotherapy
850256|NCT02842658|Exercise
850257|NCT02842645|Foetal Exposure During Pregnancy
850258|NCT02842645|Health
850259|NCT02842645|Growth
850260|NCT02842580|colorectal
850261|NCT02842580|cancer
850262|NCT02842580|metastasis
850263|NCT02842554|PDN
850264|NCT02842554|Painful Diabetic Neuropathy
850265|NCT02842554|Diabetes
850266|NCT02842502|Skin Substitutes
850267|NCT02842489|colonoscopy insertion
850268|NCT02842489|tilt-down position
850269|NCT02842476|pulse oximetry
850270|NCT02842437|dexmedetomidine
850271|NCT02842437|sepsis
850272|NCT02842437|respiration
850273|NCT02842424|Ramipril
850274|NCT02842424|Angiotensin-converting enzyme
850275|NCT02842424|Claudication
850276|NCT02842424|Myopathy
850277|NCT02842424|Peripheral Arterial Disease
850278|NCT02842411|bowel preparation
850279|NCT02842411|chronic constipation
850280|NCT02842411|risk factor
850281|NCT02842398|gait
850282|NCT02842398|balance
850283|NCT02842398|street-crossing
850284|NCT02842385|soft tissue thickness
850285|NCT02842385|dental implant
850286|NCT02842385|crestal bone loss
850287|NCT02842372|Acute Graft Versus Host Disease in Skin
850288|NCT02842372|GvHD
850289|NCT02842372|Ectoin
850290|NCT02842372|Dermatitis
850291|NCT02842372|Inflammation of the skin
850292|NCT02842372|Topical therapy skin GvHD
850293|NCT02842346|Ultrasound; umbilical Doppler; resistance index; fetal growth
850294|NCT02842307|Acupuncture
850295|NCT02842307|Expertise-based randomized controlled trial
850296|NCT02842307|Nausea
850297|NCT02842307|Vomiting
850298|NCT02842307|Cancer
850299|NCT02842294|bevacizumab
850300|NCT02842294|health related quality of life
850301|NCT02842255|Sleep apnea
850302|NCT02842255|Oximeter
850303|NCT02842255|Calibration
850304|NCT02842255|Oxygen partial pressure
850305|NCT02842229|Myelodysplastic Syndromes
850306|NCT02842229|Leukemia Myeloid Acute
850307|NCT02842229|Multiple Myeloma
850308|NCT02842229|Leukemia, Lymphocytic, Chronic
850309|NCT02842229|Elderly Patients
850310|NCT02842229|Haematological malignancy
850311|NCT02842229|Elderly
850312|NCT02842229|Health Status
850313|NCT02842229|Scale validation
850314|NCT02842229|Retrospective
850315|NCT02842216|Pharmaceutical preparations
850316|NCT02842216|Dietary supplements
850317|NCT02842203|colorectal cancer
850318|NCT02842190|Neonatal
850319|NCT02842190|NIPPV
850320|NCT02842190|BIPAP
850321|NCT02842190|Extubation failure
850322|NCT02842151|IOL
850323|NCT02842125|Colorectal
850324|NCT02842125|solid tumors
850325|NCT02842125|hepatocellular
850326|NCT02842125|Ad-P53
850327|NCT02842125|metastatic
850328|NCT02842125|capecitabine
850329|NCT02842112|Acute myeloid leukemia
850330|NCT02842112|prognosis
850331|NCT02842112|stem cell harvest
850332|NCT02842112|autologous transplant
850333|NCT02842112|leukemia stem cell
850334|NCT02842060|Prevention & Control
850335|NCT02842060|Young Adult
850336|NCT02842060|Internet
850337|NCT02842047|caregiver
850338|NCT02842047|end of life
850339|NCT02842034|schizophrenia
850340|NCT02842034|rTMS
850341|NCT02842008|Exercise Therapy
850342|NCT02842008|Shoulder pain
850343|NCT02842008|Shoulder injuries
850344|NCT02842008|Shoulder function
850345|NCT02842008|Prevention
850346|NCT02842008|Wheelchair users
850347|NCT02841995|cGVHD
850348|NCT02841995|Allogeneic hematopoietic stem cell transplantation
850349|NCT02841995|Immune System Diseases
850350|NCT02841995|Steroid refractory chronic graft vs host disease (cGVHD)
850351|NCT02841995|Bone Marrow Transplantation
850352|NCT02841995|Anti-Inflammatory Agents
850353|NCT02841995|Glucocorticoids
850354|NCT02841995|Corticosteroids
850355|NCT02841969|Ulcer
850356|NCT02841969|Electrolysed
850357|NCT02841969|Water
850358|NCT02841943|Fluid responsiveness
850359|NCT02841943|Near-infrared spectroscopy
850360|NCT02841943|Thoracic surgery
850361|NCT02841943|Hypovolemia
850362|NCT02841943|veno-arterial carbon dioxide gradient
850363|NCT02841943|arterio-venous oxygen gradient
850364|NCT02841943|hypercarbia
850365|NCT02841943|Carotid artery
850366|NCT02841943|ultrasonography
850367|NCT02841943|Doppler
850368|NCT02841930|Healthcare Access
850369|NCT02841930|Undocumented Immigrants
850370|NCT02841930|Primary Prevention
850371|NCT02841800|radiofrequency ablation
850372|NCT02841800|malignant biliary stenosis
850373|NCT02841787|Depression
850374|NCT02841787|Web-based intervention
850375|NCT02841787|Aging
850376|NCT02841787|Geriatrics
850377|NCT02841787|Social network
850378|NCT02841787|Older adults
850379|NCT02841748|Pembrolizumab
850380|NCT02841748|HNSCC
850381|NCT02841735|brief intervention
850382|NCT02841735|web-based interventions
850383|NCT02841735|harm reduction
850384|NCT02841735|young adult
850385|NCT02841735|college student
850386|NCT02841709|insomnia
850387|NCT02841709|elderly
850388|NCT02841709|Polysomnography
850389|NCT02841696|Heart failure
850390|NCT02841696|Systolic dysfunction
850391|NCT02841696|GLS
850392|NCT02841696|Arterial stiffness
850393|NCT02841696|Left ventricular hypertrophy
850394|NCT02841657|3 Dimensional Laparoscopy
850395|NCT02841657|Visual work load
850396|NCT02841657|Nasa Task Load Index
850397|NCT02841657|Simulator Sickness Questionnaire
850398|NCT02841553|Endoplasmic Reticulum Stress
850399|NCT02841540|Myelodysplastic Syndromes
850400|NCT02841540|Acute Myeloid Leukemia
850401|NCT02841540|Chronic Myelomonocytic Leukemia
850402|NCT02841540|H3B-8800
850403|NCT02841501|Gene Expression Profiling
850404|NCT02841501|Genome-Wide Association Study
850405|NCT02841501|Polymorphism, Single Nucleotide
850406|NCT02841501|Drug Resistance, Fungal
850407|NCT02841475|Atrial Fibrillation , Comorbidities
850408|NCT02841462|thermal ablation
850409|NCT02841462|recurrent Bursitis
850410|NCT02841462|chronic Bursitis
850411|NCT02841462|olecranon
850412|NCT02841462|intra-bursal perfusion
850413|NCT02841449|Hydration
850414|NCT02841449|Glycemic control
850415|NCT02841449|Appetite
850416|NCT02841449|Endocrinology
850417|NCT02841436|irreversible electroporation
850418|NCT02841436|pancreatic cancer
850419|NCT02841423|physical status I-III;
850420|NCT02841423|age > 55 yr)
850421|NCT02841423|undergoing surgery (duration, > 1 h)
850422|NCT02841410|Food
850423|NCT02841410|Emotion
850424|NCT02841410|Health
850425|NCT02841410|Nutrition
850426|NCT02841410|Heuristic
850427|NCT02841410|Reasoning
850428|NCT02841410|Magnetic Resonance Imaging
850429|NCT02841384|patellofemoral pain syndrome
850430|NCT02841384|postural balance
850431|NCT02841384|knee
850432|NCT02841384|physiotherapy
850433|NCT02841371|estimated glomerular filtration rate
850434|NCT02841371|serum creatinine
850435|NCT02841371|serum cystatin C
850436|NCT02841371|chronic kidney disease
850437|NCT02841358|Niemann-Pick Disease, Type C
850438|NCT02841358|Psychiatric
850439|NCT02841358|Psychotic disorders
850440|NCT02841345|emotional processing
850441|NCT02841345|action
850442|NCT02841332|Recurrent Glioblastoma
850443|NCT02841332|Positron emission tomography
850444|NCT02841332|Fluoro misonidazole
850445|NCT02841332|MRI multimodal
850446|NCT02841319|Virtual reality
850447|NCT02841319|Hemiplegic
850448|NCT02841319|Cerebral Palsy
850449|NCT02841319|upper extremity
850450|NCT02841319|hand function
850451|NCT02841293|Anorectal cancer
850452|NCT02841293|perineal morbidity
850453|NCT02841293|cost-utility analysis
850454|NCT02841293|biological meshes
850458|NCT02841228|SIB-IMRT
850459|NCT02841228|NSCLC
850460|NCT02841228|Radiochemothearpy
850461|NCT02841215|Gale
850462|NCT02841215|Severe forms of scabies
850463|NCT02841215|Oral parasitic drug
850464|NCT02841215|Ivermectin
850465|NCT02841202|optical coherence tomography
850466|NCT02841202|oral contraceptive pills
850467|NCT02841163|Magnetic Resonance Imaging
850468|NCT02841163|Patient Satisfaction
850469|NCT02841163|Numeric Rating Scale
850470|NCT02841124|Decision making
850471|NCT02841098|Carotid stenosis,stroke,endarterectomy,medical therapy
850472|NCT02841085|Genetic
850473|NCT02841085|Thrombophilia
850474|NCT02841059|quality of life
850475|NCT02841059|urinary incontinence
850476|NCT02841059|POP
850477|NCT02841046|stroke volume variation
850478|NCT02841046|cardiac index
850479|NCT02841046|non-severe patients
850480|NCT02841046|gastrointestinal surgery
850481|NCT02840955|Atopic dermatitis
850482|NCT02840955|Staphylococcus aureus
850483|NCT02840955|Microbiome
850484|NCT02840955|Staphefekt
850485|NCT02840942|intravenous line
850486|NCT02840942|robot
850487|NCT02840916|Laser acupuncture
850488|NCT02840916|Postpartum weight retention
850489|NCT02840916|Obesity
850490|NCT02840903|CTA
850491|NCT02840903|Computed Tomographic Angiography
850492|NCT02840877|tuberculosis culture
850493|NCT02840877|alcohol use
850494|NCT02840851|Magnetic Resonance Imaging
850495|NCT02840851|Transcranial Doppler Ultrasound
850496|NCT02840851|Hypercapnia
850497|NCT02840799|Heart Failure
850498|NCT02840799|Exercise Intolerance
850499|NCT02840799|Ejection Fraction
850500|NCT02840786|stents
850501|NCT02840786|atherectomy
850502|NCT02840786|femoral artery
850503|NCT02840786|popliteal artery
850504|NCT02840773|RANKL
850505|NCT02840773|OPG
850506|NCT02840773|Peri-implant crevicular fluid
850507|NCT02840760|tardive dyskinesia.
850508|NCT02840760|rTMS
850509|NCT02840747|Lymphomatoid Papulosis
850510|NCT02840747|Sézary Syndrome
850511|NCT02840747|T-Cell Lymphoma
850512|NCT02840734|Kinesio taping
850513|NCT02840734|Obese adults
850514|NCT02840734|Muscular function
850515|NCT02840734|Fatigue
850516|NCT02840682|resource limited setting
850517|NCT02840682|Thailand-Myanmar border
850518|NCT02840669|Cardiomyopathy
850519|NCT02840643|hemispherectomy
850520|NCT02840643|brain
850521|NCT02840643|hand function
850522|NCT02840630|n3 LC-PUFA
850523|NCT02840630|Type 2 Diabetes Mellitus
850524|NCT02840630|South Asian
850525|NCT02840630|HbA1c
850526|NCT02840630|Omega 3 status
850527|NCT02840617|ICG
850528|NCT02840617|prostate cancer
850529|NCT02840591|Citicoline, Ramelteon, Rozerem
850530|NCT02840539|Mantle cell lymphoma
850531|NCT02840539|Bortezomib
850532|NCT02840539|Cytarabine
850533|NCT02840526|PVB
850534|NCT02840526|PCA
850535|NCT02840526|nephrectomy
850536|NCT02840526|postoperative pain
850537|NCT02840513|Smartphone app
850538|NCT02840513|CO self-monitoring
850555|NCT02840435|Nicotine addiction
850556|NCT02840435|Cigarette smoking
850557|NCT02840422|Hyaluronic acid
850558|NCT02840422|Knee osteoarthritis
850559|NCT02840422|Quality of life
850560|NCT02840396|language
850561|NCT02840396|DLPFC
850562|NCT02840396|rTMS
850563|NCT02840396|Executive Functions
850564|NCT02840370|transcranial direct current stimulation
850565|NCT02840370|aphasia
850566|NCT02840370|language production
850567|NCT02840370|prefrontal cortex
850568|NCT02840357|Chronic inflammation
850569|NCT02840357|Adults
850570|NCT02840357|overweight
850571|NCT02840357|obese
850572|NCT02840344|Couple Functioning
850573|NCT02840344|Stress Reduction
850574|NCT02840331|Gastric carcinoma
850575|NCT02840331|Peritoneal carcinomatosis
850576|NCT02840331|Photodynamic diagnosis
850577|NCT02840331|Photodynamic therapy
850578|NCT02840331|St. John's Wort
850579|NCT02840331|Peritoneal metastasis
850580|NCT02840318|Terminal care
850581|NCT02840318|Residential facilities
850582|NCT02840318|Integrated health care systems
850583|NCT02840318|Interdisciplinary health team
850584|NCT02840318|Palliative care
850585|NCT02840305|Natural scenes
850586|NCT02840305|Brain bases
850587|NCT02840305|Visual perception
850588|NCT02840305|MRI
850589|NCT02840292|Late Preterms
850590|NCT02840292|Neurobehavioral Assessment of Preterm Infants (NAPI)
850591|NCT02840279|cognition
850592|NCT02840279|dementia
850593|NCT02840279|phosphodiesterase type 4D
850594|NCT02840279|PDE4D
850595|NCT02840227|Cancer
850596|NCT02840227|General anesthesia
850597|NCT02840227|Epidural anesthesia
850599|NCT02840188|goalkeeper's fracture
850600|NCT02840175|Treatment tapering
850601|NCT02840175|Oligoarticular
850602|NCT02840175|Juvenile Idiopathic Arthritis
850603|NCT02840175|Inactive disease
850604|NCT02840175|Biologic therapy
850605|NCT02840162|prostate cancer
850606|NCT02840162|NSAIDs
850607|NCT02840162|chemoprevention
850608|NCT02840162|celecoxib
850609|NCT02840162|COX-2 inhibitors
850610|NCT02840149|68Ga-DOTA-NOC, PET/CT
850611|NCT02840136|Respiratory infection
850612|NCT02840136|Antibiotic therapy
850613|NCT02840136|LC-MS/MS
850614|NCT02840136|Sputum antibiotic concentrations
850615|NCT02840097|Brain injuries
850616|NCT02840097|Wounds and injuries
850617|NCT02840097|Hemorrhage
850618|NCT02840097|Tranexamic acid
850619|NCT02840097|Child
850620|NCT02840084|breast implant capsular contracture
850621|NCT02840045|electroencephalography (EEG)
850630|NCT02840006|Vasoconstrictor Agents
850631|NCT02840006|Vasodilator Agents
850632|NCT02839993|tDCS effects
850633|NCT02839993|associative learning
850634|NCT02839980|oropharyngeal colonization
850635|NCT02839915|Language Impairment
850636|NCT02839850|Arthroplasty
850637|NCT02839850|replacement
850638|NCT02839850|Knee
850639|NCT02839850|function
850640|NCT02839850|radiographic
850641|NCT02839850|survivorship
850642|NCT02839837|Depression
850643|NCT02839837|Depressive Disorder
850644|NCT02839837|Exercise
850645|NCT02839837|Neuroplasticity
850646|NCT02839837|Non-invasive brain stimulation
850647|NCT02839837|Healthy Control
850648|NCT02839824|bowel cleansing
850649|NCT02839824|bowel preparation
850650|NCT02839811|Betalactams
850651|NCT02839811|In vitro diagnosis
850652|NCT02839798|sTMS
850653|NCT02839798|NEST
850654|NCT02839798|NeoSync
850655|NCT02839798|synchronous
850656|NCT02839798|non-invasive neuromodulation
850657|NCT02839798|TMS
850658|NCT02839798|transcranial magnetic stimulation
850659|NCT02839798|EEG
850660|NCT02839798|bipolar
850661|NCT02839798|depression
850662|NCT02839785|Cerebral palsy
850663|NCT02839785|Physiotherapy
850664|NCT02839785|Children
850665|NCT02839785|Ibuprofen
850666|NCT02839785|Pain
850667|NCT02839785|Anxiety
850668|NCT02839772|podoconiosis
850669|NCT02839772|glycerine
850670|NCT02839772|RCT
850671|NCT02839772|SBF
850672|NCT02839772|TEWL
850673|NCT02839772|SC hydration
850674|NCT02839759|Hearing loss
850675|NCT02839759|Presbycusis
850676|NCT02839759|Aging
850677|NCT02839759|Teleaudiology
850682|NCT02839694|Lung Resection
850683|NCT02839694|Surgery
850684|NCT02839694|Bilateral Lung Metastases
850688|NCT02839668|breast cancer
850689|NCT02839668|angiogenesis
850690|NCT02839668|VEGF
850691|NCT02839603|Visceral leishmaniasis
850692|NCT02839603|HIV co-infection
850693|NCT02839603|Asymptomatic
850694|NCT02839590|Glaucoma
850695|NCT02839590|Ocular hypertension
850696|NCT02839590|Aqueous dynamics
850697|NCT02839564|chronic abdominal pain
850698|NCT02839564|laparoscopic adhesiolysis
850699|NCT02839564|placebo
850700|NCT02839551|Betalactams
850701|NCT02839551|Drug hypersensitivity
850702|NCT02839551|Drug provocation test
850703|NCT02839551|Reactive dose
850704|NCT02839538|infiltration
850705|NCT02839538|hemorrhoidectomy
850706|NCT02839538|postoperative pain
850707|NCT02839525|Eccentric exercise
850708|NCT02839525|Dietary supplement
850709|NCT02839525|Muscle damage
850710|NCT02839499|seniors
850711|NCT02839499|mixed food
850712|NCT02839499|normal texture food
850713|NCT02839486|antibiotic prophylaxis
850714|NCT02839486|pharmacokinetics
850715|NCT02839486|cardiopulmonary bypass
850716|NCT02839447|semen
850717|NCT02839447|sperm
850718|NCT02839447|oxidative stress
850719|NCT02839447|reactive oxygen species
850720|NCT02839447|idiopathic male infertility
850721|NCT02839408|periodontitis
850722|NCT02839408|azithromycin
850723|NCT02839408|probiotic
850724|NCT02839395|screen illumination
850725|NCT02839395|melatonin
850726|NCT02839395|body temperature
850727|NCT02839395|cognitive functioning
850728|NCT02839395|light pollution
850729|NCT02839369|walking performance
850730|NCT02839369|Cerebral Palsy, Typically Developed
850731|NCT02839330|Influenza
850732|NCT02839330|Vaccine
850733|NCT02839330|Flu
850734|NCT02839330|Avian
850735|NCT02839330|Pandemic
850736|NCT02839330|H5N1
850737|NCT02839330|MF59
850738|NCT02839317|Dysbiosis
850739|NCT02839317|Crohn's disease
850740|NCT02839317|Age
850741|NCT02839278|Immunomodulation
850742|NCT02839226|ulcers
850743|NCT02839226|wounds
850744|NCT02839226|diabetes
850745|NCT02839226|venous ulcers
850746|NCT02839226|arterial ulcers
850747|NCT02839226|granulation tissue
850748|NCT02839226|protein kinase c
850749|NCT02839200|Insomnia
850750|NCT02839200|Polysomnography
850751|NCT02839174|low carbohydrate diet
850752|NCT02839161|Hookworm
850753|NCT02839161|Vaccine
850754|NCT02839161|Na-GST-1
850755|NCT02839161|Na-APR-1
850756|NCT02839161|Necator americanus
850757|NCT02839148|Appetite, Stunting, Satiety, Children
850758|NCT02839122|Dutasteride
850759|NCT02839122|Tadalafil
850760|NCT02839070|Sleep
850761|NCT02839070|Learning
850762|NCT02839070|Circadian Rhythms
850763|NCT02839057|Axis fractures
850764|NCT02839057|Elderly
850765|NCT02839057|Mortality
850766|NCT02839057|Surgical treatment
850767|NCT02839031|diabetes mellitus
850768|NCT02839031|glycaemia
850769|NCT02839031|cognitive-behavioral treatment
850770|NCT02839031|coping
850771|NCT02839031|parents
850772|NCT02839031|children
850773|NCT02839005|Wound Closure Thechnical
850774|NCT02839005|Wound Healing
850775|NCT02838992|Cyclophosphamide
850776|NCT02838992|Umbilical Cord Blood
850777|NCT02838992|ATG
850778|NCT02838979|Glutamine
850779|NCT02838979|Chronic Kidney Disease
850780|NCT02838966|immunomodulation
850781|NCT02838966|immunonutrition
850782|NCT02838953|Ultrasonography
850783|NCT02838953|Respiratory Function Tests
850784|NCT02838953|Pulmonary Disease, Chronic Obstructive
850785|NCT02838953|Rehabilitation
850786|NCT02838927|Hypoparathyroidism
850787|NCT02838927|Epidemiology
850788|NCT02838927|Medication Therapy Management
850789|NCT02838914|Right atrium
850790|NCT02838914|Echocardiography
850791|NCT02838914|Remodeling
850792|NCT02838888|Adenoma
850793|NCT02838888|computer
850794|NCT02838888|automatic
850795|NCT02838888|polyp
850796|NCT02838888|detection
850797|NCT02838862|Neuroendocrine Tumors
850798|NCT02838862|MALDI-MS
850799|NCT02838862|Proteomics
850800|NCT02838862|Biomarkers, Tumor
850801|NCT02838862|Precision Medicine
850802|NCT02838836|Cancer
850803|NCT02838836|Circulating tumor cells (CTCs)
850804|NCT02838836|Disseminated tumor cells (DTCs)
850805|NCT02838836|Circulating tumor DNA (ctDNA)
850806|NCT02838823|anti-PD-1 monoclonal antibody
850807|NCT02838823|triple negative breast cancer
850808|NCT02838823|safety
850809|NCT02838810|peginterferon alfa
850810|NCT02838810|Chronic Hepatitis B
850811|NCT02838797|Parkinson's disease
850812|NCT02838797|Gastroparesis
850813|NCT02838797|Constipation
850814|NCT02838797|Prokinetic
850815|NCT02838797|5-HT4-receptor partial agonist
850816|NCT02838771|Swallowing Disorder
850817|NCT02838771|Dysphagia
850818|NCT02838758|Morton's neuroma
850819|NCT02838758|Intermetatarsal neuroma
850820|NCT02838758|forefoot pain
850821|NCT02838758|ultrasound guided cryoablation
850822|NCT02838758|ultrasound guided perineural lidocaine injection
850823|NCT02838706|postoperative anemia
850824|NCT02838706|perfusion index
850825|NCT02838680|aortic stenosis
850826|NCT02838680|transcatheter aortic valve replacement (TAVR)
850827|NCT02838654|cervical epidural space
850828|NCT02838654|wave form analysis
850829|NCT02838615|spinal stenosis
850830|NCT02838615|epidural steroid injection
850831|NCT02838602|carbon ions therapy
850832|NCT02838602|radiotherapy
850833|NCT02838602|radioresistant tumors
850834|NCT02838602|cancer
850835|NCT02838602|randomized trial
850836|NCT02838589|Cerebrovascular Stroke
850837|NCT02838589|Ischemic Stroke
850838|NCT02838589|Glucagon like peptide - 1
850839|NCT02838563|Dementia
850840|NCT02838563|Alzheimer
850841|NCT02838563|Well-Being
850842|NCT02838550|Physical Activity
850843|NCT02838550|Motivational Online Intervention
850844|NCT02838550|Pedometers
850845|NCT02838537|Triptan
850846|NCT02838537|Drug utilization
850847|NCT02838537|Elderly
850848|NCT02838537|Drug abuse
850849|NCT02838537|Cardiovascular disease
850850|NCT02838524|Spontaneous Breathing Trial
850851|NCT02838524|Inspiratory Effort
850852|NCT02838524|Mechanical Ventilation
850853|NCT02838524|Respiratory muscle load-capacity balance
850854|NCT02838498|ERCP
850855|NCT02838498|EMS
850856|NCT02838498|Cannulation
850857|NCT02838498|Successful rate
850858|NCT02838498|Trainee
850859|NCT02838407|Chronic lower respiratory tract infection
850860|NCT02838407|Bonchoalveolar lavage
850861|NCT02838407|Nasopharyngeal swabs
850862|NCT02838290|Burnout
850863|NCT02838290|Psychiatric morbidity
850864|NCT02838290|Anxiety
850865|NCT02838290|Grief
850866|NCT02838290|Alcohol and drug use
850867|NCT02838277|lymphatic vessels
850868|NCT02838277|leaky vessels
850869|NCT02838277|hypertrophic adipocyte
850870|NCT02838212|adverse drug reaction
850871|NCT02838212|hospital mortality
850872|NCT02838212|incidence
850873|NCT02838199|Transcatheter aortic valve replacement
850874|NCT02838199|TAVR
850875|NCT02838199|TAVI
850876|NCT02838199|SAVR
850877|NCT02838186|colonoscopy
850878|NCT02838186|right colon retroflexion
850879|NCT02838186|adenoma detection rate
850880|NCT02838186|feasibility
850881|NCT02838186|surveillance interval
850882|NCT02838160|educational strategies
850883|NCT02838160|KAP
850884|NCT02838160|psychological and clinical outcomes
850885|NCT02838160|intensive care unit
850886|NCT02838160|follow-up study
850887|NCT02838160|RCT
850888|NCT02838134|Laparoscopic donor nephrectomy
850889|NCT02838134|Early quality of recovery
850890|NCT02838121|bisphosphonate
850891|NCT02838121|Total hip replacement
850892|NCT02838121|functional outcomes
850893|NCT02838121|bone mineral density
850894|NCT02838095|nap
850895|NCT02838095|sleep restriction
850896|NCT02838095|recovery sleep
850897|NCT02838095|cognitive performance
850898|NCT02838095|subjective sleepiness
850899|NCT02838095|mood
850900|NCT02838095|neurobehavioural functions
850901|NCT02838082|traumatic brain injury
850902|NCT02838082|sleep-wake cycle disturbance
850903|NCT02838082|circadian disruption
850904|NCT02838056|anesthesia, epidural
850905|NCT02838056|skin temperature
850906|NCT02838030|Preeclampsia
850907|NCT02838030|L-arginine
850908|NCT02838004|Refractive lens exchange (RLE) or cataract surgery
850909|NCT02837991|Kidney Cancer
850910|NCT02837991|Celldex
850911|NCT02837991|Dose Escalation
850912|NCT02837978|Arthritis, Rheumatoid
850913|NCT02837978|Tacrolimus
850914|NCT02837978|Treatment outcome
850915|NCT02837978|Safety
850916|NCT02837952|Ibuprofen, acetaminophen, pain, molar extraction
850917|NCT02837913|Perioperative Warming
850918|NCT02837887|Cancer
850919|NCT02837887|Depression
850920|NCT02837874|Gastric cancer
850921|NCT02837874|gastrojejunostomy
850922|NCT02837874|isoperistaltic
850923|NCT02837874|antiperistaltic
850924|NCT02837861|Metabolic Support
850925|NCT02837861|Nutritional Support
850926|NCT02837861|Neuro-endocrine Event
850927|NCT02837861|Enteral feedings
850928|NCT02837861|Parenteral feeding
850929|NCT02837848|Rotator Cuff Tendinopathy
850930|NCT02837848|Exercises
850931|NCT02837848|Coactivation
850932|NCT02837848|Strengthening
850933|NCT02837822|Spinal Cord Stimulation
850934|NCT02837822|Quantitative Sensory Testing
850935|NCT02837809|low-dose computed tomography
850936|NCT02837809|lung
850937|NCT02837809|randomized controlled trial
850938|NCT02837809|neoplasms
850939|NCT02837809|screening
850940|NCT02837809|smoking
850941|NCT02837770|pain
850942|NCT02837770|intravitreal injection
850943|NCT02837770|anti-VEGF
850944|NCT02837770|diclofenac eye drops
850945|NCT02837770|oral diclofenac
850946|NCT02837770|Short Form of McGill Pain Questionnaire
850947|NCT02837653|cardiovascular Risk
850948|NCT02837640|Retinitis Pigmentosa
850949|NCT02837640|Levodopa
850950|NCT02837627|gastroesophageal reflux
850951|NCT02837627|tube enteral feeding
850952|NCT02837627|preterm infants
850953|NCT02837601|Laparoscopic surgical procedures
850954|NCT02837601|Shoulder Pain
850955|NCT02837601|Abdominal Pain
850956|NCT02837601|Pediatrics
850957|NCT02837588|chronic pelvic pain
850958|NCT02837588|trigger points
850959|NCT02837588|hiperthermy
850960|NCT02837575|HSV-2
850961|NCT02837575|Genital Herpes
850962|NCT02837575|Herpes
850963|NCT02837575|Herpes Simplex Virus, Type 2
850964|NCT02837562|Radiation exposure
850965|NCT02837562|Cardiac catheterization
850966|NCT02837523|Lysosomal Storage Diseases
850967|NCT02837497|pediatric
850968|NCT02837497|heart arrest
850969|NCT02837471|Pedometer usability
850970|NCT02837471|Usability and feasibility
850971|NCT02837471|web application
850972|NCT02837458|Electric current
850973|NCT02837458|Nerve block
850974|NCT02837458|somatosensory evaluation
850975|NCT02837432|Depression
850976|NCT02837432|Cortisol
850977|NCT02837432|Sadness
850978|NCT02837432|Genetics
850979|NCT02837432|Stress
850980|NCT02837419|extracorporeal life support
850981|NCT02837419|health related quality of life
850982|NCT02837380|Long-acting muscarinic antagonist
850983|NCT02837380|Long-acting beta2 agonist
850984|NCT02837380|Dry powder inhaler
850985|NCT02837380|Inhaled corticosteroid
850986|NCT02837367|nutrigenetics
850987|NCT02837367|medical foods
850988|NCT02837367|obesity
850989|NCT02837367|children
850990|NCT02837367|adults
850991|NCT02837354|Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
850992|NCT02837341|medical device
850993|NCT02837328|Magnesium Supplementation
850994|NCT02837328|Magnesium
850995|NCT02837328|Dietary Supplement
850996|NCT02837328|Arrhythmia
850997|NCT02837302|Liver cirrhosis
850998|NCT02837302|Branched chain amino acid
850999|NCT02837302|End-Stage Liver Disease score
851000|NCT02837289|patellofemoral pain syndrome
851001|NCT02837289|therapy taping
851002|NCT02837289|knee
851003|NCT02837289|physical therapy
851004|NCT02837289|runners
851005|NCT02837276|Intermittent Hypoxemia
851006|NCT02837276|Acute Kidney Injury
851007|NCT02837276|Preterm infant
851008|NCT02837250|HIV
851009|NCT02837250|Substance Use
851010|NCT02837224|retained surgical sponge
851011|NCT02837224|adverse event
851012|NCT02837185|Cervical dystonia
851013|NCT02837185|Transcranial magnetic stimulation
851014|NCT02837185|Electromyography
851015|NCT02837185|TMS
851016|NCT02837185|EMG
851017|NCT02837159|colorectal cancer
851018|NCT02837159|Health Life Style Habits
851019|NCT02837159|Health
851020|NCT02837146|RA
851021|NCT02837120|retrospective study
851022|NCT02837120|acute myocardial infarction
851023|NCT02837120|acute aortic dissection
851024|NCT02837120|pulmonary embolism
851025|NCT02837120|unstable angina
851026|NCT02837068|Hemiplegia
851027|NCT02837068|shoulder pain
851028|NCT02837068|wheelchair
851029|NCT02837068|stroke
851030|NCT02837068|rehabilitation
851031|NCT02837055|intubation, intratracheal
851032|NCT02837055|critical care
851037|NCT02837016|Self-Control
851038|NCT02837016|Biofeedback
851039|NCT02837016|Respiration
851040|NCT02837003|Drug-Eluting Stent
851041|NCT02836977|tegafur-uracil
851042|NCT02836925|hepatitis C
851043|NCT02836925|NHL
851044|NCT02836925|Indolent B-cell lymphoma
851045|NCT02836912|Rehabilitation
851046|NCT02836899|acute kidney injury; nitric oxide; cardiopulmonary bypass; endothelial dysfunction; cardiac surgery
851047|NCT02836834|immunotherapy
851048|NCT02836834|check point inhibitor
851049|NCT02836834|PD-1 antibody
851050|NCT02836834|solid tumor
851051|NCT02836834|lymphoma
851052|NCT02836834|phase 1 trial
851053|NCT02836808|Multidisciplinary interventions
851054|NCT02836808|Long term control
851055|NCT02836808|Empowerment
851056|NCT02836795|anti-PD-1 monoclonal antibody
851057|NCT02836795|advanced solid tumors
851058|NCT02836795|safety
851059|NCT02836782|HIV/HCV
851060|NCT02836782|Antiretroviral therapy
851061|NCT02836782|HIV-DNA
851062|NCT02836782|Direct acting antiviral
851063|NCT02836769|Rehabilitation
851064|NCT02836769|Head and neck cancer
851065|NCT02836769|Quality of life
851066|NCT02836769|self-efficacy
851067|NCT02836743|REM sleep behavior disorder
851068|NCT02836743|Melatonin
851069|NCT02836717|sacral nerve modulation
851070|NCT02836717|quality of life
851071|NCT02836717|stimulator maintenance
851072|NCT02836717|SNM
851073|NCT02836691|Autonomic nervous system
851074|NCT02836691|Uncontrolled severe asthma
851075|NCT02836691|Paucigranulocitic asthma phenotype
851076|NCT02836691|Stress
851077|NCT02836665|Emergency Room
851078|NCT02836665|Manchester Triage System
851079|NCT02836665|Telemedicine
851080|NCT02836665|Patients
851081|NCT02836652|HeartMate II (HMII)
851082|NCT02836652|Left Ventricular Assist Device (LVAD)
851083|NCT02836600|notch inhibitor
851084|NCT02836548|advanced melanoma
851085|NCT02836548|BRAF V600 mutation
851086|NCT02836548|vorinostat
851087|NCT02836548|HDAC inhibitor
851090|NCT02836522|Health-Related Symptom Index
851091|NCT02836522|ANCHOR( ANal Cancer HSIL (high grade squamous intraepithelial lesions) Outcomes Research study)
851092|NCT02836509|Low Back Pain
851093|NCT02836509|Ibuprofen
851094|NCT02836509|Paracetamol
851095|NCT02836509|Emergency Medicine
851101|NCT02836470|Post-operative Ileus
851102|NCT02836470|Post-Operative Abdominal Adhesions
851103|NCT02836470|Return of Gastrointestinal Function
851104|NCT02836470|Anastomosis
851105|NCT02836470|Enterotomy
851106|NCT02836470|Enterostomy
851107|NCT02836470|Colorectal Surgery
851108|NCT02836470|Intestines Surgery
851109|NCT02836431|Pediatric
851110|NCT02836431|Sedation
851111|NCT02836431|Dexmedetomidine
851112|NCT02836418|FSHD
851113|NCT02836418|LGMD
851114|NCT02836405|Autism
851115|NCT02836405|ASD
851116|NCT02836405|Autistic Disorder
851117|NCT02836405|Pervasive Development Disorders
851118|NCT02836405|Pervasive Child Development Disorders
851119|NCT02836405|Asperger's Syndrome
851120|NCT02836405|Transcranial Magnetic Stimulation
851121|NCT02836405|TMS
851122|NCT02836405|Autism Spectrum Disorder
851126|NCT02836366|Proximal humerus
851127|NCT02836366|Fracture
851128|NCT02836366|Nailing
851130|NCT02836327|MRI
851131|NCT02836327|Multiple Sclerosis
851132|NCT02836327|Neuromyelitis Optica Spectrum Disorders
851133|NCT02836327|Multimodel
851134|NCT02836314|Anorganic bovine bone mineral;
851135|NCT02836314|Graft
851136|NCT02836314|Intrabony periodontal defect
851137|NCT02836314|platelet rich fibrin
851138|NCT02836288|Ketamine
851139|NCT02836288|Treatment of Depression
851140|NCT02836275|Adnexal Diseases
851141|NCT02836275|Ovary
851142|NCT02836275|Ovarian Neoplasms
851143|NCT02836275|Ovarian Cysts
851144|NCT02836275|Ovarian Diseases
851145|NCT02836275|Ultrasonography
851146|NCT02836275|Ultrasonography, Doppler
851147|NCT02836275|Magnetic Resonance Imaging
851148|NCT02836275|Diffusion Magnetic Resonance Imaging
851149|NCT02836275|Diagnosis
851150|NCT02836275|Early Diagnosis
851151|NCT02836275|Early Detection of Cancer
851152|NCT02836275|Genital Neoplasms, Female
851153|NCT02836275|Genital Diseases, Female
851154|NCT02836275|Urogenital Neoplasms
851155|NCT02836275|Cysts
851156|NCT02836275|Endocrine System Diseases
851157|NCT02836275|Gonadal Disorders
851158|NCT02836275|Neoplasms
851289|NCT02835456|micropattern
851159|NCT02836275|Endocrine Gland Neoplasms
851160|NCT02836275|International Ovarian Tumor Analysis
851161|NCT02836275|Simple Rules
851162|NCT02836275|Preoperative Evaluation
851163|NCT02836275|Perfusion -and Diffusion-weighted Imaging
851164|NCT02836275|Adnexal Masses
851165|NCT02836275|Ovarian Tumors
851166|NCT02836249|Hepatitis
851167|NCT02836249|Tenofovir
851168|NCT02836249|Viread
851169|NCT02836236|Hepatitis
851170|NCT02836236|Tenofovir
851171|NCT02836236|Viread
851172|NCT02836210|27-gauge Pars plana vitrectomy
851174|NCT02836184|Hemodialysis,Hyperphosphatemia,Nicotinic Acids
851175|NCT02836119|Gut Microbiota
851176|NCT02836119|Gut Microbiome
851177|NCT02836119|Sleep
851178|NCT02836119|Infancy
851179|NCT02836119|Development
851180|NCT02836106|Healthy Volunteers
851181|NCT02836106|Obese Volunteers
851182|NCT02836093|Exercise
851183|NCT02836093|Radiation Treatment
851184|NCT02836093|16-941
851185|NCT02836080|Mental Health
851186|NCT02836080|Randomized
851187|NCT02836080|Pragmatic
851188|NCT02836080|Integrated Collaborative Care
851189|NCT02836080|Addiction
851190|NCT02836080|Youth
851191|NCT02836054|biomarkers
851192|NCT02836054|CSF
851193|NCT02836054|MRI
851194|NCT02836054|Alzheimer's disease
851195|NCT02836054|bipolar disorder
851196|NCT02836054|cognitive functions
851200|NCT02836015|Shared Medical Visits
851201|NCT02836015|Spanish-speaking
851202|NCT02835989|Community Paramedicine
851203|NCT02835989|Paramedic
851204|NCT02835989|Emergency Medical Services
851205|NCT02835989|High Frequency Callers
851206|NCT02835989|Lift Assists
851207|NCT02835963|acute heart failure
851208|NCT02835963|dyspnea
851209|NCT02835963|predictive value
851210|NCT02835924|regorafenib
851211|NCT02835924|metastatic colorectal cancer
851212|NCT02835872|fiber
851213|NCT02835872|cholesterol
851214|NCT02835859|Obesity, sweet taste receptors
851215|NCT02835846|Overactive Bladder Syndrome
851216|NCT02835846|Female Urinary Microbiome
851217|NCT02835846|Urinary Urgency
851218|NCT02835846|Estrogen
851219|NCT02835846|Nocturia
851220|NCT02835846|Incontinence
851221|NCT02835833|advanced solid tumors
851222|NCT02835833|Nintedanib
851223|NCT02835833|Bevacizumab
851224|NCT02835833|dose escalation
851225|NCT02835820|HIV
851226|NCT02835820|Neurocognitive
851227|NCT02835820|Ketogenic Diet
851228|NCT02835807|skin cancer
851229|NCT02835794|Myelodysplastic Syndromes
851230|NCT02835781|Breast Implants
851231|NCT02835781|Acellular Dermal Matrix
851232|NCT02835729|AML
851233|NCT02835716|Phosphodiesterase type 4 inhibitor
851234|NCT02835716|ustekinumab
851235|NCT02835716|secukinumab
851236|NCT02835716|P40 subunit
851237|NCT02835716|Interleukin IL-12
851238|NCT02835716|Interleukin IL-23
851239|NCT02835716|Apoprotein e4
851240|NCT02835716|Interleukin IL-17A
851241|NCT02835703|Congenital heart disease
851242|NCT02835703|Coarctation of aorta
851243|NCT02835703|Aortic arch hypoplasia
851244|NCT02835703|Cerebral selective antegrade perfusion
851245|NCT02835703|Double arterial cannulation
851246|NCT02835690|PD1
851247|NCT02835690|PD-1
851248|NCT02835690|PDL1
851249|NCT02835690|PD-L1
851250|NCT02835677|Caregivers
851251|NCT02835677|Activities of Daily Living
851252|NCT02835664|Nicotinamide Riboside
851253|NCT02835664|Obesity
851254|NCT02835664|Metabolic health
851255|NCT02835664|Insulin resistance
851256|NCT02835664|Mitochondrial function
851257|NCT02835664|Brown adipose tissue
851258|NCT02835664|Energy expenditure
851259|NCT02835664|Ectopic lipid accumulation
851260|NCT02835664|Cardiovascular risk
851261|NCT02835664|Acetylcarnitine
851262|NCT02835651|Palmitic acid
851263|NCT02835651|Stearic acid
851264|NCT02835651|HDL-metabolism
851265|NCT02835651|Human intervention study
851266|NCT02835625|Diagnostic Imaging
851267|NCT02835625|Mammography
851268|NCT02835625|Randomized Controlled Trial
851269|NCT02835625|Tomosynthesis
851270|NCT02835625|Early performance measures
851271|NCT02835625|Recall
851272|NCT02835625|Radiation dose
851273|NCT02835625|Cancer detection
851274|NCT02835625|Sensitivity
851275|NCT02835625|Specificity
851276|NCT02835625|Cost
851277|NCT02835625|Economy
851278|NCT02835586|paclitaxel
851279|NCT02835586|critical ischemia
851280|NCT02835586|restenosis
851281|NCT02835586|femoropopliteal artery lesions TASC C and D
851282|NCT02835547|cardiovascular event
851283|NCT02835547|risk factors
851284|NCT02835547|inflammatory diseases and acquired dysimmune
851285|NCT02835534|acute ST elevation myocardial infarction
851286|NCT02835456|CAUTI
851287|NCT02835456|Biofilm
851288|NCT02835456|Urinary tract infections
851290|NCT02835456|Catheter
851291|NCT02835443|Ischemic Stroke
851292|NCT02835443|Deep Brain Stimulation
851293|NCT02835443|DBS
851294|NCT02835443|Physical Therapy
851295|NCT02835443|Rehab
851296|NCT02835430|Coronally advanced flap
851297|NCT02835430|Gingival recession
851298|NCT02835430|Bone, demineralized
851299|NCT02835430|Bone, freeze-dried
851300|NCT02835430|platelet-rich fibrin
851301|NCT02835430|root coverage procedures
851302|NCT02835417|fetal heart rate variability
851303|NCT02835417|entropy
851304|NCT02835417|multifractal analysis
851305|NCT02835417|scattering transform
851306|NCT02835417|sparse vector machine
851307|NCT02835417|acidosis
851308|NCT02835378|bilateral upper limb amputation
851309|NCT02835378|prosthetic fitting
851310|NCT02835378|epidemiology
851311|NCT02835378|clinical practices
851312|NCT02835378|totally non-functional hand
851313|NCT02835365|baclofen
851314|NCT02835365|alcohol
851315|NCT02835365|withdrawal
851316|NCT02835352|anxiety
851317|NCT02835326|Older Adults
851318|NCT02835326|Weight Loss
851319|NCT02835326|Exercise
851320|NCT02835326|Knee pain
851325|NCT02835274|parkinson disease
851326|NCT02835274|deep brain stimulation
851327|NCT02835274|directional stimulation
851328|NCT02835261|Obesity
851329|NCT02835261|Metabolic Disorders
851330|NCT02835209|spontaneous breathing test
851331|NCT02835209|premature infant
851332|NCT02835209|work of breathing
851333|NCT02835170|Immunoglobulin G
851334|NCT02835170|Treatment
851335|NCT02835157|Normal saline
851336|NCT02835157|Balanced saline
851337|NCT02835157|Septic shock
851338|NCT02835157|Children
851339|NCT02835157|Hyperchloremia
851340|NCT02835157|Acute kidney injury
851341|NCT02835131|hyperinsulinemia
851342|NCT02835131|hypoglycemia
851343|NCT02835131|somatostatin
851344|NCT02835131|pasireotide
851345|NCT02835131|congenital
851346|NCT02835079|Duchenne Tamoxifen
851347|NCT02835066|Stage I
851348|NCT02835066|Stage II
851349|NCT02835066|Stage IIIA
851350|NCT02835066|Stage IIIB
851351|NCT02835066|Stage IV
851352|NCT02835066|Non-Small Cell
851353|NCT02835040|Corticosteroid
851354|NCT02835040|Antibiotic
851355|NCT02835040|Early mobilization
851356|NCT02835040|Malnutrition
851357|NCT02835027|Acute limb ischaemia(ALI)
851358|NCT02835027|Acute ischaemia of the lower extremity
851359|NCT02835027|Thrombosis
851360|NCT02835027|Emboli
851361|NCT02835027|Endovascular surgery
851362|NCT02835027|Surgery
851363|NCT02835027|Amputation free survival
851364|NCT02835027|Long time survival
851365|NCT02835027|Demographics
851366|NCT02835014|Diabetes Mellitus Type I
851367|NCT02835014|Adolescents
851368|NCT02835014|Mental Health
851369|NCT02835014|Self efficacy
851370|NCT02835014|parenting styles
851371|NCT02834988|Endometrial Cancer
851372|NCT02834988|Sentinel Lymph Node Dissection
851373|NCT02834988|SLND
851374|NCT02834975|Fallopian Tube Carcinoma
851375|NCT02834975|Peritoneal Carcinoma
851376|NCT02834975|Epithelial Ovarian Cancer
851377|NCT02834962|Anterior Cruciate Ligament Reconstruction
851378|NCT02834897|EOS imagery
851379|NCT02834884|rare cancer
851380|NCT02834884|biomarker
851381|NCT02834884|screening
851382|NCT02834858|Umbilical Cord Mesenchymal Stem Cells
851383|NCT02834819|bronchiolitis
851384|NCT02834819|hypoxia
851385|NCT02834819|hypertonic saline
851386|NCT02834793|Lennox-Gastaut Syndrome (LGS)
851387|NCT02834793|Inadequately controlled seizures
851388|NCT02834780|Advanced Hepatocellular Carcinoma
851389|NCT02834780|H3B-6527
851390|NCT02834754|post-operative
851391|NCT02834715|Diabetes
851392|NCT02834715|Stevia
851393|NCT02834715|insulin secretion
851394|NCT02834715|insulin sensitivity
851395|NCT02834715|Sweetener
851396|NCT02834702|sinew acupuncture
851397|NCT02834702|neck pain
851398|NCT02834702|chronic pain
851399|NCT02834676|DiscoGel(R)
851400|NCT02834676|gelified ethanol
851401|NCT02834676|percutaneous treatment
851402|NCT02834676|Oswestry Disability Index (ODI)
851403|NCT02834676|Visual analog Scale (VAS)
851404|NCT02834676|Neuropathic Pain Questionnaire (DN-4)
851405|NCT02834676|cervical
851412|NCT02834624|surfactant
851413|NCT02834624|respiratory distress syndrome
851414|NCT02834624|inflammation
851415|NCT02834624|c-reactive protein
851416|NCT02834624|lipid peroxidation
851417|NCT02834546|Hepatocellular Carcinoma
851418|NCT02834546|Sorafenib
851419|NCT02834546|Toxicity
851420|NCT02834546|Plasmatic concentration
851421|NCT02834533|Lokomat;
851422|NCT02834533|robotic rehabilitation.
851423|NCT02834533|Multiple Sclerosis;
851424|NCT02834533|Virtual reality
851425|NCT02834494|locally advanced breast cancer
851426|NCT02834494|neoadjuvant chemotherapy
851427|NCT02834481|Pain Care
851428|NCT02834481|Pediatric and Neonatal Intensive Care Units
851429|NCT02834468|Dexamethasone
851430|NCT02834468|Rituximab
851431|NCT02834468|Cyclosporin
851432|NCT02834468|Intravenous Immunoglobulin
851433|NCT02834455|Thoracoscopy
851434|NCT02834403|breast cancer
851435|NCT02834403|nitric oxide synthase
851436|NCT02834403|docetaxel
851437|NCT02834403|L-NMMA
851438|NCT02834390|AML
851439|NCT02834390|phase 1
851440|NCT02834390|hematology
851441|NCT02834390|malignancy
851442|NCT02834390|newly diagnosed
851443|NCT02834377|Cardiac Output
851444|NCT02834377|Hemodynamics
851445|NCT02834377|Perioperative Care
851446|NCT02834338|activity tracking
851447|NCT02834338|postoperative recovery
851448|NCT02834338|ERAS
851449|NCT02834338|fast-track surgery
851450|NCT02834325|high flow nasal cannula
851451|NCT02834325|success
851452|NCT02834325|failure
851453|NCT02834325|ROX index
851454|NCT02834312|Estetrol
851455|NCT02834312|Vasomotor symptoms
851456|NCT02834312|Menopause
851457|NCT02834260|absorbable implant
851458|NCT02834260|subconjunctival
851459|NCT02834260|immune rejection
851460|NCT02834260|safety profile
851461|NCT02834260|dexamethasone
851462|NCT02834234|mesothelioma
851463|NCT02834234|peritoneum
851464|NCT02834234|genomic
851465|NCT02834234|CGH arrays
851466|NCT02834221|Femoral vein puncture
851467|NCT02834195|Cerebral palsy
851468|NCT02834195|reliability
851469|NCT02834195|upper limb and hand patterns
851470|NCT02834195|classification
851471|NCT02834169|Rare peritoneal surface malignancies
851472|NCT02834169|pseudomyxoma peritonei
851473|NCT02834169|peritoneal mesothelioma
851474|NCT02834169|desmoplastic small round cell tumor
851475|NCT02834169|psammocarcinoma
851476|NCT02834169|primary peritoneal serous carcinoma
851477|NCT02834169|diffuse peritoneal leiomyomatosis
851478|NCT02834169|appendiceal mucinous neoplasms
851479|NCT02834169|registry
851480|NCT02834169|population-based database
851481|NCT02834143|vascular
851482|NCT02834143|Limb Ischemia
851483|NCT02834117|Ovulation Induction
851484|NCT02834117|quality of life
851485|NCT02834117|Reproductive Physiological Processes
851486|NCT02834117|fertility
851487|NCT02834078|HbA1c
851488|NCT02834078|Pre Diabetes
851489|NCT02834078|Berberine
851490|NCT02834065|Postoperative Cognitive Decline
851491|NCT02834065|Deep Hypothermic Circulatory Arrest
851492|NCT02834065|Cardiovascular Surgical Procedures
851493|NCT02834065|Functional Magnetic Resonance Imaging
851494|NCT02834065|Small Ubiquitin-Related Modifier Proteins
851495|NCT02834052|Immunotherapy
851496|NCT02834052|Anti-programmed death 1 (PD-1) inhibitor
851497|NCT02834052|Immunostimulant
851498|NCT02834052|monoclonal antibody
851499|NCT02834052|TLR3 agonist
851500|NCT02834052|Immunologic factors
851501|NCT02834039|Tidal volume
851502|NCT02834039|renal transplant
851503|NCT02834039|donor
851504|NCT02834039|nephrectomy
851505|NCT02834039|ventilation
851506|NCT02834039|Living renal transplant donor patient
851507|NCT02834026|Muscle Strength
851508|NCT02834026|Muscle Strength Dynamometer
851509|NCT02834026|Chronic Renal Disease
851510|NCT02834026|Exercise
851511|NCT02834026|Physical therapy modalities
851512|NCT02833987|Direct oral anticoagulants
851513|NCT02833987|Safety
851514|NCT02833987|Major bleed
851515|NCT02833987|Adverse events
851516|NCT02833974|GSK2245035
851517|NCT02833974|TLR7 agonist
851518|NCT02833974|allergic asthma
851519|NCT02833974|FEV1
851520|NCT02833948|Heart Valve Disease
851521|NCT02833948|Randomized Controlled Trial
851522|NCT02833948|Transcatheter Aortic Valve Replacement
851523|NCT02833948|TAVR
851524|NCT02833948|Valve Thrombosis
851525|NCT02833935|spinal cord injury
851526|NCT02833935|physical activity
851527|NCT02833935|self-determination theory
851528|NCT02833935|life satisfaction
851529|NCT02833883|Enzalutamide
851530|NCT02833883|CC-115
851531|NCT02833883|16-074
851532|NCT02833857|Secondary Hyperparathyroidism, chronic kidney disease, hemodialysis
851533|NCT02833844|Hyperlipidemia
851534|NCT02833844|Dyslipidemia
851535|NCT02833844|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
851536|NCT02833844|Inhibition
851537|NCT02833844|HIV infection
851538|NCT02833844|Cluster of differentiation
851539|NCT02833844|Viral load
851540|NCT02833805|immunosuppression
851541|NCT02833805|nonmyeloablative
851542|NCT02833805|non-myeloablative
851543|NCT02833805|allogeneic
851544|NCT02833805|tacrolimus
851545|NCT02833805|bone marrow
851546|NCT02833805|bone marrow transplant
851547|NCT02833805|cyclophosphamide
851548|NCT02833805|thymoglobulin
851549|NCT02833805|ATG
851550|NCT02833805|fludarabine
851551|NCT02833766|Breast Cancer
851552|NCT02833766|advanced triple Negative, EGFR positive breast cancer
851553|NCT02833766|doxorubicin
851554|NCT02833766|triple negative breast cancer (TNBC)
851555|NCT02833740|Mid-Upper Arm Circumference (MUAC)
851556|NCT02833740|Mother MUAC
851557|NCT02833740|Community screening for acute malnutrition
851558|NCT02833727|asthma; smoking; Eosinophils; health care costs
851559|NCT02833675|angioedema
851560|NCT02833675|C1Inhibitor
851561|NCT02833675|bradykinin
851562|NCT02833675|Histamin
851563|NCT02833662|Hypoxia
851564|NCT02833662|Perioperative outcomes
851565|NCT02833649|Keratoconus
851566|NCT02833649|Crosslinking
851567|NCT02833649|Toric ICL
851568|NCT02833623|Helicobacter Pylori eradication rate
851569|NCT02833623|Efficacy of Short-message-based Re-education (SMRE)
851570|NCT02833610|Multiple Myeloma
851571|NCT02833597|peripheral artery disease
851572|NCT02833597|transcutaneous oxygen pressure
851573|NCT02833597|claudication
851574|NCT02833597|rowing ergometer
851575|NCT02833584|Paracetamol
851576|NCT02833558|Endoscopy, Gastrointestinal
851577|NCT02833558|Endoscopic Submucosal Dissection
851578|NCT02833558|Bleeding
851579|NCT02833519|pregnant women
851580|NCT02833519|exercise
851581|NCT02833519|depression
851582|NCT02833519|anxiety
851583|NCT02833493|Magnetic Resonance Imaging
851584|NCT02833493|Iron overload
851585|NCT02833493|Iron chelation therapy
851586|NCT02833493|Follow-up
851587|NCT02833467|Circulating Tumor DNA
851588|NCT02833467|Heterogeneous
851589|NCT02833467|Multiple primary lung cancer
851590|NCT02833454|Anterior Cruciate Ligament Reconstruction
851591|NCT02833454|Direct Insertion of Anterior Cruciate Ligament
851592|NCT02833415|Visceral
851593|NCT02833415|Obesity
851594|NCT02833415|Adipose
851595|NCT02833415|Diabetes
851596|NCT02833402|Sacral Neuromodulation
851597|NCT02833402|Urinary leakage
851598|NCT02833402|Urinary incontinence
851599|NCT02833402|Urinary microbiome
851600|NCT02833376|microbiota
851601|NCT02833376|ethanol
851602|NCT02833376|chlorhexidine
851603|NCT02833363|gastric microbiota
851604|NCT02833363|Helicobacter pylori
851605|NCT02833363|Non-atrophic Gasrititis
851606|NCT02833363|Atrophic gastritis
851607|NCT02833363|Intestinal metaplasia
851608|NCT02833363|intraepithelial neoplasia
851609|NCT02833363|Gastric cancer
851610|NCT02833337|Bone
851611|NCT02833337|Maxilla
851612|NCT02833337|Cone-Beam Computed Tomography
851613|NCT02833337|Regeneration
851614|NCT02833324|Postoperative Period
851615|NCT02833324|Colorectal Surgery
851616|NCT02833324|Surgery
851617|NCT02833311|Neuromusculoskeletal condition
851618|NCT02833298|Sustained Virological Response
851619|NCT02833298|SVR
851620|NCT02833298|patient navigation
851621|NCT02833298|screening
851622|NCT02833298|HCC
851623|NCT02833298|HCV
851624|NCT02833272|benzodiazepines
851625|NCT02833272|Z-drugs
851626|NCT02833259|Pneumonia
851627|NCT02833259|Patient readmission
851628|NCT02833259|Community-acquired infections
851629|NCT02833259|Observational study
851630|NCT02833259|Quality of health care
851631|NCT02833259|Models, Statistical
851632|NCT02833246|texting
851633|NCT02833246|Adherence to Oral Anticancer Medications
851634|NCT02833246|16-810
851635|NCT02833233|Early stage
851636|NCT02833233|Resectable
851637|NCT02833233|Ipilimumab
851638|NCT02833233|Nivolumab
851639|NCT02833233|Cryoablation
851640|NCT02833233|16-495
851641|NCT02833220|blood pressure
851642|NCT02833207|blood flow
851643|NCT02833207|vasodilation
851644|NCT02833207|skeletal muscle
851645|NCT02833207|Doppler Ultrasound
851646|NCT02833207|diabetes prevention program
851647|NCT02833207|endothelium dependent dilation
851648|NCT02833168|Neuromuscular disorders
851649|NCT02833168|Sleep disordered breathing
851650|NCT02833168|Dyspnea
851651|NCT02833155|entinostat
851652|NCT02833155|breast cancer
851653|NCT02833142|Healthy Volunteer
851654|NCT02833142|opicinumab
851655|NCT02833116|radiculalgia
851656|NCT02833116|chronic pain
851657|NCT02833116|quality of life
851658|NCT02833103|Pinaverium Bromide
851659|NCT02833103|cholecystectomy
851660|NCT02833103|Sphincter of Oddi Dysfunction
851661|NCT02833012|Healthy volunteers
851662|NCT02833012|Caprylic triglyceride oil
851663|NCT02833012|AC-1202
851664|NCT02833012|AC-1204
851665|NCT02833012|Pharmacokinetic
851666|NCT02833012|ketone body
851667|NCT02833012|Axona
851668|NCT02832999|Diabetes
851669|NCT02832999|GLP-1
851670|NCT02832999|Insulin secretion
851671|NCT02832999|insulin sensitivity
851672|NCT02832999|Africa
851673|NCT02832999|Liraglutide
851674|NCT02832999|Vildaglipin
851675|NCT02832986|Frailty consultation
851676|NCT02832973|Hypertension Resistant to Conventional Therapy
851677|NCT02832973|Natriuretic Agents
851678|NCT02832973|Renin-Angiotensin System
851679|NCT02832973|Bisoprolol
851680|NCT02832960|Thyroid Dysfunction
851681|NCT02832960|Atherosclerosis
851682|NCT02832960|Heart Failure
851683|NCT02832960|Cardiovascular imaging
851684|NCT02832960|Randomized Controlled Trial
851685|NCT02832934|Thyroid Dysfunction
851686|NCT02832934|Atherosclerosis
851687|NCT02832934|Heart Failure
851688|NCT02832934|Cardiovascular Imaging
851689|NCT02832934|Randomized Controlled Trial
851690|NCT02832921|Alzheimer's disease
851691|NCT02832921|virtual reality
851692|NCT02832921|cognitive training
851693|NCT02832895|Adults
851694|NCT02832895|Frontal bone window
851695|NCT02832895|Transcranial doppler
851696|NCT02832882|HCC
851697|NCT02832882|RFA
851698|NCT02832869|Polyp detection rate
851699|NCT02832869|Adenoma detection rate
851700|NCT02832869|Boston Bowel Preparation Scale
851701|NCT02832830|bony metastases
851702|NCT02832830|palliative radiotherapy
851703|NCT02832817|Oxygen therapy
851704|NCT02832817|Pulse oximeter
851705|NCT02832817|Hypoxia
851706|NCT02832817|Hypoxemia
851707|NCT02832817|Arterial blood gas
851708|NCT02832791|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
851709|NCT02832791|QUADRICEPS TENDON
851710|NCT02832791|HAMSTRING TENDON
851711|NCT02832765|Palliative radiotherapy
851712|NCT02832765|Bone metastases
851713|NCT02832739|Technology acceptance
851714|NCT02832739|Usability
851715|NCT02832739|eHealth
851716|NCT02832739|self-management support in chronic illness
851717|NCT02832739|prevention
851718|NCT02832739|Special Orthopaedic Co-Morbidity after hip/knee replacement
851719|NCT02832726|absorption of Vitamin B12
851720|NCT02832713|Knee osteoarthritis
851721|NCT02832713|Intra-articular botulinum toxin
851722|NCT02832713|Hyaluronic acid
851723|NCT02832713|Pain
851724|NCT02832713|Function
851725|NCT02832700|glycopeptides
851726|NCT02832700|dietary proteins
851727|NCT02832700|whey protein
851728|NCT02832700|caseinomacropeptide
851729|NCT02832700|antiinflammatories
851730|NCT02832700|human microbiome
851731|NCT02832661|renal allograft
851732|NCT02832661|graft injuries
851733|NCT02832661|biopsy
851734|NCT02832661|biomarkers
851735|NCT02832661|omics approach
851736|NCT02832635|brain metastasis
851737|NCT02832635|whole-brain radiotherapy
851738|NCT02832635|TMZ
851739|NCT02832635|avoidance of hippocampus
851740|NCT02832622|MultiPoint Pacing
851741|NCT02832622|Heart Failure
851742|NCT02832622|Cardiac Resynchronization Therapy
851743|NCT02832622|SJM Quadripolar Biventricular Pacing
851744|NCT02832609|closing volume
851745|NCT02832609|expiratory flow limitation
851746|NCT02832609|obesity
851747|NCT02832609|orthopnea
851748|NCT02832596|Anesthesia
851749|NCT02832596|Blood pressure
851750|NCT02832596|Plasma Volume
851751|NCT02832596|Vasopressor agents
851752|NCT02832596|Coronary artery bypass
851753|NCT02832596|Glycocalyx
851754|NCT02832596|ANP
851755|NCT02832596|Coagulation
851756|NCT02832583|PRP, hyaluronic acid, mesotherapy, skin wrinkle, skin rejuvenation
851757|NCT02832557|Autism
851758|NCT02832557|Asperger's Syndrome
851759|NCT02832557|microRNA
851760|NCT02832557|epigenetic
851761|NCT02832557|biomarker
851762|NCT02832544|atrial fibrillation
851763|NCT02832544|stroke
851764|NCT02832531|atrial fibrillation
851765|NCT02832531|stroke
851766|NCT02832492|disorders of consciousness
851767|NCT02832492|unresponsive wakefulness syndrome
851768|NCT02832492|pupil near response
851769|NCT02832492|prognosis of consciousness recovery
851770|NCT02832453|High intensity physical exercise
851771|NCT02832453|Primary health care
851772|NCT02832453|Behaviour change interventions
851773|NCT02832427|Coronary artery bypass grafting
851774|NCT02832427|Heart valve surgery
851775|NCT02832427|Postoperative morbidity
851776|NCT02832427|Operative mortality
851777|NCT02832401|event-related potentials
851778|NCT02832401|EEG
851779|NCT02832401|caffeine
851780|NCT02832401|psychosis
851781|NCT02832401|schizophrenia
851782|NCT02832336|Caffeine
851783|NCT02832336|Caffeine citrate
851784|NCT02832336|Neurological disorder
851785|NCT02832336|Excessive daytime sleepiness
851786|NCT02832336|Orexin
851787|NCT02832336|adenosine antagonist
851791|NCT02832310|valsalva
851792|NCT02832258|Enterobacteria
851793|NCT02832258|Children
851794|NCT02832258|Febrile urinary tract infection
851795|NCT02832258|Cystitis
851796|NCT02832258|Extended-spectrum beta-lactamase-producing Enterobacteriaceae
851797|NCT02832232|Physiotherapy
851798|NCT02832232|Manual Therapy
851799|NCT02832232|Neck Pain
851800|NCT02832219|Overweight
851801|NCT02832219|Molecular hydrogen
851802|NCT02832219|Insulin
851803|NCT02832206|Atrial fibrillation
851804|NCT02832206|Hybrid ablation
851805|NCT02832180|Rheumatoid
851806|NCT02832141|Skin blood flow
851807|NCT02832141|Skin redness
851808|NCT02832141|Sympathetic nervous system
851809|NCT02832141|Regional Blood Flow
851810|NCT02832128|Cochlear Implant
851811|NCT02832115|Radial Artery Spasm
851812|NCT02832115|Cardiac Catheterization
851813|NCT02832115|Vascular Access Site Complications
851814|NCT02832115|Vasodilator
851815|NCT02832115|Nitroglycerine
851816|NCT02832115|Lidocaine
851817|NCT02832102|prognostic modelling
851818|NCT02832102|radiomics
851819|NCT02832102|clinical decision support system
851820|NCT02832102|big data analysis
851821|NCT02832102|multiscale prognostic signatures
851822|NCT02832102|patient-clinician co-decision tools
851823|NCT02832089|atrial fibrillation
851824|NCT02832089|rate reduction
851825|NCT02832050|play
851826|NCT02832050|therapy
851827|NCT02832024|stents
851828|NCT02832024|atherectomy
851829|NCT02832024|femoral artery
851830|NCT02832024|popliteal artery
851831|NCT02832024|In-stent Restenosis
851832|NCT02831985|Child
851833|NCT02831985|Middle ear ventilation
851834|NCT02831985|Follow-up studies
851835|NCT02831985|General practitioners
851837|NCT02831959|Non-Small Cell Lung Cancer
851838|NCT02831959|NSCLC
851839|NCT02831959|Brain metastases
851840|NCT02831959|Treatment
851841|NCT02831959|Minimal toxicity
851842|NCT02831959|TTFields
851843|NCT02831959|TTF
851844|NCT02831959|Tumor Treating Fields
851845|NCT02831959|Novocure
851846|NCT02831959|SRS
851847|NCT02831959|Stereotactic radiosurgery
851848|NCT02831946|skin closure
851849|NCT02831946|intracuticular suture
851850|NCT02831946|glue (dermabond)
851851|NCT02831933|lung cancer
851852|NCT02831933|metastatic
851853|NCT02831933|gene therapy
851854|NCT02831933|immunotherapy
851855|NCT02831920|Prostate Cancer
851856|NCT02831920|MRI
851857|NCT02831920|CEUS
851858|NCT02831920|Contrast Ultrasound
851859|NCT02831920|Fusion
851860|NCT02831920|targeted biopsy
851861|NCT02831907|Ultrasonography
851862|NCT02831907|Portal vein Doppler
851863|NCT02831907|Renal Doppler
851864|NCT02831907|Cardio-Intestinal syndrome
851865|NCT02831907|Delirium
851866|NCT02831907|Renal congestion
851867|NCT02831907|Intra-renal hemodynamics
851868|NCT02831894|insomnia
851869|NCT02831894|sedative hypnotics
851870|NCT02831894|hypnotic tapering
851871|NCT02831855|Rheumatoid Arthritis
851872|NCT02831855|Tofacitinib
851873|NCT02831855|CP-690,550
851874|NCT02831855|Xeljanz
851875|NCT02831855|methotrexate withdrawal
851876|NCT02831855|withdrawal study
851877|NCT02831829|cardiac rehabilitation
851878|NCT02831829|coronary artery disease
851879|NCT02831777|non-invasive blood pressure
851887|NCT02831751|Influenza
851888|NCT02831751|Human
851889|NCT02831751|RNA Virus Infections
851890|NCT02831751|Immulogic
851891|NCT02831751|Immunogenic Factors
851892|NCT02831751|Physiological Effects of Drug
851893|NCT02831751|Virus Diseases
851894|NCT02831751|Orthomyxoviridae Infections
851895|NCT02831751|Infection
851896|NCT02831738|Fiber
851897|NCT02831738|Polydextrose
851898|NCT02831738|Glycemic Index
851899|NCT02831712|NTBI
851900|NCT02831712|Iron status
851901|NCT02831712|Iron supplement
851902|NCT02831699|Zika
851903|NCT02831699|Guillain Barré
851904|NCT02831686|Selinexor (KPT-330)
851905|NCT02831686|Ixazomib
851906|NCT02831686|dexamethasone
851907|NCT02831686|15-310
851908|NCT02831673|safety
851909|NCT02831673|treatment naïve
851910|NCT02831673|HIV 1
851911|NCT02831673|dolutegravir plus lamivudine
851912|NCT02831673|non inferiority
851913|NCT02831673|tolerability
851914|NCT02831673|dolutegravir plus tenofovir/emtricitabine
851915|NCT02831673|efficacy
851916|NCT02831634|Breast cancer
851917|NCT02831634|cutaneous melanoma
851918|NCT02831621|overweight
851919|NCT02831621|ectopic fat
851920|NCT02831621|exercise
851921|NCT02831621|diet
851922|NCT02831582|Breast Cancer
851923|NCT02831582|Postmenopausal
851924|NCT02831582|Stage IA
851925|NCT02831582|Stage IB
851926|NCT02831582|Stage IIA
851927|NCT02831582|Stage IIB
851928|NCT02831582|Stage IIIA
851929|NCT02831582|Stage IIIB
851930|NCT02831582|Stage IIIC
851931|NCT02831556|Ultrasound
851932|NCT02831556|Abdomen
851933|NCT02831556|Pelvis
851934|NCT02831556|3D
852059|NCT02830529|African American
851935|NCT02831504|Myotonic Dystrophy type 1
851936|NCT02831504|DM1
851937|NCT02831504|Muscular Dystrophy
851938|NCT02831504|Neuromuscular Diseases
851939|NCT02831491|metastatic
851940|NCT02831465|Dynamic hyperinflation
851941|NCT02831465|Maximal Voluntary Ventilation
851942|NCT02831465|Inspiratory capacity
851943|NCT02831465|healthy subjects
851944|NCT02831452|pelvic floor muscles
851945|NCT02831452|evaluation
851946|NCT02831452|dynamometer
851947|NCT02831452|perineometer
851948|NCT02831439|Choosing Wisely
851949|NCT02831439|Breast cancer
851950|NCT02831439|Controlled trial
851951|NCT02831439|High-value health care
851952|NCT02831439|Health services research
851953|NCT02831348|Asthma
851954|NCT02831348|Allergic rhinitis
851955|NCT02831348|Rhinitis
851956|NCT02831348|Pneumonia
851957|NCT02831348|Cystic fibrosis
851958|NCT02831322|Transradial
851959|NCT02831322|ﬂow-mediated vasodilation
851960|NCT02831309|physical activity
851961|NCT02831296|SMA
851962|NCT02831296|Werdnig-Hoffmann disease
851963|NCT02831296|Kugelberg-Welander disease
851964|NCT02831283|inflammation
851965|NCT02831283|aging
851966|NCT02831283|mild cognitive impairment
851967|NCT02831270|cardiac surgery
851968|NCT02831270|acute normovolemic hemodilution
851969|NCT02831257|Neurofibromatosis 2
851970|NCT02831218|bioresorbable vascular scaffold
851971|NCT02831218|coronary artery disease
852098|NCT02830308|Endocrine
851972|NCT02831205|bioresorbable vascular scaffold
851973|NCT02831205|coronary artery disease
851974|NCT02831166|Vascular closure devices
851975|NCT02831166|Transradial approach
851976|NCT02831166|Transfemoral approach
851977|NCT02831140|Fast track
851978|NCT02831140|rehabilitation
851979|NCT02831140|post operative complications
851980|NCT02831127|short message service; adherence; stent exchange; ERCP
851981|NCT02831101|BIS
851982|NCT02831101|Elderly
851983|NCT02831101|Propofol
851984|NCT02831101|Sufentanil
851985|NCT02831101|Loss of consciousness
851986|NCT02831088|Neu2000KWL
851987|NCT02831088|Neuroprotection
851988|NCT02831088|endovascular therapy
851989|NCT02831088|glutamate
851990|NCT02831088|free radical
851991|NCT02831075|Adipose-derived Stem Cells
851992|NCT02831062|nutrition
851993|NCT02831062|progression
851995|NCT02831010|prematurity
851996|NCT02830971|standardized learning curve
851997|NCT02830971|Nurse
851998|NCT02830971|intensive care unit
851999|NCT02830971|Mastery
852000|NCT02830971|Training
852001|NCT02830971|Developing
852002|NCT02830971|Skills
852003|NCT02830919|Osteoarthritis of knee
852004|NCT02830919|Glucosamine sulfate
852005|NCT02830919|Chondroitin sulfate
852006|NCT02830906|Total Knee Arthroplasty
852007|NCT02830906|Intrathecal Morphine
852008|NCT02830906|Ramosetron
852009|NCT02830906|Ondansetron
852010|NCT02830906|postoperative nausea and vomiting
852011|NCT02830867|glutathione
852012|NCT02830867|glutathione synthetase deficiency
852013|NCT02830867|autosomal inheritance
852014|NCT02830867|recessive
852015|NCT02830841|RIPC
852016|NCT02830841|hepatic ischemic and reperfusion injury
852017|NCT02830841|pediatric living donor liver transplantation
852018|NCT02830815|Broadband click stimulus testing
852019|NCT02830815|General Anesthesia
852020|NCT02830815|Sevoflurane
852021|NCT02830815|Propofol
852022|NCT02830815|Amplitude latency
852023|NCT02830815|Wave V
852024|NCT02830776|dermatochalasis
852025|NCT02830776|bimatoprost
852026|NCT02830776|blepharoplasty
852027|NCT02830763|neutral lipid storage disease
852028|NCT02830763|CNT-02
852029|NCT02830763|primary triglyceride deposit cardiomyovasculopathy (TGCV)
852030|NCT02830763|neutral lipid storage disease with myopathy (NLSD-M)
852031|NCT02830737|Small Hepatocellular Carcinoma
852032|NCT02830737|No-touch RFA
852033|NCT02830737|Traditional RFA
852034|NCT02830737|Recurrence rate
852035|NCT02830724|Metastatic Solid Cancers
852036|NCT02830724|Renal Cell Cancer
852037|NCT02830724|Cell Therapy
852038|NCT02830724|CAR T Cells
852039|NCT02830711|happiness
852040|NCT02830711|anger
852041|NCT02830711|sadness
852042|NCT02830711|anticipation
852043|NCT02830698|Nervous System
852044|NCT02830698|Hypnosis
852045|NCT02830698|Electrocardiography, Ambulatory
852046|NCT02830685|pre-pectoral breast reconstruction
852047|NCT02830685|subcutaneous breast reconstruction
852048|NCT02830633|laparoscopy
852049|NCT02830633|rectal cancer
852050|NCT02830633|pelvic autonomic nerve
852051|NCT02830568|Kidney transplantation
852052|NCT02830568|Surgical procedures
852053|NCT02830568|Kidney living donors
852054|NCT02830568|Quality of life
852055|NCT02830542|Clostridium difficile
852056|NCT02830542|C Diff
852057|NCT02830542|CDI
852058|NCT02830529|Mindfulness
852060|NCT02830529|fMRI
852061|NCT02830477|Previously treated patients
852062|NCT02830451|Registry
852063|NCT02830451|Spine
852064|NCT02830451|Surgery
852065|NCT02830451|Medical Oncology
852066|NCT02830451|Radiation Oncology
852067|NCT02830451|Neoplasms
852068|NCT02830451|Metastasis
852069|NCT02830451|Chemotherapy
852070|NCT02830451|Radiation Therapy
852071|NCT02830451|Tumor Markers
852072|NCT02830438|kidney disease
852073|NCT02830438|fibrosis
852074|NCT02830438|ultrasound
852075|NCT02830438|elastography
852076|NCT02830425|Multimorbidity
852077|NCT02830425|Polypharmacy
852078|NCT02830425|Appropriateness
852079|NCT02830425|STOPP
852080|NCT02830425|START
852081|NCT02830399|treatment-resistant-depression
852082|NCT02830399|rTMS
852083|NCT02830399|ECT
852084|NCT02830399|Augmentation strategy
852085|NCT02830373|LVIS stents
852086|NCT02830373|Intracranial aneurysm
852087|NCT02830373|Unruptured aneurysm
852088|NCT02830373|Wide-necked aneurysm
852089|NCT02830360|Antiarrhythmic drug therapy
852090|NCT02830360|VT Catheter ablation
852091|NCT02830360|ICD Therapy
852092|NCT02830360|Ischemic Heart Disease
852093|NCT02830347|antibiotic resistance
852094|NCT02830347|oral microbiome
852095|NCT02830334|Suicide
852096|NCT02830334|Youth Suicide
852097|NCT02830308|Hormones
852099|NCT02830308|Hypercortisolism
852100|NCT02830308|Bone
852101|NCT02830308|Hypothalamic-Pituitary Dysfunction
852102|NCT02830295|body awareness therapy
852103|NCT02830295|physical therapy
852104|NCT02830295|movement therapy
852105|NCT02830269|Neuro-ICU
852106|NCT02830269|Third ventricle
852107|NCT02830269|Computer Tomography
852108|NCT02830269|Transcranial Doppler ultrasonography
852109|NCT02830256|Intensive care unit
852110|NCT02830256|Neuro-ICU
852111|NCT02830256|Pain
852112|NCT02830256|Intubation
852113|NCT02830256|critical care
852114|NCT02830256|patients
852115|NCT02830217|STEMI
852116|NCT02830217|primary PCI
852117|NCT02830217|sST2
852118|NCT02830217|prognosis
852119|NCT02830204|mitral valve regurgitation
852120|NCT02830204|mitral valve stenosis
852121|NCT02830191|Cyclosporine, Dried blood spot
852122|NCT02830152|Stroke
852123|NCT02830152|intracerebral hemorrhage
852124|NCT02830152|left atrial appendage occlusion
852125|NCT02830152|atrial fibrillation
852126|NCT02830152|oral anticoagulation
852127|NCT02830152|preventive therapy
852128|NCT02830126|Outcomes
852129|NCT02830126|Information technology
852130|NCT02830113|periodontitis
852131|NCT02830113|diabetes
852132|NCT02830113|prevention
852133|NCT02830113|impaired glucose tolerance
852134|NCT02830113|insulin resistance
852135|NCT02830100|Intern speech
852136|NCT02830100|Speech and visual imaging
852137|NCT02830100|Mind and oral drift
852138|NCT02830100|Cognitive performance
852139|NCT02830100|Magnetic Resonance Imaging
852140|NCT02830087|randomized controlled trial
852141|NCT02830087|tourniquet
852142|NCT02830087|tourniquet cuff pressure
852143|NCT02830087|total knee arthroplasty
852144|NCT02830087|total knee replacement
852145|NCT02830087|pain, postoperative
852146|NCT02830087|range of motion, articular
852147|NCT02830087|blood loss, surgical
852148|NCT02830087|muscle strength, quadriceps
852149|NCT02830087|walking
852150|NCT02830087|manipulation, orthopedic/therapeutic use
852151|NCT02830087|wound healing/surgery
852152|NCT02830074|Sleep Apnea Syndromes
852153|NCT02830074|Spinal Cord Injuries
852154|NCT02830074|Sleep
852155|NCT02830074|Quality of life
852156|NCT02830061|Cancer
852157|NCT02830061|Teenage
852158|NCT02830061|Young Adult
852159|NCT02830061|Fertility
852160|NCT02830061|Cryopreservation
852161|NCT02830061|Experience
852162|NCT02830048|diabetes
852163|NCT02830048|glibenclamide
852164|NCT02830048|glucagon
852165|NCT02830035|ultrasound guided
852166|NCT02830035|spinal anesthesia
852167|NCT02830035|neuraxial block
852168|NCT02830035|paramedian
852169|NCT02830022|autism spectrum disorder
852170|NCT02829996|glaucoma
852171|NCT02829996|primary open-angle glaucoma
852172|NCT02829996|ocular hypertension
852173|NCT02829996|adenosine agonist
852174|NCT02829996|eye drop
852175|NCT02829996|trabodenoson
852176|NCT02829996|trabecular meshwork
852177|NCT02829983|clarithromycin
852178|NCT02829983|periodontal debridement
852179|NCT02829983|aggressive periodontitis
852180|NCT02829970|Attention Deficit Hyperactivity Disorder
852181|NCT02829970|Alcohol-Related Disorders
852182|NCT02829970|Substance-Related Disorders
852183|NCT02829970|Motivational Interviewing
852184|NCT02829970|Behavior Therapy
852185|NCT02829944|Cesarean section
852186|NCT02829931|recurrent glioma
852187|NCT02829931|high grade glioma
852188|NCT02829931|head and neck disease
852189|NCT02829931|grade III glioma
852190|NCT02829931|grade IV glioma
852191|NCT02829931|radiation therapy
852192|NCT02829918|advanced biliary tract cancer
852193|NCT02829918|refractory biliary tract cancer
852194|NCT02829918|digestive diseases
852195|NCT02829918|immunotherapy
852196|NCT02829905|mass screening
852197|NCT02829905|patient satisfaction
852198|NCT02829905|radiography
852199|NCT02829905|mammography
852200|NCT02829879|Dentin Sensitivity
852201|NCT02829879|Arginin
852202|NCT02829879|Potassium Nitrate
852203|NCT02829879|Dentifrice
852204|NCT02829879|RCT
852205|NCT02829853|SARCOIDOSIS
852206|NCT02829853|GRANULOMA DISEASES
852207|NCT02829853|GENETICS
852208|NCT02829853|PREDISPOSITION
852209|NCT02829853|EXOME (WES-NGS)
852210|NCT02829840|Leukemia
852211|NCT02829840|FLT3-Mutated Acute Myeloid Leukemia
852212|NCT02829840|FLT3-Mutated High-Risk Myelodysplastic Syndrome
852213|NCT02829840|Acute Myeloid Leukemia
852214|NCT02829840|AML
852215|NCT02829840|Myelodysplastic Syndrome
852216|NCT02829840|MDS
852217|NCT02829840|Ponatinib
852218|NCT02829840|Iclusig
852219|NCT02829840|AP24534
852220|NCT02829840|5-azacytidine
852221|NCT02829840|Azacitidine
852222|NCT02829840|5-aza
852223|NCT02829840|Vidaza
852224|NCT02829840|5-AZC
852225|NCT02829840|AZA-CR
852226|NCT02829840|Ladakamycin
852227|NCT02829840|NSC-102816
852228|NCT02829840|Azacytidine
852229|NCT02829827|Radiprodil
852230|NCT02829827|Infantile spasms
852231|NCT02829827|IS
852232|NCT02829827|Infantile
852233|NCT02829827|Spasms
852234|NCT02829827|Epilepsy
852235|NCT02829827|Paediatrics
852236|NCT02829827|Drug-resistant
852237|NCT02829827|West Syndrome
852238|NCT02829827|Hypsarrhythmia
852239|NCT02829814|Pain
852240|NCT02829814|Sleep
852241|NCT02829814|Fibromyalgia
852242|NCT02829814|FM
852243|NCT02829801|animal assisted therapy
852244|NCT02829801|well-being
852245|NCT02829801|Alzheimer's Disease
852246|NCT02829788|Digestive peritoneal carcinomatosis
852247|NCT02829788|laparoscopy
852248|NCT02829788|laparotomy
852249|NCT02829788|peritoneal cancer index (PCI)
852250|NCT02829788|staging
852251|NCT02829762|isolated
852252|NCT02829762|at risk of isolation
852253|NCT02829762|patients
852254|NCT02829749|Heart Valve Diseases
852255|NCT02829749|Heart failure
852256|NCT02829749|Heart diseases
852257|NCT02829749|Mitral valve insufficiency
852258|NCT02829736|lung neoplasm
852259|NCT02829736|lung metastasis
852260|NCT02829736|enhanced recovery after surgery
852261|NCT02829736|fast-track surgery
852262|NCT02829736|intraoperative chest tube removal
852263|NCT02829736|pain
852264|NCT02829736|lung function
852265|NCT02829736|reasons for admission
852266|NCT02829723|Phase I/II
852267|NCT02829723|BLZ945
852268|NCT02829723|PDR001
852269|NCT02829723|CSF-1R
852270|NCT02829723|PD-1
852271|NCT02829710|Analgesia
852272|NCT02829710|intensive care units
852273|NCT02829710|clinical protocol
852274|NCT02829710|deep sedation
852275|NCT02829710|nursing assessment
852276|NCT02829697|Regional anaesthesia
852277|NCT02829671|Loneliness
852278|NCT02829671|Suicidal behavior
852279|NCT02829671|Depression
852280|NCT02829645|eating disoders
852281|NCT02829645|neuropsychology
852282|NCT02829645|pronostic
852283|NCT02829632|mobile technology
852284|NCT02829632|feedback message
852285|NCT02829632|self-monitoring
852286|NCT02829619|Obesity
852287|NCT02829619|Nutrigenetics
852288|NCT02829619|Food Timing
852289|NCT02829619|Weight loss
852290|NCT02829606|Age-related Macular Degeneration
852291|NCT02829606|Central Scotoma
852292|NCT02829606|Head Mounted Display
852293|NCT02829580|endothelial function
852294|NCT02829580|flow-mediated dilation
852295|NCT02829580|vascular elastic properties
852296|NCT02829554|Emotion
852297|NCT02829554|Judgment
852298|NCT02829554|Decision Making
852299|NCT02829541|Single Ascending Dose (SAD), Healthy Volunteers
852300|NCT02829502|Cerebrovascular disease
852301|NCT02829502|Glucagon like peptide 1
852302|NCT02829489|nutrition
852303|NCT02829489|foregut tumors
852304|NCT02829489|patient related outcomes
852305|NCT02829489|audit
852306|NCT02829476|Adolescent idiopathic Scoliosis
852307|NCT02829476|Ghrelin
852308|NCT02829450|peritoneal ultrafiltration
852309|NCT02829450|congestive heart failure
852310|NCT02829450|chronic kidney disease
852311|NCT02829398|cerebral ischemia
852312|NCT02829385|Apatinib
852313|NCT02829385|XELOX Regimen
852314|NCT02829385|metastatic colorectal cancer
852315|NCT02829346|Tranexamic acid
852316|NCT02829346|Peri-articular injection
852317|NCT02829346|Total knee arthroplasty
852318|NCT02829346|Blood loss
852319|NCT02829346|Osteoarthritis, Knee
852320|NCT02829333|analgesia
852321|NCT02829333|anesthesia
852322|NCT02829333|leiomyomas
852323|NCT02829333|tumor
852324|NCT02829333|vascular endothelial growth factor
852325|NCT02829333|anesthesia technique on tumor
852326|NCT02829320|efficacy
852327|NCT02829320|hemodialysis (HD)
852328|NCT02829320|hemoglobin (Hgb)
852329|NCT02829320|erythropoiesis-stimulating agents (ESAs)
852330|NCT02829320|GSK1278863
852331|NCT02829307|89Zirconium
852332|NCT02829307|Open label
852333|NCT02829307|Pharmacokinetics
852334|NCT02829307|Radioactive
852335|NCT02829307|Clearance
852336|NCT02829307|Biodistribution
852337|NCT02829281|knee osteoarthritis
852338|NCT02829281|Intra-articular injection
852339|NCT02829281|Botulinum Toxin Type A
852340|NCT02829281|Corticosteroid
852341|NCT02829268|Wolfram syndrome
852342|NCT02829268|Diabetes Mellitus
852343|NCT02829268|Optic Nerve Atrophy
852344|NCT02829268|Ataxia
852345|NCT02829268|Endoplasmic Reticulum Stress
852346|NCT02829255|High altitude
852347|NCT02829255|Cerebral autoregulation
852348|NCT02829255|Transfer function analysis
852349|NCT02829242|Near Infrared Spectroscopy
852350|NCT02829242|Somatic Saturation
852351|NCT02829242|Well Leg Compartment Syndrome
852352|NCT02829242|Robotic Assisted Laparoscopic Surgery
852353|NCT02829242|Trendelenburg Position
852354|NCT02829216|myelosuppression
852355|NCT02829216|mesenchymal stromal cells
852356|NCT02829203|Frailty
852357|NCT02829203|Surgery
852358|NCT02829190|External carotid artery
852359|NCT02829190|Facial artery
852360|NCT02829190|Lingual artery
852361|NCT02829190|Superior thyroid artery
852362|NCT02829190|Internal maxillary artery
852363|NCT02829190|Phase-contrast MRI
852364|NCT02829190|Rate of flow
852365|NCT02829190|Superficial temporal artery
852366|NCT02829177|Type 1 diabetes
852367|NCT02829177|Diabetic nephropathy
852368|NCT02829177|Albuminuria
852369|NCT02829177|Allopurinol
852370|NCT02829164|Tonsillectomy
852371|NCT02829164|primary IgA nephropathy
852372|NCT02829164|primary nephropathy
852373|NCT02829164|IgA
852374|NCT02829164|Berger's disease
852375|NCT02829164|Purpura rheumatoid
852376|NCT02829164|kidney failure
852377|NCT02829151|Peripheral artery disease
852378|NCT02829151|Critical limb ischemia
852379|NCT02829151|Angioplasty
852380|NCT02829151|Antiplatelet therapy
852381|NCT02829125|Early rehabilitation
852382|NCT02829125|abdominal surgery
852383|NCT02829125|ERAS
852384|NCT02829112|Shulman
852385|NCT02829112|fasciitis
852386|NCT02829112|Shulman fasciitis
852387|NCT02829112|eosinophilic fasciitis
852388|NCT02829112|inflammatory disease
852389|NCT02829112|prevalence
852390|NCT02829073|Tinnitus
852391|NCT02829073|Double-blind
852392|NCT02829073|Neuromonic Tinnitus Treatment Program
852393|NCT02829073|Oasis™
852394|NCT02829060|nephrolithiasis
852395|NCT02829060|percutaneous nephrolithiasis
852396|NCT02829060|urinary tract infection (UTI)
852397|NCT02829060|Sepsis
852401|NCT02829021|Sensitivity
852402|NCT02829021|Specificity
852403|NCT02829021|Breast cancer
852404|NCT02829021|Mammography
852405|NCT02829021|Thermography
852406|NCT02829021|Infrared
852407|NCT02829021|Dynamic
852408|NCT02829021|Diagnostic accuracy
852409|NCT02829021|Diagnostic odds ratio
852410|NCT02829008|HER2 negative breast cancer
852411|NCT02829008|low-dose bevacizumab
852412|NCT02829008|pemetrexed
852413|NCT02828995|Diabetes Mellitus
852414|NCT02828995|Stigma
852415|NCT02828995|Social Determinants of Health
852416|NCT02828982|powered ankle prosthesis
852417|NCT02828982|activity monitoring
852418|NCT02828982|muscle fatigue
852419|NCT02828982|below knee amputation
852420|NCT02828969|Trajectory
852421|NCT02828969|Emergency room
852422|NCT02828969|Conduct disorder
852423|NCT02828969|Care management
852424|NCT02828956|eating disorders
852425|NCT02828956|ANSOCQ
852426|NCT02828956|anorexia nervosa
852427|NCT02828878|Apoptosis
852428|NCT02828878|FAS Ligand
852429|NCT02828878|Bone marrow transplantation
852430|NCT02828878|GvHD
852431|NCT02828878|Stem cells
852432|NCT02828865|Hepatocellular Carcinoma
852433|NCT02828865|irreversible electroporation
852434|NCT02828865|liver cancer
852435|NCT02828852|pregnancy
852436|NCT02828852|platelets
852437|NCT02828839|Transperineal
852438|NCT02828839|Transrectal
852439|NCT02828839|Needle Guide
852440|NCT02828839|Biopsy
852441|NCT02828761|chest pain
852442|NCT02828761|calcium score
852443|NCT02828761|coronary calcium score
852444|NCT02828761|coronary calcium scoring
852445|NCT02828761|calcium scoring
852446|NCT02828761|cacs
852447|NCT02828761|ccs
852448|NCT02828748|cannabinoids
852449|NCT02828748|inflammatory bowel disease
852450|NCT02828722|Circadian rhythm
852451|NCT02828722|Critical Illness
852452|NCT02828722|Mechanical ventilation
852453|NCT02828722|Environmental modulation
852454|NCT02828696|CAD-CAM composites
852455|NCT02828696|Worn dentition
852456|NCT02828696|minimally invasive treatment
852457|NCT02828683|DES
852458|NCT02828683|PCI
852459|NCT02828683|STEMI
852460|NCT02828683|Interventional Cardiology
852462|NCT02828644|ADHD
852463|NCT02828592|SAA
852464|NCT02828579|obesity
852465|NCT02828579|bariatric surgery
852466|NCT02828579|non-alcoholic fatty liver disease
852467|NCT02828553|Wearable device
852468|NCT02828553|Fitbit
852469|NCT02828553|Inpatient
852470|NCT02828540|HT047
852471|NCT02828540|Pueraria lobata
852472|NCT02828540|Scutellaria baicalensis
852473|NCT02828501|Pain Threshold
852474|NCT02828436|Hypertension
852475|NCT02828436|High Blood Pressure
852476|NCT02828423|periodontal regeneration
852478|NCT02828332|Autism Spectrum Disorders
852479|NCT02828332|Cohort
852480|NCT02828306|stroke
852481|NCT02828306|head trauma
852482|NCT02828306|Patient Specific Implant
852483|NCT02828306|skull defect
852484|NCT02828267|Tanzania
852485|NCT02828267|Alcohol Use
852486|NCT02828267|Brief Intervention
852487|NCT02828228|obesity
852488|NCT02828228|weight loss
852489|NCT02828228|vitamin D deficiency
852490|NCT02828228|body composition
852491|NCT02828202|Melanoma
852492|NCT02828202|Skin
852493|NCT02828202|Biobank
852494|NCT02828189|Physical Therapy Modalities
852495|NCT02828189|Breast Cancer Treatment
852496|NCT02828189|Exercise Therapy
852497|NCT02828189|Dyspnea
852498|NCT02828176|cardiometry
852499|NCT02828176|uterine displacement
852500|NCT02828111|Gorlin Syndrome
852501|NCT02828111|Basal Cell Nevus Syndrome BCNS
852502|NCT02828111|nevoid basal cell carcinoma syndrome
852503|NCT02828111|Basal cell carcinoma
852504|NCT02828111|Hedgehog inhibitor
852505|NCT02828111|Surgically Eligible Basal Cell Carcinomas
852506|NCT02828098|aggressive solid tumors
852507|NCT02828059|Caesarean section
852508|NCT02828007|EIT
852509|NCT02828007|NIV
852510|NCT02827968|PDL-1
852511|NCT02827942|pylori
852512|NCT02827903|Metformin
852513|NCT02827903|Rosuvastatin
852514|NCT02827903|type 2 diabetes
852515|NCT02827903|dyslipidemia
852516|NCT02827864|Mirror therapy
852517|NCT02827864|transcranial direct current stimulation
852518|NCT02827864|stroke
852519|NCT02827864|neurorehabilitation
852520|NCT02827851|Damage of articular cartilage
852521|NCT02827851|Cartilage degeneration
852522|NCT02827851|Intraarticular injection
852523|NCT02827851|SVF
852524|NCT02827851|Stromal vascular fraction
852525|NCT02827851|Adipose-derived regenerative cells (ADRC)
852526|NCT02827851|Adipose tissue
852527|NCT02827851|Stem cells
852528|NCT02827825|Neurosurgical
852529|NCT02827825|Intensive Care
852530|NCT02827799|heart failure
852531|NCT02827799|insomnia
852532|NCT02827799|sleep disorders
852533|NCT02827799|actigraphy
852534|NCT02827799|cardiomyopathy
852535|NCT02827799|depression
852536|NCT02827799|sleepiness
852537|NCT02827799|anxiety
852538|NCT02827799|fatigue
852539|NCT02827786|hepatic tumours
852540|NCT02827773|Literacy
852541|NCT02827747|Keratoconus progression
852542|NCT02827747|Vitamins and keratoconus
852543|NCT02827747|Vitamin supplementation
852544|NCT02827682|IoC
852545|NCT02827682|monitor
852546|NCT02827682|elderly
852547|NCT02827682|postoperative effectiveness
852548|NCT02827656|Fertilization in vitro
852549|NCT02827656|Luteal Phase
852550|NCT02827656|ovarian hyperstimulation syndrome
852551|NCT02827617|Ibrutinib
852552|NCT02827617|TP53
852553|NCT02827617|Chronic lymphocytic leukemia
852554|NCT02827604|Caesarean section
852555|NCT02827604|lower uterine segment
852556|NCT02827604|sonography
852557|NCT02827591|repeat cesarean section
852558|NCT02827591|lower uterine segment
852559|NCT02827591|quantitative sonography
852560|NCT02827565|colorectal cancer
852561|NCT02827565|Kras mutation
852562|NCT02827565|Nras mutation
852563|NCT02827565|Braf mutation
852564|NCT02827552|pediatric oncology
852565|NCT02827552|radiotherapy
852566|NCT02827552|radiosensitivity
852567|NCT02827513|Centanafadine
852568|NCT02827513|Adult attention-deficit hyperactivity disorder
852569|NCT02827513|Healthy participants
852570|NCT02827448|Left Ventricular Assist Device
852571|NCT02827448|Heart transplantation
852572|NCT02827448|Perioperative
852573|NCT02827448|Acute Kidney Injury
852574|NCT02827448|Renal
852575|NCT02827448|Kidney
852576|NCT02827448|Total Artificial Heart
852577|NCT02827422|therapeutic hypothermia
852578|NCT02827409|Delayed cord clamping
852579|NCT02827396|Disability
852580|NCT02827396|children
852581|NCT02827396|parents
852582|NCT02827396|depression
852583|NCT02827396|knowledge
852584|NCT02827396|psychosocial intervention
852585|NCT02827344|PD-1/PD-L1
852586|NCT02827344|Immune checkpoints
852587|NCT02827344|Immunotherapy
852588|NCT02827344|lung cancer
852589|NCT02827344|circulating tumor cells
852590|NCT02827344|immunocytochemistry
852591|NCT02827344|ISET
852592|NCT02827344|MDSC
852593|NCT02827344|Stage IV non-small cell lung cancer
852594|NCT02827331|Benzodiazepines
852595|NCT02827331|Fracture
852596|NCT02827318|Blood glucose
852597|NCT02827305|antiplaque
852598|NCT02827305|antigingivitis
852599|NCT02827292|music
852600|NCT02827292|inflammation
852601|NCT02827279|Autism Spectrum Disorder
852602|NCT02827279|Emotion
852603|NCT02827253|brain
852604|NCT02827253|haemodialysis
852605|NCT02827253|intradialytic hypotension
852606|NCT02827240|Female sex workers
852607|NCT02827240|HIV testing
852608|NCT02827240|HIV self-test
852609|NCT02827227|HIV-infected patients
852610|NCT02827227|cART
852611|NCT02827227|immune restoration
852612|NCT02827227|markers
852613|NCT02827214|Thoracolumbar spine
852614|NCT02827214|Burst fractures
852615|NCT02827214|Conservative treatment
852616|NCT02827214|Surgical treatment
852617|NCT02827214|Thoracic or lumbar vertebrae
852618|NCT02827201|pancreatic cancer
852622|NCT02827149|HSCT
852623|NCT02827149|high resolution HLA typing
852624|NCT02827149|unrelated donor
852625|NCT02827084|electromyography
852626|NCT02827084|torque
852627|NCT02827084|quadriceps muscle
852628|NCT02827058|Delivery, obstetric
852629|NCT02827058|Analgesia, Epidural
852630|NCT02827058|Injections, Epidural
852631|NCT02827058|Needles
852632|NCT02827058|Cesarean Section
852633|NCT02827032|Hypertension
852634|NCT02827006|Bone graft
852635|NCT02827006|Calcium phosphate bone cement
852636|NCT02827006|RCT
852637|NCT02827006|Xray
852638|NCT02827006|CT
852639|NCT02826993|PillCAM2
852640|NCT02826967|Hydro-San Plus colonic irrigation system
852641|NCT02826967|Screening colonoscopy
852642|NCT02826954|Paranasal Sinus Diseases
852643|NCT02826954|Nasal Obstruction
852644|NCT02826941|hypothermia treatment
852645|NCT02826915|newborn
852646|NCT02826915|infant
852647|NCT02826915|child
852648|NCT02826915|EEG
852649|NCT02826915|NIRS
852650|NCT02826902|Total intravenous anesthesia
852651|NCT02826902|desflurane
852652|NCT02826902|QoR-40
852653|NCT02826902|cosmetic lower limb lengthening
852654|NCT02826889|Fluid responsiveness
852655|NCT02826889|pulse pressure variation
852656|NCT02826889|pleth variability index
852657|NCT02826889|prone position
852658|NCT02826876|Laparoscopic surgery
852659|NCT02826863|seizure
852660|NCT02826863|tonic-atonic
852661|NCT02826863|epilepsy
852662|NCT02826863|myoclonic
852663|NCT02826863|encephalopathy
852664|NCT02826850|Osteoarthritis, Knee
852665|NCT02826850|Pulsed Radiofrequency Treatment
852666|NCT02826850|Ultrasonography, Interventional
852667|NCT02826837|Advanced Colorectal Cancer
852668|NCT02826824|corpus callosum agenesis
852669|NCT02826824|agenesis
852670|NCT02826824|corpus callosum
852671|NCT02826811|Graft dysfunction
852672|NCT02826811|Graft loss
852673|NCT02826811|kidney
852674|NCT02826811|Transplantation
852675|NCT02826811|BKV
852676|NCT02826811|Anti-BKV
852677|NCT02826811|Nephropathy
852678|NCT02826811|Immunosuppression
852679|NCT02826811|Prognostic markers
852680|NCT02826798|VBI-1501A
852681|NCT02826798|VBI-1501
852682|NCT02826798|prophylactic vaccine
852683|NCT02826798|virus diseases
852684|NCT02826798|cytomegalovirus
852685|NCT02826798|CMV
852686|NCT02826798|cytomegalovirus infections
852687|NCT02826798|cytomegalovirus vaccines
852688|NCT02826798|Herpesviridae Infections
852689|NCT02826798|Phase 1
852690|NCT02826798|Human Herpesvirus 5
852691|NCT02826798|HHV5
852692|NCT02826798|Vaccines, virus-like particle
852693|NCT02826798|VLP
852694|NCT02826798|enveloped virus-like particle
852695|NCT02826798|eVLP
852696|NCT02826759|sphingolipid
852697|NCT02826759|diabetes mellitus
852698|NCT02826759|biomarker
852699|NCT02826759|obesity
852700|NCT02826759|insulin resistance
852701|NCT02826733|preterm infants
852702|NCT02826733|term infants
852703|NCT02826733|hemispheric dominance
852704|NCT02826720|HDL cholesterol
852705|NCT02826720|Hyperlipidemia
852706|NCT02826720|LDL cholesterol
852707|NCT02826720|Periodontal disease
852708|NCT02826720|Triglyceride
852709|NCT02826655|WF-OCT
852710|NCT02826655|OCT
852711|NCT02826655|diabetic retinopathy
852712|NCT02826655|diabetic macular edema
852713|NCT02826642|newly diagnosed acute myeloid leukemia
852714|NCT02826642|AML
852715|NCT02826642|myeloid dysplastic syndrome
852716|NCT02826642|MDS
852717|NCT02826642|IDH305
852718|NCT02826642|standard of care in IDH1 mutant acute myeloid leukemia
852719|NCT02826629|Sensorimotor Integration
852720|NCT02826629|Schizophrenia
852721|NCT02826629|TMS
852722|NCT02826629|Oculomotor
852723|NCT02826629|Motor Control
852724|NCT02826616|Trimetazidine
852725|NCT02826616|ST-segment elevation myocardial
852726|NCT02826616|Reperfusion injury
852727|NCT02826616|Percutaneous coronary intervention
852728|NCT02826603|Plaque psoriasis,
852729|NCT02826603|secukinumab,
852730|NCT02826603|ustekinumab
852731|NCT02826564|radiotherapy
852732|NCT02826564|immunotherapy
852733|NCT02826512|BRCA1-like
852734|NCT02826512|HER2 negative
852735|NCT02826499|Pediguard
852736|NCT02826499|Pedicular screws
852737|NCT02826499|Fluoroscopy
852738|NCT02826473|Dementia
852739|NCT02826473|Dementia screening
852740|NCT02826473|General Hospital
852741|NCT02826473|Inpatients
852742|NCT02826460|Transplant
852743|NCT02826460|Adherence
852744|NCT02826434|Breast Cancer
852745|NCT02826434|vaccine
852746|NCT02826434|immunotherapy
852747|NCT02826434|PD-L1 Inhibitor
852748|NCT02826434|triple negative breast cancer
852749|NCT02826421|Intraocular lens
852750|NCT02826395|Prostate cancer
852751|NCT02826395|diagnostic
852752|NCT02826395|imaging
852753|NCT02826395|PET/CT
852754|NCT02826395|Acetate carbon-11
852755|NCT02826369|Algorithms
852756|NCT02826369|Image Processing, Computer-Assisted/methods*
852757|NCT02826369|Magnetic Resonance Imaging/methods*
852758|NCT02826369|Data Compression
852759|NCT02826369|Breast Neoplasms
852760|NCT02826356|Angioedema
852761|NCT02826356|Emergency treatment
852762|NCT02826356|Treatment availability
852763|NCT02826356|Health Equity
852764|NCT02826343|COPD
852765|NCT02826330|Crohn's Disease
852766|NCT02826330|Healthy relatives
852767|NCT02826330|Dysbiosis
852768|NCT02826330|Biomarkers
852769|NCT02826304|Vaginal Hysterectomy
852770|NCT02826304|Laparoscopic assisted vaginal hysterectomy
852771|NCT02826304|Large uteri
852772|NCT02826291|OSNA
852773|NCT02826291|sentinel
852774|NCT02826291|lymph
852775|NCT02826291|node
852776|NCT02826291|endometrial
852777|NCT02826291|cancer
852778|NCT02826278|Newborn genitalia
852779|NCT02826278|reference charts
852780|NCT02826252|Pulmonary Arterial Hypertension (PAH)
852781|NCT02826213|Renal infusion
852782|NCT02826213|Renal infusion device
852783|NCT02826200|Transcatheter aortic valve implantation
852784|NCT02826200|Transcatheter aortic valve replacement
852785|NCT02826200|Prosthetic Cardiac Valve Thrombosis
852786|NCT02826200|Cerebrovascular Accident
852787|NCT02826200|Prosthetic Valve Malfunction
852788|NCT02826200|Four-dimensional volume rendered cardiac CT
852789|NCT02826200|Transesophageal echocardiography
852790|NCT02826200|Transthoracic echocardiography
852791|NCT02826200|Brain MRI
852792|NCT02826187|Acetabular implant
852793|NCT02826161|Neoplasms
852794|NCT02826161|Neoplasms by Site
852795|NCT02826161|Lung Neoplasms
852796|NCT02826161|Thoracic Neoplasms
852797|NCT02826161|Respiratory Tract Neoplasms
852798|NCT02826161|Bronchial Neoplasms
852799|NCT02826096|Psychiatry
852800|NCT02826096|psychological
852801|NCT02826096|psychotherapy
852802|NCT02826096|randomize
852803|NCT02826096|Biofeedback
852804|NCT02826070|Chronic Hepatitis B
852805|NCT02826031|Sodium Hyaluronate
852806|NCT02826031|mild to moderate knee osteoarthritis
852807|NCT02826018|RNAi therapeutic
852808|NCT02826018|Hepatitis B
852809|NCT02826018|Chronic Hepatitis B
852810|NCT02826018|Hepatitis B, Chronic
852811|NCT02826018|Hepatitis B Infection
852812|NCT02826018|HBV
852813|NCT02825927|Dysphagia
852814|NCT02825927|Oral screen
852815|NCT02825927|Intervention
852816|NCT02825927|Oral Health
852817|NCT02825927|Food Intake
852818|NCT02825927|Quality of life
852819|NCT02825927|Elderly
852820|NCT02825927|Short-term care facilities
852821|NCT02825914|glycopeptides
852822|NCT02825914|human microbiome
852823|NCT02825914|caseinomacropeptide
852824|NCT02825914|whey protein
852825|NCT02825914|dietary proteins
852826|NCT02825849|endometrium
852827|NCT02825849|thin uterine lining
852828|NCT02825849|uterine scarring
852829|NCT02825836|M7583
852830|NCT02825836|Bruton's Tyrosine Kinase Inhibitor
852831|NCT02825836|Lymphoma
852832|NCT02825836|Open
852833|NCT02825836|Phase I
852834|NCT02825810|breast cancer
852835|NCT02825810|long-term survival
852836|NCT02825810|motor control
852837|NCT02825810|cervical pain
852838|NCT02825797|Broadly neutralizing antibody
852839|NCT02825797|3BNC117
852840|NCT02825797|10-1074
852841|NCT02825784|potassium chronic kidney disease CKD children
852847|NCT02825732|Alzheimer's disease or related disorder
852848|NCT02825732|Comorbidity
852849|NCT02825732|Charlson comorbidity index
852850|NCT02825732|Caregiver burden
852851|NCT02825732|Cohort
852852|NCT02825732|Dementia
852853|NCT02825732|Behavioral disorders
852854|NCT02825732|Functional dependency
852855|NCT02825719|Fibroid
852856|NCT02825719|Ulipristal
852980|NCT02825043|COPD
852857|NCT02825719|Selective progesterone receptor modulator
852858|NCT02825719|Chinese
852859|NCT02825706|Hemophilia
852860|NCT02825706|Educational Physiotherapy
852861|NCT02825706|Pain
852862|NCT02825706|Quality of life
852863|NCT02825706|Illness Behaviour
852864|NCT02825706|Elbow
852865|NCT02825680|Weight Loss
852866|NCT02825680|Body Weight Maintenance
852867|NCT02825680|Quality Improvement
852868|NCT02825667|Haemophilia
852869|NCT02825667|Ankle
852870|NCT02825667|Arthropathy
852871|NCT02825667|Pain
852872|NCT02825667|Range of motion
852873|NCT02825667|Myofascial techniques
852874|NCT02825654|Pulmonary
852875|NCT02825654|Lung
852876|NCT02825654|Military and environmental exposures
852877|NCT02825654|Epidemiologic
852878|NCT02825654|Observational
852879|NCT02825654|Interview or questionnaire
852880|NCT02825654|Deployment related
852881|NCT02825654|Enduring Freedom
852882|NCT02825654|Iraqi Freedom
852883|NCT02825615|radial artery cannulation
852884|NCT02825615|ultrasound guided
852885|NCT02825615|first success rate
852886|NCT02825615|systolic blood pressure
852887|NCT02825615|shock
852888|NCT02825602|Vietnam veteran
852889|NCT02825602|aging
852890|NCT02825602|health
852891|NCT02825602|War Injury
852892|NCT02825602|Conventional Warfare
852893|NCT02825602|Toxic Effect
852894|NCT02825602|Chemical
852895|NCT02825589|BIA
852896|NCT02825589|chronic hemodialysis
852897|NCT02825589|sleep quality
852898|NCT02825550|Hepatoma
852899|NCT02825550|Transcatheter Arterial chemo-embolization
852900|NCT02825550|microsphere
852901|NCT02825511|basal cell carcinoma, histological diagnosis, prognostic impact
852902|NCT02825472|Congenital Heart Disease
852903|NCT02825472|Sport
852904|NCT02825472|Exercise training
852905|NCT02825459|abstinence
852906|NCT02825459|abuse liability
852907|NCT02825459|electronic cigarette
852908|NCT02825459|e-cigarette
852909|NCT02825459|electronic nicotine delivery device
852910|NCT02825459|harm reduction
852911|NCT02825459|nicotine
852912|NCT02825459|nicotine dependence
852913|NCT02825459|smoking
852914|NCT02825459|smoking cessation
852915|NCT02825459|tobacco
852916|NCT02825459|vape
852917|NCT02825459|vaping
852918|NCT02825459|withdrawal
852919|NCT02825446|radio frequency denervation
852920|NCT02825446|tibial arteries
852921|NCT02825446|atherosclerosis of the peripheral arteries
852922|NCT02825381|Arthroplasty
852923|NCT02825381|Hip
852924|NCT02825355|robotic surgery procedure
852925|NCT02825355|indocyanine green
852926|NCT02825355|sentinel lymph node mapping
852927|NCT02825342|Gastroesophageal Reflux Disease (GERD)
852928|NCT02825342|Proton Pump Inhibitor (PPI)
852929|NCT02825316|Crohn's disease
852930|NCT02825316|inflammatory bowel diseases
852931|NCT02825316|Mediterranean diet
852932|NCT02825316|microbiome
852933|NCT02825303|postural changes
852934|NCT02825303|Height adjustable desk
852935|NCT02825303|Prolonged sitting
852936|NCT02825303|Cognitive performance
852937|NCT02825290|Frozen-thawed embryo transfer (FET)
852938|NCT02825290|Luteal support
852939|NCT02825290|Progesterone
852940|NCT02825290|Natural cycle
852941|NCT02825290|Cryopreservation
852942|NCT02825290|IVF
852943|NCT02825290|hCG
852944|NCT02825290|GnRH-Agonist
852945|NCT02825290|Pregnancy rate
852946|NCT02825277|3D Power Doppler
852947|NCT02825277|uteroplacental vascularization
852948|NCT02825277|preeclampsia
852949|NCT02825277|intra-uterine growth restriction
852950|NCT02825277|placental morphology
852951|NCT02825264|Glaucoma Drainage Device
852952|NCT02825264|STARflo
852953|NCT02825238|exercise
852954|NCT02825238|osteoarthritis
852955|NCT02825238|knee
852956|NCT02825238|patellofemoral pain
852957|NCT02825225|Prostatic Neoplasms
852958|NCT02825225|Biopsy
852959|NCT02825225|Anesthesia
852960|NCT02825225|Detection
852961|NCT02825212|Hepatitis C
852962|NCT02825212|Cryoglobulinemia
852963|NCT02825160|Iloprost
852964|NCT02825160|Ventavis
852965|NCT02825160|Prostacycline analogue
852966|NCT02825160|Pulmonary arterial hypertension
852967|NCT02825160|Japan
852968|NCT02825160|Post-marketing surveillance
852969|NCT02825147|pegaspargase,methotrexate
852970|NCT02825134|heart valve disease
852971|NCT02825134|valvular bioprosthesis
852972|NCT02825134|aortic valve replacement
852973|NCT02825134|Randomized clinical trial
852974|NCT02825108|human chorionic gonadotropin (hCG), implantation rate intrauterine hCG clinical pregnancy rate frozen embryo transfer cycles
852975|NCT02825095|malignant pleural effusion,talc pleurodesis,quality of life
852976|NCT02825082|Emergency general surgery
852977|NCT02825082|Geriatric
852978|NCT02825082|Outcomes
852979|NCT02825082|Frailty
852981|NCT02825004|Burnout
852982|NCT02825004|Health Care Workers
852983|NCT02825004|Coping Skills
852984|NCT02825004|Clinical Trial
852985|NCT02824952|Tagrisso
852986|NCT02824952|AZD9291
852987|NCT02824952|EGFRm
852988|NCT02824952|NSCLC
852989|NCT02824900|Vibration Stimuli
852990|NCT02824900|Contraversive Pusher Syndrome
852991|NCT02824887|Electroacupuncture
852992|NCT02824887|Deep needling
852993|NCT02824887|Lumbar disc herniation five points
852994|NCT02824887|Long term effect
852995|NCT02824887|Prospective cohort study
852996|NCT02824848|congenital muscular torticollis
852997|NCT02824848|infants
852998|NCT02824848|passive stretching
852999|NCT02824848|perception-action approach
853000|NCT02824822|Sudden Unexpected Death in Epilepsy
853001|NCT02824822|SUDEP
853002|NCT02824822|Sudden Cardiac Arrest
853003|NCT02824822|Sudden Cardiac Death
853004|NCT02824822|Sleep
853005|NCT02824822|Ion channel disease
853006|NCT02824822|Long QT syndrome
853007|NCT02824822|Brugada
853008|NCT02824822|Catecholaminergic Polymorphic Ventricular Tachycardia
853009|NCT02824809|hypogonadism
853010|NCT02824809|Chronic Obstructive Pulmonary Disease
853011|NCT02824809|Severity of Illness Index
853012|NCT02824809|Testosterone
853013|NCT02824796|ADHD
853014|NCT02824783|colorectal surgery
853015|NCT02824783|enhanced recovery
853016|NCT02824757|interstitial lung disease
853017|NCT02824757|glucocorticcoid
853018|NCT02824757|glucose
853019|NCT02824757|continuous glucose monitor
853020|NCT02824744|Bronchiolitis
853021|NCT02824744|High flow nasal canula
853022|NCT02824731|brain tumors
853023|NCT02824731|proton radiotherapy
853024|NCT02824731|photon radiotherapy
853030|NCT02824705|Heart
853031|NCT02824705|Abnormality
853032|NCT02824705|Thoracic Aorta
853033|NCT02824705|Pericardium
853034|NCT02824679|Normal labour
853035|NCT02824679|Augmentation of labour
853036|NCT02824679|Hyoscine butylbromide
853037|NCT02824653|acute GVHD
853038|NCT02824653|chronic GVHD
853039|NCT02824653|steroid-refractory
853040|NCT02824653|Mesenchymal Stem Cells
853041|NCT02824640|Addiction
853042|NCT02824640|Adherence
853043|NCT02824640|Adverse Effects
853044|NCT02824640|Direct Acting Antiviral Agent
853045|NCT02824640|Chronic Hepatitis C
853046|NCT02824640|Resistance Development
853047|NCT02824640|Methadone Clinic
853048|NCT02824640|Primary Care
853049|NCT02824640|Directly Observed Therapy
853050|NCT02824640|Randomized Controlled Trial
853051|NCT02824640|Resistance
853052|NCT02824640|Reinfection
853053|NCT02824640|Treatment Outcome
853054|NCT02824640|Patient Navigation
853055|NCT02824640|Multi-Site
853056|NCT02824640|Liver Disease
853057|NCT02824640|Intervention
853058|NCT02824640|Sustained Viral Response
853059|NCT02824588|Pain
853060|NCT02824588|Working memory
853061|NCT02824575|breast cancer
853062|NCT02824575|chemotherapy
853063|NCT02824575|metastasis
853064|NCT02824575|tumor micro-environment
853065|NCT02824549|Flash glucose monitoring
853066|NCT02824549|skin reactions
853067|NCT02824549|usability
853068|NCT02824549|accuracy
853069|NCT02824536|3BNC117
853070|NCT02824536|10-1074
853071|NCT02824536|Broadly neutralizing antibody
853072|NCT02824536|HIV Prevention
853073|NCT02824523|asthma
853074|NCT02824523|nasal polyps
853075|NCT02824523|aspirin sensitivity
853076|NCT02824523|AERD
853077|NCT02824484|Guided written disclosure protocol
853078|NCT02824484|Emotional disclosure
853079|NCT02824484|Meaning
853080|NCT02824484|Post-Traumatic Growth
853081|NCT02824484|Cancer
853082|NCT02824471|Sickle Cell Disease
853083|NCT02824471|Biofluidic Chip Technology
853084|NCT02824458|EGFR tyrosine kinase inhibitors
853085|NCT02824458|VEGFR inhibitor
853086|NCT02824458|NSCLC
853087|NCT02824406|Sickle Cell Anemia
853088|NCT02824406|Cerebrovascular Reserve
853089|NCT02824406|Perfusion
853090|NCT02824406|Vasculopathy
853091|NCT02824406|Magnetic Resonance Imaging
853092|NCT02824393|Mesenchymal stem cell
853093|NCT02824393|Chronic autoimmune urticaria
853094|NCT02824367|Parkinson
853095|NCT02824367|Perfectionism
853096|NCT02824341|Parkinson 's disease
853097|NCT02824341|REM sleep behavior disorder
853098|NCT02824341|Reward system
853099|NCT02824341|Functional MRI
853100|NCT02824289|skin cancer
853101|NCT02824289|prevention
853102|NCT02824289|worksite
853103|NCT02824289|policy
853104|NCT02824263|obstructive sleep apnea
853105|NCT02824263|CPAP
853106|NCT02824263|metabolism
853107|NCT02824250|Migraine
853108|NCT02824250|Mindfulness
853109|NCT02824250|MBSR
853110|NCT02824224|levonorgestrel
853111|NCT02824224|breakthrough bleeding
853112|NCT02824198|Dengue Hemorrhagic Fever
853113|NCT02824198|Dengue Virus
853114|NCT02824198|CYD Dengue Vaccine
853115|NCT02824185|FCH-PET/MRI
853116|NCT02824185|primary HCC
853117|NCT02824185|curative treatment
853118|NCT02824185|resection
853119|NCT02824185|thermo-ablation
853120|NCT02824185|transplantation
853121|NCT02824172|Cast immobilization
853122|NCT02824172|Complete rest
853123|NCT02824172|Osgood Schlatter
853124|NCT02824159|ibrutinib
853125|NCT02824159|idelalisib
853126|NCT02824159|side effect
853127|NCT02824159|pharmacokinetic
853128|NCT02824159|plasma balance mean concentration
853129|NCT02824146|atelectasis
853130|NCT02824146|children
853131|NCT02824146|lung ultrasound
853132|NCT02824146|lung recruitment
853133|NCT02824133|Glioma grade III
853134|NCT02824133|Glioma grade IV
853135|NCT02824133|Glioma recurrent
853136|NCT02824133|IDHwt
853137|NCT02824133|FGFR-TACC fusion
853138|NCT02824120|ischemic heart disease
853139|NCT02824120|laugh therapy
853140|NCT02824094|Expanded Access Protocol
853141|NCT02824094|crizotinib
853142|NCT02824094|Xalkori
853143|NCT02824094|ROS1
853144|NCT02824094|Japanese
853145|NCT02824094|A8081064
853146|NCT02824081|Psychiatry
853147|NCT02824081|Depressive disorder
853148|NCT02824081|Suicide
853149|NCT02824081|Inflammation
853156|NCT02823977|ketamine
853157|NCT02823977|dexmedetomidine
853158|NCT02823977|alcohol
853159|NCT02823964|exocrine pancreatic insufficiency
853160|NCT02823964|cystic fibrosis
853161|NCT02823964|pancreatic enzyme replacement therapy
853162|NCT02823912|Capsaicin
853163|NCT02823912|Dyslipidemia
853164|NCT02823912|Inflammatory cytokines
853165|NCT02823899|cholera vaccine
853166|NCT02823899|hikojima serotype
853167|NCT02823899|randomized trial
853168|NCT02823899|immunogenicity
853169|NCT02823886|myocardial infarction
853170|NCT02823886|MRI
853171|NCT02823886|inflammatory biomarkers
853172|NCT02823873|Hypertension
853173|NCT02823873|Pregnant
853174|NCT02823873|Preeclampsia
853175|NCT02823873|Gestational Hypertension
853176|NCT02823873|Blood Pressure
853177|NCT02823873|Pregnant Women
853178|NCT02823873|Postpartum Women
853179|NCT02823860|Peritoneal carcinomatosis
853180|NCT02823860|Biobanking
853181|NCT02823860|Biospecimen research
853182|NCT02823860|Prospective clinical database
853183|NCT02823860|Tissue banking
853184|NCT02823860|Quality of Life
853185|NCT02823860|various histological subtypes
853186|NCT02823847|Malignant neoplasms of mesothelial and soft tissue
853187|NCT02823847|Human immunodeficiency virus
853188|NCT02823847|HIV
853189|NCT02823847|Carbon monoxide test
853190|NCT02823847|Self-help materials
853191|NCT02823847|Visual Oral Screening Examination
853192|NCT02823847|Direct Fluorescent Oral Visualization Examination
853193|NCT02823847|Oral Biopsy
853201|NCT02823821|End-Stage Kidney Disease
853202|NCT02823821|Hemodialysis
853203|NCT02823821|Dialysate
853204|NCT02823821|Sodium
853205|NCT02823821|Cluster-randomisation
853206|NCT02823795|Patient participation
853207|NCT02823795|Empowerment
853208|NCT02823795|Medication management
853209|NCT02823795|Symptom management
853210|NCT02823795|Self determination theory
853211|NCT02823795|Motivational Interviewing
853212|NCT02823782|Laminar HP
853213|NCT02823782|Complex HP
853214|NCT02823769|clinical study
853215|NCT02823769|dental fillings
853216|NCT02823743|recurrent pregnancy loss, Habitual abortion
853217|NCT02823704|Sepsis
853218|NCT02823704|Chest pain
853219|NCT02823704|Abdominal pain
853220|NCT02823704|Electrolyte disturbances
853221|NCT02823704|Stroke
853222|NCT02823704|Triage
853223|NCT02823704|Risk for death
853224|NCT02823691|NETs
853225|NCT02823665|gastric bypass surgery
853226|NCT02823665|Hypoglycemia
853227|NCT02823665|sleeve gastrectomy
853228|NCT02823665|glucose tolerance
853229|NCT02823613|ENaC
853230|NCT02823613|Exosomes
853231|NCT02823613|Urinary biomarker
853232|NCT02823613|Salt regulation
853235|NCT02823587|Bronchiectasis
853236|NCT02823587|Mucociliary clearance
853237|NCT02823587|Exercise
853238|NCT02823587|Inflammation
853239|NCT02823535|military
853240|NCT02823444|Magnetic Resonance Imaging
853241|NCT02823444|Magnetic Resonance Angiography
853242|NCT02823431|voiding efficiency
853243|NCT02823431|detrusor underactivity
853244|NCT02823431|urodynamics
853245|NCT02823418|primipara
853246|NCT02823418|childbirth
853247|NCT02823418|neuraxial labor analgesia
853248|NCT02823418|postpartum depression
853249|NCT02823405|Advance malignancy
853250|NCT02823392|unexpected difficult bag mask ventilation
853251|NCT02823392|difficult intubation
853252|NCT02823392|predictors
853253|NCT02823392|pediatric anesthesia
853254|NCT02823379|physical activity
853255|NCT02823379|overweight
853256|NCT02823379|obese
853257|NCT02823379|exercise
853258|NCT02823379|women
853259|NCT02823379|African American
853260|NCT02823379|Smartphone
853261|NCT02823379|cardiovascular disease risk
853262|NCT02823366|PBC
853263|NCT02823366|UDCA
853264|NCT02823366|Fenofibrate
853265|NCT02823353|PBC
853266|NCT02823353|UDCA
853267|NCT02823353|Fenofibrate
853268|NCT02823288|intimate partner violence
853269|NCT02823288|masculinity
853270|NCT02823288|community mobilization
853271|NCT02823288|social intervention
853272|NCT02823288|rape
853273|NCT02823262|Breast Cancer
853274|NCT02823262|Estrogen Receptor Positive Breast Cancer
853275|NCT02823262|Node-negative Breast Cancer
853276|NCT02823262|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
853277|NCT02823236|Keloid
853278|NCT02823236|Scar
853279|NCT02823223|Endobronchial Valve
853280|NCT02823197|determinants
853281|NCT02823197|active transport
853282|NCT02823197|intervention
853283|NCT02823197|adolescents
853284|NCT02823184|Myeloproliferative neoplasms
853285|NCT02823184|Endoplasmic reticulum stress
853286|NCT02823171|Bioequivalence Study
853287|NCT02823171|Healthy subjects
853288|NCT02823158|Parkinson Disease
853289|NCT02823158|Morbus Parkinson
853290|NCT02823158|Basal Ganglia
853291|NCT02823158|Pallidal Stimulation
853292|NCT02823145|seizure
853293|NCT02823145|tonic clonic
853294|NCT02823145|epilepsy
853295|NCT02823145|myoclonic
853296|NCT02823145|encephalopathy
853297|NCT02823119|Mini-hysteroscopy
853298|NCT02823119|Office hysteroscopy
853299|NCT02823119|Pain
853300|NCT02823093|vascular calcification
853301|NCT02823093|aortic calcification
853302|NCT02823093|vitamin K antagonist
853303|NCT02823093|fluindione
853304|NCT02823093|warfarin
853305|NCT02823093|matrix gla protein
853306|NCT02823067|Pemphigoid
853307|NCT02823067|Bullous pemphigoid
853308|NCT02823067|Pruritus
853309|NCT02823067|Senile pruritus
853310|NCT02823067|Neuropsychiatric symptoms
853311|NCT02823054|elective surgery
853312|NCT02823054|CABG
853313|NCT02823054|One-lung ventilation
853314|NCT02823054|EZ Blockers
853315|NCT02823054|pleural effusion
853316|NCT02823041|cognitive training
853317|NCT02823041|aerobic exercise
853318|NCT02823041|neurotrophic factors
853319|NCT02823041|randomized controlled trial
853320|NCT02823041|functional outcome
853321|NCT02823028|Smoking
853322|NCT02823028|Social Media
853323|NCT02823028|Twitter
853324|NCT02823028|Behavior Change
853325|NCT02823028|Social Support
853326|NCT02822989|Lupus Erythematosus, Systemic
853327|NCT02822989|Musculoskeletal Pain
853328|NCT02822989|Inflammation
853329|NCT02822963|Transurethral resection of the prostate
853330|NCT02822963|Anticoagulants
853331|NCT02822963|Platelet aggregation inhibitors
853332|NCT02822911|elderly
853333|NCT02822911|chronic alcoholism
853334|NCT02822911|Carbohydrate Deficient Transferrin
853335|NCT02822911|Biological Detection / Diagnosis
853336|NCT02822898|Maintenance
853337|NCT02822898|Intravenous solutions
853338|NCT02822898|Intravenous fluids
853339|NCT02822898|Tonicity
853340|NCT02822898|Potassium
853341|NCT02822898|Sodium
853342|NCT02822898|Fluid retention
853343|NCT02822872|infertility
853344|NCT02822872|stress
853345|NCT02822872|scalp hair
853346|NCT02822872|cortisol
853347|NCT02822846|Lung ultrasound
853348|NCT02822846|Sliding lung
853349|NCT02822846|Probe position
853350|NCT02822755|Exercise
853351|NCT02822755|Adherence
853352|NCT02822755|Physical Therapy
853353|NCT02822703|smoking cessation
853354|NCT02822703|tobacco use disorder
853355|NCT02822703|delay discounting
853356|NCT02822703|repetitive transcranial magnetic stimulation
853357|NCT02822703|relapse prevention
853358|NCT02822690|palliative care
853359|NCT02822690|Quality of dying
853360|NCT02822664|Brain, pedophilia, neuroimaging
853361|NCT02822638|Myocardial infarction
853362|NCT02822638|biomarkers
853363|NCT02822638|STEMI
853364|NCT02822625|Capsaicin
853365|NCT02822625|QUTENZA®
853366|NCT02822625|Hypnosis
853367|NCT02822625|Peripheral Neuropathic
853368|NCT02822612|optical coherence tomography
853369|NCT02822612|optical imaging
853370|NCT02822612|retinal imaging
853371|NCT02822599|CBP, congenital heart defects, cardiopulmonary bypass
853372|NCT02822586|CD30-positive
853373|NCT02822586|Stage IB to Stage IVA
853374|NCT02822560|Endovascular Aortic Repair (EVAR)
853375|NCT02822560|percutaneous EVAR (pEVAR)
853376|NCT02822560|cost analysis
853377|NCT02822560|procedure time
853378|NCT02822521|Rheumatoid Arthritis
853379|NCT02822521|Mobile Health
853380|NCT02822521|Pain
853381|NCT02822521|Arthritis
853382|NCT02822495|Lymphoproliferative Disorders
853383|NCT02822495|Epstein-Barr Virus
853384|NCT02822495|Epstein-Barr Viremia
853385|NCT02822495|Post Transplant Lymphoproliferative Disorder
853386|NCT02822495|EBV-PTLD
853387|NCT02822495|Solid Organ Transplant
853388|NCT02822495|Hematopoietic Cell Transplant
853389|NCT02822495|primary immunodeficiency
853390|NCT02822495|acquired immunodeficiency
853391|NCT02822495|Epstein-Barr Virus Lymphoma
853392|NCT02822469|TMD Infrared Thermography Physical Therapy Modalities
853393|NCT02822456|dysphagia
853394|NCT02822456|intermittent tube
853395|NCT02822456|individual 3D printed guiding tube
853396|NCT02822430|Pain
853397|NCT02822430|Psychiatric disorders
853398|NCT02822417|Recover time
853399|NCT02822404|kidney toxicity
853400|NCT02822378|Postmenopausal Osteoporosis
853401|NCT02822378|Human
853402|NCT02822378|Female
853403|NCT02822378|Non-pharmacologic therapy
853404|NCT02822326|Leukemia
853405|NCT02822326|CART CD19
853406|NCT02822326|Chemotherapy Resistant
853407|NCT02822326|Chemotherapy Refractory
853408|NCT02822326|CD19 +
853409|NCT02822326|Lymphoma
853410|NCT02822235|Drug Therapy
853411|NCT02822222|essential hypertension
853412|NCT02822222|hypertension
853413|NCT02822222|high blood pressure
853414|NCT02822222|cardiovascular diseases
853415|NCT02822222|RMJH-111b
853416|NCT02822222|magnesium
853417|NCT02822222|magnesium citrate
853418|NCT02822222|calcium channel blockers
853419|NCT02822222|vasodilators
853420|NCT02822222|antihypertensive agents
853421|NCT02822209|coordinating nurse of thoracic oncology
853422|NCT02822209|quality of care in thoracic oncology
853423|NCT02822209|lung cancer quality of life
853424|NCT02822144|ischemic stroke
853425|NCT02822144|thrombectomy
853426|NCT02822144|anesthesia
853427|NCT02822144|sedation
853428|NCT02822118|IBS-D; Chang'an I Recipe; Placebo
853429|NCT02822066|Effectivity
853430|NCT02822066|safety
853431|NCT02822066|irreversible electroporation
853432|NCT02822066|liver
853433|NCT02822066|pancreas
853434|NCT02822053|Ultrasonography-guided Laser Ablation
853435|NCT02822040|Root Resorption
853436|NCT02822040|Panoramic Radiograph
853437|NCT02822001|Sugammadex
853438|NCT02821975|Depression
853439|NCT02821975|Cognitive function
853440|NCT02821975|Work
853441|NCT02821962|Sedentary behaviour
853442|NCT02821949|Non Small Cells Lung Cancer
853443|NCT02821949|Procalcitonin
853444|NCT02821936|positron emission tomography
853445|NCT02821936|parametric imaging
853446|NCT02821936|lung cancer
853447|NCT02821884|Stroke
853448|NCT02821884|Transcranial direct current stimulation
853449|NCT02821884|Neuromuscular electrical stimulation
853450|NCT02821884|upper extremity motor recovery
853455|NCT02821819|ovarian stimulation
853456|NCT02821819|random
853457|NCT02821819|egg donation
853458|NCT02821819|antagonist
853459|NCT02821819|gnrh agonist trigger
853460|NCT02821806|Normal Volunteer
853461|NCT02821806|Donation
853462|NCT02821806|Adoptive T Cell Therapy
853463|NCT02821806|Peripheral Blood Mononuclear Cells
853464|NCT02821780|Biospecimen Procurement
853465|NCT02821780|Laboratory Research Specimens
853470|NCT02821754|PDL1-Mediated Adaptive Resistance
853471|NCT02821754|Monoclonal Antibody
853472|NCT02821754|CTLA-4
853473|NCT02821754|Ablative Therapy
853474|NCT02821754|Combination of Tremelimumab and Durvalumab
853475|NCT02821741|Sensory Stimulation
853476|NCT02821728|Prostate
853477|NCT02821728|Sulphate
853478|NCT02821728|ATP
853479|NCT02821728|PTEN
853480|NCT02821702|placenta accreta
853481|NCT02821702|cesarean section
853482|NCT02821702|artery embolization
853483|NCT02821689|Dermatopolymyositis
853484|NCT02821689|Interstitial lung disease
853485|NCT02821689|Pirfenidone
853486|NCT02821637|teens
853487|NCT02821637|effort rehabilitation
853488|NCT02821637|quality of life
853489|NCT02821637|wellbeing
853490|NCT02821637|physical skills assessment
853491|NCT02821611|Student Stress
853492|NCT02821611|Meditation
853493|NCT02821611|Sleep Quality
853494|NCT02821611|Blood Pressure
853495|NCT02821559|Colorectal cancer
853496|NCT02821559|raltitrexed
853497|NCT02821559|oxaliplatin
853498|NCT02821559|bevacizumab
853499|NCT02821559|biweekly
853500|NCT02821559|triweekly
853501|NCT02821520|Polypoidal Choroidal Vasculopathy
853502|NCT02821520|Photodynamic Therapy
853503|NCT02821520|Conbercept
853504|NCT02821520|Efficacy
853505|NCT02821520|Safety
853506|NCT02821520|vascular endothelial growth factor
853507|NCT02821494|HPV
853508|NCT02821494|Vaccination
853509|NCT02821494|Immunotherapy
853510|NCT02821481|Neuromuscular
853511|NCT02821481|Supplementation
853512|NCT02821481|Elderly
853513|NCT02821455|Isoflurane
853514|NCT02821455|Sevoflurane
853515|NCT02821455|Bispectral Index
853516|NCT02821455|Pulmonary Surgical Procedures
853517|NCT02821442|Electroacupuncture
853518|NCT02821442|Neuropathic Pain
853519|NCT02821442|Chemotherapy Induced Peripheral Neuropathy
853520|NCT02821429|Respiratory weaning
853521|NCT02821429|Pulmonary ventilation
853523|NCT02821390|intravitreal injection
853524|NCT02821390|pain
853525|NCT02821390|non-steroidal anti-inflammatory drugs
853526|NCT02821390|anti-VEGF
853527|NCT02821390|nepafenac
853528|NCT02821377|cirrhosis
853529|NCT02821377|ascites
853530|NCT02821377|immunology
853531|NCT02821377|inflammation
853532|NCT02821377|nutrition
853533|NCT02821351|Afib
853534|NCT02821338|Bioequivalence
853535|NCT02821338|Lamotrigine Extended Release
853536|NCT02821338|Generic
853537|NCT02821338|Pharmacokinetic
853538|NCT02821299|Laryngeal transplantation
853539|NCT02821299|Laryngeal function
853540|NCT02821299|Swallowing
853541|NCT02821299|Voice production
853542|NCT02821299|Respiration
853543|NCT02821299|Quality of life
853544|NCT02821247|Treatment Naïve Patients
853545|NCT02821234|Insomnia
853546|NCT02821234|Hyperarousal
853547|NCT02821208|Psychogenic nonepileptic seizure, quality of life
853548|NCT02821169|sinus surgery
853549|NCT02821169|sphenopalatin ganglion
853550|NCT02821169|ropivacaine
853551|NCT02821169|local anesthesia
853552|NCT02821143|Telemedicine
853553|NCT02821143|Nursing Home
853554|NCT02821143|Hospitalization
853555|NCT02821130|Dyspnea
853556|NCT02821130|Exercise
853557|NCT02821130|Cystic Fibrosis
853558|NCT02821117|Diabetes Mellitus, Paediatric
853559|NCT02821117|Sensing Technology
853560|NCT02821104|Complement
853561|NCT02821104|endothelial function
853562|NCT02821104|insulin sensitivity
853563|NCT02821104|adolescents
853564|NCT02821104|inflammation
853565|NCT02821078|phase-contrast MRI
853566|NCT02821078|blood flow
853567|NCT02821078|velocity mapping
853568|NCT02821078|abdominal imaging
853569|NCT02821078|Quantitative MRI
853570|NCT02821039|Idiopathic Pulmonary Fibrosis, Usual Interstitial Pneumonia
853571|NCT02821000|PD1
853572|NCT02821000|PD-1
853573|NCT02821000|PDL1
853574|NCT02821000|PD-L1
853575|NCT02820987|Septic shock, Beta Lactams, Extended infusion, PK/PD
853576|NCT02820961|Breast Neoplasms
853577|NCT02820961|Breast Diseases
853578|NCT02820961|Exemestane
853579|NCT02820961|Protein Kinase Inhibitors
853580|NCT02820961|Aromatase Inhibitors
853581|NCT02820961|entinostat
853582|NCT02820961|Cancer of the Breast
853583|NCT02820961|Metastatic Breast Cancer
853584|NCT02820961|Hormone Receptor Positive Breast Cancer
853585|NCT02820961|Estrogen Receptor
853586|NCT02820961|ER+ Breast Cancer
853587|NCT02820961|Breast Tumor
853588|NCT02820935|Cytochrome P450
853589|NCT02820935|Pharmacokinetics
853590|NCT02820935|CC-220
853591|NCT02820935|Healthy Subjects
853592|NCT02820922|Emergency orthopedic surgery
853593|NCT02820922|anesthesia
853594|NCT02820922|general anesthesia
853595|NCT02820922|regional anesthesia
853596|NCT02820909|ultrasound guidance
853597|NCT02820909|emergency wards
853598|NCT02820909|arterial and venous catheters
853599|NCT02820909|femoral
853600|NCT02820909|complications
853601|NCT02820870|Cardiovascular Disease
853602|NCT02820870|Quality Improvement
853603|NCT02820870|Decision Support Tool
853604|NCT02820870|Performance Measurement
853605|NCT02820870|Primary Prevention
853606|NCT02820857|Gastroentero-pancreatic neuroendocrine carcinomas
853607|NCT02820857|Second-line treatment
853608|NCT02820857|Bevacizumab
853609|NCT02820857|Folfiri
853610|NCT02820844|Overactive bladder
853611|NCT02820844|Botulinum toxin type A
853612|NCT02820844|Urinary incontinence
853613|NCT02820831|Frail Elderly
853614|NCT02820831|Peripheral Vascular Surgery
853615|NCT02820831|Risk Assessment
853616|NCT02820831|Functional status
853617|NCT02820818|thoracic magnetic resonance imaging
853618|NCT02820818|pulmonary function test
853619|NCT02820805|children
853620|NCT02820805|dietary carbohydrates
853621|NCT02820805|solanum tuberosum
853622|NCT02820805|cognition
853623|NCT02820805|memory
853624|NCT02820805|emotions
853625|NCT02820805|blood glucose
853626|NCT02820779|Willis
853627|NCT02820779|Intracranial aneurysms
853628|NCT02820766|Posterior Stabilized Knee
853629|NCT02820766|Total Knee Arthroscopy
853630|NCT02820766|Journey II BCS
853631|NCT02820753|Universal Medication Schedule
853632|NCT02820753|Health Literacy
853633|NCT02820753|Medication adherence
853634|NCT02820740|Epilepsy
853635|NCT02820740|Medial Temporal Lobe Epilepsy
853636|NCT02820740|Seizure
853637|NCT02820740|NeuroBlate
853638|NCT02820740|LITT
853639|NCT02820740|Quality of Life
853640|NCT02820701|Osteopathic Manipulation
853641|NCT02820701|Somatic Dysfunction
853642|NCT02820701|Musculoskeletal Ultrasound
853643|NCT02820688|Local Anesthtetics
853644|NCT02820688|Nerve Block
853645|NCT02820688|Bupivacaine
853646|NCT02820688|Prilocaine
853647|NCT02820675|quality improvement
853648|NCT02820675|routine data
853649|NCT02820675|risk adjustment
853650|NCT02820675|sepsis, severe sepsis, septic shock
853651|NCT02820675|quality of coding
853652|NCT02820649|Exercise training
853653|NCT02820649|Endothelial function
853654|NCT02820623|implementation
853655|NCT02820623|fidelity
853656|NCT02820623|cognitive behavioral therapy
853657|NCT02820558|Neuropeptide
853658|NCT02820558|Therapy
853659|NCT02820558|Onset
853660|NCT02820545|patient safety culture
853661|NCT02820545|hospital
853662|NCT02820545|patient perception
853663|NCT02820545|healthcare professional perception
853664|NCT02820545|sociological
853665|NCT02820545|qualitative
853666|NCT02820545|questionnaire construct
853667|NCT02820545|psychometrics
853668|NCT02820519|Neuropathic pain
853669|NCT02820519|Loxapine
853670|NCT02820519|Antipsychotics
853671|NCT02820519|Co-Analgesics
853672|NCT02820519|Tolerability
853673|NCT02820519|Analgesic efficacy
853674|NCT02820506|robotic surgery procedures
853675|NCT02820506|indocyanine green
853676|NCT02820506|sentinel lymph node mapping
853677|NCT02820480|stroke
853678|NCT02820480|rehabilitation
853679|NCT02820480|robotics
853680|NCT02820480|cerebral palsy
853681|NCT02820480|therapy
853682|NCT02820467|Indocyanine
853683|NCT02820467|Angiography
853684|NCT02820467|Ischemia
853685|NCT02820454|AGuIX
853686|NCT02820454|polysiloxane gadolinium-chelates based nanoparticles
853687|NCT02820415|aneuploidy
853688|NCT02820415|next generation sequencing
853689|NCT02820415|oocyte vitrification
853690|NCT02820415|preimplantation genetic diagnosis
853691|NCT02820415|preimplantation genetic screening
853692|NCT02820402|Pregnancy
853693|NCT02820402|Obesity
853694|NCT02820402|Diet
853695|NCT02820402|Maternal/child health
853696|NCT02820402|Asthma/allergy
853697|NCT02820402|Air pollution
853698|NCT02820402|Epigenetics
853699|NCT02820402|Cognition/behavior
853700|NCT02820376|4D computed tomography
853701|NCT02820376|Kidney function tests
853702|NCT02820376|Living Donors
853703|NCT02820363|wound
853704|NCT02820363|open fracture
853705|NCT02820363|fracture
853706|NCT02820363|tibial
853707|NCT02820350|Acute Renal Failure
853708|NCT02820350|Acute kidney injury
853709|NCT02820350|Continuous Renal Replacement Therapy
853710|NCT02820350|Selective cytopheretic device
853711|NCT02820350|Pediatric
853712|NCT02820311|Thorough QT (TQT)
853713|NCT02820311|cardiac safety
853714|NCT02820272|Cold water
853715|NCT02820272|Negative pressure wound therapy
853716|NCT02820272|pain
853717|NCT02820246|nutrition assessment
853718|NCT02820246|nutrition therapy
853719|NCT02820246|nutrition surveys
853720|NCT02820246|patient outcome assessment
853721|NCT02820246|outcome and process assessment
853722|NCT02820246|benchmarking
853723|NCT02820246|risk assessment
853724|NCT02820246|scoring system
853725|NCT02820220|Knowledge
853726|NCT02820220|Programs
853727|NCT02820220|Patients
853728|NCT02820220|Students
853729|NCT02820220|Nurses
853730|NCT02820207|Carotid Artery Plaque
854235|NCT02817191|phacoemulsification
853731|NCT02820207|Contrast Enhanced Ultrasound
853732|NCT02820207|Plague Histopathology
853733|NCT02820181|tracheostomy ties
853734|NCT02820168|Designing
853735|NCT02820168|Patient-Oriented
853736|NCT02820168|Prescriptions
853737|NCT02820155|Alzheimer's disease,cognitive function
853738|NCT02820142|biomarker
853739|NCT02820142|Renal Function
853740|NCT02820129|polypharmacy
853741|NCT02820129|wallet card
853742|NCT02820129|medication
853743|NCT02820129|self-efficacy
853744|NCT02820129|patient enablement
853745|NCT02820103|Patient delay
853746|NCT02820103|Behaviour change
853747|NCT02820103|Intervention Modelling Experiment
853748|NCT02820090|Inflammatory Factor
853749|NCT02820090|Mechanical Ventilation
853750|NCT02820077|Endoscopy, Gastrointestinal
853751|NCT02820051|bronchoscopy
853752|NCT02820051|conscious sedation
853753|NCT02820051|midazolam
853754|NCT02820051|patient comfort
853755|NCT02820051|propofol
853756|NCT02820012|Scoliosis
853757|NCT02820012|ST2R
853758|NCT02819986|occupational functioning
853759|NCT02819986|Worries
853760|NCT02819986|Pain
853761|NCT02819986|Disability
853762|NCT02819973|Patient Education
853763|NCT02819973|ICD
853764|NCT02819973|Implantable Cardioverter Defibrillator
853765|NCT02819973|Video
853766|NCT02819973|Decision
853767|NCT02819973|Decision making
853768|NCT02819960|probiotics
853769|NCT02819960|irinotecan
853770|NCT02819960|diarrhea
853771|NCT02819960|Lactobacillus rhamnosus
853772|NCT02819960|Bifidobacterium animalis
853773|NCT02819960|prevention
853774|NCT02819960|chemotherapy
853775|NCT02819947|systemic sclerosis
853776|NCT02819947|cohort
853777|NCT02819947|Korean
853778|NCT02819921|Hot Flashes
853779|NCT02819921|Breast Neoplasms
853780|NCT02819921|Tamoxifen
853781|NCT02819921|Desvenlafaxine Succinate
853782|NCT02819895|Phone Appointment Reminder
853783|NCT02819895|Immunization Rates
853784|NCT02819895|mHealth
853789|NCT02819843|T-VEC (Talimogene Laherparepvec)
853790|NCT02819843|Radiotherapy
853791|NCT02819843|16-224
853792|NCT02819830|Aerobic exercise
853793|NCT02819830|Strength training
853794|NCT02819830|Inflammation
853795|NCT02819830|cardiovascular disease
853796|NCT02819817|Aloe Vera, wound, healing
853797|NCT02819791|Cardiovascular
853798|NCT02819791|therapeutic education
853799|NCT02819778|Diagnosis
853800|NCT02819778|Craniocerebral Trauma
853801|NCT02819778|Pediatrics
853802|NCT02819778|S100B
853803|NCT02819778|mild traumatic brain injury
853804|NCT02819752|squamous cell carcinoma
853805|NCT02819752|squamous cell carcinoma of the head and neck
853806|NCT02819713|Prostate Biopsy
853807|NCT02819713|NRS-score
853808|NCT02819713|instillagel
853809|NCT02819713|ultrasound conductive gel
853810|NCT02819700|behavioural disorders
853811|NCT02819687|Phase I
853812|NCT02819687|Healthy
853813|NCT02819687|Pharmacokinetics
853814|NCT02819687|Pharmacodynamics
853815|NCT02819674|hypertension
853816|NCT02819674|early onset
853817|NCT02819674|target organ damage
853818|NCT02819661|Elective Caesarean Section
853819|NCT02819661|obese women
853820|NCT02819661|BMI≥30
853821|NCT02819661|spinal anesthesia combined with intrathecal morphine
853822|NCT02819648|symptomatic
853823|NCT02819648|irreversible
853824|NCT02819635|ABT-494
853825|NCT02819635|Moderately to Severely Active UC
853826|NCT02819570|early-onset neonatal sepsis
853827|NCT02819570|Prophylactic antibiotics
853828|NCT02819570|Pregnancy
853829|NCT02819570|PPROM
853830|NCT02819570|EOS
853831|NCT02819544|Digestive System
853832|NCT02819531|Coronary Atherectomy
853833|NCT02819531|percutaneous coronary intervention
853838|NCT02819505|beta-alanine
853839|NCT02819505|carnosine
853840|NCT02819505|neuromuscular
853841|NCT02819505|stimulation
853842|NCT02819505|skeletal muscle
853843|NCT02819492|Adenoma
853844|NCT02819492|Colonoscopy
853845|NCT02819492|Withdrawal
853846|NCT02819492|Proximal
853847|NCT02819492|Observation Time
853848|NCT02819479|Radiation necrosis
853849|NCT02819479|Radiation adverse event
853850|NCT02819479|Intra-arterial chemotherapy
853851|NCT02819479|Bevacizumab
853852|NCT02819479|Blood brain barrier disruption
853853|NCT02819479|Blood brain barrier breakdown
853854|NCT02819466|intragastric volume
853855|NCT02819466|stomach
853856|NCT02819466|fasting
853857|NCT02819453|Corticosteroid
853858|NCT02819427|Spectroscopy, Near-Infrared
853859|NCT02819427|Electroencephalography
853860|NCT02819427|children
853861|NCT02819388|randomized control trial; contraception; inequalities
853862|NCT02819375|propofol
853863|NCT02819375|ketamine
853864|NCT02819375|remifentanil
853865|NCT02819349|Relapse Prevention
853866|NCT02819349|People with Schizophrenia
853867|NCT02819349|Text-Messaging
854001|NCT02818647|visual analogue scale
853868|NCT02819349|Assertive Community Treatment (ACT)
853875|NCT02819284|Ocular Discomfort
853876|NCT02819284|Pain
853877|NCT02819284|Corticosteroid
853878|NCT02819284|Hyperemia
853879|NCT02819284|Dry Eye
853880|NCT02819219|Dietary Supplements
853881|NCT02819219|Exercise
853882|NCT02819193|Breastfeeding
853883|NCT02819193|mother's milk
853884|NCT02819193|breast milk
853885|NCT02819193|raw milk
853886|NCT02819193|neonate
853887|NCT02819193|Neonatal intensive care unit (NICU)
853888|NCT02819180|Influenza
853889|NCT02819167|ischemic stroke
853890|NCT02819167|brain reserve
853891|NCT02819167|cognitive reserve
853892|NCT02819167|cognitive prognosis
853893|NCT02819115|Influenza
853894|NCT02819089|anterior cervical spine surgery
853895|NCT02819089|ACDF
853896|NCT02819089|Dexmedetomidine
853897|NCT02819089|Anesthesia
853898|NCT02819089|Agitation
853899|NCT02819089|Riker sedation agitation scores
853900|NCT02819050|CPAP
853901|NCT02819050|Extremely Low Birth Weight Infant (ELBW)
853902|NCT02819050|Non-invasive respiratory support
853903|NCT02819050|Premature infants
853904|NCT02819050|Non invasive ventilation weaning
853905|NCT02819037|Gastric bypass
853906|NCT02819037|Intestinal Bacterial Overgrowth Syndrome
853907|NCT02819037|Gas chromatography
853908|NCT02819011|Ankle Foot Orthoses
853909|NCT02819011|falls
853910|NCT02819011|Fall Prevention
853911|NCT02819011|Frailty
853912|NCT02819011|Concern for falls
853913|NCT02819011|Footwear
853914|NCT02819011|Mobility
853915|NCT02818998|Diabetic macular edema
853916|NCT02818998|DME
853917|NCT02818959|Aortic Valve Disease
853918|NCT02818959|Aortic Valve Replacement
853919|NCT02818959|Transcatheter
853920|NCT02818959|Transfemoral
853921|NCT02818959|Aortic Stenosis
853922|NCT02818946|MRI
853923|NCT02818946|Spontaneous Nipple Discharge
853924|NCT02818946|Breast Cancer
853925|NCT02818933|24-hour diet recall
853926|NCT02818933|Adolescents
853927|NCT02818933|Web-based diet recall
853928|NCT02818920|Pembrolizumab
853929|NCT02818920|Neoadjuvant
853930|NCT02818920|Tumor Infiltrating Lymphocytes (TILs)
853931|NCT02818894|THA, Hip Replacement, Spinal Anesthesia
853932|NCT02818894|Total hip arthroplasty
853933|NCT02818894|anterior total hip replacement
853934|NCT02818881|aerobic
853935|NCT02818881|muscle activity
853936|NCT02818881|energy expenditure
853937|NCT02818855|Root coverage
853938|NCT02818855|Gingival recession
853939|NCT02818855|Plastic surgery
853940|NCT02818855|Connective tissue graft
853941|NCT02818855|Mucograft
853942|NCT02818842|Database
853943|NCT02818842|Birth defects
853944|NCT02818842|Neonatal pathologies
853945|NCT02818829|Adenocarcinoma
853946|NCT02818829|Endoscopic ultrasonography
853947|NCT02818829|Fine-needle aspiration
853948|NCT02818829|Biomarkers
853949|NCT02818829|Epidemiology
853950|NCT02818829|DNA tumors
853951|NCT02818816|Brimonidine tartrate
853952|NCT02818816|Intraocular pressure
853953|NCT02818816|Prostate Cancer
853954|NCT02818816|Prostatectomy
853955|NCT02818803|propolis
853956|NCT02818803|therapeutic
853957|NCT02818803|miconazole
853958|NCT02818803|denture stomatitis
853959|NCT02818790|mHealth
853960|NCT02818790|Motivational Interviewing
853961|NCT02818790|Obesity
853962|NCT02818790|Prevention
853963|NCT02818790|Diet
853964|NCT02818790|Physical Activity
853965|NCT02818790|Health Preventive System
853966|NCT02818777|Parkinson's Disease
853967|NCT02818777|Tremor
853968|NCT02818777|tolerability
853969|NCT02818777|safety
853970|NCT02818777|cognition
853971|NCT02818777|anxiety
853972|NCT02818777|psychosis
853973|NCT02818777|mood
853974|NCT02818777|dyskinesia
853975|NCT02818777|cannabidiol
853976|NCT02818777|cannabis
853977|NCT02818777|efficacy
853978|NCT02818777|sleep
853979|NCT02818777|motor symptoms
853980|NCT02818777|non-motor symptoms
853981|NCT02818777|quality of life
853982|NCT02818777|marijuana
853983|NCT02818764|serum biomarkers
853984|NCT02818764|cerebral blood flow
853985|NCT02818764|modified Blessed Dementia Rating scale
853986|NCT02818764|Confusion Assessment Method
853987|NCT02818764|Delirium Rating Scale-98
853988|NCT02818751|Anxiety
853989|NCT02818751|Adolescents with Anxiety
853990|NCT02818738|Idiopathic nephrotic syndrome
853991|NCT02818738|Steroid sensitive nephrotic syndrome
853992|NCT02818738|Levamisole
853993|NCT02818738|Prednisone
853994|NCT02818738|Children
853995|NCT02818686|Ulcerative Colitis, Active Moderate and Severe
853996|NCT02818673|diagnostic performances
853997|NCT02818673|ascites
853998|NCT02818647|tonsillectomy
853999|NCT02818647|electrocautery
854000|NCT02818647|postoperative pain
854002|NCT02818608|Cerebrovascular Accident
854003|NCT02818608|Cerebrovascular Stroke
854004|NCT02818608|Cerebral Stroke
854005|NCT02818595|voice recognition
854009|NCT02818504|obesity
854010|NCT02818504|dysglycemia
854011|NCT02818504|hypercholesterolemia
854012|NCT02818504|lifestyle
854013|NCT02818504|smoking
854014|NCT02818504|physical activity
854015|NCT02818439|Old person
854016|NCT02818426|cancer immunotherapy
854017|NCT02818426|CD4 T lymphocyte helper
854018|NCT02818426|telomerase
854019|NCT02818413|Stool microbiome
854020|NCT02818413|Stool metabolome
854021|NCT02818413|Single nucleotide polymorphisms
854022|NCT02818400|maxillofacial surgery
854023|NCT02818400|face graft
854024|NCT02818400|composite tissue
854025|NCT02818400|stem cell infusion
854026|NCT02818400|allotransplantation
854027|NCT02818400|microsurgery
854028|NCT02818387|propofol
854029|NCT02818387|midazolam
854030|NCT02818387|remifentanil
854031|NCT02818387|combination
854032|NCT02818387|synergic
854033|NCT02818387|pharmacodynamics
854034|NCT02818387|Loss of consciousness
854035|NCT02818361|Rheumatoid Arthritis
854036|NCT02818361|Tripterygium wilfordii Hook F
854037|NCT02818361|double-blinded
854038|NCT02818361|randomized controlled trial
854039|NCT02818361|Tripterygium
854040|NCT02818361|Administration
854041|NCT02818361|Topical
854042|NCT02818348|HIV infection
854043|NCT02818348|Darunavir/cobicistat
854044|NCT02818348|Etravirine, drug-drug interactions
854045|NCT02818348|Population PK analysis
854046|NCT02818296|Intolerance of uncertainty
854047|NCT02818296|Anxiety
854048|NCT02818283|Human Immunodeficiency Virus
854049|NCT02818283|hypercholesterolemia
854050|NCT02818283|pretzels
854051|NCT02818283|nutritional study
854052|NCT02818283|dietary soy
854053|NCT02818283|antiretroviral therapy
854054|NCT02818244|commercial heart monitors
854055|NCT02818244|accuracy
854056|NCT02818244|EKG
854057|NCT02818244|varying degrees of exertion
854058|NCT02818166|magnetic resonance
854059|NCT02818166|right mini-thoracotomy
854060|NCT02818153|Allergic rhinitis
854061|NCT02818140|Postoperative pain
854062|NCT02818140|Transmuscular quadratus lumborum block
854063|NCT02818140|Block
854064|NCT02818140|Ropivacaine
854065|NCT02818140|TQL
854066|NCT02818140|percutaneous nephrolithotomy
854067|NCT02818140|PNL
854068|NCT02818140|Ultrasound-guided
854069|NCT02818114|PTSD
854070|NCT02818114|Prolonged Exposure
854071|NCT02818114|Peer Support
854072|NCT02818075|Peer support
854073|NCT02818075|Postpartum Depression
854074|NCT02818075|Adolescent Pregnancy
854075|NCT02818062|Endophthalmitis
854076|NCT02818062|Cytokines
854077|NCT02818062|Chemokines
854078|NCT02818062|Inflammation
854079|NCT02818062|Regulation
854080|NCT02818049|Bronchioalveolar Lavage
854081|NCT02818010|physical activity
854082|NCT02818010|chronic kidney disease
854083|NCT02818010|nephrology
854084|NCT02818010|stage 3
854085|NCT02818010|stage 4
854086|NCT02818010|stage 5
854097|NCT02817984|Abdominoplasty
854098|NCT02817971|feedback
854099|NCT02817971|pneumonia
854100|NCT02817971|quality of care
854101|NCT02817958|inguinal lymph nodes
854102|NCT02817958|penile cancer
854103|NCT02817958|squamous
854104|NCT02817958|TIP chemotherapy
854105|NCT02817945|TATE-RGD
854106|NCT02817945|SSTR2
854107|NCT02817945|integrin αvβ3
854108|NCT02817919|Pharmacovigilance
854109|NCT02817919|Africa
854110|NCT02817893|∆POP: variation of the plethysmographic waveform of pulse oximetry
854111|NCT02817893|∆PP: pulse pressure variation
854112|NCT02817893|pulse oximetry plethysmographic
854113|NCT02817893|abdominal surgery
854114|NCT02817880|rTMS, tDCS, tsDCS, pain, algoneurodystrophy , neurostimulation
854115|NCT02817841|Estetrol
854116|NCT02817841|Drospirenone
854117|NCT02817841|Prevention of pregnancy
854118|NCT02817841|Oral contraception
854119|NCT02817828|Estetrol
854120|NCT02817815|Atrial fibrillation, blood platelet
854121|NCT02817802|Registry
854122|NCT02817802|Magmaris
854123|NCT02817802|Coronary Artery Disease
854124|NCT02817802|PCI
854125|NCT02817789|TAVI
854126|NCT02817789|Antiplatelet agent
854127|NCT02817789|Ticagrelor
854128|NCT02817789|Cerebrovascular events
854132|NCT02817750|volunteers
854133|NCT02817750|Pharmacokinetics
854134|NCT02817724|Breast Neoplasms
854135|NCT02817724|survivor
854136|NCT02817724|occupational therapy
854137|NCT02817724|mobile applications
854138|NCT02817724|Quality of Life
854139|NCT02817711|infection
854140|NCT02817711|bone and joint infection
854141|NCT02817711|relapse
854142|NCT02817711|adverse event
854143|NCT02817698|smoking
854144|NCT02817698|cannabis
854145|NCT02817698|cocaine
854146|NCT02817685|surveillance
854147|NCT02817685|hepatocellular carcinoma
854148|NCT02817685|ultrasound
854149|NCT02817685|cirrhosis
854150|NCT02817685|chronic hepatitis B
854151|NCT02817672|Human
854152|NCT02817672|Mental Disorders
854153|NCT02817672|intervention
854154|NCT02817672|digital health
854155|NCT02817659|Glucagon
854156|NCT02817646|Intensive Care Unit
854157|NCT02817646|Critical Illness
854158|NCT02817646|Body composition
854159|NCT02817646|Protein nutrition
854160|NCT02817633|Anitibodies
854161|NCT02817633|TSR-022
854162|NCT02817633|Advanced solid tumors
854163|NCT02817633|Metastatic solid tumors
854164|NCT02817633|Immunotherapy
854165|NCT02817633|PD-1
854166|NCT02817633|Anti-PD-1
854167|NCT02817633|colorectal cancer
854168|NCT02817633|non-small cell lung cancer
854169|NCT02817633|Melanoma
854170|NCT02817607|Sensation
854171|NCT02817594|Sustained Virological Response
854172|NCT02817594|Chronic Hepatitis C genotype 4
854173|NCT02817594|Chronic Hepatitis C genotype 1
854174|NCT02817594|Observational Study
854175|NCT02817594|Paritaprevir/r - Ombitasvir, ± Dasabuvir
854176|NCT02817594|Chronic Hepatitis C
854177|NCT02817581|National Early Warning Score (NEWS)
854178|NCT02817581|Lactate
854179|NCT02817581|Emergency Department
854180|NCT02817568|Aggressive Periodontitis
854181|NCT02817568|C-C chemokine receptor 2
854182|NCT02817568|Gene expression
854183|NCT02817568|monocyte chemoattractant protein-1,
854184|NCT02817568|restriction fragment length polymorphism
854185|NCT02817555|Anemia
854186|NCT02817555|Hemodialysis
854187|NCT02817555|Erythropoiesis Stimulating Agent
854188|NCT02817555|Cost
854189|NCT02817516|Drug Therapy
854190|NCT02817503|hypertension
854191|NCT02817503|BP titration
854192|NCT02817503|intensive blood pressure control
854193|NCT02817503|primary prevention
854194|NCT02817503|China
854195|NCT02817503|H-type Hypertension
854196|NCT02817490|hypermobility
854197|NCT02817490|Ehlers-Danlos Syndrome
854198|NCT02817490|patient education program
854199|NCT02817477|Intranasal Ketamine, Analgesia, Trauma, Morphine, Mass Casualty
854206|NCT02817425|S-1
854207|NCT02817425|Adjuvant Chemotherapy
854208|NCT02817425|TEGAFOX
854209|NCT02817412|binge eating
854210|NCT02817412|obesity
854211|NCT02817412|overeating
854212|NCT02817399|anterior cruciate ligament reconstruction
854213|NCT02817399|Functional Electrical stimulation
854214|NCT02817399|Gait analysis
854215|NCT02817399|Physical therapy
854216|NCT02817386|postoperative delirium
854217|NCT02817386|microRNA
854218|NCT02817373|IVF
854219|NCT02817373|embryo transfer
854220|NCT02817373|ultrasound
854221|NCT02817373|implantation
854222|NCT02817334|Near-infrared fluorescence
854223|NCT02817334|Indocyanine green, ICG
854224|NCT02817334|breast cancer
854225|NCT02817308|Antigen, CA-19-9
854226|NCT02817308|Salivas
854227|NCT02817308|body fluids
854228|NCT02817269|Shoulder pain
854229|NCT02817269|Trigger points
854230|NCT02817269|Referred pain
854231|NCT02817269|Visual analogue scale
854232|NCT02817191|age-related cataract
854233|NCT02817191|Holy-Comod
854234|NCT02817191|Tears Naturale Forte
854236|NCT02817191|inflammatory mediators
854237|NCT02817165|Probiotics, diarrhea, antibiotic, children, hospital
854238|NCT02817152|periodontal treatment
854239|NCT02817152|low-level light therapy
854240|NCT02817126|Minimally Invasive Surgical Procedures
854241|NCT02817126|Robotic Surgical Procedures
854242|NCT02817126|Laparoscopic Surgical Procedures
854243|NCT02817126|Rectal Cancer
854244|NCT02817126|Intraoperative Complications
854245|NCT02817126|Postoperative Complications
854246|NCT02817126|Recovery of Function
854247|NCT02817126|Recurrence
854248|NCT02817126|Disease Progression
854249|NCT02817126|Survival
854250|NCT02817087|Stroke
854252|NCT02817035|interstitial lung disease
854253|NCT02817035|chronic obstructive pulmonary disease
854254|NCT02817035|mechanical ventilation
854255|NCT02817035|expiratory delay
854256|NCT02817035|neural inspiratory time
854257|NCT02817022|Developmentally Supportive Care
854258|NCT02817009|Behavioral Health Intervention
854259|NCT02817009|Randomized Control Trial
854260|NCT02817009|Family Intervention
854261|NCT02817009|Nutrition
854262|NCT02817009|Weight Management
854263|NCT02817009|Multidisciplinary Program
854264|NCT02816944|Endoscopic ultrasonography
854265|NCT02816944|Laser ablation
854266|NCT02816931|Treatment
854267|NCT02816931|Drug Monitoring
854268|NCT02816931|Minimum Inhibitory Concentration
854269|NCT02816931|Dried Blood Spot Method
854270|NCT02816931|Pharmacokinetics
854271|NCT02816931|Pharmacodynamics
854272|NCT02816905|intraocular pressure
854273|NCT02816905|topical steroids
854274|NCT02816905|strabismus
854275|NCT02816892|aortic dissection
854276|NCT02816892|biomarkers
854277|NCT02816892|diagnosis
854278|NCT02816866|childhood cancer
854279|NCT02816866|survivorship care
854280|NCT02816866|health services
854281|NCT02816866|barriers
854282|NCT02816840|prostate cancer
854283|NCT02816840|radiotherapy
854284|NCT02816840|PET-CT/MRI
854285|NCT02816814|Menopause
854286|NCT02816814|Diet
854287|NCT02816814|Lipidomic profile
854288|NCT02816814|Vasomotor symptoms
854289|NCT02816814|Omega-3 fatty acids
854290|NCT02816788|PTSD
854291|NCT02816788|Equine Assisted Therapy
854292|NCT02816775|hemodynamics
854293|NCT02816775|QT interval
854294|NCT02816762|CPAP
854295|NCT02816762|Sleep apnea
854296|NCT02816762|Diabetes
854297|NCT02816762|Nephropathy
854298|NCT02816762|Albuminuria
854299|NCT02816749|Diabetic Foot
854300|NCT02816749|Wound Healing
854301|NCT02816749|Larva
854302|NCT02816749|Occlusive Dressings
854303|NCT02816736|Heart Failure
854304|NCT02816736|Heart Diseases
854305|NCT02816736|Cardiovascular Diseases
854306|NCT02816736|Valsartan
854307|NCT02816736|Entresto
854308|NCT02816723|mindfulness
854309|NCT02816723|aging
854310|NCT02816723|Veterans
854311|NCT02816697|Smoking Habits
854312|NCT02816684|phobic disorders
854313|NCT02816684|anxiety disorders
854314|NCT02816645|Parkinson's Disease
854315|NCT02816645|Biomarker
854316|NCT02816645|Iron
854317|NCT02816645|R2*
854318|NCT02816645|MRI
854319|NCT02816645|Patients
854320|NCT02816645|UK Parkinson's Disease Society Brain Bank
854321|NCT02816632|functional Magnetic Resonance Imaging
854322|NCT02816632|Galvanic Vestibular Stimulation
854323|NCT02816632|Feedback Processing
854324|NCT02816632|Reward, Social, Vestibular System
854325|NCT02816632|Cingulate Cortex
854326|NCT02816632|Decision-making
854327|NCT02816619|Parkinson's disease
854328|NCT02816619|Physical activity
854329|NCT02816619|Physical exercise
854330|NCT02816606|ACL reconstruction
854331|NCT02816593|carbamide peroxide
854332|NCT02816593|Hydrogen peroxide
854333|NCT02816593|Quality of life
854334|NCT02816554|Japanese Encephalitis
854335|NCT02816554|JECEVAX
854336|NCT02816554|Vietnam
854337|NCT02816528|Antibiotics
854338|NCT02816528|Primary care
854339|NCT02816528|Stewardship
854340|NCT02816528|General practitioners
854341|NCT02816515|Non interventional study
854342|NCT02816515|Ectoin
854343|NCT02816515|Mouth wash
854344|NCT02816515|Mucositis
854345|NCT02816515|Chemotherapy
854346|NCT02816515|Radiotherapy
854347|NCT02816502|childhood
854348|NCT02816502|adversity
854349|NCT02816450|Water
854350|NCT02816450|Children
854351|NCT02816450|Cognition
854352|NCT02816450|Hydration
854353|NCT02816424|Screening and Brief Intervention
854354|NCT02816424|Motivational Interviewing
854355|NCT02816424|Teen Pregnancy Prevention
854356|NCT02816385|PV-loops (pressure-volume loops)
854357|NCT02816385|Myocardial contractility
854358|NCT02816385|Cardioplegia
854359|NCT02816385|Induced
854360|NCT02816359|Position patient
854361|NCT02816359|Esophageal pressure
854362|NCT02816346|shigella
854363|NCT02816320|hospital mortality
854364|NCT02816320|standardized mortality ratios
854365|NCT02816320|patient safety
854366|NCT02816320|healthcare quality
854367|NCT02816320|hospital performance
854368|NCT02816320|administrative data
854369|NCT02816281|Surgical case cancellation
854370|NCT02816281|Pre-operative assessment clinic
854371|NCT02816242|Concept Map
854372|NCT02816242|critical thinking
854373|NCT02816242|medical student teaching
854374|NCT02816229|Haemoptysis
854375|NCT02816229|Aspergillus
854376|NCT02816229|Endobronchial valve
854377|NCT02816229|Interventional pulmonology
854378|NCT02816229|Tuberculosis
854379|NCT02816138|Geriatrics
854380|NCT02816138|Depression
854381|NCT02816138|Elderly
854382|NCT02816138|Cognition
854383|NCT02816138|Memory
854384|NCT02816125|breast cancer
854385|NCT02816125|fatty acids
854386|NCT02816125|omega-3
854387|NCT02816060|pain measurement
854388|NCT02816047|wearable cardioverter defibrillator
854389|NCT02816047|LifeVest
854390|NCT02816047|sudden death
854391|NCT02816047|defibrillator
854392|NCT02816034|Learning
854393|NCT02816034|Cerebellum
854409|NCT02816008|cognitive rehabilitation
854410|NCT02816008|memory
854411|NCT02816008|attention
854412|NCT02816008|spatial neglect
854413|NCT02816008|executive dysfunctioning
854414|NCT02815995|Malignant neoplasms of bone and articular cartilage
854415|NCT02815995|Multiple sarcoma subtypes
854416|NCT02815995|Advanced and/or metastatic sarcoma
854417|NCT02815995|Adipocytic tumors
854418|NCT02815995|Vascular tumors
854419|NCT02815995|Leiomyosarcoma
854420|NCT02815995|Angiosarcoma
854421|NCT02815995|Epithelioid hemangioendothelioma
854422|NCT02815995|Undifferentiated pleomorphic sarcoma
854423|NCT02815995|Synovial sarcoma
854424|NCT02815995|Osteosarcoma
854425|NCT02815995|Other sarcoma histologies
854426|NCT02815995|Durvalumab
854427|NCT02815995|Tremelimumab
854428|NCT02815969|neuroendocrine tumors
854429|NCT02815969|indol profile
854430|NCT02815969|catecholamines
854431|NCT02815969|LC-MS/MS
854432|NCT02815956|percutaneous tibial nerve stimulation
854433|NCT02815956|randomized
854434|NCT02815956|controlled study
854435|NCT02815930|High cost user (HCU)
854436|NCT02815930|Healthcare utilization
854437|NCT02815930|Healthcare expenditures
854438|NCT02815930|Medication use
854439|NCT02815930|Medication expenditures
854440|NCT02815930|Multimorbidity
854441|NCT02815930|Observational study
854442|NCT02815904|Neonates
854443|NCT02815904|physical therapy
854444|NCT02815904|neonatal intensive care units
854445|NCT02815904|yakson touch
854446|NCT02815904|kinesthetic stimulation
854447|NCT02815865|Primiparous
854448|NCT02815865|Foley catheter
854449|NCT02815865|Dinoprostone
854450|NCT02815865|Induction
854451|NCT02815852|breast cancer in women under 40 years old
854452|NCT02815852|biopsy
854453|NCT02815852|ultrasonography
854454|NCT02815852|Magnetic Resonance Imaging
854455|NCT02815839|urate transporter 1
854456|NCT02815839|SHR4640
854457|NCT02815839|single ascending dose
854458|NCT02815839|pharmacokinetics
854459|NCT02815839|pharmacodynamics
854460|NCT02815813|Serious Mental Illness
854461|NCT02815813|Young Adults
854462|NCT02815813|Obesity
854463|NCT02815813|Cardiometabolic Risk
854464|NCT02815813|Physical Activity
854465|NCT02815813|Weight Loss
854466|NCT02815813|Fitness
854467|NCT02815813|Peer Support
854468|NCT02815813|Smartphone
854469|NCT02815813|Mobile Technology
854470|NCT02815813|mHealth
854471|NCT02815813|Social Media
854472|NCT02815813|Facebook
854473|NCT02815800|Treatment
854474|NCT02815800|Motor signs
854475|NCT02815800|Non motor signs
854476|NCT02815800|Fluctuations
854477|NCT02815800|Open labelled
854478|NCT02815787|SP2086
854479|NCT02815787|Glyburide
854480|NCT02815787|drug-drug interaction
854481|NCT02815774|SP2086
854482|NCT02815774|Renal Insufficiency
854483|NCT02815774|Pharmacokinetic
854484|NCT02815748|SP2086
854485|NCT02815748|Metabolite identification
854486|NCT02815748|Material balance
854487|NCT02815722|SP2086
854488|NCT02815722|Simvastatin
854489|NCT02815722|drug-drug interaction
854490|NCT02815696|MRI T2 weighted
854491|NCT02815696|intervertebral disc
854492|NCT02815696|glycosaminoglycans
854493|NCT02815683|Bronchoscopy
854494|NCT02815683|Emphysema
854495|NCT02815657|SP2086
854496|NCT02815657|Valsartan
854497|NCT02815657|Drug-drug Interaction
854498|NCT02815631|fractional flow reserve
854499|NCT02815631|cardiogoniometry
854500|NCT02815618|Time-resolved spectroscopy
854501|NCT02815618|Diffuse correlation spectroscopy
854502|NCT02815618|Neonatology
854503|NCT02815579|HIV
854504|NCT02815579|Food insecurity
854505|NCT02815579|Microcredit loan
854506|NCT02815579|Agriculture
854507|NCT02815579|Livelihoods
854508|NCT02815566|kidney, antiretroviral agent, tenofovir, osteoporosis, women
854509|NCT02815527|enteral nutrition
854510|NCT02815527|intensive care unit
854511|NCT02815527|whey
854512|NCT02815527|protein
854513|NCT02815527|muscle mass
854514|NCT02815527|leucin
854515|NCT02815527|energy expenditure
854516|NCT02815514|aortic valve stenosis
854517|NCT02815514|aortic valve insufficiency
854518|NCT02815514|transapical aortic valve implantation
854519|NCT02815514|aortic valve replacement
854520|NCT02815514|percutaneous aortic valve replacement
854521|NCT02815514|aortic valve valvuloplasty
854522|NCT02815501|Thyroid dysfunction
854523|NCT02815501|obstetric complications
854524|NCT02815462|Frequent hospital admissions
854525|NCT02815462|Risk stratification
854526|NCT02815462|Readmissions
854527|NCT02815449|Iron fortification
854528|NCT02815449|Bioavailability
854529|NCT02815449|Nigeria
854530|NCT02815449|Women
854531|NCT02815449|Bouillon cubes
854532|NCT02815410|Glioblastoma Multiforme
854533|NCT02815410|Levetiracetam
854534|NCT02815410|Temozolomide
854535|NCT02815410|Survival outcome
854536|NCT02815397|Double Hit DLBCL
854537|NCT02815319|Dexamethasone
854538|NCT02815319|Chemotherapy
854539|NCT02815306|Congenital idiopathic clubfoot
854540|NCT02815306|Pirani score
854541|NCT02815306|infant
854542|NCT02815306|polyaxial brace
854545|NCT02815280|acne
854546|NCT02815267|acne
854547|NCT02815254|Physiotherapy
854548|NCT02815254|hip fracture
854549|NCT02815254|rehabilitation
854550|NCT02815254|high dose exercise
854551|NCT02815254|low dose exercise
854552|NCT02815215|congenital clubfoot
854553|NCT02815189|pain
854554|NCT02815176|Plasminogen activator inhibitor-1
854555|NCT02815176|Wide angle fluorescein angiography
854556|NCT02815176|Choroid
854557|NCT02815137|Digital PCR
854558|NCT02815137|classical
854559|NCT02815137|Hodgkin Lymphoma
854560|NCT02815137|mutation
854561|NCT02815085|heart failure
854562|NCT02815085|mHealth
854563|NCT02815072|Fontan palliation
854564|NCT02815072|Marfan's syndrome
854565|NCT02815046|urgency urinary incontinence
854566|NCT02815046|stress urinary incontinence
854567|NCT02815046|Botulinum toxin A
854568|NCT02815046|Bulkamid
854569|NCT02815033|Hormono-Sensitive prostate cancer
854570|NCT02815033|Enzalutamide
854571|NCT02815033|Imaging
854572|NCT02815033|PET/CT
854573|NCT02815033|Whole body MRI
854574|NCT02815033|Circulating tumour cells
854575|NCT02815033|Cell-free tumour DNA
854576|NCT02815020|Primary care
854577|NCT02815020|Self-management support
854578|NCT02815020|Care coordination
854579|NCT02815020|Practice-based research network
854580|NCT02814994|Mechanical Ventilation
854581|NCT02814994|ARDS
854582|NCT02814994|Ventilator Strategy
854583|NCT02814994|Outcome
854584|NCT02814981|hydroxyzine
854585|NCT02814981|Long QT
854586|NCT02814968|Castration-resistant prostate cancer
854587|NCT02814968|Enzalutamide
854588|NCT02814968|Imaging
854589|NCT02814968|PET/CT
854590|NCT02814968|Whole body MRI
854591|NCT02814968|Circulating tumour cells
854592|NCT02814968|Cell-free tumour DNA
854593|NCT02814955|atrial fibrillation
854594|NCT02814955|pulmonary veins
854595|NCT02814955|oral anticoagulant
854596|NCT02814955|electrophysiology
854597|NCT02814955|anticoagulant drugs
854598|NCT02814929|ROP
854599|NCT02814929|Risk factors
854600|NCT02814929|Incidence
854601|NCT02814929|Turkey
854602|NCT02814916|Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
854603|NCT02814903|aldosterone
854604|NCT02814903|cardiac surgery
854605|NCT02814903|atrial fibrillation
854606|NCT02814903|galectin-3
854607|NCT02814903|mitochondria
854608|NCT02814903|ngal
854609|NCT02814903|acute kidney failure
854610|NCT02814903|epicardial fat
854611|NCT02814903|right atrial sample
854612|NCT02814890|Thoracic paravertebral block
854613|NCT02814890|Dexmedetomidine
854614|NCT02814890|Video-assisted Pneumonectomy
854615|NCT02814890|Ropivacaine
854616|NCT02814890|Pain, Postoperative
854617|NCT02814877|Antibiotic stewardship
854618|NCT02814877|cost-effectiveness evaluation
854619|NCT02814877|Antibiotic use
854620|NCT02814864|Hematology
854621|NCT02814864|Mesenchymal Stromal Cell
854622|NCT02814864|radiotherapy
854623|NCT02814864|gastro-intestinal complications
854624|NCT02814864|lower digestive tract cancers
854625|NCT02814864|colitis
854626|NCT02814864|bleeding
854627|NCT02814864|diarrhea
854628|NCT02814864|pelvic radiation disease
854629|NCT02814851|Left atrium appendage (LAA) occlusion
854630|NCT02814851|Transesophageal echocardiography
854631|NCT02814851|Cardiac output hemodynamic measurement
854632|NCT02814851|Leycom Pressure/Volume Combination Catheter
854633|NCT02814838|Diabetes mellitus Type 1
854634|NCT02814838|Beta cells function
854638|NCT02814760|acute ischemic stroke
854639|NCT02814760|stepped-wedge
854640|NCT02814760|interactive training
854641|NCT02814760|implementation
854642|NCT02814760|emergency department
854643|NCT02814734|Intra-Abdominal Hypertension
854644|NCT02814734|Abdominal Compartment Syndrome
854645|NCT02814734|Round Belly Sign
854646|NCT02814734|Radiology
854647|NCT02814734|CT findings
854648|NCT02814734|Intensive Care
854649|NCT02814708|Sepsis
854650|NCT02814708|Vaccination
854651|NCT02814695|Male infertility
854652|NCT02814695|oxidative stress
854653|NCT02814695|antioxidants
854654|NCT02814695|probiotics
854655|NCT02814695|Vitamin E
854656|NCT02814695|Baker's Yeast
854657|NCT02814682|palliative care
854658|NCT02814682|quality
854659|NCT02814682|indicator
854660|NCT02814682|multi-dimensional
854661|NCT02814656|muscarinic receptor antagonist and β2 adrenoceptor agonist [MABA]
854662|NCT02814656|chronic obstructive pulmonary disease
854663|NCT02814656|Asthma (in combination with an inhaled corticosteroid [ICS]
854664|NCT02814656|alpha-lactose monohydrate
854665|NCT02814656|dry powder inhaler
854666|NCT02814656|long-acting β2-agonist (LABA)
854667|NCT02814656|long-acting muscarinic antagonist (LAMA)
854668|NCT02814656|fixed-dose combination (FDC)
854669|NCT02814643|Male and female adolescent patients
854670|NCT02814643|severe asthma
854671|NCT02814604|Front-of-Pack Labelling
854672|NCT02814604|Star rating system
854673|NCT02814604|Traffic light rating system
854674|NCT02814604|Consumer Behavior
854675|NCT02814604|Health Literacy
854676|NCT02814604|Mobile Apps
854677|NCT02814604|Nutrition Labeling
854678|NCT02814604|Healthy food choices
854682|NCT02814565|Drug therapy
854683|NCT02814513|Children
854684|NCT02814513|Adolescents
854685|NCT02814487|DAM
854686|NCT02814487|multiple sclerosis
854687|NCT02814487|MSFC
854688|NCT02814487|application
854689|NCT02814487|smartphone
854690|NCT02814474|PET/CT
854691|NCT02814474|Heart failure
854692|NCT02814474|hydroxybutyrate
854693|NCT02814435|Retina
854694|NCT02814435|Retinal Degeneration
854695|NCT02814435|Quality of Life Measures
854696|NCT02814422|Triglyceride-rich lipoprotein
854697|NCT02814422|dementia
854698|NCT02814422|Alzheimer's disease
854699|NCT02814422|mild cognition impairment
854700|NCT02814422|amyloid-beta
854701|NCT02814396|Ventricular
854702|NCT02814396|CVD
854703|NCT02814396|Ventricular arrhythmias
854704|NCT02814383|Prematurity
854705|NCT02814383|Extremely Low Birth Weight (ELBW)
854706|NCT02814383|Cerebral Perfusion
854707|NCT02814383|Cerebral Autoregulation
854708|NCT02814357|Blood glucose, serum insulin
854709|NCT02814344|labour
854710|NCT02814331|Video-EEG
854711|NCT02814331|near-infrared spectroscopy (NIRS)
854712|NCT02814318|Vancomycin
854713|NCT02814318|Penicillin
854714|NCT02814318|Clindamycin
854715|NCT02814318|Group B streptococcal infection
854716|NCT02814318|Rectovaginal GBS colonization
854717|NCT02814318|Vaginal GBS colonization
854718|NCT02814318|Intrapartum
854719|NCT02814318|Prophylaxis
854720|NCT02814227|obstructive sleep apnea screening device
854721|NCT02814201|Motor slowing
854722|NCT02814201|Computerized mental chronometry paradigm
854723|NCT02814188|Exercise
854724|NCT02814175|Psoriatic Arthritis
854725|NCT02814162|Subarachnoid Hemorrhage, Aneurysmal
854726|NCT02814162|Predictive
854727|NCT02814162|Adiponectin
854728|NCT02814149|delayed implant
854729|NCT02814149|esthetics
854730|NCT02814149|immediate implant
854731|NCT02814149|bone augmentation
854732|NCT02814123|Diabetes Mellitus, Type 1
854733|NCT02814123|Pramlintide
854734|NCT02814123|Artificial Pancreas
854735|NCT02814123|Closed-Loop System
854736|NCT02814123|Insulin
854737|NCT02814110|Granulocyte colony-stimulating factor
854738|NCT02814110|muscular dystrophy
854739|NCT02814110|muscle strength
854740|NCT02814110|children
854741|NCT02814110|adolescents
854742|NCT02814097|Heart Failure
854743|NCT02814097|HFpEF
854744|NCT02814097|elamipretide
854745|NCT02814097|MTP-131
854746|NCT02814097|Bendavia™
854747|NCT02814071|Early Feeding
854748|NCT02814071|Acute Pancreatitis
854749|NCT02814071|Pediatric
854750|NCT02814058|pharmacokinetics
854751|NCT02814058|Healthy Volunteers
854752|NCT02814045|biomarkers, sleep fragmentation, intermittent hypoxia
854753|NCT02814032|proteomic
854754|NCT02814032|cervical lymph node metastasis
854755|NCT02814019|respiratory function in DMD
854756|NCT02814006|marital relationship
854757|NCT02813993|infertility
854758|NCT02813993|fertility awareness
854759|NCT02813993|preconceptional care
854760|NCT02813993|health interventions
854761|NCT02813993|couples
854762|NCT02813980|SUDEP
854763|NCT02813980|Sudden cardiac death
854764|NCT02813980|Sudden unexpected death in epilepsy
854765|NCT02813980|Sleep
854766|NCT02813980|Polysomnography
854767|NCT02813980|Autonomic
854768|NCT02813980|Cardiovascular
854769|NCT02813941|Randomized controlled trial
854770|NCT02813941|Systematic review
854771|NCT02813941|Summary of finding tables
854772|NCT02813941|GRADE
854773|NCT02813941|AHRQ
854774|NCT02813928|ColoRectal Cancer
854775|NCT02813928|Cancerology
854776|NCT02813928|Translational Research
854777|NCT02813928|ccfDNA
854778|NCT02813915|cardiac monitoring, Cheetah Medical, passive leg raises
854779|NCT02813889|infant
854780|NCT02813889|baby
854781|NCT02813889|developmental delay
854782|NCT02813889|robotics
854783|NCT02813889|cerebral palsy
854784|NCT02813850|sickle cell disease
854785|NCT02813850|oxygen therapy
854786|NCT02813850|pregnancy
854787|NCT02813850|pregnancy in sickle cell disease
854788|NCT02813837|relapsed
854789|NCT02813837|refractory
854790|NCT02813837|CD19+
854791|NCT02813837|leukemia
854792|NCT02813837|lymphoma
854793|NCT02813811|Temperature-controlled Laminar Airflow
854794|NCT02813811|Exacerbation frequency
854795|NCT02813798|Renal Insufficiency
854796|NCT02813772|infants
854797|NCT02813772|colic
854798|NCT02813759|GLYCEMIA
854799|NCT02813759|SATIETY
854800|NCT02813759|C PEPTIDE
854801|NCT02813759|PRELOAD
854802|NCT02813759|INSULIN
854803|NCT02813746|Obesity
854804|NCT02813746|Tobacco
854805|NCT02813746|Epigenetic
854806|NCT02813746|Transcriptomic
854807|NCT02813746|microRNAs
854808|NCT02813746|miRNAs
854809|NCT02813733|thyroid surgery
854810|NCT02813733|surgical outcomes
854811|NCT02813733|patient safety
854812|NCT02813733|healthcare quality
854813|NCT02813733|surgeons performance
854814|NCT02813720|Erosions
854815|NCT02813720|Onycholysis
854816|NCT02813720|HR-pQCT
854817|NCT02813720|Psoriatic arthritis
854818|NCT02813707|Vitamins
854819|NCT02813707|Mineral
854820|NCT02813707|Surgery
854821|NCT02813694|Pneumonia
854822|NCT02813694|CABP
854823|NCT02813694|CAP
854824|NCT02813694|Community acquired bacterial pneumonia
854825|NCT02813681|Acute Pain
854826|NCT02813681|ultrasonography
854827|NCT02813668|Nutrition
854828|NCT02813668|Occupational Health
854829|NCT02813655|tetracosactide
854830|NCT02813655|Synacthène®
854831|NCT02813655|cosyntropin
854832|NCT02813655|post-dural syndrom
854833|NCT02813655|post-dural puncture headache
854834|NCT02813642|chronic kidney disease starting dialysis
854835|NCT02813642|cardiovascular risk
854836|NCT02813642|bone mineral metabolism markers
854842|NCT02813603|EBUS-TBNA
854843|NCT02813603|staging
854844|NCT02813603|lymph node metastases
854845|NCT02813577|Legs
854846|NCT02813577|Drug Coated Angioplasty Balloon
854847|NCT02813577|Experimental
854848|NCT02813577|Standard Angioplasty Balloon
854849|NCT02813564|Autism
854850|NCT02813564|Cognitive Training
854851|NCT02813564|Brain
854852|NCT02813564|fMRI
854853|NCT02813551|Preeclampsia, puerperium
854854|NCT02813538|Thrombelastography
854855|NCT02813538|Antithrombin proteins
854856|NCT02813538|Liver surgery
854857|NCT02813538|Liver function tests
854858|NCT02813525|Aortic Isthmus
854859|NCT02813525|Isthmic Systolic Index
854860|NCT02813525|feasibility
854861|NCT02813525|reproducibility
854862|NCT02813525|mortality
854863|NCT02813525|delivery
854864|NCT02813499|Acute Coronary Syndrome
854865|NCT02813473|SYNTAX Score II
854866|NCT02813473|Multi Slice Computed Tomography
854867|NCT02813473|MSCT
854868|NCT02813473|Heart Team
854869|NCT02813473|Fractional Flow Reserve Computed Tomography
854870|NCT02813473|FFR
854871|NCT02813473|FFR MSCT
854872|NCT02813473|PCI
854873|NCT02813473|CABG
854874|NCT02813473|Percutaneous Coronary Intervention
854875|NCT02813473|Coronary Artery Bypass Graft
854876|NCT02813434|Cerebral amyloid imaging
854877|NCT02813434|Florbetapir
854878|NCT02813434|18F-AV-45
854879|NCT02813434|poststroke
854880|NCT02813421|CGM
854881|NCT02813382|bupivacaine
854882|NCT02813382|prilocaine
854883|NCT02813382|2-chloroprocaine
854884|NCT02813330|Women
854885|NCT02813330|severe
854886|NCT02813330|low back ache
854887|NCT02813330|labor
854888|NCT02813317|Surgery
854889|NCT02813317|Breast cancer
854890|NCT02813317|Quality of life
854891|NCT02813317|Care pathway
854892|NCT02813317|Economic evaluation
854893|NCT02813304|Acute
854894|NCT02813304|rotator cuff tendinopathy
854895|NCT02813304|exercise
854896|NCT02813304|loading
854897|NCT02813304|ice
854898|NCT02813304|cryotherapy
854899|NCT02813304|randomised control trial
854900|NCT02813291|Motor imagery
854901|NCT02813291|transcranial direct current stimulation
854902|NCT02813291|motor learning
854903|NCT02813291|aging
854904|NCT02813265|Ocular Discomfort
854905|NCT02813265|Pain
854906|NCT02813265|Corticosteroid
854907|NCT02813265|Hyperemia
854908|NCT02813265|Dry Eye
854909|NCT02813252|long-term follow-up
854910|NCT02813252|chimeric antigen receptor (CAR) T cells
854911|NCT02813252|JCAR015
854912|NCT02813239|IVF
854913|NCT02813239|Dual trigger
854914|NCT02813239|GnRH agonist
854915|NCT02813239|hCG
854916|NCT02813239|mature oocytes
854917|NCT02813226|castration-resistant
854918|NCT02813226|molecular imaging
854919|NCT02813226|abiraterone acetate
854920|NCT02813226|enzalutamide
854921|NCT02813226|metabolic response
854922|NCT02813213|skin transplantation
854923|NCT02813213|grafting skin
854924|NCT02813200|COPD, inhaler device, handling
854925|NCT02813187|venous leg ulcer
854926|NCT02813187|venous
854927|NCT02813187|QCDR
854928|NCT02813187|quality measure
854929|NCT02813187|wound
854930|NCT02813187|Outcome
854931|NCT02813161|diabetic foot ulcer
854932|NCT02813161|diabetes
854933|NCT02813161|arterial disease
854934|NCT02813161|neuropathy
854935|NCT02813161|amputation
854936|NCT02813161|QCDR
854937|NCT02813161|quality measure
854938|NCT02813161|wound
854939|NCT02813096|HCC
854940|NCT02813096|PVTT
854941|NCT02813096|Folofox4
854942|NCT02813096|Early Recurrence
854943|NCT02813044|anesthesia
854944|NCT02813044|intravenous
854945|NCT02813044|neurosurgery
854946|NCT02813044|pituitary neoplasm
854947|NCT02813044|postoperative period
854948|NCT02813031|functional meat products
854949|NCT02813031|hypocaloric fats
854950|NCT02813031|diglyceride
854951|NCT02813031|obesity
854952|NCT02813018|child
854953|NCT02813018|analgesia
854954|NCT02813018|epidural
854955|NCT02813018|pain
854956|NCT02813018|postoperative
854957|NCT02813018|orthopedics
854958|NCT02813005|High frequency jet ventilation
854959|NCT02812966|peripheral arterial disease
854960|NCT02812966|drug coated balloon
854961|NCT02812927|Glycemic lability index
854962|NCT02812927|Continuous glucose monitoring system
854963|NCT02812927|intensive care
854964|NCT02812927|Insulin
854965|NCT02812888|Hyperthyroidism
854966|NCT02812888|Betatrophin
854967|NCT02812836|anorectal manometry
854968|NCT02812836|children
854969|NCT02812836|constipation
854970|NCT02812823|manometry
854971|NCT02812823|children
854972|NCT02812823|constipation
854973|NCT02812823|functional disorders
854974|NCT02812797|Adipokines
854975|NCT02812797|Chronic Heart Failure
854976|NCT02812797|Prognosis
854977|NCT02812784|Nephrocheck™
854978|NCT02812784|acute kidney injury
854979|NCT02812758|sedation depth
854980|NCT02812758|indices of preload dependence
854981|NCT02812745|anaesthesia
854982|NCT02812732|HPV vaccination
854983|NCT02812732|provider education
854984|NCT02812667|Metastatic
854985|NCT02812667|NSCLC
854986|NCT02812667|nivolumab
854987|NCT02812667|plinabulin
854988|NCT02812667|BPI-2358
854989|NCT02812667|opdivo
854990|NCT02812667|Non-Small Cell Lung Cancer
854991|NCT02812667|cancer
854992|NCT02812654|Sarcoma
854993|NCT02812654|soft tissue sarcoma
854994|NCT02812654|neoadjuvant chemotherapy
854995|NCT02812654|neoadjuvant radiotherapy
854996|NCT02812654|hypofractionated radiotherapy
854997|NCT02812641|Concurrent chemoradiation
854998|NCT02812641|Esophageal squamous cell carcinoma
854999|NCT02812641|Vascular endothelial growth factor
855000|NCT02812628|laparoscopic surgery
855001|NCT02812628|abdominoperineal resection
855002|NCT02812628|rectal cancer
855003|NCT02812628|individualized surgery
855004|NCT02812628|levator muscle
855005|NCT02812615|Environmental Enteric Dysfunction
855006|NCT02812602|Total Knee Replacement
855007|NCT02812602|Stitch
855008|NCT02812602|Removal
855009|NCT02812602|Pain
855010|NCT02812589|MRI
855011|NCT02812576|Group B streptococcus
855012|NCT02812576|Infants
855013|NCT02812576|China
855014|NCT02812550|full-spectrum endoscopy
855015|NCT02812550|polyp detection rate
855016|NCT02812550|colorectal cancer
855017|NCT02812550|colorectal screening
855018|NCT02812550|adenoma detection rate
855019|NCT02812550|endoscopic innovations
855020|NCT02812537|Trajectories
855021|NCT02812537|emergency room
855022|NCT02812537|conduct disorder
855023|NCT02812537|care management
855024|NCT02812524|Immunotherapy
855025|NCT02812524|Yervoy
855026|NCT02812524|Head and neck cancer
855027|NCT02812524|Pre-operative
855028|NCT02812498|teleconsultation
855029|NCT02812498|insulin therapy
855030|NCT02812498|HbA1c
855031|NCT02812459|Electrical Stimulation Therapy
855032|NCT02812459|Kinesio taping
855033|NCT02812459|Exercise
855034|NCT02812446|biofilm
855035|NCT02812446|staphylokinase
855036|NCT02812446|Staphylococcus aureus
855037|NCT02812446|microarrays
855038|NCT02812446|bone binding sialoprotein
855039|NCT02812446|bone and joint infection
855040|NCT02812446|blood group
855041|NCT02812433|birth asphyxia
855042|NCT02812433|brain
855043|NCT02812433|hypoxic-ischemic encephalopathy
855044|NCT02812433|neonate
855045|NCT02812433|neuroprotection
855046|NCT02812433|neurorestoration
855047|NCT02812433|newborn
855048|NCT02812433|sildenafil
855049|NCT02812420|Malignant neoplasms of urinary tract
855050|NCT02812420|Urothelial Carcinoma
855051|NCT02812420|Muscle-invasive, high-risk bladder cancer
855052|NCT02812420|Ineligible for neoadjuvant cisplatin-containing chemotherapies
855053|NCT02812420|Bladder cancer
855054|NCT02812420|Cystectomy
855055|NCT02812420|Bladder cancer surgery
855056|NCT02812420|Durvalumab
855057|NCT02812420|MEDI4736
855058|NCT02812420|Tremelimumab
855059|NCT02812420|Phone calls
855060|NCT02812394|Parkinson's disease
855061|NCT02812394|Episodic motor fluctuations (OFF periods)
855062|NCT02812381|Trigger Points, movement
855063|NCT02812355|off-pump
855064|NCT02812355|coronary artery bypass
855065|NCT02812355|heparinization
855066|NCT02812342|Alopecia
855067|NCT02812316|Myopia
855068|NCT02812316|Scleral lens
855069|NCT02812316|Astigmatism
855070|NCT02812316|Presbyopia
855071|NCT02812290|antibody mediated rejection, T cell mediated rejection
855072|NCT02812277|anastrozole
855073|NCT02812277|letrozole
855074|NCT02812277|postmenopausal patients
855075|NCT02812238|Inflammasome
855076|NCT02812238|Sirt3
855077|NCT02812238|Nicotinamide Riboside
855078|NCT02812238|Fasting
855079|NCT02812212|ureteropelvic junction obstruction
855080|NCT02812212|cortical transit time
855081|NCT02812186|Neuromuscular blockade
855082|NCT02812173|urinary drainage
855083|NCT02812173|urethral catheter
855084|NCT02812173|suprapubic tube
855085|NCT02812173|pain
855086|NCT02812173|discomfort
855087|NCT02812173|radical prostatectomy
855088|NCT02812173|robotic surgery
855089|NCT02812173|urinary infection
855093|NCT02812134|phosphorus supplementation
855094|NCT02812134|FGF23
855095|NCT02812134|anorexic
855096|NCT02812134|adolescents
855097|NCT02812134|undernutrition
855098|NCT02812108|intracranial aneurysm
855099|NCT02812108|endovascular treatment
855100|NCT02812108|recanalization
855101|NCT02812108|outcome
855102|NCT02812108|hemodynamics
855103|NCT02812108|computational fluid dynamic
855104|NCT02812108|stent
855105|NCT02812108|flow diversion
855106|NCT02812082|Web-based
855107|NCT02812082|patient education application
855108|NCT02812082|16-769
855109|NCT02812056|Malignant neoplasms of digestive organs
855110|NCT02812056|Malignant neoplasms of female genital organs
855111|NCT02812056|Malignant neoplasms of lip oral cavity and pharynx
855112|NCT02812056|Malignant neoplasms of male genital organs
855113|NCT02812056|Human papilloma virus associated malignancies
855114|NCT02812056|HPV
855115|NCT02812056|Alisertib
855116|NCT02812056|MLN8237
855117|NCT02812056|TAK-228
855118|NCT02812056|MLN0128
855119|NCT02812043|onychomycosis
855120|NCT02812043|amorolfine
855121|NCT02812043|long-pulsed Nd:YAG
855122|NCT02812043|fungal infection
855123|NCT02812030|Observational Study
855124|NCT02812030|aflibercept
855125|NCT02812030|Diabetic Retinopathy
855126|NCT02812030|Visual Acuity
855127|NCT02812017|educational intervention
855128|NCT02812017|language development
855129|NCT02812017|postpartum
855130|NCT02812017|parental attachment
855131|NCT02812017|achievement gap
855132|NCT02812017|language gap
855133|NCT02812017|school readiness
855134|NCT02812004|Vitreous Floaters
855135|NCT02812004|Mouches Voulantes
855136|NCT02811991|paracetamol
855137|NCT02811991|post-operative analgesia
855138|NCT02811965|heel
855139|NCT02811965|pressure ulcer
855140|NCT02811965|pressure mapping
855141|NCT02811952|bladder cancer
855149|NCT02811926|parastomal bulging
855150|NCT02811926|peristomal bulging
855151|NCT02811926|ileostomy
855152|NCT02811926|colostomy
855153|NCT02811926|enterostomy
855154|NCT02811926|incidence
855155|NCT02811926|risk factor
855156|NCT02811913|sensory impairment
855157|NCT02811913|sensory deficit
855158|NCT02811913|upper limb
855159|NCT02811913|transcranial magnetic stimulation
855160|NCT02811913|brain stimulation
855161|NCT02811913|rehabilitation
855162|NCT02811900|obesity surgery
855163|NCT02811900|Roux en Y gastric bypass
855164|NCT02811900|sleeve gastrectomy
855165|NCT02811900|excess weight loss
855166|NCT02811900|quality of life
855167|NCT02811874|diabetes education
855168|NCT02811874|community health workers
855169|NCT02811874|diabetes control
855170|NCT02811861|Renal Cell Carcinoma (RCC)
855171|NCT02811861|Lenvatinib
855172|NCT02811861|First-line RCC
855173|NCT02811861|Treatment-naive RCC
855174|NCT02811861|Everolimus
855175|NCT02811861|Pembrolizumab
855176|NCT02811861|Sunitinib
855177|NCT02811861|Phase 3 RCC
855178|NCT02811861|Phase 3 first-line RCC
855179|NCT02811861|Phase 3 treatment-naive RCC
855180|NCT02811822|GMI-1271
855181|NCT02811822|bortezomib
855182|NCT02811822|carfilzomib
855183|NCT02811822|multiple myeloma
855184|NCT02811809|Prostate cancer
855185|NCT02811809|Apalutamide
855186|NCT02811809|IHT
855187|NCT02811809|BCR
855188|NCT02811809|Biochemical recurrence
855189|NCT02811809|intermittent hormone therapy
855190|NCT02811796|drug eluting stents
855191|NCT02811796|flow fractional reserve
855192|NCT02811796|prognosis
855193|NCT02811796|angio-based FFR
855194|NCT02811783|Pruritus
855195|NCT02811783|Mycosis Fungoides
855196|NCT02811783|CTCL
855197|NCT02811783|naloxone
855198|NCT02811783|opiate antagonist
855199|NCT02811718|Stress Management
855200|NCT02811718|Resiliency
855201|NCT02811718|Skype
855202|NCT02811692|Database
855203|NCT02811692|Diabetic Macular Edema (DME)
855204|NCT02811692|Wet Age-related Macular Degeneration (wAMD)
855205|NCT02811692|Retinal Diseases
855206|NCT02811692|Optic Nerve Diseases
855207|NCT02811692|Corneal Diseases
855208|NCT02811692|Vision Disorders
855209|NCT02811679|Lymphoma
855210|NCT02811653|Motor slowing
855211|NCT02811640|Intra-Abdominal Pressure
855212|NCT02811640|Stryker Pressure Monitor
855213|NCT02811627|Magnetic Resonance Spectroscopy
855214|NCT02811627|Memantine
855215|NCT02811627|Treatment prediction biomarker
855216|NCT02811614|intracerebral hemorrhage,hypertensive
855217|NCT02811614|minimally invasive surgery
855218|NCT02811614|neuroendoscopic surgery
855219|NCT02811614|stereotactic aspiration
855220|NCT02811601|Minimally Invasive Surgical Procedures
855221|NCT02811575|Coloscopy
855222|NCT02811549|Cochlear Implant
855223|NCT02811549|HiRes™ 90K Advantage Implant
855224|NCT02811549|HiFocus™ Mid-Scala electrode
855225|NCT02811549|HiFocus™ 1J electrode
855226|NCT02811549|HiFocus Helix™ electrode
855227|NCT02811549|Cochlear Implantation
855228|NCT02811549|Listening Benefits
855229|NCT02811549|Adults
855230|NCT02811549|Cochlear Implant Benefit
855231|NCT02811549|Electrical Stimulation
855232|NCT02811484|Obesity
855233|NCT02811458|Panic Disorder
855234|NCT02811458|Agoraphobia
855235|NCT02811458|Social Anxiety Disorder
855236|NCT02811458|Generalized Anxiety Disorder
855237|NCT02811458|Cognitive-Behavioral Therapy
855238|NCT02811445|microbiome, metabolome, aging, lean mass, physical function
855239|NCT02811432|Kangaroo mother care
855240|NCT02811432|Neonates
855241|NCT02811432|Low birth weight
855242|NCT02811432|Unstable
855243|NCT02811393|Bariatric surgery, sarcopenia
855244|NCT02811380|CVC
855245|NCT02811380|Healthcare associated infections (HAI)
855246|NCT02811380|CLABSI
855247|NCT02811380|Noble metal alloy coating
855248|NCT02811380|CVC related thrombosis
855249|NCT02811341|Scopolamine butylbromide PCLE
855250|NCT02811276|High-protein diet
855251|NCT02811276|Energy metabolism
855252|NCT02811276|Substrate oxidation
855253|NCT02811250|Renal cancer
855254|NCT02811250|Stereotactic radiotherapy
855255|NCT02811185|PET
855256|NCT02811185|CT
855257|NCT02811185|PET/CT
855258|NCT02811172|Biological multi-paradigm model
855259|NCT02811172|Biomarkers
855260|NCT02811172|Triglycerides
855261|NCT02811172|Cholesterol
855262|NCT02811172|Prolactin
855263|NCT02811172|Glucose
855264|NCT02811146|Heart Failure
855265|NCT02811146|Noninvasive Ventilation
855266|NCT02811146|Positive- Pressure Respiration
855267|NCT02811133|inositol
855268|NCT02811120|meningococcal
855269|NCT02811120|conjugate
855270|NCT02811120|vaccine
855271|NCT02811120|quadrivalent
855272|NCT02811120|meningococcal quadrivalent conjugate vaccine
855273|NCT02811107|anxiety
855274|NCT02811107|pain
855275|NCT02811107|preoperative area
855276|NCT02811107|premedication
855277|NCT02811068|HPV
855278|NCT02811068|vaccine
855279|NCT02811068|Human Papillomavirus Virus Vaccine
855280|NCT02811029|neurological
855281|NCT02811029|difficulties
855282|NCT02811016|High Altitude
855283|NCT02811016|budesonide
855284|NCT02811016|hypoxia
855285|NCT02811003|Insertional Achilles
855286|NCT02810990|bosutinib
855287|NCT02810990|chronic myeloid leukemia
855288|NCT02810977|gastric volume
855289|NCT02810977|gastric content
855290|NCT02810977|ultrasound
855291|NCT02810977|perioperative fasting
855292|NCT02810964|Schizophrenia
855293|NCT02810964|Schizoaffective Disorder
855294|NCT02810964|Sulforaphane
855295|NCT02810964|Sulforaphane supplement
855297|NCT02810938|Ablation
855298|NCT02810938|Mifi technology
855299|NCT02810938|maximum voltage-guided ablation
855300|NCT02810899|child
855301|NCT02810899|craniotomy
855302|NCT02810899|intelligence tests
855303|NCT02810899|dexmedetomidine
855304|NCT02810899|Disruption
855305|NCT02810899|Dehiscence
855306|NCT02810899|Mild Cognitive Disorder
855307|NCT02810886|Prostate Cancer
855308|NCT02810860|laparoscopic cholecystectomy
855309|NCT02810847|Amblyopia
855310|NCT02810847|strabismus
855311|NCT02810847|virtual reality
855312|NCT02810847|computer games
855313|NCT02810834|Executive Function
855314|NCT02810834|Academic Performance
855315|NCT02810821|Gonadal hormones
855316|NCT02810821|Gonadotropins
855317|NCT02810821|Cardiovascular diseases
855318|NCT02810821|Lipids
855319|NCT02810821|Obesity
855320|NCT02810821|Atherosclerosis
855321|NCT02810821|Glucose metabolism disorders
855322|NCT02810821|Metabolic syndrome
855323|NCT02810821|Non-alcoholic fatty liver disease
855324|NCT02810808|Neovascular Age-related Macular Degeneration
855325|NCT02810808|Ranibizumab
855326|NCT02810808|Pro Re Nata
855327|NCT02810795|Coronary
855328|NCT02810795|Artery
855329|NCT02810795|Computed tomography
855330|NCT02810795|FFR
855331|NCT02810795|CT myocardial perfusion
855332|NCT02810795|Dynamic
855333|NCT02810782|opiate dependence
855334|NCT02810782|withdrawal
855335|NCT02810782|newborn
855336|NCT02810730|pancreas
855337|NCT02810730|adenocarcinoma
855338|NCT02810704|Anticoagulant
855339|NCT02810704|Venous Thromboembolism
855340|NCT02810704|Pulmonary Embolism
855341|NCT02810704|Total Knee Arthroplasty
855342|NCT02810704|Total Hip Arthroplasty
855343|NCT02810691|Diabetes
855344|NCT02810691|Fiber
855345|NCT02810691|Supplementation
855346|NCT02810691|Soluble fiber
855347|NCT02810691|Post-prandial blood glucose
855348|NCT02810691|Nutrition
855349|NCT02810678|Tuberculosis
855350|NCT02810665|Repeatability
855351|NCT02810665|Concordance
855352|NCT02810665|Agreement
855353|NCT02810665|ETDRS visual acuity chart
855354|NCT02810665|numeric
855355|NCT02810665|Landolt C
855356|NCT02810665|Roman alphabet
855357|NCT02810652|Cancer Surgery Care
855358|NCT02810639|pain
855359|NCT02810587|Endophthalmitis
855360|NCT02810587|Intravitreous injection
855361|NCT02810587|anti-vascular endothelial growth factor
855362|NCT02810587|topical antibiotics
855363|NCT02810561|Troponin
855364|NCT02810535|Local IgE
855365|NCT02810535|Non-allergic rhinitis
855366|NCT02810535|Allergic rhinitis to house dust mite
855367|NCT02810509|Wafarin
855368|NCT02810509|Cardioembolic (CE) stroke
855369|NCT02810509|ischemic stroke
855370|NCT02810483|Prader-Willi
855371|NCT02810483|SPW
855372|NCT02810483|impulsivity
855373|NCT02810483|eating disorders
855374|NCT02810483|topiramate
855375|NCT02810457|Cancer
855376|NCT02810457|Bevacizumab
855377|NCT02810457|Carboplatin
855378|NCT02810457|Paclitaxel
855379|NCT02810431|Transfer Protocol
855380|NCT02810431|Long-Term Storage
855381|NCT02810431|Sample Retention
855382|NCT02810418|Immunotoxin
855383|NCT02810418|Mesothelin
855384|NCT02810418|Antibody-based Therapeutics
855385|NCT02810418|Advanced Cancer
855386|NCT02810405|Sample
855387|NCT02810405|Storage
855388|NCT02810405|Molecular Profiling
855389|NCT02810405|Biopsy
855390|NCT02810405|Repository
855391|NCT02810379|informed consent
855392|NCT02810379|ERCP
855393|NCT02810379|video
855394|NCT02810366|Verbal Autopsy
855395|NCT02810366|Physician-coded verbal autopsy
855396|NCT02810366|Computer-coded verbal autopsy
855397|NCT02810366|InterVA
855398|NCT02810366|Naive Bayes Classifier (NBC)
855399|NCT02810366|Tariff
855400|NCT02810366|InSilicoVA
855401|NCT02810366|Randomised Control Trial
855402|NCT02810366|SmartVA
855403|NCT02810366|King-Lu
855404|NCT02810327|Alpha-1 antitrypsin deficiency
855405|NCT02810327|AATD
855406|NCT02810327|Alpha-1
855407|NCT02810327|SERPINA1
855408|NCT02810327|MZ
855409|NCT02810327|Carrier
855410|NCT02810327|Heterozygote
855411|NCT02810327|Smoking
855412|NCT02810327|COPD
855413|NCT02810327|Emphysema
855414|NCT02810327|Sequencing
855415|NCT02810301|gluten
855416|NCT02810301|non-celiac
855417|NCT02810301|gluten sensitivity
855418|NCT02810288|Airway anatomy
855419|NCT02810288|difficult intubation
855420|NCT02810288|congenital syndromes
855421|NCT02810262|Lung cancer
855422|NCT02810262|Bone metastases
855423|NCT02810262|EGFR
855424|NCT02810262|KRAS
855425|NCT02810262|Bone biomarkers
855426|NCT02810262|Metabolic parameters
855427|NCT02810249|African American YMSM
855428|NCT02810249|PrEP
855429|NCT02810249|HIV Pre-Exposure Prophylaxis
855430|NCT02810249|Common Sense Model
855431|NCT02810249|Healthcare
855432|NCT02810249|HIV Prevention
855433|NCT02810236|Focal breast pain
855434|NCT02810236|Directed Ultrasound
855435|NCT02810236|Reassurance
855436|NCT02810236|Anxiety
855437|NCT02810210|Zika
855438|NCT02810210|microcephaly
855439|NCT02810210|congenital abnormalities
855440|NCT02810210|new-born
855441|NCT02810210|infant
855442|NCT02810184|bone augmentation
855443|NCT02810184|long-term bone volume changes
855444|NCT02810184|immediate provisional implant
855445|NCT02810171|anxiety
855446|NCT02810171|social anxiety disorder
855447|NCT02810171|generalized anxiety disorder
855448|NCT02810171|phobias
855449|NCT02810171|fears
855450|NCT02810171|worry
855451|NCT02810145|traumatic brain injury
855452|NCT02810145|cerebral desaturation
855453|NCT02810145|intensive care
855454|NCT02810145|hemodynamics
855455|NCT02810145|Loss
855456|NCT02810145|Consciousness
855457|NCT02810106|Spect
855458|NCT02810106|Stress Test
855459|NCT02810106|Myocardial Perfusion CT
855460|NCT02810106|CT angiography
855461|NCT02810093|Breast cancer
855462|NCT02810093|Text mining
855463|NCT02810093|Big Data
855464|NCT02810093|Machine Learning
855465|NCT02810054|regeneration
855466|NCT02810054|intrabony defects
855467|NCT02810054|enamel matrix derivative
855468|NCT02810054|MIST
855469|NCT02810028|Limb girdle muscular dystrophy
855470|NCT02810028|Becker's muscular dystrophy
855471|NCT02810028|Facioscapulohumeral muscular dystrophy
855472|NCT02810028|Inclusion-body myositis
855473|NCT02810028|Acceptance and Commitment Therapy
855474|NCT02810028|ACT
855475|NCT02809950|postoperative nausea and vomiting, oral carbohydrate beverage
855476|NCT02809937|aged
855477|NCT02809937|surgical procedures, operative
855478|NCT02809937|delirium
855479|NCT02809937|dexmedetomidine
855480|NCT02809937|long-term outcome
855481|NCT02809924|endotracheal intubation
855482|NCT02809924|teaching
855483|NCT02809924|just-in-time
855484|NCT02809898|Biomarkers, Neoplasms
855485|NCT02809885|Hepatitis E
855486|NCT02809885|Pediatric
855487|NCT02809885|Transplantation
855488|NCT02809885|Prevalence
855489|NCT02809820|ACS
855490|NCT02809820|Beta Blockers
855491|NCT02809820|platelet aggregation
855492|NCT02809820|light transmission aggregometry
855493|NCT02809820|Beta-Adrenergic Blockers
855494|NCT02809807|Work of Breathing; Hypoxemia; Respiratory Acidosis; Respiratory effort; COPD
855495|NCT02809781|ankylosing spondylitis
855496|NCT02809781|mesenchymal stem cell
855497|NCT02809781|etanercept
855498|NCT02809768|Healthy participants
855499|NCT02809768|Pharmacokinetic Drug-Drug Interaction
855500|NCT02809768|Avatrombopag
855501|NCT02809755|Obesity
855502|NCT02809755|laparoscopic gastric banding
855503|NCT02809755|band revision
855504|NCT02809755|laparoscopic gastric banding sleeve gastrectomy
855505|NCT02809742|Pregnant
855506|NCT02809742|Labor
855507|NCT02809742|Epidural
855508|NCT02809742|Analgesia
855509|NCT02809742|Intermittent
855510|NCT02809651|Infrascanner
855511|NCT02809651|Intracranial hemorrhage
855512|NCT02809625|Dynamic contrast -enhanced MRI
855513|NCT02809625|brucella spondylitis
855514|NCT02809599|vertigo
855515|NCT02809599|dizziness
855516|NCT02809586|Alcohol
855517|NCT02809586|Teens
855518|NCT02809586|Young Adults
855519|NCT02809586|Social Media
855520|NCT02809573|peripheral T-cell lymphoma
855521|NCT02809573|PTCL
855522|NCT02809573|chidamide
855523|NCT02809573|CHOP
855524|NCT02809573|phase Ib
855525|NCT02809560|Lymphocytes Th2
855526|NCT02809560|Cav1 channels
855527|NCT02809534|Anlotinib
855528|NCT02809534|AL3818
855535|NCT02809482|Volunteers
855536|NCT02809443|Zika
855537|NCT02809443|Vaccine
855538|NCT02809443|DNA
855539|NCT02809391|Postural Balance
855540|NCT02809391|Gait
855541|NCT02809391|Foot Orthotic
855542|NCT02809391|Proprioception
855543|NCT02809391|Somatosensory
855544|NCT02809365|insulin treated
855545|NCT02809339|Chemotherapy
855546|NCT02809339|ovarian cancer
855547|NCT02809339|Patient reported outcome
855548|NCT02809339|Quality of Care
855549|NCT02809326|efficiency
855550|NCT02809326|exposure therapy
855551|NCT02809326|PTSD
855552|NCT02809326|combat
855553|NCT02809326|veterans
855554|NCT02809313|gingivitis
855555|NCT02809313|probiotic
855556|NCT02809313|non- surgical treatment
855557|NCT02809274|iron deficiency
855558|NCT02809274|polycythemia vera
855559|NCT02809261|Carpal Tunnel Syndrome
855560|NCT02809261|Perineural injection
855561|NCT02809261|Dextrose
855562|NCT02809248|LTX Study
855563|NCT02809235|asthma
855564|NCT02809235|smooth muscle
855565|NCT02809235|lauric acid
855566|NCT02809235|dietary supplement
855567|NCT02809222|Myelodysplastic syndrome
855568|NCT02809222|Ascorbic acid
855569|NCT02809222|Oxidative stress
855570|NCT02809222|Preleukemia
855571|NCT02809196|Food Habits
855572|NCT02809196|Adolescents
855573|NCT02809196|Digital Communication
855574|NCT02809183|metabolic acidosis
855575|NCT02809183|serum bicarbonate
855576|NCT02809183|kidney disease
855577|NCT02809131|CIED infection
855578|NCT02809118|Deafness
855579|NCT02809118|Hearing Loss
855580|NCT02809118|Hearing Loss, Sensorineural
855581|NCT02809118|Ear Diseases
855582|NCT02809118|Hearing Disorders
855583|NCT02809118|Nervous System Diseases
855584|NCT02809118|Neurologic Manifestations
855585|NCT02809118|Otorhinolaryngologic Diseases
855586|NCT02809118|Sensation Disorders
855587|NCT02809118|Signs and Symptoms
855588|NCT02809118|Hearing and Speech Impairment
855589|NCT02809118|Hearing Loss, Unilateral
855590|NCT02809105|Chronic constipation
855591|NCT02809105|Linaclotide
855592|NCT02809105|ASP0456
855593|NCT02809092|Acute Myeloid Leukemia, Natural Killer Cells
855594|NCT02809066|premenstrual syndrome
855595|NCT02809066|calcium
855596|NCT02809066|quality of life
855597|NCT02809053|low tumor burden follicular lymphoma (LTBFL)
855598|NCT02809014|Fluoride
855599|NCT02809014|Dental caries
855600|NCT02809014|Dentifrice
855601|NCT02809001|Fat grafting
855602|NCT02809001|Expansion-related complications
855603|NCT02808988|Bisphosphonate
855604|NCT02808988|osteoporosis
855605|NCT02808988|RANKL
855606|NCT02808988|OPG
855607|NCT02808988|periodontitis
855608|NCT02808975|Hurley Stage I, II, or III
855609|NCT02808975|adalimumab
855610|NCT02808975|inguinal region
855611|NCT02808975|secondary intention
855612|NCT02808975|Hidradenitis Suppurativa
855613|NCT02808975|axilla
855614|NCT02808975|abcess and inflammatory nodule (AN) count
855615|NCT02808949|Prevention
855616|NCT02808949|Lactating Women
855617|NCT02808949|Healthy
855618|NCT02808936|remote ischemic conditioning
855619|NCT02808936|orthopedic surgery
855620|NCT02808936|ischemic heart disease
855621|NCT02808910|behavior
855622|NCT02808910|food intake
855623|NCT02808910|salt
855624|NCT02808910|vegetables
855625|NCT02808910|portion size
855626|NCT02808910|weight loss
855627|NCT02808910|habits
855628|NCT02808897|Chest tubes
855629|NCT02808897|Atrial fibrillation
855630|NCT02808897|Thoracic surgery
855631|NCT02808897|Critical care
855632|NCT02808858|MDS
855633|NCT02808858|Myelodisplastic Syndrome
855634|NCT02808845|coronary angiography
855635|NCT02808845|contrast-induced acute kidney injury
855636|NCT02808845|microalbuminuria
855637|NCT02808832|Human papillomavirus (HPV) vaccine
855638|NCT02808832|Cervical cancer screening
855639|NCT02808832|Provider intervention
855640|NCT02808819|Asthma
855641|NCT02808819|Bronchial Diseases
855642|NCT02808819|Respiratory Tract Diseases
855643|NCT02808819|Lung Diseases
855644|NCT02808819|Obstructive Lung Diseases
855645|NCT02808806|stroke
855646|NCT02808806|cerebral infarction
855647|NCT02808806|brain infarction
855648|NCT02808806|ischemic stroke
855649|NCT02808806|treatment
855650|NCT02808806|intravenous thrombolysis
855651|NCT02808806|intraarterial thrombectomy
855652|NCT02808806|delay
855653|NCT02808806|total system delay
855654|NCT02808806|pre-hospital delay
855655|NCT02808806|in-hospital delay
855656|NCT02808806|feedback
855657|NCT02808806|real-time feedback
855658|NCT02808806|visual feedback
855659|NCT02808793|ISM
855660|NCT02808793|Mastocytosis
855661|NCT02808793|Indolent Mastocytosis
855662|NCT02808780|Ulcerative Colitis
855663|NCT02808780|Simponi (Golimumab)
855664|NCT02808780|Thiopurines
855665|NCT02808780|Lymphoma
855666|NCT02808780|Malignancies
855667|NCT02808767|Acute myocardial infarction
855668|NCT02808767|Primary coronary intervention
855669|NCT02808767|Antiplatelet therapy
855670|NCT02808728|Total Knee Arthroplasty
855671|NCT02808728|Total Knee Replacement
855672|NCT02808728|Exparel
855673|NCT02808728|Liposomal Bupivacaine
855674|NCT02808728|Ropivacaine
855675|NCT02808728|Postoperative Pain Management
855676|NCT02808702|Attention
855677|NCT02808702|Cognitive behavioral therapy
855678|NCT02808702|Neuroimaging
855679|NCT02808689|Moderate
855680|NCT02808689|Severe
855681|NCT02808676|Cognitive training
855682|NCT02808676|Vitamin D
855683|NCT02808676|Exercise
855684|NCT02808637|Pain management
855685|NCT02808637|vaccination
855686|NCT02808637|manual pressure
855687|NCT02808637|needle aspiration
855688|NCT02808624|Oxaliplatin, peripheral neuropathy, L-CARNOSINE
855689|NCT02808598|Clinical Trials
855690|NCT02808598|Education
855691|NCT02808598|Hispanic Americans
855692|NCT02808598|African Americans
855693|NCT02808598|Health Disparities
855694|NCT02808598|Patient Participation
855695|NCT02808598|Refusal to Participate
855696|NCT02808572|chronic kidney disease
855697|NCT02808572|vascular calcifications
855698|NCT02808572|cardiovascular risk
855699|NCT02808546|Gallbladder stone
855700|NCT02808546|Risk factor
855701|NCT02808546|Case-control study
855702|NCT02808546|Obesity
855703|NCT02808546|Hypertension
855704|NCT02808546|Alcohol consumption
855705|NCT02808520|Social participation
855706|NCT02808520|Children and adolescents with cancer
855707|NCT02808520|Quality of life with hodgkin-lymphoma
855708|NCT02808520|Social inequalities and cancer
855709|NCT02808494|Preeclampsia
855710|NCT02808494|Fetal Growth Restriction
855711|NCT02808481|systemic sclerosis
855712|NCT02808481|cardiac disease
855713|NCT02808481|Heart transplantation
855714|NCT02808481|primitive cardiac damage
855715|NCT02808468|Sexual assault
855716|NCT02808468|Posttraumatic Stress Disorder
855717|NCT02808468|Alcohol use
855718|NCT02808468|Cognitive therapy
855724|NCT02808416|Solid tumors
855725|NCT02808416|Brain metastases
855726|NCT02808416|DC vaccine
855727|NCT02808416|Personalized vaccine
855728|NCT02808416|Tumor antigens
855729|NCT02808416|PBMCs
855730|NCT02808364|Recurrent glioblastoma
855731|NCT02808364|DC vaccine
855732|NCT02808364|tumor antigen
855733|NCT02808364|personalized vaccine
855734|NCT02808299|statin
855735|NCT02808299|hepatitis B virus
855736|NCT02808273|Bemiparine
855737|NCT02808273|Antithrombotic microsurgery protocol
855738|NCT02808273|Comparative study
855739|NCT02808273|Anticoagulant microsurgery protocol
855740|NCT02808260|sub-clinical atrial fibrillation
855741|NCT02808260|biomarkers
855742|NCT02808260|implanted pacemaker or defibrillator
855743|NCT02808247|advanced metastatic soft tissue sarcoma
855744|NCT02808221|Heart failure
855745|NCT02808221|heart disease
855746|NCT02808221|left ventricular
855747|NCT02808195|Cerebral Palsy
855748|NCT02808195|Neurological Rehabilitation
855749|NCT02808195|Upper Extremity
855750|NCT02808156|Cerebral Palsy,
855751|NCT02808156|Upper limb neurorehabilitation
855752|NCT02808156|Upper Extremity
855753|NCT02808156|Neurological Rehabilitation
855754|NCT02808130|hyperlipidemia, periodontal disease, oxidative stress,
855755|NCT02808117|microfinance institution
855756|NCT02808117|MFI
855757|NCT02808078|Instrumented treadmill
855758|NCT02808078|Augmented reality
855759|NCT02808078|Neurorehabilitation
855760|NCT02808078|Gait disorders
855761|NCT02808065|Kidney transplant
855762|NCT02808065|Kidney transplantation
855763|NCT02808065|Renal transplant
855764|NCT02808065|Renal transplantation
855765|NCT02808052|Bacterial infections
855766|NCT02808026|severe hypertension
855767|NCT02808026|grade III hypertension
855768|NCT02808026|mineralocorticoid receptor antagonist
855769|NCT02807987|Mineralocorticoid receptor antagonist
855770|NCT02807987|Moderate renal impairment
855771|NCT02807987|Hypertension
855772|NCT02807974|Hypertension with Type 2 Diabetes and Albuminuria
855773|NCT02807974|Diabetic nephropathy
855774|NCT02807974|Diabetic renal disease
855775|NCT02807974|Albuminuria
855776|NCT02807974|Mineralocorticoid receptor antagonist
855777|NCT02807961|Translational read through
855778|NCT02807948|MRI Scan, pacemakers, ICD, CRT
855779|NCT02807922|Palliative Care
855780|NCT02807922|zopiclone
855781|NCT02807896|biomarker
855782|NCT02807896|pancreatic cancer
855783|NCT02807896|bile duct cancer
855784|NCT02807896|miRNA
855785|NCT02807883|Acute Lymphoblastic Leukemia
855786|NCT02807883|ALL
855787|NCT02807883|B-lineage Acute Lymphoblastic Leukemia
855788|NCT02807883|Malignant neoplasms stated as primary lymphoid haematopoietic
855789|NCT02807883|Blinatumomab
855790|NCT02807883|Blincyto
855791|NCT02807883|Post allogeneic stem cell transplant
855792|NCT02807870|Parental training
855793|NCT02807870|Preschool age
855794|NCT02807870|Attention Deficit/Hyperactivity Disorder (ADHD)
855795|NCT02807857|low-interventional observational study,
855796|NCT02807857|CHF,
855797|NCT02807857|heart failure,
855798|NCT02807857|primary care,
855799|NCT02807857|ESC guidelines,
855800|NCT02807857|Europe,
855801|NCT02807857|NT-proBNP,
855802|NCT02807857|reduced ventricular ejection fraction (EF),
855811|NCT02807831|Executive Function
855812|NCT02807831|Language
855813|NCT02807831|Preschool child
855814|NCT02807831|Development
855815|NCT02807818|Child development
855816|NCT02807818|Infant
855817|NCT02807818|Mother-Child Relations
855818|NCT02807805|castration resistant prostate cancer
855819|NCT02807792|Perianal surgery
855820|NCT02807779|angioplasty
855821|NCT02807779|peripheral artery disease
855822|NCT02807779|peripheral vascular disease
855823|NCT02807779|atherosclerosis
855824|NCT02807779|balloon angioplasty
855825|NCT02807779|dexamethasone
855826|NCT02807779|drug coated balloon
855827|NCT02807779|paclitaxel
855828|NCT02807779|walking
855829|NCT02807779|claudication
855830|NCT02807766|autism
855831|NCT02807766|Brain Plasticity
855832|NCT02807766|Behavioral Intervention
855833|NCT02807766|Magnetic Resonance Imaging
855834|NCT02807753|Hemophilia
855835|NCT02807753|Arthropathy
855836|NCT02807753|Pediatric
855837|NCT02807740|Virtual Reality
855838|NCT02807740|Rehabilitation
855839|NCT02807740|Cardiocirculatory system
855840|NCT02807740|Parkinson Disease
855841|NCT02807688|health promotion
855842|NCT02807688|lifestyles
855843|NCT02807688|physical comorbidity
855844|NCT02807688|risk factors
855845|NCT02807688|behavioural change
855846|NCT02807662|posttraumatic stress disorder
855847|NCT02807662|prenatal care
855848|NCT02807636|Urothelial carcinoma
855849|NCT02807636|Bladder cancer
855850|NCT02807636|Anti-PD-L1
855851|NCT02807636|Transitional carcinoma
855852|NCT02807636|Tecentriq
855853|NCT02807636|Atezolizumab
855854|NCT02807636|IMvigor130
855855|NCT02807610|Etomidate lipuro
855856|NCT02807610|Induction characteristics
855857|NCT02807584|Wound
855858|NCT02807584|burns
855859|NCT02807584|acute
855860|NCT02807584|chronic
855861|NCT02807584|foam
855862|NCT02807584|adhesive
855863|NCT02807584|dressing
855864|NCT02807571|Hand
855865|NCT02807558|AML
855866|NCT02807558|MDS
855867|NCT02807545|Scoliosis-Specific Exercises
855868|NCT02807545|Schroth
855869|NCT02807519|Oral health
855870|NCT02807519|Saliva
855871|NCT02807519|Biomarker
855872|NCT02807519|Cytokines
855873|NCT02807519|Cancer
855874|NCT02807519|children
855886|NCT02807493|Pregnancy
855887|NCT02807493|Labor and Delivery
855888|NCT02807493|Occlusal Support Device
855889|NCT02807467|reduction
855890|NCT02807467|delirium
855891|NCT02807467|duration
855892|NCT02807467|severity
855893|NCT02807454|Phase 2
855894|NCT02807454|Open-Label
855895|NCT02807454|Durvalumab
855896|NCT02807454|Daratumumab
855897|NCT02807454|Multiple Myeloma
855898|NCT02807454|Relapsed and Refractory (RRMM)
855899|NCT02807454|FUSION MM-003
855900|NCT02807454|PD-L1
855901|NCT02807441|Bleeding
855902|NCT02807441|Aspirin
855903|NCT02807441|Spine
855904|NCT02807441|Surgery
855905|NCT02807428|post-surgical pain
855906|NCT02807428|total knee arthroplasty
855907|NCT02807428|total knee replacement
855908|NCT02807415|cystic fibrosis
855909|NCT02807415|CFTR
855910|NCT02807415|CFTR modulation
855911|NCT02807415|sweat test
855912|NCT02807415|intestinal current measurement, ICM
855913|NCT02807415|nasal transepithelial potential difference measurement, NPD
855914|NCT02807402|Ombitasvir
855915|NCT02807402|Dasabuvir
855916|NCT02807402|Paritaprevir
855917|NCT02807402|HCV
855918|NCT02807402|Chronic Hepatitis C
855919|NCT02807363|endometriosis
855920|NCT02807363|gonadotropin-releasing hormone agonist
855921|NCT02807363|healthy volunteers
855922|NCT02807363|leuprolide oral tablet
855923|NCT02807350|Intermittent Exotropia
855924|NCT02807350|IXT
855925|NCT02807350|overminus
855926|NCT02807337|Oral mucositis
855927|NCT02807311|Malnutrition
855928|NCT02807311|Undernutrition
855929|NCT02807311|lung transplantation
855930|NCT02807311|artificial nutrition
855931|NCT02807311|nutritional supplements
855932|NCT02807311|enteral nutrition
855933|NCT02807298|Intarligamentary
855934|NCT02807298|Articaine
855935|NCT02807298|Lidocaine
855936|NCT02807246|Probiotic
855937|NCT02807246|Neonatal Hyperbilirubinemia
855938|NCT02807220|Imuneks
855939|NCT02807207|To Study pharmacokinetics and Cardiac safety pacritinib study
855940|NCT02807155|Transitional Care
855941|NCT02807155|Young Adult
855942|NCT02807155|Guided Imagery
855943|NCT02807116|Drug-Interaction Study
855944|NCT02807103|Rituximab
855945|NCT02807103|remission induction
855946|NCT02807103|eosinophilic granulomatosis with polyangiitis
855947|NCT02807090|Low Back Pain
855948|NCT02807090|Exercise
855949|NCT02807090|Dance Therapy
855950|NCT02807090|Physical Therapy
855951|NCT02807077|Healthy subjects
855952|NCT02807038|Respiratory Function Tests
855953|NCT02807038|Air pollution
855954|NCT02807038|Pregnancy
855955|NCT02807038|Spirometry
855956|NCT02807012|Home care services
855957|NCT02807012|Nursing
855958|NCT02807012|Clinical trial
855959|NCT02807012|Geriatric nursing
855960|NCT02807012|Family caregiver
855961|NCT02807012|Aged
855962|NCT02806999|Heart disease
855963|NCT02806999|Postoperative period
855964|NCT02806999|Hyperglycemia
855965|NCT02806999|Berberine
855966|NCT02806999|Insulin
855967|NCT02806999|Clinical trials as topic
855968|NCT02806947|Acute GVHD
855969|NCT02806947|Standard-Risk
855970|NCT02806947|Sirolimus
855971|NCT02806947|Refined Minnesota Risk Criteria
855972|NCT02806947|Ann Arbor
855973|NCT02806947|Biomarker
855974|NCT02806947|Steroid-Free
855975|NCT02806921|Scleral Contact Lens
855976|NCT02806921|Tear Proteases
855977|NCT02806921|Tear Cytokines
855978|NCT02806908|Driving
855979|NCT02806895|Driving
855980|NCT02806856|Middle Cerebral Artery Stroke
855981|NCT02806856|tDCS
855982|NCT02806856|Acute
855983|NCT02806843|stroke
855984|NCT02806843|hemiplegia
855985|NCT02806843|healthy
855986|NCT02806843|robotics
855987|NCT02806843|rehabilitation
855988|NCT02806843|therapy
855989|NCT02806830|Intravitreal injection
855990|NCT02806830|AMD
855991|NCT02806830|Diabetic Retinopathy
855992|NCT02806830|Retinal Artery Occlusion
855993|NCT02806830|Myopia, Degenerative
855994|NCT02806830|eye drops
855995|NCT02806804|vaccine
855996|NCT02806804|safety
855997|NCT02806804|immunogenicity
855998|NCT02806791|Patients
855999|NCT02806778|cardiac arrest
856000|NCT02806778|jugular venous oximetry
856001|NCT02806778|hypoxic brain injury
856002|NCT02806765|Dynamic Stability
856003|NCT02806765|Postural Stability
856004|NCT02806765|Gait Speed
856005|NCT02806765|Hand Grip Strength
856006|NCT02806765|Timed Get-up and Go
856007|NCT02806765|Older Adults
856008|NCT02806752|Polypoidal Choroidal Vasculopathy
856009|NCT02806739|Soy protein
856010|NCT02806739|isoflavones
856011|NCT02806739|gestational diabetes
856012|NCT02806700|Diabetes
856013|NCT02806700|Social Media
856014|NCT02806687|Locally advanced pancreatic adenocarcinoma
856015|NCT02806687|gene therapy
856016|NCT02806687|gemcitabine
856017|NCT02806687|chemosensitization
856018|NCT02806674|Helicobacter pylori
856019|NCT02806674|Antibiotic resistance
856020|NCT02806674|Sequencing
856021|NCT02806661|Robotic surgery
856022|NCT02806661|Vagus nerve preserving
856023|NCT02806635|Relationship Distress
856024|NCT02806635|Relationship Satisfaction
856025|NCT02806635|Marriage
856026|NCT02806635|Web-based
856027|NCT02806635|Internet
856028|NCT02806622|Sports
856029|NCT02806622|University
856030|NCT02806622|Lower Extremity
856031|NCT02806622|Hip Joint
856032|NCT02806609|football
856033|NCT02806609|cryotherapy
856034|NCT02806609|balance
856035|NCT02806609|electromyography
856036|NCT02804958|ST-segment elevation myocardial infarction
856037|NCT02804958|Primary percutaneous coronary intervention
856038|NCT02804958|Clinical outcomes
856039|NCT02804945|Blood And Marrow Transplantation
856040|NCT02804945|Adult Respiratory Distress Syndrome
856041|NCT02804945|ARDS
856042|NCT02804945|Allogeneic human mesenchymal stem cells
856043|NCT02804945|hMSCs
856044|NCT02804945|Placebo
856045|NCT02804945|Plasma-Lyte A solution
856046|NCT02804945|Standard of Care
856047|NCT02804945|Recent onset pulmonary toxicity
856048|NCT02804893|Lung cancer, video-assisted thoracoscopic surgery, robotic-assisted thoracoscopic surgery
856049|NCT02806557|Neoplasms
856050|NCT02806557|Neutropenia
856051|NCT02806557|drug therapy
856052|NCT02806557|Hematologic tests
856053|NCT02806557|Point-of-care Systems
856054|NCT02806557|Febrile neutropenia
856055|NCT02806544|Breast neoplasms
856056|NCT02806544|Breast cancer
856057|NCT02806544|Locally advanced breast cancer
856058|NCT02806544|Neoadjuvant endocrine therapy
856059|NCT02806544|Tamoxifen
856060|NCT02806544|Low and middle income country
856061|NCT02806531|vaccine
856062|NCT02806531|safety
856063|NCT02806518|DIEP
856064|NCT02806518|Computed Tomography
856065|NCT02806518|Doppler
856066|NCT02806518|Thermography
856067|NCT02806440|Low dose naltrexone
856068|NCT02806440|Pain
856069|NCT02806375|Myelofibrosis
856070|NCT02806375|Ruxolitinib
856071|NCT02806375|Cyclophosphamide
856072|NCT02806375|Immunosuppressive Agents
856073|NCT02806375|Immune System Diseases
856074|NCT02806375|Busulfan
856075|NCT02806375|Fludarabine
856076|NCT02806375|Antineoplastic Agents, Alkylating
856077|NCT02806375|Myeloablative Agonists
856078|NCT02806375|Hematopoietic Stem Cell Transplantation
856079|NCT02806375|Allogeneic
856080|NCT02806362|Non-cirrhotic
856081|NCT02806362|End Stage Renal Disease (ESRD)
856082|NCT02806362|moderate fibrosis
856083|NCT02806362|Chronic Hepatitis C Virus ( HCV)
856084|NCT02806362|Chronic Hepatitis C Genotype 1b
856085|NCT02806349|American ginseng
856086|NCT02806349|Konjac glucomannan fiber
856087|NCT02806336|exercise training
856088|NCT02806336|assistive device
856089|NCT02806336|weight loss
856090|NCT02806336|function
856091|NCT02806336|mobility
856092|NCT02806310|Aortic Valve
856093|NCT02806310|Bicuspid
856094|NCT02806297|cholecystectomy
856095|NCT02806284|vaccination
856096|NCT02806284|Streptococcus pneumoniae
856097|NCT02806271|Worry Postponement
856098|NCT02806271|Stimulus Control
856099|NCT02806245|Congenital Heart Disease (CHD)
856100|NCT02806245|Cardiopulmonary Bypass (CPB)
856101|NCT02806245|Cardiac Index
856102|NCT02806245|Hemodynamics
856103|NCT02806245|Pediatrics
856104|NCT02806232|Praziquantel ODT formulation
856105|NCT02806232|Biltricide
856106|NCT02806219|Bioequivalence
856107|NCT02806219|Certolizumab pegol
856108|NCT02806219|Human Volunteers
856109|NCT02806193|cardiovascular
856110|NCT02806193|cardiac
856111|NCT02806193|MRI
856112|NCT02806193|CMR
856113|NCT02806193|CT
856114|NCT02806193|ECG
856115|NCT02806193|magnetic resonance
856116|NCT02806193|imaging
856117|NCT02806154|Cancer
856118|NCT02806154|Chemotherapy toxicity
856119|NCT02806154|Elderly patients
856120|NCT02806154|DEXA
856121|NCT02806154|muscle mass
856122|NCT02806141|Aerosolized colistin
856123|NCT02806141|Intravenous colistin
856124|NCT02806128|cerebral infarction
856125|NCT02806128|kallikrein
856126|NCT02806128|KLK
856127|NCT02806089|chronic kidney disease
856128|NCT02806089|malnutrition inflammation atherogenesis syndrome
856129|NCT02806089|muscle strength
856130|NCT02806089|muscle mass
856131|NCT02806089|lean body mass
856132|NCT02806089|physical activity
856133|NCT02806076|HCC
856134|NCT02806076|RFA
856135|NCT02806063|Prosthesis
856136|NCT02806063|joint infection
856137|NCT02806063|perioperative samples
856138|NCT02806050|FES PET
856139|NCT02806050|Palbociclib
856140|NCT02805985|Degenerative Disc Disease
856141|NCT02805985|Spondylolisthesis
856142|NCT02805985|Retrolisthesis
856143|NCT02805972|Obesity
856144|NCT02805972|Binge eating
856145|NCT02805868|Severe
856146|NCT02805868|Anemia
856147|NCT02805868|Aplastic
856148|NCT02805868|Post-Polycythemic
856149|NCT02805868|Transformation
856150|NCT02805868|Thrombocythemia
856151|NCT02805868|Essential
856152|NCT02805842|non adherence
856153|NCT02805842|Tacrolimus
856154|NCT02805842|Advagraf
856155|NCT02805829|NK cells
856156|NCT02805829|Trastuzumab
856157|NCT02805816|Celiac disease
856158|NCT02805816|Tissue transglutaminase
856159|NCT02805816|Histology
856160|NCT02805790|Primary Mitochondrial Disease
856161|NCT02805790|Mitochondrial Myopathy
856162|NCT02805790|Elamipretide
856163|NCT02805790|MTP-131
856164|NCT02805790|Bendavia™
856165|NCT02804880|Smoking cessation
856166|NCT02804880|Quit to Win
856167|NCT02804880|Brief intervention
856168|NCT02804880|Personalized active referral
856169|NCT02804880|Instant messaging
856170|NCT02804880|SMS
856171|NCT02804880|Smoking Cessation Intervention
856172|NCT02805751|Achilles
856173|NCT02805751|Tendon
856174|NCT02805751|Loading
856175|NCT02805751|Rehabilitation
856176|NCT02805738|Chronic Hepatitis B
856177|NCT02805738|tenofovir
856178|NCT02805738|CKD-390
856179|NCT02805725|Advanced solid tumor
856180|NCT02805725|Advanced pretreated soft tissue sarcomas
856181|NCT02805725|Phase I/II trial
856182|NCT02805725|Dose escalation
856183|NCT02805725|PK study
856184|NCT02805712|Heart Failure
856185|NCT02805712|Palliative Care
856186|NCT02805699|Clinical Efficacy
856187|NCT02805699|Baofeikang Granules
856188|NCT02805699|Combined Pulmonary Fibrosis and Emphysema
856189|NCT02805686|Toxicity, Drug
856190|NCT02805673|Osteopathy
856191|NCT02805673|Support
856192|NCT02805673|Treatment
856193|NCT02805673|Pain
856194|NCT02805673|Quality of Life
856195|NCT02805660|MGCD0103
856196|NCT02805660|MEDI4736
856197|NCT02805660|Mocetinostat
856198|NCT02805660|Durvalumab
856199|NCT02805660|HDAC Inhibitor
856200|NCT02805660|PD-L1 Inhibitor
856201|NCT02805660|Phase 1
856202|NCT02805660|Phase 2
856203|NCT02805660|Metastatic Solid Tumor
856204|NCT02805660|Non-small cell lung cancer
856205|NCT02805660|immunotherapy
856206|NCT02805660|checkpoint inhibitor
856207|NCT02805647|25-Hydroxy-vitamin D, children, bone fractures, vitamin D receptor polymorphism
856208|NCT02805634|nine holes peg
856209|NCT02805634|triple stimulation
856210|NCT02805634|multiple sclerosis
856211|NCT02805582|Peripheral Nerve Block
856212|NCT02805569|videolaryngoscope
856213|NCT02805569|intubation stylet
856214|NCT02805569|articulating stylet
856215|NCT02805569|difficult airway
856216|NCT02805530|oligometastatic disease, radical treatment
856217|NCT02805517|Minimally Invasive Surgical Procedures
856218|NCT02805517|Transplant Donors
856219|NCT02805504|Bupivacaine
856220|NCT02805504|Minimally Invasive Surgical Procedures
856221|NCT02805491|Hypospadias
856222|NCT02805491|newborns
856223|NCT02805491|pesticide
856224|NCT02805491|Picardie
856225|NCT02805465|Heart Failure
856226|NCT02805465|Atrial Fibrillation
856227|NCT02805465|CRT
856228|NCT02805465|BiVP
856229|NCT02805465|HBP
856230|NCT02805387|labor dystocia
856231|NCT02805374|Pharmacokinetics
856232|NCT02805374|ASP1517
856233|NCT02805374|Food effect
856234|NCT02805348|Kiklin
856235|NCT02805348|Bixalomer
856236|NCT02805348|Chronic Kidney Disease
856237|NCT02805335|Central Venous Catheter
856238|NCT02805335|Catheter Bloodstream Related Infection
856239|NCT02805335|Economic evaluation
856240|NCT02805309|Transcatheter Aortic Valve Replacement
856241|NCT02805309|Exercise
856242|NCT02805309|Frailty
856243|NCT02805309|Functional Outcomes
856244|NCT02805309|Cognitive Behavioral Intervention
856246|NCT02805270|adverse drug events, preventable, potential, counselling, medication reconciliation
856247|NCT02805244|JTZ-951
856248|NCT02805244|Pharmacokinetics
856249|NCT02805244|14C-JTZ-951
856250|NCT02805244|Mass balance
856251|NCT02805244|Time course
856252|NCT02805205|PEG-rhG-CSF neutropenia
856253|NCT02805192|Emergency Department
856254|NCT02805192|Estimation of age and weight
856255|NCT02805192|Size measurement
856256|NCT02805166|PEG-rhG-CSF
856257|NCT02805153|PEG-rhG-CSF
856258|NCT02805140|mother
856259|NCT02805140|social support
856260|NCT02805140|mobile app
856261|NCT02805140|videoconference
856262|NCT02805140|sedentary
856263|NCT02805140|physical activity
856264|NCT02805127|Asthma
856265|NCT02805127|COPD
856266|NCT02805127|Capnography
856267|NCT02805114|Asthma
856268|NCT02805114|Chronic Obstructive Pulmonary Disease (COPD)
856269|NCT02805114|Capnography
856270|NCT02805062|Trapped Lung
856271|NCT02805036|alveolar recruitment
856272|NCT02805036|stroke volume/physiology
856273|NCT02805036|cardiac output/physiology
856274|NCT02804997|non-invasive ventilation
856275|NCT02804997|cardiac surgery
856276|NCT02804984|idiopathic cytopenia of undetermined significance (ICUS)
856277|NCT02804984|molecular defects
856278|NCT02804841|Vitamin D supplementation
856279|NCT02804841|Cognitive function
856280|NCT02804841|Physical function
856281|NCT02804841|Successful ageing
856282|NCT02804841|Prevention
856283|NCT02804841|Cholecalciferol
856284|NCT02804841|Dementia
856285|NCT02804841|Muscle mass
856286|NCT02804815|Aspirin
856287|NCT02804815|prostate
856288|NCT02804815|colorectal
856289|NCT02804815|breast
856290|NCT02804815|gastro-oesophageal
856291|NCT02804815|recurrence
856292|NCT02804789|Prevention
856293|NCT02804763|Systemic Lupus Erythematosus (SLE)
856294|NCT02804763|Dapirolizumab Pegol (DZP)
856295|NCT02804750|Cushing's Syndrome
856296|NCT02804750|Cushing's Disease
856297|NCT02804750|Cushings
856298|NCT02804750|Hypercortisolemia
856299|NCT02804750|Cushingoid
856300|NCT02804750|Type 2 Diabetes
856301|NCT02804750|Impaired Glucose Intolerance
856302|NCT02804750|Hypertension
856303|NCT02804750|Adrenal Corticotrophic Hormone (ACTH)
856304|NCT02804750|Adrenocortical Carcinoma
856305|NCT02804750|Primary Pigmented Nodular Adrenal Disease (PPNAD)
856306|NCT02804750|Moon Facies
856307|NCT02804750|Dorsocervical Fat Pad
856308|NCT02804750|Adrenal Adenoma
856309|NCT02804750|Adrenal Carcinoma
856310|NCT02804750|Adrenal Autonomy
856311|NCT02804750|Cortisol
856312|NCT02804724|HIV
856313|NCT02804724|Human immunodeficiency virus
856314|NCT02804724|Late diagnosis
856315|NCT02804672|Cardiovascular health
856316|NCT02804672|Diet
856317|NCT02804672|Functional limitations
856318|NCT02804672|Frailty
856319|NCT02804672|Older adults
856320|NCT02804659|micro-RNA
856321|NCT02804646|Recombinant human endostatin(Endostar)
856322|NCT02804646|Durative transfusion
856323|NCT02804646|adenocarcinoma of lung
856324|NCT02804633|IV acetaminophen
856325|NCT02804633|Colorectal Surgery
856326|NCT02804633|Enhance Recovery
856327|NCT02804633|Opioid Consumption
856328|NCT02804633|Pain Management
856329|NCT02804607|burn
856330|NCT02804607|child
856331|NCT02804607|graft
856332|NCT02804607|development
856333|NCT02804607|complications
856334|NCT02804607|autonomy
856335|NCT02804568|Schizophrenia
856336|NCT02804568|Alkermes
856337|NCT02804568|ALK 3831
856338|NCT02804568|Samidorphan
856339|NCT02804555|reactive oxygen species
856340|NCT02804555|elective cesarean section
856341|NCT02804555|oxygen therapy
856342|NCT02804555|newborn
856343|NCT02804542|fascia iliaca blocks
856344|NCT02804529|Laparoscopic entry
856345|NCT02804529|Meng's point
856346|NCT02804529|Veress needle
856347|NCT02804477|adherence
856348|NCT02804477|opioid
856349|NCT02804477|MMAS 8, morisky medication adherence scale
856350|NCT02804477|validation
856351|NCT02804425|Medical Education
856352|NCT02804425|Simulation
856353|NCT02804425|Anesthesia crisis management
856354|NCT02804425|Learning outcomes
856355|NCT02804412|communication disorders
856356|NCT02804412|language and speech disorder rehabilitation
856357|NCT02804412|stroke
856358|NCT02804399|rifampin
856359|NCT02804399|pharmacokinetics
856360|NCT02804399|PF-06463922
856361|NCT02804399|drug interaction
856362|NCT02804386|HCV
856363|NCT02804386|safety
856364|NCT02804386|efficacy
856365|NCT02804386|EVR
856366|NCT02804386|SVR
856367|NCT02804373|oxytocin
856368|NCT02804373|adults
856369|NCT02804347|Olfactory Dysfunction
856370|NCT02804347|Electroconvulsive Therapy
856371|NCT02804347|Theta Burst Stimulation
856372|NCT02804321|catheter ablation
856373|NCT02804321|galectin 3
856374|NCT02804321|ngal
856375|NCT02804321|aldosterone
856376|NCT02804321|atrial fibrillation
856377|NCT02804308|Combined Training
856378|NCT02804308|Breast Cancer
856379|NCT02804308|Body Composition
856380|NCT02804308|Postmenopausal Women
856381|NCT02804308|Aromatase Inhibitors
856382|NCT02804308|Quality of life
856383|NCT02804295|Prescription Drug
856384|NCT02804295|Misuse
856385|NCT02804269|Healthy Volunteer
856386|NCT02804269|Dilated cardiomyopathy
856387|NCT02804269|Hypertrophic cardiomyopathy
856388|NCT02804269|ischemic heart disease
856389|NCT02804269|Cardiovascular Magnetic Resonance Imaging
856390|NCT02804243|nasal high flow therapy
856391|NCT02804243|rehabilitation
856392|NCT02804243|exercise endurance
856397|NCT02804165|Type 1 diabetes
856398|NCT02804165|Enterovirus
856399|NCT02804165|Genetics
856400|NCT02804165|Gene-Virus interaction
856401|NCT02804152|pregnancy
856402|NCT02804152|pain
856403|NCT02804152|prescription opioid
856404|NCT02804139|Cesarean Section
856405|NCT02804139|Postpartum issues
856406|NCT02804126|acute pain
856407|NCT02804126|transversus abdominis plane block
856408|NCT02804126|quadratus lumborum block
856409|NCT02804126|neuropathic pain
856410|NCT02804100|Circulating Tumor DNA
856411|NCT02804100|Lung cancer
856412|NCT02804100|Plasma DNA
856413|NCT02804061|nutrition
856414|NCT02804061|exercise
856415|NCT02804061|behavior change
856416|NCT02804061|adherence
856417|NCT02804048|Dyspareunia
856418|NCT02804048|Pelvic floor muscles
856419|NCT02804048|Women
856420|NCT02804022|Respiratory Depression
856421|NCT02804009|anxiety
856422|NCT02804009|coronary angiography
856423|NCT02803957|Degenerative
856424|NCT02803957|Mitral Regurgitation
856425|NCT02803944|azithromycin
856426|NCT02803944|cystic fibrosis
856427|NCT02803944|pulmonary function
856428|NCT02803931|Cardiogoniometry
856429|NCT02803931|Electrocardiography
856430|NCT02803879|cardiac resynchronisation therapy
856431|NCT02803879|cardiogoniometry
856432|NCT02803866|Parenting Self-efficacy
856433|NCT02803866|Parent training program
856434|NCT02803866|Perceived self-efficacy tool
856435|NCT02803853|Native American
856436|NCT02803853|Obesity
856437|NCT02803853|Multi level
856438|NCT02803853|Policy
856439|NCT02803853|Schools
856440|NCT02803853|Worksite
856441|NCT02803853|Social Media
856442|NCT02803853|Food Store
856443|NCT02803840|Large B-Cell
856444|NCT02803840|Diffuse
856445|NCT02803827|diarrhoea
856446|NCT02803827|gastroenteritis
856447|NCT02803827|rapid diagnostics
856448|NCT02803827|probiotics
856449|NCT02803814|Pancreatoduodenectomy
856450|NCT02803814|Pancreatic tumors
856451|NCT02803814|Periampullary tumors
856452|NCT02803801|Parents' ability to guide their child
856453|NCT02803801|Parent perception of competence
856454|NCT02803801|Parent understanding of their child's unique learning style
856455|NCT02803788|ramosetron, ondansetron, dexamethasone,
856456|NCT02803762|ADME
856457|NCT02803762|Pacritinib
856458|NCT02803671|preterm neonates
856459|NCT02803671|EEG-NIRS
856460|NCT02803658|smoking
856461|NCT02803645|healthy subjects
856462|NCT02803645|cardiovascular risk factors
856463|NCT02803645|markers of arterial inflammation
856464|NCT02803645|markers of oxidative stress
856465|NCT02803632|young
856466|NCT02803632|disruptive mood dysregulation disorder
856467|NCT02803632|actigraphic profile
856468|NCT02803619|Non-small cell lung cancer
856469|NCT02803619|leptomeningeal metastasis
856470|NCT02803619|EGFR sensitive mutations
856471|NCT02803606|hypothermia
856472|NCT02803606|routine care
856473|NCT02803606|preterm neonates
856474|NCT02803593|a technology-based intervention
856475|NCT02803593|Asian American
856476|NCT02803593|survivorship
856477|NCT02803541|chronic kidney disease
856478|NCT02803541|exercise
856479|NCT02803541|pediatrics
856480|NCT02803541|summer camp
856481|NCT02803515|intra peritonal chemo hyperthermia
856482|NCT02803515|peritoneal carcinomatosis
856483|NCT02803515|ovarian cancer
856484|NCT02803502|thrombin generation test
856485|NCT02803502|factor VIII
856486|NCT02803502|hemophilia
856487|NCT02803489|chronic heart failure
856488|NCT02803489|chronic obstructive pulmonary disease
856489|NCT02803489|diabetes
856490|NCT02803476|PCO
856491|NCT02803476|Vitamin D
856492|NCT02803476|Insulin resistance
856493|NCT02803463|peritoneal closure
856494|NCT02803463|appendectomy
856495|NCT02803463|postoperative pain
856496|NCT02803463|life quality
856497|NCT02803450|Effects of; Anesthesia
856498|NCT02803450|spinal and epidural
856499|NCT02803437|Castration-resistant prostate cancer
856500|NCT02803424|robot-assisted laparoscopic radical prostatectomy
856501|NCT02803424|Autoflow
856502|NCT02803424|trendelenburg position
856503|NCT02803424|pneumoperitoneum
856504|NCT02803411|Coronary Heart Disease
856505|NCT02803411|Coronary Computed Tomography Angiography (CCTA)
856506|NCT02803411|Coronary Atherosclerotic Plaque
856507|NCT02803411|coronary atherosclerosis
856508|NCT02803398|Compression bandages
856509|NCT02803385|Patient Controlled Epidural Analgesia
856510|NCT02803385|Continous Epidural Infusion Analgesia
856511|NCT02803372|partial nephrectomy
856512|NCT02803372|acute kidney injury
856513|NCT02803372|LiDCOrapid
856514|NCT02803372|circulatory management
856515|NCT02803359|Laryngeal evoked brainstem response (LEBR)
856516|NCT02803359|laryngopharyngeal sensory discrimination testing (LPSDT)
856517|NCT02803359|brainstem activity
856518|NCT02803346|sepsis
856519|NCT02803346|septic shock
856520|NCT02803346|immunosuppression
856521|NCT02803346|HLA-DR
856522|NCT02803346|lymphopenia
856523|NCT02803333|NSCLC
856524|NCT02803333|Carcinoma, Non-Small-Cell Lung
856525|NCT02803333|Lung Diseases
856526|NCT02803333|Thoracic Neoplasms
856527|NCT02803320|Sunscreen active
856528|NCT02803307|osteoarthritis of the knee
856529|NCT02803307|TLC599
856530|NCT02803307|Dexamethasone
856531|NCT02803307|DSP
856532|NCT02803255|Injuries
856533|NCT02803255|Spinal Cord
856534|NCT02803242|copd
856535|NCT02803242|emphysema
856536|NCT02803242|bronchitis
856537|NCT02803242|bronchiectasis
856538|NCT02803203|Osimertinib
856539|NCT02803203|bevacizumab
856540|NCT02803203|metastatic
856541|NCT02803203|16-033
856542|NCT02803190|Spine curve
856543|NCT02803190|Posture
856544|NCT02803190|Fracture
856545|NCT02803190|sarcopenia
856546|NCT02803190|Exercise
856547|NCT02803177|large bone defect
856548|NCT02803177|bone marrow-derived mononuclear cells
856549|NCT02803151|Stereotactic ablative radiotherapy
856550|NCT02803151|Lymph node metastasis
856551|NCT02803151|T cell immunity
856552|NCT02803151|cell-free DNA
856553|NCT02803138|Sustained Virological Response
856554|NCT02803138|Observational Study
856555|NCT02803138|Chronic Hepatitis C genotype 4
856556|NCT02803138|Paritaprevir/r - Ombitasvir, ± Dasabuvir
856557|NCT02803138|Chronic Hepatitis C genotype 1
856558|NCT02803138|Chronic Hepatitis C
856559|NCT02803125|PTSD
856560|NCT02803125|Aging
856561|NCT02803125|Veteran
856562|NCT02803125|Intervention
856563|NCT02803086|Prostate cancer
856564|NCT02803086|Radiotherapy
856565|NCT02803086|Hematopoietic stem cells
856566|NCT02803086|Radiotoxicity
856567|NCT02802982|Thrombocytopenia
856568|NCT02802982|Neonates
856569|NCT02802956|Life participation
856570|NCT02802943|CLL, Peptid Vaccination
856571|NCT02802917|Eye stinging potential
856572|NCT02802904|Healthy subjects
856573|NCT02802891|Asthma
856574|NCT02802891|Allergy
856575|NCT02802891|Diagnosis
856576|NCT02802891|Endocrine disruptors
856577|NCT02802891|Children
856578|NCT02802839|Virtual Reality
856579|NCT02802839|venipuncture
856580|NCT02802826|Exercise
856581|NCT02802826|Chemotherapy
856582|NCT02802826|Physical Activity
856583|NCT02802826|Breast Cancer
856584|NCT02802813|Single-blinded controlled trial
856585|NCT02802813|Primaquine
856586|NCT02802787|Quality of life
856587|NCT02802787|Occupation
856588|NCT02802787|Pain
856589|NCT02802787|Fatigue
856590|NCT02802774|Post-operative treatment
856591|NCT02802748|Early Breast Cancer
856592|NCT02802748|Hormone Receptor-positive
856593|NCT02802748|Window-of-opportunity
856594|NCT02802748|PAM50
856595|NCT02802748|Luminal A
856596|NCT02802748|Luminal B
856597|NCT02802748|proliferation signature
856598|NCT02802748|metronomic vinorelbine
856599|NCT02802748|letrozole
856600|NCT02802735|Pharmacokinetics
856601|NCT02802735|Apremilast
856602|NCT02802735|Healthy Adult Male
856603|NCT02802735|Korean Subjects
856604|NCT02802722|convalescence
856605|NCT02802722|inflammation
856606|NCT02802722|resolution
856607|NCT02802722|vitamin D
856608|NCT02802709|knee
856609|NCT02802696|Transfusion
856610|NCT02802696|Transfusion Medicine
856611|NCT02802696|Diuretic
856612|NCT02802683|Hypotension
856613|NCT02802683|cesarean section
856614|NCT02802657|Age-related Macular Degeneration
856615|NCT02802657|Conbercept
856616|NCT02802657|Treat-and-Extend Regimen
856617|NCT02802657|Pro Re Nata
856618|NCT02802631|Bacterial infections
856619|NCT02802618|Validity
856620|NCT02802618|Reliability
856621|NCT02802618|Rehabilitation
856622|NCT02802618|Translation
856623|NCT02802618|Education
856624|NCT02802579|obesity
856625|NCT02802579|dual source CT
856626|NCT02802579|coronary CT angiography
856627|NCT02802579|prognosis
856628|NCT02802579|bariatric surgery
856629|NCT02802579|gastric bypass surgery
856630|NCT02802579|coronary arterial disease
856631|NCT02802579|major adverse coronary event
856632|NCT02802566|Maternal Obesity
856633|NCT02802566|Inflammation
856634|NCT02802553|SmartGoggles
856635|NCT02802553|sentinel lymph nodes
856636|NCT02802553|indocyanine green
856637|NCT02802553|Cardio-Green
856638|NCT02802553|Spy Elite
856639|NCT02802540|nabilone
856640|NCT02802540|anorexia
856641|NCT02802540|Non-Small Cell Lung Cancer
856642|NCT02802514|Gastrointestinal
856643|NCT02802514|Glucagon like peptide
856644|NCT02802514|Nausea
856645|NCT02802514|Magnetic resonance imaging
856646|NCT02802501|Safety
856647|NCT02802501|Artemisinin Combination Therapy
856648|NCT02802501|Efficacy
856649|NCT02802501|Tafenoquine
856650|NCT02802501|Superiority
856651|NCT02802501|Primaquine
856652|NCT02802501|Radical cure
856653|NCT02802501|Vivax
856654|NCT02802501|ACT
856655|NCT02802501|Plasmodium vivax malaria
856656|NCT02802501|Dihydroartemisinin-piperaquine
856657|NCT02802488|D-dimers
856658|NCT02802488|Atrial fibrillation
856659|NCT02802475|antibodies
856660|NCT02802475|auto-immune encephalitis
856661|NCT02802475|epilepsy
856662|NCT02802475|limbic encephalitis
856663|NCT02802462|endothelial progenitor cell
856664|NCT02802462|hemodynamic
856665|NCT02802462|Exercise
856666|NCT02802462|HIIT
856667|NCT02802449|Vitamin D
856668|NCT02802449|Hypovitaminosis D
856669|NCT02802449|HTN
856670|NCT02802423|TNBC
856671|NCT02802423|Breast cancer
856672|NCT02802423|Triple negative
856673|NCT02802397|Early ovarian reserve decreased
856674|NCT02802384|Paget's Disease of Bone
856675|NCT02802384|Healthy controls
856676|NCT02802371|caregiver burden
856677|NCT02802371|Alzheimer disease and related disorders
856678|NCT02802371|elderly
856679|NCT02802371|pharmaceutical care
856680|NCT02802371|optimization of drug prescribing
856681|NCT02802371|psychosocial intervention
856682|NCT02802358|Falls
856683|NCT02802358|Functionality
856684|NCT02802332|neonatal
856685|NCT02802332|preterm
856686|NCT02802332|Nepal
856687|NCT02802332|family-initiated identification
856688|NCT02802332|basic newborn care
856689|NCT02802306|Angioplasty
856690|NCT02802306|Peripheral Artery Disease
856691|NCT02802306|PAD
856692|NCT02802306|Lesion
856693|NCT02802306|Claudication
856694|NCT02802293|Repetitive Transcranial Magnetic Stimulation
856695|NCT02802293|Major Depressive Disorder
856696|NCT02802280|endothelial dysfunction
856697|NCT02802254|physical activity
856698|NCT02802254|patient feedback
856699|NCT02802254|risk perception
856700|NCT02802254|pedometer
856701|NCT02802215|Diabetes Mellitus
856702|NCT02802215|Pregnancy
856703|NCT02802202|Palpation
856704|NCT02802202|Chronic Pain
856705|NCT02802202|Muscle
856709|NCT02802163|untreated multiple myeloma
856710|NCT02802163|newly diagnosed myeloma
856711|NCT02802163|transplant eligible
856712|NCT02802150|Zanthoxylum schinifolium seed Oil
856713|NCT02802150|soy bean oil
856714|NCT02802150|omega-3 fatty acid
856715|NCT02802150|dry eye disease
856716|NCT02802137|tafluprost
856717|NCT02802137|dorzolamide
856718|NCT02802137|timolol
856719|NCT02802137|FC
856720|NCT02802124|hepatocellular carcinoma
856721|NCT02802124|carbon-ion radiotherapy
856722|NCT02802124|toxicity
856723|NCT02802124|efficacy
856724|NCT02802111|Beta Agonists
856725|NCT02802111|Asthma
856726|NCT02802111|Albuterol
856727|NCT02802111|Levalbuterol
856728|NCT02802098|Metastatic breast cancer
856729|NCT02802098|bevacizumab maintenance
856730|NCT02802098|Durvalumab
856741|NCT02802046|FFRCT
856742|NCT02802046|Angina pectoris grade
856743|NCT02802046|Fractional flow reserve
856744|NCT02802046|CCTA
856745|NCT02802033|Registry
856746|NCT02802033|Spine
856747|NCT02802033|Osteobiologics
856748|NCT02802033|Spinal Fusion
856749|NCT02801994|Patient-ventilator interaction
856750|NCT02801994|Inspiratory muscles
856751|NCT02801994|Electromyogram
856752|NCT02801994|Mechanical ventilation
856753|NCT02801994|Proportional Assist Ventilation
856754|NCT02801981|tolerability
856755|NCT02801981|healthy volunteers
856756|NCT02801981|Cholestasis
856757|NCT02801981|safety
856758|NCT02801955|gastric adenocarcinoma
856759|NCT02801955|tumor markers
856760|NCT02801955|peritoneal cytology
856761|NCT02801942|Biomarker
856762|NCT02801942|Immune Profile
856763|NCT02801942|Biopsy
856764|NCT02801942|Leukocyte subsets
856765|NCT02801942|Inguinal lymph nodes
856766|NCT02801942|Type 1 Diabetes Mellitus
856767|NCT02801916|Humans
856768|NCT02801916|Glycemic response
856769|NCT02801916|Oat beta-glucan
856770|NCT02801877|Depression
856771|NCT02801877|Anxiety
856772|NCT02801877|Behavior Therapy
856773|NCT02801877|Technology Assisted
856774|NCT02801877|Mobile Phone
856775|NCT02801877|Cellular Phone
856776|NCT02801877|Smartphone
856777|NCT02801877|App
856778|NCT02801877|Coach
856779|NCT02801864|tDCS
856780|NCT02801864|transcranial direct current stimulation
856781|NCT02801864|intensive speech therapy
856782|NCT02801864|chronic
856783|NCT02801864|post stroke
856784|NCT02801864|aphasia
856785|NCT02801864|production
856786|NCT02801864|language
856787|NCT02801851|Delirium
856788|NCT02801838|Inspiratory muscles
856789|NCT02801838|Patient-ventilator interaction
856790|NCT02801838|Electromyogram
856791|NCT02801838|Mechanical ventilation
856792|NCT02801825|axillay artery
856793|NCT02801825|cannulation
856794|NCT02801825|femoral artery
856795|NCT02801812|Nailfold Capillaroscopy
856796|NCT02801799|Anaesthesia
856797|NCT02801799|Analgesia
856798|NCT02801799|Nerve blocks
856799|NCT02801799|Peripheral nerve blocks
856800|NCT02801799|Regional anaesthesia
856801|NCT02801799|therapeutic techniques
856802|NCT02801799|ropivacaine
856803|NCT02801799|nerve block duration
856804|NCT02801799|lower limb
856805|NCT02801799|Postoperative pain
856806|NCT02801786|Mammography
856807|NCT02801786|Premedication
856808|NCT02801786|Pain
856809|NCT02801786|Discomfort
856810|NCT02801786|Breast
856811|NCT02801773|gingivitis
856812|NCT02801773|probiotic
856813|NCT02801773|non- surgical treatment
856814|NCT02801760|HIV
856815|NCT02801760|Self-Consent
856816|NCT02801760|PrEP
856817|NCT02801760|Autonomous Research Consent
856818|NCT02801760|Participation-associated Outcomes
856819|NCT02801747|HIV care continuum
856820|NCT02801747|antiretroviral therapy
856821|NCT02801747|engagement in HIV care
856822|NCT02801747|Multiphase Optimization Strategy (MOST)
856823|NCT02801708|Embolic stroke of undetermined source
856824|NCT02801708|Atrial fibrillation
856825|NCT02801695|pre-eclampsia
856826|NCT02801695|citrulline
856827|NCT02801695|pregnancy
856828|NCT02801669|anticoagulants
856829|NCT02801669|DU-176b
856830|NCT02801669|edoxaban
856831|NCT02801669|factor Xa
856832|NCT02801669|oral
856833|NCT02801669|prevention
856834|NCT02801669|atrial fibrillation
856835|NCT02801643|PET
856836|NCT02801643|dopamine
856837|NCT02801643|fMRI
856838|NCT02801643|reward
856839|NCT02801617|Latanoprost
856840|NCT02801617|Glaucoma
856841|NCT02801617|Ocular hypertension
856842|NCT02801617|Crossover study
856850|NCT02801552|regenerative endodontic treatment
856851|NCT02801552|platelet-rich fibrin
856852|NCT02801552|Immature permanent tooth
856853|NCT02801552|apical periodontitis
856854|NCT02801513|mindfulness
856855|NCT02801513|EEG
856856|NCT02801513|error-related negativity
856857|NCT02801513|late positive potential
856858|NCT02801513|long-range temporal correlations
856859|NCT02801500|bilioenteric anastomosis
856860|NCT02801487|Carbon Ion Therapy
856861|NCT02801487|Concurrent Chemoradiotherapy
856862|NCT02801435|EGFR inhibitor
856863|NCT02801435|topical agent
856864|NCT02801435|psoriasis
856865|NCT02801435|phase 1
856866|NCT02801422|cannabis
856867|NCT02801422|fMRI
856868|NCT02801422|addiction
856869|NCT02801422|relapse
856870|NCT02801409|Lung Cancer
856871|NCT02801409|Surgical Resection
856872|NCT02801409|Epidural Anesthesia and Analgesia
856873|NCT02801409|Long-Term Outcome
856874|NCT02801357|substance withdrawal syndrome
856875|NCT02801357|opiate addiction
856876|NCT02801357|opiate dependence
856877|NCT02801357|opioid withdrawal syndrome
856878|NCT02801357|buprenorphine
856879|NCT02801344|exercise
856880|NCT02801344|performance
856881|NCT02801344|recovery
856882|NCT02801344|muscle
856883|NCT02801344|protein
856884|NCT02801331|Stochastic Resonance
856885|NCT02801331|Fetus/Newborn Infant
856886|NCT02801331|Drug Withdrawal
856887|NCT02801331|Substance Abuse
856888|NCT02801318|Patient
856889|NCT02801305|Scleroderma
856890|NCT02801305|Diltiazem
856891|NCT02801305|Nitroglycerin
856892|NCT02801305|Topical
856893|NCT02801279|Cerebral Palsy
856894|NCT02801279|Occupational Therapy
856895|NCT02801279|Upper Limb Motor Training
856896|NCT02801266|Contraception
856897|NCT02801266|Reproductive and Sexual Health
856898|NCT02801266|Counseling
856899|NCT02801266|Contraceptive Counseling
856900|NCT02801240|Inflammatory Bowel Disease
856901|NCT02801227|premature rupture of membrane
856902|NCT02801227|primipara
856903|NCT02801227|term
856904|NCT02801227|bishop
856905|NCT02801214|cannabis
856906|NCT02801214|fMRI
856907|NCT02801214|emotion
856908|NCT02801201|sedation
856909|NCT02801201|spinal anesthesia
856910|NCT02801162|arterial blood gas
856911|NCT02801123|Complimentary Cancer Therapies
856912|NCT02801123|Psychosocial Oncology
856913|NCT02801123|Behavioural Medicine
856914|NCT02801123|Mindfulness Based Cancer Recovery
856915|NCT02801123|Tai Chi
856916|NCT02801123|Qigong
856917|NCT02801123|Mindfulness-Based Stress Reduction
856918|NCT02801123|Yoga
856919|NCT02801123|Preference-based trial
856920|NCT02801084|Restricted
856921|NCT02801084|Environmental
856922|NCT02801084|Stimulation
856923|NCT02801071|Post-Polio Syndrome
856924|NCT02801071|PPS
856925|NCT02801058|Osteopathic manipulative treatment
856926|NCT02801058|Abdominal Diaphragm mobility
856927|NCT02801058|Thoracic Ultrasounds
856928|NCT02800980|lymphocele
856929|NCT02800980|sclerotherapy
856930|NCT02800980|drainage
856931|NCT02800980|percutaneous
856932|NCT02800967|platelet activation
856933|NCT02800967|platelet aggregation
856934|NCT02800967|Aronia
856935|NCT02800967|flow cytometry
856936|NCT02800967|polyphenols
856937|NCT02800967|cardiovascular disease risk
856938|NCT02800954|Multiple Myeloma
856939|NCT02800954|bone lesions
856940|NCT02800954|Macrophage-Colony Stimulating Factor
856944|NCT02800915|Spinal Cord Injury
856945|NCT02800915|Pressure Ulcer
856946|NCT02800915|Health Related Quality of Life
856947|NCT02800915|Telemedicine
856948|NCT02800915|Service Innovation
856949|NCT02800915|Rehabilitation
856950|NCT02800915|Interdisciplinary collaboration
856951|NCT02800915|User- participation
856952|NCT02800915|Activity and participation
856953|NCT02800915|Health economics
856954|NCT02800889|relapsed
856955|NCT02800889|refractory
856956|NCT02800889|solid tumors
856957|NCT02800850|Dementia
856958|NCT02800850|Depression
856959|NCT02800850|Agitation
856960|NCT02800850|Bright Light
856961|NCT02800837|left main
856962|NCT02800837|stent
856963|NCT02800837|self-expandable
856964|NCT02800837|DES
856965|NCT02800837|Stentys
856966|NCT02800811|FR104
856967|NCT02800811|CD28
856968|NCT02800811|immunomodulation
856969|NCT02800811|T regulatory cell
856970|NCT02800811|Pegylated monovalent anti-CD28 Fab antibody
856971|NCT02800798|Obstructive sleep apnea
856972|NCT02800798|Preeclampsia
856973|NCT02800798|Pregnancy
856974|NCT02800798|Stopbang
856975|NCT02800772|pancreatic duct
856976|NCT02800772|ERCP
856977|NCT02800772|acetic acid
856978|NCT02800746|Prognathic surgery
856979|NCT02800720|Fibromyalgia Syndromey
856980|NCT02800681|Asperger Syndrome
856981|NCT02800681|Autism Spectrum Disorder
856982|NCT02800681|Schizotypal disorder
856983|NCT02800681|Schizophrenia Spectrum Disorder
856984|NCT02800681|Psychopathology
856985|NCT02800681|Examination of Anomalous Self Disorder
856986|NCT02800681|Autism Diagnostic Observation Schedule
856987|NCT02800681|Phenomenology
856988|NCT02800681|Differential diagnosis
856989|NCT02800681|Young Adult
856990|NCT02800668|Duodenal Jejunal Bypass Liner
856991|NCT02800668|obesity
856992|NCT02800668|weight loss therapy
856993|NCT02800655|ARV treatment Naive
856994|NCT02800655|Medication Adherence
856995|NCT02800655|Digital Health Feedback System
856996|NCT02800655|Proteus Digital Health
856997|NCT02800642|Bayer
856998|NCT02800642|Aflibercept
856999|NCT02800642|Eylea
857000|NCT02800642|Intravitreal,
857001|NCT02800616|Academic Achievement
857002|NCT02800616|Accelerometry
857003|NCT02800616|Children
857004|NCT02800616|Primary school Intervention
857005|NCT02800616|Nutrition
857006|NCT02800616|Obesity
857007|NCT02800616|Physical Activity
857008|NCT02800616|Prevention
857009|NCT02800616|School Health
857010|NCT02800603|preschool mental health
857011|NCT02800603|emotional and behaviour problems
857012|NCT02800590|Adult participants
857013|NCT02800590|Sedation
857014|NCT02800590|elective
857015|NCT02800525|Benign pigmented lesions
857016|NCT02800525|Picosecond laser
857017|NCT02800525|Q-switched laser
857018|NCT02800512|pelvic organ prolapse
857019|NCT02800512|cystocele
857020|NCT02800512|rectocele
857021|NCT02800512|enterocele
857022|NCT02800473|Bladder cancer
857023|NCT02800473|Hexvix
857024|NCT02800473|Bimodal Endoscopic Imager
857025|NCT02800473|Cystoscopy
857026|NCT02800460|Subthalamic nucleus
857027|NCT02800460|Basal ganglia
857028|NCT02800460|Parkinson disease
857029|NCT02800460|Magnetic Resonance Imaging
857030|NCT02800460|Susceptibility-Weighted Imaging
857031|NCT02800434|allograft
857032|NCT02800434|hands
857033|NCT02800434|immunosuppression
857034|NCT02800434|fMRI
857035|NCT02800395|Alzheimer
857036|NCT02800395|oxydative stress
857037|NCT02800395|nutrition
857038|NCT02800395|biomarkers
857039|NCT02800382|paraoxonase
857040|NCT02800382|lung diseases
857041|NCT02800369|Human papillomavirus
857042|NCT02800369|cervical intraepithelial neoplasia
857043|NCT02800369|zinc finger nuclease
857044|NCT02800356|Age-Related Macular Degeneration
857045|NCT02800356|Geographic Atrophy
857046|NCT02800356|Reticular pseudodrusen
857047|NCT02800356|Lasers
857048|NCT02800356|PASCAL 577
857049|NCT02800304|malnutrition
857050|NCT02800304|food intake
857051|NCT02800304|frailty
857052|NCT02800291|food intake
857053|NCT02800265|healthy volunteer
857054|NCT02800265|healthy
857055|NCT02800265|cancer prevention
857056|NCT02800265|prevention
857057|NCT02800252|fatty acids
857058|NCT02800252|aspirin
857059|NCT02800252|diabetes mellitus
857060|NCT02800252|chronic periodontitis
857061|NCT02800252|periodontal debridement
857062|NCT02800200|platelet rich plasma
857063|NCT02800200|extracorporeal shock wave
857064|NCT02800122|acute dyspnea
857065|NCT02800122|emergency
857066|NCT02800122|acute heart failure
857067|NCT02800109|Fetal growth
857068|NCT02800109|Newborn growth
857069|NCT02800070|autologous stem cell transplant
857070|NCT02800070|gene therapy
857071|NCT02800070|Fabry disease
857072|NCT02800070|lentivirus
857073|NCT02800070|haematopoietic stem cell transplant
857074|NCT02798276|Myocardial infarction
857075|NCT02798276|Cardiac regeneration
857076|NCT02798276|Cardiac surgery
857077|NCT02800018|hypothermia therapy
857078|NCT02800018|perinatal asphyxia
857079|NCT02800005|gastric cancer
857080|NCT02800005|gastrectomy
857081|NCT02800005|laparotomy
857082|NCT02800005|surgical outcome
857083|NCT02800005|survival
857084|NCT02800005|abdominal fat area
857085|NCT02800005|Body Mass Index
857086|NCT02799953|diabetes mellitus and hypertension
857087|NCT02799953|consumer health information technology
857088|NCT02799953|self-monitoring
857089|NCT02799953|randomized controlled trial
857090|NCT02799927|Indirect Pulp Treatment
857091|NCT02799927|Primary Teeth
857092|NCT02799927|Biodentine
857093|NCT02799927|Calcium Hydroxide
857094|NCT02799927|Split-Mouth design
857095|NCT02799901|advanced melanoma
857096|NCT02799901|high dose radiotherapy
857097|NCT02799901|Nivolumab
857098|NCT02799888|Graft-versus-host Disease
857099|NCT02799888|Hematopoietic Stem Cell Transplantation
857100|NCT02799888|Acute Leukemia
857101|NCT02799888|Myelodysplastic syndrome
857102|NCT02799888|Lymphoma
857103|NCT02799875|respiratory distress syndrome
857104|NCT02799875|permissive hypercapnia
857105|NCT02799875|ventilator strategy
857106|NCT02799862|metastatic
857107|NCT02799862|locally advanced
857108|NCT02799862|unresectable
857109|NCT02799862|NSCLC
857110|NCT02799849|narcolepsy
857111|NCT02799849|metabolism
857112|NCT02799823|aortic stenosis
857113|NCT02799823|transcatheter aortic valve replacement
857114|NCT02799810|lung transplantation
857115|NCT02799810|psychosocial functioning
857116|NCT02799810|longitudinal
857117|NCT02799810|TERS
857118|NCT02799810|adherence
857119|NCT02799810|Quality of life
857120|NCT02799797|adductor canal block
857121|NCT02799784|tiotropium
857122|NCT02799784|COPD
857123|NCT02799784|olodaterol
857124|NCT02799784|Umeclidinium bromide
857125|NCT02799784|efficacy
857126|NCT02799784|vilanterol
857127|NCT02799771|Pulmonary arterial hypertension
857128|NCT02799771|Interstitial lung disease at HRCT
857134|NCT02799732|Feasibility Study
857135|NCT02799732|HPV vaccine
857136|NCT02799732|1Dose Trial
857137|NCT02799719|Fat mass
857138|NCT02799719|hemodialysis patients
857139|NCT02799719|inflammation
857140|NCT02799719|adipocytokines
857141|NCT02799719|bioimpedance spectroscopy
857142|NCT02799706|Prostate cancer
857143|NCT02799706|GnRH antagonist
857144|NCT02799706|GnRH agonist
857145|NCT02799706|radiation therapy
857146|NCT02799706|very high risk localized prostate cancer
857147|NCT02799706|locally advanced prostate cancer
857148|NCT02799693|Catheter Ablation
857149|NCT02799693|Ventricular Tachycardia
857275|NCT02799108|language
857150|NCT02799693|Intramural Needle Catheter
857151|NCT02799680|CART
857152|NCT02799680|AML
857153|NCT02799667|negative pressure wound therapy
857154|NCT02799667|cesarean delivery
857155|NCT02799654|Total Hip Arthroplasty
857156|NCT02799641|Contraception
857157|NCT02799641|IUD
857158|NCT02799641|levonorgestrel releasing intrauterine device
857159|NCT02799641|lidocaine
857160|NCT02799641|valium
857161|NCT02799641|diazepam
857162|NCT02799641|pain
857163|NCT02799641|VAS
857164|NCT02799641|visual analog scale
857165|NCT02799628|Trust
857166|NCT02799628|Low Back Pain
857167|NCT02799628|Treatment Outcome
857168|NCT02799602|Metastatic hormone sensitive prostate cancer
857169|NCT02799576|Ultrasound
857170|NCT02799576|Regional blockade
857171|NCT02799576|Infraclavicular brachial plexus
857172|NCT02799550|CART
857173|NCT02799550|ALL
857174|NCT02799550|elderly
857175|NCT02799550|Relapsed
857176|NCT02799550|Refractory
857177|NCT02799550|CD19+
857178|NCT02799511|biological markers
857179|NCT02799498|etanercept
857180|NCT02799498|healthy subject
857181|NCT02799498|open-label
857182|NCT02799498|randomized
857183|NCT02799498|PK
857184|NCT02799498|auto-injection
857185|NCT02799498|pharmacokinetic
857186|NCT02799472|GSK3196165
857187|NCT02799472|magnetic resonance imaging (MRI)
857188|NCT02799472|disease-modifying antirheumatic drugs (DMARDs)
857189|NCT02799472|granulocyte-macrophage colony stimulating factor (GM-CSF)
857190|NCT02799472|Rheumatoid Arthritis
857191|NCT02799472|Methotrexate
857192|NCT02799459|Hypnoanesthesia
857193|NCT02799459|Hypnosis
857194|NCT02799459|conization
857195|NCT02799446|sinusitis, rhinitis, rhinosinusitis, chronic
857196|NCT02799433|Water
857197|NCT02799433|Physical activity
857198|NCT02799433|Child care
857199|NCT02799433|Weight change
857200|NCT02799420|confocal laser endomicroscopy
857201|NCT02799420|undifferentiated gastric cancer
857202|NCT02799420|target biopsy
857207|NCT02798250|Type 1 diabetes
857208|NCT02798250|Artificial pancreas
857209|NCT02798250|Closed-loop system
857210|NCT02798250|Postprandial glucose control
857211|NCT02798250|Hypoglycemia
857212|NCT02798250|Insulin
857213|NCT02798250|Glucagon
857214|NCT02798237|exercise
857215|NCT02798237|walking
857216|NCT02798237|health
857217|NCT02798224|Colorectal Cancer Screening
857218|NCT02798224|CRC Screening
857219|NCT02798224|Rectum
857220|NCT02798224|Colon
857221|NCT02798224|Screening
857222|NCT02798224|Populations at Risk
857223|NCT02798224|CRC
857224|NCT02798224|colorectal cancer (CRC)
857225|NCT02798211|PsA, ACR, CASPAR
857226|NCT02799303|screening
857227|NCT02799303|biopsy
857228|NCT02799303|magnetic resonance imaging
857229|NCT02799303|prostate specific antigen
857230|NCT02799264|fasted
857231|NCT02799264|healthy volunteers
857232|NCT02799264|cabotegravir
857233|NCT02799264|high fat
857234|NCT02799264|pharmacokinetics
857235|NCT02799264|randomized
857236|NCT02799264|Phase I
857237|NCT02799264|two way crossover
857238|NCT02799251|lymphopenia
857239|NCT02799251|postoperative infection
857240|NCT02799251|thoracic cancer surgery
857241|NCT02799251|digestive cancer surgery
857242|NCT02799238|glioblastoma, GBM, immunotherapy, autologous lymphoid effector cells specific against tumour cells, ALECSAT, Stupp regimen, TMZ, radiotherapy/TMZ
857243|NCT02799225|carbapenems
857244|NCT02799212|Hepatocellular carcinoma
857245|NCT02799212|Hepatectomy
857246|NCT02799212|Ascites
857247|NCT02799212|Somatostatin
857248|NCT02799186|Spontaneous Coronary Artery Dissection
857249|NCT02799186|haematoma
857250|NCT02799186|Fibromuscular Dysplasia
857251|NCT02799186|genetic analysis
857252|NCT02799186|Acute Coronary Syndrome
857253|NCT02799173|cardiovascular calcification
857254|NCT02799173|RANK: Receptor Activator of Nuclear Factor kappa B
857255|NCT02799173|RANKL: Receptor Activator of Nuclear Factor kappa B Ligand
857256|NCT02799173|OPG: Osteoprotegerin
857257|NCT02799173|SLE: Systemic lupus erythematosus
857258|NCT02799147|Allogeneic Transplantation
857259|NCT02799147|Hematopoietic Stem Cell Transplantation
857260|NCT02799147|Leukemia, Acute Lymphoblastic
857261|NCT02799147|Acute Myeloid Leukemia
857262|NCT02799147|Mixed-Lineage Acute Leukemias
857263|NCT02799147|Immune System Diseases
857264|NCT02799147|Immunosuppressive Agents
857265|NCT02799147|Myeloablative Agonists
857266|NCT02799147|Busulfan
857267|NCT02799147|Fludarabine
857268|NCT02799147|Antineoplastic Agents, Alkylating
857269|NCT02799147|Bendamustine Hydrochloride
857270|NCT02799134|Cortisol Awakening Response suppression
857271|NCT02799134|Dexamethasone Suppression Test
857272|NCT02799134|high-order cognition
857273|NCT02799134|social cognition
857274|NCT02799108|children
857276|NCT02799108|NIRS
857277|NCT02799095|Immunotherapy
857278|NCT02799095|IL-2
857279|NCT02799095|Interleukin-2
857280|NCT02799095|Solid tumors
857281|NCT02799056|Airway Extubation
857282|NCT02799056|Ultrasonography
857283|NCT02799056|Ventilator Weaning
857284|NCT02799043|FIRMap, Rotor, FIRM-guided procedure
857285|NCT02799017|Aphasia
857286|NCT02799017|Reading
857287|NCT02799017|Writing
857288|NCT02799017|Naming
857289|NCT02799017|Language
857290|NCT02799017|Chronic post stroke
857291|NCT02799017|Phonology
857292|NCT02799017|Semantic Feature Analysis
857293|NCT02799017|Recovery
857294|NCT02798991|REarranged during Transfection Growth Factor Receptor Tyrosine Kinase Inhibitor
857295|NCT02798978|pharmacokinetics
857296|NCT02798978|TLR4 agonist
857297|NCT02798978|cancer
857298|NCT02798978|tolerability
857299|NCT02798978|GSK1795091
857300|NCT02798978|pharmacodynamics
857301|NCT02798978|safety
857302|NCT02798965|parvovirus genome
857303|NCT02798952|Hepatitis B antibodies
857304|NCT02798952|Safety
857305|NCT02798952|Challenge dose
857306|NCT02798952|Persistence
857307|NCT02798952|Engerix B Kinder
857308|NCT02798952|Infanrix hexa
857309|NCT02798952|Immunogenicity
857310|NCT02798952|Adolescents
857311|NCT02798939|spontaneous bacterial peritonitis
857312|NCT02798939|lactoferrin
857313|NCT02798939|procalcitonin
857314|NCT02798939|Aution® urine dipsticks
857315|NCT02798926|hypothermia
857316|NCT02798926|central venous catheter placement
857317|NCT02798926|Polyethylene bag
857318|NCT02798913|dual antiplatelet therapy
857319|NCT02798913|peripheral transluminal angioplasty
857320|NCT02798900|Task-specific exercise
857321|NCT02798900|Ultrasonic Waves
857322|NCT02798900|Biomechanics
857323|NCT02798900|Gait
857324|NCT02798900|Rehabilitation
857325|NCT02798900|Exercise therapy
857326|NCT02798887|Regeneration
857327|NCT02798887|Bone regeneration
857328|NCT02798887|Grafting, Bone
857329|NCT02798887|Allograft
857330|NCT02798887|Xenograft
857331|NCT02798874|Ticagrelor
857332|NCT02798874|No-reflow
857333|NCT02798874|Acute ST-segment elevation myocardial
857334|NCT02798874|Reperfusion injury
857335|NCT02798874|Percutaneous coronary intervention
857336|NCT02798796|breast cancer
857337|NCT02798796|conservative surgery
857338|NCT02798796|MRI
857339|NCT02798783|Vestibular Aqueduct
857340|NCT02798783|SLC26A4
857341|NCT02798783|FOXI1
857342|NCT02798783|Temporal Bone
857343|NCT02798731|Heart transplant
857344|NCT02798731|Microvascular dysfunction
857345|NCT02798731|Cardiac allograft vasculopathy
857346|NCT02798731|Fractional flow reserve
857347|NCT02798731|Coronary flow reserve
857348|NCT02798731|Index of microvascular resistance
857349|NCT02798705|Cardiac amyloidosis
857350|NCT02798705|Fractional flow reserve
857351|NCT02798705|Microvascular dysfunction
857352|NCT02798705|Coronary flow reserve
857353|NCT02798705|Index of microcirculatory resistance
857354|NCT02798692|Prevention
857355|NCT02798666|Physical fitness
857356|NCT02798666|Respiratory exchange ratio
857357|NCT02798666|Insulin sensitivity
857358|NCT02798666|High intensity interval training
857359|NCT02798666|Continuous exercise training
857360|NCT02798601|Cerebral edema
857361|NCT02798601|Hypernatremia
857362|NCT02798601|Extended Glasgow Outcome Scale
857363|NCT02798601|Intracranial pressure
857364|NCT02798601|Mannitol
857365|NCT02798601|Hypertonic saline
857366|NCT02798601|Mortality
857367|NCT02798588|coma
857368|NCT02798588|prognosis
857369|NCT02798588|comparative study
857370|NCT02798588|functional imaging
857371|NCT02798588|PET-MRI
857372|NCT02798588|electrophysiology
857373|NCT02798575|COPD
857374|NCT02798575|invasive ventilation
857375|NCT02798575|exacerbation
857376|NCT02798575|home care
857377|NCT02798575|mechanical ventilation
857378|NCT02798575|unsuccessful weaning
857379|NCT02798575|ventilatory parameters
857380|NCT02798562|low dose CT
857381|NCT02798562|contrast-enhanced
857382|NCT02798562|breast cancer screening
857383|NCT02798562|computer tomography
857384|NCT02798549|HBV
857385|NCT02798549|liver
857386|NCT02798536|Immunotoxin
857387|NCT02798536|Mesothelin
857388|NCT02798536|Targeted Therapy
857389|NCT02798523|Methylprednisolone
857390|NCT02798523|Immunologic
857391|NCT02798523|Infusion
857392|NCT02798523|Topical
857393|NCT02798523|Intravenous
857394|NCT02798510|Gallbladder Carcinoma
857395|NCT02798510|Extrahepatic Cholangiocarcinoma
857396|NCT02798510|Chemoradiotherapy
857397|NCT02798497|PVL
857398|NCT02798497|Pneumonias
857399|NCT02798497|Staphylococcus aureus
857400|NCT02798484|Diffusion Weighted Magnetic Resonance Imaging
857401|NCT02798484|Breast cancer
857402|NCT02798484|Neo-adjuvant therapy
857403|NCT02798471|Pediatric
857404|NCT02798471|Venous thrombolism
857405|NCT02798471|Pulmonary embolism
857406|NCT02798458|Fabry's Disease
857407|NCT02798458|Fabry
857408|NCT02798445|venous ulcer
857409|NCT02798445|vein
857410|NCT02798445|juxta cures
857411|NCT02798445|foam
857412|NCT02798445|laser
857413|NCT02798432|Total Knee Arthroplasty
857414|NCT02798432|Hybrid
857415|NCT02798432|Cemented
857416|NCT02798432|Fixation
857417|NCT02798406|brain
857418|NCT02798406|Central Nervous System (CNS) diseases
857419|NCT02798406|Central Nervous System (CNS) neoplasms
857420|NCT02798406|CNS
857421|NCT02798406|conditionally replicative adenovirus
857422|NCT02798406|DNX-2401
857423|NCT02798406|pembrolizumab
857424|NCT02798406|KEYTRUDA
857425|NCT02798406|MK-3475
857426|NCT02798406|SCH 900475
857427|NCT02798406|lambrolizumab
857428|NCT02798406|neoplasm, germ cell and embryonal
857429|NCT02798406|neoplasm, granular and epithelial
857430|NCT02798406|Alcyone
857431|NCT02798406|Alcyone Lifesciences
857432|NCT02798406|AMC
857433|NCT02798406|cannula
857434|NCT02798406|MEMS cannula
857435|NCT02798406|DNX-2401 + pembrolizumab
857436|NCT02798406|Delta-24
857437|NCT02798406|Delta-24-RGD
857438|NCT02798406|Checkpoint inhibitor
857439|NCT02798406|anti-PD1/PD-L1
857440|NCT02798406|immunotherapy
857441|NCT02798406|monoclonal antibody
857442|NCT02798406|KEYNOTE-192
857443|NCT02798367|insomnia
857444|NCT02798367|cognitive behavioral therapy for insomnia
857445|NCT02798367|melatonin
857446|NCT02798354|Depression
857447|NCT02798354|Blood Pressure
857448|NCT02798354|Anemias, Iron-Deficiency
857449|NCT02798354|Streptococcal Infections
857450|NCT02798354|Sexually Transmitted Diseases
857451|NCT02798354|Lead Poisoning, Nervous System, Childhood
857452|NCT02798354|Thyrotropin
857459|NCT02798159|Sexual Dysfunction
857460|NCT02798159|Physiological Sexual Dysfunctions
857461|NCT02798159|Psychological Sexual and Gender Disorders
857462|NCT02798159|Sildenafil
857463|NCT02798146|in-vitro fertilization
857464|NCT02798146|luteal phase
857465|NCT02798081|augmentative and alternative communication
857466|NCT02798081|social inclusion
857467|NCT02798081|serious games
857468|NCT02798081|Information and communication technologies
857469|NCT02798068|Steroids
857470|NCT02798068|Cardiac surgery
857471|NCT02798068|Endothelial dysfunction
857472|NCT02798068|Glycocalyx
857473|NCT02798068|Flow mediated vasodilation
857474|NCT02798029|Brain Metastases
857475|NCT02798029|Parenchymal Brain Metastases
857476|NCT02798029|Oligometastatic brain metastases
857477|NCT02798029|Frameless Fractionated Stereotactic Radiation Therapy
857478|NCT02798029|FFSRT
857479|NCT02798003|Cachexia
857480|NCT02798003|Food reward
857481|NCT02797990|[G08.686.785.760.769.500]
857482|NCT02797990|[G08.686.785.760.769]
857483|NCT02797990|[N02.360]
857484|NCT02797990|[C25.775.650]
857485|NCT02797990|[C25.775.793]
857486|NCT02797990|[C25.775.635]
857487|NCT02797990|[C25.775.675]
857488|NCT02797990|[C25.775.300]
857489|NCT02797990|[C25.775.467]
857490|NCT02797990|[C25.775.225]
857491|NCT02797990|[C25.775.100]
857492|NCT02797990|[C25.775]
857493|NCT02797977|Advanced solid tumors
857494|NCT02797977|Bladder cancer
857495|NCT02797977|Pancreatic cancer
857496|NCT02797977|Phase 1
857497|NCT02797977|Dose escalation
857498|NCT02797977|Chk1 inhibitor
857499|NCT02797977|Checkpoint Kinase 1
857500|NCT02797977|Synthetic lethality
857501|NCT02797977|Next-Generation Sequencing
857502|NCT02797977|Genetic biomarkers
857503|NCT02797964|Advanced solid tumors
857504|NCT02797964|Non-Hodgkin Lymphoma
857505|NCT02797964|Metastatic Colorectal Cancer
857506|NCT02797964|Platinum-Resistant Ovarian Cancer
857507|NCT02797964|Advanced Non-Small Cell Lung Cancer
857508|NCT02797964|Metastatic Castration-Resistant Prostate Cancer
857509|NCT02797964|Head and Neck Squamous Cell Carcinoma
857510|NCT02797964|Phase 1
857511|NCT02797964|Dose escalation
857512|NCT02797964|Chk1 Inhibitor
857513|NCT02797964|Checkpoint kinase 1
857514|NCT02797964|Synthetic lethality
857515|NCT02797964|Next-Generation Sequencing
857516|NCT02797964|Genetic biomarkers
857527|NCT02797925|Achilles tendon
857528|NCT02797925|Patella tendon
857529|NCT02797925|Inflammation
857530|NCT02797925|Edema
857531|NCT02797925|Clinical
857532|NCT02797925|Structural
857533|NCT02797912|pulmonary function
857534|NCT02797912|respiratory muscle function
857535|NCT02797912|body composition
857536|NCT02797912|exercise tolerance
857537|NCT02797886|Hemiplegia
857538|NCT02797886|Drop foot
857539|NCT02797886|Foot drop
857540|NCT02797860|Transabdominal cervicoisthmic cerclage
857541|NCT02797860|Rocuronium
857542|NCT02797860|Pregnant Women
857543|NCT02797847|TTR-mediated Amyloidosis
857544|NCT02797847|Amyloidosis, Hereditary
857545|NCT02797847|Amyloid Neuropathies, Familial
857546|NCT02797847|Familial Amyloid Polyneuropathies
857547|NCT02797847|Amyloid Neuropathies
857548|NCT02797847|Amyloidosis, Hereditary, Transthyretin-Related
857549|NCT02797847|Familial Amyloidosis
857550|NCT02797847|RNAi therapeutic
857551|NCT02797834|Extracellular vesicles
857552|NCT02797834|Endometrial fluid
857553|NCT02797834|Menstrual cycle
857554|NCT02797834|Exosomes
857555|NCT02797834|Microvesicles
857556|NCT02797834|Apoptotic bodies
857557|NCT02797821|HPP
857558|NCT02797821|asfotase alfa
857559|NCT02797808|OCD
857560|NCT02797743|Healthy Volunteers
857561|NCT02797730|Art Therapy
857562|NCT02797730|Caregiver's
857563|NCT02797691|Cognitive Behavior Therapy
857564|NCT02797691|Depression
857565|NCT02797691|Anxiety
857566|NCT02797691|Pashto
857567|NCT02797691|Pakistani
857568|NCT02797691|Afghan
857569|NCT02797652|Breast cancer
857570|NCT02797652|ctDNA
857571|NCT02797652|Neoadjuvant chemotherapy
857572|NCT02797652|Adjuvant chemotherapy
857573|NCT02797639|Intellectual Disability
857574|NCT02797639|Collaborative Consultation
857575|NCT02797639|Participation
857576|NCT02797600|Appalachia
857577|NCT02797587|Alcohol Use
857578|NCT02797587|Tobacco Use
857579|NCT02797587|Smoking
857580|NCT02797587|Inflammation
857581|NCT02797587|Coronary Heart Disease
857582|NCT02797587|Russia
857583|NCT02797587|Varenicline
857584|NCT02797587|Cytisine
857585|NCT02797587|Nicotine Replacement Therapy
857586|NCT02797587|Partial Agonist Therapy
857587|NCT02797587|HIV
857588|NCT02797587|Reynolds risk score
857589|NCT02797587|VACS index
857590|NCT02797561|Fractional flow reserve
857591|NCT02797561|Tandem
857592|NCT02797561|Percutaneous Coronary Intervention
857593|NCT02797548|drug-eluting stent
857594|NCT02797548|antiplatelet therapy
857595|NCT02797548|noncardiac surgery
857596|NCT02797509|Intensive Care Unit
857597|NCT02797496|Parkinson's disease
857598|NCT02797496|Mild to moderate stage
857599|NCT02797496|Asymmetric Motor Strengthening
857600|NCT02797496|Rehabilitation
857601|NCT02797457|Bilateral amputation of the forearms
857602|NCT02797457|Bilateral allograft
857603|NCT02797457|Prosthetic forehands
857604|NCT02797457|Medical economic evaluation
857605|NCT02797418|Attentional disorders, intellectual deficiency
857606|NCT02797405|radiation therapy
857607|NCT02797405|radiosensitivity
857608|NCT02797405|in vitro diagnostic medical devices
857609|NCT02797405|Adverse Event post radiotherapy
857610|NCT02797392|Tailored lifestyle intervention
857611|NCT02797392|Selective prevention
857612|NCT02797392|Primary care
857613|NCT02797392|Web based health risk assessment
857614|NCT02797392|Patient-centered health information system
857615|NCT02797392|Lifestyle intervention
857616|NCT02797392|preventive treatment
857617|NCT02797379|Psychoeducation
857618|NCT02797379|Self-help
857619|NCT02797327|Molecular signature
857620|NCT02797327|Thailand-Myanmar border
857621|NCT02797314|Type 2 diabetes
857622|NCT02797314|Bone quality
857623|NCT02797314|Bone biopsies
857624|NCT02797314|Vertebral fractures
857625|NCT02797314|Osteodensitometry
857626|NCT02797314|Trabecular Bone Score
857627|NCT02797301|early reading skills
857628|NCT02797249|preeclampsia
857629|NCT02797249|low dose aspirin
857630|NCT02797249|prevention
857631|NCT02797236|Phase I
857632|NCT02797236|conjugate vaccine
857633|NCT02797236|Shigella flexneri 2a
857634|NCT02797236|safety
857635|NCT02797236|Immunogenicity
857636|NCT02797236|Healthy adults
857637|NCT02797223|alopecia
857638|NCT02797223|chemotherapy
857639|NCT02797223|breast cancer
857640|NCT02797158|TAVI
857641|NCT02797158|Aortic stenosis
857642|NCT02797158|Coronary artery disease
857643|NCT02797158|Coronary angiography
857644|NCT02797158|Percutaneous Coronary Intervention
857645|NCT02797158|Myocardial ischemia
857646|NCT02797158|SPECT
857647|NCT02797158|Coronary revascularization
857648|NCT02797145|Digoxin
857649|NCT02797132|CF
857650|NCT02797119|Tranexamic acid
857651|NCT02797119|Fibrinolysis
857652|NCT02797119|Cesarean section
857653|NCT02797119|Pharmacokinetics
857654|NCT02797119|D dimers
857655|NCT02797119|Fibrinogen
857656|NCT02797119|Plasmin
857657|NCT02797119|Transfusion
857658|NCT02797106|Drooling
857659|NCT02797106|Cerebral palsy
857660|NCT02797106|Botulinium toxin
857661|NCT02797106|Practice survey of health professionals
857662|NCT02797106|Children
857663|NCT02797093|anti-retroviral therapy
857664|NCT02797080|ACTIMMUNE
857665|NCT02797080|interferon y-1b
857666|NCT02797067|Extracorporeal Shock Wave lithotripsy(ESWL)
857667|NCT02797067|Prophylaxis
857668|NCT02797067|Indomethacin
857669|NCT02797067|Chronic pancreatitis
857675|NCT02797041|Multiple myeloma
857676|NCT02797041|Bortezomib
857677|NCT02797041|Relapsed multiple myeloma
857678|NCT02797041|Rechallenge
857679|NCT02797028|Hyperuricemia
857680|NCT02797028|endothelial function
857681|NCT02797028|anthocyanidins
857682|NCT02797015|MS
857683|NCT02797015|RMS
857684|NCT02797015|Multiple Sclerosis
857685|NCT02797015|Relapsing Multiple Sclerosis
857686|NCT02796976|arterial stiffness
857687|NCT02796976|retinal vessels
857688|NCT02796976|physical activity
857689|NCT02796976|ageing
857690|NCT02796963|HIV
857691|NCT02796963|MSM
857692|NCT02796963|test uptake
857693|NCT02796963|crowdsourcing
857694|NCT02796950|Acipimox
857695|NCT02796950|GLP-1
857696|NCT02796950|Insulin secretion
857697|NCT02796937|Pulmonary Emphysema
857698|NCT02796937|Alpha-1 Antitrypsin Deficiency
857699|NCT02796937|AATD
857700|NCT02796937|Alpha-1 PI Deficiency
857701|NCT02796937|Alpha-1 Proteinase Inhibitor
857702|NCT02796924|Psychogenic Non-Epileptic Seizure
857703|NCT02796924|Transcranial Magnetic Stimulation
857704|NCT02796924|Brain Stimulation
857705|NCT02796898|Prostate Cancer
857706|NCT02796898|PSA
857707|NCT02796898|Androgen Deprivation Therapy (ADT)
857711|NCT02796846|CPAP (continuous positive airway pressure)
857712|NCT02796846|OSA (Obstructive sleep apnea)
857713|NCT02796833|Home parenteral nutrition
857714|NCT02796833|Liver injury
857715|NCT02796833|Intravenous Lipid Emulsions
857716|NCT02796833|Catheter-related infections
857717|NCT02796833|Safety
857718|NCT02796820|Huaier Granule
857719|NCT02796820|After radical surgery
857720|NCT02796820|Prevention of Recurrence and Metastasis
857721|NCT02796820|Efficacy and safety
857722|NCT02796794|Enteral nutrition
857723|NCT02796794|Genistein
857724|NCT02796794|Cytokine
857725|NCT02796755|Central Nervous System (CNS) Glutamate
857726|NCT02796755|Breast Cancer Treatment
857727|NCT02796755|Fatigue
857728|NCT02796755|Cognitive Dysfunction
857729|NCT02796755|Behavioral
857730|NCT02796755|Psychometrics
857731|NCT02796755|Imaging Technology
857732|NCT02796755|Magnetic Resonance Spectroscopy
857733|NCT02796742|SSTIs
857734|NCT02796742|Methicillin-resistant Staphylococcus aureus (MRSA)
857735|NCT02796742|Methicillin susceptible Staphylococcus aureus (MSSA)
857736|NCT02796742|the toxin Panton-Valentine Leukocidin (PVL)
857737|NCT02796742|Emergency Departments
857738|NCT02796716|Wounded warriors
857739|NCT02796716|Battlefield infection
857740|NCT02796716|ESBL
857741|NCT02796716|MRSA
857742|NCT02796716|KPC
857743|NCT02796690|nasal carriage
857744|NCT02796690|Staphylococcus aureus
857745|NCT02796690|good hygiene practices
857746|NCT02796677|Safety
857747|NCT02796677|Efficacy
857748|NCT02796677|Aclidinium bromide
857749|NCT02796677|Formoterol fumarate
857750|NCT02796677|Tiotropium
857751|NCT02796677|Bronchodilation
857752|NCT02796677|COPD
857753|NCT02796664|Ginseng
857754|NCT02796664|Stroke
857755|NCT02796664|Quantitative MR flow analysis
857756|NCT02796651|Perforomist
857757|NCT02796651|Pressair
857758|NCT02796651|COPD
857759|NCT02796651|Cigarette smoking
857760|NCT02796651|Formoterol fumarate
857761|NCT02796651|long-acting β2-adrenergic agonists (LABA)
857762|NCT02796651|long-acting muscarinic antagonists (LAMA)
857763|NCT02796638|Acute Heart Failure
857764|NCT02796638|Positive-Pressure Ventilation
857765|NCT02796638|Adaptive Servo-Ventilation
857766|NCT02796625|EEG
857767|NCT02796625|healthy subjects
857768|NCT02796612|anxiety
857769|NCT02796612|breast cancer, suspected
857770|NCT02796612|breast biopsy
857771|NCT02796612|empathy
857772|NCT02796612|standardized and structured information
857773|NCT02796612|anxiety reduction
857774|NCT02796586|Refugee Health
857775|NCT02796586|Resettled Refugee
857776|NCT02796586|Family Planning
857777|NCT02796586|Contraception
857778|NCT02796586|Group Counseling
857779|NCT02796586|Group contraceptive counseling
857780|NCT02796573|blended care
857781|NCT02796573|CBT
857782|NCT02796573|B-CBT
857783|NCT02796573|depression
857784|NCT02796560|Drugs, Generic
857785|NCT02796560|Generic Equivalency
857786|NCT02796547|Episiotomy
857787|NCT02796547|Levobupivacaine
857788|NCT02796534|Obstructive Sleep Apnea Syndrome
857789|NCT02796521|malnutrition
857790|NCT02796521|aging
857791|NCT02796521|diet therapy
857792|NCT02796508|Healthy aging
857793|NCT02796508|Cognitive training
857794|NCT02796508|Video-games
857795|NCT02796508|Attention
857796|NCT02796508|Working memory
857797|NCT02796508|Wellbeing
857798|NCT02796495|Neuroplasticity
857799|NCT02796495|Sensory Feedback
857800|NCT02796495|Nerve stimulation
857801|NCT02796495|Robotic Hand
857802|NCT02796456|apelin
857803|NCT02796456|colostrum
857804|NCT02796456|plasma
857805|NCT02796456|glycemic markers
857806|NCT02796456|lipidic markers
857807|NCT02796456|pregnancy
857808|NCT02796456|postpartum
857809|NCT02796443|acute cholecystitis
857810|NCT02796443|early versus delayed surgery
857811|NCT02796430|Indirect calorimetry
857812|NCT02796430|critical care
857813|NCT02796430|mechanical ventilation
857814|NCT02796430|energy expenditure
857815|NCT02796430|ICALIC study
857816|NCT02796404|home monitoring
857817|NCT02796404|cardiac monitoring
857821|NCT02796378|physical activity
857822|NCT02796378|statin therapy
857823|NCT02796378|diabetes mellitus
857824|NCT02796378|cardiovascular disease
857825|NCT02796378|Q10-supplementation
857826|NCT02796365|Exercise
857827|NCT02796365|Cancer
857828|NCT02796365|Cardiotoxicity
857829|NCT02796365|Cardiomyopathy
857830|NCT02796365|Cardiac Rehabilitation
857831|NCT02796339|Inflammatory Bowel Diseases
857832|NCT02796339|natural Mastiha
857833|NCT02796339|supplement
857834|NCT02796326|tracheal stenosis
857835|NCT02796326|tracheal dilatation
857836|NCT02796326|ventilation
857837|NCT02796300|bioflo
857838|NCT02796300|Duramax catheter
857839|NCT02796300|dialysis
857840|NCT02796287|Amnesia
857841|NCT02796287|transient global amnesia
857842|NCT02796261|Anaplastic Astrocytoma
857843|NCT02796261|Grade 3 Glioma
857844|NCT02796261|Glioma
857845|NCT02796261|Eflornithine
857846|NCT02796261|Brain Cancer
857847|NCT02796261|Brain Tumor
857848|NCT02796261|Neuro-oncology
857849|NCT02796261|Progressive Anaplastic Astrocytoma
857850|NCT02796261|Recurrent Anaplastic Astrocytoma
857851|NCT02796261|Progressive Glioma
857852|NCT02796261|Recurrent Glioma
857853|NCT02796261|Malignant Glioma
857854|NCT02796261|Progressive Brain Tumor
857855|NCT02796261|Recurrent Brain Tumor
857856|NCT02796248|type 1 diabetes
857857|NCT02796248|glucose control
857858|NCT02796248|stigma
857859|NCT02796248|youth
857860|NCT02796222|Hemophilia
857861|NCT02796222|Recombinant factor VIII
857862|NCT02796222|Recombinant factor VIII Fc
857863|NCT02796222|Recombinant factor IX
857864|NCT02796222|Patient-reported outcomes
857865|NCT02796222|Recombinant factor IX Fc
857866|NCT02796209|atomoxetine
857867|NCT02796209|autonomic failure
857868|NCT02796196|Hematopoietic
857869|NCT02796196|Recipient
857870|NCT02796170|SGLT-2 inhibitor
857871|NCT02796170|urinary angiotensinogen
857872|NCT02796157|bioresorbable vascular scaffold, drug eluting stent, coronary artery disease
857873|NCT02796144|schizophrenia
857874|NCT02796144|schizoaffective disorder
857875|NCT02796144|overweight
857876|NCT02796144|obesity
857877|NCT02796144|weight loss
857878|NCT02796144|metformin
857879|NCT02796144|lorcaserin
857880|NCT02796131|Phase I
857881|NCT02796131|Healthy
857882|NCT02796131|Pharmacodynamics
857883|NCT02796118|Pharmacokinetics
857884|NCT02796118|Healthy non-elderly and elderly subjects
857885|NCT02796118|ASP2151
857886|NCT02796118|Safety
857887|NCT02796092|Pelvic Congestion Syndrome
857888|NCT02796092|Pelvic Venous Insufficiency
857889|NCT02796092|Chronic pelvic pain
857890|NCT02796066|Acne, topical, SCD-1 inhibitor, moderate, severe
857891|NCT02796040|Parkinson's disease
857892|NCT02796040|Impulse control disorders
857893|NCT02796040|Diffusion tensor imaging
857894|NCT02796040|MRI
857895|NCT02796040|Mesocorticolimbic pathway
857896|NCT02796027|Health Services Research
857897|NCT02795988|Secondary
857898|NCT02795962|Endovascular Procedures
857899|NCT02795962|Emergency Medical Services
857900|NCT02795949|Enterobacteriaceae
857901|NCT02795949|Bacteremia
857902|NCT02795949|Escalation
857903|NCT02795949|Bacterial resistance
857904|NCT02795949|Bloodstream infection
857905|NCT02795949|Recurrence
857906|NCT02795936|rehabilitation
857907|NCT02795936|exercise
857908|NCT02795897|genetics
857909|NCT02795897|genomics
857910|NCT02795897|amyotrophic lateral sclerosis (ALS)
857911|NCT02795897|primary lateral sclerosis (PLS)
857912|NCT02795897|progressive muscular atrophy (PMA)
857913|NCT02795897|motor neuron disease
857914|NCT02795884|Lung cancer
857915|NCT02795884|NSCLC
857916|NCT02795884|adjuvant treatment
857917|NCT02795871|Congenital Adrenal Hyperplasia
857918|NCT02795871|Prenatal treatment
857919|NCT02795871|Dexamethasone
857920|NCT02795871|Neuropsychological assessment
857921|NCT02795871|Cognitive development
857922|NCT02795858|Carcinoid Tumors
857923|NCT02795806|Address
857924|NCT02795793|appendicitis
857925|NCT02795793|non-operative management
857926|NCT02795793|children
857927|NCT02795793|pediatric
857928|NCT02795754|GSK2838232
857929|NCT02795754|HIV
857930|NCT02795754|repeated dose escalation
857931|NCT02795754|immediate release tablet
857932|NCT02795754|single dose escalation
857933|NCT02795715|tDCS
857934|NCT02795702|tDCS
857935|NCT02795676|Glomerular filtration rate
857936|NCT02795676|Proteinuria
857937|NCT02795663|Near-InfraRed Spectroscopy (NIRS)
857938|NCT02795663|Deep brain stimulation of SubThalamic Nucleus (DBS)
857939|NCT02795650|Metastatic
857940|NCT02795650|Pancreas
857941|NCT02795637|Attention deficit hyperactivity disorder (ADHD),
857942|NCT02795637|Binge-Eating Disorder (BED)
857943|NCT02795611|Family-centered
857944|NCT02795611|Autism spectrum disorder
857945|NCT02795611|Occupational therapy
857946|NCT02795611|Participation
857947|NCT02795611|Play
857948|NCT02795585|Fractional Flow Reserve
857949|NCT02795585|Coronary Artery Disease
857950|NCT02795572|Breast Neoplasms
857951|NCT02795572|Peripheral Neuropathies
857952|NCT02795559|Nutrition
857953|NCT02795559|Humans
857954|NCT02795559|Obesity
857955|NCT02795559|Blood glucose
857956|NCT02795559|Dietary fiber
857957|NCT02795559|Appetite
857958|NCT02795559|Short chain fatty acids
857959|NCT02795546|periodontal regeneration
857960|NCT02795533|Cognitive function
857961|NCT02795533|Quality of Life
857962|NCT02795507|cross education
857963|NCT02795507|visual feedback
857964|NCT02795468|Peripheral
857965|NCT02795468|Arterial
857966|NCT02795468|Catheterization
857967|NCT02795455|Eating Disorders
857968|NCT02795455|Food Avoidance
857969|NCT02795455|Reward Learning
857970|NCT02795455|Reward System
857971|NCT02795455|Family-based treatment
857972|NCT02795455|interoceptive exposure
857973|NCT02795455|insula-amygdala-ventral striatum subcircuits
857974|NCT02795429|Phase Ib/II
857975|NCT02795429|INC280
857976|NCT02795429|PDR001
857977|NCT02795429|checkpoint inhibitor
857978|NCT02795429|PD-1
857979|NCT02795416|Moderate to severe plaque psoriasis, PASI, secukinumab, monoclonal antibody, Turkish population
857980|NCT02795403|HCV, liver
857981|NCT02795390|Chinese herbal medicine
857982|NCT02795390|Placebo
857983|NCT02795390|Randomized controlled trial
857984|NCT02795390|Constipation
857985|NCT02795377|arterial hypertension
857986|NCT02795377|microparticle
857987|NCT02795377|endothelial function
857988|NCT02795364|High Grade Glioma
857989|NCT02795364|Magnetic Resonance Spectroscopy
857990|NCT02795364|Surgical resection
857991|NCT02795364|Prognosis
857992|NCT02795325|Primary Hyperoxaluria Type 1
857993|NCT02795325|PH1
857994|NCT02795325|Calcium Oxalate Stones
857995|NCT02795325|Kidney Stones
857996|NCT02795325|Liver Enzyme Deficiency
857997|NCT02795325|Genetic Diseases
857998|NCT02795325|Inborn Kidney Diseases
857999|NCT02795325|Metabolic Diseases
858000|NCT02795325|Inborn Errors
858001|NCT02795325|Urological Diseases
858002|NCT02795325|Carbohydrate Metabolism
858003|NCT02795325|Hyperoxaluria
858004|NCT02795325|AGT
858005|NCT02795325|RNAi
858006|NCT02795325|siRNA
858007|NCT02795325|DCR-PH1
858008|NCT02795312|Cigarette Smoking
858009|NCT02795286|Chronic Kidney Disease (CKD)
858010|NCT02795286|End Stage Renal Disease (ESRD)
858011|NCT02795286|Chronic Hemodialysis
858012|NCT02795286|In-center HD
858013|NCT02795286|Sodium
858014|NCT02795286|Isotonic Dialysis
858015|NCT02795273|Rhinitis
858016|NCT02795273|Conjunctivitis
858017|NCT02795273|Grass
858018|NCT02795273|Allergy
858019|NCT02795260|ESAT6
858020|NCT02795260|CFP10
858021|NCT02795260|skin test
858022|NCT02795260|diagnostic test
858023|NCT02795195|re-irradiation
858024|NCT02795195|carbon ion therapy
858025|NCT02795182|Relapsed
858026|NCT02795182|Refractory
858027|NCT02795156|regorafenib
858028|NCT02795156|afatinib
858029|NCT02795156|targeted therapy
858030|NCT02795143|TEN
858031|NCT02795104|RISE
858032|NCT02795091|clean supplies
858033|NCT02795091|ICU floor
858034|NCT02795091|bacteria colony
858035|NCT02795091|catheter associated with infection
858036|NCT02795078|Atherosclerotic Intracranial Arterial Stenosis
858037|NCT02795078|Intracranial Aneurysms
858038|NCT02795052|Neurologic Disease
858039|NCT02795052|Cerebral Vascular Accident
858040|NCT02795052|Stroke
858041|NCT02795052|Traumatic Brain Injury
858042|NCT02795052|Multiple Sclerosis
858043|NCT02795052|Parkinsons Disease
858044|NCT02795052|Neuropathy
858045|NCT02795052|Neurodegeneration
858046|NCT02795052|Diabetic Neuropathy
858047|NCT02795052|Cerebral Ischemia
858048|NCT02795026|dry needling
858049|NCT02795026|vulvodynia
858050|NCT02795026|pelvic pain chronic
858051|NCT02795013|Genetic studies
858052|NCT02795013|Pediatric
858053|NCT02795000|Primary Ovarian Insufficiency
858054|NCT02795000|nomogram
858055|NCT02794987|Bile duct
858056|NCT02794987|indeterminate stricture
858057|NCT02794987|cholangioscopy
858058|NCT02794987|Spyglass
858059|NCT02794948|primary ovarian insufficiency
858060|NCT02794948|TCM intervention
858061|NCT02794935|inspiratory muscle training
858062|NCT02794935|heart failure
858063|NCT02794935|obstructive sleep apnea
858064|NCT02794922|Vitamin B
858065|NCT02794922|Temporomandibular joint disorder
858066|NCT02794922|trpv1
858067|NCT02794909|Point-of-care ultrasound
858068|NCT02794909|ED
858069|NCT02794909|Low and middle-income country
858070|NCT02794909|Echocardiography
858071|NCT02794909|Lung ultrasound
858072|NCT02794909|Resuscitation
858073|NCT02794857|ALS
858074|NCT02794857|Amyotrophic Lateral Sclerosis
858075|NCT02794857|Motor Neuron Disease
858076|NCT02794857|Central Nervous System Diseases
858077|NCT02794857|Nervous System Diseases
858078|NCT02794857|Neurodegenerative Diseases
858079|NCT02794857|Neuromuscular Diseases
858080|NCT02794857|Inflammation
858081|NCT02794857|C-Reactive Protein
858082|NCT02794831|NSAIDs
858083|NCT02794831|Bacterial Infections
858084|NCT02794831|Severity
858085|NCT02794831|Self Medication
858086|NCT02794818|Prevention
858087|NCT02794818|Nutrition
858088|NCT02794792|Type 2 Diabetes Mellitus
858089|NCT02794792|ASP1941
858090|NCT02794792|Ipragliflozin
858091|NCT02794779|cesarean section
858092|NCT02794779|labor
858093|NCT02794779|oxytocin
858094|NCT02794753|Trichotillomania
858095|NCT02794753|Hair-pulling Disorder
858096|NCT02794753|Cognitive Training
858097|NCT02794753|Neuroplasticity
858098|NCT02794753|Working Memory
858099|NCT02794740|Osteoarthritis
858100|NCT02794714|Laparoscopic Gynecologic Surgeries
858101|NCT02794688|Non-lactating
858102|NCT02794688|idiopathic granulomatous mastitis
858103|NCT02794688|periductal mastitis
858104|NCT02794688|ductal lavage
858105|NCT02794675|resectable
858106|NCT02794675|Cesium 131
858107|NCT02794675|brachytherapy
858108|NCT02794662|Oxygen Delivery System, Nasal Cannula
858109|NCT02794662|Oxygen Delivery System, Incubator
858110|NCT02794623|cochlear implants
858111|NCT02794623|hearing loss
858112|NCT02794610|Tacrolimus
858113|NCT02794610|Ocular penetration
858114|NCT02794610|Topical
858115|NCT02794597|Unplanned Pregnancy, LARC
858116|NCT02794558|Breast Cancer, MRgFus, Focused Ultrasound
858117|NCT02794519|Asthma Control Questionnaire
858118|NCT02794519|interleukin-6
858119|NCT02794519|Sirukumab
858120|NCT02794519|severe, poorly controlled asthma
858121|NCT02794519|asthma
858122|NCT02794519|ACQ
858123|NCT02794506|Diabetes mellitus
858124|NCT02794506|Chronic periodontitis
858125|NCT02794506|Propolis
858126|NCT02794480|ELLIPTA
858127|NCT02794480|metered dose inhaler
858128|NCT02794480|Dry powder inhaler
858129|NCT02794467|Heavy menstrual bleeding
858130|NCT02794467|Adenomyosis
858131|NCT02794467|Safety
858132|NCT02794467|Epelsiban
858133|NCT02794467|Tolerability
858134|NCT02794467|Proof of concept
858135|NCT02794428|Gastric adenocarcinoma
858136|NCT02794428|Gastric intestinal metaplasia
858137|NCT02794428|Atrophic gastritis
858138|NCT02794428|Gastric premalignant lesion
858139|NCT02794415|HIV
858140|NCT02794415|disability
858141|NCT02794415|rehabilitation
858142|NCT02794415|exercise
858143|NCT02794389|Acetylcysteine
858144|NCT02794376|IBS
858145|NCT02794350|RBANS-H
858146|NCT02794350|Cochlear implantation
858147|NCT02794350|Cognition
858148|NCT02794350|Older adults
858149|NCT02794350|RBANS
858151|NCT02794272|GABA concentration
858152|NCT02794272|tDCS
858153|NCT02794259|GABA concentration
858154|NCT02794259|tDCS
858155|NCT02794233|Deep Brain Stimulation
858156|NCT02794233|Electric Impedance
858157|NCT02794233|Parkinson disease
858158|NCT02794220|E-cigarette
858159|NCT02794220|healthy volunteer study
858160|NCT02794220|Pharmacokinetics
858161|NCT02794220|Nicorette
858162|NCT02794207|Pediatric
858163|NCT02794207|Cancer
858164|NCT02794207|AML
858165|NCT02794207|Qualitative Interview
858166|NCT02794194|Chronic Ankle Instability
858167|NCT02794194|Whole Body Vibration
858168|NCT02794194|Proprioception
858169|NCT02794181|Transfusion-Transmitted Infections
858170|NCT02794181|Dengue Virus
858171|NCT02794181|Chikungunya Virus
858172|NCT02794181|Natural History
858173|NCT02794181|Blood Transfusion
858174|NCT02794142|hemodialysis
858175|NCT02794142|muscle dysfunction
858176|NCT02794142|mitochondria
858177|NCT02794142|oxidative stress
858178|NCT02794142|inflammation
858179|NCT02794142|renal transplantation
858180|NCT02794103|Virtual reality
858181|NCT02794103|Immersive distraction
858182|NCT02794103|Virtual world
858183|NCT02794103|Virtual environment
858184|NCT02794103|Procedural pain
858185|NCT02794103|Procedural anxiety
858186|NCT02794103|Acute pain
858187|NCT02794103|Pain management
858188|NCT02794103|Anxiety
858189|NCT02794103|Children, Child
858190|NCT02794103|Kid, Kids
858191|NCT02794103|Pediatric, Pediatrics
858192|NCT02794103|Young children
858193|NCT02794103|Burns
858194|NCT02794103|Burn injuries
858195|NCT02794103|Burn unit
858196|NCT02794103|Hydrotherapy
858197|NCT02794103|Burn dressing
858198|NCT02794103|Non-pharmacological
858199|NCT02794103|Clinical Research
858200|NCT02794103|Nursing Practice
858201|NCT02794090|Behavioral treatment
858202|NCT02794090|Telephone coaching
858203|NCT02794090|Outpatient clinic
858204|NCT02794077|Nasopharyngeal undifferentiated carcinoma
858205|NCT02793947|Peri-incisional injection
858206|NCT02793947|Multimodal analgesia
858207|NCT02793947|Femur fracture
858208|NCT02793934|Rehabilitation
858209|NCT02793934|ICF
858210|NCT02793934|Pilot project
858211|NCT02793934|Stroke
858212|NCT02793934|Acute myocardial infarction
858213|NCT02793934|Total hip replacement
858214|NCT02793921|Alteration
858215|NCT02793921|Cognitive Function
858216|NCT02793921|Exercise
858217|NCT02793908|Endometriosis
858218|NCT02793908|Subcutaneous progesterone
858219|NCT02793908|luteal phase
858220|NCT02793895|Atrial fibrillation/flutter
858221|NCT02793895|Postoperative atrial arrhythmia
858222|NCT02793895|Cardiac surgery
858223|NCT02793895|Stroke prevention
858224|NCT02793895|Oral anticoagulation
858225|NCT02793895|Cardiac rhythm monitoring
858226|NCT02793869|congenital cataract;anterior segment characteristics
858227|NCT02793856|lung cancer
858228|NCT02793856|immune checkpoint
858229|NCT02793856|PD-1
858230|NCT02793856|CRISPER
858231|NCT02793856|autologous cell infusion
858232|NCT02793830|medication adherence
858233|NCT02793830|mHealth
858234|NCT02793830|China
858235|NCT02793830|heart disease
858236|NCT02793817|postsurgical
858237|NCT02793817|postoperative
858238|NCT02793817|ocular
858239|NCT02793817|cataract
858240|NCT02793817|inflammation
858241|NCT02793817|pain
858242|NCT02793817|corticosteroid
858243|NCT02793804|HIV self-testing
858244|NCT02793804|HIV
858245|NCT02793804|Zambia
858246|NCT02793791|high grade dysplastic nodule (HGDN)
858247|NCT02793791|low grade dysplastic nodule (LGDN)
858248|NCT02793778|Crohn's Disease
858249|NCT02793778|Digestive System Diseases
858250|NCT02793778|Gastrointestinal Diseases
858251|NCT02793778|Intestinal Diseases
858252|NCT02793778|mucosal healing
858253|NCT02793778|inflammatory bowel disease
858254|NCT02793778|Medical Food
858255|NCT02793778|Nutritional intervention
858256|NCT02793765|Advanced Prostate Cancer
858257|NCT02793765|Castration-Resistant Prostate Cancer
858258|NCT02793765|Adenocarcinoma of the prostate
858259|NCT02793765|Metastatic disease
858260|NCT02793765|CRPC
858261|NCT02793752|IVF
858262|NCT02793752|In vitro fertilization
858263|NCT02793752|Cumulus Cells
858264|NCT02793752|Oocyte
858265|NCT02793752|Embryo
858266|NCT02793752|Fertility
858267|NCT02793739|Safety
858268|NCT02793739|Efficacy
858269|NCT02793739|Longevity
858270|NCT02793726|Hip Prosthesis
858271|NCT02793713|EBUS
858272|NCT02793713|Prediction
858273|NCT02793713|malignancy
858274|NCT02793713|lymph nodes
858275|NCT02793713|lung cancer
858276|NCT02793713|Diagnostic Techniques, Respiratory System
858277|NCT02793700|Betamethasone
858278|NCT02793674|effort of breathing
858279|NCT02793674|high flow nasal cannula
858280|NCT02793674|respiratory distress
858281|NCT02793648|Depression
858282|NCT02793648|Elderly
858283|NCT02793635|Paraplegia
858284|NCT02793635|Gait
858285|NCT02793635|Exoskeleton
858286|NCT02793622|Chemoprevention
858287|NCT02793622|Malaria
858288|NCT02793622|Sulfadoxine-Pyrimethamine
858289|NCT02793622|Dihydroartemisinin-Piperaquine
858290|NCT02793609|induction of labor
858291|NCT02793609|double balloon catheter
858292|NCT02793609|mechanical ripening
858293|NCT02793505|metformin
858294|NCT02793505|pregnancy outcomes
858295|NCT02793505|birth defects
858296|NCT02793505|spontaneous abortion
858297|NCT02793505|pharmacoepidemiology
858298|NCT02793466|Durvalumab
858299|NCT02793466|solid tumors
858300|NCT02793466|Immunotherapy
858301|NCT02793466|Check Point Inhibitor
858302|NCT02793466|pediatrics
858303|NCT02793466|children
858304|NCT02793401|High Intensity Laser
858305|NCT02793401|Ultrasound
858306|NCT02793401|Chronic Shoulder Pain
858307|NCT02793375|Montelukast
858308|NCT02793375|Tonsillectomy
858309|NCT02793349|angioplasty
858310|NCT02793349|stents
858311|NCT02793349|polymers
858312|NCT02793349|absorbable implants
858320|NCT02793258|tDCS
858321|NCT02793258|neuromodulation
858322|NCT02793258|depression
858323|NCT02793258|cognition
858324|NCT02793232|Safety
858325|NCT02793232|Tolerability
858326|NCT02793232|Pharmacokinetics
858327|NCT02793232|Alzheimer's disease
858328|NCT02793219|Advanced Prostate Cancer
858329|NCT02793219|Castration-Resistant Prostate Cancer
858330|NCT02793219|CRPC
858331|NCT02793219|Adenocarcinoma of the prostate
858332|NCT02793219|Metastatic disease
858333|NCT02793206|Drusen
858334|NCT02793206|SD-OCT
858335|NCT02793167|acute kidney injury
858336|NCT02793167|medication alert systems
858337|NCT02793154|gastric emptying
858338|NCT02793154|albiglutide
858339|NCT02793154|GMA
858340|NCT02793154|exenatide
858341|NCT02793154|type 2 diabetes mellitus
858342|NCT02793141|Pneumonia
858343|NCT02793141|Intensive Care Unit
858344|NCT02793141|Nosocomial pneumonia
858345|NCT02793141|Hospital-acquired pneumonia
858346|NCT02793141|Ventilator-associated pneumonia
858347|NCT02793141|ICU
858348|NCT02793141|HAP
858349|NCT02793141|VAP
858350|NCT02793141|Critical Care
858368|NCT02793102|mental anorexia
858369|NCT02793102|sensory workshops
858370|NCT02793102|BMI
858371|NCT02793076|Posture
858372|NCT02793076|Body image
858373|NCT02793076|Dancing
858374|NCT02793076|Group
858375|NCT02793076|Survivors
858376|NCT02793063|Brittle Bone
858377|NCT02793063|Osteogenesis Imperfecta
858378|NCT02793063|BBD
858379|NCT02793063|OI
858380|NCT02793063|Congenital Abnormalities
858381|NCT02793063|Congenital Bone Disorder
858382|NCT02793063|Lobstein Syndrome
858383|NCT02793050|Trabectedin
858384|NCT02793050|Soft Tissue Sarcoma
858385|NCT02793050|Observational
858386|NCT02793037|zirconia
858387|NCT02793037|resin bonded bridge
858388|NCT02793024|food shopping intervention
858389|NCT02792972|Analgesic
858390|NCT02792972|Medicinal plants
858391|NCT02792972|Skin
858392|NCT02792972|Antimicrobial agents
858393|NCT02792972|Pain Measurement
858394|NCT02792907|Foot Surgery
858395|NCT02792907|Compliance
858396|NCT02792907|Compressive Stockings
858397|NCT02792894|cluster randomized trial
858398|NCT02792894|developmental delays
858399|NCT02792894|neurodevelopmental disorders
858400|NCT02792894|autism
858401|NCT02792894|intellectual disability
858402|NCT02792894|low resource settings
858403|NCT02792894|family volunteers
858404|NCT02792881|Stomach Neoplasms
858405|NCT02792881|Laparoscopy
858406|NCT02792881|Remnant gastric cancer
858407|NCT02792855|Snifﬁng Position
858408|NCT02792855|Simple Head Extension
858409|NCT02792829|Bioavailability of Lenvatinib suspension
858410|NCT02792829|Palatability of Lenvatinib suspension
858411|NCT02792829|Lenvatinib
858412|NCT02792829|Lenvima
858413|NCT02792829|E7080
858414|NCT02792829|Capsule formulation
858415|NCT02792829|Healthy volunteers
858416|NCT02792803|POAG
858417|NCT02792803|Primary open angle glaucoma
858418|NCT02792803|Ocular Hypertension
858419|NCT02792803|Xalatan
858420|NCT02792803|Latanoprost
858421|NCT02792803|Ocular Hyperemia
858422|NCT02792803|IOP
858423|NCT02792803|Intraocular Pressure
858424|NCT02792803|Allergan
858425|NCT02792803|prostaglandin
858426|NCT02792790|Amyloidosis
858427|NCT02792790|Carpal tunnel syndrome
858428|NCT02792777|Concept Mapping
858429|NCT02792777|VOICe
858430|NCT02792777|Interviews
858431|NCT02792777|Patient-Centered Research
858432|NCT02792764|port
858433|NCT02792764|peripheral intravenous lines
858434|NCT02792764|oncology
858435|NCT02792751|Depth of anesthesia
858436|NCT02792751|BIS
858437|NCT02792751|ERCP
858438|NCT02792751|Positive Regulation
858439|NCT02792712|Acute myocardial infarction
858440|NCT02792712|Antiplatelet agents
858441|NCT02792712|Magnetic resonance imaging (MRI)
858442|NCT02792686|Healthy Volunteers
858443|NCT02792673|Embryo transfer media
858444|NCT02792673|improvement of embryo transfer technique
858445|NCT02792673|improvement of implantation
858446|NCT02792673|"Hyaluronan-enriched media Embryo Glue®"
858447|NCT02792673|"30% Protein-supplemented Culture Medium Global Total®"
858448|NCT02792673|Autologous Follicular Fluid as embryo transfer medium
858449|NCT02792634|Bariatric surgery
858450|NCT02792634|Nonalcoholic Steatohepatitis
858451|NCT02792634|Obesity
858452|NCT02792608|Mindfulness-based Intervention
858453|NCT02792608|Brain Tumour Survivors
858454|NCT02792608|Depressive Symptoms
858455|NCT02792608|Quality of Life
858456|NCT02792608|Perceived Stress
858457|NCT02792608|Wellbeing
858458|NCT02792608|Treatment
858459|NCT02792582|Brain tumor
858460|NCT02792582|Pediatrics
858461|NCT02792582|Radiation therapy
858462|NCT02792582|Proton therapy
858463|NCT02792582|Surgery
858464|NCT02792569|IVA
858465|NCT02792569|Hippo Pathway
858466|NCT02792569|Follicle activation
858467|NCT02792569|Low Responder
858468|NCT02792569|POI
858469|NCT02792569|Poor Ovarian Reserve
858470|NCT02792569|Poor Ovarian Response
858471|NCT02792569|Salvador/Warts/Hippo pathway
858472|NCT02792556|drug abortion
858473|NCT02792556|urine pregnancy test
858474|NCT02792556|negative predictive value
858475|NCT02792556|check Top test
858476|NCT02792556|transvaginal ultrasound
858477|NCT02792543|nutrition
858478|NCT02792543|double enterostomy
858479|NCT02792543|chyme reinfusion
858480|NCT02792543|randomized controlled trial
858481|NCT02792439|Fitness
858482|NCT02792439|Health kit
858483|NCT02792439|Researchkit
858484|NCT02792439|Walking
858485|NCT02792426|Smoking Cessation
858486|NCT02792426|Nicotine Dependence
858487|NCT02792426|Tobacco Dependence
858488|NCT02792413|osteoporosis
858489|NCT02792413|chronic kidney disease
858490|NCT02792413|anti-RANK ligand antibody
858491|NCT02792413|bone mineral density
858492|NCT02792413|vascular calcifications
858493|NCT02792387|cardio-renal syndrome
858494|NCT02792387|right heart dysfunction
858495|NCT02792387|central venous pressure
858496|NCT02792387|eGFR
858497|NCT02792387|low-flow theory
858498|NCT02792374|Dental patients
858499|NCT02792374|Psychological Profile
858500|NCT02792361|Post-Operative Pterional Craniotomy
858501|NCT02792361|Suction Drain
858502|NCT02792361|Benefits
858503|NCT02792348|congenital urine flow impairment
858504|NCT02792348|urinary metabolomics profile
858505|NCT02792348|Nuclear Magnetic Resonance
858506|NCT02792322|Cancer
858507|NCT02792322|Oropharynx
858508|NCT02792270|Surgery
858509|NCT02792231|Relapsing multiple sclerosis
858510|NCT02792231|Ofatumumab
858511|NCT02792218|Relapsing multiple sclerosis
858512|NCT02792218|Ofatumumab
858513|NCT02792205|Willebrand factor deficiency
858514|NCT02792205|hematology
858515|NCT02792205|Willebrand:Collagen-binding
858516|NCT02792166|Morbid obesity
858517|NCT02792166|Metabolic syndrome
858518|NCT02792166|Metabolic surgery
858519|NCT02792166|Bariatric surgery
858520|NCT02792166|SADI
858521|NCT02792166|BPD-DS
858522|NCT02792153|estrogen
858523|NCT02792153|anxiety
858524|NCT02792153|amenorrhea
858525|NCT02792153|eating disorders
858526|NCT02792140|Psychology
858527|NCT02792140|Dreams
858528|NCT02792127|Social Anxiety
858529|NCT02792127|Cognitive Behaviour Therapy
858530|NCT02792127|Online Program
858531|NCT02792114|T-Cell
858532|NCT02792114|Chimeric antigen receptor (CAR)
858533|NCT02792114|CAR T cells
858534|NCT02792114|Triple-negative breast cancer
858535|NCT02792114|Immunotherapy T-cell therapy
858536|NCT02792114|16-040
858537|NCT02792114|immunotherapy
858538|NCT02792114|CAR
858539|NCT02792088|HBV
858540|NCT02792075|Coronary Stenosis
858541|NCT02792075|Intracoronary Imaging
858542|NCT02792075|VH-IVUS
858543|NCT02792075|OCT
858544|NCT02792075|NIRS
858545|NCT02792075|gray scale IVUS
858546|NCT02792023|Colorectal cancer
858547|NCT02792023|Immunochemical occult blood test
858548|NCT02792010|T1rho MRI
858549|NCT02792010|hip
858550|NCT02792010|cartilage
858551|NCT02792010|Healthy participants
858552|NCT02791997|Audition
858553|NCT02791997|Stroke
858554|NCT02791997|Migraine
858555|NCT02791997|Attention
858556|NCT02791997|Short-term memory,
858557|NCT02791997|Emotions
858558|NCT02791997|EEG
858559|NCT02791997|MEG
858560|NCT02791984|Suprasternal
858561|NCT02791984|echography
858562|NCT02791984|fluid responsiveness
858563|NCT02791971|Contraception
858564|NCT02791971|Birth control
858565|NCT02791971|Social communication
858566|NCT02791971|Adolescent
858567|NCT02791971|Social network
858568|NCT02791971|Health education
858569|NCT02791971|Reproductive health
858570|NCT02791945|TBI
858571|NCT02791945|hazardous and harmful alcohol use
858572|NCT02791945|Veterans
858573|NCT02791945|co-occurring disorders
858574|NCT02791945|pharmacotherapy
858575|NCT02791932|Pregnancy
858576|NCT02791932|Postpartum period
858577|NCT02791932|Depression
858578|NCT02791906|Chronic Kidney Diseases
858579|NCT02791906|Chronic Kidney Insufficiency
858580|NCT02791906|Chronic Renal Diseases
858581|NCT02791906|Chronic Renal Insufficiency
858582|NCT02791906|Kidney Insufficiency, Chronic
858583|NCT02791906|Cardiac Failure
858584|NCT02791906|Congestive Heart Failure
858585|NCT02791906|Heart Decompensation
858586|NCT02791906|Heart Failure, Congestive
858587|NCT02791906|Myocardial Failure
858592|NCT02791841|Reading
858593|NCT02791841|Developmental Dyslexia,
858594|NCT02791841|Music
858595|NCT02791841|Rhythm
858596|NCT02791841|Action Video Games
858597|NCT02791841|Hemisphere-Specific Stimulation
858598|NCT02791815|selexipag
858599|NCT02791815|pharmacokinetics
858600|NCT02791815|midazolam
858601|NCT02791802|Lipoprotein(a)
858602|NCT02791802|lipoprotein/lipid apheresis
858603|NCT02791802|CV disease
858604|NCT02791789|Autism Spectrum Disorder
858605|NCT02791789|SEMATIC
858606|NCT02791789|software
858607|NCT02791776|scoliosis
858608|NCT02791763|Renal Anemia
858609|NCT02791763|Japanese
858610|NCT02791763|chronic kidney disease
858611|NCT02791763|Peritoneal dialysis
858612|NCT02791763|GSK1278863
858613|NCT02791763|Non-dialysis
858614|NCT02791750|hormone replacement therapy
858615|NCT02791750|breast cancer
858616|NCT02791750|follow up
858617|NCT02791737|Hematologic Malignancy
858618|NCT02791737|Exercise
858619|NCT02791737|Decreased Physical Activity
858620|NCT02791711|Bronchiolitis
858621|NCT02791711|Continuous Positive Airway Pressure
858622|NCT02791711|HFNC
858623|NCT02791698|cortisol
858624|NCT02791698|hair
858625|NCT02791698|urinary
858626|NCT02791685|Cardiac Rehabilitation
858627|NCT02791672|Perioperative Care
858628|NCT02791672|Breast Reconstruction
858629|NCT02791659|radiation exposure
858630|NCT02791659|ERCP
858631|NCT02791659|prone
858632|NCT02791659|left lateral decubitus
858633|NCT02791607|Circulating tumor cells
858634|NCT02791607|Head and neck cancer
858635|NCT02791607|Survival Prognosis
858636|NCT02791607|P16Ink4A
858637|NCT02791607|HPV
858638|NCT02791555|pradaxa
858639|NCT02791555|warfarin
858640|NCT02791542|Asthma
858646|NCT02791503|Irreversible electroporation (IRE
858647|NCT02791503|Stereotactic ablative radiotherapy (SABR
858648|NCT02791503|Efficacy
858649|NCT02791503|Tumor ablation
858650|NCT02791503|Chemotherapy
858651|NCT02791503|Locally advanced pancreatic cancer (LAPC)
858652|NCT02791477|Attune
858653|NCT02791464|Meditation
858654|NCT02791464|TM
858655|NCT02791464|PTSD
858656|NCT02791464|Trauma
858657|NCT02791464|Female Prisoners
858658|NCT02791451|COPD
858659|NCT02791451|telemonitoring
858660|NCT02791451|exacerbation
858661|NCT02791425|Brain-Computer Interface
858662|NCT02791425|Intratracheal intubation
858663|NCT02791425|Mechanical ventilation
858664|NCT02791425|Nonverbal communication
858665|NCT02791425|Critical illness
858666|NCT02791425|Electroencephalography
858667|NCT02791425|Visual Evoked Potential
858668|NCT02791412|left main
858669|NCT02791412|unprotected
858670|NCT02791412|percutaneous coronary intervention
858671|NCT02791412|coronary-artery bypass graft
858672|NCT02791399|opioid safety
858673|NCT02791399|opioid misuse
858674|NCT02791399|opioid abuse
858675|NCT02791399|patient-centered
858676|NCT02791399|opioid
858677|NCT02791399|opiate
858678|NCT02791399|chronic pain
858679|NCT02791399|primary care
858680|NCT02791399|Veteran
858681|NCT02791399|clinical care
858682|NCT02791360|Brain
858683|NCT02791360|Radiotherapy
858684|NCT02791360|MRI
858685|NCT02791360|Sequelae
858688|NCT02791295|Type 2 diabetes
858689|NCT02791295|lifestyle intervention
858690|NCT02791295|insulin pump treatment
858691|NCT02791295|body weight
858692|NCT02791295|body composition
858693|NCT02791282|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
858694|NCT02791282|MRI
858695|NCT02791282|SPECT
858701|NCT02791100|height
858702|NCT02791100|weight
858703|NCT02791100|diet
858704|NCT02791100|complementary foods
858705|NCT02791100|protein
858706|NCT02791100|calcium
858707|NCT02791009|HF
858708|NCT02791009|HFrEF
858709|NCT02791009|HFpEF
858710|NCT02791009|MRI
858711|NCT02791009|biomarker
858712|NCT02790996|sepsis
858713|NCT02790996|neonate
858714|NCT02790996|vancomycin
858715|NCT02790983|Registry
858716|NCT02790983|Spine
858717|NCT02790983|Surgery
858718|NCT02790983|Medical Oncology
858719|NCT02790983|Radiation Oncology
858720|NCT02790983|Neoplasms
858721|NCT02790944|Germline
858722|NCT02790944|Pancreatic
858723|NCT02790944|Genetic Testing
858724|NCT02790931|diabetic foot
858725|NCT02790931|therapeutic exercises
858726|NCT02790931|foot
858727|NCT02790931|biomechanics
858728|NCT02790931|preventive care
858729|NCT02790931|rehabilitation
858730|NCT02790931|Diabetic Neuropathy
858731|NCT02790931|software
858732|NCT02790918|Pulmonary Hypertension
858733|NCT02790918|MRI
858734|NCT02790905|pregnant and post-partum women
858735|NCT02790905|Validation questionnaires
858736|NCT02790905|Thai-Myanmar border
858737|NCT02790892|type 1 diabetes
858738|NCT02790892|type 2 diabetes
858739|NCT02790892|children
858740|NCT02790892|adolescents
858741|NCT02790892|young adults
858742|NCT02790892|youth
858743|NCT02790892|transition
858744|NCT02790892|art therapy
858745|NCT02790892|behavioral therapy
858746|NCT02790879|Transitional care
858747|NCT02790879|teenagers
858748|NCT02790879|cystic fibrosis
858749|NCT02790879|pulmonary function
858750|NCT02790879|nutritional function
858751|NCT02790879|Patients who experiment a transition pediatric - adult care
858752|NCT02790866|Decision Aid
858753|NCT02790866|Informed Decision Making
858754|NCT02790866|Shared Decision making
858755|NCT02790866|Screening
858756|NCT02790853|Cancer of Head and Neck
858757|NCT02790853|Oral Potentially Malignant Disorders
858758|NCT02790853|OPMD
858759|NCT02790853|Multimodal Imaging
858760|NCT02790853|Suspicious oral mucosal lesion
858761|NCT02790853|Pathologic diagnosis of dysplasia
858762|NCT02790853|History of resected oral cancer
858763|NCT02790853|White Light Examination
858764|NCT02790853|WL
858765|NCT02790853|Wide-field auto-fluorescence imaging device PS2.1/PS3
858766|NCT02790853|Proflavine Hemisulfate
858767|NCT02790853|High-Resolution Optical System
858768|NCT02790853|HRME
858769|NCT02790853|Brush Biopsy
858770|NCT02790853|Tissue Biopsy
858771|NCT02790840|Volunteers
858772|NCT02790801|chronic heart failure
858773|NCT02790801|atrial fibrillation
858774|NCT02790801|anticoagulant
858775|NCT02790762|stem cells
858776|NCT02790762|Mesenchymal Stem Cells
858777|NCT02790762|Umbilical Cord-Mesenchymal Stem Cells
858778|NCT02790762|Pneumoconiosis
858779|NCT02790749|Developmental hip dysplasia
858780|NCT02790749|Intra-articular pathology
858781|NCT02790749|Adult hip dysplasia
858782|NCT02790749|Labral tear, hip
858783|NCT02790749|Chondromalacia, hip
858784|NCT02790736|propranolol
858785|NCT02790736|public speaking anxiety
858786|NCT02790710|propanolol
858787|NCT02790710|obsessive-compulsive disorder
858788|NCT02790697|Indirect calorimetry
858789|NCT02790697|ICALIC Study
858790|NCT02790697|Energy expenditure
858791|NCT02790697|VO2
858792|NCT02790697|VCO2
858793|NCT02790697|Respiratory quotient
858794|NCT02790658|Grumixama
858795|NCT02790658|Urolithins
858796|NCT02790658|Anthocyanins
858797|NCT02790658|Metabolomic Approach
858798|NCT02790658|Ellagitannins
858799|NCT02790658|Subjects
858800|NCT02790645|Type 1 diabetes
858801|NCT02790645|Health technologies
858802|NCT02790645|Continuous subcutaneous insulin infusion
858803|NCT02790645|Telemedicine
858804|NCT02790645|Glycemic variability
858805|NCT02790645|Inflammatory markers,
858806|NCT02790645|Oxidative stress
858807|NCT02790645|Depression
858808|NCT02790645|Quality of life
858809|NCT02790645|Cost-effectiveness
858810|NCT02790632|Aneurysm, Ruptured
858811|NCT02790632|Nimodipine
858812|NCT02790632|Subarachnoid Hemorrhage
858813|NCT02790567|diagnostic performance
858814|NCT02790567|heparin-induced thrombocytopenia
858815|NCT02790567|rapid immunological diagnostic method
858816|NCT02790567|immunoassay
858817|NCT02790567|pretest scoring systems
858818|NCT02790567|4Ts score
858819|NCT02790567|HEP score
858820|NCT02790541|aging
858821|NCT02790541|HBOT
858822|NCT02790541|reverse
858823|NCT02790541|angiogenesis
858824|NCT02790541|elderly
858825|NCT02790541|mitochohndria
858826|NCT02790528|statin
858827|NCT02790528|vasospastic angina
858828|NCT02790476|Safe
858829|NCT02790476|Prescribing
858830|NCT02790476|Opioids
858831|NCT02790463|Allopurinol
858832|NCT02790398|Transdiagnostic treatment protocol
858833|NCT02790398|Transdiagnostic treatment protocol + PA component
858834|NCT02790372|Nursing homes
858835|NCT02790372|Norway
858836|NCT02790359|Carbon dioxide
858837|NCT02790359|Air
858838|NCT02790359|Colonoscopy
858839|NCT02790346|hemiparesis
858840|NCT02790346|deformity of the foot and ankle
858841|NCT02790320|Eribulin mesylate
858842|NCT02790320|Halaven
858843|NCT02790320|Breast cancer
858844|NCT02790307|multiple sclerosis
858845|NCT02790307|overactive bladder
858846|NCT02790307|urinary incontinence
858847|NCT02790307|tibial nerve stimulation
858848|NCT02790294|magnetic resonance imaging
858849|NCT02790268|Cionni Ring
858850|NCT02790268|Ultrasound Biomicroscopy
858851|NCT02790242|Mechanical Circulatory Support Device (MCSD)
858852|NCT02790242|ventricular Assist Device (VAD)
858853|NCT02790229|rehabilitation, anti-gravity treadmill
858854|NCT02790216|Image guided brachytherapy
858855|NCT02790151|working memory, recollection training, transfer
858856|NCT02790138|Drug Therapy
858857|NCT02790112|Body Mass Index
858858|NCT02790112|Body Composition
858859|NCT02790112|Glucose Metabolism Disorders
858860|NCT02790112|Bone Development
858861|NCT02790112|Gonadal Disorders
858862|NCT02790112|Fertility
858863|NCT02790112|Overweight
858864|NCT02790112|Obesity
858865|NCT02790112|Menarche
858866|NCT02790099|Pain
858867|NCT02790099|Postoperative pain control
858868|NCT02790099|Rectus sheath block
858869|NCT02790099|Intrathecal morphine
858870|NCT02790099|Caesarean section
858871|NCT02790086|hypothermia
858872|NCT02790086|prevalence
858873|NCT02790086|perioperative
858874|NCT02790086|anemia
858875|NCT02790086|myocardial injury
858876|NCT02790086|troponin T
858877|NCT02790086|noncardiac surgery
858878|NCT02790073|Calciphylaxis
858879|NCT02790073|Calcific Uremic Arteriolopathy
858880|NCT02790073|Dialysis
858881|NCT02790073|End Stage Renal Disease
858882|NCT02790073|Rare disease (ORPHA280062)
858883|NCT02790073|Calcification
858884|NCT02790073|Calcium Metabolism Disorders
858885|NCT02790073|Calcinosis
858886|NCT02790073|Metabolic Diseases
858887|NCT02790060|diabetes
858888|NCT02790047|Chronic Obstructive Pulmonary Disease
858889|NCT02790047|Exercise Therapy
858890|NCT02790047|Positive Expiratory Pressure
858891|NCT02790047|Physical Fitness
858892|NCT02790047|Quality of Life
858893|NCT02790008|echocardiography
858894|NCT02790008|magnetic resonance imaging
858895|NCT02790008|cardiopulmonary exercise test
858896|NCT02789995|Intensive Care Unit - Acquired Weakness (ICU-AW)
858897|NCT02789982|PTSD
858898|NCT02789982|Trauma related disorders
858899|NCT02789982|Reconsolidation blockade
858900|NCT02789982|Paris attacks
858901|NCT02789956|Internal connection
858902|NCT02789956|Cobalt/Chrome
858903|NCT02789956|Cad-cam Framework
858904|NCT02789956|marginal bone level
858905|NCT02789943|IHD Normal EF
858906|NCT02789930|Weight estimation
858907|NCT02789930|Patient safety
858908|NCT02789917|ACS
858909|NCT02789917|Triple-Therapy
858910|NCT02789917|AF
858911|NCT02789917|oral anticoagulation (OAC)
858912|NCT02789917|non-vitamin-K oral anticoagulant (NOAC)
858913|NCT02789878|Neoadjuvant therapy
858914|NCT02789878|High-risk Prostate Cancer
858915|NCT02789865|Acute appendicitis
858916|NCT02789865|Endoscopic retrograde appendicitis therapy
858917|NCT02789865|Endoscopic retrograde appendicography
858918|NCT02789865|Endoscopic therapy
858919|NCT02789865|Appendectomy
858920|NCT02789865|Antibiotic Therapy
858921|NCT02789787|Cleft Lip
858922|NCT02789787|Palate
858923|NCT02789787|Class III
858924|NCT02789787|Malocclusion
858925|NCT02789787|Protraction
858926|NCT02789761|Flow-mediated dilatation (FMD)
858927|NCT02789761|Vascular function
858928|NCT02789761|cognitive function
858929|NCT02789735|Pregnancy
858930|NCT02789735|laser therapy
858931|NCT02789735|persistent pain
858932|NCT02789735|pelvic pain
858933|NCT02789722|Mate
858934|NCT02789722|Vascular protection
858935|NCT02789722|Endothelial function
858936|NCT02789722|Ilex paraguariensis
858937|NCT02789657|neoadjuvant breast cancer
858938|NCT02789657|stage I-III breast cancer
858939|NCT02789657|HER 2 positive breast cancer
858940|NCT02789644|Ursodeoxycholic acid
858941|NCT02789644|Metabolomics/biomarker
858942|NCT02789644|Pharmacokinetics
858943|NCT02789605|Aphthous Stomatitis [C07.465.864.750]
858944|NCT02789592|REM Sleep Behavior Disorder
858945|NCT02789592|Parkinson Disease
858946|NCT02789592|Randomized Controlled Trial
858947|NCT02789592|Clinical Trial
858948|NCT02789592|Melatonin
858949|NCT02789592|Clonazepam
858950|NCT02789579|prophylactic
858951|NCT02789579|Urinary Tract Infections
858952|NCT02789579|Minimally invasive upper tract lithotomy
858953|NCT02789566|Primaquine
858954|NCT02789566|Pharmacokinetic
858955|NCT02789553|Glucose digestion
858956|NCT02789553|Bypass surgery
858957|NCT02789553|C13-glucose tracer
858958|NCT02789553|Insulin secretion
858959|NCT02789540|COPD symptoms
858960|NCT02789527|healthy volunteers
858961|NCT02789514|esophagogastroduodenoscopy
858962|NCT02789514|paediatric
858963|NCT02789501|Catheter
858964|NCT02789501|Dysfunctions
858965|NCT02789501|Blood Stream Infections
858966|NCT02789501|Haemodialysis
858967|NCT02789501|Taurolidine
858968|NCT02789501|Tunneled
858969|NCT02789436|halitosis
858970|NCT02789436|chronic periodontitis
858971|NCT02789436|probiotic
858972|NCT02789410|Cesarean delivery
858973|NCT02789410|Analgesia
858974|NCT02789410|Intrathecal opioids
858975|NCT02789397|Granulomatous and lymphocytic interstitial lung disease
858976|NCT02789397|common variable immunodeficiency
858977|NCT02789397|Rituximab
858978|NCT02789397|Azathioprine
858979|NCT02789397|primary immunodeficiency
858980|NCT02789397|GLIILD
858981|NCT02789397|CVID
858982|NCT02789384|soft-tissue sarcomas
858983|NCT02789384|CINSARC
858984|NCT02789384|biomarker
858985|NCT02789384|efficacy
858986|NCT02789384|pronostic
858987|NCT02789371|EUS-FNA
858988|NCT02789371|modified wet suction technique
858989|NCT02789371|dry suction technique
858990|NCT02789358|cryotherapy
859003|NCT02789319|Blood Glucose Monitoring System
859004|NCT02789319|BGMS
859005|NCT02789319|Diabetes
859006|NCT02789319|Patient Use
859007|NCT02789306|Preventive therapy
859008|NCT02789306|Dental implants
859009|NCT02789293|Glaucoma
859010|NCT02789293|Ultrasound
859011|NCT02789293|Ciliary body
859012|NCT02789267|Cancer - Quality of life - Dietary support
859013|NCT02789254|acute myeloid leukemia
859014|NCT02789254|Fms-like receptor tyrosine kinase (FLT3)
859015|NCT02789254|stem cell transplantation
859016|NCT02789254|complete remission
859017|NCT02789254|CD135
859018|NCT02789254|antibodies
859019|NCT02789254|Leukemia
859020|NCT02789254|AML
859021|NCT02789254|Fc-optimized
859022|NCT02789241|Endotoxin
859023|NCT02789241|healthy
859024|NCT02789241|volunteers
859025|NCT02789241|males
859026|NCT02789241|females
859027|NCT02789215|Child care food costs
859028|NCT02789215|Meal participation rates
859029|NCT02789215|Child and Adult Care Food Program
859030|NCT02789202|dental caries
859031|NCT02789202|deciduous tooth
859036|NCT02789163|breast
859037|NCT02789163|ultrasound
859038|NCT02789163|diagnostic exam
859039|NCT02789163|automated volume breast scanner
859040|NCT02789137|metastatic renal cell carcinoma
859041|NCT02789124|fluid responsiveness
859042|NCT02789124|carotid artery flow time
859043|NCT02789124|passive leg raise
859044|NCT02789098|ST Elevation Myocardial Infarction
859045|NCT02789098|Ventricular remodeling
859046|NCT02789098|Biomarkers
859047|NCT02789098|Coronary endothelial function
859048|NCT02789098|Positron Emission Tomography
859049|NCT02789085|TENS
859050|NCT02789085|ULF-TENS
859051|NCT02789085|ANS
859052|NCT02789085|Dentistry
859053|NCT02789085|TMD
859054|NCT02789059|Becker muscular dystrophy
859055|NCT02789059|Facioscapulohumeral dystrophy
859056|NCT02789059|congenital myopathy
859057|NCT02789059|motor neurone diseases
859058|NCT02789046|adult
859059|NCT02789046|vascular access
859060|NCT02789046|preoperative period
859061|NCT02789046|peripheral venous catheterization
859062|NCT02789033|diabetic foot ulcers
859063|NCT02789033|chitosan
859064|NCT02789033|isosorbide dinitrate spray
859065|NCT02788981|triple-negative breast cancer
859066|NCT02788981|advanced breast cancer
859067|NCT02788981|nab-paclitaxel
859068|NCT02788981|mifepristone
859069|NCT02788981|glucocorticoid receptor-positive breast cancer
859070|NCT02788968|Psychology and Cognitive Neuroscience of development
859071|NCT02788968|Adolescent and young adult healthy volunteers
859072|NCT02788968|Anatomical and functionally Magnetic Resonance Imaging (MRI)
859073|NCT02788968|Conflict detection
859074|NCT02788968|Reasoning
859075|NCT02788955|Protein
859076|NCT02788955|Diet intervention
859077|NCT02788955|Muscle
859078|NCT02788955|Colorectal cancer
859079|NCT02788942|Port
859080|NCT02788942|Infection
859081|NCT02788942|cholecystectomy
859082|NCT02788929|Percutaneous Transluminal Coronary Intervention
859083|NCT02788929|Cardiac Rehabilitation
859084|NCT02788929|Fitbit Charge HR
859085|NCT02788916|Drug Therapy
859086|NCT02788903|Obesity Counseling
859087|NCT02788864|Forest ranger
859088|NCT02788864|P.falciparum
859089|NCT02788864|P.vivax
859090|NCT02788864|Dihydroartemisinine-piperaquine (DP)
859091|NCT02788864|Primaquine
859092|NCT02788851|Stimulant Medication
859093|NCT02788851|Exercise
859094|NCT02788851|Functional Outcome
859095|NCT02788851|Effectiveness
859096|NCT02788851|Symptoms
859097|NCT02788838|Magnetic Resonance Imaging
859098|NCT02788838|Energy Intake
859099|NCT02788838|Commercials
859100|NCT02788838|Children
859101|NCT02788799|ST Elevation
859102|NCT02788799|LCX Artery
859103|NCT02788786|chlorhexidine
859104|NCT02788786|cetylpyridinium chloride
859105|NCT02788786|gingival crevicular fluid
859106|NCT02788734|carpal tunnel syndrome
859107|NCT02788734|CTS
859108|NCT02788734|inherited peripheral neuropathy
859109|NCT02788734|Charcot-Marie-Tooth disease
859110|NCT02788734|Hereditary Neuropathy
859111|NCT02788734|Pressure Palsies
859112|NCT02788734|CMT
859113|NCT02788734|HNPP
859114|NCT02788708|paclitaxel
859115|NCT02788708|lenvatinib
859116|NCT02788695|Visual Nonspecific
859117|NCT02788682|VDBP
859118|NCT02788682|single nucleotide polymorphisms (SNPs)
859119|NCT02788682|interferon based therapy
859120|NCT02788682|Egypt
859121|NCT02788656|heart failure
859122|NCT02788656|neprilysin
859123|NCT02788656|implantable hemodynamic monitor
859124|NCT02788656|angiotensin-receptor blocker
859125|NCT02788656|angiotensin-converting enzyme inhibitor
859126|NCT02788604|psychosocial screening, quality of life
859127|NCT02788552|Neurological
859128|NCT02788552|Diet and Nutrition
859129|NCT02788552|Mental Health
859130|NCT02788539|Chronic Pain
859131|NCT02788539|mhealth
859132|NCT02788539|Integrative Medicine
859133|NCT02788539|MBSR
859134|NCT02788539|Mindfulness Based Stress Reduction
859135|NCT02788539|Web based
859136|NCT02788539|Internet Based
859137|NCT02788526|Carcinoma,Hepatocellular
859138|NCT02788526|Chemoembolization
859139|NCT02788526|Adjuvant therapy
859140|NCT02788526|Hepatocellular
859141|NCT02788526|Microvessels invasion
859142|NCT02788500|Epidemiology
859143|NCT02788500|Sports medicine
859144|NCT02788500|Research protocol
859145|NCT02788500|Athletic injuries
859146|NCT02788500|Sports for persons with disabilities
859147|NCT02788448|Percutaneous vascular closure device
859148|NCT02788448|Large hole closure device
859149|NCT02788396|STEMI
859150|NCT02788396|PPCI
859151|NCT02788396|post-dilatation
859152|NCT02788396|coronary microcirculation
859153|NCT02788370|Positive expiratory pressure
859154|NCT02788370|Cardiopulmonary responses
859155|NCT02788370|Exercise
859156|NCT02788370|Older people
859157|NCT02788357|motor training
859158|NCT02788357|motor recovery
859159|NCT02788357|human
859160|NCT02788357|neuroplasticity
859161|NCT02788357|transcranial magnetic stimulation
859162|NCT02788344|Observational study
859163|NCT02788344|Myocardial revascularization
859164|NCT02788344|Thrombolytic therapy
859165|NCT02788344|Hospital mortality
859166|NCT02788344|Hemorrhage
859167|NCT02788344|Quality of health care
859168|NCT02788344|Angioplasty
859169|NCT02788318|Epilepsy
859170|NCT02788318|SUDEP
859171|NCT02788318|Serotonin
859172|NCT02788292|acetylcysteine
859173|NCT02788292|three-dimensional reconstruction
859174|NCT02788292|autologous fat grafting
859176|NCT02788266|Cervical lesion
859177|NCT02788266|gingival recession
859178|NCT02788266|restorative materials
859179|NCT02788253|Mallampati
859180|NCT02788253|Intubation difficult
859181|NCT02788253|Mask ventilation difficult
859182|NCT02788227|Ebola Vaccine
859183|NCT02788214|Gastric Cancer
859184|NCT02788214|Bacterial Risk Factors
859185|NCT02788214|DNA Methylation
859186|NCT02788214|DNA Sequencing
859187|NCT02788214|Biobank
859188|NCT02788201|COXEN
859189|NCT02788201|Bladder Cancer
859190|NCT02788201|Molecular Profiles
859191|NCT02788201|Algorithm
859192|NCT02788201|Biomarkers
859193|NCT02788188|First in Human
859194|NCT02788188|Middle East Respiratory Syndrome (MERS)
859195|NCT02788188|Tc Bovine-Derived
859196|NCT02788188|Transchromosomic Cattle
859197|NCT02788175|HIV Immune Therapy
859198|NCT02788175|Monoclonal Antibody
859199|NCT02788175|Integrin
859200|NCT02788149|Ultrasonography
859201|NCT02788149|Submental
859202|NCT02788149|Lateral Parapharyngeal wall
859203|NCT02788149|Tongue base thickness
859204|NCT02788149|Polysomnography
859205|NCT02788123|De-Nol
859206|NCT02788123|NSAID-induced gastropathy
859207|NCT02788123|Pantoprazole
859208|NCT02788123|Bismuth tripotassium dicitrate
859209|NCT02788123|Russia
859210|NCT02788097|blastocysts
859211|NCT02788097|progesterone
859212|NCT02788097|implantation
859213|NCT02788097|artificial frozen embryo transfer
859216|NCT02788071|Irritable Bowel Syndrome
859217|NCT02788071|Fecal Microbiota Transplantation
859218|NCT02788071|Microbiota
859219|NCT02788058|Hypofractionated Radiotherapy
859220|NCT02788058|EGFR Positive
859221|NCT02788058|Lung Adenocarcinoma
859222|NCT02788058|Limited Metastases
859223|NCT02788019|Adductor canal block, nerve block
859224|NCT02787941|acute coronary syndrome
859225|NCT02787941|medication adherence
859226|NCT02787941|pharmacist-led interventions
859227|NCT02787941|Vietnam
859228|NCT02787915|dendritic cells
859229|NCT02787915|cytotoxic T lymphocyte
859230|NCT02787915|DC vaccine
859231|NCT02787863|Pneumococcal vaccine
859232|NCT02787863|Polioxidonium
859233|NCT02787837|Prognostic
859234|NCT02787837|Castration
859235|NCT02787837|Resistant
859236|NCT02787837|Abiraterone
859237|NCT02787824|iron deficiency
859238|NCT02787824|hemodialysis
859239|NCT02787811|IUI
859240|NCT02787811|Pregnancy rate
859241|NCT02787811|predictors
859242|NCT02787798|Nervous System
859243|NCT02787798|Cardiac disease
859244|NCT02787785|Subcutaneous
859245|NCT02787785|Implantable Cardioverter Defibrillator
859246|NCT02787785|MADIT
859247|NCT02787785|Diabetes
859248|NCT02787785|Myocardial Infarction
859249|NCT02787759|stroke
859250|NCT02787759|walking
859251|NCT02787759|balance
859252|NCT02787759|exercise
859253|NCT02787746|AD
859254|NCT02787746|Donepezil
859255|NCT02787746|Safety
859256|NCT02787733|performance
859257|NCT02787733|recovery
859258|NCT02787720|Acute Respiratory Distress Syndrome
859259|NCT02787720|Pulmonary Rehabilitation
859260|NCT02787720|Rehabilitation Plan
859261|NCT02787720|Rehabilitation Techniques
859262|NCT02787720|Survivor
859263|NCT02787720|Randomized Controlled Trial
859264|NCT02787707|Breast cancer
859265|NCT02787707|Traditional medicine
859266|NCT02787707|Chemotherapy Induced Nausea and Vomiting
859267|NCT02787707|Bunium Persicum
859268|NCT02787707|Rhus Coriaria
859269|NCT02787694|stroke
859270|NCT02787694|walking
859271|NCT02787694|balance
859272|NCT02787694|exercise
859277|NCT02787655|Aging
859278|NCT02787642|Advanced soft-tissue sarcoma
859279|NCT02787642|Unresectable Soft-tissue Sarcoma
859280|NCT02787629|D007440
859281|NCT02787590|Neurology
859282|NCT02787577|Sleep Duration
859283|NCT02787577|Sleep Quality
859284|NCT02787577|Body Composition
859285|NCT02787577|Energy Intake
859286|NCT02787577|Energy Expenditure
859287|NCT02787577|Energy Balance
859288|NCT02787577|Cardiovascular Risk
859289|NCT02787564|fruit, vegetables
859290|NCT02787538|Rheumatoid Arthritis
859291|NCT02787538|Decision Aids
859292|NCT02787538|Biologics
859293|NCT02787512|ERCP
859294|NCT02787512|stent
859295|NCT02787512|preoperative biliary drainage
859296|NCT02787499|Drug resistance
859297|NCT02787499|Standard of care
859298|NCT02787499|sub-saharan africa
859299|NCT02787499|antiretroviral therapy
859300|NCT02787499|diagnostics
859301|NCT02787499|implementation
859302|NCT02787486|Down syndrome
859303|NCT02787486|Edwards syndrome
859304|NCT02787486|Patau syndrome
859305|NCT02787486|Klinefelter syndrome
859306|NCT02787486|DiGeorge syndrome
859307|NCT02787486|Chromosome Deletion
859308|NCT02787486|Aneuploidy
859309|NCT02787473|Squamous cell lung cancer
859310|NCT02787473|Pemetrexed
859311|NCT02787473|Radiosensitivity
859312|NCT02787460|Parenting
859313|NCT02787460|Family Relations
859314|NCT02787460|Marriage
859315|NCT02787460|Relationships
859316|NCT02787447|Hypofractionated Radiotherapy
859317|NCT02787447|Thymosin Alpha 1
859318|NCT02787447|Lung Adenocarcinoma
859319|NCT02787447|Tyrosine Kinase Inhibitors
859320|NCT02787434|African american men
859321|NCT02787434|prostate cancer screening
859322|NCT02787434|web-based decision aid
859323|NCT02787434|informed decision making
859324|NCT02787434|shared decision-making
859325|NCT02787421|Reconstructive Surgery
859326|NCT02787421|Rhinoplasty
859327|NCT02787382|cytomegalovirus
859328|NCT02787382|TORCH
859329|NCT02787382|prenatal diagnosis
859330|NCT02787382|congenital infections
859331|NCT02787382|fetal abnormalities
859332|NCT02787382|echocardiography
859333|NCT02787382|myocardial deformation
859334|NCT02787369|Refractory Leukemia
859335|NCT02787369|Leukemia
859336|NCT02787356|Skin Diseases, Erythema
859337|NCT02787330|pediatric cancer
859338|NCT02787330|psychosocial
859339|NCT02787330|siblings
859340|NCT02787317|bivalirudin
859341|NCT02787317|myocardial injure
859342|NCT02787304|NAFLD activity score
859343|NCT02787304|ASBTi
859344|NCT02787304|MRI PDFF
859345|NCT02787304|NAS
859346|NCT02787304|NAFLD
859347|NCT02787304|liver disease
859348|NCT02787304|ASBT
859349|NCT02787304|MRI proton density fat fraction
859350|NCT02787304|nonalcoholic steatohepatitis
859351|NCT02787304|apical sodium dependent bile acid transporter inhibitor
859352|NCT02787304|fatty liver
859353|NCT02787304|NASH
859354|NCT02787278|rtPA
859355|NCT02787278|Intracranial hemorrhage
859356|NCT02787265|High density spinal cord stimulation
859357|NCT02787265|Virtual expert registry
859358|NCT02787226|liposomal bupivacaine
859359|NCT02787226|analgesia for total shoulder arthroplasty
859360|NCT02787226|peripheral nerve blocks for total shoulder arthroplasty
859361|NCT02787213|proteomics
859362|NCT02787213|pregnancy
859363|NCT02787213|biomarkers
859364|NCT02787213|preterm birth
859365|NCT02787200|electroencephalogram (EEG),Human brain,Brain-Computer Interface
859366|NCT02787187|Standard lymphadenectomy
859367|NCT02787187|extended lymphadenectomy
859368|NCT02787187|pancreaticoduodenectomy
859369|NCT02787174|Asthma
859370|NCT02787174|Medication adherence
859371|NCT02787174|Intervention study
859372|NCT02787161|Chronic Kidney Disease
859373|NCT02787161|Hemodialysis
859374|NCT02787161|Hemodiafiltration
859375|NCT02787161|Renal Replacement Therapy
859376|NCT02787161|Physical Activity
859377|NCT02787161|Accelerometer
859378|NCT02787148|cognitive behavioral therapy
859379|NCT02787148|psychotherapy
859380|NCT02787148|cardiovascular health
859381|NCT02787148|psychoneuroimmunology
859382|NCT02787135|Delusions
859383|NCT02787135|Schizophrenia
859384|NCT02787135|Cognitive Behavior Therapy
859385|NCT02787135|Emotion
859386|NCT02787135|Emotion regulation
859387|NCT02787135|self-esteem
859388|NCT02787135|sleep quality
859389|NCT02787135|Efficacy of change
859390|NCT02787122|Schizophrenia
859391|NCT02787122|psychotic disorders
859392|NCT02787122|Cognitive Behavior Therapy
859393|NCT02787122|emotion regulation
859394|NCT02787122|self-esteem
859395|NCT02787122|randomized-controlled trial
859396|NCT02787109|Safety
859397|NCT02787109|Immunogenicity
859398|NCT02787109|Phase I
859399|NCT02787096|dynamic knee laxity measurement
859400|NCT02787096|laxi-MRI
859401|NCT02787096|partial anterior cruciate ligament tear
859402|NCT02787083|Interstitial Cystitis
859403|NCT02787044|influenza vaccine
859404|NCT02787044|cardiopulmonary hospitalization
859405|NCT02787044|heart failure
859406|NCT02787044|myocardial infarction
859407|NCT02787044|clinical trial
859408|NCT02787031|hip fracture
859409|NCT02787031|geriatric
859410|NCT02787031|epidemiology
859411|NCT02787031|practice variation
859412|NCT02787031|anesthesia
859413|NCT02787018|Brachial plexus block
859414|NCT02787018|Ropivacaine
859415|NCT02787018|Dexmedetomidine
859416|NCT02787018|Dexamethasone
859417|NCT02787018|Adjuvants, anesthesia
859418|NCT02787005|PD1
859419|NCT02787005|PD-1
859420|NCT02787005|PDL1
859421|NCT02787005|PD-L1
859422|NCT02786992|Misoprostol
859423|NCT02786992|Oxytocin
859424|NCT02786992|Carbetocin
859425|NCT02786992|Prevention
859426|NCT02786992|Post-partum hemorrhage
859427|NCT02786979|Type 2 Diabetes Mellitus
859428|NCT02786979|Arteriosclerosis
859429|NCT02786979|beraprost
859430|NCT02786979|Aspirin
859431|NCT02786966|Cervical spine injuries
859432|NCT02786966|Canadian C-spine Rule
859433|NCT02786966|Emergency Medical Services
859434|NCT02786966|Paramedic
859435|NCT02786966|Cervical spine fracture
859436|NCT02786953|Sleep
859437|NCT02786953|Adherence
859438|NCT02786953|Diabetes Management
859439|NCT02786953|Adolescent
859440|NCT02786940|remote
859441|NCT02786940|cardiac monitoring
859442|NCT02786940|mortality
859443|NCT02786927|HANDIHALER
859444|NCT02786927|Dry Powder Inhaler
859445|NCT02786927|COPD
859446|NCT02786927|ELLIPTA
859447|NCT02786927|Inhaler preference attributes
859448|NCT02786875|lifestyle
859449|NCT02786875|low glycemic index diet
859450|NCT02786875|exercise
859451|NCT02786875|vitamin D
859452|NCT02786875|breast cancer
859453|NCT02786875|Mediterranean diet
859454|NCT02786862|mechanical ventilation
859455|NCT02786862|independent ventilation
859456|NCT02786862|ventilation/perfusion mismatch
859457|NCT02786862|thoracic anesthesia
859458|NCT02786849|Electric Stimulation
859459|NCT02786849|Electric Stimulation Therapy
859460|NCT02786836|acute liver failure
859461|NCT02786836|methacetin
859462|NCT02786836|breath test
859463|NCT02786836|severe acute liver injury
859464|NCT02786836|hepatic encephalopathy
859465|NCT02786836|ALFSG Registry
859466|NCT02786836|acetaminophen toxicity
859467|NCT02786797|breast cancer
859468|NCT02786797|mindfulness-based stress reduction
859469|NCT02786797|cognitive impairment
859470|NCT02786771|Stress Management
859471|NCT02786771|Mindfulness
859472|NCT02786771|Meditation
859473|NCT02786771|Stress Resilience
859474|NCT02786732|Psoriasis
859475|NCT02786719|Sargramostim
859476|NCT02786719|Cyclophosphamide
859477|NCT02786719|Topotecan
859478|NCT02786719|Cisplatin
859479|NCT02786719|Dexrazoxane
859480|NCT02786719|Doxorubicin
859481|NCT02786719|Etoposide
859482|NCT02786719|Filgrastim
859483|NCT02786719|Vincristine
859484|NCT02786719|Mesna
859485|NCT02786706|Traumatic Brain Injury
859486|NCT02786706|Intracranial Pressure
859487|NCT02786706|Ultrasonography
859488|NCT02786706|Computer-Assisted Image Analysis
859489|NCT02786706|Intracranial Hypertension
859490|NCT02786706|Acute brain injuries
859491|NCT02786693|TEP-scan
859492|NCT02786654|Acute myocardial infarction
859493|NCT02786654|mortality
859494|NCT02786654|evidence-based care
859495|NCT02786654|Myocardial Ischaemia National Audit Project
859496|NCT02786654|β blockers
859497|NCT02786641|nasopharyngeal carcinoma
859498|NCT02786641|induction chemotherapy
859499|NCT02786641|concurrent chemotherapy
859500|NCT02786641|docetaxel
859501|NCT02786641|cisplatin
859502|NCT02786641|xeloda
859503|NCT02786641|nomogram
859504|NCT02786615|men who have sex with men (MSM)
859505|NCT02786589|Lung cancer Immunotherapy
859506|NCT02786589|Plasmodium vivax
859507|NCT02786589|Immunotherapy
859508|NCT02786576|Moderate to Severe Hidradenitis Suppurativa
859509|NCT02786576|Adalimumab
859510|NCT02786563|ultrasonographic (US)
859511|NCT02786563|rheumatoid arthritis (RA)
859512|NCT02786563|C-reactive protein (CRP)
859513|NCT02786563|power doppler (PD)
859514|NCT02786563|disease activity scale (DAS)
859515|NCT02786550|Lower blepharoplasty, Botulinum toxin, Scar
859516|NCT02786537|Hepatitis C
859517|NCT02786524|Palliative Care
859518|NCT02786524|Triage
859519|NCT02786524|Symptom Evaluation
859520|NCT02786524|Chemotherapy
859521|NCT02786524|Patient Distress
859522|NCT02786498|Tibial Shaft
859523|NCT02786498|Tibia
859524|NCT02786498|Femoral Shaft
859525|NCT02786498|Femur
859526|NCT02786498|Vitamin D
859527|NCT02786498|Fracture Healing
859528|NCT02786485|BPX-501
859529|NCT02786485|Rimiducid
859530|NCT02786485|AP1903
859531|NCT02786485|Hematological malignancies
859532|NCT02786485|Hematologic diseases
859533|NCT02786485|Leukemias and Myelodysplastic Syndromes
859534|NCT02786485|Lymphomas
859535|NCT02786485|Multiple myeloma
859536|NCT02786472|Bystander behaviors
859537|NCT02786472|Incoming students
859538|NCT02786472|CampusSave
859539|NCT02786472|Prevention
859540|NCT02786472|Sexual Assault
859541|NCT02786472|Incapacitation
859542|NCT02786459|Prostate
859543|NCT02786459|Local Recurrence
859544|NCT02786459|Radical Prostatectomy
859545|NCT02786446|Lidocaine gel
859546|NCT02786446|Extracorporeal shockwave lithotripsy
859547|NCT02786446|Naproxen sodium
859548|NCT02786446|Pain score
859549|NCT02786420|pregnancy
859550|NCT02786420|magnetic resonance imaging
859551|NCT02786420|environmental air pollutants
859552|NCT02786407|overactive bladder
859553|NCT02786407|Botulinum Toxin Type A for Injection
859554|NCT02786368|Food Production
859555|NCT02786368|Inadequacy
859556|NCT02786368|Dietary zinc
859557|NCT02786368|Iron
859558|NCT02786368|vitamin A
859559|NCT02786342|Hepatocellular Carcinoma
859560|NCT02786342|Sorafenib
859561|NCT02786342|HCC
859562|NCT02786342|Angiogenesis
859563|NCT02786342|Polymorphisms
859564|NCT02786329|colorectal cancer
859565|NCT02786329|TIVA
859566|NCT02786329|sevoflurane
859567|NCT02786329|lidocaine
859568|NCT02786264|transcatheter aortic valve replacement
859569|NCT02786264|anesthesia
859570|NCT02786264|conscious sedation
859571|NCT02786264|managed anesthesia care
859572|NCT02786199|Hepatocellular Carcinoma(HCC)
859573|NCT02786199|Ultrasound
859574|NCT02786199|Backscatter
859575|NCT02786199|Differentiation grade
859576|NCT02786199|Survival
859577|NCT02786186|Psoriasis
859578|NCT02786186|Plaque Psoriasis
859579|NCT02786186|Chronic Plaque Psoriasis
859580|NCT02786186|Cosentyx
859581|NCT02786186|Secukinumab
859582|NCT02786186|Moderate to severe plaque psoriasis
859583|NCT02786186|PURE registry
859584|NCT02786186|Registry
859585|NCT02786173|PRIME
859586|NCT02786173|PAD
859587|NCT02786173|PVD
859588|NCT02786173|Observational
859589|NCT02786173|CLI
859590|NCT02786173|PRIME Registry
859591|NCT02786147|Breast Cancer
859592|NCT02786147|Ovarian Cancer
859593|NCT02786147|B-RST
859594|NCT02786121|hip replacement,
859595|NCT02786121|rehabilitation,
859596|NCT02786121|early ambulation,
859597|NCT02786108|left gastric artery
859598|NCT02786108|embolization
859599|NCT02786108|obesity
859600|NCT02786095|Atrial fibrillation
859601|NCT02786095|anti arrhythmic drug
859602|NCT02786095|NOAC
859603|NCT02786095|warfarin
859604|NCT02786095|coumadin
859605|NCT02786056|Respiratory Function Tests
859606|NCT02786056|Lung
859607|NCT02785965|electroacupuncture
859608|NCT02785965|lifestyle modification
859609|NCT02785965|diet
859610|NCT02785965|exercise
859611|NCT02785965|Dai Meridian
859612|NCT02785926|pesticide exposure
859613|NCT02785926|respiratory control
859614|NCT02785926|sleep
859615|NCT02785900|Antibodies, monoclonal
859616|NCT02785900|Antibody drug conjugate
859617|NCT02785900|Antigens, cluster of differentiation 33 (CD33)
859618|NCT02785900|Drug therapy
859619|NCT02785900|Immunotherapy
859620|NCT02785887|Breast cancer
859621|NCT02785887|lung cancer
859622|NCT02785887|Gastrointestinal Cancer
859623|NCT02785887|Ovarian cancer
859624|NCT02785887|Prostate cancer
859625|NCT02785887|bladder cancer
859626|NCT02785861|hormonal therapy
859627|NCT02785861|walking
859628|NCT02785861|fatigue
859629|NCT02785822|Reproductive Techniques, Assisted
859630|NCT02785809|Oral contraceptives
859631|NCT02785809|long-term use
859632|NCT02785809|AMH
859633|NCT02785809|Ovarian reserve parameters
859634|NCT02785783|EndoRings™
859635|NCT02785757|adenocarcinoma
859636|NCT02785757|venous thromboembolism
859637|NCT02785757|thrombin generation assay
859638|NCT02785731|pelvic mass
859639|NCT02785731|ovarian cancer
859640|NCT02785731|gynecological cancer
859641|NCT02785731|risk prediction
859642|NCT02785718|Contact system
859643|NCT02785718|Factor XI deficiency
859644|NCT02785718|Factor XII deficiency
859645|NCT02785718|Global haemostasis assays
859646|NCT02785705|immunization
859647|NCT02785705|vaccine schedule
859648|NCT02785705|poliomyelitis
859649|NCT02785705|polio
859650|NCT02785705|oral polio vaccine
859651|NCT02785705|inactivated polio vaccine
859652|NCT02785692|soft tissue sarcoma
859653|NCT02785692|IMRT and sarcoma
859654|NCT02785692|preoperative highly conformal radiation therapy
859655|NCT02785692|soft tissue sarcoma and wound healing
859656|NCT02785692|postoperative complications
859657|NCT02785692|treatment tolerance of soft tissue IMRT
859658|NCT02785679|Allergy
859659|NCT02785679|Cow's milk
859660|NCT02785679|breast feeding
859661|NCT02785679|Cow's milk formula
859662|NCT02785679|prevention
859663|NCT02785666|Men who have sex with men
859664|NCT02785666|Elimination
859665|NCT02785653|sevoflurane
859666|NCT02785653|rocuronium
859667|NCT02785653|intubation
859668|NCT02785627|Bone health
859669|NCT02785627|Bone microarchitecture
859670|NCT02785627|Androgen deprivation therapy (ADT)
859671|NCT02785588|MR Scanner
859672|NCT02785588|NICU
859673|NCT02785562|PDL1 expression : Protein Death Ligand 1 expression .
859674|NCT02785549|Acute diverticulitis
859675|NCT02785549|Antibiotic
859676|NCT02785549|Outpatient treatment
859677|NCT02785536|minority health
859678|NCT02785536|social class
859679|NCT02785536|healthcare disparities
859680|NCT02785536|tobacco use disorder
859681|NCT02785497|Electrical stimulation
859682|NCT02785497|wound healing
859683|NCT02785497|Polarity current
859684|NCT02785497|Burn
859685|NCT02785497|Chronic ulcer
859686|NCT02785484|Cigarette smoking
859687|NCT02785484|Smoking
859688|NCT02785484|Tobacco use
859689|NCT02785471|Suicide prevention
859690|NCT02785471|men's mental health
859691|NCT02785471|depression
859692|NCT02785471|suicide ideation and behaviors
859693|NCT02785419|Rehabilitation
859694|NCT02785419|Upper Extremity
859695|NCT02785419|Physical Therapy
859696|NCT02785406|cocaine
859697|NCT02785406|sleep
859698|NCT02785406|anxiety
859699|NCT02785406|craving
859700|NCT02785406|addiction
859701|NCT02785406|orexin
859702|NCT02785406|cue reactivity
859703|NCT02785406|suvorexant
859704|NCT02785406|Belsomra
859705|NCT02785393|Methamphetamine
859706|NCT02785393|Dependence
859707|NCT02785341|adapted physical activity
859708|NCT02785328|Memory
859709|NCT02785328|sleep
859710|NCT02785328|narcolepsy
859711|NCT02785328|apnea
859712|NCT02785328|epilepsy
859713|NCT02785302|Pediatric
859714|NCT02785302|HIV
859715|NCT02785302|Transition
859716|NCT02785302|Adult Care
859717|NCT02785263|Anal cancer
859718|NCT02785263|Shared decision making
859719|NCT02785250|vaccine
859720|NCT02785250|immunotherapy
859721|NCT02785250|IDO1 inhibitor
859722|NCT02785250|ovarian
859723|NCT02785250|fallopian tube
859724|NCT02785250|peritoneal
859725|NCT02785250|cancer
859726|NCT02785250|recurrent
859727|NCT02785250|tumor
859728|NCT02785250|measurable
859729|NCT02785237|Drug-eluting stent
859730|NCT02785237|OCT
859731|NCT02785237|Re-endothelialization
859732|NCT02785146|Huaier Granule
859733|NCT02785146|After radical surgery
859734|NCT02785146|Prevention of recurrence and metastasis
859735|NCT02785146|Efficacy and safety
859736|NCT02785120|Phase 2
859737|NCT02785120|Efficacy
859738|NCT02785120|Safety
859739|NCT02785120|Ischemic Stroke
859740|NCT02785107|Exercise
859741|NCT02785107|Habit
859742|NCT02785107|MVPA
859743|NCT02785107|M-PAC
859744|NCT02785107|Automaticity
859745|NCT02785107|Physical Activity
859746|NCT02785094|Caesarean Section Rate
859747|NCT02785094|Primigravida
859748|NCT02785081|Thoracic epidural
859749|NCT02785081|Magnetic Resonance Imaging
859750|NCT02785081|Children
859751|NCT02785068|Phase I
859752|NCT02785068|Cancer
859753|NCT02785068|EGFR
859754|NCT02785068|Metastatic Colorectal Cancer
859755|NCT02785068|Oncology
859756|NCT02785068|RAS/RAF Wild-Type
859757|NCT02785068|Nal-IRI
859758|NCT02785068|EGFR Inhibitor
859759|NCT02785068|Oligoclonal Antibody
859760|NCT02785068|Nanoliposome
859761|NCT02785068|Nanoliposomal Irinotecan
859889|NCT02784262|Botulinum Toxin Type A
859762|NCT02785016|Stress Urinary Incontinence
859763|NCT02785016|Suburethral Sling
859764|NCT02785003|Colorectal Surgery
859765|NCT02785003|Acute Pain
859766|NCT02785003|Pain
859767|NCT02785003|post-operative pain
859768|NCT02785003|ketamine
859769|NCT02784938|Employment
859770|NCT02784938|Mental Illness
859771|NCT02784938|Photovoice
859772|NCT02784912|Biomarkers
859773|NCT02784912|Ventricular Dysfunction
859774|NCT02784912|Ventricular Tachycardia
859775|NCT02784912|Electrical Storm
859776|NCT02784912|ST2
859777|NCT02784912|Galectin-3
859778|NCT02784912|NT-proBNP
859779|NCT02784912|Iron Deficiency
859780|NCT02784912|hs-CRP
859781|NCT02784912|hs-TnT
859782|NCT02784886|Placenta accreta
859783|NCT02784886|previous caesarean
859784|NCT02784886|placenta praevia
859785|NCT02784886|Cell-free fetal DNA
859786|NCT02784886|Biological markers
859787|NCT02784873|High intensity interval training
859788|NCT02784873|Coronary heart disease
859789|NCT02784873|Exercise training
859790|NCT02784873|Cardiac rehabilitation
859791|NCT02784873|Interval training
859792|NCT02784860|colonoscopy
859793|NCT02784860|lidocaine
859794|NCT02784860|propofol
859795|NCT02784860|sedation
859796|NCT02784834|CLL
859797|NCT02784834|cancer
859798|NCT02784834|DMF
859799|NCT02784834|SLL
859800|NCT02784834|dimethylfumarate
859801|NCT02784834|relapsed
859802|NCT02784834|refractory
859803|NCT02784795|Notch Inhibitor
859804|NCT02784782|Spinal
859805|NCT02784782|Vertebral
859806|NCT02784782|Burstfracture
859807|NCT02784782|Orthesis
859808|NCT02784782|Brace
859809|NCT02784782|Thoracolumbar
859810|NCT02784756|Quantiferon-CMV
859811|NCT02784756|solid organ transplant
859812|NCT02784756|CMV Disease
859813|NCT02784743|Wuchereria bancrofti
859814|NCT02784743|Anopheles
859815|NCT02784743|Albendazole
859816|NCT02784743|Ivermectin
859817|NCT02784743|MDA
859818|NCT02784730|breast cancer
859819|NCT02784730|chemotherapy
859820|NCT02784730|peripherally inserted central catheter
859821|NCT02784730|implantable device
859822|NCT02784730|randomized controlled trial
859823|NCT02784730|iterative placement
859824|NCT02784730|Catheterization, Central Venous
859825|NCT02784717|rivaroxaban,
859826|NCT02784717|non-interventional,
859827|NCT02784717|atrial fibrillation,
859828|NCT02784717|stroke prevention,
859829|NCT02784665|CSC
859830|NCT02784665|Micropulse Laser
859831|NCT02784665|Traditional Laser
859832|NCT02784639|KRAS/BRAF mutational status
859833|NCT02784626|Dexmedetomidine
859834|NCT02784626|Propofol
859835|NCT02784626|Pain, Postoperative
859836|NCT02784600|Partial-thickness
859837|NCT02784600|Full-thickness
859840|NCT02784574|Rehabilitation
859841|NCT02784574|Aftercare
859842|NCT02784561|allogeneic peripheral blood stem cell transplantation
859843|NCT02784561|conditioning regimen
859844|NCT02784561|acute leukemia
859845|NCT02784561|relapsed/refractory
859846|NCT02784509|Physical Activity
859847|NCT02784509|Sedentary Behavior
859848|NCT02784509|Cardiometabolic Risk Factors
859849|NCT02784509|Childhood and Adolescence
859850|NCT02784496|Myelofibrosis
859851|NCT02784496|Primary Myelofibrosis
859852|NCT02784496|PMF
859853|NCT02784496|Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
859854|NCT02784496|Post-PV/ET MF
859855|NCT02784496|Ruxolitinib
859856|NCT02784496|Jakafi
859857|NCT02784496|INCB018424
859858|NCT02784496|INC424
859859|NCT02784496|Questionnaires
859860|NCT02784496|Surveys
859862|NCT02784405|percutaneous coronary intervention
859863|NCT02784405|stent implantation
859864|NCT02784379|Mastalgia
859865|NCT02784379|electromyography
859866|NCT02784379|Pectoral
859867|NCT02784366|Cancer immunotherapy
859868|NCT02784366|Ipilimumab
859869|NCT02784353|Rehabilitation
859870|NCT02784353|Quality of life
859871|NCT02784353|Surgery
859872|NCT02784353|Hepatic neoplasms
859873|NCT02784353|Biliary tract neoplasms
859874|NCT02784353|Pancreatic neoplasms
859875|NCT02784340|Postoperative pain
859876|NCT02784340|dexamethasone
859877|NCT02784340|cesarean section
859878|NCT02784314|Clinically localized prostate cancer
859879|NCT02784314|Robotic-assisted prostatectomy
859880|NCT02784314|Laparoscopic prostatectomy
859881|NCT02784314|Erectile function ;
859882|NCT02784314|Cost efficacy study
859883|NCT02784288|head and neck neoplasms
859884|NCT02784288|HPV
859885|NCT02784288|human papilloma virus
859886|NCT02784288|de-escalation
859887|NCT02784288|low-risk
859888|NCT02784288|oropharyngeal cancer
859890|NCT02784262|Block
859891|NCT02784262|Sphenopalatine Ganglion
859892|NCT02784249|Glaucoma
859893|NCT02784249|glaucoma surgery
859894|NCT02784249|ab interno
859895|NCT02784223|F18-choline
859896|NCT02784223|Surgery
859897|NCT02784223|Indeterminate
859898|NCT02784223|Thyroid node
859899|NCT02784210|Multiple Sclerosis
859900|NCT02784210|Corticosteroids
859901|NCT02784184|Hypothalamic-pituitary-gonadal axis
859902|NCT02784158|Non-small cell lung cancer
859903|NCT02784158|Non-small cell lung carcinoma
859904|NCT02784158|Epithelial lung cancer
859905|NCT02784158|Squamous cell carcinoma
859906|NCT02784158|Large cell carcinoma
859907|NCT02784158|Adenocarcinoma
859908|NCT02784158|Anaplastic lymphoma kinase (ALK)
859909|NCT02784158|Carcinoma
859910|NCT02784158|Advanced Cancers
859911|NCT02784158|Brigatinib
859912|NCT02784158|AP26113
859913|NCT02784119|temporary porto-caval shunt
859914|NCT02784119|liver graft
859915|NCT02784119|extended criteria donor
859916|NCT02784106|Rheumatoid Arthritis
859917|NCT02784106|M2951
859918|NCT02784106|Bruton's Tyrosine Kinase (BTK)
859919|NCT02784093|Chronic Constipation
859920|NCT02784093|Fecal impaction
859921|NCT02784093|Gastrografin
859922|NCT02784093|Randomized Controlled Trial
859923|NCT02784080|Liver Transplantation
859924|NCT02784080|HLA alloantibodies
859925|NCT02784080|donor specific antibodies
859926|NCT02784080|Mortality
859927|NCT02784080|Re-transplantation
859928|NCT02784080|Rejection
859929|NCT02784080|Acute rejection
859930|NCT02784080|Chronic rejection
859931|NCT02784080|Biliary complications
859932|NCT02784080|Biliary stricture
859933|NCT02784080|Arterial thrombosis
859934|NCT02784080|Arterial stenosis
859935|NCT02784080|Portal vein thrombosis
859936|NCT02784080|Fibrosis
859937|NCT02784080|Single antigen bead
859938|NCT02784080|Cross-match
859939|NCT02784041|knee arthroplasty
859940|NCT02784041|adductor canal block
859941|NCT02784041|periarticular infiltration
859942|NCT02784028|Peritoneal Carcinomatosis
859943|NCT02784028|SGM-101
859944|NCT02783989|Endothelial function
859945|NCT02783989|Inflammation
859946|NCT02783989|Genes related to vascular risk
859947|NCT02783963|Coronary Artery Disease
859948|NCT02783963|Coronary Thrombosis
859949|NCT02783963|Coronary Stenosis
859950|NCT02783963|Tomography, Optical Coherence
859951|NCT02783963|Magnetic Resonance Imaging
859952|NCT02783950|Genomics
859953|NCT02783950|Adjuvant Treatment
859954|NCT02783937|Premature
859955|NCT02783937|Ovarian
859956|NCT02783937|Failure
859957|NCT02783937|Filgrastim
859958|NCT02783924|vitamin D
859959|NCT02783924|genomics
859960|NCT02783924|proteomics
859961|NCT02783924|metabolomics
859962|NCT02783924|adipose tissue
859963|NCT02783911|Clinical and Radiograph
859964|NCT02783898|pre syncope, palpitations
859965|NCT02783859|Children
859966|NCT02783859|Anti-Bacterial Agents
859967|NCT02783859|Indigenous Population
859968|NCT02783859|Hospitals
859969|NCT02783846|Propofol
859970|NCT02783846|Dexmedetomidine
859971|NCT02783846|Dose
859972|NCT02783846|Bispectral index monitor
859973|NCT02783833|malaria, induced blood stage model challenge
859974|NCT02783820|malaria, single ascending dose,
859975|NCT02783794|BP-C1
859976|NCT02783794|CDBPA
859977|NCT02783794|Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
859978|NCT02783794|Benzene polycarboxylic acids complex with cis-diammineplatinum(II)
859979|NCT02783794|Metastatic Breast Cancer
859980|NCT02783794|Platinum analogue
859981|NCT02783794|Metronomic chemotherapy
859982|NCT02783794|Breast cancer
859983|NCT02783794|Cisplatin
859984|NCT02783781|Cardiac surgery (extracorporeal circulation; beating heart)
859985|NCT02783781|Biological data
859986|NCT02783781|Preoperative biological variables
859987|NCT02783781|EuroSCORE II
859988|NCT02783781|Risk prediction
859989|NCT02783768|E-cigarettes
859990|NCT02783768|COPD
859995|NCT02783742|provider-patient communication
859996|NCT02783742|coaching
859997|NCT02783742|feedback
859998|NCT02783742|burnout
859999|NCT02783729|E2006
860000|NCT02783729|Lemborexant
860001|NCT02783729|zolpidem tartrate
860002|NCT02783729|Ambien CR
860003|NCT02783729|Insomnia
860004|NCT02783703|Insulin resistance
860005|NCT02783664|Breast Cancer
860006|NCT02783664|BRCA1
860007|NCT02783664|BRCA2
860008|NCT02783664|stress
860009|NCT02783664|gene testing
860010|NCT02783664|genetic screening
860011|NCT02783664|psychological support
860012|NCT02783664|State-Trait Anxiety Inventory
860013|NCT02783664|Cancer Worry Scale
860014|NCT02783664|Health Anxiety Inventory
860015|NCT02783664|gene mutations
860016|NCT02783625|Duvelisib
860017|NCT02783625|Romidepsin
860018|NCT02783625|Bortezomib
860019|NCT02783625|16-042
860030|NCT02783560|Sleep
860031|NCT02783560|Electrodermal Activity
860032|NCT02783560|Mealtimes
860033|NCT02783534|Acupuncture
860034|NCT02783534|Primary Dysmenorrhea
860035|NCT02783534|Randomized Controlled Trial
860036|NCT02783534|Placebo Effect
860037|NCT02783521|Hispanic men
860038|NCT02783521|Weight loss
860039|NCT02783521|Diet
860040|NCT02783521|Physical activity
860041|NCT02783521|Intervention
860042|NCT02783508|Labor analgesia
860043|NCT02783508|Nitrous Oxide
860044|NCT02783508|Meperidine
860045|NCT02783508|Multiparous
860046|NCT02783508|Visual analogue scale
860050|NCT02783456|renal hemodynamic
860051|NCT02783456|central hemodynamic
860052|NCT02783456|pilot study
860053|NCT02783456|flight noise
860054|NCT02783456|healthy participant
860055|NCT02783456|renal plasma flow
860056|NCT02783456|filtration fraction
860057|NCT02783456|renal vascular resistance
860058|NCT02783456|calculated intra glomerular pressure
860059|NCT02783443|Anesthesia, glycocalyx, perfused boundary region
860060|NCT02783430|Ketamine
860061|NCT02783430|Palliative care
860062|NCT02783430|Supportive care
860063|NCT02783430|Early palliative care
860064|NCT02783430|Fast acting antidepressant
860065|NCT02783430|End of life care
860066|NCT02783430|Cancer
860067|NCT02783430|psychological distress
860068|NCT02783430|antidepressant
860069|NCT02783430|serotonin norepinephrine reuptake inhibitors
860070|NCT02783417|Visceral fat
860071|NCT02783404|bacteraemia
860072|NCT02783404|endocarditis
860073|NCT02783404|antibiotic prophylaxis
860074|NCT02783404|dentistry
860075|NCT02783378|impedance metry
860076|NCT02783378|gaviscon
860077|NCT02783339|Next Generation Neuroform Stent System
860078|NCT02783339|Intracranial
860079|NCT02783339|Stent system
860080|NCT02783339|Saccular aneurysm
860081|NCT02783339|Stent assisted coiling
860082|NCT02783326|Chronic Disease Obstructive Pulmonary
860083|NCT02783326|Rehabilitation
860084|NCT02783326|Physical Therapy
860085|NCT02783313|pathogen inactivation
860086|NCT02783313|platelets
860087|NCT02783300|GSK3326595
860088|NCT02783300|glioblastoma multiforme (GBM)
860089|NCT02783300|Solid tumor
860090|NCT02783300|Non-Hodgkin's lymphoma (NHL)
860091|NCT02783300|breast cancer
860092|NCT02783300|bladder cancer
860093|NCT02783300|dose escalation
860094|NCT02783287|Exercise adherence
860095|NCT02783287|Medication adherence
860096|NCT02783287|Mobile health
860097|NCT02783287|Cardiac rehabilitation
860098|NCT02783261|radioembolization
860099|NCT02783261|hypertrophy
860100|NCT02783261|Y90
860101|NCT02783248|Percutaneous mitral commissurotomy
860102|NCT02783248|Mitral Stenosis
860103|NCT02783235|VIA
860104|NCT02783235|Cervical Cancer
860105|NCT02783235|Training
860106|NCT02783222|breast cancer
860107|NCT02783222|elderly patients
860108|NCT02783170|Tdap vaccine
860109|NCT02783170|Flu vaccine
860110|NCT02783170|vaccines in pregnancy
860111|NCT02783170|immunizations in pregnancy
860112|NCT02783170|Whooping Cough
860113|NCT02783170|Pertussis
860114|NCT02783170|Influenza
860115|NCT02783157|Autonomic
860116|NCT02783157|Vagal nerve stimulation
860117|NCT02783157|Postoperative atrial fibrillation
860118|NCT02783144|Analgesia
860119|NCT02783144|Dexamethasone
860120|NCT02783144|Levobupivacaine
860121|NCT02783144|Ultrasound-guided
860122|NCT02783144|Tranversus Abdominis
860123|NCT02783131|inventions
860124|NCT02783131|Simulation Training
860125|NCT02783131|Postpartum Haemorrhage
860126|NCT02783131|Non Technical Skills
860127|NCT02783131|teamwork
860128|NCT02783131|Crew Resource Management, Healthcare
860129|NCT02783118|Depression
860130|NCT02783118|Prevention
860131|NCT02783118|CBT
860132|NCT02783118|Smartphone app
860133|NCT02783105|Music therapy
860134|NCT02783105|Paroxysmal sympathetic hyperactivity
860135|NCT02783105|Traumatic brain injury
860136|NCT02783079|Breast Cancer
860137|NCT02783079|Prostate Cancer
860138|NCT02783079|Colon Cancer
860139|NCT02783079|Lung Cancer
860140|NCT02783079|Gynecologic Cancer
860141|NCT02783014|overactive bladder
860142|NCT02782988|Olfaction
860143|NCT02782988|CMV
860144|NCT02782962|nystagmus
860145|NCT02782962|vertigo
860146|NCT02782962|unsteadiness
860147|NCT02782962|emergency duplex ultrasonography
860148|NCT02782936|Work of Breathing; Hypoxemia; Respiratory Acidosis; Respiratory effort
860149|NCT02782923|Cervical Spine Surgery
860150|NCT02782923|Simulation
860151|NCT02782897|intravenous immunoglobulin
860152|NCT02782897|intracerebral hemorrhage
860153|NCT02782897|perihematomal edema
860154|NCT02782884|post-operative pain
860155|NCT02782871|Transfer
860156|NCT02782871|Intra-hospital
860157|NCT02782871|Ventilator
860158|NCT02782871|Manual ventilation
860159|NCT02782871|Head and neck surgery
860160|NCT02782858|Multiple Sclerosis
860161|NCT02782858|Multiple Sclerosis Relapsing-Remitting
860162|NCT02782858|GNbAC1
860163|NCT02782858|MRI
860164|NCT02782858|Monoclonal antibody
860165|NCT02782858|Multiple Sclerosis associated retrovirus MSRV
860166|NCT02782858|MS
860167|NCT02782858|RRMS
860168|NCT02782858|HERV-W
860169|NCT02782832|Neuromuscular
860170|NCT02782832|Blockade
860171|NCT02782832|Surgery
860172|NCT02782819|Shock resuscitation
860173|NCT02782819|colloid
860174|NCT02782819|crystalloid
860179|NCT02782793|Endoscopic
860180|NCT02782793|Mucosal
860181|NCT02782793|Resection
860182|NCT02782780|insomnia
860183|NCT02782780|insomnia disorder
860184|NCT02782780|Gulf War Illness
860185|NCT02782780|Chronic Multisymptom Illness
860186|NCT02782728|intimate partner violence
860187|NCT02782728|reproductive coercion
860188|NCT02782728|women's health
860189|NCT02782728|relationship abuse
860190|NCT02782702|Botulism Toxin
860191|NCT02782663|Crohn's Disease
860192|NCT02782663|Tolerability
860193|NCT02782663|ABT-494
860194|NCT02782663|Efficacy
860195|NCT02782663|Safety
860196|NCT02782650|Limits
860197|NCT02782650|Prenatal Counseling
860198|NCT02782650|Decision-making
860199|NCT02782650|Foetal Complications
860200|NCT02782650|Counseling
860201|NCT02782650|Viability
860202|NCT02782637|limits of viability
860203|NCT02782637|Prenatal Counseling
860204|NCT02782637|Decision-making
860205|NCT02782637|Viability
860206|NCT02782637|Counseling
860207|NCT02782611|Happiness
860208|NCT02782611|Subjective Well-Being
860209|NCT02782611|Psychological Flourishing
860210|NCT02782611|Well-Being
860211|NCT02782611|Health
860212|NCT02782611|Behavioral Change
860213|NCT02782611|Life Satisfaction
860214|NCT02782611|Affect
860215|NCT02782611|Emotion
860216|NCT02782611|Goals
860217|NCT02782611|Meaning in Life
860218|NCT02782598|Negative
860219|NCT02782598|Atrioventricular
860220|NCT02782598|Hysteresis
860221|NCT02782598|Cardiac Resynchronization
860222|NCT02782598|MultiPoint
860223|NCT02782585|neck pain
860224|NCT02782585|Manual therapy
860225|NCT02782585|psychological interaction
860226|NCT02782572|Exercise
860227|NCT02782572|Cardiac Rehabilitation
860228|NCT02782572|Non-invasive ventilation
860229|NCT02782520|Cardiopulmonary bypass
860230|NCT02782520|Swan Ganz
860231|NCT02782520|Fluid expansion
860232|NCT02782520|hypertonic saline solution
860233|NCT02782507|pilot study
860234|NCT02782507|CBT trial
860235|NCT02782494|Latent tuberculosis infection, dialysis
860236|NCT02782468|Drug Therapy
860237|NCT02782429|ketamine
860238|NCT02782429|Cardiac Surgery
860239|NCT02782429|Neurocognitive Disorders
860240|NCT02782416|Renal
860241|NCT02782416|Latent
860242|NCT02782416|Tuberculosis
860243|NCT02782403|Leukemia
860244|NCT02782403|Chronic Myeloid Leukemia
860245|NCT02782403|CML
860246|NCT02782403|Chronic Myeloid Leukemia, Chronic Phase
860247|NCT02782403|CML-CP
860248|NCT02782403|Chronic Myeloid Leukemia in Accelerated Phase
860249|NCT02782403|CML-AP
860250|NCT02782403|Chronic Myeloid Leukemia in Blast Phase
860251|NCT02782403|CML-BP
860252|NCT02782403|Axitinib
860253|NCT02782403|AG-013736
860254|NCT02782403|Inlyta
860255|NCT02782403|Bosutinib
860256|NCT02782403|SKI-606
860257|NCT02782390|Stainless dental crown
860258|NCT02782390|Composite Resin
860259|NCT02782390|Primary teeth
860260|NCT02782377|Faecal Incontinence
860261|NCT02782377|Obstructive Defaecation
860262|NCT02782377|Rectal Prolapse
860263|NCT02782364|Faecal Incontinence
860264|NCT02782338|warfarin
860265|NCT02782338|Voltaren eye drops
860266|NCT02782338|INR
860267|NCT02782312|Bronchiectasis
860268|NCT02782312|ICS+LABA
860269|NCT02782299|Decision aid
860270|NCT02782299|Shared decision making
860271|NCT02782299|Older adult patients
860272|NCT02782299|Distal radius fracture
860273|NCT02782286|ketorolac
860274|NCT02782286|pain relieve
860275|NCT02782286|morphine
860276|NCT02782273|ketorolac
860277|NCT02782273|pain relieve
860278|NCT02782273|morphine
860279|NCT02782221|lipolysis
860280|NCT02782221|ATGL
860281|NCT02782182|Pancreatic ductal adenocarcinoma
860282|NCT02782182|FOLFIRINOX
860283|NCT02782182|resectable pancreatic cancer
860284|NCT02782156|Process Evaluation
860285|NCT02782156|alcohol withdrawal syndrome
860286|NCT02782143|delirium detection
860287|NCT02782130|HIV
860288|NCT02782130|YMSM
860289|NCT02782130|Trans women
860290|NCT02782130|ART Adherence
860291|NCT02782130|Intervention
860292|NCT02782104|Depressive Disorder, Treatment-Resistant
860293|NCT02782104|Esketamine
860294|NCT02782104|JNJ-54135419
860295|NCT02782091|MET
860296|NCT02782091|Prognosis
860297|NCT02782091|Cognition
860298|NCT02782091|Ecological
860299|NCT02782091|Executive function
860300|NCT02782078|osteoarticular infection
860301|NCT02782078|rifampicin
860302|NCT02782078|clindamycin
860303|NCT02782078|enzymatic induction
860304|NCT02782078|antibiotherapy resistance
860305|NCT02782065|validation
860306|NCT02782065|pediatrics
860307|NCT02782065|asthma severity
860308|NCT02782052|pulmonary arterial hypertension
860309|NCT02782052|spirometry
860310|NCT02782052|dynamic lung hyperinflation
860311|NCT02782052|bronchodilator
860312|NCT02782052|dyspnoea
860313|NCT02782052|Idiopathic
860314|NCT02782052|heritable
860315|NCT02782052|PAH
860316|NCT02782026|pulmonary hypertension
860317|NCT02782026|early detection
860318|NCT02782013|community acquired pneumonia
860319|NCT02782013|CAP
860320|NCT02782013|disease progression
860321|NCT02782000|dementia,early recognition
860322|NCT02782000|early recognition
860323|NCT02782000|general practitioner
860324|NCT02782000|training
860325|NCT02781935|unresectable colorectal liver metastasis
860326|NCT02781935|diffusion weighted MRI
860327|NCT02781935|disappearing liver metastasis
860328|NCT02781922|cardiac stem/progenitor cells
860329|NCT02781922|autologous cell therapy
860330|NCT02781922|functional single ventricle
860331|NCT02781922|congenital heart disease
860332|NCT02781909|NSAIDS
860333|NCT02781909|tuberculosis treatment
860334|NCT02781909|anti-inflammatories
860335|NCT02781909|Host-directed therapies
860336|NCT02781909|TB
860337|NCT02781896|TAVI
860338|NCT02781896|aortic valve bioprothesis
860339|NCT02781896|TAVI simplification
860340|NCT02781896|aortic stenosis
860341|NCT02781896|rapid left ventricular pacing
860342|NCT02781896|TAVR
860343|NCT02781883|Liposomal Grb-2 treatment of AML
860344|NCT02781883|Liposomal Grb-2 with LDAC for AML
860345|NCT02781857|Exhaled Breath
860346|NCT02781857|Mass Spectrometry
860347|NCT02781857|Fingerprinting
860348|NCT02781818|hidradenitis
860349|NCT02781818|intralesional
860350|NCT02781818|triamcinolone
860351|NCT02781779|Cardiac Implantable Electronic Device
860352|NCT02781779|Implant
860353|NCT02781766|Haemophilia A
860354|NCT02781766|prophylaxis
860355|NCT02781766|thrombin generation assay
860356|NCT02781766|factor VIII
860357|NCT02781766|prophylactic therapy
860358|NCT02781740|Continous Positive Airway Pressure
860359|NCT02781740|CPAP
860360|NCT02781740|Sham CPAP
860361|NCT02781740|CPAP withdrawal
860362|NCT02781740|suboptimal CPAP
860363|NCT02781727|Human Growth Hormone
860364|NCT02781727|hGH
860365|NCT02781727|GHD
860366|NCT02781727|rHGH
860367|NCT02781727|Pediatric Growth Hormone Deficiency
860368|NCT02781727|Long Acting Growth Hormone
860369|NCT02781727|Somatropin
860370|NCT02781727|Prodrug
860371|NCT02781727|Growth Failure
860372|NCT02781727|Growth Hormone Replacement Therapy
860373|NCT02781727|Sustained Release
860374|NCT02781727|Sustained Release Growth Hormone
860375|NCT02781727|Growth Hormone Deficiency
860376|NCT02781714|contraception
860377|NCT02781714|postpartum period
860378|NCT02781714|mobile health
860379|NCT02781714|mHealth
860380|NCT02781714|Kenya
860381|NCT02781714|couples
860382|NCT02781675|Diet
860383|NCT02781675|Mediterranean
860384|NCT02781675|Cholesterol
860385|NCT02781675|Inflammation
860386|NCT02781662|Safety
860387|NCT02781662|Hospitalization
860388|NCT02781662|Older Persons
860389|NCT02781662|High-Risk
860390|NCT02781649|Renal
860391|NCT02781649|Transplants
860392|NCT02781649|Hepatitis C
860393|NCT02781649|HCV-negative
860394|NCT02781649|Infected
860395|NCT02781649|Donors
860396|NCT02781636|Efficacy
860397|NCT02781636|Implantable
860398|NCT02781636|Wireless
860399|NCT02781636|Neuromodulation
860400|NCT02781636|Device
860401|NCT02781636|Tibial
860402|NCT02781623|Quadriceps
860403|NCT02781623|Tibial Plateau
860404|NCT02781623|Fracture
860405|NCT02781610|Cystic fibrosis
860406|NCT02781610|Pulmonary exacerbation
860407|NCT02781610|Antibiotic
860408|NCT02781610|Treatment duration
860409|NCT02781610|Lung infection
860410|NCT02781610|Cystic Fibrosis Foundation
860411|NCT02781610|Cystic Fibrosis Foundation National Patient Registry
860412|NCT02781597|Hemoptysis
860413|NCT02781597|Tranexamic acid
860414|NCT02781597|VAS score
860415|NCT02781545|Child Development
860416|NCT02781545|Psychomotor Performance
860417|NCT02781545|Newborns
860418|NCT02781545|Surgery
860419|NCT02781493|Prucalopride
860420|NCT02781493|Polyethylene Glycol
860421|NCT02781493|bowel preparation
860422|NCT02781467|Acute Myeloid
860423|NCT02781467|Leukemia
860424|NCT02781467|PNK-007
860425|NCT02781467|Human IL-2
860426|NCT02781467|RHIL-2
860427|NCT02781467|Fludarabine
860428|NCT02781467|Cyclophosphamide
860429|NCT02781454|SALS
860430|NCT02781454|Mexiletine
860431|NCT02781454|TMS
860432|NCT02781454|NCS
860433|NCT02781402|Overweight BMI Individuals
860434|NCT02781402|Normal BMI Individuals
860435|NCT02781389|Basal cell carcinoma (BCC)
860436|NCT02781389|advanced BCC (aBCC)
860437|NCT02781389|metastatic BCC (mBCC)
860438|NCT02781376|Primary Care
860439|NCT02781376|Computer Decision Support System
860440|NCT02781376|Guidelines
860441|NCT02781376|Snoring
860442|NCT02781363|thoracic ultrasound
860443|NCT02781363|children
860444|NCT02781363|efficacy
860445|NCT02781363|emergency service
860446|NCT02781350|high fat diet
860447|NCT02781350|insulinogenesis
860448|NCT02781350|Fiber
860449|NCT02781350|inflammation
860450|NCT02781324|Ultrasonic Bone Scalpel
860451|NCT02781324|Adolescent Idiopathic Scoliosis
860452|NCT02781324|Posterior Spinal Fusion
860453|NCT02781324|Estimated Blood Loss
860454|NCT02781272|pelvic mass
860455|NCT02781272|ovarian cancer
860456|NCT02781272|gynecological cancer
860457|NCT02781272|risk prediction
860458|NCT02781259|Sentinel Lymph Node Biopsy
860459|NCT02781259|Fluorescence
860460|NCT02781259|Breast Neoplasms
860461|NCT02781259|Indocyanine Green
860462|NCT02781220|MCI
860463|NCT02781220|Dementia
860464|NCT02781220|amyloid PET
860465|NCT02781220|physician diagnosis
860466|NCT02781220|Alzheimer's disease
860467|NCT02781220|AD
860468|NCT02781220|PET imaging
860469|NCT02781220|Appropriate Use Criteria
860470|NCT02781220|patient-reported outcomes
860471|NCT02781220|patient adherence
860472|NCT02781207|syncope
860473|NCT02781207|point-of-care ultrasound
860477|NCT02781168|Premature newborn
860478|NCT02781168|Cortisol
860479|NCT02781168|Stress
860480|NCT02781155|Health related quality of life
860481|NCT02781155|Moxibustion
860482|NCT02781155|Cancer
860483|NCT02781155|Chemotherapy
860484|NCT02781155|Neutropenia
860485|NCT02781155|Anaemia
860486|NCT02781155|Thrombocytopenia
860487|NCT02781155|Self management
860488|NCT02781155|Wellbeing
860489|NCT02781129|Memory
860490|NCT02781129|Responsive Neurostimulator System
860491|NCT02781090|HIV
860492|NCT02781090|Tobacco
860493|NCT02781090|Cigarette
860494|NCT02781090|Smoking
860495|NCT02781090|Social Network
860496|NCT02781090|Internet
860497|NCT02781090|Cessation
860498|NCT02781077|Stroke
860499|NCT02781077|walking competency
860500|NCT02781077|Task-oriented exercise program
860501|NCT02781077|Exercise intensity
860502|NCT02781012|Pancreatic Disease
860503|NCT02781012|Pancreas
860504|NCT02781012|Borderline Resectable
860505|NCT02781012|Pancreatic Cancer
860506|NCT02781012|Pancreatitis
860507|NCT02781012|Family history of pancreatic cancer
860508|NCT02781012|Healthy
860509|NCT02781012|Healthy at risk
860510|NCT02780999|Osteoarthritis
860511|NCT02780999|hand
860512|NCT02780999|orthotic
860513|NCT02780999|rehabilitation
860514|NCT02780986|female entertainment worker
860515|NCT02780986|heterosexual men
860516|NCT02780986|entertainment establishment
860517|NCT02780986|condom use
860518|NCT02780986|sexually transmitted infection
860519|NCT02780986|Singapore
860520|NCT02780947|Ventricular tachycardia
860521|NCT02780947|Ablation
860522|NCT02780947|Myocardial Infarction
860523|NCT02780947|Heart Failure
860524|NCT02780934|Pressure Dressing
860525|NCT02780934|Post-operative Care
860526|NCT02780934|Simple Adhesive Dressing
860527|NCT02780934|Mohs
860528|NCT02780921|Prehabilitation
860529|NCT02780921|Oesophageal cancer
860530|NCT02780921|Gastric cancer
860531|NCT02780921|Fitness
860532|NCT02780921|Preconditionning
860533|NCT02780921|two parallel arms
860534|NCT02780895|Parkinson Disease
860535|NCT02780895|stereotactic surgery
860536|NCT02780895|human allogeneic fetal derived stem cells
860543|NCT02780843|Stroke
860544|NCT02780843|Tomography, X-Ray Computed
860545|NCT02780843|Magnetic Resonance Imaging
860546|NCT02780843|Thrombolytic Therapy
860547|NCT02780830|Lymphoma
860548|NCT02780830|Diffuse Large B-Cell Lymphoma
860549|NCT02780830|non-GCB Diffuse Large B-Cell Lymphoma
860550|NCT02780830|Relapsed or Refractory non-GCB Diffuse Large B-Cell Lymphoma
860551|NCT02780830|Vistusertib
860552|NCT02780830|AZD2014
860553|NCT02780830|Ibrutinib
860554|NCT02780830|Imbruvica
860555|NCT02780791|Infertility
860556|NCT02780791|Ovarian Failure, Premature
860557|NCT02780791|Ovarian Follicle
860558|NCT02780791|Ovary
860559|NCT02780791|Tissue Transplantation
860560|NCT02780791|Cryopreservation
860561|NCT02780791|Pelvis
860562|NCT02780791|Chemotherapy
860563|NCT02780791|Pregnancy Rate
860564|NCT02780791|Folliculogenesis
860565|NCT02780791|Endometrium
860566|NCT02780791|Estrogens
860567|NCT02780791|Progestins
860568|NCT02780791|Follicle Stimulating Hormone
860569|NCT02780791|Estradiol
860570|NCT02780791|Progesterone
860571|NCT02780791|Hormones
860572|NCT02780791|Maturation of Follicles
860573|NCT02780791|Pregnant Women
860574|NCT02780791|Premature Menopause
860575|NCT02780791|Ovarian Insufficiency
860576|NCT02780791|Ovarian Insufficiency, Premature
860577|NCT02780791|Cytotoxic therapy
860578|NCT02780791|Fertility Protection
860579|NCT02780791|Reproductive Medicine
860580|NCT02780791|Reproductive Techniques
860581|NCT02780791|Reproductive Technology
860582|NCT02780791|Cryotherapy
860583|NCT02780791|Pregnancy
860584|NCT02780739|Psychological Tests
860585|NCT02780739|Neuropsychological Tests
860586|NCT02780739|Transcranial Direct Current Stimulation
860587|NCT02780739|Exercise
860588|NCT02780739|Circuit-Based Exercise
860589|NCT02780739|Video Games
860590|NCT02780739|Magnetic Resonance Imaging
860591|NCT02780739|Magnetic Resonance Spectroscopy
860592|NCT02780739|Cognition
860593|NCT02780739|Executive Function
860594|NCT02780739|Learning
860595|NCT02780739|Problem Solving
860596|NCT02780739|Transfer (Psychology)
860597|NCT02780739|Decision Making
860598|NCT02780739|Brain
860599|NCT02780739|Gray Matter
860600|NCT02780739|White Matter
860601|NCT02780726|Peritoneal dialysis
860602|NCT02780726|Roxadustat
860603|NCT02780726|Renal anemia
860604|NCT02780726|ASP1517
860605|NCT02780713|Breast cancer
860606|NCT02780713|Healthy volunteers
860607|NCT02780713|Pharmacokinetics
860608|NCT02780713|AZD9496
860609|NCT02780713|Safety
860610|NCT02780713|Tolerability
860611|NCT02780674|Polymyositis, dermatomyositis, Sjogren's syndrome, SLE, SSc
860612|NCT02780648|stereotactic radiotherapy
860613|NCT02780648|pancreatic adenocarcinoma
860618|NCT02780596|Infant
860619|NCT02780596|Toddler
860620|NCT02780596|Primary Care
860621|NCT02780570|SVPE
860622|NCT02780570|intravenous immunoglobulin
860623|NCT02780570|plasmapheresis
860624|NCT02780557|Vocabulary
860625|NCT02780557|Book reading
860626|NCT02780557|Infancy
860627|NCT02780557|Parenting
860628|NCT02780544|Infant, premature
860629|NCT02780544|Pain
860630|NCT02780544|Stress, physiological
860631|NCT02780544|Stress, psychological
860632|NCT02780544|skin-to-skin contact
860633|NCT02780518|oxygen
860634|NCT02780518|carbon dioxide
860635|NCT02780492|Duchenne muscular dystrophy
860636|NCT02780492|Natural history
860637|NCT02780492|Outcome measures
860638|NCT02780492|North Star Ambulatory Assessment (NSAA)
860639|NCT02780492|6 minute walk distance (6MWD)
860640|NCT02780492|Myoset
860641|NCT02780492|Exon skipping
860642|NCT02780479|Prednisone
860643|NCT02780479|Dexamethasone
860644|NCT02780479|Asthma exacerbation
860645|NCT02780479|Hospitalized
860646|NCT02780466|Septic shock
860647|NCT02780466|Endotracheal intubation
860648|NCT02780466|Outcome
860649|NCT02780440|Post Stroke Recovery
860650|NCT02780440|Mirror Therapy
860651|NCT02780440|Unimanual mirror therapy
860652|NCT02780440|Bimanual mirror therapy
860653|NCT02780440|Stroke
860654|NCT02780427|Dose-Response Relationship, Drug
860655|NCT02780414|Hypertension
860656|NCT02780414|Proteinuria
860657|NCT02780414|Thrombocytopenia
860658|NCT02780414|Renal Insufficiency
860659|NCT02780414|Impaired Liver Function
860660|NCT02780414|Pulmonary Edema
860661|NCT02780401|Stage I
860662|NCT02780401|Stage II
860663|NCT02780401|Stage III
860664|NCT02780388|MEDI4920, CD40L, RA, rheumatoid arthritis
860665|NCT02780375|Transcriptional Responses
860666|NCT02780375|Radiation
860667|NCT02780323|Celecoxib
860668|NCT02780323|CELBESTA
860669|NCT02780310|Lenvatinib
860670|NCT02780310|15-327
860671|NCT02780297|primary hyperoxaluria
860672|NCT02780297|Dent Disease
860673|NCT02780297|enteric hyperoxaluria
860674|NCT02780297|cystinuria
860675|NCT02780297|Lowe Syndrome
860676|NCT02780297|Adenine phosphoribosyltransferase deficiency
860677|NCT02780297|PH
860678|NCT02780297|APRTd
860679|NCT02780297|APRT
860680|NCT02780297|hyperoxaluria
860681|NCT02780297|oxalate
860682|NCT02780297|oxalosis
860683|NCT02780297|PH type 1
860684|NCT02780297|PH type 2
860685|NCT02780297|PH type 3
860686|NCT02780297|Dents
860687|NCT02780297|Dent
860688|NCT02780297|Dent 1
860689|NCT02780297|Dent 2
860690|NCT02780297|APRT deficiency
860691|NCT02780284|Gut Microbiota
860692|NCT02780284|Butyrate
860693|NCT02780284|Physical activity
860694|NCT02780271|Breast Cancer
860695|NCT02780271|Cancer survivor
860696|NCT02780271|e-communication
860697|NCT02780271|diet and physical activity
860698|NCT02780271|fruits/vegetables daily servings
860699|NCT02780271|energy density
860700|NCT02780245|Caesarean Section
860701|NCT02780245|Tranexamic Acid
860702|NCT02780245|Postpartum Hemorrhage
860703|NCT02780245|Ecbolics
860704|NCT02780232|Depression
860705|NCT02780232|Adolescence
860706|NCT02780232|Prevention
860707|NCT02780232|Early intervention
860708|NCT02780232|E-Mental Health
860716|NCT02780167|Phase 2
860717|NCT02780167|randomized
860718|NCT02780167|double-blind
860719|NCT02780167|placebo
860720|NCT02780167|atopic dermatitis
860721|NCT02780167|safety
860722|NCT02780167|efficacy
860723|NCT02780167|JAK
860724|NCT02780167|janus kinase
860725|NCT02780167|moderate
860726|NCT02780167|severe
860727|NCT02780154|7G8 clone
860728|NCT02780154|NF54 strain
860729|NCT02780154|Non-immune
860730|NCT02780154|PCR
860731|NCT02780154|PfSPZ Challenge
860732|NCT02780154|Plasmodium falciparum
860733|NCT02780154|qPCR
860734|NCT02780154|Sporozoites
860735|NCT02780141|Renal anemia
860736|NCT02780141|ASP1517
860737|NCT02780141|Hemodialysis
860738|NCT02780128|neuroblastoma
860739|NCT02780128|cancer
860740|NCT02780128|genetic profiling
860741|NCT02780128|ceritinib
860742|NCT02780128|ribociclib
860743|NCT02780128|trametinib
860744|NCT02780128|HDM201
860745|NCT02780102|ADHD
860746|NCT02780102|Cognitive-motor rehabilitation
860747|NCT02780102|Active Control Group
860748|NCT02780102|Stimulant Medication
860749|NCT02780089|Metastatic
860750|NCT02780089|Unresectable
860751|NCT02780063|Dilation
860752|NCT02780063|Intraocular
860753|NCT02780063|Ophthalmology
860754|NCT02780050|cardiopulmonary resuscitation
860755|NCT02780050|manikins
860756|NCT02780050|physical fitness
860757|NCT02780024|Neo-Adjuvant Metformin
860758|NCT02780024|Neo-Adjuvant Temozolomide
860759|NCT02780024|Temozolomide and accelerated hypofractionation
860760|NCT02780024|Metformin and accelerated hypofractionation
860761|NCT02780024|Adjuvant Temozolomide
860762|NCT02780024|Adjuvant Metformin
860763|NCT02780011|CD30+
860764|NCT02780011|Relapsed
860765|NCT02780011|Refractory
860766|NCT02780011|ALCL
860767|NCT02779985|Lycium Barbarum
860768|NCT02779985|Energy expenditure
860769|NCT02779985|Postprandial metabolism
860770|NCT02779972|Cardiac Physiology
860771|NCT02779972|Physiology
860772|NCT02779933|Hospital-acquired Pneumonia
860773|NCT02779933|Epidemiology
860774|NCT02779933|Risk Factors
860775|NCT02779920|refractory gastroparesis
860776|NCT02779920|per oral pyloromyotomy
860777|NCT02779907|Paediatric
860778|NCT02779907|Malawi
860779|NCT02779894|Sleep Apnea
860780|NCT02779894|Communication Based Technology
860781|NCT02779894|ICT
860782|NCT02779868|body composition
860783|NCT02779868|functional capacity
860784|NCT02779868|quality of life
860785|NCT02779855|triple negative breast cancer (TNBC)
860786|NCT02779855|estrogen receptor
860787|NCT02779855|progesterone receptor
860788|NCT02779855|invasive ductal carcinoma
860789|NCT02779855|breast cancer tumors
860790|NCT02779790|Systematic Review and Meta-Analysis
860791|NCT02779790|Evidence-Based Medicine
860792|NCT02779790|Evidence-Based Nutrition
860793|NCT02779790|Clinical Practice Guidelines
860794|NCT02779790|Liquid Meal Replacements
860795|NCT02779790|Body Weight
860796|NCT02779790|Systolic Blood Pressure
860797|NCT02779790|Diastolic Blood Pressure
860798|NCT02779790|Fasting Blood Glucose
860799|NCT02779790|Fasting Blood Insulin
860800|NCT02779790|HbA1c
860801|NCT02779790|Total Cholesterol
860802|NCT02779790|Triglycerides
860803|NCT02779790|LDL-C
860804|NCT02779790|HDL-C
860805|NCT02779790|Controlled Feeding Trials
860806|NCT02779764|Hemodialysis
860807|NCT02779764|ASP1517
860808|NCT02779764|Renal anemia
860809|NCT02779725|Symptom Management
860810|NCT02779712|Remote ischaemic conditioning
860811|NCT02779686|Macular Degeneration
860812|NCT02779686|Genetic testing
860813|NCT02779686|Age-Related Macular degeneration
860814|NCT02779686|Age-Related Maculopathies
860815|NCT02779660|Atrial Fibrillation
860816|NCT02779647|Overweight, obesity, play, physical activity, accelerometry.
860817|NCT02779608|malignant ascites
860818|NCT02779582|Progesterone
860819|NCT02779582|Menstrual Flow
860820|NCT02779556|Health Literacy
860821|NCT02779556|Diabetes
860822|NCT02779543|In lab sleep studies
860823|NCT02779517|upper extremity
860824|NCT02779517|stroke
860825|NCT02779517|rehabilitation
860826|NCT02779517|robotics
860827|NCT02779517|telepresence
860828|NCT02779517|elderly
860829|NCT02779517|aged
860830|NCT02779517|Housing for the elderly
860831|NCT02779517|retirement
860832|NCT02779517|homes for the aged
860833|NCT02779491|fruit and vegetables
860834|NCT02779491|food intake
860835|NCT02779491|knowledge
860836|NCT02779478|chronic obstructive pulmonary disease (COPD)
860837|NCT02779478|cavitary
860838|NCT02779478|nodular bronchiectatic disease
860839|NCT02779478|NTM
860840|NCT02779465|vitamin D treatment
860841|NCT02779465|chronic hepatitis B
860842|NCT02779452|neurodevelopment
860843|NCT02779452|electroencephalography
860844|NCT02779452|gestational diabetes mellitus
860845|NCT02779452|omega 3 polyunsaturated fatty acids
860846|NCT02779426|Atopic dermatitis
860847|NCT02779426|Text Messages
860848|NCT02779426|Health literacy
860849|NCT02779400|INR
860850|NCT02779400|coagulation
860851|NCT02779400|vitamin K antagonist
860852|NCT02779387|GnRH-a
860853|NCT02779387|endometriosis
860854|NCT02779387|efficiency
860855|NCT02779374|ovarian insufficiency Bone Marrow
860856|NCT02779361|green tea
860857|NCT02779361|steroid profile
860858|NCT02779348|Nebicapone
860859|NCT02779348|Warfarin
860860|NCT02779335|tube-fed
860861|NCT02779335|Formula Tolerance
860862|NCT02779335|Pediatric Patients
860863|NCT02779322|gastric bypass
860864|NCT02779322|hospital charges
860865|NCT02779322|mini gastric bypass
860866|NCT02779309|Frail Older Adults
860867|NCT02779309|Mortality
860868|NCT02779309|Home Care
860869|NCT02779309|Survival Analysis
860870|NCT02779309|Clinical Prediction Rule
860871|NCT02779296|Cyanoacrylates
860872|NCT02779296|Mammaplasty
860873|NCT02779296|Mastectomy
860874|NCT02779257|hypoglycemia
860875|NCT02779244|Orthopedic
860876|NCT02779244|Post-operative
860877|NCT02779244|Weight bearing
860878|NCT02779244|Range of motion
860879|NCT02779218|Hemiplegia
860880|NCT02779205|Cell therapy
860881|NCT02779205|Stromal Cells
860882|NCT02779205|Stem cells
860883|NCT02779205|Adipose tissue
860884|NCT02779205|Children
860885|NCT02779166|hip arthroscopy
860886|NCT02779153|SLE
860887|NCT02779153|H.P. Acthar Gel
860888|NCT02779140|BoNT
860889|NCT02779140|botulinum
860890|NCT02779140|Botulism
860891|NCT02779140|Clostridium
860892|NCT02779140|Neurotoxin
860893|NCT02779140|NTM-1632
860894|NCT02779127|Smoking
860895|NCT02779127|Endothelium
860896|NCT02779127|Passive smoking
860897|NCT02779114|Rheumatoid Arthritis
860898|NCT02779114|Remission
860899|NCT02779114|Dose reduction
860900|NCT02779101|Central nervous system lymphoma
860901|NCT02779101|Pembrolizumab
860902|NCT02779075|Sleeve Gastrectomy
860903|NCT02779075|Roux-en-Y Gastric Bypass
860904|NCT02779036|Stroke
860905|NCT02779036|task-oriented home exercise
860906|NCT02779036|walking competency
860907|NCT02779036|Usual Physiotherapy care
860908|NCT02778997|Shunt
860909|NCT02778997|CSF
860910|NCT02778997|Dysfunction
860911|NCT02778997|Complication
860912|NCT02778984|Anesthesia
860913|NCT02778984|facial mask
860914|NCT02778971|MCI
860915|NCT02778971|Dementia
860916|NCT02778971|amyloid PET
860917|NCT02778971|physician diagnosis
860918|NCT02778971|Alzheimer's disease
860919|NCT02778971|AD
860920|NCT02778971|PET imaging
860921|NCT02778971|Appropriate Use Criteria
860922|NCT02778971|patient-reported outcomes
860923|NCT02778958|bariatric surgery
860924|NCT02778958|morbid obesity
860925|NCT02778958|nonopioid analgesics
860926|NCT02778945|spinal surgery
860927|NCT02778945|sugammadex
860928|NCT02778945|deep neuromuscular block
860929|NCT02778945|shear wave elastography
860930|NCT02778945|neuromuscular monitoring
860931|NCT02778919|Endometriosis
860932|NCT02778906|Abatacept
860933|NCT02778893|Conmana
860934|NCT02778893|Thalidomide
860935|NCT02778893|NSCLC
860936|NCT02778893|EGFR mutation
860937|NCT02778854|NSCLC
860938|NCT02778854|liquid biopsy
860939|NCT02778854|driver mutation
860940|NCT02778828|linezolide
860941|NCT02778828|tuberculosis
860942|NCT02778828|MDR-TB
860943|NCT02778802|Pulmonary Hypertension
860944|NCT02778802|Emphysema
860945|NCT02778802|COPD
860946|NCT02778776|Metformin
860947|NCT02778776|Agave Inulin
860948|NCT02778776|METS
860949|NCT02778776|Inflammation parameters
860950|NCT02778776|Urodynamic parameters
860951|NCT02778776|Prostate hyperplasia
860952|NCT02778763|Breast cancer
860953|NCT02778763|TLR2
860954|NCT02778763|Neutropenia
860955|NCT02778750|Cystic Fibrosis (CF)
860956|NCT02778737|ACT, CBT, Randomized controlled trial, Chronic Pain
860957|NCT02778711|anti-IL-17
860958|NCT02778711|secukinumab
860959|NCT02778672|bacterial pneumonia
860960|NCT02778672|children
860961|NCT02778672|diagnosing pneumonia
860962|NCT02778672|thermal imaging
860963|NCT02778633|Volume responsiveness mean systemic filling pressure
860964|NCT02778620|Volume responsiveness mean systemic filling pressure
860965|NCT02778607|Atypical Parkinsonism Syndrome (APS)
860966|NCT02778581|Cognitive Impairment, Alzheimer's Disease, Vegetal Oil
860967|NCT02778542|Automated Hovering
860968|NCT02778542|Remote Monitoring
860969|NCT02778542|Bidirectional Text Messaging
860970|NCT02778529|stroke
860971|NCT02778529|amputees
860972|NCT02778529|spinal cord injuries
860973|NCT02778529|cerebral palsy
860974|NCT02778529|robotics
860975|NCT02778529|rehabilitation
860976|NCT02778503|Tooth, Deciduous
860977|NCT02778503|Dentition, Permanent
860978|NCT02778503|Dental Atraumatic Restorative Treatment
860979|NCT02778503|Glass Ionomer Cements
860980|NCT02778503|Dental Caries
860981|NCT02778490|sleeve gastrectomy, bariatric surgery
860988|NCT02778425|partial splenic embolization
860989|NCT02778412|Thyroid cancer
860990|NCT02778412|Thyroid nodules
860991|NCT02778412|Thyroid neoplasia
860992|NCT02778412|Thyroiditis
860993|NCT02778399|Pelvic Pain
860994|NCT02778399|Endometriosis
860995|NCT02778399|Dysmenorrhea
860996|NCT02778399|Dyspareunia
860997|NCT02778360|Attention deficit
860998|NCT02778360|Neurofeedback
860999|NCT02778360|ADHD
861000|NCT02778360|Methylphenidate
861001|NCT02778347|Palliative care
861002|NCT02778347|Need assessment
861003|NCT02778347|Tools
861004|NCT02778347|Validity
861005|NCT02778347|Quality of care
861006|NCT02778308|Gallbladder cancer, adjuvant chemotherapy, gemcitabine
861007|NCT02778269|ECG
861008|NCT02778269|CGM
861009|NCT02778269|Hypoglycaemia
861010|NCT02778269|Sudden Cardiac Death
861011|NCT02778256|depression, bipolar disorder
861012|NCT02778230|fiber
861013|NCT02778230|gastrointestinal
861014|NCT02778230|microbiota
861015|NCT02778191|Head and neck squamous cell carcinoma
861016|NCT02778191|cisplatin
861017|NCT02778191|carboplatin
861018|NCT02778191|5-fluorouracil
861019|NCT02778087|motor recovery
861020|NCT02778087|mirror therapy
861021|NCT02778087|upper extremity
861022|NCT02778074|Internet Cognitive Behavioural Therapy
861023|NCT02778061|Intra Uterine Ball
861024|NCT02778061|IUD
861025|NCT02778061|copper
861026|NCT02778061|contraception
861027|NCT02778022|Child behavior disorders
861028|NCT02778022|Parent child relationship
861029|NCT02778022|Primary care
861030|NCT02778009|Medical student
861031|NCT02778009|Activity Monitor
861032|NCT02778009|Medical school
861033|NCT02778009|Fitness
861034|NCT02777996|screening
861035|NCT02777983|patient education
861036|NCT02777983|low back pain
861037|NCT02777983|technology
861038|NCT02777970|Acute pain
861039|NCT02777970|Acute moderate to severe pain
861040|NCT02777970|Postoperative pain
861041|NCT02777970|Dexketoprofen Tramadol
861042|NCT02777970|Dexketoprofen trometamol
861043|NCT02777970|Tramadol hydrochloride
861044|NCT02777970|Multimodal analgesia
861045|NCT02777970|Third molar extraction
861046|NCT02777970|Fixed drug combination
861047|NCT02777970|Paracetamol
861048|NCT02777970|Analgesics
861049|NCT02777957|Echocardiography
861050|NCT02777957|Lung Transplantation
861051|NCT02777944|motivation
861052|NCT02777944|attendance
861053|NCT02777918|food intake
861054|NCT02777905|late life
861055|NCT02777905|mindfulness meditation
861056|NCT02777879|Chronic Obstructive Pulmonary Disease (COPD)
861057|NCT02777853|tea
861058|NCT02777853|cardiovascular
861059|NCT02777853|vascular
861060|NCT02777853|metabolism
861061|NCT02777853|microcirculation
861062|NCT02777853|physical inactivity
861063|NCT02777853|polyphenols
861064|NCT02777853|conduit artery
861065|NCT02777853|endothelial function
861066|NCT02777853|cerebrovascular
861067|NCT02777853|insulin sensitivity
861068|NCT02777827|Abediterol
861069|NCT02777827|Dry powder inhaler
861070|NCT02777827|Pressured metered-dose inhaler
861071|NCT02777827|Pharmacokinetic
861072|NCT02777827|Pharmacodynamic
861073|NCT02777827|Safety
861074|NCT02777814|colorectal cancer
861075|NCT02777814|Entecavir
861076|NCT02777814|Hepatitis B Carrier
861077|NCT02777801|gastric cancer
861078|NCT02777801|hepatitis B carrier
861079|NCT02777801|entecavir
861080|NCT02777788|Chinese Traditional Medicine
861081|NCT02777775|NF1
861082|NCT02777775|CNF
861083|NCT02777775|PNF
861084|NCT02777775|Skin Tumors
861085|NCT02777736|Lymphoma, B cell
861086|NCT02777736|Central nervous system relapse
861087|NCT02777736|Methotrexate
861088|NCT02777736|Intrathecal chemotherapy
861089|NCT02777723|Dry Eye Syndrome
861090|NCT02777723|Sodium Hyaluronate
861091|NCT02777723|CKD-350
861092|NCT02777697|cancer treatment protocols
861093|NCT02777697|chronic cancer pain
861094|NCT02777697|cognitive function
861095|NCT02777697|quality of life
861096|NCT02777697|anxiety
861097|NCT02777697|depression
861098|NCT02777684|Physical activity
861099|NCT02777684|Knee osteoarthritis
861100|NCT02777684|Non pharmacological treatment
861101|NCT02777684|Qualitative study
861103|NCT02777619|Pharmacodynamic
861104|NCT02777619|Dexmedetomidine
861105|NCT02777619|Propofol
861106|NCT02777619|Target-controlled Infusion Intravenous Anesthesia
861107|NCT02777606|Severe Sepsis
861108|NCT02777606|Sini Decoction
861109|NCT02777606|Immune Function
861110|NCT02777606|Mortality
861111|NCT02777580|Thrombolytic Therapy
861112|NCT02777580|Primary PCI
861113|NCT02777554|Healthy Subjects
861114|NCT02777554|Apremilast
861115|NCT02777554|Pharmacokinetic
861116|NCT02777541|early enteral nutrition
861117|NCT02777541|children
861118|NCT02777541|percutaneous endoscopic gastrostomy
861119|NCT02777515|electronic cigarette
861120|NCT02777489|obesity
861121|NCT02777489|perindopril
861122|NCT02777489|carboxypeptidase D
861123|NCT02777489|genotyping
861124|NCT02777489|theranostic
861125|NCT02777450|low back pain
861126|NCT02777450|physical examination
861127|NCT02777450|local anesthesia
861128|NCT02777437|Colonic Neoplasms
861129|NCT02777437|Laparoscopic Surgery
861130|NCT02777437|Neoadjuvant chemotherapy
861131|NCT02777437|T4
861132|NCT02777411|Vaccines
861133|NCT02777411|Hand, Foot and Mouth Disease
861134|NCT02777411|EV71 enteroviruses vaccine
861135|NCT02777398|Intra-spinal Canal
861136|NCT02777398|Tumor
861137|NCT02777398|Minimal Invasive Surgery
861138|NCT02777398|Clinical Trial
861139|NCT02777398|Quadrant Channel
861140|NCT02777385|Head and Neck
861141|NCT02777385|Locally Advanced
861142|NCT02777385|Squamous Cell Carcinoma
861143|NCT02777385|SCCHN
861144|NCT02777385|Untreated
861145|NCT02777385|High Risk
861146|NCT02777385|Intermediate Risk
861147|NCT02777385|Radiation Therapy
861148|NCT02777385|Cisplatin
861149|NCT02777372|Zoloft
861150|NCT02777372|PMS
861151|NCT02777372|Menses
861152|NCT02777359|patent foramen ovale
861153|NCT02777359|migraine
861154|NCT02777359|treatment
861155|NCT02777346|WOUNDS, PENETRATING
861156|NCT02777346|CHILD, PRESCHOOL
861157|NCT02777346|CHILD
861158|NCT02777346|INFANT
861159|NCT02777346|ADOLESCENT
861160|NCT02777346|SUTURES
861161|NCT02777346|POLYGLACTIN 910
861162|NCT02777346|POLYPROPYLENES
861163|NCT02777333|Simulation
861164|NCT02777333|Arthroscopy
861165|NCT02777333|Motion analysis
861166|NCT02777320|Sciatica
861167|NCT02777320|Ibuprofen
861168|NCT02777320|Paracetamol
861169|NCT02777320|Emergency Medicine
861170|NCT02777307|Laparoscopic
861171|NCT02777307|Cholecistectomy
861172|NCT02777307|Collection
861173|NCT02777307|Bleeding
861174|NCT02777307|reoperation
861175|NCT02777281|Shoulder Pain
861176|NCT02777281|Wheelchair
861177|NCT02777281|Spinal Cord injury
861178|NCT02777242|Hypogonadism
861179|NCT02777242|Testosterone enanthate
861181|NCT02777203|morcellation
861182|NCT02777203|myomectomy
861183|NCT02777203|hysterectomy
861184|NCT02777190|misoprostol
861185|NCT02777190|cytotec
861186|NCT02777190|cervical ripening
861187|NCT02777190|labor, induced
861188|NCT02777190|active labor
861189|NCT02777138|Adipose tissue
861190|NCT02777138|Inflammation
861191|NCT02777138|Age Comparison
861192|NCT02777138|Macrophages
861193|NCT02777138|T-lymphocytes
861194|NCT02777138|Adipose Progenitors
861195|NCT02777125|pediatrics
861196|NCT02777125|metered dose inhalers
861197|NCT02777125|breath actuated nebulizers
861198|NCT02777112|high-risk
861199|NCT02777112|early prevention
861200|NCT02777112|productivity
861201|NCT02777112|return on investment
861202|NCT02777112|workplace
861203|NCT02777112|e-mental health program
861204|NCT02777112|job coach
861205|NCT02777099|remote ischemic postconditioning
861206|NCT02777099|autonomic function
861207|NCT02777099|heart rate variability
861208|NCT02777099|acute ischemic stroke
861209|NCT02777099|prognosis
861210|NCT02777086|HIV
861211|NCT02777086|Risk Behaviors
861212|NCT02777086|Decision-making
861213|NCT02777073|Diabetic ketoacidosis
861214|NCT02777073|Insulin
861215|NCT02777073|Type 1 Diabetes
861216|NCT02777073|glucose (sugar) control
861217|NCT02777073|SGLT-2 inhibitors
861218|NCT02777060|virtual reality
861219|NCT02777060|sensor-based balance training
861220|NCT02777060|gait
861221|NCT02777060|balance
861222|NCT02777047|Thromboembolism
861223|NCT02777047|Medication Safety
861224|NCT02777047|Hospital-community collaboration
861225|NCT02777047|Pilot RCT
861226|NCT02777047|Telehealth
861227|NCT02777034|Laparoscopy
861228|NCT02777034|Enhanced Recovery
861229|NCT02777034|Fast-track
861230|NCT02777021|Pediatric
861231|NCT02777021|Acute Myeloid Leukemia
861232|NCT02777021|Quality of Life
861233|NCT02777021|Neutropenia Management
861234|NCT02777021|Patient Centered Outcomes
861235|NCT02777021|Chemotherapy
861236|NCT02776982|Gastroesophageal reflux disease
861237|NCT02776982|GERD
861238|NCT02776982|Barrett's Esophagus
861239|NCT02776982|Esophageal adenocarcinoma
861240|NCT02776969|Papillary Carcinoma
861241|NCT02776969|Gene Hunting
861242|NCT02776969|Familial
861243|NCT02776956|atrial fibrillation;left atrial function
861244|NCT02776930|Injury Prediction
861245|NCT02776930|Return to Work
861246|NCT02776930|Injury Prevention
861247|NCT02776917|metastatic breast cancer
861248|NCT02776917|locally advanced, unresectable breast cancer
861249|NCT02776917|HER2/NEU negative
861250|NCT02776904|Concussion
861251|NCT02776904|Football player
861252|NCT02776904|Movement assessment
861253|NCT02776904|Soccer player
861254|NCT02776891|lymphoma
861255|NCT02776891|gallium citrate
861256|NCT02776891|PET
861257|NCT02776865|suprascapular nerve block
861258|NCT02776813|CD20+
861259|NCT02776813|B-cell
861260|NCT02776813|ACTR087
861261|NCT02776813|Relapsed
861262|NCT02776813|Refractory
861263|NCT02776800|Wound
861264|NCT02776800|Surgical Wound
861265|NCT02776800|Trauma Wound
861266|NCT02776800|Home Health Care
861267|NCT02776800|Home Health Nurse
861268|NCT02776800|Pressure Ulcer
861269|NCT02776800|Diabetic Foot Ulcer
861270|NCT02776800|Venous Leg Ulcer
861271|NCT02776800|Arterial Ulcer
861272|NCT02776800|Wound Dehiscence
861273|NCT02776800|Open Wound
861274|NCT02776774|spine
861275|NCT02776748|Tenofovir disoproxil
861276|NCT02776748|Pre-exposure prophylaxis
861277|NCT02776748|Breastfeeding
861278|NCT02776748|Emtricitabine
861279|NCT02776748|Tenofovir
861280|NCT02776748|Post-partum
861281|NCT02776748|HIV prevention
861282|NCT02776748|Women
861283|NCT02776748|Pharmacokinetics
861284|NCT02776722|Systematic Review and Meta-analysis
861285|NCT02776722|randomized controlled trial
861286|NCT02776722|Evidence-Based Medicine
861287|NCT02776722|carbohydrate metabolism
861288|NCT02776722|postprandial
861289|NCT02776722|glycemic response
861290|NCT02776722|glycemic control
861291|NCT02776722|insulin sensitivity
861292|NCT02776722|beta-cell function
861293|NCT02776722|sugars
861294|NCT02776722|fructose
861295|NCT02776722|allulose
861296|NCT02776722|tagatose
861297|NCT02776722|sorbose
861298|NCT02776696|Closed Loop
861299|NCT02776696|Artificial Pancreas
861300|NCT02776644|renal cell carcinoma
861301|NCT02776644|sunitinib, pazopanib
861302|NCT02776644|temsirolimus
861303|NCT02776644|sorafenib
861304|NCT02776644|everolimus
861305|NCT02776644|interferon alpha
861306|NCT02776644|interleukin 2
861307|NCT02776592|Healthy Children
861308|NCT02776579|Resistance Training; Muscle Strength
861309|NCT02776566|Anticoagulation
861310|NCT02776566|Anticoagulation Management
861311|NCT02776566|Self-Testing
861312|NCT02776566|Self-Management
861313|NCT02776566|Warfarin
861314|NCT02776566|Thromboembolism
861315|NCT02776566|Blood Coagulation Disorders
861316|NCT02776566|Health Disparities
861317|NCT02776566|Minorities
861318|NCT02776566|African American
861319|NCT02776566|Hispanic
861320|NCT02776566|Cardiovascular Disease
861321|NCT02776566|Models of Anticoagulation Care
861322|NCT02776566|Tele-Health
861323|NCT02776566|Home Self-Testing
861324|NCT02776527|Gastric cancer
861325|NCT02776527|D2 Lymphadenectomy
861326|NCT02776527|postoprative adjuvant chemotherapy
861327|NCT02776527|Apatinib
861328|NCT02776527|disease free survival
861329|NCT02776488|brain trauma, metabolic therapy
861330|NCT02776462|Eye Tracking
861331|NCT02776462|Concussion
861332|NCT02776462|Outcome Measures
861333|NCT02776410|sustainable healthy eating
861334|NCT02776410|consumer behaviour
861335|NCT02776410|consumer attitudes
861336|NCT02776384|Heart Failure
861337|NCT02776384|Biomarkers
861338|NCT02776384|Echocardiography
861339|NCT02776384|Cardiopulmonary Function Tests
861340|NCT02776371|Helicobacter pylori
861341|NCT02776371|Sequential therapy
861342|NCT02776371|Modified non-clarithromycin triple therapy
861343|NCT02776345|calcific tendonitis
861344|NCT02776345|rotator cuff calcific tendonitis
861345|NCT02776332|breastfeeding
861346|NCT02776332|premature infants
861347|NCT02776332|manual expression
861348|NCT02776319|Non-invasive brain stimulation
861349|NCT02776319|tobacco use disorder
861350|NCT02776319|craving
861351|NCT02776280|water
861352|NCT02776280|salt
861353|NCT02776280|oral fluids
861354|NCT02776280|plaque
861355|NCT02776280|dental caries
861356|NCT02776254|anti-retroviral therapy
861357|NCT02776254|differentiated care
861358|NCT02776241|ADPKD
861359|NCT02776241|total kidney volume
861360|NCT02776241|kidney disease
861361|NCT02776189|Anaesthesia
861362|NCT02776189|MRI
861363|NCT02776189|Brain
861364|NCT02776176|enhanced recovery after surgery
861365|NCT02776176|hirschsprung disease
861366|NCT02776163|Salivary Gland Tumors
861367|NCT02776163|Head-an-Neck cancer
861368|NCT02776163|Concurrent Chemoradiotherapy
861369|NCT02776163|High-Risk
861370|NCT02776163|Cisplatin
861371|NCT02776163|Docetaxel
861372|NCT02776150|probe melting curve
861373|NCT02776150|Drug resistance
861374|NCT02776150|Tuberculosis, Pulmonary
861375|NCT02776137|Docetaxel
861376|NCT02776137|Concurrent Chemoradiotherapy
861377|NCT02776137|High-Risk
861378|NCT02776137|Squamous Cell Carcinoma
861379|NCT02776137|Head-and-Neck Cancer
861380|NCT02776124|Nutritional status
861381|NCT02776124|nasopharyngeal carcinoma
861382|NCT02776124|Nutritional Counseling
861383|NCT02776124|concurrent chemoradiotherapy
861384|NCT02776124|oral nutritional supplements
861385|NCT02776111|Kidney Transplant
861386|NCT02776098|Cystic Fibrosis
861387|NCT02776098|Glucose Intolerance
861388|NCT02776098|Muscle Accrual
861389|NCT02776098|Cystic Fibrosis-related Diabetes
861390|NCT02776085|optic nerve sheath diameter
861391|NCT02776085|ultrasound
861392|NCT02776085|shunt failure
861393|NCT02776072|Tecfidera, DMF, dimethyl fumarate, Fingolimod, Glatiramer acetate, Teriflunomide, Gilenya, Copaxone, Aubagio
861394|NCT02776059|survival
861395|NCT02776059|pegfilgrastim
861396|NCT02776059|cirrhosis, alcoholic
861397|NCT02776046|Oxygen, surgical site infection, postoperative complication, recruitment maneuvers, open lung strategy
861398|NCT02776033|tolerability
861399|NCT02776033|safety
861400|NCT02776033|GSK2982772
861401|NCT02776033|RIP1 kinase inhibitor
861402|NCT02776033|psoriasis
861403|NCT02776007|Continuous Glucose Monitoring System
861404|NCT02775955|Pharmacokinetics
861405|NCT02775929|Tenofovir disoproxil
861406|NCT02775929|Emtricitabine
861407|NCT02775929|Pre-exposure Prophylaxis
861408|NCT02775929|Antiretroviral Therapy
861409|NCT02775929|HIV Prevention
861410|NCT02775929|FTC TDF
861411|NCT02775929|PrEP
861412|NCT02775929|HIV Infected Partners
861413|NCT02775929|HIV Uninfected Partners
861426|NCT02775786|Pancreatic Adenocarcinoma
861427|NCT02775786|Pancreatic Cancer
861428|NCT02775773|TXA
861429|NCT02775773|PPH
861452|NCT02775734|Polycystic Ovary Syndrome
861453|NCT02775734|N-acetyl-cysteine
861454|NCT02775734|Clomiphene citrate
861455|NCT02775734|Clomiphene citrate resistant
861456|NCT02775734|Laparoscopic ovarian drilling
861457|NCT02775734|therapy
861458|NCT02775721|Nursing Education
861459|NCT02775721|Weight Loss
861460|NCT02775721|Gastrostomy Tube Care
861461|NCT02775695|pancreatic cancer
861462|NCT02775695|Resectable Pancreatic Cancer
861463|NCT02775695|Doxycycline
861464|NCT02775695|Metakaryote cells
861465|NCT02775695|Eukaryotic cells
861466|NCT02775695|Cancer Stem Cells
861467|NCT02775695|Targeted Cancer Stem Cell Therapy
861468|NCT02775695|Multi-metakaryocide therapy
861469|NCT02775695|Doxycycline Hyclate
861470|NCT02775695|Tetracycline
861471|NCT02775682|epilepsy, dynamic cerebral autoregulation
861472|NCT02775669|noninvasive ICP monitoring
861473|NCT02775656|Cimzia®
861474|NCT02775656|CZP
861475|NCT02775656|Pregnancy Follow up study
861476|NCT02775656|Autoimmune diseases
861477|NCT02775656|Pregnancy outcomes
861478|NCT02775656|major congenital malformations
861479|NCT02775656|birth outcomes
861480|NCT02775656|malformation
861481|NCT02775656|birth defect
861482|NCT02775643|Melanoma
861483|NCT02775643|Spitzoid Melanoma
861484|NCT02775643|Congenital Melanoma
861485|NCT02775643|Melanoma Arising in Giant Nevi
861486|NCT02775643|Melanocytic lesions with indeterminate biological behavior
861487|NCT02775643|Pigment synthesizing melanomas
861488|NCT02775604|fall risks at home
861489|NCT02775604|video technology
861490|NCT02775604|home assessment
861491|NCT02775578|heart failure
861492|NCT02775578|coronary artery disease
861493|NCT02775578|biomarkers
861494|NCT02775578|Percutaneous Coronary Intervention, PCI
861495|NCT02775578|Coronary Artery Bypass Grafting, CABG
861496|NCT02775552|Child Nutrition
861497|NCT02775552|Breastfeeding
861498|NCT02775552|Complementary Feeding
861499|NCT02775552|Infant and Young Child Feeding
861500|NCT02775552|Social and Behavior Change Communication
861501|NCT02775552|Ethiopia
861502|NCT02775539|Pulmonary hypertension
861503|NCT02775539|Mirabegron
861504|NCT02775539|Heart failure
861505|NCT02775539|B3 adrenergic
861506|NCT02775526|Mixed urinary incontinence
861507|NCT02775526|Transobturator tape (TOT)
861508|NCT02775526|Tension-Free Vaginal Tape (TVT)
861509|NCT02775526|Burch colposuspension
861510|NCT02775526|Urinary incontinence
861511|NCT02775500|pregnancy
861512|NCT02775500|apremilast
861513|NCT02775500|Otezla
861514|NCT02775500|autoimmune disease
861515|NCT02775500|psoriatic arthritis
861516|NCT02775500|psoriasis
861517|NCT02775500|TNF
861518|NCT02775500|tumor necrosis factor
861519|NCT02775500|birth outcome
861520|NCT02775500|birth defect
861521|NCT02775487|COPD
861522|NCT02775487|Air quality
861523|NCT02775474|Methadone
861524|NCT02775474|Pain, Postoperative
861525|NCT02775474|Chronic Pain
861526|NCT02775474|Bariatric Surgery
861527|NCT02775461|Pancreas Cancer
861528|NCT02775461|Chronic Pancreatitis
861529|NCT02775461|Pancreatic Cyst
861530|NCT02775461|BRCA1
861531|NCT02775461|BRCA2
861532|NCT02775461|Lynch Syndrome
861533|NCT02775461|Peutz-Jeghers syndrome
861534|NCT02775461|ATM mutation
861535|NCT02775461|FAMMM Syndrome
861536|NCT02775461|Pancreatitis
861537|NCT02775461|Family History of Pancreas Cancer
861538|NCT02775461|Family History of Cancer
861539|NCT02775448|Homeopathy
861540|NCT02775448|Carduus marianus
861541|NCT02775448|Dyslipidemia
861542|NCT02775448|Climacteric
861543|NCT02775448|Obesity
861544|NCT02775448|Triglycerides
861545|NCT02775448|Cholesterol
861546|NCT02775448|Insulin resistance
861547|NCT02775448|LDL-cholesterol
861548|NCT02775448|HDL-cholesterol
861549|NCT02775435|PD1
861550|NCT02775435|PD-1
861551|NCT02775435|PDL1
861552|NCT02775435|PD-L1
861553|NCT02775383|National MDS Study
861554|NCT02775383|MDS
861555|NCT02775383|Idiopathic
861556|NCT02775383|cytopenia
861557|NCT02775383|cytopenias
861558|NCT02775383|ICUS
861559|NCT02775383|MDS/MPN
861560|NCT02775383|Myeloproliferative Neoplasm
861561|NCT02775383|Biorepository
861562|NCT02775344|Laparoscopy
861563|NCT02775344|ovarian cystectomy
861564|NCT02775344|three dimension laparoscopy
861565|NCT02775331|shift scheduling
861566|NCT02775331|work-life interaction
861567|NCT02775331|working time control
861568|NCT02775331|public sector
861569|NCT02775318|Stellate Ganglion
861570|NCT02775318|Digital Subtraction Angiography
861571|NCT02775318|Transcranial Doppler Ultrasonography
861572|NCT02775279|acute coronary syndrome, telomere length, predictive factor
861573|NCT02775253|Brown adipose tissue
861574|NCT02775253|Subcutaneous white adipose tissue
861575|NCT02775253|White adipose tissue
861576|NCT02775240|Maribavir
861577|NCT02775214|Storz C-MAC
861578|NCT02775214|direct laryngoscopy
861579|NCT02775214|pyloromyotomy
861580|NCT02775214|rapid sequence
861581|NCT02775201|plantaris
861582|NCT02775201|Tendinopathy
861583|NCT02775201|Achilles
861584|NCT02775201|Release
861585|NCT02775175|Ramadan
861586|NCT02775175|Fasting
861587|NCT02775175|Nutrition
861588|NCT02775175|Quality of Life
861589|NCT02775136|brain injuries
861590|NCT02775136|neurological monitoring
861591|NCT02775084|n-3
861592|NCT02775084|Polyunsaturated
861593|NCT02775084|Fatty acids
861594|NCT02775084|Antigens
861595|NCT02775084|Cognition
861596|NCT02775084|CD4
861598|NCT02775032|advance care planning
861599|NCT02775032|general practice
861600|NCT02775032|family practice
861601|NCT02775032|palliative care
861602|NCT02775032|end-of-life care
861603|NCT02774967|root coverage
861604|NCT02774967|gingival recession
861605|NCT02774967|periodontal surgery
861606|NCT02774954|Change the cycle
861607|NCT02774954|social learning theory
861608|NCT02774954|people who inject drugs
861609|NCT02774954|injection drug use
861610|NCT02774954|Information, Motivation, Behavior Skills Model
861611|NCT02774954|Longitudinal cohort study
861612|NCT02774928|Pulmonary Hypertension
861613|NCT02774928|COPD
861614|NCT02774928|ILD
861615|NCT02774928|OSA
861616|NCT02774902|Drug Therapy
861617|NCT02774889|Falls Prevention
861618|NCT02774889|Stepping On
861619|NCT02774889|Health Promotion
861620|NCT02774889|Implementation
861621|NCT02774889|Health Maintenance
861622|NCT02774876|Closed-loop system
861623|NCT02774876|Artificial pancreas
861624|NCT02774876|Glucose control
861625|NCT02774876|Meal
861626|NCT02774850|Pediatric
861627|NCT02774850|Neutropenia Management
861628|NCT02774850|Acute Myeloid Leukemia
861629|NCT02774850|Chart Abstraction
861630|NCT02774850|Chemotherapy
861631|NCT02774837|nucleoside analogues
861632|NCT02774837|tenofovir
861633|NCT02774837|telbivudine
861634|NCT02774837|quantitative HBsAg
861635|NCT02774837|combination therapy
861636|NCT02774798|Rectal Prolapse
861637|NCT02774798|Rectal Intussuception
861638|NCT02774759|Malignant neoplasms of female genital organs
861639|NCT02774759|Endometrial cancer survivors
861640|NCT02774759|Obese
861641|NCT02774759|Weight loss intervention
861642|NCT02774759|Resistance training
861643|NCT02774759|Aerobic exercise
861644|NCT02774759|Questionnaires
861645|NCT02774759|Surveys
861646|NCT02774759|Accelerometer
861647|NCT02774759|Fitness Test
861648|NCT02774759|Telephone Coaching
861649|NCT02774759|Video Chat Sessions
861650|NCT02774707|Dry eye
861651|NCT02774694|nociceptive flexion reflex
861652|NCT02774694|interventional pain management
861653|NCT02774668|gender
861654|NCT02774668|arterial stiffness
861655|NCT02774668|blood pressure
861656|NCT02774668|weight loss
861657|NCT02774668|uric acid
861658|NCT02774655|healthy volunteers
861659|NCT02774655|patient compliance
861660|NCT02774655|exercise
861661|NCT02774655|motivation
861662|NCT02774642|PTSD
861663|NCT02774642|insomnia
861664|NCT02774642|CBT-I
861665|NCT02774642|Prolonged Exposure
861666|NCT02774642|Veteran
861667|NCT02774629|food allergy
861668|NCT02774629|skin prick test
861669|NCT02774629|atopy patch test
861670|NCT02774590|Acne vulgaris
861671|NCT02774590|Rosacea
861672|NCT02774577|Oxygen Consumption
861673|NCT02774577|Aged
861674|NCT02774577|Whole Body Vibration
861675|NCT02774551|Body composition
861676|NCT02774551|Muscle strength
861677|NCT02774551|Health related quality of life
861678|NCT02774538|Cervical HPV infection
861679|NCT02774538|Oral HPV infection
861680|NCT02774538|Sexually transmitted infection
861681|NCT02774525|child welfare system
861682|NCT02774525|parental substance use problem
861683|NCT02774525|child maltreatment
861684|NCT02774525|parenting
861685|NCT02774473|Metastatic
861686|NCT02774473|Rb+
861687|NCT02774473|Breast Cancer
861688|NCT02774408|backup ventilation
861689|NCT02774408|preterm infants
861690|NCT02774408|functional residual capacity
861691|NCT02774408|chronic lung disease
861692|NCT02774382|Recurrence
861693|NCT02774382|Infection
861694|NCT02774369|cancer
861695|NCT02774369|insomnia
861696|NCT02774369|sleep
861697|NCT02774369|physical exercise
861698|NCT02774369|aerobic
861699|NCT02774369|cognitive-behavioral therapy
861700|NCT02774369|self-help
861701|NCT02774369|RCT
861702|NCT02774356|Brainstem
861703|NCT02774356|Encoding
861704|NCT02774356|Pitch
861705|NCT02774304|elastance
861706|NCT02774304|fluid responsiveness
861707|NCT02774265|Fracture
861708|NCT02774265|Prophylaxis
861709|NCT02774226|Flow-Mediated Dilation
861710|NCT02774226|Kuvan
861711|NCT02774226|Antioxidant
861712|NCT02774226|FEV1
861713|NCT02774187|Hepatocellular Carcinoma
861714|NCT02774187|Hepatic arterial infusion chemotherapy
861715|NCT02774187|Sorafenib
861716|NCT02774174|Proximal Humerus
861717|NCT02774109|low back pain
861718|NCT02774109|fish oil
861719|NCT02774109|omega 3
861720|NCT02774096|Aortic dissection
861721|NCT02774096|Cerebral and Spinal Protection
861722|NCT02774096|Post-conditioning
861723|NCT02774083|older people
861724|NCT02774083|cognitive training
861725|NCT02774070|AAJ RA MRI synovitis
861726|NCT02774057|Captafer®
861727|NCT02774057|Iron Sulfate
861728|NCT02774057|Iron deficiency anemia
861729|NCT02774057|inflammatory bowel disease
861730|NCT02774044|preterm neonates, surfactant
861731|NCT02774031|Anesthesia, Inhalation
861732|NCT02774031|Laparoscopy
861733|NCT02774031|Prostatectomy
861734|NCT02774031|Cystectomy
861862|NCT02773121|Exercise
861735|NCT02774031|Gynecologic Surgical Procedures
861736|NCT02774018|Mindfulness
861737|NCT02774018|Elderly
861738|NCT02774018|Psychopathology
861739|NCT02773992|Solitary Pulmonary Nodule
861740|NCT02773992|Itos
861741|NCT02773992|lung cancer
861742|NCT02773979|challenge
861743|NCT02773979|malaria
861744|NCT02773979|P. falciparum
861745|NCT02773979|PfSPZ
861746|NCT02773979|sporozoites
861747|NCT02773979|vaccine
861748|NCT02773953|CPAP
861749|NCT02773953|Telemonitoring
861750|NCT02773927|Agave inulin
861751|NCT02773927|Adiponectin
861752|NCT02773927|Metabolic syndrome
861753|NCT02773927|Metformin
861754|NCT02773927|Insulin resistance
861755|NCT02773914|Activity of Daily Living (ADL)
861756|NCT02773914|Comprehensive Geriatric Assessment
861757|NCT02773914|Elderly
861758|NCT02773914|Frailty
861759|NCT02773914|Randomized controlled study
861760|NCT02773901|intracranial pressure
861761|NCT02773901|noninvasive monitoring
861762|NCT02773901|lumbar puncture
861763|NCT02773888|intracranial pressure
861764|NCT02773888|noninvasive monitoring
861765|NCT02773875|artificial pancreas
861766|NCT02773862|brain injuries
861767|NCT02773862|noninvasive monitoring
861768|NCT02773862|intracranial pressure
861769|NCT02773849|IFN
861770|NCT02773849|BCG-unresponsive
861771|NCT02773849|Non-Muscle Invasive Bladder Cancer
861772|NCT02773836|tobacco use
861773|NCT02773836|e-cigarettes
861774|NCT02773836|public policy
861775|NCT02773836|ITC
861776|NCT02773823|obesity
861777|NCT02773823|children
861778|NCT02773823|cardiovascular health
861779|NCT02773823|intervention study
861780|NCT02773797|Sedation
861781|NCT02773797|Dexmedetomidine
861782|NCT02773771|Muscle Atrophy
861783|NCT02773771|Critical Illness
861784|NCT02773771|Ultrasound
861785|NCT02773771|beta-hydroxy-beta-methylbutyrate
861786|NCT02773771|ICU
861787|NCT02773680|respiration
861788|NCT02773680|monitoring, physiologic
861789|NCT02773680|diagnostic techniques, respiratory system
861790|NCT02773654|shoulder
861791|NCT02773654|motion
861792|NCT02773654|measurement
861793|NCT02773654|healthy shoulder
861794|NCT02773654|shoulder motion
861795|NCT02773602|Analgesia
861796|NCT02773602|caudal analgesia
861797|NCT02773602|ropivacaine
861798|NCT02773602|clonidine
861799|NCT02773602|dexamethasone
861800|NCT02773550|Multiple Myeloma
861801|NCT02773524|Metastatic
861802|NCT02773524|Locally recurrent
861803|NCT02773524|Oesophago-gastric junction
861804|NCT02773524|Stomach
861805|NCT02773524|Adenocarcinoma
861806|NCT02773524|Undifferentiated Carcinoma
861807|NCT02773472|colorectal
861808|NCT02773472|electroacupuncture
861809|NCT02773472|laparoscopic surgery
861810|NCT02773446|ETEC
861811|NCT02773446|Escherichia coli
861812|NCT02773446|enteritis
861813|NCT02773446|Challenge
861814|NCT02773446|CS6
861815|NCT02773446|Enterotoxigenic
861816|NCT02773407|Undifferentiated febrile illness
861817|NCT02773407|Azithromycin
861818|NCT02773407|Cotrimoxazole
861819|NCT02773407|Efficacy
861820|NCT02773407|Enteric fever
861821|NCT02773407|Fever clearance time
861822|NCT02773394|Hepatitis C Virus
861823|NCT02773394|Observational
861824|NCT02773394|Brazil
861825|NCT02773342|Invasive Pulmonal Aspergillosis
861826|NCT02773342|Neutropenic Patients
861827|NCT02773342|Haematological Malignancies
861828|NCT02773342|Chest Computed Tomography
861829|NCT02773329|chemotherapy induced peripheral neuropathy
861830|NCT02773329|Cancer
861831|NCT02773329|game-based exercise
861832|NCT02773329|exercise
861833|NCT02773329|wearable sensors
861834|NCT02773329|balance
861835|NCT02773329|falls
861836|NCT02773329|virtual reality
861837|NCT02773303|Neurofeedback
861838|NCT02773303|balance, postural
861839|NCT02773303|postural equilibrium
861840|NCT02773303|EEG
861841|NCT02773290|Aplastic Anemia
861842|NCT02773251|Postoperative adhesion
861843|NCT02773251|Laparoscopy
861844|NCT02773251|Adhesion barrier
861845|NCT02773225|non severe Aplastic Anemia,
861846|NCT02773186|postoperative
861847|NCT02773186|behavioral changes
861848|NCT02773173|Colorectal Laparoscopic Surgery
861849|NCT02773134|Post-operative Bracing
861850|NCT02773134|Rigid Lumbosacral Orthosis
861851|NCT02773134|Posterior Spine Fusion
861852|NCT02773134|Quality of Life
861853|NCT02773134|Lumbar Degenerative Conditions
861854|NCT02773121|Cognition
861855|NCT02773121|Learning
861856|NCT02773121|Memory
861857|NCT02773121|Executive Function
861858|NCT02773121|Attention
861859|NCT02773121|Neuropsychological Tests
861860|NCT02773121|Physical Activity
861861|NCT02773121|Physical Fitness
861863|NCT02773121|Resistance Training
861864|NCT02773121|Walking
861865|NCT02773121|Muscle Stretching Exercises
861866|NCT02773121|Exercise Test
861867|NCT02773121|Balance
861868|NCT02773121|Flexibility
861869|NCT02773121|Body Composition
861870|NCT02773082|Treatment-Resistant
861871|NCT02773082|Anxiety
861872|NCT02773056|transfemoral
861873|NCT02773056|amputation
861874|NCT02773056|perspiration
861875|NCT02773056|socket
861876|NCT02773056|socket comfort
861877|NCT02773030|Multiple Myeloma
861878|NCT02773030|Relapsed
861879|NCT02773030|Refractory
861880|NCT02773030|Pharmacokinetics
861881|NCT02773030|Safety
861882|NCT02773030|Efficacy
861883|NCT02773030|CC-220
861884|NCT02773030|Relapsed and refractory multiple myeloma
861885|NCT02773017|sedation
861886|NCT02773017|age
861887|NCT02773017|dexmedetomidine
861888|NCT02773004|Genomic test
861889|NCT02773004|Chemotherapy decision
861890|NCT02772978|decision making
861891|NCT02772978|impulsivity
861892|NCT02772926|Benfotiamine
861893|NCT02772926|Advanced glycation end products
861894|NCT02772926|Soluble receptor for AGEs
861895|NCT02772926|Endogenous secretory receptor for AGEs
861896|NCT02772900|Aging
861897|NCT02772900|Beetroot
861898|NCT02772900|Dietary Nitrate
861899|NCT02772900|Functional Food
861900|NCT02772900|Vascular Function
861901|NCT02772887|pregnancy
861902|NCT02772887|type 2 diabetes
861903|NCT02772887|asymmetric dimethylarginine
861904|NCT02772887|L-arginine
861905|NCT02772887|L-citrulline
861906|NCT02772887|placental growth factor (PlGF)
861907|NCT02772887|blood pressure
861908|NCT02772874|fecal incontinence
861909|NCT02772874|severity
861910|NCT02772874|ultrasound
861911|NCT02772874|anorectal manometry
861912|NCT02772874|classification
861913|NCT02772835|nCPAP
861914|NCT02772835|nHFOV
861915|NCT02772835|Preterm
861916|NCT02772835|RDS
861917|NCT02772835|CO2 Elimination
861918|NCT02772809|stroke
861919|NCT02772809|hemiplegia
861920|NCT02772809|rehabilitation
861921|NCT02772809|robotics
861922|NCT02772809|neuroplasticity
861923|NCT02772796|Pharmacokinetics
861924|NCT02772796|Healthy Volunteer Study
861925|NCT02772783|brain
861926|NCT02772783|fMRI
861927|NCT02772783|carbohydrate
861928|NCT02772783|insulin clamp
861929|NCT02772783|intake regulation
861930|NCT02772783|overweight
861931|NCT02772783|glycemic index
861932|NCT02772757|hearing loss
861933|NCT02772757|hearing aids
861934|NCT02772757|outcome assessment
861935|NCT02772744|Hepatitis C virus genotype 4
861936|NCT02772744|Antiviral
861937|NCT02772744|Virologic Response
861938|NCT02772731|mastectomy
861939|NCT02772718|Hypoglycemia
861940|NCT02772705|Standardized Uptake Value
861941|NCT02772705|Diagnosis
861942|NCT02772679|Diabetes
861943|NCT02772679|Treg
861944|NCT02772679|Proluekin
861945|NCT02772666|Relative afferent pupillary defect (RAPD)
861946|NCT02772666|Multiple sclerosis
861947|NCT02772666|Glaucoma
861948|NCT02772653|Microcirculation
861949|NCT02772653|Videomicroscopy
861950|NCT02772653|Spectroscopy, Near-Infrared
861951|NCT02772653|B-Type Natriuretic Peptide
861952|NCT02772653|Thromboelastometry
861953|NCT02772653|Trauma
861954|NCT02772653|Resuscitation
861955|NCT02772653|Hypovolemic shock
861956|NCT02772640|Hypercholesterolemia
861957|NCT02772640|Rosuvastatin
861958|NCT02772640|Statin
861959|NCT02772640|Ezetimibe
861960|NCT02772640|Compliance
861961|NCT02772640|Cholesterol
861962|NCT02772640|Secondary prevention
861963|NCT02772640|Coronary artery disease
861964|NCT02772640|Cholesterol absorption inhibitor
861965|NCT02772627|Parkinson's disease, Nebicapone
861966|NCT02772614|Nebicapone, Parkinson's disease
861967|NCT02772601|ABBV-066
861968|NCT02772601|BI 655066
861969|NCT02772601|risankizumab
861970|NCT02772588|ARN-509
861971|NCT02772588|Abiraterone
861972|NCT02772588|Leuprolide
861973|NCT02772588|Intensity-Modulated and Image-Guided Radiation Therapy
861974|NCT02772588|15-334
861975|NCT02772588|apalutamide,
861976|NCT02772588|JNJ-56021927
861977|NCT02772575|MOLECULAR PREDICTORS
861978|NCT02772575|Hepatic trans-arterial embolization (TAE)
861979|NCT02772575|16-385
861980|NCT02772562|prostate cancer
861981|NCT02772549|Diagnosis
861982|NCT02772536|Chronic Tinnitus Tinted Light Change in Perception
861983|NCT02772523|Primary Prevention
861984|NCT02772510|Stroke
861985|NCT02772510|Rehabilitation
861986|NCT02772510|Hand
861987|NCT02772510|Game
861988|NCT02772510|Functional electrical stimulation
861989|NCT02772510|Virtual reality
861990|NCT02772497|DME
861991|NCT02772497|Anti VEGF
861992|NCT02772497|VEGF trap
861993|NCT02772497|Diabetes
861994|NCT02772497|Diabetic retinopathy
861995|NCT02772497|ZALTRAP
861996|NCT02772497|Ziv aflibercept
861997|NCT02772484|noninvasive monitoring
861998|NCT02772471|intracranial pressure
861999|NCT02772471|noninvasive monitoring
862000|NCT02772458|Crohn's Disease
862001|NCT02772458|gut brain axis
862002|NCT02772458|reduced appetite
862003|NCT02772445|Empowerment
862004|NCT02772445|Caregiver
862008|NCT02772406|ulcerative colitis
862009|NCT02772406|colonoscopy
862010|NCT02772406|Dysplasia
862011|NCT02772406|Diagnosis
862012|NCT02772367|cardiotoxicity
862013|NCT02772367|16-025
862014|NCT02772354|Pediatric population, ablation
862015|NCT02772341|Asthma
862016|NCT02772341|Halotherapy
862017|NCT02772341|Airway hyper-reactivity
862018|NCT02772341|Metacholine
862019|NCT02772328|Testing
862020|NCT02772328|Access
862021|NCT02772315|genomics
862022|NCT02772315|proteomics
862023|NCT02772315|metabolomics
862024|NCT02772315|endocrine hypertension
862025|NCT02772315|primary aldosteronism
862026|NCT02772315|Cushing syndrom
862027|NCT02772315|pheochromocytoma
862028|NCT02772289|Mesenchyme Stem Cells
862029|NCT02772289|Cesarean Section
862030|NCT02772289|Scars
862031|NCT02772276|Glomerular Filtration Rate
862032|NCT02772263|Paramedicine
862033|NCT02772263|Community Paramedic
862034|NCT02772263|Elderly
862035|NCT02772250|bowel preparation
862036|NCT02772250|polyethylene glycol
862037|NCT02772250|face-to-face re-education
862038|NCT02772250|telephone re-education
862039|NCT02772250|Boston Bowel Preparation Scale
862040|NCT02772237|concussion
862041|NCT02772237|sports-related concussion
862042|NCT02772237|mTBI
862043|NCT02772237|Riboflavin
862044|NCT02772237|Vitamin B2
862045|NCT02772159|COPD
862046|NCT02772159|ADME
862047|NCT02772159|Healthy Normal Males
862048|NCT02772159|Phase 1
862049|NCT02772120|Infertility
862050|NCT02772120|In vitro fertilization
862051|NCT02772120|Embryo transfer
862052|NCT02772120|Blastocyst
862053|NCT02772120|Progesterone
862054|NCT02772120|Crinone
862055|NCT02772107|Small Cell Lung Carcinoma
862056|NCT02772094|glioblastoma multiforme
862057|NCT02772094|glioblastoma
862058|NCT02772094|newly diagnosed glioblastoma
862059|NCT02772094|immunotherapy
862060|NCT02772094|dendritic cells
862061|NCT02772094|grade IV astrocytoma
862062|NCT02772094|oncology
862063|NCT02772094|neurology
862064|NCT02772094|glioma
862065|NCT02772094|brain tumor
862066|NCT02772094|ADCTA-G
862067|NCT02772055|Moxa smoke
862068|NCT02772055|Moxibustion
862069|NCT02772055|Knee osteoarthritis
862070|NCT02772042|Manual Therapy
862071|NCT02772042|Physiotherapy
862072|NCT02772042|Manipulation
862073|NCT02772003|Chronic HCV
862074|NCT02772003|Immunotherapy
862075|NCT02772003|DNA Vaccine
862076|NCT02772003|Electroporation
862077|NCT02771990|Back Pain
862078|NCT02771964|outcome assessment
862079|NCT02771964|postoperative period
862080|NCT02771951|Childhood
862081|NCT02771951|Obesity
862082|NCT02771938|radiotherapy, breast cancer, DIEP flap
862083|NCT02771925|Gabapentin
862084|NCT02771925|Alcohol Dependence
862085|NCT02771899|Imaging, Three-Dimensional
862086|NCT02771899|Spine
862087|NCT02771899|Scoliosis
862088|NCT02771886|mindfulness
862089|NCT02771886|urges
862090|NCT02771886|adolescents
862091|NCT02771886|risk behaviors
862092|NCT02771886|therapy intervention
862093|NCT02771860|denosumab
862094|NCT02771860|RANKL-blockade
862095|NCT02771834|Postural balance
862096|NCT02771834|Osteoporosis
862097|NCT02771834|Postmenopause
862098|NCT02771834|Vitamin D
862099|NCT02771834|Kyfhosis
862100|NCT02771834|Muscle strength
862101|NCT02771808|CABG
862102|NCT02771795|HER2
862103|NCT02771795|Trastuzumab
862104|NCT02771795|Biosimilar
862105|NCT02771795|Cancer
862106|NCT02771795|Breast
862107|NCT02771795|Positive
862108|NCT02771782|BCG
862109|NCT02771782|TDaP-IPV
862110|NCT02771782|DPT Vaccine
862111|NCT02771769|cell-free DNA
862112|NCT02771769|copy number instability
862113|NCT02771769|liquid biopsy
862114|NCT02771769|cancer
862115|NCT02771756|Breast cancer
862116|NCT02771756|Lung cancer
862117|NCT02771756|Nutritional support
862118|NCT02771756|Safety
862119|NCT02771756|Effectiveness
862120|NCT02771743|Neuroblastoma
862121|NCT02771743|High risk
862122|NCT02771743|Tandem high dose chemotherapy
862123|NCT02771691|Adolescent
862124|NCT02771652|Multiple Sclerosis
862125|NCT02771652|Quality of Life
862126|NCT02771652|exercise
862127|NCT02771652|internet
862128|NCT02771639|Hip arthroplasty
862129|NCT02771639|periprosthetic joint infection
862130|NCT02771639|outcome
862131|NCT02771626|RCC
862132|NCT02771626|MEL
862133|NCT02771626|NSCLC
862134|NCT02771626|Immuno-Oncology
862135|NCT02771626|Tumor Metabolism
862136|NCT02771626|Glutaminase
862137|NCT02771626|Glutaminase Inhibitor
862138|NCT02771613|Morbidity Mortality Review
862139|NCT02771613|medical simulation
862140|NCT02771613|in situ simulation
862141|NCT02771613|multi professional simulation
862142|NCT02771613|hospital adverse event
862143|NCT02771600|Procedural pain
862144|NCT02771600|Procedural anxiety
862145|NCT02771600|Pediatrics
862146|NCT02771600|Needle-related procedures
862147|NCT02771587|alcohol
862148|NCT02771587|energy drink
862149|NCT02771587|coagulability
862150|NCT02771587|caffeine
862151|NCT02771587|taurine
862152|NCT02771587|driving performance
862153|NCT02771574|Bariatric surgery complications
862154|NCT02771574|Glucose Metabolism Disorders
862155|NCT02771574|Exendin (9-39)
862156|NCT02771574|GLP-1
862157|NCT02771561|Patent Foramen Ovale
862158|NCT02771561|Obstructive Sleep Apnea
862159|NCT02771561|Apnea-Hypopnea Index
862160|NCT02771561|Oxygen Desaturation Index
862161|NCT02771561|Epworth Sleepiness Scale
862162|NCT02771561|Quality of life
862163|NCT02771561|Continuous Positive Airway Pressure
862164|NCT02771561|Obstructive Sleep Apnea-Hypopnea Syndrome
862165|NCT02771561|Gore™ septal occluder device
862166|NCT02771548|Knee injuries
862167|NCT02771548|Rehabilitation
862168|NCT02771548|Return to sport
862169|NCT02771548|Biomechanics
862171|NCT02771509|CPB
862172|NCT02771509|Cardiac Surgery
862173|NCT02771509|Acute Kidney Injury
862174|NCT02771470|Gut microflora
862175|NCT02771470|Lung cancer
862176|NCT02771470|Chemotherapy
862177|NCT02771470|Immunity
862178|NCT02771470|Nutrition
862179|NCT02771457|Influximab
862180|NCT02771457|IFX
862181|NCT02771457|Remicade
862182|NCT02771418|Carotid endarterectomy
862183|NCT02771418|postoperative cognitive dysfunction
862184|NCT02771405|HCV-HCC-DAAs
862185|NCT02771366|neuroinflammation
862186|NCT02771366|cognitive function
862187|NCT02771366|aging adults
862188|NCT02771314|NSCLC
862189|NCT02771314|AZD9291
862190|NCT02771314|>= 2nd line
862191|NCT02771314|liquid biopsy
862192|NCT02771314|EGFR TKIs
862193|NCT02771314|EGFR mutant
862194|NCT02771301|IDH1R132H Dendritic cell glioma
862195|NCT02771288|Kawasaki disease
862196|NCT02771288|optical coherence tomography
862197|NCT02771288|multislice computed tomography
862198|NCT02771249|Latent Tuberculosis Infection (LTBI)
862199|NCT02771249|Antiretrovirals (ARVs)
862200|NCT02771249|HIV
862201|NCT02771249|UGT1A1
862202|NCT02771249|Drug-Drug Interaction (DDI)
862203|NCT02771236|Inherited Eye Disease
862210|NCT02771197|AML
862211|NCT02771171|Pediatric Airway, Three-dimensional Imaging, CT Scan
862212|NCT02771158|critical care
862213|NCT02771158|shock, septic
862214|NCT02771158|sepsis
862215|NCT02771158|hypotension
862216|NCT02771158|midodrine
862217|NCT02771093|Type 2, Diabetes, Diabetes Mellitus
862218|NCT02771041|Hip prothesis
862225|NCT02770989|Cardiac Ablation
862226|NCT02770989|Safety
862227|NCT02770989|Performance
862228|NCT02770989|Laser
862229|NCT02770963|discogenic
862230|NCT02770963|Acupuncture Therapy
862231|NCT02770963|randomized controlled trial
862232|NCT02770950|Knee Osteoarthritis
862233|NCT02770937|laparoscopy, simulator
862234|NCT02770924|cataract
862235|NCT02770924|phacoemulsification
862236|NCT02770924|AT LISA TRI TORIC
862237|NCT02770924|IOL
862238|NCT02770911|Rectal Carcinoma
862239|NCT02770911|Laparoscopy
862240|NCT02770911|Anastomotic Leak
862241|NCT02770911|Double-stapling technique
862242|NCT02770898|probation
862243|NCT02770898|evidence-based
862244|NCT02770898|well-being
862245|NCT02770898|physical exercise
862246|NCT02770898|family well-being
862247|NCT02770872|serum amyloid a
862248|NCT02770872|lipoprotein
862249|NCT02770872|insulin resistance
862250|NCT02770872|dyslipidemia
862251|NCT02770859|Achalasia
862252|NCT02770833|Proteins (seafood and meat)
862253|NCT02770833|GI
862254|NCT02770833|Energy expenditure
862255|NCT02770833|Energy balance
862256|NCT02770833|Thermogenesis (DIT)
862257|NCT02770833|Appetite regulating hormones
862258|NCT02770833|Appetite sensations
862259|NCT02770833|Glucose allostatis
862260|NCT02770833|Amino acid metabolism
862261|NCT02770833|Satiety
862262|NCT02770833|Food preferences
862263|NCT02770807|Ataxia Teleangiectasia
862264|NCT02770807|AT
862265|NCT02770807|EryDex system
862266|NCT02770807|Dexamethasone
862267|NCT02770807|Dexamethasone sodium phosphate
862268|NCT02770781|survivors
862269|NCT02770781|physical fitness
862270|NCT02770768|HSDD (Hypoactive Sexual Desire Disorder)
862271|NCT02770768|EEG (Electroencephalogram)
862272|NCT02770742|patient satisfaction
862273|NCT02770742|unsedated colonoscopy
862274|NCT02770742|intestinal diseases
862275|NCT02770729|intracameral moxifloxacin
862276|NCT02770729|endophthalmitis
862277|NCT02770729|Vigamox
862278|NCT02770729|endothelial cell density
862279|NCT02770677|Yoga
862280|NCT02770677|COPD
862281|NCT02770677|rehabilitation
862282|NCT02770651|optical coherence tomography
862283|NCT02770651|everolimus-eluting stent
862284|NCT02770651|zotarolimus-eluting stent
862285|NCT02770638|Healthy
862286|NCT02770638|Sport
862287|NCT02770638|Athlete
862288|NCT02770638|Male
862289|NCT02770638|University
862290|NCT02770638|Adults
862291|NCT02770638|Rugby Football Union
862292|NCT02770638|Professional
862293|NCT02770638|Competitive sport
862294|NCT02770638|Scoop Stretcher
862295|NCT02770638|Ferno Scoop Stretcher
862296|NCT02770638|Long back spinal board
862297|NCT02770638|Emergency Medical Services
862298|NCT02770638|Long backboard
862299|NCT02770638|Patient Extrication
862300|NCT02770638|Triple Immobilisation
862301|NCT02770638|Pre hospital Medicine
862302|NCT02770638|Rigid Cervical Collar
862303|NCT02770638|Pressure Testing
862304|NCT02770638|Tissue Pressure Testing
862305|NCT02770638|Visual Analogue Scale
862306|NCT02770638|Pressure Sores
862307|NCT02770638|Pressure area damage
862308|NCT02770638|Tissue Viability
862309|NCT02770638|Tissue Interface Pressure
862310|NCT02770638|Comfort
862311|NCT02770638|Pain
862312|NCT02770625|Type I Gaucher
862313|NCT02770625|ISU302
862314|NCT02770625|Imiglucerase
862321|NCT02770573|nano-hydroxyapatite
862322|NCT02770508|antiretroviral naive
862323|NCT02770508|dual therapy
862324|NCT02770482|dementia
862325|NCT02770482|biomarkers
862326|NCT02770482|cerebrospinal fluid
862327|NCT02770469|Breast Cancer
862328|NCT02770469|Korean Americans
862329|NCT02770469|Survivorship
862330|NCT02770469|Quality of Life
862331|NCT02770469|Coping Skills
862332|NCT02770469|Perceived Stress
862333|NCT02770456|fish oil, preterm birth, pregnancy, China, prevention
862334|NCT02770443|Recovered LVEF
862335|NCT02770443|DCM
862336|NCT02770391|HSD3B1 Genotype
862337|NCT02770391|Steroid Metabolism
862338|NCT02770391|High-risk Prostate Cancer
862339|NCT02770391|ARN-509
862340|NCT02770378|Temozolomide
862341|NCT02770378|Recurrent Glioblastoma
862342|NCT02770352|retrospective chart review
862343|NCT02770352|prospective chart review
862344|NCT02770352|fistula formation and repair
862345|NCT02770352|database
862346|NCT02770352|demographics of women with fistulas
862347|NCT02770352|internationally accepted risks factors for fistula formation
862348|NCT02770339|Pharmacogenomics
862349|NCT02770339|Psychiatric crisis
862350|NCT02770339|Drug overdose
862351|NCT02770339|Psychotropic medications
862352|NCT02770326|Safety of Stool Transplant
862353|NCT02770326|Fecal Microbiota Transplantation (FMT)
862354|NCT02770326|15-337
862355|NCT02770300|automatic
862356|NCT02770300|personalized
862357|NCT02770300|robotic therapy
862358|NCT02770261|DP-R208
862359|NCT02770222|Pharmacokinetics
862360|NCT02770196|Community-Supported Agriculture
862361|NCT02770196|Local Food System
862362|NCT02770196|Vegetable
862363|NCT02770196|Fruit
862364|NCT02770196|Childhood Obesity
862365|NCT02770183|Myocardial stunning
862366|NCT02770183|Echocardiography, Transesophageal
862367|NCT02770183|Extracorporeal Circulation
862368|NCT02770144|Child Quality of Life
862369|NCT02770144|Financial Coaching
862370|NCT02770144|Socioeconomic Status
862371|NCT02770144|Social Determinants of Health
862374|NCT02770118|sleep restriction
862375|NCT02770118|obesity
862376|NCT02770118|brown adipose tissue
862377|NCT02770105|L-theanine
862378|NCT02770105|caffeine
862379|NCT02770105|selective attention
862380|NCT02770105|fMRI
862381|NCT02770105|RVRT
862382|NCT02770079|Insulin sensitivity
862383|NCT02770053|Foraminal enlargement
862384|NCT02770053|Root canal treatment
862385|NCT02770040|Acute Severe Ulcerative Colitis
862386|NCT02770040|Steroid Refractory Ulcerative Colitis
862387|NCT02770027|Colon Surgery
862388|NCT02770027|blood viscosity
862389|NCT02770014|Non-Small Cell Lung Cancer
862390|NCT02770014|Epidermal Growth Factor Receptor
862391|NCT02770001|Admixture
862392|NCT02770001|African American
862393|NCT02770001|African American Genetics
862394|NCT02769988|Adolescents
862395|NCT02769988|Health Information Literacy
862396|NCT02769988|Health Education
862397|NCT02769975|Endocrinology
862398|NCT02769975|Obesity
862399|NCT02769975|Pediatric
862400|NCT02769975|Growth Disorder
862401|NCT02769975|Pubertal Development
862402|NCT02769962|PARP Inhibitor
862403|NCT02769962|Topoisomerase I (Top1)
862404|NCT02769962|Camptothecins
862405|NCT02769962|Nanoparticle Drug Conjugate
862406|NCT02769949|Genetics
862407|NCT02769949|Metabolic
862408|NCT02769949|Dysmorphic Syndromes
862409|NCT02769949|Developmental Delay
862410|NCT02769949|Genetic Counseling
862411|NCT02769936|Receptors
862412|NCT02769936|N-Methyl-D-Aspartate
862413|NCT02769923|WestPharma ID-adapter
862414|NCT02769923|Star ID syringe
862415|NCT02769923|BCG needle syringe
862416|NCT02769923|fractional dose IPV
862417|NCT02769923|fIPV
862418|NCT02769923|polio
862419|NCT02769923|Polio Endgame
862420|NCT02769923|IPV
862421|NCT02769884|artificial pancreas
862422|NCT02769832|Abraxane
862423|NCT02769832|Albumin-bound Paclitaxel
862424|NCT02769832|SCLC
862425|NCT02769832|Gemzar
862426|NCT02769819|Flexible fiberscope
862427|NCT02769754|LIVER
862428|NCT02769754|RESECTION
862429|NCT02769754|SURGERY
862430|NCT02769741|Cashew
862431|NCT02769741|Lipoprotein
862432|NCT02769715|Removable partial dentures
862433|NCT02769715|partial edentulism
862434|NCT02769702|Uveitis
862435|NCT02769689|Multiple sclerosis
862436|NCT02769689|Natalizumab
862437|NCT02769689|Fingolimod
862438|NCT02769689|Methylprednisolone
862439|NCT02769650|Coronary stenosis
862440|NCT02769650|Drug-eluting stent
862441|NCT02769650|Coronary angioplasty with stenting
862442|NCT02769650|Ischemic Heart Disease
862443|NCT02769650|Chronic total occlusion
862444|NCT02769650|Right coronary artery
862445|NCT02769650|Stress-MRI
862446|NCT02769637|upper gastrointestinal tract
862447|NCT02769637|lung microbiota and inflammation
862448|NCT02769624|Congenital heart disease
862449|NCT02769598|Pain
862450|NCT02769598|Nociception
862451|NCT02769598|Pediatric intensive care
862452|NCT02769598|Pain assessment scale
862453|NCT02769598|ANI index
862454|NCT02769585|Obesity
862455|NCT02769585|Diabetes Mellitus, Type 2
862456|NCT02769585|weight reduction
862457|NCT02769572|Knee osteoarthritis
862458|NCT02769572|moxibustion
862459|NCT02769572|diclofenac sodium gel
862460|NCT02769520|squamous cell carcinoma head and neck
862461|NCT02769520|pembrolizumab
862462|NCT02769494|Oral ulcer
862463|NCT02769494|Crohn's disease
862464|NCT02769468|Temperature-Probe Placement-preterm infant-case room
862465|NCT02769455|Food Labelling
862466|NCT02769442|Intravenous
862467|NCT02769442|Catheter
862468|NCT02769442|Puncture
862469|NCT02769442|Peripheral Catheterization
862470|NCT02769442|First Stick Success
862471|NCT02769442|Contamination
862472|NCT02769442|Terumo
862473|NCT02769442|SurFlash
862474|NCT02769416|spinal cord injury
862475|NCT02769416|traumatic brain injury
862476|NCT02769403|Job Satisfaction
862477|NCT02769403|Job Performance
862478|NCT02769403|Primary Care
862479|NCT02769390|Analgesia
862480|NCT02769390|Bupivacaine
862481|NCT02769390|Clonidine
862482|NCT02769377|diabetes, glucometer, mobile-phone
862483|NCT02769364|Advanced or Metastatic Breast Cancer
862484|NCT02769364|Eribulin
862485|NCT02769351|volume overload
862486|NCT02769351|heart failure
862487|NCT02769351|cardiac decompensation
862488|NCT02769351|ultrafiltration
862489|NCT02769338|Implementation
862490|NCT02769338|Quality Improvement
862491|NCT02769338|Stroke
862492|NCT02769338|Transient Ischemic Attack
862493|NCT02769338|TIA
862494|NCT02769338|System Redesign
862495|NCT02769338|QI Intervention
862496|NCT02769325|atropine
862497|NCT02769325|pain, postoperative
862498|NCT02769312|Quality of Life
862499|NCT02769312|Post-Traumatic Stress Disorder
862500|NCT02769312|Transcranial Magnetic Stimulation
862501|NCT02769312|Feasibility studies
862502|NCT02769260|pyrosequencing
862503|NCT02769260|16S DNA gene
862504|NCT02769260|Confocal Laser Scanning Microscope
862505|NCT02769260|bacterial viability
862506|NCT02769260|bacterial diversity
862507|NCT02769247|naproxen
862508|NCT02769247|lidocaine
862509|NCT02769247|intrauterine device
862510|NCT02769247|IUD
862511|NCT02769247|pain
862512|NCT02769234|EEG
862513|NCT02769234|ERP
862514|NCT02769234|Event-related Potentials
862515|NCT02769234|Alzheimer's
862516|NCT02769234|P300
862517|NCT02769208|Air Pollution
862518|NCT02769208|Air Filtration
862519|NCT02769208|Exposure Assessment
862520|NCT02769208|HEPA Filter
862521|NCT02769208|Electrostatic Precipitator
862522|NCT02769208|Cardiovascular Disease Biomarkers
862523|NCT02769208|Respiratory Disease Biomarkers
862524|NCT02769182|Older adults
862525|NCT02769182|falls
862526|NCT02769182|cognition
862527|NCT02769182|smart phone
862528|NCT02769169|Ranibizumab, regression of the polyps
862529|NCT02769143|Postmenopausal
862530|NCT02769143|Bone Density
862531|NCT02769143|Exercise
862532|NCT02769104|aromatase inhibitors
862533|NCT02769104|chemotherapy
862534|NCT02769104|neoadjuvant
862535|NCT02769104|postmenopausal
862536|NCT02769104|breast cancer
862537|NCT02769078|Anticoagulation
862538|NCT02769065|Drug Therapy
862539|NCT02769052|endometriosis
862540|NCT02769052|dyspareunia
862541|NCT02769052|physical therapy
862542|NCT02769052|sexuality
862543|NCT02769052|transcutaneous electrical nerve stimulation
862544|NCT02769013|Schistosoma haematobium plasmodium falciparum transmission
862545|NCT02768987|exercise
862546|NCT02768987|physical activity
862547|NCT02768987|behavior modification
862548|NCT02768987|coping skills
862549|NCT02768987|self management
862550|NCT02768987|glycemic control
862551|NCT02768987|overweight
862552|NCT02768987|obesity
862553|NCT02768987|body composition
862554|NCT02768987|adherence
862555|NCT02768961|sofosbuvir
862556|NCT02768961|ledipasvir
862557|NCT02768961|ribavirin
862558|NCT02768961|prisoner
862559|NCT02768961|hepatitis c
862560|NCT02768961|prevalence
862561|NCT02768961|hepatitis b
862562|NCT02768922|Telemedicine
862563|NCT02768922|Telerehabilitation
862564|NCT02768922|Speech and language therapy
862565|NCT02768883|Childhood asthma
862566|NCT02768883|Latino
862567|NCT02768844|Stochastic Resonance
862568|NCT02768844|Fetus/Newborn Infant
862569|NCT02768844|Drug Withdrawal
862570|NCT02768844|Substance Abuse
862571|NCT02768818|Maternal Obesity Complicating Pregnancy
862572|NCT02768805|Influenza
862573|NCT02768805|Human
862574|NCT02768805|RNA Virus Infections
862575|NCT02768805|Immunologic
862576|NCT02768805|Immunogenic Factors
862577|NCT02768805|Physiological Effects of Drug
862578|NCT02768805|Virus Diseases
862579|NCT02768805|Orthomyxoviridae Infections
862580|NCT02768805|Infection
862581|NCT02768779|hair
862582|NCT02768766|MEK inhibitor
862583|NCT02768766|Selumetinib
862584|NCT02768766|hyd-sulfate AZD6244
862585|NCT02768766|Uveal melanoma
862586|NCT02768766|Melanoma
862587|NCT02768753|Robotic thyroidectomy
862588|NCT02768753|Robotic central neck dissection
862589|NCT02768753|Axillary bilateral-breast approach
862590|NCT02768753|Bilateral axillo-breast approach
862591|NCT02768727|neurocognitive function
862592|NCT02768727|neural inertia
862593|NCT02768727|xenon gas
862594|NCT02768714|Breast Cancer High risk Stage II or Stage III / IV
862595|NCT02768701|Pembrolizumab
862596|NCT02768701|cyclophosphamide
862597|NCT02768688|Human Brain
862598|NCT02768688|Magnetic Resonance Imaging (MRI)
862599|NCT02768688|Dexmedetomidine
862600|NCT02768688|Cerebral blood flow
862601|NCT02768675|Kyphotic
862602|NCT02768675|Corrective Surgery
862603|NCT02768675|Spinal fractures
862604|NCT02768636|Omega-3, ANS, HRV, SDNN
862605|NCT02768610|dexmedetomidine
862606|NCT02768584|severe mental illness
862607|NCT02768584|nursing
862608|NCT02768584|therapeutic alliance
862609|NCT02768584|psychiatric diseases
862610|NCT02768571|cerebrolysin, stroke, motor function
862611|NCT02768558|Lung Cancer
862612|NCT02768558|NSCLC
862613|NCT02768558|Nivolumab
862614|NCT02768545|Hepatitis C
862615|NCT02768545|Ezetimibe
862616|NCT02768545|Cholesterol
862617|NCT02768545|Enterohepatic Circulation
862618|NCT02768545|Bile
862619|NCT02768545|Feces
862620|NCT02768532|Crohn's disease
862621|NCT02768532|Vedolizumab
862622|NCT02768532|TNF (Tumor Necrosis Factor)
862623|NCT02768532|Clinical response
862624|NCT02768532|Clinical remission
862625|NCT02768519|Participants
862626|NCT02768506|obesity, malabsorption, gastric bypass, SADI-S
862627|NCT02768480|Diabetes
862628|NCT02768480|phone calls
862629|NCT02768480|glycemic control
862630|NCT02768467|Alloderm graft
862631|NCT02768467|Allograft
862632|NCT02768467|Buccal Mucosa
862633|NCT02768454|broad-spectrum antimicrobial
862634|NCT02768454|antibiotics pharmacist
862635|NCT02768428|Knowledge [K01.468]
862636|NCT02768428|Video-Audio Media [V01.255.500]
862637|NCT02768428|Handbooks [V02.520]
862638|NCT02768402|Mitral Valve Regurgitation
862639|NCT02768402|Primary MR
862640|NCT02768402|Secondary MR
862641|NCT02768402|MR
862642|NCT02768402|Heart Failure
862643|NCT02768402|Structural Heart
862644|NCT02768402|Secondary Mitral Valve Regurgitation
862645|NCT02768402|Primary Mitral Valve Regurgitation
862646|NCT02768389|Modified Atkins Diet
862647|NCT02768389|MAD
862648|NCT02768389|Brain Tumor
862649|NCT02768389|Glioblastoma
862650|NCT02768363|Immunotherapy
862651|NCT02768363|Tumor vaccine
862652|NCT02768363|Immuno-oncology
862653|NCT02768363|Cytotoxicity
862654|NCT02768363|Prostate cancer
862655|NCT02768363|Active Surveillance
862656|NCT02768350|lung collapse
862657|NCT02768350|ventilator hyper inflation
862658|NCT02768350|hemodynamic responses
862659|NCT02768350|ventilatory responses
862660|NCT02768350|trauma patients
862661|NCT02768337|brain metastasis
862662|NCT02768337|operable brain metastasis
862663|NCT02768324|sepsis
862664|NCT02768324|Gastrointestinal Microbiome
862665|NCT02768324|Gut microbiota
862666|NCT02768324|Gut Flora
862667|NCT02768324|Intestinal Flora
862668|NCT02768311|Instrumentation Post-operative pain Root canal preparation
862669|NCT02768298|Heart failure
862670|NCT02768298|systolic heart failure
862671|NCT02768298|heart failure with reduced ejection fraction
862672|NCT02768298|exercise capacity
862673|NCT02768285|apical patency
862674|NCT02768285|root canal treatment
862675|NCT02768233|Medication-overuse Headache
862676|NCT02768233|Educational Programme
862677|NCT02768233|Personality Profiles
862678|NCT02768181|nutrition-specific behaviour change communication
862679|NCT02768181|dietary supplements
862680|NCT02768168|Dezocine
862681|NCT02768168|Dexamethasone 21-phosphate
862682|NCT02768168|Pain
862683|NCT02768168|Pruritus
862684|NCT02768155|OA, Osteoarthritis, Knee
862685|NCT02768116|Active Transfer of Plaque
862686|NCT02768103|upper extremity
862687|NCT02768103|spinal cord injury
862688|NCT02768103|surgical reconstruction
862689|NCT02768103|MRI, functional
862690|NCT02768103|rehabilitation
862691|NCT02768077|melatonin
862692|NCT02768077|sleep disturbances
862693|NCT02768025|smoking cessation
862694|NCT02768025|tobacco control
862695|NCT02768025|acupuncture
862696|NCT02768025|Korean Medicine
862697|NCT02768025|Traditional & Complementary Medicine
862698|NCT02767999|Acute ischemic stroke
862699|NCT02767986|Hispanic
862700|NCT02767986|Health Belief Model
862701|NCT02767986|Cultural Consensus Theory
862702|NCT02767986|Cancer Genetics
862703|NCT02767986|Qualitative
862704|NCT02767960|Tenascin-C
862705|NCT02767908|Tobacco
862706|NCT02767908|Smoking Cessation
862707|NCT02767869|Metabolic syndrome
862708|NCT02767869|central obesity
862709|NCT02767869|Banaba
862710|NCT02767869|insulin secretion
862711|NCT02767869|insulin sensitivity
862712|NCT02767804|ALK-positive NSCLC
862713|NCT02767778|Acute ischemic stroke
862714|NCT02767778|Neuroprotection
862715|NCT02767778|Extremely low frequency magnetic fields
862716|NCT02767752|Resectable pancreatic cancer
862717|NCT02767752|Adjuvant
862718|NCT02767713|Cognition Disorders
862719|NCT02767713|Cardiac Surgical Procedures
862720|NCT02767713|dexamethasone
862721|NCT02767687|Postoperative Care
862722|NCT02767687|Postoperative Period
862723|NCT02767687|Heart Surgery
862724|NCT02767674|R-Gemox
862725|NCT02767674|R-miniCHOP
862726|NCT02767674|elderly patients with diffuse large B cell lymphoma
862727|NCT02767661|metronomic capecitabine
862728|NCT02767661|aromatase inhibitor
862729|NCT02767661|first line treatment
862730|NCT02767661|metastatic breast cancer
862731|NCT02767648|cholestasis
862732|NCT02767648|neonatal
862733|NCT02767648|infant
862734|NCT02767596|Type 2 Diabetes Mellitus
862735|NCT02767596|treatment
862736|NCT02767596|GLP-1
862737|NCT02767583|Neuropathology
862738|NCT02767570|Osteoarthritis, Knee
862739|NCT02767570|Arthritis
862740|NCT02767570|Joint Diseases
862741|NCT02767570|Musculoskeletal Diseases
862742|NCT02767570|Rheumatic Diseases
862743|NCT02767544|laparoscopic hysterectomy
862744|NCT02767544|postoperative pain
862745|NCT02767544|local analgesia
862746|NCT02767544|vaginal wound
862750|NCT02767453|Shoulder arthroplasty
862751|NCT02767453|Closed suction drainage
862752|NCT02767453|Glenohumeral
862753|NCT02767453|Drainage tube
862754|NCT02767427|Infection Control
862755|NCT02767427|Preoperative Care
862756|NCT02767427|Chlorhexidine
862757|NCT02767427|Pre-Surgical Wash
862758|NCT02767427|Spine Surgery
862759|NCT02767427|Surgical site infections
862760|NCT02767427|Cutaneous bacterial load on skin
862761|NCT02767401|PET-CT
862762|NCT02767401|Cardiac magnetic resonance (CMR) imaging
862763|NCT02767401|Major adverse cardiac events (MACEs)
862764|NCT02767401|coronary artery disease
862765|NCT02767375|Hepatocellular Carcinoma
862766|NCT02767375|Hepatic arterial infusion chemotherapy
862767|NCT02767362|atorvastatin
862768|NCT02767362|endometrium
862769|NCT02767362|endometrial cancer
862770|NCT02767310|Bioequivalence
862771|NCT02767310|two rosuvastatin-containing products
862772|NCT02767284|Contrast Sensitivity
862773|NCT02767284|Diagnostic Techniques, Ophthalmological
862774|NCT02767258|Dry eye
862775|NCT02767258|Diseases of the eye and adnexa
862776|NCT02767245|Thiamine
862777|NCT02767245|Congestive heart failure
862778|NCT02767245|Atrial fibrillation
862779|NCT02767245|Graves' disease
862780|NCT02767232|PHLO
862781|NCT02767232|deep vein thrombosis
862782|NCT02767232|deep venous thrombosis
862783|NCT02767232|blood clot
862784|NCT02767232|catheter-directed thrombolysis
862785|NCT02767232|thrombolysis
862786|NCT02767232|post-thrombotic syndrome
862787|NCT02767232|PTS
862788|NCT02767232|recombinant tissue plasminogen activator
862789|NCT02767232|rt-PA
862790|NCT02767232|Activase
862791|NCT02767232|Alteplase
862792|NCT02767219|Ophthalmology
862793|NCT02767206|Transnasal endoscopy
862794|NCT02767206|ultrathin endoscopes
862795|NCT02767206|esophageal varices
862796|NCT02767206|gastric varices
862797|NCT02767167|Cow's milk
862798|NCT02767167|Iodine
862799|NCT02767167|Selenium
862800|NCT02767167|Women
862801|NCT02767167|Child-bearing age
862802|NCT02767154|extracorporeal circulation
862803|NCT02767141|Hunger
862804|NCT02767141|food insecurity
862805|NCT02767141|behaviors
862806|NCT02767128|pharmacokinetics
862807|NCT02767128|healthy adult volunteer
862808|NCT02767102|Mediterranean diet
862809|NCT02767102|indoleamine
862810|NCT02767102|nutraceuticals
862811|NCT02767102|nutrition
862812|NCT02767102|oxidative stress
862813|NCT02767089|Glucocorticoids, Biomarkers, Dissociated Agonist of the Glucocorticoid Receptor
862814|NCT02767076|paramedian spinal anesthesia
862815|NCT02767076|real time
862816|NCT02767076|ultrasound
862817|NCT02767076|knee surgeries
862818|NCT02767076|conventional
862819|NCT02767050|DENTAL CARIES
862820|NCT02767050|TOBACCO USERS
862821|NCT02767050|SMOKERS
862822|NCT02767050|SMOKELESS TOBACCO CHEWERS
862823|NCT02767011|surgical site infection
862824|NCT02766985|FSHD
862825|NCT02766985|muscular dystrophy
862826|NCT02766972|Intracranial Aneurysm
862827|NCT02766972|Surgical Clipping
862828|NCT02766972|Rapid Ventricular Pacing
862829|NCT02766959|chronic rhinosinusitis
862830|NCT02766959|airway physiology
862831|NCT02766959|taste receptors
862832|NCT02766959|tas2r
862833|NCT02766959|epithelial biology
862834|NCT02766959|upper respiratory disease
862835|NCT02766946|Mechanical Ventilation
862836|NCT02766933|tenofovir
862837|NCT02766933|hepatocellular carcinoma
862838|NCT02766933|cirrhosis
862839|NCT02766881|Ductal Carcinoma in Situ
862840|NCT02766881|DSC
862841|NCT02766881|Breast Conserving Surgery
862842|NCT02766855|cysteamine
862843|NCT02766855|nephropathic cystinosis
862844|NCT02766855|cystine crystals
862845|NCT02766842|SharkCore
862846|NCT02766842|ProCore
862847|NCT02766829|spinal
862848|NCT02766829|anesthesia
862849|NCT02766829|sitting
862850|NCT02766829|cross leg
862851|NCT02766829|spinal-bone contact
862852|NCT02766738|residential aged care
862853|NCT02766738|mobility
862854|NCT02766738|social participation
862855|NCT02766738|functional capability
862856|NCT02766712|catheter ablation
862857|NCT02766712|atrial fibrillation
862858|NCT02766699|Astrocytoma, Grade IV
862859|NCT02766699|Doxorubicin
862860|NCT02766699|Glioblastoma
862861|NCT02766699|Neoplasms
862862|NCT02766699|Neoplasms by Site
862863|NCT02766699|Antineoplastic Agents
862864|NCT02766699|Drug Delivery Systems
862865|NCT02766699|Molecular Targeted Therapy
862866|NCT02766699|Nanoparticles
862867|NCT02766699|Disease Progression
862868|NCT02766699|Recurrence
862869|NCT02766699|Brain Neoplasms
862870|NCT02766699|Immunotherapy
862871|NCT02766699|Receptor, Epidermal Growth Factor
862872|NCT02766699|Antibodies, Bispecific
862873|NCT02766686|Prostate cancer
862874|NCT02766686|proton radiotherapy
862875|NCT02766686|photon radiotherapy
862876|NCT02766660|Thyroid ophthalmopathy
862877|NCT02766660|optical coherence tomography
862878|NCT02766647|Filgrastim
862879|NCT02766634|filgrastim
862880|NCT02766621|First in human, Phase 1, Healthy volunteers
862881|NCT02766608|COPD
862882|NCT02766582|Ovarian
862883|NCT02766582|platinum
862884|NCT02766582|pembrolizumab
862885|NCT02766569|IRFACODE II, ASD closure, ASD device, erosion, arrhythmia
862891|NCT02766491|Stretching
862892|NCT02766465|Sickle Cell Disease
862893|NCT02766465|Young Adults
862894|NCT02766465|Phase II Trial
862895|NCT02766465|Hematopoietic Cell Transplantation (HCT)
862896|NCT02766465|Human Leukocyte Antigen (HLA)
862897|NCT02766400|Stroke
862898|NCT02766400|Rehabilitation
862899|NCT02766400|Cognition
862900|NCT02766400|Disability
862901|NCT02766400|Intervention
862902|NCT02766374|Asthma
862903|NCT02766374|Biofeedback
862904|NCT02766374|Heart rate variability biofeedback
862905|NCT02766374|Inhaled corticosteroids
862906|NCT02766361|Bipolar disorder
862907|NCT02766361|Psychotherapy
862908|NCT02766361|Cognitive rehabilitation
862909|NCT02766348|DC-CTL, NSCLC
862910|NCT02766322|Alcohol metabolism
862911|NCT02766322|Bariatric surgery
862912|NCT02766322|Effects of alcohol on driving
862913|NCT02766309|Self-assessment of health, Sf12-v2
862914|NCT02766296|PTSD
862915|NCT02766296|trauma
862916|NCT02766296|working memory
862917|NCT02766296|working memory training
862918|NCT02766283|Children
862919|NCT02766283|Iodinated contrast agents
862920|NCT02766270|Grade II/III Glioma
862921|NCT02766270|IDH
862922|NCT02766270|TERT
862923|NCT02766270|Chemoradiotherapy
862924|NCT02766270|Temozolomide
862925|NCT02766218|toddler obesity
862926|NCT02766218|responsive feeding
862927|NCT02766218|behavioral weight control
862928|NCT02766218|pregnancy weight gain
862929|NCT02766218|early life risk factors
862930|NCT02766205|Embolic Stroke of Undetermined Source
862931|NCT02766205|Atrial fibrillation
862932|NCT02766205|prognostic score
862933|NCT02766192|ketamine
862934|NCT02766192|mindfulness based cognitive therapy
862935|NCT02766192|PTSD
862936|NCT02766192|trauma memory
862937|NCT02766192|memory extinction
862938|NCT02766192|memory re-consolidation
862939|NCT02766192|metabolomics
862940|NCT02766192|TIMBER (Trauma Intervention using Mindfulness Based Extinction and Re-consolidation of trauma memories)
862941|NCT02766127|radiotherapy
862942|NCT02766114|CTS
862943|NCT02766114|Carpal tunnel syndrome
862944|NCT02766114|Carpal tunnel release
862945|NCT02766114|Mini incision of carpal tunnel release
862946|NCT02766114|Cosmetic surgery of carpal tunnel syndrome
862947|NCT02766114|endoscopic carpal tunnel surgery
862948|NCT02766114|Carpal Tunnel Release Through Mini Transverse Approach
862949|NCT02766114|Dr. Sayed Issa's Approach
862950|NCT02766114|CTRMTA
862951|NCT02766114|OCTR
862952|NCT02766114|ECTR
862953|NCT02766114|Open Carpal Tunnel Release
862954|NCT02766114|Endoscopic Carpal Tunnel Release
862955|NCT02766114|Syria
862956|NCT02766114|Cosmetic
862957|NCT02766114|Safety
862958|NCT02766114|Rehabilitation,
862959|NCT02766114|Complications
862960|NCT02766114|Surgery
862961|NCT02766114|Satisfaction
862962|NCT02766088|Dengue
862963|NCT02766088|Household
862964|NCT02766088|Southeast Asia
862965|NCT02766088|Latin America
862966|NCT02766088|Surveillance
862967|NCT02766075|Transcatheter Aortic Valve Disease
862968|NCT02766075|Supervised TAVR Exercise Program
862969|NCT02766062|Postoperative cognitive dysfunction
862970|NCT02766062|metabolic syndrome
862971|NCT02766062|propofol
862972|NCT02766062|sevoflurane
862973|NCT02766049|HIV
862974|NCT02766049|immunotherapy
862975|NCT02766049|clinical trial
862976|NCT02766049|dendritic cell
862977|NCT02766036|Proteinuria
862978|NCT02766036|Propolis
862979|NCT02766023|CTV-05
862980|NCT02766023|LACTIN-V
862981|NCT02766023|Lactobacillus
862982|NCT02766023|MetroGel®
862983|NCT02766023|Vaginitis
862984|NCT02765997|AML
862985|NCT02765997|ALL
862986|NCT02765997|MDS
862987|NCT02765984|implantation site
862988|NCT02765984|placental site
862989|NCT02765984|Doppler
862990|NCT02765971|chewing gums
862991|NCT02765971|laxatives
862992|NCT02765971|bowel function
862993|NCT02765945|Exercise
862994|NCT02765945|Osteoporosis
862995|NCT02765945|Cytokines
862996|NCT02765932|Hip
862997|NCT02765932|Knee
862998|NCT02765932|replacement
862999|NCT02765932|surgery
863000|NCT02765919|Carcinoma cervix
863001|NCT02765919|RCT(randomised controlled trial)
863002|NCT02765919|9 Gray
863003|NCT02765919|Brachytherapy
863004|NCT02765906|video
863005|NCT02765906|educational tool
863006|NCT02765906|preeclampsia
863007|NCT02765906|hypertension
863008|NCT02765906|pregnancy
863009|NCT02765906|patient education
863010|NCT02765906|graphic card
863011|NCT02765906|eclampsia
863012|NCT02765906|HELLP
863013|NCT02765906|anxiety
863014|NCT02765906|anxiety assessment
863015|NCT02765906|STAI 6
863016|NCT02765841|HoFH
863017|NCT02765815|TKA
863018|NCT02765815|Knee replacement
863019|NCT02765815|Arthritis
863020|NCT02765815|Knee
863021|NCT02765776|Anti-HIV Drugs
863022|NCT02765776|Raltegravir Potassium
863023|NCT02765776|Aged
863024|NCT02765776|Retrospective Study
863025|NCT02765776|Medical Records
863027|NCT02765711|ticagrelor
863028|NCT02765711|acute coronary syndrome
863029|NCT02765698|Magnetic Resonance Imaging
863030|NCT02765672|Combat Veterans
863031|NCT02765672|Automobile Driving
863032|NCT02765672|Fitness to Drive
863033|NCT02765659|HIV
863034|NCT02765659|Prevention
863035|NCT02765659|Implementation
863036|NCT02765659|Community based participatory research
863037|NCT02765620|Positron-Emission Tomography
863038|NCT02765620|Response Criteria
863039|NCT02765620|solid tumor
863040|NCT02765607|Blood circulation
863041|NCT02765607|Cardiac surgical procedures
863042|NCT02765607|Homeostasis
863043|NCT02765594|Glomerulonephritis, IGA
863044|NCT02765594|Kidney Diseases
863045|NCT02765594|Autoimmune Diseases
863046|NCT02765594|Glomerulonephritis
863047|NCT02765594|Nephritis
863048|NCT02765594|Immune System Diseases
863049|NCT02765594|Urologic Diseases
863050|NCT02765594|Hydroxychloroquine
863051|NCT02765594|Anti-Infective Agents
863052|NCT02765594|Antimalarials
863053|NCT02765594|Antiparasitic Agents
863054|NCT02765594|Antiprotozoal Agents
863055|NCT02765594|Antirheumatic Agents
863056|NCT02765594|Enzyme Inhibitors
863057|NCT02765594|Molecular Mechanisms of Pharmacological Action
863058|NCT02765594|Pharmacologic Actions
863059|NCT02765594|Therapeutic Uses
863060|NCT02765594|interleukin-6
863061|NCT02765594|interferon-alpha
863062|NCT02765594|tumor necrosis factor-alpha
863063|NCT02765581|Acupuncture
863064|NCT02765581|Migraine
863065|NCT02765581|Randomized Controlled Trial
863066|NCT02765581|Placebo Effect
863067|NCT02765568|Coronary Artery Disease
863068|NCT02765568|Percutaneous Coronary Intervention (PCI)
863069|NCT02765542|Depression
863070|NCT02765542|mHealth
863071|NCT02765542|Interactive Voice Response
863072|NCT02765542|Bolivia
863073|NCT02765542|Mental health
863074|NCT02765529|Environmental Pollution
863075|NCT02765529|Fine particles
863076|NCT02765529|Biomarkers
863077|NCT02765529|Elderly
863087|NCT02765477|Acute myocardial infarction
863088|NCT02765477|ST Elevation Myocardial Infarction
863089|NCT02765477|Acute Coronary Occlusion
863090|NCT02765477|Electrocardiogram
863091|NCT02765477|Ventricular Paced Rhythm
863092|NCT02765477|Modified Sgarbossa Criteria
863093|NCT02765451|non-academic
863094|NCT02765451|health institution
863095|NCT02765451|development
863096|NCT02765451|clinical research
863097|NCT02765451|cancer
863098|NCT02765451|private hospital
863099|NCT02765451|public hospital
863100|NCT02765451|northwestern france
863101|NCT02765451|france
863102|NCT02765451|hospitals
863106|NCT02765386|Cochlear implants
863107|NCT02765386|Hybrid fittings
863108|NCT02765386|Cross-over frequency
863109|NCT02765373|aromatase inhibitors
863110|NCT02765373|lipid levels
863111|NCT02765360|EIT
863112|NCT02765360|NIV
863113|NCT02765308|Uveitis
863114|NCT02765308|Glaucoma
863115|NCT02765308|Aqueous humor dynamics
863116|NCT02765295|Hydrogen
863117|NCT02765295|Inhalation
863118|NCT02765295|bronchiectasis
863119|NCT02765282|Deep brain stimulation (DBS)
863120|NCT02765282|Kinesia
863121|NCT02765269|cancer pain
863122|NCT02765269|mobile applications
863123|NCT02765243|neuroblastoma
863124|NCT02765243|GD2
863125|NCT02765243|Chimeric antigen receptor
863126|NCT02765243|Immunotherapy
863127|NCT02765243|Cyclophosphamide
863128|NCT02765243|Fludarabine
863129|NCT02765217|Antibiotic associated diarrhea
863130|NCT02765217|Children
863131|NCT02765217|Prevention
863132|NCT02765217|Lactobacillus reuteri DSM 17938
863133|NCT02765217|Probiotic
863134|NCT02765191|Magnetic Resonance Imaging
863135|NCT02765191|Norepinephrine
863136|NCT02765191|Fluid Therapy
863137|NCT02765191|Renal Circulation
863138|NCT02765165|Phase 1
863139|NCT02765165|Phase 2
863140|NCT02765165|Glioblastoma Multiforme
863141|NCT02765165|Glioblastoma
863142|NCT02765165|GBM
863143|NCT02765165|Brain Tumor
863144|NCT02765165|Brain Cancer
863145|NCT02765165|Tumor
863146|NCT02765165|Solid Tumor
863147|NCT02765165|Tumour
863148|NCT02765165|Lomustine
863149|NCT02765165|CCNU
863150|NCT02765165|CXCR4
863151|NCT02765165|Phase 1 Clinical Trial
863152|NCT02765165|Phase 2 Clinical Trial
863153|NCT02765152|exercise
863154|NCT02765152|rhythmic movement
863155|NCT02765152|discrete movement
863156|NCT02765100|Bipolar Disorder
863157|NCT02765100|Obesity
863158|NCT02765100|Depression
863159|NCT02765074|subcutaneous tocilizumab
863160|NCT02765074|High Resolution peripheral QCT (HR-pQCT)
863161|NCT02765074|bone erosion
863162|NCT02765074|bone microarchitecture
863163|NCT02765074|rheumatoid arthritis
863164|NCT02765048|Adolescent girls
863165|NCT02765048|Child welfare
863166|NCT02765048|Trauma treatment
863167|NCT02765048|PTSD
863168|NCT02765048|Depression
863169|NCT02765048|Social problem-solving
863170|NCT02765009|Fluid overload
863171|NCT02765009|Multiple organ failure
863172|NCT02765009|Diuretics
863173|NCT02765009|Fluid restriction
863174|NCT02765009|Body weight
863175|NCT02764983|Combat Veterans
863176|NCT02764983|Automobile Driving
863177|NCT02764983|Fitness to Drive
863178|NCT02764905|Diabetes
863179|NCT02764905|Cognitive-physical rehabilitation
863180|NCT02764905|Self care management
863181|NCT02764879|Omega 3 fatty acids
863182|NCT02764879|Root planning
863183|NCT02764879|chronic periodontitis
863184|NCT02764866|Lung cancer
863185|NCT02764866|Sleep apnea
863186|NCT02764866|Sleep disordered breathing
863187|NCT02764853|HIV
863188|NCT02764853|Black
863189|NCT02764853|African American
863190|NCT02764853|Women
863191|NCT02764853|Cognitive Behavioral Therapy
863192|NCT02764853|Racism
863193|NCT02764853|Stigma
863194|NCT02764853|Discrimination
863195|NCT02764853|Gender related stressors
863196|NCT02764853|Resilience
863197|NCT02764853|Behavioral Medicine
863198|NCT02764827|skin prick test
863199|NCT02764827|grass and weed pollens
863200|NCT02764788|Auriculotherapy
863201|NCT02764762|Drug Therapy
863202|NCT02764749|vascular function
863203|NCT02764749|endothelial function
863204|NCT02764749|polyphenols
863205|NCT02764697|Glaucoma associated with uveitis
863206|NCT02764671|recombinant hepatitis B vaccine
863207|NCT02764671|safety
863208|NCT02764671|immunogenicity
863209|NCT02764645|Cardiopulmonary Bypass
863210|NCT02764619|Upstream therapy, spironolactone
863211|NCT02764619|Atrial remodelling
863212|NCT02764619|Modified look-locker inversion recover (MOLLI) sequences
863213|NCT02764619|T1 mapping
863214|NCT02764619|Diffuse myocardial fibrosis
863215|NCT02764606|Lung Cancer
863216|NCT02764606|Biomarkers
863217|NCT02764606|Bone
863218|NCT02764606|Metastases
863219|NCT02764593|Head and Neck Squamous Cell Carcinoma
863220|NCT02764593|HNSCC
863221|NCT02764593|Nivolumab
863222|NCT02763540|ILD
863223|NCT02763540|Pathology
863224|NCT02763540|diagnosis
863225|NCT02763540|lung biopsy
863226|NCT02763527|smoking cessation
863227|NCT02763501|bariatric surgery
863228|NCT02763501|gastric bypass
863229|NCT02763501|intestinal obstruction
863230|NCT02763501|postoperative complication
863231|NCT02763501|methods
863232|NCT02763501|laparoscopy
863233|NCT02763488|blood flow restriction training
863234|NCT02763488|occlusion training
863235|NCT02763488|total knee arthroplasty
863236|NCT02763488|post-operative rehabilitation
863237|NCT02763475|Killer Cells, Natural
863238|NCT02763475|Consolidation treatment
863239|NCT02763475|cytologic remission
863240|NCT02763475|Haploidentical NK Cells
863241|NCT02763475|allogeneic
863242|NCT02763475|IL-2 Expanded NK Cells
863243|NCT02763462|Acute Febrile Illness
863244|NCT02763436|term infant, neonatal transition, cord clamping, NIRS, arterial oxygen saturation, regional cerebral oxygen saturation, cerebral blood volume
863245|NCT02763423|umbilical cord stem cell
863246|NCT02763423|diabetic ketoacidosis
863247|NCT02763371|high GI lunch
863248|NCT02763371|low GI lunch
863249|NCT02763358|obesity
863250|NCT02763358|weight loss
863251|NCT02764554|Post-Marketing Surveillance
863252|NCT02764554|Lenvima
863253|NCT02764554|Lenvatinib
863254|NCT02764554|E7080
863255|NCT02764554|Differentiated thyroid carcinoma
863256|NCT02764554|Refractory to radioactive iodine
863257|NCT02764554|Progressive
863258|NCT02764554|locally recurrent
863259|NCT02764554|metastatic
863260|NCT02764541|Breast Cancer
863261|NCT02764541|Invasive Lobular Carcinoma
863262|NCT02764515|Kunxian Capsule
863263|NCT02764515|efficacy
863264|NCT02764515|rheumatoid arthritis
863265|NCT02764515|Methotrexate
863266|NCT02764502|Epidural Identification pressure gauge
863267|NCT02764476|psychogenic
863268|NCT02764476|non-epileptic seizures
863269|NCT02764476|functional neurological symptom disorder
863270|NCT02764476|PNES
863271|NCT02764476|PMD
863272|NCT02764476|virtual reality
863273|NCT02764476|3D augmented reality
863274|NCT02764476|mirror therapy
863275|NCT02764463|Fiber Reinforced Composites
863276|NCT02764463|Resin cements
863277|NCT02764463|Survival
863278|NCT02764450|composite
863279|NCT02764450|restoration
863280|NCT02764450|polymerization
863281|NCT02764424|Newborn
863282|NCT02764424|Heart Rate Variability (HRV)
863283|NCT02764424|Analgesic Nociception Index (ANI)
863284|NCT02764424|Autonomous Nervous System (ANS)
863285|NCT02764411|Capillary malformations
863286|NCT02764411|Onrealtea
863287|NCT02764411|port-wine stain
863288|NCT02764411|treatment
863289|NCT02764411|topical
863290|NCT02764372|Arm rehabilitation
863291|NCT02764372|Serious games
863292|NCT02764372|stroke
863293|NCT02764372|Multiple sclerosis
863294|NCT02764346|Arthritis
863295|NCT02764346|Self-management
863296|NCT02764346|Pain
863297|NCT02764333|TPIV200/huFR-1
863298|NCT02764333|Anti-PD-L1
863299|NCT02764333|vaccine
863300|NCT02764333|16-011
863301|NCT02764294|anxiety
863302|NCT02764294|pain
863303|NCT02764294|satisfaction
863304|NCT02764294|cystoscopy
863305|NCT02764294|distraction methods
863306|NCT02764268|Gastric Cancer
863307|NCT02764268|Pharmacokinetics
863308|NCT02764268|Dose titration
863309|NCT02764242|insect sting allergy
863310|NCT02764242|recombinant venom allergen
863311|NCT02764203|Dark Chocolate
863312|NCT02764203|Blood Pressure
863313|NCT02764203|Wearable Devices
863314|NCT02764203|Digital Health
863315|NCT02764164|TDCS
863316|NCT02764151|GBM
863317|NCT02764151|malignant glioma
863318|NCT02764151|glioma
863319|NCT02764151|anaplastic glioma
863320|NCT02764151|astrocytoma
863321|NCT02764151|IDO
863322|NCT02764151|IDO1
863323|NCT02764151|PF-06840003
863324|NCT02764138|poverty
863325|NCT02764138|discrimination
863326|NCT02764125|Parkinson's Disease
863327|NCT02764125|Wearing-off
863328|NCT02764112|warfarin
863329|NCT02764073|Heart failure
863330|NCT02764073|Bioimpedance
863331|NCT02764073|Lung ultrasonography
863332|NCT02764060|Periodontitis
863333|NCT02764060|Tongue coating
863334|NCT02764060|Tongue cleaning
863335|NCT02764060|Bacterial load
863336|NCT02764047|Non-alcoholic Fatty Liver Disease
863337|NCT02764047|Nonalcoholic Steatohepatitis
863338|NCT02764047|NAFLD
863339|NCT02764047|NASH
863340|NCT02764034|Low level Laser
863341|NCT02764034|Tissue culture
863342|NCT02764034|Endometrial receptivity
863343|NCT02764021|HbA1c
863344|NCT02764021|Diabetes-Releated Complications
863345|NCT02764021|Diet, Low Carbohydrate
863346|NCT02764021|Carbohydrate-Restricted Diet
863347|NCT02764021|Diabetes Mellitus
863348|NCT02764021|Metabolic Disorder
863349|NCT02764021|Glucose Metabolism Disorders
863350|NCT02764021|Endocrine System Diseases
863351|NCT02764008|Postoperative Analgesia
863352|NCT02764008|Peritubal infiltration
863353|NCT02764008|Ultrasound guided low thoracic paravertebral block
863354|NCT02764008|Percutaneous Nephrolithotomy pain
863355|NCT02763995|HIV
863356|NCT02763995|pharmaceutical care
863357|NCT02763995|older patients
863358|NCT02763995|cardiovascular risk
863359|NCT02763995|pharmacotherapy follow up
863360|NCT02763982|left ventricular ejection fraction
863361|NCT02763982|peak oxygen uptake
863362|NCT02763982|respiratory muscles
863363|NCT02763982|quality of life
863364|NCT02763956|Gelstix, Hydrogel
863365|NCT02763930|Cardiovascular disease
863366|NCT02763930|Blood pressure
863367|NCT02763930|Hypertension
863368|NCT02763930|Dairy products
863369|NCT02763930|Milk
863370|NCT02763930|Cheese
863371|NCT02763891|Balance
863372|NCT02763891|Mobility
863373|NCT02763891|Trunk control
863374|NCT02763878|Uncut Roux-en-Y
863375|NCT02763878|Billroth II anastomosis
863376|NCT02763878|Distal gastric cancer
863377|NCT02763878|Nutrition status
863378|NCT02763878|Postoperative complications
863379|NCT02763852|Parkinson's Disease
863380|NCT02763852|Nebicapone
863381|NCT02763839|Parkinson's disease
863382|NCT02763839|Nebicapone
863383|NCT02763826|Transcranial Direct Current Stimulation
863384|NCT02763826|tDCS
863385|NCT02763800|Parkinson's disease
863386|NCT02763800|Nebicapone
863387|NCT02763774|coronary artery bypass
863388|NCT02763774|sistemic inflammatory response syndrome
863389|NCT02763774|left ventricular dysfunction
863390|NCT02763774|postoperative complications
863391|NCT02763774|physical fitness
863392|NCT02763735|Pulmonary arterial hypertension
863393|NCT02763735|Right ventricle
863394|NCT02763735|Right ventricular function
863395|NCT02763735|Metabolism
863396|NCT02763735|Non-invasive imaging
863397|NCT02763735|Healthy Subjects
863398|NCT02763722|atopic dermatitis
863399|NCT02763722|allergic contact dermatitis
863400|NCT02763722|cosmetics
863401|NCT02763722|transepidermal water loos
863402|NCT02763696|Metagenomics
863403|NCT02763696|Vaginal microflora
863404|NCT02763696|High-throughput sequencing
863405|NCT02763683|Parkinsons Disease
863406|NCT02763683|PET Imaging
863407|NCT02763683|PIB
863408|NCT02763683|VAT
863409|NCT02763683|Dementia
863410|NCT02763670|Heart failure
863411|NCT02763670|patient education as topic
863412|NCT02763670|patient care management
863413|NCT02763657|fMRI
863414|NCT02763657|reasoning
863415|NCT02763657|development
863417|NCT02763618|Neurofeedback
863418|NCT02763618|theta/beta ratio
863419|NCT02763618|multiple baseline
863420|NCT02763605|Acanthamoeba Keratitis
863421|NCT02763605|in vivo confocal microscopic
863422|NCT02763592|Localized Neuropathic pain
863423|NCT02763592|5% lidocaine medicated plaster
863424|NCT02763592|Knee surgery
863429|NCT02763553|Ketone Bodies
863430|NCT02763553|Enteral Nutrition
863431|NCT02763553|Ketogenic Diet
863432|NCT02763332|Fibromyalgia
863433|NCT02763332|Efficacy
863434|NCT02763332|Taping
863441|NCT02763293|pain
863442|NCT02763293|effectiveness
863443|NCT02763293|manual therapy
863444|NCT02763267|Insulin sensitivity
863445|NCT02763267|Insulin secretion
863446|NCT02763267|Pregnancy
863447|NCT02763267|Placental proteins
863448|NCT02763254|Epstein-Barr Virus
863449|NCT02763254|DLBCL
863450|NCT02763254|PTLD
863451|NCT02763254|EBV
863452|NCT02763254|CIVIC
863453|NCT02763254|HL
863454|NCT02763254|T cell
863455|NCT02763241|rhinitis
863456|NCT02763228|Physical Activity
863457|NCT02763228|Breast Cancer
863458|NCT02763228|minority
863459|NCT02763228|African American
863460|NCT02763202|transition of care
863461|NCT02763202|pragmatic clinical trial
863462|NCT02763202|telemedicine
863463|NCT02763202|emergency medical technician
863464|NCT02763189|Mentoring
863465|NCT02763189|Endotracheal Tube Exchange
863466|NCT02763189|Training
863467|NCT02763176|hCG testing, multi-level pregnancy test
863468|NCT02763150|Gestational Diabetes Prevention
863469|NCT02763124|Pseudophakic
863470|NCT02763111|ankylosing spondylitis
863471|NCT02763111|interleukin 17
863472|NCT02763111|monoclonal antibody
863473|NCT02763098|cardiovascular responses
863474|NCT02763098|analgesics opioid
863475|NCT02763098|remifentanil
863476|NCT02763046|Ankylosing Spondylitis
863477|NCT02763046|NSAID
863478|NCT02763046|ASAS
863479|NCT02763046|Secukinumab
863480|NCT02763046|Subcutaneous
863481|NCT02763020|high glycemic index, polyphenols, blood glucose, satiety
863482|NCT02762994|interleukin 17
863483|NCT02762994|monoclonal antibody
863484|NCT02762994|psoriasis
863485|NCT02762981|CORT125134
863486|NCT02762981|nabpaclitaxel
863487|NCT02762981|Triple-Negative Breast Cancer
863488|NCT02762981|Ovarian Epithelial Cancer
863489|NCT02762981|GR Antagonist
863490|NCT02762981|Glucocorticoid Receptor Antagonist
863491|NCT02762955|adalimumab
863492|NCT02762955|biosimilar
863493|NCT02762955|BCD-057
863494|NCT02762955|psoriasis
863495|NCT02762955|tumor necrosis factor
863496|NCT02762955|monoclonal antibody
863497|NCT02762942|cervical ripening
863498|NCT02762942|misoprostol
863499|NCT02762942|supracervical balloon
863500|NCT02762942|Foley catheter
863501|NCT02762929|Analgesia
863502|NCT02762929|Bunionectomy
863503|NCT02762903|Shoulder arthroplasty
863504|NCT02762903|Lesser Tuberosity Osteotomy
863505|NCT02762903|Subscapularis tenotomy
863506|NCT02762864|aspirin
863507|NCT02762864|ticagrelor
863508|NCT02762864|clopidogrel
863509|NCT02762851|Influenza
863510|NCT02762851|Vaccine
863511|NCT02762851|Heart failure
863512|NCT02762851|Vascular
863513|NCT02762799|neutrophil count
863514|NCT02762799|filgrastim
863515|NCT02762799|granulocyte colony-stimulating factor
863516|NCT02762747|Hernia, Inguinal
863517|NCT02762747|Extraperitoneal Hernioplasty
863518|NCT02762747|Drain
863519|NCT02762747|Mesh Repair
863520|NCT02762747|Laparoscopic
863521|NCT02762734|adolescent
863522|NCT02762734|suicide
863523|NCT02762721|FGFR2 fusion
863524|NCT02762721|iCCA
863525|NCT02762721|mixed HCC-CCA
863526|NCT02762721|Intrahepatic Cholangiocarcinoma
863527|NCT02762721|Mixed Hepatocellular Cholangiocarcinoma
863528|NCT02762721|Cholangiocarcinoma
863529|NCT02762721|ArQule
863530|NCT02762708|Bariatric Surgery
863531|NCT02762708|Weight loss
863532|NCT02762695|Hypertension
863533|NCT02762695|Diabetes Mellitus, Type 2
863534|NCT02762695|Case Management
863535|NCT02762669|Uterine contraction
863536|NCT02762669|Oxytocin desensitization
863537|NCT02762643|DP-R213
863538|NCT02762617|Healthy Volunteers
863539|NCT02762617|Women's Health
863540|NCT02762552|Stroke
863541|NCT02762552|Etiology
863542|NCT02762552|Recurrence
863543|NCT02762552|Transcranial holter
863544|NCT02762552|Microembolic signals
863545|NCT02762526|lipectomy
863546|NCT02762526|abdominoplasty
863547|NCT02762526|plethysmography optoelectronics
863548|NCT02762526|diaphragmatic mobility
863549|NCT02762526|lung function
863550|NCT02762526|respiratory muscles
863551|NCT02762474|nab-paclitaxel
863552|NCT02762474|IMRT
863553|NCT02762474|esophageal cancer
863554|NCT02762461|Fertilization in Vitro
863555|NCT02762461|Sperm Injections, Intracytoplasmic
863556|NCT02762461|Endometriosis
863557|NCT02762422|endothelial function
863558|NCT02762422|iron stores
863559|NCT02762422|red blood cell
863560|NCT02762422|blood donation
863561|NCT02762409|critical care
863562|NCT02762409|reduction of depression syndrome
863563|NCT02762409|anxiety
863564|NCT02762409|quality of life
863565|NCT02762409|post traumatic stress
863566|NCT02762409|discomforts
863567|NCT02762396|Young ischemic stroke
863568|NCT02762396|Risk factors
863569|NCT02762396|Causes
863570|NCT02762396|Consequences
863571|NCT02762370|Osteoarthritis
863572|NCT02762370|Knee
863573|NCT02762370|Pain
863574|NCT02762370|Diabetes
863575|NCT02762370|Intra-articular
863576|NCT02762370|Injection
863577|NCT02762357|Novosyn Quick
863578|NCT02762357|Episiotomy
863579|NCT02762331|Vitamin C
863580|NCT02762331|Coronary Artery Bypass Grafting
863581|NCT02762331|Atrial Fibrillation
863582|NCT02762331|Cardiac Valve Repair
863583|NCT02762305|fall risk
863584|NCT02762305|RSVP bone builders
863585|NCT02762305|Group Exercise
863586|NCT02762305|Older adults
863587|NCT02762305|Balance confidence
863588|NCT02762305|life satisfaction
863589|NCT02762305|balance
863590|NCT02762292|Mechanical ventilation
863591|NCT02762292|Children
863592|NCT02762292|Work of breathing
863593|NCT02762279|Mechanical ventilation
863594|NCT02762279|Children
863595|NCT02762279|Esophageal Pressure
863596|NCT02762279|Pleural Pressure
863597|NCT02762240|Accreditation
863598|NCT02762240|Certification
863599|NCT02762240|General Practice
863600|NCT02762240|Family Medicine
863601|NCT02762240|Randomized Controlled Trial
863602|NCT02762227|CEUS
863603|NCT02762227|CT
863604|NCT02762227|gallbladder cholesterol polyps
863605|NCT02762227|adenoma
863606|NCT02762227|gallbladder cancer
863607|NCT02762214|Uterin manipulator
863608|NCT02762214|Endometrial Cancer
863609|NCT02762214|Laparoscopy
863610|NCT02762214|Robotic
863611|NCT02762188|wet ARMD
863612|NCT02762188|VEGF
863613|NCT02762188|intra vitreal injections
863614|NCT02762175|maxillomandibular advancement
863615|NCT02762175|obstructive sleep apnea
863616|NCT02762175|apnea-hypopnea index
863617|NCT02762175|quality of life
863618|NCT02762162|antiplatelet
863619|NCT02762162|stent thrombosis
863620|NCT02762149|Tsui Test
863621|NCT02762149|Labour
863622|NCT02762149|Epidural catheter
863623|NCT02762097|polyps
863624|NCT02762097|saline sonography
863625|NCT02762097|infertility
863626|NCT02762084|Gorlin Syndrome
863627|NCT02762084|Basal Cell
863628|NCT02762084|Nevus Syndrome
863629|NCT02762084|BCNS
863630|NCT02762084|nevoid basal cell carcinoma syndrome
863631|NCT02762084|Basal cell carcinoma
863632|NCT02762084|Hedgehog
863633|NCT02762084|Surgically Eligible Basal Cell Carcinomas
863634|NCT02762058|Acquired Brain Injury
863635|NCT02762058|Stroke Rehabilitation
863636|NCT02762045|Therapeutic Vaccine HIV Adenovirus type 5 vector
863637|NCT02762032|Skin Biopsy
863638|NCT02762032|PrimaVie
863639|NCT02762032|Herbal Supplement
863640|NCT02762019|Stomatitis
863641|NCT02762019|Laser
863642|NCT02762019|Children
863643|NCT02762019|Chemotherapy
863644|NCT02762019|Treatment
863645|NCT02762006|durvalumab
863646|NCT02762006|tremelimumab
863647|NCT02762006|Phase Ib
863648|NCT02762006|Locally Advanced
863649|NCT02761980|ibuprofen; acetaminophen; induced fever; fever
863650|NCT02761967|Physical activity
863651|NCT02761967|Pregnancy
863652|NCT02761967|Childbirth
863653|NCT02761967|Postpartum period
863654|NCT02761967|Exercise
863655|NCT02761954|regional anesthesia
863656|NCT02761954|caudal block
863657|NCT02761928|Facet Joint
863658|NCT02761928|Sacroiliac Joint
863659|NCT02761928|Myofascial Trigger Point Pain
863660|NCT02761928|Injectables
863661|NCT02761915|Neuroblastoma
863662|NCT02761915|Immunotherapy
863663|NCT02761915|1RG-CART
863664|NCT02761915|Cyclophosphamide
863665|NCT02761915|Fludarabine
863666|NCT02761915|CAR T-cells
863667|NCT02761915|Anti-GD2
863668|NCT02761915|GD2
863669|NCT02761915|CAR
863670|NCT02761915|Chimeric Antigen Receptor
863671|NCT02761902|Children
863672|NCT02761902|Polysomnography
863673|NCT02761902|sleep
863674|NCT02761902|obstructive sleep apnea;
863675|NCT02761902|Chinese
863676|NCT02761863|Mesothelioma
863677|NCT02761863|CD 74
863678|NCT02761863|VEGF
863679|NCT02761824|Quality of Life
863680|NCT02761824|Occupation
863681|NCT02761772|Preimplantation Factor
863682|NCT02761746|HIV
863683|NCT02761746|Adherence
863684|NCT02761746|Health Outcomes
863685|NCT02761733|Shared Decision Making
863686|NCT02761733|Case Management
863687|NCT02761733|Decision Aid
863688|NCT02761694|AKT1
863689|NCT02761694|AKT2
863690|NCT02761694|AKT3
863691|NCT02761694|PI3K
863692|NCT02761694|PTEN-null
863693|NCT02761694|solid tumors
863694|NCT02761694|cancer
863695|NCT02761694|ARQ 751
863696|NCT02761694|ArQule
863697|NCT02761681|Acceptance and Commitment Therapy
863698|NCT02761681|Mindfulness
863699|NCT02761681|Guided self-help
863700|NCT02761681|College students
863701|NCT02761681|Focused Interviews
863702|NCT02761681|RCT Control Condition
863703|NCT02761681|RCT ACT-CL Condition
863704|NCT02761668|Pathological tooth migration
863705|NCT02761668|periodontal regenerative surgery
863706|NCT02761668|vertical infrabony defects
863707|NCT02761668|xenogeneic bone graft
863708|NCT02761668|orthodontic therapy
863709|NCT02761655|Dementia
863710|NCT02761655|Medication Adherence
863711|NCT02761655|Perspective Memory
863712|NCT02761590|intermuscular fat
863713|NCT02761590|circuit training
863714|NCT02761590|adipokines
863715|NCT02761590|inflammation
863716|NCT02761590|computed tomography scan
863717|NCT02761577|Acetylcysteine
863718|NCT02761577|Sodium Bicarbonate
863719|NCT02761577|Lipocalins
863720|NCT02761577|Creatinine
863721|NCT02761577|Blood Urea Nitrogen
863722|NCT02761564|Cardiac surgery
863723|NCT02761564|Blood transfusion
863724|NCT02761564|ScvO2
863725|NCT02761538|obesity
863726|NCT02761538|Overweight
863727|NCT02761538|ICTs
863728|NCT02761538|Cost-effectiveness
863729|NCT02761525|silver nanoparticles antimicrobial activity
863730|NCT02761486|aspirin
863731|NCT02761486|gut microbiome
863732|NCT02761486|inflammation
863733|NCT02761486|placebo
863734|NCT02761486|circulating biomarker
863735|NCT02761447|Motor control Laterality
863736|NCT02761447|Pain Perception
863737|NCT02761447|Lower Extremity
863738|NCT02761447|Complementary Therapies
863739|NCT02761447|Physical Therapy Modalities
863740|NCT02761434|copeptin
863741|NCT02761434|vasopressin
863742|NCT02761434|dehydration
863743|NCT02761434|insulin resistance
863744|NCT02761434|Diabetes
863745|NCT02761434|Glucose regulation
863746|NCT02761421|IOPD
863747|NCT02761408|Head and neck cancer
863748|NCT02761408|Asian
863749|NCT02761408|ALDH2
863750|NCT02761369|food addiction
863751|NCT02761369|obesity
863752|NCT02761369|deep TMS
863753|NCT02761369|PAS
863754|NCT02761369|Food Stroop
863755|NCT02761369|brain laterality
863756|NCT02761369|EEG
863757|NCT02761369|INP
863758|NCT02761343|cardiac arrhythmia
863759|NCT02761343|cardiac ablation
863760|NCT02761343|congenital cardiac disease
863761|NCT02761343|cardiac ablation lesions under Magnetic Resonance imaging
863778|NCT02761317|bowel preparation
863779|NCT02761317|bisacodyl
863780|NCT02761317|polyethyleneglycol
863781|NCT02761317|colorectal surgery
863782|NCT02761291|Nasopharyngeal carcinoma
863783|NCT02761291|EB virus
863784|NCT02761291|metastasis
863785|NCT02761291|recurrence
863786|NCT02761291|cytolytic viral activation therapy
863787|NCT02761291|gemcitabine
863788|NCT02761291|valproic acid
863789|NCT02761291|ganciclovir
863790|NCT02761291|valganciclovir
863791|NCT02761265|Degenerative Adult Scoliosis
863792|NCT02761265|Gait Analysis
863793|NCT02761265|Balance Analysis
863794|NCT02761265|Biomechanics
863795|NCT02761265|Neuromuscular Control
863796|NCT02761265|Thoracolumbar Deformity
863797|NCT02761252|Bilastine
863798|NCT02761252|Montelukast
863799|NCT02761252|total symptom score
863800|NCT02761252|AQLQ
863801|NCT02761239|cricopharyngeal muscle
863802|NCT02761239|innervation by EBSLN
863803|NCT02761239|A prospective case-controlled study
863804|NCT02761226|platform switching
863805|NCT02761226|dental implant
863806|NCT02761226|crestal bone level
863807|NCT02761226|implant stability
863808|NCT02761226|postoperative complication
863809|NCT02761187|Drug Therapy
863810|NCT02761174|Vascular lesions
863811|NCT02761174|inflammation
863812|NCT02761174|IPL
863813|NCT02761161|PTSD
863814|NCT02761161|Sleep
863815|NCT02761161|Refugee
863816|NCT02761161|IRT
863817|NCT02761161|Mianserin
863818|NCT02761148|white matter hyperintensity
863819|NCT02761148|brain network
863820|NCT02761148|MRI
863821|NCT02761148|cognition
863822|NCT02761148|emotion
863823|NCT02761135|Biopsy technique
863824|NCT02761135|Transrectal ultrasonography probe
863825|NCT02761135|Side-fire
863826|NCT02761135|Prostate cancer
863827|NCT02761135|End-fire
863828|NCT02761083|Eye surgery
863829|NCT02761083|Suture material
863830|NCT02761083|Novosyn Quick
863831|NCT02761083|Vicryl Rapid
863832|NCT02761070|glioblastoma
863833|NCT02761070|recurrent
863834|NCT02761070|dose-dense temozolomide
863835|NCT02761070|bevacizumab
863836|NCT02761031|Heart rate variability
863837|NCT02761031|Electrocardiography
863838|NCT02761031|Observational study
863839|NCT02761031|Non-interventional study
863840|NCT02761031|Risk assessment
863841|NCT02761031|Perioperative
863842|NCT02761005|Eradication therapy
863843|NCT02761005|Mutation of 23S rRNA of H. pylori
863844|NCT02761005|Personalized therapy
863845|NCT02760979|knee arthroplasty
863846|NCT02760940|Inflammatory bowel diseases
863847|NCT02760940|Anemia
863848|NCT02760940|Crohn's disease
863849|NCT02760940|Ulcerative colitis
863850|NCT02760940|Oral iron
863851|NCT02760940|Quality of life
863852|NCT02760914|adipose tissue
863853|NCT02760914|inflammatory mediators
863854|NCT02760914|gene expression
863855|NCT02760875|Achilles Tendon Rupture
863856|NCT02760875|Conservative treatment
863857|NCT02760875|early weight bearing
863858|NCT02760875|Achilles Tendon Length
863859|NCT02760875|Ultrasound
863860|NCT02760875|Foot Pressure Mapping
863861|NCT02760875|ATRA
863862|NCT02760875|Heel Raise Work
863863|NCT02760849|Hereditary Breast and Ovarian Cancer Syndrome
863864|NCT02760849|HBOC
863865|NCT02760849|Deleterious mutation in ovarian cancer genes
863866|NCT02760849|Changes in female sexual function
863867|NCT02760849|Salpingectomy with delayed oophorectomy
863868|NCT02760849|ISDO
863869|NCT02760849|Risk-reducing salpingo-oophorectomy (RRSO)
863870|NCT02760849|RRSO
863871|NCT02760849|Questionnaires
863872|NCT02760849|Surveys
863873|NCT02760836|Crohn's disease
863874|NCT02760836|disease outcomes
863875|NCT02760784|Achilles Tendon Rupture
863876|NCT02760784|Conservative treatment
863877|NCT02760784|early weight bearing
863878|NCT02760784|Dynamic
863879|NCT02760784|ATRS
863880|NCT02760784|ATRA
863881|NCT02760784|Heel Raise Work
863882|NCT02760771|THV (trans-catheter heart valve)
863883|NCT02760771|severe aortic stenosis
863884|NCT02760771|pre-dilation
863885|NCT02760771|rapid pacing
863886|NCT02760771|BAV (balloon artery valvuloplasty
863887|NCT02760758|non-nucleoside inhibitor
863888|NCT02760758|NNI
863889|NCT02760758|HCV
863890|NCT02760758|DAA
863891|NCT02760745|fever
863892|NCT02760745|shivering
863893|NCT02760745|chills
863894|NCT02760745|rigors
863895|NCT02760745|severe bacterial infection
863896|NCT02760719|3% hypertonic solution
863897|NCT02760719|duration of hospitalisation
863898|NCT02760693|bipolar disorder, naturalistic cohort study,
863899|NCT02760693|defined catchment area,long term treatment
863900|NCT02760680|Chronic Heart Failure
863901|NCT02760680|Sleep-Disordered Breathing
863902|NCT02760680|Peripheral Arterial Tone
863903|NCT02760667|Oropharyngeal cancer
863904|NCT02760667|Laryngeal cancer
863905|NCT02760641|obesity
863906|NCT02760641|low carbohydrate diet
863907|NCT02760641|metabolism
863908|NCT02760641|body composition
863909|NCT02760641|visceral fat
863910|NCT02760641|older adults
863911|NCT02760641|insulin sensitivity
863913|NCT02760602|anti-amyloid
863914|NCT02760602|monoclonal antibody
863921|NCT02760537|Liver Neoplasms
863922|NCT02760537|Hepatitis B
863923|NCT02760537|Hepatitis B vaccination
863924|NCT02760537|Asian Americans
863925|NCT02760537|Lay health workers
863926|NCT02760537|Community health workers
863927|NCT02760511|Randomized Controlled Trial
863928|NCT02760511|Anthocyanin
863929|NCT02760511|Antioxidants
863930|NCT02760485|Diffuse large B-cell lymphoma
863931|NCT02760485|Relapsed Diffuse large B-cell lymphoma
863932|NCT02760485|Refractory Diffuse large B-cell lymphoma
863933|NCT02760485|activated B cell
863934|NCT02760485|germinal center B-cell
863935|NCT02760485|non-Hodgkin lymphoma
863936|NCT02760485|JAK1 inhibitor
863937|NCT02760485|Bruton's tyrosine kinase (BTK) inhibitor
863938|NCT02760472|Retinopathy of Prematurity
863939|NCT02760472|Preterm
863940|NCT02760472|Fatty acids
863941|NCT02760433|moderate Rheumatoid Arthritis
863942|NCT02760433|severe Rheumatoid Arthritis
863943|NCT02760433|Olokizumab
863944|NCT02760407|moderate Rheumatoid Arthritis
863945|NCT02760407|severe Rheumatoid Arthritis
863946|NCT02760407|subcutaneous
863947|NCT02760407|Olokizumab
863948|NCT02760394|chronic ischemic heart disease
863949|NCT02760394|coronary bypass
863950|NCT02760394|refractory stable angina
863951|NCT02760394|HBOT
863952|NCT02760394|reperfusion
863953|NCT02760394|neoangiogenesis
863954|NCT02760394|microvascular
863955|NCT02760394|myocardial perfusion
863956|NCT02760368|moderate Rheumatoid Arthritis
863957|NCT02760368|severe Rheumatoid Arthritis
863958|NCT02760368|subcutaneous
863959|NCT02760368|Olokizumab
863960|NCT02760342|Pharmacokinetics
863961|NCT02760342|Metformin
863962|NCT02760342|Drug-drug interaction
863963|NCT02760342|ASP015K
863974|NCT02760303|insulin dependent diabetes mellitus
863975|NCT02760303|adolescents and young adults
863976|NCT02760303|stress reduction
863977|NCT02760303|metabolic control
863978|NCT02760290|Forced Expiratory Volume in 1 second
863979|NCT02760290|Forced expiratory vital capacity
863980|NCT02760290|Peak expiratory flow
863981|NCT02760277|Duchenne muscular dystrophy
863982|NCT02760277|vamorolone
863983|NCT02760264|Duchenne Muscular Dystrophy
863984|NCT02760264|vamorolone
863985|NCT02760251|immunomodulation
863986|NCT02760238|myeloproliferative neoplasm
863987|NCT02760238|myelodysplastic syndrome
863988|NCT02760238|registry
863989|NCT02760238|leukemia
863990|NCT02760238|Bone Marrow Diseases
863991|NCT02760238|Hematologic Diseases
863992|NCT02760238|Neoplasms
863993|NCT02760225|Pembrolizumab
863994|NCT02760225|PET imaging
863995|NCT02760225|Melanoma
863996|NCT02760225|Non-small cell lung cancer
863997|NCT02760212|Shockwave therapy
863998|NCT02760212|fMRI
863999|NCT02760212|blood biomarkers
864000|NCT02760173|verticality perception
864001|NCT02760147|Pressure Support Ventilation
864002|NCT02760134|Super-Mini Percutaneous Nephrolithotomy(SMP)
864003|NCT02760134|Renal Pelvic Pressure
864004|NCT02760121|Acetazolamide
864005|NCT02760121|Methazolamide
864006|NCT02760121|Control of breathing
864007|NCT02760121|Hypoxic pulmonary vasoconstriction
864008|NCT02760108|Early onset Parkinson's disease
864009|NCT02760108|Familial Parkinson's disease
864010|NCT02760108|Parkinson's disease
864011|NCT02760108|Genetics
864012|NCT02760095|environmental enteric dysfunction
864013|NCT02760095|environmental enteropathy
864014|NCT02760095|zinc
864015|NCT02760095|vitamin A
864016|NCT02760095|Bangladesh
864017|NCT02760082|Multiple Sclerosis
864018|NCT02760082|Qualitative study
864019|NCT02760082|Motivation
864020|NCT02760056|Thyroid hormone
864021|NCT02760056|Remyelination
864022|NCT02760004|Depression
864023|NCT02759991|Hepatitis E virus
864024|NCT02759991|Viral Hepatitis Vaccines
864025|NCT02759978|Imaging
864026|NCT02759978|Computed Tomography
864027|NCT02759978|Magnetic Resonance Imaging
864028|NCT02759978|Positron Emission Tomography
864029|NCT02759978|Leukocyte Scintigraphy
864030|NCT02759978|Microbiological diagnostics
864031|NCT02759978|Sonication
864032|NCT02759978|Drug Monitoring
864033|NCT02759978|Cardiac Surgery
864034|NCT02759952|retinitis pigmentosa
864035|NCT02759952|PDE6A
864036|NCT02759952|gene therapy trial
864037|NCT02759939|Shared Decision-Making
864038|NCT02759939|Patient-Provider Communication
864039|NCT02759926|Healthy volunteers
864040|NCT02759926|Obesity
864041|NCT02759926|Bitter
864042|NCT02759913|neuromuscular diseases
864043|NCT02759848|COPD, tuberculosis, mortality
864044|NCT02759835|EGFR Tyrosine Kinase Inhibitors
864045|NCT02759835|T790M Mutation
864046|NCT02759835|Local Ablative Therapies
864047|NCT02759835|Oligoprogressive Disease
864048|NCT02759835|Acquired Resistance
864049|NCT02759822|Haploidentical Hematopoietic Stem Cell Transplantation
864050|NCT02759822|Partially Matched Hematopoietic Stem Cell Transplantation
864051|NCT02759822|Post-transplant Cyclophosphamide
864052|NCT02759822|Hematopoietic Stem Cell Transplantation
864053|NCT02759783|Radiotherapy
864054|NCT02759783|oligometastases
864055|NCT02759783|SBRT
864056|NCT02759757|Kinesio Taping
864057|NCT02759757|Low back Pain
864058|NCT02759757|Electromyographic
864059|NCT02759757|EMG
864060|NCT02759744|Thermal Ablation
864061|NCT02759744|Localized Prostate Cancer
864062|NCT02759744|Medtronic-Visualase
864063|NCT02759744|Thermal Damage
864064|NCT02759744|PSA Levels
864065|NCT02759731|Murine Models
864066|NCT02759731|Rheumatoid Arthritis
864067|NCT02759731|Corticosteroids
864068|NCT02759731|Systemic Therapy
864069|NCT02759731|Inflammatory Cytokines
864070|NCT02759718|pancreatic neuroendocrine tumor
864071|NCT02759718|chromogranin A
864072|NCT02759705|fertility
864073|NCT02759705|sexuality
864074|NCT02759705|male
864075|NCT02759705|exstrophy-epispadias complex
864076|NCT02759705|bladder exstrophy
864077|NCT02759705|epispadias
864078|NCT02759666|PARP
864079|NCT02759666|advanced solid tumor
864080|NCT02759640|c-Met kinase inhibitor
864081|NCT02759640|Advanced solid tumors
864082|NCT02759627|Rehabilitation
864083|NCT02759627|Gait
864084|NCT02759627|Ambulation
864085|NCT02759627|Exercise Therapy
864086|NCT02759627|Physical Exertion
864087|NCT02759627|Motor Skills
864088|NCT02759601|HDAC Inhibitor
864089|NCT02759601|Tefinostat
864090|NCT02759601|Inflammation
864091|NCT02759601|Hepatocellular Carcinoma
864092|NCT02759601|Cancer associated Inflammation in Hepatocellular Carcinoma
864093|NCT02759588|GL-ONC1
864094|NCT02759588|oncolytic virus
864095|NCT02759588|virotherapy
864096|NCT02759588|Viral therapy
864097|NCT02759588|immunotherapy
864098|NCT02759588|immune therapy
864099|NCT02759588|vaccinia
864100|NCT02759588|vaccinia virus
864101|NCT02759588|Genelux
864102|NCT02759588|ovarian cancer
864103|NCT02759588|platinum resistant
864104|NCT02759588|platinum refractory
864105|NCT02759588|peritoneal carcinomatosis
864106|NCT02759588|fallopian cancer
864107|NCT02759588|cancer
864108|NCT02759588|abdominal cancer
864109|NCT02759588|imaging
864110|NCT02759588|carcinoma
864111|NCT02759588|DNA virus
864112|NCT02759588|neoplasms
864113|NCT02759588|neoplasms by histological type
864114|NCT02759588|neoplasms, Glandular and Epithelial
864115|NCT02759588|Poxviridae infections
864116|NCT02759588|Virus diseases
864117|NCT02759588|recurrent ovarian cancer
864118|NCT02759588|intermediate platinum-sensitive
864119|NCT02759549|Radiation Therapy
864120|NCT02759523|Magnetic Resonance Imaging
864121|NCT02759523|Portion Size
864122|NCT02759523|Energy Intake
864123|NCT02759510|cardiac output
864124|NCT02759510|norepinephrin
864125|NCT02759510|cesarean section
864126|NCT02759484|CHWs
864127|NCT02759484|Health Education
864128|NCT02759484|Disease Self Management
864129|NCT02759445|alcohol induced cardiomyopathy
864130|NCT02759445|myocardial deformation imaging
864131|NCT02759432|high-intensity interval training
864132|NCT02759432|adolescents
864133|NCT02759432|physical fitness
864134|NCT02759432|quality of life
864135|NCT02759432|school-based intervention
864136|NCT02759367|Nutrition
864137|NCT02759367|Potassium
864138|NCT02759354|Immune response
864139|NCT02759328|Stroke
864140|NCT02759328|Rehabilitation
864141|NCT02759328|Serious games
864142|NCT02759328|Virtual reality
864143|NCT02759328|Xbox Kinect™
864144|NCT02759302|MRI
864145|NCT02759302|LGMD
864146|NCT02759302|POMT2
864147|NCT02759289|Arsenic
864148|NCT02759276|Nailfold Videocapillaroscopy
864149|NCT02759276|Venous Occlusion Plethysmography
864150|NCT02759276|Endothelial Function
864151|NCT02759276|Microcirculation
864152|NCT02759276|Inflammatory Biomarkers
864153|NCT02759185|PTSD
864154|NCT02759185|marijuana
864155|NCT02759185|cannabis
864156|NCT02759185|sleep
864157|NCT02759185|THC
864158|NCT02759185|CBD
864159|NCT02759172|Suicide prevention
864160|NCT02759172|Jail
864161|NCT02759120|Idiopathic Pulmonary Fibrosis
864162|NCT02759120|IPF
864163|NCT02759120|pulmonary fibrosis
864164|NCT02759120|antimicrobial therapy
864165|NCT02759120|doxycycline
864166|NCT02759120|co-trimoxazole
864167|NCT02759094|GERD
864168|NCT02759094|Implantable medical device
864169|NCT02759094|RefluxStop
864170|NCT02759094|Reflux
864171|NCT02759094|Gastroesophageal Reflux
864172|NCT02759094|Laparoscopy
864173|NCT02759094|pH-Monitoring
864174|NCT02759094|PPI proton pump inhibitors
864175|NCT02759068|vegetative state
864176|NCT02759068|minimally conscious state
864177|NCT02759068|music
864178|NCT02759068|preference
864179|NCT02758990|Food
864180|NCT02758990|Nutrigenomics
864181|NCT02758990|Precision Medicine
864182|NCT02758990|Pharmacogenetics
864183|NCT02758990|Lifestyle
864184|NCT02758977|Colorectal liver metastases
864185|NCT02758977|Liver Surgery
864186|NCT02758977|ALPPS
864187|NCT02758977|Two Stage Hepatectomy
864188|NCT02758977|Surgical Oncology
864189|NCT02758977|Hepatectomy
864190|NCT02758964|TAVR
864191|NCT02758964|TAVI
864192|NCT02758964|Transcatheter Aortic Valve Replacement
864193|NCT02758964|Intracranial Embolism
864194|NCT02758951|Induction Chemotherapy
864195|NCT02758951|Chemotherapy, Adjuvant
864196|NCT02758951|Molecular Targeted Therapy
864197|NCT02758951|Colorectal Surgery
864198|NCT02758951|Cytoreductive Surgery
864199|NCT02758951|Hyperthermic Intraperitoneal Chemotherapy
864200|NCT02758951|Peritoneum
864201|NCT02758951|Peritoneal Lavage
864202|NCT02758951|Peritoneal Cavity
864203|NCT02758951|Ascitic Fluid
864204|NCT02758951|Chemotherapy, Cancer, Regional Perfusion
864205|NCT02758951|Antineoplastic Combined Chemotherapy Protocols
864206|NCT02758951|Drug Therapy, Combination
864207|NCT02758951|Drug Therapy
864208|NCT02758951|Morbidity
864209|NCT02758951|Mortality
864210|NCT02758951|Hospital Mortality
864211|NCT02758951|Chemically-Induced Disorders
864212|NCT02758951|Drug-Related Side Effects and Adverse Reactions
864213|NCT02758951|Laparotomy
864214|NCT02758899|Anterior cervical discectomy
864215|NCT02758899|Anterior cervical fusion
864216|NCT02758860|Colonoscopy
864217|NCT02758860|Diverticular disease of the colon
864218|NCT02758860|Classification
864219|NCT02758847|critical lower limb ischemia with tissue loss
864220|NCT02758834|Preterm Infants
864221|NCT02758834|Phytosterols
864222|NCT02758834|Parenteral Nutrition
864223|NCT02758821|C-reactive protein
864224|NCT02758821|antibiotic
864225|NCT02758795|protein
864226|NCT02758795|inflammation
864227|NCT02758795|anti-inflammatory agents
864231|NCT02758730|GBA mutation
864232|NCT02758704|Intubation
864233|NCT02758704|Neonatal
864234|NCT02758704|Teaching
864235|NCT02758704|Stress
864236|NCT02758704|Simulation
864237|NCT02758691|memory
864238|NCT02758691|insulin
864239|NCT02758678|P-selectin
864240|NCT02758678|Lung Cancer
864241|NCT02758678|Raman Spectroscopy
864242|NCT02758665|CLL
864243|NCT02758665|chronic lymphocytic leukemia
864244|NCT02758665|ibrutinib
864245|NCT02758665|venetoclax
864246|NCT02758665|obinutuzumab
864247|NCT02758665|TP53 Deletion
864248|NCT02758652|chemoresistance
864249|NCT02758652|miRNA
864250|NCT02758652|microRNA
864251|NCT02758639|parental cancer
864252|NCT02758639|children psychosocial adjustment
864253|NCT02758639|psychosocial intervention
864254|NCT02758574|acute pulmonary embolism
864255|NCT02758574|submassive pulmonary embolism
864256|NCT02758574|thrombolysis
864257|NCT02758574|catheter directed thrombolysis
864258|NCT02758574|ultrasound assisted thrombolysis
864259|NCT02758561|decisional aid
864260|NCT02758561|workshops
864261|NCT02758561|urinary incontinence
864262|NCT02758561|pelvic organ prolapse
864263|NCT02758561|pelvic floor dysfunction
864264|NCT02758561|decisional conflict
864265|NCT02758548|Total IgE measurement
864266|NCT02758548|Novel Point-of-care test device
864267|NCT02758548|atopic conditions
864268|NCT02758548|in vitro diagnostic test
864269|NCT02758522|Diabetes Mellitus
864270|NCT02758522|Hospital Hyperglycemia
864271|NCT02758496|Autism, chart review, transcranial magnetic stimulation (TMS)
864272|NCT02758470|Muscle Fatigue
864273|NCT02758470|Acetazolamide
864274|NCT02758470|Methazolamide
864275|NCT02758457|cad/cam
864276|NCT02758457|dental porcelain
864277|NCT02758457|zirconia
864278|NCT02758457|press on metal
864279|NCT02758444|environmental enteric dysfunction
864280|NCT02758444|environmental enteropathy
864281|NCT02758444|zinc absorption
864282|NCT02758444|Bangladesh
864283|NCT02758444|toddlers
864284|NCT02758444|zinc isotope
864285|NCT02758431|testosterone
864286|NCT02758418|Adjustment disorders online
864287|NCT02758418|Psychological Treatments
864288|NCT02758418|Information and Communication Technologies
864289|NCT02758418|Internet
864290|NCT02758418|Bibliotherapy
864291|NCT02758405|Epidural
864292|NCT02758405|Labor analgesia
864293|NCT02758405|Programmed intermittent epidural bolus
864294|NCT02758392|Healthy
864295|NCT02758392|JNJ-61178104
864296|NCT02758392|Placebo
864297|NCT02758392|Safety
864298|NCT02758379|coronary artery disease
864299|NCT02758379|calcified lesions
864300|NCT02758379|lithotripsy
864301|NCT02758366|glioblastoma multiforme
864302|NCT02758366|high grade glioma
864303|NCT02758366|diffuse intrinsic pontine glioma
864304|NCT02758366|DIPG
864305|NCT02758366|doxorubicin
864306|NCT02758366|temozolomide
864307|NCT02758366|malignant glioma
864308|NCT02758353|Malaria in Pregnancy
864309|NCT02758353|Nigeria
864310|NCT02758353|Sulfadoxine-Pyrimethamine
864311|NCT02758353|Scale up
864312|NCT02758353|Primary Health Care
864313|NCT02758340|induction of labor
864314|NCT02758340|misoprostol
864315|NCT02758340|foley's balloon catheter
864316|NCT02758327|Tear Osmolarity
864317|NCT02758327|Keratitis Sicca
864318|NCT02758327|Ocular Surface Disease
864319|NCT02758327|TheraTears
864320|NCT02758314|PD-1
864321|NCT02758314|PD-L1
864322|NCT02758314|NSCLC
864323|NCT02758288|Kidney transplant
864324|NCT02758288|BK Viremia
864325|NCT02758288|BK Nephropathy
864326|NCT02758275|Medication adherence
864327|NCT02758275|Patient compliance
864328|NCT02758275|Diabetes mellitus, Type 2
864329|NCT02758275|Hypertension
864330|NCT02758275|Nursing
864331|NCT02758275|Nursing process
864332|NCT02758275|Teaching
864333|NCT02758275|Randomized controlled trial
864334|NCT02758210|Bradycardia
864335|NCT02758210|Atrial Tachyarrhythmia
864336|NCT02758210|Smart Phone
864337|NCT02758210|Tablet
864338|NCT02758197|Mindfulness
864339|NCT02758197|Chronic Pain
864340|NCT02758197|Quality of Life
864341|NCT02758197|Immune Function
864342|NCT02758197|Cancer survivors
864343|NCT02758197|Disability
864467|NCT02757391|SCH-900475
864344|NCT02758132|Castrate-resistant prostate cancer with bone metastases
864345|NCT02758106|chest wall oscillation
864346|NCT02758106|acute respiratory failure
864347|NCT02758106|airway secretion
864348|NCT02758080|Personalized medicine
864349|NCT02758080|Next generation sequencing
864350|NCT02758041|Acne
864351|NCT02758028|Youth
864352|NCT02758015|betaine
864353|NCT02758015|betaine hydrochloride
864354|NCT02758015|healthy volunteer
864355|NCT02758015|gastric pH
864356|NCT02758002|atrial fibrillation ablation
864357|NCT02758002|ablation
864358|NCT02758002|atrial fibrillation rotors
864359|NCT02757989|Low risk MDS
864360|NCT02757989|Transplantation
864361|NCT02757963|Screening tool
864362|NCT02757963|International Prostate Symptom Score
864363|NCT02757963|Lower urinary tract symptoms
864364|NCT02757963|BPO
864365|NCT02757963|BPE
864366|NCT02757963|Benign prostatic enlargement
864367|NCT02757963|Benign prostatic obstruction
864368|NCT02757963|LUTS
864369|NCT02757963|Benign prostatic hyperplasia
864370|NCT02757963|IPSS
864371|NCT02757963|BPH
864372|NCT02757950|exposed and unexposed cohorts
864373|NCT02757950|post-marketing, maternal immunization
864374|NCT02757950|neonate related Adverse Events
864375|NCT02757950|Congenital anomaly
864376|NCT02757950|RefortrixTM
864377|NCT02757950|Pregnancy related Adverse Events
864378|NCT02757937|Medication Adherence
864379|NCT02757937|Self-efficacy
864380|NCT02757937|Behavior
864381|NCT02757937|Diabetes
864382|NCT02757937|Diabetes Mellitus
864383|NCT02757911|XCGD
864384|NCT02757898|Red Blood Cell (RBC) transfusion
864385|NCT02757898|Biotin labeled red blood cells
864386|NCT02757885|bone marrow transplant
864387|NCT02757872|Hypertension
864388|NCT02757872|Kidney Diseases
864389|NCT02757872|Vitamin D
864390|NCT02757872|Omega 3 fatty acids
864391|NCT02757846|Radiomics
864392|NCT02757846|prognosis
864393|NCT02757846|medical images
864394|NCT02757846|Hepatocellular carcinoma
864395|NCT02757820|anesthesia; airway; laryngeal mask airway; I-gel; Air-Q
864396|NCT02757807|Erectile Dysfunction
864397|NCT02757781|Patient empowerment
864398|NCT02757781|Patient involvement
864399|NCT02757781|Patient participation
864400|NCT02757781|Healthcare professional attitudes
864401|NCT02757781|Chronic diseases
864402|NCT02757768|Myrbetriq
864403|NCT02757768|Lower Urinary Tract Symptoms
864404|NCT02757768|Benign Prostatic Hyperplasia
864405|NCT02757768|Overactive Bladder
864406|NCT02757768|Betmiga
864407|NCT02757768|Mirabegron
864408|NCT02757768|Tamsulosin Hydrochloride
864409|NCT02757742|sudden cardiac death
864410|NCT02757742|ventricular arrhythmias
864411|NCT02757742|cardiopathy
864412|NCT02757742|late gadolinium enhancement
864413|NCT02757716|addiction remission
864414|NCT02757716|addiction transfer
864415|NCT02757703|somatostatin
864416|NCT02757703|variceal bleeding
864417|NCT02757703|terlipressin
864418|NCT02757664|achilles
864419|NCT02757664|tendinopathy
864420|NCT02757664|Physical Therapy Modalities
864421|NCT02757664|High-Energy Shock Waves
864422|NCT02757612|laser diode, pain
864423|NCT02757586|chronic lymphocytic leukemia
864424|NCT02757586|XPO1
864425|NCT02757586|in vitro
864426|NCT02757586|in vivo
864427|NCT02757560|saturated fat
864428|NCT02757560|acute insulin resistance
864429|NCT02757560|insulin suppression test
864430|NCT02757560|dietary fatty acids
864431|NCT02757521|Bipolar Depressive Disorder
864432|NCT02757521|Treatment- Resistant Bipolar Disorder
864433|NCT02757521|Nitrous Oxide
864434|NCT02757495|sevoflurane emergence agitation
864435|NCT02757495|caudal dexmedetomidine
864436|NCT02757482|Patient training
864437|NCT02757482|Warfarin
864438|NCT02757482|International Normalized Ratio
864439|NCT02757482|Nursing
864440|NCT02757456|exercise
864441|NCT02757456|hemodialysis
864442|NCT02757456|pulse wave velocity
864443|NCT02757456|micro RNAs
864444|NCT02757443|Phosphocreatine
864445|NCT02757443|Creatine Phosphate
864446|NCT02757443|Neoton
864447|NCT02757443|Phosphate, Creatine
864448|NCT02757443|Phosphorylcreatine
864449|NCT02757404|botulinum toxin
864450|NCT02757404|spasticity
864451|NCT02757404|injection technique
864452|NCT02757404|neuronox
864453|NCT02757404|meditoxin
864454|NCT02757391|Advanced gastrointestinal malignancies
864455|NCT02757391|Metastatic gastrointestinal tumor
864456|NCT02757391|Adoptive T cell infusion
864457|NCT02757391|Cyclophosphamide
864458|NCT02757391|Cytoxan
864459|NCT02757391|Neosar
864460|NCT02757391|IL-2
864461|NCT02757391|Aldesleukin
864462|NCT02757391|Interleukin-2
864463|NCT02757391|Proleukin
864464|NCT02757391|Pembrolizumab
864465|NCT02757391|Keytruda
864466|NCT02757391|MK-3475
864468|NCT02757391|Phone calls
864469|NCT02757378|Pain
864470|NCT02757378|Brain
864471|NCT02757378|Plasticity
864472|NCT02757378|Education
864473|NCT02757378|Manual Therapy
864474|NCT02757378|Straight Leg Raise
864475|NCT02757378|Remapping
864476|NCT02757365|aspirin
864477|NCT02757352|ankylosing
864478|NCT02757352|nonradiographic spondyloarthritis
864479|NCT02757339|neurobiology
864480|NCT02757339|PTSD
864481|NCT02757339|DID
864482|NCT02757326|sphingosine kinase 2 inhibitor
864483|NCT02757326|sphingosine kinase 2
864484|NCT02757326|SK2 inhibitor
864485|NCT02757326|SK2
864486|NCT02757313|marijuana
864487|NCT02757313|driving
864488|NCT02757313|THC
864489|NCT02757313|cannabis
864490|NCT02757313|intoxication
864491|NCT02757313|MRI
864492|NCT02757287|Ovarian stimulation
864493|NCT02757287|LH inhibition
864494|NCT02757274|Urologic Surgical Procedure
864495|NCT02757274|Male
864496|NCT02757261|Bruxism
864497|NCT02757261|Child
864498|NCT02757261|Occlusal splint
864499|NCT02757261|Bite force
864500|NCT02757261|Acunpuncture
864501|NCT02757261|Laser
864502|NCT02757261|Muscle actvity
864503|NCT02757261|Salivary Cortisol
864504|NCT02757235|chronic subdural hematoma
864505|NCT02757235|irrigation
864506|NCT02757235|recurrence
864507|NCT02757235|burr hole evacuation
864508|NCT02757235|temperature
864509|NCT02757209|ASTHMA
864510|NCT02757209|COPD
864511|NCT02757209|budesonide
864512|NCT02757209|formoterol
864513|NCT02757209|Salmeterol
864514|NCT02757209|Fluticasone
864515|NCT02757209|Spiromax
864516|NCT02757209|DPI
864517|NCT02757209|Diskus
864518|NCT02757196|Immune Thrombocytopenia
864519|NCT02757196|Rituximab
864520|NCT02757196|methylprednisolone
864521|NCT02757157|Hydrotherapy
864522|NCT02757157|Walking
864523|NCT02757131|Mobility
864524|NCT02757131|Elderly
864525|NCT02757131|Hospitalized patient
864526|NCT02757118|Cardiac Surgery, blood viscosity
864527|NCT02757092|Pulmonary rehabilitation
864528|NCT02757092|lung cancer
864529|NCT02757092|Thoracoscopy
864530|NCT02757079|Melatonin
864531|NCT02757079|NPC-15
864532|NCT02757079|Sleep disorders
864533|NCT02757079|Neurodevelopmental disorder
864534|NCT02757079|Sleep latency
864535|NCT02757079|DSM-5
864536|NCT02757066|Melatonin
864537|NCT02757066|NPC-15
864538|NCT02757066|Sleep disorders
864539|NCT02757066|Autism spectrum disorders
864540|NCT02757066|DSM-5
864541|NCT02757053|Brain Concussion
864542|NCT02757053|Brain Injuries
864543|NCT02757053|Diffuse Axonal Injury
864544|NCT02757053|Football
864545|NCT02757053|Head Protective Devices
864546|NCT02757053|Magnetic Resonance Imaging
864547|NCT02757053|Helmet
864548|NCT02757053|Third party add-on
864549|NCT02757040|chronic lymphocytic leukemia
864550|NCT02757040|ibrutinib
864551|NCT02757040|arsenic trioxide
864552|NCT02757040|phosphatidylinositol 3-kinase
864553|NCT02757027|CABG surgery
864554|NCT02757027|blood viscosity
864555|NCT02757001|Retrievable Inferior Vena Cava Filters
864556|NCT02757001|Pulmonary Embolism
864557|NCT02756923|Male Infertility
864558|NCT02756923|Spermatogonial stem cell
864559|NCT02756910|open abdominal surgery
864560|NCT02756910|anesthesia, general
864561|NCT02756897|Leukemia
864562|NCT02756897|Chronic Lymphocytic Leukemia
864563|NCT02756897|CLL
864564|NCT02756897|Small Lymphocytic Lymphoma
864565|NCT02756897|SLL
864566|NCT02756897|Refractory and/or relapsed
864567|NCT02756897|Ibrutinib
864568|NCT02756897|PCI-32765
864569|NCT02756897|Imbruvica
864570|NCT02756897|Venetoclax
864571|NCT02756897|ABT-199
864572|NCT02756897|GDC-0199
864573|NCT02756845|Non CNS Tumor
864574|NCT02756832|Drug Therapy
864575|NCT02756819|Drug Therapy
864576|NCT02756806|Tattoo removal, Picosecond Laser, Q-switched Laser
864577|NCT02756780|Remission
864578|NCT02756780|Carer
864579|NCT02756780|Psychological
864580|NCT02756780|Bereaved
864581|NCT02756780|Cancer
864582|NCT02756780|Breast
864583|NCT02756780|Prostate
864584|NCT02756780|Colorectal
864585|NCT02756780|Music
864586|NCT02756741|Cirrhosis
864587|NCT02756741|hepatitis B virus
864588|NCT02756741|Alcohol
864589|NCT02756741|varices
864590|NCT02756702|TKA
864591|NCT02756702|TKR
864592|NCT02756702|All-Poly
864593|NCT02756702|posterior stabilized
864594|NCT02756689|Mechanical cervical ripening
864595|NCT02756689|Transcervical catheter
864596|NCT02756689|Foley catheter for labor induction
864597|NCT02756689|Cervical ripening
864598|NCT02756689|Induction of labor
864599|NCT02756676|Parkinson Disease
864600|NCT02756676|Quality of Life
864601|NCT02756676|Rehabilitation
864602|NCT02756663|multiple myeloma
864603|NCT02756663|MM
864604|NCT02756663|relapsed
864605|NCT02756663|relapsed and refractory
864606|NCT02756663|panobinostat
864607|NCT02756663|LBH589
864608|NCT02756663|histone deacetylase inhibitor
864609|NCT02756663|carfilzomib
864610|NCT02756663|proteasome inhibitor
864611|NCT02756650|Behcet Disease
864612|NCT02756650|Inflammation
864613|NCT02756650|Immune system
864614|NCT02756650|Arthritis
864615|NCT02756611|Oncology
864616|NCT02756611|TP53 Mutation
864617|NCT02756611|Refractory
864618|NCT02756611|Relapsed
864619|NCT02756611|B-Cell receptor inhibitor
864620|NCT02756611|17p Deletion
864621|NCT02756611|Chronic Lymphocytic Leukemia
864622|NCT02756598|sufentanil
864623|NCT02756598|propofol
864624|NCT02756598|personality/stress test
864625|NCT02756598|fast-track
864626|NCT02756585|computed tomography
864627|NCT02756585|perfusion imaging
864628|NCT02756585|brain death
864629|NCT02756585|traumatic brain injury
864630|NCT02756559|sepsis
864631|NCT02756559|microRNAs
864632|NCT02756520|chronic kidney disease, pre-dialytic
864633|NCT02756520|Ketosteril, keto-acids
864634|NCT02756520|diet, protein-restricted
864635|NCT02756520|renal function
864636|NCT02756507|anxiety
864637|NCT02756507|depression
864638|NCT02756507|internalizing symptoms
864639|NCT02756468|pancreatic cancer
864640|NCT02756468|procalcitonin
864641|NCT02756455|gastric cancer
864642|NCT02756455|procalcitonin
864643|NCT02756429|atrial fibrillation
864644|NCT02756429|stroke
864645|NCT02756429|thromboembolism
864646|NCT02756429|inflammation
864647|NCT02756416|Reversible Cerebral Vasoconstriction Syndrome (RCVS)
864648|NCT02756416|Arterial spin labeling (ASL) MRI
864649|NCT02756390|Insomnia cancer Survivor
864650|NCT02756364|Drug Therapy
864651|NCT02756325|Azoospermia, IVF, MRI
864652|NCT02756299|Sleep Apnea
864653|NCT02756299|Positive Airway Pressure
864654|NCT02756299|Patient Education
864655|NCT02756286|Electroencephalography
864656|NCT02756286|Attention
864657|NCT02756273|ileostomy
864658|NCT02756273|morbidity
864659|NCT02756273|colorectal surgery
864660|NCT02754245|multicenter study
864661|NCT02754245|emergency department
864662|NCT02754245|overcrowding status
864663|NCT02754245|estimation tool
864664|NCT02754245|validation
864665|NCT02754232|Physical training
864666|NCT02754232|Telemedicine
864667|NCT02754232|Daily activities
864668|NCT02754232|Cross sectoral
864669|NCT02754219|Diabetes Mellitus, Type II
864670|NCT02756247|Buparlisib
864671|NCT02756247|BKM120
864672|NCT02756247|Ibrutinib
864673|NCT02756247|16-009
864674|NCT02756221|symptoms
864675|NCT02756208|vaccine
864676|NCT02756208|healthy volunteer
864677|NCT02756195|Patient safety
864678|NCT02756195|adverse events
864679|NCT02756195|pediatric surgery
864680|NCT02756195|quality improvement
864681|NCT02756195|health systems
864682|NCT02756195|observational study
864683|NCT02756195|non-routine event
864684|NCT02756195|National Surgical Improvement Program
864685|NCT02756169|Obesity
864686|NCT02756169|Breastfeeding
864687|NCT02756169|Grow up
864688|NCT02756169|Milk composition
864689|NCT02756169|Mexico
864690|NCT02756156|interscalene
864691|NCT02756156|infraclavicular
864692|NCT02756156|humerus surgery
864693|NCT02756143|fetal heart
864694|NCT02756143|cesarean section
864695|NCT02756143|exercise
864696|NCT02756143|pregnancy
864697|NCT02756091|Intracranial Artery Dissection
864698|NCT02756091|IAD
864699|NCT02756091|Stroke
864700|NCT02756091|Observational Study
864701|NCT02756065|Bipolar
864702|NCT02756065|schizophrenia
864703|NCT02756065|schizoaffective
864704|NCT02756026|Breast milk
864705|NCT02756026|mineral
864706|NCT02756026|vitamin
864707|NCT02756013|chemotherapy dosing
864708|NCT02756013|Body surface area
864709|NCT02756013|BSA
864710|NCT02756013|paclitaxel
864711|NCT02756013|carboplatin
864712|NCT02756013|dose dense
864713|NCT02756000|myocardial infarction
864714|NCT02756000|percutaneous coronary intervention
864715|NCT02756000|multivessel coronary artery disease
864716|NCT02756000|dobutamine stress echocardiography
864717|NCT02755961|End-stage renal disease
864718|NCT02755961|Phosphate binders
864719|NCT02755961|Hyperphosphatemia
864720|NCT02755961|Dietary education
864721|NCT02755922|Mesenchymal Stem Cells
864722|NCT02755922|Treatment
864723|NCT02755909|Cardiac surgery, anxiety, education
864724|NCT02755883|Physical activity
864725|NCT02755883|non-small lung cancer
864726|NCT02755883|positive affect
864727|NCT02755857|Prophylaxis
864728|NCT02755857|Bioavailability
864729|NCT02755857|Pharmacokinetics
864730|NCT02755844|endometrial carcinomas
864731|NCT02755844|metronomic cyclophosphamide
864732|NCT02755844|metformin
864733|NCT02755844|olaparib
864734|NCT02755844|dose-escalation study
864735|NCT02755818|high density lipoprotein (HDL)
864736|NCT02755818|lipid
864737|NCT02755818|insulin resistance
864738|NCT02755818|glomerular filtration rate (GFR)
864739|NCT02755818|obesity
864740|NCT02755805|Stroke
864741|NCT02755805|Rehabilitation
864742|NCT02755805|Cognition
864743|NCT02755805|Intervention
864744|NCT02755805|Strategy training
864745|NCT02755792|Mild Cognitive Impairment
864746|NCT02755792|Cognitive training
864747|NCT02755792|Calligraphy
864748|NCT02755792|Emotional calmness
864749|NCT02755792|Working memory
864750|NCT02755753|Rebamipide
864751|NCT02755740|Female
864752|NCT02755688|atrial fibrillation
864753|NCT02755688|catheter ablation
864754|NCT02755688|thoracoscopic surgical ablation
864755|NCT02755688|long standing persistent atrial fibrillation
864756|NCT02755662|Obstructive Sleep Apnea Syndrome
864757|NCT02755662|mandibular repositioning device
864758|NCT02755636|Health Behavior Change
864759|NCT02755636|Primary Health Care
864760|NCT02755636|Patient Participation
864761|NCT02755636|Provider-Patient Communication
864762|NCT02755636|Cluster-Randomized Trial
864763|NCT02755636|Mobile Health
864764|NCT02755610|Peritoneal Dialysis
864765|NCT02755610|Checklist
864766|NCT02755597|relapsed/refractory multiple myeloma
864767|NCT02755597|refractory multiple myeloma
864768|NCT02755597|multiple myeloma
864769|NCT02755597|relapsed multiple myeloma
864772|NCT02755532|Pharmacokinetics
864773|NCT02755532|Bupivacaine
864774|NCT02755532|Axillary brachial plexus block
864775|NCT02755519|primary aldosteronism
864776|NCT02755519|confirmatory test
864777|NCT02755519|hypertension
864778|NCT02755506|Ultrasound elastography
864779|NCT02755506|Thoracic lesions
864780|NCT02755506|EBUS-TBNA
864781|NCT02755480|bone marrow transplant
864782|NCT02755480|infection
864783|NCT02755480|computed tomography
864784|NCT02755480|radiation dose
864785|NCT02755441|Diagnosis
864786|NCT02755441|Prognosis
864787|NCT02755441|Biomarker
864788|NCT02755415|Rehabilitation
864789|NCT02755415|Robotic
864790|NCT02755415|Gait
864791|NCT02755415|Quality of Life
864792|NCT02755389|Tracheal intubation
864793|NCT02755389|High flow nasal oxygen
864794|NCT02755389|Airway management
864795|NCT02755389|Apneic oxygenation
864796|NCT02755363|COPD
864797|NCT02755363|residual volume
864798|NCT02755363|osteopathy
864799|NCT02755363|hyperinflation
864800|NCT02755350|PrEP
864801|NCT02755350|HIV Prevention
864802|NCT02755350|combination prevention
864803|NCT02755350|demonstration project
864804|NCT02755337|adenocarcinoma
864805|NCT02755337|non-adenocarcinoma
864806|NCT02755298|Treatment Outcome
864807|NCT02755298|Acetazolamide
864808|NCT02754193|Venous-Arterial ExtraCorporeal Membrane Oxygenation
864809|NCT02754180|adjuvant
864810|NCT02754180|pancreatic cancer
864811|NCT02754180|R1 resection
864812|NCT02754180|positive lymph nodes
864813|NCT02754167|Hepcidin
864814|NCT02754167|hemoglobin
864815|NCT02754167|iron
864816|NCT02754167|anemia of chronic disease
864817|NCT02755272|Triple Negative Breast Cancer
864818|NCT02755259|Acetazolamide
864819|NCT02755259|Hemodynamics
864820|NCT02755246|subjective cognitive decline
864821|NCT02755246|dementia
864822|NCT02755246|lifestyle
864823|NCT02755246|polyamine
864824|NCT02755246|memory
864825|NCT02755246|elderly
864826|NCT02755246|prevention
864827|NCT02755246|treatment
864828|NCT02755246|dietary supplement
864829|NCT02755246|Polyamine-enriched diet
864830|NCT02755194|pharmacokinetics
864831|NCT02755194|Drug-in-milk
864832|NCT02755194|breastfeeding
864833|NCT02755194|drug safety
864834|NCT02755194|population pharmacokinetics
864835|NCT02755155|acute circulatory failure requiring norepinephrine
864836|NCT02755155|SIRS
864837|NCT02755155|Albumin, therapeutic
864838|NCT02755116|Nausea
864839|NCT02755116|Vomiting
864840|NCT02755103|Mindfulness
864841|NCT02755103|Comorbid PTSD and SUD
864842|NCT02755103|Meditation
864843|NCT02755090|nitrous
864844|NCT02755090|pain
864845|NCT02755077|Anesthesia induction
864846|NCT02755077|Airway
864847|NCT02755077|Mask ventilation
864848|NCT02755038|postmenopausal women
864849|NCT02755038|scalp hair
864850|NCT02755038|estrogen
864851|NCT02755038|progesterone
864852|NCT02755025|Sepsis
864853|NCT02755025|SOFA score
864854|NCT02755025|Automated calculation
864855|NCT02755012|Maternal Health
864856|NCT02755012|Guatemala
864857|NCT02755012|Indigenous Population
864858|NCT02755012|Stunting
864859|NCT02755012|Food Insecurity
864860|NCT02755012|Poverty
864861|NCT02755012|Social Support
864862|NCT02755012|Maternal Autonomy
864863|NCT02755012|Paternal Support
864864|NCT02755012|Cortisol Rhythm
864865|NCT02754986|heart rate variability
864866|NCT02754960|Gastrointestinal bleeding
864867|NCT02754960|Vascular malformation
864868|NCT02754960|Angiodysplasia
864869|NCT02754960|Thalidomide
864870|NCT02754947|Assessment and Consultation Team (ACT)
864871|NCT02754947|Rapid Response Team (RRT)
864872|NCT02754947|Perioperative complications
864873|NCT02754947|Respiratory insufficiency
864874|NCT02754947|ASA status
864875|NCT02754934|chronic
864876|NCT02754895|acute coronary syndrome
864877|NCT02754895|health behavior
864878|NCT02754895|factorial design
864879|NCT02754895|positive psychology
864880|NCT02754882|NSCLC
864881|NCT02754882|bevacizumab
864882|NCT02754882|avastin
864883|NCT02754856|Colorectal Cancer
864884|NCT02754856|Liver Metastases
864885|NCT02754856|Resectable liver metastases
864886|NCT02754856|Tremelimumab
864887|NCT02754856|Fluorouracil
864888|NCT02754856|5-Fluorouracil
864889|NCT02754856|5-FU
864890|NCT02754856|Adrucil
864891|NCT02754856|Efudex
864892|NCT02754856|Leucovorin
864893|NCT02754856|Citrovorum
864894|NCT02754856|Wellcovorin
864895|NCT02754856|Oxaliplatin
864896|NCT02754856|Eloxatin
864897|NCT02754856|Bevacizumab
864898|NCT02754856|Avastin
864899|NCT02754856|Anti-VEGF monoclonal antibody
864900|NCT02754856|MEDI4736
864901|NCT02754856|Durvalumab
864902|NCT02754778|arterial stiffness
864903|NCT02754778|preeclampsia
864904|NCT02754778|HELLP-syndrome
864905|NCT02754778|pulse wave velocity
864906|NCT02754778|advanced glycation endproducts
864907|NCT02754778|skin autofluorescence
864908|NCT02754778|conditional workout
864909|NCT02754778|postpartum
864910|NCT02754778|cardiovascular risk
864911|NCT02754778|pregnancy
864912|NCT02754778|vicorder
864913|NCT02754778|age reader
864921|NCT02754739|Pravastatin
864922|NCT02754739|Insulin Resistance
864923|NCT02754700|Anterior Cruciate Ligament
864924|NCT02754687|male contraception
864925|NCT02754687|healthy men
864926|NCT02754687|androgen
864927|NCT02754687|Nortestosterone
864928|NCT02754687|Dodecylcarbonate
864929|NCT02754687|11-Beta
864930|NCT02754687|11β
864931|NCT02754687|contraception
864932|NCT02754661|Polyps; Capsule endoscopy; CT Colonography; Colonoscopy; Average risk patients for colorectal cancer screening
864933|NCT02754635|Abnormal first or second trimester biochemical markers
864934|NCT02754635|maternal and perinatal morbidity/mortality
864935|NCT02754622|Rehabilitation
864936|NCT02754609|Celiac Disease
864937|NCT02754609|Necator americanus
864938|NCT02754609|Helminths
864939|NCT02754609|Autoimmunity
864940|NCT02754609|Clinical Trials, Phase I
864941|NCT02754609|Randomized Controlled Trial
864942|NCT02754583|trachoma
864943|NCT02754583|soil transmitted helminths
864944|NCT02754583|sanitation
864945|NCT02754583|face washing
864946|NCT02754583|antibiotics
864947|NCT02754570|Open-angle glaucoma
864948|NCT02754570|Ocular hypertension
864949|NCT02754570|Latanoprost
864950|NCT02754570|Pilocarpine
864951|NCT02754544|Brain tumor
864952|NCT02754544|Metastatic brain tumor
864953|NCT02754544|Neurosurgery
864954|NCT02754544|Electrocorticogram
864955|NCT02754544|ECoG
864956|NCT02754544|Transcranial magnetic stimulation
864957|NCT02754544|TMS
864958|NCT02754544|Direct electrical stimulation
864959|NCT02754544|DES
864960|NCT02754544|Functional MRI
864961|NCT02754544|fMRI
864962|NCT02754544|PMT High-Resolution Grids
864963|NCT02754544|CorTec High-Resolution Hybrid Grids
864964|NCT02754544|Digital glove
864965|NCT02754544|Neurological exam
864966|NCT02754544|Ad-Tech Grids
864967|NCT02754544|Grip Sensor
864968|NCT02754531|Cole formula
864969|NCT02754531|Pediatric patients
864970|NCT02754531|intubation
864971|NCT02754531|Ultrasonography
864972|NCT02754531|Endotracheal tube
864973|NCT02754531|uncuffed
864974|NCT02754531|pediatric
864975|NCT02754505|Keywords: intensive care, muscle wasting, discharge, neuromuscular weakness, mobilization
864976|NCT02754453|Weight Regain
864977|NCT02754453|Group Treatment
864978|NCT02754453|Weight Loss
864979|NCT02754427|Surveillance
864980|NCT02754427|Physiotherapy
864981|NCT02754427|Arm morbidity
864982|NCT02754414|platelets
864983|NCT02754414|transfusion
864984|NCT02754414|cold storage
864985|NCT02754414|apheresis
864986|NCT02754401|public health
864987|NCT02754401|periodontitis
864988|NCT02754401|self-reported questionnaire
864989|NCT02754388|LDCT, screening, health behavior, psychological factors
864990|NCT02754375|biological markers
864991|NCT02754375|rTMS
864992|NCT02754362|Poly-ICLC and bevacizumab
864993|NCT02754362|humanized monoclonal antibody
864994|NCT02754349|pulse wave velocity
864995|NCT02754349|augmentation index
864996|NCT02754349|central pulse pressure
864997|NCT02754310|Education, medical
864998|NCT02754310|Simulation Training
864999|NCT02754297|Neuroendocrine tumors
865000|NCT02754297|Personalized
865001|NCT02754297|Peptide receptor radionuclide therapy
865002|NCT02754297|PRRT
865003|NCT02754297|177Lu-DOTATATE
865004|NCT02754297|177Lu-octreotate
865005|NCT02754089|Body weight changes
865006|NCT02754089|Medicine, Traditional
865007|NCT02754089|Herbal medicine
865008|NCT02754089|Rhus
865009|NCT02754089|Waist Circumference
865010|NCT02754089|Waist-Hip Ratio
865011|NCT02754089|Body mass index
865012|NCT02754076|Sanfilippo Syndrome Type B
865013|NCT02754024|Stemless shoulder prosthesis
865014|NCT02754011|HER2 negative
865015|NCT02754011|Locally advanced or metastatic
865016|NCT02753998|Stenosis of arteriovenous fistula
865017|NCT02753998|Angioplasty
865018|NCT02753998|Paclitaxel-Coated Balloon Angioplasty
865021|NCT02753894|Dose-finding
865022|NCT02753894|Hemodialysis
865023|NCT02753894|ASP1585
865024|NCT02753894|Chronic kidney disease
865025|NCT02753868|Intradialytic exercise
865026|NCT02753868|Cardiac and arterial function
865031|NCT02753816|Tranexamic Acid
865032|NCT02753816|Burn
865033|NCT02753816|Surgery
865034|NCT02753816|Tangential
865035|NCT02753816|Excision
865036|NCT02753790|Brain
865037|NCT02753790|Metastasis
865038|NCT02753790|IMRT
865039|NCT02753790|Radiation
865040|NCT02753790|Cancer
865041|NCT02753790|Hippocampus
865042|NCT02753790|Intensity modulated radiotherapy
865043|NCT02753790|Quality of life
865044|NCT02753790|QOL
865045|NCT02753712|Small airway disease
865046|NCT02753712|asthma
865047|NCT02753699|Chronic hepatitis C
865048|NCT02753686|HR+ HER2
865049|NCT02753686|postmenopausal
865050|NCT02753686|advanced breast cancer
865051|NCT02753686|non steroidal aromatase inhibitor (NSAI) exposure
865052|NCT02753686|metastatic
865053|NCT02753686|endocrine therapy
865054|NCT02753686|targeted therapy
865055|NCT02753686|prospective
865056|NCT02753686|observational
865057|NCT02753686|registry
865058|NCT02753686|real world setting
865059|NCT02753686|non-interventional
865060|NCT02753686|Canadian
865061|NCT02753673|Breast Conserving Therapy
865062|NCT02753673|Reported Outcomes Instrument
865063|NCT02753673|16-325
865064|NCT02753660|spinal, anesthesia, pendant, spinal-bone contact, puncture
865065|NCT02753608|exhaled breath condensate
865066|NCT02753608|volatile organic compounds
865067|NCT02753595|PEGylated Recombinant Human Hyaluronidase
865068|NCT02753595|Eribulin Mesylate
865069|NCT02753595|E7389
865070|NCT02753595|PEGPH20
865071|NCT02753595|Human Epidermal Growth Factor Receptor 2-Negative
865072|NCT02753595|High-Hyaluronan
865073|NCT02753582|Elderly, pre-frail, SOD
865074|NCT02753569|Magnetic Resonance Imaging
865075|NCT02753569|PET/CT
865076|NCT02753569|non-small cell lung cancer
865077|NCT02753556|Chronic Obstructive Pulmonary Disease
865078|NCT02753556|COPD
865079|NCT02753556|ScreenFlow
865080|NCT02753556|Screening
865081|NCT02753556|Lung Disease
865082|NCT02753556|Mobile Health
865083|NCT02753556|Peak Flow Meter
865084|NCT02753556|Usability
865085|NCT02753517|hepatobiliary scintigraphy
865086|NCT02753517|extended hepatectomy
865087|NCT02753517|volumetry
865088|NCT02753504|Dyslipidemia
865089|NCT02753491|short interview, diabetes, lifestyle changes, primary care
865090|NCT02753478|hypothermia
865091|NCT02753465|Rectal Neoplasms
865092|NCT02753465|anastomosis
865093|NCT02753465|OS
865094|NCT02753465|DFS
865095|NCT02753465|LCA
865096|NCT02753465|laparoscopic surgery
865097|NCT02753452|youth
865098|NCT02753452|disability
865099|NCT02753452|transition
865100|NCT02753452|life skills
865101|NCT02753452|adolescence
865102|NCT02753413|Vaccine
865103|NCT02753413|Safety
865104|NCT02753413|Reactogenicity
865105|NCT02753413|Respiratory syncytial virus (RSV)
865106|NCT02753387|mouthwash
865107|NCT02753387|head and neck cancer
865108|NCT02753387|chlorhexidine
865109|NCT02753387|pathogens germs
865110|NCT02753374|cystic fibrosis, Chinese, children
865111|NCT02753361|Ultrasound
865112|NCT02753361|regional blockade
865113|NCT02753361|lipoma
865114|NCT02753335|CRPS, graded motor imagery, desensitization, fMRI, DMN
865115|NCT02753322|Dual task training
865116|NCT02753322|Dual task interference
865117|NCT02753322|Sub-acute stroke
865118|NCT02753322|Physiotherapy training
865119|NCT02753322|Community ambulation
865120|NCT02753322|Balance
865123|NCT02753296|Cancer
865124|NCT02753296|Fertility Preservation
865125|NCT02753296|Patient Decision Aid
865126|NCT02753283|Bone loss
865127|NCT02753283|Frail Geriatric Patients
865128|NCT02753283|Nursing Home Patients
865129|NCT02753283|Long-term Care Patients
865130|NCT02753283|Osteoporosis
865131|NCT02753283|Osteoporotic Fractures
865132|NCT02753257|stroke
865133|NCT02753257|stroke mimic
865134|NCT02753244|Cognitive VideoGames
865135|NCT02753179|Bilateral vestibular hypofunction
865136|NCT02753179|Video Head Impulse Test
865137|NCT02753179|Covert-saccades
865138|NCT02753179|Quality of life
865139|NCT02753179|Dynamic visual acuity
865140|NCT02753166|PTSD (Post Traumatic Stress Disorder)
865141|NCT02753166|Emergency Department
865142|NCT02753127|Colorectal Neoplasms
865143|NCT02753127|Colonic Diseases
865144|NCT02753127|Digestive System Diseases
865145|NCT02753127|Digestive System Neoplasms
865146|NCT02753127|Gastrointestinal Diseases
865147|NCT02753127|Gastrointestinal Neoplasms
865148|NCT02753127|Intestinal Diseases
865149|NCT02753127|Intestinal Neoplasms
865150|NCT02753127|Neoplasms
865151|NCT02753127|Neoplasms by Histologic Type
865152|NCT02753127|Neoplasms by Site
865153|NCT02753127|Neoplasms, Glandular and Epithelial
865154|NCT02753127|Rectal Diseases
865155|NCT02753114|Ketamine
865156|NCT02753114|Intranasal
865157|NCT02753114|Emergency Medical Services
865158|NCT02753114|Pain
865159|NCT02753114|Analgesia
865160|NCT02753101|Positron Emission Tomography
865161|NCT02753101|Magnetic Resonance Imaging
865162|NCT02753101|PET/MRI
865163|NCT02753101|sigma-1 receptor
865164|NCT02753101|radiopharmaceutical
865165|NCT02753101|complex regional pain syndrome
865166|NCT02753101|sciatica
865167|NCT02753101|chronic pain
865168|NCT02753088|Equivalence
865169|NCT02753088|BCD-063
865170|NCT02753088|Copaxone-Teva
865171|NCT02753049|HIV
865172|NCT02753049|AIDS
865173|NCT02753049|Adolescent
865174|NCT02753049|Adherence
865175|NCT02753049|Retention
865176|NCT02753049|mHealth
865177|NCT02753036|cognition
865178|NCT02753036|chemotherapy
865179|NCT02753036|polyneuropathy
865180|NCT02753036|paclitaxel
865181|NCT02753036|carboplatin
865182|NCT02753036|cancer
865183|NCT02752984|Peripherally inserted central venous catheter
865184|NCT02752932|Head and neck cancer
865185|NCT02752932|Patient derived Xenograft
865186|NCT02752932|Chemotherapy
865187|NCT02752932|Metastases
865193|NCT02752893|estrogen
865194|NCT02752893|estrogen receptor
865195|NCT02752893|ER+
865196|NCT02752893|HER2
865197|NCT02752893|HER2-
865198|NCT02752893|HER2-negative
865199|NCT02752893|xenograft
865200|NCT02752893|co-clinical
865201|NCT02752893|mice
865202|NCT02752893|patient-derived xenograft
865203|NCT02752893|patient-derived
865204|NCT02752893|breast cancer
865205|NCT02752893|precision medicine
865206|NCT02752893|personalized medicine
865207|NCT02752867|traditional Chinese medicine granules
865208|NCT02752867|Cognitive Impairment
865209|NCT02752867|Acute cerebral infraction
865210|NCT02752867|treatment
865211|NCT02752854|pain scores
865212|NCT02752854|pressure algometer
865213|NCT02752854|healthy volunteer adults
865214|NCT02752802|Contrast Media
865215|NCT02752802|Angiography
865216|NCT02752789|alloantibodies
865217|NCT02752789|donor specific antibodies (DSA)-preformed, de novo
865218|NCT02752789|self-antigens
865219|NCT02752789|chronic allograft function
865220|NCT02752776|Moderate to severe plaque psoriasis
865221|NCT02752763|Dry eye
865222|NCT02752763|isotretinoin, AS
865223|NCT02752763|Autologous serum
865224|NCT02752724|major depressive disorder
865225|NCT02752724|electroconvulsive therapy
865226|NCT02752724|metabolomics
865227|NCT02752724|treatment resistant depression
865228|NCT02752724|anesthesiology
865229|NCT02752724|ketamine
865230|NCT02752724|prospective randomized clinical trial
865231|NCT02752711|Minor head trauma
865232|NCT02752711|Children
865233|NCT02752711|Clinical decision rule
865234|NCT02752685|Nab-Paclitaxel
865235|NCT02752685|Abraxane
865236|NCT02752685|MK-3475
865237|NCT02752672|dithranol
865238|NCT02752672|therapeutic mechanisms
865239|NCT02752659|Monitoring
865240|NCT02752646|cataract
865241|NCT02752633|Xanthine dehydrogenase inhibitor treatment, pharmacotherapy
865242|NCT02752620|osteopathic manipulative treatment
865243|NCT02752620|Chronic nonspecific low back pain
865244|NCT02752620|low back pain
865245|NCT02752594|probiotic
865246|NCT02752594|mutans streptococci
865247|NCT02752594|bacillus coagulans
865248|NCT02752594|caries
865249|NCT02752581|suction drain
865250|NCT02752581|knee arthroscopy
865251|NCT02752581|knee pain
865252|NCT02752555|Oligoasthenoteratozoospermia
865253|NCT02752555|Male factor managment
865254|NCT02752555|Intacytoplasmic sperm injection
865255|NCT02752529|Liver Transplantation
865256|NCT02752529|Individualized Therapy
865257|NCT02752529|Polymorphism
865258|NCT02752477|Opioid-sparing
865259|NCT02752464|Weight Loss
865260|NCT02752464|Health Status Disparities
865261|NCT02752438|high frequency oscillatory ventilation
865262|NCT02752438|rescue
865263|NCT02752438|newborn
865264|NCT02752425|Speech disorders
865265|NCT02752425|Speech therapy
865266|NCT02752425|Visual feedback
865267|NCT02752425|Buccopharyngeal surgery
865268|NCT02752425|Central nervous system damage
865269|NCT02752373|GTC Seizures
865272|NCT02752321|patient discharge
865273|NCT02752321|patient engagement
865274|NCT02752321|patient satisfaction
865275|NCT02752321|continuity of patient care
865276|NCT02752321|hospital discharge
865277|NCT02752321|health technology
865278|NCT02752321|eDischarge
865279|NCT02752321|multimedia
865280|NCT02752321|mobile applications
865281|NCT02752321|software applications
865282|NCT02752321|portable electronic applications
865283|NCT02752282|Family Planning
865284|NCT02752282|LNG-IUS
865285|NCT02752282|Health Education
865286|NCT02752256|tissue plasminogen activator
865287|NCT02752243|acute leukemia
865288|NCT02752243|myelodysplastic syndrome (MDS)
865289|NCT02752243|Stem Cell Transplantation
865290|NCT02752230|Post operative pain
865291|NCT02752230|Bariatric Surgery
865292|NCT02752204|Relapsed
865293|NCT02752204|Refractory
865294|NCT02752204|Lymphoma
865295|NCT02752191|ferumoxytol
865296|NCT02752178|Depression
865297|NCT02752178|Major depressive disorder
865298|NCT02752178|MDD
865299|NCT02752152|Counseling
865300|NCT02752139|Sleep Disorders
865301|NCT02752139|Cerebral Hemodynamics
865302|NCT02752139|Dynamic Cerebral Auto-Regulation
865303|NCT02752139|Stroke
865304|NCT02752126|Esophageal sparing
865305|NCT02752126|Conventional radiotherapy
865306|NCT02752126|Palliative radiation
865307|NCT02752126|Central lung tumors
865308|NCT02752113|diabetes mellitus type 2
865309|NCT02752113|Metformin
865310|NCT02752113|Micro- and macrocirculation
865311|NCT02752113|HbA1c >= 7%
865312|NCT02752100|Lower Extremity Arterial Occlusive Disease
865313|NCT02752100|Interventional Therapy
865314|NCT02752074|Melanoma
865315|NCT02752074|Metastatic Melanoma
865316|NCT02752035|AML
865317|NCT02752035|ASP2215
865318|NCT02752035|Newly Diagnosed AML
865319|NCT02752035|Acute Myeloid Leukemia (AML)
865320|NCT02752035|FLT3
865321|NCT02752022|e-cigarettes
865322|NCT02752022|nitrosamines
865323|NCT02752022|smoking cessation
865324|NCT02752009|Breast Cancer
865325|NCT02752009|Armpit lymph nodes Cancer
865326|NCT02751996|Chronic Hepatitis
865327|NCT02751996|HBV
865328|NCT02751996|Double blind
865329|NCT02751983|Suicide
865330|NCT02751983|Psychiatric Rehabilitation
865331|NCT02751983|Acceptance and Commitment Therapy
865332|NCT02751983|Brief Psychotherapy
865333|NCT02751983|Inpatients
865334|NCT02751970|Dental adhesive
865335|NCT02751970|adhesive systems
865336|NCT02751970|Dental Restoration Failure
865337|NCT02751944|exercise-induced
865338|NCT02751944|joint pain
865339|NCT02751944|joint stiffness
865340|NCT02751944|post-menopausal
865341|NCT02751944|women
865342|NCT02751944|cartilage turnover
865343|NCT02751944|CTX-II
865344|NCT02751931|Pediatrics
865345|NCT02751931|Urodynamics
865346|NCT02751931|Mirabegron
865347|NCT02751931|Phase 3
865348|NCT02751931|Neurogenic Detrusor Overactivity
865350|NCT02751814|Childcare Center Regulations
865351|NCT02751814|Physical Activity
865352|NCT02751814|Sedentary Behavior
865353|NCT02751814|Screen-time Behavior
865354|NCT02751788|childcare center regulations
865355|NCT02751788|physical activity
865356|NCT02751788|sedentary behavior
865357|NCT02751788|screen-time behavior
865358|NCT02751775|Childcare center regulations
865359|NCT02751775|Physical Activity
865360|NCT02751775|Sedentary Behavior
865361|NCT02751775|Screen-Time Behavior
865362|NCT02751775|Focus groups
865363|NCT02751723|cancer disease
865364|NCT02751723|palliative care
865365|NCT02751723|palliative therapy
865366|NCT02751723|cancer
865367|NCT02751723|patient´s needs
865368|NCT02751723|patient care
865369|NCT02751723|disease burden
865370|NCT02751684|Rapid Sequence Induction
865371|NCT02751684|European
865372|NCT02751684|Evaluation
865373|NCT02751684|EUROpE RSI
865374|NCT02751684|Standards
865375|NCT02751684|RSI
865376|NCT02751645|Pediatric
865377|NCT02751645|Cardiac
865378|NCT02751645|Surgery
865379|NCT02751632|Ultra High Risk of Psychosis
865380|NCT02751632|Prodrome
865381|NCT02751619|Pre-emptive analgesia
865382|NCT02751619|Post-thoracotomy pain
865383|NCT02751619|Lidocaine patch
865384|NCT02751606|Ferumoxtran
865385|NCT02751606|MRI Scans
865386|NCT02751593|pregnancy
865387|NCT02751593|Immune Thrombocytopenia
865388|NCT02751593|dexamethasone
865389|NCT02751554|124I-PU-AD
865390|NCT02751554|PET Imaging
865391|NCT02751554|16-004
865392|NCT02751528|Breast Cancer
865393|NCT02751528|Breast Cancer male
865394|NCT02751528|Breast Neoplasms
865395|NCT02751528|Breast Neoplasms male
865396|NCT02751528|Vaccine
865397|NCT02751528|HER2
865398|NCT02751528|Metastatic
865399|NCT02751528|Locally Advanced
865400|NCT02751528|Unresectable
865401|NCT02751528|Solid Tumor
865402|NCT02751528|Phase 1
865403|NCT02751528|Cancer Vaccine
865404|NCT02751502|Children
865405|NCT02751502|Pediatrics
865406|NCT02751502|Arm
865407|NCT02751502|Upper limb
865408|NCT02751502|bimanual training
865409|NCT02751502|physical training
865410|NCT02751437|preterm
865411|NCT02751437|arginine
865412|NCT02751437|immune function
865413|NCT02751437|nutrition
865414|NCT02751424|Multidrug-resistant
865415|NCT02751424|Gram negative bacterial infection
865416|NCT02751424|Safety
865417|NCT02751424|Pharmacokinetic
865418|NCT02751333|Esophageal stricture
865419|NCT02751333|Esophageal leak
865420|NCT02751333|Esophageal perforation
865421|NCT02751333|Esophageal fistula
865422|NCT02751333|Endostitch
865423|NCT02751333|Esophageal stent
865424|NCT02751307|metformin
865425|NCT02751307|clozapine
865426|NCT02751307|schizophrenia
865427|NCT02751307|metabolic traits
865428|NCT02751294|Healthy Volunteer
865429|NCT02751294|Malaria
865430|NCT02751294|Pharmacokinetics
865431|NCT02751294|Tafenoquine
865432|NCT02751281|pneumatic
865433|NCT02751281|ultra-sonic
865434|NCT02751281|percutaneous nephrolithotomy
865435|NCT02751268|infraorbital nerve block
865436|NCT02751268|infratrochlear nerve block
865437|NCT02751268|septorhinoplasty
865438|NCT02751268|general anesthesia
865439|NCT02751268|postoperative analgesia
865440|NCT02751242|Diuretic Resistance
865441|NCT02751242|Emergency Medicine
865442|NCT02751229|Mental illness
865443|NCT02751229|adolescents
865444|NCT02751229|intervention
865445|NCT02751229|stigma
865446|NCT02751229|disclosure
865447|NCT02751229|secrecy
865448|NCT02751216|high frequency / high density spinal cord stimulation
865449|NCT02751216|EEG
865450|NCT02751216|conditioned pain modulation
865451|NCT02751177|KRAS gene mutation
865452|NCT02751177|NRAS gene mutation
865453|NCT02751177|BRAF gene mutation
865454|NCT02751138|Immune phenotype
865455|NCT02751138|Cytokines
865456|NCT02751138|Genetic aberration
865457|NCT02751138|Overall survival
865458|NCT02751138|Progression free survival
865459|NCT02751125|Mesenchymal stem cells
865460|NCT02751125|bone augmentation
865461|NCT02751125|bone regeneration
865462|NCT02751086|minimally invasive surgery
865463|NCT02751086|gastrectomy
865464|NCT02751086|robotic surgery
865465|NCT02751086|laparoscopic surgery
865466|NCT02751086|laparoscopy
865467|NCT02751086|robot-assisted
865468|NCT02751086|robotic
865469|NCT02751086|robotic gastrectomy
865470|NCT02751086|laparoscopic gastrectomy
865471|NCT02751086|minimally invasive gastrectomy
865472|NCT02751073|Microbiota
865473|NCT02751073|Proteome
865474|NCT02751034|Wrinkle Severity Rating Scale
865475|NCT02751034|Global Aesthetic Improvement Scale
865476|NCT02751034|Hyaluronic acid filler
865477|NCT02751034|filler
865478|NCT02751034|Nasolabial Fold
865479|NCT02750995|myelodysplastic syndrome
865480|NCT02750995|acute myeloid leukemia
865481|NCT02750995|azacitidine
865482|NCT02750995|peptide vaccine
865483|NCT02750995|cancer testis antigen
865484|NCT02750995|cancer vaccine
865485|NCT02750995|immunotherapy
865486|NCT02750995|combination therapy
865487|NCT02750995|NY-ESO-1
865488|NCT02750995|PRAME
865489|NCT02750995|MAGE-A3
865490|NCT02750995|WT-1
865491|NCT02750995|vaccine
865492|NCT02750969|tinnitus
865493|NCT02750969|lidocain patch
865494|NCT02750956|endocan protein
865495|NCT02750956|VEGF A
865496|NCT02750956|TNF-alpha
865497|NCT02750956|after treatment
865498|NCT02750930|Extension
865499|NCT02750930|Long-term Safety
865500|NCT02750930|Pharmacodynamics
865501|NCT02750930|Albiglutide
865502|NCT02750930|Type 2 Diabetes Mellitus
865503|NCT02750917|postoperative pain
865504|NCT02750917|lornoxicam
865505|NCT02750917|etoricoxib
865506|NCT02750917|total knee arthroplasty
865507|NCT02750904|Smoking Cessation
865508|NCT02750904|Acceptance & Commitment Therapy
865509|NCT02750904|Cognitive Behavioral Therapy
865510|NCT02750904|Bipolar Disorder
865511|NCT02750891|high grade glioma
865512|NCT02750891|HGG
865513|NCT02750891|DIPG
865514|NCT02750878|Urinary Incontinence, Stress [C13.351.968.934.814.500]
865515|NCT02750865|biomedical technology
865516|NCT02750865|palliative care
865517|NCT02750800|Patient related outcomes
865518|NCT02750800|Psoriatic arthritis
865519|NCT02750800|Rheumatoid arthritis
865520|NCT02750800|Patient support program
865521|NCT02750800|Ankylosing spondylitis
865522|NCT02750800|Quality of life
865523|NCT02750800|Psoriasis
865524|NCT02750800|Observational study
865525|NCT02750800|Ulcerative colitis
865526|NCT02750800|Crohn's disease
865527|NCT02750722|Exercise
865528|NCT02750722|Lung diffusion capacity
865529|NCT02750722|Sputum viscoelasticity
865530|NCT02750722|Lung disease
865531|NCT02750709|HT-1
865532|NCT02750709|Tyrosinemia
865533|NCT02750709|Nitisinone
865534|NCT02750709|Bioequivalence
865535|NCT02750709|Healthy Volunteer
865536|NCT02750709|Orfadin
865537|NCT02750696|Acetaminophen
865538|NCT02750696|Analgesia
865539|NCT02750696|Codeine
865540|NCT02750696|Drug Combinations
865541|NCT02750696|Endodontics
865542|NCT02750696|Periapical abscess
865543|NCT02750696|Randomized Controlled Trial
865544|NCT02750696|Tramadol
865545|NCT02750696|Visual analog scale
865546|NCT02750683|inotropic effect, norepinephrine, septic shock,
865547|NCT02750670|Lymphoma
865548|NCT02750670|Non-Hodgkin's
865549|NCT02750670|CD20+
865550|NCT02750670|Obinutuzumab
865551|NCT02750670|GDP Chemotherapy
865552|NCT02750670|Refractory and aggressive non-Hodgkin lymphoma
865553|NCT02750631|depression
865554|NCT02750631|melatonin
865555|NCT02750631|light therapy
865556|NCT02750631|Wake Therapy
865557|NCT02750631|chronobiology
865558|NCT02750592|Ankylosing Spondylitis
865559|NCT02750540|Tenofovir enema
865560|NCT02750423|Cardiology
865561|NCT02750423|Surgery
865562|NCT02750397|HIV
865563|NCT02750397|Kidney Transplant
865564|NCT02750397|Liver Transplant
865565|NCT02750397|Transplant
865566|NCT02750371|Cavernous sinus meningioma
865567|NCT02750371|Pituitary adenoma
865568|NCT02750371|Hippocampus
865569|NCT02750371|Irradiation
865570|NCT02750371|Autobiographical memory
865571|NCT02750358|Enzalutamide
865572|NCT02750358|15-307
865573|NCT02750345|HT-1
865574|NCT02750345|Tyrosinemia
865575|NCT02750345|Nitisinone
865576|NCT02750345|Bioavailability
865577|NCT02750345|Healthy Volunteer
865578|NCT02750345|Food-Effect
865579|NCT02750332|HT-1
865580|NCT02750332|Tyrosinemia
865581|NCT02750332|Nitisinone
865582|NCT02750332|Bioavailability
865583|NCT02750332|Healthy Volunteer
865584|NCT02750332|Food-Effect
865588|NCT02750293|vitamin D
865589|NCT02750293|blood pressure
865590|NCT02750293|serum lipids
865591|NCT02750293|glucose metabolism
865592|NCT02750293|muscle function
865593|NCT02750293|arterial stiffness
865594|NCT02750293|depression
865595|NCT02750293|psoriasis
865596|NCT02750293|sleep
865597|NCT02750293|bone density
865598|NCT02750267|Type 1 Diabetes Mellitus (T1DM)
865599|NCT02750267|Artificial Pancreas Project (APP)
865600|NCT02750267|Diabetes Assistant (DiAs)
865601|NCT02750267|Closed-Loop Control (CLC)
865602|NCT02750267|Continuous Glucose Monitor
865603|NCT02750267|Pediatric
865604|NCT02750267|Insulin Pump
865605|NCT02750241|active video game
865606|NCT02750241|mHealth
865607|NCT02750241|cancer survivor
865608|NCT02750241|women's health
865609|NCT02750241|breast cancer
865610|NCT02750241|physical activity
865611|NCT02750241|support group
865612|NCT02750241|survivorship
865613|NCT02750215|MET exon 14 skipping
865614|NCT02750215|Stage IV non-small cell lung cancer NSCLC
865615|NCT02750202|Genital warts
865616|NCT02750202|HPV types
865617|NCT02750202|HPV vaccine
865618|NCT02750202|Cervical cytology
865619|NCT02750202|Therapeutic vaccine
865620|NCT02750202|Quadrivalent HPV vaccine
865621|NCT02750176|Rehabilitation
865622|NCT02750176|Closed chain exercises
865623|NCT02750137|Tetracaine
865624|NCT02750124|participation
865625|NCT02750124|self sampling
865626|NCT02750124|Screening
865627|NCT02750098|Diabetes Mellitus, Cataract, Aqueous humor
865628|NCT02750085|Hemophilia A
865629|NCT02750085|pharmacokinetics
865630|NCT02750085|myPKFiT
865631|NCT02750020|Telephone survey
865632|NCT02749955|HIV prevention
865633|NCT02749955|Pre exposure prophylaxis
865634|NCT02749955|Men who have sex with men
865635|NCT02749955|Partner services
865636|NCT02749955|Linkage to care
865637|NCT02749955|Seronegative
865638|NCT02749955|Sexually transmitted diseases
865639|NCT02749942|Diabetes
865640|NCT02749942|Remote Ischemic Conditioning
865641|NCT02749942|Neuropathy
865642|NCT02749942|Angiopathy
865643|NCT02749929|Distal radius fracture, Low Level Laser Therapy
865644|NCT02749916|SWI
865645|NCT02749916|MP-RAGE
865646|NCT02749916|DANTE T1-SPACE
865647|NCT02749877|Pediatric Cancer
865648|NCT02749877|Training
865649|NCT02749877|Working Memory
865650|NCT02749877|Physical Activity
865651|NCT02749877|Brain Tumor
865652|NCT02749877|Physical Exercise
865653|NCT02749864|Hepatitis
865654|NCT02749864|Prevalence
865655|NCT02749864|Epidemiology
865656|NCT02749864|Infectious diseases
865657|NCT02749851|pregnancy
865658|NCT02749851|growth restriction
865659|NCT02749838|Cancer
865660|NCT02749838|Genomic testing
865661|NCT02749838|Genetic testing
865662|NCT02749838|Molecular screening
865663|NCT02749838|Molecular Profiling
865664|NCT02749838|Biomarker
865665|NCT02749838|Biopsy
865666|NCT02749838|Tumor sampling
865667|NCT02749838|Registry
865668|NCT02749825|Prostate
865669|NCT02749825|Cancer
865670|NCT02749825|Trelstar
865671|NCT02749760|Ulnar collateral ligament
865672|NCT02749760|elbow injuries
865673|NCT02749760|dynamic elbow stabilizers
865674|NCT02749760|Tommy John's procedure
865675|NCT02749760|elbow injuries in pitchers
865676|NCT02749747|Menopause
865677|NCT02749747|nonhormonal treatment
865678|NCT02749747|sulpiride
865679|NCT02749734|Human embryo stem cell derived retinal pigment epitheliums
865680|NCT02749734|Subretinal transplantation
865681|NCT02749734|Wet Age related Macular degeneration
865682|NCT02749734|Stargardt's macular dystrophy
865683|NCT02749721|depression
865684|NCT02749721|brain network activation
865685|NCT02749721|vortioxetine
865686|NCT02749708|IRX5183
865687|NCT02749708|relapsed/refractory AML
865688|NCT02749708|high-risk MDS
865689|NCT02749695|menopause, climacteric syndrome, insomnia, placental extract
865690|NCT02749682|Nyhus classification
865691|NCT02749682|constipation severity scale
865692|NCT02749682|groin hernia
865693|NCT02749669|Inappropriate hospitalization
865694|NCT02749669|elderly
865695|NCT02749669|mild or moderate cognitive impairment
865696|NCT02749669|qualitative research
865697|NCT02749669|economic evaluation
865698|NCT02749656|Scalp psoriasis
865699|NCT02749656|0.25% Desoximetasone cream
865700|NCT02749591|stroke rehabilitation
865701|NCT02749591|spasticity
865702|NCT02749591|Botulinum toxin type A injection
865703|NCT02749591|robot-assisted therapy
865704|NCT02749591|mirror therapy
865705|NCT02749591|randomized controlled trial
865706|NCT02749565|asthma
865707|NCT02749565|fibrocyte
865708|NCT02749565|airway remodeling
865709|NCT02749565|OSA
865710|NCT02749565|hypoxia
865711|NCT02749539|Mastectomy
865712|NCT02749539|Shoulder Pain
865713|NCT02749539|ROM
865714|NCT02749539|Kinesio Tape
865715|NCT02749526|Recombinant human endostatin，Endo
865716|NCT02749500|Motor control
865717|NCT02749487|Critical Care
865718|NCT02749487|Neutrophils
865719|NCT02749487|Lymphocytes
865720|NCT02749461|preterm infants
865721|NCT02749461|pain
865722|NCT02749461|assessment
865723|NCT02749461|contextual factors
865724|NCT02749461|diagnostic accuracy
865725|NCT02749435|Digital disease management tool
865726|NCT02749435|Type 2 diabetes mellitus/ T2DM
865727|NCT02749435|HbA1c
865728|NCT02749435|Standard care
865729|NCT02749435|PRO questionnaires
865730|NCT02749435|Smart phone/ personal computer with internet access
865731|NCT02749422|cognitive dysfunction
865732|NCT02749422|memory loss
865733|NCT02749422|non-invasive transcranial magnetic stimulation (TMS)
865734|NCT02749422|rTMS
865735|NCT02749422|Magstim Rapid2
865736|NCT02749357|gait
865737|NCT02749357|robotic orthosis
865738|NCT02749344|Frozen Embryo Transfer, Progesterone, Endometrium
865739|NCT02749318|Behavior Modification
865740|NCT02749318|Genetic Testing
865741|NCT02749318|Risk Management
865742|NCT02749318|Oral Health Care
865743|NCT02749292|rituximab
865744|NCT02749292|maintenance
865745|NCT02749292|remission
865746|NCT02749266|chiropractic, cognition
865747|NCT02749253|Post Traumatic Stress Disorder (PTSD)
865748|NCT02749253|Sudarshan Kriya Yoga (SKY)
865749|NCT02749227|Clinically non-functioning pituitary adenomas (CNFAs)
865750|NCT02749227|silent corticotroph adenomas
865751|NCT02749201|Obesity
865752|NCT02749201|sleeve gastrectomy
865753|NCT02749188|Urine Specimen Collection/methods
865754|NCT02749188|Infant
865755|NCT02749188|Newborn
865756|NCT02749188|Feasibility Studies
865757|NCT02749188|Bladder stimulation
865758|NCT02749175|cricoid pressure
865759|NCT02749149|Cardiac
865760|NCT02749149|Surgery
865761|NCT02749149|Frailty
865762|NCT02749149|Frail
865763|NCT02749149|Patients
865764|NCT02749149|Recovery
865765|NCT02749149|Morbidity
865766|NCT02749149|Outcomes
865767|NCT02749149|Mortality
865768|NCT02749149|Heart
865769|NCT02749149|Perioperative
865770|NCT02749149|Disability
865771|NCT02749149|WHODAS
865772|NCT02749136|Pancreatic adenocarcinoma
865773|NCT02749136|Borderline resectable
865774|NCT02749136|Neoadjuvant chemotherapy
865775|NCT02749136|FOLFIRINOX
865776|NCT02749110|Mass screening
865777|NCT02749110|Family medicine
865778|NCT02749110|Human Papillomavirus DNA tests
865779|NCT02749110|Papanicolaou test
865780|NCT02749110|Early detection of cancer/methods*
865781|NCT02749110|Specimen Handling/methods*
865782|NCT02749110|Patient compliance
865783|NCT02749110|Adult
865784|NCT02749110|Female
865785|NCT02749110|Humans
865786|NCT02749110|Randomized controlled trial
865787|NCT02749084|chronic graft versus host disease
865788|NCT02749084|T regulatory cell
865789|NCT02749058|capsulectomy
865790|NCT02749058|capsulotomy
865791|NCT02749019|BBN-RGD
865792|NCT02749019|GRPR
865793|NCT02749019|integrin αvβ3
865794|NCT02749006|Bipolar-I disorder
865795|NCT02749006|Depression
865796|NCT02749006|intermittent Theta-Burst Stimulation (rTMS)
865797|NCT02749006|neuromodulatory technique
865798|NCT02748967|Healthy
865799|NCT02748967|ExPEC4V
865800|NCT02748967|JNJ-63871860
865801|NCT02748967|Safety
865802|NCT02748941|unstable/stable atherosclerotic plaque
865803|NCT02748941|HITS
865804|NCT02748941|GSM
865805|NCT02748941|CEUS
865806|NCT02748941|HR MRI
865807|NCT02748941|mi-RNA
865808|NCT02748915|Cochlear Implant
865809|NCT02748915|ECAP
865810|NCT02748915|EABR
865811|NCT02748915|perceptual levels
865812|NCT02748915|hearing performances
865813|NCT02748902|Verruca vulgaris
865814|NCT02748902|Common warts
865815|NCT02748902|Verruca
865816|NCT02748902|Warts
865817|NCT02748902|Papilloma virus
865818|NCT02748902|ingenol mebutate 0.05% gel
865819|NCT02748902|hands
865820|NCT02748889|SCLC
865821|NCT02748889|Small Cell
865822|NCT02748889|Lung Cancer
865823|NCT02748889|MPDL3280A
865824|NCT02748889|atezolizumab
865825|NCT02748863|psoriasis
865826|NCT02748863|secukinumab
865827|NCT02748863|pre-filled syringes
865828|NCT02748850|apheresis patients
865829|NCT02748824|Age- Related Macular Degeneration; Diabetic Retinopathy; Glaucoma; Cataract
865830|NCT02748811|elderly
865831|NCT02748811|intervention study
865832|NCT02748811|geriatrics
865833|NCT02748811|chemotherapy
865834|NCT02748772|Anti-angiogenesis Drugs
865835|NCT02748772|Advanced Colorectal Cancer
865836|NCT02748772|Endostar
865837|NCT02748772|Thalidomide
865838|NCT02748772|Vascular Endothelial Growth Factor A
865839|NCT02748759|Continous Passive Motion
865840|NCT02748759|Manual Physical Therapy
865841|NCT02748759|Range of Motion, Articular
865842|NCT02748759|Anterior Cruciate Ligament Reconstruction
865843|NCT02748759|Rehabilitation
865844|NCT02748759|Kaltenborn Manual Therapy
865845|NCT02748746|Lymphedema
865846|NCT02748746|Electric Impedance
865847|NCT02748746|Breast Cancer
865848|NCT02748733|Adapted APD
865849|NCT02748733|Dialytic Sodium Removal
865850|NCT02748733|Ultrafiltration
865851|NCT02748733|Clearance rate
865852|NCT02748733|Intraperitoneal pressure
865853|NCT02748720|Premature
865854|NCT02748720|Respiratory Function Monitor
865855|NCT02748694|Drug Therapy
865856|NCT02748681|obstructive sleep apnea
865857|NCT02748681|CPAP
865858|NCT02748681|stroke
865859|NCT02748681|telemedicine
865860|NCT02748681|neurorehabilitation
865861|NCT02748681|systolic blood pressure
865862|NCT02748629|inguinal hernia
865863|NCT02748629|mesh
865864|NCT02748629|lichtenstein
865865|NCT02748629|hernia repair
865866|NCT02748629|selfgripping mesh
865867|NCT02748616|Colitis
865868|NCT02748616|Bile
865869|NCT02748577|Migraines
865870|NCT02748577|Pain responses
865871|NCT02748551|Gastric cancer
865872|NCT02748551|locally advanced gastric cancer
865873|NCT02748551|laparoscopic surgery
865874|NCT02748551|laparoscopic procedure
865875|NCT02748551|comparison laparoscopic with open procedure
865876|NCT02748551|multicenter trials
865877|NCT02748486|schizophrenia
865878|NCT02748486|randomized controlled trial
865879|NCT02748486|metacognitive training
865880|NCT02748486|single sessions
865881|NCT02748473|Pilates exercises
865882|NCT02748473|pelvic floor muscle contraction
865883|NCT02748434|iPro2 Continuous Blood Glucose Recorder
865884|NCT02748434|Subclinical
865885|NCT02748421|retina surgery
865886|NCT02748421|image guided surgery
865887|NCT02748421|optical coherence tomography assisted
865888|NCT02748369|TCA cycle flux
865889|NCT02748369|in vivo measurements
865890|NCT02748369|Stable isotopes
865891|NCT02748369|Arteriovenous balance
865892|NCT02748369|Metabolome
865893|NCT02748369|Proteome
865894|NCT02748369|Exosomes
865895|NCT02748356|Spina Bifida
865896|NCT02748356|Spinal Cord Injury
865897|NCT02748317|Spina Bifida
865898|NCT02748317|Spinal Cord Injury
865899|NCT02748317|Lower Urinary Tract Symptoms
865900|NCT02748317|Probiotics
865901|NCT02748317|Intermittent Catheterization
865902|NCT02748291|Sedentary
865903|NCT02748291|Knee osteoarthritis
865904|NCT02748291|Knee pain
865905|NCT02748291|Gonarthritis
865906|NCT02748291|Arthritis
865907|NCT02748291|Walking
865908|NCT02748291|Pedometer
865909|NCT02748291|Physical Activity
865910|NCT02748291|Activities of Daily Function
865911|NCT02748291|Department of Health Physical Activity Guidelines
865912|NCT02748291|Improve pain
865913|NCT02748291|Decrease pain
865914|NCT02748291|Improve function
865915|NCT02748291|Increase function
865916|NCT02748291|Activity Monitoring
865917|NCT02748291|Monitoring, Ambulatory/instrumentation
865918|NCT02748278|subfertility
865919|NCT02748278|In-vitro fertilization
865920|NCT02748239|diabetes self-management education
865921|NCT02748239|insulin therapy
865922|NCT02748174|Migraine
865923|NCT02748174|Curelator
865924|NCT02748161|Hepatocellular carcinoma
865925|NCT02748161|DEB-TACE
865926|NCT02748161|QED
865927|NCT02748148|Medication Therapy Management
865928|NCT02748148|Pharmacogenomics
865929|NCT02748122|Adolescents
865930|NCT02748122|Insulin
865931|NCT02748122|T2DM
865932|NCT02748109|Physical Therapy
865933|NCT02748109|Balance Disorder
865934|NCT02748109|Concussion
865935|NCT02748109|Mild Traumatic Brain Injury
865936|NCT02748096|Unicompartmental Knee Replacement
865937|NCT02748096|Patient Specific Instrumentation
865938|NCT02748083|tDCS
865939|NCT02748083|schizophrenia
865940|NCT02748083|cognition
865941|NCT02748083|fMRI
865942|NCT02748031|Congenital cataracts
865943|NCT02748031|Opacity location
865944|NCT02748031|Opacity shape
865945|NCT02748031|Classification
865946|NCT02748031|Clinical applicability
865947|NCT02748005|Fenugreek seed extract
865948|NCT02748005|testosterone
865949|NCT02748005|protodioscin
865950|NCT02748005|hypogonadism
865951|NCT02747979|hemodialysis
865952|NCT02747979|hyperparathyroidism
865953|NCT02747979|refractory pruritus
865954|NCT02747979|ostalgia
865955|NCT02747979|insomnia
865956|NCT02747979|CVD incidence
865957|NCT02747979|life quality
865958|NCT02747966|access flow
865959|NCT02747966|access recirculation
865960|NCT02747966|cardiac output
865961|NCT02747966|cardiac index
865962|NCT02747966|hemodialysis
865963|NCT02747927|Drug therapy
865964|NCT02747901|KINESIOTAPING
865965|NCT02747901|COLD THERAPY
865966|NCT02747901|FUNCTIONAL PERFORMANCE
865967|NCT02747888|Thyroid
865968|NCT02747875|pediatric
865969|NCT02747875|cardiac bypass surgery
865970|NCT02747875|methadone
865971|NCT02747875|fentanyl
865972|NCT02747875|morphine
865973|NCT02747862|Attenuated Familial Adenomatous Polyposis
865974|NCT02747862|AFAP
865975|NCT02747862|Deleterious Familial Adenomatous Polyposis
865976|NCT02747862|FAP
865977|NCT02747862|Chart review
865978|NCT02747797|Advanced Cancer
865979|NCT02747797|Lucitanib (E3810)
865980|NCT02747797|Fibroblast Growth Factor Receptor
865981|NCT02747797|FGFR
865982|NCT02747797|Vascular Endothelial Growth Factor Receptor
865983|NCT02747797|VEGFR
865984|NCT02747797|Platelet Derived Growth Factor Receptor
865985|NCT02747797|PDGFR
865986|NCT02747797|metastatic malignancy
865987|NCT02747784|cognitive dysfunction
865988|NCT02747784|cognitive training
865989|NCT02747771|effectiveness
865990|NCT02747771|trichotillomania
865991|NCT02747771|hair pulling
865992|NCT02747771|habit reversal training
865993|NCT02747771|acceptance and commitment therapy
865994|NCT02747771|cognitive behavioral therapy
865995|NCT02747758|neuropathic pain
865996|NCT02747758|neuralgia
865997|NCT02747758|tDCS
865998|NCT02747758|transcranial direct current stimulation
865999|NCT02747745|Caregivers
866000|NCT02747745|Case Management
866001|NCT02747745|Community Dwelling
866002|NCT02747706|peer mentor
866003|NCT02747706|health coach
866004|NCT02747706|parent support
866005|NCT02747706|parent mentor
866006|NCT02747680|type 1 diabetes
866007|NCT02747680|hypoglycemia unawareness
866008|NCT02747680|healthy control
866009|NCT02747667|iol dislocation
866010|NCT02747667|iol complication
866011|NCT02747667|intraocular lens
866012|NCT02747667|Implant or Graft
866013|NCT02747667|Eye
866014|NCT02747654|NAT2 genotype guided dosing
866015|NCT02747628|Transdermal nicotine
866016|NCT02747628|Transdermal melatonin
866017|NCT02747628|Postoperative pain
866018|NCT02747628|Laparoscopic cholecystectomy
866019|NCT02747615|Preoperative autologous blood donation, allogeneic blood transfusion, parenteral iron, tranexamic acid, revision total hip arthroplasty, hemoglobin, hematocrit
866020|NCT02747602|Healthy volunteers
866021|NCT02747602|Caprylic triglyceride oil
866022|NCT02747602|AC-1204
866023|NCT02747602|Pharmacokinetic
866024|NCT02747602|Ketone body
866025|NCT02747576|Childhood Cancer Survivor
866026|NCT02747576|Social-cognition
866027|NCT02747576|Healthy Volunteers
866028|NCT02747563|prostate cancer
866029|NCT02747563|PSA
866030|NCT02747563|digital rectal examination
866031|NCT02747472|GIP
866032|NCT02747472|GIP receptor antagonist
866033|NCT02747446|fructose, triglyceride, oral glucose tolerance
866034|NCT02747433|robot-assisted therapy
866035|NCT02747433|task-oriented training
866036|NCT02747433|motor learning
866037|NCT02747420|Posterior Tibial Nerve Stimulation, Bladder
866038|NCT02747368|Wet age-related macular degeneration
866039|NCT02747368|Age-related macular degeneration
866040|NCT02747368|Ocusweep
866041|NCT02747368|Driving health
866042|NCT02747368|Visual field
866043|NCT02747368|Contrast sensitivity
866044|NCT02747342|Metastatic castration-resistant prostate cancer
866045|NCT02747342|Monotherapy
866046|NCT02747329|BuMA Supreme
866047|NCT02747329|Xience V/Prime
866048|NCT02747329|OCT
866049|NCT02747329|neointima formation
866050|NCT02747316|Iron bioavailability
866051|NCT02747316|Hepcidin
866052|NCT02747316|Iron absorption
866053|NCT02747303|brain metastases
866054|NCT02747303|Stereotactic Radiosurgery
866055|NCT02747290|BBN-RGD
866056|NCT02747290|PET
866057|NCT02747290|integrin αvβ3
866058|NCT02747290|GRPR
866059|NCT02747264|eRAPID
866060|NCT02747264|PRO
866061|NCT02747264|PROM
866062|NCT02747264|Adverse event
866063|NCT02747264|QTool
866064|NCT02747264|CTCAE
866065|NCT02747251|"Shoulder Impingement Syndrome[Mesh]"
866066|NCT02747251|"Rehabilitation[Mesh]"
866067|NCT02747251|"Exercise[Mesh]"
866068|NCT02747251|"Rotator Cuff[Mesh]"
866069|NCT02747238|Pregnancy
866070|NCT02747238|Epidural
866071|NCT02747238|Labor
866072|NCT02747225|electrical properties
866073|NCT02747225|malignant tissues
866074|NCT02747225|in vivo
866075|NCT02747212|electrical properties
866076|NCT02747212|malignant tissues
866077|NCT02747212|ex vivo
866078|NCT02747199|SYNERGY
866079|NCT02747199|Neointimal formation
866080|NCT02747199|OCT
866081|NCT02747199|coronary angioscopy
866082|NCT02747199|coronary artery disease
866083|NCT02747186|lidocaine, jaw
866084|NCT02747173|metastatic, bone metastases
866085|NCT02747160|Cancer
866086|NCT02747160|Anxiety
866087|NCT02747160|Cognitive behavior therapy
866088|NCT02747160|Elderly
866089|NCT02747160|Caregivers
866090|NCT02747121|External inspections
866091|NCT02747108|Veterans
866092|NCT02747108|Type 2 Diabetes Mellitus
866093|NCT02747108|Prediabetes
866094|NCT02747108|Decision-making
866095|NCT02747108|Motivation
866096|NCT02747108|Health Promotion
866097|NCT02747108|Prevention and Control
866098|NCT02747082|endodontic retreatment
866099|NCT02747082|sodium hypochlorite
866100|NCT02747082|chlorhexidine
866101|NCT02747082|calcium hydroxide
866102|NCT02747082|Retreatment
866103|NCT02747069|Heart rate
866104|NCT02747069|Electronic Stethoscope
866105|NCT02747069|Electrocardiogram
866106|NCT02747069|Resuscitation
866107|NCT02747030|Central retinal vein occlusion
866108|NCT02747030|Retinal endovascular surgery
866109|NCT02747030|Retinal vein cannulation
866110|NCT02747030|Ocriplasmin
866111|NCT02747017|transplant
866112|NCT02746965|magnetic seizure therapy
866113|NCT02746965|randomized controlled trials
866114|NCT02746965|schizophrenia
866115|NCT02746965|cognition
866116|NCT02746939|program evaluation
866117|NCT02746939|health literacy
866118|NCT02746939|fitness
866119|NCT02746939|nutrition
866120|NCT02746939|education
866121|NCT02746913|Pelvic, Urodynamic, Vaginal Wall
866123|NCT02746861|peer mentor
866124|NCT02746861|peer supporter
866125|NCT02746861|peer coach
866126|NCT02746861|peer-to-peer mentoring
866127|NCT02746848|cornea epithelium healing Amniotic Membrane Eye Drop
866128|NCT02746835|physical condition
866129|NCT02746835|self-efficacy
866130|NCT02746835|fall risk
866131|NCT02746835|exercise program
866132|NCT02746822|acute myocardial infarction,
866133|NCT02746822|thrombus aspiration
866134|NCT02746679|Asherman syndrome
866135|NCT02746679|Mindfulness
866136|NCT02746679|Anxiety
866137|NCT02746679|Depression
866138|NCT02746679|Quality of Life
866139|NCT02746653|Fascia Closure Device, hernia,
866140|NCT02746614|adaptive behavior
866141|NCT02746614|motor proficiency
866142|NCT02746614|psychomotor therapy
866143|NCT02746614|intellectual disability
866144|NCT02746588|miscarriage
866145|NCT02746588|uterine abnormalities
866146|NCT02746588|Chronic infection
866147|NCT02746562|Assisted reproduction
866148|NCT02746562|In vitro fertilisation
866149|NCT02746562|Frozen embryo transfer (FER)
866150|NCT02746536|COPD
866151|NCT02746536|Inspiratory capacity
866152|NCT02746536|Exercise
866153|NCT02746523|NHL
866154|NCT02746523|Concussion
866155|NCT02746523|Biomarkers
866156|NCT02746497|Menopause
866157|NCT02746497|Hot flushes
866158|NCT02746497|Acupuncture
866159|NCT02746497|Randomized controlled trial
866160|NCT02746458|Blood Flow Restriction
866161|NCT02746458|Muscle Weakness
866162|NCT02746458|Physical therapy techniques
866163|NCT02746458|closed femoral fracture injuries
866164|NCT02746445|Autism
866165|NCT02746445|ASD
866166|NCT02746445|Autism Spectrum Disorder
866167|NCT02746432|CRC-Insulin
866168|NCT02746354|Chronic Pain
866169|NCT02746354|Analgesics, Opioid
866170|NCT02746354|Primary Health Care
866171|NCT02746276|malnutrition
866172|NCT02746276|antibiotics
866173|NCT02746276|antimicrobial resistance
866174|NCT02746276|pharmacokinetics
866175|NCT02746263|Elective total knee arthroplasty
866176|NCT02746237|Serotonin
866177|NCT02746237|Pulmonary Arterial Hypertension
866178|NCT02746237|Pharmacokinetics
866179|NCT02746237|Phase 1
866180|NCT02746237|Healthy Volunteers
866181|NCT02746224|Colorectal cancer
866182|NCT02746224|Colorectal surgery
866183|NCT02746211|immunology
866184|NCT02746211|pathogenicity
866185|NCT02746198|Probiotics, Antibiotics, AAD, Helicobacter p.
866186|NCT02746185|cancer
866187|NCT02746185|venous thromboembolism
866188|NCT02746185|low-molecular weight heparin
866189|NCT02746185|rivaroxaban
866190|NCT02746172|cochlear implants
866191|NCT02746172|Mapping
866192|NCT02746172|in-situ audiometry
866193|NCT02746107|shared decision making
866194|NCT02746107|oral anticoagulant
866195|NCT02746107|atrial fibrillation
866196|NCT02746107|stroke
866197|NCT02746107|decision to treat
866207|NCT02746068|Bone Marrow Lesions
866208|NCT02746068|AXS02
866209|NCT02746068|Axsome
866210|NCT02746068|Knee OA
866211|NCT02746068|Osteoarthritis
866212|NCT02746042|chronic rhinosinusitis
866213|NCT02746042|Sinupret extract
866214|NCT02746042|herbal medicinal product
866215|NCT02746003|drinking water
866216|NCT02746003|salinity
866217|NCT02745990|erythropoietin
866218|NCT02745990|preterm
866219|NCT02745990|brain injury
866220|NCT02745990|cerebral palsy
866221|NCT02745990|PVL
866222|NCT02745951|cardiopulmonary bypass
866223|NCT02745951|cardioplegia
866224|NCT02745951|cardioprotection
866225|NCT02745951|coronary artery bypass graft surgery
866226|NCT02745951|heliox
866227|NCT02745938|Exercise test
866228|NCT02745938|GDF-15
866229|NCT02745938|Growth and Differentiation Factor 15
866230|NCT02745925|Iron bioavailability
866231|NCT02745925|Inflammation
866232|NCT02745925|Hepcidin
866233|NCT02745925|Iron absorption
866234|NCT02745912|Drug Therapy
866235|NCT02745899|asthma
866236|NCT02745899|cow milk
866237|NCT02745899|pulmonary function testing
866238|NCT02745899|children
866239|NCT02745899|mucus
866240|NCT02745860|selexipag
866241|NCT02745860|pharmacokinetics
866242|NCT02745821|coronary flow reserve
866243|NCT02745821|fractional flow reserve
866244|NCT02745821|diabetes mellitus
866245|NCT02745821|coronary artery disease
866246|NCT02745821|percutaneous coronary intervention
866247|NCT02745821|coronary physiology
866248|NCT02745821|index of microcirculatory resistance
866249|NCT02745795|Motivational interview
866250|NCT02745795|adolescents
866251|NCT02745795|obesity
866252|NCT02745795|overweight
866253|NCT02745795|physical activity
866254|NCT02745795|diet
866255|NCT02745782|Pulpitis
866256|NCT02745782|Syncope
866257|NCT02745782|Trigeminal Cardio-Reflex
866258|NCT02745756|Children
866259|NCT02745756|Cancer
866260|NCT02745756|High-risk neuroblastoma
866261|NCT02745743|Phase 1
866262|NCT02745743|Dose escalation
866263|NCT02745743|Dose expansion
866264|NCT02745743|Positive transcription elongation factor b inhibitor
866265|NCT02745743|Cyclin-dependent kinase 9 inhibitor
866266|NCT02745717|Severe aplastic anemia
866267|NCT02745717|immunosuppressive therapy
866268|NCT02745717|cord blood transfusion
866269|NCT02745704|chronic hepatitis B
866270|NCT02745704|peginterferon alfa
866271|NCT02745678|Enema
866272|NCT02745678|Ulcerative Colitis
866273|NCT02745652|median nerve
866274|NCT02745652|wrist joint
866275|NCT02745652|carpal tunnel
866276|NCT02745639|rectal cancer
866277|NCT02745639|radiotherapy
866278|NCT02745639|chemotherapy
866279|NCT02745639|VMAT
866280|NCT02745639|toxicity
866281|NCT02745600|RFA
866282|NCT02745600|Liver
866283|NCT02745600|Ablation Techniques
866284|NCT02745600|Treatment Simulation
866285|NCT02745600|Computer assisted therapy
866286|NCT02745574|should and upper abdominal pain, post-laparoscopy
866287|NCT02745561|Endostatin
866288|NCT02745561|Oxaliplatin
866289|NCT02745561|Esophageal Cancer
866290|NCT02745561|chemoradiotherapy
866291|NCT02745548|Lung Cancer
866292|NCT02745548|NSCLC (Non Small Cell Lung Cancer)
866293|NCT02745548|SABR (Stereotactic ablative radiotherapy)
866294|NCT02745522|Placebo analgesia
866295|NCT02745522|Working memory
866296|NCT02745509|Extensive Intraoperative Peritoneal Lavage
866297|NCT02745509|EIPL
866298|NCT02745509|Gastric Cancer
866299|NCT02745496|Image-guided biopsy
866300|NCT02745496|Tumour detection
866301|NCT02745496|Diagnostic
866302|NCT02745496|Biomarkers
866303|NCT02745483|RFA
866304|NCT02745470|lean/obese diabetes mellitus
866305|NCT02745470|functional MRI
866306|NCT02745470|GLP-1
866307|NCT02745470|appetite
866308|NCT02745470|activation of brain
866309|NCT02745470|connectivity
866310|NCT02745444|Living kidney transplantation
866311|NCT02745444|Chronic kidney disease
866312|NCT02745444|Acute kidney injury
866313|NCT02745431|Likeability
866314|NCT02745431|Being liked
866315|NCT02745431|Prospective taking
866316|NCT02745405|Weight Stigma
866317|NCT02745405|Cortisol Reactivity
866318|NCT02745405|Eating Behavior
866319|NCT02745392|migraine
866320|NCT02745392|migraine headache
866321|NCT02745392|acute migraine
866322|NCT02745392|acute migraine headache
866323|NCT02745353|Cancer
866324|NCT02745353|Constipation
866325|NCT02745353|Opioid
866326|NCT02745327|oral vaccination
866327|NCT02745327|nutrition
866328|NCT02745314|Aortic Stenosis, Frailty, Elderly, moertality
866329|NCT02745275|Peer Education
866330|NCT02745275|Health Coaches
866331|NCT02745275|Community Dwelling Seniors
866332|NCT02745275|Health Literacy
866333|NCT02745275|Health Education
866334|NCT02745275|Healthy Ageing
866335|NCT02745236|Atrial Fibrillation
866336|NCT02745236|Health Related Quality of Life
866337|NCT02745236|Nurse Practitioner
866338|NCT02745236|Sustainable Models of Healthcare
866339|NCT02745236|Patient Satisfaction
866340|NCT02745171|Parkinson's disease
866341|NCT02745171|Quality of life
866342|NCT02745171|Functional mobility
866343|NCT02745171|Follow up
866344|NCT02745158|Fibrodysplasia ossificans progressiva
866345|NCT02745158|FOP
866346|NCT02745158|International FOP Association
866347|NCT02745158|Patient Advocacy Group
866348|NCT02745158|Patient Registry
866349|NCT02745158|Natural History
866350|NCT02745158|Patient-Reported Outcomes
866351|NCT02745158|Observational Database
866352|NCT02745158|Bone Morphogenetic Protein
866353|NCT02745158|BMP
866354|NCT02745158|Bone Growth
866355|NCT02745158|Joint
866356|NCT02745158|Mobility
866357|NCT02745158|Flare-Up
866358|NCT02745158|Heterotopic Ossification
866359|NCT02745158|Ectopic Bone
866360|NCT02745158|Osteochondroma
866361|NCT02745158|Hallux Valgus
866362|NCT02745158|ALK2
866363|NCT02745158|ACVR1
866364|NCT02745158|Activin A
866365|NCT02745158|IFOPA
866366|NCT02745158|Activin A Receptor Type I
866367|NCT02745158|Activin Receptor-like Kinase-2
866368|NCT02745145|Double-Blind Method
866369|NCT02745145|Interstitial Lung Diseases
866370|NCT02745145|Systemic Scleroderma
866371|NCT02745145|Abituzumab
866372|NCT02745145|Mycophenolate
866373|NCT02745145|Efficacy, Safety
866374|NCT02745132|Chronic, Cognition Disorders
866375|NCT02745132|Neurocognition Disorders
866376|NCT02745132|Cognitive Impairments
866377|NCT02745132|Diffusion Magnetic Resonance Imaging
866378|NCT02745132|MRI functional
866379|NCT02745132|Verbal fluency
866380|NCT02745106|Chronic thromboembolic pulmonary hypertension, Navigation system, Ablation
866381|NCT02745093|Abortion induced
866382|NCT02745093|Patient Acceptance of Healthcare
866383|NCT02745093|safety
866384|NCT02745093|effectiveness
866385|NCT02745093|misoprostol
866386|NCT02745093|mifepristone
866387|NCT02745080|Psoriatic Arthritis
866388|NCT02745080|secukinumab
866389|NCT02745080|adalimumab
866390|NCT02745080|monoclonal antibody
866391|NCT02745080|CASPAR
866392|NCT02745054|oral anticoagulants
866393|NCT02745054|bleeding
866394|NCT02745054|anticoagulation reversal
866395|NCT02745041|Fibrinogen
866396|NCT02745041|Cryoprecipitate
866397|NCT02745028|delayed gastric emptying
866398|NCT02745028|children
866399|NCT02745028|monosodium glutamate
866400|NCT02745015|periodontitis
866401|NCT02745015|diabetes
866402|NCT02745015|HbA1c
866403|NCT02745015|inflammation
866404|NCT02745002|Bronchoscopy
866405|NCT02745002|Bronchoscopes
866406|NCT02744989|Schizophrenia
866407|NCT02744989|Transcranial direct-current stimulation (tDCS)
866408|NCT02744989|Sham
866409|NCT02744989|Positive and Negative Syndrome Scale (PANSS)
866410|NCT02744989|Functional Magnetic Resonance Imaging (fRMI)
866411|NCT02744989|Brain-Derived-Neurotrophic Factor (BDNF)
866412|NCT02744976|Coronary artery disease
866413|NCT02744976|Atherosclerosis
866414|NCT02744976|Prediabetes
866415|NCT02744976|Intravascular ultrasound
866416|NCT02744976|Insulin resistance
866417|NCT02744976|Percutaneous coronary intervention
866418|NCT02744976|Metformin
866419|NCT02744950|pulley
866420|NCT02744950|scalp defects
866421|NCT02744911|speech problems
866422|NCT02744898|uterus
866423|NCT02744898|gynecological
866424|NCT02744872|lung transplantation
866425|NCT02744872|chronic renal insufficiency
866426|NCT02744859|Decision Making
866427|NCT02744859|Consumption
866428|NCT02744859|Economics
866429|NCT02744846|antibiotics
866430|NCT02744846|children
866431|NCT02744846|pediatric
866432|NCT02744846|body mass index
866433|NCT02744846|Observational Study
866434|NCT02744846|Comparative Effectiveness Research
866435|NCT02744846|Obesity
866436|NCT02744846|Growth Trajectory
866437|NCT02744846|Cohort Study
866438|NCT02744846|Electronic Medical Record
866439|NCT02744846|Qualitative Research
866440|NCT02744833|DVT
866441|NCT02744807|intrauterine adhesions
866442|NCT02744807|Chronic endometritis
866443|NCT02744807|infections
866444|NCT02744807|Hysteroscopy
866445|NCT02743741|Somatostatin Receptor Positive Neuroendocrine Tumors
866446|NCT02743728|perinatal stroke
866447|NCT02743728|transcranial magnetic stimulation
866448|NCT02743728|magnetic resonance imaging
866449|NCT02743728|diffusion tensor imaging
866450|NCT02743728|non-invasive brain stimulation
866451|NCT02743728|infant
866452|NCT02743715|Obsessive-Compulsive Disorder
866453|NCT02743715|Transcranial direct current stimulation
866454|NCT02743715|Neuromodulation
866455|NCT02743702|Effectiveness
866456|NCT02743702|Physical therapy modalities
866457|NCT02743702|neuromuscular diseases
866458|NCT02743689|Postoperative
866459|NCT02743689|Cardiac surgery
866460|NCT02743676|Avian Influenza
866461|NCT02743663|pediatric
866462|NCT02743663|lung ventilation inhomogeneity
866463|NCT02743663|preschool
866464|NCT02743663|asthma
866465|NCT02743663|wheeze
866466|NCT02743650|Low Serum Bicarbonate Level
866467|NCT02743650|Sodium Bicarbonate
866468|NCT02744781|Muscular Atrophy
866469|NCT02744781|Asymmetry
866470|NCT02744781|Athletes
866471|NCT02744768|Acute Lymphoblastic Leukemia, adult, dasatinib, blinatumomab
866472|NCT02744716|intrauterine balloon
866473|NCT02744716|uterine endometrial repair
866474|NCT02744716|intrauterine adhesion
866475|NCT02744716|aspirin
866476|NCT02744690|Eye Disease
866477|NCT02744690|Intraocular Pressure
866478|NCT02744690|Visual Acuity
866479|NCT02744690|Trabeculectomy
866480|NCT02744677|Tetralogy of Fallot
866481|NCT02744677|Aortic Valve Defect/Disease Resulting in Ross Procedure
866482|NCT02744677|Pulmonary Atresia
866483|NCT02744677|Pulmonary Stenosis
866484|NCT02744677|Truncus Arteriosus
866485|NCT02744677|Transposition of the Great Arteries
866486|NCT02744677|Transcatheter pulmonary valve implantation
866487|NCT02744677|Transcatheter pulmonary valve replacement
866488|NCT02744677|TPV
866489|NCT02744677|TPVR
866490|NCT02744677|TPVI
866491|NCT02744664|Lung Neoplasms
866492|NCT02744664|EGFR mutation
866493|NCT02744664|Cryotherapy
866494|NCT02744664|Icotinib
866495|NCT02744638|bacterial vaginosis
866496|NCT02744638|probiotics
866497|NCT02744638|Amsel Score
866498|NCT02744638|Nugent Score
866499|NCT02744599|Feasibility trial
866500|NCT02744586|Sexually transmitted infections
866501|NCT02744586|Neglected tropical diseases
866502|NCT02744586|Non-communicable diseases
866503|NCT02744534|Prostate Cancer
866504|NCT02744534|Imaging Technology
866505|NCT02744534|Oncology
866506|NCT02744534|Prostate Biopsy
866507|NCT02744508|palonosetron, dexamethasone, PONV (postoperative nausea and vomiting)
866508|NCT02744495|cardiac surgery
866509|NCT02744495|corticoids
866510|NCT02744495|droperidol
866511|NCT02744495|antiemetics
866512|NCT02744495|Postoperative Vomiting
866513|NCT02744495|Postoperative Nausea
866514|NCT02744495|Postoperative Emesis
866515|NCT02744495|prophylaxis
866516|NCT02744469|Tuberculosis
866517|NCT02744469|population structure
866518|NCT02744469|implications
866519|NCT02744469|lineages
866520|NCT02744469|spoligotyping
866521|NCT02744469|sputum
866522|NCT02744469|resistance
866523|NCT02744469|culture
866524|NCT02744469|diagnostics
866525|NCT02744469|outcome
866526|NCT02744469|new/retreatment patient
866527|NCT02744456|Hydrochlorothiazide tablet
866528|NCT02744456|Norvasc
866529|NCT02744456|Cozaar
866530|NCT02744456|amlodipine besylate tablets
866531|NCT02744456|losartan potassium tablets
866532|NCT02744456|Hypertension
866533|NCT02744456|High Blood Pressure
866534|NCT02744430|Medical expulsive therapy
866535|NCT02744430|ureteral stone
866536|NCT02744430|stent pain
866537|NCT02744417|smoking cessation
866538|NCT02744417|tobacco
866539|NCT02744417|periodontal
866540|NCT02744417|subgingival microorganisms
866541|NCT02744352|infraclavicular brachial plexus block
866542|NCT02744352|quality of recovery score
866543|NCT02744352|pain score
866544|NCT02744352|disability assessment of shoulder and hand questionnaire
866545|NCT02744339|PH-HFpEF
866546|NCT02744300|Gestational diabetes mellitus (GDM) in most recent pregnancy
866547|NCT02744287|Non Resectable Pancreatic Cancer
866548|NCT02744287|BPX-601
866549|NCT02744287|AP1903
866550|NCT02744287|CAR T
866551|NCT02744287|PSCA-CAR
866552|NCT02744274|acupuncture
866553|NCT02744274|chemotherapy
866554|NCT02744274|peripheral neuropathy
866555|NCT02744274|randomized clinical trial
866556|NCT02744274|numbness
866557|NCT02744261|HIV
866558|NCT02744261|STI
866559|NCT02744261|Primary Prevention
866560|NCT02744261|Topical Microbicides
866561|NCT02744261|User Experience
866562|NCT02744261|Drug Delivery Systems
866563|NCT02744248|Magnetic Resonance Imaging (MRI)
866564|NCT02744196|rheumatoid arthritis
866565|NCT02744196|rheumatism
866566|NCT02744196|Acellbia
866567|NCT02744196|methotrexate
866568|NCT02744196|biologic therapy
866569|NCT02744196|monoclonal antibody
866570|NCT02744196|rituximab
866571|NCT02744183|Exercise
866572|NCT02744183|Fasted
866573|NCT02744183|Glucose
866574|NCT02744183|Energy Balance
866575|NCT02744170|COPD
866576|NCT02744170|Incremental Shuttle Walk Test
866577|NCT02744170|Endurance Shuttle Walk Test
866578|NCT02744170|oxygen therapy
866579|NCT02744131|PCOS
866580|NCT02744131|Metformin
866581|NCT02744131|OCP
866582|NCT02744131|metabolic parameters
866583|NCT02744118|Media Use
866584|NCT02744092|Rivaroxaban (Xarelto)
866585|NCT02744092|Apixaban (Eliquis)
866586|NCT02744092|Edoxaban (Savaysa)
866587|NCT02744092|Dabigatran (Pradaxa)
866588|NCT02744092|Warfarin (Coumadin)
866589|NCT02744092|Low molecular weight heparin (LMWH)
866600|NCT02744053|Breast Cancer
866601|NCT02744053|Malignant neoplasm of breast
866602|NCT02744053|Triple Negative Breast Cancer
866603|NCT02744053|TNBC
866604|NCT02744053|Tc99m Sestamibi Molecular Breast Imaging
866605|NCT02744053|MBI
866606|NCT02744053|Dynamic Contrast Enhanced Molecular Resonance Imaging
866607|NCT02744053|DCE-MRI
866608|NCT02744040|HIV reservoir
866609|NCT02744040|alcohol
866610|NCT02744040|ART
866611|NCT02744027|Generalized Lymphatic Anomaly
866612|NCT02744027|Kaposiform Lymphangiomatosis
866613|NCT02744027|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram
866614|NCT02744027|Magnetic Resonance Imaging
866615|NCT02743988|cerebral oxygenation
866616|NCT02743988|NIRS
866617|NCT02743988|near-infrared spectroscopy
866618|NCT02743988|bradycardia
866619|NCT02743988|hypoxemia
866620|NCT02743988|cerebral perfusion
866621|NCT02743988|cardiac output
866622|NCT02743988|apnea
866623|NCT02743988|desaturation
866624|NCT02743988|oxygen saturation target range
866625|NCT02743949|Drug therapy
866626|NCT02743910|preoperative
866627|NCT02743910|neoadjuvant
866628|NCT02743910|plasma tumor DNA
866629|NCT02743910|ptDNA
866630|NCT02743897|end-stage renal disease
866632|NCT02743858|Lymphedema
866633|NCT02743858|Surveillance Program
866634|NCT02743858|Axillary Lymph Node Dissection
866635|NCT02743858|16-220
866636|NCT02743845|Rare
866637|NCT02743845|Undiagnosed
866638|NCT02743845|Orphan Disease
866639|NCT02743845|Genomic Sequencing
866640|NCT02743832|Surgery, Oral
866641|NCT02743832|Tumor budding
866642|NCT02743819|Melanoma
866643|NCT02743819|Pembrolizumab
866644|NCT02743819|Ipilimumab
866645|NCT02743806|Drug Therapy
866646|NCT02743793|single organ liver or kidney allograft
866647|NCT02743793|operationally tolerant allograft recipients
866648|NCT02743793|longitudinal follow-up
866649|NCT02743780|Ocular Hypertension
866650|NCT02743780|Open-Angle Glaucoma
866651|NCT02743780|POAG
866652|NCT02743780|Glaucoma
866653|NCT02743767|Airway management
866654|NCT02743767|General anaesthesia
866655|NCT02743767|Critical incidents
866656|NCT02743767|Complications
866657|NCT02743637|Cancer
866658|NCT02743637|Oncology
866659|NCT02743637|Solid Tumors
866660|NCT02743637|Phase 1
866661|NCT02743637|SDX-7320
866662|NCT02743637|SynDevRx
866663|NCT02743637|MetAP2
866664|NCT02743637|Breast
866665|NCT02743637|Post menopausal
866666|NCT02743637|Colorectal
866667|NCT02743637|Pancreatic
866668|NCT02743637|Ovarian
866669|NCT02743637|Endometrial
866670|NCT02743637|Esophageal
866671|NCT02743637|Lung
866672|NCT02743637|Renal
866673|NCT02743637|Prostate
866674|NCT02743637|Liver
866675|NCT02743611|BPX-701
866676|NCT02743611|AP1903
866677|NCT02743611|Rimiducid
866678|NCT02743611|AML
866679|NCT02743611|MDS
866680|NCT02743611|Primary Refractory AML
866681|NCT02743611|Relapsed AML
866682|NCT02743611|Refractory Myeloid Neoplasms
866683|NCT02743598|HIV infection
866684|NCT02743598|Diabetes Mellitus type 2
866685|NCT02743598|Obesity
866686|NCT02743598|Neurocognitive function
866687|NCT02743572|premature infant
866688|NCT02743572|anemia
866689|NCT02743572|iron-fortification
866690|NCT02743572|parenteral nutrition
866691|NCT02743572|randomized controlled trial
866692|NCT02743546|B-Cell, Malignancy
866693|NCT02743546|Lymphoma, Large B-Cell, Diffuse
866694|NCT02743546|Lymphoma, Mantle-Cell
866695|NCT02743546|Lymphoma, Follicular
866696|NCT02743546|Lymphocytic, Chronic, B-Cell
866697|NCT02743546|JNJ-64052781
866698|NCT02743546|Ibrutinib
866699|NCT02743533|cardiovascular diseases, prognosis
866700|NCT02743520|sleep apnea
866701|NCT02743481|Pesticide
866702|NCT02743481|Agriculture
866703|NCT02743481|Cancer
866704|NCT02743481|Childhood
866705|NCT02743481|Leukemia
866706|NCT02743468|Bronchoscopy
866707|NCT02743468|Pollutants
866708|NCT02743468|Human Pulmonary Cells
866709|NCT02743468|Cytochrome P450
866710|NCT02743468|Soluble Epoxide Hydrolase
866711|NCT02743455|Fever
866712|NCT02743455|Immunogenicity
866713|NCT02743455|MVA-BN
866714|NCT02743455|Reactogenicity
866715|NCT02743455|Vaccine
866716|NCT02743455|Yellow
866717|NCT02743429|ch14.18/CHO
866718|NCT02743429|neuroblastoma
866719|NCT02743429|long term infusion
866720|NCT02743416|Screening
866721|NCT02743416|Stroke prevention
866722|NCT02743416|Cost effectiveness
866723|NCT02743390|blood pressure
866724|NCT02743390|inflammation
866725|NCT02743390|tumor Necrosis Factor-alpha
866726|NCT02743377|GsI+/-
866727|NCT02743377|Camp
866728|NCT02743377|GNAS
866729|NCT02743351|Cell Transplants
866730|NCT02743351|Hematopoietic Cell Transplant
866731|NCT02743351|HCT
866732|NCT02743351|Hematologic Malignancies
866733|NCT02743351|Hematologic Malignancy
866734|NCT02743351|Acute Myeloid Leukemia
866735|NCT02743351|Acute Lymphoblastic Leukemia
866736|NCT02743338|Sleep Restriction
866737|NCT02743338|Sleep Compression
866738|NCT02743338|Cognitive Behavioral Therapy
866739|NCT02743312|Balance-Based Torso-Weighting
866740|NCT02743312|Physical Activity
866741|NCT02743312|Neurorehabilitation
866742|NCT02743286|sedentary behavior
866743|NCT02743286|sitting
866744|NCT02743286|feasibility
866745|NCT02743286|endothelial function
866746|NCT02743286|metabolism
866747|NCT02743260|phenotype
866748|NCT02743260|transporter
866749|NCT02743260|cocktail
866750|NCT02743247|Healthy volunteer
866751|NCT02743221|metastatic
866752|NCT02743221|colorectal
866753|NCT02743221|cancer
866754|NCT02743221|untreated
866755|NCT02743221|first-line
866756|NCT02743221|S95005
866757|NCT02743221|bevacizumab
866758|NCT02743221|capecitabine
866759|NCT02743208|Arthroplasty, Replacement, Hip
866760|NCT02743208|Surgical Procedures, Operative
866761|NCT02743208|Hip Prosthesis
866762|NCT02743169|Geographic Information Systems
866763|NCT02743169|Spatial Analysis
866764|NCT02743169|Emergency Medical Services
866765|NCT02743156|IVUS
866766|NCT02743156|Acute Renal Failure
866767|NCT02743156|Angioplasty
866768|NCT02743156|stent
866769|NCT02743156|contrast
866770|NCT02743156|percutaneous coronary intervention
866771|NCT02743156|intravascular ultrasound
866772|NCT02743143|Exercise therapy
866773|NCT02743143|Cardiovascular disease
866774|NCT02743143|Risk
866775|NCT02743130|Berries
866776|NCT02743130|Blackcurrant (Ribes nigrum)
866777|NCT02743130|Lingonberry (Vaccinium vitis-idaea)
866778|NCT02743130|Sucrose
866779|NCT02743130|Inverted sugar
866780|NCT02743130|Postprandial glucose response
866781|NCT02743130|Postprandial insulin response
866782|NCT02743117|Trivalent
866783|NCT02743117|Influenza
866784|NCT02743117|FluMist Quadrivalent
866785|NCT02743117|Vaccine
866786|NCT02743117|Prevention
866787|NCT02743117|Healthy
866788|NCT02743117|Monovalent
866789|NCT02743091|heart failure
866790|NCT02743091|survival
866791|NCT02743091|end-stage kidney disease
866792|NCT02743078|Glioblastoma
866793|NCT02743078|Glioma
866794|NCT02743078|Gliosarcoma
866795|NCT02743078|Optune
866796|NCT02743078|TTFields
866797|NCT02743065|HepaSphere
866798|NCT02743039|Low income
866799|NCT02743039|Education
866800|NCT02743039|Poverty
866801|NCT02743039|Children
866802|NCT02743039|Parents
866803|NCT02743039|Head Start
866804|NCT02743000|fMRI
866805|NCT02743000|emotion conflict task
866806|NCT02743000|monetary incentive delay
866807|NCT02742974|Trauma
866808|NCT02742974|Minimally Invasive Hemodynamic Monitoring
866809|NCT02742974|Perioperative
866810|NCT02742974|Complications
866811|NCT02742974|Hemodynamics
866812|NCT02742974|Operative procedures
866813|NCT02742961|orthopedics
866814|NCT02742961|anesthesiology
866815|NCT02742961|nerve block
866816|NCT02742961|length of stay
866817|NCT02742961|Patient readmission
866818|NCT02742948|elective caesarean section
866819|NCT02742948|antibiotics
866820|NCT02742948|endometritis
866821|NCT02742922|self harm
866822|NCT02742922|culturally adapted therapy
866823|NCT02742922|problem solving therapy
866824|NCT02742922|low and middle income countries
866825|NCT02742896|Erectile dysfunction
866826|NCT02742896|cognitive function
866827|NCT02742870|Diffusion MRI
866828|NCT02742870|ADC histograms
866829|NCT02742870|Adnexal tumor
866830|NCT02742844|phase I/IIa
866831|NCT02742844|mesenchymal stem cells
866832|NCT02742844|ABCB5+
866833|NCT02742844|APZ2
866834|NCT02742844|chronic venous ulcer
866835|NCT02742844|varicose ulcer
866836|NCT02742844|skin ulcer
866837|NCT02742844|advanced therapy medicinal product
866838|NCT02742844|APZ2-II-01
866839|NCT02742844|autologous use
866840|NCT02742844|somatic cell therapy
866841|NCT02742818|forced-air warming
866842|NCT02742818|hypothermia
866843|NCT02742818|endovascular surgery
866844|NCT02742818|blanket
866845|NCT02742805|hives
866846|NCT02742792|sleep apnea
866847|NCT02742792|elderly
866848|NCT02742792|exercise
866849|NCT02742766|Dose escalation study
866850|NCT02742766|Safety
866851|NCT02742766|Pharmacodynamics
866852|NCT02742766|Pharmacokinetics
866853|NCT02742766|GSK3008356
866854|NCT02742766|Tolerability
866855|NCT02742753|Otitis
866856|NCT02742753|Vaccine
866857|NCT02742753|Sweden
866858|NCT02742753|Database
866859|NCT02742675|prostate cancer
866860|NCT02742675|androgen deprivation therapy
866861|NCT02742675|local treatment
866862|NCT02742662|Obesity
866863|NCT02742662|Overweight
866864|NCT02742662|Prediabetes
866865|NCT02742662|Smartphone application
866866|NCT02742662|Technology
866867|NCT02742662|Weight Loss
866868|NCT02742662|Lifestyle Intervention
866869|NCT02742623|Cancer
866870|NCT02742623|Deep Venous Thrombosis
866871|NCT02742623|Pulmonary Embolism
866872|NCT02742584|cough stress test
866873|NCT02742584|urodynamics
866874|NCT02742584|pad test
866875|NCT02742571|Biological evaluation of denutrition
866876|NCT02742571|Denutrition
866877|NCT02742571|PINI score
866878|NCT02742558|cholera vaccine
866879|NCT02742558|randomized trial
866880|NCT02742558|immunogenicity
866881|NCT02742506|Brain-damaged
866882|NCT02742506|Disorders of consciousness
866883|NCT02742506|Post-coma
866884|NCT02742506|consciousness
866885|NCT02742506|coma
866886|NCT02742506|vegetative state
866887|NCT02742506|minimally conscious state
866888|NCT02742506|music
866889|NCT02742506|P300
866890|NCT02742493|relapse
866891|NCT02742493|irregularity
866892|NCT02742493|recession
866893|NCT02742493|retention
866894|NCT02742480|stroke
866895|NCT02742480|oral anticoagulants
866896|NCT02742480|cardioembolic
866897|NCT02742454|Umbilical Cord Clamping
866898|NCT02742454|Intraventricular Hemorrhage
866899|NCT02742454|Extremely Preterm Infants
866900|NCT02742337|Epigenetic
866901|NCT02742324|efficacy
866902|NCT02742324|safety
866903|NCT02742298|Neuromuscular Ultrasound
866904|NCT02742298|Electrical Impedance Myography
866905|NCT02742285|antimalarials
866906|NCT02742285|blood samples
866907|NCT02742285|drug concentrations
866908|NCT02742285|pharmacokinetics
866909|NCT02742285|lumefantrine
866910|NCT02742285|healthy volunteers
866911|NCT02742233|Diabetes
866912|NCT02742233|Wound Healing
866913|NCT02742233|Dipeptidyl Peptidase 4 Inhibition
866914|NCT02742220|intermittent claudication
866915|NCT02742220|exercise
866916|NCT02742220|blood pressure
866917|NCT02742220|cardiovascular system
866918|NCT02742194|ginger obesity
866919|NCT02742194|ginger inflammation
866920|NCT02742194|treatment of obesity
866921|NCT02742155|Family Research
866922|NCT02742116|Expanded carrier screening
866923|NCT02742090|CLL
866924|NCT02742025|Coronary Angiography
866925|NCT02742012|electroencephalogram
866926|NCT02742012|hemodynamic monitoring
866927|NCT02742012|respiratory monitoring
866928|NCT02741986|risk assessment
866929|NCT02741986|sepsis
866930|NCT02741986|acute kidney injury (AKI)
866931|NCT02741973|Yoga
866932|NCT02741973|Stress
866933|NCT02741973|Adolescents
866934|NCT02741973|School
866935|NCT02741973|Children
866936|NCT02741960|metformin
866937|NCT02741960|systemic lupus erythematosus
866938|NCT02741947|Parkinson
866939|NCT02741947|Therapeutic Equivalence
866940|NCT02741947|Levodopa
866941|NCT02741895|Biosensing Techniques
866942|NCT02741895|Patient Readmission
866943|NCT02741882|Microcephaly
866944|NCT02741882|zika Virus
866945|NCT02741882|Case-control study
866946|NCT02741869|Staphylococcus aureus; nare carriage
866947|NCT02741804|Memory
866948|NCT02741791|AXS-05
866949|NCT02741791|Major Depressive Disorder
866950|NCT02741791|Treatment Resistant Depression
866951|NCT02741791|TRD
866952|NCT02741791|MDD
866953|NCT02741791|Axsome
866954|NCT02741791|NMDA receptor
866955|NCT02741791|Refractory depression
866956|NCT02741791|Resistant depression
866957|NCT02741791|Depression
866958|NCT02741778|Esophagogastric Junction
866959|NCT02741778|Adenocarcinoma
866960|NCT02741778|Cardia
866961|NCT02741765|Transcranial Magnetic Stimulation
866962|NCT02741765|Exercise
866963|NCT02741765|Brain Plasticity
866964|NCT02741752|histomorphometry
866965|NCT02741739|Drug concentration
866966|NCT02741739|REGN1033
866967|NCT02741739|blood
866968|NCT02741700|Adherence
866969|NCT02741700|Disparities
866970|NCT02741700|Patient Outcomes
866971|NCT02741687|stress hyperglycemia
866972|NCT02741687|blood glucose
866973|NCT02741674|Observational Study
866974|NCT02741674|Comparative Effectiveness Research
866975|NCT02741648|Red Blood Cell Transfusion
866976|NCT02741648|Digestive tract problems
866977|NCT02741648|Extremely Low Birth Weight
866978|NCT02741622|Exercise therapy
866983|NCT02741596|DX-2930
866984|NCT02741596|Dyax
866985|NCT02741596|Hereditary Angioedema
866986|NCT02741557|Fixed-dose Combination (FDC)
866987|NCT02741557|Bioequivalence
866988|NCT02741557|Dolutegravir
866989|NCT02741557|Rilpivirine
866990|NCT02741544|Second primary cancers
866991|NCT02741544|Cataracts
866992|NCT02741544|Newly-diagnosed multiple myeloma
866993|NCT02741544|Revlimid capsules
866994|NCT02741518|obesity
866995|NCT02741518|FMT
866996|NCT02741505|cerebrospinal fluid (CSF)
866997|NCT02741505|sleep
866998|NCT02741505|Obstructive Sleep Apnea (OSA)
866999|NCT02741505|Sleep Disordered Breathing (SDB)
867000|NCT02741505|Period Limb Movement during Sleep (PLMS)
867001|NCT02741479|dancers
867002|NCT02741440|Spinocerebellar Ataxia
867003|NCT02741427|Tooth discoloration
867004|NCT02741427|Toothpaste
867005|NCT02741427|Tooth bleaching
867006|NCT02741427|Clinical trial
867007|NCT02741414|Helicobacter pylori
867008|NCT02741414|Antibiotic resistance
867009|NCT02741414|Sequencing
867010|NCT02741414|Mechanism
867011|NCT02741401|Complementary therapies
867012|NCT02741401|Massage
867013|NCT02741401|Gastrointestinal cancer
867014|NCT02741388|selinexor
867015|NCT02741388|lymphoma
867016|NCT02741388|inhibitor of nuclear export
867017|NCT02741362|Type III hypersensitivity autoimmune disease
867018|NCT02741349|Atrial fibrillation
867019|NCT02741349|Risk score
867020|NCT02741297|Spinal Cord Stimulation
867021|NCT02741297|Chronic Pain
867022|NCT02741232|analgesics, opioids
867023|NCT02741232|pectoral block
867024|NCT02741206|psycho-education
867025|NCT02741206|maternal depression
867026|NCT02741206|Reach Out Stay Strong Essentials
867027|NCT02741193|Transcranial magnet stimulation (nTMS)
867028|NCT02741193|Brainsight Neuronavigation
867029|NCT02741193|Electromyography
867030|NCT02741193|EMG
867031|NCT02741167|peritoneal surface malignancies
867032|NCT02741167|cytoreductive surgery
867033|NCT02741167|hyperthermic intraperitoneal chemotherapy
867034|NCT02741154|aromataze inhibitor, poor responder ,induction
867044|NCT02741102|Infertility
867045|NCT02741102|AUFI
867046|NCT02741089|Analgosedation
867047|NCT02741089|Internal Quality Assurance
867048|NCT02741063|oxytocin
867049|NCT02741063|attentional bias
867050|NCT02741063|Autism
867051|NCT02741011|Cone-Beam Computed Tomography
867052|NCT02741011|Mentally Handicapped
867053|NCT02740998|Microbiome
867054|NCT02740998|Progestin
867055|NCT02740998|Long-acting contraception
867060|NCT02740933|Brain Tumor Surgery
867061|NCT02740868|Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy
867062|NCT02740855|sclerotherapy
867063|NCT02740855|ethanol
867064|NCT02740855|pulmonal hypertension
867065|NCT02740790|Human papillomavirus
867066|NCT02740790|vaccine
867067|NCT02740790|cervical infection
867068|NCT02740790|cervical cancer
867069|NCT02740764|Functional autonomy level
867070|NCT02740764|Lawton Instrumental Activities of Daily Living
867071|NCT02740764|Cognitive disorders
867072|NCT02740764|Potentially inappropriate medication
867073|NCT02740764|elderly
867074|NCT02740764|Optimization of drug prescribing
867075|NCT02740738|Knee Arthroplasty
867076|NCT02740738|Hip Arthroplasty
867077|NCT02740725|Amblyopia
867078|NCT02740725|Interaction Binocular Treatment (I-BiTTM)
867079|NCT02740725|Patch Therapy
867080|NCT02740712|rucaparib
867081|NCT02740712|CO-338
867082|NCT02740712|Clovis
867083|NCT02740712|Clovis Oncology
867084|NCT02740712|PARP Inhibitor
867085|NCT02740712|Drug-Drug Interaction
867086|NCT02740699|Cholesterol
867087|NCT02740699|Heart Disease
867088|NCT02740699|CT Scan
867089|NCT02740699|Crestor
867090|NCT02740699|Lipitor
867091|NCT02740686|COPD
867092|NCT02740686|Exercise
867093|NCT02740686|Immunity
867094|NCT02740686|Inflammation
867095|NCT02740686|Biomarkers
867096|NCT02740660|Albuterol
867097|NCT02740660|Caffeine
867098|NCT02740660|Lean Body Mass
867099|NCT02740660|Fat Mass
867100|NCT02740634|PCA
867101|NCT02740634|LPA
867102|NCT02740595|nicotine
867103|NCT02740595|endothelial function
867104|NCT02740595|oxidative stress
867105|NCT02740569|scleroderma
867106|NCT02740569|sleep apnea
867107|NCT02740569|pulmonary disease
867108|NCT02740556|Hepatitis C
867109|NCT02740556|Adherence
867110|NCT02740556|Adheretech
867111|NCT02740556|HepCure
867112|NCT02740556|Telehealth
867113|NCT02740556|Health apps
867114|NCT02740543|World Trade Center
867115|NCT02740543|WTC
867116|NCT02740543|Induced Sputum
867117|NCT02740543|Exhaled Breath Condensate
867118|NCT02740504|Respiration rate
867119|NCT02740465|ACE
867120|NCT02740465|Anxiety
867121|NCT02740465|COPD
867122|NCT02740452|Rupture
867123|NCT02740452|Anterior Cruciate Ligament (ACL)
867124|NCT02740452|Laxity knee
867125|NCT02740452|Instability knee
867126|NCT02740400|Endobronchial ultrasonography
867127|NCT02740400|guided sheath
867128|NCT02740400|diagnosis
867129|NCT02740400|accuracy
867130|NCT02740400|complication
867131|NCT02740374|ROTEM
867132|NCT02740374|Thromboelastometry
867133|NCT02740374|spine surgery
867134|NCT02740374|allogenic blood transfusion
867135|NCT02740374|blood loss
867136|NCT02740374|red blood cell transfusion
867137|NCT02740335|anticoagulant reversal
867138|NCT02740335|urgent surgery
867139|NCT02740335|invasive procedures
867140|NCT02740335|vitamin K
867141|NCT02740335|prothrombin complex concentrate
867142|NCT02740335|four-factor prothrombin complex concentrate (4F-PCC)
867143|NCT02740322|Hum Test, Weber test, audiogram
867144|NCT02740309|inflammatory bowel disease
867145|NCT02740309|childhood chronic disease
867146|NCT02740309|adolescent depression
867147|NCT02740309|adolescent anxiety
867148|NCT02740309|integrated brief behavioral therapy
867149|NCT02740309|adolescent psychosocial risks
867150|NCT02740309|adolescent chronic disease
867151|NCT02740309|childhood depression
867152|NCT02740309|childhood anxiety
867153|NCT02740309|childhood psychosocial risks
867154|NCT02740283|Gestational Diabetes Mellitus
867155|NCT02740283|Oral Glucose Tolerance Test
867156|NCT02740270|advanced solid tumors
867157|NCT02740270|lymphomas
867158|NCT02740270|GWN323
867159|NCT02740270|PDR001
867160|NCT02740270|advanced malignancies
867161|NCT02740270|anti-GITR
867162|NCT02740270|anti-PD-1
867163|NCT02740270|adults
867164|NCT02740231|viscosupplement
867165|NCT02740231|osteoarthritis
867166|NCT02740231|knee
867167|NCT02740231|intra-articular injection
867168|NCT02740231|arthritis
867169|NCT02740231|degenerative
867170|NCT02740218|Psoriasis
867171|NCT02740218|Apremilast
867172|NCT02740218|APPRECIATE
867173|NCT02740218|Dermatology
867174|NCT02740218|Retrospective
867175|NCT02740218|Observational
867176|NCT02740205|Patients with Enteral Feeding
867185|NCT02740166|Esophageal Varices; propranolol; banding ligation
867186|NCT02740140|chronic coinfection
867187|NCT02740127|Malignant neoplasms of male genital organs
867188|NCT02740127|Adult Penile Prosthesis Surgery
867189|NCT02740127|Caudal nerve block
867190|NCT02740127|CNB
867191|NCT02740127|General anesthesia
867192|NCT02740127|GA
867193|NCT02740127|Ropivacaine
867194|NCT02740127|Naropin
867195|NCT02740127|Epinephrine
867196|NCT02740127|Decadron
867197|NCT02740127|Dexamethasone
867198|NCT02740127|Clonidine
867199|NCT02740127|Propofol
867200|NCT02740127|Diprivan
867201|NCT02740114|Malignant neoplasms of female genital organs
867202|NCT02740114|Open gynecologic surgery
867203|NCT02740114|Local wound infiltration
867204|NCT02740114|Gynecologic cancer
867205|NCT02740114|Bupivacaine
867206|NCT02740114|Liposomal Bupivacaine
867207|NCT02740114|Oxycodone
867208|NCT02740114|ETH-Oxydose [DSC]
867209|NCT02740114|OxyContin
867210|NCT02740114|OxyIR
867211|NCT02740114|Roxicodone
867212|NCT02740114|Questionnaires
867213|NCT02740114|Surveys
867214|NCT02740114|MD Anderson Symptom Inventory
867215|NCT02740114|MDASI
867216|NCT02740114|Pill diary
867217|NCT02740114|Medication log
867218|NCT02740101|oxytocin
867219|NCT02740101|social reward
867220|NCT02740101|social punishment
867221|NCT02740075|Mechanical versus hand ventilation
867222|NCT02740075|Transport ventilation
867223|NCT02740049|Epithelial Cells
867224|NCT02740010|MIOL
867225|NCT02740010|extended depth of focus
867226|NCT02740010|cataract
867227|NCT02740010|visual acuity
867228|NCT02740010|halos
867229|NCT02739984|diabetes
867230|NCT02739984|type 2 diabetes
867231|NCT02739984|high blood cholesterol
867232|NCT02739984|hypercholesterolemia
867233|NCT02739984|mixed dyslipidemia
867234|NCT02739984|high cholesterol
867235|NCT02739984|statin intolerant
867236|NCT02739945|Ulnar Nerve Compression, Cubital Tunnel
867237|NCT02739932|Attenuated Psychotic Symptoms
867238|NCT02739919|Kidney stones
867239|NCT02739919|Renal Calculi
867242|NCT02739867|occult cancer
867243|NCT02739867|venous thromboembolism
867244|NCT02739867|tumor-educated platelets
867245|NCT02739867|platelet RNA profiling
867246|NCT02739867|early diagnosis
867247|NCT02739867|screening
867248|NCT02739854|trauma
867249|NCT02739854|atelectasis
867250|NCT02739841|hemodynamic response
867251|NCT02739828|Quality of life
867252|NCT02739815|Caesarean Section
867253|NCT02739815|Tranexamic Acid
867254|NCT02739815|Postpartum Hemorrhage
867255|NCT02739815|Ecbolics
867256|NCT02739789|tDCS rejection affect mood fMRI
867257|NCT02739763|PfSPZ
867258|NCT02739763|Semi-immune adults
867259|NCT02739763|Kenya
867260|NCT02739763|challenge
867261|NCT02739763|CHMI
867262|NCT02739763|malaria
867263|NCT02739737|Bias
867264|NCT02739737|Orthopedics
867265|NCT02739737|Peer Review
867266|NCT02739698|ovarian cancer
867267|NCT02739659|prostate carcinoma
867268|NCT02739659|carbon-ion radiotherapy
867269|NCT02739659|efficacy
867270|NCT02739659|toxicity
867271|NCT02739633|Chemotherapy
867272|NCT02739633|Gemcitabine
867273|NCT02739633|Recurrent and metastatic adenocarcinoma of the pancreas
867274|NCT02739633|Genexol-PM
867275|NCT02739633|Paclitaxel
867276|NCT02739607|emotional disorders
867277|NCT02739607|internet-delivered intervention
867278|NCT02739607|anxiety
867279|NCT02739607|depression
867280|NCT02739607|transdiagnostic
867281|NCT02739568|EDS
867282|NCT02739568|OSA
867283|NCT02739555|Osteoid osteoma
867284|NCT02739555|Bisphophonates
867285|NCT02739542|Radiologically Isolated Syndrome (RIS)
867286|NCT02739490|physiotherapeutic techniques
867287|NCT02739490|pelvis
867288|NCT02739490|Muscle strength
867289|NCT02739477|Favipiravir
867290|NCT02739477|Tolerance
867291|NCT02739477|Survivor
867292|NCT02739477|Ebola Virus
867293|NCT02739477|Genital reservoir
867294|NCT02739477|Guinea
867295|NCT02739464|Burn
867296|NCT02739464|Exercise
867297|NCT02739464|Ergometer
867298|NCT02739464|MP-10
867301|NCT02739438|Pulmonary inflammation
867302|NCT02739438|Endothelial dysfunction
867303|NCT02739438|Electronic Cigarettes
867304|NCT02739425|Sentinel lymph node biopsy (SLNB)
867305|NCT02739425|Superparamagnetic iron oxide (SPIO) tracer
867306|NCT02739399|phenylephrine
867307|NCT02739399|alpha mimetics
867308|NCT02739399|pulse pressure variation
867309|NCT02739399|venous return
867310|NCT02739347|tDCS
867311|NCT02739347|cognitive control
867312|NCT02739347|working memory
867313|NCT02739347|EEG
867314|NCT02739347|gamma oscillations
867315|NCT02739321|Autism
867316|NCT02739321|ASD
867317|NCT02739321|Sleep
867318|NCT02739321|Mattress
867319|NCT02739308|proprioception
867320|NCT02739308|ankle sprain
867321|NCT02739308|fencing
867322|NCT02739269|ovarian response
867323|NCT02739269|anti-Mullerian hormone
867324|NCT02739269|antral follicle count
867325|NCT02739256|voiding trial
867326|NCT02739256|pelvic organ prolapse
867327|NCT02739256|post-operative catheterization
867328|NCT02739204|Celecoxib
867329|NCT02739204|Relapse-free OSCC patient
867330|NCT02739204|Recurrence
867331|NCT02739204|Survival
867332|NCT02739204|Prognosis
867333|NCT02739191|NPWT
867334|NCT02739165|Acute exacerbations
867335|NCT02739165|Idiopathic pulmonary fibrosis
867336|NCT02739165|Recombinant human soluble thrombomodulin
867337|NCT02739165|ART-123
867338|NCT02739152|Sepsis
867339|NCT02739152|Severe sepsis
867340|NCT02739152|Infections
867341|NCT02739152|Worsening
867342|NCT02739126|Diagnosis
867343|NCT02739113|OMECs
867344|NCT02739113|Cornea
867345|NCT02739113|Amniotic membrane
867346|NCT02739113|Collagenase
867347|NCT02739100|pharmacokinetics
867348|NCT02739100|bioequivalence
867349|NCT02739087|radiation free cardiac catheterization
867350|NCT02739061|pathogenesis
867351|NCT02739061|cognitive behavioral group therapy
867352|NCT02738996|Diabetes
867353|NCT02738996|Sedentary Lifestyle
867354|NCT02738983|Non-small cell lung cancer
867355|NCT02738983|epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
867356|NCT02738983|Radiotherapy
867357|NCT02738983|wild type
867358|NCT02738931|dolutegravir
867359|NCT02738931|lamivudine
867360|NCT02738931|Bioavailability
867361|NCT02738931|fixed dose combinations
867362|NCT02738918|Renal Transplant
867363|NCT02738918|Anti HLA antibodies
867364|NCT02738918|Humoral rejection
867365|NCT02738892|Pregnancy
867366|NCT02738892|Stillbirth
867367|NCT02738892|Preterm birth
867368|NCT02738866|breast cancer
867369|NCT02738866|Metastatic Breast Cancer
867370|NCT02738866|palbociclib
867371|NCT02738866|fulvestrant
867372|NCT02738814|emergence agitation
867373|NCT02738814|emergence delirium
867374|NCT02738814|PAED scale
867375|NCT02738814|The Modified Aldrete Scoring System
867376|NCT02738814|treatment
867377|NCT02738814|pediatric
867378|NCT02738814|sevoflurane
867379|NCT02738801|Idiopathic Pulmonary Fibrosis
867380|NCT02738801|GLPG1690
867381|NCT02738801|Autotaxin
867382|NCT02738788|airway
867383|NCT02738788|airway changes
867384|NCT02738788|MMS
867385|NCT02738788|prone position
867386|NCT02738788|Trendelenburg position
867387|NCT02738775|multiple sclerosis
867388|NCT02738762|intensive care
867389|NCT02738762|glutamine
867390|NCT02738762|length of stay
867391|NCT02738749|sudden cardiac death, sodium channel splicing variant
867392|NCT02738723|Limited-stage small cell lung cancer
867393|NCT02738723|Stereotactic body radiation therapy
867394|NCT02738723|Intensity modulated radiation therapy
867395|NCT02738723|Radiation
867396|NCT02738723|Chemotherapy
867397|NCT02738697|Carcinoma,Hepatocellular
867398|NCT02738697|Adjuvant chemotherapy
867399|NCT02738697|Microvessels invasion
867400|NCT02738697|Survival
867401|NCT02738697|Recurrence
867402|NCT02738684|lung cancer
867403|NCT02738684|adenocarcinoma
867404|NCT02738684|EGFR
867405|NCT02738684|plasma free nucleic acids
867406|NCT02738671|functional MRI
867407|NCT02738671|olfactory function
867408|NCT02738671|bariatric surgery
867409|NCT02738658|Coronary microcirculatory dysfunction
867410|NCT02738658|Coronary endothelium dysfunction
867411|NCT02738619|allergic rhinitis
867412|NCT02738619|immunotherapy
867413|NCT02738619|vitamin D
867414|NCT02738606|Colorectal Cancer
867415|NCT02738606|Other diseases of intestines
867416|NCT02738606|Liver and Unresectable Pulmonary Metastases
867417|NCT02738606|Resectable liver metastases
867418|NCT02738606|Liver resection
867419|NCT02738606|Chemotherapy
867420|NCT02738554|HBV
867421|NCT02738554|treatment cessation
867422|NCT02738554|HBsAg
867423|NCT02738554|HBcrAg
867424|NCT02738554|nucleoside analogue
867425|NCT02738554|entecavir
867426|NCT02738554|tenofovir
867427|NCT02738502|HIV
867428|NCT02738502|prevention of mother-to-child transmission
867429|NCT02738502|Ritonavir boosted darunavir monotherapy
867430|NCT02738489|PD-1/PD-L1 advanced Melanoma immunotherapy
867431|NCT02738463|ferritin LBW
867432|NCT02738450|cognitive decline
867433|NCT02738437|osteogenesis
867434|NCT02738437|Positron-Emission Tomography
867435|NCT02738437|Radiostereometric analysis
867436|NCT02738424|Low Back Pain
867437|NCT02738424|MRI
867438|NCT02738372|Chronic Pain
867439|NCT02738372|Biopsychosocial Factors
867440|NCT02738372|Shoulder pain
867441|NCT02738372|Prognosis
867442|NCT02738372|Central Nervous System Sensitization
867443|NCT02738346|Small Cell Lung Cancer
867444|NCT02738346|Topotecan
867445|NCT02738346|Etoposide
867446|NCT02738307|High Altitude
867447|NCT02738307|Attention
867448|NCT02738307|Cognitive Function
867449|NCT02738307|Acclimatization
867450|NCT02738307|Sleep
867451|NCT02738255|Obstructive sleep apnea
867452|NCT02738255|Mouth breathing
867453|NCT02738255|Apnea-Hypopnea Index (AHI)
867454|NCT02738242|Functional Electrical Stimulation
867455|NCT02738242|Upper motor neuron injury or disease
867456|NCT02738242|Drop foot
867457|NCT02738242|Thigh muscle weakness
867458|NCT02738203|Pain Management
867459|NCT02738203|IUD insertion
867460|NCT02738203|Endometrial Biopsy
867461|NCT02738190|albumin
867462|NCT02738190|fresh frozen plasma
867463|NCT02738190|extracorporeal circulation
867464|NCT02738190|cardiovascular surgery
867465|NCT02738190|pediatric population
867466|NCT02738177|misopristol
867467|NCT02738177|effox
867468|NCT02738177|cervical ripening
867469|NCT02738138|HCV Genotype 3
867470|NCT02738138|Non-cirrhotic
867471|NCT02738138|HCV Genotype 1
867472|NCT02738138|HCV Genotype 6
867473|NCT02738138|Human Immunodeficiency Virus (HIV) Infection
867474|NCT02738138|HCV Genotype 5
867475|NCT02738138|HCV Treatment Naive
867476|NCT02738138|HCV Genotype 4
867477|NCT02738138|HCV Treatment Experienced
867478|NCT02738138|HCV Genotype 2
867479|NCT02738138|Hepatitis C Virus (HCV) Infection
867480|NCT02738138|Compensated Cirrhosis
867481|NCT02738125|SOTHIS
867482|NCT02738125|Adalimumab
867483|NCT02738125|Ulcerative Colitis
867484|NCT02738125|Effectiveness
867485|NCT02738086|Amputation
867486|NCT02738086|Physical Activity
867487|NCT02738086|Rehabilitation
867488|NCT02738034|Hypertension
867489|NCT02738034|Cognition
867490|NCT02738034|Computerized Training
867491|NCT02738034|Cogmed
867492|NCT02738021|Psychosocial
867493|NCT02738021|Psychotherapy
867494|NCT02738021|Maternal
867495|NCT02737995|Iron deficiency
867496|NCT02737982|coronary heart disease
867497|NCT02737982|gender
867498|NCT02737982|platelet
867499|NCT02737982|microvascular dysfunction
867500|NCT02737982|sexual hormones
867501|NCT02737982|cardiac magnetic resonance
867502|NCT02737982|percutaneous coronary interventions
867503|NCT02737969|Transesophageal Echocardiography/angiography (TEE/Angio)
867504|NCT02737943|Skin graft
867505|NCT02737943|Burn
867506|NCT02737943|MEBO
867507|NCT02737943|Wound dressing
867508|NCT02737943|Wound care
867509|NCT02737943|Raw Area
867510|NCT02737930|Acute ischemic stroke
867511|NCT02737930|Homonymous hemianopia
867512|NCT02737930|Homonymous quadrantanopia
867513|NCT02737930|Visual field loss
867514|NCT02737930|Post-stroke recovery
867515|NCT02737930|Fluoxetine
867516|NCT02737930|Selective serotonin reuptake inhibitor
867517|NCT02737904|Muscle spasticity
867518|NCT02737865|Focal nodular hyperplasia
867519|NCT02737865|Ultrasonography
867520|NCT02737865|Superb-Microvascular imaging
867521|NCT02737865|Contrast-enhanced ultrasonography
867522|NCT02737254|Attachment
867523|NCT02737254|Oxytocin
867524|NCT02737254|Cognitive bias modification
867525|NCT02737254|Middle childhood
867526|NCT02737813|isobaric marcaine
867527|NCT02737813|hyperbaric marcaine
867528|NCT02737787|Second or Greater Remission
867529|NCT02737787|WT1 Analog Peptide Vaccine
867530|NCT02737787|Montanide
867531|NCT02737787|GM-CSF
867532|NCT02737787|Nivolumab
867533|NCT02737787|15-247
867534|NCT02737774|Icotinib
867535|NCT02737774|chemotherapy
867536|NCT02737774|EGFR
867537|NCT02737761|Heart Failure
867538|NCT02737761|Positive Psychology
867539|NCT02737761|Adherence to Health Behaviors
867540|NCT02737748|Donor Site Wounds
867541|NCT02737696|prescription opioid
867542|NCT02737696|prevention
867543|NCT02737696|computer-based
867544|NCT02737696|adolescent
867545|NCT02737683|Disease
867546|NCT02737683|anxiety
867547|NCT02737683|depression
867548|NCT02737683|combine
867549|NCT02737683|negative emotional states
867550|NCT02737683|functional dyspepsia
867551|NCT02737657|Canagliflozin
867552|NCT02737657|Metformin
867553|NCT02737657|Diabetes Mellitus, Type 2
867554|NCT02737657|INVOKANA
867555|NCT02737657|Sulfonylurea
867556|NCT02737644|Congenital Heart Disease
867557|NCT02737644|Key Nutritional Factors
867558|NCT02737644|conception
867559|NCT02737644|pregnant
867560|NCT02737605|Esketamine
867561|NCT02737605|Healthy
867562|NCT02737605|Pharmacokinetics
867563|NCT02737605|Electrocardiogram
867564|NCT02737605|Repolarization
867565|NCT02737579|cardiac catheterization
867566|NCT02737579|cardiac MRI
867567|NCT02737566|Smoking Cessation
867568|NCT02737566|Financial Incentives
867569|NCT02737566|Contingency Management
867570|NCT02737566|Vulnerable Populations
867571|NCT02737566|Medically Uninsured
867572|NCT02737566|Medicaid
867573|NCT02737527|ultrasound
867574|NCT02737527|lumbar sympathetic block
867575|NCT02737514|adenoma detection rate
867576|NCT02737514|colonoscopy
867577|NCT02737514|water exchange
867578|NCT02737501|Non-small cell lung cancer
867579|NCT02737501|Non-small cell lung carcinoma
867580|NCT02737501|Epithelial lung cancer
867581|NCT02737501|Squamous cell carcinoma
867582|NCT02737501|Large cell carcinoma
867583|NCT02737501|Adenocarcinoma
867584|NCT02737501|Carcinoma
867585|NCT02737501|Anaplastic Lymphoma Kinase (ALK)
867586|NCT02737501|Advanced Cancers
867587|NCT02737501|Brigatinib
867588|NCT02737501|AP26113
867589|NCT02737488|Therapy
867590|NCT02737488|Trauma Systems Therapy
867591|NCT02737410|Resilience
867592|NCT02737410|Coping
867593|NCT02737410|Psychosomatic
867594|NCT02737410|Hypnosis
867595|NCT02737410|Construct Validation
867596|NCT02737384|Combined immunodeficiencies
867597|NCT02737384|hematopoietic stem cell transplantation
867598|NCT02737384|CD45RA
867599|NCT02737384|primitive immunodeficiencies
867600|NCT02737384|pediatric transplantation
867601|NCT02737384|CD45RA depletion
867602|NCT02737358|nicotine
867603|NCT02737358|tobacco
867604|NCT02737358|smoking
867605|NCT02737358|cessation
867606|NCT02737358|N-acetylcysteine
867607|NCT02737358|NAC
867608|NCT02737358|pharmacotherapy
867609|NCT02737358|relapse
867610|NCT02737358|tobacco use disorder
867611|NCT02737345|fibrinolysis
867612|NCT02737345|liver transplant
867613|NCT02737345|thromboelastometry
867614|NCT02737319|Contrast,nephropathy, angioplasty, stable coronary
867615|NCT02737306|Allogeneic Stem-Cell Transplantation
867616|NCT02737280|infant
867617|NCT02737280|high flow nasal cannulae
867618|NCT02737280|oxygen therapy
867619|NCT02737280|bronchiolitis
867620|NCT02737267|Genetics
867621|NCT02737267|Polymorphism
867622|NCT02737267|Epigenetics
867623|NCT02737267|Metagenomics
867624|NCT02737267|Metabolomics
867625|NCT02737267|Metabolic syndrome conditions
867626|NCT02737267|Precision nutrition
867627|NCT02737241|Prostate
867628|NCT02737241|Laser
867629|NCT02737241|Enucleation
867630|NCT02737202|LAM
867631|NCT02737189|Basilar Artery Occlusion
867632|NCT02737189|Ischemic Stroke
867633|NCT02737189|Mechanical Embolectomy
867634|NCT02737176|Smoking Cessation
867635|NCT02737176|Mouth Diseases
867636|NCT02737176|Periodontal Diseases
867637|NCT02737176|Leukoplakia
867638|NCT02737176|Keratosis
867639|NCT02737176|Implant
867640|NCT02737176|Lichen Planus
867641|NCT02737163|Programmable shunts
867642|NCT02737163|Strata valve
867643|NCT02737124|Acetaminophen
867644|NCT02737124|Surgery
867645|NCT02737124|Meniscectomy
867646|NCT02737098|PTSD
867647|NCT02737098|virtual care
867648|NCT02737098|implementation
867649|NCT02737098|telepsychiatry
867650|NCT02737098|telepsychology
867651|NCT02737085|CD19-targeted CAR-T Cell
867652|NCT02737085|CD20-targeted CAR-T Cell
867653|NCT02737085|Diffuse Large B Cell Lymphoma
867654|NCT02737072|immuno-oncology
867655|NCT02737046|Adult T-cell Leukemia-Lymphoma
867656|NCT02737046|ATLL
867657|NCT02737033|ADHD
867658|NCT02737033|Adults
867659|NCT02737033|Treatment
867660|NCT02737033|Rhodiola
867661|NCT02737020|ADHD
867662|NCT02737020|Adults
867663|NCT02737020|Treatment
867664|NCT02737020|Rhodiola rosea
867665|NCT02737007|Malaria
867666|NCT02737007|Microdose
867667|NCT02737007|GSK3191607
867668|NCT02736994|edentulous
867669|NCT02736994|patients
867670|NCT02736994|with full
867671|NCT02736981|Obesity
867672|NCT02736981|Weight Loss
867673|NCT02736981|Young Adults
867674|NCT02736968|Amebic
867675|NCT02736968|Auranofin
867676|NCT02736968|GI Protozoa
867677|NCT02736968|Giardiasis
867678|NCT02736968|Reprofiled
867679|NCT02736890|Botulinum Toxin A
867680|NCT02736890|Neuropathic pain
867681|NCT02736890|Spinal cord injury
867682|NCT02736890|Pain management
867683|NCT02736890|Rehabilitation
867684|NCT02736877|keratoconus
867685|NCT02736877|bullous keratopathy
867686|NCT02736877|corneal dystrophy
867687|NCT02736851|disability
867688|NCT02736851|home
867689|NCT02736851|stretching exercises
867690|NCT02736838|Pressure
867691|NCT02736838|Pressure Ulcer
867692|NCT02736838|Skin perfusion
867693|NCT02736838|Skin oxygenation
867694|NCT02736812|Randomized controlled trial
867695|NCT02736812|Lyophilized Plasma
867696|NCT02736812|Advanced Trauma Life Support Care
867697|NCT02736786|proton
867698|NCT02736773|Guided Bone
867699|NCT02736773|Pre-implant referred
867700|NCT02736773|Regeneration
867701|NCT02736747|Stroke
867702|NCT02736747|Muscle Spasticity
867703|NCT02736747|Cryotherapy
867704|NCT02736747|Gait
867705|NCT02736747|Muscle Weakness
867706|NCT02736747|Proprioception
867707|NCT02736708|Primary sclerosing cholangitis
867708|NCT02736695|PPA
867709|NCT02736669|weight loss
867710|NCT02736669|body weight
867711|NCT02736669|behavioral
867712|NCT02736643|LDCT, screening
867713|NCT02736630|general anaesthesia
867714|NCT02736630|elective surgery
867715|NCT02736630|national epidemiology
867716|NCT02736630|turkey
867717|NCT02736565|metastatic
867718|NCT02736565|askin tumor
867719|NCT02736565|neuroectodermal tumor
867720|NCT02736565|pNET
867721|NCT02736565|sarcoma
867722|NCT02736565|soft tissue
867723|NCT02736552|Gastric cancer
867724|NCT02736552|Adjuvant chemotherapy
867725|NCT02736552|S-1
867726|NCT02736552|D2 resection
867727|NCT02736526|moderate intermittent exotropia
867728|NCT02736526|surgical treatment
867729|NCT02736526|observation
867730|NCT02736513|Tagrisso
867731|NCT02736513|AZD9291
867732|NCT02736513|EGFRm
867733|NCT02736513|brain metastases
867734|NCT02736513|NSCLC
867735|NCT02736500|neuroendocrine tumors
867736|NCT02736500|gastro entero pancreatic neuroendocrine tumors
867737|NCT02736500|Radioisotope therapy
867738|NCT02736500|177Lu-DOTATATE
867739|NCT02736500|METRONOMIC CAPECITABINE
867740|NCT02736487|Air Pollution
867741|NCT02736487|Exposure Assessment
867742|NCT02736487|Filtration
867743|NCT02736487|Cardiovascular Outcomes
867744|NCT02736487|Respiratory Outcomes
867745|NCT02736487|Short-term Intervention
867746|NCT02736461|Orbital fractures
867747|NCT02736461|Strabismus
867748|NCT02736461|Predicting factors
867749|NCT02736461|orbital floor fractures
867750|NCT02736448|GEP-NET tumors
867751|NCT02736448|Lu-PRRT
867752|NCT02736448|177Lutethium - Peptide Receptor Radionuclide Therapy
867753|NCT02736448|gastro-entero-pancreatic neuroendocrine tumors
867754|NCT02736448|18-FDG Positron Emission Tomography (PET) positive
867755|NCT02736448|low dose of capecitabine
867756|NCT02736435|Magnetic Resonance Guided High Intensity Focused Ultrasound
867757|NCT02736435|MR-HIFU
867758|NCT02736435|Fibroids
867759|NCT02736435|Leuprolide Acetate
867760|NCT02736357|Lymphoma
867761|NCT02736357|Cohort
867762|NCT02736357|non-Hodgkin
867763|NCT02736344|coronary luminal diameter
867764|NCT02736344|lesions
867765|NCT02736344|vessels
867766|NCT02736331|Cognitive performance
867767|NCT02736331|Metabolic control
867768|NCT02736331|Pharmacokinetic profile
867769|NCT02736331|Anthocyanins
867770|NCT02736305|ovarian
867771|NCT02736305|regorafenib
867772|NCT02736305|platinum resistant
867773|NCT02736305|clear cell
867774|NCT02736305|endometrioid
867775|NCT02736266|Muscle-invasive
867776|NCT02736266|Urothelial bladder carcinoma
867777|NCT02736266|Neoadjuvant therapy
867778|NCT02736266|Radical cystectomy
867779|NCT02736253|foot amputation
867780|NCT02736253|Osteomyelitis
867781|NCT02736253|Diabetic Foot
867782|NCT02736227|liver transplantation
867783|NCT02736227|immunosuppression
867784|NCT02736227|everolimus
867785|NCT02736227|tacrolimus
867786|NCT02736227|kidney function
867787|NCT02736227|liver function
867788|NCT02736227|biomarkers
867789|NCT02736188|GNE Myopathy
867790|NCT02736188|GNEM
867791|NCT02736188|Nonaka
867792|NCT02736188|Hereditary Inclusion Body Myopathy
867793|NCT02736188|HIBM
867794|NCT02736188|DMRV
867795|NCT02736188|QSM
867796|NCT02736162|Perampanel
867797|NCT02736162|E2007
867798|NCT02736162|Phase 4
867799|NCT02736162|Fycompa
867800|NCT02736136|maternal parenting self-efficacy
867801|NCT02736136|parental stress
867802|NCT02736136|maternal sensitivity
867803|NCT02736136|mother-infant bond
867804|NCT02736110|Osteoarthritis, knee
867805|NCT02736084|optimism
867806|NCT02736084|positive affect
867807|NCT02736084|adherence
867808|NCT02736084|health behavior
867809|NCT02736084|diabetes
867810|NCT02736006|Alveolo-capillar membrane
867811|NCT02736006|decompression illness
867812|NCT02736006|diving
867813|NCT02736006|occupational
867814|NCT02735993|Celution
867815|NCT02735993|ADRC
867816|NCT02735993|Heart Failure
867817|NCT02735993|Device
867818|NCT02735980|SCLC
867819|NCT02735980|LY2606368
867820|NCT02735980|CHK1
867821|NCT02735915|Immunogenicity
867822|NCT02735915|Safety
867823|NCT02735915|Long term follow-up
867824|NCT02735915|Adults
867825|NCT02735915|Herpes zoster
867826|NCT02735902|antivitamins K
867827|NCT02735876|Bruton tyrosine kinase inhibitor
867828|NCT02735876|Btk
867829|NCT02735876|ACP-196
867830|NCT02735876|Mantle Cell Lymphoma
867831|NCT02735876|MCL
867832|NCT02735811|Implantable defibrillator
867833|NCT02735811|Cardiomyopathies
867834|NCT02735720|thoracic endovascular aortic repair
867835|NCT02735720|endograft
867836|NCT02735720|cardiac remodelling
867837|NCT02735720|thoracic aortic aneurysm
867838|NCT02735720|penetrating aortic ulcer
867839|NCT02735720|MRI
867840|NCT02735694|Sleep apnea
867841|NCT02735694|Hypoglossal Nerve
867842|NCT02735694|N-methyl-D-aspartate receptors
867843|NCT02735694|Cycloserine
867844|NCT02735694|Short-term potentiation
867845|NCT02735668|Shoulder Pain
867846|NCT02735668|Pattern Motor
867847|NCT02735668|Physical Therapy Modalities
867848|NCT02735668|Breast Cancer Treatment
867849|NCT02735655|endoscopy
867850|NCT02735655|Education
867851|NCT02735655|capsule endoscopy
867852|NCT02735655|Cholangiopancreatography, Endoscopic Retrograde
867853|NCT02735655|esophagogastroduodenoscopy
867854|NCT02735655|colonoscopy
867855|NCT02735655|Double-Balloon Enteroscopy
867856|NCT02735655|Global status
867857|NCT02735655|unmet need
867858|NCT02735616|heart rate variability
867859|NCT02735616|stroke
867860|NCT02735577|Alcohol
867861|NCT02735577|Craving
867862|NCT02735577|Functional MRI
867863|NCT02735577|Cognitive control
867864|NCT02735577|Risky decision-making
867865|NCT02735577|Disulfiram
867866|NCT02735564|Weight Loss
867867|NCT02735564|Magnetic Resonance Imaging
867868|NCT02735564|gut microbiota
867869|NCT02735551|LARC
867870|NCT02735551|IUD
867871|NCT02735551|Contraceptive Implant
867872|NCT02735551|Contraception
867873|NCT02735551|Community college
867874|NCT02735525|telemedicine
867875|NCT02735525|smartphone
867876|NCT02735499|onabotulinum toxin A
867877|NCT02735499|Urinary bladder
867878|NCT02735499|EMDA
867879|NCT02735499|iontophoresis
867880|NCT02735499|electrophoresis
867881|NCT02735499|Urinary incontinence
867882|NCT02735486|Ginger
867883|NCT02735486|blood pressure
867884|NCT02735486|flow mediated dilatation
867885|NCT02735434|Health anxiety
867886|NCT02735434|illness anxiety disorder
867887|NCT02735434|ACT
867888|NCT02735434|internet
867889|NCT02735421|acne
867890|NCT02735421|scars
867891|NCT02735395|Periodontal Diseases
867892|NCT02735395|Metronidazole
867893|NCT02735395|Amoxicillin
867894|NCT02735395|Chronic periodontitis
867895|NCT02735395|Root Planing
867896|NCT02735382|Translational Medical Research
867897|NCT02735382|Clinical Practice Guidelines
867898|NCT02735382|Electronic Health Records
867899|NCT02735382|Smoking
867900|NCT02735382|Tobacco
867901|NCT02735382|Quitline
867902|NCT02735330|CCP
867903|NCT02735317|Nasopharyngeal carcinoma (NPC)
867904|NCT02735317|radiotherapy
867905|NCT02735317|oral mucositis (OM)
867906|NCT02735291|Leukemia CAR-T
867907|NCT02735265|Rehabilitation
867908|NCT02735265|Virtual reality
867909|NCT02735252|Castration Resistant
867910|NCT02735252|Metastatic
867911|NCT02735239|Oesophageal Cancer
867912|NCT02735239|Oesophageal adenocarcinoma
867913|NCT02735239|Oesophageal squamous cell carcinoma
867914|NCT02735239|Immunotherapy
867915|NCT02735239|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
867916|NCT02735239|Programmed cell death protein 1 (PD-1)
867917|NCT02735239|Programmed death ligand 1 (PD-L1)
867918|NCT02735226|stroke
867919|NCT02735226|Shanghai Healthcare
867920|NCT02735226|Healthcare Quality, Access, and Evaluation
867921|NCT02735213|Central Serous Choroidopathy
867922|NCT02735213|Micropulse Laser Treatment
867923|NCT02735213|Traditional laser Treatment
867924|NCT02735213|optical coherence tomography
867925|NCT02735174|Telehealth
867926|NCT02735174|Sensor cap
867927|NCT02735174|School based care
867928|NCT02735174|Community health
867929|NCT02735174|AsthmaTreatSmart Application
867930|NCT02735161|Sarcoidosis
867931|NCT02735161|Fatigue
867932|NCT02735161|Exercise
867933|NCT02735148|Postural balance
867934|NCT02735148|Accidental falls
867935|NCT02735148|Rehabilitation
867936|NCT02735148|Cerebrovascular Accident
867937|NCT02735148|Walking
867938|NCT02735148|Mobility limitation
867939|NCT02735135|bedridden
867940|NCT02735109|VIN
867941|NCT02735096|Bilateral Vestibular Hypofunction
867942|NCT02735096|Unilateral Vestibular Hypofunction
867943|NCT02735096|Imbalance
867944|NCT02735070|Common cold treatment
867945|NCT02735057|oesophagus cancer
867946|NCT02735031|Glucagon-Like Peptide 1
867947|NCT02735031|Impaired hypoglycemic awareness
867948|NCT02734992|Migraines
867949|NCT02734992|Tension-type Headache
867950|NCT02734992|Acceptance
867951|NCT02734979|lymphedema
867952|NCT02734979|edema
867953|NCT02734966|Drug-Induced
867954|NCT02734966|Acute Liver Injury
867955|NCT02734953|Inhaled nitric oxide
867956|NCT02734953|Exercise
867957|NCT02734953|6 minute walk test
867958|NCT02734953|CardioMems
867959|NCT02734927|schizophrenia
867960|NCT02734927|motivation
867961|NCT02734927|executive control
867962|NCT02734901|polyphenols
867963|NCT02734901|vascular function
867964|NCT02734901|endothelial function
867965|NCT02734901|raspberry
867966|NCT02734888|arterial inflammation
867967|NCT02734888|electronic cigarettes
867968|NCT02734888|PET scan
867969|NCT02734875|anticoagulants
867970|NCT02734875|NOACs
867971|NCT02734875|warfarin
867972|NCT02734875|randomized designed delay
867973|NCT02734875|intervention
867974|NCT02734875|machine learning algorithm
867975|NCT02734875|primary care
867977|NCT02734810|Exocrine Pancreatic Insufficiency
867978|NCT02734810|Cystic Fibrosis
867979|NCT02734810|Liprotamase
867980|NCT02734810|Pancreatic Enzyme Replacement Therapy (PERT)
867981|NCT02734771|DLBCL
867982|NCT02734745|diabetes type 1
867983|NCT02734745|flash glucose monitoring
867984|NCT02734732|Prostate
867985|NCT02734732|Biopsy
867986|NCT02734732|Infection
867987|NCT02734732|Prophylaxis
867988|NCT02734732|Antibiotic
867989|NCT02734693|Attention-Deficit Hyperactivity Disorder (ADHD)
867990|NCT02734680|Pancreatic cancer
867991|NCT02734680|Intraoperative radiotherapy(IORT)
867992|NCT02734680|Postoperative radiochemotherapy
867993|NCT02734654|oxidative stress
867994|NCT02734654|lung lobectomy
868007|NCT02734602|depression
868008|NCT02734602|post-traumatic stress disorder
868009|NCT02734602|sv2a
868010|NCT02734602|ketamine
868011|NCT02734602|PET
868012|NCT02734589|Ulcerative Colitis
868013|NCT02734589|Nutrition
868014|NCT02734589|microbiome
868015|NCT02734576|Venous Sinus Stenting
868016|NCT02734576|Dural Sinus Stenting
868017|NCT02734550|Sepsis
868018|NCT02734550|Invasive Candida Infection
868019|NCT02734550|Biomarker
868020|NCT02734550|(1,3)-β-D-glucan
868021|NCT02734550|Antifungal therapy
868022|NCT02734550|Intensive care medicine
868023|NCT02734550|Critically ill
868024|NCT02734524|Natural killer cells
868025|NCT02734524|NSCLC
868026|NCT02734524|NCT
868027|NCT02734524|Combined therapy
868028|NCT02734485|Progressive supranuclear palsy
868029|NCT02734485|Deep transcranial magnetic stimulation
868030|NCT02734472|blood pressure
868031|NCT02734472|Hypertrophy, Left Ventricular
868032|NCT02734472|Vascular Stiffness
868033|NCT02734472|Proteinuria
868034|NCT02734472|Carotid Artery Diseases
868035|NCT02734446|Bronchial Inflammation
868036|NCT02734446|Asthma
868037|NCT02734446|Childhood Asthma Control Test (C-ACT)
868038|NCT02734446|Asthma Exacerbations
868039|NCT02734433|Advanced solid tumors
868040|NCT02734433|Asian subjects
868041|NCT02734433|Developmental Phase I
868042|NCT02734420|Dental caries
868043|NCT02734420|PDT
868044|NCT02734420|LLLT
868045|NCT02734420|pediatric dentistry
868046|NCT02734394|exercise
868047|NCT02734394|body composition
868048|NCT02734394|metabolism
868049|NCT02734394|nutrition
868050|NCT02734381|elderly patients
868051|NCT02734381|prevalence
868052|NCT02734381|emergency department use
868053|NCT02734381|main presenting disease
868054|NCT02734355|atrial fibrillation
868055|NCT02734355|catheter ablation
868056|NCT02734355|left atrium
868057|NCT02734355|mechanical function
868058|NCT02734355|contractility
868059|NCT02734329|Nephron sparing surgery
868060|NCT02734329|Zero ischemia
868061|NCT02734329|Warm ischemia
868062|NCT02734329|Laparoscopic
868063|NCT02734329|Radiofrequency ablation
868064|NCT02734329|Microwave ablation
868065|NCT02734303|Dietary Radioactivity
868066|NCT02734303|Dietary Assessment
868067|NCT02734303|Retrospective Recall
868068|NCT02734303|Focus Group
868069|NCT02734290|metastatic
868070|NCT02734290|Human epidermal growth factor receptor 2 (Her2) negative breast cancer
868071|NCT02734290|Estrogen Receptor (ER) negative breast cancer
868072|NCT02734290|Progesterone Receptor (PR) negative breast cancer
868073|NCT02734290|Immunotherapy
868074|NCT02734290|Breast Cancer
868075|NCT02734277|Insulin
868076|NCT02734277|Glucose Intolerance
868077|NCT02734277|Prior ITN027AI Study Participants-NCT00129259
868078|NCT02734277|Prior ITN045AI Study Participants-NCT00965458
868079|NCT02734251|Healthy mood
868080|NCT02734251|Stress management
868081|NCT02734251|Relora
868082|NCT02734251|Healthy subjects
868083|NCT02734225|total knee replacement
868084|NCT02734225|total knee arthroplasty
868085|NCT02734225|rehabilitation
868086|NCT02734225|physical therapy
868087|NCT02734225|balance
868088|NCT02734212|Stigmatization
868089|NCT02734199|Birth Control
868090|NCT02734199|Contraception
868091|NCT02734199|IUD
868092|NCT02734186|Filariasis
868093|NCT02734186|Schistosoma Mansoni
868094|NCT02734186|Coinfection
868095|NCT02734160|immunotherapy
868096|NCT02734160|check point inhibitors
868097|NCT02734160|transforming growth factor (TGF)-beta R1 kinase inhibitor
868098|NCT02734134|Periprosthetic joint infection
868099|NCT02734121|breast cancer
868100|NCT02734121|breast reconstruction
868101|NCT02734121|shared decision making
868102|NCT02734121|decision support intervention
868103|NCT02734108|Sever anorexia nervosa
868104|NCT02734082|stroke
868105|NCT02734082|ischemia
868106|NCT02734082|Berne
868107|NCT02734069|carboplatin
868108|NCT02734043|bundled payment
868109|NCT02734030|Anterior Knee Pain Syndrome
868110|NCT02734030|Quadriceps Femoris
868111|NCT02734030|Muscle Inhibition
868112|NCT02734030|Interpolated Twitch Technique
868113|NCT02734030|Muscle Architecture
868114|NCT02734030|Single Leg Squat
868115|NCT02734030|Women Knee Pain
868116|NCT02734004|MEDIOLA
868117|NCT02734004|Olaparib
868118|NCT02734004|MEDI4736
868119|NCT02734004|Ovarian cancer
868120|NCT02734004|Breast cancer
868121|NCT02734004|Small Cell Lung Cancer
868122|NCT02734004|Gastric Cancer
868123|NCT02734004|Phase I/II, Adults
868124|NCT02734004|PDL-1
868125|NCT02733978|Ozone oxygen
868126|NCT02733978|ulcer healing
868127|NCT02733965|clinical pharmacy consultations
868128|NCT02733965|oral anti-cancer therapy
868129|NCT02733965|serious adverse events
868130|NCT02733965|medication reconciliation
868131|NCT02733939|technology
868132|NCT02733939|informal care
868133|NCT02733939|caregiver burden
868134|NCT02733913|atrial fibrillation
868135|NCT02733913|pulmonary vein isolation
868136|NCT02733913|heart rate turbulence
868137|NCT02733913|baroreflex sensitivity
868138|NCT02733900|aseptic osteonecrosis
868139|NCT02733900|femoral head
868140|NCT02733900|micro scanner
868141|NCT02733900|Raman spectrometry
868142|NCT02733900|MRI
868143|NCT02733861|dental implant
868144|NCT02733861|stability
868145|NCT02733861|implant stability quotient
868146|NCT02733848|Roux-en-Y gastric bypass
868147|NCT02733848|Hypoglycemia
868148|NCT02733848|Creon
868149|NCT02733822|opiate
868150|NCT02733822|heroin
868151|NCT02733822|opioid
868152|NCT02733822|overdose
868153|NCT02733822|naloxone
868154|NCT02733809|Hepatocellular Carcinoma
868155|NCT02733809|Sorafenib
868156|NCT02733796|zika virus
868157|NCT02733796|semen analysis
868158|NCT02733796|sexual transmission
868159|NCT02733757|Clonidine
868160|NCT02733757|Sub-Tenon's and Peribulbar block
868161|NCT02733757|IOP
868162|NCT02733757|OPP
868163|NCT02733757|OPA
868164|NCT02733744|Stem cell transplant
868165|NCT02733744|fecal microbiota transplantation
868166|NCT02733718|Necrotizing enterocolitis
868167|NCT02733718|Transfusion
868168|NCT02733718|Mesenteric Oxygenisation
868169|NCT02733705|Pain
868170|NCT02733705|TRUS biopsy
868171|NCT02733692|HIV
868172|NCT02733692|STDs
868173|NCT02733692|web-based app
868174|NCT02733692|women
868175|NCT02733666|Absorbable screw
868176|NCT02733666|Internal fixation
868177|NCT02733666|Children
868178|NCT02733653|Superficial Femoral Artery
868179|NCT02733653|Proximal Popliteal Artery
868180|NCT02733653|Endovascular therapy
868181|NCT02733653|Atherectomy
868182|NCT02733601|breast cancer epidemiology algeria registry
868183|NCT02733588|hypoglycemia
868184|NCT02733588|glucagon
868185|NCT02733588|glucose metabolism disorders
868186|NCT02733588|hormones
868187|NCT02733588|gastrointestinal agents
868188|NCT02733588|bariatric surgery
868189|NCT02733588|incretins
868194|NCT02733510|kidney transplantation
868195|NCT02733510|subclinical rejection
868196|NCT02733510|steroid pulse therapy
868197|NCT02733497|sympathectomy, sympathicotomy, heart rate variability,
868198|NCT02733484|Obesity,Probiotics,Treatment
868199|NCT02733471|Lidocaine
868200|NCT02733471|Endoscopy
868201|NCT02733471|Tolerance
868202|NCT02733393|Thoracotomy
868203|NCT02733393|Postoperative
868204|NCT02733393|Lidocaine
868205|NCT02733393|Sphenopalatine Ganglion Block
868206|NCT02733380|Diffuse Large B-Cell Lymphoma
868207|NCT02733380|Relapsed and refractory
868208|NCT02733380|Histone deacetylase inhibitor
868209|NCT02733380|Chidamide
868210|NCT02733341|Adenosine Diphosphate
868211|NCT02733341|Cardiovascular Magnetic Resonance (CMR)
868212|NCT02733341|Index of microvascular resistance (IMR)
868213|NCT02733341|Vasodilator stimulated phosphoprotein phosphorylation (VASP)
868214|NCT02733341|Pharmacodynamic
868215|NCT02733341|Antiplatelet
868216|NCT02733341|Myocardial Infarction (MI)
868217|NCT02733341|Cangrelor
868218|NCT02733341|Ticagrelor
868219|NCT02733341|Coronary artery bypass graft (CABG)
868220|NCT02733341|Primary percutaneous coronary intervention (PPCI)
868221|NCT02733328|Cardio-pulmonary bypass (CPB)
868222|NCT02733328|renal replacement therapy (RRT)
868223|NCT02733328|enzyme-linked immunosorbent assay (ELISA)
868224|NCT02733263|gut microbiota
868225|NCT02733263|fiber
868226|NCT02733263|diet quality
868227|NCT02733263|immunity
868228|NCT02733250|NSCLC
868229|NCT02733250|Pembrolizumab
868230|NCT02733250|Nab-paclitaxel
868231|NCT02733237|oxytocin
868232|NCT02733237|infidelity
868233|NCT02733224|lenalidomide adherence MEMS
868234|NCT02733211|Closed Loop
868235|NCT02733185|chelation
868236|NCT02733172|Vulvodynia
868237|NCT02733172|Endophenotypes
868238|NCT02733172|functional MRI
868239|NCT02733159|Performance Status 2
868240|NCT02733159|Pembrolizumab
868241|NCT02733159|MK-3475
868242|NCT02733133|Testosterone
868243|NCT02733133|AndroGel
868244|NCT02733133|Transference
868245|NCT02733133|Women
868246|NCT02733133|Children
868247|NCT02733107|Non-small Cell Lung Cancer
868248|NCT02733107|Apatinib
868249|NCT02733107|Etoposide
868250|NCT02733081|Long Acting Reversible Contraception
868251|NCT02733081|Intrauterine Device (IUD)
868252|NCT02733081|Intrauterine Device (IUD) Insertion
868253|NCT02733081|Family Planning
868254|NCT02733081|International Family Planning
868255|NCT02733055|Postural Equilibrium
868256|NCT02733055|Musculoskeletal Equilibrium
868257|NCT02733055|Eye Movements
868258|NCT02733055|Saccades
868259|NCT02733055|Pursuit, Smooth
868260|NCT02733042|Lymphoma
868261|NCT02733042|Chronic Lymphocytic Leukemia
868262|NCT02733042|Durvalumab
868263|NCT02733042|Anti-PD-L1 Antibody
868264|NCT02733042|MEDI4736
868265|NCT02733042|Immune Checkpoint
868266|NCT02733042|Lymphatic Disease
868267|NCT02733042|B-Cell Malignancies
868268|NCT02733042|Abscopal Effect
868269|NCT02733042|Lenalidomide
868270|NCT02733042|Bendamustine
868271|NCT02733042|Rituximab
868272|NCT02733042|Ibrutinib
868273|NCT02733042|Lymphoma, B-Cell
868274|NCT02733042|Lymphoma, Non Hodgkin,
868275|NCT02733042|Hodgkin Disease
868276|NCT02733042|Leukemia, Lymphocytic, Chronic, B-Cell,
868277|NCT02733042|Lymphoma, Follicular
868278|NCT02733042|Lymphoma, Diffuse Large B-Cell
868279|NCT02733042|Lymphoma, Mantle Cell
868280|NCT02733042|Lymphoma, Small Lymphocytic
868281|NCT02733042|Immune System Diseases
868282|NCT02733042|Immunoproliferative Disorders
868283|NCT02733042|Lymphoproliferative Disorders
868284|NCT02733003|Implementation Science
868285|NCT02733003|HIV
868286|NCT02733003|Sexual Risk
868287|NCT02733003|Sexually Transmitted Diseases
868288|NCT02733003|Substance Abuse
868289|NCT02733003|Violence and Victimization
868290|NCT02733003|Linkage to care
868291|NCT02732990|Training
868292|NCT02732990|One-legged exercise
868293|NCT02732990|Peripheral blood flow
868294|NCT02732990|Cardiac function
868295|NCT02732990|Muscle metaboreflex
868296|NCT02732964|satisfaction
868297|NCT02732938|CCR2i, nab-paclitaxel, Abraxane, gemcitabine, pancreas
868298|NCT02732925|Vertebral Compression Fracture
868299|NCT02732925|Balloon Kyphoplasty
868300|NCT02732925|Conservative treatment
868301|NCT02732925|Sham procedure
868302|NCT02732925|VCFs
868303|NCT02732925|Multiple Myeloma
868304|NCT02732912|falls
868305|NCT02732912|sleep
868306|NCT02732899|AMD
868307|NCT02732886|foam dressing
868308|NCT02732860|personalized patient-derived xenografts (pPDX)
868309|NCT02732860|molecular profiling
868310|NCT02732860|epigenetic analysis
868311|NCT02732860|drug sensitivity testing
868312|NCT02732860|triple negative
868313|NCT02732860|metastatic
868314|NCT02732847|Respiratory infections
868315|NCT02732847|Primary care
868316|NCT02732847|Antibiotics
868317|NCT02732847|Delayed prescriptions
868318|NCT02732834|Doctor-Patient Communication
868319|NCT02732834|16-001
868320|NCT02732821|Gastroparesis
868321|NCT02732821|G-POEM
868322|NCT02732821|Gastric Per Oral Endoscopic Myotomy
868323|NCT02732808|Double stimulations
868324|NCT02732808|luteal-phase ovarian stimulation
868325|NCT02732808|poor ovarian response
868326|NCT02732782|Achilles tendon
868327|NCT02732782|isometric muscle training
868328|NCT02732782|competitive sports
868329|NCT02732782|strength training
868330|NCT02732782|eccentric exercise
868331|NCT02732782|isometric exercise
868332|NCT02732782|chronic condition
868333|NCT02732782|regeneration
868334|NCT02732782|tendon
868335|NCT02732782|tendon properties
868336|NCT02732782|tendinopathy
868337|NCT02732782|tendinosis
868338|NCT02732782|intervention
868339|NCT02732782|training load
868340|NCT02732782|high performance sports
868341|NCT02732756|ADHD
868342|NCT02732756|Sleep
868343|NCT02732756|Attention
868344|NCT02732756|Adolescence
868345|NCT02732743|childhod constipation
868346|NCT02732730|ART (Antir-retroviral therapy)
868347|NCT02732730|PrEP (Pre-Exposure Prophylaxis)
868348|NCT02732730|DAIDS (Division of AIDS)
868349|NCT02732730|HPTN (HIV Prevention Trials Network)
868350|NCT02732613|Laryngeal Mask Airway
868351|NCT02732613|Body weight
868352|NCT02732613|Complication
868359|NCT02732522|misoprostol
868360|NCT02732522|induction of labor
868361|NCT02732522|sublingual
868362|NCT02732496|Attention-Deficit/Hyperactivity Disorder
868363|NCT02732496|Tourette Syndrome
868364|NCT02732496|Working Memory Training
868365|NCT02732483|gastric cancer
868366|NCT02732483|bleeding
868367|NCT02732483|gastrointestinal hemorrhage
868368|NCT02732470|Systemic Lupus Erythematous
868369|NCT02732470|Qi Gong
868370|NCT02732470|Quality of life
868371|NCT02732457|HIV
868372|NCT02732457|Persistence
868373|NCT02732457|Reservoirs
868374|NCT02732457|Stem Cell Transplant
868375|NCT02732457|Functional Cure
868376|NCT02732444|Erythrocytes Membranes Stability
868377|NCT02732444|Oxidative Stress
868378|NCT02732444|Chronic Obstructive Pulmonary Disease (COPD)
868379|NCT02732444|Advanced Pulmonary Disease (APD)
868380|NCT02732444|Long-Term Home Oxygen Therapy (LTOT)
868381|NCT02732418|CI-contraceptive injection
868382|NCT02732418|DMPA-Depot medroxyprogesterone acetate
868383|NCT02732418|MPA-Medroxyprogesterone Acetate
868384|NCT02732418|subQ-subcutaneous
868385|NCT02732379|Postoperative Nausea and Vomiting
868386|NCT02732379|Aromatherapy
868387|NCT02732379|Quality of Health Care
868388|NCT02732366|aged [MeSH term]
868389|NCT02732366|exercise [MeSH term]
868390|NCT02732340|triple-branched stent graft
868391|NCT02732340|hemi-arch replace
868392|NCT02732340|the occluded rate of false lumen
868393|NCT02732275|Relapsed non-hodgkin lymphoma.
868394|NCT02732275|phase 1
868395|NCT02732275|oncology
868396|NCT02732262|acute pain
868397|NCT02732262|postoperative
868398|NCT02732262|surgery
868399|NCT02732249|Helicobacter pylori
868400|NCT02732249|Clarithromycin
868401|NCT02732249|Amoxicillin
868402|NCT02732249|Metronidazole
868403|NCT02732249|Eradication
868404|NCT02732236|marginal zone lymphoma
868405|NCT02732236|Cohort
868406|NCT02732236|Rituximab
868407|NCT02732236|HBV
868408|NCT02732223|Atherosclerosis
868409|NCT02732223|omega 3
868410|NCT02732223|plant sterols
868411|NCT02732223|polyphenols
868412|NCT02732184|AML
868413|NCT02732184|MDS
868414|NCT02732158|Novel laboratory methods
868415|NCT02732145|Three-Vulvar-Rings
868416|NCT02732145|Three-Rings-Vulvoscopy
868417|NCT02732145|N-S-P scheme
868418|NCT02732145|Vulvoscopy Index
868419|NCT02732145|Vulvar Dermatosis
868420|NCT02732145|Vulvar Lichen Sclerosus
868421|NCT02732145|Lichen Planus
868422|NCT02732145|Lichen Simplex Chronicus
868423|NCT02732145|Vulvodynia
868424|NCT02732145|Provoked Vestibulodynia
868425|NCT02732145|Vulvar Vestibulitis
868426|NCT02732145|Vulvar Diseases
868427|NCT02732119|HR-positive
868428|NCT02732119|HER2-negative
868429|NCT02732119|Advanced breast cancer
868430|NCT02732119|LEE011
868431|NCT02732119|ribociclib
868432|NCT02732119|everolimus
868433|NCT02732119|Afinitor
868434|NCT02732119|exemestane
868435|NCT02732119|Aromasin
868436|NCT02732119|CDK
868437|NCT02732119|CDK4
868438|NCT02732119|CDK6
868439|NCT02732119|CDK4/6
868440|NCT02732119|CDK4/6 inhibitor
868441|NCT02732119|Phase III
868442|NCT02732119|ER-positive
868443|NCT02732119|PR-positive
868444|NCT02732119|Postmenopausal
868445|NCT02732106|ADRCs, cell characterization
868576|NCT02731378|inadequately responsive
868446|NCT02732080|primary percutaneous coronary intervention
868447|NCT02732080|microvascular obstruction
868448|NCT02732080|myocardial edema
868449|NCT02732080|microvascular resistance
868450|NCT02732080|acute myocardial infarction
868451|NCT02732067|Anesthesia
868452|NCT02732054|HBV vaccination, immunity
868453|NCT02732015|Sarcoma
868454|NCT02732015|Locally advanced
868455|NCT02732015|High risk for relapse
868456|NCT02732015|Metastatic
868457|NCT02732015|Questionnaires
868458|NCT02732015|Surveys
868459|NCT02732015|Rolapitant
868460|NCT02732015|Fosaprepitant
868461|NCT02732015|Dexamethasone
868462|NCT02732015|Decadron
868463|NCT02732015|Ondansetron
868464|NCT02732015|Zofran
868465|NCT02732015|Doxorubicin
868466|NCT02732015|Adriamycin PFS
868467|NCT02732015|Adriamycin RDF
868468|NCT02732015|Rubex
868469|NCT02732015|Mesna
868470|NCT02732015|Mesnex
868471|NCT02732015|Ifosfamide
868472|NCT02732015|Ifex
868473|NCT02732015|Vincristine
868474|NCT02732015|Nausea
868475|NCT02732015|Vomiting
868476|NCT02732002|shoulder
868477|NCT02732002|rotator cuff- injury
868478|NCT02732002|management
868479|NCT02732002|rehabilitation model
868480|NCT02731976|Gluten-Free diet
868481|NCT02731976|Healthy individuals
868482|NCT02731963|Outcomes
868483|NCT02731963|Bowel preparation
868484|NCT02731950|Sternotomy , cardiac surgery , pain
868485|NCT02731924|Appendicitis
868486|NCT02731924|Ultrasound
868487|NCT02731924|Emergency Department
868491|NCT02731846|Efficacy
868492|NCT02731846|Triple therapy
868493|NCT02731846|Parallel
868494|NCT02731846|Respiratory
868495|NCT02731820|potassium citrate
868496|NCT02731807|TA-65
868497|NCT02731807|Telemorase
868498|NCT02731807|Dietary Supplement
868499|NCT02731794|cardiopulmonary bypass
868500|NCT02731794|coronary artery bypass grafting
868501|NCT02731794|inflammatory response
868502|NCT02731794|cardiac dysfunction
868503|NCT02731781|OUTCOME
868504|NCT02731781|PROGNOSIS
868505|NCT02731781|PEDIATRIC HEAd injury
868506|NCT02731781|CT SCAN
868507|NCT02731755|Oats
868508|NCT02731755|Phenolic acid
868509|NCT02731755|FMD
868510|NCT02731755|LDI
868511|NCT02731755|Renin angiotensin
868512|NCT02731755|Nitric oxide
868513|NCT02731729|Ipilimumab
868514|NCT02731729|Nivolumab
868515|NCT02731729|Stage III-IV Melanoma
868516|NCT02731729|Progressed or Relapsed on PD-1 Inhibitor Therapy
868517|NCT02731729|16-043
868518|NCT02731703|overdenture
868519|NCT02731703|overlay
868520|NCT02731703|implant supported
868521|NCT02731703|denture
868522|NCT02731703|dental prosthesis
868523|NCT02731703|maxillary
868524|NCT02731690|GNE Myopathy
868525|NCT02731690|Nonaka
868526|NCT02731690|GNEM
868527|NCT02731690|Hereditary Inclusion Body Myopathy
868528|NCT02731690|HIBM
868529|NCT02731690|DMRV
868530|NCT02731690|QSM
868531|NCT02731664|Irritable bowel syndrome
868532|NCT02731664|Functional dyspepsia
868533|NCT02731664|Gastric emptying
868534|NCT02731664|Gastrointestinal peptide hormones
868535|NCT02731638|cornea
868536|NCT02731638|ulcer
868537|NCT02731638|fungal
868538|NCT02731638|keratitis
868539|NCT02731625|Kettlebell training
868540|NCT02731625|High-intensity interval training
868541|NCT02731612|Bipolar Disorder
868542|NCT02731612|Cognition
868543|NCT02731612|Euthymic
868544|NCT02731612|Lurasidone
868545|NCT02731599|Parkinson Disease
868546|NCT02731599|treadmill
868547|NCT02731599|Rehabilitation
868548|NCT02731586|Dental Implants
868549|NCT02731586|Allogenic mesenchymal stem cells
868550|NCT02731586|osseointegration
868551|NCT02731586|primary stability
868552|NCT02731586|resonance frequency analysis
868553|NCT02731586|RFA
868554|NCT02731586|implants and stem cells
868555|NCT02731586|use of stem cells
868556|NCT02731586|stem cells
868557|NCT02731573|Mediastenitis
868558|NCT02731560|Pakistan, Rituximab
868559|NCT02731560|RA
868560|NCT02731521|MRS Biomarkers
868561|NCT02731508|Transcranial Direct Current Stimulation
868562|NCT02731508|Neuroplasticity
868563|NCT02731482|Bronchiectasis
868564|NCT02731482|Rehabilitation
868565|NCT02731482|Quality of Life
868566|NCT02731482|Physiotherapy Specialty
868567|NCT02731456|high altitude
868568|NCT02731456|cognition
868569|NCT02731456|sleep
868570|NCT02731443|dreaming
868571|NCT02731443|epilepsy
868572|NCT02731443|neurosurgery
868573|NCT02731443|temporal lobectomy
868574|NCT02731378|erythropoietin
868575|NCT02731378|iron supplementation
868577|NCT02731378|chemotherapy-induced anaemia
868578|NCT02731365|Parkinson's Disease
868579|NCT02731300|Transcranial direct current stimulation
868580|NCT02731300|Cathodal stimulation
868581|NCT02731300|Childhood Pharmacoresistant epilepsy
868582|NCT02731300|Lennox-Gastaut syndrome
868583|NCT02731235|Stroke
868584|NCT02731235|stroke, acute
868585|NCT02731235|Cerebral small vessel disease
868586|NCT02731222|CEAP clasification, CVI:Chronic venous insufficiency,
868587|NCT02731222|CVD: Chronic venous disease , PTS: Posthrombotic syndrome,
868588|NCT02731222|Deep venous system, VH venous hipertension
868589|NCT02731222|Superficial venous system
868590|NCT02731222|Onychodystrophy
868591|NCT02731196|exercise
868592|NCT02731196|lumbar microdiscectomy
868593|NCT02731183|Fecal Microbiota Transplantation
868594|NCT02731183|Chronic intestinal pseudo obstruction
868595|NCT02731183|Efficacy and safety
868596|NCT02731170|Parkinson Disease
868597|NCT02731170|Advanced Stages
868598|NCT02731170|Rehabilitation
868599|NCT02731144|Loss of Physical Function
868600|NCT02731118|glaucoma
868601|NCT02731118|intraocular pressure lowering treatment
868602|NCT02731118|antisectory factor (AF)
868603|NCT02731118|Salovum
868604|NCT02731105|acne
868605|NCT02731105|vulgaris
868606|NCT02731105|Clindamycin
868607|NCT02731105|Tretinoin
868608|NCT02731105|Adapalen
868609|NCT02731105|Benzoylperoxid
868610|NCT02731105|Epiduo
868611|NCT02731105|Acnatac
868612|NCT02731092|lactoferrin
868613|NCT02731092|very low birth weight infants
868614|NCT02731092|preterm infants
868615|NCT02731079|Sleeve gastrectomy stapler Covidien Ethicon bleeding leak
868616|NCT02731053|Depression
868617|NCT02731053|Prevention
868618|NCT02731053|Adolescents
868619|NCT02731053|School
868620|NCT02731053|Effectiveness
868621|NCT02731014|Dry Needling
868622|NCT02730975|pharmacokinetics
868623|NCT02730975|food-effect
868624|NCT02730975|fat diet
868625|NCT02730975|abiraterone acetate
868626|NCT02730949|D-Chiro-Inositol, type 1 diabetes
868627|NCT02730923|Clinical Trials, Randomized
868628|NCT02730923|Clinical Trial, Phase I
868629|NCT02730923|Clinical Trial, Phase II
868630|NCT02730923|Multicenter Trials
868631|NCT02730923|Aromatase Inhibitors
868632|NCT02730923|mTOR kinase inhibitor
868633|NCT02730910|Bioavailability
868634|NCT02730910|adults
868635|NCT02730897|Surgery
868636|NCT02730897|Thoracotomy
868637|NCT02730897|VATS
868638|NCT02730884|Leukemia
868639|NCT02730884|Myelofibrosis
868640|NCT02730884|MF
868641|NCT02730884|Anemia
868642|NCT02730884|Splenomegaly
868643|NCT02730884|Post-polycythemia vera MF
868644|NCT02730884|post-PV
868645|NCT02730884|post-essential thrombocythemia MF
868646|NCT02730884|post-ET
868647|NCT02730884|Rigosertib
868648|NCT02730884|ON 01910.Na
868649|NCT02730884|Questionnaire
868650|NCT02730884|Survey
868651|NCT02730858|Metastatic Breast Cancer
868652|NCT02730858|Palliative Care
868653|NCT02730858|Breast Cancer
868654|NCT02730858|End of life
868655|NCT02730858|Health service research
868656|NCT02730845|Elective
868657|NCT02730845|local anesthesia
868658|NCT02730845|knee arthroscopy
868659|NCT02730845|Dexmedetomidine
868660|NCT02730793|Cystic Fibrosis
868661|NCT02730793|P. aeruginosa (PA)
868662|NCT02730754|Mood Disorders
868663|NCT02730754|Illness Perception
868664|NCT02730754|Primary Care
868665|NCT02730754|Medication Adherence
868666|NCT02730741|diarrhoea
868667|NCT02730741|metfomin
868668|NCT02730741|type 2 diabetes
868669|NCT02730741|microbiota
868670|NCT02730728|adductor canal block
868671|NCT02730728|tinetti score
868672|NCT02730728|time to up and go test
868673|NCT02730728|Ambulation distance
868674|NCT02730728|pain score
868675|NCT02730728|quality of recovery score
868676|NCT02730689|DP-R207
868677|NCT02730689|Rosuvastatin
868678|NCT02730689|Ezetimibe
868679|NCT02730676|electronic cigarettes
868680|NCT02730676|e-cigarette
868681|NCT02730676|combustible cigarette
868682|NCT02730676|cigarette
868683|NCT02730676|menthol
868684|NCT02730676|cig-alike
868685|NCT02730676|subjective measures
868686|NCT02730676|pharmacokinetics
868687|NCT02730676|craving
868688|NCT02730663|Endoscopic ultrasound guided transluminal drainage
868689|NCT02730650|FACE-Q
868690|NCT02730650|Platelet Rich Therapy
868691|NCT02730650|PRT
868692|NCT02730624|piperacillin/tazobactam
868693|NCT02730624|critically ill
868694|NCT02730624|severe sepsis
868695|NCT02730624|septic shock
868696|NCT02730611|Vertical sleeve gastrectomy
868697|NCT02730611|Metabolic syndrome
868698|NCT02730611|Disorder of Bile Acid and Cholesterol Metabolism
868699|NCT02730611|Cholangiocarcinoma
868700|NCT02730611|Hepatocellular carcinoma
868701|NCT02730585|C-reactive protein
868702|NCT02730572|Attention Deficit Hyperactivity Disorder
868703|NCT02730572|Methylphenidate
868704|NCT02730559|Motivational Interviewing
868705|NCT02730533|endoscopic submucosal dissection
868706|NCT02730533|proton pump inhibitor
868707|NCT02730533|bleeding
868708|NCT02730520|respiratory disease
868709|NCT02730520|allergen sensitization
868710|NCT02730520|aging
868711|NCT02730520|skin tests
868712|NCT02730520|air allergens
868713|NCT02730494|mycosis
868714|NCT02730494|Candidiasis
868715|NCT02730494|Lcr35®
868716|NCT02730494|Lcr Regenerans®
868717|NCT02730455|Stroke
868718|NCT02730351|Fluticasone furoate
868719|NCT02730351|activity monitoring
868720|NCT02730351|Vilanterol
868721|NCT02730351|Cross-over
868722|NCT02730351|exercise-induced bronchoconstriction
868723|NCT02730351|exercise challenge
868724|NCT02730351|double-dummy
868725|NCT02730351|asthma
868726|NCT02730351|spirometry
868727|NCT02730351|fluticasone propionate
868728|NCT02730338|Castrate-Resistant
868729|NCT02730325|CDI
868730|NCT02730325|C. diff
868731|NCT02730325|Ulcerative Colitis
868732|NCT02730325|UC
868733|NCT02730325|IBD
868734|NCT02730325|Inflammatory Bowel Disease
868735|NCT02730312|AML
868736|NCT02730312|B-ALL
868737|NCT02730312|BPDCN
868738|NCT02730312|CML
868739|NCT02730312|Blast Crisis
868740|NCT02730286|human activity
868741|NCT02730286|International Classification of Functioning
868742|NCT02730260|Directive coaching
868743|NCT02730260|Nondirective coaching
868744|NCT02730260|smoking cessation quitline
868745|NCT02730260|social support
868746|NCT02730247|ramucirumab
868747|NCT02730247|docetaxel
868748|NCT02730221|Administrative workload
868749|NCT02730221|Patient data management system
868750|NCT02730221|Intensive Care Unit
868751|NCT02730221|Work sampling method
868752|NCT02730221|Nursing Activity Score
868753|NCT02730182|postural control
868754|NCT02730182|high altitude
868758|NCT02730143|Altitude
868759|NCT02730143|Nocturnal breathing pattern
868760|NCT02730130|Pembrolizumab
868761|NCT02730130|Radiotherapy
868762|NCT02730130|16-032
868763|NCT02730117|Acute kidney injury
868764|NCT02730117|Furosemide stress test
868765|NCT02730117|critical care
868766|NCT02730078|Mood Disorders
868767|NCT02730078|Self Care
868768|NCT02730078|Primary Care
868769|NCT02730065|Cerebral small vessel disease
868770|NCT02730065|Lifestyle modification
868771|NCT02730065|Physical activity
868772|NCT02730065|Primary prevention
868773|NCT02730065|Aerobic dance
868774|NCT02730065|Cognition
868775|NCT02730065|Depression
868776|NCT02730065|Activities of daily living
868777|NCT02730065|Cerebral autoregulation
868778|NCT02730052|Blood pressure control
868779|NCT02730052|Hypertension
868780|NCT02730052|Office blood pressure
868781|NCT02730052|Self-measured blood pressure,
868782|NCT02730052|Telemonitoring
868783|NCT02730039|Cancer Care Providers
868784|NCT02730039|Psychotherapy
868785|NCT02730039|15-321
868786|NCT02730026|Ketofrofen
868787|NCT02730026|Omeprazole
868788|NCT02730026|Lower Third Molar
868789|NCT02730026|Oral Surgery
868790|NCT02730013|Older adults
868791|NCT02730013|Square stepping exercise
868792|NCT02730013|Mind-motor exercise
868793|NCT02730013|Long-term care
868794|NCT02730013|Global cognitive functioning
868795|NCT02730000|Dental Atraumatic Restorative Treatment
868796|NCT02730000|Primary Teeth
868797|NCT02730000|Clinical Efficacy
868798|NCT02730000|Cost Analysis
868799|NCT02730000|Glass Ionomer Cement
868800|NCT02729987|online
868801|NCT02729987|internet
868802|NCT02729987|CBT
868803|NCT02729987|Stress
868804|NCT02729987|Work
868805|NCT02729987|Internet based treatment
868806|NCT02729974|thromboelastography
868807|NCT02729935|Parecoxib
868808|NCT02729935|Bladder Discomfort
868809|NCT02729909|Drug therapy
868810|NCT02729870|Ketones
868811|NCT02729870|Gastroenteritis
868812|NCT02729844|Incidence
868813|NCT02729844|Risk factors
868814|NCT02729844|Outcome
868815|NCT02729831|decision making
868816|NCT02729831|decision aids
868817|NCT02729831|decision quality instruments
868818|NCT02729831|osteoarthritis
868819|NCT02729831|shared decision making
868820|NCT02729818|Retina
868821|NCT02729818|Microperimetry
868822|NCT02729818|Visual Fields
868823|NCT02729805|ketamine
868824|NCT02729805|chronic pain
868825|NCT02729805|mastectomy
868826|NCT02729805|acute pain
868827|NCT02729792|depression
868828|NCT02729792|treatment resistance
868829|NCT02729792|biomarkers
868830|NCT02729792|repetitive transcranial magnetic stimulation
868831|NCT02729766|Hyponatremia
868832|NCT02729766|SGLT2 inhibitor
868833|NCT02729740|Penumbra Smart coils
868834|NCT02729740|PC 400
868835|NCT02729740|AV malformations
868836|NCT02729740|AV fistulae
868837|NCT02729688|Venous insufficiency
868838|NCT02729688|Compression
868839|NCT02729688|Bandaging
868840|NCT02729675|fruit & vegetable, market, education, worksite, food access
868841|NCT02729597|neuromuscular disorders
868842|NCT02729597|MRI
868843|NCT02729597|white matter
868844|NCT02729597|brain
868845|NCT02729597|myotonic dystrophy
868846|NCT02729558|brain metastases
868847|NCT02729558|radiotherapy
868848|NCT02729558|resection
868849|NCT02729545|acupuncture, POCS
868854|NCT02729506|hepatocellular carcinoma
868855|NCT02729506|transarterial radioembolization
868981|NCT02728726|Neuromuscular Agents
868856|NCT02729506|chemoembolization chemoembolization
868857|NCT02729506|clinical trial
868858|NCT02729493|Liver Cancer CAR-T
868859|NCT02729467|Healthy
868860|NCT02729467|JNJ-53718678
868861|NCT02729467|Itraconazole
868862|NCT02729467|Rifampicin
868863|NCT02729467|Pharmacokinetics
868864|NCT02729428|Aging
868865|NCT02729428|White Matter Hyperintensity Volume
868866|NCT02729428|Default Mode Network Connectivity
868867|NCT02729428|Cognitive Function
868868|NCT02729428|Cardiorespiratory Fitness
868869|NCT02729428|Magnetic Resonance Imaging
868870|NCT02729415|Hair Diseases
868871|NCT02729415|Alopecia
868872|NCT02729402|Adults
868873|NCT02729389|Social Status
868874|NCT02729389|Hispanics
868875|NCT02729389|Energy Balance
868876|NCT02729389|Stress
868877|NCT02729376|Healthy Volunteers
868878|NCT02729337|technology
868879|NCT02729337|adolescent
868880|NCT02729337|developing country
868881|NCT02729337|hiv prevention
868882|NCT02729337|mHealth
868883|NCT02729324|nasopharyngeal carcinoma (NPC)
868884|NCT02729324|radiation dermatitis
868885|NCT02729324|intensity modulated radiation therapy (IMRT)
868886|NCT02729311|exercise
868887|NCT02729311|function
868888|NCT02729311|quality of life
868889|NCT02729311|caregiver
868890|NCT02729298|Tolero
868891|NCT02729298|Phase 1
868892|NCT02729298|First in human
868893|NCT02729298|Solid Tumors
868894|NCT02729298|AXL inhibitor
868895|NCT02729298|Advanced Malignancy
868896|NCT02729298|Cancer
868897|NCT02729259|VRD
868898|NCT02729233|mucosal barrier function
868899|NCT02729220|Aging
868900|NCT02729220|Oxidative stress
868901|NCT02729220|Proteases
868902|NCT02729220|Bronchoscopy
868903|NCT02729207|NSAID Patch
868904|NCT02729168|Rabies
868905|NCT02729168|Vaccine
868906|NCT02729168|Safety
868907|NCT02729168|INDIRAB
868908|NCT02729168|Vietnam
868909|NCT02729155|Ischemic Preconditioning
868910|NCT02729155|Postconditioning
868911|NCT02729155|Angioplasty
868912|NCT02729155|Angiography
868913|NCT02729155|Contrast-Induced Nephropathy
868914|NCT02729142|HRpQCT
868915|NCT02729142|transplant
868916|NCT02729142|bone microarchitecture
868917|NCT02729129|Diesel exhaust
868918|NCT02729129|Air pollution
868919|NCT02729129|Intervention
868920|NCT02729129|Plethysmography
868921|NCT02729116|Extended-Spectrum ß-lactamase-producing Escherichia coli
868922|NCT02729116|Extended-Spectrum ß-lactamase-producing Klebsiella pneumoniae
868923|NCT02729116|Kidney Transplantation
868924|NCT02729116|Urinary Tract Infections
868925|NCT02729090|Peripheral Arterial Disease, exercise
868926|NCT02729064|Intranasal Insulin
868927|NCT02729064|Insulin concentration
868928|NCT02729064|Blood glucose
868929|NCT02729064|Cerebro Spinal Fluid insulin
868930|NCT02729064|Intraoperative blood glucose
868931|NCT02729064|Cardiac Surgery
868932|NCT02729064|Thoracic Surgery
868933|NCT02729051|Chronic Obstructive Pulmonary Disease (COPD)
868934|NCT02729051|fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI)
868935|NCT02729051|Umeclidinium bromide (UMEC)
868936|NCT02729051|Closed triple therapy
868937|NCT02729051|Placebo
868938|NCT02729051|Open triple therapy
868939|NCT02729051|fluticasone furoate/vilanterol (FF/VI)
868940|NCT02729038|Normal Renal Function
868941|NCT02729038|end stage renal disease (ESRD)
868942|NCT02729038|Pharmacokinetics
868943|NCT02729038|Gepotidacin
868944|NCT02729038|Renal Impairment
868945|NCT02729025|Hyperlipidemia
868946|NCT02729025|Dyslipidemia
868947|NCT02729025|Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition
868948|NCT02729025|Arterial Wall Inflamation
868949|NCT02729025|Elevated lipoprotein a
868950|NCT02729012|Children
868951|NCT02728999|Trendelenburg position
868952|NCT02728999|Robotic assisted gynecologic procedures
868953|NCT02728999|benign gynecologic conditions
868954|NCT02728986|Costs and Cost Analysis
868955|NCT02728986|Humans
868956|NCT02728986|Health Care Costs
868957|NCT02728986|varicose ulcer
868958|NCT02728986|Compression Bandages
868959|NCT02728973|colorectal resection
868960|NCT02728973|enhanced recovery after surgery
868961|NCT02728973|Postoperative Complications
868962|NCT02728973|length of hospital stay
868963|NCT02728947|Parkinson's Disease
868964|NCT02728934|Rheumatoid Arthritis
868965|NCT02728934|Golimumab
868966|NCT02728934|Infliximab
868967|NCT02728895|Drug Therapy
868968|NCT02728882|Lymphoma CAR-T
868971|NCT02728830|gynecologic cancers
868972|NCT02728830|mullerian cancers
868973|NCT02728830|tumoral immunoprofile
868974|NCT02728817|Vascular access
868975|NCT02728817|Hemodialysis
868976|NCT02728817|Arteriovenous fistula
868977|NCT02728817|Stenosis
868978|NCT02728817|Failure
868979|NCT02728752|DM
868980|NCT02728726|Postoperative respiratory depression
868982|NCT02728713|Cranial manipulation
868983|NCT02728713|Visual function
868984|NCT02728687|peripheral neuropathy
868985|NCT02728687|Diabetes
868986|NCT02728687|Pain
868987|NCT02728674|COPD
868988|NCT02728674|Breathlessness
868989|NCT02728674|Symptom
868990|NCT02728674|Opioids
868991|NCT02728674|Gender bias
868992|NCT02728648|Pain Management
868993|NCT02728648|Pharmacokinetics
868994|NCT02728648|Pharmacodynamics
868995|NCT02728635|Adipose tissue, epigenetic, abdominal gluteal fat
868996|NCT02728622|ovarian cancer
868997|NCT02728622|platinum-resistant
868998|NCT02728622|endocrine treatment
868999|NCT02728622|chemotherapy
869000|NCT02728622|tamoxifen
869001|NCT02728583|Plant sterols
869002|NCT02728583|Fish oil
869003|NCT02728583|Blood lipids
869004|NCT02728570|flavonoids
869005|NCT02728570|insulin resistance
869006|NCT02728570|plasma lipids
869007|NCT02728570|intestinal microbiome
869008|NCT02728570|intestinal inflammation
869009|NCT02728570|subclinical inflammation
869010|NCT02728557|Therapeutic alliance
869011|NCT02728557|Psychotherapy
869012|NCT02728557|Psychodynamic psychotherapy
869013|NCT02728557|supportive-expressive treatment
869014|NCT02728557|Process research
869015|NCT02728557|Attachment theory
869016|NCT02728557|Attachment orientation
869017|NCT02728557|Mechanism of change in psychotherapy
869018|NCT02728466|flavanols
869019|NCT02728466|cocoa procyanidins
869020|NCT02728466|vascular function
869021|NCT02728466|endothelial function
869022|NCT02728427|Suprapubic Catheterization
869023|NCT02728427|Transurethral Catheterization
869024|NCT02728427|Rectal Cancer
869025|NCT02728427|Laparoscopic Surgery
869026|NCT02728414|Diabetes Mellitus, Type 2, Probiotics, Treatment
869027|NCT02728401|inflammation
869028|NCT02728401|sepsis
869029|NCT02728401|pediatric
869030|NCT02728401|transcripts
869031|NCT02728401|serum proteins
869032|NCT02728401|cardiopulmonary bypass
869033|NCT02728388|NF1
869034|NCT02728388|Neurofibroma
869035|NCT02728388|Neurofibromatosis Type 1
869036|NCT02728362|tibial shaft fractures
869037|NCT02728284|Magnetic Resonance Imaging (MRI)
869038|NCT02728219|Recurrent Hepatocellular Carcinoma
869039|NCT02728219|transcatheter arterial chemoembolization
869040|NCT02728219|AFP conversion
869041|NCT02728193|treatments
869042|NCT02728193|hepatocellular carcinoma
869043|NCT02728180|Acute Ischemic Stroke
869044|NCT02728180|Xingnaojing injection
869045|NCT02728180|Randomized Controlled Trial
869046|NCT02728180|Traditional Chinese Medicine
869047|NCT02728167|Hepatectomy
869048|NCT02728167|Liver metastasis
869049|NCT02728167|High-Intensity Focused Ultrasound
869050|NCT02728167|Liver metastases (LM) requiring surgery
869051|NCT02728154|pre-clinical diastolic dysfunction (pre-HFpEF)
869052|NCT02728128|Milrinone
869053|NCT02728115|Huntington's Disease
869054|NCT02728115|Stem Cell
869055|NCT02728115|Dental Pulp Stem Cells
869056|NCT02728102|Multiple Myeloma
869057|NCT02728102|Lenalidomide
869058|NCT02728102|Maintenance Therapy
869059|NCT02728102|Hematologic Disorders
869060|NCT02728102|Vaccine
869061|NCT02728102|GM-CSF
869062|NCT02728102|Transplant
869063|NCT02728102|Anti-Myeloma Agents
869064|NCT02728076|Breast Cancer
869065|NCT02728076|Accelerated Partial Breast Irradiation
869066|NCT02728037|Myofascial Trigger Points
869067|NCT02728037|Myofascial Pain
869068|NCT02728037|Intramuscular Anesthetic Injection
869069|NCT02727998|PTSD
869070|NCT02727972|depression
869071|NCT02727972|bipolar
869072|NCT02727972|post-traumatic stress disorder
869073|NCT02727972|mood disorders
869074|NCT02727972|PET
869075|NCT02727972|mGluRr
869076|NCT02727972|glutamate system
869077|NCT02727972|MRI
869078|NCT02727959|UC
869079|NCT02727959|CD
869080|NCT02727959|IBD
869081|NCT02727894|Screening
869082|NCT02727894|pTNM
869083|NCT02727894|Metastasis
869084|NCT02727894|Chemotherapy
869085|NCT02727894|Resection Margins
869086|NCT02727881|AMD, CNV, choroidal neovascularization, retinal eye disease
869087|NCT02727855|Cholera
869088|NCT02727855|Vaccine
869089|NCT02727855|Strategy
869090|NCT02727803|Acute Myelogenous Leukemia
869091|NCT02727803|AML
869092|NCT02727803|Myelodysplastic syndrome
869093|NCT02727803|MDS
869094|NCT02727803|Multiple myeloma
869095|NCT02727803|MM
869096|NCT02727803|Umbilical cord blood transplant
869097|NCT02727803|UCB
869098|NCT02727803|Natural killer cells
869099|NCT02727803|NK
869100|NCT02727803|Busulfan
869101|NCT02727803|Busulfex
869102|NCT02727803|Myleran
869103|NCT02727803|Fludarabine
869104|NCT02727803|Fludarabine Phosphate
869105|NCT02727803|Fludara
869106|NCT02727803|Clofarabine
869107|NCT02727803|Clofarex
869108|NCT02727803|Clolar
869109|NCT02727803|Rabbit ATB
869110|NCT02727803|ATG (Rabbit)
869111|NCT02727803|Rabbit Antithymocyte Globulin
869112|NCT02727803|Rabbit Antilymphocyte Globulin
869113|NCT02727803|rATG Thymoglobulin
869114|NCT02727803|Total Body Irradiation
869115|NCT02727803|TBI
869116|NCT02727803|Radiation therapy
869117|NCT02727803|XRT
869118|NCT02727803|Rituximab
869119|NCT02727803|Rituxan
869120|NCT02727803|Cyclophosphamide
869121|NCT02727803|Cytoxan
869122|NCT02727803|Neosar
869123|NCT02727803|Melphalan
869124|NCT02727803|Alkeran
869125|NCT02727777|Lymphoma
869126|NCT02727777|Relapsed Lymphoma
869127|NCT02727777|MLN0128
869128|NCT02727777|Blood sugar
869129|NCT02727777|Glucometer
869130|NCT02727777|TK228
869135|NCT02727738|Hyperthyroidism
869136|NCT02727738|Methimazole
869137|NCT02727738|Selenium
869138|NCT02727712|coronary artery bypass graft
869139|NCT02727712|thoracic paravertebral block
869140|NCT02727699|Mild Dementia
869141|NCT02727699|Actinogen
869142|NCT02727699|Alzheimer's Disease
869143|NCT02727699|Xanamem
869144|NCT02727699|Cortisol
869145|NCT02727699|UE2343
869146|NCT02727699|XanADu
869147|NCT02727686|transsphenoidal pituitary surgery
869148|NCT02727673|cancer stem cells
869149|NCT02727660|COPD
869150|NCT02727647|Moderate hemophilia A
869151|NCT02727647|Severe hemophilia A
869152|NCT02727647|Intermediate dose prophylaxis
869153|NCT02727647|Low dose prophylaxis
869154|NCT02727634|Hemodynamics
869155|NCT02727634|Echocardiography, Doppler, Pulsed
869156|NCT02727621|Dexmedetomidine
869157|NCT02727621|Cardiac
869158|NCT02727621|Coronary Artery Bypass Grapht
869159|NCT02727621|Sedation
869160|NCT02727621|Propofol
869161|NCT02727621|Intravenous Anesthetics
869162|NCT02727582|MDR
869163|NCT02727556|skin conductance response
869164|NCT02727556|facial muscle activity
869165|NCT02727556|heart rate variability
869166|NCT02727556|eyetracking
869167|NCT02727543|Hypertension
869168|NCT02727543|mHealth
869169|NCT02727543|Medication Non-adherence
869170|NCT02727530|Infant Colic
869171|NCT02727530|Manual Therapy
869172|NCT02727530|Effectiveness
869173|NCT02727517|Resuscitation
869174|NCT02727517|Cord clamping
869175|NCT02727504|Aortic valve stenosis
869176|NCT02727504|low flow
869177|NCT02727504|dobutamine stress echocardiography
869178|NCT02727491|opioid analgesics,
869179|NCT02727491|opioid consumption
869180|NCT02727491|adverse effects
869181|NCT02727491|postoperative pain
869182|NCT02727491|tonsillectomy
869183|NCT02727478|Balance
869184|NCT02727478|Rehabilitation
869185|NCT02727478|Exercise
869186|NCT02727478|basal ganglia
869187|NCT02727478|Gait
869188|NCT02727478|Training
869189|NCT02727478|physical activity
869190|NCT02727439|microvascular function
869191|NCT02727439|laser Doppler flowmetry
869192|NCT02727439|exercise
869193|NCT02727426|microvascular function
869194|NCT02727426|laser Doppler flowmetry
869195|NCT02727426|high salt diet
869196|NCT02727374|Fear to Fall
869197|NCT02727374|Geriatric
869198|NCT02727374|Rehabilitation
869199|NCT02727374|Psychology
869200|NCT02727361|Dystonia
869201|NCT02727361|Binding potential
869202|NCT02727361|FEOBV
869203|NCT02727348|femoral sciatic block spinal diabetic foot haemodynamic pain
869204|NCT02727335|Non-squamous non-small cell lung cancer
869205|NCT02727335|crizotinib
869206|NCT02727309|Apatinib
869207|NCT02727309|Second-line Treatment
869208|NCT02727309|Hepatocellular Cancer
869209|NCT02727309|TACE
869210|NCT02727283|Healthy volunteer
869211|NCT02727283|Safety
869212|NCT02727283|Pharmacokinetics
869213|NCT02727283|Dose escalation
869214|NCT02727283|GSK3179106
869215|NCT02727283|Rearranged during Transfection
869216|NCT02727283|Irritable Bowel Syndrome
869217|NCT02727283|Adults
869218|NCT02727270|Movement disorders
869219|NCT02727270|Metabolic Stress
869220|NCT02727257|Parkinson's disease
869221|NCT02727257|rehabilitation
869222|NCT02727257|attention
869223|NCT02727257|executive functions
869224|NCT02727244|Pain Catastrophizing Scale
869225|NCT02727231|closed loop glucose control
869226|NCT02727231|hypoglycemia
869227|NCT02727231|type 1 diabetes
869228|NCT02727231|HbA1C<7.5%
869229|NCT02727166|intestinal gas
869230|NCT02727166|functional gut symptoms
869231|NCT02727166|intestinal sensitivity
869232|NCT02727166|intestinal motility
869233|NCT02727153|Colonic cancer
869234|NCT02727153|E.R.A.S. programs
869235|NCT02727153|Safety
869236|NCT02727114|skin thickness
869237|NCT02727114|high-frequency ultrasound
869238|NCT02727101|Focal epilepsy, Perampanel
869239|NCT02727088|Dental Pulp Disease
869240|NCT02727088|Endodontics
869241|NCT02727088|Pulp Capping
869242|NCT02727088|Pulpotomy
869243|NCT02727088|Pulpectomy
869244|NCT02727075|Occult Gastrointestinal Bleeding
869245|NCT02727075|Iron Deficiency Anemia
869246|NCT02727075|Aged 75 Years and Older
869247|NCT02727062|pain
869248|NCT02727062|radiation
869249|NCT02727062|head and neck cancer
869250|NCT02727062|smartphone pain app
869251|NCT02727062|OM Pain App
869252|NCT02727023|Healthy
869253|NCT02727010|Motor disability
869254|NCT02727010|Motor impairment
869255|NCT02727010|Pregnancy
869256|NCT02727010|Parenthood
869257|NCT02727010|Child psychology
869258|NCT02726997|Malignant neoplasms of female genital organs
869259|NCT02726997|Ovarian Cancer
869260|NCT02726997|Primary Peritoneal Carcinoma
869261|NCT02726997|Fallopian Tube Cancer
869262|NCT02726997|High-grade epithelial non-mucinous ovarian cancer
869263|NCT02726997|Laparoscopy surgery
869264|NCT02726997|Durvalumab
869265|NCT02726997|MEDI4736
869266|NCT02726997|Carboplatin
869267|NCT02726997|Paraplatin
869268|NCT02726997|Paclitaxel
869269|NCT02726997|Taxol
869270|NCT02726984|stroke
869271|NCT02726984|carotid plaque
869272|NCT02726984|18F-sodium fluoride PET/MR
869273|NCT02726971|Intrauterine Adhesion
869274|NCT02726971|Oestrogen Artificial Periodic Therapy
869275|NCT02726958|aortic valve replacement
869276|NCT02726958|percutaneous valve
869277|NCT02726958|blood glucose variability
869278|NCT02726958|TAVI
869279|NCT02726932|Peritonitis
869280|NCT02726932|Inflammatory Markers
869281|NCT02726932|Patient Outcome Assessment
869282|NCT02726932|Classification
869283|NCT02726932|Multiple Organ Failure
869284|NCT02726932|Intraabdominal Infections
869285|NCT02726919|focal epilepsy
869286|NCT02726919|clobazam
869287|NCT02726906|Alzheimer's disease
869288|NCT02726906|Mild Cognitive Impairment
869289|NCT02726906|Brain Imaging
869290|NCT02726867|refractory status epilepticus
869291|NCT02726867|levetiracetam
869292|NCT02726867|lacosamide
869293|NCT02726867|ketamine
869294|NCT02726841|Thoracic aorta
869295|NCT02726841|Abdominal aorta
869296|NCT02726841|Stents
869297|NCT02726789|nucleic acid polymer REP 2139 HBsAg hepatitis B
869298|NCT02726763|Transcranial Direct Current Stimulation (tDCS)
869299|NCT02726763|Cognitive Training
869300|NCT02726763|16-034
869301|NCT02726750|Monoclonal gammopathy of unknown significance
869302|NCT02726750|MGUS
869303|NCT02726750|Smoldering multiple myeloma
869304|NCT02726750|SMM
869305|NCT02726750|Asymptomatic monoclonal gammopathies
869306|NCT02726750|Biomarker testing
869307|NCT02726750|Blood collection
869308|NCT02726750|Blood draw
869309|NCT02726737|inferior alveolar nerve block
869310|NCT02726737|irreversible pulpitis
869311|NCT02726737|local anesthesia
869312|NCT02726737|sodium bicarbonate
869313|NCT02726724|Stress-Resident performance-Observers
869314|NCT02726685|respiratory training
869315|NCT02726685|functional performance
869316|NCT02726672|inspiratory muscles
869317|NCT02726672|multiple sclerosis
869318|NCT02726672|rehabilitation
869319|NCT02726646|Local Drug Delivery
869320|NCT02726646|Antibiotics
869321|NCT02726646|Doxycycline
869322|NCT02726646|Smokers
869323|NCT02726646|Chronic Periodontitis
869324|NCT02726620|Decision support
869325|NCT02726620|Decision Support Systems, Clinical
869452|NCT02725918|EGFR-TKI failure
869326|NCT02726620|Decision Support Techniques
869327|NCT02726620|Hypotension
869328|NCT02726620|Intraoperative Hypotension
869329|NCT02726620|Acute Kidney Injury
869330|NCT02726620|Postoperative Myocardial Injury
869331|NCT02726620|Postoperative Mortality
869332|NCT02726620|Blood Pressure
869333|NCT02726607|Prevention of mother-to-child transmission (PMTCT)
869334|NCT02726607|Kenya
869335|NCT02726607|HITSystem 2.0
869336|NCT02726607|retention through PMTCT cascade of care
869337|NCT02726607|Early Infant Diagnosis
869338|NCT02726607|eHealth system-level intervention
869339|NCT02726594|Magnetic Resonance Imaging, Patient Satisfaction
869340|NCT02726568|EGFR-TKI
869341|NCT02726568|NSCLC
869342|NCT02726568|Icotinib
869343|NCT02726555|Red yeast rice
869344|NCT02726555|Atorvastatin
869345|NCT02726555|Mild cardiovascular disease
869346|NCT02726542|obesity
869347|NCT02726542|adolescence
869348|NCT02726542|fatty liver
869349|NCT02726542|growth hormone
869350|NCT02726516|Performance
869351|NCT02726503|anaplastic thyroid cancer, lenvatinib
869352|NCT02726490|gestational diabetes, pregnancy, diabetes
869353|NCT02726464|Platelet-rich Plasma
869354|NCT02726464|Cell-Derived Microparticles
869355|NCT02726464|Pain Management
869356|NCT02726464|Blood Platelets
869357|NCT02726464|Therapeutics
869358|NCT02726464|Inflammation
869359|NCT02726464|ThromboLUX
869360|NCT02726464|Dynamic Light Scattering
869361|NCT02726399|Ramucirumab
869362|NCT02726399|Trastuzumab
869363|NCT02726399|Capecitabine
869364|NCT02726399|Cisplatin
869365|NCT02726399|HER2-Positive
869366|NCT02726399|15-301
869367|NCT02726360|Communication
869368|NCT02726360|15-316
869369|NCT02726360|Physician
869370|NCT02726360|Use
869371|NCT02726360|Non-English
869372|NCT02726360|Language Skills
869373|NCT02726334|Metastatic
869374|NCT02726308|Dexamethasone
869375|NCT02726308|Super-hydration
869376|NCT02726308|Laparoscopic Cholecystectomy
869377|NCT02726308|Nausea
869378|NCT02726308|Vomiting
869379|NCT02726308|Postoperative
869380|NCT02726269|Helicobacter Pylory infections
869381|NCT02726269|Levofloxacin
869382|NCT02726269|Antibiotic resistance
869383|NCT02726269|Clarithromycin
869384|NCT02726269|Mutations
869385|NCT02726269|Fluorescence
869386|NCT02726269|Hybridization
869387|NCT02726256|Diabetes
869388|NCT02726256|DM complication
869389|NCT02726243|Inflammatory bowel disease
869390|NCT02726243|Crohn's Disease
869391|NCT02726243|Ulcerative Colitis
869392|NCT02726243|colorectal cancer
869393|NCT02726243|primary sclerosing cholangitis
869394|NCT02726217|CareSmarts
869395|NCT02726217|SMS-based mobile
869396|NCT02726178|Apnea
869397|NCT02726178|bradycardia
869398|NCT02726178|immunization
869399|NCT02726178|inflammation
869400|NCT02726178|preterms
869401|NCT02726152|Diagnostic laparoscopy
869402|NCT02726152|Acute appendicitis
869403|NCT02726152|Appendiceal stump
869404|NCT02726139|Factor VIII
869405|NCT02726139|inhibitor
869406|NCT02726139|assay
869407|NCT02726126|Transdermal fentanyl
869408|NCT02726126|Transdermal melatonin
869409|NCT02726126|Postoperative pain
869410|NCT02726126|lumber laminectomy
869411|NCT02726126|Relief
869412|NCT02726113|prostate cancer
869413|NCT02726113|vitamin D
869414|NCT02726100|Telemedicine
869415|NCT02726100|Diabetes Mellitus, Type 2
869416|NCT02726100|Decision Support Systems, Clinical
869417|NCT02726100|Family Health Promoter
869418|NCT02726100|Primary Health Care
869419|NCT02726087|Ministernotomy
869420|NCT02726087|aortic valve stenosis
869421|NCT02726087|quality of life
869422|NCT02726087|satisfaction
869423|NCT02726087|cardiac surgery
869424|NCT02726074|epilepsy
869425|NCT02726074|partial-onset seizures
869426|NCT02726074|secondarily generalized seizures
869427|NCT02726035|Self-injurious behavior
869428|NCT02726035|Self mutilation
869429|NCT02726035|naltrexone
869430|NCT02725996|Hepatocellular Carcinoma
869431|NCT02725996|Natural Killer cells
869432|NCT02725983|Gingivitis
869433|NCT02725983|Oral Hygiene
869434|NCT02725983|Intra oral camera
869435|NCT02725983|Self regulation
869436|NCT02725983|bleeding
869437|NCT02725970|HEALTH
869438|NCT02725970|barriers
869439|NCT02725970|facilitators
869440|NCT02725970|DGA
869441|NCT02725970|BMI
869442|NCT02725970|Public Schools
869443|NCT02725957|Bioblast
869444|NCT02725944|Cryptogenic stroke
869445|NCT02725944|Occult paroxysmal atrial fibrillation
869446|NCT02725931|Chronic obstructive pulmonary disease
869447|NCT02725931|COPD
869448|NCT02725931|Pulmonary rehabilitation
869449|NCT02725931|Physical activity
869450|NCT02725931|Exercise
869451|NCT02725918|NSCLC
869453|NCT02725918|chemotherapy
869454|NCT02725905|Weight Management Counseling
869455|NCT02725905|Medical School Education
869456|NCT02725892|lung cancer epidemiology algeria registry
869457|NCT02725866|Observational Study
869458|NCT02725866|Sustained Virological Response
869459|NCT02725866|Chronic Hepatitis C genotype 1
869460|NCT02725866|Chronic Hepatitis C
869461|NCT02725866|Paritaprevir/r - Ombitasvir, ± Dasabuvir,
869462|NCT02725866|Chronic Hepatitis C genotype 4
869463|NCT02725853|Transcranial Direct Current Stimulation
869464|NCT02725853|Arm Training
869465|NCT02725853|Virtual Reality Exposure Therapy
869466|NCT02725840|pulmonary vasculature
869467|NCT02725840|radiation late effects
869468|NCT02725840|proton therapy
869469|NCT02725814|Sucrose
869470|NCT02725814|Effectiveness
869471|NCT02725814|Healthcare Delivery
869472|NCT02725814|Neonates
869473|NCT02725814|Nursing
869474|NCT02725775|Orange Juice, Polyphenol, Cognition
869475|NCT02725762|Dry AMD
869476|NCT02725762|Vision Loss
869477|NCT02725762|AMD
869478|NCT02725749|shoulder
869479|NCT02725749|low level laser therapy
869480|NCT02725749|exercises
869481|NCT02725710|uterine aspiration
869482|NCT02725658|Neoadjuvant Therapy
869483|NCT02725658|Diffuse Optical Spectroscopic Imaging
869484|NCT02725658|DOSI
869485|NCT02725658|Neoadjuvant Chemotherapy
869486|NCT02725645|Surface electromyography
869487|NCT02725645|children
869488|NCT02725645|backpack
869489|NCT02725632|Sodium channel
869490|NCT02725632|splicing variant
869491|NCT02725632|sleep apnea syndrome
869492|NCT02725606|Neutropenia
869493|NCT02725606|Breast Cancer
869494|NCT02725606|GW003
869500|NCT02725580|Neuronal ceroid lipofuscinosis
869501|NCT02725580|NCL
869502|NCT02725580|Gene Transfer
869503|NCT02725580|Gray Foundation
869504|NCT02725541|HER2 equivocal
869505|NCT02725541|Trastuzumab emtansine
869506|NCT02725541|Breast cancer
869507|NCT02725502|T1DM
869508|NCT02725502|Linagliptin
869509|NCT02725502|mix meal test
869510|NCT02725489|Vigil
869511|NCT02725489|durvalumab
869512|NCT02725489|MEDI4736
869513|NCT02725489|PD-L1
869514|NCT02725489|anti PD-L1
869515|NCT02725489|immunotherapy
869516|NCT02725489|PD-L1 inhibitor
869517|NCT02725489|breast cancer
869518|NCT02725489|ovarian cancer
869519|NCT02725489|fallopian tube cancer
869520|NCT02725489|primary peritoneal cancer
869521|NCT02725489|uterine cancer
869522|NCT02725489|cervical cancer
869523|NCT02725489|endometrial cancer
869524|NCT02725463|vestibular
869525|NCT02725463|implant
869526|NCT02725463|prosthesis
869527|NCT02725463|labyrinth
869528|NCT02725463|ototoxicity
869529|NCT02725463|gentamicin
869530|NCT02725463|oscillopsia
869531|NCT02725463|disequilibrium
869532|NCT02725463|dizziness
869533|NCT02725463|vestibulopathy
869534|NCT02725463|inner ear
869535|NCT02725450|Motor Imagery
869536|NCT02725450|Fine motor skills
869537|NCT02725450|Disabled
869540|NCT02725398|Buscopan
869541|NCT02725398|probe-based confocal laser endomicroscopy
869542|NCT02725398|Imaging Quality
869543|NCT02725385|No Evidence of Disease
869544|NCT02725372|Pulmonary Arterial Hypertension
869545|NCT02725372|PAH
869546|NCT02725372|Inhaled Nitric Oxide
869547|NCT02725372|iNO
869548|NCT02725372|long term oxygen therapy
869549|NCT02725372|oxygen therapy
869550|NCT02725359|Thyroidectomy pain
869551|NCT02725359|Tizanidine
869552|NCT02725359|Postoperative analgesia
869553|NCT02725359|Ultrasound guided Superficial cervical plexus block
869554|NCT02725346|Surgical Planning Solution
869555|NCT02725346|Acromioplasty
869556|NCT02725346|Shoulder Surgery
869557|NCT02725346|Critical Shoulder Angle
869558|NCT02725333|Glenohumeral stabilization
869559|NCT02725333|Computer tomography
869560|NCT02725333|Subtle or minor instability
869561|NCT02725333|Unstable painful shoulder
869562|NCT02725333|Apprehension
869563|NCT02725333|Dislocation
869564|NCT02725333|Subluxation
869565|NCT02725333|Kinematics modeling
869566|NCT02725333|Biomechanics
869567|NCT02725333|Motion capture
869568|NCT02725333|3D simulation
869569|NCT02725320|rotator cuff
869570|NCT02725320|shoulder reconstruction
869571|NCT02725294|exacerbation
869572|NCT02725294|access to care
869573|NCT02725294|telemedicine
869574|NCT02725268|Drug Therapy
869575|NCT02725229|Postoperative pain
869576|NCT02725229|Parasternal block
869577|NCT02725229|Sternotomy
869578|NCT02725229|TENS
869579|NCT02725203|Cardiovascular risk management
869580|NCT02725203|behaviour change techniques
869581|NCT02725203|self-management
869582|NCT02725203|physical activity
869583|NCT02725203|nurse-led
869584|NCT02725203|behaviour change wheel
869585|NCT02725203|primary care
869586|NCT02725203|clustered RCT
869587|NCT02725177|Ocular Sarcoidosis
869588|NCT02725164|oxygen
869589|NCT02725164|nitrous oxide
869590|NCT02725164|sevoflurane
869591|NCT02725164|carbon dioxide
869592|NCT02725164|endotracheal tube
869593|NCT02725164|respiration
869594|NCT02725151|inferior vena cava ultrasound
869595|NCT02725151|acute
869596|NCT02725151|heart failure
869597|NCT02725151|management
869598|NCT02725151|decompensation
869599|NCT02725138|Helicobacter pylori
869600|NCT02725138|probiotic
869601|NCT02725138|bacterial density
869602|NCT02725125|Stomach Cancer CAR-T
869603|NCT02725099|STEMI
869604|NCT02725060|POTS
869605|NCT02725060|Orthostatic Intolerance
869606|NCT02725060|Orthostatic Tachycardia
869607|NCT02725047|Osteoarthritis, Knee
869608|NCT02725047|Cryotherapy
869609|NCT02725047|Thermotherapy
869610|NCT02725047|Hypothermia
869611|NCT02725047|Knee
869612|NCT02725047|Physiotherapy
869613|NCT02725021|tobacco prevention
869614|NCT02725008|Asthma
869615|NCT02725008|Pediatric
869616|NCT02725008|Emergency Department
869617|NCT02725008|Dexamethasone
869618|NCT02725008|Steroid
869619|NCT02724982|Self esteem
869620|NCT02724982|Body mass index
869621|NCT02724969|text messaging
869622|NCT02724969|short message service
869623|NCT02724943|child obesity
869624|NCT02724943|primary prevention
869625|NCT02724943|primary care
869626|NCT02724943|weight management
869627|NCT02724943|child overweight
869628|NCT02724943|BMI
869629|NCT02724930|low back pain, chronic pain, cognitive behavior therapy
869630|NCT02724904|Allogeneic hematopoietic stem cell transplantation
869631|NCT02724904|CNS Non-Hodgkin lymphoma
869632|NCT02724891|Pelvic Floor Dysfunction
869633|NCT02724878|Kidney Cancer
869634|NCT02724865|Oral Appliance Therapy
869635|NCT02724852|MMR
869636|NCT02724852|vaccination
869637|NCT02724852|HIV
869638|NCT02724852|Serologic response
869639|NCT02724826|Expectations
869640|NCT02724826|Outcomes
869641|NCT02724826|Qigong
869642|NCT02724826|Exercise therapy
869643|NCT02724826|Disability
869644|NCT02724826|Neck movements,
869645|NCT02724800|Insomnia
869646|NCT02724800|Veterans
869647|NCT02724800|Cognitive Behavioral Therapy for Insomnia
869648|NCT02724800|Brief Behavioral Treatment for Insomnia
869649|NCT02724800|Comparative Effectiveness Research
869650|NCT02724787|Post-traumatic stress disorder
869651|NCT02724787|Veterans
869652|NCT02724787|Aggression
869653|NCT02724787|Emotion regulation
869654|NCT02724774|infants
869655|NCT02724774|mental health
869656|NCT02724774|postpartum period
869657|NCT02724748|Aggression
869658|NCT02724748|Mental Health
869659|NCT02724748|Education, Continuing
869660|NCT02724735|Depression
869661|NCT02724735|Major Depressive Disorder (MDD)
869662|NCT02724735|Major Depressive Disorder
869663|NCT02724735|Neurogenesis
869664|NCT02724735|Synaptogenesis
869665|NCT02724735|NSI-189
869666|NCT02724735|Neuralstem
869667|NCT02724722|melamine
869668|NCT02724722|phthalate
869669|NCT02724709|Automatic Data Processing
869670|NCT02724709|Three-Dimensional Echocardiography
869671|NCT02724709|Aortic Valve
869672|NCT02724683|ascites
869673|NCT02724683|drainage
869674|NCT02724683|catheter
869675|NCT02724683|symptoms
869676|NCT02724683|management
869677|NCT02724683|quality of life
869678|NCT02724683|malignant
869679|NCT02724683|cancer
869680|NCT02724657|Child
869681|NCT02724657|Breathing exercises
869682|NCT02724631|Clogged enteral access devices
869683|NCT02724631|Occluded enteral access device
869684|NCT02724631|Enteral nutrition
869685|NCT02724631|Enteral access device
869686|NCT02724631|Tube Feeding
869687|NCT02724631|Gastric Feeding Tubes
869688|NCT02724618|Curcumin
869689|NCT02724618|Protection, Radiation
869690|NCT02724618|Controlled Clinical Trials, Randomized
869691|NCT02724618|Radiation Therapy
869692|NCT02724618|Prostate Cancer
869693|NCT02724605|RBCS,
869694|NCT02724605|Transfusion,
869695|NCT02724605|Pediatric
869696|NCT02724605|Changes
869697|NCT02724566|Type 2 diabetic volunteers
869698|NCT02724527|Cystic Fibrosis
869699|NCT02724527|N91115
869700|NCT02724527|Cavosonstat
869701|NCT02724488|Advanced cancer
869702|NCT02724488|Advanced solid tumors
869703|NCT02724488|Phase I clinical trial candidates
869704|NCT02724488|Phase II clinical trial candidates
869830|NCT02723916|Preschool
869705|NCT02724488|Phase III clinical trial candidates
869706|NCT02724488|Head and Neck
869707|NCT02724488|Melanoma
869708|NCT02724488|Upper Aerodigestive cancer
869709|NCT02724488|Oral Cavity
869710|NCT02724488|Immune Checkpoint Inhibitors
869711|NCT02724488|ICIs
869712|NCT02724488|ctDNA
869713|NCT02724488|Whole Exome Sequencing
869714|NCT02724488|Molecular Profiling
869715|NCT02724475|Laser Ablation
869716|NCT02724475|Portal Vein Tumor
869717|NCT02724475|Thrombus
869718|NCT02724462|smoking cessation
869719|NCT02724462|app for quitting smoking
869720|NCT02724449|IAD
869721|NCT02724449|Fecal incontinence
869722|NCT02724436|Yittrium-90
869723|NCT02724436|Hepatocellular Carcinoma
869724|NCT02724423|epilepsy
869725|NCT02724423|seizure
869726|NCT02724410|appendectomy
869727|NCT02724397|Colon cancer
869728|NCT02724397|Diagnosis
869729|NCT02724397|Adenoma
869730|NCT02724397|Serrated lesions
869731|NCT02724358|Carcinoma
869732|NCT02724358|Hepatocellular
869733|NCT02724358|Notch1
869734|NCT02724345|Cell keratin 18
869735|NCT02724332|Aspartate beta hydroxylase
869736|NCT02724332|transcatheter arterial chemoembolization
869737|NCT02724319|percutaneous coronary intervention
869738|NCT02724319|clopidogrel
869739|NCT02724319|loss-of-function allele
869740|NCT02724267|131I-chTNT-1/B treatment
869741|NCT02724254|Genital warts
869742|NCT02724254|HPV types
869743|NCT02724254|Sexually Transmitted Disease
869744|NCT02724254|Papillomavirus Infections
869745|NCT02724254|Viral Disease
869746|NCT02724254|Anogenital warts
869747|NCT02724254|AGW
869748|NCT02724254|HPV6
869749|NCT02724254|HPV11
869750|NCT02724254|Human papillomavirus infection
869751|NCT02724254|HPV
869752|NCT02724254|Aviragen Therapeutics, Inc.
869753|NCT02724254|Aviragen Therapeutics
869754|NCT02724254|Aviragen
869755|NCT02724241|nicotine
869756|NCT02724241|autonomic tone
869757|NCT02724241|oxidative stress
869758|NCT02724228|Achondroplasia
869759|NCT02724228|Dwarfism
869760|NCT02724228|Bone Diseases, Developmental
869761|NCT02724228|Bone Diseases
869762|NCT02724215|Subarachnoid hemorrhage
869763|NCT02724215|Sleep Apnea
869764|NCT02724202|Curcumin
869765|NCT02724202|5FU
869766|NCT02724202|5-fluorouracil
869767|NCT02724202|Adracil
869768|NCT02724202|5FU Resistant
869769|NCT02724202|Metastatic Colon Cancer
869770|NCT02724202|Colon Cancer
869771|NCT02724189|electronic pre-assessment
869772|NCT02724189|preoperative assessment
869773|NCT02724163|Acute Myeloid Leukaemia
869774|NCT02724163|Children
869775|NCT02724163|Gemtuzumab ozogamicin
869776|NCT02724163|Liposomal daunorubicin
869777|NCT02724163|Mitoxantrone
869778|NCT02724163|Randomised controlled trial
869779|NCT02724163|Risk stratification
869780|NCT02724163|Minimal residual disease
869781|NCT02724163|Stem cell transplant
869782|NCT02724150|Gastroduodenal Ulcer
869783|NCT02724150|Marginal Ulcer
869784|NCT02724150|Peptic Ulcer Hemorrhage
869785|NCT02724150|Peptic Ulcer
869786|NCT02724137|Total Knee Replacement
869787|NCT02724137|Physical Therapy
869788|NCT02724137|Fitbit®
869789|NCT02724124|exercise muscle stretching
869790|NCT02724124|electromyography
869791|NCT02724111|Neuromuscular blockade
869792|NCT02724111|Surgical rating scale
869793|NCT02724111|Rocuronium
869794|NCT02724111|Sugammadex
869795|NCT02724111|Spinal surgery
869796|NCT02724111|General anesthesia
869797|NCT02724098|Palliative Therapy
869798|NCT02724072|Thoracic Surgery
869799|NCT02724072|Aortic Arch
869800|NCT02724072|Frozen Elephant Trunk
869801|NCT02724072|Performance Goal
869802|NCT02724046|Neisseria meningitidis
869803|NCT02724046|Ciprofloxacin
869804|NCT02724046|Chemoprevention
869805|NCT02724033|post operative nausea vomiting
869806|NCT02724033|Inner ear surgery
869807|NCT02724020|Drug Therapy
869808|NCT02724007|Trauma
869809|NCT02724007|India
869810|NCT02724007|ICISS
869811|NCT02723994|B-cell acute lymphoblastic leukemia (ALL)
869812|NCT02723994|pediatric
869813|NCT02723994|multi-agent chemotherapy
869814|NCT02723994|JAK inhibitor
869815|NCT02723981|Stent , COMBO Stent, anticoagulation
869816|NCT02723955|ICOS receptor agonist antibody
869817|NCT02723955|Pembrolizumab
869818|NCT02723955|KEYNOTE-478
869819|NCT02723955|GSK3359609
869820|NCT02723955|Dose expansion
869821|NCT02723955|Dose escalation
869822|NCT02723942|glypican-3(GPC3)
869823|NCT02723942|chimeric antigen receptor-modified T cell(CAR-T)
869824|NCT02723942|hepatocellular carcinoma(HCC)
869825|NCT02723929|transcranial direct current stimulation
869826|NCT02723929|transcranial ultrasound
869827|NCT02723929|non-invasive brain stimulation
869828|NCT02723916|Parents
869829|NCT02723916|Child
869831|NCT02723916|eHealth
869832|NCT02723903|somatization symptom score
869833|NCT02723903|SSS checklist
869834|NCT02723903|coronary angiography
869835|NCT02723903|Patient Health Questionnaire
869836|NCT02723903|Generalized Anxiety Disorder 7-items
869837|NCT02723877|TNBC
869838|NCT02723864|Pharmacodynamic
869839|NCT02723864|DNA Damage Repair
869840|NCT02723864|BRCA Null
869841|NCT02723864|Apoptosis
869842|NCT02723864|Combination Therapy
869843|NCT02723838|Bladder
869844|NCT02723838|Cancer
869845|NCT02723838|REOLYSIN®
869846|NCT02723838|Gemcitabine
869847|NCT02723838|Cisplatin
869848|NCT02723838|Reovirus
869849|NCT02723838|Oncolytic virus
869850|NCT02723825|Distal tibia
869851|NCT02723825|fractures
869852|NCT02723825|epiphyses
869853|NCT02723825|children
869854|NCT02723812|Influenza
869855|NCT02723812|GCFLU
869856|NCT02723812|vaccine
869857|NCT02723812|Vietnam
869858|NCT02723799|Hope
869859|NCT02723786|Delayed Graft Function
869860|NCT02723786|Renal Transplantation
869861|NCT02723786|Prevention
869862|NCT02723786|GSK1070806
869863|NCT02723773|Efficacy
869864|NCT02723773|Immunogenicity
869865|NCT02723773|Safety
869866|NCT02723773|Adults
869867|NCT02723773|Herpes zoster
869868|NCT02723747|myocardial ischemia
869869|NCT02723747|magnetic resonance imaging
869870|NCT02723747|perfusion
869871|NCT02723747|software
869872|NCT02723734|Decipher®
869873|NCT02723734|African-American men
869874|NCT02723734|prostate
869875|NCT02723734|low risk PCa
869876|NCT02723734|intermediate risk PCa
869877|NCT02723734|genomic classifier (GC)
869878|NCT02723721|Lentigo maligna
869879|NCT02723695|Cochlear implant
869880|NCT02723695|Perception
869881|NCT02723695|Posture
869882|NCT02723695|Quality of life
869883|NCT02723669|Relative Bioavailability
869884|NCT02723656|smoking
869885|NCT02723656|cancer
869886|NCT02723656|cancer registry
869887|NCT02723656|smoking cessation
869888|NCT02723643|Hypertension
869889|NCT02723643|Essential hypertension
869890|NCT02723643|Blood pressure
869891|NCT02723643|Cardiovascular diseases
869892|NCT02723630|Bioequivalence
869893|NCT02723630|Lenvatinib
869894|NCT02723630|Healthy Volunteers
869895|NCT02723630|Lenvima
869896|NCT02723630|E7080
869897|NCT02723591|FK506
869898|NCT02723591|Kidney Transplantation
869899|NCT02723591|Tacrolimus
869900|NCT02723591|Astagraf XL
869901|NCT02723552|preeclampsia
869902|NCT02723552|young adult hypertension
869903|NCT02723552|preterm birth
869904|NCT02723526|Metastatic Hormone-Sensitive Prostate Cancer；circulating tumor cells；Prognosis；Liquid biopsy
869905|NCT02723513|Proton MRI
869906|NCT02723513|Noble Gas MRI
869907|NCT02723513|Pulmonary Function
869908|NCT02723500|Magnetic Resonance Imaging
869909|NCT02723500|Pulmonary Function
869910|NCT02723487|TAP block
869911|NCT02723487|pediatric
869912|NCT02723487|Laparoscopic
869913|NCT02723487|postoperative pain
869914|NCT02723474|Magnetic Resonance Imaging
869915|NCT02723474|Pulmonary Function
869916|NCT02723396|Parkinson's disease
869917|NCT02723396|Sleep Benefit
869918|NCT02723383|alcoholism
869919|NCT02723383|intensive care
869920|NCT02723383|Baclofen
869921|NCT02723383|restlessness
869922|NCT02723383|Delirium tremens
869923|NCT02723383|Alcohol withdrawal syndrome
869924|NCT02723370|Quality of Healthcare
869925|NCT02723370|Colorectal neoplasms
869926|NCT02723370|Health Literacy
869927|NCT02723370|Teach-Back Communication
869928|NCT02723370|Evidence Based Practice
869929|NCT02723370|Colonoscopy
869930|NCT02723357|Financial Coaching
869931|NCT02723357|Mental Health
869932|NCT02723357|Social Determinants
869933|NCT02723357|Medical-Financial Partnership
869934|NCT02723357|Toxic Stress
869935|NCT02723344|PTSD
869936|NCT02723344|Mild TBI
869937|NCT02723344|Probiotic
869938|NCT02723344|Inflammation
869948|NCT02723318|Cognition
869949|NCT02723318|Financial Coaching
869950|NCT02723318|Social Determinants of Health
869951|NCT02723318|Socioeconomic Status
869952|NCT02723305|Klinefelter syndrome
869953|NCT02723305|XXY
869954|NCT02723305|Sex chromosome aneuploidy
869955|NCT02723305|sex chromosome variation
869956|NCT02723305|hypogonadism
869957|NCT02723305|cardiometabolic
869958|NCT02723305|body composition
869959|NCT02723305|exercise capacity
869960|NCT02723279|Urgency-frequency Syndrome
869961|NCT02723279|Electrical Pudendal Nerve Stimulation
869962|NCT02723279|Tolterodine Tartrate
869963|NCT02723266|American Indian, Alaska Native Adolescents
869964|NCT02723266|Preconception Counseling
869965|NCT02723266|Reproductive Health
869966|NCT02723266|Gestational Diabetes Mellitus
869967|NCT02723253|rectal cancer
869968|NCT02723253|radiotherapy
869969|NCT02723253|chemotherapy
869970|NCT02723253|Raltitrexed
869971|NCT02723253|Oxaliplatin
869972|NCT02723240|NUC-3373
869973|NCT02723240|Dose escalation
869974|NCT02723240|Nucleotide Analogue
869975|NCT02723227|Parenting Stress
869976|NCT02723227|Stress
869977|NCT02723227|Social Determinants
869978|NCT02723227|Socioeconomic status
869979|NCT02723227|Financial Coaching
869980|NCT02723175|Fibromyalgia
869981|NCT02723175|Pain
869982|NCT02723136|Smartphone
869983|NCT02723136|Internship
869984|NCT02723136|Internal Medicine
869985|NCT02723123|CPAP
869986|NCT02723123|NIPPV
869987|NCT02723123|Extubation failure
869988|NCT02723123|Cardiorespiratory behaviour
869989|NCT02723123|NIV-NAVA
869990|NCT02723110|Type 2 Diabetes Risk
869991|NCT02723084|Hepatitis C Virus
869992|NCT02723084|Non-cirrhotic
869993|NCT02723084|Hepatitis C Genotype 2
869994|NCT02723084|Chronic Hepatitis C Virus
869995|NCT02723058|Depression
869996|NCT02723058|Homelessness
869997|NCT02723058|Primary care
869998|NCT02723006|Drug Therapy
869999|NCT02722954|malignancy
870000|NCT02722954|metastatic
870001|NCT02722954|Demcizumab
870002|NCT02722954|Pembrolizumab
870003|NCT02722954|Phase 1b
870004|NCT02722941|autologous hematopoietic cell transplant (HCT)
870005|NCT02722941|autologous
870006|NCT02722928|Postoperative pneumocephalus
870007|NCT02722928|Fraction of inspired oxygen
870008|NCT02722928|Intracranial surgery
870009|NCT02722915|fMRI
870010|NCT02722915|neurofeedback
870011|NCT02722915|hallucination
870012|NCT02722915|schizophrenia
870013|NCT02722902|Metabolic flexibility
870014|NCT02722902|Insulin sensitivity
870015|NCT02722889|Ascending aorta
870016|NCT02722889|Elongation of the aorta
870017|NCT02722889|Type A dissection
870018|NCT02722889|Aortic rupture
870019|NCT02722889|Aortic length
870020|NCT02722876|Rehabilitation
870021|NCT02722876|Cross-education
870022|NCT02722850|breast cancer
870023|NCT02722850|cancer survivorship
870024|NCT02722850|dietary intake
870025|NCT02722850|physical activity
870026|NCT02722850|quality of life
870027|NCT02722824|motor symptoms
870028|NCT02722811|Etanercept
870029|NCT02722811|Osteoarthritis Of Knee
870030|NCT02722811|TNF-α
870031|NCT02722811|IL-1α
870032|NCT02722811|Subcutaneous Injection
870033|NCT02722785|Exercise training
870034|NCT02722785|Surgical complications
870035|NCT02722785|Cancer prognosis
870036|NCT02722785|Muscle function
870037|NCT02722785|Body composition
870038|NCT02722785|Pulmonary function
870039|NCT02722785|Quality of life
870040|NCT02722772|Intra-Articular Injection
870041|NCT02722772|Etanercept
870042|NCT02722772|TNF-α
870043|NCT02722772|IL-1
870044|NCT02722772|Osteoarthritis of Knee
870045|NCT02722746|Epidural Analgesia
870046|NCT02722733|Hodgkin's lymphoma
870047|NCT02722733|Non-Hodgkin's lymphoma
870048|NCT02722733|mobilization
870049|NCT02722733|G-CSF
870050|NCT02722733|filgrastim
870051|NCT02722733|cytosine arabinoside
870052|NCT02722733|autologous stem cell transplantation
870064|NCT02722668|AML
870065|NCT02722668|ALL
870066|NCT02722668|CML
870067|NCT02722668|CLL
870068|NCT02722668|SLL
870069|NCT02722655|Pediatrics
870070|NCT02722629|COPD
870071|NCT02722629|Respiratory Aspiration
870072|NCT02722629|COPD acute exacerbation
870073|NCT02722616|Ultrasound
870074|NCT02722590|Epilepsy
870075|NCT02722590|Partial-onset seizures
870076|NCT02722590|secondarily generalized seizures
870077|NCT02722551|Mitral
870078|NCT02722551|Regurgitation
870079|NCT02722551|Insufficiency
870080|NCT02722551|Degenerative
870081|NCT02722551|Functional
870082|NCT02722551|Primary
870083|NCT02722551|Secondary
870084|NCT02722551|Organic
870085|NCT02722551|Transcatheter
870086|NCT02722551|TMVR
870087|NCT02722551|TMVI
870088|NCT02722551|Heart valve
870089|NCT02722551|Mitral valve
870090|NCT02722551|Transapical
870091|NCT02722551|Transfemoral
870092|NCT02722551|Trans-septal
870093|NCT02722551|Transeptal
870094|NCT02722551|Severe
870095|NCT02722525|ADT
870096|NCT02722525|Prostate cancer
870097|NCT02722499|Diabetes Mellitus, Type 2
870098|NCT02722499|Diabetes Mellitus, Adult-Onset
870099|NCT02722499|Diabetes Mellitus, Non-Insulin-Dependent
870100|NCT02722499|Diabetes Mellitus, Noninsulin Dependent
870101|NCT02722499|Diabetes Mellitus, Type II
870102|NCT02722499|African American
870103|NCT02722499|Blacks
870104|NCT02722499|non-Hispanic Blacks
870105|NCT02722499|Randomized Control Trial
870106|NCT02722499|Controlled Clinical Trial
870107|NCT02722499|Behavioral Research
870108|NCT02722499|Behavioral Medicine
870112|NCT02722408|LDL-C
870113|NCT02722408|Lipid Regulator
870114|NCT02722382|Chronic Kidney Disease
870115|NCT02722291|presbyopia
870116|NCT02722265|Essential hypertension
870117|NCT02722265|Long-term treatment
870118|NCT02722265|Mineralocorticoid receptor antagonist
870119|NCT02722252|In Vitro Fertilization with ICSI
870120|NCT02722239|Xigduo;
870121|NCT02722239|bioequivalence;
870122|NCT02722239|crossover;
870123|NCT02722239|Russia
870124|NCT02722226|High fidelity simulation
870125|NCT02722226|Sedation
870126|NCT02722226|Medical education
870127|NCT02722200|fMRI obesity
870128|NCT02722148|Eosinophilic Esophagitis
870129|NCT02722148|Diet Elimination Therapy
870130|NCT02722122|Cystic Fibrosis
870131|NCT02722122|CF
870132|NCT02722122|AIR DNase™
870133|NCT02722122|Digestive System Diseases
870134|NCT02722122|Genetic Diseases, Inborn
870135|NCT02722122|Infant, New born, Diseases
870136|NCT02722122|Lung diseases
870137|NCT02722122|Pancreatic Diseases
870138|NCT02722122|Respiratory Tract Diseases
870139|NCT02722096|arteriovenous fistula
870140|NCT02722096|regional anesthesia
870141|NCT02722096|local anesthesia
870142|NCT02722096|early complication
870143|NCT02722031|intensive care
870144|NCT02722031|prevalence
870145|NCT02722031|hypoxemia
870146|NCT02722031|ARDS
870147|NCT02722005|Health related quality of life
870148|NCT02722005|Financial Coaching
870149|NCT02722005|Medical Financial Partnership
870150|NCT02722005|Social Determinants of Health
870151|NCT02722005|Socioeconomic status
870152|NCT02721966|Assessment of spondyloarthritis international society (ASAS)
870153|NCT02721966|ASAS
870154|NCT02721966|axial
870155|NCT02721966|Psoriatic Arthritis (PsA)
870156|NCT02721966|PsA
870157|NCT02721966|Magnetic resonance imaging (MRI)
870158|NCT02721966|MRI
870159|NCT02721927|refugees
870160|NCT02721927|Syrian
870161|NCT02721927|cost
870162|NCT02721927|visit
870163|NCT02721914|low-back pain
870164|NCT02721914|massage therapy
870165|NCT02721914|Gymnastics
870166|NCT02721914|disability
870167|NCT02721901|Gastrointestinal Disorders
870168|NCT02721901|Nutrition
870169|NCT02721901|Behavioral
870170|NCT02721862|gallstones
870171|NCT02721862|cholelithiasis
870172|NCT02721862|sleeve gastrectomy
870173|NCT02721797|hypermobility
870174|NCT02721797|collagen
870175|NCT02721797|joint
870176|NCT02721797|hyperflexation
870177|NCT02721784|MRI
870178|NCT02721784|Radiotherapy
870179|NCT02721758|Motivational Interviewing
870180|NCT02721758|Health Behavior
870181|NCT02721758|Cardiac Rehabilitation
870197|NCT02721719|Ulcerative Colitis
870198|NCT02721719|UC
870199|NCT02721719|Vedolizumab
870200|NCT02721719|Entyvio
870201|NCT02721719|Inflammatory Bowl Disease
870202|NCT02721719|IBD
870203|NCT02721719|T-Lymphocytes, Regulatory
870204|NCT02721706|Nutrition assessment
870205|NCT02721706|inpatients
870206|NCT02721706|cost-benefit analysis
870207|NCT02721706|quality of life
870208|NCT02721706|body composition
870209|NCT02721706|mass screening
870210|NCT02721693|Troponin
870211|NCT02721693|Exercise
870212|NCT02721667|Blood pressure
870213|NCT02721667|Telemonitoring
870214|NCT02721667|Case management
870215|NCT02721667|Seniors
870216|NCT02721654|Plasma-Lyte
870217|NCT02721654|Sodium chloride
870218|NCT02721654|Saline
870219|NCT02721654|Fluid resuscitation
870220|NCT02721654|Intravenous fluid therapy
870221|NCT02721654|Critically ill
870222|NCT02721654|Critical care
870223|NCT02721628|Keratoconus
870224|NCT02721615|intra spinal pressure
870225|NCT02721615|spinal cord perfusion pressure
870226|NCT02721615|microdialysis
870227|NCT02721615|duroplasty
870228|NCT02721537|Brain Nicotinamide Adenine Dinucleotide (NAD+)
870229|NCT02721537|Adenosine Triphosphate (ATP) Depletion
870230|NCT02721537|Polyadenosine Diphosphate-Ribosepolymerase (PARP) Activation
870231|NCT02721524|Ring Annuloplasty
870232|NCT02721524|Suture Annuloplasty
870233|NCT02721524|Functional Tricuspid Regurgitation
870234|NCT02721498|Respiratory Physiotherapy
870235|NCT02721498|Airway clearance techniques
870236|NCT02721498|Outcome measures
870237|NCT02721485|Ringer's Lactate
870238|NCT02721485|Normal Saline
870239|NCT02721485|resuscitation fluids
870240|NCT02721485|hypovolemia
870241|NCT02721459|unresectable melanoma
870242|NCT02721459|stage III melanoma
870243|NCT02721459|stage IV melanoma
870244|NCT02721459|AJCC melanoma staging
870245|NCT02721459|American Joint Committee on Cancer (AJCC)
870246|NCT02721459|BRAF V600 E mutation
870247|NCT02721459|BRAF V600 K mutation
870248|NCT02721394|Challenging Behaviour
870249|NCT02721394|Functional Communication Training
870250|NCT02721394|Positive Behavioural Support
870251|NCT02721394|Family carer training
870252|NCT02721381|Autism Spectrum Disorder
870253|NCT02721381|Parent training
870254|NCT02721381|Telehealth
870255|NCT02721381|RCT
870256|NCT02721355|Chronic gastritis
870257|NCT02721355|Gastric ulcer
870258|NCT02721355|Helicobacter pylori
870259|NCT02721355|IgY
870260|NCT02721342|Chronic proteinuric nephropathies
870261|NCT02721329|Obstructive Sleep Apnea
870262|NCT02721329|OSA
870263|NCT02721329|Insomnia
870264|NCT02721329|CPAP
870265|NCT02721329|SensAwake
870266|NCT02721290|Knee surgery
870267|NCT02721277|Parenteral nutrition, Total
870268|NCT02721277|Infant, newborn
870269|NCT02721277|Cholestasis
870270|NCT02721277|Enterocolitis, Necrotizing
870271|NCT02721251|exercise
870272|NCT02721251|weight loss
870273|NCT02721251|sleep apnea
870274|NCT02721212|Robotic
870275|NCT02721212|Stroke
870276|NCT02721212|Upper Limb Rehabilitation
870277|NCT02721186|Malaria
870278|NCT02721186|Plasmodium
870279|NCT02721186|Mass drug administration
870280|NCT02721186|Malaria elimination
870281|NCT02721186|Zanzibar
870282|NCT02721186|Dihydroartemisinin-Piperaquine
870283|NCT02721186|Single low dose Primaquine
870284|NCT02721173|Tazarotene
870285|NCT02721173|Adapalene
870286|NCT02721173|Clindamycin
870287|NCT02721160|performance-based financing
870288|NCT02721160|malnutrition
870289|NCT02721160|impact evaluation
870290|NCT02721108|Mindfulness
870291|NCT02721108|Headspace
870292|NCT02721108|Psychological approaches
870293|NCT02721108|Progressive muscle relaxation
870294|NCT02721082|tobacco treatment
870295|NCT02721069|Seizures
870296|NCT02721069|Epilepsy
870297|NCT02721043|Personalized vaccine
870298|NCT02721043|Poly-ICLC
870299|NCT02721043|Immunotherapy
870300|NCT02721043|Cancer
870301|NCT02721030|Heartfailure
870302|NCT02721030|1-year mortality
870303|NCT02721030|heartfailure quality of life
870304|NCT02721030|sub-Saharan Africa
870305|NCT02721017|Nuss
870306|NCT02721017|Nuss Procedure
870307|NCT02721017|pectus excavatum
870308|NCT02721017|cryoanalgesia
870309|NCT02721004|Rheumatoid arthritis
870310|NCT02721004|RoActemra
870311|NCT02721004|Tocilizumab
870312|NCT02720965|Pain Acute
870313|NCT02720965|Orthopedic Surgery
870314|NCT02720965|Satisfaction Nerve Blocks
870315|NCT02720913|Time
870316|NCT02720913|COR-KNOT
870317|NCT02720913|Standard
870318|NCT02720913|Cost
870319|NCT02720887|pregnant women
870320|NCT02720887|nanoparticles
870321|NCT02720887|amniotic fluid
870322|NCT02720861|RNF213 rs112735431 Gene
870323|NCT02720861|Acute Non-embolic ischemic stroke
870324|NCT02720848|double-balloon enteroscopy
870325|NCT02720809|micronutrients
870326|NCT02720809|blood pressure
870327|NCT02720809|allergy
870328|NCT02720809|lung function
870329|NCT02720796|PDX
870330|NCT02720796|TumorGraft
870331|NCT02720796|Patient derived xenograft
870332|NCT02720796|sarcoma
870333|NCT02720783|Pharmacokinetics
870334|NCT02720783|Econazole nitrate 150mg
870335|NCT02720783|Benzydamine HCl 6mg
870336|NCT02720783|Vaginal pessary
870337|NCT02720783|Tolerability
870338|NCT02720770|growth hormone
870339|NCT02720718|Gastric Bypass Status for Obesity Complicating Pregnancy, Childbirth and the Puerperium
870340|NCT02720718|Laparoscopy
870341|NCT02720718|Suture Techniques
870342|NCT02720718|Sutures
870343|NCT02720705|sevoflurane emergence agitation
870344|NCT02720692|Pain
870345|NCT02720692|Analgesia
870346|NCT02720692|N1539
870347|NCT02720692|Phase 3
870348|NCT02720679|Genetics
870349|NCT02720679|Whole genome sequencing
870350|NCT02720679|Pediatrics and hematology
870351|NCT02720627|acne
870352|NCT02720627|cortexolone
870353|NCT02720627|anti-androgen
870354|NCT02720614|accelerated hypofractionated radiotherapy
870355|NCT02720614|three-dimensional conformal radiation therapy
870356|NCT02720614|concurrent radiochemotherapy
870357|NCT02720601|irinotecan
870358|NCT02720601|capecitabine
870359|NCT02720601|gemcitabine
870360|NCT02720601|biliary tract cancer
870361|NCT02720601|gallbladder cancer
870362|NCT02720601|second-line
870363|NCT02720575|Vitamin D
870364|NCT02720575|Bioavailability
870365|NCT02720575|Fortified Bread
870366|NCT02720536|Anemia.
870367|NCT02720536|Myelodysplastic Syndrome
870368|NCT02720536|Thalassemia
870369|NCT02720536|Film coated tablet
870370|NCT02720523|rheumatoid arthritis
870371|NCT02720523|ABT-494
870372|NCT02720523|Antirheumatic agents
870373|NCT02720523|Japanese
870374|NCT02720510|multiple myeloma
870375|NCT02720510|farydak
870376|NCT02720510|panobinostat
870377|NCT02720510|LBH589
870378|NCT02720510|ASCT
870379|NCT02720510|transplant
870380|NCT02720471|local analgesia
870381|NCT02720471|total hip replacement
870382|NCT02720471|local infiltrations
870383|NCT02720458|Hypnotics withdrawal in insomniac patients
870384|NCT02720458|Cognitive-Behavioural Therapy (CBT)
870385|NCT02720458|Internet-delivered self-help program
870386|NCT02720458|Sleep restriction
870387|NCT02720458|Stimulus control
870388|NCT02720458|Half-life benzodiazepine
870389|NCT02720458|Z-drug
870393|NCT02720432|early intervention, infant
870394|NCT02720419|drug eluting stent
870395|NCT02720419|percutaneous coronary intervention
870396|NCT02720419|real world
870397|NCT02720380|Asthma
870398|NCT02720380|Physical Therapy Specialty
870399|NCT02720380|Breathing Exercises
870400|NCT02720380|Child
870401|NCT02720380|Clinical Trail
870402|NCT02720302|Overweight
870403|NCT02720302|Children
870404|NCT02720302|Treatment
870405|NCT02720302|Prevention
870406|NCT02720302|Lifestyle intervention
870407|NCT02720289|injury prevention
870408|NCT02720276|stroke
870409|NCT02720276|exercise
870410|NCT02720276|walking
870411|NCT02720276|mobility
870414|NCT02720250|omega-3 fatty acids, microcirculation, laser Doppler flowmetry, lipid profile
870415|NCT02720237|Alcohol use
870416|NCT02720237|HIV
870417|NCT02720237|Viral Load
870418|NCT02720237|ART
870419|NCT02720211|headache
870420|NCT02720211|photophobia
870421|NCT02720211|migraine
870422|NCT02720211|light sensitivity
870423|NCT02720211|tints
870424|NCT02720211|thin films
870425|NCT02720146|Dry eye
870426|NCT02720133|ramadan fasting
870427|NCT02720133|variation of biochemical parameters
870428|NCT02720133|variation of hematological parameters
870429|NCT02720133|verify now assay
870430|NCT02720107|fingolimod,
870431|NCT02720107|Biomarker,
870432|NCT02720107|Multiple sclerosis,
870433|NCT02720107|Relapsing-remitting multiple sclerosis
870436|NCT02720068|PD1
870437|NCT02720068|PD-1
870438|NCT02720068|PDL1
870439|NCT02720068|PD-L1
870440|NCT02720055|Distal Radius Fracture
870441|NCT02720055|Outcomes
870442|NCT02720055|Psychological Intervention
870443|NCT02720029|aspiration
870444|NCT02720029|reflux
870445|NCT02720016|Post Traumatic Stress Disorder
870446|NCT02720016|Marital Therapy
870447|NCT02720016|Veterans
870448|NCT02720016|Telemedicine
870449|NCT02720003|Atherosclerosis
870450|NCT02720003|Superficial Femoral Artery
870451|NCT02720003|Proximal Popliteal Artery
870452|NCT02719990|VRS-317
870453|NCT02719990|Long Acting Growth Hormone
870454|NCT02719990|Versartis
870455|NCT02719990|somavaratan
870456|NCT02719990|Growth Hormone Deficiency
870457|NCT02719990|Adult Growth Hormone Deficiency
870458|NCT02719990|AGHD
870459|NCT02719990|Growth Hormone Replacement
870460|NCT02719990|Growth Hormone Replacement Therapy
870461|NCT02719990|XTEN
870462|NCT02719964|Cognitive Training
870463|NCT02719964|Traumatic Brain Injury
870464|NCT02719964|Video Games
870465|NCT02719951|autism
870466|NCT02719951|fragile X syndrome (FXS)
870467|NCT02719951|PET (Positron Emission Tomography)
870468|NCT02719951|glutamate
870469|NCT02719925|magnesium deficiency
870470|NCT02719925|stress psycological
870471|NCT02719925|sleep duration and quality
870472|NCT02719925|mineral water rich in magnesium
870473|NCT02719899|NLRP3 Inflammasome
870474|NCT02719899|Sirtuin 3
870475|NCT02719899|T-Cell Polarity
870476|NCT02719899|Caloric Restriction
870477|NCT02719873|obesity , pregnancy , maternal and fetal outcome
870478|NCT02719847|Lung cancer
870479|NCT02719847|Non-Small Cell Lung
870480|NCT02719847|NSCLC
870481|NCT02719847|Suspected non small cell lung cancer
870482|NCT02719847|Endobronchial ultrasound-guided transbronchial needle aspiration
870483|NCT02719847|EBUS-TBNA
870484|NCT02719821|Hematopoietic Stem Cell Transplantation
870485|NCT02719821|Fatigue
870486|NCT02719821|Insomnia
870487|NCT02719821|Depression
870488|NCT02719821|Behavioral Intervention
870489|NCT02719808|Vertical infection transmission
870490|NCT02719808|Tenofovir
870491|NCT02719795|Breast Neoplasms
870492|NCT02719795|Nerve block
870493|NCT02719795|Anesthesia
870494|NCT02719769|Positive Blood Culture
870495|NCT02719743|children
870496|NCT02719743|H5N1
870497|NCT02719743|observer-blind
870498|NCT02719743|Influenza
870499|NCT02719743|dose-ranging
870500|NCT02719717|VATS lobectomy
870501|NCT02719717|vascular sealing
870502|NCT02719717|energy
870503|NCT02719717|pulmonary artery
870504|NCT02719691|MLN0128
870505|NCT02719691|Dual TORC1/2 Inhibitor
870506|NCT02719691|MLN8237
870507|NCT02719691|Aurora A inhibitor
870508|NCT02719691|Alisertib
870509|NCT02719691|Triple-Negative Breast Cancer
870510|NCT02719652|intracranial atherosclerotic disease（ICAD）
870511|NCT02719652|vulnerable plaque
870512|NCT02719652|high-resolution magnetic resonance imaging （HR-MRI）
870513|NCT02719626|senior
870514|NCT02719626|nutrition
870515|NCT02719626|home delivered meals
870516|NCT02719626|food safety
870517|NCT02719626|emergency prep
870518|NCT02719600|Virtual Reality
870519|NCT02719587|saliva
870520|NCT02719587|omega-3
870521|NCT02719574|AML
870522|NCT02719574|MDS
870523|NCT02719574|IDH1
870524|NCT02719574|IDH
870525|NCT02719535|corneal reshaping therapy
870526|NCT02719535|corneal biomechanics
870527|NCT02719483|Children
870528|NCT02719483|Spasticity
870529|NCT02719483|Extracorporeal shock wave therapy
870530|NCT02719483|Cerebral palsy
870531|NCT02719483|Gross motor function
870532|NCT02719470|Cognition Impairment
870533|NCT02719470|Rehabilitation
870534|NCT02719470|Parkinson's Disease
870535|NCT02719457|Exercise testing
870536|NCT02719457|COPD
870537|NCT02719457|Upper and Lower limb exercise
870538|NCT02719418|Thromboembolism
870539|NCT02719418|Venous Thrombosis
870540|NCT02719418|Embolism and Thrombosis
870541|NCT02719418|Chronic Renal Diseases
870542|NCT02719418|Kidney Failure, Chronic
870543|NCT02719418|Renal Failure, Chronic
870544|NCT02719418|Venous Thromboembolism
870545|NCT02719418|Tinzaparin
870546|NCT02719418|Innohep
870547|NCT02719418|Heparin, Low-Molecular-Weight
870548|NCT02719405|milk
870549|NCT02719405|allergy
870550|NCT02719405|tolerance
870551|NCT02718313|intraventricular conduction delay
870552|NCT02718300|Primary myelofibrosis (PMF)
870553|NCT02718300|post-polycythemia vera myelofibrosis (PPV-MF)
870554|NCT02718300|post-essential thrombocythemia myelofibrosis (PET-MF)
870555|NCT02718300|myeloproliferative neoplasms (MPNs)
870556|NCT02718300|phosphoinositide 3-kinase (PI3K) inhibitor
870557|NCT02718300|Janus kinase (JAK) inhibitor
870558|NCT02718287|language development
870559|NCT02718287|socio-emotional development
870560|NCT02718287|cognitive development
870561|NCT02718287|motor skills
870562|NCT02718274|HIV self-testing
870563|NCT02718274|Malawi
870564|NCT02718274|HIV
870565|NCT02718248|self-harm
870566|NCT02718248|problem-solving therapy
870567|NCT02718248|emergency department
870568|NCT02718248|e-therapy
870569|NCT02718248|suicide prevention
870570|NCT02718222|Post-partum intrauterine device (PPIUD)
870571|NCT02717117|Motility
870572|NCT02717117|MRI
870573|NCT02717117|Gut peptides
870574|NCT02717117|Feeding
870575|NCT02717104|femoropopliteal
870576|NCT02719327|Alzheimer's disease
870577|NCT02719327|Cerebrospinal fluid
870578|NCT02719327|brain blood flow
870579|NCT02719327|cognition
870580|NCT02719327|icosapent ethyl
870581|NCT02719327|Vascepa
870582|NCT02719327|omega-3 fatty acids
870583|NCT02719327|eicosapentaenoic acid
870584|NCT02719262|Melamine
870585|NCT02719262|Renal damage
870586|NCT02719262|Workplace intervention
870587|NCT02719249|ESRD
870588|NCT02719249|Fabry disease
870589|NCT02719236|Coxarthrosis
870590|NCT02719236|Hip arthroplasty
870591|NCT02719236|Direct Anterior Approach
870592|NCT02719236|Direct Lateral Approach
870593|NCT02719223|Intradialytic hypotension
870594|NCT02719223|hemodynamic parameters
870595|NCT02719223|Hemodiafiltration
870596|NCT02719223|NICAS device (non-invasive cardiac system)
870597|NCT02719158|Acute otitis media with tympanostomy tubes
870598|NCT02719158|OTIPRIO
870599|NCT02719145|micro RNA
870600|NCT02719145|asthma
870601|NCT02719145|COPD
870602|NCT02719132|Diabetes Mellitus type 2, dapagliflozin, quality of life
870606|NCT02719093|Infertility Male
870607|NCT02719093|Receptors FSH
870608|NCT02719093|Varicocele
870609|NCT02719093|FSH therapy
870610|NCT02719080|anaesthetists, surgeons, stress, burnout
870611|NCT02719067|neuropsychological function
870612|NCT02719067|neuroimage
870613|NCT02719067|developmental changes
870614|NCT02719054|Depression
870615|NCT02719054|Child Development
870616|NCT02719054|Stimulation
870617|NCT02719054|CBT
870618|NCT02719054|Bangladesh
870619|NCT02719015|Melanoma
870620|NCT02719015|Refractory Metastatic Melanoma
870621|NCT02719015|rAd.CD40L
870622|NCT02719015|ISF35
870623|NCT02719015|Intratumoral
870624|NCT02719015|IT
870625|NCT02719015|Pembrolizumab
870626|NCT02719015|Keytruda
870627|NCT02719015|MK-3475
870628|NCT02719015|SCH-900475
870629|NCT02719015|MM
870630|NCT02718989|H-reflex
870631|NCT02718989|TENS
870632|NCT02718989|Tone
870633|NCT02718976|Hip surgery anesthesia
870634|NCT02718976|Perioperative analgesia
870635|NCT02718950|Brown Adipose Tissue
870636|NCT02718950|Hypothalamic Activation
870637|NCT02718950|Non-shivering Thermogenesis
870638|NCT02718950|Basal Metabolic Rate
870639|NCT02718950|Liraglutide
870640|NCT02718950|Victoza
870641|NCT02718950|Body Composition
870642|NCT02718950|Body weight
870643|NCT02718950|Adipose Tissue Biopsy
870644|NCT02718937|Viral diseases
870645|NCT02718937|Antiviral
870646|NCT02718937|Paramyxoviridae infections
870647|NCT02718937|RSV
870648|NCT02718937|Aviragen Therapeutics, Inc.
870649|NCT02718937|Aviragen Therapeutics
870650|NCT02718937|Aviragen
870651|NCT02718924|Thromboelastometry
870652|NCT02718924|pregnancy
870653|NCT02718924|obesity
870654|NCT02718898|genital
870655|NCT02718885|inulin-type fructans
870656|NCT02718885|hemodialysis
870657|NCT02718885|gut microbiome
870658|NCT02718885|mineral and bone disorder
870659|NCT02718859|advanced pancreatic cancer
870660|NCT02718859|nature killer cell
870661|NCT02718859|irreversible electroporation
870662|NCT02718833|Multiple Myeloma
870663|NCT02718833|Relapse
870664|NCT02718807|Patient Care
870665|NCT02718807|Education
870666|NCT02718794|Simulation Training [I02.903.847]
870667|NCT02718794|Problem-Based Learning [F02.463.425.720]
870668|NCT02718794|Airway Management [E02.041]
870669|NCT02718755|Hematologic malignancy
870670|NCT02718755|Relapsed and refractory hematologic malignancies
870671|NCT02718755|Acute myeloid leukemia
870672|NCT02718755|AML
870673|NCT02718755|Acute lymphoblastic leukemia
870674|NCT02718755|ALL
870675|NCT02718755|Burkitt's leukemia/lymphoma
870676|NCT02718755|Prolymphocytic leukemia
870677|NCT02718755|Biphenotypic acute leukemia
870678|NCT02718755|Blast-phase of chronic myeloid leukemia
870679|NCT02718755|CML
870680|NCT02718755|B-cell lymphoma
870681|NCT02718755|Richter's transformation of chronic lymphocytic leukemia
870682|NCT02718755|CLL
870683|NCT02718755|Fludarabine
870684|NCT02718755|Fludarabine phosphate
870685|NCT02718755|Fludara
870686|NCT02718755|Cytarabine
870687|NCT02718755|Ara-C
870688|NCT02718755|Cytosar
870689|NCT02718755|DepoCyt
870690|NCT02718755|Cytosine arabinosine hydrochloride
870691|NCT02718729|Anastomotic leakage
870692|NCT02718729|Rectal cancer
870693|NCT02718729|Laparoscopic
870694|NCT02718729|Rectal resection
870695|NCT02718716|ITP
870696|NCT02718690|H-Reflex
870697|NCT02718690|Current Density
870698|NCT02718690|TENS
870699|NCT02718651|ALK rearrangement
870700|NCT02718651|Circulating tumor DNA
870701|NCT02718651|Plasma DNA
870702|NCT02718651|Non-small cell lung cancer
870703|NCT02718651|Tyrosine kinase inhibitors
870704|NCT02718625|Pressure Ulcers
870705|NCT02718625|Bed sores
870706|NCT02718625|Long-term care
870707|NCT02718625|Nursing home
870708|NCT02718612|Uraemic Sarcopenia
870709|NCT02718612|Sarcopenic Obesity
870710|NCT02718586|Myokines
870711|NCT02718586|Protein Energy Wasting
870712|NCT02718586|Hemodialysis
870713|NCT02718573|Hepatitis C
870714|NCT02718573|Interferon-free
870715|NCT02718573|DDA's
870716|NCT02718547|Diabetes mellitus
870717|NCT02718547|Diabetic macular edema
870718|NCT02718547|Intra ocular pressure
870719|NCT02718547|Ocular perfusion pressure
870720|NCT02718547|Retinal perfusion
870721|NCT02718521|contrast-induced nephropathy
870722|NCT02718521|hydration therapy combined with intravenous infusion of isosorbide
870723|NCT02718521|percutaneous coronary intervention
870724|NCT02718469|Ebola
870725|NCT02718469|VSV
870726|NCT02718469|Vesicular Stomatitis Virus
870727|NCT02718469|Vaccine
870728|NCT02718469|Zaire
870729|NCT02718417|untreated epithelial ovarian
870730|NCT02718417|fallopian tube
870731|NCT02718417|primary peritoneal cancer
870732|NCT02718404|MR-HIFU
870733|NCT02718404|bone metastases
870734|NCT02718404|pain treatment
870735|NCT02718391|Intradermal Autologous Dendritic Cell Vaccine
870736|NCT02718391|Malignant Melanoma
870737|NCT02718391|Adjuvant
870738|NCT02718391|vaccin
870739|NCT02718391|therapy
870740|NCT02718391|randomized trial
870741|NCT02718391|observation
870742|NCT02718378|safety
870743|NCT02718378|pharmacokinetics
870744|NCT02718378|pharmacodynamics
870745|NCT02718378|randomized
870746|NCT02718365|Lung Neoplasms
870747|NCT02718365|Surgery
870748|NCT02718365|VATS
870749|NCT02718365|GGO
870750|NCT02718365|GGN
870751|NCT02718365|Segmentectomy
870752|NCT02718365|Wedge Resection
870753|NCT02718365|Prognosis
870754|NCT02718144|dose-escalation
870755|NCT02718144|safety
870756|NCT02718144|dose-limiting toxicity
870757|NCT02718131|Tibial Pseudarthrosis
870758|NCT02718105|KIR HLA-C
870759|NCT02718105|ART
870760|NCT02718066|HBI-8000
870761|NCT02718066|nivolumab
870762|NCT02718066|Melanoma
870763|NCT02718066|Renal Cell Carcinoma
870764|NCT02718066|Non-Small Cell Lung Cancer
870765|NCT02718027|Hereditary Nephritis
870766|NCT02718027|Nephritis, Familial
870767|NCT02718027|Hereditary Familial Congenital Hemorrhagic Nephritis
870768|NCT02718014|Non Surgical Therapy
870769|NCT02718001|Mitral
870770|NCT02718001|Regurgitation
870771|NCT02718001|Insufficiency
870772|NCT02718001|Degenerative
870773|NCT02718001|Functional
870774|NCT02718001|Primary
870775|NCT02718001|Secondary
870776|NCT02718001|Organic
870777|NCT02718001|Transcatheter
870778|NCT02718001|TMVR
870779|NCT02718001|TMVI
870780|NCT02718001|Heart Valve
870781|NCT02718001|Mitral Valve
870782|NCT02718001|Transapical
870783|NCT02718001|Transseptal
870784|NCT02718001|Trans-Septal
870785|NCT02718001|Transeptal
870786|NCT02718001|Severe
870787|NCT02717988|rheumatoid arthritis
870788|NCT02717988|healthy volunteers
870789|NCT02717988|moderately to severely active
870790|NCT02717975|Urinary retention
870791|NCT02717975|trial removal of catheter
870792|NCT02717975|valve
870793|NCT02717962|Glioma
870794|NCT02717962|Glioblastoma
870795|NCT02717962|Glioblastoma multiforme
870796|NCT02717962|GBM
870797|NCT02717962|brain tumor
870798|NCT02717962|brain cancer
870799|NCT02717962|recurrent brain tumor
870800|NCT02717962|recurrent brain cancer
870801|NCT02717962|refractory brain tumor
870802|NCT02717962|refractory brain cancer
870803|NCT02717962|recurrent GBM
870804|NCT02717962|refractory GBM
870805|NCT02717962|recurrent glioma
870806|NCT02717962|refractory glioma
870807|NCT02717962|recurrent glioblastoma
870808|NCT02717962|refractory glioblastoma
870809|NCT02717962|recurrent glioblastoma multiforme
870810|NCT02717962|refractory glioblastoma multiforme
870811|NCT02717962|failed bevacizumab
870812|NCT02717962|temodar failure
870813|NCT02717962|temozolomide failure
870814|NCT02717949|hepatitis C
870815|NCT02717949|low-grade lymphoma
870816|NCT02717936|squamous cell carcinoma
870817|NCT02717936|dermatosurgery
870818|NCT02717936|immunohistochemistry
870819|NCT02717923|metastatic colorectal cancer
870820|NCT02717923|maintenance treatment
870821|NCT02717923|cetuximab
870822|NCT02717910|Games
870823|NCT02717910|Adolescent
870824|NCT02717910|Health education
870825|NCT02717910|Smoking
870826|NCT02717910|Health literacy
870827|NCT02717884|AML
870828|NCT02717884|MDS
870829|NCT02717884|relapsed
870830|NCT02717884|trans-retinoic acid ATRA
870831|NCT02717884|epigenetic treatment
870832|NCT02717884|non-M3 AML blasts
870833|NCT02717884|tranylcypromine TCP
870834|NCT02717884|LSD1
870835|NCT02717884|refractory
870836|NCT02717871|Collagen cross-linking, PACK-CXL, infectious keratitis, CXL.
870837|NCT02717845|varus malignment
870838|NCT02717845|osteoarthritis
870839|NCT02717845|knee
870840|NCT02717819|Sarcopenia
870841|NCT02717819|Muscular atrophy
870842|NCT02717819|Frailty
870843|NCT02717819|Acute illness
870844|NCT02717819|Ageing
870845|NCT02717819|Protein supplementation
870846|NCT02717819|Whey protein
870847|NCT02717819|Resistance training
870848|NCT02717819|Strength training
870849|NCT02717767|pneumonia
870850|NCT02717767|diagnosis
870851|NCT02717767|prognosis
870852|NCT02717767|tracheal aspirate
870853|NCT02717767|bronchoalveolar lavage
870854|NCT02717663|Reinforcement
870855|NCT02717663|Walking
870856|NCT02717663|Exercise
870857|NCT02717663|Built Environment
870858|NCT02717663|Adaptive
870859|NCT02717663|Financial incentive
870860|NCT02717663|Walkability
870861|NCT02717650|Exercise Testing
870862|NCT02717650|Maximal Exercise Testing
870863|NCT02717650|Maximal Exercise Capacity
870864|NCT02717650|Peak Exercise Capacity
870865|NCT02717650|Adults
870866|NCT02717650|Step Tests
870867|NCT02717637|oxycodone, caesarean, spinal anesthesia
870868|NCT02717624|Bruton tyrosine kinase inhibitor
870869|NCT02717624|Btk
870870|NCT02717624|ACP-196
870871|NCT02717624|Mantle Cell Lymphoma
870872|NCT02717624|MCL
870873|NCT02717624|acalabrutinib
870874|NCT02717624|ACE-LY-106
870875|NCT02717611|Chronic Lymphocytic Leukemia
870876|NCT02717611|Ibrutinib Intolerant
870877|NCT02717598|cold snare polypectomy
870878|NCT02717598|hot snare polypectomy
870879|NCT02717585|Continuous Positive Airway Pressure therapy
870880|NCT02717585|Chronic Pain
870881|NCT02717585|Sleep Disturbance
870882|NCT02717559|Anterior cruciate ligament / injuries
870883|NCT02717559|Anterior cruciate ligament / surgery
870884|NCT02717559|knee injuries / surgery
870885|NCT02717559|outcomes research
870886|NCT02717559|prospective studies
870887|NCT02717559|osteoarthritis
870888|NCT02717546|Distal Tibia Fracture Screw
870889|NCT02717520|glass hybrid
870890|NCT02717520|composite
870891|NCT02717494|PPV-23
870892|NCT02717494|PCV-10
870893|NCT02717494|HIV
870894|NCT02717494|Immunization
870895|NCT02717494|Pregnancy
870896|NCT02717455|Diffuse Intrinsic Pontine Glioma
870897|NCT02717442|Meniere's Disease
870898|NCT02717442|Vertigo
870899|NCT02717403|Chronic Disease Management
870900|NCT02717403|Rheumatoid Arthritis
870901|NCT02717403|Facebook
870902|NCT02717403|Social networking
870903|NCT02717403|Internet
870904|NCT02717403|Questionnaires
870905|NCT02717403|Surveys
870906|NCT02717403|Phone interview
870907|NCT02717390|Reading
870908|NCT02717390|Early Childhood development
870909|NCT02717390|Talking
870910|NCT02717390|Playing
870911|NCT02717390|Praising
870912|NCT02717390|Safety
870913|NCT02717390|Injury prevention
870914|NCT02717377|Micro bouts
870915|NCT02717377|Physical Activity
870916|NCT02717338|blood donor
870917|NCT02717338|retention
870918|NCT02717338|motivation
870919|NCT02717338|self-determination theory
870920|NCT02717247|tRNS
870921|NCT02717247|Food addiction,
870922|NCT02717247|Obesity
870923|NCT02717247|Craving
870924|NCT02717247|functional magnetic resonance imaging (fMRI)
870925|NCT02717182|self management program
870926|NCT02717182|patient education
870927|NCT02717182|self care program
870928|NCT02717169|health promotion
870929|NCT02717169|health action process
870930|NCT02717169|activity tracker
870931|NCT02717169|sleep regulation
870932|NCT02717143|Acute myocarditis
870933|NCT02717143|Dilated cardiomyopathy
870934|NCT02717143|Magnetic resonance imaging
870935|NCT02717078|diet
870936|NCT02717078|carbohydrate
870937|NCT02717065|Neuromodulation
870938|NCT02717065|Noninvasive
870939|NCT02717065|Plasticity
870940|NCT02717065|Hearing
870941|NCT02717065|Hyperacusis
870942|NCT02717013|Muscle
870943|NCT02717013|Bone
870944|NCT02717013|Fat
870945|NCT02716974|Lupron
870946|NCT02716974|Bicalutamide
870947|NCT02716974|Docetaxel
870948|NCT02716896|cystectomy
870949|NCT02716896|radiation
870950|NCT02716896|chemotherapy
870951|NCT02716883|keratitis
870952|NCT02716883|AMT
870953|NCT02716883|bacterial keratitis
870954|NCT02716883|medication
870955|NCT02716870|Systematic review and meta-analysis
870956|NCT02716870|Evidence-based medicine (EBM)
870957|NCT02716870|Evidence-based nutrition (EBN)
870958|NCT02716870|Clinical practice guidelines
870959|NCT02716870|Clinical trials
870960|NCT02716870|Dietary sugars
870961|NCT02716870|Fructose
870962|NCT02716870|High fructose corn syrup
870963|NCT02716870|Fruit
870964|NCT02716870|Isocaloric
870965|NCT02716870|Hypercaloric
870966|NCT02716870|Cardiometabolic risk factors
870967|NCT02716870|Triglycerides
870968|NCT02716870|Cholesterol
870969|NCT02716870|Glycemic control
870970|NCT02716870|Insulin resistance
870971|NCT02716870|Body weight
870972|NCT02716870|Uric acid
870973|NCT02716870|Blood pressure
870974|NCT02716870|Fatty liver
870975|NCT02716870|Fasting
870976|NCT02716870|Postprandial
870977|NCT02716844|Osteoporosis
870978|NCT02716844|Clinic Pilates Exercise
870979|NCT02716844|Kinesiophobia
870980|NCT02716844|Pain
870981|NCT02716831|Bulimia Nervosa
870982|NCT02716831|Eating Disorders
870983|NCT02716831|Binge Eating
870984|NCT02716831|Bulimia
870985|NCT02716831|Purging
870986|NCT02716818|Glucocorticoid therapy
870987|NCT02716805|autologous stem cell transplant
870988|NCT02716805|HDT/ASCT
870989|NCT02716805|CTLA-4
870990|NCT02716805|PD-L1
870991|NCT02716805|peripheral blood mononuclear cells
870992|NCT02716805|PBMC
870993|NCT02716805|ASCT
870994|NCT02716766|Sorafenib
870995|NCT02716766|Drug Therapy
870996|NCT02716740|Post-obesity surgery
870997|NCT02716740|Leucine-enriched amino acid supplementation
870998|NCT02716740|Anabolic substance
870999|NCT02716740|Physical training
871000|NCT02716740|Muscular mass
871001|NCT02716740|Loss of weight
871002|NCT02716714|Korean
871003|NCT02716701|Exercise
871004|NCT02716688|Esophageal cancer
871005|NCT02716688|Radiotherapy
871006|NCT02716688|elder
871007|NCT02716688|S-1
871008|NCT02716675|HIV-1 Infections
871009|NCT02716649|Trauma
871010|NCT02716649|ICISS
871011|NCT02716649|India
871012|NCT02716649|ICD-10
871013|NCT02716597|albumin, septic shock
871014|NCT02716571|Healthy Subjects
871015|NCT02716571|Healthy Participants
871016|NCT02716545|Gastrointestinal vascular malformation
871017|NCT02716545|Endoscopic Therapy
871018|NCT02716519|Diabetes
871019|NCT02716519|diabetic foot ulcer
871020|NCT02716519|foot sore
871021|NCT02716519|type 2 diabetes
871022|NCT02716519|type 1 diabetes
871023|NCT02716519|DFU
871024|NCT02716519|pressure ulcers
871025|NCT02716519|bed sores
871026|NCT02716506|POP surgery
871027|NCT02716493|Telerehabilitation
871028|NCT02716480|Nutrition
871029|NCT02716480|Physical activity
871030|NCT02716480|Bariatric surgery
871031|NCT02716480|Obesity
871032|NCT02716480|Health technology
871033|NCT02716480|Health-connected devices
871034|NCT02716467|nursing
871035|NCT02716467|intercessory prayer
871036|NCT02716467|spirituality
871037|NCT02716467|clinical trials
871038|NCT02716454|Early surgery
871039|NCT02716454|Crohn's disease
871040|NCT02716454|Step-up therapy
871041|NCT02716415|neonates
871042|NCT02716415|infants
871043|NCT02716402|Cyanotic congenital heart disease
871044|NCT02716402|pulmonary thrombosis
871045|NCT02716402|cerebral thrombosis
871046|NCT02716376|Head and neck neoplasms
871047|NCT02716376|Radiotherapy
871048|NCT02716376|Otitis media
871049|NCT02716337|human milk target fortification
871050|NCT02716324|Attention-Deficit/Hyperactivity Disorder
871051|NCT02716324|Shared-Decision Making
871052|NCT02716324|Care Manager
871053|NCT02716324|Children
871054|NCT02716324|Parents
871055|NCT02716324|Teachers
871056|NCT02716311|EGFR
871057|NCT02716311|Lung Cancer
871058|NCT02716285|Irritable Bowel Syndrome
871059|NCT02716285|Abdominal pain
871060|NCT02716285|Targeted Delivery
871061|NCT02716285|Peppermint oil
871062|NCT02716272|mesothelioma
871063|NCT02716272|immunotherapy
871064|NCT02716272|nivolumab
871065|NCT02716272|ipilimumab
871066|NCT02716259|Periodontitis
871067|NCT02716259|Cardiovascular diseases
871068|NCT02716259|Bacteremia
871069|NCT02716259|Scaling and root planing
871070|NCT02716259|Flow-mediated dilation
871071|NCT02716259|carotid intima-media thickness
871072|NCT02716259|Porphyromonas gingivalis
871073|NCT02716259|Aggregatibacter actinomycetemcomitans
871074|NCT02716246|MPS IIIA
871075|NCT02716220|DREAMS 2G
871076|NCT02716220|Scaffold
871077|NCT02716220|Drug Eluting Absorbable Metal Scaffold
871078|NCT02716220|Coronary Artery Disease
871079|NCT02716207|Stereotactic Body Radiotherapy (SBRT)
871080|NCT02716207|CyberKnife
871081|NCT02716207|Dose Escalation
871082|NCT02716181|Atopic Dermatitis
871083|NCT02716181|Topical therapy
871084|NCT02716168|Cancer
871085|NCT02716168|tele-health
871086|NCT02716168|Shared care
871087|NCT02716168|Continuity
871088|NCT02716116|NSCLC
871089|NCT02716116|EGFR
871090|NCT02716116|HER2
871091|NCT02716116|human epidermal growth factor receptor 2
871092|NCT02716116|exon 20 insertions
871093|NCT02716116|exon 19 deletions
871094|NCT02716116|exon 21 substitution
871095|NCT02716116|T790M
871096|NCT02716116|ErbB-2
871097|NCT02716116|Epidermal Growth Factor Receptor
871098|NCT02716103|AL amyloidosis, systemic primary amyloidosis
871099|NCT02716064|chronic conditions, self-management, PHR
871100|NCT02716038|Non-Small Cell Lung Cancer
871101|NCT02716038|Non-Small-Cell Lung Carcinoma
871102|NCT02716038|Nonsmall Cell Lung Cancer
871103|NCT02716038|NSCLC
871104|NCT02716012|Oligonucleotide
871105|NCT02716012|RNA
871106|NCT02716012|saRNA
871107|NCT02716012|Fibrosis
871108|NCT02716012|Cirrhosis
871109|NCT02715986|ECT
871110|NCT02715986|Diffusion Tensor Imaging (DTI)
871111|NCT02715986|fMRI
871112|NCT02715947|Psoriasis Vulgaris
871113|NCT02715947|Methotrexate
871114|NCT02715934|Diabetes Education
871115|NCT02715934|Chronic Disease Management
871116|NCT02715934|Health Care Delivery
871117|NCT02715934|Patient-Centered Medical Home
871118|NCT02715934|Primary Care
871119|NCT02715895|Infant
871120|NCT02715895|Growth
871121|NCT02715895|Body Weight Changes
871122|NCT02715895|Infant Formula
871123|NCT02715895|Randomized Controlled Trial
871124|NCT02715882|Colorectal cancer
871125|NCT02715882|TLR5
871126|NCT02715882|Immunotherapy
871127|NCT02715869|Myocardial Preconditioning, inotropic score
871128|NCT02715856|Bone metastases
871129|NCT02715856|Intramedullary nailing surgery
871130|NCT02715856|IM
871131|NCT02715856|Physical tasks
871132|NCT02715856|Surveys
871133|NCT02715856|Questionnaires
871134|NCT02715856|Smartphone
871135|NCT02715856|Tablet
871136|NCT02715856|Telemedicine
871137|NCT02715856|Telemonitoring
871138|NCT02715843|CD20
871139|NCT02715843|immunotoxin
871140|NCT02715843|NHL
871141|NCT02715843|non-Hodgkin's lymphoma
871142|NCT02715843|lymphoma
871143|NCT02715843|cancer
871144|NCT02715843|antibodies
871145|NCT02715843|immunotherapy
871146|NCT02715843|safety
871147|NCT02715843|pharmacokinetics
871148|NCT02715843|MT-3724
871149|NCT02715843|relapsed
871150|NCT02715843|refractory
871151|NCT02715817|Stroke
871152|NCT02715817|Hemiparesis
871153|NCT02715817|Physical Therapy
871154|NCT02715817|Virtual Reality Exposure Therapy
871155|NCT02715817|Video Games
871156|NCT02715804|Pancreatic ductal adenocarcinoma (PDA)
871157|NCT02715804|Pancreatic ductal carcinoma
871158|NCT02715804|PEGylated Recombinant Human Hyaluronidase (PEGPH20)
871159|NCT02715804|Nab-paclitaxel
871160|NCT02715804|Gemcitabine
871161|NCT02715804|Metastatic
871162|NCT02715804|Stage IV
871163|NCT02715791|Self-Management
871164|NCT02715791|Health Connectors
871165|NCT02715791|Volunteers
871166|NCT02715791|Technology
871167|NCT02715791|Interprofessional team
871168|NCT02715791|Chronic disease
871169|NCT02715791|Self-efficacy
871170|NCT02715791|Patient-centredness
871171|NCT02715791|Community Engagement
871172|NCT02715739|Trauma
871173|NCT02715739|India
871174|NCT02715739|ICISS
871175|NCT02715713|Autonomic neuropathy, Testosterone Deficiency
871176|NCT02715661|blood flow
871177|NCT02715661|brain health
871178|NCT02715661|exercise
871179|NCT02715661|endothelial activation
871180|NCT02715596|head and neck
871181|NCT02715596|eicosapentanoic acid
871182|NCT02715596|body composition
871183|NCT02715570|Aspergillus species
871184|NCT02715570|Filamentous fungi
871185|NCT02715570|14-alpha Demethylase Inhibitors
871186|NCT02715570|Anti-Infective Agents
871187|NCT02715570|Antifungal Agents
871188|NCT02715570|Enzyme Inhibitors
871189|NCT02715570|Aspergillosis
871190|NCT02715570|Allergic Bronchopulmonary
871191|NCT02715570|Asthma
871192|NCT02715544|Intervention
871193|NCT02715544|Physical activity
871194|NCT02715544|Eating habit
871195|NCT02715544|Connectedness to nature
871196|NCT02715518|Acute ST-segment elevation myocardial infarction
871197|NCT02715518|Acute myocardial infarction
871198|NCT02715518|Fractional flow reserve
871199|NCT02715518|Percutaneous coronary intervention
871200|NCT02715518|Multivessel disease
871201|NCT02715518|STEMI
871202|NCT02715518|NSTEMI
871203|NCT02715505|Hurler syndrome, MLD, Krabbe, cALD, Hematopoietic Stem Cell Transplantation (HSCT)
871204|NCT02715453|Frailty
871205|NCT02715453|Acute myocardial infarction
871206|NCT02715440|Benzodiazepines
871207|NCT02715440|drugs
871208|NCT02715440|withdrawal
871209|NCT02715440|nursing home
871210|NCT02715440|elderly
871211|NCT02715440|therapy elderly
871212|NCT02715440|Adverse Effect
871213|NCT02715440|pharmacokinetics
871214|NCT02715440|Decreased Drug Tolerance
871215|NCT02715375|asthma environment
871216|NCT02715362|immunotherapy GPC3 CAR-T HCC
871217|NCT02715349|schizophrenia
871218|NCT02715349|psychoeducation
871219|NCT02715349|Vietnam
871220|NCT02715336|In vitro fertilization
871221|NCT02715336|IVF
871222|NCT02715336|Assisted Reproductive Technologies
871223|NCT02715336|ART
871224|NCT02715336|OHSS
871225|NCT02715336|Ovarian hyperstimulation
871226|NCT02715336|dual triggering
871227|NCT02715336|GnRH
871228|NCT02715323|dry eye
871229|NCT02715323|immunological profile
871230|NCT02715323|autoimmune
871231|NCT02715297|glioblastoma
871232|NCT02715297|GBM
871233|NCT02715297|radiotherapy
871234|NCT02715297|Re-irradiation
871235|NCT02715297|progression
871236|NCT02715284|Metastatic solid tumors
871237|NCT02715284|Advanced solid tumors
871238|NCT02715284|anti-PD-1
871239|NCT02715284|TSR-042
871240|NCT02715284|Immunotherapy
871241|NCT02715284|PD-1
871242|NCT02715245|home rehabilitation
871243|NCT02715245|Primary Health Care
871244|NCT02715245|Physiotherapy
871245|NCT02715245|chronic disease
871246|NCT02715206|rural adolescents, substance use, prevention, adaptation
871247|NCT02715154|Epidural Anaesthesia
871248|NCT02715154|Cesarean Section
871249|NCT02715154|Dexmedetomidine
871250|NCT02715141|surveillance, molecular stool testing
871251|NCT02715115|Autism
871252|NCT02715115|Rett's syndrome
871253|NCT02715115|Rett disorder
871254|NCT02715115|Rett's disorder
871255|NCT02715115|Ataxia
871256|NCT02715102|lung cancer
871257|NCT02715102|lung neoplasms
871258|NCT02715102|lung nodules
871259|NCT02715102|screening tests for cancer
871260|NCT02715089|NGS
871261|NCT02715089|Liver Neoplasms
871262|NCT02715089|Biliary Tract Neoplasms
871263|NCT02715089|Hepatobiliary Neoplasms
871264|NCT02715076|Thoracic Surgery
871265|NCT02715076|Thoracic surgery, Video assisted
871266|NCT02715076|Open Abdominal Surgery
871267|NCT02715076|Anesthesia, General
871268|NCT02715050|phototherapy
871269|NCT02715050|photobiostimulation
871270|NCT02715050|muscle training
871271|NCT02715050|muscular adaptation
871272|NCT02715037|fusobacterium necrophorum
871273|NCT02715037|acute tonsillitis
871274|NCT02715037|peritonsillar cellulitis
871275|NCT02715037|infectious mononucleosis
871276|NCT02715037|microbiology
871277|NCT02715037|antibody development
871278|NCT02715024|Tamsulosin
871279|NCT02715024|Solifenacin
871280|NCT02715024|Lower urinary tract symptoms
871281|NCT02715024|Overactive bladder
871282|NCT02715011|Leukemia, Myeloid, Acute
871283|NCT02715011|JNJ-63709178
871284|NCT02714998|ectopic pregnancy
871285|NCT02714998|ovarian reserve
871286|NCT02714998|salpingectomy
871287|NCT02714998|methotrexate
871288|NCT02714985|chikungunya virus
871289|NCT02714985|RT-PCR
871290|NCT02714985|urine
871291|NCT02714985|diagnosis
871292|NCT02714946|Thyroid Nodule
871293|NCT02714946|Percutaneous radiofrequency ablation (RFA)
871294|NCT02714946|Percutaneous laser ablation (LA)
871295|NCT02714933|pulmonary
871296|NCT02714933|parenchyma
871297|NCT02714933|MRI sequence Advanced ZTE
871298|NCT02714933|chest computed tomography
871299|NCT02714920|DNA Repair Enzyme Signature
871300|NCT02714920|instrinsic radio- or chemo-resistance
871301|NCT02714920|treatment-induced radio- or chemo-resistance
871302|NCT02714894|magnetic resonance imaging
871303|NCT02714894|magnetic resonance spectroscopy
871304|NCT02714868|repeated measures
871305|NCT02714868|matched comparison
871306|NCT02714868|manualized intervention
871307|NCT02714868|self-determination
871308|NCT02714868|participation
871309|NCT02714868|advocacy
871310|NCT02714868|problem-solving
871311|NCT02714868|commuinity participation
871312|NCT02714868|occupational therapy
871313|NCT02714868|environment
871314|NCT02713854|Subfertility
871315|NCT02713854|In-vitro fertilization
871316|NCT02713854|BAP-EB
871317|NCT02713854|Endometrial epithelial cells
871318|NCT02713854|Repeated implantation failure
871319|NCT02713828|gpNMB-Expressing Squamous Cell Carcinoma of the Lung
871320|NCT02713828|Stage IIIb
871321|NCT02713828|Stage IV
871322|NCT02713828|Advanced Squamous Cell Cancer of the Lung
871323|NCT02713828|Metastatic Squamous Cell Cancer of the Lung
871324|NCT02713828|gpNMB-Expressing
871325|NCT02713828|Glembatumumab Vedotin
871326|NCT02713815|Amphetamine-type stimulants
871327|NCT02713815|prefrontal-striatal circuits
871328|NCT02713815|Glutamate/GABA
871329|NCT02713815|motivational and cognitive intervention
871330|NCT02713815|rTMS
871331|NCT02714829|Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
871332|NCT02714790|Acute Myeloid Leukemia
871333|NCT02714790|Minimal Residual Disease
871334|NCT02714790|Wilms Tumor
871335|NCT02714777|General anesthesia
871336|NCT02714777|Autonomic nervous system
871337|NCT02714777|Children
871338|NCT02714764|Alexander Disease
871339|NCT02714738|Brachial plexus block
871340|NCT02714738|Regional anesthesia
871341|NCT02714738|Ultrasound
871342|NCT02714725|Dexmedetomidine
871343|NCT02714725|Microcirculation
871344|NCT02714725|On Pump
871345|NCT02714725|CABG
871346|NCT02714686|Fertility
871347|NCT02714686|Total Contraception Prevalence Rate
871348|NCT02714686|Family planning methods
871349|NCT02714686|Birth Control
871350|NCT02714686|Mass Media Campaign
871351|NCT02714686|Demand for contraception
871352|NCT02714686|Modern Contraception Prevalence Rate
871353|NCT02714686|Birth intervals
871358|NCT02714621|Magnetic Resonance Imaging (MRI)
871359|NCT02714621|High Intensity Focused Ultrasound (HIFU)
871360|NCT02714621|Focused Ultrasound Surgery
871361|NCT02714595|cefiderocol
871362|NCT02714595|Bloodstream infections (BSI)
871363|NCT02714595|Complicated urinary tract infection (cUTI)
871364|NCT02714595|Ventilator associated pneumonia (VAP)
871365|NCT02714595|Hospital acquired pneumonia (HAP)
871366|NCT02714595|Sepsis
871367|NCT02714595|multi-drug resistant pathogens
871368|NCT02714595|S-649266
871369|NCT02714595|Gram-negative pathogens
871370|NCT02714595|Healthcare-associated pneumonia (HCAP)
871371|NCT02714595|carbapenem resistant pathogens
871372|NCT02714582|Shift report
871373|NCT02714582|Bedside
871374|NCT02714582|Nursing
871375|NCT02714582|Matched controlled trial
871376|NCT02714582|Mixed method
871377|NCT02714582|Patient participation
871378|NCT02714556|Lung volume
871379|NCT02714556|Lung Clearance Index
871380|NCT02714556|Functional Residual Capacity
871381|NCT02714556|Respiratory function
871382|NCT02714543|OSMF
871383|NCT02714543|Aloevera
871384|NCT02714543|Hydrocortisone
871385|NCT02714543|Hyaluronidase
871386|NCT02714504|Prophylaxis
871387|NCT02714465|Hyperbaric Oxygen Therapy; Gamma Knife Radiosurgery
871388|NCT02714452|Person-centred care
871389|NCT02714452|Thriving
871390|NCT02714452|Satisfaction with care
871391|NCT02714452|Residential aged care
871392|NCT02714452|Caring environment
871393|NCT02714439|Malignant neoplasms of female genital organs
871394|NCT02714439|Cervical Cancer Prevention
871395|NCT02714439|Abnormal Pap test
871396|NCT02714439|Positive HPV test
871397|NCT02714439|History of cervical dysplasia
871398|NCT02714439|Colposcopy
871399|NCT02714439|Proflavine
871400|NCT02714439|Proflavine hemisulfate
871401|NCT02714439|High-Resolution Microendoscopy
871402|NCT02714439|HRME
871403|NCT02714439|Human papillomavirus
871404|NCT02714426|Cognitive Aging
871405|NCT02714426|Attention
871406|NCT02714426|Mindfulness
871407|NCT02714413|D-allulose
871408|NCT02714413|Caucasian
871409|NCT02714413|African American
871410|NCT02714400|Obstructive Sleep Apnea
871411|NCT02714400|Arousal threshold
871412|NCT02714400|Venlafaxine
871413|NCT02714387|Non traumatic acute brain injury
871432|NCT02714361|Iron deficiency
871433|NCT02714361|Vitamin D
871434|NCT02714361|Iron absorption
871435|NCT02714361|Hepcidin
871436|NCT02714348|Helminth infection
871437|NCT02714348|Vaccination
871438|NCT02714322|Adalimumab
871439|NCT02714322|Biologics
871440|NCT02714322|Biosimilar
871441|NCT02714309|Postprandial glycemia
871442|NCT02714309|Metabolic health measures
871443|NCT02714296|colon preparation for endoscopy
871444|NCT02714296|enteral feeding
871445|NCT02714296|sip feeding
871446|NCT02714296|nutridrink
871447|NCT02714296|nutridrink compact protein
871448|NCT02714283|nontuberculous mycobacteria
871449|NCT02714283|corticosteroids
871450|NCT02714283|macrolides
871451|NCT02714283|antibiotics
871452|NCT02714205|Hot flash
871453|NCT02714153|Lead extraction
871454|NCT02714153|Superior Vena Cava Tear
871455|NCT02714153|Pacemaker/Defibrillator lead extraction
871456|NCT02714127|Human Papillomavirus
871457|NCT02714127|Biomarker
871458|NCT02714127|Self-sampling
871459|NCT02714127|First-void urine
871460|NCT02714127|Cervicovaginal fluid
871461|NCT02714127|Colposcopy
871462|NCT02714114|Antibodies
871463|NCT02714114|Vaccination
871464|NCT02714114|Self-sampling
871465|NCT02714114|First-void urine
871466|NCT02714114|Serum
871467|NCT02714088|High-intensity interval training
871468|NCT02714088|Functional fitness
871469|NCT02714088|Quality of life
871470|NCT02714088|Older adults
871471|NCT02714062|Adolescent Obesity
871472|NCT02714062|Childhood Obesity
871473|NCT02714062|Qsymia
871474|NCT02714062|Pharmacokinetics
871475|NCT02714062|VI-0521
871476|NCT02714049|hypoactive sexual desire disorder
871477|NCT02714049|Addyi
871478|NCT02714049|flibanserin
871479|NCT02714049|low sexual desire
871480|NCT02714049|HSDD
871481|NCT02714036|ALS
871482|NCT02714010|EGFR-TKI
871483|NCT02714010|whole brain radiotherapy
871484|NCT02714010|brain metastasis
871485|NCT02714010|non-small cell lung cancer
871486|NCT02713984|HER2 CAR-T
871487|NCT02713984|safety
871488|NCT02713984|efficiency
871489|NCT02713984|refractory and relapsed cancer
871490|NCT02713971|Rehabilitation
871491|NCT02713971|Balance
871492|NCT02713971|Gait
871493|NCT02713971|Biofeedback
871494|NCT02713958|Telerehabilitation
871495|NCT02713958|Elbow fractures
871496|NCT02713958|Arthrolysis
871497|NCT02713958|MediTouch
871498|NCT02713958|Occupational Therapy
871499|NCT02713958|Active exercises
871500|NCT02713945|Simvastatin
871501|NCT02713945|Ras
871502|NCT02713945|MAPK
871503|NCT02713932|Aortic valve stenosis
871504|NCT02713932|Aortic valve regurgitation
871505|NCT02713932|Transcatheter aortic valve implantation
871506|NCT02713919|Cancer
871507|NCT02713919|Outpatients
871508|NCT02713919|Family Caregivers
871509|NCT02713893|Pharmacokinetics
871510|NCT02713893|Econazole nitrate 1%
871511|NCT02713893|Benzydamine HCl 0.12%
871512|NCT02713893|Intravaginal cream
871513|NCT02713893|Antimycotic
871514|NCT02713893|Tolerability
871515|NCT02713880|Peripheral Nervous System Diseases
871516|NCT02713880|Neuromuscular Diseases
871517|NCT02713880|Metabolism, Inborn Errors
871518|NCT02713880|Genetic Diseases, Inborn
871519|NCT02713789|ED
871520|NCT02713776|High-Output Enterostomy
871521|NCT02713776|Pasireotide
871522|NCT02713776|Somatostatin Analogues
871523|NCT02713763|Sunitinib
871524|NCT02713750|Combined Oral Contraceptives
871525|NCT02713750|Highly Active Antiretroviral Therapy
871526|NCT02713750|Hormonal Contraception
871527|NCT02713750|Human Immunodeficiency Virus
871528|NCT02713750|Intrauterine Device
871529|NCT02713750|Pharmacokinetic
871530|NCT02713750|Sexually Transmitted Diseases
871531|NCT02713750|Reproductive Health
871532|NCT02713737|hypoxemia
871533|NCT02713737|high-flow
871534|NCT02713737|atrial fibrillation
871535|NCT02713737|sleep
871536|NCT02713711|Psoriasis
871537|NCT02713711|balneotherapy
871538|NCT02713711|phototherapy
871539|NCT02713711|balneophototherapy
871540|NCT02713698|Anaesthetics
871541|NCT02713698|Intravenous
871542|NCT02713698|Propofol
871543|NCT02713698|Pharmacokinetics
871544|NCT02713698|Pharmacodynamics
871545|NCT02713698|Propofol pharmacokinetic-pharmacodynamic model
871546|NCT02713685|regional anesthesia
871547|NCT02713685|lower limb surgery
871548|NCT02713685|Bupivacaine
871549|NCT02713659|Literacy
871550|NCT02713659|Child Development
871551|NCT02713659|Reading
871552|NCT02713646|MRI
871553|NCT02713646|Virtual Endoscopy
871554|NCT02713646|Pain Measurement
871555|NCT02713620|HBV vaccination, immunity
871556|NCT02713581|Proximal venous thromboembolism
871557|NCT02713568|Macrosomia
871558|NCT02713568|Magnetic Resonance- Estimated Fetal Weight
871559|NCT02713568|Ultrasound-Estimated Fetal Weight
871560|NCT02713568|Large-for-date fetus
871565|NCT02713516|Anxiety
871566|NCT02713516|OCD
871567|NCT02713516|Obsessive Compulsive Disorder
871568|NCT02713516|Generalized Anxiety
871569|NCT02713516|Social Phobia
871570|NCT02713516|Separation Anxiety
871571|NCT02713516|GAD
871572|NCT02713516|Youth
871573|NCT02713516|Teen
871574|NCT02713516|Therapy
871575|NCT02713451|Oxygen
871576|NCT02713438|Physical activity
871577|NCT02713438|Planning
871578|NCT02713438|Implementation intention
871579|NCT02713438|Quality of life
871580|NCT02713438|Body weight
871581|NCT02713425|Anxiety
871582|NCT02713425|Social Phobia
871583|NCT02713425|Separation Anxiety
871584|NCT02713425|Generalized Anxiety
871585|NCT02713425|GAD
871586|NCT02713425|Phobia
871587|NCT02713425|video game
871588|NCT02713425|teen
871589|NCT02713425|youth
871590|NCT02713425|child
871591|NCT02713425|adolescent
871592|NCT02713347|Quality of Life
871593|NCT02713347|Symptom Assessment
871594|NCT02713347|Palliative Care
871595|NCT02713347|Disease Management
871596|NCT02713347|Delivery of Health Care
871597|NCT02713347|Advance Care Planning
871601|NCT02713321|diabetes
871602|NCT02713321|vulnerable populations
871603|NCT02713321|comorbidity
871604|NCT02713321|patient-centered outcomes research
871605|NCT02713321|Medicaid reform
871606|NCT02713321|health disparities
871607|NCT02713295|Moderate Plaque Psoriasis
871608|NCT02713295|Plaque Psoriasis
871609|NCT02713295|Severe Plaque Psoriasis
871610|NCT02713282|Schizophrenia
871611|NCT02713282|R092670
871612|NCT02713282|Paliperidone Palmitate
871613|NCT02713269|Secondary Malignant Neoplasm of Vertebral Column
871614|NCT02713269|Spine Metastases
871615|NCT02713269|Epidural spinal cord compression
871616|NCT02713269|Stereotactic spine radiosurgery
871617|NCT02713269|SSRS
871618|NCT02713269|Thermal ablation
871619|NCT02713269|Symptom questionnaire
871620|NCT02713269|Surveys
871621|NCT02713256|Graves' disease
871622|NCT02713256|Hyperthyroidism
871623|NCT02713256|CFZ533
871624|NCT02713256|TSH
871625|NCT02713243|Primary bile acid diarrhea,
871626|NCT02713243|FXR agonist,
871627|NCT02713243|bile acid malabsorption.
871628|NCT02713217|depressive disorder
871629|NCT02713217|alcohol-related disorders
871630|NCT02713217|telemedicine
871631|NCT02713217|rural health
871632|NCT02713217|collaborative care
871633|NCT02713191|Bronchoscopy
871634|NCT02713191|Sedation
871635|NCT02713191|Dexmedetomidine
871636|NCT02713165|Gut Microbiota
871637|NCT02713139|vaginal
871638|NCT02713139|discharge
871639|NCT02713139|women
871640|NCT02713048|Cardiac arrest
871641|NCT02713048|Troponin I
871642|NCT02713048|coronary anatomy
871643|NCT02713022|DEXA Scan
871644|NCT02713022|15-235
871645|NCT02713009|Maternal body weight
871646|NCT02713009|Vitamin D
871647|NCT02713009|Pregnancy
871648|NCT02712996|Traumatic Brain Injury
871649|NCT02712996|Attention Deficit
871650|NCT02712996|TBI
871651|NCT02712996|Vyvanse
871652|NCT02712983|Inhaled tobramycin; tobramycin inhalation powder; bronchiectasis; pulmonary Pseudomonas aeruginosa infection; dose-finding study
871653|NCT02712918|Depression
871654|NCT02712918|Inpatient
871655|NCT02712918|Acute
871656|NCT02712918|Brief Behavioral Activation Treatment for Depression
871657|NCT02712905|Acute myeloid leukemia (AML)
871658|NCT02712905|myelodysplastic syndrome (MDS)
871659|NCT02712905|small cell lung cancer (SCLC)
871660|NCT02712905|myelofibrosis (MF)
871661|NCT02712905|solid tumor, lysine-specific demethylase 1 (LSD1) inhibitor
871662|NCT02712840|Single embryo transfer
871663|NCT02712840|Freeze-all
871664|NCT02712840|Fresh
871665|NCT02712840|Vitrification
871666|NCT02712840|Clinical Pregnancy
871667|NCT02712840|Blastocyst
871668|NCT02712827|self-gripping mesh, fibrin glue, total extraperitoneal
871669|NCT02712801|HIV
871670|NCT02712801|antiretroviral treatment
871671|NCT02712801|child
871672|NCT02712801|testing
871673|NCT02712788|Subarachnoid Hemorrhage
871674|NCT02712788|Cerebral Vasospasm
871675|NCT02712788|Milrinone
871676|NCT02712788|Hyperdynamic Therapy
871677|NCT02712762|immunological profiles
871678|NCT02712749|Binaural Beat
871679|NCT02712749|Elderly
871680|NCT02712749|preoperative medication
871681|NCT02712736|Primary Sclerosing Cholangitis
871682|NCT02712723|ER+, HER2-negative breast cancer
871683|NCT02712723|Stage II or III
871684|NCT02712723|Letrozole
871685|NCT02712723|Femara
871686|NCT02712723|Ribociclib
871687|NCT02712723|LEE011
871688|NCT02712723|Neo-adjuvant
871689|NCT02712710|knee, osteoarthritis, brace
871690|NCT02712697|liver-kidney yin deficiency syndrome
871691|NCT02712697|primary severe IgA nephropathy
871692|NCT02712697|Lee's grade Ⅲ
871693|NCT02712671|Cost-Benefit Analysis
871694|NCT02712671|Quality of Life
871695|NCT02712593|Healthy participants
871696|NCT02712593|Dietary supplement
871697|NCT02712593|Bioavailability
871698|NCT02712593|Niagen™
871699|NCT02712593|Nicotinamide riboside
871700|NCT02712593|N-methylnicotinamide
871701|NCT02712580|pediatric burns
871702|NCT02712580|deep dermal wounds
871703|NCT02712580|wound healing
871704|NCT02712580|ChildPain Measurement
871705|NCT02712580|Treatment Outcome Wound Healing/physiology
871706|NCT02712580|wireless electric stimulation
871707|NCT02712580|wireless current stimulation
871708|NCT02712580|wireless technology
871709|NCT02712580|children
871710|NCT02712580|conservative treatment
871711|NCT02712580|deep dermal scalds
871712|NCT02712580|humans
871713|NCT02712580|deep dermal burns
871714|NCT02712580|burns
871715|NCT02712580|wound healing process
871716|NCT02712554|Pain
871717|NCT02712554|Nausea
871718|NCT02712554|Vomiting
871719|NCT02712541|Caregiver burden Index
871720|NCT02712489|HAART-treated participants
871721|NCT02712489|Tat
871722|NCT02712489|Therapeutic immunization
871723|NCT02712476|Mannitol
871724|NCT02712476|Furosemid
871725|NCT02712476|Brain Relaxation
871726|NCT02712463|Schizophrenia
871727|NCT02712463|Oral antipsychotics
871728|NCT02712463|Long acting Injectable antipsychotics
871729|NCT02712450|geriatric
871730|NCT02712450|emergency
871731|NCT02712450|clinical pathway
871732|NCT02712450|regulation
871733|NCT02712450|SAMU
871734|NCT02712450|training
871735|NCT02712437|Insomnia
871736|NCT02712437|Quality of Life
871737|NCT02712437|Cognitive behavioral therapy
871738|NCT02712424|Vaccine
871739|NCT02712372|AZD4831 oral suspension
871740|NCT02712372|Healthy male subjects
871741|NCT02712372|Safety
871742|NCT02712372|Tolerability
871743|NCT02712372|Pharmacokinetics
871744|NCT02712372|Pharmacodynamics
871745|NCT02712359|Havrix
871746|NCT02712359|Cross-sectional seroprevalence survey
871747|NCT02712359|Panama
871748|NCT02712359|Long-term persistence
871749|NCT02712359|Hepatitis
871755|NCT02712333|PM2.5
871756|NCT02712333|air purification
871757|NCT02712333|randomized controlled trial
871758|NCT02712333|metabolomics
871759|NCT02712333|Metabolites
871760|NCT02712333|exhaled nitric oxide
871761|NCT02712320|Prostate Neoplasm Cancer Carcinoma
871762|NCT02712320|Safety Extension
871763|NCT02712294|pulmonary hypertension
871764|NCT02712294|peripheral muscle electrostimulation
871765|NCT02712294|capacity of the exercises
871766|NCT02712294|quality of life
871767|NCT02712281|Food Selectivity
871768|NCT02712281|Autism MEAL Plan
871769|NCT02712281|Parent Education
871770|NCT02712268|Polypharmacy
871771|NCT02712268|Clinical decision-making
871772|NCT02712255|Physical activity
871773|NCT02712255|Quality of life
871774|NCT02712255|Planning
871775|NCT02712255|Implementation intentions
871776|NCT02712255|Cardiovascular disease
871777|NCT02712255|Diabetes
871778|NCT02712203|Measles vaccine
871779|NCT02712203|Priorix
871780|NCT02712203|Priorix-Tetra
871781|NCT02712203|Age at vaccination
871782|NCT02712177|vaccine safety
871783|NCT02712177|interaction
871784|NCT02712164|Split-thickness skin graft
871785|NCT02712164|STSG
871786|NCT02712164|donor site
871787|NCT02712164|negative-pressure wound therapy
871788|NCT02712164|NPWT
871789|NCT02712164|dressing
871790|NCT02712151|transversus abdominal plane block
871791|NCT02712138|Hyperbilirubinemia
871792|NCT02712138|Unconjugated Benign Bilirubinemia
871793|NCT02712060|Ehlers-Danlos Syndrome
871794|NCT02712060|Obstructive Sleep Apnea
871795|NCT02712060|Prevalence
871796|NCT02712060|Children
871797|NCT02712060|Pediatric
871798|NCT02712060|Adolescents
871799|NCT02712047|Fluticasone furoate/vilanterol
871800|NCT02712047|Asthma
871801|NCT02712047|fraction of exhaled nitric oxide
871802|NCT02712047|cross-over
871803|NCT02712034|Medication-assisted treatment (MAT)
871804|NCT02712034|Buprenorphine
871805|NCT02712034|Methadone
871806|NCT02712034|Naltrexone
871807|NCT02712021|Cerebral Palsy
871808|NCT02712021|Lycra
871809|NCT02712021|Motor Function
871810|NCT02712021|Static Balance
871811|NCT02711995|botulinum toxin
871812|NCT02711995|injection augmentation
871813|NCT02711995|essential voice tremor
871814|NCT02711956|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
871815|NCT02711956|Phase 1b
871816|NCT02711956|Prostate Cancer
871817|NCT02711956|Pharmacokinetics (PK)
871818|NCT02711956|ZEN003694
871819|NCT02711956|ZEN-3694
871820|NCT02711956|Metastatic Castrate-Resistant Prostate Cancer
871821|NCT02711956|BET inhibitor (BETi)
871822|NCT02711956|Bromodomain
871823|NCT02711956|Pharmacodynamics (PD)
871824|NCT02711956|Enzalutamide
871825|NCT02711956|XTANDI
871826|NCT02711956|MDV3100
871827|NCT02711956|Epigenetics
871828|NCT02711930|intra-ocular pressure
871829|NCT02711930|prone ventilation
871830|NCT02711917|Propofol
871831|NCT02711917|Sevoflurane
871832|NCT02711917|Etomidate
871833|NCT02711917|Rocuronium
871834|NCT02711917|BIS
871835|NCT02711917|Closed loop infusion system
871836|NCT02711904|Extubation
871837|NCT02711904|Cough
871838|NCT02711904|Target Controlled Anesthesia (TACAN)
871839|NCT02711891|fingerstick
871840|NCT02711891|opioid
871841|NCT02711891|heelstick
871842|NCT02711891|loperamide
871843|NCT02711891|topical opioid
871844|NCT02711826|graft inflammation
871845|NCT02711826|Treg
871846|NCT02711826|polyclonally expanded Tregs (polyTregs)
871847|NCT02711826|darTregs
871848|NCT02711826|calcineurin inhibitors (CNIs)
871849|NCT02711826|mTOR inhibitors
871850|NCT02711787|Hand
871851|NCT02711787|Paralysis
871852|NCT02711787|Stroke
871853|NCT02711722|Neurally adjusted ventilatory assist
871854|NCT02711709|Intra-abdominal sepsis
871855|NCT02711709|Surgical ICU
871856|NCT02711696|Celiac Disease,
871857|NCT02711696|Gluten Free Diet
871858|NCT02711696|Gluten contamination
871859|NCT02711670|nephrolithiasis
871860|NCT02711670|calcium stones
871861|NCT02711670|kidney stones
871862|NCT02711670|hypercalciuria
871863|NCT02711670|thiazide
871864|NCT02711657|Fibrocytes
871865|NCT02711657|Interstitial Lung Diseases
871866|NCT02711657|Rheumatoid Arthritis
871867|NCT02711657|Asthma
871868|NCT02711644|Pregnancy
871869|NCT02711644|Prenatal
871870|NCT02711644|Nutrition
871871|NCT02711631|coronary angioplasty
871872|NCT02711631|cardiac rehabilitation
871873|NCT02711631|coronary artery bypass graft
871874|NCT02711605|ultrasound
871875|NCT02711605|fat
871876|NCT02711592|Orthopaedic Pain Management
871877|NCT02711566|Rehabilitation
871878|NCT02711566|Robot-assisted therapy
871879|NCT02711501|post-operative pain
871880|NCT02711501|diode laser
871881|NCT02711488|school-based intervention
871882|NCT02711488|sedentary behavior
871883|NCT02711488|physical activity
871884|NCT02711488|sugar sweetened beverages
871885|NCT02711462|Healthy Subjects
871886|NCT02711449|acute surgery
871887|NCT02711449|laparoscopy
871888|NCT02711371|addiction
871889|NCT02711371|cannabis
871890|NCT02711371|fMRI
871891|NCT02711345|LTT462
871892|NCT02711345|ERK
871893|NCT02711345|MAPK
871894|NCT02711345|solid tumor
871895|NCT02711267|Open Flow Microperfusion
871896|NCT02711241|Gastroenteritis
871897|NCT02711241|Analgesia
871898|NCT02711241|Emergency department
871899|NCT02711189|Addiction
871900|NCT02711189|Oxytocin
871901|NCT02711189|Functional Magnetic Resonance Imaging (fMRI)
871902|NCT02711189|Alcohol
871903|NCT02711189|Cue Reactivity
871904|NCT02711137|Solid tumor
871905|NCT02711137|lymphoma
871906|NCT02711137|leukemia
871907|NCT02711137|AML
871908|NCT02711137|myelodysplastic syndrome (MDS)
871909|NCT02711137|multiple myeloma
871910|NCT02711137|myeloproliferative neoplasm (MPN)
871911|NCT02711137|MDS/MPN
871912|NCT02711137|myelofibrosis (MF)
871913|NCT02711137|pancreatic cancer
871914|NCT02711137|colorectal cancer
871915|NCT02711137|non-small cell lung cancer
871916|NCT02711137|prostate cancer
871917|NCT02711137|breast cancer
871918|NCT02711137|ovarian cancer
871919|NCT02711137|glioblastoma multiforme (GBM)
871920|NCT02711137|NUT midline carcinoma
871921|NCT02711137|non-Hodgkin lymphoma
871922|NCT02711137|diffuse large B-cell lymphoma (DLBCL)
871923|NCT02711137|double-hit
871924|NCT02711137|triple-hit
871925|NCT02711137|myc
871926|NCT02711137|bromodomain and extra-terminal (BET) inhibitor
871927|NCT02711124|hemoglobin A1c
871928|NCT02711124|coronary artery bypass grafting
871929|NCT02711124|impedance aggregometry
871930|NCT02711124|platelet reactivity
871931|NCT02711124|clinical outcomes
871932|NCT02711098|cardiac arrest
871933|NCT02711098|hypothermia
871934|NCT02711098|critical care
871935|NCT02711059|hyperparathyroidism
871936|NCT02711059|insulin resistance
871937|NCT02711020|Depressive symptoms
871938|NCT02711020|Fibromyalgia
871939|NCT02711020|Cognitive Behavioral Therapy
871940|NCT02711020|Personal Constructs Therapy
871941|NCT02711020|Differential Efficacy
871942|NCT02711007|osteosarcoma
871943|NCT02711007|metastasis
871944|NCT02711007|advanced
871945|NCT02711007|apatinib
871946|NCT02710994|Immediate release omeprazole
871947|NCT02710994|Integrated gastric acidity
871948|NCT02710981|Sildenafil vaginal gel
871949|NCT02710981|endometrium
871950|NCT02710981|clomiphene
871951|NCT02710981|anovulation
871952|NCT02710968|FETO
871953|NCT02710916|Optical Coherence Tomography
871954|NCT02710916|Intraocular pressure
871955|NCT02710916|Optic Nerve Head
871956|NCT02710916|Nerve fiber layer
871957|NCT02710916|Bruch Membrane Opening -Minimum Rim Width
871958|NCT02710903|Periodontitis
871959|NCT02710903|SNP
871960|NCT02710903|Pathogenesis
871961|NCT02710903|IL29
871962|NCT02710903|IL28B
871970|NCT02710877|epidural analgesia
871971|NCT02710877|patient controlled analgesia
871972|NCT02710877|obstetric outcome
871973|NCT02710864|Cytomegalovirus
871974|NCT02710851|human papillomavirus vaccine
871975|NCT02710851|condylomata acuminata
871976|NCT02710838|Early gastric cancer
871977|NCT02710838|Infrared endoscope
871978|NCT02710799|Endocrinology
871979|NCT02710799|Referral list
871980|NCT02710799|Teleconsultation
871981|NCT02710799|Telemedicine
871982|NCT02710799|Cluster randomized clinical trial
871983|NCT02710773|Gait
871984|NCT02710773|Randomized controlled trial
871985|NCT02710773|Chronic Stroke
871986|NCT02710773|Treadmill training
871987|NCT02710760|Biomarkers
871988|NCT02710760|Child Nutrition Sciences
871989|NCT02710760|Economics, Behavioral
871990|NCT02710747|warfarin
871991|NCT02710747|Chinese patients
871992|NCT02710747|heart valve replacement
871993|NCT02710734|Urothelial
871994|NCT02710721|Fasting
871995|NCT02710721|Prostatic Neoplasms
871996|NCT02710721|Complementary Therapies
871997|NCT02710721|Urology
872002|NCT02710682|Lateral Epicondylitis of the elbow
872003|NCT02710682|Tendon Fenestration
872004|NCT02710682|Minimally invasive Surgery
872005|NCT02710682|Ultrasound-guided procedure
872006|NCT02710682|Ultrasonography
872007|NCT02710682|Elastography
872008|NCT02710669|ablation
872009|NCT02710656|Atherosclerosis
872010|NCT02710656|SFA
872011|NCT02710656|Poplitea
872012|NCT02710656|Drug coated balloon
872013|NCT02710656|Angioplasty
872014|NCT02710656|Restenosis
872015|NCT02710656|Peripheral artery disease (PAD)
872016|NCT02710643|Follicular
872017|NCT02710643|Lymphoma
872018|NCT02710643|Grade 1
872019|NCT02710643|Grade 2
872020|NCT02710604|chronic hepatitis B(CHB)
872021|NCT02710591|Rimeporide
872022|NCT02710578|Alcohol impaired driving
872023|NCT02710578|Driving simulation
872024|NCT02710578|Residual effects of alcohol
872025|NCT02710578|Acute psychomotor effects of alcohol
872026|NCT02710578|Young drivers
872027|NCT02710565|Endo bronchial ultrasound
872028|NCT02710565|Trans bronchial needle aspiration
872029|NCT02710565|Cell line
872030|NCT02710565|Lung cancer
872031|NCT02710552|arterial hypertension
872032|NCT02710552|antihypertensive drugs
872033|NCT02710539|arterial hypertension
872034|NCT02710539|antihypertensive drugs
872035|NCT02710513|beta-glucans
872036|NCT02710513|gut microbiota
872037|NCT02710513|p-cresyl sulphate (pCS)
872038|NCT02710513|indoxyl sulphate (IS)
872039|NCT02710513|short-chain fatty acid (SCFA)
872040|NCT02710500|LGMD2B
872041|NCT02710500|Limb Girdle Muscular Dystrophy
872042|NCT02710500|Miyoshi
872043|NCT02710500|Gene Transfer
872044|NCT02710500|Dysferlin
872045|NCT02710487|Parkinson's disease, Sleep Benefit
872046|NCT02710474|preterm birth
872047|NCT02710474|NICU
872048|NCT02710474|neonatal
872049|NCT02710474|kangaroo care
872050|NCT02710474|separation stress
872051|NCT02710474|family nurture
872052|NCT02710474|maternal confidence
872053|NCT02710474|maternal competence
872054|NCT02710474|calming cycle
872055|NCT02710474|infant neurodevelopment
872056|NCT02710474|infant psychological development
872057|NCT02710474|mother-infant co-regulation
872058|NCT02710474|post-partum depression
872059|NCT02710461|Polyphenols
872060|NCT02710461|Grape
872061|NCT02710461|Pomegranate
872062|NCT02710461|Metabolic syndrome
872063|NCT02710461|Abdominal obesity
872064|NCT02710461|Postprandial glucose
872065|NCT02710461|Insulin resistance
872066|NCT02710435|Coronary Sinus
872067|NCT02710435|Reducer
872068|NCT02710435|Refractory Angina
872069|NCT02710435|Angina Pectoris
872070|NCT02710435|Angina Pectoris, Stable
872071|NCT02710435|Chronic Stable Angina
872072|NCT02710435|Persistent Angina
872073|NCT02710435|Neovasc Reducer System
872074|NCT02710435|Refractory Angina Pectoris
872075|NCT02710435|Coronary Sinus Narrowing
872076|NCT02710435|Reversible Ischemic Heart Disease
872077|NCT02710435|Chronic Angina
872078|NCT02710435|End Stage Angina
872079|NCT02710435|Coronary Sinus Reduction
872080|NCT02710435|Coronary Sinus Reducer
872081|NCT02710435|Chronic Refractory Angina
872082|NCT02710435|Chronic Refractory Angina Pectoris
872083|NCT02710422|Prostate Cancer
872084|NCT02710422|Amniotic Membrane Placement
872085|NCT02710422|Robotic Assisted Radical Prostatectomy
872086|NCT02710422|RARP
872087|NCT02710422|Human Amniotic Membrane Allograft
872088|NCT02710409|safety, immunogenicity , quadrivalent influenza vaccine
872089|NCT02710396|Carcinoma, Non-Small-Cell Lung
872090|NCT02710396|Non-Small Cell Lung Cancer
872091|NCT02710396|Non-Small-Cell Lung Carcinoma
872092|NCT02710396|Nonsmall Cell Lung Cancer
872093|NCT02710396|NSCLC
872094|NCT02710396|Cancer of Neck
872095|NCT02710396|Neoplasms, Head and Neck
872096|NCT02710396|Cancer of the Head
872097|NCT02710396|Cancer of the Head and Neck
872098|NCT02710396|Head, Neck Neoplasms
872099|NCT02710396|Bladder Cancer
872100|NCT02710396|Bladder Neoplasms
872101|NCT02710396|Malignant Tumor of Urinary Bladder
872102|NCT02710396|Urinary Bladder Cancer
872103|NCT02710396|Esophageal Squamous Cell Carcinoma
872104|NCT02710396|Carcinoma, Transitional Cell
872105|NCT02710370|Bariatric Surgery
872106|NCT02710370|Gastric Bypass
872107|NCT02710370|Obesity/surgery
872108|NCT02710370|Endoscopy, Digestive System
872109|NCT02710370|Blood Glucose/metabolism
872110|NCT02710370|Diabetes Mellitus, Experimental/metabolism
872111|NCT02710370|Energy Metabolism
872112|NCT02710370|Glucose/metabolism
872113|NCT02710370|Jejunum/metabolism
872114|NCT02710370|Metabolomics
872115|NCT02710370|Gene Expression
872116|NCT02710357|Mandibular Prosthesis Implantation
872117|NCT02710357|Prostheses and Implants
872118|NCT02710357|Denture, Complete, Lower
872119|NCT02710279|Psychiatry
872120|NCT02710279|Depressive disorder
872121|NCT02710279|Suicide
872122|NCT02710266|Synthetic Protease Inhibitor
872123|NCT02710266|Hepatectomy
872124|NCT02710266|Postoperative Complications
872125|NCT02710253|Metastatic cancer
872126|NCT02710253|Prior treatment with immunotherapy agent
872127|NCT02710253|Salvage radiation therapy
872128|NCT02710253|Radiation therapy
872129|NCT02710253|XRT
872130|NCT02710253|Progressive disease
872131|NCT02710253|PD
872132|NCT02710253|Stereotactic radiation
872133|NCT02710253|External beam radiation
872134|NCT02710253|Whole brain radiation therapy
872135|NCT02710253|WBRT
872136|NCT02710214|Hot flash
872137|NCT02710214|Estrogen
872138|NCT02710214|Women
872139|NCT02710149|CAR-T
872140|NCT02710149|Leukemia
872141|NCT02710149|Lymphoma
872142|NCT02710136|Asthma
872143|NCT02710136|Glycerinated German cockroach allergenic extract
872144|NCT02710136|Cockroach Nasal Allergen Challenge
872145|NCT02710058|support group
872146|NCT02710058|15-246
872147|NCT02710058|The Arab American Breast Cancer Education and Referral Program (AMBER)
872148|NCT02710045|Immunity, Innate
872149|NCT02710045|Immunity, Non-Specific
872150|NCT02710045|Transcriptome
872151|NCT02710045|Antibodies
872152|NCT02710045|Cytokines
872153|NCT02710045|Immunity, Cellular
872154|NCT02710032|Transgender women
872155|NCT02710032|HIV Pre-Exposure Prophylaxis
872156|NCT02710032|Adherence
872157|NCT02710032|Peru
872158|NCT02710032|Social Networks
872159|NCT02710019|substance use
872160|NCT02710019|psychosis
872161|NCT02710019|youth
872162|NCT02710019|video game
872163|NCT02710006|Uterus
872164|NCT02710006|Ultrasound
872165|NCT02709980|Brain Injury
872166|NCT02709980|Insomnia
872167|NCT02709980|Sleep
872168|NCT02709941|Obstructive Sleep Apnea
872169|NCT02709941|Inspiratory Muscle Strength Training
872170|NCT02709941|Baroreceptor Sensitivity
872171|NCT02709941|Blood Pressure
872172|NCT02709928|Multiple ascending dose
872173|NCT02709850|ANGPTL-3
872174|NCT02709837|bioavailability
872175|NCT02709837|amino acid
872176|NCT02709837|carnosine
872177|NCT02709837|lycopene
872178|NCT02709837|mastication
872179|NCT02709837|meat
872180|NCT02709798|Shenfu Injection
872181|NCT02709798|Reperfusion Injury
872182|NCT02709798|Myocardial Protection
872183|NCT02709798|Percutaneous Coronary Intervention
872184|NCT02709746|paediatric patients
872185|NCT02709733|Virtual Reality
872186|NCT02709733|Negative Symptoms
872187|NCT02709720|Lung Cancer
872188|NCT02709720|Cancer Lung Disease
872189|NCT02709720|NORA
872190|NCT02709720|GECP 15/02
872191|NCT02709720|Metronomic administration
872192|NCT02709707|Diabetes, Blood Sugar
872193|NCT02709681|Sickle Cell Disease
872194|NCT02709681|Hydroxyurea
872195|NCT02709668|MTHFR depression vitamins Homocysteine
872196|NCT02709655|paediatric
872197|NCT02709616|Glioblastoma
872198|NCT02709616|DC vaccine
872199|NCT02709616|tumor antigen
872200|NCT02709616|personalized vaccine
872201|NCT02709551|corporate health management
872202|NCT02709551|hrv
872203|NCT02709551|mindfulness
872204|NCT02709525|hyaluronic acid
872205|NCT02709525|bone repair
872206|NCT02709525|dental socket
872207|NCT02709525|cone beam computed tomography
872208|NCT02709512|Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression
872210|NCT02709473|propofol
872211|NCT02709473|remifentanil
872212|NCT02709473|rocuronium
872213|NCT02709460|hematoma
872214|NCT02709460|complication
872215|NCT02709460|hysterectomy
872216|NCT02709447|Intimate Partner Violence
872217|NCT02709447|Juvenile Delinquency
872218|NCT02709447|Sexual Behavior
872352|NCT02708472|Anxiety
872219|NCT02709421|post-Endoscopic Retrograde cholangiopancreatography pancreatitis
872220|NCT02709421|Risk factors
872221|NCT02709421|Indomethacin
872222|NCT02709408|Carbapenem resistance
872223|NCT02709408|Enterobacteriaceae
872224|NCT02709408|Acinetobacter baumannii
872225|NCT02709408|Bloodstream infections
872226|NCT02709408|Intrabdominal infections
872227|NCT02709408|Urinary tract infections
872228|NCT02709408|Pneumonia
872229|NCT02709408|Risk factors
872230|NCT02709408|Outcome
872231|NCT02709408|Hospitalised patients
872232|NCT02709408|Mortality
872233|NCT02709408|Clinical response
872234|NCT02709408|Length of hospital stay
872235|NCT02709369|HIRREM
872236|NCT02709369|Neuro-technology
872237|NCT02709369|Closed-loop
872238|NCT02709369|Acoustic stimulation
872239|NCT02709369|Allostatic
872240|NCT02709369|heart rate variability
872241|NCT02709369|baroreflex sensitivity
872242|NCT02709369|traumatic brain injury
872243|NCT02709369|sports concussion
872244|NCT02709369|PTSD
872245|NCT02709369|hot flashes
872246|NCT02709369|headache
872247|NCT02709369|insomnia
872248|NCT02709304|urinary catheter discomfort
872249|NCT02709278|BCG
872250|NCT02709278|Aerosol
872251|NCT02709278|Tuberculosis
872252|NCT02709278|Challenge
872257|NCT02709187|DP-R208
872258|NCT02709174|Pulmonary Embolism
872259|NCT02709174|Pregnancy
872260|NCT02709174|D-Dimer
872261|NCT02709161|neurofeedback
872262|NCT02709161|major depressive disorder
872263|NCT02709161|amygdala
872264|NCT02709148|Parkinson's Disease
872265|NCT02709070|highly-purified CTL
872266|NCT02709044|Acute pancreatitis
872267|NCT02709044|Fluid resuscitation
872268|NCT02709044|Crystalloids
872269|NCT02709031|Cicletanine
872270|NCT02709031|Magnesium
872271|NCT02709031|Metabolic disease
872272|NCT02709018|posttraumatic stress disorder
872273|NCT02709018|losartan
872274|NCT02709018|angiotensin receptor blocker
872275|NCT02709005|Bacterial Vaginosis
872276|NCT02709005|Monolaurin Vaginal Gel
872277|NCT02708992|Azithromycin
872278|NCT02708992|Cefixime
872279|NCT02708992|Duration
872280|NCT02708992|High-Dose
872281|NCT02708992|Neisseria gonorrhoeae
872282|NCT02708992|Pharmacokinetics
872283|NCT02708992|Susceptibility
872284|NCT02708979|Stress
872285|NCT02708979|Eating
872286|NCT02708966|Gymnema Sylvestre
872287|NCT02708966|Glycemic control
872288|NCT02708927|social integration
872289|NCT02708927|cognitive impairment
872290|NCT02708927|emotional processing
872291|NCT02708927|quality of life
872292|NCT02708901|Autism Spectrum Disorder
872293|NCT02708901|Probiotic Vivomixx®
872294|NCT02708901|Gastrointestinal Symptoms
872295|NCT02708901|Gut-Brain Axis
872296|NCT02708901|Endophenotypes
872297|NCT02708888|Trunk
872298|NCT02708888|Biomechanical Phenomena
872299|NCT02708888|Gait
872300|NCT02708888|Electromyography
872301|NCT02708888|Rehabilitation
872302|NCT02708888|Balance
872303|NCT02708875|Microvascular
872304|NCT02708875|Insulin resistance
872305|NCT02708875|Mixed Meal
872306|NCT02708875|Glucose tolerance
872307|NCT02708823|Postoperative delirium
872308|NCT02708823|Risk assessment
872309|NCT02708823|Clinical screening tool
872310|NCT02708823|Tablet computer
872311|NCT02708810|radiosurgery (RS)
872312|NCT02708810|trigeminal neuralgia (TGN)
872313|NCT02708797|Cerebral autoregulation
872314|NCT02708797|MRI
872315|NCT02708797|VBM
872316|NCT02708797|Doppler Transcranial
872317|NCT02708784|Glykogen storage disease type 2)
872318|NCT02708784|Dystrophia Myotonica
872319|NCT02708784|Muscular disorders
872320|NCT02708784|MR-imaging
872321|NCT02708784|Muscle strength
872322|NCT02708784|Myopathies
872323|NCT02708745|communication
872324|NCT02708745|immunization
872325|NCT02708719|COPD
872326|NCT02708719|MID
872327|NCT02708719|1-minute sit-to-stand-test
872328|NCT02708706|adhesive capsulitis
872329|NCT02708706|hyaluronic acid
872330|NCT02708667|non-small cell lung cancer
872331|NCT02708667|crizotinib
872332|NCT02708667|hepatic toxicity
872335|NCT02708628|scar prevention
872336|NCT02708628|sectio
872337|NCT02708628|extract of allium cepae
872338|NCT02708628|allantoin
872339|NCT02708628|heparin
872340|NCT02708602|β2-adrenergic receptor
872341|NCT02708602|genetic polymorphisms
872342|NCT02708602|labor progress
872343|NCT02708563|meconium
872344|NCT02708563|neonatal resuscitation
872345|NCT02708498|Palliative care
872346|NCT02708498|Frail elderly
872347|NCT02708498|Comorbidity
872348|NCT02708498|Staff Development
872349|NCT02708498|Nursing Homes
872350|NCT02708472|Generalized Anxiety Disorder
872351|NCT02708472|synchronized Transcranial Magnetic Stimulation
872353|NCT02708472|Neurostimulation
872354|NCT02708472|TMS
872355|NCT02708446|Second Trimester
872356|NCT02708446|Abortion
872357|NCT02708446|Misoprostol
872358|NCT02708446|Sublingual
872359|NCT02708446|Buccal
872360|NCT02708433|lidocaine, jaw
872361|NCT02708420|Glidescope
872362|NCT02708420|Cardiovascular surgery
872363|NCT02708420|Macintosh Laryngoscope
872364|NCT02708420|Hemodynamic response
872365|NCT02708420|Anesthesia
872366|NCT02708381|Population 70 years and older
872367|NCT02708381|Geriatric
872368|NCT02708381|Oncogeriatric
872369|NCT02708381|Senior adult
872370|NCT02708368|Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
872371|NCT02708329|Coronary stenosis
872372|NCT02708329|Drug-eluting stent
872373|NCT02708329|Coronary angioplasty with stenting
872374|NCT02708329|Ischemic Heart Disease
872375|NCT02708329|Chronic total occlusion
872376|NCT02708329|Bifurcational lesion
872377|NCT02708329|Bifurcational stenting
872378|NCT02708303|Esophageal Reflux
872379|NCT02708303|Gastric Acid Reflux
872380|NCT02708303|Gastric Acid Reflux Disease
872381|NCT02708303|Gastro-Esophageal Reflux
872382|NCT02708303|Gastro-oesophageal Reflux
872383|NCT02708303|Gastroesophageal Reflux Disease
872384|NCT02708303|Reflux, Gastroesophageal
872385|NCT02708303|Esophageal Hernia
872386|NCT02708303|Hernia, Esophageal
872387|NCT02708303|Hernia, Paraesophageal
872388|NCT02708303|Hiatal Hernia
872389|NCT02708303|Sliding Hiatal Hernia
872390|NCT02708303|Sliding Esophageal Hernia
872391|NCT02708303|Hernia, Hiatus
872392|NCT02708303|Paraesophageal Hiatal Hernia
872393|NCT02708303|Questionnaires
872394|NCT02708277|intrauterine contraceptive device
872395|NCT02708277|intrauterine balloon
872396|NCT02708238|Infantile colics
872397|NCT02708199|Drug resistance malaria
872398|NCT02708199|Myanmar Artemisinin Resistance Containment Zone
872399|NCT02708199|Asymptomatic malaria
872400|NCT02708199|Serology
872401|NCT02708186|Dementia with Lewy bodies
872402|NCT02708186|Lewy bodies
872403|NCT02708186|REM sleep behavior disorder
872404|NCT02708186|Parkinson's disease dementia
872405|NCT02708173|vaccine
872406|NCT02708173|safety
872407|NCT02708134|Chest compressions
872408|NCT02708134|Cardiopulmonary Resuscitation
872409|NCT02708069|Autism Spectrum Disorder
872410|NCT02708056|Sugammadex
872411|NCT02708056|Rocuronium
872412|NCT02708056|Infant patients
872413|NCT02708017|Subcostal TAP block
872414|NCT02708017|Posterior TAP block
872415|NCT02708017|Ultrasound
872416|NCT02708017|Laparoscopic cholecystectomy
872417|NCT02707991|Continuity of Patient Care
872418|NCT02707991|Treatment Cascade
872419|NCT02707978|Dementia
872420|NCT02707978|Brain Diseases
872421|NCT02707978|Central Nervous System Diseases
872422|NCT02707978|Mild Cognitive Impairment
872423|NCT02707978|tauopathies
872424|NCT02707978|Neurodegenerative Disease
872425|NCT02707965|Generic brittle
872426|NCT02707965|Anti-epileptic drug
872427|NCT02707965|Bioequivalence
872428|NCT02707952|Compensated cirrhosis
872429|NCT02707952|Hepatitis C Genotype 1
872430|NCT02707952|Hepatitis C Genotype 5
872431|NCT02707952|Non-cirrhotic
872432|NCT02707952|Hepatitis C virus
872433|NCT02707952|Hepatitis C Genotype 6
872434|NCT02707952|Hepatitis C Genotype 3
872435|NCT02707952|Hepatitis C Genotype 4
872436|NCT02707952|Renal impairment
872437|NCT02707952|Hepatitis C Genotype 2
872438|NCT02707952|Chronic Hepatitis C
872439|NCT02707900|Vorinostat
872440|NCT02707900|AGS-004
872441|NCT02707900|HIV virus
872442|NCT02707900|AIDS
872443|NCT02707887|Mental Disorders
872444|NCT02707887|Mood Disorders
872445|NCT02707887|Behavioral Activation
872446|NCT02707861|HIV
872447|NCT02707861|Resistant
872448|NCT02707861|Salvage
872449|NCT02707861|ibalizumab
872450|NCT02707861|antibody
872451|NCT02707861|AIDS
872452|NCT02707835|Edema,taping,ultrasound
872453|NCT02707822|tacrolimus
872454|NCT02707822|pharmacokinetics
872455|NCT02707822|gene polymorphism
872456|NCT02707822|clinical factors
872457|NCT02707796|oxygen reserve index, partial oxygen pressure, hemicolectomy
872458|NCT02707783|stable and unstable angina
872459|NCT02707783|bioresorbable vascular scaffold
872460|NCT02707783|BVS
872461|NCT02707783|PCI
872462|NCT02707770|COPD, pulmonary rehabilitation, ambulatory oxygen therapy
872463|NCT02707757|Haemodialysis
872464|NCT02707757|Anaemia
872465|NCT02707757|Iron
872466|NCT02707757|Erythropoeitin stimulating agents
872467|NCT02707744|Heart Failure
872468|NCT02707744|Atrial Fibrillation
872469|NCT02707744|Ambulatory ECG monitor
872470|NCT02707718|sepsis
872471|NCT02707718|biomarker
872472|NCT02707718|prognostic
872473|NCT02707718|emergency department
872474|NCT02707718|diagnosis
872475|NCT02707692|HIV
872476|NCT02707692|AIDS
872477|NCT02707692|Immune Stimulation
872478|NCT02707692|HIV Reservoir
872479|NCT02707679|Knee
872480|NCT02707679|Mobilization
872481|NCT02707679|Taping
872482|NCT02707679|Function
872483|NCT02707679|Balance
872484|NCT02707666|resectable malignant pleural mesothelioma
872485|NCT02707666|Pembrolizumab
872486|NCT02707627|Pediatric
872487|NCT02707627|Laser
872488|NCT02707627|Burn
872489|NCT02707627|Scar
872490|NCT02707627|Photothermolysis
872491|NCT02707601|HIV
872492|NCT02707601|HCV
872493|NCT02707601|Antiretroviral therapy
872494|NCT02707601|HCV direct acting antiviral(s) (DAA)
872495|NCT02707588|Determine the tolerance and efficacy of Pembrolizumab
872496|NCT02707575|Keratin
872497|NCT02707575|Ranibizumab
872498|NCT02707562|Cystic fibrosis G551D mutation
872499|NCT02707562|GLPG1837
872500|NCT02707549|crystalloid solutions
872501|NCT02707549|acid-base imbalance
872502|NCT02707549|water-electrolyte Imbalance
872503|NCT02707523|RSV
872504|NCT02707523|respiratory support
872505|NCT02707523|RSV induced respiratory failure
872506|NCT02707510|logotherapy
872507|NCT02707510|cognitive behavior therapy
872508|NCT02707510|metastatic breast cancer
872509|NCT02707497|sepsis
872510|NCT02707497|thrombocytopenia
872511|NCT02707497|recombinant human thrombopoietin
872512|NCT02707497|platelet
872513|NCT02707497|28-day mortality
872514|NCT02707484|Gastrointestinal vascular malformation
872515|NCT02707484|thalidomide
872516|NCT02707484|Small intestinal bleeding
872517|NCT02707458|apolipoprotein E
872518|NCT02707458|Alzheimer
872519|NCT02707458|pre-clinical
872520|NCT02707458|pre-symptomatic
872521|NCT02707458|dose-finding
872522|NCT02707458|prevention
872523|NCT02707432|Cardiovascular Diseases
872524|NCT02707432|Community-Based Participatory Research
872525|NCT02707432|African Americans
872526|NCT02707419|Total knee replacement
872527|NCT02707419|Action observation treatment
872528|NCT02707419|Rehabilitation
872529|NCT02707393|stem cell transplantation
872530|NCT02707393|pediatrics
872531|NCT02707354|GVHD
872532|NCT02707354|confocal endomicroscopy
872533|NCT02707341|psoriasis
872534|NCT02707341|disease registry
872535|NCT02707328|Gemcitabine
872536|NCT02707328|Gemzar
872537|NCT02707328|CyberKnife
872538|NCT02707328|Cyber knife
872539|NCT02707328|CK
872540|NCT02707328|abraxane
872541|NCT02707328|nab-paclitaxel
872542|NCT02707315|Cyber Knife
872543|NCT02707315|CyberKnife
872544|NCT02707315|Stereotactic Radiosurgery
872545|NCT02707315|CK
872546|NCT02707276|Bipolar Depression
872547|NCT02707276|Geriatric
872548|NCT02707276|Low Field Magnetic Stimulation
872549|NCT02707263|heparin
872550|NCT02707250|pethidine
872551|NCT02707250|laparoscopic cholecystectomy
872552|NCT02707250|bupivacaine
872553|NCT02707224|DP-R208
872554|NCT02707172|Diethylhexyl Phthalate
872555|NCT02707172|Hand hygiene
872556|NCT02707172|Soaps
872557|NCT02707172|N-of-1 design
872558|NCT02707172|Cross-Over Studies
872559|NCT02707159|Circulating tumor cells
872560|NCT02707159|Nab-paclitaxel
872561|NCT02707159|Metastatic pancreatic cancer
872562|NCT02707159|Gemcitabine
872563|NCT02707120|PRGF, Neurotrophic Keratitis, platelet rich plasma, PRP
872564|NCT02707094|back
872565|NCT02707094|pain
872566|NCT02707094|chronic
872567|NCT02707068|Quality of Life
872568|NCT02707068|Self-help intervention
872569|NCT02707055|Alcohol Consumption
872570|NCT02707055|Alcohol Treatment
872571|NCT02707055|Alcoholism
872572|NCT02707055|Ghrelin
872573|NCT02707055|Ghrelin Antagonism
872582|NCT02707016|Emergence delirium
872583|NCT02707016|Sevoflurane
872584|NCT02707016|Pediatric anesthesia
872586|NCT02706977|Ophthalmology
872587|NCT02706964|metastasis
872588|NCT02706964|3D imaging
872589|NCT02706964|early detection
872590|NCT02706951|Musculoskeletal Disease
872591|NCT02706951|anti-inflammatory agents
872592|NCT02706951|Arthritis
872593|NCT02706951|Joint Disease
872594|NCT02706951|antirheumatic agents
872595|NCT02706938|Gastroesophageal reflux disease
872596|NCT02706938|Head of bed elevation
872597|NCT02706938|Quality of life
872598|NCT02706938|Nocturnal symptoms
872599|NCT02706938|Lifestyle measures
872600|NCT02706912|Stroke
872601|NCT02706912|Hemiparesis
872602|NCT02706912|Activities of Daily Living
872603|NCT02706912|Virtual World
872604|NCT02706912|Occupational Therapy
872605|NCT02706899|Antibody-Drug Conjugate CD33 Antigen
872606|NCT02706886|PH1
872607|NCT02706886|Primary Hyperoxaluria
872608|NCT02706886|RNAi therapeutic
872609|NCT02706886|siRNA
872610|NCT02706886|AGT
872611|NCT02706873|Musculoskeletal disease
872612|NCT02706873|Anti-inflammatory agents
872613|NCT02706873|Arthritis
872614|NCT02706873|Joint disease
872615|NCT02706873|Antirheumatic agents
872616|NCT02706847|Antirheumatic agents
872617|NCT02706847|Anti-inflammatory agents
872618|NCT02706847|Musculoskeletal Disease
872619|NCT02706847|Joint Disease
872620|NCT02706847|Arthritis
872621|NCT02706834|Drug therapy
872622|NCT02706821|prediabetes
872623|NCT02706821|blood glucose
872624|NCT02706821|clinical trial
872625|NCT02706808|chronic kidney disease
872626|NCT02706808|hemodialysis
872627|NCT02706808|conservative treatment
872628|NCT02706808|resistance starch
872629|NCT02706795|Cervical dystonia
872630|NCT02706795|Spasmodic torticollis
872631|NCT02706704|Intravitreal Adalimumab
872632|NCT02706704|Subcutaneous Adalimumab
872633|NCT02706678|FK506
872634|NCT02706678|Renal transplant recipients
872635|NCT02706678|cyclosporin
872636|NCT02706665|Anesthetics
872637|NCT02706665|Propofol
872638|NCT02706665|Electroencephalography
872639|NCT02706665|SEDline monitor
872640|NCT02706652|Screening
872641|NCT02706652|Genotype
872642|NCT02706652|Drug Dosing
872643|NCT02706652|Trial Selection
872644|NCT02706639|Biospecimen Procurement
872645|NCT02706639|Laboratory Research Specimens
872646|NCT02706639|Sample Collection
872647|NCT02706639|Rare Diseases
872648|NCT02706587|Critical illness polyneuropathy
872649|NCT02706587|Neuromuscular Electrical Stimulation
872650|NCT02706574|Eye Tracking
872651|NCT02706574|Blood-based Biomarkers
872652|NCT02706574|CSF-based Biomarkers
872653|NCT02706574|Magnetic Resonance Imaging
872654|NCT02706574|Computed Tomography Scan
872655|NCT02706574|Outcome Measures
872656|NCT02706561|15-317
872657|NCT02706548|occupational therapy
872658|NCT02706548|medication adherence
872659|NCT02706548|intervention studies
872660|NCT02706535|Itraconazole
872661|NCT02706535|Rifampicin
872662|NCT02706535|Pharmacokinetics
872663|NCT02706535|Cross-over
872664|NCT02706496|aging of elderly
872665|NCT02706496|falling prevention
872666|NCT02706496|electroencephalography
872667|NCT02706496|postural control
872668|NCT02706496|biomechanics
872669|NCT02706470|recurrent miscarriage; immunology
872670|NCT02706457|intensive care
872671|NCT02706457|functionality
872672|NCT02706405|PD-L1
872673|NCT02706405|immunotherapy
872674|NCT02706405|non-Hodgkin lymphoma
872675|NCT02706353|Melanoma
872676|NCT02706353|Metastatic Melanoma
872677|NCT02706353|Intratumoral APX005M
872678|NCT02706353|Pembrolizumab
872679|NCT02706353|Keytruda
872680|NCT02706353|MK-3475
872681|NCT02706353|SCH-900475
872682|NCT02706327|orthotic insoles
872683|NCT02706327|pain
872684|NCT02706327|quality of life
872685|NCT02706327|athletic performance
872686|NCT02706301|colorectal cancer survivor
872687|NCT02706301|cancer pain
872688|NCT02706301|psychological distress
872689|NCT02706301|coping skills training
872690|NCT02706301|symptom management
872691|NCT02706301|cancer survivorship
872692|NCT02706210|Mild Cognitive Impairment
872693|NCT02706210|Diffusion Tensor Imaging
872694|NCT02706197|Electron Paramagnetic Resonance
872695|NCT02706197|Hypoxia
872696|NCT02706197|OxyChip
872697|NCT02706184|gastric cancer
872698|NCT02706184|colorectal cancer
872699|NCT02706184|chemotherapy induced diarrhea
872700|NCT02706184|5-Fluoruracil
872701|NCT02706184|chemotherapeutic remedy
872702|NCT02706145|social norms
872703|NCT02706145|youth violence
872704|NCT02706145|media
872705|NCT02706132|Mesenchymal stromal cells
872706|NCT02706132|Liver Transplantation
872707|NCT02706132|ABO blood group
872708|NCT02706119|total parenteral nutrition
872709|NCT02706119|glargine insulin
872710|NCT02706119|insulin
872711|NCT02706080|Antithrombotic agents
872712|NCT02706080|VKA
872713|NCT02706080|Direct Oral Anticoagulant
872714|NCT02706080|Antiplatelet
872715|NCT02706080|Bleeding
872716|NCT02706080|Emergency
872717|NCT02706041|Exploratory Lap (Ex Lap)
872718|NCT02706041|Damage Control Laparotomy (DCL)
872719|NCT02706041|Definitive
872720|NCT02706028|underwater ultrasound
872721|NCT02706028|rheumatoid arthritis
872722|NCT02706015|Headache
872723|NCT02706015|Aura
872724|NCT02706015|Migraine
872725|NCT02705937|xerostomia, Saliva, iatrogenic oral dryness, dairy product
872726|NCT02705898|alcohol use disorders
872727|NCT02705898|physical activity
872728|NCT02705898|women's health
872729|NCT02705885|IgY
872730|NCT02705885|Periodontitis
872731|NCT02705885|Porphyromonas gingivalis
872732|NCT02705885|gingipains
872733|NCT02705885|Efficacy
872734|NCT02705872|Epidural
872735|NCT02705872|Programmed intermittent boluses
872736|NCT02705872|Cesarian section
872737|NCT02705872|Instrumented delivery
872738|NCT02705846|BRCA1
872739|NCT02705846|BRCA2
872740|NCT02705846|Lynch Syndrome
872741|NCT02705820|Metastatic, Lung Cancer, Switch, Maintenance, Pembrolizumab.
872742|NCT02705807|Pulmonary Arterial Hypertension (PAH)
872743|NCT02705807|safety
872744|NCT02705807|FLOLAN
872745|NCT02705807|New Thermostable Formulation
872746|NCT02705807|dose adjustment
872747|NCT02705807|reformulated diluents
872748|NCT02705807|currently marketed diluent
872749|NCT02705794|intubation, laryngoscopy
872750|NCT02705768|Neuron-specific enolase (NSE)
872751|NCT02705768|Carbamazepine
872752|NCT02705768|Oxcarbazepine
872753|NCT02705742|Mesenchymal stem cells
872754|NCT02705742|Liver cirrhosis
872755|NCT02705742|Hepatitis C
872756|NCT02705729|dental caries
872757|NCT02705729|proximal surfaces
872758|NCT02705729|posterior teeth
872759|NCT02705729|carious lesions
872760|NCT02705729|tooth diseases
872761|NCT02705729|dental restorations
872762|NCT02705729|glass-ionomer
872763|NCT02705664|Onychomycosis
872764|NCT02705612|Cervical cancer
872765|NCT02705612|cisplatin
872766|NCT02705612|nimotuzumab
872767|NCT02705599|Ischemic stroke
872768|NCT02705599|High resolution MRI
872769|NCT02705599|Perfusion
872770|NCT02705599|Mechanism
872771|NCT02705586|Movement disorders
872772|NCT02705586|Metabolic Stress
872773|NCT02705547|Friedreich Ataxia
872774|NCT02705534|Hepatitis C
872775|NCT02705534|Cirrhosis
872776|NCT02705534|Sofosbuvir
872777|NCT02705534|Ledipasvir
872778|NCT02705534|Ribavirin
872779|NCT02705521|shoulder
872780|NCT02705521|impingement
872781|NCT02705521|rehabilitation
872782|NCT02705521|physiotherapy
872783|NCT02705521|gamification
872784|NCT02705521|activation
872785|NCT02705521|engagement
872786|NCT02705508|extranodal natural killer/T-cell lymphoma
872787|NCT02705508|nasal type
872788|NCT02705508|chemotherapy
872789|NCT02705508|radiotherapy
872790|NCT02705482|Advanced solid tumors
872791|NCT02705482|MEDI0562
872792|NCT02705482|durvalumab
872793|NCT02705482|tremelimumab
872794|NCT02705482|OX40
872795|NCT02705482|PD-L1
872796|NCT02705482|CTLA-4
872797|NCT02705482|immuno-oncology
872798|NCT02705482|Cancer
872799|NCT02705469|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
872800|NCT02705469|Phase 1
872801|NCT02705469|Prostate Cancer
872802|NCT02705469|Pharmacokinetics (PK)
872803|NCT02705469|ZEN003694
872804|NCT02705469|ZEN-3694
872805|NCT02705469|Metastatic Castrate-Resistant Prostate Cancer
872806|NCT02705469|BET inhibitor (BETi)
872807|NCT02705469|Bromodomain
872808|NCT02705469|Pharmacodynamics (PD)
872809|NCT02705469|Epigenetics
872810|NCT02705456|Dental Caries
872811|NCT02705456|Tooth Paste
872812|NCT02705456|Orthodontics
872813|NCT02705456|Fluorides
872814|NCT02705417|arteriovenous fistula
872815|NCT02705417|colour Doppler
872816|NCT02705417|physical examination
872817|NCT02705417|renal dialysis
872818|NCT02705417|retrospective studies
872819|NCT02705404|multifocal
872820|NCT02705404|genetic
872821|NCT02705404|bronchoalveolar carcinoma
872822|NCT02705404|adenocarcinoma in situ
872823|NCT02705404|ground glass opacity
872824|NCT02705404|next generation sequencing
872825|NCT02705378|Intensive care unit
872826|NCT02705378|ICU
872827|NCT02705378|Critical Illness
872828|NCT02705378|Constipation
872829|NCT02705365|Lung Screening
872830|NCT02705365|Low-Dose Computer Tomography
872831|NCT02705365|Patient Navigation
872832|NCT02705352|Skin graft
872833|NCT02705352|5-Fluorouracil
872834|NCT02705352|Periocular reconstruction
872835|NCT02705313|neuroendocrine tumor
872836|NCT02705313|177Lu-DOTA0-Tyr3-Octreotate
872837|NCT02705287|vitamin D
872838|NCT02705287|half life
872839|NCT02705287|kinetics
872840|NCT02705261|child
872841|NCT02705261|behavior therapy
872842|NCT02705261|cognitive therapy
872843|NCT02705261|parent
872844|NCT02705261|anxiety
872845|NCT02705222|Abnormal uterine bleeding
872846|NCT02705222|Dilatation and curettage
872847|NCT02705222|Hysteroscopy
872848|NCT02705196|oncolytic
872849|NCT02705196|adenovirus
872850|NCT02705196|pancreatic
872851|NCT02705196|cancer
872852|NCT02705196|LOKON
872853|NCT02705196|LOAd703
872854|NCT02705183|surgical treatment
872855|NCT02705183|post-operative radiotherapy
872856|NCT02705183|quality of life
872857|NCT02705183|complications
872858|NCT02705183|survival
872859|NCT02705183|long bones
872860|NCT02705170|index of microvascular resistance
872861|NCT02705157|long bones
872862|NCT02705157|survival
872863|NCT02705157|prognosis
872864|NCT02705157|treatment
872865|NCT02705157|quality of life
872866|NCT02705131|Cervical radiculopathy
872867|NCT02705131|Balance chiropractic therapy
872868|NCT02705118|radiofrequency ablation
872869|NCT02705118|image fusion
872870|NCT02705105|Metastatic Solid Tumors
872871|NCT02705105|Advanced Solid Tumors
872872|NCT02705105|KW-0761
872873|NCT02705105|ONO-4538/BMS-936558
872874|NCT02705105|Anti-tumor
872875|NCT02705105|Mogamulizumab
872876|NCT02705105|Nivolumab
872877|NCT02705105|Oncology
872878|NCT02705053|Diabetes Mellitus, Type 1
872879|NCT02705053|Artificial Pancreas
872880|NCT02705053|Autoimmune Diseases
872881|NCT02705053|Diabetes Mellitus
872882|NCT02705053|Hyperglycemia
872883|NCT02705053|Hypoglycemia
872884|NCT02705040|male osteoporosis
872885|NCT02705040|miRNA
872886|NCT02705040|biomarker
872887|NCT02705014|pituitary stalk interruption syndrome
872888|NCT02705014|pulsatile GnRH therapy
872889|NCT02705014|hypogonadotropic hypogonadism
872890|NCT02705014|hypopituitarism
872891|NCT02704975|Dry Needling, Shoulder Stabilization
872892|NCT02704962|schizophrenia
872893|NCT02704962|olanzapine
872894|NCT02704962|trifluoperazine
872895|NCT02704962|antipsychotic polypharmacy
872896|NCT02704949|Urolithiasis
872897|NCT02704949|Fluoroscopy
872898|NCT02704949|Radiation
872899|NCT02704949|Ureteroscopy
872900|NCT02704923|Atropine
872901|NCT02704923|Pneumonia
872902|NCT02704923|Ventilator
872903|NCT02704923|Adults
872904|NCT02704923|Intensive care unit.
872905|NCT02704871|SeptiCyte
872906|NCT02704858|recurrent glioblastoma
872907|NCT02704858|recurrent GBM
872908|NCT02704845|Inflammatory back pain
872909|NCT02704845|Ankylosing spondylitis
872910|NCT02704845|Non-specific low back pain
872911|NCT02704845|Pain experience
872912|NCT02704845|Disability
872913|NCT02704845|Behavioural
872914|NCT02704845|Psychological
872915|NCT02704845|Biopsychosocial
872916|NCT02704845|Pain profiles
872917|NCT02704832|Geriatric oncology
872918|NCT02704832|Intervention
872919|NCT02704832|Case management
872920|NCT02704819|Decision Support System
872921|NCT02704819|Dizziness
872922|NCT02704819|Vertigo
872923|NCT02704819|Balance
872924|NCT02704780|Retained placenta
872925|NCT02704780|Misoprostol
872926|NCT02704780|double blind
872927|NCT02704780|Randomization
872928|NCT02704780|Haemorrhage
872929|NCT02704715|postoperative pain
872930|NCT02704715|general anesthesia
872931|NCT02704702|Fimasartan
872932|NCT02704676|CA-125
872933|NCT02704676|Pre-Eclampsia
872934|NCT02704663|adnexal mass
872935|NCT02704663|laparoscopy
872936|NCT02704663|removal route
872937|NCT02704663|postoperative pain
872938|NCT02704637|vasospasm
872939|NCT02704624|Crohn Disease
872940|NCT02704624|Fatigue
872941|NCT02704624|Osteopenia
872942|NCT02704624|Exercise Tolerance
872943|NCT02704624|Vitamin d
872944|NCT02704585|Neonatal resuscitation
872945|NCT02704585|Pulse oximetry
872946|NCT02704572|Herpes zoster vaccine
872947|NCT02704572|cell-mediated immunity
872948|NCT02704533|Plasmodium falciparum
872949|NCT02704533|PfSPZ Vaccine
872950|NCT02704533|PfSPZ Challenge (NF54)
872951|NCT02704533|PfSPZ Challenge (7G8)
872952|NCT02704533|CHMI
872958|NCT02704507|tretinoin
872959|NCT02704507|topical steroid
872960|NCT02704507|irritation
872961|NCT02704507|retinoid induced irritation
872962|NCT02704494|Resveratrol
872963|NCT02704494|Diabetes mellitus
872964|NCT02704494|Diabetes complications
872965|NCT02704494|Diabetic nephropathies
872966|NCT02704494|Proteinuria
872967|NCT02704494|Albuminuria
872968|NCT02704494|renal insufficiency
872969|NCT02704481|mifepristone
872970|NCT02704481|misoprostol
872971|NCT02704481|medical abortion
872972|NCT02704468|CAVI
872973|NCT02704468|FGF-21
872974|NCT02704468|arterial stiffness
872975|NCT02704468|renal transplant
872976|NCT02704455|children
872977|NCT02704442|anesthesiology
872978|NCT02704442|ophthalmology
872979|NCT02704416|Ventricular arrhythmias
872980|NCT02704416|aborted cardiac arrest
872981|NCT02704416|cardiac death
872982|NCT02704403|Elafibranor
872983|NCT02704403|NASH
872984|NCT02704403|Nonalcoholic steatohepatitis
872985|NCT02704403|Fatty liver disease
872986|NCT02704403|Fibrosis
872987|NCT02704390|ORADUR®-Methylphenidate
872988|NCT02704377|Prostate Cancer Survivor
872989|NCT02704338|Autoimmune Diseases, Treg
872990|NCT02704325|DMD
872991|NCT02704325|Duchenne Muscular Dystrophy
872994|NCT02704208|Antiretroviral Therapy
872995|NCT02704208|Medication Adherence
872996|NCT02704208|Technology-based Intervention
872997|NCT02704195|Parkinson disease
872998|NCT02704195|Deep brain stimulation
872999|NCT02704195|Freezing of Gait
873000|NCT02704182|Arthroplasties, Knee Replacement
873001|NCT02704169|head and neck cancer
873002|NCT02704169|H&N cancer
873003|NCT02704156|Stereotactic body radiation therapy
873004|NCT02704156|CyberKnife
873005|NCT02704156|Initial treatment
873006|NCT02704130|Therapeutic Chemoembolization
873007|NCT02704130|Ablation Techniques
873008|NCT02704130|Transarterial Chemoembolization
873009|NCT02704130|TACE
873010|NCT02704130|Microwave Ablation
873011|NCT02704130|MWA
873012|NCT02704065|amyloidosis
873013|NCT02704065|renal transplantation
873014|NCT02704026|Body composition
873015|NCT02704026|Nutritional status
873016|NCT02704013|Neurotrophins
873017|NCT02704013|Nerve Growth Factor
873018|NCT02704013|Brain-Derived Neurotrophic Factor
873019|NCT02704013|Urinary Biomarkers
873020|NCT02704013|Urodynamics
873021|NCT02704013|Anticholinergics
873022|NCT02704013|Children
873023|NCT02703961|CCRT
873024|NCT02703961|adjuvant chemotherapy
873025|NCT02703961|cisplatin and docetaxel
873026|NCT02703909|morbid obesity
873027|NCT02703909|laparoscopic surgery
873028|NCT02703909|neuromuscular blockade
873029|NCT02703896|g a, bile reflux. PPIs, H2RAs, prokinetic agents
873030|NCT02703831|adult spine deformity
873031|NCT02703831|time-driven activity-based costing
873032|NCT02703831|three-column posterior osteotomy
873033|NCT02703805|Community program
873034|NCT02703805|Wellness
873035|NCT02703805|Exercise
873036|NCT02703805|Physical Activity
873037|NCT02703805|Education
873038|NCT02703805|Stroke
873039|NCT02703805|Self-management
873040|NCT02703779|Multiple Myeloma
873041|NCT02703779|Bortezomib
873042|NCT02703779|Autologous
873043|NCT02703779|Stem Cell
873044|NCT02703779|Purging
873045|NCT02703779|In-vivo purging
873046|NCT02703779|Ex-vivo purging
873047|NCT02703779|Leukapheresis
873048|NCT02703779|Contaminated
873049|NCT02703779|Stem Cell Harvest
873050|NCT02703779|Stem Cell Transplant
873051|NCT02703779|Transplantation
873052|NCT02703727|polypharmacy
873053|NCT02703727|polymedication check
873054|NCT02703727|anticoagulation treatment
873055|NCT02703714|Advanced
873056|NCT02703714|Locally-advanced
873057|NCT02703714|Not eligible for resection
873058|NCT02703714|Prior chemotherapy treatment
873059|NCT02703701|Patient Satisfaction
873060|NCT02703701|Emergency Department efficiency
873061|NCT02703662|Biologic mesh
873062|NCT02703662|abdominal wall reconstruction
873063|NCT02703649|Aromatase inhibitor
873064|NCT02703649|induction of ovulation
873066|NCT02703623|Prostate cancer
873067|NCT02703623|Metastatic castration-resistant prostate cancer to the bone
873068|NCT02703623|mCRPC
873069|NCT02703623|Adenocarcinoma of the prostate
873070|NCT02703623|Biomarkers
873071|NCT02703623|Abiraterone Acetate
873072|NCT02703623|Zytiga
873073|NCT02703623|Prednisone
873074|NCT02703623|ARN509
873075|NCT02703623|Ipilimumab
873076|NCT02703623|Yervoy
873077|NCT02703623|BMS-734016
873078|NCT02703623|MDX010
873079|NCT02703623|Cabazitaxel
873080|NCT02703623|Jevtana
873081|NCT02703623|Carboplatin
873082|NCT02703623|Paraplatin
873083|NCT02703610|Pain
873084|NCT02703610|Elderly
873085|NCT02703597|Cigarette Smoking Behavior
873086|NCT02703597|Smoking curiosity
873087|NCT02703597|Smoking Cessation
873088|NCT02703597|Smoking Prevention
873089|NCT02703597|Health improvement
873090|NCT02703597|Smoking prevention interactive experience
873091|NCT02703597|ASPIRE
873092|NCT02703597|Game-based social activities
873093|NCT02703597|GSA's
873094|NCT02703597|Surveys
873095|NCT02703597|Questionnaires
873096|NCT02703597|Interviews
873097|NCT02703584|Double trigger
873098|NCT02703571|Trametinib
873099|NCT02703571|Ribociclib
873100|NCT02703571|LEE011
873101|NCT02703571|TMT212
873102|NCT02703571|advanced solid tumors
873103|NCT02703571|pancreatic cancer
873104|NCT02703571|KRAS-mutant colorectal cancer
873105|NCT02703571|colorectal cancer
873106|NCT02703571|advanced pancreatic cancer
873107|NCT02703571|metastatic pancreatic cancer
873108|NCT02703545|familial pancreas cancer
873109|NCT02703545|pancreatic cyst
873110|NCT02703532|Therapy
873111|NCT02703532|Rehabilitation
873112|NCT02703532|Caregiver
873113|NCT02703519|cesarean section, repeat
873114|NCT02703519|uterine scar tissue
873115|NCT02703519|transvaginal ultrasound
873116|NCT02703519|uterine rupture
873117|NCT02703519|placenta accreta
873118|NCT02703519|placenta percreta
873119|NCT02703519|placenta increta
873120|NCT02703467|Exhaled hydrogen sulphide
873121|NCT02703428|Abdominal
873122|NCT02703428|Aortic
873123|NCT02703428|Aneurysm
873124|NCT02703415|immune
873125|NCT02703415|interleukin
873126|NCT02703415|tramadol
873127|NCT02703415|postoperartive analgesia
873128|NCT02703415|pediatric
873129|NCT02703415|caudal bupivacaine
873130|NCT02703402|low back pain
873131|NCT02703402|physical exercise and quality of life
873132|NCT02703389|knowledge translation
873133|NCT02703389|antimicrobial stewardship
873134|NCT02703311|Valtech Cardio
873135|NCT02703311|Cardioband
873136|NCT02703311|Mitral Valve
873137|NCT02703298|Advanced Solid Malignancy
873138|NCT02703298|Safety and Tolerability
873139|NCT02703298|Tumor Response
873140|NCT02703298|Oncology
873141|NCT02703272|Lymphoma, Non-Hodgkin
873142|NCT02703272|Ibrutinib
873143|NCT02703272|JNJ-54179060
873144|NCT02703246|Hysterectomy, Vaginal
873145|NCT02703246|Hysterectomy, Abdominal
873146|NCT02703220|sleep apnea
873147|NCT02703220|chemoresponsiveness
873148|NCT02703220|cerebrovascular response
873149|NCT02703220|hyperoxia
873150|NCT02703220|acetazolamide
873151|NCT02703220|finasteride
873152|NCT02703220|apneic threshold
873153|NCT02703220|carbon-dioxide reserve
873154|NCT02703207|obstructive sleep apnea
873155|NCT02703207|COPD
873156|NCT02703207|Overlap syndrome
873157|NCT02703207|quality of life
873158|NCT02703207|neurocognitive function
873159|NCT02703207|sleepiness
873160|NCT02703207|elderly
873161|NCT02703194|IgG4-related disease
873162|NCT02703194|IgG4-related sclerosing cholangitis
873163|NCT02703194|Mikulicz disease
873164|NCT02703194|Pancreatitis
873165|NCT02703194|Retroperitoneal fibrosis
873166|NCT02703194|Lymphadenopathy
873167|NCT02703181|Safety
873168|NCT02703181|Dose Escalation
873169|NCT02703181|Repeat Dosing
873170|NCT02703181|Epelsiban
873171|NCT02703181|Pharmacokinetics
873172|NCT02703181|Healthy Women Volunteers
873173|NCT02703181|Tolerability
873174|NCT02703181|Oxytocin
873175|NCT02703168|Dental implants
873176|NCT02703142|esophagogastrostomy
873177|NCT02703142|gastric conduit ischemia
873178|NCT02703142|endoscopy
873179|NCT02703129|Migraine
873180|NCT02703129|Diet quality
873181|NCT02703129|Nutritional intervention
873182|NCT02703129|Severity of disease
873183|NCT02703129|Depressive symptoms
873184|NCT02703116|HIV
873185|NCT02703116|Substance Use
873186|NCT02703103|cardiopulmonary resuscitation
873187|NCT02703103|chest compression
873188|NCT02703103|adult
873189|NCT02703103|simulation
873190|NCT02703064|Furocyst
873191|NCT02703064|PCOS
873192|NCT02703038|cardiogenic shock
873193|NCT02703038|observatory
873194|NCT02703025|Obesity, green coffee bean extract, weight management
873195|NCT02702973|Characteristic analysis
873196|NCT02702960|FL-HCC
873197|NCT02702960|living donor liver transplant
873198|NCT02702960|HLA matched first degree relative
873199|NCT02702960|Milan Criteria
873200|NCT02702960|Ephraim Fuchs
873201|NCT02702960|Fibrolamellar Cancer Foundation
873202|NCT02702960|fibrolamellar
873203|NCT02702960|non-fibrolamellar
873204|NCT02702947|BPH
873205|NCT02702947|Prunus Domestica extract
873206|NCT02702882|Fenugreek seed extract, hypogonadism, protodioscin, testosterone
873207|NCT02702869|cleft lip
873208|NCT02702869|cleft palate
873209|NCT02702869|cleft lip and palate
873210|NCT02702869|cleft alveolus
873211|NCT02702869|multidisciplinary team
873212|NCT02702869|interdisciplinary team
873213|NCT02702856|Prostate Cancer
873214|NCT02702856|Gleason Grade
873215|NCT02702856|Prostatic Neoplasms
873340|NCT02702375|Diabetes Mellitus
873216|NCT02702817|Alzheimer's disease, biomarkers, cognitive decline, pre-clinical
873217|NCT02702791|Physical activity
873218|NCT02702791|Pulmonary rehabilitation
873219|NCT02702791|COPD
873220|NCT02702778|Polymyalgia Rheumatica (PMR)
873221|NCT02702765|sCD163
873222|NCT02702765|liver cirrhosis
873223|NCT02702765|disease severity
873224|NCT02702752|Heart diseases stromal differentiation factor alpha 1
873225|NCT02702713|bioactive
873226|NCT02702713|enriched foods
873227|NCT02702713|anthocyanins (AC)
873228|NCT02702713|beta-glucans (BG)
873229|NCT02702713|docosahexaenoic acid (DHA)
873230|NCT02702687|Asthma
873231|NCT02702687|Childhood Asthma
873232|NCT02702687|Bronchial Diseases
873233|NCT02702687|Immune System Diseases
873234|NCT02702687|Lung Diseases
873235|NCT02702687|Lung Diseases, Obstructive
873236|NCT02702687|Respiratory Tract Diseases
873237|NCT02702687|Peak Flow Meter
873238|NCT02702687|Symptom Perception
873239|NCT02702687|Illness Representation
873240|NCT02702661|Fascia Iliaca Block
873241|NCT02702661|Local Anaesthetic Infiltration
873242|NCT02702661|Hip Arthroscopy
873243|NCT02702648|healthy subjects
873244|NCT02702648|first-in-man
873245|NCT02702648|safety
873246|NCT02702622|bananas
873247|NCT02702622|biofortified
873248|NCT02702622|carotenoids
873249|NCT02702622|vitamin A
873250|NCT02702583|Myelosuppressive Chemotherapy
873251|NCT02702583|Febrile Neutropenia
873252|NCT02702583|Solid Tumors
873253|NCT02702583|Dental Infection
873254|NCT02702583|Oral Infection
873255|NCT02702557|Frail Elderly
873256|NCT02702557|Elastic Band Exercises
873257|NCT02702557|Unsupervised Exercises
873258|NCT02702557|Monitoring Technology
873259|NCT02702557|Bandcizer
873260|NCT02702557|Adherence
873261|NCT02702557|Feasibility
873262|NCT02702531|Laparoscopic Surgery
873263|NCT02702531|FloShield Defogging and Cleaning System
873264|NCT02702531|Clearify Defogging and Cleaning System
873265|NCT02702531|gynecologic
873266|NCT02702518|rhDNase I, Pulmozyme, oGVHD, Dry Eye
873267|NCT02702505|Pulp
873268|NCT02702505|pulpotomies
873269|NCT02702505|mineral trioxide aggregate
873270|NCT02702492|PAK4
873271|NCT02702492|KPT-9274
873272|NCT02702492|Karyopharm
873273|NCT02702492|NHL
873274|NCT02702492|solid tumors
873275|NCT02702479|Systematic review and meta-analysis
873276|NCT02702479|Evidence-based medicine (EBM)
873277|NCT02702479|Evidence-based nutrition (EBN)
873278|NCT02702479|Clinical practice guidelines
873279|NCT02702479|Clinical trials
873280|NCT02702479|Dietary sugars
873281|NCT02702479|Fructose
873282|NCT02702479|High fructose corn syrup
873283|NCT02702479|Isocaloric
873284|NCT02702479|Hypercaloric
873285|NCT02702479|Cardiometabolic Risk Factors
873286|NCT02702479|Triglycerides
873287|NCT02702479|Cholesterol
873288|NCT02702479|Glycemic control
873289|NCT02702479|Body weight
873290|NCT02702479|Uric acid
873291|NCT02702479|Blood pressure
873292|NCT02702479|Fatty liver
873293|NCT02702479|Fasting
873294|NCT02702479|Postprandial
873295|NCT02702466|Upper limb musculoskeletal disorders
873296|NCT02702466|Spa treatment
873297|NCT02702466|Randomized controlled trials
873298|NCT02702466|Education
873299|NCT02702466|Self- management
873300|NCT02702466|Self-care
873301|NCT02702466|Exercise
873302|NCT02702466|Non pharmacological treatment
873303|NCT02702440|Systematic review and meta-analysis
873304|NCT02702440|Sugars
873305|NCT02702440|Liquid calories
873306|NCT02702440|Solid calories
873307|NCT02702440|Clinical trials
873308|NCT02702440|Body weight
873309|NCT02702440|Body Mass Index
873310|NCT02702440|Evidence-base nutrition (EBN)
873311|NCT02702440|Evidence-base medicine (EBM)
873312|NCT02702440|Clinical practice guidelines
873313|NCT02702427|viral infections post HSCT, virus-specific T-cells
873314|NCT02702414|PD1
873315|NCT02702414|PD-1
873316|NCT02702414|PDL1
873317|NCT02702414|PD-L1
873322|NCT02702388|Lenvatinib
873323|NCT02702388|E7080
873324|NCT02702388|Iodine-131 Refractory Differentiated Thyroid Cancer
873325|NCT02702388|Lenvima
873326|NCT02702388|Phase 2
873327|NCT02702388|RR-DTC
873328|NCT02702375|Systematic review and meta-analysis
873329|NCT02702375|Evidence-based medicine (EBM)
873330|NCT02702375|Evidence-based nutrition (EBN)
873331|NCT02702375|Clinical practice guidelines
873332|NCT02702375|Prospective cohort studies
873333|NCT02702375|Dietary sugars
873334|NCT02702375|Fructose
873335|NCT02702375|Sucrose
873336|NCT02702375|High fructose corn syrup
873337|NCT02702375|HFCS
873338|NCT02702375|Cohort studies
873339|NCT02702375|Prospective studies
873341|NCT02702375|Metabolic syndrome
873342|NCT02702375|Coronary heart disease
873343|NCT02702375|Stroke
873344|NCT02702375|Hypertension
873345|NCT02702375|Gout
873346|NCT02702362|disorders of consciousness
873347|NCT02702362|minimally conscious state
873348|NCT02702362|traumatic brain injury
873349|NCT02702362|stroke
873350|NCT02702362|transcranial direct current stimulation
873351|NCT02702323|hepatocellular carcinoma
873352|NCT02702323|pulmonary metastasis
873353|NCT02702323|Apatinib
873354|NCT02702323|efficacy
873355|NCT02702323|safety
873356|NCT02702297|Preterm premature rupture of the membranes
873357|NCT02702297|PPROM
873358|NCT02702297|PROM
873359|NCT02702297|fetal membranes
873360|NCT02702297|premature rupture
873361|NCT02702297|neonatal early onset sepsis
873362|NCT02702297|amniotic fluid
873363|NCT02702297|amniotic infection
873364|NCT02702297|fetal inflammatory response syndrome
873365|NCT02702297|adverse neonatal outcome
873366|NCT02702297|FIRS
873367|NCT02702284|Advance Directives
873368|NCT02702284|Healthcare power of attorney
873369|NCT02702258|mindfulness
873370|NCT02702258|blood pressure
873371|NCT02702258|hypertension
873372|NCT02702258|prehypertension
873373|NCT02702206|Shoulder pain
873374|NCT02702206|subdeltoid bursitis
873375|NCT02702206|subacromial bursitis
873376|NCT02702206|intra-bursa injection
873377|NCT02702167|brain stimulation
873378|NCT02702167|rTMS
873379|NCT02702154|brain stimulation
873380|NCT02702154|rTMS
873387|NCT02702128|Bleeding perioperative
873388|NCT02702128|EXACYL
873389|NCT02702128|Oorthognathism surgery
873390|NCT02702128|Hematoma
873391|NCT02702115|gene specific targeted insertion
873392|NCT02702076|Apomorphine
873393|NCT02702024|efficacy
873394|NCT02702024|double incision technique
873395|NCT02702024|uterus preserving surgery
873396|NCT02701998|Ischemic Stroke
873397|NCT02701998|Transient Ischemic Attack
873398|NCT02701998|Physical Activity
873399|NCT02701998|Sedentary Behavior
873400|NCT02701998|Lifestyle
873401|NCT02701998|Behavior
873402|NCT02701959|Nitric oxide
873403|NCT02701959|Dietary intervention trail
873404|NCT02701946|Blood loss
873405|NCT02701946|Total knee arthroplasty
873406|NCT02701946|Bandage
873407|NCT02701946|Dressing
873408|NCT02701920|Premature Birth
873409|NCT02701920|Infant
873410|NCT02701920|Heart rate
873411|NCT02701881|Femoropopliteal Artery
873412|NCT02701881|Drug-eluting Stent
873413|NCT02701881|Endovascular Therapy
873414|NCT02701868|Infant Formula
873415|NCT02701829|taxi cab drivers
873416|NCT02701829|high blood pressure
873417|NCT02701829|16-038
873418|NCT02701816|Peripheral Artery Disease
873419|NCT02701816|Femoropopliteal Artery
873420|NCT02701816|Nitinol Stent
873421|NCT02701816|Restenosis
873422|NCT02701777|spike timing dependant plasticity
873423|NCT02701764|laser-assisted in situ keratomileusis
873424|NCT02701764|dry eye symptoms
873425|NCT02701764|LASIK
873426|NCT02701764|prevention
873427|NCT02701712|magnetic resonance
873428|NCT02701712|external beam radiotherapy
873429|NCT02701712|brachytherapy
873430|NCT02701712|radiotherapy
873431|NCT02701699|Lung Cancer
873432|NCT02701699|FAZA PET Imaging
873433|NCT02701699|Lung Radiotherapy
873434|NCT02701686|smoking cessation
873435|NCT02701673|Refractory or Relapsed Lymphoma
873436|NCT02701673|Busulfan
873437|NCT02701673|Busulfex
873438|NCT02701673|Myleran
873439|NCT02701673|Caphosol
873440|NCT02701673|Glutamine
873441|NCT02701673|Enterex
873442|NCT02701673|Glutapak-10
873443|NCT02701673|NutreStore
873444|NCT02701673|Resource
873445|NCT02701673|GlutaSolve
873446|NCT02701673|Sympt-X-G.I.
873447|NCT02701673|Sympt-X
873448|NCT02701673|Pyridoxine
873449|NCT02701673|Belinostat
873450|NCT02701673|Azacitidine
873451|NCT02701673|5-azacytidine
873452|NCT02701673|5-aza
873453|NCT02701673|Azacytidine
873454|NCT02701673|Vidaza
873455|NCT02701673|5-AZC
873456|NCT02701673|AZA-CR
873457|NCT02701673|Ladakamycin
873458|NCT02701673|Gemcitabine
873459|NCT02701673|Gemcitabine Hydrochloride
873460|NCT02701673|Gemzar
873461|NCT02701673|Stem cell transplant
873462|NCT02701673|SCT
873463|NCT02701673|Melphalan
873464|NCT02701673|Alkeran
873465|NCT02701660|Pharmaceutical Care
873466|NCT02701660|Adherence
873467|NCT02701660|Polypharmacy
873468|NCT02701660|e-Health
873469|NCT02701660|opioid substitution therapy
873470|NCT02701647|Transcranial Magnetic Stimulation
873471|NCT02701634|Chronic Graft Versus Host Disease (cGVHD)
873472|NCT02701634|newly diagnosed cGVHD
873473|NCT02701634|immune reconstitution
873474|NCT02701634|Immune System Diseases
873475|NCT02701634|allogeneic stem cell transplantation
873476|NCT02701634|SYK inhibitor
873477|NCT02701621|Parkinson's disease, aquatic therapy, balance, MIRT
873478|NCT02701517|conditioning treatment
873479|NCT02701517|alemtuzumab
873480|NCT02701517|allogeneic hematopoietic stem cell transplantation
873481|NCT02701517|chronic lymphoproliferative disorders
873482|NCT02701504|sleep apnea
873483|NCT02701504|coronary artery bypass grafting
873484|NCT02701504|outcomes
873485|NCT02701465|Shoulder
873486|NCT02701465|Exercise therapy
873487|NCT02701452|GnRH agonist triggering
873488|NCT02701426|Macrosomia
873489|NCT02701426|Weight gain
873490|NCT02701426|Participation
873491|NCT02701426|Adhesion
873492|NCT02701426|Physical activity
873493|NCT02701426|Nutrition
873494|NCT02701413|Apex M
873495|NCT02701413|Postpartum
873496|NCT02701413|Pelvic Floor rehabilitation
873497|NCT02701387|bone implant interaction
873498|NCT02701387|implant stability
873499|NCT02701387|resonance frequency analysis (RFA)
873500|NCT02701387|implant stability quotient (ISQ)
873501|NCT02701374|TRK-700
873502|NCT02701374|Post-Herpetic Neuralgia
873503|NCT02701361|mindfulness
873504|NCT02701361|critical illness
873505|NCT02701361|intensive care unit
873506|NCT02701361|mindfulness-based stress reduction
873507|NCT02701348|neoadjuvant endocrine
873508|NCT02701335|Osteoarthritis
873509|NCT02701335|Hand
873510|NCT02701335|Rehabilitation
873511|NCT02701322|Velopharyngeal Insufficiency
873512|NCT02701322|Fluoroscopy
873513|NCT02701309|Iron deficiency
873514|NCT02701309|Child
873515|NCT02701309|Infancy
873516|NCT02701309|Preschool children
873517|NCT02701309|iron deficiency anemia
873518|NCT02701296|Infiltration between popliteal artery and capsule of knee (iPACK)
873519|NCT02701270|Glycemic Index
873520|NCT02701270|Dietary Fiber
873525|NCT02701244|Infiltrating Ductal Carcinoma
873526|NCT02701244|Ductal Carcinoma In Situ
873527|NCT02701244|Brachytherapy
873528|NCT02701244|Breast Neoplasms
873529|NCT02701244|Breast Diseases
873530|NCT02701244|Neoplasms
873531|NCT02701244|Neoplasms by Site
873532|NCT02701231|lung cancer
873533|NCT02701231|Low-frequency rotating magnetic therapy system
873534|NCT02701231|systemic anti-tumor therapy
873535|NCT02701218|Canalith repositioning procedure (CRP)
873536|NCT02701218|BPPV
873537|NCT02701205|Plaque Psoriasis
873538|NCT02701205|Skin Disease
873539|NCT02701192|coccygodynia
873540|NCT02701192|coccygectomy
873541|NCT02701192|coccyx
873542|NCT02701179|Lignocaine
873543|NCT02701166|Pruritus
873544|NCT02701166|itch
873545|NCT02701166|cholestasis
873546|NCT02701075|peripheral neuropathy
873547|NCT02701075|traumatic tissue injury
873548|NCT02701075|radiculopathy
873554|NCT02701010|behavioral therapy
873555|NCT02701010|overactive bladder
873556|NCT02701010|urinary incontinence
873557|NCT02700958|Remote ischemic preconditioning
873558|NCT02700958|Contrast-induced Nephropathy
873559|NCT02700958|Stable coronary artery disease
873560|NCT02700958|Lower extremity arterial disease
873561|NCT02700958|Low molecular weight metabolites
873562|NCT02700958|Functional properties of arteries
873563|NCT02700932|non-invasive
873564|NCT02700906|Lateral epicondylitis
873565|NCT02700906|tennis elbow
873566|NCT02700906|Lidocaine
873567|NCT02700906|corticosteroid
873568|NCT02700880|wearable cardioverter defibrillator
873569|NCT02700880|ischemic cardiomyopathy
873570|NCT02700880|new onset heart failure
873571|NCT02700880|sudden cardiac death
873572|NCT02700867|intraosseous access
873573|NCT02700867|cardiopulmonary resuscitation
873574|NCT02700867|paramedic
873575|NCT02700867|simulation
873576|NCT02700867|cadaver
873577|NCT02700854|Hypothermia treatment
873578|NCT02700854|Hypocapnia
873579|NCT02700854|Inhaled CO2
873580|NCT02700854|Neuroprotection
873581|NCT02700828|Hypothermia treatment
873582|NCT02700828|Circulatory failure
873583|NCT02700828|Neonatal hypotension
873584|NCT02700828|Relative adrenal insufficiency
873585|NCT02700828|Hydrocortisone supplementation
873586|NCT02700802|food insecurity
873587|NCT02700802|informal caregiver health
873588|NCT02700802|clinic-to-community linkages
873589|NCT02700802|community resources
873590|NCT02700789|diagnostic accuracy
873591|NCT02700789|double decidual sac sign
873592|NCT02700789|intrauterine pregnancy
873593|NCT02700776|screening mammogram
873594|NCT02700776|GP88
873595|NCT02700776|breast cancer
873596|NCT02700763|Brain metastasis
873597|NCT02700737|cardiovascular modeling
873598|NCT02700737|aortic coarctation
873599|NCT02700737|virtual stenting
873600|NCT02700698|Mitochondria
873601|NCT02700698|women
873602|NCT02700698|muscle
873603|NCT02700698|PBMC
873604|NCT02700672|Ageing
873605|NCT02700672|Cognition
873606|NCT02700672|Executive Function
873607|NCT02700672|Gait
873608|NCT02700620|emotional eating
873609|NCT02700620|restrictive eating
873610|NCT02700620|body dissatisfaction
873611|NCT02700607|cerebral aneurysm, coiling embolization, blood viscosity
873612|NCT02700555|colorectal cancer
873613|NCT02700555|diabetes
873614|NCT02700555|metabolic parameters
873615|NCT02700555|Surveillance
873616|NCT02700542|asthma
873617|NCT02700542|pest management
873618|NCT02700503|Diabetes prevention
873619|NCT02700503|type 2 diabetes
873620|NCT02700503|prediabetes
873621|NCT02700503|family
873622|NCT02700477|Type-2 Diabetic
873623|NCT02700477|HbA1c
873624|NCT02700477|FBS
873625|NCT02700477|PPBS
873626|NCT02700477|C-peptide
873627|NCT02700451|IV acetaminophen
873628|NCT02700451|IV Ketorolac
873629|NCT02700451|Post-operative analgesia
873630|NCT02700451|Opioid use
873631|NCT02700425|Wide QRS
873632|NCT02700425|Ventricular Dyssynchrony
873633|NCT02700399|Rehabilitation
873634|NCT02700386|Breast
873635|NCT02700386|Cancer
873636|NCT02700386|Hypofractionated
873637|NCT02700386|Node-Positive Breast Cancer
873638|NCT02700386|Radiation Therapy
873639|NCT02700386|Comprehensive Radiation Therapy
873640|NCT02700360|EC-18
873641|NCT02700360|Hematology
873642|NCT02700360|Cancer
873643|NCT02700360|Neutropenia
873644|NCT02700334|Prediabetes
873645|NCT02700334|Impaired fasting glucose
873646|NCT02700334|Hyperglycemia
873647|NCT02700334|Impaired glucose tolerance
873648|NCT02700334|Glucose intolerance
873649|NCT02700334|Dapagliflozin
873650|NCT02700334|Sodium glucose cotransporter 2 inhibitor
873651|NCT02700334|SGLT2
873652|NCT02700321|non severely hypoxemic respiratory failure
873653|NCT02700321|preoxygenation
873654|NCT02700321|crash induction
873655|NCT02700308|Solid tumors
873656|NCT02700308|Spine metastasis
873657|NCT02700308|Vertebroplasty
873658|NCT02700308|kyphoplasty
873659|NCT02700308|randomization
873660|NCT02700295|Orthokeratology
873661|NCT02700282|Cystic fibrosis
873662|NCT02700282|Backpack carrying
873663|NCT02700282|Respiratory function
873664|NCT02700282|Children
873665|NCT02700256|surgery
873666|NCT02700256|15-315
873667|NCT02700243|Cystic Fibrosis
873668|NCT02700243|Exercise
873669|NCT02700243|Fitbit
873670|NCT02700217|Donor Nephrectomy
873671|NCT02700139|Myopia control, aspheric lenses, children
873672|NCT02700126|propofol
873673|NCT02700126|total intravenous anesthesia
873674|NCT02700126|cerebral aneurysm
873675|NCT02700126|single nucleotide polymorphism
873676|NCT02700087|Laryngomalacia
873677|NCT02700061|Induced Constraint Therapy
873678|NCT02700061|Robotic Occupational Therapy
873679|NCT02700061|Neuroplasticity
873680|NCT02700048|type 1 diabetes
873681|NCT02700048|hypoglycemia
873682|NCT02700048|hypoglycemia unawareness
873687|NCT02700022|Lineberger Comprehensive Cancer Center
873688|NCT02700022|Alisertib
873689|NCT02699905|Sepsis
873690|NCT02699905|Septic Shock
873691|NCT02699905|Multiple Organ Dysfunction
873692|NCT02699905|FFA2
873693|NCT02699905|GPR43
873694|NCT02699866|Small diameter implant
873695|NCT02699840|Meningitis
873696|NCT02699840|Meningococcal Meningitis
873697|NCT02699840|Meningococcal Infections
873698|NCT02699840|Menactra®
873699|NCT02699840|Meningococcal Vaccine
873700|NCT02699827|Levobupivacaine
873701|NCT02699827|Magnesium
873702|NCT02699827|Preeclampsia
873703|NCT02699827|Epidural
873704|NCT02699814|Depression
873705|NCT02699814|Children
873706|NCT02699814|Anxiety
873707|NCT02699775|Botulinum toxin injections
873708|NCT02699775|Stroke
873709|NCT02699775|3D motion analysis
873710|NCT02699775|Gait pattern
873711|NCT02699762|self rehabilitation
873712|NCT02699762|stroke
873713|NCT02699762|botulinum toxin injection
873714|NCT02699762|arm functions
873715|NCT02699749|Drug Therapy
873716|NCT02699736|HIV
873717|NCT02699736|HIV-1
873718|NCT02699736|Hepatitis C
873719|NCT02699736|HCV
873720|NCT02699736|prospective
873721|NCT02699736|cohort
873722|NCT02699736|coinfection
873729|NCT02699658|levofloxacin
873730|NCT02699658|population pharmacokinetics
873731|NCT02699658|pharmacodynamics
873732|NCT02699632|Survey
873733|NCT02699619|Undisplaced
873734|NCT02699606|Tumor
873735|NCT02699606|Fibroblast Growth Factor Receptor (FGFR)
873736|NCT02699606|Non-Small Cell Lung Cancer (NSCLC)
873737|NCT02699606|Erdafitinib
873738|NCT02699606|Urothelial Cancer
873739|NCT02699606|Esophageal Cancer
873740|NCT02699606|Cholangiocarcinoma
873741|NCT02699580|Biodegradable collagen implant
873742|NCT02699580|scleral thinning
873743|NCT02699580|strabismus surgery
873744|NCT02699567|taste perception
873745|NCT02699567|individual differences
873746|NCT02699567|fat
873747|NCT02699567|genetics
873748|NCT02699541|Diabetes Self-Management Education
873749|NCT02699541|Behavioural change theory
873750|NCT02699541|IMB model
873751|NCT02699541|Diabetes Type 2
873753|NCT02699476|NFL
873754|NCT02699476|veterans
873755|NCT02699476|cognitive training
873756|NCT02699476|TBI
873757|NCT02699476|concussion
873758|NCT02699437|Preeclampsia
873759|NCT02699437|Antiphospholipid Antibodies
873760|NCT02699411|ligament anterior cruciate , dry needling, physioterapy, propioception, knee arthroplasty, vastus medialis.
873761|NCT02699385|Gastroenteritis
873762|NCT02699385|Domperidone
873763|NCT02699385|Pediatric participants
873764|NCT02699372|Healthy Volunteers
873765|NCT02699359|concussion
873766|NCT02699359|mild traumatic brain injuries
873767|NCT02699346|concussion
873768|NCT02699346|mild traumatic brain injuries
873769|NCT02699320|Short bowel syndrome
873770|NCT02699320|Intestinal microbiota
873771|NCT02699320|immune
873772|NCT02699307|physical activity
873773|NCT02699294|Pain Threshold
873774|NCT02699294|Pectoralis Minor
873775|NCT02699294|Proprioceptive Neuromuscular Facilitation (PNF) Stretching
873776|NCT02699294|Physiotherapy
873777|NCT02699294|Rehabilitation
873779|NCT02699216|Macular Degeneration
873780|NCT02699216|Eye Diseases
873781|NCT02699216|Retinal Degeneration
873782|NCT02699216|Retinal Diseases
873783|NCT02699190|Leukodystrophy
873784|NCT02699190|White Matter Disease
873785|NCT02699190|Whole Genome Sequencing
873786|NCT02699190|WGS
873787|NCT02699177|ciliary beat frequency,
873788|NCT02699164|non surgical spinal decompression therapy
873789|NCT02699164|deep friction massage
873790|NCT02699164|exercise
873801|NCT02699073|colorectal cancer
873802|NCT02699073|metastatic
873803|NCT02699073|regorafenib
873804|NCT02699073|CHOI criteria
873805|NCT02699073|RECIST criteria
873806|NCT02699060|GERD
873807|NCT02699060|Barrett`s esophagus
873808|NCT02699060|macrophage
873809|NCT02699060|FSSG questionnaire
873810|NCT02699047|Gastrointestinal cancer
873811|NCT02699047|Fish oil
873812|NCT02699047|Oxidative stress
873813|NCT02699047|Inflammation
873814|NCT02699047|Quality of life
873815|NCT02699047|Nutritional status
873816|NCT02699047|Colorectal cancer
873817|NCT02699047|Stomach cancer
873818|NCT02699047|Chemotherapy
873819|NCT02699047|polyunsaturated fatty acids n-3
873820|NCT02699034|real-time MRI
873821|NCT02699034|electrophysiology study
873822|NCT02699034|atrial flutter ablation
873823|NCT02699034|active tracking
873824|NCT02699008|clopidogrel；antiplatelet therapy
873825|NCT02698982|elderly
873826|NCT02698982|postoperative cognitive dysfunction
873827|NCT02698982|postoperative delirium
873828|NCT02698982|depth of anesthesia
873829|NCT02698982|intraoperative blood pressure monitoring
873830|NCT02698969|Sugammadex
873831|NCT02698969|Post-operative residual curarization
873832|NCT02698969|Diaphragm Ultrasonography
873833|NCT02698956|SAPIEN 3 THV
873834|NCT02698956|TAVI
873835|NCT02698956|Transfemoral
873836|NCT02698956|Transaortic
873837|NCT02698956|Transapical
873838|NCT02698956|Aortic valve
873960|NCT02698228|anesthesia
873839|NCT02698943|cataract; intraocular lens; posterior capsule opacification; glistening; ENVISTA
873840|NCT02698930|Infective endocarditis
873841|NCT02698930|acute kidney injury
873842|NCT02698930|dexmedetomidine
873843|NCT02698917|Out-of-Hospital Cardiac Arrest
873844|NCT02698917|Resuscitation
873845|NCT02698917|Hypoxia-Ischemia, Brain
873846|NCT02698904|Chronic Obstructive Pulmonary Disease (COPD)
873847|NCT02698904|Relaxation Technique
873848|NCT02698904|Anxiety
873849|NCT02698891|Early Stage Breast Cancer
873850|NCT02698878|Lupin Protein
873851|NCT02698878|Glucose Metabolism
873852|NCT02698878|GLUT4
873853|NCT02698878|Muscle Unloading
873854|NCT02698878|Neuromuscular Electrical Stimulation
873855|NCT02698852|Drug eluting stents
873856|NCT02698852|Interventional Cardiology
873857|NCT02698839|Drug eluting stents
873858|NCT02698839|Interventional Cardiology
873859|NCT02698826|Cardiac Arrest, Hyperoxia, Ischemia-reperfusion Injury, Reactive Oxygen Species, Oxidative Stress, Neuropsychological Tests
873861|NCT02697916|aspirin
873862|NCT02697916|ACSD
873863|NCT02697916|PCORI
873864|NCT02697903|Creatine kinase supplementation
873865|NCT02697903|C-reactive protein
873866|NCT02697903|resistance training
873867|NCT02697903|Pomegranate supplementation
873868|NCT02697903|pomegranate juice
873869|NCT02697903|muscle damage response
873870|NCT02698761|Vaso-Occlusive Crises
873871|NCT02698761|Sickle Cell Disease
873872|NCT02698761|Decreasing Length of Stay
873873|NCT02698761|Comprehensive Care Plan
873874|NCT02698748|Chloroquine
873875|NCT02698748|Malaria Elimination
873876|NCT02698748|P.falciparum
873877|NCT02698748|Clinical Trial
873878|NCT02698748|Mozambique
873879|NCT02698748|Adults
873880|NCT02698709|Keratoconus
873881|NCT02698709|Corneal Topography
873882|NCT02698709|Diagnosis
873883|NCT02698709|Keratomileusis, Laser In Situ
873884|NCT02698696|Cognitive Remediation
873885|NCT02698696|Mood disorders
873886|NCT02698696|Neuropsychology
873887|NCT02698683|Nutrition
873888|NCT02698683|Lymphocyte Count
873889|NCT02698683|Immunoparalysis
873890|NCT02698683|nutritional status of septic patients
873891|NCT02698670|Cardiac Arrhythmias
873892|NCT02698670|Cardiovascular Disease
873893|NCT02698670|Radiofrequency Ablation
873894|NCT02698670|Cardiac Mapping
873898|NCT02698631|Catheter Ablation
873899|NCT02698631|Radiofrequency
873900|NCT02698631|Fibrosis
873901|NCT02698631|Late-gadolinium enhanced MRI
873902|NCT02698618|Diabetes
873903|NCT02698618|IMR
873904|NCT02698618|Microcirculation
873905|NCT02698618|Ticagrelor
873906|NCT02698618|CFR
873907|NCT02698618|FFR
873908|NCT02698618|Coronary microcirculation
873909|NCT02698592|atrial flutter
873910|NCT02698592|ablation
873911|NCT02698592|Thermocool SF catheter
873912|NCT02698579|Adrenoleukodystrophy
873913|NCT02698579|X-linked Adrenoleukodystrophy
873914|NCT02698579|Hematopoietic Stem Cells
873915|NCT02698553|Major depressive disorder
873916|NCT02698553|Extended release Bupropion
873917|NCT02698527|lidocaine
873918|NCT02698501|Asthma
873919|NCT02698501|Airway hyperresponsiveness
873920|NCT02698501|TSLP
873921|NCT02698501|Mast cell
873922|NCT02698501|Eosinophil
873923|NCT02698475|Psoriasis
873924|NCT02698475|Ustekinumab
873925|NCT02698475|STELARA
873926|NCT02698462|Advanced neoplasia
873927|NCT02698462|Colorectal cancer
873928|NCT02698462|Population screening
873929|NCT02698462|Family history
873930|NCT02698436|Acne
873931|NCT02698371|composite resins
873932|NCT02698371|dental restoration
873933|NCT02698371|adhesives
873934|NCT02698371|non-carious cervical lesions
873935|NCT02698371|clinical effectiveness
873936|NCT02698371|Adhese universal
873937|NCT02698371|Futurabond U
873938|NCT02698371|Futurabond DC
873939|NCT02698371|self-etch
873940|NCT02698371|multimode/universal
873941|NCT02698371|clinical trial
873942|NCT02698358|Peripheral artery disease, Iliac artery, nitinol stent, restenosis
873943|NCT02698345|Popliteal artery disease, drug-eluting balloon, angioplasty
873944|NCT02698319|Triage
873945|NCT02698319|Systematic Triage
873946|NCT02698280|Bevacizumab
873947|NCT02698280|Nimustine
873948|NCT02698280|Pathology, Molecular
873949|NCT02698254|Brain cancer
873950|NCT02698254|Recurrent brain tumor
873951|NCT02698254|Prior radiation treatment to brain
873952|NCT02698254|Radiation therapy
873953|NCT02698254|XRT
873954|NCT02698254|Questionnaires
873955|NCT02698254|Surveys
873956|NCT02698241|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
873957|NCT02698241|heart failure
873958|NCT02698241|integrated diagnostics
873959|NCT02698241|chronic medication management
873961|NCT02698202|Tomosynthesis,sensitivity,specificity,screening,mammography
873962|NCT02698176|OTX015
873963|NCT02698176|MK-8628
873964|NCT02698163|Root Canal Therapy
873965|NCT02698150|Mitral regurgitation
873966|NCT02698150|Mitraclip
873967|NCT02698150|Remote monitoring
873968|NCT02698150|Wearables
873969|NCT02698111|nasopharyngeal carcinoma,donafeinib
873970|NCT02698098|Malaysia
873971|NCT02698098|Asia
873972|NCT02698098|Southeast Asia
873973|NCT02698098|Compulsory Drug Detention Centers
873974|NCT02698098|Compulsory Centers for Drug Users
873975|NCT02698098|Methadone
873976|NCT02698098|Drug Relapse
873977|NCT02698098|Drug and Narcotic Control
873978|NCT02698098|Opiate Substitution Treatment
873979|NCT02698098|Prisons
873980|NCT02698085|carpal tunnel syndrome
873981|NCT02698085|physiotherapy
873982|NCT02698085|manual therapy
873983|NCT02698072|Stiffness
873984|NCT02698072|Pain
873985|NCT02698072|Disfunction
873986|NCT02698046|Heart failure
873987|NCT02698046|Iron
873988|NCT02698046|Anemia
873989|NCT02698046|Chronic disease
873990|NCT02698033|food allergy
873991|NCT02698033|peanut
873992|NCT02698033|food challenge
873993|NCT02698020|Newborn
873994|NCT02698020|Anesthesia
873995|NCT02698020|Oxygen
873996|NCT02698020|Hyperoxia
873997|NCT02697994|Sterile Water Injection
873998|NCT02697994|Midwifery
873999|NCT02697981|sleeve gastrectomy
874000|NCT02697786|Aortic valve surgery
874001|NCT02697773|osteoarthritis of the knee
874002|NCT02697773|osteoarthritis of the hip
874003|NCT02697773|nerve growth factor inhibitor
874004|NCT02697773|tanezumab
874005|NCT02697760|cadmium-zinc-telluride，CZT cameras
874006|NCT02697760|myocardial blood flow，MBF
874007|NCT02697760|myocardial flow reserve，MFR
874008|NCT02697747|Ultrasound
874009|NCT02697747|Palpation
874010|NCT02697747|Analgesia
874011|NCT02697747|Epidural
874020|NCT02697721|Caregivers
874021|NCT02697721|Behavioral symptoms
874022|NCT02697721|Dementia
874023|NCT02697721|Alzheimer disease
874024|NCT02697721|Physical activity
874025|NCT02697721|Depressive symptoms
874026|NCT02697721|Powerful Tools for Caregivers
874027|NCT02697721|Chronic Disease Self-Management Program
874028|NCT02697695|chronic inflammation
874029|NCT02697695|fatty liver index
874030|NCT02697669|Heart failure
874031|NCT02697669|myocardial perfusion
874032|NCT02697669|single-photon emission tomography
874033|NCT02697643|clinical decision support
874034|NCT02697643|substance use
874035|NCT02697643|opioid
874036|NCT02697630|Uveal melanoma
874037|NCT02697591|Solid tumor
874038|NCT02697591|adenocarcinoma of the endometrium
874039|NCT02697591|melanoma, non-small cell lung cancer (NSCLC)
874040|NCT02697591|renal cell carcinoma (RCC)
874041|NCT02697591|glucocorticoid-induced tumor necrosis factor receptor (GITR)
874042|NCT02697565|childhood obesity
874043|NCT02697565|obesity
874044|NCT02697565|prevention
874045|NCT02697565|nutrition
874046|NCT02697565|health
874047|NCT02697565|preschool
874048|NCT02697565|childcare
874049|NCT02697565|role model
874050|NCT02697565|pediatric obesity
874051|NCT02697565|weight
874052|NCT02697565|overweight
874053|NCT02697565|early childhood
874054|NCT02697565|train the trainer
874055|NCT02697526|radial artery
874056|NCT02697526|occlusion
874057|NCT02697526|functional
874058|NCT02697526|complications
874059|NCT02697526|consequences
874060|NCT02697487|Depression
874061|NCT02697487|Cohort
874062|NCT02697474|Hepatitis B
874063|NCT02697474|DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine
874064|NCT02697474|Euvax-B®
874065|NCT02697474|Hexaxim®
874066|NCT02697474|Infanrix® hexa
874067|NCT02697435|Chronic Low Back Pain
874068|NCT02697435|Aged
874069|NCT02697435|Elderly
874070|NCT02697435|Primary Care
874071|NCT02697435|Assessment
874072|NCT02697435|Lumbar
874073|NCT02697435|Spinal Stenosis
874074|NCT02697435|Hip Osteoarthritis
874075|NCT02697435|Myofascial Pain Syndrome
874076|NCT02697435|Fibromyalgia
874077|NCT02697435|Depression
874078|NCT02697435|Maladaptive Coping
874079|NCT02697435|Lumbar Spinal Stenosis
874080|NCT02697435|Insomnia
874081|NCT02697435|Sacroiliac Joint Pain
874082|NCT02697435|Lateral Hip and Thigh Pain
874083|NCT02697435|Anxiety
874084|NCT02697435|Dementia
874085|NCT02697435|Recent Leg Length Discrepancy
874086|NCT02697422|Smoking (tobacco use)
874087|NCT02697422|Peer health coach
874088|NCT02697422|Systolic blood pressure
874089|NCT02697422|Framingham Cardiovascular risk score
874090|NCT02697422|Lipid
874091|NCT02697422|Health related quality of life
874092|NCT02697422|Health care utilization
874093|NCT02697422|Medication adherence
874094|NCT02697422|Physical activity
874095|NCT02697422|Nutrition
874096|NCT02697422|Alcohol use
874097|NCT02697422|Stress management
874098|NCT02697396|Social Marketing Campaign
874099|NCT02697396|Mexican American Children
874100|NCT02697396|16-069
874101|NCT02697383|Ixazomib (MLN9708)
874102|NCT02697383|Dexamethasone
874103|NCT02697383|15-294
874104|NCT02697370|Haemophilia A prophylaxis pharmacokinetic dosing
874105|NCT02697357|Emotion Regulation Therapy
874106|NCT02697357|Distress Among Caregivers
874107|NCT02697357|15-219
874108|NCT02697331|Short cervix, twins, progesterone
874109|NCT02697305|Insulin response
874110|NCT02697305|Incretin effect
874111|NCT02697305|GLP-1
874112|NCT02697305|GIP
874113|NCT02697305|Valine
874114|NCT02697305|Leucine
874115|NCT02697305|Isoleucine
874116|NCT02697305|Branched chain amino acids
874117|NCT02697292|Intravenous Immunoglobulin
874118|NCT02697292|VGKC
874119|NCT02697292|Autoimmune epilepsy
874120|NCT02697292|Gamumex-C
874121|NCT02697279|Abscess
874122|NCT02697279|Loop
874123|NCT02697279|Drainage
874124|NCT02697253|Roux-en-Y Bariatric Surgery
874125|NCT02697253|Psychosocial Variables
874126|NCT02697253|Behavioral Variables
874127|NCT02697253|Weight Loss
874128|NCT02697253|Food Intake
874129|NCT02697253|GLP-1
874130|NCT02697253|Reinforcing Value of Food
874131|NCT02697253|Exendin 9-39
874132|NCT02697240|sickle cell disease
874133|NCT02697240|citrulline
874134|NCT02697227|Smoking cessation
874135|NCT02697227|Smoking behavior
874136|NCT02697227|Behavioral Activation Treatment
874137|NCT02697227|BATS
874138|NCT02697227|Standard Smoking Cessation Counseling
874139|NCT02697227|SC
874140|NCT02697227|Nicotine Replacement Therapy
874141|NCT02697227|NRT
874142|NCT02697227|Nicotine patch
874143|NCT02697227|Questionnaires
874144|NCT02697227|Surveys
874145|NCT02697227|CO Level
874146|NCT02697227|Cotinine Level
874147|NCT02697227|Saliva test
874148|NCT02697214|commercial heart rate monitors
874149|NCT02697214|accuracy
874150|NCT02697214|EKG
874151|NCT02697214|varying degrees of exertion
874152|NCT02697201|Mitochondrial Dynamics
874153|NCT02697201|Insulin Resistance
874154|NCT02697188|testosterone
874155|NCT02697188|male hypogonadism
874156|NCT02697188|low testosterone
874157|NCT02697175|live video-colposcopy
874158|NCT02697175|cervical dysplasia
874159|NCT02697175|anxiety
874160|NCT02697175|randomized controlled trial
874161|NCT02697175|colposcopy
874162|NCT02697162|Intermittent catheterisation
874163|NCT02697162|Antiseptic
874164|NCT02697162|Octenidine chloride
874165|NCT02697162|Children
874166|NCT02697149|ERCP
874167|NCT02697149|nonradiation-to-endoscopist
874168|NCT02697149|gallstones
874169|NCT02697136|Low HDL
874170|NCT02697136|Low apoA-I
874171|NCT02697136|ABCA-1 mutations
874172|NCT02697136|ApoA-I mutations
874173|NCT02697123|Venous Thrombosis
874174|NCT02697123|Pregnancy
874175|NCT02697123|postpartum
874176|NCT02697123|antepartum
874177|NCT02697110|Cognition
874178|NCT02697110|Brain Stimulation
874179|NCT02697110|Early Child Development
874180|NCT02697097|Hip Muscle Strength
874181|NCT02697097|FAI
874182|NCT02697071|Ketamine
874183|NCT02697071|Migraine
874184|NCT02697071|Headache
874185|NCT02697071|Emergency Department
874186|NCT02697045|Schizophrenia
874187|NCT02697045|Quality of Life
874188|NCT02697045|Functionality
874189|NCT02697045|Long Acting Injectable
874190|NCT02697045|Aripiprazole
874191|NCT02697045|Naturalistic
874192|NCT02697045|Open-label
874193|NCT02697045|Single Arm
874194|NCT02697045|Uncontrolled Study
874195|NCT02697032|FDHT
874196|NCT02697032|PET
874197|NCT02697032|Breast cancer
874198|NCT02697032|Bicalutamide
874199|NCT02697019|Nonsuicidal Self-Injury (NSSI), Deliberate Self-Harm (DSH), Self-harm, Self-injury
874200|NCT02696993|Metastatic Brain Cancer
874201|NCT02696993|Non-small cell lung cancer with brain metastasis
874202|NCT02696993|NSCLC
874203|NCT02696993|Intracranial disease
874204|NCT02696993|Stereotactic radiosurgery
874205|NCT02696993|SRS
874206|NCT02696993|Whole brain radiation therapy
874207|NCT02696993|WBRT
874208|NCT02696993|Neurocognitive exam
874209|NCT02696993|Nivolumab
874210|NCT02696993|BMS-936558
874211|NCT02696993|Opdivo
874212|NCT02696993|Ipilimumab
874213|NCT02696993|Yervoy
874214|NCT02696993|BMS-734016
874215|NCT02696993|MDX010
874216|NCT02696980|obesity
874217|NCT02696980|asthma
874218|NCT02696967|Heart Failure
874219|NCT02696954|Artemether-lumefantrine
874220|NCT02696954|Amodiaquine
874221|NCT02696954|Primaquine
874222|NCT02696902|Pseudomonas aeruginosa, Pneumonia
874223|NCT02696889|Infertility
874224|NCT02696889|Premature Ovarian Failure
874225|NCT02696889|Stem Cells
874226|NCT02696889|Amenorrhea
874227|NCT02696876|Cartilage
874228|NCT02696876|Mesenchymal stromal cell
874229|NCT02696876|Microfracture
874230|NCT02696876|Knee
874231|NCT02696876|Defect
874232|NCT02696876|Injury
874233|NCT02696876|Stem cell
874234|NCT02696876|Autologous
874235|NCT02696876|Minimally manipulated
874236|NCT02696850|sinusitis
874237|NCT02696850|rhinosinusitis
874238|NCT02696850|rhinitis
874239|NCT02696850|nasal lavage
874240|NCT02696811|cancer
874241|NCT02696811|inflammation
874242|NCT02696811|dietary intervention trial
874245|NCT02696759|Breast
874246|NCT02696759|Cancer
874247|NCT02696733|TURBT
874248|NCT02696733|ultrasound guided
874249|NCT02696733|ONB
874250|NCT02696733|interadductor approach
874251|NCT02696720|lidocaine
874252|NCT02696720|phantom limb pain (PLP)
874253|NCT02696720|Primary/secondary scar hyperalgesia
874254|NCT02696707|cardiac toxicities
874255|NCT02696668|multisensory exercises
874256|NCT02696668|group-based balance exercise programme
874257|NCT02696655|transplantation
874258|NCT02696642|mesothelin-expressing advanced solid cancers
874259|NCT02696629|Ventilatory control
874260|NCT02696629|Obstructive sleep apnea
874261|NCT02696629|Loop gain
874262|NCT02696629|Upper airway
874263|NCT02696629|Surgery
874264|NCT02696603|Health app research
874265|NCT02696603|mHealth research
874266|NCT02696603|Mobile health research
874267|NCT02696603|Mobile application health research
874272|NCT02696551|Medical education
874273|NCT02696551|Spondyloarthritis
874274|NCT02696551|Physician action
874275|NCT02696538|Fall risk
874276|NCT02696538|Rehabiliation
874277|NCT02696538|Physical Therapy
874278|NCT02696538|Functional Gait Assessment
874279|NCT02696538|mini-Balance Evaluation Systems Test
874280|NCT02696538|Berg Balance Scale
874281|NCT02696538|Psychometric properties
874282|NCT02696538|Validity
874283|NCT02696538|Inter-rater reliability
874284|NCT02696538|Montreal Cognitive Assessment
874285|NCT02696525|Circulating Tumor DNA
874286|NCT02696525|Lung cancer
874287|NCT02696525|lead time
874288|NCT02696512|Severe Disorders of Consciousness (SDOC)
874289|NCT02696512|Coma
874290|NCT02696512|Vegetative State
874291|NCT02696512|Minimally Conscious State
874292|NCT02696499|Uremic pruritus
874293|NCT02696499|Pruritus
874294|NCT02696499|Chronic itch
874295|NCT02696499|Itch
874296|NCT02696499|Hemodialysis
874297|NCT02696499|End-stage renal disease
874298|NCT02696473|Bioavailability
874299|NCT02696473|Polyacetylenes
874300|NCT02696473|Falcarinol
874301|NCT02696473|Falcarindiol
874302|NCT02696473|Falcarindiol-3-acetate
874303|NCT02696473|Carrot
874304|NCT02696473|Biological Availability
874305|NCT02696460|debridement
874306|NCT02696460|analgesia
874307|NCT02696447|Radiation therapy
874308|NCT02696447|Thrombosis
874309|NCT02696434|naltrexone
874310|NCT02696434|VIVITROL
874311|NCT02696434|buprenorphine
874312|NCT02696434|opioid
874313|NCT02696434|addiction
874314|NCT02696382|Veterans
874315|NCT02696382|Progressive High Intensity Physical Therapy
874316|NCT02696382|Gait Speed
874317|NCT02696382|Acute Hospitalization
874318|NCT02696382|Hospital Associated Deconditioning
874319|NCT02696356|HLA-A*02
874320|NCT02696343|somatosensory stimulation
874321|NCT02696343|orocutaneous
874322|NCT02696343|gene expression
874333|NCT02696278|gut microbiota
874334|NCT02696278|obesity
874335|NCT02696278|toddlers
874336|NCT02696278|fiber
874337|NCT02696278|unsaturated fats
874338|NCT02696265|Atrial Fibrillation
874339|NCT02696265|Complex Fractionated Atrial Electrocardiograms
874340|NCT02696265|Pulmonary Vein Isolation
874341|NCT02696265|Ablation
874342|NCT02696265|CFAE/spatiotemporal dispersion guided ablation
874343|NCT02696252|Endocrine System Diseases
874344|NCT02696252|Glucose Metabolism Disorders
874345|NCT02696252|Metabolic Diseases
874346|NCT02696239|vaginal cuff closure
874347|NCT02696239|Robotic Hysterectomy
874348|NCT02696200|Concussion
874349|NCT02696187|Pulmonary Disease, Chronic Obstructive
874350|NCT02696187|Feasibility
874351|NCT02696187|Health promotion tool
874352|NCT02696187|Self management
874353|NCT02696187|Evidence based care
874354|NCT02696187|Knowledge transfer
874355|NCT02696187|Implementation
874356|NCT02696161|platelet rich plasma
874357|NCT02696161|Perineural injection therapy
874358|NCT02696135|Hypertrophic cardiomyopathy
874359|NCT02696135|Heart failure
874360|NCT02696135|Stroke
874361|NCT02696122|Pain, postoperative
874362|NCT02696122|Hernia, abdominal
874363|NCT02696122|Anesthesia, spinal
874364|NCT02696122|Anesthesia, local
874365|NCT02696122|Anesthesia, general
874366|NCT02696122|Quality of life
874367|NCT02696122|Anesthesia recovery period
874368|NCT02696122|Personal satisfaction
874369|NCT02696122|Postoperative complications
874370|NCT02696122|Quality of recovery
874371|NCT02696109|Transition age youth
874372|NCT02696109|Mental health
874373|NCT02696109|Mental health services
874374|NCT02696109|Engagement
874375|NCT02696070|Pain
874376|NCT02696070|Diabetic Neuropathy
874377|NCT02696070|Pulsed Electromagnetic Energy Field
874378|NCT02696070|PEMF
874379|NCT02696070|PPDN
874380|NCT02696044|Gastrointestinal Disorders
874381|NCT02696031|non-radiographic spondyloarthritis
874382|NCT02696031|axial spondyloarthritis
874383|NCT02696018|Diaphragm
874384|NCT02696018|Ultrasound
874385|NCT02696018|Critically ill patients
874386|NCT02695992|Rate control in atrial fibrillation
874387|NCT02695992|Beta blockers
874388|NCT02695992|Calcium channel blockers
874389|NCT02695992|Permanent atrial fibrillation
874390|NCT02695992|Management of atrial fibrillation
874391|NCT02695992|Atrial fibrillation and biomarkers
874392|NCT02695992|Arrhythmias, cardiac
874393|NCT02695992|Heart Diseases
874394|NCT02695992|Pathological processes
874395|NCT02695992|Diltiazem
874396|NCT02695992|Metoprolol
874397|NCT02695992|Adrenergic Agents
874398|NCT02695992|Adrenergic Antagonists
874399|NCT02695992|Adrenergic beta-1 Receptor Antagonists
874400|NCT02695992|Adrenergic beta-Antagonists
874401|NCT02695992|Anti-Arrhythmia Agents
874402|NCT02695992|Antihypertensive Agents
874403|NCT02695992|Autonomic Agents
874404|NCT02695992|Cardiovascular Agents
874405|NCT02695992|Membrane Transport Modulators
874406|NCT02695992|Molecular Mechanisms of Pharmacological Action
874407|NCT02695992|Neurotransmitter Agents
874408|NCT02695992|Peripheral Nervous System Agents
874409|NCT02695992|Physiological Effects of Drugs
874410|NCT02695992|Sympatholytics
874411|NCT02695992|Therapeutic Uses
874412|NCT02695992|Vasodilator Agents
874413|NCT02695992|Troponins
874414|NCT02695992|NT-proBNP
874415|NCT02695992|Biomarkers
874416|NCT02695953|PTSD
874417|NCT02695953|biomarker
874418|NCT02695953|Cognitive Processing Therapy
874419|NCT02695914|Inflammatory markers
874420|NCT02695901|Plaque index
874421|NCT02695901|Melaleuca alternifolia oil.
874422|NCT02695901|Nanoparticles
874423|NCT02695875|Fibromyalgia
874424|NCT02695875|Pain
874425|NCT02695875|Postural balance
874426|NCT02695875|Physical therapy
874427|NCT02695875|Aquatic therapy
874428|NCT02695849|Non-small cell lung cancer (NSCLC)
874429|NCT02695836|Audit and Feedback
874430|NCT02695836|Nursing Homes
874431|NCT02695836|Organizational Context
874432|NCT02695836|Quality Improvement
874433|NCT02695836|Care Aides
874434|NCT02695836|Leadership
874435|NCT02695836|Resident Assessment Instrument (RAI)
874436|NCT02695836|Alberta Context Tool (ACT)
874437|NCT02695823|intracranial hypertension
874438|NCT02695823|liver transplantation
874439|NCT02695823|transcranial Doppler
874440|NCT02695823|optic nerve sheath diameter
874441|NCT02695797|Intractable cryptogenic epilepsy with autoimmune antibody
874442|NCT02695797|Immunotherapy
874443|NCT02695771|bladder tumors
874444|NCT02695771|urinary tumors
874445|NCT02695771|non-muscle invasive bladder tumors
874446|NCT02695771|NMIBC
874447|NCT02695732|Esophageal and Gastric Varices
874448|NCT02695732|Primary Prophylaxis
874449|NCT02695732|Carvedilol
874450|NCT02695732|Endoscopy
874451|NCT02695719|Drug therapy
874452|NCT02695706|Diabetes
874453|NCT02695706|Skin acceptability
874454|NCT02695706|Clinical Research
874455|NCT02695680|Lung Cancer
874456|NCT02695680|SBRT
874457|NCT02695680|Motion Management
874458|NCT02695641|Arteriovenous Fistula
874459|NCT02695641|Arteriovenous Graft
874460|NCT02695641|Bevacizumab
874461|NCT02695641|Hemodialysis
874462|NCT02695641|VEGF
874463|NCT02695641|Avastin
874464|NCT02695615|cesarean operation
874465|NCT02695615|Spielberger State Trait Anxiety Inventory
874466|NCT02695615|pain
874467|NCT02695563|Amniocentesis
874468|NCT02695524|Rehabilitation
874469|NCT02695524|Shoulder
874470|NCT02695498|migraine with aura
874471|NCT02695498|migraine without aura
874472|NCT02695498|pain
874473|NCT02695498|controls
874474|NCT02695498|mind-body
874475|NCT02695485|dorsal digital island flap
874476|NCT02695485|sensory reconstruction
874477|NCT02695472|Depression
874478|NCT02695472|Major Depressive Disorder (MDD)
874479|NCT02695472|Major Depressive Disorder
874480|NCT02695472|Neurogenesis
874481|NCT02695472|Synaptogenesis
874482|NCT02695472|NSI-189
874483|NCT02695472|Neuralstem
874484|NCT02695433|Pre-diabetes
874485|NCT02695433|Metabolic syndrome
874486|NCT02695433|Matsuda composite index of insulin sensitivity (MISI)
874487|NCT02695433|Blood glucose
874488|NCT02695433|Insulin response
874489|NCT02695433|HbA1c
874490|NCT02695433|Lipid
874491|NCT02695433|Inflammation
874492|NCT02695420|Heart Failure
874493|NCT02695407|artery cannulation
874494|NCT02695407|haemodynamic monitoring
874495|NCT02695342|Balance
874496|NCT02695342|Falls
874497|NCT02695342|Exercise
874498|NCT02695342|COPD
874502|NCT02695316|Migrants
874503|NCT02695316|Communication Barriers
874504|NCT02695316|Maternal Health Services
874505|NCT02695316|Health Services Needs and Demand
874506|NCT02695316|Access to Health Care
874507|NCT02695316|Professional-Patient Relations
874508|NCT02695316|Eritrea
874509|NCT02695316|Kosovo
874510|NCT02695316|Switzerland
874511|NCT02695277|Atrial Fibrillation
874512|NCT02695277|Persistent and Longstanding Persistent AF
874513|NCT02695277|Hybrid Procedure
874514|NCT02695277|Catheter Ablation
874515|NCT02695264|intracranial pressure
874516|NCT02695264|intracranial hypertension
874517|NCT02695264|severe traumatic brain injury
874518|NCT02695199|Doppler Ultrasound
874519|NCT02695199|Laparoscopic
874520|NCT02695199|Microscopic Subinguinal Varicocelectomy
874521|NCT02695186|Intestinal metaplasia
874522|NCT02695186|Metabolic syndrome
874523|NCT02695186|Oxidative stress
874524|NCT02695108|Scapula
874525|NCT02695108|Neck
874526|NCT02695108|Pain
874527|NCT02695108|Therapy
874528|NCT02695108|Kinematic
874529|NCT02695069|Complete Placenta Previa
874530|NCT02695069|Random Placenta Margin Incision
874531|NCT02695069|Cesarean Section
874532|NCT02695069|Hemorrhage
874533|NCT02694991|surgery
874534|NCT02694991|outcome
874535|NCT02694991|pain
874536|NCT02694991|osteopathic manipulative treatment
874537|NCT02694978|iron deficiency anemia
874538|NCT02694978|IDA
874539|NCT02694978|ferumoxytol
874540|NCT02694978|ferric carboxymaltose
874541|NCT02694978|FCM
874542|NCT02694978|Injectafer
874543|NCT02694926|adrenal crisis
874544|NCT02694926|education programme
874545|NCT02694887|Capillary blood
874546|NCT02694887|Venous blood
874547|NCT02694887|Lactate
874548|NCT02694887|Emergency Department
874549|NCT02694874|Adjunctive treatment
874550|NCT02694874|Severe malaria
874551|NCT02694861|Angina Pectoris
874552|NCT02694861|Angina, Stable
874553|NCT02694861|Chest Pain
874554|NCT02694796|Web and smartphone-based physical activity program
874555|NCT02694796|Connected devices
874556|NCT02694796|Balneotherapy
874559|NCT02694770|aGvHD
874560|NCT02694770|GvHD
874561|NCT02694770|sr-aGvHD
874562|NCT02694770|biologics
874563|NCT02694770|monoclonal antibody
874564|NCT02694757|Ostom-i
874565|NCT02694757|OIA device
874566|NCT02694744|Treatment of Hyperkalemia
874567|NCT02694744|Hyperkalemia
874568|NCT02694744|Potassium
874569|NCT02694744|Chronic Kidney Disease
874570|NCT02694731|Craving
874571|NCT02694731|Mobile Apps
874572|NCT02694705|Oxygen Inhalation Therapy
874573|NCT02694705|Intubation
874574|NCT02694705|Emergency Medicine
874575|NCT02694679|social networks, maternal and child health, global health
874576|NCT02694653|C/section, Acetaminophen
874577|NCT02694640|Breast cancer
874578|NCT02694640|Exercise
874579|NCT02694640|Physical activity
874580|NCT02694640|Community volunteers
874581|NCT02694640|Peer mentors
874582|NCT02694640|Peer coaches
874583|NCT02694640|Social support
874584|NCT02694640|Exercise maintenance
874585|NCT02694627|gender, caregiving, MNCH, violence, sexual and reproductive health, parenting
874586|NCT02694614|weight loss
874587|NCT02694614|individualised dietary coaching
874588|NCT02694614|smartphone-assisted dietary coaching
874589|NCT02694614|health behavior change
874590|NCT02694588|Vedolizumab
874591|NCT02694588|Infliximab
874592|NCT02694562|Metastatic Colorectal Carcinoma
874593|NCT02694549|Vascular Closure Devices
874594|NCT02694549|Catheterization Closure Devices
874595|NCT02694549|Vascular Access Devices
874596|NCT02694523|Psoriasis
874597|NCT02694523|Skin Diseases
874598|NCT02694523|Skin Diseases, Papulosquamous
874599|NCT02694523|Adalimumab
874600|NCT02694523|Anti-Inflammatory Agents
874601|NCT02694523|ABBV-066
874602|NCT02694523|BI 655066
874603|NCT02694523|Risankizumab
874604|NCT02694510|Preterm infants
874605|NCT02694510|Oxidative stress
874606|NCT02694510|Parenteral nutrition
874607|NCT02694497|transmission
874608|NCT02694497|women
874609|NCT02694497|genital
874610|NCT02694497|anorectal
874611|NCT02694484|Cytomegalovirus
874612|NCT02694484|Stool sample
874613|NCT02694484|Healthy Volunteers
874614|NCT02694484|Fecal microbiota transplant
874615|NCT02694471|Ageing
874616|NCT02694471|Physical inactivity
874617|NCT02694471|Functional decline
874618|NCT02694471|Reconditioning
874619|NCT02694458|Vancomycin
874620|NCT02694458|Children
874621|NCT02694458|Infection
874622|NCT02694458|Antibiotic
874623|NCT02694458|Methicillin-resistant Staphylococcus aureus (MRSA)
874624|NCT02694458|Population-based pharmacokinetic modeling
874625|NCT02694458|Pharmacokinetics
874626|NCT02694458|Pharmacodynamics
874627|NCT02694458|Bayesian approach
874628|NCT02694458|Therapeutic drug monitoring
874629|NCT02694432|high blood pressure, systolic, diastolic
874630|NCT02694432|complementary therapies, meditation
874631|NCT02694419|endometrium
874632|NCT02694406|Diagnosis
874633|NCT02694367|genetic basis
874634|NCT02694341|Management
874635|NCT02694328|Alkermes
874636|NCT02694328|ALKS 3831
874637|NCT02694328|Samidorphan
874638|NCT02694328|Schizophrenia
874639|NCT02694328|Olanzapine
874640|NCT02694328|Weight
874641|NCT02694302|Stroke
874642|NCT02694250|cervical
874643|NCT02694250|fusion
874644|NCT02694250|radiculopathy
874645|NCT02694250|DTRAX
874646|NCT02694224|breast cancer
874647|NCT02694224|triple negative
874648|NCT02694224|neoadjuvant
874649|NCT02694211|work related stress
874650|NCT02694185|Medication Adherence
874651|NCT02694185|Randomized Controlled Trial
874652|NCT02694185|Veterans
874653|NCT02694172|diabetes mellitus type 2
874654|NCT02694172|healthy subjects
874655|NCT02694172|human microbiome
874656|NCT02694172|cereal bar
874657|NCT02694146|platelet-rich plasma (PRP)
874658|NCT02694146|hyaluronic acid (Hylan G-F 20).
874659|NCT02694146|NSAIDs
874660|NCT02694146|WOMAC
874661|NCT02694133|telerehabilitation
874662|NCT02694133|aphasia
874663|NCT02694133|speech therapy
874664|NCT02694133|rehabilitation device
874665|NCT02694133|visual action therapy
874666|NCT02694133|naming drills
874667|NCT02694094|cholesterol
874668|NCT02694094|seizure
874669|NCT02694094|epilepsy
874670|NCT02694094|ketogenic
874671|NCT02694094|diet
874672|NCT02694081|reflux
874673|NCT02694081|residue
874674|NCT02694081|Gastric stasis
874675|NCT02694081|Emptying time
874676|NCT02694068|Peritoneal Dialysis
874677|NCT02694068|Genetic
874678|NCT02694068|Peritoneal Membrane
874679|NCT02694068|Peritoneal Equilibrium Test
874680|NCT02694068|Ultrafiltration Capacity
874681|NCT02694068|End Stage Renal Disease (ESRD)
874682|NCT02694055|Community Health Workers
874683|NCT02694055|Community Case Management
874684|NCT02694055|Proactive Case Detection
874685|NCT02694055|Under-five Child Mortality
874686|NCT02694055|Access to Health Care
874687|NCT02694042|Pediatric inflammatory bowel disease
874688|NCT02694042|Crohn's disease
874689|NCT02694042|Ulcerative colitis
874690|NCT02694042|Web-based teaching and support
874691|NCT02694042|disease self-management
874692|NCT02694042|peer support
874693|NCT02694016|Remote ischemic preconditioning
874694|NCT02694016|Neuroprotection
874695|NCT02694003|Autism Spectrum Disorder (ASD)
874696|NCT02694003|Fetal Alcohol Spectrum Disorder (FASD)
874697|NCT02694003|Cerebral Palsy (CP)
874698|NCT02694003|Attention-Deficit/Hyperactivity Disorder (ADHD)
874699|NCT02694003|Behavioural Insomnia
874700|NCT02694003|Neurodevelopmental Disorders
874701|NCT02693990|Tumor lining the brain
874702|NCT02693990|Meningioma
874703|NCT02693990|Brain Tumor
874704|NCT02693977|OSA
874705|NCT02693977|sleep apnea
874706|NCT02693977|AT
874707|NCT02693977|adenotonsillectomy
874708|NCT02693977|pediatric
874709|NCT02693964|Type 1 Diabetes
874710|NCT02693964|Menopause
874711|NCT02693964|Cardiovascular Risk
874712|NCT02693964|Bone Density
874713|NCT02693951|gastric varices
874714|NCT02693951|endoscopic injection of tissue adhesive
874715|NCT02693938|diabetes
874716|NCT02693938|menstrual cycle
874717|NCT02693938|insulin
874718|NCT02693912|efferocytosis
874719|NCT02693912|macrophage
874720|NCT02693873|Osteoarthritis, Hip
874721|NCT02693873|Osteoarthritis, Knee
874722|NCT02693873|Patient Education
874723|NCT02693873|Exercise, Neuromuscular
874724|NCT02693873|Disease Management
874725|NCT02693873|Evidence-Based Health Care
874726|NCT02693873|Pilot Study
874727|NCT02693847|HCV
874728|NCT02693847|HIV
874729|NCT02693847|Liver cirrhosis
874730|NCT02693847|Hepatocellular carcinoma
874731|NCT02693847|Liver transplant
874732|NCT02693847|Liver stiffness
874733|NCT02693847|Transient elastography
874734|NCT02693834|foot drop
874735|NCT02693834|Subacute stroke
874736|NCT02693834|AFO
874737|NCT02693834|gait symmetry
874738|NCT02693834|Gait endurance
874739|NCT02693821|Gabapentin
874740|NCT02693821|prevention
874741|NCT02693821|incidence
874742|NCT02693808|Temporal hollowing
874743|NCT02693808|Lateral orbital wall decompression
874744|NCT02693808|Thyroid eye disease
874745|NCT02693795|myocardial infarction
874746|NCT02693795|left ventricular remodeling
874747|NCT02693782|Fibre
874748|NCT02693782|Wheat Bran Extract
874749|NCT02693782|Microbiota
874750|NCT02693782|Microbiota metabolites
874751|NCT02693782|Gastrointestinal tolerance
874755|NCT02693730|Irritable Bowel Syndrome
874756|NCT02693730|IBS
874757|NCT02693730|Ulcerative Colitis
874758|NCT02693730|UC
874759|NCT02693730|Inflammatory Bowel Disease
874760|NCT02693730|IBD
874761|NCT02693730|Healthy Control
874762|NCT02693730|HC
874763|NCT02693730|Visceral Pain
874764|NCT02693730|Gut
874765|NCT02693730|Neuroimaging
874766|NCT02693730|fMRI
874767|NCT02693730|resting state
874768|NCT02693730|structural MRI
874769|NCT02693730|functional MRI
874770|NCT02693730|diffusion tensor imaging
874771|NCT02693730|MR Spectroscopy
874772|NCT02693717|Cancer of urethra
874773|NCT02693717|Cancer of ureters
874774|NCT02693717|MTAP-deficient bladder cancer
874775|NCT02693717|MTAP wild-type bladder cancer
874776|NCT02693717|Metastatic
874777|NCT02693717|Pemetrexed
874778|NCT02693717|LY231514
874779|NCT02693717|Alimta
874780|NCT02693717|MTA
874781|NCT02693717|Multitargeted Antifolate
874782|NCT02693717|NSC-698037
874783|NCT02693717|Folic Acid
874784|NCT02693717|Folinic Acid
874785|NCT02693717|Vitamin B12
874786|NCT02693717|Dexamethasone
874787|NCT02693717|Decadron
874788|NCT02693678|Proprioception
874789|NCT02693678|Doms
874790|NCT02693678|Pain
874791|NCT02693678|Massage
874792|NCT02693678|Diathermy
874793|NCT02693665|pediatric advance care planning
874794|NCT02693665|adolescent
874795|NCT02693665|family
874796|NCT02693665|palliative care
874797|NCT02693665|end of life
874798|NCT02693665|communication
874799|NCT02693665|decision making
874800|NCT02693665|surrogate decision maker
874801|NCT02693665|health care proxy
874802|NCT02693665|intervention
874803|NCT02693665|randomized clinical trial
874804|NCT02693665|cancer
874805|NCT02693665|quality of life
874806|NCT02693665|spiritual
874807|NCT02693665|religion
874808|NCT02693665|treatment congruence
874809|NCT02693665|treatment preferences
874810|NCT02693665|FAmily CEntered (FACE) Advance Care Planning
874811|NCT02693639|PANX1
874812|NCT02693639|Infection
874813|NCT02693639|Liver transplantation
874814|NCT02693626|mobile phone-based text message interventions
874815|NCT02693626|'Happy Quit'
874816|NCT02693626|smoking cessation
874817|NCT02693613|Drug-drug interaction
874818|NCT02693613|Kremezin
874819|NCT02693613|Pharmacokinetics
874820|NCT02693613|ASP1517
874821|NCT02693600|Total Trapeziectomy
874822|NCT02693600|Partial Trapeziectomy
874823|NCT02693600|Ligamentoplasty
874824|NCT02693574|Helicobacter pylori
874825|NCT02693574|Helicobacter Infections
874826|NCT02693574|Proton Pump Inhibitors
874827|NCT02693561|Self-help book
874828|NCT02693561|Deep breathing
874829|NCT02693548|Familial Hypercholesterolaemia
874830|NCT02693548|Prognosis
874831|NCT02693548|Cardiovascular disease
874836|NCT02693496|ResearchKit
874837|NCT02693496|CT screening
874838|NCT02693496|Early Diagnosis
874839|NCT02693496|Lung Cancer
874840|NCT02693392|Fenugreek seed extract
874841|NCT02693392|HbA1c
874842|NCT02693392|Blood glucose
874843|NCT02693379|cervical cancer
874844|NCT02693379|HPV
874845|NCT02693379|VIA
874846|NCT02693379|screening
874847|NCT02693379|smartphone
874848|NCT02693379|telemedicine
874849|NCT02693366|bone marrow cells, stem cells, cell therapy
874850|NCT02693366|Glomerulosclerosis, Focal Segmental
874851|NCT02693366|Renal Insufficiency, Chronic
874852|NCT02693327|Gut Microbiome
874853|NCT02693327|Mental Disorder
874854|NCT02693327|Dysbiosis
874855|NCT02693314|Jarro-Dophilus
874856|NCT02693314|probiotic
874857|NCT02693314|microbiota
874858|NCT02693314|gastrointestinal
874859|NCT02693301|Asthma
874860|NCT02693301|Respiratory symptoms
874861|NCT02693301|Exercise program
874862|NCT02693301|Functional capacity
874863|NCT02693301|Body composition
874864|NCT02693288|Wrist fracture
874865|NCT02693288|postoperative pain
874866|NCT02693288|local anesthesia
874867|NCT02693275|Community Sampling
874868|NCT02693262|defibrillator
874869|NCT02693262|heart failure
874870|NCT02693262|ICD
874871|NCT02693262|CRT-D
874872|NCT02693262|cardiac resynchronization therapy
874873|NCT02693262|rate response
874874|NCT02693262|CLS
874875|NCT02693262|closed-loop stimulation
874876|NCT02693262|accelerometer
874877|NCT02693262|chronotropic incompetence
874878|NCT02693249|accidents
874879|NCT02693249|adolescents
874880|NCT02693249|children
874881|NCT02693249|posttraumatic cognitions
874882|NCT02693223|stroke
874883|NCT02693197|Hepatic Impairment
874884|NCT02693145|HIV/AIDS
874885|NCT02693145|re-engagement in care
874886|NCT02693145|data to care
874887|NCT02693132|Obesity
874888|NCT02693132|Exercise
874889|NCT02693119|LHON
874890|NCT02693119|Ocuvia™
874891|NCT02693119|elamipretide
874892|NCT02693119|MTP-131
874893|NCT02693041|Probiotics
874894|NCT02693041|inflammation
874895|NCT02693041|immunological response
874896|NCT02693041|preterm birth
874897|NCT02693041|preeclampsia
874898|NCT02693028|Microbiome
874899|NCT02693028|probiotic
874900|NCT02692976|Castration-resistant prostate cancer
874901|NCT02692976|Dendritic Cells
874902|NCT02692976|Immunotherapy
874903|NCT02692976|Vaccines
874904|NCT02692937|Neurosurgical Procedures
874905|NCT02692937|Nerve Block
874906|NCT02692937|Exercise therapy
874907|NCT02692937|Physical Therapy Specialty
874908|NCT02692924|Pregnancy Complications
874909|NCT02692924|Ultrasound
874910|NCT02692911|Gallbaldder
874911|NCT02692911|Cancer
874912|NCT02692911|Gallstones
874913|NCT02692911|Cholecystectomy
874914|NCT02692911|Inflammation
874915|NCT02692898|Brain Tumor
874916|NCT02692898|Molecular Pathology
874917|NCT02692898|Clinical Data
874918|NCT02692898|Imaging Data
874919|NCT02692885|Phenotype
874920|NCT02692885|Adipose Tissue
874921|NCT02692885|Brown Adipose Tissue
874922|NCT02692872|Alpha Thalassemia
874923|NCT02692872|Double Deletion
874924|NCT02692846|CONNECTIVE TISSUE DISEASES
874925|NCT02692846|Cardiovascular Disease
874926|NCT02692846|Elastin Gene Mutation
874927|NCT02692846|Multisystem Developmental Disorder
874928|NCT02692833|Telomere
874929|NCT02692833|Telomerase
874930|NCT02692833|DNA methylation
874931|NCT02692833|Cell aging
874932|NCT02692833|Thoracic Surgery
874933|NCT02692820|Preterm
874934|NCT02692820|Probiotic
874935|NCT02692807|hip arthroscopy
874936|NCT02692807|femoroacetabular impingement
874937|NCT02692807|exercise therapy after hip arthroscopy
874938|NCT02692807|rehabilitation after hip arthroscopy
874939|NCT02692794|sinusitis
874940|NCT02692794|oximetry
874941|NCT02692794|paranasal sinus diseases
874942|NCT02692781|Obesity
874943|NCT02692768|total shoulder arthroplasty
874944|NCT02692768|total shoulder replacement
874945|NCT02692768|adult
874946|NCT02692768|reverse shoulder arthroplasty
874947|NCT02692755|African American
874953|NCT02692703|HCV Treatment Experienced
874954|NCT02692703|Hepatitis C
874955|NCT02692703|HCV Genotype 3
874956|NCT02692703|Without cirrhosis
874957|NCT02692703|Non-cirrhotic
874958|NCT02692703|HCV Genotype 2
874959|NCT02692703|Renal Transplant
874960|NCT02692703|HCV Treatment Naive
874961|NCT02692703|Post transplant
874962|NCT02692703|HCV Genotype 6
874963|NCT02692703|Liver Transplant
874964|NCT02692703|HCV Genotype 5
874965|NCT02692703|HCV Genotype 4
874966|NCT02692703|Kidney Transplant
874967|NCT02692703|HCV Genotype 1
874968|NCT02692677|Healthy
874969|NCT02692677|JNJ-42756493
874970|NCT02692664|iliac side branch
874971|NCT02692651|vancomycin
874972|NCT02692651|fidaxomicin
874973|NCT02692651|CDI
874974|NCT02692651|diarrhea
874975|NCT02692599|live attenuated mumps vaccine
874976|NCT02692599|safety
874977|NCT02692599|immunogenicity
874978|NCT02692599|infant
874979|NCT02692586|Thromboembolism
874980|NCT02692586|Thrombectomy
874981|NCT02692586|Right Heart Strain
874982|NCT02692586|Submassive PE
874983|NCT02692586|Right Ventricle Dysfunction
874984|NCT02692586|Massive PE
874985|NCT02692560|Sedentary time
874986|NCT02692560|Sit-to-stand transitions
874987|NCT02692534|Anesthesia
874988|NCT02692534|Cocaine Use
874989|NCT02692508|cardiovascular MRI
874990|NCT02692508|apical hypertrophic cardiomyopathy
874991|NCT02692508|giant negative T-wave
874992|NCT02692508|wall thickness
874993|NCT02692508|Nuclear Magnetic Resonance
874994|NCT02692508|Early Diagnosis
874995|NCT02692508|Prognosis
874996|NCT02692495|body odor
874997|NCT02692495|halitosis
874998|NCT02692495|dysbiosis
874999|NCT02692495|leaky gut
875000|NCT02692495|microbiome
875001|NCT02692469|Bariatric Surgery, Obesity, Laparoscopy
875002|NCT02692443|Congenital Heart Disease
875003|NCT02692443|Magnetic Brain Resonance
875004|NCT02692443|CHD
875005|NCT02692443|MRI
875006|NCT02692443|Neurodevelopmental
875007|NCT02692430|Portosystemic Shunt
875008|NCT02692430|Hepatic encephalopathy
875009|NCT02692430|Portal hypertension
875010|NCT02692430|Liver cirrhosis
875011|NCT02692417|hypoactive desire disorder
875012|NCT02692417|female sexual dysfunction
875013|NCT02692417|genital arousal disorder
875014|NCT02692417|sexual
875015|NCT02692417|dysfunction
875016|NCT02692417|female
875017|NCT02692417|arousal
875018|NCT02692417|electrical stimulation
875019|NCT02692417|transcutaneous electrical stimulation
875020|NCT02692417|women
875021|NCT02692404|Postpartum Depression
875022|NCT02692404|Perinatal Depression
875023|NCT02692404|Pregnancy
875024|NCT02692404|Anesthesia
875025|NCT02692404|Obstetric
875026|NCT02692404|Pain
875027|NCT02692404|Analgesia
875028|NCT02692404|Epidural
875029|NCT02692404|Midwife
875030|NCT02692404|Infant Development
875031|NCT02692404|Pain Management
875032|NCT02692391|Acute pancreatitis
875033|NCT02692391|Indomethacin
875034|NCT02692391|Organ failure
875035|NCT02692391|Prevention
875036|NCT02692378|Haemodialysis
875037|NCT02692378|sodium bicarbonate
875038|NCT02692378|potassium
875039|NCT02692378|arrhythmia
875040|NCT02692378|muscle
875041|NCT02692378|symptoms
875042|NCT02692339|Relapsed Multiple Myeloma
875043|NCT02692339|Refractory Multiple Myeloma
875044|NCT02692339|Lenalidomide
875045|NCT02692339|Dexamethasone
875046|NCT02692339|Observational Study
875047|NCT02692339|Safety of Len/Dex
875048|NCT02692326|intrahepatic cholestasis
875049|NCT02692326|infant newborn
875050|NCT02692326|cyclic parenteral nutrition
875051|NCT02692313|epinephrine
875052|NCT02692313|counterregulation
875053|NCT02692313|dose responses
875054|NCT02692300|anesthesia
875055|NCT02692300|delirium
875056|NCT02692300|surgery
875057|NCT02692300|electroencephalography
875058|NCT02692300|burst suppression
875059|NCT02692300|PTSD
875060|NCT02692300|anxiety
875061|NCT02692300|depression
875062|NCT02692300|falls
875063|NCT02692274|Point-of-care diagnostics
875064|NCT02692274|Rural primary health care
875065|NCT02692274|Access
875066|NCT02692274|Need
875067|NCT02692274|Usage
875068|NCT02692274|Maternal Health
875069|NCT02692235|carnitine
875070|NCT02692235|leucine
875071|NCT02692222|pulse pressure variation monitoring
875072|NCT02692222|Captesia
875073|NCT02692222|cardiac output monitoring
875074|NCT02692209|Mammography
875075|NCT02692196|Neurofeedback
875076|NCT02692196|Emotion processing
875077|NCT02692196|Real-time
875078|NCT02692196|fMRI
875079|NCT02692183|Parkinson's disease
875080|NCT02692183|ET
875081|NCT02692183|EEG
875082|NCT02692183|FUS
875083|NCT02692183|BNA
875084|NCT02692183|Essential tremor
875085|NCT02692131|Left Ventricle strain, speckle strain
875086|NCT02692105|prostate adenocarcinoma
875087|NCT02692105|intermediate risk group
875088|NCT02692105|brachytherapy
875089|NCT02692105|High Dose Rate vs Low Dose Rate
875090|NCT02692105|Quality of Life
875091|NCT02692092|Complications
875092|NCT02692092|Arthroplasty, Hip Replacement
875093|NCT02692092|Arthroplasty, Knee Replacement
875094|NCT02692079|Angiogenesis
875095|NCT02692079|Bilateral infrabony defect
875096|NCT02692079|Flap surgery
875097|NCT02692079|Titanium-prepared, platelet-rich ﬁbrin
875098|NCT02692040|obesity
875099|NCT02692040|diabetes mellitus
875100|NCT02692040|glucagon-like peptide-1
875101|NCT02692027|Community-based initiation of antiretroviral therapy
875102|NCT02692027|Home-based HIV testing and counseling
875103|NCT02692027|Lesotho
875104|NCT02692027|Sub-sahara Africa
875105|NCT02692027|antiretroviral therapy
875106|NCT02692027|AIDS
875107|NCT02692027|Test and treat
875108|NCT02691988|Inhaled corticosteroids
875109|NCT02691988|General practice
875110|NCT02691988|Primary care
875111|NCT02691988|Pharmacotherapy
875112|NCT02691936|Genitourinary symptoms of menopause
875113|NCT02691936|Menopause
875114|NCT02691936|Atrophic vaginitis
875115|NCT02691923|High Grade Glioma
875116|NCT02691923|Low Grade Glioma
875117|NCT02691923|Brain Tumor
875118|NCT02691910|malaria
875119|NCT02691910|Plasmodium vivax
875120|NCT02691910|treatment
875121|NCT02691910|Chloroquine
875122|NCT02691910|Primaquine
875123|NCT02691897|Diabetes mellitus
875124|NCT02691897|Melatonin
875125|NCT02691897|Blood Glucose
875126|NCT02691897|Therapeutics
875127|NCT02691897|Pineal gland
875128|NCT02691884|Heart Rate, Fetal
875129|NCT02691884|Electronic Fetal Monitoring
875130|NCT02691884|Transducers, Pressure
875131|NCT02691858|Intussusception
875132|NCT02691819|jailed-balloon technique
875133|NCT02691754|Paracetamol
875134|NCT02691754|PPI
875135|NCT02691754|Opioids
875136|NCT02691754|NSAID
875137|NCT02691754|Drug Prescription
875145|NCT02691676|crystalloids, fluid therapy, Plasmalyte, Ringerfundin
875146|NCT02691663|Geriatric
875147|NCT02691663|bicarbonate
875148|NCT02691650|serum cholinesterase
875149|NCT02691650|plasma cholinesterase
875150|NCT02691650|pseudocholinesterase
875151|NCT02691650|systemic inflammation
875152|NCT02691650|SIRS
875153|NCT02691650|polytrauma
875154|NCT02691637|Helicobacter pylori infection
875155|NCT02691637|Eradication treatment
875156|NCT02691637|Reversibility
875157|NCT02691637|atrophic gastritis
875158|NCT02691637|intestinal metaplasia
875159|NCT02691624|Lymphedema of Upper Arm
875160|NCT02691624|Breast cancer
875161|NCT02691624|Breast cancer-related Lymphedema
875162|NCT02691624|Lymphoscintigraphy
875163|NCT02691546|Chronic Kidney Diseases
875164|NCT02691546|Older
875165|NCT02691546|Geriatric assessment
875166|NCT02691546|Biomarkers
875167|NCT02691533|Acute
875168|NCT02691520|Treatment Resistant Depression
875169|NCT02691507|Eczema, Itchy Skin
875170|NCT02691494|Elagolix
875171|NCT02691494|Menorrhagia
875172|NCT02691494|Elagolix + Norethindrone acetate
875173|NCT02691494|Elagolix Sodium
875174|NCT02691494|HMB
875175|NCT02691494|Heavy menstrual bleeding
875176|NCT02691494|Leiomyomata
875177|NCT02691494|Heavy uterine bleeding
875178|NCT02691494|ABT-620
875179|NCT02691494|Elagolix + E2/NETA
875184|NCT02691442|Peripheral nerve block
875185|NCT02691429|Vitreoretinal surgery
875186|NCT02691429|euterpe oleracea
875187|NCT02691429|chromovitrectomy
875188|NCT02691325|ELLIPTA
875189|NCT02691325|GSK2269557
875190|NCT02691325|Tolerability
875191|NCT02691325|Safety
875192|NCT02691325|Dry powder Inhaler (DPI)
875193|NCT02691325|Pharmacokinetics
875194|NCT02691312|type 1 diabetes
875195|NCT02691312|retinopathy
875196|NCT02691299|NSCLC
875197|NCT02691260|obesity
875198|NCT02691260|behavioral intervention
875199|NCT02691260|diet
875200|NCT02691247|T1DM
875201|NCT02691247|Type 1 Diabetes Mellitus
875202|NCT02691247|T regulatory cell
875203|NCT02691247|Immunotherapy
875204|NCT02691247|Cell therapy
875205|NCT02691247|T-Reg
875206|NCT02691221|Suicidal behavior, Mobile Application, Mobile Health Tool
875207|NCT02691208|acupuncture
875208|NCT02691208|breast cancer
875209|NCT02691208|rehabilitation
875210|NCT02691208|pain
875211|NCT02691195|Ultrasound
875212|NCT02691195|Serratus Plane Block
875213|NCT02691195|Quality of recovery
875214|NCT02691156|Hematofluorometer
875215|NCT02691130|influenza
875216|NCT02691130|vaccine
875217|NCT02691130|universal
875218|NCT02691130|peptide
875219|NCT02691130|prime
875220|NCT02691130|boost
875221|NCT02691130|HAI
875222|NCT02691130|CMI
875223|NCT02691130|UNISEC
875224|NCT02691117|Alopecia Areata
875225|NCT02691117|Garlic concentrate
875226|NCT02691052|pancreatic cancer
875227|NCT02691052|metastatic
875228|NCT02691026|MPNST
875229|NCT02691026|Pembrolizumab
875230|NCT02691000|depression
875231|NCT02691000|depressive symptoms
875232|NCT02691000|stage b heart failure
875233|NCT02691000|bright white light
875234|NCT02691000|light therapy
875235|NCT02690987|tobacco
875236|NCT02690987|GLP1
875237|NCT02690987|ghrelin
875238|NCT02690987|alcohol
875239|NCT02690987|appetite
875240|NCT02690987|reward
875241|NCT02690987|addiction
875242|NCT02690987|hormone
875243|NCT02690987|cigarette
875244|NCT02690987|fMRI
875245|NCT02690974|HFrEF,
875246|NCT02690974|ACEi,
875247|NCT02690974|ACE inhibitor,
875248|NCT02690974|ARBs,
875249|NCT02690974|systolic heart failure,
875250|NCT02690974|chronic heart failure,
875251|NCT02690974|CHF,
875252|NCT02690974|reduced EF,
875253|NCT02690974|Ejection Fraction
875254|NCT02690961|Healthy
875255|NCT02690935|grass pollen
875256|NCT02690935|homeopathy
875257|NCT02690935|placebo
875258|NCT02690935|quality of life
875259|NCT02690909|Uncontrolled Hypertension
875260|NCT02690909|Resistant Hypertension
875261|NCT02690909|Renal Denervation
875262|NCT02690896|caregiver burden
875263|NCT02690896|caregiver support groups
875264|NCT02690870|tamoxifen
875265|NCT02690870|clomiphene
875266|NCT02690870|mild stimulation
875267|NCT02690870|poor ovarian response
875268|NCT02690870|clinical pregnancy rate
875269|NCT02690831|Asthma
875270|NCT02690831|Inspiratory Muscle Training
875271|NCT02690831|Manual Therapies
875272|NCT02690818|Tuberculosis
875273|NCT02690818|Latent Tuberculosis
875274|NCT02690818|Texting
875275|NCT02690818|Adherence
875276|NCT02690818|Medication
875277|NCT02690792|Healthy
875278|NCT02690792|NAFLD
875279|NCT02690792|NASH
875280|NCT02690792|Liver Metabolism
875281|NCT02690792|Vitamin E
875282|NCT02690766|Cancer
875283|NCT02690766|Breast Cancer
875284|NCT02690766|Endometrial cancer,
875285|NCT02690766|Type 2 Diabetes
875286|NCT02690753|Repositioning
875287|NCT02690753|Incontinence care
875288|NCT02690753|Prevention
875289|NCT02690740|titrated quantitative conjunctival provocation test
875290|NCT02690727|Fasting
875291|NCT02690727|Fed condition
875292|NCT02690727|Pharmacokinetics
875293|NCT02690701|psoriasis
875294|NCT02690701|plaque psoriasis
875295|NCT02690701|secukinumab
875296|NCT02690701|AIN457
875297|NCT02690701|biologic
875298|NCT02690701|monoclonal antibody
875299|NCT02690688|Pulse Pressure Variation
875300|NCT02690688|NIRS
875301|NCT02690688|Pneumoperitoneum
875302|NCT02690688|Abdominal surgery
875303|NCT02690675|Neurodevelopment
875304|NCT02690675|Bayley Scale
875305|NCT02690675|Growth
875306|NCT02690675|Iron fortification
875307|NCT02690662|Obesity
875308|NCT02690662|Kidney stones
875309|NCT02690662|Diet
875310|NCT02690649|anticoagulants
875311|NCT02690649|Personal Health Records
875312|NCT02690623|hospitalist
875313|NCT02690623|pediatric inpatient care
875314|NCT02690610|EBUS, Mediastinal lesions, Mediastinal lymph node
875315|NCT02690597|Anxiety analogic visual scale
875316|NCT02690597|Pain
875317|NCT02690597|State Trait Inventory anxiety scale
875318|NCT02690597|Anxiety
875319|NCT02690584|Psychotherapy
875320|NCT02690571|Air Pollution
875321|NCT02690571|Biodiesel exhaust
875322|NCT02690571|Bronchoscopy
875323|NCT02690571|Metabolomics
875324|NCT02690558|muscle-invasive
875325|NCT02690545|CAR T cells
875326|NCT02690545|CD30
875327|NCT02690545|Lymphoma
875328|NCT02690545|T Lymphocytes
875329|NCT02690532|Celiac
875330|NCT02690532|Gluten
875331|NCT02690532|Sensitivity
875332|NCT02690532|Permeability
875333|NCT02690532|Non-celiac gluten intolerance
875334|NCT02690532|Gastrointestinal Diseases
875335|NCT02690532|Digestive System Diseases
875336|NCT02690519|Cystic fibrosis S1251N mutation
875337|NCT02690519|GLPG1837
875338|NCT02690506|pregabalin
875339|NCT02690506|spinal anesthesia
875340|NCT02690480|fulvestrant
875341|NCT02690480|palbociclib
875342|NCT02690480|metastases
875343|NCT02690480|postmenopausal
875344|NCT02690480|breast cancer
875345|NCT02690480|hormone receptor positive
875346|NCT02690467|Insulin therapy
875347|NCT02690467|Needle
875348|NCT02690454|ticagrelor
875349|NCT02690454|ticagrelor active metabolite (AR-C124910XX)
875350|NCT02690454|platelet function tests
875351|NCT02690454|the flow cytometric VASP assay
875352|NCT02690454|the VerifyNow® device
875353|NCT02690454|the Multiplate® analyzer
875354|NCT02690454|pharmacokinetics
875355|NCT02690454|pharmacodynamics
875356|NCT02690454|Multiplate® ADPtest
875357|NCT02690454|VerifyNow® PRUTest™
875358|NCT02690454|Platelet VASP/P2Y12 assay
875359|NCT02690441|GAD
875360|NCT02690441|CBT
875361|NCT02690441|Physical exercise
875362|NCT02690441|Older adults
875363|NCT02690428|Hyperthermia, Induced
875364|NCT02690428|Laser Coagulation
875365|NCT02690428|Laser Therapy
875366|NCT02690389|Acupuncture
875367|NCT02690389|Flumazenil
875368|NCT02690389|Narcotrend
875369|NCT02690389|General Anaesthesia
875370|NCT02690389|Sedation
875371|NCT02690337|Advanced solid malignant tumors
875372|NCT02690337|phase 1
875373|NCT02690337|oncology
875374|NCT02690337|refractory
875375|NCT02690337|no standard treatment
875376|NCT02690272|kidney transplant
875377|NCT02690272|psychic process
875378|NCT02690259|Sentinel Lymph Node Biopsy
875379|NCT02690233|endothelial dysfunction
875380|NCT02690233|surgery
875381|NCT02690233|cardiovascular complications
875382|NCT02690233|EndoPat
875383|NCT02690233|myocardial injury
875384|NCT02690233|myocardial infarction
875385|NCT02690220|polypropylene mesh
875386|NCT02690220|prolapse
875387|NCT02690220|cystocele
875388|NCT02690220|surgical mesh
875389|NCT02690207|Herpes Zoster
875390|NCT02690207|Safety
875391|NCT02690207|Adults
875392|NCT02690207|Cross-vaccination
875393|NCT02690194|Buddhify
875394|NCT02690194|Stress
875395|NCT02690194|Anxiety
875396|NCT02690194|Relaxation Technique
875397|NCT02690168|Fasting
875398|NCT02690168|Carbon-13 Magnetic Resonance Spectroscopy
875399|NCT02690168|Neuroimaging
875400|NCT02690155|Non-valvular atrial fibrillation (NVAF)
875401|NCT02690155|Prevention
875402|NCT02690155|Stroke
875403|NCT02690129|progesterone
875404|NCT02690129|threatened abortion
875405|NCT02690116|Meditative movement
875406|NCT02690116|Breast cancer survivors
875407|NCT02690116|Qigong
875408|NCT02690116|Tai Chi Easy
875409|NCT02690116|Fatigue
875410|NCT02690103|Arabinoxylan
875411|NCT02690103|HCV
875412|NCT02690103|Viremia
875413|NCT02690103|Biobran
875414|NCT02690103|PEG interferon
875415|NCT02690090|Deep Vein Thrombosis
875416|NCT02690090|Prophylaxis
875417|NCT02690090|Critically ill adults
875418|NCT02690077|Patient Satisfaction
875419|NCT02690077|Earlier Family Bond Initiation
875420|NCT02690077|Maternal and Neonatal Outcomes
875421|NCT02690064|Endothelial Function
875422|NCT02690064|Maximal Exercise Capacity
875423|NCT02690064|Flow Mediated Dilation
875424|NCT02690064|Antioxidant
875425|NCT02690064|FEV1
875426|NCT02690038|AECOPD
875427|NCT02690038|COPD
875428|NCT02689999|Gastroesophageal Reflux Disease (GERD), GERD, impedence
875429|NCT02689986|Cold agglutinin
875430|NCT02689986|Cold agglutinin disease
875431|NCT02689986|Anemia
875432|NCT02689986|Hemolytic
875433|NCT02689986|Autoimmune
875434|NCT02689986|Bendamustine
875435|NCT02689986|Rituximab
875436|NCT02689973|adolescence
875437|NCT02689973|body fat
875438|NCT02689973|physical activity
875439|NCT02689973|psychosocial intervention
875440|NCT02689973|self-efficacy
875441|NCT02689973|planning
875445|NCT02689934|hypercholesterolemia
875446|NCT02689934|bifidobacterium longum BB536
875447|NCT02689934|red yeast rice
875448|NCT02689934|monacolin K
875449|NCT02689934|lactoflorene colesterolo
875450|NCT02689908|Thorax CT
875451|NCT02689908|Low Dose
875452|NCT02689908|Body Mass Index
875453|NCT02689908|Neck Circumference
875454|NCT02689895|adolescents
875455|NCT02689895|second line treatment failure
875456|NCT02689895|adherence
875457|NCT02689895|drug resistance
875458|NCT02689882|nicotinamide riboside
875459|NCT02689882|nicotinamide ribonucleoside
875460|NCT02689882|Nicotinamide-Adenine Dinucleotide
875461|NCT02689869|indolent lymphoma
875462|NCT02689869|novel agents
875463|NCT02689869|chemotherapy free treatment
875464|NCT02689869|ibrutinib
875465|NCT02689869|obinutuzumab
875466|NCT02689869|GA101
875467|NCT02689843|Inflammation
875468|NCT02689843|Complement system proteins
875469|NCT02689843|Homocysteine
875470|NCT02689843|C-Reactive Protein
875471|NCT02689843|Cyproterone
875472|NCT02689843|Ethinyl Estradiol
875473|NCT02689843|Androgen Antagonists
875474|NCT02689843|Metformin
875475|NCT02689843|Thiazolidinediones
875476|NCT02689843|Pioglitazone
875477|NCT02689817|Pressure ulcer
875478|NCT02689817|Monitoring
875479|NCT02689817|Pressure
875480|NCT02689817|Physiologic feedback
875481|NCT02689804|Emergency contraception
875482|NCT02689791|Appetite
875483|NCT02689791|Food Intake
875484|NCT02689791|Satiety Hormones
875485|NCT02689778|Pirfenidone
875486|NCT02689778|Diabetic nephropathy
875487|NCT02689752|mass balance
875488|NCT02689752|14C
875489|NCT02689713|Burn Pain
875490|NCT02689713|Hyperalgesia
875491|NCT02689713|TRPV1
875492|NCT02689713|OLAMs
875493|NCT02689700|Human Cytomegalovirus
875494|NCT02689700|Varicella Zoster Virus
875495|NCT02689700|Materno-fetal antibody transfer
875496|NCT02689700|Pregnancy
875497|NCT02689700|Gestational age
875498|NCT02689622|Hematology
875499|NCT02689622|Elderly
875500|NCT02689622|High Risk Myelodysplastic Syndrome
875501|NCT02689609|Nasopharyngeal carcinoma
875502|NCT02689609|Intensity-modulated radiation therapy
875503|NCT02689609|Hypothyroidism
875504|NCT02689609|Predictors
875505|NCT02689583|Helicobacter pylori
875506|NCT02689583|Antibiotic resistance
875507|NCT02689583|Sequencing
875508|NCT02689583|Mechanism
875509|NCT02689583|Cause
875510|NCT02689570|type 1 diabetes
875511|NCT02689570|coronary artery calcifications
875512|NCT02689570|diastolic dysfunction
875513|NCT02689570|adipokines
875514|NCT02689570|visceral adipose tissue
875515|NCT02689544|exercise muscle stretching
875516|NCT02689544|range of motion
875517|NCT02689544|dynamometer of muscle strength
875518|NCT02689544|electromyography
875519|NCT02689518|AMD
875520|NCT02689518|Wet AMD
875521|NCT02689518|Macular degeneration
875522|NCT02689518|Wet macular degeneration
875523|NCT02689518|Neovascularization
875524|NCT02689518|Retina
875525|NCT02689518|Retinal degeneration
875526|NCT02689479|Clinical Islet Transplantation
875527|NCT02689479|Positron Emission Tomography (PET) Computed Tomography (CT) imaging
875528|NCT02689466|Adult
875529|NCT02689466|Acetylcholine
875530|NCT02689466|Movement Disorder
875531|NCT02689466|Magnetic Resonance Imaging (MRI)
875532|NCT02689466|PET Imaging
875537|NCT02689440|Chronic Myelogenous Leukemia
875538|NCT02689440|CML
875539|NCT02689440|Ph-positive chronic myelogenous leukemia
875540|NCT02689440|BCR-ABL positive chronic myelogenous leukemia
875541|NCT02689440|Dasatinib
875542|NCT02689440|BMS-354825
875543|NCT02689440|Sprycel
875544|NCT02689427|Breast cancer
875545|NCT02689427|Invasive carcinoma of the breast
875546|NCT02689427|Triple-negative breast cancer
875547|NCT02689427|TNBC
875548|NCT02689427|Enzalutamide
875549|NCT02689427|MDV3100
875550|NCT02689427|XTANDI
875551|NCT02689427|Paclitaxel
875552|NCT02689427|Taxol
875553|NCT02689414|Atherosclerosis
875554|NCT02689401|Esophageal Cancer
875555|NCT02689401|lymph nodes tumor
875556|NCT02689388|analgesia
875557|NCT02689388|regional analgesia
875558|NCT02689388|femoral nerve block
875559|NCT02689388|older persons
875560|NCT02689388|frail
875561|NCT02689362|Diabetes Mellitus Type 2
875562|NCT02689349|hearing
875563|NCT02689349|implant
875564|NCT02689349|moderate degree
875565|NCT02689349|severe degree
875566|NCT02689310|Wound Care
875567|NCT02689310|Medical Grade Honey
875568|NCT02689310|Pressure Ulcers
875569|NCT02689284|Stomach Cancer
875570|NCT02689284|Gastroesophageal Junction
875571|NCT02689284|Gastric Cancer
875572|NCT02689284|Cancer of the Stomach
875573|NCT02689284|Cancer of Stomach
875574|NCT02689284|Stomach
875575|NCT02689284|Pembrolizumab
875576|NCT02689284|Keytruda
875577|NCT02689284|HER2+
875578|NCT02689284|GEJ
875579|NCT02689284|HER2 positive
875580|NCT02689284|Metastatic
875581|NCT02689284|Margetuximab
875582|NCT02689284|Immunotherapy
875583|NCT02689284|Trastuzumab
875584|NCT02689284|Human epidermal growth factor receptor 2
875585|NCT02689284|Human epidermal growth factor receptor 2-positive
875586|NCT02689284|gastroesophageal junction cancer
875587|NCT02689284|Pembro
875588|NCT02689284|PD-L1
875589|NCT02689284|PD-1
875590|NCT02689284|PD
875591|NCT02689284|Tumor
875592|NCT02689284|Cancer
875593|NCT02689271|MRI
875594|NCT02689271|Magnetic resonance imaging
875595|NCT02689271|Biomarkers
875596|NCT02689271|Fluidics
875597|NCT02689271|Diffusion MRI
875598|NCT02689219|Antigens, CD30, Embryonal Germ Cell Tumors
875599|NCT02689206|Chronic kidney disease
875600|NCT02689206|Efficacy
875601|NCT02689206|Erythropoiesis-stimulating agent
875602|NCT02689206|GSK1278863
875603|NCT02689206|Safety
875604|NCT02689206|Hemodialysis-dependent anemia
875605|NCT02689206|Pharmacokinetics
875606|NCT02689193|Proteomics
875607|NCT02689193|Rapid Diagnostic Test
875608|NCT02689193|Salmonellosis
875609|NCT02689180|heart failure
875610|NCT02689180|diuretics
875611|NCT02689180|furosemide
875612|NCT02689167|renal cell carcinoma
875613|NCT02689167|sunitinib
875614|NCT02689167|metastatic
875615|NCT02689167|schedule
875616|NCT02689167|toxicity
875617|NCT02689167|safety
875618|NCT02689154|Pediatric Obesity
875619|NCT02689154|Food Addiction
875620|NCT02689154|Mobile Health (mHealth)
875621|NCT02689154|Weight Management
875622|NCT02689141|chronic lymphocytic leukemia CLL
875623|NCT02689141|untreated chronic lymphocytic leukemia
875624|NCT02689141|relapsed chronic lymphocytic leukemia
875625|NCT02689141|refractory chronic lymphocytic leukemia
875626|NCT02689128|Anesthesia
875627|NCT02689128|postoperative
875628|NCT02689128|nausea
875629|NCT02689128|vomiting
875630|NCT02689115|Nuclear factor Kappa B
875631|NCT02689115|IKK epsilon
875632|NCT02689102|Optical coherence tomography
875633|NCT02689102|Confocal laser endomicroscopy
875634|NCT02689076|Patient transfer
875635|NCT02689076|Patient care management
875636|NCT02689076|Health information exchange
875637|NCT02689063|Analgesic
875638|NCT02689024|Nerve block
875639|NCT02689024|Analgesia
875640|NCT02689011|Total Knee Arthroplasty
875641|NCT02689011|Femoral Nerve Block
875642|NCT02689011|Epidural Analgesia
875643|NCT02689011|Urinary Retention
875644|NCT02689011|Lumbar Epidural
875645|NCT02688998|HER2 negative
875646|NCT02688959|motor attention training
875647|NCT02688959|exercise
875648|NCT02688959|tai chi
875649|NCT02688959|ADHD
875650|NCT02688855|Bone Growth Stimulator
875651|NCT02688855|Ankle Fracture
875652|NCT02688829|stents,percutaneous coronary intervention
875653|NCT02688816|visual inspection with acetic acid
875654|NCT02688816|Xpert HPV
875655|NCT02688816|OncoE6
875656|NCT02688816|screening
875657|NCT02688803|HER2 Negative
875658|NCT02688790|Dalbavancin
875659|NCT02688790|DALVANCE®
875660|NCT02688790|Suspected or Confirmed Bacterial Infection
875661|NCT02688777|Rehabilitation
875662|NCT02688777|Gait
875663|NCT02688777|Postural Balance
875664|NCT02688777|Exercise
875665|NCT02688777|Accidental Falls
875666|NCT02688777|Kinesiology, Applied
875667|NCT02688764|PA21
875668|NCT02688764|phosphate binder
875669|NCT02688712|IIA
875670|NCT02688712|Xeloda
875671|NCT02688712|radiation therapy
875672|NCT02688712|LY2157299
875673|NCT02688712|tumor resection
875674|NCT02688712|capecitabine
875675|NCT02688712|5FU
875676|NCT02688712|Fluorouracil
875677|NCT02688712|IIB
875678|NCT02688712|IIC
875679|NCT02688712|IV
875680|NCT02688712|neoadjuvant
875681|NCT02688712|Rectal cancer
875682|NCT02688712|Immunotherapy
875683|NCT02688660|Pediatrics
875684|NCT02688660|Neuroimaging
875685|NCT02688647|Pulmonary Fibrosis
875686|NCT02688647|Fibrosis
875687|NCT02688647|Idiopathic Interstitial Pneumonias
875688|NCT02688647|Lung Diseases
875689|NCT02688634|Cleft Palate Surgery
875690|NCT02688634|Antibiotic treatment
875691|NCT02688621|weight loss
875692|NCT02688621|financial incentives
875693|NCT02688621|internet weight loss
875694|NCT02688595|Infant, Newborn
875695|NCT02688595|Ultrasonography
875696|NCT02688582|Target Controlled Infusion
875697|NCT02688582|Pharmacokinetics
875698|NCT02688582|Cefepime
875699|NCT02688582|critically ill patients
875700|NCT02688556|KCS
875701|NCT02688556|dry eye
875702|NCT02688556|cyclosporine
875703|NCT02688543|radio frequency treatment
875704|NCT02688543|genicular nerves
875705|NCT02688543|osteoarthritis of the knee
875706|NCT02688504|labelled medicines
875707|NCT02688504|drivers involved in serious and non-serious road accidents
875708|NCT02688504|relevance and effectiveness of pictograms on medicines packaging
875709|NCT02688478|Phthalate
875710|NCT02688478|Dibutylphthalate (DBP)
875711|NCT02688478|Airway responsiveness
875712|NCT02688478|Allergies
875713|NCT02688452|strenuous exercise
875714|NCT02688452|muscle soreness
875715|NCT02688413|Virtual reality
875716|NCT02688413|Stroke
875717|NCT02688413|Neurorehabilitation
875718|NCT02688413|Upper-limb rehabilitation
875719|NCT02688413|Training games
875720|NCT02688400|Osteoarthritis
875721|NCT02688400|Knee
875722|NCT02688400|Osteoarthritis, Knee
875723|NCT02688400|Diacerein
875724|NCT02688400|Celecoxib
875725|NCT02688400|Phase III
875726|NCT02688400|Phase IV
875727|NCT02688400|Phase III-IV
875728|NCT02688400|Canada
875729|NCT02688400|Spain
875730|NCT02688400|Austria
875731|NCT02688400|Czech Republic
875732|NCT02688400|WOMAC
875733|NCT02688387|Ambrisentan
875734|NCT02688387|Bioavailability
875735|NCT02688387|Tadalafil
875736|NCT02688387|Fixed Dose combination
875737|NCT02688322|sulbactam
875738|NCT02688322|pharmacokinetics
875739|NCT02688322|pharmacodynamics
875740|NCT02688322|Acinetobacter infections
875741|NCT02688257|Magnetic Resonance Imaging
875742|NCT02688257|Ultrasound
875743|NCT02688257|Breast Cancer
875744|NCT02688244|complicated appendicitis
875745|NCT02688244|laparoscopic appendectomy
875746|NCT02688244|irrigation
875747|NCT02688244|suction
875748|NCT02688244|abdominal abscess
875749|NCT02688231|Multiple Sclerosis
875750|NCT02688231|Upper limb rehabilitation
875751|NCT02688218|exercise
875752|NCT02688218|artificial pancreas
875753|NCT02688218|hypoglycemia
875754|NCT02688218|type 1 diabetes
875755|NCT02688205|Cyriax's functional examination
875756|NCT02688205|Ultrasound
875757|NCT02688205|Correlation
875758|NCT02688205|Resisted test
875759|NCT02688153|Aortic Valve Replacement
875760|NCT02688153|Aortic Stenosis
875761|NCT02688153|EDWARDS INTUITY
875762|NCT02688140|APL
875763|NCT02688140|acute promyelocytic leukemia (M3)
875764|NCT02688140|high-risk acute promyelocytic leukemia (APL/AML M3)
875765|NCT02688140|acute myeloid leukemia with t(15;17)(q22;q12)
875766|NCT02688140|newly diagnosed
875767|NCT02688140|high-risk
875768|NCT02688127|obstetric bleeding placenta previa
875769|NCT02688075|Diabetes Mellitus Type 2
875770|NCT02688075|Canagliflozin
875771|NCT02688075|Observational Study
875772|NCT02688036|Limited Disease Small Cell Lung Cancer
875773|NCT02688036|concurrent chemoradiotherapy
875774|NCT02688036|dose fractionation
875775|NCT02688023|5-fluorouracil
875776|NCT02688023|Irinotecan
875777|NCT02688023|Oxaliplatin
875778|NCT02688023|Colorectal cancer
875779|NCT02688023|neoadjuvant
875780|NCT02688023|chemotherapy
875781|NCT02688010|noise
875782|NCT02688010|sound
875783|NCT02688010|cycled light
875784|NCT02688010|preterm infants
875785|NCT02688010|neonatal care
875786|NCT02688010|growth
875787|NCT02688010|visual development
875788|NCT02687984|Schizophrenia
875789|NCT02687984|Long-acting Risperidone
875790|NCT02687984|Atrigel
875791|NCT02687958|GEP/ NEC
875792|NCT02687932|Functional Mitral Regurgitation
875793|NCT02687932|Ischemic Mitral Regurgitation
875794|NCT02687919|diet (gluten-free)
875795|NCT02687919|diet therapy
875796|NCT02687919|quality of life
875797|NCT02687893|Sleep
875798|NCT02687893|Exercise
875799|NCT02687867|Non-valvular atrial fibrillation (NVAF)
875800|NCT02687867|Prevention
875801|NCT02687867|Stroke
875802|NCT02687854|Non-valvular atrial fibrillation (NVAF)
875803|NCT02687854|Prevention
875804|NCT02687854|Stroke
875805|NCT02687841|acute kidney injury
875806|NCT02687841|indoxylsulfate
875807|NCT02687841|p-cresol
875808|NCT02687841|AST-120
875809|NCT02687828|Safety
875810|NCT02687828|Adalimumab
875811|NCT02687828|Effectiveness
875812|NCT02687828|AMORE study
875813|NCT02687828|Intestinal Behcet's disease (BD)
875814|NCT02687815|Vitamin D, severe asthma exacerbations, children
875815|NCT02687802|respiratory mechanics
875816|NCT02687802|Respiratory Insufficiency
875817|NCT02687802|artificial, ventilation
875818|NCT02687789|Bacterial Vaginosis
875819|NCT02687789|BV
875820|NCT02687776|Copeptin, human
875821|NCT02687763|vaccines
875822|NCT02687763|ProQuad
875823|NCT02687763|immunosuppressed
875824|NCT02687763|solid organ transplant
875825|NCT02687763|MMRV
875826|NCT02687737|Tongue
875827|NCT02687737|Genioglossus
875828|NCT02687737|genioglossus recruitment
875829|NCT02687711|Non-interventional (NIS)
875830|NCT02687711|Epilepsy
875831|NCT02687711|Partial Onset Seizures (POS)
875832|NCT02687711|add-on therapy
875833|NCT02687685|Skin to Skin Contact
875834|NCT02687685|Infant, Newborn
875835|NCT02687607|Endovascular
875836|NCT02687607|Brain aneurysm
875837|NCT02687607|Ruptured aneurysm
875838|NCT02687542|Parkinson Disease
875839|NCT02687542|Motor Fluctuation
875840|NCT02687529|Tuberculosis
875841|NCT02687529|TB
875842|NCT02687516|Treatment
875843|NCT02687516|Child
875844|NCT02687516|Obesity
875845|NCT02687516|Behavioral treatment
875846|NCT02687503|Immune system
875847|NCT02687503|Probiotics
875848|NCT02687464|Pediatric Surgery
875849|NCT02687464|Pediatrics
875850|NCT02687464|Randomized controlled trial,
875851|NCT02687464|Antibiotics
875852|NCT02687464|Cost effectiveness
875853|NCT02687451|Surgical Pain
875854|NCT02687451|Acute Post-Surgical Pain
875855|NCT02687438|Steroid-eluting implant Mometasone Furoate
875856|NCT02687425|Pioglitazone
875857|NCT02687425|Chronic Myeloid Leukemia
875858|NCT02687412|Fast-track surgery
875859|NCT02687412|Gynecological oncology
875860|NCT02687412|Hospitalization post-operation
875861|NCT02687412|Complication
875862|NCT02687399|knee arthroplasty
875863|NCT02687386|Recurrent
875864|NCT02687386|Refractory
875865|NCT02687373|Plasmodium falciparum
875866|NCT02687373|PfSPZ Vaccine
875867|NCT02687308|Prostatic cancer
875868|NCT02687308|Radical prostatectomy
875869|NCT02687308|Minimally invasive prostate cancer surgery
875870|NCT02687282|Modified Mallampati score
875871|NCT02687282|Cesarean delivery
875872|NCT02687269|myocardial protection
875873|NCT02687269|coronary artery bypass grafting
875874|NCT02687243|pediatrics
875875|NCT02687243|anxiety
875876|NCT02687243|anesthesia
875877|NCT02687243|preoperative
875878|NCT02687217|PerioperativeHyperoxygenation
875879|NCT02687217|Wound Site Infection
875880|NCT02687217|Appendicitis
875881|NCT02687191|safety, maximum tolerated dose, modified continual reassessment method, intracerebral, hemorrhage, hematoma
875882|NCT02687113|ablation
875883|NCT02687113|fusion
875884|NCT02687100|intubation
875885|NCT02687100|intensive care
875886|NCT02687100|cardiac surgery
875887|NCT02687100|sore throat
875888|NCT02687087|Radiotherapy Induced Xerostomia (RIX)
875889|NCT02687074|HFNC
875890|NCT02687074|Respiratory Failure
875891|NCT02687074|Intubation
875892|NCT02687074|Mortality
875893|NCT02687061|Recall study
875894|NCT02687061|Lost to follow-up
875895|NCT02687048|mindful meditation
875896|NCT02687035|S3iCAP
875897|NCT02687035|SAPIEN 3
875898|NCT02687035|Transfemoral
875899|NCT02687035|Commander
875900|NCT02687035|Certitude
875901|NCT02687035|TAVR
875902|NCT02687035|TAVI
875903|NCT02687035|Aortic stenosis
875904|NCT02687035|THV
875905|NCT02687035|Transcatheter Heart Valve
875906|NCT02687035|TVT
875907|NCT02687035|TVTR
875908|NCT02687009|colon cancer
875909|NCT02687009|Wnt pathway
875910|NCT02687009|Frizzled
875911|NCT02686996|carnosine
875912|NCT02686996|Insulin sensitivity
875913|NCT02686996|low grade inflammation
875914|NCT02686996|Oxidative stress
875915|NCT02686996|Advanced glycation
875916|NCT02686996|Type 2 diabetes
875917|NCT02686996|Cardiovascular disease
875918|NCT02686970|Family
875919|NCT02686970|Quality
875920|NCT02686970|Validate
875921|NCT02686970|ICU
875922|NCT02686944|GIST
875923|NCT02686931|Developmental delayed
875924|NCT02686931|Orthopedic disease
875925|NCT02686931|Longitudinal study
875926|NCT02686892|Inflamatory bowel disease
875927|NCT02686892|Crohns disease
875928|NCT02686892|ulcerative colitis
875929|NCT02686892|incidence
875930|NCT02686892|epidemiology
875931|NCT02686879|hyperopes
875932|NCT02686879|axial length
875933|NCT02686879|peripheral defocus
875934|NCT02686853|Intrathecal administration
875935|NCT02686853|Liposomal amphotericin B
875936|NCT02686853|Without Acquired Immune Deficiency Syndrome
875937|NCT02686814|Valvular heart disease
875938|NCT02686814|Severe aortic stenosis
875939|NCT02686814|Aortic valve replacement
875940|NCT02686801|nutrition
875941|NCT02686801|prematurity
875942|NCT02686801|body composition
875943|NCT02686788|multiple sclerosis
875944|NCT02686788|relapsing remitting
875945|NCT02686788|nonsteroidal anti-inflammatory drug
875946|NCT02686788|contrast enhancing lesions
875947|NCT02686762|NASH
875948|NCT02686736|internet-based educational intervention
875949|NCT02686736|risky sexual behaviors
875950|NCT02686736|prevention
875951|NCT02686723|ACL injury
875952|NCT02686723|Return to sport
875953|NCT02686723|Motion analysis
875954|NCT02686723|Isokinetic evaluation
875955|NCT02686723|Risk factor
875956|NCT02686697|L-Carnosine
875957|NCT02686697|Schizophrenia
875958|NCT02686697|Psychosis
875959|NCT02686697|Cognition
875960|NCT02686671|Bursitis
875961|NCT02686671|Injections
875962|NCT02686671|Shoulder Pain
875963|NCT02686658|Geographic Atrophy
875964|NCT02686658|Dry age-related macular degeneration
875965|NCT02686658|AMD
875966|NCT02686658|Zimura®
875967|NCT02686658|Anti-inflammatory
875968|NCT02686658|Complement C5 inhibition
875969|NCT02686645|Fecal Microbiota Transplantation
875970|NCT02686632|Denture Stomatitis
875971|NCT02686632|Denture Erythematous Stomatitis
875972|NCT02686632|Prosthesis Stomatitis
875973|NCT02686632|Oral Candidiasis
875974|NCT02686632|Palatal inflammation
875975|NCT02686593|Clofarabine
875976|NCT02686593|Acute Myeloid Leukemia
875977|NCT02686567|transanal drainage tube
875978|NCT02686567|anastomotic leakage
875979|NCT02686567|laparoscopic anterior resection
875980|NCT02686567|rectal cancer
875981|NCT02686554|Alzheimer´s Disease
875982|NCT02686528|total hip arthroplasty
875983|NCT02686528|hip precautions
875984|NCT02686528|posterior approach
875985|NCT02686515|balance
875986|NCT02686476|Empagliflozin, Fatty Liver Disease
875987|NCT02686463|malignant ovarian cancer
875988|NCT02686463|laparoscopy
875989|NCT02686463|laparotomy
875990|NCT02686437|shoulder dysfunction
875991|NCT02686437|kinesiology tape
875992|NCT02686437|rehabilitation
875993|NCT02686424|MAGE-A3 protein
875994|NCT02686424|NY-ESO-1 protein
875995|NCT02686424|WT1 Proteins
875996|NCT02686424|PRAME protein
875997|NCT02686411|Benign neoplasms
875998|NCT02686411|In situ neoplasms
875999|NCT02686411|Malignant neoplasms of independent (primary) multiple sites
876000|NCT02686411|Consult with palliative care doctor
876001|NCT02686411|Palliative care unit
876002|NCT02686411|PCU
876003|NCT02686411|Questionnaires
876004|NCT02686411|Surveys
876005|NCT02686398|Influenza Vaccines
876006|NCT02686398|MF59 oil emulsion
876007|NCT02686398|End Stage Renal Failure on Dialysis
876008|NCT02686372|hepatocellular carcinoma
876009|NCT02686359|physiology
876010|NCT02686359|pain
876011|NCT02686359|analgesia
876012|NCT02686359|saliva
876013|NCT02686359|opiorphin
876014|NCT02686346|Relapsed
876015|NCT02686346|Refractory
876016|NCT02686333|Meditation
876017|NCT02686333|Dialysis
876018|NCT02686320|Rheumatoid arthritis
876019|NCT02686320|Elderly
876020|NCT02686320|infections
876021|NCT02686320|cardio-vascular disease
876022|NCT02686320|osteoporosis
876023|NCT02686320|cancer
876024|NCT02686268|Amyotrophic Lateral Sclerosis
876025|NCT02686268|ALS
876026|NCT02686268|C9ORF72 gene mutation
876027|NCT02686268|Chromosome 9 open reading frame 72 protein
876028|NCT02686268|Natural history
876029|NCT02686268|Biomarkers
876030|NCT02686268|Amyotrophic Lateral Sclerosis, Familial
876031|NCT02686268|Amyotrophic Lateral Sclerosis, Sporadic
876032|NCT02686268|Frontotemporal Dementia-Amyotrophic Lateral Sclerosis
876033|NCT02686242|cesarean section
876034|NCT02686242|spinal anesthesia
876035|NCT02686242|general anesthesia
876036|NCT02686229|Low grade glioma, registry, neurosurgery, brain tumor
876037|NCT02686216|F-18 THK-5351 PET
876038|NCT02686190|Alzheimer; luxtherapy, sleep disturbance, behaviour disturbance
876039|NCT02686177|Type 2 diabetes
876040|NCT02686177|Angiogenesis
876041|NCT02686177|Liraglutide
876042|NCT02686177|Glucagon like peptide 1 receptor agonist
876043|NCT02686164|Lenvatinib
876044|NCT02686164|Lenvima
876045|NCT02686164|E7080
876046|NCT02686164|Phase 1
876047|NCT02686164|Solid tumors
876048|NCT02686164|Midazolam
876049|NCT02686164|CYP3A4
876050|NCT02686151|Letrozole
876051|NCT02686151|OHSS
876052|NCT02686099|Rigid Fixation
876053|NCT02686099|Sternal Plating
876054|NCT02686099|Sternal Closure
876055|NCT02686099|Sternalock
876056|NCT02686073|BMI
876057|NCT02686073|progress of labor
876058|NCT02686073|nulliparous women
876059|NCT02686047|Knee osteoarthritis
876060|NCT02686047|Hyaluronic acid
876061|NCT02686047|Viscosupplementation
876062|NCT02686034|Migraine
876063|NCT02686034|Non-invasive vagus nerve stimulation
876064|NCT02686034|Vagus nerve stimulation
876065|NCT02686034|Vagal nerve stimulation
876066|NCT02686034|gammaCore
876067|NCT02686034|episodic migraine
876076|NCT02685969|Prevention
876077|NCT02685969|Positron Emission Tomography
876078|NCT02685930|invasive mechanical ventilation
876079|NCT02685878|urinary continence
876080|NCT02685878|prevalence of depression
876081|NCT02685878|reproductive outcomes
876082|NCT02685878|quality of life
876083|NCT02685878|HIV status
876084|NCT02685878|obstetric fistula
876085|NCT02685865|pancreatic fluid collection; pancreatic necrosis; stent;
876086|NCT02685839|frailty syndrome, Intelligent POWER Rehabilitation Cluster Machine, Internet of Things, wearable
876087|NCT02685826|Open-label
876088|NCT02685826|Phase 1/2
876089|NCT02685826|Durvalumab
876090|NCT02685826|MEDI4736
876091|NCT02685826|Lenalidomide (Len)
876092|NCT02685826|Dexamethasone (dex)
876093|NCT02685826|Multiple Myeloma
876094|NCT02685826|Newly-Diagnosed (NDMM)
876095|NCT02685826|Transplant Non-eligible (TNE)
876096|NCT02685826|PD-L1
876097|NCT02685813|Ultra sound
876098|NCT02685813|birth defects
876099|NCT02685787|Care-giver burden
876100|NCT02685787|Dementia
876101|NCT02685787|Alzheimer's disease
876102|NCT02685787|Care-giver depression
876103|NCT02685787|Care-giver anxiety
876104|NCT02685709|Octreotide Capsules
876105|NCT02685709|Acromegaly
876106|NCT02685709|Somatostatin
876107|NCT02685709|Mpowered
876108|NCT02685709|OOC-ACM-302
876109|NCT02685683|Crohn's Disease
876110|NCT02685683|GED-0301
876111|NCT02685683|Open-label
876112|NCT02685683|Pharmacodynamic
876113|NCT02685683|Mongersen
876114|NCT02685644|endometrioma
876115|NCT02685644|laparoscopy
876116|NCT02685644|anti-mullerian hormone
876117|NCT02685644|ovarian reserve
876118|NCT02685631|Hepatocellular carcinoma
876119|NCT02685631|Colorectal cancer
876120|NCT02685631|Neuroendocrine tumor
876121|NCT02685631|Cholangiocarcinoma
876122|NCT02685631|Breast cancer
876123|NCT02685631|Tumor of unknown primary
876124|NCT02685631|Pancreatic cancer
876125|NCT02685605|Glioblastoma
876126|NCT02685605|Intraoperative Radiotherapy
876127|NCT02685605|Radiotherapy Dose Escalation
876128|NCT02685592|Lentigo Maligna
876129|NCT02685592|Photodynamic Therapy
876130|NCT02685592|Hyperspectral Imaging
876131|NCT02685566|Mammography
876132|NCT02685540|Anesthesia
876133|NCT02685540|mortality
876134|NCT02685514|HIFU
876135|NCT02685514|Graves' disease
876136|NCT02685514|treatment
876137|NCT02685475|Diabetes mellitus
876138|NCT02685475|Axillary brachial plexus block
876139|NCT02685475|Block duration
876140|NCT02685475|Time-to-first pain
876141|NCT02685475|Postoperative analgesia
876142|NCT02685449|diabetes type 1
876143|NCT02685449|insulin pump
876144|NCT02685449|prandial insulin requirement
876145|NCT02685449|pure protein meal
876146|NCT02685449|high protein meal
876147|NCT02685449|square bolus
876148|NCT02685449|square-wave bolus
876149|NCT02685449|insulin bolus
876150|NCT02685449|dietary protein
876151|NCT02685423|Amblyopia
876152|NCT02685423|Lazy Eye
876153|NCT02685423|Anisometropia
876154|NCT02685384|healthcare access
876155|NCT02685384|healthcare utilization
876156|NCT02685384|health expenditures
876157|NCT02685384|preventive services
876158|NCT02685384|biomarkers
876163|NCT02685345|Type 2 Diabetes Mellitus
876164|NCT02685345|sitagliptin
876165|NCT02685345|adult
876166|NCT02685345|Phase 2
876167|NCT02685280|rechargeable neurostimulators
876168|NCT02685254|Group Therapy
876169|NCT02685254|Structured Skills Training
876170|NCT02685254|Dialectic Behavioural Therapy
876171|NCT02685241|Exhaled breath
876172|NCT02685241|Biomarker
876173|NCT02685215|intensive care unit
876174|NCT02685215|muscular dystrophy
876175|NCT02685215|mortality
876176|NCT02685215|prognosis
876177|NCT02685215|tracheostomy
876178|NCT02685202|orofacial pain
876179|NCT02685202|sleep-disordered breathing
876180|NCT02685202|temporomandibular disorder
876181|NCT02685202|oral appliance
876182|NCT02685202|upper airway collapse
876183|NCT02685176|hypothermia
876184|NCT02685176|rewarming
876185|NCT02685176|non-shivering
876186|NCT02685150|Endoscopic Tri-Modal Imaging
876187|NCT02685150|Gastric juice
876188|NCT02685150|Functional dyspepsia
876189|NCT02685150|Acid reflux disease
876190|NCT02685150|Bile reflux
876191|NCT02685137|Kernicterus
876192|NCT02685137|Neonatal Jaundice
876193|NCT02685137|Newborn Jaundice
876194|NCT02685111|Breast cancer
876195|NCT02685111|Adjuvant
876196|NCT02685111|Docetaxel
876197|NCT02685111|Adriamycin
876198|NCT02685111|Cyclophosphamide
876199|NCT02685111|Neutropenia
876200|NCT02685111|Filgrastim
876201|NCT02685111|Pegfilgrastim
876202|NCT02685098|Stem cells
876203|NCT02685098|MSCs
876204|NCT02685098|Mesenchymal
876205|NCT02685098|Amputation
876206|NCT02685098|BKA
876207|NCT02685098|below knee amputation
876208|NCT02685098|CHAMP
876211|NCT02685059|breast cancer
876212|NCT02685059|Medi4736
876213|NCT02685059|Anti PD-L1
876214|NCT02685059|Nab-Paclitaxel
876215|NCT02685059|Placebo
876216|NCT02685059|triple negative
876217|NCT02685033|Osteomyelitis
876218|NCT02685033|dalbavancin
876219|NCT02685033|antibiotic
876228|NCT02685007|minimal invasive surgery
876229|NCT02684994|Trauma
876230|NCT02684994|Sexual assault
876231|NCT02684994|Sexual abuse
876232|NCT02684994|Physical assault
876233|NCT02684994|Physical abuse
876234|NCT02684994|PTSD
876235|NCT02684994|Interpersonal Violence
876236|NCT02684994|Women
876237|NCT02684955|cardiac arrest
876238|NCT02684955|near-infrared spectroscopy
876239|NCT02684955|automated infrared pupillometry
876240|NCT02684955|prognostication
876241|NCT02684942|Meperidine
876242|NCT02684942|Fentanyl
876243|NCT02684942|Pain management
876244|NCT02684942|brachytherapy
876245|NCT02684929|insulin resistance
876246|NCT02684929|bcaa
876247|NCT02684929|mitochondrial biogenesis
876248|NCT02684916|Chiropractic spinal manipulation
876249|NCT02684916|Children
876250|NCT02684916|Pediatric
876251|NCT02684916|Headache
876252|NCT02684903|Child Abuse
876253|NCT02684903|Parent Child Interaction Therapy (PCIT)
876254|NCT02684903|Evidenced Based Intervention
876255|NCT02684903|Self-control
876256|NCT02684877|Fatigue
876257|NCT02684877|Quality of life
876258|NCT02684877|Critically ill patients
876259|NCT02684864|biomarker
876260|NCT02684864|inflammation
876261|NCT02684864|knee
876262|NCT02684864|prognosis
876263|NCT02684838|Gliadel, Carmustine wafer implant
876264|NCT02684825|Stroke
876265|NCT02684825|ischemic stroke
876266|NCT02684825|atrial fibrillation
876267|NCT02684825|continuous cardiac monitoring
876268|NCT02684825|insertable cardiac monitoring
876269|NCT02684825|implantable loop recorder
876270|NCT02684825|antithrombotics
876271|NCT02684825|anticoagulants
876272|NCT02684825|stroke subtype
876273|NCT02684825|atherothrombotic stroke
876274|NCT02684825|lacunar stroke
876275|NCT02684812|antifibrinolytic therapy
876276|NCT02684812|recurrent bleeding
876277|NCT02684812|tranexamic acid
876278|NCT02684773|Hemodialysis
876279|NCT02684773|Left Ventricular Mass
876280|NCT02684773|Cardiac Magnetic resonance Imaging
876281|NCT02684760|Inflammatory Bowel Disease
876286|NCT02684734|Ulcerative Colitis
876287|NCT02684734|UC
876288|NCT02684734|Cytomegalovirus
876289|NCT02684734|CMV
876290|NCT02684721|rehabilitation
876291|NCT02684721|physical capacity
876292|NCT02684721|quality of life
876293|NCT02684695|Magnetic resonance imaging
876294|NCT02684695|Imaging biomarker
876295|NCT02684695|Diffusion-weighted imaging
876296|NCT02684682|Toothbrushing
876297|NCT02684682|Gingivitis
876298|NCT02684682|Dental Plaque
876299|NCT02684682|Periodontal Diseases
876300|NCT02684682|Clinical Trial
876301|NCT02684669|burn injury
876302|NCT02684669|controlled trial
876303|NCT02684669|latent sensitization
876304|NCT02684669|naloxone
876305|NCT02684669|secondary hyperalgesia
876306|NCT02684669|volunteers
876307|NCT02684656|Oxalate
876308|NCT02684656|Inflammation
876309|NCT02684656|Hemodiafiltration
876310|NCT02684656|Hemodialysis
876311|NCT02684656|Oxalate Blood Sample
876312|NCT02684643|individualised therapy
876313|NCT02684643|hyperphosphatemia
876314|NCT02684643|hemodialysis
876315|NCT02684643|clinical trials
876316|NCT02684643|restricted phosphate diet
876317|NCT02684643|phosphate binders
876318|NCT02684565|pre-diabetes
876319|NCT02684565|blood glucose regulation
876320|NCT02684565|branching chain amino acids
876321|NCT02684565|diabetes
876322|NCT02684565|lower blood sugar
876323|NCT02684513|Well-being
876324|NCT02684513|Quality of Recovery
876325|NCT02684513|Maternal complications
876326|NCT02684500|aSAH
876327|NCT02684487|vitamin D
876328|NCT02684487|vitamin D3
876329|NCT02684487|sepsis
876330|NCT02684487|severe sepsis
876331|NCT02684487|critical illness
876332|NCT02684487|ICU
876333|NCT02684396|Drug therapy
876334|NCT02684383|Dengue Vaccine
876335|NCT02684370|Psoriasis
876336|NCT02684370|Skin Diseases
876337|NCT02684370|Skin Diseases, Papulosquamous
876338|NCT02684370|ustekinumab
876339|NCT02684370|Dermatologic Agents
876340|NCT02684370|ABBV-066
876341|NCT02684370|BI 655066
876342|NCT02684370|risankizumab
876343|NCT02684357|ABBV-066
876344|NCT02684357|BI 655066
876345|NCT02684357|risankizumab
876346|NCT02684344|Post-Operative Urinary Retention
876347|NCT02684292|PD1
876348|NCT02684292|PD-1
876349|NCT02684292|PDL1
876350|NCT02684292|PD-L1
876351|NCT02684266|neoplasm, Cycline-Dependent Kinase
876352|NCT02684253|Nivolumab
876353|NCT02684253|Stereotactic Body Radiotherapy (SBRT)
876354|NCT02684253|15-253
876355|NCT02684227|Endometrial cancer
876356|NCT02684227|Advanced Stage Endometrioid Endometrial Cancer
876357|NCT02684227|Recurrent Endometrioid Endometrial Cancer
876358|NCT02684227|Enzalutamide
876359|NCT02684227|MDV3100
876360|NCT02684227|XTANDI
876361|NCT02684227|Carboplatin
876362|NCT02684227|Paclitaxel
876363|NCT02684227|Taxol
876364|NCT02684214|food security
876365|NCT02684201|Phantom Limb
876366|NCT02684201|Upper Amputee
876367|NCT02684201|Electrodes
876368|NCT02684201|Implant
876369|NCT02684201|Pain
876370|NCT02684175|Audiometry
876371|NCT02684175|Cochlear Implants
876372|NCT02684175|Adult
876373|NCT02684175|Telemedicine
876374|NCT02684175|Health Services Accessibility
876375|NCT02684175|Rural Population
876376|NCT02684175|Technology Assessment, Biomedical
876377|NCT02684162|Leukemia
876378|NCT02684162|Myeloproliferative Diseases
876379|NCT02684162|Acute myelogenous leukemia
876380|NCT02684162|AML
876381|NCT02684162|Myelodysplastic syndrome
876382|NCT02684162|MDS
876383|NCT02684162|Donor lymphocyte infusion
876384|NCT02684162|DLI
876385|NCT02684162|Allogeneic stem cell transplant
876386|NCT02684162|Stem cell transplantation
876387|NCT02684162|AlloSCT
876388|NCT02684149|Intensive care
876389|NCT02684149|Arterial puncture
876390|NCT02684149|Cross-over
876391|NCT02684149|Relational touch
876392|NCT02684149|Pain
876393|NCT02684136|insomnia
876394|NCT02684136|fibromyalgia
876395|NCT02684136|polysomnography
876396|NCT02684136|pain management
876397|NCT02684123|Alopecia areata
876398|NCT02684097|Alopecia, Alopecia Totalis, Alopecia Universalis
876399|NCT02684084|Diabetic Macular Edema
876400|NCT02684084|Ozurdex
876401|NCT02684084|Lucentis
876402|NCT02684071|medulloblastoma, ependymoma, AT/RT, embryonal
876403|NCT02684058|Glioma
876404|NCT02684058|Anaplastic astrocytoma
876405|NCT02684058|Glioblastoma
876406|NCT02684058|Giant cell glioblastoma
876407|NCT02684058|Gliosarcoma
876408|NCT02684058|Anaplastic oligodendroglioma
876409|NCT02684058|Anaplastic oligoastrocytoma
876410|NCT02684058|Anaplastic ependymoma
876411|NCT02684058|Choroid plexus carcinoma
876412|NCT02684058|Anaplastic ganglioglioma
876413|NCT02684058|Pineal parenchymal tumor
876414|NCT02684058|Pineoblastoma
876415|NCT02684058|Medulloblastoma
876416|NCT02684058|PNET
876417|NCT02684058|Rhabdoid tumor
876418|NCT02684058|Perineurioma
876419|NCT02684058|MPNST
876420|NCT02684058|Malignant meningloma
876421|NCT02684058|Anaplastic hemangiopericytoma
876422|NCT02684058|Dabrafenib
876423|NCT02684058|Pediatrics
876424|NCT02684058|Brain neoplasma
876425|NCT02684032|PI3K (phosphoinositide 3-kinase)
876426|NCT02684032|mTOR (mechanistic target of rapamycin)
876427|NCT02684032|PI3K/mTOR
876428|NCT02684032|metastatic breast cancer (MBC)
876429|NCT02684032|ER+ (estrogen receptor positive)
876430|NCT02684032|HER2- (human epidermal growth factor receptor 2 negative)
876431|NCT02684019|Endoscopic retrograde cholangiopancreatography
876432|NCT02684019|sedation
876433|NCT02684019|dexmedetomidine
876434|NCT02684019|propofol
876435|NCT02684019|Magnesium sulphate
876436|NCT02684019|Bispectral index monitoring
876437|NCT02684006|Cancer
876438|NCT02684006|renal cell cancer
876439|NCT02684006|kidney disease
876440|NCT02684006|kidney neoplasms
876441|NCT02684006|axitinib, sunitinib
876442|NCT02683915|Acute kidney injury
876443|NCT02683915|Perinatal asphyxia
876444|NCT02683915|Therapeutic hypothermia
876445|NCT02683915|Serum NGAL
876446|NCT02683915|Serum cystatin-C
876447|NCT02683902|prediabetes
876448|NCT02683902|tDCS
876449|NCT02683902|transcranial direct current stimulation
876450|NCT02683902|obesity
876451|NCT02683902|diabetes
876452|NCT02683876|body odor, malodor, halitosis
876453|NCT02683837|Intraoperative Neurophysiological Monitoring
876454|NCT02683837|Reflex, Pupillary
876455|NCT02683837|remifentanil
876456|NCT02683811|adolescence
876457|NCT02683811|prevention
876458|NCT02683811|wellbeing
876459|NCT02683811|evaluation
876460|NCT02683811|effectiveness
876461|NCT02683811|school-based program
876462|NCT02683798|Weight loss maintenance
876469|NCT02683746|Pharmacodynamics
876470|NCT02683746|Safety
876471|NCT02683746|Albiglutide
876472|NCT02683746|Tolerability
876473|NCT02683746|Type 2 Diabetes Mellitus
876474|NCT02683746|Efficacy
876475|NCT02683707|Percutaneous Coronary Intervention
876476|NCT02683707|Blood Platelets
876477|NCT02683707|Fentanyl
876478|NCT02683694|Epiretinal membrane
876479|NCT02683694|lamellar holes of the macula
876480|NCT02683694|macular holes
876481|NCT02683694|vitreomacular traction syndrome
876482|NCT02683668|Inhalers
876483|NCT02683668|Tiotropium
876484|NCT02683629|Parkinson's Disease
876485|NCT02683629|Xenotransplantation
876486|NCT02683629|choroid plexus
876487|NCT02683603|colistin
876488|NCT02683603|aerosol
876489|NCT02683603|ventilator associated pneumonia
876490|NCT02683603|nephrotoxicity
876491|NCT02683603|intravenous
876492|NCT02683590|Sternectomie
876493|NCT02683590|Ceramic Implant
876494|NCT02683590|Bones Tumors
876495|NCT02683538|RFA
876496|NCT02683525|Allogeneic
876497|NCT02683525|Sitagliptin
876498|NCT02683499|Tooth preparation
876499|NCT02683499|Prosthodontics
876500|NCT02683447|Continuing Medical Education
876501|NCT02683447|Simulation
876502|NCT02683447|Non-technical Skills
876503|NCT02683447|Crisis Resource Management
876504|NCT02683434|soccer
876505|NCT02683421|Rheumatoid arthritis
876506|NCT02683421|tilmanocept
876507|NCT02683421|imaging
876508|NCT02683395|PLX51107
876509|NCT02683395|Acute Myeloid Leukemia
876510|NCT02683395|Myelodysplastic Syndrome
876511|NCT02683395|Neoplasms
876512|NCT02683369|Non-anemic Iron Deficiency, Iron Supplementation
876513|NCT02683356|Percutaneous Coronary Intervention
876514|NCT02683356|Stents
876515|NCT02683330|PD
876516|NCT02683330|Parkinson's
876517|NCT02683317|DHA
876518|NCT02683317|Retinopathy of Prematurity
876519|NCT02683291|Kidney transplantation
876520|NCT02683291|sirolimus
876521|NCT02683291|cytomegalovirus
876522|NCT02683291|aged
876523|NCT02683252|Magnetic resonance imaging
876524|NCT02683252|perfusion
876525|NCT02683252|quantitative
876526|NCT02683213|fluoxetine
876527|NCT02683213|outcome
876528|NCT02683213|depression
876529|NCT02683213|plasticity
876530|NCT02683187|insulin secretion
876531|NCT02683187|GLP-1
876532|NCT02683187|alpha cell
876533|NCT02683187|paracrine effect
876534|NCT02683187|Glucagon-Like Peptide 1
876535|NCT02683174|syncope
876536|NCT02683122|Organ dysfunction scores
876537|NCT02683122|Pneumonia, Ventilator-Associated
876538|NCT02683122|Intensive care units
876539|NCT02683070|Catheter-related bladder discomfort
876540|NCT02683070|Pudendal nerve block
876541|NCT02683070|Tramadol
876542|NCT02683070|Randomized controlled trial
876543|NCT02683070|catheter-related bladder discomfort prevention
876544|NCT02683044|Erectile dysfunction
876545|NCT02683044|Low-Density Shock Waves
876546|NCT02683044|Randomized Clinical Trial
876547|NCT02683031|fertilization arrest
876548|NCT02683031|Cleavage failure
876549|NCT02683031|Embryonic development
876550|NCT02683031|Calcium ionophore
876551|NCT02683005|treatment
876552|NCT02683005|pharmacokinetics
876553|NCT02682979|therapeutic limitation code
876554|NCT02682979|emergency unit admittance
876555|NCT02682966|troponin
876556|NCT02682966|coronary artery disease
876557|NCT02682966|pulmonary embolism
876558|NCT02682966|Computed Tomography Angiography
876559|NCT02682966|postoperative myocardial injury
876566|NCT02682914|Psychological distress
876567|NCT02682914|Stroke etiology
876568|NCT02682914|Young patients
876569|NCT02682888|brain functional connectivity changes
876570|NCT02682862|tiotropium
876571|NCT02682862|olodaterol
876572|NCT02682862|smoker
876573|NCT02682862|cigarette
876574|NCT02682862|bronchodilator
876575|NCT02682836|physical activity
876576|NCT02682836|chemotherapy
876577|NCT02682836|fatigue
876578|NCT02682810|HIV
876579|NCT02682810|point-of-care HIV diagnosis
876580|NCT02682810|Alere Q
876581|NCT02682810|diagnostic
876582|NCT02682810|children
876583|NCT02682771|gastroplasty, breathing exercices, positive pressure
876584|NCT02682758|xenon
876585|NCT02682758|transpulmonary pressure
876586|NCT02682758|electrical impedance tomography
876587|NCT02682758|tidal volume
876588|NCT02682758|esophageal pressure measurement
876589|NCT02682732|Acute Myeloid Leukemia
876590|NCT02682732|PET/CT Scan
876591|NCT02682719|Natriuretic peptide, brain
876592|NCT02682719|Diabetes Mellitus, Type 2
876593|NCT02682719|Hypertension
876594|NCT02682719|Cardiovascular prevention
876595|NCT02682719|Left atrial volume index
876596|NCT02682719|Angiotensin receptor neprilysin inhibitor
876597|NCT02682719|LCZ696
876598|NCT02682719|Valsartan
876599|NCT02682719|Sacubitril
876600|NCT02682706|brown adipose tissue
876601|NCT02682706|magnetic resonance imaging
876602|NCT02682706|energy expenditure
876603|NCT02682706|non-shivering thermogenesis
876604|NCT02682680|diabetes
876605|NCT02682680|hyperlipidaemia
876606|NCT02682680|colesevelam
876607|NCT02682680|ezetimibe
876608|NCT02682680|LDL cholesterol
876609|NCT02682680|glycated hemoglobin
876610|NCT02682667|Apheresis Products
876611|NCT02682667|Immunological
876612|NCT02682667|Diverse Malignan
876613|NCT02682667|Premalignant
876614|NCT02682667|Protein
876615|NCT02682654|Pain
876616|NCT02682654|Ankle
876617|NCT02682654|Knee
876618|NCT02682654|Brace
876619|NCT02682615|Cardiac Index
876620|NCT02682615|Noninvasive
876621|NCT02682615|esCCO
876622|NCT02682615|PiCCO
876623|NCT02682615|Thermodilution
876624|NCT02682602|total hip arthroplasty
876625|NCT02682589|Complete Mesocolic Excision
876626|NCT02682589|locally advanced Colon Cancer
876627|NCT02682589|Laparoscopic
876628|NCT02682576|brachial artery ultrasound imaging
876629|NCT02682576|flow-mediated dilation
876630|NCT02682576|endothelium
876631|NCT02682563|SGLT-2 inhibition, Renal, Cardiovascular, Type 2 diabetes, forxiga, dapagliflozin
876632|NCT02682550|polytrauma
876633|NCT02682550|hemorrhagic shock
876634|NCT02682550|sepsis
876635|NCT02682550|MODS
876636|NCT02682537|Resting energy expenditure
876637|NCT02682537|Calorie requirements
876638|NCT02682537|Indirect Calorimetry
876639|NCT02682511|Ifetroban
876640|NCT02682511|Scleroderma
876641|NCT02682511|Systemic Sclerosis
876642|NCT02682498|Knee Arthroplasty, Total
876643|NCT02682498|Liposomal Bupivicaine
876644|NCT02682485|Rectal Cancer
876645|NCT02682485|low anterior resection
876646|NCT02682485|SES
876647|NCT02682485|SES-DTA
876648|NCT02682485|anastomotic leak
876649|NCT02682485|anastomotic healing
876650|NCT02682485|intestinal healing
876651|NCT02682485|anastomosis
876652|NCT02682459|Extracapillary glomerulonephritis
876653|NCT02682459|crescentic glomerulonephritis
876654|NCT02682459|rapidly progressive renal failure
876655|NCT02682459|chronic kidney disease
876656|NCT02682459|ACE-inhibitors
876657|NCT02682459|fibrosis
876658|NCT02682446|Early gastric cancer
876659|NCT02682446|endoscopic submucosal dissection
876660|NCT02682446|serum pepsinogen
876661|NCT02682446|Helicobacter pylori
876662|NCT02682407|IgAN
876663|NCT02682407|MN
876664|NCT02682407|C3 Glomerulopathy
876665|NCT02682407|Lupus Nephritis
876666|NCT02682394|Cancer of pancreas
876667|NCT02682394|steatosis
876668|NCT02682394|MRI
876669|NCT02682381|Teduglutide
876670|NCT02682381|pediatric
876671|NCT02682381|GLP-2
876672|NCT02682381|parenteral support
876673|NCT02682381|Short Bowel Syndrome
876674|NCT02682381|short gut syndrome
876675|NCT02682381|short gut
876676|NCT02682381|SBS
876677|NCT02682381|parenteral nutrition
876678|NCT02682368|surgeon performed ultrasound
876679|NCT02682329|Peroxide
876680|NCT02682316|undergoing laparotomy
876681|NCT02682316|15-309
876682|NCT02682303|Adhesive elastic bandaging
876683|NCT02682303|balance
876684|NCT02682303|posturography
876685|NCT02682290|SPUTUM
876686|NCT02682290|RHEOLOGY
876687|NCT02682277|obesity
876688|NCT02682277|body weight
876689|NCT02682277|overweight
876690|NCT02682277|weight loss
876691|NCT02682277|polyglucosamine
876692|NCT02682277|L112
876693|NCT02682277|caloric restriction
876694|NCT02682277|physical activity
876695|NCT02682264|acne
876696|NCT02682251|Cardiac Resynchronization Therapy Devices
876697|NCT02682251|Cardiac Resynchronization Therapy
876698|NCT02682225|Esketamine
876699|NCT02682225|Placebo
876700|NCT02682225|Racemic ketamine
876701|NCT02682225|Pharmacokinetics
876702|NCT02682212|Pelvic floor
876703|NCT02682212|obstetrics
876704|NCT02682212|perineal tear
876705|NCT02682212|physiotherapy
876706|NCT02682186|Prosthetic breast surgery
876707|NCT02682186|Locoregional anesthesia
876708|NCT02682186|Pectoral nerve block
876709|NCT02682186|Pain
876710|NCT02682186|Postoperative analgesia
876711|NCT02682160|bariatric surgery
876712|NCT02682134|Sore Throat
876713|NCT02682134|Intubation
876714|NCT02682134|Xylocaine
876715|NCT02682134|Dexamethasone
876716|NCT02682108|Hepatitis B
876717|NCT02682108|Hepatitis C
876718|NCT02682108|Fibrosis, Liver
876719|NCT02682108|Magnetic Resonance Imaging
876720|NCT02682095|Hypertension
876721|NCT02682095|Blood Pressure Control
876722|NCT02682095|Adherence
876723|NCT02682095|Mixed Methods
876724|NCT02682082|Pancreatic cancer
876725|NCT02682082|Pain Management
876726|NCT02682082|Celiac plexus neurolysis
876727|NCT02682082|Bupivacaine
876728|NCT02682082|Palliative treatment
876729|NCT02682069|Diabetic foot ulcer
876730|NCT02682069|venous leg ulcer
876731|NCT02682069|fluorescence imaging
876732|NCT02682069|wound imaging
876733|NCT02682056|Pediatrics
876734|NCT02682056|Endocrinology
876735|NCT02682056|Adolescent
876736|NCT02682056|Microneedle
876737|NCT02682030|Airway Clearance Devices
876738|NCT02682030|High Frequency Chest Compression Devices
876739|NCT02682030|Cough Assist
876740|NCT02682017|Seaweed
876741|NCT02682017|Pork
876742|NCT02682017|Fucoidan
876743|NCT02682017|Laminarin
876744|NCT02682017|Functional Food
876745|NCT02682017|Antioxidant activity
876746|NCT02681913|Cardioplegia
876747|NCT02681913|Cardiac Surgery
876748|NCT02681913|Adenosine
876749|NCT02681913|Therapeutic Uses
876750|NCT02681913|Intermittent warm blood cardioplegia
876751|NCT02681913|Minimally Invasive Surgery
876752|NCT02681913|minimally invasive mitral valve plasty (mini-MPL)
876753|NCT02681913|minimally invasive mitral valve replacement (mini-MVR)
876754|NCT02681874|dietary pattern
876755|NCT02681874|stress
876756|NCT02681874|nutrition
876757|NCT02681874|health
876758|NCT02681874|obesity
876759|NCT02681874|children
876760|NCT02681874|minority
876761|NCT02681874|pre-schoolers
876762|NCT02681861|Pharmacodynamics
876763|NCT02681861|Pharmacokinetics
876764|NCT02681861|ASP6294
876765|NCT02681861|Maximum tolerated dose
876766|NCT02681861|Healthy subjects
876767|NCT02681848|Primary care attendance
876768|NCT02681848|All-cause
876769|NCT02681848|Cause specific
876770|NCT02681848|Hospital attendance
876771|NCT02681822|Genome-wide association studies
876772|NCT02681822|Environmental factors
876773|NCT02681822|Behavioral Assessment
876774|NCT02681822|Pathway analysis
876775|NCT02681783|aflibercept
876776|NCT02681770|kidney transplantation
876777|NCT02681770|adherence
876778|NCT02681770|quality of life
876779|NCT02681770|couples
876780|NCT02681770|fundamental frequency
876781|NCT02681770|communication
876782|NCT02681770|social support
876783|NCT02681757|pediatric hand burn
876784|NCT02681757|pediatric foot burn
876785|NCT02681757|mepitel Ag
876786|NCT02681757|soft cast technique for burn wound heaing
876787|NCT02681718|A1C≥9%
876788|NCT02681718|minorities
876789|NCT02681718|economically disadvantaged
876790|NCT02681692|colonoscopy
876791|NCT02681692|colonoscopy education
876792|NCT02681692|magnetic endoscope imaging
876793|NCT02681692|Colonic Diseases
876800|NCT02681653|Statins
876801|NCT02681653|Septic Shock
876802|NCT02681614|Imaging
876803|NCT02681614|Prostate
876804|NCT02681614|Multiparametric MRI
876805|NCT02681614|brachytherapy
876806|NCT02681601|Diet, Food, and Nutrition
876807|NCT02681588|diabetes, obesity, skinfold, newborn
876808|NCT02681562|olaparib
876809|NCT02681510|medication tolerability
876810|NCT02681497|canagliflozin
876811|NCT02681497|diabetes
876812|NCT02681497|SGLT2
876813|NCT02681497|real-world data
876814|NCT02681471|Monopolar
876815|NCT02681471|Bipolar
876816|NCT02681471|TURP syndrome
876817|NCT02681471|hyponatremia
876818|NCT02681432|HIPEC
876819|NCT02681432|ovarian cancer
876820|NCT02681432|peritoneal carcinomatosis
876821|NCT02681393|Physical activity, brochures, telephone support, stroke
876822|NCT02681380|simulated patient
876823|NCT02681380|Balint
876824|NCT02681380|empathy
876825|NCT02681380|medical student
876826|NCT02681367|Recurrent implantation failure
876827|NCT02681367|Freeze all policy
876828|NCT02681367|endometrial receptivity
876829|NCT02681367|implantation
876830|NCT02681367|clinical outcome
876831|NCT02681354|elderly
876832|NCT02681289|infant
876833|NCT02681289|risk
876834|NCT02681289|rehabilitation
876835|NCT02681276|Irrigation during root canal treatment
876836|NCT02681276|Sodium Hypochlorite
876837|NCT02681250|Zirconium
876838|NCT02681250|Randomized Controlled Trial
876839|NCT02681250|Dental Implants
876840|NCT02681250|Dental Material
876841|NCT02681250|Titanium
876842|NCT02681211|migraine headache
876843|NCT02681211|acupuncture
876844|NCT02681198|Healthy
876845|NCT02681198|Lofexidine
876846|NCT02681198|Paroxetine
876847|NCT02681198|Volunteer
876848|NCT02681172|CSF
876849|NCT02681172|Alzheimer's Disease (AD) and related dementia
876850|NCT02681172|HAS recommendations
876851|NCT02681159|Anesthesia
876852|NCT02681146|education
876853|NCT02681146|physiotherapy
876854|NCT02681133|Physical activity level
876855|NCT02681133|Knee osteoarthritis
876856|NCT02681133|Non pharmacological treatment
876857|NCT02681133|Survey
876858|NCT02681133|Socio-demographic, clinical variables
876859|NCT02681133|Barriers, facilitators Fears and beliefs
876860|NCT02681133|Function
876861|NCT02681120|Biomarkers
876862|NCT02681120|Breast imaging
876863|NCT02681107|Radiation therapy
876864|NCT02681107|Accelerated partial breast irradiation (APBI)
876865|NCT02681107|Breast conserving surgery
876866|NCT02681107|Stage 1
876867|NCT02681094|Diabetes Mellitus Type 2,
876868|NCT02681094|saxagliptin,
876869|NCT02681094|dapagliflozin,
876870|NCT02681094|metformin
876871|NCT02681081|Neuroplasticity
876872|NCT02681068|Fecal microbiota transplantation (FMT)
876873|NCT02681068|Clostridium difficile associated diarrhea (CDAD)
876874|NCT02681055|NASH
876875|NCT02681055|NAFLD
876876|NCT02681029|Cleavage stage blastocyst transfer cryopreservation
876877|NCT02681016|Calypso
876878|NCT02681016|Xience
876879|NCT02681016|Coronary stenosis
876880|NCT02681016|Drug-eluting stent
876881|NCT02681016|Coronary angioplasty with stenting
876882|NCT02681016|Ischemic Heart Disease
876883|NCT02680977|Mucuna pruriens
876884|NCT02680977|Levodopa
876885|NCT02680951|Pediatric
876886|NCT02680951|Adolescent
876887|NCT02680912|Bi syndrome
876888|NCT02680899|science education
876889|NCT02680899|health promotion
876890|NCT02680899|mental health promotion
876891|NCT02680899|stigmatization
876892|NCT02680899|behavioral intervention
876896|NCT02680873|type 2 diabetes , obesity , SASI
876897|NCT02679755|Hormone receptor positive advanced breast cancer
876898|NCT02679742|beta hydroxy beta methylbutyrate
876899|NCT02679742|older people
876900|NCT02679742|muscle mass
876901|NCT02679742|muscle strength
876902|NCT02679742|post-acute
876903|NCT02679729|inhaled dose
876904|NCT02679729|intravenous dose
876905|NCT02679729|healthy subjects
876906|NCT02679729|safety
876907|NCT02679729|tolerability
876908|NCT02679729|pharmacokinetics
876909|NCT02679729|AZD5634
876910|NCT02679729|jet nebulizer
876911|NCT02679677|Chronic obstructive pulmonary disease
876912|NCT02679677|Randomized controlled trial
876913|NCT02679677|Physical activity
876917|NCT02680834|venous stasis ulcer
876918|NCT02680834|wound
876919|NCT02680834|chronic venous insufficiency
876920|NCT02680821|Laxity
876921|NCT02680821|Knee
876922|NCT02680821|Rupture
876923|NCT02680821|ALL
876924|NCT02680795|UGT1A1*28
876925|NCT02680795|Belinostat
876926|NCT02680795|beleodaq
876927|NCT02680795|wild type genotypes
876928|NCT02680795|heterozygous genotypes
876929|NCT02680795|homozygous genotypes
876930|NCT02680782|Healthy Volunteers
876931|NCT02680782|Comparison
876932|NCT02680782|Once-Daily
876933|NCT02680782|Twice-Daily
876934|NCT02680782|X4P-001
876935|NCT02680756|Iron Deficiency
876936|NCT02680756|Anaemia
876937|NCT02680756|Crohn's Disease
876938|NCT02680756|Deficiency Diseases
876939|NCT02680756|Inflammatory Bowel Diseases
876940|NCT02680756|Intestinal Diseases
876941|NCT02680730|Autonomic nervous system
876942|NCT02680730|Auditory processing disorder
876943|NCT02680730|Social behavior
876944|NCT02680691|infratentorial stroke
876945|NCT02680691|robot
876946|NCT02680691|postural balance
876947|NCT02680691|Rehabilitation
876948|NCT02680652|CVID
876949|NCT02680652|Common Variable Immune Deficiency
876950|NCT02680639|High-Frequency Ventilation
876951|NCT02680639|Biphasic Continuous Positive Airway Pressure
876952|NCT02680587|Prostate Cancer
876953|NCT02680587|Stereotactic Body Radiation Therapy
876954|NCT02680587|Stereotactic Ablative Radiotherapy
876955|NCT02680587|Oligometastasis
876956|NCT02680574|vadadustat
876957|NCT02680574|AKB-6548
876958|NCT02680574|Chronic kidney disease
876959|NCT02680574|anemia
876960|NCT02680574|CKD
876961|NCT02680574|chronic renal insufficiency
876962|NCT02680574|renal impairment
876963|NCT02680574|erythropoietin
876964|NCT02680574|kidney
876965|NCT02680574|renal
876966|NCT02680574|oral anemia treatment
876967|NCT02680574|hemoglobin
876968|NCT02680574|hypoxia-inducible factor
876969|NCT02680574|HIF
876970|NCT02680574|hypoxia-inducible factor prolyl-hydroxylase inhibitor
876971|NCT02680574|HIF-PHI
876972|NCT02680574|efficacy
876973|NCT02680574|safety
876974|NCT02680574|Phase 3
876975|NCT02680574|cardiovascular
876976|NCT02680574|NDD-CKD
876977|NCT02680548|ankle pain
876978|NCT02680548|foot pain
876979|NCT02680548|methylprednisolone
876980|NCT02680548|neuropathic pain
876981|NCT02680522|Parkinson's disease
876982|NCT02680522|Heart Rate Variability
876983|NCT02680522|Physiotherapy
876984|NCT02680496|Robot-Assistance
876985|NCT02680496|Gait [MeSH]
876986|NCT02680496|Energy Consumption
876987|NCT02680496|Cardiorespiratory Load
876988|NCT02680496|Stroke [MeSH]
876989|NCT02680483|Atrial fibrillation
876990|NCT02680483|Registry
876991|NCT02680483|Middle East
876992|NCT02680483|Jordan
876993|NCT02680483|risk factors
876994|NCT02680483|in hospital management
876995|NCT02680483|long term management
876996|NCT02680470|Tuberculosis
876997|NCT02680470|Management
876998|NCT02680470|Observed therapy
876999|NCT02680444|Mindfulness
877000|NCT02680444|Primary Promotion
877001|NCT02680444|Mental Health
877002|NCT02680444|Well-being
877003|NCT02680444|Positive Reappraisal
877004|NCT02680392|Pulsed and Continuous Radiofrequency Treatment
877005|NCT02680392|Continuous adductor canal block
877006|NCT02680392|Postoperative pain
877007|NCT02680392|Functional recovery
877008|NCT02680392|Total Knee Joint Replacement
877009|NCT02680379|Fragile X Syndrome
877010|NCT02680379|Autism
877011|NCT02680379|FMR1
877012|NCT02680379|FRAXA
877013|NCT02680340|Total Hip Arthroplasty THA
877014|NCT02680314|unripe cervix
877015|NCT02680301|Wet Wraps
877016|NCT02680301|Topical Steroid
877017|NCT02680288|Psychostimulant, Craving, Cocaine.
877018|NCT02680275|Chronic endometritis
877019|NCT02680275|Miscarriage
877020|NCT02680275|Infertility
877021|NCT02680262|HPV self-sampling, cervical cancer screening
877022|NCT02680249|Safety, Bioavailability and Pharmacokinetics
877023|NCT02680236|Pain
877024|NCT02680236|Cancer
877025|NCT02680236|Chemotherapy
877026|NCT02680236|Anxiety
877027|NCT02680236|Depression
877028|NCT02680236|Isolation
877029|NCT02680197|COPD
877030|NCT02680184|Malignant melanoma
877031|NCT02680171|Cognitive Rehabilitation
877032|NCT02680171|Prism Adaptation
877033|NCT02680171|Stroke
877034|NCT02680171|Spatial Neglect
877035|NCT02680145|Pessary
877036|NCT02680145|Prolapse
877037|NCT02680145|Cystocele
877038|NCT02680106|Nanofibers
877039|NCT02680106|Dressing
877040|NCT02680106|Donor site
877041|NCT02680106|Polycaprolactone
877042|NCT02680067|Healthy Individual
877043|NCT02680067|Lymphatic Transport
877044|NCT02680067|Near InfraRed
877045|NCT02680067|Imaging
877046|NCT02680067|Indocyanine Green
877047|NCT02680067|ICG
877048|NCT02680067|NIR
877049|NCT02680067|NIR-ICG
877050|NCT02680067|MSImager
877051|NCT02680067|rheumatoid arthritis
877052|NCT02680015|PEERS
877053|NCT02680015|friendships
877054|NCT02680015|brain
877055|NCT02679989|Insulin sensitivity
877056|NCT02679989|Weight loss
877057|NCT02679989|Intermittent fasting
877058|NCT02679989|Sympathetic nervous system
877059|NCT02679950|Next generation genome sequencing
877060|NCT02679950|Late relapse
877061|NCT02679950|Genetic profiles
877062|NCT02679937|U.S. Military
877063|NCT02679937|Overweight
877064|NCT02679937|Obesity
877065|NCT02679937|Service Members
877066|NCT02679937|Prevention
877067|NCT02679911|Onychomycosis
877068|NCT02679898|Arterial function
877069|NCT02679898|Whole-body vibration training
877070|NCT02679898|Aortic blood pressures
877071|NCT02679898|Wave reflection
877072|NCT02679898|Muscle strength
877073|NCT02679898|Endothelial function
877074|NCT02679898|Blood flow
877075|NCT02679872|Non-technical skills
877076|NCT02679872|Patient safety
877077|NCT02679872|Video-assisted thoracoscopic surgery
877078|NCT02679872|Operating theatre team
877079|NCT02679872|Operating room
877080|NCT02679859|Natriuretic Peptide, Brain
877081|NCT02679859|Surgery
877082|NCT02679846|withdrawal of antiepileptic drugs
877083|NCT02679846|monitoring VEEG
877084|NCT02679846|safety
877085|NCT02679846|adverse event
877086|NCT02679846|standardized protocol
877087|NCT02679833|Cobalamin biomarkers
877088|NCT02679833|Anemia
877089|NCT02679833|Vegan diet
877090|NCT02679833|Subclinical
877091|NCT02679833|Metabolic functional markers
877092|NCT02679833|Holotranscobalamin
877093|NCT02679833|Methylmalonic acid
877094|NCT02679638|breast cancer
877095|NCT02679638|treatment choice
877096|NCT02679638|factor
877097|NCT02679638|perception
877098|NCT02679573|Pneumonia
877099|NCT02679560|femur fracture, hip fracture, exparel, liposomal bupivacaine
877100|NCT02679547|Appendix
877101|NCT02679547|Breastfeeding
877102|NCT02679547|Adult
877103|NCT02679534|pain
877104|NCT02679534|thoracic surgery
877105|NCT02679534|massage
877106|NCT02679521|Extracorporeal Shock Wave Therapy
877107|NCT02679521|Painful Heel
877108|NCT02679521|Plantar fasciitis
877109|NCT02679508|Esophagitis
877110|NCT02679495|early gastric cancer
877111|NCT02679495|lifestyle
877112|NCT02679482|Primary Open Angle Glaucoma
877113|NCT02679482|Selective Laser Trabeculoplasty
877114|NCT02679482|Pattern Scan Laser Trabeculoplasty
877115|NCT02679443|Lung Adenocarcinoma
877116|NCT02679443|Non-squamous NSCLC
877117|NCT02679443|Chemotherapy
877118|NCT02679443|Pemetrexed
877119|NCT02679443|Vitamin B12
877120|NCT02679443|Folate
877121|NCT02679443|Supplementation
877122|NCT02679443|Cytopenia
877123|NCT02679417|Aminotransferase
877124|NCT02679417|Fibrosis, liver
877125|NCT02679417|Anthropometry
877126|NCT02679417|Exercise
877127|NCT02679404|Biological aortic valves
877128|NCT02679404|Mechanical aortic valves
877129|NCT02679404|Aortic conduits
877130|NCT02679404|Sutureless Aortic Valve
877131|NCT02679391|Abdominoplasty
877132|NCT02679391|Early complications
877133|NCT02679391|Guidelines
877134|NCT02679391|Sequelae
877135|NCT02679391|bariatric patients
877137|NCT02679300|Chronic Low Back Pain
877138|NCT02679300|Virtual Reality
877139|NCT02679300|Serious Gaming
877140|NCT02679300|Exercise Therapy
877141|NCT02679300|Distraction
877142|NCT02679287|Closed-Loop Control (CLC)
877143|NCT02679287|Sensor-Augmented Therapy (SAP)
877144|NCT02679287|USS Virginia
877145|NCT02679287|Continuous Glucose Monitor (CGM)
877146|NCT02679287|Insulin Pump
877147|NCT02679287|Artificial Pancreas (AP)
877148|NCT02679274|Aging, Frailty, Hypogonadism
877149|NCT02679261|Aortic dilation
877150|NCT02679261|Statins
877151|NCT02679261|Aortic degeneration
877152|NCT02679248|Pre-hypertension
877153|NCT02679248|Mild hypertension
877154|NCT02679248|Dietary supplement
877155|NCT02679248|Efficacy
877156|NCT02679248|Nitric oxide
877157|NCT02679248|Neo40 Daily
877158|NCT02679170|ALK+
877159|NCT02679157|Posttraumatic stress disorder
877160|NCT02679157|Depression
877161|NCT02679157|Anxiety
877162|NCT02679157|ADL
877163|NCT02679157|Health-related quality of life
877164|NCT02679157|ICU survivorship
877165|NCT02679131|relapsed/refractory solid tumors
877166|NCT02679131|beleodaq
877167|NCT02679131|renal impairment
877168|NCT02679131|belinostat
877169|NCT02679131|hematological malignancies
877170|NCT02679118|intestinal perforation
877171|NCT02679118|bariatric surgery
877172|NCT02679118|gastric bypass
877173|NCT02679118|gastric perforation
877174|NCT02679118|colonic perforation
877175|NCT02679092|Induced Abortion
877176|NCT02679092|Mifepristone
877177|NCT02679092|Dilation and Evacuation
877178|NCT02679092|Cervical Preparation
877179|NCT02679092|Osmotic Dilators
877180|NCT02679092|Misoprostol
877181|NCT02678962|Multifocal Intraocular Lenses
877182|NCT02678962|bilateral implantation
877183|NCT02678897|Abortion, Drug-Induced
877184|NCT02678897|Pain Management
877185|NCT02678884|Head and Neck Squamous Cell Carcinoma
877186|NCT02678884|Radiation therapy
877187|NCT02678884|Head and Neck Cancers
877188|NCT02678871|Aortic Valve Stenosis
877189|NCT02678871|Left atrial appendage
877190|NCT02678858|social cognition
877191|NCT02678858|social skills
877192|NCT02678858|cognitive remediation
877193|NCT02678858|functional outcome
877194|NCT02678858|treatment adherence
877195|NCT02678767|HIV
877196|NCT02678767|Dementia
877197|NCT02678767|Neuroimaging
877198|NCT02678702|Sleep
877199|NCT02678702|Depression
877200|NCT02678702|Comorbid Insomnia
877201|NCT02678702|Cognitive Behavioral Therapy
877202|NCT02678702|Sleep Restriction
877203|NCT02678702|Stimulus Control therapy
877204|NCT02678702|Relaxation
877205|NCT02678676|Drug Therapy
877206|NCT02678663|Colon polyp
877207|NCT02678663|Polypectomy
877208|NCT02678663|Cold snare
877209|NCT02678663|Endoscopic mucosal resection
877210|NCT02678650|Volatile Anesthetics
877211|NCT02678650|MicroRNA
877212|NCT02678650|Off-pump Coronary Artery Bypass Surgery
877213|NCT02678650|Internal Mammary Artery
877214|NCT02678650|Ascending Aorta
877215|NCT02678637|MRI
877216|NCT02678637|CCSA
877217|NCT02678637|Contractile Cross Sectional Area
877218|NCT02678637|Strength
877219|NCT02678637|Calf muscle
877220|NCT02678611|Healthy participants
877221|NCT02678611|Dietary supplement
877222|NCT02678611|Safety
877223|NCT02678611|Tolerability
877224|NCT02678611|Older Adults
877225|NCT02678611|Basis
877226|NCT02678611|Nicotinamide riboside
877227|NCT02678611|Pterostilbene
877228|NCT02678598|Micafungin
877229|NCT02678598|Candida
877230|NCT02678598|Aspergillosis
877231|NCT02678598|Antifungal
877232|NCT02678572|uveal liver PHP hepatic perfusion chemosaturation Delcath
877233|NCT02678559|Alveolar recruitment manoeuvre
877234|NCT02678559|Lung recruitment
877235|NCT02678559|Preload dependency
877236|NCT02678559|Cardiac surgery
877237|NCT02678559|Transoesophageal echocardiography
877238|NCT02678546|Traditional Chinese Medicine
877239|NCT02678533|Fanconi Anemia
877240|NCT02678533|CD34+ cells mobilization
877241|NCT02678533|G-CSF
877242|NCT02678533|Plerixafor
877243|NCT02678533|gene therapy
877244|NCT02678520|Prostate Cancer
877245|NCT02678520|Post Operative
877246|NCT02678520|Radiation
877247|NCT02678520|Prostatectomy
877248|NCT02678520|3-D CRT
877249|NCT02678520|IMRT
877250|NCT02678520|RT
877251|NCT02678520|CRT
877252|NCT02678520|Conformal Radiation Therapy
877253|NCT02678520|Intensity Modulated Radiation Therapy
877254|NCT02678520|Hormone
877255|NCT02678520|Surgery
877256|NCT02678520|Hormonal Therapy
877257|NCT02678494|Spinal Cord Injury
877258|NCT02678481|multiparametric magnetic resonance imaging
877259|NCT02678481|MR-targeted prostate biopsy
877260|NCT02678481|saturation TRUS-guided prostate biopsy
877261|NCT02678455|Dengue Virus
877262|NCT02678416|comparison
877263|NCT02678403|peripheral artery disease
877264|NCT02678403|transcutaneous electrical nerve stimulation
877265|NCT02678403|walking ability
877266|NCT02678403|endothelial function
877267|NCT02678364|Vitamin D-biofortified eggs
877268|NCT02678364|Vitamin D status
877269|NCT02678364|RCT
877270|NCT02678312|Pediatric Heart failure,
877271|NCT02678312|systemic left ventricle,
877272|NCT02678312|reduced ejection fraction
877273|NCT02678286|Abdominoplasty
877274|NCT02678286|Pain
877275|NCT02678286|Analgesia
877276|NCT02678286|N1539
877277|NCT02678286|Phase 3
877278|NCT02678273|population
877279|NCT02678273|Singapore
877280|NCT02678260|Advanced malignancies
877281|NCT02678260|PDR001
877282|NCT02678260|Japanese patients
877283|NCT02678260|adults
877284|NCT02678247|prosthesis
877285|NCT02678247|prosthetic socket
877286|NCT02678247|transfemoral amputation
877287|NCT02678247|socket comfort
877288|NCT02678247|gait biomechanics
877289|NCT02678156|Dura mater substitute
877290|NCT02678156|Graft
877291|NCT02678156|Lyoplant
877292|NCT02678156|Lyostypt
877293|NCT02678156|Lyoplant onlay
877294|NCT02678156|Xenograft
877295|NCT02678130|Intervertebral disc degeneration
877296|NCT02678130|Bone Disease
877297|NCT02678130|Musculoskeletal disease
877298|NCT02678130|Spinal disease
877299|NCT02678104|Dry Socket
877300|NCT02678104|Honey
877301|NCT02678104|Tooth Extraction
877302|NCT02678078|cancer
877303|NCT02678078|diagnosis
877304|NCT02678078|biopsy
877305|NCT02678078|chemotherapy drugs
877306|NCT02678078|tumor
877307|NCT02678052|Drug therapy
877308|NCT02677961|sarcoma
877309|NCT02677961|registry
877310|NCT02677922|Acute Myeloid Leukemia
877311|NCT02677922|Leukemia
877312|NCT02677922|Azacitidine
877313|NCT02677922|AG-120
877314|NCT02677922|AG-221
877315|NCT02677909|Parenteral Nutrition
877316|NCT02677909|Critical Care
877317|NCT02677896|Androgen Deprivation Therapy (ADT)
877318|NCT02677896|Metastatic hormone sensitive prostate cancer
877319|NCT02677896|Xtandi
877320|NCT02677896|Enzalutamide
877321|NCT02677870|Saproterin dihydrochloride
877322|NCT02677870|Kuvan
877323|NCT02677870|Amish
877324|NCT02677831|Physical functioning
877325|NCT02677831|Neuropsychiatric Disorders
877326|NCT02677831|Frailty
877327|NCT02677818|Plasma Factor VIII Levels
877328|NCT02677818|Ischemic stroke
877329|NCT02677818|Antithrombotic therapy
877330|NCT02677818|Bleeding
877331|NCT02677766|Occupational Therapy
877332|NCT02677766|Complex patients
877333|NCT02677766|Randomized controlled trial
877334|NCT02677766|Occupational performance problem
877335|NCT02677766|Rehabilitation Complexity Scale
877336|NCT02677740|MRI
877337|NCT02677740|MRS
877338|NCT02677740|rTMS
877339|NCT02677727|Cisplatin-based chemotherapy
877340|NCT02677727|Chemotherapy-induced peripheral neuropathy
877341|NCT02677688|systemic lupus erythematosus
877342|NCT02677688|autologous anti-EBV CTL
877343|NCT02677688|adoptive therapy
877344|NCT02677688|phase 1 -2
877345|NCT02677662|Diesel exhaust
877346|NCT02677662|Oxidative stress
877347|NCT02677662|Systemic inflammation
877348|NCT02677662|Air pollution
877349|NCT02677649|cranberry, microbiome, polyphenols, healthy
877350|NCT02677636|Dermatitis, Atopic
877351|NCT02677636|Eczema
877352|NCT02677636|Dermatitis
877353|NCT02677636|Pruritus
877354|NCT02677636|Genetic Diseases, Inborn
877355|NCT02677636|Hypersensitivity
877356|NCT02677636|Hypersensitivity, Immediate
877357|NCT02677636|Immune System Diseases
877358|NCT02677636|Skin Diseases, Eczematous
877359|NCT02677636|Skin Diseases, Genetic
877360|NCT02677636|Skin Diseases
877361|NCT02677636|Itching
877362|NCT02677636|Rash
877363|NCT02677636|Steroid
877364|NCT02677610|Dermatitis, Atopic
877365|NCT02677610|Eczema
877366|NCT02677610|Dermatitis
877367|NCT02677610|Pruritus
877368|NCT02677610|Genetic Diseases, Inborn
877369|NCT02677610|Hypersensitivity
877370|NCT02677610|Hypersensitivity, Immediate
877371|NCT02677610|Immune System Diseases
877372|NCT02677610|Skin Diseases, Eczematous
877373|NCT02677610|Skin Diseases, Genetic
877374|NCT02677610|Skin Diseases
877375|NCT02677610|Itching
877376|NCT02677610|Rash
877377|NCT02677610|Steroid
877378|NCT02677584|caffeine
877379|NCT02677584|apnea
877380|NCT02677584|preterm infant
877381|NCT02677558|Pregnancy
877382|NCT02677558|Obesity
877383|NCT02677558|Echocardiography
877384|NCT02677519|ADHD
877385|NCT02677519|children
877386|NCT02677519|methylphenidate
877387|NCT02677506|elbow
877388|NCT02677480|Microflora
877389|NCT02677480|Probiotics
877390|NCT02677480|Hyposalivation
877391|NCT02677480|Lactobacilli
877392|NCT02677480|Mutans streptococci
877393|NCT02677480|pH-rising components
877394|NCT02677454|Blood Glucose
877395|NCT02677454|Blood Glucose Self-Monitoring
877396|NCT02677428|Veterans
877397|NCT02677428|world wide web
877398|NCT02677428|Counseling
877399|NCT02677428|Workman's Compensation
877400|NCT02677415|Ischemic Stroke
877401|NCT02677415|Anesthesia
877402|NCT02677415|Endovascular Procedures
877403|NCT02677402|femoral vein
877404|NCT02677402|saphenous vein
877405|NCT02677402|hydrostatic pressure
877406|NCT02677402|temperature
877407|NCT02677402|recovery
877408|NCT02677363|Elderly
877409|NCT02677363|Older
877410|NCT02677363|Adults
877411|NCT02677363|Resistant Exercise
877412|NCT02677363|Strength Training
877413|NCT02677363|Cognitive function
877414|NCT02677324|Waldenstrom Macroglobulinemia
877415|NCT02677324|WM
877416|NCT02677272|Nursing home
877417|NCT02677272|emergency department
877418|NCT02677272|inappropriate transfer
877419|NCT02677272|elderly
877420|NCT02677259|luteal phase
877421|NCT02677259|estradiol
877422|NCT02677259|pregnancy rate
877423|NCT02677246|Bone marrow transplantation
877424|NCT02677246|Children
877425|NCT02677246|Bone complications
877426|NCT02677246|Denosumab.
877427|NCT02677181|ATG
877428|NCT02677181|Matched sibling donor
877429|NCT02677181|peripheral blood stem cell transplantation
877430|NCT02677168|obstructive sleep apnea
877431|NCT02677168|sleep apnea
877432|NCT02677168|OSA
877433|NCT02677168|cNEP
877434|NCT02677168|continuous negative external pressure
877435|NCT02677155|Follicular lymphoma
877436|NCT02677155|Intranodal therapy
877437|NCT02677155|Autologous dendritic cells
877438|NCT02677155|Rituximab
877439|NCT02677155|Immunotherapy
877440|NCT02677155|Cancer vaccine
877441|NCT02677155|Anti-PD1
877442|NCT02677155|Pembrolizumab
877443|NCT02677155|Radiotherapy
877444|NCT02677142|pediatric
877445|NCT02677142|Childhood Brain Tumour Survivors
877446|NCT02677142|Social Skills Rating System
877447|NCT02677142|social skills intervention program (SSIP)
877448|NCT02677103|Radial shock wave therapy,calcific tendinitis, ultrasound guidance
877449|NCT02677090|Fiber tolerability
877450|NCT02677090|Children
877451|NCT02677077|RRMS
877452|NCT02677077|MRI
877453|NCT02677064|Allogeneic Hematopoietic Stem Cell Transplantation
877454|NCT02677064|Identify Barriers
877455|NCT02677064|16-024
877456|NCT02677038|Pancreatic Cancer
877457|NCT02677038|Stage IV pancreatic ductal adenocarcinoma (PDAC) with BRCAness
877458|NCT02677038|PDAC
877459|NCT02677038|Metastatic adenocarcinoma of the pancreas
877460|NCT02677038|Family history of breast cancer
877461|NCT02677038|Family history of ovarian cancer
877462|NCT02677038|Family history of pancreatic cancer
877463|NCT02677038|Family history of gastric cancer
877464|NCT02677038|Family history of prostate cancer
877465|NCT02677038|Olaparib
877466|NCT02677038|Lynparza
877467|NCT02677025|HIV
877468|NCT02677025|Sexual Risk
877469|NCT02677025|Sexually Transmitted Diseases
877470|NCT02677025|Substance Abuse
877471|NCT02677025|Violence and Victimization
877472|NCT02677012|Autologous fat grafting
877473|NCT02677012|AFG
877474|NCT02677012|Reconstructive surgery
877475|NCT02677012|Fatty tissue processing
877476|NCT02676986|Primary Breast Cancer
877477|NCT02676986|ER
877478|NCT02676986|AR
877479|NCT02676986|TNBC
877480|NCT02676973|pelvic organ prolapse
877481|NCT02676973|POP
877482|NCT02676973|vault prolapse
877483|NCT02676973|cystocele
877484|NCT02676973|vaginal prolapse
877485|NCT02676973|post-hysterectomy vaginal prolapse
877486|NCT02676921|sinus membrane
877487|NCT02676921|osteogenic
877488|NCT02676908|endovenous ablation
877489|NCT02676908|laser
877490|NCT02676908|radiofrequency
877491|NCT02676908|stockings
877492|NCT02676882|Depressive Disorder
877493|NCT02676882|Depression
877494|NCT02676882|Antidepressants
877495|NCT02676882|Pregnancy
877496|NCT02676882|Folate
877497|NCT02676882|Dietary Supplements
877498|NCT02676882|Omega-3 Fatty Acids
877499|NCT02676882|Women's Health
877500|NCT02676882|Vitamins
877501|NCT02676856|acute myeloid leukemia
877502|NCT02676856|hematopoietic stem cell microtransplantation
877503|NCT02676817|colitis
877504|NCT02676817|endoscopy
877505|NCT02676804|Exercise
877510|NCT02676765|Allergic rhinitis
877511|NCT02676765|Immunotherapy, Allergen
877512|NCT02676765|Sublingual Immunotherapy
877513|NCT02676752|head and neck cancer
877514|NCT02676752|lymphedema and fibrosis
877515|NCT02676726|extraperitoneal
877516|NCT02676726|transperitoneal
877517|NCT02676726|laparoscopic aortic lymphadenectomy
877518|NCT02676726|endometrial cancer
877519|NCT02676726|ovarian cancer
877520|NCT02676726|surgical staging
877521|NCT02676713|Traditional Chinese Medicine
877522|NCT02676713|Chinese Herbal
877523|NCT02676700|Urinary stress incontinence
877524|NCT02676700|pelvic floor muscle
877525|NCT02676700|Kaatsu training
877526|NCT02676687|surgery, noneloquent area
877527|NCT02676661|peri-implant disease
877528|NCT02676661|risk factors
877529|NCT02676661|prevalence
877530|NCT02676622|Crohn's Disease
877531|NCT02676622|Autologous Hematopoietic Stem cell Transplant
877532|NCT02676622|Cyclophosphamide
877533|NCT02676622|IL-2
877534|NCT02676622|Aldesleukin
877535|NCT02676622|Proleukin
877536|NCT02676622|PCDAI
877537|NCT02676609|Type 1 diabetes
877538|NCT02676609|Smart phone application
877539|NCT02676609|carbohydrate counting
877540|NCT02676609|meal insulin dose
877541|NCT02676583|pain
877542|NCT02676583|tonsillectomy
877543|NCT02676583|tonsillar fossa
877544|NCT02676583|suture
877545|NCT02676583|tonsil fossa closure
877546|NCT02676544|Prostate Artery Embolization (PAE)
877547|NCT02676544|Benign Prostatic Hyperplasia (BPH)
877548|NCT02676544|Lower Urinary Tract Symptoms (LUTS)
877549|NCT02676544|PAE
877550|NCT02676544|BPH
877551|NCT02676544|LUTS
877552|NCT02676544|Prostate Artery Embolization
877553|NCT02676544|Embospheres
877554|NCT02676531|Walking Meditation
877555|NCT02676531|Vascular Function
877556|NCT02676531|Flow-mediated dilatation
877557|NCT02676531|Breast Cancer Patients
877558|NCT02676531|Anthracyclines Chemotherapy
877559|NCT02676518|polycystic ovary syndrome
877560|NCT02676518|Serum anti-Mullerian hormone
877561|NCT02676518|glucose intolerance
877562|NCT02676518|metabolic syndrome
877563|NCT02676466|Mobility
877564|NCT02676440|Oral Health
877565|NCT02676401|Diabetic Nephropathy
877566|NCT02676388|Slow Transit Constipation
877567|NCT02676388|Freeze-dried, Capsulized FMT
877568|NCT02676388|Fresh FMT
877569|NCT02676349|mFolfirinox
877570|NCT02676349|Chemoradiotherapy
877571|NCT02676349|Neoadjuvant treatment
877572|NCT02676349|Borderline
877573|NCT02676336|FBC
877574|NCT02676336|cyclic mastalgia
877575|NCT02676336|breast discomfort
877576|NCT02676323|Maximum tolerated dose
877577|NCT02676323|Childhood leukemia
877578|NCT02676323|Hematological malignancies
877579|NCT02676297|inhalation
877580|NCT02676297|anticholinergic
877581|NCT02676258|silicone hydrogel daily disposable soft contact lens
877582|NCT02676245|Prenatal Education
877583|NCT02676245|Residual Specimens
877584|NCT02676232|Online Intervention
877585|NCT02676232|Recurrent Abdominal Pain
877586|NCT02676232|Children
877587|NCT02676193|Tobacco Smoking
877588|NCT02676193|Cigarettes
877589|NCT02676193|Packaging
877590|NCT02676193|Text messaging
877591|NCT02676193|Graphic Images
877592|NCT02676193|Sensor-Based Assessments
877593|NCT02676167|HIV prevention
877594|NCT02676167|men who have sex with men
877595|NCT02676167|pre-exposure prophylaxis
877596|NCT02676167|PrEP
877597|NCT02676167|Greece
877598|NCT02676167|people who inject drugs
877599|NCT02676154|Episodic Hypertension
877600|NCT02676154|Spinal Cord Injury
877601|NCT02676154|Traumatic Spinal Cord Injury
877602|NCT02676154|Blood Pressure
877603|NCT02676154|Fesoterodine
877604|NCT02676154|Neurogenic Detrusor Overactivity
877605|NCT02676154|Autonomic Dysreflexia
877606|NCT02676154|Urodynamic Studies
877607|NCT02676154|24 Hour Ambulatory Blood Pressure Monitoring
877608|NCT02676128|HIV
877609|NCT02676128|Medication Adherence
877610|NCT02676128|Mobile Health
877611|NCT02676115|Cosmetic Wound Healing
877612|NCT02676115|anterior cruciate ligament (ACL)
877613|NCT02676102|barber shops
877614|NCT02676102|organ transplant
877615|NCT02676102|transplants
877616|NCT02676102|organ donor registration
877617|NCT02676089|Asthma, Anticholinergics, Triple combination
877618|NCT02676076|asthma, anticholinergics, triple combination
877619|NCT02676063|predictive factors
877620|NCT02676063|neurodevelopmental disabilities
877621|NCT02676011|Atropine
877622|NCT02676011|Succinycholine
877623|NCT02676011|Laparoscopy
877624|NCT02676011|Gynecology
877626|NCT02675972|stroke, blood pressure, prognosis
877627|NCT02675959|stem cell transplantation
877628|NCT02675959|sickle cell disease
877629|NCT02675959|haploidentical
877630|NCT02675959|defibrotide
877631|NCT02675946|WNT inhibitor
877632|NCT02675920|surveillance
877633|NCT02675920|ultrasonography
877634|NCT02675920|computed tomography
877635|NCT02675907|Bunion
877636|NCT02675907|Bunionectomy
877637|NCT02675907|Pain
877638|NCT02675907|Analgesia
877639|NCT02675907|N1539
877640|NCT02675907|Phase 3
877641|NCT02675894|RFA
877642|NCT02675881|RFA
877643|NCT02675868|noradrenaline
877644|NCT02675868|vasopressin
877645|NCT02675868|phenylephrine
877646|NCT02675868|endotoxemia
877647|NCT02675868|Lipopolysaccharide
877648|NCT02675868|vasopressor
877649|NCT02675855|Grafix
877650|NCT02675829|HER2 mutant
877651|NCT02675829|HER2 amplified
877652|NCT02675829|Ado-Trastuzumab Emtansine
877653|NCT02675829|15-335
877654|NCT02675816|Obstructive Sleep Apnea
877655|NCT02675816|OSA
877656|NCT02675816|neurostimulation
877657|NCT02675816|hypoglossal nerve
877658|NCT02675816|tongue
877659|NCT02675816|upper airway stimulation
877660|NCT02675816|surgery
877661|NCT02675803|Rheumatoid arthritis
877662|NCT02675790|hydroxyurea
877663|NCT02675790|sub-Saharan Africa
877664|NCT02675790|secondary stroke prevention
877665|NCT02675777|Alcohol misuse
877666|NCT02675777|Unhealthy alcohol use
877667|NCT02675777|Alcoholism
877668|NCT02675777|Alcohol dependence
877669|NCT02675777|Alcohol abuse
877670|NCT02675777|Risky drinking
877671|NCT02675764|hand function
877672|NCT02675751|myopia
877673|NCT02675673|Enteral Feeding
877674|NCT02675673|G-Tube
877675|NCT02675673|GJ Tube
877676|NCT02675660|kinetic data
877677|NCT02675660|volunteers
877678|NCT02675608|vaccine efficacy
877679|NCT02675608|inflammation
877680|NCT02675608|aging
877681|NCT02675608|Type 2 Diabetes Mellitus
877682|NCT02675608|flu vaccine
877683|NCT02675569|Vascular access
877684|NCT02675569|Hemodialysis
877685|NCT02675569|Kidney failure
877686|NCT02675569|Catheter
877687|NCT02675569|Fistula
877688|NCT02675556|Depression
877689|NCT02675530|NMDA
877690|NCT02675530|glutamate
877691|NCT02675530|schizophrenia
877692|NCT02675504|scary scale
877693|NCT02675491|Advanced solid tumor
877694|NCT02675491|DS-6051b
877695|NCT02675491|ROS1
877696|NCT02675491|NTRK
877697|NCT02675491|refractory to standard therapy
877698|NCT02675491|no standard therapy
877699|NCT02675478|AML
877700|NCT02675478|phase 1
877701|NCT02675478|oncology
877703|NCT02675426|Anti-inflammatory agents
877704|NCT02675426|Joint Disease
877705|NCT02675426|Musculoskeletal Disease
877706|NCT02675426|Antirheumatic agents
877707|NCT02675426|Arthritis
877708|NCT02675413|Cerebral Spinal Fluid
877709|NCT02675413|Dimethyl Fumarate
877710|NCT02675413|Tecfidera
877711|NCT02675413|Multiple Sclerosis
877712|NCT02675413|Relapsing MS
877713|NCT02675413|RRMS
877714|NCT02675413|Mechanism of Action
877715|NCT02675400|ADHD
877716|NCT02675400|ADD
877717|NCT02675400|Attention Deficit/Hyperactivity Disorder
877718|NCT02675400|Attention
877719|NCT02675400|Hyperactivity
877720|NCT02675374|Cardiac surgery
877721|NCT02675374|cardiopulmonary bypass
877722|NCT02675374|dexchlorpheniramine
877723|NCT02675374|H1 blockers
877724|NCT02675374|norepinephrine
877725|NCT02675374|histamine release
877726|NCT02675361|Transfer to adult care
877727|NCT02675361|Continuity of patient care
877728|NCT02675361|Transition program
877729|NCT02675335|Diabetic foot ulcer, Sitagliptin
877730|NCT02675296|outcome
877731|NCT02675283|Point of care test
877732|NCT02675283|Diagnosis
877733|NCT02675283|Case finding
877734|NCT02675257|Diabetes mellitus
877735|NCT02675257|Affective disorders
877736|NCT02675257|Depressive symptoms
877737|NCT02675257|Diabetes distress
877738|NCT02675257|Hyperglycaemia
877739|NCT02675257|Dysglycaemia
877740|NCT02675257|Glycaemic control
877741|NCT02675257|Self-care behaviour
877742|NCT02675257|Quality of Life
877743|NCT02675257|Diabetes acceptance
877744|NCT02675257|Diabetes complications
877745|NCT02675257|Low-grade inflammation
877746|NCT02675257|Inflammatory markers
877747|NCT02675257|Stress reactivity
877748|NCT02675257|Health-care costs
877749|NCT02675244|Tricuspid Valve Regurgitation
877750|NCT02675192|sarcopenia
877751|NCT02675192|elderly
877752|NCT02675192|muscle biopsy
877753|NCT02675166|Childhood cancer
877754|NCT02675166|Sequels
877755|NCT02675166|Complications
877756|NCT02675166|Surgery
877757|NCT02675166|Radiotherapy
877758|NCT02675166|Chemotherapy
877759|NCT02675166|Cancer
877760|NCT02675153|Inflammatory Bowel Disease
877761|NCT02675153|stenosis
877762|NCT02675153|sirolimus
877763|NCT02675153|rapamycin
877764|NCT02675153|stricture
877765|NCT02675114|Sapien 3
877766|NCT02675114|cardiovascular disease
877767|NCT02675114|heart disease
877768|NCT02675114|aortic stenosis
877769|NCT02675114|SAVR
877770|NCT02675114|TAVR
877771|NCT02675088|Extensive Stage Small Cell Lung Cancer
877772|NCT02675088|thoracic radiotherapy
877773|NCT02675088|radiotherapy regimen
877774|NCT02675075|Amyotrophic Lateral Sclerosis
877775|NCT02675075|Voice
877776|NCT02675075|Voice Quality
877777|NCT02675075|Total Lung Capacity
877778|NCT02675062|Accelerometry
877779|NCT02675062|Osteoarthritis
877780|NCT02675062|Habitual physical activity
877781|NCT02675062|Sedentary behaviour
877782|NCT02675062|Knee arthroplasty
877783|NCT02675049|Intranasal
877784|NCT02675049|Dexmedetomidine
877785|NCT02675049|Anaesthesia
877786|NCT02675049|Breast Lumpectomy
877787|NCT02675036|ectopiccanine teeth, impacted teeth, tooth eruption, orthodontics
877788|NCT02674997|Goal setting
877789|NCT02674997|Feasibility
877790|NCT02674997|Standardized Goal Attainment Scaling menu for Hemophilia (GAS-Hem)
877791|NCT02674997|Patient reported outcome (PRO)
877792|NCT02674997|Goal attainment scaling (GAS)
877793|NCT02674958|endothelial progenitor cells
877794|NCT02674958|aspirin
877795|NCT02674958|acetylsalicylic acid
877796|NCT02674958|alcohol septal ablation
877797|NCT02674945|fitbit
877798|NCT02674945|activity tracker
877799|NCT02674945|sleep
877800|NCT02674945|quality of life
877801|NCT02674919|Repeated-sprint ability
877802|NCT02674919|Nordic Hamstring exercise
877803|NCT02674919|Eccentric hamstring muscle strength
877804|NCT02674893|BMI>27
877805|NCT02674893|Treatment with Liraglutide
877806|NCT02674841|Adolescent
877807|NCT02674841|Physical therapy modalities
877808|NCT02674841|Exercise intervention
877809|NCT02674841|Auditive feedback
877810|NCT02674841|Visual feedback
877811|NCT02674815|Exercise
877812|NCT02674815|Preoperative
877813|NCT02674815|High Intensity Interval Training
877814|NCT02674815|Colorectal
877815|NCT02674815|Thoracic
877816|NCT02674815|Postoperative
877817|NCT02674802|Reinfection
877818|NCT02674802|Eradication therapy
877819|NCT02674802|C-urea breath test
877820|NCT02674802|Helicobacter Pylori
877821|NCT02674789|Exercise
877822|NCT02674789|Athletes
877823|NCT02674789|Ionized Magnesium
877824|NCT02674789|Variation
877825|NCT02674789|Blood
877826|NCT02674763|Acute Myeloid Leukemia
877827|NCT02674763|AML
877828|NCT02674763|IMGN779
877829|NCT02674763|ImmunoGen
877830|NCT02674763|Phase 1
877831|NCT02674763|Relapsed
877832|NCT02674763|Refractory
877833|NCT02674763|CD33
877834|NCT02674763|Dose Escalation
877835|NCT02674763|Dose Expansion
877836|NCT02674750|DLBCL
877837|NCT02674750|MYC
877838|NCT02674724|Resistance Training
877839|NCT02674724|Postural Balance
877840|NCT02674724|Exercise
877841|NCT02674711|patient education
877842|NCT02674711|low back pain
877843|NCT02674711|post-surgical pain
877844|NCT02674711|chronic opioid use
877845|NCT02674711|Neck Pain
877846|NCT02674672|VenaTech® Retrievable Vena Cava Filter
877847|NCT02674672|safety
877848|NCT02674672|efficacy
877849|NCT02674659|resistance training, PCSK9, coronary artery bypass
877851|NCT02674594|Anticoagulation
877852|NCT02674568|SCLC
877853|NCT02674568|Small Cell Lung Cancer
877854|NCT02674568|DLL3
877855|NCT02674568|Relapsed
877856|NCT02674568|Refractory
877857|NCT02674555|Phase 1
877858|NCT02674555|Metabolism
877859|NCT02674555|Excretion
877860|NCT02674555|Absorption
877861|NCT02674555|[14C]-radioactivity
877862|NCT02674555|Pharmacokinetics
877863|NCT02674555|Oncology
877864|NCT02674542|Family planning
877865|NCT02674542|Birth spacing
877866|NCT02674529|Depression
877867|NCT02674529|Neuroimaging biomarkers
877868|NCT02674529|MDD
877869|NCT02674529|Neurofeedback
877870|NCT02674516|antisocial behavior
877871|NCT02674516|aggression
877872|NCT02674516|transcranial direct current stimulation
877873|NCT02674516|dorsolateral prefrontal cortex
877874|NCT02674516|associated risk factors
877875|NCT02674503|Walking
877876|NCT02674503|Hospitalization
877877|NCT02674503|Randomized controlled trial
877878|NCT02674490|aphasia, language
877879|NCT02674373|gastric cancer
877880|NCT02674373|biomarker
877881|NCT02674373|Circulating tumor DNA
877882|NCT02674373|Chemotherapy
877883|NCT02674373|Prognosis
877884|NCT02674373|Predictive
877885|NCT02674334|orthopedic procedures
877886|NCT02674321|Tourette Syndrome
877887|NCT02674321|adolescents
877888|NCT02674308|Drug therapy
877889|NCT02674295|Healthy
877890|NCT02674295|JNJ-54135419
877891|NCT02674295|Esketamine
877892|NCT02674282|anterior cruciate ligament reconstruction
877893|NCT02674282|anterior cruciate ligament
877894|NCT02674282|sports medicine
877895|NCT02674282|soccer
877896|NCT02674282|maximum oxygen uptake
877897|NCT02674282|return to play
877898|NCT02674269|Overactive bladder
877899|NCT02674269|Botox
877900|NCT02674269|TC-3 Gel
877901|NCT02674269|Intravesical
877902|NCT02674269|UroGen Pharma
877903|NCT02674269|Botulinum Toxin
877904|NCT02674269|Urgency
877905|NCT02674269|OAB
877906|NCT02674269|Incontinence
877907|NCT02674269|I-QOL
877908|NCT02674269|KHQ
877909|NCT02674269|TBS
877910|NCT02674269|RTG
877911|NCT02674256|health
877912|NCT02674256|age between 18 to 60 years old
877913|NCT02674256|no history of gastrointestinal symptoms or complaints
877914|NCT02674243|Malignant pleural effusion
877915|NCT02674243|Pleurodesis
877916|NCT02674243|Talc
877917|NCT02674243|Iodopovidone solution
877918|NCT02674243|Povidone-iodine
877919|NCT02674204|Statin therapy
877920|NCT02674204|HER2-Negative
877921|NCT02674191|miniplates ,molar intrusion, hyperdivergent
877922|NCT02674139|post placental-caesarean-IUD
877923|NCT02674126|Cardiac Surgery
877924|NCT02674126|Maternal sound
877925|NCT02674126|Cortisol
877926|NCT02674126|Blood sugar
877927|NCT02674126|Stress
877928|NCT02674061|PD1
877929|NCT02674061|PD-1
877930|NCT02674061|PDL1
877931|NCT02674061|PD-L1
877932|NCT02674035|Abdominoplasty
877933|NCT02674035|Sutures
877934|NCT02674035|Abdominal deformities
877935|NCT02674035|Plication
877936|NCT02674035|Monofilament nylon suture
877937|NCT02674035|Barbed suture
877938|NCT02674022|Maternal Health
877939|NCT02674022|Autistic Disorder
877940|NCT02674022|Metabolism
877941|NCT02674022|Folic Acid
877942|NCT02673996|antibody
877943|NCT02673996|autoimmune
877944|NCT02673996|adrenergic
877945|NCT02673996|autonomic
877946|NCT02673983|Intestinal
877947|NCT02673983|Biopsy
877948|NCT02673983|full thickness
877949|NCT02673983|endoscopic
877950|NCT02673970|Melanoma
877951|NCT02673931|Open Heart Surgery
877952|NCT02673931|Organ protection
877953|NCT02673918|Rehabilitation
877954|NCT02673918|Home-Based Intervention
877960|NCT02673892|discharge
877961|NCT02673892|transitions
877962|NCT02673892|patient experience
877963|NCT02673866|Diabetic Peripheral Neuropathic Pain (DPNP)
877964|NCT02673866|Diabetes
877965|NCT02673866|Pregabalin
877966|NCT02673866|Spontaneous Pain
877967|NCT02673866|Hyperalgesia
877968|NCT02673866|Allodynia
877969|NCT02673866|Average Daily Pain Score (ADPS)
877970|NCT02673866|Pain Associated Sleep Interference
877971|NCT02673853|Supraglottic airway
877972|NCT02673853|Mini-dose atracurium
877973|NCT02673853|Postoperative residual paralysis
877974|NCT02673840|dengue fever
877975|NCT02673840|dengue hemorrhagic fever
877976|NCT02673840|ketotifen
877977|NCT02673840|vascular leakage
877978|NCT02673840|pleural effusion
877979|NCT02673840|plasma leakage
877980|NCT02673801|Referral and Consultation
877981|NCT02673801|Orthopedics
877982|NCT02673775|Macrophage
877983|NCT02673749|Lactose maldigestion
877984|NCT02673749|Dairy intolerance
877985|NCT02673749|Intolerance to milk
877986|NCT02673749|Intolerance to dairy
877987|NCT02673749|Milk intolerance
877988|NCT02673749|GI disorder
877989|NCT02673749|Lactose metabolism
877990|NCT02673749|GI symptoms after dairy ingestion
877991|NCT02673736|PLX73086
877992|NCT02673736|Synovitis, Pigmented Villonodular
877993|NCT02673736|Tenosynovial Giant Cell Tumor
877994|NCT02673736|Joint Diseases
877995|NCT02673736|Neoplasms
877996|NCT02673736|Synovitis
877997|NCT02673723|docozine
877998|NCT02673697|Sutureless valve
877999|NCT02673658|infant development, early intervention
878000|NCT02673645|Educational Achievement
878001|NCT02673632|Anti-Müllerian hormone
878002|NCT02673632|Ovarian stimulation
878003|NCT02673632|Polycystic ovary syndrome
878004|NCT02673632|Intracytoplasmic sperm injection
878005|NCT02673619|Topical
878006|NCT02673619|Palmar Hyperhidrosis
878007|NCT02673619|Umeclidinium
878008|NCT02673593|Safety
878009|NCT02673593|Pharmacokinetics
878010|NCT02673593|Food Effect
878011|NCT02673554|Glucose-dependent Insulinotropic Polypeptide (GIP)
878012|NCT02673554|Glucagon-Like Peptide 1 (GLP-1)
878013|NCT02673554|Incretin
878014|NCT02673554|Insulin secretion
878015|NCT02673554|Tachyphylaxis
878016|NCT02673528|appendectomy
878017|NCT02673528|laparoscopy
878018|NCT02673528|laparoscopic assisted appendectomy
878019|NCT02673528|cost utility
878020|NCT02673515|Alternate Day Fasting
878021|NCT02673502|Carbohydrate drink
878022|NCT02673502|Post operative complication
878023|NCT02673502|insulin resistance
878024|NCT02673502|Fasting blood glucose
878025|NCT02673437|Acute coronary syndrome
878026|NCT02673411|elastography
878027|NCT02673411|ultrasonography
878028|NCT02673372|Geriatric, Pain, Ketamine, Emergency Medicine
878029|NCT02673359|Preterm labor
878030|NCT02673359|Short cervix
878031|NCT02673359|Progesterone
878032|NCT02673359|Cervical cerclage
878033|NCT02673333|Pembrolizumab
878034|NCT02673333|15-286
878035|NCT02673320|Acute Traumatic Cervical Central Cord Syndrom Injury
878036|NCT02673320|Delay of Surgery
878037|NCT02673320|Decompressive Surgery
878038|NCT02673320|Canal Stenosis
878039|NCT02673320|Schneider Syndrom
878040|NCT02673320|Quality of life
878041|NCT02673320|Functional Outcome
878042|NCT02673281|walnuts
878043|NCT02673281|brain
878044|NCT02673281|appetite
878045|NCT02673281|energy intake
878046|NCT02673281|obesity
878047|NCT02673255|Plasma
878048|NCT02673255|Plasma Donor
878049|NCT02673255|Plasma Donation
878050|NCT02673255|Tetanus
878051|NCT02673255|Td
878052|NCT02673255|Immunoglobulin
878053|NCT02673255|Hyper-immunization
878054|NCT02673229|Santyl
878055|NCT02673229|Burn
878056|NCT02673229|Partial Thickness Burn
878057|NCT02673229|Second Degree Burn
878058|NCT02673229|Minor Burn Bacitracin
878059|NCT02673229|Scar Appearance
878060|NCT02673203|glucose monitoring
878061|NCT02673203|hunger levels
878062|NCT02673203|food intake
878063|NCT02673177|robot-assisted total mesorectal excision(RTME)
878064|NCT02673177|laparoscopic total mesorectal excision(LTME)
878065|NCT02673177|urinary function
878066|NCT02673177|sexual function
878067|NCT02673177|sphincter- preservation
878068|NCT02673177|low rectal cancer
878069|NCT02673164|Heart failure
878070|NCT02673164|stem cell
878071|NCT02673164|adipose derived stem cell
878072|NCT02673164|Stem cell therapy
878073|NCT02673164|ischemic heart disease
878074|NCT02673125|Preimplantation Genetic Screening
878075|NCT02673112|Concussion
878076|NCT02673112|mild traumatic brain injury
878077|NCT02673112|post concussion syndrome
878078|NCT02673112|child
878079|NCT02673099|HDF online
878080|NCT02673099|ESRD
878081|NCT02673099|Hemodialysis
878082|NCT02673099|oxidative stress
878083|NCT02673099|quality of life
878084|NCT02673099|Hemodialysis treatment
878085|NCT02673086|retroclavicular approach
878086|NCT02673086|coracoid approach
878087|NCT02673086|ultrasound
878088|NCT02673086|upper limb surgery
878089|NCT02673086|needle visibility
878090|NCT02673086|infraclavicular brachial plexus block
878091|NCT02673073|Heart failure
878092|NCT02673073|patient's diary
878093|NCT02673073|self awareness
878094|NCT02672995|stereotactic radiosurgery,Bevacizumab
878095|NCT02672969|smoke evacuation system
878096|NCT02672969|surgical smoke
878097|NCT02672943|Parkinson disease
878098|NCT02672943|Autonomic nervous system
878099|NCT02672943|MicroRNA
878100|NCT02672943|Inflammation
878101|NCT02672943|Oxidative stress
878102|NCT02672943|noradrenergic network
878103|NCT02672943|Rehabilitation treatment
878104|NCT02672930|calcium gluconate
878105|NCT02672930|hyperpotassemia treatment
878106|NCT02672917|CA19-9 Positive Malignancies
878107|NCT02672904|vocal cord
878108|NCT02672904|carcinoma
878109|NCT02672904|ktp laser
878110|NCT02672904|co2 laser
878111|NCT02672904|endoscopic surgery
878112|NCT02672891|Postpartum Hemorrhage
878113|NCT02672891|Uterine Tamponade
878114|NCT02672891|Condom Catheter
878115|NCT02672878|In-stent restenosis
878116|NCT02672878|Bioresorbable vascular scaffold
878117|NCT02672878|Stent
878118|NCT02672878|Drug-eluting stent
878119|NCT02672878|Coronary angiography
878120|NCT02672852|ABBV-066
878121|NCT02672852|BI 655066
878122|NCT02672852|risankizumab
878123|NCT02672813|Pectoral nerve I and II blocks
878124|NCT02672813|Breast surgery
878125|NCT02672813|Ropivacaine
878126|NCT02672813|Postoperative opioid consumption
878127|NCT02672787|Antihypertensive adherence
878128|NCT02672787|Emergency medicine
878129|NCT02672787|Antihypertensives
878130|NCT02672748|garden
878131|NCT02672748|Native American
878132|NCT02672748|BMI
878133|NCT02672748|Emotional health
878134|NCT02672748|Physical health
878135|NCT02672735|corrective exercise program
878136|NCT02672735|movement efficiency
878137|NCT02672722|This term was found doing the MeSH search and is the only thing that fits since we will be working with healthy subjects with no conditions.
878138|NCT02672709|Factor Xa Inhibitors
878139|NCT02672709|Renal Dialysis
878140|NCT02672696|Navigation
878141|NCT02672696|Gamma Nail
878142|NCT02672657|Health-Related Quality of life
878143|NCT02672657|Cancer
878144|NCT02672657|Elderly
878145|NCT02672657|Caregivers
878146|NCT02672618|heart failure
878147|NCT02672618|infrared thermal imaging
878148|NCT02672592|Metabolic syndrome X
878149|NCT02672592|Hypogonadism
878150|NCT02672592|Testosterone
878151|NCT02672592|Inflammation
878152|NCT02672592|Obesity
878153|NCT02672553|Aortic Valve Replacement
878154|NCT02672553|Minimal Invasive Sternotomy
878155|NCT02672540|Sickle Cell
878156|NCT02672540|Anemia
878157|NCT02672540|VOC
878158|NCT02672540|Vaso occlusive crisis
878159|NCT02672501|immunotherapy
878160|NCT02672501|CAR-T
878161|NCT02672501|leukemia
878162|NCT02672449|Prostate cancer
878163|NCT02672449|Carbon ions
878164|NCT02672449|Radiobiology
878165|NCT02672449|Radiotherapy
878166|NCT02672436|Diabetic Foot Ulcer
878167|NCT02672436|Diabetes Mellitus
878168|NCT02672436|Wound Healing
878169|NCT02672397|Epidural
878170|NCT02672397|Ethnicity
878171|NCT02672397|Education
878172|NCT02672397|Labor
878173|NCT02672397|obstetrical analgesia
878174|NCT02672384|Intensive care unit
878175|NCT02672384|Invasive mechanical ventilation
878176|NCT02672384|Chronic periodontitis
878177|NCT02672384|Point of Care P. gingivalis test
878178|NCT02672358|Non-Small-Cell Lung Cancer
878179|NCT02672358|NSCLC
878180|NCT02672358|dabrafenib
878181|NCT02672358|trametinib
878182|NCT02672358|Japanese patients
878183|NCT02672358|BRAF V600E mutation positive metastatic
878184|NCT02672358|stage IV
878185|NCT02672345|Sevoflurane
878186|NCT02672345|MicroRNAs
878187|NCT02672345|Inflammatory Response
878188|NCT02672345|Cytokines
878189|NCT02672345|Anesthetics, Inhalation
878190|NCT02672345|Macrophage Inflammatory Proteins
878191|NCT02672267|AMI, hBMMSCs, stem cells,
878192|NCT02672241|Radiation Therapy
878193|NCT02672241|Brainstem Tumor in Children
878194|NCT02672202|Chronic Pain
878195|NCT02672202|Pain Modulation Profile
878196|NCT02672202|CPM
878197|NCT02672202|acute post operative pain
878204|NCT02672176|Diabetes mellitus
878205|NCT02672176|Motivational Interviewing
878206|NCT02672176|Mobile Health Technology
878207|NCT02672176|Patient-generated Health Data (PGHD)
878208|NCT02672163|autologous micrografts
878209|NCT02672163|heart failure
878210|NCT02672163|coronary artery bypass surgery
878211|NCT02672163|cell therapy
878212|NCT02672163|atrial appendage
878213|NCT02672163|epicardial cell delivery
878214|NCT02672150|evidence-based practice implementation
878215|NCT02672150|system change
878216|NCT02672150|interagency collaboration
878217|NCT02672150|substance use
878218|NCT02672150|treatment services
878219|NCT02672150|data-driven decision making
878220|NCT02672150|juvenile justice
878221|NCT02672150|adolescents
878222|NCT02672150|justice-involved youth
878223|NCT02672150|cluster randomized trial
878224|NCT02672137|myocardial infarction
878225|NCT02672137|knowledge transfer
878226|NCT02672137|acute coronary syndromes
878227|NCT02672020|pheochromocytoma
878228|NCT02672020|paraganglioma
878229|NCT02672020|adrenocortical carcinoma
878230|NCT02672007|Respiratory rate measurement methods.
878231|NCT02671994|Geriatric Assessment
878232|NCT02671994|G8 screening
878233|NCT02671994|Oncologic treatment
878234|NCT02671968|CGM
878235|NCT02671968|hypoglycemic events
878236|NCT02671955|Advanced Cancer
878237|NCT02671955|JNJ-61610588
878238|NCT02671942|roflumilast
878363|NCT02670941|cancer
878239|NCT02671916|QoL and Survival one year after ICU stay
878240|NCT02671864|Incretin-based therapy
878241|NCT02671864|GLP1
878242|NCT02671864|Angiogenesis Inflammation
878243|NCT02671864|Hypoglycaemic treatment
878244|NCT02671851|Thoracic Paravertebral Blocks
878245|NCT02671851|Ultrasound Guidance
878246|NCT02671851|Reduction Mammoplasty
878247|NCT02671851|Time to First Pain
878248|NCT02671851|Postoperative Analgesia
878249|NCT02671825|Pharmacokinetics
878250|NCT02671812|dental implant
878251|NCT02671812|patient satisfaction
878252|NCT02671812|treatment outcome
878253|NCT02671812|cytokine profile
878254|NCT02671812|risk factor
878255|NCT02671812|risk predictor
878256|NCT02671786|Severe Acute Malnutrition
878257|NCT02671786|Severe Underweight
878258|NCT02671786|IAP Grade III-IV
878259|NCT02671786|Severe Stunting
878260|NCT02671786|Village Health Workers
878261|NCT02671786|MAHAN RUTF & MAHAN Vit-Mim mix
878262|NCT02671773|Microbiota
878263|NCT02671760|Short-term insomnia
878264|NCT02671760|difficulty sleeping
878265|NCT02671760|sedative
878266|NCT02671760|hypnotic
878267|NCT02671734|endoscopy
878268|NCT02671682|Immunoadsorption
878269|NCT02671682|Plasmapheresis
878270|NCT02671656|Uricemia
878271|NCT02671630|Cognitive function
878272|NCT02671630|Depression
878273|NCT02671630|Quality of life
878274|NCT02671630|Community-based computerized cognitive training program
878275|NCT02671630|Randomized controlled trial
878276|NCT02671617|Abdominal Cavity
878277|NCT02671617|Aged
878278|NCT02671604|acute renal failure
878279|NCT02671604|prostatectomy
878280|NCT02671604|minimal invasive surgery
878281|NCT02671578|nitrous oxide
878282|NCT02671578|conscious sedation
878283|NCT02671578|pain
878284|NCT02671578|anxiety
878285|NCT02671565|Intraarticular hyaluronic acid injections
878286|NCT02671565|Total knee replacement
878287|NCT02671565|Observational study
878288|NCT02671565|Intraarticular corticosteroid injections
878289|NCT02671565|Comparative effectiveness
878290|NCT02671539|gene therapy
878291|NCT02671539|hereditary retinal degeneration
878292|NCT02671539|rAAV2.REP1
878293|NCT02671513|Melanoma
878294|NCT02671513|Cycline-Dependent Kinase
878295|NCT02671487|Problem Behavior
878296|NCT02671487|Aggression
878297|NCT02671487|Posttraumatic Stress Disorder
878298|NCT02671487|Adolescents
878299|NCT02671448|Homebound
878300|NCT02671448|Homecare
878301|NCT02671448|15-022
878302|NCT02671396|Virtual Reality
878303|NCT02671396|Postural Stability
878304|NCT02671396|Balance Training
878305|NCT02671396|Parkinson's Disease
878306|NCT02671383|Antiretroviral Agents
878307|NCT02671383|Treatment
878308|NCT02671383|Viral Load
878309|NCT02671357|pancreatic surgery; neoplasms
878310|NCT02671318|cytomegalovirus
878311|NCT02671318|sirolimus
878312|NCT02671318|cytomegalovirus recurrence
878313|NCT02671318|kidney transplant
878314|NCT02671318|conversion
878315|NCT02671305|delayed cord clamping
878316|NCT02671305|cord milking
878317|NCT02671305|bedside neonatal resuscitation
878318|NCT02671292|Loss of Control Eating
878319|NCT02671292|Binge Eating
878320|NCT02671292|Obesity
878321|NCT02671292|Prevention
878322|NCT02671292|Interpersonal Psychotherapy
878323|NCT02671292|Adolescent
878324|NCT02671266|Oxytocin
878325|NCT02671266|Body dysmorphic disorder
878326|NCT02671266|Obsessive-compulsive disorder
878327|NCT02671240|Parkinson disease
878328|NCT02671240|behavioral addiction
878329|NCT02671240|akinéto-rigid syndrome
878330|NCT02671240|dopamine agonist
878331|NCT02671214|guar gum
878332|NCT02671214|konjac mannan
878333|NCT02671214|blood glucose
878334|NCT02671214|legume flour
878335|NCT02671188|C-C chemokine receptor
878336|NCT02671188|Psoriatic arthritis
878337|NCT02671188|Chemokine (C-C motif) ligand 20
878338|NCT02671188|Monoclonal antibody
878339|NCT02671188|psoriasis
878340|NCT02671188|Humanized Immunoglobulin G
878341|NCT02671162|Pruritus
878342|NCT02671162|End-Stage Renal Disease
878343|NCT02671110|weight loss treatment
878344|NCT02671110|Obesity
878345|NCT02671084|Sevoflurane
878346|NCT02671084|Ck-MB
878347|NCT02671071|Cervix Cancer
878348|NCT02671058|bioavailability
878349|NCT02671045|lung cancer
878350|NCT02671045|genomic profile
878351|NCT02671045|targeted therapy
878352|NCT02671045|FoundationOne
878353|NCT02671032|Cochlear Prosthesis Implantation
878354|NCT02670980|Retina Implant
878355|NCT02670980|Visual Prosthesis
878356|NCT02670941|aromatherapy
878357|NCT02670941|chemotherapy
878358|NCT02670941|ginger
878359|NCT02670941|lavender
878360|NCT02670941|orange
878361|NCT02670941|jojoba
878362|NCT02670941|essential oils
878364|NCT02670928|Diabetes
878365|NCT02670928|lifestyle change
878366|NCT02670928|weight management
878367|NCT02670928|control of glycemic in HbA1C and FPG
878368|NCT02670889|Urea Cycle Disorder
878369|NCT02670850|Mild Cognitive Impairment
878370|NCT02670850|Family caregiver
878371|NCT02670850|Intervention program
878372|NCT02670850|Elders
878373|NCT02670811|Hypertension
878374|NCT02670811|Fermented Milk
878375|NCT02670811|Clinical Study
878376|NCT02670811|Randomized
878377|NCT02670811|Double-blind
878378|NCT02670798|neuromuscular
878379|NCT02670798|scoliosis
878380|NCT02670772|Antiretroviral Agents
878381|NCT02670746|Pancreatic Cancer
878382|NCT02670746|Observational
878383|NCT02670746|Nab-Paclitaxel
878384|NCT02670746|Abraxane
878385|NCT02670746|ABI-007
878386|NCT02670746|Gemcitabine
878387|NCT02670746|Non-interventional
878388|NCT02670746|Netherlands
878389|NCT02670746|Quality of Life
878390|NCT02670733|mechanical ventilation
878391|NCT02670733|positive end-expiratory pressure
878392|NCT02670720|BCX4161
878393|NCT02670720|avoralstat
878394|NCT02670720|HAE
878395|NCT02670720|hereditary angioedema
878396|NCT02670720|prophylaxis
878397|NCT02670707|vinblastine
878398|NCT02670707|prednisone
878399|NCT02670707|cytarabine
878400|NCT02670707|Langerhans Cell Histiocytosis (LCH)
878401|NCT02670694|Rett Syndrome
878402|NCT02670694|Prader-Willi Syndrome
878403|NCT02670694|Angelman Syndrome
878404|NCT02670694|Sleep Problems
878405|NCT02670681|Exercise
878406|NCT02670681|Aerobic Exercise
878407|NCT02670668|BRCA1/2;Mutations;Neoadjuvant chemotherapy;TNBC
878408|NCT02670655|Ablative fractional laser
878409|NCT02670655|Iontophoresis
878410|NCT02670655|Actinic keratosis
878411|NCT02670655|Photodynamic therapy
878412|NCT02670629|Pediatric orthopedics
878417|NCT02670564|pharmacogenetics
878418|NCT02670564|busulfan
878419|NCT02670564|treosulfan
878420|NCT02670564|hematopoietic stem cell transplantation
878421|NCT02670564|fludarabine
878422|NCT02670564|pediatric patients
878423|NCT02670564|TBI
878424|NCT02670564|leukemia
878425|NCT02670564|leukemia, lymphoid
878426|NCT02670564|precursor cell lymphoblastic Leukemia-Lymphoma
878427|NCT02670564|Immune System disease
878428|NCT02670564|Immunoproliferative Disorders
878429|NCT02670564|stem cell transplantation
878430|NCT02670564|children and adolescent
878431|NCT02670564|high risk acute lymphoblastic leukemia
878432|NCT02670564|NCT01949129 add-on
878433|NCT02670564|ALL SCTped FORUM
878434|NCT02670525|Recurrent, Refractory, or High Risk Leukemias
878435|NCT02670525|Matched targeted therapy
878436|NCT02670512|End-Stage Renal Disease
878437|NCT02670512|Peritoneal Dialysis
878438|NCT02670512|Telehomecare
878439|NCT02670512|Telehome Monitoring
878440|NCT02670486|Overactive bladder
878441|NCT02670486|Urge urinary incontinence
878442|NCT02670486|Urodynamics
878446|NCT02670395|Healthy
878447|NCT02670395|JNJ-54416076
878448|NCT02670395|Ascending Dose
878449|NCT02670369|Sedentary time
878450|NCT02670369|Sit-to-stand transitions
878451|NCT02670356|fish oil
878452|NCT02670356|EPA
878453|NCT02670356|DHA
878454|NCT02670356|krill oil
878455|NCT02670356|Metabolic Syndrome
878456|NCT02670330|Epidermolysis Bullosa
878457|NCT02670330|Simplex
878458|NCT02670330|Recessive Dystrophic
878459|NCT02670330|Junctional non-Herlitz
878460|NCT02670317|DLBCL
878461|NCT02670317|large B cell lymphoma
878462|NCT02670317|NHL
878463|NCT02670304|letrozole
878464|NCT02670304|ovarian hyperstimulating syndrome
878465|NCT02670291|auditory hallucinations
878466|NCT02670291|schizophrenia
878467|NCT02670291|cTBS
878468|NCT02670291|noninvasive brain stimulation
878469|NCT02670265|malnutrition
878470|NCT02670265|parenteral nutrition
878471|NCT02670265|weight loss
878472|NCT02670265|pancreatic cancer
878473|NCT02670265|biliary tract cancer
878474|NCT02670265|quality of life
878475|NCT02670226|Amyotrophic Lateral Sclerosis
878476|NCT02670226|Muscle metabolism
878477|NCT02670226|Metabolomics
878478|NCT02670226|Transcriptomics
878479|NCT02670200|psychooncology
878480|NCT02670200|mental health support
878481|NCT02670200|ICBT
878482|NCT02670200|supportive treatment for cancer patients
878483|NCT02670200|depression
878484|NCT02670200|online-therapy
878485|NCT02670200|Psycho-oncological support via internet
878486|NCT02670200|internet-delivered cognitive behavior medicine
878487|NCT02670187|MERS CoV, Vaccine, DNA
878488|NCT02670174|Shoulder impingement syndrome
878489|NCT02670174|Overhead athletes
878490|NCT02670174|Kinetic chain
878491|NCT02670174|Exercise treatment
878497|NCT02670122|Hepatocellular Carcinoma
878498|NCT02670122|TACE
878499|NCT02670096|acetazolamide
878500|NCT02670096|Treatment Emergent Sleep Disordered Breathing
878501|NCT02670096|Sleep Apnea
878502|NCT02670031|Hypertensive Heart Disease
878503|NCT02670031|Hypertension
878504|NCT02670031|Left Ventricular Hypertrophy
878505|NCT02670031|Myocardial Fibrosis
878506|NCT02670031|Cardiovascular Magnetic Resonance Imaging
878507|NCT02669992|Ileostomy
878508|NCT02669979|elderly
878509|NCT02669979|oral care
878510|NCT02669966|Kidney Transplantation
878511|NCT02669940|Ombitasvir
878512|NCT02669940|Dasabuvir
878513|NCT02669940|Paritaprevir
878514|NCT02669927|hip surgery
878515|NCT02669927|frail older people
878516|NCT02669901|Opioid-Related Disorders
878517|NCT02669901|Naloxone
878518|NCT02669901|Harm Reduction
878519|NCT02669901|Drug Overdose Deaths
878520|NCT02669901|Opioid Misuse
878521|NCT02669901|Naloxone Coprescribing
878522|NCT02669901|Universal Precautions
878523|NCT02669901|Opioid Substance Use Disorder
878524|NCT02669888|Indigo Naturalis
878525|NCT02669888|Atopic Dermatitis
878526|NCT02669888|TCM
878527|NCT02669823|Diagnosis
878528|NCT02669797|Obesity
878529|NCT02669797|Ecological Momentary Intervention
878530|NCT02669797|Video Feedback
878531|NCT02669771|Xtandi
878532|NCT02669771|MDV3100
878533|NCT02669771|long term use
878534|NCT02669771|enzalutamide
878535|NCT02669758|Alkermes
878536|NCT02669758|ALKS 3831
878537|NCT02669758|Samidorphan
878538|NCT02669758|Schizophrenia
878539|NCT02669758|Safety
878540|NCT02669745|Chinese women
878541|NCT02669745|Breast cancer
878542|NCT02669732|Type 2 Diabetes Mellitus
878543|NCT02669732|Adult
878544|NCT02669732|Developmental Phase II
878545|NCT02669719|Lung Cancer
878546|NCT02669719|Chemotherapy
878547|NCT02669719|Immunotherapy
878548|NCT02669693|Olives, oleuropein
878549|NCT02669667|MEDI9314
878550|NCT02669667|Safety
878551|NCT02669667|Tolerability
878552|NCT02669667|Pharmacokinetics
878553|NCT02669667|Immunogenicity
878554|NCT02669641|Steatosis, Fatty liver, Steatohepatitis
878555|NCT02669615|multiple myeloma
878556|NCT02669615|Melphalan HCl
878557|NCT02669615|Autologous Transplantation
878558|NCT02669602|Nutritional epidemiology
878559|NCT02669602|Prospective
878560|NCT02669589|CRRT
878561|NCT02669589|AKI
878562|NCT02669589|anticoagulation
878563|NCT02669589|KDIGO
878564|NCT02669576|Breast cancer
878565|NCT02669576|meopausal syptoms
878566|NCT02669576|mind body medecine
878567|NCT02669576|yoga
878568|NCT02669576|acupuncture
878569|NCT02669550|Fiberoptic bronchoscope
878570|NCT02669550|Disposcope endoscope
878571|NCT02669550|Awake orotracheal intubation
878572|NCT02669511|DLBCL
878573|NCT02669485|ICG
878574|NCT02669485|colectomy
878575|NCT02669485|anastomotic leak
878576|NCT02669485|anastomotic leakage rate
878577|NCT02669485|surgical decision
878578|NCT02669459|Cervical Intraepithelial Neoplasia
878579|NCT02669459|Imiquimod
878580|NCT02669459|Human papillomavirus
878581|NCT02669459|quality of life
878582|NCT02669459|biological markers
878583|NCT02669446|Non interventional study
878584|NCT02669446|Ectoin
878585|NCT02669446|Lozenges
878586|NCT02669446|pharyngitis
878587|NCT02669433|Dementia with Lewy bodies
878588|NCT02669433|Lewy bodies
878589|NCT02669433|intepirdine
878590|NCT02669433|RVT-101
878591|NCT02669433|dementia
878592|NCT02669381|Phenylalanine
878593|NCT02669381|Direct Amino Acid Oxidation
878594|NCT02669381|Stable isotopes
878595|NCT02669355|White coat physician attire
878596|NCT02669342|Infection
878597|NCT02669342|Urinary Catheter
878598|NCT02669342|Sharklet
878599|NCT02669316|diet
878604|NCT02669251|Optimal Biologic Dose
878605|NCT02669251|Safety
878606|NCT02669251|Chronic Graft-Versus-Host Disease (cGVHD)
878607|NCT02669251|Inflammatory Lung Disease
878608|NCT02669251|FEV1
878609|NCT02669225|18 F florbetaben
878610|NCT02669225|Sleep Deprivation
878611|NCT02669225|rested wakefulness
878612|NCT02669225|glymphatic system
878613|NCT02669212|Chronic Fatigue Syndrome
878614|NCT02669212|Lyme Disease
878615|NCT02669212|Healthy Volunteers
878616|NCT02669212|Movement Disorder
878617|NCT02669186|analgesia
878618|NCT02669186|cancer
878619|NCT02669186|natural killer cell
878620|NCT02669186|opioid
878621|NCT02669173|Myeloid derived suppressor cells
878622|NCT02669173|brain tumor
878623|NCT02669173|MDSC
878624|NCT02669173|GBM
878625|NCT02669173|recurrent
878626|NCT02669160|Motorized Orthotic Devices
878627|NCT02669160|Minors
878628|NCT02669160|CP (Cerebral Palsy)
878629|NCT02669160|Exoskeleton Device
878630|NCT02669134|cardiac resynchronization therapy
878631|NCT02669134|optimization
878632|NCT02669134|heart failure
878633|NCT02669134|reverse left ventricular remodeling
878634|NCT02669121|Drug therapy
878635|NCT02669108|testis
878636|NCT02669108|spermatogenesis
878637|NCT02669082|Drug Therapy
878638|NCT02669004|Analgesia, Epidural,Pain, Postoperative
878639|NCT02668991|Autism Spectrum Disorder
878640|NCT02668991|Janssen Autism Knowledge Engine
878641|NCT02668991|Autism Behavior Inventory
878642|NCT02668978|lung surgery
878643|NCT02668978|air leak
878644|NCT02668978|prevention
878645|NCT02668965|Clinical pregnancy rate
878646|NCT02668913|gynaecology
878647|NCT02668913|Oncology
878648|NCT02668900|Feasibility trial
878649|NCT02668900|Cardiovascular disease
878650|NCT02668900|Decision Support
878651|NCT02668900|Patient Decision Aid
878652|NCT02668900|implantable cardioverter defibrillator
878653|NCT02668900|implantable cardioverter defibrillator replacement
878654|NCT02668874|Pit and Fissure sealants
878655|NCT02668874|Isolation
878656|NCT02668874|permanent teeth
878657|NCT02668874|children
878658|NCT02668874|Isolite®
878659|NCT02668874|Dental caries
878663|NCT02668770|Advanced Cancers
878664|NCT02668770|Melanoma
878665|NCT02668770|Advanced solid malignancies
878666|NCT02668770|Metastatic
878667|NCT02668770|MGN1703
878668|NCT02668770|Ipilimumab
878669|NCT02668770|Yervoy
878670|NCT02668770|BMS-734016
878671|NCT02668770|MDX010
878672|NCT02668770|Refractory
878673|NCT02668770|Relapsed
878674|NCT02668718|radiotherapy, adjuvant
878675|NCT02668718|prostatectomy
878676|NCT02668692|LEO 80185 gel, calcipotriol, betamethasone
878677|NCT02668679|Dream Doctors
878678|NCT02668679|Medical Clown
878679|NCT02668679|Pediatrics
878680|NCT02668679|Sedation
878681|NCT02668679|Endoscopy
878682|NCT02668666|Palbociclib
878683|NCT02668666|Tamoxifen
878684|NCT02668666|CDK4/6 Inhibitor
878685|NCT02668653|Newly diagnosed Acute Myeloid Leukemia
878686|NCT02668653|FLT3-ITD positive
878687|NCT02668653|Chemotherapy
878688|NCT02668653|Induction chemotherapy
878689|NCT02668653|Consolidation chemotherapy
878690|NCT02668653|Maintenance chemotherapy
878691|NCT02668653|Quizartinib
878692|NCT02668653|Receptor tyrosine kinase inhibitor
878693|NCT02668653|FMS-like tyrosine kinase 3
878694|NCT02668653|AC220
878695|NCT02668653|FLT3-ITD
878696|NCT02668653|AML
878697|NCT02668640|Work productivity
878698|NCT02668640|Rheumatoid arthritis (RA)
878699|NCT02668640|Adalimumab
878700|NCT02668640|Quality of life (QOL)
878701|NCT02668627|Stroke
878702|NCT02668627|Collateral status
878703|NCT02668627|Endovascular treatment
878704|NCT02668614|Detection
878705|NCT02668601|Gestational Diabetes Mellitus
878706|NCT02668601|Childhood Obesity
878707|NCT02668601|Offspring
878708|NCT02668575|Pulmonary Cystic Fibrosis
878709|NCT02668562|acute coronary syndrome
878710|NCT02668562|coronary artery bypass surgery
878711|NCT02668562|ticagrelor
878712|NCT02668562|antiplatelet therapy
878713|NCT02668562|platelet function testing
878714|NCT02668536|sunscreen
878715|NCT02668536|melanoma
878716|NCT02668536|improved protection from uv rays
878717|NCT02668523|Presbyopia
878718|NCT02668523|Corneal Inlay
878719|NCT02668523|Pseudophakic
878720|NCT02668523|Pseudophakia
878721|NCT02668510|Heel Pain
878722|NCT02668510|extracorporeal shock wave therapy
878723|NCT02668510|ESWT
878724|NCT02668510|shock wave
878725|NCT02668510|Soldiers
878726|NCT02668510|Platelet rich plasma
878727|NCT02668510|PRP
878728|NCT02668510|Autologous conditioned plasma
878729|NCT02668510|Military
878730|NCT02668497|Movement disorders
878731|NCT02668497|Botulinum toxin type A
878732|NCT02668497|Tremor
878733|NCT02668497|Kinematics
878734|NCT02668484|TAVI
878735|NCT02668484|trans-femoral
878736|NCT02668484|Sapien
878737|NCT02668484|Lotus
878738|NCT02668445|Concurrent
878739|NCT02668445|muscle
878740|NCT02668445|glycogen
878741|NCT02668445|molecular
878742|NCT02668406|Blood infection, melioidosis, rapid diagnostic test
878743|NCT02668380|Apatinib
878744|NCT02668380|metastatic gastric cancer
878745|NCT02668380|Non-interventionalStudy
878746|NCT02668367|Viral Diseases
878747|NCT02668367|Antiviral
878748|NCT02668367|Paramyxoviridae Infections
878749|NCT02668367|RSV
878750|NCT02668367|Respiratory Syncytial Virus
878751|NCT02668367|Aviragen Therapeutics, Inc.
878752|NCT02668367|Aviragen Therapeutics
878753|NCT02668367|Aviragen
878757|NCT02668302|Steroid-eluting implant
878758|NCT02668302|Mometasone furoate
878759|NCT02668276|Prostatic neoplasms
878760|NCT02668276|Oncotype DX
878761|NCT02668276|Treatment Decisions
878762|NCT02668263|Breast cancer
878763|NCT02668263|mastectomy
878764|NCT02668263|seromas
878765|NCT02668211|osteoarthritis
878766|NCT02668211|radiostereometric analysis
878767|NCT02668211|correction of functional deformity
878768|NCT02668211|procedures
878769|NCT02668211|total hip arthroplasty
878770|NCT02668211|musculoskeletal diseases
878771|NCT02668198|Endoscopic mucosal resection, residual polyp, near focus imaging
878772|NCT02668172|pegvisomant
878773|NCT02668172|pasireotide LAR
878774|NCT02668172|long acting somatostatin analogues
878775|NCT02668146|essential tremor
878776|NCT02668146|Perampanel
878777|NCT02668146|clinical trial
878778|NCT02668133|zinc deficiency
878779|NCT02668133|zinc absorption
878780|NCT02668120|chronic histiocytic intervillositis
878781|NCT02668120|serum alkaline phosphatase
878782|NCT02668120|placenta
878783|NCT02668120|case-control study
878784|NCT02668094|propofol
878785|NCT02668094|lidocaine
878786|NCT02668094|pregabalin
878787|NCT02668081|Endoscopic sphincterotomy
878788|NCT02668081|Endoscopic papillary balloon dilation
878789|NCT02668081|Metagenomics
878790|NCT02668068|Pneumoconiosis
878791|NCT02668068|Mesenchymal Stem Cells
878792|NCT02668068|whole-lung lavage (WLL)
878793|NCT02668055|TB4
878794|NCT02668055|Difficult to heal
878795|NCT02668029|Oxygen therapy
878796|NCT02668003|Prevention trial
878797|NCT02668003|Cognitive Behaviour Therapy
878798|NCT02668003|CWP
878799|NCT02668003|Chronic widespread pain
878800|NCT02668003|RCT
878801|NCT02668003|Fibromyalgia
878802|NCT02668003|Prevention
878803|NCT02667990|metatarsalgia
878804|NCT02667990|pedobar
878805|NCT02667990|foot
878806|NCT02667990|stiletto
878807|NCT02667990|insoles
878808|NCT02667977|fluids, pediatric, gastroenteritis
878809|NCT02667951|Elderly
878810|NCT02667951|Dementia
878811|NCT02667951|Intervention program
878812|NCT02667925|ovarian cancer
878813|NCT02667925|intraperitoneal chemotherapy
878814|NCT02667912|Hypertension, Endovascular Procedures, Catheter Ablation, Renal Artery
878815|NCT02667899|disorders of consciousness
878816|NCT02667899|deep brain stimulation
878817|NCT02667899|transcranial magnetic stimulation
878818|NCT02667860|intracorporeal anastomosis
878819|NCT02667860|laparoscopic colectomy
878820|NCT02667860|outcomes
878821|NCT02667860|length of stay
878822|NCT02667860|analgesia
878823|NCT02667860|aesthetic
878824|NCT02667860|extracorporeal anastomosis
878825|NCT02667860|laparoscopic
878826|NCT02667847|preoperative anxiety assessment
878827|NCT02667847|levels of preoperative anxiety using two different scales
878828|NCT02667834|social cognition
878829|NCT02667834|cognitive remediation
878830|NCT02667782|Mindfulness-based interventions
878831|NCT02667782|Dementia
878832|NCT02667782|Caregiving
878833|NCT02667782|Burden
878834|NCT02667782|Stress
878835|NCT02667782|Anxiety
878836|NCT02667782|Depression
878837|NCT02667782|Community care
878838|NCT02667756|biomarker
878839|NCT02667756|inflammation
878840|NCT02667756|prognosis
878841|NCT02667756|knee
878842|NCT02667743|NSCLC
878843|NCT02667743|Paclitaxel Micelles for Injection
878844|NCT02667691|superoxyde dismutase
878845|NCT02667691|melon concentrate
878846|NCT02667691|oxydative stress
878847|NCT02667691|overweight women
878848|NCT02667665|Alzheimer's Disease Dementia
878849|NCT02667652|T2DM
878850|NCT02667652|RYGB
878851|NCT02667652|RCT
878852|NCT02667639|safety
878853|NCT02667639|tolerability
878854|NCT02667639|RPH-104
878855|NCT02667639|RPH104
878856|NCT02667626|Breast cancer survivor
878857|NCT02667626|Cancer survivorship
878858|NCT02667626|Survivorship care plan
878859|NCT02667626|Vaginal dryness
878860|NCT02667626|Vulvovaginal atrophy
878861|NCT02667626|Vasomotor symptom
878862|NCT02667626|Infertility
878863|NCT02667626|Family planning
878864|NCT02667613|motor skill learning
878865|NCT02667613|functional changes
878866|NCT02667613|neuroplastic changes
878867|NCT02667600|Cesarean
878868|NCT02667600|Blood Loss
878869|NCT02667600|Triton
878870|NCT02667574|basal cell carcinoma
878871|NCT02667574|surgery
878872|NCT02667574|stage
878873|NCT02667574|vismodegib
878874|NCT02667548|percutaneous coronary intervention
878875|NCT02667509|Evolutionary Model
878876|NCT02667483|Duchenne muscular dystrophy
878877|NCT02667483|DMD
878878|NCT02667483|Oligonucleotides, Antisense
878879|NCT02667470|Solifenacin
878880|NCT02667470|Overactive bladder
878881|NCT02667431|SUI
878882|NCT02667418|Clostridium
878883|NCT02667418|Difficile
878884|NCT02667418|Fidaxomicin
878885|NCT02667418|Vancomycin
878886|NCT02667418|Recurrent
878887|NCT02667418|Pulse
878888|NCT02667418|Taper
878889|NCT02667392|Stroke
878890|NCT02667392|Gait
878891|NCT02667392|Walking
878892|NCT02667392|Rehabilitation
878893|NCT02667392|Exercise
878894|NCT02667392|Exercise Therapy
878895|NCT02667392|Physical Therapy Modalities
878896|NCT02667392|Exercise Movement Techniques
878897|NCT02667379|Cat
878898|NCT02667379|allergy
878899|NCT02667379|dander
878900|NCT02667379|Fel d 1
878901|NCT02667379|Felis domesticus
878902|NCT02667366|mild and moderate depression
878903|NCT02667353|electroconvulsive
878904|NCT02667353|hippocampus
878905|NCT02667353|elderly
878906|NCT02667353|working mechanism
878907|NCT02667340|exercise
878908|NCT02667340|carbohydrate
878909|NCT02667340|Superstarch
878910|NCT02667327|diabetic foot ulcer
878911|NCT02667327|diabetic complications
878912|NCT02667327|diabetes
878913|NCT02667327|wound healing
878914|NCT02667327|Granexin gel
878915|NCT02667327|FirstString Research
878916|NCT02667314|Cognition
878917|NCT02667314|Cognitive Aging
878918|NCT02667314|Dementia
878919|NCT02667314|Neurocognitive Disorders
878920|NCT02667314|Cognitive Therapy
878921|NCT02667314|Cognitive Reserve
878922|NCT02667314|Cognitive Enrichment
878923|NCT02667314|Jigsaw Puzzles
878924|NCT02667275|seborrheic keratosis
878925|NCT02667249|cholecystectomy, check list
878926|NCT02667236|seborrheic keratosis
878927|NCT02667223|pharmacokinetics
878928|NCT02667223|pharmacodynamics
878929|NCT02667223|RN316
878930|NCT02667223|recombinant human hyaluronidase
878931|NCT02667145|hand osteoarthritis
878932|NCT02667145|self care program
878933|NCT02667145|assistive tecnology
878934|NCT02667132|Granulomatous, Mastitis
878935|NCT02667132|C17.800.090.968.400
878936|NCT02667132|C13.703.844.603.400
878937|NCT02667093|Acute Leukemia
878938|NCT02667093|Acute Myeloid Leukemia
878939|NCT02667093|AML
878940|NCT02667080|Semen quality
878941|NCT02667080|Sexual Abstinence
878942|NCT02667080|sperm motility
878943|NCT02667080|DNA fragmentation
878944|NCT02667015|Substance Use Disorders
878945|NCT02667015|Anxiety
878946|NCT02667015|Anxiety Sensitivity
878947|NCT02667015|Brief Intervention
878948|NCT02667015|Treatment
878949|NCT02666989|Depression
878950|NCT02666989|Placebo
878951|NCT02666989|Open-label
878952|NCT02666989|Clinical practice
878953|NCT02666976|Gastroesophageal reflux, proton pump inhibitors, ilaprazole
878954|NCT02666963|RTA 901
878955|NCT02666963|RTA 901 capsules
878956|NCT02666898|Residual disease
878957|NCT02666885|Personalized Medicine
878958|NCT02666885|Radiation Oncology
878959|NCT02666885|Functional Imaging
878960|NCT02666885|Biomarker
878961|NCT02666885|Decision Support System
878962|NCT02666885|Radiomics
878963|NCT02666872|Vaccination
878964|NCT02666872|Infant
878965|NCT02666872|Parents
878966|NCT02666872|Intention
878967|NCT02666846|UVB Pain Model
878968|NCT02666846|PK
878969|NCT02666846|Topical
878970|NCT02666846|NSAIDs
878971|NCT02666833|Skin Cancer
878972|NCT02666833|Basal Cell Carcinoma
878973|NCT02666833|Squamous Cell Carcinoma
878974|NCT02666833|Mohs Surgery
878975|NCT02666833|Imaging
878976|NCT02666807|NF-κB
878977|NCT02666807|Ginger
878978|NCT02666794|analgesia
878979|NCT02666794|fetal bradycardia
878980|NCT02666794|hypertonic uterine
878981|NCT02666781|OSA, Surgery, Postoperative, Rostral Fluid Shift
878982|NCT02666755|Lung Neoplasms digital polymerase chain reaction
878983|NCT02666716|pharmacokinetics
878984|NCT02666716|fluconazole
878985|NCT02666716|invasive fungal infection
878986|NCT02666716|candidiasis
878987|NCT02666716|intensive care unit
878988|NCT02666703|cardiac surgery
878989|NCT02666703|systemic inflammatory response
878990|NCT02666703|immunoadsorption
878991|NCT02666677|polytrauma, emergency medicine
878992|NCT02666664|hyperlipidemia
878993|NCT02666664|cholesterol
878994|NCT02666664|heterozygous familial hypercholesterolemia
878995|NCT02666664|atherosclerotic cardiovascular disease
878996|NCT02666664|ASCVD
878997|NCT02666664|HeFH
878998|NCT02666664|LDL
878999|NCT02666638|Magnetic Resonance Imaging (MRI)
879000|NCT02666612|Patients
879001|NCT02666599|F-18-FDG
879002|NCT02666599|neoplasm
879003|NCT02666599|probe
879004|NCT02666599|positron
879005|NCT02666599|diagnosis
879006|NCT02666599|surgery
879007|NCT02666599|radioguided surgery
879008|NCT02666573|drug therapy
879009|NCT02666573|Photosensitizing Agents
879010|NCT02666573|therapeutic use
879011|NCT02666560|Auditory Cueing
879012|NCT02666560|Gait
879013|NCT02666547|68Ga-NODAGA-RGD
879014|NCT02666547|18F-FDG
879015|NCT02666547|18F-FET
879016|NCT02666547|PET/CT
879017|NCT02666547|neoangiogenesis
879018|NCT02666534|Ablative fractional laser
879019|NCT02666534|microinvasive squamous cell carcinoma
879020|NCT02666534|photodynamic therapy
879021|NCT02666521|Primary Health Care
879022|NCT02666508|plaque identifying toothpaste
879023|NCT02666508|plaque score
879024|NCT02666508|C-reactive protein
879025|NCT02666495|Schema Therapy
879026|NCT02666482|smoking
879027|NCT02666482|stop smoking
879028|NCT02666482|tobacco use cessation
879029|NCT02666469|Hyperbaric oxygen treatment, rehabilitation
879030|NCT02666443|brachial plexus
879031|NCT02666443|supraclavicular
879032|NCT02666443|duration
879033|NCT02666443|dexamethasone
879034|NCT02666443|block
879035|NCT02666417|Iron fortification
879036|NCT02666417|Anemia
879037|NCT02666417|Iron Deficiency
879038|NCT02666417|Iron Absorption
879039|NCT02666417|Prebiotics
879040|NCT02666417|Stable isotopes
879041|NCT02666404|Volume Resuscitation
879042|NCT02666404|Shock
879043|NCT02666404|Body Impedance Measurement
879044|NCT02666404|Renal Resistive Index
879045|NCT02666404|Acute Kidney Injury
879046|NCT02666404|Renal Replacement Therapy
879047|NCT02666378|HER-2 Positive Breast Cancer
879048|NCT02666365|anesthesia
879049|NCT02666365|surgical antimicrobial prophylaxis
879050|NCT02666365|surgical site infections
879051|NCT02666339|Hortitherapy
879052|NCT02666339|Care-garden
879053|NCT02666339|Anxiety
879054|NCT02666339|Therapeutic alliance
879055|NCT02666326|Acute Coronary Syndrome
879056|NCT02666326|Prehospital emergency care
879057|NCT02666326|Biological markers
879058|NCT02666326|Copeptin
879059|NCT02666326|Troponin
879060|NCT02666326|Rule-out
879061|NCT02666326|Point-of-Care systems
879062|NCT02666326|Infarction
879063|NCT02666326|Cardiovascular Diseases
879064|NCT02666326|Heart Diseases
879065|NCT02666326|Ischemia
879066|NCT02666326|Myocardial Ischemia
879067|NCT02666326|copeptins
879068|NCT02666326|Troponin T
879069|NCT02666326|Diagnostic Techniques (Cardiovascular)
879070|NCT02666300|Postoperative sore throat,Anesthesia
879071|NCT02666287|Fluticasone furoate
879072|NCT02666287|Chronic obstructive pulmonary disease
879073|NCT02666287|Batefenterol
879074|NCT02666287|Dry Powder Inhaler
879075|NCT02666287|Respiratory
879076|NCT02666287|Pharmacokinetics
879077|NCT02666287|Ellipta
879078|NCT02666287|Healthy Subjects
879079|NCT02666274|carbapenem resistance
879080|NCT02666274|bacterial carriage
879081|NCT02666274|multi-drug resistant gram negative bacteria
879082|NCT02666222|hearing loss
879083|NCT02666222|sensorineural
879084|NCT02666222|hearing implant
879085|NCT02666209|Multiple Myeloma
879086|NCT02666209|Relapsed Multiple Myeloma
879087|NCT02666209|Refractory Multiple Myeloma
879088|NCT02666183|cancer
879089|NCT02666183|caregiver
879090|NCT02666183|videoconferencing
879091|NCT02666157|atrial fibrillation
879092|NCT02666157|stroke
879093|NCT02666157|systemic embolism
879094|NCT02666157|bleeding
879095|NCT02666157|oral anticoagulant
879096|NCT02666131|diabetic foot ulcer
879097|NCT02666131|diabetic complications
879098|NCT02666131|diabetes
879099|NCT02666131|wound healing
879100|NCT02666131|Granexin gel
879101|NCT02666131|FirstString Research
879102|NCT02666118|pain
879103|NCT02666118|pain management
879104|NCT02666118|shoulder repair
879105|NCT02666118|nerve blockade
879106|NCT02666118|regional anesthesia
879107|NCT02666118|pediatrics
879108|NCT02666105|NSCLC
879109|NCT02666092|IgE
879110|NCT02666092|Immunoelectrophoresis
879111|NCT02666092|Western Blot
879112|NCT02666092|ImmunoCAP
879113|NCT02666079|Wide local excision (WLE) for breast cancer
879114|NCT02666027|Fluid monitoring
879115|NCT02666014|PONV
879116|NCT02666014|nausea
879117|NCT02666014|vomiting
879118|NCT02666014|sugammadex
879119|NCT02666014|neostigmine
879120|NCT02665988|Transcranial Direct Current Stimulation
879124|NCT02665962|newly diagnosed patients
879125|NCT02665936|epidural analgesia
879126|NCT02665871|vaccine
879127|NCT02665871|safety
879128|NCT02665871|intranasal administration
879129|NCT02665806|Ciclesonide
879130|NCT02665806|Fluticasone propionate
879131|NCT02665806|Nasal Polyposis
879132|NCT02665806|Chronic Sinuitis
879133|NCT02665806|Chronic rhinosinusitis
879138|NCT02665780|halitosis, periodontal debridement, chemotherapeutics
879139|NCT02665767|Telesonography, Appendix
879140|NCT02665754|Allergic rhinitis
879141|NCT02665754|Injection, intralymphatic
879142|NCT02665754|Immunotherapy
879143|NCT02665754|Dermatophagoides farinae
879144|NCT02665754|Dermatophagoides pteronyssinus
879145|NCT02665754|Dogs
879146|NCT02665754|Cats
879147|NCT02665741|distal colonoscope attachments, colon cancer screening, screening colonoscopy, adenoma detection
879148|NCT02665715|Reactive hypoglycemia
879149|NCT02665715|Hyperinsulinaemia
879150|NCT02665715|Diet
879151|NCT02665715|Glucagon-like Peptide-1
879152|NCT02665715|Glucagon
879153|NCT02665715|Peptide YY
879154|NCT02665715|Ghrelin
879155|NCT02665689|Diabetic Macular Edema, Ranibizumab, Visual Acuity, Diabetic Control,
879156|NCT02665676|Childhood Cancer
879157|NCT02665676|Pediatric Oncology
879158|NCT02665676|Embryonal Neoplasms
879159|NCT02665676|Embryonic Neoplasms
879160|NCT02665676|Embryonic Tumors
879161|NCT02665676|Embryonal Tumors
879162|NCT02665624|Bowel cleansing
879163|NCT02665624|Colonoscopy
879164|NCT02665624|Stewed apricot juice
879165|NCT02665624|Senna
879166|NCT02665598|Posterior Reversible Encephalopathy Syndrome,Prognosis
879167|NCT02665585|carotid disease
879168|NCT02665585|stroke
879169|NCT02665585|stent
879170|NCT02665585|carotid stenting
879174|NCT02665559|HIV
879175|NCT02665559|Hypogonadism
879176|NCT02665559|Metabolic Syndrom
879177|NCT02665559|Reservoirs
879178|NCT02665559|Osteodensitometry
879179|NCT02665559|Erectil dysfonction
879180|NCT02665559|Depression
879181|NCT02665546|Dyspnea
879182|NCT02665546|pulmonary hypertension
879183|NCT02665546|Histiocytosis Langerhans cells
879184|NCT02665546|exercise test
879185|NCT02665533|pain measurement
879186|NCT02665533|edema
879187|NCT02665533|trismus
879188|NCT02665520|stem cells injections
879189|NCT02665520|erectile dysfunction
879190|NCT02665507|Photobiomodulation
879191|NCT02665507|Aviation
879192|NCT02665481|Exercise
879193|NCT02665481|Mindfulness
879194|NCT02665481|Education
879195|NCT02665481|Elderly
879196|NCT02665468|Supported adoption
879197|NCT02665468|Secure messaging
879198|NCT02665468|Patient aligned care team (PACT)
879199|NCT02665468|My HealtheVet Coordinator
879200|NCT02665455|Diabetes Mellitus
879201|NCT02665455|Sensing Technology
879202|NCT02665442|Esophageal Stylet
879203|NCT02665442|EsoSure
879204|NCT02665442|Atrial Fibrillation
879205|NCT02665442|Catheter Ablation
879206|NCT02665442|Mechanical esophageal displacement
879207|NCT02665429|Emergency Medicine
879208|NCT02665390|lung cancer
879209|NCT02665390|Percutaneous cryoablation
879210|NCT02665390|treatment of medically inoperable
879211|NCT02665338|transcranial magnetic stimulation
879212|NCT02665338|fMRI
879213|NCT02665338|cue craving
879214|NCT02665325|TSH-suppressive therapy
879215|NCT02665325|cognitive function
879216|NCT02665312|cardiotoxicity
879217|NCT02665312|fluoropyrimidine
879218|NCT02665312|colorectal cancer
879219|NCT02665299|colon cancer
879220|NCT02665299|colon polyps
879221|NCT02665299|colon adenomas
879222|NCT02665299|colonoscopy
879223|NCT02665299|circulating tumor DNA
879224|NCT02665234|Dry Eye
879225|NCT02665221|Multiple Sclerosis
879226|NCT02665221|erythema
879227|NCT02665208|cigarettes
879228|NCT02665208|smoking
879229|NCT02665208|opiate-dependence
879230|NCT02665208|alcohol
879231|NCT02665208|detoxification
879232|NCT02665182|orchitis
879233|NCT02665182|testicular diseases
879234|NCT02665169|Postural Balance
879235|NCT02665169|Cost-Benefit Analysis
879236|NCT02665169|Morbidity
879237|NCT02665169|Exercise
879238|NCT02665143|acute myeloid leukemia
879239|NCT02665130|COPD
879240|NCT02665130|Pulmonary rehabilitation
879241|NCT02665117|Hypokalemia
879242|NCT02665117|Isoprostanes
879243|NCT02665117|Insulin resistance
879244|NCT02665117|Aldosterone
879245|NCT02665117|Hepatic fat
879246|NCT02665117|Muscle Magnesium
879247|NCT02665117|Liver fat
879248|NCT02665104|Cerebral oxygen saturation
879249|NCT02665104|TCD
879250|NCT02665104|NIRS
879251|NCT02665104|Carotid endarterectomy
879252|NCT02665078|Lung Cancer
879273|NCT02665052|Rehabilitation
879274|NCT02665052|Motor Recovery
879275|NCT02665052|upper extremity
879276|NCT02664987|pain management, pain control, cancer
879277|NCT02664961|TRC105
879278|NCT02664961|CD105
879279|NCT02664961|Endoglin
879280|NCT02664961|Angiogenesis inhibitor
879281|NCT02664961|GTN
879282|NCT02664961|Bevacizumab
879283|NCT02664961|Avastin
879284|NCT02664948|early follow-up
879285|NCT02664948|geriatrics
879286|NCT02664935|NSCLC
879287|NCT02664935|Lung Cancer
879288|NCT02664935|Adenocarcinoma
879289|NCT02664935|Matrix
879290|NCT02664935|SMP2
879291|NCT02664935|Umbrella Trial Design
879292|NCT02664935|Multi-arm
879293|NCT02664922|Electrophysiology
879294|NCT02664922|Anesthetics
879295|NCT02664909|Hip Hemiarthroplasty
879296|NCT02664909|Tranexamic Acid
879297|NCT02664909|Topical
879298|NCT02664909|Blood Transfusion
879299|NCT02664896|Knee pain
879300|NCT02664896|Knee Osteoarthritis
879301|NCT02664870|synovial fluid
879302|NCT02664870|biomarkers
879303|NCT02664857|Vitamin D
879304|NCT02664857|Postoperative Pain
879305|NCT02664857|Mental Motor Retardation
879306|NCT02664844|Obesity
879307|NCT02664844|Appetite regulation
879308|NCT02664844|Insulin sensitivity
879309|NCT02664844|Adolescents
879310|NCT02664844|Exercise
879311|NCT02664831|cardiac arrest
879312|NCT02664831|inflammation
879313|NCT02664831|obesity
879314|NCT02664831|neuregulin
879315|NCT02664831|lipids
879316|NCT02664818|Heart failure
879317|NCT02664818|China
879318|NCT02664818|Registry
879319|NCT02664818|Characteristic
879320|NCT02664818|Outcome
879321|NCT02664792|Non-small cell lung carcinoma
879322|NCT02664792|PET/CT
879323|NCT02664792|18F-FDG
879324|NCT02664766|Heavy drinking
879325|NCT02664766|Heavy drinking cessation
879326|NCT02664766|Alcohol abuse
879327|NCT02664766|alcohol use disorder
879329|NCT02664727|alcohol
879330|NCT02664727|alcohol abuse
879331|NCT02664727|alcohol dependence
879332|NCT02664727|alcohol use disorder
879333|NCT02664727|heavy drinking
879334|NCT02664727|alcohol abuse cessation
879335|NCT02664714|physiotherapy, perineometer, adherence
879336|NCT02664688|spondylolisthesis
879337|NCT02664688|low back pain
879338|NCT02664688|stabilization exercise
879339|NCT02664662|randomized controlled trial, breast cancer, health literacy, tailored education
879340|NCT02664649|TAVR
879341|NCT02664649|Apixaban
879342|NCT02664649|Anticoagulant
879343|NCT02664649|VKA
879344|NCT02664649|Antiplatelet therapy
879345|NCT02664649|Aortic stenosis
879346|NCT02664610|hypertension treatment
879347|NCT02664610|stroke prevention
879348|NCT02664597|ADNEXMR SCORING system
879349|NCT02664597|MRI
879350|NCT02664597|adnexal masses
879351|NCT02664519|Chronic Kidney Disease
879352|NCT02664519|Functional sympatholysis
879353|NCT02664519|Exercise training
879354|NCT02664519|Exercise intolerance
879355|NCT02664519|Handgrip exercise
879356|NCT02664519|Near infrared spectroscopy
879357|NCT02664519|Lower body negative pressure
879358|NCT02664493|kidney transplantation
879359|NCT02664493|subclinical borderline rejection
879360|NCT02664493|steroid pulse therapy
879361|NCT02664480|Salivary Alpha-amylase
879362|NCT02664480|ovulation
879363|NCT02664454|Elderly
879364|NCT02664454|Health care organization
879365|NCT02664454|Primary care
879366|NCT02664441|Obesity
879367|NCT02664441|Drug intervention
879368|NCT02664441|Children
879369|NCT02664441|Adolescents
879370|NCT02664441|Young adults
879371|NCT02664441|Hypothalamic lesion
879372|NCT02664441|Change of weight status
879373|NCT02664441|Food intake
879374|NCT02664441|Energy expenditure
879375|NCT02664441|Hormonal changes
879376|NCT02664441|Glucagon-like peptide-1 agonist
879377|NCT02664441|Bydureon
879378|NCT02664441|Weight Loss
879379|NCT02664441|Energy balance
879380|NCT02664415|Human Monoclonal Antibody
879381|NCT02664402|Palliative Care
879382|NCT02664402|Pain
879383|NCT02664402|Community Health
879384|NCT02664376|sarcopenia
879385|NCT02664376|geriatry
879386|NCT02664311|Pulmonary Vein Isolation
879387|NCT02664311|Jet Ventilation
879388|NCT02664311|Atrial Fibrillation
879389|NCT02664298|severely atrophic jaw
879390|NCT02664298|cranial bone-graft
879391|NCT02664298|dental implants
879392|NCT02664298|immediate loading
879393|NCT02664298|augmentation maxilla/mandible
879394|NCT02664298|sinus-floor elevation/sinuslift
879395|NCT02664298|dental prosthesis
879396|NCT02664298|implant supported
879397|NCT02664298|provisional implants
879398|NCT02664298|temporary implants
879399|NCT02664298|one-stage surgery
879400|NCT02664298|alveolar ridge augmentation
879401|NCT02664298|maxilla
879402|NCT02664259|Endobronchial ultrasonography
879403|NCT02664259|Peripheral pulmonary lesions
879404|NCT02664259|Ultrathin bronchoscopy
879405|NCT02664246|contrast-induced nephropathy
879406|NCT02664246|Percutaneous coronary intervention
879407|NCT02664246|risk factors
879408|NCT02664246|incidence
879409|NCT02664233|Diabetes
879410|NCT02664233|Diabetes Mellitus, Type 2
879411|NCT02664233|obesity
879412|NCT02664233|self-monitoring
879413|NCT02664233|goal setting
879414|NCT02664233|mobile health
879415|NCT02664233|connected health
879416|NCT02664220|Povidone-iodine irrigation
879417|NCT02664207|Myelomeningocele repair
879418|NCT02664207|Open Neural Tube Defect
879419|NCT02664207|BMI of 35-40 kg/m2,
879420|NCT02664207|Open Fetal Surgery
879421|NCT02664207|Elevated body mass index
879422|NCT02664194|Hypothermia
879423|NCT02664194|Rewarming
879424|NCT02664194|Myocardial Infarction
879425|NCT02664194|Percutaneous Cornonary Intervention
879426|NCT02664181|Cancer
879427|NCT02664181|Nivolumab
879428|NCT02664181|Decitabine
879429|NCT02664181|Tetrahydrouridine
879430|NCT02664155|Renal insufficiency
879431|NCT02664155|Direct oral anticoagulants (DOA)
879432|NCT02664155|Deep Vein Thrombosis (DVT)
879433|NCT02664155|Pulmonary Embolism (PE)
879434|NCT02664155|Venous Thromboembolism (VTE)
879435|NCT02664155|Heparins
879436|NCT02664142|General Surgery
879437|NCT02664142|Child
879438|NCT02664142|Anaesthesia
879439|NCT02664142|Depth of anaesthesia
879440|NCT02664142|BIS monitoring
879441|NCT02664116|Severe Migraine Headache
879442|NCT02664090|acute respiratory distress syndrome
879443|NCT02664090|prone ventilation
879444|NCT02664090|trans-esophageal doppler
879445|NCT02664077|NSABP
879446|NCT02664077|Colon cancer
879447|NCT02664077|Regorafenib
879448|NCT02664077|Stage III
879449|NCT02664077|Adjuvant therapy
879450|NCT02664064|prediabetes, weight loss, behavior modification
879451|NCT02664038|AUD
879452|NCT02664038|Neuropsychology
879453|NCT02664038|Cognitive Remediation
879454|NCT02664025|teaching vaginal examination
879455|NCT02664012|adoption
879456|NCT02664012|electronic cigarettes
879457|NCT02664012|e-cigarettes
879458|NCT02664012|menthol
879459|NCT02664012|combustible cigarettes
879460|NCT02664012|nicotine polacrilex
879461|NCT02664012|own brand cigarette
879462|NCT02664012|subjective measures
879463|NCT02664012|pharmacokinetics
879464|NCT02664012|pharmacodynamics
879465|NCT02664012|cigarette
879466|NCT02663999|dose proportionality
879467|NCT02663999|diazepam nasal spray
879468|NCT02663986|Organization, Time Management, and Planning (OTMP)
879469|NCT02663973|Breast cancer
879470|NCT02663960|Regional citrate anticoagulation
879471|NCT02663960|Protocol
879472|NCT02663960|Filter lifespan
879473|NCT02663947|ventriculoperitoneal shunt
879474|NCT02663947|optic nerve sheath diameter
879475|NCT02663947|intracranial pressure
879476|NCT02663934|HIV, AIDS, Cognition, Memory, Exercise, Stretching
879477|NCT02663921|Fitzpatrick Skin-Type
879478|NCT02663921|Melanin
879479|NCT02663921|Ultraviolet Light (UV)
879480|NCT02663882|smoking
879481|NCT02663882|self control
879482|NCT02662738|Blood glucose
879483|NCT02662725|melanoma
879484|NCT02662725|brain metastasis
879485|NCT02662725|stereotactic radiosurgery
879486|NCT02662725|Ipilimumab
879487|NCT02662725|survival
879488|NCT02662725|safety
879489|NCT02662725|efficacy
879490|NCT02662712|Healthy
879491|NCT02662712|Hepatitis, Chronic
879492|NCT02662712|JNJ-56136379
879493|NCT02662712|Placebo
879494|NCT02662699|Anemia
879495|NCT02662699|Hematologic Diseases
879496|NCT02662699|Erythrocytes
879497|NCT02662699|Hemoglobin
879498|NCT02662699|Hemolytic
879499|NCT02662686|Embryo Implantation
879500|NCT02662686|Mitochondrial genes
879501|NCT02662686|Mitochondrial DNA
879502|NCT02662686|MitoScore
879503|NCT02662686|Embryo selection
879504|NCT02662686|Embryo viability
879505|NCT02662686|Embryo biomarker
879506|NCT02662686|Diagnosis of embryo viability in euploids embryos
879507|NCT02662673|HIFU
879508|NCT02662673|Prostate Cancer
879509|NCT02662673|Focal
879510|NCT02662673|Quality of life
879511|NCT02662673|Index study
879512|NCT02662647|demethylating agent
879513|NCT02662647|lymphocyte infusion
879514|NCT02663791|Alcohol
879515|NCT02663791|Aortic stiffness
879516|NCT02663791|Arterial stiffness
879517|NCT02663791|Pulse wave velocity
879518|NCT02663791|Longitudinal
879519|NCT02663752|deferasirox
879520|NCT02663752|MDS
879521|NCT02663752|RNA expression
879522|NCT02663752|predictive biomarker
879523|NCT02663739|Stanford type B aortic dissection
879524|NCT02663739|Malperfusion
879525|NCT02663739|Rupture
879526|NCT02663739|Acute disease
879527|NCT02663739|Endovascular procedures
879528|NCT02663726|Physically inactive
879529|NCT02663726|Older adults
879530|NCT02663713|Pharmacodynamics
879531|NCT02663713|Ticagrelor
879532|NCT02663713|Clopidogrel
879533|NCT02663713|MI
879534|NCT02663700|Burkina Faso
879535|NCT02663700|healthy adults
879536|NCT02663700|Irradiated
879537|NCT02663700|malaria
879538|NCT02663700|PfSPZ Vaccine
879539|NCT02663700|Sanaria
879540|NCT02663700|Sporozoite
879541|NCT02663700|Vaccine
879542|NCT02663674|Pneumonia, Coccidioidomycosis, Fluconazole, FLEET, Parent Study of 16-0008
879543|NCT02663661|Diabetes Mellitus, Type 1 (T1DM)
879544|NCT02663661|TrialNet
879545|NCT02663661|Pathway to Prevention (PTP)
879546|NCT02663661|First and second degree relatives of persons with T1DM
879547|NCT02663661|Insulin-glucagon-glucose (IGG)
879548|NCT02663648|myeloproliferative disorders
879549|NCT02663648|cell cycle regulatory protein
879550|NCT02663609|Cushing's Syndrome
879551|NCT02663609|Mifepristone
879552|NCT02663609|Adrenal
879553|NCT02663609|Retrospective
879554|NCT02663609|Chart Review
879555|NCT02663596|Pediatric
879556|NCT02663596|Continuous Renal Replacement Therapy
879557|NCT02663596|Dialysis
879558|NCT02663596|Therapeutic drug monitoring
879559|NCT02663596|Pharmacokinetics
879560|NCT02663596|Pharmacodynamics
879561|NCT02663583|Oropharynx squamous cell carcinoma
879562|NCT02663583|OPSCC
879563|NCT02663583|Actigraph accelerometer
879564|NCT02663583|MD Anderson Symptom Inventory - Head and Neck module
879565|NCT02663583|MDASI-HN
879566|NCT02663583|Intensity-Modulated Proton Therapy
879567|NCT02663583|IMPT
879568|NCT02663583|TransOral Robotic Surgery
879569|NCT02663583|TORS
879570|NCT02663583|Surveys
879571|NCT02663583|Questionnaires
879572|NCT02663557|stroke, blood pressure, prognosis
879573|NCT02663544|Diabetes
879574|NCT02663544|Metabolic syndrome
879575|NCT02663544|Obesity
879576|NCT02663544|NAFLD
879577|NCT02663492|Acupuncture
879578|NCT02663492|electrical stimulation of acupoints
879579|NCT02663492|chemotherapy
879580|NCT02663492|Diyu Shengbai Pian
879581|NCT02663492|nursing care
879582|NCT02663466|pilonidal sinus
879583|NCT02663466|Limberg flap
879584|NCT02663466|off-midline closure concept
879585|NCT02663466|recurrence
879586|NCT02663453|preterm
879587|NCT02663453|parenteral nutrition
879588|NCT02663453|cholestasis
879589|NCT02663453|fish oil
879590|NCT02663427|pepsinogen Ⅰ
879591|NCT02663427|pepsinogen Ⅱ
879592|NCT02663427|gastric cancer screening
879593|NCT02663427|helicobacter pylori
879594|NCT02663427|gastrin
879595|NCT02663375|TAVI
879596|NCT02663375|Aortic Stenosis
879597|NCT02663375|Transcatheter aortic valve replacement
879598|NCT02663375|Transcatheter aortic valve implantation
879599|NCT02663375|Transapical Access
879600|NCT02663362|magnetic resonance imaging
879601|NCT02663362|magnetic resonance spectroscopy
879602|NCT02663336|masked hypertension, chronic kidney disease
879603|NCT02663323|Coronary Artery Disease
879604|NCT02663323|MeRes-1 Extend
879605|NCT02663323|MeRes100
879606|NCT02663323|Sirolimus Eluting Bioresorbable Vascular Scaffold System
879607|NCT02663310|spinal cord injury
879608|NCT02663310|Kunming Locomotor Scale
879609|NCT02663310|surgical decompression
879610|NCT02663310|untethering
879611|NCT02663310|weight bearing rehabilitation
879612|NCT02663297|CAR T cells
879613|NCT02663297|CD30
879614|NCT02663297|Lymphoma
879615|NCT02663297|T Lymphocytes
879616|NCT02663245|Type 2 diabetes mellitus
879617|NCT02663245|glycemic control
879618|NCT02663232|V600 BRAF mutation
879619|NCT02663232|Metastatic melanoma
879620|NCT02663219|MSM
879621|NCT02663219|ART
879622|NCT02663219|CCM
879623|NCT02663219|DAIDS
879624|NCT02663219|HPTN
879625|NCT02663219|ACA
879626|NCT02663219|PAF
879627|NCT02663219|PEP
879628|NCT02663219|RDS
879629|NCT02663206|spastic esophageal disorders
879630|NCT02663206|achalasia
879631|NCT02663206|diffuse esophageal spasm
879632|NCT02663206|hypercontractile (jackhammer) esophagus
879633|NCT02663206|Botulinum toxin injection
879634|NCT02663206|peroral endoscopic myotomy
879635|NCT02663193|Prostate Cancer
879636|NCT02663193|Observational study
879637|NCT02663193|Enzalutamide
879638|NCT02663193|Abiraterone Acetate
879639|NCT02663193|Prednisone
879640|NCT02663193|Tolerability
879641|NCT02663154|Aromatherapy
879642|NCT02663102|Safety
879643|NCT02663102|Post-marketing
879644|NCT02663102|Korea
879645|NCT02663102|Drug utilization study
879646|NCT02663102|Fluarix Tetra
879647|NCT02663089|total radioactivity
879648|NCT02663089|[14C]-GSK961081
879649|NCT02663089|Pharmacokinetics
879650|NCT02663089|Chronic Obstructive Pulmonary Disease (COPD)
879651|NCT02663089|Microtracer
879652|NCT02663063|Complementary and alternative medicine
879653|NCT02663063|Hospice Palliative Care
879654|NCT02663050|Dysmenorrhea
879655|NCT02663050|kinesio tape
879656|NCT02663037|Segmentation
879657|NCT02663037|Health needs
879658|NCT02662985|Power Doppler Ultrasonography, Psoriatic Arthritis, Enthesitis, Synovitis, Outcome Measures in Rheumatology, Spondyloarthritis Research Consortium of Canada
879659|NCT02662972|Nerve block
879660|NCT02662972|Sphenopalatine Ganglion Block
879661|NCT02662972|Botulinum Toxins, Type A
879662|NCT02662959|Chemotherapy, metastatic gastric cancer, irinotecan
879663|NCT02662907|Head and Neck Cancer
879664|NCT02662907|Post-radiotherapy H&N cancer survivors
879665|NCT02662907|Aspiration
879666|NCT02662907|Expiratory muscle strength training
879667|NCT02662907|EMST
879668|NCT02662907|Dysphagia therapy
879669|NCT02662907|Modified barium swallow
879670|NCT02662907|Neurocognitive exams
879671|NCT02662907|Questionnaires
879672|NCT02662907|Surveys
879673|NCT02662907|Digital Manometer
879674|NCT02662868|Breast cancer
879675|NCT02662868|Metastasis
879676|NCT02662842|infusion set
879677|NCT02662842|continuous subcutaneous insulin infusion
879678|NCT02662829|Lesotho
879679|NCT02662829|tuberculosis
879680|NCT02662829|TB
879681|NCT02662829|HIV
879682|NCT02662829|adherence
879683|NCT02662829|community-based intervention
879684|NCT02662829|retention
879685|NCT02662816|Glutathione
879686|NCT02662816|Liver
879687|NCT02662816|Muscle
879688|NCT02662816|Proton magnetic resonance spectroscopy
879689|NCT02662816|Healthy human
879690|NCT02662803|Generalized Anxiety Disorder
879691|NCT02662803|GAD
879692|NCT02662803|physical exercise
879693|NCT02662803|aerobe exercise
879694|NCT02662803|mental disorder
879695|NCT02662803|high-intensive aerobe exercise
879696|NCT02662777|esophageal anastomosis leakage
879697|NCT02662777|endoscopic vacuum therapy
879698|NCT02662777|esophageal perforation
879699|NCT02662777|upper gastrointestinal tract
879700|NCT02662777|esophageal leak
879701|NCT02662777|endoscopy
879702|NCT02662634|NSCLC
879703|NCT02662634|resectable
879704|NCT02662634|non-small cell lung cancer
879705|NCT02662634|immunotherapy
879706|NCT02662634|autologous
879707|NCT02662634|dendritic cell
879715|NCT02662608|Brontictuzumab
879716|NCT02662595|mHealth
879717|NCT02662595|mobile phones
879718|NCT02662595|measles vaccination
879719|NCT02662582|Chronic Obstructive Pulmonary Disease
879720|NCT02662582|CK-2127107
879721|NCT02662582|COPD
879722|NCT02662543|rotavirus,
879723|NCT02662543|acute gastroenteritis
879724|NCT02662543|vaccination
879725|NCT02662543|Estonia
879726|NCT02662543|impact
879727|NCT02662543|severity scales
879728|NCT02662517|Neurotrophins
879729|NCT02662517|Stem Cells
879730|NCT02662517|Prematurity
879731|NCT02662504|mesothelioma
879732|NCT02662504|multimodal treatment
879733|NCT02662504|PDT
879734|NCT02662504|pleura
879735|NCT02662478|Laparoscopic gastric resection
879736|NCT02662478|gastrointestinal stromal tumor
879737|NCT02662478|laparoscopic surgery
879738|NCT02662465|Interventional
879739|NCT02662465|Treatment
879740|NCT02662465|Laser
879741|NCT02662439|Heart Failure
879742|NCT02662439|Bioimpedance analysis
879743|NCT02662439|Fluid overload
879744|NCT02662426|Seasonal Influenza
879745|NCT02662426|Lingdancao
879746|NCT02662426|RCT
879747|NCT02662361|peri-implant disease; risk factors; prevalence
879748|NCT02662322|Communication
879749|NCT02662322|Confusion
879750|NCT02662322|Intravenous Catheterization
879751|NCT02662322|Comfort
879752|NCT02662309|Muscle invasive bladder cancer
879753|NCT02662309|Transitional cell carcinoma
879754|NCT02662283|IGA Nephropathy
879755|NCT02662283|proteinurien
879756|NCT02662283|Reh-acteoside
879757|NCT02662283|Prednisolone
879758|NCT02662270|Fibromyalgia
879759|NCT02662270|QEEG
879760|NCT02662270|Brain activity
879761|NCT02662270|fMRI
879762|NCT02662270|Diagnosis
879770|NCT02662231|Surgical Site Infection
879771|NCT02662231|General Surgery
879772|NCT02662231|Laparotomy
879773|NCT02662231|Outcome and Process Assessment (Health Care)
879774|NCT02662231|Developing Countries
879775|NCT02662231|International Cooperation
879776|NCT02662231|Specialties, Surgical
879777|NCT02662231|Developed Countries
879778|NCT02662231|Quality of Health Care
879779|NCT02662179|Elderly patients
879780|NCT02662179|Onco-geriatrics
879781|NCT02662179|Fried criteria
879782|NCT02662166|bladder cancer
879783|NCT02662166|MRI
879784|NCT02662166|TUR-BT
879785|NCT02662166|cystectomy
879786|NCT02662166|chemotherapy
879787|NCT02662075|alternative tobacco products (ATPs)
879788|NCT02662075|electronic cigarettes
879789|NCT02662062|Non-metastatic muscle invasive bladder cancer
879790|NCT02662023|Healthy Human Volunteers
879791|NCT02662010|AGEs
879792|NCT02662010|glycemic control
879793|NCT02662010|T2DM
879794|NCT02661997|Tai Chi
879795|NCT02661997|Wellness
879796|NCT02661997|Mind-body
879797|NCT02661997|Gulf War Illness
879798|NCT02661997|Gulf War Veteran's Illness
879799|NCT02661997|GWVI
879800|NCT02661984|FeNO, exhaled nitric oxide
879801|NCT02661958|acne vulgaris
879802|NCT02661958|acne
879803|NCT02661945|near focus with narrow band imaging
879804|NCT02661945|tumor margin
879805|NCT02661945|indigocarmine chromoendoscopy
879806|NCT02661932|Fertility preservation
879807|NCT02661932|letrozole
879808|NCT02661932|Ovarian stimulation
879809|NCT02661919|Epilepsy
879810|NCT02661919|Seizure
879811|NCT02661919|Seizures
879812|NCT02661919|Mattress monitor
879813|NCT02661919|Bed monitor
879814|NCT02661919|Bed alarm
879815|NCT02661919|Generalized tonic-clonic seizure
879816|NCT02661919|GTC
879817|NCT02661893|Healthy
879818|NCT02661893|JNJ-42847922
879819|NCT02661893|Rifampin
879820|NCT02661893|Pharmacokinetics
879821|NCT02661867|Childbirth
879822|NCT02661867|Pelvic organ prolapse
879823|NCT02661867|Urinary incontinence
879824|NCT02661867|Fecal incontinence
879825|NCT02661854|Rhinitis / Rhinoconjunctivitis
879826|NCT02661854|Vaccine
879827|NCT02661854|Immunotherapy
879828|NCT02661854|Mite
879829|NCT02661854|Allergy
879830|NCT02661828|Tapering Antidepressant Regimen
879831|NCT02661828|Antidepressant Discontinuation Syndrome
879832|NCT02661789|Mental health
879833|NCT02661789|Brain Imaging
879834|NCT02661789|Steroid hormones
879835|NCT02661789|Serotonin
879836|NCT02661789|PET
879837|NCT02661789|MRI
879838|NCT02661789|fMRI
879839|NCT02661789|human
879840|NCT02661789|gender
879841|NCT02661789|risk model
879842|NCT02661776|natural killer cell
879843|NCT02661776|head and neck cancer
879844|NCT02661776|opioid
879845|NCT02661763|Rheumatic heart disease
879846|NCT02661750|Cleansing the colon
879847|NCT02661711|Macular Oedema Retinitis Pigmentosa
879848|NCT02661685|Cancer immunotherapy
879849|NCT02661685|IFN-γ-producing killer dendritic cell-like cells
879850|NCT02661685|Natural killer cells
879851|NCT02661672|Intracranial hemorrhage
879852|NCT02661672|Neurosurgery
879853|NCT02661659|mesothelioma
879854|NCT02661659|multipeptide vaccine
879855|NCT02661659|S-588210
879856|NCT02661646|Chronic Swelling
879857|NCT02661646|Leg Lymphedema
879858|NCT02661646|Primary Lymphedema
879859|NCT02661646|Secondary Lymphedema
879860|NCT02661620|REDAPT Femoral System modular stem implant
879861|NCT02661620|Total Hip arthroplasty revision
879862|NCT02661594|TQT
879863|NCT02661594|amisulpride
879864|NCT02661594|volunteer
879865|NCT02661594|ECG
879866|NCT02661581|Diabetes
879867|NCT02661581|Peer Leader Support
879868|NCT02661529|Shunt
879869|NCT02661529|Echocardiogram
879870|NCT02661490|Norovirus
879871|NCT02661464|Healthy
879872|NCT02661464|Ebola viruses
879873|NCT02661464|Ebola virus disease (EVD)
879874|NCT02661464|Filoviruses
879875|NCT02661464|Safety
879876|NCT02661464|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
879877|NCT02661464|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector (MVA‐BN Filo)
879878|NCT02661464|Hemorrhagic fever
879879|NCT02661451|Valve
879880|NCT02661438|Usability Test
879881|NCT02661425|IBS-D
879882|NCT02661425|IBS
879883|NCT02661412|immediate loading
879884|NCT02661412|biological stability
879885|NCT02661412|mechanical stability
879886|NCT02661412|long-term
879887|NCT02661412|marginal bone level
879888|NCT02661412|maxilla
879889|NCT02661412|immediate placement
879890|NCT02661412|dental implant
879891|NCT02661412|fibre-reinforced provisional fixed prosthesis
879892|NCT02661399|CIPN
879893|NCT02661373|Antimalarial
879894|NCT02661373|First-in-Human
879895|NCT02661373|Pharmacokinetic
879896|NCT02661360|swaddling
879897|NCT02661347|First Episode
879898|NCT02661347|Schizophreniform
879899|NCT02661347|Schizoaffective Disorder
879900|NCT02661347|Psychosis
879901|NCT02661347|Schizophrenia
879902|NCT02661347|tDCS
879903|NCT02661347|Risperidone
879904|NCT02661347|Anti-psychotic medication
879905|NCT02661334|creatine
879906|NCT02661334|creatine monohydrate
879907|NCT02661334|supplement
879908|NCT02661334|exercise
879909|NCT02661334|fitness
879910|NCT02661282|Glioblastoma
879911|NCT02661282|Gliosarcoma
879912|NCT02661282|Brain tumor
879913|NCT02661282|Cytomegalovirus stimulated adoptive T cells
879914|NCT02661282|CMV
879915|NCT02661282|Temozolomide
879916|NCT02661282|Temodar
879917|NCT02661282|TMZ
879918|NCT02661282|Phone call
879919|NCT02661282|T cell infusion
879920|NCT02661282|Surgery
879921|NCT02661256|pharyngeal swallow
879922|NCT02661256|airway compromise
879923|NCT02661256|NICU
879924|NCT02661243|Sjogren's Syndrome
879925|NCT02661243|Dental Implants
879926|NCT02661230|exergaming
879927|NCT02661230|intensive care unit
879928|NCT02661230|feasibility acceptability
879929|NCT02661230|heart
879930|NCT02661230|brain function
879931|NCT02661217|Acute decompensated heart failure
879932|NCT02661217|Reduced ejection fraction
879933|NCT02661217|Pre-discharge treatment
879934|NCT02661217|Post-discharge treatment
879935|NCT02661217|Angiotensin receptor neprilysine inhibitor
879936|NCT02661217|HFrEF
879937|NCT02661191|asthma
879938|NCT02661191|vitamin D
879939|NCT02661191|exacerbations
879940|NCT02661191|airway obstruction
879941|NCT02661178|Parasitic Diseases
879942|NCT02661178|Helminthiasis
879943|NCT02661178|Nematode Infections
879944|NCT02661178|Secernentea Infections
879945|NCT02661178|Spirurida Infections
879946|NCT02661178|Filariasis
879947|NCT02661178|Skin Diseases, Parasitic
879948|NCT02661178|Skin and Connective Tissue Diseases
879949|NCT02661178|Skin Diseases
879950|NCT02661178|Skin Diseases, Infectious
879951|NCT02661178|Depsipeptides
879952|NCT02661178|Emodepside
879953|NCT02661178|Neglected disease
879954|NCT02661178|Africa
879955|NCT02661178|New drug
879956|NCT02661178|Oral drug
879957|NCT02661178|Parasite
879958|NCT02661178|Anthelmintic drug
879959|NCT02661178|Cyclooctadepsipeptide
879960|NCT02661178|Single ascending dose
879961|NCT02661178|Volunteers
879962|NCT02661178|Phase 1
879963|NCT02661178|Safety
879964|NCT02661178|Tolerability
879965|NCT02661178|Pharmacokinetics
879966|NCT02661178|Relative bioavailability
879967|NCT02661178|Onchocerciasis
879968|NCT02661139|bisphosphonates and/or targeted therapy by monoclonal antibodies
879969|NCT02661139|jaw reconstruction
879970|NCT02661139|prosthetic rehabilitation
879971|NCT02661139|quality of life
879972|NCT02661113|Brain
879973|NCT02661113|CNS Disease
879974|NCT02661113|CNS
879975|NCT02661113|Intracranial Supratentorial GBM
879976|NCT02661113|Gliosarcoma
879977|NCT02661113|GS
879978|NCT02661113|Glioblastoma
879979|NCT02661113|GBM
879980|NCT02661113|Dasatinib
879981|NCT02661113|Sprycel
879982|NCT02661113|Temozolomide
879983|NCT02661113|TMZ
879984|NCT02661113|Temodar
879985|NCT02661113|Radiation Therapy
879986|NCT02661113|Radiotherapy
879987|NCT02661113|RT
879988|NCT02661100|Vaccine
879989|NCT02661100|NY-ESO-1
879990|NCT02661100|DEC-205
879991|NCT02661100|Poly-ICLC
879992|NCT02661100|Pembrolizumab
879993|NCT02661100|Cancer
879994|NCT02661087|submucosal myoma
879995|NCT02661087|hysteroscopic resection
879996|NCT02661087|bipolar energy
879997|NCT02661087|monopolar energy
879998|NCT02661074|Fisherman
879999|NCT02661074|Fish industry
880000|NCT02661061|ketamine
880001|NCT02661061|glutamate
880002|NCT02661061|relapse prevention
880003|NCT02661035|AML
880004|NCT02661035|ALL
880005|NCT02661035|CML
880006|NCT02661035|MDS
880007|NCT02661035|CLL
880008|NCT02661035|SLL
880009|NCT02661035|NHL
880010|NCT02661009|NSCLC
880011|NCT02661009|EGFR
880012|NCT02661009|EGFR-TKI
880013|NCT02661009|PCR
880014|NCT02660970|Iberogast
880015|NCT02660970|Acupressure
880016|NCT02660970|gut-brain-axis
880017|NCT02660957|Smoking cessation
880018|NCT02660931|Pediatrics
880019|NCT02660905|HIV-HCV co-infected
880020|NCT02660905|HCV
880021|NCT02660905|HIV
880022|NCT02660905|Hep C
880023|NCT02660905|Hepatitis C
880024|NCT02660905|HCV positive
880025|NCT02660892|IAAO
880026|NCT02660892|Threonine
880027|NCT02660892|Children
880028|NCT02660879|Education
880029|NCT02660879|Inhaler
880030|NCT02660866|intermittent claudication
880031|NCT02660866|randomized controlled trial
880032|NCT02660853|Exacerbations
880033|NCT02660814|Chemerin
880034|NCT02660814|Interleukin-6
880035|NCT02660814|Gingival crevicular fluid
880036|NCT02660801|spinal manipulation
880037|NCT02660801|spinal mobilization
880038|NCT02660801|spinal stiffness
880039|NCT02660788|6-24 months overdue
880040|NCT02660788|screening mammography
880041|NCT02660775|schizophrenia
880042|NCT02660736|Albiglutide
880043|NCT02660736|Randomized
880044|NCT02660736|Pharmacokinetics
880045|NCT02660736|GSK716155
880046|NCT02660736|Bioequivalence study
880047|NCT02660723|M01.774.500
880048|NCT02660723|Volunteers
880049|NCT02660710|single arm phase 2
880050|NCT02660710|safety and efficacy
880051|NCT02660710|R-CHOP
880052|NCT02660697|socket preservation, implant site development
880053|NCT02660684|Prograf
880054|NCT02660684|Graft versus host disease
880055|NCT02660684|Hematopoietic stem cell transplantation
880056|NCT02660684|Prophylaxis
880057|NCT02660684|Peripheral hematopoietic stem cell transplantation
880058|NCT02660645|Cysview
880059|NCT02660645|Hexaminolevulinate
880060|NCT02660645|Hexvix
880061|NCT02660645|NMIBC
880062|NCT02660645|BLCC
880063|NCT02660645|Blue Light Cystoscopy with Cysview
880064|NCT02660645|Cystoscopy
880065|NCT02660645|TURBT
880066|NCT02660645|TUR
880067|NCT02660645|Fluorescent cystoscopy
880068|NCT02660645|Non-muscle invasive bladder cancer (NMIBC)
880069|NCT02660645|Transurethral resection (TUR)
880070|NCT02660593|Diabetes Mellitus
880071|NCT02660593|Chinese medicine
880072|NCT02660593|exercise
880073|NCT02660593|diet
880074|NCT02660580|Adalimumab
880075|NCT02660580|MSB11022
880076|NCT02660580|Psoriasis
880077|NCT02660580|Phase III
880078|NCT02660567|postpartum hemorrhage
880079|NCT02660567|PPH
880080|NCT02660567|atonic
880081|NCT02660567|new maneuver
880082|NCT02660554|Pneumonia
880083|NCT02660554|Methicillin-Resistant Staphylococcus aureus
880084|NCT02660554|Polymerase Chain Reaction
880085|NCT02660554|Intensive care units
880086|NCT02660554|Drug Resistance
880087|NCT02660541|Dressing for burn wounds
880088|NCT02660515|complete articular distal radius fracture
880089|NCT02660515|wrist arthroscopy
880090|NCT02660489|CRTH2 antagonist
880091|NCT02660489|Prostaglandin D2 receptor
880092|NCT02660489|Anti-Asthmatic Agents
880093|NCT02660489|OC459
880094|NCT02660489|Allergic asthma
880095|NCT02660489|Eosinophilia
880096|NCT02660476|Diet
880097|NCT02660476|Middle East and North Africa country
880098|NCT02660476|Health
880099|NCT02660476|Complication
880100|NCT02660476|Cardiovascular disease
880101|NCT02660476|Obesity
880102|NCT02660476|Stress
880103|NCT02660476|Obstructive Sleep Apnoea (OSA)
880104|NCT02660463|incidence
880105|NCT02660463|risk factors
880106|NCT02660437|COPD
880107|NCT02660437|Carbon dioxide partial pressure (pCO2)
880108|NCT02660437|Cerebral blood flow (CBF)
880109|NCT02660437|Cognitive dysfunction
880110|NCT02660437|Mild/Moderate Cognitive Impairment (MCI)
880111|NCT02660437|Pulmonary Rehabilitation (PR)
880112|NCT02660437|Standardized Mini Mental State Examination (SMMSE)
880113|NCT02660437|Addenbrooke's Cognitive Examination (ACE-R)
880114|NCT02660437|Montreal Cognitive Assessment (MoCA)
880115|NCT02660437|Telephone Interview for Cognitive Status (TICS)
880116|NCT02660437|Stroop test (Reaction Time)
880123|NCT02660385|pain
880124|NCT02660385|insomnia
880125|NCT02660385|cardiac failure
880126|NCT02660385|sleep
880127|NCT02660385|fatigue
880128|NCT02660385|heart disease
880129|NCT02660385|anxiety
880130|NCT02660385|actigraphy
880131|NCT02660385|psychomotor vigilance
880132|NCT02660385|six minute walk
880133|NCT02660385|depression
880134|NCT02660385|cognitive behavioral therapy
880135|NCT02660385|self-management
880136|NCT02660385|self-care
880137|NCT02660346|IL-10
880138|NCT02660346|MRSA
880139|NCT02660346|Bacteremia
880140|NCT02660333|Obesity
880141|NCT02660333|Inflammation
880142|NCT02660333|Nutritional status
880143|NCT02660333|Prebiotic
880144|NCT02660333|Synbiotic
880145|NCT02660307|stress
880146|NCT02660307|work
880147|NCT02660307|employees
880148|NCT02660307|mindfulness
880149|NCT02660307|depression
880150|NCT02660307|anxiety
880151|NCT02660268|Clinical pathway
880152|NCT02660268|Infection
880153|NCT02660268|Hip
880154|NCT02660268|Prosthesis
880155|NCT02660255|CBD
880156|NCT02660255|Epidiolex
880157|NCT02660255|Myoclonic
880158|NCT02660255|Brain Disease
880159|NCT02660255|Central Nervous System Disease
880160|NCT02660255|GWP42003
880161|NCT02660242|T1D
880162|NCT02660242|Type 1 Diabetes
880163|NCT02660242|Mini-dose Glucagon
880164|NCT02660242|Adults
880165|NCT02660242|Exercise
880166|NCT02660242|Hypoglycemia
880167|NCT02660229|Intravenous injection in cancer pain
880168|NCT02660216|minimally invasive
880169|NCT02660216|le fort I osteotomy
880170|NCT02660216|3D virtual treatment planning
880171|NCT02660216|accuracy
880172|NCT02660203|chest physiotherapy
880173|NCT02660203|post operative period
880174|NCT02660203|forced expiration
880175|NCT02660203|pleural drainage duration
880176|NCT02660164|Concussion
880177|NCT02660125|ICSI
880178|NCT02660125|endometrial injury
880179|NCT02660125|implantation rate
880180|NCT02660086|Weight
880181|NCT02660086|Prevention
880182|NCT02660086|Food choice
880183|NCT02660086|Nutrition
880184|NCT02660086|Behavior change
880185|NCT02660086|Behavioral economics
880186|NCT02660086|Feedback
880187|NCT02660086|Incentives
880188|NCT02660060|Pramipexole
880189|NCT02660060|Bioequivalence
880190|NCT02660060|Pharmacokinetics
880191|NCT02660047|South Asian descent
880192|NCT02660034|Dose Escalation
880193|NCT02660034|Dose Expansion
880194|NCT02660034|BGB-A317
880195|NCT02660034|BGB-290
880196|NCT02660021|three-dimensional virtual treatment planning
880197|NCT02660021|orthognathic surgery
880198|NCT02659995|glycemic variability
880199|NCT02659995|infection
880200|NCT02659956|Multiple Sclerosis
880201|NCT02659956|Longitudinal Prospective Follow-Up
880202|NCT02659943|Gene Therapy
880203|NCT02659943|Adoptive T Cell Therapy
880204|NCT02659943|Allogeneic Stem Cell Transplantation
880205|NCT02659943|T-cell infusion
880206|NCT02659943|Residual Malignancy
880207|NCT02659930|HIV
880208|NCT02659930|AIDS
880209|NCT02659930|Multicentric Castleman Disease
880210|NCT02659917|glass-ionomer cement
880211|NCT02659917|atraumatic restorative treatment
880212|NCT02659917|pit and fissure sealants
880213|NCT02659904|Free gingival graft
880214|NCT02659904|Palatal donor site healing
880215|NCT02659878|Takotsubo cardiomyopathy;NT-proBNP;urine metanephrine
880216|NCT02659852|Hilar malignant biliary obstruction
880217|NCT02659852|bilateral metal stent
880218|NCT02659852|stent in stent
880219|NCT02659852|side by side
880220|NCT02659839|Cancer
880221|NCT02659839|Intensive care unit
880222|NCT02659839|Mortality
880223|NCT02659826|Transcutaneous spinal direct current stimulation
880224|NCT02659826|Transcranial Magnetic Stimulation
880225|NCT02659826|Gait Training
880226|NCT02659826|Central Nervous System Excitability
880227|NCT02659826|Healthy
880228|NCT02659813|Orthodontic wires
880229|NCT02659774|Smoking cessation interventions
880230|NCT02659761|Human Immunodeficiency Virus
880231|NCT02659761|Injection drug use
880232|NCT02659761|Single-tablet antiretroviral treatment
880233|NCT02659761|Dolutegravir
880234|NCT02659761|Tolerability
880235|NCT02659761|Adherence
880236|NCT02659761|Efficacy
880237|NCT02659748|Bioactive fatty acids
880238|NCT02659748|Insulin sensitivity
880239|NCT02659748|Diet
880240|NCT02659748|Milk fat
880241|NCT02659748|Lipid metabolism
880242|NCT02659748|Inflammation markers
880243|NCT02659748|Fecal microbiota composition
880244|NCT02659735|Influenza A virus
880245|NCT02659735|JNJ-63623872
880246|NCT02659735|Healthy
880247|NCT02659722|INTERVERTEBRAL DISC DEGENERATION
880248|NCT02659722|Bone Disease
880249|NCT02659722|Musculoskeletal disease
880250|NCT02659722|Spinal disease
880251|NCT02659709|Glaucoma
880252|NCT02659709|Smartphone
880253|NCT02659709|Tablet
880254|NCT02659709|Application
880255|NCT02659631|P-cadherin
880256|NCT02659631|PF-06671008
880257|NCT02659631|solid tumors
880258|NCT02659631|lung cancer
880259|NCT02659631|breast cancer
880260|NCT02659631|colorectal cancer
880261|NCT02659631|NSCLC
880262|NCT02659631|TNBC
880263|NCT02659631|CRC
880264|NCT02659631|neoplasms
880265|NCT02659631|Triple negative breast cancer
880266|NCT02659631|Non-small cell lung cancer
880267|NCT02659618|Asthma
880268|NCT02659605|pre-term birth
880269|NCT02659605|delayed cord clamping
880270|NCT02659605|skin to skin
880271|NCT02659592|fertility preservation
880272|NCT02659592|ovarian tissue transplantation
880273|NCT02659592|ovarian endocrine function
880274|NCT02659592|assisted reproductive technology
880275|NCT02659592|pregnancy and live birth
880276|NCT02659579|Shared Book Reading
880277|NCT02659579|Vocabulary
880278|NCT02659579|Language Development
880279|NCT02659579|Young Children
880280|NCT02659579|Randomised Control Trial
880281|NCT02659566|Markers
880282|NCT02659566|Parasitemia
880283|NCT02659566|Coartem
880284|NCT02659566|Plasmodium
880285|NCT02659566|Infection
880286|NCT02659553|Liver Transplantation - Steatosis - Fatty Liver
880287|NCT02659540|Ipilimumab
880288|NCT02659540|Nivolumab
880289|NCT02659540|Radiotherapy
880290|NCT02659514|Poziotinib
880291|NCT02659514|Metastatic Breast Cancer
880292|NCT02659514|HER2-positive
880293|NCT02659514|Pan-HER inhibitor
880294|NCT02659501|Breast reconstruction
880295|NCT02659501|Bupivacaine
880296|NCT02659501|Liposomal bupivacaine
880297|NCT02659501|Postoperative analgesia
880298|NCT02659462|Repaired Congenital Heart Disease
880299|NCT02659462|Cardio Pulmonary Exercise Testing
880300|NCT02659462|Fontan
880301|NCT02659462|Fontan Palliation
880302|NCT02659462|functional capacity
880303|NCT02659449|hands
880304|NCT02659436|Cognitive Behavioural Therapy
880305|NCT02659423|Bystanding behaviors
880306|NCT02659423|Campus
880307|NCT02659423|Prevention
880308|NCT02659423|Sexual Assault
880309|NCT02659423|CampusSave
880310|NCT02659410|Physiologically based pharmacokinetic modeling
880311|NCT02659410|Organic solvents
880312|NCT02659397|LDL-cholesterol
880313|NCT02659397|Hypercholesterolemia
880314|NCT02659397|ETC-1002
880315|NCT02659397|Adenosine triphosphate citrate lyase
880316|NCT02659397|Atorvastatin
880317|NCT02659358|Advanced solid malignancy
880318|NCT02659358|Activity monitor
880319|NCT02659358|Biosensor
880320|NCT02659358|Fitbit
880321|NCT02659358|Patient Reported Outcomes (PRO)
880322|NCT02659358|Stage 3/4 cancer
880323|NCT02659358|Performance Status
880324|NCT02659358|Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
880325|NCT02659345|Art Therapy
880326|NCT02659345|Chemotherapy
880327|NCT02659319|Child overweight
880328|NCT02659319|Child obesity
880329|NCT02659319|Family dynamics
880330|NCT02659319|Peer relationships
880331|NCT02659319|Family intervention
880332|NCT02659319|School intervention
880333|NCT02659319|Parenting
880334|NCT02659293|Multiple myeloma
880335|NCT02659293|stem-cell transplant
880336|NCT02659293|Symptomatic myeloma
880337|NCT02659293|lenalidomide
880338|NCT02659293|carfilzomib
880339|NCT02659293|dexamethasone
880340|NCT02659280|telerehabilitation
880341|NCT02659267|Health Promotion
880342|NCT02659267|Physical Activity
880343|NCT02659267|Eating habits
880344|NCT02659267|Health System
880345|NCT02659267|Users from Health Academy Program
880346|NCT02659254|Drug-Eluting Stents,Absorbable Implants,Stents
880347|NCT02659241|Molecular results
880348|NCT02659241|DNA
880349|NCT02659241|RNA
880350|NCT02659241|Protein expression
880351|NCT02659241|AZD1775
880352|NCT02659215|Hyaluronic Acid
880353|NCT02659215|Cartilage Repair
880354|NCT02659215|Knee
880355|NCT02659202|Exercise
880356|NCT02659202|Heart Failure
880357|NCT02659202|Blood Pressure
880358|NCT02659163|cardiometabolic risk
880359|NCT02659163|obesity
880360|NCT02659163|mHealth
880361|NCT02659163|health behaviors
880362|NCT02659150|tocilizumab
880363|NCT02659150|subcutaneous injection
880364|NCT02659150|rheumatoid arthritis
880365|NCT02659150|plaque inflammation
880366|NCT02659150|atherosclerotic plaque
880367|NCT02659150|joint inflammation
880368|NCT02659150|FDG-PET
880369|NCT02659150|PET-MR
880370|NCT02659150|ACTEMRA
880371|NCT02659137|LBBB
880372|NCT02659137|TAVI
880373|NCT02659124|facial laser
880374|NCT02659124|fraction ablative resurfacing
880375|NCT02659124|total ablative resurfacing
880376|NCT02659124|EpiFix
880377|NCT02659124|rhytides
880378|NCT02659124|wrinkles
880379|NCT02659124|AmnioFix
880380|NCT02659111|Exercise Therapy
880381|NCT02659098|Best Corrected Visual Acuity
880382|NCT02659098|Geographic Atrophy
880383|NCT02659098|Macular Degeneration
880384|NCT02659098|CNTO 2476
880385|NCT02659085|Depressive Disorder, Major
880386|NCT02659085|Antidepressive Agents/adverse effects
880387|NCT02659085|Depressive Disorder, Major/drug therapy
880388|NCT02659085|Infusions, Intravenous
880389|NCT02659085|Ketamine/administration & dosage*
880390|NCT02659085|Ketamine/adverse effects
880391|NCT02659085|Treatment Outcome
880392|NCT02659085|Electroconvulsive therapy
880393|NCT02659046|Traumatic Brain Injury
880394|NCT02659033|microbiota
880395|NCT02659033|resistant bacteria
880396|NCT02659007|yoga
880397|NCT02659007|balance
880398|NCT02658968|Radioimmunotherapy
880399|NCT02658968|Lu-177
880400|NCT02658968|Phase I study
880401|NCT02658968|Betalutin
880402|NCT02658968|ARC
880403|NCT02658968|Antibody Radionuclide Conjugate
880404|NCT02658968|HH1
880405|NCT02658968|Rituximab
880406|NCT02658968|177Lu-DOTA-HH1
880407|NCT02658968|Lilotomab
880408|NCT02658968|Lutetium (177Lu)-lilotomab satetraxetan
880409|NCT02658968|Additional relevant MeSH terms:
880410|NCT02658968|Lymphoma
880411|NCT02658968|Lymphoma, Non-Hodgkin
880412|NCT02658968|Immune System Diseases
880413|NCT02658968|Immunoproliferative Disorders
880414|NCT02658968|Diffuse Large B-Cell Lymphoma
880415|NCT02658968|Lymphatic Diseases
880416|NCT02658968|Lymphoproliferative Disorders
880417|NCT02658968|Neoplasms
880418|NCT02658968|Neoplasms by Histologic Type
880419|NCT02658968|DLBCL
880420|NCT02658968|Refractory DLBCL
880421|NCT02658968|Relapsed DLBCL
880422|NCT02658955|Abdominal wall closure
880423|NCT02658942|renal stones
880424|NCT02658942|lower calyx
880425|NCT02658942|Ureteroscopy
880426|NCT02658942|Shockwave lithotripsy
880427|NCT02658942|Holmium laser
880428|NCT02658942|Adult
880429|NCT02658942|Kidney
880430|NCT02658903|Foley
880431|NCT02658903|Infection
880432|NCT02658903|Hospital acquired
880433|NCT02658903|catheter associated
880434|NCT02658903|urinary
880435|NCT02658877|Xolair
880436|NCT02658877|corticosteroids
880437|NCT02658877|asthma
880438|NCT02658877|long-acting beta-agonists
880439|NCT02658864|lafutidine tablet
880440|NCT02658864|pharmacokinetics
880441|NCT02658864|food
880442|NCT02658864|safety
880443|NCT02658864|healthy subjects
880444|NCT02658851|lymphocele
880445|NCT02658851|pelvic lymph node dissection
880446|NCT02658851|robotic assisted radical prostatectomy
880447|NCT02658851|PLND
880448|NCT02658851|RARP
880449|NCT02658851|prostatectomy
880450|NCT02658851|Patel
880451|NCT02658825|Healthy
880452|NCT02658825|JNJ-63623872
880453|NCT02658825|Moxifloxacin
880454|NCT02658812|Breast Cancer
880455|NCT02658812|Inflammatory breast cancer
880456|NCT02658812|IBC
880457|NCT02658812|Non-inflammatory breast cancer
880458|NCT02658812|Inoperable local recurrence
880459|NCT02658812|Talimogene laherparepvec
880460|NCT02658812|T-VEC
880461|NCT02658812|OncoVEX GM-CSF
880462|NCT02658799|periodontitis
880463|NCT02658799|anti-inflammatory agents
880464|NCT02658760|Femoral Fractures
880465|NCT02658721|Systemic Tramadol
880466|NCT02658721|Adjunct Tramadol
880467|NCT02658721|Lidocain
880468|NCT02658695|ICSI
880469|NCT02658695|embryo transfer
880470|NCT02658695|air bubbles depth
880471|NCT02658669|Insomnia
880472|NCT02658669|Injury, Brain, Traumatic Mild
880473|NCT02658656|Exoskeleton
880474|NCT02658643|biliodigestive anastomosis techniques
880475|NCT02658630|arm rehabilitation
880476|NCT02658630|recovery of function
880477|NCT02658617|Empathy
880478|NCT02658617|Interoceptive Awareness
880479|NCT02658617|fMRI
880480|NCT02658617|MRS
880481|NCT02658591|Food intake
880482|NCT02658591|Satiety
880483|NCT02658591|Appetite
880484|NCT02658591|Glycemia
880485|NCT02658591|Faba bean
880486|NCT02658591|Protein
880487|NCT02658591|Snack
880488|NCT02658565|Intraoperative Consultation
880489|NCT02658552|HIFU
880490|NCT02658552|Benign thyroid nodule
880491|NCT02658552|Low risk
880492|NCT02658552|New treatment
880493|NCT02658539|Body fat distribution
880494|NCT02658539|Bone mineral density
880495|NCT02658539|Dual-energy x-ray absorptiometry
880496|NCT02658526|cognition
880497|NCT02658526|anesthesia
880498|NCT02658526|surgery
880499|NCT02658526|stress
880500|NCT02658526|child
880501|NCT02658500|early infant feeding
880502|NCT02658500|infant intestinal flora
880503|NCT02658500|infant health
880504|NCT02658474|Chronic pain
880505|NCT02658474|Acceptance and Commitment Therapy
880506|NCT02658474|Multidisciplinary treatment
880507|NCT02658474|Group treatment
880508|NCT02658435|Malaria
880509|NCT02658435|Retinal
880510|NCT02658435|Ophthalmic
880511|NCT02658435|Plasmodium. vivax
880512|NCT02658435|Tafenoquine
880513|NCT02658435|Pharmacodynamic
880514|NCT02658409|CCIV
880515|NCT02658409|quadrivalent cell-culture based influenza vaccine
880516|NCT02658409|Influenza vaccine
880517|NCT02658409|Vaccination
880518|NCT02658396|Multiple Myeloma
880519|NCT02658396|Relapsed Multiple Myeloma
880520|NCT02658396|Refractory Multiple Myeloma
880521|NCT02658370|physical exercises
880522|NCT02658370|physical therapy
880523|NCT02658370|Wii game console
880524|NCT02658370|patients perspective
880525|NCT02658344|Stem cell
880526|NCT02658344|adipose tissue derived mesenchymal stem cell
880527|NCT02658344|osteoarthritis
880528|NCT02658344|degenerative arthritis
880529|NCT02658344|biostar
880530|NCT02658344|Rbio
880531|NCT02658331|Ebola Virus Disease
880532|NCT02658331|Rapid Diagnosis
880533|NCT02658331|Point of care
880534|NCT02658331|Molecular platform
880535|NCT02658318|peri- and postoperative complications
880536|NCT02658318|airway obstruction
880537|NCT02658318|adapted Furlow palatoplasty
880538|NCT02658305|transoral approach
880539|NCT02658305|transbuccal approach
880540|NCT02658305|postoperative complications
880541|NCT02658292|fungus
880542|NCT02658292|antifungal
880543|NCT02658292|skin infection
880544|NCT02658292|hair infection
880545|NCT02658292|dermatophyte
880546|NCT02658292|scalp
880547|NCT02658292|skin
880548|NCT02658292|eyebrows
880549|NCT02658292|eyelashes
880550|NCT02658292|hair
880551|NCT02658292|Trichophyton
880552|NCT02658292|Microsporum
880553|NCT02658292|Endothrix
880554|NCT02658292|spores
880555|NCT02658279|Pembrolizumab (MK-3475)
880556|NCT02658279|15-227
880557|NCT02658279|Hypermutator Phenotype
880558|NCT02658266|resistance training
880559|NCT02658266|adult
880560|NCT02658266|muscle strength
880561|NCT02658266|muscle endurance
880562|NCT02658266|muscle metabolism
880563|NCT02658253|Placental malaria vaccine
880564|NCT02658253|Plasmodium
880565|NCT02658253|PRIMALVAC
880566|NCT02658240|Nerve block
880567|NCT02658240|Periarticular infiltration
880568|NCT02658240|Ropivacaine
880569|NCT02658240|Pain
880570|NCT02658214|durvalumab, MEDI4736, tremelimumab, small-cell lung, head and neck, triple negative breast, gastric/GEJ or ovarian cancer, immuno oncology, first-line chemo
880571|NCT02658188|Restless legs syndrome patients
880572|NCT02658188|ASP8825
880573|NCT02658188|XP13512
880574|NCT02658110|Postprandial glycemia
880575|NCT02658110|Metabolic health measures
880576|NCT02658097|Lung Cancer
880577|NCT02658097|pembrolizumab
880578|NCT02658097|focal radiation
880579|NCT02658097|RT
880580|NCT02658084|HER2-Positive
880581|NCT02658084|Metastatic Breast Cancer
880582|NCT02658071|exfoliative glaucoma
880583|NCT02658071|cataract
880584|NCT02658071|ocular pressure
880585|NCT02658058|Ultrasound
880586|NCT02658058|Spinal anesthesia
880587|NCT02658058|Elderly
880588|NCT02658058|Landmark
880589|NCT02658045|oxygen saturation
880590|NCT02658045|monitoring
880591|NCT02658045|oximeter
880592|NCT02658019|Hepatocellular Carcinoma
880593|NCT02658019|Advanced Hepatocellular Carcinoma
880594|NCT02658019|Unresectable Hepatocellular Carcinoma
880595|NCT02658006|Near Infrared Spectroscopy
880596|NCT02658006|Ultrasonography
880597|NCT02658006|Hepatic vein Doppler
880598|NCT02658006|Portal vein Doppler
880599|NCT02658006|Lung ultrasound
880600|NCT02658006|Positive fluid balance
880601|NCT02658006|Mixed venous saturation
880602|NCT02657993|Breast Neoplasms
880603|NCT02657993|Aromatase Inhibitors
880604|NCT02657993|Musculoskeletal Pain
880605|NCT02657993|Hypnosis
880606|NCT02657993|Medication Adherence
880607|NCT02657993|Cost-Benefit Analysis
880608|NCT02657993|Treatment Outcomes
880609|NCT02657980|Major Depressive Disorder
880610|NCT02657980|tDCS
880611|NCT02657980|MDD
880612|NCT02657980|transcranial Direct Current Stimulation
880613|NCT02657954|Homeless persons
880614|NCT02657954|Veterans
880615|NCT02657954|Mental disorders
880616|NCT02657954|Cognition
880617|NCT02657954|Rehabilitation
880618|NCT02657941|Schizophrenia
880619|NCT02657941|Obesity
880620|NCT02657941|Metabolic Syndrome
880621|NCT02657915|FF-VEP
880622|NCT02657915|mfVEP
880623|NCT02657915|Human anti-LINGO-1
880624|NCT02657915|BIIB033
880625|NCT02657915|AON
880626|NCT02657889|PARP inhibitor
880627|NCT02657889|PD-1
880628|NCT02657889|Niraparib
880629|NCT02657889|Pembrolizumab
880630|NCT02657889|Keynote
880631|NCT02657889|TOPACIO
880632|NCT02657837|CF
880633|NCT02657837|Multiple Breath Washout
880634|NCT02657837|Lung Clearance Index
880635|NCT02657837|Pediatrics
880636|NCT02657824|Ejection fraction
880637|NCT02657824|mitral valve
880638|NCT02657824|e-point septal separation
880639|NCT02657811|Time-Lapse Imaging
880640|NCT02657811|Embryo Culture Techniques
880641|NCT02657811|Fertilization in Vitro
880642|NCT02657811|Embryology
880643|NCT02657811|Assisted Reproductive Techniques
880644|NCT02657811|Infertility
880645|NCT02657811|Preimplantation diagnosis
880646|NCT02657772|Target Ultra coils
880647|NCT02657772|small aneurysms
880648|NCT02657746|blood pressure monitoring
880649|NCT02657746|high blood pressure
880650|NCT02657746|cardiovascular disease
880651|NCT02657746|Antihypertensive agents
880652|NCT02657746|Non-pharmacological treatment
880653|NCT02657746|community health care workers
880654|NCT02657746|cost-effectiveness
880655|NCT02657733|Respiratory Conditions for Adults
880656|NCT02657720|Respiratory Conditions for Adults
880657|NCT02657707|stent
880658|NCT02657707|stenosis
880659|NCT02657707|artery
880660|NCT02657707|carotid
880661|NCT02657668|Irritable Bowel Syndrome
880662|NCT02657668|Emotion Focused Therapy
880663|NCT02657668|Stress
880664|NCT02657668|Resilience
880665|NCT02657668|Coping Strategies
880666|NCT02657655|Parkinson's Disease
880667|NCT02657655|Dyskinesia
880668|NCT02657655|Tremor
880669|NCT02657655|Symptom Management
880670|NCT02657655|Technology
880671|NCT02657655|Wearable Sensors
880672|NCT02657655|Continuous Monitoring
880673|NCT02657655|Mobility
880674|NCT02657642|drug related problems, elderly
880675|NCT02657603|Peripheral Nerve Blocks
880676|NCT02657577|Women
880677|NCT02657577|Infants and Children
880678|NCT02657551|Thyroid Cancer
880679|NCT02657538|Interproximal caries
880680|NCT02657538|Enamel caries
880681|NCT02657538|Caries detection
880682|NCT02657538|Caries diagnostics
880683|NCT02657538|Near-infrared light transillumination
880684|NCT02657538|DIAGNOcam
880685|NCT02657512|Rivaroxaban, pharmacokinetics, activated charcoal, poisoning
880686|NCT02657499|healthcare access
880687|NCT02657499|utilization
880688|NCT02657499|expenditures
880689|NCT02657499|preventive services
880690|NCT02657486|BGJ398
880691|NCT02657486|15-090
880692|NCT02657460|chemotherapy
880693|NCT02657460|microparticle
880694|NCT02657460|malignant pleural effusion
880695|NCT02657447|Radioimmunotherapy
880696|NCT02657447|Lu-177
880697|NCT02657447|Phase I study
880698|NCT02657447|Betalutin
880699|NCT02657447|ARC
880700|NCT02657447|Antibody Radionuclide Conjugate
880701|NCT02657447|HH1
880702|NCT02657447|Rituximab
880703|NCT02657447|177Lu-DOTA-HH1
880704|NCT02657447|Lymphoma
880705|NCT02657447|Lymphoma Non-Hodgkin
880706|NCT02657447|Immune System Diseases
880707|NCT02657447|Follicular Lymphoma
880708|NCT02657447|Marginal Zone Lymphoma
880709|NCT02657447|Lymphoplasmacytoid
880710|NCT02657447|Lymphatic Diseases
880711|NCT02657447|Lymphoproliferative Disorders
880712|NCT02657447|Neoplasms
880713|NCT02657447|Neoplasms by Histological Type
880714|NCT02657447|Small Lymphocytic Lymphoma
880715|NCT02657447|Classical Mantle Cell Lymphoma
880716|NCT02657447|Lilotomab
880717|NCT02657447|Lutetium (177Lu) lilotomab satetraxetan
880720|NCT02657369|Lenvatinib
880721|NCT02657369|Thyroid Cancer, Anaplastic
880722|NCT02657369|Lenvima
880723|NCT02657369|E7080
880724|NCT02657356|Pulmonary Hypertension
880725|NCT02657356|Pulmonary Arterial Hypertension
880726|NCT02657356|Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
880727|NCT02657356|Bardoxolone methyl
880728|NCT02657356|PAH
880729|NCT02657356|RTA 402
880730|NCT02657356|6-minute walk distance
880731|NCT02657343|Breast Cancer With Positive HER2
880732|NCT02657330|Locally Advanced
880733|NCT02657330|Metastatic
880734|NCT02657317|chronic pain
880735|NCT02657317|pain management
880736|NCT02657317|trauma
880737|NCT02657317|ptsd
880738|NCT02657317|tbi
880739|NCT02657317|opioid medication
880740|NCT02657304|Sleep Apnea
880741|NCT02657304|CPAP
880742|NCT02657278|Peripheral arterial disease,
880743|NCT02657278|Cardipulmonary Exercise Test
880744|NCT02657252|telangiectasis
880745|NCT02657252|varicose veins
880746|NCT02657252|veins
880747|NCT02657252|glucose
880748|NCT02657252|sclerotherapy
880749|NCT02657239|Physical Function
880750|NCT02657213|Diabetes, Type 1
880751|NCT02657213|Hypoglycemia
880752|NCT02657213|Insulin Infusion Systems
880753|NCT02657200|miscarriage
880754|NCT02657200|Flanders
880755|NCT02657200|spontaneous abortion
880756|NCT02657200|KAP
880757|NCT02657200|midwives
880758|NCT02657174|third molar
880759|NCT02657174|auriculotherapy
880760|NCT02657174|inflammation
880761|NCT02657174|pain
880762|NCT02657122|Single ascending dose
880763|NCT02657122|SAD
880764|NCT02657122|multiple ascending dose
880765|NCT02657122|MAD
880766|NCT02657122|Phase 1
880767|NCT02657122|first-in-human
880768|NCT02657122|volunteers
880769|NCT02657122|TD-1473
880770|NCT02657109|valve replacement
880771|NCT02657109|physical therapy
880772|NCT02657109|early mobilization
880773|NCT02657096|Chronic Periodontitis
880774|NCT02657096|Hybenx
880775|NCT02657096|Desiccant agent
880776|NCT02657096|Healing
880777|NCT02657096|Microbiology
880778|NCT02657096|Periodontal Diseases
880779|NCT02657096|Periodontitis
880780|NCT02657096|Split-mouth clinical Study
880781|NCT02657070|Stroke
880782|NCT02657070|learned non-use
880783|NCT02657070|Virtual Reality
880784|NCT02657070|Hemiparesis
880785|NCT02657044|EMR
880786|NCT02657044|ESD
880787|NCT02657044|endoscopic mucosal resection
880788|NCT02657044|endoscopic submucosal resection
880789|NCT02657044|colorectal adenomas
880790|NCT02657031|Headache, Migraine
880791|NCT02656992|Bronchiectasis
880792|NCT02656992|High-intensity inspiratory muscle training
880793|NCT02656979|Glaucoma
880794|NCT02656979|Blood flow
880795|NCT02656979|Pseudoexfoliation
880796|NCT02656979|Intraocular pressure
880797|NCT02656979|Brain perfusion
880798|NCT02656979|Magnetic Resonance Imaging
880799|NCT02656953|VDU workers
880800|NCT02656953|VDU lenses
880801|NCT02656953|Neck complaints
880802|NCT02656953|Visual complaints
880803|NCT02656940|obesity
880804|NCT02656940|lipids
880805|NCT02656940|energy expenditure
880806|NCT02656940|gene expression
880807|NCT02656927|Spinal Cord Injury
880808|NCT02656927|Yoga
880809|NCT02656927|Psychological Flexibility
880810|NCT02656927|Mindfulness
880811|NCT02656927|Pain
880812|NCT02656849|Solid Tumor
880813|NCT02656823|ANKYLOS
880814|NCT02656823|Simplant
880815|NCT02656823|maxilla
880816|NCT02656823|edentulous
880817|NCT02656823|short implants
880818|NCT02656797|Leishmania major
880819|NCT02656797|Leishmania tropica
880820|NCT02656797|Amphotericin B
880821|NCT02656771|THA
880822|NCT02656771|Hip
880823|NCT02656771|arthroplasties
880824|NCT02656745|Smoking
880825|NCT02656745|Cigarette Smoking
880826|NCT02656745|Tobacco Smoking
880827|NCT02656745|Nicotine
880828|NCT02656745|Drug
880829|NCT02656745|Addiction
880830|NCT02656745|Tobacco
880831|NCT02656719|tracheostomy
880832|NCT02656719|complications
880833|NCT02656719|ultrasound
880834|NCT02656719|bronchoscopy
880835|NCT02656706|Adjuvant melanoma
880836|NCT02656706|Advanced melanoma
880837|NCT02656693|Weight Reduction Programs
880838|NCT02656693|Weight Loss Programs
880839|NCT02656693|Obesity
880840|NCT02656667|COPD pulmonary rehabilitation
880841|NCT02656667|neuromuscular electrical stimulation
880842|NCT02656667|sit to stand test COPD
880843|NCT02656667|quadriceps strengthening
880844|NCT02656602|Computer Assisted Instruction
880845|NCT02656602|Patient Counselling
880846|NCT02656602|Endoscopy
880847|NCT02656589|breast cancer
880848|NCT02656589|herceptin
880849|NCT02656589|microRNA
880850|NCT02656576|Human Papillomavirus
880851|NCT02656576|oropharynx biopsy
880852|NCT02656576|tonsillar lesion
880853|NCT02656550|Uterine Transplant
880854|NCT02656550|AUI
880855|NCT02656550|Rokitansky Syndrome
880856|NCT02656524|Metastatic colorectal cancer
880857|NCT02656511|immediate antiretroviral therapy
880858|NCT02656511|hyperacute infection
880859|NCT02656498|Tau, neurodegeneration, positron emission computed tomography
880860|NCT02656472|Pediatric Cardiac surgery
880861|NCT02656472|Inflammatory response
880862|NCT02656472|Tranexamic acid
880863|NCT02656472|Epsilon Aminocaproic Acid
880864|NCT02656459|gene expression
880865|NCT02656446|Neuraxial
880866|NCT02656446|Ultrasound
880867|NCT02656433|QEEG
880868|NCT02656433|ERP
880869|NCT02656433|tRNS
880870|NCT02656433|Brain injury
880871|NCT02656433|Motor Impairment
880872|NCT02656433|Transcranial Brain non-invasive stimulation
880873|NCT02656433|electroencephalogram
880874|NCT02656407|Functional Ultrasound
880875|NCT02656407|Intraoperative
880876|NCT02656407|Brain
880877|NCT02656407|Doppler
880878|NCT02656407|Ultrasound
880879|NCT02656394|ocular surface disease
880880|NCT02656394|glaucoma medications
880881|NCT02656381|Sarcoidosis
880882|NCT02656381|Behcet's Disease
880883|NCT02656381|Natural History Study
880884|NCT02656381|Biological Specimens
880885|NCT02656381|Immune System
880886|NCT02656355|Gait Initiation
880887|NCT02656355|Freezing of gait
880888|NCT02656355|Balance training
880889|NCT02656355|Anticipatory postural adjustments
880890|NCT02656342|OCD
880891|NCT02656329|Heart Failure (HF)
880892|NCT02656329|Single photon emission computer tomography scan (SPECT)
880893|NCT02656329|Implantable cardioverter defibrillator (ICD)
880894|NCT02656329|Left Ventricular ejection fraction (LVEF)
880895|NCT02656329|New York Health Association (NYHA)
880896|NCT02656329|Metaiodobenzylguanidine (mIBG)
880897|NCT02656329|123I-iobenguane
880898|NCT02656329|Heart-to-mediastinal ratio (H/M)
880899|NCT02656329|ADMIRE-ICD (AdreView Myocardial Imaging for Risk Evaluation - Implantable Cardioverter Defibrillator
880900|NCT02656329|All-cause mortality
880901|NCT02656329|Cardiac mortality
880902|NCT02656251|biofilms
880903|NCT02656251|cross over trial
880904|NCT02656251|chlorhexidine
880905|NCT02656238|CTEPH
880906|NCT02656238|Balloon pulmonary angioplasty
880907|NCT02656238|Chronic thromboembolic pulmonary hypertension
880908|NCT02656238|Pulmonary endarterectomy
880909|NCT02656238|BPA
880910|NCT02656238|PEA
880911|NCT02656225|postpartum anemia
880912|NCT02656225|hemoglobin
880913|NCT02656225|iron metabolism
880914|NCT02656225|Traditional Chinese Medicine
880915|NCT02656225|Ejiao
880916|NCT02656212|epicatechin
880917|NCT02656212|pre-diabetes
880918|NCT02656199|Diaphragm
880919|NCT02656199|Ventilators, Mechanical
880924|NCT02656147|Leukemia
880925|NCT02656147|Lymphoma
880926|NCT02656147|CAR γδT
880927|NCT02656134|Familial Adenomatous Polyposis
880928|NCT02656121|PCOS, vitamin D
880929|NCT02656082|Discoid lupus erythematosus
880930|NCT02656082|Intradermal injection of etanercept
880936|NCT02656004|Eucalyptus
880937|NCT02656004|Autonomic nervous system
880938|NCT02656004|Isometric resistance exercise
880939|NCT02655991|Stress Disorders, Post-Traumatic
880940|NCT02655991|Ambulatory Care
880941|NCT02655991|Telemedicine
880942|NCT02655991|Remote Consultation
880943|NCT02655991|Health Services Accessibility
880944|NCT02655965|Breast cancer
880945|NCT02655965|lumpectomy
880946|NCT02655965|mastectomy
880947|NCT02655965|PECS bloc
880948|NCT02655939|Gonarthrosis
880949|NCT02655926|OCD
880950|NCT02655926|DBS
880951|NCT02655926|Deep Brain Stimulation
880952|NCT02655913|Sodium ascorbate
880953|NCT02655913|Non-Small-Cell Lung cancer
880954|NCT02655913|Oncothermia
880955|NCT02655913|Immune function
880956|NCT02655913|Life quality
880957|NCT02655913|Tumor marker
880958|NCT02655913|Survival time
880959|NCT02655900|Obstetric anal sphincter injury,
880960|NCT02655900|Ultrasound diagnosis
880961|NCT02655874|Seasonal Influenza
880962|NCT02655874|Antibody response
880963|NCT02655874|Influenza Vaccines
880964|NCT02655874|Hemagglutination Inhibition
880965|NCT02655874|Elderly
880966|NCT02655874|immunosenescence
880967|NCT02655874|Tropics
880968|NCT02655848|Popeye
880969|NCT02655848|Long Head Biceps Tendon
880970|NCT02655848|Arthroscopy
880971|NCT02655848|Functional result
880972|NCT02655835|mindfulness
880973|NCT02655835|meditation
880974|NCT02655835|internet
880975|NCT02655822|NSCLC
880976|NCT02655822|MEL
880977|NCT02655822|RCC
880978|NCT02655822|TNBC
880979|NCT02655822|Triple Negative Breast Neoplasms
880980|NCT02655822|Neoplasms
880981|NCT02655822|CRC
880982|NCT02655822|Lung Cancer
880983|NCT02655822|Kidney Cancer
880984|NCT02655822|Colon Cancer
880985|NCT02655822|Rectal Cancer
880986|NCT02655822|Skin Cancer
880987|NCT02655822|Breast Cancer
880991|NCT02655783|induction of labor
880992|NCT02655744|Neurobehavioral Assessment
880993|NCT02655744|Radiotherapy (RT)
880994|NCT02655744|Chemotherapy
880995|NCT02655744|Neurotoxicity
880996|NCT02655718|ACS
880997|NCT02655718|Non obstructive coronary atherosclerosis
880998|NCT02655705|Cyclosporine
880999|NCT02655705|Methotrexate
881000|NCT02655692|PTSD
881001|NCT02655692|Ketamine
881002|NCT02655692|Veteran
881003|NCT02655692|Military
881004|NCT02655692|Clinical Trial
881005|NCT02655679|eczema
881006|NCT02655640|illness perceptions
881007|NCT02655627|Type 2 DM
881008|NCT02655627|internet based exercise training
881009|NCT02655627|group exercise training
881010|NCT02655627|glycemic control
881011|NCT02655575|dizziness
881012|NCT02655575|cognitive therapy
881013|NCT02655575|primary care
881014|NCT02655575|vestibular rehabilitation
881015|NCT02655575|chronic
881016|NCT02655484|COPD
881017|NCT02655484|noninvasive ventilation
881018|NCT02655484|exercise
881019|NCT02655484|CO2 rebreathing
881020|NCT02655458|Multiple Myeloma
881021|NCT02655458|Induction Therapy
881022|NCT02655458|Autologous Stem Cell Transplant
881023|NCT02655458|ASCT
881024|NCT02655458|Auto-SCT
881025|NCT02655419|cIAIs in hospitalized adults
881026|NCT02655406|Foam sclerotherapy
881027|NCT02655406|Compression
881028|NCT02655367|MRI
881029|NCT02655367|oats
881030|NCT02655367|porridge
881031|NCT02655367|satiety
881032|NCT02655367|GI hormones
881033|NCT02655367|processing
881034|NCT02655341|Dehydration
881035|NCT02655341|Primary PCI
881036|NCT02655341|Acute Myocardial Infarction
881037|NCT02655341|Bioimpedance
881038|NCT02655341|Renal Angiography
881039|NCT02655328|asthma
881040|NCT02655328|athlete
881041|NCT02655315|Parkinson
881042|NCT02655315|Deferiprone
881043|NCT02655315|Chelation
881044|NCT02655302|Interleukin-17
881045|NCT02655302|Interleukin-22
881046|NCT02655302|Microbiota
881047|NCT02655302|Exacerbations
881048|NCT02655302|Immunity
881049|NCT02655302|Mucosal
881050|NCT02655276|microencapsulated glycine
881051|NCT02655276|attentional performance
881052|NCT02655276|motoric activity
881053|NCT02655276|hyperactivity
881054|NCT02655198|refractory childhood epilepsy
881055|NCT02655198|Lennox Gastaut syndrome
881056|NCT02655198|fenfluramine
881057|NCT02655198|anti-epileptic treatment
881058|NCT02655185|Lipids
881059|NCT02655185|Atrial Fibrillation
881060|NCT02655185|Heart Failure
881061|NCT02655172|Schizophrenia, affordance,
881062|NCT02655172|perception-action binding,
881063|NCT02655172|stimulus-response-compatibility
881064|NCT02655159|Breast Cancer
881065|NCT02655159|Metastatic breast cancer
881066|NCT02655159|nab-paclitaxel
881067|NCT02655159|Abraxane
881068|NCT02655159|Observational
881069|NCT02655159|Retrospective
881070|NCT02655159|AMBER
881071|NCT02655146|Frozen embryo transfer,luteal support, GnRHa
881072|NCT02655120|Femoral head necrosis
881073|NCT02655120|Autologous Bone Marrow
881074|NCT02655120|BMP7
881075|NCT02655107|blood gas monitoring
881076|NCT02655107|non-invasive
881077|NCT02655107|hemoglobin
881078|NCT02655094|minimal-invasive surgery, mitral valve
881079|NCT02655081|Urinary diversion
881080|NCT02655081|Bladder Neoplasm
881081|NCT02655081|Nutritional Supplement
881082|NCT02655081|Cystectomy
881083|NCT02655068|Head and Neck Cancer
881084|NCT02655068|Definitive Therapy
881085|NCT02655068|Positron Emission Tomography - Computed Tomography (PET/CT)
881086|NCT02655068|Computed Tomography (CT)
881087|NCT02655055|apheresis
881088|NCT02655055|citrate anticoagulation
881089|NCT02655055|blood donor
881090|NCT02655055|bone
881091|NCT02655016|Ovarian Cancer
881092|NCT02655016|PARP Inhibitor
881093|NCT02655016|HRD
881094|NCT02655016|HRD positive
881095|NCT02655016|PRIMA
881096|NCT02655016|PRIMA Clinical Trial
881097|NCT02655016|PRIMA Study
881098|NCT02655003|behavioral symptoms
881099|NCT02655003|psychological symptoms
881100|NCT02655003|dementia
881101|NCT02655003|neuropsychiatric symptoms
881108|NCT02654951|Stroke
881109|NCT02654951|Rehabilitation Robotics
881110|NCT02654951|Bimanual
881111|NCT02654951|Compensatory movements
881112|NCT02654951|Hemiplegia
881113|NCT02654951|Kinematics
881114|NCT02654951|Reaching
881115|NCT02654951|Trunk
881116|NCT02654938|prostate cancer
881117|NCT02654938|adenovirus
881118|NCT02654938|TLR5
881119|NCT02654938|immunotherapy
881120|NCT02654912|malaria
881121|NCT02654912|elimination
881122|NCT02654912|surveillance and response
881123|NCT02654912|dihydroartemisinin+piperaquine
881124|NCT02654899|Healthy subjects
881125|NCT02654899|Single Ascending Dose
881126|NCT02654899|Hyperlipidemia
881127|NCT02654899|Dyslipidemia
881128|NCT02654886|exercise
881129|NCT02654886|Pompe disease
881130|NCT02654886|Pompe
881131|NCT02654873|histopathology
881132|NCT02654873|gallbladder
881133|NCT02654873|specimen
881134|NCT02654847|vasopressor
881135|NCT02654847|blood pressure
881136|NCT02654847|Cesarean section
881137|NCT02654847|spinal anesthesia
881138|NCT02654821|Melanoma
881139|NCT02654821|TCR
881140|NCT02654808|gynecology
881141|NCT02654808|laparoscopy
881142|NCT02654808|pneumoperitoneum
881143|NCT02654808|CO2 absorption
881144|NCT02654756|Risk Assessment
881145|NCT02654704|Personalized Medicine
881146|NCT02654704|Precision Medicine
881147|NCT02654691|Chemotherapy
881148|NCT02654639|Metastatic Colorectal Cancer
881149|NCT02654639|Advanced Colorectal Cancer
881150|NCT02654600|cardiac surgery
881151|NCT02654600|thoracopulmonary compliance
881152|NCT02654587|Non-Small-Cell Lung Cancer
881153|NCT02654587|NSCLC
881154|NCT02654587|Immunotherapy
881155|NCT02654587|Cancer vaccine
881156|NCT02654587|Metastasis
881157|NCT02654574|Alzheimer's disease or related disorders
881158|NCT02654574|Functional autonomy level
881159|NCT02654574|Lawton Instrumental Activities of Daily Living
881160|NCT02654574|The Functional autonomy level
881161|NCT02654561|Severe sepsis
881162|NCT02654561|Disseminated intravascular coagulation
881163|NCT02654561|Unfractionated heparin
881164|NCT02654535|Systematic review and meta-analysis
881165|NCT02654535|Evidence-based medicine (EBM)
881166|NCT02654535|Evidence-based nutrition (EBN)
881167|NCT02654535|Clinical practice guidelines
881168|NCT02654535|Clinical trials
881169|NCT02654535|Tree Nuts
881170|NCT02654535|Peanuts
881171|NCT02654535|Body weight
881172|NCT02654535|Prospective cohort studies
881173|NCT02654496|Gut Microbiota
881174|NCT02654496|Weight Regain
881175|NCT02654496|Gastric Bypass
881176|NCT02654457|Immunohistochemical
881177|NCT02654457|Ki-67
881178|NCT02654457|Breast cancer
881179|NCT02654457|IHC
881180|NCT02654444|Immunohistochemical (IHC)
881181|NCT02654444|Her2/Neu
881182|NCT02654444|Breast cancer
881183|NCT02654431|Immunohistochemical (IHC)
881184|NCT02654431|ER/PR
881185|NCT02654431|Breast cancer
881186|NCT02654418|colonic polyps ≥20 mm,
881187|NCT02654418|adenomas
881188|NCT02654418|polyps
881189|NCT02654405|HDAC inhibitors
881190|NCT02654405|Inflammation
881191|NCT02654392|Omega-3
881192|NCT02654392|Omega-6
881193|NCT02654392|Exercise Performance
881194|NCT02654366|Syringe exchange
881195|NCT02654366|HIV risk reduction
881196|NCT02654366|Drug-free community support
881197|NCT02654353|Persistent atrial fibrillation, catheter ablation, outcome
881198|NCT02654327|Extracorporeal
881199|NCT02654327|Acute Respiratory Distress Syndrome
881200|NCT02654327|Protective Lung Ventilation
881201|NCT02654327|Ventilator Induced Lung Injury
881202|NCT02654327|Carbon Dioxide Removal
881203|NCT02654327|Lung
881204|NCT02654327|Lung Injury
881205|NCT02654314|prevention; delirium; in-patients; melatonin,
881206|NCT02654301|Xylose
881207|NCT02654301|prediabetes
881208|NCT02654301|postprandial hyperglycemia
881209|NCT02654301|glucose
881210|NCT02654288|pancreatic cancer
881211|NCT02654288|gemcitabine
881212|NCT02654288|chemotherapy
881213|NCT02654288|immunoglobulin G 4
881214|NCT02654249|Hemorrhoids grade III and IV
881215|NCT02654249|transanal hemorrhoidal dearterialization
881216|NCT02654249|hemorroidectomy
881217|NCT02654249|THD
881218|NCT02654249|LigaSure
881219|NCT02654223|Rhinitis / Rhinoconjunctivitis
881220|NCT02654223|Vaccine
881221|NCT02654223|Immunotherapy
881222|NCT02654223|Grass pollen
881223|NCT02654223|Allergy
881224|NCT02654210|birth cohort
881225|NCT02654210|infectious diseases
881226|NCT02654210|microbiome
881227|NCT02654210|immune system
881228|NCT02654210|immune response
881229|NCT02654184|Right lateral
881230|NCT02654184|Induction
881231|NCT02654184|Children
881232|NCT02654184|Anesthesia
881233|NCT02654171|RSV
881234|NCT02654171|AK0529
881235|NCT02654158|acute upper respiratory infection
881236|NCT02654145|mepolizumab
881237|NCT02654145|Omalizumab
881238|NCT02654145|SGRQ
881239|NCT02654145|severe eosinophilic asthma
881240|NCT02654145|ACQ
881241|NCT02654145|exacerbations
881242|NCT02654106|multiple brain metastases
881243|NCT02654106|large brain metastases
881244|NCT02654106|meningeal metastases
881245|NCT02654106|fractionated stereotactic radiotherapy
881246|NCT02654106|temozolomide
881247|NCT02654054|Elagolix + E2/NETA
881248|NCT02654054|Menorrhagia
881249|NCT02654054|HMB
881250|NCT02654054|Elagolix + Norethindrone Acetate
881251|NCT02654054|ABT-620
881252|NCT02654054|Heavy Menstrual Bleeding
881253|NCT02654054|Heavy Uterine Bleeding
881254|NCT02654054|Elagolix Sodium
881255|NCT02654054|Leiomyomata
881256|NCT02654054|Elagolix
881259|NCT02653963|Steroid, Triamcinolone, Ahmed Glaucoma valve
881260|NCT02653937|IBS
881261|NCT02653937|MUPS
881262|NCT02653937|FSS
881263|NCT02653937|shigyakusan
881264|NCT02653937|Katsumi's points
881265|NCT02653937|Nakatani's N line
881266|NCT02653924|Suture
881267|NCT02653924|bacteria
881268|NCT02653911|Acupuncture
881269|NCT02653898|Malaria
881270|NCT02653898|Antimalarials
881271|NCT02653898|Malaria Elimination
881272|NCT02653898|Mass Drug Administration
881273|NCT02653898|Malaria Prophylaxis
881274|NCT02653898|Mobile population
881275|NCT02653898|Drug resistance
881276|NCT02653898|Focused screening and treatment
881277|NCT02653898|Monthly Malaria Prophylaxis
881278|NCT02653898|Mass screening and treatment
881279|NCT02653898|Primaquine
881280|NCT02653898|Malaria transmission
881281|NCT02653898|Permethrin insecticide
881282|NCT02653898|Thai-Cambodian border
881283|NCT02653898|Cambodia
881284|NCT02653898|AFRIMS
881285|NCT02653885|cardiac surgery
881286|NCT02653885|open heart surgery
881287|NCT02653885|hemogram
881288|NCT02653872|Non-randomized
881289|NCT02653872|Verapamil
881290|NCT02653872|Itraconazole
881291|NCT02653872|Diltiazem
881292|NCT02653872|Safety
881293|NCT02653872|Tolerability
881294|NCT02653872|Pharmacokinetics
881295|NCT02653859|CTC
881296|NCT02653859|PCR
881297|NCT02653833|Becker
881298|NCT02653833|Muscular Dystrophy
881299|NCT02653833|Skeletal Muscle
881300|NCT02653833|blood flow
881301|NCT02653833|Ultrasound
881302|NCT02653807|manual therapy
881303|NCT02653807|osteopathy
881304|NCT02653807|mobilization with movement
881305|NCT02653807|ankle
881306|NCT02653807|stiffness
881307|NCT02653794|Juvenile Subjects'characteristics
881308|NCT02653768|Osteoarthritis, Knee
881309|NCT02653768|Exercise
881310|NCT02653755|Breast Cancer Radiation
881311|NCT02653755|Radiotherapy for Favorable-Risk Breast cancer
881312|NCT02653755|Radiotherapy Omission
881313|NCT02653729|cognitive behaviour therapy
881314|NCT02653729|first episode
881315|NCT02653716|New Orleans Intervention Model
881316|NCT02653716|Case Management
881317|NCT02653716|Maltreatment
881318|NCT02653716|Child
881319|NCT02653664|Chronic Pain
881320|NCT02653664|Sleep
881321|NCT02653651|Ketamine
881322|NCT02653651|Lidocaine
881323|NCT02653651|Nephrectomy
881324|NCT02653651|Chronic pain
881325|NCT02653638|Cerebral Vasodilator Function
881326|NCT02653638|White Matter Hyperintensity Volume
881327|NCT02653638|Default Mode Network Connectivity
881328|NCT02653638|Cognitive Function
881329|NCT02653638|Cardiorespiratory Fitness
881330|NCT02653638|Aging
881332|NCT02653612|surgery
881333|NCT02653612|folate receptor
881334|NCT02653586|resilience
881335|NCT02653586|prevention program
881336|NCT02653586|body image
881337|NCT02653586|self esteem
881338|NCT02653573|young adult
881339|NCT02653560|Potassium
881340|NCT02653560|Magnesium
881341|NCT02653560|Citrate
881342|NCT02653560|DASH
881343|NCT02653547|tinnitus
881344|NCT02653547|transcranial random noise stimulation
881345|NCT02653547|rTMS
881346|NCT02653547|multisite stimulation
881347|NCT02653547|non-invasive brain stimulation
881348|NCT02653534|Kangaroo Mother Care in community
881349|NCT02653534|mortality
881350|NCT02653521|Esophageal Cancer
881351|NCT02653521|Adaptive Radiation Therapy
881352|NCT02653508|BMI: Body Mass Index
881353|NCT02653508|obesity
881354|NCT02653508|adolescents
881355|NCT02653508|overweight
881356|NCT02653508|CI:confidence interval
881357|NCT02653508|CDC: Center Disease Control
881358|NCT02653482|diabetes
881359|NCT02653482|heart failure
881360|NCT02653482|dapagliflozin
881361|NCT02653482|SGLT-2 inhibitors
881362|NCT02653443|INTERCEPT
881363|NCT02653443|Platelet
881364|NCT02653443|Pathogen Inactivation
881365|NCT02653443|Platelets Components Stored
881366|NCT02653443|Therapeutic Efficacy
881367|NCT02653430|obesity
881368|NCT02653430|BMI
881369|NCT02653430|efficacy
881370|NCT02653430|bariatric surgery
881371|NCT02653430|gut flora
881372|NCT02653430|fMRI
881373|NCT02653391|Fuchs' Corneal Endothelial Dystrophy
881374|NCT02653391|FCED
881375|NCT02653391|Ocuvia™
881376|NCT02653391|MTP-131
881377|NCT02653352|randomized controlled trials
881378|NCT02653352|soft drinks
881379|NCT02653352|hypercholesterolemia
881380|NCT02653352|serum cholesterol
881381|NCT02653352|blood glucose
881382|NCT02653352|overweight
881383|NCT02653352|carbonated beverages
881384|NCT02653339|traditional Chinese medicine
881385|NCT02653339|Loratadine
881386|NCT02653339|questionnaire survey
881387|NCT02653326|Tertiary Prevention
881388|NCT02653326|Telerehabilitation
881389|NCT02653287|Fatigue, Physical Activity, Lupus
881390|NCT02653274|MRI
881391|NCT02653274|blood glucose
881392|NCT02653274|satiety
881393|NCT02653274|breakfast
881394|NCT02653274|porridge
881395|NCT02653274|grains
881396|NCT02653261|tranexamic acid
881397|NCT02653261|Transurethral Resection of the Prostate (TURP)
881398|NCT02653261|Transurethral Resection of a Bladder Tumor (TURBT)
881399|NCT02653261|Hemorrhage
881400|NCT02653261|Blood Transfusion
881401|NCT02653222|Ethanol Sympathicolysis
881402|NCT02653222|Computer Tomography guidance
881403|NCT02653222|Denervation
881404|NCT02653222|Kidney Transplantation
881405|NCT02653222|Dialysis
881406|NCT02653209|Type 2 diabetes
881407|NCT02653209|Stratification
881408|NCT02653209|Biomarkers
881409|NCT02653209|Pharmacogenetics
881410|NCT02653209|SGLT2 inhibitors
881411|NCT02653209|Thiazolidinediones
881412|NCT02653209|DPP4 inhibitors
881413|NCT02653170|acute stroke
881414|NCT02653170|care transitions
881415|NCT02653170|patient engagement
881416|NCT02653170|patient education
881417|NCT02653170|caregivers
881418|NCT02653170|social workers
881419|NCT02653157|multidrug resistance
881420|NCT02653157|burns
881421|NCT02653157|infections, gram-negative bacilli
881422|NCT02653157|ventilator-associated pneumonia
881423|NCT02653157|ventilator-associated tracheobronchitis
881424|NCT02653157|gram-negative bacilli colonization
881425|NCT02653144|post operative pain, Dexmedetomidine, Regional anesthesia
881426|NCT02653131|Short bowel syndrome
881427|NCT02653105|High risk of cancer, BRCA1 or 2 mutation, Olfactomedine 4
881428|NCT02653066|recruitment
881429|NCT02653040|Lighting
881430|NCT02653040|Inpatients
881431|NCT02653040|Recovery
881432|NCT02653040|Sleep
881433|NCT02653027|Genetics
881434|NCT02652988|tDCS
881435|NCT02652988|chronic pain
881436|NCT02652988|fibromyalgia
881437|NCT02652923|ultrasound contrast agent
881438|NCT02652923|lymphosonography
881439|NCT02652923|breast cancer
881440|NCT02652897|bleeding
881441|NCT02652897|clotting tests
881442|NCT02652897|neurosurgery
881443|NCT02652897|clotting time
881444|NCT02652897|maximum clot firmness
881445|NCT02652897|kinetics
881446|NCT02652897|lysis
881447|NCT02652897|primary hemostasis
881448|NCT02652897|platelet dysfunction
881449|NCT02652897|coagulation
881450|NCT02652884|transient hypoparathyroidism
881451|NCT02652884|steroids
881452|NCT02652884|total thyroidectomy
881453|NCT02652871|Leukemia
881454|NCT02652871|Acute Myeloid Leukemia
881455|NCT02652871|AML
881456|NCT02652871|Relapsed or Refractory
881457|NCT02652871|Acute myelogenous leukemia
881458|NCT02652871|LY2510924
881459|NCT02652871|Idarubicin
881460|NCT02652871|Idamycin
881461|NCT02652871|Cytarabine
881462|NCT02652871|Ara-C
881463|NCT02652871|Cytosar
881464|NCT02652871|DepoCyt
881465|NCT02652871|Cytosine Arabinosine Hydrochloride
881466|NCT02652819|Chronic Kidney Disease
881467|NCT02652806|Chronic Kidney Disease
881468|NCT02652780|Leber Hereditary Optic Neuropathy
881469|NCT02652780|Leber Hereditary Optic Atrophy
881470|NCT02652780|Heredity Optic Atrophy
881471|NCT02652780|Eye Diseases
881472|NCT02652780|Hereditary Eye Diseases
881473|NCT02652780|Inborn Genetic Disease
881474|NCT02652780|Genetic Therapy
881475|NCT02652780|Intravitreal Injections
881476|NCT02652780|Mitochondrial Disease
881477|NCT02652780|AAV2 Vectors
881478|NCT02652780|Nervous System Diseases
881479|NCT02652780|Neurodegenerative Disease
881480|NCT02652780|Heredodegenerative Disorders of the Nervous System
881481|NCT02652767|Leber Hereditary Optic Neuropathy
881482|NCT02652767|Leber Hereditary Optic Atrophy
881483|NCT02652767|Heredity Optic Atrophy
881484|NCT02652767|Eye Diseases
881485|NCT02652767|Hereditary Eye Diseases
881486|NCT02652767|Inborn Genetic Disease
881487|NCT02652767|Genetic Therapy
881488|NCT02652767|Intravitreal Injections
881489|NCT02652767|Mitochondrial Disease
881490|NCT02652767|AAV2 Vectors
881491|NCT02652767|Nervous System Diseases
881492|NCT02652767|Neurodegenerative Disease
881493|NCT02652767|Heredodegenerative Disorders of the Nervous System
881494|NCT02652754|Granexin
881495|NCT02652754|diabetic foot ulcers
881496|NCT02652754|pharmacokinetic study
881497|NCT02652754|FirstString Research
881498|NCT02652702|circular stapler-assisted colostomy
881499|NCT02652689|pulmonary embolism
881500|NCT02652689|pulmonary disease
881501|NCT02652689|Lung Doppler signals
881502|NCT02652676|Infant Cardiac Transplantation
881503|NCT02652676|End-stage Idiopathic Dilated Cardiomyopathy
881504|NCT02652676|Mechanical Circulatory Device
881505|NCT02652676|End Stage Dilated Left Ventriculopathy
881506|NCT02652676|Acute-on-Chronic Left Ventricular Failure
881507|NCT02652663|colorectal cancer
881508|NCT02652663|liver
881509|NCT02652663|MRI
881510|NCT02652663|contrast
881511|NCT02652663|gadoxetic acid
881512|NCT02652650|Healthy
881513|NCT02652650|JNJ-63623872
881514|NCT02652650|Ethinylestradiol
881515|NCT02652650|Norethindrone
881516|NCT02652611|Screw Removal vs. Non-screw removal
881517|NCT02652611|Complications
881518|NCT02652611|SI Screw Stabilization
881519|NCT02652585|Alcoholism
881520|NCT02652585|alcohol self-administration
881521|NCT02652572|Granexin
881522|NCT02652572|venous leg ulcer
881523|NCT02652572|pharmacokinetic study
881524|NCT02652572|FirstString Research
881525|NCT02652559|Chronic Obstructive Pulmonary Disease
881526|NCT02652559|Non-invasive ventilation
881527|NCT02652559|Home initiation
881528|NCT02652546|HIV/AIDS
881529|NCT02652546|Immune Activation
881530|NCT02652546|Anti-Inflammatory
881531|NCT02652546|TNF
881532|NCT02652546|Phosphodieterase Inhibitor
881533|NCT02652520|Kidney transplantation
881534|NCT02652520|Organ preservation
881535|NCT02652507|Sedation
881536|NCT02652507|MRI
881537|NCT02652507|Dexmedetomidine
881538|NCT02652507|Ketamine
881539|NCT02652507|General anesthesia
881540|NCT02652507|MRI of Brain
881541|NCT02652507|MRI of Brain/Spine
881542|NCT02652494|Psoriasis
881543|NCT02652494|Observational
881544|NCT02652494|Apremilast
881545|NCT02652494|APRIL
881546|NCT02652494|Non-Interventional
881547|NCT02652494|The Netherlands
881548|NCT02652455|cutaneous
881549|NCT02652455|unresectable
881550|NCT02652455|mucosal metastatic stage III/IV melanoma
881551|NCT02652455|ocular metastatic stage III/IV melanoma
881552|NCT02652442|dizziness
881553|NCT02652442|postural balance
881554|NCT02652442|rehabilitation
881555|NCT02652429|PAH
881556|NCT02652429|Pulmonary Arterial Hypertension
881557|NCT02652429|Inhaled Nitric Oxide
881558|NCT02652429|iNO
881559|NCT02652403|Denture, Complete
881560|NCT02652403|Mouth, Edentulous
881561|NCT02652351|Stem cell
881562|NCT02652351|Human Umbilical Cord Mesenchymal Stem Cell
881563|NCT02652351|Mesenchymal Stem Cell
881564|NCT02652351|Hepatic Cirrhosis
881565|NCT02652338|heart rhythm disturbances and symptoms
881566|NCT02652338|dietary supplement
881567|NCT02652312|Dexmedetomidine
881568|NCT02652312|Desflurane
881569|NCT02652312|Bispectral Index BIS
881570|NCT02652299|Fibrocytes
881571|NCT02652299|Synovial biopsy
881572|NCT02652286|VATS
881573|NCT02652286|Energy sealing
881574|NCT02652247|trauma
881575|NCT02652247|ventilator
881576|NCT02652247|surgical ICU
881577|NCT02652208|decision making
881578|NCT02652208|decision aids
881579|NCT02652208|shared decision making
881580|NCT02652208|stable angina
881581|NCT02652208|cardiology
881582|NCT02652195|Neural correlates
881583|NCT02652195|oxytocin administration
881584|NCT02652156|transversus abdominis plane
881585|NCT02652156|postoperative
881586|NCT02652156|pain
881587|NCT02652143|in vivo culture
881588|NCT02652130|GVHD, Graft versus Host Disease
881589|NCT02652104|Advanced
881590|NCT02652104|Deep brain stimulation
881591|NCT02652091|Adherence
881592|NCT02652091|Persistence
881593|NCT02652091|Patient satisfaction
881594|NCT02652065|Psoriasis
881595|NCT02652065|Microcirculation
881596|NCT02652065|TRPV1
881597|NCT02652026|dental root planing and scaling
881598|NCT02652026|periodontal disease
881599|NCT02652026|type 2 diabetes mellitus
881600|NCT02652026|glycosylated hemoglobin A
881601|NCT02651974|neoplasm
881602|NCT02651974|colorectal
881603|NCT02651974|cancer
881604|NCT02651974|uninsured
881605|NCT02651974|FIT
881606|NCT02651974|fecal immunochemical test
881607|NCT02651961|Total hip prosthesis
881608|NCT02651961|Total knee prosthesis
881609|NCT02651961|Chronic infection
881610|NCT02651961|One stage exchange
881611|NCT02651961|Two stage exchange
881612|NCT02651961|Cost-effectiveness
881613|NCT02651935|Respiration, Artificial
881614|NCT02651935|weaning
881615|NCT02651935|critical care
881616|NCT02651922|Nervous restlessness
881617|NCT02651922|Pascoflair
881618|NCT02651922|Passiflora incarnata
881619|NCT02651922|Benzodiazepine
881620|NCT02651883|Cervical cancer screening
881621|NCT02651883|HPV testing
881622|NCT02651883|Self-collection
881623|NCT02651870|Hypertension
881624|NCT02651844|Progesterone receptor isoforms
881625|NCT02651844|Antiprogestins
881626|NCT02651844|Mifepristone
881627|NCT02651844|Neoadjuvant
881628|NCT02651844|Breast cancer
881629|NCT02651831|ICMs
881630|NCT02651831|Immune checkpoint modulators
881631|NCT02651818|Goiter
881632|NCT02651818|Thyroid disease
881633|NCT02651818|Struma
881634|NCT02651805|Palliative Care
881635|NCT02651805|Respiratory Secretion
881636|NCT02651792|ketamine
881637|NCT02651792|propofol
881638|NCT02651792|pethidine
881639|NCT02651792|ERCP
881640|NCT02651792|endoscopist
881641|NCT02651740|Rifaximin
881642|NCT02651740|Fecal microbiota transplantation
881643|NCT02651740|Gut microbiota
881644|NCT02651610|PPHM 1401
881645|NCT02651610|bavituximab
881646|NCT02651610|Peregrine
881647|NCT02651610|Breast Cancer
881648|NCT02651610|HER-2 Negative
881649|NCT02651610|HER2 Negative
881650|NCT02651597|Oatmeal
881651|NCT02651597|Beta glucan
881652|NCT02651597|Postprandial Glycemic Response
881653|NCT02651597|Blood Glucose
881654|NCT02651571|Knee
881655|NCT02651571|Replacement
881656|NCT02651571|Prosthesis
881657|NCT02651571|Mobile-bearing
881658|NCT02651532|Confocal Laser Endomicroscopy
881659|NCT02651532|inflammation
881660|NCT02651532|Irritable Bowel Syndrome
881661|NCT02651519|bispectral index
881662|NCT02651519|regional cerebral oxygen saturation
881663|NCT02651519|Stellate-ganglion block
881664|NCT02651506|Lung cancer biopsy
881665|NCT02651506|Electromagnetic Navigation Bronchoscopy
881666|NCT02651506|Transthoracic Needle Biopsy
881667|NCT02651480|Diet, Vegetarian
881668|NCT02651480|Diet, Fat-Restricted
881669|NCT02651480|Quality of Life
881670|NCT02651480|Glycemic Index
881671|NCT02651454|metabolic syndrome
881672|NCT02651454|Daesiho-tang
881673|NCT02651454|Taeeumjowi-tang
881674|NCT02651454|Korean medicine
881675|NCT02651441|D-CIK
881676|NCT02651441|lung cancer
881677|NCT02651428|Kidney Failure, Chronic
881678|NCT02651428|Catheter-Related Infections
881679|NCT02651428|Central Venous Catheter
881680|NCT02651415|Metastatic colorectal cancer
881681|NCT02651415|Metastatic colorectal carcinoma
881682|NCT02651415|mCRC
881683|NCT02651415|Regorafenib
881684|NCT02651415|Stivarga
881685|NCT02651415|Perindopril
881686|NCT02651415|Perindopril erbumine
881687|NCT02651415|Coversyl
881688|NCT02651402|Anxiety Disorders
881689|NCT02651402|Internalizing
881690|NCT02651402|Anxiety
881691|NCT02651389|Digital Orthoptic Platform
881692|NCT02651389|Vision test
881693|NCT02651376|Immunodeficiency
881694|NCT02651376|Allogenic HLA-Mismatched Stem-Cell Transplantation
881695|NCT02651350|Drug-induced Liver Injury
881696|NCT02651350|Recurrence
881697|NCT02651350|Methylprednisolone
881698|NCT02651285|G-CSF
881699|NCT02651285|BLASTOCYST
881700|NCT02651285|IVF
881701|NCT02651272|Pulmonary Hypertension
881702|NCT02651272|Sickle Cell Disease
881703|NCT02651272|Pulmonary Arterial Hypertension
881704|NCT02651272|Macitentan
881705|NCT02651194|Treatment-naïve
881706|NCT02651194|HCV Gentoype 6
881707|NCT02651194|HCV Gentoype 1
881708|NCT02651194|Compensated cirrhotic
881709|NCT02651194|HCV Gentoype 2
881710|NCT02651194|Treatment-experienced
881711|NCT02651194|Non-cirrhotic
881712|NCT02651194|Chronic Hepatitis C
881713|NCT02651194|HCV Gentoype 5
881714|NCT02651194|HCV Gentoype 3
881715|NCT02651194|HCV Gentoype 4
881716|NCT02651168|Diabetic Macular Edema
881717|NCT02651168|Ocular Cytokines
881718|NCT02651168|aflibercept
881719|NCT02651168|ranibizumab
881720|NCT02651155|Drug therapy
881721|NCT02651129|noise
881722|NCT02651129|obstetric
881723|NCT02651129|operating rooms
881725|NCT02651090|contraindication for CECT
881726|NCT02651090|contraindication for CEMRI
881727|NCT02651090|liver pathology
881728|NCT02651090|renal failure
881729|NCT02651090|contrast enhanced ultrasound
881730|NCT02651090|sonazoid
881731|NCT02651077|Endometriosis, chemical contaminants, BFRs
881732|NCT02651064|Supplemental Nutrition Assistance Program (SNAP)
881733|NCT02651064|fruits and vegetables
881734|NCT02651064|price incentive
881735|NCT02651051|Postprandial glycemia
881736|NCT02651051|Metabolic health measures
881737|NCT02651012|acne
881738|NCT02651012|acne vulgaris
881739|NCT02651012|papule
881740|NCT02651012|pustule
881741|NCT02651012|adolescent acne
881742|NCT02650973|Bioequivalence
881743|NCT02650947|Sucralose
881744|NCT02650947|Insulin Secretion
881745|NCT02650947|Insulin Sensitivity
881746|NCT02650947|Incretin
881747|NCT02650947|Gut Microbiota
881748|NCT02650947|Food and Eating Behaviour
881749|NCT02650947|Healthy Volunteers
881750|NCT02650934|STEMI, Heart Failure, Inflammation, Haptoglobin Polymorphisms, Adverse Remodeling, Genetics, GWAS, MRI
881751|NCT02650908|Lesion
881752|NCT02650908|Meniscus
881753|NCT02650908|Avivement
881754|NCT02650908|Suturing area
881755|NCT02650882|Respiratory muscles
881756|NCT02650882|athletic performance
881757|NCT02650882|handball
881758|NCT02650869|Necrotizing Enterocolitis
881759|NCT02650869|probiotics
881760|NCT02650869|very low birth weight
881761|NCT02650856|Blood loss
881762|NCT02650856|Tranexamic acid
881763|NCT02650856|Platelet rich plasma
881764|NCT02650856|Total knee arthroplasty
881765|NCT02650843|Parkinsonism
881766|NCT02650843|DAT Dopamine transporter
881767|NCT02650843|SPECT
881768|NCT02650830|type 2 diabetes
881769|NCT02650830|prediabetes
881770|NCT02650830|bile acids profile
881771|NCT02650830|GLP-1
881772|NCT02650830|FGF-19
881773|NCT02650804|Cancer
881774|NCT02650804|Advanced Pancreatic Cancer
881775|NCT02650778|Breast Cancer
881776|NCT02650778|Automated whole breast ultrasound
881777|NCT02650778|BI-RADS category 3 lesions
881778|NCT02650765|Brain injury
881779|NCT02650765|Head injury
881780|NCT02650765|Computed tomography
881781|NCT02650765|Emergency department
881782|NCT02650752|Lapatinib
881783|NCT02650752|Capecitabine
881784|NCT02650752|HER2
881785|NCT02650752|15-278
881786|NCT02650687|Postoperative Cognitive Dysfunction
881787|NCT02650687|Elderly, geriatric
881788|NCT02650687|Anesthesia
881789|NCT02650687|Anesthetic depth
881790|NCT02650687|Bispectral index monitor
881791|NCT02650687|Function
881792|NCT02650687|Recovery after surgery
881793|NCT02650687|Surgery
881794|NCT02650674|glycemic & insulin response
881795|NCT02650674|SDS
881796|NCT02650674|cereal product
881797|NCT02650674|Nutrition
881798|NCT02650674|Carbohydrate
881799|NCT02650674|Absorption
881800|NCT02650674|Intestine
881801|NCT02650661|Cancer survivors
881802|NCT02650648|Humanized Anti-GD2 Antibody Hu3F8
881803|NCT02650648|Allogeneic Natural Killer Cells
881804|NCT02650648|rIL-2
881805|NCT02650648|15-272
881806|NCT02650622|Metabolism
881807|NCT02650622|Genetics
881808|NCT02650622|Metabolomics
881809|NCT02650622|Genomics
881810|NCT02650609|chronic subdural hematomas
881811|NCT02650609|surgical treatment
881812|NCT02650609|corticosteroids
881813|NCT02650570|Cancer
881814|NCT02650570|Cachexia
881815|NCT02650557|coronary slow flow
881816|NCT02650557|P-wave dispersion
881817|NCT02650544|Carcinoma, Non-Small-Cell Lung
881818|NCT02650544|Depression
881819|NCT02650544|mirtazapine
881820|NCT02650544|patients health questionnaire (PHQ-9)
881821|NCT02650531|Follow up studies
881822|NCT02650531|Risk factors
881823|NCT02650518|Catheter-Associated Urinary Tract Infections
881824|NCT02650518|Antimicrobial Stewardship
881825|NCT02650518|Short-Course Antimicrobials
881826|NCT02650492|Hyperthermia, Induced
881827|NCT02650492|Laser Coagulation
881828|NCT02650492|Laser Therapy
881829|NCT02650453|Stent
881830|NCT02650453|Angioplasty
881831|NCT02650453|Endophlebectomy
881832|NCT02650440|robotics
881833|NCT02650440|locomotion
881834|NCT02650440|gait
881835|NCT02650440|walking
881836|NCT02650440|rehabilitation
881837|NCT02650414|Biological: CART 22
881838|NCT02650401|TRK
881839|NCT02650401|Tyrosine kinase
881840|NCT02650401|NTRK
881841|NCT02650401|NTRK1
881842|NCT02650401|NTRK2
881843|NCT02650401|NTRK3
881844|NCT02650401|ROS1
881845|NCT02650401|ALK
881846|NCT02650401|Pediatric
881847|NCT02650401|Relapsed
881848|NCT02650401|Refractory
881849|NCT02650401|Solid Tumor
881850|NCT02650401|Metastatic Cancer
881851|NCT02650401|Gene rearrangement
881852|NCT02650401|Neuroblastoma
881853|NCT02650401|Infantile fibrosarcoma
881854|NCT02650401|Secretory breast cancer
881855|NCT02650401|Congenital mesoblastic nephroma
881856|NCT02650401|Pontine glioma
881857|NCT02650401|Brain tumors
881858|NCT02650401|CNS tumors
881859|NCT02650401|Sarcoma
881860|NCT02650401|Ewing sarcoma
881861|NCT02650401|Glial tumors
881862|NCT02650401|Salivary Gland Cancer (MASC)
881863|NCT02650401|Papillary thyroid cancer
881864|NCT02650401|Medulloblastoma
881865|NCT02650401|Wilms tumor (anaplastic)
881866|NCT02650362|spinal cord stimulation
881867|NCT02650362|resting state functional magnetic resonance
881868|NCT02650362|voxel-based magnetic resonance morphometry
881869|NCT02650349|spinal cord stimulation
881870|NCT02650349|resting state functional magnetic resonance
881871|NCT02650349|voxel-based magnetic resonance morphometry
881872|NCT02650297|Lymphedema secondary to breast cancer
881873|NCT02650297|Breast cancer
881874|NCT02650297|Body image
881875|NCT02650271|adjuvant
881876|NCT02650271|entecavir
881877|NCT02650271|hepatocellular carcinoma
881878|NCT02650271|hepatic resection
881879|NCT02650245|breath
881880|NCT02650245|gastroenterology
881881|NCT02650245|ammonia
881882|NCT02650245|blood
881883|NCT02650245|protein
881884|NCT02650245|cirrhosis
881885|NCT02650245|encephalopathy
881886|NCT02650232|Volunteers
881887|NCT02650206|diabetes
881888|NCT02650206|macrophage
881889|NCT02650206|inflammation
881890|NCT02650206|adipose tissue
881891|NCT02650206|weight loss
881892|NCT02650206|liraglutide
881894|NCT02650180|Rehabilitation
881895|NCT02650154|sedation
881896|NCT02650154|children
881897|NCT02650154|infants
881898|NCT02650154|ketamine
881899|NCT02650154|neurotoxicity
881900|NCT02650128|Coronary Artery Disease
881901|NCT02650128|Calcified Coronary Lesions
881902|NCT02650128|Coronary Arterial Stenosis
881903|NCT02650089|Resistance Exercise
881904|NCT02650089|Postexercise Hypotension
881905|NCT02650089|Sympathovagal balance
881906|NCT02650089|Professor
881907|NCT02650011|Chronic liver disease
881908|NCT02650011|Liver cirrhosis
881909|NCT02649998|Fursemide
881910|NCT02649998|Isosorbide Dinitrate
881911|NCT02649998|Heart Decompensation
881912|NCT02649998|Clinical Trials, Randomized
881913|NCT02649998|Clinical Efficacy
881914|NCT02649972|Cobimetinib
881915|NCT02649972|15-216
881916|NCT02649959|Autism
881917|NCT02649933|pregnancy
881918|NCT02649933|obstructive sleep apnea
881919|NCT02649920|unfavorable cervix
881920|NCT02649920|obese pregnant women
881921|NCT02649894|malignant pleural effusion
881922|NCT02649881|macrophage
881923|NCT02649881|vulnerable coronary plaque
881924|NCT02649868|Radio-Opaque Bland Beads
881925|NCT02649868|Thermal Ablation
881926|NCT02649868|Transarterial Embolization
881932|NCT02649829|dendritic cell vaccination
881933|NCT02649829|chemo-immunotherapy
881934|NCT02649829|Wilms' tumor 1 (WT1)
881935|NCT02649816|Pit and fissure sealants
881936|NCT02649816|Dental Caries
881937|NCT02649816|Prevention
881938|NCT02649816|Dental undergraduate students
881939|NCT02649816|patient's caries risk
881940|NCT02649803|pediatric
881941|NCT02649803|asthma control
881942|NCT02649803|community
881943|NCT02649790|Multiple Myeloma
881944|NCT02649790|Karyopharm
881945|NCT02649790|KPT-8602
881946|NCT02649790|MM
881947|NCT02649790|Phase 1
881948|NCT02649790|Relapsed/refractory Multiple Myeloma
881949|NCT02649777|oxidative stress
881950|NCT02649764|Acute Myelogenous Leukemia
881951|NCT02649764|AML
881952|NCT02649764|Relapsed/Refractory
881953|NCT02649764|High-Risk Myelodysplastic Syndrome
881954|NCT02649764|HRMDS
881955|NCT02649764|LY2606368
881956|NCT02649764|Fludarabine
881957|NCT02649764|Fludarabine Phosphate
881958|NCT02649764|Fludara
881959|NCT02649764|Cytarabine
881960|NCT02649764|Ara-C
881961|NCT02649764|Cytosar
881962|NCT02649764|DepoCyt
881963|NCT02649764|Cytosine Arabinosine Hydrochloride
881964|NCT02649751|Cystic Fibrosis
881965|NCT02649751|Roscovitine
881966|NCT02649751|Seliciclib
881967|NCT02649751|CYC202
881968|NCT02649738|keratoconus
881969|NCT02649738|corneal tissue inlay
881970|NCT02649699|Primary Brain Cancer
881971|NCT02649673|lung carcinoma
881972|NCT02649673|topotecan
881973|NCT02649673|Hycamtin
881974|NCT02649673|ovarian neoplasms
881975|NCT02649673|LCL161
881976|NCT02649673|IAP inhibitors
881977|NCT02649660|Fabry Disease
881978|NCT02649660|Platelets
881979|NCT02649660|Lipidomics
881980|NCT02649660|Sphingolipids
881981|NCT02649660|α-Galactosidase A
881982|NCT02649660|Globotriaosylceramide
881983|NCT02649660|Gb3
881984|NCT02649660|GL-3
881985|NCT02649660|CD77
881986|NCT02649660|Alpha-galactosidase
881987|NCT02649660|Platelet activation
881988|NCT02649660|Lysosomal storage disease
881989|NCT02649660|LysoGb3
881990|NCT02649660|Spingosine-1-Phosphate
881991|NCT02649660|Platelet function
881992|NCT02649660|CD62P
881993|NCT02649660|P-selectin
881994|NCT02649647|Rectal cancer
881995|NCT02649647|Neoadjuvant therapy
881996|NCT02649647|Chemoradiotherapy
881997|NCT02649647|Resection margin
881998|NCT02649647|Bowel function
881999|NCT02649647|Anastomosis
882000|NCT02649634|Motivational Interviewing
882001|NCT02649634|Obesity
882002|NCT02649634|Weight Loss
882003|NCT02649634|Behavioral Medicine
882004|NCT02649621|Limbal Stem Cell Deficiency Amniotic Membrane Extract Eye Drop in vivo cultivation
882005|NCT02649595|Homeless
882006|NCT02649595|Homelessness
882007|NCT02649595|Respite care
882008|NCT02649595|EQ-5D
882009|NCT02649595|Quality of life questionnaire
882010|NCT02649595|Economic evaluation
882011|NCT02649595|Cost-utility analysis
882012|NCT02649582|Dendritic cells
882013|NCT02649582|Chemoimmunotherapy
882014|NCT02649582|Adjuvant therapy
882015|NCT02649556|Candidate modified risk tobacco product
882016|NCT02649556|Conventional cigarette
882017|NCT02649556|Exposure response
882018|NCT02649556|Smoking
882019|NCT02649556|Tobacco Heating System
882020|NCT02649543|Surgical Wound Infection
882021|NCT02649543|Negative-Pressure Wound Therapy
882022|NCT02649543|Wound Closure Techniques
882023|NCT02649543|Laparotomy.
882024|NCT02649543|Abdominal Wound Closure Techniques
882025|NCT02649517|decompensated heart failure
882026|NCT02649517|ischemic heart disease
882027|NCT02649517|inflammatory cardiomyopathy
882028|NCT02649491|Radiotherapy
882029|NCT02649491|Chemotherapy
882030|NCT02649491|Metabonomics
882031|NCT02649491|Electronic Sensing
882032|NCT02649491|GI Toxicity
882033|NCT02649452|Whole body Vibration
882034|NCT02649439|Vaccine
882035|NCT02649439|PSA
882036|NCT02649439|Surveillance
882037|NCT02649439|Immunotherapy
882038|NCT02649426|denervation
882039|NCT02649426|resistant hypertension
882040|NCT02649426|essential hypertension
882041|NCT02649361|Anlotinib
882042|NCT02649335|Non selective beta blockers
882043|NCT02649335|Ascites
882044|NCT02649309|Ischemic Preconditioning
882045|NCT02649309|Postconditioning
882046|NCT02649309|Angioplasty
882047|NCT02649270|Tolerability
882048|NCT02649270|Safety
882049|NCT02649270|Pharmacokinetic Study
882050|NCT02649270|preliminary pharmacodynamic study
882051|NCT02649270|Humanized Anti-CD6 Monoclonal Antibody(T1h)
882052|NCT02649257|IOL rotation
882053|NCT02649257|capsular tension ring
882054|NCT02649257|IOL rotational stability
882055|NCT02649218|QGE031
882056|NCT02649218|chronic
882057|NCT02649218|spontaneous
882058|NCT02649218|Urticaria
882059|NCT02649218|CSU
882060|NCT02649218|adults
882061|NCT02649218|Safety
882062|NCT02649192|Children
882063|NCT02649192|Vitamin Supplements
882064|NCT02649192|Influenza virus vaccine
882065|NCT02649166|Essential tremor
882066|NCT02649166|Kinetic tremor
882067|NCT02649166|Intention tremor
882068|NCT02649140|24-hour urine
882069|NCT02649140|Calcium oxalate
882070|NCT02649140|Vinegar
882071|NCT02649127|exercise
882072|NCT02649127|biomarker
882073|NCT02649088|microcirculation
882074|NCT02649088|tissue oxygenation
882075|NCT02649088|outcome
882076|NCT02649075|IBD
882077|NCT02649075|Inflammatory Bowel Disease
882078|NCT02649075|Crohn's
882079|NCT02649075|Crohns
882080|NCT02649075|SBI
882081|NCT02649075|Serum-derived bovine immunoglobulin / protein isolate
882082|NCT02649075|EnteraGam
882083|NCT02649010|Type 1 Diabetes
882084|NCT02649010|Type 2 Diabetes
882085|NCT02649010|Enlite 3 Sensor
882086|NCT02649010|Continuous Glucose Monitoring
882087|NCT02648997|Atypical Meningioma
882088|NCT02648997|Anaplastic Meningioma
882089|NCT02648984|Pulmonary vascular disease
882090|NCT02648971|knee
882091|NCT02648971|arthroscopy
882092|NCT02648971|portal
882093|NCT02648971|meniscus
882094|NCT02648971|cartilage injury
882095|NCT02648932|Acute Myeloid Leukemia (AML)
882096|NCT02648932|High-Risk Myelodysplastic Syndrome (MDS)
882097|NCT02648932|hematopoietic cell transplantation
882098|NCT02648932|haplo-cord search
882099|NCT02648932|matched unrelated donor search
882100|NCT02648893|iron
882101|NCT02648893|zinc
882102|NCT02648893|vitamin A
882103|NCT02648893|biofortified
882104|NCT02648893|efficacy
882105|NCT02648893|India
882106|NCT02648893|infant
882107|NCT02648893|trial
882108|NCT02648880|Exercise
882109|NCT02648880|Physical Activity
882110|NCT02648841|gastric cancer
882111|NCT02648841|adjuvant chemo-radiotherapy
882112|NCT02648828|Judgment
882113|NCT02648828|risk assessment
882114|NCT02648828|clinical deterioration
882115|NCT02648828|cardiac arrest
882116|NCT02648828|Rothman Index
882117|NCT02648815|Necrotizing pancreatitis
882118|NCT02648815|Sepsis
882119|NCT02648815|Infection
882120|NCT02648815|Drainage
882121|NCT02648802|breast-conserving surgery(BCS)
882122|NCT02648802|Cavity shave margin
882123|NCT02648802|Proportion of positive margins
882124|NCT02648789|Primary oral cancer
882125|NCT02648789|DNA methylation
882126|NCT02648789|Recurrence oral cancer
882127|NCT02648776|hypnotic agents
882128|NCT02648776|sleep disorders
882129|NCT02648776|elderly
882130|NCT02648750|self-management
882131|NCT02648750|rehabilitation
882132|NCT02648737|Parkinson's disease
882133|NCT02648737|Cognitive Behavioural therapy
882134|NCT02648737|generalized anxiety disorder
882135|NCT02648737|social phobia
882136|NCT02648737|cerebral connectivity
882137|NCT02648724|Advanced Solid Tumor Malignancies
882138|NCT02648711|solid tumors
882139|NCT02648698|chronic endometritis
882140|NCT02648698|CD138
882141|NCT02648685|post prandial glucose (PPG)
882142|NCT02648685|basal blood glucose (BBG)
882143|NCT02648685|overall glycaemia
882144|NCT02648633|Brain Cancer
882145|NCT02648633|Immunotherapy
882146|NCT02648633|Nivolumab
882147|NCT02648633|Radiosurgery
882148|NCT02648633|Gamma Knife
882149|NCT02648620|Paclitaxel
882150|NCT02648620|Percutaneous Transluminal Angioplasty
882151|NCT02648620|PAD
882152|NCT02648620|Peripheral Artery Disease
882153|NCT02648620|Pharmacokinetics
882154|NCT02648607|Pelvic Girdle Pain
882155|NCT02648607|Chronic Pelvic Girdle Pain
882156|NCT02648607|Symphysis Pubis Dysfunction
882157|NCT02648607|Sacroiliac Joint Dysfunction
882158|NCT02648607|Physiotherapy
882159|NCT02648607|Physical Therapy
882160|NCT02648607|Orthoses
882161|NCT02648607|Orthosis
882162|NCT02648607|Orthotic Devices
882163|NCT02648594|lung
882164|NCT02648594|thoracoscopy
882165|NCT02648594|hook wire localization
882166|NCT02648581|Behçet
882167|NCT02648581|ulcers
882168|NCT02648581|uveitis
882169|NCT02648581|ustekinumab
882170|NCT02648581|biologics
882171|NCT02648568|Sleepwalking
882172|NCT02648568|sleep terrors
882173|NCT02648568|arousal disorders
882174|NCT02648568|F513 (CIM-10)
882175|NCT02648568|F514 (CIM-10)
882176|NCT02648529|Benign childhood epilepsy with centro-temporal spikes
882177|NCT02648529|rolandic epilepsy
882178|NCT02648529|brain development
882179|NCT02648529|DTI
882180|NCT02648529|functional MRI
882181|NCT02648529|structural MRI
882182|NCT02648529|idiopathic focal epilepsy
882183|NCT02648529|cryptogenic epilepsy of childhood
882184|NCT02648516|Immune Reconstitution
882185|NCT02648516|Allogenic HLA-Mismatched Stem-Cell Transplantation
882186|NCT02648503|Sugammadex
882187|NCT02648503|Post-operative Quality Recovery Scale (PQRS)
882188|NCT02648490|metastatic or recurrent epithelial cancer
882189|NCT02648464|Hydroxychloroquine
882190|NCT02648464|anti-inflammatory
882191|NCT02648464|Myocardial infarction
882192|NCT02648464|cardiovascular diseases
882193|NCT02648438|AZD7594
882194|NCT02648438|Bioavailability
882195|NCT02648438|Healthy male subjects
882196|NCT02648438|Safety
882197|NCT02648438|Tolerability
882198|NCT02648438|Pharmacokinetics
882199|NCT02648438|Monodose inhaler
882200|NCT02648438|Multiple-dose dry powder inhaler
882201|NCT02648425|ASLAN001
882202|NCT02648399|thyroid carcinoma
882203|NCT02648399|center lymph node dissection
882204|NCT02648360|exercise
882205|NCT02648360|diet
882206|NCT02648360|patients, underserved
882207|NCT02648360|text messaging
882208|NCT02648347|vadadustat
882209|NCT02648347|AKB-6548
882210|NCT02648347|Chronic kidney disease
882211|NCT02648347|anemia
882212|NCT02648347|CKD
882213|NCT02648347|chronic renal insufficiency
882214|NCT02648347|renal impairment
882215|NCT02648347|erythropoietin
882216|NCT02648347|kidney
882217|NCT02648347|renal
882218|NCT02648347|oral anemia treatment
882219|NCT02648347|hemoglobin
882220|NCT02648347|hypoxia-inducible factor
882221|NCT02648347|HIF
882222|NCT02648347|hypoxia-inducible factor prolyl-hydroxylase inhibitor
882223|NCT02648347|HIF-PHI
882224|NCT02648347|efficacy
882225|NCT02648347|safety
882226|NCT02648347|Phase 3
882227|NCT02648347|cardiovascular
882228|NCT02648347|NDD-CKD
882232|NCT02648321|Motivational Interviewing
882233|NCT02648321|Exercise
882234|NCT02648308|Education, Medical
882235|NCT02648282|vaccine
882236|NCT02648282|immunotherapy
882237|NCT02648282|antibody
882238|NCT02648282|PD-1
882239|NCT02648282|radiation
882240|NCT02648256|Pneumocystis jirovecii
882241|NCT02648256|Polymerase Chain Reaction
882242|NCT02648256|Oropharyngeal Rinse
882243|NCT02648243|Qatar
882244|NCT02648243|Acute Coronary Syndrome
882245|NCT02648243|Pharmacist
882246|NCT02648243|Medication burden
882247|NCT02648243|Mortality
882248|NCT02648243|Readmission
882249|NCT02648243|Adherence
882250|NCT02648243|Impact
882251|NCT02648230|Ischemia
882252|NCT02648230|Fractional Flow Reserve
882253|NCT02648230|Stent
882254|NCT02648191|Obesity
882255|NCT02648191|Bariatric Surgery
882256|NCT02648191|No invasive intra-auricular vagus nerve stimulation
882257|NCT02648191|Weight loss
882258|NCT02648191|Autonomic nervous system
882259|NCT02648113|Myocardial Infarction
882260|NCT02648113|Anemia
882261|NCT02648113|Blood Transfusion
882266|NCT02648074|asthma
882267|NCT02648074|eosinophils
882268|NCT02648074|airway smooth muscle
882269|NCT02648074|airway remodelling
882270|NCT02648074|integrins
882271|NCT02648074|cytokines
882272|NCT02648061|Blood circulation
882273|NCT02648061|Follow-up studies
882274|NCT02648061|Biological markers
882275|NCT02648061|Hemodynamics
882276|NCT02648048|Idiopathic Pulmonary Fibrosis
882277|NCT02648048|Vismodegib
882278|NCT02648048|Pirfenidone
882279|NCT02648022|Care Integration
882280|NCT02648022|Hepatitis C
882281|NCT02648022|Substance Use Disorder
882282|NCT02648022|PTSD
882283|NCT02647970|Energy metabolism
882284|NCT02647957|acute ischemic stroke
882285|NCT02647957|quality
882292|NCT02647840|dysphonia
882293|NCT02647840|voice therapy
882294|NCT02647827|Acupuncture
882295|NCT02647827|Metformin
882296|NCT02647827|Glucose metabolism
882297|NCT02647827|Hba1c
882298|NCT02647814|Parent activation
882299|NCT02647814|Text-messages
882300|NCT02647814|LEP
882301|NCT02647814|Latino populations
882302|NCT02647814|pediatrics
882303|NCT02647801|Network approach
882304|NCT02647801|mindfulness
882305|NCT02647801|self-control
882306|NCT02647801|ambulatory assessment
882307|NCT02647788|Pain, Postoperative
882308|NCT02647775|Thoracoscopic surgery
882309|NCT02647723|Omega-3
882310|NCT02647723|Fatty acid
882311|NCT02647723|docosahexaenoic
882312|NCT02647723|Pregnant
882313|NCT02647723|neurodevelopment
882314|NCT02647723|stress
882315|NCT02647723|urban
882316|NCT02647723|african-american
882317|NCT02647723|supplement
882318|NCT02647723|nutrition
882319|NCT02647723|mental health
882320|NCT02647710|HIV Prevention
882321|NCT02647710|Juvenile Justice
882322|NCT02647710|Sexual Health
882323|NCT02647710|Evidence Based Intervention
882324|NCT02647697|UCB3491
882325|NCT02647697|Phase 1
882326|NCT02647697|Pharmacokinetics
882327|NCT02647697|Radiprodil
882328|NCT02647697|Healthy volunteers
882329|NCT02647684|Cancer
882330|NCT02647684|Parenting
882331|NCT02647684|Self-directed Triple P
882332|NCT02647671|Colon polyp
882333|NCT02647671|Colorectal cancer
882334|NCT02647671|Chemoprevention
882335|NCT02647671|Natural product
882336|NCT02647658|acute low back pain
882337|NCT02647658|primary care
882338|NCT02647658|psychologically informed physical therapy
882339|NCT02647658|cluster randomized pragmatic trial
882340|NCT02647658|comparative effectiveness
882341|NCT02647658|secondary prevention
882344|NCT02647619|Primary Dd disase
882345|NCT02647619|MCP joint
882346|NCT02647580|Growth
882347|NCT02647580|Children
882348|NCT02647580|Appetite-regulating hormones
882349|NCT02647580|Gut Microbiota
882350|NCT02647567|Cognitive
882351|NCT02647567|Aerobic Exercise
882352|NCT02647567|Performance
882353|NCT02647554|sepsis
882354|NCT02647554|septic shock
882355|NCT02647554|Ulinastatin
882356|NCT02647554|adult
882357|NCT02647554|China
882358|NCT02647541|Children
882359|NCT02647541|Congenital heart disease
882360|NCT02647541|Nutritional status
882361|NCT02647541|Bioelectrical impedance
882362|NCT02647476|immunonutrition
882363|NCT02647476|gastric cancer
882364|NCT02647476|enteral nutrition
882365|NCT02647463|Attachment
882366|NCT02647463|Cortisol
882367|NCT02647463|Parent sensitivity
882368|NCT02647411|Prevalence
882369|NCT02647411|Myopia
882370|NCT02647398|Cancer survivors
882371|NCT02647398|training
882372|NCT02647398|exercise
882373|NCT02647398|cancer-related fatigue
882380|NCT02647372|parkinson
882381|NCT02647372|deep brain stimulation
882382|NCT02647372|globus pallidus
882383|NCT02647372|subthalamic nucleus
882384|NCT02647320|type 2 diabetes mellitus
882385|NCT02647320|interventional
882386|NCT02647320|double blind
882387|NCT02647320|phase 2
882388|NCT02647281|Single dose
882389|NCT02647281|Multiple ascending doses (MAD)
882390|NCT02647281|Pharmacokinetics
882391|NCT02647281|Safety
882392|NCT02647281|GSK3389404
882393|NCT02647281|Tolerability
882394|NCT02647268|Uterine contraction
882395|NCT02647268|Oxytocin
882396|NCT02647268|Magnesium sulphate
882397|NCT02647255|crescentic IgA nephropathy
882398|NCT02647255|plasma exchange treatment or plasmapheresis
882399|NCT02647255|randomized controlled trial
882400|NCT02647255|intensive immunosuppressive treatment
882401|NCT02647255|methylprednisolone pulse
882402|NCT02647216|Mindfulness Based Cognitive Therapy (MBCT)
882403|NCT02647216|anxiety
882404|NCT02647216|depression
882405|NCT02647203|Fluoride toothpaste
882406|NCT02647203|Root caries
882407|NCT02647203|Randomized clinical trial
882408|NCT02647190|Erwinia Chrysanthemi Asparaginase
882409|NCT02647190|15-107
882410|NCT02647164|Non-small-cell lung carcinoma
882411|NCT02647164|Circulating tumor cells
882412|NCT02647151|Acid Methyl Aminolevulinate (MAL)
882413|NCT02647151|Aminolevulinic Gel (ALA) and Actinic Keratosis
882414|NCT02647112|Bladder cancer
882415|NCT02647112|Urine
882416|NCT02647112|Methylation
882417|NCT02647099|Aspirin
882418|NCT02647099|PI3K signaling pathway
882419|NCT02647086|Eczema
882420|NCT02647073|Mobile Monitoring
882421|NCT02647073|Post-Opioid Consumption
882422|NCT02647073|Vital Signs
882423|NCT02647060|cardiopulmonary exercise testing
882424|NCT02647060|right ventricle function
882425|NCT02647060|cardio output
882426|NCT02647060|pulmonary hypertension
882427|NCT02647060|quality of life
882428|NCT02647047|spinal analgesia
882429|NCT02647047|epidural analgesia
882430|NCT02647047|laparotomic liver resection
882431|NCT02647047|ERAS
882432|NCT02647047|length of stay
882433|NCT02647021|physical therapy
882434|NCT02647021|cancer rehabilitation
882435|NCT02647021|exercise
882436|NCT02647008|outpatient hysteroscopy, TENS
882437|NCT02646982|Alzheimer's disease
882438|NCT02646982|Vascular function
882439|NCT02646982|Neuroinflammation
882440|NCT02646956|Sweet Taste
882441|NCT02646956|Psychophysics
882442|NCT02646956|Genetics
882443|NCT02646956|Diet
882444|NCT02646956|Age
882445|NCT02646956|Nonnutritive Sweetener
882446|NCT02646943|Cohort
882447|NCT02646943|Biomarkers
882448|NCT02646943|Cardiomyopathy
882452|NCT02646891|Rotavirus Vaccine
882453|NCT02646878|Type 1 Diabetes
882454|NCT02646878|Type 2 Diabetes
882455|NCT02646878|Harmony Sensor
882456|NCT02646878|Continuous Glucose Monitoring
882457|NCT02646878|CGM
882458|NCT02646865|social phobia
882459|NCT02646865|compassion
882460|NCT02646865|shame
882461|NCT02646839|Acute Lymphoblastic Leukemia (ALL)
882462|NCT02646839|Acute Myeloid Leukemia (AML)
882463|NCT02646839|Myelodysplastic Syndrome (MDS)
882464|NCT02646839|KIR-Favorable
882465|NCT02646839|Haploidentical Transplantation
882466|NCT02646839|Allogeneic Hematopoietic Cell Transplantation
882467|NCT02646800|Micafungin
882468|NCT02646800|Candidiasis
882469|NCT02646800|Aspergillosis
882470|NCT02646800|Antifungal
882471|NCT02646774|Aspergillosis
882472|NCT02646774|Antifungal
882473|NCT02646774|Micafungin
882474|NCT02646748|Advanced
882475|NCT02646670|diabetic macular edema
882476|NCT02646670|aflibercept
882477|NCT02646670|ranibizumab
882478|NCT02646605|Depression
882479|NCT02646605|AIDS
882480|NCT02646605|HIV
882481|NCT02646579|Orthopedics
882482|NCT02646527|dignity, end of life, existential, treatment
882483|NCT02646514|Cholangiocarcinoma, radiofrequency ablation, metal stent
882484|NCT02646488|cholesterol
882485|NCT02646488|smoking
882486|NCT02646488|aspirin
882487|NCT02646488|chronic care model
882488|NCT02646475|renin-angiotensin system
882489|NCT02646475|angiotensin
882490|NCT02646475|insulin resistance
882491|NCT02646475|blood pressure
882492|NCT02646462|pancreas adenocarcinoma, lymph node metastases
882493|NCT02646449|Major Depressive Disorder
882494|NCT02646449|Alcohol Use Disorder
882495|NCT02646436|unplanned peritoneal dialysis
882496|NCT02646436|unplanned heamodialysis
882497|NCT02646423|Trial of labor after cesarean
882498|NCT02646423|Elective repeat cesarean delivery
882499|NCT02646423|Decision tool
882500|NCT02646423|Shared decision making
882501|NCT02646410|malaria
882502|NCT02646410|seasonal malaria chemoprevention
882503|NCT02646410|immunity
882504|NCT02646410|resistance
882505|NCT02646410|sulfadoxine-pyrimethamine
882506|NCT02646410|amodiaquine
882507|NCT02646410|delivery method
882508|NCT02646397|glomerular filtration rate
882509|NCT02646397|hypertension
882510|NCT02646345|Checklist
882511|NCT02646345|Mortality
882512|NCT02646345|Latin America
882513|NCT02646345|Surgery
882514|NCT02646345|Morbidity
882515|NCT02646332|Helicobacter pylori
882516|NCT02646332|Eradication rate
882517|NCT02646306|shoulder
882518|NCT02646306|proprioception
882519|NCT02646306|movement
882520|NCT02646306|reaching
882521|NCT02646280|Low back pain
882522|NCT02646280|interoceptive awareness
882523|NCT02646280|motor imagery
882524|NCT02646280|massage
882525|NCT02646267|Atrial fibrillation
882526|NCT02646267|Dabigatran
882527|NCT02646267|Warfarin
882528|NCT02646267|Anticoagulation
882529|NCT02646267|Elderly
882530|NCT02646254|tetralogy of fallot, cardioplegia
882531|NCT02646241|stomach neoplasm
882532|NCT02646241|biopsy
882537|NCT02646111|"Hepatitis C Virus"
882538|NCT02646111|"Triple Therapy"
882539|NCT02646111|"PI Failure"
882540|NCT02646111|"Genotype 1"
882541|NCT02646098|NHL
882542|NCT02646098|mantle cell lymphoma
882543|NCT02646098|diffuse large B-cell lymphoma
882544|NCT02646072|diabetes mellitus
882545|NCT02646072|aqueous humor
882546|NCT02646072|inflammatory cytokines
882547|NCT02646072|cystoid macular edema, postoperative
882548|NCT02646072|nonsteroidal anti-inflammatory drugs
882549|NCT02646046|Cardiopulmonary Resuscitation
882550|NCT02646046|Emergency Medical Services
882551|NCT02646046|Cell phones
882552|NCT02646046|Simulation Training
882553|NCT02646033|Intraocular Pressure, Trendelenburg position
882554|NCT02646020|pruritus
882555|NCT02646020|Non-small Cell Lung Cancer
882556|NCT02646020|Receptor, Epidermal Growth Factor
882557|NCT02646020|tyrosine kinase inhibitor
882558|NCT02646007|Autologous Cell therapy Kienböck's disease
882559|NCT02646007|bone marrow derived mesenchymal stromal/stem cell
882560|NCT02645994|Closed Loop Anesthesia Delivery System
882561|NCT02645994|Target Controlled Infusion
882562|NCT02645981|Donafeinb
882563|NCT02645981|Sorafenib
882564|NCT02645981|Phase 3
882565|NCT02645981|Overall Survival
882566|NCT02645968|Pneumology
882567|NCT02645968|Registry
882568|NCT02645968|EXCITING
882569|NCT02645968|Interstitial lung disease
882570|NCT02645968|ILD
882571|NCT02645942|Carnitine
882572|NCT02645942|placebo
882573|NCT02645942|risk factors
882574|NCT02645916|Cold Hypersensitivity in the Hands
882575|NCT02645916|Korean medicine
882576|NCT02645916|DSGOST
882577|NCT02645903|transversus abdominis plane block
882578|NCT02645903|living liver transplantation
882579|NCT02645903|postoperative analgesia
882580|NCT02645890|Benign Prostatic Hyperplasia
882581|NCT02645890|Healthy Male Volunteer
882582|NCT02645890|Tamsulosin
882583|NCT02645890|Tadalafil
882584|NCT02645877|Pre-hospital Care
882585|NCT02645877|Diseases Spectrum
882586|NCT02645877|Call Demands
882587|NCT02645877|Emergency Response Time
882588|NCT02645864|Esophageal squamous cell carcinoma
882589|NCT02645864|Apatinib
882590|NCT02645864|Irinotecan
882591|NCT02645851|Fluid Therapy
882592|NCT02645851|Plasma Substitutes
882593|NCT02645851|Fluid Balance
882594|NCT02645838|Motivational Interviewing
882595|NCT02645838|Smoking Cessation
882596|NCT02645825|superficial adenopathy - echography
882597|NCT02645812|Fatigue
882598|NCT02645812|Brief Fatigue Inventory (BFI)
882599|NCT02645812|Primary care
882600|NCT02645812|General Practitioners
882601|NCT02645786|thyroid neoplasms
882602|NCT02645786|heart
882603|NCT02645786|thyroxine
882604|NCT02645786|thyrotoxicosis
882605|NCT02645708|RIRS
882606|NCT02645708|EPVL
882607|NCT02645708|PDI(Percussion,Diuresis,Inversion)
882608|NCT02645708|Randomized Controlled Trial
882609|NCT02645695|Pulmonary Rehabilitation
882610|NCT02645695|Chest Physiotherapy
882611|NCT02645695|High Frequency Chest Wall Oscillation
882612|NCT02645682|central venous catheter (CVC)
882613|NCT02645682|catheter-related bloodstream infection (CRBSI)
882614|NCT02645682|catheter-related thrombosis (CRT)
882615|NCT02645656|Oral Submucous Fibrosis
882616|NCT02645656|Curcumin
882617|NCT02645643|medical students
882618|NCT02645643|professionalism
882619|NCT02645643|medical education
882620|NCT02645643|study emotion
882621|NCT02645630|Cervical spine
882622|NCT02645630|Spinal manipulation
882623|NCT02645604|Artemisinin Combination Therapy (ACT)
882624|NCT02645591|Prostate cancer
882625|NCT02645591|Dehydrated human amnion/chorion membrane
882626|NCT02645591|dHACM
882627|NCT02645591|Robotic assisted laparoscopic radical prostatectomy
882628|NCT02645591|RARP
882629|NCT02645591|AmnioFix®
882630|NCT02645591|Sexual function score
882631|NCT02645591|Neurovascular bundle inflammation
882632|NCT02645591|Questionnaire
882633|NCT02645591|Survey
882634|NCT02645578|Coma
882635|NCT02645578|traumatic brain injury
882636|NCT02645578|median nerve stimulation
882637|NCT02645552|Traumatic brain injury
882638|NCT02645513|mHealth
882639|NCT02645513|text message
882640|NCT02645513|case management
882641|NCT02645500|Physical Activity
882642|NCT02645500|Family well-being
882643|NCT02645448|Resistance Exercise
882644|NCT02645448|Diabetes Mellitus
882645|NCT02645448|Heart Rate Variability
882646|NCT02645409|Fluorescence
882647|NCT02645409|Imaging
882648|NCT02645409|Partial nephrectomy
882649|NCT02645409|Radical nephrectomy
882650|NCT02645396|Cytomegalovirus
882651|NCT02645383|Pattern scan laser
882652|NCT02645383|Proliferative diabetic retinopathy
882653|NCT02645383|Pain
882654|NCT02645370|Migraine
882655|NCT02645370|Danzhen
882656|NCT02645370|Topiramate
882657|NCT02645370|Headache diary APP
882658|NCT02645370|preventive treatment
882659|NCT02645357|Oncology Patients
882660|NCT02645357|evidence-based
882661|NCT02645357|computerized
882662|NCT02645357|decision
882663|NCT02645357|support system
882664|NCT02645357|linked
882665|NCT02645357|electronic health records
882666|NCT02645344|Unilateral neglect
882667|NCT02645344|Right hemiplegia
882668|NCT02645318|Circulating Tumor DNA
882669|NCT02645318|Lung cancer
882670|NCT02645318|Targeted sequencing
882671|NCT02645305|Safety and Efficacy
882672|NCT02645305|Adipose stem cells
882673|NCT02645305|Stem Cell therapy
882674|NCT02645279|newborn
882675|NCT02645279|MRI
882676|NCT02645279|oral 30% glucose
882677|NCT02645253|Safety
882678|NCT02645253|Pharmacokinetics
882679|NCT02645253|Pharmacodynamics
882680|NCT02645253|Glucocorticoid receptor modulator
882681|NCT02645253|Healthy male subjects
882682|NCT02645201|probiotic
882683|NCT02645188|Electromyography
882684|NCT02645188|Exercise
882685|NCT02645175|Paclitaxel
882686|NCT02645175|docetaxel
882687|NCT02645175|vinorelbine
882688|NCT02645175|eribulin
882689|NCT02645162|Pakistan
882690|NCT02645162|Early Child Development, Care and Education
882691|NCT02645162|Youth Leaders
882692|NCT02645149|Metastatic Melanoma
882693|NCT02645149|Molecular Testing
882694|NCT02645149|Targeted Therapy
882695|NCT02645123|spinal mobilization
882696|NCT02645123|manual therapy
882697|NCT02645123|gait analysis
882698|NCT02645123|low back pain
882699|NCT02645123|chronic
882700|NCT02645097|Adult
882701|NCT02645097|nerve blocks in foot and ankle surgery
882702|NCT02645097|saphenous
882703|NCT02645071|physical activity
882704|NCT02645071|family well being,
882705|NCT02645071|health
882706|NCT02645058|Ureterorenoscopy
882707|NCT02645058|extracorporeal shock waves lithotripsy
882708|NCT02645045|Dry eye
882709|NCT02645045|Lipiview
882710|NCT02645045|Tear Lipid Layer
882711|NCT02645045|meibomian gland dysfunction
882712|NCT02645032|Typhoid conjugate vaccine
882713|NCT02645032|Vi-DT
882714|NCT02645032|Safety
882715|NCT02645032|Immunogenicuty
882716|NCT02645006|falls
882717|NCT02645006|elderly
882718|NCT02645006|Exercise,Physical
882719|NCT02645006|vitamin d
882720|NCT02645006|home hazards
882721|NCT02645006|mediterranean diet
882722|NCT02645006|body mass index
882723|NCT02645006|lower extremity exercise movement technics
882724|NCT02645006|vitamin D intake
882725|NCT02645006|Short Physical Performance Battery (SPPB o Test de Guralnik)
882726|NCT02644980|Target Controlled Infusion
882727|NCT02644954|psoriasis
882728|NCT02644954|Metformin
882729|NCT02644928|Chronic kidney disease
882730|NCT02644928|Bariatric Surgery Candidate
882731|NCT02644928|Caloric restriction
882732|NCT02644915|ischemia-reperfusion(I/R) injury
882733|NCT02644915|Edaravone
882734|NCT02644902|Avatar assisted cascade training and supervision
882735|NCT02644902|maternal depression
882736|NCT02644902|postconflict
882737|NCT02644902|THP
882738|NCT02644889|Epidermal growth factor receptor(EGFR)
882739|NCT02644889|NSCLC
882740|NCT02644876|Postoperative pulmonary complications
882741|NCT02644876|Selective anticholinergic bronchodilator
882742|NCT02644876|High risk patients
882743|NCT02644876|Postoperative period
882744|NCT02644876|Postoperative complications
882745|NCT02644824|Congenital Heart Disease (CHD)
882746|NCT02644824|Cardiopulmonary Bypass (CPB)
882747|NCT02644824|Cardiac Index
882748|NCT02644824|Hemodynamics
882749|NCT02644824|Pediatrics
882750|NCT02644811|Miniscrew
882751|NCT02644811|Temporary anchorage device (TAD)
882752|NCT02644811|mini-implants
882753|NCT02644798|ARDS
882754|NCT02644798|Gene polymorphism
882755|NCT02644785|cardiac by-pass
882756|NCT02644785|protamine
882757|NCT02644785|tryptase
882758|NCT02644785|hypotension
882759|NCT02644785|anaphylaxis
882760|NCT02644772|Acute Exacerbation of COPD
882761|NCT02644772|Clinical problems in COPD
882762|NCT02644759|Stem Cells
882763|NCT02644759|Transplantation
882764|NCT02644759|Immunomodulation
882765|NCT02644759|CD34
882766|NCT02644759|CD133
882767|NCT02644759|ClinicMACS
882768|NCT02644746|degenerative lumbar spinal stenosis
882769|NCT02644746|acupuncture
882770|NCT02644746|randomized controlled trial
882771|NCT02644655|Recurrent B-Cell Tumor
882772|NCT02644655|Refractory B-Cell Tumor
882773|NCT02644655|New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T Cells
882774|NCT02644655|safety
882775|NCT02644655|prognosis
882776|NCT02644616|tolvaptan
882777|NCT02644616|safety and efficacy
882778|NCT02644616|left heart valves replacement
882779|NCT02644603|Enhanced Recovery After Surgery
882780|NCT02644603|hepatocellular carcinoma
882781|NCT02644590|Melatonin
882782|NCT02644590|Nocturnal Hypertension
882783|NCT02644590|Type 1 Diabetes Melitus
882784|NCT02644577|Metformin
882785|NCT02644577|antipsychotic-induced metabolic syndrome
882786|NCT02644577|bipolar disorder
882787|NCT02644564|Soft tissue shoulder injury
882788|NCT02644564|Rotator cuff tear
882789|NCT02644564|Ultrasonography
882790|NCT02644538|HBsAg clearance
882791|NCT02644525|Cameroon
882792|NCT02644525|Filaricidal
882793|NCT02644525|Randomized
882794|NCT02644525|Ivermectin
882795|NCT02644525|Worm
882796|NCT02644434|Percutaneous Coronary Intervention
882797|NCT02644434|Coronary Bifurcation Intervention
882798|NCT02644434|Randomized Clinical Trial
882799|NCT02644421|Neuropathic Pain
882800|NCT02644421|Sciatica
882801|NCT02644408|Chemoradiotherapy
882802|NCT02644408|Esophageal Squamous Cancer
882803|NCT02644408|Megestrol
882804|NCT02644382|breast cancer
882805|NCT02644382|decision making
882806|NCT02644382|surgery
882807|NCT02644382|qualitative
882808|NCT02644317|Motor development delay
882809|NCT02644317|balance
882810|NCT02644317|flatfoot
882811|NCT02644317|shoe insert
882812|NCT02644291|medulloblastoma
882813|NCT02644291|Diffuse Intrinsic Pontine Glioma (DIPG)
882814|NCT02644291|high grade glioma
882815|NCT02644291|glioblastoma
882816|NCT02644291|brain stem malignant glioma
882817|NCT02644265|Acute acquired brain injury
882818|NCT02644265|Disorders of consciousness
882819|NCT02644265|Traumatic brain injury
882820|NCT02644265|Non-traumatic brain injury
882821|NCT02644265|Anoxic-ischemic encephalopathy
882822|NCT02644265|Stroke
882823|NCT02644265|Vegetative state
882824|NCT02644265|Minimal conscious state
882825|NCT02644265|Locked-in syndrome
882826|NCT02644265|Functional magnetic resonance imaging
882827|NCT02644265|Electroencephalography
882828|NCT02644174|Obesity
882829|NCT02644174|Lung function test
882830|NCT02644174|Bariatric surgery
882831|NCT02644161|stroke
882832|NCT02644161|depression
882833|NCT02644161|stroke sequelae
882834|NCT02644161|acupuncture
882835|NCT02644161|DCEAS
882836|NCT02644161|CAI
882837|NCT02644161|LAS
882838|NCT02644135|Healthy volunteer
882839|NCT02644122|advanced cancer
882840|NCT02644122|metastatic cancer
882841|NCT02644122|Squamous Cell Carcinoma of the Head and Neck
882842|NCT02644122|SCCHN
882843|NCT02644122|gene mutation
882844|NCT02644122|PIK3R1, PIK3R5 and PIK3AP1
882845|NCT02644122|PIK3CG
882846|NCT02644122|AKT and mTOR
882847|NCT02644122|PIK3CA gene
882848|NCT02644122|PI-3 kinase inhibitor
882849|NCT02644122|PI-3 kinase pathway genes
882850|NCT02644096|Rehabilitation
882851|NCT02644096|RCT
882852|NCT02644096|User Involvement
882853|NCT02644096|Self-Rated Health
882854|NCT02644070|Alveolar bone loss
882855|NCT02644070|Alveoloplasty
882856|NCT02644070|Bone remodeling
882857|NCT02644070|Xenograft
882858|NCT02644070|Tooth socket
882859|NCT02644070|Dental implant
882860|NCT02644044|Progressive multiple sclerosis
882861|NCT02644044|methotrexate
882862|NCT02644031|Instrumentation
882863|NCT02644031|Post-operative pain
882864|NCT02644031|Root canal preparation
882865|NCT02644018|Ingavirin
882866|NCT02644018|Common Cold
882867|NCT02644018|Influenza
882868|NCT02644018|Acute Respiratory Viral Infections
882869|NCT02644018|pediatric clinical trial
882870|NCT02644018|Imidazolyl ethanamide pentandioic acid
882871|NCT02643979|Ketamine
882872|NCT02643979|Propofol
882873|NCT02643979|Ketofol
882874|NCT02643979|Obese
882875|NCT02643979|Upper gastrointestinal endoscopy
882876|NCT02643979|Sedation
882877|NCT02643979|Bariatric
882878|NCT02643966|whole breast ultrasound
882879|NCT02643966|digital breast tomosynthesis
882880|NCT02643966|breast density
882881|NCT02643966|breast cancer screening
882882|NCT02643953|Maternal Health
882883|NCT02643953|Maternal Mortality
882884|NCT02643953|Global Health
882885|NCT02643953|RCT
882886|NCT02643940|Percutaneous Coronary Intervention (PCI)
882887|NCT02643940|Chronic Total Occlusion (CTO)
882888|NCT02643940|Cardiac MRI
882889|NCT02643940|Instantaneous wave-free ratio (iFR)
882892|NCT02643823|Human Umbilical Cord Mesenchymal Stem Cell
882893|NCT02643823|Mesenchymal Stem Cell
882894|NCT02643823|Rheumatoid Arthritis
882895|NCT02643810|exercise training
882896|NCT02643797|diabetes
882897|NCT02643797|medical assistant
882898|NCT02643797|health coach
882899|NCT02643797|glycemic control
882900|NCT02643797|pragmatic trial
882901|NCT02643784|acute ischemic stroke
882902|NCT02643771|Dental Scaling
882903|NCT02643771|Blood Glucose
882904|NCT02643771|Hemoglobin A, Glycosylated
882905|NCT02643758|Myopia control, bifocal soft contact lenses, children
882906|NCT02643745|acute kidney injury
882907|NCT02643745|cardiac surgery
882908|NCT02643732|Activity
882909|NCT02643719|migraine
882910|NCT02643719|topiramate
882911|NCT02643706|Aldehyde dehydrogenase 2
882912|NCT02643706|contrast induced nephropathy
882913|NCT02643706|Gene polymorphism
882914|NCT02643693|Conventional cigarette
882915|NCT02643693|Nicotine lactate delivery system
882916|NCT02643693|e-cigarette
882917|NCT02643693|VUSE
882918|NCT02643693|Combustible cigarette
882919|NCT02643680|Biocellulose
882920|NCT02643680|Silk sericin
882921|NCT02643680|Polyhexamethylene biguanide
882922|NCT02643680|Split thickness skin graft donor site
882923|NCT02643667|Radical prostatectomy (RP)
882924|NCT02643654|interleukin-1alpha
882925|NCT02643641|Grass pollen allergy
882926|NCT02643641|subcutaneous immunotherapy
882927|NCT02643641|allergy vaccine
882928|NCT02643641|dose regimen
882929|NCT02643615|Visual Evoked Potentials
882930|NCT02643589|haploidentical hematopoietic Stem Cell Transplantation Antithymocyte globulin
882931|NCT02643589|acute graft-versus-host disease
882932|NCT02643589|antithymocyte globulin
882933|NCT02643563|Brachial Plexus Block
882934|NCT02643563|Anesthetics, Local
882935|NCT02643524|Adult
882936|NCT02643524|CAM boot
882937|NCT02643524|controlled ankle movement
882938|NCT02643498|Stereotactic Body Radiotherapy (SBRT)
882939|NCT02643498|15-109
882940|NCT02643472|neonate
882941|NCT02643472|newborn
882942|NCT02643472|neonatal intensive care unit
882943|NCT02643472|NICU
882944|NCT02643472|NICU discharge
882945|NCT02643472|parent navigator
882946|NCT02643472|peer to peer
882947|NCT02643472|peer coaching
882952|NCT02643446|Poliovirus Vaccine, Inactivated
882953|NCT02643446|Poliovirus Vaccine, Oral
882954|NCT02643446|Immunity
882955|NCT02643446|Seroconversion
882956|NCT02643433|Immunogenicity
882957|NCT02643433|Coadministration
882958|NCT02643433|Measles
882959|NCT02643433|Rubella
882960|NCT02643433|Japanese encephalitis
882961|NCT02643433|Vaccine
882962|NCT02643420|Neutropenia
882963|NCT02643420|Breast Cancer
882964|NCT02643420|Long-acting Myeloid Growth Factor
882965|NCT02643420|Early Stage Breast Cancer
882966|NCT02643420|Docetaxel + Cyclophosphamide (TC) chemotherapy
882967|NCT02643407|squamous cell carcinoma
882968|NCT02643407|nedaplatin
882969|NCT02643407|cisplatin
882970|NCT02643407|docetaxel
882971|NCT02643394|Acetaminophen
882972|NCT02643394|Postoperative pain
882973|NCT02643394|Sinus Surgery
882974|NCT02643381|etomidate
882975|NCT02643381|ketamine
882976|NCT02643381|endotracheal intubation
882977|NCT02643381|anesthesia induction medications
882978|NCT02643368|Polio
882979|NCT02643368|Inactivated polio vaccine
882980|NCT02643368|oral polio vaccine
882981|NCT02643368|monovalent type 2 oral polio vaccine
882982|NCT02643355|Narcotic Withdrawal
882983|NCT02643355|Opiate Withdrawal
882984|NCT02643355|Emergency Department
882987|NCT02643303|Durvalumab
882988|NCT02643303|MEDI4736
882989|NCT02643303|Tremelimumab
882990|NCT02643303|PolyICLC
882991|NCT02643303|Hiltonol
882992|NCT02643303|Locally Recurrent Breast Cancer
882993|NCT02643303|Metastatic Melanoma
882994|NCT02643303|In Situ
882995|NCT02643303|CTLA-4 Antibody
882996|NCT02643303|PD-L1 Antibody
882997|NCT02643303|TLR3 Agonist
882998|NCT02643290|Adult Scoliosis
882999|NCT02643290|Pain Management
883000|NCT02643290|Orthosis
883001|NCT02643264|insula
883002|NCT02643264|alcohol addiction
883003|NCT02643264|transcranial magnetic stimulation
883004|NCT02643251|Diabetes Mellitus
883005|NCT02643251|Pain
883006|NCT02643251|Foot Pain
883007|NCT02643251|Neuropathy
883008|NCT02643160|Trunk Training
883009|NCT02643160|Motor Function
883010|NCT02643147|Heart Failure
883011|NCT02643147|Renal Failure
883012|NCT02643147|Biomarker guided-therapy
883013|NCT02643147|Loop diuretics
883014|NCT02643147|Carbohydrate antigen 125
883015|NCT02643134|ESWL
883016|NCT02643134|EPVL
883017|NCT02643134|PDI(Percussion,Diuresis,Inversion)
883018|NCT02643134|Randomized Controlled Trial(RCT)
883019|NCT02643108|Lateral episiotomy
883020|NCT02643108|Obstetrical anal sphincter injury
883021|NCT02643108|Vacuum extraction
883022|NCT02643108|Anal incontinence
883023|NCT02643069|Frailty
883024|NCT02643069|Frailty tools
883025|NCT02643069|Clinical settings
883026|NCT02643069|Disability
883027|NCT02643069|Quality of life
883028|NCT02643069|Functional Autonomy
883031|NCT02643017|cognitive function
883032|NCT02643017|desflurane
883033|NCT02643017|dexmedetomidine
883038|NCT02642952|arterial stiffness, central hemodynamics
883039|NCT02642926|menorrhagia
883040|NCT02642926|higham PBAC score
883041|NCT02642926|endometrial ablation
883042|NCT02642926|bipolar energy
883043|NCT02642926|monopolar energy
883047|NCT02642900|Complete denture
883048|NCT02642900|Candida spp
883049|NCT02642900|Photodynamic therapy
883050|NCT02642887|gingival recession
883051|NCT02642887|tunnel technique
883052|NCT02642887|Miller Class I and II
883053|NCT02642835|mesh
883054|NCT02642835|pelvic organ prolapse
883055|NCT02642822|Cytomegalovirus
883056|NCT02642796|Percutaneous Electric Nerve Stimulation
883057|NCT02642796|Lumbosacral plexus
883058|NCT02642796|surgical wound
883059|NCT02642796|postoperative analgesia
883060|NCT02642796|transcutaneous electrical stimulation
883061|NCT02642783|laxatives
883062|NCT02642783|sensory evaluation
883063|NCT02642783|acceptability
883064|NCT02642783|colonoscopy
883065|NCT02642770|Transesophageal echocardiography, Speckle tracking strain
883066|NCT02642757|alcohol drinking
883067|NCT02642757|hazardous alcohol use
883068|NCT02642757|risky alcohol consumption
883069|NCT02642757|heavy alcohol consumption
883070|NCT02642731|total knee arthroplasty
883071|NCT02642731|Kidney function
883072|NCT02642731|Renal markers
883073|NCT02642718|preemptive analgesia
883074|NCT02642718|postoperative pain
883075|NCT02642718|NSAIDs
883076|NCT02642718|ketorolac
883077|NCT02642718|abdominal hysterectomy
883078|NCT02642692|ACL reconstruction
883079|NCT02642692|Single bundle
883080|NCT02642692|Clinical results
883081|NCT02642692|Soccer players
883082|NCT02642679|Split-thickness skin graft, donor site, chitosan, dressing
883083|NCT02642666|Attention
883084|NCT02642666|Hyperactivity
883085|NCT02642666|Impulsivity
883086|NCT02642666|Yoga
883087|NCT02642666|Preschool
883088|NCT02642653|Fra(X) Syndrome
883089|NCT02642653|Trinucleotide Repeat Expansion
883090|NCT02642653|Fragile X Syndrome
883091|NCT02642653|Fragile X Mental Retardation Syndrome
883092|NCT02642653|Intellectual Disability
883093|NCT02642653|Parent Implemented Language Intervention (PILI)
883094|NCT02642653|FXS
883095|NCT02642653|Mental Retardation, X-linked
883096|NCT02642653|Genetic Diseases, X-linked
883097|NCT02642653|Neurobehavioral Manifestations
883098|NCT02642653|Chromosome Disorders
883099|NCT02642601|indomethacin, ICSI, difficult embryo transfer
883100|NCT02642562|Intravenous iron
883101|NCT02642562|PROBE design
883102|NCT02642536|Veteran
883103|NCT02642523|natriuretic peptide
883104|NCT02642523|insulin
883105|NCT02642523|lipolysis
883106|NCT02642523|hormones
883107|NCT02642523|metabolism
883108|NCT02642497|postoperative analgesia
883109|NCT02642497|ketamine
883110|NCT02642497|total thyroidectomy
883111|NCT02642471|sentinel lymph node
883112|NCT02642471|pelvic lymphadenectomy
883113|NCT02642471|cervical carcinoma
883114|NCT02642471|surgery
883115|NCT02642471|radiotherapy
883116|NCT02642445|Renal sympathetic denervation;hypertension
883117|NCT02642432|HCV Genotype 1
883118|NCT02642432|HCV Genotype 4
883119|NCT02642432|HCV Genotype 2
883120|NCT02642432|Cirrhotic
883121|NCT02642432|Interferon-Free
883122|NCT02642432|Compensated Cirrhosis
883123|NCT02642432|HCV Genotype 5
883124|NCT02642432|Hepatitis C
883125|NCT02642432|HCV Genotype 6
883132|NCT02642380|ITP
883133|NCT02642380|high-dose dexamethasone
883134|NCT02642328|VO2Max
883135|NCT02642328|Aerobic Exercise
883136|NCT02642328|Physical Conditioning
883137|NCT02642302|VO2Max
883138|NCT02642302|Aerobic Exercise
883139|NCT02642302|Physical Conditioning
883140|NCT02642289|Probiotics
883141|NCT02642276|exercise training
883142|NCT02642250|safety
883143|NCT02642250|efficacy
883144|NCT02642237|Fluenz
883145|NCT02642237|innate immune response
883146|NCT02642237|endotoxin tolerance
883147|NCT02642237|priming
883148|NCT02642224|Violence
883149|NCT02642224|firearm
883150|NCT02642224|guns
883151|NCT02642224|homicide
883152|NCT02642224|trauma
883153|NCT02642224|injury
883154|NCT02642198|NiBP
883155|NCT02642185|microwave
883156|NCT02642185|ablation
883157|NCT02642185|resection
883158|NCT02642185|liver
883159|NCT02642185|colorectal
883160|NCT02642185|survival
883161|NCT02642185|metastasis
883162|NCT02642172|Inulin, OFS (oligofructose)
883163|NCT02642107|nasopharyngeal carcinoma
883164|NCT02642107|elective neck irradiation
883165|NCT02642081|NSAIDs
883166|NCT02642081|Heart failure
883167|NCT02642081|Acute kidney injury
883168|NCT02642068|Drug-naïve Adult ADHD
883169|NCT02642068|Neuropsychology
883170|NCT02642068|Neurophysiology
883171|NCT02642068|Neuroimaging
883172|NCT02642068|Follow-up
883173|NCT02642055|ADHD
883174|NCT02642055|Neurofeedback
883175|NCT02642055|Biofeedback
883176|NCT02642055|Neuro+
883177|NCT02642055|Go/no-go
883178|NCT02642055|Attention training
883179|NCT02642029|time perception
883180|NCT02642029|executive function
883181|NCT02642029|psychosis
883182|NCT02642029|mood symptoms
883183|NCT02642016|KTN0158
883184|NCT02642016|Advanced Cancer
883185|NCT02642016|Phase 1
883186|NCT02642016|Monoclonal Antibody
883187|NCT02642016|Safety and Pharmacokinetics
883188|NCT02641925|Metabolic syndrome
883189|NCT02641925|gastric cancer
883190|NCT02641925|omentectomy
883191|NCT02641899|Adult
883192|NCT02641899|Male
883193|NCT02641899|Female
883194|NCT02641899|Volunteers
883195|NCT02641886|traditional Chinese medicine granules
883196|NCT02641886|Cognitive Impairment
883197|NCT02641886|Acute cerebral infraction
883198|NCT02641886|prevention
883199|NCT02641873|metastatic Colorectal Cancer
883200|NCT02641873|mCRC
883201|NCT02641847|triple negative breast cancer
883202|NCT02641847|mRNA-lncRNA signature
883203|NCT02641847|chemotherapy
883204|NCT02641847|high risk
883205|NCT02641834|diet
883206|NCT02641834|vegetarian
883207|NCT02641834|cardiovascular risk
883208|NCT02641795|cochlear implantation
883209|NCT02641795|robotics
883210|NCT02641795|image guidance
883211|NCT02641782|High Risk Neuroblastoma
883212|NCT02641756|HIV reservoir
883213|NCT02641756|phylogenetic analysis
883214|NCT02641756|sequencing
883215|NCT02641730|Guselkumab
883216|NCT02641730|CNTO 1959
883217|NCT02641730|Placebo
883218|NCT02641730|Palmoplantar Pustulosis
883219|NCT02641717|patient-collected
883220|NCT02641717|self-collected
883221|NCT02641717|vaginitis
883222|NCT02641717|vaginosis, bacterial
883223|NCT02641717|candidiasis
883224|NCT02641717|trichomonas
883225|NCT02641717|vaginal discharge
883226|NCT02641678|Atrial Fibrillation
883227|NCT02641678|stroke
883228|NCT02641678|implantable cardiac monitor
883229|NCT02641678|automated ECG analysis
883230|NCT02641652|paroxysmal hypertension
883231|NCT02641652|pseudopheochromocytoma
883232|NCT02641626|cardiac arrest
883233|NCT02641626|survival
883234|NCT02641626|neurologic prognosis
883235|NCT02641626|coronariography
883236|NCT02641626|hypothermia
883237|NCT02641587|Smoking
883238|NCT02641587|Combustible cigarette
883239|NCT02641587|Reduced exposure
883240|NCT02641587|Confinement
883241|NCT02641587|Ambulatory
883242|NCT02641587|Carbon Heated Tobacco Product
883243|NCT02641561|Pancreatitis
883244|NCT02641561|ERCP
883245|NCT02641561|Indomethacin
883246|NCT02641561|Lactated ringer's
883247|NCT02641522|T1D
883248|NCT02641522|Type 1 diabetes
883249|NCT02641496|Obstructive Sleep Apnea
883250|NCT02641496|PTSD
883251|NCT02641496|Posttraumatic Stress Disorder
883252|NCT02641496|Cognitive Behavioral Therapy
883253|NCT02641496|Continuous Positive Airway Pressure
883254|NCT02641496|CPAP
883255|NCT02641496|Cognition
883256|NCT02641496|Memory
883257|NCT02641496|Quality of Life
883258|NCT02641496|Self Efficacy
883259|NCT02641496|CBT
883260|NCT02641457|rubeosis iridis
883261|NCT02641457|glaucoma
883262|NCT02641457|ranibizumab
883263|NCT02641457|aflibercept
883264|NCT02641431|radiofrequency ablation
883265|NCT02641431|mapping
883266|NCT02641431|sudden death
883267|NCT02641431|syncope
883268|NCT02641418|Exercise
883269|NCT02641405|Gait analysis
883270|NCT02641405|Proprioceptive focal stimulation
883271|NCT02641405|Parkinson
883272|NCT02641392|Crohn's Disease
883273|NCT02641392|GED 0301
883274|NCT02641392|Mongersen
883275|NCT02641392|Safety
883276|NCT02641392|IBD
883277|NCT02641353|Apremilast
883278|NCT02641353|Healthy volunteers
883279|NCT02641353|Bioavailability
883280|NCT02641353|Food effect
883281|NCT02641353|Pharmacokinetic
883282|NCT02641327|Inhospital patients
883283|NCT02641314|high risk neuroblastoma
883284|NCT02641301|obesity
883285|NCT02641301|Roux-en-Y-gastric bypass
883286|NCT02641301|pharmacokinetics
883287|NCT02641301|Pain
883288|NCT02641301|morphine
883289|NCT02641275|Parental stress
883290|NCT02641275|Muscular Dystrophies
883291|NCT02641275|Coping
883292|NCT02641275|Parental support
883293|NCT02641262|Myocardial Infarction
883294|NCT02641262|Angioplasty, Balloon, Coronary
883295|NCT02641262|Drug Therapy
883296|NCT02641236|Hematopoietic Stem Cell Transplantation (HSCT)
883297|NCT02641236|Acute GVH Disease
883298|NCT02641210|Chronic periodontitis
883299|NCT02641210|Hepcidin
883300|NCT02641210|Hemoglobin
883301|NCT02641210|Inflammation
883302|NCT02641197|flow-mediated dilation
883303|NCT02641197|AngioDefender
883304|NCT02641197|device precision
883305|NCT02641197|repeatability
883306|NCT02641197|reproducibility
883307|NCT02641197|cardiovascular diseases
883308|NCT02641184|Myocardial Infarction
883309|NCT02641184|Cardiovascular Diseases
883310|NCT02641184|Heart Diseases
883311|NCT02641184|Infarction
883312|NCT02641184|Diabetes
883313|NCT02641158|HIV
883314|NCT02641158|Hepatitis C
883315|NCT02641158|Substance users
883316|NCT02641158|Drug users
883317|NCT02641145|amyloidosis
883318|NCT02641145|F-18 florbetapir
883319|NCT02641145|Positron emission tomography
883320|NCT02641145|cardiac magnetic resonance imaging
883321|NCT02641119|Albumin
883322|NCT02641119|Resuscitation
883323|NCT02641106|Telemedicine
883324|NCT02641106|Mobile Phone
883325|NCT02641106|Adherence
883326|NCT02641106|Latent Tuberculosis Infection
883327|NCT02641106|Directly Observed Therapy
883328|NCT02641106|Video DOT
883329|NCT02641041|Japanese
883330|NCT02641041|Single Ascending Dose (SAD)
883331|NCT02641041|Multiple Ascending Dose (MAD)
883332|NCT02641015|UTI
883333|NCT02641002|CC-90002
883334|NCT02641002|Monoclonal
883335|NCT02641002|Antibody
883336|NCT02641002|CD47
883337|NCT02641002|Hematologic Cancers
883338|NCT02641002|Acute Myeloid Leukemia
883339|NCT02641002|AML
883340|NCT02641002|Myelodysplastic syndrome
883341|NCT02641002|MDS
883342|NCT02641002|Blood disorder
883343|NCT02640989|Influenza Vaccine
883344|NCT02640989|Safety
883345|NCT02640989|Immunogenicity
883346|NCT02640976|in vitro fertilization
883347|NCT02640976|controlled ovarian hyperstimulation
883348|NCT02640976|poor ovarian response
883349|NCT02640976|estrogen receptor 2 gene polymorphism
883350|NCT02640976|follicle stimulating hormone receptor gene polymorphism
883351|NCT02640976|anti-mullerian hormone
883352|NCT02640963|exercise
883353|NCT02640963|older adults
883354|NCT02640963|physical performance
883355|NCT02640937|Staphylococcus epidermidis
883356|NCT02640937|biofilm formation
883357|NCT02640937|antibiotic resistance
883358|NCT02640937|Orthopaedic device related infections
883359|NCT02640937|risk factor
883360|NCT02640924|Hepatocellular carcinoma
883361|NCT02640924|Proton therapy
883362|NCT02640924|Radiation therapy
883363|NCT02640924|Switching control radiofrequency ablation
883364|NCT02640872|sarcopenia
883365|NCT02640872|sarcopenic obesity
883366|NCT02640872|osteoporosis
883367|NCT02640872|fracture
883368|NCT02640872|cardiovascular disease
883369|NCT02640872|mortality
883370|NCT02640846|Levosimendan
883371|NCT02640846|Milrinone
883372|NCT02640846|Myocardial strain
883373|NCT02640846|Septic cardiomyopathy
883374|NCT02640833|Refractory Lymphoma
883375|NCT02640833|Relapsed Leukemia
883376|NCT02640820|HPV
883377|NCT02640820|Verruca Vulgaris
883378|NCT02640807|sepsis lymphocytopenia IL-7
883379|NCT02640807|immune reconstitution
883380|NCT02640794|Transcatheter aortic valve implantation
883381|NCT02640794|Antithrombotic treatment
883382|NCT02640794|Clopidogrel
883383|NCT02640794|Aspirin/acetylsalicylic acid
883384|NCT02640794|Myocardial Infarction
883385|NCT02640794|Ischemic stroke
883386|NCT02640794|Major bleeding
883387|NCT02640768|in-hospital diabetes
883388|NCT02640768|clinical and management model
883389|NCT02640755|Radiolabelled
883390|NCT02640729|Lewy body dementia
883391|NCT02640729|Dementia with Lewy bodies
883392|NCT02640729|Parkinson's disease dementia
883393|NCT02640729|Lewy bodies
883394|NCT02640729|Visual hallucinations
883395|NCT02640690|Stress Disorders, Post-traumatic
883396|NCT02640690|Yoga
883397|NCT02640690|Cognitive Therapy
883398|NCT02640690|Chronic Pain
883399|NCT02640690|Veterans
883400|NCT02640690|cytokines
883401|NCT02640690|acoustic startle reflex
883402|NCT02640664|open-label, long-term, extension study
883403|NCT02640664|intravitreal ranibizumab
883404|NCT02640664|laser ablation therapy
883405|NCT02640664|retinopathy of prematurity
883406|NCT02640664|preterm infants
883407|NCT02640664|RAINBOW
883408|NCT02640638|Racial disparities
883409|NCT02640625|HIV
883410|NCT02640625|Probiotics
883411|NCT02640625|Microbiota
883412|NCT02640625|Mucosal immunology
883413|NCT02640625|Gut biopsy
883414|NCT02640599|Vestibular
883415|NCT02640599|Rehabilitation
883416|NCT02640560|Children
883417|NCT02640560|Allergy
883418|NCT02640560|Peanuts
883419|NCT02640560|Hazelnuts
883420|NCT02640560|Walnuts
883421|NCT02640560|Mollusks
883422|NCT02640560|Shellfish
883423|NCT02640560|Food
883424|NCT02640547|Fibrosis
883425|NCT02640547|Chronic Hepatitis C
883426|NCT02640547|Cirrhosis
883427|NCT02640547|Work Ability
883428|NCT02640547|Dasabuvir
883429|NCT02640547|Quality of Life
883430|NCT02640547|Observational Study
883431|NCT02640547|Paritaprevir/r/Ombitasvir
883432|NCT02640534|Prostate cancer
883433|NCT02640534|Cancer of the prostate
883434|NCT02640534|Metformin
883435|NCT02640534|Enzalutamide
883436|NCT02640534|Xtandi
883437|NCT02640534|castration resistant prostate cancer
883438|NCT02640534|phase II
883439|NCT02640534|Androgen deprivation therapy
883440|NCT02640495|Treatment Efficacy
883441|NCT02640495|drug resistance
883442|NCT02640495|Artemisinin
883443|NCT02640482|Treatment-Naive
883444|NCT02640482|Hepatitis C Virus Genotype 2
883445|NCT02640482|Sofosbuvir (SOF)-Experienced
883446|NCT02640482|Treatment-Experienced
883447|NCT02640482|Non-cirrhotic
883448|NCT02640469|chlorhexidine
883449|NCT02640469|sterility
883450|NCT02640469|sterile hands
883451|NCT02640456|retropharyngeal abscess
883452|NCT02640456|parapharyngeal abscess
883453|NCT02640456|peritonsillar abscess
883454|NCT02640456|bacteriology
883455|NCT02640456|Fusobacterium necrophorum
883456|NCT02640417|Nucleotides (uridine, cytidine)
883457|NCT02640417|Vitamin B1
883458|NCT02640417|Vitamin B6
883459|NCT02640417|Vitamin B12
883460|NCT02640404|Meningitis
883461|NCT02640404|Meningococcal Meningitis
883462|NCT02640404|Meningococcal Infections
883463|NCT02640404|Menactra®
883464|NCT02640404|Meningococcal Vaccine
883465|NCT02640391|Ulcerative colitis
883466|NCT02640391|fecal calprotectin
883467|NCT02640391|mucosal healing
883468|NCT02639390|Robotics
883469|NCT02639390|upper extremity
883470|NCT02639390|neurorehabilitation
883471|NCT02639390|movement therapy
883472|NCT02639377|Dental Implantation
883473|NCT02639377|Chlorhexidine gluconate
883474|NCT02639338|Chronic
883475|NCT02639325|Brain Tumor
883476|NCT02639325|Brain Cancer
883477|NCT02639325|Seizure Disorder
883478|NCT02639325|Seizures
883484|NCT02639299|Subjects
883485|NCT02639299|Venipuncture
883486|NCT02639299|Research
883487|NCT02639299|Evaluate
883488|NCT02639299|Recruit
883489|NCT02639286|Lipodystrophy
883490|NCT02639286|Hypertriglyceridemia
883496|NCT02639260|Nephrotic Syndrome
883497|NCT02639260|Glomerular Filtration Rate
883498|NCT02639260|Sialic Acid
883499|NCT02639260|Proteinuria
883500|NCT02640365|cancer
883501|NCT02640365|GERCOR
883502|NCT02640365|unresectable
883503|NCT02640365|MM-398
883504|NCT02640365|CPT-11
883505|NCT02640365|colorectal
883506|NCT02640365|non colorectal
883507|NCT02640326|Urinary Catheterization
883508|NCT02640326|Randomized Controlled Trial
883509|NCT02640326|Thoracic Surgery, Video-Assisted
883510|NCT02640326|Quality Improvement
883511|NCT02640326|Evidence-Based Practice
883512|NCT02640326|Post-operative complications
883513|NCT02640313|18F-fluormethylcholine
883514|NCT02640313|[F18] choline
883515|NCT02640313|[F18] fluormethylcholine
883516|NCT02640300|antipsychotics, clozapine, schizophrenia, switching strategy
883517|NCT02640274|Practise Patterns, Nurses'
883518|NCT02640274|Directive Counseling
883519|NCT02640274|Self Care
883520|NCT02640261|r-hLH
883521|NCT02640261|Cytokines
883522|NCT02640261|Follicular Fluid
883523|NCT02640235|Hemostasis
883524|NCT02640235|Oxidized Cellulose Strip
883525|NCT02640235|Traumacel
883526|NCT02640235|Traumastem
883527|NCT02640235|Cardiothoracic Surgery
883528|NCT02640235|General Surgery
883529|NCT02640235|Vascular Surgery
883530|NCT02640196|Laryngoscope
883531|NCT02640196|Macintosh
883532|NCT02640196|Glidescope
883533|NCT02640196|King Vision
883534|NCT02640196|Airtraq
883535|NCT02640196|Double Lumen Tube
883536|NCT02640157|interferon free
883537|NCT02640157|Hepatitis C
883538|NCT02640157|daclatasvir
883539|NCT02640157|Sovaldi
883540|NCT02640157|HCV
883541|NCT02640157|Hepatitis C Virus
883542|NCT02640157|Hepatitis C Genotype 3
883543|NCT02640157|Hep C
883544|NCT02640157|sofosbuvir
883545|NCT02640157|Chronic Hepatitis C
883546|NCT02640157|Daklinza
883547|NCT02640144|Hyaluronic acid
883548|NCT02640144|Knee arthroscopy
883549|NCT02640144|pain reduction
883550|NCT02640144|swelling
883551|NCT02640144|osteoarthritis
883552|NCT02640144|cartilage lesion
883553|NCT02640144|rehabilitation following knee arthroscopy
883554|NCT02640144|Hyaluronic acid injection
883555|NCT02640131|prostate cancer
883556|NCT02640131|radical prostatectomy
883557|NCT02640131|survivorship
883558|NCT02640131|quality of life
883559|NCT02640131|erectile dysfunction
883560|NCT02640131|sexual dysfunction
883561|NCT02640131|feasibility study
883562|NCT02640079|Cognitive behavioral therapy
883563|NCT02640079|Laboratory pain responsivity
883564|NCT02640014|Food allergy
883565|NCT02640014|Health-related quality of life (HRQL)
883566|NCT02640014|Quality-adjusted life-years (QALYs)
883567|NCT02640014|Oral immunotherapy (OIT)
883568|NCT02640014|Cow´s milk allergy (CMA)
883569|NCT02640014|Milk oral immunotherapy (MOIT)
883570|NCT02639988|type 2 diabetes mellitus
883571|NCT02639988|Rheumatoid arthritis
883572|NCT02639975|Adenosine A3 receptor antagonist
883573|NCT02639962|culprit lesion
883574|NCT02639962|arteriosclerosis
883575|NCT02639962|cardiac CT
883576|NCT02639923|TBI
883577|NCT02639923|microRNA
883578|NCT02639923|S-100B
883579|NCT02639910|CD19
883580|NCT02639910|MOR208
883581|NCT02639910|MOR00208
883582|NCT02639910|CLL
883583|NCT02639910|SLL
883584|NCT02639910|COSMOS
883585|NCT02639871|Huntington disease
883586|NCT02639871|Neuroimaging metabolic biomarker
883587|NCT02639832|Triple Negative Breast Cancer
883588|NCT02639832|Breast Cancer
883589|NCT02639832|Natural Killer Cells
883590|NCT02639832|BRCA Mutation
883591|NCT02639819|Intracerebral Hemorrhage
883592|NCT02639819|Stroke
883593|NCT02639819|Cerebrovascular
883594|NCT02639806|stroke
883595|NCT02639806|endovascular
883596|NCT02639806|thrombectomy
883597|NCT02639806|ischemic stroke
883598|NCT02639806|general anesthetic
883599|NCT02639806|local anesthetic
883600|NCT02639806|recanalization
883601|NCT02639793|arrhythmias, quality of life
883602|NCT02639767|Pemetrexed
883603|NCT02639767|Cisplatin
883604|NCT02639767|Intensity Modulated Radiation Therapy
883605|NCT02639767|15-304
883606|NCT02639741|Melatonin
883607|NCT02639741|Vitamin C
883608|NCT02639741|Morphine consumption
883609|NCT02639728|Bowel surgery
883610|NCT02639728|Postoperative bowel recovery
883611|NCT02639702|Clozapine
883612|NCT02639702|Dosing
883613|NCT02639702|Once daily
883614|NCT02639702|Regimen
883615|NCT02639702|Schizophrenia
883616|NCT02639689|Deficits of foot relievers of central origin
883617|NCT02639689|Walkaide
883618|NCT02639676|Infant
883619|NCT02639676|Bronchopulmonary Dysplasia
883620|NCT02639676|Premature
883621|NCT02639650|gestational trophoblastic tumor
883622|NCT02639650|paclitaxel
883623|NCT02639650|cisplatin
883624|NCT02639650|carboplatin
883625|NCT02639650|chemotherapy
883626|NCT02639637|Type 2 Diabetes Mellitus
883627|NCT02639637|Sitagliptin
883628|NCT02639637|Dipeptidyl Peptidase IV Inhibitors
883629|NCT02639637|Angiotensin Converting Enzyme Inhibitors
883630|NCT02639637|Enalaprilat
883631|NCT02639637|Neuropeptide Y
883632|NCT02639624|hemodialysis
883633|NCT02639624|kidney
883634|NCT02639624|dialysis
883635|NCT02639611|Breast Expanders
883636|NCT02639598|chronic migraine
883637|NCT02639598|prophylaxis
883638|NCT02639598|flunarizine
883639|NCT02639598|topiramate
883640|NCT02639585|daclatasvir
883641|NCT02639585|asunaprevir
883642|NCT02639533|fibromyalgia
883643|NCT02639533|pregabalin
883644|NCT02639533|cortical excitability
883645|NCT02639533|functional near infrared spectroscopy
883646|NCT02639520|Uncomplicated urinary tract infection
883647|NCT02639481|traumatic brain injury
883648|NCT02639481|stroke
883649|NCT02639481|disorders of consciousness
883650|NCT02639481|rehabilitation
883651|NCT02639481|robotic rehabilitation device
883652|NCT02639416|severe acute malnutrition
883653|NCT02639416|polymeric therapeutic formula
883654|NCT02639416|elemental therapeutic formula
883655|NCT02639403|Rectal cancer
883656|NCT02639403|Radiotherapy
883657|NCT02639403|Occlusion
883658|NCT02639247|Chronic
883659|NCT02639208|Breast Cancer I
883660|NCT02639208|Breast Cancer Stage II
883661|NCT02639208|Breast Cancer Stage III
883662|NCT02639182|Axitinib
883663|NCT02639182|Metastatic Renal Cell Carcinoma
883664|NCT02639182|AGS-16C3F
883665|NCT02639169|music therapy
883666|NCT02639169|Distress
883667|NCT02639169|Mood
883668|NCT02639169|HSCT
883669|NCT02639130|Gastric Inhibitory Polypeptide (GIP)
883670|NCT02639130|Glucagon-Like Peptide 1 (GLP-1)
883671|NCT02639130|DPP-4 inhibition; Exendin [9-39]
883672|NCT02639130|Gastric emptying
883673|NCT02639130|Glucagon
883674|NCT02639130|Incretin
883675|NCT02639130|Insulin Secretion
883676|NCT02639130|Normal glucose-tolerant
883677|NCT02639117|basal cell carcinoma, photodynamic therapy, vismodegib
883678|NCT02639104|neck pain
883679|NCT02639104|cervical lordosis
883680|NCT02639104|long thoracic nerve
883681|NCT02639091|Phase 1
883682|NCT02639091|Solid tumors
883683|NCT02639091|Mesothelioma
883684|NCT02639091|Lung cancer
883685|NCT02639091|Pemetrexed
883686|NCT02639091|Cisplatin
883687|NCT02639078|Single ascending dose
883688|NCT02639078|volunteers
883689|NCT02639078|Phase 1
883690|NCT02639078|first-in-human
883691|NCT02639078|TD-0714
883692|NCT02639065|Durvalumab
883693|NCT02639065|MEDI4736
883694|NCT02639065|PD-L1 inhibitor
883695|NCT02639052|Itch
883696|NCT02639052|Botox
883697|NCT02639052|Healthy Volunteers
883698|NCT02638987|Dry needling
883699|NCT02638987|office workers
883700|NCT02638987|myofascial pain
883701|NCT02638987|electromyography
883702|NCT02638961|heart failure with preserved ejection fraction
883703|NCT02638961|physical therapy
883704|NCT02638961|exercise capacity
883705|NCT02638961|quality of life
883706|NCT02638935|Virtual Touch Tissue Imaging
883707|NCT02638935|VTIQ
883708|NCT02638935|Elastography
883709|NCT02638935|Breast Cancer
883710|NCT02638935|BI-RADS
883711|NCT02638935|Differentiation of breast lesions
883712|NCT02638935|Breast Lesion
883713|NCT02638909|Gastrointestinal malignancies
883714|NCT02638896|Ankylosing Spondylitis
883715|NCT02638896|Etanercept
883716|NCT02638896|Sulfasalazine
883717|NCT02638896|Efficacy
883718|NCT02638896|Safety
883719|NCT02638896|dose
883720|NCT02638896|reduction
883721|NCT02638857|Recurrence Hepatocellular Carcinoma
883722|NCT02638857|Advanced Hepatocellular Carcinoma
883723|NCT02638857|Dendritic Cell -Precision Multiple Antigen T Cells
883724|NCT02638857|Transcatheter Arterial Chemoembolization
883725|NCT02638844|echocardiography
883726|NCT02638831|Pain
883727|NCT02638831|Gonarthrosis
883728|NCT02638831|Low Back Pain
883729|NCT02638831|Ketorolac Tromethamine
883730|NCT02638831|Ketoprofen
883731|NCT02638818|pancreaticoduodenectomy
883732|NCT02638818|Whipple
883733|NCT02638779|Septic shock
883734|NCT02638779|severe trauma
883735|NCT02638779|severe burn
883736|NCT02638779|major surgery
883737|NCT02638779|immunosuppression
883738|NCT02638779|Healthcare-Associated Infections
883739|NCT02638766|metastatic
883740|NCT02638766|unresectable
883741|NCT02638766|KIT/PDGFR wild type GIST
883742|NCT02638753|non specific chronic low back pain
883743|NCT02638753|education on pain neurophysiology
883744|NCT02638753|education on pain biology
883745|NCT02638753|education on pain neuroscience
883746|NCT02638753|hypnosis
883747|NCT02638727|vascular disease
883748|NCT02638727|endothelial function
883749|NCT02638727|L-Citrulline
883750|NCT02638714|Optic Neuropathies
883751|NCT02638714|Stem Cell Therapy
883752|NCT02638675|financial health incentives
883753|NCT02638675|physical activity
883754|NCT02638675|behavioral economics
883755|NCT02638675|randomized control trial
883756|NCT02638675|workplace health
883757|NCT02638649|lung ultrasound
883758|NCT02638636|Cognitive behavior therapy
883759|NCT02638636|Randomized controlled trial
883760|NCT02638636|Exposure therapy
883761|NCT02638636|Fibromyalgia
883762|NCT02638623|Knee Arthroplasty
883763|NCT02638623|Hip Arthroplasty
883764|NCT02638584|Ilaprazole
883765|NCT02638584|Gastric Adenoma
883766|NCT02638584|Early Gastric Cancer
883767|NCT02638584|Endoscopic Submucosal Dissection
883768|NCT02638532|Fat Pad
883769|NCT02638532|Fat Pad Atrophy
883770|NCT02638532|Foot
883771|NCT02638532|Feet
883772|NCT02638532|Heel
883773|NCT02638532|Forefoot
883774|NCT02638506|Headaches, Migraines, Fentanyl
883775|NCT02638493|HIV
883776|NCT02638493|tenofovir-emtrictabine
883777|NCT02638493|antiretroviral therapy
883778|NCT02638493|Prevention
883779|NCT02638493|tenofovir alafenamide
883780|NCT02638454|Exercise
883781|NCT02638454|Anabolic Resistance
883782|NCT02638454|Skeletal Muscle
883783|NCT02638454|microRNA
883784|NCT02638441|psychological health
883785|NCT02638441|women
883786|NCT02638441|anxiety
883787|NCT02638441|depression
883788|NCT02638415|HVPG
883789|NCT02638402|glycosylation
883790|NCT02638402|mucin
883791|NCT02638402|receptor tyrosin kinases
883792|NCT02638402|ovarian cancer
883793|NCT02638402|endometrial cancer
883794|NCT02638376|Keraroconus
883795|NCT02638376|keratectasia
883796|NCT02638376|treatment
883797|NCT02638350|lung ultrasound
883798|NCT02638350|Pulmonary Edema
883799|NCT02638350|Respiratory Distress Syndrome
883800|NCT02638337|Vulvo-vaginal Atrophy
883801|NCT02638337|menopause
883802|NCT02638259|Biosimilars
883803|NCT02638259|Rheumatoid Arthritis
883804|NCT02638259|Etanercept
883805|NCT02638233|CHC
883806|NCT02638233|IVDA (intravenous drug abuse)
883807|NCT02638233|Hepatitis C
883808|NCT02638233|Sofosbuvir
883809|NCT02638233|Ledipasvir
883810|NCT02638233|Opiate Substitution Therapy
883820|NCT02638207|Chronic Inflammatory Demyelinating Poly Neuropathy (CIDP)
883821|NCT02638194|Chronic Obstructive Pulmonary Disease (COPD)
883822|NCT02638194|smoking
883823|NCT02638194|secondhand smoke
883824|NCT02638181|matrix metalloproteinase 13
883825|NCT02638181|tissue inhibitor of metalloproteinases 3
883826|NCT02638181|calcium-sensing receptor
883827|NCT02638181|trabecular meshwork
883828|NCT02638181|open-angle glaucoma
883829|NCT02638142|loop diuretic
883830|NCT02638142|heart failure
883831|NCT02638142|renal dysfunction
883832|NCT02638142|congestion signs
883833|NCT02638142|BNP
883834|NCT02638129|Drug therapy
883835|NCT02638116|Ibrutinib
883836|NCT02638116|Proton pump inhibitors
883837|NCT02638116|Pharmacokinetics
883838|NCT02638116|Drug Interaction
883839|NCT02638090|advanced lung cancer
883840|NCT02638090|immune therapy naive
883841|NCT02638090|immune therapy pre-treated
883842|NCT02638090|NSCLC
883843|NCT02638090|Stage IV lung cancer
883844|NCT02638090|pembrolizumab
883845|NCT02638090|vorinostat
883846|NCT02638090|immunogenicity
883847|NCT02638077|Differentiated Thyroid Cancer
883848|NCT02638077|the initial management
883849|NCT02638051|Peritoneal Carcinomatosis
883850|NCT02638051|Malignant Ascites
883851|NCT02638051|Modulated Electro-Hyperthermia
883852|NCT02638051|Traditional Chinese Medicine
883853|NCT02637960|VA106483, fedovapagon, BPH, nocturia, EQUINOC
883854|NCT02637921|bed rest
883855|NCT02637921|bone metabolism
883856|NCT02637908|Mindfulness
883857|NCT02637908|Parents
883858|NCT02637908|Families
883859|NCT02637895|PTSD,
883860|NCT02637895|trauma
883861|NCT02637895|stress disorder
883862|NCT02637895|post-traumatic stress disorder
883863|NCT02637895|anxiety disorder
883868|NCT02637843|radial
883869|NCT02637843|angiography
883870|NCT02637843|angioplasty
883871|NCT02637843|randomized
883872|NCT02637843|sheath
883873|NCT02637843|slender
883874|NCT02637791|Stroke
883875|NCT02637791|Rehabilitation
883876|NCT02637791|Virtual Reality
883877|NCT02637778|nutrient profiles
883878|NCT02637778|menu plans
883879|NCT02637778|n-3 LC-PUFA
883880|NCT02637778|SFA
883881|NCT02637778|MUFA
883882|NCT02637778|PUFA
883883|NCT02637778|cardiovascular risk
883884|NCT02637765|Breast Cancer
883885|NCT02637765|Physical Activity
883886|NCT02637765|Quality of life
883887|NCT02637752|Pediatric Obesity
883888|NCT02637752|Body Mass Index
883889|NCT02637752|Dentistry
883890|NCT02637739|hysteroscope
883891|NCT02637726|Total intravenous anesthesia
883892|NCT02637726|Target Controlled Infusion
883893|NCT02637726|Propofol
883894|NCT02637726|Bispectral index
883895|NCT02637726|Children
883896|NCT02637713|GERD
883897|NCT02637713|sleeve gastrectomy
883898|NCT02637713|reflux
883899|NCT02637713|morbidly obese
883900|NCT02637700|Small Fiber Neuropathy
883901|NCT02637700|Painful Neuropathy
883902|NCT02637700|Intravenous Immunoglobulin Therapy
883940|NCT02637674|allotransplantation
883941|NCT02637661|earlobe crease
883942|NCT02637661|acute myocardial infarction
883943|NCT02637661|risk factor
883944|NCT02637635|Mammaplasty
883945|NCT02637635|Transplantation, Autologous
883946|NCT02637635|Mastectomy
883947|NCT02637635|Breast Implants
883948|NCT02637635|Radiotherapy, Adjuvant
883949|NCT02637622|conjoint analysis
883950|NCT02637622|stated-preference methods
883951|NCT02637622|patient centered outcome research (PCOR)
883952|NCT02637622|community-based participatory research (CBPR)
883953|NCT02637622|patient preference
883954|NCT02637622|diabetes
883955|NCT02637609|conjoint analysis
883956|NCT02637609|stated-preference methods
883957|NCT02637609|patient centered outcome research (PCOR)
883958|NCT02637609|community-based participatory research (CBPR)
883959|NCT02637609|patient priority
883960|NCT02637609|diabetes
883961|NCT02637583|conjugate vaccine
883962|NCT02637583|polysaccharide vaccine
883963|NCT02637570|healthy male athletes
883964|NCT02637570|18-35 years old
883965|NCT02637531|IPI-549
883966|NCT02637531|Phase 1
883967|NCT02637531|Advanced Solid Tumor
883968|NCT02637531|Non-small cell lung cancer
883969|NCT02637531|Melanoma
883970|NCT02637531|PI3K
883971|NCT02637531|Squamous Cell Cancer of the Head and Neck
883972|NCT02637518|Frailty
883973|NCT02637518|Frailty screening tools
883974|NCT02637518|Clinical settings
883975|NCT02637518|Social settings
883976|NCT02637518|Geriatrics
883977|NCT02637518|Functional autonomy
883978|NCT02637518|Disability
883979|NCT02637505|Articular cartilage
883980|NCT02637505|Focal cartilage injury
883981|NCT02637505|Focal cartilage injury in the knee
883982|NCT02637505|Knee cartilage
883983|NCT02637505|Microfracture
883984|NCT02637505|Debridement
883985|NCT02637492|Critical limb ischaemia
883986|NCT02637492|Peripheral occlusive arterial disease
883987|NCT02637492|Clinical prediction
883988|NCT02637492|Ankle pressure
883989|NCT02637492|Transcutaneous oxygen pressure
883990|NCT02637492|Toe pressure
883991|NCT02637492|Microcirculation
883992|NCT02637453|Paroxysmal Atrial Fibrillation;Additional Linear Ablation
883993|NCT02637427|Fresh frozen plasma
883994|NCT02637427|Bleeding
883998|NCT02637388|Appetite
883999|NCT02637388|Beta-glucans
884000|NCT02637388|Energy Intake
884001|NCT02637388|Glucagon-Like Peptide 1
884002|NCT02637388|Glucose
884003|NCT02637388|Insulin
884004|NCT02637388|Incretins
884005|NCT02637375|triple-negative breast cancer
884006|NCT02637336|Therapies. Autonomic nervous system. Cardiovascular stress
884007|NCT02637323|Osteoarthritis
884008|NCT02637323|Knee
884009|NCT02637323|Pain
884010|NCT02637323|Steroid
884011|NCT02637323|Intra-articular
884012|NCT02637323|Injection
884013|NCT02637284|Healthy volunteers
884014|NCT02637271|Calorie restriction
884015|NCT02637271|Meal replacement
884016|NCT02637271|fMRI
884017|NCT02637271|Food-cue reactivity
884018|NCT02637271|Obesity
884019|NCT02637258|optic nerve sheath diameter
884020|NCT02637258|neurological outcome
884021|NCT02637258|OHCA
884022|NCT02637245|diabetic macular edema
884023|NCT02637245|diabetic retinopathy
884024|NCT02637206|Healthy Japanese
884025|NCT02637206|GSK2894512
884026|NCT02637206|skin safety
884027|NCT02637180|osteoporosis
884028|NCT02637180|fracture
884029|NCT02637180|liaison service
884030|NCT02637167|Heart failure
884031|NCT02637167|inflammation
884032|NCT02637167|rifaximin
884033|NCT02637167|Saccharomyces boulardii
884034|NCT02637167|gut microbiota
884035|NCT02637154|Adolescent
884036|NCT02637154|Type 1 diabetes
884037|NCT02637154|Metabolic control
884038|NCT02637154|Motivational interviewing
884039|NCT02637141|celiac
884040|NCT02637141|gluten
884041|NCT02637141|IL-15
884042|NCT02637141|AMG 714
884043|NCT02637128|MALARIA, FALCIPARUM
884044|NCT02637128|MALAWI
884045|NCT02637128|ARTEMETHER-LUMEFANTRINE
884046|NCT02637128|ARTESUNATE-AMODIAQUINE
884047|NCT02637115|Gut microbiota
884048|NCT02637115|Akkermansia muciniphila
884049|NCT02637076|Xyrem
884050|NCT02637076|narcolepsy with cataplexy
884051|NCT02637076|positron emission tomography
884052|NCT02637076|dopamine
884053|NCT02637063|Lifestyle behavior change
884054|NCT02637050|Type IV Pulmonary Hypertension
884055|NCT02637050|Chronic Thromboembolic Pulmonary Hypertension
884056|NCT02637050|CTEPH
884057|NCT02637037|dapagliflozin/metformin XR 5/500 mg
884058|NCT02637037|dapagliflozin/metformin XR10/1000 mg
884059|NCT02637037|bioequivalence
884060|NCT02637037|fixed dose combination tablets
884061|NCT02637037|pharmacokinetic
884062|NCT02637037|type 2 Diabetes Mellitus (T2DM)
884063|NCT02637037|safety
884064|NCT02637024|Breast Cancer
884065|NCT02637024|DCIS
884066|NCT02637024|Radiotherapy
884067|NCT02637024|Partial breast irradiation
884068|NCT02637024|Radiation fractions
884069|NCT02637011|acute respiratory distress syndrome
884070|NCT02637011|intensive care medicine
884071|NCT02637011|critical illness
884072|NCT02637011|long-term outcomes
884073|NCT02637011|quality of life
884074|NCT02637011|return to work
884075|NCT02637011|quality of care
884076|NCT02636972|TLR2
884077|NCT02636972|TLR4
884078|NCT02636972|Biomarker
884079|NCT02636972|TLR responsiveness
884080|NCT02636972|Peripheral blood responsiveness
884081|NCT02636972|Inflammatory pain
884082|NCT02636933|Asthma
884083|NCT02636933|Allergic Rhinitis
884084|NCT02636933|Children
884085|NCT02636933|Atopy
884086|NCT02636920|Asthma
884087|NCT02636920|Children
884095|NCT02636842|Schizophrenia
884096|NCT02636842|Schizoaffective Disorder
884097|NCT02636842|Aripiprazole Lauroxil
884098|NCT02636842|Aripiprazole
884099|NCT02636842|ALKS 9072
884100|NCT02636842|Alkermes
884101|NCT02636803|trichuris
884102|NCT02636803|hookworms
884103|NCT02636803|Ascaris
884104|NCT02636777|low back pain
884105|NCT02636777|chronic pain
884106|NCT02636777|self-management
884107|NCT02636777|longitudinal study
884108|NCT02636777|predictive modelling
884109|NCT02636751|Prehabilitation
884110|NCT02636751|Telemedicine
884111|NCT02636751|Osteoarthritis
884112|NCT02636751|Arthroplasty
884113|NCT02636751|Hip
884114|NCT02636751|Knee
884115|NCT02636725|Advanced Alveolar Soft Part Sarcoma
884116|NCT02636725|ASPS
884117|NCT02636725|Soft Tissue Sarcomas
884118|NCT02636725|STS
884119|NCT02636725|Alveolar Soft Part Sarcoma
884120|NCT02636686|DMD
884121|NCT02636686|Duchenne Muscular Dystrophy
884122|NCT02636686|Drisapersen
884123|NCT02636686|Kyndrisa
884124|NCT02636686|exon-skipping
884125|NCT02636686|exon-51
884126|NCT02636686|BMN-051-302
884127|NCT02636686|051-302
884128|NCT02636660|Critical care
884129|NCT02636660|Mechanical Ventilation
884130|NCT02636660|Quality of Life
884131|NCT02636660|Stressors
884132|NCT02636660|Nursing Sensitive Outcomes
884133|NCT02636660|Nursing
884134|NCT02636647|hepatic encephalopathy
884135|NCT02636647|fecal transplant
884136|NCT02636647|cirrhosis
884137|NCT02636634|diagnostic strategy
884138|NCT02636634|brain metastases
884139|NCT02636634|radiation necrosis
884140|NCT02636634|relapse
884141|NCT02636634|PET-FET and MSR
884142|NCT02636634|radiosurgery
884143|NCT02636621|Fatigue
884144|NCT02636621|excessive daytime sleepiness
884145|NCT02636621|flow limitation
884146|NCT02636608|Observational Study
884147|NCT02636608|Chronic Hepatitis C
884148|NCT02636608|Cirrhosis
884149|NCT02636608|Paritaprevir/r/Ombitasvir
884150|NCT02636608|Dasabuvir
884151|NCT02636608|Work Ability
884152|NCT02636608|Quality of Life
884153|NCT02636608|Fibrosis
884154|NCT02636595|Hepatitis C Genotype 4
884155|NCT02636595|Hepatitis C
884156|NCT02636595|Chronic Hepatitis C
884157|NCT02636595|Hepatitis C Genotype 6
884158|NCT02636595|Hepatitis C Genotype 5
884159|NCT02636556|thymoma
884160|NCT02636556|thymic carcinoma
884161|NCT02636556|chemoradiotherapy
884162|NCT02636556|inoperable
884163|NCT02636543|genetic diagnosis
884164|NCT02636543|information
884165|NCT02636543|letter model
884166|NCT02636517|Fecal Microbiota transplant
884167|NCT02636504|Pulp vitality
884168|NCT02636504|Pulp testing
884169|NCT02636439|Diastolic heart failure
884170|NCT02636439|Heart Failure
884171|NCT02636439|Elderly
884172|NCT02636439|Obesity
884173|NCT02636426|phase I study
884174|NCT02636426|sorafenib
884175|NCT02636426|high-dose schedule
884176|NCT02636426|pharmacokinetics
884177|NCT02636426|drug monitoring
884178|NCT02636400|Infertility
884179|NCT02636400|endometriosis
884180|NCT02636348|Calcium
884181|NCT02636348|Vitamin D
884182|NCT02636322|Lymphoma
884183|NCT02636322|High Risk Diffuse Large B-Cell Lymphoma
884184|NCT02636322|DLBCL
884185|NCT02636322|Rituximab
884186|NCT02636322|Rituxan
884187|NCT02636322|Ibrutinib
884188|NCT02636322|PCI-32765
884189|NCT02636322|Imbruvica
884190|NCT02636322|Lenalidomide
884191|NCT02636322|CC-5013
884192|NCT02636322|Revlimid
884193|NCT02636322|Etoposide
884194|NCT02636322|VePesid
884195|NCT02636322|Prednisone
884196|NCT02636322|Vincristine
884197|NCT02636322|Oncovin
884198|NCT02636322|Cyclophosphamide
884199|NCT02636322|Cytoxan
884200|NCT02636322|Neosar
884201|NCT02636322|Doxorubicin
884202|NCT02636322|Hydroxydaunorubicin
884203|NCT02636322|Adriamycin PFS
884204|NCT02636322|Adriamycin RDF
884205|NCT02636322|Adriamycin
884206|NCT02636322|Rubex
884207|NCT02636309|ergonomics
884208|NCT02636309|multifaceted intervention
884209|NCT02636309|industry
884210|NCT02636309|physiotherapy
884211|NCT02636309|physical exercises
884212|NCT02636309|workplace
884213|NCT02636309|acupuncture
884214|NCT02636309|work
884215|NCT02636309|quality of life
884216|NCT02636309|absenteeism
884217|NCT02636309|efficiency
884218|NCT02636309|musculoskeletal pain
884219|NCT02636309|WMSD
884220|NCT02636296|Pilates method
884221|NCT02636296|elderly
884222|NCT02636296|postural balance
884223|NCT02636257|Silicone Nasolacrimal Intubation
884224|NCT02636257|Dacryocystorhinostomy
884225|NCT02636231|Endostar
884226|NCT02636231|IMRT
884227|NCT02636231|recurrent
884228|NCT02636231|NPC
884229|NCT02636218|Ketamine
884230|NCT02636192|Sodium-glucose co-transporter 2 inhibitors
884231|NCT02636192|Diabetes Mellitus, Type 2
884232|NCT02636179|In Vitro Fertilization, follow-up of children
884233|NCT02636166|Pregnancy
884234|NCT02636153|phosphorus,dietary
884235|NCT02636153|circadian rhythm
884236|NCT02636153|phosphorus
884237|NCT02636088|Phase II study, clinical trial
884238|NCT02636062|Coronary disease
884239|NCT02636062|Coronary artery disease (CAD)
884240|NCT02636062|Endothelial dysfunction
884241|NCT02636062|Coronary artery calcium (CAC)
884242|NCT02636049|pharmacokinetics
884243|NCT02636049|healthy adult volunteer
884244|NCT02635997|osteoporosis
884245|NCT02635997|ibandronate
884246|NCT02635997|vitamine D
884247|NCT02635997|calcium
884248|NCT02635997|bone mineral density
884249|NCT02635997|health-related quality of life
884250|NCT02635971|transcatheter arterial infusion
884251|NCT02635971|randomized controlled trial
884252|NCT02635971|chemotherapy
884253|NCT02635958|Body Mass Index
884254|NCT02635958|BMI
884255|NCT02635958|InBody
884256|NCT02635958|iDXA
884257|NCT02635958|validation
884258|NCT02635945|adenosine A1 receptor antagonist
884259|NCT02635945|adenosine receptor modulator
884260|NCT02635945|COPD
884261|NCT02635945|asthma
884262|NCT02635919|Nicotine addiction
884263|NCT02635919|Cigarette smoking
884264|NCT02635919|Smoking cessation
884265|NCT02635919|Quit smoking
884266|NCT02635906|BED REST
884267|NCT02635906|CORONARY ANGIOPLASTY
884268|NCT02635893|SCI
884269|NCT02635867|vital pulp
884270|NCT02635867|reversible pulpitis
884271|NCT02635867|pulp capping
884272|NCT02635867|deep cavity
884273|NCT02635867|Management of Deep Dental Caries
884274|NCT02635854|leukocyte and platelet aggregates
884275|NCT02635854|platelet activation
884282|NCT02635828|Palonosetron
884283|NCT02635828|Craniotomy
884284|NCT02635828|Nausea
884285|NCT02635828|Vomiting
884286|NCT02635802|remifentanil
884287|NCT02635802|analgesia
884288|NCT02635802|intensive care units
884289|NCT02635789|Sirolimus
884290|NCT02635789|Skin lesions
884291|NCT02635789|TSC
884292|NCT02635789|Tuberous Sclerosis Complex
884293|NCT02635789|NPC-12G
884294|NCT02635789|Angiofibroma
884295|NCT02635789|Hypomelanotic macule
884296|NCT02635789|Plaque
884297|NCT02635776|AR101 (Characterized Peanut Allergen)
884298|NCT02635776|Characterized Peanut Allergen
884299|NCT02635776|CPNA (Characterized Peanut Allergen)
884300|NCT02635776|OIT (oral immunotherapy)
884301|NCT02635776|Oral Immunotherapy
884302|NCT02635776|Peanut Allergy
884303|NCT02635776|Allergy
884304|NCT02635776|Peanut-Allergic Children
884305|NCT02635776|Peanut-Allergic Adults
884306|NCT02635776|Desensitization
884307|NCT02635763|nerve block
884308|NCT02635763|general anesthesia
884309|NCT02635763|hip fracture
884310|NCT02635763|recovery
884311|NCT02635724|Acute uncomplicated
884312|NCT02635724|Elderly
884313|NCT02635685|Atrial fibrillation
884314|NCT02635685|Stroke
884315|NCT02635685|Clinical Decision Support
884316|NCT02635685|Anticoagulants
884317|NCT02635672|Solid tumors
884318|NCT02635672|Aggressive non-hodgkin's lymphoma (NHL)
884319|NCT02635659|food intake, satiety, satiation, nutrients, ileal brake
884320|NCT02635633|partial epilepsy
884321|NCT02635633|unifocal neocortical
884322|NCT02635633|treatment resistant
884323|NCT02635633|transcranial magnetic stimulation
884324|NCT02635633|thetaburst stimulation
884325|NCT02635620|e-cigarette, electronic cigarette, lung function
884326|NCT02635607|GnRH antagonist
884327|NCT02635607|fixed protocol
884328|NCT02635607|flexible protocol
884329|NCT02635542|Postoperative Pulmonary Complications
884330|NCT02635542|Residual Neuromuscular Blockade
884331|NCT02635542|Cardiac Surgical Procedures
884332|NCT02635503|colorectal cancer
884333|NCT02635503|laparoscopic surgery
884334|NCT02635503|natural orifice specimen extraction
884335|NCT02635503|Inflammatory response
884336|NCT02635490|prophylactic antibiotics, urinary tract infection.
884337|NCT02635451|vitamin c
884338|NCT02635451|Preterm Premature Rupture of Membranes
884339|NCT02635438|Oropharyngeal Candidiasis
884340|NCT02635412|Placenta
884341|NCT02635412|Accreta
884342|NCT02635412|Morbidly
884343|NCT02635412|Adherent Placenta
884344|NCT02635399|pancreaticoduodenectomy, delayed gastric emptying, duodenojejunopexy
884345|NCT02635386|PCOS
884346|NCT02635386|GLP1 agonists
884347|NCT02635386|SGLT2 inhibitors
884348|NCT02635373|Calciphylaxis
884349|NCT02635373|Rare disease (ORPHA280062)
884350|NCT02635373|Renal insufficiency
884351|NCT02635373|ESRD
884352|NCT02635373|Calcification
884353|NCT02635373|Chronic kidney disease
884354|NCT02635373|Dialysis
884355|NCT02635373|Vascular disease
884356|NCT02635360|advanced
884357|NCT02635360|cervical cancer
884358|NCT02635360|pembrolizumab
884359|NCT02635360|chemoradiation
884360|NCT02635360|immunotherapy
884361|NCT02635347|Remote ischemic preconditioning
884362|NCT02635347|Remote ischemic perconditioning
884363|NCT02635347|Remote ischemic postconditioning
884364|NCT02635347|Remote ischemic conditioning
884365|NCT02635347|Orthotopic liver transplant
884366|NCT02635347|Brain Death Organ Donor
884367|NCT02635321|MRI
884368|NCT02635321|LGMD
884369|NCT02635321|GMPPB
884370|NCT02635308|hip fracture
884371|NCT02635308|physical function
884372|NCT02635308|muscle function
884373|NCT02635308|symmetry
884374|NCT02635295|Clinical practicum
884375|NCT02635295|Nursing student
884376|NCT02635295|Nurse teacher
884377|NCT02635295|Mobile technology
884378|NCT02635295|Cooperation
884379|NCT02635295|Nurse competence
884380|NCT02635269|Ergometry
884381|NCT02635269|Stable isotope tracers
884382|NCT02635256|hypofractionation
884383|NCT02635256|prostate cancer
884384|NCT02635256|radiotherapy
884385|NCT02635230|Atrial Fibrillations
884386|NCT02635230|Heart Valve Prostheses
884387|NCT02635230|Acute Coronary Syndromes
884388|NCT02635230|Percutaneous Coronary Revascularization
884389|NCT02635230|Coronary Artery Bypass Grafting
884390|NCT02635230|Coronary Artery Diseases
884391|NCT02635230|Myocardial Infarction
884392|NCT02635230|Ischemic stroke
884393|NCT02635230|Bleeding
884394|NCT02635230|Thrombosis
884395|NCT02635230|Myocardial Ischemia
884396|NCT02635230|Heart Diseases
884397|NCT02635230|Cardiovascular Diseases
884398|NCT02635230|Embolism and Thrombosis
884399|NCT02635230|Platelet Aggregation Inhibitors
884400|NCT02635230|Aspirin
884401|NCT02635230|Clopidogrel
884402|NCT02635230|Ticagrelor
884403|NCT02635230|Prasugrel
884404|NCT02635230|Antithrombotic treatment
884405|NCT02635230|Oral anticoagulation
884406|NCT02635230|Warfarin
884407|NCT02635230|Dabigatran etexilate mesylate
884408|NCT02635230|Apixaban
884409|NCT02635230|Rivaroxaban
884410|NCT02635230|Direct Factor Xa Inhibitors
884411|NCT02635230|Direct Thrombin Inhibitors
884412|NCT02635217|Colonoscopy
884413|NCT02635217|Esophagogastroduodenoscopy
884414|NCT02635217|Patient satisfaction
884415|NCT02635217|Bidirectional endoscopies
884416|NCT02635191|Helicobacter pylori
884417|NCT02635191|Therapy
884418|NCT02635191|Children
884419|NCT02635139|meal skipping
884420|NCT02635139|isocaloric diet
884421|NCT02635139|macronutrient oxidation
884422|NCT02635139|glucose homeostasis
884423|NCT02635139|arterial stiffness
884424|NCT02635113|balance
884425|NCT02635113|gait
884426|NCT02635113|falls
884427|NCT02635113|sensory deficits
884428|NCT02635113|vibration
884429|NCT02635113|visual acuity
884430|NCT02635113|dizziness
884431|NCT02635113|postural control
884432|NCT02635113|proprioceptive function
884433|NCT02635113|stereoacuity
884434|NCT02635113|depth perception
884435|NCT02635113|vestibular dysfunction
884436|NCT02635100|Sleep Disordered Breathing
884437|NCT02635100|Sleep Apnea
884438|NCT02635048|Percutaneous nephrolithotomy
884439|NCT02635048|Kidney stones
884440|NCT02635048|Efficacy
884441|NCT02635022|Fracture
884442|NCT02635022|Sarcopenia
884443|NCT02635022|Osteoporosis
884444|NCT02635022|Care management
884445|NCT02635022|Medication adherence
884446|NCT02634983|COPD
884447|NCT02634983|Smokers
884448|NCT02634983|Ex-smokers
884449|NCT02634970|wet AMD, ranibizumab, aflibercept, neovascularization
884450|NCT02634957|phonomicrosurgery
884451|NCT02634957|benign vocal fold lesions
884452|NCT02634957|voice rest
884453|NCT02634957|vhi-10
884454|NCT02634957|CPP
884455|NCT02634944|Concussion
884456|NCT02634944|Vestibular
884457|NCT02634944|Ocular-Motor
884458|NCT02634931|Sirolimus
884459|NCT02634931|Skin lesions
884460|NCT02634931|TSC
884461|NCT02634931|Tuberous Sclerosis Complex
884462|NCT02634931|NPC-12G
884463|NCT02634931|Angiofibroma
884464|NCT02634931|Hypomelanotic Macule
884465|NCT02634931|Plaque
884466|NCT02634918|ultrasound,
884467|NCT02634918|ultrasonography
884468|NCT02634918|hemophilic joint
884469|NCT02634918|Doppler
884470|NCT02634905|atopic dermatitis
884471|NCT02634905|Therapeutic patient education
884472|NCT02634905|pediatric dermatology
884473|NCT02634892|Sacral
884474|NCT02634892|Overlay Mattress
884475|NCT02634892|Cooling
884476|NCT02634866|hypertension
884477|NCT02634866|exercise
884478|NCT02634866|diastolic heart failure
884479|NCT02634853|Dry Eye
884480|NCT02634840|inferior alveolar nerve
884481|NCT02634840|neurosensory disturbance
884482|NCT02634840|bilateral sagittal spilt osteotomy
884483|NCT02634840|mandibular surgery
884484|NCT02634840|neurosensory function
884485|NCT02634801|Fumaderm
884486|NCT02634788|Post-Surgical Pain
884487|NCT02634788|Bunionectomy
884488|NCT02634775|Pediatrics
884489|NCT02634775|Nephrology
884490|NCT02634775|Dialysis
884491|NCT02634749|Nordic countries
884492|NCT02634749|Eating behavior
884493|NCT02634749|Human microbiome
884494|NCT02634749|Child nutrition
884495|NCT02634749|Metabolic profile
884496|NCT02634749|Body composition
884497|NCT02634710|soft tissue sarcoma
884498|NCT02634697|Atrial Fibrillation
884499|NCT02634697|Relaxation Response Resiliency Program Intervention
884500|NCT02634697|AF Symptom Severity and Burden
884501|NCT02634697|Stress, Anxiety, Depression and Hostility
884502|NCT02634697|Quality of Life
884503|NCT02634697|AF
884504|NCT02634697|QOL
884505|NCT02634697|3RP
884506|NCT02634684|Schizophrenia
884507|NCT02634684|Schizoaffective Disorder
884508|NCT02634684|Mental Disorders
884509|NCT02634684|Anti-Dyskinesia Agents
884510|NCT02634684|Antiparkinson Agents
884511|NCT02634684|Central Nervous System Agents
884512|NCT02634684|Dopamine Agents
884513|NCT02634684|Excitatory Amino Acid Agents
884514|NCT02634684|Excitatory Amino Acid Antagonists
884515|NCT02634684|Molecular Mechanisms of Pharmacological Action
884516|NCT02634684|Neurotransmitter Agents
884517|NCT02634684|Pharmacologic Actions
884518|NCT02634684|Physiological Effects of Drugs
884519|NCT02634684|Therapeutic Uses
884520|NCT02634684|Prepulse inhibition
884521|NCT02634684|Neurocognition
884522|NCT02634684|Working memory
884523|NCT02634684|Dextroamphetamine
884524|NCT02634684|MATRICS Consensus Cognitive Battery
884525|NCT02634684|Pharmacologic Augmentation of Cognitive Therapies
884526|NCT02634684|Sensory discrimination learning
884527|NCT02634684|Targeted Cognitive Training
884528|NCT02634684|rs4680 polymorphism of catechol-O-methyltransferase (COMT)
884529|NCT02634671|schizophrenia
884530|NCT02634671|Facial emotions
884531|NCT02634619|urethral stricture
884532|NCT02634606|Cholesterol
884533|NCT02634593|nutrition
884534|NCT02634580|Japanese
884535|NCT02634580|High cholesterol
884536|NCT02634580|Treatment of high cholesterol
884537|NCT02634580|Lowering cholesterol
884538|NCT02634580|Lowering high cholesterol
884539|NCT02634580|Hypercholesterolemia
884540|NCT02634580|Statin intolerant
884541|NCT02634528|intermediate-acting human isophane insulin, biosimilar
884542|NCT02634515|soluble human insulin, biosimilar
884543|NCT02634502|radiofrequency
884544|NCT02634502|chemotherapy
884545|NCT02634502|microRNA
884546|NCT02634489|Bladder outlet obstruction
884547|NCT02634489|Overactive bladder
884548|NCT02634489|Urinary incontinence
884549|NCT02634489|Omnic OCAS®
884550|NCT02634489|Vesicare®
884551|NCT02634489|Tamsulosin hydrochloride
884552|NCT02634489|Solifenacin succinate
884553|NCT02634476|Alcohol
884554|NCT02634476|Substance use disorder
884555|NCT02634476|cognitive bias
884556|NCT02634476|behavioral intervention
884557|NCT02634476|computerised training
884558|NCT02634463|Immunoassay
884559|NCT02634463|Antipsychotic
884560|NCT02634463|Aripiprazole
884561|NCT02634463|Olanzapine
884562|NCT02634463|Paliperidone
884563|NCT02634463|Risperidone
884564|NCT02634450|HIV
884565|NCT02634450|Diagnostic
884566|NCT02634450|children
884567|NCT02634424|Hemophilia A
884568|NCT02634424|Prophylaxy
884569|NCT02634424|Pharmacokinetic
884570|NCT02634424|Bayesian
884571|NCT02634411|Ventilator Associated
884572|NCT02634411|Pneumonia
884573|NCT02634411|Antibiotic treatment
884574|NCT02634411|Pseudomonas aeruginosa
884575|NCT02634372|Bipolar Disorder
884576|NCT02634372|Traumatic event
884577|NCT02634372|Eye Movement Desensitization Reprocessing
884578|NCT02634372|Supportive therapy
884579|NCT02634372|Relapse prevention
884580|NCT02634346|Alkermes
884581|NCT02634346|ALKS 3831
884582|NCT02634346|Samidorphan
884583|NCT02634346|Schizophrenia
884584|NCT02634346|Acute Exacerbation of Schizophrenia
884585|NCT02634333|anti-vascular endothelial growth factor
884586|NCT02634333|nonproliferative diabetic retinopathy
884587|NCT02634320|Alkermes
884588|NCT02634320|ARISTADA
884589|NCT02634320|Aripiprazole Lauroxil
884590|NCT02634320|Schizophrenia
884591|NCT02634307|Multiple Sclerosis
884592|NCT02634307|MS
884593|NCT02634307|Relapsing Remitting Multiple Sclerosis
884594|NCT02634307|RRMS
884595|NCT02634307|dimethyl fumarate
884596|NCT02634307|DMF
884597|NCT02634294|Hematological Neoplasms
884598|NCT02634294|recurrence
884599|NCT02634294|Hematopoietic Stem Cell Transplantation
884600|NCT02634294|peginterferon alfa-2b
884601|NCT02634294|Graft vs Host Disease
884602|NCT02634268|randomized controlled trial
884603|NCT02634268|diet
884604|NCT02634268|exercise
884605|NCT02634268|obesity
884606|NCT02634268|overweight
884607|NCT02634268|chronic obstructive pulmonary disease
884608|NCT02634268|lifestyle
884609|NCT02634255|rocuronium
884610|NCT02634255|onset time
884611|NCT02634255|anxiety
884612|NCT02634242|Si Wu Tang
884613|NCT02634242|antioxidation
884614|NCT02634242|anthropometric measurements
884615|NCT02634242|liver
884616|NCT02634242|skin
884617|NCT02634229|monogenic diabetes
884618|NCT02634229|MODY
884619|NCT02634229|beta-cell
884620|NCT02634229|insulin secretion
884621|NCT02634216|Hyperglycemia
884622|NCT02634216|Capros
884623|NCT02634216|Type 1 Diabetes
884624|NCT02634203|Chronic Thromboembolic Pulmonary Hypertension
884625|NCT02634203|Balloon Pulmonary Angioplasty
884626|NCT02634203|Riociguat
884627|NCT02634190|Cervical cancer screening
884628|NCT02634190|High risk Human Papillomavirus
884629|NCT02634190|Aptima HPV Assay
884630|NCT02634177|Genotyping
884631|NCT02634177|Genecept Assay™
884632|NCT02634164|leucine
884633|NCT02634164|isoleucine
884634|NCT02634151|LDL‐C
884635|NCT02634151|Lipid Regulator
884636|NCT02634138|Peripheral Vascular Disease
884637|NCT02634138|Critical Limb Ischaemia
884638|NCT02634112|anastomotic leakage
884639|NCT02634112|rectal cancer surgery
884640|NCT02634112|anastomotic leakage predictive score
884641|NCT02634099|major pediatric surgery
884642|NCT02634099|hemoglobin measurement
884643|NCT02634086|Coronary artery disease
884644|NCT02634086|Percutaneous coronary intervention
884645|NCT02634086|Coronary artery bypass graft
884646|NCT02634086|Medication therapy
884647|NCT02634073|Lamivudine
884648|NCT02634073|Safety
884649|NCT02634073|Sorbitol
884650|NCT02634073|Pharmacokinetics
884651|NCT02634060|adalimumab
884652|NCT02634060|fecal calprotectin
884653|NCT02634060|home based
884654|NCT02634047|transesophageal echocardiography
884655|NCT02634047|videolaryngoscope
884656|NCT02634047|oropharyngeal injury
884657|NCT02634008|Genotype 1
884658|NCT02633956|Non-alcoholic Fatty Liver Disease
884659|NCT02633956|NAFLD
884660|NCT02633956|Fatty Liver Disease
884661|NCT02633956|NASH
884662|NCT02633930|helicobacter pylori
884663|NCT02633930|berberine-containing quadruple therapy
884664|NCT02633930|clarithromycin-containing quadruple therapy
884665|NCT02633917|Low back pain
884666|NCT02633917|Motor control
884667|NCT02633917|Joint mobilization
884668|NCT02633904|Hip Dislocation
884669|NCT02633904|Congenital
884670|NCT02633904|osteotomy
884671|NCT02633904|Femur Head Necrosis
884672|NCT02633891|neuropathies
884673|NCT02633891|metabolic diseases
884674|NCT02633891|nervous system diseases
884675|NCT02633891|peripheral nervous system diseases
884676|NCT02633865|patient characteristics
884677|NCT02633852|Diabetic Macular Edema (DME)
884678|NCT02633852|Aflibercept (EYLEA)
884679|NCT02633839|Adults
884680|NCT02633826|alloreactive T cell
884681|NCT02633826|donor-specific antibody
884682|NCT02633813|Bioequivalence
884683|NCT02633813|Tinea pedis
884684|NCT02633813|Naftin
884685|NCT02633800|Squamous cell cancer of the head and neck
884686|NCT02633800|Squamous cell carcinoma
884687|NCT02633800|Head and neck cancer
884688|NCT02633800|Neoplasms by site
884689|NCT02633787|Meningitis
884690|NCT02633787|Meningococcal Meningitis
884691|NCT02633787|Meningococcal Infections
884692|NCT02633787|Menactra®
884693|NCT02633761|Fetal death
884694|NCT02633761|mifepristone
884695|NCT02633761|misoprostol
884696|NCT02633735|Clinical Decision Support
884697|NCT02633696|Clinical trial
884698|NCT02633696|Phase I
884699|NCT02633696|Healthy volunteers
884700|NCT02633696|Clinical Pharmacology
884701|NCT02633696|Bioavailability
884702|NCT02633696|Silybin
884703|NCT02633696|Liver Trasplantation
884704|NCT02633683|Restless Legs Syndrome
884705|NCT02633683|RLS
884706|NCT02633657|Restless Legs Syndrome
884707|NCT02633657|RLS
884708|NCT02633644|Heart Failure
884709|NCT02633644|Cardiovascular Diseases
884710|NCT02633644|Heart Diseases
884711|NCT02633592|High Resolution Anorectal Manometry
884712|NCT02633592|Magnetic Resonance Imaging
884713|NCT02633592|Balloon Expulsion
884714|NCT02633592|Position
884715|NCT02633579|Healthy volunteers
884716|NCT02633566|Flatfoot
884717|NCT02633566|orthoses
884718|NCT02633566|children
884719|NCT02633553|thymoma
884720|NCT02633553|adjuvant radiotherapy
884721|NCT02633553|complete resection
884722|NCT02633540|T1a Larynx Cancer
884723|NCT02633540|T2a Larynx Cancer
884724|NCT02633514|thymoma
884725|NCT02633514|thymic carcinoma
884726|NCT02633514|adjuvant radiotherapy
884727|NCT02633514|adjuvant radiochemotherapy
884728|NCT02633514|incomplete resection
884729|NCT02633475|interleukin-10
884730|NCT02633475|Polymorphism, Single Nucleotide
884731|NCT02633449|tDCS
884732|NCT02633449|cognitive behavioral therapy
884733|NCT02633436|esophageal cancer
884734|NCT02633436|SLC1A5
884735|NCT02633423|Cardiopulmonary bypass
884736|NCT02633423|Mechanical ventilation
884737|NCT02633423|Expiratory Flow Limitation
884738|NCT02633423|Best PEEP
884739|NCT02633397|SCD
884740|NCT02633397|Sickle Cell Disease
884741|NCT02633397|Riociguat
884742|NCT02633397|Adempas
884743|NCT02633384|Parenteral nutrition associated cholestasis
884744|NCT02633384|Intravenous lipid emulsions
884745|NCT02633384|Surgical neonates
884746|NCT02633384|Congenital gastrointestinal abnormalities
884747|NCT02633358|Acute myocardial infarction, cardiogenic shock
884754|NCT02633306|trigeminal region pain
884760|NCT02633267|social anxiety
884761|NCT02633267|unemployment
884762|NCT02633267|cognitive behavioral therapy
884763|NCT02633267|group therapy
884764|NCT02633267|work
884765|NCT02633267|vocation
884766|NCT02633241|pediatrics
884767|NCT02633241|sedation
884768|NCT02633241|dexmedetomidine
884769|NCT02633241|propofol
884770|NCT02633241|MRI
884780|NCT02633215|motor recovery
884781|NCT02633215|neuroplasticity
884782|NCT02633215|chronic
884783|NCT02633215|human
884784|NCT02633215|sensory
884789|NCT02633189|stage IV
884790|NCT02633189|stage IIIB
884791|NCT02633189|EGFR mutation
884792|NCT02633189|non-squamous
884793|NCT02633189|liquid biopsy
884794|NCT02633189|erlotinib
884795|NCT02633189|bevacizumab
884796|NCT02633163|Systemic Lupus Erythematosus
884797|NCT02633163|Stem Cell
884798|NCT02633163|Lupus
884799|NCT02633150|Obesity
884800|NCT02633150|insulinoresistant
884801|NCT02633150|menopausal women
884802|NCT02633150|polyphenol
884803|NCT02633137|Lenalidomide
884804|NCT02633137|15-196
884805|NCT02633124|Premature infants
884806|NCT02633124|Catheter-related bacteremia
884807|NCT02633124|Infusion device
884808|NCT02633124|Neonatal intensive care
884809|NCT02633124|Central Venous Catheter
884810|NCT02633124|Drug Infusion Systems
884811|NCT02633111|DNA Sequencing
884812|NCT02633111|15-180
884813|NCT02633098|Artesunate
884814|NCT02633098|Artemisinins
884815|NCT02633098|Antimalarial
884816|NCT02633098|Neoadjuvant
884817|NCT02633098|Pre-operative
884818|NCT02633085|Unicompartment Knee Replacement
884828|NCT02633046|FSGS
884829|NCT02633046|primary FSGS
884830|NCT02633046|idiopathic FSGS
884831|NCT02632981|Interleukin-32
884832|NCT02632981|periodontitis
884833|NCT02632955|arteriovenous fistula
884834|NCT02632955|hemodialysis
884835|NCT02632955|drug coated balloon
884836|NCT02632942|arteriovenous fistula
884837|NCT02632942|hemodialysis
884838|NCT02632942|maturation
884839|NCT02632929|foot ulcer, diabetic
884840|NCT02632929|wound healing
884841|NCT02632929|diabetic foot ulcer
884842|NCT02632877|pirfenidone
884843|NCT02632877|Modified oxide diallyl disulfide (MODD)
884844|NCT02632877|ketanserin
884845|NCT02632877|diabetic foot ulcer
884846|NCT02632851|inhalation
884847|NCT02632851|isotonic saline
884848|NCT02632851|NaCl solution 0.9 %
884849|NCT02632851|Ectoin
884850|NCT02632851|bronchitis
884851|NCT02632851|respiratory tract infection
884852|NCT02632838|Hypertension
884853|NCT02632838|mHealth
884854|NCT02632838|underserved community
884855|NCT02632825|Nasal High Flow
884856|NCT02632825|gas exchange
884857|NCT02632825|newborn
884858|NCT02632799|Nasal High Flow
884859|NCT02632799|CPAP
884860|NCT02632799|airway pressure
884861|NCT02632799|newborn
884862|NCT02632786|amyloidosis
884863|NCT02632786|ntprobnp
884864|NCT02632786|NEOD001
884865|NCT02632786|Prothena
884866|NCT02632786|PRONTO
884867|NCT02632786|amyloid
884868|NCT02632786|plasma cell dyscrasia
884869|NCT02632786|immunotherapy
884870|NCT02632773|Language Intervention
884871|NCT02632773|Parent-Mediated Intervention
884872|NCT02632734|alveolar bone preservation
884873|NCT02632734|coral grafting device
884874|NCT02632708|Acute Myeloid Leukemia
884875|NCT02632708|AML
884876|NCT02632708|Untreated AML
884877|NCT02632708|De novo AML
884878|NCT02632708|Secondary AML
884879|NCT02632708|Newly diagnosed AML
884880|NCT02632708|IDH1
884881|NCT02632708|IDH2
884882|NCT02632708|Induction therapy
884883|NCT02632708|Consolidation therapy
884884|NCT02632708|IDH
884885|NCT02632682|probe-based confocal laser endomicroscopy
884886|NCT02632669|Focal brachytherapy
884887|NCT02632669|Seed implant
884888|NCT02632669|Quality of life
884889|NCT02632669|Toxicity
884890|NCT02632643|TMD
884891|NCT02632643|HYPERTONIA
884892|NCT02632643|PARAFUNCTIONS
884893|NCT02632643|SENSORIMOTOR APPROACH
884894|NCT02632630|Peripheral Parenteral Nutrition
884895|NCT02632630|Oral nutritional supplementation
884896|NCT02632630|Acute Care hospitals
884897|NCT02632617|Heart Valve Diseases
884898|NCT02632617|Coronary Artery Disease
884899|NCT02632617|Computed Tomographic Angiography
884900|NCT02632617|Preoperative Procedure
884901|NCT02632565|osteoarthritis
884902|NCT02632565|lidocaine
884903|NCT02632565|pain
884904|NCT02632565|ultrasound
884905|NCT02632552|care transition
884906|NCT02632552|technology
884907|NCT02632552|chronic heart failure
884908|NCT02632552|chronic obstructive pulmonary disease
884909|NCT02632552|virtual nurse
884910|NCT02632552|texting
884911|NCT02632552|informatics
884912|NCT02632552|Veterans
884913|NCT02632539|ventilator associated pneumonia
884914|NCT02632539|Subglottic Secretion Drainage
884915|NCT02632539|manual air-impingement operation
884916|NCT02632526|AZD5718 oral suspension crystalline
884917|NCT02632526|AZD5718 oral suspension amorphous
884918|NCT02632526|Single ascending dose/multiple ascending dose (SAD/MAD)
884919|NCT02632526|Placebo-controlled
884920|NCT02632526|Safety
884921|NCT02632526|Tolerability
884922|NCT02632526|Pharmacokinetics
884923|NCT02632526|Pharmacodynamics
884924|NCT02632513|continuous ultrasonic irrigation, syringe irrigation
884925|NCT02632500|Cardio-Pulmonary Resuscitation
884926|NCT02632500|Cardiac Arrest
884927|NCT02632500|Training
884928|NCT02632474|HIV Infections
884929|NCT02632474|Tenofovir
884930|NCT02632474|Efavirenz
884931|NCT02632461|Diet
884932|NCT02632461|Weight Loss
884933|NCT02632461|Tracking
884934|NCT02632461|Calories
884935|NCT02632448|Metastatic cancer
884936|NCT02632448|Advanced cancer
884937|NCT02632448|Recurrent cancer
884938|NCT02632448|Colorectal neoplasms
884939|NCT02632448|Triple negative breast cancer
884940|NCT02632448|Ovarian neoplasms
884941|NCT02632448|Colon neoplasms
884942|NCT02632448|Rectal neoplasms
884943|NCT02632448|Triple negative breast neoplasms
884944|NCT02632435|HER2 positive
884945|NCT02632383|Diabetes type 1
884946|NCT02632383|Transition
884947|NCT02632383|Telemedicine
884948|NCT02632383|mHealth app
884949|NCT02632383|Youth
884950|NCT02632383|Self-management
884951|NCT02632370|Malignant Gliomas
884952|NCT02632370|5-ALA
884953|NCT02632370|tumor resection
884954|NCT02632370|malignant tumor
884955|NCT02632357|Neurodynamics
884956|NCT02632344|Laryngeal papilloma, recurrent
884957|NCT02632344|Respiratory papillomatosis
884958|NCT02632344|Juvenile-onset recurrent respiratory papillomatosis
884959|NCT02632344|Human papillomavirus
884960|NCT02632344|Virally-related diseases
884961|NCT02632331|Food effect
884962|NCT02632331|Pharmacokinetics
884963|NCT02632331|ASP8825
884964|NCT02632331|XP13512
884965|NCT02632305|unresectable biliary tract cancer
884966|NCT02632305|nab-paclitaxel
884967|NCT02632305|cisplatin
884968|NCT02632305|gemcitabine
884969|NCT02632279|Parkinson's disease
884970|NCT02632279|Deep Brain Stimulation
884971|NCT02632279|Subthalamic nucleus
884972|NCT02632279|Tryptophan depletion
884973|NCT02632279|Serotonin
884974|NCT02632266|prematurity
884975|NCT02632266|growth
884976|NCT02632266|nutrition
884977|NCT02632266|human milk fortifier
884978|NCT02632253|exercise therapy
884979|NCT02632253|GUCH
884980|NCT02632253|ventricular ejection fraction
884981|NCT02632253|HIIT
884982|NCT02632253|MICE
884983|NCT02632240|gingival recession
884984|NCT02632240|mucogingival surgery
884985|NCT02632240|collagen matrix
884986|NCT02632240|connective tissue graft
884987|NCT02632240|tunnel technique
884988|NCT02632214|Face processing
884989|NCT02632214|asymmetry
884990|NCT02632214|deaf
884991|NCT02632214|fMRI
884992|NCT02632201|gastric cancer
884993|NCT02632201|liver metastasis
884994|NCT02632201|PIK-HER2 cells
884995|NCT02632201|dendritic cell-precision multiple antigen T cells
884996|NCT02632188|Recurrence
884997|NCT02632188|Metastasis
884998|NCT02632188|liver cancer
884999|NCT02632175|Ulcerative Colitis
885000|NCT02632149|PINS Vagus Nerve Stimulator
885001|NCT02632136|Laparoscopic
885002|NCT02632136|TAP Block
885003|NCT02632136|Total extra peritoneal Inguinal hernia repair
885004|NCT02632123|idiopathic pulmonary fibrosis
885005|NCT02632123|outcome
885006|NCT02632123|prognosis
885007|NCT02632123|survival
885008|NCT02632110|Actinic Keratosis
885009|NCT02632097|inguinal hernia
885010|NCT02632097|mesh fixation
885011|NCT02632097|glue
885012|NCT02632097|cyanoacrylate
885013|NCT02632097|Lichtenstein
885014|NCT02632097|ambulatory surgery
885015|NCT02632071|Breast Cancer
885016|NCT02632071|Breast Carcinoma
885017|NCT02632071|Breast tumors
885018|NCT02632071|Cancer of the Breast
885019|NCT02632071|Malignant tumor of the breast
885020|NCT02632071|Metastatic Breast Cancer
885021|NCT02632071|Unresectable breast cancer
885022|NCT02632045|Breast Neoplasms
885023|NCT02632045|Breast Cancer
885024|NCT02632045|Breast Carcinoma
885025|NCT02632045|Breast tumors
885026|NCT02632045|Cancer of the Breast
885027|NCT02632032|Type 1 diabetes
885028|NCT02632032|children
885029|NCT02632032|diabetes camps
885030|NCT02632032|glycemic control
885031|NCT02632019|advanced biliary tract malignant tumor
885032|NCT02632019|dendritic cell
885033|NCT02632019|precision T cell for neo-antigen
885034|NCT02632006|PIK-PD-1 Cells
885035|NCT02632006|dendritic cell-precision multiple antigen T cells
885036|NCT02632006|advanced hepatocellular carcinoma
885037|NCT02631993|Psoralen
885038|NCT02631993|UVA
885039|NCT02631993|Time-to-treatment
885040|NCT02631993|GVL
885041|NCT02631980|Hepcidin
885042|NCT02631967|Crohn disease
885043|NCT02631967|ileocecal resection
885044|NCT02631967|anastomosis
885045|NCT02631967|Kono
885046|NCT02631928|biphasic human insulin
885047|NCT02631928|biosimilar
885048|NCT02631902|Community-based intervention
885049|NCT02631902|Exercise program
885050|NCT02631902|Dietary intervention program
885051|NCT02631902|Health promotion
885052|NCT02631902|Subjective well-being
885053|NCT02631902|Cardiovascular risk
885054|NCT02631876|Epithelial ovarian cancer
885055|NCT02631876|Fallopian tube cancer
885056|NCT02631876|Primary peritoneal cancer
885057|NCT02631876|IMGN853
885058|NCT02631876|ADC
885059|NCT02631876|Antibody drug conjugate
885060|NCT02631876|ImmunoGen
885061|NCT02631876|Antibody
885062|NCT02631876|Folate receptor alpha
885063|NCT02631876|mirvetuximab soravtansine
885064|NCT02631876|Phase 3
885065|NCT02631876|platinum-resistant
885066|NCT02631850|Constraint-induced movement therapy
885067|NCT02631850|gaming
885068|NCT02631850|virtual reality
885069|NCT02631850|upper extremity
885070|NCT02631850|CI therapy
885071|NCT02631850|rehabilitation
885072|NCT02631850|stroke
885073|NCT02631850|hemiparesis
885074|NCT02631850|therapy
885075|NCT02631837|NOTES
885076|NCT02631837|Laparoscopic surgery
885077|NCT02631824|fragility fractures
885078|NCT02631824|hip fractures
885079|NCT02631824|augmentation
885080|NCT02631824|tip-apex distance
885081|NCT02631811|acute leukaemia
885082|NCT02631811|supportive / palliative care
885083|NCT02631785|ANXIETY
885084|NCT02631785|CBT
885085|NCT02631785|fMRI
885086|NCT02631785|Fear conditioning
885087|NCT02631785|Fear extinction
885088|NCT02631759|Acute intraCerebral Haemorrhage, Epileptic seizures, Lévétiracetam
885089|NCT02631668|iron deficiency anemia, vitamin C, ferrous succinate
885090|NCT02631629|Vitamin D
885091|NCT02631629|Fortification
885092|NCT02631616|Prostatic Neoplasma, Castration-Resistant
885093|NCT02631616|neuroendocrine differentiation
885094|NCT02631616|68Ga-DOTATET
885095|NCT02631616|PET/CT
885096|NCT02631590|intra-hepatic biliary system
885097|NCT02631590|extra-hepatic biliary system
885098|NCT02631590|gall bladder
885099|NCT02631590|advanced biliary cancer
885100|NCT02631590|unresectable
885101|NCT02631590|locally advanced
885102|NCT02631590|metastatic disease
885103|NCT02631564|mCRC;TACE;hepatic infusion;raltitrexed
885104|NCT02631551|Seasonal Allergic Rhinitis
885105|NCT02631538|Subcutaneous
885106|NCT02631538|Rituximab
885107|NCT02631538|Intravenous
885108|NCT02631538|Safety
885109|NCT02631538|Efficacy
885110|NCT02631538|Sjogren's syndrome
885111|NCT02631538|Belimumab
885112|NCT02631525|Airway extubation
885113|NCT02631525|Anesthesia Recovery Period
885114|NCT02631525|Desflurane
885115|NCT02631525|Propofol
885116|NCT02631525|Intravenous anesthesia
885117|NCT02631525|Balanced Anesthesia
885118|NCT02631499|Circulating Tumor Cells
885119|NCT02631499|Hepatoectomy
885120|NCT02631499|TACE
885121|NCT02631499|prognosis
885122|NCT02631499|relapse
885123|NCT02631499|Chemoembolization, Therapeutic
885124|NCT02631486|Rotator Cuff Tears
885125|NCT02631447|Metastatic Melanoma
885126|NCT02631447|BRAF mutation
885127|NCT02631408|spinal fusion
885128|NCT02631408|topical antibiotics
885129|NCT02631408|vancomycin
885130|NCT02631408|surgical site infection
885131|NCT02631395|Exercise movement techniques
885132|NCT02631382|wet cupping Saudi Arabia
885133|NCT02631343|Kangaroo mother care in the community
885134|NCT02631330|Geriatric Assessment
885135|NCT02631330|Physical Education and Training
885136|NCT02631317|acute ischemic stroke
885137|NCT02631317|intravenous rt-PA thrombolysis
885138|NCT02631317|process reengineering
885139|NCT02631317|door-to-needle time
885140|NCT02631304|Postoperative delirium
885141|NCT02631304|Cholinesterase activity
885142|NCT02631304|Buturylcholinesterase activity
885143|NCT02631304|Acetylcholinesterase activity
885144|NCT02631304|Elderly patients
885145|NCT02631304|Cardiac surgery
885146|NCT02631265|Type 1 diabetes
885147|NCT02631265|Exercise
885148|NCT02631265|Hypoglycemia
885149|NCT02631265|Insulin pump
885150|NCT02631252|Leukemia
885151|NCT02631252|Acute Myelogenous
885152|NCT02631252|Phase I
885153|NCT02631252|Mitoxantrone
885154|NCT02631252|Etoposide
885155|NCT02631252|Hydroxychloroquine
885156|NCT02631252|Relapsed
885157|NCT02631252|Autophagy inhibitor
885158|NCT02631252|AML
885159|NCT02631252|Relapsed AML
885160|NCT02631200|Advance Care Planning
885161|NCT02631200|Palliative care
885162|NCT02631200|Frail Elderly
885163|NCT02631200|Renal Dialysis
885164|NCT02631187|Grade 2 retraction of the pars tensa of the tympanic membrane
885165|NCT02631187|Grade 3 retraction of the pars tensa of the tympanic membrane
885166|NCT02631135|Dexmedetomidine
885167|NCT02631135|cognitive functions
885168|NCT02631135|MMSE
885169|NCT02631122|Retroclavicular
885170|NCT02631122|Supraclavicular
885171|NCT02631122|Diagphram
885172|NCT02631122|hemiparesis
885173|NCT02631122|nerve block
885174|NCT02631122|regional anesthesia
885175|NCT02631122|anesthesiology
885176|NCT02631109|Pegaspargase
885177|NCT02631109|hemophagocytic lymphohistiocytosis
885178|NCT02631109|Epstein Barr virus
885179|NCT02631070|Luspatercept
885180|NCT02631070|Transfusion dependent
885181|NCT02631070|Lower risk
885182|NCT02631070|Low risk
885183|NCT02631070|Myelodysplastic Syndromes
885184|NCT02631070|ESA refractory
885185|NCT02631070|ESA intolerant
885186|NCT02631070|ESA ineligible
885187|NCT02631070|ACE-536
885188|NCT02631070|Anemia
885189|NCT02631070|Ring Sideroblasts
885190|NCT02631070|Require Red Blood Cell Transfusions
885191|NCT02631070|MEDALIST
885192|NCT02631070|MDS
885193|NCT02631070|IPSS-R very low/IPSS-R low/IPSS-R intermediate
885194|NCT02631044|JCAR017
885195|NCT02631044|chimeric antigen receptor
885196|NCT02631044|non-Hodgkin lymphoma
885197|NCT02631044|CAR
885198|NCT02631044|CAR T cells
885199|NCT02631044|autologous T cell therapy
885200|NCT02631044|cell therapy
885201|NCT02631044|NHL
885202|NCT02631031|Chronokinetics
885203|NCT02631031|chronodynamics
885204|NCT02631031|chronopharmacology
885205|NCT02631031|valsartan
885206|NCT02631005|systemic lupus erythematosus
885207|NCT02631005|exercise
885208|NCT02630992|ear infections
885209|NCT02630992|antibiotics
885210|NCT02630992|antibiotic resistance
885211|NCT02630992|pediatrics
885212|NCT02630992|infants
885213|NCT02630992|children
885214|NCT02630992|amoxicillin-clavulanate
885215|NCT02630966|Drug therapy
885216|NCT02630953|Physical Activity
885217|NCT02630953|Latinas
885218|NCT02630953|Spanish-language
885219|NCT02630953|Text-Message
885220|NCT02630927|Safety and Tolerability
885221|NCT02630927|Pharmacokinetic Study
885222|NCT02630927|Healthy Volunteer
885223|NCT02630927|Pyruvate Kinase
885224|NCT02630927|Rare Genetic
885225|NCT02630914|Epicardial surgical removal
885226|NCT02630914|Closure of the left atrial
885227|NCT02630914|Left atrial appendage (LAA)
885228|NCT02630888|Bipolar Disorder
885229|NCT02630888|Memantine
885230|NCT02630888|Lithium
885231|NCT02630888|Aripiprazole
885232|NCT02630888|Quetiapine
885233|NCT02630888|Central Nervous System Agents
885234|NCT02630888|Therapeutic Uses
885235|NCT02630888|Pharmacologic Actions
885236|NCT02630888|Psychotropic Drugs
885237|NCT02630888|Cognitive effect of drugs
885238|NCT02630862|oxidative stress
885239|NCT02630862|atherosclerosis
885240|NCT02630862|carotid stenosis
885241|NCT02630862|oxysterols
885242|NCT02630862|vitamin E
885243|NCT02630862|lipid peroxidation
885244|NCT02630862|antioxidants
885245|NCT02630862|aspirin
885246|NCT02630862|dipyridamole
885247|NCT02630836|mesenchymal stromal cells
885248|NCT02630836|stem cells
885249|NCT02630836|elderly
885250|NCT02630836|allogeneic
885251|NCT02630836|bone marrow
885252|NCT02630836|bone regeneration
885253|NCT02630836|fracture
885254|NCT02630784|Non-invasive ventilation
885255|NCT02630784|NIV ventilator
885256|NCT02630784|Exhalation by a calibrated leak
885257|NCT02630784|ICU ventilator
885258|NCT02630784|Respiratory acidosis
885259|NCT02630784|ICU
885260|NCT02630758|depression
885261|NCT02630758|yoga
885262|NCT02630758|mindfulness
885263|NCT02630745|endodontic treatment
885264|NCT02630745|open flap debridement
885269|NCT02630719|headache
885270|NCT02630628|Lupus Nephritis
885271|NCT02630628|mycophenolate mofetil
885272|NCT02630628|tacrolimus
885273|NCT02630615|Circulating tumor cells
885274|NCT02630589|tinnitus
885275|NCT02630589|auditory brainstem implant
885276|NCT02630589|electrical stimulation
885277|NCT02630576|electromyography
885278|NCT02630576|neuromuscular blockade
885279|NCT02630550|Cardiac output
885280|NCT02630550|Intraoperative Monitoring
885281|NCT02630550|Echocardiography, Transesophageal
885282|NCT02630550|Vascular cross-clamping
885283|NCT02630550|Endarterectomy
885284|NCT02630550|Monitoring, Physiologic/instrumentation
885285|NCT02630550|Cardiography, Impedance
885286|NCT02630537|Cytomegalovirus
885287|NCT02630537|Epstein- Barr virus
885288|NCT02630537|Cell-mediated immunity
885289|NCT02630537|T-Track® CMV
885290|NCT02630537|T-Track® EBV
885291|NCT02630537|hemodialysis
885292|NCT02630537|ELISpot
885293|NCT02630498|pain
885294|NCT02630498|surgical
885295|NCT02630498|brachial plexus
885296|NCT02630485|Randomized Controlled Trial
885297|NCT02630459|Migraine Prevention
885298|NCT02630459|Headache
885299|NCT02630459|Prophylaxis
885300|NCT02630446|respite care
885301|NCT02630446|effectiveness
885302|NCT02630446|cost-effectiveness
885303|NCT02630446|support
885304|NCT02630446|caregiver
885305|NCT02630446|dementia
885306|NCT02630446|community-based
885307|NCT02630433|Biliary pancreatitis
885308|NCT02630433|Cholecystectomy
885309|NCT02630394|sickle cell disease
885310|NCT02630394|acute chest syndrome
885311|NCT02630381|high-energy shock waves
885312|NCT02630368|Advanced Soft-tissue Sarcoma
885313|NCT02630368|Advanced Breast Cancer
885314|NCT02630368|Maximum Tolerated Dose
885315|NCT02630368|Efficacy and safety
885316|NCT02630342|Mock Scanner
885317|NCT02630342|Child Life Specialist
885318|NCT02630342|Patient Preparation
885319|NCT02630342|Child, Preschool
885320|NCT02630342|Child
885321|NCT02630342|Anxiety
885322|NCT02630342|Human
885323|NCT02630342|Anesthesia, General
885324|NCT02630329|NOTES
885325|NCT02630329|Benign adnexal disease
885326|NCT02630329|Laparoscopy
885332|NCT02630303|light emitting diode-red light
885333|NCT02630303|LED-RL
885334|NCT02630303|high fluence
885335|NCT02630303|skin fibrosis
885336|NCT02630303|wound healing
885337|NCT02630303|scar
885338|NCT02630303|keloid
885339|NCT02630303|RCT
885340|NCT02630290|Brachial plexus block
885341|NCT02630290|Dexmedetomidine
885342|NCT02630290|Ropivacaine
885343|NCT02630290|ultrasound-guided nerve block
885344|NCT02630290|supraclavicular brachial plexus block
885345|NCT02630277|Proliferative Diabetic Retinopathy
885346|NCT02630277|High Risk PDR
885347|NCT02630277|aflibercept
885348|NCT02630277|regression of retinal neovascularization
885349|NCT02630264|clinical trial
885350|NCT02630264|Recombinant Human Endostatin Adenovirus
885351|NCT02630264|randomized
885352|NCT02630251|Cancer
885353|NCT02630251|Safety
885354|NCT02630251|GSK2820151
885355|NCT02630251|Dose escalation
885356|NCT02630251|Tolerability
885357|NCT02630251|Pharmacodynamics
885358|NCT02630251|Pharmacokinetics
885359|NCT02630238|Exercise
885360|NCT02630238|Amino Acids, Branched-Chain
885361|NCT02630225|case management
885362|NCT02630225|motivational interviewing
885363|NCT02630212|Aortic dissection
885364|NCT02630212|Aldehyde dehydrogenase 2 polymorphism
885365|NCT02630212|Risk factor
885366|NCT02630212|aldehyde dehydrogenase 2
885367|NCT02630173|endodontic treatment
885368|NCT02630173|scaling
885369|NCT02630173|root planning
885370|NCT02630147|Late preterm
885371|NCT02630147|Vanilla
885372|NCT02630147|Hypoxic intermittent events
885373|NCT02630108|HCC
885374|NCT02630108|TACE
885375|NCT02630108|Thermal Ablation
885376|NCT02630108|Safety/Efficacy
885377|NCT02630095|anticoagulation
885378|NCT02630082|HIV Preventive Vaccine
885379|NCT02630082|HIV Seronegativity
885380|NCT02630082|Immune Response, Mucosal
885381|NCT02630069|amphetamine type stimulant
885382|NCT02630069|adolescents
885383|NCT02630056|radiotherapy hematologic toxicity pelvic bone marrow
885384|NCT02630004|Mucositis
885385|NCT02630004|Head and Neck cancer
885386|NCT02630004|Chemoradiation
885387|NCT02629991|Prader-Willi Syndrome (PWS)
885388|NCT02629991|Hyperphagia
885389|NCT02629978|pulmonary
885390|NCT02629978|lung
885391|NCT02629978|cancer
885392|NCT02629978|carcinoma
885393|NCT02629978|nodule
885394|NCT02629978|malignant
885395|NCT02629978|radiofrequency ablation
885396|NCT02629978|RFA
885397|NCT02629952|glucose tolerance
885398|NCT02629952|type 2 diabetes
885399|NCT02629952|blueberry tea
885400|NCT02629900|Weight Loss
885401|NCT02629900|Intermittent fasting
885402|NCT02629887|supraglottic airway
885403|NCT02629887|neonatal resuscitation
885404|NCT02629887|ventilation
885405|NCT02629887|term infant
885406|NCT02629874|EA-230
885407|NCT02629874|Inflammatory response
885408|NCT02629874|Kidney Injury
885409|NCT02629874|Endotoxemia
885410|NCT02629848|Drug therapy
885411|NCT02629809|Leukemia
885412|NCT02629809|Chronic lymphocytic leukemia
885413|NCT02629809|CLL
885414|NCT02629809|Mutated immunoglobulin heavy chair variable region
885415|NCT02629809|IGHV
885416|NCT02629809|non-del(17p) fluorescence in-situ hybridization
885417|NCT02629809|FISH
885418|NCT02629809|Obinutuzumab
885419|NCT02629809|GA101
885420|NCT02629809|Gazyva
885421|NCT02629809|Fludarabine
885422|NCT02629809|Fludarabine Phosphate
885423|NCT02629809|Fludara
885424|NCT02629809|Cyclophosphamide
885425|NCT02629809|Cytoxan
885426|NCT02629809|Neosar
885427|NCT02629809|Ibrutinib
885428|NCT02629809|PCI-32765
885429|NCT02629809|Imbruvica
885430|NCT02629809|Allopurinol
885431|NCT02629809|Lopurin
885432|NCT02629809|Zurinol
885433|NCT02629809|Zyloprim
885434|NCT02629809|Valacyclovir
885435|NCT02629809|Valtrex
885436|NCT02629796|Biomarker
885437|NCT02629796|CIDP
885438|NCT02629796|IVIG
885439|NCT02629796|treatment response
885440|NCT02629757|High-grade glioma
885441|NCT02629757|chemotherapy
885442|NCT02629757|β-elemene
885443|NCT02629731|foot
885444|NCT02629731|ankle
885445|NCT02629731|osteoarthritis
885446|NCT02629731|flat foot
885447|NCT02629718|neoadjuvant chemotherapy
885448|NCT02629718|radical surgery
885449|NCT02629718|cervical carcinoma
885450|NCT02629653|carotid endarterectomy
885451|NCT02629653|stroke
885452|NCT02629653|hypothermia
885453|NCT02629653|endovascular cooling
885454|NCT02629640|vCJD
885455|NCT02629640|prion disease
885456|NCT02629640|dementia
885457|NCT02629640|old-age
885458|NCT02629640|surveillance
885459|NCT02629640|brain banking
885460|NCT02629640|public health
885461|NCT02629627|Conjugated Linoleic Acid
885462|NCT02629627|Leucine
885463|NCT02629627|visceral fat area
885464|NCT02629627|Epicardial Fat
885465|NCT02629627|Hemodinamic Parameters
885466|NCT02629601|physical activity
885467|NCT02629601|financial incentives
885468|NCT02629601|behavioral economics
885469|NCT02629588|Coma
885470|NCT02629588|Persistent Vegetative State
885471|NCT02629588|Sensory Stimulation
885472|NCT02629497|platelets
885473|NCT02629497|12-lipoxygenase
885474|NCT02629497|fatty acids
885475|NCT02629497|DGLA
885476|NCT02629497|DHA
885477|NCT02629497|EPA
885478|NCT02629497|12-LOX
885479|NCT02629484|echocardiography
885480|NCT02629484|hip fracture
885481|NCT02629484|surgery
885482|NCT02629484|outcomes
885483|NCT02629432|MRI
885484|NCT02629432|COPD
885485|NCT02629419|STAT3 deficient Hyper IgE syndrome
885486|NCT02629419|Gain of function STAT1 defects
885487|NCT02629419|Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
885488|NCT02629419|IL-17/IL-22 autoantibodies from thymoma
885489|NCT02629419|Job's Syndrome (Hyperimmunoglobulin E Syndrome, Buckley Syndrome)
885490|NCT02629406|HIF
885491|NCT02629406|hypoxia
885492|NCT02629406|chemoreflex
885493|NCT02629406|baroreflex
885494|NCT02629406|MIR210
885495|NCT02629393|Molybdenum Cofactor Deficiency (MoCD)
885496|NCT02629393|Molybdenum Cofactor (MoCo) biosynthesis
885497|NCT02629393|sulfite oxidase (SO)
885498|NCT02629393|S sulfocysteine (SSC)
885499|NCT02629393|xanthine oxidoreductase
885500|NCT02629393|aldehyde oxidase
885501|NCT02629380|meniscectomy
885502|NCT02629380|hyaluronic acid
885503|NCT02629380|intra-op injection
885504|NCT02629380|randomized controlled trial
885505|NCT02629380|placebo
885506|NCT02629341|woman osteopenia osteoporosis enriched calcium vit D yogurt
885507|NCT02629328|CardioCel
885508|NCT02629328|FDA cleared
885509|NCT02629328|Tri-leaflet repair
885510|NCT02629328|Aortic valves
885511|NCT02629289|HSP-130
885512|NCT02629289|Pharmacodynamic and Pharmacokinetic equivalence
885513|NCT02629289|Pegfilgrastim
885514|NCT02629276|neck pain
885515|NCT02629276|arm pain
885516|NCT02629276|neurodynamic tests
885517|NCT02629276|quantitative sensory testing
885518|NCT02629276|somatosensory profile
885519|NCT02629250|proximal femoral fracture
885520|NCT02629250|goal-directed therapy
885521|NCT02629250|myocardial injury
885522|NCT02629250|supernormal oxygen delivery
885523|NCT02629250|elders
885524|NCT02629250|stroke volume maximization
885525|NCT02629237|glaucoma surgery
885526|NCT02629237|educational intervention
885527|NCT02629237|satisfaction
885528|NCT02629237|rural
885529|NCT02629224|Impaired renal function
885530|NCT02629224|Haemodialysis
885531|NCT02629224|ASP8825
885532|NCT02629224|XP13512
885533|NCT02629211|Inflammatory Bowel Diseases
885534|NCT02629211|Colitis, Ulcerative
885535|NCT02629211|Crohn Disease
885536|NCT02629211|Single-Balloon Enteroscopy
885537|NCT02629211|NaviAid AB™ Device
885538|NCT02629211|NaviAid AB™ Procedure
885539|NCT02629211|AB Device
885540|NCT02629211|Pediatric IBD
885541|NCT02629211|Pediatric Enteroscopy
885542|NCT02629198|Vitamin D
885543|NCT02629185|Bone
885544|NCT02629185|Vitamin D
885545|NCT02629185|Cardiovascular
885546|NCT02629172|Genotype 1
885547|NCT02629172|Ritonavir
885548|NCT02629172|Hepatitis C Virus (HCV)
885549|NCT02629172|Ombitasvir
885550|NCT02629172|Paritaprevir
885551|NCT02629159|Antirheumatic agents
885552|NCT02629159|Anti-inflammatory agents
885553|NCT02629159|Musculoskeletal disease
885554|NCT02629159|Arthritis
885555|NCT02629159|Joint disease
885556|NCT02629146|Midazolam
885557|NCT02629146|Fentanyl
885558|NCT02629133|Intimate Partner Violence
885559|NCT02629133|Sheltered Battered Women
885560|NCT02629133|Substance Use
885561|NCT02629120|Chronic Granulomatous Disease
885562|NCT02629120|Allogeneic Stem Cell Transplantation
885563|NCT02629120|Graft Versus Host Disease
885564|NCT02629120|Matched Unrelated Donor BMT
885565|NCT02629120|Nonmyeloablative Conditioning Regimen
885566|NCT02629107|Sleep
885567|NCT02629107|Functional Magnetic Resonance Imaging (fMRI)
885568|NCT02629107|Electroencephalogram (EEG)
885569|NCT02629094|Hepatic Steatosis
885570|NCT02629094|Cardiac Steatosis
885571|NCT02629094|Aldosterone
885572|NCT02629094|Eplerenone
885573|NCT02629094|Mineralcorticoid Receptor
885574|NCT02629081|heartburn
885575|NCT02629081|GERD
885576|NCT02629081|NERD
885577|NCT02629081|non-erosive reflux disease
885578|NCT02629068|Adolescent
885579|NCT02629068|Social Support
885580|NCT02629068|Social Media
885581|NCT02629068|Parents
885582|NCT02629068|Shame
885583|NCT02629068|Stigma
885584|NCT02629055|Non-invasive ventilation
885585|NCT02629055|Respiratory electromyography
885586|NCT02629042|Anesthesia
885587|NCT02629042|Corticosteroids
885588|NCT02629042|Dental Emergency
885589|NCT02629042|Irreversible Pulpitis
885590|NCT02629042|Mandibulae
885591|NCT02629042|Pain Management
885592|NCT02629042|Partial Endodontic Treatment
885593|NCT02629003|Positron Emission Tomography
885594|NCT02629003|Serotonin
885595|NCT02629003|5-HT2A
885596|NCT02629003|Radioligand
885597|NCT02629003|Radiation dosimetry
885598|NCT02629003|Radiation dosage
885599|NCT02628964|smoking
885600|NCT02628964|cigarettes
885601|NCT02628938|Halitosis
885602|NCT02628938|Oral Malodor
885603|NCT02628938|Miswak
885604|NCT02628938|Salvadora Persica
885605|NCT02628925|mass screening
885606|NCT02628925|Nursing diagnosis
885607|NCT02628925|Psychiatric Status Rating Scale
885608|NCT02628912|Cardiopulmonary Fitness
885609|NCT02628912|Long-Term Survivors
885610|NCT02628912|15-277
885611|NCT02628912|HPV
885612|NCT02628912|Survivors
885613|NCT02628886|maternal and neonatal pneumococcal conjugate vaccination
885614|NCT02628886|pneumococcal carriage
885615|NCT02628873|HSG
885616|NCT02628873|HyCoSy
885617|NCT02628873|Contraception
885618|NCT02628873|Essure
885619|NCT02628873|Saline Infused sonography
885620|NCT02628873|SIS
885621|NCT02628873|Air bubbles
885622|NCT02628860|ferric carboxymaltose
885623|NCT02628860|Ferinject®
885624|NCT02628860|pancreatoduodenectomy
885625|NCT02628847|stroke
885626|NCT02628847|rehabilitation
885627|NCT02628847|motor skills
885628|NCT02628847|sildenafil citrate
885629|NCT02628847|White matter
885630|NCT02628834|Loading
885631|NCT02628834|Gait
885632|NCT02628834|Multiple Sclerosis
885633|NCT02628834|Manual Therapy
885634|NCT02628808|autism
885635|NCT02628808|asperger
885636|NCT02628808|Pervasive Developmental Disorder No Otherwise Specify
885637|NCT02628808|gene
885638|NCT02628808|polymorphism
885639|NCT02628808|mutation
885640|NCT02628795|total hip arthroplasty
885641|NCT02628795|total knee arthroplasty
885642|NCT02628782|large bore endovascular catheterization procedures
885643|NCT02628782|Vascular Closure Device
885644|NCT02628769|Solithromycin
885645|NCT02628769|Chronic Obstructive Pulmonary Disease
885646|NCT02628769|Inflammation
885647|NCT02628769|Macrolide
885648|NCT02628730|Atrial Fibrillation
885649|NCT02628730|Ablation
885650|NCT02628730|Pulmonary vein isolation
885651|NCT02628730|Ablation Index
885652|NCT02628717|Hepatitis C
885653|NCT02628717|sofosbuvir
885654|NCT02628717|ledipasvir
885655|NCT02628717|daclatasvir
885656|NCT02628717|simeprevir
885657|NCT02628704|Karyopharm
885658|NCT02628704|selinexor
885659|NCT02628704|KPT-330
885660|NCT02628704|multiple myeloma
885661|NCT02628704|SCORE
885662|NCT02628678|Prebiotic
885663|NCT02628678|FOS
885664|NCT02628678|fructooligosaccharide
885665|NCT02628678|polyglycan
885666|NCT02628678|microbiome
885667|NCT02628678|microbiota
885668|NCT02628678|Healthy Volunteers
885669|NCT02628652|Microbiome
885670|NCT02628652|FOS
885671|NCT02628652|polyglycan
885672|NCT02628652|prebiotic
885673|NCT02628652|Healthy Volunteers
885674|NCT02628626|Incontinence
885675|NCT02628626|Diarrhea
885676|NCT02628626|Bile acid
885677|NCT02628626|Microbiome
885678|NCT02628613|Breast cancer
885679|NCT02628613|Neoadjuvant chemotherapy
885680|NCT02628613|TEKT4
885681|NCT02628587|Acute Coronary Syndrome
885682|NCT02628587|Clopidogrel
885683|NCT02628587|Platelet reactivity
885684|NCT02628574|Metastatic
885685|NCT02628574|Stage III or IV
885686|NCT02628574|recurrent
885687|NCT02628574|refractory
885688|NCT02628574|solid tumors
885689|NCT02628535|B7-H3-expressing neoplasms
885690|NCT02628522|ADRC
885691|NCT02628522|Celution
885692|NCT02628509|Acquired Von Willebrand
885693|NCT02628509|Trans aortic valve replacement
885694|NCT02628509|mechanical circulatory support
885695|NCT02628470|Cervical pain, cervicalgia
885696|NCT02628457|occupation ratio
885697|NCT02628457|pseudoatrophy
885702|NCT02628418|Rehabilitation
885703|NCT02628418|Robotics
885704|NCT02628392|Type 2 Diabetes Mellitus
885705|NCT02628392|Adult
885706|NCT02628392|Developmental Phase II
885707|NCT02628379|Genomic Testing
885708|NCT02628379|Cancer of Unknown Primary
885709|NCT02628379|CUP
885710|NCT02628366|Cluster Randomized Controlled Trial
885711|NCT02628366|Personalized Dialysate Temperature
885712|NCT02628366|Cardiovascular Events
885713|NCT02628366|Mortality
885714|NCT02628353|Cardiovascular diseases
885715|NCT02628353|endothelial function
885716|NCT02628353|systolic blood pressure
885717|NCT02628353|metabolomics
885718|NCT02628353|cardiovascular risk factor
885719|NCT02628353|bioavailability
885720|NCT02628353|phenolic compounds
885721|NCT02628353|hypertension
885722|NCT02628327|glaucoma care
885723|NCT02628327|quality of life
885724|NCT02628327|patient satisfaction
885725|NCT02628301|Obesity
885726|NCT02628301|Type 2 Diabetes Mellitus
885727|NCT02628301|Hypercaloric diet
885728|NCT02628301|Microcirculation
885729|NCT02628301|Microvascular dysfunction
885730|NCT02628301|Insulin Resistance
885731|NCT02628301|Insulin Sensitivity
885732|NCT02628301|Insulin signaling
885733|NCT02628262|Macular hole
885734|NCT02628236|Actinic keratosis
885735|NCT02628223|glaucoma
885736|NCT02628223|Elevated IOP
885737|NCT02628223|Selective Laser Trabeculoplasty
885738|NCT02628223|SLT
885739|NCT02628223|open angle glaucoma
885740|NCT02628223|ocular hypertension
885741|NCT02628223|Glaucoma, Open Angle, Pseudo-exfoliative
885742|NCT02628223|pigment dispersion syndrome
885743|NCT02628223|Pseudoexfoliation
885744|NCT02628223|IOP ≥ 21 mmHg
885745|NCT02628158|Epiretinal membrane
885746|NCT02628145|Sarcopenia
885747|NCT02628145|aging
885748|NCT02628145|resistance training
885749|NCT02628145|physical functioning
885750|NCT02628132|triple negative
885751|NCT02628132|breast cancer
885752|NCT02628132|durvalumab
885753|NCT02628132|paclitaxel
885754|NCT02628132|safety
885755|NCT02628132|efficacy
885756|NCT02628132|PD-L1
885757|NCT02628132|PD-1
885758|NCT02628132|Metastatic
885759|NCT02628132|AstraZeneca
885760|NCT02628132|MEDI4736
885761|NCT02628119|Hemodialysis
885762|NCT02628119|vascular access
885763|NCT02628119|access flow
885764|NCT02628080|Hypoxia
885765|NCT02628067|PD1
885766|NCT02628067|PDL1
885767|NCT02628067|PD-1
885768|NCT02628067|PD-L1
885769|NCT02628067|MSI
885770|NCT02628067|microsatellite instability
885771|NCT02628067|MMR
885772|NCT02628067|mismatch repair
885773|NCT02628067|anal carcinoma
885774|NCT02628067|anal cancer
885775|NCT02628067|biliary adenocarcinoma
885776|NCT02628067|biliary cancer
885777|NCT02628067|cholangiocarcinoma
885778|NCT02628067|bile duct cancer
885779|NCT02628067|neuroendocrine tumor
885780|NCT02628067|carcinoid tumor
885781|NCT02628067|endometrial carcinoma
885782|NCT02628067|endometrial cancer
885783|NCT02628067|cervical carcinoma
885784|NCT02628067|cervical cancer
885785|NCT02628067|vulvar carcinoma
885786|NCT02628067|vulvar cancer
885787|NCT02628067|small cell lung carcinoma
885788|NCT02628067|small cell lung cancer
885789|NCT02628067|SCLC
885790|NCT02628067|mesothelioma
885791|NCT02628067|thyroid carcinoma
885792|NCT02628067|thyroid cancer
885793|NCT02628067|salivary gland carcinoma
885794|NCT02628067|salivary gland cancer
885795|NCT02628067|salivary cancer
885796|NCT02628067|parotid gland cancer
885797|NCT02628067|advanced solid tumors
885798|NCT02628054|PSG
885799|NCT02628054|Typhoid Vaccine
885800|NCT02628054|Depression
885801|NCT02628054|Inflammation
885802|NCT02628041|High-Dose-Rate Brachytherapy
885803|NCT02628041|HDR Monotherapy
885804|NCT02628041|LDR monotherapy
885805|NCT02628015|Theory of Mind
885806|NCT02628015|Very Low Birthweight Infants
885807|NCT02628002|antigravity treadmill
885808|NCT02628002|bruce protocol
885809|NCT02628002|stress myocardial perfusion imaging
885810|NCT02628002|single photon emission computed tomography
885811|NCT02628002|cardiac catheterization
885812|NCT02628002|[E01.370.370.380.500]
885813|NCT02628002|[E01.370.370.380.250]
885814|NCT02628002|[E01.370.370.380.140]
885815|NCT02627937|Pediatric obstructive sleep apnea/hypopnea syndrome
885816|NCT02627937|Polysomnography
885817|NCT02627924|patient-reported QoL(Quality of Life)
885818|NCT02627924|Work productivity
885819|NCT02627924|Rheumatoid Arthritis
885820|NCT02627898|Green tea extract
885821|NCT02627898|Arterial stiffness
885822|NCT02627898|PWVao
885823|NCT02627885|internet treatment
885824|NCT02627885|cognitive behavioral therapy
885825|NCT02627885|level of functioning
885826|NCT02627885|quality of life
885827|NCT02627833|induced Sputum
885828|NCT02627833|lung clearance index
885829|NCT02627833|miRNA
885830|NCT02627833|inflammation
885831|NCT02627833|chronic lung disease
885832|NCT02627820|Senile
885833|NCT02627820|ATTRwt
885834|NCT02627820|wild-type transthyretin amyloidosis
885835|NCT02627807|Nasopharyngeal carcinoma
885836|NCT02627807|Intensity modulated radiotherapy
885837|NCT02627807|Clinical target volume
885838|NCT02627807|Clinical trial
885839|NCT02627794|Middle Meatus
885840|NCT02627794|Synechiae
885841|NCT02627794|Endoscopic Sinus Surgery
885842|NCT02627794|Silastic spacer
885843|NCT02627794|Restora™ steroid eluting MM spacer
885844|NCT02627781|acute appendicitis
885845|NCT02627781|Alvarado Score
885846|NCT02627781|negative appendectomy
885847|NCT02627781|right abdominal pain
885851|NCT02627755|videolaryngoscopy
885852|NCT02627755|difficult airway management
885853|NCT02627716|Psychiatric advanced directives
885854|NCT02627716|Joint crisis plan
885855|NCT02627716|Schizophrenia
885856|NCT02627716|Primary care
885857|NCT02627677|CML
885858|NCT02627677|CP-CML
885859|NCT02627677|Leukemia
885860|NCT02627677|Leukemia, Myeloid
885861|NCT02627677|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
885862|NCT02627677|Neoplasms by Histologic Type
885863|NCT02627677|Neoplasms
885864|NCT02627677|Myeloproliferative Disorders
885865|NCT02627677|Bone Marrow Diseases
885866|NCT02627677|Hematologic Diseases
885867|NCT02627664|Idiopathic early
885868|NCT02627664|Parkinson's Disease
885869|NCT02627638|osteopathy
885870|NCT02627638|complementary therapy
885871|NCT02627638|symptoms in cancer patients
885872|NCT02627625|inhalation
885873|NCT02627625|anticholinergic
885874|NCT02627612|veteran
885875|NCT02627612|mentorship
885876|NCT02627612|Iraq/Afghanistan
885877|NCT02627612|treatment
885878|NCT02627612|PTSD
885879|NCT02627612|Suicide
885880|NCT02627612|Criminal Activity
885881|NCT02627599|COPD
885882|NCT02627599|LTOT
885883|NCT02627599|Long-Term Oxygen Therapy
885884|NCT02627599|Oxygen Conserving Device
885885|NCT02627599|Quality of Life
885886|NCT02627599|Six Minute Walk Distance
885887|NCT02627599|Portable Oxygen Source
885888|NCT02627599|Oxygen Saturation
885889|NCT02627599|Breath Responsive Variable Bolus Oxygen Conserving Device
885890|NCT02627599|BRVB-OCD
885891|NCT02627599|Pulse Oximetry
885892|NCT02627586|exercise therapy
885893|NCT02627586|left ventricular remodeling
885894|NCT02627586|ventricular ejection fraction
885895|NCT02627586|high-intensity interval training
885896|NCT02627573|Cyclophosphamide
885897|NCT02627573|Thymoglobulin
885898|NCT02627573|Myelodysplastic Syndromes
885899|NCT02627573|Immunosuppressive Agents
885900|NCT02627573|Immune System Diseases
885901|NCT02627573|Busulfan
885902|NCT02627573|Fludarabine
885903|NCT02627573|Tacrolimus
885904|NCT02627573|Mycophenolate mofetil
885905|NCT02627573|Antineoplastic Agents, Alkylating
885906|NCT02627573|Myeloablative Agonists
885907|NCT02627573|Hematopoietic Stem Cell Transplantation
885908|NCT02627573|Allogeneic Transplantation
885909|NCT02627573|Leukemia, Chronic Myeloid
885910|NCT02627573|Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
885911|NCT02627560|Administration, topical
885912|NCT02627560|Tranexamic acid
885913|NCT02627560|Postoperative care
885914|NCT02627560|Mastectomy
885915|NCT02627547|Flavanones
885916|NCT02627547|Endurance-trained athletes
885917|NCT02627547|Biological availability
885918|NCT02627534|Photodynamic therapy
885919|NCT02627534|Ultrasonic debridement
885920|NCT02627534|Chronic periodontitis
885921|NCT02627534|Type 2 diabetes
885922|NCT02627508|Autism Spectrum Disorder
885923|NCT02627508|Autism
885924|NCT02627508|Pregnenolone
885925|NCT02627495|maladaptive plasticity
885926|NCT02627495|Limb amputation
885927|NCT02627495|phantom limb pain
885928|NCT02627495|tDCS
885929|NCT02627495|non-invasive brain stimulation
885930|NCT02627469|Microbiota
885931|NCT02627469|aged
885932|NCT02627469|oral health
885933|NCT02627456|Malaria
885934|NCT02627456|Cryopreserved
885935|NCT02627456|Infection
885936|NCT02627456|Human
885937|NCT02627456|Immunization
885938|NCT02627417|ITP
885939|NCT02627417|Dapsone
885940|NCT02627404|Bipolar disorders
885941|NCT02627404|Genetic
885942|NCT02627404|Biomarkers
885943|NCT02627404|Circadian rhythm
885944|NCT02627391|Aortic valve
885945|NCT02627391|Stenosis
885946|NCT02627391|Surgery
885947|NCT02627365|ART
885948|NCT02627365|mobile messaging
885949|NCT02627365|behaviour
885950|NCT02627365|motivation
885951|NCT02627352|Glaucoma
885952|NCT02627352|Micropulse Transscleral Cyclophotocoagulation
885953|NCT02627352|IOP
885954|NCT02627339|Contrast Sensitivity
885955|NCT02627326|chlorhexidine
885956|NCT02627326|endodontic treatment
885957|NCT02627313|Feasibility Studies
885958|NCT02627300|PID
885959|NCT02627261|residual disease
885960|NCT02627235|Physical Activity
885961|NCT02627235|Cancer Prevention
885962|NCT02627222|Pro-vitamin A
885963|NCT02627222|Cassava
885964|NCT02627222|Vitamin A deficiency
885965|NCT02627222|Retinol Isotope Dilution
885966|NCT02627222|Preschool children
885967|NCT02627222|Nigeria
885968|NCT02627209|Angiotensin converting enzyme
885969|NCT02627209|Lysozyme
885970|NCT02627209|Ankylosing spondylitis
885971|NCT02627209|Behcet's disease
885972|NCT02627209|Sarcoidosis
885973|NCT02627209|Syphilis
885974|NCT02627209|Tuberculosis
885975|NCT02627209|Ocular inflammation
885982|NCT02627183|Atrial Fibrillation
885983|NCT02627170|Adults
885984|NCT02627144|Metastatic renal cell carcinoma
885985|NCT02627144|Avastin
885986|NCT02627144|Bevacizumab
885987|NCT02627131|Autism
885988|NCT02627131|Stem Cells
885989|NCT02627105|weight loss
885990|NCT02627066|Exercise
885991|NCT02627066|Nutrition
885992|NCT02627066|Hemodialysis
885993|NCT02627014|Chronic Migraine
885994|NCT02627014|Temporomandibular Disorders
885995|NCT02627014|Physical Therapy
885996|NCT02627014|Manual Therapy
885997|NCT02627014|Home physical Therapy
885998|NCT02626988|Diet Diversity
885999|NCT02626988|Biodiversity
886000|NCT02626988|Agrobiodiversity
886001|NCT02626988|Nutrition
886002|NCT02626988|Vietnam
886003|NCT02626975|knee
886004|NCT02626975|short hamstring autograft
886005|NCT02626975|ligament
886006|NCT02626975|MRI
886007|NCT02626962|melanoma
886008|NCT02626949|HIV
886009|NCT02626949|AIDS
886010|NCT02626949|Mindfulness
886011|NCT02626949|Mindfulness-based stress reduction
886012|NCT02626949|Stress
886013|NCT02626949|Intervention
886014|NCT02626949|Inflammation
886015|NCT02626936|Type 1 diabetes
886016|NCT02626936|Artificial pancreas
886017|NCT02626936|Closed-loop system
886018|NCT02626936|Postprandial glucose control
886019|NCT02626936|Hypoglycemia
886020|NCT02626936|Insulin
886021|NCT02626936|Glucagon
886022|NCT02626910|Disability
886023|NCT02626910|Activity of Daily Living
886024|NCT02626910|Patient Satisfaction
886025|NCT02626897|Sarcoidosis
886026|NCT02626897|Daily activity
886027|NCT02626897|Exercise
886028|NCT02626897|Accelerometer
886029|NCT02626845|Granulomatosis with Polyangiitis
886030|NCT02626845|Wegener's Granulomatosis
886031|NCT02626845|GPA
886032|NCT02626845|Rituximab
886033|NCT02626845|Rituxan
886034|NCT02626845|ENT GPA
886035|NCT02626832|vasopressin
886036|NCT02626832|AVP
886037|NCT02626832|NMDA
886038|NCT02626832|osmolality
886039|NCT02626819|Obesity
886040|NCT02626819|Weight Management
886041|NCT02626819|Primary Care
886042|NCT02626819|Health Coach
886043|NCT02626819|iPad
886044|NCT02626819|Goal Setting
886045|NCT02626819|5As
886046|NCT02626819|technology
886047|NCT02626806|exercise test
886048|NCT02626806|HS -troponin
886049|NCT02626806|Coronary artery disease
886050|NCT02626793|Plaque psoriasis
886051|NCT02626793|Apremilast
886052|NCT02626793|Otezla®
886053|NCT02626793|LAPIS-Pso
886054|NCT02626793|Observational
886055|NCT02626793|CC-10004
886056|NCT02626793|non-interventional
886057|NCT02626793|Germany
886058|NCT02626767|high-intensity interval training
886059|NCT02626767|adolescents
886060|NCT02626767|school-based exercise
886061|NCT02626767|cardiometabolic health
886062|NCT02626754|Sunitinib, 2/1 schedule, Renal cell carcinoma
886063|NCT02626702|immune modulators
886064|NCT02626702|IVF outcomes
886065|NCT02626702|relationship
886066|NCT02626689|Beta-Thalassemia
886067|NCT02626689|Quality of Life
886068|NCT02626689|Healthcare Utilization
886069|NCT02626689|Transfusion dependent (TD) β-thalassemia
886070|NCT02626689|Non-transfusion dependent β-thalassemia
886071|NCT02626689|Standard of care
886072|NCT02626689|TransQoL
886073|NCT02626689|SF36v2
886074|NCT02626689|Fact-An
886075|NCT02626689|NTD beta-thalassemia PRO
886076|NCT02626676|renal dialysis, hyperphosphatemia, educational programme
886077|NCT02626637|children with cancer
886078|NCT02626637|fatigue
886079|NCT02626637|physical activity
886080|NCT02626598|facial wrinkles
886081|NCT02626598|photoaging
886082|NCT02626585|rhinoplasty
886083|NCT02626585|postrhinoplasty taping
886084|NCT02626585|edema
886085|NCT02626585|draping
886086|NCT02626585|postoperative edema
886087|NCT02626585|nasal skin thickness
886088|NCT02626585|supratip fullness
886089|NCT02626585|postoperative swelling
886090|NCT02626533|Cytokines
886091|NCT02626507|ER+/HER2
886092|NCT02626481|Multiple Myeloma
886093|NCT02626481|Cancer
886094|NCT02626481|refractory
886095|NCT02626481|daratumumab
886096|NCT02626455|Clinical trial, Phase III
886097|NCT02626455|Phosphatidylinositol-3-kinase
886098|NCT02626455|Non-Hodgkin's lymphoma
886099|NCT02626455|Indolent B-cell non-Hodgkin's lymphoma
886100|NCT02626442|Cognition
886101|NCT02626442|Exercise
886102|NCT02626416|Telemedicine
886103|NCT02626403|vegetative state
886104|NCT02626403|minimally conscious state
886105|NCT02626403|disorder of consciousness
886106|NCT02626403|transcranial current direct stimulation
886107|NCT02626403|non invasive brain stimulation
886108|NCT02626403|neuromodulation
886109|NCT02626377|Informal caregivers
886110|NCT02626377|Elderly
886111|NCT02626377|Quality of life
886112|NCT02626377|Cost effectiveness
886113|NCT02626377|Cohort study
886114|NCT02626377|Randomized study
886115|NCT02626351|postnatal
886116|NCT02626312|Liver Cancer
886117|NCT02626312|Impaired Liver Function
886118|NCT02626312|Liver tumors
886119|NCT02626312|Hepatocellular carcinoma
886120|NCT02626312|HCC
886121|NCT02626312|Cholangiocarcinoma
886122|NCT02626312|Liver metastases
886123|NCT02626312|Low functional liver volume
886124|NCT02626312|Radiation therapy
886125|NCT02626312|XRT
886126|NCT02626312|Chemotherapy
886127|NCT02626312|Questionnaire
886128|NCT02626312|Survey
886129|NCT02626312|High dose radiotherapy
886130|NCT02626299|Preterm birth, very low birth weight
886131|NCT02626286|HIV
886132|NCT02626286|Men who have sex with men
886133|NCT02626273|obesity
886134|NCT02626273|adolescents
886135|NCT02626273|physical activity
886136|NCT02626273|adipocytes
886137|NCT02626273|osteocytes
886138|NCT02626273|weight loss
886139|NCT02626273|bone
886140|NCT02626273|fat
886141|NCT02626247|elderly
886142|NCT02626234|cMET, INC280, rosuvastatin, digoxin
886143|NCT02626208|Contraceptive vaginal ring
886144|NCT02626195|malnutrition
886145|NCT02626195|nutrition
886146|NCT02626195|nutritional support
886147|NCT02626195|hepatobiliary pancreatic cancer
886148|NCT02626195|hepatobiliary pancreatic surgery
886149|NCT02626169|15-epi-lipoxin A4
886150|NCT02626169|inflammation
886151|NCT02626169|atherosclerosis
886152|NCT02626156|post healed venous leg ulcer
886153|NCT02626156|posted healed diabetic foot ulcer
886158|NCT02626104|lactoferrin
886159|NCT02626104|clostridium difficile
886160|NCT02626104|antibiotic associated diarrhoea
886161|NCT02626104|children
886162|NCT02626104|antibiotic therapy
886163|NCT02626104|diarrhoea
886164|NCT02626091|Anastomotic perfusion
886165|NCT02626091|ICG Fluorescence
886166|NCT02626091|Enhanced reality
886167|NCT02626091|Left-sided colonic resection
886168|NCT02626078|Malnutrition
886169|NCT02626078|Food practices
886170|NCT02626078|Elderly
886171|NCT02626078|Nursing Home
886172|NCT02626078|Aging
886173|NCT02626078|Nutritional status
886174|NCT02626078|Quality of life
886175|NCT02626065|Melanoma
886176|NCT02626065|Anti-PD1 monoclonal antibodies
886177|NCT02626065|Immune modulation
886178|NCT02626065|BRAF
886179|NCT02626052|Skull vibration induced nystagmus test
886180|NCT02626052|mastoid vibration test
886181|NCT02626039|Metastatic Breast Cancer
886182|NCT02626039|CTCs
886183|NCT02626039|cfDNA
886184|NCT02626039|genomics
886185|NCT02626039|somatic mutations
886186|NCT02626000|Recurrent Metastatic Squamous Cell Carcinoma Head and Neck
886187|NCT02625987|Appendicectomy, wound complications, skin closure
886192|NCT02625948|Intracerebral Hemorrhage
886193|NCT02625948|tranexamic acid
886194|NCT02625948|spot sign
886195|NCT02625935|Prosigna
886196|NCT02625935|estrogen receptor positive
886197|NCT02625935|node negative
886198|NCT02625935|HER2 negative
886207|NCT02625883|Resuscitation, quality of life
886211|NCT02625831|ficolin-3
886212|NCT02625831|anti-ficolin-3 antibodies
886213|NCT02625831|lupus nephritis
886214|NCT02625831|Lupus Erythematosus, Systemic
886215|NCT02625831|biomarker
886216|NCT02625818|Emergency Services, Psychiatric
886217|NCT02625818|Prognosis
886218|NCT02625818|Biological markers
886219|NCT02625818|Anxiety
886220|NCT02625818|Panic
886221|NCT02625818|Psychomotor Agitation
886222|NCT02625818|Self-injurious Behavior
886223|NCT02625792|Post ESD ulcer
886224|NCT02625792|Bleeding
886225|NCT02625792|Prophylaxis
886226|NCT02625779|Bipolar depression
886227|NCT02625779|Cytidine
886228|NCT02625779|Creatine
886229|NCT02625779|Magnetic resonance spectroscopy
886230|NCT02625766|Operative vs. Non-operative
886231|NCT02625766|LC pelvic fracture
886232|NCT02625766|Complications
886233|NCT02625753|photorefractive keratectomy
886234|NCT02625753|pain
886235|NCT02625753|analgesia
886236|NCT02625753|opioid
886237|NCT02625727|knee osteoarthritis
886238|NCT02625727|hyaluronic acid
886239|NCT02625727|corticosteroid
886240|NCT02625727|intra-articular injection
886241|NCT02625727|therapeutic effect
886242|NCT02625701|operative mortality
886243|NCT02625701|myocardial infarct, arrhythmia, heart failure, stroke
886244|NCT02625701|pneumonia, atelectasis, acute lung injury
886245|NCT02625701|surgical site infection
886246|NCT02625701|acute kidney injury
886247|NCT02625701|body weight
886248|NCT02625662|muscular dystrophy
886249|NCT02625662|natural history
886250|NCT02625662|genetic profilling
886251|NCT02625649|Roux-en-Y gastric bypass
886252|NCT02625649|obesity
886253|NCT02625649|type 2 diabetes mellitus
886254|NCT02625649|diabetic nephropathy
886255|NCT02625649|diabetic retinopathy
886256|NCT02625623|Avelumab
886257|NCT02625623|Gastric cancer
886258|NCT02625623|Gastroesophageal junction adenocarcinoma
886259|NCT02625610|Avelumab
886260|NCT02625610|Cancer
886261|NCT02625610|Unresectable
886262|NCT02625610|Locally advanced
886263|NCT02625610|Metastatic
886264|NCT02625610|Adenocarcinoma of the stomach
886265|NCT02625610|Gastro-esophageal junction
886266|NCT02625584|Shared Book Reading
886267|NCT02625584|Dialogic Reading
886268|NCT02625584|Language Development
886269|NCT02625584|Syntax
886270|NCT02625584|Vocabulary
886271|NCT02625584|Young Children
886272|NCT02625584|Randomised Control Trial
886273|NCT02625584|Language Intervention
886274|NCT02625558|riociguat
886275|NCT02625558|saph
886276|NCT02625558|sarcoidosis
886277|NCT02625558|sarcoidosis associated pulmonary hypertension
886278|NCT02625532|Controlled Ovarian stimulation
886279|NCT02625532|Follicular phase
886280|NCT02625532|Luteal phase
886281|NCT02625532|Reproductive Techniques, Assisted
886282|NCT02625519|Controlled ovarian stimulation
886283|NCT02625519|Follicle-stimulating hormone
886284|NCT02625519|Receptor N680S follicle-stimulating hormone receptor (FSHR) gene polymorphism
886285|NCT02625519|Oocyte donors
886286|NCT02625493|Percutaneous coronary intervention
886287|NCT02625493|Patient Preference
886288|NCT02625493|Radial access
886289|NCT02625493|Femoral access
886290|NCT02625493|Coronary angiography
886291|NCT02625493|Shared decision making
886292|NCT02625467|Keratoconus
886293|NCT02625454|Acetaminophen
886294|NCT02625454|Labor
886295|NCT02625454|Intrapartum Fever
886296|NCT02625454|Maternal Fever
886297|NCT02625454|Fetal Tachycardia
886298|NCT02625454|Intravenous Acetaminophen
886299|NCT02625441|Breast cancer
886300|NCT02625441|docetaxel
886301|NCT02625441|pertuzumab
886302|NCT02625441|trastuzumab
886303|NCT02625441|HER2
886304|NCT02625402|decision making
886305|NCT02625402|decision aids
886306|NCT02625402|decision quality instruments
886307|NCT02625402|osteoarthritis
886308|NCT02625402|shared decision making
886309|NCT02625389|scheduled for selective transarterial catheterization
886310|NCT02625363|Glycemic Index
886311|NCT02625363|Water Intake
886312|NCT02625363|Glycemic Response
886313|NCT02625350|instant noodle
886314|NCT02625350|water content
886315|NCT02625350|glycemic index
886316|NCT02625350|serving method
886317|NCT02625298|periapical diseases
886318|NCT02625298|dental injuries
886319|NCT02625298|MTA
886320|NCT02625272|hand-assisted laparoscopic surgery
886321|NCT02625272|right colon cancer
886322|NCT02625272|complete mesocolic excision
886323|NCT02625272|no touch isolation
886324|NCT02625272|recurrence
886325|NCT02625272|overall survival
886326|NCT02625246|bronchiectasis
886327|NCT02625246|mesenchymal stem cell
886328|NCT02625246|lung
886329|NCT02625246|pulmonary
886330|NCT02625246|interstitial lung disease
886331|NCT02625207|Maraviroc, CYP3A5, pharmacokinetics, pharmacogenomics
886332|NCT02625181|Decision support
886333|NCT02625181|Prediction models
886334|NCT02625181|PONV
886335|NCT02625181|prophylaxis
886336|NCT02625181|Decision Support Systems, Clinical
886337|NCT02625181|Decision Support Techniques
886338|NCT02625168|Afatinib
886339|NCT02625168|Erlotinib
886340|NCT02625168|Metastatic non-small cell lung cancer
886341|NCT02625168|Efficacy
886342|NCT02625168|Safety
886343|NCT02625155|Pharmacogenomics
886344|NCT02625155|Urine Drug Testing
886345|NCT02625155|antidepressants
886346|NCT02625155|benzodiazepines
886347|NCT02625155|opioids
886348|NCT02625155|muscle relaxants
886349|NCT02625155|non-steroidal anti-inflammatory agents
886350|NCT02625155|TDRAE
886351|NCT02625142|Morning Rounds
886352|NCT02625142|Patient-centered Care
886353|NCT02625142|Hospital Medicine
886354|NCT02625142|Pediatrics
886355|NCT02625142|Hospitals, Pediatric
886356|NCT02625116|Cohort
886357|NCT02625103|Schizophrenia, Clozapine, TDM, Serum Concentration
886358|NCT02625090|Drug-resistance
886359|NCT02625090|focal epilepsy
886360|NCT02625090|partial-onset seizures
886361|NCT02625077|Valvuloplasty
886362|NCT02625077|Fundoplication
886363|NCT02625077|Acid reflux
886364|NCT02625077|GERD
886365|NCT02625077|Reflux disease
886366|NCT02625077|Hiatal hernia
886367|NCT02625064|ARDS
886368|NCT02625064|biomarkers
886369|NCT02625064|proteomic
886370|NCT02625012|Ultraviolet Therapy
886371|NCT02625012|Vitiligo
886372|NCT02625012|Melanocytes
886373|NCT02625012|Pigmentation
886374|NCT02624999|Head and Neck Cancer
886375|NCT02624999|SCCHN
886376|NCT02624999|R/M SCCHN
886377|NCT02624999|Carcinoma
886378|NCT02624973|neoadjuvant treatment
886379|NCT02624973|personalized medicine
886380|NCT02624947|RSV
886382|NCT02624882|blistering distal dactylitis
886383|NCT02624882|Streptococcus pyogenes
886384|NCT02624882|antibiotics
886385|NCT02624869|Hypercholesterolemia
886386|NCT02624869|Elevated Cholesterol
886387|NCT02624869|High Cholesterol
886388|NCT02624869|PCSK9 mutations
886389|NCT02624869|Severe Familial Hypercholesterolemia
886390|NCT02624869|evolocumab
886391|NCT02624869|Repatha
886392|NCT02624869|Heterozygous Familial Hypercholesterolemia
886393|NCT02624869|Homozygous Familial Hypercholesterolemia
886394|NCT02624869|Pediatric
886395|NCT02624869|Paediatric
886396|NCT02624856|primary total knee arthroplasty
886397|NCT02624856|liposomal bupivacaine
886398|NCT02624804|Diabetes
886399|NCT02624791|astigmatism, contact lens, driving
886400|NCT02624765|RCT A: Fetal Atrial Flutter without Hydrops
886401|NCT02624765|RCT B: Fetal Supraventricular Tachycardia without Hydrops
886402|NCT02624765|RCT C: Fetal Supraventricular Tachycardia with Hydrops
886403|NCT02624752|Oral Nutrition Supplementation
886404|NCT02623699|Isis-SOD1Rx
886405|NCT02623699|SOD1
886406|NCT02623699|ALS
886407|NCT02623686|Sleep
886408|NCT02623686|ICU
886409|NCT02623686|Massage Therapy
886410|NCT02623686|Inhalation Patch
886411|NCT02623660|Inflammation
886412|NCT02623660|Edema
886413|NCT02623660|Arthroplasty
886414|NCT02623660|Rehabilitation
886415|NCT02623660|Replacement
886416|NCT02623660|Knee
886417|NCT02623660|Total Knee Replacement
886418|NCT02623660|Pain, Postoperative
886419|NCT02623660|Exercise Therapy
886420|NCT02623660|Therapeutics
886421|NCT02623660|Early Ambulation
886422|NCT02623660|Myofunctional Therapy
886423|NCT02623660|Electric Stimulation Therapy
886424|NCT02623660|Orthopedic Procedures
886425|NCT02623660|Wound Healing
886426|NCT02623660|Total Knee Arthroplasty
886427|NCT02623634|Cuff leak test, relative factors
886428|NCT02623608|type 2 diabetes risk
886429|NCT02623608|cardiovascular disease risk
886430|NCT02624726|1st line
886431|NCT02624726|FOLFIRI
886432|NCT02624726|Aflibercept
886433|NCT02624726|mCRC
886434|NCT02624713|eating disorder
886435|NCT02624713|childhood obesity
886436|NCT02624713|family based treatment
886437|NCT02624700|ER-negative
886438|NCT02624700|PgR-negative
886439|NCT02624700|Human epidermal growth factor receptor 2 (HER2-negative)
886440|NCT02624700|Triple Negative Breast Cancer
886441|NCT02624700|HER2-negative
886442|NCT02624661|Trigeminal ganglion
886443|NCT02624661|Glycerol
886444|NCT02624661|Nerve block
886445|NCT02624648|Sexual Dysfunction
886446|NCT02624648|Postmenopausal women
886447|NCT02624648|Sexual desire
886448|NCT02624635|Manual Therapy
886449|NCT02624635|Pain
886450|NCT02624635|Hip
886451|NCT02624635|Muscle Strength
886452|NCT02624622|omphalitis
886453|NCT02624622|neonate
886454|NCT02624622|developing countries
886455|NCT02624596|OCD
886456|NCT02624583|Fasting
886457|NCT02624583|Clopidogrel
886458|NCT02624570|AML
886459|NCT02624570|FLT3
886460|NCT02624570|ITD
886461|NCT02624570|TKD
886462|NCT02624570|acute myeloid leukemia
886463|NCT02624570|induction
886464|NCT02624570|consolidation
886465|NCT02624570|continuation
886466|NCT02624570|EAP
886467|NCT02624570|ETP
886468|NCT02624570|midostaurin
886469|NCT02624570|PKC412
886470|NCT02624557|Hepatic impairment
886471|NCT02624557|Healthy volunteers
886472|NCT02624557|Clinical pharmacology study
886473|NCT02624557|BYL719
886474|NCT02624557|alpelisib
886475|NCT02624531|NACT
886476|NCT02624531|Cervical cancer
886477|NCT02624531|Fertility sparing
886478|NCT02624531|Pregnancy
886479|NCT02624531|Treatment Strategy
886480|NCT02624479|Pharmacokinetics
886481|NCT02624466|Pediatrics
886482|NCT02624466|Nephrology
886483|NCT02624466|Dialysis
886484|NCT02624453|cryptococcus
886485|NCT02624453|IMMY LFA
886486|NCT02624453|meningitis
886487|NCT02624453|antigen
886488|NCT02624440|Multiple Myeloma
886489|NCT02624440|Infection
886490|NCT02624440|Clarithromycin
886491|NCT02624440|Trimethoprim-Sulfamethoxazole Combination
886499|NCT02624362|Odor
886500|NCT02624362|trigger
886501|NCT02624362|inflammation
886502|NCT02624362|nocebo
886503|NCT02624336|periodontal disease
886504|NCT02624336|caries
886505|NCT02624323|ultrasonography
886506|NCT02624323|catheterization
886507|NCT02624323|central line
886508|NCT02624323|mechanical ventilation
886509|NCT02624323|intensive care
886510|NCT02624323|axillary vein
886511|NCT02624323|jugular vein
886512|NCT02624323|randomization
886513|NCT02624297|Coronary artery disease
886514|NCT02624297|Chemoreceptors
886515|NCT02624297|Sympathetic nerve activity
886516|NCT02624297|Exercise
886517|NCT02624271|gastric cancer
886518|NCT02624271|gastric precancerous lesions
886519|NCT02624271|blood test
886520|NCT02624232|Anorectal malformation
886521|NCT02624232|Anorectal atresia
886522|NCT02624232|anorectal stenosis
886523|NCT02624232|Follow-Up Studies
886524|NCT02624219|A/H5N8
886525|NCT02624219|AS03
886526|NCT02624219|Controlled
886527|NCT02624219|Double-Blind
886528|NCT02624219|Immunogenicity
886529|NCT02624219|Inactivated
886530|NCT02624219|Influenza
886531|NCT02624219|MF59
886532|NCT02624219|Monovalent
886533|NCT02624219|Randomized
886534|NCT02624219|Reactogenicity
886535|NCT02624219|Safety
886536|NCT02624219|Trial
886537|NCT02624219|Vaccine
886538|NCT02624193|Treatment Adherence
886539|NCT02624193|Mental Health
886540|NCT02624193|Well-being
886541|NCT02624193|Emerging Adults
886542|NCT02624193|Youth
886543|NCT02624128|head and neck cancer
886544|NCT02624128|valproic acid
886545|NCT02624128|recurrent
886546|NCT02624128|metastatic
886547|NCT02624102|Major depressive disorder
886548|NCT02624102|Cognitive behavioral therapy
886549|NCT02624102|Trial based cognitive therapy
886550|NCT02624102|Behavioral activation
886551|NCT02624076|unexplained infertility
886552|NCT02624076|Acupuncture
886553|NCT02624050|ACEI
886554|NCT02624050|ARB
886555|NCT02624050|Hypotension
886556|NCT02624050|General Anesthesia
886557|NCT02624050|Methohexital
886558|NCT02624050|Propofol
886559|NCT02624037|Inflammatory Bowel Disease, Ulcerative Colitis
886560|NCT02624037|Crohn's Disease
886561|NCT02624037|Pharmacokinetics, Individualized Dosage, Dashboard System
886562|NCT02624037|Remicade, Infliximab
886563|NCT02623998|Diabetes
886564|NCT02623998|Insulin
886565|NCT02623998|Glargine
886566|NCT02623998|Metformin
886567|NCT02623998|Sitagliptin
886568|NCT02623998|Diet
886569|NCT02623998|Excercise
886570|NCT02623998|Lifestyle
886571|NCT02623972|inflammatory breast cancer
886572|NCT02623972|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
886573|NCT02623959|Advanced Cancers
886574|NCT02623959|Malignant pleural effusions
886575|NCT02623959|MPE
886576|NCT02623959|Indwelling pleural catheter
886577|NCT02623959|IPC
886578|NCT02623959|Questionnaires
886579|NCT02623959|Surveys
886580|NCT02623959|Fentanyl patch
886581|NCT02623959|Fentanyl by vein
886582|NCT02623959|Sublimaze
886583|NCT02623959|Doxycycline
886584|NCT02623959|Vibramycin
886585|NCT02623959|Periostat
886586|NCT02623959|Doryx
886587|NCT02623959|:Phone calls
886588|NCT02623946|motor evoked potentials
886589|NCT02623933|HDR monotherapy
886590|NCT02623933|MRI guidance
886591|NCT02623933|Intraprostatic lesion
886592|NCT02623933|dose paining
886593|NCT02623894|Vascular aging.
886594|NCT02623894|Arterial stiffness.
886595|NCT02623894|Lifestyles.
886596|NCT02623894|Vascular structure.
886597|NCT02623894|Telomere length,
886598|NCT02623894|Psychological factors.
886599|NCT02623894|Inflammatory factors.
886600|NCT02623894|Oxidative stress
886601|NCT02623881|Cervical pessary
886602|NCT02623881|Vaginal progesterone
886603|NCT02623881|Twins
886604|NCT02623881|Premature birth
886605|NCT02623855|Parks
886606|NCT02623855|Well-being
886607|NCT02623855|Stress
886608|NCT02623855|Physical Activity
886609|NCT02623855|Nature
886610|NCT02623855|Greenspace
886611|NCT02623842|urinary incontinence
886612|NCT02623842|woman
886613|NCT02623842|radiofrequency
886614|NCT02623829|scar prophylaxis
886615|NCT02623829|Botulinum Toxin
886616|NCT02623764|Alzheimer´s disease
886617|NCT02623764|Lewy body dementia
886618|NCT02623764|Parkinson dementia
886619|NCT02623764|EEG
886620|NCT02623764|Cholinergic index
886625|NCT02623595|non-small cell lung cancer
886626|NCT02623595|Granulocyte-Macrophage Colony-Stimulating Factor
886627|NCT02623595|Stereotactic body radiotherapy
886628|NCT02623595|abscopal effect
886629|NCT02623595|safety
886630|NCT02623595|immunotherapy
886631|NCT02623556|diagnosis of tuberculosis
886632|NCT02623556|ESAT6-CFP10
886633|NCT02623556|skin test
886634|NCT02623556|diagnostic test
886635|NCT02623530|Nursing
886636|NCT02623530|Nursing education research
886637|NCT02623530|Critical thinking
886638|NCT02623530|Decision Making
886639|NCT02623517|CIED
886640|NCT02623517|AF
886641|NCT02623517|arrhythmia
886642|NCT02623517|atrial fibrillation
886643|NCT02623517|cardiac device
886644|NCT02623517|pacemaker
886645|NCT02623517|defibrillator
886646|NCT02623504|Carbamazepine
886647|NCT02623504|Equetro
886648|NCT02623504|Bipolar I Disorder
886649|NCT02623504|Bipolar I Disorder in Children
886650|NCT02623491|JNJ-55375515
886651|NCT02623491|Healthy
886652|NCT02623491|Placebo
886653|NCT02623439|hematologic malignancies
886654|NCT02623426|uveitic macular edema
886655|NCT02623426|uveitis
886656|NCT02623400|preterm birth
886657|NCT02623400|perinatal stress
886658|NCT02623400|growth and development
886659|NCT02623387|paravertebral block
886660|NCT02623348|dialysis
886661|NCT02623348|end-stage renal disease
886662|NCT02623335|patient decision making
886663|NCT02623335|surgical decision making
886664|NCT02623335|question prompt list
886665|NCT02623335|shared decision making
886666|NCT02623335|decision support techniques
886667|NCT02623257|Non-small Cell Lung Cancer
886668|NCT02623257|circulating tumor DNA
886669|NCT02623257|amplification refractory mutation system
886670|NCT02623244|ovarian endometrioma
886671|NCT02623244|lower urinary tract symptoms
886672|NCT02623244|sexual dysfunction
886673|NCT02623244|gastrointestinal symptoms
886674|NCT02623218|traumatic brain injury
886675|NCT02623218|acupuncture
886676|NCT02623218|transcranial doppler ultrasound
886677|NCT02623166|Pneumonia
886678|NCT02623166|Fever
886679|NCT02623166|Diarrhoea
886680|NCT02623140|Coronary drug eluting stents
886681|NCT02623140|Outcomes
886682|NCT02623127|Thymic carcinoma
886683|NCT02623127|Sunitinib
886684|NCT02623127|Metastatic
886685|NCT02623127|Recurrent
886686|NCT02623101|Reflectance confocal microscopy
886687|NCT02623101|Basal cell carcinoma
886688|NCT02623101|Biopsy
886689|NCT02623101|Diagnostics
886690|NCT02623088|Obstructive Sleep Apnea
886691|NCT02623088|Endothelial dysfunction
886692|NCT02623088|Arterial stiffness
886693|NCT02623088|PAP therapies
886694|NCT02623049|New oral anticoagulants
886695|NCT02623049|Blood levels
886696|NCT02623049|Octogenarians
886697|NCT02623036|chronotherapy
886698|NCT02623036|angiotensin converting enzyme inhibitors
886699|NCT02623036|ambulatory blood pressure monitoring
886700|NCT02623010|Primary CNS lymphoma
886701|NCT02623010|Ibrutinib
886702|NCT02623010|Elderly
886703|NCT02623010|Maintenance
886704|NCT02622997|HPV self-sampling
886705|NCT02622971|phototherapy
886706|NCT02622971|cryotherapy
886707|NCT02622971|exercise
886708|NCT02622971|fatigue
886709|NCT02622971|recovery
886710|NCT02622958|Social Anxiety Disorder
886711|NCT02622958|Social Phobia
886712|NCT02622958|Performance Anxiety
886713|NCT02622958|Social Anxiety
886714|NCT02622958|Anxiety
886715|NCT02622906|Gastrointestinal angiodysplasia
886716|NCT02622906|Pasireotide
886717|NCT02622906|Gastrointestinal bleeding
886718|NCT02622867|Lactobacillus plantarum
886719|NCT02622867|Maltodextrin
886720|NCT02622867|Probiotics
886721|NCT02622867|Randomized Controlled Trial
886722|NCT02622854|plasma exchange
886723|NCT02622854|hypertriglyceridemia
886724|NCT02622841|First in man
886725|NCT02622841|Spinal metastases
886726|NCT02622841|Stereotactic bodyradiotherapy
886727|NCT02622841|Palliative care
886728|NCT02622841|Safety
886729|NCT02622841|Surgical stabilisation
886730|NCT02622828|wheelchairs
886731|NCT02622828|social participation
886732|NCT02622815|Hypercoagulation
886733|NCT02622815|Thrombosis
886734|NCT02622815|Cancer Risk Assessment
886735|NCT02622815|Cancer Prognosis
886736|NCT02622802|ex-vivo placenta perfusion
886737|NCT02622802|transplacental transfer
886738|NCT02622802|paracetamol
886739|NCT02622802|erythromycin
886740|NCT02622802|azithromycin
886741|NCT02622789|Spinal alignment
886742|NCT02622789|Kinematics
886743|NCT02622789|Pilates
886744|NCT02622789|Physical Therapy
886746|NCT02622750|triple-branched stent graft
886747|NCT02622750|total arch replace
886748|NCT02622750|the occluded rate of false lumen
886749|NCT02622737|Parkinson disease
886750|NCT02622737|Accidental Falls
886751|NCT02622737|Exercise therapy
886752|NCT02622737|Virtual Reality Exposure Therapy
886753|NCT02622724|ARDS, human
886754|NCT02622724|Acute Respiratory Distress Syndrome
886755|NCT02622724|Respiratory Insufficiency
886756|NCT02622711|breast cancer
886757|NCT02622711|obesity
886758|NCT02622711|weight control
886759|NCT02622711|exercise and physical fitness
886760|NCT02622672|Antioxidation
886761|NCT02622672|Anti-inflammation
886762|NCT02622672|Blood glucose
886763|NCT02622672|Blood lipids
886764|NCT02622659|acute upper respiratory infection
886765|NCT02622620|dynamic contrast-enhanced MR imaging
886766|NCT02622620|three-dimensional arterial spin labeling
886767|NCT02622620|diffusion-weighted imaging
886768|NCT02622607|ZOL
886769|NCT02622607|Prevention
886770|NCT02622607|NSCLC
886771|NCT02622529|Awake craniotomy
886772|NCT02622529|Psychological consequences
886773|NCT02622529|Fear and Anxiety
886774|NCT02622516|Rehabilitation
886775|NCT02622516|Physical Therapy Specialty
886776|NCT02622516|Postural Balance
886777|NCT02622516|Vertigo
886778|NCT02622516|Dizziness
886779|NCT02622438|FSHD
886780|NCT02622438|Usual care performed at Montpellier hospital
886781|NCT02622438|Muscle function
886782|NCT02622438|Antioxidants
886783|NCT02622438|Oxidative stress
886784|NCT02622438|Quality of life
886785|NCT02622438|Physical activities, development of food-based dietary guidelines
886786|NCT02622438|Co-morbidity
886787|NCT02622425|Carotenoid
886788|NCT02622425|Bacillus
886789|NCT02622425|Microbiota
886790|NCT02622425|Cardiovascular health
886791|NCT02622412|Quality of Life
886792|NCT02622412|Palliative Therapy
886793|NCT02622412|Outpatient Services
886794|NCT02622386|Psoriasis
886795|NCT02622373|Pea Pod
886796|NCT02622373|Body composition
886797|NCT02622308|Arterial leg ulcers
886798|NCT02622308|Intermittent Negative Pressure
886799|NCT02622308|Peripheral Circulation
886800|NCT02622308|Wound healing
886801|NCT02622308|Peripheral blood flow
886802|NCT02622295|metabolism
886803|NCT02622295|glucose
886804|NCT02622295|osteoporosis
886805|NCT02622295|secondary health conditions
886806|NCT02622295|quality of life
886807|NCT02622295|standing
886808|NCT02622295|electrical stimulation
886809|NCT02622295|diabetes
886810|NCT02622295|insulin
886811|NCT02622295|skeletal muscle
886812|NCT02622282|physical activity
886813|NCT02622282|physical inactivity
886814|NCT02622282|PAD
886815|NCT02622282|Diabetes
886816|NCT02622282|High blood pressure
886817|NCT02622282|High cholesterol
886818|NCT02622282|Smoking
886819|NCT02622269|Urography
886820|NCT02622269|Radiation dosage
886821|NCT02622269|image enhancement
886822|NCT02622256|Social Media
886823|NCT02622256|Twitter
886824|NCT02622256|Hypertension
886825|NCT02622256|Cardiovascular
886826|NCT02622256|CVD
886827|NCT02622256|HTN
886828|NCT02622230|Uygur Medicine
886829|NCT02622217|anesthesiology
886830|NCT02622217|non technical kills
886831|NCT02622191|Glaucoma
886832|NCT02622191|Optical Coherence Tomography
886833|NCT02622191|Primary Open Angle Glaucoma
886834|NCT02622191|Visual Field
886835|NCT02622165|health promotion
886836|NCT02622165|nutrition
886837|NCT02622165|intervention
886838|NCT02622165|adolescents
886839|NCT02622165|serious game
886840|NCT02622152|Right lateral
886841|NCT02622152|Oxygenation
886842|NCT02622152|Cardiac
886843|NCT02622152|Congenital
886844|NCT02622152|Pediatric
886845|NCT02622152|Postoperative
886846|NCT02622139|Photoacoustics
886847|NCT02622139|Optoacoustics
886848|NCT02622139|Ultrasound
886849|NCT02622126|Preloading
886850|NCT02622126|Colloid
886851|NCT02622126|Cesarean section
886852|NCT02622126|D-dimer
886853|NCT02622126|Hypotension
886854|NCT02622113|insulin resistance
886860|NCT02622074|PD1
886861|NCT02622074|PD-1
886862|NCT02622074|PDL1
886863|NCT02622074|PD-L1
886864|NCT02622074|Triple Negative Breast Cancer
886865|NCT02622048|Mental Health
886866|NCT02622048|Psychosis
886867|NCT02622048|Parent
886868|NCT02622035|Virtual Reality Technology
886869|NCT02622035|Methodology
886870|NCT02622022|randomised
886871|NCT02622022|placebo controlled
886872|NCT02622022|clinical trial
886873|NCT02622009|stable COPD; bronchoalveolar lavage; biopsy; HRV; RSV
886874|NCT02621996|Surface Electromyography
886875|NCT02621996|Hypotonia
886876|NCT02621996|Patient Positioning
886877|NCT02621983|Schizophrenia
886878|NCT02621983|Exercise
886879|NCT02621983|Cognition
886880|NCT02621905|Prophylaxis
886881|NCT02621905|Steady-State
886882|NCT02621905|Bioavailability
886883|NCT02621866|hypertension
886884|NCT02621866|ultraviolet
886885|NCT02621853|Steatosis
886886|NCT02621827|vitamin D
886887|NCT02621827|Africa
886888|NCT02621814|Infant
886889|NCT02621814|Growth
886890|NCT02621814|Body Weight Changes
886891|NCT02621814|Infant Formula
886892|NCT02621814|Randomized Controlled Trial
886893|NCT02621788|mind/body medicine
886894|NCT02621788|3RP
886895|NCT02621788|stress management
886896|NCT02621788|resident burnout
886897|NCT02621775|Stress management
886898|NCT02621775|Cognitive behavioural therapy (CBT)
886899|NCT02621775|Self-help
886900|NCT02621775|e-health
886901|NCT02621775|Adjustment disorder with anxiety
886902|NCT02621736|children
886903|NCT02621736|desmopressin
886904|NCT02621736|copeptin
886905|NCT02621723|Preventability
886906|NCT02621697|dual task
886907|NCT02621697|aging
886908|NCT02621671|Healthy Volunteers
886909|NCT02621658|Colorectal Cancer
886910|NCT02621658|Colonoscopy
886911|NCT02621658|Adenoma Detection Rate
886912|NCT02621658|Bowel Preparation
886913|NCT02621658|Time to Cecal Intubation
886914|NCT02621645|monochorionic
886915|NCT02621645|TRAP
886916|NCT02621645|acardiac twin
886917|NCT02621632|Compression therapy
886918|NCT02621619|Older adults
886919|NCT02621619|Elderly
886920|NCT02621619|Acute pain
886921|NCT02621619|IV acetaminophen
886922|NCT02621619|IV hydromorphone
886923|NCT02621619|Analgesia
886924|NCT02621619|Adjunctive analgesia
886925|NCT02621593|Meibomian Gland Dysfunction
886926|NCT02621593|Dry eye symptoms
886927|NCT02621593|Intense Pulsed Light
886928|NCT02621580|Panretinal Photocoagulation
886929|NCT02621554|Memory
886930|NCT02621554|Resveratrol
886931|NCT02621554|elderly
886932|NCT02621554|cognition
886933|NCT02621541|neuroendocrine tumor
886934|NCT02621541|pancreas
886935|NCT02621541|diagnosis
887072|NCT02620800|leucovorin
886936|NCT02621541|positron emission tomography
886937|NCT02621528|CeraFlex occluder
886938|NCT02621515|Nivolumab
886939|NCT02621515|Brain metastasis
886940|NCT02621515|Melanoma
886941|NCT02621502|Quinoa
886942|NCT02621502|Satiety
886943|NCT02621502|Visual analogue scale
886944|NCT02621502|Cross-over studies
886945|NCT02621489|Glucagon-like peptide-1
886946|NCT02621489|Endothelialization
886947|NCT02621489|Cardiac Function
886948|NCT02621489|Exenatide
886949|NCT02621489|Optical Coherence Tomography
886950|NCT02621450|chronic renal failure
886951|NCT02621450|hypertension
886952|NCT02621450|ampulatory blood pressure
886953|NCT02621437|pain
886954|NCT02621437|quality of life
886955|NCT02621437|osteopathy
886956|NCT02621437|oncology
886957|NCT02621437|surgery
886958|NCT02621437|breast
886959|NCT02621424|dementia
886960|NCT02621424|Mild Cognitive Impairment (MCI)
886961|NCT02621424|RTMS
886962|NCT02621424|CVLT
886963|NCT02621411|Substance abuse
886964|NCT02621411|Emergency operation
886965|NCT02621411|Preoperative screen
886966|NCT02621320|Vitamin D
886967|NCT02621320|Exercise Performance
886968|NCT02621320|Wheelchair Athletes
886969|NCT02621320|Indoor sports
886970|NCT02621320|Wingate
886971|NCT02621320|Isokinetic Dynamometer
886972|NCT02621307|postprandial glycemia
886973|NCT02621307|subjective appetite
886974|NCT02621307|Salba
886975|NCT02621307|Flax
886976|NCT02621294|Protein
886977|NCT02621294|indicator amino acid oxidation method
886978|NCT02621294|athletes
886979|NCT02621281|hypothermic machine perfusion
886980|NCT02621281|Kidney Transplantation
886981|NCT02621281|Delayed graft function
886982|NCT02621281|perfusion pressure
886983|NCT02621229|Optimal rate of refeeding
886984|NCT02621229|inpatients
886985|NCT02621229|hospitalized
886986|NCT02621216|percutaneous coronary intervention
886987|NCT02621190|circulating tumor cells
886988|NCT02621190|predictive factor
886989|NCT02621151|combination therapy
886990|NCT02621151|immunotherapy
886991|NCT02621151|immune checkpoint inhibition
886992|NCT02621099|handheld gamma camera
886993|NCT02621086|Oligosaccharide, Tolerability,
886994|NCT02621073|lower extremity
886995|NCT02621073|status-post ORIF
886996|NCT02621060|Chlorogenic acid
886997|NCT02621060|Control glucose
886998|NCT02621060|Insulin Secretion
886999|NCT02621060|Insulin Sensitivity
887003|NCT02621034|Root canal treatment
887004|NCT02621034|pain
887005|NCT02621034|endodontic instruments
887006|NCT02621021|Melanoma
887007|NCT02621021|Skin Cancer
887008|NCT02621021|Immunotherapy
887009|NCT02621021|Cell Therapy
887010|NCT02621008|diabetes
887011|NCT02621008|hypertension
887012|NCT02621008|obesity
887013|NCT02621008|mobile phone
887014|NCT02621008|stress
887015|NCT02621008|healthy living
887016|NCT02621008|pre-diabetes
887017|NCT02620995|hypertension
887018|NCT02620995|endothelial dysfunction
887019|NCT02620995|erectile dysfunction
887020|NCT02620995|sildenafil
887021|NCT02620982|Shockwave
887022|NCT02620982|vascular ED
887023|NCT02620982|Organic ED
887024|NCT02620969|Paediatrics
887025|NCT02620969|Haemodialysis
887026|NCT02620969|Kinetics
887027|NCT02620943|Anemia
887028|NCT02620943|Pregnancy Outcome
887029|NCT02620943|Pregnancy
887030|NCT02620943|Dietary Diversity
887031|NCT02620943|Birth Weight
887032|NCT02620930|Sleep Disorders
887033|NCT02620930|Sleep Apnea
887034|NCT02620930|Apnea-Hypopnea Index (AHI)
887035|NCT02620930|Respiratory Disturbance Index (RDI)
887036|NCT02620917|type 1 diabetes
887037|NCT02620917|CSII
887038|NCT02620904|mifepristone
887039|NCT02620904|randomized controlled trial
887040|NCT02620904|vaginal delivery
887041|NCT02620904|progesterone receptor modulator
887042|NCT02620904|induction of labor
887043|NCT02620891|helium oxygen mixture
887044|NCT02620891|Meconium aspiration syndrome
887045|NCT02620878|Artificial pancreas
887046|NCT02620878|SAP therapy
887047|NCT02620878|children
887048|NCT02620878|adolescents
887049|NCT02620878|type 1 diabetes
887050|NCT02620852|Breast cancer
887051|NCT02620852|Ductal carcinoma in situ
887052|NCT02620852|DCIS
887053|NCT02620839|HPV+
887058|NCT02620800|Metastatic Pancreatic Cancer
887059|NCT02620800|Adenocarcinoma
887060|NCT02620800|Open-label
887061|NCT02620800|Phase 1/2
887062|NCT02620800|Metronomic
887063|NCT02620800|Chemotherapy
887064|NCT02620800|ABI-007
887065|NCT02620800|nab-paclitaxel
887066|NCT02620800|Abraxane
887067|NCT02620800|gemcitabine
887068|NCT02620800|Gemzar
887069|NCT02620800|bevacizumab
887070|NCT02620800|Avastin
887071|NCT02620800|5-Fluorouracil (5-FU)
887073|NCT02620800|oxaliplatin
887074|NCT02620800|Eloxatin
887075|NCT02620735|Exercise, health coaching, RCT, telehealth,
887076|NCT02620722|tourniquet
887077|NCT02620722|safety
887078|NCT02620722|personalized
887079|NCT02620722|surgery
887080|NCT02620709|Native Hawaiians
887081|NCT02620709|Community-based participatory research
887082|NCT02620709|Health disparities
887083|NCT02620709|Minority populations
887084|NCT02620709|Chronic disease
887085|NCT02620683|lidocaine, jaw
887086|NCT02620670|Physical Activity
887087|NCT02620670|Glycemic Variability
887088|NCT02620644|no retinopathy
887089|NCT02620631|Morphine
887090|NCT02620631|TKA
887091|NCT02620631|Pain
887092|NCT02620631|TKR
887093|NCT02620631|Arthroplasty
887094|NCT02620618|Safety
887095|NCT02620618|Efficacy
887096|NCT02620618|intravitreal infliximab
887097|NCT02620618|ocular behcets
887098|NCT02620618|refractory posterior uveitis
887099|NCT02620605|Cabergoline
887100|NCT02620605|Ovarian Hyper Stimulation Syndrome (OHSS)
887101|NCT02620592|Healthy Subject
887102|NCT02620592|ZYDPLA1
887103|NCT02620592|DPPIV inhibitor
887104|NCT02620592|Pharmacokinetics
887105|NCT02620592|Safety
887106|NCT02620579|Personalized Pharmaceutical
887107|NCT02620579|Personalized Education
887108|NCT02620566|caudal block
887109|NCT02620566|local wound infiltration
887110|NCT02620566|hernia repair
887111|NCT02620553|Type 1 Diabetes
887112|NCT02620553|Diabetes
887113|NCT02620553|Autoimmune Diabetes
887114|NCT02620540|Broselow Tape
887115|NCT02620540|Weight estimation
887116|NCT02620540|Patient safety
887117|NCT02620527|Circulating Tumor DNA
887118|NCT02620527|Cancer
887119|NCT02620527|Neoplasms
887120|NCT02620527|Genomic Testing
887121|NCT02620527|FoundationOne
887122|NCT02620527|Cell Free DNA
887123|NCT02620527|ctDNA
887124|NCT02620527|cfDNA
887125|NCT02620514|Digestive Disease and Disorders
887126|NCT02620514|Inflammation
887127|NCT02620501|EGD
887128|NCT02620501|topical lidocaine
887129|NCT02620501|recovery time
887130|NCT02620501|intravenous sedation
887131|NCT02620488|Pain Perception
887132|NCT02620488|Autonomic Nervous System
887133|NCT02620488|Sickle Cell Disease
887134|NCT02620488|Hypnosis
887135|NCT02620488|Guided Imagery
887136|NCT02620462|Postural Balance
887137|NCT02620462|Pain
887138|NCT02620462|Gait
887139|NCT02620462|Physical Activity Level
887140|NCT02620449|phosphorus
887141|NCT02620449|fibroblast growth factor 23
887142|NCT02620449|diet
887143|NCT02620436|Maternal & Child Health
887144|NCT02620436|Mother Shelters
887145|NCT02620436|Maternity Waiting Homes
887146|NCT02620423|Pancreatic
887147|NCT02620423|Cancer
887148|NCT02620423|REOLYSIN®
887149|NCT02620423|Chemotherapy
887150|NCT02620423|Pembrolizumab
887151|NCT02620423|KEYTRUDA®
887152|NCT02620423|Pelareorep
887153|NCT02620423|Reovirus
887154|NCT02620423|Oncolytic virus
887155|NCT02620410|OAB
887158|NCT02620358|Mechanical Ventilation
887159|NCT02620358|Weaning
887160|NCT02620345|Fibroids
887161|NCT02620319|bronchoscopy
887162|NCT02620319|polydioxanone
887163|NCT02620319|absorbable implants
887164|NCT02620319|stents
887165|NCT02620280|Triple Negative Breast Cancer
887166|NCT02620267|Mismatch Negativity
887167|NCT02620267|Transcranial Direct Current Stimulation
887168|NCT02620267|MMN
887169|NCT02620267|tDCS
887170|NCT02620254|mastocytosis
887171|NCT02620254|cutaneous mastocytosis
887172|NCT02620254|urticaria pigmentosa
887173|NCT02620254|telangiectasia macularis eruptiva perstans (TMEP)
887174|NCT02620254|diffuse cutaneous mastocytosis
887175|NCT02620254|solitary cutaneous mastocytosis
887176|NCT02620254|systemic mastocytosis
887177|NCT02620254|indolent systemic mastocytosis
887178|NCT02620254|smoldering systemic mastocytosis
887179|NCT02620254|aggressive systemic mastocytosis
887180|NCT02620254|systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease
887181|NCT02620254|mast cell leukemia
887182|NCT02620241|gastro-oesophageal reflux
887183|NCT02620241|intrapulmonary percussive ventilation
887184|NCT02620241|positioning
887185|NCT02620228|Bioimpedance
887186|NCT02620228|Biopsy
887187|NCT02620228|Liver tumour
887188|NCT02620228|Biopsy needle guidance
887189|NCT02620202|Troponin
887190|NCT02620202|Myocardial infarction
887191|NCT02620150|HIV
887192|NCT02620150|AIDS
887193|NCT02620150|Depression
887194|NCT02620150|SSRI
887195|NCT02620150|Escitalopram
887196|NCT02620150|Immunity
887197|NCT02620085|Graves' disease
887198|NCT02620085|Hyperthyroidism
887199|NCT02620085|Personality traits
887200|NCT02620072|Type 1 diabetes
887201|NCT02620072|T1D
887202|NCT02620072|diabetes mellitus
887203|NCT02620072|oral insulin
887204|NCT02620072|oral tolerance
887205|NCT02620072|autoantigen
887206|NCT02620072|self tolerance
887207|NCT02620072|prevention
887208|NCT02620072|at risk for developing type 1 diabetes
887209|NCT02620072|juvenile diabetes
887210|NCT02620072|dysglycemia
887211|NCT02620059|Postpartum Period
887212|NCT02620046|Drug therapy
887213|NCT02620033|Prostatectomy
887214|NCT02620033|Yoga therapy
887215|NCT02620033|Health related quality of life
887216|NCT02620007|Adult
887217|NCT02620007|AIEC
887218|NCT02619994|MDR tuberculosis
887219|NCT02619994|linezolid
887220|NCT02619994|delamanid
887221|NCT02619994|Korea
887222|NCT02619968|Chronic renal failure
887223|NCT02619968|Arteriovenous fistula
887224|NCT02619968|Isometric exercises
887225|NCT02619968|Vascular endothelium
887226|NCT02619955|hepcidin deficiency
887227|NCT02619955|genetic
887228|NCT02619955|except C282Y Homozygosity
887229|NCT02619942|Right colon cancer, Survival, Laparoscopic surgery
887230|NCT02619929|Oral Vinorelbine
887231|NCT02619929|Advanced Non-Small-Cell Lung Cancer
887232|NCT02619929|Metastatic Breast Cancer
887233|NCT02619916|Cancer
887234|NCT02619916|Depression
887235|NCT02619916|MBCT
887236|NCT02619916|CBT
887237|NCT02619890|Adult Glioma
887238|NCT02619890|MRI
887239|NCT02619838|Double Arthrodesis
887240|NCT02619838|Triple Arthrodesis
887241|NCT02619838|Subtalar Arthrodesis
887242|NCT02619825|Child
887243|NCT02619799|magnesium sulphate
887244|NCT02619799|intrathecal route
887245|NCT02619799|midazolam
887246|NCT02619773|Colorectal Surgery
887247|NCT02619760|Percutaneous Coronary Intervention
887248|NCT02619760|Platelet Aggregation Inhibitors
887249|NCT02619747|pH monitoring
887250|NCT02619734|Cell Therapy
887251|NCT02619734|Sickle cell disease
887252|NCT02619734|Autologous implantation
887253|NCT02619734|Mesenchymal stromal cell
887254|NCT02619734|Edothelial Progenitor cell
887255|NCT02619721|PINS SNS OAB
887256|NCT02619708|immersive preoperative experience
887257|NCT02619695|ketoprofen
887258|NCT02619695|gel
887259|NCT02619695|low back pain
887260|NCT02619695|emergency department
887261|NCT02619669|Neoadjuvant
887262|NCT02619669|TAK-228 (MLN0128)
887263|NCT02619669|Letrozole
887264|NCT02619669|ER+
887265|NCT02619669|HER2-
887266|NCT02619656|PEG
887267|NCT02619656|CO2 insufflation
887268|NCT02619656|Room Air insufflation
887269|NCT02619656|pneumoperitoneum
887270|NCT02619617|Cluster Headache
887271|NCT02619617|Patient Diary collection of headache pain
887272|NCT02619617|Biomarker - saliva samples
887273|NCT02619578|Transcutaneous electric acupoint stimulation (TEAS)
887274|NCT02619578|gynecological laparoscopic surgery
887275|NCT02619578|QoQ-40
887276|NCT02619578|MMSE
887277|NCT02619578|VAS
887278|NCT02619565|Myelodysplastic syndromes
887279|NCT02619565|mutations
887280|NCT02619565|overall survival
887281|NCT02619565|prognosis
887282|NCT02619513|Paravertebral Blocks
887283|NCT02619513|Dexmedetomidine
887284|NCT02619513|Analgesia
887285|NCT02619513|Inflammatory response
887286|NCT02619513|Thoracotomy
887287|NCT02619474|Parent Satisfaction
887288|NCT02619474|Patient Satisfaction
887289|NCT02619474|Whiteboard
887290|NCT02619474|Communication
887291|NCT02619448|inoperable
887292|NCT02619448|Solitary [T1bN0, T2aN0, T2bN0] lesion measuring 2-7 cm
887293|NCT02619435|RAS-mutant
887294|NCT02619422|Cardiac rehabilitation programs
887295|NCT02619422|Adherence to secondary preventive measures
887296|NCT02619422|Acute coronary syndrome
887297|NCT02619422|More intensive cardiac rehabilitation program in less time
887298|NCT02619396|radiofrequency power
887299|NCT02619396|lesion size index
887300|NCT02619396|esophageal temperature alerts
887301|NCT02619383|HBOT
887302|NCT02619383|hyperbaric oxygen
887303|NCT02619383|DCE
887304|NCT02619383|ED
887305|NCT02619383|erectile dysfunction
887306|NCT02619370|advance care planning
887307|NCT02619370|advance directive
887308|NCT02619370|caregiving
887309|NCT02619357|Asthma
887310|NCT02619357|wearable physical activity monitor
887311|NCT02619357|step counts
887312|NCT02619357|Exercise
887313|NCT02619357|energy expenditure
887314|NCT02619357|COPD
887315|NCT02619357|indirect calorimetry
887316|NCT02619318|Balancing Everyday Life (BEL)
887317|NCT02619318|activity-based lifestyle intervention
887318|NCT02619318|standard occupational therapy
887319|NCT02619292|cancer survivor
887320|NCT02619292|immune function
887321|NCT02619266|Cancer Anorexia Cachexia Syndrome
887322|NCT02619266|Acupuncture
887323|NCT02619266|Megestrol acetate
887324|NCT02619266|Poor Appetite
887325|NCT02619266|Anorexia
887326|NCT02619266|Randomized Controlled Trial
887327|NCT02619253|Immunotherapy
887328|NCT02619253|Safety
887329|NCT02619253|Pharmacodynamics
887330|NCT02619253|Efficacy
887331|NCT02619214|Oxidative Stress
887332|NCT02619214|Oxygen
887333|NCT02619214|General Anesthesia
887334|NCT02619201|vomiting in children
887335|NCT02619201|ondansetron
887336|NCT02619201|metoclopramide
887337|NCT02619201|antiemetics
887338|NCT02619188|Nutrition
887339|NCT02619188|Hyperemesis gravidarum
887340|NCT02619188|Prealbumin
887341|NCT02619188|Questionnaire
887342|NCT02619162|breast cancer non metastatic
887343|NCT02619162|adjuvant letrozole
887344|NCT02619162|Nintedanib BIFF1120
887345|NCT02619136|Blood Transfusion
887346|NCT02619123|breast density
887347|NCT02619123|breast cancer
887348|NCT02619123|risk-based screening
887349|NCT02619123|Tailored breast cancer screening
887350|NCT02619123|premenopausal women
887351|NCT02619110|Chronic Stroke
887352|NCT02619110|cardiopulmonary
887353|NCT02619110|Berg Balance Scale (BBS)
887354|NCT02619084|Tourette Syndrome
887355|NCT02619084|Subthalamic Nucleus
887356|NCT02619084|STN
887357|NCT02619084|Deep Brain Stimulation
887358|NCT02619084|DBS
887359|NCT02619084|Tic
887360|NCT02619084|Obsessive-compulsive disorders
887361|NCT02619071|acute myeloid leukemia- refractory AML- relapsed AML- precision medecine-
887362|NCT02619058|NKT
887363|NCT02619058|metastatic melanoma
887364|NCT02619032|remifentanil
887365|NCT02619032|fentanyl
887366|NCT02619032|dental surgery
887367|NCT02619006|Anemia, Iron-Deficiency
887368|NCT02619006|Myelination
887369|NCT02619006|Ferritin
887370|NCT02619006|Umbilical cord clamping
887371|NCT02619006|Umbilical Cord Milking
887372|NCT02619006|Placental Transfusion
887373|NCT02619006|Brain Development
887374|NCT02618993|mandibular nerve block
887375|NCT02618993|mandibular osteotomy
887376|NCT02618980|acute coronary syndrome
887377|NCT02618980|gastrointestinal bleeding
887378|NCT02618980|endoscopy
887379|NCT02618967|Lupus
887380|NCT02618967|Healthy Volunteer
887381|NCT02618967|Safety Study
887382|NCT02618967|Placebo Control
887383|NCT02618967|Phase 1
887384|NCT02618954|Rheumatoid arthritis
887385|NCT02618954|Articular ultrasound
887386|NCT02618954|Synovitis
887387|NCT02618954|Relapse risk
887388|NCT02618928|Chronic Hepatitis C
887389|NCT02618928|HCV
887390|NCT02618915|gene therapy
887391|NCT02618915|Hemophilia B
887392|NCT02618902|patient safety
887393|NCT02618902|tolerogenic dendritic cells
887394|NCT02618902|tolDC
887395|NCT02618850|metabolic response
887396|NCT02618850|chemotherapy
887397|NCT02618850|PET
887398|NCT02618837|NSTEMI
887399|NCT02618837|NSTEACS
887400|NCT02618837|prasugrel
887401|NCT02618837|ticagrelor
887402|NCT02618837|Downstream versus Upstream strategy
887403|NCT02618811|sarcopenia
887404|NCT02618811|myosteatosis
887405|NCT02618811|enhanced recovery after surgery
887406|NCT02618811|colorectal cancer
887407|NCT02618811|minimally invasive surgery
887408|NCT02618811|complications
887409|NCT02618798|chronic liver disease
887410|NCT02618798|CLD
887411|NCT02618798|platelet function
887412|NCT02618785|Hysterosalpingography
887413|NCT02618785|antispasmodic drug
887414|NCT02618785|infertile women
887415|NCT02618772|Pediatrics
887416|NCT02618772|Laceration
887417|NCT02618772|Anxiety
887418|NCT02618772|Anti-Anxiety Agents
887419|NCT02618746|Telemonitoring
887420|NCT02618746|Home Rehabilitation
887421|NCT02618746|Exacerbations
887422|NCT02618746|Physical Activity
887423|NCT02618746|COPD
887424|NCT02618720|Antimicrobial prophylaxis
887425|NCT02618720|Colorectal surgery
887426|NCT02618720|Surgical Site Infection
887427|NCT02618720|Postoperative morbidity
887428|NCT02618707|Lactate
887429|NCT02618707|Congenital cardiac defect
887430|NCT02618707|CPB
887431|NCT02618707|Pediatric
887432|NCT02618694|adrenal
887433|NCT02618694|supra-renal
887434|NCT02618694|adrenalectomy
887435|NCT02618694|retroperitoneoscopy
887436|NCT02618694|posterior retroperitoneoscopy
887437|NCT02618694|Laparoscopic adrenalectomy
887438|NCT02618681|earlobe crease
887439|NCT02618681|acute myocardial infarction
887440|NCT02618655|TBDs；diagnosis
887441|NCT02618603|Stroke
887442|NCT02618603|Should pain
887443|NCT02618603|Botulinum Toxin
887444|NCT02618590|non-small cell lung cancer
887445|NCT02618590|EGFR mutant type
887446|NCT02618590|first/second line EGFR-TKI
887447|NCT02618577|Anticoagulation
887448|NCT02618577|atrial high rate episodes
887449|NCT02618577|Atrial Fibrillation
887450|NCT02618577|VKA
887451|NCT02618577|NOAC
887452|NCT02618551|Thermoplasty
887453|NCT02618551|Severe asthma
887454|NCT02618551|Dynamic hyperinflation
887455|NCT02618499|birth
887456|NCT02618499|oxytocin
887457|NCT02618499|placental transfusion
887458|NCT02618499|umbilical cord clamping
887459|NCT02618473|Coronary computed tomography angiography
887460|NCT02618473|motion artifacts
887461|NCT02618473|motion correction algorithm
887462|NCT02618473|diagnostic utility
887463|NCT02618460|Non-contrast enhanced MRI
887464|NCT02618460|healthy volunteers
887465|NCT02618460|renal diffusion
887466|NCT02618460|renal perfusion
887467|NCT02618369|High Intensity Focused Ultrasound
887468|NCT02618317|renal dialysis
887469|NCT02618304|Meibomian gland dysfunction
887470|NCT02618304|Lipiview
887471|NCT02618304|Tear Lipid Layer
887472|NCT02618291|primary health care
887473|NCT02618265|stroke
887474|NCT02618265|secondary prevention
887475|NCT02618265|platelet response polymorphism
887476|NCT02618265|mobile terminal
887477|NCT02618252|difficult IV access
887478|NCT02618252|ultrasound
887479|NCT02618252|veinviewer
887480|NCT02618252|near infrared device
887481|NCT02618239|intestinal gas
887482|NCT02618239|Healthy subjects
887483|NCT02618239|microbiota
887484|NCT02618239|prebiotics
887485|NCT02618226|Traumatic Brain Injury
887486|NCT02618226|TBI
887487|NCT02618226|Optic nerve ultrasound
887488|NCT02618226|ONUS
887489|NCT02618226|Intracranial pressure
887490|NCT02618226|ICP
887491|NCT02618226|Intracranial hypertension
887492|NCT02618213|Continuous Positive Airway Pressure
887493|NCT02618213|High Flow Oxygenation therapy
887494|NCT02618213|Bronchiolitis
887495|NCT02618213|Children
887496|NCT02618200|Prostate cancer
887497|NCT02618200|Computer-Aided Diagnosis
887498|NCT02618161|EBRT and HDR Brachytherapy
887499|NCT02618109|B acute lymphoblastic leukemia
887500|NCT02618109|leukemia relapse
887501|NCT02618109|pediatric onco-hematology
887502|NCT02618096|membrane sweeping
887503|NCT02618096|dinoprostone
887504|NCT02618096|multiparas
887505|NCT02618096|labor induction
887506|NCT02618096|cesarean delivery
887507|NCT02618044|Gastroesophageal reflux
887508|NCT02618044|Obesity
887509|NCT02618044|Esophageal manometry
887510|NCT02618044|24 H impedance pH-monitoring
887511|NCT02618044|Laparoscopic Roux-en-Y Gastric Bypass
887512|NCT02618031|capillary index score
887513|NCT02618031|acute ischemic stroke
887514|NCT02618031|collateral circulation
887515|NCT02618031|cerebral ischemia
887516|NCT02618031|diagnostic imaging
887517|NCT02618018|astigmatism
887518|NCT02618018|toric intraocular lens
887519|NCT02618005|Astronauts
887520|NCT02618005|Probiotics
887521|NCT02618005|Immune function
887522|NCT02618005|Intestinal microbiota
887523|NCT02617966|Retina
887524|NCT02617966|Retinal Degeneration
887525|NCT02617966|Retinitis Pigmentosa
887526|NCT02617966|Stargardt's Disease
887527|NCT02617966|Dark Adaptation
887528|NCT02617953|Tinnitus
887529|NCT02617953|EEG
887530|NCT02617953|ERP
887531|NCT02617940|dental caries
887532|NCT02617940|primary tooth
887533|NCT02617940|resin-based sealants
887534|NCT02617914|ARDS
887535|NCT02617914|PEEP
887536|NCT02617914|ECMO
887537|NCT02617901|Bone age
887538|NCT02617901|Greulich & Pyle
887539|NCT02617901|TW3
887540|NCT02617901|Radiography
887541|NCT02617901|Dual energy x-ray absorptiometry
887542|NCT02617888|radiation
887543|NCT02617888|cardiac computed tomography
887544|NCT02617888|CCTA
887545|NCT02617888|breast shielding
887546|NCT02617888|Myocardial perfusion scintigraphy
887547|NCT02617888|MPS
887548|NCT02617888|Invasive coronary angiography
887549|NCT02617888|ICA
887550|NCT02617875|Pre-hospital
887551|NCT02617875|Emergency medical system
887552|NCT02617875|Telemedicine
887553|NCT02617875|Tele consultation
887554|NCT02617875|Remote treatment
887555|NCT02617862|Diagnostic imaging
887556|NCT02617862|Retina
887557|NCT02617862|Pediatrics
887558|NCT02617810|Healthy
887559|NCT02617810|JNJ-42847922
887560|NCT02617810|Midazolam
887561|NCT02617810|Warfarin
887562|NCT02617810|Pharmacokinetics
887563|NCT02617797|Urinary Stress Incontinence
887564|NCT02617797|Radiofrequency
887565|NCT02617797|Women
887566|NCT02617758|Healthy
887567|NCT02617758|Bioequivalence Study
887568|NCT02617758|JNJ-35685-AAA-G021
887569|NCT02617758|DURAGESIC
887570|NCT02617745|Stupp protocol, glioblastoma, thrombocytopenia
887571|NCT02617732|glucose variability
887572|NCT02617732|continuous glucose mornitoring system
887573|NCT02617732|traditional Chinese medicine
887574|NCT02617706|Anorectal surgeries
887575|NCT02617706|infection
887576|NCT02617706|topical oxygen
887577|NCT02617680|Desflurane
887578|NCT02617680|end tidal concentration
887579|NCT02617680|age
887580|NCT02617680|anesthesia
887581|NCT02617641|Secondary Prevention
887582|NCT02617641|Walking
887583|NCT02617641|Health Behavior
887584|NCT02617641|Internet
887585|NCT02617641|eHealth
887586|NCT02617641|Computer-Assisted Instruction
887587|NCT02617641|Multicenter Study
887588|NCT02617641|Randomized Controlled Trial
887589|NCT02617641|Intervention Studies
887590|NCT02617641|Motivation
887591|NCT02617641|Self Efficacy
887592|NCT02617641|Theory, Nursing
887593|NCT02617641|Theory, Psychological
887594|NCT02617641|Nursing Research
887595|NCT02617628|opioid addiction
887596|NCT02617615|MB-110
887597|NCT02617602|Congenital heart defect
887598|NCT02617602|Cardiopulmonary bypass
887599|NCT02617602|Goal directed therapy
887600|NCT02617602|Acute heart failure
887601|NCT02617563|spondylolisthesis
887602|NCT02617563|CD Horizon® Spinal Systems
887603|NCT02617563|minimal invasive
887604|NCT02617563|Spinal Fusion
887605|NCT02617563|MAST procedure
887606|NCT02617563|Lumbar fusion
887607|NCT02617524|dedicated sheath
887608|NCT02617498|living donor liver transplantation
887609|NCT02617459|Safety
887610|NCT02617459|efficacy
887611|NCT02617459|Levobetaxolol eye drops
887612|NCT02617459|Chinese patients
887613|NCT02617446|safety
887614|NCT02617446|efficacy
887615|NCT02617446|istaroxime
887616|NCT02617407|Dental Plaque
887617|NCT02617407|Gingivitis
887618|NCT02617407|Bacterial Infection
887619|NCT02617407|Oral Hygiene
887620|NCT02617407|HSCT
887621|NCT02617407|Oral Microbiome
887622|NCT02617368|Keratoconus, Corneal crosslinking, Fourier Analysis of Topographic Data
887623|NCT02617342|Intervention
887624|NCT02617342|Autism Spectrum Disorder
887625|NCT02617342|Social Skills
887626|NCT02617329|Extracorporeal shock wave therapy (ESWT), Neck Pain
887627|NCT02617316|running speeds, strike patterns
887628|NCT02617303|elderly
887629|NCT02617303|accidental falls
887630|NCT02617303|osteoporosis
887631|NCT02617303|fractures
887632|NCT02617303|Primary Care
887633|NCT02617303|Randomized clinical trial
887634|NCT02617303|Otago exercise programme
887635|NCT02617290|Coronary Artery Disease (CAD)
887636|NCT02617290|Percutaneous Coronary Intervention (PCI)
887637|NCT02617277|AZD1775
887638|NCT02617277|MEDI4736
887639|NCT02617277|AZD1775 + MEDI4736
887640|NCT02617277|Advanced Solid Tumours
887641|NCT02617277|Durvalumab
887642|NCT02617238|arterial stiffness
887643|NCT02617238|cardiovascular risk
887644|NCT02617238|cardiovascular events
887645|NCT02617238|renal events
887646|NCT02617212|dental implant
887647|NCT02617212|bone preservation
887648|NCT02617212|definitive abutment
887649|NCT02617212|one abutment one time
887650|NCT02617199|epidural anesthesia
887651|NCT02617199|pain management
887652|NCT02617199|microcirculation
887653|NCT02617160|Insulin Pump Treatment
887654|NCT02617160|Type 1 Diabetes
887655|NCT02617160|Insulin Pump Setting
887656|NCT02617160|Pump Advisor
887657|NCT02617108|uterine septum
887658|NCT02617108|intrauterine adhesions
887659|NCT02617108|Foley balloon
887660|NCT02617082|breast cancer
887661|NCT02617082|partial breast irradiation
887662|NCT02617082|DCIS
887663|NCT02617069|Atrial fibrillation
887664|NCT02617069|botulinum toxin
887665|NCT02617056|electrodermal response
887666|NCT02617043|breast cancer
887667|NCT02617043|hypofractionated whole breast irradiation
887668|NCT02617017|Parkinson disease
887669|NCT02617017|Levodopa induce dyskinesia
887670|NCT02616952|Stress urinary incontinence
887671|NCT02616952|Chinese Herb
887672|NCT02616952|Traditional Chinese medicine
887673|NCT02616952|Pelvic floor muscle training
887674|NCT02616939|Multidetector computed tomography
887675|NCT02616926|hepatocellular carcinoma
887676|NCT02616926|hepatectomy
887677|NCT02616926|transarterial chemoembolization
887678|NCT02616926|radiofrequency ablation
887679|NCT02616874|HIV infection
887680|NCT02616874|Early treatment
887681|NCT02616874|Romidepsin
887682|NCT02616874|HDACi
887683|NCT02616874|Therapeutic Vaccines
887684|NCT02616874|HIVconsv
887685|NCT02616874|HIV reservoir
887686|NCT02616874|Population PK/PD analysis
887687|NCT02616848|Everolimus
887688|NCT02616848|eribulin
887689|NCT02616822|hypertension
887690|NCT02616822|endothelium
887691|NCT02616822|resveratrol
887692|NCT02616822|clinical trials
887693|NCT02616783|HIV 1 Infection
887694|NCT02616783|HIV
887695|NCT02616783|Virologically-Suppressed
887696|NCT02616744|aromatase inhibitors
887697|NCT02616744|breast cancer
887698|NCT02616744|bone mineral density
887699|NCT02616692|HCC
887700|NCT02616692|Patient preferences
887701|NCT02616666|Type 2 diabetes mellitus
887702|NCT02616666|Randomised
887703|NCT02616666|Pragmatic
887704|NCT02616666|Standard of Care
887705|NCT02616666|Dapagliflozin
887706|NCT02616666|FORXIGA
887707|NCT02616640|Multiple Myeloma
887708|NCT02616640|Relapsed
887709|NCT02616640|Refractory
887710|NCT02616640|MEDI4736
887711|NCT02616640|Durvalumab
887712|NCT02616640|Pomalidomide (POM)
887713|NCT02616640|Dexamethasone (DEX)
887714|NCT02616640|PD-L1
887715|NCT02616627|bone mineral density
887716|NCT02616627|chronic dialysis
887717|NCT02616627|end-stage renal disease
887718|NCT02616627|body composition analysis
887719|NCT02616627|sarcopenia
887720|NCT02616588|advanced stage cancer,
887721|NCT02616588|patient navigator,
887722|NCT02616588|social work
887723|NCT02616575|home care
887724|NCT02616575|monitoring system
887725|NCT02616575|risk assessment
887726|NCT02616575|telehealth
887727|NCT02616536|Flipped classroom
887728|NCT02616536|Teaching methods
887729|NCT02616536|Knowledge gain
887730|NCT02616523|dexmedetomidine
887731|NCT02616523|lidocaine
887732|NCT02616523|neuropathic pain
887733|NCT02616523|laparoscopic intestine resection
887734|NCT02616523|cognitive function
887735|NCT02616497|aspirin
887736|NCT02616497|triflusal
887737|NCT02616497|antiplatelet drugs
887738|NCT02616497|atherothrombosis
887739|NCT02616497|secondary prevention
887740|NCT02616484|Sodium Dichloroacetate
887741|NCT02616484|Treatment of PDCD with Dichloroacetate
887742|NCT02616471|Cheese
887743|NCT02616471|Dairy
887744|NCT02616471|Saturated fat
887745|NCT02616471|Blood lipid concentrations
887746|NCT02616471|Lipoprotein particle size
887747|NCT02616471|Metabolic Syndrome
887748|NCT02616471|Insulin sensitivity
887749|NCT02616471|Blood glucose concentrations
887750|NCT02616445|Xanamem
887751|NCT02616432|Tomosynthesis
887752|NCT02616432|Digital Breast Tomosynthesis (DBT)
887753|NCT02616432|Breast Imaging
887754|NCT02616432|Full-field digital mammography
887755|NCT02616432|Breast screening
887756|NCT02616419|Emergency Department
887757|NCT02616419|Procedural pain
887758|NCT02616419|Procedural anxiety
887759|NCT02616419|Needle-related procedures
887760|NCT02616419|Clinical Nursing Research
887761|NCT02616419|Nursing practice
887762|NCT02616419|Non-pharmacological method
887763|NCT02616406|recovery of function
887764|NCT02616380|Work productivity
887765|NCT02616380|Quality of life (QOL)
887766|NCT02616380|Rheumatoid arthritis (RA)
887767|NCT02616354|Pharmacokinetics; pharmacodynamic; imipenem; sepsis
887768|NCT02616315|Drug therapy
887769|NCT02616302|Drug therapy
887770|NCT02616276|Glycemic Index
887771|NCT02616276|Postprandial Period
887772|NCT02616276|Vascular Stiffness
887773|NCT02616276|Blood glucose
887774|NCT02616276|Cognition
887775|NCT02616237|Chinese population
887776|NCT02616237|acupressure
887777|NCT02616237|physical activity
887778|NCT02616237|nutrition
887779|NCT02616237|Facebook
887780|NCT02616198|glass ionomers
887781|NCT02616198|surface coating
887782|NCT02616198|clinical trial
887783|NCT02616120|Herbal therapy
887784|NCT02616120|Parkinson's Disease
887785|NCT02616120|Non-motor Symptoms
887786|NCT02616120|Randomized controlled trial
887787|NCT02616107|Caregiver
887788|NCT02616107|Self-management
887789|NCT02616107|Care options
887790|NCT02616107|Goals of care
887791|NCT02616107|Breast cancer
887792|NCT02616107|Palliative care
887793|NCT02616081|Urinary Bladder
887794|NCT02616081|Neurogenic
887795|NCT02616081|Quality of Life
887796|NCT02616081|Spinal cord injury
887797|NCT02616081|incontinence
887798|NCT02616081|Bladder
887799|NCT02616042|Centella asiatica
887800|NCT02616042|bamboo salt
887801|NCT02616042|dentifrice
887802|NCT02616003|Morbid Obesity
887803|NCT02616003|Giant Obese
887804|NCT02616003|Preoperative Procedure
887805|NCT02616003|Liraglutide
887806|NCT02616003|Leucine
887807|NCT02615977|Pavlovian conditioning, Operant conditioning
887808|NCT02615977|Pavlovian-to-instrumental transfer
887809|NCT02615977|Functional imaging
887810|NCT02615977|Relapse risk
887811|NCT02615977|Behavioural Intervention
887812|NCT02615951|Regulatory B cells (Breg)
887813|NCT02615951|Genes
887814|NCT02615951|Cell surface proteins
887815|NCT02615951|Nutrient transporters
887816|NCT02615951|Chemokine receptors
887817|NCT02615899|Older Adults, Falls
887818|NCT02615886|rice bran
887819|NCT02615886|infants
887820|NCT02615886|stool metabolome
887821|NCT02615886|stool microbiome
887822|NCT02615886|dietary intervention
887823|NCT02615873|Parkinson's Disease
887824|NCT02615873|Fluctuating Parkinson's Disease
887825|NCT02615873|Carbidopa
887826|NCT02615873|Levodopa
887827|NCT02615873|Accordion
887828|NCT02615860|HIV-infection
887829|NCT02615860|anal cancer (AC)
887830|NCT02615860|anal cancer prevention
887831|NCT02615860|anal dysplasia
887832|NCT02615860|anal intraepithelial neoplasia (AIN)
887833|NCT02615860|human papillomavirus (HPV)
887834|NCT02615860|HPV-induced anal cancer precursor lesions
887835|NCT02615860|electrocautery (ECA)
887836|NCT02615860|topical trichloroacetic acid (TCA) treatment.
887838|NCT02615678|neuropathy
887839|NCT02615678|peripheral
887840|NCT02615678|chemotherapy
887841|NCT02615678|breast cancer
887842|NCT02615665|NK-cells
887843|NCT02615665|T-cells
887844|NCT02615639|HPDC-T cells
887845|NCT02615639|CHB
887846|NCT02615639|immuno therapy
887847|NCT02615626|Visfatin
887848|NCT02615626|GCF
887849|NCT02615626|serum
887850|NCT02615626|Non-surgical Periodontal Treatment.
887851|NCT02615613|Hedonics, Ghrelin, Hunger
887852|NCT02615600|tinnitus
887853|NCT02615600|transcranial random noise stimulation
887854|NCT02615600|tRNS
887855|NCT02615600|auditory cortex
887856|NCT02615600|non-invasive brain stimulation
887857|NCT02615587|non-valvular Atrial Fibrillation
887858|NCT02615561|Safety
887859|NCT02615561|Efficacy
887860|NCT02615561|Atopic dermatitis
887861|NCT02615561|Cosmetic products
887862|NCT02615548|exercises
887863|NCT02615535|traumatic brain injury
887864|NCT02615522|primary TKR
887865|NCT02615496|Health Care Surveys
887866|NCT02615496|Vascular Endothelial Growth Factor
887867|NCT02615470|Pneumococcal Vaccines
887868|NCT02615470|Shingles
887869|NCT02615470|Pharmacy
887870|NCT02615470|Vaccine
887871|NCT02615470|Immunization
887872|NCT02615444|Metabolic Syndrome X
887873|NCT02615444|Overweight
887874|NCT02615444|Waist Circumference
887875|NCT02615444|Blood Pressure
887876|NCT02615444|Cholesterol
887877|NCT02615444|Oat beta glucan
887878|NCT02615392|RCT
887879|NCT02615392|Park Prescription
887880|NCT02615392|Park Use
887881|NCT02615392|Physical Activity
887882|NCT02615392|Health Promotion
887883|NCT02615392|Health Behavior
887884|NCT02615392|Mental Well-Being
887885|NCT02615392|Body composition
887886|NCT02615392|Blood levels
887887|NCT02615392|Accelerometry
887888|NCT02615392|Improving general physical and mental health
887889|NCT02615379|instrumented spinal fusion
887890|NCT02615379|infection
887891|NCT02615379|topical oxygen
887892|NCT02615340|delirium
887893|NCT02615340|melatonin
887894|NCT02615340|pharmacokinetics
887895|NCT02615340|feasibility
887896|NCT02615340|prevention
887897|NCT02615327|Fiber
887898|NCT02615327|Polydextrose
887899|NCT02615327|Glycemic Index
887900|NCT02615314|migraine
887901|NCT02615314|benign paroxysmal positional vertigo
887902|NCT02615288|Vitamin D
887903|NCT02615275|Head and Neck Cancer
887904|NCT02615275|Bioelectrical impedance analysis
887905|NCT02615275|BIA
887906|NCT02615275|Eight-electrode BIA device
887907|NCT02615275|SECA mBCA
887908|NCT02615275|Computed tomography
887909|NCT02615275|CT
887910|NCT02615275|Positron emission tomography
887911|NCT02615275|PET
887912|NCT02615275|Symptom questionnaire
887913|NCT02615275|Survey
887914|NCT02615275|Radiation therapy
887915|NCT02615275|RT
887916|NCT02615275|XRT
887917|NCT02615262|Pediatric cardiac surgery
887918|NCT02615262|Dexamethasone
887919|NCT02615262|Steroids
887920|NCT02615262|Cardiopulmonary bypass
887921|NCT02615262|Congenital heart defects
887922|NCT02615262|Infants
887923|NCT02615197|PTSD
887924|NCT02615197|Multi-diagnostic
887925|NCT02615197|Dialectical Behavior Therapy
887926|NCT02615197|Prolonged Exposure Therapy
887927|NCT02615184|Drug therapy
887928|NCT02615158|Feeding practices
887929|NCT02615158|Diet
887930|NCT02615158|Physical activity
887931|NCT02615158|Prevention
887932|NCT02615145|Quality of life
887933|NCT02615145|Chronic Hepatitis C
887934|NCT02615145|Dasabuvir
887935|NCT02615145|Observational Study
887936|NCT02615145|Work-ability
887937|NCT02615145|Cirrhosis
887938|NCT02615145|Ombitasvir+Paritaprevir+Ritonavir
887939|NCT02615145|Fibrosis
887940|NCT02615119|heartbeat
887941|NCT02615119|respiration
887942|NCT02615119|interoception
887943|NCT02615119|anxiety
887944|NCT02615119|eating
887945|NCT02615106|Radiation Therapy
887946|NCT02615106|Neuroblastoma
887947|NCT02615067|Diagnostic
887948|NCT02615067|Active surveillance
887949|NCT02615067|Very low risk
887950|NCT02615067|Imaging
887951|NCT02615067|PSMA
887952|NCT02615067|SPECT/CT
887953|NCT02615067|99mTc
887954|NCT02615067|Newly Diagnosed
887955|NCT02615067|Prostatectomy
887956|NCT02615067|Biopsy
887957|NCT02615054|Cardiovascular Impairment
887958|NCT02615054|15-258
887959|NCT02615041|Meropenem
887960|NCT02615041|Ventilator-Associated Pneumonia
887961|NCT02615041|population pharmacokinetics
887962|NCT02615041|pharmacokinetics
887963|NCT02615041|pharmacodynamics
887964|NCT02615028|Force plate, Balance ability
887965|NCT02615015|Deoxyribonuclease
887966|NCT02615002|Cognition
887967|NCT02615002|mild Alzheimer's disease
887968|NCT02615002|Sleep
887969|NCT02614989|Tremor
887970|NCT02614989|Thalamotomy
887971|NCT02614963|Irritable Bowel Syndrome
887972|NCT02614963|Clostridium Butyricum
887973|NCT02614911|Early Onset Entheropathy
887974|NCT02614833|Hormone receptor positive
887975|NCT02614820|Ischemic preconditioning
887976|NCT02614820|sefety
887977|NCT02614820|efficacy
887978|NCT02614820|DMD
887979|NCT02614807|Dietary Supplement
887980|NCT02614794|Tucatinib
887981|NCT02614794|Capecitabine
887982|NCT02614794|Trastuzumab
887983|NCT02614794|Xeloda
887984|NCT02614794|Herceptin
887985|NCT02614794|Breast Cancer
887986|NCT02614794|ARRY-380
887987|NCT02614794|ONT-380
887988|NCT02614794|HER2 Positive Breast Carcinoma
887989|NCT02614794|HER2 Positive Locally Advanced Breast Cancer
887990|NCT02614794|HER-2 Positive Breast Cancer
887991|NCT02614794|HER-2 Positive Breast Carcinoma
887992|NCT02614794|HER-2 Positive Locally Advanced Breast Cancer
887993|NCT02614794|Recurrent Breast Carcinoma
887994|NCT02614794|Stage IV Breast Cancer
887995|NCT02614794|Metastatic Breast Cancer
887996|NCT02614794|Breast Carcinoma
887997|NCT02614794|Metastatic Malignant Neoplasm in the Brain
887998|NCT02614794|Brain Metastases in Breast Cancer
887999|NCT02614794|Asymptomatic Brain Metastases in Breast Cancer
888000|NCT02614794|Low Symptomatic Brain Metastases in Breast Cancer
888001|NCT02614768|Glucose Monitoring System
888002|NCT02614755|Older Adults Volunteers
888003|NCT02614755|Seniors
888004|NCT02614755|Brain Performance Test
888005|NCT02614729|High Protein
888006|NCT02614729|Satiety
888007|NCT02614729|Appetite Control
888008|NCT02614729|Protein Distribution
888009|NCT02614729|Cognitive Function
888010|NCT02614729|Ad libitum Food Intake
888011|NCT02614729|Obesity prevention
888012|NCT02614729|Obesity treatment
888013|NCT02614703|Barrett's Esophagus
888014|NCT02614703|Acetic Acid Chromoendoscopy
888015|NCT02614690|Fracture of the upper limb
888016|NCT02614677|Disability Evaluation System
888017|NCT02614677|SF-12
888018|NCT02614677|ICF model
888019|NCT02614612|Acute Graft Versus Host Disease
888020|NCT02614599|ADD
888021|NCT02614599|ADHD
888022|NCT02614599|Proteins
888023|NCT02614599|Dietary
888024|NCT02614599|Nutrition
888025|NCT02614599|QEEG
888026|NCT02614599|ERP
888027|NCT02614599|ICA
888028|NCT02614586|Drug Therapy
888029|NCT02614573|Dependent
888030|NCT02614573|Aged, 80 and over
888031|NCT02614573|Aged
888032|NCT02614560|acute myeloid leukemia
888033|NCT02614560|AML
888034|NCT02614560|antibody-drug conjugate
888035|NCT02614521|Pulmonary veins ablation
888036|NCT02614521|Paroxysmal atrial fibrillation
888037|NCT02614482|Children
888038|NCT02614482|Antimuscarinics
888039|NCT02614482|Antocholinergics
888040|NCT02614482|Overactive bladder
888041|NCT02614443|Depression
888042|NCT02614443|Anxiety
888043|NCT02614443|Stress
888044|NCT02614443|Online interventions
888045|NCT02614443|University students
888046|NCT02614443|CBT
888047|NCT02614430|Rehabilitation
888048|NCT02614430|Prediction
888049|NCT02614430|Inflammation
888050|NCT02614404|Plasmodium falciparum
888051|NCT02614404|Uncomplicated malarial
888052|NCT02614404|imatinib mesylate
888053|NCT02614404|antimalarials
888054|NCT02614391|Procedural pain
888055|NCT02614391|Phlebotomy
888056|NCT02614391|Distraction
888057|NCT02614391|Videogame
888058|NCT02614391|Computer tablet
888059|NCT02614391|Child
888060|NCT02614378|abortive effect
888061|NCT02614326|Depression
888062|NCT02614326|Cognitive risk factors
888063|NCT02614326|Autobiographical memory
888064|NCT02614326|Cognitive bias
888065|NCT02614326|Relapse prevention
888066|NCT02614313|Fructose
888067|NCT02614313|Irritable Bowel Syndrome
888068|NCT02614313|Breath test
888069|NCT02614313|Placebo
888070|NCT02614300|pulmonary rehabilitation
888071|NCT02614300|chest physiotherapy
888072|NCT02614300|non-cystic fibrosis bronchiectasis
888073|NCT02614300|exercise tolerance
888074|NCT02614300|bronchiectasis
888075|NCT02614300|respiratory therapy
888076|NCT02614287|prevention
888077|NCT02614287|prophylaxis
888078|NCT02614287|headache
888079|NCT02614274|knee
888080|NCT02614274|pain
888081|NCT02614274|osteoarthritis
888082|NCT02614274|nutraceutical
888083|NCT02614274|nutrition
888084|NCT02614274|supplement
888085|NCT02614274|non-surgical
888086|NCT02614274|biomarker
888087|NCT02614274|joint health
888088|NCT02614261|prevention
888089|NCT02614261|prophylaxis
888090|NCT02614261|headache
888094|NCT02614222|Computer Assisted Instrument Guidance (CAIG)
888095|NCT02614222|Peripheral Nerve Block
888096|NCT02614222|Clear Guide ONE
888097|NCT02614222|Needle path
888098|NCT02614222|Needle Guidance
888099|NCT02614222|Ultrasound
888100|NCT02614209|ED
888101|NCT02614209|BNP
888102|NCT02614196|prevention
888103|NCT02614196|prophylaxis
888104|NCT02614196|headache
888105|NCT02614183|prevention
888106|NCT02614183|prophylaxis
888107|NCT02614183|headache
888108|NCT02614157|rectal cancer
888109|NCT02614157|lateral lymph node dissection
888110|NCT02614157|neoadjuvant chemoradiation
888111|NCT02614157|total mesorectal excision
888112|NCT02614157|surgery
888113|NCT02614157|recurrence
888114|NCT02614157|metastasis
888115|NCT02614157|overall survival
888116|NCT02614144|Hospital Acquired Pneumonia
888117|NCT02614144|Mortality
888118|NCT02614118|Endodontic treatment
888119|NCT02614118|non steroid
888120|NCT02614118|pain
888121|NCT02614118|pre medication
888122|NCT02614092|Mild Cognitive Impairment
888123|NCT02614092|memory impairment
888124|NCT02614092|Physical Activity
888125|NCT02614092|Exercise
888126|NCT02614092|Cognitive Training
888127|NCT02614092|Veterans
888128|NCT02614092|Older Adults
888129|NCT02614079|lumbago
888130|NCT02614079|low back pain
888131|NCT02614079|leg pain
888132|NCT02614040|crystalloid
888133|NCT02614040|acute kidney injury
888134|NCT02614001|breathing training, congestive heart failure, stroke
888135|NCT02613988|Glioblastoma
888136|NCT02613988|MRI
888137|NCT02613988|standard treatment
888138|NCT02613949|fibromyalgia
888139|NCT02613949|pain
888140|NCT02613949|stimulation
888141|NCT02613936|traumatic brain injury
888142|NCT02613936|post concussive symptoms
888143|NCT02613936|depression
888144|NCT02613936|executive dysfunction
888145|NCT02613936|brain stimulation
888146|NCT02613923|Breast Cancer
888147|NCT02613923|GO! to sleep
888148|NCT02613923|sleep
888149|NCT02613910|Ofatumumab
888150|NCT02613910|Pemphigus Vulgaris
888151|NCT02613910|Long-Term Extension Study
888152|NCT02613845|Postoperative delirium
888153|NCT02613845|Cardiac surgery
888154|NCT02613845|Cardiopulmonary bypass
888155|NCT02613845|Risk factor
888156|NCT02613832|Noncooperative patients
888157|NCT02613806|Dexmedetomidine
888158|NCT02613806|Coughing Response
888159|NCT02613806|Postoperative Recovery Quality
888160|NCT02613806|Thyroid Surgery
888161|NCT02613793|Preterm pre-eclampsia
888162|NCT02613793|Neurological dysfunction
888163|NCT02613793|Saccadic reaction time
888164|NCT02613728|Colorectal cancer
888165|NCT02613728|Colorectal cancer surgery
888166|NCT02613728|Polyp(s)
888167|NCT02613728|Accelerated Enhanced Recovery
888168|NCT02613728|RecoverMI
888169|NCT02613728|Fluid diary
888170|NCT02613728|Questionnaires
888171|NCT02613728|Surveys
888172|NCT02613728|RecoverMI device
888173|NCT02613715|Flavonoids
888174|NCT02613715|Anthocyanins
888175|NCT02613715|Blackberry Juice
888176|NCT02613715|Bioavailability
888177|NCT02613715|Obesity
888178|NCT02613702|Free gingival graft
888179|NCT02613702|keratinized gingival tissue
888180|NCT02613689|smokeless tobacco, text message, tobacco cessation, tobacco
888181|NCT02613637|lung cancer
888182|NCT02613637|registry study
888183|NCT02613637|Biological Disease Profile
888184|NCT02613624|KMC in community
888185|NCT02613559|Neovascular Age-Related Macular Degeneration, Subfoveal CNV, TK001
888186|NCT02613546|cognitive-behavioral psychotherapy
888187|NCT02613546|Sexual Dysfunctions
888188|NCT02613546|Women
888189|NCT02613520|PfSPZ Vaccine
888190|NCT02613520|Plasmodium falciparum
888191|NCT02613494|clozapine
888192|NCT02613494|hypersalivation
888193|NCT02613494|refractory schizophrenia
888194|NCT02613468|Pregnancy
888195|NCT02613468|Low birth weight
888196|NCT02613468|Gingivitis
888197|NCT02613468|Inflammation
888198|NCT02613468|Periodontitis
888199|NCT02613390|Epidural metastasis
888200|NCT02613390|Magnetic resonance imaging
888201|NCT02613390|MRI
888202|NCT02613390|Guidance system
888203|NCT02613390|Spinal surgery
888204|NCT02613390|Questionnaires
888205|NCT02613390|Surveys
888206|NCT02613377|Transfusion-related acute lung injury, Red Blood Cell
888207|NCT02613351|Exercise Tolerance
888208|NCT02613351|Lung Diseases, Obstructive
888209|NCT02613325|Melanoma
888210|NCT02613325|Imaging
888211|NCT02613325|Pigmented Lesions
888212|NCT02613325|Melanoma Management
888213|NCT02613247|Viscosupplementation
888214|NCT02613247|Hyaluronic acid
888215|NCT02613247|Synvisc
888216|NCT02613247|Synvisc-One
888217|NCT02613247|Patellofemoral pain syndrome
888218|NCT02613247|PFPS
888219|NCT02613247|Anterior knee pain
888220|NCT02613247|Runner's knee
888221|NCT02613234|Epilepsy
888222|NCT02613234|128-Channel EEG
888223|NCT02613234|Dipole Localization
888224|NCT02613234|Transcranial Direct Current Stimulation
888225|NCT02613221|Metastatic colorectal cancer, Panitumumab, TAS-102
888226|NCT02613208|Bevacizumab
888227|NCT02613208|Paclitaxel
888228|NCT02613208|Metastatic Breast Cancer
888229|NCT02613208|Human Epidermal Growth Factor Receptor-Type 2
888230|NCT02613195|Ischemia-Reperfusion Injury
888231|NCT02613195|oxidative stress
888232|NCT02613195|organ preservation
888233|NCT02613195|Hydrogen
888234|NCT02613195|Kidney Transplantation
888235|NCT02613169|M. tuberculosis infection
888236|NCT02613169|isoniazid
888237|NCT02613169|HIV-exposed infants
888238|NCT02613156|laparoscopic
888239|NCT02613156|hepatocellular carcinoma
888240|NCT02613156|recurrence
888241|NCT02613143|malignant glaucoma
888242|NCT02613143|zonulo-hyaloido-vitrectomy
888243|NCT02613091|volunteers
888244|NCT02613078|Children
888245|NCT02613078|Functional Abdominal Pain Syndrome
888246|NCT02613078|Irritable Bowel Syndrome
888247|NCT02613078|Gut-Directed Hypnotherapy
888248|NCT02613078|Probiotic
888249|NCT02613065|Ad libitum
888250|NCT02613065|Energy balance
888251|NCT02613065|Protein
888252|NCT02613039|oral contraceptives
888253|NCT02613039|female sexuality
888254|NCT02613026|Breast tumor
888255|NCT02613026|Neoadjuvant chemotherapy
888256|NCT02613026|Pathological complete remission
888257|NCT02612987|CBT
888258|NCT02612987|Internet based
888259|NCT02612974|Qurse mafasil
888260|NCT02612974|leech therapy
888261|NCT02612974|Hirudinaria granulosa
888262|NCT02612961|Mechanically ventilated patients
888263|NCT02612961|Normal Saline
888264|NCT02612961|Tracheostomy Tube Suctioning
888265|NCT02612922|Influenza
888266|NCT02612909|Avian Influenza
888267|NCT02612909|A/H5N1 vaccine
888268|NCT02612909|IVAC
888269|NCT02612896|Taenia solium
888270|NCT02612896|control
888271|NCT02612896|elimination
888272|NCT02612896|One Health
888273|NCT02612883|Flux measurement
888274|NCT02612870|Breast Cancer
888275|NCT02612870|Sentinel Node
888276|NCT02612870|Sentinel Node Biopsy
888277|NCT02612870|Breast Surgery
888281|NCT02612818|coelioscopy
888282|NCT02612766|celiac disease
888283|NCT02612766|oat
888284|NCT02612766|gluten free diet
888285|NCT02612753|Aphasia
888286|NCT02612753|Speaking therapy
888287|NCT02612753|Language therapy
888288|NCT02612753|transcranial Direct current stimulation
888289|NCT02612740|Bio Oss
888290|NCT02612740|critical-size defect
888291|NCT02612740|bone grafting
888292|NCT02612740|cyst
888293|NCT02612740|CT bone analysis
888294|NCT02612740|alveolar bone
888295|NCT02612727|Hyperbilirubinemia, Neonatal
888296|NCT02612714|diabetes
888297|NCT02612714|hypercholesterolemia
888298|NCT02612714|sexual dysfunction
888299|NCT02612714|statin
888300|NCT02612714|testosterone
888301|NCT02612701|Myocardial perfusion
888302|NCT02612701|Electronic cigarettes
888303|NCT02612701|Cigarettes
888304|NCT02612701|Cigarette smoking
888305|NCT02612688|Advance Care Planning
888306|NCT02612688|Advance Directives
888307|NCT02612688|Alzheimer Disease
888308|NCT02612688|Dementia
888309|NCT02612688|Do-Not-Resuscitate Orders
888310|NCT02612688|Enteral Nutrition
888311|NCT02612688|Heart Failure
888312|NCT02612688|Hospices
888313|NCT02612688|Hospitalization
888314|NCT02612688|Instructional Films and Videos
888315|NCT02612688|Intubation
888316|NCT02612688|Nursing Homes
888317|NCT02612688|Parenteral Nutrition
888318|NCT02612688|Pragmatic Clinical Trials
888319|NCT02612688|Pulmonary Disease, Chronic Obstructive
888320|NCT02612688|Randomized Controlled Trials
888321|NCT02612688|Resuscitation Orders
888322|NCT02612688|Skilled Nursing Facilities
888323|NCT02612662|AZD4076
888324|NCT02612662|Healthy male subjects
888325|NCT02612662|Safety
888326|NCT02612662|Subcutaneous
888327|NCT02612662|Tolerability
888328|NCT02612649|Irritable bowel syndrome
888329|NCT02612649|YM060
888330|NCT02612649|Ramosetron
888331|NCT02612649|Survey
888332|NCT02612636|Delirium
888333|NCT02612636|Ear Plug
888334|NCT02612636|Eye Mask
888335|NCT02612636|Mechanical ventilation
888336|NCT02612636|Sleep
888337|NCT02612597|before and after bedrest
888338|NCT02612597|healthy untrained
888339|NCT02612597|before and after exercise training
888340|NCT02612558|Warm antibody autoimmune hemolytic anemia (AIHA)
888346|NCT02612493|obesity surgery
888347|NCT02612493|type I diabetes
888348|NCT02612493|weight loss
888349|NCT02612493|insulin dosage
888350|NCT02612493|postsurgery metabolic changes
888351|NCT02612480|endotoxin
888352|NCT02612480|LPS
888353|NCT02612480|ticagrelor
888354|NCT02612480|clopidogrel
888355|NCT02612480|acetylsalicyclic acid
888356|NCT02612480|placebo
888357|NCT02612467|start back tool
888358|NCT02612467|stratified care
888359|NCT02612467|targeted treatment
888360|NCT02612454|Eczema
888361|NCT02612441|stroke
888362|NCT02612389|COPD
888363|NCT02612389|Qigong
888364|NCT02612389|ANS
888365|NCT02612389|Meditative Movement
888366|NCT02612389|Flight Attendants
888367|NCT02612389|Secondhand Smoke
888368|NCT02612389|Nicotine
888369|NCT02612389|Blood Pressure
888370|NCT02612389|6 minute walk test
888371|NCT02612363|septic shock
888372|NCT02612363|sedation
888373|NCT02612363|microcirculation
888374|NCT02612350|ctDNA
888375|NCT02612350|high risk for developing cancer
888376|NCT02612350|Plasma
888377|NCT02612350|Relative Risk
888378|NCT02612350|Early Detection of Cancer
888379|NCT02612350|Cancer Screening Tests
888380|NCT02612350|Cancer Screening
888381|NCT02612337|Meniere's Disease
888382|NCT02612337|Vertigo
888383|NCT02612324|adolescents
888384|NCT02612324|teen pregnancy prevention
888385|NCT02612324|sexually transmitted infections prevention
888386|NCT02612324|place-based programs
888387|NCT02612324|health education
888388|NCT02612298|Essential Hypertension
888389|NCT02612298|Arotinolol
888390|NCT02612298|Morning Blood Pressure
888391|NCT02612233|Pain
888392|NCT02612220|liver resection
888393|NCT02612181|dexmedetomidine
888394|NCT02612181|microcirculation
888395|NCT02612181|septic shock
888396|NCT02612168|Diagnosis
888397|NCT02612168|skin imaging
888401|NCT02612129|NPC1
888402|NCT02612129|Niemann-Pick Type C
888403|NCT02612129|Niemann-Pick
888404|NCT02612129|arimoclomol
888405|NCT02612129|lysosomal storage disorder
888406|NCT02612129|lysosomal storage disease
888407|NCT02612129|NPC2
888408|NCT02612129|NP-C
888409|NCT02612103|Biochemical markers
888410|NCT02612090|Nutrition
888411|NCT02612090|Polyphenols
888412|NCT02612090|Berries
888413|NCT02612090|Lipid Panels
888414|NCT02612051|patients
888415|NCT02612051|FTIH
888416|NCT02612051|healthy volunteers
888417|NCT02612051|GSK3008348
888418|NCT02612051|[18F]-FBA-A20FMDV2
888419|NCT02612051|Idiopathic Pulmonary Fibrosis
888420|NCT02612051|PET
888421|NCT02612038|Obstructive sleep apnea
888422|NCT02612038|Expiratory flow limitation
888423|NCT02612012|breast cancer
888424|NCT02612012|positive sentinel lymph nodes
888425|NCT02612012|axillary radiotherapy
888426|NCT02611999|Physicians' ordering behavior with price information
888427|NCT02611986|Airway management
888428|NCT02611986|video laryngoscope
888429|NCT02611973|Essential Thrombocythemia
888430|NCT02611973|Aspirin
888431|NCT02611960|PD-1
888432|NCT02611960|PD1
888433|NCT02611960|PD-L1
888434|NCT02611960|PDL1
888435|NCT02611947|emphysema
888436|NCT02611947|airway remodelling
888437|NCT02611947|multidetector computed tomography
888438|NCT02611921|Ketamine
888439|NCT02611921|Social Impairment
888440|NCT02611921|Autism
888441|NCT02611921|Autistic Disorder
888442|NCT02611908|CLL
888443|NCT02611908|cancer
888444|NCT02611908|obinutuzumab
888445|NCT02611908|ibrutinib
888446|NCT02611908|SLL
888447|NCT02611895|Aviremic HIV-1 infected patients
888448|NCT02611895|HAART
888449|NCT02611895|Integrase inhibitor Raltegravir
888450|NCT02611895|Ongoing HIV infection
888451|NCT02611856|twin to twin,
888452|NCT02611856|transfusion syndrome
888453|NCT02611843|peer support
888454|NCT02611843|web-based treatment
888455|NCT02611843|veterans
888456|NCT02611843|PTSD
888457|NCT02611843|Substance Use Disorders
888458|NCT02611830|Drug therapy
888459|NCT02611817|Drug therapy
888460|NCT02611791|Treatment by Pulsed Radio Frequency, Collagen, Female
888461|NCT02611713|effectiveness
888462|NCT02611713|Caregiver Burden
888463|NCT02611713|motor and non-motor symptoms
888464|NCT02611713|Duodopa/Duopa
888465|NCT02611713|fluctuations
888466|NCT02611713|OFF time
888467|NCT02611713|carbidopa levodopa enteral suspension (CLES)
888468|NCT02611713|dyskinesia
888469|NCT02611713|Observational
888470|NCT02611713|tremor
888597|NCT02610803|recurrent stroke
888471|NCT02611713|levodopa-carbidopa intestinal gel (LCIG)
888472|NCT02611713|Quality of Life
888473|NCT02611713|Advanced Parkinson's Disease
888474|NCT02611713|Long-term
888475|NCT02611635|non-valvular Atrial Fibrillation
888476|NCT02611635|Patient treatment preference
888477|NCT02611635|NOAC
888478|NCT02611635|VKA
888479|NCT02611583|TENS
888480|NCT02611570|Lung cancer
888481|NCT02611570|Low dose computed tomography
888482|NCT02611570|Screening
888483|NCT02611570|Non-smoker
888484|NCT02611570|Gender issue
888485|NCT02611557|MRI
888486|NCT02611557|lymphedema
888487|NCT02611557|manual lymphatic drainage
888488|NCT02611544|Fear of Cancer Recurrence
888489|NCT02611544|Fear of Cancer Return
888490|NCT02611544|Breast Cancer Survivor
888491|NCT02611544|Breast Cancer Remission
888492|NCT02611518|Healthy
888493|NCT02611518|JNJ-54861911
888494|NCT02611518|Rosuvastatin
888495|NCT02611518|Metformin
888496|NCT02611505|Healthy
888497|NCT02611505|Esketamine
888498|NCT02611505|Hepatic Impairment
888499|NCT02611505|Pharmacokinetics
888500|NCT02611479|patient reported outcomes
888501|NCT02611466|Osteoarthritis
888502|NCT02611466|ASP7962
888503|NCT02611453|choledocholithiasis
888504|NCT02611453|ERCP
888505|NCT02611453|cholangiography
888506|NCT02611453|biliary stricture
888507|NCT02611453|bile ducts
888508|NCT02611453|carbon dioxide
888509|NCT02611440|ischemic stroke
888510|NCT02611440|medication adherence
888511|NCT02611440|cardiovascular disease prevention
888512|NCT02611427|spine
888513|NCT02611427|lumbar
888514|NCT02611427|postoperative
888515|NCT02611427|physical activity
888516|NCT02611414|functional dyspepsia
888517|NCT02611414|tDCS
888518|NCT02611401|multiple sclerosis
888519|NCT02611401|depression
888520|NCT02611401|mindfulness
888521|NCT02611336|Left Ventricular Hypertrophy
888522|NCT02611336|Diastolic Dysfunction
888523|NCT02611336|Myocardial Fibrosis
888524|NCT02611336|Acromegaly
888525|NCT02611297|Cryoprobes
888526|NCT02611297|Cryobiopsy
888527|NCT02611297|Transbronchial lung biopsy
888528|NCT02611284|Beractant
888529|NCT02611284|Feasibility Studies
888530|NCT02611284|Infant, Premature
888531|NCT02611284|Noninvasive Ventilation
888532|NCT02611258|Left Ventricular Hypertrophy
888533|NCT02611258|Diastolic Dysfunction
888534|NCT02611258|Myocardial Fibrosis
888535|NCT02611258|Cushing's Syndrome
888536|NCT02611245|Thoracic Duct
888537|NCT02611245|Sentinel lymph node biopsy
888538|NCT02611232|Diabetes Type 1
888539|NCT02611232|Diabetes, Insulin-Dependent
888540|NCT02611232|Liraglutide
888541|NCT02611232|Preclinical Type 1 Diabetes
888542|NCT02611232|GLP-1 Analogue
888543|NCT02611206|rTMS
888544|NCT02611167|mesenchymal stem cells
888545|NCT02611154|Healthy Volunteers
888546|NCT02611154|Sports Medicine
888547|NCT02611154|Men's Health
888548|NCT02611154|Athletes
888549|NCT02611154|Anti-Doping
888550|NCT02611141|Retromolar Intubation
888551|NCT02611115|Pulmonary Embolism
888552|NCT02611115|Multidetector Computed Tomography
888553|NCT02611115|Radiation Dosage
888554|NCT02611115|Contrast Media
888555|NCT02611115|Individualized Medicine
888556|NCT02611089|Muscle connective tissue
888557|NCT02611089|Small leucine-rich proteoglycans
888558|NCT02611089|Limb development
888559|NCT02611076|smoking cessation
888560|NCT02611076|self-help
888561|NCT02611076|Spanish language
888562|NCT02611063|allogeneic stem cell transplant
888563|NCT02611050|patient decision aid
888564|NCT02611050|multi-vessel coronary artery disease
888565|NCT02611037|MPM
888566|NCT02611037|Unresectable
888567|NCT02611037|Respiratory
888568|NCT02611037|Intrathoracic
888569|NCT02611037|Transarterial
888570|NCT02611037|Chemoperfusion
888571|NCT02611024|lurbinectedin
888572|NCT02611024|PM01183
888573|NCT02611024|tumors
888574|NCT02611024|cancer
888575|NCT02611024|Pharma Mar
888576|NCT02611011|Congo Red Dot Test
888577|NCT02610985|Imaging, Three-Dimensional
888578|NCT02610985|Hysterectomy
888579|NCT02610985|laparoscopic hysterectomy
888580|NCT02610972|Congo Red test GV-005
888581|NCT02610946|pediatric
888582|NCT02610946|adolescent
888583|NCT02610946|compliance
888584|NCT02610933|vascular calcification
888585|NCT02610933|hemodialysis
888586|NCT02610933|rivaroxaban
888587|NCT02610933|vitamin K2
888588|NCT02610894|postoperative symptom management
888589|NCT02610894|symptom management
888590|NCT02610894|mHealth application
888591|NCT02610868|Cerebral Palsy
888592|NCT02610868|ALS
888593|NCT02610868|Stroke
888594|NCT02610868|Neuroleptics
888595|NCT02610803|stroke
888596|NCT02610803|ischemic stroke
888598|NCT02610803|atrial fibrillation
888599|NCT02610803|premature atrial complexes
888600|NCT02610803|heart rhythm monitoring
888601|NCT02610803|cardiac telemetry
888602|NCT02610790|connected bracelets, footsteps
888604|NCT02610764|Circulating Tumor Cells
888605|NCT02610764|Response evaluation
888606|NCT02610751|Maternal Smoking
888607|NCT02610751|Female Fetal Testosterone
888608|NCT02610751|Anogenital Distance
888609|NCT02610751|Maternal Testosterone
888610|NCT02610751|Maternal Cotinine
888611|NCT02610712|ketamine
888612|NCT02610712|treatment-resistant
888613|NCT02610712|depression
888614|NCT02610712|spectroscopy
888615|NCT02610712|neuroinflammation
888616|NCT02610686|Plasmodium vivax
888617|NCT02610686|recurrence
888618|NCT02610686|drug resistance
888619|NCT02610634|Parkinson's disease
888620|NCT02610634|Older adults
888621|NCT02610634|Vision
888622|NCT02610634|Cognition
888623|NCT02610634|Visual cues
888624|NCT02610634|Eye-tracking
888625|NCT02610634|Gait
888626|NCT02610634|Saccades
888627|NCT02610634|Dual task
888628|NCT02610634|Visual sampling
888629|NCT02610621|Clinically node negative
888630|NCT02610621|T1 and T2 invasive breast cancer
888631|NCT02610595|Idiopathic Membranous Nephropathy
888632|NCT02610595|Jianpiyiqi Recipe
888633|NCT02610595|Huoxuejiedu Recipe
888634|NCT02610595|Effectiveness
888635|NCT02610595|Safety
888636|NCT02610582|CNGA3-linked
888637|NCT02610569|Colonic capsule
888638|NCT02610569|ulcerative colitis
888639|NCT02610569|mucosal healing
888640|NCT02610569|endoscopic score
888641|NCT02610556|NPC
888642|NCT02610556|concurrent chemotherapy
888643|NCT02610556|docetaxel
888644|NCT02610556|cisplatin
888646|NCT02610530|type 2 diabetes
888647|NCT02610530|metabolic surgery
888648|NCT02610530|medical treatment
888649|NCT02610517|Hazardous alcohol use
888650|NCT02610517|Computer based intervention (CBI)
888651|NCT02610517|Pharmacotherapy
888652|NCT02610504|degenerative arthritis
888653|NCT02610478|HAI Testing
888654|NCT02610478|Multi-Center Trial
888655|NCT02610478|Oropharyngeal Swab
888656|NCT02610478|Standard of Care
888657|NCT02610478|Viral Shedding
888658|NCT02610465|Computed Tomography
888659|NCT02610465|Image Reconstruction
888660|NCT02610465|Iterative Reconstruction
888661|NCT02610452|clown therapy
888662|NCT02610387|tDCS
888663|NCT02610387|stroke
888664|NCT02610387|Spasticity
888665|NCT02610374|Gut microbiota composition
888666|NCT02610348|Hepatitis B
888667|NCT02610348|Hexaxim®
888668|NCT02610348|Hexyon®
888669|NCT02610348|Hexacima®
888670|NCT02610348|Prevnar®
888671|NCT02610348|DTaP-IPV-HB-Hib hexavalent vaccine
888672|NCT02610335|lumbar spinal stenosis
888673|NCT02610309|family-based crisis intervention
888674|NCT02610309|adolescent suicide
888676|NCT02610270|Sport
888677|NCT02610270|fatty acid
888678|NCT02610270|omega 3
888679|NCT02610257|Parkinson's disease
888680|NCT02610257|Freezing of gait
888681|NCT02610257|Motor blocks
888682|NCT02610257|Somatosensory
888683|NCT02610257|Proprioception
888684|NCT02610257|Muscle vibration
888685|NCT02610257|Handwriting
888686|NCT02610231|Parkinson's disease
888687|NCT02610231|Moderate to Severe Parkinson's Disease
888688|NCT02610218|Cell free DNA
888689|NCT02610218|Circulating tumor cell
888690|NCT02610218|Therapeutic efficacy
888691|NCT02610205|Caring touch
888692|NCT02610205|Tactile massage
888693|NCT02610205|Healing touch
888694|NCT02610192|Autologous Protein Solution
888695|NCT02610192|Patellofemoral Osteoarthritis
888696|NCT02610192|Female
888697|NCT02610114|Assisted reproductive technology (ART)
888698|NCT02610114|zygotes
888699|NCT02610114|Z-score (Zygote Score)
888700|NCT02610114|Infertility
888701|NCT02610088|Diabetes
888702|NCT02610088|Atherosclerosis
888703|NCT02610088|Cardiovascular disease
888704|NCT02610088|Endothelial dysfunction
888705|NCT02610088|Vascular function
888706|NCT02610088|Dapagliflozin
888707|NCT02610088|Gliclazide
888711|NCT02610062|AML
888712|NCT02610062|Acute Myeloid Leukemia
888713|NCT02610049|veterans
888714|NCT02610049|PTSD
888715|NCT02610049|art therapy
888716|NCT02610049|african americans
888717|NCT02610036|diabetes
888718|NCT02610036|foot ulcer
888719|NCT02610010|NPC
888720|NCT02610010|concurrent chemotherapy
888721|NCT02610010|IMRT
888722|NCT02610010|stage II
888723|NCT02609997|Intraocular lens
888724|NCT02609984|immunotherapy
888725|NCT02609984|CMB305
888726|NCT02609984|LV305
888727|NCT02609984|GLA-SE
888728|NCT02609984|Atezolizumab
888729|NCT02609984|NY-ESO-1
888730|NCT02609971|Anterior cruciate ligament
888731|NCT02609971|Neuromuscular Performance and balance
888732|NCT02609945|Migraine attacks
888733|NCT02609932|Interferon-gamma
888734|NCT02609932|innate immunity
888735|NCT02609919|study of contrast reaction in children under 2 years of age
888736|NCT02609919|safety
888737|NCT02609906|proximal humerus
888738|NCT02609906|AO 11-A3 fracture
888739|NCT02609906|MultiLoc
888740|NCT02609906|Philos augmented
888741|NCT02609893|HCV
888742|NCT02609880|Psycho-Oncology
888743|NCT02609880|Psychoneuroimmunology
888744|NCT02609880|Cognitive Behavioral Therapy
888745|NCT02609880|Gynecologic Cancer
888746|NCT02609880|Insomnia
888747|NCT02609880|Pain
888748|NCT02609880|Distress
888749|NCT02609880|Cortisol
888750|NCT02609880|Cytokines
888751|NCT02609854|herniated disc
888752|NCT02609854|sustained acoustic medicine
888753|NCT02609854|ultrasound
888754|NCT02609854|CLBP
888755|NCT02609828|Metastatic cancer bone pain
888756|NCT02609828|Multiple myeloma
888757|NCT02609789|Systemic Lupus Erythematosus
888758|NCT02609789|JNJ-55920839
888759|NCT02609789|Healthy Volunteers
888760|NCT02609789|CNTO 6358
888761|NCT02609776|Non-Small-Cell Lung Cancer
888762|NCT02609776|JNJ-61186372
888763|NCT02609776|First-in-Human
888764|NCT02609776|Human Bispecific Epidermal Growth Factor Receptor (EGFR)
888765|NCT02609776|cMet Antibody
888766|NCT02609737|Radiolabeled Somatostatin Antagonists
888767|NCT02609737|68Ga-DOTA-JR11
888768|NCT02609737|177Lu-DOTA-JR11
888769|NCT02609737|Pet scan
888770|NCT02609737|CT scan
888771|NCT02609737|15-161
888772|NCT02609724|breast cancer
888773|NCT02609724|lymphedema
888774|NCT02609724|manual lymph drainage
888775|NCT02609724|near infrared fluorescence imaging
888776|NCT02609698|Stent
888777|NCT02609698|Polymer-free
888778|NCT02609698|Antiplatelet therapy
888779|NCT02609698|Clopidogrel
888780|NCT02609698|DES
888781|NCT02609698|DAPT
888782|NCT02609685|Thyroid cancer
888783|NCT02609685|Active surveillance
888784|NCT02609685|PTMC
888785|NCT02609672|Exercise
888786|NCT02609672|Resilience
888787|NCT02609659|Chronic Hepatitis C Infection
888788|NCT02609646|Anti-Infective Agents
888789|NCT02609646|Pharmacokinetics
888790|NCT02609646|Critically ill patients
888791|NCT02609594|human amniotic membrane
888792|NCT02609594|compression therapy
888793|NCT02609594|venous leg ulcer
888794|NCT02609581|Non Interventional Study
888795|NCT02609581|NIS
888796|NCT02609581|sublingual immunotherapy
888797|NCT02609581|allergen
888798|NCT02609581|Mites
888799|NCT02609568|Children
888800|NCT02609568|Head injury
888801|NCT02609568|Salivary biomarker
888802|NCT02609568|Trauma Brain Injury
888803|NCT02609555|TEM
888804|NCT02609555|Rectopexy
888805|NCT02609555|rectal prolapse
888806|NCT02609542|oral language
888807|NCT02609542|STOL
888808|NCT02609542|memory
888809|NCT02609542|eye tracking
888810|NCT02609529|Irritable Bowel Syndrome
888811|NCT02609529|Pediatrics
888812|NCT02609529|Nutrition
888813|NCT02609516|Multimorbidity
888814|NCT02609516|Health inequalities
888815|NCT02609516|Ageing
888816|NCT02609516|Mortality
888817|NCT02609477|Recreational stimulant users
888818|NCT02609477|Recreational Drug Users
888819|NCT02609451|quality of life
888820|NCT02609451|feasibility
888821|NCT02609451|safety
888822|NCT02609451|protective ileostomy closure
888823|NCT02609438|worksite
888824|NCT02609438|intervention
888825|NCT02609438|sitting
888826|NCT02609399|Influenza
888827|NCT02609399|Antiviral treatment
888828|NCT02609399|Emergency department
888829|NCT02609399|Influenza therapeutics
888830|NCT02609399|Rapid influenza testing
888831|NCT02609386|Head and Neck Neoplasms
888832|NCT02609386|Immunotherapy
888833|NCT02609386|Cancer
888834|NCT02609386|Oral Cavity
888835|NCT02609373|shiftwork
888836|NCT02609373|sleep hygiene
888837|NCT02609373|prevention
888838|NCT02609373|intervention
888839|NCT02609373|occupational
888840|NCT02609373|biological
888841|NCT02609373|breast cancer
888842|NCT02609373|lifestyle
888843|NCT02609360|Acute Respiratory Failure
888844|NCT02609360|ARDS
888845|NCT02609360|ECMO
888846|NCT02609360|Lung transplantation
888847|NCT02609360|Acid-Base Equilibrium
888848|NCT02609347|Manual Therapy
888849|NCT02609347|Ankle Fracture
888850|NCT02609347|Hindfoot Fracture
888851|NCT02609321|Paravertebral
888852|NCT02609321|Single injection
888853|NCT02609321|Breast surgery
888854|NCT02609321|Analgesia
888855|NCT02609308|ankle sprain
888856|NCT02609308|platelet-rich plasma
888857|NCT02609308|ankle injuries
888858|NCT02609295|α-linolenic acid
888859|NCT02609295|perilla oil
888860|NCT02609295|aPTT
888861|NCT02609295|Collagen-epinephrine closure time
888862|NCT02609295|Lp-PLA2
888863|NCT02609282|Sedentary behaviour
888864|NCT02609282|sitting
888865|NCT02609282|workplace
888866|NCT02609282|prompts
888867|NCT02609256|Intracranial hypertension
888868|NCT02609256|cerebral herniation
888869|NCT02609256|Stereotactic infarct tissue aspiration
888870|NCT02609256|fatality
888871|NCT02609256|disability
888872|NCT02609243|prediabetes
888873|NCT02609243|diabetes mellitus type 2
888874|NCT02609243|obesity
888875|NCT02609243|NAFLD
888876|NCT02609243|dyslipoproteinemia
888877|NCT02609217|elective
888878|NCT02609217|cesarean
888879|NCT02609178|artificial crown
888880|NCT02609178|biomorphic
888881|NCT02609178|functional generated path
888882|NCT02609178|muscle-action theory
888883|NCT02609178|anatomic theory
888884|NCT02609126|osteoarthritis
888885|NCT02609126|knee
888886|NCT02609113|Carpal Tunnel Syndrome
888887|NCT02609074|bone substitute
888888|NCT02609074|CPC
888889|NCT02609074|rhBMP-2
888890|NCT02609048|PBC
888891|NCT02609022|Myasthenia Gravis
888892|NCT02609022|CV-MG01 therapeutic vaccine
888893|NCT02609022|Acetylcholine receptor mimetic peptides
888894|NCT02609022|Safety
888895|NCT02609022|Immunogenic response
888896|NCT02609022|First-in-Human
888897|NCT02609022|Proof-of-Concept
888898|NCT02609022|Myasterix
888899|NCT02609009|Back Pain
888900|NCT02609009|Adolescent Idiopathic Scoliosis
888901|NCT02609009|Spinal Manipulation
888902|NCT02608983|Seaweed
888903|NCT02608983|Hydrocolloid
888904|NCT02608983|Functional Food
888905|NCT02608983|Dietary Fibre
888906|NCT02608983|Prebiotic
888907|NCT02608983|Low molecular weight polysaccharides
888908|NCT02608983|Alginate
888909|NCT02608983|Agar
888910|NCT02608983|HYFFI
888911|NCT02608983|Low molecular weight seaweed derived hydrocolloids as functional food ingredients
888912|NCT02608983|subjects
888913|NCT02608931|delta-9-tetrahydrocannabinol (THC)
888914|NCT02608892|Breastfeeding
888915|NCT02608892|Skin to skin care
888916|NCT02608892|Sucrose
888917|NCT02608892|Newborn screening
888918|NCT02608892|Blood test
888919|NCT02608892|Neonate
888920|NCT02608892|Infant
888921|NCT02608892|Knowledge translation
888922|NCT02608879|proinflammatory cytokines
888923|NCT02608879|microbiome
888924|NCT02608879|radiation therapy
888925|NCT02608866|stereotactic ablative radiotherapy
888926|NCT02608866|spine metastasis
888927|NCT02608840|slow-wave sleep
888928|NCT02608840|cognition
888929|NCT02608840|auditory stimulation
888930|NCT02608827|Hypertension; slow breathing; sympathetic nerve activity
888931|NCT02608788|postoperative sore throat
888932|NCT02608788|American Society of Anesthesiologists status
888933|NCT02608788|general anesthesia
888934|NCT02608788|post-anesthesia care unit(PACU)
888935|NCT02608775|ANI
888936|NCT02608775|SPI
888937|NCT02608775|Autonomic balance
888938|NCT02608775|Nociception measurement
888939|NCT02608762|Pediatric brain tumors
888940|NCT02608762|Radiation therapy
888941|NCT02608762|Neurobehavioral functions
888942|NCT02608762|Proton radiotherapy
888943|NCT02608749|Osteoporosis
888944|NCT02608749|Fall
888945|NCT02608749|Fracture
888946|NCT02608749|Sacopenia
888947|NCT02608749|Body Composition
888948|NCT02608736|head and neck squamous cell carcinoma
888949|NCT02608736|histone deacetylases
888950|NCT02608736|valproic acid
888951|NCT02608736|acetylation
888952|NCT02608736|chemoprevention
888953|NCT02608736|DNA methyltransferase
888954|NCT02608736|methylation
888955|NCT02608723|shock wave
888956|NCT02608723|plantar fasciitis
888957|NCT02608723|placebo effect
888958|NCT02608723|nocebo effect
888959|NCT02608684|immunotherapy, platinum-resistant ovarian cancer, immune checkpoint inhibitors
888960|NCT02608671|Episiotomy
888961|NCT02608671|continuous suture
888962|NCT02608671|Skin adhesive tape
888963|NCT02608658|Cirrhosis
888964|NCT02608658|Ascites
888965|NCT02608658|SBP
888966|NCT02608632|Renal denervation
888967|NCT02608632|Ablation
888968|NCT02608619|18F-fluorocholine
888969|NCT02608619|Pet imaging
888970|NCT02608619|Biopsy
888971|NCT02608619|15-268
888972|NCT02608580|pediatric hospital care
888973|NCT02608580|adult hospital care
888974|NCT02608580|sickle cell disease
888975|NCT02608554|Polycystic ovary sybdrome
888976|NCT02608554|Taichi
888977|NCT02608541|Multiple Rib Fractures, Frail Chest
888978|NCT02608476|acne
888979|NCT02608463|neuropathic pain
888980|NCT02608463|pregnancy
888981|NCT02608450|acne
888982|NCT02608437|melanoma
888983|NCT02608437|ipilimumab
888984|NCT02608437|SGI-110
888985|NCT02608424|Foot mechanical stimulation
888986|NCT02608424|Autonomic nervous system
888987|NCT02608424|Inflammation
888988|NCT02608424|Parkinson's disease
888989|NCT02608424|Spectral analysis
888990|NCT02608424|Heart rate variability
888991|NCT02608424|Blood pressure variability
888992|NCT02608398|obesity
888993|NCT02608398|weight-loss
888994|NCT02608398|metabonomics
888995|NCT02608398|gut microbiome
888996|NCT02608372|Seaweed
888997|NCT02608372|Insulin
888998|NCT02608372|Glucose tolerance
888999|NCT02608372|C-peptide
889000|NCT02608372|Appetide
889001|NCT02608372|Metabolomics
889002|NCT02608359|Post-Marketing Surveillance
889003|NCT02608359|Abiraterone Acetate
889004|NCT02608359|Zytiga
889005|NCT02608346|Circulating tumor DNA
889006|NCT02608346|BRCA1 mutation
889007|NCT02608346|Circulating tumor cells
889008|NCT02608333|Early intervention
889009|NCT02608333|ESDM
889010|NCT02608333|behavioral and developmental intervention
889011|NCT02608320|Healthy
889012|NCT02608320|JNJ-35685-AAA-G016
889013|NCT02608320|JNJ-35685-AAA-G021
889014|NCT02608320|DURAGESIC
889015|NCT02608320|Fentanyl
889016|NCT02608307|Treatment Decision-Making
889017|NCT02608307|Adolescents and Young Adult Oncology
889018|NCT02608294|stroke
889019|NCT02608294|gait
889020|NCT02608294|balance
889021|NCT02608281|Spectral Mammography
889022|NCT02608281|Dual energy
889023|NCT02608281|Contrast enhanced
889036|NCT02608164|Healthy adults
889037|NCT02608151|neurodevelopement
889038|NCT02608151|Very preterm infant
889039|NCT02608138|iodine
889040|NCT02608138|urine
889041|NCT02608138|children
889042|NCT02608138|schools
889043|NCT02608138|cognitive performance
889044|NCT02608138|salt fortification
889045|NCT02608125|FGFR
889046|NCT02608099|Atrial fibrillation
889047|NCT02608099|Non-valvular atrial fibrillation
889048|NCT02608099|Catheter ablation
889049|NCT02608099|Apixaban
889050|NCT02608099|Warfarin
889051|NCT02608099|Harvard Clinical Research Institute
889052|NCT02608086|PTSD
889053|NCT02608086|Trauma
889054|NCT02608086|Emergency
889055|NCT02608086|RCT
889056|NCT02608086|Psychological First Aid
889057|NCT02608021|Alzheimer's Disease
889058|NCT02608021|MRI
889059|NCT02608008|3D-Ultrasound
889060|NCT02608008|Live X-rays
889061|NCT02608008|EchoNavigator System
889062|NCT02607982|Esophageal cancer
889063|NCT02607982|Concurrent chemoradiotherapy
889064|NCT02607982|Oxaliplatin
889065|NCT02607982|Paclitaxel
889066|NCT02607982|Survival
889067|NCT02607982|Toxicity
889068|NCT02607969|Deformational Plagiocephaly,Treatment,Compliance
889069|NCT02607956|HIV
889070|NCT02607943|acute stroke
889071|NCT02607943|hyperglycemia
889072|NCT02607943|regular insulin
889073|NCT02607943|long-acting insulin
889074|NCT02607930|HIV
889075|NCT02607917|Cardiovascular Disease
889076|NCT02607904|Cannabidiol
889077|NCT02607904|GWP42003-P
889078|NCT02607904|Epidiolex
889079|NCT02607904|Stiripentol
889080|NCT02607904|Valproate
889081|NCT02607891|Cannabidiol
889082|NCT02607891|GWP42003-P
889083|NCT02607891|Epidiolex
889084|NCT02607891|Stiripentol
889085|NCT02607891|Valproate
889086|NCT02607878|Cardiac arrest
889087|NCT02607878|Coma
889088|NCT02607878|Prognosis
889089|NCT02607878|Automated pupillometry
889090|NCT02607878|EEG
889091|NCT02607878|Evoked potentials
889092|NCT02607878|Targeted Temperature Management (TTM)
889095|NCT02607839|lipid handling by the gut and liver
889096|NCT02607813|LXH254, CRAF, MAPK, solid tumor, PDR001
889097|NCT02607800|Chronic Hepatitis C Infection
889098|NCT02607787|Exercise Rehabilitation
889099|NCT02607774|Plaque psoriasis
889100|NCT02607774|disease-drug-drug-interaction
889101|NCT02607774|midazolam
889102|NCT02607774|secukinumab
889103|NCT02607761|infertility
889104|NCT02607761|fertility awareness
889105|NCT02607761|health interventions
889106|NCT02607761|young adults
889107|NCT02607748|18F-NaF PET
889108|NCT02607748|18F-sodium fluoride PET
889109|NCT02607748|Coronary CTA
889110|NCT02607735|Chronic Hepatitis C Infection
889111|NCT02607644|Intubation
889112|NCT02607644|Ventilation
889113|NCT02607644|Cardiac arrest
889114|NCT02607644|prehospital
889115|NCT02607644|Laryngeal Masks
889116|NCT02607644|Laryngeal Tube
889117|NCT02607644|airway management
889118|NCT02607631|Thymic epithelial tumors
889119|NCT02607631|Pembrolizumab
889120|NCT02607605|lung cancer
889121|NCT02607605|leptomeningeal metastases
889122|NCT02607605|cell-free DNA
889123|NCT02607592|Non-Small-Cell Lung cancer
889124|NCT02607592|overall toxicity value
889125|NCT02607566|Diabetes
889126|NCT02607566|Yoga
889127|NCT02607566|Walking
889128|NCT02607566|Stress
889129|NCT02607540|Chemoradiotherapy
889130|NCT02607540|Esophageal Squamous Cancer
889131|NCT02607540|Cisplatin-5-fluorouracil
889132|NCT02607501|coil embolization
889133|NCT02607501|bifurcation
889134|NCT02607488|Obese patients
889135|NCT02607488|Undergoing bariatric surgery
889139|NCT02607449|MDR TB
889140|NCT02607449|Tuberculosis
889141|NCT02607410|Type 2 diabetes
889142|NCT02607410|sitagliptin
889143|NCT02607410|NPH insulin
889144|NCT02607410|GLP-1
889145|NCT02607371|Patient treatment preference
889146|NCT02607371|Non-valvular Atrial Fibrillation
889147|NCT02607371|NOAC
889148|NCT02607371|VKA
889149|NCT02607358|Clopidogrel
889150|NCT02607358|acetacylic acid
889151|NCT02607358|antiplatelet therapy
889152|NCT02607358|HOTPR
889153|NCT02607358|VerifyNow
889154|NCT02607332|single-center
889155|NCT02607332|prospective
889156|NCT02607332|single-arm
889157|NCT02607332|open-label
889158|NCT02607332|phase II
889159|NCT02607319|Recurrent Implantation Failure
889160|NCT02607319|Implantation
889161|NCT02607319|low molecular weight heparin
889162|NCT02607319|In vitro Fertilization
889163|NCT02607319|Assisted Reproductive Technology
889164|NCT02607319|Pregnancy
889165|NCT02607293|Polycystic Ovary Syndrome
889166|NCT02607293|Gonadotropin releasing hormone agonist (GnRH-a)
889167|NCT02607293|Gonal-f
889168|NCT02607293|Assisted Reproductive Technology
889169|NCT02607280|Diabetic peripheral neuropathic pain
889170|NCT02607280|post-herpetic neuralgia
889171|NCT02607280|renal impairment
889172|NCT02607267|EOSS
889173|NCT02607267|Metabolic Surgery
889174|NCT02607267|postoperative outcome
889175|NCT02607267|30 - day mortality
889176|NCT02607241|drug-coated balloon
889177|NCT02607241|bioresorbable scaffold
889178|NCT02607241|fractional flow reserve
889179|NCT02607241|optical coherence tomography
889180|NCT02607150|Spinal Fusion
889181|NCT02607150|Cerebral Oxygenation
889182|NCT02607150|Blood Transfusion
889183|NCT02607124|DIPG
889184|NCT02607111|Dalteparin
889185|NCT02607111|Dosage
889186|NCT02607111|Home Hemodialysis
889187|NCT02607072|APREMEC, aspirin, colorectal cancer, adjuvant therapy, recurrence, metastasis, survival
889188|NCT02607046|rehabilitation
889189|NCT02607046|exercise training
889190|NCT02607033|Exercise
889191|NCT02607033|Weight Loss
889192|NCT02607033|Mobility Limitation
889193|NCT02607007|Dairy
889194|NCT02607007|Post-prandial Glycemia
889195|NCT02607007|Satiety
889196|NCT02607007|Food Intake
889197|NCT02607007|Insulin
889198|NCT02607007|Milk
889199|NCT02607007|Greek yogurt
889200|NCT02607007|Cheese
889201|NCT02607007|Soy beverage
889202|NCT02606994|oral mucositis
889203|NCT02606994|chemotherapy
889204|NCT02606994|toothpaste
889205|NCT02606981|Water treatment
889206|NCT02606981|Child growth
889207|NCT02606981|Enteric infection
889208|NCT02606955|Bioimpedance
889209|NCT02606955|Dry weight
889210|NCT02606955|Hemodialysis
889211|NCT02606955|Resistance
889212|NCT02606942|chondromalacia patellae (CMP)
889213|NCT02606942|patella
889214|NCT02606916|Once-daily Simultaneous Modulated Accelerated Radiotherapy
889215|NCT02606916|S-1
889216|NCT02606916|DDP
889217|NCT02606916|elderly patients
889218|NCT02606890|Magnetic Resonance Imaging
889219|NCT02606890|Stroke Lesion Pattern
889220|NCT02606890|Atrial Fibrillation
889221|NCT02606890|Stroke
889222|NCT02606851|Proton Pump Inhibitor, GERD, GERD Q
889223|NCT02606799|Esophagectomy Inflammation Hemoperfusion Cytokines
889224|NCT02606786|stabilization exercises
889225|NCT02606773|vitamin C supplementation
889226|NCT02606760|Nail psoriasis
889227|NCT02606747|DPN
889228|NCT02606747|fall
889229|NCT02606747|fMRI
889230|NCT02606747|balance
889231|NCT02606721|Food Hypersensitivity
889232|NCT02606721|Oral Food Challenge
889233|NCT02606721|Skin Prick Test
889234|NCT02606721|Food Biomarkers
889235|NCT02606695|Spine Surgery Patients
889236|NCT02606682|Phase 1
889237|NCT02606682|Safety
889238|NCT02606682|Tolerability
889239|NCT02606682|Pharmacokinetics
889240|NCT02606682|Parkinson's Disease
889241|NCT02606630|Relapsing multiple sclerosis
889242|NCT02606617|Mosapride
889243|NCT02606617|blood glucose
889244|NCT02606617|serum lipid
889245|NCT02606604|Functional Electrical Stimulation
889246|NCT02606604|Cycling
889247|NCT02606591|Electroencephalograph
889248|NCT02606591|EEG
889249|NCT02606591|Hair sample
889250|NCT02606591|Cognitive tests
889251|NCT02606591|Cortisol analysis
889252|NCT02606591|Brain activity
889253|NCT02606591|Stress hormones
889254|NCT02606552|drug eluting stent
889255|NCT02606552|atrial appendage closure
889256|NCT02606539|gestaional trophoblastic neoplasm
889257|NCT02606539|hystrectomy
889258|NCT02606539|chemotherapy
889259|NCT02606539|methotrxate
889260|NCT02606513|Computed Tomography Urography
889261|NCT02606513|Magnetic Resonance Urography
889262|NCT02606487|CF
889263|NCT02606487|Exacerbation
889264|NCT02606487|Hyerpolarized xenon MRI
889265|NCT02606487|Pediatrics
889266|NCT02606487|Lung Clearance Index
889267|NCT02606461|Advanced unresectable dedifferentiated liposarcoma
889268|NCT02606461|selinexor
889269|NCT02606461|KCP-330
889270|NCT02606461|Karyopharm
889271|NCT02606461|Phase 2 / 3
889272|NCT02606461|dedifferentiated liposarcoma
889273|NCT02606461|liposarcoma
889274|NCT02606448|pain control
889275|NCT02606448|patient satisfaction
889276|NCT02606448|liposomal bupivacaine
889277|NCT02606448|Anterior cruciate ligament reconstruction
889278|NCT02606422|transcranial direct current stimulation (tDCS)
889279|NCT02606422|neurodegeneration
889280|NCT02606422|language therapy
889281|NCT02606422|Primary Progressive Aphasia (PPA)
889282|NCT02606370|Unstable Shoes;Trunk muscles;Lumbar lordosis;Low Back Pain
889283|NCT02606318|Occupational Therapy
889284|NCT02606318|Quality of Life
889285|NCT02606305|Epithelial ovarian cancer
889286|NCT02606305|Fallopian tube cancer
889287|NCT02606305|Primary peritoneal cancer
889288|NCT02606305|Endometrial cancer
889289|NCT02606305|IMGN853
889290|NCT02606305|ADC
889291|NCT02606305|Antibody drug conjugate
889292|NCT02606305|ImmunoGen
889293|NCT02606305|Antibody
889294|NCT02606305|Phase 1
889295|NCT02606305|Folate receptor alpha
889296|NCT02606253|loop diuretics
889297|NCT02606253|thiazide diuretics
889298|NCT02606253|vasopressin antagonists
889299|NCT02606253|diuretic resistance
889300|NCT02606253|heart failure
889301|NCT02606227|Pregnant smokers
889302|NCT02606227|smoking cessation
889303|NCT02606227|financial incentives
889304|NCT02606227|control group
889305|NCT02606227|randomized study
889306|NCT02606214|Tuberculosis
889307|NCT02606214|TBA-354
889308|NCT02606214|Pulmonary Tuberculosis
889309|NCT02606214|TB
889316|NCT02606188|Modified High-flow nasal cannula
889317|NCT02606188|Bronchoscopy
889318|NCT02606188|Oxygen therapy
889319|NCT02606175|health literacy
889320|NCT02606175|patient medication knowledge
889321|NCT02606175|kidney transplantation
889322|NCT02606175|medication adherence
889323|NCT02606175|kidney transplant
889324|NCT02606175|renal transplantation
889325|NCT02606149|Lung cancer
889326|NCT02606149|chemotherapy outcome
889327|NCT02606149|ethics
889328|NCT02606149|information
889329|NCT02606136|Duchenne
889330|NCT02606136|muscular
889331|NCT02606136|dystrophy
889332|NCT02606136|DMD
889333|NCT02606136|non-ambulatory
889334|NCT02606123|Prostate Cancer
889335|NCT02606123|Metastatic castration-resistant prostate cancer
889336|NCT02606110|ReBuilder
889337|NCT02606110|breast cancer
889338|NCT02606110|chemotherapy induced
889339|NCT02606084|Renal Impairment
889340|NCT02606084|Healthy
889341|NCT02606084|Esketamine
889342|NCT02606071|cardiac resynchronization therapy
889343|NCT02606071|multipoint left ventricular pacing
889344|NCT02606045|menorrhagia
889345|NCT02606045|VWD
889346|NCT02606032|Fecal Microbiota Transplant
889347|NCT02606032|Antibiotics
889348|NCT02606019|Pentraxin 3
889349|NCT02606019|Vascular Endothelial Growth Factor
889350|NCT02606019|dengue
889351|NCT02606006|Physical Therapy Modalities
889352|NCT02606006|Motivation
889353|NCT02606006|Patient Participation
889354|NCT02606006|Animal Assisted Therapy
889355|NCT02605993|complement inhibitor
889356|NCT02605967|PDR001,
889357|NCT02605967|nasopharyngeal cancer,
889358|NCT02605967|moderately differentiated/undifferentiated,
889359|NCT02605967|locally advanced,
889360|NCT02605967|recurrent or metastatic NPC,
889361|NCT02605967|after first- line platinum-based therapy
889362|NCT02605954|HIV 1 Infection
889363|NCT02605954|HIV
889364|NCT02605954|Virologically-Suppressed
889365|NCT02605954|Antiretroviral agents
889366|NCT02605941|DNA methylation
889367|NCT02605941|Cervical cancer
889368|NCT02605928|Arthritis
889369|NCT02605928|Bioimpedance
889370|NCT02605928|Glucocorticoid
889371|NCT02605928|Intra-articular injection
889372|NCT02605928|Needle Guidance
889373|NCT02605902|Chronic tic disorders
889374|NCT02605902|Tourette syndrome
889375|NCT02605876|anterior cruciate ligament reconstruction
889376|NCT02605863|Enzalutamide
889377|NCT02605863|Non-Muscle Invasive Bladder Cancer
889378|NCT02605863|Androgen Deprivation Therapy
889379|NCT02605850|heart health
889380|NCT02605811|limited small cell lung cancer
889381|NCT02605811|brain metastases
889529|NCT02604953|SD-tVEP
889382|NCT02605811|prophylactic cranial radiotherapy
889383|NCT02605811|temozolomide
889384|NCT02605785|PSP
889388|NCT02605707|Endothelial Progenitor Cells
889389|NCT02605707|Transplantation
889390|NCT02605707|Stroke
889391|NCT02605681|midkine
889392|NCT02605681|endothelial injury
889393|NCT02605681|sepsis
889394|NCT02605668|Anxiety Disorders
889395|NCT02605668|Extinction Learning
889396|NCT02605668|Optimized Extinction
889397|NCT02605668|Behavioral Therapy
889398|NCT02605668|Massed Confrontation
889399|NCT02605668|Social Anxiety Disorder
889400|NCT02605668|Specific Phobia
889401|NCT02605668|Panic Disorder
889402|NCT02605668|Agoraphobia
889403|NCT02605655|obesity
889404|NCT02605655|hyperlipidemia
889405|NCT02605655|hyperglycemia
889406|NCT02605642|Inflectra
889407|NCT02605642|Infliximab
889408|NCT02605642|Observational
889409|NCT02605642|Remicade
889410|NCT02605603|Gaucher Type 1, Gaucher Type 2, Gaucher Type 3
889411|NCT02605577|late preterm infants
889412|NCT02605577|nutrition
889413|NCT02605577|systemic management
889414|NCT02605525|IgAN
889415|NCT02605512|Radiotherapy
889416|NCT02605512|Echocardiography
889417|NCT02605512|Strain strain rate
889418|NCT02605512|Coronary computed tomography angiography
889419|NCT02605512|Segments of coronary arteries
889420|NCT02605512|Subclinical functional and anatomical cardiac lesions
889421|NCT02605512|Biomarkers
889422|NCT02605512|Heart dosimetry
889427|NCT02605473|Melanoma
889428|NCT02605473|Malignant melanoma
889429|NCT02605473|Unresectable
889430|NCT02605473|Decitabine
889431|NCT02605473|PEG Interferon Alpha-2b
889432|NCT02605473|PEG Intron
889433|NCT02605473|5-Aza-Deoxycytidine
889434|NCT02605473|Dacogen
889435|NCT02605460|Bone Marrow Transplantation
889436|NCT02605460|Conditioning Regimen
889437|NCT02605434|Parkinson's Disease
889438|NCT02605434|Fluctuating Parkinson's Disease
889439|NCT02605434|Advanced Parkinson's Disease
889440|NCT02605434|Carbidopa
889441|NCT02605434|Levodopa
889442|NCT02605434|Accordion
889443|NCT02605434|Accordance
889444|NCT02605421|High-risk neuroblastoma
889445|NCT02605421|Neuroblastoma
889446|NCT02605421|Myeloablative chemotherapy
889447|NCT02605421|Myeloablative consolidation chemotherapy
889448|NCT02605421|Autologous peripheral blood stem cell rescue
889449|NCT02605421|PBSC
889450|NCT02605421|Autologous stem cell rescue
889451|NCT02605395|Bioequivalence
889452|NCT02605395|Fed condition
889453|NCT02605395|PARIET 20 mg
889454|NCT02605395|IDIAZOLE 20mg
889455|NCT02605395|Rabeprazole
889456|NCT02605382|Dental Implantation
889457|NCT02605382|Chlorhexidine gluconate
889458|NCT02605356|Radium-223 dichloride
889459|NCT02605356|bortezomib
889460|NCT02605356|dexamethasone
889461|NCT02605356|early relapsed multiple myeloma
889462|NCT02605356|combination therapy multiple myeloma
889463|NCT02605343|PGx
889464|NCT02605343|pharmacogenetic testing
889465|NCT02605343|Pain Management
889466|NCT02605343|AltheaDx
889467|NCT02605343|Post-Operative Pain Management
889468|NCT02605317|Emergency Physicians
889469|NCT02605317|Consulting Physicians
889470|NCT02605317|WhatsApp
889471|NCT02605278|Primary Health Care, Patient Education, Care Managament
889472|NCT02605265|Neoadjuvant Chemoradiation
889473|NCT02605265|Irinotecan
889474|NCT02605265|UGT1A1
889475|NCT02605252|Chronic hepatitis B
889476|NCT02605252|Peginterferon alfa-2b
889477|NCT02605252|Nucleotide analogue
889478|NCT02605200|Diabetes
889479|NCT02605200|Endocrinology
889480|NCT02605200|Pediatrics
889481|NCT02605187|cesarean
889482|NCT02605187|postoperative pain
889483|NCT02605187|patient choice
889484|NCT02605161|Blood brain barrier
889485|NCT02605161|movement disorder
889486|NCT02605161|deep brain stimulation
889487|NCT02605161|essential tremor
889488|NCT02605161|cervical dystonia
889489|NCT02605161|magnetic resonance imaging
889490|NCT02605161|neostriatum
889491|NCT02605148|Islet autoimmunity
889492|NCT02605148|gluten free diet
889493|NCT02605148|prediabetes
889494|NCT02605148|prevention
889495|NCT02605148|type 1 diabetes
889496|NCT02605148|glucose tolerance test
889497|NCT02605122|pneumonia
889498|NCT02605122|macrolide
889499|NCT02605122|pediatric
889500|NCT02605109|MERS-CoV
889501|NCT02605109|Infection control
889502|NCT02605109|Case-control studies
889503|NCT02605096|suspected scaphoid fracture
889521|NCT02605005|interscalene block, general anesthesia, shoulder arthroscopy, cerebral oxygen saturation, beach chair position
889522|NCT02604992|Comparative Bioavailability
889523|NCT02604966|P. falciparum
889524|NCT02604966|resistance to artemisinin
889525|NCT02604966|Central Vietnam
889526|NCT02604953|glaucoma
889527|NCT02604953|VEP
889528|NCT02604953|PERG
889530|NCT02604953|ss-PERG
889531|NCT02604940|Postoperative narcotic requirements
889532|NCT02604940|Dexmedetomidine
889533|NCT02604940|Bariatric Surgery
889534|NCT02604901|medication adherence
889535|NCT02604901|community pharmacies
889536|NCT02604901|screening and brief intervention
889537|NCT02604888|Baldness
889538|NCT02604888|Alopecia Areata
889539|NCT02604888|Alopecia
889540|NCT02604888|Hair loss
889541|NCT02604784|Pressurized Intra Peritoneal Air-flow Chemotherapy (PIPAC)
889542|NCT02604784|Chemotherapy
889543|NCT02604784|Peritoneal Carcinomatosis
889544|NCT02604758|Alcoholics [M01.066]
889545|NCT02604745|degenerative mitral regurgitation
889546|NCT02604667|Biomarkers
889547|NCT02604667|Mechanisms
889548|NCT02604667|Transcranial Doppler
889549|NCT02604641|skin rejuvenation
889550|NCT02604641|anti-ageing effects
889551|NCT02604641|minimal erythema dose
889552|NCT02604641|dermis structure
889553|NCT02604641|physiological skin condition
889554|NCT02604641|wrinkling
889555|NCT02604641|dry skin
889556|NCT02604628|Pneumonia
889557|NCT02604628|Antibiotic Stewardship
889558|NCT02604628|Stepped wedge
889559|NCT02604628|Antibiotic
889560|NCT02604615|Chemoradiotherapy
889561|NCT02604615|Esophageal Squamous Cancer
889562|NCT02604615|Capecitabine and oxaliplatin
889563|NCT02604615|Chinese
889564|NCT02604615|Randomized Controlled Trials
889565|NCT02604602|PPH
889566|NCT02604589|Catheters, Indwelling
889567|NCT02604589|Infusion Pumps
889568|NCT02604589|Anesthesia, Local
889569|NCT02604589|Analgesia, Patient-Controlled
889570|NCT02604589|Bupivacaine
889571|NCT02604576|functional dyspepsia
889572|NCT02604524|Type 1 Diabetes Mellitus (T1DM)
889573|NCT02604524|Artificial Pancreas (AP)
889574|NCT02604524|Sensor-Augmented Pump (SAP) Therapy
889575|NCT02604524|Closed Loop Control
889576|NCT02604524|Insulin Pump
889577|NCT02604524|Continuous Glucose Monitor (CGM)
889578|NCT02604511|Waldenstrom's Macroglobulinemia
889579|NCT02604485|Hypoglycemia
889580|NCT02604485|Congenital Hyperinsulinism
889581|NCT02604472|Nasopharyngeal carcinoma
889582|NCT02604472|induction chemotherapy
889583|NCT02604472|concurrent chemoradiotherapy
889584|NCT02604446|Arthroplasty, Replacement, Knee
889585|NCT02604446|Analgesics
889586|NCT02604446|Administration and dosage
889587|NCT02604446|Knee
889588|NCT02604446|Postoperational care
889589|NCT02604446|Pain management
889590|NCT02604433|ACE-536
889591|NCT02604433|Safety
889592|NCT02604433|Efficacy
889593|NCT02604433|Placebo
889594|NCT02604433|Red Blood Cell Transfusions
889595|NCT02604433|Beta -Thalassemia
889596|NCT02604394|Rheolytic Thrombectomy
889597|NCT02604394|Percutaneous Coronary Intervention
889598|NCT02604394|Angioplasty
889599|NCT02604394|Cardiac Magnetic Resonance Imaging
889600|NCT02604394|Myocardial Salvage Index
889601|NCT02604394|STEMI, ST elevation Myocardial Infarction
889602|NCT02604394|Corrected TIMI Frame Count, cTFC
889603|NCT02604394|Index of microcirculatory resistance, thermodilution, IMR
889604|NCT02604381|Osteoarthritis
889605|NCT02604381|Knee
889606|NCT02604381|Glucosamine Sulfate
889607|NCT02604381|Ginkgo Biloba
889608|NCT02604381|WOMAC
889609|NCT02604381|Joint Health Wellness
889610|NCT02604381|Interleukin-1-beta
889611|NCT02604368|hemoglobin SS
889612|NCT02604368|hemoglobin SC
889613|NCT02604368|hemoglobin S/β°-thalassemia
889614|NCT02604329|low level laser therapy
889615|NCT02604329|oral mucositis
889616|NCT02604329|child
889617|NCT02604316|Overweight and Obesity
889618|NCT02604316|Appetite
889619|NCT02604316|Gut hormones and obesity
889620|NCT02604316|Arabinoxylan, Beta-Glucan
889621|NCT02604316|SmartPill
889622|NCT02604303|Abdominal Aortic Aneurysm
889623|NCT02604303|RhoA
889624|NCT02604303|Biomarker
889625|NCT02604290|Kinesio taping
889626|NCT02604290|Neuromuscular taping
889627|NCT02604290|Targeted treatment
889628|NCT02604290|Chronic low back pain
889629|NCT02604290|Randomised controlled trial
889630|NCT02604277|Psychology
889631|NCT02604238|Pulmonary Embolism at intermediate risk
889632|NCT02604225|Anaethesiology
889633|NCT02604186|Spasticity
889634|NCT02604186|Botulinum Toxin
889635|NCT02604186|Hereditary Spastic Paraplegia
889636|NCT02604134|silver nitrate
889637|NCT02604134|children
889638|NCT02604134|dental caries
889639|NCT02604134|medical management
889640|NCT02604134|quality of life
889641|NCT02604121|oral cavity
889642|NCT02604121|cancerous and precancerous lesions
889643|NCT02604108|physical activity
889644|NCT02604108|healthy diet
889645|NCT02604095|Acanthosis nigricans
889646|NCT02604095|Obesity
889647|NCT02604069|Breast reconstruction
889648|NCT02604069|Breast cancer
889649|NCT02604069|Microsurgery
889650|NCT02604069|Continuous flap monitor
889651|NCT02604043|supraglottic pH
889652|NCT02604017|HCV GT1
889653|NCT02604017|Non-cirrhotic
889654|NCT02604017|RBV Free
889655|NCT02604017|Without cirrhosis
889656|NCT02604017|Chronic Hepatitis C
889657|NCT02604017|Hepatitis C Genotype 1 (GT1)
889658|NCT02604017|IFN free
889659|NCT02604017|Hepatitis C
889660|NCT02604017|Ribavirin Free
889661|NCT02604017|Interferon (IFN) Free
889662|NCT02604017|HCV
889663|NCT02604017|Hepatitis C virus
889664|NCT02604017|DAA
889665|NCT02604004|lamivudine
889666|NCT02604004|bioequivalence test
889667|NCT02604004|pharmacokinetics
889668|NCT02604004|high-performance liquid chromatography
889669|NCT02604004|3TC
889670|NCT02604004|LC-MS/MS
889671|NCT02604004|mass spectrometry
889672|NCT02603991|children and adolescents
889799|NCT02603393|COPD, QVA149
889673|NCT02603991|Prospective cohort study
889674|NCT02603991|vagus nerve stimulation
889675|NCT02603991|PINS
889676|NCT02603952|Influenza
889677|NCT02603952|Influenza A
889678|NCT02603952|Flu
889679|NCT02603952|Flu A
889680|NCT02603939|Pain
889681|NCT02603939|Magnetic resonance imaging
889682|NCT02603913|Pre-eclampsia
889683|NCT02603913|Pregnancy induced hypertension
889684|NCT02603913|Preterm birth
889685|NCT02603913|Intra-uterine growth restriction
889686|NCT02603913|Oxidative stress
889687|NCT02603900|Adductor Canal Catheter
889688|NCT02603900|Arthroplasty, Replacement, Knee
889689|NCT02603900|Local infiltration of analgesia
889690|NCT02603887|Smoldering Multiple Myeloma
889691|NCT02603887|SMM
889692|NCT02603887|Intermediate or high-risk
889693|NCT02603887|Pembrolizumab
889694|NCT02603887|Keytruda
889695|NCT02603887|MK-3475
889696|NCT02603887|SCH-900475
889697|NCT02603874|Fluoroscopy
889698|NCT02603874|Spinal Fusion
889699|NCT02603874|Wrong Level Surgery
889700|NCT02603848|Inguinal surgery
889701|NCT02603848|Hernia Repair
889702|NCT02603848|Orchidopexy
889703|NCT02603848|Hydrocele
889704|NCT02603848|Pediatric
889705|NCT02603848|Post-operative pain
889706|NCT02603848|Morphine sulfate
889707|NCT02603848|Ibuprofen
889708|NCT02603835|SSO2 Therapy
889709|NCT02603835|Acute myocardial infarction
889710|NCT02603835|Anterior myocardial infarction
889711|NCT02603835|SuperSaturated oxygen delivery
889712|NCT02603835|Left main coronary artery
889713|NCT02603835|Myocardial infarction
889714|NCT02603835|Heart attack
889715|NCT02603835|Percutaneous coronary intervention
889716|NCT02603835|Cardiac catheterization laboratory
889717|NCT02603835|PCI
889718|NCT02603835|Stent
889719|NCT02603835|Stenting
889720|NCT02603835|Stents
889721|NCT02603835|Angioplasty
889722|NCT02603835|LMCA
889723|NCT02603835|Delivery of supersaturated oxygen (SSO2) therapy for the treatment of anterior acute myocardial infarction
889724|NCT02603796|3-Dimensional
889725|NCT02603796|continuous positive airway pressure
889726|NCT02603796|nasal changes
889727|NCT02603757|Vitamin D
889728|NCT02603744|Premature ovarian failure adipose derived stromal cells intraovarian injection
889729|NCT02603718|Stroke
889730|NCT02603718|On-line EEG
889731|NCT02603718|BEI index
889732|NCT02603718|Attention
889733|NCT02603718|Rehabilitation
889734|NCT02603705|chronic pain
889735|NCT02603705|opioid
889736|NCT02603705|oxycodone
889737|NCT02603705|non cancer pain
889738|NCT02603705|moderate to severe
889739|NCT02603692|Newly diagnosed brain tumor
889740|NCT02603692|Progressive brain tumor
889741|NCT02603692|PROMIS
889742|NCT02603692|Quality of life
889743|NCT02603679|Cyclin-Dependent Kinase Inhibitor p16
889744|NCT02603666|cystic fibrosis
889745|NCT02603666|elastography
889746|NCT02603666|liver biopsy
889747|NCT02603614|Chronic Heart Failure
889748|NCT02603614|Renal Insufficiency
889749|NCT02603614|Natriuretic Peptides
889750|NCT02603614|Cenderitide
889751|NCT02603601|Randomized controlled trial
889752|NCT02603601|Mindfulness
889753|NCT02603601|Obesity
889754|NCT02603588|Acupuncture
889755|NCT02603588|Sphenopalatine ganglion
889756|NCT02603588|Nasal ventilation
889757|NCT02603588|Neuropeptides
889758|NCT02603575|Caspofungin
889759|NCT02603575|corticosteroids
889760|NCT02603575|Pneumocystis Pneumonia
889761|NCT02603575|Immunocompromised
889762|NCT02603575|Non-HIV
889763|NCT02603575|respiratory failure
889764|NCT02603562|FSHD
889765|NCT02603536|Text Messaging
889766|NCT02603536|Harm Reduction
889767|NCT02603523|accidental falls
889768|NCT02603523|older people
889769|NCT02603523|dance
889770|NCT02603523|randomized controlled trial
889771|NCT02603497|ASP015K
889772|NCT02603497|impaired renal function
889773|NCT02603497|Pharmacokinetics
889774|NCT02603471|HIV+
889775|NCT02603471|Alcohol dependence
889776|NCT02603471|Mobile Technology
889777|NCT02603458|Schizophrenia
889778|NCT02603458|Naurex
889779|NCT02603458|Intravenous Treatment
889780|NCT02603458|NRX-1074
889781|NCT02603445|BCL201
889782|NCT02603445|idelalisib
889783|NCT02603445|Follicular lymphoma
889784|NCT02603445|FL
889785|NCT02603445|mantle cell lymphoma
889786|NCT02603445|MCL
889787|NCT02603432|Bladder cancer
889788|NCT02603432|Urologic neoplasms
889789|NCT02603432|urothelial carcinoma
889790|NCT02603432|PD-L1
889791|NCT02603432|programmed cell death protein
889792|NCT02603432|maintenance treatment
889793|NCT02603419|classical Hodgkins Lymphoma (relapsed/refractory)
889794|NCT02603419|anti PD-L1
889795|NCT02603419|Phase 1
889796|NCT02603419|PK
889797|NCT02603419|Receptor occupancy
889798|NCT02603419|Immunophenotypic biomarkers
889800|NCT02603380|Delirium
889801|NCT02603380|Feasibility study
889802|NCT02603380|software application
889803|NCT02603380|qualitative
889804|NCT02603328|Cerebral cavernous malformation
889805|NCT02603328|Statins
889806|NCT02603328|MRI
889807|NCT02603328|Permeability
889808|NCT02603328|Quantitative susceptibility mapping
889809|NCT02603302|rectal cancer
889810|NCT02603302|radiotherapy
889811|NCT02603302|escalated dose
889812|NCT02603302|interval
889813|NCT02603276|hypercholesterolemia
889814|NCT02603276|dietary supplements
889815|NCT02603276|red yeast rice
889816|NCT02603276|plant sterols
889817|NCT02603263|social norms
889818|NCT02603263|healthy eating
889819|NCT02603263|vegetables
889820|NCT02603263|field study
889821|NCT02603250|Anemia
889822|NCT02603250|Iron deficiency
889823|NCT02603250|noninvasive anemia screening
889824|NCT02603211|breast cancer
889825|NCT02603198|third molar
889826|NCT02603198|tooth extraction
889827|NCT02603198|impacted tooth
889828|NCT02603185|Phase 1, Healthy subjects
889829|NCT02603172|GSK3039294
889830|NCT02603172|GSK2315698
889831|NCT02603172|systemic amyloidosis
889832|NCT02603172|CPHPC
889833|NCT02603172|dose-escalation
889834|NCT02603159|Chemoradiotherapy
889835|NCT02603159|Esophageal Squamous Cancer
889836|NCT02603159|Capecitabine
889837|NCT02603146|RA prevention
889838|NCT02603146|hydroxychloroquine (HCQ)
889839|NCT02603146|anti-CCP
889840|NCT02603133|healthcare
889841|NCT02603133|burnout
889842|NCT02603133|resilience
889843|NCT02603133|fatigue
889844|NCT02603133|NICU
889845|NCT02603133|safety culture
889846|NCT02603133|quality of care
889847|NCT02603081|Meniere's
889848|NCT02603081|hearing loss
889849|NCT02603081|vertigo
889850|NCT02603081|tinnitus
889851|NCT02603081|ebselen
889852|NCT02603055|Safety
889853|NCT02603055|immunogenicity
889854|NCT02603055|Hepatitis E
889855|NCT02603029|skin rejuvenation
889856|NCT02603029|anti-ageing effects
889857|NCT02603029|minimal erythema dose
889858|NCT02603029|dermis structure
889859|NCT02603029|physiological skin condition
889860|NCT02603029|wrinkling
889861|NCT02603016|Clinical Nutrition
889862|NCT02603003|Circulating tumor cells(CTCs)
889863|NCT02603003|Traditional Chinese Medicine(TCM)
889864|NCT02603003|Myeloid-derived suppressor cells(MDSCs)
889865|NCT02602990|Cerebral
889866|NCT02602990|Arteriovenous
889867|NCT02602990|Malformation
889868|NCT02602990|Embolization
889869|NCT02602990|Endovascular
889870|NCT02602977|inflammation
889871|NCT02602977|remote ischemic preconditioning
889872|NCT02602938|aspirin
889873|NCT02602938|circulating tumor cells
889874|NCT02602938|metastatic breast cancer
889875|NCT02602938|metastatic colorectal cancer
889876|NCT02602899|PINS
889877|NCT02602899|Deep Brain Stimulator
889878|NCT02602899|Refractory Epilepsy
889879|NCT02602899|Anterior Thalamic Nucleus
889880|NCT02602860|SV2A
889881|NCT02602860|Levetiracetam
889882|NCT02602860|Brivaracetam
889883|NCT02602860|PET
889884|NCT02602847|Liver transplantation
889885|NCT02602847|HBV
889886|NCT02602847|cccDNA
889887|NCT02602834|exercise test
889888|NCT02602834|biological markers
889889|NCT02602808|acute pancreatitis
889890|NCT02602808|non-coding RNA
889891|NCT02602808|biological markers
889892|NCT02602808|receiver operating characteristic curve
889893|NCT02602795|Opiate Dependence
889894|NCT02602795|Sexually Transmitted Diseases
889895|NCT02602795|HIV
889896|NCT02602795|Extended release naltrexone
889897|NCT02602756|Choroid Melanoma
889898|NCT02602743|sedation
889899|NCT02602743|remifentanyl
889900|NCT02602743|pediatric patient
889901|NCT02602743|colonoscopy
889902|NCT02602730|Cigarette smoking
889903|NCT02602730|Smoking, Tobacco
889904|NCT02602730|postpartum
889905|NCT02602730|internet
889906|NCT02602730|interactive
889907|NCT02602730|coach
889908|NCT02602717|follicular origin
889909|NCT02602691|Heart transplantation
889910|NCT02602691|AlloMap® gene expression profiling test
889911|NCT02602691|Medico-economic study
889912|NCT02602678|Children.
889913|NCT02602678|prone position
889914|NCT02602678|acute viral bronchiolitis
889915|NCT02602678|syncytial virus
889916|NCT02602678|work of breathing
889917|NCT02602678|intrinsic PEEP
889918|NCT02602665|catheter placement
889919|NCT02602652|geometric mean titer
889920|NCT02602652|seroprotection
889921|NCT02602652|live attenuated chimeric JE vaccine
889922|NCT02602652|JE-CV
889923|NCT02602652|SA14-14-2 vaccine
889924|NCT02602626|Human Papillomavirus
889925|NCT02602626|HPV
889926|NCT02602626|Postpartum
889927|NCT02602587|acute myeloid leukemia
889928|NCT02602587|Dendrogenin A
889929|NCT02602587|5,6-cholesterol epoxide
889930|NCT02602587|6-oxo-cholestane-3beta
889931|NCT02602587|5alpha-diol
889932|NCT02602587|cholesterol epoxide hydrolase
889933|NCT02602587|oxysterols
889934|NCT02602574|Cholangiopancreatography, Endoscopic Retrograde
889935|NCT02602574|Pancreatitis
889936|NCT02602574|Heat-Shock Proteins
889937|NCT02602574|Pentraxin 3 protein
889938|NCT02602574|C-Reactive Protein
889939|NCT02602574|procalcitonin
889940|NCT02602574|Interleukin-1 beta
889941|NCT02602574|Leukocytes, Mononuclear
889942|NCT02602574|Killer Cells, Natural
889943|NCT02602574|natural-killer group 2, member D receptor
889944|NCT02602561|HMB
889945|NCT02602561|beta-hydroxy-beta-methylbutyrate
889946|NCT02602561|ACL
889947|NCT02602561|surgery
889948|NCT02602561|muscle mass
889949|NCT02602548|Propionibacterium acnes
889950|NCT02602548|shoulder surgery
889951|NCT02602548|infection
889952|NCT02602496|Diet
889953|NCT02602496|Whole grain
889954|NCT02602496|Fruits
889955|NCT02602496|Vegetables
889956|NCT02602496|Gut health
889957|NCT02602496|Anti-inflammatory
889958|NCT02602483|temporomandibular
889959|NCT02602483|joint
889960|NCT02602483|pain
889961|NCT02602483|ibuprofen
889962|NCT02602483|magnesium
889963|NCT02602483|vitamin C
889965|NCT02602444|ticagrelor
889966|NCT02602444|STEMI
889967|NCT02602444|NSTEMI
889968|NCT02602444|pharmacokinetics
889969|NCT02602444|pharmacodynamics
889970|NCT02602431|laser
889971|NCT02602431|third molar
889972|NCT02602431|low laser
889973|NCT02602431|inflammatory response
889974|NCT02602418|Human Immunodeficiency Virus (HIV)
889975|NCT02602418|working memory training
889976|NCT02602418|brain function
889977|NCT02602418|functional magnetic resonance imaging (fMRI)
889978|NCT02602405|Outcome Assessment (Health Care)
889979|NCT02602405|Return to work
889980|NCT02602405|Registries
889981|NCT02602405|Norway
889982|NCT02602392|Self management
889983|NCT02602392|Education
889984|NCT02602392|Children
889985|NCT02602392|Caregivers
889986|NCT02602392|Health Care Providers
889987|NCT02602379|Pain
889988|NCT02602379|Monitoring
889989|NCT02602379|Analgesia Nociception Index
889990|NCT02602379|NoL
889991|NCT02602379|Nociception Level
889992|NCT02602379|Remifentanil
889993|NCT02602366|HIV
889994|NCT02602366|DCE
889995|NCT02602366|MPT
889996|NCT02602366|Microbicide
889997|NCT02602327|radioembolization
889998|NCT02602327|Yttrium-90
889999|NCT02602327|90Y
890000|NCT02602327|Resin microspheres
890001|NCT02602327|Tas-102
890002|NCT02602327|Lonsurf
890003|NCT02602327|SIR-Sphere
890004|NCT02602314|Chronic myeloid leukemia
890005|NCT02602314|Nilotinib
890006|NCT02602314|Imatinib
890007|NCT02602301|oxytocin
890008|NCT02602223|Alveolar Ridge Augmentation
890009|NCT02602223|Tooth Socket
890010|NCT02602223|Guided Tissue Regeneration
890011|NCT02602223|Membranes
890012|NCT02602210|cirrhosis
890013|NCT02602210|liver
890014|NCT02602210|corticosteroids
890015|NCT02602210|hypotension
890016|NCT02602210|sepsis
890017|NCT02602210|cortisol
890018|NCT02602197|Paracetamol
890019|NCT02602197|Dexketoprofen
890020|NCT02602197|postoperative pain
890021|NCT02602197|septoplasty
890022|NCT02602184|skin regeneration
890023|NCT02602184|re-epithelialization
890024|NCT02602184|split thickness wounds
890025|NCT02602184|Abdominoplasty
890026|NCT02602158|breath test
890027|NCT02602158|lipid emulsions
890028|NCT02602158|MRI
890029|NCT02602158|gastric emptying
890030|NCT02602145|femoral
890031|NCT02602145|popliteal
890032|NCT02602145|stent
890033|NCT02602145|modeling
890034|NCT02602145|flexion
890035|NCT02602132|INDWELLING URINARY CATHETER
890036|NCT02602132|CLAMPING
890037|NCT02602132|REMOVAL
890038|NCT02602106|Aquatic activities
890039|NCT02602106|Aerobic exercise
890040|NCT02602106|Resistance exercise
890041|NCT02602106|Pregnancy
890042|NCT02602106|Maternal weight gain
890043|NCT02602106|birthweight
890044|NCT02602093|Lumbar Disk Herniation
890045|NCT02602093|Percutaneous Transforaminal Endoscopic Discectomy
890046|NCT02602093|Micro Discectomy
890047|NCT02602093|Minimal Invasive Spine Surgery
890048|NCT02602054|persistent ductus arteriosus
890049|NCT02602054|preterm infants
890050|NCT02602054|surgical treatment
890051|NCT02602054|pharmacological treatment
890052|NCT02602028|Familial Mediterranean Fever
890053|NCT02602028|Colchicine
890054|NCT02602002|Remifentanil, Pharmacodynamic Pain assessments, Intravenous, South Korea
890055|NCT02601976|PegInterferon alpha-2a
890056|NCT02601976|Ribavirin
890057|NCT02601976|Hepatitis C Virus
890058|NCT02601976|Sustained Virological Response
890059|NCT02601976|End of Treatment Response
890060|NCT02601976|Unipeg
890061|NCT02601976|Ribazole
890062|NCT02601924|Anesthesia
890063|NCT02601924|injection
890064|NCT02601924|pain
890065|NCT02601924|pressure massage
890066|NCT02601924|topical gel
890067|NCT02601911|Failure
890068|NCT02601911|Injection
890069|NCT02601911|Ketorolac
890070|NCT02601911|Premedication
890071|NCT02601885|Secondary progressive
890072|NCT02601885|Relapsing-remitting
890073|NCT02601885|Relapsing forms
890074|NCT02601833|Caries
890075|NCT02601833|Cavity
890076|NCT02601820|patient-reported outcomes
890077|NCT02601820|observational
890078|NCT02601820|HCV
890079|NCT02601820|Hepatitis
890080|NCT02601820|Hepatitis C
890081|NCT02601820|Chronic Liver Disease
890082|NCT02601820|Liver Disease
890083|NCT02601820|Liver
890084|NCT02601820|Infectious Disease
890085|NCT02601820|Hep C
890086|NCT02601820|HepC
890087|NCT02601820|PROs
890088|NCT02601807|Back
890089|NCT02601807|Pain
890090|NCT02601807|PSWT
890091|NCT02601807|ActiPatch
890092|NCT02601807|Pulsed shortwave therapy
890093|NCT02601794|Breast Cancer
890094|NCT02601794|mHealth
890095|NCT02601794|Mindfulness
890096|NCT02601794|Complementary Therapies
890097|NCT02601781|Bioresorbable Vascular Scaffold (BVS)
890098|NCT02601781|STEMI
890099|NCT02601781|Primary PCI
890100|NCT02601768|ASD II
890101|NCT02601768|transcatheter closure
890102|NCT02601768|percutaneous closure
890103|NCT02601768|3D TEE
890104|NCT02601768|balloon-sizing
890105|NCT02601742|zinc
890106|NCT02601742|Duration
890107|NCT02601729|Type 1 diabetes
890108|NCT02601729|real-time continuous glucose monitoring
890109|NCT02601729|observational study
890110|NCT02601729|insulin pump
890111|NCT02601729|Belgium
890112|NCT02601716|Plasmodium falciparum
890113|NCT02601716|PfSPZ Vaccine
890114|NCT02601716|Sporozoites
890115|NCT02601716|Controlled Human Malaria Infection
890116|NCT02601690|Rye Grass
890117|NCT02601690|Ragweed
890118|NCT02601690|Cat
890119|NCT02601690|House Dust Mite
890120|NCT02601677|Obsessive Compulsive Disorder
890121|NCT02601677|Deep Brain Stimulation
890122|NCT02601677|Nucleus accumbens
890123|NCT02601651|Totally Extraperitoneal Inguinal Hernioplasty
890124|NCT02601651|Lidocaine infusion
890125|NCT02601651|Postoperative opioid consumption
890126|NCT02601625|Tolerability
890127|NCT02601625|Anifrolumab
890128|NCT02601625|Subcutaneous injection
890129|NCT02601625|Intravenous infusion
890130|NCT02601599|Smoking Cessation
890131|NCT02601599|Tobacco Use Cessation
890132|NCT02601599|Motivational Interviewing
890133|NCT02601599|Students, Medical
890134|NCT02601599|Randomized Controlled Trial
890135|NCT02601560|Coronary Artery Disease
890136|NCT02601560|CAD
890137|NCT02601547|Positron-Emission Tomography
890138|NCT02601547|chemotherapy-induced brain damage
890139|NCT02601547|neuro-cognitive function alteration
890140|NCT02601534|sedentary behaviour
890141|NCT02601534|physical activity
890142|NCT02601508|deep NM block
890143|NCT02601508|Surgeon's satisfaction
890144|NCT02601508|bridion
890145|NCT02601482|Glycemic control
890146|NCT02601482|exercise
890147|NCT02601482|Interval Training
890148|NCT02601456|Amputation, Traumatic
890149|NCT02601456|Biomechanics
890150|NCT02601456|Asymmetry
890151|NCT02601456|Amputee Running
890152|NCT02601456|Prolonged Effort
890153|NCT02601417|Cholangitis
890154|NCT02601417|Bile culture
890155|NCT02601391|STEPPS-HI
890156|NCT02601391|personality disorder
890157|NCT02601391|evaluation
890158|NCT02601391|forensic
890159|NCT02601378|Uveal melanoma
890160|NCT02601378|Metastatic uveal melanoma
890161|NCT02601378|Phase I
890162|NCT02601378|LXS196
890163|NCT02601378|PKC inhibitor
890164|NCT02601378|dose escalation
890165|NCT02601339|spectroscopy, Near-Infrared
890166|NCT02601300|Ulcerative Colitis
890167|NCT02601300|GED-0301
890168|NCT02601300|Mongersen
890169|NCT02601300|Efficacy
890170|NCT02601300|Safety
890171|NCT02601261|pregnant
890172|NCT02601261|gestational ages
890173|NCT02601261|hospitalized
890174|NCT02601261|problem of pregnancy
890175|NCT02601248|safety, PK
890176|NCT02601235|rhinitis
890177|NCT02601222|chronic eczema
890178|NCT02601222|efficacy and safety
890179|NCT02601222|Runzao zhiyang capsule
890180|NCT02601196|Leiomyoma
890181|NCT02601196|Infertility
890182|NCT02601196|IVF
890183|NCT02601196|Ulipristal acetate
890184|NCT02601183|brain temperture，thrombolysis，early diagnosis
890185|NCT02601170|Platelet Rich Plasma
890186|NCT02601170|Hemophilia
890187|NCT02601170|Hemophilic arthropathy
890188|NCT02601157|stent
890189|NCT02601157|polymer
890190|NCT02601157|antiplatelet therapy
890191|NCT02601157|clopidogrel
890192|NCT02601144|DBS
890193|NCT02601144|VFS
890194|NCT02601144|FOG
890195|NCT02601131|platelet count
890196|NCT02601131|platelet transfusion
890197|NCT02601131|complement factors
890198|NCT02601131|endothelial markers
890199|NCT02601131|stem cell transplantation
890200|NCT02601105|gotu kola
890201|NCT02601105|centella asiatica
890202|NCT02601092|Mini Gastric Bypass
890203|NCT02601092|Roux-en-Y Gastric Bypass
890204|NCT02601092|RCT
890205|NCT02601079|Biopsy
890206|NCT02601079|Diagnostics
890207|NCT02601079|Genetic analysis
890208|NCT02601066|LMNA
890209|NCT02601066|Sudden Death
890210|NCT02601066|Neuromuscular
890211|NCT02601040|Safety
890212|NCT02601040|Immunogenicity
890213|NCT02601040|Vaccine
890214|NCT02601040|Hepatitis A
890215|NCT02601014|Hormone-Resistant Prostate Cancer
890216|NCT02601014|Prostate Carcinoma Metastatic in the Bone
890217|NCT02600988|Graft-Versus-Host-Disease
890218|NCT02600988|post-allogeneic transplant
890219|NCT02600988|haematopoietic progenitors
890220|NCT02600949|Pancreatic cancer
890221|NCT02600949|Colorectal Cancer
890222|NCT02600949|Pancreatic ductal adenocarcinoma
890223|NCT02600949|PDA
890224|NCT02600949|CRC
890225|NCT02600949|Personalized peptide vaccine
890226|NCT02600949|Phone call
890227|NCT02600949|Advanced/metastatic
890228|NCT02600936|venous outflow obstruction
890229|NCT02600936|peripheral venous disease
890230|NCT02600936|vein stent
890231|NCT02600936|Wallstent
890232|NCT02600936|registry
890233|NCT02600936|May Thurner
890234|NCT02600923|palbociclib, ibrance, breast cancer
890235|NCT02600910|Manual Wheelchair
890236|NCT02600910|Shoulder injury
890237|NCT02600910|Shoulder function
890238|NCT02600910|rotator cuff
890239|NCT02600910|Tendinopathy
890240|NCT02600910|Spinal cord injury
890241|NCT02600910|Shoulder pain
890242|NCT02600910|Shoulder impingement
890243|NCT02600871|Abscess
890244|NCT02600871|Antiseptic
890245|NCT02600871|Provodine
890246|NCT02600871|Povidone-Iodine
890247|NCT02600819|end stage renal disease (ESRD)
890248|NCT02600819|hemodialysis (HD)
890249|NCT02600819|open-label
890250|NCT02600819|HIV-1 Infection
890251|NCT02600806|Community-acquired pneumonia
890252|NCT02600806|Procalcitonin
890253|NCT02600806|Outpatients
890254|NCT02600806|Outcomes
890255|NCT02600806|Azithromycin
890256|NCT02600806|Fluoroquinolones
890257|NCT02600780|Febuxostat
890258|NCT02600780|Efficacy
890259|NCT02600780|Safety
890260|NCT02600780|Allopurinol
890261|NCT02600780|Hyperuricemia
890262|NCT02600780|Zurig
890263|NCT02600780|Getz Pharma
890264|NCT02600754|older adults, depressive symptoms, psychosocial treatment
890265|NCT02600741|Schizophrenia
890266|NCT02600741|Caregiver
890267|NCT02600741|Psycho-education and skills training
890268|NCT02600741|Paliperidone Palmitate
890269|NCT02600741|Oral Antipsychotic
890270|NCT02600728|Parkinson Disease
890271|NCT02600728|Gait
890272|NCT02600728|cues
890273|NCT02600728|memory
890274|NCT02600728|training
890275|NCT02600702|Home base exercise
890276|NCT02600689|Pulmonary rehab
890277|NCT02600689|Exergame
890278|NCT02600689|Home-based
890279|NCT02600637|stroke
890280|NCT02600637|depression
890281|NCT02600637|anxiety
890282|NCT02600637|mindfulness
890283|NCT02600637|meditation
890284|NCT02600572|balance, postural
890285|NCT02600572|postural equilibrium
890286|NCT02600572|mental speed
890287|NCT02600572|isometric exercise
890288|NCT02600572|eccentric exercise
890289|NCT02600559|Otitis media
890290|NCT02600559|Ear infection
890291|NCT02600559|Tympanostomy tubes
890292|NCT02600533|minority group recruitment
890293|NCT02600533|stages of implementation
890294|NCT02600533|clinical trials education
890295|NCT02600481|standard-pressure pneumoperitoneum
890296|NCT02600481|prolonged pneumoperitoneum
890297|NCT02600481|myocardial injuries
890298|NCT02600481|troponin T(TnT)
890299|NCT02600481|Trendelenburg position
890300|NCT02600481|chest CT scan
890301|NCT02600481|low-pressure pneumoperitoneum
890302|NCT02600481|robot-assisted surgery
890303|NCT02600442|Neoadjuvant Therapy
890304|NCT02600442|Chemotherapy
890305|NCT02600442|Positron-Emission Tomography
890306|NCT02600442|PET-CT
890307|NCT02600442|FDG
890308|NCT02600442|Fluorodeoxyglucose
890309|NCT02600442|Diagnosis
890310|NCT02600442|Prognosis
890311|NCT02600442|Pathological complete response
890312|NCT02600442|molecular biology
890313|NCT02600442|proliferation genes
890314|NCT02600429|Neurotrophic Keratopathy
890315|NCT02600429|NK
890316|NCT02600403|Visual Evoked Potentials
890317|NCT02600403|Optical Coherence Tomography
890318|NCT02600403|Visual Fields
890319|NCT02600390|Leg Ulcer
890320|NCT02600390|LU
890321|NCT02600390|SANGUINATE
890322|NCT02600390|QOL
890323|NCT02600390|SCD
890324|NCT02600390|Sickle Cell Disease
890325|NCT02600390|Sickle Cell
890326|NCT02600390|Anemia
890327|NCT02600390|Leg Wound
890328|NCT02600390|Leg
890329|NCT02600390|Skin Lesion
890330|NCT02600364|Aneurysm
890331|NCT02600364|intracerebral
890332|NCT02600364|stroke
890333|NCT02600364|p64
890334|NCT02600351|Hepatitis C Virus (HCV)
890335|NCT02600351|Ledipasvir/Sofosbuvir
890336|NCT02600351|Ribavirin
890337|NCT02600338|Systematic review and meta-analysis
890338|NCT02600338|Evidence-based medicine (EBM)
890339|NCT02600338|Evidence-based nutrition (EBN)
890340|NCT02600338|Clinical practice guidelines
890341|NCT02600338|Clinical trials
890342|NCT02600338|Legumes
890343|NCT02600338|Beans, peas, chickpeas, lentils, soy, peanuts, lupins
890344|NCT02600338|Cardiometabolic risk factors
890345|NCT02600338|Blood pressure
890346|NCT02600325|Acute Hepatitis C
890347|NCT02600325|Human Immunodeficiency virus
890348|NCT02600325|Grazoprevir
890349|NCT02600325|Elbasvir
890350|NCT02600286|Physical medicine and rehabilitation
890351|NCT02600286|Neurology
890352|NCT02600260|thrombophilia
890353|NCT02600260|thrombosis
890354|NCT02600260|Pregnancy, High-Risk
890355|NCT02600260|venous thrombosis
890356|NCT02600260|enoxaparin
890357|NCT02600260|risk assessment
890358|NCT02600260|deep vein thrombosis
890359|NCT02600260|pulmonary embolism
890360|NCT02600260|hospitalization
890361|NCT02600247|Total knee arthroplasty
890362|NCT02600247|Duloxetine
890363|NCT02600221|ACOS
890364|NCT02600195|Intensive Care, Neonatal
890365|NCT02600195|Nosocomial Infections
890366|NCT02600195|Quality Improvement
890367|NCT02600182|Thoracic surgery
890368|NCT02600182|Non-invasive ventilation
890369|NCT02600182|Physiotherapy
890370|NCT02600143|Melanoma
890371|NCT02600143|Colitis
890372|NCT02600143|Ipilimumab
890373|NCT02600143|Nivolumab
890374|NCT02600143|Pembrolizumab
890375|NCT02600091|Anxiety
890376|NCT02600091|Depression
890377|NCT02600091|Type 1 Diabetes
890378|NCT02600091|Mindfulness-based Cognitive Therapy
890379|NCT02600091|Glycaemic control
890380|NCT02600078|hypoxia
890381|NCT02600078|ataxia
890382|NCT02600013|incomplete motor SCI
890383|NCT02600013|robotic gait training
890384|NCT02600013|exoskeleton
890385|NCT02600013|rehabilitation tool
890386|NCT02600013|EKSO-GT
890387|NCT02599961|Glut 1 DS
890388|NCT02599935|Nutritional status
890389|NCT02599935|MNA
890390|NCT02599935|GSA
890391|NCT02599909|Liver Cancer
890392|NCT02599909|Hepatocellular Carcinoma
890393|NCT02599909|Liver Tumors
890394|NCT02599909|Liver Resection
890400|NCT02599883|Chronic Obstructive Pulmonary Disease
890401|NCT02599883|Diagnostic Imaging
890402|NCT02599883|Disease Management
890403|NCT02599883|Clinical Decision Support Systems
890404|NCT02599883|Cost-Utility Analysis
890405|NCT02599870|PGx
890406|NCT02599870|pharmacogenetic testing
890407|NCT02599870|IDgenetix
890408|NCT02599870|Pain Management
890409|NCT02599870|AltheaDx
890410|NCT02599870|Post-Operative Pain Management
890411|NCT02599844|acute kidney injury
890412|NCT02599831|Electrical pudendal nerve stimulation
890413|NCT02599831|Pelvic floor muscle training
890414|NCT02599831|Transanal electrical stimulation
890415|NCT02599831|Male Stress urinary incontinence
890416|NCT02599831|Comparative study
890417|NCT02599792|Safety and Pharmacokinetics
890418|NCT02599779|Renal cell cancer
890419|NCT02599779|SBRT
890420|NCT02599779|Pembrolizumab
890421|NCT02599766|animal assisted intervention, brain injury, rehabilitation
890422|NCT02599740|Blood glucose
890423|NCT02599727|balance, postural
890424|NCT02599727|postural equilibrium
890425|NCT02599727|heart rate
890426|NCT02599727|blood pressure
890427|NCT02599727|pulse oxygenation
890428|NCT02599727|mental speed
890429|NCT02599714|AZD2014, Palbociclib, Fulvestrant, Hormonal Therapy, Estrogen, Receptor, Positive, Locally-Advanced, Metastatic, Breast Cancer
890430|NCT02599701|Delta Sleep
890431|NCT02599701|Growth Hormone
890432|NCT02599701|IGF-1
890433|NCT02599675|Muscle
890434|NCT02599675|Vitamin D
890435|NCT02599675|Strength
890436|NCT02599675|Endurance
890437|NCT02599675|Muscle fiber
890438|NCT02599662|Cancer
890439|NCT02599662|Intraoperative Radiation Therapy - IORT
890440|NCT02599649|Myelodysplastic syndrome
890441|NCT02599649|MDS
890442|NCT02599649|Low or intermediate-1 MDS
890443|NCT02599649|High Risk MDS
890444|NCT02599649|Lirilumab
890445|NCT02599649|Nivolumab
890446|NCT02599649|BMS-936558
890447|NCT02599649|Opdivo
890448|NCT02599649|Azacitidine
890449|NCT02599649|5-azacytidine
890450|NCT02599649|5-aza
890451|NCT02599649|Vidaza
890452|NCT02599649|5-AZC
890453|NCT02599649|AZA-CR
890454|NCT02599649|Ladakamycin
890455|NCT02599649|NSC-102816
890456|NCT02599649|Azacytidine
890457|NCT02599623|Incarcerated
890458|NCT02599623|Anesthesia
890459|NCT02599623|Hernia
890460|NCT02599610|labor, vaginal examination, transperineal ultrasound, pain, anxiety
890461|NCT02599584|behaviour
890462|NCT02599558|EOE
890463|NCT02599532|Apixaban
890464|NCT02599532|Pharmacokinetics
890465|NCT02599532|Pharmacodynamics
890466|NCT02599506|breast cancer
890467|NCT02599506|fear of recurrence
890468|NCT02599506|longitudinal study
890469|NCT02599506|radiation therapy
890470|NCT02599506|emotional concerns
890471|NCT02599506|trajectory
890472|NCT02599506|psychological constructs
890473|NCT02599506|diary keeping
890474|NCT02599480|HFpEF
890475|NCT02599480|left ventricular hypertrophy
890476|NCT02599480|cardiac remodeling,
890477|NCT02599467|Nerve Pain
890478|NCT02599467|Electromyography
890479|NCT02599467|Median Nerve
890480|NCT02599467|Breast Neoplasms
890481|NCT02599415|psoriasis patients referred to receive TL01 NB-UVB therapy
890482|NCT02599389|in-stent restenosis; drug-coated balloons; Excimer Laser, cost effectiveness study, quality of life
890483|NCT02599350|Ventilation
890484|NCT02599350|Gas exchange
890485|NCT02599350|V/Q ratio
890486|NCT02599350|Requirement for mechanical ventilation
890487|NCT02599337|bioequivalence
890488|NCT02599311|pelvic organ prolapse
890489|NCT02599298|sleep
890490|NCT02599298|treatment
890491|NCT02599259|Stroke
890492|NCT02599259|Oral anticoagulants
890493|NCT02599259|NOAC
890494|NCT02599259|wireless monitoring
890495|NCT02599259|Warfarin
890496|NCT02599259|Xarelto
890497|NCT02599259|compliance
890498|NCT02599259|adherence
890499|NCT02599259|monitoring
890500|NCT02599259|directly observed therapy
890501|NCT02599259|DOT
890502|NCT02599259|mobile device
890503|NCT02599259|electronic monitoring
890504|NCT02599259|artificial intelligence
890505|NCT02599259|oral anticoagulation therapy
890506|NCT02599259|adherence monitoring methods
890507|NCT02599259|nonadherence
890508|NCT02599259|non-adherence
890509|NCT02599246|Home ventilator
890510|NCT02599246|FiO2
890511|NCT02599246|O2
890512|NCT02599246|NIV
890513|NCT02599246|COPD
890514|NCT02599233|pain trajectory
890515|NCT02599181|Perineural cathether
890516|NCT02599181|Catheter infection
890517|NCT02599168|dexmedetomidine
890518|NCT02599168|propofol
890519|NCT02599168|BIS
890520|NCT02599168|CLADS
890521|NCT02599155|crystalloid
890522|NCT02599155|colloid
890523|NCT02599155|children
890524|NCT02599155|infant
890525|NCT02599155|cardiac surgery
890526|NCT02599142|radiotherapy immobilisation
890527|NCT02599142|open-face shells
890528|NCT02599129|Alopecia areata
890529|NCT02599116|cytoreductive surgery
890530|NCT02599116|hyperthermic intraperitoneal chemotherapy
890531|NCT02599116|microbiome
890532|NCT02599090|Glioblastoma
890533|NCT02599090|Gliosarcoma
890534|NCT02599090|Brain Cancer
890535|NCT02599090|Sorafenib
890536|NCT02599090|Temozolomide
890537|NCT02599090|Radiation
890538|NCT02599090|Radiotherapy
890539|NCT02599090|XRT
890540|NCT02599077|oral contraceptives
890541|NCT02599077|endometrioma
890542|NCT02599077|dienogest
890543|NCT02599064|Age-related macular degeneration
890544|NCT02599064|RXI-109
890545|NCT02599064|NVAMD
890546|NCT02599064|Retinal scarring
890547|NCT02599064|Subretinal scarring
890548|NCT02599064|Retinal fibrosis
890549|NCT02599064|Subretinal fibrosis
890550|NCT02599064|Eye diseases
890551|NCT02599038|NAFLD
890552|NCT02599038|NASH
890553|NCT02599038|Serine
890554|NCT02599038|Glutathione
890555|NCT02599025|Cerebral palsy
890556|NCT02599025|passive cycling
890557|NCT02599025|autonomic control system
890558|NCT02598986|glycemic index, pita bread, phosphorus, potassium, magnesium
890559|NCT02598973|Parkinson Disease
890560|NCT02598973|exercise
890561|NCT02598947|posterior shoulder tightness
890562|NCT02598947|shoulder impingement syndrome
890563|NCT02598947|Glenohumeral joint
890564|NCT02598947|exercise
890565|NCT02598921|Assisted reproductive technology
890566|NCT02598882|Elderly
890567|NCT02598882|Videogame
890568|NCT02598882|energy expenditure
890569|NCT02598882|electromyography
890570|NCT02598882|rehabilitation
890571|NCT02598869|Triamcinolone acetonide
890572|NCT02598856|Emergency Treatment
890573|NCT02598856|Morphine Derivates
890574|NCT02598856|Heroin
890575|NCT02598856|Antidotes
890576|NCT02598856|Administration, Intravenous
890577|NCT02598856|Pharmacology
890578|NCT02598856|Naloxone
890579|NCT02598856|Healthy volunteers
890580|NCT02598856|Administration, intramuscular
890581|NCT02598856|Administration, intranasal
890582|NCT02598830|Cachexia
890583|NCT02598830|Vitamin D
890584|NCT02598830|Muscle
890585|NCT02598830|Strength training
890586|NCT02598804|Physical activity level
890587|NCT02598804|Knee osteoarthritis
890588|NCT02598804|Randomized controlled trials
890589|NCT02598804|Alternate month design study
890590|NCT02598804|Self-management
890591|NCT02598804|Self-care
890592|NCT02598804|Education and exercise in knee osteoarthritis
890593|NCT02598804|Education
890594|NCT02598804|Non pharmacological treatment
890595|NCT02598791|incretin hormones
890596|NCT02598791|GIP
890597|NCT02598791|GLP-1
890598|NCT02598765|Glaucoma
890599|NCT02598765|Trabeculectomy
890600|NCT02598765|Eye Disease
890601|NCT02598765|Intraocular Pressure
890602|NCT02598765|Visual Acuity
890603|NCT02598752|functional performance testing
890604|NCT02598752|exercise fitness testing
890605|NCT02598752|15-274
890606|NCT02598739|Physical exercise
890607|NCT02598739|Psoriatic arthritis
890608|NCT02598739|Quality of life
890609|NCT02598700|total hip arthroplasty
890610|NCT02598700|imaging
890611|NCT02598700|arthritis
890612|NCT02598700|surgical technique
890613|NCT02598674|acute kidney injury
890614|NCT02598661|Myelodysplastic Syndromes
890615|NCT02598661|Imetelstat
890616|NCT02598648|FXR
890617|NCT02598648|RIPK3
890618|NCT02598648|Neonates
890619|NCT02598648|Acute Respiratory Distress Syndrome
890620|NCT02598648|Acute Lung Injury
890621|NCT02598635|Cholecalciferol
890622|NCT02598635|peritoneal dialysis
890623|NCT02598635|FGF23
890624|NCT02598635|Calcium
890625|NCT02598635|Phosphorus
890626|NCT02598609|Adverse event
890627|NCT02598609|Neonatal Intensive Care Unit
890628|NCT02598609|Catheter-related Bloodstream Infection (CRBSI) nos
890629|NCT02598609|Extravasation injury
890630|NCT02598609|Medication error
890631|NCT02598609|Central venous catheter complication
890632|NCT02598609|Unprogrammed extubation
890633|NCT02598596|Refractory gout
890634|NCT02598596|Chronic gout
890635|NCT02598583|Paroxysmal Nocturnal Hemoglobinuria
890636|NCT02598583|PNH
890637|NCT02598583|complement inhibitor
890638|NCT02598570|Relapsed Lymphoma
890639|NCT02598570|Phosphoinositide 3-kinase (PI3K) Inhibitor
890640|NCT02598570|Duvelisib
890641|NCT02598570|Japanese
890642|NCT02598570|Refractory Lymphoma
890643|NCT02598518|Integrating Combined Therapies
890644|NCT02598518|Alcohol Use Disorder
890645|NCT02598518|Mental Health Disorder
890646|NCT02598492|Mechanical Ventilator
890647|NCT02598479|Cancer
890648|NCT02598479|Insulin Potentiation Low Dose Chemotherapy
890649|NCT02598479|IPT
890650|NCT02598479|IPTLD
890651|NCT02598479|Nutrition therapy
890652|NCT02598427|Breast Cancer
890653|NCT02598427|HER2 Positive
890654|NCT02598427|HER2+
890655|NCT02598427|Brain Metastases
890656|NCT02598427|Metastatic Breast Cancer
890657|NCT02598427|Intrathecal Treatment
890658|NCT02598427|Lumbar Puncture
890659|NCT02598427|Pertuzumab
890660|NCT02598427|Trastuzumab
890661|NCT02598427|Advanced Breast Cancer
890662|NCT02598427|Duke University
890663|NCT02598414|Colorectal Disease
890664|NCT02598414|Robotic Surgery
890665|NCT02598414|Indocyanine Green Fluorescence Imaging
890666|NCT02598414|Anastomotic Leak
890667|NCT02598414|Short-term Outcomes
890929|NCT02596711|Handouts
890679|NCT02598375|Early reached target enteral nutrition in PICU feeding intolerance IFABP
890680|NCT02598362|ciprofloxacin
890681|NCT02598362|pharmacokinetics
890682|NCT02598362|excretion
890683|NCT02598362|clearance
890684|NCT02598362|infant
890685|NCT02598362|children
890686|NCT02598362|adolescent
890687|NCT02598349|Unresectable
890688|NCT02598349|Borderline resectable
890689|NCT02598336|Structured Light Plethysmography
890690|NCT02598336|Spirometry
890691|NCT02598336|Pneumotachograph
890692|NCT02598297|Ruxolitinib
890693|NCT02598297|INC424
890694|NCT02598297|early myelofibrosis
890695|NCT02598297|High molecular risk mutations
890696|NCT02598297|HMR
890697|NCT02598284|Preventive measures
890698|NCT02598284|Quality Improvement
890699|NCT02598271|Acute Kidney Injury
890700|NCT02598271|Cardiac Surgery
890701|NCT02598258|Sauna
890702|NCT02598258|Cold water bath
890703|NCT02598245|urinary incontinence, CESA, VASA, TOT, TVT
890704|NCT02598219|Sentinel node
890705|NCT02598206|food effect
890706|NCT02598206|healthy volunteers
890707|NCT02598206|pharmacokinetics
890708|NCT02598206|CCR2i
890709|NCT02598141|Protheses, nails, screws or plates
890710|NCT02598115|collaborative pharmaceutical care
890711|NCT02598089|Seasonal Influenza
890712|NCT02598089|Trivalent Vaccine
890713|NCT02598089|Inactivated Vaccine
890714|NCT02598050|postoperative health outcomes
890715|NCT02598050|older surgical patients
890716|NCT02598037|Obesity
890717|NCT02598037|Polymorphism
890718|NCT02598037|Hormones
890719|NCT02597985|Frailty
890720|NCT02597959|ergonomic risk factors
890721|NCT02597959|allied health professionals
890722|NCT02597959|surgical care
890723|NCT02597881|natural history
890724|NCT02597868|therapy
890725|NCT02597868|Capecitabine
890726|NCT02597868|breast cancer
890727|NCT02597842|Postoperative nausea and vomiting
890728|NCT02597842|TEAS
890729|NCT02597829|Inflammatory Bowel Disease
890730|NCT02597829|Mucosal Healing
890731|NCT02597829|Certolizumab pegol
890732|NCT02597803|Dry Eye Syndrome
890733|NCT02597803|Dry Eye
890734|NCT02597803|DES
890735|NCT02597790|endothelial function
890736|NCT02597790|cardiovascular risk
890737|NCT02597790|HIV
890738|NCT02597790|Hepatitis C
890739|NCT02597790|metabolic disease
890740|NCT02597790|inflammation
890741|NCT02597764|Diaphragmatic breathing (DB)
890742|NCT02597764|Bladder and bowel disorders (BBD)
890743|NCT02597764|Autonomic nervous system (ANS)
890744|NCT02597764|Heart rate variability (HRV)
890745|NCT02597764|Deep breathing
890746|NCT02597764|Randomized controlled trial (RCT)
890747|NCT02597751|DCD
890748|NCT02597751|Neuroimaging
890749|NCT02597751|Rehabilitation
890750|NCT02597725|Urodynamics
890751|NCT02597725|Late effects
890752|NCT02597725|Urinary Incontinence
890753|NCT02597712|acid reflux
890754|NCT02597712|intragastric pH
890755|NCT02597712|gastrin
890756|NCT02597712|hypergastrinemia
890757|NCT02597699|Termination of pregnancy
890758|NCT02597699|Feticide
890759|NCT02597699|Fetal pain
890760|NCT02597699|Remifentanil Ultiva®
890761|NCT02597699|Fetal asystole
890762|NCT02597699|Fetopathologic analysis
890763|NCT02597660|patellar tendinopathy
890764|NCT02597660|somatropin
890765|NCT02597660|jumper's knee
890766|NCT02597647|immunology
890767|NCT02597647|Microbiota
890768|NCT02597582|LigaSure
890769|NCT02597582|Neck dissection
890770|NCT02597582|Operative duration
890771|NCT02597582|Postoperative drainage
890772|NCT02597582|Postoperative pain
890773|NCT02597569|stroke
890774|NCT02597569|Cognitive Orientation to daily Occupational Performance
890775|NCT02597569|health services accessibility
890776|NCT02597569|cognitive impairment
890777|NCT02597569|rehabilitation
890778|NCT02597569|integrated knowledge translation
890779|NCT02597569|interrupted time series
890780|NCT02597569|The CO-OP Approach
890781|NCT02597556|Albendazole
890782|NCT02597556|Ancylostoma duodenale
890783|NCT02597556|Ascariasis lumbricoides
890784|NCT02597556|Coinfection
890785|NCT02597556|Diarrhea
890786|NCT02597556|Helminths
890787|NCT02597556|Necator americanus
890788|NCT02597556|Microbiota
890789|NCT02597556|Trichuris trichiura
890790|NCT02597543|heart transplantation
890791|NCT02597543|cardiac MRI
890792|NCT02597543|graft rejection
890793|NCT02597543|nonspecific allograft dysfunction
890794|NCT02597543|allograft vasculopathy
890795|NCT02597530|TEAS
890796|NCT02597530|anesthesia
890797|NCT02597517|gastritis
890798|NCT02597517|chromoendoscopy
890799|NCT02597517|magnification
890800|NCT02597517|Helicobacter pylori
890801|NCT02597517|Atrophic gastritis
890802|NCT02597491|Smoking,
890803|NCT02597491|Smoking cessation
890804|NCT02597491|Sequential, multiple assignment, randomized trials (SMART)
890805|NCT02597491|Lung cancer screening
890806|NCT02597478|Advanced Cancers
890807|NCT02597478|Fentanyl Sublingual Spray
890808|NCT02597478|Fentanyl SL Spray
890809|NCT02597478|FSS
890810|NCT02597478|Questionnaires
890811|NCT02597478|Surveys
890812|NCT02597478|Mental Abilities Test
890813|NCT02597478|Phone Call
890814|NCT02597478|Shuttle Walk Test
890815|NCT02597452|breast lump
890816|NCT02597452|breast exam
890817|NCT02597452|breast cancer screening
890818|NCT02597452|breast lump detection
890819|NCT02597439|Ultra-high risk
890820|NCT02597439|UHR
890821|NCT02597439|psychosis
890822|NCT02597426|Nasopharyngeal Carcinoma
890823|NCT02597426|Intensity-Modulated Radiotherapy
890824|NCT02597426|Post treatment
890825|NCT02597374|Electroencephalography
890826|NCT02597374|mu rhythm
890827|NCT02597374|Sensorimotor Cortex
890828|NCT02597374|Unilateral Cerebral Palsy
890829|NCT02597374|Child
890830|NCT02597361|Ehlers-Danlos syndrome, vascular type
890831|NCT02597361|Type 2 Angiotensin Receptor Blockers
890832|NCT02597348|Liver
890833|NCT02597348|Metastasis
890834|NCT02597348|Colorectal cancer
890835|NCT02597348|Liver transplantation
890836|NCT02597335|Glioma
890837|NCT02597335|IDH1/IDH2 mutation
890838|NCT02597335|Spectroscopy MRI
890839|NCT02597335|D-2-hydroxyglutarate
890840|NCT02597335|Free circulating DNA
890841|NCT02597322|Axitinib
890842|NCT02597322|T2a Renal tumor
890843|NCT02597322|organ confined tumors
890844|NCT02597322|nephron sparing surgery
890845|NCT02597322|nephron sparing procedure
890846|NCT02597322|radical nephrectomy
890847|NCT02597283|Bifurcation lesions
890848|NCT02597283|Percutaneous coronary intervention
890849|NCT02597283|Randomized controlled trial
890850|NCT02597270|Hepatitis C virus
890851|NCT02597257|Lidocaine infusion therapy
890852|NCT02597244|Lumbar foraminal stenosis
890853|NCT02597231|Delirium
890854|NCT02597231|Melatonin
890855|NCT02597218|Hepatectomy
890856|NCT02597218|Prophylaxis
890857|NCT02597205|Medical adherence
890858|NCT02597205|Lifestyle modification
890859|NCT02597205|Mobile Health
890860|NCT02597205|Secondary Prevention
890861|NCT02597192|gingivitis
890862|NCT02597192|gingival inflammation
890863|NCT02597192|probiotics
890864|NCT02597192|Bacillus
890865|NCT02597075|Colorectal Cancer
890866|NCT02597075|Metastatic Colorectal Cancer
890867|NCT02597075|Physical Activity
890868|NCT02597075|Quality of life
890869|NCT02597036|Advanced, Angiopoietin
890870|NCT02596997|Adenovirus Brincidofovir
890871|NCT02596984|Intensive Care Unit
890872|NCT02596984|Shock
890873|NCT02596984|Antifungal agent
890874|NCT02596984|Pharmacokinetics
890875|NCT02596984|Sepsis
890876|NCT02596932|Intrapartum
890877|NCT02596893|Crohn's Disease
890878|NCT02596893|GED-0301
890879|NCT02596893|Mongersen
890880|NCT02596893|IBD
890881|NCT02596893|Safety
890882|NCT02596893|Efficacy
890883|NCT02596880|Hepatitis C
890884|NCT02596880|Cirrhosis
890885|NCT02596880|Sofosbuvir
890886|NCT02596880|Daclatasvir
890887|NCT02596880|Ribavirin
890888|NCT02596867|B adrenergic pathway
890889|NCT02596867|B Blocker
890890|NCT02596841|Lung diffusing capacity
890891|NCT02596841|Idiopathic Interstitial Pneumonias
890892|NCT02596828|molecular targeted therapy
890893|NCT02596828|protein kinase inhibitor
890894|NCT02596828|mTOR Inhibitor
890895|NCT02596828|cytostatic topoisomerase-I-inhibitor
890896|NCT02596828|temozolomide
890897|NCT02596828|irinotecan
890898|NCT02596828|dasatinib
890899|NCT02596828|rapamycin
890900|NCT02596802|Fetoscopic Endoluminal Tracheal Occlusion
890901|NCT02596802|Congenital Diaphragmatic Hernia
890902|NCT02596763|Off-label prescription
890903|NCT02596763|Alcoholism
890904|NCT02596763|Pharmacovigilance
890905|NCT02596763|Pharmacoepidemiology
890906|NCT02596763|Baclofen
890907|NCT02596737|health
890908|NCT02596737|work
890909|NCT02596737|lifestyle
890910|NCT02596737|behavior
890911|NCT02596737|management
890912|NCT02596737|stress
890913|NCT02596737|physical activity
890914|NCT02596737|nutrition
890915|NCT02596737|mortality
890916|NCT02596737|morbidity
890917|NCT02596737|public health
890918|NCT02596724|Breast Cancer
890919|NCT02596724|Neoadjuvant therapy for breast cancer
890920|NCT02596711|Cancer Prevention
890921|NCT02596711|Tobacco Use Cessation
890922|NCT02596711|Nicotine Patch
890923|NCT02596711|NRT
890924|NCT02596711|Questionnaires
890925|NCT02596711|Surveys
890926|NCT02596711|Carbon Monoxide Test
890927|NCT02596711|CO
890928|NCT02596711|Health Education
890930|NCT02596711|Pamphlets
890931|NCT02596711|Counseling sessions
890932|NCT02596698|Mood Disorder
890933|NCT02596672|physical activity
890934|NCT02596672|older adults
890935|NCT02596672|retirement homes
890936|NCT02596672|walking
890937|NCT02596672|feasibility study
890938|NCT02596659|lateral epicondylosis
890939|NCT02596659|lateral epicondylitis
890940|NCT02596659|shockwave
890941|NCT02596659|sonoelastography
890942|NCT02596659|tennis elbow
890943|NCT02596659|pain intensity
890944|NCT02596659|grip strength
890945|NCT02596659|upper limb function
890946|NCT02596659|stiffness of common extensor tendon
890947|NCT02596620|Helicobacter pylori
890948|NCT02596620|Proton pump inhibitor
890949|NCT02596620|Eradication
890950|NCT02596607|ischemic stroke, acute phase, thrombolysis, management times
890951|NCT02596594|IUGR
890952|NCT02596594|severe IUGR
890953|NCT02596594|brain sparing
890954|NCT02596594|fetal nutrition
890955|NCT02596594|Prolongation
890956|NCT02596594|pregnancy
890957|NCT02596594|neonatal outcome
890958|NCT02596581|periodontitis
890959|NCT02596581|diabetes mellitus
890960|NCT02596581|chemerin
890961|NCT02596581|interleukin-6
890962|NCT02596503|young adults
890963|NCT02596503|adolescents
890964|NCT02596490|Non-Small Cell Lung Cancer
890965|NCT02596490|NSCLC
890966|NCT02596490|Couples-based meditation program
890967|NCT02596490|Couples-based cancer-related discussion program
890968|NCT02596490|Questionnaires
890969|NCT02596490|Surveys
890970|NCT02596490|Metastatic lung cancer
890971|NCT02596490|Quality of life
890972|NCT02596490|QOL
890973|NCT02596477|Heart failure
890974|NCT02595411|Children
890975|NCT02595411|Rehabilitation
890976|NCT02595411|Upper Limb
890977|NCT02595411|Assessments
890978|NCT02595411|Outcome Measures
890979|NCT02595398|Uveitis
890980|NCT02595398|UME
890981|NCT02595398|Posterior Uveitis
890982|NCT02595398|Anterior Uveitis
890983|NCT02595398|Intermediate Uveitis
890984|NCT02595398|Panuveitis
890985|NCT02595398|Non-infectious Uveitis
890986|NCT02595398|Triamcinolone
890987|NCT02595398|Choroid
890988|NCT02595398|Choroidal Injection
890989|NCT02595398|Suprachoroidal
890990|NCT02595398|Microneedle
890991|NCT02595398|Microinjection
890992|NCT02595359|endophthalmitis
890993|NCT02595359|antibiotic therapy
890994|NCT02595359|cataract surgery
890995|NCT02595359|prevention
890996|NCT02595333|repeat cesarean section
890997|NCT02595333|pain
890998|NCT02595320|breast, gastrointestinal,capecitabine, cancer, metastatic
890999|NCT02596412|children
891000|NCT02596412|botulinum toxin
891001|NCT02596412|augmented reality
891002|NCT02596412|Pain
891003|NCT02596399|Healthy volunteers
891004|NCT02596399|DSTA4637S
891005|NCT02596360|Antinociception
891006|NCT02596360|Freeze-induced hyperalgesia model
891007|NCT02596360|Dextromethorphan
891008|NCT02596360|NMDA-receptors
891009|NCT02596360|Pharmacogenetic
891010|NCT02596360|CYP3A4 gene
891011|NCT02596360|MDR1 gene
891012|NCT02596334|HIV-1 infected patient
891013|NCT02596334|monotherapy
891014|NCT02596334|dolutegravir
891015|NCT02596321|House Dust Mite
891016|NCT02596308|Plague vaccine
891017|NCT02596308|Immunogenicity
891018|NCT02596308|Safety
891019|NCT02596282|neonatal male circumcision
891020|NCT02596282|Clinical officers vs Nurse midwives
891021|NCT02596282|Rakai, Uganda
891022|NCT02596282|acceptability and safety of neonatal male circumcision
891023|NCT02596243|CIN2, CIN2/3, CIN3
891024|NCT02596243|Cervical Intraepithelial Neoplasia
891025|NCT02596243|High-Risk HPV
891026|NCT02596243|HPV infection
891027|NCT02596243|precancer Diseases
891028|NCT02596243|Double Blind
891029|NCT02596243|Safety/Efficacy
891033|NCT02596165|validation
891034|NCT02596165|pulse wave analysis
891035|NCT02596165|blood pressure monitoring
891036|NCT02596152|balance
891037|NCT02596152|strength
891038|NCT02596152|barriers towards exercise
891039|NCT02596152|quality of life
891040|NCT02596152|body dissatisfaction
891041|NCT02596152|executive functions
891042|NCT02596152|eating behavior
891043|NCT02596152|fitness
891044|NCT02596126|Polypill
891045|NCT02596126|Prevention of Secondary Cardiovascular Disease
891046|NCT02596126|Cardiovascular Disease
891047|NCT02596126|Myocardial Infarction
891048|NCT02596126|Cardiovascular Combination Polypill AAR
891049|NCT02596126|Cardiovascular Disease in the Elderly
891050|NCT02596126|Adherence
891051|NCT02596126|SECURE
891052|NCT02596126|Elderly
891053|NCT02596126|Secondary Cardiovascular Disease
891054|NCT02596126|Secondary Cardiovascular Prevention
891055|NCT02596126|Randomized Cardiovascular Trial
891056|NCT02596126|Randomized Trial
891057|NCT02596126|Cardiovascular Polypill
891058|NCT02596113|colorectal cancer
891059|NCT02596113|genes involved in carcinogenesis of the colon
891060|NCT02596113|screening colorectal cancer
891061|NCT02596100|Bioequivalence
891062|NCT02596009|COPD
891063|NCT02595983|FAP
891064|NCT02595983|Familial Amyloidotic Polyneuropathy
891065|NCT02595983|ATTR Amyloidosis
891066|NCT02595983|Orthotopic Liver Transplant
891067|NCT02595983|RNAi therapeutic
891068|NCT02595970|Psoriasis
891069|NCT02595970|Secukinumab
891070|NCT02595970|Simplified Psoriasis Index
891071|NCT02595970|CAIN457A
891072|NCT02595970|AIN457AFR01
891073|NCT02595970|AIN457A
891074|NCT02595957|Exome Sequencing
891075|NCT02595957|Incidental or Secondary Findings
891076|NCT02595853|Upper GastroIntestinal bleeding, endoscopy, Hemospray
891077|NCT02595827|Pediatrics
891078|NCT02595827|Epidemiology
891079|NCT02595827|Fever
891080|NCT02595827|Democratic Republic of the Congo
891081|NCT02595827|Randomized Controlled Trial
891082|NCT02595814|Registry
891083|NCT02595814|Heart failure
891084|NCT02595814|Hospitalized
891085|NCT02595814|Global
891086|NCT02595814|Morbidity
891087|NCT02595814|Mortality
891088|NCT02595814|Quality of life
891089|NCT02595814|AHF
891090|NCT02595775|endoscopy measures
891091|NCT02595775|audit and feedback
891092|NCT02595775|quality improvement
891093|NCT02595775|randomized controlled trial
891094|NCT02595775|Colonoscopy
891095|NCT02595710|Cryptogenic Chronic Hepatitis
891096|NCT02595710|Bartonellosis
891097|NCT02595684|Obesity
891098|NCT02595684|Tadalfil
891099|NCT02595684|Insulin secretion
891100|NCT02595684|Insulin sensitivity
891101|NCT02595671|Digital coaching
891102|NCT02595671|Sustainable weight loss
891103|NCT02595671|Self-determination theory
891104|NCT02595671|Obesity
891105|NCT02595671|Overweight
891106|NCT02595671|Diet
891107|NCT02595671|Physical activity
891108|NCT02595645|colorectal adenoma
891109|NCT02595645|colorectal cancer
891110|NCT02595645|next generation sequencing
891111|NCT02595645|liquid biopsy
891112|NCT02595645|screening colonoscopy
891113|NCT02595645|surveillance strategies
891114|NCT02595619|AKI
891115|NCT02595619|Extracorporeal Carbon Dioxide Removal
891116|NCT02595619|Renal Replacement Therapy
891117|NCT02595619|Mechanical Ventilation
891118|NCT02595606|dry eye syndromes
891119|NCT02595606|diabetes mellitus
891120|NCT02595593|Trauma
891121|NCT02595593|Rib Plate
891122|NCT02595593|Rib Fixation
891123|NCT02595580|Blood Glucose Self-Monitoring
891124|NCT02595567|Liver disease
891125|NCT02595567|Pleural effusion
891126|NCT02595554|Cervical cancer, Stage IIB, Neoadjuvant chemotherapy
891127|NCT02595541|pediatric
891128|NCT02595541|cardiac
891129|NCT02595541|sildenfil
891130|NCT02595541|milrinone
891131|NCT02595541|pulmonary hypertension
891132|NCT02595489|Leukodystrophy
891133|NCT02595489|ABCD1
891134|NCT02595489|Demyelination
891135|NCT02595489|Inflammation
891136|NCT02595489|ALD
891137|NCT02595489|Vitamin D
891138|NCT02595489|Oxidative Stress
891139|NCT02595489|X- linked
891140|NCT02595489|Adrenoleukodystrophy
891141|NCT02595476|analgesia
891142|NCT02595476|pupillometry
891143|NCT02595476|general anesthesia
891144|NCT02595450|Non-small cell lung cancer
891145|NCT02595437|dialysis
891146|NCT02595437|pediatric
891147|NCT02595437|chronic kidney disease
891148|NCT02595307|Risk Recall
891149|NCT02595307|Pamphlet
891150|NCT02595307|Brochure
891151|NCT02595307|Patient satisfaction
891152|NCT02595307|Informed Consent
891153|NCT02595281|Ovarian Carcinoma
891154|NCT02595281|neoadjuvant
891155|NCT02595281|ROMA
891156|NCT02595281|Ca125
891157|NCT02595281|HE4
891158|NCT02595281|biomarker
891159|NCT02595268|Healthy
891160|NCT02595268|Pitavastatin
891161|NCT02595268|JNJ-63623872
891162|NCT02595255|chemotherapy/GnRH analogues/lymphoma/children/fertility
891163|NCT02595203|Bioavailability
891164|NCT02595190|Sacral perineurial cysts(Tarlov Cysts)
891165|NCT02595190|Resting state functional magnetic resonance imaging (rfMRI)
891166|NCT02595190|VAS
891167|NCT02595190|Medicine conservative treatment
891168|NCT02595190|Surgical treatment
891169|NCT02595177|multifocal IOL
891170|NCT02595177|monovision
891171|NCT02595177|hybrid monovision
891172|NCT02595177|spectacles independence
891173|NCT02595151|Probe-based confocal laser endomicroscopy
891174|NCT02595151|chronic atrophic antral gastritis
891175|NCT02595151|microcirculatory dynamics
891176|NCT02595138|zoledronic acid
891177|NCT02595138|triple-negative breast cancer
891178|NCT02595138|adjuvant treatment
891184|NCT02595112|staphylococcal infections
891185|NCT02595112|nasal carriage
891186|NCT02595112|nasal cavity
891187|NCT02595112|Staphylococcus aureus
891188|NCT02595060|acute lung injury, molgramostim, GM-CSF, pneumonia, barrier restoration
891189|NCT02595047|Self-regeneration, in vivo tissue prefabrication,
891190|NCT02595021|Total or subtotal colectomy
891191|NCT02595021|Ovarian cancer
891192|NCT02595021|Complications
891193|NCT02595021|One-year disease-free survival
891194|NCT02595021|Stage IIIc
891195|NCT02595021|Stage IV
891196|NCT02594982|Delirium
891197|NCT02594982|intensive care nursing
891198|NCT02594982|Acute acquired brain injury
891199|NCT02594982|neurointensive care
891200|NCT02594982|Intensive care delirium screening checklist
891201|NCT02594982|Confusion Assessment Method for the ICU
891202|NCT02594969|atopic dermatitis
891203|NCT02594956|nasogastric decompression
891204|NCT02594943|Diagnostics
891205|NCT02594943|Biopsy
891206|NCT02594943|Diffuse gastric cancer
891207|NCT02594930|synovial biopsy
891208|NCT02594930|knee arthroplasty
891209|NCT02594930|infection
891210|NCT02594904|G6PD Deficiency
891211|NCT02594904|Neonatal Hyperbilirubinemia
891212|NCT02594904|Yinzhihuang Oral Liquid
891213|NCT02594904|Indirect Bilirubin
891214|NCT02594891|cholangitis
891215|NCT02594891|endoscopic retrograde cholangiopancreatography
891216|NCT02594891|complication
891217|NCT02594878|Chronic non-bacterial osteomyelitis
891218|NCT02594878|Chronic recurrent multifocal osteomyelitis
891219|NCT02594878|Non- bacterial osteomyelitis
891220|NCT02594878|SAPHO syndrome
891221|NCT02594878|Whole body MRI
891222|NCT02594878|Pamidronate
891223|NCT02594878|Inflammatory bone disease
891224|NCT02594878|Autoinflammatory disease
891225|NCT02594865|Enteral Nutrition
891226|NCT02594865|Continuous Glucose Monitoring
891227|NCT02594839|interstitial lung disease
891228|NCT02594839|idiopathic interstitial pneumonia
891229|NCT02594839|idiopathic pulmonary fibrosis
891230|NCT02594839|stem cells
891231|NCT02594800|Atherosclerotic Intracranial Arterial Stenosis
891232|NCT02594800|Intensive Rosuvastatin Therapy
891233|NCT02594800|Computed Tomography Perfusion (CTP)
891234|NCT02594735|Juvenile dermatomyositis
891235|NCT02594735|inflammatory myopathies
891236|NCT02594735|Orencia
891237|NCT02594735|Abatacept
891238|NCT02594722|COPD
891239|NCT02594722|Functional Electrical Stimulation Cycling
891240|NCT02594722|Pulmonary Rehabilitation
891241|NCT02594696|Major depression and Cancer
891242|NCT02594696|Schizophrenia and Cancer
891243|NCT02594696|Bipolar disorder and Cancer
891244|NCT02594696|Lung Cancer
891245|NCT02594696|Breast Cancer
891246|NCT02594696|Head and Neck cancer
891247|NCT02594696|GI cancer
891248|NCT02594696|Schizophrenia
891249|NCT02594696|Bipolar disorder
891250|NCT02594670|acupoints
891251|NCT02594670|insomnia
891252|NCT02594670|acupuncture
891253|NCT02594670|randomized controlled trial
891254|NCT02594657|Eccentric
891255|NCT02594657|Ergometer
891256|NCT02594657|Pedal rate
891257|NCT02594657|Oxygen consumption
891258|NCT02594657|Only health volunteers
891259|NCT02594631|Urethral stones
891260|NCT02594631|Acute Cacular urinary retention
891261|NCT02594631|Extracorporeal Shock Wave Lithotripsy (ESWL)
891262|NCT02594631|Visual lithotripsy
891263|NCT02594631|bladder stone
891264|NCT02594592|Osteoporosis
891265|NCT02594592|Osteoporosis Self-Assessment Tool
891266|NCT02594592|One-Minute Osteoporosis Risk Test
891267|NCT02594592|Asians
891268|NCT02594566|Cytomegalovirus
891269|NCT02594566|Vaccine
891270|NCT02594566|Congenital Infection
891271|NCT02594553|Antibiotics
891272|NCT02594553|Children
891273|NCT02594553|General Practitioner
891274|NCT02594553|GP
891275|NCT02594553|After-hours care
891276|NCT02594553|Out-of-hours care
891277|NCT02594553|Booklet
891278|NCT02594553|Primary Health Care
891279|NCT02594553|Child
891280|NCT02594527|Older people
891281|NCT02594527|Physical activity
891282|NCT02594527|Hospital
891283|NCT02594514|cardiovascular risk
891284|NCT02594514|metabolic profile
891285|NCT02594488|Myocardial infarction
891286|NCT02594488|Autonomic nervous system
891287|NCT02594488|Risk stratification
891288|NCT02594488|Implantable cardiac monitor
891289|NCT02594488|Sudden cardiac death
891290|NCT02594488|ECG
891291|NCT02594475|endoscopic retrograde cholangiopancreatography, position
891292|NCT02594462|contraception
891293|NCT02594462|Anemia, Sickle Cell
891294|NCT02594449|Pharmacodynamic Study of BCS
891295|NCT02594436|Actinic Keratosis
891296|NCT02594436|topical
891297|NCT02594436|ingenol mebutate
891298|NCT02594436|Picato®
891299|NCT02594384|Phase 1
891300|NCT02594384|Safety
891301|NCT02594384|Apilimod dimesylate
891302|NCT02594384|Pharmacokinetics
891303|NCT02594384|Non-Hodgkin's Lymphoma
891304|NCT02594358|Caffeine
891305|NCT02594332|eosinophilic asthma
891306|NCT02594332|mepolizumab
891307|NCT02594332|treatment
891308|NCT02594306|drug addiction
891309|NCT02594306|Heroin
891310|NCT02594306|craving
891311|NCT02594306|event related potential
891312|NCT02594306|crystal methamphetamine
891313|NCT02594267|PTCL
891314|NCT02594267|Peripheral T-Cell Lymphoma
891315|NCT02594267|Folotyn
891316|NCT02594267|Pralatrexate
891317|NCT02594267|CHOP
891318|NCT02594241|Ventral hernia
891319|NCT02594241|Abdominal wall reconstruction
891320|NCT02594241|Enhanced recovery after surgery
891321|NCT02594241|Steroid
891322|NCT02594215|Overgrowth
891323|NCT02594202|Specimen Collection
891324|NCT02594202|Carcinogenesis
891325|NCT02594202|Prognostic Biomarkers
891326|NCT02594202|Molecular Mechanims
891327|NCT02594202|Cell Lines
891328|NCT02594189|Influenza A
891329|NCT02594189|H3N2
891330|NCT02594189|Challenge Model
891331|NCT02594189|Influenza
891332|NCT02594189|Human Challenge
891333|NCT02594176|Osteoarthritis
891334|NCT02594176|Pain
891335|NCT02594176|NSAID
891336|NCT02594176|Sequessome
891337|NCT02594137|Decompressive craniectomy
891338|NCT02594137|Brain Edema
891339|NCT02594124|Spinal Muscular Atrophy
891340|NCT02594124|SMA
891341|NCT02594124|SMN
891342|NCT02594124|SMNRx
891343|NCT02594124|ISIS-SMNRx
891344|NCT02594124|ISIS-SMN Rx
891345|NCT02594124|ISIS 396443
891346|NCT02594124|SHINE
891347|NCT02594124|IONIS-SMNRx
891348|NCT02594124|IONIS-SMN Rx
891349|NCT02594124|Spinraza
891350|NCT02594124|nusinersen
891351|NCT02594111|inflammation
891352|NCT02594111|percutaneous coronary intervention
891353|NCT02594111|coronary artery disease
891354|NCT02594111|colchicine
891355|NCT02594098|Atopic dermatitis
891356|NCT02594098|extrinsic atopic dermatitis
891357|NCT02594098|intrinsic atopic dermatitis
891358|NCT02594059|endothelial function, idiopathic pulmonary fibrosis
891359|NCT02594020|suspected caries
891360|NCT02594020|initial enamel lesions
891361|NCT02594007|telehealth
891362|NCT02594007|heart failure
891363|NCT02593994|Onyx
891364|NCT02593994|drug eluting stent
891365|NCT02593994|Routine Clinical Practice
891366|NCT02593994|Angioplasty, Transluminal, Percutaneous Coronary
891367|NCT02593994|Coronary Artery Disease
891368|NCT02593981|sleep
891369|NCT02593981|fruit
891370|NCT02593981|honey
891371|NCT02593981|geriatric
891372|NCT02593929|squamous cell carcinoma
891373|NCT02593929|head and neck cancer
891374|NCT02593929|operable
891375|NCT02593903|Antibiotic Prophylaxis
891376|NCT02593890|Breast Cancer
891377|NCT02593890|Breast Surgery
891378|NCT02593890|Mastectomy
891379|NCT02593890|Lumpectomy
891380|NCT02593890|Post-operative
891381|NCT02593890|Bra
891382|NCT02593890|Lingerie
891383|NCT02593890|Body Image
891384|NCT02593890|Psycho-social
891385|NCT02593890|Impact
891386|NCT02593877|Trauma
891387|NCT02593877|Hemostasis
891388|NCT02593877|Resuscitation
891389|NCT02593877|Coagulopathy
891390|NCT02593877|Transfusion
891391|NCT02593851|Respiratory Syncytial Virus Infections
891392|NCT02593851|JNJ-53718678
891393|NCT02593851|Placebo
891394|NCT02593851|Infants
891395|NCT02593812|Learning
891396|NCT02593812|Practice
891397|NCT02593799|Liver cirrhosis
891398|NCT02593799|Esophageal and Gastric Varices
891399|NCT02593799|Endoscopy
891400|NCT02593773|Interferon gamma
891401|NCT02593747|Allergy
891402|NCT02593708|HER2+
891403|NCT02593695|Anorexia Nervosa
891404|NCT02593695|Deep Brain Stimulation
891405|NCT02593695|Nucleus accumbens
891406|NCT02593656|protein ingestion
891407|NCT02593656|resistance exercise
891408|NCT02593656|interval exercise
891409|NCT02593656|stretching exercise
891410|NCT02593656|endurance exercise
891411|NCT02593643|Major Depressive Disorder
891412|NCT02593643|Bipolar Disorder
891413|NCT02593643|Depression
891414|NCT02593643|Suicide
891415|NCT02593643|Suicidal Ideation
891416|NCT02593643|Ketamine
891417|NCT02593643|Midazolam
891418|NCT02593643|Inpatients
891419|NCT02593617|Energy Drinks
891420|NCT02593617|Alcohol Drinking
891421|NCT02593617|Substance Use
891422|NCT02593604|Hidradenitis suppurativa
891423|NCT02593604|Wide excision
891424|NCT02593604|Quality of Life
891425|NCT02593604|Sexual Function
891426|NCT02593539|APDS
891427|NCT02593539|Safety
891428|NCT02593539|Pharmacokinetics
891429|NCT02593539|GSK2269557
891430|NCT02593539|PASLI
891431|NCT02593513|Embryo Transfer
891432|NCT02593513|Embryo Selection Criteria for Implantation
891433|NCT02593513|Assisted Reproductive Technology
891434|NCT02593500|Bioequivalence, budesonide,
891435|NCT02593487|Coronary Artery Disease
891436|NCT02593487|Hyperlipidemia
891437|NCT02593487|Rosuvastatin
891438|NCT02593487|Lipoproteins
891439|NCT02593487|high-density lipoprotein
891440|NCT02593487|HDL2
891441|NCT02593474|Adolescent
891442|NCT02593474|Youth
891443|NCT02593461|Embryo Transfer
891444|NCT02593461|Embryo Selection Criteria for Implantation
891445|NCT02593461|Assisted Reproductive Technology
891446|NCT02593448|Cardiopulmonary Bypass
891447|NCT02593448|Anoxia
891448|NCT02593435|BRCA1/2 gene mutation
891449|NCT02593435|Breast Cancer
891450|NCT02593435|Chinese high risk group
891451|NCT02593422|ovarian cancer
891452|NCT02593422|expressive writing
891453|NCT02593422|writing interventions
891454|NCT02593422|psychosocial support
891455|NCT02593409|HIV-1
891456|NCT02593409|pre-exposure prophylaxis (PrEP)
891457|NCT02593409|immune response
891458|NCT02593396|sexual dysfunctions
891459|NCT02593396|erectile dysfunctions
891460|NCT02593396|hypoactive sexual desire dysfunctions
891461|NCT02593383|safety
891462|NCT02593383|efficacy
891463|NCT02593370|Hip surgery anesthesia
891464|NCT02593370|Perioperative analgesia
891465|NCT02593357|endothelial function
891466|NCT02593357|COPD
891467|NCT02593357|pulmonary function
891468|NCT02593344|asthma, endothelial function
891469|NCT02593318|energy metabolism
891470|NCT02593318|oxaloacetate
891471|NCT02593305|nitrate
891472|NCT02593305|blood flow
891473|NCT02593305|blood pressure
891474|NCT02593305|vascular function
891475|NCT02593305|hypoxia
891476|NCT02593292|Clinical pathway
891477|NCT02593292|Electronic Health Records
891478|NCT02593292|Maternal Health Services & administration
891479|NCT02593292|Patient Access to Records
891480|NCT02593292|Patient Satisfaction
891481|NCT02593292|Prenatal Care/methods
891482|NCT02593279|Asthma
891483|NCT02593279|phenotype
891484|NCT02593279|small
891485|NCT02593279|airway
891486|NCT02593279|proximal
891487|NCT02593279|dysfunction
891488|NCT02593266|Prevention
891489|NCT02593266|Family
891490|NCT02593266|Intervention
891491|NCT02593266|Depression
891492|NCT02593266|Children
891493|NCT02593253|Quality Improvement
891494|NCT02593253|Quality Indicators, Health Care
891495|NCT02593253|Hospital Medicine
891496|NCT02593240|Energy
891497|NCT02593240|Presenteeism
891498|NCT02593240|Absenteeism
891499|NCT02593240|Cardiometabolic health
891500|NCT02593240|Obesity
891501|NCT02593240|Overweight
891502|NCT02593240|Weight Loss
891503|NCT02593240|Quality of Life
891504|NCT02593240|Weight Control
891505|NCT02593240|Eating Behavior
891506|NCT02593240|Food Cravings
891507|NCT02593240|Hunger
891508|NCT02593240|Worksite Wellness
891509|NCT02593227|TNBC
891510|NCT02593214|Condoms, Female
891511|NCT02593214|Contraception, Barrier
891512|NCT02593175|Triple-Negative Breast Cancer
891513|NCT02593175|TNBC
891514|NCT02593175|Panitumumab
891515|NCT02593175|Vectibix
891516|NCT02593175|Paclitaxel
891517|NCT02593175|Taxol
891518|NCT02593175|Carboplatin
891519|NCT02593175|Paraplatin
891520|NCT02593175|Biopsy
891521|NCT02593175|Fine-needle aspiration
891522|NCT02593175|FNA
891523|NCT02593136|Vitamins
891524|NCT02593136|Public Health
891525|NCT02593136|Nutrition
891526|NCT02593084|Resistance Training
891527|NCT02593084|Exercise
891528|NCT02593084|Walking
891529|NCT02593084|Safety
891530|NCT02593084|Feasibility Studies
891531|NCT02593058|Anhedonia
891532|NCT02593058|Apathy
891533|NCT02593058|Negative symptoms
891534|NCT02593058|Anticipatory pleasure
891535|NCT02593058|Savoring
891536|NCT02593032|hemoglobin A1c protein, human > 7.5
891537|NCT02593006|Joint Diseases
891538|NCT02593006|Juvenile Arthritis
891539|NCT02593006|treatment
891540|NCT02593006|biologic therapy
891541|NCT02593006|comparative effectiveness
891542|NCT02592967|Carcinoma, Non-Small-Cell Lung
891543|NCT02592967|JNJ-64041757
891544|NCT02592967|Listeria monocytogenes
891545|NCT02592928|eHealth
891546|NCT02592928|Spirometry
891547|NCT02592928|Lung Function
891548|NCT02592928|Primary Care
891549|NCT02592928|Telehealth
891550|NCT02592928|Integrated Care
891551|NCT02592902|recurrent respiratory papillomatosis
891552|NCT02592902|extra oesophageal reflux
891553|NCT02592902|laryngeal cyst
891554|NCT02592902|phonosurgery
891555|NCT02592902|oesophageal impedance
891556|NCT02592889|MITRAL REGURGITATION
891580|NCT02592850|Osteopathic manipulative treatment
891581|NCT02592850|Frequent Episodic Tension-Type Headache
891582|NCT02592850|Randomized Controlled Trial
891583|NCT02592837|Endobronchial ultrasound
891584|NCT02592837|EBUS
891585|NCT02592837|TBNA
891586|NCT02592837|Mediastinal ymphadenopathy
891587|NCT02592837|Hilar lymphadenopathy
891588|NCT02592837|Lung cancer
891589|NCT02592824|glutamate, heart failure, coronary artery bypass surgery
891590|NCT02592811|Cholangiopancreatography
891591|NCT02592811|therapeutic strategy
891592|NCT02592811|Endoscopic Retrograde
891593|NCT02592772|menthol
891594|NCT02592772|nicotine
891595|NCT02592772|reduced nicotine
891596|NCT02592772|smoking
891597|NCT02592772|cigarette
891598|NCT02592772|cigarettes
891599|NCT02592772|men smoking
891600|NCT02592772|smoking research
891601|NCT02592772|nicotine dependence
891602|NCT02592720|Acute Coronary Syndromes
891603|NCT02592720|Fractional Flow Reserve
891604|NCT02592720|Percutaneous Coronary Intervention
891605|NCT02592681|menstrual migraine
891606|NCT02592681|acupuncture
891607|NCT02592681|acupressure
891608|NCT02592655|tourniquet
891609|NCT02592655|arterial
891610|NCT02592655|pre-hospital
891611|NCT02592655|SOFTT-W
891612|NCT02592655|Battle Wrap
891613|NCT02592655|windlass
891614|NCT02592655|exsanguination
891615|NCT02592655|hemorrhage
891616|NCT02592655|amputation
891617|NCT02592642|lumbar spinal stenosis
891618|NCT02592642|neurogenic claudication
891619|NCT02592642|non-operative
891620|NCT02592642|treatment
891621|NCT02592642|outcomes
891622|NCT02592642|clinical trial
891623|NCT02592629|subacromial injection
891624|NCT02592629|rotator cuff disease
891625|NCT02592629|steroid injection
891626|NCT02592616|Exercise
891627|NCT02592616|Appetite
891628|NCT02592616|Energy intake
891629|NCT02592603|Serrated lesions
891630|NCT02592603|Surveillance
891631|NCT02592603|Colorectal cancer
891632|NCT02592603|Endocuff
891633|NCT02592603|Sessile serrated adenoma
891634|NCT02592603|Colonoscopy
891635|NCT02592590|Exercise
891636|NCT02592590|Physical Activity
891637|NCT02592590|Smartphone
891638|NCT02592590|Technology
891646|NCT02592564|Magnetic Resonance Imaging
891647|NCT02592564|Cognitive Behavior Therapy
891648|NCT02592564|Telomerase
891649|NCT02592564|Telomere Length, Mean Leukocyte
891650|NCT02592538|Biliary duct carcinoma;
891651|NCT02592538|radiofrequency ablation
891652|NCT02592538|S-1
891655|NCT02592499|HM III
891656|NCT02592499|survival
891657|NCT02592499|LVAD
891658|NCT02592486|quadrivalent influenza vaccine
891659|NCT02592486|23-valent pneumococcal vaccine
891660|NCT02592486|immunogenicity
891661|NCT02592473|Prostate Artery Embolization (PAE)
891662|NCT02592473|Benign Prostatic Hyperplasia (BPH)
891663|NCT02592473|Lower Urinary Tract Symptoms (LUTS)
891664|NCT02592473|BPH
891665|NCT02592473|PAE
891666|NCT02592473|LUTS
891667|NCT02592473|Prostatic Artery Embolization
891668|NCT02592447|CML
891669|NCT02592447|chronic phase CML
891670|NCT02592447|leukemia
891671|NCT02592434|Arthritis
891672|NCT02592434|Pediatric
891673|NCT02592434|Tofacitinib
891674|NCT02592434|Long-term
891675|NCT02592434|JIA
891676|NCT02592434|polyarticular
891677|NCT02592434|CP-690,550
891678|NCT02592434|Xeljanz
891679|NCT02592395|pancreatic adenocarcinoma
891680|NCT02592395|electrochemotherapy
891681|NCT02592395|electroporation
891682|NCT02592395|radiogenomics
891683|NCT02592395|imaging
891684|NCT02592395|magnetic resonance spectroscopy
891809|NCT02591576|Relative survival
891685|NCT02592356|Full-body dual-energy x-ray absorptiometry
891686|NCT02592356|DXA
891687|NCT02592356|Body measurement
891688|NCT02592356|Weight of participant
891689|NCT02592356|Questionnaires
891690|NCT02592356|Surveys
891691|NCT02592356|Chemotherapy
891692|NCT02592356|Advanced Cancers
891693|NCT02592356|Endocrine Tumor
891694|NCT02592343|fecal microbiota transplantation
891695|NCT02592343|lyophilized
891696|NCT02592330|CALEC
891697|NCT02592330|Limbal Stem Cell Deficiency
891698|NCT02592330|LSCD
891699|NCT02592317|JNJ-56021927
891700|NCT02592317|Prostatic Neoplasms, Castration-Resistant
891701|NCT02592291|Mobile health
891702|NCT02592291|Apps
891703|NCT02592291|Applications
891704|NCT02592291|Smart phone
891705|NCT02592291|mHealth
891706|NCT02592291|Chronic and Complex Conditions
891707|NCT02592291|Self-Management
891708|NCT02592291|Self-Care
891709|NCT02592278|Dental Caries
891710|NCT02592278|Fluoride Varnish
891711|NCT02592278|Preschool child
891712|NCT02592278|Prevention
891713|NCT02592239|Functional brain MRI
891714|NCT02592239|functional dyspepsia
891715|NCT02592239|hedonic response
891716|NCT02592200|Female
891717|NCT02592200|Constipation
891718|NCT02592200|Lactobacillus gasseri DSM 27123
891719|NCT02592200|Probiotics
891720|NCT02592187|Life-logging
891721|NCT02592187|Cognitive Training
891722|NCT02592187|Mild Cognitive Impairment
891723|NCT02592187|Memory
891724|NCT02592187|Information and communications technology (ICT) in healthcare
891725|NCT02592187|Portable camera
891726|NCT02592135|Acute Cardiac Insufficiency
891727|NCT02592135|Acute Heart Failure
891728|NCT02592122|Mechanical ventilation
891729|NCT02592122|Chronic obstructive pulmonary disease
891730|NCT02592122|Airway resistance
891731|NCT02592122|Bronchial dilation test
891732|NCT02592109|Complementary Feeding Recommendation
891733|NCT02592109|Linear Programming
891734|NCT02592109|Nutritional Status
891735|NCT02592109|Omega-3 Fatty Acids
891736|NCT02592109|Malondialdehyde
891737|NCT02592109|alpha-Tocopherol
891738|NCT02592096|safety and bioavailability
891739|NCT02592083|Neoadjuvant Therapy
891740|NCT02592083|Cyclin-Dependent Kinase Inhibitor p16
891741|NCT02592044|pain
891742|NCT02592044|anxiety
891743|NCT02592044|Catheterization, Peripheral
891744|NCT02592005|pollution
891745|NCT02591979|Sleep Apnea Syndrome
891746|NCT02591979|Primary Health Care
891747|NCT02591940|cardiovascular modeling
891748|NCT02591940|aortic coarctation
891749|NCT02591940|aortic valve disease
891750|NCT02591927|myocardial infarction
891751|NCT02591927|glucose-insulin-potassium
891752|NCT02591901|Spinal Cord Injuries
891753|NCT02591901|Multiple Sclerosis
891754|NCT02591901|Transverse Myelitis
891755|NCT02591901|Neurogenic Bladder Dysfunction
891756|NCT02591901|Feasibility Study
891757|NCT02591901|Urinary Tract Infection
891758|NCT02591875|Cardiac Catheter Ablation
891759|NCT02591875|Cardiac Arrhythmias
891760|NCT02591875|Atrial Flutter
891761|NCT02591836|LDL‐C
891762|NCT02591836|Lipid Regulator
891763|NCT02591797|pain
891764|NCT02591797|Infant Behavior
891765|NCT02591797|Heart rate
891766|NCT02591797|Dental Anxiety
891767|NCT02591784|nimotuzumab esophageal radiotherapy
891768|NCT02591771|Adrenaline
891769|NCT02591771|Extra Corporeal Life Support
891770|NCT02591771|Inotropes
891771|NCT02591758|Hexo-Skin
891772|NCT02591758|Hexoskin
891773|NCT02591758|NOVA-SKIN
891774|NCT02591758|angina
891775|NCT02591758|biometric vest
891776|NCT02591706|Single missing tooth
891777|NCT02591706|Implants
891778|NCT02591706|Peri-implant bone remodeling
891779|NCT02591706|Bone thickness
891780|NCT02591706|Thickness of soft tissue
891781|NCT02591693|Family Caregivers
891782|NCT02591693|Occupational Therapy
891783|NCT02591693|Activities of Daily Living
891784|NCT02591667|Colorectal cancer
891785|NCT02591667|Peritoneal metastasis
891786|NCT02591667|Neoadjuvant chemotherapy
891787|NCT02591667|5-Fluorouracil
891788|NCT02591667|Oxaliplatin
891789|NCT02591667|Irinotecan
891790|NCT02591667|Bevacizumab
891791|NCT02591667|Histopathological response
891792|NCT02591654|FLT
891793|NCT02591654|Pembrolizumab
891794|NCT02591654|Metastatic Melanoma
891795|NCT02591654|MK-3475
891796|NCT02591641|pre-hospital transport
891797|NCT02591641|shear force
891798|NCT02591641|tissue interface pressure
891799|NCT02591628|Hypertension
891800|NCT02591628|Thiazide diuretics
891801|NCT02591589|Hyperoxia
891802|NCT02591589|Delirium
891803|NCT02591589|Normoxic
891804|NCT02591589|t-MoCA
891805|NCT02591576|Diabetes
891806|NCT02591576|ST-elevation myocardial infarction (STEMI)
891807|NCT02591576|non-STEMI
891808|NCT02591576|Excess mortality
891810|NCT02591550|chronic cough
891811|NCT02591550|cough reflex sensitivity
891812|NCT02591550|transient receptor potential vanilloid 1
891813|NCT02591550|transient receptor potential ankyrin 1
891814|NCT02591498|cognitive training
891815|NCT02591485|PTSD prevention
891816|NCT02591485|Acute stress disorder
891817|NCT02591485|Attention training
891818|NCT02591485|Cognitive bias modification
891819|NCT02591459|Autism
891820|NCT02591446|TMS
891821|NCT02591446|Autism Spectrum Disorders
891822|NCT02591446|Plasticity
891823|NCT02591407|Continuous Epidural Analgesia
891824|NCT02591407|Transversus Abdominis Plane block
891825|NCT02591381|urinary stress incontinence
891826|NCT02591355|Platelet Rich Plasma
891827|NCT02591355|Hair Loss
891828|NCT02591342|femoral neck fracture
891829|NCT02591342|hip arthroplasty
891830|NCT02591342|complication
891831|NCT02591342|periprosthetic femoral fracture
891832|NCT02591316|nutrition
891833|NCT02591316|physical activity
891834|NCT02591316|breast cancer survivor
891835|NCT02591316|cognition
891836|NCT02591303|Insomnia
891837|NCT02591303|Stress
891838|NCT02591303|Real-life stressful events
891839|NCT02591290|Meningitis
891840|NCT02591290|Meningococcal Meningitis
891841|NCT02591290|Meningococcal Infections
891842|NCT02591290|Menactra®
891843|NCT02591290|Meningococcal Vaccine
891844|NCT02591277|Hepatitis C virus
891845|NCT02591277|observational
891846|NCT02591277|post-marketing
891847|NCT02591277|ledipasvir/sofosbuvir
891848|NCT02591277|Japan
891849|NCT02591238|smoking
891850|NCT02591238|melatonin
891851|NCT02591238|vascular injury
891852|NCT02591225|left atrial thrombus size
891853|NCT02591225|transesophageale echocardiography
891854|NCT02591225|silent cerebral embolism
891855|NCT02591212|Bystanding behaviors
891856|NCT02591212|Campus
891857|NCT02591212|Prevention
891858|NCT02591212|Sexual Assault
891859|NCT02591212|CampusSave
891860|NCT02591173|Autonomic
891861|NCT02591173|Hypertension
891862|NCT02591173|Renin-Angiotensin System
891863|NCT02591134|weight loss
891864|NCT02591134|NNS
891865|NCT02591134|beverages
891866|NCT02591134|diet
891867|NCT02591134|appetite
891868|NCT02591134|satiety
891869|NCT02591134|weight control
891870|NCT02591108|train of four
891871|NCT02591108|neuromuscular blockade
891872|NCT02591108|surgery
891873|NCT02591069|Vagus nerve stimulation
891874|NCT02591069|vegetative state
891875|NCT02591069|minimally conscious state
891876|NCT02591069|akinetic mutism
891877|NCT02591069|consciousness
891878|NCT02591069|connectivity
891879|NCT02591043|Pelvic
891880|NCT02591043|Treatment Outcome
891885|NCT02591004|Neuroprotection
891886|NCT02591004|calcium channel blockers
891887|NCT02591004|magnesium sulhate
891888|NCT02591004|Middle cerebral artery doppler
891889|NCT02590978|gallstone pancreatitis
891890|NCT02590978|mild acute pancreatitis
891891|NCT02590978|adult
891892|NCT02590952|safety, PK
891893|NCT02590926|Fractional Flow Reserve, Myocardial
891894|NCT02590913|fructose
891895|NCT02590913|metabolism
891896|NCT02590913|acute
891897|NCT02590900|pharmacokinetics
891898|NCT02590900|pregnancy
891899|NCT02590900|oral contraceptives
891900|NCT02590900|oestradiol
891901|NCT02590874|Mild Cognitive Impairment
891902|NCT02590874|Cognition
891903|NCT02590874|Memory
891904|NCT02590874|Depression
891905|NCT02590874|Depressive disorder
891906|NCT02590874|Antidepressive agents
891907|NCT02590874|Duloxetine
891908|NCT02590874|Cymbalta
891909|NCT02590874|Selective serotonin and norepinephrine uptake inhibitors
891910|NCT02590861|Partial Dentures
891911|NCT02590861|Dental Implants
891912|NCT02590861|Quality of Life
891913|NCT02590861|Partial Edentulism
891914|NCT02590848|Walnut intake
891915|NCT02590848|Brain development
891916|NCT02590848|Nutritional intervention
891917|NCT02590848|Healthy adolescents
891918|NCT02590835|Adult patients
891919|NCT02590835|Patient demand for orthodontic treatment
891920|NCT02590822|Diabetes
891921|NCT02590822|T2DM
891922|NCT02590822|young adults
891923|NCT02590822|heart
891924|NCT02590822|weight loss
891925|NCT02590822|MRI
891926|NCT02590822|exercise
891927|NCT02590822|diastolic function
891928|NCT02590809|Left ventricular obstruction
891929|NCT02590796|Delirium
891930|NCT02590796|Inattention
891931|NCT02590796|Medical device
891932|NCT02590796|Software application
891933|NCT02590796|Validation study
891934|NCT02590796|Diagnosis
891935|NCT02590796|Dementia
891936|NCT02590783|treatment
891937|NCT02590757|non-invasive ventilation
891938|NCT02590757|non-invasive neurally adjusted ventilatory assist
891939|NCT02590757|nasal continuous positive airway pressure
891940|NCT02590744|Emergence Agitation
891941|NCT02590744|eye patch
891942|NCT02590744|preschool children
891943|NCT02590653|STEMI
891944|NCT02590653|myocardial strain
891945|NCT02590653|atorvastatin
891946|NCT02590627|Parasite clearance, Treatment failure
891947|NCT02590601|PPCM
891948|NCT02590601|Bromocriptine
891949|NCT02590601|Peripartum cardiomyopathy
891950|NCT02590588|IgM-associated AL amyloidosis
891951|NCT02590575|extracorporeal CO2 removal
891952|NCT02590575|renal replacement therapy
891953|NCT02590575|Prismalung
891954|NCT02590575|ARDS
891955|NCT02590575|hypercapnia
891956|NCT02590575|Changes in the arterial pCO2 value
891957|NCT02590575|ventilated
891958|NCT02590575|Hypercapnic
891959|NCT02590549|Keratoconus
891960|NCT02590549|riboflavin
891961|NCT02590549|corneal collagen crosslinking
891962|NCT02590549|intrasromal ring
891963|NCT02590536|Sildenafil
891964|NCT02590536|Fetal growth Restriction
891965|NCT02590536|Umbilical Artery Doppler
891966|NCT02590510|Intrathecal chemotherapy
891967|NCT02590471|Angioplasty with stenting of the superficial femoral artery
891968|NCT02590471|Fasciotomy in Hunter's channel
891969|NCT02590471|Breakage of stent
891976|NCT02590432|Immunogenicity
891977|NCT02590432|Irritable Bowel Syndrome with Constipation
891978|NCT02590432|Chronic Idiopathic Constipation
891979|NCT02590432|Linaclotide
891980|NCT02590432|Linzess
891981|NCT02590406|Morbid Obesity
891982|NCT02590406|Bariatric Surgery
891983|NCT02590406|Pre-Oxygenation
891984|NCT02590406|Anesthesia Induction
891985|NCT02590406|Positive pressure ventilation
891986|NCT02590406|Non hypoxic apnea time
891987|NCT02590406|Positive-Pressure Respiration
891988|NCT02590406|Anesthesia, General
891989|NCT02590393|Nicotine addiction
891990|NCT02590393|Cigarette smoking
891991|NCT02590393|E-cigarettes
891992|NCT02590380|Adolescent
891993|NCT02590380|paediatric
891994|NCT02590380|pediatric
891995|NCT02590380|scoliosis
891996|NCT02590380|spine deformity
891997|NCT02590367|oxaliplatin-induced peripheral neuropathy
891998|NCT02590367|HD6610 granule
891999|NCT02590367|colorectal cancer
892000|NCT02590354|Treatment interruption
892001|NCT02590354|functional cure
892002|NCT02590341|myocarditis
892003|NCT02590341|children
892004|NCT02590341|adolescents
892005|NCT02590341|registry
892006|NCT02590341|multi-center
892007|NCT02590341|pediatric
892008|NCT02590341|heart failure
892009|NCT02590341|inflammatory heart disease
892010|NCT02590341|inflammatory cardiomyopathy
892011|NCT02590328|Neonatal Screening
892012|NCT02590328|Severe Combined Immunodeficiency
892013|NCT02590328|Immunologic Deficiency Syndromes
892014|NCT02590328|DNA Repair-Deficiency Disorders
892015|NCT02590328|T-cell Receptor Excision Circle
892016|NCT02590315|BC
892017|NCT02590302|Clinical pathway
892018|NCT02590302|Mental Health
892019|NCT02590302|Emergency Department
892020|NCT02590302|Paediatric
892021|NCT02590302|Risk assessment
892022|NCT02590302|Service integration
892023|NCT02590302|Transitions in care
892024|NCT02590302|Implementation
892025|NCT02590302|Scoring tools
892026|NCT02590302|Clinical Pathway Evaluation
892027|NCT02590276|frontotemporal Dementia
892028|NCT02590276|Amyotrophic lateral sclerosis
892029|NCT02590276|Biomarkers
892030|NCT02590276|brain Imaging PET
892031|NCT02590263|WHO grade III
892032|NCT02590263|WHO grade IV
892033|NCT02590237|Laryngoscopy
892034|NCT02590237|Video Laryngoscopy
892035|NCT02590211|experimental study
892036|NCT02590211|cognitive mechanisms
892037|NCT02590211|poker
892038|NCT02590211|cognitive remediation therapy
892039|NCT02590133|Refractory Nasopharyngeal Carcinoma, Endostar, 5-Fu
892040|NCT02590081|Normal saline
892041|NCT02590081|Destrose 5%
892042|NCT02590081|Blood pressure
892043|NCT02590081|Interdialytic weight gain
892044|NCT02590081|thirst level
892045|NCT02590081|End Stage Renal Failure
892046|NCT02589990|health
892047|NCT02589990|muscle strength
892048|NCT02589990|exercise genomics
892049|NCT02589977|magnetic resonance imaging
892050|NCT02589977|positron-emission tomography
892051|NCT02589977|echocardiography
892052|NCT02589977|myocardial blood flow
892053|NCT02589977|energy metabolism
892054|NCT02589964|probiotics
892055|NCT02589964|antibiotic associated diarrhea
892056|NCT02589964|clostridium difficile
892057|NCT02589925|deep brain stimulation
892058|NCT02589925|subthalamic nucleus
892059|NCT02589925|Nucleus basalis Meynert
892060|NCT02589886|Self-help
892061|NCT02589886|Education
892062|NCT02589886|e-Health
892063|NCT02589873|Lifestyle Intervention
892064|NCT02589873|Workplace
892065|NCT02589873|Diabetes Prevention
892066|NCT02589860|Stem Cell Transplantation
892067|NCT02589847|Clostridium difficile
892068|NCT02589847|C diff
892069|NCT02589847|CDI
892070|NCT02589847|CDAD
892071|NCT02589847|Fecal transplant
892072|NCT02589847|Fecal Microbiota transplant
892073|NCT02589847|diarrhea
892074|NCT02589847|FMT
892075|NCT02589847|microbiota restoration therapy
892076|NCT02589847|microbiota suspension
892077|NCT02589847|fecal bacteriotherapy
892078|NCT02589847|C diff diarrhea
892079|NCT02589808|pre-operative
892080|NCT02589808|transthoracic echocardiography
892081|NCT02589808|handheld
892082|NCT02589795|safety
892083|NCT02589795|immunogenicity
892084|NCT02589795|HIV vaccine
892085|NCT02589782|bedaquiline
892086|NCT02589782|Nitroimidazoles
892087|NCT02589782|diarylquinolines
892088|NCT02589782|linezolid
892089|NCT02589782|clofazimine
892090|NCT02589782|pretomanid
892091|NCT02589782|moxifloxacin
892092|NCT02589756|obesity
892093|NCT02589756|persistent organic pollutants
892094|NCT02589756|metabolic syndrome
892095|NCT02589743|clinical trial
892096|NCT02589743|pit and fissure sealants
892097|NCT02589743|tooth eruption
892098|NCT02589743|retention
892099|NCT02589743|adhesive system
892100|NCT02589743|intermediary layer
892101|NCT02589730|Smartphone app
892102|NCT02589730|diabetic management
892103|NCT02589730|lifestyle behaviors
892104|NCT02589730|medication management
892105|NCT02589678|AIDS
892106|NCT02589678|Immunology
892107|NCT02589678|Public Health
892108|NCT02589678|Female sex workers
892109|NCT02589678|Single mothers
892111|NCT02589652|Pegylated interferon
892112|NCT02589652|Entecavir
892113|NCT02589600|Bone loss
892114|NCT02589600|Frail Geriatric Women
892115|NCT02589600|Nursing Home Patients
892116|NCT02589600|Long-term Care Patients
892117|NCT02589600|Osteoporosis
892118|NCT02589600|Osteoporotic Fractures
892119|NCT02589561|hearing loss
892120|NCT02589561|hearing aids
892121|NCT02589548|Hodgkin Lymphoma
892122|NCT02589548|Hodgkin Disease
892123|NCT02589509|Event-related potentials
892124|NCT02589509|Attention
892125|NCT02589509|Cognitive rehabilitation
892126|NCT02589509|Independent activities of daily living
892127|NCT02589470|cognitive rehabilitation
892128|NCT02589470|memory
892129|NCT02589470|epilepsy
892130|NCT02589457|Chronic Hepatitis B virus, HIV-1 infection
892131|NCT02589457|Healthy Male Volunteer
892132|NCT02589457|Tenofovir Disoproxil Fumarate
892133|NCT02589444|Clinical Endocrinology
892134|NCT02589444|Immunology
892135|NCT02589444|Inflammation
892136|NCT02589444|Microbiology
892137|NCT02589444|Respiratory Disorders
892138|NCT02589444|Vitamins
892139|NCT02589431|hypothalamo pituitary adrenal axis
892140|NCT02589418|Manual acupuncture
892141|NCT02589418|Experimental dental pain
892142|NCT02589418|Psychophysics
892143|NCT02589418|Autonomic nervous system
892144|NCT02589418|Subjective pain ratings
892145|NCT02589379|postoperative pancreatic fistula
892146|NCT02589379|soft and hard pancreas
892147|NCT02589366|Lymphoseek
892148|NCT02589366|endometrial cancer
892149|NCT02589366|sentinel lymph node
892150|NCT02589366|lymph node dissection
892151|NCT02589275|TNX-102 SL
892152|NCT02589275|bedtime
892153|NCT02589275|sublingual
892154|NCT02589275|3-month
892155|NCT02589275|long term safety
892156|NCT02589275|long term efficacy
892157|NCT02589275|Fibromyalgia
892158|NCT02589236|Cystic Fibrosis
892159|NCT02589236|N91115
892160|NCT02589236|Cavosonstat
892161|NCT02589223|multisensory stimulation
892162|NCT02589210|Diabetes Mellitus
892163|NCT02589210|Foot Disease
892164|NCT02589210|Foot Ulcer
892165|NCT02589197|osteoarthritis
892166|NCT02589197|correction of functional deformity
892167|NCT02589197|procedures
892168|NCT02589197|traumatic osteoarthritis
892169|NCT02589197|degenerative osteoarthritis
892170|NCT02589197|total knee arthroplasty
892171|NCT02589197|Healthy Volunteers
892172|NCT02589197|electromyography
892173|NCT02589197|Musculoskeletal Diseases
892174|NCT02589184|balance, postural
892175|NCT02589184|postural equilibrium
892176|NCT02589184|pain scale
892177|NCT02589184|range of motion
892178|NCT02589145|Blood And Marrow Transplantation
892179|NCT02589145|Diffuse large B-cell lymphoma
892180|NCT02589145|DLBCL
892181|NCT02589145|Busulfan
892182|NCT02589145|Busulfex
892183|NCT02589145|Myleran
892184|NCT02589145|Lenalidomide
892185|NCT02589145|CC-5013
892186|NCT02589145|Revlimid
892187|NCT02589145|Vorinostat
892188|NCT02589145|SAHA
892189|NCT02589145|Suberoylanilide Hydroxamic Acid
892190|NCT02589145|MSK-390
892191|NCT02589145|Zolinza
892192|NCT02589145|Gemcitabine
892193|NCT02589145|Gemcitabine Hydrochloride
892194|NCT02589145|Gemzar
892195|NCT02589145|Melphalan
892196|NCT02589145|Alkeran
892197|NCT02589145|Rituximab
892198|NCT02589145|Rituxan
892199|NCT02589145|Dexamethasone
892200|NCT02589145|Decadron
892201|NCT02589145|Glutamine
892202|NCT02589145|Enterex
892203|NCT02589145|Glutapack-10
892204|NCT02589145|NutreStore
892205|NCT02589145|Resource
892206|NCT02589145|GlutaSolve
892207|NCT02589145|Sympt-X G.I.
892208|NCT02589145|Symptx-X
892209|NCT02589145|Pyridoxine
892210|NCT02589145|Enoxaparin
892211|NCT02589145|Lovenox Injection
892212|NCT02589145|Palifermin
892213|NCT02589145|Kepivance
892214|NCT02589119|cryptoglandular
892215|NCT02589119|perianal fistula
892216|NCT02589119|cryptoglandular perianal fistulas
892217|NCT02589106|Anisotropic Textile Braces
892218|NCT02589093|Analgesia
892219|NCT02589093|Monitoring
892220|NCT02589093|Analgesia Nociception Index
892221|NCT02589093|ANI
892222|NCT02589093|PhysioDoloris
892223|NCT02589093|Pain
892224|NCT02589041|intraneural sciatic block
892225|NCT02589028|diabetes mellitus
892226|NCT02589028|incretin hormone
892227|NCT02589028|glucose level
892228|NCT02589028|GLP-1
892229|NCT02589028|GIP
892230|NCT02589028|premeal protein
892231|NCT02589015|morbid obesity
892232|NCT02589015|neck circumference
892233|NCT02589015|difficult mask ventilation
892234|NCT02589015|difficult laryngoscopy
892235|NCT02589002|sucralose
892236|NCT02589002|insulin sensitivity
892237|NCT02589002|beta-cell response
892238|NCT02589002|appetite regulating hormone
892239|NCT02588976|Activated clotting time
892240|NCT02588976|Sonoclot
892241|NCT02588963|upper respiratory tract infections
892242|NCT02588963|lower respiratory tract infections
892243|NCT02588963|health promotion
892244|NCT02588963|respiratory physiotherapy
892245|NCT02588963|infant
892246|NCT02588937|Entecavir, EntecaBell ODT., Hepatitis B
892247|NCT02588924|Parkinson Disease
892248|NCT02588924|ENVIRONMENTAL AND OCCUPATIONAL EXPOSURE TO METALS
892249|NCT02588911|Radiofrequency Catheter Ablation
892250|NCT02588911|Operative Surgical Procedure
892251|NCT02588911|Saphenous Vein
892252|NCT02588885|physical therapy
892253|NCT02588885|psychotherapy
892254|NCT02588885|dysfunctional sexual behavior
892255|NCT02588885|pelvic pain
892256|NCT02588885|posttraumatic stress
892257|NCT02588885|PTSD
892258|NCT02588885|chronic pain
892259|NCT02588872|platelet-rich plasma
892260|NCT02588872|hyaluronic acid
892261|NCT02588859|T2DM, Diabetes
892262|NCT02588846|Prostate
892263|NCT02588846|Radiotherapy
892264|NCT02588846|IGRT
892265|NCT02588846|VMAT
892266|NCT02588846|Image-guided radiation therapy
892267|NCT02588846|Volumetric modulated arc therapy
892268|NCT02588846|Adaptive radiotherapy
892269|NCT02588820|HIV
892270|NCT02588794|sepsis, acute kidney injury , CytoSorb
892271|NCT02588768|Low-level laser therapy
892272|NCT02588768|Light emitting diodes
892273|NCT02588768|Rugby
892274|NCT02588768|Field test
892275|NCT02588768|Photobiomodulation
892276|NCT02588755|Chemoembolization
892277|NCT02588755|Therapeutic
892278|NCT02588755|Tegafur
892279|NCT02588742|elderly ICU patients
892280|NCT02588729|Gestational diabetes
892281|NCT02588729|app
892282|NCT02588729|RCT
892283|NCT02588729|diet
892284|NCT02588729|physical activity
892285|NCT02588716|Hepatectomy, Surgical Blood Loss, terlipressin
892286|NCT02588677|Amyotrophic Lateral Sclerosis (ALS) - masitinib
892287|NCT02588664|Early Supported Discharge
892288|NCT02588651|Lymphoma
892289|NCT02588651|Leukemia
892290|NCT02588651|Brentuximab Vedotin
892291|NCT02588638|NGS
892292|NCT02588638|Quality of life
892293|NCT02588638|Diagnosis
892294|NCT02588638|Rare disease
892295|NCT02588638|Next-generation sequencing
892302|NCT02588586|HIV
892303|NCT02588586|3BNC117
892304|NCT02588586|Broadly neutralizing antibody
892305|NCT02588560|lymphoma, hepatitis C virus, chemotherapy
892306|NCT02588547|Shivering
892307|NCT02588547|Granisetron
892308|NCT02588547|Pethidine
892309|NCT02588547|Spinal
892310|NCT02588547|Cesarean section
892311|NCT02588534|etanercept, healthy subject,open-label, randomized, auto-injection, bioequivalence, pharmacokinetic
892312|NCT02588508|perineal tear
892313|NCT02588508|pain
892314|NCT02588508|pelvic floor
892315|NCT02588508|Labour
892316|NCT02588495|Ultrasound
892317|NCT02588495|Gastric area
892318|NCT02588495|Accuracy
892319|NCT02588495|Aspirate
892320|NCT02588482|electroencephalography (EEG)
892321|NCT02588482|mismatch negativity (MMN)
892322|NCT02588469|pediatric obesity
892323|NCT02588469|obstructive sleep apnea
892324|NCT02588469|physical exercise
892325|NCT02588469|compression socks
892326|NCT02588469|rostral fluid shift
892327|NCT02588391|premature birth; executive function; preschool
892328|NCT02588365|Attention Deficit Hyperactivity Disorder; executive function; preschool
892329|NCT02588339|Hematologic disorder
892330|NCT02588339|allogeneic hematopoietic cell transplantation
892331|NCT02588326|Bioequivalence
892332|NCT02588326|Suspension nasal spray
892333|NCT02588326|Mometasone furoate
892334|NCT02588326|Pharmacokinetics
892335|NCT02588326|Particle size distribution
892336|NCT02588274|Chronic prostatitis
892337|NCT02588274|chronic pelvic pain syndrome
892338|NCT02588274|acupuncture
892339|NCT02588274|placebo needle
892340|NCT02588274|randomized controlled trial
892346|NCT02588183|atrial fibrillation
892347|NCT02588183|catheter ablation
892348|NCT02588183|pulmonary vein
892349|NCT02588183|cryoenergy
892350|NCT02588183|cryoablation
892351|NCT02588183|ArcticFront
892352|NCT02588157|Rapid sequence induction intubation
892353|NCT02588157|McGrath X-Blade
892354|NCT02588157|Glidescope
892355|NCT02588157|Macintosh
892356|NCT02588144|Parkinson's disease
892357|NCT02588144|freezing of gait
892358|NCT02588144|deep brain stimulation
892359|NCT02588144|substantia nigra pars reticulata
892360|NCT02588144|subthalamic nucleus
892361|NCT02588131|tremelimumab
892362|NCT02588131|anti-PD-L1 MEDI4736 (Durvalumab)
892363|NCT02588131|malignant mesothelioma
892365|NCT02588079|Dental Fear
892366|NCT02588079|Dental Phobia
892367|NCT02588079|Internet based cognitive behavioral therapy
892368|NCT02588079|specific phobia
892369|NCT02588079|children and adolescents anxiety
892370|NCT02588079|Self Efficacy
892371|NCT02588040|Chronic Lateral Epicondylitis
892372|NCT02588040|Leukocyte- and Platelet-Rich Plasma
892373|NCT02588040|Recover-L-PRP
892374|NCT02587988|Erectile dysfunction & Hypertension
892375|NCT02587949|acute cerebrovascular stroke
892376|NCT02587936|Chronic
892377|NCT02587936|Risk prediction model
892378|NCT02587936|Quality Improvement (QI)
892379|NCT02587936|Pragmatic trial
892380|NCT02587936|Cluster randomization
892381|NCT02587936|Collaborative care
892382|NCT02587936|clinical informatics
892383|NCT02587936|Chronic kidney disease
892384|NCT02587936|hypertension
892385|NCT02587936|high BP
892386|NCT02587936|diabetes
892387|NCT02587897|Ultrasonography
892388|NCT02587897|Nerve Conduction Velocity
892389|NCT02587897|Ergonomics
892390|NCT02587897|Work Related Injury
892391|NCT02587897|Cumulative Trauma Disorders
892392|NCT02587884|Recurrence
892393|NCT02587884|Microvascular Invasion
892394|NCT02587884|Aspartate beta-hydroxylase
892395|NCT02587858|NBIA
892396|NCT02587858|PKAN
892397|NCT02587858|brain iron
892398|NCT02587858|Neurodegeneration with Brain Iron Accumulation
892399|NCT02587858|Hallervorden Spatz Syndrome
892400|NCT02587858|Pantothenate Kinase Associated Neurodegeneration
892401|NCT02587845|total hip arthroplasty
892402|NCT02587845|transexamic acid
892403|NCT02587832|cpap
892404|NCT02587832|HHHFNC
892405|NCT02587832|RDS
892406|NCT02587832|ELBW
892407|NCT02587806|RRMS
892408|NCT02587793|Hepatocellular Carcinoma
892409|NCT02587793|primary culture
892410|NCT02587793|fine-needle aspiration
892411|NCT02587793|cancer-associated fibroblast
892412|NCT02587741|type 2 diabetes mellitus
892413|NCT02587741|Diabetic Retinopathy
892414|NCT02587741|glucose fluctuation
892415|NCT02587741|oxidative stress
892416|NCT02587741|Insulin
892417|NCT02587741|Oral drugs
892418|NCT02587728|Carpal Tunnel Syndrome
892419|NCT02587728|Amyloidosis
892420|NCT02587715|RRMS
892421|NCT02587702|Term Infants
892422|NCT02587650|Metastatic
892423|NCT02587650|BRAF Wild-Type (WT)
892424|NCT02587650|NRAS Wild-Type (WT)
892425|NCT02587650|KRAS Wild-Type (WT)
892426|NCT02587650|HRAS Wild-Type (WT)
892427|NCT02587650|GNAQ Wild-Type (WT)
892428|NCT02587650|GNA11 Wild-Type (WT)
892429|NCT02587650|KIT Wild-Type (WT)
892430|NCT02587624|atrial fibrillation
892431|NCT02587624|catheter ablation
892432|NCT02587624|remote magnetic navigation
892433|NCT02587598|leukemia
892434|NCT02587598|myelodysplastic syndrome (MDS)
892435|NCT02587598|myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
892436|NCT02587598|myelofibrosis (MF)
892437|NCT02587598|lymphoproliferative disorders
892438|NCT02587598|acute myeloid leukemia (AML)
892439|NCT02587598|lymphomas
892440|NCT02587598|multiple myeloma (MM)
892441|NCT02587598|PIM kinases
892442|NCT02587559|physical therapy
892443|NCT02587546|laryngeal carcinoma
892444|NCT02587546|bilateral vocal cord paralysis
892445|NCT02587546|laryngotracheal stenosis
892446|NCT02587546|laser treatment
892447|NCT02587546|decannulation
892448|NCT02587546|voice
892449|NCT02587546|swallowing
892450|NCT02587533|Baroreflex
892451|NCT02587533|Chemoreflex
892452|NCT02587533|Autonomic nervous system
892453|NCT02587533|Sympathetic activity
892454|NCT02587533|Muscle sympathetic nerve activity (MSNA)
892455|NCT02587533|Microneurography
892456|NCT02587533|Electrical baroreflex stimulation
892457|NCT02587533|Resistant hypertension
892458|NCT02587533|Device-based therapy
892464|NCT02587481|Acute coronary syndrom
892465|NCT02587481|Chronic obstructive pulmonary disease
892466|NCT02587481|Myocardial infarction
892467|NCT02587481|Blood based biomarkers
892468|NCT02587468|phenolics
892469|NCT02587468|absorption
892470|NCT02587468|fruit & vegetable concentrate
892471|NCT02587468|Bioavailability of phenolic compounds
892472|NCT02587455|Non-small cell carcinoma
892473|NCT02587442|Acute Radiation Syndrome
892474|NCT02587442|ARS
892475|NCT02587442|Amifostine
892476|NCT02587442|Radio-protectants
892477|NCT02587416|Pharmacokinetics
892478|NCT02587416|Lipid Regulator
892479|NCT02587390|Pharmacokinetics
892480|NCT02587390|Lipid Regulator
892481|NCT02587364|Pharmacokinetics
892482|NCT02587364|Lipid Regulator
892483|NCT02587351|Chronic Obstructive Pulmonary Disease
892484|NCT02587351|COPD
892485|NCT02587351|Exacerbation
892486|NCT02587351|Lung function
892487|NCT02587351|Cardiac
892488|NCT02587351|Cardiovascular
892489|NCT02587351|Beta blockers
892490|NCT02587351|Metoprolol succinate
892491|NCT02587351|Smoking
892492|NCT02587338|Subjective Memory Impairment
892493|NCT02587338|tDCS
892494|NCT02587338|NIRS
892495|NCT02587338|Cognitive Training
892496|NCT02587338|Working Memory
892497|NCT02587286|mHealth
892498|NCT02587286|Telemedicine
892499|NCT02587286|Randomized Controlled Trial
892500|NCT02587286|Glucose control
892501|NCT02587273|Critical care
892502|NCT02587273|Intensive Care
892503|NCT02587273|Fentanyl
892504|NCT02587273|Pharmacokinetics
892505|NCT02587273|Multiple Organ Failure
892506|NCT02587260|P2Y12 inhibitors
892507|NCT02587260|Acute Coronary Syndrome (ACS)
892508|NCT02587260|Endothelial function
892509|NCT02587260|Adenosine measurement in human subject
892510|NCT02587260|Endopath
892511|NCT02587234|motor recovery
892512|NCT02587234|chronic
892513|NCT02587234|human
892514|NCT02587234|sensory
892515|NCT02587234|afferent input
892516|NCT02587234|motor training
892517|NCT02587208|circumcision
892518|NCT02587208|plastibell
892519|NCT02587208|infants
892520|NCT02587208|open sleeve
892521|NCT02587195|Multiple Sclerosis
892522|NCT02587169|liposarcoma
892523|NCT02587169|leiomyosarcoma
892524|NCT02587169|retroperitoneum
892525|NCT02587169|chondrosarcoma
892526|NCT02587130|intractable pain
892527|NCT02587130|pressure ulcer
892528|NCT02587130|bed sore
892529|NCT02587130|palliative medicine
892530|NCT02587130|ketamine
892531|NCT02587130|pain management
892532|NCT02587117|Antioxidant
892533|NCT02587117|Lycopene
892534|NCT02587117|Prednisolone
892535|NCT02587104|Diabetes Mellitus
892536|NCT02587104|Foot Diseases
892537|NCT02587104|Foot Ulcer
892538|NCT02587078|Haemodynamic stabilization
892539|NCT02587052|biopsy-proven acute rejection
892540|NCT02587052|graft loss
892541|NCT02587052|graft survival
892542|NCT02587039|delirium
892543|NCT02587039|heart
892544|NCT02587039|valve
892545|NCT02587039|graft
892546|NCT02587039|surgery
892547|NCT02587039|coronary
892548|NCT02587026|Biorepository
892549|NCT02587026|Precision Genomics
892550|NCT02587000|adenomyosis
892551|NCT02587000|ulipristal acetate
892552|NCT02587000|sonography
892553|NCT02587000|Magnetic resonance imaging [MRI]
892554|NCT02587000|Pictorial Blood-loss Assessment Chart [PBAC]
892555|NCT02586987|Selumetinib
892556|NCT02586987|Tremelimumab
892557|NCT02586987|MEDI4736
892558|NCT02586987|Safety
892559|NCT02586987|Tolerability
892560|NCT02586987|Pharmacokinetics
892561|NCT02586987|Patients with advanced solid tumours
892562|NCT02586987|Disease progression
892563|NCT02586974|CO2 insufflation
892564|NCT02586974|robot assisted radical prostatectomy
892565|NCT02586974|laparoscopy
892566|NCT02586974|hypothermia
892567|NCT02586974|cytokine response
892568|NCT02586961|randomized prospective study
892569|NCT02586961|complication rate
892570|NCT02586961|bronchiolitis
892571|NCT02586961|children
892572|NCT02586948|extracorporeal CO2 removal
892573|NCT02586935|ASD
892574|NCT02586935|Autism
892575|NCT02586909|Alzheimer's disease
892576|NCT02586909|RVT-101
892577|NCT02586909|donepezil
892578|NCT02586883|Dilation of the Bronchi
892579|NCT02586883|Bronchial potential difference
892580|NCT02586883|Dilation of the Bronchi (DDB)
892581|NCT02586857|Glioblastoma Multiforme
892582|NCT02586857|GBM
892583|NCT02586844|NET
892584|NCT02586844|PanNET
892585|NCT02586844|Molecular profiling
892586|NCT02586844|Transcriptome sequencing
892587|NCT02586831|Diabetes Mellitus, Type 1
892588|NCT02586831|Hypoglycemia
892589|NCT02586831|Autoimmune Diseases
892590|NCT02586831|Diabetes Mellitus
892591|NCT02586805|DX-2930
892592|NCT02586805|Hereditary Angioedema
892593|NCT02586805|Dyax
892594|NCT02586792|H7N7
892595|NCT02586792|H7N9
892596|NCT02586792|Influenza
892597|NCT02586792|Intramusclar
892598|NCT02586792|Non-adjuvanted
892599|NCT02586792|Open-Label
892600|NCT02586792|sub-study
892601|NCT02586792|Vaccine
892602|NCT02586779|Referral and consultation
892603|NCT02586779|emergency department
892604|NCT02586779|WhatsApp
892605|NCT02586766|Youth Violence
892606|NCT02586727|Radiation Retinopathy
892607|NCT02586727|aflibercept
892608|NCT02586688|child depression
892609|NCT02586688|depression
892610|NCT02586688|Transcranial Magnetic Stimulation
892611|NCT02586688|Adolescent Major Depressive Disorder
892612|NCT02586688|TMS
892613|NCT02586688|adolescent depression
892614|NCT02586675|ER+ breast cancer
892615|NCT02586675|PR+ breast cancer
892616|NCT02586675|hormone receptor positive
892617|NCT02586675|HER2- breast cancer
892618|NCT02586675|HER2 negative
892619|NCT02586675|locally advanced
892620|NCT02586675|metastatic
892621|NCT02586662|scapular dyskinesis
892622|NCT02586662|kinematics
892623|NCT02586649|tiotropium bromide
892624|NCT02586636|Metformin
892625|NCT02586636|OCT1
892626|NCT02586610|Pembrolizumab
892627|NCT02586610|Chemoradiation
892628|NCT02586610|Anti-PD-1 Antibody
892629|NCT02586610|MK-3475
892630|NCT02586597|Stroke
892631|NCT02586597|PAS
892632|NCT02586597|TMS
892633|NCT02586597|cortical excitability
892634|NCT02586597|plasticity
892635|NCT02586584|Patient-Reported Outcome, Antiretroviral Therapy
892636|NCT02586571|Body Composition
892637|NCT02586571|Breast Feeding
892638|NCT02586571|Growth
892639|NCT02586571|Infant
892640|NCT02586571|Milk, Human
892641|NCT02586571|Nutritional Sciences
892642|NCT02586571|Weaning
892643|NCT02586532|Detection
892644|NCT02586532|Cancer
892645|NCT02586532|Antibody
892646|NCT02586532|Biopsy
892647|NCT02586532|Registry
892648|NCT02586519|wearable technology
892649|NCT02586519|Orpyx
892650|NCT02586519|SurroSense Rx
892651|NCT02586519|smart insole
892652|NCT02586519|TCC
892653|NCT02586519|total contact cast
892654|NCT02586519|insole
892655|NCT02586519|removable cast walker
892656|NCT02586519|RCW
892657|NCT02586506|correct use of inhaler
892658|NCT02586506|dose left
892659|NCT02586506|ease of use
892660|NCT02586506|ELLIPTA
892661|NCT02586506|Asthma
892662|NCT02586493|Placebo
892663|NCT02586493|ELLIPTA inhaler
892664|NCT02586493|Correct use
892665|NCT02586493|COPD
892666|NCT02586493|Ease of use
892667|NCT02586480|bradycardia
892669|NCT02586441|Bispectral index (BIS)
892670|NCT02586441|EEG
892671|NCT02586441|Depth of anesthesia
892672|NCT02586415|endovascular
892673|NCT02586415|endovascular procedure
892674|NCT02586415|Mechanical Thrombectomy
892675|NCT02586402|ESAs CKD
892676|NCT02586363|Entecavir
892677|NCT02586363|Food effect
892678|NCT02586363|Cavir Tab 0.5mg
892679|NCT02586363|Baraclude Tab. 0.5mg
892680|NCT02586285|S-Adenosyl Methionine
892681|NCT02586285|Recurrence
892682|NCT02586272|Embryo Transfer
892683|NCT02586272|assisted reproductive technology
892684|NCT02586246|CDP870
892685|NCT02586246|Rheumatoid arthritis
892686|NCT02586246|Long-term
892687|NCT02586233|Acute Ischemic Stroke in the anterior circulation
892688|NCT02586207|Larynx
892689|NCT02586207|Squamous Cell
892690|NCT02586207|Oral cavity
892691|NCT02586207|Oropharynx
892692|NCT02586207|Hypopharynx
892693|NCT02586194|Impaired hepatic function
892694|NCT02586194|Pharmacokinetics
892695|NCT02586194|ASP015K
892696|NCT02586168|Insulin Resistance
892697|NCT02586168|Lipid Regulator
892698|NCT02586142|spasticity
892699|NCT02586142|claw toe
892700|NCT02586142|ultrasounds guidance
892701|NCT02586142|botulinum toxin
892702|NCT02586142|stretching exercise
892703|NCT02586090|Pediatric Obesity
892704|NCT02586090|Lifestyle Intervention
892705|NCT02586090|Family-based Intervention
892706|NCT02586090|Motivational Interviewing
892707|NCT02586064|posttraumatic stress disorder
892708|NCT02586064|Veterans
892709|NCT02586064|Psychotherapy
892710|NCT02586064|Randomized Controlled Trial
892711|NCT02585999|Hormonal contraception, hormone pharmacokinetics
892712|NCT02585973|AZD1775
892713|NCT02585973|Cisplatin
892714|NCT02585973|Head and Neck Squamous Cell Carcinoma
892715|NCT02585973|HNSCC
892716|NCT02585973|Chemoradiotherapy
892717|NCT02585973|Radiotherapy
892718|NCT02585973|CRT
892719|NCT02585947|Non-Hodgkin's Lymphoma
892720|NCT02585947|Tenofovir
892721|NCT02585934|Alzheimer's disease
892722|NCT02585934|RVT-101
892723|NCT02585934|donepezil
892724|NCT02585934|intepirdine
892725|NCT02585934|dementia
892726|NCT02585921|Urban Health
892727|NCT02585895|LDL-C Apheresis
892728|NCT02585895|Hypercholesterolemia
892729|NCT02585895|Elevated Cholesterol
892730|NCT02585895|High Cholesterol
892731|NCT02585895|PCSK9 mutations
892732|NCT02585895|Severe Familial Hypercholesterolemia
892733|NCT02585895|evolocumab
892734|NCT02585895|Repatha
892735|NCT02585869|Lipid Regulator
892736|NCT02585869|TG
892737|NCT02585856|Biliary duct carcinoma
892738|NCT02585856|Photodynamic therapy
892739|NCT02585843|Heart Failure
892740|NCT02585843|Mineralocorticoid receptor antagonists
892741|NCT02585843|Loop diuretic resistance
892742|NCT02585817|Cardiac Implantable Electronic Devices
892743|NCT02585804|FSGS, SGLT2, chronic kidney disease, GFR, proteinuria
892744|NCT02585791|electronic cigarette
892745|NCT02585791|airway inflammation
892746|NCT02585791|nasal potential difference
892747|NCT02585726|Varicose Veins
892748|NCT02585726|Great Saphenous Vein
892749|NCT02585726|Venous Insufficiency
892750|NCT02585687|Liver Perfusion MRI, Hepatocellular carcinoma
892751|NCT02585622|Diabetic Kidney Disease
892752|NCT02585622|Mesenchymal Stromal Cells (MSC)
892753|NCT02585622|immune response
892754|NCT02585622|allogeneic
892755|NCT02585622|disease progression
892756|NCT02585609|Sleep
892757|NCT02585583|Deep Brain
892758|NCT02585583|Essential tremor
892759|NCT02585583|Parkinson Disease
892760|NCT02585583|Tremor
892761|NCT02585583|Radiosurgery
892762|NCT02585583|Thalamotomy
892763|NCT02585583|deep brain stimulation
892764|NCT02585583|DBS
892765|NCT02585583|intractable, drug resistant, invalidating tremor
892766|NCT02585570|shoulder
892767|NCT02585570|phenylephrine
892768|NCT02585570|hypotension
892769|NCT02585544|genital prolapse
892770|NCT02585544|day-care management
892771|NCT02585544|vaginal route
892772|NCT02585544|prosthetic reinforcement
892773|NCT02585531|Bronchiolitis
892774|NCT02585531|Dexamethasone
892775|NCT02585531|Epinephrine
892776|NCT02585531|Hypertonic saline
892777|NCT02585427|Diabetes
892778|NCT02585427|Obesity
892779|NCT02585427|metabolic disorders
892780|NCT02585388|pretreated metastatic breast cancer
892781|NCT02585362|palliative
892782|NCT02585336|Sugar-Sweetened beverages
892783|NCT02585336|Metabolic health
892784|NCT02585336|Soft drinks
892785|NCT02585323|Physical activity
892786|NCT02585323|Osteoarthritis
892787|NCT02585323|Knee
892788|NCT02585323|Exercise
892789|NCT02585323|Arthritis
892790|NCT02585310|PRBC transfusion
892791|NCT02585310|CABGs
892792|NCT02585245|Hospital Nutrition screens
892793|NCT02585232|Behavioral sciences
892794|NCT02585232|Counseling
892795|NCT02585232|Intervention Studies
892796|NCT02585232|Cognitive Behavioral Therapy
892797|NCT02585232|Telemedicine
892798|NCT02585232|Mindfulness
892799|NCT02585206|Mobile Phone
892800|NCT02585206|Text Messaging
892801|NCT02585206|Internet
892802|NCT02585206|Tobacco Use
892803|NCT02585180|Ventilator-associated pneumonia
892804|NCT02585180|Surveillance
892805|NCT02585180|Subglottic-secretions
892806|NCT02585180|Critically ill patients
892807|NCT02585180|Prevention
892808|NCT02585167|VAAFT
892809|NCT02585167|anal fistula
892810|NCT02585167|sphincter reconstruction
892811|NCT02585154|Deep Brain Stimulation
892812|NCT02585128|Delirium
892813|NCT02585128|Transcatheter Aortic Valve Implantation
892814|NCT02585128|Elderly
892815|NCT02585102|Vegetables
892816|NCT02585089|Hypertension
892817|NCT02585089|active biopeptide
892818|NCT02585089|cardiovascular pathophysiology
892819|NCT02585089|angiotensin converting enzyme inhibition
892820|NCT02585089|cured-pork ham
892821|NCT02585076|Stroke prevention
892822|NCT02585076|Risk assessment
892823|NCT02585063|independent prescribing,
892824|NCT02585063|optometrist
892825|NCT02585063|acute care
892826|NCT02585050|do not attempt resuscitation
892827|NCT02585050|neurological outcome
892828|NCT02585050|live discharged ratio
892829|NCT02585024|smoking
892830|NCT02585024|cytisine
892831|NCT02585024|Pharmacokinetics
892832|NCT02585011|Hemiarthroplasty
892833|NCT02585011|Anesthesia, Local
892834|NCT02585011|Pain, Postoperative
892835|NCT02584972|Postural control
892836|NCT02584972|Gait
892837|NCT02584972|Children
892838|NCT02584972|Autism Spectrum Disorder
892839|NCT02584933|ALK
892840|NCT02584933|Malignancies
892841|NCT02584907|Critically ill
892842|NCT02584907|Diet
892843|NCT02584907|Blood glucose
892844|NCT02584894|Stress Disorders, Post-Traumatic
892845|NCT02584894|trauma exposure
892846|NCT02584894|Repeated transcranial magnetic stimulation
892847|NCT02584855|Spondyloarthritis
892848|NCT02584855|Spondylarthropathy
892849|NCT02584816|BRV-PV
892850|NCT02584816|Rotavirus vaccine
892851|NCT02584816|lot-to-lot consistency
892852|NCT02584816|interference with routine immunization
892853|NCT02584790|Nasopharyngeal carcinoma
892854|NCT02584790|Narrow band imaging
892855|NCT02584777|Post-essential thrombocythemia myelofibrosis
892856|NCT02584777|Post-Polycythemia Vera Myelofibrosis
892857|NCT02584738|Asthma
892858|NCT02584738|Exacerbation
892859|NCT02584738|Nebulization
892860|NCT02584738|Magnesium
892861|NCT02584738|Pediatric
892862|NCT02584725|Tranexamic Acid
892863|NCT02584725|Total Joint Arthroplasty
892864|NCT02584725|Intraoperative Blood Loss
892865|NCT02584660|Rivaroxaban
892866|NCT02584660|JNJ39039039
892867|NCT02584660|Pulmonary embolism
892868|NCT02584647|Unresectable
892869|NCT02584634|Non-Small Cell Lung Cancer
892870|NCT02584634|NSCLC
892871|NCT02584634|ALK
892872|NCT02584634|avelumab
892873|NCT02584634|crizotinib
892874|NCT02584634|PF-06463922
892875|NCT02584595|Tachycardia
892876|NCT02584595|Ventricular Tachycardia
892877|NCT02584595|Cardiac Arrhythmias
892878|NCT02584595|Cardiovascular Diseases
892879|NCT02584595|Heart Diseases
892880|NCT02584582|Glucagon
892881|NCT02584582|Glukagon-like peptide-1 (GLP-1)
892882|NCT02584582|GLP-1 receptor agonist (GLP-1RA)
892883|NCT02584582|Incretins
892884|NCT02584569|Drug therapy
892885|NCT02584530|ultrasound
892886|NCT02584530|PICC line
892887|NCT02584530|neonate
892888|NCT02584517|Vasculitis
892889|NCT02584517|Autoimmune disease
892890|NCT02584517|Connective tissue disease
892891|NCT02584517|Polymyalgia rheumatica
892892|NCT02584517|Musculoskeletal Diseases
892893|NCT02584517|Immune disorder
892894|NCT02584517|Rheumatic disease
892895|NCT02584478|Dual receptor Tyrosine Kinase Inhibitor
892896|NCT02584478|Anti-angiogenic therapy
892897|NCT02584478|Combination Therapy
892898|NCT02584439|ivabradine
892899|NCT02584439|heart rate
892900|NCT02584439|aging
892901|NCT02584439|visco-elasticity
892902|NCT02584426|Cefazolin
892903|NCT02584400|prostatic tumors
892904|NCT02584400|[18F]HX4 Pet imaging
892905|NCT02584400|hypoxia
892906|NCT02584400|phase II trial
892907|NCT02584400|esophageal tumors
892908|NCT02584400|rectal tumors
892909|NCT02584400|brain metastases
892910|NCT02584400|primary brain tumors
892911|NCT02584374|iliac vein compression
892912|NCT02584361|Hearing loss
892913|NCT02584361|Cochlear implant
892914|NCT02584348|ultrasound, antrum, pulmonary aspiration, emergency surgery
892915|NCT02584335|wound treatment
892916|NCT02584335|lidocaine
892917|NCT02584335|pain reduction
892918|NCT02584335|local anesthetic
892919|NCT02584283|Liver Transplantation
892920|NCT02584283|Donation after Circulatory Death
892921|NCT02584283|Machine Perfusion
892922|NCT02584270|palatal drop prosthesis
892923|NCT02584231|Desmopressin
892924|NCT02584231|Paediatrics
892925|NCT02584231|urinary concentration test
892926|NCT02584205|inspiratory muscle training
892927|NCT02584205|obstructive sleep apnea
892928|NCT02584205|functional capacity
892929|NCT02584179|mpMRI, significant cancer
892930|NCT02584166|Morbidity
892931|NCT02584166|Mortality
892932|NCT02584166|conferences
892933|NCT02584166|human science
892934|NCT02584153|Hernia
892935|NCT02584153|Ventral
892936|NCT02584153|Incisional
892937|NCT02584153|Abdominal
892938|NCT02584153|Herniorrhaphy
892939|NCT02584153|Recurrence
892940|NCT02584153|laparotomy
892941|NCT02584153|prevention
892942|NCT02584140|PrEP
892943|NCT02584140|Pre-exposure Prophylaxis
892944|NCT02584140|HIV Prevention
892945|NCT02584127|Smoking
892946|NCT02584127|cessation
892947|NCT02584127|Internet program
892948|NCT02584101|Acceptance and Commitment Therapy
892949|NCT02584088|NovaSure
892950|NCT02584088|Ablation
892951|NCT02584088|Menorrhagia
892952|NCT02584088|Endometrium
892953|NCT02584049|Osteopathic treatment
892954|NCT02584049|Care-induced Pain
892955|NCT02584049|Pain
892956|NCT02584049|Elderly
892957|NCT02584036|influenza
892958|NCT02584036|vaccine
892959|NCT02584036|public health
892960|NCT02584036|preventable disease
892961|NCT02584036|vaccine history
892962|NCT02584036|point-of-care
892963|NCT02584023|ultrasonography
892964|NCT02584023|infant
892965|NCT02584023|perioperative period
892966|NCT02584023|general anesthesia
892967|NCT02584010|Postoperative scars
892968|NCT02584010|Cicatrix
892969|NCT02584010|Cicatrization
892970|NCT02583997|To suture or not to suture....
892971|NCT02583997|Tooth extraction
892972|NCT02583997|Third molar
892973|NCT02583971|Direct current cardioversion
892974|NCT02583971|Medical management
892975|NCT02583971|Atrial fibrillation ablation
892976|NCT02583945|acute kidney injury
892977|NCT02583945|hemodynamic stabilisation
892978|NCT02583945|nephrotoxic medication
892979|NCT02583932|Randomized controlled trial
892980|NCT02583932|Psychological
892981|NCT02583932|Meaning
892982|NCT02583932|Existential
892983|NCT02583932|Quality of life
892984|NCT02583932|Intervention
892985|NCT02583932|Cancer
892986|NCT02583932|Advanced disease
892987|NCT02583932|New diagnosis
892988|NCT02583880|nutritional status
892989|NCT02583880|malnutrition
892990|NCT02583880|energy intake
892991|NCT02583880|caloric deficit
892992|NCT02583880|ICU
892993|NCT02583880|hospital
892994|NCT02583880|enteral nutrition
892995|NCT02583880|parenteral nutrition
892996|NCT02583880|nutrition
892997|NCT02583854|Coronary angiography
892998|NCT02583854|Transradial
892999|NCT02583854|Patient experience
893000|NCT02583854|VAS
893001|NCT02583854|Compression device
893002|NCT02583802|MHD
893003|NCT02583802|ear pills
893004|NCT02583802|Shengmai capsule
893005|NCT02583802|Chinese medicine treatment
893006|NCT02583776|continuous glucose monitoring (cgm)
893007|NCT02583776|neonatal hypoglycemia
893008|NCT02583776|very low birth weight infants (VLBWI)
893009|NCT02583776|preterm infants
893010|NCT02583763|pro-brain natriuretic peptide (1-76)
893011|NCT02583763|Insulin-Like Growth Factor Binding Proteins
893012|NCT02583763|Insulin-Like Growth Factor I
893013|NCT02583763|Echocardiography
893014|NCT02583763|Velocity Vector Imaging
893015|NCT02583763|Heart Function Tests
893016|NCT02583750|glucose metabolism
893017|NCT02583750|sleep deprivation
893018|NCT02583737|bone
893019|NCT02583737|maxillary sinus
893020|NCT02583672|Gaucher Disease
893021|NCT02583659|Gastric cancer
893022|NCT02583659|First-line chemotherapy
893023|NCT02583659|Biomarker
893024|NCT02583646|Obesity
893025|NCT02583646|Puberty
893026|NCT02583646|Ultrasound
893027|NCT02583646|Pediatric
893028|NCT02583620|high myopia
893029|NCT02583568|breast cancer
893030|NCT02583568|image-guided surgery
893031|NCT02583555|Quality of Life
893032|NCT02583555|Health Care Utilization
893033|NCT02583542|breast
893034|NCT02583542|lung
893035|NCT02583542|squamous
893036|NCT02583542|KRAS
893037|NCT02583542|AZD
893038|NCT02583542|selumetinib
893039|NCT02583529|Parkinson Disease
893040|NCT02583529|Neurogenic Overactive Bladder
893041|NCT02583529|Posterior Tibial Nerve Electrostimulation
893042|NCT02583503|Total knee arthroplasty
893043|NCT02583503|Total knee replacement
893044|NCT02583503|TKA
893045|NCT02583503|TKR
893046|NCT02583490|Electroconvulsive Therapy
893047|NCT02583490|Low Pulse Amplitude Focal Electroconvulsive Therapy
893048|NCT02583490|ECT
893049|NCT02583490|Depression
893050|NCT02583490|Suicidal Ideation
893051|NCT02583477|Pancreatic Ductal Adenocarcinoma, PDAC, immunotherapy, PDL1, AZD5069, MEDI4736
893052|NCT02583438|Gut Microbiota
893053|NCT02583438|inflammatory marker
893054|NCT02583438|Glucose and lipid metabolism
893055|NCT02583399|Pediatric (Birth to less than 6 months of age)
893056|NCT02583399|Pain
893057|NCT02583399|Fever
893058|NCT02583386|mobility
893059|NCT02583386|falls
893060|NCT02583386|fall prevention
893061|NCT02583386|gait and balance
893062|NCT02583386|automatic fall detector
893063|NCT02583373|Pneumonia
893064|NCT02583373|Streptococcus pneumoniae
893065|NCT02583373|Pneumolysin
893066|NCT02583360|Infant
893067|NCT02583360|Feeding difficulties
893068|NCT02583360|Dysphagia
893069|NCT02583334|acupuncture
893070|NCT02583334|fibromyalgia
893071|NCT02583334|rheumatism
893072|NCT02583334|clinical trial
893073|NCT02583321|chlorhexidine gluconate
893074|NCT02583321|oral care
893075|NCT02583321|mechanical ventilation
893076|NCT02583321|critically ill patients
893077|NCT02583321|tracheal secretions
893078|NCT02583321|subglottic secretions
893079|NCT02583308|Ventilator-associated pneumonia
893080|NCT02583308|Surveillance
893081|NCT02583308|Subglottic-secretions
893082|NCT02583308|Critically ill patients
893083|NCT02583308|Prevention
893084|NCT02583295|Awareness
893085|NCT02583295|Cardiac Surgery
893086|NCT02583295|Maternal
893087|NCT02583295|Pediatric
893088|NCT02583295|Sound
893089|NCT02583295|Music
893090|NCT02583243|Opioid dependence
893091|NCT02583243|HIV/AIDS
893092|NCT02583243|Hepatitis C
893093|NCT02583243|Severe mental illness
893094|NCT02583243|Injection Drug Use
893095|NCT02583230|Antidepressant Medication
893096|NCT02583230|Adherence
893097|NCT02583230|Mobile Smartphone Intervention
893098|NCT02583230|Telemedicine
893099|NCT02583230|Primary Care
893100|NCT02583217|Laryngeal mask
893101|NCT02583217|Ketamine
893102|NCT02583217|Remifentanyl
893103|NCT02583165|advanced solid tumors
893104|NCT02583165|immunotherapy
893105|NCT02583165|immuno-oncology
893106|NCT02583139|Children, Moderate and/or highly emetogenic chemotherapy
893107|NCT02583126|Teenager
893108|NCT02583126|moderate and/or highly emetogenic chemotherapy
893109|NCT02583113|Total Knee Replacement
893110|NCT02583113|Unicompartment Knee Replacement
893111|NCT02583087|Barrett esophagus
893112|NCT02583087|Esophageal adenocarcinoma
893113|NCT02583087|Endoscopic submucosal dissection
893114|NCT02583074|deep brain stimulation
893115|NCT02583074|Subthalamic Nucleus
893116|NCT02583074|dystonia
893117|NCT02583035|cancer
893118|NCT02583035|geriatric
893119|NCT02582996|Headache
893120|NCT02582996|Aura
893121|NCT02582996|Migraine
893122|NCT02582996|Moderate to Severe
893123|NCT02582957|ARDS
893124|NCT02582957|Shock Lung
893125|NCT02582957|Acute Chest Syndrome
893126|NCT02582957|Respiratory Distress Syndrome, Adult
893127|NCT02582957|Respiratory insufficiency
893128|NCT02582957|Trauma
893129|NCT02582918|Randomized Controlled Trial
893130|NCT02582918|Mass Screening
893131|NCT02582905|Alcohol Use Disorder
893132|NCT02582905|Bipolar Disorder
893133|NCT02582905|Mood
893134|NCT02582905|Alcohol craving
893135|NCT02582905|Pregnenolone
893136|NCT02582905|Citicoline
893141|NCT02582866|Lacosamide
893142|NCT02582866|Vimpat
893143|NCT02582866|Epilepsy
893144|NCT02582866|Partial onset seizures
893145|NCT02582866|Tonic-clonic seizures
893146|NCT02582866|Monotherapy
893147|NCT02582866|AED
893148|NCT02582853|GBS
893149|NCT02582853|AIDP
893150|NCT02582853|Spinal fluid
893151|NCT02582853|sCD163
893152|NCT02582840|Japanese patients with type 1 diabetes with inadequate glycemic control on insulin
893153|NCT02582827|Advanced Solid Tumors
893154|NCT02582827|solid tumor
893155|NCT02582827|lymphoma
893156|NCT02582814|Japanese patients with type 1 diabetes with inadequate glycemic control on insulin
893157|NCT02582801|PET/CT
893158|NCT02582801|Alfatide Ⅱ
893159|NCT02582801|breast cancer
893160|NCT02582762|Nail gel
893161|NCT02582762|Nail surface abnormality
893162|NCT02582762|Efficacy
893163|NCT02582749|Androgen Deprivation Therapy
893164|NCT02582749|Androgen Receptor Antagonist
893165|NCT02582749|Radium-223 Dichloride
893166|NCT02582749|Placebo
893167|NCT02582736|Antipsychotics
893168|NCT02582736|Drug side effects
893169|NCT02582736|Psychosis
893170|NCT02582736|Hyperglycemic emergencies
893171|NCT02582736|Diabetes
893172|NCT02582736|Epidemiology
893173|NCT02582736|Database research
893174|NCT02582736|CNODES
893175|NCT02582697|Germ Cell
893176|NCT02582697|Intermediate and poor-risk metastatic germ cell tumours
893177|NCT02582671|Real World Effectiveness
893178|NCT02582658|Paritaprevir
893179|NCT02582658|Dasabuvir
893180|NCT02582658|Ombitasvir
893181|NCT02582658|Chronic Hepatitis C
893182|NCT02582658|HCV
893183|NCT02582645|impaction
893184|NCT02582645|impacted canine
893185|NCT02582645|palatally
893186|NCT02582645|open window
893187|NCT02582645|closed window
893188|NCT02582645|management
893189|NCT02582632|Hepatitis C Virus
893190|NCT02582632|Interferon-Free
893191|NCT02582632|Ribavirin-Free
893192|NCT02582632|Hepatitis C
893193|NCT02582632|Hepatitis C Genotype 1b
893194|NCT02582619|Spinal Cord Injury and Employment
893195|NCT02582606|Insulin Resistance
893196|NCT02582606|Meal pattern
893197|NCT02582606|Obese
893198|NCT02582593|Cognitive Aging
893199|NCT02582593|Neuromodulation
893200|NCT02582593|Low Level Light Therapy
893201|NCT02582593|Near Infrared Light
893202|NCT02582593|Neurostimulation
893203|NCT02582580|pelvic floor
893204|NCT02582580|perineal trauma
893205|NCT02582580|physiotherapy
893206|NCT02582580|perineal integrity
893207|NCT02582567|Pregnant Women
893208|NCT02582567|Quality of Life
893209|NCT02582567|Exercise
893210|NCT02582567|Sleep
893211|NCT02582567|Fetal Research
893212|NCT02582567|Diet, Mediterranean
893213|NCT02582567|Physical Fitness
893214|NCT02582567|Oxidative stress
893215|NCT02582567|Inflammation
893216|NCT02582528|cognitive remediation
893217|NCT02582528|cognition
893218|NCT02582528|youth
893219|NCT02582528|mental health
893220|NCT02582528|functional outcome
893221|NCT02582515|d-cycloserine
893222|NCT02582515|comprehensive behavioral intervention for tics
893223|NCT02582515|habit reversal training
893224|NCT02582502|Hyperbaric Oxygen
893225|NCT02582502|HBOT
893226|NCT02582502|Hyperbaric Chamber
893227|NCT02582502|Pressurized Oxygen
893228|NCT02582489|Mesenchymal stem cells
893229|NCT02582489|Bone marrow aspirate concentrate
893230|NCT02582476|Hypokalemic Periodic Paralysis
893231|NCT02582476|Bumetanide
893232|NCT02582476|Periodic Paralysis
893233|NCT02582463|Risk Assessment
893234|NCT02582463|Hospitals
893235|NCT02582463|Pharmacists
893236|NCT02582463|Medication Systems
893237|NCT02582463|Patient Selection
893238|NCT02582463|Prognosis research
893239|NCT02582450|Haemophilia
893240|NCT02582450|Adherence of Treatment
893241|NCT02582450|Knowledge of Illness
893242|NCT02582450|Medical-patient Relationship
893243|NCT02582450|Illness Behavior
893244|NCT02582450|Treatment Difficulties
893245|NCT02582450|Veritas
893246|NCT02582437|Minimum Alveolar Concentration
893247|NCT02582411|Healthy Subjects
893248|NCT02582385|Amyotrophic lateral sclerosis (ALS)
893249|NCT02582385|Cytokines
893250|NCT02582385|Neuropathology
893251|NCT02582359|Acute Myeloid Leukemia
893252|NCT02582346|MRI
893253|NCT02582346|Neurography
893254|NCT02582346|Tractography
893255|NCT02582346|Pelvic nerves
893256|NCT02582203|Ceftaroline fosamil
893257|NCT02582203|Vancomycin
893258|NCT02582203|Acute bacterial skin and skin structure infections
893259|NCT02582203|Methicillin-resistant S. aureus
893260|NCT02582190|electrical cardioversion
893261|NCT02582190|persistent atrial fibrillation
893262|NCT02582177|Fungal infection
893263|NCT02582177|Skin infection
893264|NCT02582177|Dermatophytoses
893265|NCT02582164|Optical Coherence Tomography (OCT)
893266|NCT02582164|Swept Source OCT
893267|NCT02582138|physical frailty
893268|NCT02582138|sarcopenia
893269|NCT02582138|exercise
893270|NCT02582138|nutrition
893271|NCT02582138|information and communications technology
893272|NCT02582125|ONO-4538
893273|NCT02582125|Advanced non-small cell lung cancer
893274|NCT02582047|influenza vaccine
893275|NCT02582047|pneumococcal vaccine
893276|NCT02582047|simultaneous vaccination
893277|NCT02582034|Optimized Dosimetry versus standard Dosimetry
893278|NCT02582034|Internal Radiation Therapy
893279|NCT02582021|Microvascular Coronary Dysfunction (MCD)
893280|NCT02582021|Magnetic resonance imaging (MRI)
893281|NCT02582021|Coronary angiography
893282|NCT02582021|Coronary Vascular Dysfunction (CVD)
893283|NCT02581995|Diabetic macular edema
893284|NCT02581995|Intravitreal injection
893285|NCT02581969|Hemophilia A, Congenital
893286|NCT02581956|Immunology
893287|NCT02581891|Neovascular age-related macular degeneration
893288|NCT02581891|nAMD)
893289|NCT02581878|Thorium-227
893290|NCT02581878|BAY1862864 Injection
893291|NCT02581878|Safety
893292|NCT02581878|Pharmacokinetics
893293|NCT02581878|CD22
893294|NCT02581878|Radioimmunotherapy
893295|NCT02581839|eribulin
893296|NCT02581839|central nervous system
893297|NCT02581839|CNS
893298|NCT02581839|Eribulin Mesylate
893299|NCT02581839|Halaven
893300|NCT02581813|Bone health
893301|NCT02581813|Body composition
893302|NCT02581813|Dairy foods
893303|NCT02581813|Exercise
893304|NCT02581813|inflammation
893305|NCT02581813|nutrition intervention
893306|NCT02581813|weight management
893307|NCT02581774|induction
893308|NCT02581774|cesarean delivery
893309|NCT02581761|Hemodynamically stable women >18 years old
893310|NCT02581761|with abnormal plateauing serum βHCG
893311|NCT02581735|Haemophilia
893312|NCT02581735|Adherence
893313|NCT02581735|Prophylaxis treatment
893314|NCT02581735|Quality of Life
893315|NCT02581735|Illness Behavior
893316|NCT02581735|Veritas-Pro questionnaire
893317|NCT02581735|uPatient
893318|NCT02581722|PrePex, Male Circumcision, HIV Prevention, Adolescents
893319|NCT02581709|Feasibility study
893320|NCT02581709|Cognition
893321|NCT02581709|Chemotherapy
893322|NCT02581709|Neoplasms
893323|NCT02581670|oligometastatic breast cancer
893324|NCT02581618|ischemic preconditioning
893325|NCT02581618|myocardial injury
893326|NCT02581618|percutaneous coronary intervention
893327|NCT02581592|Hepatic Impairment
893328|NCT02581592|Hepatitis
893329|NCT02581592|Liver Cirrhosis
893330|NCT02581579|Tuberculosis
893331|NCT02581579|Tregs
893332|NCT02581579|Tolerance
893333|NCT02581579|Probiotic
893334|NCT02581579|Mycobacteria
893335|NCT02581540|Troponin
893336|NCT02581540|High Sensitivity Troponin T
893337|NCT02581540|MACE
893338|NCT02581540|risk stratification
893339|NCT02581540|suspected cardiac chest pain
893340|NCT02581540|Acute Coronary Syndrome
893341|NCT02581540|GRACE
893342|NCT02581540|TIMI
893343|NCT02581540|HEART
893344|NCT02581514|decision algorithm
893345|NCT02581501|Xeloda
893346|NCT02581501|Gemcitabine
893347|NCT02581501|Abraxane
893348|NCT02581501|Pancreatic Cancer
893349|NCT02581501|Metastatic Cancer
893350|NCT02581501|Phase I
893351|NCT02581501|5-FU
893352|NCT02581501|Capecitabine
893353|NCT02581501|Gemzar
893354|NCT02581501|NAB-Paclitaxel
893355|NCT02581501|Chemotherapy
893356|NCT02581488|Diabetes
893357|NCT02581488|diabetic foot ulcer
893358|NCT02581488|foot sore
893359|NCT02581488|type 2 diabetes
893360|NCT02581488|type 1 diabetes
893361|NCT02581488|neuropathy
893362|NCT02581488|DFU
893363|NCT02581475|Adenoma detection rate
893364|NCT02581475|Colonoscopy
893365|NCT02581475|Withdrawal time
893366|NCT02581449|omega-3 fatty acids
893367|NCT02581449|hemodialysis
893368|NCT02581449|oxidative stress
893369|NCT02581449|dyslipidemia
893370|NCT02581436|Prediction test
893371|NCT02581436|genetic transcription profile
893372|NCT02581436|Transplant follow-up
893373|NCT02581436|Chronic index
893374|NCT02581436|Graft Function
893375|NCT02581410|Zostavax®
893376|NCT02581410|≥ 65 years of age
893377|NCT02581410|Herpes Zoster
893378|NCT02581410|Shingles
893379|NCT02581410|Immunogenicity
893380|NCT02581410|Safety
893381|NCT02581397|cough
893382|NCT02581397|expectorant
893383|NCT02581397|upper respiratory tract infections
893384|NCT02581397|respiratory tract infections
893385|NCT02581397|antitussive agents
893386|NCT02581384|Ewing Sarcoma
893387|NCT02581384|Rhabdomyosarcoma
893388|NCT02581384|Wilms Tumor
893389|NCT02581371|Cerebrolysin
893390|NCT02581371|neuroplasticity
893391|NCT02581371|upper limb
893392|NCT02581371|middle cerebral artery
893393|NCT02581371|NBS
893394|NCT02581371|navigation brain stimulation
893395|NCT02581371|paretic limb
893396|NCT02581371|stroke
893397|NCT02581371|ischemic stroke
893398|NCT02581371|rehabilitation
893399|NCT02581371|Frenchay Arm Test
893400|NCT02581371|NBS eXimia Nexstim
893401|NCT02581371|Barthel index
893402|NCT02581358|scoliosis
893403|NCT02581358|spinal deformity
893404|NCT02581358|Cobb angle
893405|NCT02581358|assessment
893406|NCT02581358|ultrasound
893407|NCT02581345|Moderate to severe chronic plaque psoriasis
893408|NCT02581345|Psoriasis
893409|NCT02581332|behavioral intervention
893410|NCT02581254|Snare
893411|NCT02581254|Polypectomy
893412|NCT02581241|QT interval prolongation
893413|NCT02581215|mFOLFIRINOX
893414|NCT02581215|Ramucirumab
893415|NCT02581202|antiretroviral therapy
893416|NCT02581189|Chronic Hepatitis C
893417|NCT02581189|Patient reported outcomes
893418|NCT02581189|Effectiveness
893419|NCT02581189|Influence of adherence
893420|NCT02581189|Genotype 1 or 4
893421|NCT02581163|Effectiveness
893422|NCT02581163|Influence of adherence
893423|NCT02581150|Outpatient hospitalization
893424|NCT02581150|Randomized trial
893425|NCT02581150|Peripheral arterial disease
893426|NCT02581150|Endovascular treatment
893427|NCT02581150|Health Economics
893428|NCT02581124|JTZ-951
893429|NCT02581124|Lapatinib
893430|NCT02581124|Pharmacokinetics
893431|NCT02581085|Tocotrienol
893432|NCT02581085|Vitamin E
893433|NCT02581059|Regorafenib
893434|NCT02581059|American Ginseng
893435|NCT02581059|Fatigue
893436|NCT02581020|Observation
893437|NCT02581020|Japanese
893438|NCT02581020|Hepatitis C
893439|NCT02581020|Follow-up
893440|NCT02581007|CML
893441|NCT02581007|AML
893442|NCT02581007|MDS
893443|NCT02581007|ALL
893444|NCT02581007|CLL/CPL
893445|NCT02581007|HD
893446|NCT02581007|NHL
893447|NCT02581007|MPS
893448|NCT02581007|CMML
893449|NCT02581007|MM
893450|NCT02580994|Small Cell Lung Cancer
893451|NCT02580994|phase II
893452|NCT02580994|randomized
893453|NCT02580994|pembrolizumab
893454|NCT02580981|Cancer
893455|NCT02580981|Oncology
893456|NCT02580981|Acute Lymphoblastic Leukemia
893457|NCT02580981|ALL
893458|NCT02580981|Genomics
893459|NCT02580981|Genetics
893460|NCT02580981|Sequencing
893461|NCT02580981|DNA
893462|NCT02580981|RNA
893463|NCT02580981|Ph-like
893464|NCT02580968|Electroacupuncture therapy
893465|NCT02580968|Migraine
893466|NCT02580968|Acupuncture Therapy
893467|NCT02580929|Radiotherapy
893468|NCT02580929|General Surgery
893469|NCT02580916|non-melanoma skin cancer
893470|NCT02580916|outcome assessment
893471|NCT02580916|quality of life
893472|NCT02580877|oral insulin
893473|NCT02580838|Stroke
893474|NCT02580838|Spasticity
893475|NCT02580838|OnabotulinumtoxinA
893476|NCT02580825|Childhood obesity
893477|NCT02580825|Ground reaction force
893478|NCT02580825|Knee pain
893479|NCT02580812|Perinatal listeriosis
893480|NCT02580812|Neurological impairment
893481|NCT02580812|Sepsis
893482|NCT02580812|Prematurity
893483|NCT02580812|Neurotropism
893484|NCT02580812|Listeria monocytogenes
893485|NCT02580812|Intellectual Quotient
893486|NCT02580773|Sickle cell disease
893487|NCT02580773|Anemia
893488|NCT02580773|Rare disease
893489|NCT02580773|Reanimation
893490|NCT02580773|Prophylactic anticoagulation
893491|NCT02580760|Silicone
893492|NCT02580760|Transgender
893493|NCT02580760|Dermatology
893494|NCT02580760|Blood contamination
893495|NCT02580760|Adverse event after injection
893496|NCT02580734|burning mouth syndrome
893497|NCT02580734|treatment
893498|NCT02580734|oral chronic pain
893499|NCT02580721|mucosal tissue thickness
893500|NCT02580721|dental implant
893501|NCT02580721|marginal bone loss
893502|NCT02580721|soft tissue
893503|NCT02580643|Autologous Protein Solution
893504|NCT02580643|Osteoarthritis
893505|NCT02580643|Intra-articular Injection
893506|NCT02580630|Strength training, injection, glucocorticoid
893507|NCT02580565|sickle cell disease
893508|NCT02580552|Cutaneous T-cell Lymphoma
893509|NCT02580552|CTCL
893510|NCT02580552|Mycosis Fungoides
893511|NCT02580539|Allogeneic Transplantation
893512|NCT02580539|T cell
893513|NCT02580539|Epstein-Barr Virus
893514|NCT02580513|Circadian Rhythm
893515|NCT02580513|Circadian Misalignment
893516|NCT02580513|Insulin Sensitivity
893517|NCT02580500|Epidural anesthesia
893518|NCT02580500|Spinal anesthesia
893519|NCT02580500|pilonidal dermoid sinus
893520|NCT02580487|acute appendicitis
893521|NCT02580487|pain management
893522|NCT02580487|analgesics
893523|NCT02580487|pediatric patients
893524|NCT02580487|laparoscopy
893525|NCT02580487|open surgery
893526|NCT02580461|family caregivers
893527|NCT02580461|cancer
893528|NCT02580461|exercise intervention
893529|NCT02580461|center based
893538|NCT02580435|multiple sclerosis
893539|NCT02580435|microbiome
893540|NCT02580435|prediction
893541|NCT02580435|outcome
893542|NCT02580422|Echocardiography
893543|NCT02580409|health care utilization
893544|NCT02580409|health care costs
893545|NCT02580383|Radiofrequency ablation
893546|NCT02580383|RF-MB
893547|NCT02580383|Lumbar RF
893548|NCT02580383|Facet joint syndrome
893549|NCT02580383|Multifidus twitching
893550|NCT02580383|Sensory stimulation
893551|NCT02580370|REALISE 1
893552|NCT02580357|Connective tissue graft
893553|NCT02580357|Gingival recession
893554|NCT02580357|Low level laser therapy
893555|NCT02580305|SUVN-502
893556|NCT02580305|5-HT6
893557|NCT02580305|Phase 2
893558|NCT02580305|Cognition
893559|NCT02580305|Donepezil
893560|NCT02580305|Memantine
893561|NCT02580305|Alzheimer's Disease
893562|NCT02580279|Breast Neoplasms
893563|NCT02580279|prevention & control
893564|NCT02580279|Epigallocatechin gallate
893565|NCT02580279|Dermatitis
893566|NCT02580266|Kidney
893567|NCT02580266|Diabetes
893568|NCT02580240|septic shock
893569|NCT02580240|hydrocortisone
893570|NCT02580240|mortality
893571|NCT02580227|Tranexamic Acid
893572|NCT02580227|Blood Transfusions
893573|NCT02580188|Neuromuscular blockade
893574|NCT02580188|Sugammadex
893575|NCT02580188|Laparoscopic surgery
893576|NCT02580188|Intra abdominal pressure alarm
893577|NCT02580136|Esthesioneuroblastoma
893578|NCT02580136|Tumor
893579|NCT02580136|Skull Base Surgery
893580|NCT02580136|Sinonasal Cancer
893581|NCT02580110|no specific condition
893582|NCT02580097|Arterial Spin Labeling
893583|NCT02580097|Ischemic stroke
893584|NCT02580097|Collateral Circulation
893585|NCT02580097|Perfusion imaging
893586|NCT02580084|atherosclerosis of the peripheral arteries
893587|NCT02580084|Aorta-femoral Bypass
893588|NCT02580084|Hybrid Intervention
893589|NCT02580084|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
893590|NCT02580084|plastic arteries with lesions of the common femoral artery and deep femoral artery
893591|NCT02580071|Hematopoietic Stem Cell Transplant
893592|NCT02580071|Chinese Herbal Medicine
893593|NCT02580071|immune reconstitution
893594|NCT02580071|clinical trial
893595|NCT02580071|ALL
893596|NCT02580071|AML
893597|NCT02580058|platinum resistant
893598|NCT02580058|platinum refractory
893599|NCT02580045|metastatic cancer
893600|NCT02580045|lumbar puncture
893601|NCT02580045|advanced cancer
893602|NCT02580045|brain metastases
893603|NCT02580045|chemotherapy
893604|NCT02580045|endocrine therapy
893605|NCT02580045|HER2 targeted therapy
893606|NCT02580045|immune therapy
893607|NCT02580045|anti-cancer therapy
893608|NCT02580045|blood brain barrier
893609|NCT02580045|pharmacokinetics
893610|NCT02580045|Duke University
893611|NCT02580045|brain metastasis
893612|NCT02580019|Cellular therapy
893613|NCT02580019|Stroke
893614|NCT02580019|Neuronal Plasticity
893615|NCT02580019|Recovery
893616|NCT02580019|umbilical cord mesenchymal stem cells
893617|NCT02580019|Transplantation
893618|NCT02580019|Cardiovascular Diseases
893619|NCT02580019|Ischemia
893620|NCT02580019|Brain Infarction
893621|NCT02580019|Brain Ischemia
893622|NCT02580019|Cerebrovascular Disorders
893623|NCT02579993|Cornea
893624|NCT02579993|Limbal stem cell
893625|NCT02579967|Haploidentical
893626|NCT02579967|Autoimmunity
893627|NCT02579967|Immune Dysregulation
893628|NCT02579967|Congenital
893629|NCT02579967|Opportunistic Infection
893630|NCT02579941|Hyperfibrinolysis
893631|NCT02579941|Pregnant women at term
893632|NCT02579941|Tranexamic acid
893633|NCT02579928|Ketamine
893634|NCT02579928|Depression
893635|NCT02579928|Major Depressive Disorder
893636|NCT02579928|Anxiety
893637|NCT02579928|School refusal
893638|NCT02579928|Suicide
893639|NCT02579928|Generalized Anxiety
893640|NCT02579928|Suicidal Ideation
893641|NCT02579902|Irritable Bowel Syndrome
893642|NCT02579902|inflammation
893643|NCT02579902|oxidative stress
893644|NCT02579902|clinical signs
893645|NCT02579902|vitamin D3
893646|NCT02579889|Closed Loop Stimulation
893647|NCT02579889|Atrial Fibrillation
893648|NCT02579889|Stroke
893649|NCT02579889|Heart Failure
893650|NCT02579889|Pacemaker
893651|NCT02579889|ICD
893652|NCT02579876|Milk Allergy
893653|NCT02579876|Viaskin Milk
893654|NCT02579876|Epicutaneous ImmunoTherapy (EPIT)
893655|NCT02579876|Eosinophilic Esophagitis
893656|NCT02579876|Milk-Induced Eosinophilic Esophagitis
893657|NCT02579863|PD1
893658|NCT02579863|PD-1
893659|NCT02579863|PD-L1
893660|NCT02579863|PDL1
893661|NCT02579850|COPD
893662|NCT02579850|COPD Exacerbation
893663|NCT02579850|EXACT-PRO
893664|NCT02579837|screening
893665|NCT02579824|Myeloma
893666|NCT02579824|Relapsed and/or Refractory
893667|NCT02579824|Multiple Myeloma
893668|NCT02579824|MM
893669|NCT02579824|DS-3032b
893670|NCT02579811|Kidney
893671|NCT02579811|Cancer
893672|NCT02579811|Axitinib
893673|NCT02579811|Pd-1 inhibitor
893674|NCT02579811|Pd-L1 inhibitor
893675|NCT02579798|Bariatric surgery
893676|NCT02579798|Post-surgery hypoxemia
893677|NCT02579798|Obesity
893678|NCT02579785|Family Planning
893679|NCT02579785|Abortion
893680|NCT02579785|mHealth
893681|NCT02579785|Behaviour Change Communication
893682|NCT02579785|Menstrual Regulation
893683|NCT02579785|Postabortion
893684|NCT02579785|Bangladesh
893685|NCT02579759|PXT3003
893686|NCT02579746|hypertension
893687|NCT02579746|immigrant
893688|NCT02579746|dietary intervention
893689|NCT02579746|lifestyle modification
893690|NCT02579720|Recurrent Grass Pollen Allergy
893691|NCT02579720|Pollinex® Quattro
893692|NCT02579707|Healthy Volunteers
893693|NCT02579681|Cognition
893694|NCT02579681|Tecfidera
893695|NCT02579681|RRMS
893696|NCT02579681|BG00012
893697|NCT02579642|Moderate to severe depression
893698|NCT02579642|Monopolar
893699|NCT02579642|Bipolar
893700|NCT02579642|Ketamine
893701|NCT02579642|ECT
893702|NCT02579642|Electroconvulsive therapy
893703|NCT02579642|NMDA
893704|NCT02579629|Analgesia
893705|NCT02579629|Cesarean section
893706|NCT02579629|Opiates
893707|NCT02579616|Lenvatinib
893708|NCT02579616|E7080
893709|NCT02579616|Unresectable biliary tract cancer
893710|NCT02579616|BTC
893711|NCT02579616|Gemcitabine-based combination chemotherapy
893712|NCT02579616|Lenvima
893713|NCT02579538|Total Knee Arthroplasty
893714|NCT02579538|Thoracotomy
893715|NCT02579538|Mastectomy
893716|NCT02579538|Video-Assisted Thoracoscopic Surgery (VATS)
893717|NCT02579538|Persistent Pain
893718|NCT02579538|Cognitive Flexibility
893719|NCT02579525|septic shock
893720|NCT02579525|tissue perfusion
893721|NCT02579525|macrocirculatory
893722|NCT02579525|mean arterial pressure
893723|NCT02579525|vasopressor use
893724|NCT02579525|days alive free of organ support
893725|NCT02579499|Coronary artery disease
893726|NCT02579499|LDL choelsterol
893727|NCT02579499|Statin
893728|NCT02579473|Continuous dopaminergic stimulation
893729|NCT02579460|Barrett's esophagus
893730|NCT02579460|Gastroesophageal Reflux Disease
893731|NCT02579434|CYP3A
893732|NCT02579408|NAFLD
893733|NCT02579408|LDLT
893734|NCT02579408|steatosis
893735|NCT02579408|CAP
893736|NCT02579408|transient elastography
893737|NCT02579382|HBV
893738|NCT02579382|Hepatitis
893739|NCT02579382|Liver Disease
893740|NCT02579369|Epidermolysis Bullosa
893741|NCT02579369|stem cell
893742|NCT02579317|Baroreflex mechanism
893743|NCT02579317|Alcohol Use Disorder
893744|NCT02579317|Substance Use Disorder
893745|NCT02579317|Heart Rate Variability
893746|NCT02579317|Breathing
893747|NCT02579291|Stroke
893748|NCT02579291|Dry needling
893749|NCT02579291|Spasticity
893750|NCT02579291|Motor function
893751|NCT02579291|Stabilometry
893752|NCT02579278|EMVI
893753|NCT02579278|Extramural Venous Invasion
893754|NCT02579278|mrEMVI
893755|NCT02579278|Rectal Cancer
893756|NCT02579278|ctDNA
893757|NCT02579278|Neoplasm DNA
893758|NCT02579278|MRI
893759|NCT02579265|Parenteral nutrition
893760|NCT02579265|Neonates
893761|NCT02579265|Infants
893762|NCT02579265|Lipid emulsions
893763|NCT02579265|Intravenous
893764|NCT02579252|vaccine
893765|NCT02579252|tau protein
893766|NCT02579252|active
893767|NCT02579252|immunization
893768|NCT02579252|KLH
893769|NCT02579252|immunotherapy
893770|NCT02579252|tau
893771|NCT02579239|LGMD2B
893772|NCT02579239|FSHD
893773|NCT02579226|AZD2811
893774|NCT02579226|Irinotecan
893775|NCT02579226|Advanced solid tumours
893776|NCT02579213|electronic nose
893777|NCT02579213|abnormal fetal karyotype
893778|NCT02579161|Percutaneous Nephrolithotomy
893779|NCT02579161|Kidney Stones
893780|NCT02579161|Antibiotics
893781|NCT02579148|erectile dysfunction
893782|NCT02579148|stem cell
893783|NCT02579148|collagen scaffold
893784|NCT02579135|Condoms
893785|NCT02579135|Sexual Abstinence
893786|NCT02579135|Sexual Communication
893787|NCT02579122|Reviparin
893788|NCT02579122|Bridging
893789|NCT02579122|Phenprocoumon
893790|NCT02579096|Gout
893791|NCT02579096|Allopurinol
893792|NCT02579096|Febuxostat
893793|NCT02579096|CKD
893794|NCT02579070|Diabetic Foot
893795|NCT02579070|foot temperature
893796|NCT02579070|diabetic foot ulcer
893797|NCT02579057|Congestive heart failure
893798|NCT02579057|Furosemide
893799|NCT02579031|Percutaneous Coronary Intervention
893800|NCT02579031|Stents
893801|NCT02579031|Drug-Eluting Stents
893802|NCT02579031|Coronary Artery Disease
893803|NCT02579031|Acute Coronary Syndrome
893804|NCT02579018|Anorexia Nervosa
893805|NCT02579018|Exercise
893806|NCT02579018|Healthy Adults
893807|NCT02579018|Physical Activity
893808|NCT02579005|Radiation
893809|NCT02579005|Immune response
893810|NCT02579005|Anti-tumor
893811|NCT02579005|Lung Cancer
893812|NCT02578992|intubating stylet
893813|NCT02578992|head and neck position
893814|NCT02578979|atrial fibrillation
893815|NCT02578979|ischemic stroke
893816|NCT02578979|electrocardiogram
893817|NCT02578979|holter
893818|NCT02578966|Early Childhood Caries
893819|NCT02578966|Randomized clinical trial
893820|NCT02578966|Motivational Interviewing
893821|NCT02578953|Bioequivalence
893822|NCT02578953|Fasted state
893823|NCT02578953|Japanese male healthy subjects
893824|NCT02578953|Dutasteride
893825|NCT02578914|allergic conjunctivitis
893826|NCT02578914|seasonal allergies
893827|NCT02578914|ragweed allergy
893828|NCT02578914|grass allergy
893829|NCT02578914|tree allergy
893830|NCT02578914|NS2
893831|NCT02578914|Aldeyra
893832|NCT02578901|Thrombocytopenia
893833|NCT02578901|Tranexamic Acid
893834|NCT02578901|TXA
893835|NCT02578901|Chemotherapy induced thrombocytopenia
893836|NCT02578875|Sequence Technique
893837|NCT02578875|Infectious Disease
893838|NCT02578875|Pathogen Detection
893839|NCT02578875|Diagnostic
893840|NCT02578836|Weight Loss
893841|NCT02578836|Overweight
893842|NCT02578836|Endoscopic treatment for obesity
893843|NCT02578823|Targeted Temperature Management(TTM)
893844|NCT02578823|in-hospital cardiac arrest(IHCA)
893845|NCT02578823|restoration of spontaneous circulation(ROSC)
893846|NCT02578823|unconsciousness
893847|NCT02578823|brain injury
893848|NCT02578797|Castration-Resistant Prostate Cancer (CRPC)
893849|NCT02578797|Prostatic Neoplasms
893850|NCT02578797|Genital Diseases, Male
893851|NCT02578797|Genital Neoplasms, Male
893852|NCT02578797|Neoplasms
893853|NCT02578797|Neoplasms by Site
893854|NCT02578797|Prostatic Diseases
893855|NCT02578797|Urogenital Neoplasms
893856|NCT02578784|Dialysis
893857|NCT02578758|Transdiagnostic Internet-based Protocol
893858|NCT02578758|Positive affect regulation
893859|NCT02578706|HIV
893860|NCT02578706|Aspirin
893861|NCT02578706|Clopidogrel
893862|NCT02578706|Platelet
893863|NCT02578706|Inflammation
893864|NCT02578706|Cardiovascular disease
893865|NCT02578706|Arachidonic acid
893866|NCT02578706|Cyclooxygenase inhibitor
893867|NCT02578706|ADP inhibitor
893868|NCT02578706|Immune activation
893869|NCT02578706|Monocyte
893870|NCT02578706|Coagulation
893871|NCT02578706|Thrombogenicity
893872|NCT02578680|PD1
893873|NCT02578680|PD-1
893874|NCT02578680|PDL1
893875|NCT02578680|PD-L1
893876|NCT02578680|Non-Small-Cell Lung Cancer
893881|NCT02578576|Diagnostic Techniques
893882|NCT02578576|Digestive System
893883|NCT02578550|Immunodeficiency Virus Type 1, Human
893884|NCT02578550|Darunavir
893885|NCT02578550|Cobicistat
893886|NCT02578550|Emtricitabine
893887|NCT02578550|Tenofovir alafenamide
893888|NCT02578550|Healthy participants
893889|NCT02578537|Ticagrelor
893890|NCT02578537|Pharmacokinetics
893891|NCT02578537|NSTE-ACS
893892|NCT02578537|CKD
893893|NCT02578524|cataract satisfaction
893894|NCT02578511|Acute Lymphoblastic Leukemia in Complete Remission
893895|NCT02578511|Lymphoblastic Lymphoma in Complete Remission
893896|NCT02578511|Mixed Phenotype Acute Leukemia in Complete Remission
893897|NCT02578511|IXAZOMIB
893898|NCT02578511|POMP/D
893899|NCT02578511|Phase I
893900|NCT02578511|Early Phase
893901|NCT02578511|Acute Lymphoblastic Leukemia
893902|NCT02578511|Lymphoblastic Lymphoma
893903|NCT02578511|Mixed Phenotype Acute Leukemia
893904|NCT02578511|ALL
893905|NCT02578498|glucagon
893906|NCT02578498|Carbohydrate diet
893907|NCT02578472|Healthy
893908|NCT02578472|JNJ-42847922
893909|NCT02578472|zolpidem
893910|NCT02578472|Placebo
893911|NCT02578459|Cancer pain
893912|NCT02578459|Intrathecal therapy
893913|NCT02578459|Pain
893914|NCT02578459|Pancreatic cancer
893915|NCT02578433|Mindful Self Compassion short form
893916|NCT02578433|Progressive Muscle Relaxation
893917|NCT02578394|Gout
893918|NCT02578394|Kidney
893919|NCT02578394|Depo-Medrone
893920|NCT02578394|Anakinra
893921|NCT02578381|pressure wire
893922|NCT02578381|coronary angiogram
893923|NCT02578381|validation
893924|NCT02578368|gastric cancer
893925|NCT02578368|perioperative
893926|NCT02578368|FLOT
893927|NCT02578368|limited metastatic
893928|NCT02578368|GEJ cancer
893929|NCT02578355|Atherosclerosis
893930|NCT02578355|Coronary Artery Disease
893931|NCT02578355|Cardiovascular Disease
893932|NCT02578355|Coronary Computed Tomographic Angiography
893933|NCT02578355|CCTA
893934|NCT02578355|Myocardial Infarction
893935|NCT02578355|MI
893936|NCT02578355|OPeRA
893937|NCT02578329|Mediterranean diet
893938|NCT02578329|blood fatty acid
893939|NCT02578329|Coronary Artery Disease
893940|NCT02578316|Advanced Solid Tumors
893941|NCT02578316|Lymphomas
893942|NCT02578303|sleep apnea
893943|NCT02578303|phase-contrast MRI
893944|NCT02578303|cerebral blood flow
893945|NCT02578303|vascular risk factor
893946|NCT02578303|dementia
893947|NCT02578290|decision support systems
893948|NCT02578290|clinical
893949|NCT02578238|Korea
893950|NCT02578238|Humira
893951|NCT02578238|Pediatric Crohn's Disease
893952|NCT02578225|Heart
893953|NCT02578225|Chronic
893954|NCT02578225|Failure
893955|NCT02578225|MI
893956|NCT02578225|real life
893957|NCT02578225|Turkey
893958|NCT02578160|pain
893959|NCT02578160|infant behaviour
893960|NCT02578160|heart rate
893961|NCT02578160|dental anxiety
893962|NCT02578147|risky sexual behavior
893963|NCT02578147|early intervention
893964|NCT02578121|Relapsed
893965|NCT02578121|Response Rate
893966|NCT02578121|Progression free
893967|NCT02578082|Renal Impairment
893968|NCT02578082|Renal Insufficiency
893969|NCT02578069|Ischemic Stroke
893970|NCT02578069|Intracranial Stenting
893971|NCT02578056|pelvic organ prolapse
893972|NCT02578056|urinary incontinence
893973|NCT02578017|Sickle Cell Disease
893974|NCT02578017|Hydroxyurea
893975|NCT02578017|Adherence
893976|NCT02578004|Difficult
893977|NCT02578004|environmental, microbial, immunological and genetic factors
893978|NCT02578004|significantly different
893979|NCT02577965|ST segment Elevation Myocardial Infarction
893980|NCT02577965|Optical Coherence Tomography
893981|NCT02577965|Percutaneous Coronary Intervention
893982|NCT02577965|Thrombus histopathology
893983|NCT02577965|Gender differences
893984|NCT02577952|lipodystrophy
893985|NCT02577952|lipodystrophy, congenital generalized
893986|NCT02577952|Berardinelli-Seip Congenital Lipodystrophy
893987|NCT02577952|Congenital generalized lipodystrophy
893988|NCT02577952|generalized lipodystrophy
893989|NCT02577952|lipodystrophy, familial partial
893990|NCT02577952|partial lipodystrophy
893991|NCT02577952|lipodystrophy, partial, acquired
893992|NCT02577952|acquired lipodystrophy
893993|NCT02577913|contraception
893994|NCT02577913|contraceptive patch
893995|NCT02577913|Levonorgestrel
893996|NCT02577913|gestodene
893997|NCT02577913|safety
893998|NCT02577900|foot ulcer and honey and silver
893999|NCT02577861|limbal stem cells deficinecy, LSCD, ocular burn
894000|NCT02577848|Glucagon-like peptide-1
894001|NCT02577848|Non-ST-segment elevation myocardial infarction
894002|NCT02577848|Left ventricular ejection fraction
894003|NCT02577835|Hypertension
894004|NCT02577835|Arterial Stiffness
894005|NCT02577835|Ambulatory blood pressure
894006|NCT02577796|radial artery spasm
894007|NCT02577796|radial artery occlusion
894008|NCT02577796|radial access
894009|NCT02577783|Doxorubicin Hydrochloride
894010|NCT02577770|Acupuncture
894011|NCT02577770|caffeine
894012|NCT02577770|pain
894013|NCT02577757|Languages network
894014|NCT02577757|Functional MRI
894015|NCT02577744|Electrical Impedance Tomography
894016|NCT02577731|Trauma
894017|NCT02577705|food insecurity
894018|NCT02577705|adverse childhood experiences
894019|NCT02577705|violence exposure
894020|NCT02577705|trauma
894021|NCT02577705|poverty
894022|NCT02577705|TANF
894023|NCT02577705|assets
894024|NCT02577705|depression
894025|NCT02577705|randomized control trial
894026|NCT02577679|Dentistry
894027|NCT02577653|balance, postural
894028|NCT02577653|postural equilibrium
894029|NCT02577614|Cardiopulmonary Bypass
894030|NCT02577614|Aortic Valve Repair
894031|NCT02577614|Coronary Re-Implantation
894032|NCT02577614|Deep Hypothermic Circulatory Arrest
894033|NCT02577614|Factor VIII Inhibitor Bypass Activity
894034|NCT02577614|Transfusion
894035|NCT02577601|Emergency contraception
894036|NCT02577601|Birth Control Pills
894037|NCT02577588|p53 Antigen
894038|NCT02577588|T cell therapy
894039|NCT02577588|autologous
894040|NCT02577588|Adoptive Cellular Immunotherapy
894041|NCT02577575|Oxytocin
894042|NCT02577575|Syntocinon
894043|NCT02577575|Social Cognition
894044|NCT02577575|Schizophrenia
894045|NCT02577549|Knee Pain
894046|NCT02577549|Exercise
894047|NCT02577549|Diet
894048|NCT02577549|Weight Loss
894049|NCT02577536|Pregnancy outcome
894050|NCT02577536|Neonatal outcome
894051|NCT02577536|Birth weight
894052|NCT02577536|Weight gain
894053|NCT02577536|Physical disability
894054|NCT02577510|Lateral Femoral Cutaneous Nerve Block
894055|NCT02577510|Meralgia Parasthetica
894056|NCT02577510|nerve stimulator
894057|NCT02577510|ultrasound
894058|NCT02577484|Fractional Flow Reserve
894059|NCT02577484|Rapid Exchange
894060|NCT02577484|Catheter
894061|NCT02577471|Constipation
894062|NCT02577471|pregnancy
894063|NCT02577471|delivery
894064|NCT02577432|spinal anesthesia
894065|NCT02577419|breast milk
894066|NCT02577419|chylothorax
894067|NCT02577419|infants
894068|NCT02577419|cardiac surgery
894069|NCT02577419|modified fat breast milk
894070|NCT02577406|AG-221
894071|NCT02577406|CC-90007
894072|NCT02577406|Efficacy
894073|NCT02577406|Safety
894074|NCT02577406|Leukemia
894075|NCT02577406|Acute myloid meukemia
894076|NCT02577406|Isocitrate dehydrogenase 2 mutation
894077|NCT02577406|Enasidenib
894078|NCT02577393|Lung Neoplasms
894079|NCT02577393|esophagitis
894080|NCT02577393|Prevention & Control
894081|NCT02577393|Epigallocatechin Gallate
894082|NCT02577367|Hypothyroidism
894083|NCT02577367|Tube Feeding
894084|NCT02577341|Nimotuzumab, Chemoradiotherapy,Squamous Cell Lung Cancer
894085|NCT02577289|simultaneous implantation
894086|NCT02577289|Dental implant
894087|NCT02577289|Open sinus Lifting
894088|NCT02577289|PRF
894089|NCT02577289|platelet rich fibrin (PRF)
894090|NCT02577276|stroke
894091|NCT02577276|remote monitoring
894092|NCT02577276|hemiparesis
894093|NCT02577250|ketamine
894094|NCT02577250|stress disorders, post-traumatic
894095|NCT02577250|stress disorders, traumatic
894096|NCT02577250|anxiety disorders
894097|NCT02577250|mental disorders
894098|NCT02577250|adjuvants, anesthesia
894099|NCT02577250|analgesics
894100|NCT02577250|anesthetics
894101|NCT02577250|anesthetics, dissociative
894102|NCT02577250|anesthetics, general
894103|NCT02577250|anesthetics, intravenous
894104|NCT02577250|excitatory amino acid agents
894105|NCT02577250|excitatory amino acid antagonists
894106|NCT02577250|hypnotics and sedatives
894107|NCT02577250|molecular mechanisms of pharmacological action
894108|NCT02577250|neurotransmitter agents
894109|NCT02577250|peripheral nervous system agents
894110|NCT02577250|pharmacologic actions
894111|NCT02577250|physiological effects of drugs
894112|NCT02577250|psychotropic drugs
894113|NCT02577250|sensory system agents
894114|NCT02577250|central nervous system agents
894115|NCT02577250|central nervous system depressants
894116|NCT02577250|depression
894117|NCT02577250|depressive disorder
894118|NCT02577250|depressive disorder, treatment-resistant
894119|NCT02577250|behavioral symptoms
894120|NCT02577250|mood disorders
894121|NCT02577250|therapeutic uses
894122|NCT02577237|caregiver
894123|NCT02577237|simulation
894124|NCT02577224|Patient-led care
894125|NCT02577224|Botulinum toxin
894126|NCT02577224|Dystonia
894127|NCT02577224|Randomised controlled trial
894128|NCT02577224|Acceptability
894129|NCT02577211|Critically ill
894130|NCT02577211|Enteral nutrition
894131|NCT02577172|Testicular cancer
894132|NCT02577172|Physical Exercise
894133|NCT02577172|Chemotherapy
894134|NCT02577159|sodium-glucose cotransporter 2 inhibitor
894135|NCT02577159|Diabetes Mellitus, Type 2
894136|NCT02577159|dyslipidemia
894137|NCT02577159|remnants
894138|NCT02577159|apolipoprotein B-48
894139|NCT02577146|stone
894140|NCT02577146|ureter
894141|NCT02577146|ultrasound
894142|NCT02577133|colic
894143|NCT02577133|probiotic
894144|NCT02577133|Lactobacillus reuteri
894145|NCT02577133|prevention
894146|NCT02577120|Epiceram
894147|NCT02577120|Ceramiseal
894148|NCT02577107|Age-related macular degeneration,
894149|NCT02577107|ranibizumab,
894150|NCT02577107|conbercept,
894151|NCT02577107|plasma VEGF
894152|NCT02577107|PK
894153|NCT02577094|CD22 positive- lymphoblastic leukemia-RIT-Yttrium
894154|NCT02577055|Multiple leiomyoma
894155|NCT02577055|Uterine Artery Embolization
894156|NCT02577055|Surgery
894157|NCT02577055|childbearing age
894158|NCT02577055|Fertility
894159|NCT02577055|Noninferiority trial
894160|NCT02577042|Raltegravir
894161|NCT02577042|protease inhibitors
894162|NCT02577042|darunavir
894163|NCT02577042|inflammation
894164|NCT02577042|statins
894165|NCT02577042|comorbidities
894170|NCT02576977|PDL1
894171|NCT02576977|PD1
894172|NCT02576977|Multiple Myeloma
894173|NCT02576938|Atopic Eczema
894180|NCT02576899|smoking cessation
894181|NCT02576899|posttraumatic stress disorder
894182|NCT02576899|tobacco
894183|NCT02576899|treatment
894184|NCT02576899|smoking
894185|NCT02576899|mindfulness
894186|NCT02576899|acceptance
894187|NCT02576899|functioning
894188|NCT02576886|supine
894189|NCT02576886|prone
894190|NCT02576886|myocardial perfusion imaging
894191|NCT02576886|radiation exposure
894192|NCT02576886|pre-screening tool
894193|NCT02576873|Survival
894194|NCT02576873|Hemodiafiltration
894195|NCT02576873|End-stage renal disease
894196|NCT02576873|Hemodialysis
894197|NCT02576821|Amnesia, Alzheimer, hippocampal sclerosis, fronto-temporal lobar degeneration
894198|NCT02576795|Haemophilia A
894199|NCT02576795|Gene Therapy
894200|NCT02576795|Clotting Disorders
894201|NCT02576795|Blood Disorder
894202|NCT02576782|regional anesthesia
894203|NCT02576782|dexamethasone
894204|NCT02576782|bupivacaine
894205|NCT02576782|femoral
894206|NCT02576782|sciatic
894207|NCT02576769|Basal cell carcinoma
894208|NCT02576769|Pigmentation
894209|NCT02576769|Melanocyte
894210|NCT02576769|Melanin
894211|NCT02576769|Skin cancer
894212|NCT02576756|Risk on aspiration
894213|NCT02576756|Postoperative
894214|NCT02576756|Difficult Intubation
894215|NCT02576743|Stroke
894216|NCT02576743|AVM
894217|NCT02576743|Aneurysm
894218|NCT02576717|MS
894219|NCT02576717|RMS
894220|NCT02576717|Multiple Sclerosis
894221|NCT02576717|Relapsing Multiple Sclerosis
894222|NCT02576691|cardiac arrest
894223|NCT02576691|percutaneous coronary intervention
894224|NCT02576691|cardiogenic shock
894225|NCT02576691|outcome
894226|NCT02576678|Psoriasis
894227|NCT02576678|Moderate to Severe Plaque Psoriasis
894228|NCT02576678|Plaque Psoriasis
894229|NCT02576678|CC-10004
894230|NCT02576678|Apremilast
894231|NCT02576678|Pharmacokinetics
894232|NCT02576678|Open-label
894233|NCT02576678|Safety
894234|NCT02576678|Pediatric
894235|NCT02576652|bone biopsy
894236|NCT02576652|tetracycline
894237|NCT02576652|demeclocycline
894238|NCT02576652|total hip replacement
894239|NCT02576639|Alzheimer's Disease,
894240|NCT02576639|Amyloid Beta,
894241|NCT02576639|cerebrospinal fluid,
894242|NCT02576639|beta secretase
894243|NCT02576626|Nebulizer
894244|NCT02576626|DPI
894245|NCT02576626|COPD
894246|NCT02576626|indacaterol
894247|NCT02576626|ipratropium
894248|NCT02576626|glycopyrronium
894249|NCT02576626|salbutamol
894250|NCT02576626|Breezhaler
894251|NCT02576626|Nebuliser
894252|NCT02576626|Hyperinflation
894253|NCT02576626|Dyspnea
894254|NCT02576626|SABA
894255|NCT02576626|short-acting muscarinic antagonists (SAMA)
894256|NCT02576626|long-acting beta2-agonist (LABA)
894257|NCT02576626|LAMA
894258|NCT02576626|FEV1
894259|NCT02576574|Avelumab
894260|NCT02576574|MSB0010718C
894261|NCT02576574|Non-Small Cell Lung Cancer
894262|NCT02576561|human papillomavirus
894263|NCT02576561|Cervical Intraepithelial Neoplasia
894264|NCT02576561|Cold Knife Conization
894265|NCT02576561|hysterectomy
894266|NCT02576561|Loop Electrosurgical Excision Procedure
894267|NCT02576561|LEEP
894268|NCT02576561|HSIL
894269|NCT02576561|High-Grade Squamous Intraepithelial Lesion
894270|NCT02576496|phase 1 clinical trial
894271|NCT02576496|multiple myeloma
894272|NCT02576496|Hodgkin's lymphoma
894273|NCT02576496|peripheral T-cell lymphoma
894274|NCT02576496|non-Hodgkin's lymphoma
894275|NCT02576470|swallowing
894276|NCT02576470|stroke
894277|NCT02576470|dysphagia
894278|NCT02576470|deglutition
894279|NCT02576431|NTRK Fusion Positive
894280|NCT02576431|LOXO-101
894281|NCT02576431|Loxo
894282|NCT02576431|TRK
894283|NCT02576431|TRK Fusion
894284|NCT02576431|NTRK1
894285|NCT02576431|NTRK2
894286|NCT02576431|NTRK3
894287|NCT02576431|TRKA
894288|NCT02576431|TRKB
894289|NCT02576431|TRKC
894290|NCT02576431|ETV6
894291|NCT02576431|NTRK
894292|NCT02576431|larotrectinib
894293|NCT02576431|fusion
894294|NCT02576431|tumors
894295|NCT02576431|CNS tumors
894296|NCT02576431|solid tumors
894297|NCT02576431|central nervous system tumors
894298|NCT02576431|solid CNS tumors
894299|NCT02576431|primary CNS tumor
894300|NCT02576431|Advanced CNS tumor
894301|NCT02576431|Metastatic CNS tumor
894302|NCT02576431|NTRK1 fusion
894303|NCT02576431|NTRK2 fusion
894304|NCT02576431|NTRK3 fusion
894305|NCT02576431|ETV6-NTRK3
894306|NCT02576431|ETV6 fusion
894307|NCT02576418|Partosure TTD test
894308|NCT02576418|CL
894309|NCT02576418|ART
894310|NCT02576418|SN
894311|NCT02576418|SP
894312|NCT02576418|PPV
894313|NCT02576418|NPV
894314|NCT02576379|Helicopter Emergency Medical System
894315|NCT02576379|Mortality
894316|NCT02576379|Labour market affiliation
894317|NCT02576379|Modified Rankin Scale
894318|NCT02576327|Lymphoma
894319|NCT02576327|Aprepitant
894320|NCT02576327|Chemotherapy-induced nausea and vomiting (CINV)
894321|NCT02576327|Autologous Hematopoietic Stem Cell Transplantation
894322|NCT02576327|Hematological Malignancies
894323|NCT02576301|AML
894324|NCT02576301|MDS
894325|NCT02576288|Sitagliptin
894326|NCT02576288|Brachial artery flow mediated dilation
894327|NCT02576288|Carotid stiffness
894328|NCT02576288|Pro-inflammatory
894329|NCT02576288|Pro-atherogenic
894330|NCT02576288|M1 macrophages
894331|NCT02576275|Phase 3
894332|NCT02576275|iNHL
894333|NCT02576275|Follicular Lymphoma
894334|NCT02576275|FL
894335|NCT02576275|PI3K
894336|NCT02576275|Small Lymphocytic Lymphoma
894337|NCT02576275|SLL
894338|NCT02576275|Marginal Zone Lymphoma
894339|NCT02576275|MZL
894340|NCT02576249|osteoarthritis
894341|NCT02576249|injection
894342|NCT02576249|steroid
894343|NCT02576249|anesthetic
894349|NCT02576223|Peripheral Nerve Blocks
894350|NCT02576197|mild to moderate
894351|NCT02576197|probiotic
894352|NCT02576184|Incisional hernia
894353|NCT02576184|Stoma
894354|NCT02576184|rectal cancer
894355|NCT02576184|synthetic mesh
894356|NCT02576184|biologic mesh
894360|NCT02576067|Atherosclerotic cardiovascular disease
894361|NCT02576067|Inflammation reduction
894362|NCT02576041|driving simulator
894363|NCT02576028|Total Hip Replacement
894364|NCT02576028|Manipulation Therapy
894365|NCT02576002|Pulmonary Arterial Hypertension
894366|NCT02575989|Trauma
894367|NCT02575989|Prehospital
894368|NCT02575989|Hypothermia
894369|NCT02575976|Rehabilitation
894370|NCT02575976|Coronary artery disease
894371|NCT02575976|Patient Education
894372|NCT02575976|Randomized Controlled Trial
894373|NCT02575976|Protocol
894374|NCT02575937|low glycemic diet
894375|NCT02575937|diabetes
894376|NCT02575924|media
894377|NCT02575924|blastocyst
894378|NCT02575924|male infertility
894379|NCT02575924|poor responders
894380|NCT02575924|pgs
894381|NCT02575859|HIPEC
894382|NCT02575859|peritoneal lavage
894383|NCT02575833|Angina
894384|NCT02575833|Stable Angina
894385|NCT02575833|Cardiovascular Disease
894386|NCT02575833|Exercise-induced Angina
894387|NCT02575807|Ovarian cancer
894388|NCT02575807|Fallopian cancer
894389|NCT02575807|Primary peritoneal cancer
894390|NCT02575755|Azithromycin
894391|NCT02575755|Piperaquine
894392|NCT02575755|IPTp
894393|NCT02575755|Pharmacokinetics
894394|NCT02575755|Efficacy
894395|NCT02575729|carpal tunnel syndrome
894396|NCT02575729|local steroid injection
894397|NCT02575729|sonography
894398|NCT02575729|sonography-guided
894399|NCT02575716|McGrath®
894400|NCT02575716|Videolaryngoscope
894401|NCT02575716|intubating condition
894402|NCT02575716|muscle relaxant
894403|NCT02575716|intubation
894404|NCT02575690|spirulina, placebo, obesity,antihypertensive treatment
894405|NCT02575677|labor pain
894406|NCT02575677|oxycodone
894407|NCT02575664|Pain
894408|NCT02575664|Arthroplasty
894409|NCT02575664|Buprenorphine
894410|NCT02575651|PARP
894411|NCT02575651|Advanced Solid Malignancies
894412|NCT02575651|Fluzoparib
894413|NCT02575651|Ovarian Cancer
894414|NCT02575651|BRCA
894415|NCT02575625|Liver steatosis
894416|NCT02575625|Steatohepatitis
894417|NCT02575625|Fibroscan
894418|NCT02575599|Self-management
894419|NCT02575599|web-based
894420|NCT02575599|quantitative approach
894421|NCT02575586|Trigger Points
894422|NCT02575586|Dry needling
894423|NCT02575586|Torque
894424|NCT02575586|H-Reflex
894425|NCT02575573|resuscitation decision
894426|NCT02575560|Progression-Free Survival
894427|NCT02575547|Nutritional Status
894428|NCT02575547|Locoregionally Advanced Nasopharyngeal Carcinoma
894429|NCT02575534|anti-arrhythmic therapy
894430|NCT02575482|SUVN-D4010
894431|NCT02575482|serotonin 4 (5-HT4) receptor
894432|NCT02575482|first in human
894433|NCT02575482|safety
894434|NCT02575482|pharmacokinetics
894435|NCT02575482|tolerability
894436|NCT02575482|single dose
894437|NCT02575482|repeat dose
894438|NCT02575417|advance care planning
894439|NCT02575417|end-of-life care
894440|NCT02575417|health games
894441|NCT02575417|Family caregivers
894442|NCT02575417|Advance directives
894443|NCT02575404|Metastatic
894444|NCT02575404|Keytruda
894445|NCT02575404|pembrolizumab
894446|NCT02575404|GR-MD-02
894447|NCT02575404|Galactoarabino-rhamnogalacturonate
894448|NCT02575404|Immunotherapy
894449|NCT02575391|L-Glutamine
894450|NCT02575391|chemotherapy
894451|NCT02575391|radiotherapy
894452|NCT02575391|therapeutic toxicity
894453|NCT02575378|Metastatic Colorectal Cancer
894454|NCT02575378|Maintenance Treatment
894455|NCT02575378|Chinese Traditional Medicine
894456|NCT02575378|Clinical Trial
894457|NCT02575378|efficacy
894458|NCT02575378|safety
894459|NCT02575365|RRMS,
894460|NCT02575365|Cognition,
894461|NCT02575365|brain,
894462|NCT02575365|Fingolimod,
894463|NCT02575365|Multiple Sclerosis,
894464|NCT02575365|neurodegeneration,
894465|NCT02575365|Brain atrophy,
894466|NCT02575365|gray matter atrophy,
894467|NCT02575365|thalamic atrophy,
894468|NCT02575365|biomarkers,
894469|NCT02575365|BICAMS Battery,
894470|NCT02575352|Bone Substitute
894471|NCT02575352|Calcium Phosphate Cement
894472|NCT02575352|GRAFTYS
894473|NCT02575352|GRAFTYS®HBS
894474|NCT02575352|GRAFTYS®QUICKSET
894475|NCT02575352|Bone void filler
894476|NCT02575352|Bone growth
894477|NCT02575352|Registry
894478|NCT02575352|Bone defect
894479|NCT02575352|Revision arthroplasty
894480|NCT02575352|Arthrodesis
894481|NCT02575339|MLN0128
894482|NCT02575339|Sapanisertib
894483|NCT02575339|TORC1/2 inhibitor
894484|NCT02575339|INK128
894485|NCT02575339|Nexavar
894486|NCT02575339|Sorafenib
894487|NCT02575326|Asthma, Body Mass Idex, BMI, Overweight, Obesity
894488|NCT02575313|L-Glutamine
894489|NCT02575313|chemotherapy
894490|NCT02575313|radiotherapy
894491|NCT02575313|therapeutic toxicity
894492|NCT02575300|neuroendocrine tumors (NETs)
894493|NCT02575300|gastroenteropancreatic NETs
894494|NCT02575300|pancreatic NETs
894495|NCT02575300|gastrointestinal (GI) tract NET
894496|NCT02575300|advanced carcinoid tumors
894497|NCT02575274|Peri-implantitis
894498|NCT02575274|Peri-implant disease
894499|NCT02575274|Dental implants
894500|NCT02575274|Guided bone regeneration
894501|NCT02575261|CAR-T cell immunotherapy
894502|NCT02575261|EphA2
894503|NCT02575261|malignant glioma
894507|NCT02575235|Sarcopenia
894508|NCT02575235|Cetylpyridinium chloride
894509|NCT02575222|Immunotherapy
894510|NCT02575222|PD-1
894511|NCT02575222|anti-PD-1
894512|NCT02575222|antibody
894513|NCT02575222|Kidney Cancer
894514|NCT02575222|RCC
894515|NCT02575222|non-metastatic
894516|NCT02575196|Cardiac arrest
894517|NCT02575196|Cardiopulmonary Resuscitation
894518|NCT02575196|CPR
894519|NCT02575196|cerebral blood flow
894520|NCT02575196|cerebral perfusion
894521|NCT02575183|Waterpipe smoking
894522|NCT02575183|Nicotine dependence
894523|NCT02575183|Smoking cessation
894524|NCT02575183|Varinecline, Chantix therapy
894525|NCT02575183|Behavioral therapy
894526|NCT02575170|amino acid
894527|NCT02575170|cesarean delivery
894528|NCT02575170|hypothermia
894529|NCT02575131|satiety
894530|NCT02575131|overweight
894531|NCT02575131|breakfast
894532|NCT02575131|ecological validity
894533|NCT02575105|Bispectral Index Hydrocephalus
894534|NCT02575092|Hyperhomocysteinemia
894535|NCT02575092|Coronary angiography
894536|NCT02575092|Percutaneous coronary intervention
894537|NCT02575092|Hypertension
894538|NCT02575092|Contrast-induced nephropathy
894539|NCT02575066|pazopanib
894540|NCT02575066|radiotherapy
894541|NCT02575053|latex allergy
894542|NCT02575053|latex hypersensitivity
894543|NCT02575053|powder free latex surgical gloves
894544|NCT02575053|latex safe protocol
894545|NCT02575001|Type 1 diabetes
894546|NCT02575001|Children and adolescents
894547|NCT02575001|Stress
894548|NCT02575001|Genetic factors
894549|NCT02575001|Psychological background
894550|NCT02574988|drug allergy
894551|NCT02574988|drug hypersensitivity
894552|NCT02574988|adverse drug reactions
894553|NCT02574988|severe cutaneous adverse reactions
894554|NCT02574949|radiation
894555|NCT02574949|fluoroscopy
894556|NCT02574949|diagnostic
894557|NCT02574936|karydakis modification
894558|NCT02574936|pilonidal sinus
894559|NCT02574936|complication
894560|NCT02574923|Cerebral Palsy
894561|NCT02574923|Stem Cells
894562|NCT02574871|Stress
894563|NCT02574871|Chronic stress
894564|NCT02574871|Perceived stress
894565|NCT02574871|Psychological distress
894566|NCT02574832|Pain
894567|NCT02574832|Surgery
894568|NCT02574832|Pregnancy
894569|NCT02574832|Anesthesia
894570|NCT02574819|opioid-induced constipation
894571|NCT02574806|BNP
894572|NCT02574806|Reference values
894573|NCT02574806|Newborn
894574|NCT02574806|Ventricular function
894575|NCT02574806|Stress
894576|NCT02574806|Pediatrics
894577|NCT02574806|Biomarkers
894578|NCT02574793|Glucose Fluctuation
894579|NCT02574793|GH-Secreting Adenoma
894580|NCT02574793|Cushing Syndrome
894581|NCT02574780|lymphedema
894582|NCT02574780|complex physical therapy
894583|NCT02574780|muscle strength
894584|NCT02574767|Weight gain, Fatty Acids, Omega-3
894585|NCT02574754|warfarin
894586|NCT02574754|pharmacokinetics
894587|NCT02574754|bioequivalence
894588|NCT02574754|healthy volunteer
894589|NCT02574728|Pediatrics
894590|NCT02574728|Brain Tumors
894591|NCT02574728|Neuroblastoma
894592|NCT02574728|Osteosarcoma
894593|NCT02574728|Ewing's Sarcoma
894594|NCT02574728|Rhabdomyosarcoma
894595|NCT02574728|Wilms Tumors
894596|NCT02574728|Soft Tissue Sarcomas
894597|NCT02574702|superficial surgical site infection
894598|NCT02574702|loop ileostomy
894599|NCT02574702|Ileostomy closure
894600|NCT02574689|Physical Activity
894601|NCT02574689|Cancer Prevention
894602|NCT02574637|MEDI2070
894603|NCT02574637|inflammatory bowel disease
894604|NCT02574637|moderate to severe Crohn's Disease
894605|NCT02574637|IL-23
894606|NCT02574598|PDL1
894607|NCT02574598|monoclonal antibody
894608|NCT02574585|Spinal cord injury
894609|NCT02574585|Paraplegia
894610|NCT02574585|Stem cells
894611|NCT02574585|Mesenchymal cells
894612|NCT02574572|Spinal cord injury
894613|NCT02574572|Mesenchymal cells
894614|NCT02574572|Stem cells
894615|NCT02574559|Caregiver
894616|NCT02574559|Stress
894617|NCT02574559|Depression
894618|NCT02574559|Autism Spectrum Disorder
894619|NCT02574559|Compassion Meditation
894620|NCT02574546|Mastectomy
894621|NCT02574533|Immunotherapy
894622|NCT02574533|PD-1 inhibitor
894623|NCT02574533|Keytruda
894624|NCT02574533|checkpoint inhibitor
894625|NCT02574533|vaccine
894626|NCT02574533|FANG
894627|NCT02574533|Vigil
894628|NCT02574520|Post-operative pain
894629|NCT02574520|opioid
894630|NCT02574520|opioid reduction
894631|NCT02574520|laparoscopic cholecystectomy
894632|NCT02574520|laparoscopic surgery
894633|NCT02574520|bupivacaine
894634|NCT02574520|extended release
894635|NCT02574520|locally acting analgesic
894636|NCT02574507|breast cancer
894637|NCT02574507|weight management
894638|NCT02574507|couples
894639|NCT02574507|symptom management
894640|NCT02574481|atherosclerosis
894641|NCT02574481|Superficial Femoral Artery (SFA)
894642|NCT02574481|Proximal Popliteal Artery (PPA)
894643|NCT02574481|lower extremities
894644|NCT02574481|stenting
894645|NCT02574481|paclitaxel
894646|NCT02574468|Dexamethasone
894647|NCT02574468|Direct pulp capping
894648|NCT02574468|MTA
894649|NCT02574468|pulpotomy
894650|NCT02574442|cervical intraepithelial neoplasia grade 1
894651|NCT02574442|cervical intraepithelial neoplasia grade 2
894652|NCT02574442|cervical intraepithelial neoplasia grade 3
894653|NCT02574442|adenocarcinoma in situ
894654|NCT02574429|Borderline Personality Disorder
894655|NCT02574429|Posttraumatic Stress Disorder
894656|NCT02574429|Cognitive Processing Therapy
894657|NCT02574429|Group Therapy
894658|NCT02574429|Comorbidity
894659|NCT02574429|Dialectical Behavior Therapy
894660|NCT02574416|Health behaviour
894661|NCT02574416|Health outcomes
894662|NCT02574416|Diet quality
894663|NCT02574416|Physical function
894664|NCT02574416|Lifestyle
894665|NCT02574416|Older adults
894666|NCT02574403|atypical hemolytic uremic syndrome (aHUS)
894667|NCT02574403|eculizumab discontinuation
894668|NCT02574390|ALS
894669|NCT02574390|stem cell
894670|NCT02574390|biomarker
894671|NCT02574390|disease progression
894672|NCT02574364|abdomen CT
894673|NCT02574364|open appendicectomy
894676|NCT02574299|dyslexia
894677|NCT02574299|training
894678|NCT02574299|auditory rehabilitation
894679|NCT02574299|hearing loss
894680|NCT02574299|evoked potentials
894681|NCT02574299|dichotic
894682|NCT02574299|plasticity
894683|NCT02574299|noise
894684|NCT02574247|Audiology
894685|NCT02574247|Auditory Pathways
894686|NCT02574247|Auditory Perception
894687|NCT02574247|Brain Stem
894688|NCT02574247|Cochlea
894689|NCT02574247|Ear, Inner
894690|NCT02574247|Efferent Pathways
894691|NCT02574247|Hair Cells, Auditory, Outer
894692|NCT02574247|Learning
894693|NCT02574247|Neurons, Efferent
894694|NCT02574247|Speech Perception
894695|NCT02574234|Postoperative cognitive disorders POCD
894696|NCT02574234|inflammation
894697|NCT02574234|Surgery
894698|NCT02574208|Adult outpatients
894699|NCT02574208|Paris, France
894700|NCT02574195|Diabetes Mellitus
894701|NCT02574195|microvascular complications
894702|NCT02574195|macrovascular complications
894703|NCT02574195|epidemiology
894704|NCT02574195|Russia
894705|NCT02574182|Mild Cognitive Impairment
894706|NCT02574182|Magnetic Resonance Imaging
894707|NCT02574169|Alveolar Recruitment Maneuvers (ARM)
894708|NCT02574169|Continuous Positive Airway Pressure (CPAP)
894709|NCT02574169|Extended Sigh (eSigh)
894710|NCT02574143|Prognosis
894711|NCT02574143|Prospective Study
894712|NCT02574143|Quality of Life
894713|NCT02574143|Radiology
894714|NCT02574143|Rehabilitation
894715|NCT02574143|Registry;
894716|NCT02574143|Signs and Symptoms
894717|NCT02574143|Therapy
894718|NCT02574143|Bronchiectiasis
894719|NCT02574143|Diagnosis
894720|NCT02574143|Epidemiology
894721|NCT02574143|Etiology
894722|NCT02574143|Longitudinal Study
894723|NCT02574143|Microbiology
894724|NCT02574104|Intensive Care Units, Neonatal
894725|NCT02574104|Patient simulation
894726|NCT02574104|Interdisciplinary Communication
894727|NCT02574104|Human factors
894728|NCT02574104|Hazard Analysis and Critical Control Points
894729|NCT02574091|EGFR inhibitor
894730|NCT02574091|topical agent
894731|NCT02574091|psoriasis
894732|NCT02574091|phase 1
894733|NCT02574065|crying
894734|NCT02574065|colicky
894735|NCT02574065|infants
894736|NCT02574065|Lactobacillus reuteri DSM 17938
894737|NCT02574052|Menu Labelling;
894738|NCT02574052|Nutrition Education;
894739|NCT02574052|dietary assessment tools;
894740|NCT02574039|volunteers
894741|NCT02574039|oat
894742|NCT02574039|phenolic acid
894743|NCT02574039|bioavailability
894744|NCT02574026|MEG
894745|NCT02574026|EEG
894746|NCT02574026|MRI
894747|NCT02574026|Brain mapping
894748|NCT02574026|functional imaging
894749|NCT02574026|brain computer interface
894750|NCT02573974|undernutrition
894751|NCT02573974|gastrointestinal cancer
894752|NCT02573974|skeletal muscle
894753|NCT02573974|energy metabolism
894754|NCT02573948|People who inject drugs
894755|NCT02573948|Vietnam
894756|NCT02573948|Community support groups
894757|NCT02573935|Multiple Myeloma
894758|NCT02573935|Clarithromycin
894759|NCT02573935|Induction Chemotherapy
894760|NCT02573935|Transplantation, Autologous
894761|NCT02573922|constipation
894762|NCT02573922|opioid
894763|NCT02573922|Oxycodone
894764|NCT02573922|Oxycodone-naloxone
894765|NCT02573922|spine surgery
894766|NCT02573896|relapsed refractory neuroblastoma
894767|NCT02573883|Vulva
894768|NCT02573883|Lichen Sclerosus
894769|NCT02573883|Fractionated Carbon Dioxide Laser
894770|NCT02573883|Mona Lisa Laser
894771|NCT02573883|Clobetasol Proprionate
894772|NCT02573883|Vulvodynia
894773|NCT02573870|COPD
894774|NCT02573870|DPI
894775|NCT02573870|Batefenterol
894776|NCT02573870|Fluticasone Furoate
894777|NCT02573857|Induced blood stage malaria
894778|NCT02573857|Transmission
894779|NCT02573857|Gametocytemia
894780|NCT02573844|irritable bowel syndrome
894781|NCT02573844|abdominal pain
894782|NCT02573844|rome III criteria
894783|NCT02573844|abdominal distension
894784|NCT02573844|consistency of stools
894785|NCT02573844|stool frequency
894786|NCT02573844|meteorism
894787|NCT02573844|flatulence
894788|NCT02573844|abdominal discomfort
894789|NCT02573844|proklama
894790|NCT02573844|probiotics
894791|NCT02573844|alga klamath
894792|NCT02573844|aphanizomenon flos-aquae
894793|NCT02573844|prebiotics
894794|NCT02573844|colitis ulcerosa
894795|NCT02573831|labor
894796|NCT02573831|pain
894797|NCT02573831|oxycodone
894798|NCT02573831|placenta
894799|NCT02573818|sedation for EGD and colonoscopy procedures
894800|NCT02573805|nocturnal penile tumescence and rigidity
894801|NCT02573805|erectile dysfunction
894802|NCT02573805|Chinese males
894803|NCT02573792|First onset of optical neuritis
894804|NCT02573779|human milk
894805|NCT02573779|enteral nutrition
894806|NCT02573779|microbiome
894807|NCT02573779|Microbiota
894808|NCT02573766|Neurofeedback training
894809|NCT02573766|EEG
894810|NCT02573766|electroencephalograph
894811|NCT02573766|Questionnaires
894812|NCT02573766|Surveys
894813|NCT02573766|Chemotherapy-Induced Peripheral Neuropathy
894814|NCT02573766|CIPN
894815|NCT02573740|Mild Cognitive Impairment
894816|NCT02573740|Alzheimer's Disease
894817|NCT02573714|Ketamine
894818|NCT02573714|Intranasal
894819|NCT02573714|Pain crisis
894820|NCT02573714|Vasoocclusive Pain
894821|NCT02573714|Sickle cell disease
894822|NCT02573701|Schizophrenia
894823|NCT02573701|Adolescents
894824|NCT02573701|Treatment
894825|NCT02573701|Guidelines
894826|NCT02573688|Obesity
894827|NCT02573688|Metabolic Syndrome X
894952|NCT02572999|risk factors
894828|NCT02573688|Interdisciplinary Studies
894829|NCT02573675|hemodialysis
894830|NCT02573675|peritoneal dialysis
894831|NCT02573662|Metabolic complications
894832|NCT02573662|Type 2 diabetes
894833|NCT02573662|Sedentary lifestyle
894834|NCT02573662|Low grade inflammation
894835|NCT02573662|Lipid metabolism
894836|NCT02573662|Glucose metabolism
894837|NCT02573662|Bone metabolism
894838|NCT02573662|Physical inactivity
894839|NCT02573623|Immunology diagnosis test
894840|NCT02573623|Children
894841|NCT02573623|Zambia
894842|NCT02573571|single nucleotide polymorphisms
894843|NCT02573571|cytokines
894844|NCT02573571|microbiome
894845|NCT02573545|liver
894846|NCT02573532|myocardial ischemia/diagnosis
894847|NCT02573532|myocardial ischemia/epidemiology
894848|NCT02573532|perioperative
894849|NCT02573532|perioperative complications/diagnosis
894850|NCT02573532|prognosis
894851|NCT02573519|11C Donepezil PET/CT scan
894852|NCT02573519|3D-Transit
894853|NCT02573519|Diabetes Mellitus
894854|NCT02573519|Gastrointestinal motility disorder
894855|NCT02573519|Diabetic autonomic neuropathy
894856|NCT02573506|Non-small cell lung cancer
894857|NCT02573506|Split-course Chemoradiotherapy
894858|NCT02573506|Consolidation chemotherapy
894859|NCT02573480|youth violence, intervention, emergency medicine
894865|NCT02573428|Autism Spectrum Disorder
894866|NCT02573428|Eye Gaze
894867|NCT02573428|Remote Eye Gaze Tracking
894868|NCT02573428|Autism
894869|NCT02573402|electric stimulation
894870|NCT02573402|urodynamic study
894871|NCT02573389|pancreatic fistula, pancreatectomy, endoscopic stenting, pancreatic stenting, distal pancreatectomy
894872|NCT02573376|HIV
894873|NCT02573376|Hepatitis C
894874|NCT02573376|Drug Abuse
894875|NCT02573376|Hepatitis C Virus
894876|NCT02573376|sofosbuvir
894877|NCT02573376|ledipasvir
894878|NCT02573376|pharmacology
894879|NCT02573376|pharmacokinetics
894880|NCT02573324|Newly Diagnosed Glioblastoma
894881|NCT02573324|Brain Cancer
894882|NCT02573324|Temozolomide
894883|NCT02573324|EGFR Amplified
894884|NCT02573324|Radiology Therapy Oncology Group
894885|NCT02573324|ABT-414
894886|NCT02573324|EGFRvIII
894887|NCT02573324|Antibody Drug Conjugate
894888|NCT02573324|Epithelial Growth Factor Receptor
894889|NCT02573324|Brain Tumor Group
894890|NCT02573324|First Line Therapy
894891|NCT02573324|Brain Tumor
894892|NCT02573298|cryotherapy
894893|NCT02573298|power Doppler score
894894|NCT02573298|synovial fluid cytokines
894895|NCT02573298|pain VAS
894896|NCT02573259|efficacy
894897|NCT02573259|safety
894898|NCT02573259|pharmacokinetics
894899|NCT02573259|pharmacodynamics
894900|NCT02573259|open label
894901|NCT02573259|dose response
894902|NCT02573259|multiple ascending dose
894903|NCT02573259|immunogenicity
894904|NCT02573246|neurostimulation
894905|NCT02573246|cognitive restructuring
894906|NCT02573246|TMS
894907|NCT02573194|Appetite
894908|NCT02573194|Amino acids
894909|NCT02573194|Protein Source
894910|NCT02573168|Pharmacogenomic
894911|NCT02573168|Pharmacogenomic Testing
894912|NCT02573168|Pharmacogenomics
894913|NCT02573168|Genetic Testing
894914|NCT02573168|Genetics
894915|NCT02573168|GeneSight
894916|NCT02573168|Enhanced GeneSight
894917|NCT02573168|Psychotropic
894918|NCT02573155|Pharmacokinetics
894919|NCT02573155|Pharmacodynamics
894920|NCT02573155|AZD8871
894921|NCT02573155|Safety
894922|NCT02573155|Tolerability
894923|NCT02573155|mild persistent asthma
894924|NCT02573155|moderate to severe COPD
894925|NCT02573142|obesity
894926|NCT02573142|treatment
894927|NCT02573142|community
894928|NCT02573142|integrated
894929|NCT02573129|cardiovascular disease risk
894930|NCT02573129|Mediterranean diet
894931|NCT02573129|red meat
894932|NCT02573116|obstructive sleep apnea
894933|NCT02573116|endothelial dysfunction
894934|NCT02573116|periodontitis
894935|NCT02573090|Occlusal caries
894936|NCT02573090|Resin based fissure sealant
894937|NCT02573090|Composite resin restoration
894938|NCT02573090|Effectiveness
894939|NCT02573090|Longevity
894940|NCT02573077|Hyponatremia due to SIADH
894941|NCT02573077|Cancer
894942|NCT02573038|Aflibercept
894943|NCT02573038|choroidal neovascularization
894944|NCT02573038|angioid streaks
894945|NCT02573038|young patient
894946|NCT02572999|Aged
894947|NCT02572999|Frail
894948|NCT02572999|Functional decline
894949|NCT02572999|Impairment
894950|NCT02572999|valvular heart disease
894951|NCT02572999|Cohort
894953|NCT02572947|Dolutegravir
894954|NCT02572947|HIV infection
894955|NCT02572947|Anti-Retroviral Agents
894956|NCT02572947|HIV Integrase Inhibitors
894957|NCT02572947|Integrase Inhibitors
894958|NCT02572947|Pharmacologic Actions
894959|NCT02572947|Therapeutic Uses
894960|NCT02572934|Testicular cancer
894961|NCT02572934|Survivorship
894962|NCT02572934|late adverse treatment effects
894963|NCT02572921|Positive Psychotherapy
894964|NCT02572921|Depression
894965|NCT02572921|Happiness
894966|NCT02572908|wheat, IBS, gluten, ATI
894967|NCT02572895|Cranberry
894968|NCT02572895|Proanthocyanidins
894969|NCT02572895|Urinary catabolites
894970|NCT02572882|hemodialysis
894971|NCT02572882|p-inulin
894972|NCT02572882|gut microbiome
894973|NCT02572869|Mandible Reconstruction
894974|NCT02572869|Fibula Osteomyocutaneous Free Flaps
894975|NCT02572869|Quality of Life
894976|NCT02572869|15-244
894977|NCT02572856|Feasibility
894978|NCT02572856|continuous glucose monitor
894979|NCT02572856|surgery
894980|NCT02572843|NSCLC
894981|NCT02572843|lung cancer
894982|NCT02572843|MEDI4736
894983|NCT02572843|non-small cell lung cancer
894984|NCT02572843|immunotherapy
894985|NCT02572843|anti-PD-L1
894986|NCT02572830|Reconsolidation
894987|NCT02572830|EMDR
894988|NCT02572830|PTSD
894989|NCT02572817|Anti-Influenza Immune Plasma
894990|NCT02572804|bladder cancer-cystectomy
894991|NCT02572804|rectus sheath catheter
894992|NCT02572804|epidural
894993|NCT02572713|Parkinson's Disease
894994|NCT02572713|alpha-synuclein
894995|NCT02572713|biomarker
894996|NCT02572687|metastatic
894997|NCT02572687|advanced
894998|NCT02572687|immuno-oncology
894999|NCT02572687|vascular endothelial growth factor (VEGF)
895000|NCT02572687|angiogenesis
895001|NCT02572687|PD-1
895002|NCT02572687|PD-L1
895006|NCT02572661|Radiotherapy, Sentinel Node Mapping, Spect
895007|NCT02572648|Cardiomyopathy
895008|NCT02572648|Magnetic Resonance Imaging (MRI)
895009|NCT02572635|Pneumococcal Infection
895010|NCT02572635|Phase I
895011|NCT02572635|Immunogenicity
895012|NCT02572635|Safety
895013|NCT02572635|Vaccination
895014|NCT02572622|exercise
895015|NCT02572622|deep friction massage
895016|NCT02572622|spinal decompression
895017|NCT02572622|non-surgical spinal decompression
895018|NCT02572596|Hematopoietic Stem Cell Mobilization
895019|NCT02572596|Thrombopoietin
895020|NCT02572583|Reconciling Exterior and Interior Therapy
895021|NCT02572583|Influenza
895022|NCT02572570|Adult dental care
895024|NCT02572544|young healthy adults
895025|NCT02572544|single pinhole glasses
895026|NCT02572544|multiple pinhole glasses
895027|NCT02572531|Lactobacillus reuteri
895028|NCT02572531|Wound Healing
895029|NCT02572531|Third Molar
895030|NCT02572531|Postoperative Complications
895031|NCT02572518|immunity yellow fever vaccine
895032|NCT02572505|HIV-Discordant
895033|NCT02572505|Preexposure Prophylaxis
895034|NCT02572492|Multiple Myeloma
895035|NCT02572492|Recurrence
895036|NCT02572492|Carfilzomib
895037|NCT02572492|Salvage Therapy
895038|NCT02572492|Transplantation, Autologous
895039|NCT02572479|fatty acids, amyotrophic lateral sclerosis, nutrient status
895040|NCT02572466|high-sensitive troponin-I
895041|NCT02572466|End-stage renal disease
895042|NCT02572466|hemodialysis
895043|NCT02572440|Aortic arch surgery; Blood conservation; aPRP
895044|NCT02572401|Human immunodeficiency virus
895045|NCT02572401|Sexually transmitted disease
895046|NCT02572401|Behavioral intervention
895047|NCT02572401|Randomized controlled trial
895048|NCT02572401|Text messages
895049|NCT02572401|Social cognitive theory
895050|NCT02572401|Theory of planned behavior
895051|NCT02572401|Sexual behavior
895052|NCT02572401|African Americans
895053|NCT02572401|Men
895054|NCT02572349|Healthy Subjects
895059|NCT02572284|Stereotactic Body Radiation Therapy (SBRT)
895060|NCT02572284|High Risk Prostate Cancer
895061|NCT02572284|Preoperative SBRT
895062|NCT02572284|Prostate Adenocarcinoma
895063|NCT02572284|Prostatectomy
895064|NCT02572284|Quality of Life
895065|NCT02572271|Autologous augmentation
895066|NCT02572271|Mastopexy
895067|NCT02572271|Massive weight loss
895068|NCT02572245|Healthy Subjects
895069|NCT02572245|Device
895070|NCT02572245|PK
895071|NCT02572245|Phase 1
895072|NCT02572245|Bioequivalence
895073|NCT02572245|Adalimumab
895074|NCT02572245|Single Dose
895075|NCT02572193|achalasia
895076|NCT02572193|surgery
895083|NCT02572115|After-Hours Care
895084|NCT02572115|Primary Care
895085|NCT02572115|Emergency Medical Services/utilization
895086|NCT02572115|Denmark
895087|NCT02572115|Questionnaires
895088|NCT02572115|Patient Satisfaction
895089|NCT02572115|Patient feeling of safety
895090|NCT02572115|Triage/standards
895091|NCT02572115|Referral and Consultation/statistics & numerical data
895092|NCT02572115|Humans
895093|NCT02572115|Male
895094|NCT02572115|Female
895095|NCT02572115|Hotlines
895096|NCT02572115|telenursing
895097|NCT02572115|Night Care/utilization
895098|NCT02572115|postal service
895099|NCT02572102|ECG
895100|NCT02572102|Blood Pressure
895101|NCT02572102|Energy Drinks
895102|NCT02572102|Panax Ginseng
895103|NCT02572037|Premature ejaculation
895104|NCT02572037|Dapoxetine
895105|NCT02572037|local anaesthetics
895106|NCT02572037|nerve electrophysiology
895107|NCT02572011|Lower limb amputation
895108|NCT02572011|Transtibial
895109|NCT02572011|Balance
895110|NCT02572011|Postural Control
895111|NCT02572011|Limits of Stability
895112|NCT02572011|Rehabilitation
895113|NCT02572011|Home-based intervention
895114|NCT02572011|Nintendo Wii
895115|NCT02572011|Balance Board
895116|NCT02571985|Zenith aortoiliac aneurysm
895117|NCT02571985|iliac aneurysm
895118|NCT02571985|branch
895119|NCT02571985|connections
895120|NCT02571985|endovascular graft
895121|NCT02571985|graft-iliac bifurcation
895122|NCT02571985|Aneurysm
895123|NCT02571985|Vascular Diseases
895124|NCT02571985|Cardiovascular Diseases
895125|NCT02571972|dorzolamide-timolol
895126|NCT02571972|topical aqueous suppression
895127|NCT02571972|neovascular age-related macular degeneration
895128|NCT02571972|macular edema
895129|NCT02571972|intravitreal injection
895130|NCT02571972|anti-vascular endothelial growth factor
895131|NCT02571959|Obesity
895132|NCT02571959|Pharmacology
895133|NCT02571959|Amoxicillin-Potassium Clavulanate Combination
895134|NCT02571933|Pediatrics
895135|NCT02571933|Pain Scale
895136|NCT02571933|Faces Pain Scale - Revised
895137|NCT02571933|Cameroon
895138|NCT02571920|cardiac surgery
895139|NCT02571920|cardiac output
895140|NCT02571907|Zenith aortoiliac aneurysm
895141|NCT02571907|Iliac aneurysm
895142|NCT02571907|Branch
895143|NCT02571907|Connections
895144|NCT02571907|Endovascular graft
895145|NCT02571907|Graft-iliac bifurcation
895146|NCT02571907|Aneurysm
895147|NCT02571907|Vascular Diseases
895148|NCT02571907|Cardiovascular Diseases
895149|NCT02571881|constipation
895150|NCT02571881|oxycodone
895151|NCT02571881|caesarean section
895152|NCT02571855|insomnia
895153|NCT02571855|Pharmacokinetics
895154|NCT02571855|Safety
895155|NCT02571855|Pharmacodynamics
895156|NCT02571855|Healthy
895157|NCT02571842|Recurrent IgA nephropathy
895158|NCT02571842|Rituximab
895159|NCT02571829|Liposarcoma
895160|NCT02571829|Soft tissue sarcoma
895161|NCT02571829|CDK4
895162|NCT02571829|CDK6
895163|NCT02571829|LEE011
895164|NCT02571829|ribociclib
895165|NCT02571816|ASP2215
895166|NCT02571816|Healthy
895167|NCT02571816|Hepatic Impairment
895168|NCT02571816|Mild Hepatic Impairment
895169|NCT02571816|Moderate Hepatic Impairment
895170|NCT02571803|coronary artery disease
895171|NCT02571803|atherosclerosis
895172|NCT02571803|DASH diet
895173|NCT02571790|Patient with Generalized Anxiety Disorders
895174|NCT02571777|Asthma
895175|NCT02571725|Ovarian cancer
895176|NCT02571725|Fallopian tube cancer
895177|NCT02571725|Peritoneal cancer
895178|NCT02571725|PARP
895179|NCT02571725|BRCA
895180|NCT02571725|Immunotherapy
895181|NCT02571725|Olaparib
895182|NCT02571725|Tremelimumab
895183|NCT02571725|CTLA4
895184|NCT02571673|Survivorship
895185|NCT02571673|Quality of Life
895186|NCT02571673|HN-STAR web-based
895187|NCT02571673|15-245
895188|NCT02571660|vitamin d levels
895189|NCT02571660|exacerbation of asthma
895190|NCT02571660|asthma control
895191|NCT02571634|intranasal fentanyl
895192|NCT02571634|conscious sedation
895193|NCT02571608|Type 2 diabetes mellitus, Metformin, peri-operative
895194|NCT02571595|HIV - Human Immunodeficiency Virus
895195|NCT02571595|digital cognitive behavioural therapy for insomnia (dCBT-I)
895196|NCT02571595|insomnia
895197|NCT02571595|cognitive Impairment
895198|NCT02571595|concentration
895199|NCT02571595|productivity
895200|NCT02571582|Predictors of mortality
895201|NCT02571543|Ibuprofen
895202|NCT02571543|IVF
895203|NCT02571543|minimal stimulation
895204|NCT02571543|modified natural-cycle
895205|NCT02571543|nonsteroidal anti-inflammatory drug (NSAID)
895206|NCT02571543|Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
895207|NCT02571543|Oocyte Retrieval
895208|NCT02571543|Ovarian Follicle/drug effects
895209|NCT02571517|Respiratory viral infection.
895210|NCT02571517|Respiratory syncytial virus bronchiolitis
895211|NCT02571517|METHYLPREDNISOLONE SODIUM SUCCINATE
895212|NCT02571504|HIV - Human Immunodeficiency Virus
895213|NCT02571504|Memory
895214|NCT02571504|Concentration
895215|NCT02571478|Military Couples
895216|NCT02571478|Marriage
895217|NCT02571478|Primary Care
895218|NCT02571478|Marriage Intervention
895219|NCT02571478|Air Force
895220|NCT02571465|functional hemodynamic parameter
895221|NCT02571465|passive leg raising
895222|NCT02571465|stroke volume variation
895223|NCT02571465|pulse pressure variation
895224|NCT02571452|Veteran
895225|NCT02571452|Insomnia
895226|NCT02571452|Primary Healthcare
895227|NCT02571439|TAP block, post-cesarean analgesia
895228|NCT02571413|animated cartoon-aided teaching
895229|NCT02571413|oral presentation
895230|NCT02571413|allergic rhinitis
895231|NCT02571413|intranasal corticosteroid
895232|NCT02571413|how to use intranasal corticosteroid
895233|NCT02571400|Risk
895234|NCT02571400|Opioid analgesics
895235|NCT02571400|Opioid-related disorders
895236|NCT02571400|Surgery
895237|NCT02571400|Post-operative care
895238|NCT02571400|Post-operative period
895239|NCT02571400|Post-operative complications
895240|NCT02571400|Opioid Use disorders
895241|NCT02571400|Pain, post-operative
895242|NCT02571400|Opiate Addiction
895243|NCT02571387|Motivation
895244|NCT02571387|Impulsive eating
895245|NCT02571387|Mindfulness
895246|NCT02571387|Self-help
895247|NCT02571387|Physical activity
895248|NCT02571387|Weight-loss
895249|NCT02571374|symbiotic
895250|NCT02571374|colorectal cancer
895251|NCT02571361|Acetaminophen
895252|NCT02571361|Ibuprofen
895253|NCT02571361|Arthroplasty, Replacement, Hip
895254|NCT02571309|Self-management
895255|NCT02571309|Asthma
895256|NCT02571309|Patient education
895257|NCT02571309|Health literacy
895258|NCT02571309|Health-related quality of life
895259|NCT02571309|Asthma control
895260|NCT02571309|Adherence
895261|NCT02571296|Preterm Birth
895262|NCT02571296|Oral Micronized Progesterone
895263|NCT02571283|Total Knee Arthroplasty
895264|NCT02571283|Total Knee Replacement
895265|NCT02571283|Exparel
895266|NCT02571283|Cocktail Injection
895267|NCT02571283|Pain Management
895268|NCT02571270|Exercise
895269|NCT02571270|quality of life
895270|NCT02571270|healthy
895271|NCT02571270|cardiac remodeling
895272|NCT02571257|LDL-C
895273|NCT02571257|Lipid Regulator
895274|NCT02571244|Tobacco Use Disorder
895275|NCT02571244|Hospitalized patients
895276|NCT02571244|Text message
895277|NCT02571244|Motivational Interview
895278|NCT02571244|Substance-Related Disorders
895279|NCT02571244|Behaviors and Mental Disorders
895280|NCT02571218|atrial fibrillation
895281|NCT02571218|mapping
895282|NCT02571218|substrate
895283|NCT02571218|ablation
895284|NCT02571205|testosterone
895285|NCT02571205|pubertal delay
895286|NCT02571192|ADME
895287|NCT02571179|Labor pain
895288|NCT02571179|Fentanyl
895289|NCT02571179|Transmucosal
895290|NCT02571153|Intravenous anesthesia
895291|NCT02571153|Postoperative nausea vomiting
895292|NCT02571153|Postoperative pain
895293|NCT02571153|Patient satisfaction
895294|NCT02571153|Quality of health care
895295|NCT02571153|Ketamine
895296|NCT02571114|Glycemic Responses
895297|NCT02571114|Metabolic Responses
895298|NCT02571114|Males
895299|NCT02571114|Females
895300|NCT02571101|Clomipramine
895301|NCT02571101|Premature ejaculation
895302|NCT02571101|CDFR0812
895303|NCT02571101|Sildenafil
895304|NCT02571088|Sickle Cell Hemoglobin C Disease
895305|NCT02571088|Sports Training
895306|NCT02571088|Hemoglobin S Disease
895307|NCT02571088|Lactate
895308|NCT02571075|auricular
895309|NCT02571075|acupuncture
895310|NCT02571075|pain
895311|NCT02571062|bioequivalence
895312|NCT02571036|Gastrointestinal stromal tumors (GIST)
895313|NCT02571036|systemic mastocytosis (SM)
895314|NCT02571036|PDGFR-alpha
895315|NCT02571036|KIT
895316|NCT02571036|mast cell leukemia (MCL)
895317|NCT02571036|mast cell disease (MCD)
895318|NCT02571036|DCC-2618
895319|NCT02571036|melanoma
895320|NCT02571036|aggressive systemic mastocytosis (ASM)
895321|NCT02571023|Skull Base Trauma
895322|NCT02571023|microscope surgery
895323|NCT02571023|neuroendoscope surgery
895324|NCT02571010|static mechanical allodynia
895325|NCT02571010|somatosensory rehabilitation
895326|NCT02571010|vibrotactile stimulation
895327|NCT02570997|Alzheimer's Disease
895328|NCT02570997|Mild Cognitive Impairment
895329|NCT02570971|mannitol
895330|NCT02570971|treatment
895331|NCT02570958|robotic surgery
895332|NCT02570958|indocyanine green
895333|NCT02570958|electromagnetic navigational bronchoscopy
895334|NCT02570932|Adult Autologous Bone Marrow Mesenchymal Cells Expanded
895335|NCT02570932|chronic spinal cord injury (SCI)
895336|NCT02570919|Prostate cancer
895337|NCT02570919|IGRT
895338|NCT02570919|Hypofractionation
895339|NCT02570919|Extreme
895340|NCT02570919|Single Fraction
895341|NCT02570919|Urethral Sparing
895342|NCT02570919|MRI
895343|NCT02570893|Esophageal cancer;adjuvant therapy;chemotherapy;radiotherapy
895344|NCT02570867|glaucoma
895345|NCT02570867|brain function
895346|NCT02570867|fMRI
895347|NCT02570854|Anemia
895348|NCT02570841|Heat pain threshold
895349|NCT02570841|Cold pain threshold
895350|NCT02570841|Mechanical pain threshold
895351|NCT02570841|High dose Capsaicin
895352|NCT02570828|healthy neonate, tachypnea, thermal imaging, pneumonia
895353|NCT02570815|lung cancer
895354|NCT02570815|segmentectomy
895355|NCT02570815|robotic surgery
895356|NCT02570815|near-infrared fluorescent
895357|NCT02570815|IC-GREEN
895358|NCT02570815|indocyanine green
895359|NCT02570815|early-stage lung cancer
895360|NCT02570776|Helicobacter pylori
895361|NCT02570776|UBT
895362|NCT02570776|Sensitivity
895363|NCT02570776|specificity
895364|NCT02570776|prevalence
895365|NCT02570763|neurostimulation
895366|NCT02570763|comorbidity
895367|NCT02570763|tDCS
895368|NCT02570763|CBT
895369|NCT02570763|anxiety
895370|NCT02570763|alcohol
895371|NCT02570685|Gratitude Intervention
895372|NCT02570685|positive emotion
895373|NCT02570685|friendships
895374|NCT02570685|positive psychology
895375|NCT02570685|life satisfaction
895376|NCT02570659|WAD
895377|NCT02570659|Whiplash
895378|NCT02570659|Information Video
895379|NCT02570633|Migraine
895380|NCT02570633|Ginger
895381|NCT02570633|Prophylactic treatment
895382|NCT02570594|Cognition
895383|NCT02570594|Autobiographical
895384|NCT02570594|memoryCognitive
895385|NCT02570594|remediation
895386|NCT02570581|volonteeres
895387|NCT02570568|Venepuncture
895388|NCT02570568|Transillumination
895389|NCT02570555|driving
895390|NCT02570542|CD34+ Cell Dose
895391|NCT02570542|Autologous Stem Cell Transplantation
895392|NCT02570542|15-193
895393|NCT02570529|Pancreatic cancer
895394|NCT02570529|Chemoradiotherapy
895395|NCT02570529|Gastrointestinal toxicity
895396|NCT02570529|Albis
895397|NCT02570516|Indigo carmine chromoendoscopy
895398|NCT02570516|Narrow band imaging
895399|NCT02570516|Colonoscopy
895400|NCT02570490|fusidic acid
895401|NCT02570490|skin infection
895402|NCT02570451|cognitive impairment
895403|NCT02570451|post surgical outcomes
895404|NCT02570451|elective joint replacement surgery
895405|NCT02570438|postoperative outcomes
895406|NCT02570438|older surgical patients
895407|NCT02570386|In-vitro fertilization
895408|NCT02570386|frozen thawed embryo transfer
895409|NCT02570386|fresh embryo transfer
895410|NCT02570373|Healthy
895411|NCT02570373|Guselkumab
895412|NCT02570347|Snake Envenomation
895413|NCT02570347|Antibiotic Prophylaxis
895414|NCT02570347|Viperidae
895415|NCT02570334|early ART
895416|NCT02570334|neurocognitive evaluation
895417|NCT02570321|Cornea
895418|NCT02570321|Ulcer
895419|NCT02570321|Infectious keratitis
895420|NCT02570321|Bacterial
895421|NCT02570321|Fungal
895422|NCT02570295|Army
895423|NCT02570295|Sport
895424|NCT02570295|Physical Fitness
895425|NCT02570295|Injuries
895426|NCT02570295|Psychological Tests
895427|NCT02570295|Attrition
895428|NCT02570282|Female
895429|NCT02570256|stroke
895430|NCT02570256|upper extremity
895431|NCT02570256|motor exploration
895432|NCT02570256|error augmentation
895433|NCT02570256|robotic rehabilitation
895434|NCT02570243|heparin
895435|NCT02570243|radial artery
895436|NCT02570230|Thoracotomy
895437|NCT02570230|Postoperative pain
895438|NCT02570230|Ketamine
895439|NCT02570217|NCPAP, High Flow Nasal Cannula, pretem infants, NICU
895440|NCT02570178|clinical trial
895441|NCT02570178|accidental falls
895442|NCT02570178|postural balance
895443|NCT02570178|elderly
895444|NCT02570178|primary Health Care
895445|NCT02570165|efficacy
895446|NCT02570165|dry powder inhaler
895447|NCT02570165|vilanterol
895448|NCT02570165|batefenterol
895449|NCT02570152|Dengue
895450|NCT02570152|Non-laboratory confirmed dengue (non-LCD)
895451|NCT02570152|Acute febrile illness (AFI)
895452|NCT02570152|Laboratory confirmed dengue (LCD)
895453|NCT02570126|Immunogenicity
895454|NCT02570126|Varicella
895455|NCT02570126|Safety
895456|NCT02570126|Human serum albumin
895457|NCT02570126|Healthy children
895458|NCT02570126|12 to 23 months
895459|NCT02570100|Cancer Stem Cells
895460|NCT02570087|Coronary ChronicTotal Occlusion
895461|NCT02570087|Coronary Angioplasty
895462|NCT02570087|Reduced Ejection Fraction
895463|NCT02570061|recruitment
895464|NCT02570061|comprehension
895465|NCT02570061|satisfaction
895466|NCT02570061|informed consent
895467|NCT02570061|telephone
895468|NCT02570035|Mirabegron
895469|NCT02570035|Overactive Bladder
895470|NCT02570035|Cardiovascular Disease
895471|NCT02570022|Pain control
895472|NCT02570022|liposomal bupivacaine
895473|NCT02570022|exparel
895474|NCT02570022|shoulder arthroplasty
895475|NCT02570009|couples
895476|NCT02570009|weight loss treatment
895477|NCT02570009|home environment
895478|NCT02569970|Epilepsy
895479|NCT02569970|SUDEP
895480|NCT02569970|fluoxetine
895481|NCT02569970|placebo
895482|NCT02569970|SpO2
895483|NCT02569918|Neuroplasticity
895484|NCT02569918|Sensory Feedback
895485|NCT02569918|Transcutaneous electrical stimulation
895486|NCT02569918|Robotic hand
895487|NCT02569905|flurbiprofen
895488|NCT02569905|Parecoxib sodium
895489|NCT02569905|Postoperative Shivering
895490|NCT02569879|Boostrix™
895491|NCT02569879|Bagota
895492|NCT02569879|maternal vaccination
895493|NCT02569879|Pertussis
895494|NCT02569879|Mortality
895495|NCT02569879|Morbidity
895496|NCT02569866|plastic surgery
895497|NCT02569866|mammaplasty
895498|NCT02569866|wound infection
895499|NCT02569866|prophylaxis
895500|NCT02569827|Uncomplicated Dengue Fever
895501|NCT02569827|Treatment
895502|NCT02569827|Phase Ib/IIa
895503|NCT02569827|single centre
895504|NCT02569827|double-blind
895505|NCT02569827|placebo-controlled
895506|NCT02569827|parallel-group dose ranging trial
895507|NCT02569827|Modipafant
895508|NCT02569827|Celgosivir
895509|NCT02569788|re-irradiation
895510|NCT02569788|carbon ion radiotherapy
895511|NCT02569775|Cerebral Palsy
895512|NCT02569775|Stem Cells
895513|NCT02569762|Non-Nutritive Sweeteners
895514|NCT02569762|Artificial Sweeteners
895515|NCT02569762|Glucose Metabolism
895516|NCT02569762|Microbiota
895517|NCT02569762|Dysbiosis
895518|NCT02569671|Dental Implants, Single-Tooth
895519|NCT02569645|Rectal cancer
895520|NCT02569645|Rosuvastatin
895521|NCT02569632|Meningococcal Vaccines
895522|NCT02569632|Neisseria Meningitidis
895523|NCT02569632|Factor H-binding Protein
895524|NCT02569619|Physical Activity
895525|NCT02569619|Mental Health
895526|NCT02569619|Physical Exercise
895527|NCT02569619|Mental disorder
895528|NCT02569619|Promotion
895529|NCT02569606|consumption of blood
895530|NCT02569606|consumption of coagulation products
895531|NCT02569606|coagulation algorithm
895532|NCT02569606|trauma related transfusion
895533|NCT02569580|anti-lice treatment
895534|NCT02569567|Smart-Shear Wave(SSW)
895535|NCT02569567|Transient Elastography(TE)
895536|NCT02569567|Liver cirrhosis
895537|NCT02569554|PF-06463922
895538|NCT02569554|rabeprazole
895539|NCT02569554|proton pump inhibitor (PPI)
895540|NCT02569554|pharmacokinetics(PK)
895541|NCT02569554|food effect
895546|NCT02569528|atrial fibrillation
895547|NCT02569528|anticoagulation
895548|NCT02569476|BGB-3111
895549|NCT02569476|Obinutuzumab
895550|NCT02569476|B-cell
895551|NCT02569476|Lymphoma
895552|NCT02569476|Leukemia
895553|NCT02569476|Therapeutic uses
895554|NCT02569450|Surgery
895555|NCT02569450|Performance
895556|NCT02569450|Outcome
895557|NCT02569450|Control chart
895558|NCT02569437|doxycycline
895559|NCT02569437|oral methylprednisone
895560|NCT02569437|sinusitis with nasal polyps
895561|NCT02569424|PEEP level
895562|NCT02569424|Trendelenburg position
895563|NCT02569424|cross-sectional area of the jugular and subclavian veins
895564|NCT02569424|central venous catheter
895565|NCT02569398|Alzheimer disease
895566|NCT02569398|JNJ-54861911
895567|NCT02569398|Dementia
895568|NCT02569385|Weaning TTE
895569|NCT02569385|patients in prolonged weaning
895570|NCT02569346|Triumeq
895571|NCT02569346|Pharmacokinetics
895572|NCT02569346|Crushing
895573|NCT02569346|Drip feed
895574|NCT02569333|ulcerative colitis
895575|NCT02569333|inflammatory bowel disease
895576|NCT02569333|education
895577|NCT02569333|patient-reported outcomes
895578|NCT02569307|At Risk of Mental State
895579|NCT02569307|Prodromal Phase
895580|NCT02569307|Psychosis
895581|NCT02569294|group interventions
895582|NCT02569294|emotional distress
895583|NCT02569294|breast cancer
895584|NCT02569294|yoga
895585|NCT02569294|hypnosis
895586|NCT02569294|cognitive-behavioral therapy
895587|NCT02569281|Subacromial pain syndrome
895588|NCT02569281|Eccentric exercise
895589|NCT02569281|Pressure pain
895590|NCT02569281|US-guided percutaneous electrolysis
895591|NCT02569268|Arteriosclerosis
895592|NCT02569268|Vascular function
895593|NCT02569268|Vascular disease early detection system
895594|NCT02569229|children
895595|NCT02569229|cystic fibrosis
895596|NCT02569229|glucose intolerance
895597|NCT02569229|continuous glucose measurement
895598|NCT02569216|Electrical Inhibition
895599|NCT02569216|Preterm Birth
895600|NCT02569216|Premature Birth
895601|NCT02569216|Preterm Labor
895602|NCT02569216|Premature Labor
895603|NCT02569216|tocolytic
895604|NCT02569216|uterus
895605|NCT02569177|myocardial infarction
895606|NCT02569177|cardiac surgery
895607|NCT02569177|troponin
895608|NCT02569177|heart-type fatty acid binding protein
895609|NCT02569138|Balance
895610|NCT02569138|Footwear
895611|NCT02569138|Shoes
895612|NCT02569138|Falls
895613|NCT02569125|segmental overgrowth syndrome
895614|NCT02569099|stroke survivors
895615|NCT02569099|caregivers
895616|NCT02569099|burden of care
895617|NCT02569099|quality of life
895618|NCT02569099|function
895619|NCT02569099|community reintegration
895620|NCT02569099|caregiver training
895621|NCT02569073|Functional Chest Pain
895622|NCT02569073|Non-Cardiac Chest Pain
895623|NCT02569073|Esophageal Hypersensitivity
895624|NCT02569060|diabetes mellitus
895625|NCT02569060|community intervention
895626|NCT02569060|intervention
895627|NCT02569060|randomized
895628|NCT02569060|dietary intervention
895629|NCT02569060|self-management support
895630|NCT02569060|food bank
895631|NCT02569047|Atraumatic Restorative Treatment
895632|NCT02569047|Occlusoproximal
895633|NCT02569047|Primary Teeth
895634|NCT02569047|Glass Ionomer Cements
895635|NCT02569047|Hall Technique
895636|NCT02569021|Parkinsons Disease
895637|NCT02569021|Essential Tremor
895638|NCT02569021|DBS
895639|NCT02569021|Depp Brain Stimulation
895640|NCT02569008|Fluid Challenge
895641|NCT02569008|Mean systemic filling pressure
895642|NCT02569008|Fluid therapy
895643|NCT02568995|postoperative pain
895644|NCT02568995|morphine
895645|NCT02568995|total hip arthroplasty
895646|NCT02568995|femoral nerve block
895647|NCT02568982|Cushing's disease
895648|NCT02568982|Quality of life
895649|NCT02568982|Metabolic
895650|NCT02568982|patients with Cushing's disease
895651|NCT02568982|cardiovascular
895652|NCT02568982|thromboembolic
895653|NCT02568982|bone complications
895654|NCT02568969|Cardiosurgery, lactate
895655|NCT02568943|multiple myelome, MM, expanded treatment, panobinostat, bortezomib, dexamethasone, relapsed, refractory, LBH589
895656|NCT02568930|quality of life heart failure mechanical support transplant
895657|NCT02568917|Dental Atraumatic Restorative Treatment
895658|NCT02568917|Composite Resins
895659|NCT02568917|Primary Teeth
895660|NCT02568917|Permanent Teeth
895661|NCT02568917|Clinical Effectiveness
895662|NCT02568917|Cost Analysis
895663|NCT02568878|Depression
895664|NCT02568878|Anxiety
895665|NCT02568878|Methamphetamine dependence
895666|NCT02568852|D-dimer
895667|NCT02568852|Fibrinogen
895668|NCT02568852|Laparoscopic cholecystectomy
895669|NCT02568839|Neoadjuvant therapy
895670|NCT02568826|Low Back Pain
895671|NCT02568826|Muscle relaxant
895672|NCT02568813|epilepsy
895673|NCT02568813|depression
895674|NCT02568813|mood disorder
895675|NCT02568813|anxiety
895676|NCT02568813|cyclothymia
895677|NCT02568813|Behavioral neuropsychiatric features
895678|NCT02568787|NAFLD
895679|NCT02568787|cytokines
895680|NCT02568787|interleukin (IL)
895681|NCT02568787|interferon (IFN)
895682|NCT02568787|liver function test (LFTS)
895683|NCT02568787|nutrition
895684|NCT02568787|bran arabinoxylan compound (RBAC)
895685|NCT02568787|tumor necrosis factor -- type I receptor (TNF-RI)
895686|NCT02568787|TNF-RII (tumor necrosis factor -- type II receptor (TNF-RII)
895687|NCT02568774|Post-stroke
895688|NCT02568761|Snoring
895689|NCT02568761|Sleep apnea
895690|NCT02568761|Obstructive sleep apnea
895691|NCT02568761|Speech therapy
895692|NCT02568761|Injection snoreplasty
895693|NCT02568761|Ethanol
895694|NCT02568761|Oropharyngeal exercises
895695|NCT02568735|Dexketoprofen
895696|NCT02568735|Etoricoxib
895697|NCT02568735|hip arthroplasty
895698|NCT02568735|pain
895699|NCT02568722|Renal replacement therapy
895700|NCT02568722|Acute kidney injury
895701|NCT02568722|Dialysis
895702|NCT02568722|Hemodialysis
895703|NCT02568722|Critical illness
895704|NCT02568709|Oxytocin
895705|NCT02568709|Syntocinon
895706|NCT02568709|Social Cognition
895707|NCT02568709|Schizophrenia
895708|NCT02568709|Magnetoencephalography (MEG)
895709|NCT02568696|kidney transplantation
895710|NCT02568696|renal transplantation
895711|NCT02568696|fibrinolysis
895712|NCT02568696|cell mediated rejection
895713|NCT02568696|coagulation
895714|NCT02568696|delayed graft function
895715|NCT02568696|Halloran criteria
895716|NCT02568696|graft rejection
895717|NCT02568696|thrombin generation
895718|NCT02568696|fibrin generation
895719|NCT02568683|DLBCL
895720|NCT02568683|Relapsed
895721|NCT02568683|Refractory
895722|NCT02568644|Migraine
895723|NCT02568644|Ginger
895724|NCT02568644|Acute treatment
895725|NCT02568631|Autistic Disorder
895726|NCT02568618|Military
895727|NCT02568618|Genomics
895728|NCT02568618|Pain
895729|NCT02568605|Dietary intervention
895730|NCT02568605|Prebiotic fibre
895731|NCT02568605|Weight loss
895732|NCT02568605|Gut microbiota
895733|NCT02568605|Obesity
895734|NCT02568605|Liver fat
895735|NCT02568605|Hepatic fibrosis
895736|NCT02568540|Hepatitis C
895737|NCT02568540|Smartphone
895738|NCT02568540|app
895739|NCT02568540|Tracker
895740|NCT02568540|C Tracker
895741|NCT02568527|LSCD
895742|NCT02568527|SLET
895743|NCT02568527|Donor Human Amniotic Membrane (hAM)
895744|NCT02568527|PLGA
895745|NCT02568514|mhealth
895746|NCT02568514|text messaging
895747|NCT02568514|secure text messaging
895748|NCT02568514|communication
895749|NCT02568501|diabetes
895750|NCT02568501|adolescent
895751|NCT02568501|young adult
895752|NCT02568501|behavioral economics
895753|NCT02568501|financial incentives
895754|NCT02568501|social incentives
895755|NCT02568475|nursing home residents, decision aid, acute care transfers
895756|NCT02568462|Stents
895757|NCT02568462|Angioplasty
895758|NCT02568462|Coronary Vessels
895759|NCT02568462|Coronary Artery Disease
895760|NCT02568462|Angina Pectoris
895761|NCT02568462|Myocardial Ischemia
895762|NCT02568462|Myocardial Infarction
895763|NCT02568462|Myocardial Revascularization
895764|NCT02568410|Mast Cells
895765|NCT02568410|Blood Platelets
895766|NCT02568410|cardiac surgical procedures
895767|NCT02567344|Cannabis
895768|NCT02567344|rTMS
895769|NCT02567344|Craving
895770|NCT02567344|Decision making
895771|NCT02567318|Pain
895772|NCT02567318|Secondary hyperalgesia
895773|NCT02567318|Healthy volunteers
895774|NCT02567318|Magnetic Resonance Imaging
895775|NCT02567292|Digestive Disease and Disorders
895776|NCT02567292|Neonatal
895777|NCT02567292|Pediatric Disorders
895778|NCT02567253|Cytoreductive surgery
895779|NCT02567253|(H)ipec
895780|NCT02567253|Ovarian cancer
895781|NCT02567253|Cisplatin
895782|NCT02567253|Peritoneal carcinomatosis
895783|NCT02567253|Pharmacokinetics
895784|NCT02567253|Pharmacodynamics
895785|NCT02567214|dyspnea
895786|NCT02567214|exercise
895787|NCT02567214|shuttle test
895788|NCT02567214|long-acting β2-agonists
895789|NCT02567214|longacting muscarinic antagonist
895790|NCT02567214|indacaterol
895791|NCT02567214|glycopyrronium
895792|NCT02567214|tiotropium
895793|NCT02567201|Voluntary attention
895794|NCT02567201|Electroencephalogram
895795|NCT02567201|Brain-computer interface
895796|NCT02567201|Disorders of consciousness
895797|NCT02567162|Intracerebral hemorrhage
895798|NCT02567162|Hemorrhagic stroke
895799|NCT02567162|Intraparenchymal hemorrhage
895800|NCT02567162|Cerebrovascular disease
895801|NCT02567162|Stroke
895802|NCT02567149|Wart
895803|NCT02568371|biobank
895804|NCT02568371|DNA
895805|NCT02568371|genetic
895806|NCT02568371|young adults
895807|NCT02568371|cohort study
895808|NCT02568345|Dose-Response Relationship
895809|NCT02568345|Drug
895810|NCT02568345|Obesity
895811|NCT02568345|Cyclodextrins
895844|NCT02568241|Interferon Alfa-2b
895845|NCT02568241|Relapse
895846|NCT02568241|Donor lymphocyte infusion
895847|NCT02568228|Triacylglycerols
895848|NCT02568228|Omega-3 fatty acids
895849|NCT02568228|Krill oil
895850|NCT02568228|Fish
895851|NCT02568228|Healthy Volunteers
895852|NCT02568215|HIV-1 Infections
895853|NCT02568189|Sepsis
895854|NCT02568189|Gastroenteritis
895855|NCT02568189|Dehydration
895856|NCT02568189|Ultrasound
895857|NCT02568189|Ultrasonography
895858|NCT02568189|Inferior Vena Cava
895859|NCT02568176|Healthy
895860|NCT02568176|Pharmacokinetics
895861|NCT02568176|Esketamine
895862|NCT02568176|JNJ-54135419
895863|NCT02568176|Midazolam
895864|NCT02568176|Bupropion
895865|NCT02568137|mobile health
895866|NCT02568137|Behavior change
895867|NCT02568137|Africa
895868|NCT02568124|Tranexamic acid
895869|NCT02568124|Cyklokapron
895870|NCT02568124|Conservative management
895871|NCT02568124|Medical management
895872|NCT02568111|erythema
895873|NCT02568111|PLEGRIDY
895874|NCT02568111|injection site reaction (ISR)
895875|NCT02568111|MS
895876|NCT02568111|RRMS
895877|NCT02568098|Drug combination
895878|NCT02568098|Ivermectin
895879|NCT02568098|Primaquine
895880|NCT02568098|Dihydroartemisinin-Piperaquine
895881|NCT02568098|Albendazole
895882|NCT02568098|Pharmacokinetics
895883|NCT02568098|Mosquito-Lethal Effect
895884|NCT02568098|Healthy adult subject
895885|NCT02568072|exercise
895886|NCT02568072|cardiac remodelling
895887|NCT02568072|left ventricular non-compaction cardiomyopathy
895888|NCT02568046|Metastatic Colorectal Cancer
895889|NCT02567981|chronic undernutrition
895890|NCT02567981|anemia
895891|NCT02567981|micronutrient supplement
895892|NCT02567955|HPV vaccines, interchangeable use
895893|NCT02567877|hypothyroidism
895894|NCT02567877|deiodinase polymorphism
895895|NCT02567877|cognitive function
895896|NCT02567877|thyroidectomy
895897|NCT02567877|levothyroxine
895898|NCT02567851|Brentuximab Vedotin
895899|NCT02567851|PET scans
895900|NCT02567851|Lymphoma
895901|NCT02567825|ear infection
895902|NCT02567825|antibiotics
895903|NCT02567825|infants
895904|NCT02567825|children
895905|NCT02567825|pediatrics
895906|NCT02567825|tympanostomy tubes
895907|NCT02567799|Lung Neoplasms
895908|NCT02567773|Itraconazole
895909|NCT02567773|GSK2881078
895910|NCT02567773|CYP3A4
895911|NCT02567773|Selective Androgen Receptor Modulator
895912|NCT02567773|Safety
895913|NCT02567773|Pharmacokinetics
895914|NCT02567773|Tolerability
895915|NCT02567760|MP1
895916|NCT02567760|cognitive enhancing effect
895917|NCT02567760|menopausal women
895918|NCT02567747|Colombia
895919|NCT02567747|otitis
895920|NCT02567747|Database
895921|NCT02567747|pneumonia
895922|NCT02567734|irreversible electroporation
895923|NCT02567734|ablation
895924|NCT02567734|neoplasms
895925|NCT02567734|cancer
895926|NCT02567734|carcinoma
895927|NCT02567734|NanoKnife
895928|NCT02567734|Ablation Techniques
895929|NCT02567721|Post-authorisation safety study (PASS)
895930|NCT02567721|Adverse Drug Reaction Reporting Systems
895931|NCT02567721|Post marketing product surveillance
895932|NCT02567721|European Medicines Agency (EMA)
895933|NCT02567721|Influenza Vaccine
895934|NCT02567721|Computerized Medical Record System
895935|NCT02567721|United Kingdom
895936|NCT02567721|Primary Health Care
895937|NCT02567708|GSK2269557
895938|NCT02567708|Asthma
895939|NCT02567708|Pharmacokinetics
895940|NCT02567708|Safety
895941|NCT02567708|Adults
895942|NCT02567708|DISKUS Dry Powder Inhaler
895943|NCT02567708|Efficacy
895944|NCT02567682|anemia, sickle cell
895945|NCT02567669|radiotherapy
895946|NCT02567656|CTCL
895947|NCT02567656|PTCL
895948|NCT02567656|RP6530
895949|NCT02567643|Brain
895950|NCT02567643|CNS
895951|NCT02567643|Metastases
895952|NCT02567630|Cerebral Palsy
895953|NCT02567630|physical
895954|NCT02567630|sensory
895955|NCT02567630|motor impairments
895956|NCT02567630|upper extremity
895957|NCT02567630|Constraint-Induced Movement Therapy
896081|NCT02566629|microbiota community
895958|NCT02567617|Polyphenols, Prostaglandin E2, hormonal contraceptives
895959|NCT02567591|pre liver transplantation patients
895960|NCT02567552|endometrial receptivity
895961|NCT02567552|endometrial predecidualization
895962|NCT02567552|endometrial genomics
895963|NCT02567552|endometrial receptivity array
895964|NCT02567526|food and fluid intake
895965|NCT02567526|nursing home residents
895966|NCT02567526|staffing
895967|NCT02567513|food and fluid intake
895968|NCT02567513|nursing homes
895969|NCT02567500|emotional
895970|NCT02567500|auditory hallucinations
895971|NCT02567500|non-psychotic children
895972|NCT02567474|chronic lung disease
895973|NCT02567461|dual antiplatelet therapy
895974|NCT02567461|clopidogrel
895975|NCT02567461|aspirin
895976|NCT02567461|edoxaban
895977|NCT02567448|Obstructive Sleep Apnea
895978|NCT02567448|Chronic Obstructive Pulmonary Disease
895979|NCT02567448|Overlap syndrome
895980|NCT02567448|Pcrit
895981|NCT02567448|Critical closing pressure
895982|NCT02567383|head and neck cancer
895983|NCT02567383|hyperthermia, Thermotron RF-8
895984|NCT02567383|radiotherapy
895985|NCT02567370|Schizophrenia or Schizoaffective Disorder
895986|NCT02567357|change triggered temper outbursts
895987|NCT02567357|parent training
895988|NCT02567357|autism
895989|NCT02567357|intellectual disability
895990|NCT02567357|Prader-Willi syndrome
895991|NCT02567357|Fragile X syndrome
895992|NCT02567357|web-based training
895993|NCT02567357|Down syndrome
895994|NCT02567110|Mid-life Depression
895995|NCT02567110|Bipolar Disorder
895996|NCT02567110|DSM-5 MDE
895997|NCT02567110|Inflammation
895998|NCT02567110|CNS Glutamate
895999|NCT02567084|Bone substitute
896000|NCT02567084|benign bone cyst
896001|NCT02567084|ceramic
896002|NCT02567084|remodelling
896003|NCT02567071|C-section
896004|NCT02567071|Microbiota
896005|NCT02567058|Achilles tendon
896006|NCT02567045|Immunochemical fecal occult blood test
896007|NCT02567045|Colonoscopy
896008|NCT02567045|Screening uptake
896009|NCT02567045|Screening participation
896010|NCT02567045|Familiar risk
896011|NCT02567045|Colorectal Cancer
896012|NCT02567032|Oxytocin
896013|NCT02567032|Syntocinon
896014|NCT02567032|Social Cognition
896015|NCT02567032|Schizophrenia
896016|NCT02567006|vaccines
896017|NCT02567006|reminders
896018|NCT02567006|immunization timeliness
896019|NCT02567006|vaccine coverage
896020|NCT02566980|depression
896021|NCT02566980|mood disorder
896022|NCT02566980|post-partum depression
896023|NCT02566980|suicidality
896024|NCT02566980|post-partum suicidality
896025|NCT02566980|perinatal depression
896026|NCT02566980|perinatal mood disorder
896027|NCT02566980|inflammation
896028|NCT02566980|kynurenine pathway
896029|NCT02566980|glutamate
896030|NCT02566954|radiology
896031|NCT02566954|3D measurement
896032|NCT02566954|lower limb
896033|NCT02566941|critical illness polyneuropathy
896034|NCT02566941|critical illness myopathy
896035|NCT02566941|neuromuscular electrical stimulation
896036|NCT02566941|intensive care unit acquired weakness
896037|NCT02566941|prevention of critical illness polyneuropathy
896038|NCT02566928|Methicillin-Resistant Staphylococcus aureus
896039|NCT02566928|Recurrence
896040|NCT02566928|Practice Based Research Network
896041|NCT02566928|Community Health Workers/Promotoras
896042|NCT02566928|Decolonization and Decontamination
896043|NCT02566928|Staphylococcal Skin Infections
896044|NCT02566928|Household Transmission
896045|NCT02566889|Pediatric Inflammatory Bowel Disease
896046|NCT02566889|Infliximab
896047|NCT02566889|Pediatric Participants
896048|NCT02566889|Pediatric Ulcerative Colitis
896049|NCT02566889|Pediatric Crohn's Disease
896050|NCT02566889|Dose Escalation
896051|NCT02566876|Children
896052|NCT02566876|Abdominal Pain
896053|NCT02566876|Functional Dyspepsia
896054|NCT02566876|Irritable Bowel Syndrome
896055|NCT02566876|Quality of Life
896056|NCT02566863|dexmedetomidine
896057|NCT02566863|heart rate
896058|NCT02566863|heart rate variability
896059|NCT02566837|ultrasound
896060|NCT02566837|Electrical stimulation guidance
896061|NCT02566837|botulinum toxin
896062|NCT02566772|Prostate Cancer
896063|NCT02566759|Drug therapy
896064|NCT02566733|remifentanil
896065|NCT02566720|amantadine
896066|NCT02566720|tractography
896067|NCT02566720|mri
896068|NCT02566720|coma
896069|NCT02566720|abi
896070|NCT02566720|tbi
896071|NCT02566720|traumatic brain injury
896072|NCT02566720|acquired brain injury
896073|NCT02566668|Asthma
896074|NCT02566668|Severe Asthma
896075|NCT02566668|IL-10
896076|NCT02566668|IL-27
896077|NCT02566668|IL-13
896078|NCT02566668|Epithelial Cells
896079|NCT02566668|T lymphocytes
896080|NCT02566668|Interferon-g
896082|NCT02566629|IBS
896083|NCT02566603|ITP
896084|NCT02566603|Thrombocytopenia
896085|NCT02566577|Chronic anemia
896086|NCT02566577|Cardiopulmonary testing
896087|NCT02566577|Transfusion-dependent anemia
896088|NCT02566551|Prostatic artery embolization
896089|NCT02566551|Transurethral resection of the prostate
896090|NCT02566538|Cohort study
896091|NCT02566538|psychometric tests
896092|NCT02566538|cognitive function
896093|NCT02566538|cardiovascular risk
896094|NCT02566538|prediction algorithm
896095|NCT02566525|CytoSorb device
896096|NCT02566525|Plasma free hemoglobin
896097|NCT02566525|inflammation
896098|NCT02566525|extracorporeal bypass
896099|NCT02566512|Tracheostomy
896100|NCT02566512|weaning
896101|NCT02566512|respiratory failure
896102|NCT02566512|cough strength
896103|NCT02566499|Medical imaging
896104|NCT02566499|Microwaves
896105|NCT02566473|Patient reported outcomes
896106|NCT02566473|Osteoarthritis
896107|NCT02566473|Total joint replacement
896108|NCT02566460|Lactate clearance
896109|NCT02566460|systemic central venous oxygen saturation
896110|NCT02566460|septic shock
896111|NCT02566460|haemodynamic therapy
896112|NCT02566434|Dietary Supplements
896113|NCT02566395|Stem Cell Transplantation
896114|NCT02566395|Haploidentical Donors
896115|NCT02566369|Efficacy
896116|NCT02566369|Safety
896117|NCT02566369|Acne vulgaris
896118|NCT02566356|Oxytocin
896119|NCT02566356|Syntocinon
896120|NCT02566356|Social Cognition
896121|NCT02566356|Schizophrenia
896122|NCT02566356|Functional Magnetic Resonance Imaging (fMRI)
896123|NCT02566343|Spirometry
896124|NCT02566343|Exercise Test
896125|NCT02566343|Blood Gas Analysis
896126|NCT02566343|Respiratory Function Tests
896127|NCT02566343|Diagnostic Techniques, Respiratory System
896128|NCT02566343|Surgical Procedures, Operative
896129|NCT02566330|EndoBarrier
896130|NCT02566330|Duodenojejunal Bypass Liner
896131|NCT02566291|laryngeal mask
896132|NCT02566291|airway leakage
896133|NCT02566291|airway morbidity
896134|NCT02566278|Obstructive Sleep Apnea
896135|NCT02566278|Pcrit
896136|NCT02566278|Upper airway collapsibility
896137|NCT02566265|influenza
896138|NCT02566265|multiple myeloma
896139|NCT02566265|Waldenstrom's macroglobulinemia
896140|NCT02566252|Safety
896141|NCT02566252|tolerability
896142|NCT02566239|aging
896143|NCT02566239|ORCATECH
896144|NCT02566239|Oregon Center for Aging & Technology
896145|NCT02566239|Life Lab
896146|NCT02566239|Living Lab
896147|NCT02566239|in-home assessment
896148|NCT02566239|technology and aging
896149|NCT02566213|volunteers
896150|NCT02566200|Acute coronary syndrome
896151|NCT02566200|Cardiology
896152|NCT02566174|Cancer Caregivers
896153|NCT02566174|Cancer Patients
896154|NCT02566174|Role Adjustment
896155|NCT02566174|Mutuality
896156|NCT02566174|Well-Being
896159|NCT02566148|Life-event survey
896160|NCT02566148|observational survey among migrants in France
896161|NCT02566135|C-LMA
896162|NCT02566135|I-gel
896163|NCT02566135|ventilating bougie
896164|NCT02566135|intubation
896165|NCT02566096|major abdominal cancer
896166|NCT02566070|Enteral feeding
896167|NCT02566070|Continuous gastric feeding
896168|NCT02566070|Bolus gastric feeding
896169|NCT02566044|Cystic Fibrosis
896170|NCT02566031|COPD
896171|NCT02566031|open-label
896172|NCT02566031|QVA149
896173|NCT02566031|symptomatic
896174|NCT02566031|tiotropium
896175|NCT02566018|elderly
896176|NCT02566005|Misoprostol
896177|NCT02566005|Induction
896178|NCT02566005|Foley
896179|NCT02565992|pembrolizumab
896180|NCT02565992|coxsackievirus A21
896181|NCT02565992|melanoma
896182|NCT02565992|CAVATAK
896183|NCT02565992|CVA21
896184|NCT02565979|Resveratrol
896185|NCT02565979|Diabetes Mellitus, Type 2
896186|NCT02565979|Insulin Resistance
896187|NCT02565979|Metabolic Diseases
896188|NCT02565979|Glucose Metabolism Disorders
896189|NCT02565953|Vascular access devices obstruction
896190|NCT02565927|Trachea
896191|NCT02565927|Stent
896192|NCT02565927|Intraluminal brachytherapy
896193|NCT02565888|Hepatitis C
896194|NCT02565888|HIV
896195|NCT02565888|atazanavir
896196|NCT02565888|ritonavir
896197|NCT02565888|daclatasvir
896198|NCT02565888|cobicistat
896199|NCT02565875|Efficiency, Organizational
896200|NCT02565875|Simulation
896201|NCT02565875|Communication
896202|NCT02565875|Laparoscopy
896203|NCT02565875|Medical Education
896204|NCT02565862|HCV
896205|NCT02565862|Diabetes Mellitus
896206|NCT02565862|Daclatasvir
896207|NCT02565862|Metformin
896208|NCT02565862|drug-drug interaction
896209|NCT02565862|pharmacokinetics
896210|NCT02565836|Vitamin K 1
896211|NCT02565836|prothrombin complex concentrates
896212|NCT02565836|warfarin
896213|NCT02565823|Exercise
896214|NCT02565797|Decubitus Ulcer, Peri-operative, support surface, alternating pressure, neurosurgery
896215|NCT02565771|Childhood cancer
896216|NCT02565771|Cancer
896217|NCT02565771|Sequels
896218|NCT02565771|Surgery
896219|NCT02565771|Complications
896220|NCT02565771|Chemotherapy
896221|NCT02565771|Radiotherapy
896222|NCT02565758|Advanced Solid Tumor
896223|NCT02565758|Cancer
896224|NCT02565758|Neoplasm
896227|NCT02565706|Fruit, vegetables, income, WIC program, farmers' market
896228|NCT02565680|acute urticaria
896229|NCT02565680|glucocorticoids
896230|NCT02565680|antihistamines
896231|NCT02565680|prurit
896232|NCT02565680|itch score
896233|NCT02565680|rash
896234|NCT02565667|low rectal carcinoma
896235|NCT02565667|anastomosis
896236|NCT02565667|anterior rectal resection
896237|NCT02565654|Irritable bowel syndrome(IBS)
896238|NCT02565654|Small intestinal bacterial overgrowth (SIBO)
896239|NCT02565654|Rifaximin
896240|NCT02565602|Calcium metabolism
896241|NCT02565602|Osteoporosis
896242|NCT02565602|Postmenopausal women
896243|NCT02565576|CFZ533, Myasthenia Gravis
896244|NCT02565563|EMDR
896245|NCT02565563|Mechanisms
896246|NCT02565563|Eye Movement Desensitisation Reprocessing
896247|NCT02565550|Microbiota Community
896248|NCT02565550|FODMAPs
896249|NCT02565550|IBS
896250|NCT02565524|schizophrenia
896251|NCT02565524|early dissociative disorder
896252|NCT02565524|genetic
896254|NCT02565498|Soft tissue sarcoma
896255|NCT02565498|Extremity
896256|NCT02565498|Preoperative radiotherapy
896257|NCT02565498|Postoperative radiotherapy
896258|NCT02565485|pulse pressure
896259|NCT02565485|fetal heart rate
896260|NCT02565485|epidural analgesia
896261|NCT02565485|hypotension
896262|NCT02565485|preload
896263|NCT02565485|fluid bolus
896264|NCT02565485|central hypovolemia
896265|NCT02565459|Mesenchymal stromal cells
896266|NCT02565459|kidney transplantation
896267|NCT02565459|tolerance
896268|NCT02565433|brain metastases
896269|NCT02565433|Gamma Knife
896270|NCT02565433|Radiosurgery
896271|NCT02565433|Quality of Life
896272|NCT02565355|Pediatric Gastroenterology
896273|NCT02565342|Clavicle
896274|NCT02565303|cesarean section
896275|NCT02565303|ropivacaine
896276|NCT02565303|minimum effective dose
896277|NCT02565303|dose-response
896278|NCT02565303|subarachnoid
896279|NCT02565290|polyunsaturated fatty acid
896280|NCT02565290|fetal ductus arteriosus
896281|NCT02565290|inflammation
896282|NCT02565251|sepsis
896283|NCT02565251|hemodynamic monitoring
896284|NCT02565251|septic shock
896285|NCT02565251|volemic resuscitation
896286|NCT02565251|fluid resuscitation
896287|NCT02565212|Montelukast
896288|NCT02565212|Sniffin' Sticks test
896289|NCT02565212|allergic rhinitis
896290|NCT02565212|mometasone furoate
896291|NCT02565199|Transcranial Magnetic Stimulation
896292|NCT02565173|glaucoma
896293|NCT02565173|primary open-angle glaucoma
896294|NCT02565173|ocular hypertension
896295|NCT02565173|adenosine agonist
896296|NCT02565173|eye drop
896297|NCT02565173|trabodenoson
896298|NCT02565173|trabecular meshwork
896299|NCT02565147|STEMI, infarct size, CMR, bivalirudin
896300|NCT02565121|Olfactory perception
896301|NCT02565121|Adrenal cortex hormones
896302|NCT02565121|Steroids
896303|NCT02565121|Education
896304|NCT02565108|Cannabidiol
896305|NCT02565108|GWP42003-P
896306|NCT02565108|Clobazam
896307|NCT02565108|Epidiolex
896308|NCT02565082|Hemostatic potential
896309|NCT02565082|Sickle cell disease
896310|NCT02565082|Thrombin generation test
896311|NCT02565056|Acceptance and Commitment Therapy
896312|NCT02565030|Chronic thromboembolic Pulmonary Hypertension
896313|NCT02565030|Distal Chronic thromboembolic Pulmonary Hypertension
896314|NCT02565030|Proximal Chronic thromboembolic Pulmonary Hypertension
896315|NCT02565030|Operable disease
896316|NCT02565030|In-operable disease
896317|NCT02565030|Pulmonary Endarterectomy
896318|NCT02565030|PH specific targeted therapy
896319|NCT02565030|Phosphodiesterase type 5 Inhibitors
896320|NCT02565030|Endothelin Receptor Antagonist
896321|NCT02565030|Prostacyclin analogues
896322|NCT02565030|Soluble Guanylate cyclase stimulator
896323|NCT02565030|Sildenafil
896324|NCT02565030|Tadalafil
896325|NCT02565030|Bosentan
896326|NCT02565030|Ambrisentan
896327|NCT02565030|Macitentan
896328|NCT02565030|Iloprost
896329|NCT02565030|Riociguat
896330|NCT02565030|Idiopathic Pulmonary Arterial Hypertension
896331|NCT02565017|IBM Watson
896332|NCT02565017|Clinical Decision Support System
896333|NCT02565017|Patient Preferences
896334|NCT02565017|15-226
896335|NCT02565004|Genetic
896336|NCT02565004|Sample Collection
896337|NCT02564991|Alcoholism
896338|NCT02564991|MRI
896339|NCT02564991|Structural MRI
896340|NCT02564991|Cerebellum
896341|NCT02564978|Age-Related Macular Degeneration
896342|NCT02564978|Age-Related Macular Degeneration (AMD)
896343|NCT02564978|Geographic Atrophy
896344|NCT02564978|Minocycline
896345|NCT02564978|Atrophic Macular Degeneration
896346|NCT02564965|Acute Necrotizing Pancreatitis
896347|NCT02564965|Walled-Off Pancreatic Necrosis
896348|NCT02564952|Cannabidiol
896349|NCT02564952|GWP42003-P
896350|NCT02564952|Clobazam
896351|NCT02564952|Epidiolex
896352|NCT02564939|prevention
896353|NCT02564926|DM
896354|NCT02564913|tongue diagnosis
896355|NCT02564913|heart rate variability
896356|NCT02564913|nailfold videocapillaroscopy
896357|NCT02564900|Advanced solid tumors
896358|NCT02564900|phase 1
896359|NCT02564900|oncology
896360|NCT02564900|HER2
896361|NCT02564900|Antibody drug conjugate (ADC)
896362|NCT02564887|dysphagia
896363|NCT02564887|oral pharyngeal cancer
896364|NCT02564887|Iowa Oral Performance Instrument (IOPI)
896365|NCT02564887|IOPI
896366|NCT02564861|pharmacokinetics
896367|NCT02564848|Clinical T1-2N0 ER+
896368|NCT02564848|Invasive breast cancer
896369|NCT02564848|estrogen-positive
896370|NCT02564822|migraine disorders
896371|NCT02564822|cortical excitability
896372|NCT02564822|transcranial magnetic stimulation
896373|NCT02564822|electroencephalography
896374|NCT02564796|Erythropoetin
896375|NCT02564796|Cyanotic Heart Disease
896376|NCT02564796|Transfusion
896377|NCT02564796|Congenital Heart Disease
896378|NCT02564731|children
896379|NCT02564731|prognosis
896380|NCT02564718|Pediatric
896381|NCT02564679|bariatric surgery
896382|NCT02564679|sleeve gastrectomy
896383|NCT02564666|hepatocellular carcinoma
896384|NCT02564666|sorafenib
896385|NCT02564666|telephone counseling
896386|NCT02564640|videolaryngoscope
896387|NCT02564640|direct laryngoscope
896388|NCT02564640|hemodynamic changes
896389|NCT02564640|elderly patients
896390|NCT02564601|intervention
896391|NCT02564601|cognition
896392|NCT02564601|aging
896393|NCT02564601|piano training
896394|NCT02564601|computer brain training
896395|NCT02564575|Ebolavirus
896396|NCT02564562|PF-06463922
896397|NCT02564562|[14C]PF-06463922
896398|NCT02564562|Human ADME
896399|NCT02564562|Radiolabel
896400|NCT02564562|Mass Balance
896401|NCT02564562|Pharmacokinetics
896402|NCT02564549|low risk prostate cancer
896414|NCT02564484|Cancer Therapy
896415|NCT02564484|Pharmacogenomics
896416|NCT02564484|Drug Response
896417|NCT02564484|Genetic Variants
896418|NCT02564484|Vincristine-Induced Neuropathy
896419|NCT02564484|Cancer Survivor
896420|NCT02564432|amputee
896421|NCT02564354|Cystic Fibrosis
896422|NCT02564354|CF
896423|NCT02564354|ΔF508
896424|NCT02564354|CFTR
896425|NCT02564354|QR-010
896426|NCT02564354|antisense oligonucleotide
896427|NCT02564354|RNA therapy
896428|NCT02564354|F508del
896429|NCT02564354|NPD
896430|NCT02564354|nasal potential difference
896431|NCT02564341|HIV Infection
896432|NCT02564341|Pain
896433|NCT02564341|Collaborative Care
896434|NCT02564341|Chronic Opioid Therapy
896435|NCT02564341|Addiction
896436|NCT02564341|Analgesics, Opioid
896437|NCT02564328|Stroke
896438|NCT02564328|Bone Marrow Mesenchymal Stem Cell
896439|NCT02564328|Transplantation
896440|NCT02564315|Smoking
896441|NCT02564315|Cessation
896442|NCT02564315|Tobacco
896443|NCT02564315|Relapse
896444|NCT02564302|PVI
896445|NCT02564302|Atrial Fibrillation
896446|NCT02564302|MUSE Headband
896447|NCT02564302|Mindfulness
896448|NCT02564289|microvesicles, microparticles
896449|NCT02564289|Plethysmography
896450|NCT02564289|Snus
896451|NCT02564289|Arterial Stiffness
896452|NCT02564289|EPC
896453|NCT02564276|Indocyanine Green
896454|NCT02564276|Sentinel Lymph Node Biopsy
896459|NCT02564237|Group A streptococcal
896460|NCT02564198|relapsed pediatric solid tumors
896461|NCT02564198|unspecified childhood solid tumor
896462|NCT02564198|brain and central nervous system tumors
896463|NCT02564159|malnutrition
896464|NCT02564159|muscle ultrasound
896465|NCT02564159|intensive care unit
896466|NCT02564159|mechanical ventilation
896467|NCT02564159|albumin
896468|NCT02564159|prealbumin
896469|NCT02564159|nutrition
896475|NCT02564042|Double blind
896476|NCT02564042|Dose-finding
896477|NCT02564042|Vehicle-Controlled
896478|NCT02564042|GSK2894512
896479|NCT02564042|Plaque Psoriasis
896480|NCT02563977|Breast reconstruction
896481|NCT02563977|Deep inferior epigastric perforator flap
896482|NCT02563977|Abdominal wall morbidity
896483|NCT02563977|Plastic and reconstructive surgery
896484|NCT02563964|Myocardial infarction
896485|NCT02563964|vulnerable plaque
896486|NCT02563964|Positron emission tomography (PET)
896487|NCT02563964|Cardiac magnetic resonance imaging (CMR)
896488|NCT02563964|Biomarkers
896489|NCT02563951|Nausea
896490|NCT02563951|Vomiting
896491|NCT02563951|Chemotherapy
896492|NCT02563951|Radiation therapy
896493|NCT02563925|Brain Irradiation
896494|NCT02563925|Tremelimumab
896495|NCT02563925|15-038
896496|NCT02563912|Children
896497|NCT02563912|resuscitation
896498|NCT02563912|simulation
896499|NCT02563912|medication error
896500|NCT02563899|Primary Axillary Hyperhidrosis
896501|NCT02563899|GSK573719
896502|NCT02563899|Hyperhidrosis Disease Severity Scale (HDSS)
896503|NCT02563899|Topical
896504|NCT02563899|PRO
896505|NCT02563899|Hyperhidrosis Symptom Severity Measure (HSSM)
896506|NCT02563899|Umeclidinium
896507|NCT02563821|Termination of pregancy
896508|NCT02563821|Third trimester
896509|NCT02563821|Programmed intermittent epidural bolus
896510|NCT02563821|Continuous epidural infusion
896511|NCT02563821|Epidural analgesia
896512|NCT02563821|Legally induced abortion
896513|NCT02563795|Spinal anesthesia
896514|NCT02563795|Cesarean
896515|NCT02563795|Maternal hypotension
896516|NCT02563769|Cocaine
896517|NCT02563769|Clavulanic Acid
896518|NCT02563756|Medial gonarthritis, knee osteoarthritis,
896519|NCT02563756|Muscle function, muscle mass, muscle atrophy
896520|NCT02563756|Total knee arthroplasty (TKA)
896521|NCT02563756|Unicondylar knee arthroplasty (UKA)
896522|NCT02563756|Total knee replacement (TKR)
896523|NCT02563756|Unicondylar knee replacement (UKR)
896524|NCT02563756|Health-related quality of life (HRQoL)
896525|NCT02563756|Patient related outcome measurements (PROMs)
896526|NCT02563743|Sick-leave
896527|NCT02563743|Return to work
896528|NCT02563743|Occupational health
896529|NCT02563743|Common mental disorder
896530|NCT02563743|Depression
896531|NCT02563743|Anxiety disorders
896532|NCT02563743|Adjustment disorders
896533|NCT02563743|Problem solving therapy
896534|NCT02563743|Occupational Health Services
896535|NCT02563743|Randomized controlled trial
896536|NCT02563743|Intervention studies
896537|NCT02563743|Occupational stress
896538|NCT02563730|Cryobiopsy
896539|NCT02563730|lung biopsy
896540|NCT02563730|interstitial lung disease
896546|NCT02563704|Artesunate
896547|NCT02563704|Quinine
896548|NCT02563704|Efficacy
896549|NCT02563704|Malaria
896550|NCT02563704|Children
896551|NCT02563704|Cameroon
896552|NCT02563652|Abdomen/surgery
896553|NCT02563652|Biological markers
896554|NCT02563652|Length of stay
896555|NCT02563652|Postoperative care
896556|NCT02563652|Anesthesia recovery period
896557|NCT02563652|Prognosis
896558|NCT02563639|newly diagnosed
896559|NCT02563639|paroxysmal
896560|NCT02563639|persistent
896561|NCT02563626|coronary artery aneurysm
896562|NCT02563626|prognosis
896563|NCT02563626|outcomes
896564|NCT02563626|management
896565|NCT02563626|incidence
896566|NCT02563626|heart failure
896567|NCT02563626|acute coronary syndrome
896568|NCT02563626|death
896569|NCT02563613|community-based intervention
896570|NCT02563613|family holistic health
896571|NCT02563613|positive psychology
896572|NCT02563613|physical exercise
896573|NCT02563613|healthy diet
896574|NCT02563587|Laughter
896575|NCT02563587|children
896576|NCT02563587|postoperative
896577|NCT02563587|pain
896578|NCT02563587|anxiety
896579|NCT02563587|cortisol
896583|NCT02563561|Bladder Cancer
896584|NCT02563561|Non-muscle invasive bladder cancer
896585|NCT02563561|Apaziquone
896586|NCT02563561|TURBT
896587|NCT02563561|Stage Ta, G1-G2
896588|NCT02563522|non healing ulcers
896589|NCT02563522|VM202
896590|NCT02563522|Diabetic ulcers
896591|NCT02563522|foot ulcers
896592|NCT02563509|HIV
896593|NCT02563509|cellular immunity therapy
896594|NCT02563509|functional cure
896595|NCT02563496|pharmacokinetic
896596|NCT02563496|pediatric
896597|NCT02563496|Tafenoquine
896598|NCT02563496|Plasmodium vivax Malaria
896599|NCT02563496|G6PD deficiency
896600|NCT02563483|caregivers
896601|NCT02563483|anxiety
896602|NCT02563483|depression
896603|NCT02563483|yoga
896604|NCT02563483|meditation
896605|NCT02563483|stress
896606|NCT02563457|diabetic patients
896607|NCT02563457|periodontal treatment
896608|NCT02563457|glycaemic control
896609|NCT02563444|Diagnostic (Biopsy) or Therapeutic Procedure (Infiltration, Ablation)
896610|NCT02563431|shoulder pain
896611|NCT02563431|prevention program
896612|NCT02563418|video oculography
896613|NCT02563405|alpha receptor blocker
896614|NCT02563405|uric acid
896615|NCT02563405|CCB
896616|NCT02563405|blood pressure variability
896617|NCT02563366|kidney transplantation
896618|NCT02563366|mesenchymal stem cell therapy
896619|NCT02563366|poor early graft function
896620|NCT02563366|delayed graft function
896621|NCT02563366|ischemia reperfusion injury
896622|NCT02563366|donation after cardiac death
896623|NCT02563353|whole body vibration
896624|NCT02563353|PTH
896625|NCT02563340|kidney transplantation
896626|NCT02563340|antibody-mediated rejection
896627|NCT02563340|mesenchymal stem cell therapy
896628|NCT02563340|donor specific antibody
896629|NCT02563340|acute rejection
896630|NCT02563314|Noninvasive Ventilation
896631|NCT02563314|Pulmonary Disease
896632|NCT02563314|Chronic Obstructive
896633|NCT02563314|Renal Doppler
896634|NCT02563314|Oxygen
896635|NCT02563314|Hypercapnia
896636|NCT02563288|esmolol
896637|NCT02563288|dexmedetomidine
896638|NCT02563288|opioids
896639|NCT02563197|Device study
896640|NCT02563197|Peak inspiratory flow rate
896641|NCT02563197|Non-cystic fibrosis bronchiectasis
896642|NCT02563197|T-326 Inhaler
896643|NCT02563171|visceral adipose-specific serpin
896644|NCT02563171|intelectin 1 (omentin)
896645|NCT02563171|Tumor Necrosis Factor-alpha
896646|NCT02563158|liver resection
896647|NCT02563158|blood inflow control
896648|NCT02563158|ischemia-reperfusion injury
896649|NCT02563158|inflammatory response
896650|NCT02563158|randomized controlled trial
896652|NCT02563132|colonoscopy
896653|NCT02563132|carbon dioxide
896654|NCT02563132|inflammatory bowel disease
896655|NCT02563093|Influenza
896656|NCT02563093|Fluzone® Quadrivalent, Influenza Vaccine
896657|NCT02563093|Fluzone® Intradermal Quadrivalent, Influenza Vaccine
896658|NCT02563093|Fluzone® High Dose, Influenza Vaccine
896659|NCT02563080|exocrine insufficiency
896660|NCT02563080|acute pancreatitis
896661|NCT02563080|severe
896662|NCT02563080|moderately severe
896663|NCT02563067|Asthma
896664|NCT02563067|QAW039
896665|NCT02563028|Visual Evoked Potentials
896666|NCT02563028|Microdiscectomy
896667|NCT02563028|SightSaver
896668|NCT02563015|Infant
896669|NCT02563015|Vitamin D
896670|NCT02563015|Deficiency
896671|NCT02563015|Lean Mass
896675|NCT02562924|MEDIHONEY
896676|NCT02562924|Chronic Rhinosinusitis With Nasal Polyposis
896677|NCT02562924|Functional Endoscopic Sinus Surgery
896678|NCT02562911|cystic fibrosis
896679|NCT02562911|menstrual cycle
896680|NCT02562911|puberty
896681|NCT02562885|Benign epilepsy with centro-temporal spikes
896682|NCT02562885|Continuous spike waves in slow wave sleep
896683|NCT02562885|Electroencephalography
896684|NCT02562885|Sleep, slow wave
896685|NCT02562872|Controlled
896686|NCT02562872|Human
896687|NCT02562872|Malaria
896688|NCT02562872|Infection
896689|NCT02562872|Healthy
896690|NCT02562872|Volunteer
896691|NCT02562846|electroconvulsive therapy
896692|NCT02562846|response prediction
896693|NCT02562846|cognitive side effects
896694|NCT02562833|Osteoarthritis
896695|NCT02562833|Self-management
896696|NCT02562833|Multi-Component Exercise
896697|NCT02562807|Urinary Incontinence
896698|NCT02562807|Urinary Incontinence, Stress
896699|NCT02562807|Lower Urinary Tract Symptoms
896700|NCT02562794|refugee
896701|NCT02562781|postoperative complications
896702|NCT02562781|postoperative cognitive dysfunction
896703|NCT02562781|oxygen
896713|NCT02562742|Hepatitis C virus
896714|NCT02562742|observational
896715|NCT02562742|post-marketing
896716|NCT02562742|sofosbuvir
896717|NCT02562742|Infection
896718|NCT02562729|Cervical cancer; Nerve-sparing hysterectomy; simplified
896719|NCT02562690|Coronary Artery Disease
896720|NCT02562690|Myocardial Ischemia
896721|NCT02562690|Arterial Occlusive Diseases
896722|NCT02562690|Coronary Thrombosis
896723|NCT02562651|STEMI, adverse LVR (left ventricular remodeling), MMPs, Doxycycline
896724|NCT02562638|NPO
896725|NCT02562638|NBM
896726|NCT02562638|pre-procedure
896727|NCT02562638|cardiac
896728|NCT02562599|Induction Chemotherapy
896729|NCT02562599|Concurrent Chemoradiotherapy
896730|NCT02562586|Suction
896731|NCT02562586|Arthroplasty
896732|NCT02562586|Replacement
896733|NCT02562586|Hip
896734|NCT02562534|ECG
896735|NCT02562534|MRI
896736|NCT02562534|rythm troubles
896737|NCT02562534|conductive troubles
896738|NCT02562534|ECG artifacts
896739|NCT02562534|Database
896740|NCT02562508|Human Papilloma Virus 16
896741|NCT02562508|Human Papilloma Virus 18
896742|NCT02562508|vaccine
896743|NCT02562508|adolescent girl
896744|NCT02562508|bridging trial
896745|NCT02562508|non-inferiority
896746|NCT02562495|severe cerebral pathology
896747|NCT02562495|Ultrasound
896748|NCT02562495|thickness of the quadriceps
896749|NCT02562482|Antibody Response
896750|NCT02562482|Immune Response
896751|NCT02562482|Healthy Volunteer
896752|NCT02562482|Vaccine-Mediated Protection
896753|NCT02562482|Chikungunya Virus
896754|NCT02562482|Vaccines, Virus-like Particles
896755|NCT02562456|Dental Atraumatic Restorative Treatment
896756|NCT02562456|Composite Resins
896757|NCT02562456|Primary Teeth
896758|NCT02562456|Clinical Efficacy
896759|NCT02562456|Cost Analysis
896760|NCT02562443|Myelodysplastic Syndrome
896761|NCT02562443|MDS
896762|NCT02562430|Placebo response
896763|NCT02562391|atrial fibrillation
896764|NCT02562391|ablation
896765|NCT02562391|thoracoscopy
896766|NCT02562391|left atrial appendage
896767|NCT02562365|adjuvent chemotherapy
896768|NCT02562365|ovarian cancer
896775|NCT02562274|Menopause
896776|NCT02562274|Cognitive impairment
896777|NCT02562274|Working memory
896778|NCT02562274|Bone formation markers
896779|NCT02562274|Osteoporosis
896780|NCT02562261|sepsis
896781|NCT02562261|platelet
896782|NCT02562261|platelet reactivity
896783|NCT02562261|P2Y12
896784|NCT02562235|Pulmonary arterial hypertension
896785|NCT02562222|migraine disorders
896786|NCT02562222|transcranial direct current stimulation
896787|NCT02562222|electric stimulation therapy
896788|NCT02562222|pain
896789|NCT02562222|rehabilitation
896790|NCT02562209|Obesity
896791|NCT02562209|Abdominal adiposity
896792|NCT02562209|High protein diet
896793|NCT02562196|migraine disorders
896794|NCT02562196|transcranial direct current stimulation
896795|NCT02562196|electric stimulation therapy
896796|NCT02562196|pain
896797|NCT02562170|breast
896798|NCT02562170|reconstruction
896799|NCT02562170|mesh
896800|NCT02562170|acellular dermal matrix
896801|NCT02562131|PET-MR
896802|NCT02562131|recidive
896803|NCT02562131|PET/MR imaging
896804|NCT02562131|18F-Fluciclovine
896805|NCT02562131|radical treatment
896806|NCT02562131|recurrence
896807|NCT02562105|Intensive care unit
896808|NCT02562105|Hematological malignancy
896809|NCT02562105|Acute respiratory failure
896810|NCT02562105|Prognosis
896811|NCT02562105|Mechanical ventilation
896812|NCT02562092|AIDS
896813|NCT02562092|Health Promotion
896814|NCT02562079|T lymphocyte
896815|NCT02562079|OX40/OX40L
896816|NCT02562040|Pediatrics
896817|NCT02562040|Primary Snoring
896818|NCT02562040|Adenotonsillectomy
896819|NCT02562001|Spinal Cord Injuries
896820|NCT02562001|gait training
896821|NCT02562001|robotic
896822|NCT02562001|Lokomat
896823|NCT02562001|Transcranial Magnetic Stimulation
896824|NCT02562001|transcranial direct-current stimulation
896825|NCT02562001|Electroencephalography
896826|NCT02561975|Double pulmonary diffusing capacity to carbon monoxyd (CO) associated to nitric oxide (NO)
896827|NCT02561975|Evolution of membrane and capillar damages
896828|NCT02561975|Early pronostic value of congenital heart disease
896829|NCT02561962|Multiple Myeloma
896830|NCT02561962|Relapsed Multiple Myeloma
896831|NCT02561962|Refractory Multiple Myeloma
896832|NCT02561949|Depression/therapy
896833|NCT02561949|Developing Countries
896834|NCT02561949|Interpersonal Relations
896835|NCT02561949|Life Change Events
896836|NCT02561949|Psychotherapy, group
896837|NCT02561949|Resilience, Psychological
896838|NCT02561949|Sierra Leone
896839|NCT02561949|Survivors/psychology
896840|NCT02561949|Social Adjustment
896841|NCT02561949|Social Behavior
896842|NCT02561949|War
896843|NCT02561936|Healthy
896844|NCT02561936|EUDRANT
896845|NCT02561936|Rilpivirine
896846|NCT02561923|Healthy
896847|NCT02561923|Rivaroxaban
896848|NCT02561923|XARELTO
896849|NCT02561910|Inguinal hernia repair
896850|NCT02561910|laparoscopic inguinal hernia repair
896851|NCT02561910|TAPP
896852|NCT02561871|Ad26.RSV.FA2 (JNJ-61187165-AAA)
896853|NCT02561871|Ad35.RSV.FA2 (JNJ-61187191-AAA)
896854|NCT02561871|Healthy participants
896855|NCT02561858|Renal Ammonium ;uric acid
896856|NCT02561845|Effectiveness of statins, on lipid goal attainment and lipid parameters in Percutaneous Coronary Intervention patients
896857|NCT02561832|breast cancer
896858|NCT02561819|Short Bowel Syndrome
896859|NCT02561819|Congenital Short Bowel Syndrome
896860|NCT02561819|Body Composition
896861|NCT02561819|Parenteral Nutrition
896862|NCT02561819|Intestinal Failure
896863|NCT02561780|Mental Health Knowledge
896864|NCT02561780|Stigma
896865|NCT02561780|Mental Health Literacy
896866|NCT02561767|kidney transplantation
896867|NCT02561767|mesenchymal stem cell
896868|NCT02561767|donation after citizen's death
896869|NCT02561767|ischemia reperfusion injury
896870|NCT02561767|renal function recovery
896871|NCT02561754|Diet
896872|NCT02561754|Obesity
896873|NCT02561754|Adolescents
896874|NCT02561754|Intellectual and Developmental Disability
896875|NCT02561728|Helmet
896876|NCT02561728|Hangar
896877|NCT02561728|P-Pod
896878|NCT02561728|Plagiocephaly
896879|NCT02561728|Surgery
896880|NCT02561715|Parkinson's
896881|NCT02561715|Anosognosia
896882|NCT02561715|DBS
896883|NCT02561715|Deep Brain Surgery
896884|NCT02561689|Occlusal caries
896885|NCT02561689|Resin fissure sealant
896886|NCT02561689|Longevity
896887|NCT02561689|Effectiveness
896888|NCT02561676|Mindfulness
896889|NCT02561676|Spinal Cord Injury
896890|NCT02561663|microcirculation
896891|NCT02561663|blood pressure
896892|NCT02561663|pulse wave analysis
896893|NCT02561663|pulse wave velocity
896894|NCT02561637|Case management
896895|NCT02561624|mHealth
896896|NCT02561624|Text message
896897|NCT02561611|Pedal Desk
896898|NCT02561611|Workplace Intervention
896899|NCT02561611|Physical Activity
896900|NCT02561611|Energy Expenditure
896901|NCT02561546|concurrent
896902|NCT02561520|platelet rich plasma
896903|NCT02561520|platelet poor plasma
896904|NCT02561520|ocular GVHD
896905|NCT02561455|Advanced solid tumors
896906|NCT02561455|Acute myeloid leukemia
896907|NCT02561455|ASP2215
896908|NCT02561416|Fibromyalgia syndrome
896909|NCT02561416|Mindfulness (MBSR)
896910|NCT02561416|Neuroimaging
896911|NCT02561416|Cytokines
896912|NCT02561416|Randomized Controlled Trial
896913|NCT02561416|Cost-effectiveness
896914|NCT02561416|Psychoeducation (FibroQol)
896915|NCT02561403|traumatic brain injury (TBI)
896916|NCT02561403|aging
896917|NCT02561403|cognitive training
896918|NCT02561403|Cognitive Aging
896919|NCT02561377|resistance training
896920|NCT02561377|Prediabetic state
896921|NCT02561377|Metabolomics
896922|NCT02561364|Fetal Biophysical Profile
896923|NCT02561351|bronchial asthma
896924|NCT02561351|fractional exhaled nitric oxide (FeNO)
896925|NCT02561351|asthma exacerbation
896926|NCT02561338|GKA,T2DM,HMS5552
896927|NCT02561325|Blood pressure
896928|NCT02561325|Sodium Chloride
896929|NCT02561325|Sodium Bicarbonate
896930|NCT02561299|Drug-coated Balloons
896931|NCT02561299|Calcified Lesions
896932|NCT02561299|Orbital Atherectomy
896933|NCT02561299|Below the Knee
896934|NCT02561299|Paclitaxel
896935|NCT02561299|Lutonix 014 Drug-coated Balloon
896936|NCT02561286|Human immunodeficiency virus
896937|NCT02561286|Sexually transmitted disease
896938|NCT02561286|Men who have sex with men
896939|NCT02561286|African Americans
896940|NCT02561286|Behavioral intervention
896941|NCT02561286|Randomized controlled trial
896942|NCT02561286|Sexual behavior
896943|NCT02561286|Mediation analysis
896944|NCT02561286|Social cognitive theory
896945|NCT02561286|Theory of planned behavior
896958|NCT02561208|Patient adherence
896959|NCT02561208|Mobile Health
896960|NCT02561208|HPV DNA Tests
896961|NCT02561208|Self-collected
896962|NCT02561195|Clostridium difficile, Vaccine.
896963|NCT02561169|antiviral
896964|NCT02561169|oseltamivir
896965|NCT02561156|Drug therapy
896971|NCT02561130|Diabetes
896972|NCT02561130|Insulin
896973|NCT02561130|Glargine
896974|NCT02561130|Metformin
896975|NCT02561130|Forxiga
896976|NCT02561130|Diet
896977|NCT02561130|Exercise
896978|NCT02561130|Lifestyle
896979|NCT02561104|cataract
896980|NCT02561104|phacoemulsification
896981|NCT02561104|laser-assisted surgery
896982|NCT02561104|femtosecond laser
896983|NCT02561091|Deafness
896984|NCT02561091|Hearing Loss, Sensorineural
896985|NCT02561091|Ear Diseases
896986|NCT02561091|Hearing Disorders
896987|NCT02561091|Otorhinolaryngologic Diseases
896988|NCT02561091|Sensation Disorders
896989|NCT02561091|Signs and Symptoms
896990|NCT02561091|Hearing and Speech impairment
896991|NCT02561091|Hearing Loss, Unilateral
896992|NCT02561078|insulin pumps
896993|NCT02561078|concentrated insulin
896994|NCT02561078|OmniPod
896995|NCT02561065|Health Lifestyle
896996|NCT02561065|Lifestyle Risk Reduction
896997|NCT02561065|Health Behavior
896998|NCT02561065|Sedentary Lifestyle
896999|NCT02561065|Intervention Studies
897000|NCT02561065|Cardiovascular risk in office workers
897001|NCT02561065|Motivational Interview
897002|NCT02561065|Preventive health services
897003|NCT02561065|Health education
897004|NCT02561065|Physical activity
897005|NCT02561065|Dietary behaviour intervention
897006|NCT02561065|Workplace
897007|NCT02560012|Renal Cell Carcinoma
897008|NCT02560012|RCC
897009|NCT02560012|Personalized therapy
897010|NCT02560012|targeted inhibitors
897011|NCT02561026|Frozen plasma
897012|NCT02561026|INR
897013|NCT02561026|procedures
897014|NCT02561000|Platelets
897015|NCT02561000|Platelet Aggregation Inhibitors
897016|NCT02561000|Protease-Activated Receptor 1
897017|NCT02561000|Hemorrhage
897018|NCT02560961|Kinesio Taping
897019|NCT02560961|Soccer
897020|NCT02560961|Hop Test
897021|NCT02560961|Vertical Jump
897022|NCT02560935|primary stroke prevention
897023|NCT02560935|hydroxyurea
897024|NCT02560935|low income country
897025|NCT02560935|sub-Saharan Africa
897026|NCT02560922|Osteoarthritis
897027|NCT02560922|Knee Osteoarthritis
897028|NCT02560922|Hip Osteoarthritis
897029|NCT02560896|Family
897030|NCT02560896|History
897031|NCT02560896|Pancreas
897032|NCT02560896|Cancer
897033|NCT02560896|Genetic
897034|NCT02560883|Hairy Cell
897035|NCT02560857|Quantiferon-Monitor
897036|NCT02560857|organ rejection
897037|NCT02560857|global immunity
897038|NCT02560831|Osteoarthritis
897039|NCT02560831|Therapeutic exercises
897040|NCT02560831|Pain
897041|NCT02560831|Muscle strength
897042|NCT02560831|Postural balance
897043|NCT02560818|splice profiles of messenger RNA
897044|NCT02560779|TRC105
897045|NCT02560779|CD105
897046|NCT02560779|Endoglin
897047|NCT02560779|Angiogenesis inhibitor
897048|NCT02560779|HCC
897049|NCT02560779|TKI
897050|NCT02560779|Tyrosine Kinase Inhibitor
897051|NCT02560779|Sorafenib
897052|NCT02560779|Nexavar
897053|NCT02560766|Restless Leg Syndrome
897054|NCT02560766|RLS
897055|NCT02560727|Inflammatory Bowel Diseases
897056|NCT02560727|Fecal Microbiota Transplantation
897057|NCT02560727|transendoscopic enteral tubing
897058|NCT02560714|sacroiliac joint fusion
897059|NCT02560714|SIJ Fusion
897060|NCT02560714|SI Joint
897061|NCT02560714|SIJ
897062|NCT02560701|high-deductible health plans
897063|NCT02560701|medication adherence
897064|NCT02560688|drug interaction
897065|NCT02560688|clopidogrel
897066|NCT02560688|healthy subjects
897067|NCT02560675|Whiplash Injury Pain
897068|NCT02560675|Chronic Pain
897069|NCT02560675|TBI
897070|NCT02560662|Breast cancer, physical exercise, recovery
897071|NCT02560636|Muscle Invasive
897072|NCT02560636|Metastatic
897073|NCT02560636|Advanced
897074|NCT02560623|Barrett's
897075|NCT02560623|esophagus
897076|NCT02560623|reflux
897077|NCT02560623|esophageal adenocarcinoma
897078|NCT02560597|epilepsy
897079|NCT02560597|epilepsia partialis continua
897080|NCT02560597|status epilepticus
897081|NCT02560597|treatment resistant
897082|NCT02560597|repetitive transcranial magnetic stimulation
897083|NCT02560584|Non-muscle invasive bladder cancer
897084|NCT02560584|NMIBC
897085|NCT02560584|Cysview
897086|NCT02560558|Immunosuppression
897087|NCT02560558|Transplantation Immunology
897088|NCT02560532|aneurysmal subarachnoid hemorrhage
897089|NCT02560532|cerebral vasospasm
897090|NCT02560532|clazosentan
897091|NCT02560519|human serum albumin solution
897092|NCT02560519|Cardiopulmonary Bypass
897093|NCT02560493|BMIz
897094|NCT02560493|Exergaming
897095|NCT02560493|Cardiovascular Disease
897096|NCT02560480|groin pain, groin injury, magnetic resonance imaging
897097|NCT02560454|Cognitive Remediation
897098|NCT02560454|Working Memory Training
897099|NCT02560454|Cognitive training
897100|NCT02560428|Mixed Methods
897101|NCT02560428|Cardiovascular Health
897102|NCT02560428|Implementation Evaluation
897103|NCT02560428|Cardiovascular Prevention Screening
897104|NCT02560415|Autism Spectrum Disorder
897105|NCT02560415|Serious Game
897106|NCT02560415|Controlled trial
897107|NCT02560415|Denver model
897108|NCT02560402|Glomerular hyperfiltration
897109|NCT02560402|Renal Resistive Index (RRI)
897110|NCT02560389|Posttraumatic Stress Disorder
897111|NCT02560389|functional Magnetic Resonance Imaging
897112|NCT02560389|Levodopa (L-DOPA)
897113|NCT02560389|Exposure Therapy
897114|NCT02560389|Fear Extinction
897115|NCT02560376|PET/CT
897116|NCT02560376|glucagon-like peptide-1 receptor (GLP-1R) imaging
897117|NCT02560363|AZD9977
897118|NCT02560363|Safety
897119|NCT02560363|Tolerability
897120|NCT02560363|Pharmacokinetics
897121|NCT02560363|Food effect
897122|NCT02560363|AZD9977 capsules
897123|NCT02560363|AZD9977 suspension
897124|NCT02560350|adipose-derived stem cells
897125|NCT02560350|small intestinal submucosa
897126|NCT02560350|adipocyte-containing hypodermis
897127|NCT02560337|Ovarian cancer
897128|NCT02560337|Relapse
897129|NCT02560337|Recurrence
897130|NCT02560337|Chemotherapy resistance
897131|NCT02560324|Ramelteon
897132|NCT02560324|Nicotine
897133|NCT02560324|Nicotine dependence
897134|NCT02560324|Insomnia
897135|NCT02560324|Tobacco Dependence
897136|NCT02560285|Risk assessment
897137|NCT02560285|Mortality
897138|NCT02560285|Morbidity
897139|NCT02560285|Risk factor
897140|NCT02560272|vaccine
897141|NCT02560272|haemophilus influenzae type b
897142|NCT02560259|knee pain
897144|NCT02560233|Neurofeedback
897145|NCT02560233|Stress
897146|NCT02560233|fMRI
897147|NCT02560233|Real-time fMRI Neurofeedback
897148|NCT02560233|Anterior cingulate cortex
897149|NCT02560233|Hypothalamic-pituitary-adrenal axis
897150|NCT02560233|Cortisol
897151|NCT02560233|EEG
897152|NCT02560233|Heart rate variability
897153|NCT02560233|Blood pressure
897154|NCT02560233|Simultaneous EEG/fMRI
897155|NCT02560181|recurrent prostate cancer,HDR whole gland salvage
897156|NCT02560168|Coronary artery disease
897157|NCT02560168|iECG
897158|NCT02560168|MyoVista
897159|NCT02560168|Heart Test Labs
897160|NCT02560168|Wavelet analysis
897161|NCT02560168|Surface electrocardiogram
897162|NCT02560155|Orthopedic surgery
897163|NCT02560155|Surgical site infection
897164|NCT02560155|Decolonization
897165|NCT02560155|Staphylococcus aureus
897166|NCT02560129|recovery
897167|NCT02560129|ICU
897168|NCT02560129|clinic
897169|NCT02560129|survivor
897170|NCT02560129|physical function
897171|NCT02560116|Pulmonary artery systolic pressure
897172|NCT02560116|Optison
897173|NCT02560090|Diabetes
897174|NCT02560077|cognitive
897175|NCT02560077|memory
897176|NCT02560077|physical fitness
897177|NCT02560077|psychological fitness
897178|NCT02560077|elderly
897179|NCT02560077|middle aged
897180|NCT02560051|Prostate Cancer
897181|NCT02560051|Advanced
897182|NCT02560051|Local Failures
897183|NCT02560038|Urothelial Cancer
897184|NCT02560038|Bladder Cancer
897185|NCT02560038|Metastatic
897186|NCT02560025|Acute Myeloid Leukemia
897187|NCT02559999|Healthy Volunteers
897188|NCT02559999|Pain
897189|NCT02559999|EEG
897190|NCT02559973|Buprenorphine
897191|NCT02559973|opioid use disorder
897192|NCT02559921|Recombinant Human Rabies Immunoglobin (rhRIG)
897193|NCT02559869|Biofluid
897194|NCT02559869|ALS
897195|NCT02559869|MRI
897196|NCT02559869|PET
897197|NCT02559869|Imaging
897198|NCT02559869|Biomarkers
897199|NCT02559869|Amyotrophic Lateral Sclerosis
897200|NCT02559869|TRACK ALS
897201|NCT02559869|pathology
897202|NCT02559843|pomegranate
897203|NCT02559843|diabetes
897204|NCT02559843|oxidative stress
897205|NCT02559817|Irritable Bowel Syndrome with Constipation in children
897206|NCT02559817|Linzess
897207|NCT02559791|Reslizumab
897208|NCT02559791|Eosinophils
897209|NCT02559791|Asthma
897210|NCT02559791|Airway inflammation
897211|NCT02559791|Prednisone
897212|NCT02559765|physiotherapy
897213|NCT02559765|progressive multiple sclerosis
897214|NCT02559765|rehabilitation
897215|NCT02559765|rehabilitation services
897216|NCT02559739|Stroke
897217|NCT02559739|Ischemic Attack, Transient
897218|NCT02559739|Cardiovascular Diseases
897219|NCT02559739|Sleep Apnea Syndromes
897220|NCT02559739|Sleep Initiation and Maintenance Disorders
897221|NCT02559739|Insomnia
897222|NCT02559739|Restless Legs Syndrome
897223|NCT02559739|Sleep Deprivation
897224|NCT02559726|Hypertrophic cardiomyopathy, hyper-synchronicity, outflow-tract obstruction, dual chamber pacing
897225|NCT02559713|Lactation
897226|NCT02559713|Lactating Women
897227|NCT02559713|Vedolizumab
897228|NCT02559713|Colitis Ulcerative
897229|NCT02559713|Crohn Disease
897230|NCT02559713|Crohn's
897231|NCT02559700|Healthy Ageing
897232|NCT02559687|PD1
897233|NCT02559687|PD-L1
897234|NCT02559687|PDL1
897235|NCT02559674|Pancreas
897236|NCT02559674|Pancreatic
897237|NCT02559674|Cancer
897238|NCT02559674|Advanced Pancreatic Cancer
897239|NCT02559674|Immunotherapy
897240|NCT02559674|Immunotherapeutic
897241|NCT02559674|Interleukin-15
897242|NCT02559674|Gemcitabine
897243|NCT02559674|Nab-paclitaxel
897244|NCT02559674|Solid Tumor
897245|NCT02559674|Metastatic Disease
897246|NCT02559674|Combination Immunotherapy
897247|NCT02559583|Multiple Myeloma
897248|NCT02559583|chronic lymphocytic leukemia
897249|NCT02559583|Non-Hodgkin lymphoma
897250|NCT02559570|Functional constipation in children
897251|NCT02559570|Linzess
897252|NCT02559544|failed prior endocrine therapy
897253|NCT02559518|Cerebellum
897254|NCT02559518|Transcranial Direct Current Stimulation
897255|NCT02559518|Repetitive Transcranial Magnetic Stimulation
897256|NCT02559518|Motor Learning
897257|NCT02559518|Serial Reaction Time Task
897258|NCT02559518|HandwritingTask
897259|NCT02559505|natural influenza infection
897260|NCT02559505|live attenuated influenza vaccination (LAIV)
897261|NCT02559505|inactivated influenza vaccination (IIV)
897262|NCT02559505|infants
897263|NCT02559505|children
897264|NCT02559466|pharmaco-resistant depressed patients
897265|NCT02559427|sleep apnea
897266|NCT02559427|Venous Insufficiency
897267|NCT02559427|SPA treatment
897268|NCT02559401|Eloquent cortex
897269|NCT02559349|Stereotactic Body Radiotherapy
897270|NCT02559349|SBRT
897271|NCT02559336|Palliative Care
897272|NCT02559336|Cancer
897273|NCT02559336|Health Services Research
897274|NCT02559310|Pneumonia
897275|NCT02559310|CABP
897276|NCT02559310|CAP
897277|NCT02559310|Community acquired bacterial pneumonia
897278|NCT02559297|Regulatory T cells
897279|NCT02559297|Sevoflurane
897280|NCT02559297|Desflurane
897281|NCT02559297|Cytokines
897282|NCT02559297|Flow cytometry
897283|NCT02559297|Living Donor Kidney Transplant
897284|NCT02559284|Saline Solution, Isotonic / Administration & dosage
897285|NCT02559284|Therapeutic Irrigation / methods
897286|NCT02559284|Postoperative Care / methods
897287|NCT02559284|Quality of life
897288|NCT02559180|Diabetes
897289|NCT02559180|Macular Edema
897290|NCT02559180|Diabetic Retinopathy
897291|NCT02559141|haemodynamic optimization
897292|NCT02559141|cardiac index
897293|NCT02559141|non-invasive
897294|NCT02559141|pulse pressure variation
897295|NCT02559128|Insulin Resistance
897296|NCT02559128|Chronic Heart Failure
897297|NCT02559128|Type 2 Diabetes
897298|NCT02559128|Endothelial Dysfunction
897299|NCT02559115|68Ga-RM2
897300|NCT02559115|PET/CT scan
897301|NCT02559115|Gastrin Releasing Peptide Receptor (GRPr)
897302|NCT02559115|14-146
897303|NCT02559102|Dexmedetomidine sedation
897304|NCT02559102|General anaesthesia
897305|NCT02559102|Neurodevelopment
897306|NCT02559102|Infants
897307|NCT02559102|Neonates
897308|NCT02559076|Overweight
897309|NCT02559076|Obesity
897310|NCT02559076|Preschool children
897311|NCT02559076|United Arab Emirates
897312|NCT02559076|Dietary patterns
897313|NCT02559076|BMI z-scores
897314|NCT02559063|cognitive training
897315|NCT02559063|speed of processing
897316|NCT02559063|neuroplasticity
897317|NCT02559063|cognitive aging
897318|NCT02559037|acupuncture
897319|NCT02559037|moxibustion
897320|NCT02559037|intestinal microbiota
897321|NCT02559037|Mucosal immunity
897322|NCT02559024|Metastatic colorectal cancer
897323|NCT02559024|liver lesion
897324|NCT02559024|anti-OX40 antibody
897325|NCT02559024|MEDI6469
897326|NCT02559024|Immunotherapy
897327|NCT02559011|Arrhythmias, Cardiac
897328|NCT02559011|Transcatheter Aortic Valve implantation
897329|NCT02559011|Aortic Valve Stenosis
897330|NCT02558985|Pulmonary Compliance
897331|NCT02558985|Casting
897332|NCT02558972|Postural Tachycardia Syndrome (POTS)
897333|NCT02558972|Vasovagal Syncope (VVS)
897334|NCT02558972|Fainting
897335|NCT02558972|Orthostatic Intolerance
897336|NCT02558972|Droxidopa
897337|NCT02558972|Northera
897338|NCT02558933|Fetal Alcohol Syndrome
897339|NCT02558933|Prenatal exposure
897340|NCT02558933|Biomarkers
897341|NCT02558933|Oxidative stress
897342|NCT02558933|Epigallocatechin gallate
897343|NCT02558920|Systematic review and meta-analysis
897344|NCT02558920|Evidence-based medicine (EBM)
897345|NCT02558920|Evidence-based nutrition (EBN)
897346|NCT02558920|Clinical practice guidelines
897347|NCT02558920|Clinical trials
897348|NCT02558920|Dietary sugars
897349|NCT02558920|Fructose
897350|NCT02558920|Sucrose
897351|NCT02558920|High fructose corn syrup
897352|NCT02558920|Isocaloric
897353|NCT02558920|Hypercaloric
897354|NCT02558920|Body weight
897355|NCT02558920|Prospective cohort studies
897356|NCT02558907|geriatrics
897357|NCT02558907|cancer
897358|NCT02558907|MMS test
897359|NCT02558907|MoCA test
897360|NCT02558907|cognitive evaluation
897361|NCT02558894|Pancreatic Ductal Adenocarcinoma, PDAC
897362|NCT02558881|screening
897363|NCT02558881|colorectal cancer
897364|NCT02558881|colon capsule
897365|NCT02558881|virtual colonoscopy
897366|NCT02558855|Thrust Joint Manipulation
897367|NCT02558855|Non-thrust Joint Manipulation
897368|NCT02558855|Transversus Abdominis
897369|NCT02558829|Adult Growth Hormone Deficiency
897370|NCT02558803|HPV Vaccinations
897371|NCT02558803|Quadrivalent Vaccine
897372|NCT02558790|Attention Deficit/Hyperactivity Disorder
897373|NCT02558790|ADHD
897374|NCT02558790|Attention Deficit Disorder
897375|NCT02558790|ADD
897376|NCT02558790|Magnesium
897377|NCT02558777|Delirium
897378|NCT02558777|Pilot Study
897379|NCT02558777|Nurse intervention
897380|NCT02558777|Hospitalization
897381|NCT02558751|pneumococcal conjugate vaccine
897382|NCT02558751|aging HIV
897383|NCT02558738|dermatitis and irritations at the outer ear canal
897384|NCT02558738|prevention of subacute otitis externa
897385|NCT02558712|screening
897386|NCT02558712|tele-ophthalmology
897387|NCT02558686|trigger points
897388|NCT02558686|disability
897389|NCT02558686|post-dry needling soreness
897390|NCT02558686|eccentric exercise
897391|NCT02558673|Trimethylamine-N-oxide
897392|NCT02558673|Biomarkers
897393|NCT02558673|Production
897394|NCT02558673|Metabolism
897395|NCT02558673|Gut microbiome
897396|NCT02558673|Healthy
897397|NCT02558660|Supplemental Nutrition Incentive Program (SNAP)
897398|NCT02558660|economic incentive
897399|NCT02558621|Robotic Spinal Fusion Surgery
897400|NCT02558608|Prime Spontaneous Pneumothorax
897401|NCT02558608|recurrence
897402|NCT02558595|PKD
897403|NCT02558595|Kidney disease
897404|NCT02558595|Vitamin B3
897405|NCT02558582|Pulmonary arterial hypertension
897406|NCT02558582|Chronic thromboembolic pulmonary hypertension
897407|NCT02558582|Rehabilitation
897408|NCT02558582|Oxygen
897409|NCT02558569|fentanyl, scalp block
897410|NCT02558556|Laparoscopic cholecystectomy (LC)
897411|NCT02558556|Indocyanine green (ICG)
897412|NCT02558556|Near-Infrared Fluorescence Imaging (NIRF)
897413|NCT02558556|Critical View of Safety (CVS)
897414|NCT02558517|Systemic Lupus Erythematosus
897415|NCT02558517|Corticosteroids
897416|NCT02558517|Chronic disease
897417|NCT02558491|Type 1 Diabetes Mellitus (T1DM)
897418|NCT02558491|Artificial Pancreas Project (APP)
897419|NCT02558491|Diabetes Assistant (DiAs)
897420|NCT02558491|Insulin Pump
897421|NCT02558491|Continuous Glucose Monitor
897422|NCT02558491|Exercise
897423|NCT02558491|Glucose Variability
897424|NCT02558491|Decision Support System
897425|NCT02558491|Multiple Daily Injections (MDI)
897426|NCT02558478|Whole exome sequencing
897427|NCT02558465|Xarelto, rivaroxaban, VTE, PE, DVT, Japan, PMS, SDUI
897428|NCT02558452|elderly kidney transplant recipient
897429|NCT02558452|registry
897430|NCT02558452|tacrolimus once daily
897431|NCT02558426|Chronic Venous Disease
897432|NCT02558426|Estrogen receptors
897433|NCT02558426|GPER
897434|NCT02558413|Viral Diseases
897435|NCT02558413|Antiviral
897436|NCT02558413|Paramyxoviridae Infections
897437|NCT02558413|RSV
897438|NCT02558413|Respiratory Syncytial Virus
897439|NCT02558413|Aviragen Therapeutics, Inc.
897440|NCT02558413|Aviragen Therapeutics
897441|NCT02558413|Aviragen
897442|NCT02558348|Dual receptor Tyrosine Kinase Inhibitor
897443|NCT02558348|Anti-angiogenic therapy
897444|NCT02558257|Advanced Cancers
897445|NCT02558257|Survey
897446|NCT02558257|Questionnaire
897447|NCT02558244|Childhood Cancer
897448|NCT02558244|Image-defined Risk Factors
897449|NCT02558244|Pediatric Oncology
897450|NCT02558192|LGG
897451|NCT02558192|Probiotics
897452|NCT02558192|nosocomial infection prevention
897453|NCT02558192|pediatrics
897454|NCT02558166|Acute Kidney Injury (AKI)
897455|NCT02558166|Renal Resistive Index (RRI)
897456|NCT02558153|drug eluting balloon
897457|NCT02558153|percutaneous balloon angioplasty
897458|NCT02558127|asthma
897459|NCT02558127|cystic fibrosis
897460|NCT02558101|Screening
897461|NCT02558101|Early detection
897462|NCT02558101|Health inequality
897463|NCT02558101|Uptake
897464|NCT02558088|salmeterol
897465|NCT02558088|pharmacokinetics
897466|NCT02558088|doping
897467|NCT02558088|beta2-agonists
897468|NCT02558088|long-acting beta2-agonists
897469|NCT02558062|Ventilator Associated Pneumonia
897470|NCT02558062|Distal lung
897471|NCT02558049|Patient decision aid
897472|NCT02558036|Head Neck Position Videolaryngoscopy
897473|NCT02558023|PRE-ECLAMPSIA
897474|NCT02558023|URAPIDIL
897475|NCT02558023|NICARDIPINE
897476|NCT02558010|Methadone
897477|NCT02558010|Gabapentin
897478|NCT02558010|Postoperative Pain
897479|NCT02558010|Posterior Spinal Fusion
897480|NCT02558010|Pediatric
897481|NCT02557997|HIV reservoir
897482|NCT02557997|HIV-1 DNA
897483|NCT02557997|Immune activation
897484|NCT02557997|Monocyte function
897485|NCT02557997|Activation biomarkers
897486|NCT02557984|Dopamine
897487|NCT02557984|Opioid
897488|NCT02557984|Reward
897489|NCT02557958|COPD, pulmonary disease
897490|NCT02557932|PPI standard triple therapy
897491|NCT02557932|Bismuth quadruple therapy
897492|NCT02557932|Helicobacter
897493|NCT02557906|Acellular dermal matrix
897494|NCT02557906|ADM
897495|NCT02557906|SurgiMend
897496|NCT02557906|Breast reconstruction
897497|NCT02557906|Immediate breast reconstruction
897498|NCT02557906|Autologous reconstruction
897499|NCT02557906|Biological mesh
897500|NCT02557867|dexmedetomidine
897501|NCT02557867|pharmacokinetic
897502|NCT02557867|obesity
897503|NCT02557841|Cerebellum
897504|NCT02557841|Transcranial Direct Current Stimulation
897505|NCT02557841|Motor Learning
897506|NCT02557841|Serial Reaction Time Task
897507|NCT02557841|Handwriting
897508|NCT02557815|Repetitive Transcranial Magnetic Stimulation
897509|NCT02557815|Emotion Regulation
897510|NCT02557815|Craving
897511|NCT02557789|Absolute bioavailability
897512|NCT02557789|Pharmacokinetics
897513|NCT02557776|BRCA1
897514|NCT02557776|BRCA2
897515|NCT02557776|hereditary breast cancer
897516|NCT02557776|genetic counseling
897517|NCT02557763|Oxford UKA
897518|NCT02557763|anterior knee pain
897519|NCT02557763|lateral facet of patella
897522|NCT02557737|stroke
897523|NCT02557737|upper extremity
897524|NCT02557737|spasticity
897525|NCT02557737|botulinum toxin
897526|NCT02557737|ultrasonography
897527|NCT02557737|electric stimulation
897528|NCT02557711|spasticity
897529|NCT02557711|stroke
897530|NCT02557711|ultrasound elastography
897531|NCT02557711|acoustic radiation force impulse
897532|NCT02557659|Low Profile
897533|NCT02557659|Abdominal Aortic Aneurysms
897534|NCT02557659|Endovascular
897535|NCT02557594|Hepatitis B
897536|NCT02557568|nasal carriage
897537|NCT02557568|Staphylococcus aureus
897538|NCT02557568|hemodialysis patients
897539|NCT02557542|Varicose Veins; One Stop Clinic
897540|NCT02557529|Head and Neck Cancer
897541|NCT02557529|Concomitant chemoradiotherapy
897542|NCT02557529|Exercise Training
897543|NCT02557529|Progressive Resistance Training
897544|NCT02557529|Weight loss
897545|NCT02557529|Lean Body Mass
897546|NCT02557529|Body Composition
897547|NCT02557503|TACE; oxaliplatin; fluorouracil; liver cancer
897548|NCT02557490|TACE; hepatic artery infusion; oxaliplatin; raltitrexed
897549|NCT02557464|semantic memory
897550|NCT02557464|eye movements
897551|NCT02557464|reading
897552|NCT02557438|Bone
897553|NCT02557438|Child Health
897554|NCT02557438|Nutrition
897555|NCT02557425|malaria
897556|NCT02557425|infant
897557|NCT02557425|pregnancy
897558|NCT02557425|prophylaxis
897559|NCT02557425|dihyroartemisinin-piperaquine
897560|NCT02557425|sulfadoxine-pyrimethamine
897561|NCT02557425|behavior
897562|NCT02557425|neurodevelopment
897563|NCT02557425|cognitive
897564|NCT02557399|Clindamycin
897565|NCT02557399|Gel
897566|NCT02557399|Benzoyl Peroxide
897567|NCT02557399|Acne Vulgaris
897568|NCT02557386|Cruciate ligament surgery
897569|NCT02557386|Adductor canal
897570|NCT02557386|Nerve block
897571|NCT02557373|rice bran
897572|NCT02557373|infants
897573|NCT02557373|stool metabolome and microbiome
897574|NCT02557373|dietary intervention
897575|NCT02557360|liver injury
897576|NCT02557360|detoxification
897577|NCT02557360|S-adenosyl-L-methionine
897578|NCT02557360|quality of life
897579|NCT02557334|Strawberry Powder
897580|NCT02557334|Cardiovascular Disease Risk Factors
897581|NCT02557269|Pollenosis
897582|NCT02557269|Congestion
897583|NCT02557269|Mucoadhesive Treatment
897584|NCT02557269|Nasal Decongestant
897585|NCT02557269|Nasal Antihistamine
897586|NCT02557269|Nasal Corticosteroid
897587|NCT02557256|Childhood Cancer
897588|NCT02557256|Abdominal Tumors
897589|NCT02557256|Pelvic Tumors
897590|NCT02557256|Pediatric Oncology
897596|NCT02557230|Childhood Cancer
897597|NCT02557230|Genitourinary tumors
897598|NCT02557230|urogenital tumors
897599|NCT02557230|Pediatric Oncology
897600|NCT02557204|nasogastric tube insertion
897601|NCT02557204|Video laryngoscope
897602|NCT02557204|success rate
897603|NCT02557165|Muscle regeneration
897604|NCT02557113|cement leakage
897605|NCT02557113|cement augmentation
897606|NCT02557113|vertebral body fracture
897607|NCT02557113|vertebral cavity
897608|NCT02557113|vertebroplasty
897609|NCT02557048|Childhood Cancer
897610|NCT02557048|Head and Neck Tumors
897611|NCT02557048|Pediatric Oncology
897612|NCT02557022|Systematic review and meta-analysis
897613|NCT02557022|Evidence-based medicine (EBM)
897614|NCT02557022|Evidence-based nutrition (EBN)
897615|NCT02557022|Clinical practice guidelines
897616|NCT02557022|Glycemic index
897617|NCT02557022|Glycemic load
897618|NCT02557022|Body weight
897619|NCT02557022|Cardiovascular risk factors
897620|NCT02557022|Cardiovascular disease
897621|NCT02557009|Hemodynamics
897622|NCT02557009|Central Venous Pressure
897623|NCT02557009|Pulmonary Artery Pressure
897624|NCT02557009|Cardiac Output
897625|NCT02556983|Appendicitis
897626|NCT02556983|Tomography, X-Ray Computed
897627|NCT02556983|Receiver operating characteristic (ROC) Curve
897628|NCT02556983|Computer Simulation
897629|NCT02556944|Depth of focus
897630|NCT02556931|immunosuppression
897631|NCT02556931|nonmyeloablative
897632|NCT02556931|non-myeloablative
897633|NCT02556931|allogeneic
897634|NCT02556931|tacrolimus
897635|NCT02556931|peripheral blood
897636|NCT02556931|cyclophosphamide
897637|NCT02556931|mycophenolate mofetil
897638|NCT02556918|Coronary artery bypass graft surgery (CABG)
897639|NCT02556918|Type 2 Diabetes
897640|NCT02556905|Multiple Myeloma
897641|NCT02556905|Revlimid
897642|NCT02556905|Lenalidomide
897643|NCT02556905|Observational
897644|NCT02556905|Korea
897645|NCT02556905|Post Marketing Surveillance[PMS]
897646|NCT02556892|Lymphocytic Leukemia
897647|NCT02556892|Ibrutinib
897648|NCT02556892|PCI-32765
897649|NCT02556892|JNJ-54179060
897650|NCT02556879|Liver transplantation
897651|NCT02556879|Graft failure
897652|NCT02556879|Donor specific antibodies
897653|NCT02556853|Ultrasound
897654|NCT02556853|Double lumen tube
897655|NCT02556840|Monogenic diabetes
897656|NCT02556840|maturity-onset diabetes of the young
897657|NCT02556840|MODY
897658|NCT02556840|Pregnancy
897659|NCT02556840|Gestational diabetes
897660|NCT02556840|Glucokinase
897661|NCT02556840|Insulin therapy during pregnancy
897662|NCT02556840|Evaluation of fetal growth by ultrasonography measurements
897663|NCT02556827|demodex
897664|NCT02556827|oxidative stress
897665|NCT02556827|reflectance confocal microscopy
897666|NCT02556814|ITP
897667|NCT02556814|Caffeic Acid
897668|NCT02556814|dexamethasone
897669|NCT02556801|Sublingual immunotherapy
897670|NCT02556801|Dose range finding
897671|NCT02556801|Grass pollen
897672|NCT02556801|Allergic rhinitis/rhinoconjunctivitis
897673|NCT02556801|Immunogenicity
897674|NCT02556788|Efficacy
897675|NCT02556788|Safety
897676|NCT02556788|Acne vulgaris
897677|NCT02556762|Esophageal cancer
897678|NCT02556762|Simultaneous modulated accelerated boost
897679|NCT02556762|Standard dose radiotherapy
897680|NCT02556762|Chemotherapy
897681|NCT02556762|Survival
897682|NCT02556749|Cranberries
897683|NCT02556749|blood pressure
897684|NCT02556749|cholesterol
897685|NCT02556749|SphygmoCor
897686|NCT02556736|gene therapy
897687|NCT02556736|optogenetics
897688|NCT02556736|channelrhodopsin
897689|NCT02556736|retina
897690|NCT02556736|retinitis pigmentosa
897691|NCT02556710|Osteoarthritis
897692|NCT02556710|Osteoarthritis of the Knee
897693|NCT02556684|Breast-Specific Gamma Imaging
897694|NCT02556684|Locally Advanced Breast Cancer
897695|NCT02556684|Neoadjuvant Chemotherapy
897696|NCT02556684|BSGI
897697|NCT02556658|Smartpilot View
897698|NCT02556658|Hip fracture surgery
897699|NCT02556658|Depth of anaesthesia
897700|NCT02556658|Intraoperative hypotension
897701|NCT02556658|Quality of anaesthesia
897702|NCT02556645|Combat
897703|NCT02556645|Psychological Treatment
897704|NCT02556645|Military
897705|NCT02556645|Psychotherapy
897706|NCT02556645|Trauma
897707|NCT02556645|Posttraumatic Stress
897708|NCT02556645|Posttraumatic Stress Disorder
897709|NCT02556619|Liver Cancer
897710|NCT02556619|Randomized Control Trial
897711|NCT02556619|Palliative Care
897712|NCT02556619|Liver Cell Carcinoma
897713|NCT02556619|Palliative Therapy
897714|NCT02556606|ketamine
897715|NCT02556606|depression
897716|NCT02556606|treatment resistant
897717|NCT02556606|treatment resistant depression
897718|NCT02556606|late life depression
897719|NCT02556606|depression in the elderly
897720|NCT02556606|geriatric depression
897721|NCT02556593|Non-Small Cell Lung Cancer
897722|NCT02556593|IMRT
897723|NCT02556593|erlotinib
897724|NCT02556593|whole-brain radiotherapy
897725|NCT02556580|albumin
897726|NCT02556580|surgery
897727|NCT02556580|inflammation
897728|NCT02556580|volume kinetics
897729|NCT02556567|Sleep patterns
897730|NCT02556567|Physical activity
897731|NCT02556567|Fitbit
897732|NCT02556515|CMC1
897733|NCT02556515|arthritis
897734|NCT02556515|degenerative arthritis
897735|NCT02556515|thumb
897736|NCT02556515|interpositional arthroplasty
897737|NCT02556515|total joint replacement
897738|NCT02555501|children
897739|NCT02555501|cancer
897740|NCT02555501|stomatitis
897741|NCT02555501|clinical trial
897742|NCT02555501|laser therapy, low-level
897743|NCT02555501|methylene blue
897744|NCT02555501|photochemotherapy
897745|NCT02555475|Hepatitis C
897746|NCT02555475|primary care
897747|NCT02555397|Prostate Cancer
897748|NCT02555397|Locally Recurrent
897749|NCT02555397|Gene Therapy
897750|NCT02555397|IL-12
897751|NCT02555397|Adenovirus
897752|NCT02555371|Severe eosinophilic asthma
897753|NCT02555371|mepolizumab
897754|NCT02555371|asthma exacerbation
897755|NCT02555358|Resectable advanced gastric cancer
897756|NCT02555345|classic asthma, cough variant asthma,eosinophilic bronchitis
897757|NCT02555319|Pulmonary Valve
897758|NCT02555319|Transcatheter Pulmonary Valve
897759|NCT02555319|Congenital Heart Disease
897760|NCT02555306|Macular Degeneration
897761|NCT02555293|Liver resection
897762|NCT02555293|fibrosis
897763|NCT02555293|inflammation
897764|NCT02555293|Rifaximin
897765|NCT02555267|geriatric assessment
897766|NCT02555267|diffuse large B-cell lymphoma
897767|NCT02555267|activity of daily living
897768|NCT02555267|instrumental activity of daily living
897769|NCT02555267|Charlson's comorbidity index
897770|NCT02555254|cardiac arrest
897771|NCT02555254|targeted temperature management
897772|NCT02555254|hypothermia induced
897773|NCT02555254|shockable rhythm
897774|NCT02555241|ASD, Children
897775|NCT02555228|simethicone
897776|NCT02555228|gastroscopy
897777|NCT02555228|McNalley score
897778|NCT02555215|Pediatrics
897779|NCT02556489|immunological memory
897780|NCT02556476|critical care
897781|NCT02556476|intensive care
897782|NCT02556476|health related quality of life
897783|NCT02556476|cost benefit analysis
897784|NCT02556463|MEDI9197
897785|NCT02556463|TLR 7/8 Agonist
897786|NCT02556463|Durvalumab
897787|NCT02556463|MEDI4736
897788|NCT02556437|Subcutaneous immunoglobulin
897789|NCT02556437|MMN
897790|NCT02556424|Ophthalmology
897791|NCT02556424|Uveitic macular edema
897792|NCT02556424|Triamcinolone subconjunctival injection
897793|NCT02556424|Dexamethasone intraocular implant
897794|NCT02556372|AIH
897795|NCT02556372|JKB-122
897796|NCT02556372|autoimmune
897797|NCT02556372|hepatitis
897798|NCT02556346|CD20
897799|NCT02556346|immunotoxin
897800|NCT02556346|CLL
897801|NCT02556346|SLL
897802|NCT02556346|leukemia
897803|NCT02556346|lymphocytic lymphoma
897804|NCT02556346|lymphocytic leukemia
897805|NCT02556346|MT-3724
897806|NCT02556346|relapsed
897807|NCT02556346|refractory
897808|NCT02556346|immunotherapy
897809|NCT02556346|cancer
897810|NCT02556346|antibodies
897811|NCT02556346|safety
897812|NCT02556346|pharmacokinetics
897813|NCT02556333|TAF
897814|NCT02556333|F/TAF
897815|NCT02556333|ART
897816|NCT02556333|TDF
897817|NCT02556333|DOT
897818|NCT02556294|HIV risk behavior
897819|NCT02556268|Single-Dose, Open-Label, Non-Blinded, Non-Placebo-
897820|NCT02556268|Controlled, Stratified Design
897821|NCT02556255|Peripheral Arterial Disease
897822|NCT02556255|Peripheral Artery Disease
897823|NCT02556255|PAD
897824|NCT02556255|Atherosclerosis
897825|NCT02556255|Arterial Occlusive Diseases
897826|NCT02556255|Peripheral Vascular Diseases
897827|NCT02556255|PVD
897828|NCT02556242|vector control
897829|NCT02556242|insecticide
897833|NCT02556216|bone biopsy; bone density
897834|NCT02556203|TAVR
897835|NCT02556203|TAVI
897836|NCT02556203|Transfemoral aortic valve implantation
897837|NCT02556177|TBI
897838|NCT02556177|MR
897839|NCT02556177|mTBI
897840|NCT02556177|NFL
897841|NCT02556177|MRI
897842|NCT02556164|Electroacupuncture
897843|NCT02556164|Body Worn Sensor
897844|NCT02556164|Gait
897845|NCT02556164|Balance
897846|NCT02556138|Intragastric Balloon
897847|NCT02556138|ORBERA Intragastric Balloon
897848|NCT02556138|Weight Loss
897849|NCT02556138|BMI >35
897850|NCT02556125|SCI
897851|NCT02556125|Respiratory impairment
897852|NCT02556125|Diaphragm pacing
897853|NCT02556125|Diaphragm stimulation
897854|NCT02556073|asthma control
897855|NCT02556073|adherence
897856|NCT02556073|asthma self management plan
897857|NCT02556073|airway inflammation
897858|NCT02556060|ketamine use disorder
897859|NCT02556060|lamotrigine
897860|NCT02556060|craving
897861|NCT02556008|Children
897862|NCT02556008|Epilepsy
897863|NCT02556008|Cannabidiol
897864|NCT02555995|AMD
897865|NCT02555995|OCT
897866|NCT02555982|Essential Head tremor
897867|NCT02555982|Botulinum toxin injections
897868|NCT02555982|Quality of life
897869|NCT02555982|Embarrassment assessment
897870|NCT02555956|Macular grid
897871|NCT02555956|Subthreshold
897872|NCT02555956|diabetic macular edema
897873|NCT02555956|decrease in visual acuity
897874|NCT02555891|Prescriptions
897875|NCT02555891|Epidemiology
897876|NCT02555891|Health Administration Databases
897877|NCT02555891|Elderly
897878|NCT02555891|STOPP/START criteria
897879|NCT02555878|Cancer
897880|NCT02555878|Rivaroxaban
897881|NCT02555878|Venous thromboembolism
897882|NCT02555865|etiology
897883|NCT02555865|children
897884|NCT02555852|Proton Pump Inhibitors
897885|NCT02555852|Pneumonia
897886|NCT02555852|NSAIDs
897887|NCT02555852|Histamine H2 Antagonists
897888|NCT02555852|Drug safety
897889|NCT02555839|Relapsed Multiple Myeloma
897890|NCT02555839|Refractory Multiple Myeloma
897891|NCT02555839|Pomalidomide
897892|NCT02555839|Imnovid
897893|NCT02555839|Non-interventional
897894|NCT02555813|Metastatic Pancreatic Cancer
897895|NCT02555813|nab-Paclitaxel
897896|NCT02555813|Gemcitabine
897897|NCT02555813|Non-interventional
897898|NCT02555800|Laryngeal papillomatosis
897899|NCT02555800|Cidofovir
897900|NCT02555800|Bevacizumab
897901|NCT02555800|Recurrent respiratory papillomatosis
897902|NCT02555787|FK506E
897903|NCT02555787|Tacrolimus
897904|NCT02555787|Observational
897905|NCT02555787|Kidney transplantation
897906|NCT02555787|Advagraf
897907|NCT02555774|subjective memory impairment
897908|NCT02555774|cognitive training
897909|NCT02555735|pancreatic cancer
897910|NCT02555696|Metastatic Breast Cancer
897911|NCT02555696|nab-paclitaxel
897912|NCT02555696|Abraxane
897913|NCT02555683|Asthma
897914|NCT02555683|QAW039
897915|NCT02555670|Muscles
897916|NCT02555670|Intensive Care
897917|NCT02555670|Tomography, X-Ray Computed
897918|NCT02555670|Electric Impedance
897919|NCT02555657|PD1
897920|NCT02555657|PD-1
897921|NCT02555657|PDL1
897922|NCT02555657|PD-LI
897923|NCT02555644|cancer
897924|NCT02555631|type 2 diabetes
897925|NCT02555631|prevention
897926|NCT02555631|men
897927|NCT02555618|Vaccine
897928|NCT02555605|children
897929|NCT02555605|dexmedetomidine
897930|NCT02555605|magnetic resonance imaging scans
897931|NCT02555605|deep sedation
897932|NCT02555605|adverse respiratory events
897933|NCT02555553|Cognitive behavioral therapy guided self-help
897934|NCT02555553|Mobile Mental Health
897935|NCT02555553|Binge Eating
897936|NCT02555553|Cognitive Behavioral Therapy
897937|NCT02555553|Eating Disorder Treatment
897938|NCT02555553|Self-monitoring
897939|NCT02555553|Eating Disorders
897940|NCT02555553|Ecological Momentary Intervention
897941|NCT02555202|dyspnea
897942|NCT02555163|bladder cancer, laser
897943|NCT02555137|chronic thromboembolic pulmonary hypertension
897944|NCT02555137|pulmonary embolism
897945|NCT02555137|pulmonary hypertension
897946|NCT02555137|screening
897947|NCT02555137|echocardiography
897948|NCT02555124|Healthy
897949|NCT02555124|JNJ-42847922
897950|NCT02555111|thrombosis
897951|NCT02555072|Yellow Fever Vaccine, immunity evolution
897952|NCT02555059|Ciprofloxacin
897953|NCT02555059|Japan
897954|NCT02555059|Post-marketing surveillance
897955|NCT02555046|Spectroscopy, Near-Infrared
897956|NCT02555046|Endovascular Procedures
897957|NCT02555046|Local Anesthesia
897958|NCT02555046|General Anesthesia
897959|NCT02555033|Instability resistance training
897960|NCT02555033|unstable surface
897961|NCT02555033|elderly people
897962|NCT02554994|ASPRA cohort
897963|NCT02554994|multifactorial intervention
897964|NCT02554994|Medicaid services
897965|NCT02554994|Geriatric disorder
897966|NCT02554994|Short Physical Performance Battery
897967|NCT02554929|Social Anxiety Disorder
897968|NCT02554929|Selective Mutism
897969|NCT02554929|CBT
897970|NCT02554929|preschool anxiety disorders
897971|NCT02554916|Mobility decline
897972|NCT02554903|LVAD
897973|NCT02554890|Acute
897974|NCT02554890|Heart Failure
897975|NCT02554890|reduced ejection fraction
897976|NCT02554890|NTproBNP
897977|NCT02554890|Heart failure with reduced ejection fraction (HFREF)
897978|NCT02554838|Specific phobia
897979|NCT02554838|Fear of Falling
897980|NCT02554838|Life-space area
897981|NCT02554812|anti PD-L1
897982|NCT02554812|anti 4-1BB
897983|NCT02554812|Non-small cell lung cancer (NSCLC)
897984|NCT02554812|melanoma
897985|NCT02554812|squamous cell carcinoma of head and neck (SCCHN)
897986|NCT02554812|triple negative breast cancer (TNBC)
897987|NCT02554812|colorectal cancer (CRC)
897988|NCT02554786|QMF149, Mometasone furoate (MF), asthma
897989|NCT02554773|Hemophilia
897990|NCT02554773|RNAi therapeutic
897991|NCT02554721|Healthy Volunteers
897992|NCT02554708|Aneurysm
897993|NCT02554708|bifurcation
897994|NCT02554708|wide neck
897995|NCT02554708|pCONus
897996|NCT02554708|intracerebral
897997|NCT02554708|stroke
897998|NCT02554695|adrenergic
897999|NCT02554682|Adolescent Health
898000|NCT02554682|Sexual Health
898001|NCT02554682|Parent-Teen Communication
898002|NCT02554682|Teen Driving
898003|NCT02554682|Alcohol Prevention
898004|NCT02554669|Blood glucose (indicated by interstitial glucose)
898005|NCT02554669|Markers of systemic inflammation
898006|NCT02554643|intermittent exercise
898007|NCT02554643|continuous exercise
898008|NCT02554643|blood glucose
898009|NCT02554643|intramyocellular lipids
898010|NCT02554643|diabetes
898011|NCT02554643|gene expression
898012|NCT02554617|healthy people
898013|NCT02554617|fractional exhaled nitric oxide (FeNo)
898014|NCT02554617|factors
898015|NCT02554604|HDL
898016|NCT02554604|Preeclampsia
898017|NCT02554604|saliva
898018|NCT02554578|mHealth
898019|NCT02554578|multidisciplinary team
898020|NCT02554578|immunosuppressive medication
898021|NCT02554578|pharmaceutical care
898022|NCT02554578|adherence
898023|NCT02554578|heart transplant
898024|NCT02554578|recipients
898025|NCT02554565|Patients with cervical cancer
898026|NCT02554552|Osteoarthritis
898027|NCT02554526|hemophilia A
898028|NCT02554526|inhibitor
898029|NCT02554526|bypassing therapy
898030|NCT02554526|factor VIII
898031|NCT02554513|Apraxia of Speech
898032|NCT02554513|Treatment
898033|NCT02554487|stroke
898034|NCT02554487|sleep disordered breathing
898035|NCT02554487|sleep apnea
898036|NCT02554487|infarct volume
898037|NCT02554487|penumbra
898038|NCT02554474|Physical activity
898039|NCT02554474|Exercise
898040|NCT02554474|Rheumatoid
898041|NCT02554474|Arthritis
898042|NCT02554474|Lupus
898043|NCT02554474|SLE
898044|NCT02554448|Circulating Tumor Cells
898045|NCT02554448|rectal Neoplasms
898046|NCT02554448|neoadjuvant otherapy
898047|NCT02554435|physical activity
898048|NCT02554435|activity monitor
898049|NCT02554435|older adults
898050|NCT02554435|5 A's counseling
898054|NCT02554396|ophthalmology
898055|NCT02554396|vision
898056|NCT02554396|ocular
898057|NCT02554383|pediatrics
898058|NCT02554383|antibiotics
898059|NCT02554383|placebo
898060|NCT02554344|CIN3
898061|NCT02554344|Squamous CIN3
898062|NCT02554331|Gait
898063|NCT02554331|REM sleep behavior disorder
898064|NCT02554331|Parkinson's disease
898065|NCT02554331|Follow-up
898066|NCT02554318|Tempeh
898067|NCT02554318|Body weight
898068|NCT02554318|Handgrip strength
898069|NCT02554318|6MWT
898070|NCT02554318|Supplementation
898071|NCT02554318|Wasting
898072|NCT02554305|efficacy and safety of fusion Oxygenation System
898073|NCT02554305|isolated Coronary Artery Bypass Grafting
898074|NCT02554305|Bypass Grafting
898075|NCT02554227|Spondylodiscitis
898076|NCT02554227|erosive osteochondrosis
898077|NCT02554227|infection
898078|NCT02554227|cytokine profiles
898079|NCT02554227|lumbar spine
898080|NCT02554201|pudendal nerve modulation
898081|NCT02554201|transanal/transvaginal electrical stimulation
898082|NCT02554188|Dietary Intervention
898083|NCT02554188|Fasting-mimicking
898084|NCT02554188|Influenza Vaccines
898085|NCT02554175|Propofol
898086|NCT02554175|Schnider model
898087|NCT02554162|Satiety, appetite, wholegrain rye
898088|NCT02554149|total hip
898089|NCT02554149|stem version
898090|NCT02554149|replacement
898091|NCT02554149|hip
898092|NCT02554097|laparoscopic transcystic common bile duct exploration
898093|NCT02554097|laparoscopic common bile duct exploration
898094|NCT02554097|endoscopic sphincterotomy,
898095|NCT02554097|cost-effective analysis
898096|NCT02554058|Spinal cord injury
898097|NCT02554058|rehabilitation
898098|NCT02554058|cycling
898099|NCT02554032|antegrade cerebral perfusion
898100|NCT02554032|innominate artery cannulation
898101|NCT02554032|axillary artery cannulation
898102|NCT02554032|aortic surgery
898103|NCT02554032|deep hypothermic circulatory arrest
898104|NCT02554019|SLE, Lupus
898105|NCT02554019|IL10, IL-10, BT063, BT-063
898106|NCT02553993|Stroke
898107|NCT02553993|Cognition
898108|NCT02553993|Exergames
898109|NCT02553993|Weight shifting
898110|NCT02553993|Balance
898111|NCT02553993|Rehabilitation
898112|NCT02553980|Physical activity
898113|NCT02553980|Information technology
898114|NCT02553980|Middle-aged
898115|NCT02553980|Health promotion
898116|NCT02553967|functional Magnetic Resonance Imaging (fMRI)
898117|NCT02553967|Breast reconstructive surgery
898118|NCT02553967|Breast Q questionnaire
898119|NCT02553954|Mechanisms of Senescence
898120|NCT02553954|Senescence markers
898121|NCT02553915|Omega-3
898122|NCT02553915|EPA
898123|NCT02553915|Depression
898124|NCT02553915|Overweight
898125|NCT02553915|Inflammation
898126|NCT02553915|Eicosapentaenoic acid
898127|NCT02553902|Positional therapy
898128|NCT02553902|MAD
898129|NCT02553902|Oral appliance
898130|NCT02553902|Sleep position trainer
898131|NCT02553902|POSA
898132|NCT02553876|neurostimulation
898133|NCT02553876|dorsal root ganglion
898134|NCT02553876|hand pain
898135|NCT02553876|upper limb pain
898136|NCT02553863|chemotherapy induced peripheral neuropathy
898137|NCT02553863|acupuncture
898138|NCT02553863|pain
898139|NCT02553863|cost-effectiveness
898140|NCT02553837|Healthy Volunteers
898141|NCT02553824|binge eating
898142|NCT02553824|bulimia nervosa
898143|NCT02553824|binge eating disorder
898144|NCT02553824|eating disorder treatment
898145|NCT02553811|carpal tunnel syndrome
898146|NCT02553811|clinical examination
898147|NCT02553811|diagnosis
898148|NCT02553811|clinical trial
898149|NCT02553811|median nerve compression
898150|NCT02553811|accuracy
898151|NCT02553811|ultrasonography
898152|NCT02553811|electromyography
898153|NCT02553811|electrodiagnostic testing
898154|NCT02553785|BioVentrix
898155|NCT02553785|Revivent
898156|NCT02553785|Revivent TC
898157|NCT02553759|observed action
898158|NCT02553759|range of motion
898159|NCT02553759|mirror neuron
898160|NCT02553746|Ultrasound
898161|NCT02553746|Spinal anesthesia
898162|NCT02553746|Epidural anesthesia
898163|NCT02553733|Dietary nitrate supplementation
898164|NCT02553733|Beetroot juice
898165|NCT02553720|Post thrombotic syndrome
898166|NCT02553720|Chronic venous insufficiency
898167|NCT02553694|OSA, Apnea
898168|NCT02553668|Proteomics
898169|NCT02553668|Oxygen
898170|NCT02553668|Pathways
898171|NCT02553642|Tumor Mutation
898172|NCT02553642|Nivolumab
898173|NCT02553642|Nivolumab plus Ipilimumab
898174|NCT02553642|Predicted Neo-antigen Burden
898175|NCT02553642|15-126
898176|NCT02553590|Non Interventional Study
898177|NCT02553590|NIS
898178|NCT02553590|sublingual immunotherapy
898179|NCT02553590|allergen
898180|NCT02553590|tree
898181|NCT02553590|birch
898182|NCT02553590|alder
898185|NCT02553538|cancer screening
898186|NCT02553538|patient navigation
898187|NCT02553525|Deep Brain Stimulation
898188|NCT02553525|Movement Disorders
898189|NCT02553525|Parkinson Disease
898190|NCT02553525|Essential Tremor
898191|NCT02553525|Subthalamic Nucleus
898192|NCT02553525|Globus Pallidus
898193|NCT02553525|Thalamus
898194|NCT02553525|Tremor
898195|NCT02553525|Bradykinesia
898196|NCT02553525|Temporal Pattern
898197|NCT02553525|Electrical Stimulation
898198|NCT02553525|Neuromodulation
898199|NCT02553525|PD
898200|NCT02553525|ET
898201|NCT02553525|MS
898202|NCT02553525|STN
898203|NCT02553525|GPi
898204|NCT02553525|DBS
898205|NCT02553525|Nervous System Diseases
898206|NCT02553525|Neurodegenerative Diseases
898207|NCT02553499|Solid tumor
898208|NCT02553499|PD1
898209|NCT02553499|PD-L1
898210|NCT02553499|PDL1
898211|NCT02553486|adoption
898212|NCT02553486|children
898213|NCT02553486|quality of life
898214|NCT02553460|Infants
898215|NCT02553434|pigtail catheter
898216|NCT02553434|small-bore catheter
898217|NCT02553434|trauma
898218|NCT02553434|hemothorax
898219|NCT02553421|infiltration
898220|NCT02553421|extravasation
898221|NCT02553421|peripheral intravenous therapy
898222|NCT02553356|Female Subjects
898223|NCT02553343|Influenza
898224|NCT02553343|High-Dose Quadrivalent Influenza Vaccine
898225|NCT02553343|High-Dose Trivalent Influenza Vaccine
898226|NCT02553330|Hair loss
898227|NCT02553330|alopecia areata
898228|NCT02553330|alopecia totalis
898229|NCT02553330|alopecia universalis
898230|NCT02553330|JAK inhibitors
898231|NCT02553330|topical hair growth
898232|NCT02553278|abdominoplasty
898233|NCT02553265|Familial dysautonomia (HSAN III)
898234|NCT02553265|Norepinephrine
898235|NCT02553265|Sympathetic nervous system
898236|NCT02553265|Autonomic nervous system
898237|NCT02553265|Blood pressure variability
898238|NCT02553265|Hypertension
898239|NCT02553265|Carbidopa/Lodosyn
898240|NCT02553265|Afferent baroreflex failure
898241|NCT02553265|Clinical trial
898242|NCT02553252|post traumatic stress disorder (PTSD)
898243|NCT02553252|Sudarshan Kriya Yoga (SKY)
898244|NCT02553239|Atrial Fibrillation
898245|NCT02553239|Paroxysmal
898246|NCT02553239|Cryoablation
898247|NCT02553226|Active phase of labour
898248|NCT02553226|Discontinuation
898249|NCT02553226|Caesarean section
898250|NCT02553200|intubated patients
898251|NCT02553200|secretion clearance
898252|NCT02553200|lung function
898253|NCT02553200|breathing exercise
898254|NCT02553161|Depression
898255|NCT02553148|prevalence
898256|NCT02553148|epidemiology
898257|NCT02553148|palliative care
898258|NCT02553148|pediatric
898259|NCT02553135|choroideremia, gene therapy
898260|NCT02553122|Blood Loss
898261|NCT02553122|Tranexamic Acid
898262|NCT02553122|Evicel
898263|NCT02553109|small paraclinoid
898264|NCT02553096|exacerbations
898265|NCT02553096|self-management support
898266|NCT02553096|software application
898267|NCT02553031|Application of MR-PET
898268|NCT02553005|Acupuncture
898269|NCT02553005|Rheumatoid Arthritis
898270|NCT02553005|Quality of life
898271|NCT02553005|Hand Strength
898272|NCT02552979|atopic dermatitis
898273|NCT02552979|atopic patch test
898274|NCT02552927|PDA
898275|NCT02552927|Jaundice
898276|NCT02552927|Phototherapy
898277|NCT02552914|Colli-Pee
898278|NCT02552914|STI
898279|NCT02552914|first-void urine
898280|NCT02552901|hepatic
898281|NCT02552901|liver
898282|NCT02552901|LFT
898283|NCT02552901|hepatic assessment
898284|NCT02552901|ICG dye
898285|NCT02552901|indocyanine green dye
898286|NCT02552901|Diagnostic Green
898287|NCT02552901|Pulsion
898288|NCT02552901|Akorn
898289|NCT02552901|Cardiox
898290|NCT02552901|anazen
898291|NCT02552901|essence
898292|NCT02552901|dye detection monitor
898293|NCT02552901|Earpads
898294|NCT02552901|flow sensor
898295|NCT02552901|scaphoid fossa
898296|NCT02552901|liver disease
898297|NCT02552901|acute hepatic failure
898298|NCT02552901|AHF
898299|NCT02552901|NASH
898300|NCT02552901|hepatitis C
898301|NCT02552901|cirrhosis
898302|NCT02552901|MELD
898303|NCT02552901|pulse dye densitometry
898304|NCT02552901|liver transplant
898305|NCT02552901|fluorescence
898306|NCT02552901|near infra-red
898307|NCT02552901|serial blood draws
898308|NCT02552901|PDR
898309|NCT02552901|plasma disappearance rate
898310|NCT02552901|R15
898311|NCT02552901|k coefficient
898312|NCT02552901|transcutaneously
898313|NCT02552901|liver donor
898314|NCT02552901|liver dysfunction
898315|NCT02552901|Child-Pugh
898316|NCT02552901|AST
898317|NCT02552901|ALT
898318|NCT02552901|GGT
898319|NCT02552901|alk phos
898320|NCT02552901|prothrombin time
898321|NCT02552901|albumin
898322|NCT02552901|serum ICG
898323|NCT02552901|liver function tests
898324|NCT02552888|Endothelial Dysfunction
898325|NCT02552888|Inflammation
898326|NCT02552875|Acceleromyography
898327|NCT02552875|staircase phenomenon
898328|NCT02552875|tetanic stimulation
898329|NCT02552797|Shared Decision Making
898330|NCT02552797|CAMHS
898331|NCT02552758|violence
898332|NCT02552758|PET
898333|NCT02552758|omega-3 fatty acid
898334|NCT02552758|schizophrenia
898335|NCT02552758|patient
898336|NCT02552719|Injustice Experience
898337|NCT02552719|Questionnaire
898338|NCT02552719|Validation
898339|NCT02552719|German translation
898340|NCT02552706|probiotics
898341|NCT02552706|preterm very low birth weight infants
898342|NCT02552706|necrotizing enterocolitis
898343|NCT02552706|gut microflora
898344|NCT02552706|TLR
898345|NCT02552706|NF-KB
898346|NCT02552706|inflammatory factors
898347|NCT02552693|Enhancing retention
898348|NCT02552680|Work-Related Musculoskeletal Disorders
898349|NCT02552680|Quality of life
898350|NCT02552680|Health Education
898351|NCT02552667|Asthma
898352|NCT02552667|Allergic rhinitis
898353|NCT02552628|Wilson's Disease
898354|NCT02552628|Deep Brain Stimulation
898355|NCT02552628|dystonia
898356|NCT02552615|scoliosis, verticality perception, body symmetry
898357|NCT02552602|HIV
898358|NCT02552602|Multivitamins
898359|NCT02552589|clinical trial, phase III
898360|NCT02552589|plaque index
898361|NCT02552589|gingivitis index
898362|NCT02552589|fluoride
898363|NCT02552589|toothpaste
898364|NCT02552550|squamous cell carcinoma of the oropharynx
898365|NCT02552550|swallowing, speech
898366|NCT02552550|quality of life
898367|NCT02552524|pathological gambling
898368|NCT02552524|rTMS
898369|NCT02552524|cognitive tests
898370|NCT02552524|autonomic nervous system
898371|NCT02552524|craving
898372|NCT02552472|Asthma
898373|NCT02552472|Inhaler Use
898374|NCT02552472|Adherence
898375|NCT02552472|Chronic Obstructive Pulmonary Disease
898376|NCT02552459|dexmedetomidine
898377|NCT02552459|patient controlled analgesia
898378|NCT02552433|nutritional deficiencies
898379|NCT02552433|plastic surgery
898380|NCT02552433|post-bariatric
898381|NCT02552433|protein
898382|NCT02552433|skin surplus
898383|NCT02552420|infrared thermal imaging
898384|NCT02552420|deep venous thrombosis
898385|NCT02552407|thrombectomy
898386|NCT02552407|acute coronary syndromes
898387|NCT02552407|percutaneous coronary intervention
898388|NCT02552407|STEMI
898389|NCT02552381|Cancer
898390|NCT02552381|Thromboembolic event
898391|NCT02552381|Fibrin Structure
898392|NCT02552381|LMWH
898393|NCT02552368|Stroke Rehabilitation
898394|NCT02552368|BCI
898395|NCT02552368|Stroke
898396|NCT02552368|Upper Extremity Rehabilitation
898397|NCT02552368|paresis
898398|NCT02552368|hemiparesis
898399|NCT02552329|mild cognitive impairment
898400|NCT02552329|Tai Chi
898401|NCT02552329|cognitive functions
898402|NCT02552316|microbiome
898403|NCT02552316|bacteria
898404|NCT02552316|NB-UVB Phototherapy
898405|NCT02552316|light therapy
898406|NCT02552277|Diabetic
898407|NCT02552277|PDA-002
898408|NCT02552277|Placenta-Derived Cells
898409|NCT02552277|Peripheral neuropathy
898410|NCT02552277|Neuropathy
898411|NCT02552277|Double-Blind
898412|NCT02552277|Safety
898413|NCT02552277|Efficacy
898414|NCT02552277|Human Placenta-derived Cells
898415|NCT02552238|Lumason
898416|NCT02552238|Dobutamine stress echo
898417|NCT02552238|stress echo
898418|NCT02552238|coronary artery disease
898419|NCT02552225|laryngeal sensory neuropathy, chronic laryngeal neuropathy
898431|NCT02552160|Chronic Obstructive Pulmonary Disease
898432|NCT02552160|Fixed-dose Combination
898433|NCT02552160|LAMA/LABA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists)
898434|NCT02552160|Inhaler
898435|NCT02552160|Aclidinium/Formoterol
898436|NCT02552160|Glycopyrronium/Indacaterol
898437|NCT02552160|Umeclidinium/Vilanterol
898438|NCT02552147|Autism spectrum disorder
898439|NCT02552147|Aggression
898440|NCT02552147|Irritability
898441|NCT02552147|Nicotine
898442|NCT02552147|Nicotinic acetylcholine receptor
898443|NCT02552147|Nicotinic agonist
898444|NCT02552147|Adult autism
898445|NCT02552134|Access to physical activity resources, community based exercise programme, sports-clubs, health resort,
898446|NCT02552121|ovary cancer
898447|NCT02552121|cervix cancer
898448|NCT02552121|endometrium cancer
898449|NCT02552121|bladder cancer
898450|NCT02552121|prostate cancer (CRPC)
898451|NCT02552121|esophagus cancer
898452|NCT02552121|lung cancer (NSCLC)
898453|NCT02552108|Cognitive-behavioural therapy
898454|NCT02552056|Child Adolescent Mental Integration PHC Traditional Healers
898455|NCT02552043|Cystic fibrosis
898456|NCT02552043|Exercise capacity
898457|NCT02552043|Interactive gaming console
898458|NCT02552043|Pulmonary rehabilitation
898459|NCT02552017|adenoma detection rate
898460|NCT02552017|Endocuff
898461|NCT02552017|Endocuff Vision
898462|NCT02552017|colonoscopy
898463|NCT02552017|bowel cancer screening
898464|NCT02552017|bowel cancer
898465|NCT02552004|pCLE
898466|NCT02552004|Digestive surgery
898467|NCT02552004|Endocrine surgery
898468|NCT02551991|Pancreatic cancer
898469|NCT02551991|MM-398
898470|NCT02551991|Metastatic pancreatic cancer
898471|NCT02551991|First line pancreatic cancer treatment
898472|NCT02551978|obesity
898473|NCT02551978|child
898474|NCT02551978|primary prevention
898475|NCT02551978|serious game
898476|NCT02551978|nutrition
898477|NCT02551978|physical activity
898478|NCT02551978|psychosocial
898479|NCT02551978|stress
898480|NCT02551978|knowledge
898481|NCT02551978|diet
898482|NCT02551965|Cancer
898483|NCT02551965|Patient
898484|NCT02551965|Oncology
898485|NCT02551965|Caregiver
898486|NCT02551952|Games
898487|NCT02551952|Cognitive Tests
898488|NCT02551952|General Anesthesia
898489|NCT02551952|Surgery
898490|NCT02551913|Psychological Theory
898491|NCT02551913|adolescents
898492|NCT02551900|Type 2 Diabetes
898493|NCT02551900|Vascular Function
898494|NCT02551900|Water Exercise
898495|NCT02551900|Warm Water
898496|NCT02551900|Cold Water
898497|NCT02551887|HPV Vaccinations
898498|NCT02551887|Quadrivalent Vaccine
898499|NCT02551848|Movement disorders
898500|NCT02551848|Botulinum toxin type A
898501|NCT02551848|Kinematics
898502|NCT02551835|ODIN
898503|NCT02551835|Meta-analysis
898504|NCT02551835|Cholecalciferol
898505|NCT02551835|25(OH)D
898506|NCT02551835|Subgroup effects
898507|NCT02551822|Urge Urinary Incontinence, sacral neuromodulation
898508|NCT02551796|lenticule extraction
898509|NCT02551796|laser in situ keratomileusis
898510|NCT02551796|femtosecond laser-assisted laser in situ keratomileusis
898511|NCT02551796|tear
898512|NCT02551796|inflammatory mediators
898513|NCT02551783|urethral stricture
898514|NCT02551783|urethroplasty
898515|NCT02551783|buccal mucosa
898516|NCT02551783|graft
898517|NCT02551757|Rehabilitation
898518|NCT02551757|Continuous Positive Airway Pressure
898519|NCT02551744|histamine-2 receptor antagonist
898520|NCT02551744|proton pump inhibitor
898521|NCT02551744|thienopyridine
898522|NCT02551744|clopidogrel
898523|NCT02551744|prevention
898524|NCT02551679|Stem cells
898525|NCT02551679|Endothelial progenitor cells
898526|NCT02551679|Autologous cells
898527|NCT02551679|Vascular disease
898528|NCT02551679|Peripheral arterial disease
898529|NCT02551679|Regenerative medicine
898530|NCT02551653|Idiopathic Pulmonary Arterial Hypertension
898531|NCT02551653|Biodistribution
898532|NCT02551653|Positron Emission Tomography
898533|NCT02551653|[11C]-GSK2256098
898534|NCT02551653|Healthy subjects
898535|NCT02551614|lipopolysaccharide
898536|NCT02551614|COPD
898537|NCT02551614|neutrophil
898538|NCT02551601|subfoveal choroidal thickness
898539|NCT02551601|optical coherence tomography
898540|NCT02551601|enhanced depth imaging
898541|NCT02551588|fibrosis
898542|NCT02551588|Magnetic resonance imaging
898543|NCT02551549|Subjects
898544|NCT02551536|Allergic rhinitis
898545|NCT02551536|montelukast
898546|NCT02551536|fexofenadine
898547|NCT02551536|levocetrizine
898548|NCT02551510|Skin Adhesive
898549|NCT02551510|Suture
898550|NCT02551510|Port Incisions
898551|NCT02551497|volunteer drug interaction study
898552|NCT02551471|Locally advanced rectal cancer
898553|NCT02551471|Fixed primary rectal cancer
898554|NCT02551471|Pelvic recurrence
898555|NCT02551471|Benchmarking France Australia
898556|NCT02551432|pembrolizumab
898557|NCT02551432|paclitaxel
898558|NCT02551419|mild cognitive impairment
898559|NCT02551419|ketones
898560|NCT02551419|medium chain triglycerides
898561|NCT02551419|Positron emission tomography
898562|NCT02551419|magnetic resonance imaging
898563|NCT02551419|cognition
898564|NCT02551419|brain
898565|NCT02551419|neuroimaging
898566|NCT02551406|nocturnal hypoventilation
898567|NCT02551406|capno-oxymetry
898568|NCT02551393|Older adults
898569|NCT02551393|Home Blood Pressure Monitoring
898570|NCT02551367|letrozole
898571|NCT02551354|Labor, Obstetric
898572|NCT02551354|pain
898573|NCT02551354|pupil diameter
898574|NCT02551354|Visual Analogic Scale (VAS)
898575|NCT02551341|prostatectomy
898576|NCT02551341|robotic
898577|NCT02551315|Intra-cortical pore volume
898578|NCT02551315|HR-pQCT
898579|NCT02551315|DXA
898580|NCT02551315|bone mineral density
898581|NCT02551315|bone turnover markers
898582|NCT02551315|urinary pentosidine
898583|NCT02551289|MRI
898584|NCT02551289|Gluten
898585|NCT02551289|Imaging
898586|NCT02551289|Enteropathy-Associated T-Cell Lymphoma
898587|NCT02551263|Breast Cancer
898588|NCT02551263|Eribulin
898589|NCT02551263|HER2-negative
898590|NCT02551263|hormone-resistant
898591|NCT02551263|inoperable
898592|NCT02551263|recurrent metastatic
898593|NCT02551250|hepatocellular carcinoma
898594|NCT02551250|surveillance
898595|NCT02551250|liver cirrhosis
898596|NCT02551250|ultrasonography
898597|NCT02551250|magnetic resonance imaging
898598|NCT02551237|Elderly patient
898599|NCT02551237|Radiotherapy
898600|NCT02551237|Radio chemotherapy
898601|NCT02551237|Neoadjuvant treatment
898602|NCT02551224|COPD
898603|NCT02551198|polyethylene glycol with ascorbic acid
898604|NCT02551198|oral sulfate solution
898605|NCT02551198|bowel preparation
898606|NCT02551159|programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen 4 {CTLA-4}, PFS, SCCHN
898607|NCT02551133|Dexamethasone
898608|NCT02551133|mastectomy
898609|NCT02551133|persistent surgical pain
898610|NCT02551120|Idiopathic hypoparathyroidism
898611|NCT02551120|Autosomal dominant hypocalcaemia
898612|NCT02551120|Pseudohypoparathyroidism
898613|NCT02551120|Quality of Life
898614|NCT02551120|Bone Mineral Density
898615|NCT02551120|Muscle strength
898616|NCT02551120|Cardiovascular indices
898617|NCT02551055|Drug Therapy
898618|NCT02551042|Digital Ulcers
898619|NCT02551042|Raynauds Phenomenon
898620|NCT02551042|Factor XIII
898621|NCT02551029|Magnetic Resonance Imaging
898622|NCT02551029|Brainstem
898623|NCT02551029|Solitary Nucleus
898624|NCT02551029|Visceral Nervous System
898625|NCT02551029|Transient Receptor Potential Channels
898626|NCT02550977|Contraception
898627|NCT02550977|Transdermal contraceptive patch
898628|NCT02550977|Safety
898629|NCT02550977|Efficacy
898630|NCT02550977|Pharmacokinetic
898631|NCT02550964|Autoimmune Disease
898632|NCT02550964|Rheumatoid Arthritis
898633|NCT02550964|Systemic Lupus Erythematosus
898634|NCT02550964|Hydroxychloroquine(HCQ)
898635|NCT02550964|Chloroquine(CQ)
898636|NCT02550964|Toxic Maculopathy
898637|NCT02550925|Cancer survivors
898638|NCT02550886|Work Burden
898639|NCT02550886|Ambulatory Orthopedic Surgery
898640|NCT02550886|Anesthesiology
898641|NCT02550886|Perioperative Care
898642|NCT02550860|intravenous fat emulsions
898643|NCT02550860|parenteral nutrition
898644|NCT02550860|skin barrier function
898645|NCT02550860|essential fatty acids
898646|NCT02550860|transepidermal water loss
898647|NCT02550847|MR/PET
898648|NCT02550847|pancreatic cancer
898649|NCT02550834|Core stability
898650|NCT02550834|Indoors curling exercises
898651|NCT02550834|Motivation
898652|NCT02550821|Physical activity levels
898653|NCT02550821|Bronchiectasis
898654|NCT02550782|perineural dexmedetomidine
898655|NCT02550782|infraclavicular perineural catheter
898656|NCT02550782|postoperative analgesia
898657|NCT02550769|Transanal NOTES
898658|NCT02550769|Transanal TME
898659|NCT02550769|Laparoscopic Low Anterior Resection
898660|NCT02550769|Surgery
898661|NCT02550717|Low-dose Acetylsalicylic Acid,
898662|NCT02550717|Bleeding,
898663|NCT02550717|The Health Improvement Network (THIN),
898664|NCT02550717|Cardiovascular
898665|NCT02550717|Secondary prevention of cardiovascular events
898666|NCT02550704|Irritable Bowel syndrome
898667|NCT02550704|Intestinal permeability
898668|NCT02550704|Visceral hypersensitivity
898669|NCT02550704|Low grade inflammation
898670|NCT02550678|Untreated nBCC
898671|NCT02550678|Low-Risk
898672|NCT02550665|Alzheimer's disease
898673|NCT02550665|donepezil
898674|NCT02550626|delirium
898675|NCT02550626|alpha synucleinopathy
898676|NCT02550626|spine surgery
898677|NCT02550613|MR/PET, hepatocellular carcinoma, HCC
898678|NCT02550600|ARDS
898679|NCT02550600|Acute lung impairment
898680|NCT02550600|Extracorporeal lung assist
898681|NCT02550600|ECMO
898682|NCT02550600|ECLA
898683|NCT02550600|Murray-score
898684|NCT02550600|SOFA-score
898685|NCT02550587|Patient Satisfaction
898686|NCT02550587|anesthesia Care
898687|NCT02550561|Posterior tibial nerve stimulation
898688|NCT02550561|PTNS
898689|NCT02550561|IC
898694|NCT02550535|Gene Therapy
898695|NCT02550535|WT1 TCR
898696|NCT02550535|Gene modified T cels
898698|NCT02550509|stroke
898699|NCT02550509|Botulinum toxin
898700|NCT02550509|Muscle alterations
898701|NCT02550483|Healthy volunteers
898702|NCT02550444|Clonidine
898703|NCT02550444|Anesthesia, Obstetrical
898704|NCT02550379|Social Anxiety
898705|NCT02550379|Social Phobia
898706|NCT02550379|Depression
898707|NCT02550379|Emotion Recognition Training
898708|NCT02550366|Cardiac MRI
898709|NCT02550366|Accelerate imaging
898710|NCT02550366|coronary artery disease
898711|NCT02550353|lenticule extraction
898712|NCT02550353|femtosecond laser-assisted laser in situ keratomileusis
898713|NCT02550353|tear
898714|NCT02550353|inflammatory mediators
898715|NCT02550340|Arrhythmia
898716|NCT02550340|Alcohol
898717|NCT02550340|ECG
898718|NCT02550327|resectable
898719|NCT02550327|potentially resectable
898720|NCT02550327|Pancreatic adenocarcinoma
898721|NCT02550327|PDAC
898722|NCT02550301|mean platelet volume
898723|NCT02550262|Epidural
898724|NCT02550262|Labor analgesia
898725|NCT02550262|Programmed intermittent epidural bolus
898726|NCT02550236|Children
898727|NCT02550236|Obesity
898728|NCT02550236|Pregnancy
898729|NCT02550236|Growth
898730|NCT02550236|Lifestyle
898731|NCT02550236|Metabolic and cardiovascular health
898732|NCT02550236|Birth
898733|NCT02550236|Development
898734|NCT02550210|Breast Conserving Surgery
898735|NCT02550210|Breast Imaging
898736|NCT02550210|Breast Diagnostics
898737|NCT02550197|Influenza
898738|NCT02550197|Quadrivalent influenza vaccine
898739|NCT02550197|Trivalent influenza vaccine
898740|NCT02550184|Patients with symptoms of acute respiratory problems
898741|NCT02550171|Biobank
898742|NCT02550171|Genetics
898743|NCT02550171|DNA
898744|NCT02550171|Cohort
898745|NCT02550171|normal control
898746|NCT02550158|Crohn's Disease
898747|NCT02550158|Ulcerative Colitis
898748|NCT02550158|Educational program
898749|NCT02550158|Inflammatory Bowel Disease
898750|NCT02550158|Psycho-pedagogic score
898751|NCT02550158|IBD
898752|NCT02550145|Hyperinsulinemic
898753|NCT02550145|post-bariatric surgery
898754|NCT02550132|electromyography
898755|NCT02550132|biomechanical phenomena
898756|NCT02550132|dose-response relationship
898757|NCT02550132|musculoskeletal manipulations
898758|NCT02550132|spinal manipulation
898759|NCT02550106|CHRONIC SPONTANEOUS URTICARIA, OMALIZUMAB, URTICARIA CONTROL TEST
898760|NCT02550093|Volunteers
898761|NCT02550067|HIV infection
898762|NCT02550067|DepoLevonorgestrel
898763|NCT02550067|Contraception
898764|NCT02550067|DMPA
898765|NCT02550067|Copper IUD
898766|NCT02550067|Levonorgestrel implant
898767|NCT02550067|IUD
898768|NCT02550041|Bronchitis aspergillus
898769|NCT02550041|cystic fibrosis
898770|NCT02550028|Neonates
898771|NCT02550028|Seizure
898772|NCT02550015|Exercise training
898773|NCT02550015|Oxygen consumption
898774|NCT02549989|LY3023414
898775|NCT02549989|15-079
898776|NCT02549989|Persistent Endometrial Cancer
898777|NCT02549976|Crohn's Disease
898778|NCT02549976|Digestive Damage
898779|NCT02549976|Lemann Index
898780|NCT02549950|Accelerated orthodontic tooth movement (AOTM)
898781|NCT02549950|Peizo-corticission
898782|NCT02549924|Resveratrol
898783|NCT02549924|Glycemic Variability
898784|NCT02549924|MAGE
898785|NCT02549911|chemotherapy
898786|NCT02549911|surgery
898787|NCT02549911|Surgically-Created Resection Cavity
898788|NCT02549911|Adverse Reaction to Drug
898789|NCT02549885|Migraine disorders
898790|NCT02549885|Muscle stretching exercises
898791|NCT02549872|Dementia
898792|NCT02549872|Validity
898793|NCT02549872|Mortality
898794|NCT02549872|Electronic health records
898795|NCT02549859|DBS
898796|NCT02549859|Low frequency stimulation
898797|NCT02549859|Dysphagia
898798|NCT02549859|Freezing of gait
898799|NCT02549833|low-grade glioma
898800|NCT02549833|WHO grade II
898801|NCT02549833|vaccine
898802|NCT02549833|immunotherapy
898803|NCT02549833|glioma
898804|NCT02549820|Congenital Diaphragmatic Hernia
898805|NCT02549820|Tracheal Occlusion
898806|NCT02549807|Vascular hemiplegia
898807|NCT02549807|2D ultrasound
898808|NCT02549807|Muscle elasticity
898809|NCT02549807|Pennation angle
898810|NCT02549794|low concentration contrast agent
898811|NCT02549794|Low dose contrast agent
898812|NCT02549794|computed tomography
898813|NCT02549781|pathological gambler
898814|NCT02549781|Go-Nogo test
898815|NCT02549768|Dexmedetomidine
898816|NCT02549768|Pituitary
898817|NCT02549768|Transsphenoidal
898818|NCT02549768|Cortisol
898819|NCT02549742|Electrochemotherapy
898820|NCT02549742|head neck cancer
898821|NCT02549742|bleomycin
898822|NCT02549716|Acetaminophen
898823|NCT02549716|interleukin-6
898824|NCT02549716|interleukin-1
898825|NCT02549716|thromboxane A2
898826|NCT02549703|multiple sclerosis
898827|NCT02549703|progressive multiple sclerosis
898828|NCT02549703|mitochondria
898829|NCT02549703|neurodegeneration
898830|NCT02549690|IVF, Testosterone gel, DHEA, poor responder.
898831|NCT02549664|Hypertrophic Cardiomyopathy (HCM)
898832|NCT02549664|Long QT Syndrome (LQTS)
898833|NCT02549651|DLBCL
898834|NCT02549651|MEDI4736
898835|NCT02549651|tremelimumab
898836|NCT02549651|AZD9150
898837|NCT02549651|anti-PD-L1
898838|NCT02549651|anti-CTLA-4
898839|NCT02549651|immunotherapy
898840|NCT02549651|IMTC
898841|NCT02549651|STAT3
898842|NCT02549625|Single right ventricular failure
898843|NCT02549612|Conductive hearing loss
898844|NCT02549612|middle ear pressure equalization
898845|NCT02549612|middle ear effusion
898846|NCT02549599|Digital and mobile health
898847|NCT02549599|Sexual and reproductive health
898848|NCT02549599|Adolescents and young adults
898849|NCT02549586|solid organ transplant
898850|NCT02549586|immune tolerance
898851|NCT02549586|autologous stem cell transplant
898852|NCT02549586|blood and marrow transplant
898853|NCT02549586|autoimmune disease
898854|NCT02549573|Motor Symptoms
898855|NCT02549573|Parkinson's disease
898856|NCT02549573|Apokyn
898857|NCT02549573|Apomorphine
898858|NCT02549573|PD
898859|NCT02549560|tDCS
898860|NCT02549560|Cardiac Surgery
898861|NCT02549547|anxiety
898862|NCT02549547|depression
898863|NCT02549547|exercise
898864|NCT02549547|group
898865|NCT02549547|group medical visit
898866|NCT02549547|mood disorder
898867|NCT02549547|physical activity
898868|NCT02549547|primary care
898869|NCT02549534|Taxane
898870|NCT02549534|Neuropathy
898871|NCT02549534|Chemotherapy-Induced Peripheral Neuropathy (CIPN)
898872|NCT02549534|Breast Cancer
898873|NCT02549534|Local skin heating
898874|NCT02549534|Axon reflex
898875|NCT02549534|Axon flare
898876|NCT02549534|Total Neuropathy Score (TNS)
898877|NCT02549534|Laser Doppler Flowmetry (LDF)
898878|NCT02549534|Laser Speckle Contrast Imaging (LSCI)
898879|NCT02549534|Full-field laser perfusion imaging (FLPI)
898880|NCT02549534|Paclitaxel
898881|NCT02549534|Taxol
898882|NCT02549521|calcium
898883|NCT02549521|magnesium
898884|NCT02549521|vitamin D
898885|NCT02549521|bone turnover markers
898886|NCT02549482|Central volume deficit
898887|NCT02549482|Head-up tilt
898888|NCT02549482|Systolic pressure variation
898889|NCT02549456|natural orifice surgery
898890|NCT02549456|natural orifice specimen extraction
898891|NCT02549456|taTME
898892|NCT02549443|Catabolic response
898893|NCT02549443|Amino Acids
898894|NCT02549443|Insulin
898895|NCT02549430|Advanced breast cancer
898896|NCT02549430|Postmenopausal
898897|NCT02549430|ER positive
898898|NCT02549430|Her2 negative
898899|NCT02549378|microcirculation
898900|NCT02549378|confocal microscopy
898901|NCT02549378|hypocapnia
898902|NCT02549326|Vitamin D
898903|NCT02549313|brain lesion
898904|NCT02549313|intracranial pressure
898905|NCT02549313|cerebral perfusion pressure
898906|NCT02549300|connective tissue massage
898907|NCT02549300|adolescent tension-type headache
898908|NCT02549274|Cervicalgia
898909|NCT02549274|self-rehabilitation
898910|NCT02549274|physiotherapy
898911|NCT02549261|nimotuzumab
898912|NCT02549261|non-small cell lung cancer
898913|NCT02549261|radiochemotherapy
898914|NCT02549261|stage IIIA/IIIB non-small cell lung cancer
898915|NCT02549248|Interstitial Lung Diseases
898916|NCT02549248|nanoparticles
898917|NCT02549248|lung
898918|NCT02549248|broncho-alveolar lavage
898919|NCT02549248|bronchial washings
898920|NCT02549235|IVF
898921|NCT02549235|Miscarriage
898922|NCT02549235|Uterine septum
898923|NCT02549222|pathogen reduction
898924|NCT02549222|INTERCEPT
898925|NCT02549222|platelet
898926|NCT02549222|pulmonary
898927|NCT02549222|ARDS
898928|NCT02549222|hematology
898929|NCT02549222|oncology
898930|NCT02549222|assisted ventilation
898931|NCT02549222|transfusion of platelet components
898932|NCT02549222|hematology-oncology patients
898933|NCT02549209|Pembrolizumab
898934|NCT02549209|Keytruda
898935|NCT02549209|Anti-Programmed [Cell] Death Protein 1 (PD-1) Antibody
898936|NCT02549209|Carboplatin
898937|NCT02549209|Paclitaxel
898938|NCT02549183|Spinal Cord Stimulation
898939|NCT02549170|Autoimmune Diseases
898940|NCT02549170|Polyneuropathies
898941|NCT02549170|Nervous System Diseases
898942|NCT02549170|Peripheral Nervous System Diseases
898943|NCT02549170|Polyradiculoneuropathy
898944|NCT02549170|Autoimmune Diseases of the Nervous System
898945|NCT02549170|Immunoglobulins
898946|NCT02549170|Immune System Diseases
898947|NCT02549170|Demyelinating Diseases
898948|NCT02549170|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
898949|NCT02549170|Neuromuscular Diseases
898950|NCT02549144|HDL biochemical composition and function
898951|NCT02549105|EMLA CREAM
898952|NCT02549105|LIDOCAINE INFILTERATION
898953|NCT02549105|PAIN RELIEF
898954|NCT02549092|carbidopa
898955|NCT02549092|efficacy
898956|NCT02549092|Advanced Parkinson's Disease
898957|NCT02549092|Parkinson's Disease Sleep Scale PDSS-2
898958|NCT02549092|levodopa-carbidopa intestinal gel
898959|NCT02549092|Non-Motor Symptom Scale NMSS
898960|NCT02549092|levodopa
898961|NCT02549066|cardiopulmonary bypass
898962|NCT02549066|renal blood flow
898963|NCT02549066|renal function
898964|NCT02549066|renal oxygenation
898965|NCT02549001|Onychomycosis
898966|NCT02549001|Nail fungus
898967|NCT02548975|Cardiac surgery
898968|NCT02548975|Risk factors
898969|NCT02548975|Postoperative delirium
898970|NCT02548962|Multiple Myeloma
898971|NCT02548962|Bruton's Tyrosine Kinase
898972|NCT02548962|PCI-32765
898973|NCT02548962|Pomalidomide
898974|NCT02548962|Dexamethasone
898975|NCT02548962|Relapsed Refractory Multiple Myeloma
898976|NCT02548962|Ibrutinib
898977|NCT02548936|Cholesterol, LDL
898978|NCT02548936|Carotid Intima-Media Thickness
898979|NCT02548936|Atherosclerosis
898980|NCT02548936|Ezetimibe, Simvastatin Drug Combination
898981|NCT02548936|Lupus Erythematosus, Systemic
898982|NCT02548897|Parkinson's Disease with Freezing of Gait Symptoms
898983|NCT02548858|Perineorrhaphy
898984|NCT02548858|Pelvic organ prolapse
898985|NCT02548858|Vaginal or abdominal reconstruction
898986|NCT02548858|Body image
898987|NCT02548845|hyponatremia
898988|NCT02548845|SIADH
898989|NCT02548845|Oncologic patients
898990|NCT02548832|Berberine
898991|NCT02548832|Bezafibrate
898992|NCT02548806|Clonidine
898993|NCT02548793|Cardiac Arrest
898994|NCT02548793|CPR
898995|NCT02548793|Family-centered Care
898996|NCT02548793|Health Literacy
898997|NCT02548793|Health Education
898998|NCT02548793|Education Dissemination
898999|NCT02548780|unresectable
899000|NCT02548767|High fructose corn syrup
899001|NCT02548767|Sugar
899002|NCT02548754|atrial fibrillation
899003|NCT02548754|neuromodulation
899004|NCT02548754|inflammation
899005|NCT02548741|Metformin
899006|NCT02548741|diabetes
899007|NCT02548741|type 2 diabetes
899008|NCT02548741|diabetes complications
899009|NCT02548741|methylglyoxal
899010|NCT02548741|Prediabetes
899011|NCT02548728|Opioid Dependence
899012|NCT02548728|Opioid Withdrawal
899013|NCT02548728|Opioid
899014|NCT02548728|Oxytocin
899015|NCT02548728|OT (oxytocin)
899016|NCT02548728|Intranasal administration
899017|NCT02548715|thyroxine
899018|NCT02548715|Otolaryngology
899019|NCT02548702|Sport
899020|NCT02548702|type 2 diabetes
899021|NCT02548702|community intervention programme
899022|NCT02548702|Fit4life
899023|NCT02548702|Exercise
899024|NCT02548689|alopecia
899025|NCT02548689|hair loss
899026|NCT02548663|amyotrophic lateral sclerosis
899027|NCT02548663|sport therapy
899028|NCT02548663|osteopathic manual treatment
899029|NCT02548663|muscle oxidative metabolism
899030|NCT02548650|myocardial infarction
899031|NCT02548650|diabetes mellitus
899032|NCT02548650|vorapaxar
899033|NCT02548650|peripheral arterial disease
899034|NCT02548585|MEDI0382, diabetes
899035|NCT02548572|Transcorneal Electrical Stimulation
899036|NCT02548572|TES
899037|NCT02548572|Retinitis Pigmentosa
899038|NCT02548572|RP
899039|NCT02548416|Atelectasis
899040|NCT02548416|Positive End-Expiratory Pressure
899041|NCT02548416|Oxygenation
899042|NCT02548416|Anaesthesia
899043|NCT02548416|Computed tomography
899044|NCT02548403|Bowel preparation
899045|NCT02548403|Simethicone
899046|NCT02548403|Polyethylene glycol with ascorbic acid
899047|NCT02548390|Phase 1/1b
899048|NCT02548390|open-label
899049|NCT02548390|dose-escalation
899050|NCT02548390|pharmacokinetics
899051|NCT02548390|solid tumor
899052|NCT02548390|metastatic cancer
899053|NCT02548390|chemotherapy
899054|NCT02548390|nano formulation
899055|NCT02548390|alkylator
899056|NCT02548377|Head and Neck Neoplasms
899057|NCT02548377|Surgical Flaps
899058|NCT02548377|Ischemic Preconditioning
899059|NCT02548377|Hemostasis
899060|NCT02548377|Thrombosis
899061|NCT02548377|Immune System
899062|NCT02548377|Reperfusion Injury
899063|NCT02548364|Vitamin D
899064|NCT02548364|Myocardial Infarction
899065|NCT02548364|Ventricular remodeling
899066|NCT02548364|Biomarkers
899067|NCT02548351|Non Alcoholic Steatohepatitis, fatty liver disease, NASH
899068|NCT02548312|Readers' perceptions
899069|NCT02548299|Diabetes
899070|NCT02548299|Cooking
899071|NCT02548299|Nutrition
899072|NCT02548299|Lifestyle Medicine
899073|NCT02548286|Hypertension
899074|NCT02548286|Healthy male volunteer
899075|NCT02548286|Candesartan, Amlodipine
899076|NCT02548273|Corneal endothelium
899077|NCT02548273|phacoemulsification
899078|NCT02548247|Stool frequency
899079|NCT02548247|Bowel motor function
899080|NCT02548247|Orafti® Inulin
899081|NCT02548247|Dietary Fiber
899082|NCT02548234|Stroke
899083|NCT02548234|Randomized control trial
899084|NCT02548234|Mirror therapy
899085|NCT02548234|Bilateral arm training
899086|NCT02548234|Comparative efficacy research
899087|NCT02548234|Neurorehabilitation
899088|NCT02548221|Thoracentesis
899089|NCT02548221|Pleural Effusions
899090|NCT02548221|Transthoracic echocardiogram
899091|NCT02548221|Lung volume measurements
899092|NCT02548195|GEMOX
899093|NCT02548195|intrahepatic cholangiocarcinoma
899094|NCT02548195|adjuvant therapy
899095|NCT02548195|oxaliplatin
899096|NCT02548195|gemcitabine
899097|NCT02548195|capecitabine
899098|NCT02548195|curative surgery
899099|NCT02548169|Dendritic Cell Vaccine
899100|NCT02548169|FOLFIRINOX
899101|NCT02548169|nab-paclitaxel
899102|NCT02548169|gemcitabine
899103|NCT02548117|Testosterone therapy
899104|NCT02548117|erythrocytosis
899105|NCT02548117|finasteride
899106|NCT02548091|non invasive ventilation
899107|NCT02548091|reperfusion pulmonary edema
899108|NCT02548091|chronic thrombolic pulmonary hypertension
899109|NCT02548091|pulmonary artery angioplasty
899110|NCT02548078|Protection against Ebola Zaire virus
899111|NCT02548065|Fibromyalgia Syndrome
899112|NCT02548065|Balneotherapy
899113|NCT02548065|Vetriolo Water
899114|NCT02548052|retinoic acid receptor-related orphan receptor (ROR) gamma inverse agonist
899115|NCT02548052|Plaque type psoriasis
899116|NCT02548052|psoriasis plaque test
899117|NCT02548052|Topical
899118|NCT02548052|GSK2981278
899119|NCT02548039|Anovulatory
899120|NCT02548039|Clomiphene
899121|NCT02548026|meal frequency
899122|NCT02548026|eating frequency
899123|NCT02548026|ingestive frequency
899124|NCT02548026|positive energy balance
899125|NCT02548026|satiety
899126|NCT02548026|appetite
899127|NCT02548026|hunger
899128|NCT02547987|breast cancer
899129|NCT02547987|triple negative
899130|NCT02547987|TNBC
899131|NCT02547987|triple negative breast cancer
899132|NCT02547974|Safety
899133|NCT02547974|Immunogenicity
899134|NCT02547974|Reactogenicity
899135|NCT02547961|breast cancer
899136|NCT02547961|HER2
899137|NCT02547961|CAR-T cell
899138|NCT02547948|CD19
899139|NCT02547948|CAR T Cells
899140|NCT02547948|Lymphoma
899141|NCT02547922|lupus, nephritis, randomized, placebo, anifrolumab, safety, efficacy, adult
899142|NCT02547896|codeine
899143|NCT02547896|diclofenac
899144|NCT02547896|impacted third molar tooth
899145|NCT02547883|Statins
899146|NCT02547883|Elderly
899147|NCT02547883|Mortality
899148|NCT02547883|Quality of life
899149|NCT02547883|Randomized trial
899150|NCT02547883|Cost effectiveness study
899151|NCT02547883|Primary care
899152|NCT02547870|Rilpivirine
899153|NCT02547870|Healthy participants
899154|NCT02547857|Pelvic ultrasound
899155|NCT02547857|Transvaginal ultrasound
899156|NCT02547818|Early stage AD
899157|NCT02547818|MCI
899158|NCT02547818|aMCI
899159|NCT02547818|prodromal
899160|NCT02547818|Memory loss
899161|NCT02547818|Memory problems
899162|NCT02547818|Aging
899163|NCT02547818|Early Alzheimer's Disease
899164|NCT02547818|Early AD
899165|NCT02547805|Urine Oxalate
899166|NCT02547805|Nephrolithiasis
899167|NCT02547805|Kidney Stones
899168|NCT02547805|Hyperoxaluria
899169|NCT02547805|Enteric Hyperoxaluria
899170|NCT02547805|Idiopathic Hyperoxaluria
899171|NCT02547805|Urological Diseases
899172|NCT02547805|Kidney Diseases
899173|NCT02547805|Supersaturation
899174|NCT02547805|Dietary Oxalate
899175|NCT02547792|Influenza B
899176|NCT02547779|crystalloid
899177|NCT02547779|acute kidney injury
899178|NCT02547766|Ventricular Assist Device
899179|NCT02547766|Recovery of Function
899180|NCT02547753|Tooth extraction
899181|NCT02547753|Antibiotic prophylaxis
899182|NCT02547753|Postoperative complications
899183|NCT02547740|macula
899184|NCT02547740|visual fields
899185|NCT02547740|optical coherence tomography
899186|NCT02547740|glaucoma progression
899187|NCT02547740|retinal ganglion cells
899188|NCT02547727|rabies vaccination
899189|NCT02547714|cyclosporine A
899190|NCT02547610|MR/PET in the evaluation
899191|NCT02547610|patients
899192|NCT02547597|Beta-blockers
899193|NCT02547597|Anti-anginal effect
899194|NCT02547597|Lipid metabolism
899195|NCT02547597|Glucose metabolism
899196|NCT02547571|Outpatient
899197|NCT02547558|Indacaterol
899198|NCT02547558|Pulmonary gas exchange
899199|NCT02547558|Long-acting bronchodilators
899200|NCT02547532|COPD
899201|NCT02547532|alpha-1 antitrypsin deficiency
899202|NCT02547532|microbioma
899203|NCT02547519|Type 1 diabetes
899204|NCT02547519|T1D
899205|NCT02547519|diabetes mellitus
899206|NCT02547519|oral insulin
899207|NCT02547519|oral tolerance
899208|NCT02547519|autoantigen
899209|NCT02547519|self tolerance
899210|NCT02547519|prevention
899211|NCT02547519|at risk for developing type 1 diabetes
899212|NCT02547519|juvenile diabetes
899213|NCT02547506|cardiorespiratory fitness
899214|NCT02547506|group exercise
899215|NCT02547493|Vaccination against Pneumococcal
899216|NCT02547493|Naïve Abatacept patients
899217|NCT02547480|liver
899218|NCT02547480|metastatic
899219|NCT02547467|mortality
899220|NCT02547415|Pain, Chronic
899221|NCT02547415|children
899222|NCT02547376|Telomeres
899223|NCT02547376|Telomerase
899224|NCT02547376|Alternative lengthening of Telomeres Mechanism
899225|NCT02547285|biomechanics of walking
899226|NCT02547285|footwear
899227|NCT02547272|Intensive care
899228|NCT02547272|S Aureus
899229|NCT02547259|schizophrenia
899230|NCT02547259|memory
899231|NCT02547259|pain
899232|NCT02547246|bulimia
899233|NCT02547246|repetitive transcranial magnetic stimulation (rTMS)
899234|NCT02547194|coronary artery bypass grafting
899235|NCT02547194|saphenous vein
899236|NCT02547194|no-touch technique
899237|NCT02547181|Fracture
899238|NCT02547181|Follow-up
899239|NCT02547181|metacarpal
899240|NCT02547168|Atrial Fibrillation
899241|NCT02547168|Symptomatic Atrial Fibrillation
899242|NCT02547168|Asymptomatic Atrial Fibrillation
899243|NCT02547168|Lung Resection
899244|NCT02547168|Ambulatory Cardiac Monitor
899245|NCT02547142|Randomized Controlled Trial
899246|NCT02547142|Early Palliative care
899247|NCT02547142|FACT-E questionnaire
899248|NCT02547142|HADS questionnaire
899249|NCT02547142|Patient Health Questionnaire-9 (PHQ-9)
899250|NCT02547103|Chlorhexidine gluconate
899251|NCT02547103|Mupirocin ointment
899252|NCT02547103|Normal saline
899253|NCT02547103|Peritonitis
899254|NCT02547103|Peritoneal dialysis
899255|NCT02547064|intubation
899256|NCT02547064|stylet
899257|NCT02547064|videolaryngoscope
899258|NCT02547051|Stuttering
899259|NCT02547051|Stammering
899260|NCT02547051|Speech Disorders
899261|NCT02547051|Fluency Disorders
899262|NCT02547038|Helicobacter pylori
899263|NCT02547038|Eradication rate
899264|NCT02547025|Helicobacter pylori
899265|NCT02547025|third-line therapy
899266|NCT02547025|antibiotic susceptibility
899267|NCT02547025|Eradication
899268|NCT02547012|Helicobacter pylori
899269|NCT02547012|Eradication rate
899270|NCT02547012|Rescue treatment
899273|NCT02546986|CC-486
899274|NCT02546986|Azacitidine
899275|NCT02546986|Oral azacitidine
899276|NCT02546986|Methyltransferase inhibitor
899277|NCT02546986|Hypomethylation
899278|NCT02546986|Hypomethylating agent
899279|NCT02546986|Epigenetic
899280|NCT02546986|MK-3475
899281|NCT02546986|Pembrolizumab
899282|NCT02546986|Keytruda
899283|NCT02546986|PD-1
899284|NCT02546986|PD-L1
899285|NCT02546986|ImmunotherapyAdvanced non-small cell lung cancer
899286|NCT02546986|Metastatic non-small cell lung cancer
899287|NCT02546986|Non-small cell lung cancer
899288|NCT02546986|NSCLC
899289|NCT02546986|Merck Pembrolizumab (Keynote-117)
899290|NCT02546960|Healthy
899291|NCT02546960|JNJ-63871860
899292|NCT02546960|ExPEC4V
899293|NCT02546947|Respiratory Distress Syndrome, Adult
899294|NCT02546947|Neuromuscular Blocking Agents
899295|NCT02546947|Atracurium
899296|NCT02546947|Mechanical ventilation
899297|NCT02546947|ARDS
899298|NCT02546947|partial pressure of oxygen(PaO2) /inspired oxygen (FiO2) < 200
899299|NCT02546947|Positive End Expiratory Pressure (PEEP) > 5 since less than 48 hrs
899300|NCT02546934|triple negative breast cancer
899301|NCT02546934|fine line chemotherapy
899302|NCT02546921|IgE antibody
899303|NCT02546921|Folate receptor
899304|NCT02546921|Cancer Immunotherapy
899305|NCT02546921|First in class
899306|NCT02546908|Prostatic Neoplasms
899307|NCT02546908|Non-interventional
899308|NCT02546908|Observational
899309|NCT02546895|head and neck cancer patients
899310|NCT02546895|clinical data
899311|NCT02546895|tissue collection
899312|NCT02546895|prospective registration
899313|NCT02546895|patients
899314|NCT02546882|stromal vascular fraction
899315|NCT02546882|skin graft
899316|NCT02546843|rocuronium
899317|NCT02546843|sugammadex
899318|NCT02546843|pediatric anesthesia
899319|NCT02546843|cisatracurium
899320|NCT02546843|surgical conditions
899324|NCT02546778|Radio frequency
899325|NCT02546778|Female
899326|NCT02546778|Humans
899327|NCT02546778|Esthetics
899328|NCT02546765|analgesics
899329|NCT02546765|cardiac surgery
899330|NCT02546765|sedation
899331|NCT02546739|Leukemia
899332|NCT02546739|Lymphoma
899333|NCT02546739|CAR T
899334|NCT02546726|heat therapy
899335|NCT02546726|steam-room
899336|NCT02546726|aerobic exercise
899337|NCT02546726|hypertension
899338|NCT02546726|multiple behavior change
899339|NCT02546726|lifestyle modification
899340|NCT02546713|dental implants
899341|NCT02546687|Anastomotic Leak
899342|NCT02546687|Esophagectomy Gastric Pull-up
899343|NCT02546674|Chronic Myeloid Leukemia
899344|NCT02546674|Nilotinib
899345|NCT02546674|Molecular Response
899346|NCT02546674|MR4.5
899347|NCT02546661|AZD4547
899348|NCT02546661|MEDI4736
899349|NCT02546661|Durvalumab
899350|NCT02546661|Olaparib
899351|NCT02546661|AZD2281
899352|NCT02546661|AZD1775
899353|NCT02546661|Muscle invasive bladder cancer
899354|NCT02546661|MIBC
899355|NCT02546661|BISCAY
899356|NCT02546661|AZD2014
899357|NCT02546661|Vistusertib
899358|NCT02546622|Factor
899359|NCT02546622|Coagulation
899360|NCT02546622|Inhibitor
899361|NCT02546622|HTC
899362|NCT02546622|Bleeding
899363|NCT02546557|CABG
899364|NCT02546557|Coronary Artery Bypass Grafting
899365|NCT02546544|Linsitinib
899366|NCT02546544|anti-IGF-1R/IR
899367|NCT02546544|Ewing Sarcoma
899368|NCT02546544|dual IGF-1R/IR inhibition
899369|NCT02546544|Relapsed Ewing Sarcoma
899370|NCT02546544|Refractory Ewing Sarcoma
899371|NCT02546544|Metastatic Ewing Sarcoma
899372|NCT02546518|Conductive hearing loss
899373|NCT02546518|Middle ear effusion
899374|NCT02546518|Middle ear pressure equalization
899375|NCT02546505|Consumer behavior
899376|NCT02546505|Nutrition Labeling
899377|NCT02546479|Mortality
899378|NCT02546479|Radiation
899379|NCT02546479|Spine deformities
899380|NCT02546466|low back pain
899381|NCT02546466|functional taping
899382|NCT02546466|balance
899383|NCT02546466|posture
899384|NCT02546466|rehabilitation
899385|NCT02546466|psychosocial factors
899386|NCT02546466|minimal intervention strategy
899387|NCT02546453|high risk solid tumor pediatric, genetic alteration, Metastatic solid tumor pediatric
899388|NCT02546414|Platelet count/spleen diameter ratio
899389|NCT02546414|China
899390|NCT02546375|Bosutinib
899391|NCT02546375|chronic myeloid leukaemia
899392|NCT02546375|retrospective
899393|NCT02546375|observational
899394|NCT02546349|chronic obstructive pulmonary disease
899395|NCT02546349|airway inflammation
899396|NCT02546349|eosinophilic airway inflammation
899397|NCT02546349|exhaled nitric oxide
899398|NCT02546336|Ultrasound Guidance
899399|NCT02546336|Cooled Radiofrequency
899400|NCT02546336|Hip Denervation
899401|NCT02546323|Rosuvastatin 20 mg treatment, Carotid Intima-Media Thickness, Chinese subjects, Subclinical atherosclerosis
899402|NCT02546297|LAMA,ICS+LABA
899403|NCT02546284|CMML
899404|NCT02546258|Fungal Nail
899405|NCT02546232|locally advanced breast cancer
899406|NCT02546232|metastatic breast cancer
899407|NCT02546219|eosinophilic esophagitis
899408|NCT02546219|EoE
899409|NCT02546219|integrins
899410|NCT02546206|Bifidobacterium
899411|NCT02546206|Gingivitis
899412|NCT02546206|Gingival crevicular fluid
899413|NCT02546206|Interleukin-1beta
899414|NCT02546206|Probiotics
899415|NCT02546180|Patient education
899416|NCT02546180|Preoperative anxiety
899417|NCT02546154|Iron
899418|NCT02546154|Anaemia
899419|NCT02546154|Anaemia, Iron-Deficiency
899420|NCT02546154|Kidney Diseases
899421|NCT02546154|Inflammatory Bowel Diseases
899422|NCT02546154|Fatigue
899423|NCT02546076|Keloid
899424|NCT02546076|Hypertrophic scars
899425|NCT02546076|Er-YAG Lasers
899426|NCT02546050|Gut microbiota
899427|NCT02546050|metformin
899428|NCT02546050|Metabolism
899429|NCT02546050|Metagenomics
899430|NCT02546050|Metabolomics
899431|NCT02546037|coagulation
899432|NCT02546037|haemodialysis
899433|NCT02546024|Major depressive disorder
899434|NCT02546024|late-onset
899435|NCT02546024|treatment response
899436|NCT02546024|predictors
899437|NCT02546024|moderators
899438|NCT02545998|Telehealthcare
899439|NCT02545985|sirolimus
899440|NCT02545985|coronary stent
899441|NCT02545985|Prolim
899442|NCT02545972|immunosuppression
899443|NCT02545959|Intrathecal Rituximab
899444|NCT02545959|intrathecal chemotherapy
899445|NCT02545959|cerebrospinal fluid
899446|NCT02545959|lumbar puncture
899447|NCT02545959|Physiological Effects of Drugs
899448|NCT02545959|Rituximab
899449|NCT02545946|traditional incision and drainage
899572|NCT02545205|Rehabilitation
899450|NCT02545946|minimally invasive incision and drainage
899451|NCT02545946|vessel loop
899452|NCT02545946|emergency department
899453|NCT02545946|pediatrics
899454|NCT02545933|prasugrel
899455|NCT02545933|ticagrelor
899456|NCT02545933|vorapaxar
899457|NCT02545920|haemodialysis
899458|NCT02545920|hypotension
899459|NCT02545907|Amyloidosis
899460|NCT02545907|AL Amyloidosis
899461|NCT02545855|myAIRVO2
899462|NCT02545855|high-flow nasal cannula therapy
899463|NCT02545855|home oxygen therapy
899464|NCT02545855|HOT
899465|NCT02545790|coarctation of aorta
899466|NCT02545790|aortic stenosis
899467|NCT02545790|biomarkers
899468|NCT02545790|cardiac hypertrophy
899469|NCT02545777|Acute gouty arthritis
899470|NCT02545777|tonifying spleen and descending the turbid
899471|NCT02545777|soaking
899472|NCT02545777|wet wrapping
899473|NCT02545764|Gait Analysis
899474|NCT02545764|Knee Adduction Moment
899475|NCT02545764|Physiotherapy
899476|NCT02545764|Obesity
899477|NCT02545751|Esophageal cancer
899478|NCT02545751|Metastatic esophageal cancer
899479|NCT02545751|Radiotherapy
899480|NCT02545751|Thymalfasin
899481|NCT02545751|ZADAXIN's®
899482|NCT02545751|Stereotactic Body Radiation Therapy
899483|NCT02545725|Colorectal Cancer
899484|NCT02545725|Quality of life
899485|NCT02545725|Questionnaires
899486|NCT02545712|Ethanol
899487|NCT02545712|Propylene glycol
899488|NCT02545712|Benzyl alcohol
899489|NCT02545712|Acesulfam potassium
899490|NCT02545712|Aspartame
899491|NCT02545712|Glycerin
899492|NCT02545712|Sorbitol
899493|NCT02545712|Methyl-p-hydroxybenzoate
899494|NCT02545712|Propanyl-p-hydroxybenzoate
899495|NCT02545712|Patients
899496|NCT02545699|Adenoma
899497|NCT02545699|Polyp
899498|NCT02545699|CRC
899499|NCT02545699|Colonoscopy
899500|NCT02545699|Detection Yield
899501|NCT02545673|Intervention Studies
899502|NCT02545673|Access to Health Care
899503|NCT02545673|Social Stigma
899504|NCT02545673|Social Support
899505|NCT02545634|probiotic
899506|NCT02545634|ADHD
899507|NCT02545634|anxiety
899508|NCT02545634|digestive health
899509|NCT02545634|children
899510|NCT02545634|attention deficit
899511|NCT02545634|gut brain axis
899512|NCT02545634|nutritional supplement
899513|NCT02545634|microbiome
899514|NCT02545621|Receptor for advanced glycation end products (RAGE)
899515|NCT02545621|Acute respiratory distress syndrome (ARDS)
899516|NCT02545621|Monocyte/Macrophage activation
899517|NCT02545621|Fluorescence-Activated Cell Sorting (FACS) analysis
899518|NCT02545621|Thioredoxin interacting protein (TXNIP)
899519|NCT02545621|NOD-like receptor family, pyrin domain containing 3 (NLRP3)
899520|NCT02545621|Inflammasome
899521|NCT02545595|General anaesthesia
899522|NCT02545595|Curarization with rocuronium
899523|NCT02545556|Liver Cancer
899524|NCT02545556|HepaSphere
899525|NCT02545556|cryosurgery
899526|NCT02545530|renal dialysis
899527|NCT02545530|hypertension
899528|NCT02545530|clonidine
899529|NCT02545504|Gastroesophageal junction (GEJ)
899530|NCT02545504|Stomach cancer
899531|NCT02545491|CCD
899532|NCT02545491|Child development
899533|NCT02545491|daycare
899534|NCT02545491|caregiver
899535|NCT02545478|septic shock
899536|NCT02545478|infection
899537|NCT02545478|inflammation
899538|NCT02545478|pathologic process
899539|NCT02545478|biomarkers
899540|NCT02545465|Pulmonary Arterial Hypertension
899541|NCT02545465|Inoperable Chronic Thromboembolic Pulmonary Hypertension
899542|NCT02545465|Persistent Chronic Thromboembolic Pulmonary Hypertension
899543|NCT02545465|Recurrent Chronic Thromboembolic Pulmonary Hypertension
899544|NCT02545465|Switch of therapy
899545|NCT02545465|Titration phase
899546|NCT02545465|Retrospective chart review
899547|NCT02545439|Alkermes
899548|NCT02545439|Samidorphan
899549|NCT02545439|ALKS 5461
899550|NCT02545439|Healthy Volunteer
899551|NCT02545439|Pharmacokinetics
899552|NCT02545426|myocardial stunning
899553|NCT02545426|dialysate calcium concentration
899554|NCT02545426|nutritional status
899555|NCT02545426|hemodinamic
899556|NCT02545426|hemodialysis
899557|NCT02545374|chronic wound
899558|NCT02545374|tablet
899559|NCT02545374|telemedicine
899560|NCT02545374|wounds consultation
899561|NCT02545374|Smartphone
899562|NCT02545296|In-vitro Diagnostics
899563|NCT02545296|paediatrics
899564|NCT02545270|Surgery, Laparoscopic
899565|NCT02545270|surgical rating scale
899566|NCT02545257|Aged people
899567|NCT02545257|Home care
899568|NCT02545257|Drug related problems, DRPs
899569|NCT02545257|Coordinated medication management model
899570|NCT02545244|Gingivitis, Black Tea, Green Tea,Chlorhexidine, Biofilm,
899571|NCT02545218|Perineum. Perineorraphy. Pelvic floor exercise.
899573|NCT02545205|Robotics
899574|NCT02545192|PTSD
899575|NCT02545166|Stroke
899576|NCT02545166|Purines
899577|NCT02545166|SMARTChip
899578|NCT02545166|Ischaemia
899579|NCT02545166|Carotid endarterectomy
899580|NCT02545166|Biosensor
899581|NCT02545140|risk factors
899582|NCT02545140|screening
899583|NCT02545140|adolescents
899584|NCT02545127|inadequate milk production
899585|NCT02545114|Hyponatremia
899586|NCT02545114|SIADH, stroke
899587|NCT02545114|SAH; ICH
899588|NCT02545114|AIS
899589|NCT02545101|Hyponatremia due to SIADH
899590|NCT02545101|tolvaptan
899591|NCT02545088|Rehabilitation
899592|NCT02545088|Robotics
899593|NCT02545049|Type 2 Diabetes
899594|NCT02545049|Kidney diseases
899595|NCT02545036|chronic kidney disease
899596|NCT02545036|Daycare
899597|NCT02545036|Traditional Chinese Medicine(TCM)
899598|NCT02544984|prophylactic macrolides
899599|NCT02544984|RSV
899600|NCT02544984|chronic lung disease
899601|NCT02544984|respiratory infections
899602|NCT02544958|Enlarged pores
899603|NCT02544958|Er:YAG laser
899604|NCT02544945|Radiotherapy
899605|NCT02544932|anticoagulant
899606|NCT02544932|atherosclerosis
899607|NCT02544932|endothelium
899608|NCT02544919|SMOF
899609|NCT02544919|neurological complications
899610|NCT02544919|neurotoxicity
899611|NCT02544919|liver transplantation
899612|NCT02544919|Lipid emulsions
899613|NCT02544906|recipients
899614|NCT02544880|HNSCC
899615|NCT02544880|Head and Neck Squamous Cell Carcinoma
899616|NCT02544880|Tadalafil
899617|NCT02544880|PDE5 Inhibition
899618|NCT02544880|Anti-MUC1 Vaccine
899619|NCT02544880|Recurrent Head and Neck Squamous Cell Carcinoma
899620|NCT02544880|Recurrent HNSCC
899621|NCT02544880|Second primary site disease stage III
899622|NCT02544880|Second primary site disease stage IV
899623|NCT02544880|Anti-Influenza Vaccine
899624|NCT02544854|Pharmacokinetics, pharmacodynamics, propofol, pediatrics
899625|NCT02544828|Osteoarthritis
899626|NCT02544828|knee arthroplasty
899627|NCT02544828|iron
899628|NCT02544815|digoxin, eficacy, safety
899629|NCT02544776|pco
899630|NCT02544776|Amlodipine
899631|NCT02544737|Esophageal cancer
899632|NCT02544737|Metastatic esophageal cancer
899633|NCT02544737|Apatinib
899634|NCT02544724|Relapsed
899635|NCT02544724|Refractory
899636|NCT02544724|DLBCL
899637|NCT02544724|Chemotherapy
899638|NCT02544711|Pelvis
899639|NCT02544711|Surgical resection
899640|NCT02544711|Patient specific instrument
899641|NCT02544698|vaccine
899642|NCT02544698|safety
899643|NCT02544685|Febrile neutropenia
899644|NCT02544685|Synbiotic
899645|NCT02544685|Probiotic
899646|NCT02544685|Prebiotic
899647|NCT02544685|Safety
899648|NCT02544685|Cancer
899649|NCT02544685|Oncology
899650|NCT02544685|Chemotherapy
899651|NCT02544685|Symbiotic
899652|NCT02544659|Treatment
899653|NCT02544659|Bisphosphonates
899654|NCT02544659|Response rate
899655|NCT02544646|trabeculectomy
899664|NCT02544568|high fat
899665|NCT02544568|high protein
899666|NCT02544568|high carbohydrate
899667|NCT02544568|insulin
899668|NCT02544568|glucose
899669|NCT02544555|Peripheral arterial disease
899670|NCT02544555|Atherosclerosis
899671|NCT02544555|Intraluminal approach
899672|NCT02544555|Subintimal approach
899673|NCT02544542|Mild Hypothermia
899674|NCT02544542|Hypoxic-Ischemic Encephalopathy
899675|NCT02544516|Schizophrenia
899676|NCT02544516|motor and sensory perceptions
899677|NCT02544490|Sepsis
899678|NCT02544490|MicroRNAs
899679|NCT02544490|Diagnosis
899680|NCT02544490|Prognosis
899681|NCT02544464|osteoarthritis
899682|NCT02544464|knee arthroplasty
899683|NCT02544464|iron
899684|NCT02544412|Mindfulness
899685|NCT02544412|School Teachers
899686|NCT02544412|preservice teachers
899687|NCT02544412|teacher education
899688|NCT02544399|Bone microarchitecture
899689|NCT02544399|Playing golf
899690|NCT02544399|Walkers
899691|NCT02544386|bone microarchitecture
899692|NCT02544386|hemiplegia
899693|NCT02544373|OSA
899694|NCT02544373|Obstructive Sleep Apnea
899695|NCT02544373|Cognition
899696|NCT02544373|Cognitive Dysfunction
899697|NCT02544373|Memory
899698|NCT02544373|Positive Aiway Pressure
899699|NCT02544373|CPAP
899700|NCT02544373|MS
899701|NCT02544360|photoaging mobile apps
899702|NCT02544360|adolescent smoking
899703|NCT02544360|tobacco prevention
899704|NCT02544360|school-based prevention
899705|NCT02544360|adolescent health
899706|NCT02544360|school health
899707|NCT02544360|smoking
899708|NCT02544360|tobacco
899709|NCT02544347|vaspin
899710|NCT02544347|omentin
899711|NCT02544347|diabetes mellitus
899712|NCT02544347|chronic periodontitis
899713|NCT02544347|tumor-necrosis factor alfa
899714|NCT02544347|gingival crevicular fluid
899715|NCT02544334|Rheumatoid arthritis
899716|NCT02544334|Metagenome
899717|NCT02544334|microbiome
899718|NCT02544308|Solitary, Bone
899719|NCT02544282|Analgesics
899720|NCT02544282|Opioid
899721|NCT02544282|Mastectomy
899722|NCT02544282|Segmental Mastectomy
899723|NCT02544282|Pecs II
899724|NCT02544269|Lumbosacral plexus blockade
899725|NCT02544269|Continuous spinal anesthesia
899726|NCT02544269|Hemodynamics
899727|NCT02544256|Microcirculation
899728|NCT02544256|Mild Hypothermia, Induced
899729|NCT02544256|Subarachnoid Hemorrhage, Aneurysmal
899730|NCT02544256|Aneurysmal Clipping
899731|NCT02544256|Vasospasms
899732|NCT02544230|granulocyte transfusions
899733|NCT02544191|azoospermia nonobstructive
899734|NCT02544191|male infertility
899735|NCT02544178|radiotherapy
899736|NCT02544178|neurocognitive defect
899737|NCT02544178|leukoencephalopathy
899738|NCT02544165|smoking
899739|NCT02544165|caffeine intake
899740|NCT02544165|haemodynamic parameters
899741|NCT02544165|Advanced Glycation End Products (AGEs)
899742|NCT02544165|Non-invasive measurements devices
899743|NCT02544087|fire-heat syndrome
899744|NCT02544087|blood stasis syndrome
899745|NCT02544087|method of clearing heat
899746|NCT02544087|method of promoting blood circulation
899747|NCT02544048|Immune
899748|NCT02544048|Parasitemia
899749|NCT02544048|Menactra
899750|NCT02544048|Polymerase Chain Reaction (PCR)
899751|NCT02544048|Coartem
899752|NCT02544035|Childhood Growth and Development
899753|NCT02544035|Development
899754|NCT02544022|Pain Scale
899755|NCT02544022|QOL
899756|NCT02544022|Tool Validation
899757|NCT02544022|Cognitive Interviews
899758|NCT02544009|Energy Expenditure
899759|NCT02544009|Obesity
899760|NCT02544009|Behavioral Weight Loss Treatment
899761|NCT02543996|Sample Collection
899762|NCT02543996|Laboratory Research Specimens
899763|NCT02543996|Biospecimen Procurement
899764|NCT02543996|Rare Diseases
899765|NCT02543983|Neurobiology
899766|NCT02543983|Suicide
899767|NCT02543983|Ketamine
899768|NCT02543983|Major Depression Disorder
899769|NCT02543983|Biomarkers
899770|NCT02543957|ERCP
899771|NCT02543957|Cholangitis
899772|NCT02543957|Bacteremia
899773|NCT02543957|Antibiotics
899774|NCT02543931|turmeric
899775|NCT02543931|curcumin
899776|NCT02543931|curcuminoids
899777|NCT02543931|arthritis
899778|NCT02543931|methotrexate
899779|NCT02543892|Vaccine
899780|NCT02543879|AML
899781|NCT02543879|BET Inhibitor
899782|NCT02543879|FT-1101
899783|NCT02543879|Acute Leukemia
899784|NCT02543879|Myelodysplastic Syndrome
899785|NCT02543840|Quality Improvement
899786|NCT02543840|Organization of Services
899787|NCT02543840|Implementation
899788|NCT02543827|Vaccine
899789|NCT02543827|Recurrent Urinary Tract Infections (RUTI)
899790|NCT02543827|Female Urogenital Diseases and Pregnancy Complications
899791|NCT02543788|optic neuritis
899792|NCT02543788|vision
899793|NCT02543788|quality of life
899794|NCT02543788|pathophysiology
899795|NCT02543775|Cervical Cancer
899796|NCT02543775|Sentinel Lymph Node
899797|NCT02543775|Lymphadenectomy
899798|NCT02543762|Chromoendoscopy
899799|NCT02543762|Ulcerative Colitis
899800|NCT02543762|Crohn disease
899801|NCT02543762|Colorectal Neoplasia
899802|NCT02543749|CML
899803|NCT02543749|DC vaccine
899804|NCT02543723|medication adherence, telehealth strategies, nurse coaching
899805|NCT02543684|glycemic response
899806|NCT02543684|diabetes
899807|NCT02543684|insulinemic response
899808|NCT02543684|mixed meals
899809|NCT02543684|glycemic index
899810|NCT02543671|vitamin D status
899811|NCT02543671|25-hydroxyvitamin D
899812|NCT02543671|cheese
899813|NCT02543671|Randomized controlled trial
899814|NCT02543671|postmenopausal women
899815|NCT02543671|enriched
899816|NCT02543671|vitamin D3
899817|NCT02543658|Acute Pancreatitis
899818|NCT02543658|Intra-abdominal hypertension
899819|NCT02543658|Abdominal compartment syndrome
899820|NCT02543658|Curative Effect
899821|NCT02543658|Security
899822|NCT02543658|Neostigmine
899826|NCT02543593|tDCS
899827|NCT02543567|Ebola viruses
899828|NCT02543567|Ebola virus disease (EVD)
899829|NCT02543567|Filoviruses
899830|NCT02543567|Monovalent vaccine
899831|NCT02543567|Safety
899832|NCT02543567|Immunogenicity
899833|NCT02543567|Ebola vaccine
899834|NCT02543567|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
899835|NCT02543567|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector (MVA‐BN Filo)
899836|NCT02543567|Healthy participants
899837|NCT02543541|Palliative Care
899838|NCT02543541|Supportive Care
899839|NCT02543541|Caregiver
899840|NCT02543541|Phase I
899841|NCT02543515|following hysteroscopy
899842|NCT02543502|Periodontitis
899843|NCT02543502|atherosclerosis
899844|NCT02543502|Heart Disease
899845|NCT02543476|PD-L1 status, biomarkers, prevalence, SCCHN, overall survival
899846|NCT02543450|Chronic stroke
899847|NCT02543450|Participation
899848|NCT02543450|Walking ability
899849|NCT02543385|S Ketamine
899850|NCT02543385|Morphine
899851|NCT02543385|Consumption
899852|NCT02543372|concerned significant other
899853|NCT02543372|problem gambling
899854|NCT02543372|internet-delivered cognitive-behavioral therapy
899855|NCT02543372|behavioral couples therapy
899856|NCT02543359|Training
899857|NCT02543359|Implementation
899858|NCT02543359|Community-Based Mental Health Services
899859|NCT02543359|Parent-Child Interaction Therapy
899860|NCT02543359|Children
899861|NCT02543333|Acute Asthma,
899862|NCT02543320|Head and Neck Cancer
899863|NCT02543320|LORETA
899864|NCT02543320|Low Resolution Electromagnetic Tomography
899865|NCT02543320|Pain
899866|NCT02543320|Radiotherapy
899867|NCT02543320|Electroencephalograph
899868|NCT02543320|EEG
899869|NCT02543320|Questionnaires
899870|NCT02543320|Surveys
899871|NCT02543320|Neurofeedback training
899872|NCT02543307|Hip Replacement
899873|NCT02543307|Spinal Diseases
899874|NCT02543307|Rotator Cuff Reconstruction
899875|NCT02543307|Nursing
899876|NCT02543307|Nurse-led
899877|NCT02543307|Pathways
899878|NCT02543307|Patient Satisfaction
899879|NCT02543307|Quality of Nursing Care
899880|NCT02543294|Heart Failure
899881|NCT02543294|Echocardiogram
899882|NCT02543294|ECHO
899883|NCT02543294|Electrocardiogram
899884|NCT02543294|ECG
899885|NCT02543294|Questionnaire
899886|NCT02543294|Survey
899887|NCT02543294|Telephone Follow-Up
899888|NCT02543294|HF
899889|NCT02543294|Cancer treatment induced left ventricular dysfunction
899890|NCT02543294|CILVD
899891|NCT02543294|Left ventricular ejection fraction
899892|NCT02543294|LVEF
899893|NCT02543268|Ebola viruses
899894|NCT02543268|Ebola virus disease (EVD)
899895|NCT02543268|Filoviruses
899896|NCT02543268|Monovalent vaccine
899897|NCT02543268|Safety
899898|NCT02543268|Immunogenicity
899899|NCT02543268|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
899900|NCT02543268|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector (MVA‐BN Filo)
899901|NCT02543268|Healthy participants
899902|NCT02543255|High risk
899903|NCT02543242|Urinary Incontinence
899904|NCT02543242|Stress Urinary Incontinence
899905|NCT02543242|Urge Incontinence
899906|NCT02543242|Mixed Urinary Incontience
899907|NCT02543242|Female Pelvic Health
899908|NCT02543216|fatty acids, FADS gene, genotype, diet
899909|NCT02543203|Relaxation
899910|NCT02543190|Care Transition
899911|NCT02543190|Readmission
899912|NCT02543190|Rehospitalization
899913|NCT02543177|NSTEMI, CKD
899914|NCT02543164|Glycemic Index
899915|NCT02543164|glycemic response
899916|NCT02543151|Biliary stricture
899917|NCT02543151|Cholangioscopy
899918|NCT02543151|Spyglass
899919|NCT02543151|Liver transplant
899920|NCT02543125|very low birth weight
899921|NCT02543125|respiratory distress
899922|NCT02543125|NHFOV
899923|NCT02543125|NIPPV
899924|NCT02543099|endothelial function
899925|NCT02543099|policosanol
899926|NCT02543099|efficacy
899927|NCT02543099|safety
899928|NCT02543086|Phase 1, malaria, inoculum, P. falciparum, KAE609, Piperaquine
899929|NCT02543021|Colitis
899930|NCT02543021|Dysplasia
899931|NCT02543021|Chromoendoscopy
899932|NCT02543008|Asymptomatic individuals
899933|NCT02542982|tDCS
899934|NCT02542982|motor recovery
899935|NCT02542956|Tummy tuck (abdominoplasty)
899936|NCT02542956|Breast Surgery
899937|NCT02542930|Non-small cell lung cancer
899938|NCT02542930|Metastatic Non-small cell lung cancer
899939|NCT02542930|Radiotherapy
899940|NCT02542930|Thymalfasin
899941|NCT02542930|ZADAXIN's®
899942|NCT02542891|e-health
899943|NCT02542891|depressive disorder
899944|NCT02542891|cost-effectiveness
899945|NCT02542891|Cognitive behavioral treatment
899946|NCT02542878|myofascial release
899947|NCT02542878|back extensors endurance
899948|NCT02542878|foam roller
899949|NCT02542878|sport
899950|NCT02542852|HIV-1
899951|NCT02542839|Botulinum Toxin
899952|NCT02542839|Transcranial Magnetic Stimulation
899953|NCT02542826|Pulmonary Rehabilitation
899954|NCT02542826|3-minute constant rate shuttle walk test
899955|NCT02542826|3-minute constant rate step test
899956|NCT02542826|Dyspnea
899957|NCT02542813|Pharmacokinetics
899958|NCT02542813|safety
899959|NCT02542813|tolerability
899960|NCT02542813|oxytocin
899961|NCT02542787|MS
899962|NCT02542787|Spasticity
899963|NCT02542787|VSN16R
899964|NCT02542774|Diabetes mellitus
899965|NCT02542774|Stroke
899966|NCT02542774|Myocardial infarction
899967|NCT02542774|Stable angina pectoris
899968|NCT02542774|Heart failure
899969|NCT02542774|Quality of care
899970|NCT02542748|norepinephrine
899971|NCT02542748|ephedrine
899972|NCT02542722|lifestyle modification
899973|NCT02542722|olive oil
899974|NCT02542722|Mediterranean diet
899975|NCT02542683|congenital heart diseases
899976|NCT02542683|cognition
899977|NCT02542683|adaptive behavior
899978|NCT02542683|physical activity
899979|NCT02542683|neurodevelopment
899980|NCT02542644|Fuchs' Endothelial Dystrophy, DMEK
899981|NCT02542618|Depression
899982|NCT02542618|Treatment
899983|NCT02542618|IBSR
899984|NCT02542618|CBT
899985|NCT02542605|Migraine
899986|NCT02542605|Headache
899987|NCT02542605|Migraine Headache
899988|NCT02542605|Headache, Migraine
899989|NCT02542605|Amgen
899990|NCT02542592|Glucocorticoids
899991|NCT02542592|Immune Signaling
899992|NCT02542592|Recovery
899993|NCT02542592|Hip arthroplasty, total
899994|NCT02542540|Osteogenesis Imperfecta
899995|NCT02542540|physical exercise training
899996|NCT02542540|Wii
899997|NCT02542540|muscular strength
899998|NCT02542514|PCNSL
899999|NCT02542514|IOL
900000|NCT02542462|mechanisms for intussusception
900001|NCT02542462|rotavirus vaccine
900002|NCT02542449|Green tea
900003|NCT02542449|weight maintenance
900004|NCT02542449|obesity
900005|NCT02542449|fat mass
900006|NCT02542384|abdominal surgery
900007|NCT02542384|laparoscopy
900008|NCT02542384|Hysterectomy
900009|NCT02542384|Prostatectomy
900010|NCT02542384|Hemi-colectomy
900011|NCT02542384|Ventral Hernia repair
900012|NCT02542384|CR845
900013|NCT02542384|analgesic
900014|NCT02542384|kappa opioid
900015|NCT02542384|partial bowel resection
900016|NCT02542371|HIV
900017|NCT02542371|Atherosclerosis
900018|NCT02542371|Tilmanocept
900019|NCT02542345|Cardiac Multislice CT
900020|NCT02542345|MRI coronarography
900021|NCT02542332|lung cancer screening
900022|NCT02542332|statistical background
900023|NCT02542306|Blood loss
900024|NCT02542306|coagulopathy
900025|NCT02542306|fibrinogen concentrate
900026|NCT02542306|transfusion
900027|NCT02542293|NSCLC
900028|NCT02542293|PDL1
900029|NCT02542293|MEDI4736
900030|NCT02542293|Durvalumab
900031|NCT02542293|Tremelimumab
900032|NCT02542293|OS
900033|NCT02542267|Bare Metal Stent
900034|NCT02542267|In-Stent Restenosis
900035|NCT02542241|Open abdomen
900036|NCT02542241|hypertonic saline solution
900037|NCT02542241|intensive care
900038|NCT02542228|Immune Deficiency, antibody
900039|NCT02542228|Quality of Life survey
900040|NCT02542176|Metabolic Syndrome
900041|NCT02542176|Grape
900042|NCT02542176|HDL
900043|NCT02542176|Lipoproteins
900044|NCT02542137|Small cell lung cancer
900045|NCT02542137|Metastatic small cell lung cancer
900046|NCT02542137|ZADAXIN
900047|NCT02542137|radiotherapy
900048|NCT02542137|Thymalfasin
900049|NCT02542124|CTCL
900050|NCT02542124|Total Skin Electron Beam Therapy (TSEBT)
900051|NCT02542124|Mycosis fungoides
900052|NCT02542124|Sézary syndrome
900053|NCT02542124|recombinant human Interleukin-12 (rHuIL-12)
900054|NCT02542124|T Cell
900055|NCT02542111|diffuse large b-cell lymphoma
900056|NCT02542085|incisional hernia
900057|NCT02542085|laparoscopic repair
900058|NCT02542085|hybrid repair
900059|NCT02542085|seroma
900060|NCT02542085|recurrent hernia
900061|NCT02542033|postprandial glycemia; apple juice; sugar reduction; glucose oxidase
900062|NCT02542007|intracoronary stent
900063|NCT02542007|drug eluting stent
900064|NCT02542007|sirolimus
900065|NCT02542007|endothelial progenitor cells
900066|NCT02541981|Heart transplant
900067|NCT02541981|renal insufficiency
900068|NCT02541955|Rheumatoid arthritis (RA)
900069|NCT02541955|Musculoskeletal ultrasound (MSUS)
900070|NCT02541929|Alzheimer's disease
900071|NCT02541929|Docosahexaenoic acid
900072|NCT02541929|brain health
900073|NCT02541929|memory
900074|NCT02541929|fish oil
900075|NCT02541929|cognition
900076|NCT02541929|DHA
900077|NCT02541929|omega 3 fatty acid
900078|NCT02541929|brain
900079|NCT02541916|Transplantation Tolerance
900080|NCT02541916|Immune Tolerance
900081|NCT02541916|Transplantation
900082|NCT02541916|Liver Transplantation
900083|NCT02541916|Biological Markers
900084|NCT02541916|Gene Expression
900085|NCT02541916|Immunosuppression
900086|NCT02541916|Immunology
900087|NCT02541916|Multiplex Polymerase Chain Reaction
900088|NCT02541916|Real-Time Polymerase Chain Reaction
900093|NCT02541890|Rehabilitation
900094|NCT02541890|Return to Work
900095|NCT02541864|Helicobacter pylori
900096|NCT02541864|Hybrid therapy
900097|NCT02541864|Bismuth containing quadruple therapy
900098|NCT02541864|Eradication
900099|NCT02541838|Autonomic Neuropathy
900100|NCT02541838|diabetes
900101|NCT02541838|balance control
900102|NCT02541825|transjugular intrahepatic portosystemic shunt
900103|NCT02541812|Obsessive-Compulsive Disorder
900104|NCT02541812|Transcranial Magnetic Stimulation
900105|NCT02541812|Error processing
900106|NCT02541799|informed consent
900107|NCT02541799|telemedicine
900108|NCT02541799|research methods
900109|NCT02541786|dexlansoprazole MR
900110|NCT02541786|rabeprazole
900111|NCT02541786|Helicobacter pylori
900112|NCT02541786|triple therapy
900113|NCT02541773|Chronic Heart Failure
900114|NCT02541773|Cardiac Resynchronization Therapy
900115|NCT02541773|Vascular Biomarker
900116|NCT02541773|miRNA
900117|NCT02541773|Extracellular Matrix
900118|NCT02541773|Brain Natruetic Peptide
900119|NCT02541773|Growth Degradation Factor-15
900120|NCT02541773|Body Composition
900121|NCT02541734|SPECT
900122|NCT02541734|radiopeptides
900123|NCT02541734|gelofusine
900124|NCT02541734|Beta cell
900125|NCT02541695|Experimental challenge trial
900126|NCT02541669|Drug therapy
900127|NCT02541656|Preload dependence indices
900128|NCT02541656|pulse pressure variation
900129|NCT02541656|plethysmographic waveform of pulse oximetry variation
900130|NCT02541656|stroke volume variation
900131|NCT02541656|laparoscopy
900132|NCT02541656|pneumoperitoneum
900133|NCT02541643|Relapsed/Refractory Multiple Myeloma
900134|NCT02541630|Mindfulness
900135|NCT02541591|post cardiac arrest
900136|NCT02541591|hemodynamics
900137|NCT02541578|stroke, acute; gait, complexity
900138|NCT02541552|Knee arthroscopy
900139|NCT02541552|Quadriceps weakness
900140|NCT02541552|ropivacaine
900141|NCT02541552|saphenous nerve block
900142|NCT02541552|Adductor canal
900143|NCT02541526|amphetamine type stimulant dependence
900144|NCT02541526|mirtazepine
900145|NCT02541513|paliparidone
900146|NCT02541513|amphetamine type stimulant dependence
900147|NCT02541500|minocycline
900148|NCT02541500|amphetamine type stimulant dependence
900149|NCT02541474|Controlled trial
900150|NCT02541474|Matched
900151|NCT02541474|Before-After design
900152|NCT02541474|Prospective
900153|NCT02541474|complex interventions
900154|NCT02541461|Procedure: Laparoscopic gastrectomy with Billroth I
900155|NCT02541461|Procedure: Laparoscopic gastrectomy with Roux-en-Y
900156|NCT02541461|Other: Body composition measurement
900157|NCT02541461|Other: Lipid profile
900158|NCT02541435|Radiotherapy
900159|NCT02541435|Biological markers
900160|NCT02541435|Magnetic resonance imaging
900161|NCT02541435|Echocardiography
900162|NCT02541435|Tomography, X-Ray Computed
900163|NCT02541435|Risk factors
900164|NCT02541435|Heart
900165|NCT02541435|Quality of Life
900166|NCT02541409|directly observed therapy
900167|NCT02541409|sofosbuvir
900168|NCT02541409|ribavirin
900169|NCT02541409|pegylated interferon
900170|NCT02541409|resource-limited setting
900171|NCT02541396|Bunion
900172|NCT02541396|Bunionectomy
900173|NCT02541383|Untreated Multiple Myeloma
900174|NCT02541383|daratumumab
900175|NCT02541357|Colorectal Surgery
900176|NCT02541331|IgE-dependent asthma
900177|NCT02541318|peri-menopausal women
900178|NCT02541318|sleep disturbances
900179|NCT02541318|Dao-in exercise
900180|NCT02541318|body constitution
900181|NCT02541305|falls prevention
900182|NCT02541305|proprioception
900183|NCT02541305|physical condition
900184|NCT02541266|Imaging
900185|NCT02541266|Questionnaire
900186|NCT02541240|resilience
900187|NCT02541240|optimism
900188|NCT02541240|stress
900189|NCT02541240|coping
900190|NCT02541240|curriculum
900191|NCT02541201|Plant sterols
900192|NCT02541201|Low-Density Lipoprotein Cholesterol
900193|NCT02541201|Phytosterols
900194|NCT02541188|Breast cancer
900195|NCT02541175|Electrocardiography
900196|NCT02541175|Automation
900197|NCT02541175|Arrhythmias, Cardiac
900198|NCT02541175|Atrial Fibrillation
900199|NCT02541175|Atrial Flutter
900200|NCT02541175|Atrial Premature Complexes
900201|NCT02541175|Esophagus
900202|NCT02541136|exercise
900203|NCT02541136|resilience
900204|NCT02541136|physiotherapy
900205|NCT02541136|fMRI
900206|NCT02541123|Traumatic Brain Injury
900207|NCT02541123|Head Injury
900208|NCT02541084|Age-related macular degeneration
900209|NCT02541084|Caregiver burden
900210|NCT02541084|Anti-vascular endothelial growth factor (VEGF) therapy
900338|NCT02540382|Portasystemic Shunt
900211|NCT02541058|Velocardiofacial Syndrome
900212|NCT02541058|Shprintzen Syndrome
900213|NCT02541058|Conotruncal Defects
900214|NCT02541058|Chromosomal Abnormalities
900215|NCT02541058|22q, 22q.11.2
900216|NCT02541058|deletion
900217|NCT02541058|duplication
900218|NCT02541045|non-alcoholic steatohepatitis
900219|NCT02541045|metadoxine
900220|NCT02541045|efficacy
900221|NCT02541045|therapy
900222|NCT02541019|C23.888.821.712.700
900223|NCT02541006|FEV1
900224|NCT02541006|FVC
900225|NCT02541006|AUC 0-24
900226|NCT02541006|bronchodilator efficacy
900227|NCT02541006|tiotropium
900228|NCT02540993|Type 2 Diabetes
900229|NCT02540993|Kidney diseases
900230|NCT02540967|Contrast enhancement in the following MR imaging
900231|NCT02540967|Brain and spine
900232|NCT02540967|Body and extremities
900233|NCT02540967|Gadobutrol
900234|NCT02540954|Age-related macular degeneration (AMD)
900235|NCT02540954|Eylea treatment
900236|NCT02540954|Treat and Extend
900237|NCT02540954|Intravitreal
900238|NCT02540902|Knee replacement
900239|NCT02540902|Knee arthroplasty
900240|NCT02540902|All-polyethylene tibia
900241|NCT02540902|Bone density
900242|NCT02540863|myofascial pain syndrome
900243|NCT02540863|exercise therapy
900244|NCT02540863|randomized controlled trial
900245|NCT02540850|septin 9
900246|NCT02540850|SEPT9
900247|NCT02540850|colorectal cancer
900248|NCT02540850|CRC
900249|NCT02540850|screening
900250|NCT02540850|methylation
900251|NCT02540850|adenoma
900252|NCT02540850|polyps
900253|NCT02540850|FIT
900254|NCT02540850|FOBT
900255|NCT02540850|colonoscopy
900256|NCT02540824|Apatinib
900257|NCT02540824|RET
900258|NCT02540824|gene fusion
900259|NCT02540824|Non-small Cell Lung Cancer
900260|NCT02540798|Anxiety
900261|NCT02540798|Urodynamics
900262|NCT02540798|Symptom reproducibility
900263|NCT02540798|Lower urinary tract symptoms
900264|NCT02540798|Women
900265|NCT02540785|Refractive Surgical Procedures
900266|NCT02540785|small-incision lenticule extraction
900267|NCT02540785|lenticule extraction
900268|NCT02540785|inflammatory mediators
900269|NCT02540772|Confabulations
900270|NCT02540772|Neuropsychological rehabilitation
900271|NCT02540772|Memory
900272|NCT02540759|Buglossoides arvensis
900273|NCT02540759|vegetable oil
900274|NCT02540759|omega-3 fatty acids
900275|NCT02540759|participants
900276|NCT02540746|Emotional Dysregulation
900277|NCT02540746|Early Intervention
900278|NCT02540746|Youth Mental Health
900279|NCT02540746|Staging
900280|NCT02540746|Motivational Enhancement
900281|NCT02540746|Family Connections
900282|NCT02540746|Family Skills Training
900283|NCT02540733|cerebral infarction
900284|NCT02540733|diabetes
900285|NCT02540733|rehabilitation
900286|NCT02540733|MRI
900287|NCT02540681|Transtibial amputation
900288|NCT02540681|Prosthetic fit
900289|NCT02540681|Prosthetic alignment
900290|NCT02540655|Stem Cells
900291|NCT02540655|Adult Stem Cells
900292|NCT02540655|Spinocerebellar Ataxia
900293|NCT02540655|Steminent
900294|NCT02540629|Cardiopulmonary resuscitation
900295|NCT02540629|Emergency Medicine
900296|NCT02540616|MdDS
900297|NCT02540616|TES
900298|NCT02540616|TMS
900299|NCT02540590|microcirculation
900300|NCT02540590|wound healing
900301|NCT02540590|tunnel technique
900302|NCT02540590|gingival recession
900303|NCT02540590|Mucograft
900304|NCT02540590|laser speckle contrast analyzer
900305|NCT02540538|Adjuvants, immunologic
900306|NCT02540538|Interleukin-2
900307|NCT02540538|Hepatitis B vaccines
900308|NCT02540538|Non-responders
900309|NCT02540525|stress incontinence
900310|NCT02540525|transobturator sling
900311|NCT02540525|single-incision mini-sling
900312|NCT02540499|lung cancer
900313|NCT02540499|breath hold
900314|NCT02540499|radiotherapy
900315|NCT02540486|Type 2 diabetes
900316|NCT02540486|T2DM
900317|NCT02540473|Resilience
900318|NCT02540447|Liver transplantation
900319|NCT02540447|Graft rinse
900320|NCT02540447|Ischemia reperfusion injury
900321|NCT02540434|Hypofibrinogenemia
900322|NCT02540434|ROTEM
900323|NCT02540434|Cardiac Surgery
900324|NCT02540434|Concentrated Fibrinogen
900325|NCT02540421|cervical intraepithelial neoplasia
900326|NCT02540421|human papillomavirus
900327|NCT02540421|conization
900328|NCT02540408|Occupational COPD
900329|NCT02540408|Pathophysiology
900330|NCT02540408|Exercise limitation
900331|NCT02540408|Pulmonary hyperinflation
900332|NCT02540408|Arterial stiffness
900333|NCT02540395|Kidney transplantation
900334|NCT02540395|Immunosuppression
900335|NCT02540395|IFN-γ
900336|NCT02540382|TIPS
900337|NCT02540382|Hepatocellular Carcinoma
900341|NCT02540343|Translation
900342|NCT02540343|Validation
900343|NCT02540343|Orebro-G
900344|NCT02540291|E7046
900345|NCT02540291|Advanced malignancies
900346|NCT02540291|malignancies
900347|NCT02540265|Bunion
900348|NCT02540265|Bunionectomy
900349|NCT02540265|Pain
900350|NCT02540265|Analgesia
900351|NCT02540265|N1539
900352|NCT02540252|Lower Limb Amputation
900353|NCT02540252|Nutrition
900354|NCT02540252|Eating
900355|NCT02540252|Inflammation
900356|NCT02540252|Nursing
900357|NCT02540226|Tranexamic Acid
900358|NCT02540226|Total Knee Arthroplasty
900359|NCT02540226|Total Knee Replacement
900360|NCT02540187|haemophilia
900361|NCT02540187|TFPI
900362|NCT02540187|thrombin generation
900363|NCT02540187|hemorrhagic score
900364|NCT02540174|alcohol and tobacco consumption
900365|NCT02540174|addiction treatment
900366|NCT02540161|Sym004
900367|NCT02540161|Glioblastoma
900368|NCT02540161|Desjardins
900369|NCT02540161|Pro00063483
900370|NCT02540161|Symphogen
900371|NCT02540161|Duke Cancer Institute
900372|NCT02540135|high grade glioma
900373|NCT02540135|glioblastoma multiforme
900374|NCT02540135|anaplastic astrocytoma
900375|NCT02540135|flourescein
900376|NCT02540135|flourescence-guided surgery
900377|NCT02540135|intraoperative MRI
900378|NCT02540135|iMRI
900379|NCT02540109|Stroke
900380|NCT02540109|Anomia
900381|NCT02540096|mental practice
900382|NCT02540096|motor imagery
900383|NCT02540096|hemiparesis
900384|NCT02540096|stroke
900385|NCT02540096|gait
900386|NCT02540096|mobility
900387|NCT02540070|Adductor canal Block
900388|NCT02540070|ultrasound
900389|NCT02540070|periarticular injections
900390|NCT02540070|Dexmedetomidine
900391|NCT02540018|DEB, drug-eluting balloon, Paclitaxel, peripheral artery disease
900392|NCT02539979|IV Paracetamol
900393|NCT02539979|Radiofrequency Lesion/Ablation of medial branch nerve
900394|NCT02539979|Preventative Pain Management
900395|NCT02539940|Below-the-knee
900396|NCT02539914|Virtual reality
900397|NCT02539914|Motor and cognitive rehabilitation
900398|NCT02539914|Positive emotion stimuli
900399|NCT02539901|cochlear implant
900400|NCT02539901|Developmental Psychology
900401|NCT02539901|cognitive development
900402|NCT02539901|communicative development
900403|NCT02539901|perceptual development
900404|NCT02539901|deaf child
900405|NCT02539875|Effectiveness of quit immediately (QI) and cut down to quit (CDTQ) interventions in achieving smoking abstinence
900406|NCT02539862|Insomnia
900407|NCT02539862|behavioral and cognitive therapies
900408|NCT02539836|children's obesity
900409|NCT02539836|gut microbiome
900410|NCT02539836|body mass index
900411|NCT02539836|fruit and vegetable fermentation extraction
900412|NCT02539836|dietary nutrition intervention
900413|NCT02539784|stimulation
900417|NCT02539758|acute angle closure
900418|NCT02539758|ocular massage
900419|NCT02539745|vitamin D
900420|NCT02539745|primary open- angle glaucoma
900421|NCT02539732|Weaning
900422|NCT02539732|Spontaneous breathing trial
900423|NCT02539732|Neurally-adjusted ventilator assist
900424|NCT02539732|Electrical activity of the diaphragm
900425|NCT02539719|Platinum-Resistant
900426|NCT02539719|Refractory
900427|NCT02539680|Phosphate transporter
900428|NCT02539680|CKD
900429|NCT02539680|duodenal biopsies
900430|NCT02539602|High school
900431|NCT02539602|Longitudnal
900432|NCT02539602|Sexual initiation
900433|NCT02539602|Contraception
900434|NCT02539602|Adolescents
900435|NCT02539602|Pregnancy prevention
900436|NCT02539602|Sexual health
900437|NCT02539576|pharmacokinetics
900438|NCT02539576|Healthy subjects
900439|NCT02539576|Abacavir/dolutegravir/lamivudine
900440|NCT02539576|Japanese
900441|NCT02539576|Fixed-dose combination
900442|NCT02539576|safety
900443|NCT02539563|labor duration
900444|NCT02539550|PF-06266047
900445|NCT02539550|safety
900446|NCT02539550|tolerability
900447|NCT02539550|pharmacokinetics
900448|NCT02539550|first-in-human
900449|NCT02539550|healthy volunteers
900450|NCT02539550|PDE4
900451|NCT02539550|phosphodiesterase-4
900452|NCT02539537|locally advanced pancreatic carcinoma
900453|NCT02539537|FOLFIRINOX
900454|NCT02539524|clinical impact
900455|NCT02539524|anxiety
900456|NCT02539524|quality of life
900457|NCT02539524|Yoga
900458|NCT02539498|Primary Hyperparathyroidism
900459|NCT02539498|Parathyroid Hormone
900460|NCT02539498|High-Resolution peripheral Quantitative Computed Tomography
900461|NCT02539498|Bone densitometry
900462|NCT02539498|Bone microarchitecture
900463|NCT02539446|Aging
900464|NCT02539446|External focus
900465|NCT02539446|Internal focus
900466|NCT02539446|Attention
900467|NCT02539446|Posture balance
900468|NCT02539446|Parkinson's disease
900469|NCT02539407|β-lactam antibiotics
900470|NCT02539407|Children
900471|NCT02539407|Anti-infectives
900472|NCT02539407|Aminoglycosides, glycopeptides
900473|NCT02539407|Fluoroquinolone
900474|NCT02539407|Fungal
900475|NCT02539407|Antiviral
900476|NCT02539394|Anterior Cervical Discectomy and Fusion
900477|NCT02539394|Dysphagia
900478|NCT02539394|ACDF
900479|NCT02539368|Infliximab
900480|NCT02539368|Observational
900481|NCT02539368|Follow-up
900482|NCT02539368|Safety
900483|NCT02539368|Effectiveness
900484|NCT02539355|Insulin resistance
900485|NCT02539355|Diabetes
900486|NCT02539355|Cancer
900487|NCT02539355|Obesity
900488|NCT02539355|Inflammation
900489|NCT02539342|Oral Mucositis
900490|NCT02539342|Cancer
900491|NCT02539342|Chemotherapy
900492|NCT02539329|neuropathy
900493|NCT02539329|antibodies antiFGFR3
900494|NCT02539329|Biological diagnostic criteria
900495|NCT02539316|Parenteral Nutrition
900496|NCT02539290|Unexplained infertility
900497|NCT02539290|Infertility
900498|NCT02539290|Tubal flushing
900499|NCT02539290|Uterine flushing
900500|NCT02539290|Live birth
900501|NCT02539290|Pregnancy
900502|NCT02539290|Randomized controlled trial
900503|NCT02539290|Saline
900504|NCT02539290|Physiological saline
900505|NCT02539264|All patients registered for A PSG
900506|NCT02539264|polysomnography
900507|NCT02539251|Early Child Development
900508|NCT02539251|Ages and Stages Questionnaire _3
900509|NCT02539251|Validation
900510|NCT02539238|Medical Education
900511|NCT02539238|cardiopulmonary resuscitation
900512|NCT02539238|feedback
900513|NCT02539238|cost-effectiveness analysis
900514|NCT02539212|microwave
900515|NCT02539212|radiofrequency
900516|NCT02539212|ablation
900517|NCT02539160|coronary artery disease
900518|NCT02539160|diabetes mellitus
900519|NCT02539160|chronic kidney disease
900520|NCT02539160|ticagrelor
900521|NCT02539147|lipopolysaccharide
900522|NCT02539147|sepsis
900523|NCT02539147|caspase-4 and -5
900524|NCT02539147|monocytes
900525|NCT02539147|IL-1β and IL-1α
900526|NCT02539134|Drug therapy
900527|NCT02539121|Labor
900528|NCT02539121|Acupuncture
900529|NCT02539121|Postpartum hemorrhage
900530|NCT02539121|Placental expulsion time
900531|NCT02539121|Postpartum blood loss
900532|NCT02539108|Influenza
900533|NCT02539108|Influenza virus vaccine
900534|NCT02539108|Fluzone® Quadrivalent Influenza Vaccine (No Preservative)
900535|NCT02539095|intra-articular injection
900536|NCT02539095|intra-articular collagen injection
900537|NCT02539095|collagen
900538|NCT02539095|knee joint pain
900539|NCT02539082|collagen
900540|NCT02539082|collagen injection
900541|NCT02539082|plantar fasciitis
900542|NCT02539069|cartilage defects
900543|NCT02539069|Chondron
900544|NCT02539069|Autologous cultured Chondrocyte
900545|NCT02539069|arthroscopy
900546|NCT02539056|cartilage defects
900547|NCT02539056|Chondron
900548|NCT02539056|Autologous cultured Chondrocyte
900549|NCT02539043|Lipolysis
900550|NCT02539043|Subcutaneous Fat, Abdominal/metabolism
900551|NCT02539043|Subcutaneous Fat, Abdominal/ultrasonography
900552|NCT02539043|High-Intensity Focused Ultrasound Ablation/methods
900553|NCT02539043|Waist Circumference
900554|NCT02539043|Pilot Projects
900555|NCT02539043|Subcutaneous Fat
900556|NCT02539043|High-Intensity Focused Ultrasound Ablation
900557|NCT02539043|Adiposity
900558|NCT02539030|Cartilage defect of knee
900559|NCT02539030|microfracture
900560|NCT02539030|modified microfracture
900561|NCT02539030|collagen
900562|NCT02539017|cellular immune therapy
900563|NCT02539017|triple negative breast cancer
900564|NCT02539017|adjuvant therapy
900565|NCT02539004|kidney stones
900566|NCT02539004|ureteral stones
900567|NCT02538991|Bulkamid
900568|NCT02538991|Tension-Free Vaginal Tape
900569|NCT02538991|Women
900570|NCT02538978|CLI
900571|NCT02538965|Lenalidomide
900572|NCT02538965|Revlimid
900573|NCT02538965|Pediatric
900574|NCT02538965|Relapsed or Refractory
900575|NCT02538965|Acute Myeloid Leukemia
900576|NCT02538965|Leukemia
900577|NCT02538952|GeneXpert
900578|NCT02538952|Tuberculosis
900579|NCT02538952|Human immunodeficiency virus
900580|NCT02538952|Diagnostic accuracy
900581|NCT02538952|Impact
900582|NCT02538939|Calcific tendinitis, Shoulder, Needle lavage, Sodium thiosulfate
900583|NCT02538913|Exercise
900584|NCT02538913|Pelvic floor
900585|NCT02538913|Prehabilitation
900586|NCT02538913|Fecal incontinence
900587|NCT02538913|Urinary incontinence
900588|NCT02538913|Sexual dysfunction, physiological
900589|NCT02538900|peripheral arterial disease, peripheral artery disease, PAD, exercise
900590|NCT02538822|aortic aneurysm
900591|NCT02538822|thoracic ascending aorta
900592|NCT02538822|ATA
900593|NCT02538822|dynamic imaging
900594|NCT02538822|mechanical testing
900595|NCT02538796|Anorexia Nervosa
900596|NCT02538796|Cognition
900597|NCT02538796|Conscious
900598|NCT02538796|Non-Conscious
900599|NCT02538757|Vaccine Administration
900600|NCT02538757|Herpes Zoster
900601|NCT02538705|Diabetic foot syndrome
900602|NCT02538705|Ulcers
900603|NCT02538679|transversus abdominis plane block
900604|NCT02538679|tap block
900605|NCT02538679|regional anesthesia
900606|NCT02538679|colorectal surgery
900607|NCT02538653|glycemic & insulin response, SDS, cereal product, Nutrition
900608|NCT02538640|Nutrition, glycemic response, cereal products
900609|NCT02538627|Heregulin-positive
900610|NCT02538627|EGFR
900611|NCT02538627|ErbB3
900612|NCT02538627|Phase I
900613|NCT02538627|Oncology
900614|NCT02538627|Cancer
900615|NCT02538601|Post Traumatic Stress Disorder
900616|NCT02538601|PTSD
900617|NCT02538601|Cigarette Smoking
900618|NCT02538601|Lower Respiratory Symptoms
900619|NCT02538601|Cognitive Behavioral Therapy
900620|NCT02538601|CBT
900621|NCT02538601|Transdiagnostic Treatments
900622|NCT02538601|World Trade Center
900623|NCT02538588|Healthy Volunteers
900624|NCT02538575|Cystic Fibrosis
900625|NCT02538575|Adults
900626|NCT02538575|6-minute walk test
900627|NCT02538497|NBO
900628|NCT02538497|The Newborn Behavioral Observation
900629|NCT02538497|postpartum depression
900630|NCT02538497|postnatal depression
900631|NCT02538497|attachment
900632|NCT02538458|Saline Solution, Hypertonic (3 %)
900633|NCT02538458|Infant
900634|NCT02538445|Schizophrenia
900635|NCT02538445|Memory
900636|NCT02538445|Cognition
900637|NCT02538432|Disease Progression
900638|NCT02538432|Non-Responsive Disease
900639|NCT02538432|Advanced Disease
900640|NCT02538406|Adenoma
900641|NCT02538406|withdrawal time
900642|NCT02538406|Colonoscopy
900643|NCT02538380|Lung cancer
900644|NCT02538380|Adrenal gland metastasis
900645|NCT02538354|Riboflavin (vitamin B2)
900646|NCT02538354|Faecalibacterium prausnitzii
900647|NCT02538328|laparoscopy
900648|NCT02538328|obesity
900649|NCT02538328|harmonic scalpel
900650|NCT02538328|ligasure
900651|NCT02538315|[18F]FODPA, Parkinson's, PET/CT, Stem Cell transplantation
900652|NCT02538302|Minirin
900653|NCT02538302|Oxybutynin
900654|NCT02538302|Nocturnal enuresis
900655|NCT02538289|Dyspnea
900656|NCT02538289|Palliative Care
900657|NCT02538289|Heart Failure
900658|NCT02538289|Chronic Pulmonary Disease
900659|NCT02538289|Opioids
900660|NCT02538276|carotid endarterectomy, carotid stenosis, carotid stenting
900661|NCT02538250|Oral nutritional supplement
900662|NCT02538250|supplementation
900663|NCT02538250|adult patients
900664|NCT02538224|Periodontitis
900665|NCT02538224|doxycycline/ketoprofen topical gel therapeutic
900666|NCT02538198|lenalidomide (CC-5013)
900667|NCT02538198|maintenance
900668|NCT02538198|15-129
900669|NCT02538172|Cell-mediated immunity
900670|NCT02538172|Antiviral prophylaxis
900671|NCT02538172|Transplantation
900672|NCT02538159|Non-tunneled Central venous catheter
900673|NCT02538159|Bacteraemia
900674|NCT02538159|Peripherally inserted central venous catheter
900675|NCT02538146|pain
900676|NCT02538146|depression
900677|NCT02538146|cytokines
900678|NCT02538146|well-being
900679|NCT02538133|99mTc-Exametazime (HMPAO)-Labeled Leukocytes
900680|NCT02538133|suspected subdiaphragmatic vascular prosthesis infection
900681|NCT02538133|diagnosis
900682|NCT02538094|Cognitive Enhancement
900683|NCT02538094|tDCS
900684|NCT02538094|stimulation
900685|NCT02538094|MS
900686|NCT02538094|Multiple Sclerosis
900687|NCT02538094|Encephalitis
900688|NCT02538081|schizophrenia
900689|NCT02538081|olanzapine
900690|NCT02538081|risperidone
900691|NCT02538081|alpha 7 nicotinic receptors
900692|NCT02538081|cognition
900693|NCT02538068|Purpose in Life
900694|NCT02538068|Self-determination
900695|NCT02538068|Physical activity
900696|NCT02538068|Self-monitoring
900697|NCT02538068|Behavior change
900698|NCT02538055|Community Health Workers
900699|NCT02538055|Diabetes Mellitus
900700|NCT02538055|Chronic Pain
900701|NCT02538029|Dual tasking
900702|NCT02538016|Cystinuria
900703|NCT02538016|Kidney Stones
900704|NCT02537964|chlorhexidine
900705|NCT02537951|autofluorescent flavoprotein imaging, capsaicin
900706|NCT02537925|COX-2 inhibitors
900707|NCT02537925|radiosensitivity
900708|NCT02537925|nasopharyngeal carcinoma
900709|NCT02537912|peanut skin
900710|NCT02537912|body fat
900711|NCT02537912|blood glucose
900712|NCT02537912|waistline
900713|NCT02537912|body weight
900714|NCT02537886|PCOR
900715|NCT02537873|Cocaine Use Disorder
900716|NCT02537847|Sitafloxacin
900717|NCT02537847|Extended-Spectrum ß-lactamase-producing Escherichia coli
900718|NCT02537847|Treatment for Acute Pyelonephritis
900719|NCT02537847|Ertapenem
900720|NCT02537795|Deep Brain Stimulation
900721|NCT02537795|Anterior Capsulotomy
900722|NCT02537782|Cardiac Resynchronisation Therapy
900723|NCT02537782|Heart Failure
900724|NCT02537782|Left ventricular dyssynchrony
900725|NCT02537782|Echocardiography
900726|NCT02537782|Apical rocking
900727|NCT02537782|Septal flash
900728|NCT02537769|LVAD
900729|NCT02537769|Tricuspid regurgitation
900730|NCT02537769|Heart failure
900731|NCT02537769|Transplant
900732|NCT02537769|3D transesophageal echocardiography (TEE)
900733|NCT02537769|2D transesophageal echocardiography (TEE)
900734|NCT02537769|Mild
900735|NCT02537769|Moderate
900736|NCT02537743|Patient Reported Outcomes
900737|NCT02537704|Obesity
900738|NCT02537704|Translational
900739|NCT02537704|Diabetes Prevention Program
900740|NCT02537704|Group Lifestyle Balance Program
900741|NCT02537652|Central blood pressure
900742|NCT02537652|Transient ischaemic attack
900743|NCT02537639|Simulator in transesophageal echocardiography
900744|NCT02537613|Chronic Lymphocytic Leukemia
900745|NCT02537600|BRAF mutation
900746|NCT02537600|Brain metastasis
900747|NCT02537600|Cobimetinib + Vemurafenib combination treatment
900748|NCT02537587|Blood glucose
900749|NCT02537587|Blood insulin
900750|NCT02537587|Humans
900751|NCT02537587|Postprandial
900752|NCT02537587|Carbohydrate
900753|NCT02537587|Protein
900754|NCT02537587|Resistant starch
900755|NCT02537587|Sugar
900756|NCT02537574|Alkermes
900757|NCT02537574|Buprenorphine
900758|NCT02537574|Naltrexone
900759|NCT02537574|Vivitrol
900760|NCT02537574|Opioid Use
900761|NCT02537574|Opiates
900762|NCT02537574|Dependence
900763|NCT02537574|Abuse
900764|NCT02537574|Heroin
900765|NCT02537574|Painkillers
900766|NCT02537574|Substance Abuse
900767|NCT02537496|Alzheimer's Disease
900768|NCT02537496|Brain stimulation
900769|NCT02537496|Transcranial Magnetic Stimulation
900770|NCT02537496|Neuroplasticity
900771|NCT02537496|cognitive enhancement
900772|NCT02537496|TMS-EEG
900773|NCT02537496|rTMS
900774|NCT02537496|PAS
900775|NCT02537431|KRN23
900776|NCT02537431|Fibroblast growth factor 23 (FGF23)
900777|NCT02537431|XLH
900778|NCT02537431|X-linked Hypophosphatemia
900779|NCT02537379|Hepatitis C virus
900780|NCT02537379|observational
900781|NCT02537379|post-marketing
900782|NCT02537379|sofosbuvir
900783|NCT02537353|Upper gastrointestinal bleeding
900784|NCT02537353|Hemospray
900785|NCT02537353|Endoscopic hemostasis
900786|NCT02537340|PET/CT
900787|NCT02537340|MRI
900788|NCT02537340|EMVI
900789|NCT02537340|Liver metastasis
900790|NCT02537340|FDG
900791|NCT02537327|Recurrent caries
900792|NCT02537327|Secondary caries
900793|NCT02537327|Dental composite
900794|NCT02537327|Dental amalgam
900795|NCT02537314|Normal Body Weight
900796|NCT02537301|Endoscopic Retrograde Cholangiopancreatography
900797|NCT02537301|social networking
900798|NCT02537301|group chat
900799|NCT02537288|VA106483
900800|NCT02537288|fedovapagon
900801|NCT02537288|males
900802|NCT02537288|females
900803|NCT02537288|moxifloxacin
900804|NCT02537288|TQT
900805|NCT02537288|QT/QTC
900806|NCT02537288|ECG
900807|NCT02537288|Nocturia
900808|NCT02537262|carbohydrate
900809|NCT02537262|quality of recovery(QOR) 40
900810|NCT02537262|enhanced recovery after surgery(ERAS)
900811|NCT02537249|dexmedetomidine
900812|NCT02537249|quality of recovery
900813|NCT02537236|Omega-3 Fatty Acids
900814|NCT02537236|Therapeutic Lifestyle Changes
900815|NCT02537236|Human Immunodeficiency Virus
900816|NCT02537236|Cardiac Risk
900817|NCT02537236|Dyslipidemia
900818|NCT02537171|Apatinib
900819|NCT02537171|Locally Advanced Gastric Cancer
900820|NCT02537171|Metastatic Gastric Cancer
900821|NCT02537158|sorafenib
900822|NCT02537158|transcatheter arterial chemoembolization
900823|NCT02537158|hepatocellular carcinoma
900824|NCT02537158|microvascular invasion
900825|NCT02537145|compliance
900826|NCT02537145|do-it-yourself methodology
900827|NCT02537145|pilot
900828|NCT02537145|human microbiome
900829|NCT02537132|Non Invasive Ventilation (NIV)
900830|NCT02537132|Amyotrophic Lateral sclerosis (ALS)
900831|NCT02537132|adaptation
900832|NCT02537132|home care
900833|NCT02537106|Brain Tumors
900834|NCT02537106|Microcirculation
900835|NCT02537106|Osmotherapy
900836|NCT02537106|Hypertonic NaCl
900837|NCT02537106|Natremia
900838|NCT02537080|Postoperative cognitive dysfunction
900839|NCT02537080|Nimodipin
900840|NCT02537080|Anesthesia
900841|NCT02537067|a partial cartilage defect of ankle
900842|NCT02537067|Chondron
900843|NCT02537067|Autologus Chondrocyte
900844|NCT02537054|Choroidal neovascularization
900845|NCT02537054|Angioid streaks
900846|NCT02537054|Pseudoxanthoma Elasticum
900847|NCT02537054|vascular endothelial growth factor
900848|NCT02537054|aflibercept
900849|NCT02537028|MSC2364447C
900850|NCT02537028|Phase 1
900851|NCT02537028|BTK inhibitor
900852|NCT02537028|Systemic Lupus Erythematosus
900853|NCT02537028|M2951
900854|NCT02537028|Lupus
900855|NCT02537002|PF-05230907
900856|NCT02537002|Pharmacokinetics
900857|NCT02537002|Pharmacodynamic
900858|NCT02537002|Immunogenicity
900859|NCT02536989|peptic ulcer bleeding
900860|NCT02536989|blood clot
900861|NCT02536989|dose
900862|NCT02536976|mirabegron
900863|NCT02536950|bionic pancreas
900864|NCT02536950|closed-loop control
900865|NCT02536950|artificial pancreas
900866|NCT02536885|Postoperative cognitive dysfunction
900867|NCT02536885|Blood pressure
900868|NCT02536885|Anesthesia
900869|NCT02536872|infection overactive bladder
900870|NCT02536846|Healthy volunteers
900871|NCT02536846|antipsychotic drugs
900872|NCT02536846|brain metabolism
900873|NCT02536833|OA
900874|NCT02536833|Samumed
900875|NCT02536781|Anthocyanin
900876|NCT02536781|Inflammation
900877|NCT02536781|Orthodontic treatment
900878|NCT02536768|Medication adherence
900879|NCT02536768|ART
900880|NCT02536768|Counseling
900881|NCT02536768|Adherence Guidelines for Chronic Diseases (HIV, TB and NCDs)
900882|NCT02536742|Breast Cancer
900883|NCT02536742|Metastatic
900884|NCT02536742|HER2 negative
900885|NCT02536742|Palbociclib
900886|NCT02536716|Dental Implant
900887|NCT02536690|propofol
900888|NCT02536690|midazolam
900889|NCT02536690|remifentanil
900890|NCT02536690|combination
900891|NCT02536690|synergic
900892|NCT02536690|pharmacodynamics
900893|NCT02536690|Loss of consciousness
900894|NCT02536677|Acute Chest Pain
900895|NCT02536677|Acute Coronary Syndrome
900896|NCT02536677|Evaluation and Management
900897|NCT02536677|Decision Aid
900898|NCT02536677|Healthcare Utilization
900899|NCT02536651|validation studies, patient-reported outcome measures
900900|NCT02536638|urine protein
900901|NCT02536638|pregnancy
900902|NCT02536638|pyelonephritis
900903|NCT02536638|kidney infection
900904|NCT02536625|everolimus
900905|NCT02536625|NK
900906|NCT02536625|metastatic
900907|NCT02536612|Motivation
900908|NCT02536612|Behavioral Economics
900909|NCT02536612|Conditional Economic Incentives
900910|NCT02536612|Conditional cash transfers
900911|NCT02536612|Contingency management
900912|NCT02536599|Febrile Neutropenia
900913|NCT02536599|Childhood Cancer
900914|NCT02536599|Pediatric Oncology
900915|NCT02536599|Fever
900916|NCT02536599|Neutropenia
900917|NCT02536573|Total hip replacement
900918|NCT02536560|intestinal microbiota
900919|NCT02536560|antibiotics
900920|NCT02536560|infant
900921|NCT02536560|allergy
900922|NCT02536547|Clinical pulmonary infection score
900923|NCT02536547|sepsis
900924|NCT02536547|lung ultrasound
900925|NCT02536547|ventilator-associated pneumonia
900926|NCT02536534|Pulmonary Arterial Hypertension (PAH)
900927|NCT02536534|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
900928|NCT02536456|screening
900929|NCT02536456|counseling
900930|NCT02536456|follow-up
900931|NCT02536456|cardiovascular disease
900932|NCT02536456|population-based project
900933|NCT02536456|China
900934|NCT02536443|heart failure
900935|NCT02536443|prognosis
900936|NCT02536443|clinical characteristics
900937|NCT02536430|Infra alveolar nerve block
900938|NCT02536430|Ketorolac
900939|NCT02536430|Success rate
900940|NCT02536417|Melatonin
900941|NCT02536417|Delirium prevention
900942|NCT02536417|End-of-life
900943|NCT02536352|Fluoride Supplementation
900944|NCT02536352|Prenatal Vitamin
900945|NCT02536352|Pregnancy Nutrition
900946|NCT02536352|Prenatal Nutrition
900947|NCT02536287|secondary hyperparathyroidism
900948|NCT02536287|total parathyroidectomy
900949|NCT02536287|autotransplantation
900950|NCT02536287|morbidity
900951|NCT02536287|recurrence
900952|NCT02536287|postoperative hypocalcemia
900953|NCT02536261|Prolactinoma
900954|NCT02536261|dopamine agonist
900955|NCT02536261|withdrawal
900956|NCT02536261|cavernous sinus
900957|NCT02536248|sitagliptin
900958|NCT02536248|diabetes
900959|NCT02536248|inflammation
900960|NCT02536196|Cerebral protection, aortic stenosis, transcatheter aortic valve implantation, TAVI, TriGuard, Keystone Heart
900961|NCT02536183|Solid tumors
900962|NCT02536183|relapsed pediatric solid tumors
900963|NCT02536183|high intensity focused ultrasound
900964|NCT02536183|Lyso-thermosensitive liposomal doxorubicin
900965|NCT02536183|ThermoDox
900966|NCT02536183|relapsed sarcoma
900967|NCT02536183|Ewing Sarcoma family of tumors
900968|NCT02536183|Osteosarcoma
900969|NCT02536183|Neuroblastoma
900970|NCT02536183|Wilms Tumor
900971|NCT02536183|Hepatic Tumor
900972|NCT02536183|Germ Cell Tumors
900973|NCT02536170|Arginine Therapy
900974|NCT02536157|Volar plate
900975|NCT02536144|colon capsule
900976|NCT02536144|magnetic
900977|NCT02536144|maneuverability
900978|NCT02536144|colonoscopy
900979|NCT02536131|Psychosomatics
900980|NCT02536131|Gastroenterology
900981|NCT02536131|Psychoneuroimmunology
900984|NCT02536053|[E04.100.814.603]
900985|NCT02536040|silver diamine fluoride
900986|NCT02536040|diammine silver fluoride
900987|NCT02536040|children
900988|NCT02536027|continuous venovenous hemofiltration
900989|NCT02536027|neutrophil gelatinase-associated lipocalin
900990|NCT02536027|sepsis
900991|NCT02536027|acute kidney injury
900992|NCT02536014|Dexmedetomidine
900993|NCT02536014|pneumoperitoneum
900994|NCT02536014|trendelenburg position
900995|NCT02536014|QTc interval
900996|NCT02536014|Tp-e interval
900997|NCT02536014|robotic prostatectomy
900998|NCT02536001|Vaginal mesh
900999|NCT02536001|Total vaginal length
901000|NCT02536001|Quality of life
901001|NCT02535988|Colorectal Cancer
901002|NCT02535988|Metastatic Colorectal Cancer
901003|NCT02535988|ZADAXIN
901004|NCT02535988|Abscopal Effect
901005|NCT02535988|Radiotherapy
901006|NCT02535962|PFAPA
901007|NCT02535936|Cerebral Palsy
901008|NCT02535923|Schizophrenia and Disorders with Psychotic Feature
901009|NCT02535923|Mental Disorders
901010|NCT02535923|Insomnia Disorder
901011|NCT02535910|vitamin D3
901012|NCT02535910|25(OH)D3
901013|NCT02535910|vitamin D status
901014|NCT02535910|risk factors of cardiovascular diease
901015|NCT02535884|Huntington Disease
901016|NCT02535884|DBS
901017|NCT02535884|Chorea
901018|NCT02535858|Anxiety
901019|NCT02535832|Rheumatoid Arthritis
901020|NCT02535819|Cataract surgery
901021|NCT02535806|Relapsed, Refractory
901022|NCT02535767|Primaquine
901023|NCT02535741|Knee Replacement
901024|NCT02535741|Arthroplasty
901025|NCT02535728|Frail Elderly
901026|NCT02535728|Cardiac Surgical Procedure
901027|NCT02535728|Risk Assessment
901028|NCT02535728|Quality of Life
901029|NCT02535715|Oral Insulin
901030|NCT02535702|fMRI
901031|NCT02535702|EEG
901032|NCT02535689|Anti-DNA Antibody
901033|NCT02535689|Tofacitinib
901034|NCT02535689|Lupus
901035|NCT02535689|Safety
901036|NCT02535676|schizophrenia
901037|NCT02535676|transcranial stimulation
901038|NCT02535663|rhamnogalacturonan
901039|NCT02535663|Natural killer cell activity
901040|NCT02535663|interleukin-12
901041|NCT02535663|interferon-gamma
901042|NCT02535663|immune function
901043|NCT02535663|inflammatory
901044|NCT02535572|Electroconvulsive Therapy
901045|NCT02535546|Chronic obstructive pulmonary disease (COPD)
901046|NCT02535546|Streptococcus pneumoniae
901047|NCT02535546|Pneumonia
901048|NCT02535546|Pneumococcal conjugate vaccine-13 (PCV-13)
901049|NCT02535546|Pneumococcal polysaccharide vaccine-23 (PPV-23)
901050|NCT02535546|Pneumococcal vaccine
901051|NCT02535533|Kidney cancer
901052|NCT02535533|Selenium (Se)
901053|NCT02535507|pyrotinib
901054|NCT02535507|HER2
901055|NCT02535507|Non-small Cell Lung Cancer
901056|NCT02535507|Phase II
901057|NCT02535481|epidermal graft
901058|NCT02535481|suction blister
901059|NCT02535481|blister graft
901060|NCT02535481|suction graft
901061|NCT02535481|Epidermis/su, tr [Surgery, Transplantation]
901062|NCT02535390|cognitive remediation
901063|NCT02535390|vocational outcomes
901064|NCT02535377|Cryodamage
901065|NCT02535377|microarrays
901066|NCT02535377|Insemination
901067|NCT02535377|sperm
901068|NCT02535364|acute lymphoblastic leukemia
901069|NCT02535364|ALL
901070|NCT02535364|chimeric antigen receptor
901071|NCT02535364|CAR
901072|NCT02535364|CAR T cells
901073|NCT02535364|JCAR015
901074|NCT02535364|autologous T cell therapy
901075|NCT02535364|cell therapy
901076|NCT02535351|Clear cell Metastatic renal cell carcinoma
901077|NCT02535351|Cytoreductive nephrectomy
901078|NCT02535351|First line treatment
901079|NCT02535299|telomere-telomerase
901080|NCT02535299|Par-4
901081|NCT02535299|GLP-1
901082|NCT02535299|metformin
901083|NCT02535273|dexmedetomidine
901084|NCT02535273|prone position
901085|NCT02535273|spine surgery
901086|NCT02535273|Minimally invasive
901087|NCT02535273|local anesthesia
901088|NCT02535260|Pregnancy
901089|NCT02535221|Premenopausal Patients
901090|NCT02535221|Estrogen Receptor-Positive HER2 negative
901091|NCT02535169|at risk for type 2 diabetes
901092|NCT02535169|currently has type 2 diabetes
901093|NCT02535065|Low Profile
901094|NCT02535065|Abdominal Aortic Aneurysms
901095|NCT02535065|Endovascular
901096|NCT02535039|Elderly
901097|NCT02535039|cognitive retention disorder
901098|NCT02535039|methylprednisolone
901099|NCT02534974|Critical care
901100|NCT02534974|Trauma patients
901101|NCT02534961|Hepatocellular carcinoma
901102|NCT02534961|Radiofrequency ablation
901103|NCT02534961|Antibiotics
901104|NCT02534948|mindfulness
901105|NCT02534948|MABT
901106|NCT02534948|social anxiety
901107|NCT02534948|mindfulness and acceptance
901108|NCT02534948|group therapy
901116|NCT02534909|PNH
901117|NCT02534870|Volunteer
901118|NCT02534857|randomized double blinded study
901119|NCT02534857|live birth rate
901120|NCT02534857|IVF treatment
901121|NCT02534857|brief incubation of oocytes and sperm
901122|NCT02534844|Niemann-Pick Type C1 (NPC1) Disease
901123|NCT02534844|neurologic disease
901124|NCT02534844|gross motor dysfunction
901125|NCT02534844|fine motor dysfunction
901126|NCT02534844|dysphagia
901127|NCT02534844|swallowing problems
901128|NCT02534844|cognitive dysfunction
901129|NCT02534844|gait abnormalities
901130|NCT02534844|pediatrics
901131|NCT02534727|Tuberculosis
901132|NCT02534727|Non-Tuberculous Mycobacterim
901133|NCT02534727|Xpert/MDR-RIF
901134|NCT02534727|TDM
901135|NCT02534701|stroke
901136|NCT02534701|clot retrieval system
901137|NCT02534701|recanalization
901138|NCT02534649|Molecular profiling
901139|NCT02534649|Genomic alteration
901140|NCT02534649|Advanced cancer
901141|NCT02534610|preemptive
901142|NCT02534610|postoperative pain
901143|NCT02534610|etoricoxib
901144|NCT02534584|acute kidney injury
901145|NCT02534584|outcome
901146|NCT02534584|mortality
901147|NCT02534584|care-bundle
901148|NCT02534558|MicroRNA-29
901149|NCT02534558|shoulder stiffness
901150|NCT02534558|mir-29a
901151|NCT02534545|Intracranial atherosclerotic stenosis
901152|NCT02534545|ischemia
901153|NCT02534545|remote ischemic conditioning
901154|NCT02534545|stroke
901155|NCT02534532|Atrial fibrillation screening
901156|NCT02534506|Advanced malignant tumors
901157|NCT02534506|Metastatic malignant tumors
901158|NCT02534480|Amyloid
901159|NCT02534415|Antiinflammatory
901160|NCT02534415|Gingiva
901161|NCT02534415|Hyaluronic acid
901162|NCT02534415|Palate
901163|NCT02534415|Transplants
901164|NCT02534415|Wound healing
901165|NCT02534402|Biomarkers
901166|NCT02534402|Genomics
901167|NCT02534402|Prednisone
901168|NCT02534389|rectal cancer
901169|NCT02534389|inflammation
901170|NCT02534389|omega-3
901171|NCT02534389|fish oil
901172|NCT02534389|nutritional status
901173|NCT02534376|prostatectomy, cholesterol, statin
901174|NCT02534363|Cognition
901175|NCT02534363|Psychosis
901176|NCT02534363|Antipsychotic Agents
901177|NCT02534363|Treatment
901178|NCT02534363|Effectiveness
901179|NCT02534363|Aripiprazole
901180|NCT02534363|Quetiapine
901181|NCT02534363|Ziprasidone
901182|NCT02534363|Neurocognition
901183|NCT02534350|Respiratory Syncytial Virus (RSV)
901184|NCT02534350|Antiviral
901185|NCT02534350|Lung Transplant
901186|NCT02534324|Hypertension
901187|NCT02534324|Emergency
901188|NCT02534298|single sided deafness.
901189|NCT02534298|Auditory plasticity
901190|NCT02534298|Asymmetrical hearing loss
901191|NCT02534298|Cochlear implants
901192|NCT02534298|Inter hemispheric asymmetry
901193|NCT02534298|Lateralization index
901194|NCT02534298|Dichotic hearing
901195|NCT02534285|Anesthesia, Inhalation
901196|NCT02534285|Hearing
901197|NCT02534285|Noise, Occupational
901198|NCT02534246|Core tissue biopsy
901199|NCT02534246|Core needle biopsy
901200|NCT02534246|EUS
901201|NCT02534246|Fine needle biopsy
901202|NCT02534246|Fine needle aspiration
901203|NCT02534233|barrett's esophagus with dysplasia
901204|NCT02534233|early esophageal cancer
901205|NCT02534220|Toothbrushing
901206|NCT02534220|Oral hygiene
901207|NCT02534220|Dental hygiene
901208|NCT02534194|Gestation
901209|NCT02534194|Premature
901210|NCT02534194|Infants
901211|NCT02534181|Refeeding Syndrome
901212|NCT02534181|Cancer
901213|NCT02534168|genetic polymorphisms
901214|NCT02534155|MitraClip®
901215|NCT02534155|MR
901216|NCT02534155|DMR
901217|NCT02534155|high-risk patients
901218|NCT02534155|mitral regurgitation
901219|NCT02534155|surgery
901220|NCT02534155|intermediate risk patients
901221|NCT02534129|breast cancer
901222|NCT02534129|radiation
901223|NCT02534129|dermatitis
901224|NCT02534116|abdominal reconstruction
901225|NCT02534090|Premature
901226|NCT02534090|Preterm
901227|NCT02534090|Necrotizing
901228|NCT02534090|Enterocolitis
901229|NCT02534090|NIRS
901230|NCT02534077|omegaven
901231|NCT02534077|cholestasis
901232|NCT02534077|parenteral nutrition associated liver disease
901233|NCT02534064|Menopause
901234|NCT02534064|Osteoporosis
901235|NCT02534064|Hip fractures
901236|NCT02534064|vitamin D deficiency
901237|NCT02534051|clinical care path
901238|NCT02534051|care pathway
901239|NCT02534051|obesity
901240|NCT02534051|pregnancy
901241|NCT02534038|Disinhibition
901242|NCT02533986|Berry
901243|NCT02533986|Inflammation
901244|NCT02533986|Cognition
901245|NCT02533986|Polyphenols
901246|NCT02533986|Appetite
901247|NCT02533986|Glucose metabolism
901248|NCT02533960|Registry of Acute Stroke Under Novel Oral Anticoagulants
901249|NCT02533947|Allogeneic Stem Cell Transplantation
901250|NCT02533947|Hematological Malignancies
901251|NCT02533947|Exercise Intervention
901252|NCT02533947|Cognitive Function
901253|NCT02533947|Fatigue
901254|NCT02533947|Randomized Controlled Trial
901255|NCT02533934|HIV
901256|NCT02533934|Hepatitis C
901257|NCT02533934|Liver Disease
901258|NCT02533934|HCV Treatment
901259|NCT02533934|transplant
901260|NCT02533921|Palliative Care
901261|NCT02533921|Parkinson's Disease
901262|NCT02533869|low-dose computed tomography
901263|NCT02533817|Fructose
901264|NCT02533817|Insulin
901265|NCT02533817|Postprandial lipemia
901266|NCT02533817|Ambulatory blood pressure
901267|NCT02533817|Ethnicity
901268|NCT02533804|health
901269|NCT02533804|wellness
901270|NCT02533804|life expectancy
901271|NCT02533804|quality of life
901272|NCT02533804|performance
901273|NCT02533804|religion
901274|NCT02533804|skin
901275|NCT02533804|cardiovascular
901276|NCT02533804|joints
901277|NCT02533804|bone
901278|NCT02533804|respiration
901279|NCT02533804|pain
901280|NCT02533804|nervous system diseases
901281|NCT02533804|oral health
901282|NCT02533804|behavior
901283|NCT02533804|child
901284|NCT02533804|depression
901285|NCT02533804|mood
901286|NCT02533804|panic
901287|NCT02533804|sleep
901288|NCT02533804|stress
901289|NCT02533804|nutrition
901290|NCT02533804|exercise
901291|NCT02533804|life change events
901292|NCT02533804|personality
901293|NCT02533804|employment
901294|NCT02533804|social networking
901295|NCT02533804|time management
901296|NCT02533804|residence characteristics
901297|NCT02533791|Safety
901298|NCT02533791|immunogenicity
901299|NCT02533791|Ebola vaccine
901300|NCT02533791|boosting
901301|NCT02533765|Cisplatin-resistant
901302|NCT02533765|Neoplasms, Germ Cell and Embryonal
901303|NCT02533765|Salvage treatment
901304|NCT02533765|olaparib
901305|NCT02533752|Left Atrial Appendage Closure
901306|NCT02533752|Watchman device
901307|NCT02533752|LAA Closure
901308|NCT02533726|Bed Sores
901309|NCT02533726|Bedsores
901310|NCT02533726|Decubitus Ulcer
901311|NCT02533726|Pressure Sore
901312|NCT02533713|rehabilitation
901313|NCT02533713|bone strength
901314|NCT02533713|quality of life
901315|NCT02533687|prostate
901316|NCT02533687|transurethral resection
901317|NCT02533687|bipolar
901318|NCT02533687|monopolar
901319|NCT02533661|Effectiveness
901320|NCT02533661|Genes
901321|NCT02533661|Intervention
901322|NCT02533661|Neurodevelopment
901323|NCT02533661|Prematurity
901324|NCT02533661|Preschool Age
901325|NCT02533648|Type 2 diabetes mellitus, oxidative stress
901326|NCT02533648|insulin sensitivity
901327|NCT02533648|insulin resistance
901328|NCT02533648|mitochondrial dysfunction
901329|NCT02533648|skeletal muscle
901330|NCT02533648|xanthine oxidase
901331|NCT02533648|allopurinol
901332|NCT02533622|progressive mobility
901333|NCT02533583|pulse oximetry
901334|NCT02533583|clinical assessment
901335|NCT02533583|neonate
901336|NCT02533583|lung disease
901337|NCT02533570|Lupus
901338|NCT02533557|brachial plexus block
901339|NCT02533557|nerve stimulator
901340|NCT02533557|ultrasound
901341|NCT02533544|tenofovir disoproxil fumarate
901342|NCT02533505|Respiratory
901343|NCT02533505|COPD
901344|NCT02533505|O2 Consumption
901345|NCT02533492|total knee replacement
901346|NCT02533492|vicryl plus
901347|NCT02533492|surgical site infection
901348|NCT02533453|Type 2 Diabetes Mellitus, T2DM, GLP-1, GLP-1 Once weekly, Exenatide
901349|NCT02533414|kidney stone
901350|NCT02533414|retrograde intrarenal surgery
901351|NCT02533414|ureteral access sheath
901352|NCT02533414|kidney function
901353|NCT02533388|transcutaneous electrical acupoint stimulation
901354|NCT02533388|stress response
901355|NCT02533375|efficacy
901356|NCT02533375|safety
901357|NCT02533349|laryngopharyngeal reflux disease
901358|NCT02533349|prokinetics
901359|NCT02533349|proton pump inhibitor
901360|NCT02533336|Malaria control
901361|NCT02533336|Insecticide treated durable Wall Liners
901362|NCT02533336|Malaria incidence
901363|NCT02533336|Randomized Trial
901364|NCT02533323|NK/T-cell lymphoma
901365|NCT02533323|induction chemotherapy
901366|NCT02533323|survival
901367|NCT02533310|Specific phobia
901368|NCT02533310|Exposure therapy
901369|NCT02533310|Virtual reality
901370|NCT02533310|Randomized controlled trial
901371|NCT02533297|standardization,
901372|NCT02533297|performance clinical skills
901373|NCT02533297|nursing
901374|NCT02533297|learning curve
901375|NCT02533271|rectal cancer
901376|NCT02533271|short-term radiotherapy
901377|NCT02533271|neoadjuvant chemotherapy
901378|NCT02533271|total mesorectal excision
901379|NCT02533258|advanced renal cell carcinoma, disease progression, sunitinib, interferon alpha
901380|NCT02533245|Exercise Training
901381|NCT02533245|Quality of Life
901382|NCT02533245|Patient Reported Outcomes
901383|NCT02533245|Organ Transplantation
901384|NCT02533232|Schizophrenia
901385|NCT02533232|Anti-inflammatory
901386|NCT02533232|Clozapine
901387|NCT02533232|Minocycline
901388|NCT02533232|Psychosis NOS
901389|NCT02533219|Hyperinsulinemic hypoglycemia
901390|NCT02533219|PET/CT
901391|NCT02533219|PET/MRI
901392|NCT02533219|[18F]-DOPA
901393|NCT02533219|PET/MR
901394|NCT02533219|Congenital Hyperinsulinism
901395|NCT02533193|enhanced recovery after surgery protocal
901396|NCT02533193|laparoscopic hepatectomy
901397|NCT02533180|Liver allograft recipient
901398|NCT02533180|Immunosuppression withdrawal
901399|NCT02533180|Calcineurin inhibitor (CNI) based immunosuppression
901400|NCT02533180|Living Donor (of the Respective Liver Transplant Recipient)
901401|NCT02533141|Investigation of the changes of flicker induced vasodilatation before, during and after withdrawal of therapy with simvastatin
901402|NCT02533128|Intraoperative blood pressure
901403|NCT02533128|Triple low
901404|NCT02533128|Anesthetic overdose
901405|NCT02533128|Major adverse cardiac events (MACE)
901406|NCT02533128|Myocardial injury after noncardiac surgery (MINS)
901407|NCT02533128|Perioperative risk stratification
901408|NCT02533128|Brain-type natriuretic peptide (BNP)
901409|NCT02533128|High-sensitivity cardiac Troponin I (hs-cTnI)
901410|NCT02533115|VYXEOS
901411|NCT02533102|Pharmacokinetics
901412|NCT02533102|E7050
901413|NCT02533102|Healthy Subjects
901414|NCT02533050|obstructive sleep apnea
901415|NCT02533050|acute coronary event
901416|NCT02533050|cognitive functions
901417|NCT02533050|Continuous positive airway pressure night
901418|NCT02533011|Sepsis
901419|NCT02533011|Heparin Binding Protein
901420|NCT02532998|Pharmacodynamics
901421|NCT02532998|AZD9977
901422|NCT02532998|Safety
901423|NCT02532998|Tolerability
901424|NCT02532998|Pharmacokinetics
901425|NCT02532998|Eplerenone
901426|NCT02532998|Fludrocortisone
901427|NCT02532985|Gastrointestinal tolerability
901428|NCT02532985|dietary fiber
901429|NCT02532985|clinical trial
901430|NCT02532985|healthy subjects
901431|NCT02532933|Replacement, Knee
901432|NCT02532920|Natural history
901433|NCT02532920|Atopic dermatitis
901434|NCT02532920|Atopic march
901435|NCT02532907|HCV
901436|NCT02532894|endothelial dysfunction
901437|NCT02532894|microvesicles
901438|NCT02532894|endothelial progenitor cells
901439|NCT02532894|electronic cigarettes
901440|NCT02532842|Schizophrenia
901441|NCT02532842|Paliperidone palmitate
901442|NCT02532816|stunting
901443|NCT02532816|indonesia
901444|NCT02532803|Cancer
901445|NCT02532803|Rectum
901446|NCT02532803|Rectal Cancer
901447|NCT02532803|Polyps
901448|NCT02532790|Mild proteinuria
901449|NCT02532764|cystic fibrosis
901450|NCT02532764|ΔF508
901451|NCT02532764|RNA therapies
901452|NCT02532764|antisense oligonucleotide
901453|NCT02532764|CFTR
901454|NCT02532764|F508del
901455|NCT02532764|CF
901456|NCT02532764|RNA therapy
901457|NCT02532738|efficacy of MSC
901458|NCT02532738|refractory
901459|NCT02532725|heat stress response
901460|NCT02532725|cardiopulmonary exercise test
901461|NCT02532725|men
901462|NCT02532725|middle aged
901463|NCT02532725|heat-shock response
901464|NCT02532712|EC-18
901465|NCT02532712|Hematology
901466|NCT02532712|Cancer
901467|NCT02532712|Neutropenia
901468|NCT02532699|Antrodia cinnamomea mycelia
901469|NCT02532699|blood pressure
901470|NCT02532699|adenosine
901471|NCT02532699|antrosterol
901472|NCT02532699|clinical trial
901473|NCT02532699|gamma-aminobutyric acid
901474|NCT02532686|Treatment resistant
901475|NCT02532686|DAAOI
901476|NCT02532686|NMDA
901477|NCT02532634|ramosetron
901478|NCT02532634|palonosetron
901479|NCT02532634|chemotherapy induced nausea and vomiting
901480|NCT02532582|nerve compression
901481|NCT02532530|Aortic valve replacement with or without CABG
901482|NCT02532504|postnatal depression
901483|NCT02532504|Cognitive behaviour Therapy
901484|NCT02532504|Traditional Birth Attendants
901485|NCT02532504|low income country
901486|NCT02532491|Psychosis
901487|NCT02532491|Antipsychotic Agents
901488|NCT02532491|Treatment
901489|NCT02532491|Effectiveness
901490|NCT02532491|Aripiprazole
901491|NCT02532491|Risperidone
901492|NCT02532452|Epstein-Barr Virus (EBV)
901493|NCT02532452|Adenovirus (ADV)
901494|NCT02532452|Cytomegalovirus (CMV)
901495|NCT02532452|T-Cells
901496|NCT02532452|Donor
901497|NCT02532439|fracture osteoporosis
901498|NCT02532439|bone microarchitecture
901499|NCT02532439|Inflammatory joint diseases
901500|NCT02532439|Bone fragility
901501|NCT02532439|Rheumatoid Arthritis
901502|NCT02532439|Spondyloarthritis
901503|NCT02532439|Primary Hyperparathyroidism
901504|NCT02532439|constitutional thinness
901505|NCT02532439|anorexia nervosa
901506|NCT02532426|Chronic Obstructive Pulmonary Disease
901507|NCT02532426|Muscle biopsy
901508|NCT02532426|Chronic hypoxia
901509|NCT02532426|OXYPHEN
901510|NCT02532426|Oxydative phenotype
901511|NCT02532426|Exercise
901512|NCT02532400|Breast Neoplasms
901513|NCT02532400|Neoadjuvant Endocrine Therapy
901514|NCT02532400|Ovarian Function Suppression
901515|NCT02532400|Neoadjuvant chemotherapy
901516|NCT02532374|nicotine absorption
901517|NCT02532374|nicotine containing product
901518|NCT02532374|adult smoker
901519|NCT02532374|Nicorette
901520|NCT02532374|nicotine delivery system
901521|NCT02532361|Sterilization
901522|NCT02532361|Hysteroscopic Device Placement
901523|NCT02532361|Tubal Ligation
901524|NCT02532348|Human Immunodeficiency Virus
901525|NCT02532348|HIV
901526|NCT02532348|antiretroviral therapy
901527|NCT02532348|platelets
901528|NCT02532348|Immune activation
901529|NCT02532348|Inflammatory state
901530|NCT02532335|FXR
901531|NCT02532335|bile acids
901532|NCT02532335|FGF19
901533|NCT02532335|C4
901534|NCT02532335|gut microbiota
901535|NCT02532335|Pharmacodynamics of FXR activation in the small bowel
901536|NCT02532309|Rosuvastatin
901537|NCT02532309|Carotid Atherosclerosis plaque
901538|NCT02532309|Crestor
901539|NCT02532309|Rosuvastatin calcium
901543|NCT02532270|obstetric
901544|NCT02532270|anesthesia
901545|NCT02532270|hypotension
901546|NCT02532270|arterial pressure
901547|NCT02532270|measurement techniques
901560|NCT02532244|distal hereditary motor neuronopathy
901561|NCT02532231|Leukemia
901562|NCT02532231|Acute myeloid leukemia
901563|NCT02532231|AML
901564|NCT02532231|High risk for relapse
901565|NCT02532231|Nivolumab
901566|NCT02532231|BMS-936558
901567|NCT02532231|Opdivo
901568|NCT02532192|Lymphoma
901569|NCT02532192|Diffuse large B-cell lymphoma
901570|NCT02532192|DLBCL
901571|NCT02532192|Relapsed
901572|NCT02532192|Refractory
901573|NCT02532192|Belinostat
901574|NCT02532192|Rituximab
901575|NCT02532192|Rituxan
901576|NCT02532192|Cisplatin
901577|NCT02532192|Platinol-AQ
901578|NCT02532192|Platinol
901579|NCT02532192|CDDP
901580|NCT02532192|Cytarabine
901581|NCT02532192|Ara-C
901582|NCT02532192|Cytosar
901583|NCT02532192|DepoCyt
901584|NCT02532192|Cytosine arabinosine hydrochloride
901585|NCT02532192|Dexamethasone
901586|NCT02532192|Decadron
901587|NCT02532192|Ciprofloxacin
901588|NCT02532192|Ciprofloxacin hydrochloride
901589|NCT02532192|Cipro
901590|NCT02532192|Fluconazole
901591|NCT02532192|Diflucan
901592|NCT02532179|subcutaneous immunotherapy (SCIT)
901593|NCT02532179|glycerinated mouse allergenic extract
901594|NCT02532179|mouse specific IgE
901595|NCT02532179|mouse specific IgG and IgG4
901596|NCT02532179|mouse prick skin test wheal
901597|NCT02532166|narrow band imaging
901598|NCT02532166|Chromoendoscopy
901599|NCT02532166|Lugol
901600|NCT02532153|Suicidal Ideation
901601|NCT02532153|Suicide
901602|NCT02532153|Suicidal Thoughts
901603|NCT02532153|Depression
901604|NCT02532153|Ketamine
901605|NCT02532127|Low-dose risk
901606|NCT02532075|COPD
901607|NCT02532075|Respiratory Muscle Warm Up
901610|NCT02532049|Malaria
901611|NCT02532049|Vaccine
901612|NCT02532049|Immune Response
901613|NCT02532036|MVA85A
901614|NCT02532036|Tuberculosis
901615|NCT02532036|Vaccine
901616|NCT02532036|Aerosol
901617|NCT02532023|omega 3 fatty acid
901618|NCT02532023|curcumin
901619|NCT02532023|COX-2
901620|NCT02532023|iNOs
901621|NCT02532023|VCAM-1
901622|NCT02532023|ICAM-1
901623|NCT02532023|IL-1β
901624|NCT02532023|IL-6
901625|NCT02532023|TNF-α
901626|NCT02532023|hsCRP
901627|NCT02532023|migraine
901628|NCT02531997|self-image
901629|NCT02531997|sexual health
901630|NCT02531997|breast cancer
901631|NCT02531997|gynecologic cancer
901632|NCT02531997|ovarian cancer
901633|NCT02531997|cervical cancer
901634|NCT02531997|uterine cancer
901635|NCT02531997|mind body
901636|NCT02531997|hypnotic relaxation therapy
901637|NCT02531997|hypnosis
901638|NCT02531997|progressive muscle relaxation
901639|NCT02531971|Bioequivalence
901640|NCT02531971|Therapeutic Equivalency
901641|NCT02531945|topography
901642|NCT02531945|cobb angle
901643|NCT02531932|advanced triple negative breast cancer
901644|NCT02531919|tumor acidity
901645|NCT02531893|Irritability
901646|NCT02531893|Disruptive Mood
901647|NCT02531893|Tantrums
901648|NCT02531893|Frustration
901649|NCT02531893|Interpretation Bias
901650|NCT02531893|Emotional Judgment
901651|NCT02531893|Cognitive-Behavioral
901652|NCT02531893|Exposure
901653|NCT02531893|Research Psychotherapy
901659|NCT02531867|HPP
901660|NCT02531867|Bone Disease
901661|NCT02531867|Soft Bones
901662|NCT02531867|Low Alkaline Phosphatase
901663|NCT02531867|Genetic Metabolic Disorder
901664|NCT02531867|Alkaline Phosphatase
901665|NCT02531867|Rickets
901666|NCT02531867|Osteomalacia
901667|NCT02531815|safety
901668|NCT02531815|tolerability
901669|NCT02531815|pharmacokinetics
901670|NCT02531815|pharmacodynamics
901671|NCT02531815|Phase 1
901672|NCT02531815|first in human
901673|NCT02531815|monoclonal antibody
901674|NCT02531815|tissue factor pathway inhibitor
901675|NCT02531815|japanese
901676|NCT02531802|ETEC diarrhea
901677|NCT02531802|Escherichia Coli (ETEC)
901678|NCT02531776|Diabetes
901679|NCT02531776|Needle
901680|NCT02531776|Pen needle
901681|NCT02531763|mHealth
901682|NCT02531763|behavioral economics
901683|NCT02531763|social incentives
901684|NCT02531750|Metabolism
901685|NCT02531750|Bone metabolism
901686|NCT02531750|Glucose Metabolism
901687|NCT02531750|Lipid metabolism
901688|NCT02531750|Low grade inflamation
901689|NCT02531724|acute kidney injury
901690|NCT02531724|cardiac surgery
901691|NCT02531724|renal blood flow
901692|NCT02531724|levosimendan
901693|NCT02531711|Lumbosacral
901694|NCT02531711|radicular
901695|NCT02531685|dmLT
901696|NCT02531685|Enteric
901697|NCT02531685|Escherichia coli Infections
901698|NCT02531685|Shigella
901699|NCT02531685|Toxin LTR192G/L211A
901700|NCT02531672|11C-choline
901701|NCT02531672|Positron Emission Tomography
901702|NCT02531672|15-117
901703|NCT02531646|pulmonary nodule
901704|NCT02531633|Giant Cell Arteritis, Sirukumab, Prednisone
901705|NCT02531620|prehabilitation
901706|NCT02531620|colorectal surgery
901707|NCT02531555|chronic periodontitis
901708|NCT02531555|dental scaling
901709|NCT02531555|gingival crevicular fluid
901710|NCT02531555|lasers
901711|NCT02531555|periodontal pocket
901712|NCT02531555|root planing
901713|NCT02531516|Prostatic neoplasms
901714|NCT02531516|Prostate Cancer
901715|NCT02531516|High-Risk prostate cancer
901716|NCT02531516|JNJ-56021927
901717|NCT02531516|Apalutamide
901718|NCT02531516|ATLAS
901719|NCT02531516|Radiation
901720|NCT02531516|Long-term hormone therapy
901721|NCT02531516|Localized or locally advanced prostate cancer
901722|NCT02531516|Janssen
901723|NCT02531503|Asthma remission
901724|NCT02531503|Predicting factors
901725|NCT02531503|Children
901726|NCT02531464|family caregiver
901727|NCT02531464|quality of life
901728|NCT02531464|supportive care
901729|NCT02531464|distress screening
901730|NCT02531464|needs assessment
901731|NCT02531451|Muscle mass
901732|NCT02531451|strength
901733|NCT02531451|NSAID
901734|NCT02531451|Ibuprofen
901735|NCT02531451|resistance exercise
901736|NCT02531425|TNBC
901737|NCT02531425|Triple Negative Breast Cancer
901738|NCT02531412|Acute kidney injury
901739|NCT02531412|Critically ill cancer patients
901740|NCT02531412|Spironolactone
901741|NCT02531399|flicker induced changes
901742|NCT02531399|total volumetric retinal blood flow
901743|NCT02531308|diffuse large b-cell lymphoma (DLBCL),
901744|NCT02531308|lymphoma
901745|NCT02531282|Patient education as topic
901746|NCT02531282|Health promotion
901747|NCT02531282|Patient participation
901748|NCT02531282|Self efficacy
901749|NCT02531256|Laryngeal Mask Airway
901750|NCT02531243|prodrome
901751|NCT02531243|family therapy
901752|NCT02531243|clinical high risk
901753|NCT02531204|ASP1585
901754|NCT02531204|Bioequivalence
901755|NCT02531204|Pharmacodynamic
901756|NCT02531204|Phosphate binder
901757|NCT02531204|Bixalomer
901758|NCT02531204|urinary phosphorus excretion
901759|NCT02531191|ASP015K
901760|NCT02531191|JAK inhibitor
901761|NCT02531191|bioequivalence study
901762|NCT02531178|Rheumatoid Arthritis
901763|NCT02531139|Cerebrovascular Circulation
901764|NCT02531139|Anesthesia
901765|NCT02531139|Blood pressure
901766|NCT02531139|Peripheral Arterial Diseases
901767|NCT02531074|Mobile Applications
901773|NCT02531048|healthy volunteers
901774|NCT02530957|Intubation
901775|NCT02530957|Preoxygenation
901776|NCT02530957|Complications
901777|NCT02530957|Non invasive ventilation
901778|NCT02530957|High flow nasal cannula
901779|NCT02530944|Lupus
901780|NCT02530944|Systemic Lupus Erythematosus (SLE)
901781|NCT02530944|genetic
901782|NCT02530944|online
901783|NCT02530944|genome wide association
901784|NCT02530944|systemic lupus erythematosus
901785|NCT02530944|genome wide association study (GWAS)
901788|NCT02530905|Duchenne muscular dystrophy
901789|NCT02530905|Exon Skipping
901790|NCT02530892|embryo
901791|NCT02530892|in vitro fertilization
901792|NCT02530892|IVF
901793|NCT02530840|imbalanced diabetic patients
901794|NCT02530840|HbA1c
901795|NCT02530840|peers
901796|NCT02530827|energy expenditure
901797|NCT02530827|doubly labeled water
901798|NCT02530827|accelerometer
901799|NCT02530827|HIV
901800|NCT02530827|lipodystrophy syndrome.
901801|NCT02530814|organochlorine compounds
901802|NCT02530814|pesticides
901803|NCT02530788|Heart Failure
901804|NCT02530788|Cardiac Surgery
901805|NCT02530788|Ventricular Assist Device
901806|NCT02530788|Selenium
901807|NCT02530762|Gastrointestinal tolerability
901808|NCT02530762|dietary fiber
901809|NCT02530762|clinical trial
901810|NCT02530762|healthy subjects
901811|NCT02530749|Surgery
901812|NCT02530749|Frailty
901813|NCT02530736|Gait speed
901814|NCT02530736|Pulmonary Rehabilitation
901815|NCT02530723|power training
901816|NCT02530723|high-speed training
901817|NCT02530723|high-velocity training
901818|NCT02530723|function
901819|NCT02530723|older adults
901820|NCT02530723|older women
901821|NCT02530697|Leishmaniasis
901822|NCT02530697|Mucocutaneous
901823|NCT02530697|Miltefosine
901824|NCT02530697|Pentoxifylline
901825|NCT02530671|multi-directional power toothbrush
901826|NCT02530671|manual toothbrush
901827|NCT02530658|Genetic Predisposition
901828|NCT02530658|Pediatric
901829|NCT02530658|Genomic Analysis
901830|NCT02530658|Heritable Disease
901831|NCT02530658|Cancer Risk
901832|NCT02530658|Genetic Counseling
901833|NCT02530658|DNA
901834|NCT02530658|Clinical Genomics
901835|NCT02530658|Clinical Decision-Making
901836|NCT02530658|Treatment Planning
901837|NCT02530632|microperfusion
901838|NCT02530632|temperature
901839|NCT02530632|near-infrared spectroscopy
901840|NCT02530632|anesthesia
901841|NCT02530632|total intravenous anaesthesia
901842|NCT02530580|GABA modulator
901843|NCT02530580|AZD7325
901844|NCT02530580|Object manipulation
901845|NCT02530580|Cutaneous sensation
901846|NCT02530580|Manual dexterity
901847|NCT02530567|portal pressure
901848|NCT02530567|portosystemic pressure gradient
901849|NCT02530567|azygos blood flow
901850|NCT02530554|Pilot Projects
901851|NCT02530515|Leukemia
901852|NCT02530515|Chronic Lymphocytic Leukemia
901853|NCT02530515|CLL
901854|NCT02530515|T-cells
901855|NCT02530515|Immune cells
901856|NCT02530515|Rituximab
901857|NCT02530515|Rituxan
901858|NCT02530515|Cyclophosphamide
901859|NCT02530515|Cytoxan
901860|NCT02530515|Neosar
901861|NCT02530515|Fludarabine Phosphate
901862|NCT02530515|Fludarabine
901863|NCT02530515|Fludara
901864|NCT02530515|Bendamustine
901865|NCT02530515|Bendamustine Hydrochloride
901866|NCT02530515|Bendamustine HCL
901867|NCT02530515|CEP-18083
901868|NCT02530515|SDX-105
901869|NCT02530515|Treanda
901870|NCT02530515|Lenalidomide
901871|NCT02530515|CC-5013
901872|NCT02530515|Revlimid
901873|NCT02530489|Breast Cancer
901874|NCT02530489|Triple negative breast cancer
901875|NCT02530489|TNBC
901876|NCT02530489|Invasive adenocarcinoma of the breast
901877|NCT02530489|MPDL3280A
901878|NCT02530489|Nab-paclitaxel
901879|NCT02530489|Paclitaxel
901880|NCT02530489|Abraxane
901881|NCT02530489|ABI-007
901882|NCT02530476|Leukemia
901883|NCT02530476|Acute myeloid leukemia
901884|NCT02530476|AML
901885|NCT02530476|Relapsed/Refractory
901886|NCT02530476|FLT3-ITD mutation
901887|NCT02530476|FLT3-mutated high-risk myelodysplastic syndrome
901888|NCT02530476|MDS
901889|NCT02530476|Chronic Myelomonocytic Leukemia
901890|NCT02530476|CMML
901891|NCT02530476|Selinexor
901892|NCT02530476|KPT-330
901893|NCT02530476|Sorafenib
901894|NCT02530476|Nexavar
901895|NCT02530476|BAY 43-9006
901896|NCT02530476|FLT3-inhibitor therapy
901897|NCT02530463|Leukemia
901898|NCT02530463|Myelodysplastic syndrome
901899|NCT02530463|MDS
901900|NCT02530463|Nivolumab
901901|NCT02530463|BMS-936558
901902|NCT02530463|Opdivo
901903|NCT02530463|Ipilimumab
901904|NCT02530463|Yervoy
901905|NCT02530463|BMS-734016
901906|NCT02530463|MDX010
901907|NCT02530463|5-azacitidine
901908|NCT02530463|Azacitidine
901909|NCT02530463|5-AZA
901910|NCT02530463|Vidaza
901911|NCT02530463|5-AZC
901912|NCT02530463|AZA-CR
901913|NCT02530463|Ladakamycin
901914|NCT02530463|NSC-102816
901915|NCT02530463|Azacytidine
901916|NCT02530450|children
901917|NCT02530450|poor adherence
901918|NCT02530450|continuous glucose monitoring
901919|NCT02530437|Esophageal Cancer
901920|NCT02530437|Adenocarcinoma of the Esophagus
901921|NCT02530437|Adenocarcinoma of the Gastroesophageal Junction
901922|NCT02530437|Chemoradiation
901923|NCT02530437|LY2940680
901924|NCT02530437|Paclitaxel (Protein-Bound)
901925|NCT02530437|Taxol
901926|NCT02530437|Carboplatin
901927|NCT02530437|Paraplatin
901928|NCT02530437|Radiation therapy
901929|NCT02530437|XRT
901930|NCT02530437|External beam
901931|NCT02530437|Endoscopy
901932|NCT02530424|HER2-positive
901933|NCT02530424|ER-positive
901934|NCT02530424|invasive
901935|NCT02530424|CDK4,6
901936|NCT02530424|Palbociclib
901937|NCT02530424|neoadjuvant treatment
901938|NCT02530411|Hormone resistance
901939|NCT02530411|vandetanib
901940|NCT02530411|fulvestrant
901941|NCT02530359|septic acute kidney injury
901942|NCT02530359|pirfenidone
901943|NCT02530320|Palbociclib
901944|NCT02530320|oligodendroglioma
901945|NCT02530320|oligoastrocytoma anaplastic
901946|NCT02530307|Stroke,
901947|NCT02530307|Rehabilitation
901948|NCT02530307|Ischemic
901949|NCT02530307|fMRI
901950|NCT02530268|psoriatic arthritis
901951|NCT02530268|spondyloarthritis
901952|NCT02530268|disease registry
901953|NCT02530255|retinal amyloid
901954|NCT02530255|Retinal amyloid index
901955|NCT02530255|Alzheimer disease
901956|NCT02530255|telomere attrition
901957|NCT02530255|telomere activation
901958|NCT02530242|Sickle Cell Anemia
901959|NCT02530229|periprosthetic joint infection
901960|NCT02530229|septic arthritis
901961|NCT02530203|post-operative atrial fibrillation
901962|NCT02530203|spinal cord stimulation
901963|NCT02530203|CABG
901964|NCT02530177|Alopecia
901965|NCT02530177|Skin Aging
901966|NCT02530177|Nail Changes
901967|NCT02530177|Hair Changes
901968|NCT02530177|15-198
901969|NCT02530164|tDCS
901970|NCT02530164|SSRI
901971|NCT02530151|Hip arthroscopy
901972|NCT02530151|Intra-articular injection
901973|NCT02530151|Morphine
901974|NCT02530151|Clonidine
901975|NCT02530073|congenital diaphragmatic hernia
901976|NCT02530073|FETO
901977|NCT02530073|tracheal occlusion
901978|NCT02530060|Healthy
901979|NCT02530060|Rilpivirine
901980|NCT02530060|Tenofovir
901981|NCT02530060|Emtricitabine
901982|NCT02530060|Tenofovir Disoproxil Fumarate
901989|NCT02530034|Leukemia
901990|NCT02530034|Advanced Hematologic Malignancies
901991|NCT02530034|Myelodysplastic syndrome
901992|NCT02530034|MDS
901993|NCT02530034|Chronic myelomonocytic leukemia
901994|NCT02530034|CMML
901995|NCT02530034|Acute myeloid leukemia
901996|NCT02530034|AML
901997|NCT02530034|Myelofibrosis
901998|NCT02530034|Hu8F4
901999|NCT02530021|Ischemic heart disease
902000|NCT02530021|Heart rate variability
902001|NCT02530021|Exercise Strss Test
902002|NCT02529956|Psoriasis
902003|NCT02529956|UCB4940
902006|NCT02529930|HSIL
902007|NCT02529930|CIN 2/3
902008|NCT02529930|Therapeutic DNA vaccine
902009|NCT02529930|Human Papillomavirus
902010|NCT02529930|Immunotherapy
902011|NCT02529891|Chronic Obstructive Pulmonary Disease
902012|NCT02529891|COPD
902013|NCT02529891|Volatile Organic Compounds
902014|NCT02529891|Exacerbation
902015|NCT02529878|gastric caner
902016|NCT02529878|Apatinib
902017|NCT02529878|S1
902018|NCT02529878|conversion therapy
902019|NCT02529878|metastatic gastric cancer
902020|NCT02529865|Cell Transplantation
902021|NCT02529852|Lymphoma
902022|NCT02529852|Diffuse Large B Cell Lymphoma
902023|NCT02529852|DLBCL
902024|NCT02529852|Lenalidomide
902025|NCT02529852|CC-5013
902026|NCT02529852|Revlimid
902027|NCT02529852|Obinutuzumab
902028|NCT02529852|GA101
902029|NCT02529852|Gazyva
902030|NCT02529852|Cyclophosphamide
902031|NCT02529852|Cytoxan
902032|NCT02529852|Neosar
902033|NCT02529852|Doxorubicin
902034|NCT02529852|Doxorubicin Hydrochloride
902035|NCT02529852|Adriamycin PFS
902036|NCT02529852|Adriamycin RDF
902037|NCT02529852|Adriamycin
902038|NCT02529852|Rubex
902039|NCT02529852|Vincristine
902040|NCT02529852|Prednisone
902041|NCT02529839|MS
902042|NCT02529839|BMT
902043|NCT02529826|Cancer-affected prepubertal boys
902063|NCT02529761|HCC
902064|NCT02529761|sorafenib
902065|NCT02529761|TACE
902066|NCT02529761|overall survival
902067|NCT02529696|accelerometer
902068|NCT02529696|RASS
902069|NCT02529683|Nuvaring
902070|NCT02529683|contraceptive vaginal ring
902071|NCT02529683|Kenya
902072|NCT02529683|adherence
902073|NCT02529683|acceptability
902074|NCT02529683|immunological effects
902075|NCT02529670|Low Level Laser Therapy
902076|NCT02529670|Low Back Pain
902077|NCT02529670|Diagnosis
902078|NCT02529670|Genetic
902079|NCT02529670|Clinical trial
902080|NCT02529657|Lower Level Laser Therapy (LLLT)
902081|NCT02529657|inflammation
902082|NCT02529657|cytokines
902083|NCT02529657|wound healing
902084|NCT02529657|laminectomy
902085|NCT02529657|clinical study
902086|NCT02529644|HIV Screening
902087|NCT02529644|African American
902088|NCT02529644|Church
902089|NCT02529631|Polyglucosamine
902090|NCT02529631|L 112
902091|NCT02529631|overweight,
902092|NCT02529631|obesity
902093|NCT02529631|orlistat
902094|NCT02529631|weight reduction
902095|NCT02529605|dietary supplement
902096|NCT02529605|pharmacokinetics
902097|NCT02529605|Healthy Volunteers
902098|NCT02529592|Sickness behavior
902099|NCT02529592|Cytokines
902100|NCT02529592|Psychoneuroimmunology
902101|NCT02529579|adoptive Cellular Immunotherapy
902102|NCT02529579|patient safety
902103|NCT02529579|therapeutic effect
902104|NCT02529566|Lumbar Degenerative Disc Disease
902105|NCT02529566|Degenerative Spinal Conditions
902106|NCT02529566|Adjacent Segment Disease
902107|NCT02529566|Autologous Bone Marrow
902108|NCT02529566|Lower Back Pain
902109|NCT02529566|Chronic Lower Back Pain
902110|NCT02529566|Stem Cells
902111|NCT02529566|Lumbar disk
902112|NCT02529566|Mesenchymal Stem Cells
902113|NCT02529566|Stabilization
902114|NCT02529566|CLBP
902115|NCT02529566|Autograft
902116|NCT02529566|Allograft
902117|NCT02529566|Autograft versus Allograft
902118|NCT02529566|Facet Joint
902119|NCT02529566|Radicular Pain
902120|NCT02529566|Adipose
902121|NCT02529566|Disc Replacement
902122|NCT02529566|Facet Joint Replacement
902123|NCT02529553|bladder cancer
902124|NCT02529540|Myopia
902125|NCT02529540|self-refraction
902126|NCT02529540|glasses
902127|NCT02529540|spectacles
902128|NCT02529514|Baclofen
902129|NCT02529514|Cardiac Surgery
902130|NCT02529514|Polysomnography
902131|NCT02529514|Intensive Care Units
902132|NCT02529514|Sleep
902133|NCT02529449|ASP1941
902134|NCT02529449|type 1 diabetes mellitus
902135|NCT02529449|SGLT2 inhibitor
902136|NCT02529436|overuse antidepressant
902137|NCT02529436|dementia
902138|NCT02529423|food intake
902139|NCT02529423|food-related behaviour
902140|NCT02529423|obesity
902141|NCT02529423|socioeconomic environment
902142|NCT02529423|depression
902143|NCT02529423|nutritional strategies
902144|NCT02529397|Working Memory Training, Weight Loss,
902145|NCT02529384|Breast magnetic resonance imaging
902146|NCT02529384|Diffusion-weighted imaging
902147|NCT02529384|Multiple b-value diffusion weighted imaging
902148|NCT02529358|Maintenance intervention
902149|NCT02529358|Text messages
902150|NCT02529358|Emotion Regulation
902151|NCT02529332|Endoscopic Sellar/Parasellar Tumor Resection
902152|NCT02529319|atrial fibrillation
902153|NCT02529319|ablation
902154|NCT02529306|men
902155|NCT02529280|Latinas
902156|NCT02529280|Breast Cancer
902157|NCT02529280|Clinical Trials
902158|NCT02529280|Participation
902159|NCT02529267|Cohort Studies
902160|NCT02529267|intimate partner violence
902161|NCT02529267|orthopaedic surgery
902162|NCT02529267|epidemiology
902163|NCT02529267|outcomes in fracture care
902164|NCT02529254|post graduate surgical education
902165|NCT02529254|video coaching
902166|NCT02529254|Surgical education
902167|NCT02529254|coaching
902168|NCT02529202|Dexmedetomidine
902169|NCT02529202|Neonate
902170|NCT02529202|Pharmacokinetics
902171|NCT02529202|Therapeutic Hypothermia
902172|NCT02529202|Hypoxic-ischemic Encephalopathy
902173|NCT02529202|Adrenergic Agents
902174|NCT02529202|Adrenergic Agonists
902175|NCT02529202|Analgesics
902176|NCT02529202|Adrenergic alpha-2 Receptor Agonists
902177|NCT02529202|Central Nervous System Agents
902178|NCT02529202|Central Nervous System Depressants
902179|NCT02529189|Stable Angina
902180|NCT02529189|Angioplasty
902181|NCT02529189|Optical Coherence Tomography
902182|NCT02529189|Nitrate
902183|NCT02529176|telemetry
902184|NCT02529176|cardiac monitoring
902185|NCT02529163|Integrated Care Pathway
902186|NCT02529163|Acute Psychotic Episode
902187|NCT02529163|Randomised Control Trial
902188|NCT02529124|Ageing
902189|NCT02529124|Body Composition
902190|NCT02529124|Nutrition
902191|NCT02529124|Physical Activity
902192|NCT02529111|Atrial Septal Defects (ASD)
902193|NCT02529111|Percutaneous closure
902194|NCT02529098|functional magnetic resonance imaging
902195|NCT02529098|Lens implantation
902196|NCT02529098|pseudophakia
902197|NCT02529020|mouthguard
902198|NCT02529020|ventilation
902199|NCT02529020|anaerobic power
902200|NCT02529020|ergogenic effects
902201|NCT02529007|Colonoscopy
902202|NCT02529007|early cancer detection
902203|NCT02529007|cancer screening
902204|NCT02528994|Dietary supplements
902205|NCT02528994|Metabolism
902206|NCT02528981|GBS
902207|NCT02528981|Probiotics
902208|NCT02528981|Group B Streptococcal
902209|NCT02528981|Pregnancy
902210|NCT02528968|Pharmacokinetic dosing
902211|NCT02528968|Haemophilia
902212|NCT02528955|Head and neck cancer
902213|NCT02528955|postoperative
902214|NCT02528955|radiotherapy
902215|NCT02528955|de-intensification
902216|NCT02528942|Lung cancer
902217|NCT02528942|Radiation therapy
902218|NCT02528942|4DCT-ventilation imaging
902219|NCT02528890|group B streptococcus
902220|NCT02528890|GBS
902221|NCT02528864|biomarker
902222|NCT02528864|cancer metabolism
902223|NCT02528864|chemical exchange saturation transfer
902224|NCT02528864|endometrial cancer
902225|NCT02528864|diffusion-weighted imaging
902226|NCT02528864|magnetic resonance spectroscopy
902227|NCT02528864|uterine malignancy
902228|NCT02528851|CPAP
902229|NCT02528851|preterm
902230|NCT02528851|cardiac output
902231|NCT02528838|Myeloma
902232|NCT02528838|Non-interventional
902233|NCT02528838|Observational
902234|NCT02528838|Lenalidomide
902235|NCT02528838|REVIEW
902236|NCT02528838|Post-authorization
902237|NCT02528838|Netherlands
902238|NCT02528786|Drug therapy
902239|NCT02528734|pneumothorax
902240|NCT02528708|fibrinogen concentrate
902241|NCT02528708|coagulation
902242|NCT02528695|18F-FDG PET/CT
902243|NCT02528695|Adipose tissue
902244|NCT02528695|type 2 diabetes
902245|NCT02528682|dendritic cells
902246|NCT02528682|PD-L1/L2 silencing
902247|NCT02528682|vaccination
902248|NCT02528682|stem cell transplantation
902249|NCT02528682|minor histocompatibility antigens
902250|NCT02528669|accelerometer
902251|NCT02528669|patient ambulation
902252|NCT02528656|Pectus Excavatum
902253|NCT02528656|Pectus Carinatum
902254|NCT02528656|Vacuum Bell
902255|NCT02528656|Dynamic compression system
902256|NCT02528656|Hearth variability
902257|NCT02528656|Autonomic Nervous System
902263|NCT02528604|Catheter Ablation
902264|NCT02528604|Permanent pacemaker
902265|NCT02528604|AV node ablation
902266|NCT02528604|Electrical Cardioversion
902267|NCT02528604|Implantable loop recorder
902268|NCT02528591|patient
902269|NCT02528591|renal transplant
902270|NCT02528578|healthy volunteers
902271|NCT02528539|Prevention
902272|NCT02528539|lymphedema
902273|NCT02528539|acupuncture
902274|NCT02528539|self-management
902275|NCT02528526|Hypoxia
902276|NCT02528526|Pancreatic Neoplasms
902277|NCT02528526|Hepatocellular Cancer
902278|NCT02528526|Cholangiocarcinoma
902279|NCT02528526|Colorectal Neoplasms
902280|NCT02528526|Treatment
902281|NCT02528513|sedation
902282|NCT02528513|Midazolam
902283|NCT02528513|Propofol
902284|NCT02528513|Dexmedetomidine
902285|NCT02528487|Pulmonary Rehabilitation
902286|NCT02528487|Chronic Obstructive Pulmonary Disease
902287|NCT02528487|Psychiatric Disorders
902288|NCT02528461|Sofosbuvir
902289|NCT02528461|Direct acting anti-viral treatment
902290|NCT02528461|liver cirrhosis
902291|NCT02528448|Vasoactive hormones
902292|NCT02528448|bio markers
902293|NCT02528448|salt regulation
902294|NCT02528448|Renal variables
902295|NCT02528435|Methotrexate
902296|NCT02528383|Postmenopausal Women on Aromatase Inhibitors
902297|NCT02528383|Vagifem
902298|NCT02528370|COPD exacerbation
902299|NCT02528370|Telemedicine
902300|NCT02528370|Intervention Studies
902301|NCT02528370|Patient Readmission
902302|NCT02528357|mAb
902303|NCT02528357|GSK3174998
902304|NCT02528357|anticancer agent
902305|NCT02528357|checkpoint
902306|NCT02528357|OX40
902307|NCT02528357|Pembrolizumab
902308|NCT02528357|MK-3475-167
902309|NCT02528357|solid tumor
902310|NCT02528357|immunotherapy
902311|NCT02528357|KEYNOTE-167
902312|NCT02528357|monoclonal antibody
902313|NCT02528357|antitumor
902314|NCT02528344|High Intensity Interval Training
902315|NCT02528331|Transcranial magnetic stimulation (TMS)
902316|NCT02528331|Cognitive behavioral therapy (CBT)
902317|NCT02528305|High-intensity Interval Training
902318|NCT02528292|Rheumatoid Arthritis
902319|NCT02528292|Anti-TNF
902320|NCT02528292|Ultrasound
902321|NCT02528292|Synovial histomorphology
902322|NCT02528292|Ectopic Lymphoneogenesis
902323|NCT02528279|Plasmodium ovale
902324|NCT02528279|relapse
902325|NCT02528279|artemether-lumefantrine
902326|NCT02528279|mixed species malaria
902327|NCT02528279|non-falciparum malaria
902328|NCT02528253|Chronic low back pain
902329|NCT02528253|Chronic pain
902330|NCT02528240|platelets
902331|NCT02528201|Ankylosing Spondylitis
902332|NCT02528201|Celecoxib
902333|NCT02528201|Diclofenac
902334|NCT02528162|gestational diabetes
902335|NCT02528162|education
902336|NCT02528149|Fibromuscular Dysplasia
902337|NCT02528149|dysplastic renal artery aneurysm
902338|NCT02528149|renal artery aneurysms
902339|NCT02528149|non atheromatous
902340|NCT02528149|dysplastic
902341|NCT02528149|anatomopathologic
902342|NCT02528149|genetic
902343|NCT02528123|Small incision lenticule extraction (SMILE)
902344|NCT02528123|Femtosecond laser
902345|NCT02528084|rotator cuff, shoulder, rehabilitation, yoga
902346|NCT02528071|Amyotrophic Lateral Sclerosis
902347|NCT02528071|ALS
902348|NCT02528071|Diaphragmatic Endurance Test
902349|NCT02528058|Myopic traction maculopathy
902350|NCT02528045|Myopic traction maculopathy
902351|NCT02528032|Left ventricular dysfunction
902352|NCT02528032|Other cardiac dysrhythmias
902353|NCT02528006|Spasmodic Dysphonia
902354|NCT02528006|Type 2 Thyroplasty
902355|NCT02528006|Titanium Bridges
902356|NCT02528006|Operation
902357|NCT02527980|electronic cigarettes
902358|NCT02527980|nicotine dependence
902359|NCT02527980|smoking
902360|NCT02527980|tobacco use
902361|NCT02527967|colorectal cancer
902362|NCT02527967|enhanced recovery after surgery
902363|NCT02527967|perioperative care
902364|NCT02527967|fast-track surgery
902365|NCT02527967|laparoscopy
902366|NCT02527967|minimally invasive surgery
902367|NCT02527967|complications
902368|NCT02527954|Y-chromosome microdeletions
902369|NCT02527954|aneuploidy
902370|NCT02527954|embryos
902371|NCT02527954|spermatozoa
902372|NCT02527941|Genital immunology
902373|NCT02527941|HIV susceptibility
902374|NCT02527941|Microbiome
902375|NCT02527941|Bacterial vaginosis
902376|NCT02527941|Virus entry assay
902377|NCT02527928|pharmacoeconomics
902378|NCT02527902|IGA Glomerulonephritis
902379|NCT02527902|Autonomic nervous system
902380|NCT02527902|ANS
902381|NCT02527889|Exercise
902382|NCT02527889|blood flow velocity
902383|NCT02527889|tissue oxygenation
902384|NCT02527889|BCRL
902385|NCT02527876|Exercise
902386|NCT02527876|Smoking
902387|NCT02527863|Tolvaptan
902388|NCT02527863|L-NMMA
902389|NCT02527863|ADPKD
902390|NCT02527824|biliary tract neoplasm
902391|NCT02527824|oxaliplatin
902392|NCT02527824|irinotecan
902393|NCT02527824|S-1
902394|NCT02527811|ulinastatin
902395|NCT02527811|CPB
902396|NCT02527811|pediatric
902397|NCT02527785|stomach neoplasm
902398|NCT02527785|oxaliplatin
902399|NCT02527785|irinotecan
902400|NCT02527785|S-1
902401|NCT02527720|Mindfulness
902402|NCT02527720|Therapy
902403|NCT02527720|Problem Drinking
902404|NCT02527720|Breathing-based mindfulness training
902405|NCT02527694|Emergency medical services
902406|NCT02527694|Resuscitation
902407|NCT02527512|Scoliosis
902408|NCT02527512|Spine fusion
902409|NCT02527512|0.35% povidone-iodine
902410|NCT02527486|COPD
902411|NCT02527486|Asthma
902412|NCT02527486|ACOS
902413|NCT02527486|Bronchiectasis
902414|NCT02527460|Inflammation
902415|NCT02527460|Cognitive Function
902416|NCT02527460|HIV
902417|NCT02527447|Measurable Residual Disease
902418|NCT02527447|Relapsed/Refractory AML
902419|NCT02527447|Salvage Chemotherapy
902420|NCT02527434|Urothelial bladder cancer, Triple-negative breast cancer, Pancreatic ductal adenocarcinoma, Advanced Solid Tumors, Tremelimumab, MEDI4736, ORR
902421|NCT02527395|Experimental pain
902422|NCT02527395|Men
902423|NCT02527369|Fat Reduction
902424|NCT02527369|Lipolysis
902425|NCT02527330|Myocardial iron deposition
902426|NCT02527330|T2* imaging
902427|NCT02527330|heart failure
902428|NCT02527317|Early
902429|NCT02527291|Cytomegalovirus
902430|NCT02527291|Interleukin
902431|NCT02527291|Polymerase Chain Reaction
902432|NCT02527291|CMV antibodies
902433|NCT02527252|Massage
902434|NCT02527252|Craniosacral
902435|NCT02527252|Disability Evaluation
902436|NCT02527252|Randomized Controlled Trial
902437|NCT02527187|Immune System Diseases
902438|NCT02527187|Prick Test
902439|NCT02527187|Betula verrucosa
902440|NCT02527135|SMS
902441|NCT02527135|Text messages
902442|NCT02527135|Young women
902443|NCT02527135|HIV
902444|NCT02527122|Immune System Diseases
902445|NCT02527122|Prick Test
902446|NCT02527122|Dermatophagoides pteronyssinus
902447|NCT02527122|Dermatophagoides farinae
902448|NCT02527096|dolutegravir(Tivicay®)
902449|NCT02527096|lamivudine(Epivir®)
902450|NCT02527096|HIV-1
902451|NCT02527096|efficacy
902452|NCT02527096|safety
902453|NCT02527057|Diffusion-weighted magnetic resonance imaging
902454|NCT02527057|Preoperative concurrent chemoradiation
902455|NCT02527057|Response
902456|NCT02527044|Coronary Artery Bypass
902457|NCT02527044|Flow Reserve
902458|NCT02527031|Emergency Medical Services
902459|NCT02527031|Extracorporeal Membrane Oxygenation
902460|NCT02527018|OBGYN
902461|NCT02527018|Nexfin
902462|NCT02527018|Hypertensive
902463|NCT02527018|Hemodynamic
902464|NCT02527005|IPT
902465|NCT02527005|malaria
902466|NCT02527005|pregnant
902467|NCT02527005|HIV positive
902468|NCT02526979|OAB
902469|NCT02526979|overactive bladder
902470|NCT02526979|Myrbetric
902471|NCT02526979|neurogenic detrusor overactivity
902472|NCT02526979|Betanis
902473|NCT02526979|Myrbetriq
902474|NCT02526979|NDO
902475|NCT02526979|YM178
902476|NCT02526979|mirabegron
902477|NCT02526979|Betmiga
902478|NCT02526953|anal cancer
902479|NCT02526953|chemoradiation
902480|NCT02526953|intensity-modulated radiotherapy
902481|NCT02526953|paclitaxel
902482|NCT02526940|Human Immunodeficiency Virus
902483|NCT02526940|HIV
902484|NCT02526940|HAART
902485|NCT02526940|Highly Active antiretroviral therapy
902486|NCT02526940|GALT
902487|NCT02526940|Gut Associated Lymphoid Tissue
902488|NCT02526940|reservoir
902489|NCT02526940|rectum
902490|NCT02526927|Anorexia Nervosa
902491|NCT02526927|microarchitecture
902492|NCT02526927|prepubertal
902493|NCT02526914|social cognition
902494|NCT02526914|oxytocin
902495|NCT02526914|vasopressin
902496|NCT02526914|decision making
902497|NCT02526914|social decision making
902498|NCT02526914|economic games
902499|NCT02526888|pharmacokinetic
902500|NCT02526888|interaction
902501|NCT02526875|hypertension, Telmisartan/S-Amlodipine
902502|NCT02526862|noninvasive mechanical ventilation (NIVM)
902503|NCT02526862|continuous positive airway pressure (CPAP) ventilation
902504|NCT02526862|bilevel positive airway pressure (BIPAP) ventilation
902505|NCT02526862|pressure ulcer (PU)
902506|NCT02526862|nursing assessment
902507|NCT02526849|Fecal Microbiota Transplantation
902508|NCT02526849|Slow Transit Constipation
902509|NCT02526849|Randomized Controlled Trial
902510|NCT02526836|colon cancer mesocolic excision central ligation
902511|NCT02526810|glargine
902512|NCT02526810|continuous subcutaneous insulin injection
902513|NCT02526810|blood glucose control
902514|NCT02526810|blood glucose fluctuation
902515|NCT02526810|Oxidative Stress
902516|NCT02526797|prostate biopsy
902517|NCT02526797|prostate cancer
902518|NCT02526797|Magnetic resonance imaging
902519|NCT02526797|Neoplasm staging
902520|NCT02526771|lymph node dissection
902521|NCT02526758|Pulmonary disease
902522|NCT02526758|chronic obstructive
902523|NCT02526758|small airway
902524|NCT02526745|vaccine
902525|NCT02526745|safety
902526|NCT02526745|immunogenicity
902527|NCT02526732|NASH
902528|NCT02526732|fatty Liver
902529|NCT02526732|VO2 max
902530|NCT02526732|M30 antigen
902531|NCT02526719|bilateral prophylactic mastectomies
902532|NCT02526719|immediate breast reconstruction
902533|NCT02526719|nipple sparing
902534|NCT02526719|BRCA1 Protein
902535|NCT02526706|Bleb filtration
902536|NCT02526706|VisionBlue
902537|NCT02526680|OrCam
902538|NCT02526680|Low-vision device
902539|NCT02526680|End-stage glaucoma
902540|NCT02526641|Direct acting antiviral treatment
902541|NCT02526641|sCD163
902542|NCT02526641|Portal hypertension
902543|NCT02526641|Metabolic liver function
902544|NCT02526641|Cirrhosis
902545|NCT02526628|Testosterone
902546|NCT02526628|Neurocognition
902547|NCT02526615|rosiglitazone
902548|NCT02526615|metformin
902549|NCT02526615|muscle
902550|NCT02526576|Facial Atrophy
902551|NCT02526576|Autologous
902552|NCT02526576|Adult
902553|NCT02526576|Adipose Derived Stem Cells
902554|NCT02526576|Stromal Vascular Fraction
902555|NCT02526576|Collagenase
902556|NCT02526550|Live attenuated Japanese Encephalitis vaccine
902557|NCT02526550|IMOJEV
902558|NCT02526550|CD.JEVAX
902559|NCT02526550|Booster
902560|NCT02526550|Thai children
902561|NCT02526550|Immunogenicity
902562|NCT02526550|Safety
902563|NCT02526550|Interchangeability
902564|NCT02526550|Hepatitis A vaccine
902565|NCT02526550|Vaccination or Other Immunization Procedure
902566|NCT02526537|Gefitinib
902567|NCT02526537|NSCLC
902568|NCT02526537|postoperative
902569|NCT02526537|stage Ib
902570|NCT02526537|Relapse Free Survival in 2 years
902571|NCT02526485|heparin
902572|NCT02526485|thrombocytopenia
902573|NCT02526485|genomics
902574|NCT02526472|embryo transfer, in vitro fertilization
902575|NCT02526446|Chinese
902576|NCT02526446|caregiver stress
902577|NCT02526446|self-administered acupressure
902578|NCT02526433|depression
902579|NCT02526433|mental wellbeing
902580|NCT02526433|motherhood
902581|NCT02526433|music
902582|NCT02526433|alternative therapies
902583|NCT02526420|VRS-317
902584|NCT02526420|Long Acting Growth Hormone
902585|NCT02526420|Versartis
902586|NCT02526420|somavaratan
902587|NCT02526420|Growth Hormone Deficiency
902588|NCT02526420|Adult Growth Hormone Deficiency
902589|NCT02526420|AGHD
902590|NCT02526420|Growth Hormone Replacement
902591|NCT02526420|Growth Hormone Replacement Therapy
902592|NCT02526420|XTEN
902593|NCT02526407|postnatal depression
902594|NCT02526407|mental wellbeing
902595|NCT02526407|baby blues
902596|NCT02526407|mothers
902597|NCT02526407|music
902598|NCT02526407|alternative therapies
902599|NCT02526355|Postnatal depression
902600|NCT02526355|Mobile phone based intervention
902601|NCT02526355|Learning Through Play
902602|NCT02526355|CBT
902603|NCT02526355|Intelligent Real Time Therapy
902604|NCT02526316|cervical cancer
902605|NCT02526316|vulvar cancer
902606|NCT02526316|vaginal cancer
902607|NCT02526316|penile cancer
902608|NCT02526316|anal cancer
902609|NCT02526316|head and neck cancer
902610|NCT02526277|RLS
902611|NCT02526264|stoma
902612|NCT02526264|quality of life
902613|NCT02526251|IBD
902614|NCT02526251|Fecal calprotectin
902615|NCT02526251|Microbiome
902616|NCT02526251|Dysbiosis
902617|NCT02526251|Disease activity
902618|NCT02526251|telemedicine
902619|NCT02526238|transcranial magnetic stimulation
902620|NCT02526238|trunk rotation
902621|NCT02526225|acute ischemic stroke
902622|NCT02526225|safety and effectiveness
902623|NCT02526225|Ginkgo diterpene lactone meglumine injection
902624|NCT02526212|opioid use disorder
902625|NCT02526212|group counseling
902626|NCT02526212|office-based buprenorphine treatment
902627|NCT02526199|Local anesthetics
902628|NCT02526199|Perineural nerve blocks
902629|NCT02526199|Perineurial Dexamethasone
902630|NCT02526160|KRN23
902631|NCT02526160|Fibroblast growth factor 23 (FGF23)
902632|NCT02526160|XLH
902633|NCT02526160|X-linked hypophosphatemia
902634|NCT02526134|Laying of medical devices (radio opaque markers)
902635|NCT02526095|Esophagus
902636|NCT02526095|Surgery
902637|NCT02526082|cardiovascular disease
902638|NCT02526082|frailty
902639|NCT02526082|quality of life
902640|NCT02526082|mortality
902641|NCT02526082|prevention
902642|NCT02526030|psychosis
902643|NCT02526030|antipsychotic agents
902644|NCT02526030|treatment
902645|NCT02526030|effectiveness
902646|NCT02526004|Cystic Fibrosis
902647|NCT02526004|Microbiome
902648|NCT02526004|Stratified Antibacterial therapy
902649|NCT02526004|Resistance
902650|NCT02526004|Pathogen Host Interaction
902651|NCT02525991|schizophrenia
902652|NCT02525991|bipolar disorder
902653|NCT02525978|Heart Rate
902654|NCT02525965|Wide resection margin
902655|NCT02525965|Recurrence
902656|NCT02525965|Early-stage hepatocellular carcinoma
902657|NCT02525952|Carcinoma, Hepatocellular
902658|NCT02525952|Hepatectomy
902659|NCT02525952|Transarterial Chemoembolization
902660|NCT02525952|Scoring System
902661|NCT02525913|Breast
902662|NCT02525913|Mastectomy
902663|NCT02525874|Tecfidera
902664|NCT02525874|DMF
902665|NCT02525874|dimethyl fumarate
902666|NCT02525757|Lung Cancer
902667|NCT02525757|Non-small cell lung cancer
902668|NCT02525757|NSCLC
902669|NCT02525757|Unresectable
902670|NCT02525757|MPDL3280A
902671|NCT02525757|Carboplatin
902672|NCT02525757|Paraplatin
902673|NCT02525757|Paclitaxel
902674|NCT02525757|Taxol
902675|NCT02525757|Radiation therapy
902676|NCT02525757|XRT
902677|NCT02525731|HIV Infection
902678|NCT02525731|Pain
902679|NCT02525731|Chronic Opioid Therapy
902680|NCT02525731|Addiction
902681|NCT02525731|Analgesics, Opioid
902682|NCT02525718|Breast Reconstruction
902683|NCT02525718|Mastectomy
902684|NCT02525705|infants
902685|NCT02525705|oesophageal atresia
902686|NCT02525705|dumping syndrome
902687|NCT02525705|prevalence
902688|NCT02525705|Type III and IV
902689|NCT02525705|Oral glucose tolerance test
902690|NCT02525705|early hyperglycemia
902691|NCT02525705|late hypoglycemia
902692|NCT02525653|Albumin-Bound
902693|NCT02525653|Paclitaxel
902694|NCT02525653|Gemcitabine
902695|NCT02525653|15-054
902696|NCT02525640|Single sided hearing loss
902697|NCT02525640|Single sided deafness
902698|NCT02525640|Hearing loss music appreciation
902699|NCT02525536|Drug Therapy
902700|NCT02525497|Automated PD
902701|NCT02525497|Effectiveness
902702|NCT02525497|Safety
902703|NCT02525497|Manipulability
902704|NCT02525458|antimicrobial
902705|NCT02525458|biofilms
902706|NCT02525458|acrylic resin
902707|NCT02525458|polymethyl methacrylate
902708|NCT02525458|confocal laser scanning microscopy
902709|NCT02525458|split-mouth design
902710|NCT02525458|quaternary ammonium methacryloxy silicate
902711|NCT02525445|placebo effects
902712|NCT02525445|communication
902713|NCT02525445|acupuncture therapy
902714|NCT02525445|relaxation
902715|NCT02525432|Mesenchymal Stromal Cells, Multipotent
902716|NCT02525432|Multipotent Mesenchymal Stromal Cells
902717|NCT02525432|Stem Cells, Mesenchymal
902718|NCT02525393|Rehabilitation
902719|NCT02525393|Non Invasive Brain Stimulation
902720|NCT02525380|Transarterial chemoembolization
902721|NCT02525380|Doxorubicin-Eluting-Bead Embolization
902722|NCT02525380|DC Bead TACE
902723|NCT02525380|Hepatocellular carcinoma
902724|NCT02525367|Parkinson's disease
902725|NCT02525367|Multiple Sclerosis
902726|NCT02525367|Depressed Elderly
902727|NCT02525367|Cognitive Dysfunction
902728|NCT02525367|Online Cognitive Training
902729|NCT02525354|arachidonic aci
902730|NCT02525354|adiposity
902731|NCT02525354|atopy
902732|NCT02525341|Yoga
902733|NCT02525341|exercises
902734|NCT02525341|knee osteoarthritis
902735|NCT02525341|older adults
902736|NCT02525328|Constitutional Thinness
902737|NCT02525328|linkage study
902738|NCT02525328|genome wide scan (GWAS)
902739|NCT02525315|Schizophrenia
902740|NCT02525315|auditory hallucinations
902741|NCT02525315|TMS
902742|NCT02525302|DMD
902743|NCT02525302|neuromuscular
902744|NCT02525302|Duchenne
902745|NCT02525289|mobility
902746|NCT02525289|coronary artery bypass
902747|NCT02525289|positioning
902748|NCT02525289|body
902749|NCT02525263|Neo-Kidney Augment
902750|NCT02525263|Type 2 Diabetes
902751|NCT02525263|Chronic Kidney Disease
902752|NCT02525263|Cell Therapy
902753|NCT02525250|Acute myeloid leukemia or myelodysplasic syndrome
902754|NCT02525198|Mild cognitive impairment
902755|NCT02525198|Subjective memory impairment
902756|NCT02525198|Dementia
902757|NCT02525198|Flavonoids
902758|NCT02525198|Fatty acids
902759|NCT02525198|Cognition
902760|NCT02525198|Gut microflora
902761|NCT02525172|immune modulation therapy
902762|NCT02525172|acid α-glucosidase
902763|NCT02525172|antibody
902764|NCT02525159|3,3'-diindolylmethane
902765|NCT02525159|premenopause
902766|NCT02525159|2-hydroxyestrone
902767|NCT02525146|HIV
902768|NCT02525146|Reengagement in HIV Care
902769|NCT02525146|ARTAS
902770|NCT02525133|post operative pain
902771|NCT02525133|hernioplasty
902772|NCT02525133|bupivacaine
902773|NCT02525120|Disc herniation
902774|NCT02525120|Herniated disc
902775|NCT02525120|Triojection
902776|NCT02525120|Ozone
902777|NCT02525120|Lumbar spine
902778|NCT02525120|Leg pain
902779|NCT02525107|Prevention of Vaso Occlusive Painful Crisis
902780|NCT02525094|Eczema
902781|NCT02525081|Microvascular Angina
902782|NCT02525081|therapy
902783|NCT02525068|enzalutamide
902784|NCT02525068|AZD5363
902785|NCT02525068|Prostate
902786|NCT02525055|Flu
902787|NCT02525055|Influenza
902788|NCT02525055|Human Viral Challenge Model
902789|NCT02525055|Wild-Type
902790|NCT02525055|H3N2
902791|NCT02525055|H1N1
902792|NCT02525055|Universal Influenza Vaccine
902793|NCT02525055|intra-seasonal vaccines
902794|NCT02525055|antiviral
902795|NCT02525042|Ankylosing Spondylitis
902796|NCT02525042|Dendritic cells (DC)
902797|NCT02525042|RNA
902798|NCT02525042|Axial spondyloarthritis
902799|NCT02525042|Lod score
902800|NCT02525042|Human leucocyte antigen (HLA-B27)
902801|NCT02525029|GVHD
902924|NCT02524171|Veterans
902802|NCT02525016|Bariatric surgery, lidocaine, plasmatic concentration, MonoEthylGlycineXylidide (MEGx), safety
902803|NCT02525003|vitamin D
902804|NCT02525003|Serum 25-hydroxyvitamin D
902805|NCT02525003|vitamin D2
902806|NCT02525003|UV-irradiated yeast
902807|NCT02525003|serum 25-hydroxyvitamin D3
902808|NCT02525003|serum 25-hydroxyvitamin D2
902809|NCT02525003|randomized controlled trial
902810|NCT02525003|vitamin D3
902811|NCT02525003|bioavailability
902812|NCT02524990|Medical abortion
902813|NCT02524990|pregnancy tests
902814|NCT02524964|left ventricular remodeling
902815|NCT02524964|cardiac magnetic resonance imaging
902816|NCT02524964|acute myocardial infarction
902817|NCT02524938|Dietary polyphenols
902818|NCT02524938|Protein glycation
902819|NCT02524925|fast track surgery
902820|NCT02524925|eras program
902821|NCT02524925|hepatectomy
902822|NCT02524925|pancreatectomy
902823|NCT02524925|NPY
902824|NCT02524925|ACTH/Cortsiosol
902825|NCT02524925|postoperative stress
902826|NCT02524899|Schizotypal Personality Disorder
902827|NCT02524899|SPD
902828|NCT02524899|cognitive remediation therapy
902829|NCT02524899|CRT
902830|NCT02524899|guanfacine
902831|NCT02524899|cognitive impairment
902832|NCT02524899|working memory
902833|NCT02524899|pharmacological cognitive enhancing agent
902834|NCT02524899|neuropsychological testing
902835|NCT02524899|schizophrenia spectrum disorders
902836|NCT02524899|Personality Disorders
902837|NCT02524886|Deep Brain Simulation
902838|NCT02524886|Psychiatric
902839|NCT02524886|Side-effects
902840|NCT02524860|Prostate Cancer
902841|NCT02524860|Biopsy
902842|NCT02524860|Focal Healthcare
902843|NCT02524860|Fusion Targeted Biopsy
902844|NCT02524860|High Risk Cancer
902845|NCT02524860|Imaging
902846|NCT02524860|Diagnostic
902847|NCT02524860|Ultrasound
902848|NCT02524860|Multiparametric Magnetic Resonance Imaging (MP-MRI)
902849|NCT02524860|MRI-Ultrasound Fusion
902850|NCT02524860|Focal-Fusion Bx
902851|NCT02524834|Thoracoabdominal lesions
902852|NCT02524795|Omega 3, Cytokines, Adipokines, Systemic lupus erythematosus
902853|NCT02524782|MEDI-4166, diabetes
902854|NCT02524769|Urge Urinary Incontinence
902855|NCT02524769|Urinary Incontinence
902856|NCT02524756|nerve sparing radical hysterectomy
902857|NCT02524743|Rocuronium
902858|NCT02524743|lidocaine
902859|NCT02524743|acetaminophen,
902860|NCT02524743|pain
902861|NCT02524743|injection
902862|NCT02524717|Hepatic Impairment
902863|NCT02524717|JNJ-56021927
902864|NCT02524704|Cystic fibrosis
902865|NCT02524704|Electrical Impedance Tomography
902866|NCT02524626|Vagus nerve stimulation
902867|NCT02524626|Postoperative ileus
902868|NCT02524561|mammographic density
902869|NCT02524561|abnormal mammogram
902870|NCT02524561|biopsy
902871|NCT02524548|Aromatase inhibitors
902872|NCT02524548|Reminder Systems
902873|NCT02524522|Integrated Pulmonary Index
902874|NCT02524522|automated protocol-driven weaning
902875|NCT02524522|pulmonary recruitment maneuver
902876|NCT02524509|Chonodron
902877|NCT02524509|Microfracture
902878|NCT02524509|autologous cultured chondrocyte
902879|NCT02524509|cartilage defect of knee
902880|NCT02524444|Intermittent preventive therapy
902881|NCT02524444|malaria
902882|NCT02524444|pregnant
902883|NCT02524444|HIV positive
902884|NCT02524444|Prevention
902885|NCT02524431|Mitochondria
902886|NCT02524431|trabeculectomy
902887|NCT02524431|trabecular meshwork
902888|NCT02524431|Glaucoma surgery
902889|NCT02524418|Main Pancreatic Duct
902890|NCT02524392|independent medical evaluation
902891|NCT02524392|sick leave
902892|NCT02524392|sickness absence
902893|NCT02524392|physician primary care
902894|NCT02524392|general practitioner
902895|NCT02524392|family physician
902896|NCT02524366|Stress Urinary Incontinence
902897|NCT02524366|Artificial Urinary Sphincter
902898|NCT02524353|cardiac surgery
902899|NCT02524340|JIA
902900|NCT02524340|Arthritis
902901|NCT02524340|pJIA
902902|NCT02524340|PCATS
902903|NCT02524301|anorexia nervosa
902904|NCT02524301|opioid receptors
902905|NCT02524301|Positron emission tomography (PET)
902906|NCT02524301|diprenorphine
902907|NCT02524262|atrohpic gastritis
902908|NCT02524262|acetaldehyde
902909|NCT02524262|ethanol
902910|NCT02524262|L-cysteine
902911|NCT02524236|BPH, OAB, Botox, dose response
902912|NCT02524223|medically assisted procreation
902913|NCT02524210|volunteers
902914|NCT02524197|Hip
902915|NCT02524197|Knee
902916|NCT02524197|Arthritis
902917|NCT02524197|pain
902918|NCT02524197|CR845
902919|NCT02524197|kappa opioid
902920|NCT02524171|crime
902921|NCT02524171|mental health
902922|NCT02524171|substance abuse
902923|NCT02524171|homelessness
902925|NCT02524158|Yoga
902926|NCT02524158|Mind-Body Therapies
902927|NCT02524158|Chronic Low Back Pain
902928|NCT02524158|Military Veterans
902929|NCT02524158|VA patients
902930|NCT02524080|Ambulance
902931|NCT02524080|Trust
902932|NCT02524080|Patients
902933|NCT02524080|Healthcare chain
902934|NCT02524054|Dyspnea
902935|NCT02524054|Hospitalized patients
902936|NCT02524054|Ambulatory outpatients
902937|NCT02524054|Shortness of breath
902938|NCT02524054|Chronic obstructive pulmonary disease
902939|NCT02524054|Pulmonary disease
902940|NCT02524041|Hyperparathyroidism
902941|NCT02524041|microarchitecture
902942|NCT02524041|periostin
902943|NCT02524028|Atrial Fibrillation
902944|NCT02524028|fMRI
902945|NCT02524015|stroke
902946|NCT02524015|pusher syndrome
902947|NCT02524015|contraversive pushing
902948|NCT02524015|lateropulsion
902949|NCT02524015|rehabilitation
902950|NCT02524015|physical therapy
902951|NCT02524002|Abnormal Labor
902952|NCT02524002|Prolonged Induction
902953|NCT02524002|Ketosis
902954|NCT02524002|Diet
902955|NCT02523989|arsenic
902956|NCT02523989|heavy metal
902957|NCT02523976|Acute
902958|NCT02523976|Leukemia
902959|NCT02523976|Lymphoid
902960|NCT02523976|Philadelphia chromosome
902961|NCT02523976|dasatinib
902962|NCT02523963|family work shop
902963|NCT02523937|Pulmonary Embolism
902964|NCT02523937|Deep Venous Thrombosis
902965|NCT02523937|Soluble Fibrin
902966|NCT02523937|D-Dimers
902967|NCT02523937|Low and intermediate clinical probability
902968|NCT02523911|Suprep
902969|NCT02523911|Simethicone
902970|NCT02523911|Colorectal cancer screening
902971|NCT02523911|Routine colonoscopy
902972|NCT02523911|sodium sulfate/potassium sulfate/magnesium sulfate
902973|NCT02523911|Bowel cleansing
902974|NCT02523911|Mass screening
902975|NCT02523898|Clomiphene
902976|NCT02523898|infertility
902977|NCT02523898|insuline resistant
902978|NCT02523898|metformine
902979|NCT02523898|PCOS
902980|NCT02523885|Pneumonia, Bacterial [C01.252.620]
902981|NCT02523885|Bronchopneumonia [C08.381.677.127]
902982|NCT02523885|Pleuropneumonia [C08.730.610.473]
902983|NCT02523885|Anti-Inflammatory Agents, Non-Steroidal
902984|NCT02523872|Fluid overload
902985|NCT02523872|Acute respiratory failure
902986|NCT02523872|Acute respiratory distress syndrome
902987|NCT02523872|Medication administration
902988|NCT02523846|IV-Patient Controlled Analgesia (IV-PCA)
902989|NCT02523846|background morphine infusion
902990|NCT02523846|patient re-education
902991|NCT02523781|preeclampsia
902992|NCT02523781|information pamphlet
902993|NCT02523781|patient education
902994|NCT02523755|epidural analgesia for labor
902995|NCT02523755|respiratory function
902996|NCT02523755|electrical impedance tomography
902997|NCT02523729|lactation
902998|NCT02523729|human milk
902999|NCT02523729|maltz
903000|NCT02523729|antioxidant
903001|NCT02523716|Hypoxic conditioning
903002|NCT02523716|Cardio pulmonary exercise testing
903003|NCT02523651|Periodontal Diseases
903004|NCT02523651|Bone Regeneration
903005|NCT02523651|Dental Pulp Stem Cell
903006|NCT02523638|Pegylated-Proline-interferon alpha-2b (AOP2014)
903007|NCT02523638|Polycythemia Vera
903008|NCT02523638|PEN-PV
903009|NCT02523638|PROUD-PV
903010|NCT02523638|CONTINUATION-PV
903011|NCT02523638|AOP Orphan
903012|NCT02523638|Polycythemia
903013|NCT02523638|Hematologic Diseases
903014|NCT02523638|Myeloproliferative Disorders
903015|NCT02523638|Bone Marrow Diseases
903016|NCT02523638|Interferon-alpha
903017|NCT02523638|Peginterferon alfa-2b
903018|NCT02523625|Ultrasound
903019|NCT02523599|post operative pain
903020|NCT02523599|hernioplasty
903021|NCT02523599|bupivacaine
903022|NCT02523586|oxygen concentration
903023|NCT02523586|oxygen therapy
903024|NCT02523586|oxygen delivery
903025|NCT02523586|oxygen masks
903026|NCT02523560|Telerehabilitation
903027|NCT02523560|Home Monitoring
903028|NCT02523560|Heart Failure
903029|NCT02523547|entecavir
903030|NCT02523495|Molecular Targeted Therapy
903031|NCT02523495|metastasis colorectal cancer
903032|NCT02523495|biomarker
903033|NCT02523482|Prescriptions
903034|NCT02523482|Epidemiology
903035|NCT02523482|STOPP/START Criteria
903036|NCT02523482|Beers Criteria
903037|NCT02523456|Early warning score
903038|NCT02523456|Cardiac arrest
903039|NCT02523443|Epidural Analgesia
903040|NCT02523443|Intravenous Patient Controlled
903041|NCT02523443|15-148
903042|NCT02523430|Nasopharyngeal Carcinoma
903043|NCT02523430|HepaSphere
903044|NCT02523417|Breast Cancer
903045|NCT02523417|HepaSphere
903046|NCT02523404|Lung Cancer
903047|NCT02523404|HepaSphere
903048|NCT02523378|Advanced Cancers
903049|NCT02523378|Recurrent
903050|NCT02523378|Locally advanced
903051|NCT02523378|Metastatic
903052|NCT02523378|Edmonton Symptom Assessment Scale
903053|NCT02523378|ESAS
903054|NCT02523378|Survey
903055|NCT02523378|Interview
903056|NCT02523378|Symptom questionnaire
903057|NCT02523365|Cervical Carcinoma
903058|NCT02523365|HepaSphere
903059|NCT02523326|Genomic DNA
903060|NCT02523326|chronic periodontitis
903061|NCT02523326|saliva
903062|NCT02523326|mouthwash
903063|NCT02523326|PCR
903064|NCT02523326|genotyping
903065|NCT02523326|sequencing
903066|NCT02523235|moderate pain
903067|NCT02523235|severe pain
903068|NCT02523235|surgery
903069|NCT02523235|postop analgesia
903070|NCT02523235|TKA
903071|NCT02523235|adductor catheter
903072|NCT02523235|poplital catheter
903073|NCT02523235|foot/ankle surgery
903074|NCT02523222|dextrose gel
903075|NCT02523222|newborn hypoglycemia
903076|NCT02523222|late preterm infant
903077|NCT02523222|large for gestational age
903078|NCT02523222|small for gestational age
903079|NCT02523222|prophylactic
903080|NCT02523222|neonatal hypoglycemia
903081|NCT02523209|Osteoporosis
903082|NCT02523209|chronic kidney disease
903083|NCT02523209|kidney transplantation
903084|NCT02523209|fracture risk
903085|NCT02523196|Hepatic Venous Pressure Gradient (HVPG) testing
903086|NCT02523196|HepQuant-SHUNT
903087|NCT02523196|Liver Function
903090|NCT02523144|Transthoracic echocardiography
903091|NCT02523144|echo
903092|NCT02523144|TTE
903093|NCT02523131|Type 1 diabetes
903094|NCT02523131|Closed-loop glucose control
903095|NCT02523131|Artificial Pancreas
903096|NCT02523131|Continuous subcutaneous insulin infusion
903097|NCT02523131|Continuous glucose monitoring
903098|NCT02523131|threshold suspend
903099|NCT02523131|predictive low glucose suspend
903100|NCT02523092|sarcoidosis
903101|NCT02523092|Acthar
903102|NCT02523092|CXCL9
903103|NCT02523092|chemokine ligand 9
903104|NCT02523053|Hepatocellular Carcinoma
903105|NCT02523053|Recurrence
903106|NCT02523053|Microvascular Invasion
903107|NCT02523053|5-Fluorouracil
903108|NCT02523040|Langerhans cell histiocytosis (LCH)
903109|NCT02523040|Erdheim-Chester disease (ECD)
903110|NCT02523040|Histiocytic Sarcoma (HS)
903111|NCT02522988|cancer-related fatigue
903112|NCT02522975|biosimilar epoetin
903113|NCT02522975|efficacy
903114|NCT02522975|safety
903115|NCT02522975|immunogenicity
903116|NCT02522975|renal anaemia
903117|NCT02522962|physical therapy
903118|NCT02522962|group-based
903119|NCT02522962|core stability
903120|NCT02522962|balance
903121|NCT02522962|movement quality
903122|NCT02522962|somatosensory stimulation
903123|NCT02522962|coordination
903124|NCT02522923|Physical Therapy Modalities
903125|NCT02522923|Primary Care
903126|NCT02522923|Health Services Research
903127|NCT02522884|Angioplasty
903128|NCT02522884|Peripheral Artery Disease
903129|NCT02522884|PAD
903130|NCT02522884|Lesion
903131|NCT02522884|Claudication
903132|NCT02522858|premedication
903133|NCT02522858|dexmedetomidine
903134|NCT02522858|anesthesia, spinal
903135|NCT02522845|Varicose Veins
903136|NCT02522845|Compression Stockings
903137|NCT02522845|Laser Ablation
903138|NCT02522845|Catheter Ablation, Radiofrequency
903139|NCT02522819|Obstructive Sleep Apnea Syndrome
903140|NCT02522819|acute stroke
903141|NCT02522819|apnea-hypopnea index (AHI)
903142|NCT02522806|Endometrial biopsy
903143|NCT02522806|previous ovarian hyperstimulation cycle
903144|NCT02522806|first IVF
903145|NCT02522806|antagonist protocol
903146|NCT02522806|clinical pregnancy rate
903147|NCT02522793|skin lesion
903148|NCT02522728|Knee
903149|NCT02522728|Arthroplasty
903150|NCT02522728|Implant
903151|NCT02522689|kidney stone
903152|NCT02522689|percutaneous nephrolithotripsy
903153|NCT02522689|ultra-mini PCNL
903154|NCT02522689|micro PCNL
903155|NCT02522676|kidney stone
903156|NCT02522676|percutaneous nephrolithotripsy
903157|NCT02522676|retrograde intrarenal surgery
903158|NCT02522676|extracorporeal shock wave lithotripsy
903159|NCT02522676|mini PCNL
903160|NCT02522676|ultra-mini PCNL
903161|NCT02522676|micro PCNL
903162|NCT02522663|telephone support
903163|NCT02522663|discharge management
903164|NCT02522663|readmission
903165|NCT02522663|aortic valve replacement
903166|NCT02522650|amiloride
903167|NCT02522650|proteinuric kidney disease
903168|NCT02522650|urokinase plasminogen activator receptor
903169|NCT02522650|proteinuria
903170|NCT02522637|exercise
903171|NCT02522637|training
903172|NCT02522637|endurance
903173|NCT02522624|Health insurance
903174|NCT02522624|Health services accessibility
903175|NCT02522624|Decision making
903176|NCT02522624|Health literacy
903177|NCT02522611|Palliative Care
903178|NCT02522611|Adults
903179|NCT02522611|Cancer Pain
903180|NCT02522611|Nerve Block
903181|NCT02522611|Quality of Life
903182|NCT02522585|expectant management
903183|NCT02522585|p16
903184|NCT02522585|immunohistochemistry
903185|NCT02522585|regression
903186|NCT02522585|progression
903187|NCT02522585|cervical intraepithelial neoplasia
903188|NCT02522572|Renal Transplantation
903189|NCT02522572|Desensitization
903190|NCT02522572|plerixafor
903191|NCT02522572|bortezomib
903192|NCT02522520|Undergoing chemotherapy
903193|NCT02522520|Exercise intervention
903194|NCT02522520|Health counselling
903195|NCT02522520|Symptom management
903196|NCT02522481|Lumason
903197|NCT02522481|Dobutamine stress echo
903198|NCT02522481|stress echo
903199|NCT02522481|coronary artery disease
903200|NCT02522455|Flow-cycled pressure-support ventilation
903201|NCT02522403|distal radius fracture
903202|NCT02522403|laser acupuncture
903203|NCT02522403|rehabilitation
903204|NCT02522390|data collection
903205|NCT02522390|personal health services
903206|NCT02522390|personal health records
903207|NCT02522390|do-it-yourself
903208|NCT02522390|nutrition researchers
903209|NCT02522390|cohort studies
903210|NCT02522390|databases, factual
903211|NCT02522390|self-quantification methods
903212|NCT02522377|Ketamine
903213|NCT02522377|Electroconvulsive Therapy
903214|NCT02522377|Major Depressive Disorder
903215|NCT02522377|Treatment Resistant Depression
903216|NCT02522377|electroconvulsive treatment
903217|NCT02522377|Severe depression
903218|NCT02522364|Postoperative atrial fibrillation
903219|NCT02522364|Dysfunction Following Cardiac Surgery
903220|NCT02522312|Dry Eye
903221|NCT02522299|double-blind
903222|NCT02522299|PI3Kdelta
903223|NCT02522299|GSK2269557
903224|NCT02522299|exacerbation
903225|NCT02522299|Chronic Obstructive Pulmonary Disease
903226|NCT02522299|randomised
903227|NCT02522299|placebo-controlled
903228|NCT02522286|patient engagement
903229|NCT02522286|physician's role
903230|NCT02522286|patient- centered care
903231|NCT02522286|communication
903232|NCT02522273|Obstetric
903233|NCT02522273|Midwifery
903234|NCT02522273|Fetal blood sample
903235|NCT02522273|Lactate
903236|NCT02522273|Handheld meter
903237|NCT02522260|Breast cancer, chemotherapy, symptoms, optimal training
903238|NCT02522234|Neutropenia
903239|NCT02522234|Chemotherapy
903240|NCT02522221|chronic anticoagulation
903241|NCT02522221|vitamin K antagonist
903242|NCT02522221|mechanical heart valve
903243|NCT02522221|CYP2C9
903244|NCT02522221|warfarin
903245|NCT02522221|tecarfarin
903246|NCT02522195|shift work
903247|NCT02522195|nutritional status
903248|NCT02522195|nursing professionals
903249|NCT02522195|meal distribution
903250|NCT02522195|food intake
903251|NCT02522182|Cardiovascular Secondary Prevention
903252|NCT02522182|Nurse's Role
903253|NCT02522143|self-harm
903254|NCT02522143|self-mutilation
903255|NCT02522143|cutting
903256|NCT02522117|Kidney Transplantation
903257|NCT02522117|Atorvastatin
903258|NCT02522117|Human Leukocyte Antigens
903259|NCT02522117|Interleukin
903260|NCT02522104|Pharmacokinetics of Hydroxyurea
903261|NCT02522078|misoprostol
903262|NCT02522078|abortion
903263|NCT02522065|Hypokinesia
903264|NCT02522065|Patient Outcome Assessment
903265|NCT02522013|post-dural puncture headache
903266|NCT02522013|Aminophylline
903267|NCT02521948|MANTA
903268|NCT02521948|Arterial Closure Device
903269|NCT02521948|Large Bore Closure Device
903273|NCT02521870|Skin Cancer
903274|NCT02521870|Skin Tumors
903275|NCT02521870|Head and Neck Squamous Cell Carcinoma
903276|NCT02521870|Cancer Immunotherapy
903277|NCT02521857|Alkermes
903278|NCT02521857|Samidorphan
903279|NCT02521857|ALKS 5461
903280|NCT02521857|Healthy Volunteer
903281|NCT02521857|Pharmacokinetics
903284|NCT02521831|Circumcision
903285|NCT02521818|cognition
903286|NCT02521818|dementia
903287|NCT02521818|neuropsychological
903288|NCT02521818|elderly
903289|NCT02521818|nutrition
903290|NCT02521818|diet
903291|NCT02521805|Appetite
903292|NCT02521805|Protein
903293|NCT02521805|Protein quality
903294|NCT02521805|Dietary fibre
903295|NCT02521805|Satiety
903296|NCT02521792|Open-label study
903297|NCT02521792|Clinical trial Phase 2
903298|NCT02521792|Efficacy and safety
903299|NCT02521792|Heterotopic ossification
903300|NCT02521792|Fibrodysplasia Ossificans Progressiva
903301|NCT02521792|Flare-up
903302|NCT02521792|Palovarotene
903303|NCT02521792|Retinoic acid receptor agonist
903304|NCT02521792|Retinoic acid receptor gamma agonist
903305|NCT02521792|Clementia
903306|NCT02521792|Myositis Ossificans Progressiva
903307|NCT02521792|Munchmeyer's Disease
903308|NCT02521792|FOP
903309|NCT02521779|Inflammation
903310|NCT02521779|Endotoxemia
903311|NCT02521779|Lipopolysaccharide
903312|NCT02521779|Diet
903313|NCT02521779|Fat
903314|NCT02521779|Postprandial
903315|NCT02521753|Polycystic ovary syndrome
903316|NCT02521753|Obesity
903317|NCT02521753|Metformin
903318|NCT02521753|Magnesium
903319|NCT02521753|Polyunsaturated fatty acids
903320|NCT02521740|biological marker
903321|NCT02521740|frailty
903322|NCT02521740|burden
903323|NCT02521740|nutrition
903324|NCT02521740|elderly
903325|NCT02521714|Revlimid
903326|NCT02521714|lenalidomide
903327|NCT02521714|bioavailability
903328|NCT02521714|healthy volunteers
903329|NCT02521714|food effect
903330|NCT02521714|pharmacokinetics
903331|NCT02521662|Electronic Cigarettes
903332|NCT02521662|Nicotine Patch
903333|NCT02521662|Smoking Cessation
903334|NCT02521649|Gastric Cancer
903335|NCT02521649|G17DT
903336|NCT02521649|PAS
903337|NCT02521649|Insegia
903338|NCT02521649|Gastrimmune
903339|NCT02521623|Acelullar Dermal Matrix
903340|NCT02521623|Immediate Breast Reconstruction
903341|NCT02521623|Breast Implant
903342|NCT02521584|Liver transplant recipient
903343|NCT02521545|Oral Remyelination
903344|NCT02521519|Facet induced pain
903345|NCT02521519|Myofascial pain
903346|NCT02521519|Trigger points
903347|NCT02521519|Low back pain
903348|NCT02521454|policing
903349|NCT02521454|resilience
903350|NCT02521454|implicit bias
903351|NCT02521454|violence
903352|NCT02521441|Neutropenia
903353|NCT02521441|Myelotoxic Chemotherapy
903354|NCT02521441|G-CSF
903355|NCT02521363|Implantable Microdevice
903356|NCT02521363|In Vivo Drug Sensitivity Testing
903357|NCT02521363|HER2-Positive
903358|NCT02521363|Triple Negative
903359|NCT02521363|15-127
903360|NCT02521350|Acute Kidney Injury
903361|NCT02521350|Surgery
903362|NCT02521350|Perioperative care
903363|NCT02521311|multiple sclerosis
903364|NCT02521311|eye pain
903365|NCT02521311|vision loss
903366|NCT02521259|anesthetic depth
903367|NCT02521259|emergence agitation
903368|NCT02521220|L-citrulline
903369|NCT02521220|Endothelial dysfunction
903370|NCT02521194|Advanced Cancers
903371|NCT02521194|Inpatient occupational therapy
903372|NCT02521194|Questionnaire
903373|NCT02521194|Survey
903374|NCT02521168|euthyroid sick syndrome
903375|NCT02521168|cardiopulmonary bypass
903376|NCT02521168|congenital heart disease
903377|NCT02521168|time to extubation
903378|NCT02521155|Oral health literacy intervention
903379|NCT02521155|oral hygiene behavior
903380|NCT02521142|OCT Angiography
903381|NCT02521116|retinal oxygenation
903382|NCT02521116|retinal vessel diameters
903383|NCT02521116|Dynamic vessel analyzer (DVA)
903384|NCT02521116|Oxymap T1
903385|NCT02521077|Ascorbic Acid
903386|NCT02521077|Breast Neoplasms
903387|NCT02521077|Fatigue
903388|NCT02521064|IBD
903389|NCT02521064|enteral nutrition
903390|NCT02521064|corticosteroids
903391|NCT02521051|Non-Small Cell Lung Cancer (NSCLC)
903392|NCT02521051|Anaplatic lymphoma kinase
903393|NCT02521051|ALK
903394|NCT02521051|Brain metastases
903395|NCT02521012|Depression
903396|NCT02521012|Depressive symptoms
903397|NCT02521012|Vitamin D
903398|NCT02521012|Intervention
903399|NCT02520986|Sexually transmitted disease
903400|NCT02520986|Genital Warts
903401|NCT02520986|Venereal Warts
903402|NCT02520960|Catheter Ablation
903403|NCT02520960|Pulmonary Vein Isolation
903404|NCT02520960|Radiofrequency
903405|NCT02520947|desflurane
903406|NCT02520947|BIS
903407|NCT02520947|coronary artery bypass grafting surgery
903408|NCT02520934|Enzyme Replacement Therapy
903409|NCT02520934|Miglustat
903410|NCT02520934|Gaucher Disease
903411|NCT02520921|Diabetes mellitus
903412|NCT02520921|Acute coronary syndrome
903413|NCT02520921|Coronary artery disease
903414|NCT02520921|Aspirin
903415|NCT02520921|Secondary prevention
903416|NCT02520895|Chronic Lymphocytic Leukemia
903417|NCT02520895|Non-Hodgkin lymphoma
903418|NCT02520895|Follicular Lymphoma
903419|NCT02520895|Diffuse Large B Cell Lymphoma
903420|NCT02520895|MALT Lymphoma
903421|NCT02520895|T Cell Lymphoma
903422|NCT02520895|Immune Repertoire
903423|NCT02520895|Infection
903424|NCT02520895|relapse
903425|NCT02520895|survival
903426|NCT02520895|treatment response
903427|NCT02520895|VJ rearrangement
903428|NCT02520882|PET/CT
903429|NCT02520882|Bombesin
903430|NCT02520882|gastrin-releasing peptide receptor
903431|NCT02520882|68Gallium labeling
903432|NCT02520830|blueberry polyphenols
903433|NCT02520830|Polyphenol metabolites
903434|NCT02520830|endothelial function
903435|NCT02520830|Molecular mechanisms of action
903436|NCT02520830|Vascular function
903437|NCT02520830|Healthy men
903438|NCT02520817|Antioxidants
903439|NCT02520817|Zinc
903440|NCT02520817|Truck drivers
903441|NCT02520804|balanced salt solution
903442|NCT02520765|Obesity Index, ICSI
903443|NCT02520752|cMET, INC280, caffeine, midazolam
903444|NCT02520739|olive oil
903445|NCT02520739|phenolic compounds
903446|NCT02520739|triterpenes
903447|NCT02520739|oxidation and inflammation
903448|NCT02520726|Posttraumatic stress disorder
903449|NCT02520726|PTSD
903450|NCT02520726|Sertraline
903451|NCT02520726|Burns
903452|NCT02520713|Pediatric Solid Tumor
903453|NCT02520648|Back pain
903454|NCT02520648|Manual therapy
903455|NCT02520635|prognosis
903456|NCT02520635|supra-early chemotherapy
903457|NCT02520609|Metabolomics
903458|NCT02520609|Non-Alcoholic Steatohepatitis
903459|NCT02520609|Non-Alcoholic Fatty Liver Disease
903460|NCT02520609|Energy Expenditure
903461|NCT02520596|Raspberries
903462|NCT02520596|Anthocyanins
903463|NCT02520596|Ellagitannins
903464|NCT02520596|Metabolites
903465|NCT02520557|Epilepsy
903466|NCT02520557|Genetic associations with severe Cutaneous Adverse Reactions
903467|NCT02520492|intracranial pressure
903468|NCT02520479|extranodal natural killer/T-cell lymphoma
903469|NCT02520479|nasal type
903470|NCT02520479|radiotherapy
903471|NCT02520479|chemotherapy
903472|NCT02520440|Citrulline
903473|NCT02520440|GIF
903474|NCT02520440|MOF
903475|NCT02520440|Calprotectina
903476|NCT02520440|intraabdominal pressure
903477|NCT02520427|Amgen
903478|NCT02520427|Phase 1
903479|NCT02520427|Clinical Trial
903480|NCT02520427|Oncology/Hematology
903481|NCT02520427|Relapsed/Refractory AML
903482|NCT02520427|Immunotherapy
903483|NCT02520310|Mitral Regurgitation
903484|NCT02520310|mitral valve surgery
903485|NCT02520310|AVJ-514 Delivery System
903486|NCT02520310|Symptomatic Heart Failure
903487|NCT02520310|Heart Valve Disease
903488|NCT02520297|Pain
903489|NCT02520297|Long bone
903490|NCT02520297|Fracture
903491|NCT02520271|Mood Disorders
903492|NCT02520271|Motivational Interview
903493|NCT02520271|Behavioral Activation
903494|NCT02520258|artificial sweeteners
903495|NCT02520258|obesity
903496|NCT02520258|diabetes
903497|NCT02520258|metabolic syndrome
903498|NCT02520258|aspartame
903499|NCT02520232|chronic exercise
903500|NCT02520232|genetic polymorphisms
903501|NCT02520232|brain imagery
903502|NCT02520232|executive functions
903503|NCT02520232|alzheimer's disease
903504|NCT02520219|Peripheral T-cell lymphomas,Endostar
903505|NCT02520193|Early mobilisation
903506|NCT02520193|Invasive ventilation
903507|NCT02520193|Ventilator free days
903508|NCT02520193|Intensive Care Unit
903509|NCT02520167|Gestational weight gain
903530|NCT02520128|Intensity Modulated Radiotherapy
903531|NCT02520128|Radiotherapy
903532|NCT02520089|platelet-rich plasma
903533|NCT02520089|bone grafting
903534|NCT02520089|pseudoarthrosis
903535|NCT02520076|Islet Transplantation
903536|NCT02520063|hormone-receptor positive breast cancer
903537|NCT02520063|Her2 negative breast cancer
903538|NCT02520063|neoadjuvant
903539|NCT02520063|everolimus
903540|NCT02520063|TRC105
903541|NCT02520063|letrozole
903542|NCT02520050|Type 2 diabetes
903543|NCT02520050|Obesity
903544|NCT02520050|Nutrition
903545|NCT02520050|Medical Nutrition Therapy
903546|NCT02520037|Fluid responsiveness
903547|NCT02520037|Volume responsiveness
903548|NCT02520037|Hemodynamics
903549|NCT02520024|self-directed care
903550|NCT02520024|serious mental illness
903555|NCT02519998|Biomarkers
903556|NCT02519998|Electrocardiography
903557|NCT02519998|Balance
903558|NCT02519998|Neuropsychiatric assessment
903559|NCT02519998|Cortisol
903560|NCT02519998|Calcitonin-gene-related peptide
903561|NCT02519998|Electroencephalography
903562|NCT02519998|Optical coherence tomography
903563|NCT02519998|Von Frey Testing
903564|NCT02519985|VHF digital ultrasound
903565|NCT02519985|Corneal thickness
903566|NCT02519985|Epithelial thickness
903567|NCT02519985|Angle diameter
903568|NCT02519985|Sulcus diameter
903569|NCT02519985|Anterior chamber depth
903570|NCT02519985|Repeatability
903571|NCT02519985|Reproducibility
903572|NCT02519972|Low dose CT screening
903573|NCT02519972|Family history of lung cancer
903574|NCT02519946|Heart Transplantation
903575|NCT02519946|Tonometry
903576|NCT02519946|Exercise Test
903577|NCT02519946|Diet
903578|NCT02519946|Cardiovascular Physiology
903579|NCT02519946|Telemedicine
903580|NCT02519946|Pediatrics
903581|NCT02519946|Health Behavior
903582|NCT02519946|Physical Fitness
903583|NCT02519946|Exercise Movement Techniques
903584|NCT02519946|Adolescent Behavior
903585|NCT02519946|Child Behavior
903586|NCT02519933|hemodialysis
903587|NCT02519933|vascular access
903588|NCT02519907|Nerve Stimulation
903589|NCT02519907|Neuroplasticity
903590|NCT02519907|Sensory Feedback
903591|NCT02519881|cartilage defect in ankle
903592|NCT02519881|microfracture
903593|NCT02519881|modified microfracture using collagen
903594|NCT02519881|collagen
903595|NCT02519868|Neuromodulation
903596|NCT02519868|Local anaesthetics
903597|NCT02519829|Suture
903598|NCT02519829|Skin staples
903599|NCT02519829|Vicryl
903600|NCT02519829|Monocryl
903601|NCT02519816|post stem cell transplantation
903602|NCT02519816|Steroid refractory
903603|NCT02519816|dependent chronic
903604|NCT02519777|HIV-Associated Neurocognitive Disorder
903605|NCT02519764|volunteer runners who are participating in the 2015 Mont Blanc Ultra Trail
903606|NCT02519764|hydration protocol
903607|NCT02519764|natremia
903608|NCT02519764|Volunteers
903609|NCT02519725|Family
903610|NCT02519725|PTSD
903611|NCT02519725|Anxiety disorders
903612|NCT02519725|Depression disorders
903613|NCT02519725|Qualitative research
903614|NCT02519712|Induction Chemotherapy
903615|NCT02519712|G-CSF-Mobilized Stem Cells
903616|NCT02519712|Haploidentical Related Donors
903617|NCT02519712|15-141
903618|NCT02519660|Ralydan
903619|NCT02519660|EMLA cream
903620|NCT02519660|Procedural pain
903621|NCT02519660|Phlebotomy
903622|NCT02519660|Child
903623|NCT02519634|Super-Mini Percutaneous Nephrolithotomy
903624|NCT02519634|SMP
903625|NCT02519634|Retrograde Intrarenal Surgery
903626|NCT02519634|RIRS
903627|NCT02519634|Randomized Controlled Trial
903628|NCT02519634|RCT
903629|NCT02519621|diabetic ulcer
903630|NCT02519621|pressure ulcer
903631|NCT02519621|chronic or traumatic wound
903632|NCT02519621|sub-acute or dehisced wound
903633|NCT02519608|chronic obstructive pulmonary disease
903634|NCT02519608|stable coronary artery disease
903635|NCT02519608|ticagrelor
903636|NCT02519608|clopidogrel
903637|NCT02519608|endothelial function
903638|NCT02519608|inflammation
903639|NCT02519608|platelet reactivity
903640|NCT02519595|Procedural sedation
903641|NCT02519595|ketamine
903642|NCT02519595|children
903643|NCT02519582|Colorectal Cancer
903644|NCT02519582|S100A4
903645|NCT02519556|Probiotics
903646|NCT02519556|Inflammation
903647|NCT02519556|Awareness
903648|NCT02519556|Immune tolerance
903649|NCT02519543|insulin resistance
903650|NCT02519530|Positive Youth Development
903651|NCT02519530|Teen Outreach
903652|NCT02519530|Teen Pregnancy Prevention
903653|NCT02519504|Galactose-1-phosphate uridylyltransferase deficiency
903654|NCT02519504|Cognitive disorders
903655|NCT02519478|football
903656|NCT02519478|Training Techniques
903657|NCT02519478|education
903658|NCT02519478|Athletic Injuries
903659|NCT02519478|Brain Concussion
903660|NCT02519465|nasal cannula
903661|NCT02519465|Inhalation Devices
903662|NCT02519452|Multiple Myeloma
903663|NCT02519452|Daratumumab (JNJ-54767414)
903664|NCT02519452|Recombinant Human Hyaluronidase
903665|NCT02519439|Partial Onset Seizures
903666|NCT02519439|complex partial seizures
903667|NCT02519439|simple partial seizures
903668|NCT02519439|anticonvulsant
903669|NCT02519439|ganaxolone
903670|NCT02519439|neurosteroid
903671|NCT02519439|Marinus
903672|NCT02519439|epilepsy
903673|NCT02519426|Third molar
903674|NCT02519426|Classification
903675|NCT02519426|Inferior alveolar nerve
903676|NCT02519426|Lingual nerve injuries
903677|NCT02519426|Mandibular canal
903678|NCT02519413|lymphocyte
903679|NCT02519413|serious infections
903680|NCT02519413|opportunistic infections
903681|NCT02519413|Relapsing Forms
903682|NCT02519400|amitriptyline
903683|NCT02519400|cyp2d6
903684|NCT02519400|cyp2c19
903685|NCT02519374|Fiber tolerability
903686|NCT02519374|Children
903687|NCT02519361|elderly
903688|NCT02519361|immune response
903689|NCT02519361|acute infection
903690|NCT02519348|Hepatocellular Carcinoma
903691|NCT02519348|Immunotherapy
903692|NCT02519348|Antibodies, Monoclonal
903693|NCT02519348|Tremelimumab
903694|NCT02519348|MEDI4736
903695|NCT02519348|Durvalumab
903696|NCT02519335|cardiopulmonary bypass
903697|NCT02519335|ischemia reperfusion injury
903708|NCT02519283|AHF
903709|NCT02519283|HF
903710|NCT02519283|ED
903711|NCT02519283|ER
903712|NCT02519283|Emergency Department
903713|NCT02519283|Emergency Room
903714|NCT02519257|CAD
903715|NCT02519257|VHD
903716|NCT02519257|Thy-1
903717|NCT02519244|Multiple Sclerosis
903718|NCT02519244|Ambulation
903719|NCT02519244|Rehabilitation
903720|NCT02519244|Wearable Robotic Devices
903721|NCT02519231|IUD
903722|NCT02519231|naproxen
903723|NCT02519231|bleeding
903724|NCT02519153|Phosphodiesterase 5 Inhibitors
903725|NCT02519153|PDE5i
903726|NCT02519153|Sildinafil
903727|NCT02519140|Gastric cancer
903728|NCT02519140|colon cancer
903729|NCT02519140|EMR
903730|NCT02519140|biopsy
903731|NCT02519140|bariatric surgery
903732|NCT02519114|M Myeloma
903733|NCT02519114|KIR ligand mismatch
903734|NCT02519114|Haploidentical
903735|NCT02519088|Homologous Blood Transfusion
903736|NCT02519088|Total Hip Replacement
903737|NCT02519088|Patient Blood Management
903738|NCT02519075|Hepatocarcinoma
903739|NCT02519075|TARE
903740|NCT02519075|response assessment
903741|NCT02519062|Carcinoma
903742|NCT02519062|Non-Small-Cell Lung
903743|NCT02519062|FDG PET
903744|NCT02519062|hypoxia markers
903745|NCT02519062|immune markers
903746|NCT02519049|Mesothelioma
903747|NCT02519049|11C-methionine PET
903748|NCT02519049|talc pleurodesis
903749|NCT02519036|Huntington's Disease
903750|NCT02519036|HTTRx
903751|NCT02519036|Early Manifest Huntington's Disease
903752|NCT02518997|Preterm Infants
903753|NCT02518997|Bedside Reading aloud
903754|NCT02518997|Parental wellbeing
903755|NCT02518997|Parental Bonding
903756|NCT02518997|cardio-respiratory stability
903757|NCT02518945|Type 1 Diabetes
903758|NCT02518945|Liraglutide
903759|NCT02518945|Dapagliflozin
903760|NCT02518945|Triple Therapy
903761|NCT02518919|Children
903762|NCT02518919|Emergency Department
903763|NCT02518919|Sedation
903764|NCT02518906|Psychotherapy
903765|NCT02518906|psychotherapy process
903766|NCT02518906|therapeutic alliance
903767|NCT02518906|psychotherapeutic change
903768|NCT02518906|psychophysiology
903769|NCT02518893|Military Personnel
903770|NCT02518893|Air Force Personnel
903771|NCT02518893|Army Personnel
903772|NCT02518893|Navy Personnel
903773|NCT02518893|Armed Forces Personnel
903774|NCT02518893|Marines
903775|NCT02518893|Soldiers
903776|NCT02518893|Sailors
903777|NCT02518893|Airmen
903778|NCT02518893|Decision Making
903779|NCT02518893|Research Subjects
903780|NCT02518893|Life Experiences
903781|NCT02518893|Patient Participation
903782|NCT02518893|Refusal to Participate
903783|NCT02518893|Healthcare Research
903784|NCT02518893|Qualitative Research
903785|NCT02518893|Interview
903786|NCT02518893|Interviews, Telephone
903787|NCT02518893|Ethics, Research
903788|NCT02518867|Cerebral palsy
903789|NCT02518867|Transcranial magnetic stimulation
903790|NCT02518841|ThermaWedge TM
903791|NCT02518841|stretches
903792|NCT02518828|Acute Heart Failure
903793|NCT02518802|Gefitinib
903794|NCT02518802|Pemetrexed
903795|NCT02518802|Synchronous therapy
903796|NCT02518802|Adjuvent therapy
903797|NCT02518789|myoclonus
903798|NCT02518789|Etomidate
903799|NCT02518789|Dexmedetomidine
903800|NCT02518750|Hematopoietic Stem Cell Transplantation
903801|NCT02518750|Salvage Regimen
903802|NCT02518750|Re-Induction Therapy
903803|NCT02518750|Multi-agent chemotherapy
903804|NCT02518737|Glucose-dependent Insulinotropic Polypeptide
903805|NCT02518737|Receptor Deficiency
903806|NCT02518711|symptoms of ADHD
903807|NCT02518698|Castrated resistant prostate cancer
903808|NCT02518698|Patients with bone metastases
903809|NCT02518685|Obesity
903810|NCT02518685|Weight loss
903811|NCT02518685|Device
903812|NCT02518685|Non-surgical
903813|NCT02518685|Endoscopic
903814|NCT02518685|TransPyloric Shuttle
903815|NCT02518685|TPS
903816|NCT02518659|hypomagnesemia
903817|NCT02518659|hypocalcemia
903818|NCT02518659|inulin
903819|NCT02518659|FOS
903820|NCT02518659|PPI
903821|NCT02518659|proton-pump inhibitors
903822|NCT02518646|Delirium
903823|NCT02518646|Intensive care unit
903824|NCT02518646|Adult
903825|NCT02518646|Clinical prediction
903826|NCT02518633|obesity
903827|NCT02518633|hypoxia
903828|NCT02518633|adipose tissue
903829|NCT02518607|Safety and Tolerability
903830|NCT02518607|Male Volunteers
903831|NCT02518594|women
903832|NCT02518594|cervical length of less than 30 millimeters
903833|NCT02518594|carrying twins
903834|NCT02518594|short cervix
903835|NCT02518516|Statins, HMG-CoA
903836|NCT02518516|Acute kidney injury
903837|NCT02518516|Kidney diseases
903838|NCT02518516|Renal failure
903839|NCT02518503|Diabetes Mellitus
903840|NCT02518503|Statins
903841|NCT02518503|HMG-CoA reductase inhibitors
903842|NCT02518477|breast cancer surgery
903843|NCT02518477|axillary lymph node dissection
903844|NCT02518477|resistance training
903845|NCT02518477|breast cancer related lymphedema
903846|NCT02518464|headache
903847|NCT02518464|chronic
903848|NCT02518464|migraine
903849|NCT02518464|right to left shunt
903850|NCT02518451|antihypertensive
903851|NCT02518451|bioequivalence
903852|NCT02518451|formulation
903853|NCT02518451|pharmakokinetic
903854|NCT02518451|valsartan
903855|NCT02518451|subjects
903856|NCT02518451|Fasting conditions
903857|NCT02518438|Tramadol
903858|NCT02518438|Postoperative analgesia
903859|NCT02518438|Infiltration
903860|NCT02518438|Cesarean section
903861|NCT02518412|Alzheimers disease
903862|NCT02518412|Transcranial direct current stimulation (tDCS)
903863|NCT02518412|Neuromodulation
903864|NCT02518412|Neuropsychology
903865|NCT02518399|Blood vessels
903866|NCT02518399|Heat
903867|NCT02518399|Cardiovascular diseases
903868|NCT02518386|emergency department
903869|NCT02518386|epidemiology
903870|NCT02518386|prehospital care
903871|NCT02518386|dispatch
903872|NCT02518386|acute self poisoning
903873|NCT02518360|NON SPECIFIC LOW BACK PAIN
903874|NCT02518360|OSTEOPATHY
903875|NCT02518360|FOOT PRESSURE PLATFORM
903876|NCT02518360|POSTURAL BALANCE
903877|NCT02518334|type two diabetes
903878|NCT02518334|glycemic control
903879|NCT02518321|Toileting
903880|NCT02518321|Technology-Assisted Toilets
903881|NCT02518321|Rehabilitation
903882|NCT02518321|Assistive Devices
903883|NCT02518321|Activities of Daily Living
903884|NCT02518282|high-sensitivity troponin T
903885|NCT02518282|Acute myocardial infarction
903886|NCT02518282|Heart valvular surgery
903887|NCT02518282|Cardiac surgery
903888|NCT02518269|hip
903889|NCT02518269|arthroplasty
903890|NCT02518269|G7
903891|NCT02518269|EchoBimetric
903892|NCT02518269|E1
903893|NCT02518269|ceramic
903894|NCT02518269|Arcom XL
903895|NCT02518256|Neoplasms
903896|NCT02518256|Glandular and Epithelial
903897|NCT02518256|Ovarian Neoplasms
903898|NCT02518256|Ovarian cancer
903899|NCT02518204|cognitive assessment
903900|NCT02518204|neuropsychological assessment
903901|NCT02518204|Brain Performance Test
903902|NCT02518204|computerized assessment
903903|NCT02518191|GnRHa
903904|NCT02518191|ovarian function
903905|NCT02518191|anti-mullerian hormone
903906|NCT02518178|NFC
903907|NCT02518178|randomization
903908|NCT02518178|RCT
903909|NCT02518178|mHealth
903910|NCT02518178|maternal and child health
903911|NCT02518165|Cognitive Domain: Speed
903912|NCT02518165|Cognitive Domain: Reaction Time
903913|NCT02518165|Cognitive Domain: Attention
903914|NCT02518165|Cognitive Domain: Executive Function
903915|NCT02518165|Cognitive Domain Memory
903916|NCT02518165|Sleep Quality
903917|NCT02518165|Sleep Efficiency
903918|NCT02518139|Chronic Obstructive Pulmonary Disease, COPD
903919|NCT02518126|LIF IUGR
903920|NCT02518087|CPB
903921|NCT02518087|OXIRIS®
903922|NCT02518087|AKI
903923|NCT02518087|SIRS
903924|NCT02518087|Cytokines
903925|NCT02518087|LPS
903926|NCT02518074|volunteers
903927|NCT02518061|Glioma; 11C-Methionine PET
903928|NCT02518048|Psoriasis
903929|NCT02518022|Type 1 Diabetes mellitus
903930|NCT02518022|Hypoglycemia
903931|NCT02518022|continuous subcutaneous insulin infusion
903932|NCT02518022|Alcohol
903933|NCT02518022|continuous glucose monitoring system
903934|NCT02518022|Nutrition
903935|NCT02517983|chronic respiratory diseases phenotyping
903936|NCT02517970|infant feeding
903937|NCT02517970|breast-feeding
903938|NCT02517970|bottle-feeding
903939|NCT02517970|feeding interactions
903940|NCT02517970|maternal feeding practices
903941|NCT02517957|Xiashi surgical
903942|NCT02517944|Familial hypercholesterolemia
903943|NCT02517918|Advanced solid tumor
903944|NCT02517918|Bone metastasis and advanced pretreated osteosarcoma
903945|NCT02517918|Phase I trial
903946|NCT02517918|Dose escalation and expansion cohort
903947|NCT02517918|Biomarkers study
903948|NCT02517879|ITNs
903949|NCT02517879|malaria prevention
903950|NCT02517866|Drug therapy
903951|NCT02517827|common femoral artery
903952|NCT02517827|drug-coated balloon
903953|NCT02517827|surgical endarterectomy
903954|NCT02517801|anthocyanins
903955|NCT02517801|Post-menopausal women
903956|NCT02517801|endothelial function
903957|NCT02517801|vascular function
903958|NCT02517775|polyphenols
903959|NCT02517775|vascular function
903960|NCT02517775|endothelial function
903961|NCT02517775|cranberry
903962|NCT02517775|healthy
903963|NCT02517723|Borderline Personality Disorder
903964|NCT02517723|comorbid Posttraumatic Stress Disorder
903965|NCT02517723|Narrative Exposure Therapy
903966|NCT02517723|Dialectical-Behavioral Therapy
903967|NCT02517684|Crohn's disease
903968|NCT02517684|pediatric
903969|NCT02517684|infliximab
903970|NCT02517684|top-down
903971|NCT02517684|TISKids
903972|NCT02517671|Fitness
903973|NCT02517671|Run time
903974|NCT02517671|VO2max
903975|NCT02517671|VEGF
903976|NCT02517671|Central blood pressure
903977|NCT02517671|Augmentation Index
903978|NCT02517671|Pulse wave analysis
903979|NCT02517632|Physical activity
903980|NCT02517632|Cardiac rehabilitation
903981|NCT02517619|Iontophoresis
903982|NCT02517619|Ophthalmology
903983|NCT02517619|Non-Infectious Anterior Segment Uveitis
903984|NCT02517593|BCRAT
903985|NCT02517593|IBIS
903986|NCT02517593|PRS
903987|NCT02517593|breast cancer
903988|NCT02517593|Tyrer-Cuzick
903989|NCT02517554|meet National Comprehensive Cancer Network® criteria for cancer genetic testing for breast, ovarian and colorectal cancers
903990|NCT02517528|(HCV) Infection
903991|NCT02517528|Compensated Cirrhosis
903992|NCT02517515|HCV Infection
903993|NCT02517502|DHA
903994|NCT02517502|Omega-3
903995|NCT02517502|neoadjuvant chemotherapy
903996|NCT02517502|chemotherapy
903997|NCT02517502|breast cancer
903998|NCT02517489|Community-Acquired Pneumonia (CAP)
903999|NCT02517489|Hydrocortisone
904000|NCT02517489|Corticosteroids
904001|NCT02517463|Emergency contraception
904002|NCT02517463|ulipristal acetate
904003|NCT02517463|efficacy
904004|NCT02517450|Subjects
904005|NCT02517411|COPD
904006|NCT02517411|physiotherapy
904007|NCT02517411|Stable disease
904008|NCT02517398|Solid tumor
904009|NCT02517398|MSB0011359C (M7824)
904010|NCT02517398|Metastatic or Locally Advanced Solid Tumors
904011|NCT02517346|CPAP compliance
904012|NCT02517346|Telemonitoring
904013|NCT02517346|Standard management
904014|NCT02517346|Cost effectiveness
904015|NCT02517333|Motor skill proficiency
904016|NCT02517333|movement difficulties
904017|NCT02517333|Developmental Coordination Disorder (DCD)
904018|NCT02517333|Low physical fitness
904019|NCT02517320|Diabetic Nephropathy
904020|NCT02517294|Nasotracheal intubation
904021|NCT02517294|adenoid size
904022|NCT02517294|epistaxis
904023|NCT02517294|nasopharyngeal mucosal injury
904024|NCT02517255|ST segment elevation myocardial infarction
904025|NCT02517255|Failed Thrombolysis
904026|NCT02517255|Rescue Percutaneous Coronary Intervention
904027|NCT02517255|Cardiac Magnetic Resonance Imaging
904028|NCT02517229|volunteers
904029|NCT02517216|volunteers
904030|NCT02517190|volunteers
904031|NCT02517177|volunteers
904032|NCT02517151|iron
904033|NCT02517151|fatigue
904034|NCT02517151|crohn's disease
904035|NCT02517151|ulcerative colitis
904036|NCT02517151|IBD
904037|NCT02517138|volunteers
904038|NCT02517112|volunteers
904039|NCT02517099|Preschool
904040|NCT02517099|Wheeze
904041|NCT02517099|Moderate
904042|NCT02517099|Severe
904043|NCT02517086|blood circulation
904044|NCT02517073|mechanical ventilation
904045|NCT02517073|epidemiology
904046|NCT02517073|intensive care unit
904047|NCT02517073|national survey
904048|NCT02517060|Social perceptions
904049|NCT02517008|non-monetary incentive
904050|NCT02517008|institutional delivery
904051|NCT02516982|mHealth
904052|NCT02516982|Telemedicine
904053|NCT02516982|Perinatal depression
904054|NCT02516982|Screening
904055|NCT02516982|Edinburgh Postnatal Depression Scale
904056|NCT02516982|Whooley Questions
904057|NCT02516982|Data collection
904058|NCT02516982|Mood disorders
904059|NCT02516982|Mental health
904060|NCT02516982|Antenatal care
904061|NCT02516982|Prenatal Care
904062|NCT02516956|Breakfast
904063|NCT02516956|Food choices
904064|NCT02516956|Lunch
904065|NCT02516956|Eating habits
904066|NCT02516956|Appetite
904067|NCT02516956|Neural activation
904068|NCT02516956|Attention
904069|NCT02516956|Glucose
904070|NCT02516956|Insulin
904071|NCT02516956|fMRI
904072|NCT02516943|Arterial blood gas analysis
904073|NCT02516930|health promotion
904074|NCT02516930|crowdsourcing
904075|NCT02516904|Subjects
904076|NCT02516891|treatment
904077|NCT02516891|stent
904078|NCT02516891|coronary bifurcations lesions
904079|NCT02516878|acupuncture
904080|NCT02516878|Chinese Medicine
904081|NCT02516878|obesity
904082|NCT02516865|postpartum
904083|NCT02516865|physical activity
904084|NCT02516852|community development; poultry; animal-source food; stunting
904085|NCT02516839|Overweight
904086|NCT02516839|Obesity
904087|NCT02516839|Overeating
904088|NCT02516839|Body Mass Index
904089|NCT02516839|Weight
904090|NCT02516839|Treatment
904091|NCT02516839|Cravings
904092|NCT02516839|Intervention
904093|NCT02516839|Behavioral Treatment
904094|NCT02516813|M3814
904095|NCT02516813|Advanced solid tumors
904096|NCT02516813|DNA-PK Inhibitor
904097|NCT02516813|Radiotherapy
904098|NCT02516787|volunteers
904099|NCT02516761|Fibromyalgia
904100|NCT02516644|Parkinson Disease
904101|NCT02516644|Mobility
904102|NCT02516644|Balance
904103|NCT02516644|Virtual Reality
904104|NCT02516644|treadmill training
904105|NCT02516631|Labour, induced
904106|NCT02516631|Misoprostol
904107|NCT02516631|Pharmacokinetics
904108|NCT02516631|Cardiotocography
904109|NCT02516631|Safety
904110|NCT02516605|Primary Biliary Cirrhosis, PBC
904111|NCT02516605|Primary Biliary Cholangitis
904112|NCT02516566|Positive end-expiratory pressure ventilation
904113|NCT02516566|Optic nerve sheath diameter
904114|NCT02516540|hereditary breast and ovarian cancer (HBOC)
904115|NCT02516540|BRCA1/2 mutation carriers
904116|NCT02516540|Mediterranean diet
904117|NCT02516540|Structured exercise training
904118|NCT02516540|prevention
904119|NCT02516514|Blood culture
904120|NCT02516514|Bacteremia
904121|NCT02516514|Single sampling
904122|NCT02516501|Ketogenic Diet
904123|NCT02516501|Body composition
904124|NCT02516501|Radiation therapy
904125|NCT02516436|Bunavail
904126|NCT02516436|Suboxone
904127|NCT02516436|Heroin
904128|NCT02516436|Zubsolv
904129|NCT02516436|Buprenorphine
904130|NCT02516436|Naloxone
904131|NCT02516436|Opioids
904132|NCT02516436|Addiction
904133|NCT02516436|Induction
904134|NCT02516397|body fat mass reduction
904135|NCT02516384|Fecal Microbiota Transplantation
904136|NCT02516384|Ulcerative Colitis
904137|NCT02516345|Physical activity
904138|NCT02516345|Financial incentives
904139|NCT02516345|Children
904140|NCT02516345|Parents
904141|NCT02516345|RCT
904142|NCT02516345|Wireless pedometer
904143|NCT02516306|Presbyopia, Vision
904144|NCT02516280|Total knee replacement
904145|NCT02516280|Cold
904146|NCT02516280|Neurocryostimulation
904147|NCT02516280|CO2 cryotherapy
904148|NCT02516280|mobility
904149|NCT02516267|platelet aggregability
904150|NCT02516267|acute coronary syndrome
904151|NCT02516267|coronary artery bypass graft
904152|NCT02516254|vitamin D
904153|NCT02516254|fortified bread
904154|NCT02516254|efficacy
904155|NCT02516254|Vitamin D Deficiency
904156|NCT02516241|Urothelial Cancer
904157|NCT02516241|Phase III
904158|NCT02516189|Microcirculation
904159|NCT02516189|Electromyography
904160|NCT02516189|Motor Activity
904161|NCT02516176|stroke
904162|NCT02516176|cerebral vascular accident
904163|NCT02516176|balance
904164|NCT02516176|treadmill
904165|NCT02516176|falls
904166|NCT02516176|hemiparesis
904174|NCT02516137|Dry needling
904175|NCT02516124|Autoimmune diseases
904176|NCT02516124|Systemic sclerosis
904177|NCT02516124|Autologous Hematopoietic stem cell transplant
904178|NCT02516072|remote ischemic preconditioning
904179|NCT02516059|thoracic epidural analgesia
904180|NCT02516059|oxycodone
904181|NCT02516059|oral naloxone
904182|NCT02516059|radical cystectomy
904183|NCT02516059|bowel function
904184|NCT02516059|pain
904185|NCT02516033|Atrial Fibrillation
904186|NCT02516033|Hybrid Ablation
904187|NCT02516033|Efficacy
904188|NCT02516033|Risk Profile
904189|NCT02516033|Biomarkers
904190|NCT02516020|IVF
904191|NCT02516020|ICSI
904192|NCT02516020|culture media
904193|NCT02516020|sequential
904194|NCT02515981|tobacco dependence
904195|NCT02515981|smoking cessation
904196|NCT02515981|mental health
904197|NCT02515981|cardiovascular disease
904198|NCT02515981|obesity
904199|NCT02515955|Healthy
904200|NCT02515955|JNJ-54175446
904201|NCT02515929|Oligomeric Proanthocyanidins
904202|NCT02515929|Periodontal Disease
904203|NCT02515903|Endoscopy
904204|NCT02515903|Intracerebral hemorrhage
904205|NCT02515903|surgery
904206|NCT02515903|stereotactic aspiration
904207|NCT02515903|Key-hole approach
904208|NCT02515903|Intracerebral hemorrhage surgical treatment
904209|NCT02515903|Transparent endoscopic sheath
904210|NCT02515903|Agitation-aspiration device
904211|NCT02515890|midazolam
904212|NCT02515890|dexmedetomidine
904213|NCT02515890|memory
904214|NCT02515864|Male and Female Volunteers
904215|NCT02515786|Chronic respiratory failure
904216|NCT02515786|Oxygen therapy
904217|NCT02515786|Nasal catheter
904218|NCT02515786|Mucociliary clearance
904219|NCT02515747|Lipoprotein(a)
904220|NCT02515747|coronary artery bypass grafting (CABG)
904221|NCT02515747|apo(a)
904222|NCT02515747|prognosis
904223|NCT02515747|myocardial infarction
904224|NCT02515747|cardiovascular death
904225|NCT02515747|percutaneous coronary intervention (PCI)
904226|NCT02515734|FOLFOXIRI
904227|NCT02515734|Bmab
904228|NCT02515734|Cmab
904229|NCT02515617|Ventilator-associated pneumonia
904230|NCT02515617|Subglottic-secretions drainage
904231|NCT02515617|Critically ill patients
904232|NCT02515617|Cost-utility analysis
904233|NCT02515617|Prevention
904234|NCT02515591|Healthy volunteer
904235|NCT02515591|Respiratory
904236|NCT02515591|Bronchoalveolar lavage
904237|NCT02515578|Primary Health Care
904238|NCT02515578|Cardiovascular Diseases
904239|NCT02515578|Quality Improvement
904240|NCT02515565|pneumonia
904241|NCT02515565|Exacerbation
904242|NCT02515565|physiotherapy
904243|NCT02515565|hospitalization
904244|NCT02515539|Transcatheter Mitral Valve Replacement
904245|NCT02515539|Mitral Regurgitation
904246|NCT02515539|Mitral Insufficiency
904247|NCT02515539|Transapical
904248|NCT02515539|Transfemoral
904249|NCT02515513|Pancreas
904250|NCT02515513|Pancreas Cancer
904251|NCT02515513|Muscle Biopsy
904252|NCT02515513|Cachexia
904253|NCT02515513|Muscle Cachexia
904254|NCT02515500|cigarette reduction
904255|NCT02515500|digital health
904256|NCT02515500|mobile health
904257|NCT02515500|technology
904258|NCT02515500|Quitbit
904259|NCT02515500|mHealth
904260|NCT02515500|smoking cessation
904261|NCT02515500|quit smoking
904262|NCT02515500|self-regulation
904263|NCT02515487|Post-chemotherapy
904264|NCT02515487|cognitive impairment
904265|NCT02515474|Cholangiopancreatography
904266|NCT02515474|Endoscopic
904267|NCT02515474|Common bile duct
904268|NCT02515474|Complication
904269|NCT02515474|Recurrence
904270|NCT02515474|Laparoscopic
904271|NCT02515461|Diabetes mellitus
904272|NCT02515461|Low energy shockwave therapy
904273|NCT02515461|Chronic Renal Insufficiency
904274|NCT02515448|VAP
904275|NCT02515448|Critical care
904276|NCT02515448|Pharmacokinetics
904277|NCT02515448|Gentamicin
904278|NCT02515435|apatinib
904279|NCT02515435|NSCLC
904280|NCT02515435|safety
904281|NCT02515435|efficacy
904282|NCT02515422|Caesarean Section
904283|NCT02515409|Obstructive Sleep Apnea Syndrome (OSAS)
904284|NCT02515409|Heated Humidified High Flow Nasal Cannula (HHHNC)
904285|NCT02515409|Continues positive airway pressure (CPAP)
904286|NCT02515409|Children
904287|NCT02515409|Non invasive ventilation
904288|NCT02515409|Treatment
904289|NCT02515383|Adolescent Cancer
904290|NCT02515383|MD Anderson Symptom Inventory (modified for adolescent use)
904291|NCT02515383|MDASI
904292|NCT02515383|Surveys
904293|NCT02515383|Questionnaires
904294|NCT02515383|Interviews
904295|NCT02515383|Symptoms
904296|NCT02515370|Option B plus
904297|NCT02515370|HIV infected women
904298|NCT02515357|Sleep Disorders
904299|NCT02515357|Metabolic Syndrome
904300|NCT02515357|Mediterranean Diet
904301|NCT02515357|Mediterranean Lifestyle
904302|NCT02515344|Patients
904303|NCT02515344|early detection of cancer
904304|NCT02515344|patient compliance
904305|NCT02515331|resistant hypertension
904306|NCT02515318|COPD
904307|NCT02515318|Exacerbation
904308|NCT02515318|Hospitalisation
904309|NCT02515318|Physiotherapy
904310|NCT02515292|IUGR (intrauterine growth restriction)
904311|NCT02515292|IGF2 (insulin-like growth factor 2)
904312|NCT02515292|morbidity
904313|NCT02515266|protein
904314|NCT02515266|growth
904315|NCT02515266|head circumference
904316|NCT02515253|Breast Pain
904317|NCT02515253|Mastalgia
904318|NCT02515253|Bras
904319|NCT02515253|Breast Support
904320|NCT02515227|peptide
904321|NCT02515227|vaccine
904322|NCT02515227|Montanide ISA-51
904323|NCT02515227|pembrolizumab
904324|NCT02515227|PD-1
904325|NCT02515227|KEYTRUDA
904326|NCT02515214|bariatric surgery
904327|NCT02515214|reproduction
904328|NCT02515175|HSV
904329|NCT02515175|Herpes
904330|NCT02515175|Genital Herpes
904331|NCT02515175|Vaccine
904332|NCT02515162|conization
904333|NCT02515162|LLETZ
904334|NCT02515162|cervical dysplasia
904335|NCT02515162|cervical intraepithelial neoplasia
904336|NCT02515162|Fischer cone biopsy excisor
904337|NCT02515162|loop electrosurgical excision procedure
904338|NCT02515149|linkage to care
904339|NCT02515149|point of care diagnostics
904340|NCT02515149|point of care CD4
904341|NCT02515149|HIV care cascade
904342|NCT02515149|Kenya
904343|NCT02515123|intensive care unit
904344|NCT02515123|malnutrition
904345|NCT02515123|GI motility
904346|NCT02515123|nutritional intake
904347|NCT02515110|lumpectomy
904348|NCT02515110|mastectomy without reconstruction
904349|NCT02515110|mastectomy with reconstruction
904350|NCT02515110|Estrogen Receptor Negative
904351|NCT02515110|Estrogen Receptor Positive
904352|NCT02515110|HER2/Neu Negative
904353|NCT02515110|HER2/Neu Positive
904485|NCT02514460|popliteal artery
904354|NCT02515110|Progesterone Receptor Negative
904355|NCT02515110|Progesterone Receptor Positive
904356|NCT02515110|Stage IA Breast Cancer
904357|NCT02515110|Stage IB Breast Cancer
904358|NCT02515110|Stage IIA Breast Cancer
904359|NCT02515110|Stage IIB Breast Cancer
904360|NCT02515110|Stage IIIA Breast Cancer
904361|NCT02515084|recurrence Thyroid cancer
904362|NCT02515084|18F-FDG PET-CT
904363|NCT02515084|diffusion-weighted Magnetic Resonance Imaging
904364|NCT02515045|Cataract
904365|NCT02515045|Surgery
904366|NCT02515045|Prophylaxis
904367|NCT02515019|Anaesthetics inhalation
904368|NCT02515019|Bispectral index
904369|NCT02515019|Cardiopulmonary bypass
904370|NCT02514993|Sternal fracture
904371|NCT02514993|Thoracic spine fracture
904372|NCT02514993|Thoracic cage injury
904373|NCT02514967|SLE
904374|NCT02514967|Lupus
904375|NCT02514967|Lupus Erythematosus, Systemic
904376|NCT02514967|Autoimmune Diseases
904377|NCT02514967|A-623
904378|NCT02514967|Blisibimod
904379|NCT02514967|Nephritis
904380|NCT02514902|Lateral Flow Device (LFD)
904381|NCT02514902|Acute Stroke
904382|NCT02514902|Traumatic Brain Injury (TBI)
904383|NCT02514902|Point of Care (POC)
904384|NCT02514902|Biomarker
904385|NCT02514824|recurrent merkel cell carcinoma
904386|NCT02514824|metastatic merkel cell carcinoma
904387|NCT02514798|COPD
904388|NCT02514798|HFNC
904389|NCT02514798|work of breathing
904390|NCT02514746|Japanese Encephalitis Vaccines
904391|NCT02514746|Flavivirus Infections
904392|NCT02514733|kidney
904393|NCT02514733|transplant
904394|NCT02514655|Tracheal intubation
904395|NCT02514655|Cuff pressure
904396|NCT02514655|Ventilator-acquired pneumonia
904397|NCT02514655|Intensive care unit
904398|NCT02514655|Tracheal injuries
904399|NCT02514629|Hypogonadism
904400|NCT02514629|Obesity
904401|NCT02514629|Erectile Dysfunction
904402|NCT02514629|Testosterone
904403|NCT02514629|Metformin
904404|NCT02514629|Weight Loss
904405|NCT02514629|Insulin Resistance
904406|NCT02514616|Reflux
904407|NCT02514616|Reflux disease
904408|NCT02514616|Gastroesophageal reflux disease
904409|NCT02514616|Lower esophageal sphincter stimulation
904410|NCT02514603|Neoplasm metastasis
904411|NCT02514603|Checkpoint Kinase 1
904412|NCT02514603|CHK1
904413|NCT02514603|CHK1 inhibitor
904414|NCT02514551|stomach cancer
904415|NCT02514512|Lung Cancer
904416|NCT02514512|Stereotactic Ablative Radiotherapy (SABR)
904417|NCT02514512|MLC Tracking
904418|NCT02514512|Radiotherapy
904419|NCT02513784|Microbiome
904420|NCT02513784|Esophagus
904421|NCT02513784|Endoscopy
904422|NCT02513784|Mouthwash
904423|NCT02513758|HIV patients
904424|NCT02513758|Genital HIV penetration
904425|NCT02513745|cataract
904426|NCT02513745|toric
904427|NCT02513745|phacoemulsification
904432|NCT02513719|drug eluting stent
904433|NCT02513719|stent
904434|NCT02513719|real world
904435|NCT02513693|Anesthesia
904436|NCT02513693|Rocuronium
904437|NCT02513693|Sugammadex
904438|NCT02513693|Neostigmine
904439|NCT02513693|TOF
904440|NCT02513693|Radical Prostatectomy
904441|NCT02513693|Robotic Surgery
904442|NCT02513693|Accelerometry
904443|NCT02513680|Skin Aging
904444|NCT02513680|laser phototherapy
904445|NCT02513680|Rejuvenation
904446|NCT02513680|Infrared Rays/therapeutic use
904447|NCT02513680|Female
904448|NCT02513680|Humans
904449|NCT02513680|Esthetics
904450|NCT02513680|Phototherapy
904451|NCT02513680|facial rejuvenation
904452|NCT02513654|tolerability
904453|NCT02513654|repeat dosing
904454|NCT02513654|safety
904455|NCT02513654|healthy Chinese subjects
904456|NCT02513654|Pharmacokinetics
904457|NCT02513654|lamotrigine
904458|NCT02513628|Cardiac arrest
904459|NCT02513628|neuroprognostication
904460|NCT02513628|optic nerve sheath diameter
904461|NCT02513628|outcome
904462|NCT02513628|ultrasonography
904463|NCT02513615|Fibrosis
904464|NCT02513615|Peritoneal Dialysis
904465|NCT02513615|Epigenetics
904466|NCT02513615|Peritoneal membrane injury
904467|NCT02513615|Glucose exposure
904468|NCT02513602|implantology
904469|NCT02513602|kidney
904470|NCT02513602|renal disease
904471|NCT02513602|edentulism
904472|NCT02513602|tooth loss
904473|NCT02513589|Positron emission tomography
904474|NCT02513589|Carotid plaque
904475|NCT02513589|Inflammation
904476|NCT02513589|Stroke
904477|NCT02513576|Sternal instability
904478|NCT02513576|physical therapy
904479|NCT02513576|Respiratory muscle strength
904480|NCT02513563|Squamous cell lung cancer
904481|NCT02514499|patients
904482|NCT02514460|stents
904483|NCT02514460|atherectomy
904484|NCT02514460|femoral artery
904486|NCT02514447|SCLC
904487|NCT02514421|pancreatic adenocarcinoma
904488|NCT02514421|electrochemotherapy
904489|NCT02514421|electroporation
904490|NCT02514421|radiogenomics
904491|NCT02514421|imaging
904492|NCT02514421|magnetic resonance spectroscopy
904493|NCT02514395|linguistic validation
904494|NCT02514395|KOOS
904495|NCT02514395|Marathi translation
904496|NCT02514356|behavioral economics
904497|NCT02514356|antiretroviral adherence
904498|NCT02514356|SMS
904499|NCT02514356|mobile health (mHealth)
904500|NCT02514356|Adolescents
904501|NCT02514356|Uganda
904502|NCT02514356|HIV
904503|NCT02514343|radius fracture
904504|NCT02514343|magnesium sulfate
904505|NCT02514343|rehabilitation
904506|NCT02514343|bupivacaine
904507|NCT02514330|Drop Jump
904508|NCT02514330|High Intensity Interval Training
904509|NCT02514330|Muscle Fatigue
904510|NCT02514330|Aerobic Performance
904511|NCT02514278|Organ preservation
904512|NCT02514278|Local excision
904513|NCT02514278|Radiochemotherapy
904514|NCT02514278|Neoadjuvant chemotherapy
904515|NCT02514278|Folfirinox
904516|NCT02514278|Tumour response
904517|NCT02514265|pelvic pain, bladder pain
904518|NCT02514252|Advanced Cancers
904519|NCT02514252|Metastatic
904520|NCT02514252|Recurrent cancer
904521|NCT02514252|Incurable cancer
904522|NCT02514252|Fentanyl sublingual spray
904523|NCT02514252|FSS
904524|NCT02514252|Questionnaires
904525|NCT02514252|Surveys
904526|NCT02514252|Mental ability tests
904527|NCT02514252|Phone calls
904528|NCT02514252|Study diary
904529|NCT02514252|Pain control
904530|NCT02514226|microbiology
904531|NCT02514226|halitosis
904532|NCT02514213|PSA
904533|NCT02514187|Osteogenesis
904534|NCT02514161|Smokers
904535|NCT02514161|Maximum Inspiratory Pressure
904536|NCT02514148|patient education
904537|NCT02514148|therapeutic exercise
904538|NCT02514148|manual therapy
904539|NCT02514109|neuronopathy
904540|NCT02514109|antibodies
904541|NCT02514109|Clinical and biological diagnostic criteria
904546|NCT02514070|LDL-C
904547|NCT02514070|Omega-3 Fatty Acid
904548|NCT02514070|PCSK9
904549|NCT02514070|HDL-C
904550|NCT02514018|Varicella-Zoster Virus
904551|NCT02514018|Immune Activation
904552|NCT02514018|HIV Vaccine
904553|NCT02514018|Mucosal Immunity
904554|NCT02514005|Trigger points
904555|NCT02514005|Manual therapy
904556|NCT02514005|Patellofemoral syndrome
904557|NCT02514005|Dry needling
904558|NCT02513992|ictal SPECT
904559|NCT02513979|Angiotensin type II receptor (AT2R) antagonists
904560|NCT02513979|Acute postoperative pain
904561|NCT02513979|Chronic postoperative pain
904562|NCT02513979|Abdominal surgery
904563|NCT02513953|Endometriosis
904564|NCT02513953|Mesosalpinx
904565|NCT02513953|Broad Ligament
904566|NCT02513953|Laparoscopy
904567|NCT02513940|Torsades de pointes
904568|NCT02513940|Testosterone
904569|NCT02513940|Progesterone
904570|NCT02513940|Clinical trial
904571|NCT02513940|Risk reduction
904572|NCT02513940|Electrocardiography
904573|NCT02513927|Blood pressure variability
904574|NCT02513927|CCB
904575|NCT02513927|beta-receptor blockers
904576|NCT02513927|heart rate
904577|NCT02513914|endovascular neurosurgery
904578|NCT02513901|Chidamide
904579|NCT02513901|Histone Deacetylase Inhibitor
904580|NCT02513901|HIV-1 Reservoir
904581|NCT02513901|Chronic HIV infections
904582|NCT02513901|Antiretroviral Therapy
904583|NCT02513901|HIV Eradication
904584|NCT02513862|autologous platelet rich plasma
904585|NCT02513862|deep hypothermic circulatory arrest
904586|NCT02513862|transfusion
904587|NCT02513849|esophagus
904588|NCT02513849|gastroscopy
904589|NCT02513849|tamoxifen
904590|NCT02513823|blood pressure
904591|NCT02513823|vitamin D
904592|NCT02513524|hypertension
904593|NCT02513524|adherence
904594|NCT02513524|resistant hypertension
904595|NCT02513524|blood pressure
904596|NCT02513524|non-adherence
904597|NCT02513511|difficult airway
904598|NCT02513511|awake intubation
904599|NCT02513485|Inflammation
904600|NCT02513485|Anhedonia
904601|NCT02513485|Psychomotor retardation
904602|NCT02513472|Eribulin Mesylate
904603|NCT02513472|Pembrolizumab
904604|NCT02513472|Metastatic Triple-Negative Breast Cancer
904605|NCT02513472|mTNBC
904606|NCT02513459|ABBV-066
904607|NCT02513459|BI 655066
904608|NCT02513459|risankizumab
904609|NCT02513433|Lumbar epidural anaesthesia
904610|NCT02513420|levator ani avulsion
904611|NCT02513420|perineal muscle training
904612|NCT02513420|pelvic floor ultrasound
904613|NCT02513394|HR+/HER2- breast cancer
904614|NCT02513394|Palbociclib
904615|NCT02513368|aesthetic
904616|NCT02513368|connective tissue graft
904617|NCT02513368|mucosa thickness
904618|NCT02513355|Non-small cell lung cancer,Endostar
904619|NCT02513342|Endostar,Advanced lung squamous carcinoma
904620|NCT02513329|Breast Cancer
904621|NCT02513329|Anti-estrogens
904622|NCT02513329|Hot Flushes
904623|NCT02513329|Tamoxifen
904624|NCT02513329|Aromatase inhibitors
904625|NCT02513329|Hot Flashes
904626|NCT02513316|Microbleeds
904627|NCT02513303|Dialysis
904628|NCT02513303|End Stage Renal Disease
904629|NCT02513303|End Stage Kidney Disease
904630|NCT02513303|ESRD
904631|NCT02513303|Chronic Kidney Failure
904632|NCT02513303|Chronic Renal Failure
904633|NCT02513303|Chronic Kidney Disease
904634|NCT02513303|Hemodialysis
904635|NCT02513303|Vascular Access
904636|NCT02513303|Arteriovenous Fistula
904637|NCT02513303|AV Fistula
904638|NCT02513303|AVF
904639|NCT02513303|Nephrology
904640|NCT02513303|Vascular Surgery
904641|NCT02513303|Dialysis Access
904642|NCT02513290|quality of life
904643|NCT02513290|allergic rhinitis
904644|NCT02513290|bilastine
904645|NCT02513290|loratadine
904646|NCT02513290|clinical trial
904647|NCT02513277|type 2 diabetes
904648|NCT02513277|impaired glucose regulation
904649|NCT02513277|intellectual disability
904650|NCT02513277|learning disability
904651|NCT02513277|screening
904652|NCT02513277|prevention
904653|NCT02513277|lifestyle education
904654|NCT02513264|Registry
904655|NCT02513264|Asthma
904656|NCT02513212|Sensitivity
904657|NCT02513199|Hepatocellular Carcinoma
904658|NCT02513199|Trans-Arterial Chemoembolization
904659|NCT02513199|Stereotactic Body Radiation Therapy
904660|NCT02513199|HCC
904661|NCT02513199|TACE
904662|NCT02513199|SBRT
904663|NCT02513173|low back pain
904664|NCT02513173|verbal instruction
904665|NCT02513173|lumbar multifidus
904666|NCT02513173|ultrasound imaging
904667|NCT02513173|Muscle thickness
904668|NCT02513134|IOL power calculations
904669|NCT02513134|Intraoperative
904670|NCT02513134|OCT
904671|NCT02513134|Refractive outcome
904672|NCT02513134|Biometry
904673|NCT02513121|NAFLD
904674|NCT02513121|Steatohepatitis
904675|NCT02513121|NASH
904676|NCT02513121|Liver
904677|NCT02513121|Diet
904678|NCT02513121|Pediatric
904679|NCT02513121|Adolescent
904680|NCT02513056|non-conditional pacemakers
904681|NCT02513056|implantable cardioverter defibrillator
904682|NCT02513017|partially randomized clinical trial
904683|NCT02513017|cardiovascular disease
904684|NCT02513017|insomnia
904685|NCT02513017|preference
904686|NCT02513017|acceptability
904687|NCT02512978|myocardial infarction
904688|NCT02512978|hypothyroidism
904689|NCT02512978|levothyroxine
904690|NCT02512978|cardiac magnetic resonance imaging
904691|NCT02512978|myocardial perfusion/metabolism radionuclide imaging
904692|NCT02512978|myocardial fibrosis
904693|NCT02512978|myocardial perfusion/metabolism
904694|NCT02512978|cardiac function
904695|NCT02512952|Periodontal regeneration
904696|NCT02512952|Growth factors
904697|NCT02512939|tuberculosis
904698|NCT02512939|diagnostic test
904699|NCT02512926|Solid Tumors
904700|NCT02512926|Leukemia
904701|NCT02512926|Relapsed
904702|NCT02512926|Refractory
904703|NCT02512913|Smoking Cessation
904704|NCT02512913|Intervention
904705|NCT02512913|Pregnancy
904706|NCT02512913|Postnatal
904707|NCT02512900|Asthma
904708|NCT02512887|Hypospadias
904709|NCT02512887|Caudal Block
904710|NCT02512887|Dorsal Penile Block
904711|NCT02512887|Anesthesia
904712|NCT02512887|Complications
904713|NCT02512887|Post-operative
904714|NCT02512887|Urethrocutaneous Fistula
904715|NCT02512887|Glans dehiscence
904716|NCT02512861|Bupivacaine
904717|NCT02512861|Cardiac Surgery
904718|NCT02512861|Pediatrics
904719|NCT02512861|Nerve Block
904720|NCT02512848|postmenopause
904721|NCT02512848|endometrial sampling
904722|NCT02512848|vaginal bleeding
904723|NCT02512835|Primary health care
904724|NCT02512835|Public health
904725|NCT02512835|Medical Informatics
904726|NCT02512835|Social Determinants of Health
904727|NCT02512822|radiofrequency
904728|NCT02512822|submental fat
904729|NCT02512822|fat reduction
904730|NCT02512822|body contouring
904731|NCT02512796|Liver transplantation
904732|NCT02512796|Renal transplantation
904733|NCT02512796|Pancreas transplantation
904734|NCT02512783|Propofol
904735|NCT02512783|Lidocaine
904736|NCT02512783|Intravenous propofol
904737|NCT02512757|Neoplasms, Lung
904738|NCT02512757|Pulmonary Neoplasms
904739|NCT02512757|Pulmonary Cancer
904740|NCT02512744|Tracheostomy
904741|NCT02512744|Decannulation
904742|NCT02512744|Adult airway management
904743|NCT02512718|intravenous fat emulsions
904744|NCT02512718|fish oil lipid emulsion
904745|NCT02512692|intrahepatic cholangiocarcinoma
904746|NCT02512692|cholangiocarcinoma
904747|NCT02512692|90Y TARE
904748|NCT02512692|radioembolization
904749|NCT02512692|gemcitabine and cisplatin
904750|NCT02512679|Hematopoietic Stem Cell Transplantation Pediatrics,
904751|NCT02512679|stem cell transplantation
904752|NCT02512679|bone marrow transplantation
904753|NCT02512679|Peripheral Blood Stem Cell Transplantation
904754|NCT02512679|Allogeneic Transplantation
904755|NCT02512679|pediatrics
904756|NCT02512679|Combined Immune Deficiency
904757|NCT02512679|Chronic Granulomatous disease
904758|NCT02512666|Hematologic malignancy
904759|NCT02512653|Allergy to Cupressus pollen
904760|NCT02512640|Pressure-controlled ventilation
904761|NCT02512640|Volume-controlled ventilation
904762|NCT02512640|Laparoscopy
904763|NCT02512640|Oxidative stress
904764|NCT02512627|mild cognitive impairment
904765|NCT02512627|exercise
904766|NCT02512627|cognitive training
904767|NCT02512575|AZD9567
904768|NCT02512575|Healthy subjects
904769|NCT02512575|Phase 1
904770|NCT02512575|placebo controlled
904771|NCT02512575|single ascending dose
904772|NCT02512575|Pharmacokinetics
904773|NCT02512575|Pharmacodynamics
904774|NCT02512575|Rheumatoid Arthritis
904775|NCT02512549|Chronic Obstructive Pulmonary Disease
904776|NCT02512549|rehabiltation
904777|NCT02512523|Type 2 diabetes mellitus
904778|NCT02512523|CGMS
904779|NCT02512523|Teneligliptin
904780|NCT02512523|Sitagliptin
904781|NCT02512510|Chronic Obstructive Pulmonary Disease, COPD
904782|NCT02512497|Cutaneous T-cell Lymphoma
904783|NCT02512497|CTCL
904784|NCT02512497|T-Prolymphocytic Leukemia
904785|NCT02512497|T-PLL
904786|NCT02512497|T-Large Granulocytic Leukemia
904787|NCT02512497|T-LGL
904788|NCT02512497|T-Lymphoblastic Leukemia/Lymphoma
904789|NCT02512497|T-ALL
904790|NCT02512497|Peripheral T-Cell Lymphoma
904791|NCT02512497|PTCL
904792|NCT02512497|Allogeneic stem cell transplantation
904793|NCT02512497|Romidepsin
904794|NCT02512497|Istodax
904795|NCT02512497|Depsipeptide
904796|NCT02512497|FK228
904797|NCT02512497|Busulfan
904798|NCT02512497|Busulfex
904799|NCT02512497|Myleran
904800|NCT02512497|Fludarabine
904801|NCT02512497|Fludarabine phosphate
904802|NCT02512497|Fludara
904803|NCT02512484|tuberculosis
904804|NCT02512484|accident and emergency
904805|NCT02512471|minimum effective volume
904806|NCT02512471|ropivacaine
904807|NCT02512471|ultrasound-guided supraclavicular block
904808|NCT02512419|Physical Activity
904809|NCT02512419|Latinos
904810|NCT02512419|Mexican American Men
904811|NCT02512419|Spanish-Language
904812|NCT02512419|Text-Message
904813|NCT02512406|Tourette Syndrome
904814|NCT02512406|Tics
904815|NCT02512341|Computer Aided Auscultation (CAA)
904816|NCT02512341|Electronic Stethoscope
904817|NCT02512341|Phonocardiography
904818|NCT02512341|Heart Auscultation
904819|NCT02512328|Colonoscopy
904820|NCT02512328|new media
904821|NCT02512328|APP
904822|NCT02512328|colonoscopy preparation
904823|NCT02512328|SPA
904824|NCT02512328|smartphone application
904825|NCT02512315|Nasopharyngeal carcinoma
904826|NCT02512315|Neoadjuvant chemotherapy
904827|NCT02512315|Concurrent chemoradiation
904828|NCT02512315|Distant metastasis
904829|NCT02512315|Survival
904830|NCT02512302|COPD
904831|NCT02512276|Medication Non-adherence
904832|NCT02512276|Hyperlipidemia
904833|NCT02512276|Diabetes
904834|NCT02512276|Hypertension
904840|NCT02512224|parenteral nutrition
904841|NCT02512224|enteral nutrition
904842|NCT02512211|Hemophilia
904843|NCT02512211|Validation
904844|NCT02512211|Questionnaires
904845|NCT02512211|Activities
904846|NCT02512211|Sport
904847|NCT02512211|Patients
904848|NCT02512198|Professional Practice
904849|NCT02512198|General Practitioners
904850|NCT02512198|Inappropriate Prescribing
904851|NCT02512198|Persuasive Communication
904852|NCT02512198|Information Theory
904853|NCT02512198|Feedback
904854|NCT02512185|Prostate cancer
904855|NCT02512185|Chemotherapy
904856|NCT02512185|mCRPC
904857|NCT02512159|Diabetic foot ulcer
904858|NCT02512159|Foot care
904859|NCT02512159|Wound management
904860|NCT02512146|IBS
904861|NCT02512146|Ionotropic glutamate receptors
904862|NCT02512133|MIGS
904863|NCT02512133|SLT
904864|NCT02512094|Barthel index
904865|NCT02512094|Hip fracture
904866|NCT02512094|Validity
904867|NCT02512094|Reliability
904868|NCT02512081|Sciatica
904869|NCT02512081|Patient Experience
904870|NCT02512081|Investigations
904871|NCT02512081|Qualitative Research
904872|NCT02512016|Pelvic floor
904873|NCT02511990|HIV
904874|NCT02511990|10-1074
904875|NCT02511990|Monoclonal Antibody
904876|NCT02511977|Dental Prosthesis
904877|NCT02511977|Implant-Supported
904878|NCT02511964|Aerobic Exercise
904879|NCT02511964|HIT,
904880|NCT02511964|VO2Max
904881|NCT02511964|Performance
904882|NCT02511951|postoperative pancreatic fistula
904883|NCT02511951|postoperative hospital stay time
904884|NCT02511951|anastomosis time
904885|NCT02511951|reoperation rate
904886|NCT02511951|morbidity
904887|NCT02511951|pancreaticojejunostomy
904888|NCT02511951|pancreaticoduodenectomy
904889|NCT02511938|childhood obesity
904890|NCT02511938|restaurant
904891|NCT02511938|away from home foods
904892|NCT02511925|Critical care
904893|NCT02511925|Feedback
904894|NCT02511899|Microcirculation
904895|NCT02511899|Endothelial function
904896|NCT02511899|Metabolism
904897|NCT02511899|Cardiovascular Disease
904898|NCT02511899|human study
904899|NCT02511899|healthy subjects
904900|NCT02511899|Mangifera indica
904901|NCT02511899|Careless
904902|NCT02511886|Alcoholism
904903|NCT02511886|Alcohol Abuse
904904|NCT02511886|Alcohol Addiction
904905|NCT02511886|Alcohol Dependence
904906|NCT02511886|Alcohol Induced Disorders
904907|NCT02511886|Alcoholic Intoxication
904908|NCT02511873|Fycompa
904909|NCT02511873|Small Fiber Neuropathy
904910|NCT02511873|SFN
904911|NCT02511873|Neuropathy
904912|NCT02511873|Pain
904913|NCT02511847|Breast Cancer
904914|NCT02511847|EGFR
904915|NCT02511847|Afatinib
904916|NCT02511847|Paclitaxel
904917|NCT02511847|Pathologic complete remission
904918|NCT02511808|Drinking
904919|NCT02511808|Alcohol Problems
904920|NCT02511808|Alcoholism
904921|NCT02511808|Reduced Drinking
904922|NCT02511808|Problematic Drinking
904923|NCT02511808|Non-Abstinence-based Drinking
904924|NCT02511808|Controlled Drinking
904925|NCT02511808|Heavy Drinking
904926|NCT02511795|AZD1775
904927|NCT02511795|Olaparib
904928|NCT02511795|AZD1775 plus Olaparib
904929|NCT02511795|Refractory solid tumours
904930|NCT02511782|children
904931|NCT02511782|bone marrow transplant
904932|NCT02511782|GVHD
904933|NCT02511756|Perfusion-computed tomography
904934|NCT02511730|Mammography
904935|NCT02511704|Nicotine
904936|NCT02511704|Electronic cigarette
904937|NCT02511704|Cigarette
904938|NCT02511639|Hormone receptor positive
904939|NCT02511639|HER2 negative
904940|NCT02511626|endometriosis
904941|NCT02511626|quality of life
904942|NCT02511626|professional activity
904943|NCT02511626|pain
904944|NCT02511626|infertility
904945|NCT02511626|sexuality
904946|NCT02511626|partnership
904947|NCT02511626|anxiety
904948|NCT02511626|depression
904949|NCT02511626|stress
904950|NCT02511626|childhood trauma
904951|NCT02511626|medical support
904952|NCT02511626|dyspareunia
904953|NCT02511600|Lung Diseases
904954|NCT02511600|Mesothelioma
904955|NCT02511600|Pleurectomy decortication
904956|NCT02511600|Progel
904957|NCT02511600|Talcum powder
904958|NCT02511600|Pain questionnaires
904959|NCT02511600|Surveys
904960|NCT02511600|Intraoperative air leaks
904961|NCT02511600|IAL
904962|NCT02511574|progesterone
904963|NCT02511574|uterine cervix
904964|NCT02511574|cervical pessary
904965|NCT02511561|Otitis externa
904966|NCT02511561|Swimmer's ear
904967|NCT02511561|Ear infection
904968|NCT02511509|Schizophrenia
904969|NCT02511509|Electroconvulsive Therapy
904970|NCT02511509|Bifrontal ECT
904971|NCT02511509|Bitemporal ECT
904972|NCT02511509|Cognitive functions
904973|NCT02511509|Postictal delirium
904974|NCT02511483|COMT
904975|NCT02511483|Beta-blocker
904976|NCT02511483|Hemicolectomy
904977|NCT02511470|Cardiopulmonary Resuscitation
904978|NCT02511470|Pediatric simulation study
904979|NCT02511470|Metronome
904980|NCT02511444|GBS
904981|NCT02511444|GBS culture
904982|NCT02511444|GBS PCR
904983|NCT02511444|GBS colonization
904984|NCT02511431|Delta Hepatitis
904985|NCT02511431|Hepatitis D
904986|NCT02511431|Liver Disease
904987|NCT02511431|Hepatitis D Virus
904988|NCT02511431|Chronic Hepatitis
904989|NCT02511405|rGBM
904990|NCT02511405|Recurrent Glioblastoma
904991|NCT02511405|Recurrent GBM
904992|NCT02511366|ileal brake
904993|NCT02511353|malaria
904994|NCT02511353|plasmodium
904995|NCT02511353|dihydroartemisinin-piperaquine
904996|NCT02511353|ivermectin
904997|NCT02511327|Pertussis
904998|NCT02511327|Pregnancy
904999|NCT02511327|Vaccination
905000|NCT02511327|Preterm
905001|NCT02511327|Breast milk
905002|NCT02511327|Humoral immune response
905003|NCT02511327|Cellular immune response
905004|NCT02511327|Maternal antibodies
905005|NCT02511314|Nursing homes
905006|NCT02511314|quasi-experimental
905007|NCT02511314|mixed methods
905008|NCT02511314|parallel study
905009|NCT02511314|urinary incontinence
905010|NCT02511288|hematologic test
905011|NCT02511275|parenchymal clamping
905012|NCT02511275|microdialysis technique
905013|NCT02511275|partial nephrectomy
905014|NCT02511249|neonatal arterial ischemic stroke
905015|NCT02511249|language development
905016|NCT02511249|global intellectual functioning
905017|NCT02511249|motor abilities
905018|NCT02511197|PET
905019|NCT02511197|lung injury
905020|NCT02511197|integrin receptor
905021|NCT02511184|crizotinib
905022|NCT02511184|pembrolizumab
905023|NCT02511184|ALK-positive NSCLC
905024|NCT02511184|Lung Cancer
905025|NCT02511184|ALK-translocated NSCLC
905026|NCT02511184|Non Small Cell Lung Cancer
905027|NCT02511158|Anterior Cruciate Ligament, Posterior Cruciate Ligament, Medial Collateral Ligament, Lateral Collateral Ligament
905028|NCT02511145|volunteers
905029|NCT02511132|Ewing's Sarcoma Family of Tumors, ESFT, Sarcoma
905030|NCT02511132|Soft Tissue Sarcoma
905031|NCT02511106|Stage IB-IIA-IIIA Non-Small Cell Lung Cancer; EGFRm+; Ex19Del; L858R; AZD9291; Phase III, adjuvant chemotherapy; complete tumour resection; EGFR-TKI
905032|NCT02511093|Hypertension
905033|NCT02511093|Team-based care
905034|NCT02511093|Collaboration
905035|NCT02511093|Healthcare professionals
905036|NCT02511093|Healthcare services
905037|NCT02511080|Spot-on; perioperative hypothermia.
905038|NCT02511054|Immunogenicity
905039|NCT02511054|Liver Stage
905040|NCT02511054|Parasites
905041|NCT02511054|Blood
905042|NCT02511054|Infection
905043|NCT02511041|CDG
905044|NCT02511041|PGM3
905045|NCT02511041|Immune
905046|NCT02511028|MRI
905047|NCT02511028|Multiple Sclerosis
905048|NCT02511028|Healthy Volunteer
905049|NCT02511015|Early Onset Parkinson's Disease
905050|NCT02511015|Cellular Quality Control Programs
905051|NCT02511015|Mitochondria
905052|NCT02511015|Neuroinflammation
905053|NCT02511015|Immunology
905054|NCT02511002|Influenza
905055|NCT02511002|Hemagglutinin (HA)
905056|NCT02511002|Post Influenza Challenge
905057|NCT02511002|Neuranimidase (NA)
905058|NCT02511002|Influenza Illness
905059|NCT02510989|Syndromic obesity
905060|NCT02510989|Genes
905061|NCT02510989|Exome
905062|NCT02510963|Vertical infection transmission
905063|NCT02510963|Tenofovir
905064|NCT02510937|pulmonary fibrosis
905065|NCT02510937|pharmacokinetic
905066|NCT02510937|pharmacodynamics
905067|NCT02510937|CC-90001
905068|NCT02510937|Safety
905069|NCT02510924|Intubation
905070|NCT02510924|Airtraq
905071|NCT02510924|General anesthesia
905072|NCT02510924|Difficult airway
905073|NCT02510911|colectomy
905074|NCT02510911|laparoscopy
905075|NCT02510911|caffeine
905082|NCT02510846|Polyhandicap
905083|NCT02510846|Behavior disorders
905084|NCT02510846|Educative program
905085|NCT02510846|Caregivers
905086|NCT02510846|Quality of life.
905087|NCT02510833|Parkinson Disease
905088|NCT02510833|Physical Therapy Modalities
905089|NCT02510833|Quality of Life
905090|NCT02510833|Self Care
905091|NCT02510768|alba
905092|NCT02510664|Adolescence
905093|NCT02510664|Adherence
905094|NCT02510651|: non-segmental vitiligo
905095|NCT02510651|melanocyte-keratinocyte suspension
905096|NCT02510651|cryoblebbing
905097|NCT02510651|CO2 laser
905098|NCT02510612|Dexmedetomidine
905099|NCT02510612|Diabetic
905100|NCT02510612|glycometabolism
905101|NCT02510612|sedation
905102|NCT02510599|NASH
905103|NCT02510599|Liver disease
905104|NCT02510508|addiction
905105|NCT02510508|substance abuse
905106|NCT02510508|alcohol
905107|NCT02510508|drugs
905108|NCT02510508|community reinforcement
905109|NCT02510508|family treatment
905110|NCT02510508|randomized control trial
905111|NCT02510495|Sphincterotomy
905112|NCT02510495|Dilatation
905113|NCT02510495|Common bile duct
905114|NCT02510495|Pancreatitis
905115|NCT02510482|cardiac biomarkers
905116|NCT02510443|Permanent contraception method
905117|NCT02510443|Contraceptive device
905118|NCT02510391|modular
905119|NCT02510391|anxiety
905120|NCT02510391|preschool
905121|NCT02510391|exposure and response prevention
905122|NCT02510391|Cognitive behavioral therapy
905123|NCT02510352|Rotator cuff tear
905124|NCT02510352|MRI
905125|NCT02510287|analgesia, epidural
905126|NCT02510287|labor pain
905127|NCT02510287|patient satisfaction
905128|NCT02510274|ASP3325
905129|NCT02510274|pharmacokinetics
905130|NCT02510274|pharmacodynamics
905131|NCT02510274|Chronic Kidney Disease
905132|NCT02510274|Hyperphosphatemia
905133|NCT02510261|RNAi therapeutic
905134|NCT02510261|FAP
905135|NCT02510261|Familial Amyloid Polyneuropathy
905136|NCT02510261|TTR
905137|NCT02510261|Transthyretin
905138|NCT02510261|Amyloidosis
905139|NCT02510235|Dry Eye
905140|NCT02510222|child
905141|NCT02510209|Teen pregnancy
905142|NCT02510183|Acupressure
905143|NCT02510183|Perioperative Care
905144|NCT02510183|Postoperative Nausea and Vomiting
905145|NCT02510183|Nursing Care Management
905146|NCT02510170|Fetus
905147|NCT02510170|Skull
905148|NCT02510170|ultrasonography
905149|NCT02510157|sugammadex
905150|NCT02510157|dexamethasone
905151|NCT02510157|neuromuscular blockade
905152|NCT02510118|ChangTai Keli
905153|NCT02510118|Colon cancer
905154|NCT02510105|Critical Care
905155|NCT02510105|ARDS
905156|NCT02510105|Intrapulmonary Percussive Ventilation
905157|NCT02510105|VDR4
905158|NCT02510105|Lung aeration
905159|NCT02510105|CT scan
905160|NCT02510066|Pancreatic Cancer
905161|NCT02510066|Pain
905162|NCT02510066|Acupuncture
905163|NCT02510040|Convergence Insufficiency
905164|NCT02510040|Divergence Insufficiency
905165|NCT02510040|Small-angle Hypertropia
905166|NCT02510040|Strabismus
905167|NCT02510027|HPV testing
905168|NCT02510027|Triage
905169|NCT02510027|Mexico
905170|NCT02510027|Cervical cancer screening
905171|NCT02510001|RASMT CRC
905172|NCT02510001|RASWT/c-MET CRC
905173|NCT02510001|Dose Escalation
905174|NCT02510001|Histologically or cytologically confirmed
905175|NCT02510001|Dose Expansion
905176|NCT02509988|Nutrition
905177|NCT02509988|Glucose metabolism
905178|NCT02509988|Body composition
905179|NCT02509975|embolization
905180|NCT02509975|prostate
905181|NCT02509962|Energy metabolism
905182|NCT02509962|Glucose tolerance
905183|NCT02509962|Blood pressure
905184|NCT02509962|Immunoregulation
905185|NCT02509923|Male Subjects
905186|NCT02509910|Major abdominal surgery
905187|NCT02509910|Goal directed therapy
905188|NCT02509897|Hypoxia training
905189|NCT02509897|Activity energy expenditure
905190|NCT02509897|Immunoregulation
905191|NCT02509897|Energy Metabolism
905192|NCT02509897|Exercise
905193|NCT02509884|Alveolar Echinococcosis (AE)
905194|NCT02509884|Echinococcus multilocularis
905195|NCT02509884|antiparasitic treatment
905196|NCT02509884|surgery
905197|NCT02509884|classification
905198|NCT02509884|staging
905199|NCT02509884|prospective cohort study
905200|NCT02509871|Body composition
905201|NCT02509858|Diabetes mellitus, thyroxine
905202|NCT02509832|Therapeutic Hypothermia (TH)
905203|NCT02509832|Acute Myocardial Infarction (AMI)
905204|NCT02509832|Percutaneous Coronary Intervention (PCI)
905205|NCT02509819|rehabilitation
905206|NCT02509819|IDEO
905207|NCT02509780|Vichy
905208|NCT02509780|urine alkalization
905209|NCT02509767|Contraceptive Methods
905210|NCT02509767|Female Contraception
905211|NCT02509767|Contraceptive satisfaction
905212|NCT02509767|Injectable contraception
905213|NCT02509767|Birth control
905214|NCT02509754|atrial fibrillation
905215|NCT02509754|congestive heart failure
905216|NCT02509754|catheter ablation
905217|NCT02509754|rate control
905218|NCT02509754|left ventricular function
905219|NCT02509741|obesity
905220|NCT02509741|nutrition
905221|NCT02509741|intervention
905222|NCT02509741|food replacement
905223|NCT02509741|IOT
905224|NCT02509728|choline
905225|NCT02509728|docosahexaenoic acid
905226|NCT02509715|thyroidectomy
905227|NCT02509715|nerve monitoring
905228|NCT02509702|Mobile health
905229|NCT02509702|Screening
905230|NCT02509702|Early detection of cancer
905231|NCT02509702|Telemedicine
905240|NCT02509676|dynamic stretching training
905241|NCT02509676|muscle tendon unit
905242|NCT02509676|ultrasound
905243|NCT02509650|Exome sequencing
905244|NCT02509650|Skin disease
905245|NCT02509650|Familial lipomatosis
905246|NCT02509637|Respiratory System
905247|NCT02509637|Physical Therapy Modalities
905252|NCT02509559|Receptors, Adrenergic
905253|NCT02509559|Propranolol
905254|NCT02509533|Vacuum Assisted Closure
905255|NCT02509520|Nutritional supplementation
905256|NCT02509520|Neuromuscular Electric Stimulation
905257|NCT02509520|ICU acquired weakness
905258|NCT02509520|Post ICU Syndrome
905259|NCT02509520|sarcopenia
905261|NCT02509494|Vaccine
905262|NCT02509494|Ebola
905263|NCT02509494|Ebola virus disease
905264|NCT02509494|EVD
905265|NCT02509494|Hemorrhagic fever
905266|NCT02509494|Sierra Leone
905267|NCT02509494|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
905268|NCT02509494|Safety
905269|NCT02509494|Immunogenicity
905270|NCT02509494|Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector
905271|NCT02509494|(MVA‐BN Filo)
905272|NCT02509481|malaria
905273|NCT02509481|lymphatic filariasis
905274|NCT02509481|mosquito
905275|NCT02509481|ivermectin
905276|NCT02509481|mass drug administration
905277|NCT02509455|Balance control
905278|NCT02509455|Body-mounted sensors
905279|NCT02509455|Balance Measures
905280|NCT02509442|mapping brain functions
905281|NCT02509442|Direct electric stimulation (DES)
905282|NCT02509442|potential evoked
905283|NCT02509429|T1DM
905284|NCT02509429|Type 1 Diabetes
905285|NCT02509429|Artificial Pancreas
905286|NCT02509429|DiAs platform
905287|NCT02509416|endoscopic ultrasound
905288|NCT02509416|endoscopic retrograde cholangiopancreatography
905289|NCT02509416|competency
905290|NCT02509403|Perineal hygiene
905291|NCT02509403|Hygiene wipes
905292|NCT02509403|Hygiene Towels
905293|NCT02509403|Safety
905294|NCT02509403|Essential oils
905295|NCT02509403|Natural Health Product
905296|NCT02509390|Fibrinogen level
905297|NCT02509390|Hyperfibrinogenemia
905298|NCT02509390|Trauma
905299|NCT02509390|Thrombosis risk
905300|NCT02509377|Fetal Surgery
905301|NCT02509377|Open Fetal Surgery
905302|NCT02509377|Elevated BMI
905303|NCT02509377|Body Mass Index
905304|NCT02509377|Spina Bifida
905305|NCT02509364|AE-IPF
905306|NCT02509312|Analgesia, Obstetrical
905307|NCT02509312|Blood Loss, Surgical
905308|NCT02509312|Analgesics, Opioid/administration & dosage
905309|NCT02509312|Cyclooxygenase Inhibitors/administration & dosage
905310|NCT02509312|Cesarean Section
905311|NCT02509312|Female
905312|NCT02509312|Humans
905313|NCT02509312|Ketorolac/administration & dosage
905314|NCT02509312|Hydromorphone/administration & dosage
905315|NCT02509312|Pain, Postoperative/drug therapy
905316|NCT02509312|Pregnancy
905317|NCT02509312|Morphine/administration & dosage
905318|NCT02509299|COPD
905319|NCT02509299|Quality of life
905320|NCT02509299|Perceived health status
905321|NCT02509286|Esophageal neoplasms
905322|NCT02509286|gastro-esophageal junction neoplasms
905323|NCT02509286|adenocarcinoma
905324|NCT02509286|esophagectomy
905325|NCT02509286|surgery
905326|NCT02509286|radiotherapy
905327|NCT02509286|chemotherapy
905328|NCT02509260|colorectal surgery
905329|NCT02509247|sleep apnea
905330|NCT02509247|CPAP
905331|NCT02509247|telemonitoring
905332|NCT02509247|telecare
905333|NCT02509234|pediatric sarcomas
905334|NCT02509234|Ewing sarcoma
905335|NCT02509234|rhabdomyosarcoma
905336|NCT02509234|soft tissue sarcoma
905337|NCT02509208|iliac crest bone graft
905338|NCT02509208|ICBG
905339|NCT02509208|pelvic osteotomy
905340|NCT02509208|spinal fusion
905341|NCT02509208|hemostasis
905342|NCT02509208|haemostasis
905343|NCT02509208|hemostatic
905344|NCT02509208|haemostatic
905345|NCT02509208|dextran
905346|NCT02509208|SurgiClot
905347|NCT02509208|cancellous bone bleeding
905348|NCT02509182|Hyperoxia
905349|NCT02509182|One-Lung Ventilation
905350|NCT02509182|Thoracic Surgery
905351|NCT02509182|Anesthesiology
905352|NCT02509156|Cardiomyopathy
905353|NCT02509156|AIC
905354|NCT02509156|Anthracyclines
905355|NCT02509156|Chemotherapy
905356|NCT02509156|Allogeneic
905357|NCT02509156|Mesenchymal stem cells
905358|NCT02509156|MSCs
905359|NCT02509156|Cancer survivors
905360|NCT02509156|Breast Cancer
905361|NCT02509156|Leukemia
905362|NCT02509156|Lymphoma
905363|NCT02509156|Sarcoma
905364|NCT02509143|Postoperative Nausea and Vomiting
905365|NCT02509143|Colorectal Neoplasms
905366|NCT02509130|Severe Asthma
905367|NCT02509130|Asthma
905368|NCT02509130|Specialised Asthma Care
905369|NCT02509130|Asthma Care
905370|NCT02509117|Alzheimer's disease
905371|NCT02509104|Bioavailability
905372|NCT02509104|Dutasteride
905373|NCT02509104|Healthy Male Subjects
905374|NCT02509104|Fixed Dose Combination
905375|NCT02509078|ARDS
905376|NCT02509078|neuromuscular blocker
905377|NCT02509078|cisatracurium
905378|NCT02509065|bionic pancreas
905379|NCT02509065|artificial pancreas
905380|NCT02509065|insulin
905381|NCT02509065|glucagon
905382|NCT02509065|continuous glucose monitor (CGM)
905383|NCT02509065|insulin pump
905384|NCT02509065|outpatient
905385|NCT02509039|CC-122
905386|NCT02509039|Phase1
905387|NCT02509039|solid tumor
905388|NCT02509039|non-Hodgkin's lymphom
905390|NCT02509013|chronic kidney disease
905391|NCT02509013|stable coronary heart disease
905392|NCT02509013|prevalence
905393|NCT02508987|Obesity
905394|NCT02508987|oxidative stress
905395|NCT02508987|antioxidants
905396|NCT02508987|periodontal disease
905397|NCT02508961|Physical Activity
905398|NCT02508961|Exercise
905399|NCT02508961|Physiotherapy
905400|NCT02508948|airway management
905401|NCT02508948|critically ill
905402|NCT02508948|hemodynamic management
905403|NCT02508948|intubation
905404|NCT02508948|prospective study
905405|NCT02508948|risk factors
905406|NCT02508909|Videoassisted surgery
905407|NCT02508883|Cancer
905408|NCT02508883|hemorrhage
905409|NCT02508883|endoscopy
905410|NCT02508883|gastrointestinal hemorrhage
905411|NCT02508857|pain, postoperative
905412|NCT02508857|anesthesia adjuvants
905413|NCT02508857|magnesium sulfate
905414|NCT02508844|Probiotics
905415|NCT02508844|Vivomixx®
905416|NCT02508844|Microbiota
905417|NCT02508831|Bilateral amputation
905418|NCT02508831|upper limb
905419|NCT02508831|allograft
905420|NCT02508779|Diabetes
905421|NCT02508779|Blood Glucose Management
905422|NCT02508779|Preconception
905423|NCT02508779|Hypoglycemia
905424|NCT02508779|Women with diabetes
905425|NCT02508766|Postural Control
905426|NCT02508766|Plantar Stimulation
905427|NCT02508766|Volunteers
905428|NCT02508753|QT/QTc Intervals
905429|NCT02508701|HPV
905430|NCT02508701|Message Design
905431|NCT02508701|Adolescent Males
905432|NCT02508688|hepatic hydrothorax
905433|NCT02508688|thoracoscopic surgery
905434|NCT02508688|diaphragmatic defect
905435|NCT02508675|injury
905436|NCT02508675|risk factors
905437|NCT02508675|outcome
905438|NCT02508675|costs
905439|NCT02508662|Advanced Cancers
905440|NCT02508662|Solid Tumors
905441|NCT02508662|Genomic Mutations
905442|NCT02508662|FDA Approved Off-Label Chemotherapy
905443|NCT02508662|Refractory
905444|NCT02508623|Portal hypertension
905445|NCT02508623|liver cirrhosis
905446|NCT02508623|Rifaximin
905447|NCT02508597|Smoking cessation intervention
905448|NCT02508571|Infant, Premature
905449|NCT02508571|Intervention Studies
905450|NCT02508571|Bottle feeding
905451|NCT02508506|ALKS 5461
905452|NCT02508506|Alkermes
905453|NCT02508506|Samidorphan
905454|NCT02508506|Renal Impairment
905455|NCT02508506|Pharmacokinetics
905456|NCT02508506|Buprenorphine
905457|NCT02508480|Stigma
905458|NCT02508480|Community Integration
905459|NCT02508467|Liver cancer
905460|NCT02508467|FGF19 gene amplification
905461|NCT02508467|FGF19 overexpression
905462|NCT02508467|FGF19 upregulation
905463|NCT02508467|Cyclin D1 (CCND1) gene amplification
905464|NCT02508467|Cyclin D1 (CCND1) copy number gain
905465|NCT02508467|BLU-554
905466|NCT02508467|FGFR4
905467|NCT02508467|Hepatocellular carcinoma
905468|NCT02508467|Liver Disease
905469|NCT02508467|Liver Neoplasms
905470|NCT02508454|Prevention
905471|NCT02508454|Screening
905472|NCT02508454|Biobanking
905473|NCT02508441|Neoplasms
905474|NCT02508441|Solid Tumors
905475|NCT02508441|Advanced Malignancy
905476|NCT02508441|Cancer
905477|NCT02508428|Osteolysis
905478|NCT02508428|Polyethylene
905479|NCT02508428|Crosslinked Polyethylene
905480|NCT02508428|Total Hip Replacement
905481|NCT02508428|Marathon
905482|NCT02508415|obesity
905483|NCT02508415|periodontal disease
905484|NCT02508415|intervention
905485|NCT02508389|squamous cell carcinoma of the head and neck
905486|NCT02508389|oral cavity
905487|NCT02508389|oropharynx
905488|NCT02508389|intensity-modulated radiation therapy
905489|NCT02508389|chemotherapy
905490|NCT02508389|oral mucositis
905491|NCT02508389|superoxide dismutase
905492|NCT02508389|radioprotection
905493|NCT02508376|adjuvants
905494|NCT02508376|AP10-602
905495|NCT02508376|GLA-SE
905496|NCT02508376|ID93
905497|NCT02508376|Tuberculosis
905498|NCT02508376|vaccine
905499|NCT02508363|Taxi drivers
905500|NCT02508363|Health care access
905501|NCT02508363|15-163
905502|NCT02508311|Tetraplegia
905503|NCT02508311|High Paraplegia
905504|NCT02508298|ICG
905505|NCT02508298|ARFI
905506|NCT02508298|portal hypertension
905507|NCT02508298|cirrhosis
905508|NCT02508298|diagnostic study
905509|NCT02508272|Transcriptome profiling
905510|NCT02508259|mitochondria
905511|NCT02508259|purinergic signaling
905512|NCT02508259|cell danger response
905513|NCT02508194|RSV
905514|NCT02508194|Older adults
905515|NCT02508194|MEDI7510
905516|NCT02508194|Vaccine
905517|NCT02508194|Efficacy
905518|NCT02508181|intra ocular pressure
905519|NCT02508181|I-gel
905520|NCT02508181|LMA Supreme
905521|NCT02508181|strabismus surgery
905522|NCT02508168|Drug therapy
905523|NCT02508129|Insomnia
905524|NCT02508129|hypertension
905525|NCT02508129|blood pressure
905526|NCT02508129|sleep
905527|NCT02508129|behavioral treatment
905528|NCT02508129|Cognitive Behavioral Treatment of Insomnia (CBTI)
905529|NCT02508129|Brief Behavioral Treatment of Insomnia (BBTI)
905530|NCT02508129|pragmatic trial
905531|NCT02508129|internet
905532|NCT02508116|pharmacogenetics
905533|NCT02508116|clopidogrel
905534|NCT02508116|genotype
905535|NCT02508103|Premenstrual Dysphoric Disorder
905536|NCT02508103|Premenstrual Syndrome
905537|NCT02508103|PMS
905538|NCT02508103|PMDD
905539|NCT02508038|alpha beta depleted
905540|NCT02508038|alphabeta
905541|NCT02508038|TCR alpha beta depleted
905542|NCT02508038|alpha beta
905543|NCT02508038|haploidentical
905544|NCT02508038|Zoledronate
905545|NCT02508038|Zoledronic acid
905546|NCT02508038|Pediatric cancers
905547|NCT02508038|alfa beta
905548|NCT02508038|αβ T cell depleted HSCT
905549|NCT02508038|alpha beta T cell and B cell depleted HSCT
905550|NCT02508038|haploidentical HSCT
905551|NCT02508025|disability evaluation
905552|NCT02508025|psychosocial factors
905553|NCT02508012|anti-TNF
905554|NCT02508012|Immuno-monitoring
905555|NCT02508012|Anti-drug antibody (ADAb)
905556|NCT02508012|Inflammatory bowel disease (IBD)
905557|NCT02508012|Crohn's disease
905558|NCT02508012|Ulcerative colitis
905559|NCT02507973|Mechanical Ventilation
905560|NCT02507973|Intracranial Pressure
905561|NCT02507973|Airway Pressure Release Ventilation
905562|NCT02507934|Dry Eye
905563|NCT02507908|neuroendocrine tumors
905564|NCT02507908|5-hydroxyindolacetic acid
905565|NCT02507908|serotonin
905566|NCT02507908|isotope-dilution massa-spectrometer
905567|NCT02507895|Stroke
905568|NCT02507895|lower extremeties
905569|NCT02507895|Brain-computer interface
905570|NCT02507895|Motor imagery
905571|NCT02507895|Rehabilitation
905572|NCT02507895|TMS
905573|NCT02507843|Vitamin D
905574|NCT02507817|LIF,Magnesium Sulphate
905575|NCT02507791|Fitbit
905576|NCT02507791|Obesity
905577|NCT02507791|Pediatrics
905578|NCT02507778|Lung
905579|NCT02507778|Cancer
905580|NCT02507778|Biomarkers
905581|NCT02507778|Early detection
905582|NCT02507778|Circulating tumor cell
905583|NCT02507765|SBRT
905584|NCT02507713|Amyotrophic lateral sclerosis
905585|NCT02507713|Ultrasonography
905586|NCT02507713|Motor neurons
905587|NCT02507713|Neuromuscular diseases
905588|NCT02507713|Fasciculation
905589|NCT02507700|nerve block
905590|NCT02507674|appendicitis
905591|NCT02507674|pediatric
905592|NCT02507674|ultrasound
905593|NCT02507635|cytokines
905594|NCT02507635|persistent allergic rhinitis
905595|NCT02507635|H1 antihistamines
905596|NCT02507583|Brain Tumor
905597|NCT02507583|Glioma
905598|NCT02507583|Newly Diagnosed
905599|NCT02507557|Therapy, Fluid
905600|NCT02507557|Digestive System Surgical Procedures
905601|NCT02507557|Postoperative Complications
905602|NCT02507544|Advanced Solid Malignancy
905603|NCT02507544|Safety and Tolerability
905604|NCT02507544|Tumor Response
905605|NCT02507544|Hematology
905606|NCT02507544|Oncology
905607|NCT02507518|lung cancer, PET, progression free survival
905608|NCT02507492|POMC, LEPR, PCSK1
905609|NCT02507466|locomotion
905610|NCT02507453|volunteers
905611|NCT02507427|Prostate cancer, robot, nerve mapping and monitoring
905612|NCT02507414|Mesenteric Traction Syndrome
905613|NCT02507414|Upper gastrointestinal cancer surgery
905614|NCT02507375|Non-Squamous
905615|NCT02507362|keratoconus , corneal collagen cross-linking
905616|NCT02507349|serious mental illness
905617|NCT02507349|mental health services research
905618|NCT02507349|measurement-based care
905619|NCT02507349|shared decision making
905620|NCT02507349|psychiatric medication management
905621|NCT02507349|community psychiatry
905622|NCT02507349|comparative effectiveness research
905623|NCT02507349|mixed methods research
905624|NCT02507336|Mantle Cell Lymphoma (MCL)
905625|NCT02507336|Non-Hodgkin's Lymphoma (NHL)
905626|NCT02507245|GHD
905627|NCT02507232|glioma
905628|NCT02507232|temozolomide
905629|NCT02507232|brain
905630|NCT02507232|NovoTTF-200A
905631|NCT02507232|cancer
905632|NCT02507232|low-grade glioma
905633|NCT02507206|schizotypal personality disorder
905634|NCT02507206|cognitive impairment
905635|NCT02507206|working memory
905636|NCT02507206|Dopamine Agonists
905637|NCT02507206|Cognition Disorders
905638|NCT02507206|Personality Disorders
905639|NCT02507206|Delirium
905640|NCT02507206|Dementia
905641|NCT02507206|Amnestic
905642|NCT02507206|Cognitive Disorders
905643|NCT02507206|Mental Disorders
905644|NCT02507206|Dihydrexidine
905645|NCT02507206|Dopamine A
905646|NCT02507180|clinical decision rule
905647|NCT02507180|Ultrasound
905648|NCT02507180|Suspected Deep Vein Thrombosis
905649|NCT02507180|D-Dimer
905650|NCT02507154|cetuximab
905651|NCT02507154|NK cells
905652|NCT02507154|nasopharyngeal cancer
905653|NCT02507154|head and neck squamous cell cancer
905654|NCT02507141|Reflectance Confocal Microscopy
905655|NCT02507141|15-128
905656|NCT02507050|Ivabradine
905657|NCT02507050|Microvascular dysfunction
905658|NCT02507050|PCI
905659|NCT02507050|Procedural related myocardial injury
905660|NCT02507050|IMR
905661|NCT02507050|Index of Microvascular Resistance
905662|NCT02506998|Allergic rhinoconjunctivitis
905663|NCT02506998|Dialyzable Leukocyte Extracts
905664|NCT02506985|Rivaroxaban
905665|NCT02506985|CDT (Catheter directed thrombolysis)
905666|NCT02506985|PE (pulmonary embolism)
905667|NCT02506985|NETs
905668|NCT02506985|factor Xa
905669|NCT02506972|Blood glucose
905670|NCT02506972|Humans
905671|NCT02506972|Postprandial
905672|NCT02506972|Sugar
905673|NCT02506972|Carbohydrate
905674|NCT02506972|Oat beta-glucan
905675|NCT02506959|Multiple myeloma (MM)
905676|NCT02506959|MM
905677|NCT02506959|Refractory
905678|NCT02506959|Relapsed
905679|NCT02506959|Stem Cell Transplant
905680|NCT02506959|Busulfan
905681|NCT02506959|Busulfex
905682|NCT02506959|Myleran
905683|NCT02506959|Palifermin
905684|NCT02506959|Kepivance
905685|NCT02506959|Panobinostat
905686|NCT02506959|LBH589B
905687|NCT02506959|Gemcitabine
905688|NCT02506959|Gemcitabine Hydrochloride
905689|NCT02506959|Gemzar
905690|NCT02506959|Melphalan
905691|NCT02506959|Alkeran
905692|NCT02506959|Dexamethasone
905693|NCT02506959|Decadron
905694|NCT02506959|Pyridoxine
905695|NCT02506959|Caphosol
905696|NCT02506959|Glutamine
905697|NCT02506959|Enterex
905698|NCT02506959|Glutapak
905699|NCT02506959|NutreStore
905700|NCT02506959|Resource
905701|NCT02506959|GlutaSolve
905702|NCT02506959|Sympt-X
905703|NCT02506946|Polycystic Ovary Syndrome
905704|NCT02506946|Non-Alcoholic Fatty Liver Disease
905705|NCT02506946|Adolescents
905706|NCT02506946|Young Women
905707|NCT02506946|MRI
905708|NCT02506946|MRS
905709|NCT02506946|DXA
905710|NCT02506946|Hirsutism
905711|NCT02506946|Amenorrhea
905712|NCT02506946|Metabolic syndrome
905713|NCT02506946|Dyslipidemia
905714|NCT02506946|Percentage liver fat
905715|NCT02506920|Postprandial lipemia
905716|NCT02506920|glycemic response
905717|NCT02506881|darbepoetin alfa
905718|NCT02506881|pharmacokinetics
905719|NCT02506881|pharmacodynamics
905720|NCT02506881|healthy volunteers
905721|NCT02506868|darbepoetin alfa
905722|NCT02506842|Pancreatic Cancer
905723|NCT02506842|Pancreatic Adenocarcinoma
905724|NCT02506842|AG
905725|NCT02506842|OFF
905726|NCT02506842|Second-Line Adjuvant Therapy
905727|NCT02506829|Inpatients
905728|NCT02506790|Melatonin, metformin, toremifene
905729|NCT02506777|Melatonin, metformin, chemotherapy
905730|NCT02506738|telemonitoring
905731|NCT02506738|mHealth
905732|NCT02506738|functional status
905733|NCT02506738|older people
905734|NCT02506725|prenatal care
905735|NCT02506725|pregnancy
905736|NCT02506725|prematurity
905737|NCT02506673|Audiovisual Aids
905738|NCT02506673|Perioperative Period
905739|NCT02506673|Anxiety
905740|NCT02506634|symptom
905741|NCT02506608|Neuroplasticty, Sensory Feedback
905742|NCT02506556|Pi3K pathway
905743|NCT02506543|Adolescent Health
905744|NCT02506543|Ethiopia
905745|NCT02506543|Sexual Violence
905746|NCT02506530|lymphedema
905747|NCT02506530|breast cancer
905748|NCT02506517|HER pathway aberrations
905749|NCT02506439|Vitamin D
905750|NCT02506439|Cholecalciferol
905751|NCT02506439|Dose-response
905752|NCT02506439|Randomized Controlled Trial
905753|NCT02506439|Pregnancy
905754|NCT02506439|Cord blood
905755|NCT02506439|Serum 25-hydroxyvitamin D
905756|NCT02506439|Vitamin D Deficiency
905757|NCT02506439|Nutrition
905758|NCT02506439|Dietary intervention study
905759|NCT02506426|Chronic Sinusitis
905760|NCT02506426|Chronic Rhinosinusitis
905761|NCT02506426|Endoscopic sinus surgery
905762|NCT02506426|Septoplasty
905763|NCT02506413|Maternal and Newborn Health
905764|NCT02506361|TOP2α
905765|NCT02506361|anthracyclines
905766|NCT02506361|taxanes
905767|NCT02506361|non dose-dense chemotherapy
905768|NCT02506335|Liver disease
905769|NCT02506335|cardiomyopathy
905770|NCT02506335|congenital heart disease
905771|NCT02506322|Bipolar I Disorder
905772|NCT02506322|Bipolar II Disorder
905773|NCT02506322|Relapse Prevention
905774|NCT02506296|type 2 diabetes
905775|NCT02506296|endogenous insulin secretion
905776|NCT02506283|cryotherapy
905777|NCT02506283|recovery
905778|NCT02506283|athletic performance
905779|NCT02506283|maximum voluntary contraction
905780|NCT02506283|rated perceived exertion
905781|NCT02506283|delayed onset muscle soreness
905782|NCT02506283|jump performance
905791|NCT02506231|Allogeneic hematopoietic cell transplantation
905792|NCT02506231|GVHD prophylaxis
905793|NCT02506231|Methotrexate
905794|NCT02506231|Folinic acid
905795|NCT02506231|Leucovorin
905796|NCT02506231|Mucositis
905797|NCT02506192|Gulf War Illness
905798|NCT02506192|Chronic Inflammation
905799|NCT02506192|Delayed-Release Prednisone
905800|NCT02506192|Health-Related Quality of Life
905801|NCT02506179|Moderate to severe ulcerative colitis (UC)
905802|NCT02506179|Real-life effect
905803|NCT02506179|Adalimumab
905804|NCT02506179|Ulcerative colitis (UC)
905805|NCT02506179|Patient reported outcomes (PRO)
905806|NCT02506166|sleep apnea
905807|NCT02506166|sleep disordered breathing
905808|NCT02506166|sudden cardiac death
905809|NCT02506166|heart failure
905810|NCT02506166|ischemic cardiomyopathy
905811|NCT02506166|implantable cardioverter-defibrillator (ICD) therapy
905812|NCT02506166|cardiac resynchronization therapy (CRT)
905813|NCT02506166|risk stratification
905814|NCT02506166|positive airway pressure therapy
905815|NCT02506166|SERVE-HF
905816|NCT02506140|minor stroke
905817|NCT02506140|transient ischemic attack
905818|NCT02506140|ticagrelor
905819|NCT02506140|clopidogrel
905820|NCT02506140|dual anti-platelet therapy
905821|NCT02506140|platelet reactivity
905822|NCT02506127|TBS, MDD, Sham-controlled, neuromodulation, TMS
905823|NCT02506114|prostate
905824|NCT02506062|ischemic preconditioning
905825|NCT02506062|Raynaud's Phenomenon
905826|NCT02506062|(RP)
905827|NCT02506036|Treatment
905828|NCT02506036|Social-Cognitive Training
905829|NCT02506036|Web-based
905830|NCT02506036|Right Hemisphere Stroke
905831|NCT02506036|Frontotemporal Dementia
905832|NCT02506036|Right Sided Cerebral Hemisphere Cerebrovascular Accident
905833|NCT02506023|Factor VIII antigen
905834|NCT02506023|von Willebrand factor (vWF) antigen
905835|NCT02506023|Mutation type
905836|NCT02506010|Hypoxia
905837|NCT02505984|oxytocin, bonding
905838|NCT02505971|hemangioma, propranolol, nadolol
905839|NCT02505958|insulin resistance, obesity, caloric intake
905840|NCT02505945|Esophageal Reflux
905841|NCT02505945|Gastric Acid Reflux Disease
905842|NCT02505945|Heartburn
905843|NCT02505932|Shoulder instability
905844|NCT02505919|Lower Urinary Tract Symptoms (LUTS)
905845|NCT02505906|Late toxicity
905846|NCT02505906|Simultaneous integrated boost (SIB)
905847|NCT02505906|Radiotherapy
905848|NCT02505880|Hypnosis
905849|NCT02505880|Pediatric surgery
905850|NCT02505880|Anesthesia
905851|NCT02505854|Obesity
905852|NCT02505854|Probiotic
905853|NCT02505854|Symbiotic
905854|NCT02505854|Weight loss
905855|NCT02505854|Gut microbiota
905856|NCT02505854|Bifidobacterium lactis
905857|NCT02505854|Fructooligosaccharide
905858|NCT02505854|Blood sugar
905859|NCT02505854|Lipemia
905860|NCT02505841|Appendectomy
905861|NCT02505841|Laparoscopy
905862|NCT02505841|pediatric surgery
905863|NCT02505828|Arthritis
905864|NCT02505828|septic
905865|NCT02505828|Juvenile idiopathic arthritis
905866|NCT02505828|diagnosis
905867|NCT02505828|proteomic
905868|NCT02505828|cytokine
905869|NCT02505828|monocytes
905870|NCT02505802|Stroke
905871|NCT02505802|Botulinum Toxins
905872|NCT02505802|Muscle Spasticity
905873|NCT02505802|Gait
905874|NCT02505789|Epstein-Barr Virus
905875|NCT02505789|Post-transplant lymphoproliferative disease (PTLD)
905876|NCT02505789|Infection
905877|NCT02505789|Cell Transplants
905878|NCT02505789|Herpesvirus 4, Human
905879|NCT02505711|Agriculture
905880|NCT02505711|Food
905881|NCT02505711|Micronutrients
905882|NCT02505711|Pregnancy
905883|NCT02505711|Infants
905884|NCT02505711|Women's groups
905885|NCT02505711|Bangladesh
905886|NCT02505698|Breast Imaging
905887|NCT02505698|Mammography
905888|NCT02505698|Anatomical Imaging
905889|NCT02505685|Lung
905890|NCT02505685|Cancer
905891|NCT02505685|Biomarkers
905892|NCT02505685|PET-CT
905893|NCT02505685|Early detection
905894|NCT02505672|Vestibular function
905895|NCT02505672|chemoradiotherapy
905896|NCT02505659|Anterior cruciate ligament rupture
905897|NCT02505659|Preoperative re-education
905898|NCT02505659|Knee functional performance
905899|NCT02505659|Anterior cruciate ligament surgery
905900|NCT02505659|Single-leg hop for distance test performance
905901|NCT02505646|circulatory failure
905902|NCT02505646|fluid responsiveness
905903|NCT02505646|abdominal compression
905904|NCT02505633|brachial plexus block
905905|NCT02505633|nerve stimulator
905906|NCT02505633|ultrasound
905907|NCT02505620|Neurocognitive function
905908|NCT02505620|OSAS
905909|NCT02505594|Obstructive Sleep Apnea
905910|NCT02505594|Vasoreactivity
905911|NCT02505594|Endothelial function
905912|NCT02505594|Exercise
905913|NCT02505581|Postoperative Wound Infection
905914|NCT02505581|Surgical Wound Infection
905915|NCT02505581|Colorectal Surgery Infection Prophylaxis
905916|NCT02505568|Behcet Disease
905917|NCT02505568|Infliximab
905918|NCT02505568|Adult participants
905919|NCT02505555|feasibility
905920|NCT02505555|accuracy
905921|NCT02505555|tolerability
905922|NCT02505555|four dimensional hysterosalpingo-contrast sonography
905933|NCT02505529|Aging
905934|NCT02505529|Muscle
905935|NCT02505529|Weakness
905936|NCT02505529|Sarcopenia
905937|NCT02505529|Dynapenia
905938|NCT02505516|pathology
905939|NCT02505503|Claudication
905940|NCT02505503|Footwear
905941|NCT02505503|Shoes
905942|NCT02505503|Walking capacity
905943|NCT02505503|Walking distance
905944|NCT02505490|Lunch
905945|NCT02505490|Television
905946|NCT02505490|Macaroni and Cheese
905947|NCT02505490|Salad tossed in dressing
905948|NCT02505477|schiozphrenia
905949|NCT02505477|cognition
905950|NCT02505477|negative symptoms
905951|NCT02505477|glutamate
905952|NCT02505477|glutathione
905953|NCT02505477|N-acetylcysteine
905954|NCT02505451|Metabolic syndrome
905955|NCT02505451|diabetes
905956|NCT02505451|myocardial function
905957|NCT02505451|dobutamine
905958|NCT02505399|Rotational Atherectomy
905959|NCT02505399|clopidogrel
905960|NCT02505399|thrombosis
905961|NCT02505399|ticagrelor
905962|NCT02505386|Ertapenem
905963|NCT02505386|Subcutaneously
905964|NCT02505386|Aged
905965|NCT02505386|Elderly
905966|NCT02505386|Pharmacokinetics
905967|NCT02505373|Brief Therapy
905968|NCT02505373|Attempted Suicide
905969|NCT02505373|Therapeutic Alliance
905970|NCT02505373|Suicidal Ideation
905971|NCT02505373|Suicide
905972|NCT02505373|ASSIP
905973|NCT02505321|insulin resistance
905974|NCT02505321|physiology
905975|NCT02505321|genetics
905976|NCT02505321|gene variants
905977|NCT02505321|pathogenesis
905978|NCT02505321|type 2 diabetes
905979|NCT02505321|fat
905980|NCT02505321|polygenic lipodystrophy
905981|NCT02505308|insulin
905982|NCT02505308|proinsulin
905983|NCT02505308|genotype
905984|NCT02505308|beta cells
905985|NCT02505308|physiology
905986|NCT02505308|genetics
905987|NCT02505308|pathogenesis
905988|NCT02505308|rare variants
905989|NCT02505308|type 2 diabetes
905990|NCT02505282|Orthostatic hypotension
905991|NCT02505282|Vitamin K
905995|NCT02505243|ribavirin
905996|NCT02505243|direct-acting antivirals
905997|NCT02505243|pharmacokinetics
905998|NCT02505243|therapeutic drug monitoring
905999|NCT02505217|platelet reactivity, thrombin generation
906000|NCT02505204|clonidine
906001|NCT02505204|paravertebral block
906002|NCT02505204|hemodynamic stability
906003|NCT02505191|Pharmacokinetics
906004|NCT02505178|Depression
906005|NCT02505178|Depressive Disorder
906006|NCT02505178|Depressive Disorder, Major
906007|NCT02505178|Mental Disorders
906008|NCT02505178|Mood Disorders
906009|NCT02505178|Behavioural Symptoms
906010|NCT02505178|Problem Solving Therapy
906011|NCT02505165|Intervention
906012|NCT02505165|Illness Uncertainty
906013|NCT02505165|Childhood Cancer
906014|NCT02505165|Solid Tumor
906015|NCT02505165|Leukemia
906016|NCT02505165|Lymphoma
906017|NCT02505165|Brain Tumor
906018|NCT02505165|Randomized clinical trial
906019|NCT02505165|Parental uncertainty management intervention
906020|NCT02505165|Parent
906021|NCT02505165|Oncology
906022|NCT02505165|Pediatric
906023|NCT02505152|Hypertension, Portal
906024|NCT02505152|Portal Vein, Cavernous Transformation Of
906025|NCT02505152|Portosystemic shunt
906026|NCT02505152|Radiology, Interventional
906027|NCT02505139|nasopharyngeal carcinoma
906028|NCT02505139|distant metastasis
906029|NCT02505139|circulating tumor cells
906030|NCT02505139|outcome prediction
906031|NCT02505113|Portal Vein, Cavernous Transformation Of
906032|NCT02505113|Hypertension, Portal
906033|NCT02505100|threat of premature birth
906034|NCT02505087|Selenoprotein N-related myopathy
906035|NCT02505087|biomarkers
906036|NCT02505087|washout
906037|NCT02505087|N-ACETYLCYSTEINE
906038|NCT02505074|mitral valve
906039|NCT02505074|tricuspid valve
906040|NCT02505074|Melody valve
906041|NCT02505035|Palliative care
906042|NCT02505035|Pragmatic trial
906043|NCT02505022|Cognition
906044|NCT02505022|Early mental illness
906045|NCT02505022|Role functioning
906046|NCT02505009|Therapeutic Uses
906047|NCT02505009|Entecavir
906048|NCT02505009|Tenofovir
906049|NCT02505009|Engerix-B
906050|NCT02505009|DNA Virus Infections
906051|NCT02505009|Antiviral Agents
906052|NCT02505009|Vaccination
906053|NCT02504996|sciatalgia
906054|NCT02504996|emergency department
906055|NCT02504996|paracetamol
906056|NCT02504996|morphine
906057|NCT02504983|SNPs
906058|NCT02504970|Anesthesia
906059|NCT02504970|Quality Improvement
906060|NCT02504957|Photodynamic therapy
906061|NCT02504944|Retinopathy of prematurity
906062|NCT02504944|Propranolol
906063|NCT02504944|Newborn
906064|NCT02504944|Eye Drops
906065|NCT02504944|Retinal angiogenesis
906066|NCT02504944|Retinal neovascularization
906067|NCT02504931|PTSD
906068|NCT02504931|Alcohol
906069|NCT02504931|Dual Diagnosis
906070|NCT02504931|Sertraline
906071|NCT02504931|SSRI
906082|NCT02504892|Overall Response Rate
906083|NCT02504892|Hereditary Cancer Syndrome
906084|NCT02504892|mTOR Therapy Naive
906085|NCT02504879|Osteosclerosis
906086|NCT02504879|Hyperostosis
906087|NCT02504866|Aerobic Exercise Training
906088|NCT02504866|Balance
906089|NCT02504866|TBI
906090|NCT02504853|Eosinophilic Esophagitis
906091|NCT02504853|Loeys-Dietz Syndrome
906092|NCT02504853|TGFbeta
906097|NCT02504827|pharmacokinetics
906098|NCT02504827|ceftazidime/avibactam
906099|NCT02504814|nasal high flow
906100|NCT02504801|primary lung cancer patients
906101|NCT02504788|Whole Brain Radiotherapy (WBRT)
906102|NCT02504788|Neurocognitive Functions (NCFs)
906103|NCT02504788|Hippocampus
906104|NCT02504788|Hippocampus Sparing during Whole Brain Radiotherapy (HS-WBRT)
906105|NCT02504749|GIT motility
906106|NCT02504749|General anaesthesia
906107|NCT02504749|spinal anaesthesia
906108|NCT02504736|LDL cholesterol
906109|NCT02504736|A1c
906110|NCT02504736|High risk South Asians
906111|NCT02504736|Colesevelam
906112|NCT02504723|Gastric varices
906113|NCT02504723|cyanoacrylate
906114|NCT02504723|carvedilol
906115|NCT02504710|Musculoskeletal Manipulations
906116|NCT02504710|Learning
906117|NCT02504710|Feedback
906118|NCT02504710|Kinematics
906119|NCT02504710|Inertial Sensor
906120|NCT02504684|varicose veins
906121|NCT02504684|endovenous laser treatment
906122|NCT02504684|endovenous thermal ablation
906123|NCT02504684|saphenous vein
906124|NCT02504671|DMARD-IR
906125|NCT02504671|GSK3196165
906126|NCT02504671|Rheumatoid Arthritis
906127|NCT02504658|adolescents text messages eating exercise self-efficacy diabetes
906128|NCT02504632|platelet activation
906129|NCT02504632|transcatheter aortic valve implantation
906130|NCT02504593|Quality Assurance
906131|NCT02504593|Monitoring & Evaluation
906132|NCT02504593|Malaria rapid diagnostic test (RDT)
906133|NCT02504593|Community-based malaria diagnosis
906134|NCT02504593|Community health workers
906135|NCT02504567|Catheter Ablation
906136|NCT02504567|Radiofrequency
906137|NCT02504567|Laser
906138|NCT02504567|Atrial Fibrillation
906139|NCT02504554|children
906140|NCT02504541|Hypogonadism
906141|NCT02504541|Testosterone enanthate
906142|NCT02504528|asthma
906143|NCT02504528|allergy
906144|NCT02504528|bronchial hyperresponsiveness
906145|NCT02504528|provocation
906146|NCT02504502|Whole Genome Sequencing
906147|NCT02504502|Laboratory Report
906148|NCT02504502|Patient Centered
906149|NCT02504502|Communication of Results
906150|NCT02504502|Patient Provider Communication
906151|NCT02504476|Schizophrenia or Schizoaffective Disorder
906152|NCT02504463|Alkermes
906153|NCT02504463|Samidorphan
906154|NCT02504463|ALKS 33
906155|NCT02504463|Healthy Volunteer
906156|NCT02504463|Pharmacokinetics
906157|NCT02504450|Bipolar 1 disorder
906158|NCT02504450|schizophrenia
906159|NCT02504424|Tissue Expansion
906160|NCT02504424|Tissue Expander
906161|NCT02504424|Breast Tissue Expansion
906162|NCT02504424|Breast Tissue Expander
906163|NCT02504424|Breast Reconstruction
906164|NCT02504424|2 Stage Breast Reconstruction
906165|NCT02504372|NSCLC
906166|NCT02504372|PDL1
906167|NCT02504372|PD-L1
906168|NCT02504372|PDL
906169|NCT02504359|BEAM
906170|NCT02504359|allogeneic
906171|NCT02504359|myeloma
906172|NCT02504359|ixazomib
906173|NCT02504359|transplant
906174|NCT02504359|plasma cell leukemia
906175|NCT02504333|metastatic pancreatic adenocarcinoma
906176|NCT02504333|Nab-paclitaxel
906177|NCT02504333|Gemcitabine
906178|NCT02504333|modified FOLFOX
906179|NCT02504320|Drug therapy
906180|NCT02504255|Crohn disease
906181|NCT02504255|inflammatory biomarkers
906182|NCT02504255|immunologic markers
906183|NCT02504255|calprotectin
906184|NCT02504216|Rivaroxaban
906185|NCT02504216|Xarelto
906186|NCT02504216|Aspirin
906187|NCT02504216|Acetylic salicylic acid
906188|NCT02504216|Anticoagulant
906189|NCT02504216|Peripheral artery disease
906190|NCT02504216|Peripheral arterial disease
906191|NCT02504216|Revascularization
906192|NCT02504216|Acute limb ischemia
906193|NCT02504216|Amputation
906194|NCT02504216|Cardiovascular events
906198|NCT02504164|midazolam
906199|NCT02504164|satisfaction
906200|NCT02504164|endoscopic submucosal dissection
906201|NCT02504099|Chronic Hepatitis C Infection
906202|NCT02504099|Early Stage Hepatocellular Carcinoma
906203|NCT02504073|Clinical Reasoning
906204|NCT02504073|Physiotherapists
906205|NCT02504060|diarrhea
906206|NCT02504060|abdominal pain
906207|NCT02504047|Hematopoietic Stem Cell Transplantation
906208|NCT02504034|Portal Vein, Cavernous Transformation Of
906209|NCT02504034|Hypertension, Portal
906210|NCT02504034|Radiology, Interventional
906211|NCT02504034|Portalsystemic shunt
906212|NCT02504008|bisphosphonate
906213|NCT02504008|CRPS
906214|NCT02504008|RSD
906215|NCT02504008|non-opioid
906216|NCT02504008|CRPS-1
906217|NCT02504008|acute on chronic pain
906218|NCT02504008|chronic pain
906219|NCT02504008|zoledronic acid
906220|NCT02503969|Colorectal Cancer
906221|NCT02503969|Mass Screening
906222|NCT02503969|Uptake
906223|NCT02503969|Morbidity
906224|NCT02503969|Mental Health
906225|NCT02503943|GLP-1
906226|NCT02503943|Masked hypertension
906227|NCT02503943|Lipid metabolism
906228|NCT02503917|Imaging, Ultrasound
906229|NCT02503917|Image-guided radiotherapy
906230|NCT02503917|Cancer
906231|NCT02503904|Pharmacology
906232|NCT02503904|Lidocaine
906233|NCT02503904|Epinephrine
906234|NCT02503904|Cefazolin
906235|NCT02503904|Metronidazole
906236|NCT02503904|Infection
906237|NCT02503904|prevention
906238|NCT02503904|prophylaxis
906239|NCT02503904|SSI
906240|NCT02503904|Surgery
906241|NCT02503904|Complications
906242|NCT02503865|Metabolic syndrome
906243|NCT02503865|Diabetes mellitus,
906244|NCT02503865|Hypertension
906245|NCT02503865|Overweight
906246|NCT02503865|analimentary detoxication
906247|NCT02503852|Female Pattern Baldness
906248|NCT02503852|Male Pattern Baldness
906249|NCT02503852|Genetic Alopecia
906250|NCT02503852|Androgenic Alopecia
906251|NCT02503852|Hair Loss
906252|NCT02503839|Host-modulating therapy
906253|NCT02503839|Vaccine
906254|NCT02503839|Cyclooxygenase inhibitors
906255|NCT02503813|brain death
906256|NCT02503813|apnea challenge test
906257|NCT02503787|chronic pain
906258|NCT02503787|intractable pain
906259|NCT02503787|failed back surgery syndrome
906260|NCT02503774|Solid Tumours, MEDI9447, MEDI4736, durvalumab, CD73, PD-L1
906261|NCT02503761|meropenem
906262|NCT02503761|infusion
906263|NCT02503761|late-onset sepsis
906264|NCT02503761|newborn
906265|NCT02503761|management
906266|NCT02503735|CKD
906267|NCT02503735|HCV
906268|NCT02503696|Inflammatory Bowel Disease
906269|NCT02503696|Cancer
906270|NCT02503696|Colorectal Cancer
906271|NCT02503696|Neoplasm
906272|NCT02503696|Colorectal Neoplasm
906273|NCT02503696|Intestinal Neoplasms
906274|NCT02503696|Gastrointestinal Neoplasms
906275|NCT02503696|Digestive System Neoplasms
906276|NCT02503696|Neoplasms by Site
906277|NCT02503696|Neoplasms
906278|NCT02503696|Digestive System Diseases
906279|NCT02503696|Gastrointestinal Diseases
906280|NCT02503696|Colonic Diseases
906281|NCT02503696|Intestinal Diseases
906282|NCT02503696|Rectal Diseases
906283|NCT02503683|RNAi therapeutic
906284|NCT02503683|AAT
906285|NCT02503683|Alpha-1 Antitrypsin Deficiency
906286|NCT02503657|tipelukast
906287|NCT02503657|IPF
906288|NCT02503657|fibrosis
906289|NCT02503657|Idiopathic Pulmonary Fibrosis
906290|NCT02503644|diffuse cutaneous systemic sclerosis
906291|NCT02503644|scleroderma
906292|NCT02503644|IVA337
906293|NCT02503644|dcSSc
906294|NCT02503631|Cancer
906295|NCT02503631|Colorectal Cancer
906296|NCT02503631|Neoplasm
906297|NCT02503631|Colorectal Neoplasm
906298|NCT02503631|Intestinal Neoplasms
906299|NCT02503631|Gastrointestinal Neoplasms
906300|NCT02503631|Digestive System Neoplasms
906301|NCT02503631|Neoplasms by Site
906302|NCT02503631|Neoplasms
906303|NCT02503631|Digestive System Diseases
906304|NCT02503631|Gastrointestinal Diseases
906305|NCT02503631|Colonic Diseases
906306|NCT02503631|Intestinal Diseases
906307|NCT02503631|Rectal Diseases
906308|NCT02503605|Biosimilar
906309|NCT02503605|ovarian stimulation
906310|NCT02503605|oocyte donor
906311|NCT02503579|Brain-derived neurotropic factor
906312|NCT02503579|Executive function
906313|NCT02503566|CAV
906314|NCT02503566|OCT
906315|NCT02503566|heart rate
906316|NCT02503566|antibodies
906317|NCT02503553|option grid
906318|NCT02503553|neurosurgery
906319|NCT02503553|cerebral aneurysm
906320|NCT02503540|macular edema
906321|NCT02503540|rvo
906322|NCT02503540|diabetic macular edema
906323|NCT02503527|Enteral nutrition
906324|NCT02503527|Tube feeding
906325|NCT02503527|Diet, carbohydrate-restricted
906326|NCT02503527|Diabetes
906327|NCT02503527|Aneurysmal Subarachnoid Hemorrhage
906328|NCT02503527|Blood glucose
906329|NCT02503527|Insulin
906330|NCT02503501|Memory
906331|NCT02503501|Insulin glulisine
906332|NCT02503501|Alzheimer's disease
906333|NCT02503501|Mild Cognitive Impairment
906334|NCT02503501|Intranasal insulin
906335|NCT02503501|Cognition Disorders
906336|NCT02503488|Appetitive Aggression
906337|NCT02503462|HIV
906338|NCT02503462|darunavir
906339|NCT02503462|ritonavir
906340|NCT02503462|cobicistat
906341|NCT02503462|CSF
906342|NCT02503462|pharmacokinetics
906343|NCT02503449|Pulmonary Cryptococcosis
906345|NCT02503410|back
906346|NCT02503410|pain
906347|NCT02503345|Kidney Stones
906348|NCT02503345|Nephrolithiasis
906349|NCT02503345|Urine Oxalate
906350|NCT02503345|Hyperoxaluria
906351|NCT02503345|Enteric Hyperoxaluria
906352|NCT02503345|Idiopathic Hyperoxaluria
906353|NCT02503345|Urological Diseases
906354|NCT02503345|Kidney Diseases
906355|NCT02503345|Dietary Oxalate
906356|NCT02503280|Cardiovascular
906357|NCT02503280|Secondary
906358|NCT02503267|antithrombin III deficiency
906359|NCT02503267|congenital heart diseases
906360|NCT02503254|Smoking
906361|NCT02503254|Modified risk tobacco product
906362|NCT02503254|Conventional cigarette
906363|NCT02503254|Reduced exposure
906364|NCT02503254|Confinement
906365|NCT02503254|Carbon Heated Tobacco Product
906366|NCT02503215|Hemodialysis
906367|NCT02503215|Obstructive sleep apnea
906368|NCT02503215|Compression stockings
906369|NCT02503189|Dry eye syndromes
906370|NCT02503189|Corneal diseases
906371|NCT02503189|Conjunctival diseases
906372|NCT02502487|Analgesia
906373|NCT02502487|Cystoscopy
906374|NCT02502487|Dorsal nerve of penis
906375|NCT02502487|Nerve block
906376|NCT02502487|Ropivacaine
906377|NCT02502474|staphylococcus aureus
906378|NCT02502474|digestive carriage
906379|NCT02502474|mucosal colonization
906380|NCT02502448|rotational thromboelastometry
906381|NCT02502448|cardiac surgery
906382|NCT02502448|acute normovolemic hemodilution
906383|NCT02502422|Laryngeal mask airway
906384|NCT02502409|Hemophilia B
906385|NCT02502409|Hemophilia B with Inhibitors
906386|NCT02502396|Cancer
906387|NCT02502396|Deep-vein thrombosis of the lower and upper extremities
906388|NCT02502396|Pulmonary embolism
906389|NCT02502396|Non-valvular atrial fibrillation
906390|NCT02502396|Chart review
906391|NCT02502396|VTE
906392|NCT02502396|NVAF
906393|NCT02502396|Rivaroxaban
906394|NCT02502383|Adolescent
906395|NCT02502383|Overweight
906396|NCT02502383|Obesity
906397|NCT02502383|Weight loss
906398|NCT02502383|Nutrition
906399|NCT02502383|Physical Activity
906400|NCT02502383|School-based
906401|NCT02502383|Primary care
906402|NCT02502383|Motivational Interviewing
906403|NCT02502357|pain control
906404|NCT02502357|healing statements
906405|NCT02502357|pelvic prolapse
906406|NCT02502344|insulin resistance
906407|NCT02502344|abnormal glucose tolerance
906408|NCT02502344|DM prevention
906409|NCT02502331|Oral Cholera Vaccine
906410|NCT02502331|immunogenicity
906411|NCT02502331|safety
906412|NCT02502318|Proven or suspected lung cancer treated by lobectomy
906413|NCT02502305|health literacy
906414|NCT02502305|attitude
906415|NCT02502305|motivation
906416|NCT02502292|Health Literacy
906417|NCT02502292|Health Ageing
906418|NCT02502292|Health Literacy Interventions
906419|NCT02502292|IROHLA
906420|NCT02502292|Photo Novel Study
906421|NCT02503176|Dry eye syndromes
906422|NCT02503176|Corneal diseases
906423|NCT02503176|Conjunctival diseases
906424|NCT02503163|Dry eye syndromes
906425|NCT02503163|Corneal diseases
906426|NCT02503163|Conjunctival diseases
906427|NCT02503150|Colorectal Cancer
906428|NCT02503150|Tumor Therapeutic Vaccine
906429|NCT02503150|Dendritic Cell
906430|NCT02503137|male pattern baldness
906431|NCT02503137|SM04554
906432|NCT02503137|AGA
906433|NCT02503111|Men who have sex with men
906434|NCT02503111|Human immunodeficiency virus
906435|NCT02503111|Human papillomavirus
906436|NCT02503111|Anal intraepithelial neoplasia
906437|NCT02503111|Squamous cell carcinoma
906438|NCT02503111|High-resolution anoscopy
906439|NCT02503111|Anal cancer
906440|NCT02503111|High-risk oncogenic
906441|NCT02503111|Intraepithelial lesion
906442|NCT02503111|Low-risk non-oncogenic
906443|NCT02503111|Dysplasia
906444|NCT02503111|High-grade squamous intraepithelial lesion
906445|NCT02503111|Low-grade squamous intraepithelial lesion
906446|NCT02503111|Ablative therapy
906447|NCT02503111|Electrocautery
906448|NCT02503111|Infrared coagulation
906449|NCT02503111|Active surveillance
906450|NCT02503098|Eating Disorders
906451|NCT02503098|Cognitive Behavioral Therapy
906452|NCT02503098|Mobile Phone
906453|NCT02503098|Smartphone
906454|NCT02503098|App
906455|NCT02503098|Binge Eating Disorder
906456|NCT02503098|Bulimia Nervosa
906457|NCT02503098|Signal Detection Analysis
906458|NCT02503072|ARV adherence
906459|NCT02503020|Arachidonic acid
906460|NCT02503020|Omega-6/omega-3 ratio
906461|NCT02503020|Preterm infants nutrition
906462|NCT02502981|CKD
906463|NCT02502981|left ventricle
906464|NCT02502981|aldosterone
906465|NCT02502981|spironolactone
906466|NCT02502955|Quality Control
906467|NCT02502955|Cardiosurgery
906468|NCT02502955|Cardiology
906469|NCT02502955|Vascular Surgery
906470|NCT02502955|ICU
906471|NCT02502942|Obstructive Sleep Apnea
906472|NCT02502942|Exercise
906473|NCT02502942|Upper airway muscle
906474|NCT02502929|Diabetes
906475|NCT02502929|Depression
906476|NCT02502929|Medication therapy management
906477|NCT02502929|Community health workers
906478|NCT02502929|Cambodian
906479|NCT02502929|Refugee
906480|NCT02502929|Prevention
906481|NCT02502890|asthma
906482|NCT02502890|nested case-control study
906483|NCT02502890|difficult-to-control asthma
906484|NCT02502890|asthma exacerbations
906485|NCT02502890|cold symptoms
906486|NCT02502890|gene expression
906487|NCT02502838|overactive bladder
906488|NCT02502838|pelvic organ prolapse
906489|NCT02502838|TVT
906490|NCT02502812|bioequivalence
906491|NCT02502812|SB224326
906492|NCT02502812|clopidogrel
906493|NCT02502812|Relative bioavailability
906494|NCT02502786|Humanized Monoclonal Antibody 3F8 (Hu3F8)
906495|NCT02502786|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
906496|NCT02502786|15-096
906497|NCT02502773|Goal-directed therapy
906498|NCT02502773|Fluid loading
906499|NCT02502773|Abdominal surgery
906500|NCT02502773|Postoperative morbidity
906501|NCT02502773|Postoperative mortality
906502|NCT02502773|Individualized goal-directed fluid therapy
906503|NCT02502773|Elective or emergency abdominal surgery
906504|NCT02502773|General Anesthesia
906505|NCT02502773|Moderate-to-high risk surgical patients
906506|NCT02502760|Postoperative Complications
906507|NCT02502760|Perioperative Care
906508|NCT02502760|Colorectal Surgery
906509|NCT02502760|Frail Elderly
906510|NCT02502734|inhaled corticosteroids
906511|NCT02502734|pediatric subjects
906512|NCT02502734|asthma
906513|NCT02502734|fluticasone furoate
906514|NCT02502721|Male
906515|NCT02502708|glioblastoma multiforme
906516|NCT02502708|glioma
906517|NCT02502708|gliosarcoma
906518|NCT02502708|malignant brain tumor
906519|NCT02502708|ependymoma
906520|NCT02502708|medulloblastoma
906521|NCT02502695|VATS Lobectomy and Segmentectomy for Lung Cancer
906522|NCT02502695|Lung Cancer
906523|NCT02502682|Chlorhexidine bathing
906524|NCT02502669|acne
906525|NCT02502669|nodulocystic
906526|NCT02502669|finasteride
906527|NCT02502669|5 alpha reductase inhibitor
906528|NCT02502656|RAS mutation
906529|NCT02502656|DNA
906530|NCT02502656|Colorectal Cancer
906531|NCT02502643|Safety and Efficacy
906532|NCT02502643|Thoracic Surgery
906533|NCT02502617|Psychopathology
906534|NCT02502617|Cognition
906535|NCT02502617|Depression
906536|NCT02502617|Nutrition
906537|NCT02502617|Cortisol
906538|NCT02502617|Anorexia nervosa
906539|NCT02502604|Cognitive Remediation
906540|NCT02502604|Goal Management Training
906541|NCT02502604|Major Depressive Disorder
906542|NCT02502604|Post-traumatic Stress Disorder
906543|NCT02502604|Neuropsychological Functioning
906544|NCT02502578|Triglyceride Deposit Cardiomyovasculopathy
906545|NCT02502552|Crohn's Disease
906546|NCT02502552|Ulcerative Colitis
906547|NCT02502552|Inflammatory Bowel Disease
906548|NCT02502552|anti-glycan antibodies
906549|NCT02502552|antibodies stability
906550|NCT02502552|mucosal healing
906551|NCT02502552|predictive markers
906552|NCT02502539|Juvenile idiopathic arthritis
906553|NCT02502539|Physical exercise
906554|NCT02502539|Pro-anti-inflammatory balance
906555|NCT02502539|Interleukins
906556|NCT02502539|miRNA
906557|NCT02502539|Calgranulins
906558|NCT02502240|ALK
906559|NCT02502240|Latin American
906560|NCT02502227|mindfulness
906561|NCT02502227|psychological stress
906562|NCT02502227|wellness programs
906563|NCT02502227|cortisol
906564|NCT02502214|Preimplantation Genetic Diagnosis
906565|NCT02502214|PGD
906566|NCT02502214|Next-Generation Sequencing
906567|NCT02502214|NGS
906568|NCT02502214|Single-Gene disorders
906569|NCT02502214|Cystic Fibrosis
906570|NCT02502214|CFTR
906571|NCT02502214|Single-cell analysis
906572|NCT02502214|PCR
906573|NCT02502214|SNP
906574|NCT02502214|Whole Genome Amplification
906575|NCT02502201|six-minute walk
906576|NCT02502188|Healthy Subjects
906577|NCT02502188|Severe Plaque Psoriasis
906578|NCT02502188|Moderate
906579|NCT02502188|Phase 1
906580|NCT02502188|Safety
906581|NCT02502188|Tolerability
906582|NCT02502188|CC-90005
906583|NCT02502175|Opium tincture
906584|NCT02502175|opium
906585|NCT02502175|methadone
906586|NCT02502175|opioid dependence
906587|NCT02502175|opiate dependence
906588|NCT02502175|clinical trial
906589|NCT02502175|Iran
906590|NCT02502149|rFVIIIFc
906591|NCT02502149|Eloctate
906592|NCT02502149|Hemophilia
906593|NCT02502136|CO2 insufflation
906594|NCT02502110|Atrial Fibrillation
906595|NCT02502110|statin
906596|NCT02502110|radiofrequency ablation
906597|NCT02502006|Non-steroidal Anti-inflammatory Drugs
906598|NCT02502006|Healthy volunteers
906599|NCT02502006|Celecoxib
906600|NCT02502006|Naproxen
906601|NCT02502006|Prostaglandin
906602|NCT02502006|Cyclooxygenase
906603|NCT02501980|Screening
906604|NCT02501980|Hepatocellular Cancer
906605|NCT02501980|Biomarker
906606|NCT02501980|Mortality rate
906607|NCT02501967|multiple chronic conditions
906608|NCT02501941|Ketamine
906609|NCT02501941|Cortical Spreading Depolarization
906610|NCT02501941|Cortical Spreading Depression
906614|NCT02501915|Muscle
906615|NCT02501902|Ibrance, palbociclib, Abraxane, nab-paclitaxel, pancreas,
906616|NCT02501889|obesity
906617|NCT02501889|overweight
906618|NCT02501889|weight loss
906619|NCT02501889|satiety
906620|NCT02501889|walnuts
906621|NCT02501889|gastrointestinal peptides
906622|NCT02501876|The risk of progession
906623|NCT02501876|patients
906624|NCT02501850|Lipoprotein (a)
906625|NCT02501837|Healthy women
906626|NCT02501811|Heart Failure
906627|NCT02501811|Ischemia
906628|NCT02501811|Autologous Stem Cells
906629|NCT02501811|LV dysfunction
906630|NCT02501811|Mesenchymal Stem Cells
906631|NCT02501811|ckit Cardiac Stem Cells
906632|NCT02501811|Combination Cell Therapy
906633|NCT02501811|LV function
906634|NCT02501811|Functional status
906635|NCT02501798|ADHD
906636|NCT02501798|Methylphenidate
906637|NCT02501798|Academic
906638|NCT02501798|Motivation
906639|NCT02501785|Quality of Life
906640|NCT02501785|Patient care givers
906641|NCT02501785|15-145
906642|NCT02501785|Ambulatory Extended Recovery
906643|NCT02501746|Group medical care
906644|NCT02501746|Microfinance
906645|NCT02501746|Hypertension
906646|NCT02501746|Community-based intervention
906647|NCT02501746|Global health
906648|NCT02501733|Total Knee Replacement
906649|NCT02501733|Total Knee Arthroplasty
906650|NCT02501720|burn
906651|NCT02501720|hand
906652|NCT02501720|flexion contracture
906653|NCT02501720|tourniquet
906654|NCT02501720|tumescent technique
906655|NCT02501720|children
906656|NCT02501707|echocardiography
906657|NCT02501707|radiation-induced lung injury
906658|NCT02501707|prognostic
906659|NCT02501707|chemo radiotherapy
906660|NCT02501707|non-small cell lung cancer
906661|NCT02501707|NSCLC
906662|NCT02501681|sublingual microcirculation
906663|NCT02501681|cardiovascular surgery
906664|NCT02501616|SGLT2 inhibitor
906665|NCT02501564|Osteoarthritis
906666|NCT02501564|NAPROXEN SODIUM
906667|NCT02501551|Malignant melanoma
906668|NCT02501551|C-KIT mutation
906669|NCT02501525|renal stone
906670|NCT02501525|retrograde intrarenal surgery
906671|NCT02501525|ureteral access sheath
906672|NCT02501525|pain
906673|NCT02501512|transesophageal signal
906674|NCT02501512|swallowing
906675|NCT02501512|newborn
906676|NCT02501486|adrenal insufficiency
906677|NCT02501486|adverse drug reaction
906678|NCT02501486|corticosteroid
906679|NCT02501473|follicular lymphoma
906680|NCT02501473|fNHL
906681|NCT02501473|low-grade lymphoma
906682|NCT02501473|Non-Hodgkin's Lymphoma
906683|NCT02501473|follicular NHL
906684|NCT02501473|Marginal Zone
906685|NCT02501460|Adult cancer survivors
906686|NCT02501460|Exercise
906687|NCT02501460|Dietary supplementation
906688|NCT02501434|aneurysmal subarachnoid hemorrhage
906689|NCT02501434|unfractionated heparin
906690|NCT02501434|neurobehavioral manifestations
906691|NCT02501434|delayed ischemic neurological deficits
906692|NCT02501434|cerebral aneurysm
906693|NCT02501434|coil embolization
906694|NCT02501434|Montreal Cognitive Assessment
906695|NCT02501421|vaccine
906696|NCT02501421|influenza vector
906697|NCT02501421|tuberculosis
906698|NCT02501382|Fasciitis
906699|NCT02501382|Fasciitis, Necrotizing
906700|NCT02501382|Soft tissue infections
906701|NCT02501382|Fournier's gangrene
906702|NCT02501382|Immunopathogenesis
906703|NCT02501356|prebiotic
906704|NCT02501356|dietary supplement
906705|NCT02501343|Glucose metabolism
906706|NCT02501343|Potential renal acid load
906707|NCT02501343|Postprandial glycemia
906708|NCT02501343|Body acid-base homeostasis
906709|NCT02501343|Sodium bicarbonate
906710|NCT02501330|Drug use investigation in Japan
906711|NCT02501317|urinary incontinence
906712|NCT02501317|physical therapy
906713|NCT02501317|rehabilitation
906714|NCT02501317|pelvic floor
906715|NCT02501317|perineum
906716|NCT02501317|conservative treatment
906717|NCT02501265|Nicotine addiction
906718|NCT02501265|Cigarette smoking
906719|NCT02501252|Community
906720|NCT02501252|Skilled birth attendance
906721|NCT02501252|Rural
906722|NCT02501252|Ethiopia
906723|NCT02501226|Psychiatry
906724|NCT02501226|Depression
906725|NCT02501226|Psychoeducation
906726|NCT02501226|Randomized controlled trial
906727|NCT02501226|Treatment adherence
906728|NCT02501226|Remission
906729|NCT02501213|Diuretic
906730|NCT02501213|Malignant ascites
906731|NCT02501200|Dyslipidemia
906732|NCT02501200|CKD-391
906733|NCT02501200|Atorvastatin
906734|NCT02501200|Ezetimibe
906735|NCT02501174|Geriatric oncology
906736|NCT02501148|Embolic protection
906737|NCT02501148|Carotid artery stenting
906738|NCT02501135|Femoral nerve blocks
906739|NCT02501135|children
906740|NCT02501135|knee and thigh surgery
906741|NCT02501122|Quality
906742|NCT02501122|hospital care
906743|NCT02501122|adenotonsillectomy
906744|NCT02501109|Aripiprazole
906745|NCT02501109|Oral Soluble Film
906746|NCT02501109|Schizophrenia
906747|NCT02501096|Lenvatinib
906748|NCT02501096|Lenvima
906749|NCT02501096|E7080
906750|NCT02501096|Phase 1b/2
906751|NCT02501096|Pembrolizumab
906752|NCT02501096|Solid tumors
906753|NCT02501083|cardiomyopathy
906754|NCT02501083|echocardiography
906755|NCT02501083|prognosis
906756|NCT02501083|respiratory
906757|NCT02501083|home mechanical ventilation
906758|NCT02501083|vital capacity
906759|NCT02501083|maximal inspiratory pressure
906760|NCT02501083|maximal expiratory pressure
906761|NCT02501070|Percutaneous Coronary Intervention
906762|NCT02501070|Angioplasty
906763|NCT02501070|Stent
906764|NCT02501070|Community Networks
906765|NCT02501057|Human Immunodeficiency Virus
906766|NCT02501057|Unsafe Drinking
906767|NCT02501057|Antiretroviral Therapy (ART)
906768|NCT02501031|Flaxseed
906769|NCT02501031|Postmenopause
906770|NCT02501031|Hormones
906771|NCT02501031|Lignans
906772|NCT02501031|No Evidence of Disease
906773|NCT02501018|CLI
906774|NCT02500979|Type 1 Diabetes Mellitus; Pramlintide
906775|NCT02500966|Cervical Intraepithelial Neoplasia
906776|NCT02500966|stenosis
906777|NCT02500966|cervix
906778|NCT02500966|medical device
906779|NCT02500966|inventories
906780|NCT02500966|Uterine Cervix
906781|NCT02500966|Intrauterine Devices
906782|NCT02500966|intrauterine
906783|NCT02500966|conization
906784|NCT02500966|loop electrosurgical excision
906785|NCT02500953|ASP3325
906786|NCT02500953|pharmacokinetics
906787|NCT02500953|pharmacodynamics
906788|NCT02500927|ASP8273
906789|NCT02500927|Non-Small Cell Lung Cancer
906790|NCT02500927|EGFR Tyrosine Kinase Inhibitor
906791|NCT02500927|EGFR Mutation
906792|NCT02500914|small cell lung cancer
906793|NCT02500901|Enzalutamide
906794|NCT02500901|Niraparib
906795|NCT02500901|PARP-1 inhibitor
906796|NCT02500901|PARP-2 inhibitor
906797|NCT02500901|Castrate-Resistant Prostate Cancer
906798|NCT02500888|OCD
906799|NCT02500888|Neurosurgery
906800|NCT02500888|Radiosurgery
906801|NCT02500875|Negative-Pressure Wound Therapy
906802|NCT02500875|Topical Negative Pressure Therapy
906803|NCT02500875|Sodium Hypochlorite
906804|NCT02500862|Eye
906805|NCT02500862|Imaging
906806|NCT02500849|Gene therapy
906807|NCT02500849|Acquired Immunodeficiency Syndrome
906808|NCT02500849|HIV Infections
906809|NCT02500849|Retroviridae Infections
906810|NCT02500849|RNA Virus Infections
906811|NCT02500849|Virus Diseases
906812|NCT02500849|Sexually Transmitted Diseases, Viral
906813|NCT02500849|Sexually Transmitted Diseases
906814|NCT02500849|Immunologic Deficiency Syndromes
906815|NCT02500849|Immune System Diseases
906816|NCT02500849|Busulfan
906817|NCT02500849|Pharmacologic Actions
906818|NCT02500836|Ear
906819|NCT02500836|Nose
906820|NCT02500836|Throat
906821|NCT02500823|Mitochondrial DNA copy number
906822|NCT02500823|Peripheral blood cells
906823|NCT02500810|neurotoxicity
906824|NCT02500810|chemotherapy
906825|NCT02500810|monosialoganglioside
906826|NCT02500810|prevention
906827|NCT02500758|Surgical scrubbing
906828|NCT02500758|Chlorhexidine digluconate
906829|NCT02500758|Parachlorometaxylenol
906830|NCT02500719|Posttraumatic Stress Disorder
906831|NCT02500719|Neurofeedback
906832|NCT02500719|fMRI
906833|NCT02500719|Skin Conductance Response
906834|NCT02500693|Lung Cancer, Screening, COPD
906835|NCT02500680|Influenza
906836|NCT02500680|Adjuvant
906837|NCT02500667|N91115
906838|NCT02500667|Rifampin
906839|NCT02500667|drug interaction
906840|NCT02500667|Cavosonstat
906841|NCT02500654|Peri-implantitis
906842|NCT02500654|Regenerative therapy
906843|NCT02500654|Surgical therapy
906844|NCT02500654|Enamel matrix derivative
906845|NCT02500654|Peri-implant microflora
906846|NCT02500654|Peri-implant fluid
906847|NCT02500641|Biological Markers
906848|NCT02500641|Cardiovascular disease
906849|NCT02500641|Humans
906850|NCT02500641|Pulse Wave Velocity
906851|NCT02500641|Cardiovascular risk factors
906852|NCT02500641|Allopurinol
906853|NCT02500641|Pulse Wave Analysis
906854|NCT02500641|Thiazoles
906855|NCT02500641|Inflammation
906856|NCT02500641|Uric acid
906857|NCT02500641|Febuxostat
906858|NCT02500641|Oxidative stress
906859|NCT02500641|Tumor Necrosis Factor
906860|NCT02500641|Arthritis
906861|NCT02500641|Hyperuricemia
906862|NCT02500628|metformin
906863|NCT02500628|mitochondria
906864|NCT02500628|complex 1
906865|NCT02500628|fibromyalgia
906866|NCT02500628|neurogenic pain
906867|NCT02500628|diabetes
906868|NCT02500628|tardive dyskinesia
906869|NCT02500628|heart rate variability
906870|NCT02500602|PTSD
906871|NCT02500602|alcohol use disorders
906872|NCT02500602|posttraumatic stress disorder
906873|NCT02500602|AUD
906874|NCT02500602|Veteran
906875|NCT02500589|smoking
906876|NCT02500589|tobacco
906877|NCT02500576|Melanoma
906878|NCT02500576|Metastatic
906879|NCT02500576|Cyclophosphamide
906880|NCT02500576|Cytoxan
906881|NCT02500576|Neosar
906882|NCT02500576|Mesna
906883|NCT02500576|Mesnex
906884|NCT02500576|Fludarabine
906885|NCT02500576|Fludarabine phosphate
906886|NCT02500576|MK-3475
906887|NCT02500576|Keytruda
906888|NCT02500576|Pembrolizumab
906889|NCT02500576|SCH-900475
906890|NCT02500576|IL-2
906891|NCT02500576|Aldesleukin
906892|NCT02500576|Interleukin-2
906893|NCT02500576|Proleukin
906894|NCT02500576|TIL
906895|NCT02500576|T-cells
906896|NCT02500576|Questionnaires
906897|NCT02500576|Surveys
906898|NCT02500576|Phone calls
906899|NCT02500550|Haploidentical stem cell transplantation
906900|NCT02500550|Graft versus host disease
906901|NCT02500550|Immune reconstitution
906902|NCT02500550|Alloreactive T-cells
906903|NCT02500550|Photodynamic treatment
906904|NCT02500550|Hematologic malignancy
906905|NCT02500550|Transplant-related mortality
906906|NCT02500485|SHR3824 SP2086 drug-drug interaction
906907|NCT02500472|Tobacco
906908|NCT02500472|Smoking
906909|NCT02500459|Topotecan
906910|NCT02500459|Cleveland Multiport Catheter
906911|NCT02500459|Cancer
906912|NCT02500433|Cerebral palsy
906913|NCT02500433|child
906914|NCT02500433|rehabilitation
906915|NCT02500433|video games
906916|NCT02500433|virtual reality.
906917|NCT02500420|Hypertrophic cardiomyopathy
906918|NCT02500420|Stress MRI
906919|NCT02500420|Cardiac MRI
906920|NCT02500420|Stress echocardiography
906921|NCT02500420|T1 mapping
906922|NCT02500420|2D strain
906923|NCT02500394|renal replacement therapy
906924|NCT02500342|Thyroid Dysfunction
906925|NCT02500342|Fatigue
906926|NCT02500342|Randomized Controlled Trial
906927|NCT02500342|Thyroxine
906928|NCT02500342|Hypothyroidism
906929|NCT02500316|Growth hormone deficiency (GHD)
906930|NCT02500316|r-hGH
906931|NCT02500316|Long-acting
906932|NCT02500303|Amputation
906933|NCT02500290|ACS
906934|NCT02500277|thoracoscopy
906935|NCT02500277|pleuroscopy
906936|NCT02500277|semirigid thoracoscopy
906937|NCT02500277|flexible cryoprobe
906938|NCT02500277|cryobiopsy
906939|NCT02500277|pleural biopsy
906940|NCT02500251|Transplantation
906941|NCT02500251|belimumab
906942|NCT02500251|Velcade
906943|NCT02500225|Etomidate
906944|NCT02500225|Sevoflurane
906946|NCT02500173|radiotherapy
906947|NCT02500173|side effects
906948|NCT02500147|Polycystic Ovary Syndrome
906949|NCT02500147|Non-Alcoholic Fatty Liver Disease
906950|NCT02500147|Adolescents
906951|NCT02500147|Young Women
906952|NCT02500147|MRI
906953|NCT02500147|MRS
906954|NCT02500147|DXA
906955|NCT02500147|PNPLA3
906956|NCT02500147|Metformin
906957|NCT02500147|Randomized Clinical Trial
906958|NCT02500147|Placebo
906959|NCT02500147|Hirsutism
906960|NCT02500147|Acne
906961|NCT02500147|Amenorrhea
906962|NCT02500147|Metabolic Syndrome
906963|NCT02500147|Dyslipidemia
906964|NCT02500147|Percentage liver fat
906965|NCT02500121|Pembrolizumab
906966|NCT02500121|PD-1 Inhibitor
906967|NCT02500108|Domperidone
906968|NCT02500108|Ventricular Tachyarrhythmia
906969|NCT02500108|Sudden cardiac death
906970|NCT02500108|Pharmacotherapy
906971|NCT02500108|Adverse events
906972|NCT02500082|citrate transporter deficiency
906973|NCT02500082|SLC13A5 gene
906974|NCT02500082|citric acid cycle
906975|NCT02500082|energy metabolism
906976|NCT02500056|Inguinal hernia
906977|NCT02500056|Chronic pain
906978|NCT02500056|Mesh
906979|NCT02500056|Lichtenstein hernioplasty
906980|NCT02500043|Gastric Cancer
906981|NCT02500043|Metastatic Gastric Cancer
906982|NCT02499965|Topical Anesthetic
906983|NCT02499965|Ethyl Chloride
906984|NCT02499965|Pain Reduction
906985|NCT02499965|IV cannulation
906986|NCT02499952|Pembrolizumab
906987|NCT02499952|MK-3475
906988|NCT02499952|PMNSGCT
906989|NCT02499952|PD-L1
906990|NCT02499952|Non Seminomatous Germ Cell Tumors
906991|NCT02499848|MRI Lesion
906992|NCT02499848|transperineal injection
906993|NCT02499848|prostate biopsies
906994|NCT02499822|Hypertension
906995|NCT02499822|Blood pressure variability
906996|NCT02499822|Home systolic blood pressure
906997|NCT02499822|Organ damage
906998|NCT02499822|Nifedipine GITS
906999|NCT02499822|Ramipril
907000|NCT02499809|Vibration therapy
907001|NCT02499809|Recovery from exercise
907002|NCT02499796|Invasive mechanical ventilation
907003|NCT02499796|Humidifying devices
907004|NCT02499796|Respiratory mechanics
907005|NCT02499783|Biologic
907006|NCT02499783|China
907007|NCT02499783|Tumor necrosis factor (TNF)-alpha
907008|NCT02499770|Small Cell Lung Cancer
907009|NCT02499770|CDK 4/6 Inhibitor
907010|NCT02499757|Perception
907011|NCT02499757|brain response
907012|NCT02499757|nicotine
907013|NCT02499757|taste
907014|NCT02499744|NIPPV
907015|NCT02499744|HHFNC
907016|NCT02499744|RDS
907017|NCT02499744|neonate
907018|NCT02499731|physical activity
907019|NCT02499731|nutrition
907020|NCT02499731|social network
907021|NCT02499718|Chronic Obstructive Pulmonary Disease
907022|NCT02499718|Non-invasive positive pressure ventilation
907023|NCT02499718|quality of life
907024|NCT02499718|long-term oxygen therapy
907025|NCT02499666|Exercise Capacity
907026|NCT02499666|Chronic Total Occlusion
907027|NCT02499653|Chronic Obstructive Pulmonary Disease (COPD)
907028|NCT02499653|Non Invasive Ventilation (NIV)
907029|NCT02499653|Acceptance
907030|NCT02499653|Adherence
907031|NCT02499653|Clinical Psychology
907032|NCT02499640|Recovery of function
907033|NCT02499640|Autonomic nervous system
907034|NCT02499640|Heart rate variability
907035|NCT02499640|Cryotherapy
907036|NCT02499640|Immersion
907037|NCT02499627|Lymphoma
907038|NCT02499627|Hodgkin
907039|NCT02499627|PTCL
907040|NCT02499627|CD30+
907041|NCT02499614|MET amplification
907042|NCT02499614|ROS1 translocation
907043|NCT02499614|Crizotinib
907044|NCT02499601|Heart Failure with Preserved Ejection Fraction (HFpEF)
907045|NCT02499601|Heart Failure (HF)
907046|NCT02499601|New York Heart Association functional Class (NYHA f. Cl)
907047|NCT02499575|Exparel
907048|NCT02499575|bupivacaine
907049|NCT02499575|Hallux valgus deformity
907050|NCT02499575|bunionectomy
907051|NCT02499536|Atelectasis
907052|NCT02499536|Postoperative
907053|NCT02499536|Lung ultrasound
907054|NCT02499510|femoropopliteal disease
907055|NCT02499510|restenosis
907056|NCT02499497|Prostate Cancer
907057|NCT02499432|Evidence Based Psychotherapy
907058|NCT02499432|Implementation
907059|NCT02499432|PTSD
907060|NCT02499393|newborn
907061|NCT02499393|therapeutic hypothermia
907062|NCT02499393|magnesium sulphate
907063|NCT02499380|RePneu
907064|NCT02499380|Coil
907065|NCT02499380|LVRC
907066|NCT02499380|PneumRx
907067|NCT02499367|triple negative
907068|NCT02499367|metastatic
907069|NCT02499341|Tramadol
907070|NCT02499341|Ketamine
907071|NCT02499341|Morphine
907072|NCT02499328|Carcinoma of the Head and Neck
907073|NCT02499276|mechanical ventilation
907074|NCT02499276|pressure support ventilation
907075|NCT02499276|NAVA
907076|NCT02499276|PAV
907077|NCT02499276|variable ventilation
907078|NCT02499276|patient ventilator asynchrony
907079|NCT02499263|Adalimumab trough level
907080|NCT02499263|Fecal Calprotectin
907081|NCT02499263|Fecal microbiota
907082|NCT02499250|refractory angina pectoris
907083|NCT02499250|remote ischemic conditioning
907084|NCT02499250|life quality
907085|NCT02499250|anxiety
907086|NCT02499250|depression
907087|NCT02499250|inflammation
907088|NCT02499237|osteoporosis
907089|NCT02499237|denosumab
907090|NCT02499237|zoledronic acid
907091|NCT02499237|bone mineral density
907092|NCT02499237|bone markers
907093|NCT02499211|obesity
907094|NCT02499211|health disparities
907095|NCT02499211|healthy food marketing
907096|NCT02499211|food environments
907097|NCT02499211|marketing environments
907098|NCT02499211|food access
907099|NCT02499211|food purchase decision making
907100|NCT02499198|Nornicotine
907101|NCT02499198|Tobacco
907102|NCT02499198|N'-nitrosonornicotine
907103|NCT02499198|NNN
907104|NCT02499185|Biomarker
907105|NCT02499185|Intra Abdominal Surgery
907106|NCT02499185|AKI
907107|NCT02499172|Adverse pregnancy outcome
907108|NCT02499159|Exparel
907109|NCT02499159|Thoracoscopy
907110|NCT02499159|Bupivicaine
907111|NCT02499159|Liposomal
907112|NCT02499146|Palbociclib
907113|NCT02499146|PD-0332991
907114|NCT02499146|pharmacokinetics
907115|NCT02499146|breast cancer patients
907116|NCT02499146|Chinese
907117|NCT02499120|palbociclib, cetuximab, human papillomavirus, squamous cell carcinoma, head and neck cancer
907118|NCT02499107|food intake
907119|NCT02499107|satiety
907120|NCT02499107|blood glucose
907121|NCT02499107|potato
907122|NCT02499107|insulin
907123|NCT02499081|Relapsed
907124|NCT02499081|Refractory
907125|NCT02499081|Proteasome Inhibitor
907126|NCT02499055|anxiety
907127|NCT02499055|behaviour therapy
907128|NCT02499055|computer assisted therapy
907129|NCT02499055|psychotherapy
907130|NCT02499042|post-resuscitation
907131|NCT02499042|oxygen therapy
907132|NCT02499042|out-of-hospital cardiac arrest
907133|NCT02499016|Appendicitis
907134|NCT02499016|Appendectomy
907135|NCT02499016|Single-incision
907136|NCT02499003|Diffuse large B-cell lymphoma
907137|NCT02499003|Follicular lymphoma
907138|NCT02499003|Transformed indolent lymphoma
907139|NCT02498977|Liver
907140|NCT02498977|Transplant
907141|NCT02498977|Immunosuppression
907142|NCT02498964|cardiac anesthesia simulation,NASA task load index
907143|NCT02498938|Pulmonary disease,chronic obstructive,
907144|NCT02498938|generalized chronic periodontitis
907145|NCT02498938|SERPINA1 gene polymorphism
907146|NCT02498912|T Cells
907147|NCT02498912|Cyclophosphamide
907148|NCT02498912|MUC16ecto antigen
907149|NCT02498912|Intraperitoneal Infusion
907150|NCT02498912|15-014
907151|NCT02498899|Advanced Cancers
907152|NCT02498899|Video
907153|NCT02498899|Questionnaires
907154|NCT02498899|Surveys
907155|NCT02498873|VO2Max
907156|NCT02498873|Physical Conditioning
907157|NCT02498873|Aerobic Exercise
907158|NCT02498873|Performance
907159|NCT02498860|adenocarcinoma
907160|NCT02498860|lung
907161|NCT02498860|adjuvant chemotherapy
907162|NCT02498860|pemetrexed
907163|NCT02498860|cisplatin
907164|NCT02498860|surgery
907165|NCT02498834|Communication
907166|NCT02498834|provider
907167|NCT02498834|caregiver
907168|NCT02498834|adolescent
907169|NCT02498821|PICC
907170|NCT02498821|central catheter
907171|NCT02498821|vascular access
907172|NCT02498808|Interferon lambda
907173|NCT02498808|Interleukin-29
907174|NCT02498808|Neutrophil
907175|NCT02498795|Intratissue Percutaneous Electrolysis
907176|NCT02498795|Dry needling
907177|NCT02498795|Eccentric exercise
907178|NCT02498795|Patella
907179|NCT02498782|Chagas Disease
907180|NCT02498782|Dosage forms
907181|NCT02498782|Regimens
907182|NCT02498769|Cardiac Surgery
907183|NCT02498769|Postoperative Complications
907184|NCT02498769|Autonomic Nerve Block
907185|NCT02498730|bipolar disorder
907186|NCT02498730|VO2max
907187|NCT02498730|aerobic exercise
907188|NCT02498691|endometriosis
907189|NCT02498691|preterm delivery
907190|NCT02498691|caesarean
907191|NCT02498691|Pregnancy outcomes of women with or without endometriosis
907192|NCT02498665|Wilms' Tumor 1
907193|NCT02498665|Vaccine
907194|NCT02498665|Neoplasms
907195|NCT02498639|balloon aortic valvuloplasty
907196|NCT02498639|rapid ventricular pacing
907197|NCT02498639|outcome
907198|NCT02498626|mixed venous saturation
907199|NCT02498626|open heart surgery
907200|NCT02498626|children
907204|NCT02498587|Severe Acute Respiratory Infection
907205|NCT02498496|COPD
907206|NCT02498496|AECOPD
907207|NCT02498496|Magnesium Sulfate
907208|NCT02498496|Acute exacerbation of COPD
907209|NCT02498496|Chronic Obstructive Pulmonary Disease
907210|NCT02498496|ED
907211|NCT02498496|ER
907212|NCT02498496|Emergency Department
907213|NCT02498483|Infant
907214|NCT02498457|maintenance hemodialysis patients
907215|NCT02498457|coronary artery calcification
907216|NCT02498457|low calcium dialysate
907217|NCT02498457|effects
907218|NCT02498457|safety
907219|NCT02498444|Fontan
907220|NCT02498444|Treprostinil
907221|NCT02498444|Remodulin
907222|NCT02498444|Single ventricle
907223|NCT02498431|irisin
907224|NCT02498431|myocardial infarction
907225|NCT02498431|coronary
907226|NCT02498392|Major Depressive Disorder
907227|NCT02498392|Depression
907228|NCT02498392|Anxiety symptoms
907229|NCT02498392|JNJ-42165279
907230|NCT02498379|novel radiotracer
907231|NCT02498379|biodistribution
907232|NCT02498379|safety
907233|NCT02498340|G6PD
907234|NCT02498340|genotype
907235|NCT02498340|phenotype
907236|NCT02498340|diet restriction
907237|NCT02498327|Chronic
907238|NCT02498314|Manual therapy
907239|NCT02498314|Hip osteoarthritis
907240|NCT02498314|Mobilization
907241|NCT02498301|travelers' diarrhea
907242|NCT02498301|military
907243|NCT02498301|enteric illness
907244|NCT02498301|gastrointestinal
907245|NCT02498288|capsule
907246|NCT02498288|Isotretinoin
907247|NCT02498288|Bioequivalence
907248|NCT02498262|Severe Mobility and Manipulation Impairments
907249|NCT02498249|Low-Level Laser Therapy
907250|NCT02498249|trapezius muscle
907251|NCT02498249|neck pain
907252|NCT02498236|Psychosis
907253|NCT02498236|Schizophrenia
907254|NCT02498236|Oxytocin
907255|NCT02498210|IVM
907256|NCT02498210|HIPPO signaling
907257|NCT02498171|Labour analgesia
907258|NCT02498171|Intrathecal morphine
907259|NCT02498171|Bupivacaine
907260|NCT02498171|Fentanyl
907261|NCT02498132|Mobile Technologies
907262|NCT02498119|Type 2 DM
907263|NCT02498119|lipid bodies
907264|NCT02498106|nutrition
907265|NCT02498106|aggression
907266|NCT02498106|n-3 fatty acids
907267|NCT02498106|psychiatry
907268|NCT02498106|inpatients admitted >2 years
907269|NCT02498093|Resistance training
907270|NCT02498093|Arthroplasty, Replacement, Hip
907271|NCT02498093|Professional-Patient Relations
907272|NCT02498093|Evidence-based practice
907273|NCT02498080|Drug eluting balloons
907274|NCT02498080|Critical limb ischemia
907275|NCT02498080|Infra-popliteal arteries
907276|NCT02498080|Percutaneous transluminal angioplasty
907277|NCT02498041|Ultrathin Nasal Endoscopy
907278|NCT02498041|Barrett's Esophagus
907279|NCT02498041|Transnasal Endoscopy
907280|NCT02498028|cervical fusion
907281|NCT02498028|cervical arthroplasty
907282|NCT02498028|cervicobrachial pain
907283|NCT02498002|Diet
907284|NCT02498002|Fasting
907285|NCT02498002|Intermittent Fasting
907286|NCT02498002|Alternate-day Fasting
907287|NCT02498002|Physical Activity
907288|NCT02498002|Glucose
907289|NCT02498002|Insulin
907290|NCT02498002|Appetite
907291|NCT02497989|Male circumcision
907292|NCT02497989|Demand creation
907293|NCT02497976|Interstitial
907294|NCT02497976|Cystitis
907295|NCT02497976|Bladder
907296|NCT02497976|Pain
907297|NCT02497950|HeartMate 3
907298|NCT02497950|LVAS
907299|NCT02497950|LVAD
907300|NCT02497950|Heart-assist devices
907301|NCT02497950|Thoratec Corporation
907302|NCT02497937|GSK2798745
907303|NCT02497937|TRPV4 Channel Blocker
907304|NCT02497937|Pharmacodynamics
907305|NCT02497937|Adults
907306|NCT02497937|Congestive Heart Failure
907307|NCT02497911|Adductor Canal Catheter
907308|NCT02497911|Intraarticular Catheter
907309|NCT02497911|Arthroplasty, Replacement, Knee
907310|NCT02497885|MERS
907311|NCT02497885|healthcare personnel
907312|NCT02497859|Weight Reduction
907313|NCT02497859|Weight Loss Diet
907314|NCT02497859|Satiety Response
907315|NCT02497859|Insulin
907316|NCT02497859|Glucagon-Like Peptide 1
907317|NCT02497859|PYY (3-36) peptide
907318|NCT02497859|Ghrelin
907319|NCT02497859|Glucose
907320|NCT02497859|Eggs
907321|NCT02497859|Protein
907322|NCT02497859|Energy Intake
907323|NCT02497859|Breakfast
907324|NCT02497846|Hyaluronic acid
907325|NCT02497846|MiconJet needle
907326|NCT02497807|Tourette syndrome
907327|NCT02497807|Iron deficiency
907328|NCT02497794|chew gum
907329|NCT02497794|bowel movements
907330|NCT02497794|cesarean section
907331|NCT02497781|Complicated urinary tract infections (cUTIs)
907332|NCT02497768|mastication
907333|NCT02497768|pistachios
907334|NCT02497768|brazils
907335|NCT02497768|participants
907336|NCT02497729|Endotracheal Intubation
907337|NCT02497729|Checklist
907338|NCT02497729|Positioning
907339|NCT02497690|Cochlear Implant
907340|NCT02497677|parental sensitivity
907341|NCT02497677|child attachment
907342|NCT02497664|Radiotherapy
907343|NCT02497664|Active Breathing Control Technique
907344|NCT02497651|Smoking
907345|NCT02497651|Diabetes
907346|NCT02497651|Incretin hormones
907347|NCT02497651|Glucose tolerance
907348|NCT02497638|metformin
907349|NCT02497638|atorvastatin
907350|NCT02497638|prostate-specific antigen
907351|NCT02497638|biochemical recurrence
907352|NCT02497625|Low back pain
907353|NCT02497625|Empathy
907354|NCT02497625|Subgroups
907355|NCT02497625|Minimal intervention
907356|NCT02497547|Atrophy
907357|NCT02497547|Pathological Conditions, Anatomical
907358|NCT02497547|Oxytocin
907359|NCT02497547|Oxytocics
907360|NCT02497534|ataxia
907361|NCT02497534|neuromuscular
907362|NCT02497521|polycystic kidney disease
907363|NCT02497521|autosomal dominant polycystic kidney disease
907364|NCT02497521|ADPKD
907365|NCT02497521|Tolvaptan
907366|NCT02497521|Jinarc
907367|NCT02497508|progressive disease after at least 1 course of chemotherapy
907368|NCT02497495|Immersion
907369|NCT02497495|Recovery of Function
907370|NCT02497495|Lactate
907371|NCT02497495|Creatine Kinase
907372|NCT02497495|Musculoskeletal Pain
907373|NCT02497469|Drug Therapy
907374|NCT02497456|HIV
907375|NCT02497456|Counselling
907376|NCT02497456|Care
907377|NCT02497456|antiretroviral therapy
907378|NCT02497456|linkage
907379|NCT02497456|Uganda
907380|NCT02497456|Africa
907381|NCT02497443|drug-resistant symptomatic epilepsy
907382|NCT02497443|seizure
907383|NCT02497443|autologous mesenchymal stem cells
907384|NCT02497443|safety
907385|NCT02497443|remission
907386|NCT02497443|electroencephalography
907387|NCT02497443|refractory symptomatic epilepsy
907388|NCT02497443|autologous MSC
907389|NCT02497443|efficacy
907390|NCT02497417|ARIES Clostridium difficile
907391|NCT02497378|Multiple Myeloma
907392|NCT02497378|Daratumumab
907393|NCT02497378|JNJ-54767414
907394|NCT02497378|Bortezomib
907395|NCT02497378|Dexamethasone
907396|NCT02497365|keratits
907397|NCT02497365|besifloxacin
907398|NCT02497339|Smoking cessation interventions
907399|NCT02497339|mindfulness training
907400|NCT02497326|second degree burns
907401|NCT02497326|heparin
907402|NCT02497326|topical
907403|NCT02497300|Mineralocorticoid Receptor Antagonists
907404|NCT02497300|Mineralocorticoid Effects
907405|NCT02497287|Treatment-resistant Depression
907406|NCT02497287|Esketamine
907407|NCT02497287|Oral Antidepressant
907408|NCT02497274|bariatric surgery
907409|NCT02497274|taste perception
907410|NCT02497274|lipid receptors
907417|NCT02497248|Atrial Fibrillation
907418|NCT02497248|Pulmonary Vein Ablation
907419|NCT02497248|Mitral stenosis
907420|NCT02497248|Body surface mapping
907421|NCT02497235|Drug therapy, Positron Emission Tomography, Brain enzyme occupancy, Cholesterol 24S-hydroxylase, CH24H
907422|NCT02497196|TPCS
907423|NCT02497196|tDCS
907424|NCT02497196|visceral pain
907425|NCT02497196|pancreatitis
907426|NCT02497196|healthy subjects
907427|NCT02497196|pelvic pain
907428|NCT02497196|neuromodulation
907429|NCT02497196|non-invasive brain stimulation
907430|NCT02497157|bevacizumab
907431|NCT02497157|oxaliplatin
907432|NCT02497157|irinotecan
907433|NCT02497157|hydrochloride hydrate
907434|NCT02497157|fluorouracil
907435|NCT02497157|levofolinate calcium
907436|NCT02497144|interstitial lung disease
907437|NCT02497144|neuromuscular electrical stimulation
907438|NCT02497144|exercise capacity
907439|NCT02497144|quality of life
907440|NCT02497131|PTCL
907441|NCT02497131|CD30+
907442|NCT02497118|lung cancer Anti angiogenesis therapy survival
907443|NCT02497105|Epilepsy
907444|NCT02497105|Intractable Seizures
907445|NCT02497105|Ketogenic Diet
907446|NCT02497105|Biochemical Profiles
907447|NCT02497079|Bronchoscopy
907448|NCT02497079|Ultrasonography
907449|NCT02497079|Tuberculous lymphadenitis
907450|NCT02497079|Polymerase chain reaction
907451|NCT02497079|Sensitivity and specificity
907452|NCT02497066|topical
907453|NCT02497066|compound
907454|NCT02497066|pain
907455|NCT02497053|MPM
907456|NCT02497040|craniotomy
907457|NCT02497040|local anesthetics
907458|NCT02497040|scalp block
907459|NCT02497040|head pinning
907460|NCT02497027|pharmacogenetic, pharmacogenomic, depressive, mental health
907461|NCT02496988|Cytokine-Induced Killer Cells
907462|NCT02496988|Milignant Gliomas
907463|NCT02496988|Temozolomide
907464|NCT02496962|sleep deprivation
907465|NCT02496936|Energy Expenditure
907466|NCT02496936|Appetite
907467|NCT02496936|Satiety
907471|NCT02496884|chronic kidney disease
907472|NCT02496884|. α2δ ligands
907473|NCT02496884|mirogabalin
907474|NCT02496884|pain relief
907475|NCT02496884|kidney metabolism
907476|NCT02496858|Young Patient
907477|NCT02496858|Genetic Characteristics
907478|NCT02496832|Hypoxia
907479|NCT02496832|18F-FAZA
907480|NCT02496832|18F-Fluoroazomycin arabinoside
907481|NCT02496832|Positron emission tomography
907482|NCT02496832|PET
907483|NCT02496832|Participating in study EMR200592-001
907484|NCT02496819|Children
907485|NCT02496806|Polyphenols
907486|NCT02496806|Absorption
907487|NCT02496806|Metabolism
907488|NCT02496806|Phlorotannins
907489|NCT02496806|Seaweeds
907490|NCT02496767|fast skeletal troponin activator
907491|NCT02496767|tirasemtiv
907492|NCT02496767|CK-2017357
907493|NCT02496767|double-blind
907494|NCT02496767|randomized
907495|NCT02496767|placebo-controlled
907496|NCT02496741|isocitrate dehydrogenase 1/2 mutation
907497|NCT02496741|metformin
907498|NCT02496741|chloroquine
907499|NCT02496728|Mobile Health
907500|NCT02496728|Smartphone
907501|NCT02496728|Cardiovascular health
907502|NCT02496728|College students
907503|NCT02496728|Smoking
907504|NCT02496728|Physical activity
907505|NCT02496728|Diet
907506|NCT02496728|BMI
907507|NCT02496728|Blood pressure
907508|NCT02496728|Cholesterol
907509|NCT02496728|Glucose
907510|NCT02496728|Text
907511|NCT02496728|Facebook
907512|NCT02496728|Instagram
907513|NCT02496728|Push Notifications
907514|NCT02496728|Ecological Momentary Assessment
907515|NCT02496702|exergaming
907516|NCT02496702|Senior Fitness Test
907517|NCT02496689|HPP
907518|NCT02496689|Bone Disease
907519|NCT02496689|Soft Bones
907520|NCT02496689|Low Alkaline Phosphatase
907521|NCT02496689|genetic metabolic disorder
907522|NCT02496689|alkaline phosphatase
907523|NCT02496689|rickets
907524|NCT02496689|osteomalacia
907525|NCT02496676|Lymphoma
907526|NCT02496676|Epstein-Barr Virus
907527|NCT02496676|Immunodeficiency
907528|NCT02496676|MAGT1 Gene
907529|NCT02496676|Intracellular Magnesium
907530|NCT02496650|alcohol withdrawal state
907531|NCT02496650|dexmedetomidine
907532|NCT02496650|benzodiasepines
907533|NCT02496650|intensive care
907534|NCT02496637|Obesity
907535|NCT02496637|Eating Disorders
907536|NCT02496637|Appetite regulation
907537|NCT02496637|Eating Regulation
907538|NCT02496611|Obesity
907539|NCT02496611|Pharmacotherapy
907540|NCT02496611|GLP-1
907541|NCT02496611|Children
907542|NCT02496611|Exenatide
907543|NCT02496611|BYDUREON
907544|NCT02496611|Weight Loss
907545|NCT02496611|Maintenance
907546|NCT02496598|Reproductive Techniques, Assisted
907547|NCT02496598|Ovarian Follicle
907548|NCT02496585|Nintedanib (BIBF 1120)
907549|NCT02496585|Prednisone
907550|NCT02496585|Radiation Pneumonitis
907551|NCT02496572|Tuberculosis, multidrug resistant
907552|NCT02496572|Short-course regimen
907553|NCT02496572|Medecins sans Frontieres, MSF
907554|NCT02496572|Uzbekistan, Ministry of Health
907555|NCT02496559|C-reactive Protein
907556|NCT02496559|Primary Health Care
907557|NCT02496559|Child Welfare
907558|NCT02496559|After-Hours Care
907559|NCT02496559|Anti-Bacterial Agents
907560|NCT02496559|Drug Prescriptions
907561|NCT02496520|dendritic cell vaccination
907562|NCT02496520|sarcoma
907563|NCT02496520|central nervous system tumor
907564|NCT02496520|childhood
907565|NCT02496520|adolescent
907566|NCT02496520|immunotherapy
907567|NCT02496507|sitting
907568|NCT02496507|intervention
907569|NCT02496507|desks
907570|NCT02496507|workplace
907571|NCT02496507|cardiovascular
907572|NCT02496507|metabolic
907573|NCT02496507|qualitative
907574|NCT02496507|randomised controlled trial
907575|NCT02496468|childhood asthma
907576|NCT02496468|preschool wheeze
907577|NCT02496468|adult asthma
907578|NCT02496468|transition
907579|NCT02496468|phenotype
907580|NCT02496468|endotype
907581|NCT02496468|trajectory
907582|NCT02496455|NAV1.7 Voltage-Gated Sodium Channel
907583|NCT02496455|pain, postoperative
907584|NCT02496455|cesarean section
907585|NCT02496442|Transurethral Resection of Prostate
907586|NCT02496442|Cystoscopy
907587|NCT02496442|PCNL
907588|NCT02496442|RERAS
907589|NCT02496442|Urethroscopy
907590|NCT02496403|buprenorphine-naloxone combination
907591|NCT02496403|Suboxone
907592|NCT02496403|Buprenorphine
907593|NCT02496403|Substance Use
907594|NCT02496403|Behavioral intervention
907595|NCT02496403|Opioid partial agonist
907596|NCT02496403|medication assisted therapy
907597|NCT02496403|opioid addiction
907598|NCT02496390|Fecal Microbial Transplantation
907599|NCT02496390|Gut microbiome
907600|NCT02496390|Metabolic disorders
907601|NCT02496390|Obesity
907602|NCT02496377|Anaemia
907603|NCT02496377|Iron deficiency
907604|NCT02496377|Ferric carboxymaltose
907605|NCT02496377|Patient blood management
907606|NCT02496377|Hip arthroplasty
907607|NCT02496377|Knee arthroplasty
907608|NCT02496364|Tranexamic Acid
907609|NCT02496364|Scoliosis
907610|NCT02496364|bleeding control
907611|NCT02496351|transcutaneous electrical nerve stimulation
907612|NCT02496338|Menopause
907613|NCT02496338|Quality of Life
907614|NCT02496338|Marital Satisfaction
907615|NCT02496338|training
907616|NCT02496325|Pudendal nerve block
907617|NCT02496325|Ultrasound guided
907618|NCT02496325|Transperineal puncture
907619|NCT02496325|Perineal surgery
907620|NCT02496325|children
907621|NCT02496312|Apathy
907622|NCT02496312|Goal-directed behavior
907623|NCT02496312|Quantitative evaluation
907624|NCT02496312|Sensor
907625|NCT02496312|Ethogram
907626|NCT02496299|COMPARISSON
907627|NCT02496299|CAUDAL BLOCK
907628|NCT02496299|BUPIVACAINE
907629|NCT02496299|DEXAMETHASONE
907630|NCT02496286|Necessary paracentesis for symptom control
907631|NCT02496273|Dendritic Cells
907632|NCT02496273|Cytotoxic T-Lymphocytes
907633|NCT02496273|Adeno-Associated Virus
907634|NCT02496260|Magnetic resonance imaging
907635|NCT02496260|Cardiac function
907636|NCT02496260|Breast Cancer
907637|NCT02496247|malnutrition
907638|NCT02496247|undernutrition
907639|NCT02496247|Z-score
907640|NCT02496247|Guinea-Bissau
907641|NCT02496247|food aid
907642|NCT02496234|Coronary Artery Bypass Graft Surgery
907643|NCT02496234|Acute kidney injury
907644|NCT02496234|Renal failure
907645|NCT02496234|Biomarker
907646|NCT02496221|Cholecystokinin
907647|NCT02496221|ultrasonography
907648|NCT02496221|Albiglutide
907649|NCT02496221|Gallbladder ejection fraction
907650|NCT02496169|PTCA
907651|NCT02496169|stenosis
907652|NCT02496169|sirolimus
907653|NCT02496169|stent
907654|NCT02496156|type 1 diabetes mellitus
907655|NCT02496156|adolescence
907656|NCT02496156|adherence
907657|NCT02496156|insulin pump
907658|NCT02496156|continuous subcutaneous insulin infusion
907659|NCT02496156|continuous glucose monitor
907660|NCT02496156|shared medical decision making
907661|NCT02496143|Healthy Volunteers
907662|NCT02496143|Phase I
907663|NCT02496143|Placebo controlled
907664|NCT02496143|Single Ascending Dose
907665|NCT02496143|PK
907666|NCT02496143|Oral administration
907667|NCT02496143|Softgel
907668|NCT02496130|minilaparotomy
907669|NCT02496130|morcellation
907670|NCT02496130|laparoscopy
907671|NCT02496104|Preterm
907672|NCT02496104|Infant
907673|NCT02496104|Habituation
907674|NCT02496104|APIB
907675|NCT02496065|breast cancer
907676|NCT02496065|BLZ-100
907677|NCT02496065|Tumor Paint
907678|NCT02496065|breast tumors
907679|NCT02496052|amnion graft
907680|NCT02496052|New biological barrier system
907681|NCT02496039|PBA
907682|NCT02496039|involuntary crying
907683|NCT02496039|involuntary laughing
907684|NCT02496000|Diabetes Mellitus type 2
907685|NCT02496000|Metformin
907686|NCT02496000|oral insulin
907687|NCT02495974|Xtandi
907688|NCT02495974|Enzalutamide
907689|NCT02495974|Prostate cancer
907690|NCT02495974|Metastatic castration resistant prostate cancer
907691|NCT02495961|hyperlipidemias
907692|NCT02495961|hyperglycemia
907693|NCT02495961|hypertension
907694|NCT02495961|leptin
907695|NCT02495961|hyperhomocysteinemia
907696|NCT02494063|cervical cancer
907697|NCT02494063|sentinel lymph node
907698|NCT02494063|lymphadenectomy
907699|NCT02495909|paediatric schistosomiasis
907700|NCT02495909|morbidity
907701|NCT02495909|immunology
907702|NCT02495883|Essential Tremor
907703|NCT02495883|Magnetic Resonance Imaging
907704|NCT02495883|Therapy
907705|NCT02495883|Alcohol
907706|NCT02495883|Propranolol
907707|NCT02495844|UCB0942
907708|NCT02495844|Treatment-resistant focal epilepsy
907709|NCT02495844|Partial seizures
907710|NCT02495844|Seizure therapy
907711|NCT02495831|PK study
907712|NCT02495818|Rotator cuff syndrome
907713|NCT02495818|supraspinatus tendonitis
907714|NCT02495818|suprascapular nerve block
907715|NCT02495818|ultrasound guided
907716|NCT02495818|supraspinatus
907717|NCT02495805|a continuous proximal adductor canal block (ACB)
907718|NCT02495805|continuous femoral nerve block (FNB)
907719|NCT02495779|PrEP
907720|NCT02495779|HIV
907721|NCT02495779|MSM
907722|NCT02495779|Men Having Sex With Men
907723|NCT02495779|Episodic PrEP
907724|NCT02495779|Adherence
907725|NCT02495779|Episodic HIV Risk
907726|NCT02495766|Multiple sclerosis
907727|NCT02495766|Bone marrow mesenchymal stromal cells
907728|NCT02495766|Stem cells
907729|NCT02495766|Nervous System Diseases
907730|NCT02495766|Demyelinating Diseases
907731|NCT02495766|Autoimmune Diseases
907732|NCT02495753|cesarean section
907733|NCT02495753|wound infection
907734|NCT02495753|vaginal cleansing
907735|NCT02495753|endometritis
907736|NCT02495727|Step-reduction model
907737|NCT02495727|Reduced activity
907738|NCT02495727|Atrophy
907739|NCT02495727|Skeletal Muscle
907740|NCT02495727|Sarcopenia
907741|NCT02495727|Dynapenia
907742|NCT02495714|Exercise
907743|NCT02495714|Diet
907744|NCT02495714|Learning
907745|NCT02495688|General Anesthesia
907746|NCT02495688|Regional Anesthesia
907747|NCT02495662|Vascular access
907748|NCT02495662|Hemodialysis
907749|NCT02495662|Arteriovenous shunt
907750|NCT02495662|Arteriovenous fistula
907751|NCT02495662|Maturation
907752|NCT02495662|Liposomal prednisolone
907753|NCT02495662|PEG-liposomal prednisolone sodium phosphate
907754|NCT02495662|Radio-cephalic
907755|NCT02495662|Shunt
907756|NCT02495610|NPH
907757|NCT02495610|Gait analysis
907758|NCT02495610|neuropsychology
907759|NCT02495610|micturition diary
907760|NCT02495610|MRI
907761|NCT02495597|bronchial inflammation
907762|NCT02495597|Bronchiolitis obliterans
907763|NCT02495597|Sputum
907764|NCT02495597|Blood
907765|NCT02495597|Inflammation
907766|NCT02495597|adaptive immune system
907767|NCT02495597|innate immune system
907768|NCT02495584|Vitamin D
907769|NCT02495584|Fortified milk
907770|NCT02495584|Supplementation
907771|NCT02495584|UV exposure
907772|NCT02495584|Winter
907773|NCT02495584|Healthy adults
907774|NCT02495584|Body Composition
907775|NCT02495584|Muscle function
907776|NCT02495584|Blood pressure
907777|NCT02495571|ALS and Dysphagia
907778|NCT02495571|ALS and cough
907779|NCT02495571|cough reflex test
907780|NCT02495558|Cough Reflex test
907781|NCT02495558|Decannulation
907782|NCT02495545|spinal cord injury (SCI)
907783|NCT02495532|Neoplasm Metastasis
907784|NCT02495532|Colorectal Neoplasms
907785|NCT02495532|Lymph Nodes
907786|NCT02495532|Lymph Node Revealing Solution
907787|NCT02495506|Cardiac surgery
907788|NCT02495506|bleeding
907789|NCT02495506|platelet transfusion
907790|NCT02495480|disposable sheath
907791|NCT02495480|intubation
907792|NCT02495480|colonoscopy
907793|NCT02495428|Bandage
907794|NCT02495428|Treadmill
907795|NCT02495428|Lactate Acid
907796|NCT02495389|urinary urgency incontinence
907797|NCT02495376|YACS
907798|NCT02495376|cancer
907799|NCT02495376|MBSR
907800|NCT02495311|adenomyosis
907801|NCT02495311|uterine myoma
907802|NCT02495311|lower urinary tract symptoms
907803|NCT02495311|sexual dysfunction
907804|NCT02495311|gastrointestinal symptom
907805|NCT02495298|Fascial manipulation
907806|NCT02495298|Carpal Tunnel Syndrome
907807|NCT02495285|pediatric patients gelatine
907808|NCT02495272|Postpartum hemorrhage
907809|NCT02495272|Third stage of labour
907810|NCT02495272|Oxytocin
907811|NCT02495272|Uterotonics
907812|NCT02495272|Active management of third stage of labour
907813|NCT02495259|Double-lumen endobronchial tube
907814|NCT02495259|Laryngoscopy
907815|NCT02495259|intubating stylet
907816|NCT02495233|Erlotinib
907817|NCT02495233|ASP2215
907818|NCT02495233|NSCLC
907819|NCT02495233|Non-Small-Cell Lung Cancer
907820|NCT02495220|dexmedetomidine
907821|NCT02495220|subtenon anesthesia
907822|NCT02495220|postoperative pain
907823|NCT02495220|pov
907824|NCT02495194|Promotion of psychological well-being
907825|NCT02495194|Horticultural therapy
907826|NCT02495194|Randomized Controlled Trial
907827|NCT02495194|Gardening
907828|NCT02495194|Elderly
907829|NCT02495129|Primary Sjögren's syndrome
907830|NCT02495129|Sicca syndrome
907831|NCT02495129|Salivary glands
907832|NCT02495129|Positron Emission Tomography
907833|NCT02495129|B cell depletion
907834|NCT02494050|Depression
907835|NCT02494050|Bipolar Disorder
907836|NCT02494050|Anhedonia
907837|NCT02494050|Women
907838|NCT02494024|PSP
907839|NCT02494024|C2N-8E12
907840|NCT02494024|tauopathy
907841|NCT02494024|Progressive Supranuclear Palsy
907842|NCT02494024|Steele Richardson Olszewski Syndrome
907843|NCT02494024|Humanized anti-tau antibody
907844|NCT02494011|Colles' Fracture; CKCE; Russian current
907845|NCT02493998|Sanfilippo Syndrome Type B
907846|NCT02493985|Brain physiology
907847|NCT02493985|Intracranial pressure
907848|NCT02493985|Cognition
907849|NCT02493985|Cerebrovascular
907850|NCT02493985|Head down tilt
907851|NCT02493985|Space flight
907852|NCT02493972|ovarian cancer
907853|NCT02493972|peritoneal carcinosis
907854|NCT02493972|manual exploration
907855|NCT02493972|surgery
907856|NCT02493972|GelPort
907857|NCT02493959|PYY
907858|NCT02493959|Degradation
907859|NCT02493959|kinetics
907860|NCT02493959|men
907861|NCT02493920|Respiratory Distress Syndrome, Newborn
907862|NCT02493920|Delivery Room
907863|NCT02493920|Resuscitation
907864|NCT02493920|Premature birth
907865|NCT02493920|Infant, Newborn
907866|NCT02493920|Respiration Artificial
907867|NCT02493894|Bowel preparation
907868|NCT02493894|perioperative bleeding
907869|NCT02493894|lumbar fusion
907870|NCT02493881|Motor function of the extralaryngeal branches
907871|NCT02493881|intraoperative neuromonitoring
907872|NCT02493881|recurrent laryngeal nerve
907873|NCT02493868|Treatment-resistant Depression
907874|NCT02493868|Esketamine
907875|NCT02493868|Placebo
907876|NCT02493868|Oral Antidepressant
907877|NCT02493868|Relapse prevention
907878|NCT02493855|Treatment naive
907879|NCT02493855|HCV
907880|NCT02493855|Interferon free
907881|NCT02493855|Hepatitis C Genotype 1a
907882|NCT02493855|Chronic Hepatitis C
907883|NCT02493855|Hepatitis C
907884|NCT02493842|Nerve Stimulation
907885|NCT02493842|Neuroplasticity
907886|NCT02493842|Sensory Feedback
907887|NCT02495103|Dose-Escalation
907888|NCT02495103|Maximum Tolerated Dose
907889|NCT02495103|Safety
907890|NCT02495103|Overall Response
907891|NCT02495090|Hypospadias
907892|NCT02495090|exome sequencing
907893|NCT02495090|genital malformation
907894|NCT02495077|Kidney Transplantation
907895|NCT02495077|infliximab
907896|NCT02495077|Tissue Donors
907897|NCT02495077|Remicade
907898|NCT02495077|Induction Therapy
907899|NCT02495077|Deceased Donor Kidney Transplant Recipients
907900|NCT02495051|gastroesophageal reflux
907901|NCT02495051|barrett esophagus
907902|NCT02495038|combination
907903|NCT02495038|rocuronium
907904|NCT02495038|cisatracurium
907905|NCT02495038|neuromuscular blockade monitoring
907906|NCT02495038|drug synergism
907907|NCT02495012|efficacy
907908|NCT02495012|safety
907909|NCT02495012|STEMI
907910|NCT02494999|pneumococcal conjugate vaccine
907911|NCT02494999|immunogenicity
907912|NCT02494999|safety
907913|NCT02494986|Human immunodeficiency virus type 1
907914|NCT02494986|Rilpivirine
907915|NCT02494986|Roll-over study
907916|NCT02494960|smoking cessation intervention
907917|NCT02494947|Coronary Angiography
907918|NCT02494947|Exercise
907919|NCT02494921|Metastatic
907920|NCT02494921|Castration-Resistant
907921|NCT02494908|Parkinson Disease
907922|NCT02494908|MRI
907923|NCT02494882|Ruxolitinib
907924|NCT02494882|Dasatinib
907925|NCT02494882|Dexamethasone
907926|NCT02494882|14-272
907927|NCT02494869|Aerobic Training
907928|NCT02494869|Exercise
907929|NCT02494869|Gene Expression
907930|NCT02494869|15-093
907931|NCT02494856|Naproxen
907932|NCT02494856|Lower third molar
907933|NCT02494856|Oral Surgery
907934|NCT02494856|Esomeprazole
907935|NCT02494830|Anesthetic Drugs
907936|NCT02494817|HIV prevention
907937|NCT02494817|Toolkit
907938|NCT02494817|Male couples
907939|NCT02494817|Sexual agreements
907940|NCT02494804|Cytokine-Induced Killer Cells
907941|NCT02494804|Milignant Gliomas
907942|NCT02494804|Temozolomide
907943|NCT02494765|I-gelTM
907944|NCT02494765|Ambu® AuraOnceTM
907945|NCT02494765|supraglottic devices
907946|NCT02494765|laryngeal mask effects on airway
907947|NCT02494765|3D magnetic resonance imaging
907948|NCT02494752|Contour deformities of face
907949|NCT02494752|autologous fat grafting
907950|NCT02494752|Post traumatic facial contour defects
907951|NCT02494739|antioxidant
907952|NCT02494739|oxidative stress
907953|NCT02494739|inflammation
907954|NCT02494739|polyphenols
907955|NCT02494739|yogurt
907956|NCT02494726|Ischemic stroke
907957|NCT02494726|ICH stroke
907958|NCT02494726|TEG
907959|NCT02494726|Thromboelastography
907960|NCT02494726|Stroke
907961|NCT02494713|Advanced Prostate Cancer
907962|NCT02494713|Neoadjuvant
907963|NCT02494713|Hormone therapy
907964|NCT02494713|ADT
907965|NCT02494713|Androgen Deprivation Therapy
907966|NCT02494713|Chemotherapy
907967|NCT02494713|Radical Prostatectomy
907968|NCT02494700|Lymphoma
907969|NCT02494700|Low grade B lymphocyte (B cell) lymphoma
907970|NCT02494700|Mantle cell lymphoma involving the ocular adnexa
907971|NCT02494700|Limited and advanced stage
907972|NCT02494700|Ocular adnexa
907973|NCT02494700|Radiation therapy
907974|NCT02494700|XRT
907975|NCT02494661|Public Health
907976|NCT02494661|Community
907977|NCT02494661|Obesity
907978|NCT02494661|Hispanic
907979|NCT02494661|Women
907980|NCT02494661|Nutrition
907981|NCT02494661|Mindfulness and stress
907982|NCT02494661|Food shopping
907983|NCT02494648|Obstructive sleep apnea
907984|NCT02494648|Resistive inspiratory muscle training
907985|NCT02494648|Coronary artery disease
907986|NCT02494648|Cardiac rehabilitation
907987|NCT02494583|Gastric carcinoma
907988|NCT02494583|Gastric cancer
907989|NCT02494583|Gastroesophageal junction cancer
907990|NCT02494583|Gastroesophageal junction carcinoma
907991|NCT02494583|PD1
907992|NCT02494583|PD-1
907993|NCT02494583|PDL1
907994|NCT02494583|PD-L1
907995|NCT02494531|Alzheimer Disease
907996|NCT02494531|PET
907997|NCT02494531|diagnosis
907998|NCT02494531|MCI
907999|NCT02494531|illiterate
908000|NCT02494518|stroke
908001|NCT02494518|aerobic exercise
908002|NCT02494518|forced exercise
908003|NCT02494518|repetitive task practice
908004|NCT02494518|arm function
908005|NCT02494518|upper extremity
908006|NCT02494505|chronic inflammatory demyelinating polyradiculopathy
908007|NCT02494505|intravenous immunoglobulin (IVIG)
908008|NCT02494505|withdrawal
908009|NCT02494505|quality of life
908010|NCT02494505|Clinical trial
908011|NCT02494505|cost
908012|NCT02494492|Uveitis
908013|NCT02494492|Lymphocyte cells
908014|NCT02494492|lymphocyte T regulator
908015|NCT02494492|vitreous haze
908016|NCT02494492|intravitreal injection
908017|NCT02494479|Psoriasis
908018|NCT02494479|Topical Psoriasis
908019|NCT02494479|Mild Psoriasis
908020|NCT02494479|Moderate Psoriasis
908021|NCT02494479|Active Psoriasis
908022|NCT02494479|Plaque Psoriasis
908023|NCT02494479|Skin Diseases
908024|NCT02494466|Airway Resistance
908025|NCT02494466|montelukast sodium
908026|NCT02494466|laryngeal mask airway
908027|NCT02494427|Crowns
908028|NCT02494427|Inlays
908029|NCT02494427|Onlays
908030|NCT02494414|Cardiac arrest
908031|NCT02494414|outcome
908032|NCT02494414|neurological status
908033|NCT02494401|systemic sclerosis
908034|NCT02494401|ssc
908035|NCT02494375|Sleep
908036|NCT02494375|glycemic control
908037|NCT02494375|type 1 diabetes
908038|NCT02494375|amylase
908039|NCT02494375|body composition
908040|NCT02494375|lean
908041|NCT02494375|overweight
908042|NCT02494375|obese
908043|NCT02494362|Hand exercises
908044|NCT02494362|Hand function
908045|NCT02494362|Computer based exercises
908046|NCT02494362|Therapeutic gaming
908047|NCT02494349|α1-blockers
908048|NCT02494349|antimuscarinic agent
908049|NCT02494323|Dual Channel Functional Electrical Stimulation
908050|NCT02494323|dropfoot, balanced dorsiflexion
908051|NCT02494284|Coronary artery disease
908052|NCT02494284|Dual antiplatelet platelet therapy
908053|NCT02494284|Drug eluting stent
908054|NCT02494258|CC-486
908055|NCT02494258|Oral Azacitidine
908056|NCT02494258|Solid tumors
908057|NCT02494258|hematological disorders
908058|NCT02494258|rollover study
908059|NCT02494245|Rehabilitation
908060|NCT02494245|Intervention
908061|NCT02494245|Walking
908062|NCT02494232|minor blunt thoracic trauma
908063|NCT02494232|physical examination
908064|NCT02494219|Group A streptococcal pharyngitis
908065|NCT02494219|Rapid streptococcal test
908066|NCT02494219|Throat swab culture
908067|NCT02494206|QBX258
908068|NCT02494206|human monoclonal antibodies
908069|NCT02494206|VAK694
908070|NCT02494206|QAX576
908071|NCT02494206|15-085
908072|NCT02494180|fentanyl
908073|NCT02494180|midazolam
908074|NCT02494180|pethidine
908075|NCT02494180|diazepam
908076|NCT02494167|Acute Myeloid Leukemia
908077|NCT02494167|Myelodysplastic Syndrome
908078|NCT02494167|MultiTAA Specific T cells
908079|NCT02494128|Child health service
908080|NCT02494128|Family health
908081|NCT02494128|Nurse
908082|NCT02494128|Education
908083|NCT02494128|Parental group
908084|NCT02494128|Group leadership
908085|NCT02494128|Health promotion
908086|NCT02494102|Obstructive Sleep Apnea
908087|NCT02494102|General Anesthesia
908088|NCT02494102|Modafinil
908089|NCT02494089|in situ simulation
908090|NCT02494089|in hospital cardiac arrest
908091|NCT02494089|clinical audit
908092|NCT02494089|education
908093|NCT02494089|patient simulation
908094|NCT02493790|cognitive dysfunction
908095|NCT02493790|Activity of Daily Living
908096|NCT02493790|interference
908097|NCT02493790|rehabilitation
908098|NCT02493790|cognitive-motor dual task
908099|NCT02493751|Cancer, renal cell cancer, kidney disease, kidney neoplasms, axitinib
908100|NCT02493673|Continuous Positive Airway Pressure
908101|NCT02493673|Stroke
908102|NCT02493673|Cerebrovascular reactivity
908103|NCT02493673|Brain oxygenation
908104|NCT02493660|Massive Rotator Cuff Tear
908105|NCT02493660|Arthroscopy
908106|NCT02493660|Shoulder Joint
908107|NCT02493660|Rotator cuff partial repair
908108|NCT02493634|Magnetic Resonance spectroscopy
908109|NCT02493634|Aortic Arch
908110|NCT02493621|Pain, Postoperative
908111|NCT02493621|Nerve Block
908112|NCT02493621|Anesthesia, Epidural
908113|NCT02493582|CIK
908114|NCT02493582|Apatinib
908115|NCT02493582|Lung Adenocarcinoma
908116|NCT02493569|Breast cancer, hospital, epidemiology, diagnosis, treatment
908117|NCT02493556|Phototherapy
908118|NCT02493556|Plyometric exercise
908119|NCT02493556|Muscle recovery
908120|NCT02493543|autoantibodies
908121|NCT02493530|MDS/MPN
908122|NCT02493504|Heparin
908123|NCT02493491|dysphonia
908124|NCT02493491|dysphagia
908125|NCT02493491|neurogenic
908126|NCT02493491|vocal fold augmentation
908127|NCT02493491|VFA
908128|NCT02493491|vocal fold insufficiency
908129|NCT02493491|Prolaryn
908130|NCT02493491|Radiesse
908131|NCT02493491|Coaptite
908132|NCT02493491|voice
908133|NCT02493491|Parkinson's Disease
908134|NCT02493491|Multiple Sclerosis
908135|NCT02493491|Amyotrophic Lateral Sclerosis
908136|NCT02493491|ALS
908137|NCT02493491|MS
908138|NCT02493491|calcium hydroxylapatite
908139|NCT02493491|hyaluronic acid
908140|NCT02493478|Intubation
908141|NCT02493478|Advanced airway intervention
908142|NCT02493478|Intensive care unit
908143|NCT02493465|everolimus
908144|NCT02493465|left ventricular hypertrophy
908145|NCT02493439|Best Possible Self
908146|NCT02493439|Positive Psychology
908147|NCT02493439|Romanian Immigrants
908148|NCT02493439|Optimism
908149|NCT02493439|Future Thinking
908150|NCT02493413|psychoneuroimmunology
908151|NCT02493413|stress
908152|NCT02493413|lymphocyte population
908153|NCT02493413|personality type
908154|NCT02493413|obesity
908155|NCT02493413|heart rate variability
908156|NCT02493413|awareness
908157|NCT02493400|Follow up
908158|NCT02493400|Exercise
908159|NCT02493400|Rehabilitation
908160|NCT02493387|Physiotherapist led group-based exercise
908161|NCT02493387|Physical activity
908162|NCT02493387|Atrial fibrillation
908163|NCT02493348|Fibromyalgia
908164|NCT02493348|Rhythmic Sensory Stimulation
908165|NCT02493348|Gamma Stimulation
908166|NCT02493283|dapsone
908167|NCT02493283|blood leucocytes
908168|NCT02493283|pharmacokinetics
908169|NCT02493283|metabolism
908170|NCT02493270|smoking cessation
908171|NCT02493270|tobacco
908172|NCT02493270|dental
908173|NCT02493270|periodontal
908174|NCT02493257|nonallergic irritant rhinitis
908175|NCT02493257|nasal congestion
908176|NCT02493257|rhinorrhea
908177|NCT02493218|mindfulness
908178|NCT02493218|intervention
908179|NCT02493218|african american
908180|NCT02493218|youth
908181|NCT02493218|stress
908182|NCT02493218|poverty
908183|NCT02493205|Implantable Cardiac Monitor
908184|NCT02493205|Stent
908185|NCT02493192|Parturition
908186|NCT02493192|Humanizing Deliver
908187|NCT02493192|Labor Pain
908188|NCT02493192|Natural Childbirth
908189|NCT02493192|Labor Onset
908190|NCT02493192|First Labor Stage
908191|NCT02493192|Birth ball
908192|NCT02493192|meperidine
908193|NCT02493192|pethidine
908194|NCT02493140|Weight management
908195|NCT02493140|cashew apple extract
908196|NCT02493140|overweight
908197|NCT02493101|Periostin staining
908198|NCT02493101|Urine periostin level
908199|NCT02493101|Lupus nephritis
908200|NCT02493101|IgA nephropathy
908201|NCT02493075|atrial fibrillation
908202|NCT02493075|Catheter Ablation
908203|NCT02493075|contact force
908204|NCT02493075|Chinese-specific
908205|NCT02493062|Hysterotomy
908206|NCT02493062|Myelomeningocele
908207|NCT02493062|Open fetal surgery
908208|NCT02493062|Sonohysterogram
908209|NCT02493049|Multiple Sclerosis
908210|NCT02493049|Domperidone
908211|NCT02493049|Relapsing-Remitting MS
908212|NCT02493049|Demyelinating disease
908213|NCT02493049|Remyelination
908214|NCT02493023|Bronchoscopy
908215|NCT02493023|Bronchoscopes
908216|NCT02493010|Virtual Reality Exposure Therapy
908217|NCT02493010|Computerized Cognitive Behavioral Therapy
908218|NCT02493010|Public Speaking
908219|NCT02493010|Social Phobia
908220|NCT02493010|Biofeedback
908221|NCT02492997|body fat
908222|NCT02492984|FVIII inhibitor
908223|NCT02492971|Assistive technology
908224|NCT02492971|functional needs
908225|NCT02492971|system usability
908226|NCT02492945|Tennis elbow
908227|NCT02492945|Polydeoxyribonucleotides
908228|NCT02492945|Prolotherapy
908229|NCT02492945|Randomized controlled trial
908230|NCT02492945|Visual analogue scale
908231|NCT02492945|disability
908232|NCT02492945|ultrasonography
908233|NCT02492919|cardiac surgery
908234|NCT02492919|risk factors
908235|NCT02492919|infection
908236|NCT02492880|stimulation
908237|NCT02492880|implantable
908238|NCT02492880|pulse generator
908239|NCT02492880|back pain
908240|NCT02492880|chronic pain
908241|NCT02492880|leg pain
908242|NCT02492854|Lower Extremity Bypass
908243|NCT02492854|Surgical Site Infection
908244|NCT02492854|Wound Dressing
908245|NCT02492854|Negative Pressure Wound Dressing
908246|NCT02492841|dentin substitute
908247|NCT02492841|vital pulp therapy
908248|NCT02492841|Biodentine
908249|NCT02492841|caries
908250|NCT02492789|immunotherapy
908251|NCT02492789|solid tumor
908252|NCT02492789|PD-1 blockade
908253|NCT02492776|Volunteers
908254|NCT02492737|acute myeloid leukemia
908255|NCT02492737|AML
908256|NCT02492737|myelodysplastic syndrome
908257|NCT02492737|MDS
908258|NCT02492737|dual mutation
908259|NCT02492737|MPN
908260|NCT02492737|AITL
908261|NCT02492737|hematologic malignancies
908262|NCT02492737|IDH1
908263|NCT02492737|IDH2
908264|NCT02492737|AG-881
908265|NCT02492724|cervical spine
908266|NCT02492724|total disc replacement (cTDR)
908267|NCT02492724|degenerative disc disease
908268|NCT02492724|activ® C
908269|NCT02492724|clinical outcome
908270|NCT02492724|long-term results
908271|NCT02492724|NDI
908272|NCT02492724|VAS
908273|NCT02492724|heterotopic ossification (HO)
908274|NCT02492724|range of motion (ROM)
908275|NCT02492724|adjacent segment degeneration
908276|NCT02492698|Probiotic
908277|NCT02492698|Weight loss
908278|NCT02492698|Lp-PLA2
908279|NCT02492685|Quantitative analysis
908280|NCT02492685|contrast enhanced endoscopic ultrasonography
908281|NCT02492659|femtosecond laser
908282|NCT02492633|Smoking cessation
908283|NCT02492633|Smoke-free housing
908284|NCT02492633|Affordable housing
908285|NCT02492633|Second-hand smoke
908286|NCT02492633|Tobacco control
908287|NCT02492620|ferric citrate
908288|NCT02492620|phosphate
908289|NCT02492620|kidney
908290|NCT02492607|Women
908291|NCT02492607|DCIS
908292|NCT02492607|Active surveillance
908293|NCT02492607|Standard treatment
908294|NCT02492581|Selincro
908295|NCT02492581|cohort
908296|NCT02492581|real-life
908297|NCT02492581|total alcohol consumption
908298|NCT02492581|heavy drinking days
908299|NCT02492581|clinical global impression-severity
908300|NCT02492581|EQ5D
908301|NCT02492581|AQoLS
908302|NCT02492581|Sheehan disability scale
908303|NCT02492568|recurrent
908304|NCT02492568|NSCLC
908305|NCT02492568|pembrolizumab
908306|NCT02492568|SBRT
908307|NCT02492555|IBD
908308|NCT02492555|Telemedicine
908309|NCT02492555|At-home monitoring
908310|NCT02492555|Disease activity
908311|NCT02492555|fecal calprotectin
908312|NCT02492542|electrical stimulation
908313|NCT02492542|urinary incontinence
908314|NCT02492529|Alzheimer, Recognition Memory, Mild Cognitive Impairment, fMRI
908315|NCT02492516|adipose tissue mesenchymal stem cell intravenous injection ALS
908316|NCT02492503|recurrent or metastatic carcinoma cervix chemotherapy
908317|NCT02492490|Kidney transplantation
908318|NCT02492490|DCD
908319|NCT02492490|Stromal Vascular Fraction
908320|NCT02492490|MSC
908321|NCT02492451|intrauterine insemination
908322|NCT02492451|pregnancy rate
908323|NCT02492451|endometrial injury
908324|NCT02492438|pneumococcal vaccination
908325|NCT02492438|dialysis
908326|NCT02492438|immune response
908327|NCT02492425|Community Acquired Pneumonia
908328|NCT02492425|Healthcare Associated Pneumonia
908329|NCT02492399|hypertrophic cardiomyopathy
908330|NCT02492399|mitral valve
908331|NCT02492399|SAM syndrome
908332|NCT02492386|bioabsorbable vascular scaffold
908333|NCT02492386|erectile dysfunction
908334|NCT02492373|Post inflammatory hyperpigmentation
908335|NCT02492373|topical high potency steroid
908336|NCT02492373|Qs NdYAG laser
908337|NCT02492360|Peripheral Neuropathies
908338|NCT02492360|Testicular Cancer
908339|NCT02492360|Cisplatin
908340|NCT02492360|Pharmacogenomics
908341|NCT02492308|kidney
908342|NCT02492308|transplantation
908343|NCT02492308|MSC
908344|NCT02492217|Ankylosing Spondylitis
908345|NCT02492217|adalimumab
908346|NCT02492217|TNF-alpha agents
908347|NCT02492217|spondyloarthritis
908348|NCT02492217|biologic therapies
908349|NCT02492217|AS
908350|NCT02492217|biomarkers
908351|NCT02492217|efficacy prediction
908352|NCT02492191|Smart Phones
908353|NCT02492191|Ambulatory Care
908354|NCT02492191|Outcome and Process Assessment
908355|NCT02492165|Japanese Encephalitis
908356|NCT02492165|Japanese encephalitis chimeric virus vaccine
908357|NCT02492165|IMOJEV®
908358|NCT02492165|Live attenuated vaccine
908359|NCT02492152|women
908360|NCT02492152|active labor
908361|NCT02492126|Chronic Cough
908362|NCT02492126|Gastroesophageal Reflux
908363|NCT02492126|Esophageal Motility
908364|NCT02492126|Cough Sensitivity
908365|NCT02492113|Mechanical ventilation
908366|NCT02492113|Positive end-expiratory pressure
908367|NCT02492113|Work of breathing
908368|NCT02492113|Morbidly obese
908369|NCT02492100|Sexual Dysfunction Post-Bone Marrow Transplant
908370|NCT02492087|topical
908371|NCT02492087|tranexamic acid
908372|NCT02492087|haemostasis
908373|NCT02492087|caesarean section
908374|NCT02492087|bleeding
908375|NCT02492087|postpartum hemorrhage
908376|NCT02492087|prophylactic
908377|NCT02492074|delta-9-tetrahydrocannabinol
908378|NCT02492074|cannabidiol
908379|NCT02492074|COMT
908380|NCT02492061|couples' HCT married couples
908381|NCT02492061|Rakai
908382|NCT02492061|Uganda
908383|NCT02492035|Hypertension
908384|NCT02492035|lifestyle
908385|NCT02492035|clinical trials
908386|NCT02492035|primary care setting
908387|NCT02491996|desire model
908388|NCT02491983|metastatic breast cancer
908389|NCT02491983|Endocrine receptors positive
908390|NCT02491983|HER-2 negative
908391|NCT02491957|Energy Expenditure
908392|NCT02491957|Physical Endurance
908393|NCT02491957|Muscle Stength
908394|NCT02491957|Metabolism
908395|NCT02491931|Cardiac Surgical Procedures
908396|NCT02491931|Cardiovascular Surgical Procedures
908397|NCT02491931|Dietary Supplements
908398|NCT02491931|Glutamine
908399|NCT02491931|TROPONIN I
908400|NCT02491931|cardiopulmonary bypass
908401|NCT02491879|mechanical low back pain
908402|NCT02491879|emergency department
908403|NCT02491879|ketoprofen
908404|NCT02491879|gel
908405|NCT02491840|gastric cancer
908406|NCT02491840|cardia cancer
908407|NCT02491827|optical biopsy
908408|NCT02491814|Dairy
908409|NCT02491814|Breakfast cereal
908410|NCT02491814|Postprandial Glycemia
908411|NCT02491814|Satiety
908412|NCT02491814|Food Intake
908413|NCT02491814|Milk
908414|NCT02491814|Yogurt
908415|NCT02491814|Soy
908416|NCT02491814|Almond
908417|NCT02491801|Dairy
908418|NCT02491801|Milk
908419|NCT02491801|Yogurt
908420|NCT02491801|Cheese
908421|NCT02491801|Postprandial glycaemia
908422|NCT02491801|Satiety
908423|NCT02491801|Food Intake
908424|NCT02491801|Elderly
908425|NCT02491801|Prevention and Treatment
908426|NCT02491762|Serratus Anterior
908427|NCT02491762|Accessory Respiratory
908428|NCT02491762|Tissue Expander
908429|NCT02491762|Respiratory Function Tests
908430|NCT02491749|Cardiac anesthesia
908431|NCT02491749|ultra fast track
908432|NCT02491749|ICU stay
908433|NCT02491710|Surgical education
908434|NCT02491710|Laparoscopy
908435|NCT02491710|Laparoscopic suturing
908436|NCT02491697|DC-CIK
908437|NCT02491697|Breast cancer
908438|NCT02491697|Capecitabine
908439|NCT02491684|asthma
908440|NCT02491684|Upper Respiratory Tract Infection
908441|NCT02491684|exacerbation
908442|NCT02491684|Interferon
908443|NCT02491684|efficacy
908444|NCT02491684|safety
908445|NCT02491684|prevention
908446|NCT02491671|Prevention PAL Prolonged Air Leak (PAL)
908447|NCT02491671|Lung Resection
908448|NCT02491671|Thoracic Surgery
908449|NCT02491671|Post-operative Thoracic Air Leak
908450|NCT02491645|Autistic spectrum disorder
908451|NCT02491645|Sensory processing abnormalities
908452|NCT02491645|Sensory interventions
908453|NCT02491645|occupational therapy
908454|NCT02491632|Advanced Cancers
908455|NCT02491632|Dexamethasone
908456|NCT02491632|Decadron
908457|NCT02491632|Exercise
908458|NCT02491632|Physical activity
908459|NCT02491632|Questionnaires
908460|NCT02491632|Surveys
908461|NCT02491632|Physical activity tests
908462|NCT02491632|Phone calls
908463|NCT02491619|Angle class III
908464|NCT02491619|tomography
908465|NCT02491619|tooth inclination
908466|NCT02491619|bone thickness
908467|NCT02491593|fecal occult blood
908468|NCT02491554|Deep Brain Stimulation
908469|NCT02491554|Essential tremor
908470|NCT02491554|DISTINCT
908471|NCT02491554|MR-tractography guided DBS implantation
908472|NCT02491554|Conventional AC-PC based DBS implantation
908473|NCT02491515|Osteoporosis
908474|NCT02491515|BMD
908475|NCT02491515|denosumab
908476|NCT02491515|previous therapy
908477|NCT02491489|Manual therapy
908478|NCT02491476|Safety
908479|NCT02491476|Electrodes
908480|NCT02491476|Device
908481|NCT02491476|StereoElectroencephalograph
908482|NCT02491476|Epileptogenic zone
908483|NCT02491476|Fast ripples
908484|NCT02491463|Reactogenicity
908485|NCT02491463|Safety
908486|NCT02491463|Respiratory syncytial virus (RSV)
908487|NCT02491463|Vaccine
908488|NCT02491463|Immunogenicity
908489|NCT02491424|Osseointegration
908490|NCT02491424|Direct skeletal attachment
908491|NCT02491385|Thoracic epidural analgesia
908492|NCT02491385|bowel function recovery
908493|NCT02491333|polycystic ovary syndrome
908494|NCT02491333|acupuncture
908495|NCT02491333|insulin resistance
908496|NCT02491333|HOMA-IR
908497|NCT02491333|metformin
908498|NCT02491320|polycystic ovary syndrome
908499|NCT02491320|acupuncture
908500|NCT02491320|pre-treatment
908501|NCT02491320|Letrozole
908502|NCT02491320|Live Birth
908503|NCT02491294|School
908504|NCT02491294|Family
908505|NCT02491294|Fruit and Vegetables
908506|NCT02491294|Cooking
908507|NCT02491294|Physical Activity
908509|NCT02491242|HIV
908510|NCT02491242|dolutegravir
908511|NCT02491242|intolerance
908512|NCT02491242|dual therapies
908513|NCT02491229|non-alcoholic fatty liver disease (NAFLD)
908514|NCT02491229|Obesity
908515|NCT02491229|Hepafast
908516|NCT02491216|Frailty
908517|NCT02491216|Frail elderly
908518|NCT02491216|Acupressure
908519|NCT02491216|Pragmatic Randomised Controlled Trial
908520|NCT02491203|Virtual reality
908521|NCT02491203|telerehabilitation
908522|NCT02491203|Stroke rehabilitation
908523|NCT02491177|HIV Transmission
908524|NCT02491177|Prevention of Mother to Child Transmission
908525|NCT02491177|Linkage to care
908526|NCT02491177|Retention in care
908527|NCT02491177|Community Mentor Mothers
908528|NCT02491177|Mobile phone text messaging
908529|NCT02491177|Antiretroviral therapy adherence
908530|NCT02491177|Infant Health
908531|NCT02491177|Maternal CD4/viral loads
908532|NCT02491177|Early infant diagnosis
908533|NCT02491177|Acceptability of interventions
908534|NCT02491177|Vertical transmission
908535|NCT02491138|participants
908536|NCT02491086|intervention, nicotine replacement sampling, smoking cessation, smoking hotspots
908537|NCT02491034|Depression
908538|NCT02491034|Hispanics
908539|NCT02491034|Stigma
908540|NCT02491034|Barriers to Treatment
908541|NCT02491008|Thyroid Dysfunction
908542|NCT02491008|Bone mineral density
908543|NCT02491008|Osteoporosis
908544|NCT02491008|Fractures, Bone
908545|NCT02491008|Randomized Controlled Trial
908546|NCT02490995|children
908547|NCT02490969|copeptin
908548|NCT02490969|rule out marker, emergency department, cheast pain unit
908549|NCT02490969|emergency department
908550|NCT02490969|chest pain unit
908551|NCT02490956|Diagnostic immunization with rabies vaccine
908552|NCT02490956|Primary immunodeficiency
908553|NCT02490943|peginterferon beta-1a
908554|NCT02490943|MS (Multiple Sclerosis)
908555|NCT02490943|Injection Site Reaction Erythema
908556|NCT02490930|lymphopenia
908557|NCT02490917|Female urinary incontinence
908558|NCT02490917|Sphincter deficiency
908561|NCT02490891|Lymphoma, angiogenesis, PET scan
908562|NCT02490839|Helicobacter pylori
908563|NCT02490839|high dose dual therapy
908564|NCT02490839|bismuth-containing quadruple therapy
908565|NCT02490839|antibiotic resistance
908569|NCT02490813|Fish allergy
908570|NCT02490813|shrimp allergy
908571|NCT02490813|crab allergy
908572|NCT02490813|traditional Chinese medicine
908573|NCT02490761|Geriatrics
908574|NCT02490761|Nutritional Status
908575|NCT02490761|Hospitalisation
908576|NCT02490722|Patient education
908577|NCT02490722|Empowerment
908578|NCT02490709|Rectal neoplasms
908579|NCT02490709|Colorectal neoplasms
908580|NCT02490709|Local excision
908581|NCT02490696|PET scan
908582|NCT02490696|FAZA
908583|NCT02490696|F-Miso
908584|NCT02490696|hypoxia
908585|NCT02490696|lung cancer
908586|NCT02490631|skin flora
908587|NCT02490605|Postural balance
908588|NCT02490605|Temporomandibular disorders
908589|NCT02490605|Splints
908590|NCT02490579|video messaging
908591|NCT02490579|exercise
908592|NCT02490579|diet
908593|NCT02490579|weight gain
908594|NCT02490579|pregnancy
908595|NCT02490566|chronic condition
908596|NCT02490566|telehealth
908597|NCT02490566|nutrition
908598|NCT02490566|exercise
908599|NCT02490553|air pollution
908600|NCT02490553|epidemiological survey
908601|NCT02490553|representative sample
908602|NCT02490540|opioids
908603|NCT02490540|analgesia
908604|NCT02490540|pain
908605|NCT02490540|anesthesia
908606|NCT02490527|myopathy
908607|NCT02490527|muscular weakness
908608|NCT02490527|cramping
908609|NCT02490527|fatigue
908610|NCT02490488|ovarian cancer
908611|NCT02490462|Cerebral Palsy
908612|NCT02490462|Physical Therapy
908613|NCT02490462|Family-centered Care
908614|NCT02490384|Cervical cerclage
908615|NCT02490345|gabapentin
908616|NCT02490319|radiation pneumonitis
908617|NCT02490319|lung cancer
908618|NCT02490319|prediction models
908619|NCT02490319|genetic variants
908620|NCT02490241|pregnant
908621|NCT02490241|female
908622|NCT02490241|women
908623|NCT02490241|lithium
908624|NCT02490241|bipolar
908625|NCT02490228|female
908626|NCT02490228|minimally invasive surgery
908627|NCT02490150|Corifollitropin alfa
908628|NCT02490150|Stimulation protocol
908629|NCT02490124|Diabetes Type 1
908630|NCT02490124|Vascular Function
908631|NCT02490098|Type 1 diabetes
908632|NCT02490098|Closed-loop system
908633|NCT02490098|Artificial pancreas
908634|NCT02490098|Insulin
908635|NCT02490098|Glucagon
908636|NCT02490098|Hypoglycemia
908637|NCT02490098|Postprandial glucose
908638|NCT02490085|Type 2 diabetes
908639|NCT02490085|Closed-loop strategy
908640|NCT02490085|Artificial pancreas
908641|NCT02490085|Insulin
908642|NCT02490085|Elderly
908643|NCT02490085|Multiple daily injections
908644|NCT02490085|Hypoglycemia
908645|NCT02490046|D mannose
908646|NCT02490046|multiple sclerosis
908647|NCT02490046|recurrent urinary infections
908648|NCT02490020|Renal transplantation
908649|NCT02490020|mesenchymal stem cell
908650|NCT02490020|Transplantation Rejection
908651|NCT02490020|donation after cardiac death
908652|NCT02490007|Acellular pertussis vaccine
908653|NCT02490007|whole cell pertussis vaccine
908654|NCT02490007|IgE-mediated food allergy
908655|NCT02489916|Metastatic Colorectal Cancer
908656|NCT02489916|CM4307
908657|NCT02489916|Previously treated metastatic colorectal cancer
908658|NCT02489903|Epigenetics
908659|NCT02489903|resensitization
908660|NCT02489903|Platinum doublets
908661|NCT02489903|lung cancer
908662|NCT02489903|Ovarian epithelial cancer
908663|NCT02489877|multiple sclerosis
908664|NCT02489877|HERV-W virus
908665|NCT02489877|Herpesviridae family
908666|NCT02489864|Terlipressin
908667|NCT02489864|mean arterial pressure
908668|NCT02489864|type 2 HRS
908669|NCT02489838|Liver Neoplasma
908670|NCT02489838|Lung Radiation dose
908671|NCT02489825|randomized controlled trial
908672|NCT02489825|vertebral fracture
908673|NCT02489825|osteoporosis
908674|NCT02489825|vertebroplasty
908675|NCT02489825|augmentation
908676|NCT02489812|children
908677|NCT02489812|behavior
908678|NCT02489812|anxiety
908679|NCT02489812|dentistry
908680|NCT02489799|advance care planning
908681|NCT02489773|Lucica
908682|NCT02489773|glycated albumin
908683|NCT02489773|GA
908684|NCT02489773|fructosamine
908685|NCT02489760|Etanercept
908686|NCT02489760|Adalimumab
908687|NCT02489760|Ankylosing Spondylitis
908688|NCT02489760|Switch Study
908689|NCT02489747|cognitive function
908690|NCT02489747|CNT
908691|NCT02489747|memory function
908692|NCT02489747|Triticum aestivum L
908693|NCT02489747|wheat bran
908694|NCT02489734|sevoflurane
908695|NCT02489734|emergence delirium
908696|NCT02489734|preschool
908701|NCT02489708|Bronchiolitis
908702|NCT02489708|Cough
908703|NCT02489708|Ear Infection
908704|NCT02489708|Respiratory Infection
908705|NCT02489708|Wheezing
908706|NCT02489708|Clinical Decision Support Systems
908707|NCT02489695|locally advanced or metastatic
908708|NCT02489656|Double loop ureteral stent
908709|NCT02489656|USSQ
908710|NCT02489656|Quality of life
908711|NCT02489656|Pain
908712|NCT02489604|neuroendocrine tumors
908713|NCT02489578|Community Acquired Pneumonia
908714|NCT02489578|health care associated pneumonia
908715|NCT02489565|Coronary Artery Disease
908716|NCT02489565|stable
908717|NCT02489565|Telemedicine
908718|NCT02489565|Patient Discharge
908719|NCT02489539|Aortic aneurysm
908720|NCT02489539|Abdominal aorta
908721|NCT02489539|Stent graft
908722|NCT02489539|Aneurysm
908723|NCT02489539|Vascular Diseases
908724|NCT02489539|Cardiovascular Diseases
908725|NCT02489500|AL Amyloidosis
908726|NCT02489500|Stem Cell Transplantation
908727|NCT02489448|Breast Cancer
908728|NCT02489383|Asthma
908729|NCT02489383|Continuous Exercise Training
908730|NCT02489383|interval Exercise Training
908731|NCT02489383|Clinical Control
908732|NCT02489383|Inflammation
908733|NCT02489370|home care
908734|NCT02489370|telecare
908735|NCT02489370|telehealth
908736|NCT02489370|telemonitoring
908737|NCT02489370|chronic heart failure
908738|NCT02489370|randomized controlled trial
908739|NCT02489370|Congestive Heart Failure
908740|NCT02489370|telemedicine
908741|NCT02489331|Dyslipidemias
908742|NCT02489318|Prostate Cancer
908743|NCT02489318|JNJ-56021927
908744|NCT02489318|Androgen Deprivation Therapy
908745|NCT02489318|ARN-509
908746|NCT02489318|Apalutamide
908747|NCT02489318|TITAN
908748|NCT02489318|Metastatic Hormone-sensitive Prostate Cancer
908749|NCT02489305|Depressive Disorder, Major
908750|NCT02489305|Depression
908751|NCT02489305|Anti-Depressant
908752|NCT02489305|Observational
908753|NCT02489292|Urea Cycle Disorder
908754|NCT02489292|UCD
908755|NCT02489292|cell therapy
908756|NCT02489292|stem cell
908757|NCT02489279|Attention deficit hyperactivity disorder.
908758|NCT02489279|Attention training
908759|NCT02489279|Mobile devices
908760|NCT02489279|Brain training
908761|NCT02489266|Melanoma
908762|NCT02489266|Immunotherapy
908763|NCT02489227|PsO
908764|NCT02489214|donafenib
908765|NCT02489201|donafenib
908766|NCT02489188|gait asymmetry
908767|NCT02489188|joint angles
908768|NCT02489175|Parastomal hernia
908769|NCT02489175|prevention
908770|NCT02489175|stomaplasty
908771|NCT02489175|ring
908772|NCT02489149|food insecurity
908773|NCT02489136|spiritist passe
908774|NCT02489136|laying of hands
908775|NCT02489136|newborn
908776|NCT02489136|adult
908777|NCT02489136|conditions
908778|NCT02489110|Alzheimer's Disease
908779|NCT02489110|Dementia
908780|NCT02489110|caregiving
908781|NCT02489110|caregiver
908782|NCT02489110|coping
908783|NCT02489110|coping with caregiving
908784|NCT02489110|stress
908785|NCT02489110|Hispanic caregiver
908786|NCT02489110|Latino caregiver
908787|NCT02489084|Head and Neck neoplasms
908788|NCT02489084|Genome-wide association study
908789|NCT02489084|Polymorphism, single nucleotide
908790|NCT02489084|Toxicity
908791|NCT02489019|Anesthesia
908792|NCT02489019|Fentanyl
908793|NCT02489019|Elderly
908794|NCT02488980|Falciparum Parasitaemia, Malaria
908795|NCT02488954|Ulcerative colitis
908796|NCT02488954|Probiotics
908797|NCT02488954|treatments
908798|NCT02488954|Propionibacterium freudenreichii
908799|NCT02488941|Liver Function Tests
908800|NCT02488941|Blood Coagulation
908801|NCT02488928|NSCLC
908802|NCT02488928|EBUS
908803|NCT02488928|elastography
908804|NCT02488928|predictive value
908805|NCT02488928|strain
908806|NCT02488915|Brain
908807|NCT02488915|Brain Clot
908808|NCT02488915|Brain Diseases
908809|NCT02488915|Brain Infarction
908810|NCT02488915|Cerebral Ischemia
908811|NCT02488915|Cerebrovascular Disorders
908812|NCT02488915|EmboTrap® Revascularization Device
908813|NCT02488915|EmboTrap
908814|NCT02488915|Ischemia
908815|NCT02488915|Ischemic
908816|NCT02488915|Ischemic Stroke
908817|NCT02488915|Mechanical Thrombectomy
908818|NCT02488915|Neurovascular Intervention
908819|NCT02488915|Revascularization
908820|NCT02488915|Stent Retriever
908821|NCT02488915|Stroke
908822|NCT02488915|Vascular Diseases
908823|NCT02488915|Neuravi
908824|NCT02488889|Chantix
908825|NCT02488876|Cardiac surgery
908826|NCT02488876|Tissue sample database
908827|NCT02488876|Inflammatory responds
908828|NCT02488850|immune monitoring
908829|NCT02488850|T cell activation
908830|NCT02488850|early stage
908831|NCT02488837|Deep Brain Stimulation
908832|NCT02488824|Quadriplegia
908833|NCT02488824|Paraplegia
908834|NCT02488824|Spinal Cord Injury
908835|NCT02488824|Body Temperature Regulation
908836|NCT02488824|Mild Cognitive Impairment
908837|NCT02488785|Type 2 Diabetes Mellitus
908838|NCT02488785|Telehealth
908839|NCT02488785|Hispanics
908840|NCT02488785|Latinos
908841|NCT02488785|Self-Care
908842|NCT02488785|Mobile Health
908843|NCT02488785|mHealth
908844|NCT02488772|sleep quality
908845|NCT02488772|emergency department
908846|NCT02488733|type 2 diabetes mellitus
908847|NCT02488733|obesity
908848|NCT02488733|laparoscopic sleeve gastrectomy
908849|NCT02488733|bariatric surgery
908850|NCT02488733|metabolic surgery
908851|NCT02488720|amyloid imaging
908852|NCT02488720|biomarkers
908853|NCT02488720|cognition
908854|NCT02488720|longitudinal
908855|NCT02488720|cognitive decline
908856|NCT02488720|observational
908857|NCT02488707|low rectal cancer
908858|NCT02488707|minimally invasive colorectal surgery
908859|NCT02488707|trans-anal endoscopic microsurgery
908860|NCT02488707|TEM
908861|NCT02488707|intersphincteric resection
908862|NCT02488707|ISR
908863|NCT02488707|subtotal intersphincteric resection
908864|NCT02488707|total intersphincteric resection
908865|NCT02488707|trans-anal trans-abdominal resection
908866|NCT02488707|laparoscopic intersphincteric resection
908867|NCT02488707|anal sphincter preservation
908868|NCT02488707|total mesorectal excision
908869|NCT02488707|TME
908870|NCT02488707|TATA
908871|NCT02488707|laparoscopic total mesorectal excision
908872|NCT02488707|external sphincter preservation
908873|NCT02488707|Neoadjuvant chemo-radiotherapy for rectal cancer
908874|NCT02488707|fit patients for minimally invasive surgery
908875|NCT02488668|Transcutaneous Electrical Stimulation
908876|NCT02488668|Neuroplasticity
908877|NCT02488668|Sensory Feedback
908878|NCT02488642|Isosorbide dinitrate gel solution
908879|NCT02488642|late intrauterine death
908880|NCT02488642|nitric oxide donors
908881|NCT02488629|Head and neck squamous cell carcinoma
908882|NCT02488616|Closed-loop system
908883|NCT02488616|Artificial pancreas
908884|NCT02488616|Type 1 diabetes
908885|NCT02488616|Hypoglycemia
908886|NCT02488616|Glucagon
908887|NCT02488616|Insulin
908888|NCT02488603|Breast Neoplasms
908889|NCT02488603|Tamoxifen
908890|NCT02488603|Decision Aids
908891|NCT02488564|HER-2 Positive Breast Cancer
908892|NCT02488564|operable breast cancer
908893|NCT02488564|locally advanced breast cancer
908894|NCT02488564|no prior therapy
908895|NCT02488564|pCR
908896|NCT02488525|Acquired Von Willebrand
908897|NCT02488525|Gastro-intestinal bleeding
908898|NCT02488525|LVAD
908899|NCT02488512|Relapsed/refractory diffuse large b cell
908900|NCT02488512|Relapsed/refractory mantle cell lymphomas
908901|NCT02488512|DLBCL
908902|NCT02488512|MCL
908903|NCT02488512|90Y-DOTATOC
908904|NCT02488512|SSR-positive tumour
908905|NCT02488499|Disruptive Behaviour Disorder
908906|NCT02488499|Psychosocial
908907|NCT02488499|Group Treatment
908908|NCT02488473|Volunteers
908909|NCT02488460|Motor Activity
908910|NCT02488460|Cognition
908911|NCT02488460|Academic Acheivement
908912|NCT02488460|Preadolescent Children
908913|NCT02488447|Allergy
908914|NCT02488447|Allergic rhinoconjunctivitis
908915|NCT02488447|Immunotherapy
908916|NCT02488447|Life Quality
908917|NCT02488447|Adherence
908918|NCT02488434|ICSI
908919|NCT02488434|sperm selection
908920|NCT02488434|fertile chip
908921|NCT02488434|ıcsı outcomes
908922|NCT02488395|Parkinson's disease
908923|NCT02488395|Non-motor symptoms
908924|NCT02488395|Visual deficits
908925|NCT02488395|Superior colliculus
908926|NCT02488395|fMRI
908927|NCT02488382|lymphoma
908928|NCT02488382|multiple myeloma
908929|NCT02488382|stem cell mobilization
908930|NCT02488382|autologous stem cell transplantation
908931|NCT02488369|Children and adolescents
908932|NCT02488343|Multiple Sclerosis
908933|NCT02488343|Adherence
908934|NCT02488343|Therapies
908935|NCT02488343|Psychological Intervention
908936|NCT02488317|Chronic Kidney Disease
908937|NCT02488317|Hemodialysis
908938|NCT02488317|Peritoneal Dialysis
908939|NCT02488304|HRCT
908940|NCT02488304|High Resolution Computed Tomography scans
908941|NCT02488304|Functional Respiratory Imaging
908942|NCT02488304|FRI
908943|NCT02488304|Computed Tomography
908944|NCT02488304|CT
908945|NCT02488304|Bronchiolitis Obliterans Syndrome
908946|NCT02488304|BOS
908947|NCT02488304|Lung Transplant
908948|NCT02488291|Epidural
908949|NCT02488291|Analgesia labor
908950|NCT02488291|Perinatal
908951|NCT02488291|anesthesia
908952|NCT02488278|Glucose blood measurements, glucometers ,audio communication
908953|NCT02488265|Parkinson´s disease
908954|NCT02488265|Physicaltherapy
908955|NCT02488265|Postural Balance
908956|NCT02488265|Gait
908957|NCT02488265|Rehabilitation
908958|NCT02488252|Chinese Medicine
908959|NCT02488252|ACEI
908960|NCT02488252|ARB
908961|NCT02488252|Pragmatic trial
908962|NCT02488213|Nutritional Counseling
908963|NCT02488213|Diet
908964|NCT02488187|Breast Cancer
908965|NCT02488187|MRI
908966|NCT02488187|Mammogram
908967|NCT02488187|Whole Breast Sonogram
908968|NCT02488187|ABUS
908969|NCT02488161|Colorectal cancer
908970|NCT02488161|Risk factors
908971|NCT02488161|Adverse events
908972|NCT02488161|Predictive models
908973|NCT02488122|Bone Mineral Density
908974|NCT02488122|Isometric Exercise
908975|NCT02488122|Bone Growth
908976|NCT02488109|anorexia nervosa
908977|NCT02488109|eating disorders
908978|NCT02488109|refeeding
908979|NCT02488109|adolescent medicine
908980|NCT02488109|nutritional rehabilitation
908981|NCT02488083|non-invasive
908982|NCT02488031|SCA, dysmetria
908983|NCT02488018|Glycemic index
908984|NCT02488018|honey
908985|NCT02488018|reference glucose
908986|NCT02488005|Inflammatory Bowel Disease
908987|NCT02488005|Small Bowel
908988|NCT02488005|Crohn's Disease
908989|NCT02488005|Small Bowel Ultrasound
908990|NCT02487966|tDCS
908991|NCT02487966|Mirror Therapy
908992|NCT02487966|Phantom Limb Pain
908993|NCT02487966|Traumatic amputation
908994|NCT02487953|Nicotine addiction
908995|NCT02487953|Cigarette smoking
908996|NCT02487953|Smoking cessation
908997|NCT02487953|Nicotine patches
908998|NCT02487953|E-cigarettes
908999|NCT02487940|Recurrent implantation failure
909000|NCT02487940|IVF
909001|NCT02487940|ICSI
909002|NCT02487940|Intralipid
909003|NCT02487914|Drug Delivery
909004|NCT02487914|Iontophoresis
909005|NCT02487914|Lidocaine
909006|NCT02487914|Pressure
909007|NCT02487914|Tactile perception
909008|NCT02487901|arthrodesiss
909009|NCT02487901|cervical vertebra
909010|NCT02487901|laminoplasty
909011|NCT02487888|Genetic Variation
909012|NCT02487888|Genetic Polymorphism
909013|NCT02487888|Polymorphism, Single Nucleotide
909014|NCT02487888|Genetic Association Studies
909015|NCT02487888|Healthcare Utilization
909016|NCT02487875|Sit-to-stand test
909017|NCT02487875|Muscle strength
909018|NCT02487875|Pulmonary rehabilitation
909019|NCT02487836|Laying of the biliary stent
909020|NCT02487771|DHA
909021|NCT02487771|childhood development
909022|NCT02487745|Cocaine
909023|NCT02487745|Methadone
909024|NCT02487745|Employment
909025|NCT02487745|Opioids
909026|NCT02487732|Diabetic Patients With Non-ST Elevation
909027|NCT02487719|Iron deficiecy
909028|NCT02487719|pregnancy
909029|NCT02487719|prenatal care
909030|NCT02487706|Hemodialysis
909031|NCT02487706|HIV-infection
909032|NCT02487654|Paroxysmal atrial fibrillation
909033|NCT02487654|Pulmonary vein isolation
909034|NCT02487654|Ganglionic plexi
909035|NCT02487654|Radiofrequency
909036|NCT02487654|late gadolinium enhancement cardiac MR imaging
909037|NCT02487654|High Frequency Stimulation
909038|NCT02487641|Ultrasound
909039|NCT02487641|mid-trimester
909040|NCT02487641|Obesity
909041|NCT02487641|pregnancy
909042|NCT02487615|Glycaemia
909043|NCT02487615|Subclinical Atherosclerosis
909044|NCT02487615|Carotid Doppler Ultrasound
909045|NCT02487615|Carotid Plaque
909046|NCT02487615|Intima Media Thickness
909047|NCT02487615|Ankle Brachial Index
909048|NCT02487615|Exercise Stress Test
909049|NCT02487615|Coronary Calcium Score
909050|NCT02487615|Insulinemia
909051|NCT02487615|Leptin
909052|NCT02487615|Inflammation
909053|NCT02487615|Resistin
909054|NCT02487615|Tumor Necrosis Factor alpha
909055|NCT02487615|Phospholipase A2, Group VII
909056|NCT02487615|Body Mass Index
909057|NCT02487615|Adipose Tissue Function
909058|NCT02487615|Single Gene Polymorphism
909059|NCT02487589|Falls
909060|NCT02487589|Elderly
909061|NCT02487589|e-Health
909062|NCT02487589|Telemedicine
909063|NCT02487563|Isolated thrombocytopenia
909064|NCT02487563|decitabine
909065|NCT02487563|rhTPO
909066|NCT02487550|Renal neoplasma
909067|NCT02487550|CIK cells
909068|NCT02487537|incretin release
909069|NCT02487524|Neuropathic Pain
909070|NCT02487524|Breast Cancer
909071|NCT02487524|Post surgical
909072|NCT02487498|Chronic Obstructive Pulmonary Disease (COPD)
909077|NCT02487459|acute lymphoblastic leukemia
909078|NCT02487459|acute myeloid leukemia
909079|NCT02487459|chronic myeloid leukemia
909080|NCT02487459|myelodysplastic syndrome
909081|NCT02487459|non-hodgkin lymphoma
909082|NCT02487459|hodgkin lymphoma
909083|NCT02487446|Chronic Obstructive Pulmonary Disease (COPD)
909084|NCT02487433|food effect
909085|NCT02487433|pharmacokinetics
909086|NCT02487433|healthy volunteers
909087|NCT02487381|delta-9-tetrahydrocannabinol
909088|NCT02487381|cannabidiol
909089|NCT02487381|COMT
909090|NCT02487381|Volunteers
909091|NCT02487355|dexmedetomidine
909092|NCT02487355|magnesium sulphate
909093|NCT02487342|Dairy
909094|NCT02487342|appetite
909095|NCT02487342|feeding behaviour
909096|NCT02487329|Direct pulp capping
909097|NCT02487329|Er,Cr:YSGG laser
909098|NCT02487329|Tricalcium silicate
909099|NCT02487316|Anaplastic Large Cell Lymphoma
909100|NCT02487316|anaplastic lymphoma kinase rearrangement
909101|NCT02487316|crizotinib
909102|NCT02487316|CHOP chemotherapy
909103|NCT02487303|Acetaminophen
909104|NCT02487303|Pain, Postoperative
909105|NCT02487303|Analgesia, Obstetrical
909106|NCT02487303|Cesarean Section
909107|NCT02487277|Pancreatic
909108|NCT02487251|Obesity
909109|NCT02487251|Family Mealtimes
909110|NCT02487251|Prevention
909125|NCT02487212|fractional laser
909126|NCT02487212|hypertrophic scar
909127|NCT02487212|topical corticosteroid
909128|NCT02487212|laser assisted delivery systems
909129|NCT02487199|hepatitis C infection
909130|NCT02487199|interferon
909131|NCT02487199|hepatitis C
909132|NCT02487199|treatment experienced
909133|NCT02487199|severe kidney disease
909134|NCT02487199|Chronic Kidney Disease
909135|NCT02487186|Chronic periodontitis
909136|NCT02487186|Local doxycycline
909137|NCT02487186|Ultrasonic debridement
909138|NCT02487186|PLGA microspheres
909139|NCT02487186|Microbiologic assessment
909140|NCT02487147|Live Attenuated Influenza Vaccine (FluMist)
909141|NCT02487147|Free Air Portable Air Powered Respirator
909142|NCT02487147|N95 Respirator
909143|NCT02487147|Personal Protective Equipment
909144|NCT02487147|Viral Transmission
909145|NCT02487121|weight loss
909146|NCT02487095|RB1 Inactivation
909147|NCT02487095|Kinase Inhibitor
909148|NCT02487095|DNA Damage Response Network
909149|NCT02487095|MYC And CCNE1 Activation
909150|NCT02487095|Defective ATM-p53 Signaling Pathway
909151|NCT02487082|Autism Spectrum Disorder
909152|NCT02487082|Children
909153|NCT02487082|Melatonin
909154|NCT02487082|Donepezil
909155|NCT02487082|Sleep disorder
909156|NCT02487056|Heart Failure
909157|NCT02487056|Diagnosis
909158|NCT02487056|Management
909159|NCT02487043|Caries prevention
909160|NCT02487043|Early Childhood Caries
909161|NCT02487030|HCV genotype 4 (GT-4)
909162|NCT02487030|HCV
909163|NCT02487030|Sustained Virologic Response
909164|NCT02487030|Direct Acting Antiviral
909165|NCT02487030|Combination Therapy
909166|NCT02487030|GS-7977
909167|NCT02487030|GS-5885
909168|NCT02487030|Ribavirin
909169|NCT02487030|Sofosbuvir
909170|NCT02487030|ledipasvir
909171|NCT02487030|Hepatitis C
909172|NCT02487030|Hepatitis C, Chronic
909173|NCT02487030|Liver Diseases
909174|NCT02487030|Virus Diseases
909175|NCT02487030|Antiviral Agents
909176|NCT02486965|VAS
909177|NCT02486965|thermode test
909178|NCT02486965|training program
909179|NCT02486965|6MWT
909180|NCT02486913|Primary prevention
909181|NCT02486913|National Health Service Health Check
909185|NCT02486887|telemonitoring
909186|NCT02486874|Human acellular dermal matrix, burns, wound healing
909187|NCT02486861|Tomography, Optical Coherence
909188|NCT02486848|Hairloss
909189|NCT02486848|Female Pattern Hair Loss
909190|NCT02486848|Androgenetic Alopecia
909191|NCT02486848|Minoxidil
909192|NCT02486822|Labor scale
909193|NCT02486822|Partograph
909194|NCT02486822|Spontaneous labor
909195|NCT02486822|Primigravida
909196|NCT02486744|Acthar
909197|NCT02486744|Dialysis
909198|NCT02486744|Kidney
909199|NCT02486744|Non-Diabetic
909200|NCT02486731|Hormonal sensitivity
909201|NCT02486731|bone growth
909202|NCT02486705|ptsd
909203|NCT02486705|family
909204|NCT02486705|caregiver
909205|NCT02486705|burden
909206|NCT02486692|Mental Health
909207|NCT02486692|PTSD
909208|NCT02486692|Stigma
909209|NCT02486692|Peer Education
909210|NCT02486692|Web Education
909211|NCT02486692|Self Help
909212|NCT02486653|tamsulosin
909213|NCT02486653|randomized controlled trials as topic
909214|NCT02486653|double-blind method
909215|NCT02486653|random allocation
909216|NCT02486653|placebos
909217|NCT02486653|Adrenergic alpha-Antagonists
909218|NCT02486653|urinary retention
909219|NCT02486653|urinary tract infections
909220|NCT02486653|urinary catheters
909221|NCT02486653|catheter-related infections
909222|NCT02486653|postoperative complications
909223|NCT02486640|RRMS, CIS
909224|NCT02486627|cUTI
909225|NCT02486627|AP
909226|NCT02486627|ACHN-490
909227|NCT02486627|anti-infective
909228|NCT02486627|anti-bacterial
909229|NCT02486627|antibiotic
909230|NCT02486627|anti-microbial
909231|NCT02486627|UTI
909232|NCT02486627|bacterial infection
909233|NCT02486627|Gram-negative
909234|NCT02486588|Financial incentives
909235|NCT02486588|Messaging
909236|NCT02486575|Residents
909237|NCT02486575|Training
909238|NCT02486575|simulation
909239|NCT02486575|mentoring
909240|NCT02486575|proctor
909241|NCT02486562|Multiple Sclerosis
909242|NCT02486562|MS
909243|NCT02486549|Pain
909244|NCT02486549|Anesthesia Recovery Period
909245|NCT02486549|Brachial Plexus
909249|NCT02486523|SAM, severe acute malnutrition
909250|NCT02486510|HIV-1
909251|NCT02486510|CCR5 coreceptors
909252|NCT02486510|Maraviroc
909253|NCT02486497|Pancreatic cancer
909254|NCT02486497|Adjuvant chemotherapy
909255|NCT02486497|hENT1
909256|NCT02486497|Gemcitabine
909257|NCT02486484|macular degeneration
909258|NCT02486484|diabetic retinopathy
909259|NCT02486484|macular edema
909260|NCT02486484|retinal vein occlusion
909261|NCT02486484|choroidal neovascularization
909262|NCT02486471|cervical dysplasia
909263|NCT02486471|colposcopy
909264|NCT02486471|haemostatic procedure
909265|NCT02486471|biopsy of the cervix uteri
909266|NCT02486458|Fluoride
909267|NCT02486458|Biofilm fluid
909268|NCT02486458|Calcium fluoride
909269|NCT02486458|Topical
909270|NCT02486445|Deep venous thrombosis
909271|NCT02486445|Rivaroxaban
909272|NCT02486406|Hepatitis C Genotype 4
909273|NCT02486406|Pediatric
909274|NCT02486406|Hepatitis C Genotype 1
909275|NCT02486406|Hepatitis C Virus
909276|NCT02486341|continuous glucose monitoring system
909277|NCT02486341|basal insulin
909278|NCT02486341|diabetes mellitus
909279|NCT02486341|elderly
909280|NCT02486328|Cognitive dysfunction
909281|NCT02486328|Colonoscopy
909282|NCT02486328|Sedation
909283|NCT02486315|coronary bifurcation
909284|NCT02486315|coronary stent
909285|NCT02486289|Mercury toxicity poisoning
909286|NCT02486263|infant
909287|NCT02486263|esophagitis
909288|NCT02486263|neonate
909289|NCT02486263|GERD
909290|NCT02486237|diabetes mellitus
909291|NCT02486237|complications
909292|NCT02486237|prevalence
909293|NCT02486224|deep sea mineral water
909294|NCT02486224|exercise recovery
909295|NCT02486224|hydration
909296|NCT02486224|salivary osmolar concentration
909297|NCT02486224|urinary osmolar concentration
909298|NCT02486211|heart arrest
909299|NCT02486211|resuscitation
909300|NCT02486211|seizures
909301|NCT02486211|hypothermia, induced
909302|NCT02486211|Amantadine
909303|NCT02486198|Gastrointestinal cancer
909304|NCT02486198|oxaliplatin
909305|NCT02486198|neurotoxicity
909306|NCT02486120|Genetic Counseling
909307|NCT02486120|Clinical Decision-Making
909308|NCT02486107|cervical vertebra
909309|NCT02486107|surgery
909310|NCT02486107|tubular retractor
909311|NCT02486107|endoscope
909312|NCT02486094|Imaging, Magnetic Resonance
909313|NCT02486094|Rectal Cancer
909314|NCT02486094|Apoptosis
909315|NCT02486094|Proliferation
909316|NCT02486094|Cancer
909317|NCT02486094|Tissue Study
909318|NCT02486081|Assistive device
909319|NCT02486081|the disabled
909320|NCT02486081|special education
909321|NCT02486081|movement analysis
909322|NCT02486081|system development
909323|NCT02486055|Study safety of BPM31510 in healthy subjects
909324|NCT02486042|ROP
909325|NCT02486042|Premature infant
909326|NCT02486016|Bioequivalence
909327|NCT02486016|Therapeutic Equivalency
909328|NCT02485990|Fallopian Tube
909329|NCT02485990|Epithelial Ovarian
909330|NCT02485990|EOC
909331|NCT02485977|Pulmonary hypertension
909332|NCT02485977|Magnetic Resonance Imaging
909333|NCT02485964|Vaccine
909334|NCT02485951|deep anterior lamellar keratoplasty
909335|NCT02485951|big-bubble technique
909336|NCT02485951|peripheral air injection
909337|NCT02485951|keratoconus
909338|NCT02485938|Duchenne Muscular Dystrophy
909339|NCT02485938|Cardiomyopathy
909344|NCT02485912|Ebola
909345|NCT02485912|vaccine
909346|NCT02485912|safety
909347|NCT02485912|immunogenicity
909348|NCT02485899|Late infantile Neuronal Ceroid Lipofuscinosis Type 2
909349|NCT02485899|LINCL
909350|NCT02485899|NCL2
909351|NCT02485899|CLN2
909352|NCT02485899|Jansky-Bielschowsky disease
909353|NCT02485886|PET
909354|NCT02485886|interstitial pulmonary fibrosis (IPF)
909355|NCT02485886|cysteine cathepsins
909356|NCT02485886|macrophage
909357|NCT02485873|Non-valvular atrial fibrillation (NVAF)
909358|NCT02485873|Pevention
909359|NCT02485873|Stroke
909360|NCT02485860|pilonidal cysts
909361|NCT02485860|Cavity wound
909362|NCT02485860|long healing
909363|NCT02485860|honey
909364|NCT02485847|Eye Diseases
909365|NCT02485821|Estradiol
909366|NCT02485821|Misoprostol
909367|NCT02485821|Induction of labor
909368|NCT02485821|Cervical ripening
909369|NCT02485821|Bishop score
909370|NCT02485808|Lower Urinary Tract Symptoms
909371|NCT02485808|Bladder Symptoms
909372|NCT02485808|Overactive Bladder
909373|NCT02485808|Urinary Urgency
909374|NCT02485808|Lower Urinary Tract Dysfunction
909375|NCT02485795|Pain Management
909376|NCT02485795|Genetic Variation
909377|NCT02485795|Genetic Polymorphism
909378|NCT02485795|Polymorphism, Single Nucleotide Genetic Association Studies
909379|NCT02485795|Healthcare Utilization
909380|NCT02485756|Drug interactions
909381|NCT02485743|satiation
909382|NCT02485743|satiety
909383|NCT02485743|weight loss
909384|NCT02485743|maintained weight loss
909385|NCT02485730|Prevention
909386|NCT02485730|Cohort Analysis
909387|NCT02485730|Healthy Participants
909388|NCT02485678|ambulatory toxicity management
909389|NCT02485678|adjuvant or neoadjuvant chemotherapy
909390|NCT02485665|Prostate cancer
909391|NCT02485665|Robot-assisted laparoscopic surgery
909392|NCT02485665|Radical prostatectomy
909393|NCT02485665|Post-prostatectomy incontinence
909394|NCT02485665|Pelvic floor muscle exercise
909395|NCT02485665|Extracorporeal biofeedback device
909396|NCT02485652|NSCLC
909397|NCT02485652|EGFR-TKI
909398|NCT02485652|non small cell lung cancer
909399|NCT02485652|HM61713
909400|NCT02485652|T790M-positive
909401|NCT02485652|lung cancer
909402|NCT02485652|Phase II
909403|NCT02485652|Olmutinib
909404|NCT02485639|HA-specific plasmablasts
909405|NCT02485639|humoral immunity
909406|NCT02485639|influenza
909407|NCT02485639|memory B cells
909408|NCT02485626|Anthracyclines
909409|NCT02485600|LCIG
909410|NCT02485600|Duodopa
909411|NCT02485600|Parkinson's disease
909412|NCT02485600|Observational
909413|NCT02485600|Cadence
909414|NCT02485600|Levodopa-carbidopa intestinal gel
909417|NCT02485574|Bone bridging
909418|NCT02485574|Arthrodesis
909419|NCT02485574|Lumbar
909420|NCT02485574|Cage
909421|NCT02485561|Colon cancer screening
909422|NCT02485561|Colorectal cancer screening
909423|NCT02485561|Colonoscopy
909424|NCT02485561|Sigmoidoscopy
909425|NCT02485561|Stool blood test
909426|NCT02485561|Narrative
909427|NCT02485522|fecal incontinence
909428|NCT02485522|diet
909429|NCT02485522|nutrition
909430|NCT02485522|metabolites
909431|NCT02485522|stool
909432|NCT02485522|FI
909433|NCT02485379|Prostate cancer
909434|NCT02485379|Multiparametric MRI
909435|NCT02485379|Prostate biopsy
909436|NCT02485379|Targeted biopsy
909437|NCT02485379|Comparative study
909438|NCT02485366|Rejuvenated packed red blood cells
909439|NCT02485353|Vosaroxin
909440|NCT02485353|Cytarabine
909441|NCT02485353|Remission Induction
909442|NCT02485353|Safety
909443|NCT02485353|Progression-Free Survival
909444|NCT02485353|Mortality Rate
909445|NCT02485353|Length of Stay
909446|NCT02485314|children
909447|NCT02485314|disability
909448|NCT02485314|family
909449|NCT02485314|participation
909450|NCT02485301|Protection against Ebola Zaire virus
909451|NCT02485275|High Resolution MRI
909452|NCT02485275|Infarction
909453|NCT02485275|Intracranial artery stenosis
909454|NCT02485275|Cerebral small-vessel disease
909455|NCT02485262|Protease inhibitor treatment
909456|NCT02485249|Iontophoresis
909457|NCT02485249|Macular Edema
909458|NCT02485249|Ophthalmology
909459|NCT02485223|Multiple Sclerosis
909460|NCT02485223|MS
909461|NCT02485223|Diagnostic test
909462|NCT02485223|Central veins
909463|NCT02485223|MRI
909464|NCT02485210|photodynamic therapy , Endodontic treatment
909465|NCT02485197|Muscle Metabolic Function
909466|NCT02485197|Vitamin D Status
909467|NCT02485197|25(OH)D
909468|NCT02485197|Older Adults
909469|NCT02485158|Subjective Effects
909470|NCT02485158|Alcohol
909471|NCT02485158|Amphetamine
909472|NCT02485158|THC
909473|NCT02485158|Personality
909474|NCT02485145|Topical
909475|NCT02485145|Hand osteoarthritis
909480|NCT02485119|BAY 94-9343
909481|NCT02485119|Anetumab ravtansine
909482|NCT02485119|ADC (Antibody Drug Conjugate)
909483|NCT02485119|Phase I
909484|NCT02485119|Japan
909485|NCT02485119|solid cancers
909486|NCT02485119|Advanced, refractory solid tumors
909487|NCT02485119|mesothelin
909488|NCT02485119|endometrial
909489|NCT02485119|adenocarcinoma of lung
909490|NCT02485119|gastrointestinal, ovarian, pancreatic, cholangio, mesothelioma and triple negative breast cancers
909491|NCT02485080|hepatitis C
909492|NCT02485080|liver transplantation
909493|NCT02485080|genotype 1
909494|NCT02485067|Overactive Bladder
909495|NCT02485067|Tolterodine (Detrusitol)
909496|NCT02485067|Pilocarpine
909497|NCT02485041|Dapoxetine
909498|NCT02485041|Mirodenafil
909499|NCT02485041|DDI study
909500|NCT02485028|Dapoxetine
909501|NCT02485028|Mirodenafil
909502|NCT02485028|DDI study
909503|NCT02485015|CIK
909504|NCT02485015|gastric cancer
909505|NCT02485015|Apatinib
909506|NCT02485002|kidney
909507|NCT02485002|kidney stone
909508|NCT02485002|NGAL
909509|NCT02485002|ureterorenoscopy
909510|NCT02485002|intrarenal surgery
909511|NCT02485002|kidney function
909512|NCT02484976|Family Based Behavioral Treatment
909513|NCT02484976|functional magnetic resonance imaging (fMRI)
909514|NCT02484976|Childhood Obesity
909515|NCT02484976|Satiety
909516|NCT02484976|BMI z-score
909517|NCT02484976|Impulsive
909518|NCT02484976|Non-obese controls
909519|NCT02484976|Visual food cues
909520|NCT02484976|Leptin
909521|NCT02484976|Hormones
909522|NCT02484950|Mesenchymal stem cells
909523|NCT02484937|Pain management
909524|NCT02484911|chemotherapy nausea vomiting
909525|NCT02484885|Magnetic Resonance Imaging
909526|NCT02484885|Pulmonary Function
909527|NCT02484872|Inflammation
909528|NCT02484872|Glasgow score
909529|NCT02484872|Intensive Care Unit
909530|NCT02484872|Emergency
909531|NCT02484859|Drug: remifentanil
909532|NCT02484859|Drug: tramadol
909533|NCT02484859|Drug: metoprolol
909534|NCT02484859|Functional endoscopic sinus surgery
909535|NCT02484859|Controlled hypotension
909536|NCT02484833|First line
909537|NCT02484833|metastatic colorectal cancer
909538|NCT02484833|Cetuximab
909539|NCT02484833|strategy study
909540|NCT02484820|Preterm Birth
909541|NCT02484820|pessary
909542|NCT02484820|threatened preterm labor
909543|NCT02484794|Eating Disorders
909544|NCT02484794|Smartphone
909545|NCT02484794|App
909546|NCT02484794|Mobile Health
909547|NCT02484794|Recovery Record
909548|NCT02484794|Cognitive Behavioural Therapy
909549|NCT02484794|Outpatient Program
909550|NCT02484794|Self Monitoring
909551|NCT02484781|Gait disorder
909552|NCT02484781|Resurfacing Hip Arthroplasty
909553|NCT02484781|Total Hip Arthroplasty
909554|NCT02484729|AZD9977
909555|NCT02484729|Safety
909556|NCT02484729|Tolerability
909557|NCT02484729|Pharmacokinetics
909558|NCT02484729|First-in-human
909559|NCT02484729|Single Ascending Dose
909560|NCT02484729|Regional absorption
909561|NCT02484729|Healthy male subjects
909565|NCT02484651|deep neuromuscular block
909566|NCT02484651|sugammadex
909567|NCT02484651|stability of anesthesia
909568|NCT02484651|suppression of EMG activity
909569|NCT02484651|PQRS
909570|NCT02484651|General Anesthesia
909571|NCT02484651|Quality of Recovery
909572|NCT02484625|snacking
909573|NCT02484625|food intake
909574|NCT02484625|satiety
909575|NCT02484625|obesity
909576|NCT02484625|type-2 diabetes
909577|NCT02484599|Eating Disorders
909578|NCT02484599|Anorexia Nervosa
909579|NCT02484599|Attention bias
909580|NCT02484599|Attention bias modification
909581|NCT02484586|Presbyopia
909582|NCT02484586|Refractive error
909583|NCT02484586|Contact lens
909584|NCT02484573|Cirrhosis
909585|NCT02484573|Variceal Bleeding
909586|NCT02484573|Non-selective beta blocker
909587|NCT02484573|Intestinal Permeability
909588|NCT02484573|Gene expression
909589|NCT02484573|Bacterial translocation
909590|NCT02484560|Duchenne Muscular Dystrophy
909591|NCT02484560|Neuromuscular Diseases
909592|NCT02484560|Muscular Dystrophy
909593|NCT02484560|Genetic Diseases, X-linked
909594|NCT02484560|Musculoskeletal Diseases
909595|NCT02484560|Nervous System Diseases
909596|NCT02484547|Aducanumab
909597|NCT02484547|BIIB037
909598|NCT02484534|Coagulation Factor
909599|NCT02484534|cirrhosis
909600|NCT02484508|Guli capsule
909601|NCT02484508|knee osteoarthritis
909602|NCT02484508|Changing of WOMAC and VAS score
909603|NCT02484495|Complementary feeding recommendation
909604|NCT02484495|Program evaluation
909605|NCT02484495|Process and impact evaluation
909606|NCT02484456|Major Depression
909607|NCT02484456|Glycine Receptor Antagonist
909608|NCT02484456|4-Chlorokyneurenine
909609|NCT02484456|Treatment Resistant
909610|NCT02484456|Glutamatergic System
909611|NCT02484417|Neutralizing Antibody
909612|NCT02484417|Viral Shedding
909613|NCT02484417|Mucosal Immune Reponse
909614|NCT02484417|Upper Respiratory Infection
909615|NCT02484404|Immune Checkpoint Inhibitor
909616|NCT02484404|PARP Inhibitor
909617|NCT02484404|VEGFR Inhibitor
909618|NCT02484378|ACS
909619|NCT02484378|IVUS
909620|NCT02484378|HDL
909621|NCT02484365|Hemoglobins
909622|NCT02484365|Monitoring, Outpatient
909623|NCT02484365|Preoperative Period
909624|NCT02484365|Pediatrics
909625|NCT02484352|dosage of oxycodone during intubation
909626|NCT02484326|ST-elevation myocardial infarction
909627|NCT02484326|Cardiac rupture
909628|NCT02484326|Risk assessment
909629|NCT02484300|loop gain
909630|NCT02484300|chemoreflex control
909631|NCT02484300|melatonin
909632|NCT02484300|antioxidant
909633|NCT02484300|obstructive sleep apnea
909634|NCT02484300|ventilatory control
909635|NCT02484274|iron-deficiency
909636|NCT02484274|iron-deficiency anemia
909637|NCT02484274|infants and toddlers
909638|NCT02484274|industrialised countries
909639|NCT02484274|population-based study
909640|NCT02484274|prevalence and risk factors
909641|NCT02484274|screening strategies
909642|NCT02484274|diagnosis markers
909643|NCT02484274|primary prevention
909644|NCT02484261|childhood leukemia
909645|NCT02484261|relapsed leukemia
909646|NCT02484261|Hematopoietic Stem Cell Transplantation
909647|NCT02484235|obesity
909648|NCT02484235|exercise
909649|NCT02484235|HIIT
909650|NCT02484235|Vo2
909651|NCT02484235|kinetics
909652|NCT02484222|adenotonsillectomy
909653|NCT02484222|fentanyl
909654|NCT02484209|diabetes
909655|NCT02484209|frailty
909656|NCT02484209|aged
909657|NCT02484209|metformin
909658|NCT02484209|sulphonylurea
909659|NCT02484209|hypoglycaemia
909660|NCT02484183|bubble continuous positive airway pressure (CPAP)
909661|NCT02484183|pneumonia
909662|NCT02484183|Human Immunodeficiency Virus (HIV)
909663|NCT02484183|malnutrition
909664|NCT02484183|Malawi
909665|NCT02484183|Africa
909666|NCT02484183|Noninvasive Ventilation
909667|NCT02484183|child
909668|NCT02484183|pediatric
909669|NCT02484183|hypoxemia
909670|NCT02484170|Mannitol
909671|NCT02484170|cream
909672|NCT02484170|neuropathic pain
909673|NCT02484157|Whole Blood Coagulation Time
909674|NCT02484157|cardiac surgery
909675|NCT02484144|information
909676|NCT02484144|coronarography
909677|NCT02484144|understanding
909678|NCT02484131|Osteoporosis
909679|NCT02484131|DXA Screening
909680|NCT02484131|Women
909681|NCT02484131|Breast Cancer
909682|NCT02484131|Survivors
909683|NCT02484131|Educational materials
909684|NCT02484131|Personal choices on delivery methods
909685|NCT02484092|Hemophilia B
909686|NCT02484092|Blood Coagulation Disorders
909687|NCT02484092|Gene Therapy
909688|NCT02484092|Gene Transfer
909689|NCT02484092|Factor IX Deficiency
909690|NCT02484092|Factor IX Gene
909691|NCT02484092|Factor IX Protein
909692|NCT02484092|Vector
909693|NCT02484092|AAV
909694|NCT02484066|Virtual bronchoscopic navigation
909695|NCT02484066|Endobronchial ultrasound
909696|NCT02484066|Guide Sheath
909697|NCT02484066|Transbronchial biopsy
909698|NCT02484066|Peripheral pulmonary lesions
909699|NCT02484053|adult and pediatric cancers
909700|NCT02484053|blood disorders
909701|NCT02484053|lymphoma
909702|NCT02484053|graft-versus-host-disease
909703|NCT02484053|diseases of the immune system
909704|NCT02484040|tumor response
909705|NCT02484040|toxicity
909706|NCT02484040|recurrence
909707|NCT02484040|chemoradiotherpy
909708|NCT02484040|rectum
909709|NCT02484027|acute ischemic stroke
909710|NCT02484027|mRS
909711|NCT02484027|rosuvastatin
909712|NCT02484001|Eslicarbazepine acetate
909713|NCT02484001|BIA 2-093
909714|NCT02484001|Epilepsy
909715|NCT02483975|Fluticasone Furoate
909716|NCT02483975|Asthma
909717|NCT02483975|HPA axis
909718|NCT02483975|Children
909719|NCT02483975|Inhaled corticosteroid
909720|NCT02483962|Chronic
909721|NCT02483923|serratus anterior block
909722|NCT02483923|ultrasound
909723|NCT02483923|breast cancer
909724|NCT02483923|postoperative pain
909725|NCT02483910|school-age children
909726|NCT02483884|Bombesin
909727|NCT02483884|Gastrin-Releasing Peptide
909728|NCT02483884|Prostatic Neoplasms
909729|NCT02483884|Genital Diseases, Male
909730|NCT02483884|Genital Neoplasms, Male
909731|NCT02483884|Neoplasms
909732|NCT02483884|Neoplasms by Site
909733|NCT02483884|Urogenital Neoplasms
909734|NCT02483884|Gastrointestinal Agents
909735|NCT02483884|Molecular Mechanisms of Pharmacological Action
909736|NCT02483884|Neurotransmitter Agents
909737|NCT02483884|Pharmacologic Actions
909738|NCT02483884|Physiological Effects of Drugs
909739|NCT02483884|Therapeutic Uses
909740|NCT02483871|Estrogen Receptor Positive
909741|NCT02483858|oncology, solid tumors
909742|NCT02483819|Elderly patient
909743|NCT02483819|NICOM
909744|NCT02483819|TURP
909745|NCT02483767|Premenopausal Breast Cancer
909746|NCT02483767|Preservation of Ovarian Function
909747|NCT02483767|Gonadotropin-Releasing Hormone Agonist
909748|NCT02483728|Metal Allergy
909749|NCT02483715|Helicobacter pylori
909750|NCT02483715|high dose dual therapy
909751|NCT02483715|bismuth-containing quadruple therapy
909752|NCT02483715|antibiotic resistance
909753|NCT02483702|Irradiated Blood
909754|NCT02483702|Non-Irradiated Blood
909755|NCT02483702|graft versus host disease
909756|NCT02483702|TA-GVHD
909757|NCT02483702|potassium
909758|NCT02483702|Blood transfusion
909759|NCT02483689|Post Operative Pain
909760|NCT02483689|Appendicitis
909761|NCT02483689|Appendectomy
909762|NCT02483689|Local Anesthetic
909763|NCT02483689|Saline
909764|NCT02483689|Pain Management
909765|NCT02483689|Surgery
909766|NCT02483689|Recovery
909767|NCT02483676|Rehabilitation
909768|NCT02483676|Robotics
909769|NCT02483676|Gait
909770|NCT02483663|Twins
909771|NCT02483663|Obesity
909772|NCT02483663|Appetite
909777|NCT02483611|Onset
909778|NCT02483611|Recovery
909779|NCT02483611|Lidocaine
909780|NCT02483611|Cisatracurium
909781|NCT02483611|Magnesium sulfate
909782|NCT02483611|Isotonic solution
909783|NCT02483598|buspirone
909784|NCT02483598|pharmacokinetics
909785|NCT02483598|Cytochrome P450 3A4
909786|NCT02483585|Migraine
909787|NCT02483585|Headache
909788|NCT02483585|Episodic
909789|NCT02483585|Prevention
909790|NCT02483585|Prophylaxis
909791|NCT02483559|Sleep
909792|NCT02483559|Photoreceptor Cells, Vertebrate
909793|NCT02483559|Melatonin
909794|NCT02483546|Medical education
909795|NCT02483546|simulation
909796|NCT02483546|ACLS
909797|NCT02483520|Family caregiver
909798|NCT02483507|Ultrasound guidance
909799|NCT02483507|Vascular access
909800|NCT02483507|Pediatric anesthesia
909801|NCT02483494|Telemedicine
909802|NCT02483494|Advanced Practice Nurse
909803|NCT02483481|sinusoidal obstruction syndrome
909804|NCT02483481|ultrasound elastography
909805|NCT02483481|bone marrow transplant
909806|NCT02483429|Vertigo
909807|NCT02483429|Dizziness
909808|NCT02483429|Unsteadiness
909809|NCT02483429|Stroke
909810|NCT02483429|Vestibular neuritis
909811|NCT02483429|Benign paroxysmal positional vertigo
909812|NCT02483429|Vestibulo-ocular reflex
909813|NCT02483429|Video-oculography
909814|NCT02483429|Emergency department
909815|NCT02483403|Magnetic Resonance Imaging
909816|NCT02483403|Pulmonary Function
909817|NCT02483403|Volunteers
909818|NCT02483390|palliative care
909819|NCT02483390|e-health
909820|NCT02483390|e-therapy
909821|NCT02483390|psychosocial services
909822|NCT02483377|Sign or Symptom
909823|NCT02483351|Blood Transfusion
909824|NCT02483338|Psychometric validity
909825|NCT02483338|Pain scale
909826|NCT02483338|Postoperative
909827|NCT02483338|Children
909828|NCT02483312|Recurrent
909829|NCT02483299|response to therapy
909830|NCT02483286|Osteoporosis
909831|NCT02483286|Fall
909832|NCT02483286|Fracture
909833|NCT02483286|sarcopenia
909834|NCT02483286|Exercise
909835|NCT02483273|Conjunctival microcirculation
909836|NCT02483273|Sublingual microcirculation
909837|NCT02483273|Sidestream Dark Field (SDF) microscopy
909838|NCT02483247|Neoplasms
909839|NCT02483195|Hair loss
909840|NCT02483195|Post Menopausal
909841|NCT02483182|Herpes labialis, Cold sores, ZEP-3 ointment
909842|NCT02483169|ischemic stroke
909843|NCT02483169|intracranial hemorrhage
909844|NCT02483169|cilostazol
909845|NCT02483169|probucol
909846|NCT02483169|intima media thickness
909847|NCT02483156|HCV
909848|NCT02483156|Sofosbuvir
909849|NCT02483156|Ribavirin
909850|NCT02483143|contrast media
909851|NCT02483143|pulmonary embolism
909852|NCT02483143|N-acetylcysteine
909853|NCT02483104|ABT-888
909854|NCT02483104|BRCA
909855|NCT02483104|Primary peritoneal cancer
909856|NCT02483104|carboplatin
909857|NCT02483104|Fallopian tube
909858|NCT02483104|Poly (ADP-ribose) polymerase (PARP)
909859|NCT02483104|paclitaxel
909860|NCT02483104|Ovarian cancer
909861|NCT02483104|veliparib
909862|NCT02483091|Knowledge translation
909863|NCT02483091|Clinical practice guidelines
909864|NCT02483091|Multimodal care
909865|NCT02483091|Brief Action Planning
909866|NCT02483091|Feasibility outcomes
909867|NCT02483065|dementia
909868|NCT02483065|hospital admission
909869|NCT02483065|mortality
909870|NCT02483065|health-related quality of life
909871|NCT02483065|activities of daily living
909872|NCT02483052|lobectomy
909873|NCT02483052|spray cryotherapy
909874|NCT02483052|lung cancer
909875|NCT02483039|Acute kidney injury
909876|NCT02483039|Chronic kidney disease
909877|NCT02483039|Quality improvement
909878|NCT02483013|whitening dentifrices
909879|NCT02483013|color alteration
909880|NCT02483013|tooth sensitivity
909881|NCT02482987|dental
909882|NCT02482987|extraction
909883|NCT02482987|socket preservation
909884|NCT02482987|ridge preservation
909885|NCT02482987|implant site preparation
909886|NCT02482974|Liver transplantation
909887|NCT02482974|Everolimus
909888|NCT02482974|Sirolimus
909889|NCT02482974|Treatment outcome
909890|NCT02482974|Safety
909891|NCT02482948|Debridement
909892|NCT02482948|collagenase
909893|NCT02482948|leptospermum honey
909894|NCT02482922|feasibility studies
909895|NCT02482922|intervention
909896|NCT02482922|Pre-Hypertensive
909897|NCT02482922|Pre-Hyperlipidemia
909898|NCT02482844|TAVI
909899|NCT02482844|de novo and persistent LBBB
909900|NCT02482844|electrophysiology
909901|NCT02482844|Holter
909902|NCT02482844|pacemaker
909903|NCT02482831|Sciatic nerve block
909904|NCT02482831|block duration
909905|NCT02482831|Semmes Weinstein monofilaments
909906|NCT02482831|fasting blood glucose
909907|NCT02482831|nerve block
909908|NCT02482831|sensory block duration
909909|NCT02482831|motor block duration
909910|NCT02482818|chronic cough
909911|NCT02482818|cough hypersensitivity
909912|NCT02482818|Lyrica
909913|NCT02482818|Pregabalin
909914|NCT02482818|cough reflex sensitivity
909915|NCT02482792|Musculoskeletal disorders
909916|NCT02482792|Psychosomatic
909917|NCT02482792|Pain
909918|NCT02482753|Chidamide
909919|NCT02482753|breast cancer
909920|NCT02482753|exemestane
909921|NCT02482753|Estrogen Receptor
909922|NCT02482740|Uterine Cervical Neoplasms
909923|NCT02482740|antiestrogens
909924|NCT02482727|Blood Flow Restriction
909925|NCT02482727|Occlusion training
909926|NCT02482727|Distal radius fracture
909927|NCT02482714|Quality of Life
909928|NCT02482714|Physical Activity
909929|NCT02482701|EMR
909930|NCT02482701|EAC
909931|NCT02482701|Barrett's Neoplasia
909932|NCT02482701|Multiband Mucosectomy
909933|NCT02482675|Dairy
909934|NCT02482675|Milk
909935|NCT02482675|Glucose
909936|NCT02482675|Postprandial
909937|NCT02482675|Hyperglycemia
909938|NCT02482675|Prediabetes
909939|NCT02482675|Blood glucose
909940|NCT02482675|Oxidative stress
909941|NCT02482675|Vascular health
909942|NCT02482675|Vascular function
909943|NCT02482662|Diagnosis
909944|NCT02482636|infant immunisations
909945|NCT02482636|vaccines
909946|NCT02482636|paediatric
909947|NCT02482636|pneumococcal
909948|NCT02482636|meningococcal
909949|NCT02482623|Dementia
909950|NCT02482623|neuropsychiatric symptoms
909951|NCT02482623|implementation science
909952|NCT02482623|depression
909953|NCT02482623|pain
909954|NCT02482610|Dairy
909955|NCT02482610|Milk
909956|NCT02482610|Glucose
909957|NCT02482610|Postprandial
909958|NCT02482610|Hyperglycemia
909959|NCT02482610|Prediabetes
909960|NCT02482610|Blood glucose
909961|NCT02482610|Oxidative stress
909962|NCT02482610|Vascular health
909963|NCT02482610|Vascular function
909964|NCT02482571|Functional MRS
909965|NCT02482571|Functional MRI
909966|NCT02482558|Glycaemic Index
909967|NCT02482558|NAFLD
909968|NCT02482558|Glycogen
909969|NCT02482558|Liver
909970|NCT02482558|Diet
909971|NCT02482532|Melanoma
909972|NCT02482532|metastatic
909973|NCT02482532|relapsed
909974|NCT02482532|refractory
909975|NCT02482506|African American
909976|NCT02482506|Overweight
909977|NCT02482506|Adults
909978|NCT02482480|SLEEP
909979|NCT02482480|APNEA
909980|NCT02482480|EXERCISE
909981|NCT02482467|ovarian cyst
909982|NCT02482467|prenatal diagnosis
909983|NCT02482467|puberty
909984|NCT02482454|radiofrequency ablation
909985|NCT02482454|cytokine-induced killer cells
909986|NCT02482454|cholangiocarcinoma
909987|NCT02482441|Advanced Solid Tumors and in Combination
909988|NCT02482441|FOLFIRI for Patients with Previously Treated Metastatic
909989|NCT02482441|Colorectal Cancer
909991|NCT02482415|Palliative Care
909992|NCT02482415|Randomized controlled trial
909993|NCT02482415|Family caregivers
909994|NCT02482415|Intervention
909995|NCT02482415|Family
909996|NCT02482415|Intervention studies
909997|NCT02482415|Home Care
909998|NCT02482311|AZD1775
909999|NCT02482311|Ovarian cancer (BRCA1/2 mutation)
910000|NCT02482311|Ovarian cancer (PARP-failure)
910001|NCT02482311|Triple negative breast cancer (TNBC)
910002|NCT02482311|Small-cell lung cancer (SCLC)
910003|NCT02482311|Solid tumours
910004|NCT02482298|Sickle cell disease
910005|NCT02482298|Young adults
910006|NCT02482298|Hestia2
910007|NCT02482298|Ticagrelor
910008|NCT02482233|electronic cigarette
910009|NCT02482233|nicotine replacement therapy
910010|NCT02482233|smoking cessation
910011|NCT02482233|perioperative
910012|NCT02482194|Spinal cord injury
910013|NCT02482194|mesenchymal stem cells
910014|NCT02482194|transplantation
910015|NCT02482181|diffusion weighted magnetic resonance imaging
910016|NCT02482168|immunotherapy
910017|NCT02482168|CD40
910018|NCT02482155|pharmacokinetics
910019|NCT02482155|MOMENTACT
910020|NCT02482155|ibuprofen 400 mg
910021|NCT02482155|oral
910022|NCT02482155|granules
910023|NCT02482142|phosphorus
910024|NCT02482142|lean
910025|NCT02482142|obese
910026|NCT02482142|energy expenditure
910027|NCT02482129|Acute anterior uveitis
910028|NCT02482129|LME636
910029|NCT02482116|malaria
910030|NCT02482116|pneumonia
910031|NCT02482116|Nigeria
910032|NCT02482116|IMCI
910033|NCT02482116|diagnosis
910034|NCT02482103|Therapy resistant hypertension
910035|NCT02482051|Carbapenem-resistant Enterobacteriaceae
910036|NCT02482051|Accelerate ID/AST
910037|NCT02482025|Medications
910038|NCT02482025|Hospitalization
910039|NCT02482025|Electronic medical records
910040|NCT02482012|research
910041|NCT02482012|vulnerable population
910042|NCT02482012|45 CFR 46.406
910043|NCT02481999|Depth of anesthesia
910044|NCT02481973|PMS
910045|NCT02481973|Homoeopathy
910046|NCT02481973|Grant Bentley Method
910047|NCT02481934|Recurrent multiple myeloma
910048|NCT02481934|NK cells
910049|NCT02481934|cell therapy
910050|NCT02481934|NKAE
910051|NCT02481934|Relapsed multiple myeloma
910052|NCT02481921|heart failure
910053|NCT02481921|self-management
910054|NCT02481921|group intervention
910055|NCT02481908|AECOPD
910056|NCT02481908|left ventricular dysfunction
910057|NCT02481908|valsalva maneuver
910058|NCT02481908|systolic time intervals
910059|NCT02481895|cognition
910060|NCT02481895|psychosocial functioning
910061|NCT02481869|Closed
910062|NCT02481869|unilateral
910063|NCT02481869|pilon
910064|NCT02481843|Hyperoxia
910065|NCT02481843|Microcirculation
910066|NCT02481843|Erythropoietin
910067|NCT02481843|Normobaric Oxygen Paradox
910068|NCT02481804|diet
910069|NCT02481804|vitamin
910070|NCT02481778|Radiotherapy
910071|NCT02481778|Cardiac
910072|NCT02481778|Toxicity
910073|NCT02481752|Tobacco Use
910074|NCT02481752|Nicotine Dependence
910075|NCT02481739|endometriosis
910076|NCT02481739|fertility
910077|NCT02481739|endometriosis surgery
910078|NCT02481726|68Ga
910079|NCT02481726|Alfatide II
910080|NCT02481726|RGD
910081|NCT02481726|αvβ3
910082|NCT02481726|PET/CT
910083|NCT02481713|psychosis
910084|NCT02481713|adherence
910085|NCT02481713|motivation
910086|NCT02481674|Prodromal Stage
910087|NCT02481674|Early Manifest Stage
910088|NCT02481635|Blood Vessels
910089|NCT02481635|Reconstructive Surgery
910090|NCT02481622|HIV infection
910091|NCT02481622|vaginal tissues
910092|NCT02481622|uterine tissues
910093|NCT02481609|Loss of Smell
910094|NCT02481609|Olfaction
910095|NCT02481609|Hyposmia
910096|NCT02481596|family
910097|NCT02481596|support
910098|NCT02481596|diet
910099|NCT02481596|exercise
910100|NCT02481596|social
910101|NCT02481583|levosulpiride
910102|NCT02481583|pharmacokinetics
910103|NCT02481583|adverse effects
910104|NCT02481583|bioavailability
910105|NCT02481570|Adolescent Idiopathic Scoliosis
910106|NCT02481570|Scoliosis surgery
910107|NCT02481570|Pharmacokinetic simulation
910108|NCT02481518|Cisplatin nephrotoxicity
910109|NCT02481518|Acute kidney injury
910110|NCT02481492|Circumcision, Male
910111|NCT02481492|Shang Ring
910112|NCT02481492|Children
910113|NCT02481492|Foreskin
910114|NCT02481466|Arterial plaque
910115|NCT02481466|Magnetic resonance imaging (MRI)
910116|NCT02481466|Portfolio diet
910117|NCT02481466|Dietary modification
910118|NCT02481466|Dietary trials
910119|NCT02481466|hypercholesterolemia
910120|NCT02481466|diabetes
910121|NCT02481466|exercise
910122|NCT02481466|cardiovascular disease risk
910123|NCT02481466|glycemic index (GI)
910124|NCT02481466|Carotid Ultrasound
910125|NCT02481466|Dietary Approaches to Stop Hypertension (DASH) diet
910126|NCT02481440|umbilical cord mesenchymal stem cells
910127|NCT02481440|spinal cord injury
910128|NCT02481427|Total
910129|NCT02481427|Unicondylar
910130|NCT02481427|Osteoarthritis
910131|NCT02481427|Arthroplasty
910132|NCT02481427|Replacement
910133|NCT02481427|Knee
910134|NCT02481414|HSIL, CIN II/III
910135|NCT02481401|cardiovascular health
910136|NCT02481401|behavior change
910137|NCT02481401|community-based
910138|NCT02481401|family-based
910139|NCT02481401|prevention
910140|NCT02481375|iron
910141|NCT02481375|ferritin
910142|NCT02481375|soluble transferrin receptor
910143|NCT02481375|hepcidin
910144|NCT02481375|reticulocyte count
910145|NCT02481375|hemoglobin
910146|NCT02481375|supplementation
910147|NCT02481349|Glioma
910148|NCT02481349|Hatha yoga
910149|NCT02481349|Questionnaires
910150|NCT02481349|Surveys
910151|NCT02481336|Chemotherapy
910152|NCT02481336|Peripheral Neuropathy
910153|NCT02481323|cerebral small vessel disease
910154|NCT02481323|cerebrovascular reactivity
910155|NCT02481323|cilostazol
910156|NCT02481323|isosorbide mononitrate
910167|NCT02481284|Breast reconstruction
910168|NCT02481284|Deep inferior epigastric artery perforator flap
910169|NCT02481284|Skin perfusion
910170|NCT02481284|Plastic and reconstructive surgery
910171|NCT02481271|cholecystectomy
910172|NCT02481258|Stenosis
910173|NCT02481258|Aortic Valve
910174|NCT02481258|Aorta
910175|NCT02481258|Calcified
910176|NCT02481258|Calcific
910177|NCT02481258|Calcification
910178|NCT02481245|Bipolar Disorder
910179|NCT02481245|Bezafibrate
910180|NCT02481245|Depressive Episode
910181|NCT02481219|Polyps
910182|NCT02481219|Capsule endoscopy
910183|NCT02481219|Bowel preparation regimen
910184|NCT02481219|Average risk patients for colorectal cancer screening
910185|NCT02481206|Ventricular Tachycardia
910186|NCT02481193|Cisatracurium
910187|NCT02481193|Myalgia
910188|NCT02481193|Fasciculation
910189|NCT02481193|Succinylcholine
910190|NCT02481167|Aged
910191|NCT02481167|Meibomian Glands
910192|NCT02481167|dry eye
910193|NCT02481167|Elderly
910194|NCT02481154|Glioma
910195|NCT02481154|IDH1
910196|NCT02481154|IDH2
910197|NCT02481154|Dual Mutation
910198|NCT02481154|AG-881
910199|NCT02481128|lymphoscintigraphy
910200|NCT02481128|sentinel lymph node biopsy
910201|NCT02481076|malleolar fractures
910202|NCT02481076|ORIF
910203|NCT02481076|compression
910204|NCT02481076|infection
910205|NCT02481076|wound dehisence
910206|NCT02481063|Eccentric
910207|NCT02481063|Running
910208|NCT02481063|Muscle
910209|NCT02481063|Tendon
910210|NCT02481063|Ultrasound
910211|NCT02481063|Thermography
910212|NCT02481050|Eribulin Mesylate
910213|NCT02481050|Human Epidermal Growth Factor Receptor 2
910214|NCT02481050|Metastatic Breast Cancer
910215|NCT02481050|HER2-Negative
910216|NCT02481024|Qualitative
910217|NCT02481024|Care transition
910218|NCT02481024|Medication
910219|NCT02481011|Fibrinolytic agents
910220|NCT02481011|Adverse effects
910221|NCT02481011|Registries
910222|NCT02481011|Incidence
910223|NCT02481011|Risk assessment
910224|NCT02480985|Pituitary Disorders
910225|NCT02480985|Traumatic Brain Injury
910226|NCT02480985|Critical Care
910227|NCT02480985|Outcome Research
910228|NCT02480985|Risk Factors
910229|NCT02480985|Patient Oriented Research
910230|NCT02480972|fibrosis
910231|NCT02480972|cirrhosis
910232|NCT02480972|MRI
910233|NCT02480946|Rheumatoid Arthritis
910234|NCT02480946|Osteoclastogenesis inhibitor
910235|NCT02480946|Anti-Inflammatory Agent
910236|NCT02480946|Musculoskeletal Diseases
910237|NCT02480946|Joint Diseases
910238|NCT02480920|Atrial fibrillation Drug Adherence
910239|NCT02480920|New Oral Anticoagulants
910240|NCT02480920|Drug Adherence
910241|NCT02480907|eating disorders
910242|NCT02480907|caregivers
910243|NCT02480907|parents
910244|NCT02480907|skills training
910245|NCT02480907|workshops
910246|NCT02480907|support
910247|NCT02480907|internet
910248|NCT02480907|online
910249|NCT02480907|family
910250|NCT02480855|work related stress
910251|NCT02480855|questionnaire
910252|NCT02480855|early identification
910253|NCT02480842|Breast Neoplasms
910254|NCT02480842|Mammaplasty
910255|NCT02480842|Breast Implantation
910256|NCT02480842|Range of Motion, Articular
910257|NCT02480842|Shoulder Joint
910258|NCT02480842|Physical Therapy Modalities
910259|NCT02480803|Parkinson
910260|NCT02480803|Parkinson's Disease
910261|NCT02480803|Deep Brain Stimulation
910262|NCT02480803|levodopa-carbidopa
910263|NCT02480803|Duodopa
910264|NCT02480803|continuous intrajejunal infusion
910265|NCT02480764|Drug therapy
910266|NCT02480751|Chronic Renal Failure
910267|NCT02480751|Prostaglandin
910268|NCT02480751|Prostacyclin
910269|NCT02480751|Glomerular Disease; Nephrosclerosis
910270|NCT02480738|subjective cognitive impairment
910271|NCT02480725|CJD
910272|NCT02480725|CSF
910273|NCT02480725|prion
910274|NCT02480725|thrombin
910275|NCT02480673|Metabolic Syndrome X
910276|NCT02480673|Chia
910277|NCT02480673|Dyslipidemia
910278|NCT02480660|Hospitalized
910279|NCT02480660|adolescents
910280|NCT02480660|knowledge
910281|NCT02480660|transition
910282|NCT02480660|educational intervention
910283|NCT02480634|zoledronic acid
910284|NCT02480634|radiotherapy
910285|NCT02480595|Abdominal Aortic Aneurysm
910286|NCT02480595|AAA
910287|NCT02480595|Endovascular
910288|NCT02480595|EVAR
910289|NCT02480595|Stent
910290|NCT02480595|Stent Graft
910291|NCT02480595|High Angle
910292|NCT02480595|Tortuous
910293|NCT02480556|blood loss; caesarean section ; manual placental separation
910294|NCT02480530|Medication Adherence
910295|NCT02480530|Reciprocal Peer
910296|NCT02480530|Telemonitoring
910297|NCT02480517|Hypertension
910298|NCT02480517|Renal Denervation
910299|NCT02480478|Intrahepatic Cholestasis of Pregnancy
910300|NCT02480439|Drug Therapy
910301|NCT02480413|Broselow Tape
910302|NCT02480413|Weight estimation
910303|NCT02480413|Patient safety
910304|NCT02480400|MDD
910305|NCT02480400|Escitalopram
910306|NCT02480400|Placebo
910307|NCT02480361|Acupuncture
910308|NCT02480361|Gastric cancer
910309|NCT02480322|metabolic alterations
910310|NCT02480257|intervention
910311|NCT02480257|emotion regulation
910312|NCT02480257|fMRI
910313|NCT02480257|mindfulness
910314|NCT02480257|yoga-based movement
910315|NCT02480231|Tension-Free Vaginal Tape
910316|NCT02480231|Suburethral Slings
910317|NCT02480231|Midurethral Slings
910318|NCT02480231|Mid-urethral sling
910319|NCT02480231|urinary retention
910320|NCT02480218|cognition
910321|NCT02480218|tamoxifen
910322|NCT02480218|aromatase inhibitors
910323|NCT02480205|CPAP
910324|NCT02480205|NIV
910325|NCT02480205|NIPPV
910326|NCT02480205|Edi
910327|NCT02480192|Vasomotor
910328|NCT02480192|Symptoms
910329|NCT02480179|functional MRI
910330|NCT02480179|appetite
910331|NCT02480179|neurofeedback
910332|NCT02480166|hepatitis C, genotype 6
910333|NCT02480153|Phase 3
910334|NCT02480153|adalimumab
910335|NCT02480153|rheumatoid arthritis
910336|NCT02480140|Self-regulation
910337|NCT02480140|Constraint-induced movement therapy
910338|NCT02480140|Stroke
910339|NCT02480140|Functional recovery
910340|NCT02480140|Randomized controlled trial
910341|NCT02480101|influenza vaccine pandemic
910342|NCT02480075|Genetic Variation
910343|NCT02480075|Genetic Polymorphism
910344|NCT02480075|Polymorphism, Single Nucleotide
910345|NCT02480075|Genetic Association Studies
910346|NCT02480062|Decision Support System
910347|NCT02480062|mHealth
910348|NCT02480062|Primary Health Care
910349|NCT02480062|Non-communicable diseases
910350|NCT02480036|IORT
910351|NCT02480036|Kyphoplasty
910352|NCT02480036|Spine
910353|NCT02480036|Cancer
910354|NCT02479997|Neoadjuvant chemotherapy
910355|NCT02479997|Indocyanine green (ICG)
910356|NCT02479997|Radioisotope (RI)
910357|NCT02479997|Near infrared fluorescence camera
910358|NCT02479984|staging laparoscopy
910359|NCT02479984|pancreatic cancer
910360|NCT02479984|biliary cancer
910361|NCT02479958|Photochemotherapy
910362|NCT02479958|Bacteria
910363|NCT02479932|Extra-peritoneal cesarean
910364|NCT02479932|Intra-peritoneal cesarean
910365|NCT02479919|theta burst stimulation
910366|NCT02479919|Social Cognition
910367|NCT02479919|Schizophrenia
910368|NCT02479919|transcranial magnetic stimulation
910369|NCT02479906|Post-Traumatic Stress Disorder
910370|NCT02479906|PTSD
910371|NCT02479906|dTMS
910372|NCT02479893|cold snare polypectomy
910373|NCT02479893|APC
910374|NCT02479893|hot snare polypectomy
910375|NCT02479815|Complementary feeding recommendation
910376|NCT02479815|Program evaluation
910377|NCT02479815|Process and impact evaluation
910378|NCT02479815|Micronutrient powder (MNP) safety
910379|NCT02479802|plasma exchange
910380|NCT02479802|albumin
910381|NCT02479789|Intravenous Lidocaine
910382|NCT02479789|Recurrent laryngeal nerve
910383|NCT02479789|Intra operative nerve monitoring
910384|NCT02479789|Thyroidectomy
910385|NCT02479763|Epidural waveform analysis
910386|NCT02479763|Loss of resistance
910387|NCT02479737|Chest tube
910388|NCT02479737|chest drainage
910389|NCT02479737|retained blood complications
910390|NCT02479737|chest tube clogging
910391|NCT02479737|hemothorax
910392|NCT02479737|tamponade
910393|NCT02479737|heart surgery
910394|NCT02479737|pleural effusion
910395|NCT02479737|intensive care
910396|NCT02479724|continuous, non-invasive
910397|NCT02479711|glass ionomer
910398|NCT02479711|bulk fill composite
910413|NCT02479672|breathing tube placement
910414|NCT02479672|VideoTrac® laryngoscope
910415|NCT02479672|direct laryngoscopy
910416|NCT02479659|Immunizations
910417|NCT02479646|Pegfilgrastim
910418|NCT02479646|G-CSF
910419|NCT02479646|Pharmacokinetics
910420|NCT02479646|Pharmacodynamics
910421|NCT02479633|prognostic factors
910422|NCT02479607|Breast Cancer
910423|NCT02479607|Cytostatic Agents
910424|NCT02479607|Nursing
910425|NCT02479607|Health Literacy
910426|NCT02479607|Quality of Life
910427|NCT02479607|Oncology Nursing
910428|NCT02479607|Self Care
910429|NCT02479607|Symptom Management
910430|NCT02479607|Participatory Care
910431|NCT02479607|Person-centered Care
910432|NCT02479607|Information and Communication Technology
910433|NCT02479607|Patient-reported symptoms
910434|NCT02479607|Mobile device
910435|NCT02479594|competence-feedback
910436|NCT02479581|Enhanced Recovery after Surgery
910437|NCT02479568|Cardiovascular disease
910438|NCT02479568|biomarkers
910439|NCT02479568|transcriptomics
910440|NCT02479568|orange juice
910441|NCT02479568|hesperidin
910442|NCT02479568|systolic blood pressure
910443|NCT02479568|metabolomics
910444|NCT02479568|cardiovascular risk factor
910445|NCT02479542|Negative-Pressure Wound Therapy
910446|NCT02479542|Wound Healing
910447|NCT02479542|Global Health
910448|NCT02479542|Cameroon
910449|NCT02479516|Diabetes screening
910450|NCT02479516|Health Promotion
910451|NCT02479516|Low and Middle Income Countries
910452|NCT02479516|CHAP
910453|NCT02479503|antibiotic prophylaxis heart transplantation
910454|NCT02479490|metastatic renal cancer
910455|NCT02479490|failure of VEGFR_TKI
910456|NCT02479490|prednisone
910457|NCT02479490|everolimus
910458|NCT02479477|Public Health
910459|NCT02479477|Nursing Staff, Hospital
910460|NCT02479464|AssureRx
910461|NCT02479464|Algorithm
910462|NCT02479464|Major depressive disorder
910463|NCT02479451|End stage renal disease
910464|NCT02479451|Olfaction
910465|NCT02479451|Dialysis
910466|NCT02479451|Hemodialysis
910467|NCT02479451|Malnutrition
910468|NCT02479425|pressure ulcer
910469|NCT02479425|Positioning
910470|NCT02479412|Mild to moderate asthma
910471|NCT02479412|FEV1
910472|NCT02479412|efficacy
910473|NCT02479412|safety
910474|NCT02479399|Suglat
910475|NCT02479399|SGLT-2 inhibitor
910476|NCT02479399|Ipragliflozin L-Proline
910477|NCT02479399|ASP1941 long-term use
910478|NCT02479347|General surgery
910479|NCT02479347|Postoperative
910480|NCT02479334|Spices
910481|NCT02479334|Functional food
910482|NCT02479334|Cardiometabolic risk
910483|NCT02479334|Metabolic syndrome
910484|NCT02479334|Inflammation
910485|NCT02479334|Peripheral blood mononuclear cell
910486|NCT02479334|Acute
910487|NCT02479321|Perioperative Goal-Directed Hemodynamic Therapy
910488|NCT02479321|Fluid therapy
910489|NCT02479321|Aged
910490|NCT02479321|Perioperative complications
910491|NCT02479321|Survival
910492|NCT02479308|Alkermes
910493|NCT02479308|Samidorphan
910494|NCT02479308|ALKS 5461
910495|NCT02479308|QT/QTc
910496|NCT02479308|Buprenorphine
910497|NCT02479308|Pharmacodynamics
910498|NCT02479269|Brain Natriuretic Peptide
910499|NCT02479269|aerobic execise
910500|NCT02479269|C- Reactive Protein
910501|NCT02479256|PCOS
910502|NCT02479256|Induction of ovulation
910503|NCT02479256|Clomiphene citrate
910504|NCT02479256|Tamoxifen
910505|NCT02479243|Arterial Spin Labeling
910506|NCT02479243|MRI
910507|NCT02479243|Atherosclerotic Stenosis
910508|NCT02479243|Collateral Circulation
910509|NCT02479243|Ischemic stroke
910510|NCT02479230|vaccine
910511|NCT02479230|breast cancer
910512|NCT02479230|metastatic
910513|NCT02479204|safety
910514|NCT02479204|heart rate
910515|NCT02479204|pharmacokinetics
910516|NCT02479191|Abdominal
910517|NCT02479191|Aortic
910518|NCT02479191|Aneurysm
910519|NCT02479152|Mechanical CPR
910520|NCT02479152|Hemodynamics
910521|NCT02479126|Interstitial Lung Disease
910522|NCT02479126|Idiopathic Pulmonary Fibrosis
910523|NCT02479126|Electronic Health Records
910524|NCT02479126|Computed Tomography
910525|NCT02479126|Mortality
910526|NCT02479126|Hospitalization
910527|NCT02479126|Acute care visits
910528|NCT02479126|Anti-inflammatory drug therapies
910529|NCT02479113|GDM
910530|NCT02479113|Maternal Hypertriglyceridaemia
910531|NCT02479100|Contrast Enhanced Spectral Mammography
910532|NCT02479100|Breast
910533|NCT02479100|Cancer
910534|NCT02479100|Diagnosis
910535|NCT02479100|Patient management
910536|NCT02479087|von Willebrand Factor
910537|NCT02479087|Factor VIII
910538|NCT02479087|Hemorrhage
910539|NCT02479087|Immune Tolerance
910540|NCT02479087|Hemophilia A
910541|NCT02479074|Chronic
910542|NCT02479061|Observationnal study
910543|NCT02479061|Prevalence
910544|NCT02479061|Palliative care
910545|NCT02479061|Anti cancer center
910546|NCT02479048|satiety/appetite
910547|NCT02479048|glycemic response
910548|NCT02479048|cardiometabolic risk
910549|NCT02479035|insulin sensitive
910550|NCT02479035|insulin resistant
910551|NCT02479035|red raspberry
910552|NCT02479035|polyphenols
910553|NCT02479035|bioavailability
910554|NCT02478996|perioperative
910555|NCT02478996|internet-based
910556|NCT02478996|exercise program
910557|NCT02478957|mastocytosis
910558|NCT02478957|cromolyn sodium
910559|NCT02478944|Inflammatory bowel disease
910560|NCT02478944|Manometry
910561|NCT02478892|high risk
910562|NCT02478892|specifically those with BRCA1/2 mutations
910563|NCT02478827|Cognitive Training
910564|NCT02478827|Working Memory
910565|NCT02478827|Processing Speed
910566|NCT02478788|ADHD
910567|NCT02478775|obesity
910568|NCT02478775|fertility
910569|NCT02478775|infertility
910570|NCT02478775|reproductive hormones
910571|NCT02478762|Foetal glycated hemoglobin
910572|NCT02478762|Glycemic objectives treatment
910573|NCT02478736|postoperative delirium
910574|NCT02478736|on-pump cardiac surgery
910575|NCT02478736|cerebral oximetry
910576|NCT02478736|cerebral blood flow velosity
910577|NCT02478723|requiring therapy
910578|NCT02478723|Teeth
910579|NCT02478697|tobacco smoking behavior
910580|NCT02478697|employment
910581|NCT02478697|job-seeking
910582|NCT02478697|tobacco cessation
910583|NCT02478697|transtheoretical model
910584|NCT02478697|behavior change
910585|NCT02478684|delayed cord clamping
910586|NCT02478684|premature infants
910587|NCT02478684|randomized study
910588|NCT02478684|hematocrit
910589|NCT02478658|irisin
910590|NCT02478658|resistance training
910591|NCT02478658|physical fitness
910592|NCT02478658|Volunteers
910593|NCT02478632|tenofovir disoproxil fumarate
910594|NCT02478632|dolutegravir plus rilpivirine
910595|NCT02478632|two-drug regimen
910596|NCT02478632|bone mineral density
910597|NCT02478632|dual energy X-ray absorptiometry (DEXA)
910598|NCT02478632|Human Immunodeficiency Virus-1
910599|NCT02478632|nucleoside reverse transcriptase inhibitor -sparing regimen
910600|NCT02478632|integrase inhibitor
910601|NCT02478619|Obesity
910602|NCT02478619|Respiratory Muscle Training
910603|NCT02478619|Bariatric Surgery
910604|NCT02478619|Breathing exercises
910605|NCT02478619|Gastroplasty
910606|NCT02478606|Lower Extremity
910607|NCT02478606|Muscle Stretching Exercises
910608|NCT02478606|Muscle Strength
910609|NCT02478606|Static Stretching
910610|NCT02478606|Proprioceptive Neuromuscular Facilitation (PNF) Stretching
910611|NCT02478606|Muscle Strength Dynamometer
910612|NCT02478593|Education
910613|NCT02478593|Geriatric
910614|NCT02478593|Benzodiazepine
910615|NCT02478593|Prevalence
910616|NCT02478580|Obstructive Sleep Apnea
910617|NCT02478580|Obesity
910618|NCT02478580|Postoperative Recovery
910619|NCT02478554|Fetal growth restriction
910620|NCT02478554|macrosomia
910621|NCT02478541|triglycerides
910622|NCT02478541|glucose
910623|NCT02478541|fructose
910624|NCT02478541|fatty acids
910625|NCT02478515|ranibizumab
910626|NCT02478515|PRN regimen
910627|NCT02478515|macular edema
910628|NCT02478515|branch retinal vein occlusion
910631|NCT02478489|alcohol
910632|NCT02478489|heavy drinking
910633|NCT02478489|naltrexone
910634|NCT02478489|hospital
910635|NCT02478489|alcohol use disorder
910636|NCT02478489|alcohol dependence
910637|NCT02478489|comparative effectiveness
910638|NCT02478463|Cabotegravir
910639|NCT02478463|Pharmacokinetic
910640|NCT02478463|Healthy Adult Volunteers
910641|NCT02478463|GSK1265744
910642|NCT02478437|Lumbar Facet Syndrome
910643|NCT02478411|muscle weakness
910644|NCT02478411|rehabilitation
910645|NCT02478411|intensive care
910646|NCT02478411|mechanical ventilation
910647|NCT02478411|cyclo ergometer
910648|NCT02478411|physiotherapy
910649|NCT02478385|Birth environment
910650|NCT02478385|oxytocin
910651|NCT02478385|epidural
910652|NCT02478385|analgesia
910653|NCT02478385|home-like
910654|NCT02478372|local infiltration analgesia
910655|NCT02478372|Epidural
910656|NCT02478372|Enhanced Recovery
910657|NCT02478372|Total Knee Arthroplasty
910658|NCT02478333|Healthy
910659|NCT02478333|ALS-008176
910660|NCT02478333|Japanese adult participants
910661|NCT02478320|Advanced Cancers
910662|NCT02478320|CDKN2A-Deficient Advanced Solid Cancers
910663|NCT02478320|Advanced or metastatic cancer.
910664|NCT02478320|Ilorasertib
910665|NCT02478320|ABT-348
910666|NCT02478307|chronic low back pain
910667|NCT02478307|mindfulness meditation
910668|NCT02478307|cognitive therapy
910669|NCT02478307|mindfulness-based cognitive therapy
910670|NCT02478307|efficacy
910671|NCT02478307|mechanisms
910672|NCT02478307|coping
910678|NCT02478268|idiopathic pulmonary fibrosis
910679|NCT02478268|xenon gas
910680|NCT02478255|Radiation induced lung injury
910681|NCT02478255|Xenon gas
910682|NCT02478255|hyperpolarized
910683|NCT02478229|Liver transplant
910684|NCT02478229|Genotype 1 HCV infection
910685|NCT02478229|Sofosbuvir (SOF)/ Ledipasvir (LDV)
910686|NCT02478229|Sustained virological response (SVR12 )
910687|NCT02478203|Airtraq
910688|NCT02478203|Glidescope
910689|NCT02478203|pediatric
910690|NCT02478203|face-to-face
910691|NCT02478177|Anticoagulant
910692|NCT02478177|Stroke
910693|NCT02478177|Ischemic Stroke
910694|NCT02478177|Intracerebral hemorrhage
910695|NCT02478151|Deceased donor liver transplant
910696|NCT02478151|Normothermic machine perfusion
910697|NCT02478125|metastatic castrate resistant prostate cancer
910698|NCT02478112|Intensity Modulated Radiotherapy
910699|NCT02478112|Balloon implant
910700|NCT02478099|MPDL3280A
910701|NCT02478099|bladder cancer
910702|NCT02478099|non small cell lung cancer
910703|NCT02478099|triple negative breast cancer
910704|NCT02478086|amino acids
910705|NCT02478086|renal function
910706|NCT02478086|extreme premature
910707|NCT02478060|Allergy
910708|NCT02478060|Birch
910709|NCT02478060|Rhinitis
910710|NCT02478060|Rhinoconjuntivitis
910711|NCT02478060|SPIRE
910712|NCT02478060|Toleromune
910713|NCT02478047|to Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and Vomiting
910714|NCT02478021|effects of cortisol on cognition
910715|NCT02478008|Transcatheter Mitral Valve Replacement
910716|NCT02478008|Mitral Regurgitation
910717|NCT02478008|Mitral Insufficiency
910718|NCT02478008|Transapical
910719|NCT02477995|Immunogenicity
910720|NCT02477995|Safety
910721|NCT02477995|DTaP Vaccine
910722|NCT02477982|Propofol
910723|NCT02477982|Cardiopulmonary Bypass
910724|NCT02477982|Pharmacokinetics
910725|NCT02477982|Obesity
910726|NCT02477956|vitamin D
910727|NCT02477956|obesity
910728|NCT02477956|bariatric surgery
910729|NCT02477917|allergy
910730|NCT02477917|SCIT
910731|NCT02477904|Autism
910732|NCT02477904|Autism Spectrum Disorder
910733|NCT02477904|Ketogenic Diet
910734|NCT02477904|Biochemical Profiles
910735|NCT02477891|Multiple myeloma
910736|NCT02477891|Daratumumab
910737|NCT02477891|Early access
910738|NCT02477878|Adult leukemias and myelodysplasia
910739|NCT02477878|Adult lymphomas
910740|NCT02477878|Adult multiple myeloma
910741|NCT02477852|tuberculosis
910742|NCT02477852|spinal
910743|NCT02477852|general
910744|NCT02477852|operation
910745|NCT02477852|drug
910746|NCT02477852|therapy
910748|NCT02477800|BIIB037
910749|NCT02477800|Aducanumab
910750|NCT02477787|HLA-haploidentical hematopoietic cell transplantation
910751|NCT02477787|natural killer cells
910752|NCT02477774|Anterolateral Thigh
910753|NCT02477670|Negative Symptoms
910754|NCT02477670|Schizophrenia
910755|NCT02477670|AVP-786
910756|NCT02477657|Adult patients with refractory malignant ascites secondary to GU or GI malignancy.
910757|NCT02477644|Advanced FIGO IIIB
910758|NCT02477644|IV high grade serious ovarian cancer
910759|NCT02477644|endometrioid ovarian cancer
910760|NCT02477644|standard first-line treatment
910761|NCT02477644|platinum-taxane chemotherapy
910762|NCT02477644|bevacizumab
910763|NCT02477644|olaparib
910764|NCT02477644|placebo
910765|NCT02477631|Myelodysplastic syndrome
910766|NCT02477631|oxidative stress
910767|NCT02477631|labile plasma iron
910768|NCT02477592|long standing persistent atrial fibrillation
910769|NCT02477592|novel approach
910770|NCT02477592|ablation
910771|NCT02477566|pcos
910772|NCT02477566|Long acting Triptorelin
910773|NCT02477566|Short acting Triptorelin
910774|NCT02477566|In Vitro Fertilization
910775|NCT02477553|decision aid
910776|NCT02477553|cancer screening
910777|NCT02477553|colorectal neoplasm
910778|NCT02477553|decision making
910779|NCT02477553|risk communication
910780|NCT02477553|numeracy
910781|NCT02477553|health literacy
910782|NCT02477527|atripla
910783|NCT02477527|stribild
910784|NCT02477527|dreams
910785|NCT02477501|Spinal anesthesia
910786|NCT02477501|cesarean
910787|NCT02477501|blood pressure
910788|NCT02477501|Norepinephrine
910789|NCT02477501|Ephedrine
910790|NCT02477488|Allopurinol
910791|NCT02477488|Renal Dialysis
910794|NCT02477449|safety
910795|NCT02477449|istaroxime
910796|NCT02477423|Microbiome
910797|NCT02477423|Antibiotics
910798|NCT02477410|porcine protein
910799|NCT02477410|appetite
910800|NCT02477410|muscle protein synthesis
910801|NCT02477410|gastrointestinal hormones
910802|NCT02477397|Spiromax
910803|NCT02477397|Budesonide/formoterol
910804|NCT02477397|COPD
910805|NCT02477397|exacerbations
910806|NCT02477397|SMART
910807|NCT02477345|Cholestasis
910808|NCT02477345|Parenteral Nutrition
910809|NCT02477345|Liver disease
910810|NCT02477332|QGE031
910811|NCT02477332|omalizumab
910812|NCT02477332|chronic
910813|NCT02477332|spontaneous
910814|NCT02477332|urticaria
910815|NCT02477332|adults
910816|NCT02477332|CSU
910817|NCT02477293|Hyeonggaeyeongyo-tang
910818|NCT02477293|Chronic rhinitis
910819|NCT02477293|Pattern identification
910820|NCT02477293|Korean medicine
910821|NCT02477254|lupus
910822|NCT02477241|overactive bladder syndrome
910823|NCT02477241|urgency urinary incontinence
910824|NCT02477241|fMRI
910825|NCT02477241|urodynamics
910826|NCT02477215|Multiple Myeloma
910827|NCT02477202|Mirena® IUD's
910828|NCT02477202|Women
910829|NCT02477202|risk-reducing salpingo-oophorectomy
910830|NCT02477202|risk-reducing salpingectomy
910831|NCT02477163|Nephropathy induced by drugs medicaments and biological substances
910832|NCT02477163|Other nephritis and nephropathy not specified as acute or chronic
910833|NCT02477150|lupus
910834|NCT02477137|Prostate Cancer
910835|NCT02477137|Nursing
910836|NCT02477137|Health Literacy
910837|NCT02477137|Quality of Life
910838|NCT02477137|Radiotherapy
910839|NCT02477137|Oncology Nursing
910840|NCT02477137|Self Care
910841|NCT02477137|Symptom Management
910842|NCT02477137|Participatory Care
910843|NCT02477137|Person-centered Care
910844|NCT02477137|Information and Communication Technology
910845|NCT02477137|Patient-reported symptoms
910846|NCT02477137|Mobile device
910847|NCT02477111|Endovascular repair
910848|NCT02477098|rectus sheath block
910849|NCT02477098|cytokines
910850|NCT02477098|sleep
910851|NCT02477085|Labor
910852|NCT02477085|induction
910853|NCT02477085|delivery
910854|NCT02477085|prostaglandins
910855|NCT02477085|oxytocin
910856|NCT02477085|amniotomy
910857|NCT02477085|balloon catheter
910858|NCT02477059|Hand OA
910859|NCT02477059|Tocilizumab
910860|NCT02477059|Osteoarthritis
910861|NCT02477059|Interleukin-6
910862|NCT02477020|Drug Therapy
910863|NCT02477007|Paediatric emergency
910864|NCT02477007|pain
910865|NCT02477007|long-bones fractures
910866|NCT02477007|morphine
910867|NCT02477007|ibuprofen
910868|NCT02477007|paracetamol
910869|NCT02477007|children
910870|NCT02476994|Essential Fatty Acids (EFA)
910871|NCT02476994|Parenteral Nutrition
910872|NCT02476994|Clinolipid/Clinoleic
910873|NCT02476994|Parenteral Nutrition Associated Cholestasis (PNAC)
910874|NCT02476994|Parenteral Nutrition Associated Liver Disease (PNALD)
910875|NCT02476994|Intestinal Failure Associated Liver Disease (IFALD)
910876|NCT02476994|Phytosterols
910877|NCT02476994|Intralipid
910878|NCT02476994|Infants/Preterm Infants
910879|NCT02476994|FADS1 and FADS2
910880|NCT02476994|Short Bowel Syndrome
910881|NCT02476994|Cancer Nutrition
910882|NCT02476994|Olive Oil Emulsion
910883|NCT02476994|Soybean Oil Emulsion
910884|NCT02476955|ARQ 092
910885|NCT02476955|Carboplatin
910886|NCT02476955|Paclitaxel
910887|NCT02476955|AKT inhibitor in combination therapy
910888|NCT02476955|Targeted therapy
910889|NCT02476955|Molecular therapy
910890|NCT02476955|Tyrosine kinase inhibitor (TKI)
910891|NCT02476955|Receptor tyrosine kinase (RTK)
910892|NCT02476955|Biomarkers
910893|NCT02476955|Phase 1 - Phase I
910894|NCT02476955|Solid tumors
910895|NCT02476955|Metastatic solid tumors
910896|NCT02476955|Recurrent solid tumors
910897|NCT02476955|Ovarian cancer
910898|NCT02476955|Endometrial cancer
910899|NCT02476955|Cervical cancer
910900|NCT02476955|Triple-negative breast cancer
910901|NCT02476955|AKT kinases
910902|NCT02476955|AKT pathway
910903|NCT02476955|AKT signaling
910904|NCT02476955|AKT inhibitor
910905|NCT02476955|AKT pan inhibitor
910906|NCT02476955|Chemotherapy
910907|NCT02476955|PI3K/AKT/mTOR signaling pathway
910908|NCT02476955|AKT1
910909|NCT02476955|AKT2
910910|NCT02476955|AKT3
910911|NCT02476955|Phase I Clinical Trial
910912|NCT02476955|Clinical oncology
910913|NCT02476955|Tumor
910914|NCT02476955|AKT1 inhibitor
910915|NCT02476955|AKT2 inhibitor
910916|NCT02476955|AKT3 inhibitor
910917|NCT02476955|AKT1 mutation
910918|NCT02476955|AKT2 mutation
910919|NCT02476955|AKT3 mutation
910920|NCT02476955|AKT1 amplification
910921|NCT02476955|AKT2 amplification
910922|NCT02476955|AKT3 amplification
910923|NCT02476955|Anastrozole
910924|NCT02476955|Estrogen receptor positive
910925|NCT02476929|Electronic nose
910926|NCT02476929|Nasal nitrous oxide
910927|NCT02476929|Allergic Rhinitis
910928|NCT02476929|Non-Allergic Rhinitis
910929|NCT02476929|Nasal polyps
910930|NCT02476916|Pyruvate Kinase Deficiency
910931|NCT02476916|Hemolytic anemia
910932|NCT02476916|Protein Kinase R (PKR)
910933|NCT02476916|Drive PK
910934|NCT02476877|comorbidity
910935|NCT02476877|epidemiology
910936|NCT02476877|mental illness
910937|NCT02476877|drug abuse
910938|NCT02476864|macitentan
910939|NCT02476864|biocomparison
910940|NCT02476864|safety
910941|NCT02476851|Blood Donation
910942|NCT02476851|Whole Blood
910943|NCT02476838|hand injury
910944|NCT02476838|hand amputation
910945|NCT02476838|hand amputee
910946|NCT02476838|hand surgery
910947|NCT02476825|volunteers
910948|NCT02476773|Hookworm Vaccine
910949|NCT02476773|Na-APR-1 (M74)/Alhydrogel® Hookworm Vaccine
910950|NCT02476773|Na-GST-1/Alhydrogel® Hookworm Vaccine
910951|NCT02476760|Incretins
910952|NCT02476760|Antidiabetic agents
910953|NCT02476760|Pancreatitis
910954|NCT02476747|Colonic polyp
910955|NCT02476734|REDIRECTED AUTOLOGOUS CART- 19 T-CELL IMMUNOTHERAPY
910956|NCT02476721|pulmonary embolism
910957|NCT02476721|emergency department
910962|NCT02476695|CHB
910963|NCT02476682|Sessile serrated polyps
910964|NCT02476682|Advanced mucosal neoplasia
910965|NCT02476669|plasma EBV DNA
910966|NCT02476669|biomarker
910967|NCT02476669|intensity-modulated radiation therapy
910968|NCT02476617|Treatment naive
910969|NCT02476617|Interferon free
910970|NCT02476617|HCV
910971|NCT02476617|Chronic Hepatitis C
910972|NCT02476617|Hepatitis C Genotype 1a
910973|NCT02476617|Hepatitis C
910974|NCT02476617|pegIFN/RBV experienced
910975|NCT02476604|prevention
910976|NCT02476604|adult
910977|NCT02476604|student
910978|NCT02476591|Resource utilization
910979|NCT02476591|intensive care unit
910980|NCT02476578|Hypocholesterolemia
910981|NCT02476578|Frail Elderly
910982|NCT02476578|Aged
910983|NCT02476578|Aged, 80 and over
910984|NCT02476578|Cholesterol
910985|NCT02476578|Clinical Laboratory Information Systems
910986|NCT02476578|Hemoglobin A, Glycosylated
910987|NCT02476578|diet therapy
910988|NCT02476578|Anticholesteremic Agents
910989|NCT02476578|Health Services for the Aged
910990|NCT02476578|Hypoglycemic Agents
910991|NCT02476578|Hypoglycemia
910992|NCT02476565|Intubation
910993|NCT02476461|percutanepus needle fasciotomy
910994|NCT02476461|xiapex
910995|NCT02476461|clostridium histolyticum
910996|NCT02476448|ureteral jet
910997|NCT02476448|pelvic surgery
910998|NCT02476448|cystoscopy
910999|NCT02476435|Depersonalization
911000|NCT02476435|Derealization
911001|NCT02476435|Embodiment
911002|NCT02476435|Emotional numbing
911003|NCT02476435|Transcranial magnetic stimulation
911004|NCT02476435|Angular gyrus
911005|NCT02476435|Temporo-parietal junction
911006|NCT02476422|Diclofenac potassium
911007|NCT02476422|Post-operative dental pain
911008|NCT02476422|Moderate to severe pain
911009|NCT02476409|congestive heart failure
911010|NCT02476409|tolvaptan
911011|NCT02476409|copeptin
911012|NCT02476331|Cognitive training
911013|NCT02476331|Working memory
911014|NCT02476331|Emotion regulation
911015|NCT02476266|resistance training
911016|NCT02476266|strength training
911017|NCT02476266|balance
911018|NCT02476266|muscle strength
911019|NCT02476253|acidosis
911020|NCT02476253|shock
911021|NCT02476253|sodium bicarbonate
911022|NCT02476253|renal replacement therapy
911023|NCT02476240|Exercise
911024|NCT02476240|Attention
911025|NCT02476227|atrial fibrillation
911026|NCT02476227|pulmonary vein isolation
911027|NCT02476227|RF ablation
911028|NCT02476214|group prenatal care, group guidance
911029|NCT02476201|Heart Failure
911030|NCT02476201|Cardiac Resynchronization Therapy
911031|NCT02476201|Quadripolar Left Ventricular Lead
911032|NCT02476201|Multipoint Pacing
911033|NCT02476201|Hemodynamic Response
911034|NCT02476188|Neutrophil extracellular traps, stroke
911035|NCT02476175|mirabegron
911036|NCT02476175|antimuscarinics
911037|NCT02476175|beta 3 agonist
911038|NCT02476175|overactive bladder
911039|NCT02476175|children
911040|NCT02476162|Childhood Cancer Survivor
911041|NCT02476162|Cancer Prevention and Control
911042|NCT02476162|Blood Pressure Monitoring
911043|NCT02476162|Pre-Hypertension
911044|NCT02476136|individual patient data meta-analysis
911045|NCT02476136|anxiety disorder
911046|NCT02476136|antidepressants
911047|NCT02476136|selective serotonin reuptake inhibitors
911048|NCT02476136|serotonin-norepinephrine reuptake inhibitors
911049|NCT02476110|Oral nutritive supplements
911050|NCT02476110|Nutritional risk screening
911051|NCT02476110|Homecare
911052|NCT02476097|esomeprazole randomized study
911053|NCT02476097|proton pump inhibitor
911054|NCT02476097|gastric acid rebound
911055|NCT02476097|randomized study
911056|NCT02476097|esomeprazole
911057|NCT02476071|HIV prevention
911058|NCT02476071|Demand for voluntary male circumcision
911059|NCT02476058|Major Depressive Disorder
911060|NCT02476058|JNJ-42847922
911061|NCT02476058|Diphenhydramine
911062|NCT02476058|Placebo
911063|NCT02476045|metastatic colorectal cancer
911064|NCT02476045|RAS wild-type
911065|NCT02476045|maintenance therapy
911066|NCT02476045|panitumumab
911067|NCT02476019|Obesity
911068|NCT02476019|Energy Expenditure
911069|NCT02475993|Sickle Cell Disease
911070|NCT02475980|Adolescent
911071|NCT02475980|Contraception
911072|NCT02475980|Counseling
911073|NCT02475967|E-Learning
911074|NCT02475967|coronary artery disease
911075|NCT02475967|telerehabilitation
911076|NCT02475967|e-health
911077|NCT02475954|Depression
911078|NCT02475954|Telehealth
911079|NCT02475954|Parkinson's Disease
911080|NCT02475954|Veterans
911081|NCT02475954|Care-partners
911082|NCT02475954|Cognitive-Behavioral Therapy
911083|NCT02475954|Caregiver
911084|NCT02475941|geriatric fractures
911085|NCT02475915|Treatment interruption
911086|NCT02475915|Controlling HIV
911087|NCT02475902|prevention and control
911088|NCT02475824|ERCP
911089|NCT02475824|Sedation
911090|NCT02475824|safety
911091|NCT02475811|3D ultrasonography
911092|NCT02475811|fetal Lung Volume
911093|NCT02475811|neonatal respiratory function
911094|NCT02475798|Zenith aortoiliac aneurysm
911095|NCT02475798|Iliac aneurysm
911096|NCT02475798|Branch
911097|NCT02475798|Connections
911098|NCT02475798|Endovascular graft
911099|NCT02475798|Graft-iliac bifurcation
911100|NCT02475798|Aneurysm
911101|NCT02475798|Vascular Diseases
911102|NCT02475798|Cardiovascular Diseases
911103|NCT02475785|Forsus Fatigue Resistant Device
911104|NCT02475785|Class II
911105|NCT02475785|anchorage
911106|NCT02475785|FFRD
911107|NCT02475785|mini plates
911108|NCT02475785|fixed functional appliance
911109|NCT02475772|ovarian cancer
911110|NCT02475772|recurrent
911111|NCT02475772|chemotherapy
911112|NCT02475772|intraperitoneal
911113|NCT02475772|cisplatin
911114|NCT02475772|doxorubicin
911115|NCT02475746|drug interaction, PF-06372865, itraconazole
911117|NCT02475707|leukemia
911118|NCT02475707|lymphoblastic
911119|NCT02475707|ALL
911120|NCT02475707|multiTAA-specific T cells
911121|NCT02475707|HSCT
911122|NCT02475590|Sleeve gastrectomy
911123|NCT02475590|Roux-en-Y gastric bypass
911124|NCT02475590|Excess weight loss
911125|NCT02475590|Quality of life
911126|NCT02475577|telemedicine
911127|NCT02475577|heart failure
911128|NCT02475577|home blood pressure monitoring
911129|NCT02475564|resveratrol
911130|NCT02475512|elderly
911131|NCT02475512|long-term care
911132|NCT02475499|Incretins
911133|NCT02475499|Antidiabetic agents
911134|NCT02475499|Pancreatic Cancer
911135|NCT02475486|Rheumatoid Arthritis
911136|NCT02475486|sympathetic nervous system
911137|NCT02475486|SNA
911138|NCT02475486|fatigue
911139|NCT02475473|Volunteers
911140|NCT02475460|HeartMate 3
911141|NCT02475460|LVAS
911142|NCT02475460|LVAD
911143|NCT02475460|Heart-assist Devices
911144|NCT02475460|Advanced
911145|NCT02475460|Ventricular Dysfunction
911146|NCT02475460|refractory left ventricular
911147|NCT02475460|Thoratec Corporation
911148|NCT02475434|Human Milk
911149|NCT02475434|Prematurity
911150|NCT02475434|Nutrition
911151|NCT02475421|Diabetes
911152|NCT02475421|Glucagon
911153|NCT02475421|Metabolic clearance rate of glucagon
911154|NCT02475408|Circulation, Collateral
911155|NCT02475408|Coronary Artery Disease
911156|NCT02475408|Internal Mammary-Coronary Artery Anastomosis
911157|NCT02475408|Ischemia
911158|NCT02475395|Male Fertility
911159|NCT02475395|Male Infertility
911160|NCT02475395|Fertility
911161|NCT02475395|Sperm
911162|NCT02475395|Sperm Concentration
911163|NCT02475369|pancreatic enzyme supplementation
911164|NCT02475356|Mirena
911165|NCT02475356|Heavy Menstrual Bleeding
911166|NCT02475356|Dysmenorrhea
911167|NCT02475356|Japan
911168|NCT02475356|Post-marketing surveillance
911169|NCT02475317|Volunteer
911170|NCT02475278|Drug therapy
911171|NCT02475265|Anorexia Nervosa
911172|NCT02475265|Osteoporosis
911173|NCT02475265|Eating Disorder
911174|NCT02475265|Disordered Eating
911175|NCT02475265|Estrogen
911176|NCT02475265|Bone
911177|NCT02475239|Benign Paroxysmal Positional Vertigo, Postural Restriction
911178|NCT02475226|Traumatic Brain Injury
911179|NCT02475226|Brain Damage
911180|NCT02475226|Mortality
911181|NCT02475226|C10.228.140.199
911182|NCT02475213|Malanoma, Non small cell lung cancer, SCCHN
911183|NCT02475213|Other B7-H3 expressing cancers
911184|NCT02475187|TEG
911185|NCT02475187|MEA
911186|NCT02475187|Thrombotic events
911187|NCT02475187|VTE
911188|NCT02475187|LMWH
911189|NCT02475187|Hip fractures
911190|NCT02475161|Healthy
911191|NCT02475161|Rabeprazole
911192|NCT02475161|JNJ-42847922
911193|NCT02475148|JNJ-54175446
911194|NCT02475148|Healthy
911195|NCT02475135|Immunodeficiency Virus Type 1, Human
911196|NCT02475135|Immunodeficiency Virus Type 2, Human
911197|NCT02475135|Darunavir
911198|NCT02475135|Cobicistat
911199|NCT02475135|Tenofovir Alafenamide
911200|NCT02475135|Emtricitabine
911201|NCT02475135|Elvitegravir
911202|NCT02475122|Measurement of azygos blood flow
911203|NCT02475109|Proliferative Diabetic Retinopathy
911204|NCT02475083|Stroke
911205|NCT02475083|Virtual reality
911206|NCT02475083|Balance
911207|NCT02475083|Falls
911208|NCT02475057|Prostate Cancer
911209|NCT02475057|Cardiovascular disease
911210|NCT02475057|Degarelix
911211|NCT02475044|post-concussion
911212|NCT02475044|Cognitive-Behavioral Theray
911213|NCT02475044|parenting
911214|NCT02475031|transversus abdominis plane block
911215|NCT02475018|Shuhua Milk
911216|NCT02475018|plant sterol esters
911217|NCT02475018|serum cholesterol
911218|NCT02475018|human
911219|NCT02475005|self management app
911220|NCT02475005|headache
911221|NCT02475005|adolescent
911222|NCT02474992|HIV
911223|NCT02474992|Social network
911224|NCT02474992|Social support
911225|NCT02474992|Disclosure
911226|NCT02474992|Stigma
911227|NCT02474992|Kenya
911228|NCT02474979|Pressure ulcer
911229|NCT02474979|Prevention
911230|NCT02474979|Pressure mapping
911231|NCT02474953|Curcumin
911232|NCT02474953|Pharmacokinetic
911233|NCT02474940|Multiple Sclerosis
911234|NCT02474940|Chronic Pain
911235|NCT02474940|Chronic Fatigue
911236|NCT02474940|Autoimmune Diseases
911237|NCT02474940|Autoimmune Diseases of the Nervous System
911238|NCT02474940|Central Nervous System Diseases
911239|NCT02474940|Demyelinating Autoimmune Diseases, CNS
911240|NCT02474940|Demyelinating Diseases
911241|NCT02474927|antibody-mediated rejection
911242|NCT02474927|lung transplant
911243|NCT02474927|Carfilzomib
911244|NCT02474901|Shedding
911245|NCT02474901|Immunogenicity
911246|NCT02474901|Safety
911247|NCT02474901|HIV infected
911248|NCT02474901|Children
911249|NCT02474901|Young adults
911250|NCT02474875|Fibromyalgia
911251|NCT02474875|Patient education
911252|NCT02474875|Central sensitization
911253|NCT02474836|Allergy
911254|NCT02474810|central venous catheters
911255|NCT02474810|hemodialysis
911256|NCT02474810|thrombosis
911257|NCT02474810|tissue plasminogen activator
911258|NCT02474797|Ultrasonography
911259|NCT02474797|Diaphragm
911260|NCT02474797|Lung ultrasound
911261|NCT02474797|Sepsis
911262|NCT02474797|Critical care
911263|NCT02474797|Chest physiotherapy
911264|NCT02474745|second stage of labor
911265|NCT02474745|pushing techniques
911266|NCT02474719|nephrology
911267|NCT02474719|extra-renal purification
911268|NCT02474719|peritoneal dialysis
911269|NCT02474706|cefoxitin Patient safety
911270|NCT02474706|Infectious diseases
911271|NCT02474706|Extended-Spectrum β-lactamases E.coli
911272|NCT02474706|Antibiotics
911273|NCT02474680|depression
911274|NCT02474680|Major Depressive Disorder
911275|NCT02474680|MDD
911276|NCT02474680|mental health
911277|NCT02474680|pharmacogenomics
911278|NCT02474680|personalized medicine
911279|NCT02474680|precision medicine
911280|NCT02474680|anti-depressants
911281|NCT02474667|DGF
911282|NCT02474667|Delayed Graft Function
911283|NCT02474667|Renal Transplantation
911284|NCT02474667|Deseased Donor Kidney
911285|NCT02474667|BB3
911286|NCT02474667|Kidney Transplantation
911287|NCT02474667|Acute Kidney Injury
911288|NCT02474641|Breast cancer
911289|NCT02474641|Hypofractionation with SIB
911290|NCT02474641|Non-inferiority
911291|NCT02474641|adjuvant radiotherapy with simultaneous integrated boost
911292|NCT02474628|Physiological Phenomena
911293|NCT02474615|Apicoectomy
911294|NCT02474615|Oral surgery
911295|NCT02474615|Biocompatible materials
911296|NCT02474615|Dental Cements
911297|NCT02474615|Translational Medical Research
911298|NCT02474602|phototherapy
911299|NCT02474602|strength training
911300|NCT02474602|photobiostimulation
911301|NCT02474602|muscle development
911302|NCT02474589|Treatment
911303|NCT02474589|orthopoxvirus
911304|NCT02474589|smallpox
911305|NCT02474563|Multiple Myeloma
911306|NCT02474563|Bortezomib
911307|NCT02474563|Melphalan
911308|NCT02474563|Prednisone
911309|NCT02474550|diffuse large b cell lymphoma
911310|NCT02474550|peg-filgrastim
911311|NCT02474550|febrile neutropenia
911312|NCT02474537|hepatic impairment,
911313|NCT02474537|INC280,
911314|NCT02474537|Oral cMET Inhibitor,
911315|NCT02474537|Non-Cancer
911316|NCT02474524|Psychosis
911317|NCT02474524|Schizophrenia
911318|NCT02474524|Self-management
911319|NCT02474524|Recovery
911320|NCT02474524|Tablet computer
911321|NCT02474524|Digital health
911322|NCT02474524|Internet
911323|NCT02474524|Online
911324|NCT02474524|Peer support
911325|NCT02474498|Regenerative therapy
911326|NCT02474498|Randomized clinical trial (RCT)
911327|NCT02474498|Enamel matrix derivative
911328|NCT02474498|Hydroxyapatite-beta tricalcium phosphate
911329|NCT02474498|Buccal furcation
911330|NCT02474485|bioresorbable vascular scaffold
911331|NCT02474485|Absorb
911332|NCT02474485|drug eluting balloon
911333|NCT02474485|percutaneous coronary intervention
911334|NCT02474472|Midline Laparotomy
911335|NCT02474472|Sternotomy
911336|NCT02474472|Thoracotomy
911337|NCT02474472|Thoracoabdominal Incision
911338|NCT02474459|Deep Brain Stimulation
911339|NCT02474459|DBS
911340|NCT02474459|STN
911341|NCT02474459|GPi
911342|NCT02474459|Globus pallidus
911343|NCT02474459|Subthalamic nucleus
911344|NCT02474459|Neuromodulation
911345|NCT02474407|Seizures
911346|NCT02474407|Epilepsy
911350|NCT02474329|Parkinson's disease
911351|NCT02474329|Ambulatory monitoring
911352|NCT02474329|Disease progression
911353|NCT02474303|Truvada
911354|NCT02474303|EMTRICITABINE/TENOFOVIR DISPROXIL FUMARATE
911355|NCT02474303|HIV PREEXPOSURE PROPHYLAXIS (PrEP)
911356|NCT02474303|Female Sex Workers
911357|NCT02474290|Acute Myeloid Leukemia
911358|NCT02474290|FLT3-ITD
911359|NCT02474290|Hematopoietic Stem Cell Transplantation
911360|NCT02474238|Iridotomy
911361|NCT02474225|intraocular pressure
911362|NCT02474225|intravitreal
911363|NCT02474212|Venous thromboembolism
911364|NCT02474212|pulmonary embolism
911365|NCT02474212|thromboprophylaxis
911366|NCT02474212|anticoagulant
911367|NCT02474212|anti-FXa
911368|NCT02474212|low-molecular weight heparin
911369|NCT02474212|enoxaparin
911370|NCT02474199|Regulatory T Cells ( Treg)
911371|NCT02474199|Donor Alloantigen Reactive Tregs (darTregs)
911372|NCT02474199|Liver Transplant
911373|NCT02474199|Alloantigen Reactive Tregs
911374|NCT02474199|Calcineurin Inhibitors (CNI)
911375|NCT02474199|immunosuppressants (IS)
911376|NCT02474186|breast
911377|NCT02474186|cancer
911378|NCT02474186|metastatic
911379|NCT02474186|breast cancer
911380|NCT02474186|metastatic breast cancer
911381|NCT02474186|radiation
911382|NCT02474186|radiotherapy
911383|NCT02474186|radiation therapy
911384|NCT02474186|abscopal
911385|NCT02474186|abscopal effect
911386|NCT02474186|T-cell
911387|NCT02474186|GM-CSF
911388|NCT02474186|anti-tumor
911389|NCT02474186|immune
911390|NCT02474186|immune response
911391|NCT02474186|capecitabine
911392|NCT02474186|xeloda
911393|NCT02474186|taxol
911394|NCT02474186|paclitaxel
911395|NCT02474186|other solid metastatic tumor
911396|NCT02474108|atrial fibrillation
911397|NCT02474108|radiofrequency ablation
911398|NCT02474108|prevention of AF
911399|NCT02474108|mitral valve
911400|NCT02474108|left atrium enlargement
911401|NCT02474108|cryoablation
911402|NCT02474056|decreased blood volume vein volume flow ultrasound exam
911403|NCT02474043|Injection drug use
911404|NCT02474017|Inhaler
911405|NCT02474017|Adolescent
911406|NCT02473978|During Labor
911407|NCT02473978|Complicating Anesthesia or Other Sedation
911408|NCT02473978|Cerebral
911409|NCT02473926|Physical Activity
911410|NCT02473926|Physical Function
911411|NCT02473926|Physical Impairment
911412|NCT02473926|Sedentary Lifestyle
911413|NCT02473887|ondansetron
911414|NCT02473887|palatability
911415|NCT02473887|vomiting
911416|NCT02473861|exercise training
911417|NCT02473861|breast cancer
911418|NCT02473861|taxane chemotherapy
911419|NCT02473861|peripheral neuropathy
911420|NCT02473861|fatigue
911421|NCT02473861|autonomic function
911422|NCT02473835|T-lymphocyte
911423|NCT02473835|Adipose tissue
911424|NCT02473835|Inflammation
911425|NCT02473835|Calorie restriction
911426|NCT02473822|anterior cruciate ligament
911427|NCT02473822|Tape Locking Screw
911428|NCT02473822|LCA
911429|NCT02473822|joint trauma
911430|NCT02473796|home based child care
911431|NCT02473770|Registry
911432|NCT02473770|Exposures
911433|NCT02473770|Biological Specimens
911434|NCT02473770|Occupational Health
911435|NCT02473757|Recombinant DNA Product
911436|NCT02473757|Laboratory Evaluation
911437|NCT02473757|NIH Office of Biotechnology Activities
911438|NCT02473757|Gamma-Retroviral Vectors
911439|NCT02473744|lower limb edema
911440|NCT02473744|subcutaneous drainage
911441|NCT02473744|bioelectrical impedance
911442|NCT02473744|quality of life
911443|NCT02473731|CDX3379
911444|NCT02473705|Geriatric
911445|NCT02473705|bicarbonate
911446|NCT02473705|omega polyunsaturated fatty acids
911447|NCT02473705|exercise capacity
911448|NCT02473679|First Responder
911449|NCT02473679|BLS
911450|NCT02473679|AED
911451|NCT02473679|Resuscitation
911452|NCT02473666|Patient Blood Management
911453|NCT02473666|Red Blood Cells
911454|NCT02473666|Platelet
911455|NCT02473627|Pharmacokinetics
911456|NCT02473601|mivacurium chloramine
911457|NCT02473601|patients with liver cirrhosis
911458|NCT02473601|muscle relaxation effect
911459|NCT02473575|Caffeine, running, performance
911460|NCT02473562|Parkinson's disease
911461|NCT02473562|Varenicline
911462|NCT02473562|Excessive daytime sleepiness
911463|NCT02473549|motor
911464|NCT02473549|rehabilitation
911465|NCT02473549|transcranial direct current stimulation
911466|NCT02473523|Fatigue
911467|NCT02473523|Pain Alleviation
911468|NCT02473523|Emotional Wellbeing
911469|NCT02473523|Physical Wellbeing
911470|NCT02473523|Yoga
911471|NCT02473510|Trivalent
911472|NCT02473510|Influenza
911473|NCT02473510|FluMist Quadrivalent
911474|NCT02473510|Vaccine
911475|NCT02473510|Prevention
911476|NCT02473510|Healthy
911477|NCT02473497|chromosomal rearrangement
911478|NCT02473497|activating mutation
911479|NCT02473497|activating genetic alteration
911480|NCT02473497|genetic aberration
911481|NCT02473497|ALK
911482|NCT02473497|ROS1
911483|NCT02473497|cMET
911484|NCT02473497|crizotinib
911485|NCT02473497|oral formulation
911486|NCT02473484|High Grade Glioma
911487|NCT02473484|Proteomics
911488|NCT02473484|MALDI-MSI
911489|NCT02473471|Micro-Osteoperforation (MOPs)
911490|NCT02473471|regional acceleratory phenomenon (RAP)
911491|NCT02473471|Malocculsion
911492|NCT02473458|Licorice
911493|NCT02473458|Glycyrrhizic acid
911494|NCT02473458|Ischemic Stroke
911495|NCT02473458|Acute
911496|NCT02473445|inherited mitochondrial disease
911497|NCT02473445|Leigh Syndrome
911498|NCT02473445|LHON
911499|NCT02473445|MERFF
911500|NCT02473445|MELAS
911501|NCT02473445|Kearn-Sayre syndrome
911502|NCT02473445|POLG-related disorders
911503|NCT02473445|MNGIE
911504|NCT02473432|respiratory muscle training
911505|NCT02473432|neuromuscular electrical stimulation
911506|NCT02473432|oropharyngeal dysphagia
911507|NCT02473432|stroke
911508|NCT02473432|rehabilitation
911509|NCT02473419|Medical food
911510|NCT02473419|ADHD
911511|NCT02473419|Vayarin
911512|NCT02473419|Fish Oil
911513|NCT02473380|glioma
911514|NCT02473380|fluorescence spectroscopy
911515|NCT02473341|Bovine Colostrum
911516|NCT02473341|Corticosteriods
911517|NCT02473341|Endotoxin
911518|NCT02473341|MELD
911519|NCT02473341|mDF
911520|NCT02473328|dose reduction study
911521|NCT02473289|Depressive disorder, major
911522|NCT02473289|Sirukumab
911523|NCT02473263|Severe septic syndrome
911524|NCT02473263|mobile intensive care unit
911525|NCT02473263|strategy
911526|NCT02473263|antibiotics
911527|NCT02473263|hemodynamic optimization
911528|NCT02473237|COPD
911529|NCT02473237|biomass
911530|NCT02473224|Norovirus, Snow Mountain filtrate, GII.2, HID50, challenge
911531|NCT02473198|Total Knee Arthroplasty
911532|NCT02473198|Amide Local Anesthetic
911533|NCT02473172|Weaning from mechanical ventilation
911534|NCT02473159|Near-infrared fluorescence
911535|NCT02473159|Indocyanine green, ICG
911536|NCT02473159|breast cancer
911537|NCT02473146|AML
911538|NCT02473146|untreated
911539|NCT02473146|60-80 years old
911540|NCT02473146|favorable and intermediate karyotype
911541|NCT02473133|radiotherapy
911542|NCT02473133|dose redistribution
911543|NCT02473133|boost
911544|NCT02473120|metastatic
911545|NCT02473120|ESR1
911546|NCT02473120|aromatase inhibitor
911547|NCT02473120|breast cancer
911548|NCT02473107|Dental caries
911549|NCT02473107|Primary tooth
911550|NCT02473107|Caries Detection
911551|NCT02473094|Metformin
911552|NCT02473094|Rectal Cancer
911553|NCT02473094|Rectum
911554|NCT02473094|Radiotherapy
911555|NCT02473094|Capecitabine
911556|NCT02473094|Neoadjuvant
911557|NCT02473094|Adenocarcinoma
911558|NCT02473094|Carcinoma
911559|NCT02473081|Type 2 diabetes
911560|NCT02473081|Minimal psychological intervention
911561|NCT02473081|Glycemic control
911562|NCT02473081|Depressive symptoms
911563|NCT02473081|Problem Area in Diabetes
911564|NCT02473081|Middle-aged and older adults
911565|NCT02473081|HbA1c protein, human
911566|NCT02473068|CPAP
911567|NCT02473055|kangaroo care
911568|NCT02473055|sleep
911569|NCT02473055|heart rate
911570|NCT02473055|respiratory rate
911571|NCT02473055|preterm infant
911572|NCT02473042|Post-operative nausea and vomiting
911573|NCT02473042|PONV
911574|NCT02473042|Breast cancer
911575|NCT02473042|Neuromuscular blockade monitor
911576|NCT02473042|NMBM
911577|NCT02473042|Breast cancer surgery
911578|NCT02473042|Prophylactic anti-emetics
911579|NCT02473042|Electrical stimulation
911580|NCT02473042|Zofran
911581|NCT02473042|Ondansetron
911582|NCT02473042|Dexamethasone
911583|NCT02473042|Decadron
911584|NCT02473042|Phenergan
911585|NCT02473042|Promethazine
911586|NCT02473042|Phenazine
911587|NCT02473042|Phencen
911588|NCT02473042|Prometh
911589|NCT02473042|Prorex
911590|NCT02473042|V-Gan
911591|NCT02473042|Pepcid
911592|NCT02473042|Famotidine
911593|NCT02473042|Questionnaire
911594|NCT02473042|Survey
911595|NCT02473016|Classical Trigeminal Neuralgia
911596|NCT02473003|Breast cancer
911597|NCT02473003|prostate cancer
911598|NCT02473003|colorectal cancer
911599|NCT02473003|fatigue
911600|NCT02473003|physical exercise
911601|NCT02473003|randomised trial
911602|NCT02473003|intervention
911603|NCT02472990|DMD
911604|NCT02472990|morphological predictive factors
911605|NCT02472990|Mechanical
911606|NCT02472938|Relapsing remitting Multiple Sclerosis
911607|NCT02472912|Pharmacokinetics
911608|NCT02472912|Adalimumab
911609|NCT02472912|Biosimilar Pharmaceuticals
911610|NCT02472899|Geriatrics
911611|NCT02472899|Neurocognitive Disorder
911612|NCT02472899|Biomarkers
911613|NCT02472899|Immunology
911614|NCT02472886|HCV genotype 1
911615|NCT02472886|HCV
911616|NCT02472886|Sustained Virologic Response
911617|NCT02472886|Direct Acting Antiviral
911618|NCT02472886|Combination Therapy
911619|NCT02472886|GS-7977
911620|NCT02472886|GS-5885
911621|NCT02472886|Ribavirin
911622|NCT02472886|Sofosbuvir
911623|NCT02472886|ledipasvir
911624|NCT02472886|Hepatitis C
911625|NCT02472886|Hepatitis C, Chronic
911626|NCT02472886|Liver Diseases
911627|NCT02472886|Virus Diseases
911628|NCT02472886|Antiviral Agents
911629|NCT02472886|HCV/HIV co-infection
911630|NCT02472873|endometrioma
911631|NCT02472873|endometriosis
911632|NCT02472873|sclerotherapy
911633|NCT02472873|ethanol
911634|NCT02472873|aspiration
911635|NCT02472873|laparoscopy
911636|NCT02472860|Autism Spectrum Disorder
911637|NCT02472860|Neuroplasticity-based Cognitive Training
911638|NCT02472847|Marinol
911639|NCT02472847|Dronabinol
911640|NCT02472847|Fear extinction
911641|NCT02472847|Healthy volunteers
911642|NCT02472834|Carbamylation
911643|NCT02472834|Albumin
911644|NCT02472834|Protein structure
911645|NCT02472834|Kidney disease
911646|NCT02472795|Systemic lupus erythematosus
911647|NCT02472782|osteoporosis
911648|NCT02472782|quality of life
911649|NCT02472782|adherence
911650|NCT02472782|treatment
911651|NCT02472743|Phototherapy
911652|NCT02472730|Colonoscopy
911653|NCT02472730|Training Techniques
911654|NCT02472730|Endoscopy, Gastrointestinal
911655|NCT02472717|liraglutide, GLP-1 receptor agonists
911656|NCT02472704|celiac disease
911657|NCT02472704|lymphocytic enteritis
911658|NCT02472704|non-celiac gluten sensitivity
911659|NCT02472704|double-blind gluten rechallenge
911660|NCT02472691|relapse after allogeneic transplantation
911661|NCT02472691|MDS
911662|NCT02472691|AML
911663|NCT02472691|CMML
911664|NCT02472691|DLI
911665|NCT02472691|Azacitidine
911666|NCT02472691|Lenalidomide
911667|NCT02472691|C04.557.337.539.275
911668|NCT02472691|C15.378.190.625
911669|NCT02472691|C04.557.337.539.522
911670|NCT02472665|pediatric
911671|NCT02472665|plasma-derived FVIII concentrate
911672|NCT02472613|Post－Stroke Depression
911673|NCT02472613|Acupunture
911674|NCT02472613|Fluoxetine
911675|NCT02472613|RCT
911679|NCT02472574|Intracerebral Hemorrhage
911680|NCT02472574|minimally invasive surgery
911681|NCT02472574|recombinant tissue plasminogen activator
911682|NCT02472574|Dose-effect Relationship
911683|NCT02472561|Cardiology
911684|NCT02472561|Vascular
911685|NCT02472561|Peripheral Artery Disease
911686|NCT02472561|Artery
911687|NCT02472561|Mobile Health
911688|NCT02472561|Exercise
911689|NCT02472561|PAD
911690|NCT02472535|HoFH
911691|NCT02472509|Ursodeoxycholic acid (UDCA)
911692|NCT02472509|White blood cells (WBC)
911693|NCT02472509|Alanine Transaminase (ALT)
911694|NCT02472509|Alkaline Phosphatase (ALP)
911695|NCT02472509|Aspartate Aminotransferase (AST)
911696|NCT02472509|Gamma-Glutamyl Transpeptidase (GGT)
911697|NCT02472509|Lactate dehydrogenase (LDH)
911698|NCT02472509|Low-Density Lipoprotein (LDL)
911699|NCT02472509|High-Density Lipoprotein (HDL)
911700|NCT02472509|Glucose-6-phosphate dehydrogenase (G6PD)
911701|NCT02472509|Ultrasound (US)
911702|NCT02472470|rTMS
911703|NCT02472470|Depression
911704|NCT02472470|Youth
911705|NCT02472470|TBS
911706|NCT02472470|Brain Stimulation
911707|NCT02472470|Electrophysiology
911708|NCT02472470|Imaging
911709|NCT02472431|ADRC
911710|NCT02472431|Adipose-Derived Regenerative Cells
911711|NCT02472431|Fat Tissue
911712|NCT02472431|Stem Cells
911713|NCT02472431|Erectile Dysfunction
911714|NCT02472431|Arteriogenic Impotence
911715|NCT02472431|Venogenic Impotence
911716|NCT02472431|Vasculogenic Impotence
911717|NCT02472431|Male Impotence
911718|NCT02472431|Male Sexual Impotence
911719|NCT02472392|EWINGS, SARCOMA
911720|NCT02472379|Immune System
911721|NCT02472379|Behavioral Sciences
911722|NCT02472379|Women's Health
911723|NCT02472379|Health Psychology
911724|NCT02472379|Writing
911725|NCT02472353|breast
911726|NCT02472353|cancer
911727|NCT02472353|doxorubicin
911728|NCT02472353|metformin
911729|NCT02472353|cardiotoxicity
911730|NCT02472353|ejection fraction
911731|NCT02472353|LVEF
911732|NCT02472288|urinary retention
911733|NCT02472288|poststroke
911734|NCT02472288|electroacupuncture
911735|NCT02472288|randomized controlled trial
911736|NCT02472288|effectiveness
911737|NCT02472288|safety
911738|NCT02472262|Environmental
911739|NCT02472262|Enteric
911740|NCT02472249|TACE
911741|NCT02472249|CT perfusion
911742|NCT02472249|Liver blood flow
911743|NCT02472236|Type 2 Diabetes Mellitus
911744|NCT02472223|"Pink Eye"
911745|NCT02472197|Endometrial polyp
911746|NCT02472197|Hysteroscopic resection
911747|NCT02472197|Morcellation
911748|NCT02472184|Office hysteroscopy
911749|NCT02472184|Endometrial biopsy
911750|NCT02472184|Abnormal uterine bleeding
911751|NCT02472184|Uterine fibroids
911752|NCT02472171|n-3 polyunsaturated fatty acids
911753|NCT02472171|blueberries
911754|NCT02472158|Bandages
911755|NCT02472158|Central Venous Catheters
911756|NCT02472158|Catheter-Related Infections
911757|NCT02472145|Leukemia, myeloid, acute
911758|NCT02472145|DACOGEN
911759|NCT02472145|Decitabine
911760|NCT02472145|JNJ-56022473
911761|NCT02472145|CLS362
911762|NCT02472132|Central Venous Catheter
911763|NCT02472132|Point Of Care Ultra Sound
911764|NCT02472132|Sub Clavian Vein
911765|NCT02472132|Internal Jugular Vein
911766|NCT02472132|Trans Thoracic Echocardiography
911767|NCT02472119|Celiac disease
911768|NCT02472119|Gluten-free diet
911769|NCT02472119|Wheat flour treatment
911770|NCT02472119|Microbial transglutaminase
911771|NCT02472119|Lysine Ethyl Ester
911772|NCT02472119|Celiac Disease Treatment
911773|NCT02472106|Aortic Valve
911774|NCT02472106|TAVI
911775|NCT02472106|Stenosis
911776|NCT02472093|Postural exercise
911777|NCT02472093|Back pain
911778|NCT02472093|Tender points
911779|NCT02472093|Fibromyalgia
911780|NCT02472093|Perceptive rehabilitation
911785|NCT02472054|hemophagocytic lymphohistiocytosis (HLH)
911786|NCT02472054|Alemtuzumab (CAMPATH®)
911787|NCT02472041|chest drain
911788|NCT02472028|Cerebrovascular Disorders
911789|NCT02472028|Stroke
911790|NCT02472028|Antihypertensive Agents
911791|NCT02472028|Arterial Pressure
911792|NCT02472028|Memory Disorders
911793|NCT02472015|neuropsychiatric symptoms
911794|NCT02472015|dementia
911795|NCT02472015|telemedicine
911796|NCT02472015|long-term care facilities
911797|NCT02472002|Transplant coronary diseases
911798|NCT02472002|Mesenchymal cell therapy
911799|NCT02472002|Administration of CSM by NOGA system
911800|NCT02472002|Coronary disease in heart transplant patients
911801|NCT02471989|FODMAP
911802|NCT02471989|Diet
911803|NCT02471989|pH-impedance monitoring
911806|NCT02471963|Empagliflozin
911807|NCT02471963|Diabetes mellitus
911808|NCT02471963|Macro- and Microcirculation
911809|NCT02471963|Vascular Improvement
911810|NCT02471963|Endothelium function
911811|NCT02471937|Streptococcus agalactiae
911812|NCT02471937|Group B Streptococcus
911813|NCT02471937|Neonates
911814|NCT02471937|colonization
911815|NCT02471937|meningitis
911816|NCT02471937|Clonal Complex CC17
911817|NCT02471937|microbiota
911818|NCT02471937|next generation sequencing (NGS)
911819|NCT02471924|Pregnant women
911820|NCT02471911|DLBCL
911821|NCT02471911|Aggressive
911822|NCT02471911|Diffuse
911823|NCT02471911|Large
911824|NCT02471885|remote ischaemic conditioning
911825|NCT02471885|remote ischemic conditioning
911826|NCT02471885|cardio-oncology
911827|NCT02471885|anthracycline
911828|NCT02471885|troponin
911829|NCT02471885|chemotherapy
911830|NCT02471885|myocardial reperfusion injury
911831|NCT02471833|Hypertension
911832|NCT02471833|Prevention
911833|NCT02471833|Family History
911834|NCT02471833|inflammation
911835|NCT02471833|blood brain barrier
911836|NCT02471833|amyloid
911837|NCT02471820|Multiple Myeloma
911838|NCT02471794|Type II Diabetes
911839|NCT02471794|Personalized Health Planning
911840|NCT02471794|Shared Medical Appointments
911841|NCT02471781|Aortic Aneurysm
911842|NCT02471781|Aneurysm
911843|NCT02471781|Vascular Prosthesis
911844|NCT02471781|Vascular Disease
911845|NCT02471781|Blood Vessel Prosthesis Implantation
911846|NCT02471768|central pressure
911847|NCT02471768|Gensini score
911848|NCT02471768|pulsatility
911849|NCT02471768|coronary artery disease
911850|NCT02471755|electro-acupuncture
911851|NCT02471755|menopause
911852|NCT02471755|menopausal transition symptoms
911853|NCT02471755|efficacy
911854|NCT02471755|RCT
911855|NCT02471755|placebo control
911856|NCT02471729|Cardio-Renal Syndrome
911857|NCT02471729|Chronic Heart Failure
911858|NCT02471729|Renal Denervation
911859|NCT02471729|Sympathetic activation
911860|NCT02471729|Heart Failure
911861|NCT02471729|Cardiovascular Diseases
911862|NCT02471729|Heart Diseases
911863|NCT02471716|Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)
911864|NCT02471703|Total Hip Arthroplasty
911865|NCT02471703|Total Hip Replacement
911866|NCT02471703|Inflammatory Joint Disease
911867|NCT02471703|Non-Inflammatory Joint Disease
911868|NCT02471690|Volunteers
911869|NCT02471677|Ovarian stimulation
911870|NCT02471677|corifollitropin alfa
911871|NCT02471677|GnRH antagonist protocol
911872|NCT02471677|high responders
911873|NCT02471677|follitropin beta
911874|NCT02471664|Percutaneous mitral valve repair
911875|NCT02471664|Coronary sinus annuloplasty
911876|NCT02471664|Mitral loop cerclage
911877|NCT02471625|Controls
911878|NCT02471599|IgA nephropathy
911879|NCT02471599|tonsillitis
911880|NCT02471599|tonsil provocation test
911881|NCT02471599|Tonsillectomy
911882|NCT02471573|IVF
911883|NCT02471573|Freeze-all
911884|NCT02471573|frozen embryo transfer
911885|NCT02471573|fresh transfer
911886|NCT02471560|Microbiota
911887|NCT02471560|DMF
911888|NCT02471560|Gastro intestinal
911889|NCT02471560|MS
911890|NCT02471547|Recurrence
911891|NCT02471495|NMIBC
911892|NCT02471495|Non-Muscle-Invasive Bladder Cancer
911893|NCT02471495|Nonmuscle Invasive Bladder Cancer
911894|NCT02471495|BCG refractory
911895|NCT02471495|BCG failure
911896|NCT02471495|Carcinoma in situ
911897|NCT02471495|CIS
911898|NCT02471482|Near Infra Red Spectrometry
911899|NCT02471482|Cerebral oxygenation
911900|NCT02471482|Mozart music
911901|NCT02471404|Diabetes Mellitus Type 2,
911902|NCT02471404|metformin,
911903|NCT02471404|saxagliptin,
911904|NCT02471404|dapagliflozin,
911905|NCT02471404|glimepiride,
911906|NCT02471404|inadequate glycaemic control
911907|NCT02471378|Assay
911908|NCT02471378|Women
911909|NCT02471378|Infected
911910|NCT02471378|Antibodies
911911|NCT02471365|Exposure Assessment
911912|NCT02471365|Questionnaire
911913|NCT02471365|Product Use
911914|NCT02471365|Biomonitoring
911915|NCT02471352|Dermatologic Condition
911916|NCT02471352|Skin Disease
911917|NCT02471352|Biospecimen
911918|NCT02471352|Healthy Volunteers
911919|NCT02471352|Merkel Cell Carcinoma
911920|NCT02471339|Psychological Intervention
911921|NCT02471339|Coping
911922|NCT02471339|Mindfulness
911923|NCT02471339|Randomized
911924|NCT02471326|HIV Neutralizing Antibodies
911925|NCT02471326|HIV Therapy
911926|NCT02471313|Cross-Sectional Imaging
911927|NCT02471313|Chemoembolization
911928|NCT02471313|Radiation Therapy
911929|NCT02471313|Tumor Hypoxia
911930|NCT02471313|PET Imaging
911931|NCT02471300|Asthma
911932|NCT02471300|Inflammasome
911933|NCT02471300|Fasting
911934|NCT02471300|Airflow Obstruction
911935|NCT02471287|Ocular Genetic Diseases
911936|NCT02471287|GENETIC DISEASE
911937|NCT02471144|pediatric, chronic severe plaque psoriasis, secukinumab, etanercept
911938|NCT02471131|WATCHMAN
911939|NCT02471131|Atrial Fibrillation
911940|NCT02471131|Hybrid Ablation
911941|NCT02471131|Safety
911942|NCT02471131|Feasibility
911943|NCT02471131|Stroke Prevention
911944|NCT02471118|Inflammatory Type
911945|NCT02471092|satiety
911946|NCT02471092|glycemia
911947|NCT02471092|milk protein
911948|NCT02471079|Radiation-induced health problems
911949|NCT02471079|Cardiovascular events
911950|NCT02471079|Lung toxicity
911951|NCT02471053|Exercise
911952|NCT02471053|Quality of Life
911953|NCT02471053|Complementary Therapies
911954|NCT02471053|Neoadjuvant Therapy
911955|NCT02471053|Feasibility Studies
911956|NCT02471040|brain metabolism
911957|NCT02471040|cognitive function
911958|NCT02471027|Locally advanced cervical cancer
911959|NCT02471027|Neoadjuvant chemotherapy
911960|NCT02471027|Disease-free survival
911961|NCT02471027|Overall survival
911962|NCT02471014|Pneumovax23
911963|NCT02471014|Obesity
911964|NCT02471001|concentration
911965|NCT02471001|Isoflurane
911966|NCT02471001|cardioprotective
911967|NCT02471001|cardioplegia
911968|NCT02471001|heart surgery
911969|NCT02471001|Disorder
911970|NCT02471001|Heart
911971|NCT02471001|Functional
911972|NCT02471001|Postoperative
911973|NCT02470949|body weight
911974|NCT02470949|Hispanics
911975|NCT02470949|Energy Intake
911976|NCT02470949|Social Status
911977|NCT02470923|Smoking cessation
911978|NCT02470923|Nicotine
911979|NCT02470923|Spirometry
911980|NCT02470923|Internal medicine
911981|NCT02470910|Prostate Cancer
911982|NCT02470910|Stage I-III prostate adenocarcinoma
911983|NCT02470806|Venous leg ulcer
911984|NCT02470806|ulcer
911985|NCT02470806|venous stasis
911986|NCT02470806|compression
911987|NCT02470806|diabetic foot ulcers
911988|NCT02470806|dfu
911989|NCT02470806|vlu
911990|NCT02470793|Corneal Endothelial Cell Loss
911991|NCT02470793|Fuchs' Endothelial Dystrophy
911992|NCT02470793|Lamellar Keratoplasty
911993|NCT02470793|Descemet Stripping Endothelial Keratoplasty
911994|NCT02470793|Descemet Membrane Endothelial Keratoplasty
911995|NCT02470793|Minimal Surgical Procedure
911996|NCT02470728|patient readmission
911997|NCT02470728|pain relief units
911998|NCT02470728|pain centers
911999|NCT02470728|multidisciplinary pain clinics
912000|NCT02470728|multidisciplinary pain centers
912001|NCT02470728|pain clinics
912002|NCT02470728|hospital readmission
912003|NCT02470728|emergencies
912004|NCT02470728|emergency medicine
912005|NCT02470728|critical care
912006|NCT02470728|emergency treatment
912007|NCT02470728|opioid
912008|NCT02470728|acute pain service
912009|NCT02470715|genetic sequencing
912010|NCT02470715|genome
912011|NCT02470715|cancer
912012|NCT02470715|DNA
912013|NCT02470715|RNA
912014|NCT02470715|protein
912015|NCT02470715|metabolite
912016|NCT02470702|Volunteers
912017|NCT02470650|comparative effectiveness
912018|NCT02470598|Automated Peritoneal Dialysis
912019|NCT02470598|Adapted APD (aAPD)
912020|NCT02470598|Hydration status
912021|NCT02470598|Residual Renal Function
912022|NCT02470598|Ultrafiltration
912023|NCT02470585|Overall Survival
912024|NCT02470585|BRCA
912025|NCT02470585|Veliparib
912026|NCT02470585|Ovarian
912027|NCT02470585|Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP)
912028|NCT02470585|ABT-888
912029|NCT02470585|Paclitaxel
912030|NCT02470585|Carboplatin
912031|NCT02470585|Randomized
912032|NCT02470546|Hepatic encephalopathy
912033|NCT02470546|Metformin
912034|NCT02470546|Liver cirrhosis
912035|NCT02470481|Psoriatic arthritis
912036|NCT02470468|Immunotherapy
912037|NCT02470468|Metastatic
912038|NCT02470468|NSCLC
912039|NCT02470468|Biological
912040|NCT02470468|Lung Cancer
912041|NCT02470468|Vaccine
912042|NCT02470455|Atorvastatin
912043|NCT02470455|Prediabetics
912044|NCT02470455|HbA1c
912045|NCT02470416|duodenal
912046|NCT02470416|ampulla
912047|NCT02470403|dysglycemic, normoglycemic, prediabetes, type 2 diabetes mellitus
912048|NCT02470390|Volunteer
912049|NCT02470390|Pharmacokenetics (PK) (plasma and Cerebrospinal Fluid [CSF])
912050|NCT02470377|MdDS
912051|NCT02470377|TMS
912052|NCT02470377|fMRI
912053|NCT02470377|EEG
912054|NCT02470364|Myasthenia gravis
912055|NCT02470364|Quality of life
912056|NCT02470325|Cerebral palsy
912057|NCT02470325|Genetic neurodegenerative diseases
912058|NCT02470312|utility of MediGuide system
912059|NCT02470312|CRT
912060|NCT02470312|EP
912061|NCT02470299|ketorolac
912062|NCT02470299|GTPase
912063|NCT02470299|cancer
912064|NCT02470299|peritoneal
912065|NCT02470299|fallopian
912066|NCT02470299|ovarian
912067|NCT02470273|Melanoma
912068|NCT02470260|Diabetes
912069|NCT02470260|Pre-diabetes
912070|NCT02470260|Cognition
912071|NCT02470260|Depressive symptoms
912072|NCT02470247|Transcatheter Aortic Valve Implantation
912073|NCT02470234|ADHD
912074|NCT02470234|Children
912075|NCT02470234|Pharmacokinetics
912076|NCT02470221|goal-directed fluid therapy
912077|NCT02470221|intraoperative hemodynamics
912078|NCT02470221|postoperative complications
912079|NCT02470208|Cytomegalovirus reactivation in stem cell transplant
912080|NCT02470182|sleep apnea
912081|NCT02470182|snoring
912082|NCT02470156|community based participatory research
912083|NCT02470156|healthy eating
912084|NCT02470156|physical activity
912085|NCT02470156|obesity
912086|NCT02470143|Human-computer interaction
912087|NCT02470143|Fear
912088|NCT02470143|Motivation
912089|NCT02470143|Usability
912090|NCT02470130|simulation
912091|NCT02470130|anxiety
912092|NCT02470130|debriefing
912093|NCT02470130|memorization
912094|NCT02470104|children
912095|NCT02470104|bone marrow transplant
912096|NCT02470104|autologous
912097|NCT02470104|allogeneic
912098|NCT02470104|breastmilk
912099|NCT02470104|hematopoietic stem cell transplantation (HSCT)
912100|NCT02470078|extubation
912101|NCT02470065|NSCLC
912102|NCT02470065|Early stage
912103|NCT02470065|Phase II
912104|NCT02470065|Randomized
912105|NCT02470065|EGFR mutated
912106|NCT02470052|Endobronchial Valves
912107|NCT02470052|Intrabronchial Valves
912108|NCT02470052|Bronchial Valve
912109|NCT02470052|Chronic Obstructive Pulmonary Disease
912110|NCT02470052|Pulmonary Disease, Chronic Obstructive
912111|NCT02470052|Bronchoscopic Lung Volume Reduction
912112|NCT02470052|Emphysema
912113|NCT02470052|Pulmonary Emphysema
912114|NCT02470052|Lung Diseases
912115|NCT02470052|Respiratory Tract Disease
912116|NCT02470013|Malnutrition
912117|NCT02470013|Geriatrics
912118|NCT02470013|Enteral Nutrition
912119|NCT02470000|myofascial pain
912120|NCT02470000|neck
912121|NCT02470000|laser
912122|NCT02470000|elastography
912123|NCT02470000|shear wave velocity
912124|NCT02470000|randomized control trial
912125|NCT02470000|Intravascular Laser Irradiation of Blood
912126|NCT02469987|safety
912127|NCT02469987|tolerability
912128|NCT02469987|immunogenicity
912129|NCT02469987|MYL-1402O
912130|NCT02469987|PK
912131|NCT02469987|Avastin®
912132|NCT02469987|biosimilarity
912133|NCT02469987|male
912134|NCT02469974|Myelofibrosis
912135|NCT02469974|RUXOLITINIB
912136|NCT02469974|Autologous stem cell transplant
912137|NCT02469948|spasticity
912138|NCT02469948|botulinum toxin
912139|NCT02469948|ultrasonography guidance
912140|NCT02469948|electric stimulation guidance
912141|NCT02469948|stroke
912142|NCT02469935|Validation
912143|NCT02469935|Surgeon-performed ultrasound
912144|NCT02469935|Gallstones
912145|NCT02469909|Decannulation
912146|NCT02469909|tracheostomy
912147|NCT02469896|ALS
912148|NCT02469896|tocilizumab
912149|NCT02469896|biomarker
912150|NCT02469870|Parents of children who have autism
912151|NCT02469870|video-conferencing
912152|NCT02469870|Applied Behavior Analysis
912153|NCT02469870|Acceptance Commitment Training
912154|NCT02469870|optimism training
912155|NCT02469870|Positive Behavior Support
912156|NCT02469857|AB103
912157|NCT02469857|Necrotizing fasciitis
912158|NCT02469818|pocus
912159|NCT02469818|ultrasonography
912160|NCT02469818|glenohumeral dislocation
912161|NCT02469792|Anterior cruciate ligament
912162|NCT02469792|Ligament rupture
912163|NCT02469792|Intraarticular injection
912164|NCT02469792|ADRC
912165|NCT02469792|Adipose-derived regenerative cells
912166|NCT02469792|Adipose tissue
912167|NCT02469792|Stem cells
912168|NCT02469779|Tobacco Prevention
912169|NCT02469779|ASPIRE Website
912170|NCT02469779|Surveys
912171|NCT02469779|Questionnaires
912172|NCT02469779|Focus Groups
912173|NCT02469779|Health Interactive Website
912174|NCT02469766|ureteral stones
912175|NCT02469766|ureter
912176|NCT02469766|ureteroscopy
912177|NCT02469766|flexible
912178|NCT02469766|SWL
912179|NCT02469753|NSAIDs
912180|NCT02469753|Anti-TNF
912181|NCT02469753|syndesmophytes
912182|NCT02469753|mSASSS
912183|NCT02469740|Ticagrelor
912184|NCT02469740|Clopidogrel
912185|NCT02469740|Coronary Artery Disease
912186|NCT02469740|Percutaneous Coronary Intervention
912187|NCT02469740|Acute Coronary Syndrome
912188|NCT02469714|Patient Navigator
912189|NCT02469714|Integrated Care
912190|NCT02469714|Latino
912191|NCT02469714|Mental health and wellness
912192|NCT02469714|Physical health and wellness
912193|NCT02469688|cedar pollinosis
912194|NCT02469688|immunological response,
912195|NCT02469688|ASP4070
912196|NCT02469688|vaccine
912197|NCT02469675|Spinal Cord Injuries
912198|NCT02469675|Amyotrophic Lateral Sclerosis
912199|NCT02469675|Transcranial magnetic stimulation, single pulse
912200|NCT02469675|non-invasive brain stimulation
912201|NCT02469662|Total Elbow Arthroplasty
912202|NCT02469662|TEA
912203|NCT02469662|Elbow Arthroplasty
912204|NCT02469662|Elbow Replacement
912205|NCT02469662|Advanced Rheumatoid Arthritis
912206|NCT02469662|Post-Traumatic Arthritis
912207|NCT02469662|Degenerative Arthritis
912208|NCT02469662|Elbow Joint Destruction
912209|NCT02469662|Post-Traumatic Lesions or Bone Loss
912210|NCT02469662|Ankylosed Joints
912211|NCT02469662|Acute Comminuted Articular Fracture
912212|NCT02469662|significantly compromises daily living activities
912213|NCT02469662|degree of joint or soft tissue damage precludes reliable osteosynthesis
912214|NCT02469662|precludes less radical procedures, including 13-C3 fractures of the distal humerus
912215|NCT02469610|Post surgical pain
912216|NCT02469584|prolapse
912217|NCT02469584|anterior colporrhaphy
912218|NCT02469545|depression
912219|NCT02469545|microbiota-gut-brain axis
912220|NCT02469545|Lactobacillus Plantarum 299v
912221|NCT02469545|probiotic
912222|NCT02469480|MCRC
912223|NCT02469480|iron substitution
912224|NCT02469480|iron deficiency anemia
912225|NCT02469467|phosphate binder
912226|NCT02469467|dialysis
912227|NCT02469454|etonogestrel-implant
912228|NCT02469454|newborn
912229|NCT02469454|growth
912230|NCT02469454|Child Development
912231|NCT02469441|coffee
912232|NCT02469441|postoperative ileus
912233|NCT02469441|colorectal surgery
912234|NCT02469428|Controlled human exposure study
912235|NCT02469428|Ozone
912236|NCT02469428|Inflammation
912237|NCT02469415|Leukemia
912238|NCT02469415|Myelodysplastic syndromes
912239|NCT02469415|MDS
912240|NCT02469415|Lower-risk
912241|NCT02469415|Pacritinib
912242|NCT02469415|5-azacitidine
912243|NCT02469415|Azacitidine
912244|NCT02469415|5-azacytidine
912245|NCT02469415|Vidaza
912246|NCT02469415|5-AZC
912247|NCT02469415|AZA-CR
912248|NCT02469415|Ladakamycin
912249|NCT02469415|NSC-102816
912250|NCT02469415|Azacytidine
912251|NCT02469415|Decitabine
912252|NCT02469415|Dacogen
912253|NCT02469402|reduced
912254|NCT02469402|protein
912255|NCT02469402|formula
912256|NCT02469402|Alpha-lactalbumin
912257|NCT02469402|infant
912258|NCT02469389|Schizophrenia
912259|NCT02469389|Negative Symptoms
912260|NCT02469363|Macintosh laryngoscope
912261|NCT02469363|McCoy laryngoscope
912262|NCT02469363|C-Mac videolaryngoscope
912263|NCT02469363|McGrath videolaryngoscope
912264|NCT02469363|Hemodynamic parameters
912265|NCT02469350|Gait and balance disorders
912266|NCT02469350|serious game
912267|NCT02469311|infection; arthroplasty; chlorhexidine; hip; knee
912268|NCT02469298|acute, uncomplicated influenza
912269|NCT02469298|Danirixin
912270|NCT02469298|oseltamivir
912271|NCT02469285|Fatty acids
912272|NCT02469285|Lipids
912273|NCT02469285|Nitroso compounds
912274|NCT02469285|Lipid metabolism
912275|NCT02469285|Gut metabolism
912276|NCT02469259|oxytocin
912277|NCT02469259|PTSD
912278|NCT02469259|Alcohol Use Disorder
912279|NCT02469259|social cognition
912280|NCT02469259|craving
912281|NCT02469259|fear-potentiated startle
912282|NCT02469246|HIV
912283|NCT02469246|HIV-1 Positive
912284|NCT02469246|Virologically-Suppressed
912285|NCT02469220|Diet
912286|NCT02469220|FODMAP
912287|NCT02469220|Gut microbiota
912288|NCT02469220|Inflammation
912289|NCT02469207|regenerative medicine
912290|NCT02469207|stem cells
912291|NCT02469207|immunomodulatory
912292|NCT02469207|induced pluripotent stem cells
912293|NCT02469207|gut physiology
912294|NCT02469129|positron emission tomography (PET) imaging
912295|NCT02469129|poly(ADP-ribose) polymerase 1 (PARP1)
912296|NCT02469129|[18F]FluorThanatrace ([18F]FTT)
912297|NCT02469129|PARP1 inhibitors
912298|NCT02469129|cancer treatments
912299|NCT02469103|capsule colonoscopy
912300|NCT02469103|ulcerative colitis
912301|NCT02469077|Chronic Low Back Pain
912302|NCT02469064|mechanical ventilation
912303|NCT02469064|respiratory muscle
912304|NCT02469064|weaning
912305|NCT02469064|training
912306|NCT02469064|Intensive care
912307|NCT02469012|chronic hepatitis C
912308|NCT02469012|antiviral treatment
912309|NCT02469012|interferon-free
912310|NCT02469012|neurocognitive performance
912311|NCT02469012|emotional state
912312|NCT02469012|quality of life
912313|NCT02468999|Intranasal insulin
912314|NCT02468986|Rheumatoid Arthritis
912315|NCT02468973|health behavior
912316|NCT02468973|consultation
912317|NCT02468973|undergraduate
912318|NCT02468960|Coronary Artery Disease
912319|NCT02468960|OPN NC
912320|NCT02468960|Angina
912321|NCT02468960|Stable
912322|NCT02468960|Unstable
912323|NCT02468947|Neonatal sepsis
912324|NCT02468934|electrical stimulation
912325|NCT02468934|neurostimulation
912326|NCT02468934|neuromodulation
912327|NCT02468934|TKA pain
912328|NCT02468934|pain following total knee replacement
912329|NCT02468934|total knee arthroplasty
912330|NCT02468921|Goitre
912331|NCT02468921|thyroid disease
912332|NCT02468921|struma
912333|NCT02468895|Myositis
912334|NCT02468895|Idiopathic inflammatory myopathy
912335|NCT02468895|Antibodies
912336|NCT02468895|Genetics
912337|NCT02468895|Biomarkers
912338|NCT02468882|Breast cancer
912339|NCT02468882|Radiotherapy
912340|NCT02468882|Toxicity
912341|NCT02468882|Outcomes
912342|NCT02468882|Watercress
912343|NCT02468869|recall
912344|NCT02468869|discharge communication
912345|NCT02468843|Deep brain stimulation
912346|NCT02468843|DBS
912347|NCT02468843|Dystonia
912348|NCT02468843|DYT1
912349|NCT02468830|mirabegron
912350|NCT02468830|antimuscarinics
912351|NCT02468830|beta 3 agonist
912352|NCT02468830|overactive bladder
912353|NCT02468830|children
912354|NCT02468817|parathyroid hormone (PTH)
912355|NCT02468817|bone mineral density (BMD)
912356|NCT02468804|Parkinson's
912357|NCT02468804|Non-parkinsons
912358|NCT02468791|Rheumatoid Arthritis
912359|NCT02468791|Autoimmune Diseases
912360|NCT02468791|Rituximab
912361|NCT02468791|Immune System Diseases
912362|NCT02468791|Joint Diseases
912363|NCT02468791|Rheumatic Diseases
912364|NCT02468778|HeartMate PHP
912365|NCT02468778|High Risk PCI
912366|NCT02468778|Left Ventricular Dysfunction
912367|NCT02468778|Thoratec Corporation
912368|NCT02468713|Omega-3
912369|NCT02468713|Blood lipid profiles
912370|NCT02468713|DHA
912371|NCT02468713|EPA
912372|NCT02468713|Triglyceride
912373|NCT02468713|Glucose
912374|NCT02468713|Insulin
912375|NCT02468713|LDL
912376|NCT02468713|TPN
912377|NCT02468687|Relapsed/Refractory
912378|NCT02468674|Sarcopenia, muscle wasting, elderly, strength, physical
912379|NCT02468674|function, muscle, gait speed
912381|NCT02468648|Oral Therapy
912382|NCT02468648|Liver Biopsy
912383|NCT02468648|Chronic Hepatitis C
912384|NCT02468635|Pulmonary rehabilitation
912385|NCT02468635|chronic obstructive pulmonary disease
912386|NCT02468635|physical ability
912387|NCT02468635|pulmonary function
912388|NCT02468635|quality of daily life
912389|NCT02468596|Axonal excitability
912390|NCT02468596|Neuropathy
912391|NCT02468596|QTRAC
912392|NCT02468596|anti-MAG
912393|NCT02468596|Electrophysiology
912394|NCT02468583|Osteoarthritis
912395|NCT02468583|Post-traumatic
912396|NCT02468583|Knee
912397|NCT02468583|Pain
912398|NCT02468583|Steroid
912399|NCT02468583|Intra-articular
912400|NCT02468583|Injection
912401|NCT02468570|PKU
912402|NCT02468570|PEG-PAL
912403|NCT02468570|Pegvaliase
912404|NCT02468570|BMN 165
912405|NCT02468570|rAv-PAL PEG
912406|NCT02468570|PRISM 302
912407|NCT02468570|PRISM 303
912408|NCT02468570|BioMarin
912409|NCT02468570|165-302
912410|NCT02468557|Relapsed/refractory pancreatic ductal adenocarcinoma
912411|NCT02468557|Previously untreated pancreatic ductal adenocarcinoma
912412|NCT02468544|Engagement in care
912413|NCT02468544|mHealth
912414|NCT02468531|Xenon
912415|NCT02468531|Standford A acute aortic dissection
912416|NCT02468505|Structured transition support program
912417|NCT02468505|Transition 'as usual'
912418|NCT02468492|Knee Osteoarthritis
912419|NCT02468492|Platelet Rich Plasma
912420|NCT02468492|Mechanism of Action
912421|NCT02468492|Stem Cells
912422|NCT02468492|Synovial Fluid
912423|NCT02468479|Liver cirrhosis
912424|NCT02468466|suicide
912425|NCT02468466|prevention
912426|NCT02468453|velos
912427|NCT02468453|Vascular
912428|NCT02468453|Rejuvenation
912429|NCT02468440|renal insufficiency
912430|NCT02468440|kidney transplant
912431|NCT02468440|educational therapy
912432|NCT02468414|Peritoneal Dialysis
912433|NCT02468414|End Stage Renal Disease
912434|NCT02468414|Anemia
912435|NCT02468388|maltitol
912436|NCT02468388|xylitol
912437|NCT02468388|quantitative light-induced fluorescence
912438|NCT02468388|saliva pH
912439|NCT02468388|re-mineralization
912440|NCT02468388|dental caries
912441|NCT02468362|Intersphincteric resection
912442|NCT02468362|laparoscopic rectal rescetion
912443|NCT02468362|total mesorectal excsison
912444|NCT02468349|Acute Myocardial Infarction
912445|NCT02468349|Telemedicine
912446|NCT02468349|Readmissions
912447|NCT02468336|Physiology
912448|NCT02468323|PONV
912449|NCT02468323|Palonosetron
912450|NCT02468323|Ondansetron
912451|NCT02468323|Cesarean section
912452|NCT02468310|Maternal mortality
912453|NCT02468310|Neonatal mortality
912454|NCT02468310|Neonatal morbidity
912455|NCT02468310|Text messaging
912456|NCT02468310|Clinical decision making
912457|NCT02468310|Maternal Morbidity
912458|NCT02468271|Clinimetrics
912459|NCT02468271|Lung function
912460|NCT02468271|Lung clearance index
912461|NCT02468258|Assisted Reproduction
912462|NCT02468245|Nursing intervention
912463|NCT02468245|compliance
912464|NCT02468232|chronic heart failure
912465|NCT02468232|cardiovascular death
912466|NCT02468232|hospitalization
912467|NCT02468232|outcome study
912468|NCT02468232|worsening heart failure
912469|NCT02468232|NT-proBNP
912470|NCT02468232|NYHA
912471|NCT02468232|KCCQ
912472|NCT02468232|HF-rEF
912473|NCT02468219|aortic stenosis
912474|NCT02468219|aortic valve replacement
912475|NCT02468219|transcatheter aortic valve implantation
912476|NCT02468219|frailty
912477|NCT02468219|cardiac rehabilitation
912478|NCT02468193|Cushing's syndrome
912479|NCT02468193|osilodrostat
912480|NCT02468193|LCI699
912481|NCT02468193|ectopic corticotropin syndrome
912482|NCT02468193|adrenal adenoma
912483|NCT02468193|adrenal carcinoma
912484|NCT02468193|ACTH-Independent Macronodular Adrenal Hyperplasia
912485|NCT02468193|AIMAH
912486|NCT02468193|Primary Pigmented Nodular Adrenal Dysplasia
912487|NCT02468193|PPNAD
912488|NCT02468128|Analgesic
912489|NCT02468128|Opioids
912490|NCT02468128|Pain relief after surgery
912491|NCT02468128|Dinalbuphine
912492|NCT02468128|Sebacoyl Dinalbuphine Ester
912493|NCT02468128|SDE
912494|NCT02468128|SDN
912495|NCT02468128|LT1001
912496|NCT02468102|Rivaroxaban
912497|NCT02468102|Venous Thrombosis/Pulmonary Embolism
912498|NCT02468102|Stroke Prevention in Atrial Fibrillation
912499|NCT02468102|Anticoagulants
912500|NCT02468102|Hematologic Agents
912501|NCT02468102|Therapeutic Uses
912502|NCT02468102|Observational
912503|NCT02468102|Pulmonary Embolism
912504|NCT02468102|Venous Thrombosis
912505|NCT02468102|Venous Thromboembolism
912506|NCT02468102|Intracranial Hemorrhages
912507|NCT02468102|Gastrointestinal Hemorrhage
912508|NCT02468076|ERCP
912509|NCT02468076|radiofrequency ablation
912510|NCT02468076|obstructive jaundice
912511|NCT02468050|Anxiety
912512|NCT02468050|Depression
912513|NCT02468050|Exercise
912514|NCT02468050|Breast Cancer
912515|NCT02468050|Biopsy
912516|NCT02468050|Screening
912517|NCT02468050|Diagnosis
912518|NCT02468037|iron
912519|NCT02468037|diabetes
912520|NCT02468037|phlebotomy
912521|NCT02467998|meaningful use
912522|NCT02467998|electronic health records
912523|NCT02467998|structured language
912524|NCT02467998|NPWT
912525|NCT02467998|PQRS
912526|NCT02467985|gynecological laparoscopic surgery
912527|NCT02467972|Hunger and satiety
912528|NCT02467972|Hormones gastrointestinal
912529|NCT02467972|Bowel movements
912530|NCT02467959|emergency ultrasound
912531|NCT02467959|acute appendicitis
912532|NCT02467959|bedside ultrasound
912533|NCT02467920|exenatide
912534|NCT02467920|glargine
912535|NCT02467920|aspart 30
912536|NCT02467894|Adherence
912537|NCT02467894|Exercise
912538|NCT02467881|Physical Activity
912539|NCT02467881|Sedentary
912540|NCT02467881|Lifestyle Intervention
912541|NCT02467868|Pegfilgrastim
912542|NCT02467868|Granulocyte Colony Stimulating Factor (G-CSF)
912543|NCT02467868|Breast Cancer
912544|NCT02467868|Neutropenia
912545|NCT02467855|Drug therapy
912546|NCT02467842|Influenza vaccine
912547|NCT02467842|Quadrivalent
912548|NCT02467842|Inactivated cell culture-derived
912549|NCT02467829|Cerebral Palsy
912550|NCT02467829|Walking Aids
912551|NCT02467816|Secondary schools
912552|NCT02467816|School lunch
912553|NCT02467816|Plate waste
912554|NCT02467803|humeral fracture
912555|NCT02467803|exercise
912556|NCT02467803|musculoskeletal manipulations
912557|NCT02467777|orthopaedics
912558|NCT02467777|post-operative warming
912559|NCT02467764|Knee
912560|NCT02467764|Knee osteoarthritis
912561|NCT02467764|Knee replacement
912562|NCT02467764|Hip
912563|NCT02467764|Hip osteoarthritis
912564|NCT02467764|Hip replacement
912565|NCT02467725|Preimplantation Embryo Development
912566|NCT02467712|Fongal infection
912567|NCT02467712|joint prosthesis
912568|NCT02467712|prosthetic reconstruction
912569|NCT02467699|Knee
912570|NCT02467699|Knee osteoarthritis
912571|NCT02467699|Knee replacement
912572|NCT02467621|Stress ulcer prophylaxis
912573|NCT02467621|Proton pump inhibitor
912574|NCT02467621|Pneumonia
912575|NCT02467621|Clostridium difficile infection
912576|NCT02467608|HUEXC030
912577|NCT02467608|Pulmonary Tuberculosis
912578|NCT02467595|no muscle relaxant
912579|NCT02467595|rocuronium
912580|NCT02467595|intubation condition
912581|NCT02467595|tracheal intubation
912582|NCT02467595|operating room time
912583|NCT02467595|low-dose rocuronium
912584|NCT02467582|Aspirin
912585|NCT02467582|colon cancer
912586|NCT02467582|stage II
912587|NCT02467582|stage III
912588|NCT02467582|PIK3CA
912589|NCT02467582|double-blind
912590|NCT02467582|placebo
912591|NCT02467582|Adjuvant Treatment
912592|NCT02467556|CRPS
912593|NCT02467556|intervention
912594|NCT02467556|multimodal
912595|NCT02467543|Primary dysmenorrhea
912596|NCT02467543|Viburnum opulus 3X
912597|NCT02467543|Homoeopathic
912598|NCT02467530|end stage renal disease
912599|NCT02467530|peritoneal dialysis (PD)
912600|NCT02467530|advanced glycation end products
912601|NCT02467530|Gut Microbiota Inflammation
912602|NCT02467517|Neuropathic pain
912603|NCT02467517|Ketamine
912604|NCT02467517|Magnesium sulfate
912605|NCT02467517|Quality of life
912606|NCT02467517|Anxiety and depression
912607|NCT02467517|Mood and sleep
912608|NCT02467491|Exercise
912609|NCT02467491|Technology
912610|NCT02467491|Aging
912611|NCT02467478|Diabetes Mellitus, Type 2
912612|NCT02467478|Endothelial cells
912613|NCT02467478|Cellular biomarker
912614|NCT02467478|endothelial dysfunction
912615|NCT02467478|CD34+
912616|NCT02467478|Impaired renal function
912617|NCT02467465|Fasciosis plantar
912618|NCT02467465|physiotherapy
912619|NCT02467465|fascitis plantar
912620|NCT02467465|dry needling
912621|NCT02467439|unaware intervention;
912622|NCT02467439|contract sexual partner referral
912623|NCT02467439|peer referral
912624|NCT02467426|Mesothelioma, malignant
912625|NCT02467426|Chemotherapy
912626|NCT02467413|Alzheimer's Disease
912627|NCT02467413|Vascular Dementia
912628|NCT02467400|bone formation
912629|NCT02467387|Non-ischemic Heart Failure
912630|NCT02467387|Stem Cells
912631|NCT02467374|OCD
912632|NCT02467374|Neuroimaging
912633|NCT02467374|Fear Extinction
912634|NCT02467374|Behavior Therapy
912635|NCT02467361|Neoplasms
912636|NCT02467296|Sodium
912637|NCT02467296|outcomes
912638|NCT02467283|chronic periodontitis
912639|NCT02467283|genetics
912640|NCT02467283|microarray analysis
912641|NCT02467283|gingiva
912642|NCT02467283|genes
912643|NCT02467283|inflammation
912644|NCT02467270|Chronic Phase Chronic Myeloid Leukemia
912645|NCT02467270|CML
912646|NCT02467270|Leukemia
912647|NCT02467270|Leukemia, Myeloid
912648|NCT02467270|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
912649|NCT02467270|Neoplasms by Histologic Type
912650|NCT02467270|Neoplasms
912651|NCT02467270|Myeloproliferative Disorders
912652|NCT02467270|Bone Marrow Diseases
912653|NCT02467270|Hematologic Diseases
912654|NCT02467270|CP-CML
912655|NCT02467244|Hypothyroidism
912656|NCT02467244|Serum adiponectin
912657|NCT02467244|hsCRP
912658|NCT02467244|Homeostatic Model Assessment (HOMA-IR)
912659|NCT02467244|Quantitative Insulin Sensitivity Check Index (QUICKI)
912660|NCT02467244|Cardiovascular risk assessment scoring (Framingham scoring)
912661|NCT02467244|Levothyroxin
912669|NCT02467218|Hyperbaric Oxygen Treatment
912670|NCT02467218|Fibromyalgia
912671|NCT02467218|Global Function
912672|NCT02467218|Sleep
912673|NCT02467218|Chronic Pain
912674|NCT02467218|Depression
912675|NCT02467218|Anxiety
912676|NCT02467205|Physical Activity
912677|NCT02467179|Arrhythmia
912678|NCT02467179|cavo-tricuspid isthmus
912679|NCT02467179|atrial fibrillation
912680|NCT02467179|atrial fibrillation ablation
912681|NCT02467166|esophagoscopy
912682|NCT02467166|atrial fibrillation ablation
912683|NCT02467166|radio frequency catheter ablation
912684|NCT02467166|esophageal lesion
912685|NCT02467166|arrhythmia
912686|NCT02467166|atrial fibrillation
912687|NCT02467166|AF
912688|NCT02467166|esophageal damage
912689|NCT02467153|Sarcopenia
912690|NCT02467153|Older adult
912691|NCT02467153|Vitamin D
912692|NCT02467153|Physical activity
912693|NCT02467153|Muscle atrophy
912694|NCT02467153|Muscle strength
912695|NCT02467153|Physical function
912696|NCT02467153|Frailty
912697|NCT02467153|Osteoporosis
912698|NCT02467140|Inguinal hernia repair
912699|NCT02467140|Hernia
912700|NCT02467140|ProGrib self-fixating mesh
912701|NCT02467140|Biological mesh
912702|NCT02467140|Tack fixation
912703|NCT02467101|cicatricial alopecia
912704|NCT02467101|treatment
912705|NCT02467101|placebo
912706|NCT02467101|double-blind
912707|NCT02467088|PMS
912708|NCT02467088|Individualised homoeopathic treatment
912709|NCT02467088|Indian females
912710|NCT02467075|CT, iodinated contrast, contrast-induced AKI, kidney injury
912711|NCT02467062|4D flow
912712|NCT02467049|ECG
912713|NCT02467049|Ultrasound
912714|NCT02467049|Peripherally Inserted Central Catheters
912715|NCT02467049|PICC
912716|NCT02467036|overweight children
912717|NCT02467036|overweight parents
912718|NCT02467036|eating in the absence of hunger
912719|NCT02467036|families with overweight child
912720|NCT02467036|bmi
912721|NCT02467036|body mass index
912722|NCT02467036|treatment
912723|NCT02467036|behavioral treatment
912724|NCT02467036|family based treatment
912725|NCT02467036|experiments
912726|NCT02467036|intervention
912727|NCT02467036|psychophysiological response to food cues
912728|NCT02467023|chronic critical illness
912729|NCT02467023|strength training
912730|NCT02467023|exercise
912731|NCT02467023|sepsis
912732|NCT02467023|mechanical ventilation
912733|NCT02467010|Bortezomib
912734|NCT02467010|cyclophosphamide
912735|NCT02467010|dexamethason
912736|NCT02467010|multiple myeloma
912737|NCT02466997|Vitiligo
912738|NCT02466997|Tacrolimus
912739|NCT02466997|Face
912740|NCT02466984|metoclopramide
912741|NCT02466984|subcutaneous route
912742|NCT02466984|palliative care
912743|NCT02466984|pharmacology
912744|NCT02466984|bioavailability
912745|NCT02466984|nausea
912746|NCT02466984|vomiting
912747|NCT02466958|depressed
912748|NCT02466958|older adults
912749|NCT02466958|antidepressants
912750|NCT02466958|depression
912751|NCT02466958|MDD
912752|NCT02466919|Helicobacter pylori
912753|NCT02466906|Stage III colon cancer
912754|NCT02466906|rhGM-CSF
912755|NCT02466906|Immunotherapy
912756|NCT02466906|Surgery
912757|NCT02466906|Adjuvant chemotherapy
912758|NCT02466880|Type 2
912759|NCT02466880|NIDDM
912760|NCT02466867|Ringworm
912761|NCT02466854|Bleeding
912762|NCT02466854|Acute Coronary Syndrome
912763|NCT02466854|percutaneous coronary intervention
912764|NCT02466854|1 year follow up
912765|NCT02466815|Healthy
912766|NCT02466815|JNJ-42756493
912767|NCT02466802|Advanced
912768|NCT02466789|Bleeding Disorder, inherited
912769|NCT02466789|Von Willebrands Disease
912770|NCT02466789|Hematologic Test
912771|NCT02466789|VWF
912772|NCT02466789|VWD
912773|NCT02466763|round window
912774|NCT02466763|cochlear implants
912775|NCT02466763|cochleostomy
912776|NCT02466737|axillary surgery
912777|NCT02466737|sentinel lymph node biopsy
912778|NCT02466711|gastric motility
912779|NCT02466698|Colectomy
912780|NCT02466698|Surgical Procedures, Operative
912781|NCT02466685|Bipolar
912782|NCT02466685|Depression
912783|NCT02466685|Cognition
912784|NCT02466685|Cognitive
912785|NCT02466659|IXT
912786|NCT02466646|Periodontal Debridement
912787|NCT02466646|Gingival Crevicular Fluid
912788|NCT02466646|Aggressive Periodontitis
912789|NCT02466646|Interleukin-1beta
912790|NCT02466646|Interleukin-17
912791|NCT02466620|Body Weight
912792|NCT02466620|Resuscitation
912793|NCT02466620|Pediatric weight estimation
912794|NCT02466607|Retinal function
912800|NCT02466542|Esmolol
912801|NCT02466542|Pain
912802|NCT02466542|Anesthesia
912803|NCT02466542|Analgesia
912804|NCT02466516|GS-4997
912805|NCT02466516|Non-alcoholic fatty liver disease (NAFLD)
912806|NCT02466516|Fibrosis
912807|NCT02466516|Simtuzumab
912808|NCT02466477|Pharmacogenomic
912809|NCT02466477|Pharmacogenomic Testing
912810|NCT02466477|Pharmacogenomics
912811|NCT02466477|Genetic Testing
912812|NCT02466477|Genetics
912813|NCT02466477|Major Depressive Disorder
912814|NCT02466477|GeneSight
912815|NCT02466477|Enhanced GeneSight
912816|NCT02466477|Psychotropic
912817|NCT02466438|Antibiotics
912818|NCT02466438|Piperacillin-tazobactam
912819|NCT02466438|Resistant bacteria
912820|NCT02466412|smoking
912821|NCT02466412|nicotine absorption
912822|NCT02466412|potential modified risk tobacco product
912823|NCT02466412|cigarette
912824|NCT02466412|Carbon Heated Tobacco Product
912825|NCT02466373|clonidine
912826|NCT02466373|pharmacodynamics
912827|NCT02466373|pharmacokinetics
912828|NCT02466373|intensive care
912829|NCT02466373|delirium
912830|NCT02466360|Non-specific chronic lower back pain
912831|NCT02466360|Physical activity
912832|NCT02466360|Self-exercises
912833|NCT02466360|Brakes
912834|NCT02466360|Levers
912835|NCT02466360|Adhesion
912836|NCT02466360|Self-care
912837|NCT02466321|Inverse Reverse Shoulder
912838|NCT02466308|sustained acoustic medicine
912839|NCT02466308|therapeutic ultrasound
912840|NCT02466308|SAM
912841|NCT02466308|LITUS
912842|NCT02466269|Facial Nerve Injuries
912843|NCT02466256|Intraocular lens implantation
912844|NCT02466230|Magnetic stimulation of the brain
912845|NCT02466230|Antidepressant mechanisms
912846|NCT02466217|Auto-immune disease
912847|NCT02466217|Auto-inflammatory disease
912848|NCT02466217|Omics
912849|NCT02466217|System biology
912850|NCT02466191|nystagmus
912851|NCT02466191|pharmacological trial
912852|NCT02466191|multiple sclerosis
912853|NCT02466191|oscillopsia
912856|NCT02466152|PK
912857|NCT02466152|GSK2894512
912858|NCT02466152|Atopic Dermatitis
912859|NCT02466139|microbiology
912860|NCT02466139|c reactive protein
912861|NCT02466139|urgent cardiac surgery
912862|NCT02466126|Depression
912863|NCT02466126|brief Cognitive Behavioral Therapy (bCBT)
912864|NCT02466126|Randomized Controlled Trial
912865|NCT02466074|Acetazolamide
912866|NCT02466074|Lesions
912867|NCT02466074|T1 black hole
912868|NCT02466061|BMI >= 30 kg/m2
912869|NCT02466048|spinal fusion
912870|NCT02466048|bone graft
912871|NCT02466048|collagen
912872|NCT02466009|Colorectal cancer
912873|NCT02466009|metastatic colorectal cancer
912874|NCT02466009|colorectal adenocarcinoma
912875|NCT02465996|barrier dysfunction
912876|NCT02465996|functional dyspepsia
912877|NCT02465996|Confocal Laser Endomicroscopic
912878|NCT02465996|therapeutic response
912879|NCT02465983|Pancreatic Cancer
912880|NCT02465983|CAR / CART
912881|NCT02465983|T cells
912882|NCT02465983|Immunotherapy
912883|NCT02465983|Gene therapy
912884|NCT02465983|Redirected T cells
912885|NCT02465983|Autologous T cells
912886|NCT02465970|Transcranial Direct Current Stimulation
912887|NCT02465957|Merkel Cell Carcinoma
912888|NCT02465957|Neukoplast
912889|NCT02465957|NK-92
912890|NCT02465957|Natural Killer Cell
912891|NCT02465957|MCC
912892|NCT02465957|aNK
912893|NCT02465944|inflammation
912894|NCT02465931|Informed Consent
912895|NCT02465931|Fragile X Syndrome
912896|NCT02465931|Tablets
912897|NCT02465931|Decisional Capacity
912898|NCT02465892|cancer
912899|NCT02465892|stress
912900|NCT02465892|chronic pain
912901|NCT02465892|anxiety
912902|NCT02465892|coping
912903|NCT02465892|balance
912904|NCT02465892|online course
912905|NCT02465892|psychosocial
912906|NCT02465892|support
912907|NCT02465892|tools
912908|NCT02465879|Psoriatic arthritis
912909|NCT02465879|Ankylosing spondylitis
912910|NCT02465879|Rheumatoid arthritis
912911|NCT02465879|Seronegative
912912|NCT02465866|Plasma concentration
912913|NCT02465866|Time to plasma concentration
912914|NCT02465866|Elimination rate constant
912915|NCT02465866|Elimination half life
912916|NCT02465866|Area under the curve
912917|NCT02465853|hemiplegic shoulder pain
912918|NCT02465853|quality of Life
912919|NCT02465853|stroke
912920|NCT02465840|rehabilitation
912921|NCT02465840|functional MRI
912922|NCT02465814|Uterine fibroids
912923|NCT02465814|Heavy Menstrual Bleeding
912924|NCT02465788|Helos
912925|NCT02465788|Hair Removal
912926|NCT02465788|Hair Reduction
912927|NCT02465775|non-invasive
912928|NCT02465762|non-invasive
912929|NCT02465749|Retinitis Pigmentosa
912930|NCT02465749|oxygen
912931|NCT02465749|blue light
912932|NCT02465723|Intravoxel Incoherent Motion (IVIM)
912933|NCT02465723|Diffusion-weighted Magnetic Resonance
912934|NCT02465723|Acid Sphingomyelinase/Ceramide Pathway Activation
912935|NCT02465723|15-104
912936|NCT02465710|pelvic organ prolapse
912937|NCT02465710|pelvic floor reconstruction surgery
912938|NCT02465710|transvaginal mesh surgery
912939|NCT02465710|Women
912940|NCT02465710|Surgical treatment
912941|NCT02465697|Borderline Personality Disorder
912942|NCT02465697|Avoidant Personality Disorder
912943|NCT02465697|Brain Imaging
912944|NCT02465658|uterine prolapse
912945|NCT02465658|cervical elongation
912946|NCT02465658|pelvic floor reconstruction surgery
912947|NCT02465541|Cancer Survivors
912948|NCT02465541|Yoga
912949|NCT02465541|Endometrial Cancer
912950|NCT02465528|ALK
912951|NCT02465528|NSCLC
912952|NCT02465528|hematological malignancy
912957|NCT02465502|Colorectal cancer
912958|NCT02465502|Regorafenib
912959|NCT02465489|deferiprone
912960|NCT02465489|deferiprone extended release formulation
912961|NCT02465489|pharmacokinetics
912962|NCT02465476|skin disease
912963|NCT02465476|telemedicine
912964|NCT02465463|fecal microbiota transplant
912965|NCT02465463|probiotic
912966|NCT02465424|quality of life questionnaires
912967|NCT02465398|Fracture shoulder arthroplasty
912968|NCT02465398|Three or four part fracture
912969|NCT02465398|Hemiarthroplasty
912970|NCT02465398|Multi-center
912971|NCT02465398|Europe
912972|NCT02465398|Non-controlled
912973|NCT02465398|Anatomical reconstruction
912974|NCT02465398|Proximal
912975|NCT02465372|Physical Activity
912976|NCT02465372|Youth
912977|NCT02465372|School Health
912978|NCT02465346|acute stroke
912979|NCT02465346|prehospital
912980|NCT02465346|treatment
912981|NCT02465333|heel
912982|NCT02465333|atrophy
912983|NCT02465333|fat
912984|NCT02465333|adipose tissue
912985|NCT02465333|fat pad
912986|NCT02465307|Consciousness
912987|NCT02465307|Alertness
912988|NCT02465307|Cognition
912989|NCT02465307|Activity level
912990|NCT02465307|Delirium
912991|NCT02465307|Hyperactive delirium
912992|NCT02465307|Hypoactive delirium
912993|NCT02465307|Facial expression
912994|NCT02465307|Posture
912995|NCT02465307|Intensive care unit
912996|NCT02465294|Probiotics
912997|NCT02465294|Weight loss
912998|NCT02465294|Body composition
912999|NCT02465255|Acute Abdominal Pain
913000|NCT02465255|Sublingual Analgesia
913001|NCT02465255|Children
913002|NCT02465255|Ketorolac
913003|NCT02465255|Tramadol
913004|NCT02465255|Paracetamol
913005|NCT02465255|Analgesia
913006|NCT02465216|Tuberculosis
913007|NCT02465216|TB
913008|NCT02465216|Pulmonary
913009|NCT02465216|Vaccine
913010|NCT02465216|Adjuvant
913011|NCT02465203|Hepatitis C, chronic
913012|NCT02465190|Vaccine
913013|NCT02465190|Effectiveness
913014|NCT02465190|Influenza
913015|NCT02465177|Unhealthy alcohol use
913016|NCT02465177|ICU survivors
913017|NCT02465177|Alcohol use disorder
913018|NCT02465177|SBIRT
913019|NCT02465177|Screening, brief intervention, and referral to treatment
913020|NCT02465034|Neural plasticity
913021|NCT02465034|Noninvasive brain stimulation
913022|NCT02465034|Motor cortex
913023|NCT02465021|Satiety
913024|NCT02465021|Food intake
913025|NCT02465021|Breakfast cereals/snacks
913026|NCT02465021|Postprandial glycemia
913027|NCT02465008|postoperative
913028|NCT02465008|Patient-reported
913029|NCT02464995|Asthma,
913030|NCT02464995|Asthma exacerbation
913031|NCT02464995|Bronchial thermoplasty
913032|NCT02464969|VTE, thromboembolism, thrombosis, embolism, apixaban, Eliquis
913033|NCT02464943|Aorta
913034|NCT02464943|Thoracic
913035|NCT02464943|Aortic dissection
913036|NCT02464943|Type B
913037|NCT02464943|DeBakey type III
913038|NCT02464943|Endovascular
913039|NCT02464930|Blood
913040|NCT02464930|Cytology
913041|NCT02464930|Esophagus
913042|NCT02464930|microRNA
913043|NCT02464891|Atypical Hemolytic Uremic Syndrome
913044|NCT02464891|CCX168
913045|NCT02464891|dialysis
913046|NCT02464891|C5aR antagonist
913047|NCT02464865|thiamine deficiency
913048|NCT02464865|obese children
913049|NCT02464865|Thai
913050|NCT02464839|Fungal nails and feet infection
913051|NCT02464839|Onychomycosis
913052|NCT02464839|Hallux valgus
913053|NCT02464826|Onychomycosis
913054|NCT02464826|Chronic paronychia
913055|NCT02464826|Treatment
913056|NCT02464813|pregabalin
913057|NCT02464813|idiopathic scoliosis
913058|NCT02464800|diabetic retinopathy
913062|NCT02464774|Breast Cancer
913063|NCT02464774|Triple-Negative Breast Cancer
913064|NCT02464774|Breast-Conserving Therapy
913065|NCT02464774|Mastectomy
913066|NCT02464774|Recurrence
913067|NCT02464735|Sleep disruption
913068|NCT02464735|Spontaneous breathing trial
913069|NCT02464735|Weaning
913070|NCT02464722|Remifentanil
913071|NCT02464722|Dexmedetomidine
913072|NCT02464722|Endoscopic sinus surgery
913073|NCT02464709|Actinic Keratosis
913074|NCT02464709|Photodynamic Therapy
913075|NCT02464709|Natural Daylight
913076|NCT02464696|Hematological Malignancies
913077|NCT02464696|Hypoxemic Respiratory Failure
913078|NCT02464696|Blood cancer
913079|NCT02464696|Non-invasive positive pressure ventilation
913080|NCT02464696|NIPPV
913081|NCT02464696|High flow nasal cannula oxygen therapy
913082|NCT02464670|Ebola
913083|NCT02464670|Vaccine
913084|NCT02464657|Leukemia
913085|NCT02464657|Acute myeloid leukemia
913086|NCT02464657|AML
913087|NCT02464657|Myelodysplastic Syndrome
913088|NCT02464657|MDS
913089|NCT02464657|High-risk
913090|NCT02464657|Nivolumab
913091|NCT02464657|BMS-936558
913092|NCT02464657|Opdivo
913093|NCT02464657|Idarubicin
913094|NCT02464657|Idamycin
913095|NCT02464657|Cytarabine
913096|NCT02464657|Ara-C
913097|NCT02464657|Cytosar
913098|NCT02464657|DepoCyt
913099|NCT02464657|Cytosine Arabinosine Hydrochloride
913100|NCT02464657|Solu-Medrol
913101|NCT02464657|Methylprednisolone
913102|NCT02464657|Depo-Medrol
913103|NCT02464657|Medrol
913104|NCT02464657|Dexamethasone
913105|NCT02464657|Decadron
913106|NCT02464644|On-line Questionnaire
913107|NCT02464644|No travel
913108|NCT02464644|Health
913109|NCT02464644|Medicines
913110|NCT02464644|Drugs
913111|NCT02464644|Lifestyle
913112|NCT02464644|Family
913113|NCT02464644|Help for others
913114|NCT02464644|Rare condition
913115|NCT02464644|General population
913116|NCT02464618|Colonoscopy
913117|NCT02464618|Upper endoscopy
913118|NCT02464618|Adherence
913119|NCT02464618|Disparities
913120|NCT02464592|Cryoprobes
913121|NCT02464592|Transbronchial lung biopsy
913122|NCT02464592|Cryobiopsy
913123|NCT02464579|breastfeeding rate
913124|NCT02464579|preterm infant
913125|NCT02464579|neonatal intensive care unit
913126|NCT02464553|Low Back Pain Pain
913127|NCT02464553|Periradicular therapy
913128|NCT02464553|Spinal Stenosis with neurologic changes
913129|NCT02464540|laminate veneers
913130|NCT02464540|luting agent
913131|NCT02464527|Stimulus-stimulus pairing
913132|NCT02464514|Obesity
913133|NCT02464514|Orexigen
913134|NCT02464514|Insulin
913135|NCT02464514|Leptin
913136|NCT02464514|Adiponectin
913137|NCT02464514|Growth hormone replacement
913138|NCT02464501|PAD
913139|NCT02464501|COPPER-A
913140|NCT02464501|Peripheral Arterial Disease
913141|NCT02464501|OPC
913142|NCT02464501|Occlusion Perfusion Catheter
913143|NCT02464501|Paclitaxel
913144|NCT02464501|Pressana
913145|NCT02464501|Precision Delivery System
913146|NCT02464488|Anticoagulants
913147|NCT02464488|Factor Xa Inhibitors
913148|NCT02464488|Antithrombins
913149|NCT02464488|Pharmacokinetics
913150|NCT02464488|Aged, 80 years and older
913151|NCT02464475|osteopathic manipulative treatment
913152|NCT02464475|interoception
913153|NCT02464462|serum calcidiol
913154|NCT02464462|T2DM
913155|NCT02464462|vitamin D3 supplementation
913156|NCT02464462|post-menopausal women
913157|NCT02464462|ethnic diverse
913158|NCT02464462|calcium supplementation
913159|NCT02464449|Cognitive Behavioral Therapy
913160|NCT02464449|Mobile Health Technology
913161|NCT02464449|Patient Care Management
913162|NCT02464436|RP
913163|NCT02464410|Opioid analgesics
913164|NCT02464410|Primary care
913165|NCT02464410|Veterans
913166|NCT02464410|Motivational interviewing
913167|NCT02464410|Cognitive behavioral therapy
913168|NCT02464410|Self-efficacy
913169|NCT02464410|Behavioral symptoms
913170|NCT02464410|Injuries
913171|NCT02464410|Opioid Safety
913172|NCT02464397|Vascular healing of coronary stents in patients with acute coronary syndrome
913173|NCT02464384|ultrasound and cartilage biodegradation markers
913174|NCT02464371|muscle weakness
913175|NCT02464371|microRNAs
913176|NCT02464371|septic shock
913177|NCT02464358|HPV
913178|NCT02464345|BED
913179|NCT02464345|Binge Eating Disorer
913180|NCT02464345|BN
913181|NCT02464345|Bulimia Nervosa
913182|NCT02464345|Obesity
913183|NCT02464332|soft tissue sarcoma
913184|NCT02464332|BLZ-100
913185|NCT02464332|Tumor Paint
913186|NCT02464306|recipients
913187|NCT02464293|depression
913188|NCT02464293|anxiety
913189|NCT02464293|stress
913190|NCT02464280|Tomosynthesis
913191|NCT02464280|osteosynthetic implant
913192|NCT02464280|CT
913193|NCT02464280|monitoring
913194|NCT02464267|patient reported outcome instrument
913195|NCT02464254|Physical activity, positive affect, older adults, aging
913196|NCT02464228|PTCL
913197|NCT02464228|Lymphoma
913198|NCT02464215|gastric cancer
913199|NCT02464215|D2
913200|NCT02464215|laparoscopic
913201|NCT02464215|open
913202|NCT02464215|surgery
913203|NCT02464202|Tooth autotransplantation
913204|NCT02464202|stereolithography tooth replica
913205|NCT02464202|CBCT
913206|NCT02464202|Outcome
913207|NCT02464176|Arthroplasty, Hip, Replacement
913208|NCT02464176|Anesthesia, Local
913209|NCT02464176|Anesthesia Conduction
913210|NCT02464176|Bupivacaine
913211|NCT02464176|Dexamethasone
913212|NCT02464176|Preanesthetic Medications
913213|NCT02464176|Nerve Block
913214|NCT02464176|Lumbar Plexus Block
913215|NCT02464176|Analgesia
913216|NCT02464176|Glucocorticoids
913217|NCT02464176|Local Anesthetics
913218|NCT02464163|Influenza
913219|NCT02464150|gluten
913220|NCT02464150|antigen-specific T cells
913221|NCT02464150|transcriptome
913222|NCT02464098|Hematological Malignancies
913223|NCT02464098|Solid Tumors
913224|NCT02464098|Hematopoietic Stem Cell Transplantation (HSCT)
913225|NCT02464098|Childhood Cancer
913226|NCT02464098|Polymerase Chain Reaction (PCR)
913227|NCT02464085|Stroke
913228|NCT02464085|Upper limb
913229|NCT02464085|Neuroplastic change
913230|NCT02464085|Longitudinal
913231|NCT02464085|Function
913232|NCT02464072|Parathyroidectomy
913233|NCT02464072|Renal Insufficiency, Chronic
913234|NCT02464059|cathelicidin
913235|NCT02464059|vitamin D
913236|NCT02464046|Insomnia
913237|NCT02464046|JNJ-42847922
913238|NCT02464046|Placebo
913239|NCT02464033|Diamyd
913240|NCT02464033|Diabetes
913241|NCT02464033|Juvenile Diabetes
913242|NCT02464033|Diabetes Type 1
913243|NCT02464033|Type 1 Diabetes
913244|NCT02464033|Autoimmune Diabetes
913245|NCT02464033|Insulin Dependent Diabetes
913246|NCT02464033|Type 1 Diabetes MellitusType 1 Diabetes Mellitus
913247|NCT02464033|rhGAD65
913248|NCT02464033|GAD65
913249|NCT02464033|GAD-Alum
913250|NCT02464033|Diabetes Mellitus
913251|NCT02464033|Diabetes mellitus Type 1
913252|NCT02464033|Glucose Metabolism Disorders
913253|NCT02464033|Metabolic Diseases
913254|NCT02464033|Vitamin D
913255|NCT02464033|Etanercept
913256|NCT02463955|flexible endoscopy
913257|NCT02463929|Diphenhydramine
913258|NCT02463929|emergence agitation
913259|NCT02463929|pediatric anesthesia
913260|NCT02463929|PAEDS
913261|NCT02463929|Withdrawal
913262|NCT02463903|Adaptation, Psychological
913263|NCT02463903|Heart Failure
913264|NCT02463903|Intervention Studies
913265|NCT02463903|Quality of Life
913266|NCT02463903|Hospital Readmission
913267|NCT02463903|Depression
913268|NCT02463903|Anxiety
913269|NCT02463890|Sleep Apnea Syndromes
913270|NCT02463890|Sleep Apnea, Obstructives
913271|NCT02463890|Training
913272|NCT02463864|frailty
913273|NCT02463864|older adult
913274|NCT02463864|hospital
913275|NCT02463864|exercise
913276|NCT02463864|randomised control trial
913277|NCT02463864|functional decline
913278|NCT02463851|Ablation
913279|NCT02463851|Multi-electrode catheter PVAC
913280|NCT02463851|Single-tip catheter Contact Force
913281|NCT02463851|Holter
913282|NCT02463838|Medi-Cal
913283|NCT02463838|Health Plan
913284|NCT02463838|Frequent Users
913285|NCT02463838|Heavy users
913286|NCT02463838|Care Coordination
913287|NCT02463838|Managed Care
913288|NCT02463838|Case Management
913289|NCT02463838|Mental Health
913290|NCT02463838|Substance Use
913291|NCT02463838|Emergency Department
913292|NCT02463799|prostatic neoplasms
913293|NCT02463799|castration-resistant
913294|NCT02463799|bone metastasis
913295|NCT02463799|radium-223
913296|NCT02463799|sipuleucel-T
913297|NCT02463773|ARDS, PEEP, Critical Care Ultrasound
913298|NCT02463747|Neutropenic fever
913299|NCT02463747|extended infusion
913300|NCT02463747|beta-lactam
913301|NCT02463747|empiric antibiotic treatment
913302|NCT02463721|sbp
913303|NCT02463721|culture
913304|NCT02463708|Care Giver
913305|NCT02463708|Dementia
913306|NCT02463695|partial vestibular deficit
913307|NCT02463695|cortical vestibular evoked potential
913308|NCT02463682|Artificial Pancreas
913309|NCT02463682|Diabetes Mellitus, Type 1
913310|NCT02463682|Autoimmune Diseases
913311|NCT02463682|Diabetes Mellitus
913312|NCT02463682|Endocrine System Diseases
913313|NCT02463682|Glucose Metabolism Disorders
913314|NCT02463682|Immune System Diseases
913315|NCT02463682|Metabolic Diseases
913316|NCT02463669|Point-of-care ultrasound
913317|NCT02463630|basilar invagination
913318|NCT02463630|atlantoaxial dislocation
913319|NCT02463630|surgery
913320|NCT02463630|restoration technique
913321|NCT02463591|Direct Thrombin Inhibitor
913322|NCT02463591|Prothrombin Complex Concentrate
913323|NCT02463591|Dabigatran Etexilate
913324|NCT02463591|Beriplex
913325|NCT02463591|Shed Blood
913326|NCT02463591|Washed Blood
913327|NCT02463591|Fibrinopeptide A
913328|NCT02463578|Pneumococcal infection
913329|NCT02463578|Invasive pneumococcal disease (IPD)
913330|NCT02463578|Pneumococcal vaccine
913331|NCT02463578|Vaccinology
913332|NCT02463578|Immunocompromised
913333|NCT02463578|Auto-immune diseases
913334|NCT02463578|Systemic vasculitis
913335|NCT02463578|ANCA-associated vasculitis
913336|NCT02463565|nutritional assessment
913337|NCT02463565|food survey
913338|NCT02463565|hospitalized patients
913339|NCT02463565|hospital food
913340|NCT02463539|Pneumococcal infection
913341|NCT02463539|Invasive pneumococcal disease (IPD)
913342|NCT02463539|Pneumococcal vaccine
913343|NCT02463539|Systemic vasculitis
913344|NCT02463539|ANCA-associated vasculitis
913345|NCT02463539|Vaccinology
913346|NCT02463539|Immunocompromised
913347|NCT02463539|Auto-immune disease
913348|NCT02463526|Shoulder Impingement Syndrome
913349|NCT02463526|Mulligan's Mobilization with Movement
913350|NCT02463526|Physical Therapy
913351|NCT02463513|Riboflavin
913352|NCT02463513|Blood pressure
913353|NCT02463513|MTHFR
913354|NCT02463513|Methylenetetrahydrofolate reductase
913355|NCT02463448|Underactive Bladder
913356|NCT02463435|nutritional management
913357|NCT02463435|olive oil
913358|NCT02463435|weight loss
913359|NCT02463435|body composition
913360|NCT02463435|nutrigenomics
913361|NCT02463435|polymorphisms
913362|NCT02463435|cardiovascular risk
913363|NCT02463435|sarcopenia
913364|NCT02463435|inflammation
913365|NCT02463435|food intake
913366|NCT02463435|sedentary lifestyle
913367|NCT02463435|patient adherence
913368|NCT02463435|bone density
913369|NCT02463396|MBCT
913370|NCT02463396|Mindfulness
913371|NCT02463396|ADHD
913372|NCT02463383|PPAR-gamma
913373|NCT02463383|estrogens
913374|NCT02463383|NSAIDS
913375|NCT02463383|polymorphism
913376|NCT02463383|metabolomics
913377|NCT02463357|Exercise, Aerobic
913378|NCT02463357|Cognitive Function
913379|NCT02463344|Dry AMD
913380|NCT02463344|Geographic atrophy
913381|NCT02463331|autoimmune hepatitis
913382|NCT02463331|chloroquine
913383|NCT02463331|treatment
913384|NCT02463318|Multiple sclerosis
913385|NCT02463318|SIRT1
913386|NCT02463318|MnSOD
913387|NCT02463318|Catalase
913388|NCT02463318|Oxidative stress
913389|NCT02463318|Antioxidant enzyme
913390|NCT02463305|Colitis, ulcerative
913391|NCT02463305|Inflammatory bowel diseases
913392|NCT02463292|quality of life
913393|NCT02463292|young adults
913394|NCT02463292|congenital heart disease
913395|NCT02463266|Primary Care
913396|NCT02463266|Elderly
913397|NCT02463266|Depression
913398|NCT02463253|Renal Biopsy
913399|NCT02463253|elevated serum creatinine
913400|NCT02463253|proteinuria
913403|NCT02463188|Sleep
913404|NCT02463188|Substance Use
913405|NCT02463188|Adolescents
913406|NCT02463175|Fluid Therapy;
913407|NCT02463175|Transesophageal Doppler
913408|NCT02463149|School health
913409|NCT02463136|Adolescence
913410|NCT02463136|Brain Development
913411|NCT02463136|Neuroimaging
913412|NCT02463136|Neurofeedback
913413|NCT02463136|Anxiety
913414|NCT02463110|Acute Coronary Syndrome
913415|NCT02463110|Depression
913416|NCT02463110|Coronary Artery Disease
913417|NCT02463110|Myocardial Infarction
913418|NCT02463110|Percutaneous Coronary Intervention
913419|NCT02463019|hepatitis B virus
913420|NCT02463019|tenofovir
913421|NCT02462967|Liver Cirrhosis
913422|NCT02462954|Contraception
913423|NCT02462954|Vaginal Gel
913424|NCT02462954|Diaphragm
913425|NCT02462941|Heart transplant
913426|NCT02462941|Adenosine
913427|NCT02462941|Pediatrics
913428|NCT02462863|Diabetes
913429|NCT02462863|fish oil
913430|NCT02462863|arginine
913431|NCT02462863|hyperglycemia
913432|NCT02462850|Pain
913433|NCT02462850|Nausea
913434|NCT02462850|Vomiting
913435|NCT02462837|Ureteral Stents
913436|NCT02462837|Pain and Discomfort
913437|NCT02462837|Bladder Storage Symptoms
913438|NCT02462824|Peripheral Artery Disease
913439|NCT02462824|Peripheral Arterial Disease
913440|NCT02462824|PAD
913441|NCT02462811|Pain
913442|NCT02462811|Nausea
913443|NCT02462811|Vomiting
913444|NCT02462785|Type 1 Diabetes Mellitus
913445|NCT02462785|Adolescents
913446|NCT02462785|Carbohydrate Counting
913447|NCT02462785|Glycemic Control
913448|NCT02462785|Self-Management
913449|NCT02462785|T1DM
913450|NCT02462772|Cabotegravir
913451|NCT02462772|safety
913452|NCT02462772|long-acting injectable
913453|NCT02462772|HIV prevention
913454|NCT02462772|acceptability
913455|NCT02462759|EMBRACE
913456|NCT02462759|Spinal Muscular Atrophy
913457|NCT02462759|SMA
913458|NCT02462746|Postpartum
913459|NCT02462746|Dietary Supplements
913460|NCT02462746|Breastfeeding Women
913461|NCT02462733|Self-control
913462|NCT02462733|Preschoolers
913463|NCT02462733|Tools of the Mind
913464|NCT02462733|Playing to Learn
913465|NCT02462681|ketamine
913466|NCT02462681|adjuvant
913467|NCT02462681|paravertebral block
913468|NCT02462668|Bronchoscopy
913469|NCT02462668|Intubation
913470|NCT02462668|Noninvasive positive pressure ventilation
913471|NCT02462642|Brahmi, Cognition, Anxiety, Pharmacokinetics
913472|NCT02462629|central nervous system tumor
913473|NCT02462629|BLZ-100
913474|NCT02462629|pediatrics
913475|NCT02462629|Tumor Paint
913476|NCT02462629|brain cancer
913477|NCT02462616|risk analysis
913478|NCT02462616|general Chinese population
913479|NCT02462616|cardiovascular autonomic neuropathy
913480|NCT02462603|Parkinson's Disease
913481|NCT02462603|PD
913482|NCT02462603|EPI-589
913483|NCT02462603|EPI589
913484|NCT02462590|Probiotics
913485|NCT02462590|Ventilator Associated Pneumonia
913486|NCT02462590|Infections
913487|NCT02462590|C-Difficile
913488|NCT02462590|Antibiotic-associated Diarrhea
913489|NCT02462590|Diarrhea
913490|NCT02462577|Local morphine
913491|NCT02462577|Postmastectomy pain
913492|NCT02462564|peritoneal surface malignancies
913493|NCT02462564|Post operative cognitive dysfunction
913494|NCT02462551|Depression
913495|NCT02462551|Treatment Resistant Depression
913496|NCT02462525|relapsed multiple myeloma
913497|NCT02462525|antibody drug conjugate
913498|NCT02462525|refractory multiple myeloma
913499|NCT02462512|Elastography
913500|NCT02462512|Thyroid nodule
913501|NCT02462473|Schizophrenia
913502|NCT02462473|Schizoaffective Disorder
913503|NCT02462473|Aripiprazole
913504|NCT02462473|Olanzapine
913505|NCT02462473|Paliperidone
913506|NCT02462473|Quetiapine
913507|NCT02462473|Risperidone
913508|NCT02462473|Liquid Chromatography-Tandem Mass Spectrometry
913509|NCT02462460|Breast MRI
913510|NCT02462460|T1 weighted and diffusion weighted MR
913511|NCT02462460|screening pancreatic
913512|NCT02462460|screening ovarian
913513|NCT02462460|15-120
913514|NCT02462447|prostate
913515|NCT02462447|cancer
913516|NCT02462447|biopsy
913517|NCT02462447|PET
913518|NCT02462434|Pediatric palliative care
913519|NCT02462421|SGLT2
913520|NCT02462421|SLC5A2
913521|NCT02462421|SLC5A4
913522|NCT02462421|SLC5A9
913523|NCT02462421|SLC2A9
913524|NCT02462421|GLUT9
913525|NCT02462421|SGLT3
913526|NCT02462421|SGLT4
913527|NCT02462421|pharmacogenomics
913528|NCT02462356|CVATS
913529|NCT02462356|UVATS
913530|NCT02462356|perioperative effect
913531|NCT02462356|ergonomic influence
913532|NCT02462330|Mesenchymal stem cells
913533|NCT02462330|ischemic cardiomyopathy
913534|NCT02462330|NogaStar XP system catheter
913535|NCT02462317|Spasticity
913536|NCT02462317|Post stroke motor recovery
913537|NCT02462317|Botulinum toxin
913538|NCT02462317|Baclofen
913539|NCT02462317|Pharmacological modulation
913540|NCT02462304|Diabetic Macula Edema
913541|NCT02462304|End-Point-Management
913542|NCT02462304|ranibizumab
913543|NCT02462304|bevacizumab
913544|NCT02462291|Neurological Disorders
913545|NCT02462291|Non Pharmacological Treatment
913546|NCT02462291|Ecological Therapy
913547|NCT02462278|Fertility
913548|NCT02462278|Continuous temperature monitor
913549|NCT02462278|Basal Body Temperature
913550|NCT02462278|Natural family planning
913551|NCT02462239|Muscle-invasive bladder cancer
913552|NCT02462239|Bladder cancer
913553|NCT02462239|PET imaging
913554|NCT02462239|FDG
913555|NCT02462213|Cardiac amyloidosis
913556|NCT02462213|Cardiac MRI
913557|NCT02462213|Infiltrative cardiomyopathies
913558|NCT02462187|genital warts
913559|NCT02462187|perianal warts
913560|NCT02462174|anesthesia
913561|NCT02462174|analgesia
913562|NCT02462174|caudal
913563|NCT02462174|ketamine
913564|NCT02462174|bupivacaine
913565|NCT02462148|Anesthesia
913566|NCT02462148|Anesthesia, Conduction
913567|NCT02462148|Anesthesia, Local
913568|NCT02462148|Bupivacaine
913569|NCT02462148|Dexamethasone
913570|NCT02462148|Saphenous
913571|NCT02462148|Adductor Canal
913572|NCT02462148|Nerve Block
913573|NCT02462148|Analgesia
913574|NCT02462148|Preanesthetic Medication
913575|NCT02462148|Perioperative Period
913576|NCT02462148|Peripheral Nerve Block
913577|NCT02462135|Mild cognitive impairment
913578|NCT02462135|Memory training
913579|NCT02462135|Randomized controlled study
913580|NCT02462044|Computed tomography
913581|NCT02462044|Coronary CTA
913582|NCT02462044|Contrast media
913583|NCT02462018|Cerebral Palsy
913584|NCT02462018|Muscle Spasticity
913585|NCT02462018|Orthoses
913586|NCT02462018|Functional Electrical Stimulation
913587|NCT02462018|Prospective
913588|NCT02461992|FVIII activity
913589|NCT02461953|hemodialysis
913590|NCT02461953|hemoperfusion
913591|NCT02461953|quality of life
913592|NCT02461940|Sexual behavior
913593|NCT02461940|condom use
913594|NCT02461940|secondary abstinence
913595|NCT02461914|Type 2 diabetes mellitus
913596|NCT02461901|clostridium difficile
913597|NCT02461901|environment
913598|NCT02461901|contamination
913599|NCT02461901|fidaxomicin
913600|NCT02461888|Relapsed
913601|NCT02461888|Refractory
913602|NCT02461888|Cyclophosphamide
913603|NCT02461888|Dexamethasone
913604|NCT02461875|OHSS
913605|NCT02461875|Infertility
913606|NCT02461875|Cabergoline
913607|NCT02461875|GnRH antagonist
913608|NCT02461875|IVF-ET
913609|NCT02461862|Contraception
913610|NCT02461862|Contraception Behavior
913611|NCT02461862|Intra uterine device
913612|NCT02461862|Intra uterine System
913613|NCT02461862|IUD
913614|NCT02461862|IUS
913615|NCT02461862|Acute Pain
913616|NCT02461771|AMD
913617|NCT02461771|Wet AMD
913618|NCT02461771|Neovascular AMD
913619|NCT02461745|VIEKIRA PAK
913620|NCT02461732|posttraumatic stress disorder
913621|NCT02461732|PTSD
913622|NCT02461732|substance dependence
913623|NCT02461732|substance use
913624|NCT02461706|Drug resistant epilepsy
913625|NCT02461693|Vigilance
913626|NCT02461693|Mood
913627|NCT02461693|Randomized Controlled Trial
913628|NCT02461693|Probability
913629|NCT02461680|partial section of the flexor tendons
913630|NCT02461667|alendronate, metformin
913631|NCT02461641|amniotic tissue
913632|NCT02461641|diabetic foot ulcer
913633|NCT02461641|Affinity
913634|NCT02461641|NuShield
913635|NCT02461628|Malaria
913636|NCT02461628|Antimalarial subsidy
913637|NCT02461628|Malaria rapid diagnostic test (RDT)
913638|NCT02461628|Public-private partnership
913639|NCT02461628|Community health workers
913640|NCT02461615|Pulmonary Surfactant
913641|NCT02461615|Rare Lung Disease
913642|NCT02461615|Registry
913643|NCT02461602|Warfarin
913644|NCT02461576|HIV-1
913645|NCT02461550|Irreversible Electroporation Ablation
913646|NCT02461550|15-001
913647|NCT02461498|Warfarin
913648|NCT02461485|adults
913649|NCT02461485|moderate constipation
913650|NCT02461472|risk factors
913651|NCT02461472|risk analysis
913652|NCT02461472|diabetic cardiovascular autonomic neuropathy
913653|NCT02461472|general Chinese population
913654|NCT02461459|Tuberous Sclerosis Complex
913655|NCT02461459|TSC
913656|NCT02461459|Autism
913657|NCT02461459|ASD
913658|NCT02461459|Intellectual Disability
913659|NCT02461459|ID
913660|NCT02461459|MRI
913661|NCT02461446|germline heterozygous PTEN mutations
913662|NCT02461446|MRI
913663|NCT02461446|10q23.3
913664|NCT02461446|ASD
913665|NCT02461446|Autism
913666|NCT02461446|Macrocephaly
913667|NCT02461446|PTEN Hamartoma Tumor Syndrome
913668|NCT02461446|PTEN
913669|NCT02461433|Obesity
913670|NCT02461433|Obese
913671|NCT02461433|surgical site infection
913672|NCT02461433|closed incisions
913673|NCT02461433|negative pressure therapy
913674|NCT02461420|Phelan-McDermid Syndrome
913675|NCT02461420|PMS
913676|NCT02461420|Genotype
913677|NCT02461420|Phenotype
913678|NCT02461420|Natural History
913679|NCT02461420|Mapping
913680|NCT02461420|22q13 Deletion Syndrome
913681|NCT02461420|SHANK3
913682|NCT02461420|Autism Spectrum Disorder
913683|NCT02461420|ASD
913684|NCT02461420|Intellectual Disability
913685|NCT02461420|ID
913686|NCT02461381|Bayesian estimation, short-term heart rate variability, diabetic cardiovascular autonomic neuropathy, diagnostic performance
913687|NCT02461381|Diagnostic performance
913688|NCT02461381|short-term heart rate variability
913689|NCT02461381|diabetic cardiovascular autonomic neuropathy
913690|NCT02461381|DCAN
913691|NCT02461342|Genetic
913692|NCT02461342|environment
913693|NCT02461342|interaction analysis
913694|NCT02461342|cardiovascular autonomic neuropathy
913695|NCT02461342|CAN
913696|NCT02461329|Hip Replacement, Total
913697|NCT02461329|Gelatine solution
913698|NCT02461329|Balanced Crystaloid Solution
913699|NCT02461329|Volume therapy
913700|NCT02461329|Platelet aggregation
913701|NCT02461303|Klinefelter
913702|NCT02461303|Spermatogenesis
913703|NCT02461303|Puberty
913704|NCT02461303|Fertility
913705|NCT02461277|postoperative care
913706|NCT02461277|exercise test
913707|NCT02461277|early ambulation
913708|NCT02461277|Fast-track
913709|NCT02461251|Thromboelastometry
913710|NCT02461251|Obstetric Hemorrhage
913711|NCT02461251|Blood Component Transfusion
913712|NCT02461212|HepaFat-Scan
913713|NCT02461212|Liver Disease
913714|NCT02461212|Pediatrics
913715|NCT02461199|Fecal microbiota transplantation
913716|NCT02461199|Gut colonization
913717|NCT02461199|Multidrug-resistant bacteria
913718|NCT02461199|Blood disorders
913719|NCT02461199|Drug Resistance, Multiple
913720|NCT02461199|Disease Eradication
913721|NCT02461186|Arterolane-piperaquine
913722|NCT02461186|Dehydroartemisinin-piperaquine
913723|NCT02461186|therapeutic efficacy
913724|NCT02461186|Uncomplicated falciparum malaria
913725|NCT02461186|Artemisinin-resistant
913726|NCT02461160|Drug therapy
913727|NCT02461134|GVHD
913728|NCT02461134|ponesimod
913729|NCT02461121|Acute Myeloid Leukemia
913730|NCT02461121|microtransplantationHLA-mismatched microtransplantation
913731|NCT02461121|nonmyeloablative stem cell transplantation
913732|NCT02461121|graft-versus-host disease
913733|NCT02461108|Public policy
913734|NCT02461108|Food choice
913735|NCT02461108|Nutrition labeling
913736|NCT02461108|Fat tax
913737|NCT02461108|Vegetable subsidy
913738|NCT02461108|Behavioral economics
913739|NCT02461108|Health behavior
913740|NCT02461069|dimethyl fumarate
913741|NCT02461056|ibuprofen
913742|NCT02461056|hydromorphone
913743|NCT02461056|drug interactions
913744|NCT02461043|esophageal cancer
913745|NCT02461043|adjuvant chemotherapy
913746|NCT02461043|esophageal surgery
913747|NCT02461043|paclitaxel
913748|NCT02461030|Dentin hypersensitivity
913749|NCT02461030|Periodontal disease
913750|NCT02461030|Arginine
913751|NCT02461017|intubation
913752|NCT02461017|ventilation
913753|NCT02461017|airway
913754|NCT02461017|airleak
913755|NCT02461004|Dyslipidemia
913756|NCT02461004|CKD-391
913757|NCT02461004|Atorvastatin
913758|NCT02461004|Ezetimibe
913759|NCT02460978|Dapagliflozin
913760|NCT02460978|Efficacy
913761|NCT02460978|Safety
913762|NCT02460978|Add on to insulin
913763|NCT02460978|Oral Antidiabetic
913764|NCT02460978|Type 1 diabetes
913765|NCT02460952|Pulmonary Embolism;
913766|NCT02460952|perioperative period;
913767|NCT02460952|general anesthesia
913768|NCT02460939|Pulmonary Vessel Disease
913769|NCT02460939|metabolism of small molecules
913770|NCT02460926|Scaling and root planning
913771|NCT02460926|C-reactive protein
913772|NCT02460913|acupuncture
913773|NCT02460913|morphine
913774|NCT02460913|acute pain
913775|NCT02460887|nasopharyngeal carcinoma
913776|NCT02460887|induction chemotherapy
913777|NCT02460874|Brain Metastases
913778|NCT02460874|Stereotactic Radiosurgery
913779|NCT02460874|Glyburide
913780|NCT02460861|Prostate Cancer
913781|NCT02460861|Molecular staging
913782|NCT02460861|GSTP1
913783|NCT02460861|Surgical margins
913784|NCT02460861|prostatovesiculectomy
913785|NCT02460848|Malnutrition
913786|NCT02460848|Severe Acute Malnutrition
913787|NCT02460848|Cash Transfer
913788|NCT02460848|Democratic Republic of Congo
913789|NCT02460848|Cluster randomize trial
913790|NCT02460796|Parkinson's disease
913791|NCT02460796|Quality of life
913792|NCT02460796|Gait velocity
913793|NCT02460796|Capacity
913794|NCT02460783|Biomarkers
913795|NCT02460783|Diabetes
913796|NCT02460783|Obesity
913797|NCT02460783|Dementia of the Alzheimer Type
913798|NCT02460783|Functional Magnetic Resonance Imaging (fMRI)
913799|NCT02460770|Left Ventricular Assist Device
913800|NCT02460770|stem cell therapy
913801|NCT02460770|ischemic heart failure
913802|NCT02460757|glottic movement
913803|NCT02460757|emphysema
913804|NCT02460757|copd
913805|NCT02460757|vocal cord
913806|NCT02460744|Breast cancer
913807|NCT02460744|hypofractionation
913808|NCT02460744|radiotherapy
913809|NCT02460731|PSP
913810|NCT02460731|Young Plasma
913811|NCT02460718|diabetes mellitus
913812|NCT02460718|peer support
913813|NCT02460718|pragmatic clinical trial
913814|NCT02460666|depressed
913815|NCT02460666|older adults
913816|NCT02460666|Major Depressive Disorder
913817|NCT02460666|Tai-Chi
913818|NCT02460666|geriatric
913819|NCT02460653|High flow nasal cannula
913820|NCT02460653|Oxygen therapy
913821|NCT02460653|Ventilation
913822|NCT02460640|Minimally invasive surgery
913823|NCT02460640|Partial nephrectomy
913824|NCT02460627|Arthroscopy
913825|NCT02460627|Meniscus
913826|NCT02460627|Lidocaine
913827|NCT02460614|bronchiolitis
913828|NCT02460614|respiratory physiotherapy
913829|NCT02460614|pediatrics
913830|NCT02460614|rhinopharyngeal clearance
913831|NCT02460575|Safety
913832|NCT02460562|resin denture base
913833|NCT02460549|therapeutic patient education
913834|NCT02460549|insulinoresistance
913835|NCT02460549|empowerment
913836|NCT02460549|prostate cancer
913837|NCT02460549|oral endocrine therapy
913838|NCT02460549|side effects
913839|NCT02460536|attention bias modification treatment
913840|NCT02460536|attention training
913841|NCT02460536|anxiety disorders
913842|NCT02460536|clinical trials
913843|NCT02460471|Radiotherapy
913844|NCT02460471|Palliative Care
913845|NCT02460471|IMRT
913846|NCT02460458|Factor VIII
913847|NCT02460458|Hemorrhage
913848|NCT02460458|von Willebrand Diseases
913849|NCT02460458|von Willebrand Factor
913850|NCT02460445|Functional hyperandrogenism
913851|NCT02460445|Polycystic ovary syndrome
913852|NCT02460445|Idiopathic hyperandrogenism
913853|NCT02460445|Iron tissue depots
913854|NCT02460445|Phlebotomy
913855|NCT02460445|Insulin resistance
913856|NCT02460445|Carbohydrate metabolism
913857|NCT02460445|Blood pressure
913858|NCT02460445|Autonomic dysfunction
913859|NCT02460445|Oxidative stress
913860|NCT02460445|Blood clotting tests
913861|NCT02460445|Efficacy
913862|NCT02460445|Side effects
913863|NCT02460445|Randomized clinical trial
913864|NCT02460432|Drug-eluting Biliary stent
913865|NCT02460432|Covered metalic stent
913866|NCT02460419|Nasopharyngeal carcinoma
913867|NCT02460419|metastasis
913868|NCT02460419|capecitabine
913869|NCT02460406|strength training
913870|NCT02460406|virtual reality
913871|NCT02460406|plyometric exercises
913872|NCT02460406|cerebral palsy
913873|NCT02460406|hemiplegic
913874|NCT02460393|tolerance
913875|NCT02460393|safety and pharmacokinetic characteristics
913876|NCT02460367|Non-small Cell Lung Cancer
913877|NCT02460367|Vaccine Therapy
913878|NCT02460367|Immunotherapy
913879|NCT02460367|Second line therapy
913880|NCT02460367|Progressive
913881|NCT02460367|Relapsed
913882|NCT02460367|IDO
913883|NCT02460367|IDO Inhibitor
913884|NCT02460354|Congenital nephrogenic diabetes insipidus
913885|NCT02460341|fMRI
913886|NCT02460341|Brain function
913887|NCT02460341|Sensory processing
913888|NCT02460315|time of cholecystectomy after ERCP
913899|NCT02460250|Tissue and Organ Harvesting
913900|NCT02460250|Liver graft
913901|NCT02460250|Brain Death
913902|NCT02460250|FibroScan®
913903|NCT02460237|HPV
913907|NCT02460211|Cardiovascular Disease
913908|NCT02460211|Vitamin D
913909|NCT02460211|Open Heart Surgery
913910|NCT02460198|PD1
913911|NCT02460198|PD-1
913912|NCT02460198|PDL1
913913|NCT02460198|PD-L1
913918|NCT02460081|PDA-002
913919|NCT02460081|Diabetic Foot Ulcer
913920|NCT02460081|Peripheral arterial disease
913921|NCT02460081|Phase 2
913922|NCT02460081|Randomized
913923|NCT02460068|melanoma brain metastases
913924|NCT02460068|nivolumab
913925|NCT02460068|ipilimumab
913926|NCT02460055|EGD Dysphagia
913927|NCT02460055|ETT Intubation dysphagia
913928|NCT02459990|Hypertension malformation fetal mortality
913929|NCT02459964|Advanced Cancers
913930|NCT02459964|Pain
913931|NCT02459964|Fentanyl nasal spray
913932|NCT02459964|Hydromorphone hydrochloride
913933|NCT02459964|Phone call
913934|NCT02459964|Numeric Rating Scale
913935|NCT02459964|NRS
913936|NCT02459951|Muscle Spasticity
913937|NCT02459951|Botox A
913938|NCT02459951|Upper limb hemiplegia
913939|NCT02459912|Prostate
913940|NCT02459912|Minimally
913941|NCT02459912|Low-Risk
913942|NCT02459912|Invasive
913943|NCT02459912|Cancer
913946|NCT02459860|depression
913947|NCT02459860|randomized behavioral trial
913948|NCT02459860|aged
913949|NCT02459860|Latinos
913950|NCT02459860|Spanish-speaking
913951|NCT02459860|chronic medical conditions
913952|NCT02459834|Allulose
913953|NCT02459834|Fructose
913954|NCT02459834|Dose Response
913955|NCT02459834|Catalytic Dose
913956|NCT02459834|Carbohydrate metabolism
913957|NCT02459834|Randomized clinical trials
913958|NCT02459821|Multiple sclerosis
913959|NCT02459821|Gait rehabilitation
913960|NCT02459821|Quality of life
913961|NCT02459821|Stair climbing
913962|NCT02459821|Robotic
913963|NCT02459782|Ultrasound guided peribulbar anesthesia
913964|NCT02459756|anthocyanins
913965|NCT02459756|bioavailability
913966|NCT02459743|Hematological malignancies
913967|NCT02459743|Next Generation Sequencing
913968|NCT02459743|Genotype-phenotype correlations
913969|NCT02459743|Prognosis
913970|NCT02459743|Diagnosis
913971|NCT02459730|Dental caries
913972|NCT02459730|glass ionomer cement
913973|NCT02459730|ART
913974|NCT02459704|Gingival Recession
913975|NCT02459704|Semilunar flap
913976|NCT02459704|Enamel matrix derivative
913977|NCT02459704|Periodontal regeneration
913978|NCT02459691|prediabetes
913979|NCT02459691|metabolic syndrome
913980|NCT02459691|lifestyle
913981|NCT02459691|behavior change
913982|NCT02459691|primary care
913983|NCT02459691|latinos
913984|NCT02459691|diet
913985|NCT02459691|physical activity
913986|NCT02459652|Borderline Resectable Pancreatic Cancer
913987|NCT02459639|Chronic Widespread Pain
913988|NCT02459639|Telomere length
913989|NCT02459639|Multimodal rehabilitation
913990|NCT02459639|Integrative care
913991|NCT02459639|Existential aspects
913992|NCT02459613|Radionuclide imaging
913993|NCT02459613|Annexin
913994|NCT02459600|Eye surgery
913995|NCT02459600|Children
913996|NCT02459587|Self-Injurious Behavior
913997|NCT02459587|suicide prevention
913998|NCT02459574|Heart Failure
913999|NCT02459561|Obesity
914000|NCT02459561|Diabetes
914001|NCT02459561|Overweight
914002|NCT02459561|Medical device
914003|NCT02459561|Endobarrier
914004|NCT02459561|Clinical trial
914005|NCT02459561|Diet
914006|NCT02459561|Exercise
914007|NCT02459561|Body weight
914008|NCT02459561|Medical therapy
914009|NCT02459561|Medicine
914010|NCT02459561|Device
914011|NCT02459561|Randomised
914012|NCT02459561|Control
914013|NCT02459561|Intervention
914014|NCT02459561|EndoBarrier Medical device
914015|NCT02459548|OSA
914016|NCT02459548|CPAP treatment
914017|NCT02459548|Primary care
914018|NCT02459548|Efficacy
914019|NCT02459535|incretin release
914020|NCT02459522|Bayesian estimation
914021|NCT02459522|short-term heart rate variability
914022|NCT02459522|cardiovascular autonomic neuropathy
914023|NCT02459522|diagnostic performance
914024|NCT02459509|Sedation
914025|NCT02459509|dexmedetomidine
914026|NCT02459509|pediatric
914027|NCT02459509|preoperative period
914028|NCT02459470|Fluid Responsiveness
914029|NCT02459470|Pulse Pressure Variation
914030|NCT02459470|Stroke Volume Variation
914031|NCT02459457|esophageal squamous cell carcinoma
914032|NCT02459457|concurrent chemoradiotherapy
914033|NCT02459457|paclitaxel
914034|NCT02459457|cisplatin
914035|NCT02459457|carboplatin
914036|NCT02459457|fluorouracil
914037|NCT02459444|Respiratory Muscles
914038|NCT02459444|Muscle Weakness
914039|NCT02459444|Hospitalization
914040|NCT02459444|Length of Stay
914041|NCT02459444|Mortality
914042|NCT02459418|Afolia
914043|NCT02459418|Follitropin
914044|NCT02459405|Colorectal surgery
914045|NCT02459405|Near infrared
914046|NCT02459405|Indocyanine green
914047|NCT02459405|anastomotic leak
914048|NCT02459405|Prevention of leak
914049|NCT02459392|Epiduroscopy,
914050|NCT02459392|Failed back surgery syndrome
914051|NCT02459392|Spinal Stenosis with neurologic changes
914052|NCT02459366|Thoracolumbar fascia
914053|NCT02459366|Mechanical properties
914054|NCT02459366|Low back pain
914055|NCT02459353|dapagliflozin
914056|NCT02459353|glucose variability
914057|NCT02459327|Infant behavior
914058|NCT02459327|Child behavior
914059|NCT02459327|Parenting
914060|NCT02459327|Child rearing
914061|NCT02459327|Depression
914062|NCT02459327|Personal satisfaction
914063|NCT02459327|Randomized controlled trials
914064|NCT02459327|Intervention studies
914065|NCT02459327|Behavioral symptoms
914066|NCT02459327|Social behavior
914067|NCT02459288|Acute coronary syndrome
914068|NCT02459288|Chronic kidney disease
914069|NCT02459288|End-Stage Renal Disease
914070|NCT02459288|eGFR
914071|NCT02459288|Ticagrelor
914072|NCT02459288|Clopidogrel
914073|NCT02459275|feeding protocol
914074|NCT02459275|enteral nutrition protocol
914075|NCT02459275|critically ill
914076|NCT02459275|surgical ICU
914077|NCT02459275|enteral nutrition
914078|NCT02459275|nutrition therapy
914079|NCT02459223|Nutritional intervention
914080|NCT02459223|iron deficiency anemia
914081|NCT02459210|clinical high risk for psychosis
914082|NCT02459210|psychosis prodrome
914083|NCT02459210|cognitive remediation
914084|NCT02459210|psychosis prevention
914085|NCT02459197|Pain
914086|NCT02459184|preventive medicine
914087|NCT02459184|social determinants of health
914088|NCT02459184|primary health care
914089|NCT02459184|poverty
914090|NCT02459184|income
914091|NCT02459184|health promotion
914092|NCT02459132|High-intensity interval training
914093|NCT02459132|VO2peak
914094|NCT02459132|Brachial flow-mediated dilation
914095|NCT02459132|Carotid-femoral pulse wave velocity
914096|NCT02459132|Carotid intima-media thickness
914097|NCT02459132|Carotid distensibility
914098|NCT02459132|Respiratory sinus arrhythmia
914101|NCT02459106|micro-RNA
914102|NCT02459106|insulin resistance
914103|NCT02459093|wound complications
914104|NCT02459080|Chronic Obstructive Pulmonary Disease, COPD
914105|NCT02459054|Artificial Heart
914106|NCT02459054|Biventricular Heart Failure
914107|NCT02459054|SynCardia
914108|NCT02459002|Advanced lung cancer
914109|NCT02459002|NSCLC
914110|NCT02459002|palliative care
914111|NCT02458989|Thyroidectomy
914112|NCT02458989|Thyroid surgery
914113|NCT02458989|Scalpel
914114|NCT02458989|Electrocautery
914115|NCT02458976|Scar
914116|NCT02458976|Pulsed-dye laser
914117|NCT02458976|PDL
914118|NCT02458963|PCOS
914119|NCT02458963|Clomiphene citrate resistant
914120|NCT02458963|Gonadotropin
914121|NCT02458963|IVF
914122|NCT02458950|Anorexia nervosa
914123|NCT02458950|Siriraj Hospital
914124|NCT02458950|Thai
914125|NCT02458937|Leukemia
914126|NCT02458937|Hodgkin Disease
914127|NCT02458937|Non-Hodgkin's Lymphoma
914128|NCT02458937|Sickle Cell Disease
914129|NCT02458937|Hip Core Decompression
914130|NCT02458937|Function Outcomes
914131|NCT02458885|myocardial infarction
914132|NCT02458885|observational registry
914133|NCT02458885|mortality
914134|NCT02458872|Clinical Alarms
914135|NCT02458872|Patient Safety
914136|NCT02458859|Chronic
914137|NCT02458859|Subacute
914138|NCT02458833|Obesity
914139|NCT02458833|Nutrition
914140|NCT02458833|Home Food Preparation
914141|NCT02458833|Home Food Environment
914142|NCT02458833|Peer Mentoring
914143|NCT02458833|Early Head Start
914144|NCT02458833|Cooking
914145|NCT02458833|Diet
914146|NCT02458820|Cardiopulmonary Resuscitation
914147|NCT02458820|Return of Spontaneous Circulation
914148|NCT02458820|ROSC
914149|NCT02458820|Electroencephalogram
914150|NCT02458742|spinal anesthesia
914151|NCT02458742|intrathecal morphine
914152|NCT02458742|transurethral resection of prostate
914153|NCT02458742|postoperative pain
914154|NCT02458729|Tranexamic Acid
914155|NCT02458729|Total Knee Arthroplasty
914156|NCT02458729|Rivaroxaban
914157|NCT02458703|workload
914158|NCT02458703|oxygen level
914159|NCT02458703|oxygen consumption
914160|NCT02458703|breathing reserve
914161|NCT02458703|ventilatory efficiency
914162|NCT02458690|Primary Care
914163|NCT02458690|Older Adults
914164|NCT02458690|Antidepressant Medications
914165|NCT02458690|Cognitive-Behavioral Therapy
914166|NCT02458690|Computer-Based Psychotherapy
914167|NCT02458612|cerebral palsy
914168|NCT02458612|mirror therapy
914169|NCT02458612|strength training
914170|NCT02458560|Transcatheter Aortic Valve Replacement
914171|NCT02458560|Aortic Stenosis
914172|NCT02458534|Simulated manikin
914173|NCT02458508|MC4R
914174|NCT02458508|chemotherapy
914175|NCT02458508|radiotherapy
914176|NCT02458495|Internet
914177|NCT02458495|Mobile Health
914178|NCT02458495|Hemoglobin A, Glycosylated
914179|NCT02458495|Medication Adherence
914180|NCT02458495|Psychological Theory
914181|NCT02458482|Children
914182|NCT02458482|Positive Airway Pressure
914183|NCT02458482|Nebulizer
914184|NCT02458482|Moderate
914185|NCT02458482|Acute
914186|NCT02458482|AccuPAP
914187|NCT02458417|Ablative laser
914188|NCT02458417|Fractional laser
914189|NCT02458417|Vitiligo
914190|NCT02458417|Piebaldism
914191|NCT02458417|Cell suspension grafting
914192|NCT02458391|Breast Cancer
914193|NCT02458391|Lymphedema
914194|NCT02458365|Violence
914195|NCT02458365|Bullying
914196|NCT02458365|Social skills
914197|NCT02458365|Prevention & control
914198|NCT02458365|Adolescent
914199|NCT02458339|Brain tumor
914200|NCT02458339|Malignant Fourth Ventricular Brain Tumors
914201|NCT02458326|Migraine
914202|NCT02458326|Fibromyalgia
914203|NCT02458326|Aerobic exercise
914204|NCT02458300|Bronchiolitis
914205|NCT02458300|Chest
914206|NCT02458300|Physical therapy
914207|NCT02458287|mixed dyslipidemia
914208|NCT02458248|Chronic Kidney Disease
914209|NCT02458248|Sodium Reduction
914210|NCT02458248|eGFR 30-60ml/min/1.73m2
914211|NCT02458235|pediatric leukemia myelodysplastic syndrome azacitidine
914212|NCT02458209|PK, bococizumab, comparability, LDL-C
914213|NCT02458196|IgG4 related disease
914214|NCT02458196|IgG4-RD
914215|NCT02458196|Response rate
914216|NCT02458196|Relapse
914217|NCT02458170|Rheumatoid arthritis
914218|NCT02458170|Synovial tissue
914219|NCT02458170|Joint destruction
914220|NCT02458170|Inflammation
914221|NCT02458157|ICU
914222|NCT02458157|Intensive
914223|NCT02458157|CRRT
914224|NCT02458157|Fluid Removal
914225|NCT02458157|AKI
914226|NCT02458157|Critical Care
914227|NCT02458131|community-based participatory research
914228|NCT02458131|adolescents
914229|NCT02458118|chronic
914230|NCT02458118|pancreatitis
914231|NCT02458118|secretin
914232|NCT02458118|Blood flow
914233|NCT02458105|Acceptance and commitment therapy
914234|NCT02458105|Cognitive behavior therapy
914235|NCT02458053|African American
914236|NCT02458053|male
914237|NCT02458053|couples
914238|NCT02458053|randomized control trial
914239|NCT02458014|Leukemia
914240|NCT02458014|B-cell Lineage Acute Lymphocytic Leukemia
914241|NCT02458014|Positive minimal residual disease
914242|NCT02458014|MRD
914243|NCT02458014|Acute lymphocytic leukemia
914244|NCT02458014|ALL
914245|NCT02458014|Blinatumomab
914246|NCT02458014|Blinacyto
914247|NCT02458014|Phone calls
914248|NCT02457949|Social Assistance
914249|NCT02457949|Drug Use
914250|NCT02457949|Drug-Related harm
914251|NCT02457923|mobile phone counselling
914252|NCT02457923|infant feeding
914253|NCT02457923|nutrition
914254|NCT02457897|Brown Adipose Tissue
914255|NCT02457897|Liothyronine
914256|NCT02457897|Insulin Receptors
914257|NCT02457884|Diabetic macular oedema
914258|NCT02457884|Perceptual learning
914259|NCT02457884|Chinese
914260|NCT02457884|Hong Kong
914261|NCT02457858|Type 1 Diabetes
914262|NCT02457858|Islet Transplant
914263|NCT02457845|Brain Tumor, Recurrent
914264|NCT02457845|Glioma
914265|NCT02457845|Glioblastoma
914266|NCT02457845|Gliosarcoma
914267|NCT02457845|Anaplastic Astrocytoma
914268|NCT02457845|Oligodendroglioma
914269|NCT02457845|Rhabdoid Tumor
914270|NCT02457845|Cerebral Primitive Neuroectodermal Tumor
914271|NCT02457845|PNET
914272|NCT02457845|Ependymoma
914273|NCT02457845|Germ Cell Tumor
914274|NCT02457845|Choroid Plexus Carcinoma
914275|NCT02457845|Oncolytic Virus Therapy
914276|NCT02457845|Virotherapy, Oncolytic
914277|NCT02457845|Immunotherapy
914278|NCT02457845|Central Nervous System Agents
914279|NCT02457845|Antineoplastic Agents
914280|NCT02457845|Neoplasms
914281|NCT02457845|Pediatric
914282|NCT02457845|Pediatrics
914283|NCT02457832|Magnetic Resonance Imaging
914284|NCT02457832|Neurology
914285|NCT02457832|Neurosciences
914286|NCT02457832|Physical Medicine
914287|NCT02457832|Parkinson Disease
914288|NCT02457832|Rehabilitation
914289|NCT02457806|Dental Anesthesia
914290|NCT02457780|PTSD
914291|NCT02457780|Trauma
914292|NCT02457780|World Trade Center
914293|NCT02457780|Respiratory
914294|NCT02457780|Mind-Body
914295|NCT02457741|Mechanical ventilation
914296|NCT02457741|PEEP
914297|NCT02457741|Respiratory mechanics
914298|NCT02457741|End-expiratory lung volume
914299|NCT02457689|Human Immunodeficiency Virus
914300|NCT02457689|Immunodeficiency Virus, Human
914301|NCT02457676|Self-Regulation Training
914302|NCT02457676|Neuroimaging
914303|NCT02457676|Response Inhibition
914304|NCT02457676|Behavioral Regulation
914305|NCT02457676|Emotional Regulation
914306|NCT02457663|Burns
914307|NCT02457637|chronic liver disease
914308|NCT02457637|acute liver injury
914309|NCT02457637|acute decompensation
914310|NCT02457637|multiple organ failures
914311|NCT02457637|acute on chronic liver failure
914312|NCT02457624|gastric cancer
914313|NCT02457624|chronic atrophic gastritis
914314|NCT02457624|intestinal metaplasia
914317|NCT02457494|CALVIH
914318|NCT02457494|Renal stone
914319|NCT02457494|HIV1
914320|NCT02457494|Renal colic
914321|NCT02457494|Atazanavir
914322|NCT02457494|Crystalluria
914323|NCT02457494|Chronic Kidney Disease
914324|NCT02457494|Calcium Oxalate
914325|NCT02457481|Embryo Culture Techniques
914326|NCT02457481|Embryonic Development
914327|NCT02457468|coflex
914328|NCT02457468|interlaminar stabilization
914329|NCT02457468|lumbar spinal stenosis
914330|NCT02457468|neurogenic claudication
914331|NCT02457468|decompression
914332|NCT02457455|inflight emergencies
914333|NCT02457442|Anesthetics, Inhalation
914334|NCT02457442|Anesthetics, Intravenous
914335|NCT02457442|Analgesics, Opioid
914336|NCT02457429|Gastro-oesophageal reflux
914337|NCT02457429|Children
914338|NCT02457429|Dx-pH Pharyngeal probe
914339|NCT02457429|GORD
914340|NCT02457429|Trans-nasal catheter
914341|NCT02457416|Peanut allergy
914342|NCT02457416|Oral immunotherapy
914343|NCT02457390|contrast enhanced laparoscopic ultrasound
914344|NCT02457390|CE-LUS
914345|NCT02457390|LUS
914346|NCT02457390|robot assisted CRC resection
914347|NCT02457377|recurrent abortion
914348|NCT02457377|cerclage
914349|NCT02457377|laparoscopy
914350|NCT02457377|cervical imcompetence
914351|NCT02457364|non-operative management
914352|NCT02457351|Phase 1
914353|NCT02457351|Advanced solid tumor
914354|NCT02457351|pan-CDK inhibitor
914355|NCT02457351|Drug-drug Interaction
914356|NCT02457338|C-section
914357|NCT02457338|Infants
914358|NCT02457338|Probiotic
914359|NCT02457338|B. infantis
914360|NCT02457338|Microbiota
914361|NCT02457338|Gut
914362|NCT02457338|Breast milk
914363|NCT02457338|Vaginal
914364|NCT02457325|Articaine
914365|NCT02457325|Lower third molar
914366|NCT02457325|Oral Surgery
914367|NCT02457299|Esophagectomy
914368|NCT02457299|Gastric Conduit
914369|NCT02457299|Esophageal Cancer
914370|NCT02457273|PDNC(Poorly Differentiated Neuroendocrine Carcinomas)
914371|NCT02457273|TLC-388 (Lipotecan®)
914372|NCT02457247|Drug therapy
914373|NCT02457234|fruits and vegetables
914374|NCT02457234|cultural immersion
914375|NCT02457221|Tacrolimus
914376|NCT02457221|Cyclophosphamide
914377|NCT02457221|Prograf
914378|NCT02457221|lupus nephritis
914379|NCT02457208|pharmacokinetics
914380|NCT02457195|PONV
914381|NCT02457195|anesthesia
914382|NCT02457195|granisetron
914383|NCT02457156|Pancreatico-jejunostomy
914384|NCT02457156|Pancreato-duodenectomy
914385|NCT02457156|Cattell-Warren anastomosis
914386|NCT02457156|Blumgart anastomosis
914387|NCT02457143|recall
914388|NCT02457143|income-related disparities
914389|NCT02457143|cancer screening
914390|NCT02457117|CyberKnife
914391|NCT02457117|Partial breast irradiation
914392|NCT02457117|accelerated partial breast irradiation
914393|NCT02457117|breast sbrt
914394|NCT02457091|multiple sclerosis
914395|NCT02457091|exercise
914396|NCT02457091|home-based
914397|NCT02457091|training
914398|NCT02457091|fitness
914399|NCT02457078|nutritional supplements
914400|NCT02457078|lutein
914401|NCT02457078|DHA
914402|NCT02457078|vitamin E
914403|NCT02457078|infant brain development
914404|NCT02457065|survivors
914405|NCT02457065|family
914406|NCT02457052|Medical device
914407|NCT02457039|Chemo-brain
914408|NCT02457039|Drug-Related Side Effects and Adverse Reactions
914409|NCT02457039|Mild Cognitive Impairment
914410|NCT02457039|Breast cancer
914411|NCT02457026|neovascular age-related macular degeneration
914412|NCT02457026|age-related macular degeneration
914413|NCT02457026|verteporfin
914414|NCT02457026|persistent disease activity
914415|NCT02457026|photodynamic therapy
914416|NCT02457026|Aflibercept
914417|NCT02457000|Sleep
914418|NCT02457000|Skin
914419|NCT02457000|Circadian Rhythm
914420|NCT02456961|Collagen crosslinking (CXL)
914421|NCT02456961|Standard corneal crosslinking (CXL)
914422|NCT02456961|Transepithelial CXL
914423|NCT02456961|Iontophoresis
914424|NCT02456961|Riboflavin
914425|NCT02456948|treatment resistant depression
914426|NCT02456948|inflammation
914427|NCT02456948|microglia
914428|NCT02456948|minocycline
914429|NCT02456922|Type 1 Diabetes
914430|NCT02456922|Type 2 Diabetes
914431|NCT02456922|Harmony 1
914432|NCT02456896|Oxcarbazepine
914433|NCT02456896|Brain Derived Neurotrophic Factor
914434|NCT02456896|Bipolar disorder
914435|NCT02456896|Neuroprotection
914436|NCT02456883|ASP2215
914437|NCT02456883|14C-labeled gilteritinib
914438|NCT02456883|Advanced Solid Tumors
914439|NCT02456883|Pharmacokinetics
914440|NCT02456883|gilteritinib
914441|NCT02456870|Adipose tissue
914442|NCT02456870|Overfeeding
914443|NCT02456857|Breast cancer
914444|NCT02456857|Triple-Negative Breast Cancer
914445|NCT02456857|TNBC
914446|NCT02456857|Tumors insensitive to standard neoadjuvant chemotherapy
914447|NCT02456857|Temsirolimus
914448|NCT02456857|CCI-779
914449|NCT02456857|Torisel
914450|NCT02456857|Liposomal Doxorubicin
914451|NCT02456857|Doxil
914452|NCT02456857|Doxorubicin Hydrochloride (Liposomal)
914453|NCT02456857|Bevacizumab
914454|NCT02456857|Avastin
914455|NCT02456857|Anti-VEGF Monoclonal Antibody
914456|NCT02456857|rhuMAb-VEGF
914457|NCT02456818|Colonization
914458|NCT02456818|Multi-resistant gram negative bacteria
914459|NCT02456818|Infection control measures
914460|NCT02456818|Hand hygiene program
914461|NCT02456818|Contact precautions
914462|NCT02456818|Immunocompromised host
914463|NCT02456792|PCOS
914464|NCT02456792|Clomiphene citrate resistant
914465|NCT02456792|LOD
914466|NCT02456792|IVF
914467|NCT02456779|pepsin
914468|NCT02456779|peptest
914469|NCT02456779|GERD
914470|NCT02456779|NERD
914471|NCT02456779|diagnostic
914472|NCT02456766|FibroTouch
914473|NCT02456766|acoustic attenuation parameter
914474|NCT02456766|liver biopsy
914475|NCT02456766|hepatic steatosis
914476|NCT02456753|in labor
914477|NCT02456753|Ultrasonography
914478|NCT02456753|clinical examination
914479|NCT02456753|Prenatal
914480|NCT02456740|Migraine
914481|NCT02456740|Headache
914482|NCT02456740|Prevention
914483|NCT02456740|Prophylaxis
914484|NCT02456727|Acupuncture
914485|NCT02456727|Group/Community Acupuncture
914486|NCT02456727|Individual Acupuncture
914487|NCT02456727|Chronic Pain
914488|NCT02456727|Underserved
914489|NCT02456727|Urban Primary Care
914490|NCT02456727|Osteoarthritis
914491|NCT02456727|Back Pain
914492|NCT02456727|Neck Pain
914493|NCT02456714|Cholangiocarcinoma
914494|NCT02456714|FOLFIRINOX
914495|NCT02456714|Phase II study
914496|NCT02456701|CDX3379
914497|NCT02456675|Refractory Hodgkin lymphoma
914498|NCT02456675|Relapsed Hodgkin Lymphoma
914499|NCT02456649|lumpectomy margins
914500|NCT02456636|Weight loss
914501|NCT02456636|Weight management
914502|NCT02456636|Diabetes
914503|NCT02456636|Heart disease
914504|NCT02456597|Peripheral Nerve Blocks
914505|NCT02456584|depot medroxyprogesterone acetate (DMPA)
914506|NCT02456584|confidence interval (CI)
914507|NCT02456584|Subcutaneous (sub-Q)
914508|NCT02456584|Intrauterine device (IUD)
914509|NCT02456584|Levonorgestrel (LNG)
914510|NCT02456584|intrauterine system (IUS)
914511|NCT02456558|HIV infection
914512|NCT02456558|antiretroviral drugs
914513|NCT02456558|deferiprone
914514|NCT02456558|pharmacokinetics
914515|NCT02456519|children
914516|NCT02456519|surgery
914517|NCT02456428|Incretins
914518|NCT02456428|Antidiabetic Agents
914519|NCT02456428|Heart Failure
914520|NCT02456389|Probable cancer
914521|NCT02456389|Proven cancer
914522|NCT02456389|Elective cancer surgery
914523|NCT02456389|Postoperative death
914524|NCT02456389|Postoperative complications
914525|NCT02456389|Healthcare utilization
914526|NCT02456389|Quality of life
914527|NCT02456389|Adjuvant therapy
914528|NCT02456389|Disease-free survival
914529|NCT02456389|Overall survival
914530|NCT02456376|Sensor Fusion
914531|NCT02456376|Stochastic Resonance Stimulation
914532|NCT02456376|Sensory deficits
914533|NCT02456376|Postural Control
914534|NCT02456363|Adalimumab
914535|NCT02456363|NSAIDs
914536|NCT02456363|safety
914537|NCT02456363|efficacy
914538|NCT02456337|Gingival Recession
914539|NCT02456337|Coronally advanced flap
914540|NCT02456337|Periodontal regeneration
914541|NCT02456324|Fistula, Anorectal
914542|NCT02456311|VATS
914543|NCT02456311|Energy sealing
914544|NCT02456298|Telehealth
914545|NCT02456298|Applied behavior analysis
914546|NCT02456272|Otosclerosis
914547|NCT02456272|Surgical treatment
914548|NCT02456272|Hearing aids
914549|NCT02456259|internal jugular vein patency
914550|NCT02456259|MICS
914551|NCT02456259|neck cannula
914552|NCT02456259|Jugular veins
914553|NCT02456246|Stereotactive Body Radiation Therapy (SBRT)
914554|NCT02456246|Lung Fibrosis
914555|NCT02456246|FLT-PET
914556|NCT02456246|NSCLC
914557|NCT02456233|rotor
914558|NCT02456233|FIRM
914559|NCT02456233|paroxysmal atrial fibrillation
914560|NCT02456233|persistent atrial fibrillation
914561|NCT02456233|atrial tachyarrhythmia
914562|NCT02456233|ablation
914563|NCT02456233|contact mapping
914564|NCT02456233|clinical trial
914565|NCT02456233|signal processing
914566|NCT02456220|Herbst appliance
914567|NCT02456220|Computed tomography
914568|NCT02456220|3D imaging
914569|NCT02456220|Growth and development
914570|NCT02456220|Orthodontic Appliances, Functional
914571|NCT02456168|Lupus
914572|NCT02456168|SLE
914573|NCT02456155|bedside placement
914574|NCT02456155|nasal jejunal tube
914575|NCT02456155|ultrasound
914576|NCT02456155|severe acute pancreatitis
914577|NCT02456155|endoscope
914578|NCT02456155|efficacy
914579|NCT02456155|safety
914580|NCT02456129|Clinical Trial, Phase I
914581|NCT02456077|MCV4: Meningococcal Conjugate Vaccine
914582|NCT02456077|HPV: Human Papillomavirus
914583|NCT02456051|Pancreatic Carcinoma
914584|NCT02456051|New-Onset Diabetes
914585|NCT02456051|Adrenomedullin
914586|NCT02456051|Early Diagnosis
914587|NCT02456051|Biological Markers
914588|NCT02456012|peptic ulcer hemorrhage
914589|NCT02456012|comorbidity
914590|NCT02456012|clinical trial
914591|NCT02455973|obesity
914592|NCT02455973|overweight
914593|NCT02455947|Burnout
914594|NCT02455947|Teachers
914595|NCT02455947|Meditation
914596|NCT02455947|IBSR
914597|NCT02455947|"The Work"
914598|NCT02455947|Byron Katie
914599|NCT02455895|Blepharitis
914600|NCT02455856|Healthy
914601|NCT02455856|Itraconazole
914602|NCT02455856|JNJ-42847922
914603|NCT02455843|microwave ablation
914604|NCT02455843|chemotherapy
914605|NCT02455830|Neonatal encephalopathy
914606|NCT02455830|Hypoxic-ischemic encephalopathy
914607|NCT02455830|Newborn infants
914608|NCT02455830|Cytokines
914609|NCT02455830|Trophic factors
914610|NCT02455791|Breast Cancer
914611|NCT02455791|Triple negative breast cancer
914612|NCT02455791|HER2 amplified breast cancer
914613|NCT02455791|Ultrasound-guided biopsy
914614|NCT02455791|Fine needle aspirate
914615|NCT02455791|FNA
914616|NCT02455791|Core biopsy
914617|NCT02455752|LE-TME
914618|NCT02455752|Laparoscopic rectal resection
914619|NCT02455752|Retroperitoneal resection
914620|NCT02455739|intestinal function
914621|NCT02455739|chewing gum
914622|NCT02455726|Peripheral Arterial Disease
914623|NCT02455726|Magnesium Oxide
914624|NCT02455726|Pain
914625|NCT02455687|Bronchial asthma
914626|NCT02455687|Magnesium Sulfate
914627|NCT02455687|Inhaled budesonide
914628|NCT02455674|weight estimation
914629|NCT02455674|emergency
914630|NCT02455674|child
914631|NCT02455635|Office Hysteroscopy
914632|NCT02455635|tubal patency
914633|NCT02455635|infertility
914634|NCT02455635|Lower Abdominal Pain
914635|NCT02455609|dexmedetomidine
914636|NCT02455609|ketamine
914637|NCT02455609|postoperative pain
914638|NCT02455596|Novaferon
914639|NCT02455596|Recombinant anti-tumor and anti-virus protein for injection
914640|NCT02455596|Carcinoid Tumor
914641|NCT02455596|Pancreatic Neuroendocrine Tumor
914642|NCT02455583|HIV prevention
914643|NCT02455583|Sexual activity biomarker
914644|NCT02455583|Youth
914645|NCT02455583|Adolescents
914646|NCT02455570|Endoscopic Ultrasound
914647|NCT02455570|Quality Management
914648|NCT02455570|Education and training
914649|NCT02455570|Safety
914650|NCT02455570|Learning curve
914651|NCT02455544|Urine congophilia
914652|NCT02455518|pain
914653|NCT02455505|Cancer Care and Bereavement
914654|NCT02455505|Supportive Care
914655|NCT02455505|15-095
914656|NCT02455492|Mortality
914657|NCT02455492|Perioperative period
914658|NCT02455492|Elective surgical procedures
914659|NCT02455479|cocaine vaccine
914660|NCT02455479|cocaine dependence
914661|NCT02455479|Cocaine
914662|NCT02455440|esmolol
914663|NCT02455440|anesthetics
914664|NCT02455427|transcranial direct current stimulation
914665|NCT02455427|conventional physical therapy
914666|NCT02455401|Postoperative Vomiting
914667|NCT02455388|Nutrition
914668|NCT02455388|Obesity
914669|NCT02455388|Pediatric
914670|NCT02455375|Puumala virus
914671|NCT02455375|diagnostic
914672|NCT02455375|France
914673|NCT02455349|Veterans
914674|NCT02455349|Community Engagement
914675|NCT02455349|Negative Symptoms
914681|NCT02455323|Efficacy
914682|NCT02455323|Tension-type headache
914683|NCT02455323|Manual therapy
914684|NCT02455284|MRI
914685|NCT02455284|Tractography
914686|NCT02455284|white
914687|NCT02455284|physiology
914688|NCT02455284|analysis
914689|NCT02455284|matter
914690|NCT02455284|tracts
914691|NCT02455271|Insomnia
914692|NCT02455258|Inactivity
914693|NCT02455180|Critical Care
914694|NCT02455167|HCV
914695|NCT02455167|Hepatitis C
914696|NCT02455154|Chinese Traditional Medicine
914697|NCT02455154|Osteoporosis
914698|NCT02455154|adjuvant endocrine therapy
914699|NCT02455154|early breast cancer
914700|NCT02455141|chemptherapy
914701|NCT02455141|triple negative
914702|NCT02455141|paclitaxel
914703|NCT02455141|carboplatin
914704|NCT02455128|Anxiety
914705|NCT02455128|Fear
914706|NCT02455128|Colorectal Surgery
914707|NCT02455128|Colorectal Neoplasms
914708|NCT02455115|Acute kidney injury
914709|NCT02455115|Liver transplantation
914710|NCT02455115|Postoperative care
914711|NCT02455115|Glomerular filtration rate
914712|NCT02455115|Renal blood flow
914713|NCT02455115|Vasopressor
914714|NCT02455115|Norepinephrine
914715|NCT02455102|Prevention
914716|NCT02455102|Anticoagulation
914717|NCT02455102|Electronic warning system
914718|NCT02455089|Flare
914719|NCT02455089|Therapeutic adjustments
914720|NCT02455089|Biological Marker
914721|NCT02455089|Immunologic Marker
914722|NCT02455089|Prognosis
914723|NCT02455076|Hypoglycemia
914724|NCT02455037|Concussion
914725|NCT02455037|Contact sport
914726|NCT02455037|Collision sport
914727|NCT02455037|Neck strengthening
914728|NCT02455024|Leukemia
914729|NCT02455024|Leukemia, Myeloid
914730|NCT02455024|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
914731|NCT02455024|ponatinib
914732|NCT02455024|Pharmacologic Actions
914733|NCT02455024|Protein Kinase Inhibitors
914734|NCT02455024|Risk factor
914735|NCT02455024|Leukemia, Myelogenous, Chronic
914736|NCT02455024|CML
914737|NCT02455024|CP-CML
914738|NCT02455024|Iclusig
914739|NCT02455024|AP24534
914740|NCT02455024|AP-CML
914741|NCT02455024|BP-CML
914742|NCT02455024|Ph+ALL
914743|NCT02454998|Unilateral complete cleft lip
914744|NCT02454998|Alveolar bone graft
914745|NCT02454946|Blood Group Antigens
914746|NCT02454946|erectile dysfunction
914747|NCT02454933|Phase III Open Label Study; AZD9291 plus MEDI4736 versus AZD9291 Monotherapy; NSCLC After Previous EGFR TKI Therapy; T790M Mutation Positive Tumours.
914748|NCT02454920|Strabismus
914749|NCT02454920|Optical Coherence Tomography
914750|NCT02454920|Extraocular muscles
914751|NCT02454868|Remifentanil
914752|NCT02454868|Intubation
914753|NCT02454868|Children
914757|NCT02454842|TH-4000
914758|NCT02454842|low-oxygen conditions
914759|NCT02454842|hypoxia
914760|NCT02454842|non-small cell lung cancer
914761|NCT02454842|NSCLC
914762|NCT02454842|squamous cell carcinoma
914763|NCT02454842|Tarloxotinib
914764|NCT02454829|Ovarian cortex cryopreservation
914765|NCT02454829|ovarian function
914766|NCT02454790|Acute toxicity
914767|NCT02454790|Late toxicity
914768|NCT02454790|Prediction models
914769|NCT02454738|pulmonary tuberculosis
914770|NCT02454738|chest
914771|NCT02454738|ultralow dose computed tomography
914772|NCT02454725|HIV Testing
914773|NCT02454725|Latino
914774|NCT02454712|Prodrug
914775|NCT02454712|PF614
914776|NCT02454712|oxycodone extended-release
914777|NCT02454712|oral
914778|NCT02454699|antiviral
914779|NCT02454699|ascending dose
914780|NCT02454699|Cytomegalovirus
914781|NCT02454699|food effect
914782|NCT02454699|Herpesviridae
914783|NCT02454699|MBX-400
914784|NCT02454686|Complications after hepatectomy
914785|NCT02454673|Radiotherapy
914786|NCT02454673|Neoadjuvant therapy
914787|NCT02454673|Pharmacodynamics
914788|NCT02454673|Pharmacokinetics
914789|NCT02454673|Nonlinear Dynamics
914790|NCT02454660|adherence
914791|NCT02454660|hypertension
914792|NCT02454660|mobile technology
914793|NCT02454660|intervention
914794|NCT02454647|Radiotherapy
914795|NCT02454647|Neoadjuvant therapy
914796|NCT02454647|Induction chemotherapy
914797|NCT02454647|Concurrent chemoradiotherapy
914798|NCT02454647|Preoperative factors
914799|NCT02454647|Dynamic factors
914800|NCT02454647|Prognostic Factor
914801|NCT02454634|IDH1R132H
914802|NCT02454634|peptide vaccine
914803|NCT02454634|immunotherapy
914804|NCT02454634|IDH1R132H-mutated glioma
914805|NCT02454556|Assisted reproduction technologies
914806|NCT02454556|Follicle stimulating hormone (FSH).
914807|NCT02454543|metastatic
914808|NCT02454543|prostatectomy
914809|NCT02454543|androgen deprivation
914810|NCT02454504|Sugammadex
914811|NCT02454504|Delayed Emergence from Anesthesia
914812|NCT02454504|Curare
914813|NCT02454504|Robotic Surgical Procedures
914814|NCT02454491|percutaneous coronary interventions
914815|NCT02454491|radial artery access
914816|NCT02454491|access site complications
914817|NCT02454491|verapamil
914818|NCT02454491|heparin
914819|NCT02454478|lenvatinib
914820|NCT02454478|Everolimus
914821|NCT02454478|Carcinoma
914822|NCT02454478|Unresectable advanced renal cell carcinoma
914823|NCT02454478|Metastatic renal cell carcinoma
914824|NCT02454452|Varicose Veins
914825|NCT02454439|Heart Failure with reduced ejection fraction (<35%)
914826|NCT02454439|Cardiac Resynchronisation Therapy
914827|NCT02454439|Non specific intraventricular conduction
914828|NCT02454439|Efficacy
914829|NCT02454439|Life expectancy expected to exceed one year with a good functional status
914830|NCT02454439|QRS morphology : NICD according to the AHA/ACCF/HRS Recommendations (non-LBBB and non-RBBB):
914831|NCT02454439|QRS duration > 130 ms
914832|NCT02454426|Depression
914833|NCT02454426|Heart disease
914834|NCT02454413|dentures hygiene
914835|NCT02454413|biofilm formation
914836|NCT02454413|oral health
914837|NCT02454400|physical therapy
914838|NCT02454400|lumbar spine surgery
914839|NCT02454400|pre-surgical intervention
914840|NCT02454400|RCT
914841|NCT02454374|Physiotherapy
914842|NCT02454374|Knee Loading
914843|NCT02454374|Randomised Controlled Trial
914844|NCT02454374|Pain
914845|NCT02454361|Safety
914846|NCT02454361|tolerability
914847|NCT02454361|pharmacokinetics
914848|NCT02454361|KBP-7072
914849|NCT02454348|septic shock
914850|NCT02454348|vasopressin
914851|NCT02454348|norepinephrine
914852|NCT02454296|Laminaria
914853|NCT02454270|First-in-Human
914854|NCT02454270|B-Cell Chronic Lymphocytic Leukemia
914855|NCT02454270|Diffuse Large-Cell Lymphoma
914856|NCT02454270|Follicular Lymphoma
914857|NCT02454270|Mantle-Cell Lymphoma
914858|NCT02454270|Acute Lymphoid Leukemia
914859|NCT02454270|Dose Escalation Study
914860|NCT02454270|Duvortuxizumab
914861|NCT02454231|EPC
914862|NCT02454231|CD34+
914863|NCT02454231|CD14+CD34low
914864|NCT02454218|Fibromyalgia
914865|NCT02454218|Transcranial direct current stimulation
914866|NCT02454192|Evidence-based intervention
914867|NCT02454192|Implementation
914868|NCT02454192|Underserved communities
914869|NCT02454127|nutrition
914870|NCT02454127|popular diets
914871|NCT02454127|weight loss
914872|NCT02454127|lifestyle
914873|NCT02454127|counseling
914874|NCT02454114|Pneumonia
914875|NCT02454114|Community
914876|NCT02454114|Hospital
914877|NCT02454114|Respiratory
914878|NCT02454114|Infection
914879|NCT02454088|Volume
914880|NCT02454088|Hands
914881|NCT02454088|Filler
914882|NCT02454088|Radiesse
914883|NCT02454088|Calcium hydroxylapatite
914884|NCT02454075|YF476
914885|NCT02454075|netazepide
914886|NCT02454075|gastric carcinoids
914887|NCT02454075|Zollinger-Ellison syndrome
914888|NCT02454062|Phase I
914889|NCT02454062|Solid Tumors
914890|NCT02454062|Pharmacokinetics
914891|NCT02454062|Pharmacodynamics
914892|NCT02454062|MTD
914893|NCT02454023|Stroke
914894|NCT02454023|Transient ischemic attack
914895|NCT02454023|Obstructive sleep apnea
914896|NCT02454023|Portable sleep monitor
914897|NCT02454023|Screening
914902|NCT02453984|89Zr-MPLD3280A-PET
914903|NCT02453984|triple-negative breast cancer
914904|NCT02453984|non small cell lung cancer
914905|NCT02453984|bladder cancer
914906|NCT02453971|alcohol consumption
914907|NCT02453971|binge drinking
914908|NCT02453971|web-based personalized feedback program
914909|NCT02453971|students
914910|NCT02453958|Injury
914911|NCT02453958|Brain
914912|NCT02453958|Traumatic Mild
914913|NCT02453958|Mild Traumatic Brain Injury
914914|NCT02453945|pain
914915|NCT02453945|comfort
914916|NCT02453945|healing
914917|NCT02453945|quality of life
914918|NCT02453932|Vascular dementia
914919|NCT02453932|Tianzhi granule
914920|NCT02453932|Herbal medicine
914921|NCT02453932|Randomized controlled trial
914922|NCT02453932|Three arms
914923|NCT02453919|functional cardiac abnormality
914924|NCT02453919|morphologic cardiac abnormality
914925|NCT02453919|blood pressure abnormality
914926|NCT02453893|Iloperidone
914927|NCT02453893|Risperidone
914928|NCT02453893|PANSS
914929|NCT02453880|anxiety
914930|NCT02453880|depression
914931|NCT02453880|chronic illness
914932|NCT02453880|teen
914933|NCT02453880|young adult
914934|NCT02453867|kidney transplantation
914935|NCT02453867|senior kidney transplant recipients
914936|NCT02453867|tacrolimus once daily
914937|NCT02453867|reduced immunosuppression
914938|NCT02453867|recipients >65 years
914939|NCT02453867|Senior
914940|NCT02453802|Tranexamic Acid
914941|NCT02453802|Total Knee Arthroplasty
914942|NCT02453802|Rivaroxaban
914943|NCT02453789|alginate oligosaccharide
914944|NCT02453789|cystic fibrosis
914945|NCT02453789|Burkholderia
914946|NCT02453789|aztreonam
914947|NCT02453776|Crohns Disease
914948|NCT02453776|Ulcerative Colitis
914949|NCT02453776|Infliximab
914950|NCT02453776|Sustained
914951|NCT02453776|Remission
914952|NCT02453776|Inflammatory bowel disease
914953|NCT02453776|IBD
914954|NCT02453763|Transcranial direct current stimulation
914955|NCT02453763|Noninvasive brain stimulation
914956|NCT02453763|Brain
914957|NCT02453763|Central Nervous System Diseases
914958|NCT02453763|Nervous System Diseases
914959|NCT02453763|Parkinson disease
914960|NCT02453763|Stroke
914961|NCT02453763|Epilepsy
914962|NCT02453763|Depression
914963|NCT02453763|Schizophrenia
914964|NCT02453763|Brain imaging
914965|NCT02453763|Electrical impedance tomography
914966|NCT02453763|Magnetic resonance electrical impedance tomography
914967|NCT02453763|Diffusion tensor imaging
914968|NCT02453763|Functional magnetic imaging
914969|NCT02453763|Rehabilitation
914970|NCT02453750|Congenital Diaphragmatic Hernia
914971|NCT02453750|Airway Inflammation
914972|NCT02453750|Asthma
914973|NCT02453750|Hypersaline
914974|NCT02453750|Pediatrics
914979|NCT02453724|Ultrasonography
914980|NCT02453724|Lung
914981|NCT02453724|Hemorrhage
914982|NCT02453724|Point of care ultrasound
914983|NCT02453698|Stop task
914984|NCT02453698|modulatory effect of MPH
914985|NCT02453698|bottom-up and top-down
914986|NCT02453698|cognitive processes
914987|NCT02453633|Appointment reminder
914988|NCT02453633|Attendance
914989|NCT02453633|No-show
914990|NCT02453594|PD1
914991|NCT02453594|PD-1
914992|NCT02453594|PDL1
914993|NCT02453594|PD-L1
914994|NCT02453542|hemophilia
914995|NCT02453542|inhibitors
914996|NCT02453542|thrombin
914997|NCT02453529|plasma concentration
914998|NCT02453529|pulmonary concentration
914999|NCT02453516|Serratus Block
915000|NCT02453516|Breast Surgery
915001|NCT02453503|Lichen planus
915002|NCT02453503|Mucoadhesive film
915003|NCT02453503|licorice
915004|NCT02453490|Colorectal Cancer
915005|NCT02453490|liver metastasis
915006|NCT02453490|neoadjuvant chemotherapy
915007|NCT02453477|Beta thalassemia
915008|NCT02453477|Gene therapy
915009|NCT02453477|Lentiviral vector
915010|NCT02453451|MitraClip
915011|NCT02453451|atrial septal defect
915012|NCT02453451|iatrogenic
915013|NCT02453425|renal blood flow
915014|NCT02453425|renal oxygenation
915015|NCT02453425|glomerular filtration rate
915016|NCT02453425|filtration fraction
915017|NCT02453425|blood pressure
915018|NCT02453412|Arteriovenous fistulae (AVFs)
915019|NCT02453412|Non-maturation
915020|NCT02453412|Computational simulation
915021|NCT02453386|Motor fluctuations
915022|NCT02453386|Off time
915023|NCT02453386|On time
915024|NCT02453386|Dyskinesia
915025|NCT02453360|Anesthesia
915026|NCT02453360|Analgesia
915027|NCT02453347|Stable chronic medical conditions
915028|NCT02453347|No current alcohol or substance abuse
915029|NCT02453347|Alpha Stim
915030|NCT02453321|Continuous Femoral Nerve Block
915031|NCT02453321|Continuous Adductor Canal Block
915032|NCT02453308|Artemisinin combination Therapies
915033|NCT02453295|Lymphedema
915034|NCT02453295|Arm Disability
915035|NCT02453295|Cancer Survivorship
915036|NCT02453295|Intervention
915037|NCT02453282|NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS
915038|NCT02453269|Obesity
915039|NCT02453269|Children
915040|NCT02453269|Health Colective
915041|NCT02453243|Suicide screening in the ED
915042|NCT02453243|Safety Planning
915043|NCT02453217|severe mental illness
915044|NCT02453217|physical health screening
915045|NCT02453217|randomised controlled trial
915046|NCT02453217|health behaviour change
915047|NCT02453178|physical activity
915048|NCT02453178|aging
915049|NCT02453178|cognition
915050|NCT02453178|brain
915051|NCT02453178|exercise
915052|NCT02453165|vaginal dehiscence
915053|NCT02453152|myotubular myopathy
915054|NCT02453152|respiratory muscles
915055|NCT02453152|natural history
915056|NCT02453126|Eosinophilic Esophagitis
915057|NCT02453126|Esophageal Stricture
915058|NCT02453048|Pertussis
915059|NCT02453048|Colonization
915060|NCT02453048|Vaccine
915061|NCT02453048|Immune response
915062|NCT02453048|BPZE1
915063|NCT02453048|Infection
915064|NCT02453048|Bordetella pertussis
915065|NCT02453048|B. pertussis
915066|NCT02453048|respiratory Tract Infection
915067|NCT02453035|bioresorbable scaffold
915068|NCT02453035|CAD
915069|NCT02453022|Bioavailability
915070|NCT02453022|Omeprazole
915071|NCT02453022|Danirixin
915072|NCT02453022|Food Effect
915073|NCT02453022|Pharmacokinetics
915074|NCT02452996|GNbAC1
915075|NCT02452996|Multiple Sclerosis
915076|NCT02452996|Multiple Sclerosis Associated Retrovirus (MSRV)
915077|NCT02452996|MSRV-Envelope protein
915078|NCT02452996|Monoclonal antibody
915079|NCT02452983|Anemia
915080|NCT02452983|Leukemia
915081|NCT02452983|Hematologic diseases
915082|NCT02452983|Cytopenias
915083|NCT02452983|Bone marrow diseases
915084|NCT02452983|Preleukemia
915085|NCT02452944|nerve stimulator, obturator nerve, ultrasound
915086|NCT02452918|skin infection
915087|NCT02452892|Depression
915088|NCT02452892|Major depression
915089|NCT02452892|Low-field magnetic stimulation
915090|NCT02452892|LFMS
915091|NCT02452840|neovascular age-related macular degeneration
915092|NCT02452840|anti-vascular endothelial growth factor
915093|NCT02452840|verteporfin
915094|NCT02452840|photodynamic therapy
915095|NCT02452840|persistent disease activity
915096|NCT02452710|Fatigue in Cancer Survivors
915100|NCT02452684|Insomnia
915101|NCT02452658|Fast food literacy
915102|NCT02452645|Food
915103|NCT02452645|Nutrition
915104|NCT02452645|Physical Activity
915105|NCT02452645|Family
915106|NCT02452645|Child Care
915107|NCT02452645|Home
915108|NCT02452645|Environment
915109|NCT02452632|ASP1941
915110|NCT02452632|Type 2 diabetes mellitus
915111|NCT02452619|Hyperbaric oxygen therapy
915112|NCT02452619|brain trauma
915113|NCT02452619|cognitive impairment
915114|NCT02452606|Stalevo
915115|NCT02452606|sleep disturbance
915116|NCT02452606|central circadian clock
915117|NCT02452606|narcolepsy
915118|NCT02452593|incontinence; pelvic floor exercises; neuromodulation
915119|NCT02452580|Kangaroo Mother Care
915120|NCT02452580|Neonatal Intensive Care Units
915121|NCT02452580|Postnatal growth
915122|NCT02452541|Traumatic Brain Injury
915123|NCT02452541|Critically ill Patients
915124|NCT02452541|Death
915125|NCT02452541|Head Injury
915126|NCT02452541|TBI-Prognosis
915127|NCT02452541|Critical Care Medicine
915128|NCT02452541|Withdrawal of Life Sustaining Therapy
915129|NCT02452541|Prognosis
915130|NCT02452541|Prognostic Evaluation
915131|NCT02452541|Outcome Research
915132|NCT02452541|Mortality
915133|NCT02452541|Decision-making
915134|NCT02452528|Hepatitis B Virus
915135|NCT02452528|Chronic Hepatitis B
915136|NCT02452528|HBV
915137|NCT02452502|stroke
915138|NCT02452502|thrombolytic therapy
915139|NCT02452502|atorvastatin
915140|NCT02452489|Different acupoints compatibility
915141|NCT02452437|oxycodone
915142|NCT02452437|hemodialysis
915143|NCT02452411|Internet
915144|NCT02452411|Adjustment disorders
915145|NCT02452411|Homework assignments
915146|NCT02452411|Cognitive-Behavioral treatment
915147|NCT02452411|Online therapy
915148|NCT02452411|Emotional Regulation
915149|NCT02452411|ICT's
915150|NCT02452398|Hair removal
915151|NCT02452398|depilation
915152|NCT02452398|epilation
915153|NCT02452372|RNAi therapeutic
915154|NCT02452372|Porphyria
915155|NCT02452372|AIP
915156|NCT02452359|stretch marks
915157|NCT02452346|MDS
915158|NCT02452333|Excisional breast biopsy
915159|NCT02452333|Oncoplastic surgery
915160|NCT02452333|Oncoplastic reconstruction
915161|NCT02452333|Breast conserving surgery
915162|NCT02452333|Tezel method of breast volume measurement
915163|NCT02452320|bariatric
915164|NCT02452320|Post-operative nausea and vomiting
915165|NCT02452320|laparoscopic Sleeve gastrectomy
915166|NCT02452320|intravenous acetaminophen
915167|NCT02452294|Brain
915168|NCT02452281|Therapeutically Unresectable
915169|NCT02452281|Stage III or Stage IV
915170|NCT02452281|Malignant Melanoma
915171|NCT02452281|Advanced Melanoma
915172|NCT02452203|floating
915173|NCT02452203|interoception
915174|NCT02452177|parenteral nutrition associated liver disease
915175|NCT02452177|vitamin D
915176|NCT02452177|short bowel syndrome
915177|NCT02452177|farnesoid X receptor
915178|NCT02452177|cholestasis
915179|NCT02452164|otoscopy
915180|NCT02452164|otitis media
915181|NCT02452164|cellphone
915182|NCT02452164|family
915183|NCT02452151|Inflectra
915184|NCT02452151|Infliximab
915185|NCT02452151|Biosimilar
915186|NCT02452099|DMSO
915187|NCT02452099|cryopreservation
915188|NCT02452099|autologous transplantation
915189|NCT02452099|hematopoietic stem cells
915190|NCT02452099|hematological malignancies
915191|NCT02452073|low triiodothyronine syndrome
915192|NCT02452073|chronic radiation enteritis
915193|NCT02452073|triiodothyronine
915194|NCT02452073|thyroxine
915195|NCT02452073|thyroid stimulating hormone
915196|NCT02452060|perioperative period
915197|NCT02452060|pain
915198|NCT02452060|gastric bypass
915199|NCT02452008|metastatic castration-resistant prostate cancer
915200|NCT02452008|enzalutamide
915201|NCT02452008|LY2157299
915202|NCT02452008|TGF-β receptor inhibitor
915203|NCT02451943|leiomyosarcoma
915204|NCT02451943|soft tissue sarcoma (STS)
915205|NCT02451943|advanced soft tissue sarcoma
915206|NCT02451943|metastatic soft tissue sarcoma
915207|NCT02451943|liposarcoma
915208|NCT02451943|undifferentiated pleomorphic sarcoma
915209|NCT02451943|doxorubicin
915210|NCT02451917|Glargine insulin
915211|NCT02451917|Chronic Kidney Disease
915212|NCT02451917|CGMS
915213|NCT02451904|Pathogenesis
915214|NCT02451904|Microvascular function
915215|NCT02451904|Metabolic dysregulation
915216|NCT02451904|Metabolomics
915217|NCT02451878|shyness
915218|NCT02451878|internet
915219|NCT02451878|self-help
915220|NCT02451878|psychology
915221|NCT02451878|wellbeing
915222|NCT02451839|Adalimumab
915223|NCT02451839|Quality of Life
915224|NCT02451839|Crohn Disease
915225|NCT02451839|Patient Outcome Assessment
915226|NCT02451839|Psoriasis
915227|NCT02451839|Global Health
915228|NCT02451839|Arthritis, Rheumatoid
915229|NCT02451826|ovulation inhibition
915230|NCT02451826|endometrial changes
915231|NCT02451826|bleeding patterns
915232|NCT02451813|opening injection pressure
915233|NCT02451813|femoral nerve block
915234|NCT02451813|fascia iliaca
915235|NCT02451813|ultrasound guided nerve block
915236|NCT02451774|pediatric
915237|NCT02451774|apoptosis
915238|NCT02451761|chromosomal rearrangement
915239|NCT02451761|next generation sequencing
915240|NCT02451761|intellectual disability
915241|NCT02451761|multiple congenital anomalies
915242|NCT02451761|gene disruption
915243|NCT02451735|female breast cancer
915244|NCT02451735|bilateral breast cancer
915245|NCT02451735|triple negative breast cancer
915246|NCT02451735|breast cancer diagnosis
915247|NCT02451735|BRCA 1
915248|NCT02451735|BRCA 2
915249|NCT02451735|psychoeducational intervention (PEI)
915250|NCT02451735|genetic counseling
915251|NCT02451735|hereditary breast and ovarian cancer (HBOC)
915252|NCT02451735|cancer education materials
915253|NCT02451683|SCI
915254|NCT02451631|Mobile Application
915255|NCT02451631|Diabetes management
915256|NCT02451618|Perinatal Depression
915257|NCT02451605|surgery
915258|NCT02451592|Fungemia
915259|NCT02451592|Hematologic malignancies
915260|NCT02451579|Actinic Keratoses
915261|NCT02451579|Photodynamic Therapy
915262|NCT02451579|PDT
915263|NCT02451579|Blue Light
915264|NCT02451566|Abdominal
915265|NCT02451566|Aortic
915266|NCT02451566|Aneurysm
915267|NCT02451540|Pulmonary Disease, Chronic Obstructive
915268|NCT02451540|dynamics hyperinflation
915269|NCT02451540|Computed Tomography scan
915270|NCT02451540|CT scan
915271|NCT02451540|Functional Respiratory Imaging
915272|NCT02451540|FRI
915273|NCT02451540|Roflumilast
915274|NCT02451540|PRO
915275|NCT02451514|Antibody persistence
915276|NCT02451514|Young Adults
915277|NCT02451514|Healthy Adolescents
915278|NCT02451514|MenABCWY vaccine
915279|NCT02451514|Booster response
915280|NCT02451514|MenABCWY+OMV
915281|NCT02451475|Pregabalin
915282|NCT02451475|Fibromyalgia
915283|NCT02451462|hematopoietic stem cell transplant
915284|NCT02451462|bone marrow transplant
915285|NCT02451449|Celiac disease
915286|NCT02451449|Infertility
915287|NCT02451449|Prevalence study
915288|NCT02451436|Adolescents, sleep, media use, obesity, type 2 diabetes
915289|NCT02451423|Non-metastatic
915290|NCT02451423|Bladder
915291|NCT02451410|Nutrition
915292|NCT02451410|Physical activity
915293|NCT02451410|Overweight
915294|NCT02451410|Obesity
915295|NCT02451410|Malnutrition
915296|NCT02451371|Schizophrenia
915297|NCT02451371|Refractory auditory hallucination
915298|NCT02451371|tDCS
915301|NCT02451345|Prostate cancer
915302|NCT02451345|Tranformative Impact Award
915303|NCT02451345|Early stage
915304|NCT02451345|Active Surveillance
915305|NCT02451345|Decision aid
915306|NCT02451345|Coaching session
915307|NCT02451345|Personalized
915308|NCT02451345|UCSF
915309|NCT02451345|validation
915310|NCT02451319|RIRS, holmium, 1-2 cm,stones,kidney
915311|NCT02451293|Depression
915312|NCT02451293|Acute Coronary Syndrome
915313|NCT02451293|Anxiety
915314|NCT02451293|Sleep
915315|NCT02451293|Circadian
915316|NCT02451280|stroke rehabilitation
915317|NCT02451280|robot-assisted therapy
915318|NCT02451280|hybrid therapy
915322|NCT02451241|Acupuncture
915323|NCT02451228|Pharmacokinetics
915324|NCT02451228|Pharmacodynamics
915325|NCT02451228|Preterm labor
915326|NCT02451228|Preterm birth
915327|NCT02451228|Estradiol
915328|NCT02451228|Indomethacin
915329|NCT02451228|Pregnancy
915330|NCT02451228|Short Cervix
915331|NCT02451228|CYP2C9 Genotype
915332|NCT02451202|"surgical conditions"
915333|NCT02451202|"deep neuromuscular blockade"
915334|NCT02451202|"deep neuromuscular paralysis"
915335|NCT02451189|Obesity
915336|NCT02451189|Weight maintenance
915337|NCT02451189|Appetite
915338|NCT02451189|Energy intake
915339|NCT02451189|Dietary fibre
915340|NCT02451189|Short-chain fatty acids
915341|NCT02451189|Fermentation
915342|NCT02451189|Overweight
915343|NCT02451150|Drug therapy
915344|NCT02451124|Barrett
915345|NCT02451124|Cancer
915346|NCT02451124|Screening
915347|NCT02451111|Rituximab
915348|NCT02451111|Ibrutinib
915349|NCT02451111|Follicular Lymphoma
915350|NCT02451085|hip
915351|NCT02451085|surgery
915352|NCT02451085|Replacement
915353|NCT02451059|community resource
915354|NCT02451059|well-child care visit
915355|NCT02451059|low-income
915356|NCT02451046|Liver transplantation
915357|NCT02451046|Primary dysfunction
915358|NCT02451033|Regenerative medicine
915359|NCT02451020|healthy volunteers
915360|NCT02451020|acclimatization
915361|NCT02451020|sleep
915362|NCT02451020|hypoxia
915363|NCT02450994|airway disease
915364|NCT02450994|bronchitis
915365|NCT02450994|emphysema
915366|NCT02450994|lung
915367|NCT02450994|treatment
915368|NCT02450994|sleep
915369|NCT02450968|airway disease
915370|NCT02450968|bronchitis
915371|NCT02450968|emphysema
915372|NCT02450968|lung
915373|NCT02450968|treatment
915374|NCT02450955|Tension-type headache
915375|NCT02450955|manual therapy
915376|NCT02450955|disability
915377|NCT02450955|spinal manipulation
915378|NCT02450929|post operative
915379|NCT02450929|pneumonia
915380|NCT02450929|vascular
915381|NCT02450929|orthopedic
915382|NCT02450929|urologic
915383|NCT02450929|neurologic
915384|NCT02450916|work-related injury
915385|NCT02450916|occupational disease
915386|NCT02450916|workers' compensation
915387|NCT02450916|psychological
915388|NCT02450916|policy
915389|NCT02450903|Non-Small-Cell Lung Cancer, ALK, LDK378
915390|NCT02450890|ORADUR®-Methylphenidate
915391|NCT02450877|Children
915392|NCT02450877|Young Adults
915393|NCT02450877|Azacitidine
915394|NCT02450877|Acute Myeloid Leukemia
915395|NCT02450877|Molecular Relapse
915396|NCT02450877|Vidaza
915397|NCT02450877|AZA-AML-004
915398|NCT02450864|Stiffness of Shoulder, Not Elsewhere Classified
915399|NCT02450851|Rare Diseases
915400|NCT02450851|Undiagnosed Disease
915401|NCT02450838|Dengue Vaccine
915402|NCT02450812|mCRPC
915403|NCT02450773|postpartum
915404|NCT02450773|preeclampsia
915405|NCT02450773|gestational hypertension
915406|NCT02450747|Visual Acuity
915407|NCT02450734|ultrasound-guided intermediate cervical plexus block
915408|NCT02450721|atherosclerosis
915409|NCT02450721|biomarkers
915410|NCT02450721|carotid artery stenosis
915411|NCT02450721|ischemic stroke.
915412|NCT02450708|Allogeneic Hematopoietic Cell Donors
915413|NCT02450708|KIR and HLA Genotypes
915414|NCT02450708|15-059
915415|NCT02450695|rTMS
915416|NCT02450695|treatment refractory
915417|NCT02450695|treatment resistant
915418|NCT02450695|SSRI
915419|NCT02450695|clomipramine
915420|NCT02450669|Intubation
915421|NCT02450669|Extubation
915422|NCT02450669|Weaning
915423|NCT02450669|Mechanical ventilation
915424|NCT02450617|Complex PTSD
915425|NCT02450604|Prevalence Study
915426|NCT02450604|Fabry's disease
915427|NCT02450604|Chronic pain
915428|NCT02450591|Sensitizing EGFR Mutations
915429|NCT02450591|Erlotinib
915430|NCT02450591|Surgery
915431|NCT02450591|Radiation Therapy
915432|NCT02450591|15-067
915436|NCT02450539|patient reported outcomes (PRO)
915437|NCT02450539|patient focused outcomes (PFO)
915438|NCT02450539|biomarkers
915439|NCT02450539|CDK 4 and 6
915440|NCT02450513|adalimumab
915441|NCT02450513|anti-TNF
915442|NCT02450513|pharmacokinetics
915443|NCT02450513|trough level
915444|NCT02450513|immunogenicity
915445|NCT02450487|Piroxicam
915446|NCT02450487|Pharmacogenetic
915447|NCT02450487|Lower Third molar
915448|NCT02450448|Renal Neoplasms
915449|NCT02450448|Circulating Tumor Cells
915450|NCT02450435|Prostatic Neoplasms
915451|NCT02450435|Circulating TUmor Cells
915452|NCT02450422|Colorectal Neoplasms
915453|NCT02450422|Circulating Tumor Cells
915454|NCT02450409|Total knee arthroplasty
915455|NCT02450409|Midflexion instability
915456|NCT02450409|Gap technique
915457|NCT02450409|Anatomical alignment
915458|NCT02450396|Rare diseases
915459|NCT02450396|pregnancy
915460|NCT02450396|pregnancy,
915461|NCT02450357|Breast Neoplasms
915462|NCT02450357|Circulating Tumor Cells
915463|NCT02450279|Aerosol delivery
915464|NCT02450279|Invasive mechanical ventilation
915465|NCT02450279|Jet Nebulizer
915466|NCT02450279|Vibrating-Mesh nebulizer
915467|NCT02450266|Primary disease
915468|NCT02450266|multiparametric MRI
915469|NCT02450266|targeted prostate biopsy
915470|NCT02450266|MRI/ultrasound fusion-guided prostate biopsy
915471|NCT02450266|systematic transrectal ultrasound-guided prostate biopsy
915472|NCT02450253|Vascular cognitive impairment
915473|NCT02450240|Depression
915474|NCT02450240|Anxiety
915475|NCT02450240|Eating Disorders
915476|NCT02450240|Substance Use
915477|NCT02450240|Functional Magnetic Resonance Imaging
915478|NCT02450240|Genetics
915479|NCT02450240|Behavior
915480|NCT02450240|Mental Health
915481|NCT02450214|Ketamine
915482|NCT02450214|Magnesium
915483|NCT02450214|Analgesia
915484|NCT02450214|Liposuction
915485|NCT02450214|Lipoabdominoplasty
915486|NCT02450214|Preemptive analgesia
915487|NCT02450188|Erectile Dysfunction
915488|NCT02450188|PDE5 inhibitors
915489|NCT02450188|Cognitive-behavioral Sex Therapy
915490|NCT02450175|Platelet Activation
915491|NCT02450175|metastasis
915492|NCT02450110|spinal cord stimulation
915493|NCT02450110|heart failure
915494|NCT02450110|autonomic regulation
915495|NCT02450110|BNP
915496|NCT02450110|left ventricle systolic dysfunction
915497|NCT02450071|Pre-hospital
915498|NCT02450071|Out-of-hospital
915499|NCT02450071|Prehospital emergency care (MeSH)
915500|NCT02450071|Emergency medical services (MeSH)
915501|NCT02450071|Helicopter emergency medical service
915502|NCT02450071|Critical care (MeSH)
915503|NCT02450071|Airway management (MeSH)
915504|NCT02450071|Endotracheal intubation (MeSH)
915505|NCT02450071|Difficult endotracheal intubation
915506|NCT02450071|Complications (MeSH)
915507|NCT02450071|Patient safety
915508|NCT02450058|early breast cancer
915509|NCT02450058|adjuvant chemotherapy
915510|NCT02450058|FEC
915511|NCT02450058|paclitaxel
915512|NCT02449993|diagnostic study
915513|NCT02449993|analysis of estrogen receptor
915514|NCT02449993|progesterone receptor
915515|NCT02449993|Human epidermal growth factor receptor 2
915516|NCT02449993|Ki-67
915517|NCT02449980|Spontaneous Pneumothorax
915518|NCT02449980|Video Assisted Thoracoscopic Surgery
915519|NCT02449980|Tube Thoracostomy
915520|NCT02449980|Pediatric Surgery
915521|NCT02449967|Pancreatic Cancer
915522|NCT02449967|HepaSphere
915523|NCT02449954|Stress and Immune Responses
915524|NCT02449954|morphine
915525|NCT02449954|tramadol
915526|NCT02449954|ketorolac
915527|NCT02449941|Stomach Neoplasms
915528|NCT02449941|proton pump inhibitor
915529|NCT02449941|endoscopic submucosal dissection
915530|NCT02449941|Helicobacter pylori
915531|NCT02449941|Gastritis, Atrophic
915532|NCT02449928|Severe Sepsis with Septic Shock, Lactate
915533|NCT02449915|sacrocolpopexy
915534|NCT02449915|rectocele repair
915535|NCT02449902|VVA
915536|NCT02449902|Postmenopausal
915537|NCT02449902|Painful Sex
915538|NCT02449863|Lung ultrasound
915539|NCT02449863|Mechanical ventilation
915540|NCT02449863|Respiratory distress syndrome
915541|NCT02449863|Transient tachypnea of the newborn
915542|NCT02449850|In-utero environment
915543|NCT02449850|Asthma
915544|NCT02449850|Allergic diseases
915545|NCT02449850|Food allergy
915546|NCT02449850|Birth cohort study
915547|NCT02449850|Primary prevention
915548|NCT02449850|Intervention study
915549|NCT02449850|Atopic dermatitis
915550|NCT02449850|Rhinitis
915551|NCT02449850|Allergy
915552|NCT02449850|Lung function
915553|NCT02449850|Non-communicable diseases
915554|NCT02449850|Foetal growth
915555|NCT02449824|neoadjuvant chemotherapy
915556|NCT02449824|magnetic resonance imaging
915557|NCT02449798|Difficult IV access
915558|NCT02449798|AccuCath
915559|NCT02449798|IV outcomes
915560|NCT02449798|patient satisfaction
915561|NCT02449785|Cystic fibrosis
915562|NCT02449785|MRI
915563|NCT02449785|UTE
915564|NCT02449785|CT
915565|NCT02449785|Exacerbation
915566|NCT02449785|Quality of life
915567|NCT02449785|Pulmonary function
915568|NCT02449772|N04.452.442.422.336
915569|NCT02449746|Schizophrenia
915570|NCT02449746|Psychosis
915571|NCT02449746|Mental Health
915572|NCT02449746|Autoimmunity
915573|NCT02449746|Psychoneuroimmunology
915574|NCT02449733|voluntary counseling and testing (VCT)
915575|NCT02449733|couples voluntary counseling and testing (CVCT)
915576|NCT02449733|pre-exposure prophylaxis (PrEP)
915577|NCT02449733|homosexuality
915578|NCT02449733|male
915579|NCT02449733|South Africa
915580|NCT02449720|intraperitoneal
915581|NCT02449720|ropivacaine
915582|NCT02449720|bowel resection
915583|NCT02449720|local anaesthetic
915584|NCT02449720|recovery
915585|NCT02449681|squamous cell carcinoma
915586|NCT02449681|the head and neck
915587|NCT02449681|skin
915588|NCT02449681|TH-4000
915589|NCT02449681|Hypoxia
915590|NCT02449681|Tarloxotinib
915591|NCT02449668|Acupuncture
915592|NCT02449668|Shoulder pain
915593|NCT02449668|Impingement syndrome
915594|NCT02449668|Rotator cuff tendinitis
915595|NCT02449668|Traditional Chinese medicine (TCM)
915596|NCT02449642|luteinizing hormone pulsatility
915597|NCT02449642|estradiol level
915598|NCT02449642|progesterone level
915599|NCT02449629|HIV
915600|NCT02449629|Transgender
915601|NCT02449629|HIV Continuum of Care
915602|NCT02449616|Sickle cell
915603|NCT02449616|vaso-occlusive crisis
915604|NCT02449603|Chinese population
915605|NCT02449590|Onion
915606|NCT02449590|Cardiovascular disease
915607|NCT02449590|metabolomics
915608|NCT02449590|Gene expression
915609|NCT02449590|Biomarker
915610|NCT02449577|Metabolomics
915611|NCT02449577|Beer
915612|NCT02449577|Biomarker
915613|NCT02449577|Glucose response
915614|NCT02449577|Insulin response
915615|NCT02449486|Requirement of postoperative pain medication
915616|NCT02449473|Asthma
915617|NCT02449473|Reactive Airways
915618|NCT02449473|Respiratory Tract Disease
915619|NCT02449473|Obstructive Tract Disease
915620|NCT02449473|Lung Diseases
915621|NCT02449460|hypertension
915622|NCT02449460|epidemiology
915623|NCT02449460|glucose
915624|NCT02449460|body mass index
915625|NCT02449460|lipids
915626|NCT02449460|smoking
915627|NCT02449460|coronary artery disease
915628|NCT02449460|arterial stiffness
915629|NCT02449460|carotid ultrasound
915630|NCT02449447|Major Depressive Disorder (MDD)
915631|NCT02449447|Blended treatment
915632|NCT02449447|Cognitive behavior Therapy (CBT)
915633|NCT02449447|Face-to-face
915634|NCT02449447|internet-based treatment
915635|NCT02449421|trauma
915636|NCT02449382|continuous venovenous hemofiltration
915637|NCT02449382|conventional treatment
915638|NCT02449382|mortality
915639|NCT02449382|acute severe hypernatremia
915640|NCT02449356|Prone position ventilation
915641|NCT02449356|Endotracheal intubation
915642|NCT02449356|Displacement
915643|NCT02449317|contrast induced acute kidney injury
915644|NCT02449317|bioimpedance
915645|NCT02449304|endometrial ablation, heavy menstrual bleeding, novosure
915646|NCT02449278|advanced-stage DLBCL
915647|NCT02449278|ISRT
915648|NCT02449278|chemotherapy
915649|NCT02449265|limited-stage DLBCL
915650|NCT02449265|consolidation involved-site radiotherapy
915651|NCT02449265|Chemotherapy
915652|NCT02449252|limited stage FL
915653|NCT02449252|Involved-site Radiotherapy
915654|NCT02449252|Chemotherapy
915655|NCT02449239|Urinary Bladder Cancer
915656|NCT02449239|Non-muscle invasive bladder cancer
915657|NCT02449239|Bladder Neoplasm
915658|NCT02449239|Bladder Tumor
915659|NCT02449239|CIS
915660|NCT02449239|Papillary bladder cancer
915661|NCT02449239|High grade bladder cancer
915662|NCT02449200|cervical radiculopathy
915663|NCT02449200|exercise
915664|NCT02449200|manual therapy
915665|NCT02449200|tape
915666|NCT02449174|C. difficile
915667|NCT02449174|Fecal Microbiota transplantation
915668|NCT02449161|endometrial ablation
915669|NCT02449148|energy restriction
915670|NCT02449148|fasting
915671|NCT02449148|intermittent fast
915672|NCT02449148|cancer prevention
915673|NCT02449148|subcutaneous fat tissue gene expression
915674|NCT02449135|Pancreatic Cancer
915675|NCT02449135|Nano drug
915676|NCT02449122|Lung Cancer
915677|NCT02449122|Nano drug
915678|NCT02449109|Liver Cancer
915679|NCT02449109|Nano drug
915680|NCT02449083|MRI
915681|NCT02449083|Shunt
915682|NCT02449083|COPD
915683|NCT02449083|Dynamic T2 Preparation Puls
915684|NCT02449083|new sequences
915685|NCT02449083|magnet resonance imaging
915686|NCT02449083|ventricular septal defect
915687|NCT02449083|Atrial septal defect
915688|NCT02449070|Nicorandil
915689|NCT02449070|Cardiac MRI
915690|NCT02449044|Hyponatremia
915691|NCT02449018|COPD,
915692|NCT02449018|chronic bronchitis,
915693|NCT02449018|inflammation,
915694|NCT02449018|airway,
915695|NCT02449018|LCI,
915696|NCT02449018|pulmonary function test,
915697|NCT02449018|lung function,
915698|NCT02449018|controlled clinical trial,
915699|NCT02449018|randomized,
915700|NCT02449018|airflow,
915701|NCT02449018|smoker
915702|NCT02449005|regeneration
915703|NCT02449005|stem cells
915704|NCT02449005|infrabony periodontal defect
915705|NCT02449005|fibrin glue
915706|NCT02449005|collagen fleece
915707|NCT02448992|Neurobehavioral Assessments
915708|NCT02448992|Neurocognitive Functions (NCF)
915709|NCT02448992|Prophylactic Cranial Irradiation (PCI)
915710|NCT02448992|Hippocampus
915711|NCT02448992|Hippocampal-Sparing PCI
915712|NCT02448953|Without cervical lymph node involvement
915713|NCT02448940|probiotics
915714|NCT02448940|Lactobacillus
915715|NCT02448940|obesity
915716|NCT02448940|body composition
915717|NCT02448927|transcatheter aortic valve implantation
915718|NCT02448927|Balloon aortic valvuloplasty
915719|NCT02448927|Aortic stenosis
915720|NCT02448927|TAVI
915721|NCT02448927|TAVR (transcatheter aortic valve replacement)
915722|NCT02448927|CoreValve
915723|NCT02448927|BAV
915724|NCT02448927|Evolut R
915725|NCT02448862|IV-PCA
915726|NCT02448862|Elderly patients
915727|NCT02448862|Yound adults
915728|NCT02448862|Side effect
915729|NCT02448862|Postoperative pain
915730|NCT02448862|Postoperative nausea and vomiting
915731|NCT02448849|Autologous
915732|NCT02448849|nonunion fracture
915733|NCT02448849|bone marrow
915734|NCT02448849|mesenchymal
915735|NCT02448849|stromal cell
915736|NCT02448849|platelet lysate product
915737|NCT02448823|HIV
915738|NCT02448823|combined prevention
915739|NCT02448823|demand generation
915740|NCT02448784|Donepezil Hydrochloride
915741|NCT02448784|ARICEPT
915742|NCT02448784|Dementia
915743|NCT02448784|Lewy bodies
915744|NCT02448784|Dementia with Lewy bodies
915745|NCT02448784|Post-marketing surveillance
915746|NCT02448771|Unresectable locally advanced invasive breast cancer
915747|NCT02448771|Metastatic invasive breast cancer
915748|NCT02448758|mutation
915749|NCT02448732|ACM-1
915750|NCT02448732|intravitreal injection
915751|NCT02448732|neovascularization
915752|NCT02448706|hearing aid
915753|NCT02448693|endoscopic mucosal resection
915754|NCT02448693|piecemeal polypectomy scar
915755|NCT02448693|colorectal neoplasms
915756|NCT02448693|Narrow Band Imaging
915757|NCT02448693|chromoendoscopy
915758|NCT02448641|ischemic stroke
915759|NCT02448641|chronic stroke
915760|NCT02448641|fixed motor deficits
915761|NCT02448628|Hypertension
915762|NCT02448628|moderate renal impairment
915763|NCT02448628|mineralocorticoid receptor antagonist
915764|NCT02448628|CS-3150
915765|NCT02448628|Japanese
915766|NCT02448615|Kenya
915767|NCT02448615|Cohort
915768|NCT02448602|Different acupoints compatibility
915769|NCT02448589|Advanced Solid Tumors
915770|NCT02448589|Dose Escalation
915771|NCT02448589|Dose Expansion
915772|NCT02448589|MTD
915773|NCT02448589|TAS-119
915774|NCT02448589|Aurora A Kinase Inhibitor
915775|NCT02448576|phase 3 randomized controlled trial
915776|NCT02448576|prophylactic cranial irradiation
915777|NCT02448576|triple negative breast cancer
915778|NCT02448576|brain metastasis
915779|NCT02448576|advanced breast cancer
915780|NCT02448563|Pregnancy
915781|NCT02448563|African American
915782|NCT02448563|Weight Management Program
915783|NCT02448563|Behavioral Modifications
915784|NCT02448537|Metastatic Sarcoma
915785|NCT02448537|Unresectable Sarcoma
915786|NCT02448537|PM01183
915787|NCT02448524|Treatment
915788|NCT02448524|patients
915789|NCT02448524|primary in situ CHD (de novo) lesions
915790|NCT02448511|ozone gas
915791|NCT02448511|ulcer
915792|NCT02448511|infected ulcer
915793|NCT02448433|Phototherapy
915794|NCT02448433|Light
915795|NCT02448433|Depression
915796|NCT02448433|Sleep and circadian disturbances
915797|NCT02448433|Youth
915798|NCT02448407|Knee osteoarthritis
915799|NCT02448407|Platelet-rich plasma
915800|NCT02448407|Pain's treatment
915801|NCT02448394|community support workers
915802|NCT02448394|retention in care
915803|NCT02448381|CTCL
915804|NCT02448381|Mycosis fungoides
915805|NCT02448381|Hypericin
915806|NCT02448381|SGX301
915807|NCT02448381|MF
915808|NCT02448355|OCT
915809|NCT02448342|Heart Failure
915810|NCT02448342|Remote Patient Monitoring
915811|NCT02448342|Non Invasive Lung Fluid Status Monitor
915812|NCT02448290|gastric adenocarcinoma patients with low/high MEK signature,
915813|NCT02448277|Macintosh laryngoscope, Pentax, Glidescope
915814|NCT02448264|kallikrein inhibitor
915815|NCT02448264|oral prophylaxis
915816|NCT02448264|BioCryst
915817|NCT02448264|first-in-human
915818|NCT02448264|hereditary angioedema
915819|NCT02448238|Human Immunodeficiency Virus
915820|NCT02448238|probiotic
915821|NCT02448238|microbial translocation
915822|NCT02448238|immune activation
915823|NCT02448238|inflammation
915824|NCT02448238|VSL#3
915825|NCT02448238|Mali
915826|NCT02448238|Africa
915827|NCT02448212|PET
915828|NCT02448212|Receptor Occupancy
915829|NCT02448199|pain
915830|NCT02448199|Knee
915831|NCT02448147|Heart failure
915832|NCT02448147|Exercise
915833|NCT02448147|Biomarkers
915834|NCT02448147|Sympathetic Nervous System
915835|NCT02448147|MicroRNA
915836|NCT02448121|Cell therapy
915837|NCT02448121|Sickle cell disease
915838|NCT02448121|Hip Osteonecrosis
915839|NCT02448121|Autologous implantation
915840|NCT02448121|Mesenchymal stromal cell
915841|NCT02448095|Chronic myeloid leukemia
915842|NCT02448095|Philadelphia positive
915843|NCT02448095|Compassionate use
915844|NCT02448082|Dandruff
915845|NCT02448082|Pityriasis capitis
915846|NCT02448082|Ichthyol® Pale
915847|NCT02448082|Sodium shale oil sulponate 1%
915848|NCT02448043|brittleness
915849|NCT02448030|Metaboreflex
915850|NCT02448030|Variation of blood flow
915851|NCT02448030|Functional electrical stimulation
915852|NCT02448030|Isometric exercise.
915853|NCT02448004|Healthy
915854|NCT02448004|JNJ-63623872
915855|NCT02448004|14C-JNJ-63623872
915856|NCT02447965|Rectus Sheath Blocks
915857|NCT02447965|Abdominal Surgery
915858|NCT02447952|Amyotrophic Lateral Sclerosis
915859|NCT02447952|Biotelemetry
915860|NCT02447939|pharmacokinetics
915861|NCT02447939|trametinib
915862|NCT02447939|cutaneous melanoma
915863|NCT02447939|dabrafenib
915864|NCT02447939|safety
915865|NCT02447926|leukapheresis
915866|NCT02447926|regulatory T cells
915867|NCT02447926|liver transplantation
915868|NCT02447913|Family planning
915869|NCT02447913|Voucher
915870|NCT02447913|Immunisations
915871|NCT02447835|Metabolic Disorders
915872|NCT02447809|microRNA
915873|NCT02447809|Platelet
915874|NCT02447809|Clopidogrel low response
915875|NCT02447796|(AVF)
915876|NCT02447796|surgery
915877|NCT02447783|Flavanols
915878|NCT02447783|Cocoa flavanols
915879|NCT02447783|Blood pressure
915880|NCT02447783|Platelet Function
915881|NCT02447770|Flavanols
915882|NCT02447770|Cocoa flavanols
915883|NCT02447770|Blood pressure
915884|NCT02447770|Platelet Function
915885|NCT02447757|Remifentanil, delivery, childbirth, analgesia, parturition, confinement
915886|NCT02447744|depression
915887|NCT02447744|anxiety
915888|NCT02447744|early life stress
915889|NCT02447731|respiratory insufficiency
915890|NCT02447692|Proportional Assist Ventilation
915891|NCT02447692|Pressure Support Ventilation
915892|NCT02447692|Weaning
915893|NCT02447666|Azacitidine
915894|NCT02447666|Myelodysplastic syndrome
915895|NCT02447666|Juvenile myelomonocytic leukemia
915896|NCT02447666|Hematopoietic stem cell transplantation
915897|NCT02447666|Vidaza
915898|NCT02447666|Hypomethylating agent
915899|NCT02447640|Volunteers
915900|NCT02447614|follow up
915901|NCT02447614|Primary Snoring
915902|NCT02447614|Obstructive Sleep Apnea Syndrome
915903|NCT02447588|intrauterine insemination
915904|NCT02447588|progesterone
915905|NCT02447549|IMRT
915906|NCT02447549|IGRT
915907|NCT02447549|Muscle invasive
915908|NCT02447549|Adaptive Radiotherapy
915909|NCT02447536|Immunization
915910|NCT02447536|Morbidity
915911|NCT02447536|Mortality
915912|NCT02447536|BCG
915913|NCT02447484|female sex workers
915914|NCT02447484|HIV sexual risk reduction
915915|NCT02447484|behavior maintenance
915916|NCT02447484|text messaging
915917|NCT02447458|Drug therapy
915918|NCT02447432|Invasive disease by Streptococcus pneumoniae (S. pneumoniae) (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media)
915919|NCT02447432|Infants
915920|NCT02447432|Multidose
915921|NCT02447432|Haemophilus influenzae
915922|NCT02447432|Streptococcus pneumoniae
915923|NCT02447432|Preservative
915924|NCT02447432|Safety
915925|NCT02447432|Pneumonia
915926|NCT02447432|Immunogenicity
915927|NCT02447432|Pneumococcal conjugate vaccine
915928|NCT02447432|Acute otitis media caused by non-typeable Haemophilus influenzae (NTHi).
915929|NCT02447432|Respiratory tract infections
915930|NCT02447367|α1-blockers
915931|NCT02447367|antimuscarinic agent
915932|NCT02447315|Pilocarpine
915933|NCT02447289|Dental caries
915934|NCT02447289|Moderate sedation
915935|NCT02447263|Liver Cancer
915936|NCT02447263|HepaSphere
915937|NCT02447250|Bronchopulmonary dysplasia
915938|NCT02447250|very low birth weight
915939|NCT02447250|albuterol
915940|NCT02447250|pulmonary function test
915941|NCT02447237|liquid diet
915942|NCT02447237|solid diet
915943|NCT02447224|appendicitis
915944|NCT02447224|non operative management
915945|NCT02447224|appendectomy
915946|NCT02447185|Lucentis
915947|NCT02447185|Ranibizumab
915948|NCT02447185|Triamcinolone Acetonide
915949|NCT02447185|Vitrectomy
915950|NCT02447185|PDR
915951|NCT02447185|25-Gauge Vitrectomy
915952|NCT02447159|Nigeria
915953|NCT02447159|Developing Countries
915954|NCT02447159|Hospitals, Maternity/Utilization
915955|NCT02447159|Hospitals/Economics
915956|NCT02447159|HIV
915957|NCT02447133|no known ocular pathology
915958|NCT02447120|Volunteers with Healthy Eyes
915959|NCT02447107|Chronic Pain
915960|NCT02447107|Technology
915961|NCT02447107|Mobile Phone Applications
915962|NCT02447094|ischemic
915963|NCT02447094|tPA
915964|NCT02447094|tele-medicine
915965|NCT02447094|robot
915966|NCT02447094|tele-stroke
915967|NCT02447042|sepsis
915968|NCT02447042|Fluids
915969|NCT02447042|Mean systemic filling pressure
915970|NCT02447029|abortion
915971|NCT02447029|pain management
915972|NCT02447003|PD1
915973|NCT02447003|PD-1
915974|NCT02447003|PDL1
915975|NCT02447003|PD-L1
915976|NCT02446977|ischemic
915977|NCT02446977|stroke
915978|NCT02446977|vitamin B2
915979|NCT02446938|mechanical ventilation
915980|NCT02446938|esophageal pressure
915981|NCT02446938|catheter position
915982|NCT02446938|validation
915983|NCT02446912|Active Systemic Lupus Erythematosus
915985|NCT02446886|Multiple Sclerosis
915986|NCT02446886|MS
915987|NCT02446886|RRMS
915988|NCT02446886|SPMS
915989|NCT02446886|ACTH
915990|NCT02446873|children
915991|NCT02446873|Ecuador
915992|NCT02446873|rural
915993|NCT02446873|poor
915994|NCT02446847|HIV
915995|NCT02446847|3BNC117
915996|NCT02446847|Broadly neutralizing antibody
916001|NCT02446795|Renal cell carcinoma
916002|NCT02446795|Isoquercetin
916003|NCT02446795|kidney cancer
916004|NCT02446795|sunitinib
916005|NCT02446795|fatigue
916006|NCT02446782|thoracoscopy
916007|NCT02446782|pleuroscopy
916008|NCT02446782|antibiotic prophylaxis
916009|NCT02446782|pleural effusion
916010|NCT02446756|Osteoarthritis
916011|NCT02446756|MRI
916012|NCT02446756|Cartilage
916013|NCT02446756|Acupuncture
916014|NCT02446743|Nervous System Diseases
916015|NCT02446743|Meningitis
916016|NCT02446743|Central Nervous System Diseases
916017|NCT02446717|HCV GT5
916018|NCT02446717|Interferon (IFN) free
916019|NCT02446717|Hepatitis C
916020|NCT02446717|HCV Genotype 4
916021|NCT02446717|HCV Genotype 5
916022|NCT02446717|HCV
916023|NCT02446717|HCV Genotype 6
916024|NCT02446717|Chronic Hepatitis C
916025|NCT02446717|HCV Genotype 1
916026|NCT02446717|Chronic HCV
916027|NCT02446717|Hepatitis C Genotype 1
916028|NCT02446717|HCV GT4
916029|NCT02446717|HCV GT1
916030|NCT02446704|Small Cell Lung Cancer
916031|NCT02446704|SCLC
916032|NCT02446678|Gastrointestinal bleeding
916033|NCT02446678|emergency department
916034|NCT02446678|PillCam ESO2
916035|NCT02446652|Advanced cervical cancer
916036|NCT02446652|Epigenetic therapy
916037|NCT02446652|Randomized phase III
916038|NCT02446626|Lyme Disease
916039|NCT02446626|Ixodes scapularis
916040|NCT02446626|Borrelia Burgdorferi
916041|NCT02446626|Post treatment
916042|NCT02446626|Infection
916043|NCT02446613|Allergic Rhinitis
916044|NCT02446613|Nasal allergen challenge
916045|NCT02446613|Allergic Asthma
916046|NCT02446613|Effect on Allergen Reactivity
916047|NCT02446587|endovascular therapy
916048|NCT02446587|thrombectomy
916049|NCT02446587|selection
916050|NCT02446587|imaging
916051|NCT02446587|perfusion
916052|NCT02446587|collaterals
916053|NCT02446587|ASPECTS
916054|NCT02446574|chemoradiation
916055|NCT02446574|dose escalation
916056|NCT02446561|Healthy Volunteer
916057|NCT02446561|Pharmacokinetics
916058|NCT02446548|direct renin inhibitor
916059|NCT02446548|kidney transplantation
916060|NCT02446548|albuminuria
916061|NCT02446496|Bioequivalence
916062|NCT02446496|film coated tablets
916063|NCT02446496|cefadroxil
916064|NCT02446483|Idiazole 20mg
916065|NCT02446483|PARIET 20 mg
916066|NCT02446483|Rabeprazole
916067|NCT02446483|bioequivalence
916068|NCT02446470|calcaneus
916069|NCT02446470|fracture fixation, internal
916070|NCT02446457|Lymphoma
916071|NCT02446457|Follicular lymphoma
916072|NCT02446457|FL
916073|NCT02446457|Relapsed
916074|NCT02446457|Rituximab
916075|NCT02446457|Rituxan
916076|NCT02446457|Pembrolizumab
916077|NCT02446457|Keytruda
916078|NCT02446457|MK-3475
916079|NCT02446457|SCH-900475
916080|NCT02446444|High risk
916081|NCT02446444|clinically localised prostate cancer
916082|NCT02446431|Metronomic Drug Therapy
916089|NCT02446405|metastatic prostate cancer
916090|NCT02446405|prostate cancer
916091|NCT02446405|prostate cancer treatment
916092|NCT02446405|enzalutamide
916093|NCT02446353|Male Volunteers
916094|NCT02446340|ShK-186
916095|NCT02446340|dalazatide
916096|NCT02446340|Kv1.3
916097|NCT02446340|SHK
916098|NCT02446301|Nalbuphine
916099|NCT02446301|SDE
916100|NCT02446301|dinalbuphine
916101|NCT02446301|SDN
916102|NCT02446301|pain
916103|NCT02446301|LT1001
916104|NCT02446275|efficacy, manual therapy, migraine, quality of life
916110|NCT02446249|Gene Therapy
916111|NCT02446249|Xerostomia
916112|NCT02446223|Actinic Keratosis AKs Chest Pre-Cancer
916113|NCT02446210|SCI
916114|NCT02446210|Neural Control
916115|NCT02446210|Bilateral Movement
916116|NCT02446210|TMS
916117|NCT02446184|urethral obstruction
916118|NCT02446184|posterior urethral valves
916119|NCT02446184|lower urinary tract obstruction
916120|NCT02446171|naloxegol tablet crushed
916121|NCT02446171|naloxegol oral solution
916122|NCT02446171|naloxegol whole tablet
916123|NCT02446171|relative bioavailability
916124|NCT02446171|Phase I
916125|NCT02446171|healthy subjects
916126|NCT02446106|Monosodium L-Glutamate (MSG)
916127|NCT02446106|Satiety
916128|NCT02446106|Soups
916129|NCT02446106|Energy Intake
916130|NCT02446106|Snack Intake
916131|NCT02446093|pancreas
916132|NCT02446093|pancreatic adenocarcinoma
916133|NCT02446093|GMCI
916134|NCT02446093|AdV-tk
916135|NCT02446093|aglatimagene besadenovec
916136|NCT02446080|Constipation
916137|NCT02446080|Probiotics
916138|NCT02446080|Women
916139|NCT02446067|Transcranial Doppler (TCD) sonography
916140|NCT02446067|rTMS
916141|NCT02446067|Cerebral hemodynamics
916142|NCT02446054|T2DM, type II diabetes Mellitus, HbA1c
916143|NCT02446041|COPD
916144|NCT02446041|Chronic Bronchitis
916145|NCT02446041|Pulmonary Emphysema
916146|NCT02446002|Volunteer
916147|NCT02445989|HIV
916148|NCT02445989|Contraceptive Vaginal Ring
916149|NCT02445989|Bacterial Vaginosis
916150|NCT02445976|mCRPC
916151|NCT02445976|metastatic
916152|NCT02445976|castration-resistant prostate cancer
916153|NCT02445950|Coaching
916154|NCT02445950|Well-being
916155|NCT02445950|Digital Health
916156|NCT02445950|Profiling
916157|NCT02445950|Customer Satisfaction
916158|NCT02445950|User Experience
916159|NCT02445950|Occupational Health
916160|NCT02445950|Lifestyle
916161|NCT02445950|Psychological Stress
916162|NCT02445950|Cost-Effectiveness
916163|NCT02445950|Guideline Adherence
916164|NCT02445937|decision making for incapacitated patients
916165|NCT02445937|intensive care
916166|NCT02445937|surrogate decision making
916167|NCT02445937|patient centered care
916168|NCT02445937|palliative care
916169|NCT02445924|genetic signature
916170|NCT02445924|non-small cell lung cancer
916171|NCT02445924|micro RNA
916172|NCT02445898|Glucocorticoid
916173|NCT02445898|Orthostatic Intolerance
916174|NCT02445898|Heart Rate Variability
916175|NCT02445898|Hip arthroplasty, total
916176|NCT02445885|Myocardial infarction
916177|NCT02445885|Late presenters
916178|NCT02445885|Primary percutaneous coronary intervention
916179|NCT02445885|Reperfusion
916180|NCT02445885|Angioplasty
916181|NCT02445885|Duration of ischemia
916182|NCT02445885|Cardiovascular magnetic resonance imaging
916183|NCT02445872|Nausea
916184|NCT02445872|Vomiting
916185|NCT02445872|Chemotherapy-induced Nausea and Vomiting
916186|NCT02445872|CINV
916187|NCT02445872|Aprepitant
916188|NCT02445872|Lung cancer
916189|NCT02445859|Antibiotic
916190|NCT02445859|prophylaxis
916191|NCT02445859|surgical site infection
916192|NCT02445833|Obesity
916193|NCT02445833|Internet intervention
916194|NCT02445833|Cardiovascular disease
916195|NCT02445833|Hypertension
916196|NCT02445833|Lifestyle intervention
916197|NCT02445833|Weight loss treatment
916198|NCT02445755|Neonates
916199|NCT02445755|Bilicare System
916200|NCT02445742|Chronic Myeloblastic Leukaemia
916201|NCT02445729|Cesarean Section
916202|NCT02445729|Wound Healing
916203|NCT02445677|TENS
916204|NCT02445677|chronic pain
916205|NCT02445677|rehabilitation
916206|NCT02445664|Patient education
916207|NCT02445664|Video intervention
916208|NCT02445651|Integrative Medicine
916209|NCT02445651|Alternative Medicine
916210|NCT02445651|Complementary Medicine
916211|NCT02445651|Parkinson's disease
916212|NCT02445651|Neurodegenerative Diseases
916213|NCT02445651|Idiopathic Parkinson's disease
916214|NCT02445651|Single Photon Emission Computed Tomography (SPECT)
916215|NCT02445651|Central Nervous System Diseases
916216|NCT02445651|Movement Disorders
916217|NCT02445651|Nervous System Diseases
916218|NCT02445651|Brain Diseases
916219|NCT02445651|Oral supplements
916220|NCT02445651|N-acetyl cysteine
916221|NCT02445612|fundus flavimaculatus
916222|NCT02445612|SMD
916223|NCT02445612|long term follow-up
916224|NCT02445612|juvenile macular dystrophy
916225|NCT02445599|thoracotomy
916226|NCT02445599|pain management
916227|NCT02445599|analgesia
916228|NCT02445599|postoperative care
916229|NCT02445599|premedication
916230|NCT02445599|preventive
916231|NCT02445573|stress urinary incontinence
916232|NCT02445573|electroacupuncture
916233|NCT02445573|efficacy
916234|NCT02445560|probiotics
916235|NCT02445560|prebiotics
916236|NCT02445560|high protein diet
916237|NCT02445560|microbiota
916238|NCT02445534|Cell Therapy
916239|NCT02445456|Rectal cancer
916240|NCT02445456|Sentinel Lymph Node Biopsy
916241|NCT02445417|Perinatal depression
916242|NCT02445378|Aromatherapy
916243|NCT02445378|essential oils
916244|NCT02445378|Acute Leukemia
916245|NCT02445365|Ulcerative colitis
916246|NCT02445365|Remote ischemic conditioning
916247|NCT02445339|Alcohol Dependence
916248|NCT02445339|Alcohol Use Disorder
916249|NCT02445339|Care Management
916250|NCT02445339|Case Management
916251|NCT02445339|Emergency Care Services
916252|NCT02445339|Emergency Department
916253|NCT02445339|Emergency Room
916254|NCT02445339|Extended-release naltrexone
916255|NCT02445339|Frequent Users
916256|NCT02445339|Health Care Utilization
916257|NCT02445339|Medical Management
916258|NCT02445339|Naltrexone
916259|NCT02445339|Population Health
916260|NCT02445339|Public Health
916261|NCT02445339|Vivitrol
916262|NCT02445339|XR-NTX
916263|NCT02445339|XR-NTX+CM
916264|NCT02445339|Alcoholism
916265|NCT02445339|Alcohol-Related Disorders
916266|NCT02445339|Central Nervous System Agents
916267|NCT02445339|Chemically-Induced Disorders
916268|NCT02445339|Clinical Trial
916269|NCT02445339|Emergency Medicine
916270|NCT02445339|Mental Disorders
916271|NCT02445339|Narcotic Antagonists
916272|NCT02445339|Peripheral Nervous System Agents
916273|NCT02445339|Pharmacologic Actions
916274|NCT02445339|Physiological Effects of Drugs
916275|NCT02445339|Sensory System Agents
916276|NCT02445339|Substance-Related Disorders
916277|NCT02445300|dressing
916278|NCT02445300|TKA
916279|NCT02445261|MOBILE PHONE ON AND IN AND
916280|NCT02445261|UMBILICAL ARTERY DOPPLER
916281|NCT02445261|FETAL CARDIOTOCOGRAPHY
916282|NCT02445261|GROWTH RESTRICTED FETUS
916283|NCT02445261|NORMAL GROWTH FETUS
916284|NCT02445248|Diffuse large B-cell lymphoma,
916285|NCT02445248|DLBCL,
916286|NCT02445248|Relapsed/refractory,
916287|NCT02445248|CTL019
916288|NCT02445248|CART19
916289|NCT02445248|CART
916290|NCT02445248|CAR T cells
916291|NCT02445248|Chimeric antigen receptor
916292|NCT02445235|pain
916293|NCT02445235|wound care
916294|NCT02445235|fungal infections
916295|NCT02445235|scars
916296|NCT02445235|chronic pain
916297|NCT02445235|outcomes
916298|NCT02445235|PRO
916299|NCT02445209|HER2-negative gastric and GEJ adenocarcinoma
916300|NCT02445209|first-line palliative chemotherapy
916301|NCT02445209|EOX
916302|NCT02445209|mDCF
916303|NCT02445209|efficacy
916304|NCT02445209|safety
916305|NCT02445170|Diabetes
916306|NCT02445170|amputation
916307|NCT02445170|below-knee
916308|NCT02445170|transmetatarsal
916309|NCT02445170|[M01.150.100]
916310|NCT02445170|[C19.246.099]
916311|NCT02445157|Gait speed
916312|NCT02445157|Functional outcome measure
916313|NCT02445144|Inflammation
916314|NCT02445144|Blood Flow
916315|NCT02445144|Cognition
916316|NCT02445131|CLL
916317|NCT02445118|adipose, allograft
916318|NCT02445092|Intrauterine insemination
916319|NCT02445092|Insemination catheter prewashing
916320|NCT02445092|Pregnancy outcome
916321|NCT02445066|Vitamin D
916322|NCT02445053|Cystic Fibrosis
916323|NCT02445040|High Frequency Oscillatory Ventilation
916324|NCT02445040|Infant, Very Low Birth Weight
916325|NCT02445040|Periventricular Leukomalacia
916326|NCT02445040|Intraventricular Hemorrhage
916327|NCT02445040|multi-center study
916328|NCT02445027|Primary Care
916329|NCT02445027|Healthy
916330|NCT02445014|Barrett's
916331|NCT02445014|GERD
916332|NCT02445014|Capsule
916333|NCT02445014|SECM
916334|NCT02444988|crystalloid
916335|NCT02444988|acute kidney injury
916336|NCT02444975|Urinary Tract Infections
916337|NCT02444975|Water intake
916338|NCT02444936|solid tumor
916339|NCT02444936|chemotherapy
916340|NCT02444936|vaccine
916341|NCT02444923|Corneal rigid gas permeable contact lenses
916342|NCT02444923|Scleral rigid gas permeable contact lenses
916343|NCT02444923|Custom Scleral contact lenses
916344|NCT02444923|Irregular cornea
916345|NCT02444923|Keratoconus
916346|NCT02444923|Pellucid marginal degeneration
916347|NCT02444923|Post keratoplasty irregular cornea
916348|NCT02444923|Post refractive surgery irregular cornea
916349|NCT02444923|Traumatic irregular cornea
916350|NCT02444910|KDT501
916351|NCT02444910|Diabetes
916352|NCT02444910|Diabetes Mellitus
916353|NCT02444910|Type 2
916354|NCT02444910|KinDex
916355|NCT02444897|Gastric cancer
916356|NCT02444897|epidural
916357|NCT02444897|PCA
916358|NCT02444897|laparoscopy
916359|NCT02444871|IgM-enriched immunoglobulins
916360|NCT02444871|endotoxin activity assay
916361|NCT02444871|thrombelastometry
916362|NCT02444871|aggregometry
916363|NCT02444858|paraquat poisoning
916364|NCT02444858|lung injury
916365|NCT02444858|stem cell therapy
916366|NCT02444858|human umbilical cord mesenchymal stem cell
916367|NCT02444858|phase 1/2 clinical study
916368|NCT02444858|allogeneic stem cell transplantation
916369|NCT02444819|HM61713
916370|NCT02444819|Epidermal Growth Factor Receptor mutation positive NSCLC
916371|NCT02444819|olmutinib
916372|NCT02444806|Sleep disordered breathing
916373|NCT02444806|Domiciliary NIV
916374|NCT02444741|Lung Cancer
916375|NCT02444741|Non-small cell lung cancer
916376|NCT02444741|NSCLC
916377|NCT02444741|Metastatic
916378|NCT02444741|Pembrolizumab
916379|NCT02444741|Keytruda
916380|NCT02444741|MK-3475
916381|NCT02444741|SCH-900475
916382|NCT02444741|Stereotactic body radiation therapy
916383|NCT02444741|SBRT
916384|NCT02444741|Wide-field radiation therapy
916385|NCT02444741|WFRT
916386|NCT02444741|Radiation therapy
916387|NCT02444741|XRT
916388|NCT02444728|thrombocytopenia
916389|NCT02444728|systemic lupus erythematosus
916390|NCT02444728|hydroxychloroquine
916391|NCT02444728|cyclophosphamide
916392|NCT02444728|remission
916393|NCT02444715|Lifestyle coaching
916394|NCT02444715|Phone-based system
916395|NCT02444715|CVD prevention
916396|NCT02444715|Patient-centered decision support
916397|NCT02444702|spinal stenosis, clinical predictors rules, MRI, fusion, low back pain
916398|NCT02444689|Blood pressure
916399|NCT02444689|Cardiovascular disease
916400|NCT02444689|Children
916401|NCT02444689|Adolescent
916402|NCT02444689|Pediatrics
916403|NCT02444689|End-organ damage
916404|NCT02444650|Correlation
916405|NCT02444650|pulse wave velocity measurement
916406|NCT02444650|tonometry
916407|NCT02444624|necrotizing enterocolitis
916408|NCT02444624|Clostridium
916409|NCT02444624|premature birth
916410|NCT02444611|neonates
916411|NCT02444611|BCG
916412|NCT02444611|Hepatitis B vaccine
916413|NCT02444611|vaccines
916414|NCT02444611|immunity
916415|NCT02444611|immune response
916416|NCT02444611|Bacille- Calmette-Guerin
916417|NCT02444598|wounds
916418|NCT02444598|negative-pressure wound therapy
916419|NCT02444598|conflict
916420|NCT02444598|gunshot wound
916421|NCT02444598|blast injuries
916422|NCT02444598|civilian
916423|NCT02444598|war
916424|NCT02444559|Volunteers
916425|NCT02444533|Liposomal Bupivacaine
916426|NCT02444481|Mycotic Vaginitis
916427|NCT02444455|cellular therapy
916428|NCT02444455|acute lung injury
916429|NCT02444455|acute respiratory distress snydrome
916430|NCT02444455|human umbilical cord mesenchymal stem cell
916431|NCT02444455|phase 1/2 clinical study
916432|NCT02444455|allogeneic stem cell transplantation
916433|NCT02444455|ALI
916434|NCT02444455|ARDS
916435|NCT02444442|Renal denervation
916436|NCT02444442|Blood pressure
916437|NCT02444442|Cardiovascular risk
916438|NCT02444442|Target organ damage
916439|NCT02444442|Sympathetic activity
916440|NCT02444442|Non-compliance
916441|NCT02444429|Screening renal biopsy
916442|NCT02444429|Immunosuppression
916443|NCT02444403|HIV
916444|NCT02444403|Viral hepatitis
916445|NCT02444403|HCV
916446|NCT02444403|Needle-stick injury
916447|NCT02444403|Needle/syringes
916448|NCT02444403|Structural intervention
916449|NCT02444403|Stepped wedge
916450|NCT02444403|Police
916451|NCT02444403|Occupational safety
916452|NCT02444403|Police Training
916453|NCT02444390|Failed non steroidal aromatases inhibitors
916454|NCT02444390|Eligible for everolimus+exemestane
916455|NCT02444364|diabetes
916456|NCT02444364|bone loss
916457|NCT02444364|Bone Density
916458|NCT02444325|group prenatal care
916459|NCT02444325|CenteringPregnancy
916460|NCT02444325|diabetes
916461|NCT02444312|Caregiving
916462|NCT02444312|Benefit Finding
916463|NCT02444312|Writing Intervention
916464|NCT02444273|liver diseases
916465|NCT02444273|liver transplantation
916466|NCT02444273|preoperative care
916467|NCT02444273|physical therapy
916468|NCT02444260|Inguinal Hernia,
916469|NCT02444260|Local Anesthesia
916470|NCT02444260|Randomized Clinical trial
916471|NCT02444260|HERNIOPLASTY
916472|NCT02444221|Atrial Fibrillation
916473|NCT02444221|Rivaroxaban
916474|NCT02444221|Stroke
916475|NCT02444195|gynecologic cancer
916476|NCT02444195|guided imagery
916477|NCT02444195|postoperative distress
916478|NCT02444195|perioperative distress
916482|NCT02444130|multifocality
916483|NCT02444130|monovision
916484|NCT02444117|neurophysiology
916485|NCT02444104|Left Ventricular Assist Device
916486|NCT02444091|Chronic Fatigue Syndrome
916487|NCT02444091|Myalgic Encephalomyelitis (ME)
916488|NCT02444091|Cyclophosphamide
916489|NCT02444091|Immunomodulatory treatment
916490|NCT02444091|CFS
916491|NCT02444078|Alzheimer Disease
916492|NCT02444078|Dementia
916493|NCT02444078|Physical activity
916494|NCT02444078|Functional ability
916495|NCT02444078|Disability
916496|NCT02444078|Functional limitation
916497|NCT02444065|Cognitive behavior therapy
916498|NCT02444065|Motivational interviewing
916499|NCT02444065|Bulimia nervosa
916500|NCT02444065|Rapid response
916501|NCT02444013|Contrast induced nephropathy
916502|NCT02444000|chemotherapy
916503|NCT02444000|PCV
916504|NCT02444000|radiotherapy
916505|NCT02444000|post operative treatment
916506|NCT02444000|anaplastic gliomas
916507|NCT02444000|1p/19q codeletion
916508|NCT02444000|cognition
916509|NCT02443987|Tension-Free Vaginal Tape
916510|NCT02443961|Bronchopulmonary dysplasia
916511|NCT02443961|pulmonary hypertension
916512|NCT02443961|stem cell therapy
916513|NCT02443961|mesenchymal stem cells
916514|NCT02443961|very low weight preterm babies
916515|NCT02443922|type 2 diabetes
916516|NCT02443922|beta cell function
916517|NCT02443922|meal tolerance test (MTT)
916518|NCT02443922|maximal stimulation test (MaxStim)
916519|NCT02443922|method standardization
916520|NCT02443922|insulin secretion
916521|NCT02443922|prediabetes
916522|NCT02443922|insulin sensitivity
916523|NCT02443922|glimepiride
916524|NCT02443922|sitagliptin
916525|NCT02443922|metformin
916526|NCT02443909|Holmium Laser
916527|NCT02443909|Kidney Stones
916528|NCT02443909|RIRS
916529|NCT02443883|stomach cancer
916530|NCT02443844|BPH
916531|NCT02443844|bladder cancer
916532|NCT02443844|treatment
916533|NCT02443844|recurrence
916534|NCT02443844|progression
916535|NCT02443831|high risk relapsed CD19+ hematological malignancies
916536|NCT02443766|Integrative Medicine
916537|NCT02443766|Alternative Medicine
916538|NCT02443766|Complementary Medicine
916539|NCT02443766|Meditation Retreat
916540|NCT02443766|Ignatian Retreat
916668|NCT02442882|Brain Concussion
916541|NCT02443766|Single Photon Emission Computed Tomography (SPECT)
916542|NCT02443766|Functional Magnetic Resonance Imaging (fMRI)
916543|NCT02443766|Wellbeing
916544|NCT02443766|General Health
916545|NCT02443740|First in human
916546|NCT02443740|Single Ascending Dose Study
916547|NCT02443740|Safety and Tolerability
916548|NCT02443740|Pharmacokinetics
916549|NCT02443740|Plasma
916550|NCT02443740|Cerebrospinal Fluid
916551|NCT02443714|Needle-Free Jet Injection
916552|NCT02443714|Insulin Lispro
916553|NCT02443714|pharmacokinetics
916554|NCT02443714|pharmacodynamics
916555|NCT02443636|Depression
916556|NCT02443636|Mental Health
916557|NCT02443636|Registry
916558|NCT02443636|Reliability
916559|NCT02443636|Post Traumatic Stress Disorder
916560|NCT02443636|Bipolar Disorder
916561|NCT02443636|Mood disorder
916562|NCT02443636|Suicide
916563|NCT02443610|Postpartum Hemorrhage
916564|NCT02443610|Venous Thromboembolism
916565|NCT02443610|Pregnancy
916566|NCT02443597|ultrasound
916567|NCT02443597|trisomy screening
916568|NCT02443597|obesity
916569|NCT02443584|depression
916570|NCT02443584|pharmacogenetics
916571|NCT02443584|pharmacogenomics
916572|NCT02443584|major depressive disorder
916573|NCT02443584|genetics
916574|NCT02443584|anti-depressants
916575|NCT02443571|observational study
916582|NCT02443545|Iron overload
916583|NCT02443545|Sickle cell disease
916584|NCT02443545|Deferiprone
916585|NCT02443545|Ferriprox
916586|NCT02443545|Iron chelation
916587|NCT02443519|Mindfulness
916588|NCT02443519|MBCT
916589|NCT02443519|Cognitive Therapy
916590|NCT02443519|Disability
916591|NCT02443428|Breast Cancer
916592|NCT02443402|Non diabetic hyperglycemia
916593|NCT02443389|nephrotoxic
916594|NCT02443389|Fluid overload
916595|NCT02443389|Acute renal failure
916596|NCT02443389|Prematurity
916597|NCT02443389|Risk factors
916598|NCT02443389|Epidemiology
916608|NCT02443298|ABBV-066
916609|NCT02443298|BI 655066
916610|NCT02443298|risankizumab
916611|NCT02443259|NAPI
916612|NCT02443259|late preterm
916613|NCT02443207|Toothache
916614|NCT02443207|Quality of life
916615|NCT02443207|Oral Health
916616|NCT02443207|Children
916617|NCT02443194|depression
916618|NCT02443194|glioblastoma
916619|NCT02443181|Essential tremor; closed-loop DBS
916620|NCT02443168|Pharmacokinetic
916621|NCT02443168|Healthy
916622|NCT02443168|Male
916623|NCT02443168|AG-221
916624|NCT02443168|[14C]
916625|NCT02443168|Single dose
916626|NCT02443168|Oral
916627|NCT02443168|Intravenous
916628|NCT02443142|mild TBI
916629|NCT02443142|concussion
916630|NCT02443142|post-concussion syndrome
916631|NCT02443103|pilot study
916632|NCT02443103|guanabenz acetate
916633|NCT02443090|secondary hypogonadism
916634|NCT02443090|sexual dysfunction
916635|NCT02443090|erectile dysfunction
916636|NCT02443064|Pharmacokinetics/pharmacodynamics
916637|NCT02443064|vancomycin
916638|NCT02443064|blood stream infections
916639|NCT02443064|Chinese patients
916640|NCT02443064|MRSA
916641|NCT02443038|patient fall
916642|NCT02443038|yoga
916643|NCT02443038|balance
916644|NCT02443012|Diabetic Macular Edema
916645|NCT02443012|Nepafenac
916646|NCT02443012|Laser therapy
916647|NCT02443012|Clinically significant macular edema
916648|NCT02443012|Adjunct Treatment
916649|NCT02443012|Topical Nepafenac
916650|NCT02442986|weaning failure
916651|NCT02442986|polyneuropathy
916652|NCT02442986|encephalopathy
916653|NCT02442986|sepsis
916654|NCT02442947|stress when dressed
916655|NCT02442947|protective garment
916656|NCT02442947|work clothes
916657|NCT02442934|Critical Care
916658|NCT02442934|Critical Care Nursing
916659|NCT02442934|Discomfort
916660|NCT02442934|Sleep deprivation
916661|NCT02442934|Noise
916662|NCT02442934|Thirst
916663|NCT02442934|Pain
916664|NCT02442895|mature oocytes
916665|NCT02442895|antral follicles count
916666|NCT02442895|follicle stimulating hormone
916667|NCT02442895|antimullerian hormone
916669|NCT02442882|Balance
916670|NCT02442882|Locomotion
916671|NCT02442882|Mild Traumatic Brain Injury
916672|NCT02442869|Suicide
916673|NCT02442817|DPP-4 Inhibitor
916674|NCT02442817|Linagliptin
916675|NCT02442817|SDF1-α
916676|NCT02442804|Pomegranate
916677|NCT02442804|Stroke
916678|NCT02442804|Neuropsychology
916679|NCT02442791|Cardiac arrest
916680|NCT02442791|GLP-1
916681|NCT02442791|Neuroprotection
916682|NCT02442752|Drug therapy
916683|NCT02442739|Ketamine
916684|NCT02442739|Prevention of depression
916685|NCT02442726|Heat Injury
916686|NCT02442726|Humans
916687|NCT02442726|Laser Stimulation
916688|NCT02442726|Quantitative Sensory Testing
916689|NCT02442726|Reaction Time
916690|NCT02442726|Secondary Hyperalgesia
916691|NCT02442726|Thermal Thresholds
916692|NCT02442713|Polysomnograph
916693|NCT02442713|fluvoxamine
916694|NCT02442700|HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir
916695|NCT02442674|Hyponatremia
916696|NCT02442674|Euvolemic
916697|NCT02442674|Hypervolemic
916698|NCT02442674|Serum sodium
916699|NCT02442674|Dilutional hyponatremia
916700|NCT02442674|Electrolyte abnormality
916701|NCT02442674|Electrolyte imbalance
916702|NCT02442674|Metabolic disease
916703|NCT02442674|Water-Electrolyte Imbalance
916704|NCT02442648|Renal Transplantation
916705|NCT02442648|Carfilzomib
916706|NCT02442648|Kyprolis
916707|NCT02442648|Desensitization
916708|NCT02442622|de Quervain's disease
916709|NCT02442622|de Quervain's tenosynovitis.
916710|NCT02442622|ASTYM
916711|NCT02442622|de Quervain's treatment
916712|NCT02442609|internet
916713|NCT02442609|anesthesia
916714|NCT02442609|information
916715|NCT02442609|surgery
916716|NCT02442609|question
916732|NCT02442583|colorectal cancer
916733|NCT02442583|survivor
916734|NCT02442583|exercise
916735|NCT02442583|physical activity
916736|NCT02442583|sedentary
916737|NCT02442570|alpha B-crystallin
916738|NCT02442570|immune tolerance
916739|NCT02442557|alpha B-crystallin
916740|NCT02442557|immune tolerance
916741|NCT02442518|placenta accreta
916742|NCT02442518|placenta previa
916743|NCT02442518|ultrasound
916744|NCT02442505|Atrial Fibrillation; Pacemaker; Device-detected
916745|NCT02442492|sildenafil
916746|NCT02442492|IUGR
916747|NCT02442492|FGR
916748|NCT02442492|STRIDER
916749|NCT02442479|exercise
916750|NCT02442479|resistance training
916751|NCT02442479|muscle strength
916752|NCT02442479|muscle hypertrophy
916753|NCT02442440|anisodamine
916754|NCT02442440|septic shock
916755|NCT02442427|Respiratory syncytial virus
916756|NCT02442427|Palivizumab
916757|NCT02442427|Bronchiolitis
916758|NCT02442427|Treatment
916759|NCT02442414|Cancer
916760|NCT02442414|Advanced Solid Tumors
916761|NCT02442414|EGFR
916762|NCT02442414|HER2
916763|NCT02442414|HER3
916764|NCT02442414|HER4
916765|NCT02442414|ALK mutations
916766|NCT02442414|irreversible tyrosine kinase inhibitor
916767|NCT02442414|Metastatic Non Small Cell Lung Cancer
916768|NCT02442414|Gastric Cancer
916769|NCT02442414|Colorectal Cancer
916770|NCT02442388|pain
916771|NCT02442388|root canal therapy
916772|NCT02442388|endodontics
916773|NCT02442388|file
916774|NCT02442375|head and neck cancer
916775|NCT02442375|accelerated radiotherapy
916776|NCT02442375|dose reduction
916777|NCT02442375|dose de-escalation
916778|NCT02442375|elective lymph nodes
916779|NCT02442375|FDG-PET
916780|NCT02442349|Phase II, Open Label, Single-arm study, Safety and Efficacy of AZD9291, Asia Pacific, NSCLC with T790M mutation within the Epidermal Growth Factor Receptor Gene
916781|NCT02442310|deferiprone
916782|NCT02442310|deferiprone delayed release formulation
916783|NCT02442310|pharmacokinetics
916784|NCT02442297|Glioblastoma
916785|NCT02442297|T cells Expressing HER2-specific Chimeric Antigen Receptors
916786|NCT02442297|HER2-specific T cells
916787|NCT02442297|intracranial injection
916788|NCT02442284|Chronic Hepatitis C
916789|NCT02442284|Interferon-Free
916790|NCT02442284|Hepatitis C Genotype 1
916791|NCT02442284|Hepatitis C Virus
916792|NCT02442284|Hepatitis C
916793|NCT02442284|Cirrhosis
916794|NCT02442271|Chronic Hepatitis C
916795|NCT02442271|Hepatitis C Treatment Naive
916796|NCT02442271|Hepatitis C Genotype 1
916797|NCT02442271|Hepatitis C Treatment Experienced
916798|NCT02442271|Hepatitis C Virus
916799|NCT02442258|Renal Impairment
916800|NCT02442219|gluten
916801|NCT02442219|Tetramer
916802|NCT02442206|QVA149, cardiac function, ventricular enddiastolic volume, hyperinflated COPD patients
916803|NCT02442154|early tracheostomy
916804|NCT02442154|severe head injury
916805|NCT02442154|endotracheal intubation
916806|NCT02442141|Near-Infrared Spectroscopy
916807|NCT02442141|Cerebral
916808|NCT02442141|Infants
916809|NCT02442141|Anesthesia
916810|NCT02442141|Neurodevelopmental
916811|NCT02442128|Fentany
916812|NCT02442128|intubation
916813|NCT02442128|sevoflurane
916814|NCT02442128|children
916815|NCT02442128|Propofol
916816|NCT02442115|Autism
916817|NCT02442115|Autism Spectrum Disorder (ASD)
916818|NCT02442115|Tummy Troubles
916819|NCT02442115|Constipation
916820|NCT02442115|GI Disorders
916821|NCT02442115|Gastrointestinal Disorders
916822|NCT02442115|Gastrointestinal
916823|NCT02442115|Oxidative Stress
916824|NCT02442115|Stomach problems
916825|NCT02442115|Behaviors
916826|NCT02442115|Autistic
916827|NCT02442115|ASD
916828|NCT02442115|MET gene
916829|NCT02442115|GID
916830|NCT02442115|Pediatric
916831|NCT02442115|Pediatric GI disorders
916832|NCT02442115|Children with Autism
916833|NCT02442115|functional constipation
916834|NCT02442102|deglutition disorders
916835|NCT02442102|therapeutics
916836|NCT02442102|rehabilitation
916837|NCT02442102|outcome assessment
916838|NCT02442102|intubation
916839|NCT02442102|critical care
916840|NCT02442102|larynx
916841|NCT02442102|voice
916842|NCT02442089|mHealth
916843|NCT02442089|eHealth
916844|NCT02442089|Health Systems
916845|NCT02442089|Health Technology
916846|NCT02442089|No Show
916847|NCT02442089|Non-attendance
916848|NCT02442089|Chile
916849|NCT02442089|Randomized controlled trial
916850|NCT02442089|Efficiency, Organizational
916851|NCT02442089|Pediatric Hospitals
916852|NCT02442089|Global Health
916853|NCT02442089|Referral and Consultation
916854|NCT02442089|Health Care Systems
916855|NCT02442089|Community Health Systems
916856|NCT02442089|Health Information Systems
916857|NCT02442089|Integrated Health Care Systems
916858|NCT02442089|Community Medicine
916859|NCT02442076|Skin vibration
916860|NCT02442076|Acupuncture needle vibration
916861|NCT02442050|CABG
916862|NCT02442050|valve surgery
916863|NCT02442050|cardioplegia
916864|NCT02442050|heart surgery
916865|NCT02442050|cardiac surgery
916866|NCT02442050|Cardio-Pulmonary Bypass
916867|NCT02442050|myocardial arrest
916868|NCT02442050|coronary artery bypass graft
916869|NCT02442050|CPB
916870|NCT02442037|cellular therapy
916871|NCT02442037|active ulcerative colitis
916872|NCT02442037|phase 1/2 clinical study
916873|NCT02442037|human umbilical cord mesenchymal stem cell
916874|NCT02442037|allogeneic stem cell transplantation
916875|NCT02442037|UC
916876|NCT02442024|diabetes mellitus
916877|NCT02442024|diet
916878|NCT02442024|nutrient sensing
916879|NCT02442011|Hematology Biobank
916880|NCT02441998|Colorectal Cancer
916881|NCT02441998|Diminutive Polyps
916882|NCT02441998|Narrow Band Imaging
916883|NCT02441998|Colonic Polyps
916884|NCT02441998|colonoscopy
916885|NCT02441998|diagnostic imaging
916886|NCT02441998|optical diagnosis
916887|NCT02441985|Primary orthostatic tremor
916888|NCT02441946|cyclin-dependent kinase (CDK) 4/6 inhibitor
916889|NCT02441946|CDK 4 and 6 inhibitor
916890|NCT02441907|Diabetic Macular Edema
916891|NCT02441907|Ocular Cytokines
916892|NCT02441907|Triamcinolone Acetonide
916893|NCT02441881|Radiofrequency ablation
916894|NCT02441881|varicose veins
916895|NCT02441881|endothermal ablation
916896|NCT02441881|RFITT
916897|NCT02441881|Venefit
916898|NCT02441842|β-blocker
916899|NCT02441842|ACE inhibitor
916900|NCT02441842|Stress
916901|NCT02441842|Craniotomy
916902|NCT02441842|Postop hypertension
916903|NCT02441842|neurosurgical patients
916904|NCT02441829|Renal Impairment
916905|NCT02441816|wet AMD
916906|NCT02441816|neovascular AMD
916907|NCT02441803|Leukemia
916908|NCT02441803|Acute myeloid leukemia
916909|NCT02441803|AML
916910|NCT02441803|Refractory
916911|NCT02441803|Allogeneic hematopoietic stem cell transplantation
916912|NCT02441803|AHSCT
916913|NCT02441803|Busulfan
916914|NCT02441803|Busulfex
916915|NCT02441803|Myleran
916916|NCT02441803|Fludarabine
916917|NCT02441803|Fludarabine Phosphate
916918|NCT02441803|Fludara
916919|NCT02441803|Clofarabine
916920|NCT02441803|Clofarex
916921|NCT02441803|Clolar
916922|NCT02441803|Total body irradiation
916923|NCT02441803|TBI
916924|NCT02441803|XRT
916925|NCT02441803|Thymoglobulin
916926|NCT02441803|ATG (Rabbit)
916927|NCT02441803|Rabbit antithymocyte Globulin
916928|NCT02441803|Rabbit Antilymphocyte Globulin
916929|NCT02441803|Rabbit ATG
916930|NCT02441803|rATG
916931|NCT02441803|Stem cell infusion
916932|NCT02441803|Cyclophosphamide
916933|NCT02441803|Cytoxan
916934|NCT02441803|Neosar
916935|NCT02441803|Tacrolimus
916936|NCT02441803|Prograf
916937|NCT02441803|Mycophenolate mofetil
916938|NCT02441803|MMF
916939|NCT02441803|CellCept
916940|NCT02441803|Decitabine
916941|NCT02441803|Dacogen
916942|NCT02441803|Cytarabine
916943|NCT02441803|Ara-C
916944|NCT02441803|Cytosar
916945|NCT02441803|DepoCyt
916946|NCT02441803|Cytosine Arabinosine Hydrochloride
916947|NCT02441803|Idarubicin
916948|NCT02441803|Idamycin
916949|NCT02441790|5th metacarpal
916950|NCT02441790|EAROM
916951|NCT02441790|standard immobilization
916952|NCT02441790|Boxer's Fracture
916953|NCT02441790|hand function
916954|NCT02441790|DASH
916955|NCT02441790|trauma
916956|NCT02441777|retinal imaging
916957|NCT02441777|optical imaging
916958|NCT02441777|optical coherence tomography
916959|NCT02441777|polarization sensitive coherence tomography
916960|NCT02441764|Halaven
916961|NCT02441764|Eribulin Mesylate
916962|NCT02441764|locally advanced or metastatic breast cancer
916963|NCT02441751|Electrocardiography
916964|NCT02441751|Hemorrhage
916965|NCT02441751|Monitoring, Intraoperative
916966|NCT02441738|Atrial Fibrillation
916967|NCT02441738|Hybrid Ablation
916968|NCT02441738|Catheter Ablation
916969|NCT02441686|Multiple Myeloma
916970|NCT02441673|Postanaesthetic shivering
916971|NCT02441673|Subarachnoid block
916972|NCT02441673|Tramadol
916973|NCT02441673|Nefopam
916974|NCT02440594|Primary Care
916975|NCT02440594|Depression
916976|NCT02440594|Elderly
916977|NCT02440555|diabetes, capillary blood glucose, self-administered questionnaire
916978|NCT02441621|fluid responsiveness
916979|NCT02441621|diastolic dysfunction
916980|NCT02441621|left ventricular
916981|NCT02441556|thrombectomy
916982|NCT02441556|rt-PA
916983|NCT02441556|stroke
916984|NCT02441556|endovascular treatment
916985|NCT02441556|randomized
916986|NCT02441530|vitamin D
916987|NCT02441517|Xtandi
916988|NCT02441517|Metastatic Castration Resistant Prostate Cancer
916989|NCT02441517|Metastatic
916990|NCT02441517|Prostate Cancer
916991|NCT02441517|Chemotherapy
916992|NCT02441517|Castration-resistant
916993|NCT02441517|Enzalutamide
916994|NCT02441504|Exercise training
916995|NCT02441504|microvascular rarefaction
916996|NCT02441478|cooperative behavior, therapy adherence, fMRI
916997|NCT02441452|Nuss procedure
916998|NCT02441452|postoperative care
916999|NCT02441452|early ambulation
917000|NCT02441426|Cognitive development
917001|NCT02441426|Diarrheal disease
917002|NCT02441426|Enteric infections
917003|NCT02441426|Malnutrition
917004|NCT02441426|Vaccine Response
917005|NCT02441426|Enteropathy
917006|NCT02441426|Antibiotic use
917007|NCT02441426|Micronutrients
917008|NCT02441426|Breast feeding
917009|NCT02441426|Gut inflammation
917010|NCT02441413|HRCT
917011|NCT02441413|High Resolution Computed Tomography scans
917012|NCT02441413|Functional Respiratory Imaging
917013|NCT02441413|FRI
917014|NCT02441413|Computed Tomography
917015|NCT02441413|CT
917016|NCT02441413|Bronchiolitis Obliterans Syndrome
917017|NCT02441413|BOS
917018|NCT02441413|Lung Transplant
917019|NCT02441400|GERD
917020|NCT02441400|LES Pressure
917021|NCT02441400|Electrical Stimulation
917022|NCT02441387|depression
917023|NCT02441387|elderly
917024|NCT02441387|remission
917025|NCT02441387|treatment response
917026|NCT02441387|predictors of response
917027|NCT02441387|cognitive decline
917028|NCT02441387|structural neuroimage
917029|NCT02441387|genetic polymorphism
917030|NCT02441387|psychoeducation
917031|NCT02441374|Stroke
917032|NCT02441374|Hemiparesis
917033|NCT02441374|Upper limb
917034|NCT02441348|Voice Therapy
917035|NCT02441348|Muscle Tension Dysphonia
917036|NCT02441348|Lesions
917037|NCT02441309|Metastatic and/or Recurrent Osteosarcoma
917038|NCT02441283|Hepatitis C
917039|NCT02441283|Sustained virologic response
917040|NCT02441283|Direct Acting Antiviral
917041|NCT02441283|Chronic hepatitis C
917042|NCT02441283|Hepatitis C virus
917043|NCT02441257|Gastroesophageal Reflux
917044|NCT02441257|Laryngeal Mask Airway
917045|NCT02441257|Control Ventilation
917046|NCT02441257|Spontaneous Ventilation
917047|NCT02441205|High Intensity Interval Training
917048|NCT02441192|physical training
917049|NCT02441192|aerobic training
917050|NCT02441192|resistance training
917051|NCT02441179|acute intermittent hypoxia
917052|NCT02441179|rehabilitation
917053|NCT02441179|spinal cord injury
917054|NCT02441166|Bone marrow tryptase
917055|NCT02441166|cutaneous mastocytosis
917056|NCT02441140|Stage III Ovarian Cancer
917057|NCT02441140|Stage IV Ovarian Cancer
917058|NCT02441127|free gingival graft
917059|NCT02441127|diode laser
917060|NCT02441127|donor site
917061|NCT02441127|mucogingival surgery
917062|NCT02441101|Cardiac Resynchronization therapy
917063|NCT02441075|patients
917064|NCT02441075|BMT
917065|NCT02441075|cyclosporine
917066|NCT02441075|tacrolimus
917067|NCT02441075|HSCT
917068|NCT02441049|Latino
917069|NCT02441049|Hispanic
917070|NCT02441049|Diet
917071|NCT02441049|Family health
917072|NCT02441049|Promotora
917073|NCT02441049|Intervention
917074|NCT02441036|Gene expression and protein production
917075|NCT02441023|type 2 diabetes mellitus
917076|NCT02441023|nutritional therapy
917077|NCT02441023|health education
917078|NCT02441023|self-management
917079|NCT02441023|multimedia
917080|NCT02440997|aromatherapy, peppermint
917081|NCT02440984|enteric nervous system
917082|NCT02440984|anorectal disorder
917083|NCT02440984|barostat anorectal
917084|NCT02440984|physiology
917085|NCT02440984|spina bifida
917086|NCT02440971|Adaptive Servo Ventilation
917087|NCT02440971|Acute decompensated heart failure
917088|NCT02440971|SleepMinder
917089|NCT02440971|ApneaLink Plus
917090|NCT02440971|Sleep disordered breathing
917091|NCT02440971|Natriuretic peptide
917092|NCT02440932|low Phenylalanine diet
917093|NCT02440932|PKU supplements
917094|NCT02440932|diet induced thermogenesis
917095|NCT02440932|appetite
917096|NCT02440932|body weight
917097|NCT02440919|Respiratory mechanics
917098|NCT02440919|Oxygenation
917099|NCT02440919|Suction
917100|NCT02440919|Mechanical ventilation
917101|NCT02440919|Respiratory therapy
917102|NCT02440919|Capnography
917103|NCT02440919|Pulmonary Ventilation
917104|NCT02440906|Asthma
917105|NCT02440906|Cerebrovascular Disease
917106|NCT02440906|Intracranial Injury
917107|NCT02440906|Neoplasms
917108|NCT02440906|Heart Failure
917109|NCT02440906|HIV/AIDs
917110|NCT02440906|Hereditary and Degenerative Diseases of the Central Nervous System
917111|NCT02440906|Disorders of the Peripheral Nervous System
917112|NCT02440906|Rheumatoid Arthritis and Other Inflammatory Polyarthropathies
917113|NCT02440906|History of hepatitis C
917114|NCT02440906|Schizophrenia
917115|NCT02440906|Episodic Mood Disorders
917116|NCT02440906|Delusional Disorders
917117|NCT02440906|Other Non-Organic Psychoses
917118|NCT02440906|Organic Psychotic Conditions
917119|NCT02440906|Neurotic Disorders
917120|NCT02440906|Other Non-Psychotic Mental Disorders
917121|NCT02440867|theta burst stimulation
917122|NCT02440867|Social Cognition
917123|NCT02440867|MRSI
917124|NCT02440867|Schizophrenia
917125|NCT02440867|transcranial magnetic stimulation
917126|NCT02440841|VA106483
917127|NCT02440841|fedovapagon
917128|NCT02440841|drug-drug interaction
917129|NCT02440841|DDI
917130|NCT02440841|males
917131|NCT02440841|rifampicin
917132|NCT02440841|rifampin
917133|NCT02440841|itraconazole
917134|NCT02440841|CYP3A4
917135|NCT02440841|pharmacokinetics
917136|NCT02440841|PK
917137|NCT02440815|Psychotherapy
917138|NCT02440815|Problem Solving Therapy (PST)
917139|NCT02440815|Depression
917140|NCT02440815|Major Depression
917141|NCT02440815|Major Depressive Disorder
917142|NCT02440815|Late Life Depression
917143|NCT02440815|Multimodal imaging
917144|NCT02440815|Magnetic Resonance Imaging (MRI)
917145|NCT02440815|Cerebral blood flow
917146|NCT02440815|Cortical atrophy
917147|NCT02440815|White matter lesion
917149|NCT02440737|Newly diagnosed
917150|NCT02440737|Cancer patient
917151|NCT02440737|Caregiver
917152|NCT02440737|Support person
917153|NCT02440724|winged stents
917154|NCT02440724|Self-expandable Metal Stents(SEMS)
917155|NCT02440724|partial covered
917156|NCT02440724|uncovered
917157|NCT02440724|endoscopic insertion
917161|NCT02440659|Chronic Kidney Disease
917162|NCT02440659|Hemodialysis
917163|NCT02440659|Peritoneal Dialysis
917164|NCT02440646|Computed tomography angiography
917165|NCT02440646|Quantitative coronary angiography
917166|NCT02440646|Coronary artery disease
917167|NCT02440646|Natural history of atherosclerosis
917168|NCT02440646|Radiocontrast-induced thyroid dysfunction
917169|NCT02440646|Contrast-induced nephropathy
917170|NCT02440646|Plaque burden
917171|NCT02440646|Glagovian artery remodeling
917172|NCT02440646|Radiation dose
917173|NCT02440646|SYNTAX score
917174|NCT02440646|Fractional flow reserve
917175|NCT02440620|Heart failure related to medical treatment of breast cancer
917176|NCT02440607|Randomization
917177|NCT02440607|cognitive aids types
917178|NCT02440607|aids
917179|NCT02440542|Nerve block
917180|NCT02440542|Ankle
917181|NCT02440542|Talus
917182|NCT02440542|Pain, Postoperative
917183|NCT02440516|Standardized
917184|NCT02440516|Physical therapy
917185|NCT02440516|occupational therapy
917186|NCT02440516|quality of life
917187|NCT02440516|disability
917188|NCT02440516|activities of daily living
917189|NCT02440516|ambulatory therapy
917190|NCT02440516|multiple sclerosis
917191|NCT02440464|Multiple Myeloma
917192|NCT02440464|Allogeneic Transplant
917193|NCT02440464|Maintenance Therapy
917194|NCT02440464|Anti-Myeloma Agents
917195|NCT02440464|Hematologic Disorders
917196|NCT02440438|Clostridium difficile, recurrence, relapse, antibodies, immune response, prognosis
917197|NCT02440425|platinum resistant
917198|NCT02440425|recurrent
917199|NCT02440425|persistent
917200|NCT02440425|epithelial
917201|NCT02440425|ovarian
917202|NCT02440425|fallopian tube
917203|NCT02440425|primary peritoneal
917204|NCT02440425|carcinoma
917205|NCT02440412|Massage
917206|NCT02440412|Stress
917207|NCT02440412|salivary cortisol
917208|NCT02440360|chronic homelessness
917209|NCT02440347|local anesthesia
917210|NCT02440347|articaine
917211|NCT02440347|AMSA
917212|NCT02440334|cryosurgery
917213|NCT02440334|ultrasonography
917214|NCT02440282|patients
917215|NCT02440256|Cost-effectiveness
917216|NCT02440256|Opioid substitution treatment
917217|NCT02440256|Integrated care
917218|NCT02440256|HIV
917219|NCT02440256|HAART
917220|NCT02440256|Testing
917221|NCT02440256|Linkage to care
917222|NCT02440256|Treatment adherence
917223|NCT02440230|adjuvant endocrine therapy
917224|NCT02440230|safety
917225|NCT02440230|Exemestane
917226|NCT02440230|ovarian function suppression
917227|NCT02440230|anastrozole
917228|NCT02440204|sevoflurane
917229|NCT02440204|remifentanil
917230|NCT02440204|intubation without using muscle relaxants
917231|NCT02440178|leukemia
917232|NCT02440178|induction
917233|NCT02440178|prophylaxis
917234|NCT02440178|antifungal
917235|NCT02440178|micafungin
917236|NCT02440178|phase II
917237|NCT02440165|nutrition
917238|NCT02440165|nurse
917239|NCT02440165|intervention
917240|NCT02440165|malnutrition
917241|NCT02440126|Multiple Sclerosis
917242|NCT02440126|immunological
917243|NCT02440126|biomarkers
917244|NCT02440126|observational
917245|NCT02440126|Relapsing
917246|NCT02440126|Remitting Multiple Sclerosis
917247|NCT02440100|Phase 1
917248|NCT02440100|Multiple doses of PF-06648671
917249|NCT02440100|safety, tolerability, PK
917250|NCT02440100|plasma and CSF abeta
917251|NCT02440100|drug interaction
917252|NCT02440074|Lumbar pain
917253|NCT02440074|Mesenchymal Stem Cells
917254|NCT02440061|Ghrelin
917255|NCT02440061|age, BMI, and gender matched controls
917256|NCT02440048|extraction
917257|NCT02440048|Bond Apatite
917258|NCT02440035|Healthy Participants
917259|NCT02440035|Ad35.RSV.FA2
917260|NCT02440035|JNJ-61187191
917261|NCT02439996|Kawasaki disease IVIG DNA variation
917262|NCT02439970|kidney transplant allograft
917263|NCT02439970|recipients
917264|NCT02439944|Nicotine Patch
917265|NCT02439944|Nicotine Mouth Spray
917266|NCT02439944|Smoking Cessation
917267|NCT02439944|Quit Smoking
917268|NCT02439944|Abstinence
917269|NCT02439944|Dependence
917270|NCT02439944|Nicotine
917271|NCT02439944|Tobacco
917527|NCT02438371|preterm labor
917272|NCT02439944|Transdermal Nicotine Replacement Therapy
917273|NCT02439944|Functional Magnetic Resonance Imaging
917274|NCT02439944|Neuroimaging
917275|NCT02439944|Cue Reactivity
917276|NCT02439944|Resting State
917277|NCT02439944|BOLD fMRI
917278|NCT02439905|inflammatory cytokine
917279|NCT02439905|protective effect
917280|NCT02439905|Dexmedetomidine
917281|NCT02439905|Precedex
917282|NCT02439905|one lung ventilation
917283|NCT02439905|ischemia-reperfusion
917284|NCT02439892|Radiotherapy
917285|NCT02439892|Exercise
917286|NCT02439892|Diet therapy
917287|NCT02439892|Rehabilitation
917288|NCT02439892|Patient Compliance
917289|NCT02439892|Feasibility Studies
917290|NCT02439892|Sample Size
917291|NCT02439892|Patient satisfaction
917292|NCT02439853|primary progressive aphasia
917293|NCT02439853|progressive nonfluent aphasia
917294|NCT02439853|progressive aphasia
917295|NCT02439853|frontotemporal dementia
917296|NCT02439853|frontotemporal lobar degeneration
917297|NCT02439827|Lifestyle
917298|NCT02439827|Intervention
917299|NCT02439827|Motor Activity
917300|NCT02439827|Mediating Variables
917301|NCT02439827|Mental Health
917302|NCT02439827|Obesity
917303|NCT02439827|Adolescent Health
917304|NCT02439827|School
917305|NCT02439827|Health Promotion
917306|NCT02439827|Brazil
917307|NCT02439801|PEEP
917308|NCT02439801|compliance
917309|NCT02439801|peak airway pressures
917310|NCT02439788|Neuroblastoma
917311|NCT02439788|Natural Killer T Cells
917312|NCT02439788|Gene Therapy
917313|NCT02439788|Chimeric Antigen Receptor
917314|NCT02439775|Uncontrolled hypertension
917315|NCT02439775|Renal denervation
917316|NCT02439762|Veterans
917317|NCT02439762|Cognitive Behavioral Therapy
917320|NCT02439736|Traumatic Brain Injury
917321|NCT02439736|Head Injury
917322|NCT02439723|Regorafenib
917323|NCT02439723|Lean body mass
917324|NCT02439723|Proton pump inhibitors pharmacokinetics
917325|NCT02439684|HbA1c
917326|NCT02439684|Diagnostic accuracy
917327|NCT02439684|Diabetes Mellitus
917328|NCT02439684|Chinese
917329|NCT02439684|Impaired fasting glucose
917330|NCT02439671|Transition Support Program for young adults
917331|NCT02439658|genetic research
917332|NCT02439645|genetic research
917333|NCT02439606|GlideRite
917334|NCT02439606|Stylet
917335|NCT02439606|Parker
917336|NCT02439606|orotracheal
917337|NCT02439606|intubation
917338|NCT02439606|GlideScope
917339|NCT02439593|Pancreas
917340|NCT02439593|chemoradiotherapy
917341|NCT02439593|hyperthermia
917342|NCT02439580|Patients
917343|NCT02439580|After Surgery
917344|NCT02439567|Cirrhosis
917345|NCT02439567|Chronic hepatitis C
917346|NCT02439567|Clinically significant portal hypertension
917347|NCT02439567|Portal hypertension
917348|NCT02439567|Elastography
917349|NCT02439567|Antiviral therapy
917350|NCT02439541|cellular therapy
917351|NCT02439541|Chronic ischemic heart disease
917352|NCT02439541|phase 1/2 clinical study
917353|NCT02439541|human umbilical cord mesenchymal stem cell
917354|NCT02439541|ischemic heart disease
917355|NCT02439541|allogeneic stem cell transplantation
917356|NCT02439528|pulmonary fibrosis
917357|NCT02439528|syndrome
917358|NCT02439528|genetic
917359|NCT02439528|emphysema
917360|NCT02439515|post-acute stroke
917361|NCT02439515|functional electrical stimulation
917362|NCT02439515|biofeedback
917363|NCT02439515|balance
917364|NCT02439515|cycling
917365|NCT02439515|rehabilitation
917366|NCT02439515|gait
917372|NCT02439450|lung
917373|NCT02439450|cancer
917374|NCT02439450|gp96
917375|NCT02439450|vaccine
917376|NCT02439450|immunotherapy
917377|NCT02439450|Heat Biologics
917378|NCT02439450|Nivolumab
917379|NCT02439450|checkpoint inhibitor
917380|NCT02439385|Curcumin
917381|NCT02439385|Avastin
917382|NCT02439385|FOLFIRI
917383|NCT02439385|Colorectal cancer
917384|NCT02439385|Unresectable metastasis
917385|NCT02439346|Advanced solid tumors
917386|NCT02439346|Docetaxel
917387|NCT02439346|mitogen-activated protein (MAP) kinase-interacting serine / threonine-protein kinase 1, also known as Mnk1 (MKNK1 inhibitor)
917388|NCT02439346|Taxanes
917389|NCT02439346|Non-small cell lung cancer
917390|NCT02439333|Acute exacerbation of chronic obstructive pulmonary disease
917391|NCT02439333|Nasal high flow therapy
917392|NCT02439333|Oxygen therapy
917393|NCT02439307|Rifaximin
917394|NCT02439307|Minimal hepatic encephalopathy
917395|NCT02439294|Recent acute myocardial infarction
917396|NCT02439294|Obstructive sleep apnée (syndrome)
917397|NCT02439294|Ventricular remodeling
917398|NCT02439294|Continuous Positive Airway Pressure
917399|NCT02439281|Ropivacaine
917400|NCT02439281|Anesthesia adjuncts
917401|NCT02439281|clonidine
917402|NCT02439281|laparoscopic appendectomy
917403|NCT02439281|rectus sheath block
917404|NCT02439242|stroke volume, haemodynamic, fluid resucitation
917405|NCT02439216|Muscular Dystrophies
917406|NCT02439216|Musculoskeletal Diseases
917407|NCT02439216|Nervous System Diseases
917408|NCT02439216|Neuromuscular Diseases
917409|NCT02439216|Duchenne muscular dystrophy
917410|NCT02439216|DMD
917411|NCT02439216|dystrophin
917412|NCT02439216|dystrophy
917413|NCT02439216|Duchenne
917414|NCT02439203|Parkinson Disease
917415|NCT02439203|Levodopa Induced Dyskinesia (LID)
917416|NCT02439203|Dyskinesia
917417|NCT02439177|Blood glucose monitoring system
917418|NCT02439177|System Accuracy
917419|NCT02439164|sedation
917420|NCT02439164|eloquent area glioma
917421|NCT02439164|neurologic function
917422|NCT02439151|Extracorporeal Membrane Oxygenation
917423|NCT02439138|Waldenstrom's Macroglobulinemia
917424|NCT02439125|levodopa
917425|NCT02439125|dyskinesia
917426|NCT02439125|parkinsons disease
917427|NCT02439125|PD
917428|NCT02439112|Exercise
917429|NCT02439112|Physical Function
917430|NCT02439112|Physical Activity
917431|NCT02439112|Quality of Life
917432|NCT02439112|Pain
917433|NCT02439112|Bone Disease
917434|NCT02439086|rectal cancer
917435|NCT02439086|neoadjuvant chemoradiotherapy
917436|NCT02439086|long course radiotherapy
917437|NCT02439086|response
917438|NCT02439047|reconstructive surgery
917439|NCT02439047|abdominal surgery
917440|NCT02439034|pain management
917441|NCT02439034|brachytherapy
917442|NCT02439008|liver metastases of colorectal cancer
917443|NCT02439008|metastases of melanoma or renal cancer
917444|NCT02438969|Alcohol
917445|NCT02438969|Alcohol Dependence
917446|NCT02438969|Stress
917447|NCT02438969|Fear Conditioning
917448|NCT02438917|Hepatitis C
917449|NCT02438917|Cirrhosis
917450|NCT02438917|Biomarkers
917451|NCT02438917|Fibrosis
917452|NCT02438904|Blood And Marrow Transplantation
917453|NCT02438904|Stem cell transplantation
917454|NCT02438904|SCT
917455|NCT02438904|Poor graft function
917456|NCT02438904|CD34+ cell infusion
917457|NCT02438865|Upper Tract Urothelial Carcinoma
917458|NCT02438865|Intravesical Chemotherapy
917459|NCT02438865|Epirubicin
917460|NCT02438865|Urothelial Carcinoma
917461|NCT02438800|Postpartum Period
917462|NCT02438787|Ankylosing Spondylitis
917463|NCT02438787|Ustekinumab
917464|NCT02438787|Golimumab
917465|NCT02438787|STELARA
917466|NCT02438774|Post-harvest practices , complementary foods
917467|NCT02438774|aflatoxins and fumonisins exposure,
917468|NCT02438774|Maize, breast milk
917469|NCT02438774|child growth, Tanzania
917470|NCT02438761|Acute Myeloid Leukemia
917471|NCT02438761|Myelodysplastic Syndrome
917472|NCT02438761|PIK/Akt/mTor
917473|NCT02438748|Oxidized Phosphatidylcholines
917474|NCT02438735|ovarian endometriomas
917475|NCT02438735|AMH
917476|NCT02438735|ovarian reserve
917477|NCT02438670|Artificial Pancreas
917478|NCT02438670|Type 1 Diabetes
917479|NCT02438670|MPC
917480|NCT02438670|PID
917481|NCT02438631|placenta
917482|NCT02438631|placental passage
917483|NCT02438605|Nellix
917484|NCT02438605|EVAS
917485|NCT02438605|EVAR
917486|NCT02438605|Dynamic CT
917487|NCT02438605|Dyna CT
917488|NCT02438592|Continuum of care
917489|NCT02438579|Hypertonic saline
917490|NCT02438579|nasal irrigation
917491|NCT02438579|gargling
917492|NCT02438579|URTI
917493|NCT02438566|Tranexamic Acid
917494|NCT02438566|Blood Loss
917495|NCT02438566|Total Hip Replacement
917496|NCT02438566|Bilateral Knee Replacement
917497|NCT02438540|acupuncture
917498|NCT02438540|obesity
917499|NCT02438540|type 2 diabetic mellitus
917500|NCT02438540|insulin sensitivity
917501|NCT02438540|metformin
917502|NCT02438540|inflammatory factor
917503|NCT02438540|adipokines
917504|NCT02438540|lipid profile
917505|NCT02438501|low-dose involved field radiotherapy
917506|NCT02438501|recurrent
917507|NCT02438501|advanced
917508|NCT02438501|follicular lymphoma
917509|NCT02438462|Pulmonary Embolism
917510|NCT02438462|Soluble Fibrin
917511|NCT02438462|D-Dimers
917512|NCT02438462|Clinical Probability Score
917513|NCT02438462|Imaging
917514|NCT02438449|breast reconstruction
917515|NCT02438449|mastectomy
917516|NCT02438449|health-related quality of life
917517|NCT02438449|Health Utilities Index
917518|NCT02438449|HUI
917519|NCT02438449|prospective
917520|NCT02438449|quality-adjusted life years
917521|NCT02438449|QALY
917522|NCT02438410|infliximab
917523|NCT02438410|remicade
917524|NCT02438410|IBD
917525|NCT02438410|Colitis, Ulcerative
917526|NCT02438371|pregnancy
917528|NCT02438371|tocolysis
917529|NCT02438293|rhinovirus
917530|NCT02438293|cardiac surgery
917531|NCT02438293|paediatric
917532|NCT02438293|respiratory infection
917533|NCT02438293|children
917534|NCT02438280|Orthodontic
917535|NCT02438280|Orthodontic treatment
917536|NCT02438280|Accelerated orthodontics
917537|NCT02438280|Vibration
917538|NCT02438241|Pain Measurement
917539|NCT02438241|Electric Stimulation
917540|NCT02438241|Spirometry
917541|NCT02438241|Manometry
917542|NCT02438228|cardiac output
917543|NCT02438228|transpulmonary thermodilution
917544|NCT02438228|pulse contour analysis
917545|NCT02438228|G09.330.380.124
917546|NCT02438215|PD
917547|NCT02438215|Parkinson's Disease
917548|NCT02438189|Type 1 Diabetes
917549|NCT02438189|Hypoglycemia
917550|NCT02438189|Hyperglycemia
917551|NCT02438189|Artificial Pancreas
917552|NCT02438163|Theta Burst Stimulation
917553|NCT02438150|Disaster
917554|NCT02438150|Training
917555|NCT02438137|Obstructive Sleep Apnea
917556|NCT02438137|OSA
917557|NCT02438137|sleep apnea
917558|NCT02438137|snoring
917559|NCT02438137|dimethyl fumarate
917560|NCT02438137|CPAP
917561|NCT02438137|continuous positive airway pressure
917562|NCT02438124|Parkinson's disease
917563|NCT02438124|Rhythmic auditory stimulation
917564|NCT02438124|Gait
917565|NCT02438098|Rivaroxaban
917566|NCT02438098|Obesity
917567|NCT02438098|Bariatric surgery
917568|NCT02438098|Pharmacokinetics
917569|NCT02438098|Pharmacodynamics
917570|NCT02438085|acute coronary syndromes
917571|NCT02438085|outcome
917572|NCT02438085|medical management
917573|NCT02438085|comorbidities
917574|NCT02438085|registry
917575|NCT02438072|antidepressive agent
917576|NCT02438072|drug metabolism
917577|NCT02438072|CYP450
917578|NCT02438072|P-glycoprotein
917579|NCT02438072|Phenotypic study
917580|NCT02438059|Inequality in health
917581|NCT02438059|workplace health promotion
917582|NCT02438059|internet
917583|NCT02438059|mobile app
917584|NCT02438059|weight loss
917585|NCT02438059|intervention
917586|NCT02438059|randomized controlled trial
917587|NCT02438046|Connective Tissue Grafts
917588|NCT02438046|Wound healing
917589|NCT02438046|Biomaterials
917590|NCT02438046|Pain
917591|NCT02438046|Clinical Trials
917592|NCT02438046|Mucogingival Surgery
917593|NCT02438033|Deep Brain Stimulation
917594|NCT02438033|Globus Pallidus
917595|NCT02438033|GPi
917596|NCT02438033|PC+S
917597|NCT02438020|Acanthosis nigricans
917598|NCT02438020|obesity
917599|NCT02438020|children
917600|NCT02438020|metformin
917601|NCT02437942|Athletic injuries
917602|NCT02437942|chronic
917603|NCT02437942|rehabilitation
917604|NCT02437942|diagnosis
917605|NCT02437942|biomechanics
917606|NCT02437916|Melanoma
917607|NCT02437916|Non-small Cell Lung Cancer (NSCLC)
917608|NCT02437916|Squamous Cell Carcinoma
917609|NCT02437916|Carcinoma
917610|NCT02437916|Head and Neck
917611|NCT02437916|Transitional Cell Carinoma (TCC)
917612|NCT02437916|Bladder
917613|NCT02437916|Colorectal
917614|NCT02437916|Colorectal Cancer (CRC)
917615|NCT02437903|voluma temporal, facial, volume loss
917616|NCT02437877|Respiration
917617|NCT02437877|Learning
917618|NCT02437877|Speech
917619|NCT02437877|Language and Hearing Sciences
917620|NCT02437799|Pulse oximeter
917621|NCT02437799|Caesarean section
917622|NCT02437799|hypotension
917623|NCT02437799|Spinal anaesthesia
917624|NCT02437773|OCD
917625|NCT02437747|clinical trial
917626|NCT02437708|regenerative endodontics
917627|NCT02437708|platelet rich fibrin
917628|NCT02437695|Robotic Surgical Procedures
917629|NCT02437695|Trendelenburg Position
917630|NCT02437682|Gastro-esophageal Reflux Disease
917631|NCT02437682|Proton pump inhibitor
917632|NCT02437669|Intranasal
917633|NCT02437669|Hydromorphone
917634|NCT02437669|Pediatric
917635|NCT02437669|Emergency department
917636|NCT02437656|Radiochemotherapy
917637|NCT02437656|Metformin
917638|NCT02437656|Rectal cancer
917639|NCT02437617|Advanced cancers
917640|NCT02437617|Tumor tissue
917641|NCT02437617|Genomic profile test
917642|NCT02437617|Analysis of treatment outcomes
917643|NCT02437617|Molecular profiling
917644|NCT02437617|Molecular alteration
917645|NCT02437591|ASP2819
917646|NCT02437591|PAR-101
917647|NCT02437591|OPT-80
917648|NCT02437591|Inflammatory Bowel Disease (IBD)
917649|NCT02437591|Clostridium difficile Infection (CDI)
917650|NCT02437591|fidaxomicin
917651|NCT02437591|Dificlir
917652|NCT02437578|vitamin d
917653|NCT02437578|fertility
917654|NCT02437578|markers
917655|NCT02437578|endocrine disruption
917656|NCT02437578|reproduction
917657|NCT02437552|Cardiac Surgery, Coronary Artery Bypass, Exercise Movement Techniques
917658|NCT02437526|Cure
917659|NCT02437526|Analytic treatment interruption
917660|NCT02437513|Dysphagia
917661|NCT02437513|Aspiration
917662|NCT02437513|Laryngeal cancer
917663|NCT02437474|vegan diet
917664|NCT02437474|lacto-ovo-vegetarian diet
917665|NCT02437474|cancer
917666|NCT02437474|tumor remission
917667|NCT02437461|knee synovitis
917668|NCT02437461|triamcinolone hexacetonide
917669|NCT02437461|treatment response
917670|NCT02437448|Mass spectrometry
917671|NCT02437448|Exhaled breath analysis
917672|NCT02437435|assisted reproduction
917673|NCT02437435|physical therapy
917674|NCT02437435|manual therapy
917675|NCT02437435|uterine artery
917676|NCT02437435|Vascularization Index (VI)
917677|NCT02437435|Doppler ultrasonography
917678|NCT02437435|vocal
917679|NCT02437409|Ischemic, Acute
917680|NCT02437357|Psychotherapy, Group
917681|NCT02437357|Metacognition
917682|NCT02437357|Cognitive Bias
917683|NCT02437331|Advanced heart failure
917684|NCT02437331|diseased experience
917685|NCT02437318|HR+
917686|NCT02437318|HER2-negative
917687|NCT02437318|advanced breast cancer
917688|NCT02437318|alpelisib
917689|NCT02437318|fulvestrant
917690|NCT02437318|PI3K
917691|NCT02437318|Phase III
917692|NCT02437318|ER+
917693|NCT02437318|PgR+
917694|NCT02437318|men
917695|NCT02437318|postmenopausal
917696|NCT02437318|aromatase inhibitor
917697|NCT02437318|neoplasms
917698|NCT02437305|Melanoma
917699|NCT02437305|People of Color
917700|NCT02437279|Palpable
917701|NCT02437279|Stage III
917702|NCT02437279|Skin melanoma
917703|NCT02437279|Ipilimumab
917704|NCT02437279|Nivolumab
917705|NCT02437279|Surgery
917706|NCT02437253|Mucopolysaccharidosis
917707|NCT02437253|Inflammation
917708|NCT02437253|Tumor necrosis factor - alpha inhibitor
917709|NCT02437240|Pilates-based exercise
917710|NCT02437240|respiratory mechanics
917711|NCT02437240|cardiopulmonary physical therapy
917712|NCT02437240|sternotomy
917713|NCT02437175|pelvic pain
917714|NCT02437175|quality of life
917715|NCT02437175|adenomyosis
917716|NCT02437162|Axial Spondyloarthritis
917717|NCT02437162|Ustekinumab
917718|NCT02437162|Golimumab
917719|NCT02437162|Stelara
917720|NCT02437149|Texting and driving
917721|NCT02437149|Teenager and driving
917722|NCT02437149|Distracted Driving Campaign
917723|NCT02437123|mHealth
917724|NCT02437123|Indigenous
917725|NCT02437123|HIV prevention
917726|NCT02437123|substance use
917727|NCT02437110|Amyotrophic Lateral Sclerosis
917728|NCT02437110|Virus
917729|NCT02437110|Antiretroviral Therapy
917735|NCT02437032|GDF-9
917736|NCT02437032|BMP-15
917737|NCT02437032|Steroids
917738|NCT02437032|Apoptosis rate
917739|NCT02437032|Endocrinology
917740|NCT02437019|PCI-32765
917741|NCT02437019|Ibrutinib
917742|NCT02437019|Early access program
917743|NCT02437019|Chronic lymphocytic leukemia
917744|NCT02437019|Relapsed or refractory chronic lymphocytic leukemia
917745|NCT02437006|stroke
917746|NCT02437006|exercise capacity
917747|NCT02436993|Neoadjuvant Treatment
917748|NCT02436993|Carboplatin
917749|NCT02436993|Paclitaxel
917750|NCT02436993|Pertuzumab
917751|NCT02436993|Trastuzumab
917752|NCT02436993|Bevacizumab
917753|NCT02436980|premedication
917754|NCT02436980|ERCP
917755|NCT02436980|midazolam
917756|NCT02436980|tramadol
917757|NCT02436980|cognitive
917758|NCT02436928|H7N9 Influenza
917759|NCT02436928|Avian influenza A
917760|NCT02436928|cell culture derived
917761|NCT02436915|Slow gait
917762|NCT02436915|Executive function
917763|NCT02436915|Transcranial direct current stimulation
917764|NCT02436876|Osteosynthesis
917765|NCT02436876|Complications
917766|NCT02436876|Infection or Inflammation
917767|NCT02436876|Orthopedic
917768|NCT02436876|Device
917769|NCT02436876|Fracture
917770|NCT02436863|Laminectomy
917771|NCT02436863|Laminoplasty
917772|NCT02436863|Internal fixation
917773|NCT02436863|deformity
917774|NCT02436850|Thoracentesis
917775|NCT02436850|Pocket Ultrasound Device
917776|NCT02436850|Ultrasound
917777|NCT02436850|Soroka University Medical Center
917778|NCT02436850|Physical Examination
917779|NCT02436850|Ethical Committee
917780|NCT02436824|topical patch
917781|NCT02436824|chronic low back pain
917782|NCT02436811|Health literacy
917783|NCT02436811|Pregnant women
917784|NCT02436811|Feeding behaviour
917785|NCT02436811|Oral health
917786|NCT02436811|Child
917787|NCT02436798|QT prolongation
917788|NCT02436798|Genomic biomarkers
917789|NCT02436785|music therapy
917790|NCT02436785|pain management
917791|NCT02436785|self efficacy
917792|NCT02436785|patient education
917793|NCT02436785|relaxation
917794|NCT02436746|Von Recklinghausen's disease
917795|NCT02436746|Bourneville's disease
917796|NCT02436746|Cognitive variability
917797|NCT02436746|Loss of heterozygosity
917798|NCT02436733|pleural mesothelioma
917799|NCT02436733|phase II
917800|NCT02436733|randomized
917801|NCT02436733|surgery
917802|NCT02436733|chemotherapy
917803|NCT02436733|feasibility
917804|NCT02436694|Dexamethasone
917805|NCT02436694|Perineural
917806|NCT02436655|aortic stenosis
917807|NCT02436655|normal ejection fraction
917808|NCT02436655|asymptomatic
917809|NCT02436629|Red beetroot juice
917810|NCT02436629|High intensity intermittent exercise
917811|NCT02436629|Nitrite
917812|NCT02436629|Soccer
917813|NCT02436616|EEG
917814|NCT02436616|Preterm Infants
917815|NCT02436616|Neonate
917816|NCT02436616|wireless
917817|NCT02436603|Irritable Bowel Syndrome
917818|NCT02436603|IBS
917819|NCT02436603|Mind-Body Training
917820|NCT02436603|Integrative Medicine
917821|NCT02436603|FODMAP
917822|NCT02436590|osteoarthritis
917823|NCT02436590|knee
917824|NCT02436590|pulsed electromagnetic fields
917825|NCT02436590|PEMF
917826|NCT02436577|ticagrelor orodispersible tablet
917827|NCT02436577|ticagrelor immediate-release tablet
917828|NCT02436577|bioequivalence
917829|NCT02436577|Phase I
917830|NCT02436577|healthy Japanese subjects
917831|NCT02436564|pancreas
917832|NCT02436564|stem cells
917833|NCT02436564|tumours
917834|NCT02436564|in vitro models
917835|NCT02436564|organoids
917836|NCT02436564|cancer,
917837|NCT02436564|bile duct
917838|NCT02436564|liver
917839|NCT02436538|anti-Müllerian hormone (AMH)
917840|NCT02436538|Mullerian anomalies
917841|NCT02436538|ICSI
917842|NCT02436447|Renal Impairment, Renal function, MTP-131, Bendavia™
917843|NCT02436434|Pulsed radiofrequency, osteoarthritis
917844|NCT02436395|gastric cancer
917845|NCT02436395|gastrectomy
917846|NCT02436395|laparotomy
917847|NCT02436395|SSIs
917848|NCT02436395|povidone-iodine
917849|NCT02436395|normal saline
917850|NCT02436369|diabetic patients
917851|NCT02436369|flaxseed
917852|NCT02436369|lipid profile
917853|NCT02436369|cardiovascular risc factors
917854|NCT02436343|left ventricular functions
917855|NCT02436343|pregnancy
917856|NCT02436343|obesity
917857|NCT02436330|Exergaming, Weight management
917858|NCT02436317|Point Of Care Ultrasonography
917859|NCT02436317|Soroka University Medical Center
917860|NCT02436317|Heart Failure
917861|NCT02436317|cardiovascular
917862|NCT02436278|Gait speed
917863|NCT02436278|Mortality
917864|NCT02436278|Morbidity
917865|NCT02436265|Neuraxial
917866|NCT02436265|Caudal
917867|NCT02436265|Block
917868|NCT02436265|Anesthesia
917869|NCT02436265|Dexamethasone
917870|NCT02436252|Myelodysplastic Syndrome
917871|NCT02436252|MDS
917872|NCT02436226|PCOS
917873|NCT02436226|Clomiphene citrate resistant
917874|NCT02436226|HCG
917875|NCT02436213|workload
917876|NCT02436213|oxygen level
917877|NCT02436213|oxygen consumption
917878|NCT02436213|breathing reserve
917879|NCT02436213|ventilatory efficiency
917880|NCT02436200|Intermittent Claudication
917881|NCT02436200|IC
917882|NCT02436200|Peripheral Arterial Disease
917883|NCT02436200|Peripheral Vascular Disease
917884|NCT02436200|Peripheral Arterial Occlusive Disease
917885|NCT02436187|NSTEMI
917886|NCT02436187|excess mortality
917887|NCT02436187|evidence-based care
917888|NCT02436187|MINAP
917889|NCT02436161|Heart Failure
917890|NCT02436161|Comorbidity
917891|NCT02436161|Patient Care Management
917892|NCT02436161|Primary Health Care
917893|NCT02436161|Delivery of Health Care, Integrated
917894|NCT02436148|PEQ validation study, Finland
917895|NCT02436122|Prostate cancer
917896|NCT02436122|Preoperative
917897|NCT02436122|Glycemic control
917898|NCT02436122|Hemoglobin A1c
917899|NCT02436122|Pathologic outcomes
917900|NCT02436122|Oncological outcomes
917901|NCT02436122|Treatment Outcome
917902|NCT02436122|Hemoglobin A1c Protein, Human
917903|NCT02436096|Pain
917904|NCT02436096|Sleep
917905|NCT02436070|Pediatrics
917906|NCT02436070|Emergency Medicine
917907|NCT02436070|Text messaging
917908|NCT02436044|Hepatocellular Carcinoma
917909|NCT02436044|Locally advanced stge
917910|NCT02436044|HAIC
917911|NCT02436044|FOLFOX4
917912|NCT02436044|Locally advanced
917913|NCT02436018|Sedation
917914|NCT02436018|Low pulse oximetry
917915|NCT02436018|Upper gastrointestinal endoscopy
917916|NCT02436018|WEI NASAL JET
917917|NCT02435979|wrist
917918|NCT02435979|proximal strengthening
917919|NCT02435979|hand therapy
917920|NCT02435953|Hepatocellular Carcinoma,TACE,Chemoembolization, RFA,Intermediate-stage
917921|NCT02435940|inherited retinal degenerative disease
917922|NCT02435940|retinitis pigmentosa
917923|NCT02435940|Usher
917924|NCT02435940|Leber
917925|NCT02435940|Bardet-Biedl
917926|NCT02435940|Batten
917927|NCT02435940|Best
917928|NCT02435940|cone dystrophy
917929|NCT02435940|cone-rod dystrophy
917930|NCT02435940|choroideremia
917931|NCT02435940|congenital night blindness
917932|NCT02435940|enhanced s-cone
917933|NCT02435940|cone monochromacy
917934|NCT02435940|Goldmann-Favre
917935|NCT02435940|Kearns-Sayre
917936|NCT02435940|Refsum
917937|NCT02435940|retinoschisis
917938|NCT02435940|rod-cone dystrophy
917939|NCT02435940|rod dystrophy
917940|NCT02435940|rod monochromacy
917941|NCT02435940|Sorsby pseudoinflammatory dystrophy
917942|NCT02435940|stargardt
917943|NCT02435940|achromatopsia
917944|NCT02435940|juvenile inherited macular degeneration
917945|NCT02435940|cone dichromacy
917946|NCT02435940|cone trichromacy
917947|NCT02435940|Charcot-Marie-Tooth
917948|NCT02435940|albipunctate dystrophy
917949|NCT02435901|Reduced Intensity Conditioning Regimen
917950|NCT02435888|Resting energy expenditure
917951|NCT02435888|Predictive equations
917952|NCT02435888|Overweight
917953|NCT02435875|hypertension
917954|NCT02435875|perioperative
917955|NCT02435875|baroreflex sensitivity
917956|NCT02435862|Vitreolysis of the Vitreous
917957|NCT02435849|Pediatric, ALL, Cell therapy
917958|NCT02435810|Neuroinflammation
917959|NCT02435810|Infections
917960|NCT02435797|nicorandil
917961|NCT02435797|primary percutaneous coronary intervention
917962|NCT02435797|acute ST segment elevation myocardial infarction
917963|NCT02435797|thrombus aspiration
917964|NCT02435784|2-COM
917965|NCT02435745|Ehlers-Danlos Syndrome
917966|NCT02435745|Obstructive Sleep Apnea
917967|NCT02435745|Prevalence
917968|NCT02435745|Aortic Aneurysm
917969|NCT02435719|HCAIs
917970|NCT02435719|Handgel
917971|NCT02435719|Hospital
917972|NCT02435719|Effectiveness
917973|NCT02435706|Dental implants
917974|NCT02435706|surgical flap
917975|NCT02435706|esthetics
917976|NCT02435706|alveolar process
917977|NCT02435693|pharmaceutical care
917978|NCT02435680|MCS110; carboplatin; gemcitabine; TNBC; TAMs
917979|NCT02435667|Resistance Training
917980|NCT02435667|Exercise
917981|NCT02435667|Heart Failure preserved Ejection Fraction
917982|NCT02435654|Genes Polymorphisms
917983|NCT02435654|Plasma Concentration
917984|NCT02435602|endoscopy, gastrointestinal
917985|NCT02435602|cancer screening
917986|NCT02435576|Acute toxicity
917987|NCT02435576|Late toxicity
917988|NCT02435576|NTCP models
917989|NCT02435563|Anti-HIV Agents
917990|NCT02435563|cardiovascular agents
917991|NCT02435563|drug interactions
917992|NCT02435537|analgesia
917993|NCT02435537|intrathecal
917994|NCT02435537|opioids
917995|NCT02435537|morphine
917996|NCT02435537|dexmedetomidine
917997|NCT02435524|Breast Feeding, Exclusive
917998|NCT02435524|Infant Nutrition
917999|NCT02435524|Burkina Faso
918000|NCT02435511|agent-based modeling
918001|NCT02435511|community resources
918002|NCT02435511|simulation modeling
918003|NCT02435511|information intervention
918004|NCT02435511|clinic-to-community linkages
918005|NCT02435485|degerative lumbar spondylolisthesis
918006|NCT02435485|rehabilitation
918007|NCT02435485|balance
918008|NCT02435472|Active Surveillance
918009|NCT02435472|Exercise
918010|NCT02435472|Prostate cancer
918011|NCT02435472|Life style
918012|NCT02435472|Survey
918013|NCT02435472|Personalized exercise
918014|NCT02435472|Exercise trainer
918016|NCT02435420|Total Hip Arthroplasty
918017|NCT02435420|EMPERION Modular Stem
918018|NCT02435420|Survivorship
918019|NCT02435355|Sleep apnea
918020|NCT02435355|education
918021|NCT02435355|compliance
918022|NCT02435355|CPAP
918023|NCT02435342|ShK-186
918024|NCT02435342|dalazatide
918025|NCT02435342|psoriasis
918026|NCT02435342|Kv1.3,
918027|NCT02435342|autoimmune
918028|NCT02435316|Education
918029|NCT02435290|prediction
918030|NCT02435290|prescribing error
918031|NCT02435290|risk factors
918032|NCT02435277|Diabetes
918033|NCT02435212|New formulation, deferasirox, chelation, iron overload, compliance, satisfaction, palatability, PRO, PK, safety, PK/PD, ICL670
918034|NCT02435186|p53 gene
918035|NCT02435186|chemotherapy
918036|NCT02435186|recurrent
918037|NCT02435186|epithelial
918038|NCT02435186|ovarian cancer
918039|NCT02435186|fallopian tube cancer
918040|NCT02435186|primary peritoneal cancer
918042|NCT02435108|MET poisitivity is defined as at least half of tumor cells show weak, moderate or high staining
918043|NCT02435095|Schizophrenia
918044|NCT02435095|Maintenance treatment, Intermittent treatment
918045|NCT02435095|Brain volume
918046|NCT02435095|Antipsychotics
918047|NCT02435082|Concussion
918048|NCT02435082|Vascular Assessment
918049|NCT02435082|Vascular Regulation
918050|NCT02435082|mild Traumatic Brain Injury, mTBI
918051|NCT02435082|Traumatic Brain Injury, TBI
918052|NCT02435082|Cerebrovascular Regulation
918053|NCT02435082|Cerebral Blood Flow
918054|NCT02435082|Cerebral Blood Flow Velocity, CBFV
918055|NCT02435082|Cerebral Blood Flow Velocity Variability
918056|NCT02435082|Cerebrovascular Assessment
918057|NCT02435069|cecostomy
918058|NCT02435069|appendicostomy
918059|NCT02435056|medication overuse headache
918060|NCT02435056|health care system
918061|NCT02435030|NP-C
918062|NCT02435030|LSD
918063|NCT02435030|lysosomal storage disorder
918064|NCT02435030|lysosomal storage disease
918065|NCT02435030|NPC2
918066|NCT02435030|NPC1
918067|NCT02435030|Niemann-Pick Type C
918068|NCT02435030|Niemann-Pick,
918069|NCT02435030|Arimoclomol
918070|NCT02435017|kidney disease
918071|NCT02435017|recommended dietary allowances
918072|NCT02435017|nutrition assessment
918073|NCT02435017|food
918074|NCT02435017|dietary proteins
918075|NCT02435017|Vitamin D
918076|NCT02435017|dietary fats
918077|NCT02435017|ethnology
918078|NCT02435017|Continental Population Groups
918079|NCT02435017|Phosphorus, dietary
918080|NCT02435017|Phosphorus/analysis
918081|NCT02434991|trouble swallowing
918082|NCT02434991|food sticking
918083|NCT02434991|Achalasia
918084|NCT02434965|Neonates
918085|NCT02434965|hypoxic-ischemic encephalopathy
918086|NCT02434965|human placental-derived stem cells
918087|NCT02434965|autologous
918088|NCT02434952|Malaria, Falciparum
918089|NCT02434952|G6PD deficiency
918090|NCT02434952|Primaquine
918091|NCT02434952|Asia
918092|NCT02434926|fetoscopy
918093|NCT02434926|fetal surgery
918094|NCT02434926|anesthetic complications
918095|NCT02434913|Proximal interphalangeal joint deformity
918096|NCT02434913|Arthroplasty
918097|NCT02434822|Cholera
918098|NCT02434822|Shanchol™
918099|NCT02434822|Cholera Vaccine
918100|NCT02434809|Respiratory Motion-Corrected Cone-Beam CT
918101|NCT02434809|Radiation
918102|NCT02434809|14-225
918103|NCT02434796|Intimate Partner Violence
918104|NCT02434796|Gender-Based Violence
918105|NCT02434796|Gender
918106|NCT02434796|HIV
918107|NCT02434783|Blood circulation
918108|NCT02434783|Blood vessels
918109|NCT02434783|Mitochondria
918110|NCT02434783|Muscle, skeletal
918111|NCT02434783|Legs
918112|NCT02434783|Energy metabolism
918113|NCT02434731|Procedural pain
918114|NCT02434731|Phlebotomy
918115|NCT02434731|Intellectual Disability
918116|NCT02434731|Child
918117|NCT02434731|Buzzy
918118|NCT02434705|Eosinophilic
918119|NCT02434692|Primary Open Angle Glaucoma
918120|NCT02434692|POAG
918121|NCT02434692|Glaucoma
918122|NCT02434692|Cataract
918123|NCT02434692|Surgery
918124|NCT02434692|Ocular Pressure
918125|NCT02434679|antibiotics resistance integrons
918126|NCT02434679|neonatology newborns
918127|NCT02434679|digestive acquisition
918128|NCT02434679|dynamic of the acquisition of integrons
918129|NCT02434627|Becker
918130|NCT02434627|Dystrophy
918131|NCT02434601|Non-carious cervical lesions
918132|NCT02434601|Randomized clinical trial
918133|NCT02434601|Permanent dental restoration
918134|NCT02434601|Dentin
918135|NCT02434601|Adhesion
918136|NCT02434601|Restoration
918137|NCT02434601|Sensitivity
918138|NCT02434601|Prophylaxis
918139|NCT02434601|Randomized
918140|NCT02434575|Lower Urinary Tract Symptoms
918141|NCT02434575|Prostatic artery embolisation
918142|NCT02434575|Transurethral resection of the prostate
918143|NCT02434575|Benign prostatic hyperplasia
918144|NCT02434575|Benign prostatic enlargement
918145|NCT02434549|Randomized Controlled Trial
918146|NCT02434549|Placebo Controlled
918147|NCT02434549|Double Blinded
918148|NCT02434549|Botulinum Toxin Type A
918149|NCT02434549|Adults
918150|NCT02434549|Pain
918151|NCT02434549|Spasticity
918152|NCT02434549|Cerebral Palsy, Spastic
918153|NCT02434549|Dysport
918154|NCT02434536|Chronic Obstructive Pulmonary Disease
918155|NCT02434536|Disease Exacerbation Clinical Prediction Rule
918156|NCT02434536|Decision Analysis
918157|NCT02434523|laryngeal sensory neuropathy
918158|NCT02434510|Infection
918159|NCT02434510|Total Knee Arthroplasty
918160|NCT02434510|Total Hip Arthroplasty
918161|NCT02434510|Splash Basins
918162|NCT02434497|LDL-C
918163|NCT02434497|HoFH
918164|NCT02434497|Hyperlipidemia
918165|NCT02434484|Symbenda
918166|NCT02434484|Non-Hodgkin's lymphomas
918167|NCT02434484|Chronic lymphocytic leukemia
918168|NCT02434484|Multiple myeloma
918169|NCT02434484|Bendamustine Hydrochloride
918170|NCT02434458|fibromyalgia,
918171|NCT02434458|polyneuropathy
918172|NCT02434458|small fiber neuropathy
918173|NCT02434458|rheumatoid arthritis
918174|NCT02434458|sudomotor
918175|NCT02434406|Anxiety
918176|NCT02434406|Anxiety disorders
918177|NCT02434406|Mental health
918178|NCT02434406|Postpartum period
918179|NCT02434406|maternal welfare
918180|NCT02434406|internet
918181|NCT02434406|intervention studies
918182|NCT02434406|feasibility studies
918183|NCT02434406|randomized controlled trial
918184|NCT02434406|patient acceptance of health care
918185|NCT02434393|Depression
918186|NCT02434393|Late Life Depression
918187|NCT02434393|LLD
918188|NCT02434393|amyloid imaging
918189|NCT02434393|biomarkers
918190|NCT02434380|Vitamin D
918191|NCT02434380|Bone mineral content
918192|NCT02434380|Knee-heel length
918193|NCT02434380|Middle East
918194|NCT02434367|Cancer
918195|NCT02434354|Clinical stage III (nodal and/or intransit disease) or resectable stage IV melanoma (MEL), with or without prior treatment
918196|NCT02434328|AMD
918197|NCT02434328|CNV
918198|NCT02434328|IVT
918199|NCT02434315|Diabetes Mellitus
918200|NCT02434315|Sensing Technology
918201|NCT02434289|Older adults
918202|NCT02434289|Dietary protein
918203|NCT02434289|Resistance exercise
918204|NCT02434289|Feasibility study
918205|NCT02434289|Physical functioning
918206|NCT02434289|Real-life setting
918216|NCT02434198|pulmonary rehabilitation
918217|NCT02434198|balance assessment
918218|NCT02434198|Chronic Obstructive Pulmonary Disease
918219|NCT02434185|Musculoskeletal Physiological Phenomena
918220|NCT02434185|Postmenopause
918221|NCT02434185|Muscle Strength
918222|NCT02434185|Absorptiometry, Photon
918223|NCT02434172|HIV
918224|NCT02434172|Cryptococcus
918225|NCT02434172|Lateral Flow Assay
918226|NCT02434172|sub-Saharan Africa
918227|NCT02434172|Screening
918228|NCT02434172|treatment
918229|NCT02434172|cryptococcal meningitis
918230|NCT02434120|MRI
918231|NCT02434120|Orbital neoplasm
918232|NCT02434107|Sentinel Lymph Node Biopsy
918233|NCT02434107|Lymph Node Excision
918234|NCT02434094|Diabetes Assistant (DiAs)
918235|NCT02434094|Continuous Glucose Monitor (CGM)
918236|NCT02434094|Insulin Pump
918237|NCT02434094|Human Factors
918238|NCT02434094|Focus Group
918239|NCT02434094|Artificial Pancreas (AP)
918240|NCT02434094|eDAPT (electronic Diabetes Artificial Pancreas Training)
918241|NCT02434081|NSCLC
918242|NCT02434081|IIIA/B
918243|NCT02434068|kidney calculi
918244|NCT02434068|followup studies
918245|NCT02434042|probiotic
918246|NCT02434042|children
918247|NCT02434042|gastrointestinal
918248|NCT02434042|upper respiratory
918249|NCT02434016|Diaphragm
918250|NCT02434016|Mechanical ventilation
918251|NCT02434003|3D reconstruction
918252|NCT02434003|AIS
918253|NCT02434003|Computer models
918254|NCT02434003|Spinal Deformity
918255|NCT02433990|Congenital Heart Disease
918256|NCT02433990|Acquired Cardiovascular Disease
918263|NCT02433964|laser
918264|NCT02433964|LED
918265|NCT02433964|PRICE
918266|NCT02433964|pain
918267|NCT02433964|edema
918268|NCT02433951|exercise tolerance
918269|NCT02433925|resveratrol
918270|NCT02433925|oxidative stress
918271|NCT02433925|inflammation
918272|NCT02433873|Microbiota
918273|NCT02433873|Body weight
918274|NCT02433873|Digestive system
918275|NCT02433847|mosapride
918276|NCT02433821|Mechanical Neck Pain
918277|NCT02433821|Pain
918278|NCT02433821|Function
918279|NCT02433821|Quality of life
918280|NCT02433821|Pilates
918281|NCT02433795|Marginal zone B-cell lymphoma
918282|NCT02433795|bendamustine plus rituximab
918283|NCT02433782|Haemophilia
918284|NCT02433782|Arthropathy
918285|NCT02433782|Pain
918286|NCT02433782|Range of motion
918287|NCT02433782|Miofascial techniques
918288|NCT02433743|HIV/AIDS
918289|NCT02433743|RUTF
918290|NCT02433743|fat free mass
918291|NCT02433743|anemia
918292|NCT02433743|zinc
918293|NCT02433743|Senegal
918294|NCT02433717|schizophrenia
918295|NCT02433717|schizoaffective disorder
918296|NCT02433717|pharmacogenetics
918297|NCT02433717|pharmacokinetics
918298|NCT02433717|event-related potentials
918299|NCT02433717|paliperidone
918300|NCT02433691|(An)aerobic exercise
918301|NCT02433691|memory training
918302|NCT02433691|cognitive benefits
918303|NCT02433652|Dengue Vaccine
918304|NCT02433639|advanced biliary tract cancer, TH-302
918305|NCT02433613|Pulmonary Vein Isolation
918306|NCT02433613|Phased Radiofrequency Ablation
918307|NCT02433574|radiosurgery
918308|NCT02433574|Neoadjuvant Therapy
918309|NCT02433548|Analgesia
918310|NCT02433548|Emergency medicine
918311|NCT02433548|Anesthesia, Regional
918315|NCT02433522|ANCA-associated vasculitides
918316|NCT02433522|Maintenance treatment
918317|NCT02433522|Rituximab
918318|NCT02433522|Granulomatosis with polyangiitis
918319|NCT02433522|Microscopic polyangiitis
918320|NCT02433509|acute ischemic stroke
918321|NCT02433509|umbilical cord blood
918322|NCT02433496|Opioid
918323|NCT02433483|Adolescent
918324|NCT02433483|Children
918325|NCT02433483|Microtransplant
918326|NCT02433483|Leukemia
918327|NCT02433457|Healthy Volunteers
918328|NCT02433457|CC-292
918329|NCT02433457|Open-Label
918330|NCT02433457|Bioavailability Pharmacokinetics
918331|NCT02433457|Phase I
918332|NCT02433444|Biosensing Techniques
918333|NCT02433431|mindfulness
918334|NCT02433431|psychological stress
918335|NCT02433431|immune marker
918336|NCT02433431|wellness programs
918337|NCT02433431|mobile applications
918338|NCT02433431|cortisol
918339|NCT02433405|Serum Amyloid A
918340|NCT02433405|Fetuin-A
918341|NCT02433405|gingival crevicular fluid
918342|NCT02433405|serum
918343|NCT02433405|periodontal diseases
918344|NCT02433392|drug-eluting beads
918345|NCT02433392|irinotecan hydrochloride
918346|NCT02433353|PTSD
918347|NCT02433353|posttraumatic stress disorder
918348|NCT02433353|venlafaxine
918349|NCT02433353|EMDR
918350|NCT02433353|eye movement desensitization reprocessing
918351|NCT02433353|antidepressant
918352|NCT02433353|psychotherapy
918353|NCT02433340|Tolerability
918354|NCT02433340|Methotrexate
918355|NCT02433340|Safety
918356|NCT02433327|Paediatric Early Warning System
918357|NCT02433327|trigger tool
918358|NCT02433327|screening tool
918359|NCT02433327|risk assessment
918360|NCT02433327|early recognition
918361|NCT02433301|chemotherapy
918362|NCT02433301|GEJ cancer
918363|NCT02433301|PET/MR-imaging
918364|NCT02433288|smart phone-based
918365|NCT02433288|rosuvastatin
918366|NCT02433288|duration of treatment
918367|NCT02433288|Treatment adherence
918368|NCT02433223|outreach nursing
918369|NCT02433223|respiratory nursing guidelines
918370|NCT02433197|Testicular cancer
918371|NCT02433197|Germ cell cancer
918372|NCT02433197|Physical exercise
918373|NCT02433197|Cancer-related fatigue
918374|NCT02433197|Chemotherapy
918375|NCT02433197|Clinical rules
918376|NCT02433197|Metabolomics
918377|NCT02433184|Etanercept
918378|NCT02433184|treat to target
918379|NCT02433184|Disease Modifying Antirheumatic Drugs (DMARDs)
918380|NCT02433171|regrowth
918381|NCT02433171|radiosurgery
918382|NCT02433171|radiation necrosis
918388|NCT02433145|ADHD in preschoolers
918389|NCT02433145|neuropsychological functions
918390|NCT02433145|behavior inhibition
918391|NCT02433145|family function and parenting
918392|NCT02433132|Cystic fibrosis
918393|NCT02433132|Adults
918394|NCT02433132|Atypical form
918395|NCT02433132|Nasal brushing
918396|NCT02433132|Epithelial cells
918397|NCT02433132|Ion transport
918398|NCT02433106|Balance
918399|NCT02433106|Exercise
918400|NCT02433054|deep vein thrombosis
918401|NCT02433054|chronic venous disease
918402|NCT02433054|May-Thurner syndrome
918403|NCT02433054|venous stent
918404|NCT02433041|Postoperative delirium
918405|NCT02433041|Cortisol
918406|NCT02433041|NSE
918407|NCT02433041|S-100beta
918408|NCT02433041|MMSE
918409|NCT02433041|Nu-DESC
918410|NCT02433041|ICDSC
918411|NCT02433041|DOS
918412|NCT02433041|Haloperidol
918413|NCT02433041|Ketamine
918414|NCT02433041|Combination of Haloperidol and Ketamine
918415|NCT02433041|Placebo
918416|NCT02433041|Prevention of
918417|NCT02433028|MS key phases of disease evolution
918418|NCT02433028|MS New Treatment Options
918420|NCT02433002|eGFR
918421|NCT02433002|CKD
918422|NCT02433002|Cystatin
918423|NCT02433002|Creatinine
918424|NCT02433002|Albuminuria
918425|NCT02432989|Exercise Therapy
918426|NCT02432989|Concussion Management
918427|NCT02432989|Concussion Recovery
918428|NCT02432976|Quality of Life
918429|NCT02432976|Cardiac Surgery
918430|NCT02432976|Coronary Artery Bypass Graft Surgery
918431|NCT02432976|Incretin mimetic
918432|NCT02432976|Exenatide
918433|NCT02432937|Corever
918434|NCT02432937|hypertension
918435|NCT02432885|cardiac magnetic resonance
918436|NCT02432885|myocardial fibrosis
918437|NCT02432885|muscular dystrophies
918438|NCT02432820|Prostate Cancer
918439|NCT02432768|Anaplerotic diet
918440|NCT02432768|McArdle Disease
918441|NCT02432768|Glycogen Storage Disease
918442|NCT02432768|Triheptanoin
918443|NCT02432755|home-based rehabilitation
918444|NCT02432755|stroke
918445|NCT02432755|combination therapy
918446|NCT02432755|client-centered approach
918447|NCT02432755|post-acute
918448|NCT02432742|hyaluronic acid, comparative study, NLF
918449|NCT02432729|smoking cessation
918450|NCT02432729|smoking abstinence
918451|NCT02432729|clinical, biological and functional changes
918452|NCT02432729|one year
918453|NCT02432729|healthy smokers
918454|NCT02432729|quit smoking
918455|NCT02432703|Social Anxiety Disorder
918456|NCT02432703|JNJ-42165279
918457|NCT02432690|Neoplasms
918458|NCT02432677|tDCS
918459|NCT02432677|Opioid
918460|NCT02432677|Pain
918461|NCT02432677|Pain threshold
918462|NCT02432651|oxidative stress
918463|NCT02432651|hops
918464|NCT02432651|xanthohumol
918465|NCT02432651|DNA damage
918466|NCT02432651|cancer
918467|NCT02432625|Osteogenesis Imperfecta
918468|NCT02432625|Collagen
918469|NCT02432625|Brittle Bone Disorder
918470|NCT02432625|Rare Disease Clinical Research Network
918471|NCT02432625|COL1A2
918472|NCT02432599|F18-choline
918477|NCT02432573|timing
918478|NCT02432560|Lymphangioleiomyomatosis
918479|NCT02432560|LAM
918480|NCT02432560|rare lung
918481|NCT02432560|Rare Lung Disease
918482|NCT02432547|Diabetic
918483|NCT02432547|Macular Oedema
918484|NCT02432547|Retinopathy
918485|NCT02432521|stroke
918486|NCT02432521|transcranial magnetic stimulation (TMS)
918487|NCT02432521|Electroencephalography (EEG)
918488|NCT02432521|Cerebrovascular Accident
918489|NCT02432521|Brain Vascular Accident
918490|NCT02432508|acupuncture
918491|NCT02432508|laser
918492|NCT02432508|uremic pruritus
918493|NCT02432508|randomized clinical trial
918494|NCT02432482|Tobacco
918495|NCT02432482|Cigarette
918496|NCT02432482|HIV
918497|NCT02432482|Treatment
918498|NCT02432482|Mobile
918499|NCT02432482|Smartphone
918500|NCT02432469|coronary artery bypass
918501|NCT02432469|medication adherence
918502|NCT02432469|secondary prevention
918503|NCT02432469|mobile applications
918504|NCT02432443|Motor Skills
918505|NCT02432443|Pre-literacy Skills
918506|NCT02432443|Early Intervention
918507|NCT02432430|N05.300.150.410
918508|NCT02432430|practice guideline
918509|NCT02432430|D20.215.894.899.290.130
918510|NCT02432430|Health Knowledge, Attitudes, Practice
918511|NCT02432417|Glioblastoma
918512|NCT02432417|Autophagy
918513|NCT02432417|EGFR
918514|NCT02432417|EGFRvIII
918515|NCT02432417|Chloroquine
918516|NCT02432417|Radiotherapy
918517|NCT02432417|Temozolomide
918518|NCT02432404|HSV-2
918519|NCT02432404|Contraceptive Vaginal Ring
918520|NCT02432365|Paclitaxel
918521|NCT02432365|Cisplatin
918522|NCT02432365|Cervical cancer
918523|NCT02432365|Radical hysterectomy
918524|NCT02432365|Neoadjuvant
918525|NCT02432339|immune system
918526|NCT02432339|RENIN-ANGIOTENSIN SYSTEM
918527|NCT02432326|Neoplasms
918528|NCT02432300|Traumatic Brain Injury
918529|NCT02432300|Alexithymia
918530|NCT02432300|Emotions
918534|NCT02432274|E7080
918535|NCT02432274|Lenvatinib
918536|NCT02432274|Solid malignancies
918537|NCT02432274|Osteosarcoma
918538|NCT02432274|Differentiated Thyroid Cancer
918539|NCT02432261|spermatogenesis
918540|NCT02432261|androgen
918541|NCT02432261|male contraception
918542|NCT02432248|DHEA
918543|NCT02432248|live birth rate
918544|NCT02432248|poor ovarian responder
918545|NCT02432196|Mitral Valve Repair
918546|NCT02432196|Transapical
918547|NCT02432196|artificial chordae
918548|NCT02432183|individual
918549|NCT02432144|MPS 7
918550|NCT02432144|Sly Syndrome
918551|NCT02432144|MPS VII
918552|NCT02432144|Enzyme Replacement Therapy
918553|NCT02432144|Rare Disease
918554|NCT02432144|Mucopolysaccharidosis Type 7
918555|NCT02432144|Lysosomal Storage Disease
918556|NCT02432144|Metabolic Disorder
918557|NCT02432092|Cardiomegaly
918558|NCT02432092|Cardiovascular Diseases
918559|NCT02432092|Heart Diseases
918560|NCT02432092|Systolic dysfunction
918561|NCT02432092|Diastolic dysfunction
918562|NCT02432092|Ventricular hypertrophy
918563|NCT02432092|Heart failure
918564|NCT02432079|Abnormalities, Multiple
918565|NCT02432079|Asplenia
918566|NCT02432079|Bilary Atresia
918567|NCT02432079|Birth Defect
918568|NCT02432079|Cardiovascular Abnormalities
918569|NCT02432079|Cardiovascular Diseases
918570|NCT02432079|Congenital Abnormalities
918571|NCT02432079|Congenital Heart Disease
918572|NCT02432079|Dextrocardia Syndrome
918573|NCT02432079|Disturbed Internal Organ Positioning
918574|NCT02432079|Genetics
918575|NCT02432079|Genetic Testing
918576|NCT02432079|Heart Defects, Congenital
918577|NCT02432079|Heart Diseases
918578|NCT02432079|Heterotaxy syndrome
918579|NCT02432079|Intestinal malrotation
918580|NCT02432079|Laterality
918581|NCT02432079|Left Atrial Isomerism
918582|NCT02432079|Pediatrics
918583|NCT02432079|Polysplenia
918584|NCT02432079|Right Atrial Isomerism
918585|NCT02432079|Splenic Diseases
918586|NCT02432079|Cilia
918587|NCT02432079|Situs inversus
918588|NCT02432079|Dextrocardia
918589|NCT02432066|Smoking
918590|NCT02432066|Smoking Cessation
918591|NCT02432053|FK506
918592|NCT02432053|Advagraf
918593|NCT02432053|Tacrolimus
918594|NCT02432053|Transplantation
918595|NCT02432040|chronic plaque psoriasis
918596|NCT02432040|psoriasis
918597|NCT02432040|atorvastatin
918598|NCT02432040|psoriasis area and severity index
918599|NCT02432040|betamethasone valerate
918600|NCT02431988|Relapsed
918601|NCT02431988|refractory
918602|NCT02431988|DLBCL
918603|NCT02431975|HIV
918604|NCT02431975|infant
918605|NCT02431975|antiretroviral therapy, highly active
918606|NCT02431975|antiretroviral agents
918607|NCT02431962|Lung Cancer
918608|NCT02431962|Screening
918609|NCT02431962|Computed Tomography
918610|NCT02431949|Music
918611|NCT02431949|Amusia
918612|NCT02431936|Stress
918613|NCT02431936|Blood Pressure
918614|NCT02431936|Salt Sensitivity
918615|NCT02431936|Renin-Angiotensin-Aldosterone System
918616|NCT02431936|Sympathetic Nervous System
918617|NCT02431923|Sequelae
918618|NCT02431923|Seroprevalence
918619|NCT02431923|Household Contacts
918620|NCT02431910|Electromyography
918621|NCT02431910|Baropodometry
918622|NCT02431910|Torque
918623|NCT02431897|Pelvic Organ Prolapse
918624|NCT02431897|Pelvic Floor Disorders
918625|NCT02431897|Therapy, Estrogen Replacement
918626|NCT02431897|Estrogens, Conjugated
918627|NCT02431871|Developmental dysplasia of the hip
918628|NCT02431871|Hip dysplasia
918629|NCT02431871|Occlusal defect
918630|NCT02431858|Nerve block
918631|NCT02431858|Catheter
918632|NCT02431858|Catheter over needle
918633|NCT02431858|Femoral Nerve
918634|NCT02431858|Anaesthesia
918635|NCT02431858|[E04.525.210.550]
918636|NCT02431858|[E02.148]
918637|NCT02431845|Obsessive-Compulsive Disorder
918638|NCT02431845|Pharmacogenetics
918639|NCT02431832|Elderly
918640|NCT02431819|Peripheral Arterial Disease
918641|NCT02431819|Progressive compressive stockings
918642|NCT02431793|Opioids
918643|NCT02431780|Neonatal Seizures
918644|NCT02431780|Decision Support Algorithm
918645|NCT02431780|EEG
918646|NCT02431741|Presence of at least one exuding malignant (fungating) wound in need for antimicrobial treatment
918647|NCT02431728|Melatonin
918648|NCT02431728|Post-acute withdrawal symptoms
918649|NCT02431728|Anxiety
918650|NCT02431728|Depression
918651|NCT02431728|Insomnia
918652|NCT02431728|Stress
918653|NCT02431728|Substance withdrawal syndrome
918654|NCT02431702|Paliperidone Palmitate
918655|NCT02431702|Oral Antipsychotics
918656|NCT02431702|Schizophrenia
918657|NCT02431702|Psychotic Disorders
918658|NCT02431702|Cognition in Schizophrenia
918659|NCT02431702|Brain intracortical myelin volume
918660|NCT02431702|Personal and Social Performance
918661|NCT02431702|Disease Modification
918662|NCT02431663|refractory convulsive status epilepticus
918663|NCT02431663|ketamine
918664|NCT02431663|conventional anesthetics
918665|NCT02431663|children
918666|NCT02431650|Induced blood stage malaria
918667|NCT02431650|Transmission
918668|NCT02431650|Mosquito feeding
918669|NCT02431650|OZ439
918670|NCT02431650|Primaquine
918671|NCT02431650|Piperaquine
918672|NCT02431650|Artefonomel
918673|NCT02431637|Induced blood stage malaria
918674|NCT02431637|Transmission
918675|NCT02431637|Standard membrane feeding assay
918676|NCT02431624|Healthy Volunteer
918677|NCT02431585|abdominal pain
918678|NCT02431585|gluten free diet
918679|NCT02431585|functional gastrointestinal disorders
918680|NCT02431572|Intracranial Tumors
918681|NCT02431572|Glioblastoma
918682|NCT02431572|Melanoma
918683|NCT02431559|Ovarian Cancer
918684|NCT02431559|Motolimod
918685|NCT02431559|Immunotherapy
918686|NCT02431559|PD-L1
918687|NCT02431559|MEDI4736
918688|NCT02431559|Pegylated
918689|NCT02431559|Liposomal
918690|NCT02431559|Doxorubicin
918691|NCT02431559|PLD
918692|NCT02431559|TLR-8
918693|NCT02431559|Durvalumab
918694|NCT02431546|Cardiology
918695|NCT02431546|Vascular
918696|NCT02431546|CAD
918697|NCT02431546|Duke
918698|NCT02431546|Cardiac Rehabilitation
918699|NCT02431546|Prevention
918700|NCT02431546|CVD
918701|NCT02431546|Mobile Health
918702|NCT02431546|Exercise
918703|NCT02431533|IBS-D
918704|NCT02431533|diarrhea predominant
918705|NCT02431520|Patient Compliance
918706|NCT02431520|HPV-DNA probes
918707|NCT02431520|Papanicolaou test
918708|NCT02431520|Cervical cancer
918709|NCT02431507|apnea
918710|NCT02431507|sleep apnea
918711|NCT02431507|magnetic sleep apnea device
918712|NCT02431507|hyoid bone
918713|NCT02431455|Bariatric Surgery
918714|NCT02431455|obesity, morbid
918715|NCT02431455|incentive spirometry
918716|NCT02431442|Heterozygous
918717|NCT02431442|MC4R deficiency
918718|NCT02431442|associated
918719|NCT02431429|leishmaniasis
918720|NCT02431429|miltefosine
918721|NCT02431429|spermiogram
918722|NCT02431416|females
918723|NCT02431416|ghrelin
918724|NCT02431416|GnRH
918725|NCT02431416|randomized, controlled study
918726|NCT02431416|children
918727|NCT02431390|RAPAELⓇ Smart Glove digital treatment system
918728|NCT02431390|Rehabilitation
918729|NCT02431390|Stroke
918730|NCT02431390|Upper limbs
918731|NCT02431377|infant formula
918732|NCT02431364|KPT-335
918733|NCT02431364|Verdinexor
918734|NCT02431364|Karyopharm
918735|NCT02431364|First-in-Human
918736|NCT02431364|Adult Subjects
918737|NCT02431351|KPT-330
918738|NCT02431351|Karyopharm
918739|NCT02431351|Selinexor
918740|NCT02431351|SIER
918741|NCT02431351|Myelodysplastic Syndrome (MDS)
918742|NCT02431351|Erythropoietin (EPO)
918743|NCT02431351|Refractory
918744|NCT02431338|Remote ischemic conditioning
918745|NCT02431338|Cost-effectiveness analysis
918746|NCT02431325|HIV
918747|NCT02431325|Atherosclerosis
918748|NCT02431325|Microbial Translocation
918749|NCT02431325|Teduglutide
918750|NCT02431325|Gastrointestinal Permeability
918751|NCT02431325|Inflammation
918752|NCT02431312|Chronic HBV
918753|NCT02431312|immunotherapy
918754|NCT02431312|DNA vaccine
918755|NCT02431312|electroporation
918756|NCT02431286|nausea and vomiting, postoperative
918757|NCT02431286|emesis, postoperative
918758|NCT02431273|TDF
918759|NCT02431273|FTC
918760|NCT02431273|MVC
918761|NCT02431273|TDF-FTC
918762|NCT02431273|TDF-FTC-MVC
918763|NCT02431273|IVR
918764|NCT02431273|ARV
918765|NCT02431260|solid tumor
918766|NCT02431260|lymphoma
918767|NCT02431260|BET bromodomain inhibitor
918768|NCT02431260|BRD
918769|NCT02431260|Diffuse large B-cell lymphoma (DLBCL)
918770|NCT02431260|Burkitt's lymphoma
918771|NCT02431260|c-MYC
918772|NCT02431260|colorectal cancer
918773|NCT02431260|Non-small cell lung cancer
918774|NCT02431260|Pancreatic adenocarcinoma
918775|NCT02431260|castration-resistant prostate cancer
918776|NCT02431260|breast cancer
918777|NCT02431260|NUT midline carcinoma
918778|NCT02431260|leukemia
918779|NCT02431260|acute myeloid leukemia (AML)
918780|NCT02431260|atypical chronic myeloid leukemia (aCML)
918781|NCT02431260|myelodysplastic syndrome (MDS)
918782|NCT02431260|myeloproliferative neoplasms
918783|NCT02431260|myelofibrosis (MF)
918784|NCT02431260|multiple myeloma (MM)
918785|NCT02431260|CMML
918786|NCT02431260|MDS/MPN-U
918787|NCT02431260|RARS-T
918788|NCT02431247|Immunodeficiency Virus Type 1, Human
918789|NCT02431247|Darunavir
918790|NCT02431247|Cobicistat
918791|NCT02431247|Tenofovir Alafenamide
918792|NCT02431247|Emtricitabine
918793|NCT02431247|Tenofovir Disoproxil Fumarate
918794|NCT02431234|Type 2 diabetes
918795|NCT02431234|Arterial calcification
918796|NCT02431234|Mediacalcosis
918797|NCT02431234|Calcium score
918798|NCT02431221|perhexiline
918799|NCT02431221|HCM
918800|NCT02431221|Hypertrophic Cardiomyopathy
918801|NCT02431221|CPEX
918802|NCT02431195|obesity
918803|NCT02431195|bariatric surgery
918804|NCT02431195|physical activity
918805|NCT02431195|eating habits
918806|NCT02431156|presbyopia
918807|NCT02431156|monovision
918808|NCT02431156|activities of daily living,
918809|NCT02431156|pseudophakic
918810|NCT02431130|Training Program
918811|NCT02431091|Optical Coherence Tomography
918812|NCT02431078|CTCs
918813|NCT02431078|ZEB1
918814|NCT02431078|gastric cancer
918815|NCT02431065|Rectus sheath block
918816|NCT02431065|Single port laparoscopy
918817|NCT02431026|induced mild hypothermia
918818|NCT02431026|cervical cooling collar
918819|NCT02431026|mri brain thermometry
918820|NCT02431026|MRI thermometry
918821|NCT02431026|rate-of-cooling
918822|NCT02431026|Excel Cryo Cooling Collar
918823|NCT02431013|Drug-drug interaction
918824|NCT02431013|Pharmacokinetics
918825|NCT02430961|Critical Care
918826|NCT02430961|Palliative Care
918827|NCT02430948|Screening
918828|NCT02430948|Shared Decision Making
918829|NCT02430935|Psychosis
918830|NCT02430935|Psychosis NOS
918831|NCT02430935|Schizophrenia
918832|NCT02430935|Schizoaffective Disorder
918833|NCT02430935|Early Intervention
918834|NCT02430896|Neuropsychological
918835|NCT02430896|neuroimaging
918836|NCT02430896|genetic markers
918837|NCT02430896|treatment response predictor
918838|NCT02430883|pain, RIRS, kidney
918839|NCT02430870|Drug therapy
918840|NCT02430844|acute kidney injury
918841|NCT02430844|radiographic contrast
918842|NCT02430844|critically ill
918843|NCT02430844|biomarker
918844|NCT02430818|ketamine
918845|NCT02430818|emergency medicine
918846|NCT02430818|orthopedics
918847|NCT02430805|hypertension
918848|NCT02430805|microinflammation and oxidative stress
918849|NCT02430805|renal disease
918850|NCT02430805|heart failure
918851|NCT02430805|genetics markers
918852|NCT02430805|genomics markers
918853|NCT02430805|proteomics markers
918854|NCT02430792|Prostatic Neoplasms
918855|NCT02430792|Exercise
918856|NCT02430792|Football
918857|NCT02430792|Quality of Life
918858|NCT02430779|irreversible electroporation
918859|NCT02430779|Unresectable Renal Pelvic and Ureteral Neoplasms
918860|NCT02430766|irreversible electroporation
918861|NCT02430766|Unresectable Lymph Node Metastases
918862|NCT02430753|irreversible electroporation
918863|NCT02430753|Lung Neoplasms
918864|NCT02430753|Respiratory Function Insufficiency
918865|NCT02430740|Fertilization in Vitro
918866|NCT02430740|antagonist protocol
918867|NCT02430740|antral follicle count
918868|NCT02430740|Anti-Mullerian Hormone
918869|NCT02430740|Reproductive Techniques, Assisted
918870|NCT02430714|Thyroid Cancer
918871|NCT02430714|Lenvima
918872|NCT02430714|Post-marketing surveillance
918873|NCT02430714|LEN01T
918874|NCT02430714|All-Patient Investigation
918875|NCT02430714|Lenvatinib Mesylate
918876|NCT02430701|irreversible electroporation
918877|NCT02430701|Unresectable Esophageal Neoplasms
918878|NCT02430688|irreversible electroporation
918879|NCT02430688|Unresectable Extremities
918880|NCT02430675|irreversible electroporation
918881|NCT02430675|Unresectable Laryngeal Neoplasms
918882|NCT02430662|irreversible electroporation
918883|NCT02430662|Unresectable Gallbladder Neoplasms
918884|NCT02430649|irreversible electroporation
918885|NCT02430649|Unresectable Prostatic Neoplasms
918886|NCT02430636|irreversible electroporation
918887|NCT02430636|Unresectable Stomach Neoplasms
918888|NCT02430623|irreversible electroporation
918889|NCT02430623|Unresectable Urinary Neoplasms
918890|NCT02430610|irreversible electroporation
918891|NCT02430610|Unresectable Uterine Cervical Neoplasms
918892|NCT02430597|irreversible electroporation
918893|NCT02430597|Hilus Pulmonary Neoplasms
918894|NCT02430545|Glasdegib
918895|NCT02430545|PF-04449913
918896|NCT02430545|Drug-drug interaction
918897|NCT02430545|CYP3A4 inducer
918898|NCT02430545|Pharmacokinetics
918899|NCT02430532|INSPIRE
918900|NCT02430532|SPMS
918901|NCT02430532|Tecfidera
918902|NCT02430532|BG00012
918903|NCT02430519|Chronic Periodontitis
918904|NCT02430519|Clinical Parameters
918905|NCT02430519|Furcation defects
918906|NCT02430519|Radiographic bone fill
918907|NCT02430493|ACS
918908|NCT02430480|Multiparametric MRI
918909|NCT02430480|Prostatectomy
918910|NCT02430480|Focal Prostate Cancer
918911|NCT02430480|Normal Testosterone
918912|NCT02430480|Non Metastatic
918913|NCT02430454|ICU
918914|NCT02430454|decision making
918915|NCT02430402|Climatotherapy
918916|NCT02430389|hemodynamic stability
918917|NCT02430389|remifentanil
918918|NCT02430376|Non-Muscle Myosin
918919|NCT02430363|pembrolizumab
918920|NCT02430363|MK-3475
918921|NCT02430363|Glioblastoma
918922|NCT02430363|Gliosarcoma
918923|NCT02430363|Suppressor of the PI3K/Akt pathways
918924|NCT02430363|Pictilisib
918925|NCT02430363|GDC-0941
918926|NCT02430363|BEZ235
918927|NCT02430363|NVP-BEZ235
918928|NCT02430363|Ipatasertib
918929|NCT02430363|GDC-0068
918930|NCT02430311|Chinese Patients
918931|NCT02430285|biliary stone
918932|NCT02430285|cholelithiasis
918933|NCT02430285|pancreatitis
918934|NCT02430285|EUS
918935|NCT02430285|ERCP
918936|NCT02430285|early
918937|NCT02430285|choledocholithiasis
918938|NCT02430272|Child
918939|NCT02430272|outpatient
918940|NCT02430272|premedication
918941|NCT02430259|rifapentine
918942|NCT02430259|isoniazid
918943|NCT02430259|QuantiFERON Gold In-Tube
918944|NCT02430259|tuberculin skin test
918945|NCT02430207|Pulmonary Embolism
918946|NCT02430207|Temporary Pacing
918947|NCT02430207|Femoral Vein
918948|NCT02430207|Subclavian Vein
918949|NCT02430168|Stone
918950|NCT02430168|RIRs
918951|NCT02430168|PCNL
918952|NCT02430168|Pain
918953|NCT02430155|condom-loaded Foley's catheter
918954|NCT02430155|Bakri balloon
918955|NCT02430155|primary atonic postpartum hemorrhage
918956|NCT02430142|microcirculation
918957|NCT02430142|oxygen uptake
918958|NCT02430142|hypoxia
918959|NCT02430142|adenosine
918960|NCT02430142|central venous saturation
918961|NCT02430142|hypoxanthine
918962|NCT02430142|laserdoppler
918963|NCT02430103|Breast Cancer
918964|NCT02430103|Preservation of Ovarian Reserve Function
918965|NCT02430090|regionel anesthesia
918966|NCT02430090|levobupivacaine
918967|NCT02430090|ceserean section
918968|NCT02430077|Hepatic Steatosis
918969|NCT02430051|sensory processing
918970|NCT02430051|oral care
918971|NCT02430051|electrodermal activity
918972|NCT02430051|cooperation
918973|NCT02430051|anxiety
918974|NCT02430051|distress
918975|NCT02430051|stress
918976|NCT02430051|behavior
918977|NCT02430051|occupational therapy
918978|NCT02430038|transperineal ultrasound
918979|NCT02430038|labour
918980|NCT02430038|sonopartogram
918981|NCT02430038|prediction model
918982|NCT02430025|Cardiovascular Diseases
918983|NCT02430025|Vascular Diseases
918984|NCT02430025|Acute Coronary Syndrome
918985|NCT02430025|Chest Pain
918986|NCT02430025|Heart Diseases
918987|NCT02430025|Myocardial Ischemia
918988|NCT02430025|Pathologic Processes
918989|NCT02430012|coronary artery bypass grafting
918990|NCT02430012|quality improvement
918991|NCT02430012|secondary preventions
918992|NCT02429986|Adaptive Servo-Ventilation
918993|NCT02429986|Chronic Heart Failure
918994|NCT02429986|Central Sleep Apnea Syndrome
918995|NCT02429986|Central and Obstructive Sleep Apnea Syndrome
918996|NCT02429986|Complex Sleep Apnea Syndrome
918997|NCT02429986|Hunter-Cheyne-Stokes Breathing
918998|NCT02429986|Periodic Breathing
918999|NCT02429973|Osteosarcoma
919000|NCT02429960|Nociception
919001|NCT02429960|Analgesia
919002|NCT02429960|Intraoperative
919003|NCT02429960|Monitoring
919004|NCT02429947|Charcot Marie Tooth disease
919005|NCT02429947|CMT
919006|NCT02429947|HMSN
919007|NCT02429947|HMN
919008|NCT02429947|HSN
919009|NCT02429934|Systemic Lupus Erythematosus (SLE)
919010|NCT02429934|Abatacept (Orencia)
919011|NCT02429934|Arthritis
919012|NCT02429921|dietary intervention
919013|NCT02429921|arsenic poisoning
919014|NCT02429921|high-Se lentils
919015|NCT02429895|Methotrexate
919016|NCT02429895|Efficacy
919017|NCT02429895|Safety
919018|NCT02429882|Ankylosing Spondyloarthritis; non-radiographic axial spondyloarthritis
919019|NCT02429843|Non-squamous cell lung cancer
919020|NCT02429843|Non-squamous non-small cell lung cancer
919021|NCT02429843|vascular endothelial growth factor (VEGF)
919022|NCT02429843|TRC105
919023|NCT02429830|gastroesophageal reflux disease
919024|NCT02429830|GERD
919025|NCT02429830|obesity
919026|NCT02429830|LSG
919027|NCT02429830|Laparoscopic Sleeve Gastrectomy
919028|NCT02429817|Pulmonary aerosol distribution
919029|NCT02429817|SPECT-CT analysis
919030|NCT02429817|High flow nasal cannula
919031|NCT02429817|Vibrating-mesh nebulizer
919032|NCT02429817|Jet nebulizer
919033|NCT02429791|two-drug regimen
919034|NCT02429791|virologically-suppressed
919035|NCT02429791|dolutegravir plus rilpivirine
919036|NCT02429791|integrase inhibitor
919037|NCT02429791|protease inhibitor
919038|NCT02429791|NNRTI-sparing
919039|NCT02429791|non-nucleoside reverse transcriptase inhibitor
919040|NCT02429791|HIV
919041|NCT02429791|nucleoside reverse transcriptase inhibitors
919042|NCT02429752|inspiratory muscle training
919043|NCT02429752|low back pain
919044|NCT02429752|respiration
919045|NCT02429752|breathing
919046|NCT02429739|Working Memory Training, computerized
919047|NCT02429739|Dyslexia
919048|NCT02429739|Reading fluency
919049|NCT02429739|Reading comprehension
919050|NCT02429726|malignant pleural effusion, p53 gene therapy, cisplatin
919051|NCT02429713|tourniquet
919052|NCT02429713|total knee arthroplasty
919053|NCT02429713|blood loss
919054|NCT02429674|Depression
919055|NCT02429674|Adolescence
919056|NCT02429648|AF
919057|NCT02429635|Exercise
919058|NCT02429635|lifestyle diseases
919059|NCT02429635|well-being
919060|NCT02429596|antiepileptic drugs
919061|NCT02429596|generic substitution
919062|NCT02429570|meclofenamate
919063|NCT02429570|15-068
919064|NCT02429557|autonomic failure
919065|NCT02429557|orthostatic hypotension
919066|NCT02429557|compression garments
919067|NCT02429557|treatment
919068|NCT02429544|Breast cancer
919069|NCT02429544|Stage IV breast cancer
919070|NCT02429544|Metastatic
919071|NCT02429544|Residential group programs
919072|NCT02429544|Questionnaires
919073|NCT02429544|Surveys
919074|NCT02429544|EEG
919075|NCT02429544|Computer testing
919076|NCT02429544|Saliva test
919077|NCT02429544|Study diary
919078|NCT02429544|Actigraph
919079|NCT02429531|Pneumovax 23
919080|NCT02429531|Typhim Vi
919081|NCT02429531|allohemagglutinins
919082|NCT02429518|leishmaniasis
919083|NCT02429518|miltefosine
919084|NCT02429518|EKG
919085|NCT02429492|Pathophysiology
919086|NCT02429492|Spinal interneurons
919087|NCT02429492|Electrophysiology
919088|NCT02429492|EMG
919089|NCT02429492|transcranial magnetic stimulation (TMS)
919090|NCT02429479|Advance Care Planning
919091|NCT02429479|Living Will
919092|NCT02429479|Family Caregiver
919093|NCT02429479|Advance Directive
919094|NCT02429479|Surrogate Decision Maker
919095|NCT02429479|Proxy
919096|NCT02429479|Self-Efficacy
919097|NCT02429466|testicular germ cell tumor
919098|NCT02429466|ovarian germ cell tumor
919099|NCT02429466|platinum refractory
919100|NCT02429466|cisplatin
919101|NCT02429466|SGI110
919102|NCT02429466|Guadecitabine
919103|NCT02429453|Warfarin
919104|NCT02429453|Traumatic intracranial hemorrhage
919105|NCT02429453|prothrombin complex concentrate
919106|NCT02429453|fresh frozen plasma
919107|NCT02429453|Spontaneous intracranial hemorrhage
919108|NCT02429427|Primary Breast Cancer
919109|NCT02429427|Celecoxib
919110|NCT02429414|Surgical Procedure
919111|NCT02429414|Fiberoptic bronchoscopy
919112|NCT02429414|FOB
919113|NCT02429414|Non-Video Double Lumen Tube
919114|NCT02429414|DLT
919115|NCT02429414|Video Double Lumen Tube
919116|NCT02429414|VDLT
919117|NCT02429401|binge drinking
919118|NCT02429401|heavy drinking
919119|NCT02429388|Heart failure
919120|NCT02429388|Spironolactone
919121|NCT02429388|Diuretics
919122|NCT02429375|Mocetinostat (MGCD0103)
919123|NCT02429375|Brentuximab Vedotin (SGN-35)
919124|NCT02429375|Relapsed
919125|NCT02429375|Refractory
919126|NCT02429323|induction
919127|NCT02429323|pediatrics
919128|NCT02429323|sevoflurane
919129|NCT02429323|intubation time
919130|NCT02429310|Intermittent Claudication
919131|NCT02429310|IC
919132|NCT02429310|Peripheral Arterial Disease
919133|NCT02429310|Peripheral Vascular Disease
919134|NCT02429310|Peripheral Arterial Occlusive Disease
919135|NCT02429310|Lower Limb Arterial Disease
919136|NCT02429310|Supervised Exercise Therapy
919137|NCT02429310|Supervised Exercise Programme
919138|NCT02429310|Exercise Therapy
919139|NCT02429297|Hypertension
919140|NCT02429297|Diabetes
919141|NCT02429297|mHealth
919142|NCT02429297|Interactive Voice Response
919143|NCT02429297|Bolivia
919144|NCT02429297|Chronic disease
919145|NCT02429284|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
919146|NCT02429284|Pulmonary Endarterectomy (PEA)
919147|NCT02429284|Pulmonary Thromboendarterectomy (PTE)
919148|NCT02429284|Pulmonary Hypertension
919149|NCT02429284|Balloon Pulmonary Angioplasty (BPA)
919150|NCT02429271|undergoing thrombolysis
919151|NCT02429245|Knee
919152|NCT02429245|Knee osteoarthritis
919153|NCT02429245|Knee replacement
919154|NCT02429232|Pioglitazone
919155|NCT02429232|Linagliptin
919156|NCT02429232|Diabetes mellitus
919157|NCT02429232|Diabetic macular edema
919158|NCT02429232|Kidney
919159|NCT02429154|spectroscopy, near-infrared
919160|NCT02429154|Infant
919161|NCT02429154|Anesthesia, general
919162|NCT02429128|Polycystic Ovary Syndrome (PCOS)
919163|NCT02429115|peer mentoring
919164|NCT02429115|chronic kidney disease
919165|NCT02429115|quality of life
919166|NCT02429115|pcori
919167|NCT02429115|caregiver burden
919168|NCT02429102|Phase 1
919169|NCT02429102|Healthy subjects
919170|NCT02429102|Pharmacokinetics of MT-8554
919171|NCT02429089|recurrent
919172|NCT02429089|metastatic
919173|NCT02429063|Solid Tumors
919174|NCT02429050|Chronic Obstructive Pulmonary Disease
919175|NCT02429050|Dyspnea
919176|NCT02429050|Breathlessness
919177|NCT02429050|Morphine
919178|NCT02429050|Opioid
919179|NCT02429050|Symptom Management
919180|NCT02429037|p53
919181|NCT02429037|gene therapy
919182|NCT02429037|head and neck cancer
919183|NCT02429024|Diabetes Mellitus
919184|NCT02429024|A1c
919185|NCT02429011|depression
919186|NCT02429011|MRI
919187|NCT02429011|treatment-resistant
919188|NCT02429011|imaging
919189|NCT02429011|ketamine
919190|NCT02428985|Riociguat
919191|NCT02428985|Adempas
919192|NCT02428985|soluble guanylate cyclase (sGC) stimulator
919193|NCT02428985|Pulmonary arterial hypertension
919194|NCT02428985|Japan
919195|NCT02428985|Post-marketing surveillance
919196|NCT02428972|brain tumor
919197|NCT02428972|quality of life
919198|NCT02428972|cognition
919199|NCT02428972|anesthetic technique
919200|NCT02428959|Amyl Nitrite
919201|NCT02428959|High Resolution Manometry
919202|NCT02428946|Insulin Sensitivity
919203|NCT02428946|obesity
919204|NCT02428946|dopamine
919205|NCT02428933|Brown Adipose Tissue
919206|NCT02428933|Obesity
919207|NCT02428933|Insulin Sensitivity
919208|NCT02428933|Dopamine
919209|NCT02428920|cardiovascular health
919210|NCT02428920|behavior change
919211|NCT02428920|community-based
919212|NCT02428920|prevention
919213|NCT02428907|simulation training
919214|NCT02428907|minimal sedation
919215|NCT02428907|colonoscopy
919216|NCT02428907|patient satisfaction
919217|NCT02428907|teamwork
919218|NCT02428907|team training
919219|NCT02428907|patient safety
919220|NCT02428881|onabotulinumtoxin A
919221|NCT02428868|hip fracture
919222|NCT02428868|anemia
919223|NCT02428868|blood transfusion
919224|NCT02428868|tranexamic acid
919225|NCT02428868|intravenous iron
919226|NCT02428855|Cholangiocarcinoma
919227|NCT02428842|Cervical cancer
919228|NCT02428842|Tumor biopsies
919229|NCT02428842|Standard treatment
919230|NCT02428842|Molecular profile
919231|NCT02428842|Next Generation Sequencing
919232|NCT02428829|hip
919233|NCT02428829|replacement
919234|NCT02428829|arthroplasty
919235|NCT02428829|total
919236|NCT02428829|orthopaedic
919237|NCT02428829|rehabiliation
919238|NCT02428829|physiotherapy
919239|NCT02428829|therapy
919240|NCT02428816|differential diagnosis
919241|NCT02428816|multimodal MRI
919242|NCT02428816|Parkinson's Disease
919243|NCT02428816|Multiple System Atrophy
919244|NCT02428803|Peritoneal Dialysis
919245|NCT02428777|Hysteroscopy
919246|NCT02428751|Lymphoma, Large B-Cell, Diffuse
919247|NCT02428751|liposomal doxorubicin
919248|NCT02428751|doxorubicin
919249|NCT02428751|event-free survival
919250|NCT02428738|Influenza Vaccine
919251|NCT02428738|Text Message
919252|NCT02428673|Osteopenia
919253|NCT02428673|spinal muscular atrophy
919254|NCT02428673|cerebral palsy
919255|NCT02428673|muscular dystrophy
919256|NCT02428673|spina bifida
919257|NCT02428673|Rett Syndrome
919258|NCT02428660|Polypharmacy
919259|NCT02428660|Chronic conditions
919260|NCT02428660|Drug Therapy Problems
919261|NCT02428660|Medication Therapy Management
919262|NCT02428660|Medication-Related Problems
919263|NCT02428660|CYP3A4
919264|NCT02428660|CYP3A5
919265|NCT02428660|Drug-drug interactions
919266|NCT02428660|Drug-gene interactions
919267|NCT02428660|Drug-drug-gene interactions
919268|NCT02428660|Adverse Drug Reactions
919269|NCT02428660|Activities of Daily Living
919272|NCT02428634|Cardiovascular health promotion
919273|NCT02428634|Children
919274|NCT02428634|School intervention
919275|NCT02428621|early orthodontic treatment
919276|NCT02428621|activator
919277|NCT02428621|removable appliance
919278|NCT02428621|Twicare®
919279|NCT02428621|Herbst appliance
919280|NCT02428608|Glabellar Lines
919281|NCT02428608|Botulinum toxin, Type A
919282|NCT02428582|endovascular treatment
919283|NCT02428582|arterial occlusive disease
919284|NCT02428582|bare metal stent
919285|NCT02428582|polytetrafluoroethylene covered stent
919286|NCT02428569|shared decision making
919287|NCT02428569|patient education
919288|NCT02428569|decision aids
919289|NCT02428556|Decision making
919290|NCT02428543|FLT3-ITD patients in first complete remission
919291|NCT02428517|acute lymphoblastic leukemia
919292|NCT02428517|allogeneic hematopoietic stem cell transplantation
919293|NCT02428517|alternative hematopoietic stem cell donor
919294|NCT02428517|busulfan
919295|NCT02428517|antithymocyte globulin
919296|NCT02428504|Questionnaire
919303|NCT02428452|autism
919304|NCT02428452|Autism SPectrum Disorder
919305|NCT02428452|early intervention
919306|NCT02428452|infant
919307|NCT02428452|toddler
919308|NCT02428452|early identification
919309|NCT02428452|pivotal response training (PRT)
919310|NCT02428452|control group
919311|NCT02428452|treatment group
919312|NCT02428452|at risk
919313|NCT02428452|social communication
919314|NCT02428452|positive affect
919315|NCT02428452|smiling
919316|NCT02428439|genetic markers
919317|NCT02428439|predictors
919318|NCT02428439|Antidepressive Agents
919319|NCT02428439|Suicidal Ideation
919320|NCT02428439|Adolescent
919321|NCT02428426|Mucosal Microbiome
919322|NCT02428426|gastric intestinal metaplasia
919323|NCT02428426|duodenum
919324|NCT02428413|Waste Anesthetic Gas (WAG)
919325|NCT02428387|caregivers
919326|NCT02428387|intervention
919327|NCT02428387|health related quality of life
919328|NCT02428387|dementia
919329|NCT02428374|MRI
919330|NCT02428374|Ventricular function, left
919331|NCT02428309|Tregs
919332|NCT02428296|Clinical Trial
919333|NCT02428296|Congenital Malformations
919334|NCT02428296|Overgrowth
919335|NCT02428296|Pilot Drug Treatment Trial
919336|NCT02428257|hip fracture
919337|NCT02428257|elderly
919338|NCT02428257|continous spinal anesthesia
919339|NCT02428257|hypobaric bupivacaine
919340|NCT02428257|isobaric bupivacaine
919341|NCT02428257|hypotension
919342|NCT02428244|Smoking
919343|NCT02428244|Cessation
919344|NCT02428244|Trauma
919345|NCT02428244|Fracture
919346|NCT02428244|Complications
919347|NCT02428218|Randomized
919348|NCT02428218|Ages 10-17
919349|NCT02428218|Pediatrics
919350|NCT02428218|Placebo controlled
919351|NCT02428218|Relapse-Remitting
919352|NCT02428218|Multiple Sclerosis
919353|NCT02428218|Safety
919354|NCT02428218|Efficacy
919355|NCT02428218|BG00012
919356|NCT02428179|Surgical site infection
919357|NCT02428179|Intraoperative briefings
919358|NCT02428179|Mortality
919359|NCT02428179|Wound closure
919360|NCT02428179|Surgical procedure
919361|NCT02428166|crosslinking
919362|NCT02428166|keratoconus
919363|NCT02428166|keratometry
919364|NCT02428166|pachymetry
919365|NCT02428166|pentacam
919366|NCT02428153|static stretching
919367|NCT02428153|dynamic stretching
919368|NCT02428153|muscle-tendon unit
919369|NCT02428153|ultrasound
919370|NCT02428153|Subjects
919371|NCT02428140|ischemic stroke
919372|NCT02428140|atrial fibrillation
919373|NCT02428140|etiologic investigations
919374|NCT02428140|secondary prevention
919375|NCT02428140|anticoagulation
919376|NCT02428140|arrhythmias
919377|NCT02428140|embolic stroke, undetermined etiology
919378|NCT02428140|implantable loop recorder
919379|NCT02428140|external loop recorder
919380|NCT02428062|Post-operative complications
919381|NCT02428062|Mild cognitive impairment
919382|NCT02428062|Delirium
919383|NCT02428036|TBI-1401(HF10)
919384|NCT02428036|HF10
919385|NCT02428036|HSV-1
919386|NCT02428036|Oncolytic virus
919387|NCT02428036|Oncolytic virotherapy
919388|NCT02428036|Phase I
919389|NCT02428036|Melanoma
919390|NCT02428036|Intratumoral administration
919391|NCT02428023|Thalassemia
919392|NCT02428023|trait
919393|NCT02428023|coronary
919394|NCT02428023|stroke
919395|NCT02427997|Virtual Reality
919396|NCT02427997|Treadmill
919397|NCT02427997|Multiple Sclerosis
919398|NCT02427984|Internal Left Hip Prosthesis
919399|NCT02427984|Internal Right Hip Prosthesis
919400|NCT02427958|Drug Therapy
919401|NCT02427945|Information provision
919402|NCT02427932|Pharmacokinetics (PK)
919403|NCT02427932|Pharmacodynamics (PD)
919404|NCT02427919|G-CSF
919405|NCT02427919|G-CSF receptor
919406|NCT02427919|AML
919407|NCT02427919|refractory AML
919408|NCT02427919|Neutropenic fever
919409|NCT02427919|salvage chemotherapy
919410|NCT02427906|cirrhosis
919411|NCT02427906|gut microbiota
919412|NCT02427906|transjugular portosystemic shunt
919413|NCT02427906|hepatic encephalopathy
919414|NCT02427893|immunotherapy
919415|NCT02427893|Vemurafenib
919416|NCT02427893|Cobimetinib
919417|NCT02427880|Edema
919418|NCT02427880|Nephrotic syndrome
919419|NCT02427880|Acetazolamide
919420|NCT02427880|Furosemide
919421|NCT02427867|remote ischemic preconditioning
919422|NCT02427867|non cardiac surgery
919423|NCT02427867|myocardial ischemia
919424|NCT02427854|Major delivery complications
919425|NCT02427854|Perineal injuries
919426|NCT02427854|episiotomy
919427|NCT02427789|Physical exercise
919428|NCT02427789|Biomarkers
919429|NCT02427789|Neuroprotection
919430|NCT02427789|ergospirometry
919431|NCT02427789|Major Depressive Disorder
919432|NCT02427763|Removable Orthodontic Appliance;
919433|NCT02427763|malocclusion
919434|NCT02427763|Streptococcus mutans
919435|NCT02427763|Lactobacillus
919436|NCT02427763|Epithelium
919437|NCT02427737|Magnetic Resonance Imaging
919438|NCT02427737|Patient satisfaction
919439|NCT02427737|Diagnostic Imaging
919440|NCT02427711|Reduction of blood loss for revisions of knee arthroplasty
919441|NCT02427711|blood transfusions
919442|NCT02427711|Readmission
919443|NCT02427711|Bipolar sealer
919444|NCT02427672|antisocial behavior
919445|NCT02427672|aggression
919446|NCT02427672|transcranial direct current stimulation
919447|NCT02427672|dorsolateral prefrontal cortex
919448|NCT02427672|associated risk factors
919449|NCT02427659|VRD
919450|NCT02427659|Virtual Reality as Distraction during Procedure
919451|NCT02427659|Burn Wound Care
919452|NCT02427646|Kinematics
919453|NCT02427646|Botulinum toxin type A
919454|NCT02427633|recovery position
919455|NCT02427633|comatose
919456|NCT02427633|resource limited
919457|NCT02427620|Lymphoma
919458|NCT02427620|Mantle cell lymphoma
919459|NCT02427620|MCL
919460|NCT02427620|B-lymphocyte antigen
919461|NCT02427620|CD20
919462|NCT02427620|Ibrutinib
919463|NCT02427620|PCI-32765
919464|NCT02427620|Imbruvica
919465|NCT02427620|Rituximab
919466|NCT02427620|Rituxan
919467|NCT02427620|Cyclophosphamide
919468|NCT02427620|Cytoxan
919469|NCT02427620|Neosar
919470|NCT02427620|Vincristine
919471|NCT02427620|Mesna
919472|NCT02427620|Mesnex
919473|NCT02427620|Dexamethasone
919474|NCT02427620|Decadron
919475|NCT02427620|Doxorubicin
919476|NCT02427620|Doxorubicin hydrochloride
919477|NCT02427620|Adriamycin PFS
919478|NCT02427620|Adriamycin RDF
919479|NCT02427620|Adriamycin
919480|NCT02427620|Rubex
919481|NCT02427620|G-CSF
919482|NCT02427620|Filgrastim
919483|NCT02427620|Neupogen
919484|NCT02427620|Methotrexate
919485|NCT02427620|Cytarabine
919486|NCT02427620|Ara-C
919487|NCT02427620|Cytosar
919488|NCT02427620|DepoCyt
919489|NCT02427620|Cytosine arabinosine hydrochloride
919490|NCT02427620|Citrovorum
919491|NCT02427620|Leucovorin
919492|NCT02427620|Wellcovorin
919493|NCT02427607|Epilepsy
919494|NCT02427607|Perampanel
919495|NCT02427594|Kidney Diseases
919496|NCT02427594|Renal Insufficiency, Chronic
919497|NCT02427594|Dietary nonvolatile acid load
919498|NCT02427594|Blood pressure
919499|NCT02427594|Urine net acid excretion
919500|NCT02427568|Anxiety
919501|NCT02427568|MDMA
919502|NCT02427568|Life-threatening illness
919503|NCT02427568|psychotherapy
919504|NCT02427542|Randomized Controlled Trial
919505|NCT02427529|hcg
919506|NCT02427503|asthma
919507|NCT02427503|sinonasal polyposis
919508|NCT02427503|eosinophilic bronchial inflammation
919509|NCT02427503|endoscopic sinus surgery
919510|NCT02427490|Palliative Care
919511|NCT02427490|Caregivers
919512|NCT02427490|Medical Oncology
919520|NCT02427438|video
919521|NCT02427438|handout
919522|NCT02427438|home program
919523|NCT02427438|stabilization
919524|NCT02427438|strengthening
919525|NCT02427438|core
919526|NCT02427425|Transcutaneous Electric Nerve Stimulation
919527|NCT02427425|Pain
919528|NCT02427412|Tranexamic Acid
919529|NCT02427412|Knee Arthroplasty
919530|NCT02427412|Blood loss
919531|NCT02427412|Blood transfusion
919532|NCT02427412|Thrombolic complication
919533|NCT02427412|Total blood loss 24 h after ended surgery.
919534|NCT02427412|Total blood loss 2 days after ended surgery.
919535|NCT02427386|Endometriosis
919536|NCT02427386|Pelvic pain
919537|NCT02427386|Homeopathy
919538|NCT02427386|RCT
919539|NCT02427373|bioavailability
919540|NCT02427373|fish oil
919541|NCT02427373|krill oil
919542|NCT02427360|Retrospective Studies
919543|NCT02427360|Clinical Efficacy
919544|NCT02427321|Cystoscopy
919545|NCT02427321|Bladder cancer
919546|NCT02427321|Bladder imaging
919547|NCT02427308|leishmaniasis
919548|NCT02427308|miltefosine
919549|NCT02427308|pregnancy
919550|NCT02427269|Barrett's Esophagus
919551|NCT02427269|Esophageal Cancer
919552|NCT02427269|Intramucosal Adenocarcinoma
919553|NCT02427230|Pelvic Floor Muscle Training
919554|NCT02427230|Neuromuscular Electrical Stimulation
919555|NCT02427230|Urinary Incontinence
919556|NCT02427230|Spinal Cord Injury
919557|NCT02427204|Hepatitis C infection
919558|NCT02427204|Hepatitis C treatment
919559|NCT02427191|Chronic plantar fasciitis
919560|NCT02427191|Heel pain
919561|NCT02427178|Allogeneic Hematopoietic Stem Cell Transplantation
919562|NCT02427178|MNGIE
919563|NCT02427178|Stem Cell transplant
919564|NCT02427113|TMD
919565|NCT02427113|Music Medicine
919566|NCT02427113|Vibroacousitc Therapy
919567|NCT02427100|Homeless
919568|NCT02427100|Randomized Controlled Trial
919569|NCT02427100|Diet
919570|NCT02427100|Physical Activity
919571|NCT02427087|Nonalcoholic fatty liver
919572|NCT02427087|Physical activity
919573|NCT02427087|NAFLD
919574|NCT02427087|Anthropometry
919575|NCT02427087|Body Composition
919576|NCT02427048|Clinical Practice Guidelines
919577|NCT02427022|evidence based practices, critical time intervention
919578|NCT02426944|atrial fibrillation
919579|NCT02426944|cardioembolic event
919580|NCT02426944|stroke
919581|NCT02426944|left atrial appendage closure
919582|NCT02426944|novel anticoagulants
919583|NCT02426931|retrograde intrarenal surgery
919584|NCT02426931|flexible ureteroscopy
919585|NCT02426931|renal calculi
919586|NCT02426892|Solid Tumors
919587|NCT02426892|HPV-16 Positive Incurable Solid Tumors
919588|NCT02426892|ISA101
919589|NCT02426892|HPV-16 vaccination
919590|NCT02426892|Nivolumab
919591|NCT02426892|BMS-936558
919592|NCT02426892|Opdivo
919593|NCT02426879|three-field lymphadenectomy
919594|NCT02426879|cervical metastases
919595|NCT02426879|esophagectomy
919596|NCT02426853|Cancer Prevention
919597|NCT02426853|Sun protection
919598|NCT02426853|Photograph
919599|NCT02426853|UV photograph
919600|NCT02426853|Ultraviolet
919601|NCT02426853|Pamphlets
919602|NCT02426853|Handouts
919603|NCT02426853|Questionnaires
919604|NCT02426853|Surveys
919605|NCT02426853|Skin cancer risk behaviors
919606|NCT02426840|Adverse bone health
919607|NCT02426840|Bone demineralization
919608|NCT02426840|HIV-infection
919609|NCT02426840|Children
919610|NCT02426840|Adolescents
919611|NCT02426840|Calcium
919612|NCT02426840|Vitamin D
919613|NCT02426840|Supplementation
919614|NCT02426814|Patient Compliance
919615|NCT02426814|Mobile Applications
919616|NCT02426801|Patient Compliance
919617|NCT02426801|Mobile Applications
919618|NCT02426801|Medication Adherence
919619|NCT02426788|medically unexplained
919620|NCT02426788|fibromyalgia
919621|NCT02426788|PoTS
919622|NCT02426788|non-cardiac chest pain
919623|NCT02426788|CFS
919624|NCT02426788|IBS
919625|NCT02426788|functional neurological
919626|NCT02426788|chronic pain
919627|NCT02426788|hyperventilation
919628|NCT02426762|skin sealant
919629|NCT02426762|laparoscopic surgery
919630|NCT02426762|surgical site infection
919631|NCT02426762|wound healing
919632|NCT02426736|Shoulder Joint
919633|NCT02426736|Arthroscopy
919634|NCT02426736|Ambulatory surgical procedures
919635|NCT02426736|Pain, Postoperative
919636|NCT02426736|Brachial Plexus Block
919637|NCT02426736|Corticosteroid
919638|NCT02426736|Dexamethasone
919639|NCT02426736|Bupivacaine
919640|NCT02426736|Perineural
919641|NCT02426710|ablation, atrial flutter, intracardiac echocardiography
919642|NCT02426697|bone metastasis, radiotherapy, pain, prevention
919643|NCT02426684|End Stage Renal Disease
919644|NCT02426684|Kidney Transplant
919645|NCT02426684|Desensitization
919646|NCT02426684|Highly Sensitized
919647|NCT02426684|Antibodies
919648|NCT02426671|neuromodulation
919649|NCT02426671|Minimum Masking Level
919650|NCT02426645|Biomarkers
919651|NCT02426645|Sepsis
919652|NCT02426645|Multi organ dysfunction
919653|NCT02426645|Immunomonitoring
919654|NCT02426645|CEUS
919655|NCT02426632|Healthy
919656|NCT02426632|JNJ-53718678
919657|NCT02426606|Lentils
919658|NCT02426606|Post-prandial
919659|NCT02426606|Glycemic response
919660|NCT02426606|Insulin response
919661|NCT02426606|Diabetes
919662|NCT02426606|Mixed meal
919663|NCT02426606|Glycemia
919664|NCT02426606|Slowly digestible starch
919665|NCT02426606|Post-prandial glycemia
919666|NCT02426593|CHF
919667|NCT02426593|Heart Failure
919668|NCT02426567|Crohn's Disease
919669|NCT02426567|Exclusive Enteral Nutrition
919670|NCT02426567|Dietary Treatment
919671|NCT02426567|Gut microbiota
919672|NCT02426541|Diabetes Mellitus
919673|NCT02426541|Dapagliflozin
919674|NCT02426541|Placebo
919675|NCT02426541|Insulin resistance
919676|NCT02426541|Insulin sensitivity
919677|NCT02426476|heart rate variability
919678|NCT02426476|biofeedback
919679|NCT02426476|chronic pain
919680|NCT02426476|Veterans
919681|NCT02426463|Neonatal intensive care
919682|NCT02426463|need for intratracheal intubation
919683|NCT02426437|Acute Exacerbation of COPD (AECOPD)
919684|NCT02426437|COPD
919685|NCT02426437|Emphysema
919686|NCT02426437|Chronic Bronchitis
919687|NCT02426424|c-PAP
919688|NCT02426398|EEG
919689|NCT02426372|Ulcerative Colitis
919690|NCT02426372|Inflammatory Bowel Disease
919691|NCT02426346|Adolescent; Adolescent obesity; Community-based; Overweight
919692|NCT02426307|Thrombosis
919693|NCT02426307|Cardiovascular disease
919694|NCT02426307|Oral anticoagulation
919695|NCT02426307|bioprosthesis
919696|NCT02426307|Multidetector Computed Tomography
919697|NCT02426268|cardiac surgery
919698|NCT02426268|cerebral oximetry
919699|NCT02426268|lower extremity oximetry
919700|NCT02426255|Severe trauma
919701|NCT02426255|traumatic Brain injury
919702|NCT02426255|Hemorrhage
919703|NCT02426242|brain-injury
919704|NCT02426242|extubation
919705|NCT02426229|SSc
919706|NCT02426229|systemic sclerosis
919707|NCT02426229|cutaneous systemic sclerosis
919708|NCT02426216|prostate cancer
919709|NCT02426216|chemoprevention
919710|NCT02426216|biomarker
919711|NCT02426203|Echocardiography
919712|NCT02426177|postpartum hypertension
919713|NCT02426177|labetalol in postpartum hypertension
919714|NCT02426177|nifedipine in postpartum hypertension
919715|NCT02426125|carcinoma of the bladder
919716|NCT02426125|carcinoma of the urethra
919717|NCT02426125|carcinoma the of ureter
919718|NCT02426125|carcinoma of the renal pelvis
919719|NCT02426125|transitional cell carcinoma
919720|NCT02426125|transitional cell tumor
919721|NCT02426125|RANGE
919722|NCT02426125|bladder cancer
919723|NCT02426099|Resistant hypertension
919724|NCT02426099|diabetes mellitus
919725|NCT02426099|Spironolactone
919726|NCT02426099|African
919727|NCT02426086|Myelofibrosis
919728|NCT02426086|JNJ-63935937
919729|NCT02426086|Imetelstat
919730|NCT02426073|Inflammaging
919731|NCT02426047|seizures
919732|NCT02426047|epilepsy
919733|NCT02426047|catamenial
919734|NCT02426047|ketogenic diet
919735|NCT02426047|modified Atkins diet
919736|NCT02426047|intractable epilepsy
919737|NCT02426047|medically refractory epilepsy
919738|NCT02426047|adult
919739|NCT02426047|medium chain triglyceride
919740|NCT02426034|Advanced
919741|NCT02426034|Metastatic
919742|NCT02425995|ACL
919743|NCT02425995|Hidden lesions of the medial meniscus
919744|NCT02425995|Chronic knee instability
919745|NCT02425995|Intercondylar and posteromedial arthroscopy
919746|NCT02425995|Arthroscopic Posteromedial and Intercondylar portal
919747|NCT02425995|Diagnosis capacity of hidden lesions of the medial meniscus
919748|NCT02425982|Tennis Elbow
919749|NCT02425982|Lateral elbow pain
919750|NCT02425982|Latera epicondylitis
919751|NCT02425930|gastric cancer
919752|NCT02425930|complement system
919753|NCT02425930|overal survival
919754|NCT02425904|Langerhans Cell Histiocytosis
919755|NCT02425865|UC, IBD
919756|NCT02425839|shear wave elastography
919757|NCT02425839|surface electromyogram
919758|NCT02425839|masseter
919759|NCT02425826|Parapsoriasis
919760|NCT02425826|Plaque Psoriasis
919761|NCT02425826|CC-10004
919762|NCT02425826|Apremilast
919763|NCT02425826|Moderate Plaque Psoriasis
919764|NCT02425826|Safety
919765|NCT02425787|Loss of a child
919766|NCT02425787|Grief
919767|NCT02425774|Prucalopride
919768|NCT02425774|Vagus Nerve Stimulation
919769|NCT02425774|Postoperative Ileus
919770|NCT02425761|Cerebrospinal Fluid Shunts
919771|NCT02425761|Randomized Controlled Trial
919772|NCT02425748|γδ T Cell, non small lung cancer, Without EGFR Mutation
919773|NCT02425735|Immunotherapy, γδ T Cell, heptocellular liver cancer
919774|NCT02425722|ASP0456
919775|NCT02425722|linaclotide
919776|NCT02425722|chronic constipation
919777|NCT02425696|right-to-left shunt
919778|NCT02425696|contrast-enhanced transcranial Doppler
919779|NCT02425696|migraine
919780|NCT02425696|silent cerebral infarction
919781|NCT02425683|Colon Cancer
919782|NCT02425683|Rectal Cancer
919783|NCT02425683|Colorectal Cancer
919784|NCT02425683|Stage IIIC Colorectal Cancer
919785|NCT02425670|Brain attack
919786|NCT02425670|stroke
919787|NCT02425670|Ischemic stroke
919788|NCT02425670|stem cell therapy
919789|NCT02425657|Education
919790|NCT02425657|Training
919791|NCT02425657|Fast track
919792|NCT02425657|Colonoscopy
919793|NCT02425644|relapsing multiple sclerosis
919794|NCT02425631|SI joint fusion
919795|NCT02425631|SI joint pain
919796|NCT02425631|SI joint
919797|NCT02425631|SI joint treatment
919798|NCT02425631|SI joint disease
919799|NCT02425631|Sacroiliac joint
919800|NCT02425631|Simmetry
919801|NCT02425566|autonomic nervous system
919802|NCT02425566|hypertension
919803|NCT02425566|ganglionic blocker
919804|NCT02425566|trimethaphan
919805|NCT02425566|splanchnic circulation
919806|NCT02425566|capacitance
919807|NCT02425553|Diet
919808|NCT02425553|Reflux
919809|NCT02425553|Dyspepsia
919810|NCT02425553|Symptoms
919811|NCT02425553|Alcohol
919812|NCT02425540|Pelvic MRI
919813|NCT02425527|Brain Injuries
919814|NCT02425527|Traumatic Brain Injury
919815|NCT02425527|Video Games
919816|NCT02425514|Anterior cervical discectomy and fusion
919817|NCT02425514|NovoMax
919818|NCT02425514|Bioactive Glass-ceramic Intervertebral Spacer
919819|NCT02425501|Aflibercept
919820|NCT02425501|anti-VEGF
919821|NCT02425488|Nursing
919822|NCT02425488|Outcome and Process Assessment
919823|NCT02425488|Cardiac Resynchronization Therapy Devices
919824|NCT02425488|Heart Failure
919825|NCT02425488|Education
919826|NCT02425475|Dermoscopy
919827|NCT02425449|succinylcholine
919828|NCT02425449|depolarizing muscle relaxants
919829|NCT02425449|pharmacologic effects
919830|NCT02425410|Diabetes Mellitus
919831|NCT02425410|Insulin-Dependent
919832|NCT02425410|Virus Diseases
919833|NCT02425410|Questionnaires
919834|NCT02425410|Risk assessment
919835|NCT02425410|Genome-Wide Association Study
919836|NCT02425397|Ototoxicity
919837|NCT02425397|platinum derivatives
919838|NCT02425397|paediatrics
919839|NCT02425397|oncology
919840|NCT02425397|clinical research
919841|NCT02425384|adolescent
919842|NCT02425384|physical activity
919843|NCT02425384|accelerometer
919844|NCT02425358|cell therapy
919845|NCT02425358|BMC
919846|NCT02425358|timing
919847|NCT02425345|Physical Activity
919848|NCT02425345|National Institute of Aging Go4Life
919849|NCT02425345|Postmenopausal Women
919850|NCT02425345|Balance
919851|NCT02425345|Strength
919852|NCT02425345|Exercise
919853|NCT02425345|Cardiovascular Disease
919854|NCT02425345|Stroke
919855|NCT02425345|Mortality
919856|NCT02425345|Myocardial Infarction
919857|NCT02425345|Falls
919858|NCT02425345|Venous Thromboembolic Event
919859|NCT02425345|Peripheral Artery Disease
919860|NCT02425345|Physical Function
919861|NCT02425345|Mobility
919862|NCT02425345|Coronary Artery Bypass Graft (CABG)
919863|NCT02425345|Percutaneous Coronary Intervention (PCI)
919864|NCT02425345|Hip Fractures
919865|NCT02425345|Cardiovascular Mortality
919866|NCT02425332|Spinal Cord Injury
919867|NCT02425332|adaptive control
919868|NCT02425332|assessment
919869|NCT02425332|assist-as-needed
919870|NCT02425332|walking ability
919871|NCT02425332|Lokomat
919872|NCT02425306|peptide
919873|NCT02425306|vaccine
919874|NCT02425306|adjuvant
919875|NCT02425306|polyICLC
919876|NCT02425306|cyclophosphamide
919877|NCT02425306|Montanide ISA-51
919878|NCT02425267|Telerehabilitation
919879|NCT02425241|Vaccine
919880|NCT02425241|DNA
919881|NCT02425241|HIV-1
919882|NCT02425241|Serum amyloid P component (SAP)
919883|NCT02425241|Clinical trial
919884|NCT02425241|Vaccination
919885|NCT02425241|Prophylaxis
919886|NCT02425241|Adult male
919887|NCT02425228|targeted biopsy
919888|NCT02425228|conventional biopsy
919889|NCT02425228|cognitive biopsy
919890|NCT02425215|Hyperbaric Oxygen Treatment
919891|NCT02425215|Late radiation injury
919892|NCT02425215|Adult
919893|NCT02425215|Malignancy
919894|NCT02425215|Quality of Life
919895|NCT02425215|Chronic Pain
919896|NCT02425202|pediatric
919897|NCT02425202|obstructive sleep apnea
919898|NCT02425202|tonsillectomy
919899|NCT02425202|analgesia
919900|NCT02425176|botulinum toxin
919901|NCT02425176|sialorrhoea
919902|NCT02425176|drooling
919903|NCT02425163|Prostate Cancer
919904|NCT02425163|Shear Wave Elastography
919905|NCT02425163|Prostate
919906|NCT02425163|Prostate Biopsy
919907|NCT02425150|Keratoconus
919908|NCT02425150|Corneal crosslinking
919909|NCT02425150|Corneal biomechanics
919910|NCT02425150|Corneal densitometry
919911|NCT02425150|Scheimpflug photography
919912|NCT02425111|Drug therapy
919913|NCT02425098|Drug therapy
919914|NCT02425085|retinectomy
919915|NCT02425085|endodiathermy
919916|NCT02425085|inferior
919917|NCT02425085|retinal redetachment
919918|NCT02425072|Cancer
919919|NCT02425072|Brain
919920|NCT02425072|Lung
919921|NCT02425072|Small-cell
919922|NCT02425059|irreversible electroporation
919923|NCT02425059|Unresectable Rectal Neoplasms
919924|NCT02425046|family
919925|NCT02425033|POEM
919926|NCT02425033|Minimally invasive surgery
919927|NCT02425033|Achalasia
919928|NCT02425033|Spastic esophageal disorders
919929|NCT02425020|Supplement
919930|NCT02425020|performance
919931|NCT02425020|whey
919932|NCT02425020|meat
919933|NCT02425020|protein
919934|NCT02423460|Ulcerative Colitis
919935|NCT02423460|Healthy Controls
919936|NCT02423460|Crohn's Disease
920065|NCT02423187|Stomach ulcer
919937|NCT02423434|Corneal Confocal Microscopy
919938|NCT02423434|Diabetes Mellitus
919939|NCT02423434|Type 1 Diabetes Mellitus
919940|NCT02423434|Type 2 Diabetes Mellitus
919941|NCT02423434|Diabetic Neuropathy
919942|NCT02423434|Diabetes Complications
919943|NCT02423382|silicone oil
919944|NCT02423382|retinal saturation
919945|NCT02423382|retinal blood flow
919946|NCT02423382|retinal detachment
919947|NCT02423369|S-100B protein
919948|NCT02423369|Neuron-specific Enolase
919949|NCT02423356|breast cancer
919950|NCT02423356|sarcoma
919951|NCT02423356|lymphoma
919952|NCT02423356|echocardiography
919953|NCT02423356|cardiotoxicity
919954|NCT02423356|pharmacogenetics
919955|NCT02423356|doxorubicin
919956|NCT02423356|chemotherapy
919957|NCT02423291|PMLBCL
919958|NCT02423291|Brentuximab Vedotin
919959|NCT02423291|CD30-positive
919960|NCT02423291|Mediastinal Lymphoma
919961|NCT02423278|gastrectomy
919962|NCT02423278|lymphadenectomy
919963|NCT02423278|gastric cancer
919964|NCT02423278|adjuvant chemotherapy
919965|NCT02423278|overall survival
919966|NCT02423265|Chronic total coronary occlusions
919967|NCT02423265|Ranolazine
919968|NCT02423252|Critical illness
919969|NCT02423252|Intervention
919970|NCT02423252|RCT
919971|NCT02423252|Relaxation
919972|NCT02423252|Guided imagery
919973|NCT02423252|Touch/Massage
919974|NCT02423252|Music listening
919975|NCT02423252|Neuropeptides
919976|NCT02423252|Inflammatory molecules
919977|NCT02423252|Post-traumatic stress
919978|NCT02423252|Critical care nurse
919979|NCT02423252|Psychocognitive nursing intervention
919980|NCT02423252|Interpersonal support
919981|NCT02424994|Morbidity
919982|NCT02424994|Mortality
919983|NCT02424994|Health care utilization
919984|NCT02424994|Cohort
919985|NCT02424994|Epidemiology
919986|NCT02424994|Cardiovascular diseases
919987|NCT02424968|Healthy Stem Cell Donor
919988|NCT02424955|Liver cancer
919989|NCT02424955|Hepatocellular Carcinoma
919990|NCT02424955|Liver imaging
919991|NCT02424955|Stereotactic Ablative Radiotherapy
919992|NCT02424955|SABR
919993|NCT02424929|Deep Brain Stimulation
919998|NCT02424903|infection
919999|NCT02424903|prosthesis
920000|NCT02424903|hip
920001|NCT02424903|knee
920002|NCT02424903|shoulder
920003|NCT02424877|rheumatoid arthritis
920004|NCT02424877|drug treatment
920005|NCT02424877|compliance
920006|NCT02424877|outcome
920007|NCT02424864|4D PET-CT
920008|NCT02424851|myeloma
920009|NCT02424851|multiple myeloma
920010|NCT02424851|chronic kidney disease
920011|NCT02424851|renal failure
920012|NCT02424851|bortezomib
920013|NCT02424851|Velcade
920014|NCT02424851|thalidomide
920015|NCT02424851|bendamustine
920016|NCT02424851|dexamethasone
920017|NCT02424851|serum free light chains
920018|NCT02424851|proteosomal inhibition
920019|NCT02424851|immunomodulatory
920020|NCT02424825|diet
920021|NCT02424825|cooking
920022|NCT02424825|multiple sclerosis
920023|NCT02424825|fatigue
920024|NCT02424812|handwashing
920025|NCT02424812|behavior
920026|NCT02424799|Urticaria
920027|NCT02424799|SYK Inhibitor
920028|NCT02424786|Adherence
920029|NCT02424786|Polypharmacy
920030|NCT02424786|Elderly
920031|NCT02424786|Chronic kidney disease
920032|NCT02424734|Late-onset Sepsis
920033|NCT02424708|Reduced Glutathione
920034|NCT02424708|Intranasal
920035|NCT02424708|(in)GSH
920036|NCT02424708|Parkinson's Disease
920037|NCT02424708|Glutathione
920038|NCT02424708|Uptake
920039|NCT02424708|central nervous system
920040|NCT02424695|Cortical arousal intensity
920041|NCT02424695|RLS
920042|NCT02424695|Heart rate
920043|NCT02424695|Blood pressure
920044|NCT02424695|PLMs
920045|NCT02424630|sono-guided interscalene brachial plexus block
920046|NCT02424630|arthroscopy-guided suprascapular nerve block
920047|NCT02424630|arthroscopic rotator cuff repair
920048|NCT02424630|postoperative pain
920049|NCT02424591|Anesthesia Recovery Period
920050|NCT02424591|Spinal Fusion
920051|NCT02424552|severe asthma
920052|NCT02424552|vitamin D
920053|NCT02424552|treatment
920054|NCT02424539|Seasonal
920055|NCT02424539|Fluticasone Furoate
920056|NCT02424539|Perennial
920057|NCT02424539|Allergic Rhinitis
920058|NCT02424539|Nasal Spray
920059|NCT02424526|cerebral palsy
920060|NCT02424526|treadmill training
920061|NCT02424526|walking
920062|NCT02423213|OCT
920063|NCT02423213|image-guided surgery
920064|NCT02423213|ophthalmic surgery
920066|NCT02423187|Duodenal ulcer
920067|NCT02423187|Rabeprazole
920068|NCT02423187|Recurrence
920069|NCT02423161|OCT
920070|NCT02423161|image-guided surgery
920071|NCT02423161|vitreoretinal surgery
920072|NCT02423161|corneal surgery
920073|NCT02423148|Lung Cancer
920074|NCT02422056|Cleft Palate
920075|NCT02422056|Hemorrhage
920076|NCT02422056|Palatoplasty
920077|NCT02424487|Initial pressure
920078|NCT02424487|changes of intracuff pressure
920079|NCT02424487|infants and children
920080|NCT02424474|cell free fetal DNA
920081|NCT02424474|general population
920082|NCT02424474|screening
920083|NCT02424474|trisomy 21
920084|NCT02424474|IVF
920087|NCT02424422|Corrective Orthodontics
920088|NCT02424422|CBCT
920089|NCT02424422|Rapid Maxillary Expansion
920090|NCT02424422|Cone Beam Computed Tomography
920091|NCT02424422|Hyrax Expansion
920092|NCT02424422|Craniofacial Sutures
920093|NCT02424409|Asthma
920094|NCT02424409|Relapse
920095|NCT02424409|Therapeutic counselling
920096|NCT02424409|Protocol of care
920097|NCT02424396|Interleukin 2, IL2
920098|NCT02424396|Relapsing Remitting Multiple Sclerosis
920099|NCT02424396|Autoimmune diseases
920100|NCT02424396|Regulatory T cells, Tregs
920101|NCT02424370|Aortic stenosis
920102|NCT02424370|TAVR
920103|NCT02424370|Frailty
920104|NCT02424370|Elderly
920105|NCT02424357|Adjustable strabismus surgery
920106|NCT02424357|suture contamination
920107|NCT02424357|5%povidone iodine
920108|NCT02424344|COPD
920109|NCT02424331|Chronic Obstructive Pulmonary Disease
920110|NCT02424331|Respiratory mechanics
920111|NCT02424331|Plethysmography
920112|NCT02424331|Diaphragm
920113|NCT02424331|Respiratory muscles
920114|NCT02424331|Breathing exercises
920115|NCT02424292|Breast cancer
920116|NCT02424292|Physcial activity/exercise
920117|NCT02424292|anti-hormonal treatment
920118|NCT02424279|pancreatic cancer
920119|NCT02424279|pain
920120|NCT02424279|splanchnicectomy
920121|NCT02424266|Tear film
920122|NCT02424266|Imaging
920123|NCT02424266|Tomogrophy
920124|NCT02424266|dry eye
920125|NCT02424201|uterine atony
920126|NCT02424175|Fecal Transplant
920127|NCT02424175|Primary Sclerosing Cholangitis
920128|NCT02424175|Fecal Microbiota Transplantation
920129|NCT02424110|bipolar radiofrequency ablation
920130|NCT02424110|argon beam coagulator
920131|NCT02424097|Prevention
920132|NCT02424071|melatonin's
920133|NCT02424071|quality of recovery
920134|NCT02424032|Neck pain
920135|NCT02424032|stabilization exercise
920136|NCT02424032|connective tissue massage
920137|NCT02424006|keratoplasty
920138|NCT02424006|bioengineered cornea
920139|NCT02424006|donor cornea
920140|NCT02423993|Type 1 diabetes mellitus
920141|NCT02423993|Continuous subcutaneous insulin infusion
920142|NCT02423993|Quality of life
920143|NCT02423993|Therapeutic education
920144|NCT02423993|Insulin pump
920145|NCT02423941|Liver Transplantation
920146|NCT02423941|Retrograde Reperfusion
920147|NCT02423941|Graft dysfunction
920148|NCT02423941|Randomized study
920149|NCT02423928|immunotherapy
920150|NCT02423928|cryoablation
920151|NCT02423928|prostate cancer
920152|NCT02423928|dendritic cell
920184|NCT02423889|Hypofractionated radiotherapy
920185|NCT02423889|SBRT
920186|NCT02423863|Cancer
920187|NCT02423863|Immunotherapy
920188|NCT02423863|Intratumoral Injection
920189|NCT02423863|Multicenter Study
920190|NCT02423863|Autovaccination
920191|NCT02423863|Solid Tumors
920192|NCT02423850|Diabetic foot ulcers
920193|NCT02423850|Leg ulcers
920194|NCT02423850|Ulcer healing
920195|NCT02423850|Ulcer measurement
920196|NCT02423850|Ulcer area
920197|NCT02423850|Ulcer volume
920198|NCT02423850|3D measurement
920199|NCT02423837|follicular lymphoma
920200|NCT02423837|bendamustine
920201|NCT02423837|rituximab
920202|NCT02423798|Diabetes
920203|NCT02423798|Glucose sensor
920204|NCT02423798|Sensor accuracy and performance
920205|NCT02423798|CGM
920206|NCT02423759|Chemoprevention
920207|NCT02423733|depression
920208|NCT02423733|dysthymia
920209|NCT02423733|cognitive behavioural therapy
920210|NCT02423733|CBT
920211|NCT02423733|problem-solving therapy
920212|NCT02423733|PST
920213|NCT02423733|waitlist
920214|NCT02423733|secondary mental health care
920215|NCT02423733|mental health
920216|NCT02423733|e-therapy
920217|NCT02423733|computerized therapy
920218|NCT02423668|cataract surgery
920219|NCT02423668|biometry
920220|NCT02423668|second eye refinement
920221|NCT02423668|effective lens position
920222|NCT02423642|Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
920223|NCT02423616|MIP
920224|NCT02423616|Hand Grip
920225|NCT02423616|Correlation
920226|NCT02423616|Inspiratory Pressure
920227|NCT02423616|Hand Grip Force
920228|NCT02423603|Triple Negative Breast Cancer
920229|NCT02423603|Metastatic
920230|NCT02423603|AKT Inhibitor
920231|NCT02423603|Advanced
920232|NCT02423603|AZD5363
920233|NCT02423603|Paclitaxel
920234|NCT02423603|PAKT
920235|NCT02423590|Squamous
920236|NCT02423590|Lung
920237|NCT02423590|Apatorsen
920238|NCT02423577|antiviral
920239|NCT02423577|influenza
920240|NCT02423577|challenge
920241|NCT02423564|Probiotic
920242|NCT02423564|Digesta-Lac
920243|NCT02423564|Occasional Constipation
920244|NCT02423564|Constipation
920245|NCT02423551|Gut microbiota
920246|NCT02423551|Intestinal permeability
920247|NCT02423551|Gut barrier integrity
920248|NCT02423525|glioblastoma
920249|NCT02423525|astrocytoma
920250|NCT02423525|oligodendroglioma
920251|NCT02423525|mixed oligoastrocytoma
920252|NCT02423525|low grade gliomas
920253|NCT02423525|brain metastases
920254|NCT02423525|meningiomas
920255|NCT02423525|leptomeningeal metastases
920256|NCT02423512|Inflammatory Bowel Diseases
920257|NCT02423512|Vedolizumab
920258|NCT02423512|Ulcerative Colitis
920259|NCT02423512|Crohn's Disease
920260|NCT02423512|MADCAM1
920261|NCT02423512|integrin alpha4beta7
920262|NCT02423499|Autism Spectrum Disorder
920263|NCT02423499|Bipolar Disorder
920264|NCT02423499|Emotions
920265|NCT02423096|biomarker
920266|NCT02423096|neuroendocrine
920267|NCT02423096|metabolite
920268|NCT02423096|cognitive functioning
920269|NCT02423096|clinical symptoms
920270|NCT02423096|schizophrenia
920271|NCT02423083|Neuroprotection
920272|NCT02423083|Multiple Sclerosis
920273|NCT02423083|Clinical Trial
920274|NCT02423083|Safety and Tolerability
920275|NCT02423070|Cell-free DNA
920276|NCT02423070|Acute Rejection
920277|NCT02423070|Thoracic Organ Transplantation
920278|NCT02423070|Non-Invasive Testing
920279|NCT02423070|Chronic Rejection
920280|NCT02423057|Pharmacodynamics
920281|NCT02423057|DNA Methylation
920282|NCT02423057|Pharmacokinetics
920283|NCT02423057|Nucleoside Analogue
920284|NCT02423057|Epigenetics
920285|NCT02423044|Anxiety
920286|NCT02423044|fMRI
920287|NCT02423044|Virtual Reality
920288|NCT02423044|Shock Threat
920289|NCT02423044|Healthy Volunteer
920290|NCT02423031|Physiological Measures
920291|NCT02423031|Emotional Context
920292|NCT02423031|Pediatric
920293|NCT02423031|Distresss Screening
920294|NCT02423005|Stress urinary incontinence
920295|NCT02423005|Neurotech Vital Compact
920296|NCT02423005|1h Provacative Pad Test
920297|NCT02423005|Neuroelectrical Muscle Stimulation (NEMS)
920298|NCT02422992|Iron metabolism
920299|NCT02422992|MRI
920300|NCT02422992|risk factors
920301|NCT02422992|haptoglobin phenotype
920302|NCT02422953|Stunting
920303|NCT02422953|Wasting
920304|NCT02422953|Underweight
920305|NCT02422927|C-Reactive Protein
920306|NCT02422927|Endothelial Microparticles
920307|NCT02422927|Endothelium
920308|NCT02422927|Nutraceutical
920309|NCT02422927|Cholesterol
920310|NCT02422888|ST elevation myocardial infarction
920311|NCT02422888|Percutaneous coronary intervention
920312|NCT02422888|Endothelial function
920313|NCT02422888|Ticagrelor
920314|NCT02422888|Prasugrel
920315|NCT02422875|Sjögren's Syndrome
920316|NCT02422875|Scleroderma
920317|NCT02422875|Myositis
920318|NCT02422875|Juvenile Idiopathic Arthritis
920319|NCT02422875|Rheumatoid Arthritis
920320|NCT02422875|Inflammatory Arthritis
920321|NCT02422875|Undifferentiated Connective Tissue Disease
920322|NCT02422875|Idiopathic thrombocytopenic purpura
920323|NCT02422875|Graft vs Host Disease
920324|NCT02422875|Autoimmune Lymphoproliferative Syndrome
920325|NCT02422875|Immunoglobulin G4 (IgG4)-related disease
920326|NCT02422875|Hepatitis C
920327|NCT02422875|Epstein Barr Virus (infectious mononucleosis - EBV)
920328|NCT02422875|Sepsis
920329|NCT02422875|Guillain-Barre syndrome
920330|NCT02422875|Mycoplasma pneumoniae
920331|NCT02422875|Human Immunodeficiency Virus
920332|NCT02422862|Physiotherapy
920333|NCT02422862|Manual Therapy
920334|NCT02422849|Patient admission
920335|NCT02422836|photodamage
920336|NCT02422836|fine lines
920337|NCT02422836|wrinkles
920338|NCT02422836|dyschromia
920339|NCT02422823|anesthesia
920340|NCT02422823|volumes
920341|NCT02422823|articaine
920342|NCT02422823|Inferior alveolar nerve block
920343|NCT02422797|HIV
920344|NCT02422797|NNRTI-sparing
920345|NCT02422797|two-drug regimen
920346|NCT02422797|nucleoside reverse transcriptase inhibitors
920347|NCT02422797|protease inhibitor
920348|NCT02422797|integrase inhibitor
920349|NCT02422797|non-nucleoside reverse transcriptase inhibitor
920350|NCT02422797|dolutegravir plus rilpivirine
920351|NCT02422797|virologically-suppressed
920352|NCT02422784|Vitamin D insufficient
920353|NCT02422784|rooibos tea
920354|NCT02422784|calcium
920355|NCT02422758|hypothermia
920356|NCT02422758|perioperative nursing
920357|NCT02422758|prewarming
920358|NCT02422758|prevention and control
920359|NCT02422745|Cocoa extract multivitamins cardiovascular disease cancer
920360|NCT02422732|NF1
920361|NCT02422732|Children
920362|NCT02422732|Reading disability
920363|NCT02422732|Morphological and functional MRI
920364|NCT02422732|Genetic analysis
920365|NCT02422719|Chronic myeloid leukemia
920366|NCT02422719|Intolerance
920367|NCT02422719|Resitance
920368|NCT02422719|Radotinib
920369|NCT02422693|hydrotherapy
920370|NCT02422693|aquatic
920371|NCT02422680|Quality assurance
920372|NCT02422680|Caecum intubation rate
920373|NCT02422680|Patient satisfaction
920374|NCT02422667|Orthopedics
920375|NCT02422667|Outcome Assessment
920376|NCT02422628|EGFR inhibitor
920377|NCT02422628|EGFR mutation
920378|NCT02422628|EGFR
920379|NCT02422628|adenocarcinoma
920380|NCT02422628|EGFR TKI
920381|NCT02422628|treatment
920382|NCT02422628|Non small cell
920383|NCT02422615|HR-positive
920384|NCT02422615|HER2-negative
920385|NCT02422615|Advanced breast cancer
920386|NCT02422615|LEE011
920387|NCT02422615|ribociclib
920388|NCT02422615|fulvestrant
920389|NCT02422615|faslodex
920390|NCT02422615|CDK
920391|NCT02422615|CDK4
920392|NCT02422615|CDK6
920393|NCT02422615|CDK4/6
920394|NCT02422615|CDK4/6 inhibitor
920395|NCT02422615|Phase III
920396|NCT02422615|ER-positive
920397|NCT02422615|PR-positive
920398|NCT02422615|Postmenopausal
920399|NCT02422615|Men
920400|NCT02422602|Patients
920401|NCT02422602|treated by Rivaroxaban
920402|NCT02422589|ALK-positive advanced tumors,
920403|NCT02422589|midazolam,
920404|NCT02422589|warfarin,
920405|NCT02422589|ceritinib,
920406|NCT02422589|ALK,
920407|NCT02422589|CYP3A-4,
920408|NCT02422589|Drug drug intereaction
920409|NCT02422563|neoadjuvant chemotherapy
920410|NCT02422563|FIGO IB2, FIGO IIB
920411|NCT02422563|chemo-radiation
920412|NCT02422563|dose dense chemotherapy
920413|NCT02422563|cisplatin
920414|NCT02422563|paclitaxel
920415|NCT02422563|carboplatin
920416|NCT02422563|ifosfamide
920417|NCT02422550|MRI
920418|NCT02422550|15-073
920419|NCT02422550|participants undergoing radiation therapy
920420|NCT02422524|Hepatic, impairment, PA-824, Tuberculosis, Pharmacokinetics, Safety
920421|NCT02422511|Genome Sequencing
920422|NCT02422511|Exome Sequencing
920423|NCT02422511|Newborn Screening
920424|NCT02422511|Childhood Onset Genetic Conditions
920425|NCT02422498|Treated with Concurrent Cisplatin
920426|NCT02422498|Treated with Radiation Therapy
920427|NCT02422498|Homologous Recombination Repair Status
920428|NCT02422498|Biomarker of Response
920429|NCT02422498|15-032
920430|NCT02422498|Patients
920431|NCT02422485|Salsalate
920432|NCT02422446|Endothelial function
920433|NCT02422446|Eicosapentaenoic acid
920434|NCT02422446|Triglycerides
920435|NCT02422433|EGD
920436|NCT02422433|OFDI
920437|NCT02422433|Barrett's Esophagus
920438|NCT02422433|Imaging
920439|NCT02422420|Diabetes Prevention
920440|NCT02422420|Financial Incentives
920441|NCT02422420|Medicaid
920442|NCT02422420|Motivation
920443|NCT02422381|NSCLC
920444|NCT02422381|lung cancer
920445|NCT02422381|Gemzar
920446|NCT02422381|Pembrolizumab
920447|NCT02422381|Anti-PD-1
920448|NCT02422381|Immunotherapy
920449|NCT02422368|Graves' ophthalmopathy
920450|NCT02422368|Antioxidant
920451|NCT02422368|Activity
920452|NCT02422368|Severity
920453|NCT02422355|hip
920454|NCT02422355|femoral neck
920455|NCT02422355|Garden classification
920456|NCT02422355|healing
920457|NCT02422355|cut-out
920458|NCT02422355|iatrogenic fracture
920459|NCT02422355|implant
920460|NCT02422355|rotational stability
920461|NCT02422355|minimal invasive
920462|NCT02422329|Advanced Cancers
920463|NCT02422329|Constipation
920464|NCT02422329|Recurrent cancer
920465|NCT02422329|Locally advanced cancer
920466|NCT02422329|Metastatic cancer
920467|NCT02422329|Video
920468|NCT02422329|Fact sheet
920469|NCT02422329|Questionnaires
920470|NCT02422329|Surveys
920471|NCT02422303|Depression
920472|NCT02422303|Gynecoligical surgery
920473|NCT02422303|Ketamine
920474|NCT02422290|Obsessive Compulsive Disorder
920475|NCT02422290|Ketamine
920476|NCT02422290|Glutamate
920477|NCT02422290|OCD treatment
920478|NCT02422290|OCD medication
920479|NCT02422277|Cystoprostatectomy
920480|NCT02422277|Sexual function
920481|NCT02422277|Phosphodiestrase 5 inhibitors
920482|NCT02422277|Low intensity extracorporeal shock wave therapy
920483|NCT02422277|Erectile dysfunction
920484|NCT02422277|Penile rehabilitation
920485|NCT02422212|metabolism
920486|NCT02422212|Diet Induced Thermogenesis
920487|NCT02422212|weight regain
920488|NCT02422212|energy expenditure
920489|NCT02422212|bariatric
920490|NCT02422186|Depressive Disorder, Treatment-Resistant
920491|NCT02422186|Esketamine
920492|NCT02422186|Oral Antidepressant
920493|NCT02422186|Elderly Participants
920494|NCT02422134|Pregnancy
920495|NCT02422134|implantation
920496|NCT02422134|Cytokine
920497|NCT02422108|RANKL
920498|NCT02422082|Osteopenia
920499|NCT02422082|Lactobacillus reuteri
920500|NCT02422082|Volumetric bone mineral density
920501|NCT02422043|adolescence
920502|NCT02422030|Male Volunteers
920503|NCT02422017|Leg ulcer
920504|NCT02422017|wound
920505|NCT02422017|topical timolol
920506|NCT02422004|Rehabilitation
920507|NCT02422004|Weight-bearing
920508|NCT02422004|Range of motion
920509|NCT02421978|Cognitive dysfunction
920510|NCT02421978|Inflammation
920511|NCT02421978|Fatigue
920512|NCT02421978|Decreased motivation
920513|NCT02421965|Schizophrenia
920514|NCT02421965|Schizoaffective Disorder
920515|NCT02421965|Bipolar Disorder
920516|NCT02421965|Major Depressive Disorder
920517|NCT02421965|Mobile Application
920518|NCT02421965|Smartphone
920519|NCT02421965|SMI
920520|NCT02421965|Illness Self-Management
920521|NCT02421965|EHealth
920522|NCT02421965|E-Health
920523|NCT02421965|Health Technology
920524|NCT02421965|mHealth
920525|NCT02421965|m-Health
920526|NCT02421939|ASP2215
920527|NCT02421939|Relapsed Acute Myeloid Leukemia
920528|NCT02421939|FLT3 Mutation
920529|NCT02421939|Refractory Acute Myeloid Leukemia
920530|NCT02421939|Acute Myeloid Leukemia (AML)
920531|NCT02421874|Patient care team
920532|NCT02421874|Care management
920533|NCT02421874|Electronic health records
920534|NCT02421861|anxiety
920535|NCT02421861|intensive care unit
920536|NCT02421861|critical care
920537|NCT02421848|Body composition
920538|NCT02421848|Sarcopenia
920539|NCT02421848|Cirrhotic with Ascites
920540|NCT02421796|n Non-Celiac Wheat Sensitivity
920541|NCT02421796|Malnutrition
920542|NCT02421796|Celiac disease
920543|NCT02421796|Irritable Bowel Syndrome
920544|NCT02421783|Non-celiac wheat sensitivity
920545|NCT02421783|Multiple food allergy
920546|NCT02421783|Body mass index
920547|NCT02421783|Osteoporosis
920548|NCT02421757|Transcutaneous Magnetic Stimulation
920549|NCT02421757|placebo
920555|NCT02421731|Rehabilitation
920556|NCT02421731|Gait
920557|NCT02421718|Acute toxicity
920558|NCT02421718|Late toxicity
920559|NCT02421718|Prediction models
920560|NCT02421679|PTSD
920561|NCT02421679|Military-related PTSD and other related conditions
920562|NCT02421679|open-label extension
920563|NCT02421653|Micronutrient powders
920564|NCT02421653|MNP
920565|NCT02421653|Weaning
920566|NCT02421653|Home fortification
920567|NCT02421653|Iodine
920568|NCT02421653|Iodine deficiency
920569|NCT02421653|Iodine Deficiency Disorder
920570|NCT02421653|IDD
920571|NCT02421653|Infant
920572|NCT02421653|Growth
920573|NCT02421653|Iodised oil
920574|NCT02421627|moxibustion
920575|NCT02421627|irritable bowel syndrome
920576|NCT02421627|Magnetic Resonance Imaging
920577|NCT02421614|acute respiratory failure
920578|NCT02421614|lung
920579|NCT02421614|enteral feeding
920580|NCT02421614|feeding composition
920581|NCT02421614|olive
920582|NCT02421614|high fat
920583|NCT02421549|Remote Monitoring
920584|NCT02421549|Remote Care
920585|NCT02421549|Cardiac Resynchronization Therapy
920586|NCT02421549|Pacemaker
920587|NCT02421549|Implantable Cardioverter Defibrillator
920588|NCT02421523|Exercise
920589|NCT02421523|Strength training
920590|NCT02421510|High level of sugar (glucose) in the blood
920591|NCT02421484|Phase I clinical trial
920592|NCT02421484|stem cell
920593|NCT02421484|mesenchymal stromal cell
920594|NCT02421484|mesenchymal stem cell
920595|NCT02421471|Actinic Keratosis
920596|NCT02421471|topical treatment
920597|NCT02421471|ingenol mebutate
920598|NCT02421432|trananal TME
920599|NCT02421432|safety
920600|NCT02421432|efficacy
920601|NCT02421432|difficult cases
920602|NCT02421419|flexor tendon entrapment
920603|NCT02421419|snapping finger
920604|NCT02421419|trigger digits
920605|NCT02421419|trigger thumb
920606|NCT02421393|Bone quality
920607|NCT02421393|Bone strength
920608|NCT02421393|Fractures
920609|NCT02421393|Muscle strength
920610|NCT02421393|Gait and balance
920611|NCT02421393|Musculo-skeletal symptoms
920612|NCT02421393|Falls
920613|NCT02421380|Hyperpolarized Pyruvate
920614|NCT02421380|MRI
920615|NCT02421380|14-205
920616|NCT02421354|Myeloproliferative Diseases
920617|NCT02421354|Post-Essential Thrombocythemia Myelofibrosis
920618|NCT02421354|Post-Polycythemia Vera Myelofibrosis
920619|NCT02421354|MF
920620|NCT02421354|Nivolumab
920621|NCT02421354|BMS-936558
920622|NCT02421354|Questionnaire
920623|NCT02421354|Survey
920624|NCT02421354|Phone call
920625|NCT02421341|Heart, Cardiovascular
920626|NCT02421341|Pulmonary
920627|NCT02421341|Skeletal Muscle
920628|NCT02421341|Exercise
920629|NCT02421315|OCD
920630|NCT02421315|Functional Magnetic Resonance Imaging (fMRI)
920631|NCT02421315|Magnetic Resonance Imaging (MRI)
920632|NCT02421289|CYP2B6 polymorphism
920633|NCT02421289|efavirenz
920634|NCT02421289|Thai
920635|NCT02421289|HIV-infected patient
920636|NCT02421289|pharmacogenomic
920637|NCT02421263|Psilocybin
920638|NCT02421263|Pharmacologic Actions
920639|NCT02421263|Psychotropic Drugs
920640|NCT02421224|Smoking Cessation
920641|NCT02421224|Incentives
920642|NCT02421224|Health Behavior
920643|NCT02421224|Smoking
920644|NCT02421224|Work-site
920645|NCT02421211|Hepatitis C, Chronic
920646|NCT02421211|Simeprevir
920647|NCT02421211|Ledipasvir
920648|NCT02421211|Sofosbuvir
920649|NCT02421198|Intervention Studies
920650|NCT02421185|Carcinoma, Hepatocellular
920651|NCT02421185|JNJ 42756493
920652|NCT02421185|a pan-Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor
920653|NCT02421172|Hidradenitis Suppurativa
920654|NCT02421159|HIV/AIDS
920655|NCT02421159|vulnerable populations
920656|NCT02421159|heterosexuals at high risk
920657|NCT02421159|peer-driven intervention
920658|NCT02421159|tailored intervention
920659|NCT02421159|African-American
920660|NCT02421159|Latino/Hispanic
920661|NCT02421159|Seek, test, treat, and retain (STTR)
920662|NCT02421159|Brooklyn
920663|NCT02421133|Care transition program
920664|NCT02421133|Patient readmission
920665|NCT02421133|Transition Nurse
920666|NCT02421133|Stepped wedge
920667|NCT02421133|elderly
920668|NCT02421081|CD34
920669|NCT02421081|CD133
920670|NCT02421081|CD309
920671|NCT02421081|Radial Artery
920672|NCT02421081|Ulnar Artery
920673|NCT02421081|Lymphoid Cell
920674|NCT02421081|blood levels
920675|NCT02421081|endothelial progenitor cells
920676|NCT02421081|stem cells
920677|NCT02421068|Paracetamol
920678|NCT02421068|Fentanyl
920679|NCT02421068|Phenobarbital
920680|NCT02421068|Doxapram
920681|NCT02421068|Midazolam
920682|NCT02421068|Sildenafil
920683|NCT02421068|Levetiracetam
920684|NCT02421068|Pharmacokinetics
920685|NCT02421068|Pharmacology
920686|NCT02421068|Fluconazole
920687|NCT02421068|Ibuprofen
920688|NCT02421055|Bariatric Surgery
920689|NCT02421055|Gastric Bypass
920690|NCT02421055|Sleeve Gastrectomy
920691|NCT02421055|Gastroplasty
920692|NCT02421042|Hepatic Impairment
920693|NCT02421042|Hepatic Function
920694|NCT02421029|gadolinium
920695|NCT02421029|calcium disodium ethylenediaminetetraacetic acid (EDTA)
920696|NCT02421029|heavy metal toxicity
920697|NCT02421016|De novo stenosis
920698|NCT02421016|bioresorbable polymer coating
920699|NCT02421016|bioresorbable polymer backbone
920700|NCT02421003|heart surgery blood
920701|NCT02420990|ADHD
920702|NCT02420990|Adolescents
920703|NCT02420990|Substance Use Disorders
920704|NCT02420977|radiotracer
920705|NCT02420964|injectable
920706|NCT02420964|teaching methods
920707|NCT02420951|Knee
920708|NCT02420951|Arthroplasty
920709|NCT02420951|Bupivacaine
920710|NCT02420951|Anesthetics, Local
920711|NCT02420938|Leukemia
920712|NCT02420938|Chronic Lymphocytic Leukemia
920713|NCT02420938|CLL
920714|NCT02420938|Small Lymphocytic Lymphoma
920715|NCT02420938|SLL
920716|NCT02420938|Refractory/relapsed
920717|NCT02420938|High-risk molecular features
920718|NCT02420938|Rituximab
920719|NCT02420938|Rituxan
920720|NCT02420938|Urelumab
920721|NCT02420925|Gastroparesis
920722|NCT02420925|Celiac Plexus Block
920723|NCT02420912|Leukemia
920724|NCT02420912|Chronic Lymphocytic Leukemia
920725|NCT02420912|CLL
920726|NCT02420912|Relapsed
920727|NCT02420912|Refractory
920728|NCT02420912|High-risk
920729|NCT02420912|Untreated
920730|NCT02420912|Nivolumab
920731|NCT02420912|BMS-936558
920732|NCT02420912|Opdivo
920733|NCT02420912|Ibrutinib
920734|NCT02420912|PCI-32765
920735|NCT02420912|Imbruvica
920736|NCT02420899|IVUS
920737|NCT02420899|ACS
920738|NCT02420886|In Vitro culture of human embryos
920739|NCT02420873|Leukemia
920740|NCT02420873|Hematological malignancy
920741|NCT02420873|Myelofibrosis
920742|NCT02420873|MF
920743|NCT02420873|Blastic plasmacytoid dendritic cell neoplasm
920744|NCT02420873|BPDCN
920745|NCT02420873|CD56 tumor marker
920746|NCT02420873|Acute myeloid leukemia
920747|NCT02420873|AML
920748|NCT02420873|Natural-killer leukemia
920749|NCT02420873|Acute lymphoblastic leukemia
920750|NCT02420873|ALL
920751|NCT02420873|CD56 expressing hematological malignancy
920752|NCT02420873|IMGN901
920753|NCT02420873|Lorvotuzumab mertansine
920754|NCT02420860|Myeloma
920755|NCT02420860|Multiple myeloma
920756|NCT02420860|MM
920757|NCT02420860|Post autologous stem cell transplantation
920758|NCT02420860|ASCT
920759|NCT02420860|Elotuzumab
920760|NCT02420860|Lenalidomide
920761|NCT02420860|CC-5013
920762|NCT02420860|Revlimid
920763|NCT02420860|Dexamethasone
920764|NCT02420860|Decadron
920765|NCT02420860|Diphenhydramine
920766|NCT02420860|Benadryl
920767|NCT02420860|Ranitidine
920768|NCT02420860|Ranitidine hydrochloride
920769|NCT02420860|Zantac
920770|NCT02420860|Symptom questionnaire
920771|NCT02420860|Survey
920772|NCT02420847|Bladder cancer
920773|NCT02420847|Urothelial cancer
920774|NCT02420847|Transitional cell carcinoma of the urothelium
920775|NCT02420847|Metastatic
920776|NCT02420847|Locally unresectable
920777|NCT02420847|Ixazomib
920778|NCT02420847|Gemcitabine
920779|NCT02420847|Gemcitabine hydrochloride
920780|NCT02420847|Gemzar
920781|NCT02420847|Doxorubicin
920782|NCT02420847|Doxorubicin hydrochloride
920783|NCT02420847|Adriamycin PFS
920784|NCT02420847|Adriamycin RDF
920785|NCT02420847|Adriamycin
920786|NCT02420847|Rubex
920787|NCT02420808|CAD
920788|NCT02420808|STEMI
920789|NCT02420808|non STEMI
920790|NCT02420808|Unstable angina
920791|NCT02420808|Greece
920792|NCT02420795|Lymphoma
920793|NCT02420795|Non-Hodgkin's Lymphoma
920794|NCT02420795|Relapsed/Refractory
920795|NCT02420795|NHL
920796|NCT02420795|Mantle cell lymphoma
920797|NCT02420795|MCL
920798|NCT02420795|Diffuse large B-cell lymphoma
920799|NCT02420795|DLBCL
920800|NCT02420795|Transformed large cell lymphoma
920801|NCT02420795|TLCL
920802|NCT02420795|ONC201
920803|NCT02420795|Phone call
920804|NCT02420782|Pharmacokinetics
920805|NCT02420782|ASP6282
920806|NCT02420782|Pharmacodynamics
920807|NCT02420782|Drug-drug interaction
920808|NCT02420782|Midazolam
920809|NCT02420782|Safety and tolerability
920810|NCT02420782|Healthy volunteers
920811|NCT02420782|Itraconazole
920812|NCT02420769|CA 125
920813|NCT02420769|Progesterone
920814|NCT02420769|Doppler
920815|NCT02420769|Corpus Luteum
920816|NCT02420743|PTD
920817|NCT02420717|Leukemia
920818|NCT02420717|Acute Lymphoblastic Leukemia
920819|NCT02420717|ALL
920820|NCT02420717|Philadelphia Chromosome (Ph)-Like
920821|NCT02420717|Relapsed
920822|NCT02420717|Refractory
920823|NCT02420717|6-mercaptopurine
920824|NCT02420717|Mercaptopurine
920825|NCT02420717|6-MP
920826|NCT02420717|Purinethol
920827|NCT02420717|Ruxolitinib
920828|NCT02420717|Jakafi
920829|NCT02420717|INCB018424
920830|NCT02420717|INC424
920831|NCT02420717|Dasatinib
920832|NCT02420717|BMS-354825
920833|NCT02420717|Sprycel
920834|NCT02420717|Rituximab
920835|NCT02420717|Rituxan
920836|NCT02420717|G-CSF
920837|NCT02420717|Filgrastim
920838|NCT02420717|Neupogen
920839|NCT02420717|Pegfilgrastim
920840|NCT02420717|Neulasta
920841|NCT02420717|PEG-G-CSF
920842|NCT02420717|Methotrexate
920843|NCT02420717|Cytarabine
920844|NCT02420717|Ara-C
920845|NCT02420717|Cytosar
920846|NCT02420717|DepoCyt
920847|NCT02420717|Cytosine
920848|NCT02420717|Arabinosine Hydrochloride
920849|NCT02420717|Cyclophosphamide
920850|NCT02420717|Cytoxan
920851|NCT02420717|Neosar
920852|NCT02420717|Mesna
920853|NCT02420717|Mesnex
920854|NCT02420717|Doxorubicin
920855|NCT02420717|Doxorubucin hydrochloride
920856|NCT02420717|Adriamycin PFS
920857|NCT02420717|Adriamycin RDF
920858|NCT02420717|Adriamycin
920859|NCT02420717|Rubex
920860|NCT02420717|Vincristine
920861|NCT02420717|Dexamethasone
920862|NCT02420717|Decadron
920863|NCT02420717|Solumedrol
920864|NCT02420717|Methylprednisolone
920865|NCT02420717|Depo-medrol
920866|NCT02420717|Medrol
920867|NCT02420717|Solu-medrol
920868|NCT02420717|Prednisone
920869|NCT02420717|Leucovorin
920870|NCT02420717|Citrovorum
920871|NCT02420717|Wellcovorin
920872|NCT02420704|IVF
920873|NCT02420704|endometrial thickness
920874|NCT02420704|cleavage stage embryo
920875|NCT02420704|blastocyst stage embryo
920876|NCT02420704|Ongoing pregnancy rate
920877|NCT02420691|Gastrointestinal cancer
920878|NCT02420691|Foregut neuroendocrine tumors
920879|NCT02420691|NET
920880|NCT02420691|Thymic
920881|NCT02420691|Bronchopulmonary
920882|NCT02420691|Gastric
920883|NCT02420691|Duodenal
920884|NCT02420691|Pancreatic
920885|NCT02420691|LEE011
920886|NCT02420665|Cervical Cancer
920887|NCT02420665|Cervical Dysplasia
920888|NCT02420665|Abnormal Pap test
920889|NCT02420665|Positive human papillomavirus test
920890|NCT02420665|HPV
920891|NCT02420665|Visual inspection with acetic acid
920892|NCT02420665|VIA
920893|NCT02420665|Colposcopy
920894|NCT02420665|Proflavine
920895|NCT02420665|Acetic acid
920896|NCT02420665|High-Resolution Microendoscopy
920897|NCT02420665|HRME
920898|NCT02420665|Phone call
920899|NCT02420613|Diffuse Intrinsic Pontine Glioma
920900|NCT02420613|DIPG
920901|NCT02420613|Newly Diagnosed
920902|NCT02420613|Progressive
920903|NCT02420613|Pediatrics
920904|NCT02420613|Vorinostat
920905|NCT02420613|SAHA
920906|NCT02420613|Suberoylanilide Hydroxamic Acid
920907|NCT02420613|MSK-390
920908|NCT02420613|Zolinza
920909|NCT02420613|Temsirolimus
920910|NCT02420613|CCI-779
920911|NCT02420613|Torisel
920912|NCT02420613|Radiation therapy
920913|NCT02420613|XRT
920914|NCT02420600|Circulating tumor cells
920915|NCT02420600|Head and neck cancer
920916|NCT02420600|PD-1
920917|NCT02420600|natural killer cells
920918|NCT02420600|cytotoxic T lymphocytes
920919|NCT02420587|Prostate Cancer
920920|NCT02420587|Adenocarcinoma of the prostate
920921|NCT02420587|Castration resistant prostate cancer metastatic to bone
920922|NCT02420587|mCRPC
920923|NCT02420587|AMG 208
920924|NCT02420587|Questionnaire
920925|NCT02420587|Survey
920926|NCT02420561|Depression
920927|NCT02420561|Substance-Related Disorders
920928|NCT02420561|Mental Health
920929|NCT02420535|Dementia
920930|NCT02420535|Alzheimer's Disease
920931|NCT02420535|Caregivers
920932|NCT02420535|Behavioral
920933|NCT02420535|Caregiver burden
920934|NCT02420496|Parental nutrition
920935|NCT02420496|associated
920936|NCT02420470|diabetes
920937|NCT02420470|neural and vessel alteration
920938|NCT02420470|prodromal stage
920939|NCT02420457|Fitness devices
920940|NCT02420418|Tobacco use disorder and bipolar disorders
920941|NCT02420418|N-acetylcysteine
920942|NCT02420418|Oxidative stress
920943|NCT02420418|inflammation
920944|NCT02420405|Gene testing
920945|NCT02420405|Endobronchial ultrasound (EBUS)
920946|NCT02420405|Next-generation sequencing (NGS)
920947|NCT02420405|Small biopsies
920948|NCT02420379|DMD
920949|NCT02420379|Duchenne muscular dystrophy
920950|NCT02420379|eteplirsen
920951|NCT02420379|Dystrophin
920952|NCT02420379|exon 51
920953|NCT02420353|muscle atrophy
920954|NCT02420353|growth hormone
920955|NCT02420353|ACL tear
920956|NCT02420340|Serious Mental Illness
920957|NCT02420340|Psychosocial Rehabilitation
920958|NCT02420327|nicotine
920959|NCT02420327|galantamine
920960|NCT02420327|attention
920961|NCT02420327|cognition
920962|NCT02420327|non-smoker
920963|NCT02420314|Ascorbate
920964|NCT02420314|Ascorbic acid
920965|NCT02420314|Vitamin C
920966|NCT02420314|NSCLC
920967|NCT02420314|Non Small Cell Lung Cancer
920968|NCT02420314|carboplatin
920969|NCT02420314|paclitaxel
920970|NCT02420288|Pregnancy
920971|NCT02420288|Fetoplacental growth
920972|NCT02420288|Physical exercise
920973|NCT02420288|Pregnant
920974|NCT02420288|Placental development
920975|NCT02420288|Active pregnancy
920976|NCT02420275|brain injury
920977|NCT02420275|blue enriched withe bright light therapy
920978|NCT02420275|sequel fatigue
920979|NCT02420236|Exercise therapy
920980|NCT02420236|Resistance training
920981|NCT02420236|Multidisciplinary treatment
920982|NCT02420223|Recipients
920983|NCT02420197|Exercise therapy
920984|NCT02420197|Resistance training
920985|NCT02420197|Multidisciplinary treatment
920986|NCT02420171|In Vitro
920987|NCT02420171|embryo quality
920988|NCT02420171|Intracytoplasmic sperm injection
920989|NCT02420158|Irritable Bowel Syndrome
920990|NCT02420158|Vagal nerve stimulation
920991|NCT02420158|Quality of life
920992|NCT02420119|Iron Therapy
920993|NCT02420119|serum phosphates
920994|NCT02420119|vitamin D
920995|NCT02420106|cervical dystonia
920996|NCT02420106|neck pain
920997|NCT02420106|OMM
920998|NCT02420106|spasmodic torticollis
920999|NCT02420067|von Hippel-Lindau disease
921000|NCT02420067|Endolymphatic sac tumors
921001|NCT02420067|Audiological examination
921002|NCT02420067|MRI
921003|NCT02420067|Surveillance
921004|NCT02420054|intermittent fasting
921005|NCT02420054|alternate day fasting
921006|NCT02420054|diabetes mellitus
921007|NCT02420054|non-alcoholic fatty liver disease
921008|NCT02420054|insulin sensitivity
921009|NCT02420041|Sacroiliac Joint Injection
921010|NCT02420041|Fluoroscopy
921011|NCT02420041|Ultrasound
921012|NCT02419989|Nontuberculous Mycobacteria
921013|NCT02419963|microbiome
921014|NCT02419963|biomarkers
921015|NCT02419963|Vitamin D
921016|NCT02419963|Serotonin
921017|NCT02419950|inguinal hernia
921018|NCT02419950|TEP
921019|NCT02419950|chronic pain
921020|NCT02419950|male sex
921021|NCT02419950|mesh fixation
921022|NCT02419950|quality of life
921023|NCT02419950|national register
921024|NCT02419911|gastrointestinal
921025|NCT02419911|gynecologic
921026|NCT02419911|urologic
921027|NCT02419911|bariatric
921028|NCT02419911|laparoscopic surgery
921029|NCT02419898|Feasibility
921030|NCT02419885|finger amputation
921031|NCT02419885|composite graft
921032|NCT02419885|adipo-fascia flap
921033|NCT02419859|Diabetes Mellitus
921034|NCT02419859|Diabetes Mellitus, Type 2
921035|NCT02419859|Glucose Metabolism Disorders
921036|NCT02419859|Metabolic Diseases
921037|NCT02419859|Endocrine System Diseases
921038|NCT02419859|Insulin
921039|NCT02419859|Continuous subcutaneous insulin infusion (CSII)
921040|NCT02419859|Insulin pumps
921041|NCT02419846|Informed Decision Making
921042|NCT02419846|Prostate
921043|NCT02419846|Cancer
921044|NCT02419833|non-STEMI
921045|NCT02419833|immediate
921046|NCT02419833|delayed
921047|NCT02419833|PCI
921048|NCT02419807|Near Infrared Fluorescence Imaging
921049|NCT02419807|Indocyanine Green
921050|NCT02419807|axillary lymph node mapping
921051|NCT02419807|Mastectomy, Segmental
921052|NCT02419807|Sentinel Lymph Node Biopsy
921053|NCT02419807|Lumpectomy
921054|NCT02419768|Long-range autocorrelations
921055|NCT02419768|Variability
921056|NCT02419768|Physical Exercise
921057|NCT02419768|Parkinson's Disease
921058|NCT02419768|ICF
921059|NCT02419755|Infant leukemia
921060|NCT02419755|ALL
921061|NCT02419755|AML
921062|NCT02419755|Biphenotypic leukemia
921063|NCT02419755|Pediatric
921064|NCT02419729|Vulvovaginal atrophy
921065|NCT02419729|Menopause
921066|NCT02419729|Fractional CO2 laser
921067|NCT02419729|Estrogen cream
921068|NCT02419716|colorectal cancer
921069|NCT02419716|Colorectal cancer screening
921070|NCT02419677|radiofrequency ablation
921071|NCT02419677|cytokine-induced killer cells
921072|NCT02419677|colorectal cancer iver metastases
921073|NCT02419664|pituitary
921074|NCT02419664|pituitary adenomas
921075|NCT02419664|Ga-PET
921076|NCT02419664|Acromegaly
921077|NCT02419664|TSHomas
921078|NCT02419664|Cushing
921079|NCT02419651|out patient hysteroscopy
921080|NCT02419638|relapsing-remitting MS
921081|NCT02419638|lesions
921082|NCT02419638|treatment
921083|NCT02419573|cardiac arrest
921084|NCT02419573|cardiopulmonary resuscitation
921085|NCT02419573|laryngeal tube
921086|NCT02419573|endotracheal intubation
921087|NCT02419573|non-traumatic Out of Hospital Cardiac Arrest (OOHCA)
921088|NCT02419560|Relapsed
921089|NCT02419560|Laboratory biomarker research
921090|NCT02419560|Pharmacologic study
921091|NCT02419560|Bruton's tyrosine kinase inhibitor
921092|NCT02419560|BCL-2 inhibitor
921093|NCT02419547|Ventricular tachycardia
921094|NCT02419547|ventricular tachycardia ablation
921095|NCT02419547|effects of anesthesia on VT induction
921096|NCT02419547|programed stimulation
921097|NCT02419534|Pediatric, fissure in ano
921146|NCT02419482|Exercise therapy
921147|NCT02419482|Reproductive Physiological Processes
921148|NCT02419482|Fertility
921193|NCT02419443|inguinal hernia repair, chronic pain
921194|NCT02419430|well-being
921195|NCT02419430|stress
921196|NCT02419430|resilience
921197|NCT02419430|self-compassion
921198|NCT02419391|RSV Vaccines
921199|NCT02419391|Respiratory Syncytial Virus Vaccines
921200|NCT02419365|Primary Ciliary Dyskinesia (PCD)
921201|NCT02419352|Cognitive function
921202|NCT02419326|couples
921203|NCT02419326|relationships
921204|NCT02419326|binge eating
921205|NCT02419326|eating disorder
921206|NCT02419326|couple therapy
921207|NCT02419313|Tremor
921208|NCT02419313|Parkinson
921209|NCT02419313|botulinum
921210|NCT02419313|Xeomin
921211|NCT02419287|ALK
921212|NCT02419287|crizotinib
921213|NCT02419274|asthma
921214|NCT02419274|phenotype
921215|NCT02419274|childhood
921216|NCT02419274|adulthood
921217|NCT02419261|knee surgery
921218|NCT02419261|anterior cruciate ligament surgery
921219|NCT02419261|nerve block
921220|NCT02419235|Refractory hypertension
921221|NCT02419235|Homoeopathy
921222|NCT02419235|Homoeopathic complex
921223|NCT02419235|Amylenum nitrosum 6cH
921224|NCT02419235|Crataegus oxyacantha 6cH
921225|NCT02419235|Natrum muriaticum 6cH
921226|NCT02419235|Scutellaria lateriflora 6cH
921227|NCT02419209|Low sexual desire
921228|NCT02419209|Perimenopause
921229|NCT02419209|Homeopathy
921230|NCT02419209|Hypoactive Sexual Desire Disorder
921231|NCT02419183|Mild Cognitive Impairment
921232|NCT02419183|Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR)
921233|NCT02419183|Rey Auditory Verbal Learning Test (RAVLT)
921234|NCT02419183|Word List Recall (WLR)
921235|NCT02419157|Cervical lesions
921236|NCT02419157|Clinical trial
921237|NCT02419157|Self-etch adhesive
921238|NCT02419144|older adults;
921239|NCT02419144|oral hygiene;
921240|NCT02419144|adapted motivational interviewing
921241|NCT02419118|Myeloma
921242|NCT02419118|monoclonal antibody
921243|NCT02419118|Daratumumab
921244|NCT02419105|Falls
921245|NCT02419105|hypogonadal men
921246|NCT02419105|Seniors
921247|NCT02419105|Testosterone
921248|NCT02419105|Colecalciferol
921249|NCT02419092|Inflammation
921250|NCT02419092|Insulin resistance
921251|NCT02419092|Bariatric surgery
921252|NCT02419053|Surgical safety checklist
921253|NCT02419053|perioperative complications
921254|NCT02419053|pediatric
921255|NCT02419040|shoulder pain
921256|NCT02419040|rotator cuff
921257|NCT02419040|calcific tendonitis
921258|NCT02419040|barbotage
921259|NCT02419027|GI Flora
921260|NCT02419014|cranial electrotherapy
921261|NCT02419014|cranial electrical stimulation
921262|NCT02419014|restless legs syndrome
921263|NCT02418962|PfSPZ Vaccine
921264|NCT02418949|hand
921265|NCT02418949|rehabilitation
921266|NCT02418949|active movement training
921267|NCT02418949|passive cyclical stretching
921268|NCT02418936|Waardenburg syndrome
921269|NCT02418936|Large vestibular aqueduct syndrome
921270|NCT02418936|Diagnosis
921271|NCT02418936|copy number variation
921272|NCT02418936|Multiplex polymerase chain reaction
921273|NCT02418910|bipolar
921274|NCT02418910|self assessment
921275|NCT02418910|prospective randomized trial
921276|NCT02418897|Fatigue
921277|NCT02418897|multiple sclerosis
921278|NCT02418897|neuromuscular junction
921279|NCT02418897|SFEMG
921280|NCT02418871|cataract
921281|NCT02418871|presbyopia
921282|NCT02418858|Essential tremor
921283|NCT02418858|DBS
921284|NCT02418832|Azoospermia
921285|NCT02418832|Rete Testis
921286|NCT02418832|TEFNA
921287|NCT02418806|Family Caregivers
921288|NCT02418806|Psychotherapy Group
921289|NCT02418793|Hemophilia
921290|NCT02418793|Factor VII
921291|NCT02418793|Factor VIIa
921292|NCT02418793|Inhibitors
921293|NCT02418793|Long Acting
921294|NCT02418728|obesity
921295|NCT02418728|adipose tissue lipolysis
921296|NCT02418728|lipolysis
921297|NCT02418728|microdialysis
921298|NCT02418728|atrial natriuretic peptide
921299|NCT02418702|depression
921300|NCT02418702|suicide
921301|NCT02418702|ketamine
921302|NCT02418702|rapid intravenous bolus
921303|NCT02418702|sub-anesthetic dose
921304|NCT02418702|double-blind placebo control
921305|NCT02418676|Human insulin
921306|NCT02418676|Hydroxypropyl-beta-cyclodextrin
921307|NCT02418676|Pressure Ulcer
921308|NCT02418676|Wound Healing
921309|NCT02418676|Gel
921310|NCT02418663|fluid responsiveness
921311|NCT02418663|enhanced recovery program
921312|NCT02418650|volunteers
921313|NCT02418637|worksite
921314|NCT02418637|screen
921315|NCT02418637|migrant
921316|NCT02418637|agricultural
921317|NCT02418637|worker
921318|NCT02418637|hypertension
921319|NCT02418637|Hyperlipidemia
921320|NCT02418637|diabetes
921321|NCT02418637|feasibility
921322|NCT02418624|breast cancer 1, early onset (BRCA1)
921323|NCT02418624|breast cancer 2, early onset (BRCA2)
921324|NCT02418624|homologous recombination deficiency
921325|NCT02418624|carboplatin
921326|NCT02418624|olaparib
921327|NCT02418611|Aorta
921328|NCT02418611|Thoracic
921329|NCT02418611|Aortic dissection
921330|NCT02418611|Rupture
921331|NCT02418611|Type B
921332|NCT02418611|DeBakey type III
921333|NCT02418611|Endovascular
921334|NCT02418598|Adeno-associated virus
921335|NCT02418598|Aromatic L-amino acid decarboxylase
921336|NCT02418598|AAV-hAADC-2
921337|NCT02418598|AAV-2
921338|NCT02418598|Gene Therapy
921339|NCT02418598|Gene Transfer
921340|NCT02418598|Parkinson Disease
921341|NCT02418598|Basal Ganglia Disease
921342|NCT02418598|Brain Disease
921343|NCT02418585|Treatment-resistant Depression
921344|NCT02418585|Esketamine
921345|NCT02418585|Placebo
921346|NCT02418585|Oral Antidepressant
921347|NCT02418559|Healthy
921348|NCT02418559|JNJ-63623872
921349|NCT02418559|Japanese Adult Participants
921350|NCT02418533|infertility
921351|NCT02418533|in vitro fertilization
921352|NCT02418533|fertility
921353|NCT02418533|preimplantation genetic screening
921354|NCT02418533|embryo
921355|NCT02418533|PGS
921356|NCT02418533|Eeva
921357|NCT02418533|IVF
921358|NCT02418481|γδ T Cell
921359|NCT02418481|breast cancer
921360|NCT02418481|her2-
921361|NCT02418481|er-
921362|NCT02418481|pr-
921363|NCT02418468|COPD, FEV1, indacaterol
921364|NCT02418455|MPS 7
921365|NCT02418455|Sly Syndrome
921366|NCT02418455|MPS VII
921367|NCT02418455|Enzyme Replacement Therapy
921368|NCT02418455|Rare Disease
921369|NCT02418455|Mucopolysaccharidosis type 7
921370|NCT02418455|Lysosomal Storage Disease
921371|NCT02418455|Metabolic Disorder
921372|NCT02418442|Systemic Arthritis
921373|NCT02418442|Oligoarthritis
921374|NCT02418442|Polyarthritis (Rheumatoid Factor Negative)
921375|NCT02418442|Polyarthritis (Rheumatoid Factor Positive)
921376|NCT02418442|Psoriatic Arthritis
921377|NCT02418442|Enthesitis Related Arthritis (ERA)
921378|NCT02418442|Undifferianted Arthritis
921379|NCT02418442|CARRA Consensus Treatment Plans
921380|NCT02418442|FROST
921381|NCT02418429|fat oxidation
921382|NCT02418429|hunger
921383|NCT02418429|resistant starch
921384|NCT02418429|whey protein
921385|NCT02418377|Obesity
921386|NCT02418377|Genetics
921387|NCT02418377|Whole exome sequencing
921388|NCT02418377|Children
921389|NCT02418351|RRMS
921390|NCT02418325|RRMS
921391|NCT02418312|histamine-2 receptor antagonist
921392|NCT02418312|peptic ulcer
921393|NCT02418312|thienopyridine
921394|NCT02418312|prevention
921395|NCT02418299|urinary incontinence
921396|NCT02418299|Er:YAG laser
921397|NCT02418286|Low Back Pain
921398|NCT02418286|Korean Rehabilitation Clinic
921399|NCT02418286|Patient Registry
921400|NCT02418273|denosumab
921401|NCT02418273|pediatric
921402|NCT02418273|rheumatology
921403|NCT02418273|osteoporosis
921404|NCT02418273|glucocorticoid
921405|NCT02418260|Humerus
921406|NCT02418260|shaft
921407|NCT02418260|diaphyseal
921408|NCT02418260|fractures
921409|NCT02418247|radioactive iodine therapy
921410|NCT02418247|ablation
921411|NCT02418247|thyroid cancer
921412|NCT02418234|Non-small Cell Lung Cancer
921413|NCT02418234|circulating tumor DNA
921414|NCT02418234|T790M
921415|NCT02418234|amplification refractory mutation system
921416|NCT02418234|digital droplet PCR
921417|NCT02418221|histamine, biogenic amines, diamine oxidase
921418|NCT02418195|Depression
921419|NCT02418195|Ketamine
921420|NCT02418195|Suicide Attempt
921421|NCT02418195|Suicidal Ideation
921422|NCT02418195|Suicidality
921423|NCT02418182|Analgesic
921424|NCT02418182|Pain Control
921425|NCT02418182|IVF
921426|NCT02418182|Tylenol
921427|NCT02418182|Acetaminophen
921428|NCT02418182|Egg Retrieval
921429|NCT02418182|iv vitro Fertilization
921430|NCT02418117|Stereolitographic guide
921431|NCT02418117|flapless surgery
921432|NCT02418117|dental implants
921433|NCT02418091|patients with moderate DKD and uncontrolled HTN
921434|NCT02418065|Physical exercises
921435|NCT02418065|Oral nutritional supplementation
921436|NCT02418065|Multimodal
921437|NCT02418065|Hemodialysis
921438|NCT02418065|Protein-Energy Wasting
921439|NCT02418052|esophageal cancer
921440|NCT02418052|minimally invasive esophagectomy
921441|NCT02418052|anastomotic leak
921442|NCT02418052|neck flexion
921443|NCT02418039|Minimal hepatic encephalopathy
921444|NCT02418039|Nutrition
921445|NCT02418013|Frailty
921446|NCT02418013|Umbilical cord blood
921447|NCT02418013|Plasma
921448|NCT02418013|Randomized trial
921449|NCT02418013|Double-blinded trial
921450|NCT02418013|Placebo-controlled trial
921451|NCT02417974|Prevention
921452|NCT02417974|Recurrence
921453|NCT02417974|Fecal Microbiota Therapy
921454|NCT02417961|Asthma,
921455|NCT02417961|Bronchial Diseases,
921456|NCT02417961|Respiratory Tract Diseases,
921457|NCT02417961|Lung Diseases,
921458|NCT02417961|Obstructive Lung Diseases,
921459|NCT02417961|Benralizumab
921460|NCT02417909|Obesity
921461|NCT02417909|quality of life
921462|NCT02417909|teenagers
921463|NCT02417909|psychological impact
921464|NCT02417896|Acute kidney injury
921465|NCT02417896|Spironolactone
921466|NCT02417883|Furosemide
921467|NCT02417883|Interstitial Fibrosis
921468|NCT02417870|Transplantation
921469|NCT02417870|interleukin-2
921470|NCT02417870|IL-2
921471|NCT02417870|Kidney
921472|NCT02417870|Renal
921473|NCT02417857|Single İncision Laparoscopic Surgery
921474|NCT02417857|Conventional Laparoscopic Surgery
921475|NCT02417792|psoriasis
921476|NCT02417792|microbiota
921477|NCT02417766|Genetic Testing
921478|NCT02417766|Secondary Findings
921479|NCT02417766|Immune-Mediated Disorders
921480|NCT02417766|Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal in
921481|NCT02417766|Whole Exome Sequencing
921482|NCT02417753|PARACENTESIS
921483|NCT02417753|STAT3 Antisense Oligonucleotide
921484|NCT02417753|Ascites
921485|NCT02417753|AZD9150
921486|NCT02417753|Surgical Resection
921487|NCT02417740|Portal Hypertension
921488|NCT02417740|Portal Fibrosis
921489|NCT02417740|Liver Disease
921490|NCT02417740|Varices
921491|NCT02417740|Splenomegaly
921492|NCT02417727|MEMORY TESTING
921493|NCT02417727|Biomarkers
921494|NCT02417727|Learning
921495|NCT02417714|Computed Tomography
921496|NCT02417714|Radiation Reduction
921497|NCT02417714|Iterative Reconstruction
921498|NCT02417688|carotid atherosclerosis, PET imaging agent
921499|NCT02417675|Option B+
921500|NCT02417675|Adherence Club
921501|NCT02417675|Postpartum
921502|NCT02417675|Breastfeeding
921503|NCT02417675|Mother-to-child transmission
921504|NCT02417662|NSCLC
921505|NCT02417662|Stereotactic Ablative Radiotherapy
921506|NCT02417662|Radiotherapy
921507|NCT02417662|Randomised
921508|NCT02417662|Controlled
921509|NCT02417662|Oligometastatic
921510|NCT02417610|Polynucleotide
921511|NCT02417610|Hyaluronic acid
921512|NCT02417610|Intra articular injection
921513|NCT02417597|hepatitis E
921514|NCT02417571|Chronic kidney disease
921515|NCT02417571|Blood pressure
921516|NCT02417571|ambulatory blood pressure
921517|NCT02417571|glomerular filtration rate
921518|NCT02417519|Coffee
921519|NCT02417519|Chlorogenic acid
921520|NCT02417519|Insulin
921521|NCT02417519|Appetite
921522|NCT02417519|Metabolomics
921523|NCT02417506|Acute pain
921524|NCT02417506|Herbal
921525|NCT02417506|VAS
921526|NCT02417506|Stop watch
921527|NCT02417493|Food allergy
921528|NCT02417493|self-management
921529|NCT02417493|epinephrine self-injection
921530|NCT02417493|ntervention
921531|NCT02417493|adolescents
921532|NCT02417467|Electronic cigarette
921533|NCT02417467|E-cigarette
921534|NCT02417467|Smoking cessation
921535|NCT02417454|probiotic
921536|NCT02417454|stress
921537|NCT02417454|emotion psychophysiology
921538|NCT02417454|brain-body-gut interactions
921539|NCT02417441|TiLE
921540|NCT02417441|Embryo Assessment
921541|NCT02417441|Pregnancy
921542|NCT02417441|Implantation
921543|NCT02417441|Fertilization
921544|NCT02417428|Muscle function
921545|NCT02417428|Functional capacity
921546|NCT02417415|Supine hypertension
921547|NCT02417415|Autonomic failure
921548|NCT02417415|Heat intolerance
921549|NCT02417415|Orthostatic hypotension
921550|NCT02417415|Heat stress
921551|NCT02417402|back pain
921552|NCT02417402|low back pain
921553|NCT02417402|chronic low back pain
921554|NCT02417389|primary hyperparathyroidism
921555|NCT02417389|hypercalcemia
921556|NCT02417389|osteoporosis
921557|NCT02417389|bone turnover
921558|NCT02417389|bone mineral density
921559|NCT02417389|fractures
921560|NCT02417376|Coronary heart disease
921561|NCT02417376|Periodontitis
921562|NCT02417376|C-reactive protein
921563|NCT02417376|Blood pressure
921564|NCT02417363|biomarkers
921565|NCT02417363|renal disease
921566|NCT02417363|periodontitis
921567|NCT02417324|medulloblastoma
921568|NCT02417324|ependymoma
921569|NCT02417324|pineoblastoma
921570|NCT02417324|CNS-PNET
921571|NCT02417311|Engineered Heart Tissue (EHT)
921572|NCT02417311|human induced pluripotent stem cells (hiPSC)
921573|NCT02417298|ketamine
921574|NCT02417298|pain
921575|NCT02417298|sickle cell disorder
921576|NCT02417285|Non-Hodgkin's Lymphoma
921577|NCT02417285|Diffused Large B-Cell Lymphoma
921578|NCT02417285|Phase 1B
921579|NCT02417285|Open-Label
921580|NCT02417285|Safety and Efficacy
921581|NCT02417285|CC-122
921582|NCT02417285|Obinutuzumab
921583|NCT02417285|GA101
921584|NCT02417285|Relapsed
921585|NCT02417285|Refractory
921586|NCT02417272|Total Disc Replacement
921587|NCT02417272|Anterior Cervical Decompression and Fusion
921588|NCT02417259|Spectroscopy, Near-Infrared
921589|NCT02417246|pharmacokinetics
921590|NCT02417246|pharmacodynamics
921591|NCT02417246|pharmacogenetics
921592|NCT02417233|HIV-positive
921593|NCT02417233|adherence
921594|NCT02417233|engagement to care
921595|NCT02417233|mHealth
921596|NCT02417233|SMS
921597|NCT02417233|peer navigation
921598|NCT02417233|retention
921599|NCT02417207|hepatitis B immune globulin (HBIG)
921600|NCT02417207|liver transplantation
921601|NCT02417207|hepatitis B
921602|NCT02417207|entecavir
921603|NCT02417194|Renal cell carcinoma
921604|NCT02417194|hemoglobin A1c protein
921605|NCT02417194|Pathologic outcomes
921606|NCT02417194|Oncological outcomes
921607|NCT02417194|Nephrectomy
921608|NCT02417181|Physician assistants
921609|NCT02417181|Out-of-hours medical care
921610|NCT02417181|Primary healthcare
921611|NCT02417181|Emergency Medical Services
921612|NCT02417155|Autonomic Nerve System
921613|NCT02417155|Epinephrin
921614|NCT02417155|Hyperventilation
921615|NCT02417155|Hypoventilation
921616|NCT02417064|Treatment-resistant Depression
921617|NCT02417064|Esketamine
921618|NCT02417064|Placebo
921619|NCT02417064|Oral Antidepressant
921620|NCT02417051|Psychological Resilience
921621|NCT02417051|Perceived Stress
921622|NCT02417051|Psychological Stress
921623|NCT02417051|Disaster Worker
921624|NCT02417051|Superstorm Sandy
921625|NCT02417051|Mental Health
921626|NCT02417051|Prevention
921627|NCT02417038|Postoperative Respiratory Monitoring
921628|NCT02417038|Neuraxial Opioid Administration for Cesarean Delivery
921629|NCT02417025|Military
921630|NCT02417025|Health Service Delivery
921631|NCT02417025|Telepsychology
921632|NCT02417025|Prolonged Exposure
921633|NCT02417025|Off-duty Activity of Military Personnel
921634|NCT02417012|lifestyle
921635|NCT02417012|exercise
921636|NCT02417012|physical activity
921637|NCT02417012|diet
921638|NCT02417012|glycemic control
921639|NCT02417012|hba1c
921640|NCT02417012|glucose lowering drugs
921641|NCT02416999|glioma
921642|NCT02416999|high-grade glioma
921643|NCT02416960|female infertility
921644|NCT02416960|glycemic index
921645|NCT02416960|leptin
921646|NCT02416960|ghrelin
921647|NCT02416960|overweight
921648|NCT02416960|obesity
921649|NCT02416960|in vitro fertilization
921650|NCT02416947|Soluble Corn Fiber
921651|NCT02416947|Osteoporosis
921652|NCT02416947|Bone Loss
921653|NCT02416921|Facebook
921654|NCT02416921|Weight Gain Prevention
921655|NCT02416921|Women's Health
921656|NCT02416921|Online
921657|NCT02416921|Weight Gain
921658|NCT02416921|Weight Loss
921659|NCT02416921|Female Contraception
921660|NCT02416921|Obesity
921661|NCT02416921|Body Weight
921662|NCT02416921|Internet
921663|NCT02416882|active
921664|NCT02416882|not active
921665|NCT02416882|normal body weight
921666|NCT02416869|Dexamethasone
921667|NCT02416869|Lower third molar surgery
921668|NCT02416856|Aphasia
921669|NCT02416856|Brain
921670|NCT02416856|Stimulation
921671|NCT02416856|Communication
921672|NCT02416856|Stroke
921673|NCT02416856|Speech Disorders
921674|NCT02416856|Communications Disorders
921675|NCT02416856|Neurobehavioral Manifestations
921676|NCT02416856|Neurologic Manifestations
921677|NCT02416856|Nervous System Diseases
921678|NCT02416856|Signs and Symptoms
921679|NCT02416843|Adipose tissue
921680|NCT02416843|metabolism
921681|NCT02416843|inflammation
921682|NCT02416843|post-prandial
921683|NCT02416843|human
921684|NCT02416830|embolization
921685|NCT02416830|visceral Aneurysms
921686|NCT02416830|Prospective Registry
921687|NCT02416817|Thrombelastography
921688|NCT02416817|Massive Transfusion
921689|NCT02416817|Major Trauma
921690|NCT02416817|Blood products
921691|NCT02416817|Thromboelastometry
921692|NCT02416804|buprenorphine
921693|NCT02416804|transdermal system
921694|NCT02416804|Pain, postoperative
921695|NCT02416804|Quality of life
921696|NCT02416804|Spinal stenosis
921697|NCT02416804|Posterior lumbar fusion
921698|NCT02416791|robotic therapy
921699|NCT02416791|transcranial direct current stimulation
921700|NCT02416778|COPD
921701|NCT02416778|Chronic Obstructive Pulmonary Disease
921702|NCT02416778|Iron deficiency
921703|NCT02416778|6 Minute-Walking-Test
921704|NCT02416765|Closed-loop strategy
921705|NCT02416765|Artificial pancreas
921706|NCT02416765|Postprandial glucose
921707|NCT02416765|Insulin
921708|NCT02416765|Glucagon
921709|NCT02416765|Hypoglycemia
921710|NCT02416765|Type 1 diabetes
921711|NCT02416752|remifentanil
921712|NCT02416752|head and neck surgery
921713|NCT02416752|recovery pofile
921714|NCT02416752|Opioid induced hyperalgesia
921715|NCT02416752|post operative pain
921716|NCT02416739|EGFR mutated lung cancer
921717|NCT02416726|Gene testing
921718|NCT02416726|Next-generation sequecing
921719|NCT02416726|Primary tumor
921720|NCT02416726|Metastatic lymph node
921721|NCT02416726|Peripheral blood
921722|NCT02416713|Driving
921723|NCT02416713|Teens
921724|NCT02416713|Texting
921725|NCT02416713|Cellphone
921726|NCT02416713|DriveID
921727|NCT02416713|Motor vehicle accident
921728|NCT02416700|Dental prosthesis
921729|NCT02416700|Patients
921730|NCT02416700|Osseointegrated implants
921731|NCT02416674|abdominal wall
921732|NCT02416674|vascularized composite allotransplantation
921733|NCT02416661|Gaucher Disease type 1
921734|NCT02416661|Lymphatic Diseases
921735|NCT02416661|Lipid Metabolism, Inborn Errors
921736|NCT02416661|Lipid Metabolism Disorders
921737|NCT02416661|Lipidoses
921738|NCT02416648|Adult HIV patients
921739|NCT02416648|Knowledge
921740|NCT02416648|Attitudes
921741|NCT02416648|Sexual behaviors
921742|NCT02416635|Liver Neoplasms
921743|NCT02416635|Circulating Tumor Cells
921751|NCT02416609|Locally advanced pancreatic cancer
921752|NCT02416609|Stereotactic Body Radiotherapy
921753|NCT02416609|Chemopotentiator
921754|NCT02416609|Low dose radiotherapy
921755|NCT02416609|Hyper-Radiosensitivity
921756|NCT02416596|ICSI
921757|NCT02416596|IVF
921758|NCT02416596|hysteroscopy
921759|NCT02416596|Supervision
921760|NCT02416596|In-vitro Fertilization
921761|NCT02416583|membrane sweeping
921762|NCT02416583|dinoprostone
921763|NCT02416583|nulliparas
921764|NCT02416583|labor induction
921765|NCT02416570|Clarithromycin
921766|NCT02416544|Overweight
921767|NCT02416544|Obesity
921768|NCT02416544|Caloric Restriction
921769|NCT02416544|Diet, Reducing
921770|NCT02416544|Diet, Sodium-Restricted
921771|NCT02416544|Body Weight Changes
921772|NCT02416544|Energy intake
921773|NCT02416544|Feeding Behavior
921774|NCT02416531|Vulvar lichen sclerosus
921775|NCT02416531|Photodynamic therapy
921776|NCT02416531|Low-level laser therapy
921777|NCT02416531|Clobetasol propionate
921778|NCT02416518|Cancer
921779|NCT02416518|Malignancy
921780|NCT02416518|Genomic
921781|NCT02416518|Molecular
921782|NCT02416479|medication adherence
921783|NCT02416479|outcomes
921784|NCT02416479|intervention
921785|NCT02416479|randomized controlled trial
921786|NCT02416466|Colorectal cancer
921787|NCT02416466|Liver metastases
921788|NCT02416466|Breast cancer
921789|NCT02416466|Gastric cancer
921790|NCT02416466|Pancreas cancer
921791|NCT02416466|Carcinoembryonic antigen
921792|NCT02416466|CAR-T
921793|NCT02416466|Immunotherapy
921794|NCT02416453|Healthy
921795|NCT02416453|Ebola viruses
921796|NCT02416453|Ebola Viral Disease (EVD)
921797|NCT02416453|Filoviruses
921798|NCT02416453|Monovalent vaccine
921799|NCT02416453|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
921800|NCT02416453|Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)
921801|NCT02416453|Safety
921802|NCT02416453|Immunogenicity
921803|NCT02416440|South African
921804|NCT02416440|urban African
921805|NCT02416440|diabetes
921806|NCT02416440|prevalence
921807|NCT02416440|risk factors
921808|NCT02416440|genetics
921809|NCT02416427|Atorvastatin
921810|NCT02416427|TAZ
921811|NCT02416427|Hippo pathway
921812|NCT02416427|ki67
921813|NCT02416401|healthy
921814|NCT02416401|aging
921815|NCT02416401|cognition
921816|NCT02416401|age-related cognitive decline
921817|NCT02416362|Postural Balance
921818|NCT02416362|Electromyography
921819|NCT02416362|Torque
921820|NCT02416349|Stroke
921821|NCT02416349|Stretching
921822|NCT02416349|Respiratory muscle
921823|NCT02416349|Ventilatory pattern
921824|NCT02416349|Optoelectronic plethysmography
921825|NCT02416336|sentinel lymph node
921826|NCT02416336|lymphoscintigraphy
921827|NCT02416336|intraoperative gamma camera
921828|NCT02416310|TEAS
921829|NCT02416310|cesarean section
921830|NCT02416310|gastrointestinal function
921831|NCT02416297|malocclusion
921832|NCT02416297|accelerated tooth movement
921833|NCT02416297|Tomography
921834|NCT02416297|Extraction
921835|NCT02416258|Psoriasis
921836|NCT02416232|melanoma
921837|NCT02416232|dabrafenib
921838|NCT02416232|trametinib
921839|NCT02416232|BRAF V600E/K mutation
921840|NCT02416219|Cricoid cartilage, cricoid pressure, obstetric
921841|NCT02416206|Multiple myeloma
921842|NCT02416206|hematopoietic stem cell transplant
921843|NCT02416193|Diabetes
921844|NCT02416193|Cognition
921845|NCT02416193|Functioning
921846|NCT02416180|EVOHALER
921847|NCT02416180|Asthma
921848|NCT02416180|SERETIDE
921849|NCT02416180|DISKUS Inhaler
921850|NCT02416180|MDI
921851|NCT02416154|interferon-epsilon
921852|NCT02416154|female reproductive tract
921853|NCT02416154|neopterin
921854|NCT02416154|menstrual cycle
921855|NCT02416115|PONV
921856|NCT02416115|ramosetron
921857|NCT02416115|naloxone
921858|NCT02416089|Tampostat
921859|NCT02416089|Tamponade
921860|NCT02416089|Postpartum hemorrhage
921861|NCT02416076|Ulthera® System
921862|NCT02416076|Ultherapy®
921863|NCT02416076|Ulthera, Inc.
921864|NCT02416050|Cocaine
921865|NCT02416050|Dependence
921866|NCT02416050|Abstinence
921867|NCT02416050|Prediction
921868|NCT02416050|Model
921869|NCT02416050|Humans
921870|NCT02416050|MRI
921871|NCT02416050|Cognitive
921872|NCT02416050|Impulsivity
921873|NCT02416050|Craving
921874|NCT02416037|ARDS
921875|NCT02416037|prone position
921876|NCT02416037|PEEP
921877|NCT02416037|mechanical ventilation
921878|NCT02416024|angiotensin converting enzyme inhibitor
921879|NCT02416024|anesthesia
921880|NCT02416011|e-cigarette
921881|NCT02416011|nicotine dependence
921882|NCT02415998|TEE
921883|NCT02415985|pharmacokinetics of rifabutin
921884|NCT02415985|HIV/TB co-infection
921885|NCT02415985|resource limited setting
921886|NCT02415985|AUC
921887|NCT02415985|Cmax
921888|NCT02415985|Cmin
921889|NCT02415985|Ctrough
921890|NCT02415972|ultrasound imaging
921891|NCT02415972|acute ischemic stroke
921892|NCT02415972|cerebral perfusion measurement in acute ischemic stroke
921893|NCT02415959|Exocrine Pancreatic Insufficiency
921894|NCT02415946|regenerative medicine
921895|NCT02415946|bone substitutes
921896|NCT02415946|sinus floor augmentation
921897|NCT02415933|Burkina Faso
921898|NCT02415933|West Africa
921899|NCT02415933|Children
921900|NCT02415933|Child Abuse
921901|NCT02415933|Child Mental Health
921902|NCT02415933|Economic Empowerment
921903|NCT02415933|Women's Empowerment
921904|NCT02415933|Domestic Violence
921905|NCT02415933|Child and Family Well-being
921906|NCT02415933|Child Separation
921907|NCT02415933|Child Labor
921908|NCT02415933|Child Maltreatment
921909|NCT02415920|Investigating oxytocin's effects
921910|NCT02415920|human communication
921911|NCT02415881|Panitumumab
921912|NCT02415881|Optical Imaging
921913|NCT02415868|Vaginal Microbiota
921914|NCT02415842|Supra-seasonal influenza vaccine
921915|NCT02415842|Pandemic
921916|NCT02415842|Exploratory
921917|NCT02415842|Protein epitopes
921918|NCT02415842|Laboratory evaluation
921919|NCT02415842|Retrospective
921920|NCT02415829|Neoajuvant chemotherapy
921921|NCT02415816|Pediatric
921922|NCT02415816|Whole body DWI MRI
921923|NCT02415803|low-dose ticagrelor
921924|NCT02415803|clopidogrel
921925|NCT02415803|Chinese patients with NSTE-ACS
921926|NCT02415803|platelet reactivity
921927|NCT02415803|inhibition of platelet aggregation
921928|NCT02415790|E2027
921929|NCT02415790|Healthy Adult and Elderly Subjects
921930|NCT02415790|Pharmacokinetics/Pharmacodynamics
921931|NCT02415738|Near infrared spectroscopy
921932|NCT02415738|Cerebral oxygenation
921933|NCT02415738|Acute respiratory distress syndrom
921934|NCT02415738|Prone positioning
921935|NCT02415712|Pharmacotherapy
921936|NCT02415686|Dravet syndrome
921937|NCT02415686|Sudden Unexpected Death in Epilepsy (SUDEP)
921938|NCT02415686|Arrhythmias
921939|NCT02415673|Orthodontics
921940|NCT02415673|Nitinol
921941|NCT02415660|trigger point dry needling
921942|NCT02415660|thoracic spine manipulation
921943|NCT02415660|deep cervical extensor muscle
921944|NCT02415660|deep cervical flexor muscle
921945|NCT02415660|shear wave elastography
921946|NCT02415647|children
921947|NCT02415647|mental health
921948|NCT02415647|family genetic study
921949|NCT02415621|metastatic
921950|NCT02415621|castration resistant
921951|NCT02415621|abiraterone therapy
921952|NCT02415582|Hypertension
921953|NCT02415582|Bloodpressure
921954|NCT02415582|Post-exercise hypotension
921955|NCT02415582|Combined exercise
921956|NCT02415582|Aerobic exercise
921957|NCT02415582|Resistance exercise
921958|NCT02415582|Aging
921959|NCT02415582|Elderly
921960|NCT02415582|Ambulatory blood pressure monitoring
921961|NCT02415569|bowel cleansing
921962|NCT02415569|bisacodyl
921963|NCT02415569|polyethyleneglycol
921964|NCT02415569|colonoscopy
921965|NCT02415569|the bristol stool form scale
921966|NCT02415556|Type 2 Diabetes Mellitus
921967|NCT02415556|Intranasal Insulin
921968|NCT02415556|Placebo
921969|NCT02415556|Memory
921970|NCT02415556|Gait
921971|NCT02415556|Non diabetic older controls
921972|NCT02415517|Cognitive training
921973|NCT02415517|Cognitive impairment
921974|NCT02415517|Heart failure
921975|NCT02415517|Cognition
921976|NCT02415504|Care transition
921977|NCT02415504|Behavioural and psychological symptoms of dementia
921978|NCT02415504|BPSD
921979|NCT02415504|Dementia
921980|NCT02415504|Persons with dementia
921981|NCT02415504|Discharge processes
921982|NCT02415491|TGA
921983|NCT02415491|ASO
921984|NCT02415491|magnetic resonance imaging (MRI)
921985|NCT02415491|young adulthood
921986|NCT02415478|Chronic obstructive pulmonary disease (COPD)
921987|NCT02415478|endoscopic lung volume reduction
921988|NCT02415478|Endobronchial valve
921989|NCT02415478|physical capacity
921990|NCT02415478|quality of life
921991|NCT02415465|Knee
921992|NCT02415465|Replacement
921993|NCT02415452|relationship
921994|NCT02415452|retinal artery lesions
921995|NCT02415452|long-term outcomes
921996|NCT02415439|Safety
921997|NCT02415439|tolerability
921998|NCT02415439|pharmacokinetics
921999|NCT02415439|adult
922000|NCT02415439|volunteers
922001|NCT02415413|Smoldering multiple myeloma
922002|NCT02415413|Carfilzomib
922003|NCT02415413|Lenalidomide
922004|NCT02415413|Melphalan
922005|NCT02415413|Dexamethasone
922006|NCT02415413|Autologous stem cell transplantation
922007|NCT02415361|Parents
922008|NCT02415361|Follow-Up Studies
922009|NCT02415309|Melatonin
922010|NCT02415309|Lumbar medial branch block (LMBB)
922011|NCT02415309|Anxiety
922012|NCT02415309|Interventional Pain
922013|NCT02415309|Pain Procedure
922014|NCT02415296|gambling disorder
922015|NCT02415296|screening model
922016|NCT02415296|online gambling
922017|NCT02415296|clinical validation
922018|NCT02415257|Vestibular schwannoma
922019|NCT02415257|acoustic neuroma
922020|NCT02415257|cerebellopontine angle tumour
922021|NCT02415257|gentamicin
922022|NCT02415257|rehabilitation
922023|NCT02415257|postural balance
922024|NCT02415244|ultrasound
922025|NCT02415231|humor laughter C reactive protein
922026|NCT02415205|Pain and stress assessment in premature infants
922027|NCT02415192|safety data
922028|NCT02415192|hypertension therapy
922029|NCT02415179|Newly diagnosed asthma
922030|NCT02415179|peripheral airway function
922031|NCT02415127|Interferon gamma
922032|NCT02415114|Coenzyme Q10
922033|NCT02415114|Resveratrol
922034|NCT02415114|Statin
922035|NCT02415101|Adenocarcinoma
922036|NCT02415101|Squamous cell carcinoma
922037|NCT02415101|Gastroesophageal Junction
922038|NCT02415088|Nerve block
922040|NCT02415062|Parkinson's disease
922041|NCT02415062|dementia
922042|NCT02415036|HCC
922043|NCT02415036|ICC
922044|NCT02415036|Percutaneous hepatic perfusion
922045|NCT02414997|RIPC (remote ischemic preconditioning)
922046|NCT02414997|primary hypertension stage I
922047|NCT02414997|vascular function
922048|NCT02414997|microRNA-126
922049|NCT02414997|microRNA-34a
922050|NCT02414984|Rheumatoid Arthritis
922051|NCT02414984|Golimumab
922052|NCT02414984|Observational
922053|NCT02414984|Compliance
922054|NCT02414971|cancer related fatigue
922055|NCT02414971|prostate cancer
922056|NCT02414971|mitochondria
922057|NCT02414932|ketamine
922058|NCT02414932|electroconvulsive therapy
922059|NCT02414932|glutamate
922060|NCT02414906|Goal Directed Therapy
922061|NCT02414906|Acute Kidney Injury
922062|NCT02414880|Sugammadex
922063|NCT02414880|Neostigmine
922064|NCT02414880|Rocuronium
922065|NCT02414880|Cirrhosis
922066|NCT02414880|Liver resection
922067|NCT02414880|Neuromuscular
922068|NCT02414841|radiocephalic
922069|NCT02414841|arteriovenous fistula
922070|NCT02414841|AVF
922071|NCT02414841|hemodialysis
922072|NCT02414841|PRT-201
922073|NCT02414841|vonapanitase
922074|NCT02414841|vascular access
922075|NCT02414841|kidney
922076|NCT02414841|renal
922077|NCT02414841|PATENCY-2
922078|NCT02414841|secondary patency
922079|NCT02414841|fistula abandonment
922080|NCT02414841|use for hemodialysis
922081|NCT02414789|erythema migrans
922082|NCT02414789|Lyme
922083|NCT02414789|early diagnosis
922084|NCT02414789|skin biomarkers
922085|NCT02414789|proteomics diagnostic
922086|NCT02414789|mass spectrometry
922087|NCT02414750|Vemurafenib/cobimetinib (GDC-0973)
922088|NCT02414750|Melanoma
922089|NCT02414750|Positron Emission Tomography
922090|NCT02414750|Tumor Characteristics
922091|NCT02414750|Response monitoring
922092|NCT02414750|Resistance prediction
922093|NCT02414750|molecular targeted therapy
922094|NCT02414711|Depression
922095|NCT02414711|Primary care
922096|NCT02414711|General Practitioners
922097|NCT02414685|poor-prognosis germ cell cancer, paclitaxel, ifosfamid and cisplatin regimen, tumor marker decline
922098|NCT02414672|psychosocial intervention
922099|NCT02414672|advanced lung cancer
922100|NCT02414672|caregivers
922101|NCT02414672|self-care
922102|NCT02414633|Psoriatic Arthritis
922103|NCT02414620|Efficacy
922104|NCT02414620|Dental Vibe Unit
922105|NCT02414620|Reduction
922106|NCT02414620|Elimination
922107|NCT02414620|Dental Anesthetic Injection
922108|NCT02414607|Elderberry juice
922109|NCT02414607|Alzheimer's
922110|NCT02414607|Inflammation
922111|NCT02414555|Fluid Management
922112|NCT02414516|HDAC
922113|NCT02414516|Epigenetic
922114|NCT02414516|Histone
922115|NCT02414516|Acetylation
922116|NCT02414503|oxytocin
922117|NCT02414503|social cognition
922118|NCT02414490|CIDP
922119|NCT02414477|tobacco toxicants
922120|NCT02414477|smokeless tobacco
922121|NCT02414477|nitrosamines
922122|NCT02414477|tobacco specific nitrosamines (TSNAs)
922123|NCT02414464|tooth bleaching
922124|NCT02414464|adolescent
922125|NCT02414464|clinical trial
922126|NCT02414451|Propranolol
922127|NCT02414425|Fecal Incontinence
922128|NCT02414425|Botulinum Toxin A
922129|NCT02414425|Rectal injection
922130|NCT02414412|Ulmus macrocarpa water extract
922131|NCT02414412|immunity
922132|NCT02414399|post-discharge mortality
922133|NCT02414399|morbidity and mortality prevention
922134|NCT02414399|azithromycin
922135|NCT02414399|linear growth
922136|NCT02414386|Vitamin D
922137|NCT02414386|Continuous Renal Replacement Therapy
922138|NCT02414386|Multi Organ Failure
922139|NCT02414386|Acute Kidney Injury
922140|NCT02414386|Critical Care
922141|NCT02414386|Citrate anticoagulation
922142|NCT02414373|urination
922143|NCT02414373|analgesia, epidural
922144|NCT02414373|local anesthetics
922145|NCT02414360|Review Literature as Topic
922146|NCT02414347|Dementia
922147|NCT02414347|Tauopathies
922148|NCT02414347|Brain Diseases
922149|NCT02414347|Central Nervous System Diseases
922150|NCT02414347|Mild Cognitive Impairment
922151|NCT02414347|Nervous System Diseases
922152|NCT02414347|Neurodegenerative Disease
922153|NCT02414334|Oligometastases
922154|NCT02414334|Stereotactic ablative radiotherapy (SABR)
922155|NCT02414334|Metastatic tumours
922156|NCT02414308|Erectile dysfunction, Peyronie's disease, stem cell
922157|NCT02414295|Stem cell
922158|NCT02414295|Kleinfelter syndrome
922159|NCT02414295|Azoospermia
922160|NCT02414295|Sterility
922161|NCT02414295|Infertility
922162|NCT02414282|Dementia
922163|NCT02414282|Brain Diseases
922164|NCT02414282|mild cognitive impairment
922165|NCT02414282|Central Nervous System Diseases
922166|NCT02414282|Neurodegenerative Disease
922167|NCT02414269|modified T cells
922168|NCT02414269|cyclophosphamide
922169|NCT02414269|CAR T cells
922170|NCT02414269|15-007
922171|NCT02414269|CAR
922172|NCT02414269|immunotherapy
922173|NCT02414256|breast surgery
922174|NCT02414230|fronto-temporal dementia
922175|NCT02414230|Tauopathies
922176|NCT02414230|Nervous System Diseases
922177|NCT02414230|Neurodegenerative Diseases
922178|NCT02414204|Arteriovenous Fistulas (AVFS)
922179|NCT02414204|Hemodialysis Fistula Maturation (HFM)
922180|NCT02414204|Flow-Mediated Dilation (FMD)
922181|NCT02414204|Nitroglycerin-Mediated (NMD)
922182|NCT02414204|Venous Plethysmography (VP)
922183|NCT02414191|Feedback
922184|NCT02414191|Temperature management
922185|NCT02414191|Anesthesia
922186|NCT02414178|Dementia
922187|NCT02414178|Brain Diseases
922188|NCT02414178|Central Nervous System Diseases
922189|NCT02414178|Mild Cognitive Impairment
922190|NCT02414178|nervous system diseases
922191|NCT02414178|Neurodegenerative Disease
922192|NCT02414165|Recurrence
922195|NCT02414126|Heart failure
922196|NCT02414126|child
922197|NCT02414126|work of breathing
922198|NCT02414126|cardiac function
922199|NCT02414126|sleep
922200|NCT02414126|polysomnography
922201|NCT02414126|CPAP
922202|NCT02414087|flat foot
922203|NCT02414087|therapeutic effect
922204|NCT02414087|insoles
922205|NCT02414087|children
922206|NCT02414061|Postprandial glycemia
922207|NCT02414061|metabolic health measures
922208|NCT02414048|Hypoxia
922209|NCT02414048|Head and neck cancer
922210|NCT02414035|atrial fibrillation
922211|NCT02414035|anticoagulation
922212|NCT02414035|Dabigatran
922213|NCT02413996|Virtual Reality Therapy
922214|NCT02413996|Rehabilitation
922215|NCT02413996|Total Knee Replacement
922216|NCT02413996|Knee Arthroplasty
922217|NCT02413996|Exercise
922218|NCT02413996|Arthritis
922219|NCT02413996|Rheumatic Disease
922220|NCT02413970|OSA
922221|NCT02413970|Neurostimulation
922222|NCT02413970|Hypoglossal nerve
922223|NCT02413970|Tongue
922224|NCT02413970|Upper airway stimulation
922225|NCT02413970|Surgery
922226|NCT02413957|Elderly Patients
922227|NCT02413957|Medication Safety
922228|NCT02413957|Pharmaceutical Care
922229|NCT02413957|Medication Reconciliation
922230|NCT02413931|tuberculosis
922231|NCT02413931|MDR-TB
922232|NCT02413866|body composition
922233|NCT02413866|anthropometry
922234|NCT02413840|COPD
922235|NCT02413840|Baduanjin qigong
922236|NCT02413840|depression
922237|NCT02413840|anxiety
922238|NCT02413827|Yervoy™, CDX-1401
922239|NCT02413801|Psoriasis
922240|NCT02413801|PDUS
922241|NCT02413788|adolescent idiopathic scoliosis
922242|NCT02413788|inflammatory markers
922243|NCT02413788|exercise
922244|NCT02413749|Psoriatic Arthritis
922245|NCT02413723|intubation
922246|NCT02413723|critical care
922247|NCT02413723|laryngoscope
922248|NCT02413723|videolaryngoscope
922249|NCT02413723|intratracheal
922250|NCT02413658|Phenytoin
922251|NCT02413658|Skin graft donor site
922252|NCT02413658|Clean surgical site
922253|NCT02413658|Wound model
922254|NCT02413632|HIV-positive MSM (men who have sex with men)
922255|NCT02413632|asymptomatic sexually transmitted infections
922256|NCT02413632|screening
922257|NCT02413606|follow up care
922258|NCT02413606|satisfaction with care
922259|NCT02413593|HCV genotype 3 (GT-3)
922260|NCT02413593|HCV
922261|NCT02413593|Sustained Virologic Response
922262|NCT02413593|Direct Acting Antiviral
922263|NCT02413593|GS-7977
922264|NCT02413593|GS-5885
922265|NCT02413593|Ribavirin
922266|NCT02413593|Sofosbuvir
922267|NCT02413593|Ledipasvir
922268|NCT02413593|Hepatitis C
922269|NCT02413593|Hepatitis C, Chronic
922270|NCT02413554|acetylcholinesterase inhibitors
922271|NCT02413554|rivastigmine patch
922272|NCT02413554|post-operational delirium
922273|NCT02413528|Patient Compliance
922274|NCT02413528|Mobile Applications
922275|NCT02413489|Lymphoma, Mantle-Cell
922276|NCT02413489|Lymphoma, Large B-Cell, Diffuse
922277|NCT02413489|Lymphoma, Follicular
922278|NCT02413489|Daratumumab
922279|NCT02413476|robotic-assisted gastrectomy
922280|NCT02413476|laparoscopic-assisted gastrectomy
922281|NCT02413476|gastric cancer
922282|NCT02413450|induced Pluripotent Stem Cells (iPSC)
922283|NCT02413450|Channelopathies
922284|NCT02413450|Catecholaminergic
922285|NCT02413450|Arrhythmogenic
922286|NCT02413437|contrast-enhanced ultrasound
922287|NCT02413437|biopsy
922288|NCT02413424|sucralose
922289|NCT02413411|Arthroplasty
922290|NCT02413411|Osteoarthritis
922291|NCT02413411|Replacement
922292|NCT02413411|Intervention
922293|NCT02413385|lifestyle intervention
922294|NCT02413385|physical activity
922295|NCT02413385|exercise
922296|NCT02413385|eHealth
922297|NCT02413385|technology
922298|NCT02413385|coaching
922299|NCT02413385|healthy eating
922300|NCT02413372|First Line Therapy
922301|NCT02413372|NASH
922302|NCT02413333|Contact lens solution
922303|NCT02413320|TNBC, breast cancer, neoadjuvant, carboplatin, docetaxel, paclitaxel, doxorubicin, cyclophosphamide
922304|NCT02413307|Compassion Focused Therapy
922305|NCT02413281|Healthy Volunteer
922306|NCT02413281|Abuse Liability
922307|NCT02413281|ALKS 5461
922308|NCT02413281|Alkermes
922309|NCT02413255|Drug therapy
922310|NCT02413242|S. aureus
922311|NCT02413242|P. aeruginosa
922312|NCT02413242|Colonization
922313|NCT02413242|Pneumonia
922314|NCT02413242|ICU
922315|NCT02413216|Tic Disorder
922316|NCT02413216|Tourette
922317|NCT02413216|Motor tic
922318|NCT02413216|Vocal tic
922319|NCT02413216|Habit reversal training
922320|NCT02413216|CBIT
922321|NCT02413216|TicHelper
922322|NCT02413216|Behavior Therapy
922323|NCT02413203|lipidomics
922324|NCT02413203|ex vivo human whole blood assay
922325|NCT02413203|celecoxib
922326|NCT02413203|selective COX-2 inhibitor
922327|NCT02413164|Schizophrenia
922328|NCT02413164|Mental Health
922329|NCT02413164|Physical Therapy
922330|NCT02413164|Quality of life
922331|NCT02413164|Metabolic Syndrome
922332|NCT02413164|Stigma
922333|NCT02413164|Positive and negative symptoms
922334|NCT02413151|Exercise training
922335|NCT02413151|Cardiac resynchronization therapy
922336|NCT02413151|Autonomic nervous system modulation
922337|NCT02413151|Chronic Heart failure
922338|NCT02413138|GHD
922339|NCT02413112|Aging
922340|NCT02413112|Sarcopenia
922341|NCT02413112|Resistance training
922342|NCT02413112|Strength
922343|NCT02413112|Muscle mass
922344|NCT02413086|diabetic foot ulcer
922345|NCT02413086|early-stage amputation
922346|NCT02413086|external therapy of herbs chitosan
922347|NCT02413086|wound surface healing
922348|NCT02413073|whole body vibration
922349|NCT02413073|kidney disease
922350|NCT02413034|antibiotic
922351|NCT02413021|Acute Myeloid Leukemia
922352|NCT02413021|Acute Lymphoid Leukemia
922353|NCT02413021|deferasirox
922354|NCT02412995|sea buckthorn
922355|NCT02412995|strawberry
922356|NCT02412995|glucose response
922357|NCT02412995|satiety
922358|NCT02412995|metabolomics
922359|NCT02412995|intake biomarker
922360|NCT02412956|mHealth
922361|NCT02412904|follicular stimulating hormone
922362|NCT02412904|human menopausal gonadotrophin
922363|NCT02412904|Recombinant follicular stimulating hormone (rFSH)
922364|NCT02412904|Gonadotrophin releasing hormone (GnRH) antagonists
922365|NCT02412904|GnRH agonist
922366|NCT02412904|in vitro fertilization
922367|NCT02412904|controled ovarian stimulation
922368|NCT02412904|number of mature oocytes
922369|NCT02412891|introduction of urinary catheter
922370|NCT02412865|mhealth
922371|NCT02412852|neuropathy
922372|NCT02412826|pancreatitis
922373|NCT02412826|acoustic
922374|NCT02412826|sensor
922375|NCT02412813|hypersensitivity
922376|NCT02412813|metal sensitivity
922377|NCT02412813|arthroplasty
922378|NCT02412813|implant-related hypersensitivity
922379|NCT02412813|metal-on-metal implants
922380|NCT02412813|knee revision
922381|NCT02412800|Extravascular lung water
922382|NCT02412800|Pulmonary vascualr permeability index
922383|NCT02412800|Liver transplantation
922384|NCT02412774|diet beverages
922385|NCT02412774|water
922386|NCT02412774|diabetes
922387|NCT02412774|weight loss
922388|NCT02412774|insulin sensitivity
922389|NCT02412761|Anti-hypertensive medications
922390|NCT02412761|Pediatrics
922391|NCT02412761|N-of-1 trial
922392|NCT02412748|Non-Resident
922393|NCT02412748|Fathers
922394|NCT02412748|African American
922395|NCT02412735|Chronic Lumbar Back Pain
922396|NCT02412735|Low back pain
922397|NCT02412735|Back pain
922398|NCT02412735|Degenerative Disc Disease
922399|NCT02412735|Injection of Degenerated Lumbar Disc
922400|NCT02412735|Intervertebral Disc Degeneration
922401|NCT02412735|Bone Diseases
922402|NCT02412735|Musculoskeletal Diseases
922403|NCT02412735|Nervous System Diseases
922404|NCT02412735|Neurologic Manifestations
922405|NCT02412735|Pain
922406|NCT02412735|Spinal Diseases
922407|NCT02412735|Stem Cells
922408|NCT02412735|Adult Stem Cells
922409|NCT02412735|Allogeneic Mesenchymal Precursor cells (MPCs)
922410|NCT02412735|Mesoblast
922411|NCT02412735|Hyaluronic Acid
922412|NCT02412735|Pharmaceutical Solutions
922413|NCT02412735|Adjuvants, Immunologic
922414|NCT02412735|Immunologic Factors
922415|NCT02412735|Pharmacologic Actions
922416|NCT02412735|Protective Agents
922417|NCT02412735|rexlemestrocel-L
922418|NCT02412735|Viscosupplements
922419|NCT02412722|Drug therapy
922420|NCT02412709|Long QT Syndrome
922421|NCT02412709|LQTS
922422|NCT02412709|genetic testing
922423|NCT02412709|ECG
922424|NCT02412709|saliva testing
922425|NCT02412696|placental morphology
922426|NCT02412696|CPAP
922427|NCT02412696|placental secretory function
922428|NCT02412592|HBeAg positive
922429|NCT02412592|interferon
922430|NCT02412592|peginterferon
922431|NCT02412592|HBeAg seroconversion
922432|NCT02412592|sustained viral response
922433|NCT02412592|relapse
922434|NCT02412579|HCC
922435|NCT02412579|Liver Cancer
922436|NCT02412566|cholestasis
922437|NCT02412566|growth failure
922438|NCT02412566|intravenous fat emulsion
922439|NCT02412566|SMOF
922440|NCT02412514|polio
922441|NCT02412514|inactivated poliovirus vaccine
922442|NCT02412514|oral poliovirus vaccine
922443|NCT02412514|IPV
922444|NCT02412514|OPV
922451|NCT02412449|Pharmacokinetics
922452|NCT02412449|Anemia
922453|NCT02412449|Chronic kidney disease
922454|NCT02412449|CKD
922455|NCT02412449|Renal impairment
922456|NCT02412449|Chronic renal insufficiency
922457|NCT02412449|Ferrous sulfate
922458|NCT02412449|Iron
922459|NCT02412449|End stage renal disease
922460|NCT02412449|Dialysis
922461|NCT02412449|Oral anemia treatment
922462|NCT02412449|Bioavailability
922463|NCT02412449|Erythropoietin
922464|NCT02412449|Hypoxia-inducible factor
922465|NCT02412449|Volunteers
922466|NCT02412410|laborist
922467|NCT02412410|efficacy
922468|NCT02412410|sleep
922469|NCT02412410|fatigue
922470|NCT02412410|SAFTE
922471|NCT02412410|cognition
922472|NCT02412397|Shoulder
922473|NCT02412384|Lung Neoplasms
922474|NCT02412384|Circulating Tumor Cells
922475|NCT02412371|previously untreated
922476|NCT02412371|PARP inhibitor
922477|NCT02412371|radiotherapy
922478|NCT02412371|paclitaxel
922479|NCT02412371|ABT-888
922480|NCT02412371|stage III
922481|NCT02412371|first line
922482|NCT02412371|carboplatin
922483|NCT02412371|veliparib
922484|NCT02412371|non-small cell lung cancer
922485|NCT02412358|toothbrushing
922486|NCT02412358|plaque control
922487|NCT02412358|gingivitis
922488|NCT02412345|Erectile Dysfunction
922489|NCT02412345|Shockwave therapy
922490|NCT02412345|Renal Transplant
922491|NCT02412345|Male
922492|NCT02412345|Renal Transplant Recipients
922493|NCT02412332|advanced COPD (stage III)
922494|NCT02412332|Adult stem cells
922495|NCT02412332|Cell therapy
922496|NCT02412319|HBeAg positive chronic hepatitis B
922497|NCT02412319|HBeAg serum conversion rate
922498|NCT02412319|HBeAg serum disappearance rate
922499|NCT02412319|HBeAg and HBsAg titer
922501|NCT02412293|Perinatal
922502|NCT02412293|neonatal
922503|NCT02412293|newborn
922504|NCT02412293|mortality
922505|NCT02411253|IL2
922506|NCT02411253|Interleukin 2
922507|NCT02411253|IL-2
922508|NCT02411253|Auto-immune disease
922509|NCT02411253|Insulin
922510|NCT02411253|Diabetes
922511|NCT02411253|Regulatory T cells
922512|NCT02411253|Treg
922513|NCT02411253|Immunoregulation
922514|NCT02411253|Immune tolerance
922515|NCT02411253|Immunotherapy
922516|NCT02411240|Air filtration
922517|NCT02411240|cardiovascular health
922518|NCT02411240|cognition
922519|NCT02411240|particulate matter
922520|NCT02411240|mitochondrial DNA
922521|NCT02411227|Neuropsychologic Testing
922522|NCT02411227|Neurocognitive
922523|NCT02411227|Virtual Reality
922524|NCT02411227|Rehabilitation
922525|NCT02411227|Driving
922526|NCT02411175|Constipation
922527|NCT02411175|Homeopathy
922528|NCT02412189|Anesthesia
922529|NCT02412189|Blood pressure
922530|NCT02412189|Plasma volume
922531|NCT02412189|Vasopressor agents
922532|NCT02412189|Continuous noninvasive hemoglobin measurement
922533|NCT02412189|Coronary artery bypass
922534|NCT02412176|pacemaker
922535|NCT02412176|dyssynchrony
922536|NCT02412176|apical pacing
922537|NCT02412176|mid-septum
922538|NCT02412098|Hepatic Impairment
922539|NCT02412085|golimumab
922540|NCT02412085|ulcerative colitis
922541|NCT02412085|steroid-dependent
922542|NCT02412072|Endometrial hyperplasia
922543|NCT02412072|Progesterone
922544|NCT02412072|LNG-IUS
922545|NCT02412072|dilatation & curettage
922546|NCT02412072|endometrial aspiration sampling
922547|NCT02412046|Pressure ulcer
922548|NCT02412046|Interface pressure
922549|NCT02412046|Pressure mapping device
922550|NCT02412046|Ischemia reperfusion
922551|NCT02412046|Monitoring
922552|NCT02412046|Microvascularization
922553|NCT02412033|vaginal misoprostol
922554|NCT02412007|spastic diplegia;cerebral palsy;activity based therapy
922555|NCT02411981|Lung Clearance Index
922556|NCT02411981|Non cystic fibrosis Bronchiectasis
922557|NCT02411981|Multiple Breath Nitrogen Washout
922558|NCT02411968|Cryosurgery
922559|NCT02411968|Carcinoma, renal cell
922560|NCT02411968|Diagnostic Imaging
922561|NCT02411968|Diagnostic techniques, urological
922562|NCT02411968|Radionuclide imaging
922563|NCT02411968|Follow up
922564|NCT02411903|Clopidogrel-drug interactions
922565|NCT02411890|postoperative pain
922566|NCT02411890|femoral nerve block
922567|NCT02411890|adductor canal block
922568|NCT02411890|anterior cruciate ligament reconstruction
922569|NCT02411877|Acute ischemic stroke
922570|NCT02411877|Mild hypothermia
922571|NCT02411877|Stroke
922572|NCT02411877|Hypothermia
922573|NCT02411877|Cerebral infarction
922574|NCT02411877|Ischemia
922575|NCT02411877|Cerebrovascular disorder
922576|NCT02411877|Brain disease
922577|NCT02411877|Central nervous system disease
922578|NCT02411877|Nervous system disease
922579|NCT02411877|Vascular disease
922580|NCT02411877|Cardiovascular disease
922581|NCT02411877|Brain infarction
922582|NCT02411877|Brain ischemia
922583|NCT02411877|Pathologic process
922584|NCT02411877|Body temperature change
922585|NCT02411877|Signs and symptoms
922586|NCT02411864|IVIM
922587|NCT02411864|brain
922588|NCT02411864|diffusion-weighted imaging
922589|NCT02411851|Actinic Keratoses
922590|NCT02411838|Multiple sclerosis
922591|NCT02411838|calorie restriction
922592|NCT02411838|adipokines
922593|NCT02411812|Orthodontic Appliances, Functional
922594|NCT02411812|Herbst Appliance
922595|NCT02411812|Malocclusion, Angle Class II
922596|NCT02411760|MRI
922597|NCT02411747|Medical
922598|NCT02411747|Urology
922599|NCT02411747|Randomized Controlled Trial
922600|NCT02411747|Endoscopy
922601|NCT02411747|Cystoscopy
922602|NCT02411721|Anxiety
922603|NCT02411721|Dog Intervention
922604|NCT02411721|MRI
922605|NCT02411721|Children
922606|NCT02411695|Adolescent
922607|NCT02411695|Otsuka,
922608|NCT02411695|Brexpiprazole
922609|NCT02411669|Patient centred care
922610|NCT02411656|Breast cancer
922611|NCT02411656|Metastatic inflammatory breast cancer
922612|NCT02411656|MIBC
922613|NCT02411656|IBC
922614|NCT02411656|Breast carcinoma
922615|NCT02411656|Metastatic
922616|NCT02411656|MK-3475
922617|NCT02411656|Keytruda
922618|NCT02411656|Pembrolizumab
922619|NCT02411656|SCH-900475
922620|NCT02411630|PrEP
922621|NCT02411630|HIV Prevention
922622|NCT02411578|T1D
922623|NCT02411578|Type 1 diabetes
922624|NCT02411578|Mini-dose glucagon
922625|NCT02411578|adults
922626|NCT02411578|non-severe hypoglycemia
922627|NCT02411565|epithelial
922628|NCT02411565|ovarian
922629|NCT02411565|fallopian tube
922630|NCT02411565|primary peritoneal carcinoma
922631|NCT02411565|peritoneal
922632|NCT02411565|ovary
922633|NCT02411500|Healthy
922634|NCT02411500|Male
922635|NCT02411500|Pharmacokinetics
922636|NCT02411474|stem cell transplantation (SCT)
922637|NCT02411461|Pediatric obesity
922638|NCT02411461|pseudohypoparathyroidism
922639|NCT02411461|Albright Hereditary Osteodystrophy
922640|NCT02411435|rifampin
922641|NCT02411435|drug interaction
922642|NCT02411435|pharmacokinetics
922643|NCT02411435|cabotegravir
922644|NCT02411422|intubation
922645|NCT02411422|cardiopulmonary resuscitation
922646|NCT02411422|manikins
922647|NCT02411409|Health Information Technology (HIT)
922648|NCT02411409|self-care
922649|NCT02411383|Diaphragm pacing
922650|NCT02411383|Respiratory assistance
922651|NCT02411383|Lung transplant
922652|NCT02411357|Contraception
922653|NCT02411357|Unintended pregnancy
922654|NCT02411357|HIV risk
922655|NCT02411357|Sexually transmitted infections
922656|NCT02411357|Women
922657|NCT02411357|Pregnancy
922658|NCT02411357|Neonatal health
922659|NCT02411357|Drug use
922660|NCT02411357|Drug treatment
922661|NCT02411357|Opioids
922662|NCT02411344|HER2+/HR+
922663|NCT02411344|breast cancer
922664|NCT02411331|Lock Solution
922665|NCT02411331|Catheter related blood stream infections
922666|NCT02411331|Central venous catheter infection
922667|NCT02411331|Intravenous Drug Delivery Systems
922668|NCT02411331|Coagulase-negative staphylococci infection
922669|NCT02411331|Ethanol lock solution
922670|NCT02411331|Vancomycin lock solution
922671|NCT02411279|Heart failure
922672|NCT02411279|telemonitoring
922673|NCT02411279|intrusive sensors
922674|NCT02411279|intrusive devices
922675|NCT02411279|Heart failure stage II
922676|NCT02411279|Heart failure stage III
922677|NCT02411279|heart disease
922678|NCT02411162|atopic dermatitis
922679|NCT02411162|FLIM
922680|NCT02411162|chronic plaque psoriasis
922681|NCT02411162|healthy volunteers
922682|NCT02411162|GSK2894512
922683|NCT02411162|Skin residency
922684|NCT02411149|Adductor Canal Block
922685|NCT02411149|Total Knee Arthroplasty
922686|NCT02411123|PGx
922687|NCT02411123|pharmacogenetics
922688|NCT02411123|depression
922689|NCT02411123|anxiety
922690|NCT02411123|Neuropsychiatric diseases
922691|NCT02411123|IDgenetix
922692|NCT02411123|AltheaDx
922693|NCT02411097|Deep venous thromboembolism
922694|NCT02411097|Femoral nerve block
922695|NCT02411097|Total knee arthroplasty
922701|NCT02411071|HIV-1
922702|NCT02411071|antiretroviral treatment
922703|NCT02411071|low viral load
922704|NCT02411071|low-level viremia
922705|NCT02411058|information
922706|NCT02411058|incentives
922707|NCT02411045|Indirect incentives
922708|NCT02411045|Exercise more
922709|NCT02411019|Phase 2 follow up
922710|NCT02411019|Cervical Intraepithelial Neoplasia
922711|NCT02411019|Adult
922712|NCT02411019|Safety
922713|NCT02411019|Efficacy
922714|NCT02410941|Randomized controlled trial
922715|NCT02410941|Practice management
922716|NCT02410941|tomography, x-ray computed/adverse effects
922717|NCT02410941|Clinical decision support
922718|NCT02410941|Computerized clinical decision support
922719|NCT02410941|Decision support systems, clinical
922720|NCT02410941|Health Expenditures
922721|NCT02410941|Physician's practice patterns
922722|NCT02410941|Unnecessary Procedures/economics
922723|NCT02410941|Physician's Practice Patterns/economics
922724|NCT02410941|Diffusion of innovation
922725|NCT02410941|Decision Support Models
922726|NCT02410941|Clinical Prediction Rules
922727|NCT02410915|Rehabilitation
922728|NCT02410915|Robotics
922729|NCT02410902|Autism
922730|NCT02410876|Bladder
922731|NCT02410876|neurogenic lower urinary tract dysfunction
922732|NCT02410876|benign prostatic obstruction
922733|NCT02410863|Stage III or IV with BRAF V600E/K mutation
922734|NCT02410850|Oral Appliance
922735|NCT02410850|objective adherence
922736|NCT02410850|cardiovascular events
922737|NCT02410850|cardiovascular mortality
922738|NCT02410850|cerebrovascular mortality
922739|NCT02410850|cost effectiveness
922740|NCT02410837|lung lesion
922741|NCT02410837|biopsy
922742|NCT02410837|bronchoscopy
922743|NCT02410811|Sickle Cell Disease (SCD)
922744|NCT02410811|Cardiac Magnetic Resonance Imaging (CMR)
922745|NCT02410811|Cardiomyopathy
922746|NCT02410811|Pulmonary Hypertension
922747|NCT02410785|obesity,
922748|NCT02410785|body weight,
922749|NCT02410785|overweight,
922750|NCT02410785|weight loss,
922751|NCT02410785|polyglucosamine,
922752|NCT02410785|L112
922753|NCT02410785|caloric restriction
922754|NCT02410785|physical activity
922755|NCT02410746|pain
922756|NCT02410746|surgery
922757|NCT02410733|melanoma
922758|NCT02410733|Lipo-MERIT
922759|NCT02410733|cancer vaccine
922760|NCT02410733|RB_0003-01
922761|NCT02410733|BioNTech
922762|NCT02410733|BioNTech RNA Pharmaceuticals
922763|NCT02410733|BioNTech RNA
922764|NCT02410733|RNA
922765|NCT02410720|Colonoscopy Preparation
922766|NCT02410720|Polyethylene Glycols
922767|NCT02410720|Mobile application
922768|NCT02410720|Software
922769|NCT02410720|Compliance
922770|NCT02410720|Patient Compliance
922771|NCT02410720|Adherence
922772|NCT02410707|procedural sedation
922773|NCT02410707|procedural pain
922774|NCT02410707|procedural anxiolysis
922775|NCT02410655|Uterine atony
922776|NCT02410655|Postpartum hemorrhage
922777|NCT02410655|Vaginal delivery
922778|NCT02410655|Uterotonic
922779|NCT02410655|Oxytocin
922780|NCT02410655|Bolus
922781|NCT02410655|Evidence-based
922782|NCT02410655|Protocol
922783|NCT02410642|cardiopulmonary bypass
922784|NCT02410629|Stroke
922785|NCT02410616|Psychotherapy
922786|NCT02410616|Comparative Effectiveness Research
922787|NCT02410616|Randomized Controlled Trial
922788|NCT02410616|Secondary Care
922789|NCT02410603|Chemotherapy
922790|NCT02410577|89Zr-J591
922791|NCT02410577|15-002
922792|NCT02410564|insomnia
922793|NCT02410564|Sleep
922794|NCT02410564|CBT-I intervention
922795|NCT02410564|SHUTi
922796|NCT02410551|Myeloproliferative Diseases
922797|NCT02410551|Myeloproliferative Neoplasms
922798|NCT02410551|MPN
922799|NCT02410551|Myelofibrosis
922800|NCT02410551|Polycythemia vera
922801|NCT02410551|PV
922802|NCT02410551|Essential thrombocythemia
922803|NCT02410551|Allogeneic stem cell transplantation
922804|NCT02410551|Allo TP
922805|NCT02410551|Pacritinib
922806|NCT02410551|Busulfan
922807|NCT02410551|Busulfex
922808|NCT02410551|Myleran
922809|NCT02410551|Questionnaires
922810|NCT02410551|Surveys
922811|NCT02410551|Phone calls
922812|NCT02410525|hyperlipidemia
922813|NCT02410525|positron emission tomography
922814|NCT02410499|Drug therapy
922815|NCT02410473|Congenital Heart Disease
922816|NCT02410473|Point-of-care coagulation monitoring
922817|NCT02410447|Shock waves
922818|NCT02410434|Stigma
922819|NCT02410434|lesbian
922820|NCT02410434|gay
922821|NCT02410434|bisexual
922822|NCT02410434|transgender
922823|NCT02410421|Individualized Medicine
922824|NCT02410421|Functional Neuroimaging
922825|NCT02410421|Robotic Proceedure
922826|NCT02410421|Transcranial Magnetic Stimulation, Repetitive
922827|NCT02410421|Transcranial Direct Current Stimulation Monocentric
922828|NCT02410421|Compariative Cross-Over 3 Arms Study Randomized, Single-Blind Method
922829|NCT02410408|Patient Safety
922830|NCT02410408|App
922831|NCT02410408|Root Cause Analysis
922832|NCT02410408|Patient Safety Certification
922833|NCT02410382|cancer
922834|NCT02410382|radiation therapy
922835|NCT02410382|chemotherapy
922836|NCT02410382|dexamethasone
922837|NCT02410382|corticosteroids
922838|NCT02410330|Therapeutic ultrasound
922839|NCT02410330|Angiographic recanalization rate
922840|NCT02410330|Salvagability index
922841|NCT02410330|Sonothrombolysis
922842|NCT02410317|Postoperative pain
922843|NCT02410317|Postoperative morphine consumption
922844|NCT02410317|Emergency cesarean delivery
922845|NCT02410317|Ropivacaine
922846|NCT02410317|Local anesthetic wound 48-hours infusion
922847|NCT02410317|Emergency cesarean section
922848|NCT02410304|Rheumatoid arthritis / ultrasonography / synovitis
922853|NCT02410252|continuous temperature monitoring
922854|NCT02410252|patient self-management
922855|NCT02410252|iThermonitor
922856|NCT02410252|Home monitoring
922857|NCT02410239|Cerebral Adrenoleukodystrophy
922858|NCT02410239|cALD
922859|NCT02410200|Pediatrics
922860|NCT02410187|stereotactic body radiotherapy
922861|NCT02410174|Renal Cell Carcinoma
922862|NCT02410174|RCC
922863|NCT02410174|Stereotactic Body Radiotherapy
922864|NCT02410174|SBRT
922865|NCT02410161|ketone
922866|NCT02410161|α-linolenic acid
922867|NCT02410161|flaxseed
922868|NCT02410161|aging
922869|NCT02410161|β-hydroxybutyrate
922870|NCT02410161|acetoacetate
922871|NCT02410161|omega-3 fatty acids
922872|NCT02410161|ketogenesis
922873|NCT02410148|open-angle glaucoma
922874|NCT02410148|papilledema
922875|NCT02410148|non-invasive ICP
922876|NCT02410148|Intracranial pressure
922877|NCT02410135|Lower Urinary Tract Symptoms
922878|NCT02410135|Sleep Disturbance
922879|NCT02410096|exercise-induced asthma
922880|NCT02410096|cold chamber
922881|NCT02410096|exercise challenge
922882|NCT02410096|cold air challenge
922883|NCT02410096|oil supplementation
922884|NCT02410096|middle-chain and Polyunsaturated Fatty Acids
922885|NCT02410070|Distal radial fracture
922886|NCT02410070|pronator quadratus
922887|NCT02410070|mini-approach
922888|NCT02410070|volar plating
922889|NCT02410070|open reduction and internal fixation
922890|NCT02410057|growth
922891|NCT02410057|formula
922892|NCT02410057|protein
922893|NCT02410057|alpha-lactalbumin
922894|NCT02410057|amino acids
922895|NCT02410044|Patient Reported Outcomes
922896|NCT02409992|Children with ODD and low prosocial emotions
922897|NCT02409979|colonoscopy
922898|NCT02409979|carbon dioxide
922899|NCT02409979|water exchange
922900|NCT02409979|discomfort
922901|NCT02409979|colonoscopy pain
922902|NCT02409966|periodontitis
922903|NCT02409966|therapeutics
922904|NCT02409966|quality of life
922905|NCT02409966|fear
922906|NCT02409966|anxiety
922907|NCT02409966|pain
922908|NCT02409953|volunteers
922909|NCT02409927|Medium-chain triglycerides
922910|NCT02409927|Metabolism
922911|NCT02409927|Ketones
922912|NCT02409927|Lipids
922913|NCT02409927|Emulsification
922914|NCT02409914|Insulin Resistance
922915|NCT02409914|Brain metabolism
922916|NCT02409914|PET
922917|NCT02409914|MRI
922918|NCT02409901|Physical Activity
922919|NCT02409901|Exercise Rehabilitation
922920|NCT02409901|Kidney Function
922921|NCT02409901|Employment
922922|NCT02409901|Kidney Transplant
922923|NCT02409875|early intervention
922924|NCT02409875|obesity
922925|NCT02409875|body weight
922926|NCT02409875|body mass index
922927|NCT02409875|overnutrition
922928|NCT02409875|early promoters, genetic
922929|NCT02409862|oxytocin
922930|NCT02409862|socioemotional functioning
922931|NCT02409862|aging
922932|NCT02409849|Octreotide LAR
922933|NCT02409849|Neuroendocrine carcinomas
922934|NCT02409849|unresectable or metastatic
922935|NCT02409849|Disease-free survival
922936|NCT02409823|adverse drug reactions
922937|NCT02409823|adherence to treatment
922938|NCT02409823|quality of life
922939|NCT02409823|clinical status
922940|NCT02409784|Brain metabolism
922941|NCT02409784|Ketones
922942|NCT02409784|Ketogenic diet
922943|NCT02409784|TEP scan
922944|NCT02409758|Voice disorders
922945|NCT02409758|Hoarseness
922946|NCT02409758|Therapy
922947|NCT02409745|endometrial scratch
922948|NCT02409745|IVF
922949|NCT02409745|randomized controlled study
922950|NCT02409745|Prospective controlled trial
922951|NCT02409745|Different time to perform endometrial scratch
922952|NCT02409745|In vitro fertilization
922953|NCT02409745|embryo transfer
922954|NCT02409732|Actinic cheilitis
922955|NCT02409732|Photodynamic therapy
922956|NCT02409732|Levulan
922957|NCT02409732|Blue light
922958|NCT02409719|Arthritis, Degenerative
922959|NCT02409719|Recovery of function
922960|NCT02409706|Paediatric
922961|NCT02409706|Critical care
922962|NCT02409706|Micronutrients
922963|NCT02409680|Preterm birth
922964|NCT02409680|Low dose aspirin
922965|NCT02409667|plaque, psoriasis
922966|NCT02409641|IOL
922967|NCT02409628|Non-melanoma Skin Cancer
922968|NCT02409628|Basal Cell Carcinoma
922969|NCT02409628|Squamous Cell Carcinoma
922970|NCT02409628|Surgical excision
922971|NCT02409628|EktoTherix
922972|NCT02409628|Secondary intention healing
922973|NCT02409628|Acute wound repair
922974|NCT02409628|Tissue repair scaffold
922975|NCT02409628|Regenerative medicine scaffold
922976|NCT02409628|Electrospun scaffold
922977|NCT02409615|Complementary therapies
922978|NCT02409615|Hypnosis
922979|NCT02409615|Healing Touch
922980|NCT02409602|Ultrasonography, Doppler, Color
922981|NCT02409602|Postpartum hemorrhage
922982|NCT02409602|Bilateral iliac artery ligation
922983|NCT02409602|Dorsal clitoral artery
922984|NCT02409576|EWS
922985|NCT02409576|OS
922986|NCT02409576|RMS
922987|NCT02409550|Allergic Rhinitis
922988|NCT02409550|Asthma
922989|NCT02409550|Children
922990|NCT02409550|Control
922991|NCT02409537|Asymptomatic hypercholesterolemia,
922992|NCT02409537|cardiovascular risk,
922993|NCT02409537|total antioxidant capacity
922994|NCT02409537|red wine polyphenol content
922995|NCT02409537|vitamin E.
922996|NCT02409537|resveratrol
922997|NCT02409511|Type 1 Diabetic
922998|NCT02409511|Type 2 Diabetic
922999|NCT02409511|Hypertension
923000|NCT02409511|Renal Injury
923001|NCT02409511|Diabetic retinopathy
923002|NCT02409498|pudendal nerve block
923003|NCT02409498|vaginal reconstructive surgery
923004|NCT02409485|self-management
923005|NCT02409485|head and neck cancer
923006|NCT02409485|psychosocial intervention
923007|NCT02409485|couples
923008|NCT02409472|randomized clinical trial
923009|NCT02409433|lacosamide
923010|NCT02409433|phenytoin
923011|NCT02409394|Subjects
923012|NCT02409303|Autism Spectrum Disorder
923013|NCT02409303|Screening
923014|NCT02409303|Preventive intervention
923015|NCT02409303|Risk
923016|NCT02409277|Self-Management
923017|NCT02409277|Asthma
923018|NCT02409264|Insomnia
923019|NCT02409264|Females
923020|NCT02409264|Homeopathy
923021|NCT02409251|Antinuclear antibody (ANA)
923022|NCT02409251|Overuse
923023|NCT02409251|Rheumatologists
923024|NCT02409251|Quality of care
923025|NCT02409238|Mild Cognitive Impairment
923026|NCT02409238|Insulin Resistance
923027|NCT02409238|Diabetes Mellitus, Type 2
923028|NCT02409225|remote monitoring
923029|NCT02409225|ICD
923030|NCT02409225|CRT-D
923031|NCT02409199|Gastric Carcinoma
923032|NCT02409199|apatinib
923033|NCT02409173|Metabolic syndrome
923034|NCT02409173|Sleep disorders
923035|NCT02409173|Bariatric Surgery
923036|NCT02409173|Noninvasive ventilation
923037|NCT02409173|Inflammation
923038|NCT02409173|Quality of life
923039|NCT02409160|Severe Obesity
923040|NCT02409160|Sleep Disorders
923041|NCT02409160|Bariatric Surgery
923042|NCT02409160|Inflammation
923043|NCT02409160|Quality of Life
923044|NCT02409134|Bone Marrow Transplantation
923045|NCT02409134|Hematologic Malignancies
923046|NCT02409134|Adults
923047|NCT02409134|Cognition
923048|NCT02409121|hematopoietic cell transplantation
923049|NCT02409121|caregivers
923050|NCT02409121|health information technology
923051|NCT02409121|patient-centered care
923052|NCT02409069|Transcutaneous vagus nerve stimulation
923053|NCT02409069|P300
923054|NCT02409069|Memory task
923055|NCT02409056|intervention
923056|NCT02409056|translation
923057|NCT02409056|workplace
923058|NCT02409056|CVD
923059|NCT02409056|CDSMP
923060|NCT02409043|Stroke
923061|NCT02409043|Ischemic stroke
923062|NCT02409043|Hemorrhagic stroke
923063|NCT02409043|Biomarkers
923064|NCT02409043|Angiotensins
923065|NCT02409017|insulin drip
923066|NCT02409017|labor
923067|NCT02409004|Drug-drug interaction
923068|NCT02408991|Chronic lower limb ischemia
923069|NCT02408991|Art-Assist Device
923070|NCT02408991|Neupogen
923071|NCT02408926|Pertussis
923072|NCT02408926|Pregnancy
923073|NCT02408926|Humoral immune response
923074|NCT02408926|Functionality
923075|NCT02408926|Vaccination
923076|NCT02408913|Immunity
923077|NCT02408913|Ebola Virus
923078|NCT02408913|Ebola Hemorrhagic Fever
923079|NCT02408913|Healthy
923080|NCT02408913|Filovirus
923081|NCT02408900|Spasticity
923082|NCT02408900|Primary Lateral Sclerosis
923083|NCT02408900|Elastography
923084|NCT02408900|Ultrasound
923090|NCT02408874|Nanoparticles
923091|NCT02408874|Inflammatory Response
923092|NCT02408874|Silver
923093|NCT02408874|Lung Function
923094|NCT02408874|Lung Microbiome
923095|NCT02408835|negative pressure wound therapy
923096|NCT02408835|lymphadenectomy
923097|NCT02408835|wound healing
923098|NCT02408809|Orthopaedic Smoking Cessation Discussion
923099|NCT02408809|Smoking Cessation
923100|NCT02408809|Randomized Controlled Trial
923101|NCT02408796|Acute otitis media with tympanostomy tubes
923102|NCT02408757|ultrasound
923103|NCT02408757|cerebral perfusion
923104|NCT02408757|cerebrospinal fluid drainage
923105|NCT02408744|nephroprotection
923106|NCT02408744|pirfenidone
923107|NCT02408744|polymorphisms
923108|NCT02408718|Mobility
923109|NCT02408718|walking aids
923110|NCT02408718|falls
923111|NCT02408718|gait and balance
923112|NCT02408705|Endogenous Glucose Production
923113|NCT02408705|Hypoglycemic clamp
923114|NCT02408705|Tracer to Tracee Technique
923115|NCT02408705|Type 1 diabetes mellitus
923116|NCT02408692|Emergency contraception
923117|NCT02408692|Obese BMI
923118|NCT02408692|Normal BMI
923119|NCT02408679|Vitamin D
923120|NCT02408679|Vitamin D Deficiency
923121|NCT02408679|Vitamin D Insufficiency
923122|NCT02408679|Healthy adults
923123|NCT02408679|Predictive questionnaire
923124|NCT02408640|Internet-Based
923125|NCT02408640|Treatment
923126|NCT02408549|Lacosamide
923127|NCT02408549|Vimpat
923128|NCT02408549|Epilepsy
923129|NCT02408549|Children
923130|NCT02408549|Primary Generalized Tonic Clonic seizures
923131|NCT02408549|Idiopathic Generalized Epilepsy
923132|NCT02408549|Adults
923133|NCT02408536|chemotherapy
923134|NCT02408536|hormone therapy
923135|NCT02408536|borderline
923136|NCT02408536|low-grade
923137|NCT02408536|serous ovarian cancer
923138|NCT02408523|Lacosamide
923139|NCT02408523|Vimpat
923140|NCT02408523|Epilepsy
923141|NCT02408523|Children
923142|NCT02408523|Primary Generalized Tonic Clonic seizures
923143|NCT02408523|Idiopathic Generalized Epilepsy
923144|NCT02408523|Adults
923145|NCT02408510|Volunteers
923146|NCT02408471|Arthritis
923147|NCT02408471|Rheumatoid Arthritis
923148|NCT02408471|Systemic Lupus Erythematosus
923149|NCT02408471|Osteoarthritis
923150|NCT02408471|Autoimmune Diseases
923151|NCT02408471|Connective Tissue Diseases
923152|NCT02408471|Immune System Diseases
923153|NCT02408471|Joint Diseases
923154|NCT02408471|Musculoskeletal Diseases
923155|NCT02408471|Rheumatic Diseases
923156|NCT02408445|body composition
923157|NCT02408445|Klinefelter syndrome
923158|NCT02408445|XXY
923159|NCT02408445|sex chromosome variation
923160|NCT02408445|sex chromsome aneuploidy
923161|NCT02408432|Blood And Marrow Transplantation
923162|NCT02408432|Left ventricular dysfunction
923163|NCT02408432|LV
923164|NCT02408432|Heart failure secondary to chemotherapy with anthracyclines
923165|NCT02408432|Allogeneic human mesenchymal stem cells
923166|NCT02408432|hMSCs
923167|NCT02408432|Standard of care drugs for heart failure
923168|NCT02408406|TNM Finding v7
923169|NCT02408393|Surgery
923170|NCT02408393|Paravertebral block
923171|NCT02408393|Chronic pain
923172|NCT02408380|biomarker
923173|NCT02408380|disease progression
923174|NCT02408367|Training
923175|NCT02408367|Cognition
923176|NCT02408367|Multiple Sclerosis
923177|NCT02408341|Propofol, Induction anesthesia, Doppler tissue imaging
923178|NCT02408315|induction of labor
923179|NCT02408315|safety
923180|NCT02408315|pharmacokinetic
923181|NCT02408315|misoprostol
923182|NCT02408250|algorithm
923183|NCT02408250|critical illness
923184|NCT02408250|early exercise
923185|NCT02408250|feasibility
923186|NCT02408250|intensive care unit
923187|NCT02408250|physical therapy
923188|NCT02408237|Transcranial direct current stimulation (tDCS)
923189|NCT02408237|tDCS for domiciliary use
923190|NCT02408237|Healthy Participants
923192|NCT02408185|infections
923193|NCT02408185|multidrug resistant Gram negative bacteria (MDR-GNB)
923194|NCT02408185|Skin infections
923195|NCT02408185|Pneumonia
923196|NCT02408185|Bacteriemia
923197|NCT02408185|Nosocomial infections
923198|NCT02408172|hypertension
923199|NCT02408172|Sleep apnea syndrome
923200|NCT02408172|Amlodipine
923201|NCT02408172|metoprolol
923202|NCT02408159|Live, attenuated virus varicella-zoster vaccine
923203|NCT02408159|Zostavax
923204|NCT02408159|herpes zoster
923205|NCT02408159|shingles
923206|NCT02408133|Breast Cancer
923207|NCT02408133|elderly
923208|NCT02408133|quality of life
923209|NCT02408133|exercise
923210|NCT02408120|Hyperglycemia
923211|NCT02408120|Hypoglycemia
923212|NCT02408107|Physical activity
923213|NCT02408107|Randomized controlled trial
923214|NCT02408094|Rheumatoid Arthritis
923215|NCT02408094|Heat-dampness and blood stasis syndrome
923216|NCT02408094|Protein markers
923217|NCT02408081|Depression
923218|NCT02408081|Family functioning
923219|NCT02408081|Family Focused Nursing
923220|NCT02408081|Quality of life
923221|NCT02408068|subjects
923222|NCT02408029|Focus
923223|NCT02408029|Testing Performance
923224|NCT02408029|CORA Hemostasis System
923225|NCT02408003|Transesophageal
923226|NCT02408003|Echocardiography
923227|NCT02408003|Milrinone
923228|NCT02408003|Levosimendan
923229|NCT02408003|Strain
923230|NCT02408003|Deformation
923231|NCT02408003|Diastole
923232|NCT02408003|Afterload
923233|NCT02408003|Preload
923234|NCT02408003|Systole
923235|NCT02407964|Drug-Induced Liver Injury
923236|NCT02407964|DILI
923237|NCT02407938|dysphagia
923238|NCT02407938|reflux symptoms
923239|NCT02407938|retrosternal pain
923240|NCT02407925|Optical diagnosis
923241|NCT02407899|LADA
923242|NCT02407899|saxagliptin
923243|NCT02407899|vitamin D3
923244|NCT02407899|C-Peptide
923245|NCT02407873|aged of 75 years or more
923246|NCT02407860|breast feeding
923247|NCT02407860|sucking
923248|NCT02407860|dysfunction
923249|NCT02407860|Latch assessment tool
923250|NCT02407860|visual analogic scale
923251|NCT02407860|infant physiology
923252|NCT02407847|Nurse practitioners
923253|NCT02407847|Primary healthcare
923254|NCT02407847|Emergency Medical Services
923255|NCT02407847|Substitution of care
923256|NCT02407834|Biofilms
923257|NCT02407834|Dentures
923258|NCT02407834|Denture Cleansers
923259|NCT02407834|Castor Oil
923260|NCT02407834|Stomatitis
923261|NCT02407821|Controlled Clinical Trials, Randomized
923262|NCT02407821|Kidney Failure
923263|NCT02407821|Renal Insufficiency, Chronic
923264|NCT02407821|Dialysis, Renal
923265|NCT02407821|Peritoneal Dialysis
923266|NCT02407821|Hemodialysis
923267|NCT02407821|Depressive Symptoms
923268|NCT02407821|Selective Serotonin Reuptake Inhibitors
923269|NCT02407821|Antidepressants
923270|NCT02407821|Escitalopram
923271|NCT02407795|stereotactic radiotherapy
923272|NCT02407795|pain reduction
923273|NCT02407795|quality of life
923274|NCT02407782|Scabies
923275|NCT02407782|children
923276|NCT02407782|cluster
923277|NCT02407782|permethrin
923278|NCT02407782|Ivermectin
923279|NCT02407769|Liver transplantation
923280|NCT02407769|Liver cirrhosis
923281|NCT02407769|Branched chain amino acids
923282|NCT02407769|Late evening supplementation
923283|NCT02407769|Nutritional status
923284|NCT02407756|Eczema
923285|NCT02407743|postoperative pain
923286|NCT02407743|surgery
923287|NCT02407743|pain resolution
923288|NCT02407743|pain intensity
923289|NCT02407743|persistent postsurgical pain
923290|NCT02407743|pain-related genes
923291|NCT02407743|analgesic
923292|NCT02407704|Exercise
923293|NCT02407704|Physical activity
923294|NCT02407704|GABA
923295|NCT02407704|Venlafaxine
923296|NCT02407704|fMRI
923297|NCT02407704|Spectroscopy
923298|NCT02407704|Reward system
923299|NCT02407704|BDNF
923300|NCT02407704|Sleep
923301|NCT02407704|Cognitive function
923302|NCT02407704|Biomarkers
923303|NCT02407704|Aerobic exercise
923304|NCT02407665|Tai Chi
923305|NCT02407665|fMRI
923306|NCT02407639|insufflation
923307|NCT02407639|abdominal pain
923308|NCT02407626|ischemia
923309|NCT02407626|cardiac surgery
923310|NCT02407626|volatile anesthetic
923311|NCT02407626|total intravenous anesthesia
923312|NCT02407613|breast cancer
923313|NCT02407613|MR-HIFU
923314|NCT02407613|ablation
923315|NCT02407613|non-invasive treatment
923316|NCT02407600|EMEND for Injection
923317|NCT02407600|5HT-3
923318|NCT02407600|Fosaprepitant
923319|NCT02407561|rectal
923320|NCT02407561|adenocarcinoma
923321|NCT02407561|DecisionDx
923324|NCT02407522|Metabolic Syndrome
923325|NCT02407522|black rice
923326|NCT02407483|Laparoscopy
923327|NCT02407483|Training Programs
923328|NCT02407470|Severe Aplastic Anemia (SAA), Hematopoietic Stem Cells, HSC Transplantation
923329|NCT02407470|ATG, Mesenchymal Stem Cells, Transdifferentiation,
923330|NCT02407444|Proximal hip fracture
923331|NCT02407444|Elderly patients
923332|NCT02407444|Physiotherapy
923333|NCT02407444|Leg cycling ergometer
923334|NCT02407418|spinal manipulation
923335|NCT02407418|muscle strength dynamometer
923336|NCT02407418|muscle strength
923337|NCT02407379|Laser
923338|NCT02407379|periodontitis
923339|NCT02407379|scaling root planing
923340|NCT02407379|bacteria
923341|NCT02407379|PMN
923342|NCT02407366|Inoperable stage III non-small cell lung cancer
923343|NCT02407366|EGFR mutation
923344|NCT02407366|Icotinib
923345|NCT02407366|Radiotherapy
923346|NCT02407366|Chemoradiotherapy
923347|NCT02407353|Phase 1
923348|NCT02407353|Double blind
923349|NCT02407353|Placebo-Controlled
923350|NCT02407353|Parallel Design
923351|NCT02407353|CSF Aβ Concentrations
923352|NCT02407353|PF-06648671
923353|NCT02407340|Alcohol Withdrawal Delirium
923354|NCT02407327|Circulating tumour cells in Advanced Non Small Cell Lung Cancer
923355|NCT02407314|Peripheral Arterial Disease
923356|NCT02407314|Optical Coherence Tomography
923357|NCT02407314|Ticagrelor
923358|NCT02407314|Aspirin
923359|NCT02407314|Claudication
923360|NCT02407314|Clopidogrel
923361|NCT02407288|OCD
923362|NCT02407262|asthma
923363|NCT02407262|black seed
923364|NCT02407262|Nigella sativa
923365|NCT02407262|supplementation
923366|NCT02407236|Ustekinumab
923367|NCT02407236|Inflammatory Bowel Diseases (IBD)
923368|NCT02407236|Colitis, Ulcerative
923369|NCT02407223|Nonradiographic Axial Spondylitis, Ankylosing
923370|NCT02407223|Ustekinumab
923371|NCT02407210|Azilsartan，Olmesartan Medoxomil
923372|NCT02407197|T1 mapping
923373|NCT02407197|CMR
923374|NCT02407197|Outcome
923375|NCT02407197|multicenter
923376|NCT02407184|Microbiota
923377|NCT02407184|Microbiome
923378|NCT02407145|retropubic
923379|NCT02407145|midurethral sling
923380|NCT02407145|polyvinylidene fluoride
923381|NCT02407119|H. pylori eradication
923382|NCT02407119|Atrophy
923383|NCT02407119|Intestinal metaplasia
923384|NCT02407119|Endoscopic resection
923385|NCT02407106|BLIS K12
923386|NCT02407106|streptococcus
923387|NCT02407093|Body Composition
923388|NCT02407093|Military
923389|NCT02407093|High-Intensity Functional Training
923390|NCT02407093|Army Physical Fitness
923391|NCT02407093|CrossFit
923392|NCT02407002|Nitroglycerin
923393|NCT02407002|Safety
923394|NCT02406976|Exercise
923395|NCT02406976|Morbidity Obesity
923396|NCT02406963|telemedicine
923397|NCT02406950|Sitagliptin
923398|NCT02406950|Endothelium
923399|NCT02406950|Ischemia-Reperfusion Injury
923400|NCT02406950|human
923401|NCT02406924|pin
923402|NCT02406924|particulated graft
923403|NCT02406924|bone augmentation
923404|NCT02406924|vertical augmentation
923405|NCT02406924|horizontal augmentation
923406|NCT02406911|platelet
923407|NCT02406911|ticagrelor
923408|NCT02406911|clopidogrel
923409|NCT02406911|end stage renal disease
923410|NCT02406911|hemodialysis
923411|NCT02406859|Spinal Cord Injury
923412|NCT02406859|Constipation
923413|NCT02406859|Fecal Incontinence
923414|NCT02406859|Neurogenic Bowel
923415|NCT02406859|Bowel Biofeedback
923416|NCT02406859|Manometry
923417|NCT02406846|Pancreatic Neoplasms
923418|NCT02406846|Circulating Tumor Cells
923419|NCT02406833|glaucoma
923420|NCT02406833|trabeculectomy
923421|NCT02406807|chronic low back pain
923422|NCT02406807|HVLA manipulation
923423|NCT02406794|Breast cancer
923424|NCT02406794|Hormonal therapy
923425|NCT02406794|Aromatase inhibitors
923426|NCT02406794|Estrogen deprivation
923427|NCT02406794|Myalgia
923428|NCT02406794|Arthralgia
923429|NCT02406794|Carpal tunnel syndrome
923430|NCT02406794|Pressure pain threshold
923431|NCT02406794|Neuromuscular taping
923432|NCT02406794|Kinesio taping
923433|NCT02406781|Efficacy of MK 3475 with Metronomic Cyclophosphamide
923434|NCT02406781|Advanced Sarcomas
923435|NCT02406781|Leiomyosarcoma
923436|NCT02406781|Undifferentiated Sarcoma
923437|NCT02406781|Other Sarcoma
923438|NCT02406781|GIST
923439|NCT02406781|Osteosarcoma
923440|NCT02406768|normal controls
923441|NCT02406742|CC-122
923442|NCT02406742|Pharmacokinetics
923443|NCT02406742|Safety
923444|NCT02406742|Ibrutinib
923445|NCT02406742|Obinutuzumab
923446|NCT02406742|GA101
923447|NCT02406742|Chronic Lymphocytic Leukemia
923448|NCT02406742|Small Lymphocytic Lymphoma
923449|NCT02406703|local anesthesia
923450|NCT02406703|regional anesthetic
923451|NCT02406690|Endometrial Insufficiency
923452|NCT02406690|Endometrial Receptivity
923453|NCT02406677|Acute Coronary Syndromes, ACS, Myocardial Infarction, STEMI, NSTEMI, MI, Co-Payments, Copay, Cost Sharing
923454|NCT02406638|3D Pelvic floor USG
923455|NCT02406638|Mid-Urethral Sling
923456|NCT02406638|TVT
923457|NCT02406638|TVT-O
923458|NCT02406638|TVT-S
923459|NCT02406612|Vascular Closure Device
923460|NCT02406612|Femoral Artery Closure
923461|NCT02406573|Sensitivity
923462|NCT02406547|Serrated lesion
923463|NCT02406547|sessile serrated adenoma
923464|NCT02406547|Narrow Band Imaging
923465|NCT02406547|Colonoscopy
923466|NCT02406547|colorectal neoplasms
923467|NCT02406521|Metastatic renal cell carcinoma
923468|NCT02406521|mRCC
923469|NCT02406482|sex work, Kazakhstan, microfinance, drug use
923470|NCT02406443|Type 2 Diabetes, DPP-4 inhibitors, renal sodium excretion
923471|NCT02406339|Physical Therapy
923472|NCT02406339|Rehabilitation
923473|NCT02406339|Neuromuscular Electrical Stimulation
923474|NCT02406339|Muscle Strength
923475|NCT02406300|Hip Fracture
923476|NCT02406300|Regional Anesthesia
923477|NCT02406300|Peripheral Nerve Blocks
923478|NCT02406300|Post-operative Mortality
923479|NCT02406300|Cognitive Dysfunction
923480|NCT02406300|Quality of Life
923481|NCT02406274|Mammography
923482|NCT02406274|Contrast Enhanced Spectral Mammography
923483|NCT02406274|Palpable Breast Abnormalities
923484|NCT02406274|15-053
923485|NCT02406248|NSTEMI
923486|NCT02406222|Relapsed
923487|NCT02406222|Refractory
923488|NCT02406222|Pomalidomide
923489|NCT02406222|Dexamethasone
923490|NCT02406222|Cyclophosphamide
923491|NCT02406209|uveitis
923492|NCT02406209|acute uveitis
923493|NCT02406209|anterior uveitis
923494|NCT02406209|NS2
923495|NCT02406209|Aldeyra
923496|NCT02406209|prednisolone acetate
923497|NCT02406157|diabetic macular edema
923498|NCT02406157|micropulse
923499|NCT02406157|laser
923500|NCT02406157|subthreshold
923501|NCT02406144|Multiple Myeloma
923502|NCT02406131|Peripheral Vascular Diseases
923503|NCT02406131|Ischemic Preconditioning
923504|NCT02406131|Inflammation
923505|NCT02406131|Angioplasty
923506|NCT02406131|Restenosis
923507|NCT02406131|RCT
923508|NCT02406118|transanal TME quality
923509|NCT02406118|CRM
923510|NCT02406105|tremor
923511|NCT02406105|Parkinson disease
923512|NCT02406105|functional radioablation
923513|NCT02406105|Cyber Knife radiosurgery
923514|NCT02406079|tracheotomy
923515|NCT02406079|procalcitonin
923516|NCT02406079|sepsis
923517|NCT02406053|lung cancer
923518|NCT02406053|antioxidants
923519|NCT02406053|oxidative damage
923520|NCT02406040|Protein synthesis
923521|NCT02406040|Protein breakdown
923522|NCT02406040|Muscle
923523|NCT02406040|Energy restriction
923524|NCT02406027|Alzheimer's Disease
923525|NCT02406027|JNJ-54861911
923526|NCT02406027|Placebo
923527|NCT02406001|peri-implantitis
923528|NCT02406001|osseous defects
923529|NCT02406001|implant surface decontamination
923530|NCT02406001|bone grafting
923531|NCT02406001|surgical therapy
923532|NCT02406001|porous titanium granules
923533|NCT02406001|reconstruction
923534|NCT02405988|Emergency Treatment
923535|NCT02405988|Morphine Derivates
923536|NCT02405988|Heroin
923537|NCT02405988|Antidotes
923538|NCT02405988|Administration, Intravenous
923539|NCT02405988|Pharmacology
923540|NCT02405988|Naloxone
923541|NCT02405988|Healthy volunteers
923542|NCT02405962|Acceptance and Commitment Therapy
923543|NCT02405962|Childhood asthma
923544|NCT02405962|Randomized controlled trial
923545|NCT02405962|Training parents
923546|NCT02405910|advanced
923547|NCT02405910|non-squamous
923548|NCT02405910|first line therapy
923549|NCT02405897|flexible bronchoscopy
923550|NCT02405897|transbronchial lung biopsy
923551|NCT02405897|forceps
923552|NCT02405884|Glaucoma
923553|NCT02405884|Renal Insufficiency, Chronic
923554|NCT02405884|Low Tension Glaucoma
923555|NCT02405884|Ocular Hypertension
923556|NCT02405858|Metastatic Castration-Resistant Prostate Cancer
923557|NCT02405858|Abiraterone Acetate
923558|NCT02405858|ZYTIGA
923559|NCT02405858|Prednisolone
923560|NCT02405845|Atherosclerosis
923561|NCT02405845|Internal Carotid Artery
923562|NCT02405845|Free-floating thrombus
923563|NCT02405845|Ulcerated plaque
923564|NCT02405845|FFT
923565|NCT02405819|Cancer
923566|NCT02405819|Oncology
923567|NCT02405819|Survivorship
923568|NCT02405819|Care
923569|NCT02405819|Plan
923570|NCT02405780|Rheumatoid
923571|NCT02405780|Arthritis
923572|NCT02405767|Diabetic foot ulcer
923573|NCT02405754|CAD
923574|NCT02405754|Clinical Utility
923575|NCT02405754|Personalized Medicine
923576|NCT02405728|PICC
923577|NCT02405728|BLOODSTREAM INFECTIONS
923578|NCT02405728|VASCULAR ACCESS
923579|NCT02405702|Infection
923580|NCT02405702|Knee
923581|NCT02405702|knee replacement
923582|NCT02405676|Lymphoma
923583|NCT02405676|non-Hodgkin
923584|NCT02405676|B-lymphocytes
923585|NCT02405676|Child
923586|NCT02405676|Multicenter study
923587|NCT02405663|blood loss
923588|NCT02405663|caesarean section
923589|NCT02405663|placental delivery
923590|NCT02405650|CKD, chronic kidney disease, CRIC
923591|NCT02405637|Feeding intolerance
923592|NCT02405637|Simulated amniotic fluid
923593|NCT02405637|Necrotizing enterocolitis
923594|NCT02405585|Pancreatic Cancer
923595|NCT02405585|Immunotherapy
923596|NCT02405585|Vaccine Therapy
923597|NCT02405572|formula-fed
923598|NCT02405572|infants
923599|NCT02405546|Nasal intubation
923600|NCT02405546|Counterclockwise rotation
923601|NCT02405533|AHCC
923602|NCT02405533|nutritional supplement
923603|NCT02405533|HPV
923604|NCT02405520|human papillomavirus vaccine
923605|NCT02405520|condylomata acuminata
923606|NCT02405507|Gastrointestinal Discomfort
923607|NCT02405507|Wheat germ
923608|NCT02405507|Constipation
923609|NCT02405507|Glycaemic Index
923610|NCT02405507|Blood Cholesterol Level
923611|NCT02405507|Glycaemic Response
923612|NCT02405507|Cholesterol
923613|NCT02405507|PAC-SYM
923614|NCT02405507|Gut Microbiota
923615|NCT02405468|blood microbiota
923616|NCT02405468|coronary disease
923617|NCT02405468|myocardial infarction
923618|NCT02405455|cervical incompetence
923619|NCT02405455|cerclage
923620|NCT02405455|cervical pessary
923621|NCT02405416|Hepatocellular Carcinoma
923622|NCT02405416|Blood Loss
923623|NCT02405416|Haemorrhage
923624|NCT02405416|Vascular Control
923625|NCT02405403|amyotrophic lateral sclerosis disease
923626|NCT02405403|PET
923627|NCT02405403|microglial activation
923628|NCT02405390|Storz C-Mac®
923629|NCT02405390|Pediatric Airway
923630|NCT02405390|Cervical Spine Injury
923631|NCT02405390|Trauma Airway Management
923632|NCT02405377|contrast-induced nephropathy
923633|NCT02405377|hydration
923634|NCT02405377|Percutaneous coronary intervention
923635|NCT02405364|Multiple Myeloma
923636|NCT02405364|Carfilzomib
923637|NCT02405364|Lenalidomide
923638|NCT02405364|Dexamethasone
923639|NCT02405364|Patient up to 65 years
923640|NCT02405364|initial management
923641|NCT02405351|Telemedicine, Stroke, Working Memory, Cognitive Training
923642|NCT02405338|AML
923643|NCT02405325|physical activity
923644|NCT02405325|multilevel
923645|NCT02405325|cost-effectiveness
923646|NCT02405325|older adults
923647|NCT02405312|communication
923648|NCT02405312|palliative care
923649|NCT02405312|death
923650|NCT02405299|child
923651|NCT02405299|disorders inhibition
923652|NCT02405299|neuropsychology
923653|NCT02405299|rehabilitation
923654|NCT02405299|ADHD
923655|NCT02405299|assessment of neurocognitive rehabilitations in ADHD in children
923656|NCT02405273|Lung Cancer
923657|NCT02405273|Surgery
923658|NCT02405273|COPD
923659|NCT02405273|Rehabilitation
923660|NCT02405247|NSCLC
923661|NCT02405247|T790M
923662|NCT02405247|EGFR
923663|NCT02405247|TKI
923664|NCT02405247|Resistance
923665|NCT02405247|Non Small Cell Lung Cancer
923666|NCT02405247|AZD9291
923667|NCT02405234|Radial Head Arthroplasty
923668|NCT02405182|Magnetic Resonance Imaging
923669|NCT02405182|MRI
923670|NCT02405182|Biomarker
923671|NCT02405169|Implantology
923672|NCT02405169|oral surgery
923673|NCT02405169|bone level changes
923674|NCT02405169|marginal bone level
923675|NCT02405156|Letrozole
923676|NCT02405156|misoprostol
923677|NCT02405156|second trimester miscarriage
923678|NCT02405143|Controlled clinical trial
923679|NCT02405143|Electric Stimulation Therapy
923680|NCT02405117|Bipolar Disorder
923681|NCT02405117|Behavior Therapy
923682|NCT02405117|Technology Assisted
923683|NCT02405117|Mobile Phone
923684|NCT02405117|Smartphone
923685|NCT02405104|osteoarthritis
923686|NCT02405104|hip
923687|NCT02405104|knee
923688|NCT02405104|total hip arthroplasty
923689|NCT02405104|total knee arthroplasty
923690|NCT02405104|post operative pain management
923691|NCT02405078|Lymphoma
923692|NCT02405078|Diffuse Large B-cell Lymphoma
923693|NCT02405078|DLBCL
923694|NCT02405078|Relapsed/Refractory
923695|NCT02405078|Fluorodeoxyglucose-positron emission tomography/computed tomography
923696|NCT02405078|FDG-PET/CT
923697|NCT02405078|18F-Fluorodeoxyglucose
923698|NCT02405078|Blood draws
923699|NCT02405078|Chemotherapy
923700|NCT02405039|DED
923701|NCT02405039|Disease
923702|NCT02405013|Africa
923703|NCT02405013|Hepatitis C
923704|NCT02405013|HIV
923705|NCT02405013|Antiviral treatment
923706|NCT02405013|Adults
923707|NCT02405013|HCV genotype 1
923708|NCT02405013|HCV genotype 2
923709|NCT02405013|HCV genotype 4
923710|NCT02404974|physical activity
923711|NCT02404948|coronary artery disease
923712|NCT02404948|diagnosis
923713|NCT02404948|non-invasive
923714|NCT02404935|Metastatic colorectal cancer
923715|NCT02404935|cetuximab
923716|NCT02404935|maintenance
923717|NCT02404922|Safety/Efficacy Study
923718|NCT02404922|Randomized
923719|NCT02404922|Double Blind
923720|NCT02404883|Cancer
923721|NCT02404883|decisional conflict
923722|NCT02404883|online
923723|NCT02404883|decision-aid tool
923724|NCT02404870|Diabetes
923725|NCT02404870|Phosphate
923726|NCT02404870|Fibroblast Growth Factor 23 (FGF23)
923727|NCT02404870|Vitamin D
923728|NCT02404870|PTH
923729|NCT02404857|Post stroke
923730|NCT02404857|BCI
923731|NCT02404857|Reeducation
923732|NCT02404857|Hand movement
923733|NCT02404831|Physiotherapy
923734|NCT02404831|Pulmonary Rehabilitation
923735|NCT02404831|Exercise
923736|NCT02404831|Telerehab
923737|NCT02404818|Radiation
923738|NCT02404818|Cardiac
923739|NCT02404818|Hodgkin's lymphoma
923740|NCT02404805|dolutegravir
923741|NCT02404805|simeprevir
923742|NCT02404805|HIV
923743|NCT02404805|HCV
923746|NCT02404779|ICU
923747|NCT02404779|Deep sedation
923748|NCT02404779|Mechanical ventilation
923749|NCT02404779|Traumatic brain injury
923750|NCT02404779|Intracranial hypertension
923751|NCT02404779|Cisatracurium
923752|NCT02404779|Neuromuscular Blocking Agent
923753|NCT02404779|Randomization versus placebo
923754|NCT02404766|manual therapy
923755|NCT02404766|cervical
923756|NCT02404766|range of movement
923757|NCT02404753|Locally advanced gastric cancer
923758|NCT02404753|Laparoscopic distal D2 gastrectomy
923759|NCT02404753|Neoadjuvant chemotherapy
923760|NCT02404740|VP shunted
923761|NCT02404740|Normal intracranial pathology
923762|NCT02404740|patients
923763|NCT02404727|Osteoarthritis, Hip
923764|NCT02404727|acetabular fixation
923765|NCT02404727|dual mobility cup
923766|NCT02404727|Radiostereometric Analysis
923767|NCT02404727|Dual-Energy Radiographic Absorptiometry
923768|NCT02404727|Accelerometry
923769|NCT02404727|total hip arthroplasty
923770|NCT02404727|intra-prosthetic dislocation
923771|NCT02404662|Alcohol use disorder
923772|NCT02404662|Depression
923773|NCT02404662|Mood disorders
923774|NCT02404662|Bipolar disorder
923775|NCT02404662|Supportive text messages
923776|NCT02404623|Vitamin D
923777|NCT02404623|Respiratory Morbidity
923778|NCT02404623|prematurity
923779|NCT02404610|propofol
923780|NCT02404610|moderate procedural sedation
923781|NCT02404610|deep procedural sedation
923782|NCT02404610|memory
923783|NCT02404610|emergency department
923784|NCT02404597|Cardiac output
923785|NCT02404597|Low blood pressure
923786|NCT02404597|Total Body Surface Area (TBSA)
923787|NCT02404584|Metastatic kidney cancer
923791|NCT02404532|OPC-14597 Digital
923792|NCT02404532|Aripiprazole
923793|NCT02404532|Medical Information Device #1 System (MIND1)
923794|NCT02404532|Ingestible Event Marker
923795|NCT02404519|Vitamin K
923796|NCT02404519|Menaquinone-7
923797|NCT02404519|Matrix Gla Protein
923798|NCT02404519|Vascular stiffness
923799|NCT02404506|Eribulin
923800|NCT02404506|Breast Cancer
923801|NCT02404506|Elderly Patient
923802|NCT02404506|Phase II Trial
923803|NCT02404506|HER2-neg
923804|NCT02404506|adenocarcinoma
923805|NCT02404493|Atopic Dermatitis
923806|NCT02404441|Phase I/II, PDR001, Checkpoint inhibitor, PD-1, PD-L1
923807|NCT02404428|active surveillance
923808|NCT02404428|MRI
923809|NCT02404428|diet
923810|NCT02404415|catheter ablation
923811|NCT02404415|genomics
923812|NCT02404402|Traumatic Brain Injury
923813|NCT02404402|Light Emitting Diodes
923814|NCT02404402|Cognition
923815|NCT02404402|Neuromodulation
923816|NCT02404402|PTSD
923817|NCT02404402|Neurorehabilitation
923818|NCT02404402|Veterans
923819|NCT02404402|Sleep
923820|NCT02404389|Actinic keratosis, patients, topical, lesion count, clearance rate
923821|NCT02404376|STEMI
923822|NCT02404376|Reperfusion Injury
923823|NCT02404376|Myocardial Infarction
923824|NCT02404376|Myocardial Ischemia
923825|NCT02404376|Remote Ischemic Conditioning
923826|NCT02404376|Exenatide
923827|NCT02404376|Glucagon-Like Peptide-1 (GLP-1)
923828|NCT02404376|Acute Coronary Syndrome
923829|NCT02404376|Cardioprotection
923830|NCT02404363|Clopidogrel
923831|NCT02404363|Pancreatic Cancer
923832|NCT02404363|Efficacy
923833|NCT02404363|Chemotherapy
923834|NCT02404363|Microparticles
923835|NCT02404363|Disease free survival
923836|NCT02404363|First line chemotherapy
923837|NCT02404350|Psoriatic Arthritis, Arthritis, Psoriatic, Psoriatic Arthropathy
923838|NCT02404311|HIV
923839|NCT02404311|AIDS
923840|NCT02404311|Vaccine
923841|NCT02404298|Transcriptome analysis
923842|NCT02404298|peripheral blood
923843|NCT02404298|chronic inflammatory demyelinating polyradiculoneuropathy
923844|NCT02404298|auto immune diseases
923845|NCT02404298|IVIg
923846|NCT02404272|Neonate
923847|NCT02404272|oral feeding disorder
923848|NCT02404272|full oral feeding
923849|NCT02404272|training
923850|NCT02404272|quality of health care
923851|NCT02404259|pharmacokinetics
923852|NCT02404259|TDF
923853|NCT02404259|HIV-infected children
923854|NCT02404259|Thai
923855|NCT02404259|non-nucleoside reverse transcriptase inhibitor (NNRTI)
923856|NCT02404259|ritonavir-boosted protease inhibitor (bPI)
923857|NCT02404259|less than eighteen years old
923858|NCT02404246|Bipolar
923859|NCT02404246|Peers
923860|NCT02404246|DBSA
923861|NCT02404220|Syk inhibitor
923862|NCT02404220|Blood malignancy
923863|NCT02404220|Leukemia
923864|NCT02404207|Prevention
923865|NCT02404194|schizophrenia
923866|NCT02404194|psychosis
923867|NCT02404194|at risk
923868|NCT02404194|prodrome
923869|NCT02404194|attenuated psychosis syndrome
923870|NCT02404181|Validation Studies
923871|NCT02404181|EEG
923872|NCT02404142|Trachel intubation
923873|NCT02404142|IDS score
923874|NCT02404142|Videoaryngoscopy
923875|NCT02404142|Glidescope® Titanium®
923876|NCT02404142|NMBA
923877|NCT02404142|Curare (Atracurium)
923878|NCT02404129|Fall
923879|NCT02404129|Turn 180 test
923880|NCT02404129|elderly
923881|NCT02404129|balance
923882|NCT02404090|Obesity
923883|NCT02404090|Weight Loss
923884|NCT02404090|Knee Osteoarthritis
923885|NCT02404090|Subchondral Mineralization
923886|NCT02404077|Patients
923887|NCT02404077|undergoing
923888|NCT02404077|ICU
923889|NCT02404051|Breast cancer
923890|NCT02404051|HER2Negative
923891|NCT02404051|hormone receptor positive (HR+)
923892|NCT02404051|Metastatic
923893|NCT02404051|Locally Advanced
923894|NCT02404051|fulvestrant
923895|NCT02404051|everolimus
923896|NCT02404051|exemestane
923897|NCT02404038|choice
923898|NCT02404038|young women
923899|NCT02404038|adolescent girls
923900|NCT02404038|preference
923901|NCT02404025|Eltrombopag
923902|NCT02404025|rabbit anti-thymocyte globulin
923903|NCT02404025|additive effect
923904|NCT02404025|cyclosporine A
923905|NCT02404012|iron deficiency
923906|NCT02404012|sleeve gastrectomy
923907|NCT02404012|gastric bypass
923908|NCT02404012|bariatric surgery
923909|NCT02403973|Patient hotel
923910|NCT02403973|Patient Satisfaction
923911|NCT02403973|Perioperative care
923912|NCT02403973|IN2005E
923913|NCT02403947|Multiple Sclerosis
923914|NCT02403947|Bone-marrow
923915|NCT02403947|Stem cells
923916|NCT02403947|Cell therapy
923917|NCT02403934|Airway Management
923918|NCT02403934|deep sedation
923919|NCT02403934|Jaw elevation device
923920|NCT02403921|biomarker
923921|NCT02403908|radiofrequency denervation, pulmonary hypertension
923922|NCT02403882|behavioral economics
923923|NCT02403882|food pantry
923924|NCT02403882|food choice
923925|NCT02403869|Metastatic breast cancer
923926|NCT02403869|Monotherapy
923927|NCT02403869|chemotherapy
923928|NCT02403869|second line
923929|NCT02403869|treatment
923930|NCT02403869|Her 2 negative
923931|NCT02403856|calcifying tendinitis
923932|NCT02403856|Needle lavage
923933|NCT02403856|Shoulder
923934|NCT02403856|Corticosteroid injection
923935|NCT02403856|Ultrasound-guided
923936|NCT02403817|Video Games
923937|NCT02403804|Dietary supplements
923938|NCT02403804|serum choline
923939|NCT02403804|women
923940|NCT02403791|Acute Respiratory Distress Syndrome
923941|NCT02403778|Melanoma
923942|NCT02403778|Malignant Melanoma
923943|NCT02403752|dementia
923944|NCT02403752|Alzheimer's disease
923945|NCT02403752|exercise
923947|NCT02403700|bone remodeling
923948|NCT02403700|bone resorption
923949|NCT02403700|three-dimensional imaging
923950|NCT02403700|clinical trial
923951|NCT02403700|dental implant
923952|NCT02403700|maxilla
923953|NCT02403700|bone healing
923954|NCT02403635|HSV
923955|NCT02403635|Herpes
923956|NCT02403635|volunteers
923957|NCT02403635|drug-drug interaction
923958|NCT02403609|cognitive assessment
923959|NCT02403609|Brain Performance Test
923960|NCT02403609|Lumosity
923961|NCT02403609|test-retest reliability
923962|NCT02403609|computerized assessment
923963|NCT02403596|Hip replacement
923964|NCT02403596|rivaroxaban
923965|NCT02403596|exacyl
923966|NCT02403596|blood loss
923967|NCT02403583|HIV Transmission
923968|NCT02403583|Prevention of Mother to Child Transmission
923969|NCT02403583|Serodiscordancy
923970|NCT02403583|Home-based testing
923971|NCT02403583|Home-based counseling
923972|NCT02403583|Linkage to care
923973|NCT02403583|Couples HIV Testing and Counseling
923974|NCT02403583|Acceptance of repeat HIV testing during pregnancy
923975|NCT02403583|Retention in care
923976|NCT02403570|Multiple Sclerosis, MRI, rotating frame
923977|NCT02403544|Clinical Trial, Phase I
923978|NCT02403544|Concurrent Chemoradiation
923979|NCT02403544|Oxaliplatin
923980|NCT02403544|Capecitabine
923981|NCT02403544|Carcinoma, Hepatocellular
923982|NCT02403531|Esophageal cancer
923983|NCT02403531|Chemoradiotherapy
923984|NCT02403531|induction chemotherapy
923985|NCT02403505|Prostate Cancer
923986|NCT02403505|SNP
923987|NCT02403505|Single Nucleotide Polymorphism
923988|NCT02403505|Genetics
923989|NCT02403505|Pharmacogenomic
923990|NCT02403505|Pharmacogenetic
923991|NCT02403505|gene
923992|NCT02403505|genome
923993|NCT02403505|genotype
923994|NCT02403505|genotyping
923995|NCT02403505|Oncology
923996|NCT02403505|Chemotherapy
923997|NCT02403505|Personalize
923998|NCT02403505|Individualize
923999|NCT02403492|Children
924000|NCT02403492|Obesity
924001|NCT02403492|Cardiovascular
924002|NCT02403492|Sleep
924003|NCT02403492|Apnea
924004|NCT02403492|Obstructive
924005|NCT02403466|Medical errors
924006|NCT02403466|Communication
924007|NCT02403466|Resident sign-out
924008|NCT02403453|Radiculopathy
924009|NCT02403453|Myelopathy
924010|NCT02403453|Spondylosis
924011|NCT02403453|Herniated Nucleus Pulposus
924012|NCT02403453|C3-C7
924013|NCT02403453|Osteophytes
924014|NCT02403453|Neurological deficit
924015|NCT02403427|Bolus calculator
924016|NCT02403427|Insulin pump
924017|NCT02403427|basal-bolus insulin therapy
924018|NCT02403401|Pregnancy prevention
924019|NCT02403388|Patient safety
924020|NCT02403388|Primary care
924021|NCT02403388|Incident reporting
924022|NCT02403388|Pluridisciplinary care offices
924023|NCT02403388|Risk management
924024|NCT02403388|Assessment
924025|NCT02403310|adverse-risk AML
924026|NCT02403310|poor-risk karyotype
924027|NCT02403310|cytogenetic abnormality
924028|NCT02403310|poor-risk mutations
924029|NCT02403310|antecedent hematologic disorder
924030|NCT02403310|treatment related AML
924031|NCT02403297|Bleeding gums
924032|NCT02403297|Gum inflammation
924033|NCT02403297|Saliva
924034|NCT02403284|insulin resistance
924035|NCT02403284|lipid metabolism
924036|NCT02403284|glucose metabolism
924037|NCT02403284|high fat diets
924038|NCT02403271|Pharmacyclics
924039|NCT02403271|PCYC
924040|NCT02403271|Ibrutinib
924041|NCT02403271|Durvalumab (MEDI4736)
924042|NCT02403271|Relapsed Refractory Solid Tumor
924043|NCT02403271|Non-Small Cell Lung Cancer
924044|NCT02403271|NSCLC
924045|NCT02403271|Squamous
924046|NCT02403271|Squamous NSCLC
924047|NCT02403271|Squamous Non-Small Cell Lung Cancer
924048|NCT02403271|Immunotherapy
924049|NCT02403271|IMBRUVICA®
924050|NCT02403271|Tumor Immunotherapy
924051|NCT02403271|Anti-PD-L1
924052|NCT02403271|Lung Cancer
924053|NCT02403258|acupuncture
924054|NCT02403258|plum-blossom needle
924055|NCT02403258|tourette syndrome
924056|NCT02403258|randomized controlled trial
924057|NCT02403245|Social interactions
924058|NCT02403245|Dementia
924059|NCT02403245|Social stimulation
924060|NCT02403245|Direct observation
924061|NCT02403232|Autologous adipose-derived stem cells
924062|NCT02403219|Dry eye
924063|NCT02403219|Botulinum toxin A
924064|NCT02403219|Orbicularis muscle of the eye
924065|NCT02403193|Adenosine A2a receptor antagonist
924066|NCT02403193|NSCLC
924067|NCT02403193|PBF-509
924068|NCT02403193|Immunotherapy
924069|NCT02403193|adenosine
924070|NCT02403193|PDR001
924071|NCT02403193|immune checkpoint inhibitors
924072|NCT02403193|Programmed Death-1 (PD-1) receptor
924073|NCT02403193|Adenosine A2a receptor (A2AR)
924074|NCT02403180|Visual Performance
924075|NCT02403154|Anterior pelvic ring
924076|NCT02403154|Internal fixation
924077|NCT02403154|External fixation
924078|NCT02403154|Orthopaedic
924079|NCT02403154|Orthopedic
924080|NCT02403154|pubic rami
924081|NCT02403128|362.17
924082|NCT02403102|Magnetic Resonance Imaging
924083|NCT02403102|Myeloma
924084|NCT02403102|Autograft
924085|NCT02403089|MAIT (Mucosal-Associated Invariant T) cells
924086|NCT02403089|Gut microbiota
924087|NCT02403089|Preterm birth
924088|NCT02403089|Hematopoietic stem cell transplantation
924089|NCT02403089|Microbial infections
924090|NCT02403050|Neoplasm Staging
924091|NCT02403050|Radiotherapy
924092|NCT02403050|Fiducial Markers
924093|NCT02403037|Breast Neoplasms
924094|NCT02403037|Auricular Therapy
924095|NCT02403037|Acupressure
924096|NCT02403037|Chemotherapy
924097|NCT02403037|Nausea
924098|NCT02403037|Vomiting
924099|NCT02403024|Colon cancer
924100|NCT02403024|rectal cancer
924101|NCT02403024|exercise
924102|NCT02403024|physical activity
924103|NCT02403024|metabolic health
924104|NCT02403011|Congenital Muscular Torticollis
924105|NCT02403011|Manual Therapy
924106|NCT02403011|Infant
924107|NCT02402998|Primacy immune thrombocytopenia
924108|NCT02402998|Adults
924109|NCT02402998|Eltrombopag
924110|NCT02402998|Long-term remission
924111|NCT02402985|nutritional support
924112|NCT02402985|diet therapy
924113|NCT02402985|protein diet
924114|NCT02402985|isocaloric diet
924115|NCT02402972|adjuvant chemotherapy
924116|NCT02402972|intraportal chemotherapy
924117|NCT02402972|prevention
924118|NCT02402959|Insomnia
924119|NCT02402959|Traditional Chinese Medicine
924120|NCT02402959|herbal medicine
924121|NCT02402959|cohort study
924122|NCT02402959|individualized treatment
924123|NCT02402959|TCM pattern differentiation
924124|NCT02402920|Lung Cancer
924125|NCT02402920|Small Cell Lung Cancer
924126|NCT02402920|SCLC
924127|NCT02402920|Limited-Stage Small-Cell Lung Cancer
924128|NCT02402920|LS-SCLC
924129|NCT02402920|Extensive-Stage Small-Cell Lung Cancer
924130|NCT02402920|ES-SCLC
924131|NCT02402920|MK-3475
924132|NCT02402920|Keytruda
924133|NCT02402920|Pembrolizumab
924134|NCT02402920|SCH-900475
924135|NCT02402920|Etoposide
924136|NCT02402920|VePesid
924137|NCT02402920|Cisplatin
924138|NCT02402920|Platinol-AQ
924139|NCT02402920|Platinol
924140|NCT02402920|CDDP
924141|NCT02402920|Carboplatin
924142|NCT02402920|Radiation therapy
924143|NCT02402920|XRT
924144|NCT02402907|cesarean section
924145|NCT02402907|chlorhexidine gluconate
924146|NCT02402907|CHG
924147|NCT02402907|surgical site infection
924148|NCT02402907|obstetrics
924149|NCT02402907|infection prevention
924150|NCT02402907|pregnancy
924151|NCT02402881|venous thromboembolism
924152|NCT02402881|deep venous thrombosis
924153|NCT02402881|pulmonary embolism
924154|NCT02402881|blood clots
924155|NCT02402855|Couverture Maladie Universelle
924156|NCT02402855|Couverture Maladie Universelle-Complémentaire
924157|NCT02402855|free health care
924158|NCT02402842|gastrointestinal oncology
924159|NCT02402842|immunology
924160|NCT02402842|taxane
924161|NCT02402764|Triple Negative Breast Cancer (TNBC)
924162|NCT02402764|Breast - Female
924163|NCT02402764|Breast - Male
924164|NCT02402764|Metastatic Triple Negative Breast Cancer
924165|NCT02402764|Receptor Tyrosine-protein Kinase erbB-2 (HER2) Negative
924166|NCT02402764|Erythroblastosis virus oncogene B (erbB)
924167|NCT02402751|Volunteers
924168|NCT02402725|Relapsed Multiple Myeloma
924169|NCT02402699|HBV
924170|NCT02402699|HBC
924171|NCT02402647|Hoarding
924172|NCT02402647|Compulsive Hoarding
924173|NCT02402595|Drug-drug interaction
924174|NCT02402595|Healthy Volunteers
924175|NCT02402595|Pharmacokinetics
924176|NCT02402595|deuterated dextromethorphan
924177|NCT02402595|dextromethorphan
924178|NCT02402595|dextromethorphan with quinidine
924179|NCT02402595|deuterated dextromethorphan with quinidine
924180|NCT02402595|itraconazole
924181|NCT02402582|Family-Centered Empowerment Model
924182|NCT02402582|Quality of life
924183|NCT02402582|Perceived stress
924184|NCT02402582|Anxiety
924185|NCT02402582|Myocardial infarction
924186|NCT02402582|Clinical trial
924187|NCT02402582|Iran
924188|NCT02402543|preemptive analgesia
924189|NCT02402543|anorectal surgery
924190|NCT02402543|gabapentin
924191|NCT02402543|neurontin
924192|NCT02402543|ketamine
924193|NCT02402543|acetaminophen
924194|NCT02402543|tylenol
924195|NCT02402543|postoperative pain
924196|NCT02402543|postoperative narcotic usage
924197|NCT02402543|dexamethasone
924198|NCT02402543|decadron
924199|NCT02402530|Neridronic Acid
924200|NCT02402530|Neridronate
924201|NCT02402530|CRPS
924202|NCT02402530|RSD
924203|NCT02402517|Diabetes Prevention
924204|NCT02402517|Obesity Prevention
924205|NCT02402491|Dual Antiplatelet Treatment
924206|NCT02402491|In-Stent Restenosis
924207|NCT02402478|Clinical Cohort
924208|NCT02402478|Electronic Health Records
924209|NCT02402478|Prognosis
924210|NCT02402478|Stable Coronary Artery Disease
924211|NCT02402439|Type 1 diabetes
924212|NCT02402439|diabetes mellitus
924213|NCT02402439|pancreatic islet transplant
924214|NCT02402439|beta cell replacement
924215|NCT02402426|Brain Health
924216|NCT02402426|Brain Research
924217|NCT02402426|Alzheimer's Disease
924218|NCT02402426|Neurodegenerative Disease
924219|NCT02402426|Parkinson's Disease
924220|NCT02402426|Dementia
924221|NCT02402426|Stroke
924222|NCT02402426|PTSD
924223|NCT02402426|Multiple Sclerosis
924224|NCT02402400|NSTEMI
924225|NCT02402361|Neuropathic pain
924226|NCT02402361|Diabetic Neuropathy
924227|NCT02402348|head and neck squamous cell carcinoma
924228|NCT02402309|Sjögren-Larsson Syndrome
924229|NCT02402309|SLS
924230|NCT02402309|Ichthyosis
924231|NCT02402309|FALDH Deficiency
924232|NCT02402309|Neuro-ichthyosis
924233|NCT02402309|Fatty Alcohol:NAD+ Oxidoreductase Deficiency
924234|NCT02402309|Fatty Aldehyde Dehydrogenase Deficiency Disease
924235|NCT02402309|Congenital Icthyosis Mental Retardation Spasticity Syndrome
924236|NCT02402309|Spastic Neurologic Disorder
924237|NCT02402309|Oligophrenia
924238|NCT02402283|Bioequivalency
924239|NCT02402283|two metronidazole-containing products
924240|NCT02402270|Colonoscopy
924241|NCT02402270|Preparation
924242|NCT02402257|Central Venous Catheter
924243|NCT02402257|Simulation-based Mastery Learning
924244|NCT02402257|Medical Education
924245|NCT02402257|Patient Outcomes
924246|NCT02402257|Bloodstream Infection Due to Central Venous Catheter
924247|NCT02402257|Pneumothorax
924248|NCT02402257|Inadvertent Arterial Puncture
924249|NCT02402205|Implementation; TF-CBT; adjudicated youth; RTF; trauma
924250|NCT02402192|corifollitropin alfa
924251|NCT02402192|recombinant FSH
924252|NCT02402192|HP-hMG
924253|NCT02402192|time-lapse
924254|NCT02402192|kinetics of development
924255|NCT02402179|protein quality
924256|NCT02402153|evaluation of subcutaneous EEG recording
924257|NCT02402140|tacrolimus blood concentration
924258|NCT02402140|pharmaceutical intervention
924259|NCT02402140|intrasubject variability
924260|NCT02402127|Contact lenses
924261|NCT02402127|Lubricity
924262|NCT02402101|tDCS
924263|NCT02402101|Dopamine
924264|NCT02402101|PET
924265|NCT02402088|stress
924266|NCT02402088|food cues
924267|NCT02402088|obesity
924268|NCT02402075|muscle motor evoked potentials
924269|NCT02402075|spinal motor evoked potentials
924270|NCT02402075|D-wave
924271|NCT02402075|brain tumor surgery
924272|NCT02402075|intraoperative neuromonitoring
924273|NCT02402062|pNET
924274|NCT02401997|sperm
924275|NCT02401997|oxidative stress
924276|NCT02401997|sexual abstinence
924277|NCT02401971|Thalidomide
924278|NCT02401971|Irinotecan
924279|NCT02401971|Second Line
924280|NCT02401945|Macular Degeneration
924281|NCT02401919|Nursing
924282|NCT02401919|Hospital
924283|NCT02401919|Communication
924284|NCT02401919|Patient Participation
924285|NCT02401919|Individualised Care
924286|NCT02401893|aging
924287|NCT02401893|influenza vaccine
924288|NCT02401893|immune responses
924289|NCT02401867|transgender
924290|NCT02401867|female-to-male
924291|NCT02401867|cervical cancer
924292|NCT02401867|HPV
924293|NCT02401867|sexual health
924294|NCT02401854|atrial fibrillation
924295|NCT02401854|hypertension
924296|NCT02401854|risk factors
924297|NCT02401854|primary care
924298|NCT02401854|elderly
924299|NCT02401815|Gastrointestinal Stromal Tumors
924300|NCT02401815|KIT
924301|NCT02401815|Biomarkers
924302|NCT02401815|PLX9486
924303|NCT02401815|PLX3397
924304|NCT02401815|Sunitinib
924305|NCT02401802|Colonoscopy
924306|NCT02401802|Diet
924307|NCT02401802|Polyethylene glycols
924308|NCT02401802|Efficacy
924309|NCT02401802|Personal satisfaction
924310|NCT02401802|Colorectal cancer screening
924311|NCT02401789|oral surgery
924312|NCT02401789|Implantology
924313|NCT02401776|heart rate
924314|NCT02401776|blood pressure
924315|NCT02401776|caffeine
924316|NCT02401776|energy drink
924317|NCT02401763|biomarker
924318|NCT02401737|Hepatitis B
924319|NCT02401724|Hemispatial neglect
924320|NCT02401724|Transcranial direct current stimulation
924321|NCT02401724|Rehabilitation
924322|NCT02401698|Stroke
924323|NCT02401698|Transcranial Magnetic Stimulation
924324|NCT02401698|Neuronal Plasticity
924325|NCT02401698|Rehabilitation
924326|NCT02401685|breast cancer
924327|NCT02401685|sentinel lymph node biopsy
924328|NCT02401685|axillary lymph node clearance
924329|NCT02401685|axillary lymph node dissection
924330|NCT02401685|macrometastases
924331|NCT02401685|axillary radiotherapy
924332|NCT02401685|POSNOC
924333|NCT02401672|TMS
924334|NCT02401672|nicotine dependence
924335|NCT02401672|smoking cessation
924336|NCT02401659|remote monitoring
924337|NCT02401659|satisfaction
924338|NCT02401659|telemonitoring
924339|NCT02401659|quality of life
924340|NCT02401633|Cardio-Pulmonary-Resuscitation
924341|NCT02401633|Advanced Cardiac Life Support
924342|NCT02401633|Compression-Only CPR
924343|NCT02401633|Chest compression CPR
924344|NCT02401620|AR: arthritis rheumatoid
924345|NCT02401620|DMARDs: Disease-modifying antirheumatic drugs
924346|NCT02401620|ACR. American College of Rheumatology
924347|NCT02401620|EULAR: European League against rheumatology
924348|NCT02401607|stress
924349|NCT02401607|emergency physicians
924350|NCT02401607|health care workers
924351|NCT02401607|biomarkers
924352|NCT02401607|questionnaires
924353|NCT02401607|anxiety
924354|NCT02401607|depression
924355|NCT02401607|burn-out
924356|NCT02401594|Non-major orthopaedic surgery
924357|NCT02401594|deep vein thrombosis
924358|NCT02401542|Urothelial Cell Carcinoma
924359|NCT02401542|UCC
924360|NCT02401542|bladder cancer
924361|NCT02401542|B-701
924362|NCT02401542|FGFR3
924363|NCT02401542|invasive bladder cancer
924364|NCT02401542|targeted therapy
924365|NCT02401542|Transitional Cell Carcinoma
924366|NCT02401542|TCC
924367|NCT02401542|Phase 2
924368|NCT02401542|second line therapy
924369|NCT02401542|monoclonal antibody
924370|NCT02401542|docetaxel
924371|NCT02401542|combination therapy
924372|NCT02401542|Phase 1
924373|NCT02401529|Dexamethasone
924374|NCT02401529|Prednisolone
924375|NCT02401529|Tonsillectomy Nausea
924376|NCT02401529|Pain, Postoperative
924377|NCT02401529|Postoperative Nausea and Vomiting
924378|NCT02401529|Randomized controlled trial
924379|NCT02401529|Post-tonsillectomy pain
924380|NCT02401529|delayed feeding
924381|NCT02401516|Postural Reprogramming Insole
924382|NCT02401516|Blood Pressure
924383|NCT02401516|Posture
924384|NCT02401516|Quality Of Life
924385|NCT02401516|General Functional Capacity
924386|NCT02401516|Respiratory Muscles Strength
924387|NCT02401516|Flexibility
924388|NCT02401516|Arterial Systemic Hypertension
924389|NCT02401503|CLL
924390|NCT02401477|helicobacter pylori
924391|NCT02401477|ilaprazole
924392|NCT02401477|eradication
924393|NCT02401477|dual therapy
924394|NCT02401477|high dose therapy
924395|NCT02401425|Letrozole
924396|NCT02401425|Misoprostol
924397|NCT02401425|First-Trimester
924398|NCT02401425|Pretreatment
924399|NCT02401386|Fibromyalgia, The Lu Eight Brocades
924400|NCT02401373|Vaccines
924401|NCT02401373|Ebola Virus Disease
924402|NCT02401347|PALB2 mutation
924403|NCT02401347|BRIP1 mutation
924404|NCT02401347|BARD1 mutation
924405|NCT02401347|Rad51c mutation
924406|NCT02401347|PTEN mutation
924407|NCT02401347|CHEK2 mutation
924408|NCT02401347|ATM mutation
924409|NCT02401347|NBN mutation
924410|NCT02401347|Rad51d mutation
924411|NCT02401347|Rad50 mutation
924412|NCT02401347|MRE11 mutation
924413|NCT02401347|FANC mutation
924414|NCT02401347|HRD assay score
924415|NCT02401347|ATR mutation
924416|NCT02401295|Relapsed multiple myeloma
924417|NCT02401256|Efavirenz
924418|NCT02401256|metabolism
924419|NCT02401256|pharmacokinetics changes
924420|NCT02401230|Human Immunodeficiency Virus
924421|NCT02401230|Acquired Immune Deficiency Syndrome Virus
924422|NCT02401230|Pre-exposure Prophylaxis
924423|NCT02401204|Bacterial transmission
924424|NCT02401204|Surveillance
924425|NCT02401204|Neonatal
924426|NCT02401204|Drug Resistance
924427|NCT02401178|FLG-FADS genes variations-LCPUFA-atopic dermatitis
924428|NCT02401165|GADD34
924429|NCT02401165|Unfolded Protein Response
924698|NCT02399423|metabolism
924430|NCT02401165|Anti-citrullinated protein antibodies
924431|NCT02401100|Rectal Neoplasms
924432|NCT02401061|ITP
924433|NCT02401061|Thrombocytopenia
924439|NCT02401022|smoking
924440|NCT02401022|smoking cessation
924441|NCT02401022|cigarette
924442|NCT02400996|Endocrine Pancreas
924443|NCT02400996|Pancreatic Endocrine Neoplasm
924444|NCT02400983|ACAP, Automatic Algorithm
924445|NCT02400970|Polymerase Chain Reaction
924446|NCT02400970|fertility preservation
924447|NCT02400957|silver nanoparticles
924448|NCT02400957|demineralization
924449|NCT02400957|brackets
924450|NCT02400944|MSK Tobacco Cessation Program
924451|NCT02400944|smoking exposure
924452|NCT02400944|15-047
924453|NCT02400905|PAD
924454|NCT02400905|PVD
924455|NCT02400905|SFA stent
924456|NCT02400879|bispectral index
924457|NCT02400879|cardiac surgery
924458|NCT02400879|recovery
924459|NCT02400879|remifentanil
924460|NCT02400866|cancer patients receiving moderately emetogenic chemotherapy
924461|NCT02400827|Polymerase Chain Reaction
924462|NCT02400827|fertility preservation
924463|NCT02400801|endometriosis
924464|NCT02400801|infertility
924465|NCT02400801|assisted reproductive technology
924466|NCT02400775|Pharmacotherapy
924467|NCT02400749|moderate to severe non-pustular palmo-plantar psoriasis
924474|NCT02400723|behavioral intervention
924475|NCT02400723|relaxation
924476|NCT02400723|Veterans
924477|NCT02400723|geriatric
924478|NCT02400684|AFSr classification
924479|NCT02400684|laparoscopy
924480|NCT02400658|breast cancer
924481|NCT02400658|early-stage
924482|NCT02400658|IORT
924483|NCT02400658|brachytherapy
924484|NCT02400645|laparoscopic hysterectomy
924485|NCT02400645|robotic assisted hysterectomy
924486|NCT02400632|drug-eluting balloon
924487|NCT02400632|in-stent restenosis
924488|NCT02400619|shockwaves
924489|NCT02400619|Physiotherapy
924490|NCT02400619|Botulinum toxin
924491|NCT02400606|constructing VPs
924492|NCT02400606|knowledge and skills transfer
924493|NCT02400580|Laparoscopic Hysterectomy
924494|NCT02400580|IV acetaminophen
924495|NCT02400580|Postoperative pain control
924496|NCT02400580|Surgery
924497|NCT02400567|Luminal
924498|NCT02400567|Post menopausal
924499|NCT02400567|Breast conservation
924500|NCT02400567|Neoadjuvant
924501|NCT02400554|Indian, North American
924502|NCT02400554|Oklahoma
924503|NCT02400554|Female
924504|NCT02400554|health promotion
924505|NCT02400541|Anorexia nervosa
924506|NCT02400541|Cognitive remediation therapy
924507|NCT02400515|Exercise
924508|NCT02400515|Exercise Therapy
924509|NCT02400515|Diabetes Mellitus, Type 2
924510|NCT02400502|Schizophrenia
924511|NCT02400502|Treatment
924512|NCT02400502|Meditation
924513|NCT02400502|Mindfulness
924514|NCT02400502|Stress reactivity
924515|NCT02400502|First Episode Psychosis
924516|NCT02400502|Coping
924517|NCT02400489|Heart Valve Replacement Surgery
924518|NCT02400489|Perimount
924519|NCT02400489|Edwards
924523|NCT02400450|Pre-diabetes
924524|NCT02400450|prediabetes
924525|NCT02400450|glycated hemoglobin
924526|NCT02400450|hemoglobin A1c
924527|NCT02400450|LDL cholesterol
924528|NCT02400450|Cholesterol
924529|NCT02400450|metabolic function
924530|NCT02400450|vascular function
924531|NCT02400450|functional food
924532|NCT02400437|Waldenstrom's Macroglobulinemia
924533|NCT02400424|Stereotactic lung radiation therapy
924534|NCT02400424|Radiochemotherapy
924535|NCT02400424|Unresectable stage III Non-Small Cell lung Carcinoma
924536|NCT02400424|Peripheral primary tumor
924537|NCT02400411|Carbohydrate
924538|NCT02400411|Glycemic response
924539|NCT02400411|insulin
924540|NCT02400411|whole grain
924541|NCT02400411|meal
924542|NCT02400359|fMRI
924543|NCT02400359|Magnetic Resonance Imaging
924544|NCT02400359|endocrinology
924545|NCT02400359|MRI
924546|NCT02400359|obesity
924547|NCT02400359|weight loss
924548|NCT02400359|lorcaserin
924549|NCT02400333|ticagrelor orodispersible tablet
924550|NCT02400333|ticagrelor immediate-release tablet
924551|NCT02400333|relative bioavailability
924552|NCT02400333|Phase I
924553|NCT02400333|healthy subjects
924554|NCT02400307|Phase 1
924555|NCT02400307|Renally Impaired
924556|NCT02400294|Critical care
924557|NCT02400294|Mechanical ventilation
924558|NCT02400294|Ventilator associated pneumonia
924559|NCT02400294|Oral care
924560|NCT02400268|Enterobacteriaceae
924561|NCT02400268|Bloodstream
924562|NCT02400268|Bacteremia
924563|NCT02400268|Recurrence
924564|NCT02400268|Reinfection
924565|NCT02400229|coronary artery disease
924566|NCT02400229|stable chest pain
924567|NCT02400229|intermediate pretest probability
924568|NCT02400229|pragmatic randomised controlled trial
924569|NCT02400229|coronary computed tomography
924570|NCT02400229|angiography
924571|NCT02400229|invasive coronary angiography
924572|NCT02400216|Chronic Hepatitis C
924573|NCT02400216|Cirrhosis
924574|NCT02400216|Liver Biopsy
924575|NCT02400216|Microbiome
924576|NCT02400203|hemp oil,
924577|NCT02400203|hemp
924578|NCT02400203|fatty acids
924579|NCT02400203|omega-6
924580|NCT02400203|omega-3
924581|NCT02400203|blood pressure
924582|NCT02400203|blood lipids
924583|NCT02400190|radiation
924584|NCT02400190|lumpectomy
924585|NCT02400190|favorable biology
924586|NCT02400190|omission
924587|NCT02400125|Patient Registry
924588|NCT02400125|Coronary Artery Bypass
924589|NCT02400125|Cardiac Valve Annuloplasty
924590|NCT02400112|Vancomycin
924591|NCT02400086|neuroligical or neuromuscular diseases
924592|NCT02400086|bacterial respiratory tract flora
924593|NCT02400086|long term tracheostomy
924594|NCT02400047|Paediatric surgery
924595|NCT02400034|midurethral sling
924596|NCT02400034|Voiding trial
924597|NCT02400034|stress urinary incontinence
924598|NCT02399995|Quality of Life
924599|NCT02399995|Hepatectomy
924600|NCT02399995|15-057
924601|NCT02399982|Smartphone Application
924602|NCT02399982|mobile mental health
924603|NCT02399982|Binge Eating
924604|NCT02399982|Cognitive behavioral therapy
924731|NCT02399267|mechanical ventilation
924605|NCT02399982|Eating Disorder treatment
924606|NCT02399982|Cognitive behavioral therapy guided self-help
924607|NCT02399982|self-monitoring
924608|NCT02399982|eating disorders
924609|NCT02399982|ecological momentary intervention
924610|NCT02399969|Low back pain
924611|NCT02399969|Acupuncture therapy
924612|NCT02399969|Acupuncture, ear
924613|NCT02399956|Lactation
924614|NCT02399956|Pediatric malignancies
924615|NCT02399956|Cancer survivor
924616|NCT02399917|Leukemia
924617|NCT02399917|Acute Myeloid Leukemia
924618|NCT02399917|Refractory
924619|NCT02399917|Relapsed
924620|NCT02399917|AML
924621|NCT02399917|Myelodysplastic Syndrome (MDS).
924622|NCT02399917|MDS
924623|NCT02399917|High-risk
924624|NCT02399917|5-azacytidine
924625|NCT02399917|Azacitidine
924626|NCT02399917|5-aza
924627|NCT02399917|Vidaza
924628|NCT02399917|5-AZC
924629|NCT02399917|AZA-CR
924630|NCT02399917|Ladakamycin
924631|NCT02399917|NSC-102816
924632|NCT02399917|Azacytidine
924633|NCT02399917|Lirilumab
924634|NCT02399917|Phone call
924635|NCT02399891|Remodeling
924636|NCT02399891|Prognosis
924637|NCT02399891|Incidence
924638|NCT02399891|Quality Assurance
924639|NCT02399891|Ejection Fraction
924640|NCT02399891|Sudden Death
924641|NCT02399800|pancreatitis, chronic
924642|NCT02399800|endosonography
924643|NCT02399761|AADC deficiency, newborn screening
924644|NCT02399735|NK cells
924645|NCT02399735|Liver Transplantation
924646|NCT02399735|Hepatocellular Carcinoma Recurrence
924647|NCT02399722|Negative Pressure Wound Therapy, polymeric membrane dressing, wounds
924648|NCT02399670|Total hip arthroplasty
924649|NCT02399670|degenerative joint disease
924650|NCT02399670|Femoral offset
924651|NCT02399670|Patient reported outcome
924652|NCT02399657|diabetes mellitus
924653|NCT02399657|macular edema
924654|NCT02399657|hard exudate
924655|NCT02399657|intravitreal injections
924656|NCT02399657|dexamethasone
924657|NCT02399657|implant
924658|NCT02399644|pain
924659|NCT02399644|rehabilitation
924660|NCT02399644|exercise
924661|NCT02399644|psychological
924662|NCT02399644|intervention
924663|NCT02399631|Perioperative treatment
924664|NCT02399631|Laparoscopic surgery
924665|NCT02399618|Clostridium difficile Infection
924666|NCT02399618|Fecal Microbiota Transplantation
924667|NCT02399618|Freeze-dried
924668|NCT02399618|Acid-resistant Capsules
924669|NCT02399592|Platinum resistant
924670|NCT02399579|cat allergy
924671|NCT02399579|symptom score
924672|NCT02399566|erlotinib
924673|NCT02399566|pemetrexed
924674|NCT02399566|maintenance therapy
924675|NCT02399527|Vascular Anomalies
924676|NCT02399527|Lymphatic Anomalies
924677|NCT02399527|Lymphatic Malformation
924678|NCT02399514|Sleep
924679|NCT02399514|emphysema
924680|NCT02399514|coils
924681|NCT02399514|lung volume reduction
924682|NCT02399501|2D ultrasound
924683|NCT02399501|3D ultrasound
924684|NCT02399501|sonohysterography
924685|NCT02399501|hysteroscopy
924686|NCT02399501|Uterine factor of infertility
924693|NCT02399449|iron
924694|NCT02399449|pharmacokinetics
924695|NCT02399436|Community-Based Participatory Research
924696|NCT02399436|Community-Institutional Relations
924697|NCT02399423|diabetes
924699|NCT02399423|cardiovascular disease
924700|NCT02399423|weight gain
924701|NCT02399423|weight loss
924702|NCT02399423|european
924703|NCT02399423|south asian
924704|NCT02399423|obesity
924705|NCT02399410|cytoreductive surgery
924706|NCT02399410|hipec
924707|NCT02399410|perioperative chemotherapy
924708|NCT02399410|peritoneal carcinomatosis
924709|NCT02399410|bevacizumab
924710|NCT02399410|colorectal surgery
924711|NCT02399384|Cardiac Magnetic Resonance (CMR)
924712|NCT02399358|Drug induced Hyponatremia
924713|NCT02399358|Cyclophosphamide
924714|NCT02399358|Hyponatremia
924715|NCT02399358|Cyclophosphamide induced Hyponatremia
924716|NCT02399345|Treatment naive
924717|NCT02399345|Hepatitis C Genotype 1
924718|NCT02399319|anterior pelvic ring
924719|NCT02399319|symphysis disruption
924720|NCT02399293|Cognitive training
924721|NCT02399293|Cognitive rehabilitation
924722|NCT02399293|Acquired brain injury
924723|NCT02399293|N-back
924724|NCT02399293|Visual Search
924725|NCT02399293|Cognitive transfer
924726|NCT02399280|Meal pattern
924727|NCT02399280|weight loss
924728|NCT02399280|high caloric intake
924729|NCT02399280|Dinner
924730|NCT02399280|Lunch
924732|NCT02399267|weaning
924733|NCT02399267|critically ill
924734|NCT02399267|spontaneous breathing trial
924735|NCT02399267|screening
924736|NCT02399267|invasive ventilation
924737|NCT02399267|SBT technique
924738|NCT02399254|Pulmonary Rehabilitation
924742|NCT02399202|Renal impairment, osilodrostat, LCI699
924743|NCT02399189|Primary central nervous system lymphoma
924744|NCT02399189|rituximab
924745|NCT02399189|Methotrexate and Temozolomide
924746|NCT02399189|autologous stem cell transplantation
924747|NCT02399189|Carmustine and thiotepa
924748|NCT02399176|Osteoporosis
924749|NCT02399176|Yoga
924750|NCT02399150|acute abdomen
924751|NCT02399150|Pain
924752|NCT02399150|stress biomarker
924753|NCT02399137|Pancreatic Cancer
924754|NCT02399137|Front-line Pancreatic Cancer
924755|NCT02399137|Metastatic Pancreatic Cancer
924756|NCT02399137|Gemcitabine
924757|NCT02399137|Nab-paclitaxel
924758|NCT02399137|Abraxane
924759|NCT02399137|Free IGF-1
924760|NCT02399137|Heregulin
924761|NCT02399124|RCC
924762|NCT02399124|Renal Cell Carcinoma
924763|NCT02399124|Kidney tumors
924764|NCT02399111|Prevena Incision Management System (PIMS)
924765|NCT02399111|Surgical Site Infection (SSI)
924766|NCT02399085|DLBCL
924767|NCT02399085|CD19
924768|NCT02399085|monoclonal antibody
924769|NCT02399085|MOR00208
924770|NCT02399085|MOR208
924771|NCT02399059|recurrence
924772|NCT02399033|Xihuang Capsules
924773|NCT02399033|hepatocellular carcinoma
924774|NCT02399033|Recurrence
924775|NCT02399033|hepatectomy
924776|NCT02398994|Clinical Trials Unit
924777|NCT02398994|Pediatric
924778|NCT02398968|Iron
924779|NCT02398968|RURTIs
924780|NCT02398968|CARIFS
924781|NCT02398968|children
924782|NCT02398955|Drug-Eluting Stents
924783|NCT02398955|Coronary Artery Disease
924784|NCT02398955|Sirolimus
924785|NCT02398955|Absorbable Implants
924786|NCT02398903|Morbid obesity
924787|NCT02398903|bariatric surgery
924788|NCT02398903|sleeve gastrectomy
924789|NCT02398903|Roux-en-Y gastric bypass
924790|NCT02398903|hormonal contraception
924791|NCT02398903|combined oral contraceptive
924792|NCT02398903|progestin contraceptive desogestrel
924793|NCT02398903|pharmacokinetics
924794|NCT02398825|Chronic myeloid leukemia
924795|NCT02398825|Chronic phase
924796|NCT02398825|Adults
924797|NCT02398825|Ponatinib
924798|NCT02398825|Imatinib resistant
924799|NCT02398760|Low Back Pain
924800|NCT02398760|Clinical Instability
924801|NCT02398760|Motor Control Exercises
924802|NCT02398760|Clinical Tests
924803|NCT02398734|sonolysis
924804|NCT02398734|carotid endarterectomy
924805|NCT02398734|stroke prevention
924806|NCT02398734|brain infarction
924807|NCT02398721|FNAC
924808|NCT02398721|Small Incidental Thyroid Nodules
924809|NCT02398708|Hematopoietic Stem Cell Transplantation
924810|NCT02398708|Graft versus Host Disease
924811|NCT02398695|Plaque
924812|NCT02398695|Saliva
924813|NCT02398695|Caries
924814|NCT02398682|electronic alerts
924815|NCT02398682|acute kidney injury
924816|NCT02398682|NHS
924817|NCT02398682|mortality
924818|NCT02398669|Obesity
924819|NCT02398669|Lorcaserin hydrochloride
924820|NCT02398669|APD356
924821|NCT02398669|Pediatric
924822|NCT02398669|Pharmacokinetics
924823|NCT02398656|Minor Ischemic Stroke
924824|NCT02398643|Acute Exacerbation of COPD
924825|NCT02398643|COPD
924826|NCT02398643|Emphysema
924827|NCT02398643|Chronic Bronchitis
924828|NCT02398630|Histerosalpingography
924829|NCT02398630|MRI
924830|NCT02398630|Magnetic Resonance Imaging
924831|NCT02398630|HSG
924832|NCT02398630|Diagnostico Maipu
924833|NCT02398630|Imaging
924834|NCT02398630|Carrascosa Patricia
924838|NCT02398604|Pediatrics
924839|NCT02398604|HLHS
924840|NCT02398591|Healthy
924841|NCT02398591|JNJ 53718678
924842|NCT02398552|metastatic renal cell carcinoma
924843|NCT02398552|sunitinib
924844|NCT02398552|schedule 2weeks on/1 week off
924845|NCT02398526|Observational study
924846|NCT02398526|Bone metastases
924847|NCT02398526|Hormone Refractory Prostatic Cancer
924848|NCT02398526|Xofigo
924849|NCT02398526|Radium-223
924850|NCT02398500|First-in-human
924851|NCT02398500|anti-VEGF
924852|NCT02398500|neovascular AMD (nvAMD)
924853|NCT02398435|Auto-inflammatory disease
924854|NCT02398435|Still's disease
924855|NCT02398435|Arthritis Rheumatoid
924856|NCT02398435|IL-18
924857|NCT02398435|interleukin-18
924858|NCT02398435|IL-18 binding protein
924859|NCT02398422|Autonomic nervous system
924860|NCT02398422|Auditory processing disorder
924861|NCT02398422|Social behavior
924862|NCT02398409|stroke
924863|NCT02398409|Injury, Brain, Traumatic
924864|NCT02398409|Family Caregivers
924865|NCT02398409|TBI (Traumatic Brain Injury)
924866|NCT02398409|Informal Caregivers
924867|NCT02398370|ED
924868|NCT02398357|anticoagulation
924869|NCT02398357|Zelen-designed randomized controlled trial
924870|NCT02398331|Spinal cord injuries
924871|NCT02398331|Sexual function
924872|NCT02398331|Sexual response
924873|NCT02398331|Sexuality
924874|NCT02398331|Women
924875|NCT02398318|neurosurgery
924876|NCT02398318|deep brain stimulation
924877|NCT02398318|exposure response prevention
924878|NCT02398305|Cardiac catheterisation
924879|NCT02398305|Radial access
924880|NCT02398305|Compression
924881|NCT02398305|Terumo TR Band
924882|NCT02398305|radial artery
924883|NCT02398305|diagnostic
924884|NCT02398279|schizophrenia
924885|NCT02398279|L-Arginine
924886|NCT02398279|nitric oxide
924887|NCT02398279|drug augmentation
924888|NCT02398253|weight maintenance
924889|NCT02398253|cognitive behavior therapy
924890|NCT02398253|successful weight loss
924891|NCT02398227|Battered Women
924892|NCT02398227|Trauma
924893|NCT02398227|Domestic Violence
924894|NCT02398214|Sleep
924895|NCT02398214|Infants
924896|NCT02398214|Toddlers
924897|NCT02398214|Behavioral intervention
924898|NCT02398175|Pediatric polytrauma
924899|NCT02398175|thoracic injuries
924900|NCT02398162|Scrub Typhus in Pediatric
924901|NCT02398162|Immunology
924902|NCT02398136|intervention
924903|NCT02398136|ketamine
924904|NCT02398136|PTSD
924905|NCT02398136|treatment
924906|NCT02398136|posttraumatic stress disorder
924907|NCT02398123|Transversus Abdominis Plane
924908|NCT02398123|caudal block
924909|NCT02398123|postoperative pain
924910|NCT02398123|children
924911|NCT02398084|mastication
924912|NCT02398084|cashews
924913|NCT02398084|walnuts
924914|NCT02398084|participants
924915|NCT02398071|Positive Expiratory Pressure
924916|NCT02398071|Exercise Recovery
924917|NCT02398071|COPD
924918|NCT02398058|trabectedin
924919|NCT02398058|olaparib
924920|NCT02398058|sarcoma
924921|NCT02398058|bone tumor
924922|NCT02398045|Obsessive-compulsive disorder
924923|NCT02398045|cognitive behavioural therapy
924924|NCT02398045|computerised
924925|NCT02398032|sleep apnea
924926|NCT02398032|hypertension
924927|NCT02398032|mechanosensitivity
924928|NCT02398032|chemosensitivity
924929|NCT02398032|adhesion factors
924930|NCT02398019|CPB
924931|NCT02398019|OXIRIS®
924932|NCT02398019|SIRS
924933|NCT02398019|AKI
924934|NCT02398019|Cytokines
924935|NCT02398019|LPS
924936|NCT02398006|Clavicle [mh]
924937|NCT02398006|Fracture Healing [mh]
924938|NCT02398006|Fractures, Bone [mh]
924939|NCT02398006|Treatment outcome [mh]
924940|NCT02398006|Conservative treatment [tw]
924941|NCT02397980|Caregivers
924942|NCT02397967|NF1
924943|NCT02397967|children
924944|NCT02397967|reading disabilities
924945|NCT02397954|idiopathic polypoidal choroidal vasculopathy
924946|NCT02397954|IPCV
924947|NCT02397954|Zimura®
924948|NCT02397954|Avastin®
924949|NCT02397954|Eylea®
924950|NCT02397954|Lucentis®
924951|NCT02397928|Malignant Pleural Mesothelioma
924952|NCT02397928|Treatment
924953|NCT02397928|Minimal toxicity
924954|NCT02397928|TTFields
924955|NCT02397928|Tumor Treating Fields
924956|NCT02397928|Novocure
924957|NCT02397928|Pemetrexed
924958|NCT02397928|Carboplatin
924959|NCT02397928|Cisplatin
924960|NCT02397915|Nasal Spray
924961|NCT02397915|Fluticasone Furoate
924962|NCT02397915|Attributes
924963|NCT02397915|Single Dose
924964|NCT02397915|Allergic Rhinitis
924965|NCT02397915|Mometasone Furoate
924966|NCT02397915|Questionnaire
924967|NCT02397915|Preference
924968|NCT02397889|posttraumatic stress disorder
924969|NCT02397889|PTSD
924970|NCT02397889|ketamine
924971|NCT02397889|trauma
924972|NCT02397889|treatment
924973|NCT02397889|New York
924974|NCT02397889|NYC
924975|NCT02397876|Food Allergy
924976|NCT02397876|Cows Milk Allergy
924977|NCT02397850|depression, chronic, psychotherapy, telephone, feasibility
924978|NCT02397837|Bipolar Disorder
924979|NCT02397837|Cognition
924980|NCT02397785|chronic pelvic pain
924981|NCT02397785|electrical stimulation
924982|NCT02397785|pelvic floor rehabilitation
924983|NCT02397785|neuromodulation
924984|NCT02397772|Soil-transmitted helminths
924985|NCT02397772|Intestinal Nematodes
924986|NCT02397772|Hookworm
924987|NCT02397772|Ascaris
924988|NCT02397772|Mass Treatment
924989|NCT02397772|Kenya
925013|NCT02397694|Adult
925014|NCT02397694|HIV
925015|NCT02397694|naive
925016|NCT02397655|stroke
925017|NCT02397655|ischemia
925018|NCT02397655|atherosclerosis
925019|NCT02397655|ultrasonography
925020|NCT02397590|Fimasartan
925021|NCT02397564|scar
925022|NCT02397564|ICD-10 CM:L90.5
925023|NCT02397538|Fimasartan
925024|NCT02397447|Momordica Charantia
925025|NCT02397447|Insulin secretion
925026|NCT02397447|Insulin sensitivity
925027|NCT02397434|assessment of QOL (EORTC QLQ-C30)
925028|NCT02397421|Heart failure
925029|NCT02397421|Diabetes
925030|NCT02397421|Left ventricular remodelling
925031|NCT02397421|SGLT-2 inhibitors
925032|NCT02397395|Renal Impairment
925033|NCT02397395|End-stage Renal Disease
925034|NCT02397395|Simeprevir
925035|NCT02397395|Daclatasvir
925036|NCT02397382|Psoriasis
925037|NCT02397382|Guselkumab
925038|NCT02397382|Cytochromes P450
925039|NCT02397369|Education and evaluate post intervention KAP
925040|NCT02397356|ketamine
925041|NCT02397343|Reduction of secondary hyperalgesia and/-or local inflammation
925042|NCT02397304|Intra-muscular triglyceride use
925043|NCT02397291|Pregnancy
925044|NCT02397291|IUGR
925045|NCT02397265|Type 1 diabetes
925046|NCT02397265|Hypoglycaemia
925047|NCT02397265|Closed loop insulin pump
925048|NCT02397265|Artificial pancreas
925049|NCT02397265|Exercise
925050|NCT02397265|Mixed meals
925051|NCT02397265|Bihormonal pump
925052|NCT02397252|Human Papillomavirus
925053|NCT02397252|Screening
925054|NCT02397252|Self-collection test
925055|NCT02397252|Pap test
925056|NCT02397226|Radiofrequency ablation
925057|NCT02397226|Plethysmography
925058|NCT02397226|Duplex ultrasound
925059|NCT02397226|High ligation/stripping
925060|NCT02397213|Ciclosporin
925061|NCT02397213|Acute Kidney injury
925062|NCT02397213|Cardiac surgery
925063|NCT02397213|Ischemia
925064|NCT02397213|Safety
925065|NCT02397213|Cystatin C
925066|NCT02397200|Growth
925067|NCT02397200|low weight
925068|NCT02397200|low height
925069|NCT02397200|Nutritional Supplementation
925070|NCT02397174|Polycystic Ovary syndrome
925071|NCT02397174|hypocaloric diet
925072|NCT02397174|Ovarian Cysts
925073|NCT02397174|Ovarian Diseases
925074|NCT02397174|Obesity
925075|NCT02397174|Mediterranean Diet
925076|NCT02397135|genomic markers
925077|NCT02397083|Endometrial Cancer
925078|NCT02397083|Endometrial hyperplasia
925079|NCT02397083|Intrauterine device
925080|NCT02397083|IUD
925081|NCT02397083|Levonorgestrel intrauterine device
925082|NCT02397083|LIUD
925083|NCT02397083|Mirena
925084|NCT02397083|Everolimus
925085|NCT02397083|Afinitor
925086|NCT02397083|Zortress
925087|NCT02397083|RAD001
925088|NCT02397083|Questionnaires
925089|NCT02397083|Survey
925090|NCT02397083|Quality of life
925091|NCT02397083|QOL
925092|NCT02397070|Jaw exercise
925093|NCT02397070|Occlusal splint
925094|NCT02397070|Treatment
925095|NCT02397070|Muscular pain
925096|NCT02397070|Mandibular movement
925097|NCT02397044|Implants, stability, loading
925098|NCT02397031|borderline personality disorder
925099|NCT02397031|mindfulness
925100|NCT02397018|stroke
925101|NCT02397018|cord blood
925102|NCT02397018|umbilical cord blood
925103|NCT02397018|hematopoietic stem cells
925104|NCT02397018|acute ischemic stroke
925105|NCT02396992|Oropharyngeal Dysphagia
925106|NCT02396992|Aspiration pneumonia
925107|NCT02396992|Malnutrition
925108|NCT02396992|Oral Health
925109|NCT02396992|Bacterial colonization
925110|NCT02396992|Aging
925111|NCT02396940|3D
925112|NCT02396940|Three-dimensional
925113|NCT02396940|Laparoscopy
925114|NCT02396940|Inguinal hernia repair
925115|NCT02396927|3D
925116|NCT02396927|Three-dimensional
925117|NCT02396927|laparoscopy
925118|NCT02396927|cholecystectomy
925119|NCT02395848|recurrent
925120|NCT02395848|infection
925121|NCT02395835|body mass index
925122|NCT02395835|methylation
925123|NCT02395835|PPAR gamma
925124|NCT02395835|pregnancy
925125|NCT02395822|AML
925126|NCT02395822|Relapsed
925127|NCT02395822|Refractory
925128|NCT02395796|epidural
925129|NCT02395796|labor analgesia
925130|NCT02395796|pressure monitoring
925131|NCT02395783|Preterm infants
925132|NCT02395783|diagnosis of cerebral white matter injury
925133|NCT02395770|Shoulder
925134|NCT02395770|Rotator cuff
925135|NCT02395770|Rehabilitation
925136|NCT02395770|Motor control
925137|NCT02395757|Age Related Macular Degeneration (AMD)
925138|NCT02395757|Microperimetry
925139|NCT02395757|Diagnostic
925140|NCT02395731|dual eligible
925141|NCT02395731|care coordination
925142|NCT02395731|community-based
925143|NCT02395731|care quality
925144|NCT02395731|care needs
925145|NCT02395731|health services
925146|NCT02395731|care management
925147|NCT02395731|low income
925148|NCT02395731|Neuropsychiatric behaviors
925149|NCT02395718|elderly
925150|NCT02395718|quick diagnostic unit
925151|NCT02395718|short stay unit
925152|NCT02395718|randomised controlled trial
925153|NCT02395679|Dendritic cell-based immunotherapy
925154|NCT02396901|early goal direct therapy
925155|NCT02396901|preventive strategies
925156|NCT02396901|cardiac surgery
925157|NCT02396888|Blood vessel
925158|NCT02396888|Fibroplasia
925159|NCT02396888|Wound healing
925160|NCT02396888|Insulin
925161|NCT02396836|Hand hygiene
925162|NCT02396836|Hand decontamination
925163|NCT02396836|Microbial load
925164|NCT02396836|Hand coverage
925165|NCT02396836|Glove juice technique
925166|NCT02396836|Ayliffe technique
925167|NCT02396836|6 step technique
925168|NCT02396823|Blood pressure regulation
925169|NCT02396823|Respiratory Muscle Training
925170|NCT02396797|Sick leave
925171|NCT02396797|Mental Health
925172|NCT02396797|Coping
925173|NCT02396797|Social Support
925174|NCT02396797|Subjective Health Complaints
925175|NCT02396784|child overweight
925176|NCT02396784|child obesity
925177|NCT02396784|prevention
925178|NCT02396784|targeted intervention
925179|NCT02396784|development of overweight
925180|NCT02396771|Uterine
925181|NCT02396771|Massage
925182|NCT02396771|Compression
925183|NCT02396732|Aspirin
925184|NCT02396732|Enoxaparin
925185|NCT02396732|Thromboprophylaxis
925186|NCT02396732|Trauma
925187|NCT02396732|Venous thromboembolism
925188|NCT02396693|Newborn
925189|NCT02396693|non invasive ventilation
925190|NCT02396680|Ragweed Allergy
925191|NCT02396680|Rhinoconjunctivitis
925192|NCT02396680|Immunotherapy
925193|NCT02396680|Ragweed-SPIRE
925194|NCT02396641|Best Supportive Care
925195|NCT02396628|Graft-versus-Host Disease (GvHD)
925196|NCT02396628|resistance to therapy
925197|NCT02396628|allogeneic stem cell transplantation
925198|NCT02396628|Ruxolitinib
925199|NCT02396615|Ad libitum energy intake
925200|NCT02396615|Appetite
925201|NCT02396589|stroke rehabilitation
925202|NCT02396589|barriers to independence
925203|NCT02396589|environmental support
925204|NCT02396550|Expectations
925205|NCT02396537|Children
925206|NCT02396537|Midazolam
925207|NCT02396537|Lidocaine
925208|NCT02396537|Intranasal
925209|NCT02396524|Chronic Disease
925210|NCT02396524|Lifestyle Intervention
925211|NCT02396524|Health Promotion
925212|NCT02396524|Sport Mentorship
925213|NCT02396524|Men
925214|NCT02396524|Health Technology
925215|NCT02396524|Prevention
925216|NCT02396524|Exercise
925217|NCT02396524|Diet
925218|NCT02396472|social support
925219|NCT02396459|Triac
925220|NCT02396459|MCT8
925221|NCT02396459|Allan-Herndon-Dudley Syndrome
925222|NCT02396433|Halaven
925223|NCT02396433|BRCA
925224|NCT02396433|E7449
925225|NCT02396420|BPH
925226|NCT02396420|prostatic hyperplasia
925227|NCT02396420|enlarged prostate
925228|NCT02396420|benign prostatic hypertrophy
925229|NCT02396407|Chlorine water treatment
925230|NCT02396407|Point-of-use water treatment
925231|NCT02396407|Household water treatment with safe storage
925232|NCT02396407|Handwashing with soap
925233|NCT02396407|Hand hygiene
925234|NCT02396407|Latrines
925235|NCT02396407|Child potties
925236|NCT02396407|Intestinal parasitic infection
925237|NCT02396407|Soil-transmitted helminths
925238|NCT02396407|Water
925239|NCT02396407|Sanitation
925240|NCT02396407|Handwashing
925241|NCT02396407|Diarrhea
925242|NCT02396407|Herd immunity
925243|NCT02396407|Helminths
925244|NCT02396394|HIV
925245|NCT02396394|ART Adherence
925246|NCT02396394|Retention in Care
925247|NCT02396394|Pregnant Women
925248|NCT02396394|Postpartum Women
925249|NCT02396381|Candidate modified risk tobacco product
925250|NCT02396381|Conventional cigarette
925251|NCT02396381|Exposure response
925252|NCT02396381|Smoking
925253|NCT02396381|Tobacco Heating System
925254|NCT02396368|Prostate cancer
925255|NCT02396368|Bone metastatic Castration-Resistant Prostate Cancer
925256|NCT02396368|Radium 223
925257|NCT02396368|Tasquinimod
925258|NCT02396355|flow cytometry
925259|NCT02396342|Hemophilia B, gene therapy
925260|NCT02396303|General: To compare Carbetocin and Oxytocin for the control of PPH.
925261|NCT02396290|acne scar
925262|NCT02396290|fractional carbon dioxide laser
925263|NCT02396290|platelet rich plasma
925264|NCT02396264|Mediterranean Diet
925265|NCT02396264|Ovarian Cysts
925266|NCT02396264|Treatment
925267|NCT02396264|Ovarian Diseases
925268|NCT02396264|normocaloric diet
925269|NCT02396225|voriconazole
925270|NCT02396225|inhalation
925271|NCT02396225|aerosol
925272|NCT02396225|epithelial lining fluid
925273|NCT02396225|concentration
925274|NCT02396225|pharmacokinetic
925275|NCT02396199|Abdominal aortic aneurysm
925276|NCT02396199|Endovascular
925277|NCT02396199|Juxtarenal
925278|NCT02396199|Pararenal
925279|NCT02396199|Fenestrated
925280|NCT02396173|disability
925281|NCT02396173|vocational
925282|NCT02396173|rehabilitation
925283|NCT02396173|prediction
925284|NCT02396160|overactive bladder
925285|NCT02396160|urinary incontinence
925286|NCT02396160|nocturia
925287|NCT02396160|urinary frequency
925288|NCT02396147|Drug therapy
925289|NCT02396095|female
925290|NCT02396095|cancer
925291|NCT02396082|care coordination
925292|NCT02396082|quality of life
925293|NCT02396082|community-based
925294|NCT02396082|care quality
925295|NCT02396082|Long term care placement
925296|NCT02396082|memory care
925297|NCT02396082|Neuropsychiatric behaviors
925298|NCT02396056|Guided Bone Regeneration
925299|NCT02396056|Gingival Mesenchymal Stem Cells
925300|NCT02395991|gadoxetic acid
925301|NCT02395991|transient dyspnea
925302|NCT02395965|Osteopathic manipulative medicine
925303|NCT02395965|Osteopathic manipulative treatment
925304|NCT02395952|cornea
925305|NCT02395952|epithelial defect
925306|NCT02395952|amniotic membrane
925307|NCT02395939|Cryobiopsy
925308|NCT02395939|Radial EBUS
925309|NCT02395939|Guide Sheath
925310|NCT02395939|Peripheral pulmonary lesions
925311|NCT02395887|Spinal stenosis
925312|NCT02395887|Spinal decompression
925313|NCT02395887|Postural balance
925314|NCT02395887|Neurogenic claudication
925315|NCT02395666|Neuroblastoma in remission
925316|NCT02395666|Relapsed Neuroblastoma
925317|NCT02395666|Refractory Neuroblastoma
925318|NCT02395653|Pediatric
925319|NCT02395653|Postoperative
925320|NCT02395653|Pain Management
925321|NCT02395627|Hormone Therapy Resistant
925322|NCT02395627|Estrogen Receptor-Positive
925323|NCT02395627|Estrogen Receptor-Negative
925326|NCT02395601|B-Cell Lymphoma
925327|NCT02395601|EZH2 Inhibitor
925328|NCT02395601|Phase 1
925329|NCT02395497|Penile Transplant
925330|NCT02395497|VCA
925331|NCT02395497|CTA
925332|NCT02395497|Penis
925333|NCT02395497|Amputation
925334|NCT02395497|Immunosuppression
925335|NCT02395497|Composite Tissue
925336|NCT02395497|Male
925337|NCT02395497|Humans
925338|NCT02395497|Allotransplantation
925339|NCT02395458|Sequential therapy
925340|NCT02395458|Triple therapy
925341|NCT02395458|Eradication
925342|NCT02395393|Acute rejection
925343|NCT02395393|Chronic rejection
925344|NCT02395393|Confocal microscopy
925345|NCT02395380|CRP
925346|NCT02395380|Postoperative complication
925347|NCT02395380|Length of stay
925348|NCT02395367|Prognosis
925349|NCT02395367|Risk Factors
925350|NCT02395354|Endoscopic treatment
925351|NCT02395354|Stenosis
925352|NCT02395354|Crohn's Disease
925353|NCT02395354|balloon dilatation
925354|NCT02395354|self-expanding metallic stent
925355|NCT02395354|chronic transmural inflammation
925356|NCT02395354|steady narrowing of the intestinal lumen
925357|NCT02395341|reproductive hormones
925358|NCT02395341|cancer survivors
925359|NCT02395341|endocrine function
925360|NCT02395341|antral follicle counts
925361|NCT02395341|female infertility due to diminished ovarian reserve
925362|NCT02395341|perimenopause
925363|NCT02395341|premature menopause
925364|NCT02395328|Orphans and vulnerable children (OVC)
925365|NCT02395328|Home visiting intervention
925366|NCT02395328|South Africa
925367|NCT02395328|Program evaluation
925368|NCT02395315|Diabetes Mellitus
925369|NCT02395315|Osseointegration
925370|NCT02395315|Bone vascularity
925371|NCT02395315|Primary implant stability
925372|NCT02395289|Cognitive-Based Compassion Training (CBCT)
925373|NCT02395289|HIV-related clinical outcomes
925374|NCT02395289|Stress and stress-related psychological adjustment
925375|NCT02395289|Stress-related inflammatory biomarkers
925376|NCT02395276|Congenital Heart Defects
925377|NCT02395276|Hypoxic Ischemic Brain Injury
925378|NCT02395276|Hypothermia Therapy
925379|NCT02395276|Pediatrics
925380|NCT02395237|Fed Conditions
925381|NCT02395224|Follow-up studies
925382|NCT02395224|Prognosis
925383|NCT02395224|Palliative care
925384|NCT02395224|Chemotherapy, adjuvant
925385|NCT02395224|Cost-benefit analysis
925386|NCT02395224|Population
925387|NCT02395224|Antineoplastic agents/Adverse effects
925388|NCT02395224|Terminal care
925389|NCT02395224|Medical futility
925390|NCT02395224|Survival rate
925391|NCT02395224|Norway
925392|NCT02395198|hepatitis c virus
925393|NCT02395198|opioid substitution treatment
925394|NCT02395172|avelumab
925395|NCT02395172|MSB0010718C
925396|NCT02395172|Non-Small Cell Lung Cancer
925397|NCT02395172|Anti-PD-L1
925398|NCT02395159|vascular surgery patients
925399|NCT02395159|wound management
925400|NCT02395133|Eczema
925401|NCT02395120|Dental Care
925402|NCT02395120|Caregiver Illness Perception
925403|NCT02395120|Common Sense Model of Self-Regulation
925404|NCT02395120|Dental Access
925405|NCT02395120|Referral letter
925406|NCT02395120|Dental Caries
925407|NCT02395107|Aortic Valve Stenosis
925408|NCT02395107|Functional Capacity
925409|NCT02395107|Cardiomyopathies
925410|NCT02395107|Endomyocardial Fibrosis
925411|NCT02395107|Cardiovascular Diseases
925412|NCT02395107|Heart Diseases
925413|NCT02395107|Heart Valve Diseases
925414|NCT02395107|Atrial Fibrillation
925415|NCT02395107|Hypertrophy
925416|NCT02395107|Hypertrophy, Left Ventricular
925417|NCT02395107|Diastology
925418|NCT02395081|pregnancy
925419|NCT02395081|Mongolia
925420|NCT02395081|Vitamin D
925421|NCT02395081|preeclampsia
925422|NCT02395068|Pharmacokinetics
925423|NCT02395068|Nimotuzumab
925424|NCT02395068|Safety
925425|NCT02395068|Effcacy
925426|NCT02395068|Irinotecan
925427|NCT02395029|PD
925430|NCT02394977|CPR
925431|NCT02394977|Cardio first angle
925432|NCT02394977|Clinical trial
925433|NCT02394951|chemotherapy
925434|NCT02394938|Music therapy
925435|NCT02394912|vena cava filter
925436|NCT02394899|SCD
925437|NCT02394899|early childhood intervention
925438|NCT02394899|parental stress
925439|NCT02394899|neurocognition
925440|NCT02394873|Deep Second-Degree Burn Wound
925441|NCT02394847|propofol
925442|NCT02394847|electroconvulsive therapy
925443|NCT02394847|anesthesia
925444|NCT02394834|Metastatic colorectal cancer, Panitumumab, mFOLFOX6, Bevacizumab
925445|NCT02394795|Metastatic colorectal cancer, Panitumumab, mFOLFOX6, Bevacizumab
925446|NCT02394782|Multiple sclerosis, relapsing-remitting
925447|NCT02394782|Rebif
925448|NCT02394782|Interferon beta-1a
925449|NCT02394782|RebiSmart®2.0
925450|NCT02394782|MSdialog™
925451|NCT02394769|Colorectal Cancer
925452|NCT02394743|Glomerular Filtration Rate
925454|NCT02394704|Rumination
925455|NCT02394704|Sensory processing
925456|NCT02394704|Non-pharmacological intervention
925457|NCT02394704|Depression
925458|NCT02394704|Anxiety
925459|NCT02394704|PTSD
925460|NCT02394665|Glioblastoma
925461|NCT02394665|Gliosarcoma
925462|NCT02394665|GBM
925468|NCT02394613|Glaucoma
925469|NCT02394613|DARC
925470|NCT02394613|Diagnosis
925471|NCT02394600|rhinitis
925472|NCT02394600|allergy
925473|NCT02394587|mindfulness
925474|NCT02394587|MBSR
925475|NCT02394587|SCD
925476|NCT02394587|experimental
925477|NCT02394548|Locally advanced, inoperable non-small cell lung carcinoma
925478|NCT02394548|Limited stage small cell lung carcinoma
925479|NCT02394548|Acute esophagitis
925480|NCT02394548|Intensity-modulated radiation therapy
925481|NCT02394535|Pancreatic Cancer
925482|NCT02394535|Adenocarcinoma of the pancreas
925483|NCT02394535|Locally Advanced Pancreatic Cancer
925484|NCT02394535|Abraxane
925485|NCT02394535|Nab-Paclitaxel
925486|NCT02394535|Paclitaxel (Protein-Bound)
925487|NCT02394535|ABI-007
925488|NCT02394535|Radiation therapy
925489|NCT02394535|XRT
925490|NCT02394535|Capecitabine
925491|NCT02394535|Xeloda
925492|NCT02394535|Questionnaires
925493|NCT02394535|Surveys
925494|NCT02394522|Malaria
925495|NCT02394522|Spatial Repellents
925496|NCT02394522|Plasmodium
925497|NCT02394509|Epilepsy Memory Problems
925498|NCT02394509|Self-Management
925499|NCT02394496|Fulvestrant
925500|NCT02394496|Lapatinib
925501|NCT02394496|Aromatase Inhibitor
925502|NCT02394496|metastatic breast cancer
925503|NCT02394483|Single ascending dose
925504|NCT02394483|double blind
925505|NCT02394470|congestion
925506|NCT02394470|total body water
925507|NCT02394470|bioimpedentiometry
925508|NCT02394470|lung ultrasound
925509|NCT02394470|diuretics
925510|NCT02394470|dyspnea
925511|NCT02394470|pulmonary B lines
925512|NCT02394470|deuterium
925513|NCT02394457|Postdural puncture headache
925514|NCT02394457|Epidural Blood Patch
925515|NCT02394457|Cosyntropin
925516|NCT02394457|PDPH
925517|NCT02394457|Regional anesthesia
925518|NCT02394457|Lumbar puncture
925519|NCT02394457|ACTH
925520|NCT02394457|Tetracosactin
925521|NCT02394444|Intervention program
925522|NCT02394444|Parenting stress
925523|NCT02394444|Parental mental health
925524|NCT02394444|Preterm infant's development
925525|NCT02394431|Sickle Cell Disease
925526|NCT02394431|Echocardiography
925527|NCT02394431|Speckle tracking
925528|NCT02394392|Medication satisfaction
925529|NCT02394392|Quality of life
925530|NCT02394392|Drug compliance
925531|NCT02394366|Skin oxygenation
925532|NCT02394366|peripheral perfusion
925533|NCT02394353|bariatrics
925534|NCT02394353|transient elastography
925535|NCT02394314|MEDI0382, diabetes
925536|NCT02394301|Efficacy of Novel Drug Combinations for Relief of Psoriasis
925537|NCT02394288|Cardiac Troponin
925538|NCT02394288|Perioperative Period
925539|NCT02394288|surgery
925540|NCT02394262|Biological Markers
925541|NCT02394262|Multidetector Computed Tomography
925542|NCT02394249|Insulin Resistance
925543|NCT02394249|Cognition
925544|NCT02394249|Affect
925545|NCT02394249|Insulin
925546|NCT02394249|Lipids
925547|NCT02394236|exercise training
925548|NCT02394223|Cancer
925549|NCT02394223|Prostate
925550|NCT02394223|PSA
925551|NCT02394223|Biopsies
925552|NCT02394223|FFOCT procedure
925553|NCT02394210|Multiple myeloma asymptomatic relapse symptomatic relapse
925554|NCT02394210|IMW Consensus Panel
925555|NCT02394210|anti-MM therapy
925556|NCT02394197|Plasmodium vivax
925557|NCT02394197|Mexico
925558|NCT02394197|treatment
925559|NCT02394197|chloroquine
925560|NCT02394197|primaquine
925561|NCT02394197|14-day treatment (T14)
925562|NCT02394197|intermittent single doses (ISD)
925564|NCT02394171|Physical Activity
925565|NCT02394171|Social Cohesion
925566|NCT02394171|Intervention Development
925567|NCT02394171|Ethnic Minorities
925568|NCT02394171|Nutrition
925569|NCT02394158|Recurrent Gestational Diabetes Mellitus
925570|NCT02394158|Prevention
925571|NCT02394158|Metformin
925572|NCT02394145|platelet
925573|NCT02394145|ticagrelor
925574|NCT02394145|clopidogrel
925575|NCT02394145|end stage renal disease
925576|NCT02394145|hemodialysis
925577|NCT02394145|genetics
925578|NCT02394132|Lentigo maligna
925579|NCT02394132|Imiquimod
925580|NCT02394132|Radiotherapy
925581|NCT02394054|vasopressin
925582|NCT02394054|intranasal administration
925583|NCT02394054|healthy sample
925584|NCT02394041|acupuncture
925585|NCT02394041|cervical dystocia
925586|NCT02394041|caesarean section
925587|NCT02394041|obstetric labor
925588|NCT02394041|randomized controlled trial
925589|NCT02394015|Platinum-sensitive Recurrent Ovarian Cancer
925590|NCT02394002|EEG, burst-suppression, N20, SEP, median nerve, facilitation
925591|NCT02393911|vestibulitis
925592|NCT02393911|microbiome
925593|NCT02393872|Prevention
925594|NCT02393859|ALL
925595|NCT02393859|High-risk first relapse B-precursor ALL
925596|NCT02393859|Precursor Cell Lymphoblastic Leukemia
925597|NCT02393859|Neoplasms
925598|NCT02393859|Lymphoproliferative Disorders
925599|NCT02393859|Immunoproliferative Disorders
925600|NCT02393859|Antibodies, Bispecific
925601|NCT02393846|ankle sprain
925602|NCT02393846|topical ketoprofen
925603|NCT02393846|non-steroidal anti-inflammatory drug
925604|NCT02393846|emergency department
925605|NCT02393833|Vascular endothelial growth factor (VEGF)
925606|NCT02393833|Vascular cell adhesion molecule-1 (VCAM-1)
925607|NCT02393833|HER2-ECD
925608|NCT02393807|Chronic Obstructive Pulmonary Disease
925609|NCT02393794|BRCA1
925610|NCT02393794|BRCA2
925611|NCT02393794|TNBC
925612|NCT02393781|severe sepsis
925613|NCT02393781|septic shock
925614|NCT02393781|adrenomedullin
925615|NCT02393781|organ dysfunction
925616|NCT02393703|exosomes
925617|NCT02393703|15-015
925618|NCT02393664|Thoracoscopy
925619|NCT02393664|Recovery
925620|NCT02393664|Tracheal intubation
925621|NCT02393638|Endoscopic Sphincterotomy
925623|NCT02393586|Tuberculosis
925624|NCT02393586|Whole blood Bactericidal Activity
925625|NCT02393586|WBA
925626|NCT02393586|Faropenem
925627|NCT02393573|Insulin Resistance
925628|NCT02393573|Protein balance
925629|NCT02393573|Surgery
925630|NCT02393573|Post operative complications
925631|NCT02393573|metformin
925632|NCT02393573|Pre-diabetes
925633|NCT02393573|Fasting blood glucose
925634|NCT02393547|obesity
925635|NCT02393534|Primary Care
925636|NCT02393534|Health Services Research
925637|NCT02393534|Telemedicine
925638|NCT02393521|Vibration
925639|NCT02393521|Pressure Pain Threshold
925640|NCT02393521|Trigger Points
925641|NCT02393521|Neck Pain
925642|NCT02393508|transfusion, red blood cell
925643|NCT02393508|transfusion reaction
925644|NCT02393508|quality of life
925645|NCT02393443|oxytocin
925646|NCT02393443|healthy sample
925647|NCT02393443|intranasal administration
925648|NCT02393443|learning
925649|NCT02393417|Verruca vulgaris
925650|NCT02393417|Common Warts
925651|NCT02393378|Drug Therapy
925652|NCT02393365|Hepatitis C
925653|NCT02393365|HCV
925654|NCT02393365|screening
925655|NCT02393352|Body Composition
925656|NCT02393352|Autonomic Nervous System
925657|NCT02393352|Oxygen
925658|NCT02393352|Randomized Controlled Trial
925659|NCT02393300|tranexamic acid
925660|NCT02393300|blood loss
925661|NCT02393300|topical administration
925662|NCT02393300|intravenous administration
925663|NCT02393248|alterations in FGF or FGFR
925664|NCT02393248|squamous non-small cell lung cancer
925665|NCT02393248|gastric cancer
925666|NCT02393248|urothelial cancer
925667|NCT02393248|endometrial cancer
925668|NCT02393248|multiple myeloma
925669|NCT02393248|MPN
925670|NCT02393235|unexplained infertility
925671|NCT02393235|tubal infertility
925672|NCT02393235|pulsatility index
925673|NCT02393235|resistance index
925674|NCT02393235|fertile women
925675|NCT02393222|Dialysis
925676|NCT02393222|Cerebrovascular disease
925677|NCT02393222|ESRD
925678|NCT02393209|Drug therapy
925679|NCT02393196|colloid preloading
925680|NCT02393196|colloid coloading
925681|NCT02393183|Antioxidant
925682|NCT02393183|Graves' ophthalmopathy
925683|NCT02393183|Thyroid eye disease
925684|NCT02393183|Severity score
925685|NCT02393183|Activity score
925686|NCT02393183|Quality of life
925687|NCT02393144|Labor analysis
925688|NCT02393144|Transperineal ultrasound imaging
925689|NCT02393144|Labor curve
925690|NCT02393131|Brain Metastases
925691|NCT02393131|Whole Brain Radiotherapy
925692|NCT02393131|Neurocognitive function
925693|NCT02393118|Assistive technology
925694|NCT02393118|Non-surgical visual prosthetic
925695|NCT02393118|sensory substitution
925696|NCT02393118|BrainPort
925697|NCT02393118|Blindness
925698|NCT02393118|Assistive device
925699|NCT02393105|Breast Cancer
925700|NCT02393079|Traumatic Brain Injury
925701|NCT02393079|Cognitive
925702|NCT02393053|Gingival Recession
925703|NCT02393053|Case-Control Studies
925704|NCT02393053|Adipose Tissue
925705|NCT02393040|Alopecia
925706|NCT02393040|Androgenetic Alopecia
925707|NCT02393040|Alopecia, Male Pattern
925708|NCT02393040|Hair loss
925709|NCT02393040|Platelet-Rich Plasma
925710|NCT02393040|Alopecia, Female Pattern
925711|NCT02393040|placebo
925712|NCT02393040|double-blind
925713|NCT02393014|65 years old or older
925714|NCT02393014|hospitalized in
925715|NCT02393014|geriatrics
925716|NCT02393001|skin cancer
925717|NCT02393001|suspicious lesion
925718|NCT02393001|skin biopsy
925719|NCT02393001|noninvasive
925720|NCT02393001|screening
925721|NCT02392962|proprioception
925722|NCT02392962|countermovement jump
925723|NCT02392962|postural balance
925724|NCT02392949|Spine
925725|NCT02392949|mobilization
925726|NCT02392936|according to the definition of the Comité Technique des Infections Nosocomiales et Liées aux Soins (2007)
925727|NCT02392923|health related quality of life
925728|NCT02392910|Iron Sucrose
925729|NCT02392910|Mortality
925730|NCT02392910|Hospitalization
925731|NCT02392897|meal frequency
925732|NCT02392897|eating frequency
925733|NCT02392897|ingestive frequency
925734|NCT02392897|Positive energy balance
925735|NCT02392897|Satiation
925736|NCT02392884|Human Immunodeficiency Virus
925737|NCT02392884|Acquired Immunodeficiency Syndrome
925738|NCT02392884|Cognitive Rehabilitation
925739|NCT02392884|Minority Health
925740|NCT02392884|Vulnerable Populations
925741|NCT02392884|Underserved, Patients
925742|NCT02392884|Medication Adherence
925743|NCT02392884|Medication Compliance
925744|NCT02392884|Medication Non-compliance
925745|NCT02392884|Medication Persistence
925746|NCT02392884|Medication Non-Adherence
925747|NCT02392871|Metastatic melanoma
925748|NCT02392871|Palliative radiotherapy
925749|NCT02392845|Drug combination
925750|NCT02392845|Accelerated chemotherapy
925751|NCT02392845|Mathematical model
925752|NCT02392845|Hematotoxicity
925753|NCT02392845|Individualized dosage
925754|NCT02392832|long-lasting microbial larvicide
925755|NCT02392832|intervention
925756|NCT02392832|cluster randomised controlled trial
925757|NCT02392832|Anopheles mosquito
925758|NCT02392806|Continuous positive airway pressure
925759|NCT02392806|CPAP
925760|NCT02392806|Bubble CPAP
925761|NCT02392806|Extubation failure
925762|NCT02392806|Preterm infant
925763|NCT02392767|L-Arginine
925764|NCT02392767|Pycnogenol
925765|NCT02392767|vitamin K2
925766|NCT02392767|vitamin B
925767|NCT02392767|endothelial function
925768|NCT02392767|hypertension
925769|NCT02392767|Homocystein >10
925770|NCT02392754|Screening
925771|NCT02392754|Atrial Fibrillation
925772|NCT02392754|ECG
925773|NCT02392754|Primary care
925774|NCT02392741|Physical Activity
925775|NCT02392741|Microcirculation
925776|NCT02392741|Pregnancy Outcome
925777|NCT02392741|Obesity
925778|NCT02392741|Pregnancy
925779|NCT02392715|Inspiratory muscle training
925780|NCT02392715|General exercise training
925781|NCT02392715|pulmonary rehabilitation
925782|NCT02392715|chronic obstructive pulmonary disease
925783|NCT02392702|Subjects
925784|NCT02392702|Safety/Efficacy Study
925785|NCT02392702|Randomized
925786|NCT02392702|Open Label
925787|NCT02392689|procalcitonin
925788|NCT02392689|biomarker
925789|NCT02392689|antibiotic therapy
925790|NCT02392689|emergency department
925791|NCT02392689|cardiology
925792|NCT02392689|in vitro diagnostics
925793|NCT02392676|Ovarian cancer
925794|NCT02392676|Platinum
925795|NCT02392676|Somatic BRCA mutation
925796|NCT02392676|Homologous recombination repair
925797|NCT02392663|Sputum clearance
925798|NCT02392663|Cough severity
925799|NCT02392663|Hypertonic saline
925800|NCT02392663|Acid hyaluronic
925801|NCT02392663|Tolerability
925802|NCT02392637|Biliary Tract Cancer
925803|NCT02392637|Intrahepatic cholangiocarcinoma
925804|NCT02392637|Extrahepatic cholangiocarcinoma,
925805|NCT02392637|Gallbladder cancer
925806|NCT02392637|Metastatic
925807|NCT02392637|Unresectable
925808|NCT02392637|Abraxane
925809|NCT02392637|Nab-Paclitaxel
925810|NCT02392637|Paclitaxel (Protein-Bound)
925811|NCT02392637|ABI-007
925812|NCT02392637|Cisplatin
925813|NCT02392637|Platinol-AQ
925814|NCT02392637|Platinol
925815|NCT02392637|CDDP
925816|NCT02392637|Gemcitabine
925817|NCT02392637|Gemcitabine Hydrochloride
925818|NCT02392637|Gemzar
925819|NCT02392637|Phone calls
925820|NCT02392611|Estrogen Receptor Positive Breast Cancer
925821|NCT02392585|Leiomyoma of uterus
925822|NCT02392585|Hemostasis, Surgical
925823|NCT02392585|Prevention of Surgical Blood Loss
925824|NCT02392585|mechanical uterine tourniquet
925825|NCT02392572|Leukemia
925826|NCT02392572|Acute myelogenous leukemia
925827|NCT02392572|AML
925828|NCT02392572|Myelodysplastic syndrome
925829|NCT02392572|MDS
925830|NCT02392572|Acute lymphoblastic leukemia
925831|NCT02392572|ALL
925832|NCT02392572|Relapsed
925833|NCT02392572|Refractory
925834|NCT02392572|ONC201
925835|NCT02392559|Hypercholesterolemia
925836|NCT02392559|Elevated Cholesterol
925837|NCT02392559|High Cholesterol
925838|NCT02392559|Heterozygous Familial Hypercholesterolemia
925839|NCT02392559|PCSK9 mutations
925840|NCT02392559|Paediatric
925841|NCT02392559|pediatric
925842|NCT02392559|Childhood Familial Hypercholesterolemia
925843|NCT02392533|ultrasound
925844|NCT02392520|severe OHSS
925845|NCT02392520|antagonist administration
925846|NCT02392520|conventional treatment
925847|NCT02392442|Bronchoalveolar Lavage
925848|NCT02392442|Bronchoscopy
925849|NCT02392442|Endotoxin Instillation
925850|NCT02392442|Immunophenotype
925851|NCT02392442|miRNA
925852|NCT02392390|Topical Dynamic Phototherapy
925853|NCT02392390|Microbiota
925854|NCT02392351|Hypertension
925855|NCT02392351|Renal Denervation
925856|NCT02392338|Atrial fibrillation
925857|NCT02392338|Ablation
925858|NCT02392338|Hybrid
925859|NCT02392312|kidney transplant
925860|NCT02392312|ATG-F
925861|NCT02392286|Corticosteroid
925862|NCT02392273|migraine
925863|NCT02392273|cluster headache
925864|NCT02392273|primary headache
925865|NCT02392273|Ausanil
925866|NCT02392273|capsicum annuum
925867|NCT02392221|Crohn's disease (CD)
925868|NCT02392221|Pediatric
925869|NCT02392221|Inflammatory Bowel Disease
925870|NCT02392208|telavancin
925871|NCT02392208|end-stage renal disease
925872|NCT02392208|ESRD
925873|NCT02392208|pharmacokinetics
925874|NCT02392208|hemodialysis
925875|NCT02392208|chronic kidney disease
925876|NCT02392208|CKD
925877|NCT02392208|dialysis
925878|NCT02392208|Vibativ
925879|NCT02392195|Plagiocephaly
925880|NCT02392182|lung
925881|NCT02392169|neuroendocrine
925882|NCT02392169|ADHD
925883|NCT02392169|heredity
925884|NCT02392169|cognitive function
925885|NCT02392143|colorectal cancer screening
925886|NCT02392104|International Normalized Ratio
925887|NCT02392104|Warfarin
925888|NCT02392078|Procedural Success
925889|NCT02392078|Progression
925890|NCT02392078|Quality of Life
925891|NCT02392052|caregivers
925892|NCT02392039|Lymphoma
925893|NCT02392039|Diffuse Large B-cell Lymphoma
925894|NCT02392039|Mantle Cell Lymphoma
925895|NCT02392039|Grade 3B Follicular Lymphoma
925896|NCT02392039|Burkitt Lymphoma
925897|NCT02392039|Peripheral T cell Lymphoma NOS
925898|NCT02392039|NK/T cell Lymphoma
925899|NCT02392039|Transformed Lymphoma
925900|NCT02392039|Aggressive lymphoma
925901|NCT02392039|Bone pain
925902|NCT02392039|Pegfilgrastim
925903|NCT02392039|Neulasta
925904|NCT02392039|PEG-G-CSF
925905|NCT02392039|Loratadine
925906|NCT02392039|Placebo
925907|NCT02392039|Sugar pill
925908|NCT02392039|Questionnaires
925909|NCT02392039|Surveys
925910|NCT02392013|older adult falls
925911|NCT02392013|home hazards
925912|NCT02392013|home barriers
925913|NCT02392000|chronic insomnia
925914|NCT02392000|Veterans Health
925915|NCT02391974|Hyaluronic acid
925916|NCT02391974|Periodontal pockets
925917|NCT02391974|Periodontitis
925918|NCT02391948|Cerebral palsy
925919|NCT02391948|Gross motor delay
925920|NCT02391935|Chronic Effect of Ultraviolet Radiation on Normal Skin (Photo-aging)
925921|NCT02391922|out of hospital cardiac arrest
925922|NCT02391922|first aid
925923|NCT02391909|Vaccine
925924|NCT02391883|clopidogrel therapy
925925|NCT02391883|platelet aggregation inhibitor
925926|NCT02391883|adverse event
925927|NCT02391870|depression
925928|NCT02391870|mindfulness
925929|NCT02391870|pregnancy
925930|NCT02391870|prevention
925931|NCT02391870|cognitive behavioral therapy
925932|NCT02391857|cardiopulmonary resuscitation
925933|NCT02391857|Gastric emptying
925934|NCT02391844|Knee
925935|NCT02391844|Post-Operative Pain
925936|NCT02391844|Xartemis
925937|NCT02391831|SMA
925938|NCT02391831|Spinal Muscular Atrophy
925939|NCT02391831|Neuromuscular disease
925940|NCT02391818|balance
925941|NCT02391818|quality of life
925942|NCT02391818|chemotherapy
925943|NCT02391818|neuropathy
925944|NCT02391818|cancer
925945|NCT02391779|High normal blood pressure
925946|NCT02391779|Stage I
925947|NCT02391766|Self-management
925948|NCT02391766|Caregiving
925949|NCT02391766|Quality of life
925950|NCT02391766|Empowerment
925951|NCT02391753|levator avulsion
925952|NCT02391753|transperineal ultrasound
925953|NCT02391753|levator hiatus
925954|NCT02391727|SYN004
925955|NCT02391727|cetuximab
925956|NCT02391714|pain assessment
925957|NCT02391714|patient satisfaction
925958|NCT02391714|Visual Analog Scale
925959|NCT02391714|contraceptive devices
925960|NCT02391714|nulliparity
925961|NCT02391662|Metastatic Pancreatic Adenocarcinoma
925962|NCT02391662|Elderly
925963|NCT02391662|Nab-paclitaxel
925964|NCT02391662|Gemcitabine
925965|NCT02391649|schizophrenia
925966|NCT02391649|bibliotherapy program
925967|NCT02391649|problem-solving
925968|NCT02391649|family caregivers
925969|NCT02391649|randomized controlled trial
925970|NCT02391636|Postpartum Hemorrhage
925971|NCT02391636|carbetocin
925972|NCT02391636|oxytocin
925973|NCT02391623|Multiple Ascending Dose
925974|NCT02391623|Healthy Subjects
925975|NCT02391623|Hyperlipidemia
925976|NCT02391623|Lipid Metabolism Disorders
925977|NCT02391623|Metabolic Diseases
925978|NCT02391610|birth cohort study
925979|NCT02391610|environmental exposures
925980|NCT02391610|birth defects
925981|NCT02391610|pregnant outcomes
925982|NCT02391610|children development
925983|NCT02391545|Follicular Lymphoma
925984|NCT02391545|Previously Untreated
925985|NCT02391519|Pregnancy
925986|NCT02391519|High altitude
925987|NCT02391519|vasoreactivity
925988|NCT02391519|myometrial arteries
925989|NCT02391506|First CMC joint
925990|NCT02391506|Osteoarthritis
925991|NCT02391506|Cartilage Replacement
925992|NCT02391506|First CMC Joint Osteoarthritis
925993|NCT02391506|Damaged Articular Surface
925994|NCT02391493|bilinguals
925995|NCT02391493|language control
925996|NCT02391493|executive functions
925997|NCT02391493|functional MRI
925998|NCT02391493|stimulation mapping
925999|NCT02391493|brain tumors
926000|NCT02391480|Bromodomain Inhibitor
926001|NCT02391480|Cancer
926002|NCT02391454|Neoplasms
926003|NCT02391454|Cell Phones
926004|NCT02391454|Motor Activity
926005|NCT02391454|Feasibility
926006|NCT02391441|Pulmonary
926007|NCT02391441|Arterial
926008|NCT02391441|Hypertension
926009|NCT02391441|Lung
926010|NCT02391441|Transplantation
926011|NCT02391441|MRI
926012|NCT02391428|ADHD
926013|NCT02391428|omega3
926014|NCT02391402|Brain injury
926015|NCT02391402|TBI
926016|NCT02391402|PTSD
926017|NCT02391402|Polytrauma
926018|NCT02391389|preterm infant
926019|NCT02391376|superficial heat
926020|NCT02391376|hot pack
926021|NCT02391376|thermotherapy
926022|NCT02391376|physiotherapy
926023|NCT02391376|Schober Test
926024|NCT02391363|anxiety
926025|NCT02391363|worry
926026|NCT02391337|Atrial fibrillation
926027|NCT02391337|Quality of life
926028|NCT02391337|Left ventricular ejection fraction
926029|NCT02391337|Diastolic function
926030|NCT02391337|Echocardiography
926031|NCT02391337|Beta-blockers
926032|NCT02391337|Digoxin
926033|NCT02391311|tDCS
926034|NCT02391311|Cognitive remediation therapy
926035|NCT02391298|Multiple Sclerosis
926036|NCT02391298|stress
926037|NCT02391298|meditation
926038|NCT02391298|attention
926039|NCT02391272|recombinant human thrombopoietin
926040|NCT02391272|immune thrombocytopenia
926041|NCT02391272|pregnancy
926042|NCT02391246|central nervous system tumours
926043|NCT02391246|[18F]-fluorodeoxyglucose
926044|NCT02391233|Effectiveness intervention
926045|NCT02391233|Cost-effectiveness intervention
926046|NCT02391233|HIV prevention
926047|NCT02391233|Sexually transmitted infections prevention
926048|NCT02391233|Multimedia evidence-based intervention
926049|NCT02391233|Drug-users
926050|NCT02391233|Black/African-American women
926051|NCT02391233|Probation
926052|NCT02391233|HIV testing
926053|NCT02391194|AVB-620
926054|NCT02391194|stage I
926055|NCT02391194|newly diagnosed
926056|NCT02391194|breast cancer
926057|NCT02391194|stage II
926058|NCT02391194|stage III
926059|NCT02391194|ductal carcinoma in situ
926060|NCT02391181|Bioequivalence
926061|NCT02391181|Iron Status
926062|NCT02391155|follicular flushing
926063|NCT02391155|IVF
926064|NCT02391155|poor responders
926065|NCT02391155|oocyte retrival
926066|NCT02391142|heart failure
926067|NCT02391142|cardiac sympathetic nerve block
926068|NCT02391142|sympathetic nervous system
926069|NCT02391090|asthma
926070|NCT02391090|hypoxia
926071|NCT02391090|forced exhaled nitric oxide
926072|NCT02391090|inflammation
926073|NCT02391077|PrePex
926074|NCT02391077|Male Circumcision
926075|NCT02391077|Bacterial Load
926076|NCT02391064|cognition
926077|NCT02391064|brief computerized cognitive assessment
926078|NCT02391064|impairment prediction
926079|NCT02391051|prostate cancer
926080|NCT02391051|focal brachytherapy
926081|NCT02391051|PSA
926082|NCT02391051|Biological marker
926083|NCT02391038|MLN0264
926084|NCT02391038|Advanced gastrointestinal carcinoma
926085|NCT02391025|Metastatic
926086|NCT02391025|Prostate Cancer
926087|NCT02391025|Castrate Resistant
926088|NCT02391012|Ulcerative colitis
926089|NCT02391012|Crohns disease
926090|NCT02391012|Microbial transplantation
926091|NCT02390986|Cancer
926092|NCT02390986|Malignant Neoplasm
926093|NCT02390986|Anti-cancer drug
926094|NCT02390947|Colorectal Cancer
926095|NCT02390947|Famitinib
926096|NCT02390934|Radium 223
926097|NCT02390934|bone metastases
926098|NCT02390908|alcohol use
926099|NCT02390908|hazardous drinking
926100|NCT02390908|behavioral intervention
926101|NCT02390908|ART adherence
926102|NCT02390908|viral load
926103|NCT02390908|CD4
926104|NCT02390895|Minimally-invasive endoscopic repair
926105|NCT02390895|fetal surgery
926106|NCT02390895|outcome
926107|NCT02390895|Foetus
926108|NCT02390869|relapse
926109|NCT02390869|progression
926110|NCT02390804|postoperative pain
926111|NCT02390804|hysterectomy
926112|NCT02390804|single-port access laparoscopy
926113|NCT02390804|multi-port access laparoscopy
926114|NCT02390804|TLH
926115|NCT02390778|secondary traumatic stress
926116|NCT02390778|vicarious trauma
926117|NCT02390778|secondary distress
926118|NCT02390765|Stress Response
926119|NCT02390765|Binge Eating
926120|NCT02390765|Eating Behavior
926121|NCT02390765|Obesity
926122|NCT02390765|Disordered Eating
926123|NCT02390752|Maximum Tolerated Dose
926124|NCT02390752|Dose Escalation
926125|NCT02390752|Acute Lymphocytic Leukemia
926126|NCT02390752|Acute Myelogenous Leukemia
926127|NCT02390739|Immunotherapy
926128|NCT02390739|Gene Therapy
926129|NCT02390739|Metastatic Cancer
926130|NCT02390713|hepatectomy
926131|NCT02390713|post-operative liver failure
926132|NCT02390713|portal vein
926133|NCT02390713|portal flow
926134|NCT02390713|portal pressure
926135|NCT02390713|modulation
926136|NCT02390713|surgical device
926137|NCT02390700|Rheumatoid Arthritis
926138|NCT02390700|Observational
926139|NCT02390700|Golimumab
926140|NCT02390700|SIMPONI
926141|NCT02390700|Intravenous Infusion
926142|NCT02390661|seroma
926143|NCT02390661|accelerated partial breast irradiation (APBI)
926144|NCT02390661|breast lumpectomy
926145|NCT02390661|breast cancer
926146|NCT02390635|Leukemia
926147|NCT02390635|Acute myeloid leukemia
926148|NCT02390635|AML
926149|NCT02390635|Acute promyelocytic leukemia
926150|NCT02390635|APL
926151|NCT02390635|Extramedullary leukemia
926152|NCT02390635|EML
926153|NCT02390635|Whole body magnetic resonance imaging
926154|NCT02390635|MRI
926155|NCT02390635|Positron emission tomography/ computed tomography
926156|NCT02390635|PET/CT
926157|NCT02390635|18F-FDG
926158|NCT02390635|Gadolinium contrast agent
926159|NCT02390609|Healthy
926160|NCT02390609|Ibrutinib
926161|NCT02390609|Bioavailability
926162|NCT02390596|Kawasaki disease
926163|NCT02390596|anti Interleukin 1 treatment
926164|NCT02390596|anakinra
926165|NCT02390596|resistance to IVIg
926166|NCT02390596|coronary aneurysms
926167|NCT02390596|phase II trial
926168|NCT02390583|Internet dependence
926169|NCT02390583|Sleep disorders
926170|NCT02390583|pathological gambling
926171|NCT02390570|Patient Capacity
926172|NCT02390544|children
926173|NCT02390544|bone marrow transplant
926174|NCT02390544|pharmacokinetics
926175|NCT02390531|Retinopathy of Prematurity
926176|NCT02390531|Bevacizumab
926177|NCT02390531|ROP
926178|NCT02390505|vitamin C
926179|NCT02390505|CRPS
926180|NCT02390505|Upper limb surgery
926181|NCT02390479|Sclerostin
926182|NCT02390479|OPG
926183|NCT02390479|RANKL
926184|NCT02390453|mild cognitive impairment
926185|NCT02390453|randomized controlled trial
926186|NCT02390453|cognitive training
926187|NCT02390453|exercise training
926188|NCT02390453|cognition
926189|NCT02390453|physical performance
926190|NCT02390453|disability
926191|NCT02390453|mood
926192|NCT02390440|Pain management
926193|NCT02390440|Exparel
926194|NCT02390440|Rib fracture
926195|NCT02390427|Metastatic Breast Cancer
926196|NCT02390427|Advanced Breast Cancer
926197|NCT02390427|Recurrent Breast Cancer
926198|NCT02390414|Myelodysplastic syndromes (MDS)
926199|NCT02390388|pudendal block
926200|NCT02390388|Hypospadias
926201|NCT02390388|caudal block
926202|NCT02390388|child
926203|NCT02390388|analgesia
926204|NCT02390336|Osteoarthritis of the hip
926205|NCT02390336|Pain
926206|NCT02390336|Range of Motion
926207|NCT02390336|Physical Function
926208|NCT02390336|Manual Therapy
926209|NCT02390310|male circumcision
926210|NCT02390310|Shang Ring
926211|NCT02390310|male circumcision device
926212|NCT02390310|prevention
926213|NCT02390310|voluntary medical male circumcision (VMMC)
926214|NCT02390284|RGCD
926215|NCT02390284|Glaucoma Suspect
926216|NCT02390232|gut microbiota
926217|NCT02390232|Non Alcoholic Steato Hepatitis
926218|NCT02390232|Steatohepatitis
926219|NCT02390232|Escherichia coli
926220|NCT02390232|colibactin
926221|NCT02390206|Stroke
926222|NCT02390206|Spasticity
926223|NCT02390206|Botulinum Toxin type A
926224|NCT02390206|Dysport
926225|NCT02390193|Chronic kidney disease
926226|NCT02390193|Dialysis
926227|NCT02390193|Sleep
926228|NCT02390193|Pulmonary function
926229|NCT02390193|Polysomnography
926230|NCT02390193|Upper airway
926231|NCT02390128|iodine
926232|NCT02390128|thyroid
926233|NCT02390128|TSH
926234|NCT02390128|pregnancy
926235|NCT02390128|nutrition
926236|NCT02390128|diet
926237|NCT02390102|Anemia
926238|NCT02390102|Severe aortic stenosis
926239|NCT02390102|Red blood cell transfusion
926240|NCT02390102|Erythropoietin
926241|NCT02390089|Dysphagia
926242|NCT02390089|Cough
926243|NCT02390089|Aspiration pneumonia
926244|NCT02390024|Mechanical Ventilation
926245|NCT02390024|Asynchronies
926246|NCT02390024|Cognition
926247|NCT02390011|Advanced Solid Tumor
926248|NCT02389998|Functional Pain
926249|NCT02389998|Abdominal Pain
926250|NCT02389998|Irritable Bowel Syndrome
926251|NCT02389998|IBS
926252|NCT02389998|Functional Dyspepsia
926253|NCT02389998|FGID
926254|NCT02389998|Functional Gastrointestinal Disorders
926255|NCT02389959|HHT
926256|NCT02389959|Hereditary Hemorrhagic Telangiectasia
926257|NCT02389959|epistaxis
926258|NCT02389959|nose bleeds
926259|NCT02389959|nasal bleeding
926260|NCT02389959|Avastin
926261|NCT02389959|bevacizumab
926262|NCT02389946|Drug eluting coronary stents
926263|NCT02389946|Sirolimus
926264|NCT02389946|Bioabsorbable polymer
926265|NCT02389946|DES
926266|NCT02389933|Multiple Patient Program, LCZ696, heart failure, heart failure with reduced ejection fraction, HF-rEF
926267|NCT02389894|Embolic Protection Device
926268|NCT02389894|Stroke
926269|NCT02389894|Brain Infarction
926270|NCT02389894|atheroma
926271|NCT02389894|Aortic Valve Replacement
926272|NCT02389881|Drug therapy
926273|NCT02389868|Lovastatin
926274|NCT02389868|Proteome
926275|NCT02389868|Blood platelets
926276|NCT02389855|Progression
926277|NCT02389855|Quality of Life
926278|NCT02389816|Drug therapy
926279|NCT02389790|Crohn's Disease
926280|NCT02389764|Breast cancer
926281|NCT02389764|Metastatic inflammatory breast cancer
926282|NCT02389764|MIBC
926283|NCT02389764|HER2-negative
926284|NCT02389764|Breast carcinoma
926285|NCT02389764|BIBF 1120
926286|NCT02389764|Nintedanib
926287|NCT02389764|Phone call
926288|NCT02389751|Esophageal Cancer
926289|NCT02389751|Esophageal carcinoma
926290|NCT02389751|Adenocarcinoma or squamous cell carcinoma of the gastroesophageal junction
926291|NCT02389751|Adenocarcinoma or squamous cell carcinoma of the cervical esophagus
926292|NCT02389751|Adenocarcinoma or squamous cell carcinoma of thoracic esophagus
926293|NCT02389751|Ganetespib
926294|NCT02389751|Carboplatin
926295|NCT02389751|Paraplatin
926296|NCT02389751|Paclitaxel
926297|NCT02389751|Taxol
926298|NCT02389725|peripheral intravenous access
926299|NCT02389725|tourniquet techniques
926300|NCT02389712|Bipolar Disorder
926301|NCT02389712|Mayo Clinic
926302|NCT02389699|Intermediate and high grade ductal carcinoma in situ （DCIS）
926303|NCT02389686|Ductal carcinoma in situ （DCIS）
926304|NCT02389686|Nipple-sparing mastectomy (NSM)
926305|NCT02389686|Intraoperative radiotherapy (IORT)
926306|NCT02389686|INTRABEAM
926307|NCT02389673|Intermediate and high grade ductal carcinoma in situ （DCIS）
926309|NCT02389621|Elective invasive procedures
926310|NCT02389608|Transcranial direct current stimulation
926311|NCT02389608|functional electrical stimulation
926312|NCT02389608|hemiparesis
926313|NCT02389608|electromyography
926314|NCT02389608|balance
926315|NCT02389595|HIV
926316|NCT02389595|vaccine
926317|NCT02389595|T cell
926318|NCT02389582|platelet function; dabigatran;enoxaparin
926319|NCT02389569|Biomaterial
926320|NCT02389569|Dental caries
926321|NCT02389569|Composite
926322|NCT02389543|KPT-330
926323|NCT02389543|Selinexor
926324|NCT02389543|Multiple Myeloma
926325|NCT02389543|Relapsed/refractory
926326|NCT02389543|Lenalidomide
926327|NCT02389543|Dexamethasone
926328|NCT02389543|Karyopharm
926329|NCT02389530|glioma
926330|NCT02389530|neoplasms
926331|NCT02389504|Exertion
926332|NCT02389504|Efficacy of Treatment
926333|NCT02389491|high density formula
926334|NCT02389491|heart defects
926335|NCT02389491|infant
926336|NCT02389478|oropharyngeal
926337|NCT02389478|breastmilk
926338|NCT02389478|colostrum
926339|NCT02389478|human milk
926340|NCT02389478|premature infant
926341|NCT02389465|Depression
926342|NCT02389465|Geriatric
926343|NCT02389426|Multiple Sclerosis
926344|NCT02389426|Cerebral hemodynamics
926345|NCT02389426|Cerebral hypoperfusion
926346|NCT02389426|Cerebral circulation
926347|NCT02389413|PQ912
926348|NCT02389413|Glutaminy Cyclase (QC)
926349|NCT02389413|QC - Inhibitor
926350|NCT02389400|adult with Langerhans cell histiocytosis
926351|NCT02389400|newly diagnosed
926352|NCT02389400|methotrexate
926353|NCT02389400|cytosine arabinoside
926354|NCT02389387|Dialysis Facilities
926355|NCT02389387|African Americans
926356|NCT02389387|Racial Disparity
926357|NCT02389387|Kidney Transplantation
926358|NCT02389387|Community-based Participatory Research
926359|NCT02389387|Coalition
926360|NCT02389348|Induced blood stage malaria
926361|NCT02389335|type 1diabetes
926362|NCT02389335|IFN γ
926363|NCT02389335|IL-2
926364|NCT02389335|TNF α
926365|NCT02389322|ESAT6
926366|NCT02389322|CFP10
926367|NCT02389322|skin test
926368|NCT02389322|diagnostic test
926369|NCT02389309|Solid tumors
926370|NCT02389309|Advanced tumors
926371|NCT02389309|Temsirolimus
926372|NCT02389309|CCI-779
926373|NCT02389309|Torisel
926374|NCT02389309|Dasatinib
926375|NCT02389309|BMS-354825
926376|NCT02389309|Sprycel
926377|NCT02389309|Cyclophosphamide
926378|NCT02389309|Cytoxan
926379|NCT02389309|Neosar
926380|NCT02389283|Rheumatoid arthritis
926381|NCT02389283|ultrasound joint count
926382|NCT02389270|Neurotrophins
926383|NCT02389270|Nerve Growth Factor
926384|NCT02389270|Brain-Derived Neurotrophic Factor
926385|NCT02389270|Urinary Biomarkers
926386|NCT02389270|Children
926387|NCT02389257|volunteers
926388|NCT02389231|interleukine 2
926389|NCT02389231|warm autoimmune hemolytic anemia
926390|NCT02389231|CD8 regulatory T cells
926391|NCT02389218|atrial fibrillation
926392|NCT02389218|cryoablation
926393|NCT02389218|catheter ablation
926394|NCT02389192|Ebola
926395|NCT02389192|Mono-clonal Antibody
926396|NCT02389179|Vitamin D Deficiency
926397|NCT02389153|secondary prevention coronary heart disease
926398|NCT02389153|myocardial infarction
926399|NCT02389153|cardiovascular risk factors
926400|NCT02389153|collaborative care
926401|NCT02389153|quality of life
926402|NCT02389153|patients´ satisfaction with treatment
926403|NCT02389140|Blood flow
926404|NCT02389140|Glucose
926405|NCT02389140|lactic acid
926406|NCT02389127|Cirrhosis
926407|NCT02389127|Diabetes Mellitus, Type 2
926408|NCT02389127|Glycosylated hemoglobin A1c
926409|NCT02389127|Glucose
926410|NCT02389101|Lymphoma
926411|NCT02389101|68Ga-DOTANOC PET/CT
926412|NCT02389101|Somatostatin receptor
926413|NCT02389101|MRI
926414|NCT02389101|Diffusion weighted imaging
926415|NCT02389101|Early treatment response
926416|NCT02389088|Granulosa Cell
926417|NCT02389088|Androgens
926418|NCT02389088|FSH
926419|NCT02389088|Ovary
926420|NCT02389075|intraepithelial lymphocytes
926421|NCT02389075|microbiome
926422|NCT02389075|colon mucosa
926423|NCT02389049|Primary Ciliary Dyskinesia
926424|NCT02389049|Kartagener Syndrome
926425|NCT02389023|surgical site infection
926426|NCT02389023|infrainguinal bypass
926427|NCT02389023|incisional wound vacuum assisted closure
926428|NCT02389023|Prevena
926429|NCT02389010|Umbilical Cord Blood
926430|NCT02389010|Diabetic Foot
926431|NCT02389010|Ulcer
926432|NCT02389010|Cost
926433|NCT02389010|Effectiveness
926434|NCT02389010|Safety
926435|NCT02389010|Platelet Gel
926436|NCT02389010|Cord Blood Platelet Gel
926437|NCT02389010|Adverse Event
926438|NCT02388997|mild asthma
926439|NCT02388997|young adults
926440|NCT02388997|rhinovirus
926441|NCT02388971|Drug therapy
926442|NCT02388919|anlotinib
926443|NCT02388919|Cancer
926444|NCT02388919|NSCLC
926445|NCT02388919|Non-small Cell Lung Cancer
926446|NCT02388880|ITPR
926447|NCT02388880|CPP
926448|NCT02388880|TBI
926449|NCT02388880|traumatic brain injury
926450|NCT02388880|cerebral perfusion pressure
926451|NCT02388880|intrathoracic pressure regulator
926452|NCT02388841|Pulmonary embolism, Computed tomographic pulmonary
926453|NCT02388815|Diabetes Mellitus
926454|NCT02388815|Sensing Technology
926455|NCT02388802|Infertility
926456|NCT02388802|Transplant
926457|NCT02388802|IVF
926458|NCT02388802|Hysterectomy
926459|NCT02388802|Absolute uterine infertility
926460|NCT02388789|sensory receptors
926461|NCT02388789|balance control
926462|NCT02388789|gait
926463|NCT02388789|temperature
926464|NCT02388776|ROTEM
926465|NCT02388776|Fibrinogen
926466|NCT02388763|Contact lenses
926467|NCT02388750|nausea
926468|NCT02388750|vomiting
926469|NCT02388750|radiation
926470|NCT02388750|anti-emetic drug
926471|NCT02388737|Drug therapy
926472|NCT02388724|Drug therapy
926473|NCT02388711|Dementia
926474|NCT02388711|Transitional Care
926475|NCT02388711|Caregiver
926476|NCT02388698|HPV DNA
926477|NCT02388698|PET-CT
926478|NCT02388698|Recurrent cervical cancer
926479|NCT02388698|chemoradiation
926480|NCT02388685|peripheral arterial disease
926481|NCT02388685|exercise
926482|NCT02388685|perfusion
926483|NCT02388685|energetics
926484|NCT02388685|magnetic resonance imaging
926485|NCT02388685|magnetic resonance spectroscopy
926486|NCT02388659|MRS Biomarkers
926487|NCT02388581|Helicobactor pylori, Hp
926488|NCT02388581|mucosa-associated lymphoid tissue-type lymphoma, MALToma
926489|NCT02388542|cardiovascular disease
926490|NCT02388542|education
926491|NCT02388542|peer mentor
926492|NCT02388529|Heart Failure
926493|NCT02388529|Bendavia™
926494|NCT02388529|MTP-131
926495|NCT02388516|Bangladesh
926496|NCT02388516|Vitamin D
926497|NCT02388516|Acute Respiratory Infections
926498|NCT02388516|Infancy
926499|NCT02388516|Pregnancy
926500|NCT02388503|Blood glucose
926501|NCT02388490|Brentuximabvedotin
926502|NCT02388490|EBV
926503|NCT02388490|Lymphoma
926504|NCT02388477|rotator cuff repair
926505|NCT02388477|Doxycycline
926506|NCT02388464|Congestive Heart Failure
926507|NCT02388464|Bendavia™
926508|NCT02388464|MTP-131
926509|NCT02388451|Mild Cognitive Impairment
926510|NCT02388438|demineralized bone matrix
926511|NCT02387333|Radical cystectomy
926512|NCT02387333|Urinary diversion
926513|NCT02387333|Ileal conduit
926514|NCT02387333|Parastomal hernia
926515|NCT02387333|Prophylactic mesh
926516|NCT02387333|Mesh stoma reinforcement technique
926517|NCT02387320|Anxiety
926518|NCT02387320|Pain
926519|NCT02387320|Nausea
926520|NCT02387320|Fatigue
926521|NCT02387320|Sleep Disturbance
926522|NCT02387320|Breast Cancer
926523|NCT02387320|Surgery
926524|NCT02387294|immunogenicity
926525|NCT02387294|reduced dos
926526|NCT02387294|Phase III
926527|NCT02387294|tolerability
926528|NCT02387294|safety
926529|NCT02387281|Freezing of gait
926530|NCT02388412|Positron emission tomography
926531|NCT02388412|Tissue background ratio
926532|NCT02388412|Optical coherence tomography
926533|NCT02388412|Thin cap fibroous atheroma
926534|NCT02388412|Vulnerability
926535|NCT02388412|Acute coronary syndrome
926536|NCT02388399|Optical coherence tomography
926537|NCT02388399|Axial Plaque Stress
926538|NCT02388399|Wall Shear Stress
926539|NCT02388399|Vulnerability
926540|NCT02388386|Telemedicine
926541|NCT02388386|Mobile Health
926542|NCT02388360|Prostaglandin analogs
926543|NCT02388360|Corneal biomechanics
926544|NCT02388360|Corneal Hysteresis
926545|NCT02388360|Glaucoma, Open-Angle
926546|NCT02388334|Caregivers
926547|NCT02388334|Quality of life
926548|NCT02388334|Quality of care
926549|NCT02388321|Analgesia
926550|NCT02388321|pediatrics
926551|NCT02388321|pain management
926552|NCT02388308|Prostate cancer
926553|NCT02388308|Image-guided radiotherapy
926554|NCT02388308|Ultrasound guidance
926555|NCT02388295|Multiple System Atrophy (MSA), PET imaging, myeloperoxidase (MPO) inhibitor
926556|NCT02388282|dynamic intrinsic PEEP
926557|NCT02388282|diaphragm echography
926558|NCT02388282|respiratory mechanics
926559|NCT02388256|colon
926560|NCT02388256|colorectal
926561|NCT02388256|cancer
926562|NCT02388256|neoplasm
926563|NCT02388243|Brief intervention
926564|NCT02388243|Low and middle income countries (LMIC)
926565|NCT02388243|eLearning
926566|NCT02388243|Screening
926567|NCT02388243|Capacity Building
926568|NCT02388243|Primary Health Care
926569|NCT02388243|Education, Medical
926570|NCT02388243|Education, Nursing
926571|NCT02388243|Education, Professional
926572|NCT02388243|Community Health Workers
926573|NCT02388230|Breast cancer
926574|NCT02388230|Elastography
926575|NCT02388230|Ultrasound imaging
926576|NCT02388230|Quantification of toxicity
926577|NCT02388230|Side-effects
926578|NCT02388217|chronic pain
926579|NCT02388217|cannabis
926580|NCT02388217|Approved for cannabis treatment by Israeli ministry of health
926581|NCT02388217|Unrelieved chronic pain
926582|NCT02388204|Gait
926583|NCT02388204|Locomotion
926584|NCT02388204|Freezing
926589|NCT02388165|Staphylococcal Vaccine
926590|NCT02388165|Post-operative Surgical Site Infection
926591|NCT02388165|Spinal Surgery
926592|NCT02388165|MRSA
926593|NCT02388165|Staphylococcus aureus
926594|NCT02388139|acute myocardial infarction
926595|NCT02388139|renal artery stenosis
926596|NCT02388113|Exercise therapy
926597|NCT02388113|Time factors
926598|NCT02388074|Lung Cancer
926599|NCT02388074|Porphyrin
926600|NCT02388074|Fluorescence
926601|NCT02388074|Diagnostic
926602|NCT02388074|Sputum Cytology
926603|NCT02388074|Early Detection
926604|NCT02388048|Leukemia
926605|NCT02388048|Chronic
926606|NCT02388048|High-risk
926607|NCT02388048|ofatumumab
926608|NCT02388048|ibrutinib
926609|NCT02388048|Lymphoblastic
926610|NCT02388035|profiles changes
926611|NCT02388035|microorganisms
926612|NCT02388035|cefotaxime
926613|NCT02388035|SBP
926614|NCT02388035|Egyptian
926615|NCT02388035|effective antibiotics
926616|NCT02388009|bioconjugate vaccine
926617|NCT02388009|safety
926618|NCT02388009|immunogenicity
926619|NCT02388009|shigellosis
926620|NCT02387970|Dental implants
926621|NCT02387970|Partial edentulism
926622|NCT02387970|Immediate/delayed provisionalization
926623|NCT02387957|Wet AMD
926624|NCT02387957|subfoveal choroidal neovascularization
926625|NCT02387957|Fovista®
926626|NCT02387957|Avastin®
926627|NCT02387957|Lucentis®
926628|NCT02387957|Eylea®
926629|NCT02387944|Children
926630|NCT02387944|Cyanotic congenital heart defect
926631|NCT02387944|Cardiopulmonary Bypass
926632|NCT02387944|Thromboelastometry
926633|NCT02387944|Platelet Function Tests
926634|NCT02387931|Adolescent
926635|NCT02387931|Endometriosis
926636|NCT02387931|Diet
926637|NCT02387931|Nutrition
926638|NCT02387931|Pain
926639|NCT02387918|Tonsillectomy
926640|NCT02387918|postoperative vomiting (POV)
926641|NCT02387918|Dexamethasone
926642|NCT02387918|Acupuncture
926643|NCT02387905|Stereotactic spinal radiosurgery
926644|NCT02387905|Spinal Cord Diseases
926645|NCT02387905|Vertebral body compression fracture
926646|NCT02387905|SSRS
926647|NCT02387905|Brief Pain Inventory
926648|NCT02387905|MD Anderson Symptom Inventory - Spine Tumor
926649|NCT02387905|MDASI-SP
926650|NCT02387905|Questionnaires
926651|NCT02387905|Survey
926652|NCT02387879|Multiple Myeloma
926653|NCT02387879|PASS
926654|NCT02387879|Observational
926655|NCT02387879|Non-interventional
926656|NCT02387879|Relapse
926657|NCT02387879|Refractory
926658|NCT02387879|CC-5013
926659|NCT02387879|Lenalidomide
926660|NCT02387879|Turkey
926661|NCT02387866|Pharmacokinetic
926662|NCT02387866|Healthy Volunteers
926663|NCT02387866|Male
926664|NCT02387866|Japanese
926665|NCT02387866|Caucasian
926666|NCT02387866|AG-221
926667|NCT02387840|Brain
926668|NCT02387840|Cancer
926669|NCT02387840|Neurofibromatosis type 1
926670|NCT02387840|NF1
926671|NCT02387840|Magnetic resonance fingerprinting
926672|NCT02387840|MRF
926673|NCT02387827|long bout physical activity
926674|NCT02387827|short bout physical activity
926675|NCT02387827|Caloric Restriction
926676|NCT02387775|esophageal cooling device
926677|NCT02387775|post cardiac arrest
926678|NCT02387775|targetted temperature management
926679|NCT02387775|therapeutic hypothermia
926680|NCT02387775|cooling
926681|NCT02387775|rewarming
926682|NCT02387762|Acalabrutinib
926683|NCT02387749|diabetic peripheral neuropathy
926684|NCT02387749|mesenchymal stem cells
926694|NCT02387710|arousal threshold
926695|NCT02387710|phenotype
926696|NCT02387710|tiagabine
926697|NCT02387710|slow wave sleep
926698|NCT02387684|chronic hepatitis B
926699|NCT02387684|interferon
926700|NCT02387684|peginterferon
926701|NCT02387684|HBsAg loss
926702|NCT02387658|peripheral arterial disease
926703|NCT02387658|claudication
926704|NCT02387658|translesional pressure gradient
926705|NCT02387658|pressure wire
926706|NCT02387658|six minute walk
926707|NCT02387658|superficial femoral artery
926708|NCT02387658|pressure gradient
926709|NCT02387658|endovascular
926710|NCT02387645|Endometrium
926711|NCT02387645|Endometrial Neoplasms
926712|NCT02387645|Early detection
926713|NCT02387645|Carcinoma of Endometrium
926714|NCT02387645|Gynaecological Cancer
926715|NCT02387606|Respiratory Syncytial Virus Infections
926716|NCT02387606|Placebo
926717|NCT02387606|Antiviral activity
926718|NCT02387606|JNJ-53718678
926719|NCT02387593|Adenoma
926720|NCT02387593|Colonoscopy
926721|NCT02387593|Screening
926722|NCT02387580|Malaria
926723|NCT02387580|Bioavailability
926724|NCT02387580|Formulation
926725|NCT02387541|Postoperative cognitive dysfunction
926726|NCT02387528|MIndfulness
926727|NCT02387528|Primary Health Care
926728|NCT02387463|chronic hepatitis B
926729|NCT02387463|antiviral therapy
926730|NCT02387463|peginterferon
926731|NCT02387463|HBeAg seroconversion
926732|NCT02387463|HBsAg loss
926733|NCT02387450|Claudication
926734|NCT02387450|Maximal walking distance
926735|NCT02387450|Morbi-mortality
926736|NCT02387437|ARDS
926737|NCT02387437|EIT
926738|NCT02387437|recruitment maneuvers
926739|NCT02387424|depression
926740|NCT02387424|mindfulness
926741|NCT02387424|pregnancy
926742|NCT02387424|prevention
926743|NCT02387424|cognitive behavioral therapy
926744|NCT02387411|heart failure
926745|NCT02387411|aerobic exercise
926746|NCT02387411|strength training
926747|NCT02387411|cardiopulmonary rehabilitation
926748|NCT02387411|high-intensity exercise training
926749|NCT02387242|Tuberculosis
926750|NCT02387242|Whole blood Bactericidal Activity
926751|NCT02387242|WBA
926752|NCT02387242|Rifampicin
926753|NCT02387229|Atrial Fibrillation
926754|NCT02387229|Stroke
926755|NCT02387229|Neurocognitive decline
926756|NCT02387229|Rivaroxaban
926757|NCT02387229|Acetylsalicylic acid
926758|NCT02387229|Anticoagulation
926759|NCT02387216|NSCLC
926760|NCT02387216|Non-Small Cell Lung Cancer
926761|NCT02387216|heregulin
926762|NCT02387216|ErbB3
926763|NCT02387216|docetaxel
926764|NCT02387216|pemetrexed
926765|NCT02387203|Pseudomyxoma Peritonei
926766|NCT02387203|Appendiceal cancer
926767|NCT02387203|CRS/HIPEC
926768|NCT02387203|PMP
926769|NCT02387190|Heart Failure
926770|NCT02387190|Lung function test
926771|NCT02387190|Telenursing
926772|NCT02387190|Morbidity
926773|NCT02387190|Mortality
926774|NCT02387190|Quality of life
926775|NCT02387164|Type 1 diabetes
926776|NCT02387164|Islet autoantibodies
926777|NCT02387164|glutamate decarboxylase autoantibodies (GADA)
926778|NCT02387164|Immune tolerance
926779|NCT02387164|Prediabetes
926780|NCT02387164|Glucose tolerance
926781|NCT02387164|glutamate decarboxylase
926782|NCT02387164|Prevention
926783|NCT02387164|Children
926784|NCT02387151|Mesenchymal Stromal Cells
926785|NCT02387151|Rejection
926786|NCT02387112|End stage heart disease
926787|NCT02387112|Ventricular assist device
926792|NCT02387086|gefitinib
926793|NCT02387086|thalidomide
926794|NCT02387086|NSCLC
926795|NCT02387086|EGFR mutation
926796|NCT02387073|outcome assessment
926797|NCT02387073|self-reported
926798|NCT02387073|patient
926799|NCT02387073|clinical outcome
926800|NCT02387060|Anesthesia
926801|NCT02387060|Spinal and Epidural
926802|NCT02387060|Adverse Effect
926803|NCT02387060|Complications
926804|NCT02387034|Osteoarthritis
926805|NCT02387034|Sedentary
926806|NCT02387034|Physical activity
926807|NCT02387034|Health related quality of life
926808|NCT02387021|analgesia
926809|NCT02387021|nerve block
926810|NCT02387021|Total knee replacement
926811|NCT02386995|depth of anesthesia monitors
926812|NCT02386995|deep brain stimulation
926813|NCT02386969|Neuropathic Pain
926814|NCT02386969|repetitive transcranial magnetic stimulation (rTMS)
926815|NCT02386956|manual therapy
926816|NCT02386956|muscle chains
926817|NCT02386956|Dynamic stretching
926818|NCT02386956|Active stretching
926819|NCT02386930|Cognitive behavior therapy
926820|NCT02386930|Lifestyle modification
926821|NCT02386930|HbA1c
926822|NCT02386930|Carbohydrates
926823|NCT02386891|food intake
926824|NCT02386891|indoor thermal environment
926825|NCT02386878|Orphans and vulnerable children (OVC)
926826|NCT02386878|Program Evaluation
926827|NCT02386878|HIV Prevention
926828|NCT02386878|Psychosocial Wellbeing
926829|NCT02386878|Adolescents
926830|NCT02386852|Ginseng
926831|NCT02386852|Ginkgo Biloba
926832|NCT02386852|cardiovascular reactivity
926833|NCT02386852|cognition
926834|NCT02386826|INC280
926835|NCT02386826|c-MET Inhibitors
926836|NCT02386826|bevacizumab
926837|NCT02386826|Avastin
926838|NCT02386826|C-Met proto-oncogene
926839|NCT02386800|primary myelofibrosis
926840|NCT02386800|chronic idiopathic myelofibrosis,
926841|NCT02386800|post polycythemia vera myelofibrosis,
926842|NCT02386800|post essential thrombocythaemia myelofibrosis.
926843|NCT02386787|Ultrasonography
926844|NCT02386787|Non-elective surgery
926845|NCT02386787|Anesthesia
926846|NCT02386774|In vivo confocal microscopy
926847|NCT02386774|corneal disease
926848|NCT02386774|Blepharitis
926849|NCT02386774|Lacrimal Apparatus Diseases
926850|NCT02386774|Microscopy, Confocal
926851|NCT02386748|Cesarean section
926852|NCT02386748|Chewing gums
926853|NCT02386748|Intestinal motility
926854|NCT02386735|Corticosteroid treatment
926855|NCT02386735|COPD
926856|NCT02386735|Primary Health Care
926857|NCT02386735|Randomized controlled trial
926858|NCT02386722|Adherence of inhaled medication
926859|NCT02386722|pharmaceutical care intervention
926860|NCT02386683|Protective mechanical ventilation
926861|NCT02386683|ventilator-induced lung injury
926862|NCT02386683|neurosurgery
926863|NCT02386657|Sickle Cell Disease
926864|NCT02386657|Vaso-occlusive crisis
926865|NCT02386657|Emergency management
926866|NCT02386631|gait
926867|NCT02386631|orthotics
926868|NCT02386631|kinetics
926869|NCT02386631|hallux valgus
926870|NCT02386631|bunions
926871|NCT02386618|colorectal cancer
926872|NCT02386618|laterally spreading tumors
926873|NCT02386618|endoscopic mucosal resestion
926874|NCT02386618|local residual neoplasia
926875|NCT02386605|recovery
926876|NCT02386605|rehabilitation
926877|NCT02386553|NURTURE
926883|NCT02386514|sexually transmitted infection
926884|NCT02386514|gonorrhea
926885|NCT02386514|chlamydia
926886|NCT02386514|presumptive therapy
926887|NCT02386462|laryngeal mask airway
926888|NCT02386462|circulatory reflexes
926889|NCT02386436|GSK2330811
926890|NCT02386436|Dose Escalation
926891|NCT02386436|Safety
926892|NCT02386436|First Time in Human
926893|NCT02386436|Pharmacodynamics
926894|NCT02386436|Pharmacokinetics
926895|NCT02386423|RLS
926896|NCT02386423|Willis-Ekbom
926897|NCT02386384|pregnancy failure
926898|NCT02386358|Chronic Chagas Disease
926899|NCT02386358|Randomized Clinical Trial double blind
926900|NCT02386358|Benznidazole vs Placebo
926901|NCT02386358|Adult patients
926902|NCT02386345|FIRM procedure
926903|NCT02386319|Melatonin
926904|NCT02386319|Analgesic
926905|NCT02386319|Surgery
926906|NCT02386319|Pharmacokinetic
926907|NCT02386280|Primary Prevention
926908|NCT02386280|Substance-Related Disorders
926909|NCT02386280|Family
926910|NCT02386254|premorbid
926911|NCT02386254|scoring system
926912|NCT02386254|ECOG
926913|NCT02386254|ICU
926914|NCT02386254|morbidity
926915|NCT02386254|mortality
926916|NCT02386241|brain tumor
926917|NCT02386228|miRNA
926918|NCT02386228|posthemorrhagic hydrocephalus (PHH)
926919|NCT02386215|HIV self-testing
926920|NCT02386215|randomized controlled trial
926921|NCT02386215|Kenya
926922|NCT02386189|Continuity of Patient Care
926923|NCT02386189|Health Records, Personal
926924|NCT02386189|Veterans
926925|NCT02386189|Patient Participation
926926|NCT02386189|Chronic Disease
926927|NCT02386137|MR-HIFU
926928|NCT02386137|HIFU
926929|NCT02386137|Fibroid treatment
926930|NCT02386137|MR Perfusion
926931|NCT02386137|CEUS perfusion
926932|NCT02386137|Diffusion weighted imaging
926933|NCT02386137|ARFI
926934|NCT02386137|Fibroid stiffness
926935|NCT02386124|frailty
926936|NCT02386124|elderly
926937|NCT02386124|acute coronary syndrome
926938|NCT02386124|acute heart failure
926939|NCT02386124|arrhythmias
926940|NCT02386111|Sutent
926941|NCT02386085|Osteopathic Manipulative Medicine
926942|NCT02386085|Osteopathic Manipulation
926943|NCT02386085|adverse effects
926944|NCT02386085|side effects
926945|NCT02386085|undesirable effects
926946|NCT02386072|Betanis®
926947|NCT02386072|Myrbetriq®
926948|NCT02386072|Quality of Life
926949|NCT02386072|Antimuscarinics
926950|NCT02386072|Betmiga®
926951|NCT02386072|Overactive Bladder
926952|NCT02386072|Observational
926953|NCT02386059|ondansetron
926954|NCT02386059|dexamethasone
926955|NCT02386059|vitrectomy
926956|NCT02386059|local anesthesia
926957|NCT02386046|Caffeine use
926958|NCT02386046|Normative data
926959|NCT02385968|Modic
926960|NCT02385968|Microbiology
926961|NCT02385968|Immunology
926962|NCT02385942|u-health
926963|NCT02385942|chronic wound management
926964|NCT02385942|pressure ulcer
926965|NCT02385929|Head and Neck Cancer
926966|NCT02385929|Intervention
926967|NCT02385929|Rehabilitation
926968|NCT02385929|Late Effects
926969|NCT02385929|Dysphagia
926970|NCT02385916|EstroSense
926971|NCT02385916|estrogen
926972|NCT02385903|Flammacerium
926973|NCT02385903|Ischemic wound
926974|NCT02385903|Lower limb
926975|NCT02385903|Arteriopathy
926976|NCT02385903|Amputation
926977|NCT02385903|Dressing
926978|NCT02385838|Nutrition labelling
926979|NCT02385838|Front-of-pack nutrition labels
926980|NCT02385838|Purchasing intentions
926981|NCT02385838|Nutritional quality
926982|NCT02385838|Randomized controlled trial (RCT)
926983|NCT02385812|Lung Cancer
926984|NCT02385812|Mesothelioma
926985|NCT02385812|Asbestos
926986|NCT02385812|Screening
926987|NCT02385799|Autism Spectrum Disorder
926988|NCT02385799|Behavior
926989|NCT02385799|sertraline
926990|NCT02385799|treatment
926991|NCT02385786|mindfulness-based cognitive therapy
926992|NCT02385786|depression
926993|NCT02385786|treatment
926994|NCT02385786|mindfulness meditation
926995|NCT02385786|psychotherapy
926996|NCT02385773|colostrum
926997|NCT02385773|Immunoglobulin Y (IgY)
926998|NCT02385760|Facial Acne
926999|NCT02385747|perimenopausal bleeding
927000|NCT02385747|postmenopausal bleeding
927001|NCT02385747|hysteroscopy
927002|NCT02385747|Steroid receptors
927003|NCT02385734|Multiple gingival recession
927004|NCT02385734|Concentrated growth factor
927005|NCT02385734|Coronally advanced flap
927006|NCT02385695|Disc Degeneration Disease
927007|NCT02385695|DDD
927008|NCT02385695|multilevel lumbar Disc Degeneration Disease
927009|NCT02385669|vaccine
927010|NCT02385669|peptide
927011|NCT02385669|ipilimumab
927012|NCT02385669|Yervoy
927013|NCT02385669|Montanide ISA-51
927014|NCT02385643|alcohol dependence
927015|NCT02385643|abstinence
927016|NCT02385643|relapse prevention
927017|NCT02385643|mobile support system
927018|NCT02385630|Longitudinal Studies
927019|NCT02385630|Esophagectomy
927020|NCT02385630|Gastrectomy
927021|NCT02385630|Hunger
927022|NCT02385630|Appetite
927023|NCT02385630|Glucagon-like Peptide 1
927024|NCT02385630|Peptide YY
927025|NCT02385630|Ghrelin
927026|NCT02385630|Satiety Response
927027|NCT02385630|Feeding Behavior
927028|NCT02385630|Meals
927029|NCT02385630|Postprandial Period
927030|NCT02385617|Glucagon-Like Peptide 1
927031|NCT02385617|Peptide YY
927032|NCT02385617|Ghrelin
927033|NCT02385617|Satiety Response
927034|NCT02385617|Appetite
927035|NCT02385617|Hunger
927036|NCT02385617|Somatostatin
927037|NCT02385617|Octreotide
927038|NCT02385617|Anastomosis, Roux-en-Y
927039|NCT02385617|Digestive System Surgical Procedures
927040|NCT02385617|Pharmacologic Actions
927041|NCT02385617|Physiological Effects of Drugs
927042|NCT02385617|Endocrine System Diseases
927043|NCT02385617|Enteroendocrine Cells
927044|NCT02385617|Gastrointestinal Agents
927045|NCT02385604|Positron-Emission Tomography
927046|NCT02385604|Neoadjuvant Therapy
927047|NCT02385604|Chemoradiotherapy
927048|NCT02385604|Esophagectomy
927049|NCT02385604|Response Evaluation Criteria in Solid Tumors
927050|NCT02385604|Treatment Outcome
927051|NCT02385604|Survival
927052|NCT02385604|Recurrence
927053|NCT02385604|Disease-Free Survival
927054|NCT02385604|Progression-Free Survival
927055|NCT02385604|Prognosis
927056|NCT02385604|Neoplasm Grading
927057|NCT02385604|Adenocarcinoma
927058|NCT02385604|Squamous Cell Carcinoma
927059|NCT02385604|Neoplasm Metastasis
927060|NCT02385591|physical activity
927061|NCT02385591|Latinos
927062|NCT02385591|overweight
927063|NCT02385591|SMS
927064|NCT02385591|mHealth
927065|NCT02385578|VS (vessel plus surface) classification system
927066|NCT02385578|Magnified endoscopy with narrow band imaging (ME-NBI)
927067|NCT02385578|the rate of detection
927068|NCT02385552|colonoscopy
927069|NCT02385552|quality improvement
927070|NCT02385552|adenoma detection rate
927071|NCT02385526|Vagus Nerve Stimulation
927072|NCT02385526|ASCEND
927073|NCT02385526|VNS Titration to Improve Tolerance and Accelerate Adaptation
927074|NCT02385513|Immunogenicity
927075|NCT02385487|Myocardial Infarction
927076|NCT02385487|Inflammation
927077|NCT02385487|Critical Illness
927078|NCT02385487|Necrosis
927079|NCT02385487|Sepsis
927080|NCT02385487|Respiratory Insufficiency
927081|NCT02385487|Myocardial Ischemia
927082|NCT02385487|Cardiovascular Diseases
927083|NCT02385487|Heart Diseases
927084|NCT02385487|Vascular Diseases
927085|NCT02385474|silver diamine fluoride
927086|NCT02385474|randomized clinical trial
927087|NCT02385474|caries
927088|NCT02385474|children
927089|NCT02385474|fluoride
927090|NCT02385448|dienogest
927091|NCT02385448|combined oral contraceptive pills
927092|NCT02385448|endometriosis
927093|NCT02385435|caudal block
927094|NCT02385422|secondary prophylaxis
927095|NCT02385422|Propranolol
927096|NCT02385422|Carvedilol
927097|NCT02385422|comparative effectiveness research
927098|NCT02385409|Patient Blood Management
927099|NCT02385409|Preoperative anemia
927100|NCT02385409|Hip replacement
927101|NCT02385409|Knee replacement
927102|NCT02385396|Polycystic Ovary Syndrome
927103|NCT02385396|Infertility
927104|NCT02385396|Myo-inositol
927105|NCT02385396|Intracytoplasmic sperm injection
927106|NCT02385383|Patient Blood Management
927107|NCT02385383|Preoperative anemia
927108|NCT02385383|IV Iron
927109|NCT02385357|Muscle function
927110|NCT02385357|Anaerobic power
927111|NCT02385357|Muscle damage
927112|NCT02385331|Neutrophils
927113|NCT02385331|necroptosis
927114|NCT02385331|apoptosis
927115|NCT02385305|Pressure support ventilation
927116|NCT02385305|respiratory drive
927117|NCT02385305|Physiology
927118|NCT02385279|CAD
927119|NCT02385279|ACS
927120|NCT02385279|All comers
927121|NCT02385279|PCI
927122|NCT02385266|Interstitial cystitis with Painful Bladder Syndrome
927123|NCT02385266|Urological Chronic Pelvic Pain Syndrome
927124|NCT02385253|Training
927125|NCT02385253|Primary Health Care
927126|NCT02385253|Skin Cancer
927127|NCT02385253|Primary Care Physicians
927128|NCT02385253|Surveillance
927129|NCT02385253|Education
927130|NCT02385214|Malignant
927131|NCT02385214|Melanoma
927132|NCT02385214|Cancer
927133|NCT02385214|Surgery
927134|NCT02385188|Extramammary Paget's disease
927135|NCT02385188|Vulva
927136|NCT02385188|Genital, female
927137|NCT02385188|imiquimod
927138|NCT02385175|Eustachian tube
927139|NCT02385175|test accuracy
927140|NCT02385175|clinical test
927141|NCT02385175|questionnaire
927142|NCT02385162|Mucolipidoses
927143|NCT02385162|Metabolic Diseases
927144|NCT02385162|Lysosomal Storage Diseases
927145|NCT02385149|resilience
927146|NCT02385149|challenge test
927147|NCT02385149|whole grain wheat
927148|NCT02385149|metabolic flexibility
927149|NCT02385149|cardio-metabolic
927150|NCT02385149|liver and adipose tissue
927151|NCT02385136|NSCLC
927152|NCT02385136|Radiotherpy
927153|NCT02385136|Temozolomide
927154|NCT02385123|ex-vivo
927155|NCT02385123|Influenza
927156|NCT02385123|plasmablasts
927157|NCT02385110|Leukemia
927158|NCT02385110|Hemophagocytic lymphohistiocytosis
927159|NCT02385110|HLH
927160|NCT02385110|Alemtuzumab
927161|NCT02385110|CAMPATH-1H
927162|NCT02385110|Campath
927163|NCT02385110|Etoposide
927164|NCT02385110|VePesid
927165|NCT02385110|Dexamethasone
927166|NCT02385110|Decadron
927167|NCT02385110|Methotrexate
927168|NCT02385110|Phone call
927169|NCT02385071|Healthy
927170|NCT02385071|Simeprevir
927171|NCT02385071|Bioavailability
927172|NCT02385058|Helminthiasis
927173|NCT02385058|Amoebiasis
927174|NCT02385058|Mebendazole
927175|NCT02385058|Quinfamide
927176|NCT02385058|Mexican population
927177|NCT02385019|Allogeneic hematopoietic stem cell transplantation
927178|NCT02385019|Graft vs host disease
927179|NCT02385019|Regulatory T cells
927180|NCT02385006|Thromboelastography
927181|NCT02385006|simulatneous pancreas-kidney transplantation
927182|NCT02384993|Alzheimer's Disease
927183|NCT02384993|Dementia
927184|NCT02384993|aerobic exercise
927185|NCT02384993|physical activity
927186|NCT02384993|exercise
927187|NCT02384993|neuroimaging
927188|NCT02384980|Intermittent Claudication
927189|NCT02384980|Functional Electrical Stimulation
927190|NCT02384954|Lymphoma
927191|NCT02384954|indolent B Cell
927192|NCT02384954|non-Hodgkin Lymphoma
927193|NCT02384954|Cancer
927194|NCT02384954|Immunotherapy
927195|NCT02384954|Relapsed
927196|NCT02384954|Refractory
927197|NCT02384954|Rituximab
927198|NCT02384954|Interleukin-15
927199|NCT02384954|Absolute Lymphocyte Count
927200|NCT02384954|White Blood Cell
927201|NCT02384954|Follicular Lymphoma
927202|NCT02384954|Marginal Zone Lymphoma
927203|NCT02384954|Small Lymphocytic Lymphoma
927204|NCT02384954|Lymphoplasmacytic Lymphoma
927205|NCT02384954|anti-CD20
927206|NCT02384928|Acupuncture
927207|NCT02384928|Pharmacopuncture
927208|NCT02384928|Usual Care
927209|NCT02384902|glycemic index
927210|NCT02384902|diabetic nephropathy
927211|NCT02384902|low glycemic load
927212|NCT02384902|inflammation
927213|NCT02384876|pediatric
927214|NCT02384876|intraoperative arterial hypotension
927215|NCT02384876|ephedrine
927216|NCT02384876|general anesthesia
927217|NCT02384863|Chest Pain
927218|NCT02384863|Acute Coronary Syndrome
927219|NCT02384863|Cardiac
927220|NCT02384863|Emergency Department
927221|NCT02384863|Cardiac Testing
927222|NCT02384863|Healthcare Utilization
927223|NCT02384863|Patient Centered Outcomes
927224|NCT02384863|Shared Decision Making
927225|NCT02384863|Unnecessary hospital admissions
927226|NCT02384863|Decision Aid
927227|NCT02384850|metastatic
927228|NCT02384837|national Cather Lad
927229|NCT02384837|Interventional Imaging Training Base
927230|NCT02384811|Esophageal squamous cell carcinoma
927231|NCT02384811|postoperative radiotherapy
927232|NCT02384759|cancer, colorectal,
927233|NCT02384746|metastatic breast cancer
927234|NCT02384746|ER-positive
927235|NCT02384746|HER2-negative
927236|NCT02384746|Fulvestrant
927237|NCT02384746|MLN9708
927238|NCT02384733|Radiation induced morbidity, recurrence
927239|NCT02384694|cardiorespiratory fitness
927240|NCT02384694|weight
927241|NCT02384694|quality of life
927242|NCT02384694|depression
927243|NCT02384694|menopausal symptoms
927244|NCT02384694|exercise barriers
927245|NCT02384694|executive functions
927246|NCT02384681|Speech intelligibility
927247|NCT02384681|Short-term memory
927248|NCT02384681|Working memory
927249|NCT02384681|Perceived mental task load
927250|NCT02384668|Cholecalciferol
927251|NCT02384668|Vitamin D3
927252|NCT02384668|Arterial stiffness
927253|NCT02384668|Quality of Life
927254|NCT02384668|Bone density and geometry
927255|NCT02384668|Muscle strength and balance
927256|NCT02384655|Preterms
927257|NCT02384655|Breastfeeding
927258|NCT02384655|Lactation
927259|NCT02384655|Macronutrients
927260|NCT02384642|Adolescent Health
927261|NCT02384642|Democratic Republic of Congo
927262|NCT02384642|Sexual Violence
927263|NCT02384616|Lung Volume Measurements
927264|NCT02384616|airway resistance
927265|NCT02384616|general anesthesia
927266|NCT02384564|Laryngoscopy
927267|NCT02384564|Video Laryngoscopy
927268|NCT02384564|Tracheal intubation
927269|NCT02384551|GERD
927270|NCT02384551|diet
927271|NCT02384551|carbohydrate
927272|NCT02384551|obesity
927273|NCT02384538|Arthritis
927274|NCT02384538|Osteoarthritis
927275|NCT02384538|Joint diseases
927276|NCT02384538|Osteoarthritis, Hand
927277|NCT02384538|Musculoskeletal diseases
927278|NCT02384538|Rheumatic diseases
927279|NCT02384525|Septic AKI
927280|NCT02384525|CRRT
927281|NCT02384525|BIA
927282|NCT02384512|Parkinson's disease
927283|NCT02384512|akinesia
927284|NCT02384512|Azilect®
927285|NCT02384512|Rasagiline
927286|NCT02384512|Combination therapy with L-dopa
927287|NCT02384512|Wearing-off Questionnaire-32
927288|NCT02384512|Quality of life
927289|NCT02384512|Daily practice
927290|NCT02384460|Simplex
927291|NCT02384460|Recessive Dystrophic
927292|NCT02384460|Junctional non-Herlitz
927293|NCT02384460|Epidermolysis Bullosa
927294|NCT02384447|above knee amputation
927295|NCT02384447|sciatic nerve
927296|NCT02384447|ultrasonography
927297|NCT02384447|histology
927298|NCT02384408|menopause
927299|NCT02384408|drospirenone
927300|NCT02384408|tibolone
927301|NCT02384408|Bcl-2
927302|NCT02384408|steroid receptors
927303|NCT02384395|Dolutegravir
927304|NCT02384395|Abacavir
927305|NCT02384395|Lamivudine
927306|NCT02384395|acute HIV infection
927307|NCT02384395|human leukocyte antigen
927308|NCT02384395|latent HIV reservoir
927309|NCT02384395|integrase-based regimen
927310|NCT02384395|viremia
927311|NCT02384395|antiretroviral therapy
927312|NCT02384395|fixed dose combination
927313|NCT02384382|Cancer of the Prostate
927314|NCT02384356|Non-communicable diseases
927315|NCT02384356|Chronic disease
927316|NCT02384356|Mobile health
927317|NCT02384356|Diabetes Mellitus
927318|NCT02384356|Hypertension
927319|NCT02384356|Bolivia
927320|NCT02384356|Longitudinal survey
927321|NCT02384356|Health indicators
927322|NCT02384356|Primary care
927323|NCT02384356|Ambulatory care
927324|NCT02384343|Dexmedetomidine
927325|NCT02384343|Cesarean section
927326|NCT02384343|Anesthesia, Spinal
927327|NCT02384343|Anesthesia, Epidural
927328|NCT02384304|randomized controlled trial
927329|NCT02384304|alcohol
927330|NCT02384304|internet
927331|NCT02384304|internet based therapy
927332|NCT02384304|cognitive behavior therapy
927333|NCT02384278|alcohol use disorder
927334|NCT02384278|internet
927335|NCT02384278|cognitive behavior therapy
927336|NCT02384278|relapse prevention
927337|NCT02384265|Diabetes
927338|NCT02384265|Disparities
927339|NCT02384265|Behavioral
927340|NCT02384265|Text messaging
927341|NCT02384265|Social networks
927342|NCT02384265|African American
927343|NCT02384265|Female
927344|NCT02384252|obese cardiomyopathy
927345|NCT02384252|mitochondria
927346|NCT02384252|contractile dysfunction
927350|NCT02384187|Gabapentin
927351|NCT02384187|PONV
927352|NCT02384187|Adenotonsillectomy
927353|NCT02384187|Pediatrics
927354|NCT02384174|Aging
927355|NCT02384174|Resistant starch
927356|NCT02384174|Dietary fibre
927357|NCT02384174|Immune system
927358|NCT02384174|Bacteria
927359|NCT02384174|older subjects
927360|NCT02384122|Angiodysplasias
927361|NCT02384122|Sandostatin LAR
927362|NCT02384122|Gastrointestinal
927363|NCT02384122|Somatostatin
927364|NCT02384122|Octreotide
927365|NCT02384096|stimulation
927366|NCT02384096|implantable
927367|NCT02384096|pulse generator
927368|NCT02384096|back pain
927369|NCT02384096|chronic pain
927370|NCT02384096|leg pain
927371|NCT02384083|Multiple Myeloma
927372|NCT02384083|Pethema
927373|NCT02384083|Filanesib
927374|NCT02384083|Pomalidomide
927375|NCT02384044|Sensitivity
927376|NCT02383979|Phantom limb pain
927377|NCT02383979|Mirror therapy
927378|NCT02383979|Elective amputation
927379|NCT02383979|Residual limb pain
927380|NCT02383979|Functional MRI
927381|NCT02383953|twins
927382|NCT02383953|IBD
927383|NCT02383953|UC
927384|NCT02383953|CD
927385|NCT02383875|nutrition economics
927386|NCT02383875|food expenditure
927387|NCT02383875|nutritional quality
927388|NCT02383875|low income
927389|NCT02383862|Sleep
927390|NCT02383862|Pain
927391|NCT02383862|Anxiety
927392|NCT02383862|Depression
927393|NCT02383862|Fatigue
927394|NCT02383862|PROMIS
927395|NCT02383862|primary care
927396|NCT02383836|Patent Foramen Ovale
927397|NCT02383823|glucose, cholesterol, estrogen, gender, age
927398|NCT02383810|Chemotherapy Induced Diarrhea (CID)
927399|NCT02383771|Ticagrelor
927400|NCT02383771|Aspirin
927401|NCT02383771|Peri-operative treatment
927402|NCT02383758|Behavioral Symptoms
927403|NCT02383758|Child Development Disorders, Pervasive
927404|NCT02383758|Bowel Incontinence
927405|NCT02383758|Constipation
927406|NCT02383745|Acute EEG
927407|NCT02383745|status epilepticus
927408|NCT02383745|seizure
927409|NCT02383706|Sleep Apnea, Obstructive
927410|NCT02383706|Pregnancy
927411|NCT02383706|Obesity, Morbid
927412|NCT02383706|Complications, pregnancy
927413|NCT02383693|depression
927414|NCT02383693|Repetitive Transcranial Magnetic Stimulation
927415|NCT02383693|tolerability
927416|NCT02383693|efficiency
927417|NCT02383693|TMS
927418|NCT02383693|refractory
927419|NCT02383680|Methotrexate therapy
927420|NCT02383654|Amyotrophic Lateral Sclerosis
927421|NCT02383654|Autologous Adipose-Tissue Derived Stem Cells (ADSCs)
927425|NCT02383628|ICG Dye
927426|NCT02383628|endoscopic neurosurgery
927427|NCT02383628|tissue perfusion
927428|NCT02383602|6,000 Thai MSM and TG from study sites in Bangkok, Chiang Mai, Chonburi and Songkhla
927429|NCT02383550|Multiple Sclerosis
927430|NCT02383550|Cognition
927431|NCT02383498|Overall Response Rate
927432|NCT02383498|Immune Activation
927433|NCT02383498|Tumor Infiltrating Lymphocytes
927434|NCT02383498|T Cell Response
927435|NCT02383498|Cross-Over
927436|NCT02383485|arterial stiffness
927437|NCT02383472|Concussion
927438|NCT02383472|Mild Traumatic Brain Injury
927439|NCT02383472|MTBI
927440|NCT02383472|LED
927441|NCT02383472|Light Emitting Diode
927442|NCT02383472|Headache
927443|NCT02383472|Brain Concussion
927444|NCT02383446|Echeclon
927445|NCT02383446|Elan
927446|NCT02383446|TTA
927447|NCT02383446|Transtibial Amputee
927448|NCT02383394|second trimesteric pregnancy loss
927449|NCT02383368|Pharmacokinetics
927450|NCT02383368|ASP4132
927451|NCT02383368|Lymphoma
927452|NCT02383368|Refractory Solid Tumors
927453|NCT02383355|Persistent immune activation
927454|NCT02383355|Platelet hyperreactivity
927455|NCT02383342|Pain Processing
927456|NCT02383342|Genetic Factors
927457|NCT02383342|Biomarkers
927458|NCT02383329|malnutrition
927459|NCT02383329|Underweight
927460|NCT02383329|Oral Nutrition Supplements
927461|NCT02383329|Children
927462|NCT02383316|Insulin sensitivity
927463|NCT02383316|Metabolism
927464|NCT02383316|Noonan syndrome
927465|NCT02383316|Shp2
927466|NCT02383303|savings
927467|NCT02383303|assets
927468|NCT02383303|material hardship
927469|NCT02383303|poverty
927470|NCT02383303|Individual Development Account
927471|NCT02383264|feeding intolerance
927472|NCT02383264|preterm infants
927473|NCT02383264|near infrared spectroscopy
927474|NCT02383238|Dapagliflozin
927475|NCT02383238|diabetes mellitus
927476|NCT02383238|vascular
927477|NCT02383225|American Indian
927478|NCT02383225|Adolescent
927479|NCT02383225|Prevention
927480|NCT02383212|Advanced cancerous growth
927484|NCT02383160|low-intensity pulsed ultrasound
927485|NCT02383160|nonunion
927486|NCT02383160|scaphoid
927487|NCT02383147|Adult
927488|NCT02383147|Aged
927489|NCT02383147|Alpha Rhythm
927490|NCT02383147|Auditory Cortex
927491|NCT02383147|Chronic
927492|NCT02383147|Electroencephalography
927493|NCT02383147|Female
927494|NCT02383147|Humans
927495|NCT02383147|Male
927496|NCT02383147|Neurofeedback
927497|NCT02383147|Prospective Studies
927498|NCT02383147|Questionnaires
927499|NCT02383147|Tinnitus
927500|NCT02383147|Treatment Outcome
927501|NCT02383095|Schizophrenia
927502|NCT02383095|Art-therapy
927503|NCT02383095|Visual organization
927504|NCT02383069|Pulmonary rehabilitation
927505|NCT02383069|Asthma
927506|NCT02383069|Children
927507|NCT02383069|Teenager
927508|NCT02383069|Physical capacity
927509|NCT02383056|wound
927510|NCT02383056|secondary intention healing
927511|NCT02383056|lower extremity
927512|NCT02383030|Breast cancer
927513|NCT02383030|Metastatic
927514|NCT02383030|HER2 negative
927515|NCT02383030|postmenopausal
927516|NCT02383030|maintenance therapy
927517|NCT02383030|fulvestrant
927518|NCT02383017|Multi-ingredient performance supplement, High Intensity Interval Training, Concurrent training
927519|NCT02383004|myringotomy tubes
927520|NCT02383004|acupuncture
927521|NCT02383004|emergence delirium
927522|NCT02383004|pediatrics
927523|NCT02383004|general anesthesia
927524|NCT02382991|Moderately active amputees
927525|NCT02382991|C-leg Compact
927526|NCT02382991|Knee prosthesis
927527|NCT02382991|Kenevo
927528|NCT02382991|Microprocessor controlled knee
927529|NCT02382991|Amputation
927530|NCT02382991|3C60
927531|NCT02382991|TGUG
927532|NCT02382991|LCI
927533|NCT02382991|QUEST
927534|NCT02382991|SF-36
927535|NCT02382952|Abdominal surgery
927536|NCT02382952|Pelvic surgery
927537|NCT02382952|Stoma takedown
927538|NCT02382952|Bowel resection
927539|NCT02382952|Lysis of abdominal adhesions
927540|NCT02382926|capacitive electrocardiography
927541|NCT02382926|Eulerian Magnification Method
927542|NCT02382900|quadrivalent
927543|NCT02382900|vaccine
927544|NCT02382887|intubation
927545|NCT02382887|difficult airway
927546|NCT02382887|fiberscopy
927547|NCT02382887|Airtraq
927548|NCT02382887|general anesthesia
927549|NCT02382874|Idiopathic nephrotic syndrome
927677|NCT02382055|Treatment
927550|NCT02382874|adipose derived mesenchymal stromal cell
927551|NCT02382874|Focal segmental glomerulosclerosis
927552|NCT02382861|Neurally adjusted ventilatory assist
927553|NCT02382861|Weaning
927554|NCT02382861|Mechanical ventilation
927555|NCT02382861|Extubation
927556|NCT02382848|Eating Disorders
927557|NCT02382848|Bulimia Nervosa
927558|NCT02382848|Nightmares
927559|NCT02382848|Post Traumatic Stress Disorder
927560|NCT02382835|metal-on-metal
927561|NCT02382809|Alveolar osteitis
927562|NCT02382809|Third molar
927563|NCT02382809|Dry socket
927564|NCT02382809|Mouthwash
927565|NCT02382809|third molar extraction
927566|NCT02382783|Rheumatoid Arthritis
927567|NCT02382783|Disease Activity
927568|NCT02382783|Flare
927569|NCT02382783|Management of Flares
927570|NCT02382783|Pfizer
927571|NCT02382744|Saphenous Nerve
927572|NCT02382744|Nerve Block
927573|NCT02382744|Ultrasound guided
927574|NCT02382744|Neurostimulation
927575|NCT02382744|Regional Anesthesia
927576|NCT02382744|Ropivacaine
927577|NCT02382744|Foot Surgery
927578|NCT02382744|Nerve Stimulation
927579|NCT02382744|Ankle Surgery
927580|NCT02382718|fish allergy
927581|NCT02382718|parvalbumin
927582|NCT02382718|immunotherapy
927583|NCT02382718|mCyp c 1
927584|NCT02382705|capsule endoscopy
927585|NCT02382705|battery life
927586|NCT02382705|completion rate
927587|NCT02382705|diagnostic yield
927588|NCT02382640|Drug therapy
927589|NCT02382614|Endobronchial Valve
927590|NCT02382614|Minimally Invasive
927591|NCT02382614|Intrabronchial Valves
927592|NCT02382614|Digital Thoracic Drainage System
927593|NCT02382614|Spiration Valve System
927594|NCT02382614|Prolonged Air Leak
927595|NCT02382614|Persistent Air Leak
927596|NCT02382601|Pregnancy
927597|NCT02382601|IUGR
927598|NCT02382601|Small for gestational age
927599|NCT02382562|Depression
927600|NCT02382562|Asthma
927601|NCT02382562|Urticaria
927602|NCT02382549|vaccine
927603|NCT02382549|peptide
927604|NCT02382549|dabrafenib
927605|NCT02382549|trametinib
927606|NCT02382549|Montanide ISA-51
927607|NCT02382549|MEKINIST
927608|NCT02382549|Tafinlar
927609|NCT02382536|Diabetes
927610|NCT02382536|Insulin therapy
927611|NCT02382536|insulin pump
927612|NCT02382536|Infusion sets
927613|NCT02382523|acthar
927614|NCT02382523|proteinuria
927615|NCT02382523|IgA nephropathy
927616|NCT02382484|Hypertension Resistant to Conventional Therapy
927617|NCT02382471|atherosclerotic
927618|NCT02382471|BDNF
927619|NCT02382471|Follistatin
927620|NCT02382471|Irisin
927621|NCT02382432|Anesthesia
927622|NCT02382432|dexmedetomidine
927623|NCT02382432|pethidine
927624|NCT02382432|shivering
927625|NCT02382432|spinal
927626|NCT02382406|MK-3475
927627|NCT02382406|Pembrolizumab
927628|NCT02382406|Carboplatin
927629|NCT02382406|Nab-paclitaxel
927630|NCT02382393|cognitive assessment
927631|NCT02382393|Brain Performance Test
927632|NCT02382393|Lumosity
927633|NCT02382393|concurrent validity
927634|NCT02382393|computerized assessment
927635|NCT02382380|Magnetic Resonance Imaging
927636|NCT02382380|Contrast Agent
927637|NCT02382380|Gadoterate
927638|NCT02382341|ACL
927639|NCT02382341|BIOSURE
927640|NCT02382341|HEALICOIL
927641|NCT02382341|PEEK
927642|NCT02382341|In-Growth
927643|NCT02382315|fear of cancer recurrence
927644|NCT02382315|psychosocial intervention
927645|NCT02382315|randomized controlled clinical trial
927646|NCT02382302|U-health
927647|NCT02382302|chronic wound management
927648|NCT02382289|Radiofrequency
927649|NCT02382289|monopolar
927650|NCT02382289|bipolar
927651|NCT02382289|Sacroiliac Joint Arthropathy
927652|NCT02382289|three different modalities
927653|NCT02382263|Advanced pancreatic cancer
927654|NCT02382263|Fragile
927655|NCT02382263|Nab-paclitaxel
927656|NCT02382237|denutrition in Head and Neck cancer or oesophageal cancer
927657|NCT02382224|generalized anxiety disorder
927658|NCT02382224|anxiety
927659|NCT02382224|worry exposure
927660|NCT02382224|treatment
927661|NCT02382211|CMV
927662|NCT02382198|droooling, sialorrhea, parkinson's disease, parkinsons
927663|NCT02382185|Cardiac output
927664|NCT02382120|carbon dioxide
927665|NCT02382120|cardiac output
927666|NCT02382120|ventilation
927667|NCT02382120|thermodilution
927668|NCT02382107|TB
927669|NCT02382107|Tuberculosis
927670|NCT02382107|Diagnostic study
927671|NCT02382094|curative intention
927672|NCT02382094|radiation Therapy
927673|NCT02382094|health related quality of life
927674|NCT02382055|Eating Disorders
927675|NCT02382055|Psychotherapy
927676|NCT02382055|Anorexia Nervosa
927678|NCT02382042|Rural Health
927679|NCT02382042|Veterans
927680|NCT02382042|Substance Abuse
927681|NCT02382003|Anxiety
927682|NCT02382003|Cognitive bias
927683|NCT02382003|Telemedicine
927684|NCT02381990|Prostate
927685|NCT02381990|PSA
927686|NCT02381990|FUSION
927687|NCT02381990|Ultrasound
927688|NCT02381990|MRI
927689|NCT02381990|Cancer
927690|NCT02381990|Cryotherapy
927691|NCT02381990|Outcomes
927692|NCT02381990|Recurrence
927693|NCT02381990|QOL, Quality of Life
927694|NCT02381990|Urinary function
927695|NCT02381990|Sexual Function
927696|NCT02381964|cerebral blood flow
927697|NCT02381964|cognitive function
927698|NCT02381964|vitamins
927699|NCT02381964|energy expenditure
927700|NCT02381964|NIRS
927701|NCT02381964|Indirect calorimetry
927702|NCT02381938|inactivity
927703|NCT02381938|behavior change
927704|NCT02381938|worksite wellness
927705|NCT02381938|child care
927706|NCT02381925|CT
927707|NCT02381925|Scintigraphy
927708|NCT02381925|Ultrasound
927709|NCT02381899|chronic lymphocytic leukemia
927710|NCT02381899|bendamustine
927711|NCT02381899|rituximab
927712|NCT02381886|IDHR132 mutations
927713|NCT02381886|IDH305
927714|NCT02381886|IDH
927715|NCT02381886|IDH1
927716|NCT02381886|AML
927717|NCT02381886|Acute Myeloid Leukemia
927718|NCT02381886|Leukemia
927719|NCT02381886|Myeloid
927720|NCT02381886|Acute
927721|NCT02381886|MDS
927722|NCT02381886|Myelodysplastic Syndrome
927723|NCT02381886|Glioma
927724|NCT02381886|Oligodendroglioma
927725|NCT02381886|Astrocytoma
927726|NCT02381886|Glioblastoma
927727|NCT02381886|Cholangiocarcinoma
927728|NCT02381886|Solid Tumors
927729|NCT02381873|Arthroplasty
927730|NCT02381873|Replacement
927731|NCT02381873|Knee
927732|NCT02381873|Osteoarthritis
927733|NCT02381847|gastric cancer
927734|NCT02381847|intraperitoneal chemoperfusion
927735|NCT02381834|Urine Specimen Collection
927736|NCT02381834|Infant
927737|NCT02381834|Neonate
927738|NCT02381834|Bacterial Infection
927739|NCT02381821|junctional zone
927740|NCT02381821|Implantation
927741|NCT02381821|Intracytoplasmic sperm injection
927742|NCT02381717|ultrasound
927743|NCT02381717|bupivacaine
927744|NCT02381717|femoral nerve block
927745|NCT02381717|pain reduction
927746|NCT02381678|Heart Valve Replacement
927747|NCT02381678|Perimount 2900
927748|NCT02381678|China
927749|NCT02381678|Perimount 6900P
927750|NCT02381626|HEPA filter
927751|NCT02381626|14-247
927752|NCT02381613|Fish
927753|NCT02381613|Herring
927754|NCT02381613|Meat
927755|NCT02381613|Beef
927756|NCT02381600|vitamin D
927757|NCT02381600|aging
927758|NCT02381600|cognitive function
927759|NCT02381600|depression
927760|NCT02381600|executive function
927761|NCT02381574|Lumbar Total Disk Replacement
927762|NCT02381522|remote ischemic preconditioning
927763|NCT02381509|inferior vena cava filters
927764|NCT02381496|ACT-453859
927765|NCT02381496|ACT-463036
927766|NCT02381496|Setipiprant
927767|NCT02381496|Tolerability
927768|NCT02381496|safety
927769|NCT02381496|pharmacodynamics
927770|NCT02381496|pharmacokinetics
927771|NCT02381457|Microdeletion Syndrome
927772|NCT02381457|Aneuploidy
927773|NCT02381457|22q
927774|NCT02381457|Non-Invasive Prenatal Screening
927775|NCT02381457|DiGeorge Syndrome
927776|NCT02381444|Quality of life
927777|NCT02381444|Jejunal Percutaneous Endoscopic Gastrostomy
927778|NCT02381444|Observational Study
927779|NCT02381444|Levodopa Carbidopa Intestinal Gel
927780|NCT02381444|Advanced Parkinson's Disease
927781|NCT02381431|imaging
927782|NCT02381431|diagnostic
927783|NCT02381431|pediatrics
927784|NCT02381418|Influenza
927785|NCT02381418|Vaccine
927786|NCT02381418|Committee for Medicinal Products for Human Use (CHMP) criteria
927787|NCT02381392|emergency medicine
927788|NCT02381392|infrared
927789|NCT02381392|intravenous
927790|NCT02381379|CML
927791|NCT02381379|peginterferon
927792|NCT02381379|stop
927793|NCT02381379|BCR-ABL
927794|NCT02381366|Mesenchymal Stem Cells
927795|NCT02381366|Human Umbilical Cord Blood
927796|NCT02381366|Premature Infants
927797|NCT02381366|Bronchopulmonary Dysplasia
927798|NCT02381366|Chronic Lung Disease
927799|NCT02381366|Cell Therapy
927800|NCT02381353|Enucleation
927801|NCT02381353|Evisceration
927802|NCT02381353|Exparel
927803|NCT02381353|bupivacaine
927804|NCT02381340|Obesity
927805|NCT02381340|Bariatric surgery
927806|NCT02381340|Gastric plication
927807|NCT02381340|Minimal invasive surgery
927808|NCT02381340|gastrointestinal hormones
927809|NCT02381340|food-reward
927810|NCT02381340|satiety
927811|NCT02381340|microbiota
927812|NCT02381327|Speed of eating
927813|NCT02381327|body weight
927814|NCT02381327|food intake
927815|NCT02381314|Other B7-H3 expressing cancers
927816|NCT02381301|Biological Markers
927817|NCT02381301|Multidetector Computed Tomography
927818|NCT02381288|Drug therapy
927819|NCT02381262|Fitbit
927820|NCT02381249|Esophagectomy
927821|NCT02381249|Gastrectomy
927822|NCT02381249|Octreotide
927823|NCT02381249|Somatostatin
927824|NCT02381249|Appetite
927825|NCT02381249|Hunger
927826|NCT02381249|Glucagon-Like Peptide 1
927827|NCT02381249|Peptide YY
927828|NCT02381249|Reinforcement
927829|NCT02381249|Reward
927830|NCT02381249|Psychological Phenomena and Processes
927831|NCT02381249|Gastrointestinal Agents
927832|NCT02381249|Nutritional Status
927833|NCT02381249|Pancreaticoduodenectomy
927834|NCT02381249|Whipple Procedure
927835|NCT02381210|Congo Red Dot Test
927836|NCT02381197|Congo Red Dot Test
927837|NCT02381171|myofacial pain
927838|NCT02381171|neuromodulation
927839|NCT02381171|repetitive transcranial magnetic stimulation
927840|NCT02381171|electroacupuncture
927841|NCT02381158|Wheezing
927842|NCT02381158|Children
927843|NCT02381145|Polyphenols
927844|NCT02381145|Resveratrol
927845|NCT02381145|Epigallocatechin-gallate
927846|NCT02381145|Insulin sensitivity
927847|NCT02381145|mitochondrial function
927848|NCT02381145|lipid oxidation
927849|NCT02381145|tissue lipolysis
927850|NCT02381119|dietary services
927851|NCT02381119|personalized advice
927852|NCT02381119|biological markers
927853|NCT02381106|arterial contractility
927854|NCT02381106|Uterine contractility
927855|NCT02381080|B-Cell Chronic Lymphocytic Leukemia
927856|NCT02381080|Chronic Lymphocytic Leukemia
927857|NCT02381080|Small Lymphocytic Lymphoma
927858|NCT02381080|Marginal Zone Lymphoma
927859|NCT02381080|Mantle Cell Lymphoma
927860|NCT02381080|Follicular Lymphoma
927861|NCT02381080|Waldenstrom's Macroglobulinemia
927862|NCT02381080|Ibrutinib
927863|NCT02381080|IMBRUVICA
927864|NCT02381080|PCI-32765
927865|NCT02381080|JNJ-54179060
927866|NCT02381067|Cervical Fusion
927867|NCT02381067|NuCel
927868|NCT02381067|Amniotic Allograft
927869|NCT02381067|Prospective
927871|NCT02381041|Rhinoplasty
927872|NCT02381041|Topical Vasonconstrictor
927873|NCT02381041|Cocaine
927874|NCT02381041|Adrenaline
927875|NCT02381028|Atopic eczema
927876|NCT02381028|Human milk
927877|NCT02381028|Topical treatment
927878|NCT02381028|Children
927879|NCT02381015|Genetic testing
927880|NCT02381015|Genomic testing
927881|NCT02381015|Chemoprevention
927882|NCT02381015|Prostate Specific Antigen
927883|NCT02381015|Prostate Cancer
927884|NCT02381015|Predictive Genetic Testing
927885|NCT02381015|Genetic Counseling
927886|NCT02381015|Prostate-Specific Antigen
927887|NCT02381002|Serum ferritin, physical exercise, Diet
927888|NCT02380989|Ayurveda
927889|NCT02380989|Acute pain
927890|NCT02380989|Sports Injury
927891|NCT02380963|Soy
927892|NCT02380963|Obesity
927893|NCT02380963|Weight Loss
927894|NCT02380963|Muscle
927895|NCT02380963|Cardiovascular Disease
927896|NCT02380963|Colorado Diet
927897|NCT02380937|real-time MRI
927898|NCT02380937|electrophysiology study
927899|NCT02380937|atrial flutter
927900|NCT02380937|ablation
927901|NCT02380937|active tracking
927902|NCT02380924|subjects
927903|NCT02380911|Dyslipidemia
927904|NCT02380911|Global cardiovascular risk
927905|NCT02380911|Statins
927906|NCT02380911|Educational interventions
927907|NCT02380885|severe mental illness
927908|NCT02380885|social cognition
927909|NCT02380885|intervention
927910|NCT02380872|Gingival recession
927911|NCT02380872|fibrin
927912|NCT02380872|connective tissue
927913|NCT02380872|gingival crevicular fluid
927914|NCT02380872|matrix metalloproteinase
927915|NCT02380872|cytokine
927916|NCT02380859|problems of gait and balance
927917|NCT02380820|Mattress
927918|NCT02380820|Preventing bed sores
927919|NCT02380820|Skin pressure
927920|NCT02380807|Paraspinal Muscles
927921|NCT02380807|Trigger Points
927922|NCT02380807|Randomized Controlled Trial
927923|NCT02380807|Mobility Limitation
927924|NCT02380794|Danshen Gegen Capsule
927925|NCT02380768|Supraglottic airway
927926|NCT02380768|Laryngeal mask airway
927927|NCT02380768|Children
927928|NCT02380755|Flow-mediated dilatation
927929|NCT02380755|Clomiphene citrate
927930|NCT02380755|sICAM-1
927931|NCT02380755|sVCAM-1
927932|NCT02380755|sE- Selectin
927933|NCT02380755|Endothelial function
927934|NCT02380755|Cardiovascular risk
927935|NCT02380755|Endocrine System Diseases
927936|NCT02380755|Selective Estrogen Receptor Modulators
927937|NCT02380755|Estrogen Receptor Modulators
927938|NCT02380755|Infertility, Male
927939|NCT02380755|Endothelial Progenitor Cells
927940|NCT02380755|Obesity
927941|NCT02380755|Testosterone
927942|NCT02380742|Pessary
927943|NCT02380742|Pain
927944|NCT02380742|EMLA
927945|NCT02380742|lidocaine
927946|NCT02380742|prilocaine
927947|NCT02380729|Health care delivery
927948|NCT02380729|Human Phenotype Ontology
927949|NCT02380729|Mutation prioritization
927950|NCT02380729|Next Generation Sequencing
927951|NCT02380729|Mutation detection
927952|NCT02380729|Bioinformatic analysis
927953|NCT02380729|Quality of life
927954|NCT02380703|aggression
927955|NCT02380703|dementia
927956|NCT02380703|Alzheimer's disease
927957|NCT02380703|pain
927958|NCT02380703|depression
927959|NCT02380703|caregiver
927960|NCT02380703|behavioral health
927961|NCT02380703|counseling
927962|NCT02380690|self-management
927963|NCT02380690|peer support
927964|NCT02380690|social support
927965|NCT02380664|swimmers
927966|NCT02380664|adolescent swimmers
927967|NCT02380664|whole-body vibration
927968|NCT02380664|bone and bones
927969|NCT02380664|body composition
927970|NCT02380625|Ebola
927971|NCT02380625|EVD
927972|NCT02380625|Adaptive design
927973|NCT02380625|therapeutics
927974|NCT02380612|Second Degree Burn Injuries
927975|NCT02380599|Spinal Manipulation
927976|NCT02380599|Mobilization
927977|NCT02380599|Autonomic Nervous System
927978|NCT02380573|methylene blue
927979|NCT02380573|fMRI
927980|NCT02380560|myometrial thickness
927981|NCT02380560|Preterm premature rupture of membranes
927982|NCT02380560|Preterm Labour
927983|NCT02380547|Sonography
927984|NCT02380547|Diaphragmatic function
927985|NCT02380547|Non invasive ventilation
927986|NCT02380547|Critical care patients
927987|NCT02380547|Extubation after 24 hours of invasive ventilation
927988|NCT02380534|High level of Lp(a)
927989|NCT02380521|Exenatide once weekly
927990|NCT02380521|T2DM
927991|NCT02380521|IMT
927992|NCT02380521|Atherogenic lipoproteins
927993|NCT02380508|BCG study
927994|NCT02380495|Adolescents
927995|NCT02380495|Respiratory Pathology
927996|NCT02380482|Traumatic brain injury
927997|NCT02380482|Myocardial dysfunction
927998|NCT02380482|Transthoracic echocardiography
927999|NCT02380482|Speckle tracking
928000|NCT02380469|Caregivers
928001|NCT02380469|Cancer
928002|NCT02380469|Information
928003|NCT02380469|Intervention
928004|NCT02380469|Randomised trial
928005|NCT02380443|colorectal cancer
928006|NCT02380443|KRAS mutant
928007|NCT02380443|BRAF mutant
928008|NCT02380443|metastatic
928009|NCT02380443|liver metastasis
928010|NCT02380443|AlloStim®
928011|NCT02380443|cryoablation
928012|NCT02380443|cancer vaccine
928013|NCT02380443|immunotherapy
928014|NCT02380430|Ambulatory surgery
928015|NCT02380430|Pain management
928016|NCT02380430|Nausea and vomiting management
928017|NCT02380430|Questionnaire
928018|NCT02380430|Survey
928019|NCT02380430|Management
928020|NCT02380404|Edentulous maxilla
928021|NCT02380391|Platelet reactivity
928022|NCT02380391|Acute coronary syndrome
928023|NCT02380391|Antiplatelet treatment
928024|NCT02380391|Antiretroviral treatment
928025|NCT02380391|HIV
928026|NCT02380365|lung transplantation
928027|NCT02380365|electrocardiography
928028|NCT02380365|macrolides
928029|NCT02380365|QTc interval
928030|NCT02380365|arrhythmia
928031|NCT02380352|antibiotic stewardship
928032|NCT02380352|non-inferiority
928033|NCT02380352|randomized controlled trial
928034|NCT02380313|Metastatic Castration-Resistant Prostate Cancer
928035|NCT02380313|Enzalutamide
928036|NCT02380313|Abiraterone
928037|NCT02380313|Dose-Finding
928038|NCT02380313|Afuresertib
928039|NCT02380287|interleukin-17
928040|NCT02380287|maximum tolerated dose
928041|NCT02380287|novel monoclonal antibody
928045|NCT02380222|Systemic mastocytosis
928046|NCT02380222|Patient-reported outcome (PRO)
928047|NCT02380209|breast cancer
928048|NCT02380209|CEST MRI
928049|NCT02380183|anesthesia
928050|NCT02380183|nerve block
928051|NCT02380183|needle guidance
928052|NCT02380170|sepsis
928053|NCT02380170|urinary tract infection
928054|NCT02380170|resistance
928055|NCT02380170|pathogens
928056|NCT02380170|mortality
928057|NCT02380170|health economics
928058|NCT02380157|Blood pressure
928059|NCT02380157|Potassium, Dietary
928060|NCT02380157|Renin-angiotensin-aldosterone system
928061|NCT02380157|Sympathetic nervous system
928062|NCT02380144|carotenoid
928063|NCT02380144|bioavailability
928064|NCT02380144|beta-cryptoxanthin
928065|NCT02380144|flavonoid
928066|NCT02380144|hesperidin
928067|NCT02380144|narirutin
928068|NCT02380144|randomized cross-over
928069|NCT02380144|Pharmacokinetics
928070|NCT02380144|micronutrients
928071|NCT02380144|Oranges/Orange Juice
928072|NCT02380131|XELOX
928073|NCT02380131|Herceptin
928074|NCT02380131|Potentially Resectable Gastric Cancer
928075|NCT02380118|emergency
928076|NCT02380118|emergency medicine
928077|NCT02380118|sedation
928078|NCT02380118|acute agitation
928079|NCT02380092|Knee
928080|NCT02380092|Post-Market Surveillance
928081|NCT02380092|Legion
928082|NCT02380092|Verilast
928083|NCT02380092|Degenerative Joint Disease
928084|NCT02380079|Homozygous Sickle Cell Disease S/Beta 0 Thalassemia
928085|NCT02380053|Beta-blocker
928086|NCT02380053|Cardiopulmonary exercise testing
928087|NCT02380027|Prostate biopsy
928088|NCT02380027|MRI
928089|NCT02380027|transrectal
928090|NCT02380027|Detection
928091|NCT02380001|Postoperative pain
928092|NCT02380001|Dexketoprofen trometamol
928093|NCT02380001|third molar surgery
928094|NCT02379962|biobanking
928095|NCT02379962|research participation
928096|NCT02379962|China
928097|NCT02379949|virtual reality exposure therapy
928098|NCT02379949|social phobia
928099|NCT02379949|social anxiety disorder
928100|NCT02379949|cognitive behavioral therapy
928101|NCT02379936|Classification
928102|NCT02379936|HIE
928103|NCT02379936|Infections
928104|NCT02379936|Lactate dehydrogenase
928105|NCT02379936|Intensive Care
928106|NCT02379884|Mechanical ventilation
928107|NCT02379884|Elderly
928108|NCT02379884|Mortality
928109|NCT02379884|Health services
928110|NCT02379871|Thoracic Spinal Manipulation, Autonomic Nervous System
928111|NCT02379858|GI tract recovery
928112|NCT02379858|hospital discharge
928113|NCT02379832|preeclampsia
928114|NCT02379832|preterm birth
928115|NCT02379832|pregnancy
928116|NCT02379832|placenta
928117|NCT02379832|intra-uterine growth restriction
928118|NCT02379832|fetal growth restriction
928119|NCT02379832|ultrasound
928120|NCT02379832|doppler
928121|NCT02379832|biomarkers
928122|NCT02379832|serum
928123|NCT02379832|PAPP-A
928124|NCT02379832|PlGF
928125|NCT02379832|sFlt-1
928126|NCT02379832|endoglin
928127|NCT02379793|LEO 80185 gel
928128|NCT02379793|calcipotriol
928129|NCT02379793|betamethasone
928130|NCT02379754|vestibular schwannoma
928131|NCT02379754|acoustic neuroma
928132|NCT02379754|cerebellopontine angle tumour
928133|NCT02379754|gentamicin
928134|NCT02379754|rehabilitation
928135|NCT02379754|postural balance
928136|NCT02379741|Antibodies
928137|NCT02379741|Antibodies, Monoclonal
928138|NCT02379741|Antineoplastic agent
928139|NCT02379741|Physiological effects of drugs
928140|NCT02379741|Therapeutic uses
928141|NCT02379741|Clinical Trial, Phase I
928142|NCT02379741|Immunotherapy, Active
928143|NCT02379741|CD40 Antigen
928144|NCT02379741|Immunologic Factors
928145|NCT02379741|Injections, Intralesional
928146|NCT02379728|positional therapy
928147|NCT02379728|tennis ball technique
928148|NCT02379728|sleep pregnancy
928149|NCT02379728|supine position
928150|NCT02379728|supine
928151|NCT02379728|sleep position
928152|NCT02379728|low birth weight
928153|NCT02379728|stillbirth
928154|NCT02379728|intrauterine growth restriction
928155|NCT02379715|Remifentanil
928156|NCT02379715|smooth induction
928157|NCT02379715|desflurane
928158|NCT02379689|psychosocial state
928159|NCT02379637|N-acetylcysteine
928160|NCT02379637|adults
928161|NCT02379637|cough and cold
928162|NCT02379572|5-ALA
928163|NCT02379572|Intraoperative MRI
928164|NCT02379572|Extent of resection
928165|NCT02379559|prostate cancer
928166|NCT02379559|African-American
928167|NCT02379559|Metabolic Syndrome
928168|NCT02379559|Exercise
928169|NCT02379559|Men's Health
928170|NCT02379546|reflex, oculocardiac
928171|NCT02379546|monitoring, intraoperative
928172|NCT02379520|recurrent cancer
928173|NCT02379520|refractory cancer
928174|NCT02379520|virus specific T-cells
928175|NCT02379520|gene therapy
928176|NCT02379520|HPV
928177|NCT02379507|mild to moderate
928178|NCT02379468|Diabetic
928179|NCT02379468|Foot
928180|NCT02379468|Ulcer
928181|NCT02379455|Polypharmacy
928182|NCT02379455|Geriatrics
928183|NCT02379455|Elderly
928184|NCT02379455|Drug review
928185|NCT02379442|Graft-Versus-Host Disease
928186|NCT02379442|Corticosteroids
928187|NCT02379442|Mesenchymal Stromal Cell
928188|NCT02379442|Adoptive Cellular Therapy
928189|NCT02379429|Specimen Collection
928190|NCT02379429|Urine
928191|NCT02379429|Blood
928192|NCT02379429|Saliva
928193|NCT02379416|Drug Efflux
928194|NCT02379416|Taxanes
928195|NCT02379416|Combination
928196|NCT02379416|Bcr-Abl Kinase Inhibitors
928197|NCT02379416|Neoplasms
928198|NCT02379403|Flavonoid
928199|NCT02379403|Vascular
928200|NCT02379403|Biomarkers
928201|NCT02379403|Arterial Stiffness
928202|NCT02379403|Nutrigenomics
928203|NCT02379364|Physiotherapy
928204|NCT02379364|Patellofemoral Pain Syndrome
928205|NCT02379364|Manual therapy
928206|NCT02379351|Non-stress Test
928207|NCT02379351|Fetal Monitoring
928208|NCT02379351|Telemedicine
928209|NCT02379338|Dopamine D3 receptor
928210|NCT02379312|Foams
928211|NCT02379312|Satiety
928212|NCT02379312|Appetite
928213|NCT02379247|HER-2 Negative
928214|NCT02379247|Metastatic Breast Cancer
928215|NCT02379234|CVVH
928216|NCT02379234|Renal replacement therapy
928217|NCT02379234|High fidelity simulation
928218|NCT02379234|Nurse training
928219|NCT02379208|Visual Field Tests
928220|NCT02379208|Ocular Hypertension
928221|NCT02379208|Glaucoma, Open-Angle
928222|NCT02379208|Quality of Life
928223|NCT02379208|Glaucoma progression
928224|NCT02379208|Early glaucoma
928225|NCT02379208|Frequency Doubling Technology (FDT)
928226|NCT02379208|RareBit
928227|NCT02379208|Octopus 900 perimetry
928228|NCT02379182|dysphagia
928229|NCT02379182|VitalStim
928230|NCT02379182|electrical stimulation
928231|NCT02379169|macular pigment optical density, age related macular degeneration, dry eye, vision
928232|NCT02379156|Quadriplegia
928233|NCT02379156|Spinal Cord Injury
928234|NCT02379156|Body Temperature Regulation
928235|NCT02379156|Mild Cognitive Impairment
928236|NCT02379143|SWD, EPA, SAFE PRACTICE
928237|NCT02379130|Premature
928238|NCT02379130|Family Nurture Intervention
928239|NCT02379091|Drug therapy
928240|NCT02379078|Shared decision-making
928241|NCT02379078|Priority setting
928242|NCT02379078|Patient decision aid
928243|NCT02379078|Interprofessional care
928244|NCT02379078|Diabetes mellitus
928245|NCT02379078|Patient education
928246|NCT02379078|Medical informatics
928247|NCT02379078|Toolkit development
928248|NCT02379078|Study protocol
928249|NCT02379078|User-centred design
928250|NCT02379078|Qualitative methods
928251|NCT02379013|Fatigue
928252|NCT02379013|functional MRI
928253|NCT02378987|cerebral palsy
928254|NCT02378987|language
928255|NCT02378987|acoustic
928256|NCT02378987|motor speech
928257|NCT02378987|follow-up
928258|NCT02378974|Cerebral Infarction
928259|NCT02378974|Mesenchymal Stem Cells
928260|NCT02378974|Stroke
928261|NCT02378948|Esophagectomy
928262|NCT02378948|Nutrition
928263|NCT02378948|Oral feeding
928264|NCT02378948|Enteral feeding
928265|NCT02378948|Pulmonary complications
928266|NCT02378948|Anastomotic leakage
928267|NCT02378948|Quality of life
928268|NCT02378896|Cognitive Behavioral Therapy
928269|NCT02378883|Apollo
928270|NCT02378883|Onyx
928271|NCT02378883|arteriovenous malformation
928272|NCT02378883|AVM
928273|NCT02378883|Onyx™ Liquid Embolic System
928274|NCT02378883|Apollo™ Onyx™ Delivery Micro Catheter
928275|NCT02378883|Brain Diseases
928276|NCT02378870|CRPC
928277|NCT02378857|Univentricular heart defect
928278|NCT02378857|Fontan circulation
928279|NCT02378831|diagnosing sleep
928280|NCT02378818|Schizophrenia
928281|NCT02378818|Negative symptoms
928282|NCT02378818|Lack of motivation
928283|NCT02378818|Cognitive characterization
928284|NCT02378818|Computational psychiatry
928285|NCT02378818|Depression
928286|NCT02378805|Alport syndrome
928287|NCT02378805|thin basement membrane disease
928288|NCT02378805|familial benign hematuria
928289|NCT02378792|PINS VNS Refractory Epilepsy
928290|NCT02378779|Premature ejaculation
928291|NCT02378779|general practice
928292|NCT02378779|sexual dysfunction
928293|NCT02378766|tailored web-based intervention
928294|NCT02378766|health behavior
928295|NCT02378766|hiv comorbidities
928296|NCT02378766|online trial
928297|NCT02378753|Ebola
928298|NCT02378753|Sierra Leone
928299|NCT02378753|vaccine
928300|NCT02378753|rVSVΔG-ZEBOV
928301|NCT02378740|Anesthesia
928302|NCT02378740|Cervical Fusion
928303|NCT02378740|Quality of Recovery
928304|NCT02378740|Ketamine Infusion
928305|NCT02378714|Smoking Cessation
928306|NCT02378714|Major Depressive Disorder
928307|NCT02378714|Nicotine Dependence
928308|NCT02378714|Varenicline
928309|NCT02378714|Behavioral Activation Therapy
928310|NCT02378714|Cigarette Smoking
928311|NCT02378701|Leukemia
928312|NCT02378701|Myelodysplastic syndrome
928313|NCT02378701|MDS
928314|NCT02378701|Low- or intermediate-1-risk
928315|NCT02378701|Chronic Myelomonocytic Leukemia -1
928316|NCT02378701|CMML-1
928317|NCT02378701|Quality of Life in Myelodysplasia Scale
928318|NCT02378701|QUALMS-1
928319|NCT02378701|Anemia Subset of FACT
928320|NCT02378701|FACT-An
928321|NCT02378701|Questionnaires
928322|NCT02378701|Surveys
928323|NCT02378688|Crohn's Disease
928324|NCT02378675|Adipocytokines
928325|NCT02378662|Peritoneal Dialysis
928326|NCT02378662|End Stage Renal Disease
928327|NCT02378662|Anemia
928328|NCT02378649|Pulmonary Hypertension
928329|NCT02378623|paradoxical embolism
928330|NCT02378623|lead thrombus
928331|NCT02378623|ICD
928332|NCT02378623|Pacemaker
928333|NCT02378623|Cognitive decline
928334|NCT02378623|Stroke
928335|NCT02378623|TIA
928336|NCT02378597|Resiliency burnout stress
928337|NCT02378571|Medication adherence
928338|NCT02378571|Hospital readmissions
928339|NCT02378558|Breast Surgery
928340|NCT02378545|Sepsis
928341|NCT02378545|Hyperoxia
928342|NCT02378545|Sepsis Six
928343|NCT02378545|Oxygen delivery
928344|NCT02378532|Glioblastoma
928345|NCT02378532|Chloroquine
928346|NCT02378532|Autophagy
928347|NCT02378532|EGFRvIII
928348|NCT02378532|Radiotherapy
928349|NCT02378532|Temozolomide
928350|NCT02378519|Low back pain,
928351|NCT02378519|neck pain,
928352|NCT02378519|chronic pain
928353|NCT02378519|SSED
928354|NCT02378519|Pilot project
928355|NCT02378519|interactive web-based self-help programme
928356|NCT02378519|CBT-coaching
928357|NCT02378519|physiotherapy
928358|NCT02378493|Antibiogramme
928359|NCT02378493|Antibiofilmogramme
928360|NCT02378467|Cystic Fibrosis
928361|NCT02378467|Hypertonic Saline
928362|NCT02378467|Inhaled Saline
928363|NCT02378467|Digestive System Diseases
928364|NCT02378467|Genetic Diseases, Inborn
928365|NCT02378467|Lung Diseases
928366|NCT02378467|Pancreatic Diseases
928367|NCT02378467|Pathologic Processes
928368|NCT02378467|Respiratory Tract Diseases
928369|NCT02378454|Lung Clearance Index
928370|NCT02378454|Cystic Fibrosis
928371|NCT02378454|Multiple Breath Nitrogen Washout
928372|NCT02378441|volunteers
928373|NCT02378428|Neuroblastoma
928374|NCT02378415|Depression
928375|NCT02378402|Creatine
928376|NCT02378402|heart failure
928377|NCT02378402|lipid
928378|NCT02378402|MRS
928379|NCT02378402|myocardium
928380|NCT02378324|Attendance
928381|NCT02378324|Screening without fee
928382|NCT02378311|Bike
928383|NCT02378311|Bicycle
928384|NCT02378311|Scooter
928385|NCT02378311|Handlebar
928386|NCT02378285|recent lateral humeral epicondylitis
928387|NCT02378285|platelet-rich plasma
928388|NCT02378285|infiltration
928389|NCT02378285|tennis elbow
928390|NCT02378285|ultrasonography
928391|NCT02378272|Care Manager
928392|NCT02378272|Primary Care
928393|NCT02378272|Depressive symptoms
928394|NCT02378272|quality of life
928395|NCT02378272|return to work
928396|NCT02378246|Iodine
928397|NCT02378246|Double-Blind Method
928398|NCT02378246|Randomized Controlled Tria
928399|NCT02378246|Cognitive Development
928400|NCT02378233|Iodine
928401|NCT02378233|Double-Blind Method
928402|NCT02378233|Randomized Controlled Trial
928403|NCT02378220|Home Care Agencies
928404|NCT02378220|Home Health Care Agencies
928405|NCT02378220|Home Health Care Nursing
928406|NCT02378220|Home Health Nurses
928407|NCT02378220|CYP 2D6
928408|NCT02378220|CYP 2C9
928409|NCT02378220|CYP 2C19
928410|NCT02378220|CYP 3A4
928411|NCT02378220|CYP 3A5
928412|NCT02378194|in stage 3 or 4 steps
928413|NCT02378168|postconditioning
928414|NCT02378168|six month follow up
928415|NCT02378168|cardiac event
928416|NCT02378168|non-cardiac event
928417|NCT02378155|cardioversion
928418|NCT02378155|atrial fibrillation
928419|NCT02378129|Dentin Sensitivity
928420|NCT02378129|Dentin Desensitizing Agents
928421|NCT02378129|Glass Ionomer Cements
928422|NCT02378129|Randomized Controlled Trial
928423|NCT02378103|Aortic Dissection
928424|NCT02378103|Chinese XinJiang Province
928425|NCT02378077|Obesity
928426|NCT02378077|Insulin Resistance
928427|NCT02378064|Fluorodeoxyglucose F18
928428|NCT02378064|Positron-Emission Tomography and Computed Tomography
928429|NCT02378064|Plaque, Atherosclerotic
928430|NCT02378064|Renin-Angiotensin System
928431|NCT02378038|PNT2258
928432|NCT02378038|Richter's Transformation
928433|NCT02378038|NHL
928434|NCT02378038|Non-Hodgkin's Lymphoma
928435|NCT02378038|Lymphoma
928436|NCT02378038|DLBCL
928437|NCT02378038|Diffuse Large B-cell Lymphoma
928438|NCT02378038|Lymphoma, Large B-cell, Diffuse
928439|NCT02378038|Lymphoma, Non-Hodgkin
928440|NCT02378038|Lymphoma, B-cell
928441|NCT02378025|Chronic Pain
928442|NCT02378025|Veterans
928443|NCT02378025|Gulf War Illness
928444|NCT02377973|growth,
928445|NCT02377973|infancy,
928446|NCT02377973|children,
928447|NCT02377973|diet,
928448|NCT02377973|breastfeeding
928449|NCT02377973|complementary feeding
928450|NCT02377973|early life programming
928451|NCT02377973|tracking
928452|NCT02377973|physical activity
928453|NCT02377960|SMS
928454|NCT02377960|text message
928455|NCT02377960|mHealth
928456|NCT02377960|IMB
928457|NCT02377947|Lactulose Retention Enema
928458|NCT02377947|Hepatic Encephalopathy, Grade 3 or 4 West Haven Criteria
928459|NCT02377947|The Retro Study
928460|NCT02377934|Pulmonary Hypertension
928461|NCT02377934|Cardiac MRT
928462|NCT02377934|Radiotherapy
928463|NCT02377921|GNE Myopathy
928464|NCT02377921|GNEM
928465|NCT02377921|HIBM
928466|NCT02377921|Nonaka
928467|NCT02377921|Hereditary Inclusion Body Myopathy
928468|NCT02377921|DMRV
928469|NCT02377882|Intra-operative neuromonitoring
928470|NCT02377882|Neuromuscular blocking agent
928471|NCT02377882|Rocuronium
928472|NCT02377882|Thyroid surgery
928473|NCT02377856|acute hepatitis C
928474|NCT02377856|treatment
928475|NCT02377856|SVR
928476|NCT02377843|vaccine
928477|NCT02377843|physician training
928478|NCT02377843|adolescent health
928479|NCT02377817|positional therapy
928480|NCT02377817|tennis ball technique
928481|NCT02377817|sleep in pregnancy
928482|NCT02377817|supine
928483|NCT02377817|polysomnography
928484|NCT02377817|sleep position
928485|NCT02377817|supine position
928486|NCT02377804|dry needling
928487|NCT02377804|spasticity
928488|NCT02377804|pain
928489|NCT02377791|tacrolimus
928490|NCT02377791|Cytochrome P-450 CYP3A
928491|NCT02377791|Kidney transplant
928492|NCT02377791|FK506
928493|NCT02377791|Prograf
928494|NCT02377791|Rejection
928495|NCT02377791|Gene Polymorphism
928496|NCT02377765|Neuromodulation
928497|NCT02377765|Detrusor overactivity
928498|NCT02377765|Urinary urgency
928499|NCT02377765|Urgency urinary incontinence
928500|NCT02377726|Randomized Controlled Trial
928501|NCT02377726|Alcohol
928502|NCT02377726|Internet
928503|NCT02377726|Internet based therapy
928504|NCT02377726|Cognitive behavioral therapy
928505|NCT02377713|KHK6640
928506|NCT02377713|Phase 1
928507|NCT02377713|Japanese
928508|NCT02377713|single dose
928509|NCT02377713|Alzheimer's disease
928510|NCT02377687|Emergency surgery
928511|NCT02377687|HRQoL
928512|NCT02377687|Elderly
928513|NCT02377648|Cardiac Allograft Vasculopathy
928514|NCT02377648|Heart Transplant
928515|NCT02377648|Bioresorbable Vascular Scaffold
928516|NCT02377635|Arsenic
928517|NCT02377635|Arsenicosis
928518|NCT02377609|Dry Blood Spot (DBS)
928519|NCT02377609|Validation
928520|NCT02377609|Tacrolimus
928521|NCT02377609|Bioanalytical assay method cross-validation
928522|NCT02377596|Feeding
928523|NCT02377596|difficulties
928524|NCT02377596|disorders
928525|NCT02377596|childhood
928526|NCT02377596|eating
928527|NCT02377557|Dermatologic Agent
928528|NCT02377531|early glucose screen, perinatal outcome
928529|NCT02377505|Treatment-Resistant Schizophrenia
928530|NCT02377505|Deep Brain Stimulation
928531|NCT02377466|Spontaneous Preterm Labor
928532|NCT02377466|GSK221149
928533|NCT02377466|Retosiban
928534|NCT02377453|stroke
928535|NCT02377453|participation
928536|NCT02377453|brain imaging
928537|NCT02377453|biomechanical
928538|NCT02377440|ACE inhibitor
928539|NCT02377427|pharmacokinetics
928540|NCT02377427|pediatric
928541|NCT02377427|Mepolizumab
928542|NCT02377427|subcutaneous
928543|NCT02377427|eosinophilic asthma
928544|NCT02377427|pharmacodynamics
928545|NCT02377414|Preterm labor
928546|NCT02377414|Retosiban
928547|NCT02377414|Pharmacokinetics
928548|NCT02377414|Safety
928549|NCT02377414|Infusion
928550|NCT02377414|GSK2847065
928551|NCT02377401|healthy volunteer
928552|NCT02377401|Zanamivir
928553|NCT02377401|pharmacokinetics
928554|NCT02377401|intravenous
928555|NCT02377388|diabetes mellitus
928556|NCT02377388|platelet function testing
928557|NCT02377388|acute coronary syndromes
928558|NCT02377388|saxagliptin
928559|NCT02377375|Deep Brain Stimulation
928560|NCT02377375|OCD
928561|NCT02377336|GS-6615
928562|NCT02377336|coronary heart disease
928563|NCT02377336|angina pectoris
928564|NCT02377336|late sodium current
928565|NCT02377336|myocardial ischemia
928566|NCT02377336|coronary artery disease
928567|NCT02377336|chronic stable angina
928568|NCT02377323|Multiple Sclerosis
928569|NCT02377323|Patient-reported outcomes
928570|NCT02377323|Employment status
928571|NCT02377323|Quality of Life
928572|NCT02377323|Cognition
928573|NCT02377323|Rebif
928574|NCT02377297|dental atraumatic restorative treatment
928575|NCT02377297|primary tooth
928576|NCT02377297|occlusal restoration
928577|NCT02377297|glass-ionomer cement
928578|NCT02377271|Bosentan
928579|NCT02377245|Juvenile
928580|NCT02377245|Inflammatory
928581|NCT02377245|Rheumatism
928582|NCT02377245|Pediatric-Onset inflammatory diseases
928583|NCT02377206|PET
928584|NCT02377206|[18F]DPA-714
928585|NCT02377206|cognitive decline
928586|NCT02377193|kidney transplant
928587|NCT02377193|luminex method
928588|NCT02377193|simulect ATG
928589|NCT02377193|immunosuppression
928590|NCT02377180|musculoskeletal pain
928591|NCT02377180|regional anesthesia
928592|NCT02377180|diagnostic nerve block
928593|NCT02377180|intramuscular capsaicin
928594|NCT02377180|referred pain
928595|NCT02377180|hyperalgesia
928596|NCT02377180|experimental pain
928597|NCT02377180|central hypersensitivity
928598|NCT02377180|human experimental pain
928599|NCT02377154|keratometry
928600|NCT02377154|verion
928601|NCT02377154|iol
928602|NCT02377154|intraocular lens
928603|NCT02377154|iolmaster
928604|NCT02377154|lenstar
928605|NCT02377154|pentacam
928606|NCT02377154|IOL calculation
928607|NCT02377154|VERION Image Guided System
928608|NCT02377141|Oesophageal Variceal Bleed
928609|NCT02377141|TIPSS
928610|NCT02377141|Endoscopic Variceal Band Ligation
928611|NCT02377141|Decompensated Liver Disease
928612|NCT02377128|Study
928613|NCT02377128|focus
928614|NCT02377128|ovarian
928615|NCT02377128|reserve
928616|NCT02377115|Postoperative delirium
928617|NCT02377115|Postoperative cognitive decline
928618|NCT02377115|Postoperative cognitive dysfunction
928619|NCT02377115|Risk assessment
928620|NCT02377115|Tablet computer
928621|NCT02377115|Clinical screening tool
928622|NCT02377089|Trigeminal Nerve Stimulation
928623|NCT02377089|Post-Traumatic Stress Disorder
928624|NCT02377063|colonic flora
928625|NCT02377063|microbiomes
928626|NCT02377050|Nutritional support
928627|NCT02377037|Sitting
928628|NCT02377037|Standing
928629|NCT02377037|Transitions
928630|NCT02376998|Thoracic Aorta
928631|NCT02376998|Trauma
928632|NCT02376998|Endovascular
928633|NCT02376959|Anxiety
928634|NCT02376959|Complementary Therapies
928635|NCT02376959|energy therapies
928636|NCT02376933|vertebral bodies
928637|NCT02376933|vertebral fracture
928638|NCT02376933|vertebral augmentation
928639|NCT02376933|radiotherapy
928640|NCT02376933|vertebroplasty
928641|NCT02376933|kyphoplasty
928642|NCT02376920|occular melanoma
928643|NCT02376920|melanoma of eye
928644|NCT02376920|DecisionDx-UM
928645|NCT02376907|distal malignant biliary obstruction
928646|NCT02376907|endoscopic retrograde cholangiopancreatography
928647|NCT02376907|endoscopic ultrasound
928648|NCT02376907|gastric outlet obstruction
928649|NCT02376907|stent
928650|NCT02376881|Erythropoietin -Methanol - Optic Neuropathy
928651|NCT02376855|Health Services Accessibility
928652|NCT02376842|severe sepsis infection
928653|NCT02376829|Orthodontic
928654|NCT02376829|Orthodontic Treatment
928655|NCT02376829|Clear Aligners
928656|NCT02376829|Malocclusion
928657|NCT02376816|DMD
928658|NCT02376816|muscular dystrophy
928659|NCT02376816|dystrophin
928660|NCT02376803|Randomized controlled trial
928661|NCT02376803|Warfarin
928662|NCT02376803|Time in therapeutic range
928663|NCT02376803|Bleeding
928664|NCT02376803|Thromboembolic
928665|NCT02376803|Hemorrhage
928666|NCT02376803|Anticoagulant
928667|NCT02376803|TTR
928668|NCT02376803|Chronobiology
928669|NCT02376803|Chronotherapeutic
928670|NCT02376803|Coumadin
928671|NCT02376803|INR
928672|NCT02376803|International normalized ratio
928673|NCT02376803|RCT
928674|NCT02376790|Psoriatic Arthritis
928675|NCT02376790|Arthritis, Psoriasis
928676|NCT02376790|Etanercept
928677|NCT02376790|Enbrel
928678|NCT02376790|Methotrexate
928679|NCT02376790|Minimal Disease Activity
928689|NCT02376751|Cholesteryl Ester Storage Disease
928690|NCT02376751|Acid lipase disease
928691|NCT02376751|Cholesterol ester hydrolase deficiency
928692|NCT02376751|LIPA Deficiency
928693|NCT02376751|Wolman disease
928694|NCT02376751|Lysosomal Storage Disease
928695|NCT02376725|Goniosynechialysis
928696|NCT02376712|Acute Kidney Injury
928697|NCT02376712|Differential diagnosis
928698|NCT02376712|Urinary indices
928699|NCT02376712|Renal Blood Flow
928700|NCT02376712|Transesophageal Echocardiography
928715|NCT02376686|sleep Quality
928716|NCT02376686|Depression
928717|NCT02376686|Music
928718|NCT02376686|quality of life
928719|NCT02376673|Pediatric Health Literacy
928720|NCT02376673|Home Literacy Orientation
928721|NCT02376673|safe sleep
928722|NCT02376647|Patients
928723|NCT02376647|ARDS diagnosis
928724|NCT02376621|omega-3 based dietary supplements
928725|NCT02376621|Bioavailability
928726|NCT02376595|Rocuronium
928727|NCT02376595|Pharmacokinetics
928728|NCT02376595|Pharmacodynamics
928729|NCT02376582|HIV/AIDS vaccine
928730|NCT02376582|helminth infection
928731|NCT02376582|Impact of co-infection
928732|NCT02376556|Dry eye syndrome
928733|NCT02376556|Blepharoplasty
928734|NCT02376556|Muller muscle resection surgery
928735|NCT02376517|Health Behavior
928736|NCT02376517|Melanin Index
928737|NCT02376517|Spectrophotometry
928738|NCT02376517|Sun Protective Clothing
928739|NCT02376517|Education
928740|NCT02376517|Primary Prevention
928741|NCT02376439|siblings
928742|NCT02376439|overweight
928743|NCT02376439|adolescent
928744|NCT02376426|Healthy
928745|NCT02376426|Ebola viruses
928746|NCT02376426|Ebola Viral Disease (EVD)
928747|NCT02376426|Filoviruses
928748|NCT02376426|Monovalent vaccine
928749|NCT02376426|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
928750|NCT02376426|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
928751|NCT02376426|Safety
928752|NCT02376426|Immunogenicity
928753|NCT02376413|Morbidity
928754|NCT02376413|The Breast Cancer Treatment Outcome Scale
928755|NCT02376413|Disease free survival
928756|NCT02376413|Positivity cavity margin rate
928757|NCT02376413|Harvard/NSABP/RTOG breast cosmesis grading scale
928758|NCT02376400|Healthy
928759|NCT02376400|Ebola viruses
928760|NCT02376400|Ebola Viral Disease (EVD)
928761|NCT02376400|Filoviruses
928762|NCT02376400|Monovalent vaccine
928763|NCT02376400|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
928764|NCT02376400|Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)
928765|NCT02376400|Safety
928766|NCT02376400|Immunogenicity
928767|NCT02376374|transmission
928768|NCT02376374|vaccine
928769|NCT02376361|Surveillance
928770|NCT02376348|VMMC
928771|NCT02376348|Adult males
928772|NCT02376348|HIV Prevention
928773|NCT02376348|Africa
928774|NCT02376335|Fatigue
928775|NCT02376335|Primary Biliary Cirrhosis
928776|NCT02376335|Rituximab
928777|NCT02376335|PBC-40
928778|NCT02376296|metastatic prostate cancer
928779|NCT02376296|castrate resistant prostate cancer
928780|NCT02376296|CRPC
928781|NCT02376296|hormone sensitive prostate cancer
928782|NCT02376283|STEMI
928783|NCT02376283|NSTEMI
928784|NCT02376283|PPCI
928785|NCT02376244|High intensity Interval Exercise training
928786|NCT02376244|Cardiac rehabilitation
928787|NCT02376244|cardiac revascularisation
928788|NCT02376244|Percutaneous coronary interventions
928789|NCT02376244|Cardiac surgery
928790|NCT02376231|EOC Epithelial ovarian cancer
928791|NCT02376231|Surgery
928792|NCT02376231|nil macroscopic residual disease
928793|NCT02376231|Stage 3/4 Epithelial Ovarian Cancer requiring surgery
928794|NCT02376205|Anterior Cervical Discectomy and Fusion
928795|NCT02376205|Dysphagia
928796|NCT02376192|Microcirculation
928797|NCT02376192|Sidestream Dark Field (SDF) Imaging
928798|NCT02376192|Spinal Anesthesia
928799|NCT02376192|Phenylephrine
928800|NCT02376166|Prostate Cancer
928801|NCT02376140|micronutrient deficiency
928802|NCT02376140|24-H recall
928803|NCT02376140|West Africa
928804|NCT02376140|Food consumption
928805|NCT02376127|Dynamic Contrast-Enhanced Perfusion
928806|NCT02376127|14-203
928807|NCT02376114|ocular blood flow
928808|NCT02376114|ginkgo biloba
928809|NCT02376114|glaucoma
928810|NCT02376114|vasospasm
928811|NCT02376062|Continuing Medical Education
928812|NCT02376062|Chronic Diseases
928813|NCT02376062|Nepal
928814|NCT02376062|Implementation Research
928815|NCT02376049|Atopic Dermatitis
928816|NCT02376049|Eczema
928817|NCT02376049|AD
928818|NCT02376036|Normal healthy volunteer
928819|NCT02376023|Cervical Cancer
928820|NCT02376023|Women
928821|NCT02376023|Latina
928822|NCT02376023|Chile
928823|NCT02376023|Text Message
928824|NCT02376023|Technology
928825|NCT02376023|Screening
928826|NCT02376023|Cancer Prevention
928827|NCT02376023|Health Disparities
928828|NCT02376023|Mobile Health
928829|NCT02376010|atherosclerosis
928830|NCT02376010|coronary artery disease
928831|NCT02376010|cardiac CT
928832|NCT02376010|computed tomographic angiography
928833|NCT02375971|intravitreal ranibizumab
928834|NCT02375971|laser ablation therapy
928835|NCT02375971|retinopathy of prematurity
928836|NCT02375971|preterm infants
928837|NCT02375971|RAINBOW
928838|NCT02375958|PCA062, Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer, pCAD, pcadherin, solid-tumors
928839|NCT02375945|lymphedema
928840|NCT02375945|post operative compression treatment
928841|NCT02375945|compression therapy
928842|NCT02375945|adjustable fulcro wraps
928843|NCT02375945|edema
928844|NCT02375932|Electronic Medical Records
928845|NCT02375932|Primary Health Care
928846|NCT02375932|Diabetes Mellitus, Type 2
928847|NCT02375919|PERC rule
928848|NCT02375919|emergency department
928849|NCT02375919|pulmonary embolism
928850|NCT02375906|HDV, hepatitis delta
928851|NCT02375893|Coronary disease
928852|NCT02375893|Bile acids
928853|NCT02375893|Gut microbiota
928854|NCT02375893|Risk factors
928855|NCT02375893|Atherosclerosis
928856|NCT02375854|preterm
928857|NCT02375854|acute kidney injury
928858|NCT02375854|biomarkers
928859|NCT02375854|chronic kidney disease
928860|NCT02375841|Communication
928861|NCT02375841|Physicians
928862|NCT02375841|Patients
928863|NCT02375841|Caregivers
928864|NCT02375841|15-034
928865|NCT02375828|Acceptability
928866|NCT02375828|Phase 3
928867|NCT02375828|Neonatal diabetes
928868|NCT02375815|statin
928869|NCT02375815|decision aid
928870|NCT02375802|Stem cells
928871|NCT02375789|Migraine Headache
928872|NCT02375789|Cooling
928873|NCT02375789|Intranasal
928874|NCT02375789|Rhinochill
928875|NCT02375724|COPD
928876|NCT02375711|Chronic renal disease
928877|NCT02375711|Hepatitis B vaccine
928878|NCT02375711|Biological Aging
928879|NCT02375685|Uveitis
928880|NCT02375685|Non-infectious Uveitis
928881|NCT02375685|Intermediate Uveitis
928882|NCT02375685|Posterior Uveitis
928883|NCT02375685|Behçet's disease uveitis
928884|NCT02375672|Pembrolizumab
928885|NCT02375672|MK-3475
928886|NCT02375607|Pain management
928887|NCT02375581|Radiotherapy
928888|NCT02375581|Icotinib
928889|NCT02375568|mesenchymal stem cells
928890|NCT02375555|Multiple Myeloma
928891|NCT02375516|Drug abuse
928892|NCT02375503|Calcium
928893|NCT02375503|Vitamin D
928894|NCT02375503|Parathyroid Hormone
928895|NCT02375503|Bone
928896|NCT02375503|Microarchitecture
928897|NCT02375490|Exercise
928898|NCT02375490|Eating Behavior
928899|NCT02375490|Preschool Child
928900|NCT02375490|Early Childcare Center
928901|NCT02375490|Obesity
928902|NCT02375490|Physical Literacy
928903|NCT02375477|Clostridium difficile
928904|NCT02375477|C. difficile
928905|NCT02375477|adherence
928906|NCT02375464|neuroendocrine tumor
928907|NCT02375464|carcinoid tumor
928908|NCT02375438|nutrition
928909|NCT02375438|mitochondrial cytopathy
928910|NCT02375438|malnutrition
928911|NCT02375438|energy intake
928912|NCT02375438|nutritional risk
928913|NCT02375425|BV, HSV
928914|NCT02375425|contraceptive
928915|NCT02375425|ex vivo challenge model
928916|NCT02375412|heart rate variability
928917|NCT02375412|post-operative outcome
928918|NCT02375373|Gut Microbiota
928919|NCT02375347|Gut Microbiota
928920|NCT02375321|OSA
928921|NCT02375321|Depression
928922|NCT02375321|Quality of Life
928923|NCT02375321|CPAP
928924|NCT02375308|Hypnotherapy; Cognitive Behavioral Therapy; Efficacy
928925|NCT02375295|struvite
928926|NCT02375295|infection
928927|NCT02375295|stones
928928|NCT02375295|calculi
928929|NCT02375295|antibiotics
928930|NCT02375282|ambulation
928931|NCT02375282|cardiac rehabilitation
928932|NCT02375269|Visceral Surgery
928933|NCT02375269|Comprehensive Complication Index
928934|NCT02375269|Patient undergoing abdominal surgery
928935|NCT02375230|Neonatal Resuscitation
928936|NCT02375230|Respiratory Function Tests
928937|NCT02375230|Neonatal Simulation
928938|NCT02375230|Resuscitation Teaching
928939|NCT02375178|anti-infective agents
928940|NCT02375178|local/therapeutic use
928941|NCT02375178|chlorhexidine
928942|NCT02375178|dental desinfectants
928943|NCT02375178|polyhexamethylene biguanide
928944|NCT02375178|mouthrinse
928945|NCT02375152|neurosurgery
928946|NCT02375152|capsulotomy
928947|NCT02375113|Obesity prevention
928948|NCT02375113|Soy supplementation
928949|NCT02375074|Supported Employment
928950|NCT02375074|Vocational Rehabilitation
928951|NCT02375074|Youth
928952|NCT02375074|Sick leave
928953|NCT02375074|Disability
928954|NCT02375074|Coping
928955|NCT02375074|Work
928956|NCT02375074|Occupational
928957|NCT02375074|Labor market participation
928958|NCT02375074|Randomized Controlled Trial
928959|NCT02375061|Best Possible Self
928960|NCT02375061|Positive Psychology
928961|NCT02375061|Optimism
928962|NCT02375061|Positive Technologies
928963|NCT02375061|Future thinking
928964|NCT02375061|Pain Catastrophizing
928965|NCT02374983|Gamma Knife Radiosurgery
928966|NCT02374983|Radiation Dosimetry
928967|NCT02374957|leg pain
928968|NCT02374957|claudication
928969|NCT02374931|desmoid
928970|NCT02374931|FES-PET
928971|NCT02374931|aggressive fibromatosis
928972|NCT02374918|Mild traumatic brain injury
928973|NCT02374918|Concussion
928974|NCT02374918|Sleep problems
928975|NCT02374918|Brain imaging
928976|NCT02374918|fMRI
928977|NCT02374905|drinksmeter
928978|NCT02374905|alcohol counselling
928979|NCT02374892|Intervention
928980|NCT02374892|Congenital Heart Disease
928981|NCT02374892|Adolescent
928982|NCT02374892|Education
928983|NCT02374892|Self-management
928984|NCT02374866|Obesity
928985|NCT02374866|Morbid Obesity
928986|NCT02374866|Therapeutic education
928987|NCT02374840|Pharmacogenomics
928988|NCT02374840|Adverse Drug Reactions
928989|NCT02374840|Pharmacogenetics
928990|NCT02374827|complete salpingectomy
928991|NCT02374827|standard tubal ligation
928992|NCT02374827|cesarean delivery
928993|NCT02374827|feasibility
928994|NCT02374827|safety
928995|NCT02374827|partial salpingectomy
928996|NCT02374801|CRT-D device
928997|NCT02374801|Severe HF (NYHA Class III or ambulatory IV)
928998|NCT02374801|Stable, optimal drug regimen
928999|NCT02374801|Sinus rhythm
929000|NCT02374801|Heart Failure
929001|NCT02374775|axial plaque stress
929002|NCT02374775|pressure
929003|NCT02374775|pressure gradient
929004|NCT02374775|coronary plaque
929005|NCT02374775|plaque rupture
929006|NCT02374775|acute coronary syndrome
929007|NCT02374775|acute myocardial infarction
929008|NCT02374775|computational fluid dynamics
929009|NCT02374775|coronary computed tomography angiography
929010|NCT02374775|wall shear stress
929011|NCT02374762|Arteriovenous Fistula
929012|NCT02374762|Hemodialysis
929013|NCT02374762|Vascular Access
929014|NCT02374749|Axial Spondyloarthritis
929015|NCT02374749|Education
929016|NCT02374749|Co-morbidities
929017|NCT02374749|Nurse
929018|NCT02374736|recipients
929019|NCT02374736|Subclinical Antibody-mediated rejection (ABMR)
929020|NCT02374736|Intravenous immunoglobulins (IVIg)
929021|NCT02374736|Donor-specific antibodies (DSA)
929022|NCT02374723|improve
929023|NCT02374723|vision
929024|NCT02374697|Second opinion
929025|NCT02374684|Anti-Inflammatory Agents, Non-Steroidal
929026|NCT02374671|Near Vision
929027|NCT02374671|Reading Vision
929028|NCT02374671|Reading Glasses
929029|NCT02374671|Reading
929030|NCT02374671|Readers
929031|NCT02374619|eccentric exercise
929032|NCT02374619|pro-oxidants
929033|NCT02374619|free radicals
929034|NCT02374619|adults
929035|NCT02374619|children
929036|NCT02374606|outcomes measures
929037|NCT02374606|strength measurement
929038|NCT02374606|disease progression
929039|NCT02374567|geriatric psychiatry
929040|NCT02374567|pharmacovigilance
929041|NCT02374554|Respiratory Rate
929042|NCT02374554|Structured Light Plethysmography
929043|NCT02374554|Capnography
929044|NCT02374541|Patient Navigation
929045|NCT02374541|Health Disparities
929046|NCT02374541|Coordination of Services
929047|NCT02374541|Early Intervention (Education)
929048|NCT02374541|Health Services Accessibility
929049|NCT02374541|Patient Advocacy
929050|NCT02374528|Negative pressure wound therapy
929051|NCT02374528|wound
929052|NCT02374528|split-thickness skin grafting
929053|NCT02374502|Spondylarthropathies
929054|NCT02374502|Motor Activity
929055|NCT02374502|Physical Therapists
929056|NCT02374502|Accelerometry
929057|NCT02374476|VT
929058|NCT02374476|Refractory VT
929059|NCT02374476|VT Storm
929060|NCT02374476|Ventricular Fibrillation
929061|NCT02374476|V Fib
929062|NCT02374476|VF
929063|NCT02374463|Balance
929064|NCT02374463|Fall Risk
929065|NCT02374463|Older Adults
929066|NCT02374463|Tai Chi
929067|NCT02374463|Multimodal Balance Intervention
929068|NCT02374450|Malaria
929069|NCT02374450|Surveillance study
929070|NCT02374450|Adverse Events of Specific Interest (AESI)
929071|NCT02374450|Children
929072|NCT02374450|Infants
929073|NCT02374450|Meningitis
929074|NCT02374450|Epidemiology
929075|NCT02374450|Serious Adverse Events (SAE)
929076|NCT02374450|Africa
929077|NCT02374398|Tranexamic Acid
929078|NCT02374398|Blood Loss
929079|NCT02374398|Aquamantys System
929080|NCT02374398|TKA
929081|NCT02374372|hemodialysis
929082|NCT02374372|beta microglobulin
929083|NCT02374372|amyloidosis
929084|NCT02374307|Falls
929085|NCT02374307|home-care services
929086|NCT02374307|older people
929087|NCT02374307|falls-prevention
929088|NCT02374281|Newborn
929089|NCT02374281|Neonatal Screening
929090|NCT02374281|Autonomic Nervous System
929091|NCT02374281|Pain
929092|NCT02374281|non-nutritive sucking
929093|NCT02374281|sucrose administration
929094|NCT02374281|nociceptive action
929095|NCT02374281|Electro acoustical characteristics of crying
929096|NCT02374255|Advanced cancer
929097|NCT02374255|goals of care
929098|NCT02374255|quality of care
929099|NCT02374255|end of life discussions
929100|NCT02374242|Brain
929101|NCT02374242|Metastases
929102|NCT02374242|Immunotherapy
929103|NCT02374242|Intracranial response
929104|NCT02374242|Nivolumab
929105|NCT02374242|Ipilimumab
929106|NCT02374242|Biomarkers
929107|NCT02374242|Immune related response criteria
929108|NCT02374229|pulmonary hypertension
929109|NCT02374229|pulmonary artery denervation
929110|NCT02374229|mitral valve disease
929111|NCT02374216|Dental Implants
929112|NCT02374216|Periodontal Bone Loss
929113|NCT02374216|Implant-Supported Dental Prosthesis
929114|NCT02374216|Dental Prosthesis Failure
929115|NCT02374203|Critical Illness
929116|NCT02374203|Mechanical ventilator
929117|NCT02374203|Indirect Calorimetry
929118|NCT02374164|Drug therapy
929119|NCT02374151|intrauterine pressure catheter
929120|NCT02374151|electrohysterography
929121|NCT02374138|psychosocial stress
929122|NCT02374099|Breast Cancer
929123|NCT02374099|Her2 -
929124|NCT02374099|ER+
929125|NCT02374099|CC-486 (ORAL AZACITIDINE)
929126|NCT02374099|Metastatic Breast Cancer
929127|NCT02374099|Oralazacitidine
929128|NCT02374099|Fulvestrant
929129|NCT02374099|Epigenetics
929130|NCT02374021|rheumatoid arthritis
929131|NCT02374008|Peripheral nerve block
929132|NCT02374008|Total knee Arthroplasty
929133|NCT02374008|Dexamethasone
929134|NCT02373995|Graves
929135|NCT02373995|Orbithopaty
929136|NCT02373995|euthyroidism
929137|NCT02373995|microbiome
929138|NCT02373943|vitamin A
929139|NCT02373943|human
929140|NCT02373943|bioavailability
929141|NCT02373943|fortified maize
929142|NCT02373943|cross-over
929143|NCT02373943|beta-carotene
929144|NCT02373930|Dolutegravir
929145|NCT02373930|safety
929146|NCT02373930|Rilpivirine
929147|NCT02373930|fixed dose combination
929148|NCT02373930|relative bioavailability
929149|NCT02373865|Diabetes mellitus type 2
929150|NCT02373865|nocturnal hypoglycemia
929151|NCT02373865|metformin monotherapy
929152|NCT02373800|Induced
929153|NCT02373800|pre-term labor
929154|NCT02373787|Resorbable
929155|NCT02373787|Collagen membrane
929156|NCT02373787|NobelReplace CC
929157|NCT02373774|infant
929158|NCT02373774|lumbar puncture
929159|NCT02373774|patient safety
929160|NCT02373774|ultrasound
929161|NCT02373735|stroke volume variation
929162|NCT02373735|radical cystectomy
929163|NCT02373735|blood loss
929164|NCT02373735|postoperative complications
929165|NCT02373696|Pain
929166|NCT02373696|Caesarean section
929167|NCT02373670|Positive deviance
929168|NCT02373670|Peer mentors
929169|NCT02373657|trachoma
929170|NCT02373657|soil transmitted helminths
929171|NCT02373657|water
929172|NCT02373657|hand washing
929173|NCT02373592|Diabetic Neuropathies
929174|NCT02373592|Thermometry
929175|NCT02373592|Diabetes Mellitus, Type 2
929176|NCT02373592|Foot Ulcer
929177|NCT02373592|Telemedicine
929178|NCT02373579|omega-3 fatty acids
929179|NCT02373579|methotrexate
929180|NCT02373579|hepatotoxicity
929181|NCT02373566|burns
929182|NCT02373566|dermal substitute
929183|NCT02373566|scar quality
929184|NCT02373566|reconstruction
929185|NCT02373566|wound healing
929186|NCT02373566|wound closure
929187|NCT02373553|posture
929188|NCT02373553|postural
929189|NCT02373553|kinetics
929190|NCT02373540|spinal cord stimulation
929191|NCT02373540|chronic pain
929192|NCT02373540|failed back surgery syndrome
929193|NCT02373501|caesarean delivery
929194|NCT02373501|uterine incision repair
929195|NCT02373488|Constipation
929196|NCT02373488|connective tissue manipulation
929197|NCT02373488|abdominal massage
929198|NCT02373488|bowel movements
929199|NCT02373488|quality of life
929200|NCT02373475|spine surgery
929201|NCT02373475|prone position
929202|NCT02373475|intraoperative lung protective strategies
929203|NCT02373475|postoperative pulmonary complications
929204|NCT02373449|Ketamine
929205|NCT02373449|fMRI
929206|NCT02373449|refractory neuropathic pain
929207|NCT02373436|Upper Extremity
929208|NCT02373436|Rehabilitation
929209|NCT02373397|Wound healing
929210|NCT02373397|nerve regeneration
929211|NCT02373397|re-epithelialization
929212|NCT02373397|corneal epithelium
929213|NCT02373397|laser corneal surgery
929214|NCT02373384|Radiolucent renal stones
929215|NCT02373384|Oral dissolution therapy
929216|NCT02373384|Systemic chemolysis
929217|NCT02373384|Renal uric acid stones
929218|NCT02373384|Alkalinization
929219|NCT02373358|Complex trauma
929220|NCT02373358|Yoga
929221|NCT02373345|psychological factors
929222|NCT02373345|functional disability
929223|NCT02373345|pain thresholds
929224|NCT02373345|tolerance thresholds
929225|NCT02373345|motor adaptations
929226|NCT02373345|natural course
929227|NCT02373332|platelets
929228|NCT02373332|12-lipoxygenase
929229|NCT02373332|fatty acids
929230|NCT02373332|DGLA
929231|NCT02373332|DHA
929232|NCT02373332|EPA
929233|NCT02373332|12-LOX
929234|NCT02373319|Cardiovascular risk
929235|NCT02373319|Cholesterol
929236|NCT02373319|Hypertension
929237|NCT02373319|Diabetes
929238|NCT02373319|Smoking
929239|NCT02373319|Preventive Medicine
929240|NCT02373319|Epidemiology
929241|NCT02373319|Public Health
929242|NCT02373319|Diet
929243|NCT02373319|Physical Activity
929244|NCT02373306|Risk stratification
929245|NCT02373306|ICD intervention
929246|NCT02373306|occurrence during one-year follow-up after NIPS
929247|NCT02373293|Acute pancreatitis
929248|NCT02373280|Helicobacter pylori
929249|NCT02373280|tailored therapy
929250|NCT02373280|eradication
929251|NCT02373241|Anemia, Sickle Cell
929252|NCT02373241|Sickle Cell Disease
929253|NCT02373241|Kidney Disease
929254|NCT02373241|Hypertension
929255|NCT02373241|Proteinuria
929256|NCT02373241|Losartan
929257|NCT02373241|Antihypertensive Agents
929258|NCT02373241|Blood Pressure
929259|NCT02373111|Anti-aging
929260|NCT02373111|Isoflavones
929261|NCT02373111|Astaxanthine
929262|NCT02373111|Skin aging
929263|NCT02373098|Fingolimod,cytokine,chemokine,RRMS
929264|NCT02373085|Asymptomatic Bacteriuria
929265|NCT02373085|Kidney transplant recipients
929266|NCT02373085|Pyelonephritis
929267|NCT02373072|Pakinson's Disease, Movement Disorders
929268|NCT02373033|Folate
929269|NCT02373033|folic acid
929270|NCT02373033|intervention trial
929271|NCT02373033|folate status
929272|NCT02373033|women in childbearing age
929273|NCT02373033|food folate
929274|NCT02372994|chronic disease
929275|NCT02372994|continuity of patient care
929276|NCT02372994|patient engagement
929277|NCT02372994|cost effectiveness analysis
929278|NCT02372994|user-centred design
929279|NCT02372994|Interdisciplinary Health Team
929280|NCT02372994|Medical Informatics
929281|NCT02372994|Patient-centred care
929282|NCT02372942|efficacy
929283|NCT02372942|prevention
929284|NCT02372890|Otorhinolaryngeal Neoplasms
929285|NCT02372890|Cancer of Head and Neck
929286|NCT02372890|Head and Neck Squamous Cell Carcinoma
929287|NCT02372890|Positron Emission Tomography
929288|NCT02372890|PET/CT
929289|NCT02372890|FDG
929290|NCT02372877|Sickle Cell Disease
929291|NCT02372877|Hemoglobin (Hb) S Disease
929292|NCT02372877|Hb S Disease
929293|NCT02372877|Congenital Hemolytic Anemia
929294|NCT02372864|Ovariectomy
929295|NCT02372864|Mindfulness
929296|NCT02372864|Postmenopause
929297|NCT02372864|Hot Flashes
929298|NCT02372851|Arsenic
929299|NCT02372851|Household water treatment
929300|NCT02372851|Point of use water treatment
929301|NCT02372851|Water Quality
929302|NCT02372851|Total Urinary Arsenic
929303|NCT02372851|West Bengal
929304|NCT02372851|Thermotolerant coliforms
929305|NCT02372851|Compliance
929306|NCT02372851|Diarrhoea
929307|NCT02372825|Free iliac crest transfer
929308|NCT02372825|Bone reconstruction
929309|NCT02372825|Ankle reconstruction
929310|NCT02372825|Heel reconstruction
929311|NCT02372812|effect of dexamethasone
929312|NCT02372812|general surgery
929313|NCT02372812|post operative
929314|NCT02372786|7% lidocaine / 7% tetracaine cream
929315|NCT02372786|2,5% lidocaine / 2,5% prilocaine cream
929316|NCT02372773|Frontotemporal Dementia
929317|NCT02372773|MAPT
929318|NCT02372773|PGRN
929319|NCT02372773|C9ORF72
929320|NCT02372760|Bronchoscopic anesthesia lidocaine
929321|NCT02372760|Spray Catheter
929322|NCT02372760|brochoalveolar lavage
929323|NCT02372747|Totally laparoscopic gastrectomy
929324|NCT02372747|laparoscopic distal gastrectomy
929325|NCT02372747|Intracorporeal anastomosis
929326|NCT02372747|Delta-Shaped Anastomosis
929327|NCT02372747|Billroth II Anastomosis
929328|NCT02372747|Gastric cancer
929329|NCT02372721|acute kidney injury
929330|NCT02372656|Simvastatin, Metformin, Chronic periodontitis
929331|NCT02372643|clitoris
929332|NCT02372643|sexuality
929333|NCT02372643|vascularization
929334|NCT02372643|doppler
929335|NCT02372643|ultrasound
929336|NCT02372643|reference
929337|NCT02372643|female
929338|NCT02372643|Pilot Projects
929339|NCT02372643|Vagina/ultrasonography
929340|NCT02372643|Urethra/ultrasonography
929341|NCT02372643|Regional Blood Flow/physiology
929342|NCT02372643|Arteries/ultrasonography
929343|NCT02372643|Clitoris/ultrasonography
929344|NCT02372643|Reference values
929345|NCT02372643|Clitoris/blood supply
929346|NCT02372617|cerebral palsy
929347|NCT02372617|hip
929348|NCT02372617|luxation
929349|NCT02372617|subluxation
929350|NCT02372604|Chronic spontaneous urticaria
929351|NCT02372604|Levocetirizine
929352|NCT02372604|H1-antihistamine
929353|NCT02372604|Fourfold dosage
929354|NCT02372604|Efficacy
929355|NCT02372604|Tolerance
929356|NCT02372604|UAS7 (Urticaria activity score)
929357|NCT02372604|resistant
929358|NCT02372591|Quantitative Sensory Testing
929359|NCT02372591|Hydromorphone
929360|NCT02372591|Buprenorphine
929361|NCT02372578|Painful diabetic peripheral neuropathy (PDPN)
929362|NCT02372578|ASP3662
929363|NCT02372565|African American
929364|NCT02372565|Women
929365|NCT02372565|Physical Activity
929366|NCT02372565|Social Media
929367|NCT02372565|Exercise
929368|NCT02372565|Facebook
929369|NCT02372565|Text message
929370|NCT02372539|dexamethasone
929371|NCT02372526|Glucagon-like Peptide-1
929372|NCT02372526|Glucose-dependent insulinotropic peptide
929373|NCT02372526|Glucagon
929374|NCT02372526|Peptide YY 3-36
929375|NCT02372526|Ghrelin
929376|NCT02372526|Body Weight
929377|NCT02372526|Obesity
929378|NCT02372526|Overnutrition
929379|NCT02372526|Overweight
929380|NCT02372526|Gastrointestinal Agents
929381|NCT02372526|GLP-1 secretagogue
929382|NCT02372513|Cholesteryl Ester Storage Disease
929383|NCT02372513|Children
929384|NCT02372513|Liver disease
929385|NCT02372474|POF
929386|NCT02372474|ESS
929387|NCT02372474|stem cell therapy
929388|NCT02372461|Amoxicillin
929389|NCT02372461|Placebo
929390|NCT02372435|PJI
929391|NCT02372422|Twins
929392|NCT02372422|Twin gestation
929393|NCT02372422|Preterm birth
929394|NCT02372422|Prevention
929395|NCT02372396|PTSD
929396|NCT02372396|Psychotherapy
929397|NCT02372396|OEF/OIF
929398|NCT02372396|Veterans
929399|NCT02372383|Cystic Fibrosis
929400|NCT02372383|Pharmacokinetics
929401|NCT02372383|Pharmacodynamics
929402|NCT02372383|Nontuberculous Mycobacteria
929403|NCT02372383|Treatment
929404|NCT02372357|chemotherapy
929405|NCT02372357|stem cell transplantation
929406|NCT02372344|the effect of food timing on PK
929407|NCT02372344|the effect of food timing on Safety and Tolerability
929408|NCT02372344|AZD0585
929409|NCT02372344|Japanese
929410|NCT02372331|pancreaticoduodenectomy
929411|NCT02372331|ERAS
929412|NCT02372331|Whipple's operation
929413|NCT02372331|Fast track
929414|NCT02372318|opiod receptor modulator nalmefene
929415|NCT02372318|cue-reactivity
929416|NCT02372318|fMRI
929417|NCT02372318|resting-state networks
929418|NCT02372292|cardiorenal syndrome, decompensated heart failure, renal resistivity index, venous impedance index, kidney failure
929419|NCT02372279|Embryo development
929420|NCT02372279|Implantation
929421|NCT02372279|In vitro fertilization
929422|NCT02372266|Infant, Newborn
929423|NCT02372266|hospital discharge
929424|NCT02372266|Early newborn discharge
929425|NCT02372266|Newborn length of stay
929426|NCT02372266|Maternity length of stay
929427|NCT02372253|verapamil
929428|NCT02372253|type 1 diabetes
929429|NCT02372253|diabetes
929430|NCT02372253|beta cells
929431|NCT02372253|beta cell function
929432|NCT02372253|insulin
929433|NCT02372214|Endovascular Procedures
929434|NCT02372214|3D printing
929435|NCT02372214|Simulation
929436|NCT02372214|Training
929437|NCT02372214|Learning curve
929438|NCT02372214|Education
929439|NCT02372201|irritable bowel disease
929440|NCT02372201|microbiota
929441|NCT02372201|hydro colon therapy
929442|NCT02372201|food intolerance
929443|NCT02372175|Dengue
929444|NCT02372162|Hepatocellular Carcinoma
929445|NCT02372162|Molecular Diagnostics
929446|NCT02372162|Sorafenib
929447|NCT02372162|Therapeutic chemoembolization
929448|NCT02372162|Next-generation sequencing
929449|NCT02372162|Sequence analysis, DNA
929450|NCT02372162|Sequence analysis, RNA
929451|NCT02372162|Metabolomics
929452|NCT02372123|Dysmenorrhea
929453|NCT02372123|Primary dysmenorrhea
929454|NCT02372123|physiotherapy
929455|NCT02372123|massage
929456|NCT02372123|connective tissue massage
929457|NCT02372123|connective tissue manipulation
929458|NCT02372084|Hepatic impairment,
929459|NCT02372084|osilodrostat,
929460|NCT02372084|LCI699
929461|NCT02372032|Herniation
929462|NCT02372032|Discectomy
929463|NCT02372032|Ozone
929464|NCT02372019|Social Anxiety Disorder
929465|NCT02372019|Social Phobia
929466|NCT02372019|Reconsolidation
929467|NCT02372019|Cognitive Bias Modification
929468|NCT02372019|Interpretation Bias
929469|NCT02371980|Drug therapy
929477|NCT02371915|Rural access
929478|NCT02371915|Telehealth
929479|NCT02371902|Elbow pain
929480|NCT02371902|lateral epicondylitis
929481|NCT02371902|conservative treatment
929482|NCT02371902|shock wave treatment
929483|NCT02371902|therapeutic ultrasound
929484|NCT02371850|Bioequivalence
929485|NCT02371850|Therapeutic Equivalency
929486|NCT02371824|Magnetic Resonance Imaging
929487|NCT02371824|Bone Marrow
929488|NCT02371824|Hip
929489|NCT02371824|Lumbar Vertebrae
929490|NCT02371785|Peripheral Arterial Disease
929491|NCT02371785|Critical Limb Ischemia
929492|NCT02371785|Claudication
929493|NCT02371785|Percutaneous Vascular Intervention
929494|NCT02371785|Peripheral Vascular Intervention
929495|NCT02371772|Warfarin
929496|NCT02371772|Self Care
929497|NCT02371772|Conventional care
929498|NCT02371733|pulmonary arterial hypertension
929499|NCT02371733|aerobic exercise training
929500|NCT02371733|upper extremity
929501|NCT02371733|exercise capacity
929502|NCT02371694|Lipid
929503|NCT02371694|Carbohydrate counting
929504|NCT02371694|Adolescent
929505|NCT02371694|Continuous glucose monitoring
929506|NCT02371694|Insulin requirements
929507|NCT02371681|HR2E/RIPE
929508|NCT02371681|South Africa
929509|NCT02371681|Time to Positivity/TTP
929510|NCT02371681|FDG-PET/CT
929511|NCT02371668|Influenza A
929512|NCT02371668|H1N1
929513|NCT02371668|Challenge Model
929514|NCT02371668|Human Immunoglobulin and H1N1
929515|NCT02371668|Efficacy and Safety in H1N1
929516|NCT02371655|Bowel cleansing
929517|NCT02371655|CTcolonography
929518|NCT02371655|Bowel preparation
929519|NCT02371655|Faecal and fluid tagging
929520|NCT02371642|Echocardiography
929521|NCT02371629|Anticholinergic
929522|NCT02371629|Antimuscarinic
929523|NCT02371629|Chronic Obstructive Airway Disease
929524|NCT02371629|Chronic Obstructive Lung Disease
929525|NCT02371629|Chronic Obstructive Pulmonary Disease
929526|NCT02371629|COPD
929527|NCT02371629|LAMA
929528|NCT02371629|Lung Disease
929529|NCT02371629|Lung Diseases, Obstructive
929530|NCT02371629|Lung Function
929531|NCT02371629|Muscarinic receptor antagonist
929532|NCT02371629|Pulmonary Disease, Chronic Obstructive
929533|NCT02371629|Respiratory Tract Diseases
929534|NCT02371603|Prolyl hydroxylase inhibitor
929535|NCT02371603|GSK1278863
929536|NCT02371603|Anemia
929537|NCT02371603|Drug interaction
929538|NCT02371590|cancer
929539|NCT02371590|lenalidomide
929540|NCT02371590|obinutuzumab
929541|NCT02371590|CLL
929542|NCT02371577|Revlimid
929543|NCT02371551|Diffusion Magnetic Resonance Imaging
929544|NCT02371551|Medical Sonography
929545|NCT02371551|Computed Tomography, X-Ray
929546|NCT02371538|stem cell transplant
929547|NCT02371538|human breastmilk
929548|NCT02371525|adherence
929549|NCT02371525|prevention
929550|NCT02371512|Mitral Valve Insufficiency
929551|NCT02371499|Irritable Bowel Syndrome
929552|NCT02371499|Lactobacillus casei dg
929553|NCT02371499|microbiota
929554|NCT02371486|cesarean section defect
929555|NCT02371486|implantation
929556|NCT02371486|ivf
929557|NCT02371473|Acetazolamide
929558|NCT02371473|Central Sleep Apnea
929559|NCT02371473|Opium Abuse
929560|NCT02371460|Neonatal Prematurity
929561|NCT02371460|Omega-3 Fatty Acids
929562|NCT02371460|Breastfeeding
929563|NCT02371447|bladder cancer
929564|NCT02371447|recurrent non-muscle invasive bladder cancer
929565|NCT02371447|VPM1002BC
929566|NCT02371447|BCG therapy
929567|NCT02371369|Pigmented Villonodular Synovitis
929568|NCT02371369|Giant Cell Tumors of the Tendon Sheath
929569|NCT02371369|Tenosynovial Giant Cell Tumour
929570|NCT02371369|PLX3397
929571|NCT02371369|Colony Stimulating Factor 1 Receptor (CSF1R) inhibitor
929572|NCT02371330|Thrombocytopenia
929573|NCT02371330|Neonate
929574|NCT02371330|PFA-100
929575|NCT02371330|Neo-BAT
929576|NCT02371330|Hemorrhage
929577|NCT02371317|Randomized clinical trial
929578|NCT02371317|Early medical intervention
929579|NCT02371317|Intervention studies
929580|NCT02371317|Blood pressure
929581|NCT02371317|Stress Management
929582|NCT02371304|local therapy
929583|NCT02371304|adjuvant chemoradiotherapy
929584|NCT02371304|rectal preserving
929585|NCT02371291|Memory Flexibility
929586|NCT02371278|Leucine
929587|NCT02371278|Protein
929588|NCT02371278|Diet
929589|NCT02371278|Muscle protein synthesis
929590|NCT02371265|HIV
929591|NCT02371265|Mozambique
929592|NCT02371265|antenatal care
929593|NCT02371265|adherence
929594|NCT02371265|retention
929595|NCT02371265|pregnancy
929596|NCT02371265|HIV-positive mothers retained in ART after 90 days
929597|NCT02371252|Osteoporosis
929598|NCT02371252|Bisphosphonates
929599|NCT02371252|Alendronate
929600|NCT02371252|Bone mineral density
929601|NCT02371252|Bone markers
929602|NCT02371239|Glucose regulation
929603|NCT02371239|Glucose
929604|NCT02371239|Lipids
929605|NCT02371226|MPS I
929606|NCT02371213|Social Networking
929607|NCT02371213|Mobile phone
929608|NCT02371213|Antenatal Care
929609|NCT02371213|Health education
929610|NCT02371213|Maternal outcome
929611|NCT02371213|Neonatal outcome
929612|NCT02371174|HER2-Negative Inoperable or Recurrent Breast Cancer
929613|NCT02371174|Japan
929614|NCT02371174|Eribulin Mesylate
929615|NCT02371135|Gut Microbiome
929616|NCT02371135|15-016
929617|NCT02371083|Pelvic organ prolapse managed by vaginal pessary
929618|NCT02370979|Dolutegravir
929619|NCT02370979|Proviral HIV-1 DNA
929620|NCT02370979|Reservoir
929621|NCT02370953|Toric IOL alignment
929622|NCT02370953|VERION digital marker
929623|NCT02370953|Manual ink-marking
929624|NCT02370953|Randomized controlled trial
929625|NCT02370940|Iron bioavailability
929626|NCT02370940|phytate
929627|NCT02370940|serum iron curve
929628|NCT02370940|hepcidin
929629|NCT02370940|iron status
929630|NCT02370914|Concussion
929631|NCT02370888|Lenalidomide
929632|NCT02370888|Hematopoietic Stem Cell Transplantation
929633|NCT02370888|Peripheral Blood Stem Cell Transplantation
929634|NCT02370862|Spinal Cord Injury
929635|NCT02370862|Neurogenic Bowel
929636|NCT02370862|Bowel Evacuation
929637|NCT02370862|Gut Motility
929638|NCT02370849|nimotuzumab
929639|NCT02370849|gastric adenocarcinoma
929640|NCT02370849|Cisplatin
929641|NCT02370849|S-1
929642|NCT02370849|epidermal growth factor receptor
929643|NCT02370836|distress
929644|NCT02370823|Osteoarthritis
929645|NCT02370823|Knee
929647|NCT02370797|IOERT
929648|NCT02370797|Radiation
929649|NCT02370797|Single fraction
929650|NCT02370797|Lumpectomy
929651|NCT02370797|Radiation therapy
929652|NCT02370797|Avera
929653|NCT02370784|early diffuse scleroderma
929654|NCT02370784|Raynaud
929655|NCT02370758|Quantiferon-CMV
929656|NCT02370758|Quantiferon-Monitor
929657|NCT02370758|Solid Organ Transplants
929658|NCT02370758|CMV Disease
929659|NCT02370745|Incretin
929660|NCT02370745|GLP-1
929661|NCT02370745|Skeletal muscle metabolism
929662|NCT02370745|Microvascular recruitment
929663|NCT02370745|Amino Acids
929664|NCT02370745|Microvascular blood flow
929665|NCT02370732|Alcohol
929666|NCT02370732|Bariatric Surgery
929667|NCT02370732|Roux en Y Gastric bypass
929668|NCT02370732|Alcohol impairment
929669|NCT02370732|Alcohol reinforcement
929670|NCT02370732|Alcohol pharmacokinetics
929671|NCT02370719|Diabetes mellitus
929672|NCT02370719|Randomized controlled trial
929673|NCT02370719|Primary care
929674|NCT02370719|Physical activity
929675|NCT02370719|Lifestyle
929676|NCT02370719|Blood glucose
929677|NCT02370719|Mobile health
929678|NCT02370719|Hb A1c
929679|NCT02370719|Self-management
929680|NCT02370706|PIM447
929681|NCT02370706|LGH447
929682|NCT02370706|PIM inhibitor
929683|NCT02370706|LEE011
929684|NCT02370706|CDK 4/6 inhibitor
929685|NCT02370706|ruxolitinib
929686|NCT02370706|INC424
929687|NCT02370706|Jakavi®
929688|NCT02370706|Jakafi®
929689|NCT02370706|INCB18424
929690|NCT02370706|JAK inhibitor
929691|NCT02370706|myelofibrosis
929692|NCT02370706|PMF
929693|NCT02370706|PPV-MF
929694|NCT02370706|PET-MF
929695|NCT02370693|mycophenolate
929696|NCT02370693|lung scarring
929697|NCT02370680|Antiplatelet
929698|NCT02370680|Antiplatelet therapy
929699|NCT02370680|platelet turnover
929700|NCT02370680|high platelet turnover
929701|NCT02370680|platelet aggregation
929702|NCT02370680|cardiovascular disease
929703|NCT02370680|coronary artery disease
929704|NCT02370680|diabetes mellitus
929705|NCT02370667|Exercise
929706|NCT02370667|Magnetic Resonance Imaging
929707|NCT02370654|COPD
929708|NCT02370654|Tai chi
929709|NCT02370654|Pulmonary rehabilitation
929710|NCT02370641|urolithin A
929711|NCT02370641|microflora
929712|NCT02370628|percutaneous vertebroplasty
929713|NCT02370628|facet block
929714|NCT02370602|Drug therapy
929715|NCT02370589|Ebola
929716|NCT02370537|omega-3 carboxylic acid
929717|NCT02370498|Gastric cancer
929718|NCT02370498|Gastroesophageal junction cancer
929719|NCT02370472|Ultrasound
929720|NCT02370472|Image
929721|NCT02370472|Learning Tool
929722|NCT02370472|Ultrasound Guide Procedures
929723|NCT02370472|Simulated Setting
929724|NCT02370459|Papillomavirus Vaccines
929725|NCT02370459|Immunization
929726|NCT02370459|Quality Improvement
929727|NCT02370459|Adolescent Health Services
929728|NCT02370446|Medication Log
929729|NCT02370446|15-008
929730|NCT02370433|Spinal Cord Injury
929731|NCT02370433|Neurogenic Bowel
929732|NCT02370433|Bowel Evacuation
929733|NCT02370420|Platelet-rich plasma
929734|NCT02370420|Osteoarthritis
929735|NCT02370407|surgical education
929736|NCT02370407|minimally invasive surgical procedures
929737|NCT02370407|laparoscopic simulation
929738|NCT02370407|robotic simulation
929739|NCT02370407|medical education
929740|NCT02370394|Intimate Partner Violence
929741|NCT02370394|Perinatal Women
929742|NCT02370394|Mental Health
929743|NCT02370316|metacognition
929744|NCT02370316|MRI
929745|NCT02370316|Psychotherapy
929746|NCT02370251|Fat Emulsions, Intravenous
929747|NCT02370251|Parenteral-Nutrition-Associated Liver Disease
929748|NCT02370251|Cholestasis
929749|NCT02370251|Omegaven
929750|NCT02370251|Fish Oil
929751|NCT02370238|Triple negative metastatic breast cancer
929752|NCT02370238|Cancer Stem Cells
929753|NCT02370225|sjogren's syndrome
929754|NCT02370225|aerobic exercise
929755|NCT02370225|fatigue
929756|NCT02370212|Creatine
929757|NCT02370212|interval training
929758|NCT02370212|effects on performance
929759|NCT02370173|PTSD
929760|NCT02370173|Stress
929761|NCT02370173|Sleep Problems
929762|NCT02370173|Brain imaging
929763|NCT02370173|fMRI
929764|NCT02370147|smoking reduction intervention
929765|NCT02370147|no intention to quit
929766|NCT02370147|randomized controlled trial
929767|NCT02370147|telephone follow-up intervention
929768|NCT02370121|Gymnema Sylvestre
929769|NCT02370121|Insulin Secretion
929770|NCT02370121|Insulin Sensitivity
929771|NCT02370121|Central Obesity
929772|NCT02370108|electrical muscle stimulation
929773|NCT02370108|parkinson's disease
929774|NCT02370108|rest tremor
929775|NCT02370108|tremor reduction
929776|NCT02370095|ARDS
929777|NCT02370095|Acute Lung Injury
929778|NCT02370095|Acute Respiratory Failure
929779|NCT02370082|lumpectomy
929780|NCT02370082|breast conserving surgery
929781|NCT02370030|sepsis
929782|NCT02370030|citrulline
929783|NCT02370030|endothelial
929784|NCT02370030|toxemia
929785|NCT02370030|endothelial determination of progression
929786|NCT02370030|with vs without citrulline
929787|NCT02370017|Autologous Ex vivo-expanded NK cell enriched lymphocytes
929788|NCT02370004|Asthma
929789|NCT02370004|RFST
929790|NCT02370004|Bronchial Diseases
929791|NCT02370004|Respiratory Tract Diseases
929792|NCT02370004|Lung Diseases, Obstructive
929793|NCT02370004|Lung Diseases
929794|NCT02369991|latissimus dorsi flap
929795|NCT02369991|bone transport
929796|NCT02369991|bone reconstruction
929797|NCT02369991|tibia
929798|NCT02369991|tibial fracture
929799|NCT02369978|Trypanocidal therapy
929800|NCT02369978|Benznidazole
929801|NCT02369978|Nifurtimox
929802|NCT02369978|Polymerase chain reaction
929803|NCT02369978|Randomized trial
929804|NCT02369965|HIV-1
929805|NCT02369965|AIDS
929806|NCT02369965|Albuvirtide
929807|NCT02369965|Treatment-experienced
929808|NCT02369965|Fusion inhibitor
929809|NCT02369939|anal carcinoma
929810|NCT02369939|hyperthermia
929811|NCT02369939|radiotherapy
929812|NCT02369939|chemotherapy
929813|NCT02369939|radiochemotherapy
929814|NCT02369926|multiple sclerosis
929815|NCT02369926|telemedicine
929816|NCT02369926|remote monitoring
929817|NCT02369926|lisinopril
929818|NCT02369900|Esmolol
929819|NCT02369900|Septic Shock
929820|NCT02369900|Hypotension
929821|NCT02369900|Tachycardia
929822|NCT02369887|MSM/TG who agree to start PrEP
929823|NCT02369874|Head and Neck cancer; MEDI4736; Tremelimumab
929824|NCT02369822|Vitamin C
929825|NCT02369822|convulsions status
929826|NCT02369822|EEG
929827|NCT02369822|children
929828|NCT02369809|Ischemia
929829|NCT02369796|Drug therapy
929830|NCT02369770|Stroke
929831|NCT02369770|Robotics
929832|NCT02369770|Ankle
929833|NCT02369770|Active Stretching
929834|NCT02369770|Passive Stretching
929835|NCT02369770|Range of Motion
929836|NCT02369744|Ureteral calculus
929837|NCT02369744|Ureterolithiasis
929838|NCT02369744|Ureteral stone
929839|NCT02369744|Kidney stone
929840|NCT02369744|Medical expulsive therapy
929841|NCT02369744|tamsulosin
929842|NCT02369744|silodosin
929843|NCT02369744|rapaflo
929844|NCT02369744|flomax
929845|NCT02369679|upper limb
929846|NCT02369679|lymphedema
929847|NCT02369666|Inflammation
929848|NCT02369666|Lycopene
929849|NCT02369666|Exercise
929851|NCT02369614|rTMS - repetitive transcranial magnetic stimulation
929852|NCT02369614|CAPS - Clinician Administered PTSD Scale
929853|NCT02369601|amniorrhexis
929854|NCT02369601|Ruptured membranes
929855|NCT02369601|Alfa-fetoprotein
929856|NCT02369562|Dental implants
929857|NCT02369562|Periodontal Bone Loss
929858|NCT02369549|Chronic Kidney Disease (CKD)
929859|NCT02369549|Micro-particle curcumin
929860|NCT02369549|Albuminuria
929861|NCT02369536|NAFLD
929862|NCT02369536|nutraceutical mixture
929863|NCT02369523|Primary Total Knee Arthroplasty
929864|NCT02369510|spinal anesthesia
929865|NCT02369510|epinephrine
929866|NCT02369510|bupivacaine
929867|NCT02369510|repeat cesarean
929868|NCT02369484|Stage IIIb/ IV NSCLC harbouring HER2 exon 20 mutations
929869|NCT02369471|Cannabidivarin
929870|NCT02369471|CBDV
929871|NCT02369471|GWP42006
929872|NCT02369432|Drug carriers
929873|NCT02369432|Polymeric microparticles
929874|NCT02369432|Preferential accumulation in inflamed skin
929875|NCT02369432|Atopic dermatitis
929876|NCT02369432|Pilosebaceous follicles
929877|NCT02369432|Selective drug delivery
929878|NCT02369432|Drug reservoir
929879|NCT02369419|frailty
929880|NCT02369419|Heart failure
929881|NCT02369419|cardiac resynchronization therapy
929882|NCT02369406|Botswana
929883|NCT02369406|Immunology
929884|NCT02369406|Antiretroviral Therapy
929885|NCT02369393|Internet based treatment
929886|NCT02369393|Depression
929887|NCT02369393|Efficacy
929888|NCT02369393|Cost-effectiveness
929889|NCT02369393|Behavioral Activation
929890|NCT02369393|Self-applied
929891|NCT02369393|Ecological Momentary Assessment
929892|NCT02369393|Physical Activity
929893|NCT02369367|Malignant Gliomas
929894|NCT02369367|Glioblastoma Multiforme
929895|NCT02369367|Gliosarcoma
929896|NCT02369367|Anaplastic Astrocytoma
929897|NCT02369367|Anaplastic Oligodendroglioma
929898|NCT02369367|Anaplastic Oligoastrocytoma
929899|NCT02369367|Camptosar
929900|NCT02369367|Irinotecan
929901|NCT02369367|CPT-11
929902|NCT02369367|Lenalidomide
929903|NCT02369367|Revlimid
929904|NCT02369367|CC-5013
929905|NCT02369354|Kidney Transplant
929906|NCT02369354|African Americans
929907|NCT02369341|Southern Hemisphere influenza vaccine
929908|NCT02369341|Elderly
929909|NCT02369341|Seasonal flu
929910|NCT02369341|Fluarix Tetra
929911|NCT02369341|Adults
929912|NCT02369341|Immunogenicity
929913|NCT02369341|Reactogenicity
929914|NCT02369341|Influenza
929915|NCT02369315|child development
929916|NCT02369315|music training
929917|NCT02369315|self-regulation
929918|NCT02369315|exposure to violence
929919|NCT02369276|neck dissection surgery
929920|NCT02369276|shoulder disability
929921|NCT02369276|musculoskeletal ultrasonography
929922|NCT02369263|Deep Vein Thrombosis
929923|NCT02369263|DVT
929924|NCT02369263|Leg Swelling
929925|NCT02369263|Leg Pain
929926|NCT02369263|Blood Clot
929927|NCT02369250|regeneration
929928|NCT02369250|surgical therapy
929929|NCT02369250|furcation defect
929930|NCT02369211|acetaminophen
929931|NCT02369172|Herpes
929932|NCT02369172|volunteers
929933|NCT02369172|drug-drug interaction
929934|NCT02369120|patient education
929935|NCT02369120|pain cognitions
929936|NCT02369107|acupuncture
929937|NCT02369107|chemotherapy-induced nausea and vomiting
929938|NCT02369094|Frailty
929939|NCT02369094|Frail elderly
929940|NCT02369094|Acupressure
929941|NCT02369094|Pragmatic Randomised Controlled Trial
929942|NCT02369081|Hypertension
929943|NCT02369055|Rehabilitation
929944|NCT02369029|Phase I
929945|NCT02369029|Dose escalation
929946|NCT02369029|NUT-midline carcinoma
929947|NCT02369029|Acute Leucemia
929948|NCT02369029|Lymphoma
929949|NCT02369029|Melanoma
929950|NCT02369029|Myeloma
929951|NCT02369029|HCC
929952|NCT02369029|NSCLC
929953|NCT02369016|indolent Non-Hodgkin lymphoma
929954|NCT02369016|rituximab-refractory
929955|NCT02369003|Deep Brain Stimulation
929956|NCT02369003|Schwann Cells
929957|NCT02368990|NSCLC
929958|NCT02368990|T790M
929959|NCT02368990|EGFR
929960|NCT02368990|TKI Resistance
929961|NCT02368990|Non Small Cell Lung Cancer
929962|NCT02368990|AZD9291
929963|NCT02368990|Clovis
929967|NCT02368964|double triggering
929968|NCT02368964|Oocyte maturation
929969|NCT02368964|GNRH Agonist
929970|NCT02368964|hCG
929971|NCT02368964|IVF treatment
929972|NCT02368964|immature oocytes
929973|NCT02368951|Phase 1
929974|NCT02368951|Solid Tumors
929975|NCT02368951|FGFR2
929976|NCT02368951|Antibody drug conjugate
929977|NCT02368938|Cardiovascular risk factors
929978|NCT02368938|Prospective study
929979|NCT02368938|Mortality
929980|NCT02368938|Cardiovascular events
929981|NCT02368938|Asymptomatic target organ damage
929982|NCT02368938|elderly Chinese
929983|NCT02368925|Rhytids
929984|NCT02368925|Skin Laxity
929985|NCT02368912|Phase 1
929986|NCT02368912|ASP1707
929987|NCT02368912|Dose escalation
929988|NCT02368912|Food effect
929989|NCT02368912|Maximum tolerated dose (MTD)
929990|NCT02368912|Healthy subjects
929991|NCT02368912|Single ascending dose
929992|NCT02368912|Multiple ascending dose
929993|NCT02368899|technology
929994|NCT02368899|information science
929995|NCT02368899|health care
929996|NCT02368873|prevention
929997|NCT02368847|Aged
929998|NCT02368847|Psychiatric Hospitals
929999|NCT02368821|cytotrophoblast
930000|NCT02368821|syncytiotrophoblast
930001|NCT02368821|placentas
930002|NCT02368821|intrauterine growth restriction
930003|NCT02368821|preeclampsia
930004|NCT02368821|placenta accrete
930005|NCT02368808|orphans and vulnerable children
930006|NCT02368808|South Africa
930007|NCT02368808|peer support group
930008|NCT02368795|Endoscopic Retrograde Cholangiopancreatography
930009|NCT02368795|Pancreatic duct stenting
930010|NCT02368795|Post-ERCP pancreatitis
930011|NCT02368782|transient evoked otoacoustic emissions
930012|NCT02368782|distortion product otoacoustic emissions
930013|NCT02368782|ketamine
930014|NCT02368782|propofol
930015|NCT02368782|child
930017|NCT02368704|Endoplasmic Reticulum
930018|NCT02368678|Halitosis
930019|NCT02368678|Sulfur compounds
930020|NCT02368678|Periodontitis
930021|NCT02368678|Periodontal treatment
930022|NCT02368600|lifestyle intervention
930023|NCT02368600|gestational diabetes mellitus
930024|NCT02368600|Chinese
930025|NCT02368600|prevention
930026|NCT02368587|intracoronary infusion
930027|NCT02368587|intravenous infusion
930028|NCT02368587|Wharton's jelly-derived mesenchymal stem cells
930029|NCT02368587|ischemic Cardiomyopathy
930030|NCT02368587|heart function
930031|NCT02368548|Pharmaceutical care
930032|NCT02368548|Emergency Service
930033|NCT02368535|teamwork
930034|NCT02368509|sensory test
930035|NCT02368509|olfaction
930036|NCT02368509|gustation
930037|NCT02368509|taste
930038|NCT02368509|cancer
930039|NCT02368496|Long-term parenteral nutrition
930040|NCT02368496|HR-pQCT
930041|NCT02368496|DXA
930042|NCT02368496|Bone trophicity
930043|NCT02368457|Mandibular osteoradionecrosis
930044|NCT02368457|Tocopherol
930045|NCT02368457|pentoxifylline
930046|NCT02368457|vitamine E
930047|NCT02368457|wounds and injuries
930048|NCT02368457|antioxidants
930049|NCT02368457|free radical scavengers
930050|NCT02368457|radiation-protective agents
930051|NCT02368457|vasodilatadors agents
930052|NCT02368457|osteonecrosis
930053|NCT02368457|mandible
930054|NCT02368457|extraoral fistula
930055|NCT02368457|exposed bone
930056|NCT02368457|necrotic bone
930057|NCT02368457|head and neck radiotherapy
930058|NCT02368444|Posttraumatic Stress
930059|NCT02368444|Sleep
930060|NCT02368431|Alcohol Use Disorder
930061|NCT02368431|Alcoholism
930062|NCT02368431|Alcohol Dependence
930063|NCT02368431|Zonisamide
930064|NCT02368431|Alcoholic Intoxication
930065|NCT02368431|Drinking Behaviors
930066|NCT02368431|Anticonvulsants
930067|NCT02368418|Cardiovascular disease
930068|NCT02368418|Rural health
930069|NCT02368418|China
930070|NCT02368418|Cohort study
930071|NCT02368392|in-hospital cardiac arrest
930072|NCT02368392|quality of life after cardiac arrest
930073|NCT02368392|survival after cardiac arrest
930074|NCT02368392|resources for cardiac arrest
930075|NCT02368379|Metyrapone
930076|NCT02368379|ACTH stimulation test
930077|NCT02368314|Deep vein thrombosis
930078|NCT02368314|Prophylaxis
930079|NCT02368314|Sodium enoxaparin
930080|NCT02368288|chronic hepatitic B
930081|NCT02368288|peginterferon
930082|NCT02368288|HBsAg
930083|NCT02368288|entecavir
930084|NCT02368262|Cerebral Palsy
930085|NCT02368262|Risk factors
930086|NCT02368262|Child
930087|NCT02368262|urinary incontinence
930093|NCT02368223|Children
930094|NCT02368223|Rehabilitation
930095|NCT02368223|Telerehabilitation
930096|NCT02368223|Upper limb therapy
930097|NCT02368197|dialysis fistula
930098|NCT02368197|cephalic arch stenosis
930099|NCT02368197|balloon angioplasty
930100|NCT02368197|drug eluting balloon
930101|NCT02368184|noninvasive physiologic monitoring
930102|NCT02368184|acute decompensated heart failure (ADHF)
930103|NCT02368158|myocard infarction
930104|NCT02368158|arrhythmia
930105|NCT02368158|fitness of driving
930106|NCT02368145|stroke
930107|NCT02368145|acute stroke
930108|NCT02368145|post stroke depression
930109|NCT02368132|Caregivers
930110|NCT02368132|Dementia
930111|NCT02368106|patient registry
930112|NCT02368106|radiation oncology
930113|NCT02368106|technology assessment
930114|NCT02368093|Rheumatoid arthritis
930115|NCT02368080|Lung Clearance Index
930116|NCT02368080|Cystic Fibrosis
930117|NCT02368080|Multiple Breath Nitrogen Washout
930118|NCT02368054|Epinephrine
930119|NCT02368054|Bupivacaine
930120|NCT02368054|Stroke Volume
930121|NCT02368054|Cardiac Output
930122|NCT02368054|Heart Rate
930123|NCT02368054|Hemodynamics
930124|NCT02368054|Total Peripheral Resistance
930125|NCT02368054|Blood Pressure
930126|NCT02368054|Paracervical block
930127|NCT02368054|LiDCO
930128|NCT02368054|Adrenaline
930129|NCT02368054|Conization
930130|NCT02368054|PulsCO
930131|NCT02368028|Plaque
930132|NCT02368028|Saliva
930133|NCT02368028|Dental Caries
930134|NCT02368015|Penetration
930135|NCT02368015|Cefazolin
930136|NCT02368015|Hepatic cyst
930137|NCT02368002|obesity
930138|NCT02368002|diet, reducing
930139|NCT02367989|Glucose response
930140|NCT02367989|Insulin response
930141|NCT02367989|Satiety
930142|NCT02367963|Peer education
930143|NCT02367963|Comprehensive health intervention
930144|NCT02367963|Lifestyle
930145|NCT02367963|Adult
930146|NCT02367963|Mid age
930147|NCT02367963|Male
930148|NCT02367963|Female
930149|NCT02367963|Human
930150|NCT02367963|Clinical trial
930151|NCT02367963|Prevention and control
930152|NCT02367963|Cardiovascular Disease
930153|NCT02367963|Behavior
930154|NCT02367963|Risk Factors
930155|NCT02367963|Healthy lifestyle
930156|NCT02367963|Healthy people program
930157|NCT02367963|Peer-group
930158|NCT02367937|Phase I drug-drug interaction
930159|NCT02367898|Cognitive Training
930160|NCT02367898|Lumosity
930161|NCT02367898|Crossword Puzzles
930162|NCT02367885|Prevention
930163|NCT02367872|Drug therapy
930164|NCT02367859|ameloblastoma
930165|NCT02367859|BRAF
930166|NCT02367859|odontogenic cancer
930167|NCT02367859|adamantinoma
930168|NCT02367846|Calcium Tracer
930169|NCT02367846|Oral Contraceptives
930170|NCT02367846|Contraceptive Vaginal Ring
930171|NCT02367846|Impact of contraceptives on bone health using 41Ca
930172|NCT02367833|Insulin-like growth factor-1
930173|NCT02367833|Combined oral contraceptive
930174|NCT02367833|Contraceptive Vaginal Ring
930175|NCT02367833|Transdermal Contraceptive
930176|NCT02367807|HIV prevention
930177|NCT02367807|PrEP
930178|NCT02367807|young men who have sex with men
930179|NCT02367807|Truvada
930180|NCT02367768|trauma blue
930181|NCT02367768|major trauma
930182|NCT02367768|cohort study
930183|NCT02367768|prognostic factor
930184|NCT02367768|Healing Time
930185|NCT02367768|Post Operative
930186|NCT02367755|cardiopulmonary resuscitation
930187|NCT02367755|cardiac arrest
930188|NCT02367755|therapeutic hypothermia
930189|NCT02367755|propofol
930190|NCT02367755|lorazepam
930191|NCT02367755|cerebral perfusion
930192|NCT02367755|electroencephalography
930193|NCT02367742|Diet
930194|NCT02367742|Physical Activity
930195|NCT02367742|NAFLD
930196|NCT02367703|Mini-laparoscopy
930197|NCT02367703|hysterectomy
930198|NCT02367703|Benign uterine diseases
930199|NCT02367703|Operative time
930200|NCT02367690|Diabetes
930201|NCT02367690|Foot Ulcers
930202|NCT02367690|DFU
930203|NCT02367690|KPT-330
930204|NCT02367690|Selinexor
930205|NCT02367690|Karyopharm
930206|NCT02367677|Photo
930207|NCT02367664|Japanese encephalitis
930208|NCT02367664|immunogenicity
930209|NCT02367664|safety
930210|NCT02367664|vaccine
930211|NCT02367651|Soft tissue sarcoma
930212|NCT02367651|Pazopanib
930213|NCT02367651|Tyrosine kinase inhibitor
930214|NCT02367599|PrEP
930215|NCT02367599|Pre exposure Prophylaxis
930216|NCT02367599|Truvada
930217|NCT02367599|CCTG
930218|NCT02367599|595
930219|NCT02367599|Vitamin D
930220|NCT02367599|Bone mineral density
930223|NCT02367508|advance care planning
930224|NCT02367508|coping skills
930225|NCT02367508|mindfulness
930226|NCT02367508|meditation
930227|NCT02367508|cancer
930228|NCT02367508|adult
930229|NCT02367508|caregivers
930230|NCT02367508|oncology providers
930231|NCT02367508|advance directives
930232|NCT02367508|anxiety
930233|NCT02367508|depression
930234|NCT02367508|quality of life
930235|NCT02367508|pilot project
930236|NCT02367495|Coronary Restenosis
930237|NCT02367495|restenosis
930238|NCT02367495|paclitaxel-coated balloon
930239|NCT02367495|drug-eluting stent
930240|NCT02367495|drug-coated balloon
930241|NCT02367495|coronary angiography
930242|NCT02367482|rGBM
930243|NCT02367482|Recurrent GBM
930244|NCT02367482|Recurrent Glioblastoma
930245|NCT02367469|recurrent brain tumors
930246|NCT02367469|brain tumors
930247|NCT02367469|Newly diagnosed brain tumors
930248|NCT02367456|MDS
930249|NCT02367456|AML
930250|NCT02367456|CMML
930251|NCT02367443|radiotherapy
930252|NCT02367443|therapeutic use
930253|NCT02367443|Radiation
930254|NCT02367443|non-small cell lung cancer
930255|NCT02367443|chemotherapy
930256|NCT02367417|Revision
930257|NCT02367417|Knee Joint
930258|NCT02367417|PMCF
930260|NCT02367365|Neovascular Age-Related Macular Degeneration
930261|NCT02367365|anti-vascular endothelial growth factor
930262|NCT02367365|neovascular lesion morphology
930263|NCT02367365|indocyanine green angiography
930264|NCT02367365|persistent disease activity
930265|NCT02367352|Drug therapy
930266|NCT02367352|dose escalation
930267|NCT02367352|dose expansion
930268|NCT02367339|Critical Care
930269|NCT02367339|Nursing staff
930270|NCT02367339|Medical staff
930271|NCT02367339|Extended-spectrum betalactamase
930272|NCT02367339|Digestive tract colonization
930273|NCT02367339|Cross-contamination
930274|NCT02367326|score
930275|NCT02367326|inflammatory bowel disease
930276|NCT02367326|crohn's disease
930277|NCT02367326|ulcerative colitis
930278|NCT02367326|clinical response
930279|NCT02367326|thiopurines
930280|NCT02367313|Symptomatic Human Rhinovirus Infection
930281|NCT02367313|Moderate to Severe Asthma
930282|NCT02367313|Antiviral
930283|NCT02367313|Cold
930284|NCT02367313|Aviragen Therapeutics, Inc.
930285|NCT02367313|Aviragen Therapeutics
930286|NCT02367313|Aviragen
930287|NCT02367287|Diet
930288|NCT02367287|Phenotype
930289|NCT02367287|Immunology
930290|NCT02367287|Microbiota
930291|NCT02367287|Metabolomics
930292|NCT02367287|Physical activity
930293|NCT02367287|Neuroendocrine system
930294|NCT02367287|Nutritional Physiological Phenomena
930295|NCT02367248|Brain hemorrhage
930296|NCT02367248|Cerebral Hemorrhage
930297|NCT02367248|Deferoxamine
930298|NCT02367248|Xingnaojing injection
930299|NCT02367248|Hematoma edema
930300|NCT02367235|robotic
930301|NCT02367235|sacrocolpopexy
930302|NCT02367235|Colpassist
930303|NCT02367235|vaginal positioning device
930304|NCT02367209|FD MRI
930305|NCT02367209|COPD
930306|NCT02367209|SPECT/CT
930307|NCT02367209|DCE MRI
930308|NCT02367196|CC-90002
930309|NCT02367196|Monoclonal
930310|NCT02367196|Antibody
930311|NCT02367196|CD47
930312|NCT02367196|Advanced
930313|NCT02367196|Solid Cancers
930314|NCT02367196|Hematologic Cancers
930322|NCT02367170|respiratory dysfunction
930323|NCT02367170|chronic critical illness
930324|NCT02367170|diaphragm weakness
930325|NCT02367170|sepsis
930326|NCT02367170|ventilator dependance
930327|NCT02367118|chronic rhinosinusitis without nasal polyps prednisone
930328|NCT02367105|Obesity
930329|NCT02367105|Hypogonadism
930330|NCT02367105|Frailty
930331|NCT02367092|Liver Transplantation
930332|NCT02367066|patients
930333|NCT02367066|glycaemic control on metformin
930334|NCT02367040|Clinical trial, Phase III
930335|NCT02367040|Phosphatidylinositol-3-kinase
930336|NCT02367040|Non-Hodgkin's lymphoma
930337|NCT02367040|Indolent B-cell non-Hodgkin's lymphoma
930338|NCT02367027|Biological Availability
930339|NCT02367027|Relative Bioavailability Trial
930340|NCT02367014|Mitochondrial Myopathy
930341|NCT02367014|Primary Mitochondrial Disease
930342|NCT02367014|Bendavia™
930343|NCT02367014|elamipretide
930344|NCT02367001|general practitioner
930345|NCT02367001|screening
930346|NCT02367001|participation
930347|NCT02367001|organized screening
930348|NCT02366988|Chronic pancreatitis
930349|NCT02366988|Clinical Trial
930350|NCT02366988|Bile stricture
930351|NCT02366988|Endoscopy
930352|NCT02366988|Surgery
930353|NCT02366975|BPH/LUTS
930354|NCT02366975|TRT
930355|NCT02366975|Metabolic Syndrome
930356|NCT02366962|Influenza
930357|NCT02366962|Vaccine
930358|NCT02366962|ASP7374
930359|NCT02366949|Phase 1
930360|NCT02366949|Solid tumors
930361|NCT02366949|Breast cancer
930362|NCT02366949|Paclitaxel
930363|NCT02366949|MPS-1 inhibitor
930364|NCT02366949|Oncology
930365|NCT02366884|malignant
930366|NCT02366884|atavistic chemotherapy
930367|NCT02366884|cancer
930368|NCT02366858|19 gauge
930369|NCT02366858|22 gauge
930370|NCT02366858|core tissue
930371|NCT02366806|Breast Cancer
930372|NCT02366806|AJCC Stage 1, 2, 3
930373|NCT02366806|Educational Design
930374|NCT02366806|Radiation Therapy Treatment
930375|NCT02366793|accessory mobilization, nerve mobilization.
930376|NCT02366780|Lactation
930377|NCT02366780|Breastmilk
930378|NCT02366780|Macronutrients
930379|NCT02366767|Insulin Infusion Systems
930380|NCT02366767|Continuous Glucose Monitors
930381|NCT02366754|Transcranial Magnetic Stimulation
930382|NCT02366741|SCLC
930383|NCT02366741|Neuro-cognitive function
930384|NCT02366741|PCI
930385|NCT02366741|Hippocampal sparing
930386|NCT02366676|Recurrent cystitis
930387|NCT02366676|hyaluronic acid
930388|NCT02366676|chondroitin sulphate
930389|NCT02366663|Non-Hodgkin's lymphoma
930390|NCT02366663|autologous stem cell transplantation
930391|NCT02366663|radioimmunotherapy
930392|NCT02366663|Zevalin
930393|NCT02366663|Lymphoma
930394|NCT02366663|Lymphoma, Large B-Cell, Diffuse
930395|NCT02366663|Lymphoma, Non-Hodgkin
930396|NCT02366663|Immune System Diseases
930397|NCT02366663|Immunoproliferative Disorders
930398|NCT02366663|Lymphatic Diseases
930399|NCT02366663|Lymphoma, B-Cell
930400|NCT02366663|Lymphoproliferative Disorders
930401|NCT02366663|Neoplasms
930402|NCT02366663|Neoplasms by Histologic Type
930403|NCT02366663|Antibodies, Monoclonal
930404|NCT02366663|Immunologic Factors
930405|NCT02366663|Pharmacologic Actions
930406|NCT02366663|Physiological Effects of Drugs
930407|NCT02366637|COPD
930408|NCT02366637|Sputum
930409|NCT02366546|Adoptive cell transfer
930410|NCT02366546|Cell therapy
930411|NCT02366546|Immunotherapy
930412|NCT02366546|NY-ESO-1
930413|NCT02366546|Esophageal cancer
930414|NCT02366546|Melanoma
930415|NCT02366546|Head and neck cancer
930416|NCT02366546|Ovarian cancer
930417|NCT02366546|Synovial sarcoma
930418|NCT02366546|TCR gene therapy
930419|NCT02366533|Linkage to care
930420|NCT02366533|HIV
930421|NCT02366533|Efficacy of linkage to care program
930422|NCT02366520|Child
930423|NCT02366520|Child Behavior
930424|NCT02366520|Dental Anxiety/prevention & control
930425|NCT02366520|Dental Anxiety/psychology
930426|NCT02366520|Cooperative Behavior
930427|NCT02366520|Dental Care/psychology*
930428|NCT02366520|Humans
930429|NCT02366520|Videotape Recording
930430|NCT02366507|hypotension
930431|NCT02366507|doppler
930432|NCT02366507|shock
930433|NCT02366494|prostate cancer
930434|NCT02366494|treatment response
930435|NCT02366494|androgen deprivation therapy
930448|NCT02366442|dual/multitasking
930449|NCT02366442|Executive function
930450|NCT02366442|Affective function
930451|NCT02366442|Balance
930452|NCT02366416|Exercise, Physical
930453|NCT02366403|PTSD
930454|NCT02366403|Meditation
930455|NCT02366403|Yoga
930456|NCT02366403|Cognitive Therapy
930457|NCT02366390|Psychoeducative
930458|NCT02366390|HADS
930459|NCT02366390|COPD
930460|NCT02366390|dyspnea
930461|NCT02366364|NRX-1074
930462|NCT02366364|NMDA Receptor Modulator
930463|NCT02366364|Major Depressive Disorder
930464|NCT02366364|Glycine Site Modulator
930465|NCT02366312|Keratocystic odontogenic tumor
930466|NCT02366312|KCOT
930467|NCT02366273|Diabetes
930468|NCT02366273|Psoriasis
930469|NCT02366273|Inflammation
930470|NCT02366273|Insulin-resistance
930471|NCT02366247|Polyethylene Glycol Thymosin alpha1
930472|NCT02366247|Adefovir
930473|NCT02366247|Hepatitis B e Antigens positive
930474|NCT02366208|Polyethylene Glycol Thymosin alpha1
930475|NCT02366208|Adefovir
930476|NCT02366208|Hepatitis B e Antigens positive
930477|NCT02366195|T-VEC
930478|NCT02366195|CD8+ cell density
930479|NCT02366195|objective response rate
930480|NCT02366195|unresected
930481|NCT02366195|Melanoma
930482|NCT02366130|Breast cancer
930483|NCT02366130|Hormone-positive bone-dominant metastatic breast cancer
930484|NCT02366130|Ra-223 dichloride
930485|NCT02366130|Xofigo
930486|NCT02366130|Radium-223 chloride
930487|NCT02366130|Radium-223 dichloride
930488|NCT02366130|Alpharadin
930489|NCT02366130|Denosumab
930490|NCT02366130|AMG 162
930491|NCT02366130|Prolia
930492|NCT02366130|Hormone therapy
930493|NCT02366117|Quirc
930494|NCT02366117|Quality Indiciator in Rehabilitative Care
930495|NCT02366104|Cardiovascular Diseases
930496|NCT02366104|Aged
930497|NCT02366104|Primary Prevention
930498|NCT02366052|Histologically confirmed NASH
930499|NCT02366052|Hepatocyte Injury determined by M30 antigen
930500|NCT02366026|HIV
930501|NCT02366013|HIV
930502|NCT02366013|HIV Prevention
930503|NCT02366013|HIV Vaccine
930504|NCT02366013|Healthy
930505|NCT02366000|Parent-child communication
930506|NCT02366000|Health risk behaviors
930507|NCT02366000|Randomized controlled trial
930508|NCT02365987|interesterified
930509|NCT02365987|postprandial
930510|NCT02365974|arterial stiffness
930511|NCT02365974|resistant hypertension
930512|NCT02365974|sympathetic system
930513|NCT02365974|blood pressure
930514|NCT02365974|transcutaneous electrical nerve stimulation
930515|NCT02365961|Hip Arthroscopy
930516|NCT02365948|Pharmacokinetics
930517|NCT02365948|Certolizumab Pegol
930518|NCT02365948|Healthy Chinese subjects
930519|NCT02365935|adjuvant chemotherapy
930520|NCT02365922|FTLD, PSP, CBD, PPA, FTD, FTD-ALS, CBS, ALS, svPPA, nfvPPA, oPSP
930521|NCT02365883|Prostate Cancer
930522|NCT02365883|Transrectal Imaging
930523|NCT02365870|Anxiety Disorders
930524|NCT02365870|Parkinson Disease
930525|NCT02365870|rotigotine
930526|NCT02365857|spinal anesthesia
930527|NCT02365857|caesarian section
930528|NCT02365857|Dexmedetomidine
930529|NCT02365844|Narrow Band Imaging
930530|NCT02365844|oropharyngeal carcinoma
930531|NCT02365831|MBC
930532|NCT02365831|breast
930533|NCT02365831|metastatic
930534|NCT02365831|cancer
930535|NCT02365831|HER2
930536|NCT02365818|Bladder Cancer
930537|NCT02365805|BRCA 1 levels
930538|NCT02365805|HER2 Negative
930539|NCT02365792|Clinical Decision Support
930540|NCT02365792|Clinical Practice Guidelines
930541|NCT02365792|Emergency Medical Services
930542|NCT02365779|salpingectomy
930543|NCT02365779|optical biopsy
930544|NCT02365779|Cellvizio®
930545|NCT02365766|MK-3475
930546|NCT02365766|Gemcitabine
930547|NCT02365766|Cisplatin
930548|NCT02365766|Pembrolizumab
930549|NCT02365766|Neoadjuvant Bladder Cancer
930550|NCT02365753|lower transverse cesarean delivery
930551|NCT02365753|Pregnant women
930552|NCT02365740|Type 1 Diabetes mellitus
930553|NCT02365740|Gastric Emptying
930554|NCT02365740|Insulin Infusion Pump
930555|NCT02365701|Functional Dyspepsia
930556|NCT02365688|Open Abdominal Surgical Procedure
930557|NCT02365675|Pemphigus
930558|NCT02365675|Pemphigoid
930559|NCT02365675|Wound Healing
930560|NCT02365675|Itch
930561|NCT02365675|Pain
930562|NCT02365675|Wound dressing
930563|NCT02365675|Topical treatment
930564|NCT02365662|Solid Tumor types likely to exhibit elevated levels of Epidermal Growth Factor Receptor
930565|NCT02365662|Solid Tumors
930566|NCT02365662|Cancer
930567|NCT02365662|Oncology
930568|NCT02365649|Crohn's Disease
930569|NCT02365623|Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
930570|NCT02365623|TMC207
930571|NCT02365623|Bedaquiline
930572|NCT02365610|Cannabidivarin
930573|NCT02365610|CBDV
930574|NCT02365610|GWP42006
930575|NCT02365597|Urothelial Cancer
930576|NCT02365597|JNJ-42756493
930577|NCT02365597|Tyrosine Kinase Inhibitor
930578|NCT02364505|caregivers
930579|NCT02364492|[C04.588.180]
930580|NCT02364440|skin laxity
930581|NCT02364440|Ultherapy™ System
930582|NCT02364440|rhytids
930583|NCT02364427|Pulse wave velocity
930584|NCT02364427|Arterial stiffness
930585|NCT02364427|AKI
930586|NCT02365532|drug-induced long QT syndrome
930587|NCT02365532|DILQTS
930588|NCT02365532|prolonged QT
930589|NCT02365519|LME636
930590|NCT02365519|dry eye disease
930591|NCT02365519|efficacy
930592|NCT02365519|ocular discomfort
930593|NCT02365506|Congenital Long QT Syndrome
930594|NCT02365506|LQTS
930595|NCT02365506|Long QT2 Syndrome
930596|NCT02365506|LQT2
930597|NCT02365506|Sudden Cardiac Death
930598|NCT02365493|Methicillin-Resistant Staphylococcus aureus (MRSA)
930599|NCT02365467|TEVAR
930600|NCT02365467|Thoracic Aneurysm
930601|NCT02365467|Endovascular Aortic Repair
930602|NCT02365467|Type B Dissection
930603|NCT02365454|TAA
930604|NCT02365441|GIST
930605|NCT02365441|Advanced
930606|NCT02365428|Maternal welfare
930607|NCT02365402|chronic hepatitis B
930608|NCT02365402|peginterferon
930609|NCT02365402|sustained viral response
930610|NCT02365402|entecavir
930611|NCT02365402|HBeAg
930612|NCT02365337|Vitamin D
930613|NCT02365337|time lapse monitoring
930614|NCT02365337|embryo
930615|NCT02365324|culinary skills
930616|NCT02365324|menu planning
930617|NCT02365324|grocery shopping
930618|NCT02365324|children
930619|NCT02365324|healthy eating
930620|NCT02365324|physical activity
930621|NCT02365272|pharmacokinetics
930622|NCT02365272|aminoglycosides
930623|NCT02365246|atopic dermatitis
930624|NCT02365246|immunoadsorption
930625|NCT02365233|Type II Diabetes
930626|NCT02365233|Nonalcoholic fatty liver
930627|NCT02365194|Ventral Hernia
930628|NCT02365194|Prehabilitation
930629|NCT02365181|Shoulder arthroplasty
930630|NCT02365168|Fish allergy
930631|NCT02365155|Frailty
930632|NCT02365155|Heart failure
930633|NCT02365155|Physical activity
930634|NCT02365155|Cognitive state
930635|NCT02365142|Knee Osteoarthritis
930636|NCT02365142|Mesenchimal stem cell
930637|NCT02365142|Osteoarthritis
930638|NCT02365129|BRITE adipose tissue
930639|NCT02365129|physical activity
930640|NCT02365129|Thermogenesis
930641|NCT02365129|Body Temperature Regulation
930642|NCT02365129|Energy Metabolism
930643|NCT02365116|Peer Mentorship
930644|NCT02365116|Psychiatric Hospitalization
930645|NCT02365116|Suicide Risk
930646|NCT02365103|Anemia, Iron-Deficiency
930647|NCT02365103|Iron, Bioavailability
930648|NCT02365103|Hepcidins
930649|NCT02365103|Intestinal, Absorption
930650|NCT02365103|Isotope Labeling, Stable
930651|NCT02365077|Adverse Effect of Glucocorticoids
930652|NCT02365077|Femur Head Necrosis
930653|NCT02365077|Susceptibility
930654|NCT02365077|GWAS
930655|NCT02365025|Sleep patterns
930656|NCT02365025|Electronic Media Exposure
930657|NCT02365025|Parental Intervention
930658|NCT02364934|rocuronium
930659|NCT02364934|sex
930660|NCT02364934|elderly
930661|NCT02364934|Close-loop infusion system
930662|NCT02364921|venous ulcer
930663|NCT02364921|wound healing
930664|NCT02364921|compression bandages
930665|NCT02364908|systemic lupus erythematosus
930666|NCT02364908|antimalarials
930667|NCT02364908|therapeutic education
930668|NCT02364908|Coping questionnaire
930669|NCT02364908|MASRI questionnaire
930670|NCT02364908|morisky medication adherence scale
930671|NCT02364908|lupus Quality Of Life
930672|NCT02364908|internal medicine
930673|NCT02364895|Mailed invitation
930674|NCT02364895|Fecal Occult Blood Test
930675|NCT02364895|Screening
930676|NCT02364869|P-cresyl sulfate
930677|NCT02364869|Indoxyl sulfate
930678|NCT02364869|Intestine
930679|NCT02364869|Endothelial function
930680|NCT02364856|Autonomic Nervous System
930681|NCT02364856|Cerebral Palsy
930682|NCT02364856|Pain
930683|NCT02364856|Children
930684|NCT02364843|Threonine
930685|NCT02364843|enteral feedings
930686|NCT02364843|infants
930687|NCT02364843|amino acid
930688|NCT02364843|requirements
930689|NCT02364830|Pimpinella anisum L.
930690|NCT02364830|Peppermint oil
930691|NCT02364830|Irritable Bowel Syndrome
930692|NCT02364817|Attention Deficit Disorder with Hyperactivity
930693|NCT02364817|Alcohol Dependence
930694|NCT02364817|Adults
930695|NCT02364817|Treatment outcome
930696|NCT02364817|Mental Health
930697|NCT02364791|pulmonary resection
930698|NCT02364791|chest tube
930699|NCT02364791|segmentectomy
930700|NCT02364791|lobectomy
930701|NCT02364778|CAD
930702|NCT02364765|Maxillofacial Orthognathic Surgery
930703|NCT02364765|Hemoglobin
930704|NCT02364765|Red Blood Cells
930705|NCT02364765|Hematocrit
930706|NCT02364765|Blood Platelets
930707|NCT02364765|Body Weight
930708|NCT02364765|Operative Time
930709|NCT02364765|Age Groups
930710|NCT02364765|Gender
930711|NCT02364726|Acupuncture
930712|NCT02364726|Paclitaxel
930713|NCT02364726|15-011
930714|NCT02364700|stroke, robotics, hand rehabilitation
930715|NCT02364674|HRCT
930716|NCT02364674|High Resolution Computed Tomography scans
930717|NCT02364674|Functional Respiratory Imaging
930718|NCT02364674|FRI
930719|NCT02364674|Computed Tomography
930720|NCT02364674|CT
930721|NCT02364674|Bronchiolitis Obliterans
930722|NCT02364674|BOS
930723|NCT02364674|Lung Transplant
930724|NCT02364661|Hepatitis B virus
930725|NCT02364661|Metabolovirus
930726|NCT02364648|Endothelium, vascular
930727|NCT02364648|MitoQ
930728|NCT02364648|Mitochondria
930729|NCT02364648|Oxidative Stress
930730|NCT02364648|Chronic Renal Insufficiency
930731|NCT02364648|Cardiovascular Disease
930732|NCT02364635|Phase I pharmacokinetics and safety study
930733|NCT02364622|flexible intubating stylet
930734|NCT02364622|double-lumen endobronchial tube
930735|NCT02364596|Staphylococcus aureus vaccine
930736|NCT02364596|Staphylococcal infection
930737|NCT02364570|CVD
930738|NCT02364570|Hyperglycemia
930739|NCT02364570|Postprandial
930740|NCT02364570|Vascular Function
930741|NCT02364531|Prostatic Neoplasms
930742|NCT02364531|Prostate Cancer
930743|NCT02364531|Metastatic
930744|NCT02364531|Observational
930745|NCT02364531|Abiraterone Acetate
930746|NCT02364531|ZYTIGA
930747|NCT02364518|Snoring
930748|NCT02364518|snoreplasy
930749|NCT02364518|Tranquill
930750|NCT02364518|Sutures
930751|NCT02364401|Atrial Fibrillation
930752|NCT02364401|Catheter ablation
930753|NCT02364388|breast imaging diagnosis
930754|NCT02364388|breast ultrasound
930755|NCT02364388|Imagio
930756|NCT02364388|Seno Medical Instruments, Inc.
930757|NCT02364388|Seno
930758|NCT02364388|opto-acoustics
930759|NCT02364388|OA
930760|NCT02364336|Chronic Hepatitis B
930761|NCT02364310|Hypertension
930762|NCT02364310|baroreceptor stimulation
930763|NCT02364310|Hypertension resistant
930764|NCT02364297|Bleeding gastric varices
930765|NCT02364297|Transjugular intrahepatic portosystemic shunt (TIPS)
930766|NCT02364297|Injection of adhesives
930767|NCT02364271|High-sensitive troponin
930768|NCT02364271|Coronary Artery Calcium Score
930769|NCT02364271|TIMI score
930770|NCT02364271|Heart-type fatty acid binding protein
930771|NCT02364271|Major adverse cardiac event
930772|NCT02364271|HEART score
930773|NCT02364245|Cerebral Palsy.
930774|NCT02364245|Upper Extremity
930775|NCT02364245|Kinect
930776|NCT02364245|Virtual reality
930777|NCT02364219|prewarming
930778|NCT02364219|perioperative hypothermia
930779|NCT02364219|microdialysis
930780|NCT02364219|tissue oxygen saturation
930781|NCT02364219|cytoreductive surgery
930782|NCT02364206|newly diagnosed glioblastoma
930783|NCT02364206|p38 MAPK inhibitor
930784|NCT02364206|temozolomide
930785|NCT02364206|radiotherapy
930786|NCT02364193|Intrathoracic blood volume
930787|NCT02364193|Extravascular lung water
930788|NCT02364154|biomarker
930789|NCT02364154|screening
930790|NCT02364154|coloscopy
930791|NCT02364141|stroke
930792|NCT02364141|upper extremity
930793|NCT02364141|motor learning
930794|NCT02364141|rehabilitation
930795|NCT02364115|Spinal metastases
930796|NCT02364115|Spinal metastatic disease
930797|NCT02364115|Stereotactic Body Radiotherapy
930798|NCT02364115|Response
930799|NCT02364115|Bone metastases
930800|NCT02364089|Adrenal Incidentaloma
930801|NCT02364089|Subclinical Cushing's syndrome
930802|NCT02364089|Hypertension
930803|NCT02364089|Cardiovascular Risk Factors
930804|NCT02364089|Metabolic Syndrome
930805|NCT02364089|Surgery of adrenal tumor
930806|NCT02364063|Urinary incontinence
930807|NCT02364063|cerebral palsy
930808|NCT02364063|urotherapy
930809|NCT02364063|child
930810|NCT02364037|intrauterine device
930811|NCT02364037|subdermal implant
930812|NCT02364037|contraceptive counseling
930813|NCT02364024|Colon and rectum carcinoma
930814|NCT02364024|Immune response
930815|NCT02364024|Biomarker
930816|NCT02364024|Prognosis
930817|NCT02364011|Biomechanics
930818|NCT02364011|Primary Total Knee Arthroplasty
930819|NCT02364011|TKA Bearings
930820|NCT02364011|Osteoarthritis
930821|NCT02364011|Total Knee Replacement
930822|NCT02363998|detoxification
930823|NCT02363998|agonist taper
930824|NCT02363998|methadone step down
930825|NCT02363998|buprenorphine step down
930826|NCT02363998|opioid withdrawal syndrome
930827|NCT02363959|Hyperbaric Oxygen
930828|NCT02363959|Lung Transplantation
930829|NCT02363959|Central Airway Stenosis
930830|NCT02363959|Airway Exudative Plaques
930831|NCT02363959|Hyperbaric Oxygen Therapy
930832|NCT02363959|Post-Lung Transplantation
930833|NCT02363959|Airway Ischemia
930834|NCT02363959|Endobronchial Biopsy
930835|NCT02363959|Bronchoscopy
930836|NCT02363946|alpha-1 antitrypsin
930837|NCT02363946|AATD
930838|NCT02363933|Perampanel
930839|NCT02363933|Seizures
930840|NCT02363920|COPD patients
930841|NCT02363907|diabetes mellitus
930842|NCT02363907|pediatric
930843|NCT02363907|continuous glucose monitoring system
930844|NCT02363907|CGM
930845|NCT02363855|Neoplasm Metastasis
930846|NCT02363855|Metastatic castration-resistant prostate cancer
930847|NCT02363855|Castration-resistant prostate cancer (CRPC)
930848|NCT02363842|Pressure Ulcer
930849|NCT02363842|Skin IQ MCM coverlet
930850|NCT02363842|Pressure redistribution surfaces
930851|NCT02363829|clinical stages IIA, IIB, IIIA, IIIB, IVA
930852|NCT02363829|invasive carcinoma
930853|NCT02363829|uterine cervix
930854|NCT02363790|Ventral Hernia
930855|NCT02363790|Laparoscopic
930856|NCT02363764|respiratory sampling
930857|NCT02363751|Bellini
930858|NCT02363751|Metastatic
930859|NCT02363751|Chemotherapy
930860|NCT02363751|Bevacizumab
930861|NCT02363738|Bipolar Disorder
930862|NCT02363738|Bipolar Depression
930863|NCT02363738|Inflammation
930864|NCT02363738|Bipolar
930865|NCT02363725|Acute myocardial infarction
930866|NCT02363725|Inflammation
930867|NCT02363725|CRP
930868|NCT02363725|Colchicine
930869|NCT02363712|Osteoarthritis, knee
930870|NCT02363712|therapy
930871|NCT02363712|shoe
930872|NCT02363712|Randomized Controlled Trial
930873|NCT02363699|cholelithiasis
930874|NCT02363699|Cytokines
930875|NCT02363699|under general anesthesia
930876|NCT02363673|Autism Spectrum Disorder
930877|NCT02363673|Children
930878|NCT02363673|Homoeopathy
930879|NCT02363660|HIV-uninfected
930880|NCT02363647|medullary thyroid cancer
930881|NCT02363647|thyroid cancer
930882|NCT02363647|personalized therapy
930883|NCT02363647|personalized chemotherapy
930884|NCT02363647|individualized treatment
930885|NCT02363634|magnesium status
930886|NCT02363634|sleep quality
930887|NCT02363608|Canine-Assisted
930888|NCT02363608|15-010
930889|NCT02363608|post surgery patients
930890|NCT02363595|Genomic Predictors
930891|NCT02363595|14-277
930892|NCT02363569|post coital bleeding
930893|NCT02363569|vaginal bleeding
930894|NCT02363556|Cervical Dilation
930895|NCT02363556|Dilation and Evacuation
930896|NCT02363556|Misoprostol
930897|NCT02363556|Misoprostol-Dilapan
930898|NCT02363556|Abortion
930899|NCT02363530|cataract surgery
930900|NCT02363530|cornea protect
930901|NCT02363530|xerophthalmia
930902|NCT02363530|Corneal clarity
930903|NCT02363517|Hepatitis
930904|NCT02363517|Viral
930905|NCT02363517|Non-A
930906|NCT02363517|Non-B
930907|NCT02363517|Parenterally-Transmitted
930908|NCT02363504|Magnetic Resonance Imaging
930909|NCT02363504|Noradrenaline
930910|NCT02363504|locus coeruleus
930911|NCT02363504|memory
930912|NCT02363465|skin thickness
930913|NCT02363465|high-frequency ultrasound
930914|NCT02363452|Aicardi-Goutières syndrome
930915|NCT02363452|Reverse transcriptase inhibitors
930916|NCT02363452|open single study
930917|NCT02363452|interferon signature
930918|NCT02363426|intravaginal culture
930919|NCT02363426|in vitro fertilization
930920|NCT02363426|blastocyst
930921|NCT02363426|pregnancy
930922|NCT02363413|NIV
930923|NCT02363413|Overlap Syndrom
930924|NCT02363413|home
930925|NCT02363413|hospital
930926|NCT02363400|Nasopharyngeal carcinoma (NPC)
930927|NCT02363400|Epstein-Barr virus (EBV)
930928|NCT02363400|radiotherapy (RT)
930929|NCT02363400|Plasma EBV DNA(pEBV DNA)
930930|NCT02363400|Adjuvant Chemotherapy
930931|NCT02363387|HIV
930932|NCT02363387|antiretroviral medications
930933|NCT02363387|incentives
930934|NCT02363374|Rectal cancer stage II
930935|NCT02363374|Rectal cancer stage III
930936|NCT02363374|Multimodality treatment of locally advanced rectal cancer
930937|NCT02363348|L arginine
930938|NCT02363348|Preeclampsia
930939|NCT02363335|GLP-1
930940|NCT02363335|Phosphodiesterase Inhibitor
930941|NCT02363335|GLP
930945|NCT02363309|13C
930946|NCT02363309|Stable Isotopes
930947|NCT02363309|Acetate
930948|NCT02363309|Breath Tests
930949|NCT02363309|Palmitate
930950|NCT02363296|Brain Cooling - Selected
930951|NCT02363296|Brain Cooling Helmet
930952|NCT02363296|Repetitive TMS (rTMS)
930953|NCT02363270|Analgesia
930954|NCT02363270|ketamine
930955|NCT02363257|Smoke free bus policy
930956|NCT02363257|BEST commuters
930957|NCT02363257|BEST employee
930958|NCT02363244|Pap,HPVDNA
930959|NCT02363218|Liver Neoplasms
930960|NCT02363218|Stereotactic Body Radiotherapy
930961|NCT02363218|CyberKnife
930962|NCT02363192|Pharmacy
930963|NCT02363179|Emergency Service, Hospital
930964|NCT02363140|Musculoskeletal System
930965|NCT02363127|Reproductive Techniques
930966|NCT02363127|Infertility
930967|NCT02363127|Reproductive Techniques Assisted
930968|NCT02363088|cervical screening
930969|NCT02363088|uptake
930970|NCT02363088|SMS messages
930971|NCT02363088|text messages
930972|NCT02363088|reminder
930973|NCT02363075|dexamfetamine sulphate
930974|NCT02363075|severe asthenia
930975|NCT02363075|glioma
930976|NCT02363075|MFI-20
930977|NCT02363075|double-blind
930978|NCT02363075|stabilisation phase
930979|NCT02363062|frontotemporal lobar degeneration
930980|NCT02363062|genes
930981|NCT02363062|whole exome sequencing
930982|NCT02363049|Colectomy
930983|NCT02363049|primary tumor resection
930984|NCT02363049|Asymptomatic primary colon cancer
930985|NCT02363049|Unresectable synchronous liver metastasis
930986|NCT02363049|TNM Staging Primary Tumor (T)
930987|NCT02363049|Unresectable
930988|NCT02363023|Ventilator associated pneumonia
930989|NCT02363023|Bronchoalveolar lavage
930990|NCT02363010|Obesity
930991|NCT02363010|Weight loss
930992|NCT02363010|Overweight
930993|NCT02362997|Classical Hodgkin Lymphoma (cHL)
930994|NCT02362997|Diffuse Large B Cell Lymphoma (DLBCL)
930995|NCT02362997|Peripheral T-cell lymphoma (PTCL)
930996|NCT02362984|DLBS1033
930997|NCT02362984|acute ischemic stroke
930998|NCT02362984|MRS
930999|NCT02362984|mNIHSS
931000|NCT02362919|Influenza vaccination
931001|NCT02362919|Elderly individuals
931002|NCT02362919|Prospective cohort study
931003|NCT02362919|response
931004|NCT02362906|pneumonia
931005|NCT02362906|pediatrics
931006|NCT02362893|Hypertension
931007|NCT02362893|Adherence
931008|NCT02362893|Direct Observed Therapy (DOT)
931009|NCT02362893|RCT
931010|NCT02362854|dental implant
931011|NCT02362854|laser
931012|NCT02362854|diode laser
931013|NCT02362854|peri-implantitis
931014|NCT02362854|bacterial count
931015|NCT02362828|Post-Dural Puncture Headache
931016|NCT02362828|Blood Patch, epidural
931017|NCT02362828|Obstetrics
931018|NCT02362828|European Society of Anaesthesiology (ESA)
931019|NCT02362828|epidemiology
931020|NCT02362828|Accidental Dural Puncture (ADP)
931021|NCT02362828|Anaesthesia
931022|NCT02362828|childbirth complication
931023|NCT02362828|epidural analgesia
931024|NCT02362828|postdural puncture headache
931025|NCT02362828|prophylactic epidural blood patch
931026|NCT02362828|epidural
931027|NCT02362776|NMR spectroscopy
931028|NCT02362776|metabolic changes
931029|NCT02362776|blood plasma
931030|NCT02362776|biomarker
931031|NCT02362776|cancer
931032|NCT02362750|comparative effectiveness
931033|NCT02362750|survivorship
931034|NCT02362750|Patient-Centered Outcomes Research
931035|NCT02362685|Metabolic myopathies
931036|NCT02362685|Exercise testing
931037|NCT02362685|Blood sample
931038|NCT02362685|Muscle biopsy
931039|NCT02362685|Genetic analysis
931040|NCT02362685|Cycloergometer
931041|NCT02362685|Grip-test
931042|NCT02362685|Exercise physiology
931043|NCT02362685|Muscle physiology
931044|NCT02362659|non-valvular
931045|NCT02362659|atrial fibrillation
931046|NCT02362659|percutaneous coronary intervention
931047|NCT02362646|Heart Failure
931048|NCT02362646|Left Ventricular Assist Device
931049|NCT02362646|Heart Transplantation
931050|NCT02362646|Cardiomyopathy, Destination Therapy
931051|NCT02362646|Cell Therapy
931052|NCT02362646|Bridge to Transplant
931053|NCT02362594|PD1
931054|NCT02362594|PDL1
931055|NCT02362581|Prophylaxis treatment
931056|NCT02362581|On demand treatment
931057|NCT02362581|Severe hemophilia A
931058|NCT02362581|Moderate hemophilia A
931059|NCT02362568|Intubation; Difficult
931060|NCT02362555|Ossification of nuchal ligament
931061|NCT02362490|chronic hepatitis B
931062|NCT02362490|interferon
931063|NCT02362490|Nucleotide analogues
931064|NCT02362490|HBsAg
931065|NCT02362464|Multi-epitope
931066|NCT02362464|Tarp Peptide
931067|NCT02362464|Dendritic Cell Vaccine
931068|NCT02362464|D0 Prostate Cancer
931069|NCT02362451|Dendritic Cell Vaccine
931070|NCT02362451|Multi Epitope Tarp Peptide
931071|NCT02362451|Autolougous Dendritic Cell
931072|NCT02362451|D0 Prostate Cancer
931073|NCT02362451|Vaccine Therapy
931074|NCT02362438|Intrathecal
931075|NCT02362438|AAVp Mediated Gene Transfer
931076|NCT02362438|Phase 1
931077|NCT02362438|Safety Study
931078|NCT02362438|Giant Axonal Neuropathy
931079|NCT02362425|Neuromuscular Disease
931080|NCT02362425|Clinical Trial
931081|NCT02362425|Ryanodine Receptor Type 1
931082|NCT02362425|Myopathy
931083|NCT02362412|major depressive episodes
931084|NCT02362412|FK949E
931085|NCT02362412|quetiapine
931086|NCT02362412|bipolar depression
931087|NCT02362412|bipolar disorder
931088|NCT02362373|epilepsy
931089|NCT02362373|contraception
931090|NCT02362373|drug interaction
931091|NCT02362360|Ostomy
931092|NCT02362334|dual Sheimpflug analyzer
931093|NCT02362334|intraocular lens power
931094|NCT02362334|optical low-coherence reflectometry
931095|NCT02362321|[C10.228.140.300.535.450.400.120]
931096|NCT02362295|palliative care
931097|NCT02362295|vulnerable population
931098|NCT02362295|qualitative research
931099|NCT02362282|stroke
931100|NCT02362282|walking
931101|NCT02362282|cognition
931102|NCT02362282|rehabilitation
931103|NCT02362256|Opioid detoxification
931104|NCT02362256|Opioid antagonist induction
931105|NCT02362256|Conscious sedation
931106|NCT02362243|low back pain
931107|NCT02362243|low back injury
931108|NCT02362243|firefighter
931109|NCT02362243|prevention
931110|NCT02362243|physical fitness
931111|NCT02362243|exercise training
931112|NCT02362243|worksite
931113|NCT02362243|web-based
931114|NCT02362165|multiple myeloma
931115|NCT02362165|cyclophosphamide
931116|NCT02362165|bortezomib
931117|NCT02362165|doxorubicin
931118|NCT02362165|peripheral neuropathy
931119|NCT02362152|Actinic keratosis
931120|NCT02362152|Solar keratosis
931121|NCT02362152|Field treatment
931122|NCT02362152|Ingenol mebutate
931123|NCT02362152|Picato
931124|NCT02362126|Endoscopic full thickness resection
931125|NCT02362126|EFTR
931126|NCT02362126|FTRD
931127|NCT02362126|OTSC
931128|NCT02362087|pain
931129|NCT02362061|junctional zone
931130|NCT02362061|implantation
931131|NCT02362061|three D ultraosund
931132|NCT02362061|Assisted Reproductive Technology
931133|NCT02362061|Pregnancy
931134|NCT02362035|Bruton tyrosine kinase inhibitor
931135|NCT02362035|Btk
931136|NCT02362035|B-Cell Malignancies
931137|NCT02362035|Mantle Cell
931138|NCT02362035|Multiple Myeloma
931139|NCT02362035|CLL
931140|NCT02362035|SLL
931141|NCT02362035|DLBCL
931142|NCT02362035|Follicular
931143|NCT02362035|Waldenstrom
931144|NCT02362035|Burkitt lymphoma
931145|NCT02362035|marginal zone lymphomas
931146|NCT02362035|hairy cell leukemia
931147|NCT02362035|B cell acute lymphoid leukemia
931148|NCT02362035|Acalabrutinib
931149|NCT02362035|ACP-196
931150|NCT02362009|Myomas
931151|NCT02362009|Leiomyomas
931152|NCT02362009|Fibromas
931153|NCT02361970|sepsis
931154|NCT02361970|gamma delta T cells
931155|NCT02361970|immunosuppression
931156|NCT02361944|oxygen
931157|NCT02361944|hyperoxia
931158|NCT02361944|reactive oxygen species
931159|NCT02361944|oxidative stress
931160|NCT02361944|oxidative damage
931161|NCT02361944|endothelial function
931162|NCT02361944|vascular reactivity
931163|NCT02361944|mitochondrial function
931164|NCT02361944|surgery
931165|NCT02361944|anesthesia
931166|NCT02361944|kidney injury
931167|NCT02361944|renal failure
931168|NCT02361944|delirium
931169|NCT02361944|myocardial injury
931170|NCT02361944|arrythmia
931171|NCT02361931|accelerating healing
931172|NCT02361931|diabetic chronic wounds
931173|NCT02361931|diabetic patients
931174|NCT02361931|diabetic chronic ulcers
931175|NCT02361931|Wagner grade II
931176|NCT02361931|infection
931177|NCT02361931|necrosis
931178|NCT02361931|erythema
931179|NCT02361931|mild drainage
931180|NCT02361905|fibroid
931181|NCT02361905|cellular leiomyomas
931182|NCT02361905|GnRH analogue
931183|NCT02361905|ulipristal acetate
931184|NCT02361892|ovarian reserve
931185|NCT02361892|infertility
931186|NCT02361892|leiomyomas
931187|NCT02361892|ulipristal acetate
931188|NCT02361879|fibroids
931189|NCT02361879|gnrh analogue
931190|NCT02361879|ulipristal acetate
931191|NCT02361879|hysteroscopy
931192|NCT02361840|Troponin I
931193|NCT02361840|Pediatric shock
931194|NCT02361827|Vitamin D
931195|NCT02361827|IVF outcome
931201|NCT02361801|cardiac surgery
931202|NCT02361801|dobutamine
931203|NCT02361788|neonatal hyperbilirubinemia
931204|NCT02361788|etiology
931205|NCT02361788|incidence
931206|NCT02361788|risk factors
931212|NCT02361710|Vitamin D
931213|NCT02361710|pregnancy rate
931214|NCT02361710|eFET
931215|NCT02361697|pediatric multiple sclerosis
931216|NCT02361697|clinically isolated syndrome in children
931217|NCT02361697|biomarker
931218|NCT02361697|magnetic resonance imaging
931219|NCT02361697|diffusion weighted imaging
931220|NCT02361684|cost-effectiveness
931221|NCT02361684|blended treatment
931222|NCT02361684|Internet based treatment
931223|NCT02361684|Efficacy
931224|NCT02361684|Depression
931225|NCT02361684|cognitive behavioural therapy
931226|NCT02361645|nonsteroidal antiinflammatory drugs
931227|NCT02361645|prostaglandin E2
931228|NCT02361645|vitrectomy
931229|NCT02361606|adolescents
931230|NCT02361606|cognitive behavioral internet intervention
931231|NCT02361593|endoscopic sclerotherapy, esophageal varices, transparent cap
931232|NCT02361567|Post Operative Pain
931233|NCT02361567|Addiction
931234|NCT02361528|Septic shock
931235|NCT02361528|Severe sepsis
931236|NCT02361528|GM-CSF
931237|NCT02361528|Immunosuppression
931238|NCT02361528|Hospital-acquired infections
931239|NCT02361528|ICU-acquired infections
931240|NCT02361528|HLA-DR
931241|NCT02361528|Monocytes
931242|NCT02361515|Prostate
931243|NCT02361515|Hypofractionated radiotherapy
931244|NCT02361515|Stereotactic irradiation
931245|NCT02361515|Spacer
931246|NCT02361515|Rectal and bladder toxicities
931247|NCT02361476|Anaesthesia
931248|NCT02361476|Children
931249|NCT02361476|Clonidine
931250|NCT02361476|Sevoflurane
931251|NCT02361476|Postoperative agitation
931252|NCT02361476|Prevention
931253|NCT02361476|Pharmacokinetics
931254|NCT02361476|Safety
931255|NCT02361463|Laparoscopy;
931256|NCT02361463|Training;
931257|NCT02361463|Three-Dimensional
931258|NCT02361450|Faecal incontinence
931259|NCT02361450|Spina Bifida
931260|NCT02361450|Enema
931261|NCT02361450|Constipation
931262|NCT02361450|Myelomeningocele
931263|NCT02361450|Human
931264|NCT02361437|diabetes type II
931265|NCT02361437|diabetic ulcers
931266|NCT02361424|PXT00864
931267|NCT02361424|mild AD
931268|NCT02361424|phase 2a
931269|NCT02361359|Arthroplasty
931270|NCT02361346|CD20
931271|NCT02361346|immunotoxin
931272|NCT02361346|NHL
931273|NCT02361346|non-Hodgkin's lymphoma
931274|NCT02361346|lymphoma
931275|NCT02361346|cancer
931276|NCT02361346|antibodies
931277|NCT02361346|immunotherapy
931278|NCT02361346|safety
931279|NCT02361346|pharmacokinetics
931280|NCT02361346|maximum tolerated dose
931281|NCT02361346|MT-3724
931282|NCT02361346|relapsed
931283|NCT02361346|refractory
931284|NCT02361346|leukemia
931285|NCT02361346|CLL
931286|NCT02361346|SLL
931287|NCT02361320|Pancreatic cancer
931288|NCT02361320|Pancreatic ductal adenocarcinoma
931289|NCT02361320|PDAC
931290|NCT02361320|Computed tomography
931291|NCT02361320|CT
931292|NCT02361320|Questionnaire
931293|NCT02361320|Survey
931294|NCT02361268|end-stage renal disease
931295|NCT02361268|hemodialysis
931296|NCT02361268|yoga
931297|NCT02361268|mind-body medicine
931298|NCT02361268|meditation
931299|NCT02361242|PXT00864
931300|NCT02361242|mild AD
931301|NCT02361242|phase 2a
931302|NCT02361138|SHR3824 Type 2 diabetes mellitus SGLT2
931303|NCT02361125|Fatigue
931304|NCT02361125|Cancer related fatigue
931305|NCT02361125|Methylphenidate
931306|NCT02361125|Methylphenidate Hydrochloride
931307|NCT02361125|Ritalin
931308|NCT02361125|Concerta
931309|NCT02361125|Fatigue evaluations
931310|NCT02361086|castration-resistant prostate cancer
931311|NCT02361086|CYP17
931312|NCT02361086|P450c17a
931313|NCT02361086|lyase
931314|NCT02361073|Stress-induced cardiomyopathy
931315|NCT02361073|ERP
931316|NCT02361034|Safety and pharmacokinetics of drug in healthy volunteers
931317|NCT02361021|Critical Care
931318|NCT02361021|Non invasive ventilation
931319|NCT02361021|Electrical impedance tomography
931320|NCT02361021|End expiratory lung volume
931321|NCT02361021|Lung ultrasound score
931322|NCT02361008|Infundibular Ventricular Septal Defect
931323|NCT02361008|occlusion
931324|NCT02361008|TEE-guided
931325|NCT02361008|asymmetric occluder
931326|NCT02361008|surgical repair
931327|NCT02360982|Delirium
931328|NCT02360982|regional anesthesia
931329|NCT02360982|general anesthesia
931330|NCT02360969|strabismus
931331|NCT02360969|surgical procedure
931332|NCT02360969|anesthesia
931333|NCT02360969|squint
931334|NCT02360969|child
931335|NCT02360956|Olmesartan medoxomil
931336|NCT02360956|Epicardial adipose tissue
931337|NCT02360956|Multidetector Computed Tomography
931338|NCT02360943|elderly patients
931339|NCT02360943|Pulmonary embolism
931340|NCT02360943|Anticoagulant treatments
931341|NCT02360930|Acute Lymphoblastic Leukemia
931342|NCT02360930|Pharmacokinetics
931343|NCT02360930|Vincristine
931344|NCT02360917|Cognitive Dysfunction
931345|NCT02360917|Cancer Survivorship
931346|NCT02360891|multimodal biomarkers
931347|NCT02360891|prognosis
931348|NCT02360891|endophenotypes
931349|NCT02360878|DJBS
931350|NCT02360878|Duodenal-jejunal bypass sleeve
931351|NCT02360878|Duodenal-jejunal bypass liner
931352|NCT02360878|Endobarrier
931353|NCT02360878|Obesity
931354|NCT02360878|Type 2 diabetes
931355|NCT02360878|Incretin hormones
931356|NCT02360878|Postprandial glucose metabolism
931357|NCT02360813|Cognitive remediation therapy
931358|NCT02360813|Psychiatric rehabilitation
931359|NCT02360813|Forensic mental health
931360|NCT02360813|Forensic psychiatry
931361|NCT02360813|Clinical psychology
931362|NCT02360813|Randomized controlled trial
931363|NCT02360813|Principle driven intervention
931364|NCT02360813|Psychological Intervention
931365|NCT02360813|Cognitive enhancement
931366|NCT02360800|Bleeding
931367|NCT02360800|Heart Surgery
931368|NCT02360800|Ascending Aorta Replacement
931369|NCT02360787|Almonds
931370|NCT02360787|Energy restriction
931371|NCT02360787|Obesity
931372|NCT02360787|Body weight
931373|NCT02360787|Body fat
931374|NCT02360787|Blood pressure
931375|NCT02360787|Cognitive function
931376|NCT02360774|Canagliflozin
931377|NCT02360774|Obesity
931378|NCT02360774|Weight Loss
931379|NCT02360774|Body Weight
931380|NCT02360774|Body Weight Changes
931381|NCT02360774|Overweight
931382|NCT02360774|Sodium-glucose transporter subtype 2 inhibitor
931383|NCT02360761|Lung cancer;Elderly;Sublobar resection;Lobectomy
931384|NCT02360696|Duodenal Eosinophilia
931385|NCT02360696|Functional Dyspepsia
931386|NCT02360696|Mucosal Eosinophilia
931387|NCT02360683|Subthalamic neurostimulation
931388|NCT02360657|Alzheimer's Disease
931389|NCT02360657|Alzheimer Dementia
931390|NCT02360657|JNJ-54861911
931391|NCT02360657|Beta Secretase Inhibitor
931392|NCT02360631|smoking
931393|NCT02360631|quit smoking
931394|NCT02360631|smoking treatment
931395|NCT02360618|Bladder Cancer
931396|NCT02360618|Metformin
931397|NCT02360618|Simvastatin
931398|NCT02360618|Combination Therapy
931399|NCT02360605|colorectal cancer screening
931400|NCT02360605|low literacy
931401|NCT02360605|community clinics
931402|NCT02360605|Fecal Immunochemical Test
931403|NCT02360579|Autologous Adoptive Cell Transfer
931404|NCT02360579|Autologous Adoptive Cell Therapy
931405|NCT02360579|Cellular Immuno-therapy
931406|NCT02360579|Cell Therapy
931407|NCT02360579|Tumor Infiltrating Lymphocytes
931408|NCT02360579|TIL
931409|NCT02360579|LN-144
931410|NCT02360579|IL-2
931411|NCT02360579|Melanoma
931412|NCT02360566|Psychosis
931413|NCT02360566|Schizophrenia
931414|NCT02360566|Participatory Video
931415|NCT02360566|Narrative
931416|NCT02360540|Pulmonary Embolism
931417|NCT02360540|Diagnostic strategy
931418|NCT02360540|Exclusion
931419|NCT02360540|Clinical probability
931420|NCT02360540|Implicit Judgment (Gestalt)
931421|NCT02360540|PERC
931422|NCT02360501|nasopharyngeal carcinoma
931423|NCT02360501|induction chemotherapy
931424|NCT02360501|docetaxel
931425|NCT02360501|xeloda
931426|NCT02360475|Vaccine
931427|NCT02360475|Immunogenicity
931428|NCT02360475|Safety
931429|NCT02360475|Respiratory syncytial virus (RSV)
931430|NCT02360475|Reactogenicity
931431|NCT02360462|Transcranial Direct Current Stimulation
931432|NCT02360462|tDCS
931433|NCT02360462|Hallux Valgus
931434|NCT02360462|Chronic Pain
931435|NCT02360449|Pivotal Response Treatment
931436|NCT02360449|Applied Behavior Analysis
931437|NCT02360449|Peer Initiation
931438|NCT02360449|Social Skills Group
931439|NCT02360436|Rett
931440|NCT02360436|MeCP2
931441|NCT02360436|Glutathione
931442|NCT02360436|Cysteine
931443|NCT02360436|ROS
931444|NCT02360384|wireless motility capsule
931445|NCT02360332|Autism
931446|NCT02360332|transition to adulthood
931447|NCT02360332|employment
931448|NCT02360332|High School Seniors
931449|NCT02360319|First episode or recent onset
931450|NCT02360293|Exercise
931451|NCT02360293|App-mediated
931452|NCT02360293|Veterans
931453|NCT02360280|Depressive Disorder, Treatment-Resistant
931454|NCT02360267|Bipolar Disorder
931455|NCT02360267|Pediatric
931456|NCT02360267|Offspring
931457|NCT02360267|Depression
931458|NCT02360267|Mania
931459|NCT02360267|Children of parents who suffer from Bipolar disorder
931460|NCT02360228|tACS
931461|NCT02360228|tDCS
931462|NCT02360228|sham
931463|NCT02360228|auditory hallucinations
931464|NCT02360228|Schizophrenia
931465|NCT02360228|Schizoaffective Disorder
931466|NCT02360176|single port surgery
931467|NCT02360176|bariatric surgery
931468|NCT02360176|sleeve gastrectomy
931469|NCT02360176|randomise prospective study
931470|NCT02360176|complication rate
931471|NCT02360150|cardiac angiography
931472|NCT02360150|cardiac MRI
931473|NCT02360137|carotids
931474|NCT02360137|plaque
931475|NCT02360137|characteristics
931476|NCT02360137|stroke
931477|NCT02360111|GVHD Prophylaxis
931478|NCT02360111|Cyclophosphamide
931479|NCT02360111|Renal Insufficiency
931480|NCT02360111|Hematopoietic Stem Cell Transplant
931481|NCT02360111|14-273
931482|NCT02360098|Emergence from Anesthesia
931483|NCT02360098|Anterior temporal lobectomy
931484|NCT02360098|Amygdalohippocampectomy
931485|NCT02360098|Anesthesia
931486|NCT02360085|Cervical Myelopathy
931487|NCT02360085|Hypotension
931488|NCT02360072|child
931489|NCT02360072|allergic rhinitis
931490|NCT02360072|asthma
931491|NCT02360072|nitric oxide
931492|NCT02360072|bronchial hyper-responsiveness
931493|NCT02360059|Breast cancer
931494|NCT02360059|Neuropathy
931495|NCT02360059|Paclitaxel
931496|NCT02360059|Metformin
931497|NCT02360059|Metformin ER
931498|NCT02360059|Placebo
931499|NCT02360059|Sugar pill
931500|NCT02360059|Questionnaires
931501|NCT02360059|Sensory tests
931502|NCT02360059|Fine-motor tests
931503|NCT02360059|Surveys
931504|NCT02360020|coronary stent
931505|NCT02360020|outcome
931506|NCT02360007|opioids
931507|NCT02360007|buprenorphine
931508|NCT02360007|interim treatment
931509|NCT02360007|opioid dependence
931510|NCT02359994|hemostasis
931511|NCT02359981|Weight loss, Fitness
931512|NCT02359968|resectable esophageal
931513|NCT02359968|junctional cancer
931514|NCT02359968|FOLFOX
931515|NCT02359968|paclitaxel-carboplatin
931516|NCT02359942|Helicobacter pylori infection
931517|NCT02359942|Eradication
931518|NCT02359942|Urea breath test
931519|NCT02359929|graft versus host disease
931520|NCT02359929|GVHD
931521|NCT02359890|Interventional
931522|NCT02359890|Radiofrequency ablation
931523|NCT02359890|Paroxysmal Atrial Fibrillation
931524|NCT02359877|pegylated interferon beta
931525|NCT02359877|Volunteers
931526|NCT02359838|Hematologic Malignancy
931527|NCT02359838|Geriatric Assessment
931528|NCT02359838|Geriatric Oncology
931529|NCT02359838|Frailty
931530|NCT02359812|Stroke
931531|NCT02359812|Hemiplegia
931532|NCT02359812|Upper extremity
931533|NCT02359812|Muscle hypertonia
931534|NCT02359812|Arm
931535|NCT02359812|Hand
931536|NCT02359799|Cerebral palsy
931537|NCT02359799|Ankle
931538|NCT02359773|Magnetocardiography
931539|NCT02359773|Myocardial Infarction
931540|NCT02359773|Non-ischaemic chest pain
931541|NCT02359760|Rapid orthodontics
931542|NCT02359760|accelerated orthodontics
931543|NCT02359760|Piezocision
931544|NCT02359760|flapless corticotomies
931545|NCT02359760|minimaly invasive
931546|NCT02359747|free gDNA
931547|NCT02359747|culture media
931548|NCT02359734|Patient safety
931549|NCT02359734|Medication errors
931550|NCT02359734|Smart infusion pump
931551|NCT02359721|Colony forming units Antimicrobial agents
931552|NCT02359721|Microbial colonization
931553|NCT02359695|Poor ovarian response
931554|NCT02359695|IVF
931555|NCT02359695|Growth hormone
931556|NCT02359643|Kawasaki disease
931557|NCT02359617|continuous glucose sensor
931558|NCT02359617|subcutaneous insulin infusion
931559|NCT02359617|closed-loop glucose control
931560|NCT02359617|type 1 diabetes
931561|NCT02359604|infant
931562|NCT02359604|ppi
931563|NCT02359604|proton pump inhibitor
931564|NCT02359604|microbiome
931565|NCT02359604|Microbiota
931566|NCT02359578|lymphatic system
931567|NCT02359578|occlusion pressure
931568|NCT02359578|Indocyanine Green
931569|NCT02359526|Chronic Diabetic Macular Edema
931570|NCT02359526|Iluvien
931571|NCT02359526|Intra-vitreal injections
931572|NCT02359526|Pilot study
931573|NCT02359513|bulimia
931574|NCT02359513|serotoninergic brain activity
931575|NCT02359513|fluoxetine
931576|NCT02359513|serotoninergic antidepressant
931577|NCT02359513|brain serotonin profile
931578|NCT02359513|positon emission tomography
931579|NCT02359500|68Ga- DOTATOC
931580|NCT02359500|Diagnosis
931581|NCT02359500|Somatostatin Receptor-Positive Neuroendocrine Tumors
931582|NCT02359487|Namibia
931583|NCT02359487|Alcohol
931584|NCT02359487|HIV
931585|NCT02359487|Sexual risk
931586|NCT02359474|high-risk soft tissue sarcoma
931587|NCT02359474|trabectedin
931588|NCT02359461|Vascular function
931589|NCT02359461|Pulsatile cuts
931590|NCT02359461|Type 2 diabetes
931591|NCT02359461|Endothelium
931592|NCT02359461|Cardiovascular risk
931593|NCT02359461|Vasomotricity
931594|NCT02359461|FMD (Flow Mediated Dilatation)
931595|NCT02359435|Helicobacter pylori
931596|NCT02359435|Proton pump inhibitor
931597|NCT02359435|Eradication
931598|NCT02359396|Randomized open-label study
931599|NCT02359396|Chinese Herbal
931600|NCT02359396|Constipation/drug therapy
931601|NCT02359383|pleural disease
931602|NCT02359383|infecTion
931603|NCT02359383|chest physiotherapy
931604|NCT02359370|Laryngoscopy
931605|NCT02359370|Tracheal Intubation
931606|NCT02359370|Lidocaine
931607|NCT02359370|Magnesium Sulphate
931608|NCT02359370|Cardiovascular Physiological Phenomena
931609|NCT02359331|Helicobacter pylori
931610|NCT02359331|resistance
931611|NCT02359331|rescue therapy
931612|NCT02359318|White spot lesion
931613|NCT02359318|Resin Infiltration
931614|NCT02359318|Icon
931615|NCT02359318|Debonding
931616|NCT02359318|Enamel damages
931617|NCT02359318|Enamel
931618|NCT02359318|Orthodontics
931619|NCT02359266|Mood
931620|NCT02359266|Vitamin D deficiency
931621|NCT02359266|Adjuvant treatment
931622|NCT02359253|Stroke
931623|NCT02359253|Hemiplegia
931624|NCT02359253|Muscle Spasticity
931625|NCT02359253|Upper extremity
931626|NCT02359253|Arm
931627|NCT02359253|Hand
931628|NCT02359253|Passive stretching
931629|NCT02359253|Muscle Stretching Exercises
931630|NCT02359253|Occupational Therapy
931631|NCT02359253|Physical Therapy
931632|NCT02359227|Chronic Heart Failure
931633|NCT02359227|Natriuretic Peptides
931634|NCT02359227|Cenderitide
931635|NCT02359214|Vitamin D
931636|NCT02359214|Cardiovascular disease
931637|NCT02359214|Diabetes
931638|NCT02359214|Obesity
931639|NCT02359214|Cardiometabolic
931640|NCT02359214|Bone disease
931641|NCT02359201|Nicotine replacement therapy
931642|NCT02359201|craving
931643|NCT02359201|Healthy moderately dependant smokers
931644|NCT02359188|Vagus Nerve Stimulation
931645|NCT02359175|Pain
931646|NCT02359175|Pain Measurement
931647|NCT02359175|VAS
931648|NCT02359175|Visual Analog Pain Scale
931649|NCT02359175|Analgesics
931650|NCT02359175|Opioid
931651|NCT02359175|Epidural analgesia
931652|NCT02359175|VATS
931653|NCT02359175|Video-assisted Thoracic Surgery
931654|NCT02359175|Lobectomy
931655|NCT02359175|Wedge Resection
931656|NCT02359175|Segmental Resection
931657|NCT02359162|NK/T-cell lymphoma
931658|NCT02359162|induction chemotherapy
931659|NCT02359162|survival
931660|NCT02359149|Intravitreal injections
931661|NCT02359149|Nurses
931662|NCT02359149|Physicians
931663|NCT02359136|Arthroplasty, Replacement, Hip
931664|NCT02359136|Anesthesia, Local
931665|NCT02359136|Ropivacaine
931666|NCT02359136|Randomized controlled trial
931667|NCT02359110|laparoscopy
931668|NCT02359110|postoperative pain
931669|NCT02359110|gynecology
931670|NCT02359110|gabapentin
931671|NCT02359071|handoff
931672|NCT02359071|signoff
931673|NCT02359071|handover
931674|NCT02359071|sign-out
931675|NCT02359071|shift change
931676|NCT02359071|Emergency Department
931677|NCT02359045|Omega-3-carboxylic acids,
931678|NCT02359045|Phase I,
931679|NCT02359045|Healthy Subjects,
931680|NCT02359045|Pharmacokinetics,
931681|NCT02359045|Relative bioavailability
931682|NCT02359032|Healthy subjects
931683|NCT02359032|Pharmacokinetics of ASP6858
931684|NCT02359032|ASP6858
931685|NCT02359032|Pharmacodynamics of ASP6858
931686|NCT02359006|Analgesia
931687|NCT02359006|pain analgesia
931688|NCT02359006|methadone
931689|NCT02359006|opiates
931690|NCT02358993|Urinary Tract Infections
931691|NCT02358993|Catheter-Related Infections
931692|NCT02358993|Pelvic Reconstructive Surgery
931693|NCT02358993|Urogynecology
931694|NCT02358993|Urinary catheterization
931695|NCT02358993|Post-operative Infections
931696|NCT02358993|Methenamine hippurate
931697|NCT02358980|Multiple Myeloma
931698|NCT02358980|Cast Nephropathy
931699|NCT02358980|Acute kidney injury
931700|NCT02358980|KIDNEY THERAPY
931701|NCT02358980|HFR
931702|NCT02358967|ESRD
931703|NCT02358967|dyslipidemia
931704|NCT02358967|oxidative stress
931705|NCT02358967|inflammation
931706|NCT02358967|Hemodialysis
931707|NCT02358967|CKD
931708|NCT02358954|quantitative sensory testing
931709|NCT02358954|contact heat evoked potentials
931710|NCT02358954|vection stimulation
931711|NCT02358954|3D-turntable
931712|NCT02358954|Volunteers
931713|NCT02358941|ADHD, neurofeedback, computerized cognitive training, school
931714|NCT02358928|NAFLD
931715|NCT02358928|Metabolic syndrome
931716|NCT02358928|Hepatic Magnetic Resonance Spectroscopy
931717|NCT02358928|Obesity
931718|NCT02358902|Transcranial Direct Current Stimulation
931719|NCT02358902|Exercise
931720|NCT02358902|Fibromyalgia
931721|NCT02358876|Parkinson's disease
931722|NCT02358876|Deep brain stimulation
931723|NCT02358876|Bradykinesia
931724|NCT02358850|Tonsillectomy
931725|NCT02358850|Adenoidectomy
931726|NCT02358837|elastosonography
931727|NCT02358837|comparing conventional sonography with ductosonography
931728|NCT02358824|Hypertension
931729|NCT02358824|CKD-828
931730|NCT02358824|Telmisartan
931731|NCT02358824|S-amlodipine
931732|NCT02358824|Pharmacokinetic
931733|NCT02358811|Obstructive Sleep Apnea
931734|NCT02358811|Voxel-Based Morphometry
931735|NCT02358811|Polysomnography
931736|NCT02358811|Magnetic resonance imaging
931737|NCT02358798|Time evolution of respiratory function
931738|NCT02358798|Longitudinal multicenter monitoring of large cohorts
931739|NCT02358798|Preschool aged children
931740|NCT02358798|Detection of cystic fibrosis in neonatal period
931741|NCT02358772|stroke
931742|NCT02358772|thrombolysis
931743|NCT02358772|STEMO
931744|NCT02358759|Abnormal zygote fertilization
931745|NCT02358759|3PNs correction
931746|NCT02358759|Giant oocyte management
931747|NCT02358759|triploidy fertilization
931748|NCT02358759|Maternal nucleus removal
931749|NCT02358746|epicardial catheter ablation
931750|NCT02358733|POR
931751|NCT02358733|IMSI
931752|NCT02358720|bone metastases
931753|NCT02358707|ibuprofen phonophoresis
931754|NCT02358707|High performance liquid chromatography
931755|NCT02358694|IBS
931756|NCT02358694|IBS-D
931757|NCT02358694|SBI
931758|NCT02358681|Intranasal
931759|NCT02358681|Ketorolac
931760|NCT02358681|Pediatric
931761|NCT02358681|Migraine
931762|NCT02358681|Headache
931763|NCT02358655|Oral anticoagulant
931764|NCT02358655|Knowledge translation
931765|NCT02358655|Emergency department
931766|NCT02358642|Rate of Pneumonia
931767|NCT02358642|Mortality rate
931768|NCT02358603|Chronotropic Incompetence
931769|NCT02358603|Heart Failure
931770|NCT02358564|IBS
931771|NCT02358564|Irritable Bowel Syndrome
931772|NCT02358564|Visceral Hypersensitivity
931773|NCT02358564|Permeability
931774|NCT02358564|Small Bowel
931775|NCT02358564|Lactulose
931776|NCT02358564|Mannitol
931777|NCT02358551|Pacemaker
931778|NCT02358551|Axillary Vein
931779|NCT02358551|Subclavian vein
931780|NCT02358551|Clinical Study
931781|NCT02358551|Cardiovascular implantable electronic devices
931782|NCT02358538|PCDH19
931783|NCT02358538|ganaxolone
931784|NCT02358538|neurosteroid
931785|NCT02358538|CDKL5
931786|NCT02358538|LGS
931787|NCT02358538|CSWS
931788|NCT02358512|Intensive Care
931789|NCT02358512|Recovery of Function
931790|NCT02358512|Survivors
931791|NCT02358512|Outcome Assessment (Health Care)
931792|NCT02358512|Medical Economics
931793|NCT02358499|triazoles
931794|NCT02358499|fungi
931795|NCT02358499|transplantation, hematopoietic stem cell
931796|NCT02358499|leukemia
931797|NCT02358499|pediatrics
931798|NCT02358499|pharmacokinetics
931799|NCT02358499|bone marrow failure syndrome
931800|NCT02358486|Functional Dyspepsia
931801|NCT02358486|Acupuncture
931802|NCT02358486|Functional MRI
931803|NCT02358473|Nonsmall Cell Lung Cancer
931804|NCT02358473|NSCLC
931805|NCT02358473|Non-Small-Cell Lung Carcinoma
931806|NCT02358473|Carcinoma, Non-Small Cell Lung
931807|NCT02358473|KW-0761
931808|NCT02358473|Mogamulizumab
931809|NCT02358460|neonatal
931810|NCT02358460|respiratory
931811|NCT02358460|mechanical ventilation
931812|NCT02358447|total knee arthroplasty
931813|NCT02358447|total knee prothesis
931814|NCT02358447|Spectrometry, X-Ray Emission
931815|NCT02358447|SPECT/CT
931816|NCT02358447|measurement of TKA component position
931817|NCT02358434|Implant
931818|NCT02358421|Rotterdam's diagnostic criteria of PCOS
931819|NCT02358421|Risk of OHSS
931820|NCT02358356|midgut
931821|NCT02358356|pancreatic
931822|NCT02358356|neuroendocrine
931823|NCT02358356|advanced
931824|NCT02358356|unresectable low
931825|NCT02358356|intermediate grade
931826|NCT02358356|mNETs
931827|NCT02358356|pNETs
931828|NCT02358343|Comorbid Depression
931829|NCT02358343|Major Depressive Disorder
931830|NCT02358343|Dysthymia
931831|NCT02358343|Cognitive Behavioral therapy (CBT)
931832|NCT02358343|Sertraline
931833|NCT02358343|Engagement Interview
931834|NCT02358343|End Stage Renal Disease (ESRD)
931835|NCT02358343|Hemodialysis
931836|NCT02358317|Autism
931837|NCT02358317|Postural Stability
931838|NCT02358317|Exergaming
931839|NCT02358317|White Matter
931840|NCT02358252|Heart Rate Variability
931841|NCT02358252|orthostatic hypotension
931842|NCT02358252|stroke
931843|NCT02358252|integrated intelligent biosensor system
931844|NCT02358239|dizziness and vertigo
931845|NCT02358239|emergency department (ED)
931846|NCT02358239|clinical trial
931847|NCT02358239|acupuncture
931848|NCT02358226|Substance-Related Disorders
931849|NCT02358226|Human Immunodeficiency Virus
931850|NCT02358226|Alcoholism
931851|NCT02358226|South Africa
931852|NCT02358226|Men
931853|NCT02358226|Soccer
931854|NCT02358226|Vocational Training
931855|NCT02358213|reproductibility
931856|NCT02358174|Hemorrhoids
931857|NCT02358174|MMP
931858|NCT02358174|NGAL
931859|NCT02358174|Matrix Metalloproteinases
931860|NCT02358161|Pancreatic cancer
931861|NCT02358161|LDE225
931862|NCT02358161|Gemcitabine
931863|NCT02358161|nab paclitaxel
931864|NCT02358148|Acute Coronary Syndrome
931865|NCT02358148|Chest Pain
931866|NCT02358148|ACS
931867|NCT02358148|Risk Stratification Score
931868|NCT02358148|HEART Score
931869|NCT02358148|Modified TIMI
931870|NCT02358148|Coronary Artery Disease
931871|NCT02358148|Risk Factors
931872|NCT02358148|Myocardial Infarction
931873|NCT02358135|Pragmatic
931874|NCT02358135|Equivalency
931875|NCT02358135|Teledermatology
931876|NCT02358109|Cost-Benefit Analysis, Exercise,Women,Diseases/Prevention
931877|NCT02358096|Chronic Kidney Disease
931878|NCT02358096|Type 2 Diabetes
931879|NCT02358096|ASP8232
931880|NCT02358070|Hepatocellular Carcinoma
931881|NCT02358057|Deep sedation
931882|NCT02358057|Dexmedetomidine
931883|NCT02358057|Emergency Service, Hospital
931884|NCT02358031|PD-1
931885|NCT02358031|PD-L1
931886|NCT02358018|68Ga-DOTATOC
931887|NCT02358018|PET/CT scan
931888|NCT02358018|14-226
931889|NCT02357992|Lung cancer
931890|NCT02357992|Non-small cell lung cancer
931891|NCT02357992|NSCLC
931892|NCT02357992|Squamous cell carcinoma
931893|NCT02357992|Adenocarcinoma with or without BAC features
931894|NCT02357992|Large cell carcinoma with or without neuroendocrine features
931895|NCT02357992|Neuroendocrine carcinoma
931896|NCT02357992|Bronchioloalveolar cell carcinoma
931897|NCT02357992|Stereotactic radiotherapy (SRT)
931898|NCT02357992|SRT
931899|NCT02357992|Stereotactic ablative radiotherapy
931900|NCT02357992|SABR
931901|NCT02357992|Radiation therapy
931902|NCT02357992|XRT
931903|NCT02357979|caries
931904|NCT02357979|prevention
931905|NCT02357979|laser
931906|NCT02357979|fluoride
931907|NCT02357966|Staph
931908|NCT02357966|antibody
931909|NCT02357940|Eczema
931910|NCT02357940|Skin Irritation
931911|NCT02357927|fears of recurrence
931912|NCT02357927|cancer
931913|NCT02357927|brief intervention
931914|NCT02357927|telephone counseling
931915|NCT02357927|following primary cancer treatment
931916|NCT02357914|Ultrasound
931917|NCT02357914|Shoulder
931918|NCT02357914|Spinal Cord Injury
931919|NCT02357914|Fluoroscopy
931920|NCT02357888|Nicotine replacement therapy
931921|NCT02357888|craving
931922|NCT02357862|Cardiovascular Diseases
931923|NCT02357862|Heart Diseases
931924|NCT02357862|Heart Valve Diseases
931925|NCT02357862|Mitral Valve Annuloplasty
931926|NCT02357862|Tricuspid Valve Insufficiency
931927|NCT02357823|Pneumococcal vaccine
931928|NCT02357823|HIV infection
931929|NCT02357823|13-valent Pneumococcal Conjugate Vaccine
931930|NCT02357823|23-valent Pneumococcal Polysaccharide Vaccine
931931|NCT02357784|Sacral Neuromodulation
931932|NCT02357784|SNM
931933|NCT02357784|Dual Incontinence
931934|NCT02357784|Current Perception Threshold Testing
931935|NCT02357784|CPT Testing
931936|NCT02357784|Fecal Incontinence
931937|NCT02357784|Urinary Incontinence
931938|NCT02357784|Afferent Nerve Sensation
931939|NCT02357784|InterStim
931940|NCT02357771|misalignment of the two dental arches
931941|NCT02357771|mal-align teeth
931942|NCT02357758|Antibiotic Prophylaxis
931943|NCT02357758|Urinary Microbiota
931944|NCT02357745|neopterin
931945|NCT02357745|plasma
931946|NCT02357745|urine
931947|NCT02357745|saliva
931948|NCT02357745|menopause
931949|NCT02357745|periodontitis
931950|NCT02357732|Metastatic Melanoma
931951|NCT02357719|Sleep Apnea Syndromes
931952|NCT02357719|Polysomnography
931953|NCT02357719|Holter ECG
931954|NCT02357719|Thoracic impedance
931955|NCT02357719|Heart rate variability
931956|NCT02357719|Nasal flow
931957|NCT02357693|nausea, postoperative
931958|NCT02357693|postoperative nausea
931959|NCT02357693|postoperative vomiting
931960|NCT02357693|vomiting, postoperative
931961|NCT02357641|acute coronary disease, echographic strain analysis, cut off
931962|NCT02357602|Participants
931963|NCT02357602|HIV-1 negative
931964|NCT02357589|3D
931965|NCT02357589|laparoscopy
931966|NCT02357589|cholecystectomy
931967|NCT02357563|fibroid
931968|NCT02357563|GnRH analogue
931969|NCT02357563|ulipristal acetate
931970|NCT02357537|Telemedicine
931971|NCT02357524|Effects on coagulation tests in healthy volunteers
931972|NCT02357511|sensitivity
931973|NCT02357511|specificity
931974|NCT02357511|novel blood pressure monitor
931975|NCT02357511|Saturation
931976|NCT02357498|pituitary
931977|NCT02357498|adenoma
931978|NCT02357498|transsphenoidal surgery
931979|NCT02357485|ADSC
931980|NCT02357485|osteoarthritis
931981|NCT02357485|knee
931982|NCT02357485|adipose
931983|NCT02357472|Reproductive aging
931984|NCT02357472|DHEA
931985|NCT02357472|poor ovarian responder
931986|NCT02357459|Osteoarthritis
931987|NCT02357459|Knee
931988|NCT02357459|Pain
931989|NCT02357459|Steroid
931990|NCT02357459|Intra-articular
931991|NCT02357459|Injection
931992|NCT02357420|Diabetes Mellitus
931993|NCT02357420|Delayed Gastric Emptying
931994|NCT02357420|Vomiting
931995|NCT02357420|Gastroparesis
931996|NCT02357420|Gastrointestinal Motility Disorder
931997|NCT02357407|fluoroquinolones
931998|NCT02357407|pharmacokinetic
931999|NCT02357407|infections
932000|NCT02356354|molecular factors
932001|NCT02356354|cutaneous innervation
932002|NCT02356354|skin biopsy
932003|NCT02356354|post-burn scar
932004|NCT02356315|Brain
932005|NCT02356315|Brain Stem
932006|NCT02356315|Spinal Cord
932007|NCT02356315|Neurophysiology
932008|NCT02356315|Magnetic Resonance Imaging
932009|NCT02356289|Hypertrophic Cardiomyopathy
932010|NCT02356263|stressful events
932011|NCT02356263|psychological stress
932012|NCT02356263|life experiences
932013|NCT02356250|liver biopsy f 4
932014|NCT02356237|Episiotomy
932015|NCT02356237|Obstetric Anal Sphincter Injury
932016|NCT02356224|SHR3824 Type 2 diabetes mellitus SGLT2
932017|NCT02356211|falls
932018|NCT02357368|HIV-negative
932019|NCT02357329|fat taste
932020|NCT02357329|food preference
932021|NCT02357329|consumption
932022|NCT02357329|free fatty acids
932023|NCT02357316|Taste responses of healthy individuals
932024|NCT02357303|Randomized controlled trial
932025|NCT02357303|Endoscopy
932026|NCT02357303|Gastric mucosa
932027|NCT02357303|Simethicone
932028|NCT02357303|Acetylcysteine
932034|NCT02357277|Osteoporosis
932035|NCT02357277|Glucocorticoids
932036|NCT02357277|Postmenopausal
932037|NCT02357238|Uveitis
932038|NCT02357238|Infectious
932039|NCT02357225|Pompe disease
932040|NCT02357225|Pyridostigmine
932041|NCT02357212|Non-St elevation acute coronary syndrome
932042|NCT02357199|Mouth Diseases
932043|NCT02357199|Renal Insufficiency, Chronic
932044|NCT02357199|Intervention Studies
932045|NCT02357186|Mild head injury - clinical decision rule - Child
932046|NCT02357173|smoking
932047|NCT02357173|nicotine
932048|NCT02357173|tobacco products
932049|NCT02357173|electronic cigarette
932050|NCT02357147|Amatuximab
932051|NCT02357147|Pemetrexed
932052|NCT02357147|Cisplatin
932053|NCT02357147|Unresectable Malignant Pleural Mesothelioma
932054|NCT02357147|ARTEMIS
932055|NCT02357134|Advanced cancers
932056|NCT02357134|Primary or secondary lung involvement
932057|NCT02357134|Dyspnea
932058|NCT02357134|Difficulty breathing
932059|NCT02357134|Stationary cycle test
932060|NCT02357134|Questionnaires
932061|NCT02357134|Surveys
932062|NCT02357134|High flow oxygen
932063|NCT02357134|High flow air
932064|NCT02357134|Low flow oxygen
932065|NCT02357134|Low flow air
932066|NCT02357108|Supportive Care
932067|NCT02357108|treatment options
932068|NCT02357108|doctor's compassion
932069|NCT02357095|Caesarean Scar Pregnancy
932070|NCT02357095|uterine artery chemo-embolization
932071|NCT02357095|treatment
932072|NCT02357030|Gulf War Illness
932073|NCT02357030|nutrients
932074|NCT02357030|methylphenidate
932075|NCT02357030|mitochondria
932076|NCT02356991|Famitinib
932077|NCT02356991|Phase II
932078|NCT02356991|NSCLC
932079|NCT02356978|Rare disease
932080|NCT02356978|Crigler-Najjar disease
932081|NCT02356978|Paediatric
932082|NCT02356978|Experimental device
932083|NCT02356965|Third molar extraction
932084|NCT02356965|Wisdom tooth extraction
932085|NCT02356952|Metabolic Syndrome X
932086|NCT02356952|Low Glycemic Index Mediterranean Diet
932087|NCT02356952|Low Glycemic Index Diet
932088|NCT02356952|Randomized Clinical Trial
932089|NCT02356926|Adverse events
932090|NCT02356926|Medical errors
932091|NCT02356926|Emergency department
932092|NCT02356926|Cross checking
932093|NCT02356900|interval training
932094|NCT02356900|hyperbaric oxygen
932095|NCT02356900|VO2 max
932096|NCT02356900|altitude
932097|NCT02356900|exercise performance
932098|NCT02356900|mitochondrial oxidative capacity
932099|NCT02356900|mitochondrial biogenesis
932100|NCT02356861|treatment
932101|NCT02356861|photobiomodulation
932102|NCT02356861|Veterans
932103|NCT02356861|brain-injury
932104|NCT02356861|TBI
932105|NCT02356861|PTSD
932106|NCT02356848|self-care
932107|NCT02356848|self-monitoring
932108|NCT02356848|secondary prevention
932109|NCT02356848|foot ulcer
932110|NCT02356809|Gene therapy, plasmid, vegf, systemic scleroderma,secondary raynaud's phenomenon
932111|NCT02356757|self-care
932112|NCT02356757|self-monitoring
932113|NCT02356757|medication adherence
932114|NCT02356757|diet
932115|NCT02356757|physical activity
932116|NCT02356757|primary prevention
932117|NCT02356744|Maternal outcome
932118|NCT02356744|Fetal outcome
932119|NCT02356744|bariatric surgery
932120|NCT02356744|Third Trimester
932121|NCT02356731|seizures,
932122|NCT02356731|quality of life
932123|NCT02356640|Celiac plexus neurolysis
932124|NCT02356640|Celiac ganglion neurolysis
932125|NCT02356640|Pancreatic cancer
932126|NCT02356627|Occupational therapy
932127|NCT02356627|Adaptive intervention
932128|NCT02356627|Home-based
932129|NCT02356627|Assistive Technology
932130|NCT02356627|Home modification
932131|NCT02356627|Clinical effectiveness
932132|NCT02356627|Cost-effectiveness
932133|NCT02356627|Cost-utility
932134|NCT02356614|Lap Band
932135|NCT02356601|MRI
932136|NCT02356601|Lumbar spine
932137|NCT02356601|Ultrasound
932138|NCT02356575|surgery
932139|NCT02356575|chemotherapy
932140|NCT02356575|radiation
932141|NCT02356575|Acupuncture
932142|NCT02356575|16-947
932143|NCT02356562|Hepatitis C
932144|NCT02356562|Interferon-Free
932145|NCT02356562|Treatment Experienced
932146|NCT02356562|Chronic Hepatitis C
932147|NCT02356562|Hepatitis C Virus
932148|NCT02356510|myocardial infarction
932149|NCT02356510|TIMI flow
932150|NCT02356510|culprit lesion
932151|NCT02356510|culprit vessel
932152|NCT02356497|Bone metastases
932153|NCT02356497|Metastatic bone disease
932154|NCT02356497|Multi-trial facility
932155|NCT02356458|Mantle cell lymphoma
932156|NCT02356458|Relapsed
932157|NCT02356458|Refractory
932158|NCT02356458|Cancer
932159|NCT02356458|Lymphoma
932160|NCT02356458|Ibrutinib Imbruvica
932161|NCT02356458|Bortezomib Velcade
932162|NCT02356432|non-valvular atrial fibrillation
932163|NCT02356432|cerebral microbleeds
932164|NCT02356432|warfarin
932165|NCT02356432|NOACs
932166|NCT02356432|acute ischemic stroke
932167|NCT02356406|Radiosurgery
932168|NCT02356406|Celiac Plexus
932169|NCT02356406|Pain
932170|NCT02356406|Quality of Life
932171|NCT02356393|Desalinated Sea Water
932172|NCT02356393|Magnesium
932173|NCT02356393|Drinking Water
932174|NCT02356367|telemonitoring
932175|NCT02356367|Adaptive servo-ventilation
932176|NCT02356185|Alcohol Drinking
932177|NCT02356185|Injecting drug
932178|NCT02356185|Antiretroviral therapy
932179|NCT02356185|sub-Saharan Africa
932180|NCT02356172|Quality of Life
932181|NCT02356172|Depression
932182|NCT02356172|Kallmann Syndrome
932183|NCT02356172|Hypogonadotropic Hypogonadism
932184|NCT02356159|Hematopoietic Stem Cell Transplant
932185|NCT02356159|Lymphoma
932186|NCT02356159|Leukemia
932187|NCT02356159|Unrelated Donors
932188|NCT02356146|Kidney transplantation
932189|NCT02356146|genotype
932190|NCT02356146|tacrolimus
932191|NCT02356146|CYP3A5
932192|NCT02356133|Near-Infrared Spectroscopy
932193|NCT02356094|glaucoma
932194|NCT02356094|primary open angle glaucoma
932195|NCT02356094|cornea
932196|NCT02356068|liver transplantation, rotem, bleeding, transfusion
932197|NCT02356055|activities of daily living
932198|NCT02356055|massed practice
932199|NCT02356055|occupational therapy
932200|NCT02356029|Cardiopulmonary Arrest
932201|NCT02356029|Emergency Medical Services
932202|NCT02356029|Medical Futility
932203|NCT02356029|Decision Making
932204|NCT02356029|Emotional Stress
932205|NCT02356029|Burnout, Professional
932206|NCT02356016|Sarcopenic Obesity
932207|NCT02356016|community dwelling elderly women
932208|NCT02356016|electromyostimulation
932209|NCT02356016|exercise
932210|NCT02356016|dietary supplements
932211|NCT02356003|Tourette Syndrome
932212|NCT02356003|Children
932213|NCT02356003|Tics
932214|NCT02355977|Chronic periodontitis
932215|NCT02355977|Minocycline
932216|NCT02355977|Surface and root planning
932217|NCT02355977|Pocket depth
932218|NCT02355977|Sulcus bleeding index
932219|NCT02355977|Prevotella intermedia
932220|NCT02355912|Transfemoral
932221|NCT02355873|heparin-coated
932222|NCT02355873|surface-treated polyacrylonitrile membrane hemofilter
932223|NCT02355873|critical ill
932224|NCT02355873|acute kidney injury
932225|NCT02355873|chronic kidney disease
932226|NCT02355873|continuous renal replacement therapy
932227|NCT02355834|Fecal Incontinence (FI)
932228|NCT02355834|Inflammatory bowel disease (IBD)
932229|NCT02355834|bowel control
932230|NCT02355834|Chronic diarrhoea
932231|NCT02355834|rectal inflammation
932232|NCT02355821|cellular aging
932233|NCT02355821|vascular aging
932234|NCT02355821|bone metabolism
932235|NCT02355821|collagen type 1 C-telopeptide
932236|NCT02355821|nuclear factor kappa-B ligand (RANKL)
932237|NCT02355821|pulse wave velocity
932238|NCT02355821|telomerase activity
932239|NCT02355795|weight change
932240|NCT02355795|diet
932241|NCT02355795|dietary fat
932242|NCT02355795|feeding design
932243|NCT02355782|TMA, aHUS, TTP, stem cell transplant-associated TMA
932244|NCT02355769|heart failure
932245|NCT02355769|renal failure
932246|NCT02355769|prognosis
932247|NCT02355769|impedance cardiography
932253|NCT02355704|Kidney Transplantation
932254|NCT02355704|Atorvastatin
932255|NCT02355704|C-Reactive Protein
932256|NCT02355704|Biopsy
932257|NCT02355704|Interleukin
932258|NCT02355652|Total knee arthroplasty
932259|NCT02355652|IKS Score
932260|NCT02355652|cemented, uncemented
932261|NCT02355626|Anxiety
932262|NCT02355626|level of anxiety
932263|NCT02355626|delirium
932264|NCT02355626|agitation
932265|NCT02355626|tools for measuring anxiety
932266|NCT02355626|neuroendocrine system
932267|NCT02355613|Radiosurgery, brain, metastases
932268|NCT02355600|Oocyte
932269|NCT02355600|Tamoxifen
932270|NCT02355600|Fertility preservation
932271|NCT02355587|melanoma
932272|NCT02355587|cutaneous melanoma
932273|NCT02355587|DecisionDx-Melanoma
932274|NCT02355574|melanoma
932275|NCT02355574|cutaneous melanoma
932276|NCT02355574|DecisionDx-Melanoma
932277|NCT02355561|Bioavailability
932278|NCT02355561|Healthy Participants
932279|NCT02355561|JNJ-54861911
932280|NCT02355561|Food Effect
932281|NCT02355535|refractory
932282|NCT02355535|intolerant
932283|NCT02355535|solid tumors
932284|NCT02355535|lymphoma
932285|NCT02355522|saline infusion sonohysterography
932286|NCT02355509|Acarbose
932287|NCT02355509|Postprandial lipemia
932288|NCT02355509|Cardiovascular risk
932289|NCT02355496|Cost Control
932290|NCT02355496|Data Display
932291|NCT02355496|Diagnostic Tests, Routine
932292|NCT02355496|Physician's Practice Patterns
932293|NCT02355470|Sexual assault
932294|NCT02355470|Alcohol consumption
932295|NCT02355470|Intimate partner violence
932296|NCT02355457|troponin
932297|NCT02355457|myocardial infarction
932298|NCT02355457|acs
932299|NCT02355457|AMI
932300|NCT02355457|biomarker
932301|NCT02355457|BACC
932302|NCT02355457|high-sensitivity
932303|NCT02355431|EGFR
932304|NCT02355431|mutation
932305|NCT02355405|lung ultrasound
932306|NCT02355405|atelectasis
932307|NCT02355405|thoracic computed Tomography
932308|NCT02355379|Adjuvant chemotherapy in colonic adenocarcinoma in elderly
932309|NCT02355366|Offspring
932310|NCT02355366|significant mood symptoms
932311|NCT02355353|DWI-MRI
932312|NCT02355353|resectable liver metastases
932313|NCT02355340|Bone mineral density
932314|NCT02355340|Childhood cancer survivors
932315|NCT02355314|ICU patients
932316|NCT02355314|Doppler-based renal
932317|NCT02355301|ICF, impairment, activity, satisfaction, quality of care
932318|NCT02355288|Coronary Artery Disease
932319|NCT02355288|Diabetes Mellitus
932320|NCT02355288|Minimally Invasive Cardiac Surgery
932321|NCT02355288|Percutaneous Coronary Intervention
932322|NCT02355275|Home Exercise
932323|NCT02355275|Resistance Exercise
932324|NCT02355262|Insurance Coverage
932325|NCT02355262|Insurance Continuity
932326|NCT02355249|traditional three incisions
932327|NCT02355249|minimally invasive thoracol-laparoscopic esophagectomy
932328|NCT02355249|MIE
932329|NCT02355249|esophageal cancer
932330|NCT02355236|Naxozol
932331|NCT02355236|LDQ
932332|NCT02355236|GSRS
932333|NCT02355236|Osteoarthritis
932334|NCT02355236|Gastroprotective
932335|NCT02355223|Tuberculosis
932336|NCT02355223|Infection Control
932337|NCT02355223|Transmission
932338|NCT02355197|antioxidants
932339|NCT02355197|Gestational diabetes mellitus
932340|NCT02355197|oxidative stress
932341|NCT02355158|pain
932342|NCT02355158|diabetic neuropathy
932343|NCT02355158|pain in feet
932344|NCT02355145|type 2 diabetes, add-on diabetes therapy, rationale
932345|NCT02355132|Medicaid
932346|NCT02355132|public insurance
932347|NCT02355132|cardiovascular disease
932348|NCT02355132|prevention
932349|NCT02355132|community health centers
932350|NCT02355132|electronic health records
932351|NCT02355132|cancer prevention
932352|NCT02355080|HIV
932353|NCT02355080|HCV
932354|NCT02355067|parenting
932355|NCT02355067|postpartum depression
932356|NCT02355067|mothers
932357|NCT02355067|infants
932358|NCT02355067|depression
932359|NCT02355054|Recurrent
932360|NCT02355041|diet
932361|NCT02355041|body weight
932362|NCT02355041|eating
932363|NCT02355041|meal replacement
932364|NCT02355028|LHA510
932365|NCT02355028|PoC
932366|NCT02355028|Age-related macular degeneration
932367|NCT02354976|omega-3 carboxylic acid
932368|NCT02354963|Poor ovarian response
932369|NCT02354963|Salvador/Warts/Hippo pathway
932370|NCT02354963|Follicular activation
932371|NCT02354963|Poor ovarian reserve
932372|NCT02354950|GSK1265744
932373|NCT02354950|healthy controls
932374|NCT02354950|pharmacokinetic
932375|NCT02354950|Hepatic Impairment
932376|NCT02354937|Pharmacokinetics
932377|NCT02354937|GSK1265744
932378|NCT02354937|Severe Renal Impairment
932379|NCT02354911|Immunomodulation
932380|NCT02354872|Nicotine
932381|NCT02354859|Cystic Fibrosis
932382|NCT02354859|Gallium Nitrate
932383|NCT02354859|IV Gallium
932384|NCT02354859|Pseudomonas aeruginosa
932385|NCT02354833|Hypotension
932386|NCT02354833|Cesarean Delivery
932387|NCT02354833|Phenylephrine
932388|NCT02354833|Spinal Anesthesia
932389|NCT02354833|Norepinephrine
932390|NCT02354807|BAT activation
932391|NCT02354807|quantitative PET imaging
932392|NCT02354807|Mirabegron effect on BAT
932393|NCT02354794|arginine
932394|NCT02354794|supplementation
932395|NCT02354794|metabolic syndrome
932396|NCT02354794|endothelial function
932397|NCT02354781|DMD
932398|NCT02354781|muscular dystrophy
932399|NCT02354781|Follistatin
932400|NCT02354742|Echocardiography
932401|NCT02354742|EGDT
932402|NCT02354742|Sepsis
932403|NCT02354716|esophagus
932404|NCT02354716|upper GI
932405|NCT02354716|endoscopy
932406|NCT02354716|endoFLIP
932407|NCT02354716|functional luminal imaging
932408|NCT02354716|esophageal stricture
932409|NCT02354716|narrow esophagus
932410|NCT02354716|narrow caliber esophagus
932411|NCT02354716|esophageal narrowing
932412|NCT02354716|eosinophilic esophagitis
932413|NCT02354716|Zenkers diverticulum
932414|NCT02354716|Schatzki ring
932415|NCT02354703|alcoholism, treatment, serotonin transporter
932416|NCT02354677|Bronchial epithelium
932417|NCT02354677|COPD
932418|NCT02354677|Repair
932419|NCT02354677|Remodelling
932420|NCT02354677|Club Cells
932421|NCT02354664|respiratory test
932422|NCT02354664|respiratory muscle endurance
932423|NCT02354664|spirometry
932424|NCT02354651|Pompe disease
932425|NCT02354651|mechanical ventilation
932426|NCT02354651|diaphragm pacing
932427|NCT02354638|Perceptions
932428|NCT02354638|Education and evaluate post intervention KAP
932429|NCT02354625|Schwann cells
932430|NCT02354599|Randomized, double-blind, placebo-controlled, single-dose subcutaneous administration study
932431|NCT02354586|gBRCAmut
932432|NCT02354586|BRCA
932433|NCT02354586|PARP inhibitor
932434|NCT02354586|HRD
932435|NCT02354586|Ovarian cancer
932436|NCT02354586|Serous Epithelial
932437|NCT02354586|Fallopian Tube
932438|NCT02354586|Primary Peritoneal
932439|NCT02354560|Erythromycin
932440|NCT02354560|Familial Adenomatous Polyposis (FAP)
932441|NCT02354560|APC gene
932442|NCT02354560|nonsense mutations
932443|NCT02354534|cervical dysplasia
932444|NCT02354534|HPV
932445|NCT02354534|Treatment
932446|NCT02354534|preinvasive
932447|NCT02354534|cervix
932448|NCT02354534|vaginal suppository
932449|NCT02354534|Johns Hopkins
932450|NCT02354534|Cornelia Trimble
932451|NCT02354534|abnormal pap
932452|NCT02354534|CIN
932453|NCT02354521|Protein
932454|NCT02354521|Mechanical ventilation
932455|NCT02354521|Children
932456|NCT02354521|Outcomes
932457|NCT02354508|acromegaly
932458|NCT02354508|GH
932459|NCT02354508|IGF-1
932460|NCT02354508|pasireotide LAR
932461|NCT02354495|Indirect calorimetry
932462|NCT02354495|Protein
932463|NCT02354495|Mechanical ventilation
932464|NCT02354495|Respiratory failure
932465|NCT02354469|TBI
932466|NCT02354469|Mild Traumatic Brain Injury
932467|NCT02354469|Post-Concussion Syndrome
932468|NCT02354469|Recovery of Function
932469|NCT02354469|Motor Activity
932470|NCT02354469|Diffusion Tensor Imaging
932471|NCT02354469|Neural Injury
932472|NCT02354469|Biomarkers
932473|NCT02354456|atrial fibrillation
932474|NCT02354456|epidemiology
932475|NCT02354456|antiocaogulation
932476|NCT02354430|pregnancy
932477|NCT02354430|low back pain
932478|NCT02354430|sick leave,
932479|NCT02354430|motor activity
932480|NCT02354404|Ebola virus
932481|NCT02354404|Filoviridae Infections
932482|NCT02354404|Hemorrhagic Fever, Ebola
932483|NCT02354404|Viral Diseases
932484|NCT02354404|Hemorrhagic Fevers, Viral
932485|NCT02354365|PEEP adjustment
932486|NCT02354365|Tidal Volume
932487|NCT02354365|Driving Pressure
932488|NCT02354365|Compliance
932489|NCT02354339|Metabolic Syndrome
932490|NCT02354339|Irvingia gabonensis
932491|NCT02354339|African mango
932492|NCT02354339|Insulin resistance
932493|NCT02354313|MANTLE CELL LYMPHOMA (MCL)
932494|NCT02354313|Lenalidomide (Len)
932495|NCT02354313|Rituximab
932496|NCT02354313|ASCT
932497|NCT02354313|Revlimid
932498|NCT02354313|High dose chemotherapy
932499|NCT02354313|transplant
932500|NCT02354261|Basal Cell Carcinoma Nevus Syndrome
932501|NCT02354261|BCCNS
932502|NCT02354261|BCC
932503|NCT02354261|itraconazole
932504|NCT02354261|basal cell carcinoma
932505|NCT02354261|locally advanced basal cell carcinoma
932506|NCT02354248|TST
932507|NCT02354248|TMS
932508|NCT02354248|Stroke patients
932509|NCT02354248|EMG
932510|NCT02354235|MT-2412
932511|NCT02354235|MP-513
932512|NCT02354235|TA-7284
932513|NCT02354235|Teneligliptin
932514|NCT02354235|Canagliflozin
932515|NCT02354222|MT-2412
932516|NCT02354222|MP-513
932517|NCT02354222|TA-7284
932518|NCT02354222|Teneligliptin
932519|NCT02354222|Canagliflozin
932520|NCT02354183|Commitment strategies
932521|NCT02354183|Motivation
932522|NCT02354183|DBT skills
932523|NCT02354183|Self-harm
932524|NCT02354183|Brief intervention
932525|NCT02354170|Central Serous Chorioretinopathy, CSC
932526|NCT02354157|children dietary pattern
932527|NCT02354157|control rules
932528|NCT02354157|instrumental learning
932529|NCT02354157|food reinforcement
932530|NCT02354144|Human papillomavirus
932531|NCT02354144|Carrageenan
932532|NCT02354144|Microbicide
932533|NCT02354144|Anal HPV infection
932534|NCT02354131|Ovarian cancer
932535|NCT02354131|Niraparib
932536|NCT02354131|Bevacizumab
932537|NCT02354131|PARP
932538|NCT02354131|Phase 2 randomized
932539|NCT02354105|Axial Spondyloarthritis
932540|NCT02354105|Radiographic Axial Spondyloarthritis
932541|NCT02354105|Non-radiographic Axial Spondyloarthritis
932542|NCT02354105|Ankylosing spondylitis
932543|NCT02354105|Diagnosis
932544|NCT02354105|Cimzia
932545|NCT02354105|CZP
932546|NCT02354105|Certolizumab Pegol
932547|NCT02354105|CDP870
932548|NCT02354092|cervical dilation
932549|NCT02354092|pain
932550|NCT02354092|paracervical block
932551|NCT02354092|osmotic dilators
932552|NCT02354079|Low LDL-C
932553|NCT02354079|Target Identification
932554|NCT02354079|Genetic
932555|NCT02354079|Endocrinology
932556|NCT02354079|Cardiovascular Disease
932557|NCT02354066|Hallux valgus surgery
932558|NCT02354066|forefoot surgery
932559|NCT02354066|brake response time
932560|NCT02354066|foot orthoses
932561|NCT02354053|HIV
932562|NCT02354053|Triumeq
932563|NCT02354053|vulnerable populations
932564|NCT02354040|Stroke, Myocardial Infarction, Adherence, Health Literacy, Implementation, Developing Country
932565|NCT02354027|SHR3824 metformin drug-drug interaction
932569|NCT02354001|schizophrenia
932570|NCT02354001|mental illness
932571|NCT02354001|serm
932572|NCT02354001|raloxifene
932573|NCT02354001|clinical trial
932574|NCT02353988|AR-positive
932575|NCT02353988|Androgen Antagonists
932576|NCT02353988|Bicalutamide
932577|NCT02353988|TNBC
932578|NCT02353988|metastatic
932579|NCT02353975|SHR3824
932580|NCT02353975|food effect
932581|NCT02353975|mass
932582|NCT02353975|balance
932583|NCT02353975|Phase I
932584|NCT02353962|neglect
932585|NCT02353962|exergames
932586|NCT02353949|Mild cognitive impairment
932587|NCT02353949|Alzheimer
932588|NCT02353949|PET
932589|NCT02353949|Amyloid
932590|NCT02353949|Frontotemporal
932591|NCT02353871|Moderate to Severe
932592|NCT02353858|Rectal Cancer
932593|NCT02353858|Hyperthermia
932594|NCT02353858|Radiochemotherapy
932595|NCT02353858|Chemoradiotherapy
932596|NCT02353858|Deep regional hyperthermia
932597|NCT02353858|pathologic complete response
932598|NCT02353858|Regression Grade
932599|NCT02353858|Locally advanced rectal cancer
932600|NCT02353858|complete response
932601|NCT02353806|Amlodipine besylate
932602|NCT02353806|Breast milk
932603|NCT02353806|Pharmacokinetics
932604|NCT02353806|Chronic hypertension
932605|NCT02353806|Pregnancy
932606|NCT02353793|Hypothermia
932607|NCT02353793|(Poly) Trauma
932608|NCT02353793|Emergency Room
932609|NCT02353793|Warming Blanket
932610|NCT02353780|Rheumatoid arthritis
932611|NCT02353780|TNF inhibitors
932612|NCT02353702|Diaphragmatic function
932613|NCT02353702|sniff-test
932614|NCT02353702|pulmonary complications
932615|NCT02353702|upper abdominal surgery
932616|NCT02353663|Rheumatic heart disease
932617|NCT02353663|Rheumatic fever
932618|NCT02353663|Mitral regurgitation
932619|NCT02353663|Aortic regurgitation
932620|NCT02353663|Mitral stenosis
932621|NCT02353650|Q10
932622|NCT02353650|ubiquinol
932623|NCT02353611|tooth
932624|NCT02353611|bleaching
932625|NCT02353585|vitamin K-antagonist
932626|NCT02353585|novel oral anticoagulants
932627|NCT02353585|apixaban
932628|NCT02353585|dabigatran
932629|NCT02353585|rivaroxaban
932630|NCT02353585|edoxaban
932631|NCT02353585|direct oral anticoagulants
932632|NCT02353559|acute leukemia
932633|NCT02353559|traumatic stress
932634|NCT02353559|quality of life
932635|NCT02353559|symptom burden
932636|NCT02353559|psychosocial oncology
932637|NCT02353559|palliative care
932638|NCT02353559|intervention
932639|NCT02353559|hematological malignancies
932640|NCT02353559|supportive care
932641|NCT02353546|affective symptoms
932642|NCT02353546|cancer
932643|NCT02353546|depression
932644|NCT02353546|palliative care
932645|NCT02353546|pilot trial
932646|NCT02353546|psychotherapy
932647|NCT02353533|adenoma
932648|NCT02353533|EMR
932649|NCT02353533|FTRD
932650|NCT02353533|non- lifting
932651|NCT02353533|colon
932652|NCT02353442|Pain
932653|NCT02353442|Rotator cuff
932654|NCT02353442|Stretching
932655|NCT02353442|Mobilization
932656|NCT02353442|Scapula
932657|NCT02353442|Posterior capsule
932658|NCT02353416|Mediterranean Diet
932659|NCT02353416|Low-Glycemic Index
932660|NCT02353416|AGEs
932661|NCT02353403|Fructo-oligosaccharides
932662|NCT02353403|Sugar-reduced foods
932663|NCT02353403|Postprandial glucose response
932664|NCT02353390|presyncope
932665|NCT02353390|syncope
932666|NCT02353390|adolescent
932667|NCT02353390|young adult
932668|NCT02353390|immunization
932669|NCT02353390|vaccination
932670|NCT02353390|water consumption
932671|NCT02353364|Advanced maternal age
932672|NCT02353364|Aneuploidy
932673|NCT02353325|Iron deficiency
932674|NCT02353325|Iron fortification
932675|NCT02353325|Iron encapsulation
932676|NCT02353312|Diastolic
932677|NCT02353312|Biopterin
932678|NCT02353312|Therapeutic Use
932679|NCT02353312|Drug Therapy
932680|NCT02353312|Quality of Life
932681|NCT02353299|Cognition
932682|NCT02353299|Balance
932683|NCT02353273|WH-1,Diabetic Foot,Ulcer
932684|NCT02353234|Phenolics
932685|NCT02353234|Aleurone
932686|NCT02353234|Bioavailability
932687|NCT02353234|Pharmacokinetics
932688|NCT02353221|Early arthritis
932689|NCT02353221|undiferentiated arthritis
932690|NCT02353182|abdominal
932691|NCT02353182|lower extremity
932692|NCT02353169|changes in myocardial repolarization in healthy children
932693|NCT02353156|Hemorrhoidectomy
932694|NCT02353156|postoperative pain
932695|NCT02353156|Sitz bath
932696|NCT02353156|Electronic bidet
932697|NCT02353143|Acute Myeloid Leukemia
932698|NCT02353143|AML
932699|NCT02353143|Relapsed
932700|NCT02353143|Refractory
932701|NCT02353143|MEN1112
932702|NCT02353143|Monoclonal antibody
932703|NCT02353130|autism spectrum disorders
932704|NCT02353130|memantine
932705|NCT02353130|cortical metrics
932706|NCT02353130|sensory testing
932707|NCT02353078|Eosinophilic Esophagitis (EOE)
932708|NCT02353065|Colles' Fracture
932709|NCT02353065|ultrasonography
932710|NCT02353052|morphology standards
932711|NCT02353013|protein intake
932712|NCT02353013|body composition
932713|NCT02352974|Diamyd
932714|NCT02352974|Diabetes
932715|NCT02352974|Juvenile Diabetes
932716|NCT02352974|Diabetes Type 1
932717|NCT02352974|Type 1 Diabetes
932718|NCT02352974|Autoimmune Diabetes
932719|NCT02352974|Insulin Dependent Diabetes
932720|NCT02352974|Type 1 Diabetes Mellitus
932721|NCT02352974|rhGAD65
932722|NCT02352974|GAD65
932723|NCT02352974|GAD-Alum
932724|NCT02352974|Diabetes Mellitus
932725|NCT02352974|Diabetes mellitus Type 1
932726|NCT02352974|Glucose Metabolism Disorders
932727|NCT02352974|Metabolic Diseases
932728|NCT02352974|Vitamin D
932729|NCT02352961|Unrecognised condition
932730|NCT02352922|Laparoscopy
932731|NCT02352922|Robotic Surgical Procedures
932732|NCT02352922|Hysterectomy
932733|NCT02352922|Anesthetics, Local
932734|NCT02352922|Bupivacaine
932735|NCT02352922|Pain, Postoperative
932736|NCT02352896|Leigh syndrome
932737|NCT02352896|Mitochondrial disorders
932738|NCT02352896|EPI743
932739|NCT02352896|Vincerinone
932740|NCT02352870|Feasibility study
932741|NCT02352870|Randomised controlled trial
932742|NCT02352870|Cognitive behavioural therapy
932743|NCT02352870|Psychological distress
932744|NCT02352870|Cognitive illness representations
932745|NCT02352870|Common sense model
932746|NCT02352857|Fructo-oligosaccharides
932747|NCT02352857|Sugar-reduced foods
932748|NCT02352857|Postprandial glucose response
932749|NCT02352805|Extracorporeal circulation, ventricular assist device
932750|NCT02352792|Local control
932751|NCT02352779|Cancer Survivor
932752|NCT02352766|Thyroid cancer
932753|NCT02352766|Thyroid nodules
932754|NCT02352766|Palpable nodules
932755|NCT02352766|FNA
932756|NCT02352753|Amgen, OI, Bone
932757|NCT02352740|arginine
932758|NCT02352740|supplementation
932759|NCT02352740|metabolic syndrome
932760|NCT02352740|nitric oxide
932761|NCT02352727|Nocturnal hypokinesia
932762|NCT02352727|Accelerometers
932763|NCT02352714|Adolescents
932764|NCT02352714|Women's Health
932765|NCT02352714|Contraception
932766|NCT02352714|Reproduction
932767|NCT02352714|Comparative Effectiveness Research
932768|NCT02352714|Pregnancy Prevention
932769|NCT02352714|Intrauterine Device
932770|NCT02352701|helicobacter pylori
932771|NCT02352701|ilaprazole
932772|NCT02352701|eradication
932773|NCT02352701|triple therapy
932774|NCT02352688|elderly
932775|NCT02352688|enhanced recovery after surgery
932776|NCT02352662|Congenital Heart Disease
932777|NCT02352662|Point-of-care coagulation monitoring
932778|NCT02352662|Rotaional Thromboelastometry
932779|NCT02352649|Peripheral nerve injury
932780|NCT02352649|Neurotmesis
932781|NCT02352649|Gene therapy
932782|NCT02352649|Plasmid
932783|NCT02352649|Nerve regeneration therapy
932784|NCT02352610|carpometacarpal joints
932785|NCT02352597|PCOS
932786|NCT02352597|Phytoestrogens
932787|NCT02352597|ovulation induction
932788|NCT02352584|QIV
932789|NCT02352584|Quadrivalent Influenza Vaccine
932790|NCT02352584|Influenza vaccine
932791|NCT02352584|Vaccination
932792|NCT02352558|Multiple Myeloma
932793|NCT02352558|Lymphoma
932794|NCT02352558|Acute Myeloid Leukemia
932795|NCT02352558|Myelo-Dysplastic Syndrome
932796|NCT02352558|Chronic Myeloid Leukemia
932797|NCT02352558|Chronic Lymphocytic Leukemia
932798|NCT02352532|Dry Needling
932799|NCT02352532|Shear Wave Elastography
932800|NCT02352532|Ultrasound
932801|NCT02352493|PNH
932802|NCT02352493|RNAi therapeutic
932803|NCT02352480|Non Healing Wound
932804|NCT02352467|Non Healing Wound
932805|NCT02352454|Non Healing Wound
932809|NCT02352402|CABG
932810|NCT02352402|Ticagrelor
932811|NCT02352402|Graft
932812|NCT02352402|Patency
932813|NCT02352389|Childhood
932814|NCT02352389|Cancer
932815|NCT02352389|Genetic mutations
932816|NCT02352376|Noninvasive ventilation
932817|NCT02352376|Heart rate variability
932818|NCT02352376|Thoracic surgery
932819|NCT02352363|Parkinson's Disease
932820|NCT02352363|Motor fluctuations
932821|NCT02352363|levodopa
932822|NCT02352363|inhaled drugs
932823|NCT02352363|OFF episodes
932824|NCT02352350|Pre-Hospital Cardiac Arrest
932825|NCT02352350|Blood Lactate Level
932826|NCT02352350|Neurological Injury
932827|NCT02352337|cancer
932828|NCT02352337|pancreatic cancer
932829|NCT02352337|metastatic pancreatic cancer
932830|NCT02352324|cardiac output
932831|NCT02352324|coronary artery bypass grafting
932832|NCT02352324|minimally invasive hemodynamic monitoring
932833|NCT02352324|fluid responsiveness
932834|NCT02352272|sleep extension
932835|NCT02352272|attention
932836|NCT02352272|physical performance
932837|NCT02352259|Liver metastases of colorectal cancer Electrochemotherapy
932838|NCT02352259|Bleomycin
932839|NCT02352259|Electrochemotherapy
932840|NCT02352246|intermittent sprinting
932841|NCT02352246|abdominal fat mass
932842|NCT02352246|type 2 diabetes
932843|NCT02352246|postmenopausal women
932844|NCT02352233|retroview colonoscope
932845|NCT02352233|retroflexion colonoscopy
932846|NCT02352233|colonoscopy
932847|NCT02352207|Neonatal respiratory distress
932848|NCT02352207|prenatal lung malformation
932849|NCT02352207|KRAS mutation
932850|NCT02352207|pregnant woman
932851|NCT02352194|Multiple Sclerosis, Physical therapy, Physical capacity, Fatigue
932852|NCT02352181|Cirrhosis, transplantation, transfusion, Rotem®
932853|NCT02352168|allergic rhinitis；airway inflammation；hyperreactivity
932854|NCT02352155|haemostasis
932855|NCT02352142|Separation stress
932856|NCT02352142|Family Nurture
932857|NCT02352142|Maternal Confidence
932858|NCT02352142|Maternal Competence
932859|NCT02352142|Calming Cycle
932860|NCT02352142|Kangaroo Care
932861|NCT02352142|Infant Neurodevelopment
932862|NCT02352142|Infant Psychological Development
932863|NCT02352142|Post-partum depression
932864|NCT02352142|Mother-infant Co-regulation
932865|NCT02352116|Postoperative Experience
932866|NCT02352116|Postoperative Behavioral Changes
932867|NCT02352116|Maladaptive Behavioral Changes
932868|NCT02352103|prostate cancer
932869|NCT02352103|Urinary continence
932870|NCT02352103|robotic assisted radical prostatectomy
932871|NCT02352103|Vattikuti Urology Institute (VIP) radical prostatectomy
932872|NCT02352103|Retzius sparing radical prostatectomy
932873|NCT02352090|Contraception, oral
932874|NCT02352090|Ethinyl Estradiol
932875|NCT02352090|Estradiol Valerate
932876|NCT02352090|Dienogest
932877|NCT02352090|Insulin resistance
932878|NCT02352090|Chronic inflammation
932879|NCT02352090|Coagulation
932880|NCT02352051|attention deficit-hyperactivity disorder (ADHD).
932881|NCT02352051|executive functions
932882|NCT02352038|malocclusion
932883|NCT02352038|low-level laser therapy
932884|NCT02352025|S-equol
932885|NCT02352025|breast cancer
932886|NCT02352025|triple negative
932887|NCT02352012|Interventional Treatment
932888|NCT02352012|Refractory Pneumothorax
932889|NCT02352012|Bronchoscope
932890|NCT02351999|Atrial fibrillation
932891|NCT02351999|Transseptal puncture
932892|NCT02351999|Atrial fibrillation ablation
932893|NCT02351986|subacromial impingement
932894|NCT02351986|physical therapy
932895|NCT02351986|cryotherapy
932896|NCT02351960|Drug therapy
932897|NCT02351960|GERD
932898|NCT02351960|Dexlansoprazole
932899|NCT02351947|stroke
932900|NCT02351947|Cerebrovascular accident
932901|NCT02351947|rehabilitation
932902|NCT02351947|motor learning
932903|NCT02351947|fMRI
932904|NCT02351947|plasticity
932905|NCT02351934|colorectal surgery
932906|NCT02351934|volume status
932907|NCT02351921|transcranial magnetic stimulation
932908|NCT02351921|spinal cord injury
932909|NCT02351921|motor cortex
932910|NCT02351921|somatosensory cortex
932911|NCT02351895|infection control
932912|NCT02351895|Prevention of hospital acquired infection
932913|NCT02351856|laminopathy
932914|NCT02351804|US-guided peripheral nerve block
932915|NCT02351804|Anesthetics, Local
932916|NCT02351804|duration
932917|NCT02351804|Sensation
932918|NCT02351804|adductor canal block
932919|NCT02351804|lower limb
932920|NCT02351804|Adjuvants, Anesthesia
932921|NCT02351778|Developing Countries
932922|NCT02351778|Quality of Life
932923|NCT02351778|Mixed Methods
932924|NCT02351778|Validation
932925|NCT02351778|Caregiver Burden
932926|NCT02351726|aortic valve replacement
932927|NCT02351726|aortic stenosis
933052|NCT02350855|Palliative care
932928|NCT02351726|aortic steno-insufficiency
932929|NCT02351713|primary prevention
932930|NCT02351687|Moderate Acute Malnutrition
932931|NCT02351674|Heart Rate
932932|NCT02351674|Percutaneous coronary intervention
932933|NCT02351674|outcome
932934|NCT02351648|readmission
932935|NCT02351648|care transition
932936|NCT02351635|Calprotectin
932937|NCT02351635|Diagnosis
932938|NCT02351609|smoking cessation
932939|NCT02351609|patient navigation
932940|NCT02351609|financial incentives
932941|NCT02351609|health disparities
932942|NCT02351596|Core Stability
932943|NCT02351596|Balance
932944|NCT02351596|Core Control
932945|NCT02351505|Small Cell Lung Cancer
932946|NCT02351492|Bile duct obstruction
932947|NCT02351492|intraoperative cholangiography
932948|NCT02351492|MRCP
932949|NCT02351479|hula
932950|NCT02351479|breast cancer
932951|NCT02351479|female
932952|NCT02351479|hawaii
932953|NCT02351479|physical activity
932954|NCT02351479|cervical cancer
932955|NCT02351479|ovarian cancer
932956|NCT02351479|endometrial cancer
932957|NCT02351466|Brain Growth and Development
932958|NCT02351466|Cognition
932959|NCT02351466|Children
932960|NCT02351466|Continuous Glucose Monitoring
932961|NCT02351466|MRI
932962|NCT02351466|Functional MRI
932963|NCT02351440|duloxetine
932964|NCT02351414|Osteoarthritis
932965|NCT02351414|Ankylosis
932966|NCT02351414|Revision procedures
932967|NCT02351414|Correction of functional deformity
932968|NCT02351414|Rheumatoid arthritis
932969|NCT02351414|Arthritis
932970|NCT02351388|Alzheimer's disease
932971|NCT02351388|Depressive symptoms
932972|NCT02351388|Neuropsychiatric symptoms
932973|NCT02351388|Behavioral and Psychological Symptoms of Dementia
932974|NCT02351388|Neuromodulation
932975|NCT02351388|Transcranial Direct Current Stimulation
932976|NCT02351375|microbiota
932977|NCT02351375|small intestine
932978|NCT02351375|diet
932979|NCT02351375|feces
932980|NCT02351362|Retention
932981|NCT02351362|Attrition
932982|NCT02351362|Incentive
932983|NCT02351362|Pregnant women
932984|NCT02351349|frailty
932985|NCT02351349|CKD
932986|NCT02351349|Physical Therapy Modalities
932987|NCT02351349|Elder Nutritional Physiological Phenomena
932988|NCT02351336|Threatened preterm birth
932989|NCT02351336|Fetal adrenal gland volume
932990|NCT02351336|Fetal zone enlargement
932991|NCT02351336|Prediction of preterm birth
932992|NCT02351297|High protein diet
932993|NCT02351297|Microbiota
932994|NCT02351297|Rectal biopsies
932995|NCT02351297|Metabolomics
932996|NCT02351297|Bacterial metabolites
932997|NCT02351297|volunteers
932998|NCT02351284|HIV, vitamin D, osteoporosis
932999|NCT02351258|Pediatrics
933000|NCT02351258|Medical Oncology
933001|NCT02351258|Catheters
933002|NCT02351258|Infection
933003|NCT02351206|X-Rays
933004|NCT02351206|Magnetic Resonance Imaging
933005|NCT02351206|Sensitivity and Specificity
933006|NCT02351180|Chronic lung allograft dysfunction
933007|NCT02351180|Community-acquired respiratory viral infection
933008|NCT02351167|smoking cessation
933009|NCT02351167|counseling
933010|NCT02351167|Genetics and Genomics
933011|NCT02351141|Noble Gas MRI
933012|NCT02351141|Pulmonary Function
933013|NCT02351141|Quality of Life Questionnaires
933014|NCT02351128|lanreotide
933015|NCT02351102|Congenital CMV
933016|NCT02351102|Congenital Cytomegalovirus
933017|NCT02351063|Heart failure
933018|NCT02351063|BNP
933019|NCT02351063|home testing
933020|NCT02351063|remote monitoring
933021|NCT02351050|sonolysis, brain infarction, coronary angioplasty
933022|NCT02351037|Acute Myeloid Leukemia
933023|NCT02351037|AML
933024|NCT02351037|Ibrutinib
933025|NCT02351037|Cytarabine
933026|NCT02351037|LD-AraC
933027|NCT02351037|Azacitidine
933028|NCT02350985|Migraine
933029|NCT02350985|Migrainous Vertigo
933030|NCT02350985|Headache Disorders
933031|NCT02350985|Central Nervous System Origin Vertigo
933032|NCT02350985|Paroxysmal Vertigo
933033|NCT02350985|Adrenergic beta-Antagonist
933034|NCT02350985|Vasodilator Agent
933035|NCT02350985|Anti Arrhythmia Agent
933036|NCT02350985|Serotonin Uptake Inhibitor
933037|NCT02350985|Antidepressive Agent
933038|NCT02350985|Propranolol
933039|NCT02350985|Venlafaxine
933040|NCT02350959|Plaque
933041|NCT02350959|coronary computed tomography angiography
933042|NCT02350933|tracheal damages
933043|NCT02350920|IBD
933044|NCT02350920|Crohn's disease
933045|NCT02350920|ulcerative colitis
933046|NCT02350920|ACT
933047|NCT02350907|antimicrobial resistance
933048|NCT02350907|point-of-care testing
933049|NCT02350907|Neisseria gonorrhoeae
933050|NCT02350868|without Standard Treatment
933051|NCT02350855|Nutrition intervention
933053|NCT02350855|Public Health
933054|NCT02350855|Quality of life
933055|NCT02350855|Tailored food formula
933056|NCT02350855|Body weight
933057|NCT02350842|non-Left Bundle Branch Block morphology
933058|NCT02350842|Triple-site biventricular pacing
933059|NCT02350842|cardiac resynchronization therapy
933060|NCT02350803|distraction osteogenesis
933061|NCT02350803|mini plate
933062|NCT02350803|Lefort 1 osteotomy
933063|NCT02350790|Robotics
933064|NCT02350790|Laparoscopy
933065|NCT02350790|Endometriosis
933066|NCT02350790|Argon
933067|NCT02350790|Gynecology
933068|NCT02350777|T-cell Depleted Hematopoietic Stem Cell
933069|NCT02350777|Allogeneic Hematopoietic Stem Cell Transplantation
933070|NCT02350777|CliniMACS Cell Selection System
933071|NCT02350777|14-228
933072|NCT02350777|HSCT
933073|NCT02350764|Nivolumab
933074|NCT02350764|Lung
933075|NCT02350764|ipilimumab
933076|NCT02350764|NSCLC
933077|NCT02350764|14-137
933078|NCT02350751|Influenza, Flu, Flu A, Influenza A
933079|NCT02350738|Mild cognitive impairment
933080|NCT02350738|Dementia
933081|NCT02350738|Cognitive training
933082|NCT02350738|Cognitive rehabilitation
933083|NCT02350738|Cognitive therapy
933084|NCT02350725|Chronic Fluid Overload
933085|NCT02350712|Recurrent or metastatic squamous cell carcinoma of the head and neck
933086|NCT02350712|SCCHN
933087|NCT02350647|Rotator cuff
933088|NCT02350647|Ossification
933089|NCT02350647|Suture anchors
933090|NCT02350621|cervical foraminal stenosis minimal invasive foraminotomy
933091|NCT02350582|breast cancer
933092|NCT02350582|telerehabilitation
933093|NCT02350582|strength
933094|NCT02350582|fatigue
933095|NCT02350582|quality of life
933096|NCT02350569|liver transplant
933097|NCT02350569|hepatitis C
933098|NCT02350569|Gilead
933099|NCT02350569|Communicable Diseases
933100|NCT02350569|Infection
933101|NCT02350569|Liver Diseases
933102|NCT02350569|RNA Virus Infections
933103|NCT02350543|Aspirin usage
933104|NCT02350543|Transurethral resection of bladder tumor (TURBT)
933105|NCT02350530|Colorectal cancer
933106|NCT02350530|Metastatic colorectal cancer
933107|NCT02350530|Liver metastases
933108|NCT02350530|Liver resection
933109|NCT02350530|Liver ablation
933110|NCT02350530|Conversion therapy
933111|NCT02350530|FOLFOXIRI
933112|NCT02350530|Oxaliplatin
933113|NCT02350530|Irinotecan
933114|NCT02350530|Fluorouracil
933115|NCT02350530|Bevacizumab
933116|NCT02350530|RAS mutation
933117|NCT02350491|Pregnancy
933118|NCT02350491|miRNA
933119|NCT02350491|Rheumatoid Arthritis (RA)
933120|NCT02350491|Systemic Lupus Erythematosus (SLE)
933121|NCT02350465|sarcopenia
933122|NCT02350465|aging
933123|NCT02350465|myosteatosis
933124|NCT02350465|exercise
933125|NCT02350465|screening
933126|NCT02350452|laparoscopic surgery
933127|NCT02350452|diode laser
933128|NCT02350452|AMH
933129|NCT02350452|AFC
933130|NCT02350439|Coronary artery disease
933131|NCT02350439|Fractional floe reserve
933132|NCT02350400|Drug eluting beads
933133|NCT02350400|Irinotecan
933134|NCT02350400|Pharmacogenetics
933135|NCT02350400|Pharmacokinetics
933136|NCT02350374|diabetes
933137|NCT02350374|children
933138|NCT02350361|endostar
933139|NCT02350361|angiogenesis
933140|NCT02350361|EGFR-TKI
933141|NCT02350361|lung caner
933142|NCT02350348|neonates
933143|NCT02350348|infants
933144|NCT02350348|anaesthesia
933145|NCT02350348|mortality
933146|NCT02350348|adverse effects
933147|NCT02350348|Epidemiological Study
933148|NCT02350348|European Society of Anaesthesiology
933149|NCT02350335|aneurysm
933150|NCT02350335|nicotine replacement therapy
933151|NCT02350335|cerebral vasospasm
933152|NCT02350335|outcome
933153|NCT02350322|Diet
933154|NCT02350322|concentration
933155|NCT02350322|seafood
933156|NCT02350322|youths
933157|NCT02350322|Norway
933158|NCT02350322|Nutrient status in blood
933159|NCT02350322|Inflammatory markers
933160|NCT02350309|Insomnia Disorder
933161|NCT02350309|E2006
933162|NCT02350309|Multiple Sleep Latency Test
933163|NCT02350296|headache
933164|NCT02350296|dental pain
933165|NCT02350296|neuralgia
933166|NCT02350296|dysmenorrhoea
933167|NCT02350296|muscular and osteoarticular pain
933172|NCT02350270|cognitively healthy individuals
933173|NCT02350257|cognitive behavior therapy
933174|NCT02350257|child
933175|NCT02350257|randomized controlled trial
933176|NCT02350257|internet
933177|NCT02350244|musculoskeletal diseases
933178|NCT02350244|eyestrain
933179|NCT02350244|occupational diseases
933180|NCT02350244|computer work
933181|NCT02350244|muscle stretching exercise
933182|NCT02350244|computer software application
933183|NCT02350244|MSDs
933184|NCT02350231|preterm birth
933185|NCT02350231|Twin pregnancy
933186|NCT02350231|progesterone
933187|NCT02350218|Transplantation
933188|NCT02350218|Living donor
933189|NCT02350218|Eglandin
933190|NCT02350218|Alprostadil
933191|NCT02350205|Burn wounds
933192|NCT02350205|Burns
933193|NCT02350205|Skin substitute
933194|NCT02350192|ehealth
933195|NCT02350192|intervention
933196|NCT02350192|effectiveness
933197|NCT02350192|randomized controlled trial
933198|NCT02350166|colorectal cancer
933199|NCT02350166|hepatectomy
933200|NCT02350166|laparoscopic surgery
933201|NCT02350166|laparotomy
933202|NCT02350166|complications
933203|NCT02350153|Mortality
933204|NCT02350153|Morbidity
933205|NCT02350153|Incidence
933206|NCT02350153|Prevalence
933207|NCT02350140|HIV
933208|NCT02350140|Prevention of mother-to-child HIV transmission
933209|NCT02350140|PMTCT
933210|NCT02350140|mobile health (mHealth)
933211|NCT02350140|mobile phone
933212|NCT02350140|text messaging
933213|NCT02350140|short message services (SMS)
933214|NCT02350127|dementia
933215|NCT02350127|clinical trial
933216|NCT02350127|behavioral intervention
933217|NCT02350127|exercise
933218|NCT02350127|complementary and alternative medicine
933219|NCT02350127|cognition
933220|NCT02350127|function
933221|NCT02350127|quality of life
933222|NCT02350114|Heart failure
933223|NCT02350114|6 Minute Walk Test
933224|NCT02350088|fast-track surgery
933225|NCT02350075|short implants
933226|NCT02350075|sinus floor elevation
933227|NCT02350075|randomized controlled trial
933228|NCT02350036|Preeclampsia
933229|NCT02350036|placental protein 13
933230|NCT02350036|Uterine artery doppler
933231|NCT02350023|alopecia areata
933232|NCT02350023|betamethasone
933233|NCT02350023|latanoprost
933234|NCT02350023|topical steroid
933235|NCT02350023|prostaglandin
933236|NCT02350010|Etiology
933237|NCT02350010|Prognostic risk factors
933238|NCT02350010|Intracerebral Hemorrhage
933239|NCT02350010|non-invasive imaging
933240|NCT02350010|CT angiography
933241|NCT02349997|central sleep apnea
933242|NCT02349997|Cheyne-Stokes respiration
933243|NCT02349997|obstructive sleep apnea
933244|NCT02349997|chronic heart failure
933245|NCT02349997|fluid shift
933246|NCT02349919|postinfectious cough, postviral cough
933247|NCT02349906|non-malignant diseases, allogeneic stem cell transplantation
933248|NCT02349854|pruritus
933249|NCT02349854|itch
933250|NCT02349854|skin
933251|NCT02349854|scalp
933252|NCT02349854|seborrheic dermatitis
933253|NCT02349828|antiviral
933254|NCT02349828|herpes simplex virus
933255|NCT02349828|herpes
933256|NCT02349828|burn patients
933257|NCT02349828|HSV
933258|NCT02349828|acyclovir
933259|NCT02349815|Drug Utilization Study
933260|NCT02349802|Auto-injector Device, device-related injection, Auto-injector
933261|NCT02349789|Gait
933262|NCT02349789|Cerebellum
933263|NCT02349789|Non invasive electrical stimulation
933264|NCT02349789|tDCS
933265|NCT02349789|TMS
933266|NCT02349789|Balance
933267|NCT02349763|Dexamethasone
933268|NCT02349763|Hypersensitivity reaction
933269|NCT02349763|Paclitaxel
933270|NCT02349750|Endometrial Scratch Injury
933271|NCT02349750|Unexplained infertility
933272|NCT02349750|intrauterine insemenation
933273|NCT02349750|ovulation induction
933274|NCT02349737|Bioelectrical Impedance Analysis
933275|NCT02349737|Body composition
933276|NCT02349737|ICD
933277|NCT02349724|CEA
933278|NCT02349724|CAR T
933279|NCT02349711|probiotic
933280|NCT02349711|allergy
933281|NCT02349711|immune
933282|NCT02349698|CAR T
933283|NCT02349698|Leukemia
933284|NCT02349698|Lymphoma
933285|NCT02349685|Helicobacter pylori
933286|NCT02349685|Personalized therapy
933287|NCT02349685|antimicrobial susceptibility
933288|NCT02349685|rescue therapy
933289|NCT02349685|culture
933292|NCT02349633|EGFRm - Epidermal Growth Factor Receptor Mutation
933293|NCT02349633|Advanced EGFRm (del19 or L858R +/- T790M NSCLC
933294|NCT02349581|Anesthetics, Local
933295|NCT02349581|Mastectomy
933296|NCT02349581|Neuralgia
933297|NCT02349581|Nerve block
933298|NCT02349542|Liposomal Bupivacaine
933299|NCT02349542|Simultaneous Bilateral Total Knee Arthroplasty
933300|NCT02349542|Safety
933301|NCT02349529|Epilepsy
933302|NCT02349529|psychosocial
933303|NCT02349503|Adrenocortical function
933304|NCT02349503|Adrenal hyperplasia, Congenital
933305|NCT02349503|21-hydroxylase deficiency
933306|NCT02349503|Adrenogenital Syndrome
933307|NCT02349503|Adolescents
933308|NCT02349503|Female
933309|NCT02349503|Hyperplasia
933310|NCT02349503|Adrenal Gland Diseases
933311|NCT02349503|Congenital Abnormalities
933312|NCT02349503|Adrenocortical Hyperfunction
933313|NCT02349503|Disorders of Sex Development
933314|NCT02349503|Endocrine System Diseases
933315|NCT02349503|Genetic Diseases, Inborn
933316|NCT02349503|Gonadal Disorders
933317|NCT02349503|Metabolic Diseases
933318|NCT02349503|Metabolism, Inborn Errors
933319|NCT02349503|Pathologic Processes
933320|NCT02349503|Steroid Metabolism, Inborn Errors
933321|NCT02349503|Urogenital Abnormalities
933322|NCT02349503|Corticotropin Releasing Factor
933323|NCT02349490|gastrointestinal hemorrhage
933324|NCT02349490|endoscopy
933325|NCT02349490|hemostasis
933326|NCT02349451|Efficacy
933327|NCT02349451|Methotrexate
933328|NCT02349451|Safety
933329|NCT02349373|Overuse injury
933330|NCT02349373|Running related injury
933331|NCT02349373|Running pattern
933332|NCT02349360|safety
933333|NCT02349360|tolerability
933334|NCT02349321|physical or sexual intimate partner violence
933335|NCT02349321|adolescents
933336|NCT02349321|primary prevention
933337|NCT02349321|randomised controlled trial
933338|NCT02349321|school
933339|NCT02349321|South Africa
933340|NCT02349321|parenting
933341|NCT02349282|muscle strength
933342|NCT02349282|physical performance
933343|NCT02349282|vitamin D3
933344|NCT02349282|Cholecalciferol
933345|NCT02349282|Calcifediol
933346|NCT02349269|Atrial fibrillation
933347|NCT02349269|CABG
933348|NCT02349269|Stroke
933349|NCT02349256|MUS
933350|NCT02349256|British South Asians
933351|NCT02349256|Somatic Symptoms
933352|NCT02349256|Qualitative interviews
933353|NCT02349243|obese
933354|NCT02349243|weight loss
933355|NCT02349243|entacapone
933356|NCT02349217|Breast cancer
933357|NCT02349217|Breast cancer survivors
933358|NCT02349217|Breast cancer partners
933359|NCT02349217|Mindfulness-Based Relationship Enhancement
933360|NCT02349217|MBRE
933361|NCT02349217|Standard of care
933362|NCT02349217|Pain Assessment
933363|NCT02349217|Questionnaires
933364|NCT02349217|Surveys
933365|NCT02349217|Neurocognitive Tests
933366|NCT02349217|Cortisol Tests
933367|NCT02349217|Saliva tests
933368|NCT02349217|Interviews
933369|NCT02349217|Meditation
933370|NCT02349217|Yoga
933371|NCT02349217|Self-help materials
933372|NCT02349204|Simulator
933373|NCT02349204|Music
933374|NCT02349204|Mozart Effect
933375|NCT02349191|Alzheimers
933376|NCT02349191|dementia
933377|NCT02349191|omental transposition
933378|NCT02349191|neurological
933381|NCT02349126|Hepatitis B
933382|NCT02349126|HBV infection
933383|NCT02349126|Hepatitis B Surface Antigen
933384|NCT02349113|estrogen, aging
933385|NCT02349087|EEG
933386|NCT02349087|cardiac arrest
933387|NCT02349087|resuscitation
933388|NCT02349087|seizures
933389|NCT02349061|Systemic Lupus Erythematosus
933390|NCT02349061|Ustekinumab
933391|NCT02349048|Hepatitis C virus
933392|NCT02349048|Hepatitis C virus genotype 1
933393|NCT02349048|Chronic Hepatitis C Virus Genotype 1 Infection
933394|NCT02349048|Liver fibrosis
933395|NCT02349048|Cirrhosis
933396|NCT02349048|Simeprevir
933397|NCT02349048|Daclatasvir
933398|NCT02349048|Sofosbuvir
933399|NCT02349035|Transradial amputee
933400|NCT02349022|[89Zr]Df-IAB2M
933401|NCT02349022|Prostate cancer
933402|NCT02349022|PET scan
933403|NCT02349009|systemic sclerosis
933404|NCT02349009|scleroderma
933405|NCT02348970|mandibular advancement devices ONIRIS®
933406|NCT02348970|obstructive sleep apnea and hypopneas
933407|NCT02348957|Chronic myeloid leukemia
933408|NCT02348957|Dasatinib
933409|NCT02348957|Any line
933410|NCT02348957|Chronic phase
933411|NCT02348944|Biological markers
933412|NCT02348944|Cartilage
933413|NCT02348840|Midwives
933414|NCT02348840|Pregnant Women
933415|NCT02348827|Unipolar depression
933416|NCT02348827|Family Therapies
933417|NCT02348827|Psychoeducation
933418|NCT02348827|Family psychoeducation
933419|NCT02348814|NAFLD, NASH
933420|NCT02348788|Vivax
933421|NCT02348788|Malaria
933422|NCT02348788|artemether-lumefantrine
933423|NCT02348788|chloroquine
933424|NCT02348788|RCT
933425|NCT02348749|18F-MFBG Imaging
933426|NCT02348749|14-138
933427|NCT02348749|PET/MR
933428|NCT02348749|PET/CT scan
933429|NCT02348736|airway
933430|NCT02348736|videolaryngoscope
933431|NCT02348697|Cartilage Defect in the Knee
933432|NCT02348697|MACT
933433|NCT02348684|Breast Cancer
933434|NCT02348658|Pharmacological therapy
933435|NCT02348645|Pilot projects
933436|NCT02348645|Feasibility studies
933437|NCT02348645|Intervention studies
933438|NCT02348645|Orthopedics
933439|NCT02348645|Orthopedic Procedures
933440|NCT02348645|Neurosurgical Procedures
933441|NCT02348645|Neurosurgery
933442|NCT02348645|Spine
933443|NCT02348645|Spinal Fusion
933444|NCT02348645|Spondylodesis
933445|NCT02348645|Spondylosyndesis
933446|NCT02348645|Laminectomy
933447|NCT02348645|Foraminotomy
933448|NCT02348645|Decompression, surgical
933449|NCT02348645|Low Back Pain
933450|NCT02348645|Quality of Life
933451|NCT02348580|teaching
933452|NCT02348580|education
933453|NCT02348580|active learning
933454|NCT02348580|time on task
933455|NCT02348580|financial education
933456|NCT02348580|social education
933457|NCT02348580|rights based education
933458|NCT02348580|primary school
933459|NCT02348580|life-skills
933460|NCT02348567|Health care, accreditation, unannounced survey, cluster randomized controlled trial, quality improvement, organisational development
933461|NCT02348554|obesity
933462|NCT02348554|energy expenditure
933463|NCT02348554|daily living physical activity
933464|NCT02348554|smartphone
933465|NCT02348554|accelerometry
933466|NCT02348554|prediction algorithm
933467|NCT02348528|Multiple Myeloma
933468|NCT02348528|Relapsed
933469|NCT02348528|Refractory
933470|NCT02348528|Lenalidomide
933471|NCT02348528|Dexamethasone
933472|NCT02348528|open-label
933473|NCT02348528|CC-5013-MM-021
933474|NCT02348502|HBsAg loss
933475|NCT02348502|interferon
933476|NCT02348502|HBV reaction
933477|NCT02348502|Hepatitis B
933478|NCT02348489|AML
933479|NCT02348489|Acute Myeloid Leukemia
933480|NCT02348489|SGI-110
933481|NCT02348489|DNA Hypomethylating Agen
933482|NCT02348437|Pronator quadratus
933483|NCT02348437|Distal radius fracture
933484|NCT02348437|Repair
933485|NCT02348437|Volar plating
933486|NCT02348437|PRWE
933487|NCT02348424|genitourinary
933488|NCT02348424|Neisseriaceae
933489|NCT02348424|pharyngeal
933490|NCT02348424|Solithromycin
933491|NCT02348411|Medication-refractory
933492|NCT02348398|Cervical Cancer
933493|NCT02348398|Recurrent cervical cancer
933494|NCT02348398|Squamous cervical cancer
933495|NCT02348398|Adenocarcinoma of the cervix
933496|NCT02348398|Adenosquamous cervical cancer
933497|NCT02348398|Persistent cervical cancer
933498|NCT02348398|Pazopanib
933499|NCT02348398|GW786034
933500|NCT02348398|Topotecan
933501|NCT02348398|Hycamtin
933502|NCT02348385|amphetamine
933503|NCT02348385|cigarette smokers
933504|NCT02348359|Vascular Endothelial Growth Factor (VEGF)
933505|NCT02348359|Platelet Derived Growth Factor (PDGF)
933506|NCT02348359|AMD
933507|NCT02348346|self-disinfecting surfaces
933508|NCT02348346|titanium dioxide
933509|NCT02348281|triple negative breast cancer
933510|NCT02348281|androgen receptor
933511|NCT02348281|bicalutamide
933512|NCT02348268|Neck Pain
933513|NCT02348268|Myofascial release
933514|NCT02348268|Manual therapy
933515|NCT02348242|Intensive care
933516|NCT02348242|corneal damage
933517|NCT02348242|prevention
933518|NCT02348242|nursing protocol
933519|NCT02348229|Enhanced recovery after surgery
933520|NCT02348229|laparoscopic gastrectomy
933521|NCT02348229|advanced gastric cancer
933522|NCT02348229|C-reactive,visceral proteins
933523|NCT02348177|Human immunideficiency virus
933524|NCT02348177|Tuberculosis
933525|NCT02348177|superboosting
933526|NCT02348177|lopinavir/ritonavir 1:1
933527|NCT02348177|Pediatric TB/HIV co-infection
933528|NCT02348164|Carotenoids
933529|NCT02348164|absorption
933530|NCT02348164|citrus
933531|NCT02348151|COPD
933532|NCT02348151|SWTi
933533|NCT02348151|Treadmill
933534|NCT02348138|Isometric Handgrip
933535|NCT02348112|stress urinary incontinence
933536|NCT02348112|Altis 522
933537|NCT02348112|urinary incontinence
933538|NCT02348099|Diabetes
933539|NCT02348099|Lipohypertrophy
933540|NCT02348099|Ultrasound
933541|NCT02348073|Epilepsy
933542|NCT02348073|Attention Deficit Disorders
933543|NCT02348073|VAYARIN
933544|NCT02348073|Children
933545|NCT02348073|Polyunsaturated n-3 fatty acid supplementation
933546|NCT02348034|Surgical Site Infection (SSI)
933547|NCT02348034|Negative Pressure Wound Therapy (NPWT)
933548|NCT02348008|MK-3475
933549|NCT02348008|Pembrolizumab
933550|NCT02348008|Bevacizumab
933551|NCT02347995|Exercise
933552|NCT02347995|Protein
933553|NCT02347995|Nutrition
933554|NCT02347995|Stroke
933555|NCT02347982|Turkey
933556|NCT02347982|Epidemiologic
933557|NCT02347969|antioxidant
933558|NCT02347969|skin radiance
933559|NCT02347969|skin elasticity
933560|NCT02347969|skin firmness
933561|NCT02347969|skin hydration
933562|NCT02347956|robot surgery
933563|NCT02347956|reduced port
933564|NCT02347956|single-site
933565|NCT02347956|safety
933566|NCT02347956|feasibility
933567|NCT02347930|acute kidney injury
933568|NCT02347930|ultrasound technology
933569|NCT02347904|Esophageal cancer
933570|NCT02347904|Adjuvant treatment
933571|NCT02347904|S-1
933572|NCT02347904|Oxaliplatin
933573|NCT02347904|Feasibility
933574|NCT02347891|Inflammatory Myositis
933575|NCT02347891|Dermatomyositis
933576|NCT02347891|Polymyositis
933577|NCT02347891|Muscle Pain
933578|NCT02347891|Myositis
933579|NCT02347891|Refractory myositis
933580|NCT02347878|leukemia
933581|NCT02347878|lymphoma
933582|NCT02347878|lumbar puncture
933583|NCT02347878|intrathecal treatment
933584|NCT02347878|post-lumbar puncture headache
933585|NCT02347865|osteoporosis post menopausal women
933586|NCT02347826|coned wires, wire lift,
933587|NCT02347826|patient
933588|NCT02347826|discomfort
933589|NCT02347813|squamous cell carcinoma
933590|NCT02347813|pioglitazone
933591|NCT02347813|PPARgamma
933592|NCT02347813|skin cancer
933593|NCT02347774|Chronic Obstructive Pulmonary Disease
933594|NCT02347774|COPD
933595|NCT02347761|Chronic Obstructive Pulmonary Disease
933596|NCT02347748|Pain
933597|NCT02347748|Anesthesia Recovery Period
933598|NCT02347748|Postoperative Period
933599|NCT02347748|Adaptation, Psychological
933600|NCT02347748|Relaxation
933601|NCT02347748|Stress, Psychological
933602|NCT02347735|Colorectal carcinoma
933603|NCT02347735|Anastomotic leakage
933604|NCT02347735|Markers
933605|NCT02347735|Diagnosis
933609|NCT02347709|Diabetic Foot Ulcer
933610|NCT02347709|DFU
933611|NCT02347709|Type 2 Diabetes
933612|NCT02347709|Neuropathy
933613|NCT02347696|Diet
933614|NCT02347696|Physical Activity
933615|NCT02347696|Trial
933616|NCT02347696|Lipidomics
933617|NCT02347696|Occidental Diseases
933618|NCT02347657|Homozygous for the F508del CFTR Mutation
933619|NCT02347566|COPD
933620|NCT02347566|Physical Activity
933621|NCT02347566|Accelerometer
933622|NCT02347540|Heart Failure
933623|NCT02347540|Diastolic Dysfunction
933624|NCT02347540|Pre-Eclampsia
933625|NCT02347540|Endothelial dysfunction
933626|NCT02347540|Biological Markers
933627|NCT02347540|MicroRNAs
933628|NCT02347540|Circulating cells
933629|NCT02347488|ETT Holder, bite guard, airway, endotracheal tube
933630|NCT02347462|BiPAP
933631|NCT02347449|Early-stage Breast cancer, node positive
933632|NCT02347449|Prognosis
933633|NCT02347449|Oncotype Dx
933634|NCT02347436|Transurethral Resection of Prostate
933635|NCT02347423|Poliomyelitis immunization
933636|NCT02347423|primary series
933637|NCT02347371|Heart transplant
933638|NCT02347371|Cardiac allograft vasculopathy
933639|NCT02347371|Chronic rejection
933640|NCT02347371|Immunosuppressant therapy
933641|NCT02347345|HCV, injection drug use
933642|NCT02347280|clostridium difficile
933643|NCT02347280|colitis
933644|NCT02347280|colon
933645|NCT02347267|Beverages sweetened caloric, no caloric
933646|NCT02347267|Weight
933647|NCT02347267|Fat percentage
933648|NCT02347267|Body Composition
933649|NCT02347267|Blood pressure
933650|NCT02347267|Sugar
933651|NCT02347267|Sodium
933652|NCT02347267|Dietary intake
933653|NCT02347228|OB318
933654|NCT02347228|Advanced Solid Malignancies
933655|NCT02347228|Antrodia cinnamomea
933656|NCT02347228|Antrodia camphorata
933657|NCT02347202|Counseling
933658|NCT02347163|triple neg
933659|NCT02347163|breast cancer
933660|NCT02347163|zoledronate
933661|NCT02347163|mevalonate pathway
933662|NCT02347124|smoking cessation
933663|NCT02347124|oral health care
933664|NCT02347124|tobacco quitlines
933665|NCT02347098|plaque
933666|NCT02347098|LDL
933667|NCT02347098|statin
933668|NCT02347098|endothelial
933669|NCT02347098|apheresis
933670|NCT02347098|acute coronary artery syndrome
933671|NCT02347033|Sertraline
933672|NCT02347033|Selective Serotonin Reuptake Inhibitor (SSRI)
933673|NCT02347033|Cognitive Behavioural Therapy (CBT)
933674|NCT02347033|Increasing Access to Psychological Therapies (IAPT)
933675|NCT02347020|Obesity
933676|NCT02347020|Metabolic Disorders
933677|NCT02347007|Obesity
933678|NCT02347007|Overweight
933679|NCT02347007|Body Weight
933680|NCT02347007|Cardiovascular Diseases
933681|NCT02347007|Cholesterol
933682|NCT02347007|Almonds
933683|NCT02347007|Visceral Adiposity
933684|NCT02347007|Quality of Life
933685|NCT02347007|Hispanic Americans
933686|NCT02347007|African Continental Ancestry Group
933687|NCT02347007|Metabolic Syndrome X
933688|NCT02346994|Body Weight
933689|NCT02346994|Obesity in Adolescence
933690|NCT02346994|Obesity in Childhood
933691|NCT02346994|Childhood Onset Obesity
933692|NCT02346994|Childhood Obesity
933693|NCT02346994|Child Obesity
933694|NCT02346994|Adolescent Obesity
933695|NCT02346994|Teenagers
933696|NCT02346994|Teens
933697|NCT02346994|Youth
933698|NCT02346994|Adolescents
933699|NCT02346994|Adolescence
933700|NCT02346968|Kidney Transplantation
933701|NCT02346968|Delayed Graft Function
933702|NCT02346968|C-terminal fragment of agrin
933703|NCT02346968|Dialysis
933704|NCT02346955|Cancer
933705|NCT02346955|Oncology
933706|NCT02346955|cCAM Biotherapeutics Ltd
933707|NCT02346955|Immunomodulatory therapy
933708|NCT02346955|CM-24
933709|NCT02346955|Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1)
933710|NCT02346955|NSCLC (adenocarcinoma)
933711|NCT02346955|Uveal
933712|NCT02346955|Acral
933713|NCT02346955|Mucosal
933714|NCT02346955|Cutaneous
933715|NCT02346955|Colorectal
933716|NCT02346955|Gastric
933717|NCT02346955|Ovarian
933718|NCT02346955|Bladder
933719|NCT02346955|MK-6018-001
933720|NCT02346929|Hematoma block
933721|NCT02346929|distal radius fracture reduction
933722|NCT02346929|ultrasound
933723|NCT02346929|ultrasound guided hematoma block
933724|NCT02346929|traditional hematoma block for analgesia
933725|NCT02346929|bupivacaine
933726|NCT02346929|pain reduction
933727|NCT02346929|wrist fracture
933728|NCT02346890|Volunteer
933729|NCT02346877|Enbrel
933730|NCT02346877|Rheumatoid Arthritis
933731|NCT02346864|head elevated position
933732|NCT02346864|preterm
933733|NCT02346864|three-stair-position
933734|NCT02346838|Prediabetes, prebiotics, metabolic endotoxemia
933735|NCT02346825|P-CIMT
933736|NCT02346825|Pediatric Constraint Induced Movement Therapy
933737|NCT02346825|Hemiparesis
933738|NCT02346825|Cerebral Palsy
933739|NCT02346825|Infants
933740|NCT02346825|Toddlers
933741|NCT02346825|Children
933742|NCT02346786|Drinking Water
933743|NCT02346786|Mineral water
933744|NCT02346786|Sports
933745|NCT02346786|Accident prevention
933746|NCT02346747|Stage III
933747|NCT02346747|Stage IV
933748|NCT02346747|Ovarian Cancer
933749|NCT02346747|Maintenance
933750|NCT02346747|Immunotherapy
933751|NCT02346747|primary peritoneal cancer
933752|NCT02346747|fallopian tube cancer
933753|NCT02346747|endometrioid ovarian cancer
933754|NCT02346747|high-grade serous ovarian cancer
933755|NCT02346734|Multiple Sclerosis
933756|NCT02346734|Telerehablitation
933757|NCT02346721|Sofosbuvir
933758|NCT02346721|SOF/GS-5816
933759|NCT02346721|GS-5816
933760|NCT02346721|Hepatitis C
933761|NCT02346721|HCV
933762|NCT02346721|Cirrhosis
933763|NCT02346721|Velpatasvir
933764|NCT02346708|Parkinson's
933765|NCT02346708|TMS
933766|NCT02346708|Kluger
933767|NCT02346695|LV deformation
933768|NCT02346695|Endothelial glycocalyx
933769|NCT02346695|Coronary flow reserve
933770|NCT02346682|major depression disorder
933771|NCT02346682|biochemistry
933772|NCT02346682|TCM diagnosis
933773|NCT02346682|Neurological
933774|NCT02346682|metabonomics
933775|NCT02346682|neuroimaging
933776|NCT02346669|Microbiota
933777|NCT02346669|Diabetes Mellitus, Type 2
933778|NCT02346669|Obesity
933779|NCT02346617|CMV
933780|NCT02346617|T cell therapy
933781|NCT02346604|exercise
933782|NCT02346591|Positive psychology
933783|NCT02346591|Wellbeing
933784|NCT02346591|Stress reduction
933785|NCT02346591|Relaxation
933786|NCT02346591|Gratitude
933787|NCT02346591|Mobile app
933788|NCT02346591|Intervention
933789|NCT02346591|Altruism
933790|NCT02346591|Psychological well-being
933791|NCT02346591|Social well-being
933792|NCT02346591|Physical well-being
933793|NCT02346591|Workplace engagement
933794|NCT02346552|laparoscopic Cholecystectomy
933795|NCT02346552|laparoscope holder
933796|NCT02346552|Nissen fundoplication
933797|NCT02346552|paraesophageal hernia
933798|NCT02346552|sleeve surgery
933799|NCT02346539|Nicotine
933800|NCT02346539|Depression
933801|NCT02346526|Prostate Cancer
933802|NCT02346526|Castration-resistant prostate cancer
933803|NCT02346526|Castration-resistant prostate cancer metastatic to bone
933804|NCT02346513|Hip Replacement Arthroplasty
933805|NCT02346513|Ceramic on Metal Articulation
933806|NCT02346513|Serum level of Cobalt and Chromium
933807|NCT02346500|Benign Prostatic Hyperplasia
933808|NCT02346500|Lower urinary tract symptoms
933932|NCT02346006|Choroid
933809|NCT02346500|Photoselective laser vaporization of the prostate
933810|NCT02346500|Transrectal Ultrasound
933811|NCT02346487|children
933812|NCT02346474|Subcutaneous Fat
933813|NCT02346474|Visceral Fat
933814|NCT02346461|Hereditary Inclusion Body Myopathy (HIBM)
933815|NCT02346461|Sialic Acid
933816|NCT02346461|GNE Myopathy
933817|NCT02346461|N-Acetyl-D-mannosamine (ManNAc)
933818|NCT02346461|GNE Gene
933819|NCT02346448|endoscopic sphincterotomy
933820|NCT02346448|balloon dilation
933821|NCT02346448|adverse events
933822|NCT02346448|pancreatitis
933823|NCT02346448|bleeding
933824|NCT02346435|small renal mass
933825|NCT02346435|active surveillance
933826|NCT02346422|Heart Failure
933827|NCT02346422|Cardiomyopathies
933828|NCT02346422|Heart Diseases
933829|NCT02346422|Cardiovascular Diseases
933830|NCT02346422|Cardiomegaly
933831|NCT02346422|Gene Therapy
933832|NCT02346396|neuropathic pain
933833|NCT02346396|neurostimulation
933834|NCT02346396|ambulatory use
933835|NCT02346396|tDCS
933836|NCT02346383|back pain
933837|NCT02346383|neuromodulation
933838|NCT02346383|spinal peripheral neuromodulation
933839|NCT02346383|spinal cord stimulation
933840|NCT02346383|postlaminectomy pain syndrome
933841|NCT02346370|Recurrent, previously treated, locally advanced or metastatic NSCLC (non small cell lung cancer)
933842|NCT02346357|hip arthroscopy
933843|NCT02346357|analgesia
933844|NCT02346344|type 2 diabetes
933845|NCT02346344|beta cell function
933846|NCT02346344|meal tolerance test
933847|NCT02346344|maximum stimulation test
933848|NCT02346344|method standardization
933849|NCT02346344|insulin secretion
933850|NCT02346344|prediabetes
933851|NCT02346344|insulin sensitivity
933852|NCT02346318|Radiotherapy
933853|NCT02346318|Adverse Effect
933854|NCT02346318|Dermatitis or Eczema
933855|NCT02346292|COPD
933856|NCT02346292|Spirometry
933857|NCT02346292|severe and very severe COPD
933858|NCT02346292|COPD exacerbations
933859|NCT02346292|therapy schemes
933860|NCT02346292|therapy changes
933861|NCT02346279|Multiple Sclerosis
933862|NCT02346279|Rehabilitation
933863|NCT02346279|Questionnaire
933864|NCT02346279|Patient-Reported Outcome
933865|NCT02346279|Responsiveness
933866|NCT02346279|Minimal Important Clinical Difference
933867|NCT02346266|Stroke
933868|NCT02346266|Stroke Prevention
933869|NCT02346266|Children
933870|NCT02346266|Education
933871|NCT02346240|Certolizumab Pegol
933872|NCT02346240|Cimzia
933873|NCT02346240|Psoriasis
933874|NCT02346227|Human Papillomavirus
933875|NCT02346227|Uterine cervix
933876|NCT02346227|Infection
933877|NCT02346227|Antiviral Drug
933878|NCT02346227|Therapeutic use
933879|NCT02346214|Gestational Age
933880|NCT02346214|Anterior Lens Capsule Vascularity
933881|NCT02346214|Preterm
933882|NCT02346214|Method-comparison
933883|NCT02346188|blood lead, iron, zinc, child, cognition, behavior, Mexico
933884|NCT02346175|SHR3824 Type 2 diabetes mellitus SGLT2
933887|NCT02346136|Tai Chi
933888|NCT02346136|Cluster randomized controlled trial
933889|NCT02346136|Intervention
933890|NCT02346136|Elderly
933891|NCT02346136|Mobility
933892|NCT02346136|Health care utilization
933893|NCT02346123|Chagas disease
933894|NCT02346123|Polymorphisms
933895|NCT02346123|Biomarkers
933896|NCT02346097|Cardiac Resynchronization Therapy
933897|NCT02346097|Heart Failure
933898|NCT02346097|Ejection Fraction
933899|NCT02346097|Narrow
933900|NCT02346097|Pacemaker
933901|NCT02346097|Electrophysiology
933902|NCT02346097|Electrical activation mapping
933903|NCT02346097|Coronary Sinus
933904|NCT02346097|Mapping
933905|NCT02346097|QRS
933906|NCT02346097|QRS width
933907|NCT02346097|Pacing Interval
933908|NCT02346097|Left Ventricular Lead
933909|NCT02346097|Cardiac CT
933910|NCT02346097|Echocardiography
933911|NCT02346097|Myocardial Scintigraphy
933912|NCT02346097|6 Minutes Walk Test
933913|NCT02346097|Imaging
933914|NCT02346097|Left ventricular ejection fraction
933915|NCT02346097|Epicardial veins
933916|NCT02346097|Resynchronization
933917|NCT02346097|ImagingCRT
933918|NCT02346097|Optimal electrical resynchronization
933919|NCT02346097|Cardiac computed tomography
933920|NCT02346071|Bodily distress syndrome
933921|NCT02346071|Medically unexplained symptoms
933922|NCT02346071|Functional somatic symptoms
933923|NCT02346071|Functional somatic syndromes
933924|NCT02346071|Treatment
933925|NCT02346071|Acceptance and Commitment Therapy
933926|NCT02346045|hypertension
933927|NCT02346032|second line
933928|NCT02346006|Exercise
933929|NCT02346006|Visual Acuity
933930|NCT02346006|Blood Vessels
933931|NCT02346006|Retina
933933|NCT02345993|formoterol/beclomethasone in asthmatic crisis
933934|NCT02345993|asthmatic crisis treatment
933935|NCT02345967|diabetes mellitus requiring insulin
933936|NCT02345954|Uterus Prolapse
933937|NCT02345954|Laparoscopic Sacropexy
933938|NCT02345954|Laparoscopic Hysteropexy
933939|NCT02345928|Safety
933940|NCT02345928|Efficacy
933941|NCT02345928|CNTO 7160
933942|NCT02345928|Healthy
933943|NCT02345928|Asthma
933944|NCT02345928|Atopic Dermatitis
933945|NCT02345876|Dyslexia, Medial olivocochlear system, Maturation, Auditory Processing
933946|NCT02345863|CLL
933947|NCT02345850|Acute Leukemia
933948|NCT02345850|Myelodysplasia
933949|NCT02345850|GVHD Prophylaxis
933950|NCT02345850|Chronic GVHD
933951|NCT02345824|CDK4/6 Inhibitor
933952|NCT02345824|LEE011
933953|NCT02345824|Recurrent Glioblastoma
933954|NCT02345824|Anaplastic Glioma
933955|NCT02345824|Ribociclib
933956|NCT02345759|CKD patients
933957|NCT02345759|protein-restricted diets
933958|NCT02345759|compliance
933959|NCT02345759|psychological aspects
933960|NCT02345707|Cabotegravir
933961|NCT02345707|Human Immunodeficiency Virus
933962|NCT02345707|Bioavailability
933963|NCT02345707|Pharmacokinetics
933964|NCT02345694|Obstructive Sleep Apnea Syndrome
933965|NCT02345694|Gait
933966|NCT02345694|Posture
933967|NCT02345694|Continuous Positive Airway Pressure
933968|NCT02345681|furosemide
933969|NCT02345681|under strict conditions
933970|NCT02345681|normalize
933971|NCT02345681|ICU patients
933972|NCT02345681|fluid balance
933973|NCT02345668|Transdiagnostic Internet-based Protocol
933974|NCT02345668|Treatment as Usual (TAU)
933975|NCT02345655|Substances consumption
933976|NCT02345655|Opiate
933977|NCT02345655|Family practice
933978|NCT02345629|Refractory cancer pain
933979|NCT02345629|Cordotomy
933980|NCT02345629|Sharpness pain sensory testing
933981|NCT02345629|Heat pain sensory testing
933982|NCT02345629|Symptom questionnaire
933983|NCT02345629|Advanced cancers
933984|NCT02345629|Pain
933985|NCT02345616|Cardiac surgery
933986|NCT02345616|Pulmonary hypertension
933987|NCT02345616|Nitric oxide
933988|NCT02345616|Induction anesthesia
933989|NCT02345577|Kidney transplantation
933990|NCT02345577|Stochastic whole body vibration therapy
933991|NCT02345577|Muscle strength
933992|NCT02345577|Intramuscular lipid content
933993|NCT02345577|Intramyocellular lipid content
933994|NCT02345577|Short Physical Performance Battery Test
933995|NCT02345577|Prospective, randomised , double blind,placebo-controlled trial
933996|NCT02345577|Physical Therapy Modalities
933997|NCT02345551|Exercise
933998|NCT02345551|Sleep
933999|NCT02345551|Telemedicine
934000|NCT02345551|Behavior
934001|NCT02345551|Shift work
934002|NCT02345512|Falls
934003|NCT02345499|Radical cystectomy
934004|NCT02345499|Laparoscopy
934005|NCT02345486|Pilot Projects
934006|NCT02345486|Plasmalyte A
934007|NCT02345486|Ringer's lactate
934008|NCT02345486|Sodium Chloride
934009|NCT02345486|Critical Care
934010|NCT02345486|"Resuscitation"
934011|NCT02345473|Bladder cancer
934012|NCT02345473|Circulating cancer cells
934013|NCT02345421|LAL D
934014|NCT02345421|CESD
934015|NCT02345421|NASH
934016|NCT02345421|NAFLD
934017|NCT02345421|Wilson's
934018|NCT02345421|Niemann Pick
934019|NCT02345421|Familial Hypercholesterolemia
934020|NCT02345395|Brain Aneurysm
934021|NCT02345395|Pterional Craniotomy
934022|NCT02345395|MiniPterional Craniotomy
934023|NCT02345395|Transpalpebral Approach
934024|NCT02345395|Unruptured Brain Aneurysm
934025|NCT02345382|Advanced acute leukemia
934026|NCT02345356|Pharmacogenomics
934027|NCT02345356|Warfarin
934028|NCT02345356|Caribbean Hispanics
934029|NCT02345356|Polymorphisms
934030|NCT02345356|Dosing Algorithm
934031|NCT02345278|Immunotherapy
934032|NCT02345278|Allergic rhinitis/rhinoconjunctivitis
934033|NCT02345252|HIV
934034|NCT02345226|HIV
934035|NCT02345213|DLB
934036|NCT02345213|Dementia with Lewy bodies
934037|NCT02345213|Lewy Body Disease
934038|NCT02345213|Dementia
934039|NCT02345213|E2020
934040|NCT02345213|Donepezil
934041|NCT02345213|Aricept
934042|NCT02345200|dystrophy
934043|NCT02345200|body composition
934044|NCT02345200|malnutrition
934045|NCT02345174|zirconium
934046|NCT02345174|oncology
934047|NCT02345174|mAb
934048|NCT02345174|receptor occupancy
934049|NCT02345174|dose
934050|NCT02345174|PET
934051|NCT02345174|HER3
934052|NCT02345174|89-Zr
934053|NCT02345174|biodistribution
934054|NCT02345174|tumours
934055|NCT02345161|Triple Therapy
934056|NCT02345161|Formoterol
934057|NCT02345161|Respiratory
934058|NCT02345161|COPD
934059|NCT02345161|Budesonide
934060|NCT02345161|Vilanterol
934061|NCT02345161|Fluticasone Furoate
934062|NCT02345161|Umeclidinium
934063|NCT02345161|Lung Function
934064|NCT02345148|Healthy
934065|NCT02345148|Esketamine
934066|NCT02345148|JNJ-54135419
934067|NCT02345122|At-risk Drinking
934068|NCT02345122|Depression
934069|NCT02345122|Anxiety
934070|NCT02345122|Alcohol Drinking
934071|NCT02345109|weight
934072|NCT02345109|total body water
934073|NCT02345109|body fat
934074|NCT02345109|muscle mass
934075|NCT02345109|bone mass
934076|NCT02345109|BMI
934077|NCT02345109|visceral fat
934078|NCT02345109|calories
934079|NCT02345083|Frailty
934080|NCT02345083|Pre-frailty
934081|NCT02345083|Fit
934082|NCT02345083|Robust
934083|NCT02345083|Elderly
934084|NCT02345083|Sociodemography status
934085|NCT02345083|Functional status
934086|NCT02345083|Cognitive status
934087|NCT02345083|Nutrition status
934088|NCT02345083|Comorbidity
934089|NCT02345083|Polypharmacy
934090|NCT02345083|Mortality
934091|NCT02345083|Depression status
934092|NCT02345083|Health-related quality of life
934093|NCT02345083|Fall incidence
934094|NCT02345083|Hospitality
934095|NCT02345057|Diabetic Nephropathy
934096|NCT02345057|mineralocorticoid receptor antagonist
934097|NCT02345057|CS-3150
934098|NCT02345057|Japanese
934099|NCT02345044|Essential hypertension
934100|NCT02345044|mineralocorticoid receptor antagonist
934101|NCT02345044|CS-3150
934102|NCT02345044|Japanese
934103|NCT02345031|hearing loss
934104|NCT02345031|speech-in-noise
934105|NCT02345018|Mechano-chemical ablation
934106|NCT02345018|Treatment large varicose veins
934107|NCT02345018|Below-knee and branches
934108|NCT02345018|Endovenous
934109|NCT02345005|Vascular diseases
934110|NCT02345005|Aneurysm
934111|NCT02345005|Treatment Efficacy
934112|NCT02345005|Medical device
934113|NCT02345005|Population Register
934114|NCT02344979|NSCLC
934115|NCT02344979|Chemotherapy
934116|NCT02344979|thrombocytopenia
934117|NCT02344979|rhTPO
934118|NCT02344940|operable
934119|NCT02344940|premenopausal
934120|NCT02344940|endocrine therapy
934121|NCT02344940|safety
934122|NCT02344940|tamoxifen
934123|NCT02344940|toremifene
934124|NCT02344927|Cancer
934125|NCT02344927|End-of-life care
934126|NCT02344927|Clinically-assisted hydration
934127|NCT02344914|dental support
934128|NCT02344914|second stage of labor
934129|NCT02344901|non-valvular atrial fibrillation
934130|NCT02344901|stroke prevention
934131|NCT02344901|novel oral anticoagulants
934132|NCT02344901|warfarin
934133|NCT02344888|PCOS
934134|NCT02344888|Clomiphene citrate resistant
934135|NCT02344888|Prednisolone
934136|NCT02344823|cirrhosis
934137|NCT02344823|erectile dysfunction
934138|NCT02344823|portal hypertension
934139|NCT02344797|Perioperative
934140|NCT02344797|Postoperative Complications/prevention & control
934141|NCT02344784|ADD
934142|NCT02344784|ADHD
934143|NCT02344784|PPI
934144|NCT02344771|Endothelial dysfunction
934145|NCT02344771|General Surgery
934146|NCT02344771|Perioperative Care
934147|NCT02344745|Lavender
934148|NCT02344745|Aromatherapy
934149|NCT02344745|Urodynamics
934150|NCT02344732|epithelium, cornea, diabetes, vitrectomy, oxygen
934151|NCT02344719|cirrhosis
934152|NCT02344719|portal hypertension
934153|NCT02344719|taurin
934154|NCT02344706|Emergency Care, Prehospital
934155|NCT02344706|Coma
934156|NCT02344706|Electroencephalography
934157|NCT02344693|Electroencephalography
934158|NCT02344654|Fluorescence
934159|NCT02344654|Cholangiography
934160|NCT02344654|Indocyanine Green
934161|NCT02344654|Cholecystectomy, Laparoscopic
934162|NCT02344615|nerve stimulator
934163|NCT02344615|ultrasound
934164|NCT02344602|Diabetic Nephropathy
934165|NCT02344602|Diabetes Mellitus
934166|NCT02344602|Diabetes Complications
934167|NCT02344602|Uric Acid
934168|NCT02344602|Febuxostat
934169|NCT02344602|Uloric
934170|NCT02344602|Glomerular Filtration Rate
934171|NCT02344602|Kidney Disease
934172|NCT02344602|Vascular Disease
934173|NCT02344602|Cardiovascular Diseases
934174|NCT02344602|Endothelial Function
934175|NCT02344602|Arterial Stiffness
934176|NCT02344602|Pharmacologic Actions
934177|NCT02344602|Gout Suppressants
934178|NCT02344602|Therapeutic Uses
934179|NCT02344602|Free Radical Scavengers
934180|NCT02344602|Antioxidants
934181|NCT02344602|Protective Agents
934182|NCT02344602|Physiological Effects of Drugs
934183|NCT02344602|Angiotensin II Infusion
934184|NCT02344602|Flow-mediated Dilation
934185|NCT02344602|Flow-mediated Constriction
934186|NCT02344602|Nitroglycerin
934187|NCT02344602|Hyperglycemia
934188|NCT02344602|Renin-angiotensin-aldosterone System
934189|NCT02344602|Nitric Oxide
934190|NCT02344602|cGMP
934191|NCT02344602|Oxidative Stress
934192|NCT02344602|Renal Haemodynamic Function
934193|NCT02344602|Inulin Clearance
934194|NCT02344602|PAH Clearance
934195|NCT02344602|Skin Biopsy
934196|NCT02344602|T1R mRNA Expression
934197|NCT02344602|Cytokines
934198|NCT02344602|Chemokines
934199|NCT02344589|ACB
934200|NCT02344589|Adductor Canal Block
934201|NCT02344589|Peripheral Nerve Block
934202|NCT02344576|heart failure
934203|NCT02344576|heart-assist devices
934204|NCT02344576|decision making
934205|NCT02344576|decision support techniques
934206|NCT02344576|hospice care
934207|NCT02344576|palliative care
934208|NCT02344576|caregivers
934209|NCT02344563|volunteers
934210|NCT02344550|metastatic breast cancer
934211|NCT02344550|HER2 negative
934212|NCT02344550|hormone-receptor positive
934213|NCT02344537|Lyme DIsease
934214|NCT02344537|Kundalini Yoga
934215|NCT02344498|Liver cirrhosis
934216|NCT02344498|Antiviral agents
934217|NCT02344498|Liver diseases
934218|NCT02344472|MBC
934219|NCT02344472|HER2
934220|NCT02344472|CTC
934221|NCT02344472|endocrine therapy
934222|NCT02344472|Pertuzumab
934223|NCT02344472|Trastuzumab
934224|NCT02344472|HER2 therapy
934225|NCT02344446|physical therapy intervention
934226|NCT02344433|Family health history
934227|NCT02344433|Genetic literacy
934228|NCT02344433|Health literacy
934229|NCT02344433|Relational agent
934230|NCT02344433|Common chronic conditions
934231|NCT02344420|Heart Failure
934232|NCT02344420|CRT
934233|NCT02344407|Zaire Ebola Virus Disease
934234|NCT02344394|Atrial Fibrillation
934235|NCT02344394|Anti-Arrhythmia Agents
934236|NCT02344394|Catheter Ablation
934237|NCT02344394|surgical hybrid ablation
934238|NCT02344368|Sucrose
934239|NCT02344368|Anesthesia
934240|NCT02344368|Blood specimen collection
934241|NCT02344368|Injections, Intravenous
934242|NCT02344355|Ascorbic Acid
934243|NCT02344355|temozolomide
934244|NCT02344355|radiation
934245|NCT02344342|telemonitoring
934246|NCT02344290|HIV
934247|NCT02344290|Cardiovascular Disease
934248|NCT02344290|Myocardial Infarction
934249|NCT02344290|Inflammation
934250|NCT02344290|Statin
934251|NCT02344290|Computerized Tomography
934252|NCT02344290|Cholesterol
934253|NCT02344277|Subcutaneaous Implantable Cardiac Defibrillator
934254|NCT02344277|Brugada syndrome
934255|NCT02344277|Effectiveness
934256|NCT02344277|Safety
934257|NCT02344264|US guided nerve block
934258|NCT02344264|Total hip Arthroplasty
934259|NCT02344264|NCFL
934260|NCT02344264|nervus cutaneous femoralis lateralis
934261|NCT02344251|Drug study
934262|NCT02344251|Medication compliance
934263|NCT02344238|Medication compliance
934264|NCT02344238|Technology
934265|NCT02344238|Drug study
934266|NCT02344186|diabetes, endoplasmic reticulum stress, obesity, GLP1 analogs
934267|NCT02344160|Total Hip Arthroplasty
934268|NCT02344160|THA
934269|NCT02344095|recurrent, persistent
934270|NCT02344069|Fibrinogen
934271|NCT02344056|Having Lunch
934272|NCT02344056|Skipping Lunch
934273|NCT02344030|airway
934274|NCT02344030|videolaryngoscope
934275|NCT02343978|Chronic Constipation
934276|NCT02343978|CC
934277|NCT02343965|Touch-massage
934278|NCT02343965|anxiety
934279|NCT02343965|leukemia
934280|NCT02343965|haematology
934281|NCT02343965|cancerology
934282|NCT02343965|supportive care
934283|NCT02343965|complementary therapy
934284|NCT02343952|Pembrolizumab
934285|NCT02343952|MK-3475
934286|NCT02343874|Alcohol consumption
934287|NCT02343874|Primary health care
934288|NCT02343874|health care costs
934289|NCT02343874|health service utilization
934290|NCT02343861|Behavioral Research
934291|NCT02343861|Emollients
934292|NCT02343822|PRP
934293|NCT02343822|Platelet Rich Plasma
934294|NCT02343822|Lateral Epicondylitis
934295|NCT02343822|Lateral Epicondylopathy
934296|NCT02343822|Lateral Epicondylosis
934297|NCT02343822|Chronic Lateral Epicondylitis
934298|NCT02343822|PRPLE
934299|NCT02343822|Multiple PRP Injections
934300|NCT02343822|Multiple PRP
934301|NCT02343822|Platelet-Rich Plasma
934302|NCT02343822|Tennis Elbow
934303|NCT02343822|Double Blinded Randomized Controlled
934304|NCT02343822|Multiple vs Single PRP injections
934305|NCT02343822|prp tennis elbow
934306|NCT02343809|Physiotherapy
934307|NCT02343809|Lateral epicondylitis
934308|NCT02343809|Manual therapy
934309|NCT02343796|Fiberglass reinforced resins
934310|NCT02343783|Atopic Dermatitis
934311|NCT02343783|Asthma
934312|NCT02343783|Healthy
934313|NCT02343783|Skin Blisters
934314|NCT02343783|Adult Participants
934315|NCT02343744|Generalized Pustular Psoriasis
934316|NCT02343744|Erythrodermic Psoriasis
934317|NCT02343744|Guselkumab
934318|NCT02343744|CNTO1959
934319|NCT02343731|microbiome
934320|NCT02343731|hygiene hypothesis
934321|NCT02343731|human-animal interaction
934322|NCT02343731|microbiota
934323|NCT02343731|connections between human-canine microbiome
934324|NCT02343653|Malnutrition
934325|NCT02343653|Muscle mass
934326|NCT02343653|Nutrition
934327|NCT02343640|Baseball
934328|NCT02343640|Ulnar collateral ligament
934329|NCT02343614|Intermediate risk
934330|NCT02343614|Cox-2 inhibitors
934455|NCT02342028|autoimmunity
934331|NCT02343588|Chinese multi-centered school based obesity intervention
934332|NCT02343575|Hyperactive delirium
934333|NCT02343575|Mixed delirium
934334|NCT02343575|Anti-psychotic
934335|NCT02343575|Haldol
934336|NCT02343575|Valproic Acid
934337|NCT02343536|Phase 1
934338|NCT02343536|Oral Azacitidine (CC-486)
934339|NCT02343536|R-CHOP
934340|NCT02343536|Diffuse Large B-cell Lymphoma
934341|NCT02343536|Grade 3B Follicular Lymphoma
934342|NCT02343536|Follicular Lymphoma
934343|NCT02343536|Transformed Lymphoma
934344|NCT02343523|Wearable device
934345|NCT02343523|Wrist-watch
934346|NCT02343523|Longitudinal monitoring
934347|NCT02343523|Congestive Heart Failure
934348|NCT02343510|Fallopian tubal cancer, high grade serous , ovarian cancer
934349|NCT02343484|pulsed radiofrequency
934350|NCT02343484|gelified ethanol
934351|NCT02343471|Whey proteins
934352|NCT02343471|Postprandial lipemia
934353|NCT02343471|Pre-meal
934354|NCT02343471|Type 2 diabetes
934355|NCT02343458|COPD
934356|NCT02343432|Anesthesia
934357|NCT02343432|Adverse Effect
934358|NCT02343432|Spinal
934359|NCT02343432|Epidural
934360|NCT02343419|Bronchial Hyperreactivity
934361|NCT02343419|Bronchial Provocation Tests
934362|NCT02343419|Methacholine Chloride
934363|NCT02343419|Respiratory Function Tests
934364|NCT02343419|Spirometry
934365|NCT02343419|Airway Resistance
934366|NCT02343419|Plethysmography
934367|NCT02343406|European Organization for Research and Treatment of Cancer
934368|NCT02343406|Brain Tumor Group
934369|NCT02343406|Lomustine
934370|NCT02343406|Pediatric High Grade Gliomas
934371|NCT02343406|Glioblastoma Multiforme
934372|NCT02343406|Pediatric diffuse Intrinsic Pontine Glioma
934373|NCT02343406|Children
934374|NCT02343406|Epithelial Growth Factor vIII mutation
934375|NCT02343406|Antibody Drug Conjugate
934376|NCT02343406|Temozolomide
934377|NCT02343406|recurrent glioblastoma
934378|NCT02343406|Epithelial Growth Factor
934379|NCT02343406|ABT-414
934380|NCT02343406|EORTC
934381|NCT02343406|Pediatric WHO grade III glioma
934382|NCT02343406|EGFR amplification
934383|NCT02343406|Pediatric WHO grade IV glioma
934384|NCT02343406|Brain Tumor
934385|NCT02343393|Endothelial Dysfunction
934386|NCT02343393|Biomarkers
934387|NCT02343393|Hydralazine-Isosorbide Dinitrate
934388|NCT02343380|diet-induced thermogenesis
934389|NCT02343380|glucose
934390|NCT02343380|respiratory quotient
934391|NCT02343367|Hispanic
934392|NCT02343367|overweight
934393|NCT02343367|families
934394|NCT02343367|pediatric
934395|NCT02343367|primary care
934396|NCT02343354|behavioural
934397|NCT02343354|diabetes prevention
934398|NCT02343354|physical activity
934399|NCT02343354|healthy eating
934400|NCT02343354|gestational diabetes
934401|NCT02343341|early childhood education
934402|NCT02343341|cardiovascular health
934403|NCT02343341|behavior change
934404|NCT02343341|community-based
934405|NCT02343341|family-based
934406|NCT02343341|prevention
934407|NCT02343315|low back pain
934408|NCT02343315|home exercises
934409|NCT02343315|chronic pain
934410|NCT02343315|supervised exercise
934411|NCT02343315|core stability exercises
934412|NCT02343315|spinal stabilization exercises
934413|NCT02343302|Pancreatic Fistula
934414|NCT02343289|Healthy
934415|NCT02343289|Pharmacokinetics
934416|NCT02343289|Esketamine
934417|NCT02343289|JNJ-54135419
934418|NCT02343276|Radial Spasm
934419|NCT02343263|Tonsillectomy
934420|NCT02343263|Adenotonsillectomy
934421|NCT02343263|Pain
934422|NCT02343263|Hemorrhage
934423|NCT02343237|Fibromyalgia syndrome
934424|NCT02343237|pain
934425|NCT02343237|quality of life
934426|NCT02343237|osteopathic treatment
934427|NCT02343211|Paraneoplastic Neurological Syndromes
934428|NCT02343211|Onconeural antibodies
934429|NCT02343211|Cancer
934430|NCT02343185|diaphragm
934431|NCT02343185|osteopathic treatment
934432|NCT02343185|myofascial release
934433|NCT02343172|Liposarcoma,
934434|NCT02343172|MDM2 inhibition,
934435|NCT02343172|cdk4 inhibition,
934436|NCT02343172|HDM201,
934437|NCT02343172|LEE011
934438|NCT02343133|Radiation countermeasure
934439|NCT02343133|radiomitigation
934440|NCT02343107|Obesity
934441|NCT02343107|Type 2 diabetes
934442|NCT02343107|Metabolic syndrome
934443|NCT02343107|e-coaching
934444|NCT02343107|Telehealth
934445|NCT02343094|Proteinuria
934446|NCT02343094|Lipocalin 2
934447|NCT02343094|Neutrophil gelatinase associated lipocalin
934448|NCT02343094|ELISA
934449|NCT02343081|brain neoplasm
934450|NCT02343081|bioequivalence
934451|NCT02343081|temozolomide
934452|NCT02342028|sleep apnea
934453|NCT02342028|intermittent hypoxia
934454|NCT02342028|regulatory T cell
934456|NCT02342002|mifepristone
934457|NCT02342002|misoprostol
934458|NCT02342002|obstetrics
934459|NCT02342002|reproductive health
934460|NCT02342002|pregnancy
934461|NCT02342002|abortion
934462|NCT02342002|missed abortion
934463|NCT02341989|Chemotherapy, adjuvant
934464|NCT02341989|Recurrence
934465|NCT02341989|Carboplatin
934466|NCT02341989|Bleomycin
934467|NCT02341989|Etoposide
934468|NCT02341989|Cisplatin
934469|NCT02341976|whole body vibration
934470|NCT02341976|pelvic floor muscle
934471|NCT02341976|urinary incontinence
934472|NCT02341976|Urinary sphincter
934473|NCT02341950|videogame
934474|NCT02341950|health
934475|NCT02341950|behavior
934476|NCT02341950|mobile
934477|NCT02341950|spinal
934478|NCT02341950|cord
934479|NCT02341950|dysfunction
934480|NCT02341911|triple negative breast cancer
934481|NCT02341911|fine line chemotherapy
934482|NCT02341898|nursing home care
934483|NCT02341898|physical restraints
934484|NCT02341898|dementia
934485|NCT02341898|implementation research
934486|NCT02341898|cluster-randomized controlled trial
934487|NCT02343042|Selinexor
934488|NCT02343042|KCP-330
934489|NCT02343042|STOMP
934490|NCT02343042|Multiple Myeloma
934491|NCT02343042|Relapsed/Refractory
934492|NCT02343042|Dexamethasone
934493|NCT02343042|Pomalidomide
934494|NCT02343042|Bortezomib
934495|NCT02343042|Karyopharm
934496|NCT02343042|Lenalidomide
934497|NCT02343042|Daratumumab
934498|NCT02343029|Aerobic Exercise Training
934499|NCT02343029|prevention
934500|NCT02343029|magnetic resonance spectroscopic imaging
934501|NCT02343029|psychometric tests
934502|NCT02343029|cognition
934503|NCT02343029|dementia
934504|NCT02343029|cognitive impairment
934505|NCT02343003|cooled radiofrequency ablation
934506|NCT02343003|knee pain
934507|NCT02343003|osteoarthritis
934508|NCT02343003|pain management
934509|NCT02342990|working memory training
934510|NCT02342990|home-based training
934511|NCT02342990|periventricular leukomalacia
934512|NCT02342990|bilateral cerebral palsy
934513|NCT02342990|neuropsychological profile
934514|NCT02342990|high density EEG
934515|NCT02342990|slow waves activities
934516|NCT02342977|total hip arthroplasty
934517|NCT02342964|Cystic fibrosis
934518|NCT02342964|hepatic fibrosis
934519|NCT02342964|hepatic cirrhosis
934520|NCT02342964|non-invasive methods of measurement
934521|NCT02342964|hepatic elasticity
934522|NCT02342951|Cystic fibrosis,
934523|NCT02342951|lung clearance index,
934524|NCT02342951|pulmonary function
934525|NCT02342938|Epilepsy surgery
934526|NCT02342938|High frequency activity
934527|NCT02342938|icEEG
934528|NCT02342938|fMRI
934529|NCT02342938|MEG
934530|NCT02342886|Tuberculosis
934531|NCT02342886|Multi Drug-Resistant Tuberculosis
934532|NCT02342886|Drug-sensitive Tuberculosis
934533|NCT02342886|PA-824
934534|NCT02342886|Moxifloxacin
934535|NCT02342886|Pyrazinamide
934536|NCT02342886|Rifampicin
934537|NCT02342886|Isoniazid
934538|NCT02342886|Ethambutol
934539|NCT02342886|HRZE
934540|NCT02342886|HR
934541|NCT02342886|Pretomanid
934542|NCT02342886|NC-006
934543|NCT02342886|STAND
934544|NCT02342873|ultrasound
934545|NCT02342873|nerve stimulator
934546|NCT02342860|Water
934547|NCT02342860|sanitation
934548|NCT02342860|hygiene access in school
934549|NCT02342756|ARDS, HFOV
934550|NCT02342691|Safety and efficacy of BLXA4
934552|NCT02342626|Prostate
934553|NCT02342626|Cancer
934554|NCT02342626|Adenocarcinoma
934555|NCT02342587|Lapatinib
934556|NCT02342561|Infection
934557|NCT02342561|Drape
934558|NCT02342561|Ioban
934559|NCT02342561|Arthroplasty
934560|NCT02342561|Knee
934561|NCT02342561|Cylinder Sampling
934562|NCT02342561|Bacteria
934563|NCT02342548|Huntington; chorea; total motor score; CAG repeat: total functional capacity; motor cognitive and behavioral symptoms
934564|NCT02342522|Cardioprotection
934565|NCT02342522|STEMI
934566|NCT02342522|PPCI
934567|NCT02342522|Myocardial reperfusion injury
934568|NCT02342522|Myocardial infarct size
934569|NCT02342509|et Control
934570|NCT02342509|inhalational sedation
934571|NCT02342509|conserve volatile anesthetics
934572|NCT02342470|prevention
934573|NCT02342470|Recurrent peptic ulcer
934574|NCT02342444|Trauma
934575|NCT02342444|Surgery
934576|NCT02342444|Enoxaparin
934577|NCT02342444|DVTs
934578|NCT02342444|Thromboembolic events
934579|NCT02342431|Thermoregulation
934580|NCT02342431|Pediatric Anesthesia
934581|NCT02342431|Cardiac Catheterization
934582|NCT02342405|Oxidative stress
934583|NCT02342405|Nitrogen oxide
934584|NCT02342405|Reactive oxygen species
934585|NCT02342392|pterygium
934586|NCT02342392|ranibizumab
934587|NCT02342392|anti-VEGF
934588|NCT02342392|recurrence
934589|NCT02342392|vascularity
934590|NCT02342392|size
934591|NCT02342366|Sodium Oxybate, Altruism, Neurostreroids, Liquid Ecstasy
934592|NCT02342340|Beans, Lentils, Bioavailability, Phytochemical Absorption
934593|NCT02342288|Intraoperative ocular pressure
934594|NCT02342275|Infantile hemangioma
934595|NCT02342275|Propranolol
934596|NCT02342275|Atenolol
934597|NCT02342275|Efficacy
934598|NCT02342275|Safety
934599|NCT02342249|Influenza A
934600|NCT02342236|Biological Markers
934601|NCT02342223|human immunodeficiency virus
934602|NCT02342223|facial lipoatrophy
934603|NCT02342223|facial lipodystrophy
934604|NCT02342223|hyaluronic acid
934605|NCT02342223|dermal filler
934606|NCT02342223|filler agent
934607|NCT02342210|Mindfulness
934608|NCT02342210|Group Therapy
934609|NCT02342197|Low responders
934610|NCT02342197|Minidose long protocol
934611|NCT02342197|Microdose flare protocol
934612|NCT02342197|Oocyte yield
934613|NCT02342171|Ebola Viral Disease
934614|NCT02342171|Convalescent Plasma
934615|NCT02342171|Developing Countries
934616|NCT02342145|beta-Thalassemia major
934617|NCT02342119|kidney transplantation
934618|NCT02342119|race disparities
934619|NCT02342119|living donor kidney transplantation
934620|NCT02342119|transplant evaluation
934621|NCT02342093|Ambulatory Blood Pressure Monitoring
934622|NCT02342093|Drospirenone
934623|NCT02342093|Oral contraceptive
934624|NCT02342080|Rehabilitation
934625|NCT02342080|Walking
934626|NCT02342080|Robotics
934627|NCT02342080|Neuronal Plasticity
934628|NCT02342054|Cancer
934629|NCT02342054|Prostate Cancer
934630|NCT02342054|Brachytherapy
934631|NCT02342054|Dose escalation
934632|NCT02342054|High Dose Rate
934633|NCT02342054|MRI-TRUS fusion
934634|NCT02342054|Detection of DILs by MRI
934635|NCT02342054|SINGLE FRACTION
934636|NCT02342041|SUVN-G3031
934637|NCT02342041|histamine 3 (H3) receptor inverse agonist
934638|NCT02342041|first in human
934639|NCT02342041|safety
934640|NCT02342041|pharmacokinetics
934641|NCT02342041|tolerability
934642|NCT02342041|single dose
934643|NCT02342041|repeat dose
934644|NCT02341885|Kidney
934645|NCT02341885|Renal replacement
934646|NCT02341885|Acute kidney injury
934647|NCT02341885|chronic kidney disease
934648|NCT02341885|Epidemiology
934649|NCT02341885|Prevalence
934650|NCT02341872|White spot lesions
934651|NCT02341872|remineralization
934652|NCT02341872|QLF
934653|NCT02341872|antibacterial
934654|NCT02341846|cancer pain
934655|NCT02341833|Anesthetic preconditioning
934656|NCT02341833|Sevoflurane
934657|NCT02341833|Liver transplantation
934658|NCT02341833|brain-death donors
934659|NCT02341820|breast cancer
934660|NCT02341820|breast conserving surgery
934661|NCT02341820|cosmesis
934662|NCT02341807|Choroideremia
934663|NCT02341807|AAV
934664|NCT02341807|Gene therapy
934665|NCT02341807|CHM
934666|NCT02341807|Adeno-associated virus
934667|NCT02341807|Adeno-associated viral vector
934668|NCT02341794|intracranial arterial disease
934669|NCT02341794|dyslipidemia
934670|NCT02341794|rosuvastatin
934671|NCT02341781|MANTLE CELL LYMPHOMA
934672|NCT02341781|Multicenter
934673|NCT02341781|Observational
934674|NCT02341781|Lenalidomide (Revlimid®)
934675|NCT02341781|Relapsed or progressed
934676|NCT02341781|Ibrutinib
934677|NCT02341768|clinical and device functional information
934678|NCT02341768|"real world ICD patient population"
934679|NCT02341742|Physical activity
934680|NCT02341742|Bone health
934681|NCT02341742|Pediatrics
934682|NCT02341742|Bone
934683|NCT02341729|semi-urgent CABG
934684|NCT02341729|reanimation
934685|NCT02341729|ticagrelor
934686|NCT02341729|crushed tablet
934687|NCT02341716|intermittent claudication
934688|NCT02341716|exercise therapy
934689|NCT02341716|physiotherapy
934690|NCT02341690|Type 2 diabetes
934691|NCT02341690|Interval Walking Training
934692|NCT02341690|Motivation
934693|NCT02341677|Prostatic Neoplasms
934694|NCT02341677|Diagnostic Techniques and Procedures
934695|NCT02341677|Magnetic Resonance Imaging
934696|NCT02341677|Ultrasonography
934697|NCT02341677|Biopsy
934698|NCT02341677|Image Fusion
934699|NCT02341664|Mobile Tablet Device
934700|NCT02341664|Outpatient Clinic
934701|NCT02341664|Tobacco
934702|NCT02341664|Health
934703|NCT02341664|Barriers
934704|NCT02341664|Prevention
934705|NCT02341664|Prescribing Practices
934706|NCT02341664|Informed Consent
934707|NCT02341664|Statin
934708|NCT02341664|Lipid Panel
934709|NCT02341664|Low Density Lipoprotein-C
934710|NCT02341664|Blood Draw
934711|NCT02341664|ACC/AHA Guidelines
934712|NCT02341664|Adult Treatment Panel Guidelines (ATPIII)
934713|NCT02341664|Atherosclerotic Cardiovascular Disease (ASCVD)
934714|NCT02341664|Cholesterol-lowering therapies
934715|NCT02341664|Cholesterol Management
934716|NCT02341664|Cardiovascular Risk
934717|NCT02341664|10-year CVD Risk
934718|NCT02341664|Labs
934719|NCT02341664|Coronary revascularization
934720|NCT02341664|Arterial revascularization
934721|NCT02341664|Imaging
934722|NCT02341651|High blood pressure
934723|NCT02341651|Cardiovascular diseases
934724|NCT02341651|Antihypertensive agents
934725|NCT02341651|Pharmacological treatment
934726|NCT02341651|Non-pharmacological treatment
934727|NCT02341651|Community health care workers
934728|NCT02341651|Treatment algorithm
934729|NCT02341651|Public and private healthcare providers
934730|NCT02341651|Strategy
934731|NCT02341651|Referral loops
934732|NCT02341651|Intervention
934733|NCT02341612|exercise-induced muscle damage
934734|NCT02341612|skeletal muscle injury recovery
934735|NCT02341612|cryotherapy
934736|NCT02341612|recovery of function
934737|NCT02341612|rehabilitation
934738|NCT02341586|Malaria
934739|NCT02341586|Cambodia
934740|NCT02341586|Iron
934741|NCT02341586|Childbearing Age
934742|NCT02341586|Women
934743|NCT02341586|Home Fortification
934744|NCT02341573|Traditional Chinese Medicine
934745|NCT02341573|Randomized Controlled Trial
934746|NCT02341560|NAION
934747|NCT02341495|Azacitidine
934748|NCT02341495|Vidaza
934749|NCT02341495|Deferasirox
934750|NCT02341495|Exjade
934751|NCT02341495|Cholecalciferol
934752|NCT02341495|Vitamin D
934753|NCT02341482|Itraconazole
934754|NCT02341482|Healthy Volunteers
934755|NCT02341482|Drug-drug interaction
934756|NCT02341482|PF-04958242
934757|NCT02341469|Burkina Faso
934758|NCT02341469|cluster randomised
934759|NCT02341469|stepped-wedge
934760|NCT02341469|IMCI
934761|NCT02341443|bilateral double mandibular fractures
934762|NCT02341443|rigid fixation
934763|NCT02341443|no-rigid fixation
934764|NCT02341443|jaw
934765|NCT02341430|hernia
934766|NCT02341430|synthetic mesh
934767|NCT02341417|Chronic Kidney Disease, Dialysis, Secondary Hyperparathyroidism, Pediatric
934768|NCT02341391|chondrocyte cells
934769|NCT02341391|Osteoarthritis
934770|NCT02341391|gene therapy
934771|NCT02341378|chondrocyte cells
934772|NCT02341378|Osteoarthritis
934773|NCT02341378|gene therapy
934774|NCT02341365|Egg donation
934775|NCT02341365|vitaminD
934776|NCT02341365|ovarian reserve
934777|NCT02341365|ovarian stimulation
934778|NCT02341326|Lung
934779|NCT02341326|COPD
934780|NCT02341326|smoking
934781|NCT02341326|Non-smoker
934782|NCT02341313|Hypoglycaemia
934783|NCT02341300|Pregnancy
934784|NCT02341300|Cast-Iron pots
934785|NCT02341300|Iron-deficiency anemia
934786|NCT02341274|Tacrolimus
934787|NCT02341274|Drug Formulation
934788|NCT02341274|Absorption
934789|NCT02341274|Bioavailability
934790|NCT02341274|Healthy Volunteer
934791|NCT02341248|Enteral Nutrition
934792|NCT02341248|Pediatrics
934793|NCT02341248|Microbiota
934794|NCT02341248|Metabolomics
934795|NCT02341235|video game
934796|NCT02341235|narrative
934797|NCT02341235|story
934798|NCT02341235|survivorship
934799|NCT02341235|cancer survivor
934800|NCT02341235|mhealth
934801|NCT02341235|physical activity
934802|NCT02341235|women
934803|NCT02341235|women's health
934804|NCT02341222|hernia prosthetic surgery
934805|NCT02341222|incisional hernia prosthesis
934806|NCT02341222|prosthesis mesh fixation
934807|NCT02341222|prosthesis mesh biocompatibility
934808|NCT02341209|CTCL
934809|NCT02341209|Sezary Syndrome (SS)
934810|NCT02341209|Mycosis Fungoides (MF)
934811|NCT02341209|Cutaneous T-cell Lymphoma
934812|NCT02341209|MF
934813|NCT02341209|SS
934814|NCT02341131|Schizophrenia
934815|NCT02341131|Cognitive Remediation
934816|NCT02341131|BDNF
934817|NCT02341118|BRCA1/2 Mutational Status
934818|NCT02341092|Traumatic brain injury
934819|NCT02341079|Total Knee Arthroplasty
934820|NCT02341079|Osteoarthritis
934821|NCT02341079|Femoral Nerve Blockade
934822|NCT02341079|Liposomal Bupivacaine
934823|NCT02341066|Cardiovascular risk score
934824|NCT02341066|Framingham risk score 2-year
934825|NCT02341066|Endothelial dysfunction
934826|NCT02341066|EndoPAT
934827|NCT02341066|Rheumatoid arthritis
934828|NCT02341053|SMA
934829|NCT02341053|Neuromuscular disability
934830|NCT02341040|wheat allergy
934831|NCT02341040|food allergy
934832|NCT02341040|pediatric
934833|NCT02341027|Immediate postpartum contraception
934834|NCT02341027|Contraceptive implants
934835|NCT02341027|Breastfeeding
934836|NCT02341027|Jadelle
934837|NCT02341027|Lactation
934838|NCT02341027|Levonorgestrel
934839|NCT02341014|Carfilzomib
934840|NCT02341014|Romidepsin
934841|NCT02341014|Lenalidomide
934842|NCT02341014|Lymphomas
934843|NCT02341014|14-179
934844|NCT02341001|Bariatric surgery
934845|NCT02341001|Sleeve gastrectomy
934846|NCT02341001|Text messaging
934847|NCT02341001|Weight loss
934848|NCT02341001|BAROS
934849|NCT02341001|Follow-up care
934850|NCT02340975|Gastric Adenocarcinoma
934851|NCT02340975|Gastroesophageal Junction Adenocarcinoma
934852|NCT02340975|Immunotherapy
934853|NCT02340975|Antibodies, Monoclonal
934854|NCT02340975|Tremelimumab
934855|NCT02340975|MEDI4736
934856|NCT02340923|DMD
934857|NCT02340923|Duchenne Muscular Dystrophy
934858|NCT02340923|EIM
934859|NCT02340910|spasticity
934860|NCT02340910|whole body vibration
934861|NCT02340910|walking
934862|NCT02340871|Neurogenetics
934863|NCT02340871|genetic testing
934864|NCT02340845|breast,colon, ovary, uterus, cervix, lung
934865|NCT02340845|Treatments
934866|NCT02339792|COMPREHENSIVE GERIATRIC ASSESSMENT (CGA)
934867|NCT02339792|MEDICATION APPROPRIATENESS PRESCRIBING
934868|NCT02339792|DRUG INTERACTIONS
934869|NCT02339792|E-LEARNING
934870|NCT02339779|fat grafting
934871|NCT02339779|fat injection
934872|NCT02339779|lipoaspirate
934873|NCT02339779|fat transfer
934874|NCT02339779|lipofilling
934875|NCT02339779|liposculpturing
934876|NCT02339779|lipoinjection
934877|NCT02339779|lipotransfer
934878|NCT02339779|breast reconstruction
934879|NCT02339766|Cesarean
934880|NCT02339766|Quadratus Lumborum Block
934881|NCT02339766|Analgesia
934882|NCT02339766|Ultrasonography
934883|NCT02339727|Omega-3
934884|NCT02339727|Omega-6
934885|NCT02339714|allergic rhinitis
934886|NCT02339714|acupuncture
934887|NCT02339714|moxibustion
934888|NCT02339714|efficacy
934889|NCT02339714|safety
934890|NCT02339649|sepsis
934891|NCT02339649|septic shock
934892|NCT02339649|ICU
934893|NCT02339649|long-term outcome
934894|NCT02339649|neurocognitive
934895|NCT02339649|inflammatory
934896|NCT02339649|MRI
934897|NCT02339649|EEG
934898|NCT02339649|brain imaging
934899|NCT02339649|serum biomarkers
934900|NCT02339649|CSF
934901|NCT02339636|subclinical, enthesitis, synovitis
934902|NCT02339623|Threatened preterm birth - fetal adrenal gland volume
934903|NCT02339610|Osteoarthritis
934904|NCT02339610|Post-traumatic Arthritis
934905|NCT02340806|epidural bolus
934906|NCT02340806|pain management
934907|NCT02340806|labor analgesia
934908|NCT02340793|Weight loss
934909|NCT02340767|Suspicious Occlusal Caries
934910|NCT02340754|mindfulness
934911|NCT02340754|meditation
934912|NCT02340754|stress, psychological
934913|NCT02340754|quality of life
934914|NCT02340754|randomized controlled trial
934915|NCT02340741|carbon dioxide
934916|NCT02340741|postoperative cerebrovascular complications
934917|NCT02340741|air embolism
934918|NCT02340728|Stent Placement
934919|NCT02340728|Biliary Obstruction
934920|NCT02340728|14-260
934921|NCT02340715|Anal canal
934922|NCT02340715|Brain
934923|NCT02340715|Breast
934924|NCT02340715|Cervix
934925|NCT02340715|Esophagus
934926|NCT02340715|Gynecology
934927|NCT02340715|Head and Neck
934928|NCT02340715|Lung
934929|NCT02340715|Pancreas
934930|NCT02340715|Primary liver or liver metastases
934931|NCT02340715|Prostate cancer
934932|NCT02340715|Sarcoma
934933|NCT02340702|COPD and heart failure
934934|NCT02340689|PH
934935|NCT02340689|PH type 1
934936|NCT02340689|Primary Hyperoxaluria
934937|NCT02340689|Hyperoxaluria
934938|NCT02340689|Primary Oxalosis
934939|NCT02340689|PH type 2
934940|NCT02340689|PH type 3
934941|NCT02340689|Genetic testing for PH
934942|NCT02340689|Genetic testing for Primary Hyperoxaluria
934943|NCT02340689|Hereditary study for PH
934944|NCT02340689|Hereditary study for Primary Hyperoxaluria
934945|NCT02340689|AGXT
934946|NCT02340689|GRHPR
934947|NCT02340689|HOGA1
934948|NCT02340676|chronic graft-versus-host-disease
934949|NCT02340663|dental orthotic
934950|NCT02340663|bite splint
934951|NCT02340663|oral parafunction
934952|NCT02340663|clenching
934953|NCT02340663|grinding
934954|NCT02340650|suspicious bladder lesion, normal bladder tissue
934955|NCT02340585|Next Generation Neuroform Stent System
934956|NCT02340585|Wide Neck, Intracranial, Saccular Aneurysms
934957|NCT02340585|Cerebral Aneurysms
934958|NCT02340572|Healthy Subjects
934959|NCT02340559|meta-cognition
934960|NCT02340559|positive symptoms
934961|NCT02340559|early phases
934962|NCT02340559|schizophrenia
934963|NCT02340533|adenomyosis
934964|NCT02340481|Diarrhea
934965|NCT02340481|Flatulence
934966|NCT02340481|Abdominal discomfort
934967|NCT02340481|Loperamide hydrochloride
934968|NCT02340481|Simethicone
934969|NCT02340481|Placebo
934970|NCT02340442|arteriovenous ratio
934971|NCT02340442|retinal flicker stimulation
934972|NCT02340442|Dynamic vessel analyzer
934973|NCT02340416|orthopedic surgeries
934974|NCT02340416|general anesthesia
934975|NCT02340403|Neuropathy
934976|NCT02340403|Oxaliplatin
934977|NCT02340403|Insula
934978|NCT02340403|choline
934979|NCT02340390|G7 Acetabular System
934980|NCT02340377|core body temperature
934981|NCT02340377|whole-body hyperthermia
934982|NCT02340377|rectal body temperature
934983|NCT02340364|Hospital Readmissions
934984|NCT02340364|Patient Navigation
934985|NCT02340351|acupuncture
934986|NCT02340351|auricular acupuncture
934987|NCT02340351|NADA
934988|NCT02340351|anxiety
934989|NCT02340351|depression
934990|NCT02340299|High Frequency Oscillation Ventilation
934991|NCT02340299|Nasal Continuous Positive Airway Pressure
934992|NCT02340299|Airway Extubation
934993|NCT02340299|Prematurity
934994|NCT02340273|tendinopathy
934995|NCT02340273|ultrasound
934996|NCT02340273|pain
934997|NCT02340273|heat
934998|NCT02340273|strength
934999|NCT02340273|LITUS
935000|NCT02340273|long duration
935001|NCT02340273|therapeutic ultrasound
935002|NCT02340273|tendonopathy
935003|NCT02340260|Exercise
935004|NCT02340260|Risk factors
935005|NCT02340260|Exercise therapy
935006|NCT02340260|Hemoglobin A, Glycosylated
935007|NCT02340208|Non-Small Cell Lung Cancer
935008|NCT02340208|Neoplasms
935009|NCT02340208|Immunoconjugate
935010|NCT02340208|Tumor microenvironment alkalinization
935011|NCT02340195|Kidney impairment
935012|NCT02340182|gut flora
935013|NCT02340182|antibiotics
935014|NCT02340182|systemic immune response
935015|NCT02340182|Volunteers
935016|NCT02340091|facial nasolabial fold wrinkles
935017|NCT02340078|the facial nasolabial fold
935018|NCT02340065|colonoscopy
935019|NCT02340065|adenoma detection rate
935020|NCT02340065|Endocuff-assisted colonoscopy
935021|NCT02340052|postoperative pain treatment
935022|NCT02340039|Polyphenol
935023|NCT02340039|Fruit
935024|NCT02340039|Metabolic
935025|NCT02340026|Delay in motor skill development
935026|NCT02340000|acute sinusitis
935027|NCT02340000|amoxicillin/clavulanate
935028|NCT02340000|adults
935029|NCT02340000|outcomes
935030|NCT02339961|Systemic Sclerosis
935031|NCT02339961|Pulmonary hypertension
935032|NCT02339961|Lung Doppler Signals
935033|NCT02339948|Locally confined
935034|NCT02339935|Autism Spectrum Disorder
935035|NCT02339935|Autism
935036|NCT02339909|Screening
935037|NCT02339909|Incentives
935038|NCT02339896|rabies
935039|NCT02339896|modified TRC intradermal rabies vaccine
935040|NCT02339896|SPEEDA
935041|NCT02339883|Physiological Measures
935042|NCT02339883|MRI
935043|NCT02339883|Magnetic Resonance Imaging (MRI)
935044|NCT02339883|Cognitive Testing
935045|NCT02339857|coronary artery bypass grafting
935046|NCT02339857|saphenous vein
935047|NCT02339857|grafts
935048|NCT02339844|glutamate
935049|NCT02339844|dopamine
935050|NCT02339844|cognition
935051|NCT02339844|cortical thickness
935052|NCT02339844|ppi
935053|NCT02339844|p50
935054|NCT02339831|Knee
935055|NCT02339831|Arthroplasty
935056|NCT02339831|CPM
935057|NCT02339831|Camoped
935058|NCT02339831|Active vs Passive Motion Device
935059|NCT02339805|Minimal residual disease, NGS, NHL, DNA sequencing
935060|NCT02339584|OAG
935061|NCT02339584|OHT
935062|NCT02339532|HER2-positive
935063|NCT02339532|non-metastatic
935064|NCT02339532|TOP2A
935065|NCT02339519|Laryngeal Masks
935066|NCT02339506|stress
935067|NCT02339506|ACTH
935068|NCT02339506|cosyntropin
935069|NCT02339506|baroreflex sensitivity
935070|NCT02339506|cardiovagal
935071|NCT02339480|Massage therapy
935072|NCT02339480|Simple obesity
935073|NCT02339480|Energy metabolism
935074|NCT02339480|Mechanism
935075|NCT02339467|decreased outdoor walking ability
935076|NCT02339467|Older adult
935077|NCT02339454|Cardiac Shock wave therapy
935078|NCT02339454|stable angina
935079|NCT02339454|exercise tolerance
935080|NCT02339441|Systemic sclerosis
935081|NCT02339428|Colonoscopy
935082|NCT02339428|diagnostic
935083|NCT02339428|diclophenac
935084|NCT02339428|randomized controlled trial
935085|NCT02339402|Cystic fibrosis, Myotonic dystrophy, Noonan, Huntingtons
935086|NCT02339363|mindfulness
935087|NCT02339363|adolescents
935088|NCT02339363|working memory
935089|NCT02339363|stress
935090|NCT02339363|anxiety
935091|NCT02339311|The study focus is on lifestyle changes and patient activation in diabetic patients by regular monthly visit by the CHRs
935092|NCT02339298|Music Therapy
935093|NCT02339285|tACS
935094|NCT02339285|Major Depressive Disorder
935095|NCT02339285|MDD
935096|NCT02339285|mood symptoms
935097|NCT02339285|sham
935098|NCT02339272|meiosis
935099|NCT02339272|synapsis
935100|NCT02339272|recombination
935101|NCT02339272|sperm aneuploidy
935102|NCT02339259|Rickettsial disease
935103|NCT02339259|Febrile
935104|NCT02339259|Murine typhus
935105|NCT02339259|Scrub typhus
935106|NCT02339259|Diagnostic test
935107|NCT02339259|Clinical features
935108|NCT02339233|Epidural Stimulation
935109|NCT02339220|Constraint-Induced Movement Therapy
935110|NCT02339220|Physical Therapy
935111|NCT02339220|Rehabilitation
935112|NCT02339220|Occupational Therapy
935113|NCT02339220|Fitness Training
935114|NCT02339220|Recovery of Function
935115|NCT02339220|Neuroplasticity
935116|NCT02339220|Exercise Therapy
935117|NCT02339220|Brain Injuries
935118|NCT02339220|Traumatic Brain Injury
935119|NCT02339220|Physical Therapy Modalities
935120|NCT02339220|Neuroimaging
935121|NCT02339194|complete denture
935122|NCT02339194|quality of life
935123|NCT02339194|patient satisfaction
935124|NCT02339155|Anthrax Vaccine Adsorbed
935125|NCT02339155|Raxibacumab
935126|NCT02339155|Immunogenicity
935127|NCT02339103|arteriovenous anastomoses
935128|NCT02339103|accidental hypothermia
935129|NCT02339103|rewarming
935130|NCT02339090|VRS-317
935131|NCT02339090|Growth Hormone Deficiency
935132|NCT02339090|Long Acting Recombinant Growth Hormone
935133|NCT02339090|Long Acting Growth Hormone
935134|NCT02339090|Pediatric Growth Hormone Deficiency
935135|NCT02339090|Growth Hormone Replacement Therapy
935136|NCT02339090|Versartis
935137|NCT02339090|Xten
935138|NCT02339090|Human Growth Hormone
935139|NCT02339090|somavaratan
935140|NCT02339090|growth failure
935141|NCT02339077|Group B Streptococcus, stillborn
935142|NCT02339064|Parkinson's disease,
935143|NCT02339064|apomorphine
935144|NCT02339064|Apokyn
935145|NCT02339064|dopamine agonist
935146|NCT02339064|levodopa
935147|NCT02339064|advanced
935148|NCT02339064|PD
935149|NCT02339064|carbidopa
935150|NCT02339064|pramipexole
935151|NCT02339064|ropinirole
935152|NCT02339064|rotigotine
935153|NCT02339064|MAO-B inhibitors
935154|NCT02339064|COMT inhibitors
935155|NCT02339064|off
935156|NCT02339064|dyskinesia
935157|NCT02339051|Basic Science
935158|NCT02339038|Community Based Research
935159|NCT02339038|Hepatitis C Virus and Human Immunodeficiency Virus
935160|NCT02339038|Ledipasvir/Sofosbuvir
935161|NCT02339038|Fixed Dose Combination
935162|NCT02339038|Sustained Viral Response
935163|NCT02339025|Cohort
935164|NCT02339025|Participation
935165|NCT02339025|Biobank
935171|NCT02338999|Autoimmunity Pathogenesis
935172|NCT02338999|Arteriosclerosis
935173|NCT02338999|Adult
935174|NCT02338986|High Titer Antibodies
935175|NCT02338986|Convalescent Volunteers
935176|NCT02338986|Apheresis
935177|NCT02338986|Males
935178|NCT02338986|Quantitative IgG
935179|NCT02338973|Macular Edema
935180|NCT02338973|Rod-Cone Dystrophy
935181|NCT02338973|Inherited Retinal Degeneration
935182|NCT02338973|Enhanced S-Cone Syndrom
935183|NCT02338973|Interferon Gamma
935184|NCT02338960|HSDD Female
935185|NCT02338960|Sexual Desire Disorder
935186|NCT02338960|decreased desire
935187|NCT02338960|female sexual dysfunction
935188|NCT02338947|Frailty
935189|NCT02338947|Cardiopulmonary Bypass
935190|NCT02338947|Coronary artery bypass surgery
935191|NCT02338947|Mortality
935192|NCT02338947|Morbidity
935193|NCT02338921|triple combination therapy
935194|NCT02338921|sitagliptin
935195|NCT02338921|dapagliflozin
935196|NCT02338921|lobeglitazone
935197|NCT02338908|dry needling
935198|NCT02338908|trigger point
935199|NCT02338908|eccentric exercise
935200|NCT02338895|acute kidney injury, oliguria,renal ultrasound
935201|NCT02338882|Lenses
935202|NCT02338882|Intraocular
935203|NCT02338856|Obesity
935204|NCT02338830|Twins
935205|NCT02338830|Preterm labor
935206|NCT02338830|Progesterone
935207|NCT02338830|Short cervix
935208|NCT02338804|mix vaccine, breast neoplasms, immunotherapy
935209|NCT02338778|mix vaccine, liver neoplasms, immunotherapy
935210|NCT02338752|mix vaccine, pancreatic neoplasms, immunotherapy
935211|NCT02338739|Retention
935212|NCT02338739|Lost to follow up
935213|NCT02338739|Adaptive strategies
935214|NCT02338739|Dynamic regime
935215|NCT02338739|Sequentially randomized trial
935216|NCT02338739|Sequential multiple assignment randomized trial
935217|NCT02338739|Engagement in care
935218|NCT02338739|Kenya
935219|NCT02338726|urinary incontinence
935220|NCT02338726|pelvic floor
935221|NCT02338726|quality of life
935222|NCT02338726|elderly women
935223|NCT02338713|Drug therapy
935224|NCT02338700|mix vaccine, prostate carcinoma, immunotherapy
935225|NCT02338687|Calcium
935226|NCT02338687|Dietary supplements
935227|NCT02338687|Hypertension, Pregnancy-Induced
935228|NCT02338687|Pre-Eclampsia
935229|NCT02338687|Nutritional education
935230|NCT02338687|Diet therapy
935231|NCT02338687|Diet records
935232|NCT02338687|Hospitalization
935233|NCT02338687|Maternal mortality
935234|NCT02338635|ER stress
935235|NCT02338635|Peritoneal Dialysis
935236|NCT02338622|olaparib
935237|NCT02338622|AZD5363
935238|NCT02338622|intrapatient dose escalation
935239|NCT02338622|advanced solid tumours
935240|NCT02338609|TSC-associated SEGA,
935241|NCT02338609|height,
935242|NCT02338609|weight,
935243|NCT02338609|Tanner Stage,
935244|NCT02338609|growth development,
935245|NCT02338609|everolimus,
935246|NCT02338609|RAD001
935247|NCT02338557|MRP, MIRROR THERAPY, STROKE
935248|NCT02338518|gastric cancer
935249|NCT02338518|neoadjuvant chemotherapy
935250|NCT02338518|efficacy
935251|NCT02338518|safety
935252|NCT02338505|Robotic Surgery
935253|NCT02338505|Telelap-ALFX
935254|NCT02338505|Gynecological disease
935255|NCT02338453|Social Anxiety
935256|NCT02338453|Attention Modification
935257|NCT02338453|Dot-Probe
935258|NCT02338453|GCBT
935259|NCT02338362|Corticosteroids
935260|NCT02338362|Bronchodilator Agents
935261|NCT02338362|Intraocular Pressure
935262|NCT02338323|Hyperuricemia
935263|NCT02338323|Renal Function
935264|NCT02338323|Chronic kidney disease
935265|NCT02338323|Febuxostat
935266|NCT02338323|Benzbromarone
935267|NCT02338297|Hepatocellular Carcinoma
935268|NCT02338297|Arterioportal shunts
935269|NCT02338297|Transarterial Chemoembolization
935270|NCT02338297|Ethanol
935271|NCT02338297|Gelfoam
935272|NCT02338297|Polyvinyl Alcohol Foam Embolization Particles (PVA)
935273|NCT02338284|increased intracranial pressure
935274|NCT02338284|optic nerve sheath diameter
935275|NCT02338271|Low back pain
935276|NCT02338271|Mesenchymal stromal stem cell
935277|NCT02338271|Hyaluronic acid
935278|NCT02338219|postpartum pelvic floor
935279|NCT02338206|infertility
935280|NCT02338193|GDM
935281|NCT02338193|T2DM
935282|NCT02338193|prediabetes
935283|NCT02338180|dental caries
935284|NCT02338180|risk assessment
935285|NCT02338180|approximal sealant
935286|NCT02338180|permanent molar
935287|NCT02338180|preventive dentistry
935288|NCT02338180|adolescent
935289|NCT02338154|Aortic Valve Replacement
935290|NCT02338154|Aortic Stenosis
935291|NCT02338154|EDWARDS INTUITY
935292|NCT02338141|cervical cancer
935293|NCT02338141|colposcopy
935294|NCT02338141|human papillomavirus
935295|NCT02338141|human immunodeficiency virus
935296|NCT02338128|peritoneal dialysis
935297|NCT02338128|hyperuricemia
935298|NCT02338128|cardiovascular
935299|NCT02338128|Febuxostat
935300|NCT02338089|Uterine contraction
935301|NCT02338089|Oxytocin desensitization
935302|NCT02338063|Adolescent Risk Behavior
935303|NCT02338063|Emotion Regulation
935304|NCT02338063|Health Promotion
935305|NCT02338063|Intervention
935306|NCT02338063|Mental Health
935307|NCT02338050|ALL
935308|NCT02338050|Moxetumomab Pasudotox
935309|NCT02338050|Moxe
935310|NCT02338050|CAT-8015, HA22
935311|NCT02338024|Enrollment in HIV care
935312|NCT02338024|Recently detected HIV-positive
935313|NCT02338024|specialized health care clinics
935314|NCT02338024|Ukraine
935315|NCT02337998|Neurology
935316|NCT02337998|Sports Medicine
935317|NCT02337972|diabetic macular edema
935318|NCT02337972|Intravitreal injection
935319|NCT02337972|conjunctival flora
935320|NCT02337959|Healthy Volunteers
935321|NCT02337946|Metastatic colorectal cancer, Panitumumab, mFOLFOX6, First-line
935322|NCT02337933|Metabolic Syndrome
935323|NCT02337933|Central Obesity
935324|NCT02337933|Insulin Sensitivity
935325|NCT02337933|Ursolic Acid
935326|NCT02337933|Triterpenoid
935327|NCT02337894|Protein kinetics
935328|NCT02337894|liver steatosis
935329|NCT02337868|dose-ranging,double blind,female,healthy,HydroVax,male,Placebo-Controlled,Vaccine,West Nile Virus
935330|NCT02337855|Intestinal
935331|NCT02337855|Pichia pastoris
935332|NCT02337855|S. mansoni
935333|NCT02337855|Schistosomiasis
935334|NCT02337855|Sm-TSP-2/Alhydrogel
935335|NCT02337855|Sm-TSP-2/Alhydrogel/GLA-AF
935336|NCT02337855|vaccine
935337|NCT02337842|NoV, CIN-1, GII4. Norovirus, challenge, FUT-2 gene, HBGA-blocking Ab
935338|NCT02337829|CLL
935339|NCT02337829|SLL
935340|NCT02337829|Btk
935341|NCT02337829|Chronic Lymphocytic Leukemia
935342|NCT02337829|Small Lymphocytic Lymphoma
935343|NCT02337829|Leukemia
935344|NCT02337829|Lymphoma
935345|NCT02337829|Lymphocytic
935346|NCT02337829|ACP-196
935347|NCT02337829|acalabrutinib
935348|NCT02337816|Endometriosis
935349|NCT02337816|Metabolomics
935350|NCT02337803|Physical Activity
935351|NCT02337790|Hypertension
935352|NCT02337790|Heart Failure
935353|NCT02337790|Fluids
935354|NCT02337777|Magnetic Resonance Imaging
935355|NCT02337777|Magnetic Resonance Angiography
935356|NCT02337777|Diffusion Tensor Imaging
935357|NCT02337777|IDEAL
935358|NCT02337777|T2* mapping
935359|NCT02337777|Magnetic ResonanceCine
935360|NCT02337777|BOLD
935361|NCT02337777|phase contrast
935362|NCT02337777|diffusion-weighted imaging
935363|NCT02337777|Functional Magnetic Resonance Imaging
935364|NCT02337712|Small cell lung cancer
935365|NCT02337712|Radiotherapy
935366|NCT02337712|Dose fractionation
935367|NCT02337686|Keytruda
935368|NCT02337686|pembrolizumab
935369|NCT02337686|immune effector function
935370|NCT02337686|pembrolizumab monotherapy
935371|NCT02337686|ex vivo T-cell-specific cytokines profiling
935372|NCT02337686|immune effector Tcell:Treg ratio
935373|NCT02337686|immunological changes
935374|NCT02337686|immune response
935375|NCT02337673|Postoperative Pulmonary Complication
935376|NCT02337673|Electrical Impedance Tomography
935377|NCT02337673|Splenectomy
935378|NCT02337673|Gastric surgery
935379|NCT02337673|Gastrectomy
935380|NCT02337673|Pancreatic surgery
935381|NCT02337673|Pancreatectomy
935382|NCT02337673|Liver surgery
935383|NCT02337673|Hemihepatectomy
935384|NCT02337673|Cholecystectomy
935385|NCT02337673|Acute Respiratory Distress Syndrome
935386|NCT02337673|Hypoxemia
935387|NCT02337673|Atelectasis
935388|NCT02337673|Pulmonary obstruction
935389|NCT02337673|Pneumonia
935390|NCT02337673|Pneumothorax
935391|NCT02337673|Pleural effusion
935392|NCT02337673|Pulmonary edema
935393|NCT02337621|sunken chest
935394|NCT02337621|caved-in chest
935395|NCT02337621|chest deformity
935396|NCT02337621|sunken sternum
935397|NCT02337608|moderate to severe ulcerative colitis
935398|NCT02337608|GLPG1205
935399|NCT02337595|CD45RA-depletion
935400|NCT02337595|TCR-alpha/beta depletion
935401|NCT02337595|Hematopoietic Stem Cell Transplantation
935402|NCT02337595|immune reconstitution
935403|NCT02337595|Graft Enhancement, Immunologic
935404|NCT02337595|Immunocompromized Host
935405|NCT02337491|Recurrent
935406|NCT02337452|Hereditary cancer-causing mutation
935407|NCT02337452|Gene mutation
935408|NCT02337452|Family member with genetic mutation
935409|NCT02337452|Questionnaire
935410|NCT02337452|Surveys
935411|NCT02337452|Registry
935412|NCT02337452|Database
935413|NCT02337452|Communication
935414|NCT02337413|Constipation
935415|NCT02337374|Urodynamics
935416|NCT02337374|Midurethral sling
935417|NCT02337374|Transobturator tape (TOT)
935418|NCT02337374|Tension free vaginal tape (TVT)
935419|NCT02337361|risky alcohol use
935420|NCT02337361|pregnancy
935421|NCT02337348|coronary stents
935422|NCT02337335|Hemodialyisis
935423|NCT02337335|Predictive Model
935424|NCT02337335|ESAs
935425|NCT02337335|patients
935426|NCT02337322|Acquired Immune Deficiency Syndrome Virus
935427|NCT02337322|HIV
935428|NCT02337322|HIV-1
935429|NCT02337322|Antiretroviral treatment
935430|NCT02337322|HIV Advanced Disease
935431|NCT02337322|AIDS
935432|NCT02337322|Dolutegravir
935433|NCT02337322|Darunavir
935434|NCT02337296|Motivational Interviewing
935435|NCT02337296|Cognitive Behavioral Therapy
935436|NCT02337296|Cancer
935437|NCT02337296|Oral Agents
935438|NCT02337296|Adherence
935439|NCT02337270|Tuberculosis
935440|NCT02337270|Vaccine
935441|NCT02337270|Aerosol
935442|NCT02337270|Adenovirus
935443|NCT02337270|Immunogenicity
935444|NCT02337244|Osteoarthritis
935445|NCT02337244|Rheumatoid arthritis
935446|NCT02337244|Traumatic arthritis
935447|NCT02337244|Polyarthritis
935448|NCT02337244|Total knee arthroplasty
935449|NCT02337192|Orthodontic, Photochemoterapy
935450|NCT02337166|alveolar bone loss
935451|NCT02337166|periodontal attachment loss
935452|NCT02337153|Orthodontique Bone Stretching
935453|NCT02337140|TAVI
935454|NCT02337140|complete AV-block
935455|NCT02337140|HV-interval
935456|NCT02337140|permanent pacemaker
935457|NCT02337140|valve implantation
935458|NCT02337140|severe
935459|NCT02337140|conduction
935460|NCT02337140|disorders
935461|NCT02337114|Acceptance and Commitment Therapy
935462|NCT02337101|Brain concussion
935463|NCT02337101|Mild Traumatic Brain Injury
935464|NCT02337101|Post-concussion symptoms
935465|NCT02337101|Therapy
935466|NCT02337101|Randomised controlled trial
935467|NCT02337101|Cognitive assessment
935468|NCT02337088|delayed cord clamping
935469|NCT02337075|condition
935470|NCT02337075|preventing
935471|NCT02337075|physical activity
935472|NCT02337049|Preeclampsia. Cardiovascular Disease (CVD) Risk.
935473|NCT02337036|Liver transplantation
935474|NCT02337036|Child
935475|NCT02337036|Tacrolimus
935476|NCT02337036|Pharmacokinetic
935477|NCT02337023|Brain scintigraphy
935478|NCT02336997|skin regeneration
935479|NCT02336997|mechanical stretch
935480|NCT02336984|Ductal carcinoma in situ (DCIS)
935481|NCT02336958|cervical plexus
935482|NCT02336958|regional anesthesia
935483|NCT02336958|ultrasound
935484|NCT02336958|carotid surgery
935485|NCT02336932|vitamin d
935486|NCT02336932|free hormone
935487|NCT02336932|surgical stress
935488|NCT02336919|discharge
935489|NCT02336919|mHealth
935490|NCT02336919|telehealth
935491|NCT02336919|text messaging
935492|NCT02336906|Lower urinary tract dysfunction
935493|NCT02336906|constipation
935494|NCT02336893|Communication Barriers
935495|NCT02336893|Total Communication Methods
935496|NCT02336893|Quality Improvement
935497|NCT02336893|Quality of Health Care
935498|NCT02336893|Critical Care
935499|NCT02336867|Complex anal fistula, clip,
935500|NCT02336854|pharmacokinetics
935501|NCT02336841|Guided Self-Help
935502|NCT02336841|Peer Mentoring
935503|NCT02336841|Anorexia Nervosa
935504|NCT02336841|Eating Disorders
935505|NCT02336828|MEWS
935506|NCT02336828|deteriorate
935507|NCT02336828|oncology
935508|NCT02336828|ICU
935509|NCT02336828|predicting outcomes
935510|NCT02336828|MEWS in predicting outcomes in oncology patients
935511|NCT02336815|Multiple myeloma
935512|NCT02336815|Karyopharm
935513|NCT02336815|KPT-330
935514|NCT02336815|Selinexor
935515|NCT02336815|Refractory
935516|NCT02336815|Bortezomib
935517|NCT02336815|Carfilzomib
935518|NCT02336815|Lenalidomide
935519|NCT02336815|Pomalidomide
935520|NCT02336815|Dexamethasone
935521|NCT02336815|STORM
935522|NCT02336815|Daratumumab
935523|NCT02336802|Anxiety
935524|NCT02336802|Fear
935525|NCT02336802|Avoidance
935526|NCT02336776|Chronic Kidney Disease
935527|NCT02336776|Electrical Stimulation
935528|NCT02336737|breast cancer
935529|NCT02336737|sentinel lymph node biopsy
935530|NCT02336724|gastrointestinal stromal tumor
935531|NCT02336724|famitinib
935532|NCT02336698|Osteoarthritis
935533|NCT02336698|Pain
935534|NCT02336698|Fulranumab
935535|NCT02336698|JNJ-42160443
935536|NCT02336698|Monotherapy
935537|NCT02336698|Hip
935538|NCT02336698|Knee
935539|NCT02336698|Joint replacement surgery
935540|NCT02336685|Osteoarthritis
935541|NCT02336685|Pain
935542|NCT02336685|Fulranumab
935543|NCT02336685|JNJ-42160443
935544|NCT02336685|Adjunctive therapy
935545|NCT02336685|Opioid
935546|NCT02336685|Hip
935547|NCT02336685|Knee
935548|NCT02336685|Joint replacement surgery
935549|NCT02336672|Pancreatic adenocarcinoma
935550|NCT02336672|Cryothermoablation
935551|NCT02336633|Huntington disease
935552|NCT02336633|Neurodegenerative disease
935553|NCT02336633|Volumetric MRI
935554|NCT02336633|31P MR spectroscopy
935555|NCT02336633|metabolism
935556|NCT02336633|Caudate atrophy
935557|NCT02336620|Severe sepsis, Balanced Salt Solution, Normal Saline
935558|NCT02336581|Acceptance and Commitment Therapy
935559|NCT02336581|Mindfulness
935560|NCT02336581|Inpatients
935561|NCT02336581|Psychiatric Hospitalization
935562|NCT02336568|PTSD, Oxytocin
935563|NCT02336542|diagnosis of Tuberculosis
935564|NCT02336542|ESAT6
935565|NCT02336542|CFP10
935566|NCT02336542|skin test
935567|NCT02336542|diagnostic test
935568|NCT02336529|postoperative
935569|NCT02336477|non-dystrophic myotonias
935570|NCT02336477|paramyotonia congenita
935571|NCT02336477|myotonia congenita
935572|NCT02336477|Mexiletine
935573|NCT02336477|Randomized clinical trial
935574|NCT02336451|ALK-positive
935575|NCT02336451|NSCLC
935576|NCT02336451|brain metastasis
935577|NCT02336451|metastatic to the brain and/or to leptomeninges.
935578|NCT02336425|Asthma
935579|NCT02336412|Medication adherence
935580|NCT02336399|HBsAg loss, interferon, HBV reaction
935581|NCT02336386|Bortezomib
935582|NCT02336373|Hemoglobin SC disease
935583|NCT02336373|hydroxyurea
935584|NCT02336373|quality of life
935585|NCT02336373|viscosity
935586|NCT02336373|red cell density
935587|NCT02336347|Pharmacokinetics
935588|NCT02336347|Healthy Volunteers
935589|NCT02336347|deuterated dextromethorphan
935590|NCT02336347|deuterated dextromethorphan with quinidine
935595|NCT02336269|Pharmacogenomics
935596|NCT02336256|inguinal hernia repair
935597|NCT02336256|totally extraperitoneal (TEP)
935598|NCT02336256|single incision laparoscopic surgery (SILS)
935599|NCT02336256|plasma total antioxidant status
935600|NCT02336243|docosahexaenoic acid
935601|NCT02336243|premature birth
935602|NCT02336243|placentation disorders
935603|NCT02336243|preeclampsia
935604|NCT02336243|fetal growth
935605|NCT02336230|GVHD
935606|NCT02336191|living donor liver transplantation
935607|NCT02336191|graft function
935608|NCT02336191|thromboelastometry
935609|NCT02336165|Glioblastoma
935610|NCT02336165|Immunotherapy
935611|NCT02336165|T Cell
935612|NCT02336165|PD-L1
935613|NCT02336165|MEDI4736
935614|NCT02336165|Radiation
935615|NCT02336165|Radiotherapy
935616|NCT02336165|GBM
935617|NCT02336100|Diagnostic technique and procedure
935618|NCT02336074|HIV
935619|NCT02336074|Vaccine
935620|NCT02336074|Cure
935621|NCT02336074|Early Intervention
935622|NCT02336074|Infection
935623|NCT02336074|Primary infection
935624|NCT02336074|Reservoir
935625|NCT02336074|Vorinostat
935626|NCT02336074|HDAC
935627|NCT02336022|general anesthesia
935628|NCT02336009|wrist arthritis
935629|NCT02336009|total wrist arthroplasty
935630|NCT02335970|Pain
935631|NCT02335970|Range of motion
935632|NCT02335970|Quality of life
935633|NCT02335944|non small cell lung cancer,
935634|NCT02335944|NSCLC,
935635|NCT02335944|EGF816,
935636|NCT02335944|INC280,
935637|NCT02335944|tyrosine kinase inhibitor,
935638|NCT02335944|c-MET
935639|NCT02335918|Opdivo®
935640|NCT02335866|Platelet rich fibrin
935641|NCT02335866|Gingival Recession
935642|NCT02335853|urinary bladder
935643|NCT02335853|nerve growth factor
935644|NCT02335853|overactive bladder
935645|NCT02335827|irreversible electroporation
935646|NCT02335827|renal tumor
935647|NCT02335801|heart failure
935648|NCT02335801|growth hormone
935649|NCT02335801|testosterone
935650|NCT02335801|insulin resistance
935651|NCT02335801|thyroid hormones
935652|NCT02335801|survival
935653|NCT02335788|Therapeutic
935654|NCT02335788|Embolization
935655|NCT02335736|infertility
935656|NCT02335684|Heart-assist devices
935657|NCT02335684|exercise capacity
935658|NCT02335671|Early Stage Breast Cancer
935659|NCT02335671|Breast Conserving Surgery
935660|NCT02335671|Breast Cancer Stage I
935661|NCT02335671|Breast Cancer Stage II
935662|NCT02335645|ACL reconstruction
935663|NCT02335645|Running Mechanics
935664|NCT02335645|Physical Therapy
935665|NCT02335645|Knee
935666|NCT02335645|Video Analysis
935667|NCT02335645|Body Weight Supported Treadmill
935668|NCT02335632|Hepatitis
935669|NCT02335632|Probiotics
935670|NCT02335632|Lipopolysaccharides
935671|NCT02335632|Cytokines
935672|NCT02335632|Alcoholics
935673|NCT02335593|Hemodialysis patients
935674|NCT02335593|Zinc
935675|NCT02335593|Anemia
935676|NCT02335593|Oxidative stress
935677|NCT02335580|Prognosis
935678|NCT02335554|Subthreshold
935679|NCT02335554|Employees
935680|NCT02335554|Internet
935681|NCT02335554|Mobile
935682|NCT02335554|cognitive-behavioral
935683|NCT02335515|Gastroretentive System
935684|NCT02335515|Gastric Retention Time (GRT)
935685|NCT02335515|capsule
935686|NCT02335515|Soctec
935687|NCT02335515|Gastroenterology
935688|NCT02335476|optical coherence tomography
935689|NCT02335463|optical coherence tomography
935690|NCT02335450|exercise
935691|NCT02335450|motivational interviewing
935692|NCT02335424|P-D1
935693|NCT02335424|PD-1
935694|NCT02335424|PD1
935695|NCT02335424|P-DL1
935696|NCT02335424|PD-L1
935697|NCT02335424|PDL-1
935698|NCT02335424|PDL1
935699|NCT02335424|Bladder cancer
935700|NCT02335411|Gastric cancer
935701|NCT02335411|Gastroesophageal junction cancer
935702|NCT02335411|PD1
935703|NCT02335411|PDL1
935704|NCT02335398|methadone
935705|NCT02335398|chronic pain
935706|NCT02335398|noncancer pain
935707|NCT02335398|cancer pain
935708|NCT02335398|QTc prolongation
935709|NCT02335372|Cervical cancer
935710|NCT02335372|Cervical neoplasia
935711|NCT02335372|Cervical cancer screening
935712|NCT02335372|Colposcopy
935713|NCT02335372|Wide-field white light imaging
935714|NCT02335372|Wide-field fluorescence imaging
935715|NCT02335372|Acetic acid
935716|NCT02335372|Proflavine solution
935717|NCT02335333|Delayed Graft Function
935718|NCT02335333|Slow Graft Function
935719|NCT02335333|Renal Transplant
935720|NCT02335333|Extended Criteria Donor
935721|NCT02335333|Biomarker of Aging
935722|NCT02335333|Kidney Transplant
935723|NCT02335320|VHC
935724|NCT02335320|IL28-B
935725|NCT02335320|point of care
935726|NCT02335307|Pain
935727|NCT02335307|CYP2D6
935728|NCT02335294|Pain
935729|NCT02335294|abdominoplasty
935730|NCT02335294|PCA
935731|NCT02335281|Standardized Fecal Microbiota Transplantation
935732|NCT02335281|Inflammatory Bowel Disease
935733|NCT02335281|Ulcerative Colitis
935734|NCT02335281|Crohn's Disease
935735|NCT02335268|MDS classified as IPSS low/int-1
935736|NCT02335242|Sildenafil
935737|NCT02335242|Magnetic Resonance Imaging
935738|NCT02335242|Dermatology
935739|NCT02335242|Pediatrics
935740|NCT02335190|Sacroiliac joint
935741|NCT02335190|Radiofrequency ablation
935742|NCT02335190|Ultrasound
935743|NCT02335177|Falls
935744|NCT02335177|Elderly
935745|NCT02335177|Physical activities
935746|NCT02335177|Technologies for autonomy
935747|NCT02335177|Impact of intervention
935748|NCT02335177|autonomy
935749|NCT02335177|physical activity program
935750|NCT02335151|Circulating Tumor Cells
935751|NCT02335151|Anesthesia and immunity
935752|NCT02335151|Cell Search System
935753|NCT02335138|HIV
935754|NCT02335138|MSM
935755|NCT02335138|Couples
935756|NCT02335138|Home Testing
935757|NCT02335138|Sexual Agreements
935758|NCT02335112|irreversible electroporation
935759|NCT02335112|Unresectable Head and Neck Neoplasms
935760|NCT02335099|hemodialysis
935761|NCT02335099|vascular access
935762|NCT02335099|vascular access patency
935763|NCT02335099|ticagrelor
935764|NCT02335099|brilinta
935765|NCT02335073|Prognosis
935766|NCT02335060|cannabis
935767|NCT02335060|Marijuana
935768|NCT02335060|THC
935769|NCT02335060|N-acetylcysteine
935770|NCT02335060|Psychotic Disorders
935771|NCT02335047|reliability
935772|NCT02335047|clinical test
935773|NCT02335047|physical therapy
935774|NCT02335034|Osteoarthritis
935775|NCT02335034|Knee
935776|NCT02335034|Education
935777|NCT02335034|Quality of life
935778|NCT02335034|Treatment outcome
935779|NCT02335034|Musculoskeletal pain
935780|NCT02334995|solitery rectal ulcer
935781|NCT02334995|biofeedback
935782|NCT02334995|dissynergy
935783|NCT02334982|Drug therapy
935784|NCT02334969|ischemic stroke；Naoxintong Capsule
935785|NCT02334956|MRI
935786|NCT02334956|Executive Deficits
935787|NCT02334943|Immune Activation
935788|NCT02334943|HIV-1 infected subjects
935789|NCT02334943|Undetectable viral load
935790|NCT02334943|Causes of Immune Activation in HIV-1 infected patients
935791|NCT02334943|Forms of Immune Activation
935792|NCT02334943|Emergent non-AIDS related comorbidities
935793|NCT02334930|propranolol
935794|NCT02334930|betablocker
935795|NCT02334930|angiogenesis
935796|NCT02334917|Suture Comparison
935797|NCT02334891|congestive heart failure
935798|NCT02334891|heart failure, diastolic
935799|NCT02334891|heart failure, systolic
935800|NCT02334891|elderly frail
935801|NCT02334891|guideline adherence
935802|NCT02334878|Stem Cells
935803|NCT02334878|Mesenchymal
935804|NCT02334826|multivessel coronary artery disease
935805|NCT02334826|revascularization
935806|NCT02334826|bioresorbable vascular scaffold
935807|NCT02334826|percutaneous coronary intervention
935808|NCT02334826|coronary artery bypass grafting
935809|NCT02334800|Palbociclib, PD-0332991, Hepatic Impairment
935810|NCT02334761|Biopsy
935811|NCT02334735|Melanoma
935812|NCT02334735|Immunotherapy
935813|NCT02334735|DC Vaccine
935814|NCT02334735|Adjuvant Therapy
935815|NCT02334735|Immunogenicity
935816|NCT02334696|Vascular Access
935817|NCT02334683|Comparison
935818|NCT02334683|Botulinum toxin treatments
935819|NCT02334683|Ultrasound
935820|NCT02334683|Electrophysiologic
935821|NCT02334683|Spasticity
935822|NCT02334683|Focal dystonia
935823|NCT02334670|cryptococcal meningitis
935824|NCT02334670|HIV
935825|NCT02334670|AIDS
935826|NCT02334670|Fluconazole
935827|NCT02334657|non-aneurysmal
935828|NCT02334644|Treatment
935829|NCT02334644|Natural Health Product
935830|NCT02334644|Anxiety
935831|NCT02334592|the effect of tanning
935832|NCT02334592|vitamin D production
935833|NCT02334579|Radiation
935834|NCT02334579|Stereotactic Radiosurgery
935835|NCT02334579|Radiotherapy
935836|NCT02334579|Prostate Tumor
935837|NCT02334579|Prostate Surgery
935838|NCT02334579|CyberKnife
935839|NCT02334566|PTSD
935840|NCT02334566|Refugee children mental health
935841|NCT02334566|community health care
935842|NCT02334553|COPD
935843|NCT02334553|Chronic bronchitis
935844|NCT02334553|Cystic fibrosis
935845|NCT02334553|Bronchoconstriction
935846|NCT02334553|Perfluorocarbons
935847|NCT02334553|Carbon dioxide
935848|NCT02334527|metastatic urothelial carcinoma (UC)
935849|NCT02334527|LCCC 1406
935850|NCT02334527|Lineberger
935851|NCT02334527|palbociclib
935852|NCT02334514|Influenza
935853|NCT02334514|Viral shedding
935854|NCT02334514|oseltamivir
935855|NCT02334514|Polymerase Chain Reaction
935856|NCT02334501|Healthy Volunteers
935857|NCT02334462|Assays
935858|NCT02334462|Antibody
935859|NCT02334462|Reactogenicity
935860|NCT02334462|Mosquito
935861|NCT02334462|Responses
935862|NCT02334449|healthy volunteers
935863|NCT02334410|fractures
935864|NCT02334410|immobilisation
935865|NCT02334410|paraplegia
935866|NCT02334410|tetraplegia
935867|NCT02334397|Prenatal Exercise
935868|NCT02334397|Prenatal Education
935869|NCT02334397|Pregnancy
935870|NCT02334397|Exercise and Birth Outcomes
935871|NCT02334397|Education and Birth Outcomes
935872|NCT02334397|Maternal Quality of Life
935873|NCT02334397|Birth Satisfaction
935874|NCT02334371|Magnetic Resonance Imaging
935875|NCT02334371|Positron-Emission Tomography
935876|NCT02334332|Caregiver
935877|NCT02334293|Omegaven
935878|NCT02334293|parenteral nutrition
935879|NCT02334293|liver disease
935880|NCT02334293|liver injury
935881|NCT02334280|Community mental health
935882|NCT02334280|Health coach
935883|NCT02334280|Weight loss
935884|NCT02334280|Fitness
935885|NCT02334280|Serious mental illness
935886|NCT02334280|Health promotion
935887|NCT02334254|safety
935888|NCT02334254|rivaroxaban
935889|NCT02334254|ticagrel
935890|NCT02334254|triple antithrombotic regimen
935891|NCT02334254|undergoing PCI
935892|NCT02334241|Sorbact
935893|NCT02334241|Best local Cares
935894|NCT02334241|DFU
935895|NCT02334202|Adolescent
935896|NCT02334202|Obesity/Psychology
935897|NCT02334202|Loss of Control Eating
935898|NCT02334202|Child
935899|NCT02334202|Female
935900|NCT02334202|Follow-Up Studies
935901|NCT02334202|Health Behavior
935902|NCT02334202|Health Education
935903|NCT02334202|Humans
935904|NCT02334202|Intervention Studies
935905|NCT02334202|Prospective Studies
935906|NCT02334202|Psychotherapy
935907|NCT02334202|Risk Factors
935908|NCT02334202|Weight Loss
935909|NCT02334202|Weight Gain
935910|NCT02334202|Military
935911|NCT02334163|Hepatic Encephalopathy
935912|NCT02334163|Nitazoxanide
935913|NCT02334163|Serum ammonia
935914|NCT02334150|combined spinal-epidural analgesia
935915|NCT02334150|pelvic floor muscle
935916|NCT02334150|postpartum electrophysiological function
935917|NCT02334111|Parenting Support for Mothers in Recovery
935918|NCT02334111|Neonatal Abstinence Syndrome
935919|NCT02334111|Social Determinants of Health
935920|NCT02334111|Child Development
935921|NCT02334111|Child Abuse
935922|NCT02334111|Child Neglect
935923|NCT02334111|Primary Care
935924|NCT02334098|Aggression
935925|NCT02334098|Omega-3 supplementation
935926|NCT02334098|Neurocognition
935927|NCT02334098|Attention
935928|NCT02334098|Antisocial
935929|NCT02334059|opioid sparing
935930|NCT02334059|ketamine
935931|NCT02334059|obese
935932|NCT02334059|magnesium
935933|NCT02334046|tracheal extubation
935934|NCT02334046|remifentanil
935935|NCT02334033|hypertension
935936|NCT02334033|blood pressure
935937|NCT02334033|cystatin C
935938|NCT02334033|real-life
935939|NCT02334033|kidney
935940|NCT02334020|Mental illness
935941|NCT02334020|training
935942|NCT02334020|support
935943|NCT02334020|Mental Health
935944|NCT02334007|venous thromboembolism prophylaxis
935945|NCT02334007|deep vein thrombosis
935946|NCT02334007|pulmonary embolism
935947|NCT02334007|lung resection
935948|NCT02334007|low molecular weight heparin
935949|NCT02333968|Cancer pain
935950|NCT02333968|Self-management
935951|NCT02333968|Randomized controlled trial
935952|NCT02333942|Aging
935953|NCT02333942|Diagnostic Equipment
935954|NCT02333929|rivaroxaban
935955|NCT02333929|NOAC
935956|NCT02333929|anti-Xa activity
935957|NCT02333929|method comparison
935958|NCT02333929|LCMS
935959|NCT02333903|Obesity
935960|NCT02333903|Sleeve gastrectomy
935961|NCT02333903|Personalized physical activity program
935962|NCT02333903|Body Composition
935963|NCT02333903|Fat mass
935964|NCT02333903|Lean mass
935965|NCT02333890|breast
935966|NCT02333851|Type 2 diabetes mellitus treatment
935967|NCT02333851|Hospitalized patients
935968|NCT02333838|Cord Cell Transplantation
935969|NCT02333838|High risk myeloid malignancies
935970|NCT02333799|Tuberculosis
935971|NCT02333799|MDR-TB
935972|NCT02333799|XDR-TB
935973|NCT02333799|Multi-drug resistant
935974|NCT02333799|Extensively drug resistant
935975|NCT02333799|Bedaquiline
935976|NCT02333799|PA-824
935977|NCT02333799|Linezolid
935978|NCT02333799|TB
935979|NCT02333799|Pretomanid
935980|NCT02333799|TMC-207
935981|NCT02333799|NiX-TB
935982|NCT02333773|irreversible electroporation
935983|NCT02333773|Portal venous tumor emboli
935984|NCT02333734|Type 2 diabetes
935985|NCT02333734|Interval training
935986|NCT02333734|Insulin resistance
935987|NCT02333734|fat metabolism
935988|NCT02333721|Stomach Neoplasms
935989|NCT02333721|Laparoscopy
935990|NCT02333695|SCI, Spinal Cord Injury, Stroke
935991|NCT02333669|Lung fluid absorption disorders
935992|NCT02333669|Neonatal respiratory distress syndrome
935993|NCT02333669|Single nucleotide polymorphism
935994|NCT02333669|SCNN1A
935995|NCT02333630|asthma
935996|NCT02333617|Manual Therapy
935997|NCT02333617|Physical Therapy
935998|NCT02333617|Dry Needling
935999|NCT02333617|Gluteus Medius
936000|NCT02333604|cancer
936001|NCT02333604|cancer survivor ship
936002|NCT02333604|psychosocial needs
936003|NCT02333604|cancer experience
936004|NCT02333604|metastatic breast cancer
936005|NCT02333604|multiple myeloma
936006|NCT02333604|chronic myeloid leukemia
936007|NCT02333604|breast cancer
936008|NCT02333604|Prostate
936009|NCT02333604|Colon
936010|NCT02333604|Kidney
936011|NCT02333604|Lung
936012|NCT02333604|Melanoma
936013|NCT02333604|Caregiver
936014|NCT02333552|Frailty
936015|NCT02333552|Pre-frailty
936016|NCT02333552|Fit
936017|NCT02333552|Robust
936018|NCT02333552|Elderly
936019|NCT02333552|Sociodemography status
936020|NCT02333552|Functional status
936021|NCT02333552|Cognitive status
936022|NCT02333552|Nutrition status
936023|NCT02333552|Comorbidity
936024|NCT02333552|Mortality
936025|NCT02333552|Depression status
936026|NCT02333526|ulcerative colitis
936027|NCT02333526|Clostidium difficile-associated colitis
936028|NCT02333526|Syndecan-1
936029|NCT02333526|biomarker
936030|NCT02333474|mix vaccine, lung neoplasms, immunotherapy
936031|NCT02333435|Prostatectomy
936032|NCT02333435|Omega-3 fatty acids
936033|NCT02333435|Quality of life
936034|NCT02333435|inflammation
936035|NCT02333435|cellular proliferation
936036|NCT02333422|NIRS Neurofeedback
936037|NCT02333422|Attention Deficit Hyperactivity Disorder
936038|NCT02333422|Near Infrared Spectroscopy
936039|NCT02333422|ADHD
936040|NCT02333409|Cancer of pancreas
936041|NCT02333409|Acupuncture
936042|NCT02333409|Pain
936043|NCT02333396|Navigator
936044|NCT02333396|Intervention Study
936045|NCT02333396|Randomized Controlled Trial
936046|NCT02333396|Pediatric Intensive Care Unit
936047|NCT02333396|Decision Making
936048|NCT02333383|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score
936049|NCT02333383|EAMs
936050|NCT02333383|Adalimumab
936060|NCT02333344|prosthetic fixation
936061|NCT02333331|Sarcopenia, muscle wasting, elderly, strength, physical function, muscle, gait speed
936062|NCT02333305|Ataxia with Oculomotor Apraxia type 1
936063|NCT02333305|CoQ10
936064|NCT02333305|hypoalbuminemia
936065|NCT02333266|Candida bloodstream infection
936066|NCT02333266|Detection fungal cells
936067|NCT02333266|Fiber-Optic Surface Plasmon Resonance (FO-SPR)
936068|NCT02333253|poor responders
936069|NCT02333253|GnRH antagonist
936070|NCT02333253|Conventional protocol
936071|NCT02333240|Pregnancy
936072|NCT02333240|Postnatal Care
936073|NCT02333240|Blood Pressure Monitoring, Home
936074|NCT02333240|Self Care
936075|NCT02333240|Pregnancy Complications, Cardiovascular
936076|NCT02333240|Qualitative Research
936077|NCT02333240|Antihypertensive Agents
936078|NCT02333214|Virtual Reality Therapy
936079|NCT02333214|Video Game
936080|NCT02333214|Physical Exercise
936081|NCT02333214|Aged
936082|NCT02333214|Frailty
936083|NCT02333201|Deglutition Disorders
936084|NCT02333201|Dysphagia
936085|NCT02333201|Mechanical Ventilation
936086|NCT02333201|Sepsis
936087|NCT02333175|Parkinson's disease, Late stage
936088|NCT02333149|Melatonin
936089|NCT02333071|HSDD
936090|NCT02333071|Female Sexual Desire Disorder
936091|NCT02333058|ALL
936092|NCT02333058|AML
936093|NCT02333058|MDS
936094|NCT02333058|JMML
936095|NCT02333045|HIV-negative
936096|NCT02333045|Women
936097|NCT02333045|At-risk
936098|NCT02333019|risk
936099|NCT02333006|Anosognosia
936100|NCT02332993|FPP (Fermented Papaya Preparation)
936101|NCT02332993|Negative Pressure Therapy
936102|NCT02332993|Wound Vac
936103|NCT02332993|Wound
936104|NCT02332993|Type II Diabetic
936105|NCT02332954|Depression
936106|NCT02332954|Major Depressive Disorder
936107|NCT02332954|Cognition
936108|NCT02332954|Cognitive symptoms
936109|NCT02332954|vortioxetine
936110|NCT02332954|real life
936111|NCT02332954|naturalistic
936112|NCT02332915|apraxia
936113|NCT02332915|aphasia
936114|NCT02332915|rehabilitation
936115|NCT02332915|efficacy
936116|NCT02332915|intensity
936117|NCT02332902|Neurofibroma
936118|NCT02332902|NF-1
936119|NCT02332902|Everolimus
936120|NCT02332902|mTOR inhibitor
936121|NCT02332863|Pancreatic cancer
936122|NCT02332863|Image guided radiation therapy
936123|NCT02332863|Fiducial marker placement
936124|NCT02332863|Endoscopic ultrasound
936125|NCT02332850|Relapsed
936126|NCT02332850|Refractory
936127|NCT02332837|informed consent, public led trials, shared decision making,
936128|NCT02332824|Pharmacological therapy
936129|NCT02332798|Multiple ascending doses
936130|NCT02332798|safety
936131|NCT02332798|tolerability
936132|NCT02332798|pharmacokinetics
936133|NCT02332798|cognitive impairment associated with schizophrenia (CIAS)
936134|NCT02332785|Colon Serrated Polyps
936135|NCT02332785|Serrated polyp
936136|NCT02332785|Hyperplastic polyps above sigmoid colon
936137|NCT02332785|Sessile serrated adenoma
936138|NCT02332785|Traditional serrated adenoma
936139|NCT02332785|Colonoscopy
936140|NCT02332785|Endoscopy
936141|NCT02332785|Data collection
936142|NCT02332785|Data review
936143|NCT02332772|Colon Polyps
936144|NCT02332772|Large polyps
936145|NCT02332772|Flat lesions
936146|NCT02332772|Endoscopy
936147|NCT02332772|Colonoscopic resection
936148|NCT02332772|Colonoscopy
936149|NCT02332772|Data review
936150|NCT02332772|Data collection
936151|NCT02332668|PD1
936152|NCT02332668|PD-1
936153|NCT02332668|PDL1
936154|NCT02332668|PD-L1
936155|NCT02332655|Sturge-Weber syndrome
936156|NCT02332655|SWS
936157|NCT02332655|Drug resistant epilepsy
936158|NCT02332629|Glucocorticoid
936159|NCT02332629|Endothelial barrier
936160|NCT02332629|Glycocalyx
936161|NCT02332629|Knee arthroplasty, total
936162|NCT02332616|Glucocorticoid
936163|NCT02332616|Complement activation
936164|NCT02332616|Knee arthroplasty, total
936165|NCT02332603|Glucocorticoid
936166|NCT02332603|Glucose homeostasis
936167|NCT02332603|Knee arthroplasty, total
936168|NCT02332603|Hip arthroplasty, total
936169|NCT02332564|Circulation, Collateral
936170|NCT02332564|Coronary Artery Disease
936171|NCT02332564|Internal Mammary-Coronary Artery Anastomosis
936172|NCT02332564|Ischemia
936173|NCT02332538|LASER
936174|NCT02332538|PROSTATE
936175|NCT02332538|BIPOLAR
936176|NCT02332538|HYPERPLASIA
936177|NCT02332538|VAPORIZATION
936178|NCT02332525|Oral Vibrational Stimulation
936179|NCT02332525|Cognitive Function
936180|NCT02332525|Mild Cognitive Impairment
936181|NCT02332525|cognitive normal elderly
936182|NCT02332512|Non-squamous non-small cell lung cancer
936183|NCT02332512|Wild-type EGFR
936184|NCT02332512|3rd/4th line treatment
936185|NCT02332512|apatinib
936186|NCT02332499|Anlotinib
936187|NCT02332499|Metastatic Colorectal Cancer （mCRC）
936188|NCT02332499|ALTER0703
936189|NCT02332447|Tonic-clonic seizures
936190|NCT02332447|Naloxone
936191|NCT02332447|SUDEP
936192|NCT02332421|canine retraction
936193|NCT02332421|acceleration of tooth movement
936194|NCT02332421|dentoalveolar distraction osteogenesis
936195|NCT02332408|vertebral hemangioma
936196|NCT02332408|conventional radiotherapy
936197|NCT02332408|Cyber Knife radiotherapy
936198|NCT02332408|randomized trial
936199|NCT02332408|radioablation
936200|NCT02332395|pain
936201|NCT02332395|pain catastrophizing
936202|NCT02332395|cesarean section
936203|NCT02332369|Cataract
936204|NCT02332356|Crohn Disease
936205|NCT02332356|Inflammatory Bowel Diseases
936206|NCT02332356|Disease Attributes
936207|NCT02332343|Retina
936208|NCT02332343|Retinal pigment epithelium
936209|NCT02332317|Advanced cancer
936210|NCT02332317|Early integration
936211|NCT02332317|Palliative rehabilitation
936212|NCT02332304|Respiratory Distress Syndrome, Newborn
936218|NCT02332278|Cesarean section
936219|NCT02332278|Early feeding
936220|NCT02332265|Food Security
936221|NCT02332265|Microfinance
936222|NCT02332265|Village Savings and Loans
936223|NCT02332265|HIV
936224|NCT02332265|Quasi-experimental design
936225|NCT02332265|Malawi
936226|NCT02332265|Structural intervention
936227|NCT02332252|Surgical Wound Infection
936228|NCT02332252|Electrocautery
936229|NCT02332252|Scalpel
936230|NCT02332239|depression
936231|NCT02332239|violence
936232|NCT02332239|emergency department
936233|NCT02332239|text message
936234|NCT02332239|mhealth
936235|NCT02332213|Volatile organic compounds
936236|NCT02332213|Nanosensor technology
936237|NCT02332213|GC-MS
936238|NCT02332213|Breath-testing
936239|NCT02332213|Digestive cancer
936240|NCT02332213|Precancerous lesions
936241|NCT02332213|Colorectal cancer
936242|NCT02332213|Adenoma
936243|NCT02332213|Gastric cancer
936244|NCT02332213|Atrophic gastritis
936245|NCT02332213|OLGIM
936246|NCT02332200|Spondylolysis
936247|NCT02332200|Spondylolisthesis
936248|NCT02332200|Low Back Pain
936249|NCT02332174|pharmacokinetics
936250|NCT02332174|food effect
936251|NCT02332174|sex effect
936252|NCT02332174|tolerability
936253|NCT02332135|microwave ablation
936254|NCT02332135|maintenance hemodialysis
936255|NCT02332135|mild-to-moderate Secondary Hyperparathyroidism
936256|NCT02332122|COPD
936257|NCT02332122|Chronic Obstructive Pulmonary Disease
936258|NCT02332122|Aspergillus fumigatus
936259|NCT02332122|Bronchiectasis
936260|NCT02332122|Sensitization
936261|NCT02332122|Vitamin D
936262|NCT02332109|Fuchs endothelial dystrophy
936263|NCT02332109|oedema
936264|NCT02332109|sodium chloride
936265|NCT02332109|hyaluronan
936266|NCT02332109|sodium hyaluronate
936267|NCT02332070|acute kidney injury
936268|NCT02332070|coronary angiography
936269|NCT02332070|cardiac surgery
936270|NCT02332070|adverse events
936271|NCT02332070|iodinated contrast
936272|NCT02332070|Thoracic Surgery
936273|NCT02332057|IUD,Diclofenac , Lidocaine
936274|NCT02332031|Sorafenib, levothyroxine, drug interaction, pharmacokinetics, healthy volunteer
936275|NCT02331992|Continuous Positive Airway Pressure
936276|NCT02331966|FGF-23
936277|NCT02331966|GROWTH FACTORS RECEPTORS
936278|NCT02331966|RECURRENCES
936279|NCT02331953|spine surgery
936280|NCT02331953|cerebral oximetry
936281|NCT02331953|postoperative delirium
936282|NCT02331940|Chronic obstructive pulmonary disease
936283|NCT02331940|sleeping oxygen saturation
936284|NCT02331940|sleep quality
936285|NCT02331927|colorectal cancer
936286|NCT02331927|marker-driven
936287|NCT02331927|bevacizumab
936288|NCT02331927|aflibercept
936289|NCT02331927|cytokines
936290|NCT02331927|angiogenic factors
936291|NCT02331927|CAF
936292|NCT02331914|GIST
936293|NCT02331914|Bio-databank
936294|NCT02331862|urinary tract infection
936295|NCT02331862|methylprednisolone
936296|NCT02331849|Eosinophilic esophagitis (EoE)
936297|NCT02331849|GERD
936298|NCT02331849|esophageal motility
936299|NCT02331836|adenoma detection rate
936300|NCT02331836|polyp detection rate
936301|NCT02331836|withdrawal time
936302|NCT02331836|coecal and ileum intubation rate
936303|NCT02331797|endoscope
936304|NCT02331797|microscope
936305|NCT02331797|transcanal
936306|NCT02331719|intracerebral hemorrhage
936307|NCT02331719|subcortical intracerebral hemorrhage
936308|NCT02331719|ICH
936309|NCT02331719|parafascicular minimally invasive subcortical access
936310|NCT02331693|EGFR
936311|NCT02331693|CAR T cells
936312|NCT02331693|glioma
936313|NCT02331680|Undergoing Hemodialysis
936314|NCT02331680|Undergoing Hemodiafiltration
936315|NCT02331667|Diet
936316|NCT02331667|Vitamin-D
936317|NCT02331667|Meat
936318|NCT02331667|Fatty fish
936319|NCT02331667|Iodine
936320|NCT02331667|fatty acid
936321|NCT02331667|Intervention study
936322|NCT02331667|Wechsler Preschool and Primary Scale of Intelligence
936323|NCT02331667|Strengths and Difficulties Questionnaire
936324|NCT02331667|Nine hole peg test
936325|NCT02331654|Chronic pain
936326|NCT02331654|Direct Current Stimulation
936327|NCT02331641|hepatectomy
936328|NCT02331641|hepatic resection
936329|NCT02331628|TBI Traumatic Brain Injury
936330|NCT02331628|HO Heterotopic Ossification
936331|NCT02331628|NHO Neurogenic Heterotopic Ossification
936332|NCT02331628|ESWT Extracorporeal Shock Wave Therapy
936333|NCT02331615|Traumatic Brain Injury
936334|NCT02331615|Executive function difficulties
936335|NCT02331615|Transcranial direct current stimulation
936336|NCT02331602|atrial fibrillation
936337|NCT02331602|anticoagulation
936338|NCT02331602|inflammation
936339|NCT02331589|Fatigue
936340|NCT02331589|Panax ginseng
936341|NCT02331589|Chronic hepatitis
936342|NCT02331589|Non-alcoholic Fatty Liver Disease
936343|NCT02331589|Adiponectin
936344|NCT02331563|dexmedetomidine
936345|NCT02331550|Low-Grade Squamous Intraepithelial Lesions
936346|NCT02331524|exercise
936347|NCT02331524|daily activity
936348|NCT02331485|Prevention of wound infection and wound complication
936349|NCT02331472|interstitial cystitis
936350|NCT02331472|biomarker
936351|NCT02331459|mood
936352|NCT02331459|cognitive state
936353|NCT02331459|physical activity
936354|NCT02331459|frailty
936355|NCT02331394|Chinese herbs
936356|NCT02331394|lung cancer
936357|NCT02331394|quality of life
936358|NCT02331355|amputation, hand, forearm, arm, traumatic, transplantation
936359|NCT02331342|Agreement of NICOM and Innocor
936360|NCT02331329|Accuracy of NICOM
936361|NCT02331329|precision of NICOM
936362|NCT02331316|obesity
936363|NCT02331316|diet
936364|NCT02331316|weight
936365|NCT02331316|hunger
936366|NCT02331316|public led trial
936367|NCT02331264|Cardiac Toxicity
936368|NCT02331264|Metal on Metal Hip Implants
936369|NCT02331186|Obesity
936370|NCT02331186|Bariatric surgery
936371|NCT02331186|Urinary incontinence
936372|NCT02331186|Pelvic floor
936376|NCT02331160|Pregnancy
936377|NCT02331160|Breech Presentation
936378|NCT02331160|Version, fetal
936379|NCT02331160|Musculoskeletal Manipulations
936380|NCT02331160|Medicine, Traditional
936381|NCT02331134|Tissue
936382|NCT02331134|Hematopoietic Stem Cell
936383|NCT02331134|Melanoma
936384|NCT02331134|Squamous Head and Neck Cancer
936385|NCT02331121|children
936386|NCT02331121|parents
936387|NCT02331121|internet
936388|NCT02331121|video
936389|NCT02331121|training
936390|NCT02331121|interactive
936391|NCT02331082|Infant Mortality
936392|NCT02331082|Under-two mortality
936393|NCT02331082|Maternal Mortality
936394|NCT02331082|Implementation Research
936395|NCT02331082|Health Systems Strengthening
936396|NCT02331082|Chronic Disease Management
936397|NCT02331082|Commuity Health Workers
936398|NCT02331069|radial neuropathy
936399|NCT02331056|Stroke volume variation
936400|NCT02331056|fluid responsiveness
936401|NCT02331056|One-lung ventilation
936402|NCT02331056|thoracotomy
936403|NCT02331030|brachio-axillary
936404|NCT02331030|brachio-basilic
936405|NCT02331030|interfascial plane block
936406|NCT02331030|Pecs II block
936407|NCT02331030|supraclavicular brachial plexus block
936408|NCT02331017|Bimodal
936409|NCT02331017|Cochlear Implant
936410|NCT02331017|Hearing aid
936411|NCT02331017|Auditory Perception
936412|NCT02331004|Frail Elderly
936413|NCT02331004|Motor Skills
936414|NCT02331004|Upper Extremity
936415|NCT02330991|glioblastoma
936416|NCT02330991|relapse
936417|NCT02330991|Temozolomide
936418|NCT02330991|glioblastoma at first relapse
936419|NCT02330965|clinical research
936420|NCT02330965|mechanistic studies
936421|NCT02330965|blood draw
936422|NCT02330965|CSF by lumbar puncture (optional)
936423|NCT02330952|Double-blind method
936424|NCT02330952|Randomized Controlled trials
936425|NCT02330939|Postprandial glycemia
936426|NCT02330939|Momounsaturated fatty acids
936427|NCT02330939|Saturated fatty acids
936428|NCT02330939|Glycemic index
936429|NCT02330939|Glycemic load
936430|NCT02330939|Sensor augmented pump system
936436|NCT02330913|total gastrectomy
936437|NCT02330913|intracorporeal
936438|NCT02330913|totally laparoscopic
936439|NCT02330913|esophagojejunostomy
936440|NCT02330913|anastomosis
936441|NCT02330900|Implantable cardioverter defibrillator
936442|NCT02330900|Electromagnetic interference
936443|NCT02330900|Cell phone
936444|NCT02330887|Maternal Mortality
936445|NCT02330887|Institutional Birth Rate
936446|NCT02330887|Neonatal Mortality Rate
936447|NCT02330887|Preterm Birth
936448|NCT02330887|Stillbirth
936449|NCT02330887|Infant, Small for Gestational Age
936450|NCT02330887|Nepal
936451|NCT02330887|Implementation Research
936452|NCT02330887|Global Health
936453|NCT02330874|Risk
936454|NCT02330874|score
936455|NCT02330874|readmission
936456|NCT02330874|ICU
936457|NCT02330861|Coronary Circulation
936458|NCT02330848|Obesity
936459|NCT02330848|Walnuts
936460|NCT02330848|Endothelial Function
936461|NCT02330848|Adults at risk
936462|NCT02330835|school
936463|NCT02330835|bus
936464|NCT02330835|school bus
936465|NCT02330835|driver
936466|NCT02330835|training
936467|NCT02330835|behavior
936468|NCT02330835|management
936469|NCT02330835|interactive
936470|NCT02330835|computer
936471|NCT02330809|headache
936472|NCT02330809|hunger intensity
936473|NCT02330809|public led online trial
936474|NCT02330809|water intake
936475|NCT02330783|Metastatic Renal Cell Carcinoma
936476|NCT02330783|Third-line treatment
936477|NCT02330783|Sorafenib
936478|NCT02330783|Bevacizumab
936479|NCT02330770|GnRHa trigger
936480|NCT02330770|Luteal phase support
936481|NCT02330770|OHSS
936482|NCT02330757|Frozen-thawed embryo transfer
936483|NCT02330757|FET protocols
936484|NCT02330705|Intrauterine insemination
936485|NCT02330705|IUI
936486|NCT02330705|HCG
936487|NCT02330679|Major Depression, Neuroimaging, Desvenlafaxine, Machine learning
936488|NCT02330653|Colitis
936489|NCT02330653|Fecal Microbiota Transplant
936490|NCT02330653|Ulcerative colitis
936491|NCT02330653|inflammatory bowel disease
936492|NCT02330640|CABG
936493|NCT02330640|antiplatelet therapy
936494|NCT02330640|ticagrelor
936495|NCT02330614|personality
936496|NCT02330614|bleaching
936497|NCT02330588|Obesity
936498|NCT02330588|Prevention
936499|NCT02330588|Pediatric
936500|NCT02330588|Parents
936501|NCT02330588|Primary Care
936502|NCT02330588|eHealth
936503|NCT02330588|Internet
936504|NCT02330562|Marizomib
936505|NCT02330562|Bevacizumab
936506|NCT02330562|Avastin
936507|NCT02330562|Grade IV malignant glioma
936508|NCT02330562|proteasome inhibitor
936509|NCT02330562|glioblastoma
936510|NCT02330562|brain tumor
936511|NCT02330562|malignant glioma
936512|NCT02330562|brain cancer
936513|NCT02330562|gliosarcoma
936514|NCT02330562|BEV
936515|NCT02330536|Circulatory and Respiratory Physiological Phenomena
936516|NCT02330536|Thoracoscopy
936517|NCT02330510|Alzheimer's Disease
936518|NCT02330510|White Matter Hyperintensities
936519|NCT02330510|Vascular Cognitive Impairment
936520|NCT02330510|Amyloid Imaging
936521|NCT02330510|Transient Ischemic Attack
936522|NCT02330484|Community management， incentives, Medication Adherence
936523|NCT02330471|conization
936524|NCT02330471|LLETZ
936525|NCT02330471|cervical dysplasia
936526|NCT02330471|cervical intraepithelial neoplasia
936527|NCT02330458|Inflammatory Bowel Disease
936528|NCT02330458|Crohn's disease
936529|NCT02330458|Pediatric IBD
936530|NCT02330458|small bowel ultrasound
936531|NCT02330458|infliximab
936532|NCT02330419|Naltrexone
936533|NCT02330406|Dipeptidyl-Peptidase 4 Inhibitors
936534|NCT02330406|LDL Cholesterol
936535|NCT02330406|Glycosylated Hemoglobin
936536|NCT02330406|Diabetes Mellitus
936537|NCT02330406|Coronary Disease
936538|NCT02330380|psoriasis, comparative effects, inflammation
936539|NCT02330354|preschool
936540|NCT02330354|behavior change
936541|NCT02330354|social marketing
936542|NCT02330354|child care providers
936543|NCT02330354|nutrition
936544|NCT02330354|child care centers
936545|NCT02330354|physical activity
936546|NCT02330341|Glucose Intolerance
936547|NCT02330341|Artemisia dracunculus
936548|NCT02330341|Insulin
936549|NCT02330328|Chest Pain
936550|NCT02330328|Telemetry
936551|NCT02330315|transcranial direct current stimulation
936552|NCT02330315|transcranial ultrasound
936553|NCT02330315|non-invasive brain stimulation
936554|NCT02330250|Systemic Lupus Erythematosus
936555|NCT02330250|Pharmaceutical care
936556|NCT02330250|Pharmaceutical services
936557|NCT02330250|Medication adherence
936558|NCT02330224|Blood pressure
936559|NCT02330224|Lipids
936560|NCT02330224|Cardiovascular
936561|NCT02330224|Health services
936562|NCT02330224|Hypertension
936563|NCT02330211|Colitis
936564|NCT02330211|Fecal Microbiota Transplant
936565|NCT02330211|Crohn's Disease
936566|NCT02330211|inflammatory bowel disease
936567|NCT02330198|self-reported outcome instrument
936568|NCT02330185|spinal anesthesia
936569|NCT02330185|ultrasonography
936570|NCT02330185|anatomical landmark
936571|NCT02330159|Pilonidal
936572|NCT02330159|Quality of Life
936573|NCT02330133|mid-life women
936574|NCT02330133|unintended pregnancy
936575|NCT02330133|STI/HIV prevention
936576|NCT02330133|intervention
936577|NCT02330133|interactive
936578|NCT02330133|CD-ROM
936579|NCT02330133|multimedia
936580|NCT02330133|video
936581|NCT02330120|peak airway pressure
936582|NCT02330120|airway resistance
936583|NCT02330120|sedation
936584|NCT02330120|intensive care
936585|NCT02330094|aSAH
936586|NCT02330094|SAH
936587|NCT02330081|pathogen reduction technology
936588|NCT02330081|whole blood
936589|NCT02330081|Platelets
936590|NCT02330081|Mirasol
936591|NCT02330042|Diabetes
936592|NCT02330042|OCT
936593|NCT02330042|Angiography
936594|NCT02330042|Diabetic retinopathy
936595|NCT02330029|Irritable bowel syndrome,
936596|NCT02330029|Pinaverium
936597|NCT02330029|Herbal medication for IBS,
936598|NCT02330029|Tong Xie Yao Fang (Formula for pain and diarrhea)
936599|NCT02330003|Influenza
936600|NCT02330003|Influenza vaccine
936601|NCT02330003|Split influenza vaccine
936602|NCT02330003|Seasonal influenza vaccine
936603|NCT02329990|phosphorus intake
936604|NCT02329977|duodenal-biliary reflux
936605|NCT02329964|Rocuronium
936606|NCT02329964|Sugammadex
936607|NCT02329964|Succinylcholine
936608|NCT02329964|Cisatracurium
936609|NCT02329964|Neostigmine
936610|NCT02329964|acceleromyography (TOF-Watch®)
936611|NCT02329912|postoperative ileus
936612|NCT02329912|SmartPill
936613|NCT02329912|gastrointestinal transit
936614|NCT02329912|prokinetic drugs
936615|NCT02329886|chronic diseases
936616|NCT02329886|risk factors
936617|NCT02329886|health outcomes
936618|NCT02329873|Acute exacerbation of chronic obstructive pulmonary disease
936619|NCT02329873|Older adults
936620|NCT02329873|Respiratory rehabilitation exercise
936621|NCT02329847|Hematologic Neoplasms
936622|NCT02329847|JNJ54179060
936623|NCT02329847|Ibrutinib
936624|NCT02329847|Nivolumab
936625|NCT02329821|lactate
936626|NCT02329821|hartmann solution
936627|NCT02329821|hepatocellular carcinoma
936628|NCT02329808|TDM
936629|NCT02329808|dried blood spot
936630|NCT02329808|immunosuppressive
936631|NCT02329808|antifungal
936632|NCT02329769|Duchenne muscular dystrophy
936633|NCT02329769|DMD
936634|NCT02329769|BioMarin
936635|NCT02329769|PRO044
936636|NCT02329730|diagnosis of Tuberculosis (TB)
936637|NCT02329730|ESAT6
936638|NCT02329730|CFP10
936639|NCT02329730|Phase IIa Clinical Trial
936640|NCT02329704|IUI/AIH
936641|NCT02329704|Semen preparation
936642|NCT02329704|Semen processing
936643|NCT02329704|ICSI/IVF
936644|NCT02329704|ART
936645|NCT02329704|Density Gradient
936646|NCT02329704|Swimming down
936647|NCT02329704|hyaluronan affinity testing
936648|NCT02329704|Sperm vitality testin
936649|NCT02329691|safety climate
936650|NCT02329691|surgery
936651|NCT02329678|Apicomarginal defects
936652|NCT02329678|clinical study/trial
936653|NCT02329678|collagen membrane
936654|NCT02329678|guided tissue regeneration
936655|NCT02329678|endodontic microsurgery
936656|NCT02329652|Neuroprosthesis
936657|NCT02329652|Functional Electrical Stimulation
936658|NCT02329639|bevacizumab
936659|NCT02329639|paclitaxel
936660|NCT02329639|pharmacogenetics
936661|NCT02329639|breast cancer
936662|NCT02329561|Pharmacokinetics
936663|NCT02329561|Opioid
936664|NCT02329561|Geriatric
936665|NCT02329561|Pharmacodynamics
936666|NCT02329548|Alizarin
936667|NCT02329548|Orthostatic
936668|NCT02329548|POTS
936669|NCT02329548|Tilt table testing
936670|NCT02329548|Syncope
936671|NCT02329548|Anxiety
936672|NCT02329522|Haemodynamics
936673|NCT02329522|Chronic obstructive pulmonary disease
936674|NCT02329522|Ultrasonic Cardiac Output Monitor
936675|NCT02329522|severity
936676|NCT02329509|operative procedures
936677|NCT02329483|Infertility
936678|NCT02329483|Ovulation induction
936679|NCT02329483|Low-dose step-up protocol
936680|NCT02329483|Ovarian high responder
936681|NCT02329483|Androgens
936682|NCT02329483|Androstenedione
936683|NCT02329483|Testosterone
936684|NCT02329483|rhFSH
936685|NCT02329457|double-blind, randomized, intradermal, VZVv, HSCT
936686|NCT02329431|child mental health, mental health services, Latino families
936687|NCT02329340|child safety
936688|NCT02329340|injury
936689|NCT02329340|prevention
936690|NCT02329340|computer
936691|NCT02329340|internet
936692|NCT02329327|Factor Xa Inhibitors
936693|NCT02329327|Major
936694|NCT02329327|Bleeding
936695|NCT02329327|Anticoagulant
936696|NCT02329301|malaria
936697|NCT02329301|malaria, falciparum
936698|NCT02329301|antimalarials
936699|NCT02329262|exercise
936700|NCT02329262|mentors
936701|NCT02329262|health education
936702|NCT02329262|obesity
936703|NCT02329249|smoking cessation
936704|NCT02329249|coach-supported
936705|NCT02329249|tobacco use cessation
936706|NCT02329249|online
936707|NCT02329249|internet-based
936708|NCT02329249|tailored
936709|NCT02329223|Chronic spontaneous uriticaria
936710|NCT02329223|Omalizumab
936711|NCT02329197|Infertility
936712|NCT02329197|Invitro fertilization
936713|NCT02329145|renal denervation
936714|NCT02329132|diabetic macular edema
936715|NCT02329132|VEGF
936716|NCT02329132|ranibizumab
936717|NCT02329132|oxygen consumption
936718|NCT02329054|Ebola Virus Disease
936719|NCT02329054|Antivirals
936720|NCT02329054|Mortality
936721|NCT02329054|Viral load
936722|NCT02329054|Proof-of-concept
936723|NCT02329054|Phase II trial
936724|NCT02329054|Guinea
936725|NCT02329054|Adults
936726|NCT02329054|Children
936727|NCT02329041|videolaryngoscope
936728|NCT02329041|double-lumen tube
936729|NCT02329041|intubation
936730|NCT02329028|Emergency Care, Prehospital
936731|NCT02329028|Electroencephalography
936732|NCT02329028|Coma
936733|NCT02329015|stress
936734|NCT02329015|alternative
936735|NCT02329015|complementary
936736|NCT02329015|self-regulation
936737|NCT02329002|Retinoblastoma
936738|NCT02329002|Second primary tumor
936739|NCT02329002|Screening
936740|NCT02329002|Magnetic resonance imaging
936741|NCT02328989|prematurity
936742|NCT02328989|short cervix
936743|NCT02328989|twin pregnancy
936744|NCT02328989|pessary
936745|NCT02328963|Cytomegalovirus infection and disease
936746|NCT02328963|CMV-seropositive recipients
936747|NCT02328963|Everolimus
936748|NCT02328963|preemptive strategy
936749|NCT02328963|mTOR inhibitor
936750|NCT02328898|Polymer free stent
936751|NCT02328898|percutaneous coronary intervention
936752|NCT02328885|high-risk acute leukemia
936753|NCT02328885|graft versus leukemia
936754|NCT02328885|DLI
936755|NCT02328885|UCBT
936756|NCT02328872|screening
936757|NCT02328872|cervical screening
936758|NCT02328872|Human Papillomavirus (HPV)
936759|NCT02328872|cancer prevention
936763|NCT02328833|Depression
936764|NCT02328833|Clinical Practice Guideline
936765|NCT02328833|Implementation
936766|NCT02328833|Primary Care
936767|NCT02328833|Computerized Guideline
936768|NCT02328820|Fractional Flow Reserve, Myocardial
936769|NCT02328820|Coronary Flow Reserve
936770|NCT02328807|adenocarcinoma
936771|NCT02328807|prostate
936772|NCT02328807|ENCAGE™
936773|NCT02328807|focal bipolar radiofrequency ablation
936774|NCT02328807|radiofrequency ablation (RFA)
936775|NCT02328807|radiotherapy
936776|NCT02328794|smoking cessation
936777|NCT02328794|behavioral economics
936778|NCT02328794|e-cigarettes
936779|NCT02328794|NRT
936780|NCT02328781|vertebral artery stenosis
936781|NCT02328781|drug-eluting stent
936782|NCT02328703|Reiki
936783|NCT02328703|Neuropathic Pain
936784|NCT02328703|Military Service Members
936785|NCT02328703|Extermity Trauma
936786|NCT02328690|binaural beat technology
936787|NCT02328690|sound technology
936788|NCT02328690|cardiovascular stress response
936789|NCT02328690|military
936790|NCT02328690|music
936791|NCT02328690|anxiety
936792|NCT02328690|stress
936793|NCT02328677|Colorectal cancer
936794|NCT02328677|rectosigmoid
936795|NCT02328677|rectum
936796|NCT02328677|colon
936797|NCT02328664|Endoscopic resection
936798|NCT02328664|Pathology
936799|NCT02328664|Rescue surgery
936800|NCT02328651|Mild and Moderate Severe Patients With hand_foot-mouth Disease
936801|NCT02328638|ASD
936802|NCT02328625|Scleroderma
936803|NCT02328625|Device
936804|NCT02328625|ADRCs
936805|NCT02328625|adipose derived regenerative cells
936806|NCT02328625|hand
936809|NCT02328534|ICSI/IVF
936810|NCT02328534|Semen processing
936811|NCT02328534|Semen preparation
936812|NCT02328534|Swim down
936813|NCT02328534|Density gradient
936814|NCT02328534|Silica solution
936815|NCT02328521|Neointima
936816|NCT02328521|Tomography, Optical Coherence
936817|NCT02328521|drug-eluting stents
936818|NCT02328521|Nicorandil
936819|NCT02328508|hyperbaric oxygen therapy
936820|NCT02328508|diabetic foot ulcer
936821|NCT02328508|wound healing
936822|NCT02328508|inflammation
936823|NCT02328508|glycemic control
936824|NCT02328508|amputation
936825|NCT02328508|bacterial infection
936826|NCT02328508|quality of life
936827|NCT02328495|Misoprostol, Office hysteroscopy ,Pain
936828|NCT02328469|aseptic meningitis
936829|NCT02328469|tick-borne encephalitis
936830|NCT02328469|Lyme neuroborreliosis
936831|NCT02328469|inflammation
936832|NCT02328469|outcome
936833|NCT02328443|CYP3A
936834|NCT02328443|Metabolomics
936835|NCT02328404|Vitamin D
936836|NCT02328404|deficiency
936837|NCT02328404|hypovitaminosis D
936838|NCT02328404|Biodal
936839|NCT02328404|25 hydroxy Vitamin D
936840|NCT02328404|25hydroxyvitamin D
936841|NCT02328404|25(OH)D
936842|NCT02328404|PCOS
936843|NCT02328404|insulin resistance
936844|NCT02328404|BMI
936845|NCT02328404|chromium levels
936846|NCT02328404|vitamin D 3
936847|NCT02328404|cholecalciferol
936848|NCT02328404|50,000 IU
936849|NCT02328365|Colorectal Cancer
936850|NCT02328365|Comorbidity
936851|NCT02328365|Perioperative Care
936852|NCT02328365|Surgery
936853|NCT02328352|Buckypaper (BP) of Multi-Walled Carbon Nanotubes (MWCNTs)
936854|NCT02328352|surgical hernia prosthesis
936855|NCT02328352|abdominal wall defects surgery
936856|NCT02328352|prosthesis adhesion
936857|NCT02328352|disaster preparation and recovery hernia
936858|NCT02328352|Abdominal Wall Disaster Surgery
936859|NCT02328352|Fixation of prosthetic materials in general surgery
936860|NCT02328326|Diabetes
936861|NCT02328326|diabetes self-management
936862|NCT02328326|patient activation
936863|NCT02328326|social support
936864|NCT02328313|Cancer
936865|NCT02328313|Breast Cancer
936866|NCT02328313|Geriatric
936867|NCT02328313|Advance Age
936868|NCT02328313|Exercise
936869|NCT02328313|Physical Activity
936870|NCT02328313|Genetic Marker
936871|NCT02328313|p16
936872|NCT02328313|Chemotherapy
936873|NCT02328313|Breast Cancer Treatment
936874|NCT02328287|Spinal Fusion
936875|NCT02328287|Revision Surgery
936876|NCT02328287|Pseudarthrosis
936877|NCT02328287|Cell Therapy
936878|NCT02328287|Bone Graft
936879|NCT02328235|skeletal muscle, metabolism, physiology
936880|NCT02328222|Early steroid withdrawal
936881|NCT02328222|Acute allograft rejection
936882|NCT02328222|Mycophenolate
936883|NCT02328222|Tacrolimus
936884|NCT02328222|Basiliximab
936885|NCT02328196|Outcome and Process Assessment (Health Care)
936886|NCT02328196|Rasch analysis
936887|NCT02328196|Meal time performance
936888|NCT02328183|polymyxin B
936889|NCT02328183|carbapenem resistant bacteria
936890|NCT02328170|immunoglobulin E, food hypersensitivities, child, allergens
936891|NCT02328144|Hemorrhoidectomy
936892|NCT02328144|Postoperative pain
936893|NCT02328144|Metronidazole
936894|NCT02328118|Lucentis
936895|NCT02328118|Ranibizumab
936896|NCT02328118|Triamcinolone Acetonide
936897|NCT02328118|Vitrectomy
936898|NCT02328118|PDR
936899|NCT02328079|Facial Palsy (acute), Acyclovir, Prednisolone
936900|NCT02328066|NBI
936901|NCT02328066|NICE classification
936902|NCT02328066|deep submucosal invasion
936903|NCT02328066|Colonic Polyps [C23.300.825.411.235]
936904|NCT02328066|Colonoscopy [E01.370.372.250.250.200]
936905|NCT02328053|fungal keratitis
936906|NCT02328053|collagen cross linking
936907|NCT02328040|Diabetes Mellitus, Type 1
936908|NCT02328040|Closed loop
936909|NCT02328040|Artificial Pancreas
936910|NCT02328040|Insulin
936911|NCT02328040|Sitagliptin
936912|NCT02328040|Januvia
936913|NCT02328014|Bruton tyrosine kinase inhibitor
936914|NCT02328014|Btk
936915|NCT02328014|B-Cell Malignancies
936916|NCT02328014|Mantle Cell
936917|NCT02328014|Multiple Myeloma
936918|NCT02328014|CLL
936919|NCT02328014|SLL
936920|NCT02328014|DLBCL
936921|NCT02328014|Folicular
936922|NCT02328014|Waldenstrom
936923|NCT02328014|B-All
936924|NCT02327988|cryotherapy
936925|NCT02327988|laser therapy
936926|NCT02327988|eccentric exercise
936927|NCT02327988|delayed onset muscle soreness
936928|NCT02327988|muscle damage
936929|NCT02327988|dynamometry
936930|NCT02327988|electromyography
936931|NCT02327923|Laparoscopic cholecystectomy
936932|NCT02327923|lidocaine infusion
936933|NCT02327923|Esmolol infusion
936934|NCT02327923|Postoperative opioid consumption
936935|NCT02327923|Multimodal analgesia
936936|NCT02327910|Elderly patients，
936937|NCT02327910|General anesthesia，
936938|NCT02327910|Transcutaneous partial pressure of carbon dioxide(TcPCO2)，
936939|NCT02327910|Train-of-four(TOF)，
936940|NCT02327910|Extubation
936941|NCT02327910|，Respiratory events
936942|NCT02327897|Atopic Asthma
936943|NCT02327897|Exposures
936944|NCT02327897|Disease Progression
936950|NCT02327871|Therapeutic hypothermia
936951|NCT02327871|patients
936952|NCT02327871|Safety, Efficacy
936953|NCT02327845|natural history, biomarkers, phenotype, genotype
936954|NCT02327832|Confirmation
936955|NCT02327832|safety
936956|NCT02327793|Perfusion
936957|NCT02327793|Blood pressure
936958|NCT02327767|Active Assistance
936959|NCT02327767|Resonance
936960|NCT02327767|Stroke
936961|NCT02327767|Arm Rehabilitation
936962|NCT02327741|Dual antiplatelet therapy
936963|NCT02327741|clopidogrel
936964|NCT02327741|percutaneous coronary intervention
936965|NCT02327728|blepharospasm
936966|NCT02327728|botulinum A
936967|NCT02327728|injection pattern
936968|NCT02327728|tear
936969|NCT02327715|Hepatitis B virus
936970|NCT02327715|Emtricitabine
936971|NCT02327715|Pregnancy
936972|NCT02327715|Vertical transmission
936973|NCT02327702|Hepatitis B, chronic
936974|NCT02327702|Emtricitabine
936975|NCT02327702|Pregnancy
936976|NCT02327689|Hepatitis B virus
936977|NCT02327689|Cirrhosis
936978|NCT02327689|Emtricitabine
936979|NCT02327689|Adefovir dipivoxil
936980|NCT02327676|Hepatitis B, chronic
936981|NCT02327676|Emtricitabine
936982|NCT02327676|Child
936983|NCT02327663|Hepatitis B, chronic
936984|NCT02327663|Emtricitabine
936985|NCT02327663|Adefovir dipivixil
936986|NCT02327663|HBeAg
936987|NCT02327637|Preterm Premature Rupture of the Membranes
936988|NCT02327637|Bedrest
936989|NCT02327637|Physical Activity
936990|NCT02327585|Executive function training
936991|NCT02327585|child
936992|NCT02327559|childbirth
936993|NCT02327559|mindfulness
936994|NCT02327559|fear of labor
936995|NCT02327559|labor pain
936996|NCT02327559|coping
936997|NCT02327559|self-efficacy
936998|NCT02327559|childbirth satisfaction
936999|NCT02327559|depression
937000|NCT02327546|Pharmacokinetics
937001|NCT02327546|Anemia
937002|NCT02327546|Chronic kidney disease
937003|NCT02327546|CKD
937004|NCT02327546|Chronic renal insufficiency
937005|NCT02327546|Renal impairment
937006|NCT02327546|Ferrous sulfate
937007|NCT02327546|Iron
937008|NCT02327546|Drug-drug interaction
937009|NCT02327546|End stage renal disease
937010|NCT02327546|Dialysis
937011|NCT02327546|Erythropoietin
937012|NCT02327546|Oral anemia treatment
937013|NCT02327546|Hypoxia-induciable factor
937014|NCT02327546|HIF
937015|NCT02327546|Hypoxia-induciable factor prolyl-hydroxylase inhibitor
937016|NCT02327546|HIF-PHI
937017|NCT02327533|generalized aggressive periodontitis
937018|NCT02327533|microarray analysis
937019|NCT02327520|Clostridium difficile infection
937020|NCT02327520|burden
937021|NCT02327520|nationwide study
937022|NCT02327520|South East Asia
937023|NCT02327520|Thailand
937024|NCT02327520|Epidemiology
937025|NCT02327520|Outcome Assessment (Health Care) [N04.761.559.590]
937026|NCT02327507|children
937027|NCT02327507|fluoridated toothpaste
937028|NCT02327507|health education
937029|NCT02327507|Medicaid
937030|NCT02327494|Neuromuscular blockade
937031|NCT02327494|Laparoscopy
937032|NCT02327494|Oxygen measurements
937033|NCT02327481|Stomach Neoplasms Laparoscopy
937034|NCT02327442|chemokine receptor
937035|NCT02327442|galium
937036|NCT02327442|dosimetry
937037|NCT02327442|glioma
937038|NCT02327403|Proteinuria
937039|NCT02327403|Kidney transplantation
937040|NCT02327403|Allograft dysfunction
937041|NCT02327403|B7-1
937042|NCT02327403|Belatacept
937043|NCT02327377|Irritable bowel syndrome
937044|NCT02327377|Intervention studies
937045|NCT02327377|Visceral pain
937046|NCT02327377|Chronic pain
937047|NCT02327377|Abdominal pain
937048|NCT02327377|Dyspepsia
937049|NCT02327377|Nausea
937050|NCT02327377|Nociception
937051|NCT02327377|Parents
937052|NCT02327377|Coping behavior
937053|NCT02327377|Anxiety
937054|NCT02327377|Depression
937055|NCT02327377|Catastrophization
937056|NCT02327377|Reinforcement (psychology)
937057|NCT02327377|Self efficacy
937058|NCT02327377|Health services overutilization
937059|NCT02327377|Questionnaires
937060|NCT02327377|Self report
937061|NCT02327377|Health surveys
937062|NCT02327377|Prospective studies
937063|NCT02327377|Adolescent health
937064|NCT02327377|Mental health services
937065|NCT02327377|Health services accessibility
937066|NCT02327377|Health diaries
937067|NCT02327377|National Institute of Child Health & Human Development (US.)
937068|NCT02327377|Telemedicine
937069|NCT02327377|E-Health
937070|NCT02327377|Web-based intervention
937071|NCT02327377|Parenting education
937072|NCT02327325|Low Back Pain
937073|NCT02327325|Exercise
937074|NCT02327325|Cognitive Behavioral Therapy
937075|NCT02327325|Aged
937076|NCT02327299|Iron deficiency
937077|NCT02327299|Iron fortification
937078|NCT02327286|Diabetes Mellitus
937079|NCT02327286|Gestational diabetes
937080|NCT02327273|subjects
937081|NCT02327221|Crohn Disease
937082|NCT02327221|Cell therapy
937083|NCT02327221|Regulatory T lymphocytes
937084|NCT02327221|Treg
937085|NCT02327221|Autologous
937086|NCT02327221|Antigen specific T regulatory lymphocytes
937087|NCT02327208|Military Training
937088|NCT02327208|Whey Protein
937089|NCT02327208|Body Composition
937090|NCT02327182|MT-4666
937091|NCT02327182|α7 nicotinic acetylcholine receptor agonist
937092|NCT02327182|Alzheimer's Disease
937093|NCT02327182|Cognitive function
937094|NCT02327182|Dementia
937095|NCT02327182|Central Nervous System Agents
937096|NCT02327169|Drug therapy
937097|NCT02327156|Dexmedetomidine
937098|NCT02327104|mindfulness
937099|NCT02327104|tobacco dependence
937100|NCT02327104|relapse prevention
937101|NCT02327091|Alfacalcidol
937102|NCT02327091|Falls
937103|NCT02327091|Handgrip
937104|NCT02327091|Muscle strength
937105|NCT02327091|Sarcopenia
937106|NCT02327065|EUS
937107|NCT02327065|FNA
937108|NCT02327065|FNB
937109|NCT02327052|Chagas disease
937110|NCT02327052|longitudinal global strain
937111|NCT02327052|speckle tracking
937112|NCT02327026|Out-of-hospital cardiac arrest
937113|NCT02327026|Bag-valve-mask ventilation
937114|NCT02327026|Tracheal intubation
937115|NCT02326961|osteoarthritis
937116|NCT02326961|knee
937117|NCT02326961|adipose derived regenerative cells
937118|NCT02326961|ADRC
937119|NCT02326961|Celution
937120|NCT02326961|arthritis
937121|NCT02326948|Gallbladder cancer
937122|NCT02326948|Case-control study
937123|NCT02326948|Risk factor
937124|NCT02326948|Alcohol consumption
937125|NCT02326948|Polypoid lesions of gallbladder
937126|NCT02326948|Biliary stone
937127|NCT02326935|MS
937128|NCT02326935|Multiple Sclerosis, Relapsing-Remitting
937129|NCT02326935|Multiple Sclerosis, Chronic Progressive
937130|NCT02326935|Myelitis
937131|NCT02326922|Dysfunctional uterine bleeding
937132|NCT02326922|Metraplant-E
937133|NCT02326922|Levonorgestrel-releasing intrauterine device
937134|NCT02326922|Endometrial decidualization
937135|NCT02326909|Upper Urinary Tract
937136|NCT02326909|Optical Coherence Tomography
937137|NCT02326909|Transitional Cell Carcinoma
937138|NCT02326909|Urothelial Cell Carcinoma
937139|NCT02326909|Diagnostic accuracy
937140|NCT02326896|intubation
937141|NCT02326896|intensive care unit
937142|NCT02326896|MACOCHA Score
937143|NCT02326870|laparoscopic Cholecystectomy
937144|NCT02326870|laparoscope holder
937145|NCT02326870|gynecological laparoscopy procedures
937146|NCT02326870|fundoplication surgery
937147|NCT02326870|laparoscopic adnexal surgery
937148|NCT02326870|excision of endometriosis lesion
937149|NCT02326870|diagnostic laparoscopy procedures
937150|NCT02326870|right hemicolectomy
937151|NCT02326870|Diaphragmatic hernia
937152|NCT02326857|Distribution of Molecular Profiles in Latin American Women
937153|NCT02326857|AJCC 7 Clinical Stage II to III
937154|NCT02326857|Breast Cancer Observational Study
937155|NCT02326857|Prospective Cohort
937156|NCT02326857|Epidemiological, Histological, and Clinical Data
937157|NCT02326844|Germline BRCA1/2 Mutations (gBRCAm)
937158|NCT02326844|DNA Damaging Agents
937159|NCT02326844|FOX03a, 53BP1 and RAD51
937160|NCT02326818|Dystonia
937161|NCT02326818|Botulinum Toxin
937162|NCT02326818|Musician's Dystonia
937163|NCT02326818|Spasticity
937164|NCT02326792|Exercise
937165|NCT02326792|Training
937166|NCT02326792|Low back Pain
937167|NCT02326792|Physical Therapy
937168|NCT02326779|esophageal cancer
937169|NCT02326779|aspirin
937170|NCT02326779|survival
937171|NCT02326740|Pyoderma Gangrenosum
937172|NCT02326740|Classic Pyoderma Gangrenosum
937173|NCT02326727|Epidural Analgesia
937174|NCT02326727|Natural Killer Cells
937175|NCT02326675|Etoposide
937176|NCT02326675|Cryotherapy
937177|NCT02326662|spinal cord injury
937178|NCT02326662|neural stem cells
937179|NCT02326662|paraplegia
937180|NCT02326662|transplantation
937181|NCT02326649|cardiac output
937182|NCT02326610|Small for gestational age (SGA)
937183|NCT02326610|Human growth hormone (hGH)
937184|NCT02326597|Hydroxyurea
937185|NCT02326597|Bone marrow transplant
937186|NCT02326597|Chronic blood transfusion
937187|NCT02326597|Treatment options for sickle cell disease
937188|NCT02326597|Decision making
937189|NCT02326584|Acute Myeloid Leukemia
937190|NCT02326584|Antibody-Drug Conjugate
937191|NCT02326584|CD33 Antigen
937192|NCT02326584|Drug Therapy
937193|NCT02326584|Acute Myelogenous Leukemia
937194|NCT02326571|EEG
937565|NCT02324725|Vivitrol®
937195|NCT02326571|Cortical Spreading Depression
937196|NCT02326571|Cerebral Hemorrhage
937197|NCT02326571|miRNA
937198|NCT02326571|Reactivity in EEG
937199|NCT02326571|Multimodal monitoring
937200|NCT02326558|zero ischemia
937201|NCT02326558|microwave
937202|NCT02326558|ablation
937203|NCT02326558|enucleation
937204|NCT02326558|renal cell carcinoma
937205|NCT02326545|Video Games
937206|NCT02326545|Child
937207|NCT02326545|Adolescent
937208|NCT02326532|Rheumatoid Arthritis
937209|NCT02326532|Veterans
937210|NCT02326506|Extracorporeal Membrane Oxygenation
937211|NCT02326506|Cardiopulmonary Bypass
937212|NCT02326493|Cardiac Resynchronization Therapy
937213|NCT02326493|LV lead position
937214|NCT02326493|Device programming
937215|NCT02326493|Optimization
937216|NCT02326493|Vectorcardiography
937217|NCT02326480|Childhood Obesity
937218|NCT02326480|Genetics
937219|NCT02326467|chlorhexidine
937220|NCT02326467|safety
937221|NCT02326467|bath
937222|NCT02326467|rash
937223|NCT02326467|infant
937224|NCT02326441|advanced malignancies
937225|NCT02326441|refractory therapies
937226|NCT02326441|phase 1
937227|NCT02326428|Stroke
937228|NCT02326428|Cerebrovascular Accident
937229|NCT02326428|Brain ischemia
937230|NCT02326428|Intravenous thrombolysis
937231|NCT02326428|Stroke thrombectomy
937232|NCT02326428|Stent-retriever
937233|NCT02326415|Acute Appendicitis
937234|NCT02326415|Appendectomy
937235|NCT02326415|Fast-Track
937236|NCT02326415|Clinical Pathway
937237|NCT02326402|Circulatory support
937238|NCT02326402|Extracorporeal circulatory support
937239|NCT02326402|Extracorporeal bypass
937240|NCT02326389|Cognitive functioning
937241|NCT02326363|substance abuse
937242|NCT02326363|Mental Health Disorders
937243|NCT02326350|Acute Respiratory Distress syndrome
937244|NCT02326350|Aspirin
937245|NCT02326298|Certolizumab Pegol
937246|NCT02326298|Cimzia
937247|NCT02326298|Psoriasis
937248|NCT02326285|induction therapy
937249|NCT02326285|NSCLC
937250|NCT02326285|Non-small Cell Lung Cancer
937251|NCT02326285|curative surgery
937252|NCT02326272|Certolizumab Pegol
937253|NCT02326272|Cimzia
937254|NCT02326272|Psoriasis
937255|NCT02326259|Diabetic Retinopathy
937256|NCT02326259|Disease Progression
937257|NCT02326246|MRI
937258|NCT02326246|active surveillance
937259|NCT02326207|Infant, Newborn
937260|NCT02326207|Neonatal intensive care unit
937261|NCT02326207|Ventilator circuit
937262|NCT02326194|Safety,immunogenicity,Ebola
937263|NCT02326181|respiratory muscle training
937264|NCT02326181|respiratory muscle strength
937265|NCT02326181|respiratory endurance test
937266|NCT02326181|6-minute walking test
937267|NCT02326142|Premature Obstetric Labor
937268|NCT02326142|Premature Birth
937269|NCT02326103|alcoholic
937270|NCT02326103|hepatitis
937271|NCT02326103|cirrhosis
937272|NCT02326103|cholesterol metabolites
937273|NCT02326103|ciprofloxacin
937274|NCT02326077|sonopartogram
937275|NCT02326077|transperineal ultrasound
937276|NCT02326077|intrapartum ultrasound
937277|NCT02326077|labor
937278|NCT02326077|delivery
937279|NCT02326077|partogram
937280|NCT02326077|ultrasound
937281|NCT02326051|Antiphospholipid syndrome
937282|NCT02326051|APS
937283|NCT02326051|LMWH
937284|NCT02326038|Memory
937285|NCT02326038|Attention
937286|NCT02326038|MCI
937287|NCT02326038|Ritalin
937288|NCT02325999|Endoscopic Submucosal Dissection
937289|NCT02325999|Laparoscopic Regional Lymph node Dissection
937290|NCT02325999|early gastric cancer
937291|NCT02325999|Disease-free survival
937292|NCT02325986|radiotherapy
937293|NCT02325986|esophageal carcinoma
937294|NCT02325986|chemotherapy
937295|NCT02325973|STEMI
937296|NCT02325973|IMR
937297|NCT02325973|FFR
937298|NCT02325973|microcirculatory
937299|NCT02325960|exenatide
937300|NCT02325960|insulin glargine
937301|NCT02325947|Post stroke hand paresis brain injury
937302|NCT02325934|Stribild
937303|NCT02325934|pharmacokinetics
937304|NCT02325934|Crushing
937305|NCT02325934|Drip feed
937306|NCT02325921|Magnetic Resonance Imaging
937307|NCT02325921|Diffusion Weighted MRI
937308|NCT02325921|Diffusion Tensor Imaging
937309|NCT02325908|Hemodialysis
937310|NCT02325908|Estimated Dry Weight
937311|NCT02325895|Osteoporosis
937312|NCT02325895|Dried plum
937313|NCT02325895|functional food
937314|NCT02325869|Acute Coronary Syndrome, Coronary Occlusion, catheter
937315|NCT02325856|Hemodialysis
937316|NCT02325856|Body Composition Monitor
937317|NCT02325830|Functional mitral regurgitation
937318|NCT02325830|Secondary mitral regurgitation
937319|NCT02325830|Percutaneous mitral repair
937320|NCT02325817|The purpose is to observe and evaluate the safety and efficacy of drug-eluting balloon in the treatment of patients with bifurcation lesions of coronary artery.
937321|NCT02325804|overweight and obesity
937322|NCT02325804|adipose tissue
937323|NCT02325804|weight loss program
937324|NCT02325804|low-calorie diet
937325|NCT02325804|circuit-based exercise
937326|NCT02325804|metabolic cardiovascular syndrome
937327|NCT02325765|congential cardiac surgery
937328|NCT02325765|nuclearsome
937329|NCT02325765|systemic inflammation response syndrome
937330|NCT02325752|readmission
937331|NCT02325752|chronic diseases
937332|NCT02325739|FGF401, PDR001, PD-1, FGFR4, FGF19, HCC
937333|NCT02325726|Cardiac surgery
937334|NCT02325726|Extracorporeal circulation
937335|NCT02325726|Renal failure
937336|NCT02325713|ODT-PZQ
937337|NCT02325713|Bio-availability
937338|NCT02325713|Praziquantel
937339|NCT02325713|Cysticide
937340|NCT02325713|Pharmacokinetics
937341|NCT02325687|Obstructive Sleep Apnea
937342|NCT02325687|Arthroplasty, Replacement, Knee
937343|NCT02325687|Cerebrospinal Fluid
937344|NCT02325687|Inflammation
937345|NCT02325687|TNF-alpha
937346|NCT02325687|Interleukin-6 (IL-6)
937347|NCT02325687|Interleukin-8 (IL-8)
937348|NCT02325687|Interleukin-10 (IL-10)
937349|NCT02325687|Cytokines
937350|NCT02325687|Neurotrophins
937351|NCT02325687|BDNF
937352|NCT02325687|Beta-NGF
937353|NCT02325687|Proteomic Analysis
937354|NCT02325674|Lipodystrophy
937355|NCT02325674|Metreleptin Registry
937356|NCT02325635|Adenoma Detection
937357|NCT02325635|Adenoma Prediction
937358|NCT02325596|Chronic rhinosinusitis
937359|NCT02325596|microRNA
937360|NCT02325596|dendritic cell
937361|NCT02325596|helper T cell
937362|NCT02325583|Intraoral 30% glucose, newborn, MRI
937363|NCT02325544|dissociative seizures,
937364|NCT02325544|psychogenic nonepileptic seizures
937365|NCT02325531|implementation strategies
937366|NCT02325531|diabetes mellitus
937367|NCT02325531|cardiovascular disease
937368|NCT02325531|community health centers
937369|NCT02325531|quality improvement
937370|NCT02325531|translational medical research
937371|NCT02325518|Open-angle glaucoma (OAG)
937372|NCT02325518|Ocular hypertension (OHT)
937373|NCT02325518|AZORGA®
937374|NCT02325518|COSOPT®
937375|NCT02325492|bariatric surgery
937376|NCT02325492|NASH
937377|NCT02325492|ARAMCHOL
937378|NCT02325479|Low Molecular Weight (LMWH) Heparin ICSI Enaoxaprin sodium
937379|NCT02325466|Peripheral Artery Disease
937380|NCT02325466|Type 2 Diabetes
937381|NCT02325466|Blood Viscosity
937382|NCT02325466|Ticagrelor
937383|NCT02325466|Aspirin
937384|NCT02325453|Robotic Surgery
937385|NCT02325453|Laparoscopic Surgery
937386|NCT02325453|Minimally Invasive Surgery
937387|NCT02325453|Robotic Gastrectomy
937388|NCT02325453|Laparoscopic Gastrectomy
937389|NCT02325453|Open Gastrectomy
937390|NCT02325453|Gastric Surgery
937391|NCT02325440|RRMS (relapsing remitting multiple sclerosis)
937392|NCT02325440|Cluster of differentiation 49d (CD49d)
937393|NCT02325440|immune function
937394|NCT02325440|disease activity
937395|NCT02325427|stroke
937396|NCT02325427|rehabilitation
937397|NCT02325427|upper limb
937398|NCT02325427|TMS
937399|NCT02325427|tDCS
937400|NCT02325414|Osteoporosis
937401|NCT02325414|Spinal Cord Injury
937402|NCT02325414|Bone Diseases
937403|NCT02325414|Metabolic Bone Diseases
937404|NCT02325414|Musculoskeletal Diseases
937405|NCT02325414|Spinal Cord Diseases
937406|NCT02325414|Central Nervous System Diseases
937407|NCT02325414|Nervous System Diseases
937408|NCT02325414|Nervous System
937409|NCT02325414|Wounds and Injuries
937410|NCT02325414|Bone Density Conservation Agents
937411|NCT02325414|Physiological Effects of Drugs
937412|NCT02325414|Pharmacologic Actions
937413|NCT02325414|Department of Defense
937414|NCT02325388|pressure ulcer
937415|NCT02325388|decubitus ulcer
937416|NCT02325388|bed sore
937417|NCT02325388|continuous pressure mapping
937418|NCT02325388|interface pressure imaging
937419|NCT02325375|Amyotrophic Lateral Sclerosis
937420|NCT02325375|spinal fluid
937421|NCT02325375|CD163
937422|NCT02325362|Cystic fibrosis
937423|NCT02325362|CFTR
937424|NCT02325362|F508del mutation
937425|NCT02325362|Miglustat
937426|NCT02325362|Total Chloride Secretion
937427|NCT02325362|Nasal Potential Difference
937428|NCT02325349|Angiogenesis
937429|NCT02325349|Integrins
937430|NCT02325349|RGD PET/CT
937431|NCT02325349|FDG PET/CT
937432|NCT02325349|Predictive value
937433|NCT02325349|Therapeutic response
937434|NCT02325349|Efficacy
937435|NCT02325349|Tolerability
937436|NCT02325336|Medication Errors
937437|NCT02325336|nurses
937438|NCT02325336|hospital
937439|NCT02325323|stomach cancer
937440|NCT02325323|gastric intestinal metaplasia
937441|NCT02325323|prospective cohort
937442|NCT02325323|low grade dysplasia
937443|NCT02325323|high grade dysplasia
937444|NCT02325323|prognosis factor
937445|NCT02325323|gastric cancer risks
937446|NCT02325310|Vaccine strain excretion in breast milk
937447|NCT02325310|Postpartum vaccination
937448|NCT02325310|Breastfeeding women
937449|NCT02325310|Measles-mumps-rubella vaccine
937450|NCT02325310|Breast milk
937451|NCT02325310|Vaccinology
937452|NCT02325297|Intensive care unit
937453|NCT02325258|Sepsis diagnosis
937454|NCT02325258|Sepsis drug therapy
937455|NCT02325258|Sepsis outcome
937456|NCT02325245|Frailty
937457|NCT02325245|Pre-frailty
937458|NCT02325245|Metformin
937459|NCT02325245|Elderly
937460|NCT02325245|Quality of life
937461|NCT02325245|Handgrip
937462|NCT02325245|Gait speed
937463|NCT02325245|Myostatin
937464|NCT02325219|Psoriasis
937465|NCT02325219|CNTO 1959
937466|NCT02325219|Guselkumab
937467|NCT02325219|Placebo
937468|NCT02325180|ACT
937469|NCT02325180|Plasmodium falciparum
937470|NCT02325180|malaria
937471|NCT02325180|efficacy
937472|NCT02325180|Indonesia
937473|NCT02325167|informal caregivers
937474|NCT02325167|mental stress
937475|NCT02325167|quality of life
937476|NCT02325167|psychotherapeutic intervention
937477|NCT02325128|social anxiety
937478|NCT02325128|exposure therapy
937479|NCT02325128|extinction
937480|NCT02325128|sleep-dependent memory consolidation
937481|NCT02325115|well-being, mental health, schizophrenia, quality of life
937482|NCT02325089|Elderly
937483|NCT02325089|Obstructive Sleep Apnea
937484|NCT02325089|Mandibular advancement oral appliance
937485|NCT02325089|Hypertension
937486|NCT02325089|Cardiovascular disease
937487|NCT02325089|Quality of life
937488|NCT02325076|Airway Management
937489|NCT02325076|intubation
937490|NCT02325076|pulmonary function test
937491|NCT02325050|Healthy
937492|NCT02325050|Ebola viruses
937493|NCT02325050|Ebola Viral Disease (EVD)
937494|NCT02325050|Filoviruses
937495|NCT02325050|monovalent vaccine
937496|NCT02325050|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
937497|NCT02325050|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
937498|NCT02325050|Safety
937499|NCT02325050|Immunogenicity
937500|NCT02325024|Sativex
937501|NCT02325024|GW-1000-02
937502|NCT02325024|Nabiximols
937503|NCT02325024|Pharmacokinetics
937504|NCT02325024|Renal Insufficiency
937505|NCT02325024|Chronic Kidney Failure
937506|NCT02325011|Sativex
937507|NCT02325011|GW-1000-02
937508|NCT02325011|Nabiximols
937509|NCT02325011|Fluconazole
937510|NCT02325011|Pharmacokinetics
937511|NCT02325011|Drug-drug interaction
937512|NCT02324998|Radical Prostatectomy
937513|NCT02324998|Prostate Cancer
937514|NCT02324998|PARP inhibition
937515|NCT02324998|Olaparib
937516|NCT02324998|Degarelix
937517|NCT02324998|Neoadjuvant
937518|NCT02324998|Pharmacodynamics
937519|NCT02324998|Pharmacokinetics
937520|NCT02324998|Biomarkers
937521|NCT02324985|muscle soreness
937522|NCT02324972|Atopic dermatitis
937523|NCT02324972|Eczema
937524|NCT02324972|AD
937525|NCT02324972|AQX-1125
937526|NCT02324972|SHIP1
937527|NCT02324946|Sleep Apnea Syndromes
937528|NCT02324946|Perioperative Period
937529|NCT02324946|Mass Screening
937530|NCT02324920|Syncope
937531|NCT02324920|Closed Loop Stimulation
937532|NCT02324920|CLS
937533|NCT02324894|screening
937534|NCT02324894|MRI
937535|NCT02324881|smartphone
937536|NCT02324881|application
937537|NCT02324881|pain management
937538|NCT02324868|Bandages
937539|NCT02324868|Catheter
937540|NCT02324855|Autogenic drainage
937541|NCT02324855|Positive expiratory pressure
937542|NCT02324855|Airway clearance technique
937543|NCT02324855|Quality of life
937544|NCT02324855|Exacerbations
937545|NCT02324855|Chest physiotherapy
937546|NCT02324829|Total joint replacement
937547|NCT02324829|Physiotherapy
937548|NCT02324829|Kalman filtering
937549|NCT02324829|Kinematic modeling
937550|NCT02324829|Hidden Markov model
937551|NCT02324829|Motion segmentation
937552|NCT02324790|OSA, Oral Pressure Therapy (OPT)
937553|NCT02324764|transradial coronary angiography
937554|NCT02324764|radial artery occlusion
937555|NCT02324764|coronary heart disease
937556|NCT02324764|Glidesheath Slender
937557|NCT02324738|Mefloquine/Dihydroartemisinin-piperaquine
937558|NCT02324738|drug interaction
937559|NCT02324725|naltrexone
937560|NCT02324725|neuroimaging
937561|NCT02324725|heroin
937562|NCT02324725|addiction
937563|NCT02324725|dependence
937564|NCT02324725|opioid
937566|NCT02324725|functional magnetic resonance imaging
937567|NCT02324699|Vedolizumab
937568|NCT02324699|Corticosteroids
937569|NCT02324699|Prednisone
937570|NCT02324699|Crohn's disease
937571|NCT02324686|Warfarin
937572|NCT02324686|International Normalized Ratio
937573|NCT02324686|Vitamin K
937574|NCT02324673|Treatment-resistant seizures
937575|NCT02324660|screening procedure
937576|NCT02324660|peak expiratory flow
937577|NCT02324660|respiratory health screening questionnaire
937582|NCT02324621|protocol specific
937583|NCT02324595|Ovarian Cancer
937584|NCT02324595|Laparoscopy
937585|NCT02324595|Neoadjuvant Chemotherapy
937586|NCT02324595|Robotic
937587|NCT02324595|Interval Debulking Surgery
937592|NCT02324569|Pharmacological therapy
937593|NCT02324556|Rectal Cancer
937594|NCT02324556|Surgery
937595|NCT02324556|Laparoscopy
937596|NCT02324517|response to various potential therapies as managed by lab assays
937597|NCT02324478|autonomic nervous system
937598|NCT02324478|heart rate variability
937599|NCT02324478|laparoscopic surgery
937600|NCT02324478|general anesthesia
937601|NCT02324478|photoplethysmography
937602|NCT02324439|ovarian cancer
937603|NCT02324439|flaxseed
937604|NCT02324439|dietary supplement
937605|NCT02324439|organic dietary supplement
937606|NCT02324439|recurrence
937607|NCT02324426|Parkinson's Disease
937608|NCT02324426|Reduced Glutathione
937609|NCT02324426|CNS
937610|NCT02324426|Glutathione
937611|NCT02324426|Uptake
937612|NCT02324426|Intranasal
937613|NCT02324426|(in)GSH
937614|NCT02324387|Breast Cancer
937615|NCT02324387|Molecular breast imaging
937616|NCT02324387|MBI
937617|NCT02324387|Tc99m sestamibi
937618|NCT02324387|Neoadjuvant chemotherapy
937619|NCT02324387|NAC
937620|NCT02324374|colon cancer
937621|NCT02324361|Pediatric
937622|NCT02324361|Obesity
937623|NCT02324361|Intervention
937624|NCT02324361|Information and Communication Technologies
937625|NCT02324361|Social Media
937626|NCT02324361|Text Messaging
937627|NCT02324361|Mobile Health
937628|NCT02324335|Oral Mucositis
937629|NCT02324335|Brilacidin
937630|NCT02324335|Chemoradiation
937631|NCT02324322|Device: Robotic Exoskeleton
937632|NCT02324296|small cell lung cancer
937633|NCT02324296|extended disease
937634|NCT02324296|limited disease
937635|NCT02324296|chemotherapy
937636|NCT02324296|cisplatin
937637|NCT02324296|etoposide
937638|NCT02324296|ifosfamide
937639|NCT02324283|one-lung ventilation, oxygenation
937640|NCT02324270|Pain due to ankle sprain
937641|NCT02324244|Cytomegalovirus
937642|NCT02324244|critical patient
937643|NCT02324244|ICU
937644|NCT02324244|immunocompetent
937645|NCT02324244|clinical suspicion
937646|NCT02324244|risk factors
937647|NCT02324218|Diabetes mellitus
937648|NCT02324218|Hepatitis B
937649|NCT02324218|Incidence
937650|NCT02324192|Ultrasonography
937651|NCT02324192|clinical
937652|NCT02324192|hand
937653|NCT02324166|cefazolin
937654|NCT02324166|lidocaine
937655|NCT02324153|Post-operative Delirium
937656|NCT02324114|Cancer
937657|NCT02324075|sanitation, toilet, urban, behavior change
937658|NCT02324062|Cancer Genetics
937659|NCT02324062|Multi-gene cancer panel testing
937660|NCT02324049|MPS IIIB
937661|NCT02324049|Mucopolysaccharidosis
937662|NCT02324049|Mucopolysaccharidosis type IIIB
937663|NCT02324049|Sanfilippo Syndrome
937664|NCT02324049|Metabolism, Inborn Errors
937665|NCT02324049|Metabolic Diseases
937666|NCT02324049|Genetic Diseases, Inborn
937667|NCT02324049|Carbohydrate Metabolism, Inborn Errors
937668|NCT02324049|Connective Tissue Diseases
937669|NCT02324049|Lysosomal Storage Diseases
937670|NCT02324049|Mucinoses
937671|NCT02324049|Mucopolysaccharidoses
937672|NCT02324049|Pathologic Processes
937673|NCT02324023|ultrasound
937674|NCT02324023|perfusion
937675|NCT02324023|endoscopic
937676|NCT02324010|gastric emptying
937677|NCT02324010|glycemia
937678|NCT02324010|appetite
937679|NCT02324010|incretin hormones
937680|NCT02323997|HPV
937681|NCT02323997|cervical cancer
937682|NCT02323997|human papillomavirus
937683|NCT02323997|cervical pre-cancer
937684|NCT02323997|cervical neoplasia
937685|NCT02323945|acute intermittent hypoxia
937686|NCT02323945|incomplete spinal cord injury
937687|NCT02323945|strength
937688|NCT02323945|walking
937689|NCT02323945|breathing
937690|NCT02323919|myocardial infarction
937691|NCT02323919|coronary artery bypass graft (CABG)
937692|NCT02323919|angioplasty
937693|NCT02323919|exercise
937694|NCT02323919|cardiac patient
937695|NCT02323919|physical activity
937696|NCT02323906|Hepatocellular
937697|NCT02323906|Carcinoma
937698|NCT02323906|Phase 1
937699|NCT02323906|CC-122
937700|NCT02323906|Sorafenib,
937701|NCT02323906|Nexavar
937702|NCT02323906|Unresectable Hepatocellular Carcinoma
937703|NCT02323906|Unresectable HCCAdvanced,
937704|NCT02323906|Hepatocellular Carcinoma
937705|NCT02323906|liver cancer
937706|NCT02323893|Positron Emission Tomography
937707|NCT02323893|Cancer Immunotherapy
937708|NCT02323867|Transplant
937709|NCT02323867|Alternative Donor
937710|NCT02323854|primary, recurrent, metastatic lung tumor, ablation
937711|NCT02323841|cervical cancer
937712|NCT02323841|neoadjuvant chemotherapy
937713|NCT02323841|Adverse Effects
937714|NCT02323815|child acute malnutrition prevention
937715|NCT02323815|behavior change communication
937716|NCT02323815|lipid-based nutrient supplement
937717|NCT02323815|screening coverage
937718|NCT02323763|Magnetic Resonance Imaging
937719|NCT02323763|Bipolar Disorder
937720|NCT02323763|Suicidal Ideation
937721|NCT02323698|acute intermittent hypoxia
937722|NCT02323698|incomplete spinal cord injury
937723|NCT02323685|DCI
937724|NCT02323685|Delayed Cerebral Ischemia
937725|NCT02323685|SAH
937726|NCT02323685|Subarachnoid Hemorrhage
937727|NCT02323685|Aneurysmal Subarachnoid Hemorrhage
937728|NCT02323685|Cerebral Ischemia
937729|NCT02323685|Brain Ischemia
937730|NCT02323659|Mycosis Fungoides
937731|NCT02323659|Cutaneous T-Cell Lymphoma
937732|NCT02323659|Interferon
937733|NCT02323659|Methotrexate
937734|NCT02323646|uterine fibroids
937735|NCT02323646|leiomyoma
937736|NCT02323646|fibroid tumor
937737|NCT02323646|fibroma
937738|NCT02323633|Pediatric Attention Deficit Hyperactivity Disorder
937739|NCT02323620|Acute myocardial Infarction
937740|NCT02323620|bone marrow
937741|NCT02323620|stem cells
937742|NCT02323620|cardiovascular disease
937743|NCT02323620|mortality
937744|NCT02323581|Thoracoabdominal
937745|NCT02323581|Aneurysm
937746|NCT02323581|Endovascular
937747|NCT02323581|Stent-Graft
937748|NCT02323568|ovarian cancer
937749|NCT02323568|quality of life
937750|NCT02323568|remission more than 3 years
937751|NCT02323555|Cancer
937752|NCT02323555|chemotherapy
937753|NCT02323555|Targeted therapy
937754|NCT02323555|Day Hospital
937755|NCT02323542|Starch
937756|NCT02323542|cereal products
937757|NCT02323542|glucose kinetics
937758|NCT02323542|blood glucose
937759|NCT02323542|blood insulin
937760|NCT02323529|Orfadin
937761|NCT02323529|Nitisinone
937762|NCT02323529|NTBC
937763|NCT02323503|CRT-D
937764|NCT02323503|replacement
937765|NCT02323503|primary prevention
937766|NCT02323503|ventricular tachyarrhythmias
937767|NCT02323490|meniscus repair
937768|NCT02323490|bone marrow stimulation
937769|NCT02323477|cellular therapy
937770|NCT02323477|chronic ischemic heart disease
937771|NCT02323477|phase 1/2 clinical study
937772|NCT02323477|human umbilical cord multipotent stem cell
937773|NCT02323477|human umbilical cord mesenchymal stem cell
937774|NCT02323477|ischemic heart disease
937775|NCT02323477|bone marrow mononuclear cell
937776|NCT02323477|allogeneic stem cell transplantation
937777|NCT02323438|biomarkers of tobacco exposure
937778|NCT02323438|exposure
937779|NCT02323438|tobacco
937780|NCT02323438|nicotine
937781|NCT02323438|nicotine gum
937782|NCT02323438|electronic cigarette
937783|NCT02323438|e-cig
937784|NCT02323425|stroke
937785|NCT02323425|Remote ischemic postconditioning
937786|NCT02323425|symptomatic atherosclerotic intracranial arterial stenosis
937787|NCT02323412|Low back pain
937788|NCT02323412|Chronic
937789|NCT02323412|Modic Changes
937790|NCT02323412|MRI
937791|NCT02323412|epigenetics
937792|NCT02323412|antibiotics
937793|NCT02323412|randomized placebo controlled trial
937794|NCT02323386|Dynamic RSA
937795|NCT02323386|Knee
937796|NCT02323386|Total Knee Arthroplasty
937797|NCT02323386|Kinematic Analysis
937798|NCT02323373|Arthroplasty, Replacement, Knee
937799|NCT02323373|Tranexamic Acid
937800|NCT02323373|Drug Administration Routes
937801|NCT02323360|SBRT
937802|NCT02323360|TACE
937803|NCT02323360|TAE
937804|NCT02323321|heart transplant
937805|NCT02323321|heart preservation
937806|NCT02323321|beating heart transplant
937807|NCT02323295|Malignant bone tumors
937808|NCT02323282|Dose-response relationship
937809|NCT02323282|Drug
937810|NCT02323256|cochlear implant
937811|NCT02323256|deafness
937812|NCT02323256|audiometry
937813|NCT02323256|speech perception
937814|NCT02323256|severe to profound deafness restored with cochlear implantation
937815|NCT02323243|Detrusor striated sphincter dyssynergia
937816|NCT02323243|Temporary urethral stent
937817|NCT02323217|Imidazoline Receptor 2
937818|NCT02323217|(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole
937819|NCT02323217|BU99008
937820|NCT02323217|Radionuclide Imaging
937821|NCT02323217|Molecular Imaging
937822|NCT02323217|Healthy Volunteers
937823|NCT02323217|Alzheimer Disease
937824|NCT02323204|posttraumatic stress
937825|NCT02323178|Chronic myelomonocytic leukemia
937826|NCT02323178|thrombocytopenia
937827|NCT02323178|eltrombopag
937828|NCT02323152|women
937829|NCT02323152|high risk
937830|NCT02323139|High risk MDS
937831|NCT02323139|Azacitidine
937832|NCT02323139|LDE255
937833|NCT02323126|Non small cell lung cancer,
937834|NCT02323126|NSCLC,
937835|NCT02323126|EGFR-mutated,
937836|NCT02323126|EGF816,
937837|NCT02323126|INC280,
937838|NCT02323126|Nivolumab,
937839|NCT02323126|EGFR-T790M NSCLC,
937840|NCT02323126|EGFR wild-type (wt),
937841|NCT02323126|cMET positive NSCLC,
937842|NCT02323126|cMET negative NSCLC
937843|NCT02323113|Drug therapy
937844|NCT02323100|cystic fibrosis
937845|NCT02323100|corrector
937846|NCT02323100|glycerol phenylbutyrate
937847|NCT02323100|nasal potential difference
937848|NCT02323087|Antibiotic resistance
937849|NCT02323087|Point of care tests
937850|NCT02323087|Primary Health Care
937851|NCT02323022|AML
937852|NCT02323022|cladribine
937853|NCT02323022|induction therapy
937854|NCT02323009|Transpulmonary pressure
937855|NCT02323009|Esophageal balloon
937856|NCT02323009|Esophageal pressure monitoring device
937857|NCT02323009|Cstat
937858|NCT02323009|Static effective compliance
937859|NCT02323009|Ventilator weaning
937860|NCT02323009|Morbidly Obese Ventilator Dependent Tracheotomized Patients
937861|NCT02322983|Cerebral Palsy
937862|NCT02322983|Dental Care
937863|NCT02322983|Conscious Sedation
937864|NCT02322983|Autonomic Nervous System
937865|NCT02322983|Nitrous Oxide
937866|NCT02322970|intracranial hypertension
937867|NCT02322970|tcd
937868|NCT02322970|non invasive
937869|NCT02322970|ICP
937870|NCT02322944|acute myocardial infarction
937871|NCT02322944|quality improvement
937872|NCT02322944|reperfusion therapy
937880|NCT02322892|Thiamine
937881|NCT02322892|Vitamin B1
937882|NCT02322892|Coronary artery bypass grafting
937883|NCT02322892|Cardiac surgery
937884|NCT02322892|Lactate
937885|NCT02322892|Pyruvate dehydrogenase
937886|NCT02322879|acetaminophen
937887|NCT02322866|acne
937888|NCT02322853|Metastatic breast cancer
937889|NCT02322853|p38 map kinase
937890|NCT02322853|tamoxifen
937891|NCT02322853|LY2228820
937892|NCT02322853|Postmenopausal woman with advanced or metastatic breast cancer progressing on aromatase inhibitors (AI)
937893|NCT02322827|hiv/aids
937894|NCT02322788|Inhalation, Pharmacodynamic, Patients,
937895|NCT02322775|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases,
937896|NCT02322762|Type 2 diabetes mellitus
937897|NCT02322762|Anti-diabetic management patterns
937898|NCT02322749|bioequivalence
937899|NCT02322749|bioavailability
937900|NCT02322749|pharmacokinetics
937901|NCT02322749|Phase I
937902|NCT02322749|AZD6244
937903|NCT02322749|cancer
937904|NCT02322736|Metastatic Colorectal Cancer, wild type RAS, Panitumumab, Vectibix, Greece
937905|NCT02322723|Adalimumab
937906|NCT02322723|real life
937907|NCT02322723|RA
937908|NCT02322723|Humira
937909|NCT02322723|Rheumatoid Arthritis
937910|NCT02322723|effectiveness
937911|NCT02322710|non-inferiority
937912|NCT02322710|randomized
937913|NCT02322710|TulleGras
937914|NCT02322710|Urgotul
937915|NCT02322710|healing
937916|NCT02322710|surgical acute wounds
937917|NCT02322710|pain
937918|NCT02322697|Carnitine
937919|NCT02322697|hemodialysis
937920|NCT02322697|fatty acid
937921|NCT02322697|imaging
937922|NCT02322697|heart
937923|NCT02322684|Bougie
937924|NCT02322684|Air-Q
937925|NCT02322684|Insertion
937926|NCT02322671|chewable tablet
937927|NCT02322671|montelukast sodium
937928|NCT02322671|healthy adult subjects
937929|NCT02322671|relative bioavailability
937930|NCT02322671|GW483100
937931|NCT02322593|Gastric Cancer
937932|NCT02322593|Gastrointestinal Diseases
937933|NCT02322593|Gastrointestinal Neoplasms
937934|NCT02322593|First Line Treatment
937935|NCT02322593|Antineoplastic Agents
937936|NCT02322580|anti-TNF
937937|NCT02322580|therapeutic drug monitoring
937938|NCT02322580|immunogenicity
937939|NCT02322554|electronic health records
937940|NCT02322554|Qualified Clinical Data Registry
937941|NCT02322554|PQRS
937942|NCT02322554|quality reporting
937943|NCT02322554|cellular based products
937944|NCT02322554|bioengieered skin
937945|NCT02322554|USWR
937946|NCT02322528|Non-invasive instruments
937947|NCT02322528|Environment
937948|NCT02322528|Wavefront
937949|NCT02322528|Placido Disk
937950|NCT02322528|Ellipsometer
937951|NCT02322528|Thermal Imaging
937952|NCT02322515|Knee
937953|NCT02322515|Proprioception
937954|NCT02322515|Electromyography
937955|NCT02322515|Taping
937956|NCT02322502|laryngeal mask airway
937957|NCT02322502|desflurane
937958|NCT02322502|sevoflurane
937959|NCT02322502|propofol
937960|NCT02322489|microcurent
937961|NCT02322489|pain
937962|NCT02322489|flexibility
937963|NCT02322463|patients who were admitted to the pediatric ED
937964|NCT02322411|Stroke
937965|NCT02322411|Deglutition
937966|NCT02322411|Deglutition disorders
937967|NCT02322411|Resistance training
937968|NCT02322385|Autosomal Dominant Polycystic Kidney Disease
937969|NCT02322385|PKD 1 gene
937970|NCT02322385|PKD 2 gene
937971|NCT02322385|Truncational mutation
937972|NCT02322385|Hypomorphic mutation
937973|NCT02322372|femoral blockade
937974|NCT02322372|bupivacaine
937975|NCT02322346|posttonsillectomy pain
937976|NCT02322346|levobupivacaine
937977|NCT02322320|Multiple Myeloma
937978|NCT02322320|Lenalidomide
937979|NCT02322320|Maintenance Therapy
937980|NCT02322320|Progression
937981|NCT02322320|Long-term
937982|NCT02322320|Anti-Myeloma Agents
937983|NCT02322320|Hematologic Disorders
937991|NCT02322294|Protein
937992|NCT02322294|mung bean
937993|NCT02322294|glucose
937994|NCT02322294|triglycerides
937995|NCT02322294|insulin
937996|NCT02322294|body weight,
937997|NCT02322294|DXA scan
937998|NCT02322281|cancer
937999|NCT02322281|metastatic
938000|NCT02322281|locally advanced
938001|NCT02322281|lung
938002|NCT02322281|non-small cell lung cancer
938003|NCT02322281|NSCLC
938004|NCT02322281|epidermal growth factor receptor
938005|NCT02322281|EGFR
938006|NCT02322281|T790M
938007|NCT02322281|CO-1686
938008|NCT02322281|unresectable
938009|NCT02322281|recurrent
938010|NCT02322281|EGFR-directed therapy
938011|NCT02322281|irreversible EGFR inhibitor
938012|NCT02322281|TIGER
938013|NCT02322281|Rociletinib
938014|NCT02322268|Type 2 Diabetes Mellitus
938015|NCT02322268|Cosmos Caudatus
938016|NCT02322268|Ulam Raja
938017|NCT02322268|Metabolomic profiling
938018|NCT02322268|antioxidant
938019|NCT02322255|Natural History Study
938020|NCT02322255|Non-interventional Study
938021|NCT02322255|Observational Study
938022|NCT02322255|Heterotopic ossification
938023|NCT02322255|Fibrodysplasia Ossificans Progressiva
938024|NCT02322255|FOP disease progression
938025|NCT02322255|FOP flare-up progression
938026|NCT02322255|Clementia
938027|NCT02322255|Myositosis Ossificans Progressiva
938028|NCT02322255|Munchmeyer's Disease
938029|NCT02322255|FOP
938030|NCT02322255|Palovarotene
938031|NCT02322229|VMT
938032|NCT02322229|sVMA
938033|NCT02322229|vitrectomy
938034|NCT02322229|ocriplasmin
938035|NCT02322216|Allergies
938036|NCT02322216|Ocular
938037|NCT02322203|Niacin
938038|NCT02322203|Cholesterol
938039|NCT02322203|High-Density Lipoprotein
938040|NCT02322203|Low-Density Lipoprotein
938041|NCT02322203|Lipoproteins
938042|NCT02322190|Steroid Failure
938043|NCT02322190|Immunomodulation
938044|NCT02322190|Corticosteroid Therapy
938045|NCT02322177|Inborn Error of Metabolism
938046|NCT02322177|Pregnancy
938047|NCT02322177|Methylmalonic Acidemia
938048|NCT02322177|Urea Cycle Disorder
938049|NCT02322164|Skin
938050|NCT02322164|TEMPERATURE
938051|NCT02322164|Placebo
938052|NCT02322151|Filgrastim
938053|NCT02322151|Neupogen
938054|NCT02322151|Transplant
938055|NCT02322151|Breast Feeding
938056|NCT02322151|Concentration
938057|NCT02322125|walking
938058|NCT02322125|locomotion
938059|NCT02322125|rehabilitation
938060|NCT02322112|Dietary Fiber
938061|NCT02322112|Gastrointestinal Microbiome
938062|NCT02322112|Overweight and Obesity
938063|NCT02322112|Personalized Nutrition
938064|NCT02322112|Inflammation
938065|NCT02322112|Metabolism
938066|NCT02322099|human immunodeficiency virus
938067|NCT02322099|bone diseases
938068|NCT02322099|osteopenia
938069|NCT02322099|osteoporosis
938070|NCT02322099|fracture
938071|NCT02322099|bone turnover
938072|NCT02322099|alendronate
938073|NCT02322099|antiretroviral
938074|NCT02322060|IVA, ovary tissue grafting, POI
938075|NCT02322034|chronic heart failure
938076|NCT02322034|multiple neurohormonal axis disequilibrium
938077|NCT02322034|growth hormone deficiency
938078|NCT02322034|Insulin-like growth factor-1 (IGF-1)
938079|NCT02322034|metabolic deficiency syndrome
938080|NCT02322034|interval training
938086|NCT02321982|Mohs surgery
938087|NCT02321982|Preoperative consultation
938088|NCT02321969|Chemoprevention
938089|NCT02321969|Colorectal adenomatous polyp
938090|NCT02321969|Green tea extract
938091|NCT02321956|ASA class 1,2
938092|NCT02321956|age 1-6 years
938093|NCT02321956|General anesthesia with ETT
938094|NCT02321930|Rheumatoid Arthritis
938095|NCT02321930|Musculoskeletal Ultrasound
938096|NCT02321930|Tofacitinib
938097|NCT02321930|biomarker
938098|NCT02321904|Confocal microscopy
938099|NCT02321904|Cornea
938100|NCT02321904|Neuropathy
938101|NCT02321904|Detection
938102|NCT02321904|Diabetes
938103|NCT02321839|neovascular age-related macular degeneration
938104|NCT02321839|Ranibizumab
938105|NCT02321839|Treat and extend
938106|NCT02321813|quality of life
938107|NCT02321813|colorectal cancer
938108|NCT02321813|definitive RCT
938109|NCT02321813|complex intervention
938110|NCT02321800|S-649266
938111|NCT02321800|complicated urinary tract infection
938112|NCT02321800|cefiderocol
938113|NCT02321800|acute uncomplicated pyelonephritis
938114|NCT02321800|Gram-negative pathogens
938115|NCT02321800|imipenem/cilastatin
938116|NCT02321787|Anesthesia, Caudal
938117|NCT02321787|Ultrasonography
938118|NCT02321774|Stress
938119|NCT02321774|Virtual Reality
938120|NCT02321774|Wearable Sensor
938121|NCT02321774|Wellness
938122|NCT02321761|Amantadine hydrochloride
938123|NCT02321761|Rehabilitation
938124|NCT02321761|Acquired Brain Injury
938125|NCT02321761|TBI
938126|NCT02321748|HSV
938127|NCT02321748|Herpes
938128|NCT02321748|volunteers
938129|NCT02321748|drug-drug interaction
938130|NCT02321735|Long-Term Survivor
938131|NCT02321735|Genomic
938132|NCT02321735|Survivorship
938133|NCT02321735|Quality of Life
938134|NCT02321722|Colonoscopy
938135|NCT02321696|physiotherapy
938136|NCT02321696|manual therapy
938137|NCT02321696|acupuncture
938138|NCT02321696|eccentric exercise
938139|NCT02321670|operative technique
938140|NCT02321644|CC-90001
938141|NCT02321644|PHARMACOKINETICS
938142|NCT02321644|PHARMACODYNAMICS
938143|NCT02321644|HEALTHY SUBJECTS
938144|NCT02321644|SINGLE DOSE
938145|NCT02321644|MULTIPLE DOSE
938146|NCT02321644|PUNCH BIOPSY
938147|NCT02321631|Malnourished
938148|NCT02321631|Head and Neck Cancer
938149|NCT02321631|Surgery
938150|NCT02321618|Hypertension
938151|NCT02321618|High Blood Pressure
938152|NCT02321618|African American men
938153|NCT02321618|Black men
938154|NCT02321618|barbershop
938155|NCT02321605|Best Possible Self
938156|NCT02321605|Positive Psychology
938157|NCT02321605|Optimism
938158|NCT02321605|Positive Technology
938159|NCT02321605|Future Thinking
938160|NCT02321592|Hodgkin Lymphoma
938161|NCT02321592|AFM13
938162|NCT02321592|Natural Killer Cells
938163|NCT02321553|metabolic syndrome
938164|NCT02321553|glucose
938165|NCT02321553|cholesterol
938166|NCT02321553|brown rice
938167|NCT02321553|inflammation
938168|NCT02321553|oxidative stress
938169|NCT02321540|Lung Cancer
938170|NCT02321540|Non-small cell lung cancer
938171|NCT02321540|NSCLC
938172|NCT02321540|Epidermal growth factor receptor mutations
938173|NCT02321540|EGFR
938174|NCT02321540|Recurrent non-small cell lung cancer
938175|NCT02321540|Ibrutinib
938176|NCT02321540|PCI-32765
938177|NCT02321540|Imbruvica
938178|NCT02321527|Breast Cancer
938179|NCT02321527|Microbubble contrast-enhanced ultrasound
938180|NCT02321527|CEUS
938181|NCT02321527|Sentinel lymph nodes
938182|NCT02321527|SLN
938183|NCT02321527|Perflutren Protein-Type A Microspheres Injectable Suspension
938184|NCT02321527|OPTISON™
938185|NCT02321527|Ultrasound
938186|NCT02321527|Breast biopsy
938187|NCT02321527|Radioactive seed
938188|NCT02321527|Phone call
938189|NCT02321527|Fine needle aspiration
938190|NCT02321527|FNA
938210|NCT02321475|Psycho-emotional symptoms
938211|NCT02321462|preparation
938212|NCT02321423|Nail Dystrophy
938213|NCT02321423|Plantar Keratoderma
938214|NCT02321423|Palmar Keratoderma
938215|NCT02321423|Leukokeratosis
938216|NCT02321423|Cysts
938217|NCT02321423|Pain
938218|NCT02321423|KRT17
938219|NCT02321423|KRT16
938220|NCT02321423|KRT6A
938221|NCT02321423|KRT6B
938222|NCT02321423|KRT6C
938223|NCT02321397|oxycodone naloxone combination
938224|NCT02321397|severe chronic and non-malignant pain
938225|NCT02321397|Malignant and non-malignant pain that requires around-the clock opioid therapy
938226|NCT02321358|Behavior Change
938227|NCT02321358|Objectively Measured Physical Activity
938228|NCT02321358|Survivorship
938229|NCT02321345|Allogeneic Stem Cell Transplant
938230|NCT02321345|Hematological Malignancies
938231|NCT02321345|Palliative Care
938232|NCT02321345|Supportive care
938233|NCT02321332|Palmar hyperhidrosis
938234|NCT02321332|Endoscopic thoracic sympathectomy
938235|NCT02321319|chronic pain
938236|NCT02321319|pediatric
938237|NCT02321293|curcumin
938238|NCT02321293|lung cancer
938239|NCT02321293|TKI
938240|NCT02321267|AMD
938241|NCT02321267|PCV
938242|NCT02321267|RAP
938243|NCT02321267|RVO
938244|NCT02321267|DME
938245|NCT02321267|ERM
938246|NCT02321267|MH
938247|NCT02321267|mCNV
938248|NCT02321254|Stroke
938249|NCT02321254|Upper limb
938250|NCT02321254|Robotics
938251|NCT02321254|Electromyography
938252|NCT02321254|Rehabilitation
938253|NCT02321241|Wet-AMD
938254|NCT02321241|Refractory patients to ranibizumab
938255|NCT02321241|Real life
938256|NCT02321241|Switch
938257|NCT02321241|Aflibercept
938258|NCT02321228|Salpingectomy
938259|NCT02321228|Delayed oophorectomy
938260|NCT02321228|Salpingo-oophorectomy
938261|NCT02321228|Quality of life
938262|NCT02321228|Ovarian cancer
938263|NCT02321228|BRCA
938264|NCT02321215|AECOPD
938265|NCT02321215|COPD
938266|NCT02321215|education
938267|NCT02321202|omega-3
938268|NCT02321202|Progression
938269|NCT02321202|parenteral nutrition
938270|NCT02321150|Pterygium
938271|NCT02321150|Pterygiums
938272|NCT02321150|Pterygia
938273|NCT02321150|Graft
938274|NCT02321150|Autograft
938275|NCT02321150|Excision
938276|NCT02321150|Surgery
938277|NCT02321150|Eye
938278|NCT02321150|electrocautery
938279|NCT02321150|polyglactin
938280|NCT02321124|Constipation
938281|NCT02321124|connective tissue manipulation
938282|NCT02321124|conservative therapy
938283|NCT02321124|massage
938284|NCT02321124|randomized controlled trial
938285|NCT02321111|Insulin signaling and glucose disposal in muscle
938286|NCT02321111|Hepatic insulin sensitivity
938287|NCT02321111|TLR4 signaling and inflammatory gene expression
938288|NCT02321111|Plasma cytokine concentration
938289|NCT02321111|Intramyocellular diacylglycerol and ceramide content
938290|NCT02321098|Onychomycosis
938291|NCT02321098|antifungal
938292|NCT02321072|oxygen
938293|NCT02321072|hypoxia
938294|NCT02321072|hyperoxia
938295|NCT02321072|critical care
938296|NCT02321072|intensive care
938297|NCT02321059|incisional hernia
938298|NCT02321059|hernia
938299|NCT02321059|abdominal wall strength
938300|NCT02321059|validation
938301|NCT02321059|physical activity
938303|NCT02321033|glycemic index
938304|NCT02321033|inactivity
938305|NCT02321033|insulin sensitivity
938306|NCT02321033|metabolic flexibility
938307|NCT02321033|arterial stiffness
938308|NCT02321033|young men
938309|NCT02320994|stroke
938310|NCT02320994|aftercare
938311|NCT02320981|GERD
938312|NCT02320981|EGD
938313|NCT02320981|pH testing
938314|NCT02320981|eosinophilic esophagitis
938315|NCT02320981|impedance testing
938316|NCT02320955|autologous bone flap
938317|NCT02320955|decompressive craniectomy
938318|NCT02320955|malignant brain swelling
938319|NCT02320955|patient specific implant
938320|NCT02320955|bone resorption
938321|NCT02320955|aseptic bone necrosis
938322|NCT02320942|Bone Marrow Transplantation
938323|NCT02320942|Exercise
938324|NCT02320942|Rehabilitation
938325|NCT02320942|Cancer
938331|NCT02320903|Criminal Justice
938332|NCT02320903|Juvenile Delinquency
938333|NCT02320890|transcranial direct current stimulation
938334|NCT02320890|tDCS
938335|NCT02320890|Mild Cognitive Impairment
938336|NCT02320890|MCI
938337|NCT02320864|muscle strength
938338|NCT02320864|muscle weakness
938339|NCT02320864|hospitalization
938340|NCT02320864|surgery
938341|NCT02320864|total knee replacement
938342|NCT02320851|Somatoform disorder
938343|NCT02320851|Functional vertigo/dizziness
938344|NCT02320851|Chronic subjective dizziness
938345|NCT02320838|Transcutaneous Electric Nerve Stimulation
938346|NCT02320838|Electric Stimulation Therapy
938347|NCT02320838|Unmodulated Alternating Currents
938348|NCT02320838|Neural Conduction
938349|NCT02320838|Pain Threshold
938350|NCT02320825|Stereotactic Radiosurgery (SRS)
938351|NCT02320825|Single-Fraction
938352|NCT02320825|Hypofractionated
938353|NCT02320825|Spinal surgery
938354|NCT02320825|14-233
938355|NCT02320799|interpersonal psychotherapy
938356|NCT02320799|HIV
938357|NCT02320799|women
938358|NCT02320799|gender based violence
938359|NCT02320799|mental health
938360|NCT02320799|africa
938361|NCT02320799|kenya
938362|NCT02320799|global mental health
938363|NCT02320799|HIV treatment adherence
938364|NCT02320786|Power mobility
938365|NCT02320786|Wheelchair skills training
938366|NCT02320786|Spinal Cord Injury
938367|NCT02320773|Overactive Bladder
938368|NCT02320773|Quality of Life
938369|NCT02320773|Betanis®
938370|NCT02320773|Betmiga®
938371|NCT02320773|Observational
938372|NCT02320773|Myrbetriq®
938373|NCT02320747|Volunteers
938374|NCT02320734|surgical rating scale
938375|NCT02320734|neuromuscular relaxation
938376|NCT02320734|Anaesthesia
938377|NCT02320734|minimally invasive esophagectomy
938378|NCT02320708|Molar,third; Teeth,wisdom; Pain, Postoperative; Dental Surgery; Third molar extraction
938379|NCT02320643|Partially absorbable mesh
938380|NCT02320617|Lung Neoplasms
938381|NCT02320617|diffusion weighted MRI
938382|NCT02320617|ADC value
938383|NCT02320617|treatment effect
938384|NCT02320604|Liposomal amphotericin B
938385|NCT02320604|AmBisome
938386|NCT02320604|Pharmacokinetics
938387|NCT02320604|Obesity
938388|NCT02320604|Bariatric surgery
938389|NCT02320578|Neoadjuvant Chemoptherapy
938390|NCT02320578|Laparoscopy 3D
938391|NCT02320578|Cervical cancer
938392|NCT02320565|Endometrial Cancer
938393|NCT02320565|Laparoscopy 3D
938394|NCT02320552|Nutritional assessment
938395|NCT02320539|MicroRNA
938396|NCT02320539|Cerebrospinal fluid
938397|NCT02320526|Exercise
938398|NCT02320526|Training
938399|NCT02320526|Interval training
938400|NCT02320526|Systemic inflammation
938401|NCT02320526|Glucose disposal
938402|NCT02320526|Insulin sensitivity
938403|NCT02320526|Glucose effectiveness
938404|NCT02320513|Exercise
938405|NCT02320461|diabetes mellitus
938406|NCT02320461|cardiovascular diseases
938407|NCT02320461|cohort studies
938408|NCT02320461|hypertension
938409|NCT02320461|obesity
938410|NCT02320461|smoking
938411|NCT02320461|social class
938412|NCT02320422|liver transplant
938413|NCT02320422|medication adherence
938414|NCT02320422|intervention
938415|NCT02320409|Subjects
938416|NCT02320383|CLL
938417|NCT02320357|Platelet activation
938418|NCT02320357|CD40 ligand
938419|NCT02320357|CD154
938420|NCT02320357|Interferon alpha
938421|NCT02320357|clopidogrel
938422|NCT02320318|Irritable Bowel Syndrome
938423|NCT02320318|Colon, irritable
938424|NCT02320318|Bowel disease
938425|NCT02320318|Diarrhea
938426|NCT02320279|Fetal Heart Rate
938427|NCT02320279|Fetal EKG
938428|NCT02320279|FHR tracing
938429|NCT02320279|fetal R-waves
938430|NCT02320266|Deep Brain Stimulation Surgery
938431|NCT02320253|Diabetes
938432|NCT02320253|Obesity
938433|NCT02320253|Primary Care
938434|NCT02320253|Lifestyle Intervention
938435|NCT02320240|antidepressants
938436|NCT02320240|acute kidney injury
938437|NCT02320240|SNRI
938438|NCT02320240|renal failure
938439|NCT02320240|duloxetine
938440|NCT02320240|CNODES
938441|NCT02320188|modification of treatment planned
938442|NCT02320188|Exercise
938443|NCT02320175|family centered rounds
938444|NCT02320175|patient safety
938445|NCT02320175|errors
938446|NCT02320175|adverse events
938447|NCT02320175|concordance
938448|NCT02320175|patient experience
938449|NCT02320149|acne
938450|NCT02320123|Terminal Care
938451|NCT02320123|Decision Making
938452|NCT02320123|Communication
938453|NCT02320110|Irisin
938454|NCT02320110|Adiponectin
938455|NCT02320110|Leptin
938456|NCT02320110|Insulin resistance
938457|NCT02320110|Body Mass Index
938458|NCT02320110|Obesity
938459|NCT02320110|Metabolic Syndrome
938460|NCT02320110|Lipid Profile
938461|NCT02320110|Diabetes Mellitus
938462|NCT02320084|HT-1
938463|NCT02320084|Hereditary Tyrosinemia, Type I
938464|NCT02320084|hypertyrosinemia type 1
938465|NCT02320084|Orfadin
938466|NCT02320084|Long term safety
938467|NCT02320084|Hereditary Tyrosinemia Type 1
938468|NCT02320032|Alkermes
938469|NCT02320032|Schizophrenia
938470|NCT02320032|Aripiprazole
938471|NCT02320032|Aripiprazole lauroxil
938472|NCT02320032|ALKS 9072
938473|NCT02320006|hydrotubation
938474|NCT02320006|incomplete fallopian tube obstructive infertility
938475|NCT02320006|Acupuncture
938476|NCT02319993|Suan-Zao-Ren Tang
938477|NCT02319993|Tian-wang-bu-xin-dan
938478|NCT02319993|Traditional Chinese Medicine
938479|NCT02319993|Herbs
938480|NCT02319993|Quality of life
938481|NCT02319967|community health worker
938482|NCT02319967|emergency
938483|NCT02319967|asthma
938484|NCT02319941|Inhibition of Platelet Reactivity
938485|NCT02319941|ticagrelor
938486|NCT02319941|clopidogrel
938487|NCT02319941|Pharmacodynamics
938488|NCT02319941|Pharmacokinetics
938489|NCT02319915|tranexamic acid
938490|NCT02319915|knee prosthesis
938491|NCT02319915|pharmacokinetic profile
938492|NCT02319863|hepatocellular carcinoma
938493|NCT02319863|prognosis
938494|NCT02319850|sarcopenia
938495|NCT02319850|screening
938496|NCT02319850|geriatrics
938497|NCT02319850|muscle
938498|NCT02319850|aging
938499|NCT02319850|ultrasound
938500|NCT02319798|Crohn's disease
938501|NCT02319798|ulcerative colitis
938502|NCT02319798|Inflammatory bowel disease
938503|NCT02319798|IBD
938504|NCT02319772|Healthy volunteers
938505|NCT02319772|Ebola virus
938506|NCT02319772|Filovirus
938507|NCT02319759|Psoriatic Arthritis
938508|NCT02319759|Guselkumab
938509|NCT02319759|Ustekinumab
938510|NCT02319759|Placebo
938511|NCT02319694|Basal Ganglia
938512|NCT02319694|Behavior
938513|NCT02319694|Behavioral
938514|NCT02319694|Brain
938515|NCT02319694|Cognitive
938516|NCT02319694|Computer Simulation
938517|NCT02319694|Cues
938518|NCT02319694|Data
938519|NCT02319694|Deep Brain Stimulation
938520|NCT02319694|Disease
938521|NCT02319681|Caregivers
938522|NCT02319681|Anxiety
938523|NCT02319681|Depression
938524|NCT02319655|Epiretinal membrane
938525|NCT02319655|Macular pucker
938526|NCT02319655|Membrane peeling
938527|NCT02319655|pars plana vitrectomy
938528|NCT02319655|Air
938529|NCT02319655|balanced salt solution
938530|NCT02319655|Intraoperative OCT
938531|NCT02319655|Hyporeflectivity
938532|NCT02319655|Retina
938533|NCT02319642|Rheumatoid Arthritis
938534|NCT02319642|TNFα antagonist
938535|NCT02319642|Certolizumab pegol
938536|NCT02319642|Chinese patients
938537|NCT02319642|Open-label
938538|NCT02319629|Morbid obesity,
938539|NCT02319629|Cholelithiasis
938540|NCT02319629|Bariatric surgery
938541|NCT02319629|Ursodiol
938542|NCT02319577|NSCLC
938543|NCT02319577|EGFR
938544|NCT02319577|vinorelbine
938545|NCT02319577|gefitinib
938546|NCT02319564|Wheeze
938547|NCT02319564|Asthma
938548|NCT02319564|Randomized Trial
938549|NCT02319564|Pre-school aged children
938550|NCT02319525|lupus nephritis
938551|NCT02319525|lupus
938552|NCT02319525|decision-making
938553|NCT02319525|minorities
938554|NCT02319525|immunosuppressive medications
938555|NCT02319525|decision-aid
938556|NCT02319525|treatment
938557|NCT02319525|Decision conflict
938558|NCT02319525|SLE
938559|NCT02319486|Retinoblastoma
938560|NCT02319486|carboplatin
938561|NCT02319473|system of care
938562|NCT02319473|acute myocardial infarction
938563|NCT02319473|registry
938564|NCT02319473|Primary PCI
938565|NCT02319473|Fibrinolytic therapy
938566|NCT02319460|Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding
938567|NCT02319460|Warfarin Reversal
938568|NCT02319447|Living Donation
938569|NCT02319447|Kidney Transplantation
938570|NCT02319421|Alarm fatigue
938571|NCT02319395|Parkinson's Disease
938572|NCT02319395|Behaviour addiction
938573|NCT02319395|Dopamine agonist
938574|NCT02319395|Genetic.
938575|NCT02319382|Parkinson Disease
938576|NCT02319382|[18F]DPA-714
938577|NCT02319382|Positron emission tomography (PET)
938578|NCT02319382|Neuroinflammation
938579|NCT02319343|Glucocorticoid
938580|NCT02319343|Quadriceps muscle function
938581|NCT02319343|Knee arthroplasty, total
938582|NCT02319330|HIV
938583|NCT02319330|Adherence
938584|NCT02319330|Mental health
938585|NCT02319330|Depression
938586|NCT02319330|Women
938587|NCT02319330|Mobile phone technology
938588|NCT02319330|eHealth
938589|NCT02319330|India
938590|NCT02319304|Pelvic Radiotherapy
938591|NCT02319304|Rectal Adenocarcinoma
938592|NCT02319265|sepsis
938593|NCT02319265|antioxidant
938594|NCT02319265|melatonin
938595|NCT02319265|inflammation
938596|NCT02319239|Prostate neoplasms
938597|NCT02319239|Urogenital neoplasms
938598|NCT02319239|Genital neoplasms, male
938599|NCT02319239|Radiation therapy
938600|NCT02319239|PSA
938601|NCT02319239|DW-MRI, diffusion weighted MRI
938602|NCT02319239|Intra-fractional movement
938603|NCT02319239|Hypofractionated radiotherapy
938604|NCT02319239|Stereotactic
938605|NCT02319239|Toxicity due to radiotherapy
938606|NCT02319239|Quality of life
938607|NCT02319213|Intra-abdominal pressure,
938608|NCT02319213|intraocular pressure,
938609|NCT02319213|abdominal hypertension,
938610|NCT02319213|laparoscopy,
938611|NCT02319213|critical care
938612|NCT02319200|Chemoprevention
938613|NCT02319200|Decompensation of cirrhosis
938614|NCT02319200|Hepatocellular Carcinoma
938615|NCT02319200|Death
938616|NCT02319200|Efficacy
938617|NCT02319200|Safety
938618|NCT02319187|Esophageal Neoplasms
938619|NCT02319161|intravenous regional anesthesia
938620|NCT02319135|Acute Myeloid Leukemia
938621|NCT02319122|Cerebral Palsy
938622|NCT02319122|Muscle structure
938623|NCT02319122|Strength training
938624|NCT02319096|Whole body vibration therapy
938625|NCT02319096|pelvic floor muscle training
938626|NCT02319096|stress urinary incontinence
938627|NCT02319083|CABG
938628|NCT02319083|Coronary artery bypass surgery
938629|NCT02319083|Coronary artery bypass grafting
938630|NCT02319083|Coronary surgery
938631|NCT02319083|Myocardial infarction
938632|NCT02319083|Coronary artery disease
938633|NCT02319083|Off-pump
938634|NCT02319083|EuroSCORE
938635|NCT02319070|Cost
938636|NCT02319070|Clinical Outcomes
938637|NCT02319070|Quality of Life
938638|NCT02319070|On Demand Treatment
938639|NCT02319070|Secondary Prophylaxis
938640|NCT02319057|Healthy volunteer study
938641|NCT02319044|Head and neck cancer; SCCHN
938642|NCT02319005|Cardiomyopathy
938643|NCT02319005|Heart Failure
938644|NCT02319005|FAC
938645|NCT02319005|Amyloid
938646|NCT02319005|Transthyretin
938647|NCT02319005|TTR
938648|NCT02319005|RNAi therapeutic
938649|NCT02318953|Telemedicine
938650|NCT02318953|Ambulatory Surgical Procedures
938651|NCT02318953|Postoperative Care
938652|NCT02318953|Cost Effectiveness
938653|NCT02318953|Mobile Applications
938654|NCT02318953|Health Services Research
938655|NCT02318953|Breast Reconstruction
938656|NCT02318940|ultrasound guided
938657|NCT02318940|femoral vein
938658|NCT02318940|central venous catheter
938659|NCT02318940|pediatric
938660|NCT02318927|Deep Brain Stimulation
938661|NCT02318914|Pyoderma Gangrenosum
938662|NCT02318914|Classic Pyoderma Gangrenosum
938664|NCT02318875|Inflammation
938665|NCT02318875|swell
938666|NCT02318875|pain
938667|NCT02318875|functional impairment
938668|NCT02318875|stiffness
938669|NCT02318862|reflux
938670|NCT02318862|GERD
938671|NCT02318862|EGD
938672|NCT02318862|pH testing
938673|NCT02318849|designated organ donor, college students
938674|NCT02318836|hepatic, hepatic impairment, lofexidine
938675|NCT02318823|social neuroscience
938676|NCT02318823|emotion
938677|NCT02318823|face recognition
938678|NCT02318823|empathy
938679|NCT02318823|beer
938680|NCT02318823|alcohol
938681|NCT02318823|social cognition
938682|NCT02318810|Muscle relaxants
938683|NCT02318797|Chronic disease
938684|NCT02318797|Mental Health
938685|NCT02318797|Behavioral Health
938686|NCT02318797|Community mental health centers
938687|NCT02318797|Intervention studies
938688|NCT02318797|Mixed methods
938689|NCT02318797|Qualitative research
938690|NCT02318784|neuroendocrine malignancies
938691|NCT02318784|pancreatic neuroendocrine tumors (PNETs)
938692|NCT02318784|gastrointestinal (GI) carcinoids
938693|NCT02318784|carfilzomib
938694|NCT02318784|Kyprolis
938695|NCT02318784|proteasome inhibitors
938696|NCT02318758|This is a healthy volunteer study.
938697|NCT02318745|Family Therapy
938698|NCT02318745|Substance abuse prevention
938699|NCT02318745|Minority
938700|NCT02318745|randomized trials
938701|NCT02318745|outcome research
938702|NCT02318745|adolescent treatment
938703|NCT02318732|violence
938704|NCT02318719|Post-Herpetic Neuralgia
938705|NCT02318719|Developmental Phase III
938706|NCT02318706|Diabetic Peripheral Neuropathic Pain
938707|NCT02318641|oxygen consumption
938708|NCT02318641|retinal oximetry
938709|NCT02318628|Cardio ankle vascular index
938710|NCT02318628|CAVI
938711|NCT02318628|pulse wave velocity
938712|NCT02318628|PWV
938713|NCT02318628|Non invasive arterial structure assessment
938714|NCT02318615|Breast Neoplasm
938715|NCT02318615|Lymphedema
938716|NCT02318615|Autologous flap
938717|NCT02318615|lattismus dorsi flap
938718|NCT02318602|Lennox-Gastaut syndrome
938719|NCT02318602|Dravet syndrome
938720|NCT02318602|Treatment-resistant seizures
938721|NCT02318576|Multiple Sclerosis
938722|NCT02318563|Treatment-resistant seizures
938723|NCT02318537|Treatment-resistant seizures
938724|NCT02318472|Microdialysis
938725|NCT02318472|Patient related outcome
938726|NCT02318472|Heel rise test
938727|NCT02318472|Immobilization
938728|NCT02318446|Anti-epileptic drugs
938729|NCT02318446|Folic acid
938730|NCT02318446|Homocysteine
938731|NCT02318433|DRF
938732|NCT02318433|PTOA
938733|NCT02318433|dexamethasone
938734|NCT02318420|Obstetrics
938735|NCT02318420|Partogram
938736|NCT02318420|ePartogram
938737|NCT02318420|eHealth
938738|NCT02318420|Low-income
938739|NCT02318420|Quality of care
938740|NCT02318420|Perinatal death
938741|NCT02318420|Maternal death
938742|NCT02318420|Cesarean section
938743|NCT02318420|Health information technology
938744|NCT02318394|advanced solid tumors; immunotherapy; OX40; immuno-oncology
938745|NCT02318381|suprascapular nerve
938746|NCT02318381|rotator cuff tear
938747|NCT02318381|suprascapular neuropathy
938748|NCT02318381|superior transverse scapular ligament
938749|NCT02318355|hemodilution
938750|NCT02318355|hemorrhage
938751|NCT02318355|trauma
938752|NCT02318355|lactate
938753|NCT02318355|base deficit
938754|NCT02318355|randomized control trial
938755|NCT02318329|FGFR2b, FGFR2, FGFR, bladder neoplasms, esophageal cancer
938756|NCT02318316|Exhaled breath condensate
938757|NCT02318316|allogeneic stem cell transplantation
938758|NCT02318316|pulmonary complications
938759|NCT02318290|Analgesia
938760|NCT02318290|Critical Care
938761|NCT02318290|Hypnotics and Sedatives
938762|NCT02318251|Power, rate of force development
938763|NCT02318251|involuntary
938764|NCT02318251|reflexive
938765|NCT02318238|evaluation
938766|NCT02318238|exercise tolerance
938767|NCT02318238|healthy children
938768|NCT02318238|6MWT
938769|NCT02318225|Misoprostol
938770|NCT02318225|Office hysteroscopy
938771|NCT02318225|Pain
938772|NCT02318212|Cervical dilatation
938773|NCT02318199|emergence agitation
938774|NCT02318199|intracranial surgery
938775|NCT02318199|general anesthesia
938776|NCT02318199|incidence
938777|NCT02318199|risk factor
938778|NCT02318186|pharmacokinetic analysis
938779|NCT02318186|remodulin
938780|NCT02318186|trepostinil
938781|NCT02318186|pulmonary arterial hypertension
938782|NCT02318173|Cervical dilatation
938783|NCT02318160|Autoimmune Thyroiditis
938784|NCT02318160|Oxidative Status
938785|NCT02318160|Children
938786|NCT02318147|Severe acute pancreatitis
938787|NCT02318147|Fecal Microbiota Transplantation
938788|NCT02318147|Bacterial Translocation
938789|NCT02318147|Infectious Complications
938790|NCT02318134|Severe acute pancreatitis
938791|NCT02318134|Fecal Microbiota Transplantation
938792|NCT02318134|Intestinal barrier dysfunction
938793|NCT02318134|Intestinal flora
938794|NCT02318121|Labor, prolonged labor, augmentation of labor
938795|NCT02318108|Organizational Innovation
938796|NCT02318108|Primary Health Care
938797|NCT02318095|Cancer of the pancreas
938798|NCT02318082|Chronic versus Graft Host Disease
938799|NCT02318069|immune response
938800|NCT02318069|TBE-vaccine
938801|NCT02318069|elderly
938802|NCT02318069|additional doses
938803|NCT02318056|hand
938804|NCT02318056|burns
938805|NCT02318056|thermal
938806|NCT02318056|dressing
938807|NCT02318056|Aquacel®
938808|NCT02318056|Mepilex® Transfer Ag
938809|NCT02318056|Xeroform®
938810|NCT02318056|Bacitracin®
938811|NCT02318056|partial thickness
938812|NCT02318056|epithelialization
938813|NCT02318056|wound healing
938814|NCT02318056|scar
938815|NCT02318056|scarring
938816|NCT02318043|adenosine monophosphate
938817|NCT02318043|histamine
938818|NCT02318043|bronchial provocation test
938819|NCT02318043|asthma symptom score
938820|NCT02318043|asthma control
938821|NCT02318030|Transplant
938822|NCT02318030|Adaptive Immunity
938823|NCT02318030|EBV
938824|NCT02318030|Medication Adherence
938825|NCT02318030|Tacrolimus
938826|NCT02318030|PTLD
938827|NCT02318017|adhd
938828|NCT02318017|global network
938829|NCT02318017|eeg
938830|NCT02318004|telemonitoring
938831|NCT02317991|gastroesophageal adenocarcinoma
938832|NCT02317991|nab-paclitaxel
938833|NCT02317991|Abraxane
938834|NCT02317991|ramucirumab
938835|NCT02317991|Cyramza
938836|NCT02317991|GE junction
938837|NCT02317913|Kawasaki disease
938838|NCT02317913|Epidemiology
938839|NCT02317913|Incidence
938840|NCT02317913|Coronary arterial lesions
938841|NCT02317913|Shanghai
938846|NCT02317848|Diagnosis
938847|NCT02317848|prognostic marker
938848|NCT02317848|polygraphy
938849|NCT02317848|echocardiography
938850|NCT02317848|ECG
938851|NCT02317809|Healthy
938852|NCT02317809|Pergoveris
938853|NCT02317809|Bioequivalence
938854|NCT02317809|Infertility
938855|NCT02317770|lidocaine, esophago-gastro-duodenoscopy
938856|NCT02317757|elderly cancer patients, chemotherapy toxicity
938857|NCT02317731|bowel preparation
938858|NCT02317718|serum vitamin D levels
938859|NCT02317718|IVF
938860|NCT02317718|ovarian reserve
938861|NCT02317718|25 OHD3
938862|NCT02317718|pregnancy outcome
938863|NCT02317666|polypharmacy
938864|NCT02317666|drug burden index
938865|NCT02317666|aged
938866|NCT02317666|medication review
938867|NCT02317666|cholinergic agents
938868|NCT02317640|Testosterone
938869|NCT02317640|Electrical Stimulation
938870|NCT02317640|Stand Training
938871|NCT02317614|Incentives
938872|NCT02317614|Smartphone
938873|NCT02317614|Mobile intervention
938874|NCT02317614|eDOT
938875|NCT02317614|Adherence reinforcement
938876|NCT02317614|Drug users
938877|NCT02317588|Oxylipins
938878|NCT02317588|Flax oil
938879|NCT02317588|Fish oil
938880|NCT02317562|Peripheral neuropathy
938881|NCT02317562|Disimmune disease
938882|NCT02317562|Neurology chronic disease
938883|NCT02317562|Rare disease
938884|NCT02317549|sepsis
938885|NCT02317549|septic shock
938886|NCT02317549|vasodilatory shock
938887|NCT02317549|circulatory shock
938888|NCT02317549|Systemic Inflammatory Response Syndrome
938889|NCT02317549|SIRS
938890|NCT02317549|infection
938891|NCT02317549|toxemia
938892|NCT02317549|gut barrier breakdown
938893|NCT02317549|autodigestion
938894|NCT02317549|multiorgan failure
938895|NCT02317549|MOF
938896|NCT02317549|multiorgain dysfunction syndrome
938897|NCT02317549|MODS
938898|NCT02317549|hyperlactatemia
938899|NCT02317549|tissue hypoxia
938900|NCT02317536|Muscle function
938901|NCT02317536|L-Carnitine
938902|NCT02317536|Carnipure
938903|NCT02317536|DXA
938904|NCT02317536|anabolism
938905|NCT02317536|6 minute walk
938906|NCT02317536|dynamometry
938907|NCT02317536|muscle biopsy
938908|NCT02317523|Dementia
938909|NCT02317523|Caregiver
938910|NCT02317523|Cardiovascular Disease
938911|NCT02317523|Stress
938912|NCT02317523|Depression
938913|NCT02317523|Anxiety
938914|NCT02317523|Heart Disease
938915|NCT02317523|Carer
938916|NCT02317523|Care Giver
938917|NCT02317523|Caregiving
938918|NCT02317523|Psychotherapy
938919|NCT02317523|Therapy
938920|NCT02317523|Behavioral Activation
938921|NCT02317523|Education
938922|NCT02317523|Intervention
938923|NCT02317523|CBT
938924|NCT02317523|Cognitive-Behavior Therapy
938925|NCT02317510|Combined anesthesia
938926|NCT02317510|General anesthesia
938927|NCT02317510|Laparoscopic cholecystectomy
938928|NCT02317497|Neurocritical care
938929|NCT02317497|Severe Stroke
938930|NCT02317497|Ischemic stroke
938931|NCT02317497|Intracerebral hemorrhage
938932|NCT02317497|Subarachnoid hemorrhage
938933|NCT02317497|Sedation
938934|NCT02317497|RASS
938935|NCT02317497|BIS
938936|NCT02317445|helicobacter pylori
938937|NCT02317445|eradication therapy
938938|NCT02317445|major adverse cardiac events
938939|NCT02317445|long-term outcome
938940|NCT02317445|To explore the significance of Hp eradication therapy in preventing major adverse cardiac events (MACE) and upper gastrointestinal bleeding (UGIB).
938941|NCT02317432|Depression
938942|NCT02317432|Anxiety
938943|NCT02317432|Disability
938944|NCT02317432|Ethnic Minority
938945|NCT02317432|Elders
938946|NCT02317419|Solid Cancers
938947|NCT02317393|Nuclear medicine
938948|NCT02317393|Positron emission tomography
938949|NCT02317393|avb3 integrin expression
938950|NCT02317380|Self-Affirmation
938951|NCT02317380|Weight Loss
938952|NCT02317380|Self vs. Other
938953|NCT02317380|Cancer Risk and Prevention
938954|NCT02317367|Construct Validity
938955|NCT02317367|Self-Affirmation
938956|NCT02317367|Alcohol Consumption
938957|NCT02317367|Breast Cancer
938958|NCT02317354|X-Linked
938959|NCT02317354|Retinoschisis
938960|NCT02317341|Fatigue
938961|NCT02317341|Ketamine
938962|NCT02317341|Cancer
938963|NCT02317328|Retinal Images
938964|NCT02317328|Adaptive Optics
938965|NCT02317263|MS
938966|NCT02317250|Alzheimer's disease
938967|NCT02317250|Alzheimer disease
938968|NCT02317250|MDC
938969|NCT02317250|Mild Decline in Cognition
938970|NCT02317250|MCI
938971|NCT02317250|Dementia
938972|NCT02317250|PET
938973|NCT02317250|FDG-PET
938974|NCT02317250|FDG
938975|NCT02317250|amyloid
938976|NCT02317250|amyloid imaging
938977|NCT02317250|CMS
938978|NCT02317250|Coverage with Evidence Development
938979|NCT02317250|CED
938980|NCT02317250|MCI-ID
938981|NCT02317224|3-Hole approach
938982|NCT02317224|extended thymectomy
938983|NCT02317224|myasthenia gravis
938984|NCT02317224|safety
938985|NCT02317224|effectiveness
938986|NCT02317198|Elderly
938987|NCT02317198|P2Y12 inhibitors
938988|NCT02317198|clopidogrel
938989|NCT02317198|ticagrelor
938990|NCT02317172|Saliva substitute
938991|NCT02317172|Edible gel
938992|NCT02317172|Xerostomia
938993|NCT02317172|Diabetes Mellitus
938994|NCT02317172|Hypertension
938995|NCT02317133|Tregs
938996|NCT02317133|bacterial translocation
938997|NCT02317133|cytokines
938998|NCT02317107|Gait
938999|NCT02317107|Mild Traumatic Brain Injury
939000|NCT02317107|Post-Concussion Syndrome
939001|NCT02317107|Recovery of Function
939002|NCT02317107|Locomotion
939003|NCT02317107|Motor Activity
939004|NCT02317068|sick sinus syndrome
939005|NCT02317068|paroxysmal atrial fibrillation
939006|NCT02317068|atrial pacing
939007|NCT02317068|high atrial base rate pacing
939008|NCT02317055|MRI
939009|NCT02317055|Oxygenation
939010|NCT02317055|nirs
939011|NCT02317029|Cardioversion
939012|NCT02317029|Cardiac Arrythmias
939013|NCT02317029|Myocardial Injury
939014|NCT02317029|Defibrillators
939015|NCT02317029|Biomarkers
939016|NCT02317016|oncology
939017|NCT02317016|cancer
939018|NCT02317016|non small cell lung cancer
939019|NCT02317016|anticancer drug
939020|NCT02317016|pharmacokinetics
939021|NCT02317016|AZD9291
939022|NCT02317016|rosuvastatin
939023|NCT02317016|EGFR genes
939024|NCT02317003|physical exercise
939025|NCT02317003|sedentarity
939026|NCT02317003|general practice
939027|NCT02317003|family medicine
939028|NCT02317003|pedometer
939029|NCT02316977|Reproducibility of Results
939030|NCT02316964|AML
939031|NCT02316964|acute myeloid leukemia
939032|NCT02316964|decitabine
939033|NCT02316951|Postoperative
939034|NCT02316951|Pain
939035|NCT02316951|Symptoms
939036|NCT02316951|Video recording
939037|NCT02316951|Orthopedic surgery
939038|NCT02316938|kidney transplant, renal transplant, biopsy, biopsies, donor specific antibodies
939039|NCT02316912|allergy
939040|NCT02316899|ASP0456
939041|NCT02316899|constipation
939042|NCT02316899|linaclotide
939043|NCT02316899|irritable bowel syndrome (IBS)
939044|NCT02316886|Bioresorbable Vascular scaffold
939045|NCT02316886|Vulnerable Plaque
939046|NCT02316886|Insignificant Stenosis
939047|NCT02316873|music training, rhythm
939048|NCT02316847|Cluster Seizures
939049|NCT02316847|Seizures
939050|NCT02316847|Clusters
939051|NCT02316847|Acute repetitive seizures
939052|NCT02316834|Fallopian Tube Cancer
939053|NCT02316834|Ovarian Cancer
939054|NCT02316834|Peritoneal Cancer
939055|NCT02316834|BMN 673
939056|NCT02316834|Talazoparib tosylate
939057|NCT02316821|Diabetes Mellitus
939058|NCT02316821|Diabetes Mellitus, Type 2
939059|NCT02316821|Diabetic Nephropathies
939060|NCT02316821|Kidney Diseases
939061|NCT02316821|Renal Insufficiency, Chronic
939062|NCT02316821|Diabetes Complications
939063|NCT02316821|Endocrine System Diseases
939064|NCT02316821|Glucose Metabolism Disorders
939065|NCT02316821|Metabolic Diseases
939066|NCT02316821|Renal Insufficiency
939067|NCT02316821|Urologic Diseases
939068|NCT02316821|bardoxolone methyl
939211|NCT02315820|Shoulder dystocia
939212|NCT02315794|aesthetic outcome
939069|NCT02316756|Phase 1, Single-Dose Escalation, Double Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, PF-06648671, Plasma Abeta
939070|NCT02316691|Graves Disease
939071|NCT02316691|Rituximab
939072|NCT02316678|Patient Preference
939073|NCT02316665|Type 1 diabetes
939074|NCT02316665|Sleep apnea syndrome
939075|NCT02316665|Nocturnal glycemia
939076|NCT02316665|Continuous glucose monitoring system
939077|NCT02316665|Continuous positive airway pressure
939078|NCT02316665|Sleep habits
939079|NCT02316639|Neuromuscular Training
939080|NCT02316639|Skeletally Immature
939081|NCT02316639|Knee Rehabilitation
939082|NCT02316600|elderly
939083|NCT02316600|Robust volunteers for the first phase;
939084|NCT02316600|tele-monitoring
939085|NCT02316600|self-management
939086|NCT02316600|Patient 65 and over
939087|NCT02316600|Presenting a frailty syndrome for the second phase
939088|NCT02316587|Computerized Tomography
939089|NCT02316587|Magnetic Resonance Imaging
939090|NCT02316587|Echocardiography
939091|NCT02316587|Right Heart Catheterization
939092|NCT02316574|Alcohol dependence
939093|NCT02316574|Cognitive Behavioral Therapy
939094|NCT02316574|Functional neuroimaging
939095|NCT02316535|colorectal cancer
939096|NCT02316535|stage II/III
939097|NCT02316535|elderly
939098|NCT02316535|adjuvant chemotherapy
939099|NCT02316535|capecitabine
939100|NCT02316535|non-inferiority
939101|NCT02316496|Cancer
939102|NCT02316496|Colorectal
939103|NCT02316496|Metastatic
939104|NCT02316496|Thrid-line
939105|NCT02316496|Irinotecan
939106|NCT02316496|Cetuximab
939107|NCT02316470|Clostridium difficile
939108|NCT02316470|Valneva
939109|NCT02316470|Phase 2
939110|NCT02316470|Healthy adults
939117|NCT02316444|Hepatitis B vaccine HIV infection
939118|NCT02316418|Hairstetics™ anchoring system
939119|NCT02316418|hair extensions
939120|NCT02316392|Helium
939121|NCT02316392|MRI
939122|NCT02316392|Lung transplantation
939123|NCT02316379|Respiratory
939124|NCT02316314|Friedreich's Ataxia
939125|NCT02316314|Cardiomyopathy
939126|NCT02316301|Misoprostol, pain, office hysteroscopy
939127|NCT02316249|pelvic organ prolapse
939128|NCT02316249|Atrophy of Vagina
939129|NCT02316249|Gellhorn pessary
939130|NCT02316249|Ring with support pessary
939131|NCT02316249|Estrace cream
939132|NCT02316249|vaginitis with pessary
939133|NCT02316249|vaginal ulceration with pessary
939134|NCT02316249|vaginal erosion with pessary
939135|NCT02316249|pessary complications
939136|NCT02316249|vaginal bleeding with pessary
939137|NCT02316223|asthma
939138|NCT02316223|high-risk
939139|NCT02316223|adult
939140|NCT02316223|elderly
939141|NCT02316223|care coordination
939142|NCT02316223|community health worker
939143|NCT02316223|electronic medical record
939156|NCT02316184|Alcohol
939157|NCT02316158|Burden
939158|NCT02316158|Mental illness
939159|NCT02316158|Stress
939160|NCT02316158|Social support
939161|NCT02316145|ADHD
939162|NCT02316145|Autism spectrum condition
939163|NCT02316145|Tourette's disorder
939164|NCT02316145|Internet-based
939165|NCT02316145|chat
939166|NCT02316145|coach
939167|NCT02316119|bleeding risk, acute coronary syndrome, platelet agregation,
939168|NCT02316106|Smoldering multiple myeloma (SMM)
939169|NCT02316106|Daratumumab
939170|NCT02316080|dental bleaching
939171|NCT02316080|dentin sensitivity
939172|NCT02316080|biomaterials
939173|NCT02316067|Spinal cord
939174|NCT02316067|Wounds and Injuries
939175|NCT02316067|Rehabilitation
939176|NCT02316054|type 2 diabetes mellitus
939177|NCT02316054|coronary microvascular disease
939178|NCT02316054|coronary artery disease
939179|NCT02316054|myocardial perfusion imaging
939180|NCT02316054|prognosis
939181|NCT02316054|atherosclerosis
939182|NCT02316054|myocardial ischemia
939183|NCT02316054|coronary heart disease
939184|NCT02316041|Femtosecond laser
939185|NCT02316041|Small incision lenticule extraction (SMILE)
939186|NCT02316028|decitabine
939187|NCT02316028|colorectal cancer
939188|NCT02316028|hepatic arterial infusion
939189|NCT02316015|Child, Hospitalized
939190|NCT02316015|Nutritional status
939191|NCT02315976|chronic stable angina pectoris
939192|NCT02315976|propatyl nitrate
939193|NCT02315976|Seattle Angina Questionnaire
939194|NCT02315911|Tonsillectomy
939195|NCT02315911|Adenoidectomy
939196|NCT02315911|Adenoidpharyngoplasty
939197|NCT02315911|OSA
939198|NCT02315885|healthy volunteers
939199|NCT02315885|social drinkers
939200|NCT02315885|alcohol
939201|NCT02315872|Multiple Sclerosis
939202|NCT02315872|Acthar Gel
939203|NCT02315872|ACTH
939204|NCT02315872|Fatigue
939205|NCT02315859|suction work
939208|NCT02315820|Macrosomia
939209|NCT02315820|Induction of labor
939210|NCT02315820|Expectant management
939213|NCT02315794|titanium abutment
939214|NCT02315794|zirconia abutment
939215|NCT02315768|CLL
939216|NCT02315768|Chronic Lymphocytic Leukemia
939217|NCT02315768|Ibrutinib
939218|NCT02315768|Obinutuzumab
939219|NCT02315768|Cancer
939220|NCT02315755|Metastatic renal cell carcinoma, targeted molecular therapy
939221|NCT02315716|Multiple Myeloma
939222|NCT02315716|Carfilzomib
939223|NCT02315703|Healthy
939224|NCT02315703|Acquired Immuno-Deficiency Syndrome
939225|NCT02315703|Acquired Immunodeficiency Syndrome Virus
939226|NCT02315703|adenovirus serotype 26
939227|NCT02315703|Ad26.Mos.HIV
939228|NCT02315703|Modified Vaccinia Ankara
939229|NCT02315703|Glycoprotein
939230|NCT02315703|Adjuvant
939231|NCT02315703|Vaccine
939232|NCT02315703|Placebo
939233|NCT02315690|malaria, Swaziland, reactive case detection, focal mass drug administration
939234|NCT02315677|Epistaxis
939235|NCT02315677|Nasal Intubation
939236|NCT02315677|Maxillofacial surgery
939237|NCT02315664|Physical activity
939238|NCT02315664|Exercise
939239|NCT02315664|Osteoarthritis
939240|NCT02315664|Knee
939241|NCT02315664|Arthritis
939242|NCT02315638|Adeno-associated viral vectors
939243|NCT02315638|Adeno-associated virus
939244|NCT02315638|AAV
939245|NCT02315638|AAV8
939246|NCT02315638|ddRNAi
939247|NCT02315638|shRNA
939248|NCT02315638|RNAi
939249|NCT02315638|Hepatitis
939250|NCT02315638|Chronic Hepatitis C
939251|NCT02315638|HCV
939252|NCT02315638|CHC
939253|NCT02315638|Genotype 1
939254|NCT02315625|MEN1
939255|NCT02315625|VHL
939256|NCT02315625|Neoplasm
939257|NCT02315625|NF1
939258|NCT02315625|mTOR
939259|NCT02315612|CD-22 Expressing Tumor
939260|NCT02315612|Chimeric Antigen Receptor
939261|NCT02315612|Adoptive Immunotherapy
939262|NCT02315612|ALL
939263|NCT02315612|Lymphoma
939264|NCT02315599|Replication Competent Retrovirus (RCR)
939265|NCT02315599|Replication Competent Lentivirus (RCL)
939266|NCT02315599|T Cell Persistence
939267|NCT02315586|Idiopathic Pulmonary Fibrosis
939268|NCT02315586|Apoliprotein A-1
939269|NCT02315573|Carpal Tunnel Syndrome
939270|NCT02315573|Anesthetics, Local
939271|NCT02315573|Pain Perception
939272|NCT02315573|Pain Measurement
939273|NCT02315573|Analgesia
939274|NCT02315573|Lidocaine
939275|NCT02315573|Bupivacaine
939276|NCT02315560|bedwetting
939277|NCT02315547|Microbiota
939278|NCT02315547|Airway infection
939279|NCT02315547|Bronchiectasis
939280|NCT02315547|Airway inflammation
939281|NCT02315547|Oxidative stress
939282|NCT02315547|Matrix metalloproteinase
939283|NCT02315534|GBM
939284|NCT02315534|Malignant Glioma
939285|NCT02315521|lower urinary tract obstruction
939286|NCT02315521|posterior urethral valves
939287|NCT02315521|urethral atresia
939288|NCT02315521|Prune Belly Syndrome
939289|NCT02315521|Megalo-urethra
939290|NCT02315521|Fetal renal function
939291|NCT02315521|Prenatal Diagnosis
939292|NCT02315521|Ultrasound
939293|NCT02315482|autonomic nervous system
939294|NCT02315482|heart rate variability
939295|NCT02315482|prostatectomy
939296|NCT02315482|steep trendelenburg
939297|NCT02315482|pneumoperitoneum
939298|NCT02315482|Intervention Affecting Autonomic Nervous System
939299|NCT02315456|capsulorhexis
939300|NCT02315456|IOL centration
939301|NCT02315443|Stroke
939302|NCT02315443|Ischemia
939303|NCT02315443|Prehospital
939304|NCT02315443|NA-1
939305|NCT02315443|Modified Rankin Scale
939306|NCT02315417|Pyoderma Gangrenosum
939307|NCT02315417|Classic Pyoderma Gangrenosum
939308|NCT02315404|Obscure gastrointestinal bleeding
939309|NCT02315404|Overt gastrointestinal bleeding
939310|NCT02315404|Occult gastrointestinal bleeding
939311|NCT02315404|Enteroscopy
939312|NCT02315378|Anxiety, Acute Trauma
939313|NCT02315352|Healthy
939314|NCT02315352|L-PZQ
939315|NCT02315352|PZQ
939316|NCT02315352|MSC2499550A
939317|NCT02315352|Praziquantel
939318|NCT02315326|Ibrutinib,
939319|NCT02315326|Imbruvica™
939320|NCT02315326|Bruton's Tyrosine Kinase (BTK) Inhibitor
939321|NCT02315326|HD-MTX
939322|NCT02315326|14-184
939323|NCT02315300|ECG, CGM, Hypoglycaemia, Sudden Cardiac Death
939324|NCT02315287|Triple combination
939325|NCT02315287|Metformin
939326|NCT02315287|Sitagliptin
939327|NCT02315287|Pioglitazone
939328|NCT02315287|Lobeglitazone
939329|NCT02315274|Type 1 diabetes
939330|NCT02315274|Pregnancy
939331|NCT02315274|Glycemic variability
939332|NCT02315274|Between visit contact
939333|NCT02315261|Epidural analgesia
939334|NCT02315261|Pain score
939335|NCT02315248|bone density
939336|NCT02315222|Nutriomics
939337|NCT02315222|Dietary supplements
939338|NCT02315222|Scaling and root planing
939339|NCT02315222|full mouth disinfection
939340|NCT02315209|Inguinal Hernia, Quality of Life, Mesh
939341|NCT02315183|Post cardiac surgery
939342|NCT02315170|diabetic retinopathy
939343|NCT02315170|age-related macular edema
939344|NCT02315157|Partial Response
939345|NCT02315144|COPD
939346|NCT02315144|bronchodilation
939347|NCT02315092|Diabetic Foot Ulcers
939348|NCT02315092|Bacteria
939349|NCT02315092|Fluorescence
939350|NCT02315079|Ocular Inflammation
939351|NCT02315079|Matrix Metalloproteinase 9
939352|NCT02315066|Immunotherapy
939353|NCT02315066|PF-04518600
939354|NCT02315066|PF-05082566
939355|NCT02315066|solid tumors
939356|NCT02315066|tumors
939357|NCT02315066|neoplasm metastasis
939358|NCT02315066|Phase 1
939359|NCT02315066|hepatocellular carcinoma
939360|NCT02315066|HCC
939361|NCT02315066|Liver cancer
939362|NCT02315066|melanoma
939363|NCT02315066|clear cell renal cell carcinoma
939364|NCT02315066|RCC
939365|NCT02315066|kidney cancer
939366|NCT02315066|head and neck squamous cell carcinoma
939367|NCT02315066|HNSCC
939368|NCT02315066|head and neck cancer
939369|NCT02315066|cervical cancer
939370|NCT02315066|cancer of the cervix
939371|NCT02315066|gastric cancer
939372|NCT02315066|stomach cancer
939373|NCT02315066|non small cell lung cancer
939374|NCT02315066|NSCLC
939375|NCT02315066|lung cancer
939376|NCT02315066|urothelial bladder carcinoma
939377|NCT02315066|bladder cancer
939378|NCT02315066|OX40
939379|NCT02315066|4-1BB
939380|NCT02315053|NSCLC
939381|NCT02315053|CCRT
939382|NCT02315053|FDG PET/CT
939383|NCT02315040|Intrauterine insemination (IUI)
939384|NCT02315040|Insemination method
939385|NCT02315040|Slow release insemination (SRI)
939386|NCT02315040|EVIE
939387|NCT02315040|Pregnancy rate
939388|NCT02315001|Liraglutide
939389|NCT02315001|GLP-1
939390|NCT02315001|Ischaemic heart disease
939391|NCT02315001|Coronary heart disease
939392|NCT02315001|Chronic stable angina
939393|NCT02314988|Tranexamic acid
939394|NCT02314988|Antifibrinolytic
939395|NCT02314988|Perioperative blood loss
939396|NCT02314988|Postoperative drain output
939397|NCT02314988|Allogenic transfusion
939398|NCT02314949|T-regulatory cells
939399|NCT02314949|Tolerogenic protocol
939400|NCT02314949|immunomodulation
939401|NCT02314936|Constipation
939402|NCT02314936|Polydextrose
939403|NCT02314936|Dietary Fiber
939404|NCT02314936|Fiber
939405|NCT02314936|Colonic Transit Time
939406|NCT02314936|PAC-SYM
939407|NCT02314910|Innervation
939408|NCT02314910|Jaw Bone
939409|NCT02314910|Implants
939410|NCT02314910|Stereognostic
939411|NCT02314910|Osseoperception
939412|NCT02314871|perioperative analgesia
939413|NCT02314871|minimal residual disease
939414|NCT02314871|cancer recurrence
939415|NCT02314871|epidural
939416|NCT02314871|morphine
939417|NCT02314871|piritramide
939418|NCT02314871|colon
939419|NCT02314871|cancer
939420|NCT02314871|circulating cancer cells
939421|NCT02314871|colon cancer surgery
939422|NCT02314845|Pulmonary Atelectasis
939423|NCT02314845|Pulmonary Ventilation
939424|NCT02314845|Anesthesia, General
939425|NCT02314845|Electric Impedance
939426|NCT02314845|Tomography, Spiral Computed
939427|NCT02314845|Intraoperative Period
939428|NCT02314832|femoral nerve block
939429|NCT02314832|adductor canal block
939430|NCT02314832|tinetti score
939431|NCT02314832|2- Results to time to up and go (TUG ) test
939432|NCT02314832|3- Results to Tinetti test
939433|NCT02314832|4- Ambulation distance
939434|NCT02314832|5- Pain scores at rest and with movement
939435|NCT02314819|colorectal cancer
939436|NCT02314793|Pharmacokinetics
939437|NCT02314793|ASP2205
939438|NCT02314741|poem
939439|NCT02314741|per oral endoscopic myotomy
939440|NCT02314741|achalasia
939441|NCT02314728|Bishop Score
939442|NCT02314728|Induction of Labor
939443|NCT02314728|Cervical Ripening
939444|NCT02314728|Unfavorable Cervix
939445|NCT02314728|Mode of Delivery
939446|NCT02314728|C-Section
939447|NCT02314728|Cesarean Section
939448|NCT02314715|Osteoarthritis Knee
939457|NCT02314663|hypercholesterolaemia
939458|NCT02314663|medication adherence
939459|NCT02314663|primary health care
939460|NCT02314637|DPP-IV inhibitor
939469|NCT02314572|Multifocal Intraocular Lens
939470|NCT02314572|Binocular Trifocality
939471|NCT02314572|Cataract Surgery
939472|NCT02314572|Spectacle Independence
939473|NCT02314572|Intermediate Vision
939474|NCT02314572|Photopic Vision
939475|NCT02314572|Mesopic Vision
939476|NCT02314572|Scotopic Vision
939477|NCT02314572|Binocular Vision
939478|NCT02314559|propofol
939479|NCT02314559|colonoscopy
939480|NCT02314507|Gua sha
939481|NCT02314481|NSCLC
939482|NCT02314481|Clonal dominance
939483|NCT02314481|Clonal evolution
939484|NCT02314481|Intratumour heterogeneity
939485|NCT02314481|Genomic instability
939486|NCT02314481|Drug resistance
939487|NCT02314481|Immunotherapy
939488|NCT02314481|PDL1
939489|NCT02314481|BRAF V600
939490|NCT02314481|ALK
939491|NCT02314481|RET
939492|NCT02314481|HER2 amplification
939493|NCT02314481|MPDL3280A
939494|NCT02314481|Vemurafenib
939495|NCT02314481|Alectinib
939496|NCT02314481|T-DM1
939497|NCT02314481|Trastuzumab emtansine
939498|NCT02314481|TRACERX
939499|NCT02314455|Eosinophilic Esophagitis
939500|NCT02314455|EoE
939501|NCT02314455|dysphagia
939502|NCT02314442|LDL-C
939503|NCT02314442|RNAi therapeutic
939504|NCT02314416|wounds, stem cells, collagen matrix, maturation
939505|NCT02314403|ESRD
939506|NCT02314390|Depression
939507|NCT02314390|Mindfulness
939508|NCT02314390|MBCT
939509|NCT02314364|Non-small cell lung cancer
939510|NCT02314364|Metastatic
939511|NCT02314364|EGFR
939512|NCT02314364|ALK
939513|NCT02314364|ROS1
939514|NCT02314364|Stereotactic Body Radiation Therapy
939515|NCT02314351|migraine disorders
939516|NCT02314351|migraine with aura
939517|NCT02314351|migraine without aura
939518|NCT02314351|pain management
939519|NCT02314351|emergency department
939520|NCT02314325|Factor VIII deficiency
939521|NCT02314325|Arthropathy
939522|NCT02314325|MRI
939523|NCT02314325|XRay
939524|NCT02314325|Joint
939525|NCT02314325|HJHS
939526|NCT02314312|Kidney transplantation
939527|NCT02314312|ECD
939528|NCT02314299|Macular edema
939529|NCT02314299|Macular degeneration
939530|NCT02314299|MTP-131
939531|NCT02314299|Ocuvia™
939532|NCT02314286|Rosuvastatin
939533|NCT02314286|severe preeclampsia
939534|NCT02314286|48 hours following delivery
939535|NCT02314260|labour induction
939536|NCT02314260|cervical length
939537|NCT02314260|trans-vaginal assessment of cervical length
939538|NCT02314260|Bishop score
939539|NCT02314247|PTCL
939540|NCT02314247|CTCL
939541|NCT02314247|Peripheral T-cell Lymphoma
939542|NCT02314247|Cutaneous T-cell Lymphoma
939543|NCT02314247|Karyopharm
939544|NCT02314247|KPT-330
939545|NCT02314247|Selinexor
939546|NCT02314221|Exoskeletal-assisted walking
939547|NCT02314208|spastic paraplegia
939548|NCT02314208|metabolism
939549|NCT02314208|oxysterols
939550|NCT02314208|neurogenetics
939551|NCT02314195|Obsessive Compulsive Disorder
939552|NCT02314195|Music Therapy/methods
939553|NCT02314195|Combined Modality Therapy
939554|NCT02314195|Anxiety Disorders/therapy
939555|NCT02314182|Rectal adenocarcinoma
939556|NCT02314182|unresectable
939557|NCT02314182|surgery
939558|NCT02314182|chemotherapy
939559|NCT02314143|dabrafenib
939560|NCT02314143|MEK
939561|NCT02314143|trametinib
939562|NCT02314143|BRAF
939563|NCT02314143|melanoma
939564|NCT02314143|Oncology
939565|NCT02314104|Surgical procedures, Minimally invasive
939566|NCT02314104|Nerve block
939567|NCT02314104|Anesthetics, Local
939568|NCT02314078|Caesarean section
939569|NCT02314078|Emergency
939570|NCT02314078|Anaesthesia
939571|NCT02314065|Severe health anxiety
939572|NCT02314065|Somatic symptom disorder
939573|NCT02314065|Illness anxiety disorder
939574|NCT02314065|Cognitive behavioral therapy
939575|NCT02314065|Internet
939576|NCT02314065|Exposure
939577|NCT02314013|uncomplicated diverticulitis, economic cost, hospital stay
939578|NCT02313974|Lupus Nephritis Treatment
939579|NCT02313974|Renal Biopsy in Lupus
939580|NCT02313974|Lupus Flare
939581|NCT02313961|ST elevation myocardial infarction
939582|NCT02313961|Reperfusion injury
939583|NCT02313961|Remote ischaemic conditioning
939584|NCT02313909|Rivaroxaban
939585|NCT02313909|Xarelto
939586|NCT02313909|Aspirin
939587|NCT02313909|ASA
939588|NCT02313909|Oral Anticoagulant
939589|NCT02313909|Blood Thinner
939590|NCT02313909|Stroke
939591|NCT02313909|Ischemic Stroke
939592|NCT02313909|Cryptogenic Stroke
939593|NCT02313909|Embolic stroke of undetermined source
939594|NCT02313909|ESUS
939595|NCT02313909|Transient Ischemic Attack
939596|NCT02313909|Thromboembolism
939597|NCT02313909|Cerebrovascular Disease
939598|NCT02313883|periodontitis
939599|NCT02313883|taurolidine (PerioSept(r))
939600|NCT02313883|scaling and root planing
939601|NCT02313870|Bullous pemphigoid
939602|NCT02313870|superpotent topical steroids
939603|NCT02313870|methotrexate
939604|NCT02313870|safety
939605|NCT02313857|Viralym-C
939606|NCT02313857|Viral infections post HSCT
939607|NCT02313857|Virus-specific T cells
939608|NCT02313844|BK virus
939609|NCT02313844|Virus specific T cells
939610|NCT02313844|Viral infections
939611|NCT02313831|autonomic nervous system
939612|NCT02313831|ventilatory anaerobic threshold
939613|NCT02313831|oxygen consumption
939614|NCT02313831|metabolic profile
939615|NCT02313831|exercise training
939616|NCT02313831|expiratory flow limitation
939617|NCT02313818|Posttraumatic Stress Disorder
939618|NCT02313818|Cognitive Processing Therapy
939619|NCT02313818|Active Duty Military
939620|NCT02313805|Insulin initiation
939621|NCT02313805|Insulin checklist
939622|NCT02313792|Hematopoietic stem cell transplantation
939623|NCT02313792|Palifermin
939624|NCT02313740|Influenza
939625|NCT02313740|Influenza Vaccines
939626|NCT02313714|heart failure, heart transplant, electrical stimulation
939627|NCT02313688|adenocarcinomas of esophagogastric junction
939628|NCT02313688|resection margin
939629|NCT02313688|length
939630|NCT02313688|prognosis
939631|NCT02313675|carpal tunnel syndrome
939632|NCT02313675|opioid analgesics
939633|NCT02313675|postoperative pain
939634|NCT02313675|IV tylenol
939635|NCT02313675|IV toradol
939636|NCT02313649|liver
939637|NCT02313649|fibrosis
939638|NCT02313649|elastography
939639|NCT02313649|ShearWave Elastography
939640|NCT02313649|ultrasound
939641|NCT02313610|Retreatment Pulmonary Tuberculosis, Qinbudan,
939642|NCT02313584|dabigatran
939643|NCT02313571|Epidural Analgesia
939644|NCT02313571|Pain
939645|NCT02313558|dentifrice
939646|NCT02313558|gingivitis
939647|NCT02313558|dental plaque
939648|NCT02313519|Infections
939649|NCT02313519|anastomotic leakage
939650|NCT02313506|Physical activity
939651|NCT02313506|Exercise
939652|NCT02313506|Osteoarthritis
939653|NCT02313506|Knee
939654|NCT02313506|Arthritis
939655|NCT02313441|remote ischemic preconditioning
939656|NCT02313428|Diabetic Foot Ulcer
939657|NCT02313428|Topical Oxygen Therapy
939658|NCT02313428|Medicaid Recipients
939659|NCT02313428|Standard of Care
939660|NCT02313428|Diabetic Wounds
939661|NCT02313363|Health care systems
939662|NCT02313363|Mobile applications
939663|NCT02313363|Self-care
939664|NCT02313363|Diabetes mellitus
939665|NCT02313363|Smartphone
939666|NCT02313350|Sciatica,
939667|NCT02313350|herniated disc,
939668|NCT02313350|chemonucleolysis.
939669|NCT02313337|Administration route
939670|NCT02313337|Preanesthetic medication
939671|NCT02313337|Sedation
939672|NCT02313324|Coccydynia
939673|NCT02313324|Extracorporeal shock wave therapy
939674|NCT02313324|Disability
939675|NCT02313311|Cleavage pattern, timing parameter, time-lapse
939676|NCT02313272|neoplasms
939677|NCT02313272|high-grade glioma
939678|NCT02313272|recurrent glioma
939679|NCT02313272|glioma
939680|NCT02313272|Hypofractionated Stereotactic Irradiation (HFSRT)
939681|NCT02313272|Bevacizumab
939682|NCT02313272|Pembrolizumab
939683|NCT02313272|recurrent high-grade glioma
939684|NCT02313272|Grade III malignant glioma
939685|NCT02313272|Grade IV malignant glioma
939686|NCT02313272|brain and nervous system
939687|NCT02313220|Obesity
939688|NCT02313220|Dapagliflozin
939689|NCT02313220|Exenatide
939690|NCT02313220|Combination treatment
939691|NCT02313220|Type 2 diabetes
939692|NCT02313181|breastfeeding
939693|NCT02313181|lactation
939694|NCT02313181|newborn
939695|NCT02313168|difficult airway; prediction, FRONT score.
939696|NCT02313155|Prevention
939697|NCT02313129|Infertility
939698|NCT02313129|Rheumatoid Arthritis
939699|NCT02313116|Lumpectomy
939700|NCT02313116|Breast cancer
939701|NCT02313116|Optical coherence tomography
939702|NCT02313116|Tumor margin
939703|NCT02313116|Imaging
939704|NCT02313103|ESRD
939705|NCT02313103|End Stage Renal Disease
939706|NCT02313103|Normal Healthy Volunteers
939707|NCT02313103|Renally Impaired
939708|NCT02313077|Healthy
939709|NCT02313077|Ebola viruses
939710|NCT02313077|Ebola Viral Disease (EVD)
939711|NCT02313077|Filoviruses
939712|NCT02313077|monovalent vaccine
939713|NCT02313077|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
939714|NCT02313077|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
939715|NCT02313077|Safety
939716|NCT02313077|Immunogenicity
939717|NCT02313051|metastatic breast cancer, everolimus
939718|NCT02313038|Coronary heart disease
939719|NCT02313038|Percutaneous Coronary Intervention
939720|NCT02313038|Drug Eluting Stents
939721|NCT02313012|Maximum Tolerated Dose
939722|NCT02313012|Solid Tumors
939723|NCT02313012|Locally Advanced Tumors
939724|NCT02313012|Metastatic Solid Tumors
939725|NCT02313012|Relapsed or refractory, BRAFV600 or RAS-mutated solid tumors
939726|NCT02313012|Melanoma
939727|NCT02313012|Colorectal Carcinomas Papillary
939728|NCT02313012|Thyroid carcinomas
939729|NCT02313012|Pancreatic ductal Adenocarcinomas
939730|NCT02313012|Non -small cell lung cancer [NSCLC]
939731|NCT02312999|laparotomy
939732|NCT02312999|plasma-Lyte
939733|NCT02312999|volulyte
939734|NCT02312999|close loop
939735|NCT02312999|abdominal surgery
939736|NCT02312986|infection
939737|NCT02312986|colonization
939738|NCT02312986|antibiotic resistance
939739|NCT02312973|Chronic kidney disease
939740|NCT02312973|Pharmacokinetics
939741|NCT02312973|Hemodialysis
939742|NCT02312973|Peritoneal dialysis
939743|NCT02312973|Erythropoietin
939744|NCT02312934|Chemo brain
939745|NCT02312934|Chemotherapy-related cognitive impairment
939746|NCT02312934|CRCI
939747|NCT02312934|Breast cancer
939748|NCT02312934|Chemo fog
939749|NCT02312934|Nicotine
939750|NCT02312934|Transdermal nicotine
939751|NCT02312921|managed healthcare
939752|NCT02312921|child
939753|NCT02312921|dental care
939754|NCT02312908|REM Sleep Behavior Disorder
939755|NCT02312908|Parkinson Disease
939756|NCT02312908|Placebos
939757|NCT02312908|Randomized Controlled Trial
939758|NCT02312908|Double-Blind Method
939759|NCT02312908|Clinical Trial
939762|NCT02312843|Mild Cognitive Impairment
939763|NCT02312843|Cognitive disorders
939764|NCT02312843|Prediabetes
939765|NCT02312843|Exercise
939766|NCT02312817|Carcinoma, Hepatocellular
939767|NCT02312817|Liver Neoplasms
939768|NCT02312817|Liver Disease
939769|NCT02312817|Early Detection of Cancer
939770|NCT02312817|Comparative Effectiveness Research
939771|NCT02312791|Radiation
939772|NCT02312791|Prognosis
939773|NCT02312791|Palliative Care
939774|NCT02312778|non-specific low back pain
939775|NCT02312778|center of pressure
939776|NCT02312778|spinal lumbar manipulation
939777|NCT02312778|high velocity and low amplitude manipulation
939778|NCT02312778|postural control
939779|NCT02312752|Intra-epidermal stimulation in healthy control subjects
939780|NCT02312739|pain assessment
939781|NCT02312739|pain measurement
939782|NCT02312739|patient satisfaction
939783|NCT02312739|anxiety
939784|NCT02312739|analgesia and anesthesia
939785|NCT02312739|female sterilization
939786|NCT02312726|mixed methods
939787|NCT02312726|visual analog scale
939788|NCT02312726|verbal rating score
939789|NCT02312726|pain assessment
939790|NCT02312726|patient satisfaction
939791|NCT02312726|contraceptive devices
939792|NCT02312726|postpartum
939793|NCT02312713|Osteoarthritis
939794|NCT02312713|Knee Osteoarthritis
939795|NCT02312700|empowerment
939796|NCT02312700|communication
939797|NCT02312700|shared decision making
939798|NCT02312687|XLH
939799|NCT02312687|FGF23
939800|NCT02312687|KRN23
939801|NCT02312674|pancreatic carcinoma
939802|NCT02312674|hepatocellular carcinoma
939803|NCT02312674|palliative therapy
939804|NCT02312674|oral nutritional supplements
939805|NCT02312674|quality of life
939806|NCT02312674|nutritional status
939807|NCT02312661|ovarian cancer
939808|NCT02312661|metformin
939809|NCT02312661|carboplatin
939810|NCT02312661|paclitaxel
939811|NCT02312648|Functional Capacity
939812|NCT02312648|Physical Exertion
939813|NCT02312648|Patient Care
939814|NCT02312648|Early mobilization
939815|NCT02312635|cognitive rehabilitation, traumatic brain injury
939816|NCT02312596|non-healing wound
939817|NCT02312596|diabetic foot ulcer
939818|NCT02312596|platelet rich plasma
939819|NCT02312583|depression
939820|NCT02312583|cognitive-behavior intervention
939821|NCT02312570|non-healing wounds
939822|NCT02312570|pressure ulcer
939823|NCT02312570|platelet rich plasma
939824|NCT02312531|HBV
939825|NCT02312531|Intrauterine infection
939826|NCT02312531|hepatitis B immunoglobulin
939827|NCT02312531|immune barrier
939828|NCT02312531|virus replication
939829|NCT02312531|placenta
939830|NCT02312518|non-healing wounds
939831|NCT02312518|venous stasis
939832|NCT02312518|ulcer
939833|NCT02312518|platelet rich plasma
939834|NCT02312505|cardiac output monitoring
939835|NCT02312505|semi-invasive pulse contour analysis
939836|NCT02312505|transpulmonary thermodilution
939837|NCT02312492|fatty acid kinetics
939838|NCT02312440|tranexamic acid
939839|NCT02312440|blood loss
939840|NCT02312440|topical administration
939841|NCT02312440|intravenous administration
939842|NCT02312401|MRI
939843|NCT02312401|14-172
939844|NCT02312388|central venous catheters
939845|NCT02312362|HFDS
939846|NCT02312362|ab interno
939847|NCT02312362|MIGS
939848|NCT02312362|surgery
939849|NCT02312349|Celiac Disease
939850|NCT02312349|Gluten free elaborated food
939851|NCT02312336|ST Elevation Myocardial Infarction
939852|NCT02312336|Transcoronary Cooling
939853|NCT02312258|Ixazomib
939854|NCT02312258|Newly diagnosed
939861|NCT02312193|hypertension
939862|NCT02312193|myogenic tone
939863|NCT02312167|endomicroscopy
939864|NCT02312167|optical biopsy
939865|NCT02312167|exploratory surgery
939866|NCT02312167|resection surgery
939867|NCT02312167|robot-assisted
939868|NCT02312167|peritoneum carcinosis
939869|NCT02312167|inflammatory
939870|NCT02312167|rectum cancer
939871|NCT02312167|liver cancer
939872|NCT02312167|ovarian cancer
939873|NCT02312167|digestive cancer
939874|NCT02312167|pancreas cancer
939875|NCT02312167|duodenum cancer
939876|NCT02312128|distal radius fractures
939877|NCT02312128|early mobilization
939878|NCT02312128|postoperative treatment
939879|NCT02312128|outcome
939880|NCT02312115|Renal transplant
939881|NCT02312115|Kidney transplant
939882|NCT02312115|DGF
939883|NCT02312102|myelodysplastic syndrome
939884|NCT02312102|acute myeloid leukemia
939885|NCT02312102|allogeneic stem cell transplantation
939886|NCT02312089|Luteal phase support, ICSI, GnRHa
939887|NCT02312076|Luteal phase support, ICSI, GnRHa
939888|NCT02312063|DPP-4 inhibitor
939889|NCT02312063|sulfonylurea
939890|NCT02312037|Relapsed CD33 AML
939891|NCT02312037|Refractory CD33 AML
939892|NCT02312037|Relapsed CD33 APL
939893|NCT02312037|Refractory CD33 APL
939894|NCT02312037|Relapsed CD33 MDS
939895|NCT02312037|Refractory CD33 MDS
939896|NCT02312024|CytoSorb adsorber
939897|NCT02312024|sepsis
939898|NCT02312024|cytokines
939899|NCT02312024|hemofiltration
939900|NCT02312024|hemadsorption
939901|NCT02312024|inflammation
939902|NCT02312011|Myotonic Dystrophy
939903|NCT02312011|DM1
939904|NCT02312011|Adult onset
939905|NCT02312011|Neuromuscular Disease
939906|NCT02312011|DMPKRx
939917|NCT02311985|Liver cirrhosis
939918|NCT02311985|Blood coagulation
939919|NCT02311985|Thromboelastography
939920|NCT02311985|Blood transfusion
939921|NCT02311985|Catheterization, central venous
939922|NCT02311959|Breast
939923|NCT02311959|Invasive carcinoma
939924|NCT02311959|In situ carcinoma
939925|NCT02311959|Mastectomy
939926|NCT02311959|Nipple areola
939927|NCT02311959|Reconstruction
939928|NCT02311959|Local recurrence
939929|NCT02311946|Palbociclib, Rabeprazole, Proton Pump Inhibitor, Drug Interaction Study, DDI
939930|NCT02311829|Quality of life, PNES, Epilepsy,
939931|NCT02311816|Bacterial infection, empiric antibiotic therapy
939932|NCT02311790|cis-C16:1n7 supplement
939933|NCT02311790|trans-C16:1n7 supplement
939934|NCT02311790|palmitoleic acid supplement
939935|NCT02311751|Autism Spectrum Disorder
939936|NCT02311751|Executive Function
939937|NCT02311751|rTMS (Repetitive Transcranial Magnetic Stimulation)
939938|NCT02311751|MRI (Magnetic Resonance Imaging)
939939|NCT02311751|Healthy Subjects
939940|NCT02311738|Exercise and Genes in Obese (EGO)
939941|NCT02311725|narrative communication
939942|NCT02311725|depression
939943|NCT02311725|antidepressant augmentation
939944|NCT02311725|primary care
939945|NCT02311712|Esophageal cancer
939946|NCT02311712|Early detection
939947|NCT02311712|Cytological examination
939948|NCT02311699|Gender
939949|NCT02311699|Physical Violence
939950|NCT02311699|Sexual Violence
939951|NCT02311699|HIV
939952|NCT02311699|AIDS
939953|NCT02311699|Prevention
939954|NCT02311699|Community Intervention
939955|NCT02311699|Ethiopia
939956|NCT02311699|Intimate Partner Violence
939957|NCT02311686|Ethanol
939958|NCT02311686|Fatty acid ethyl esters
939959|NCT02311686|Ethyl glucoronide
939960|NCT02311686|Ethyl sulphate
939961|NCT02311686|Pharmacokinetics
939962|NCT02311673|Prader-Willi Syndrome
939963|NCT02311673|obesity
939964|NCT02311673|hyperphagia
939965|NCT02311647|Tamoxifen
939966|NCT02311647|Uterine cavity
939967|NCT02311647|endometrium
939968|NCT02311634|Electrical pudendal nerve stimulation
939969|NCT02311634|Transvaginal electrical stimulation
939970|NCT02311634|Urge urinary incontinence
939971|NCT02311634|Comparative study
939972|NCT02311608|acute variceal hemorrhage
939973|NCT02311608|terlipressin
939974|NCT02311608|somatostatin
939975|NCT02311608|octreotide
939976|NCT02311608|comparative effectiveness research
939977|NCT02311595|gastric cancer
939978|NCT02311595|laparoscope
939979|NCT02311569|JAK2
939980|NCT02311569|Mirabegron
939981|NCT02311569|Primary myelofibrosis
939982|NCT02311569|beta-3-mimetic drugs
939983|NCT02311569|Myeloproliferative neoplasm
939984|NCT02311569|Essential thrombocythemia
939985|NCT02311569|Polycythemia vera
939986|NCT02311569|Betmiga
939987|NCT02311569|JAK2-V617F
939988|NCT02311543|Axillary Lymph Node Dissection (ALND)
939989|NCT02311543|Breast Cancer
939990|NCT02311543|TachoSil®
939991|NCT02311543|Lymphatic Drainage
939992|NCT02311543|Surgical Sealing Patch
939993|NCT02311491|nano crystalline
939994|NCT02311491|archwire
939995|NCT02311465|Palliative Care
939996|NCT02311439|Locally advanced pancreatic cancer
939997|NCT02311439|Chemotherapy
939998|NCT02311439|Radiotherapy
939999|NCT02311426|Rehabilitation; Functional outcome
940000|NCT02311413|Allergic rhinoconjunctivitis
940001|NCT02311400|Emotion
940002|NCT02311400|Self-Affirmation
940003|NCT02311400|Alcohol Consumption
940004|NCT02311387|Incidence
940005|NCT02311387|Prevalence
940006|NCT02311387|Human
940007|NCT02311387|Mastomys
940008|NCT02311387|Serosurvey
940009|NCT02311374|Human Brain
940010|NCT02311374|Sleep
940011|NCT02311374|EEG
940012|NCT02311374|Magnetic Resonance Imaging (MRI)
940013|NCT02311374|Apparent Diffusion Coefficient
940014|NCT02311361|Anti-PDL1
940015|NCT02311361|Anti-CTLA4
940016|NCT02311361|Streostatic Body Radiation Therapy (SBRT)
940017|NCT02311348|Biopsy
940018|NCT02311348|Pain
940019|NCT02311335|Hypertriglyceridemia
940020|NCT02311335|Atherosclerosis
940021|NCT02311335|Genectic Variants
940022|NCT02311335|Hyperalphalipoproteinemia
940023|NCT02311335|Dyslipidemia
940024|NCT02311322|Growth Disorder
940025|NCT02311322|Growth
940026|NCT02311322|Exome Sequencing
940027|NCT02311244|All-cause mortality
940028|NCT02311244|Cardiovascular mortality
940029|NCT02311244|Myocardial infarction
940030|NCT02311244|Stroke
940031|NCT02311244|Dialysis
940032|NCT02311218|oral, microbiota, lactobacillus reuteri,
940033|NCT02311205|Transarterial Chemoembolization (TACE)
940034|NCT02311205|Hepatocellular carcinoma (HCC)
940035|NCT02311205|Metastasis
940036|NCT02311205|Sorafenib
940037|NCT02311192|Vitreous Haze
940038|NCT02311192|Ocular ultrasound
940039|NCT02311192|B scan
940040|NCT02311192|Uveitis
940041|NCT02311179|Prosthesis fixation
940042|NCT02311179|hip arthroplasty
940043|NCT02311166|Hip dysplasia
940044|NCT02311166|Soft tissue
940045|NCT02311166|Hip
940046|NCT02311166|Self-report
940047|NCT02311166|Physical activity
940048|NCT02311140|cystic fibrosis
940049|NCT02311140|nasal lavage
940050|NCT02311140|inflammation
940051|NCT02311140|Interleukin (IL)-6
940052|NCT02311140|IL-8
940053|NCT02311140|pulmonary function
940054|NCT02311127|Peripherally Inserted Central Catheters
940055|NCT02311127|Securement device
940056|NCT02311114|Program Evaluation
940057|NCT02311114|Telehomecare
940058|NCT02311114|Chronic Obstructive Pulmonary Disease
940059|NCT02311114|Heart Failure
940060|NCT02311114|LHINs
940061|NCT02311114|Local Health Integrative Network
940062|NCT02311114|OTN
940063|NCT02311114|Ontario Telemedicine Network
940064|NCT02311101|bladder cancer
940065|NCT02311101|mitomycin
940066|NCT02311101|BCG
940067|NCT02311101|intravesical
940068|NCT02311101|non-muscle invasive
940069|NCT02311062|training, soccer, eccentric, lengthening, unstable, squatting
940070|NCT02311036|Post Acute Care(PAC)
940071|NCT02311036|Cerebrovascular diseases
940072|NCT02311010|transplant
940073|NCT02311010|immunosuppressive drug
940074|NCT02310984|Early breast cancer
940075|NCT02310984|Lumpectomy
940076|NCT02310984|Breast conserving surgery
940077|NCT02310984|Radiotherapy
940078|NCT02310984|Cosmesis
940079|NCT02310971|Adenocarcinoma, resected
940080|NCT02310958|Lapraroscopic surgical procedure
940081|NCT02310958|infant
940082|NCT02310958|complications
940083|NCT02310958|inguinal hernia
940084|NCT02310958|hernia recurrence
940085|NCT02310945|pain
940086|NCT02310945|central nervous system sensitization
940087|NCT02310945|physiotherapy
940088|NCT02310932|mental health
940089|NCT02310932|cardiovascular disease
940090|NCT02310932|diabetes
940091|NCT02310932|hypertension
940092|NCT02310932|high blood pressure
940093|NCT02310919|Infertility
940094|NCT02310919|In vitro fertilization
940095|NCT02310919|IVF
940096|NCT02310906|Duchenne muscular dystrophy
940097|NCT02310906|Exon Skipping
940099|NCT02310854|anterior cruciate ligament rupture
940100|NCT02310854|autograft
940101|NCT02310854|reconstruction
940102|NCT02310854|orthopedic surgery
940103|NCT02310854|dynamic intraligament stabilization
940108|NCT02310802|IVF
940109|NCT02310802|ICSI
940111|NCT02310737|cesarean section
940112|NCT02310737|facial incision
940113|NCT02310737|postoperative pain
940114|NCT02310724|youth onset type 2 diabetes
940115|NCT02310724|insulin sensitivity
940116|NCT02310724|beta cell function
940117|NCT02310724|macrovascular comorbidities
940118|NCT02310724|microvascular comorbidities
940119|NCT02310711|Breast
940120|NCT02310711|Mastectomy
940121|NCT02310711|Lumpectomy
940122|NCT02310711|Breast Therapy
940123|NCT02310698|Ultrasound
940124|NCT02310698|Enhanced Mammography
940125|NCT02310698|14-240
940126|NCT02310685|Cardivascular risks (hypertension, sedentary, overweight)
940127|NCT02310685|Cardiovascular age
940128|NCT02310685|E-health wellness program
940129|NCT02310685|Prevention
940130|NCT02310685|Community pharmacists
940131|NCT02310685|Lifestyle change
940132|NCT02310685|Cardiometabolic age
940133|NCT02310672|Pulmonary Arterial Hypertension
940134|NCT02310633|TBI
940135|NCT02310633|memory disorder
940136|NCT02310633|injury, brain, traumatic
940137|NCT02310633|rehabilitation
940138|NCT02310607|Post-partum women
940139|NCT02310581|Bunionectomy
940140|NCT02310568|PF 06372865
940141|NCT02310568|generalized anxiety disorder
940142|NCT02310568|outpatient
940143|NCT02310568|safety
940144|NCT02310568|efficacy
940145|NCT02310568|suboptimal response
940146|NCT02310555|Metabolic surgery
940147|NCT02310529|Maternal depression
940148|NCT02310529|Interpersonal Psycotherapy
940149|NCT02310503|Mohs Surgery
940150|NCT02310490|Nasolabial Folds
940151|NCT02310477|regorafenib, cohort, metastatic colorectal cancer
940152|NCT02310438|Music therapy
940153|NCT02310438|stroke
940154|NCT02310438|hemiparesis
940155|NCT02310438|neurologic music therapy
940156|NCT02310412|INTERCEPT
940157|NCT02310412|platelet
940158|NCT02310412|pathogen inactivation
940159|NCT02310412|platelet components stored
940160|NCT02310412|therapeutic efficacy
940161|NCT02310399|Auditory Brainstem Implant
940162|NCT02310399|Deafness
940163|NCT02310399|Hearing Loss
940164|NCT02310399|ABI
940165|NCT02310386|Fibromyalgia
940166|NCT02310386|Electromagnetic field therapy
940167|NCT02310386|Randomized controlled trial
940168|NCT02310373|Nicotine-free hookah
940169|NCT02310373|Waterpipe
940170|NCT02310373|Smoking
940171|NCT02310373|Sympathetic
940172|NCT02310321|Acute Myeloid Leukemia
940173|NCT02310321|Cytarabine
940174|NCT02310321|Idarubicin
940175|NCT02310321|ASP2215
940176|NCT02310308|Xylitol
940177|NCT02310308|Magnolia
940178|NCT02310308|chewing gum
940179|NCT02310295|Diabetic retinopathy
940180|NCT02310295|Macular edema
940181|NCT02310295|Anti-VEGF
940182|NCT02310295|Triamcinolone
940183|NCT02310282|Telemedicine
940184|NCT02310282|Emergency medicine
940185|NCT02310282|Stroke
940186|NCT02310282|Stroke syndromes
940187|NCT02310269|Cushing's disease,
940188|NCT02310269|pasireotide s.c.
940189|NCT02310269|Signifor
940190|NCT02310256|Mitochondria, muscle
940191|NCT02310256|Exercise
940192|NCT02310256|Blood Flow Velocity
940193|NCT02310243|Acute myeloid leukemia
940194|NCT02310243|Acute lymphoblastic leukemia
940195|NCT02310243|MLL-rearranged leukemia
940196|NCT02310243|Palbociclib (PD-0332991-00)
940197|NCT02310230|Endoscopy, Upper
940198|NCT02310230|Minute Ventilation
940199|NCT02310230|Tidal Volume
940200|NCT02310230|Respiratory Rate
940201|NCT02310217|Hypertension
940202|NCT02310217|Cognitive impairment
940203|NCT02310217|Biomarkers
940204|NCT02310191|ischemic stroke
940205|NCT02310191|carotid stenting
940206|NCT02310191|MRI diffusion weighted imaging
940207|NCT02310191|Laboratory marker
940208|NCT02310178|weight loss
940209|NCT02310178|sleeve gastrectomy
940210|NCT02310178|gastric bypass
940211|NCT02310178|gastric banding
940212|NCT02310178|bariatric procedures
940213|NCT02310178|cohort
940214|NCT02310178|morbid obesity
940215|NCT02310178|medical and economical impact
940216|NCT02310178|severe obesity
940217|NCT02310165|Paracentesis
940218|NCT02310165|Ascites
940225|NCT02310113|NIRS
940226|NCT02310113|transfusion
940227|NCT02310113|RBC
940228|NCT02310087|male infertility
940229|NCT02310087|spermatogenesis
940230|NCT02310087|antioxidants
940231|NCT02310087|DNA damage
940232|NCT02310087|mitochondrial membrane potential
940233|NCT02310087|apoptosis
940234|NCT02310061|Dialysis
940235|NCT02310061|ESRD
940236|NCT02310061|lung congestion
940237|NCT02310061|heart failure
940238|NCT02310061|LW-US
940239|NCT02310009|Exercise
940240|NCT02310009|IL-1RA
940241|NCT02310009|Beta-cell function
940242|NCT02310009|Type 2 Diabetes
940243|NCT02309996|Randomized Controlled Trial
940244|NCT02309996|Intervention Studies
940245|NCT02309996|Inservice Training
940246|NCT02309996|Personnel Management
940247|NCT02309996|Work place
940248|NCT02309996|Work accommodation
940249|NCT02309996|Job modification
940250|NCT02309996|Supervision
940251|NCT02309996|Administration
940252|NCT02309996|Return to Work
940253|NCT02309996|Industrial Psychology
940254|NCT02309996|Human Engineering
940255|NCT02309996|Risk Management
940256|NCT02309996|Organization and Administration
940257|NCT02309996|Work Disability
940258|NCT02309996|Occupational Diseases
940259|NCT02309996|Occupational Injury
940260|NCT02309996|Occupational Health
940261|NCT02309996|Occupational Exposure
940262|NCT02309996|Sick Leave
940263|NCT02309996|Absenteeism
940264|NCT02309996|Employee Health
940265|NCT02309983|bone turnover
940266|NCT02309983|muscle atrophy
940267|NCT02309983|fiber
940268|NCT02309957|Knee Cartilage Repair, Osteochondral Defects, BioMatrix CRD
940269|NCT02309944|Wound Healing
940270|NCT02309944|Obesity
940271|NCT02309944|Gynecologic Surgery
940272|NCT02309944|Gynecologic Neoplasms
940273|NCT02309944|Surgical Complications
940274|NCT02309931|Right hemicolectomy
940275|NCT02309931|Side-to-side anastomosis
940276|NCT02309931|Orocecal time
940277|NCT02309931|Antipersitaltic
940278|NCT02309931|Isoperistaltic
940279|NCT02309931|Laparoscopic colectomy
940280|NCT02309931|Right laparoscopic hemicolectomy
940281|NCT02309918|acute HCV Genotype 1 Infection
940282|NCT02309918|HCV RNA
940283|NCT02309918|LDV/SOF FDC
940284|NCT02309905|inmates
940285|NCT02309905|skin lesion
940286|NCT02309905|telemedicine
940287|NCT02309892|Non-Small Cell Lung Cancer
940288|NCT02309892|Neoplasms
940289|NCT02309892|Immunoconjugate
940290|NCT02309892|Tumor microenvironment alkalinization
940291|NCT02309879|Intravenous lidocaine
940292|NCT02309879|Magnesium sulphate
940293|NCT02309879|Mastectomy
940294|NCT02309879|Pain
940295|NCT02309827|Inflammatory bowel disease
940296|NCT02309723|Alzheimer's Disease
940297|NCT02309723|Mild Cognitive Impairment
940298|NCT02309723|Neuroimaging
940299|NCT02309723|Diagnostic Tool
940300|NCT02309697|Development
940301|NCT02309697|Assessments
940302|NCT02309697|Premature birth
940303|NCT02309684|Diabetic Foot Ulcer (DFU)
940304|NCT02309684|Venous Leg Ulcer (VLU)
940305|NCT02309658|cervix neoplasm
940306|NCT02309658|hENT1 protein, human
940307|NCT02309658|Chemotherapy
940310|NCT02309619|esophageal cancer
940311|NCT02309619|esophagectomy
940312|NCT02309619|quality of life
940321|NCT02309580|Ibrutinib
940322|NCT02309580|14-227
940323|NCT02309567|Anti-p53 antibody
940324|NCT02309567|PET/CT
940325|NCT02309567|Lung Cancer
940326|NCT02309567|FDG
940327|NCT02309554|Contraception
940328|NCT02309554|Post coital test
940329|NCT02309554|Vaginal
940330|NCT02309554|Diaphragm
940331|NCT02309541|middle ear implant
940332|NCT02309541|feedback manager
940333|NCT02309541|Sound quality
940334|NCT02309502|diabetic retinopathy
940335|NCT02309502|retina
940336|NCT02309502|Laser
940337|NCT02309502|Pascal
940338|NCT02309489|Family Planning Services
940339|NCT02309489|Maternal Health Services
940340|NCT02309489|Breast Feeding
940341|NCT02309489|Contraception
940342|NCT02309489|Postnatal care
940343|NCT02309489|Postpartum contraception
940344|NCT02309489|Exclusive breastfeeding
940345|NCT02309489|Postpartum Period
940346|NCT02309476|diffuse diabetic macular oedema
940347|NCT02309476|Pascal
940348|NCT02309476|Laser
940349|NCT02309476|DMO
940350|NCT02309437|Nasopharyngeal carcinoma
940351|NCT02309437|Pain
940352|NCT02309437|Oxycodone
940353|NCT02309437|Opioids
940354|NCT02309437|Oral Mucositis
940355|NCT02309411|Pediatric
940356|NCT02309385|uveitis
940357|NCT02309385|acute uveitis
940358|NCT02309385|anterior uveitis
940359|NCT02309385|dexamethasone sodium phosphate
940360|NCT02309385|non-infectious uveitis
940361|NCT02309385|DSP-Visulex
940362|NCT02309385|Aciont
940363|NCT02309346|clindamycin
940364|NCT02309346|septic abortion
940365|NCT02309307|safety and performance
940366|NCT02309294|Patch Test
940367|NCT02309281|Eylea
940368|NCT02309268|left atrial appendage closure
940369|NCT02309255|Secondary coronary prevention
940370|NCT02309255|Psychosocial factors
940371|NCT02309255|Cardiac rehabilitation
940372|NCT02309229|sputum colour
940373|NCT02309229|cystic fibrosis
940374|NCT02309229|pollution
940375|NCT02309190|Transpulmonary pressure - morbid obesity
940376|NCT02309177|Pancreatic Cancer
940377|NCT02309177|Breast Cancer
940378|NCT02309177|Metastatic Breast Cancer
940379|NCT02309177|nab-Paclitaxel
940380|NCT02309177|Gemcitabine
940381|NCT02309177|Carboplatin
940382|NCT02309177|Non-Small Cell Lung Cancer
940383|NCT02309177|Lung Cancer
940384|NCT02309177|mBC
940385|NCT02309177|NSCLC
940386|NCT02309177|Triple-negative Breast Cancer
940387|NCT02309177|Hormone Receptor Positive
940388|NCT02309177|ER+
940389|NCT02309177|PR+
940390|NCT02309177|TNBC
940391|NCT02309177|Nivolumab
940392|NCT02309177|PD-1
940393|NCT02309177|Check-point Inhibitor/s
940394|NCT02309177|Immune Check-point Inhibitor/s
940395|NCT02309177|Anti-PD-1
940396|NCT02309177|BMS-936558
940397|NCT02309125|immediate gradual loading
940398|NCT02309099|Acoustic Neuroma
940399|NCT02309099|Vestibular Schwannoma
940400|NCT02309099|Meniere's Disease
940401|NCT02309060|narrative communication
940402|NCT02309060|depression
940403|NCT02309060|primary care
940404|NCT02309060|treatment development
940405|NCT02309034|Overweight
940406|NCT02309034|Obesity
940407|NCT02309034|Cardiometabolic risk factors
940408|NCT02309034|Adolescents
940409|NCT02309034|Exercise
940410|NCT02309021|craving
940411|NCT02309008|Pharmacokinetics
940412|NCT02308995|Endometriosis
940413|NCT02308995|Laparoscopy
940414|NCT02308995|Barbed sutures
940415|NCT02308982|encephalitis
940416|NCT02308982|meningoencephalitis
940417|NCT02308982|encephalomyelitis
940418|NCT02308982|brain inflammation
940419|NCT02308982|intravenous immunoglobulin
940420|NCT02308982|randomised controlled trial
940421|NCT02308982|Central Nervous System Diseases
940422|NCT02308982|Central Nervous System Infection
940423|NCT02308969|altered state of consciousness
940424|NCT02308969|functional magnetic resonance imaging (fMRI)
940425|NCT02308969|hallucination
940426|NCT02308969|model psychosis
940427|NCT02308969|serotonin receptor
940428|NCT02308969|LSD
940429|NCT02308956|task sharing
940430|NCT02308956|task shifting
940431|NCT02308956|community mental health care
940432|NCT02308956|primary care
940433|NCT02308956|Developing country
940434|NCT02308956|Sub-Saharan Africa
940435|NCT02308956|non-inferiority trial
940436|NCT02308917|IBD
940437|NCT02308917|Crohn's
940438|NCT02308917|Ulcerative
940439|NCT02308917|Colitis
940440|NCT02308904|Infertility
940441|NCT02308904|Thalassemia
940442|NCT02308904|Iron overload
940443|NCT02308904|Pituitary Iron Load
940444|NCT02308904|Oxidative Stress
940445|NCT02308904|REPRODUCTIVE CAPACITY AND ASSOCIATION TO IRON BURDEN AND CHELATION PATTERNS IN THALASSEMIA MAJOR PATIENTS
940446|NCT02308891|pancreatitis
940447|NCT02308891|ERCP
940448|NCT02308878|Opioid abuse
940449|NCT02308878|Cognitive Therapy
940450|NCT02308878|Executive Function
940451|NCT02308878|Mobile Health
940452|NCT02308878|Rehabilitation
940453|NCT02308865|Early palliative care
940454|NCT02308865|Lung cancer
940455|NCT02308865|Quality of life
940456|NCT02308852|bi-manual , motor skill learning , stroke , chronic patients,neuro-rehabilitative robot
940457|NCT02308839|Aneurysm
940458|NCT02308839|Aorta
940459|NCT02308839|Abdominal
940460|NCT02308800|diabetic foot ulcer
940461|NCT02308787|platelet depletion
940462|NCT02308787|apheresis
940463|NCT02308774|osteomyelitis, diabetic foot infection
940464|NCT02308735|gestation
940465|NCT02308735|diabetes
940466|NCT02308735|ethanol
940467|NCT02308722|Borderline resectable
940468|NCT02308709|Radiotherapy
940469|NCT02308709|Pulmonary Functional Imaging
940470|NCT02308709|Computed Tomography (CT)
940471|NCT02308709|Image Registration
940472|NCT02308709|Functional Image-guided Radiotherapy
940473|NCT02308696|Older Adults
940474|NCT02308696|Aging in Place
940475|NCT02308683|hscrp
940476|NCT02308683|hgba1c
940477|NCT02308683|diabetes mellitus
940478|NCT02308644|Diabetic Retinopathy
940479|NCT02308644|intravitreal bevacizumab
940480|NCT02308644|Contrast Sensitivity
940481|NCT02308631|Endoscopic, Colostomy, Colopexy
940482|NCT02308618|Achilles tendon rupture
940483|NCT02308618|Rehabilitation
940484|NCT02308618|Immobilization
940485|NCT02308618|Muscle architecture
940486|NCT02308618|Functionality
940487|NCT02308618|Neuromuscular parameters
940488|NCT02308618|Weight-Bearing
940489|NCT02308605|SMARTCap
940490|NCT02308592|Pregnancy
940491|NCT02308592|Depression
940492|NCT02308592|Antidepressant Use
940493|NCT02308592|Decision Aid
940494|NCT02308566|Intracranial Embolism
940495|NCT02308566|Ultrasonography, Doppler, Transcranial
940496|NCT02308553|BRAF V600 wildtype
940497|NCT02308553|cutaneous malignant melanoma
940498|NCT02308553|nintedanib
940499|NCT02308553|paclitaxel
940500|NCT02308553|kinase inhibitor
940501|NCT02308527|Children
940502|NCT02308527|Young adults
940503|NCT02308514|cryostimulation
940504|NCT02308488|prone IMRT to breast, level III & Supraclavicular
940505|NCT02308488|acute toxicity of prone IMRT to breast, level III & SCV
940506|NCT02308462|children of mentally ill parents
940507|NCT02308462|family intervention
940508|NCT02308462|randomized controlled trial
940509|NCT02308410|Tourniquet
940510|NCT02308410|Postoperative outcome
940511|NCT02308410|Total knee arthroplasty
940512|NCT02308397|non coeliac gluten sensitivity
940513|NCT02308397|gluten
940514|NCT02308397|bread
940515|NCT02308384|iFOBT
940516|NCT02308384|FIT
940517|NCT02308384|general practice
940518|NCT02308384|early diagnosis
940519|NCT02308371|critically ill pediatric patients
940520|NCT02308371|fluid resuscitation
940521|NCT02308358|Osteochondral Defect
940522|NCT02308358|Femoral condyle osteochondral defect
940523|NCT02308319|Hepatocellular carcinoma, Recurrence
940524|NCT02308306|Chronic pain
940525|NCT02308306|Opioid analgesics
940526|NCT02308306|Prediction study
940527|NCT02308306|Pharmaco-EEG
940528|NCT02308293|Type 1 Diabetes Mellitus
940529|NCT02308293|Hypoglycemia unawareness
940530|NCT02308293|Lactate
940531|NCT02308293|high intensity interval exercise
940532|NCT02308293|MRS
940533|NCT02308280|High-risk myeloma
940534|NCT02308280|Non myeloablative allogeneic transplantation
940535|NCT02308280|Bortezomib
940536|NCT02308267|Cystic Fibrosis
940537|NCT02308267|Mucosal immunity
940538|NCT02308254|Blood pressure
940539|NCT02308254|Gastric emptying
940540|NCT02308254|Glycemia
940541|NCT02308254|Appetite
940542|NCT02308254|Incretin Hormones
940543|NCT02308254|Superior mesenteric artery blood low
940544|NCT02308241|Ribavirin
940545|NCT02308241|Human Papillomavirus (HPV)
940546|NCT02308241|Recurrent/Metastatic (R/M)
940547|NCT02308241|14-211
940548|NCT02308228|Aging
940549|NCT02308228|Hypertrophy
940550|NCT02308228|Metformin
940551|NCT02308228|Strength
940552|NCT02308228|Muscle
940553|NCT02308215|Retina
940554|NCT02308215|AMD
940555|NCT02308215|OCT
940556|NCT02308202|PTSD
940557|NCT02308202|treatment
940558|NCT02308202|virtual reality
940559|NCT02308202|doxazosin
940560|NCT02308189|Exercise
940561|NCT02308163|Rheumatoid Arthritis
940562|NCT02308163|ASP015K
940570|NCT02308085|Premenopausal
940571|NCT02308085|endocrine responsive
940572|NCT02308085|Breast
940573|NCT02308085|Pregnancy
940574|NCT02308072|Squamous Cell Carcinoma
940575|NCT02308072|Head and Neck Cancer
940576|NCT02308072|Locally Advanced
940577|NCT02308072|Olaparib
940578|NCT02308072|Cisplatin
940579|NCT02308072|IMRT
940580|NCT02308072|Chemoradiotherapy
940581|NCT02308072|PARP
940582|NCT02308072|HNSCC
940583|NCT02307994|infertility
940584|NCT02307942|Randomized Clinical Trials
940585|NCT02307942|gastric banding
940586|NCT02307942|calorie restriction
940587|NCT02307942|SPPB
940588|NCT02307942|physical performance
940589|NCT02307942|elderly
940590|NCT02307916|tympanic membrane perforation
940591|NCT02307916|ear drum
940592|NCT02307916|hole
940593|NCT02307903|end-stage renal failure (ESRF)
940594|NCT02307890|Liver Transplantation
940595|NCT02307864|Healthy
940596|NCT02307864|QT interval
940597|NCT02307864|QTc interval
940598|NCT02307864|Electrocardiogram
940599|NCT02307864|Tramadol hydrochloride
940600|NCT02307864|Moxifloxacin
940601|NCT02307864|Placebo
940602|NCT02307838|Multiple Sclerosis, MS, RRMS, relapsing forms of multiple sclerosis, fingolimod, FTY720, Gilenya
940603|NCT02307825|Azithromycin
940604|NCT02307825|Endoscopic sinus surgery
940605|NCT02307799|tobacco
940606|NCT02307799|spirometry
940607|NCT02307799|cohort study
940608|NCT02307799|case-control study
940609|NCT02307799|prevalence
940610|NCT02307773|Upper Gastrointestinal Endoscopy
940611|NCT02307773|Pharyngeal Anesthesia
940612|NCT02307773|Lidocaine
940613|NCT02307773|Belching
940614|NCT02307773|Retching
940615|NCT02307773|Tolerance
940616|NCT02307747|infection in ICU
940617|NCT02307734|Lay Health Workers
940618|NCT02307734|Chinese
940619|NCT02307734|Vietnamese
940620|NCT02307734|Tobacco Use
940621|NCT02307734|Intervention
940622|NCT02307734|Behavior Change
940623|NCT02307734|Social Networks
940624|NCT02307734|Asians
940625|NCT02307721|Emergency Treatment
940626|NCT02307721|Morphine Derivates
940627|NCT02307721|Heroin
940628|NCT02307721|Antidotes
940629|NCT02307721|Administration, Intranasal
940630|NCT02307721|Pharmacology
940631|NCT02307721|Naloxone
940632|NCT02307721|Healthy volunteers
940633|NCT02307695|Saxagliptin
940634|NCT02307695|Type 1 Diabetes
940635|NCT02307695|Glycemic variability
940636|NCT02307695|C-Peptide
940637|NCT02307682|AMD
940638|NCT02307682|CNV
940639|NCT02307682|IVT
940640|NCT02307643|Systemic lupus erythematosus
940641|NCT02307630|124I-Humanized 3F8
940642|NCT02307630|PET Imaging
940643|NCT02307630|13-147
940644|NCT02307617|Major depressive disorder
940645|NCT02307617|MDD
940646|NCT02307617|healthy control
940647|NCT02307617|selective serotonin reuptake inhibitor
940648|NCT02307617|SSRI
940649|NCT02307617|depression
940650|NCT02307617|transcranial magnetic stimulation
940651|NCT02307617|TMS
940652|NCT02307617|magnetic resonance spectroscopy
940653|NCT02307617|MRS
940654|NCT02307617|adolescent
940655|NCT02307617|mild MDD
940656|NCT02307617|mild depression
940657|NCT02307617|cortical excitability
940658|NCT02307617|cortical inhibition
940659|NCT02307617|cortical silent period
940660|NCT02307617|motor threshold
940661|NCT02307617|intracortical facilitation
940662|NCT02307617|intracortical inhibition
940663|NCT02307617|motor cortex
940664|NCT02307617|dorsolateral prefrontal cortex
940665|NCT02307617|DLPFC
940666|NCT02307617|thumb twitch
940667|NCT02307617|gamma aminobutyric acid
940668|NCT02307617|GABA
940669|NCT02307617|glutamate
940670|NCT02307617|single pulse
940671|NCT02307617|paired pulse
940672|NCT02307604|Brain tumor
940673|NCT02307604|Biomarkers
940674|NCT02307604|Screening
940675|NCT02307578|Perampanel
940676|NCT02307578|Fycompa
940677|NCT02307578|Primary Generalized Tonic-Clonic Seizures
940678|NCT02307578|E2007-G000-332
940679|NCT02307578|E2007
940680|NCT02307565|Midodrine
940681|NCT02307565|Blood pressure
940682|NCT02307565|Orthostatic hypotension
940683|NCT02307565|Spinal Cord Injury
940684|NCT02307565|Sympathetic vascular control
940685|NCT02307565|Cerebral blood flow velocity
940686|NCT02307565|Cognition function tasks
940687|NCT02307565|Quality of Life
940688|NCT02307565|MRI
940689|NCT02307565|fMRI
940690|NCT02307552|Imaging
940691|NCT02307552|ultrasound
940692|NCT02307552|prostate
940693|NCT02307552|cancer
940694|NCT02307552|diagnostic tool
940695|NCT02307552|catheter
940696|NCT02307552|urethra
940697|NCT02307552|digital rectal exam
940698|NCT02307526|Hypotension, Postural
940699|NCT02307513|APREMILAST (CC-10004)
940700|NCT02307513|CC-10004
940701|NCT02307513|Efficacy
940702|NCT02307513|Safety
940703|NCT02307513|Phase 3
940704|NCT02307513|Behçet's Disease
940705|NCT02307487|TC-3 Gel
940706|NCT02307487|MMC
940707|NCT02307487|NMIBC
940708|NCT02307487|Non Muscle Invasive Bladder Cancer
940709|NCT02307487|Hydrogel Reverse thermal gelation
940710|NCT02307487|Drug retention
940711|NCT02307487|Urinary Bladder Neoplasms
940712|NCT02307487|Urologic Neoplasms
940713|NCT02307487|Urinary Bladder Diseases
940714|NCT02307487|Urologic Diseases
940715|NCT02307474|Kidney
940716|NCT02307474|Renal Cell Carcinoma
940717|NCT02307474|Cancer
940718|NCT02307474|Pilot
940719|NCT02307474|Pazopanib
940720|NCT02307474|stereotactic body radiation therapy
940721|NCT02307474|SBRT
940722|NCT02307461|Phase 1
940723|NCT02307461|Bioequivalence
940724|NCT02307461|Pharmacokinetics
940725|NCT02307461|Food
940726|NCT02307461|Healthy Adult
940727|NCT02307435|non union fracture
940728|NCT02307435|bone defect
940729|NCT02307435|mesenchymal stem cell
940730|NCT02307435|cryopreservation
940731|NCT02307383|SDD (Selective Digestive Decolonization)
940732|NCT02307383|OXA 48
940733|NCT02307383|carbapenemase
940734|NCT02307383|probiotics
940735|NCT02307331|Total Hip Replacement
940736|NCT02307318|Radial Artery
940737|NCT02307318|Hemostasis
940738|NCT02307318|Angiography
940739|NCT02307292|Superficial femoral artery
940740|NCT02307292|Self Expanding Stent System
940741|NCT02307253|EUS-guided biopsy, EUS-FNB
940742|NCT02307240|NMC
940743|NCT02307188|Atrial Fibrillation
940744|NCT02307188|Atrial Flutter
940745|NCT02307188|Multipolar Catheter
940746|NCT02307188|Atrial Arrhythmia
940747|NCT02307162|COPD
940748|NCT02307149|melanoma
940749|NCT02307149|ipilimumab
940750|NCT02307149|coxsackievirus A21
940751|NCT02307149|CAVATAK
940752|NCT02307149|CVA21
940753|NCT02307136|intensive care units
940754|NCT02307136|emergency department
940755|NCT02307123|Prehospital emergency care (MeSH)
940756|NCT02307123|Emergency medical services (MeSH)
940757|NCT02307123|Helicopter emergency medical service, Critical care (MeSH)
940758|NCT02307123|Airway management (MeSH)
940759|NCT02307123|Endotracheal intubation (MeSH)
940760|NCT02307123|Patient outcome
940761|NCT02307110|Diabetes Mellitus 1
940762|NCT02307110|long-term intensified insulin therapy
940763|NCT02307110|diabetic retinopathy
940764|NCT02307110|diabetic macular edema
940765|NCT02307097|Randomised Controlled Trial
940766|NCT02307097|Cognitive-Behavioural Bibliotherapy
940767|NCT02307097|Social Anxiety Disorder
940768|NCT02307097|Cognitive-Behavioural Therapy
940769|NCT02307097|IAPT
940770|NCT02307084|surgical site infection
940771|NCT02307084|long saphenous vein
940772|NCT02307084|coronary artery bypass grafting
940773|NCT02307058|Prostate Cancer
940774|NCT02307045|Arterial stiffness
940775|NCT02307045|Endothelial Glycocalyx
940776|NCT02307032|Atrial Fibrillation Relapses Prediction
940777|NCT02307032|P wave Signal Averaged ECG
940778|NCT02307032|P wave Wavelets
940779|NCT02307032|Strain
940780|NCT02307032|Tissue Doppler Imaging
940781|NCT02307019|Caregivers
940782|NCT02307019|Apraxias
940783|NCT02307019|Stroke
940784|NCT02307019|Cerebral Stroke
940785|NCT02307019|Rehabilitation
940786|NCT02307019|Pragmatic Clinical Trials as Topic
940787|NCT02306993|Sickle Cell Disease (SCD)
940788|NCT02306993|Sickle Cell Trait (SCT)
940789|NCT02306967|oral cancer
940790|NCT02306967|oral dysplasia
940791|NCT02306954|Kidney Cancer
940792|NCT02306954|High Dose IL-2
940793|NCT02306954|SBRT
940794|NCT02306928|Septic shock
940795|NCT02306928|Intensive care unit
940796|NCT02306928|Therapeutic drug monitoring
940797|NCT02306928|Pharmacokinetics
940798|NCT02306928|Critically ill
940799|NCT02306915|Lipegfilgrastim, Lonquex, Japanese Bridging
940800|NCT02306863|Parkinson's Disease
940801|NCT02306863|whole-body vibration
940802|NCT02306863|WBV
940803|NCT02306850|immunotherapy
940804|NCT02306850|PD-1 inhibitor
940805|NCT02306850|programmed death 1 inhibitor
940806|NCT02306850|neoadjuvant
940807|NCT02306850|pembrolizumab
940808|NCT02306850|MK-3475
940809|NCT02306837|lymphoma, consolidation chemotherapy, auto-HSCT
940810|NCT02306759|analgesia
940811|NCT02306759|ketamine
940812|NCT02306759|pain
940817|NCT02306733|Post partum hemorrhage
940818|NCT02306733|Ergometrine
940819|NCT02306733|Oxytocin
940820|NCT02306733|Obstetrics
940821|NCT02306694|hemophilia
940822|NCT02306694|bone disease
940823|NCT02306694|clinical study
940824|NCT02306694|biomarkers
940825|NCT02306668|Dry eye
940826|NCT02306655|Coital incontinence
940827|NCT02306655|Incidence
940828|NCT02306655|quality of life
940829|NCT02306629|Systemic Lupus Erythematosus
940830|NCT02306590|amyotrophic lateral sclerosis
940831|NCT02306590|survival time
940832|NCT02306590|ALS Functional Rating Scale
940833|NCT02306590|quality of life
940834|NCT02306590|survival
940835|NCT02306577|STRIBILD
940836|NCT02306577|HIV
940837|NCT02306577|Illicit dgug user
940838|NCT02306564|ICSI
940839|NCT02306564|cabergoline
940840|NCT02306564|Subendometrial vascularity
940841|NCT02306551|Offspring
940842|NCT02306551|Attachment
940843|NCT02306551|Risk development
940844|NCT02306551|Resilience
940845|NCT02306538|edema
940846|NCT02306538|inflammation
940847|NCT02306538|scar
940848|NCT02306538|ejection fraction
940849|NCT02306538|volumes
940850|NCT02306512|Melanoma In Situ
940851|NCT02306512|Lentigo Maligna
940852|NCT02306512|Confocal Microscopy
940853|NCT02306512|Direct Immunofluorescence
940854|NCT02306499|VARICOCELE-AZOOSPERMIA-ICSI
940855|NCT02306460|Neurobehavioral Manifestations
940856|NCT02306460|POCD
940857|NCT02306460|Atrial Fibrillation
940858|NCT02306460|Anti-Arrhythmia
940859|NCT02306460|Atrial Appendage Closure
940860|NCT02306434|childbirth fear
940861|NCT02306434|Internet CBT
940862|NCT02306434|counselling
940863|NCT02306434|antenatal care
940864|NCT02306434|postnatal care
940865|NCT02306434|childbirth
940866|NCT02306434|Cognitive behavioural therapy
940867|NCT02306421|RPH with the simplified Milligan-Morgan surgery
940868|NCT02306421|mixed hemorrhoids
940869|NCT02306421|the effectiveness and safety
940870|NCT02306421|A multi center clinical trial
940871|NCT02306395|endometrial local injury
940872|NCT02306395|repeated implatation failure
940873|NCT02306395|embyo transfer
940874|NCT02306382|endoanal ultrasonography
940875|NCT02306382|drainage
940876|NCT02306382|perianal abscess
940877|NCT02306382|fistulas
940878|NCT02306382|incontience
940879|NCT02306369|ICBT
940880|NCT02306369|IBS
940881|NCT02306369|FGID
940882|NCT02306369|functional abdominal pain
940883|NCT02306369|Adolescents
940884|NCT02306369|Children
940885|NCT02306369|Treatment
940886|NCT02306369|CBT
940887|NCT02306369|Exposure
940888|NCT02306369|Cognitive Behavior Therapy
940889|NCT02306369|Internet
940890|NCT02306369|Computerized
940891|NCT02306369|Abdominal Pain
940892|NCT02306369|Functional Pain
940893|NCT02306369|Functional Disorders
940894|NCT02306343|rapid acting insulin
940895|NCT02306343|insulin injection
940896|NCT02306343|insulin delivery
940897|NCT02306343|local heating
940898|NCT02306343|experimental device
940899|NCT02306343|pre and post meal glucose level
940900|NCT02306330|Malditof
940901|NCT02306330|Malditof MS
940902|NCT02306330|matrix-assisted laser desorption ionization-time
940903|NCT02306330|identifying pathogens
940904|NCT02306330|randomized diagnostic trial
940905|NCT02306304|Abdominal aortic aneurysm
940906|NCT02306304|Abdominal aortic aneurism
940907|NCT02306304|AAA
940908|NCT02306304|Screening
940909|NCT02306304|duplex ultra sound
940910|NCT02306304|Israeli Arab men
940911|NCT02306304|family physician
940912|NCT02306291|AML
940913|NCT02306291|Acute myeloid leukemia
940914|NCT02306291|E-selectin
940915|NCT02306291|relapse refractory
940916|NCT02306291|elderly newly diagnosed
940917|NCT02306291|induction
940918|NCT02306278|gabapentin
940919|NCT02306278|postoperative pain
940920|NCT02306278|vomiting
940921|NCT02306278|nausea
940922|NCT02306252|Cancer
940923|NCT02306252|Older Adult
940924|NCT02306252|Geriatric
940925|NCT02306252|Function
940926|NCT02306252|Functional Deficit
940927|NCT02306252|Occupational Therapy
940928|NCT02306252|Physical Therapy
940929|NCT02306252|Supportive Care
940930|NCT02306252|Oncology
940931|NCT02306252|physiology
940932|NCT02306252|Geriatric Assessment
940933|NCT02306252|Health Services for the Aged
940934|NCT02306252|Physical Therapy Specialty
940935|NCT02306226|TAVI
940936|NCT02306226|Aortic stenosis
940937|NCT02306226|Transcatheter aortic valve replacement
940938|NCT02306226|Transcatheter aortic valve implantation
940939|NCT02306226|Transfemoral access
940940|NCT02306200|Aorta
940941|NCT02306200|Aortic Disease
940942|NCT02306200|Abdominal Aortic Aneurysm (AAA)
940943|NCT02306200|Thoracic Aortic Aneurysm (TAA)
940944|NCT02306200|Aortic Stenosis
940945|NCT02306200|Aortic Valve Repair (AVR)
940946|NCT02306200|Bicuspid Aortic Valve (BAV)
940947|NCT02306187|The changes of bone mineral density and bone turnover markers
940948|NCT02306174|Hoarding
940949|NCT02306135|Cancer
940950|NCT02306135|Tumor
940951|NCT02306135|Everolimus
940952|NCT02306135|mTOR
940953|NCT02306135|Temsirolimus
940954|NCT02306135|Sirolimus
940955|NCT02306135|Rapamycin
940956|NCT02306122|medication adherence
940957|NCT02306122|choice architecture
940958|NCT02306122|pharmacy home
940959|NCT02306109|Motor Rehabilitation Treatment
940960|NCT02306109|Intensive versus standard
940961|NCT02306109|Motor Disability
940962|NCT02306096|prognostic and predictive biomarkers
940963|NCT02306096|RNA-sequencing
940964|NCT02306096|pathological complete response
940965|NCT02306096|minimal residual disease
940966|NCT02306096|molecular subtype
940967|NCT02306096|gene expression profiling
940968|NCT02306096|mutation screening
940969|NCT02306096|BRCA
940970|NCT02306096|translational research
940971|NCT02306096|genomics
940972|NCT02306096|transcriptomics
940973|NCT02306096|proteomics
940974|NCT02306096|metabolomics
940975|NCT02306096|liquid biopsy
940976|NCT02306096|circulating tumor cells
940977|NCT02306096|circulating tumor DNA
940978|NCT02306044|Bleeding
940979|NCT02306044|Platelet indices
940980|NCT02306044|Platelet aggregometry
940981|NCT02306044|Bleeding questionnaire
940982|NCT02306031|diclofenac
940983|NCT02306031|macular thickness
940984|NCT02306031|phacoemulsification
940985|NCT02306031|OCT(Optical coherence tomography )
940986|NCT02306031|diabetic
940987|NCT02306018|liver transplantation
940988|NCT02306018|cardiac output
940989|NCT02306005|diabetes mellitus type 1, insulin therapy, lipoproteins, HDL
940990|NCT02305966|advanced arthritis
940991|NCT02305966|shoulder
940992|NCT02305953|Psoriasis
940993|NCT02305953|Vascular Inflammation
940994|NCT02305953|Coronary Atherosclerosis
940995|NCT02305953|Ascending aorta
940996|NCT02305953|PET scan
940997|NCT02305953|Cytokine
940998|NCT02305953|Chemokine
940999|NCT02305927|Vitamin D
941000|NCT02305927|Pregnant women
941001|NCT02305914|acute pancreatitis
941002|NCT02305914|chronic pancreatitis
941003|NCT02305914|pancreatic cancer
941004|NCT02305914|pancreatic disease-associated portal hypertension
941005|NCT02305914|autoimmune pancreatitis
941006|NCT02305914|PaO2/FiO2＜200
941007|NCT02305914|diabetes mellitus
941008|NCT02305914|blood lipid
941009|NCT02305914|local complications
941010|NCT02305914|quality of life
941011|NCT02305862|Coronary Arteriosclerosis
941012|NCT02305862|Carotid Atherosclerotic Plaque
941013|NCT02305862|Rosuvastatin
941014|NCT02305849|ASP015K
941015|NCT02305849|Rheumatoid Arthritis
941016|NCT02305836|Electroacupuncture
941017|NCT02305836|Donepezil
941018|NCT02305836|Alzheimer's disease
941019|NCT02305836|Randomized controlled trial
941020|NCT02305823|psychosis
941021|NCT02305823|antipsychotic agents
941022|NCT02305823|treatment
941023|NCT02305823|effectiveness
941024|NCT02305784|Cystic fibrosis
941025|NCT02305784|Pulmonary exacerbation
941026|NCT02305784|inflammation
941027|NCT02305784|Chitinase
941028|NCT02305784|cytokine
941029|NCT02305784|Cystic fibrosis related diabetes
941030|NCT02305758|fluorouracil
941031|NCT02305758|irinotecan
941032|NCT02305758|colon cancer
941033|NCT02305758|veliparib
941034|NCT02305758|FOLFIRI
941035|NCT02305758|previously untreated
941036|NCT02305758|ABT-888
941037|NCT02305758|first line
941038|NCT02305758|metastatic colorectal cancer
941039|NCT02305758|PARP inhibitor
941040|NCT02305758|5-FU
941041|NCT02305758|rectal cancer
941042|NCT02305758|colorectal cancer
941043|NCT02305758|leucovorin
941044|NCT02305732|Chikungunya virus
941045|NCT02305732|CHIKV
941046|NCT02305732|Dengue virus
941047|NCT02305732|DENV
941048|NCT02305732|pathogen inactivation
941049|NCT02305732|platelets
941050|NCT02305732|Puerto Rico
941051|NCT02305706|insertion
941052|NCT02305706|patient comfort
941053|NCT02305667|Laryngoscope
941054|NCT02305667|Macintosh
941055|NCT02305667|Glidescope®
941056|NCT02305667|King Vision™
941057|NCT02305667|Airtraq®
941058|NCT02305667|intubation
941059|NCT02305667|double lumen tube
941060|NCT02305654|Penis cancer
941061|NCT02305654|Chemotherapy
941062|NCT02305654|Chemoradiotherapy
941063|NCT02305654|Surgery
941064|NCT02305654|Phase III
941065|NCT02305602|extracellular matrix
941066|NCT02305589|postoperative delirium
941067|NCT02305589|sugammadex
941068|NCT02305589|cholinesterase inhibitor
941069|NCT02305589|hip fracture surgery
941070|NCT02305550|Nitric Oxide
941071|NCT02305524|endotracheal intubation
941072|NCT02305511|Catheterization
941073|NCT02305511|Peripheral
941074|NCT02305498|Yoga
941075|NCT02305498|14-059
941076|NCT02305485|NeoVas
941077|NCT02305485|Bioresorbable Coronary Scaffold
941078|NCT02305485|Sirolimus
941079|NCT02305485|Randomized Controlled Trial
941080|NCT02305472|NeoVas
941081|NCT02305472|Bioresorbable Coronary Scaffold
941082|NCT02305472|Sirolimus
941083|NCT02305472|Registry Trial
941084|NCT02305459|SIRT
941085|NCT02305459|microcatheter
941086|NCT02305459|primary liver tumor
941087|NCT02305459|secondary liver tumor
941088|NCT02305459|radioembolisation
941089|NCT02305459|QLQ-C30
941090|NCT02305459|CIRSE
941091|NCT02305433|elderly
941092|NCT02305433|functional-based physiotherapy
941093|NCT02305433|frailty syndrome
941094|NCT02305433|osteoporotic hip fractures
941095|NCT02305433|home-based physiotherapy
941096|NCT02305433|home-dwelling
941097|NCT02305433|intervention
941098|NCT02305433|randomised controlled trial
941099|NCT02305433|costs of social and health care
941100|NCT02305433|quality of life
941101|NCT02305433|physical functioning
941102|NCT02305433|mobility
941103|NCT02305433|nutrition
941104|NCT02305394|ketamine
941105|NCT02305394|Electroconvulsive Therapy
941106|NCT02305394|Cognitive Function
941107|NCT02305342|Uncomplicated UTI
941108|NCT02305342|Enoxacin
941109|NCT02305303|Quality of life
941110|NCT02305303|post-traumatic stress disorder
941111|NCT02305303|trauma
941112|NCT02305238|Eylea,
941113|NCT02305238|Aflibercept
941114|NCT02305238|Treat and Extend regimen
941115|NCT02305238|Age-related macular degeneration
941116|NCT02305212|Working Memory
941117|NCT02305199|Diabetes Mellitus, Type 2
941118|NCT02305199|Hartmann's solution
941119|NCT02305186|Immunotherapy
941120|NCT02305186|Neoadjuvant
941121|NCT02305186|Resectable
941122|NCT02305186|Borderline resectable
941123|NCT02305173|dexamethasone
941124|NCT02305173|pulmonary function
941125|NCT02305173|spirometry
941126|NCT02305173|mastectomy
941127|NCT02305160|Respiratory distress syndrome
941128|NCT02305160|Pulmonary surfactant
941129|NCT02305160|Mortality
941130|NCT02305160|Prematurity
941131|NCT02305147|Parkinson Disease
941132|NCT02305147|Biomarkers
941133|NCT02305147|Prognostic factors
941134|NCT02305147|Prodromal features
941135|NCT02305147|Disease progression
941136|NCT02305134|Tipepidine, GIRK
941137|NCT02305121|Trochanteric fracture
941138|NCT02305121|Nail
941139|NCT02305121|Fracture reduction
941140|NCT02305121|Antirotation
941141|NCT02305121|trochanteric area with diaphyseal extension
941142|NCT02305121|trochanteric area with femoral shaft
941143|NCT02305043|non-interventional
941144|NCT02305043|advanced gastric cancer
941145|NCT02305043|Trastuzumab
941146|NCT02305043|HER2
941147|NCT02304991|Peanut
941148|NCT02304991|Food Allergy
941149|NCT02304978|colorectal cancer
941150|NCT02304978|Tissular factor
941151|NCT02304978|TF
941152|NCT02304965|LVAD
941153|NCT02304952|Lateral epicondylalgia
941154|NCT02304952|Pain
941155|NCT02304952|Function
941156|NCT02304952|Physiotherapy
941157|NCT02304952|Quality of Life
941158|NCT02304939|Norepinephrine
941159|NCT02304939|Intensive Care
941160|NCT02304939|Changeovers
941161|NCT02304939|Smart pumps
941162|NCT02304939|Quick change
941163|NCT02304939|Double pumping
941164|NCT02304939|Shock
941165|NCT02304926|Dyslipidemia
941166|NCT02304926|Simvastatin
941167|NCT02304926|Ezetimibe
941168|NCT02304926|Lipid profile
941169|NCT02304926|Inflammation
941170|NCT02304926|Oxidative stress
941171|NCT02304926|Endothelial function
941172|NCT02304900|cataract
941173|NCT02304887|Osteoporosis
941174|NCT02304887|Bone mineral densisty
941175|NCT02304887|Renal function
941176|NCT02304887|CKD-MBD
941177|NCT02304874|Ferritins
941178|NCT02304874|Iron Overload
941179|NCT02304874|Metabolic Syndrome
941180|NCT02304874|Venesection therapy
941181|NCT02304874|Volunteers
941182|NCT02304861|cataract
941183|NCT02304861|viscoelastic (OVD) technology
941184|NCT02304861|endothelial cell count
941185|NCT02304861|endothelial cell pattern
941186|NCT02304861|central corneal edema
941187|NCT02304848|Parkinson's Disease
941188|NCT02304848|DBS
941189|NCT02304848|Deep Brain Stimulation
941190|NCT02304848|Subthalamic Nucleus
941191|NCT02304822|kidney stones
941192|NCT02304822|retrograde intrarenal surgery
941193|NCT02304822|ciprofloxacin
941194|NCT02304822|prophylaxis
941195|NCT02304822|systemic inflammatory response syndrome
941196|NCT02304809|metastatic or unresectable locally advanced malignancies.
941197|NCT02304809|genomic alterations
941198|NCT02304809|biological vemurafenib targets BRAF
941199|NCT02304809|genomic.
941200|NCT02304796|Anxiety Disorders
941201|NCT02304796|Group Psychotherapy
941202|NCT02304796|Cognitive-Behavioral Therapy
941203|NCT02304796|Dance/Movement Therapy
941204|NCT02304796|CBT
941205|NCT02304796|DMT
941206|NCT02304796|Unified Protocol
941207|NCT02304783|Renal colic, Piroxicam
941208|NCT02304757|differentiated thyroid cancer
941209|NCT02304757|bone mineral density
941210|NCT02304757|thyroid stimulating hormone suppression
941211|NCT02304731|Physical Exercise, Atmospheric Pollution, Cognition.
941212|NCT02304718|GDM
941213|NCT02304718|pregnancy outcome
941214|NCT02304718|obesity
941215|NCT02304718|exercise
941216|NCT02304718|overweight
941217|NCT02304640|fatigue
941218|NCT02304640|chemotherapy
941219|NCT02304640|breast cancer
941220|NCT02304640|supportive care
941221|NCT02304640|Singapore
941222|NCT02304523|Colonoscopy preparation
941223|NCT02304523|Bowel cleansing
941224|NCT02304523|Colon cleansing
941225|NCT02304523|Colonoscopy
941226|NCT02304523|CDFR0612
941227|NCT02304523|CDFR0613
941228|NCT02304510|Prevalence
941229|NCT02304510|Menorrhagia
941230|NCT02304497|Diabetes mellitus
941231|NCT02304497|Platelet rich fibrin
941232|NCT02304497|growth factor
941233|NCT02304445|Radiotherapy
941234|NCT02304445|Chemoembolization
941235|NCT02304406|prevalence of ALK rearrangement, NSCLC, MENA
941236|NCT02304367|TIO
941237|NCT02304367|ENS
941238|NCT02304367|FGF23
941239|NCT02304367|KRN23
941240|NCT02304354|rheumatoid arthritis
941241|NCT02304354|T lymphocytes
941242|NCT02304354|rituximab
941243|NCT02304341|critical illness
941244|NCT02304341|disease progression
941245|NCT02304341|child
941246|NCT02304341|severity of illness index
941247|NCT02304341|monitoring
941248|NCT02304328|SAH
941249|NCT02304328|WFNS
941250|NCT02304328|hWFNS
941251|NCT02304328|grading
941252|NCT02304315|HBV-related liver transplantation
941253|NCT02304315|Hepatitis B Immuno Globulin
941254|NCT02304302|Memantine
941255|NCT02304302|Episodic Memory
941256|NCT02304302|CVLT
941257|NCT02304302|Hippocampus dependent memory
941258|NCT02304302|Short-term memory
941259|NCT02304263|tenofovir
941260|NCT02304263|aging
941261|NCT02304263|renal function
941262|NCT02304263|HIV
941263|NCT02304263|frailty
941264|NCT02304237|Premature Birth
941265|NCT02304237|progesterone
941266|NCT02304224|sepsis
941267|NCT02304224|melatonin
941268|NCT02304224|Human Leukocyte Antigen-DR
941269|NCT02304224|outcome
941270|NCT02304211|Microdosing
941271|NCT02304211|Phase 0
941272|NCT02304211|Exploratory Investigational New Drug (IND)
941273|NCT02304211|Intra-Arterial
941274|NCT02304211|PET Imaging
941275|NCT02304185|Healthy
941276|NCT02304185|Acquired Immuno-Deficiency Syndrome
941277|NCT02304185|Acquired Immunodeficiency Syndrome Virus
941278|NCT02304185|Glycoprotein
941279|NCT02304185|Adjuvant
941280|NCT02304185|Vaccine
941281|NCT02304185|Placebo
941282|NCT02304172|Thyroidectomy
941283|NCT02304172|Thunderbeat
941284|NCT02304159|HCV
941285|NCT02304159|Genotype 3
941286|NCT02304159|Treatment naive
941287|NCT02304159|Treatment experienced
941288|NCT02304146|Foam
941289|NCT02304146|UGFS
941290|NCT02304146|Stripping
941291|NCT02304146|Incompetence
941292|NCT02304120|proprioception
941293|NCT02304120|postural control
941294|NCT02304120|sensorimotor training
941295|NCT02304120|uncontrolled manifold
941296|NCT02304029|epilepsy
941297|NCT02304029|seizures
941298|NCT02304003|Shoulder tendinopathy
941299|NCT02304003|Subacromial impingement syndrome
941300|NCT02304003|Rotator cuff tendinopathy
941301|NCT02304003|Supraspinatus tendinopathy
941302|NCT02303964|Trauma
941303|NCT02303964|Hemorrhage
941304|NCT02303964|Plasma
941305|NCT02303964|Shock
941306|NCT02303964|Polytrauma
941307|NCT02303912|relapsed epithelial ovarian cancer,
941308|NCT02303912|relapsed fallopian tube cancer
941309|NCT02303912|relapsed primary peritoneal cancer.
941310|NCT02303860|Healthy volunteer study
941311|NCT02303808|Hyperosmolar agents
941312|NCT02303808|Hypertonic saline
941313|NCT02303808|Airway clearance techniques
941314|NCT02303808|Positive Expiratory Pressure
941315|NCT02303808|Autogenic drainage
941316|NCT02303795|bioprosthetic mitral valve
941317|NCT02303795|valvular heart disease
941318|NCT02303795|anticoagulant agents
941319|NCT02303795|NOACs
941320|NCT02303795|rivaroxaban
941321|NCT02303795|warfarin
941322|NCT02303769|Lower Urinary Track Syndrome
941323|NCT02303769|Harnal
941324|NCT02303769|Tamsulosin HCL 0.4mg
941325|NCT02303743|Bowel preparation; colonoscopy; Smartphone application
941326|NCT02303730|Diabetes
941327|NCT02303730|Non-alcoholic Fatty Liver Disease
941328|NCT02303717|Left main
941329|NCT02303717|PCI
941330|NCT02303717|DES
941331|NCT02303704|Multiperfusion set
941332|NCT02303704|Myocardial protection
941333|NCT02303704|Coronary Artery Bypass Grafting
941334|NCT02303691|anxiety
941335|NCT02303691|attention bias modification
941336|NCT02303691|computer
941337|NCT02303678|D2C7
941338|NCT02303678|Randazzo
941339|NCT02303678|Bigner
941340|NCT02303678|Pro00053325
941341|NCT02303678|recurrent malignant glioma
941342|NCT02303665|TCM multi-channel therapy
941343|NCT02303665|ART failure
941344|NCT02303639|implantable cardioverter defibrillator
941345|NCT02303639|antiarrhythmic medication
941346|NCT02303639|catheter ablation
941347|NCT02303626|BCX4161
941348|NCT02303626|Prophylaxis
941349|NCT02303626|Prevention
941350|NCT02303626|HAE
941351|NCT02303626|Hereditary Angioedema
941352|NCT02303600|Sub-acute cough
941353|NCT02303587|Severe mycoplasma pneumoniae
941354|NCT02303587|pneumonia
941355|NCT02303587|children
941356|NCT02303574|AZD7986, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect, First-in-human, Single Ascending Dose, Multiple Ascending Dose, Healthy Subjects
941357|NCT02303548|Sodium Bicarbonate
941358|NCT02303535|Congenital heart disease
941359|NCT02303535|European Paediatric Cardiac Code Short List
941360|NCT02303535|Specific Procedure Definitions
941361|NCT02303535|OPCS
941362|NCT02303535|paediatric
941363|NCT02303535|pediatric
941364|NCT02303522|ALL, pediatric, leukemia, childhood, lymphoblastic, lymphoma, acute, Precursor Cell
941365|NCT02303509|Healthy Subjects
941366|NCT02303509|Mild to moderate Psoriasis
941367|NCT02303509|Subjects
941368|NCT02303496|platelet rich plasma
941369|NCT02303470|Exercise
941370|NCT02303457|CO2 laser surgery
941371|NCT02303457|open surgery
941372|NCT02303457|multicenter prospective
941373|NCT02303457|randomized
941374|NCT02303457|controlled clinical studies
941375|NCT02303457|T1N0 squamous cell carcinoma of glottis with anterior commissure involved
941376|NCT02303444|Progressive radioactive iodine refractory differentiated thyroid carcinoma
941377|NCT02303431|Pediatric
941378|NCT02303431|Pharmacokinetics (PK)
941379|NCT02303431|Pharmacodynamics (PDy)
941380|NCT02303431|Anticoagulant
941381|NCT02303431|Safety
941382|NCT02303418|Obstetrics
941383|NCT02303405|Glucose Control
941384|NCT02303405|Inflammation
941385|NCT02303379|Training Protocol
941386|NCT02303379|Cardiac Rehabilitation
941387|NCT02303379|High-Intensity Interval Training
941388|NCT02303379|Continuous Training
941389|NCT02303379|Pyramid Training
941390|NCT02303379|Physical Performance
941391|NCT02303353|Breast cancer
941392|NCT02303353|Ovarian cancer
941393|NCT02303353|Lung cancer
941394|NCT02303353|Colon cancer
941395|NCT02303353|Gastric cancer
941396|NCT02303353|Pancreatic cancer
941397|NCT02303353|Rectum cancer
941398|NCT02303353|Plasmacytoma
941399|NCT02303340|Cone Beam Computed Tomography
941400|NCT02303340|Para Thyroid Hormone
941401|NCT02303340|Dual Energy X-ray Absorptiometry
941402|NCT02303340|Digital Imaging and Communication in Medicine
941403|NCT02303275|Heart Failure
941404|NCT02303275|Congestive Heart Failure
941405|NCT02303275|Lifestyle Change
941406|NCT02303236|Exercise
941407|NCT02303197|head and neck cancer
941408|NCT02303197|chemoradiotherapy
941409|NCT02303197|radioactive stomatitis
941410|NCT02303184|RVO
941411|NCT02303184|ME
941412|NCT02303184|Central Subfield Thickness
941413|NCT02303184|OCT
941414|NCT02303184|optical coherence tomography
941415|NCT02303184|cystoid macular edema
941416|NCT02303184|subretinal fluid
941417|NCT02303184|Eylea
941418|NCT02303184|aflibercept
941419|NCT02303184|anti-VEGF
941420|NCT02303171|Antiphospholipid syndrome
941421|NCT02303171|APS
941422|NCT02303171|Warfarin
941423|NCT02303158|Alzheimer's Disease
941424|NCT02303158|Biomarkers
941425|NCT02303158|Depression
941426|NCT02303158|dementia
941427|NCT02303158|cerebrospinal fluid
941428|NCT02303158|neuropsychological
941429|NCT02303145|Breast Cancer, Survivors
941430|NCT02303119|LNH
941431|NCT02303119|CD20+
941432|NCT02303119|follicular
941433|NCT02303106|AUC exposure to lamotrigine
941434|NCT02303080|whey protein microgels
941435|NCT02303080|thermogenesis
941436|NCT02303067|Cardiac
941437|NCT02303067|Computed Tomography
941438|NCT02303067|Coronary Artery Disease
941439|NCT02303054|Prostate Cancer
941440|NCT02303054|Focal Ablation
941441|NCT02303054|MRI-US Fusion Biopsy
941442|NCT02303054|Focal Therapy
941443|NCT02303028|Pediatric
941444|NCT02303028|CNS Tumor
941445|NCT02303028|Solid Tumour
941446|NCT02303015|Germ cell cancer
941447|NCT02303015|Late toxicity
941448|NCT02303015|Renal impairment
941449|NCT02303015|Cardiovascular disease
941450|NCT02302963|Diabetes Mellitus, Type 1 (T1DM)
941451|NCT02302963|Diabetes Assistant (DiAs)
941452|NCT02302963|Artificial Pancreas (AP) System
941453|NCT02302963|Closed-Loop Control (CLC)
941454|NCT02302963|Unified Safety System (USS) Virginia
941455|NCT02302963|Sensor Augmented Pump (SAP)
941456|NCT02302963|Low Blood Glucose Index (LBGI)
941457|NCT02302963|Continuous Glucose Monitor (CGM)
941458|NCT02302963|inControl Diabetes Management Platform
941459|NCT02302950|HIV infection
941460|NCT02302950|raltegravir use
941461|NCT02302950|women
941462|NCT02302937|Inguinal Hernia
941463|NCT02302937|Primary
941464|NCT02302937|laparoscopic surgery
941465|NCT02302937|single port surgery
941466|NCT02302911|Early intervention
941467|NCT02302898|Roux-en-Y Gastric Bypass Surgery
941468|NCT02302898|Weight Regain
941469|NCT02302885|cancer-free 18-60 year old men and women
941470|NCT02302859|Cancer Prevention
941471|NCT02302859|Tobacco Use Cessation
941472|NCT02302859|HIV-positive
941473|NCT02302859|Nicotine patch
941474|NCT02302859|NRT
941475|NCT02302859|Questionnaire
941476|NCT02302859|Survey
941477|NCT02302859|Smartphone
941478|NCT02302859|Counseling
941479|NCT02302859|Saliva test
941480|NCT02302859|Saliva cotinine test
941481|NCT02302859|Nicotine replacement therapy
941482|NCT02302859|Smoking abstinence
941483|NCT02302859|Aids
941484|NCT02302846|Leukemia
941485|NCT02302846|Acute myeloid leukemia
941486|NCT02302846|AML
941487|NCT02302846|High-risk myelodysplastic syndrome
941488|NCT02302846|MDS
941489|NCT02302846|Ixazomib
941490|NCT02302846|MLN9708
941491|NCT02302833|Neuroendocrine tumors
941492|NCT02302833|Pheochromocytomas
941493|NCT02302833|Paragangliomas
941494|NCT02302833|Unresectable
941495|NCT02302833|Metastatic
941496|NCT02302833|Cabozantinib
941497|NCT02302833|XL-184
941498|NCT02302833|XL184
941499|NCT02302833|Questionnaire
941500|NCT02302833|Survey
941501|NCT02302820|Advance Care Planning
941502|NCT02302820|Nurse Care Coordination
941503|NCT02302820|Comparative Effectiveness
941504|NCT02302820|Advance Directive
941505|NCT02302820|Decision Aides
941506|NCT02302781|Reasons for Dropout
941507|NCT02302781|Subfertility
941508|NCT02302781|IVF
941509|NCT02302781|NON IVF
941510|NCT02302742|Triple Negative Breast Cancer
941511|NCT02302742|TNBC
941512|NCT02302742|Hereditary Breast and Ovarian Cancer
941513|NCT02302742|HBOC
941514|NCT02302742|Prospective Registry
941515|NCT02302729|Micronutrient intervention
941516|NCT02302729|Responsive feeding intervention
941517|NCT02302729|School readiness intervention
941518|NCT02302677|bile acids
941519|NCT02302677|sleeve gastrectomy
941520|NCT02302677|obesity
941521|NCT02302677|GLP-1
941522|NCT02302677|FGF-19
941531|NCT02302651|high intensity focused ultrasound
941532|NCT02302651|osteoid osteoma
941533|NCT02302651|bone tumor
941534|NCT02302638|single-step media
941535|NCT02302638|embryo development
941536|NCT02302638|blastocyst formation
941537|NCT02302638|embryo utilization
941538|NCT02302625|Cognitive behavior therapy
941539|NCT02302612|chronic conditions
941540|NCT02302612|complex patients
941541|NCT02302612|engagement
941542|NCT02302612|activation
941543|NCT02302586|Thoracic paravertebral block
941544|NCT02302586|Patient controlled analgesia
941545|NCT02302586|Video Assisted Thoracoscopic Surgery
941546|NCT02302586|Postoperative acute pain
941547|NCT02302586|Chronic pain
941548|NCT02302573|placenta accreta
941549|NCT02302573|contrast-enhanced unltrasound
941550|NCT02302573|pregnancy
941551|NCT02302573|MRI
941552|NCT02302573|sonovue
941553|NCT02302547|HIV-DNA
941554|NCT02302547|dual therapy
941555|NCT02302547|NRTI
941556|NCT02302547|virological control
941557|NCT02302547|truvada®
941558|NCT02302534|scoliosis
941559|NCT02302534|MRI (Magnetic Resonance Imaging)
941560|NCT02302521|MRI
941561|NCT02302508|pharmacokinetics
941562|NCT02302508|drug metabolism
941563|NCT02302508|platelet reactivity
941564|NCT02302508|carboxylesterase
941565|NCT02302508|cytochromes p450
941566|NCT02302508|type 2 diabetes
941567|NCT02302508|active metabolite
941568|NCT02302495|Carfilzomib weekly
941569|NCT02302495|and Melphalan and Prednisone
941570|NCT02302482|Alzheimer's disease or related disorders
941571|NCT02302482|Functional autonomy level
941572|NCT02302482|Cognitive function
941573|NCT02302482|Predictive factors
941574|NCT02302469|Lenalidomide
941575|NCT02302469|Hematology
941576|NCT02302469|Waldenstrom Macroglobulinemia
941577|NCT02302456|Immediate postpartum hemorrhage
941578|NCT02302456|tranexamic acid
941579|NCT02302456|prevention
941580|NCT02302430|Cohesion
941581|NCT02302430|Oxytocin
941582|NCT02302430|ROTC
941583|NCT02302430|Virtual-reality
941584|NCT02302417|Asthma
941585|NCT02302417|Asthma-COPD Overlap Syndrome
941586|NCT02302417|Clinical Questionnaire
941587|NCT02302417|COPD
941588|NCT02302417|ACOS
941589|NCT02302404|FTIH
941590|NCT02302404|pharmacodynamics
941591|NCT02302404|pharmacokinetics
941592|NCT02302404|GSK2982772
941593|NCT02302404|safety
941594|NCT02302404|Repeat dose
941595|NCT02302404|tolerability
941596|NCT02302378|Hypotension
941597|NCT02302378|Anesthesia, Spinal [E03.155.086.331]
941598|NCT02302365|white blood cell depletion
941599|NCT02302365|apheresis
941600|NCT02302352|Probiotics
941601|NCT02302352|Immune system
941613|NCT02302326|reticulum endoplasmic stress
941614|NCT02302326|Polycystic Ovary Syndrome
941615|NCT02302326|mitochondrial function
941616|NCT02302326|insulin resistance
941617|NCT02302326|inflammation
941618|NCT02302326|myoinositol
941619|NCT02302326|metformin
941620|NCT02302326|oxidative stress
941621|NCT02302313|healthy volunteers
941622|NCT02302313|critical awareness
941623|NCT02302313|hypnosis
941624|NCT02302313|Analgesia Nociception Index
941625|NCT02302313|numerical verbal scale
941626|NCT02302313|Determine the validity of the index (ANI)
941627|NCT02302313|nociception in critical awareness
941628|NCT02302300|Cardiac surgery
941629|NCT02302300|Preventive non-invasive ventilation
941630|NCT02302287|Chronic kidney disease
941631|NCT02302287|mediterranean diet
941632|NCT02302287|low-protein diet
941633|NCT02302287|ketoacids
941634|NCT02302287|intestinal microbiota
941635|NCT02302274|Brugada Syndrome
941636|NCT02302274|ARVC
941637|NCT02302274|flecainide
941638|NCT02302274|ST elevation
941639|NCT02302261|Pulsus paradoxus
941640|NCT02302235|Glioblastoma multigorme
941641|NCT02302235|Ketogenic Diet
941642|NCT02302235|radiotherapy
941643|NCT02302235|chemotherapy
941644|NCT02302235|safety
941645|NCT02302235|efficiency
941646|NCT02302209|oxytocin
941647|NCT02302209|schizophrenia
941648|NCT02302209|autism spectrum disorder
941649|NCT02302183|Hypoxemic, Respiratory distress, infant
941650|NCT02302157|Cervical spinal cord injury
941651|NCT02302157|AST-OPC1
941652|NCT02302157|SCiStar
941653|NCT02302157|OPC1
941654|NCT02302157|Neural cell
941655|NCT02302157|Trauma spinal cord
941656|NCT02302157|stemcell transplant
941657|NCT02302157|Cervical spine injury
941658|NCT02302157|Paralysis
941659|NCT02302157|Quadriplegia
941660|NCT02302157|Tetraplegia
941661|NCT02302157|Spine injury
941662|NCT02302157|oligodendrocyte progenitor cell
941663|NCT02302157|Subacute spinal cord injury
941664|NCT02302144|Postural Instability (falling)
941665|NCT02302144|Gait Disturbances (e.g., freezing)
941666|NCT02302144|Bradykinesia (slowness of movement), rigidity
941667|NCT02302118|esophageal carcinoma
941668|NCT02302118|kardia carcinoma
941669|NCT02302092|Drug Therapy
941670|NCT02302079|ASP8232
941671|NCT02302079|Diabetes Mellitus
941672|NCT02302079|ranibizumab
941673|NCT02302079|Diabetic Macular Edema
941674|NCT02302066|Drug therapy
941675|NCT02302053|Hair thinning, hair loss, alopecia, women, oral supplement
941677|NCT02302027|withdrawal therapy
941678|NCT02302027|oxygen therapy
941679|NCT02302001|Breast augmentation
941680|NCT02302001|Breast implants
941681|NCT02302001|Silicone implants
941682|NCT02302001|Breast surgery
941683|NCT02301975|Adult
941684|NCT02301975|asthma
941685|NCT02301975|Fluticasone Propionate
941686|NCT02301975|Adolescents
941687|NCT02301975|Salmeterol
941688|NCT02301975|Vilanterol
941689|NCT02301975|ELLIPTA
941690|NCT02301975|ACCUHALER/DISKUS
941691|NCT02301975|Non-inferior
941692|NCT02301975|Fluticasone Furoate
941693|NCT02301962|panitumumab
941694|NCT02301962|previously treated
941695|NCT02301962|metastatic colorectal cancer
941696|NCT02301962|fully human antibody
941697|NCT02301962|wild-type KRAS and wild-type NRAS
941698|NCT02301949|gastrointestinal bleeding
941699|NCT02301949|vascular malformation
941700|NCT02301949|thalidomide retreatment
941701|NCT02301936|Sickle Cell Disease
941702|NCT02301936|Gilead
941703|NCT02301936|Hepatitis C
941704|NCT02301923|Continuous Positive Airway Pressure
941705|NCT02301910|Myocardial Infarction
941706|NCT02301910|Fibrinolysis
941707|NCT02301910|Fortelyzin
941708|NCT02301871|MNP
941709|NCT02301871|MET
941710|NCT02301871|Soft tissue mobilization
941711|NCT02301871|DNF
941712|NCT02301871|Static Stretching
941713|NCT02301858|molecular pathology
941714|NCT02301858|functional genomics
941715|NCT02301858|lung cancer
941716|NCT02301858|primary tumor
941717|NCT02301858|metastases
941718|NCT02301845|Respiration, artificial
941719|NCT02301832|acute compartment swelling (ACS)
941720|NCT02301832|near-infrared spectroscopy (NIRS)
941721|NCT02301767|MRI
941722|NCT02301767|Risk Factor
941723|NCT02301767|background Parenchymal Enhancement
941724|NCT02301767|(IMAGINE) Study
941725|NCT02301741|chronic low back pain
941726|NCT02301728|breast milk
941727|NCT02301728|short chain fatty acids
941728|NCT02301728|maternal diet
941729|NCT02301715|Intranasal oxytocin
941730|NCT02301715|Emotion regulation
941731|NCT02301715|Attachment
941732|NCT02301702|Maternal Immunization
941733|NCT02301702|Tdap
941734|NCT02301702|Td
941735|NCT02301702|Pertussis
941736|NCT02301689|Heart failure
941737|NCT02301689|Chronic heart failure
941738|NCT02301689|Sleep disordered breathing
941739|NCT02301689|Sleep apnea
941740|NCT02301689|Positive Airway Pressure
941741|NCT02301676|Geriatrics; Cognitive impairment; Interviews, Telephone
941742|NCT02301650|Hepatitis B virus
941743|NCT02301650|pregnancy
941744|NCT02301650|nucleoside (acid) analogs
941745|NCT02301650|children
941746|NCT02301650|safety
941747|NCT02301624|gMG
941748|NCT02301624|Myasthenia Gravis
941749|NCT02301624|safety
941750|NCT02301624|efficacy
941751|NCT02301598|femtosecond laser
941752|NCT02301598|anterior lamellar keratoplasty
941753|NCT02301598|atomic-force microscopy
941754|NCT02301585|shock, septic
941755|NCT02301585|hemodynamics
941756|NCT02301585|algorithms
941757|NCT02301533|HIV infection
941758|NCT02301533|antiretroviral therapy
941759|NCT02301533|adherence
941760|NCT02301533|men who have sex with men
941761|NCT02301520|Vitamin D
941762|NCT02301520|Iodine
941763|NCT02301520|Lead
941764|NCT02301520|Thyroid function
941765|NCT02301520|point-of-care test
941766|NCT02301494|CTCL
941767|NCT02301494|Mycosis Fungoides
941768|NCT02301494|Cutaneous T-cell Lymphoma
941769|NCT02301494|MF
941770|NCT02301494|topical therapy
941771|NCT02301494|early stage
941772|NCT02301455|hypertension treatment
941773|NCT02301455|stroke prevention
941774|NCT02301403|smoking
941775|NCT02301403|cessation
941776|NCT02301403|tobacco
941777|NCT02301390|INTERVENE
941778|NCT02301390|Ventricular tachycardia
941779|NCT02301390|India
941780|NCT02301364|Buparlisib (BKM120)
941781|NCT02301364|14-177
941782|NCT02301338|Videoconferencing
941783|NCT02301338|Following Surgery
941784|NCT02301338|14-213
941785|NCT02301299|stroke
941786|NCT02301299|barriers
941787|NCT02301299|community
941788|NCT02301286|Acetylsalicylic acid
941789|NCT02301286|Colon cancer
941790|NCT02301286|Survival
941791|NCT02301273|Intensive care unit
941792|NCT02301273|Physiotherapy
941793|NCT02301273|Upright position
941794|NCT02301273|Exercise
941795|NCT02301273|Long term follow up of ICU survivors
941796|NCT02301260|Processing Speed
941797|NCT02301260|Intervention
941798|NCT02301260|Multiple Sclerosis
941799|NCT02301260|Cognition
941800|NCT02301247|Multiple Sclerosis, Progressive
941801|NCT02301247|cognition
941802|NCT02301247|memory
941803|NCT02301247|treatment
941804|NCT02301234|Osteoarthritis
941805|NCT02301234|Pain
941806|NCT02301234|Fulranumab
941807|NCT02301234|JNJ-42160443
941808|NCT02301234|Adjunctive therapy
941809|NCT02301234|Celecoxib
941810|NCT02301234|Hip
941811|NCT02301234|Knee
941812|NCT02301234|Joint replacement surgery
941813|NCT02301221|Fecal Microbiota Transplantation
941814|NCT02301221|Slow Transit Constipation
941815|NCT02301221|Colonic motility
941816|NCT02301195|Therapeutic Horseback Riding
941817|NCT02301169|Pain
941818|NCT02301143|Pancreatic Neoplasms
941819|NCT02301143|Pancreatic Cancer
941820|NCT02301143|Locally advanced pacriatic cancer
941821|NCT02301143|nab-Paclitaxel
941822|NCT02301143|Abraxane
941823|NCT02301143|Gemcitabine
941824|NCT02301143|ABI-007
941825|NCT02301130|advanced solid tumors
941826|NCT02301130|solid tumors
941827|NCT02301130|mogamulizumab
941828|NCT02301130|MEDI4736 (Durvalumab)
941829|NCT02301130|Tremelimumab
941830|NCT02301130|POTELIGEO®
941831|NCT02301130|KW-0761
941832|NCT02301117|Renal
941833|NCT02301117|Kidney Diseases
941834|NCT02301117|Urologic Diseases
941835|NCT02301117|Renal Insufficiency
941836|NCT02301117|Renal Impairment
941837|NCT02301117|Pharmacokinetics
941838|NCT02301117|Advance Solid Tumor
941839|NCT02301117|Creatinine Clearance
941840|NCT02301117|Kidney Neoplasms
941841|NCT02301117|Renal Tumor
941842|NCT02301117|Kidney
941843|NCT02301117|Urology
941844|NCT02301117|Pharmacologic Action
941845|NCT02301104|Liver Neoplasms
941846|NCT02301104|Hepatic
941847|NCT02301104|TAS-102
941848|NCT02301104|mCRC
941849|NCT02301104|Liver Impairment
941850|NCT02301104|Pharmacologic Actions
941851|NCT02301104|Liver Diseases
941852|NCT02301104|Liver
941853|NCT02301104|LFT
941854|NCT02301104|Advanced Solid Tumor
941855|NCT02301104|Pharmacokinetics
941856|NCT02301091|HCC PVTT TACE RFA
941857|NCT02301078|Dupuytren disease
941858|NCT02301078|needle aponeurotomy
941859|NCT02301078|collagenase
941860|NCT02301065|Viral
941861|NCT02301065|Infection
941862|NCT02301065|Allogeneic Stem Cell Transplant
941863|NCT02301052|hemorrhoids
941864|NCT02301052|Allium Ampeloprasum
941865|NCT02301052|herbal medicine
941866|NCT02301052|traditional persian medicine
941867|NCT02301000|Clostridium difficile
941868|NCT02301000|Intestinal microbiota therapy
941869|NCT02300987|Teratoma,
941870|NCT02300987|Germ Cell tumor,
941871|NCT02300987|incurable teratoma,
941872|NCT02300987|CDK4/6,
941873|NCT02300987|LEE011
941874|NCT02300948|Pregnancy
941875|NCT02300948|Perinatal Vitamins
941876|NCT02300948|folate
941877|NCT02300935|trametinib
941878|NCT02300935|nab-paclitaxel
941879|NCT02300935|Mekinist
941880|NCT02300935|Abraxane
941881|NCT02300935|unresectable
941882|NCT02300935|metastatic
941883|NCT02300896|exercise
941884|NCT02300896|physical fitness
941885|NCT02300896|geriatrics
941886|NCT02300870|Acute rejection, myocardial blood flow
941887|NCT02300831|NSCLC
941888|NCT02300831|Lung Cancer
941889|NCT02300831|SELECT-1
941890|NCT02300831|SELECT-2
941891|NCT02300831|selumetinib
941892|NCT02300831|biomarker
941893|NCT02300831|NIS
941894|NCT02300831|Observational study
941895|NCT02300831|Disease registry
941896|NCT02300831|Clinical Outcomes
941897|NCT02300818|Hipertension ocular, Glaucoma, Magnetotherapy, seawater
941898|NCT02300805|Endometrial volume , VOCAL , Endometrial , Metrorrhagia
941899|NCT02300792|honey, hepatitis A
941900|NCT02300779|Colonoscopy
941901|NCT02300779|Diabetes Mellitus
941902|NCT02300779|Diet
941903|NCT02300779|Polyethylene glycols
941904|NCT02300779|Efficacy
941905|NCT02300779|Personal satisfaction
941906|NCT02300766|Cerebellar Mutism Syndrome
941907|NCT02300766|Posterior Fossa Tumor
941908|NCT02300766|Pediatric cancer
941909|NCT02300766|Neurosurgical techniques
941910|NCT02300727|Mucositis
941911|NCT02300727|Neoplasms
941912|NCT02300727|CANCER
941913|NCT02300727|Curcumin
941914|NCT02300727|Drug Therapy
941915|NCT02300727|ANTINEOPLASTIC AGENTS
941916|NCT02300675|therapeutic patient education
941917|NCT02300675|patient adherence
941918|NCT02300675|empowerment
941919|NCT02300675|breast cancer
941920|NCT02300675|oral adjuvant endocrine therapy
941921|NCT02300675|side effects
941922|NCT02300636|Knee joint
941923|NCT02300636|Muscle strength
941924|NCT02300636|anterior cruciate ligament
941925|NCT02300610|Ureteral Diseases
941926|NCT02300610|Urinary Bladder Diseases
941927|NCT02300610|Transitional Cell Carcinoma
941928|NCT02300610|Bladder
941929|NCT02300610|Carcinoma
941930|NCT02300610|Renal
941931|NCT02300610|Pelvis
941932|NCT02300610|Ureter
941933|NCT02300610|Urethra
941934|NCT02300597|ADHD
941935|NCT02300597|Autism Spectrum Disorders
941936|NCT02300597|controlled
941937|NCT02300597|Internet based
941938|NCT02300597|coaching
941939|NCT02300558|LQT3
941940|NCT02300558|long QT syndrome
941941|NCT02300558|congenital long QT
941942|NCT02300558|sudden cardiac death
941943|NCT02300532|Malignant Glioma
941944|NCT02300532|Glioblastoma Multiforme
941945|NCT02300519|Haemophilia
941946|NCT02300519|numerical models
941947|NCT02300519|thrombin generation
941948|NCT02300519|volunteers
941949|NCT02300519|endogenous thrombin potential
941950|NCT02300506|Malignant Glioma
941951|NCT02300506|Glioblastoma multiforme
941952|NCT02300493|among college students
941953|NCT02300480|pain
941954|NCT02300480|calot's triangle
941955|NCT02300480|local block
941956|NCT02300480|analgesia
941957|NCT02300480|patient controlled intravenous analgesia
941958|NCT02300454|in-stent restenosis
941959|NCT02300454|percutaneous coronary intervention
941960|NCT02300454|balloon
941961|NCT02300428|iron deficiency
941962|NCT02300389|high risk prostate cancer radiotherapy hypofractionation
941963|NCT02300376|GFR
941964|NCT02300376|Bayesian model
941965|NCT02300376|plasma clearance
941966|NCT02300376|Calcium edetate de sodium
941967|NCT02300376|Inulin
941968|NCT02300337|laryngeal tube
941969|NCT02300337|cuff pressure
941970|NCT02300337|leakage
941971|NCT02300337|laryngeal mask
941972|NCT02300324|bioavailability
941973|NCT02300324|Beneforte
941974|NCT02300324|sulforaphane
941975|NCT02300272|Practice-related learning
941976|NCT02300272|Sleep
941977|NCT02300272|Pain
941978|NCT02300272|Circadian Rhythm
941979|NCT02300272|Older Adults
941980|NCT02300246|alveolar socket preservation
941981|NCT02300246|tooth extraction
941982|NCT02300246|platelet concentrates
941983|NCT02300246|growth factors
941984|NCT02300207|Electroacupuncture
941985|NCT02300207|Cardiovascular function
941986|NCT02300207|Orthostatic tolerance
941987|NCT02300207|Head-down bed rest
941988|NCT02300194|Pain management
941989|NCT02300168|bariatric surgery; neuromuscular blockade
941990|NCT02300155|Pregnancy
941991|NCT02300155|Morning Sickness
941992|NCT02300155|nausea and vomiting
941993|NCT02300155|hyperemesis gravidarum
941994|NCT02300155|perinatal vitamins
941995|NCT02300142|HSV
941996|NCT02300142|Herpes
941997|NCT02300142|genital infection
941998|NCT02300142|vaccine
942000|NCT02300077|fentanyl, morphine
942001|NCT02300077|methadone
942002|NCT02300051|Compulsive sexual behavior
942003|NCT02300051|Intervention
942004|NCT02300051|Short term psychodynamic group psychotherapy
942005|NCT02300051|Sexual addiction
942006|NCT02300051|Hypersexual behavior
942007|NCT02300012|Anterior cruciate ligament
942008|NCT02300012|Performance based investigations
942009|NCT02299973|irritable bowel syndrome
942010|NCT02299973|fecal microbiota transplantation
942011|NCT02299973|bloating
942012|NCT02299960|EndoPAT
942013|NCT02299960|NICOM
942014|NCT02299960|circulating endothelial cells
942015|NCT02299908|Hernia, Inguinal
942016|NCT02299908|Herniorrhaphy
942017|NCT02299908|Abdominal Wall
942018|NCT02299908|Analgesia
942019|NCT02299908|Pain, Postoperative
942020|NCT02299895|setting approach
942021|NCT02299895|health promotion
942022|NCT02299895|organization
942023|NCT02299895|implementation research
942024|NCT02299895|qualitative study
942025|NCT02299895|comparison
942026|NCT02299882|Posterior spine surgery
942027|NCT02299882|infection
942028|NCT02299882|vancomycin
942029|NCT02299882|surgical wound infection
942030|NCT02299856|Magnetic Resonance Imaging
942031|NCT02299856|Diagnostic Imaging
942032|NCT02299843|RFA
942033|NCT02299843|ALPPS
942034|NCT02299843|hepatectomy
942035|NCT02299843|morbidity and mortality
942036|NCT02299830|neoplasm
942037|NCT02299830|central airway
942038|NCT02299830|obstruction
942039|NCT02299791|clinic-level interventions
942040|NCT02299791|quality improvement
942041|NCT02299791|translational medical research
942042|NCT02299791|community health centers
942043|NCT02299765|Advanced Non-small Cell Lung Cancer (NSCLC)
942044|NCT02299765|EGFR Mutation
942045|NCT02299765|gefitinib
942046|NCT02299765|chemotherapy
942047|NCT02299739|Herbal Medicine
942048|NCT02299739|Complementary Therapies
942049|NCT02299739|Liver Function Tests
942050|NCT02299739|Risk Factors
942051|NCT02299726|acute heart failure
942052|NCT02299726|MRA
942053|NCT02299726|emergency department
942054|NCT02299713|acupuncture
942055|NCT02299713|knee pain
942056|NCT02299700|Janssen Autism Knowledge Engine
942057|NCT02299700|Autism Spectrum Disorder
942058|NCT02299661|Hypoxia inducible factor prolyl hydroxylase inhibitor.
942059|NCT02299661|Erythropoietin stimulating agent
942060|NCT02299661|Chronic renal disease
942061|NCT02299661|renal anemia
942062|NCT02299635|PF-03084014
942063|NCT02299635|Notch Alterations
942064|NCT02299609|C14.280.647.500
942065|NCT02299596|Colorectal neoplasm
942066|NCT02299596|Physical activity
942067|NCT02299583|prevention
942068|NCT02299583|early intervention
942069|NCT02299583|trauma-informed practice
942070|NCT02299570|Clostridium difficile
942071|NCT02299570|C diff
942072|NCT02299570|CDI
942073|NCT02299570|CDAD
942074|NCT02299570|Fecal transplant
942075|NCT02299570|Fecal Microbiota Transplant
942076|NCT02299570|Diarrhea
942077|NCT02299570|FMT
942078|NCT02299570|Microbiota restoration therapy
942079|NCT02299570|Microbiota suspension
942080|NCT02299570|Fecal bacteriotherapy
942081|NCT02299570|C diff diarrhea
942082|NCT02299505|LDK378
942083|NCT02299505|ceritinib
942084|NCT02299505|Alk+
942085|NCT02299505|Alk positive
942086|NCT02299505|NSCLC
942087|NCT02299505|lung Cancer
942088|NCT02299492|Mental Health Services
942089|NCT02299479|insulin pump
942090|NCT02299479|continuous glucose monitor
942091|NCT02299479|activity monitor
942092|NCT02299466|parenteral nutrition
942093|NCT02299466|complications
942094|NCT02299466|indications
942095|NCT02299466|long-term administration
942096|NCT02299466|HTPN
942097|NCT02299453|Telemedicine
942098|NCT02299453|Interpersonal Psychotherapy (IPT)
942099|NCT02299440|treatment of acute suicidal ideation
942100|NCT02299440|ketamine
942101|NCT02299440|low-dose ketamine
942102|NCT02299414|Pregnancy
942103|NCT02299414|Chronic hypertension
942104|NCT02299401|Medical abortion
942105|NCT02299401|Induced abortion
942106|NCT02299401|Pregnancy test
942107|NCT02299401|Semi-quantitative pregnancy test
942108|NCT02299388|Type 2 Diabetes Mellitus
942109|NCT02299388|Hypertension
942110|NCT02299388|ambulatory blood pressure monitoring
942111|NCT02299388|Endothelial Dysfunction
942112|NCT02299388|Pulse pressure
942113|NCT02299388|Renin-angiotensin system
942114|NCT02299388|heart rate variability
942115|NCT02299375|Phase II clinical study
942116|NCT02299375|losmapimod
942117|NCT02299375|exacerbations
942118|NCT02299375|COPD
942119|NCT02299375|eosinophil sub-group
942120|NCT02299362|Early Onset Scoliosis
942121|NCT02299362|EOS
942122|NCT02299362|Pulmonary function
942123|NCT02299362|Infantile Idiopathic Scoliosis
942124|NCT02299362|MCGR
942125|NCT02299362|Magnetically controlled growing rods
942126|NCT02299362|Growing rods
942127|NCT02299362|Growth friendly spine surgery
942128|NCT02299362|Cast
942129|NCT02299310|Chronic kidney disease, Anti-hypertensive drugs
942130|NCT02299297|Alopecia Areata
942131|NCT02299284|Spastic
942132|NCT02299284|Hemiplegia
942133|NCT02299245|telomere
942134|NCT02299245|telomerase
942135|NCT02299245|statin
942136|NCT02299245|percutaneous coronary intervention
942137|NCT02299245|acute coronary syndrome
942138|NCT02299232|dexmedetomidine
942139|NCT02299232|sedation
942140|NCT02299232|MRI
942141|NCT02299219|Adolescent
942142|NCT02299219|Internet Self-Management
942143|NCT02299219|Managing Cancer
942144|NCT02299193|cognitive behavioral therapy for insomnia
942145|NCT02299193|sleep hygiene
942146|NCT02299180|Advanced care planning
942147|NCT02299180|End of life care
942148|NCT02299167|Perianal surgery
942149|NCT02299167|hyperbaric bupivacaine
942150|NCT02299167|saddle block
942151|NCT02299115|Vigabatrin
942152|NCT02299115|Prednisolone
942153|NCT02299102|Aspiration Procedures
942154|NCT02299102|Bone Marrow
942155|NCT02299102|To compare powered ported bone marrow aspiration procedures to manual standard bone marrow aspiration procedures
942156|NCT02299089|acromegaly
942157|NCT02299089|neuroendocrine tumour (NET)
942158|NCT02299089|carcinoid syndrome
942159|NCT02299089|octreotide
942160|NCT02299089|Sandostatin LAR
942161|NCT02299076|Tobacco smoking cessation
942162|NCT02299076|Motivation
942163|NCT02299063|Mitochondria
942164|NCT02299063|Dexmedetomidine
942165|NCT02299063|Heart Defects, Congenital
942166|NCT02299050|Type 2 Diabetes
942167|NCT02299050|T2DM
942168|NCT02299050|Cycloset
942169|NCT02299050|Glycemic Control
942170|NCT02299050|GLP-1
942171|NCT02299024|opioids
942172|NCT02299024|health literacy
942173|NCT02299011|Biomatrix drug eluting stent
942174|NCT02299011|Orsiro drug eluting stent
942175|NCT02299011|Coronary artery disease
942176|NCT02298985|curcumin; schizophrenia; neuroprotection
942177|NCT02298946|Anti-PD1 Therapy
942178|NCT02298946|Anti-Tumor Immunity
942179|NCT02298946|Liver Metastatic
942180|NCT02298946|B7-DC Fc Fushion Protein
942181|NCT02298933|Complement Inhibition
942182|NCT02298933|Platelet Refractoriness
942183|NCT02298933|Eculizumab
942184|NCT02298907|colorectal cancer
942185|NCT02298907|surgery
942186|NCT02298907|cardiopulmonary exercise testing
942187|NCT02298907|perioperative
942188|NCT02298907|fitness
942189|NCT02298894|Low Density Lipoprotein (LDL)
942190|NCT02298894|Lipoprotein
942191|NCT02298894|Nuclear Magnetic Resonance (NMR)
942192|NCT02298894|Vertical Auto Profile (VAP)
942193|NCT02298894|Ion mobility
942194|NCT02298894|Apoliproprotein B (ApoB)
942195|NCT02298881|Dry Eye
942196|NCT02298881|Microbiome
942197|NCT02298855|Gynaecological cancer
942198|NCT02298855|Nurse-led care
942199|NCT02298855|Aftercare
942200|NCT02298855|Patient self-management
942201|NCT02298855|Quality of life
942202|NCT02298855|Relapse free interval
942203|NCT02298855|Watch and wait
942204|NCT02298842|Healthy Adults
942205|NCT02298829|curvature
942206|NCT02298829|bend
942207|NCT02298816|Monoclonal gammopathy of undetermined significance (MGUS)
942208|NCT02298816|Smoldering multiple myeloma (SMM)
942209|NCT02298816|Multiple myeloma (MM)
942210|NCT02298816|Waldenstroms Macroglobulinemia (WM)
942211|NCT02298816|Monoclonal B-cell lymphocytosis (MBL)
942212|NCT02298816|Chronic lymphocytic leukemia (CLL)
942213|NCT02298816|B-Cell Non-Hodgkin lymphoma (NHL)
942214|NCT02298816|B-Cell Hematologic Malignancies
942215|NCT02298816|immunization
942216|NCT02298816|Vaccination
942217|NCT02298816|Influenza, Human
942218|NCT02298816|Pneumonia
942219|NCT02298790|Dietary Habits
942220|NCT02298790|Circadian
942221|NCT02298790|Metabolism
942222|NCT02298790|Feeding Behavior
942223|NCT02298738|Atrial fibrillation, hypertension, vitamin D
942224|NCT02298725|Insulin Resistance
942225|NCT02298725|Obesity
942226|NCT02298725|US Dietary Guidelines
942227|NCT02298712|Iduronidase
942228|NCT02298712|Lysosomal Storage Diseases
942229|NCT02298712|Genetic Diseases, Inborn
942230|NCT02298712|Metabolism, Inborn Errors
942231|NCT02298699|Lysosomal Storage Diseases
942232|NCT02298699|Hereditary Diseases
942233|NCT02298686|Inborn Errors of Metabolism
942234|NCT02298686|Lysosomal Storage Diseases
942235|NCT02298686|Metabolism Errors, Inborn
942236|NCT02298673|Lipid Metabolism, Inborn Errors
942237|NCT02298673|Hereditary Disease
942238|NCT02298673|Inborn Genetic Diseases
942239|NCT02298660|Autonomic Dysreflexia
942240|NCT02298660|Spinal Cord Injury
942241|NCT02298660|OnabotulinumtoxinA
942242|NCT02298660|Neurogenic detrusor overactivity
942243|NCT02298660|Urodynamics
942244|NCT02298660|Cardiovascular
942245|NCT02298660|Quality of life
942246|NCT02298660|Blood pressure
942247|NCT02298660|Twenty-four hour ambulatory blood pressure monitoring
942248|NCT02298647|Lysosomal Storage Diseases
942249|NCT02298634|Lysosomal Storage Diseases
942250|NCT02298634|Lipogranulomatosis
942251|NCT02298608|Renal mass
942252|NCT02298608|Kidney cancer
942253|NCT02298608|Irreversibel Electroporation
942254|NCT02298608|Ablation
942255|NCT02298608|Safety
942256|NCT02298608|Efficacy
942257|NCT02298608|IRE
942258|NCT02298595|Carcinoma
942259|NCT02298595|Squamous
942260|NCT02298595|Oropharyngeal
942261|NCT02298595|HPV
942262|NCT02298595|Resectable
942263|NCT02298582|safety
942264|NCT02298582|procedural pain
942265|NCT02298582|intranasal fentanyl
942266|NCT02298582|elderly
942267|NCT02298569|patient discharge
942268|NCT02298569|hospital readmission
942269|NCT02298569|postnatal care
942270|NCT02298569|Home Care Services
942271|NCT02298569|Cost-Benefit Analysis
942272|NCT02298569|Personal satisfaction
942273|NCT02298569|Community Care Networks
942274|NCT02298556|Hypertension
942275|NCT02298556|Diabetes Mellitus
942276|NCT02298556|ACE Inhibitors
942277|NCT02298556|Calcium Channel Blockers
942278|NCT02298517|Morbid obesity
942279|NCT02298517|bariatric surgery
942280|NCT02298517|Respiratory muscle endurance
942281|NCT02298517|Respiratory muscle strength
942282|NCT02298517|spirometry
942283|NCT02298517|physiotherapy
942284|NCT02298478|Self-help
942285|NCT02298478|Computer-aided Treatment
942286|NCT02298478|Internet
942287|NCT02298478|Flying phobia
942288|NCT02298478|minimal contact therapies
942289|NCT02298478|Cognitive-Behavioural Treatment
942290|NCT02298478|Waiting list control group
942291|NCT02298465|ESWL
942292|NCT02298465|distal ureteric stone
942293|NCT02298465|transgluteal
942294|NCT02298465|supine ESWL
942295|NCT02298439|NAFLD
942296|NCT02298426|Body Constitution Classification
942297|NCT02298426|Health Management
942298|NCT02298426|Obese Population
942299|NCT02298374|Rehabilitation
942300|NCT02298374|Evaluation studies
942301|NCT02298374|Home care services
942302|NCT02298361|Adolescent
942303|NCT02298361|Child
942304|NCT02298361|Child Health Services/organization & administration*
942305|NCT02298361|Child, Preschool
942306|NCT02298361|Cohort Studies
942307|NCT02298361|Community Health Centers/organization & administration
942308|NCT02298361|Community Health Centers/standards
942309|NCT02298361|Electronic Health Records
942310|NCT02298361|Feasibility Studies
942311|NCT02298361|Female
942312|NCT02298361|Health Services Accessibility/economics
942313|NCT02298361|Humans
942314|NCT02298361|Infant
942315|NCT02298361|Infant, Newborn
942316|NCT02298361|Insurance Coverage
942317|NCT02298361|Insurance Coverage/statistics & numerical data
942318|NCT02298361|Insurance Coverage/trends
942319|NCT02298361|Insurance, Health
942320|NCT02298361|Insurance, Health/legislation & jurisprudence
942321|NCT02298361|Insurance, Health/statistics & numerical data
942322|NCT02298361|Insurance, Health/trends
942323|NCT02298361|Logistic Models
942324|NCT02298361|Longitudinal Studies
942325|NCT02298361|Male
942326|NCT02298361|Medicaid
942327|NCT02298361|Medicaid/statistics & numerical data
942328|NCT02298361|Medicaid/trends
942329|NCT02298361|Medicaid/utilization
942330|NCT02298361|Medically Uninsured
942331|NCT02298361|Medicare/statistics & numerical data
942332|NCT02298361|Medicare/trends
942333|NCT02298361|Medicare/utilization
942334|NCT02298361|Multivariate Analysis
942335|NCT02298361|Oregon
942336|NCT02298361|Patient Protection and Affordable Care Act
942337|NCT02298361|Patient-Centered Care
942338|NCT02298361|Pediatrics/legislation & jurisprudence
942339|NCT02298361|Pediatrics/standards
942340|NCT02298361|Population Surveillance/methods
942341|NCT02298361|Primary Health Care/economics
942342|NCT02298361|Quality Assurance, Health Care/legislation & jurisprudence
942343|NCT02298361|Quality Assurance, Health Care/methods
942344|NCT02298361|Quality Indicators, Health Care
942345|NCT02298361|Retrospective Studies
942346|NCT02298361|Socioeconomic Factors
942347|NCT02298361|United States
942348|NCT02298361|Young Adult
942349|NCT02298348|Neuroblastoma
942350|NCT02298348|NANT
942351|NCT02298348|Sorafenib
942352|NCT02298348|Relapse
942353|NCT02298335|Prednisone
942354|NCT02298335|idiopathic nephrotic syndrome
942355|NCT02298335|prospective
942356|NCT02298309|TB
942357|NCT02298309|HIV
942358|NCT02298309|Test and Treat
942359|NCT02298309|Linkage
942360|NCT02298283|Hodgkin lymphoma
942361|NCT02298283|HL
942362|NCT02298283|brentuximab vedotin
942363|NCT02298270|Neurofibromatosis
942364|NCT02298270|NF I
942365|NCT02298270|NF 2
942366|NCT02298270|Schwannomatosis
942367|NCT02298270|Stress Management
942368|NCT02298270|Resiliency
942369|NCT02298270|Skype
942370|NCT02298244|Pulmonary Hypertension
942371|NCT02298244|Atrial Fibrillation
942372|NCT02298244|Pulmonary Arterial Denervation
942373|NCT02298244|Safety
942374|NCT02298244|Pulmonary Arterial GP Ablation
942375|NCT02298231|Traumatic Brain Injury
942376|NCT02298231|Balance
942377|NCT02298231|TBI
942378|NCT02298231|Veterans
942379|NCT02298231|Virtual Reality
942380|NCT02298166|Acute myeloid leukemia
942381|NCT02298166|FLT3 mutations
942382|NCT02298166|Crenolanib
942383|NCT02298166|Relapsed
942384|NCT02298166|Refractory
942385|NCT02298140|SMS reminders
942386|NCT02298140|Provider's compliance
942387|NCT02298140|malaria
942388|NCT02298127|smoking cessation
942389|NCT02298127|auricular acupressure
942390|NCT02298127|primary care settings
942391|NCT02298127|randomized controlled trial
942392|NCT02298114|electrical stimulation
942393|NCT02298114|intensive care unit
942394|NCT02298114|muscular atrophy
942395|NCT02298101|Aerosol delivery
942396|NCT02298101|Lung deposition
942397|NCT02298101|SPECT
942398|NCT02298101|subjects
942399|NCT02298075|Immune thrombocytopenia
942400|NCT02298075|Primary
942401|NCT02298075|Thrombopoietin receptor agonist
942402|NCT02298062|Kawasaki disease coronary artery lesion, IVIG- resistant, Infliximab
942403|NCT02298049|fMRI
942404|NCT02298049|reward
942405|NCT02298049|satiation
942406|NCT02298036|Health Anxiety
942407|NCT02298036|Urgent Care
942408|NCT02298036|Medically Unexplained
942409|NCT02298023|adipose derived mesenchymal stem cell
942410|NCT02298023|allogeneic stem cell
942411|NCT02298023|Rotator cuff tear
942412|NCT02297997|sarcopenia
942413|NCT02297997|cetylpyridinium chloride
942414|NCT02297984|Neuroglobin
942415|NCT02297984|HIF-α
942416|NCT02297984|Acute ischemic stroke
942417|NCT02297984|Prognosis
942418|NCT02297932|Exercise
942419|NCT02297919|Web-based education, Adolescent, Obesity
942420|NCT02297906|Intranasal
942421|NCT02297906|Ketorolac
942422|NCT02297906|Pharmacokinetics
942423|NCT02297906|Pediatric
942424|NCT02297880|low calorie sweetener satiety, intake, hunger
942425|NCT02297815|antibiotic use
942426|NCT02297815|effectiveness
942427|NCT02297815|acute respiratory infections
942428|NCT02297815|pediatrics
942429|NCT02297776|cardiac arrest
942430|NCT02297776|biomarker
942431|NCT02297776|microRNA
942432|NCT02297776|circRNA
942433|NCT02297776|NSE
942434|NCT02297776|CPC
942435|NCT02297750|The focus of the study is double-wire technique versus single wire technique in patients undergoing ERCP with biliary cannulation as the primary objective.
942436|NCT02297737|Tai Chi
942437|NCT02297698|Breast cancer, NeuVax
942438|NCT02297685|Transcutaneous electrical nerve stimulation (TENS)
942439|NCT02297685|Interferential currents therapy
942440|NCT02297685|Therapeutic exercises
942441|NCT02297685|Low back pain
942442|NCT02297685|Rehabilitation
942443|NCT02297672|breast cancer
942444|NCT02297672|brachytherapy
942445|NCT02297672|partial breast radiotherapy
942446|NCT02297672|palladium 103
942447|NCT02297659|damage control
942448|NCT02297659|resuscitation
942449|NCT02297659|laparotomy
942450|NCT02297646|Prevention
942451|NCT02297646|Exercise
942452|NCT02297646|Health
942453|NCT02297646|Endurance
942454|NCT02297633|COPD
942455|NCT02297633|reactive oxygen metabolites
942456|NCT02297620|SGLT-2 inhibitor
942457|NCT02297620|Elderly patients
942458|NCT02297620|ASP1941
942459|NCT02297607|Esophageal Cancer
942460|NCT02297607|Esophagectomy
942461|NCT02297581|Geriatrics [MeSH]
942462|NCT02297581|Osteoporotic fractures [MeSH]
942463|NCT02297581|Hip fractures [MeSH]
942464|NCT02297581|Cost benefit analysis [MeSH]
942465|NCT02297581|Quality of life [MeSH]
942466|NCT02297581|Mortality [MeSH]
942467|NCT02297581|Complications
942468|NCT02297568|Breast-fed infant
942469|NCT02297568|vitamin D supplementation
942470|NCT02297568|Lactation
942471|NCT02297555|Obesity
942472|NCT02297555|Metabolic Syndrome
942473|NCT02297555|ENDOBARRIER®
942474|NCT02297542|Influenza Vaccine
942475|NCT02297529|unresected, Melanoma, expanded access, EU
942476|NCT02297490|Environmental Exposure Chamber
942477|NCT02297490|Specific Immunotherapy
942478|NCT02297490|SIT
942479|NCT02297490|SCIT
942480|NCT02297464|Risk
942481|NCT02297438|breast cancer
942482|NCT02297438|postmenopausal women
942483|NCT02297438|estrogen-receptor positive
942484|NCT02297438|HER2 negative
942485|NCT02297438|locoregionally recurrent
942486|NCT02297438|metastatic
942487|NCT02297425|NSCLC, Non-Small Cell Lung Cancer, EGFRm, Epidermal Grown Factor Receptor mutation
942488|NCT02297399|Colonoscopy
942489|NCT02297399|Diabetes Mellitus
942490|NCT02297399|Polyethylene glycols
942491|NCT02297399|Ascorbate
942492|NCT02297399|Personal satisfaction
942493|NCT02297386|[18F] Dihydro-testosterone
942494|NCT02297386|PET Scan
942495|NCT02297386|MRI
942496|NCT02297386|14-185
942497|NCT02297360|Hair loss, hair thinning, women, marine protein supplement
942498|NCT02297334|CytoSorb(TM)
942499|NCT02297334|cytokines
942500|NCT02297334|inflammation
942501|NCT02297334|cardiac surgery
942502|NCT02297334|extracorporeal bypass
942503|NCT02297321|tattoos
942504|NCT02297321|laser
942505|NCT02297321|whitening
942506|NCT02297321|patch
942507|NCT02297295|Sequelae of; Amputation, Traumatic, Limb, Lower
942508|NCT02297282|Depression
942509|NCT02297282|Behavioural Activation
942510|NCT02297269|Deep vein thrombosis
942511|NCT02297269|Surgery
942512|NCT02297269|gastrointestinal malignancy
942513|NCT02297230|Locally Advanced Breast Cancer
942514|NCT02297191|volunteer
942515|NCT02297191|pilot study
942516|NCT02297191|adults
942517|NCT02297165|anorexic
942518|NCT02297165|olfactory stimulation
942519|NCT02297165|autobiographical memories recovery
942520|NCT02297152|Premature ejaculation treatment
942521|NCT02297152|Sexual dysfunction
942522|NCT02297152|Intravaginal Ejaculatory Latency time
942523|NCT02297152|Masturbation aid
942524|NCT02297152|Ejaculatory disorders
942525|NCT02297113|patients
942526|NCT02297113|departement
942527|NCT02297113|requiring Rapid Sequence Intubation (RSI)
942528|NCT02297100|women
942529|NCT02297100|interstitial cystitis
942530|NCT02297100|bladder pain syndrome
942531|NCT02297100|botox
942532|NCT02297100|onabotulinum toxin A
942533|NCT02297074|Bread
942534|NCT02297074|Glycemic index
942535|NCT02297074|Glycemic load
942536|NCT02297074|Insulinemic index
942537|NCT02297074|Satiety
942538|NCT02297074|Gastrointestinal hormones
942539|NCT02297061|Hip fracture
942540|NCT02297061|Thrombelastography
942541|NCT02297061|Blood loss
942542|NCT02297048|Potassium intake
942543|NCT02297048|Progesterone
942544|NCT02297048|steroidogenesis
942545|NCT02297048|RU486
942546|NCT02297048|Synachtene test
942547|NCT02297022|Deep Brain Stimulation
942548|NCT02297022|obesity
942549|NCT02297022|Prader-Willi syndrome
942550|NCT02296996|BRAF V600
942551|NCT02296996|Rechallenge
942552|NCT02296996|Combination
942553|NCT02296996|Dabrafenib
942554|NCT02296996|Trametinib
942555|NCT02296944|Childrens
942556|NCT02296944|tempanoplasty
942557|NCT02296944|tympanic membrane perforation
942558|NCT02296944|retrospective
942559|NCT02296944|cohort
942560|NCT02296918|CLL
942561|NCT02296918|SLL
942562|NCT02296918|PLL
942563|NCT02296918|Chronic Lymphocytic Leukemia
942564|NCT02296918|Small Lymphocytic Lymphoma
942565|NCT02296918|Prolymphocytic Leukemia
942566|NCT02296918|ACP-196
942567|NCT02296918|acalabrutinib
942568|NCT02296905|Hepatic Impairment
942569|NCT02296905|Hepatitis C Virus Infection
942570|NCT02296853|Severe Hepatic Impairment
942571|NCT02296840|analgesia
942572|NCT02296840|non-steroidal anti-inflammatory drugs
942573|NCT02296840|narcotic-containing pain medication
942574|NCT02296788|Gut Microbiota
942575|NCT02296775|Rheumatoid arthritis
942576|NCT02296775|Rituximab
942577|NCT02296775|Pharmacokinetics
942578|NCT02296736|computerised tomography (CT) scan
942579|NCT02296736|diagnostic accuracy
942580|NCT02296736|Pancreatic head malignancy
942581|NCT02296710|mitral valve
942582|NCT02296710|valve surgery
942583|NCT02296710|echocardiography
942584|NCT02296697|Pressure Ulcer
942585|NCT02296697|Low Level Laser Therapy
942586|NCT02296697|Dressings
942587|NCT02296632|Telemedicine
942588|NCT02296632|Patient Reported Outcomes
942589|NCT02296593|lactate
942590|NCT02296593|continuous lactate monitoring
942591|NCT02296593|continuous blood glucose monitoring
942592|NCT02296593|EIRUS
942593|NCT02296593|blood glucose
942594|NCT02296593|cardiac surgery
942595|NCT02296593|central veinous catheter
942596|NCT02296593|microdialysis
942597|NCT02296554|SLAP Repair
942598|NCT02296554|Biceps Tenodesis
942599|NCT02296528|Feeding Tube Dependent
942600|NCT02296502|DSM Diagnosis
942601|NCT02296450|Quality of Life (QoL)
942602|NCT02296450|Assessment
942603|NCT02296450|14-236
942604|NCT02296450|Patients and Survivors
942605|NCT02296411|Asthma, Anticholinergics
942606|NCT02296385|volunteers
942607|NCT02296333|Acetaminophen, ondansetron
942608|NCT02296307|Aged
942609|NCT02296307|Algorithms
942610|NCT02296307|CA-125 Antigen/blood*
942611|NCT02296307|Chi-Square Distribution
942612|NCT02296307|Early Detection of Cancer*
942613|NCT02296307|Feasibility Studies
942614|NCT02296307|Female
942615|NCT02296307|Humans
942616|NCT02296307|Logistic Models
942617|NCT02296307|Mass Screening/methods*
942618|NCT02296307|Middle Aged
942619|NCT02296307|Neoplasm Grading
942620|NCT02296307|Neoplasm Invasiveness
942621|NCT02296307|Neoplasm Staging
942622|NCT02296307|Ovarian Neoplasms/diagnosis*
942623|NCT02296307|Ovarian Neoplasms/epidemiology
942624|NCT02296307|Ovarian Neoplasms/immunology
942625|NCT02296307|Ovarian Neoplasms/ultrasonography
942626|NCT02296307|Pilot Projects
942627|NCT02296307|Predictive Value of Tests
942628|NCT02296307|Prevalence
942629|NCT02296307|Prognosis
942630|NCT02296307|Prospective Studies
942631|NCT02296307|Quebec/epidemiology
942632|NCT02296307|Tumor Burden
942633|NCT02296294|Bioimpedance Spectroscopy, Body Composition Monitor, Fluid Therapy
942634|NCT02296268|stroke
942635|NCT02296268|aerobic exercise
942636|NCT02296268|screening
942637|NCT02296268|prescription
942638|NCT02296255|cervical cancer screening
942639|NCT02296255|young women vaccination
942640|NCT02296255|impact of HPV vaccination on screening
942641|NCT02296216|have been treated or not treated by Gamma Knife Radiosurgery
942642|NCT02296203|cetuximab rechallenge
942643|NCT02296177|evidence-based intervention
942644|NCT02296177|mammography
942645|NCT02296177|underserved population
942646|NCT02296164|PROVe
942647|NCT02296164|CTCL
942648|NCT02296164|Mechlorethamine
942649|NCT02296164|Cutaneous T-cell lymphoma
942650|NCT02296164|Mycosis fungoides cutaneous T-cell lymphoma
942651|NCT02296164|Valchlor
942652|NCT02296164|Dermatology
942653|NCT02296164|MF-CTCL
942654|NCT02296164|Mycosis Fungoides
942655|NCT02296164|Oncology
942656|NCT02296125|Advanced Non-Small Cell Lung Cancer; EGFRm+; AZD9291; TKI; Phase III
942657|NCT02296099|retropubic suburethral sling
942658|NCT02296099|stress urinary incontinence
942659|NCT02296099|liposomal bupivacaine
942660|NCT02296086|Geriatrics [MeSH]
942661|NCT02296086|Hip fractures [MeSH]
942662|NCT02296086|China [MeSH]
942663|NCT02296086|Early ambulation [MeSH]
942664|NCT02296086|Immobilization [MeSH]
942665|NCT02296073|Pediatric intensive care unit
942666|NCT02296073|Sedation
942667|NCT02296073|Dexmedetomidine
942668|NCT02296073|mechanical ventilation
942669|NCT02296047|COPD, central drive, bronchodilators
942670|NCT02296021|helicobacter pylori
942671|NCT02296021|berberine-containing quadruple therapy
942672|NCT02296021|bismuth-containing quadruple therapy
942673|NCT02296008|high resolution manometry
942674|NCT02296008|children
942675|NCT02296008|congenital anorectal disorder
942676|NCT02296008|surgery
942677|NCT02295995|Aged
942678|NCT02295995|Exercise
942679|NCT02295995|Veterans
942680|NCT02295995|Adherence
942681|NCT02295995|Clinical Trials, Randomized
942682|NCT02295982|Laparoscopic nephrectomy
942683|NCT02295982|one day surgery
942684|NCT02295969|Rhinitis
942685|NCT02295969|Conjunctivitis
942686|NCT02295969|Grass pollen
942687|NCT02295969|Sublingual tablet
942688|NCT02295969|Allergen immunotherapy
942689|NCT02295969|Safety
942690|NCT02295956|Pancreatic Cancer
942691|NCT02295956|Pancreatic adenocarcinoma
942692|NCT02295956|Preoperative therapy
942693|NCT02295956|Questionnaires
942694|NCT02295956|Surveys
942695|NCT02295956|Exercises
942696|NCT02295956|Stretching
942697|NCT02295956|Walking
942698|NCT02295956|Nutrition counseling
942699|NCT02295956|Resistance exercise bands
942700|NCT02295956|Phone calls
942701|NCT02295956|Booklet
942702|NCT02295956|Pamphlet
942703|NCT02295930|colorectal cancer,
942704|NCT02295930|bevacizumab
942705|NCT02295930|cetuximab
942706|NCT02295930|folfoxiri
942707|NCT02295930|kras wild type
942708|NCT02295904|perineum
942709|NCT02295904|videoanalysis
942710|NCT02295865|Psoriasis
942711|NCT02295865|Toreforant
942712|NCT02295865|JNJ-38518168
942713|NCT02295852|Low-sodium calcium enriched diet
942714|NCT02295852|Low-sodium diet
942715|NCT02295852|Glucose and lipid metabolims
942716|NCT02295839|Sleep
942717|NCT02295839|Acute Lymphoblastic Leukemia
942718|NCT02295839|Fatigue
942719|NCT02295839|Sleep hygiene
942720|NCT02295839|Relaxation
942721|NCT02295839|RCT
942722|NCT02295800|HIV
942723|NCT02295800|PMTCT
942724|NCT02295800|Antenatal Care
942725|NCT02295787|Depression
942726|NCT02295787|Suicide
942727|NCT02295787|Suicidal Ideation
942728|NCT02295787|Ketamine
942729|NCT02295787|Late-Life
942730|NCT02295761|motor activity
942731|NCT02295761|obesity
942732|NCT02295761|overweight
942733|NCT02295761|intervention study
942734|NCT02295761|health promotion
942735|NCT02295761|lifestyle counseling
942736|NCT02295761|adherence
942737|NCT02295735|Skin, safety, wounds, intensive care
942738|NCT02295722|eligible for high-dose therapy and stem cell transplantation
942739|NCT02295709|ultrasound
942740|NCT02295709|cervical Transformational Epidural Steroid Injection
942741|NCT02295696|Adults, dialogue tools, outpatient clinic visits
942742|NCT02295644|Therapeutic ultrasound
942743|NCT02295592|hemorrhoids
942744|NCT02295592|The recurrence rate
942745|NCT02295592|PPH
942746|NCT02295592|TSTstarr+
942747|NCT02295566|Nitric Oxide
942748|NCT02295566|Pseudomonas Aeruginosa
942749|NCT02295566|Biofilm
942750|NCT02295553|Ketamine
942751|NCT02295553|Propofol
942752|NCT02295553|Children
942753|NCT02295553|Pediatrics
942754|NCT02295553|Upper endoscopy
942755|NCT02295514|Sepsis
942756|NCT02295514|Septic shock
942757|NCT02295501|Pathogen inactivation
942758|NCT02295501|ebola
942759|NCT02295501|convalescent plasma
942760|NCT02295501|EBOV
942761|NCT02295501|amotosalen
942762|NCT02295501|Provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
942763|NCT02295488|hymenoptera puncture
942764|NCT02295462|nursing homes
942765|NCT02295462|person-centered care
942766|NCT02295462|inappropriate prescriptions
942767|NCT02295462|cluster-randomised controlled trial
942768|NCT02295462|antipsychotic drugs
942769|NCT02295449|Prostate cancer
942770|NCT02295449|Contrast-enhanced ultrasound
942771|NCT02295436|minodronic acid
942772|NCT02295436|pharmacokinetics
942773|NCT02295436|tolerability
942774|NCT02295436|food
942775|NCT02295436|age
942776|NCT02295436|Chinese subjects
942777|NCT02295410|Assessment, PTSD, Veterans
942778|NCT02295397|Food provocation
942779|NCT02295397|Matrix effect
942780|NCT02295397|ED05
942781|NCT02295397|Allergy
942782|NCT02295397|Proton Pump Inhibitor
942783|NCT02295384|Polypharmacy
942784|NCT02295384|Medication Therapy Management
942785|NCT02295371|Drug therapy
942786|NCT02295371|Patient safety
942787|NCT02295371|Polydrug therapy
942788|NCT02295319|Discharge
942789|NCT02295319|Acute Admission Unit
942790|NCT02295319|Randomized Controlled Trial
942791|NCT02295306|OSA, polysomnography, ExSpiron monitor
942792|NCT02295293|Rhus
942793|NCT02295293|Cholesterol
942794|NCT02295293|Triglycerides
942795|NCT02295293|Lipids
942796|NCT02295293|Medicine, Traditional
942797|NCT02295293|Herbal medicine
942798|NCT02295280|headache
942799|NCT02295267|Food allergy
942800|NCT02295267|Walnut
942801|NCT02295267|Components
942802|NCT02295267|Allergens
942803|NCT02295241|Sarcopenia, muscles, aging
942804|NCT02295228|Vitamin D, Vitamin D deficiency, Hip Arthroplasty
942805|NCT02295215|chagas disease
942806|NCT02295215|exercise
942807|NCT02295215|baroreflex sensitivity
942808|NCT02295163|Stellate ganglion block
942809|NCT02295163|hot flushes
942810|NCT02295163|androgen deprivation therapy
942811|NCT02295163|prostate cancer
942812|NCT02295150|Nadroparin
942813|NCT02295150|Anti-Xa activity
942814|NCT02295124|Nausea
942815|NCT02295111|electro-acupuncture
942816|NCT02295111|chronic pelvic pain
942817|NCT02295111|patient practitioner interactions
942818|NCT02295111|TCM health consultation
942819|NCT02295111|meridian balanced method acupuncture
942820|NCT02295085|Cohort, Prospective, Biospecimens
942821|NCT02295072|Exercise-based Randomized Controlled Trial
942822|NCT02295072|Brain structure
942823|NCT02295072|Brain function
942824|NCT02295072|Cognitive function
942825|NCT02295072|Physical fitness
942826|NCT02295072|Body Mass Index
942827|NCT02295072|Cardiovascular disease risk factors
942828|NCT02295072|Mental health
942829|NCT02295072|Stress
942830|NCT02295072|Neurology
942831|NCT02295072|Obesity
942832|NCT02295072|brain
942833|NCT02295072|risk factors
942834|NCT02295072|bone
942835|NCT02295072|bones
942836|NCT02295072|body composition
942837|NCT02295059|Breast cancer
942838|NCT02295059|ERPR negative
942839|NCT02295059|HER-2/neu overexpression positive or negative
942840|NCT02295033|Boost versus no boost irradiation of early breast cancer
942841|NCT02294955|catheter ablation
942842|NCT02294955|atrial fibrillation
942843|NCT02294942|RNTA06
942844|NCT02294942|RANCAD
942845|NCT02294929|catheter ablation
942846|NCT02294929|cryoballoon
942847|NCT02294903|Focal radiofrequency ablation
942848|NCT02294903|Prostate cancer
942849|NCT02294903|Encage
942850|NCT02294864|focus: pulsed radiofrequency (E02.779.468.599)
942851|NCT02294825|deep endometriosis;
942852|NCT02294825|colorectal endometriosis
942853|NCT02294825|surgery
942854|NCT02294825|medical treatment
942855|NCT02294825|fertility
942856|NCT02294812|Hearing Loss
942857|NCT02294812|Speech Perception
942858|NCT02294812|Cognitive Training
942859|NCT02294812|Cognitive Fitness
942860|NCT02294812|Memory, Short-Term
942861|NCT02294799|Temporomandibular Joint Disorders
942862|NCT02294799|Magnetic Ressonance Imaging
942863|NCT02294799|Complementary Therapy
942864|NCT02294799|Physical Therapy Modalities.
942865|NCT02294786|Randomised
942866|NCT02294786|Octreotide
942867|NCT02294786|Diarrhoea
942868|NCT02294786|Phase II
942869|NCT02294786|Capecitabine
942870|NCT02294786|Quality of life
942871|NCT02294786|Metastatic breast cancer
942872|NCT02294786|HER2
942873|NCT02294786|Lapatinib
942874|NCT02294786|Diarrhoea diary
942875|NCT02294773|Infertility
942876|NCT02294773|Intrauterine insemination
942877|NCT02294773|Luteinizing hormone surge
942878|NCT02294760|Irritable Bowel Syndrome
942879|NCT02294760|Sacral Nerve Stimulation
942880|NCT02294760|Symptoms
942881|NCT02294760|Quality of Life
942882|NCT02294734|functional respiratory capacity
942883|NCT02294734|High-resolution computed tomography
942884|NCT02294734|GSK2269557
942885|NCT02294734|acute exacerbation of COPD
942886|NCT02294734|lung capacity
942887|NCT02294708|macula-off retinal detachment
942888|NCT02294708|scleral buckle
942889|NCT02294708|persistent sub-foveal fluid
942890|NCT02294708|postoperative postures
942891|NCT02294708|optical coherence tomography (OCT)
942892|NCT02294695|Empiric antibiotic therapy
942893|NCT02294682|uncomplicated urogenital gonorrhea
942894|NCT02294682|Bacterial Type II Topoisomerase Inhibitors (BTI)
942895|NCT02294682|antibiotics
942896|NCT02294682|GSK2140944
942897|NCT02294682|N. gonorrhoeae
942898|NCT02294656|CYSTOID MACULAR EDEMA
942899|NCT02294643|sarpogrelate
942900|NCT02294591|Bipolar Disorder
942901|NCT02294591|Depression
942902|NCT02294591|Acetylcystein
942903|NCT02294591|Oxidative Stress
942904|NCT02294591|Urine
942905|NCT02294578|Biomarkers
942906|NCT02294578|saliva
942907|NCT02294578|mRNA
942908|NCT02294565|Sentinel Lymph Node Biopsy
942909|NCT02294565|Breast Cancer
942910|NCT02294565|Lymphatic Mapping
942911|NCT02294552|Cyclophosphamide
942912|NCT02294552|Leukemia
942913|NCT02294552|Lymphoma
942914|NCT02294552|Myelodysplastic Syndromes
942915|NCT02294552|Chronic Lymphocytic Leukemia
942916|NCT02294552|Immunosuppressive Agents
942917|NCT02294552|Immune System Diseases
942918|NCT02294552|Busulfan
942919|NCT02294552|Fludarabine
942920|NCT02294552|Tacrolimus
942921|NCT02294552|Mycophenolate mofetil
942922|NCT02294552|Antineoplastic Agents, Alkylating
942923|NCT02294552|Myeloablative Agonists
942924|NCT02294552|Hematopoietic Stem Cell Transplantation
942925|NCT02294552|Allogeneic
942926|NCT02294526|Diet
942927|NCT02294526|Sardine
942928|NCT02294526|Type 2 diabetes
942929|NCT02294513|Alzheimer disease
942930|NCT02294513|Dementia
942931|NCT02294513|Hearing loss
942932|NCT02294513|Correction of hearing impairment
942933|NCT02294513|Hearing aids
942934|NCT02294513|Communication
942935|NCT02294513|Family caregivers
942936|NCT02294513|Third-party disability
942937|NCT02294500|ovarian function
942938|NCT02294500|female
942939|NCT02294500|Genital Function
942940|NCT02294487|influenza
942941|NCT02294487|pneumococcal
942942|NCT02294487|pneumonia
942943|NCT02294487|vaccine
942944|NCT02294487|immunization
942945|NCT02294487|#CAImmun
942946|NCT02294487|Immuno-oncology
942947|NCT02294487|supportive care
942948|NCT02294487|vaccination
942949|NCT02294487|meningococcal
942950|NCT02294487|HIB
942951|NCT02294461|Enzalutamide
942952|NCT02294461|Androgen receptor
942953|NCT02294461|Prostate cancer
942954|NCT02294461|Xtandi
942955|NCT02294448|Cervical radiculopathy
942956|NCT02294448|Neck pain
942957|NCT02294448|Qishe pill
942958|NCT02294448|raditional Chinese medicine
942959|NCT02294448|healthy Chinese subject
942960|NCT02294448|Population Pharmacokinetics
942961|NCT02294448|Personalized Medicine
942962|NCT02294448|Individualized Medicine
942963|NCT02294435|Thoracoabdominal Aneurysms
942964|NCT02294435|Endovascular
942965|NCT02294435|Ps-ide
942966|NCT02294435|Early Feasibility
942967|NCT02294435|Aneurysm
942968|NCT02294435|Aortic Aneurysm, Thoracic
942969|NCT02294435|Aortic Aneurysm
942970|NCT02294435|Aortic Diseases
942971|NCT02294435|Cardiovascular Diseases
942972|NCT02294435|Vascular Diseases
942973|NCT02294435|Pararenal aneurysm
942974|NCT02294435|Juxtarenal aneurysm
942975|NCT02294435|Aortic dissection
942976|NCT02294435|Short neck infrarenal aneurysm
942977|NCT02294435|Type 4 thoracoabdominal
942978|NCT02294435|TAAA
942979|NCT02294422|Loss of resistance
942980|NCT02294422|Pilot balloon
942981|NCT02294422|Cuff pressure
942982|NCT02294422|Endotracheal tube
942983|NCT02294409|social anxiety
942984|NCT02294409|psychosis
942985|NCT02294409|CBT
942986|NCT02294409|randomized
942987|NCT02294409|CRT
942988|NCT02294396|Anticholinergic
942989|NCT02294396|Overactive Bladder (OAB)
942990|NCT02294396|Mirabegron
942991|NCT02294396|YM178
942992|NCT02294383|Pelvic Floor Biomechanics
942993|NCT02294383|Tissue Elasticity
942994|NCT02294383|Tactile Imaging
942995|NCT02294370|type 2 diabetes
942996|NCT02294370|continuous glucose monitoring
942997|NCT02294357|carfilzomib
942998|NCT02294357|proteasome inhibitor
942999|NCT02294357|multiple myeloma
943000|NCT02294357|relapsed/refractory
943001|NCT02294344|double filtration plasmapheresis
943002|NCT02294344|ANCA-Associated Vasculitis
943003|NCT02294305|Depression
943004|NCT02294305|Social Anxiety
943005|NCT02294305|Social Phobia
943006|NCT02294305|Major Depression
943007|NCT02294305|Vortioxetine
943008|NCT02294279|cough, wheeze, dyspnoea
943009|NCT02294240|Pregnant, malnourished, energy dense biscuits, low birth weight
943010|NCT02294227|AIN457, psoriatic arthritis, chronic inflammatory disease, loading regimen, secukinumab, self-injection
943011|NCT02294214|malaria
943012|NCT02294214|Spatial Repellents
943013|NCT02294214|Plasmodium
943014|NCT02294201|Malaria
943015|NCT02294201|Spatial Repellents
943016|NCT02294201|Plasmodium
943017|NCT02294188|Malaria
943018|NCT02294188|Spatial Repellents
943019|NCT02294188|Plasmodium
943020|NCT02294175|larva
943021|NCT02294175|debridement
943022|NCT02294175|lower extremity or diabetic foot ulcer
943023|NCT02294175|biofilm
943024|NCT02294175|infection
943025|NCT02294175|chronic wound
943026|NCT02294149|chemotherapy
943027|NCT02294149|Omega 3
943028|NCT02294136|HIV
943029|NCT02294136|HCV
943030|NCT02294136|Adherence
943031|NCT02294136|Psychiatric
943032|NCT02294136|Behavioral
943033|NCT02294136|Intervention
943034|NCT02294110|failure
943035|NCT02294110|spinal anesthesia
943036|NCT02294071|acetaminophen
943037|NCT02294071|ibuprofen
943038|NCT02294058|MS
943039|NCT02294058|RMS
943040|NCT02294058|Multiple Sclerosis
943041|NCT02294058|Relapsing Multiple Sclerosis
943042|NCT02294045|Knee
943043|NCT02294045|Healthy
943044|NCT02294045|arthroscopy
943045|NCT02294045|MRI
943046|NCT02294045|amplification
943047|NCT02294045|sounds
943048|NCT02294045|pre-operative
943049|NCT02294045|analyzing
943050|NCT02294032|Bcells
943051|NCT02294032|kidney allograft dysfunction
943052|NCT02294032|antibody mediated rejection
943053|NCT02294019|ibuprofen 400 mg
943054|NCT02294019|actual use
943055|NCT02294019|compliance
943056|NCT02294006|pancreatic
943057|NCT02294006|neuroendocrine
943058|NCT02294006|everolimus
943059|NCT02294006|metformin
943060|NCT02294006|octreotide
943061|NCT02293941|liver inflammation
943062|NCT02293928|Hybrid coronary revascularization
943063|NCT02293928|Antiplatelet therapy
943064|NCT02293928|Aspirin
943065|NCT02293928|Clopidogrel
943066|NCT02293889|Knee osteoarthritis
943067|NCT02293889|Pain
943068|NCT02293889|Vitamin D
943069|NCT02293889|Physical activity
943070|NCT02293889|Pilot study
943071|NCT02293889|Qualitative Interview
943072|NCT02293889|Obesity
943073|NCT02293889|Older adults
943074|NCT02293876|Corneal Diseases
943075|NCT02293876|Corneal Ulcer
943076|NCT02293876|Nursing Diagnosis
943077|NCT02293876|Intensive Care Units
943078|NCT02293876|Nursing
943079|NCT02293876|Randomized Clinical Trial
943080|NCT02293837|interleukin-6 (IL-6) receptor inhibitor
943085|NCT02293772|Bedrest
943086|NCT02293772|Appetite
943087|NCT02293759|BPH- LASER- PROSTATE- BLEEDING TENDENCY
943088|NCT02293746|Obstructive Sleep Apnea
943089|NCT02293746|OSA
943090|NCT02293746|neurostimulation
943091|NCT02293746|hypoglossal nerve
943092|NCT02293746|tongue
943093|NCT02293746|upper airway stimulation
943094|NCT02293746|surgery
943095|NCT02293733|Retrospective
943096|NCT02293733|EGFR
943097|NCT02293733|mutation
943098|NCT02293733|TKI
943099|NCT02293733|NSCLC
943100|NCT02293707|Castration-resistant prostate cancer
943101|NCT02293707|Therapeutic vaccine
943102|NCT02293707|Telomerase vaccine
943103|NCT02293694|DMPA-SC: depo medroxyprogesterone acetate sub-cutaneous
943104|NCT02293694|DMPA-IM: depo medroxyprogesterone acetate intramuscular
943105|NCT02293681|Spondylitis, Ankylosing
943106|NCT02293681|Infliximab
943107|NCT02293681|Non-steroidal anti-inflammatory drugs
943108|NCT02293681|Disease-modifying anti-rheumatic drugs
943109|NCT02293668|poor responders
943110|NCT02293655|ADHD
943111|NCT02293655|inattention
943112|NCT02293655|hyperactivity
943113|NCT02293655|methylphenidate
943114|NCT02293642|primary cancers of the breast
943115|NCT02293642|primary cancers of the kidney
943116|NCT02293642|primary cancers of the lung
943117|NCT02293642|primary cancers of the prostate
943118|NCT02293629|Subjects
943119|NCT02293616|ICU
943120|NCT02293616|Respiratory Failure
943121|NCT02293616|Weakness
943122|NCT02293616|Nitrate supplementation
943123|NCT02293603|cardiomyopathy
943124|NCT02293603|cardiosphere-derived stem cells
943125|NCT02293603|intracoronary infusion
943126|NCT02293603|adult stem cells
943127|NCT02293603|heart disease
943128|NCT02293603|ventricular dysfunction
943129|NCT02293603|pathological processes
943130|NCT02293603|cardiovascular diseases
943131|NCT02293603|heart failure
943132|NCT02293590|Certolizumab pegol
943133|NCT02293590|DMARD
943134|NCT02293590|Joint injection
943135|NCT02293590|Glucocorticoids
943136|NCT02293564|Erosive Osteoarthritis
943137|NCT02293564|Osteoarthritis
943138|NCT02293564|Osteoarthritis of the Hand
943139|NCT02293538|Symptoms of Contact Lens Related Discomfort
943140|NCT02293512|Tinnitus
943141|NCT02293512|Coping
943142|NCT02293512|Psychoeducational intervention
943143|NCT02293499|asthma
943144|NCT02293499|adolescent
943145|NCT02293499|intervention
943146|NCT02293486|Antioxidants
943147|NCT02293486|Protein Carbonylation
943148|NCT02293486|Malondialdehyde
943149|NCT02293486|Punicaceae
943150|NCT02293486|Athletic Performance
943151|NCT02293460|Peripheral neuropathy
943152|NCT02293460|Disimmune disease
943153|NCT02293460|Neurology Chronic disease
943154|NCT02293460|Rare disease
943155|NCT02293447|Uterine
943156|NCT02293447|Fibroid
943157|NCT02293447|Embolization
943158|NCT02293447|Leiomyoma
943159|NCT02293447|Lidocaine
943160|NCT02293447|Pain
943161|NCT02293434|Malnutrition
943162|NCT02293434|Status Nutritional Weight
943163|NCT02293434|Pediatric intensive care
943164|NCT02293408|MPS IIIB
943165|NCT02293408|Mucopolysaccharidosis
943166|NCT02293408|Mucopolysaccharidosis type IIIB
943167|NCT02293408|Sanfilippo Syndrome
943168|NCT02293395|Acute Coronary Syndrome
943169|NCT02293395|Myocardial infarction
943170|NCT02293395|Unstable angina
943171|NCT02293395|Acetylsalicylic acid
943172|NCT02293395|Rivaroxaban
943173|NCT02293395|JNJ-39039039
943174|NCT02293395|Bay 59-7939
943175|NCT02293395|Xarelto
943176|NCT02293395|Clopidogrel
943177|NCT02293395|Ticagrelor
943178|NCT02293395|Plavix
943179|NCT02293395|Brilinta
943180|NCT02293395|Effient
943181|NCT02293382|MPS IIIB
943182|NCT02293382|Mucopolysaccharodosis III
943183|NCT02293382|Mucopolysaccharidosis type IIIB
943184|NCT02293382|Sanfilippo Syndrome
943185|NCT02293343|histamine profile
943186|NCT02293343|IgE Antibodies
943187|NCT02293330|continuous versus intermittent bolus sciatic nerve block
943188|NCT02293317|Influenza Prime universal vaccine M-001 Multimeric
943189|NCT02293291|Gulf war illness
943190|NCT02293278|MVPA
943191|NCT02293278|sedentary behaviour
943192|NCT02293278|PA intervention
943193|NCT02293278|preschool
943194|NCT02293278|gross motor
943195|NCT02293278|anthropometrics
943196|NCT02293278|day care
943197|NCT02293265|mepolizumab
943198|NCT02293265|omalizumab
943199|NCT02293265|SB-240563
943200|NCT02293265|Severe Asthma
943201|NCT02293265|reslizumab
943202|NCT02293252|Home Telemonitoring
943203|NCT02293239|whole-body electromyostimulation
943204|NCT02293239|cachexia
943205|NCT02293239|cancer
943206|NCT02293239|skeletal muscle mass
943207|NCT02293239|nutrition
943208|NCT02293213|Category D
943209|NCT02293213|Category X
943210|NCT02293213|Electronic Medical Records
943211|NCT02293213|Long Acting Reversible Contraception
943212|NCT02293187|vitamin D
943213|NCT02293187|muscle performance
943214|NCT02293187|falls
943215|NCT02293161|Interleukin-7 Receptor α
943216|NCT02293161|monoclonal antibody
943217|NCT02293148|Prolyl hydroxylase inhibitor
943218|NCT02293148|GSK1278863
943219|NCT02293148|Anemia
943220|NCT02293148|QTc
943221|NCT02293148|erythropoiesis stimulating agent
943222|NCT02293135|Type 2 diabetes ; endothelium stimulation
943223|NCT02293122|Agreement
943224|NCT02293122|Repeatability
943225|NCT02293122|Reproducibility
943226|NCT02293096|Genotype
943227|NCT02293096|CYP2D6
943228|NCT02293096|ADRB1
943229|NCT02293057|Adolescent
943230|NCT02293057|Juvenile Justice
943231|NCT02293057|Drug Use
943232|NCT02293057|Marijuana
943233|NCT02293057|Gender Responsive
943234|NCT02293057|Girls
943235|NCT02293057|HIV
943236|NCT02293057|Sexual Risk
943237|NCT02293044|Sensitivity
943238|NCT02293031|maxillofacial bone defects
943239|NCT02293031|alveolar ridge atrophy
943240|NCT02293031|gene-activated matrix
943241|NCT02293031|VEGF gene
943242|NCT02293031|DNA plasmid
943243|NCT02293031|bone gene therapy
943244|NCT02293005|Lung Cancer
943245|NCT02293005|Mesothelioma
943246|NCT02293005|Unresectable malignant pleural mesothelioma
943247|NCT02293005|MPM
943248|NCT02293005|Alisertib
943249|NCT02293005|MLN8237
943250|NCT02292992|Electrical impedance tomography
943251|NCT02292992|Nasal Pillow Continuous Positive Airway Pressure(CPAP)
943252|NCT02292992|High Flow Nasal Cannula
943253|NCT02292992|extubation
943254|NCT02292979|HL
943255|NCT02292966|Hepatitis C
943256|NCT02292966|Hepatitis
943257|NCT02292966|Asunaprevir
943258|NCT02292966|Daclatasvir
943259|NCT02292966|Beclabuvir
943260|NCT02292966|Neurocognitive function
943261|NCT02292966|Brain metabolites
943262|NCT02292966|Direct acting antiviral therapy
943263|NCT02292953|ICSI
943264|NCT02292953|Ovum Pickup
943265|NCT02292953|Embryo Transfer
943266|NCT02292940|patient outcome assessment
943267|NCT02292940|electronic health records
943268|NCT02292888|Doppler VTI TEE SV volume responsiveness
943269|NCT02292875|Grass Allergy
943270|NCT02292875|Rhinoconjunctivitis
943271|NCT02292875|Environmental Exposure Unit
943272|NCT02292875|Immunotherapy
943273|NCT02292875|ToleroMune Grass
943274|NCT02292849|Depression
943275|NCT02292823|STEMI
943276|NCT02292823|heart attack
943277|NCT02292823|stent
943278|NCT02292823|Bare Metal Stent
943279|NCT02292823|myocardial infarction
943280|NCT02292823|PCI
943281|NCT02292784|infants
943282|NCT02292784|retosiban
943283|NCT02292784|Preterm Labor
943284|NCT02292784|long-term safety follow-up
943285|NCT02292771|Spontaneous Preterm Labor
943286|NCT02292771|retosiban
943287|NCT02292771|GSK221149
943288|NCT02292771|atosiban
943289|NCT02292745|locally advanced pancreatic cancer
943290|NCT02292745|chemotherapy
943291|NCT02292745|stereotactic radiotherapy
943292|NCT02292732|Pharmacokinetics
943293|NCT02292732|Solid Tumors
943294|NCT02292732|Safety
943295|NCT02292732|Trametinib
943296|NCT02292732|MEK Inhibitor
943297|NCT02292732|Combined Oral Contraceptive
943298|NCT02292732|Trametinib's Metabolite M5
943299|NCT02292732|Norethindrone
943300|NCT02292732|Ethinyl Estradiol
943301|NCT02292719|Hepatitis C Virus
943302|NCT02292719|Genotype 2
943303|NCT02292719|Chronic Hepatitis C
943304|NCT02292719|Genotype 3
943305|NCT02292719|Non-cirrhotic
943306|NCT02292719|Cirrhotic
943307|NCT02292706|HCV Cirrhosis registry
943308|NCT02292706|Cirrhosis
943309|NCT02292706|Hepatitis C
943310|NCT02292693|intubation
943311|NCT02292680|dentin
943312|NCT02292680|environmental exposures
943313|NCT02292680|neurodevelopmental outcomes
943314|NCT02292667|Transversus Abdominis Plane Block
943442|NCT02292134|Intensive care unit
943315|NCT02292667|Postoperative Pain Management
943316|NCT02292667|Open Repair of Aortic Abdominal Aneurysm
943317|NCT02292641|Lower Gastrointestinal Tract
943318|NCT02292641|Rectum
943319|NCT02292641|Diagnostic Imaging
943320|NCT02292641|Magnetic Resonance Imaging
943321|NCT02292641|Pelvic Exenteration
943322|NCT02292641|Neoplasms
943323|NCT02292641|Adenocarcinoma
943324|NCT02292641|Carcinoma
943325|NCT02292602|preschool
943326|NCT02292602|obesity
943327|NCT02292602|health disparities
943328|NCT02292602|intervention
943329|NCT02292589|Traumatic Brain Injury
943330|NCT02292589|Post concussion syndrome
943331|NCT02292589|Transcranial Direct Current Stimulation
943332|NCT02292589|Neuromodulation
943333|NCT02292576|volunteers
943334|NCT02292563|Nurse; Colonoscopy; Polyp; Adenoma;
943342|NCT02292537|Spinal Muscular Atrophy
943343|NCT02292537|SMA
943344|NCT02292537|SMN
943345|NCT02292537|SMNRx
943346|NCT02292537|ISIS-SMNRx
943347|NCT02292537|ISIS-SMN Rx
943348|NCT02292537|ISIS 396443
943349|NCT02292537|CHERISH
943350|NCT02292537|IONIS-SMNRx
943351|NCT02292537|IONIS-SMN Rx
943352|NCT02292511|subjective cognitive impairment
943353|NCT02292511|mind-motor intervention
943354|NCT02292511|square-stepping exercise
943355|NCT02292511|older adults
943356|NCT02292498|imaging, diagnostic
943357|NCT02292498|feasibility
943358|NCT02292485|Lung Cancer Screening
943359|NCT02292485|LCS
943360|NCT02292485|Survey
943361|NCT02292485|Questionnaire
943362|NCT02292485|Texas Academy of Family Physicians
943363|NCT02292472|masticatory muscles
943364|NCT02292446|Polycythemia Vera
943365|NCT02292446|Hematologic Diseases
943366|NCT02292446|Myeloproliferative Disorders
943367|NCT02292446|INC424
943368|NCT02292446|Ruxolitinib
943369|NCT02292433|Phase 1
943370|NCT02292433|type 2 diabetes
943371|NCT02292433|monotherapy
943372|NCT02292433|PF-04937319
943373|NCT02292420|pulse oximetry plethymographic waveform
943374|NCT02292420|area under curve
943375|NCT02292420|amplitude
943376|NCT02292394|Depression
943377|NCT02292394|Depressive symptoms
943378|NCT02292394|Prevention
943379|NCT02292394|Caregivers
943380|NCT02292394|Telephone intervention
943381|NCT02292368|Head and Neck Cancer
943382|NCT02292368|Xerostomia
943383|NCT02292368|Radiation-induced Xerostomia
943384|NCT02292368|Acupuncture
943385|NCT02292368|Nasopharyngeal cancer
943386|NCT02292368|Radiation therapy
943387|NCT02292368|XRT
943388|NCT02292368|Electroencephalogram
943389|NCT02292368|EEG
943390|NCT02292368|Xerostomia questionnaire
943391|NCT02292368|XQ
943392|NCT02292368|MD Anderson Symptom Inventory - Head & Neck
943393|NCT02292368|MDASI-HN
943394|NCT02292368|Questionnaires
943395|NCT02292368|Surveys
943401|NCT02292342|Flow mediated dilatation
943402|NCT02292329|flow-mediated dilation
943403|NCT02292329|Acai polyphenols
943404|NCT02292316|middle-aged and aged adults
943405|NCT02292316|fall in the previous year
943406|NCT02292303|Zinc/pharmacokinetics
943407|NCT02292290|Diabetes
943408|NCT02292290|Liraglutide
943409|NCT02292290|Ramadan
943410|NCT02292290|fasting
943411|NCT02292277|Ticagrelor
943412|NCT02292277|Pharmacokinetics
943413|NCT02292277|Platelet Aggregation
943414|NCT02292277|Platelet Function Tests
943415|NCT02292251|Stroke
943416|NCT02292251|Transcranial direct current stimulation
943417|NCT02292238|Alzheimer's disease
943418|NCT02292238|benfotiamine
943419|NCT02292238|glucose
943420|NCT02292238|Amyloid
943421|NCT02292225|Phase 1b, CLL/SLL, PI3K
943422|NCT02292199|Hypertension
943423|NCT02292199|TENS
943424|NCT02292199|Sympathetic and Parasympathetic nervous system
943425|NCT02292186|Cardiomyopathy
943426|NCT02292186|Heart Failure
943427|NCT02292186|FAC
943428|NCT02292186|Amyloid
943429|NCT02292186|Transthyretin
943430|NCT02292186|TTR
943431|NCT02292186|RNAi therapeutic
943432|NCT02292173|Liver Neoplasms
943433|NCT02292173|Liver Diseases
943434|NCT02292173|Digestive System Diseases
943435|NCT02292173|Advanced
943436|NCT02292173|Mitogen-Activated Protein Kinase (MEK) Inhibitor
943437|NCT02292173|Kinase Inhibitor
943438|NCT02292147|Cerebral anoxia
943439|NCT02292147|Functional outcome
943440|NCT02292134|Sleep quality
943441|NCT02292134|Sleep architecture
943443|NCT02292134|Light
943444|NCT02292134|Noise
943445|NCT02292134|Earplug
943446|NCT02292134|Sleep mask
943447|NCT02292121|Obesity
943448|NCT02292121|Intestinal permeability
943449|NCT02292121|Adipose tissue inflammation
943450|NCT02292121|Low grade systemic inflammation
943451|NCT02292121|Bariatric surgery
943452|NCT02292108|Hypnosis
943453|NCT02292108|self-hypnosis
943454|NCT02292108|obesity
943455|NCT02292108|high food impulsiveness
943456|NCT02292095|anesthesia
943457|NCT02292095|transverse abdominis plane block
943458|NCT02292095|patient controlled intravenous analgesia
943459|NCT02292082|Nerve Block
943460|NCT02292082|Rehabilitation
943461|NCT02292082|Knee Replacement, Total
943462|NCT02291991|Safety
943463|NCT02291991|Tolerability
943464|NCT02291991|Pharmacokinetics
943465|NCT02291991|Pharmacodynamics
943466|NCT02291991|Immunogenecity
943467|NCT02291978|back pain
943468|NCT02291978|facet joint
943469|NCT02291978|spine
943470|NCT02291965|hematopoietic cell transplant
943471|NCT02291952|Circadian Misalignment, Forced Desynchrony, Metabolism, Meal-timing, Circadian
943472|NCT02291926|Human Umbilical Cord Mesenchymal Stem Cell
943473|NCT02291926|Mesenchymal Stem Cell
943474|NCT02291926|Osteoarthritis
943475|NCT02291913|ER-Positive Breast Cancer
943476|NCT02291913|HER2-Negative Breast Cancer
943477|NCT02291913|everolimus
943478|NCT02291913|anti-estrogen therapy
943479|NCT02291913|PR-Positive Breast Cancer
943480|NCT02291913|Afinitor
943481|NCT02291900|avascular necrosis, talus, medial femoral condyle
943482|NCT02291874|Diabetes
943483|NCT02291874|Ipragliflozin
943484|NCT02291874|GLP-1 receptor agonist
943485|NCT02291861|Dyskinesias
943486|NCT02291861|Movement Disorders
943487|NCT02291861|Central Nervous System Diseases
943488|NCT02291861|Nervous System Diseases
943489|NCT02291861|Neurologic Manifestations
943490|NCT02291861|Signs and Symptoms
943491|NCT02291848|Multiple Myeloma
943492|NCT02291848|Cytotoxic T-lymphocytes
943493|NCT02291809|HIV/AIDS
943494|NCT02291809|Pediatric
943495|NCT02291809|Vaccine
943496|NCT02291809|HIV-1 Immunogen
943497|NCT02291796|Bezafibrate
943498|NCT02291796|Hyperfibrinogenemia
943499|NCT02291796|Inflammatory response
943500|NCT02291796|Acute myocardial infarction
943501|NCT02291796|Mayor cardiovascular events
943502|NCT02291770|Chronic Graft-Versus-Host Disease
943503|NCT02291770|Mesenchymal Stromal Cells
943504|NCT02291744|TFS (time to failure of strategy)
943505|NCT02291731|Autologous serum eye drops
943506|NCT02291731|Silicone-hydrogel contact lens
943507|NCT02291731|Persistent epithelial defects
943508|NCT02291731|Corneal epithelial defects
943509|NCT02291718|Suspected or confirmed
943510|NCT02291718|TAA
943511|NCT02291718|Computed tomography angiography
943512|NCT02291718|CTA
943513|NCT02291718|Contrast agent
943514|NCT02291718|Radiation dose
943515|NCT02291718|Thoracoabdominal aortic aneurysm
943516|NCT02291705|Ultrasound, rectus sheath block, children, inguinal hernia
943517|NCT02291666|Cytochromes p450
943518|NCT02291666|drug metabolism
943519|NCT02291666|pharmacokinetics
943520|NCT02291666|diabetes
943521|NCT02291666|probe markers
943522|NCT02291614|Amgen
943523|NCT02291614|Phase 1
943524|NCT02291614|Clinical Trial
943525|NCT02291614|Oncology
943526|NCT02291614|GI adenocarcinoma
943527|NCT02291614|Immunotherapy
943528|NCT02291536|THC and CBD
943529|NCT02291536|Attentional blink
943530|NCT02291523|Fecal transplant
943531|NCT02291484|Computed tomography
943532|NCT02291484|Coronary angiography
943533|NCT02291484|Coronary artery disease
943534|NCT02291484|Perfusion imaging
943535|NCT02291484|Comparative effectiveness
943536|NCT02291484|Randomized controlled trial
943537|NCT02291484|Cost-effectiveness
943538|NCT02291445|Peppermint oil
943539|NCT02291445|Menthol
943540|NCT02291445|Volatile oil
943541|NCT02291445|Plant oil
943542|NCT02291445|Visceral pain
943543|NCT02291445|Abdominal pain
943544|NCT02291445|Irritable bowel syndrome (IBS)
943545|NCT02291445|Colonic disease
943546|NCT02291419|ticagrelor
943547|NCT02291419|non-cardiac surgery
943548|NCT02291419|elevated troponin
943549|NCT02291419|myocardial injury
943550|NCT02291406|Hysterectomy
943551|NCT02291406|Insulin resistance
943552|NCT02291406|Metabolism
943553|NCT02291380|Chronic Migraine
943554|NCT02291380|Botulinum Toxin Type A for Injection
943555|NCT02291354|Fecal Microbiota Transplantation
943556|NCT02291354|Soluble Dietary Fiber
943557|NCT02291354|Slow Transit Constipation
943558|NCT02291315|Triple Stable Isotope
943559|NCT02291263|Polio
943560|NCT02291263|Inactivated polio vaccine
943561|NCT02291263|IPV
943562|NCT02291263|oral polio vaccine
943563|NCT02291250|anthocyanin
943564|NCT02291250|blackcurrant
943565|NCT02291250|greencurrant
943566|NCT02291250|glucose
943567|NCT02291250|polyphenol
943568|NCT02291250|post prandial glucose
943569|NCT02291237|hypertrophic cardiomyopathy
943570|NCT02291237|hcm
943571|NCT02291237|hocm
943572|NCT02291237|hypertrophic myocardiopathy
943573|NCT02291237|hypertrophic obstructive cardiomyopathies
943574|NCT02291237|cardiomyopathy
943575|NCT02291237|hypertrophic
943576|NCT02291237|familial hypertrophic cardiomyopathy
943577|NCT02291237|genetic heart disease
943578|NCT02291237|echocardiography
943579|NCT02291237|cardiopulmonary exercise testing
943580|NCT02291237|exercise Capacity
943581|NCT02291237|heart failure
943582|NCT02291237|angina
943583|NCT02291237|dyspnea
943584|NCT02291237|diastolic dysfunction
943585|NCT02291237|microvascular ischemia
943586|NCT02291237|late sodium current inhibitor
943587|NCT02291237|GS-6615
943588|NCT02291237|late INA
943589|NCT02291224|dual protection
943590|NCT02291224|pregnancy
943591|NCT02291224|reproductive health
943592|NCT02291224|sexually transmitted diseases
943593|NCT02291224|condoms
943594|NCT02291224|contraception
943595|NCT02291224|adolescent health services
943596|NCT02291198|colorectal cancer
943597|NCT02291198|natural killer cell activity
943598|NCT02291198|screening
943599|NCT02291198|NK cells
943600|NCT02291159|stroke
943601|NCT02291159|spasticity
943602|NCT02291159|dry needling
943603|NCT02291159|upper motor neuron syndrome
943604|NCT02291159|motor function
943605|NCT02291146|gardening
943606|NCT02291146|cooking
943607|NCT02291146|nutrition education
943608|NCT02291146|Hispanic Americans
943609|NCT02291133|Primary liver tumors
943610|NCT02291133|Bleomycin
943611|NCT02291133|Electrochemotherapy
943612|NCT02291107|Gait orthosis
943613|NCT02291107|Lokomat
943614|NCT02291107|Robotic Rehabilitation
943615|NCT02291094|Intravenous lidocaine
943616|NCT02291094|Mastectomy
943617|NCT02291094|Pain
943618|NCT02291081|HIV, AIDS
943619|NCT02291081|antiretroviral therapy
943620|NCT02291081|aging
943621|NCT02291081|heart failure
943622|NCT02291081|coronary heart disease
943623|NCT02291081|myocardial infarction
943624|NCT02291081|HIV-associated neurocognitive disorders
943625|NCT02291042|Bladder
943626|NCT02291042|Surgery
943627|NCT02291029|Sjögren's syndrome, CFZ533, ESSDAI
943628|NCT02291016|COPD
943629|NCT02291016|chronic obstructive pulmonary disease
943630|NCT02291003|circadian
943631|NCT02291003|sleep
943632|NCT02290977|RT, TACE
943633|NCT02290964|Acute normovolemic hemodilution
943634|NCT02290964|allogeneic transfusion
943635|NCT02290938|adolescents
943636|NCT02290938|Native American
943637|NCT02290938|alcohol use
943638|NCT02290938|drug use
943639|NCT02290938|cultural
943640|NCT02290938|traditional activities
943641|NCT02290938|cultural identification
943642|NCT02290925|biscuit containing Salacia reticulate
943643|NCT02290925|randomised controlled trial
943644|NCT02290912|Alzheimer's disease prevention lifestyle intervention
943645|NCT02290899|Attention Deficit Hyperactivity Disorder (ADHD)
943646|NCT02290886|safety evaluation
943647|NCT02290886|intravenous administration
943648|NCT02290886|3 doses of autologous MSC
943649|NCT02290886|ALS
943650|NCT02290834|Chemotherapy related cognitive impairment
943651|NCT02290834|Chemo-brain
943652|NCT02290808|physical
943653|NCT02290808|activity
943654|NCT02290808|exercise
943655|NCT02290808|new-parents
943656|NCT02290808|intervention
943657|NCT02290808|theory-based
943658|NCT02290795|Vitreopapillary traction
943659|NCT02290782|toxicity
943660|NCT02290782|outcome
943661|NCT02290782|TARGIT
943662|NCT02290782|quality of life
943663|NCT02290782|intraoperative radiotherapy (IORT)
943664|NCT02290769|Guide wire cannulation ERCP
943665|NCT02290769|Time of cannulation
943666|NCT02290769|Rapid exchange guide wire
943667|NCT02290769|Guide wire
943668|NCT02290756|Early child development
943669|NCT02290756|Link Workers
943670|NCT02290756|Community Birth attendants
943671|NCT02290756|Parenting Program
943672|NCT02290730|Lower trapezius
943673|NCT02290730|Kinesio taping
943674|NCT02290717|ultraviolet therapy
943675|NCT02290717|non segmental
943676|NCT02290717|vitiligo
943677|NCT02290717|topical corticosteroid
943678|NCT02290717|laser
943679|NCT02290717|fractional
943680|NCT02290717|CO2
943681|NCT02290717|carbon dioxide
943682|NCT02290717|UVB
943683|NCT02290704|oxygen saturation
943684|NCT02290704|retinal vessels
943685|NCT02290704|thyroid associated ophthalmopathy
943686|NCT02290691|Needle Free, Influenza
943687|NCT02290678|Pilot Study
943688|NCT02290678|Adventure-based Programming
943689|NCT02290665|enema
943690|NCT02290652|Sexual function in Orthopaedic patients
943691|NCT02290639|Posttraumatic Stress
943692|NCT02290639|Posttraumatic Stress Disorder
943693|NCT02290639|Military
943694|NCT02290639|Primary Care
943695|NCT02290639|Cognitive Behavioral Therapy
943696|NCT02290639|Prolonged Exposure
943697|NCT02290639|Cognitive Processing Therapy
943698|NCT02290639|Behavioral Health Optimization Program
943699|NCT02290639|Behavioral Health Consultant
943700|NCT02290626|Elemental diet
943701|NCT02290626|semi-solid diet
943702|NCT02290626|gastric emptying
943703|NCT02290626|GER
943704|NCT02290626|PEG
943705|NCT02290613|pulmonary hypertension
943706|NCT02290613|systemic sclerosis
943707|NCT02290587|social cognitive
943708|NCT02290587|theory of mind
943709|NCT02290587|cognitive impairment
943710|NCT02290587|functional MRI
943711|NCT02290587|brain activation network
943712|NCT02290561|Prostatic Neoplasms
943713|NCT02290561|Therapeutics
943714|NCT02290561|Magnetic Resonance Imaging
943715|NCT02290561|Ultrasonography
943716|NCT02290561|High Intensity Focused Ultrasound
943717|NCT02290561|Image Fusion
943718|NCT02290548|high flow nasal cannula
943719|NCT02290548|extubation failure
943720|NCT02290535|obstructive pulmonary disease
943721|NCT02290535|children
943722|NCT02290535|teenager
943723|NCT02290535|EIT (Electrical Impedance Tomography)
943724|NCT02290496|Insomnia
943725|NCT02290496|Depression
943726|NCT02290496|Teen
943727|NCT02290496|SSRI
943728|NCT02290496|CBT
943729|NCT02290496|Youth
943730|NCT02290470|Nausea
943731|NCT02290470|Vomiting
943732|NCT02290457|resistance training
943733|NCT02290457|trunk muscle strength
943734|NCT02290457|physical fitness
943735|NCT02290457|adolescent
943736|NCT02290444|Acute Relapsing Multiple Sclerosis
943737|NCT02290444|Relapsing-Remitting Multiple Sclerosis
943738|NCT02290444|Multiple Sclerosis, Chronic Progressive
943739|NCT02290431|LBH589,
943740|NCT02290431|panobinostat,
943741|NCT02290431|bortezomib,
943742|NCT02290431|dexamethasone,
943743|NCT02290431|Phase II
943744|NCT02290418|Roux-en-Y Gastric Bypass
943745|NCT02290418|Omega-Loop Gastric Bypass
943746|NCT02290418|"Mini-Gastric Bypass"
943747|NCT02290405|insomnia
943748|NCT02290405|primary insomnia
943749|NCT02290405|chronic insomnia
943750|NCT02290392|African American
943751|NCT02290392|Environmental Factor
943752|NCT02290392|Transcriptome
943753|NCT02290392|Cardiovascular Disease
943754|NCT02290392|Hypertension
943755|NCT02290353|Engagement
943756|NCT02290353|Motivation
943757|NCT02290353|Exergaming
943758|NCT02290340|Respiratory Syncytial Virus, RSV
943759|NCT02290327|Stress ulcer bleeding
943760|NCT02290327|proton pump inhibitors
943761|NCT02290327|pneumonia
943762|NCT02290327|clostridium difficile infection
943763|NCT02290262|Heart disease
943764|NCT02290262|Phase one rehabilitation
943765|NCT02290223|Chronic pain
943766|NCT02290223|Analgesics, Opioid
943767|NCT02290223|Cognitive Therapy
943768|NCT02290223|Behavior Therapy
943769|NCT02290223|Mindfulness
943770|NCT02290223|Psychophysiology
943771|NCT02290223|Biofeedback, Psychology
943772|NCT02290184|type 2 diabetes
943773|NCT02290184|cardiovascular disease prevention
943774|NCT02290184|lifestyle intervention
943775|NCT02290184|physical activity
943776|NCT02290184|weight loss
943777|NCT02290184|nutrition
943778|NCT02290184|Filipinos
943779|NCT02290184|culturally appropriate
943780|NCT02290158|treatment outcomes
943781|NCT02290158|Malocclusion/therapy
943782|NCT02290145|docetaxel, cisplatin, 5-FU, cyclinD1
943783|NCT02290132|acute lymphoblastic leukemia
943784|NCT02290132|lymphoblastic lymphoma
943785|NCT02290132|stem-cell transplant
943786|NCT02290132|T-cell lymphoma
943787|NCT02290119|Primary PCL-retaining Total Knee Arthroplasty
943788|NCT02290119|Intraoperative Sensors
943789|NCT02290119|Ligament Balancing
943790|NCT02290119|Clinical Outcomes
943791|NCT02290106|obesity
943792|NCT02290106|insulin sensitivity
943793|NCT02290106|statin (HMG-CoA Reductase Inhibitor)
943794|NCT02290106|fatty liver
943795|NCT02290093|Cathartics
943796|NCT02290093|Colonoscopy
943797|NCT02290093|Polyethylene Glycols
943798|NCT02290093|Elderly
943799|NCT02290080|acute myocardial infarction (AMI)
943800|NCT02290080|acute coronary syndrome (ACS)
943801|NCT02290080|ST-segment elevation myocardial infarction (STEMI)
943802|NCT02290080|Non ST-segment elevation myocardial infarction (NSTEMI)
943803|NCT02290080|Ischemic Reperfusion injury (IR-injury)
943804|NCT02290080|Biomarkers
943805|NCT02290080|Oxygen
943806|NCT02290080|Apoptosis
943807|NCT02290080|Fluorescence-activated cell sorting (FACS)
943808|NCT02290080|Flow cytometry
943809|NCT02290080|Matrix metalloproteinase (MMP)
943810|NCT02290067|blood glucose monitoring system
943811|NCT02290067|system accuracy
943812|NCT02290054|analgesia, epidural
943813|NCT02290054|urinary retention
943814|NCT02290041|mesenchymal stem cells
943815|NCT02290041|Virus of human immunodeficiency Infection
943818|NCT02290015|Single Photon Emission Computed Tomography; Acupuncture
943819|NCT02289989|Atopic dermatitis
943820|NCT02289989|Oregano
943821|NCT02289989|Atopic Dermatitis Quick (ADQ) score
943822|NCT02289989|Eczema Area and Severity Index score
943823|NCT02289989|Reflectance confocal microscopy
943824|NCT02289976|talar avascular necrosis
943825|NCT02289976|osteochondrosis dissecans
943826|NCT02289976|femoral condyle
943827|NCT02289950|Ovarian Cancer in in first relapse
943828|NCT02289950|Platinum-Sensitive
943829|NCT02289937|Postoperative pain
943830|NCT02289937|regional anaesthesia
943831|NCT02289937|total hip replacement
943832|NCT02289937|nervus cutaneous femoral lateralis
943833|NCT02289924|wet AMD
943834|NCT02289911|ultrasound
943835|NCT02289898|1st-line metastatic pancreatic ductal adenocarcinoma
943836|NCT02289885|trauma
943837|NCT02289885|examination
943838|NCT02289885|knowledge
943839|NCT02289885|paramedic
943840|NCT02289820|RSV
943841|NCT02289820|Older adults
943842|NCT02289820|MEDI7510
943843|NCT02289820|Vaccine
943844|NCT02289807|Nasopharyngeal carcinoma
943845|NCT02289807|Concurrent chemoradiotherapy
943846|NCT02289807|intermediate risk
943847|NCT02289807|intensity-modulated radiotherapy
943848|NCT02289794|Bioconjugate vaccine
943849|NCT02289794|Urinary tract infections
943850|NCT02289755|Urine Oxalate
943851|NCT02289755|Nephrolithiasis
943852|NCT02289755|Kidney Stones
943853|NCT02289755|Hyperoxaluria
943854|NCT02289755|Enteric Hyperoxaluria
943855|NCT02289755|Idiopathic Hyperoxaluria
943856|NCT02289755|Urological Diseases
943857|NCT02289755|Kidney Diseases
943858|NCT02289742|Dailies AquaComfort Plus® Multifocal (DACP MF)
943859|NCT02289742|Dailies AquaComfort Plus® Toric (DACP Toric)
943860|NCT02289742|tear film stability
943861|NCT02289742|Non-Invasive Keratograph Break-Up Time (NIK-BUT)
943862|NCT02289729|Duodopa
943863|NCT02289729|Advanced Parkinson's Disease
943864|NCT02289729|Levodopa/Carbidopa intestinal gel
943865|NCT02289716|Osteoarthritis
943866|NCT02289716|Pain
943867|NCT02289716|Fulranumab
943868|NCT02289716|JNJ-42160443
943869|NCT02289716|Monotherapy
943870|NCT02289716|Hip
943871|NCT02289716|Knee
943872|NCT02289716|Joint replacement surgery
943873|NCT02289703|End-Stage Renal Disease
943874|NCT02289703|Healthy
943875|NCT02289703|Rivaroxaban
943876|NCT02289703|BAY 59-7939
943877|NCT02289703|JNJ-39039039
943878|NCT02289703|Xarelto
943879|NCT02289703|Hemodialysis
943880|NCT02289703|Blood Coagulation
943881|NCT02289703|Pharmacokinetics
943882|NCT02289690|Veliparib
943883|NCT02289690|PARP - Poly (ADP) ribose polymerase
943884|NCT02289690|ABT-888
943885|NCT02289690|Extensive Stage Smal Cell Lung Cancer
943886|NCT02289677|intubation
943887|NCT02289677|child
943888|NCT02289677|resuscitation
943889|NCT02289677|simulation
943890|NCT02289677|Endotracheal
943891|NCT02289664|intubation
943892|NCT02289651|intubation
943893|NCT02289638|intubation
943894|NCT02289625|Obstructive Sleep Apnea
943895|NCT02289625|cognition
943896|NCT02289625|neurovascular function
943897|NCT02289625|brain metabolism
943898|NCT02289625|exercise training
943899|NCT02289612|Risk for Type 2 Diabetes Mellitus
943900|NCT02289612|Fibre
943901|NCT02289612|Postprandial Glucose
943902|NCT02289612|Postprandial Insulin
943903|NCT02289612|Postprandial Acetaminophen
943904|NCT02289612|Satiety
943905|NCT02289599|Healthy Japanese Subjects
943906|NCT02289599|E2307
943907|NCT02289599|Pharmacokinetics
943908|NCT02289547|chemotherapy
943909|NCT02289547|stomach neoplasms
943910|NCT02289521|Transcranial Direct Current stimulation
943911|NCT02289521|Executive function
943912|NCT02289521|Bilingualism
943913|NCT02289521|Dorsolateral Prefrontal Cortex
943914|NCT02289508|Heart Failure
943915|NCT02289508|Hemodynamics
943916|NCT02289508|Echocardiography
943917|NCT02289508|Diagnostic techniques and procedures
943918|NCT02289508|Ultrasonography
943919|NCT02289508|USCOM
943920|NCT02289495|Single Dose Escalation
943921|NCT02289495|Repeat Dose Escalation
943922|NCT02289495|GSK2838232
943923|NCT02289495|Ritonavir
943924|NCT02289482|Ritonavir
943925|NCT02289482|Safety
943926|NCT02289482|Continuation Single Dose Escalation
943927|NCT02289482|GSK2838232
943928|NCT02289456|Phase II, LOCALLY ADVANCED OR METASTATIC NON SMALL
943929|NCT02289456|CELL LUNG CANCER (NSCLC) AND AN
943930|NCT02289456|EASTERN COOPERATIVE ONCOLOGY GROUP
943931|NCT02289456|PERFORMANCE STATUS OF 2
943932|NCT02289456|(ABOUND.PS2)
943933|NCT02289456|LOCALLY ADVANCED OR METASTATIC NON SMALL
943934|NCT02289456|CELL LUNG CANCER (NSCLC) SUBJECTS THAT AE NOT CANDIDATES FOR RADIATION OR CURATIVE SURGERY
943935|NCT02289443|complete dentures
943936|NCT02289443|10-year follow-up
943937|NCT02289443|patient report outcomes
943938|NCT02289417|Ulcerative Colitis
943939|NCT02289417|Inflammatory Bowel Disease
943940|NCT02289391|Dexmedetomidine
943941|NCT02289391|Inflammatory factor
943942|NCT02289391|Inflammatory mediator
943943|NCT02289391|Cytokines
943944|NCT02289391|Asthma
943945|NCT02289365|Radiodermatitis
943946|NCT02289365|Breast cancer
943947|NCT02289365|Radiotherapy
943948|NCT02289313|obesity prevention
943949|NCT02289313|CBPR
943950|NCT02289313|high risk youth
943951|NCT02289313|school health
943952|NCT02289287|Self-Management
943953|NCT02289287|Stroke
943954|NCT02289287|Intervention
943955|NCT02289287|Group Processes
943956|NCT02289261|Chronic pain
943957|NCT02289261|Morphine
943958|NCT02289261|Dexmedetomidine
943959|NCT02289235|Ginger
943960|NCT02289235|Medicine, traditional
943961|NCT02289235|Herbal medicine
943962|NCT02289222|Relapsed/Refractory
943963|NCT02289222|MK-3475 & Pomalidomide
943964|NCT02289222|Immunotherapy
943965|NCT02289209|head and neck cancer
943966|NCT02289209|reirradiation
943967|NCT02289209|MK-3475
943968|NCT02289209|Anti-PD-1 monoclonal antibody
943969|NCT02289209|Squamous cell carcinoma
943970|NCT02289209|Keytruda
943971|NCT02289209|pembrolizumab
943972|NCT02289196|Vaccine
943973|NCT02289183|Stomach Neoplasms
943974|NCT02289183|Laparoscopy
943975|NCT02289183|Billroth I Operation
943976|NCT02289170|Chronic low back pain
943977|NCT02289170|Heating and cooling combination therapeutic device
943978|NCT02289170|Heating and cooling combination therapy
943979|NCT02289170|Contrast therapy
943980|NCT02289131|oral care
943981|NCT02289105|Advance Directive
943982|NCT02289105|Active Choice
943983|NCT02289105|Decision making
943984|NCT02289053|Colorectal Cancer
943985|NCT02289040|Acute Kidney Injury
943986|NCT02289040|Microvesicles
943987|NCT02289040|microRNA
943988|NCT02289040|Paediatric cardiac surgery
943989|NCT02289027|Ebola, Ebolavirus
943990|NCT02289014|online intervention
943991|NCT02289014|stress management
943992|NCT02289014|cognitive behavioral therapy
943993|NCT02289014|acceptance and mindfulness based intervention
943994|NCT02289001|patient simulation
943995|NCT02289001|simulation
943996|NCT02289001|teamwork
943997|NCT02289001|interdisciplinary health team
943998|NCT02289001|healthcare team
943999|NCT02289001|nursing
944000|NCT02289001|training programs
944001|NCT02288988|GERD
944002|NCT02288988|Short Esophagus
944003|NCT02288988|Minimally Invasive Surgery
944004|NCT02288988|Collis gastroplasty
944005|NCT02288975|hemoadsorption
944006|NCT02288975|extracorporeal blood purification
944007|NCT02288975|CytoSorb
944008|NCT02288975|hemofiltration
944009|NCT02288975|SIRS
944010|NCT02288975|sepsis
944011|NCT02288975|septic shock
944012|NCT02288975|membranes
944013|NCT02288975|ICU
944014|NCT02288975|dialysis
944015|NCT02288975|adsorption
944016|NCT02288962|dopamine agonists
944017|NCT02288962|cabergoline
944018|NCT02288949|mechanical ventilation, stratificacion, lung severity
944022|NCT02288923|Total knee arthroplasty
944023|NCT02288923|Femoral nerve block
944024|NCT02288923|Local infiltration analgesia
944025|NCT02288910|Liver Perfusion
944026|NCT02288910|DynaCT Perfusion
944027|NCT02288910|Radioembolization
944028|NCT02288910|Chemoembolization
944029|NCT02288897|Stage III
944030|NCT02288897|Stage IIIB
944031|NCT02288897|Stage IIIC
944032|NCT02288897|Stage IV (M1a)
944033|NCT02288897|Stage 3
944034|NCT02288897|Stage 4
944035|NCT02288897|IVM1a
944036|NCT02288897|IV(M1a)
944037|NCT02288897|IV-M1a
944038|NCT02288897|in-transit
944039|NCT02288897|in transit
944040|NCT02288897|intransit
944041|NCT02288897|satellite
944042|NCT02288897|recurrent
944043|NCT02288884|Complications
944044|NCT02288884|Cesarean Section
944045|NCT02288884|Wound
944046|NCT02288884|Infection (Following Delivery)
944047|NCT02288871|aortic valve replacement
944048|NCT02288871|aortic valve bioprosthesis
944049|NCT02288871|hemodynamics
944050|NCT02288858|Hair thinning
944051|NCT02288819|loop diuretics
944052|NCT02288819|heart failure
944053|NCT02288819|natriuresis
944054|NCT02288819|urinary analysis
944055|NCT02288793|attitudes
944056|NCT02288793|knowledge
944057|NCT02288793|examination
944058|NCT02288754|DNA in Tumors
944059|NCT02288741|high-dose chemotherapy
944060|NCT02288741|autologous blood stem-cell transplantation
944061|NCT02288741|induction chemotherapy
944062|NCT02288741|elderly patients
944063|NCT02288728|Proximal gastrectomy
944064|NCT02288728|quality of life
944065|NCT02288728|mortality
944066|NCT02288728|morbidity
944067|NCT02288715|cerebral perfusion pressure
944068|NCT02288715|septic encephalopathy
944069|NCT02288676|genomics
944070|NCT02288676|molecular markers
944071|NCT02288676|genetic mutations
944072|NCT02288676|high-grade serous cancer
944073|NCT02288676|ovarian cancer
944074|NCT02288676|endometrial cancer
944075|NCT02288676|driver mutations
944076|NCT02288676|passenger mutations
944077|NCT02288676|molecular screening
944078|NCT02288598|Stammering
944079|NCT02288598|Brain stimulation
944080|NCT02288585|plant sterols
944081|NCT02288585|blood lipids
944082|NCT02288572|metabolic syndrome X
944083|NCT02288572|obesity
944084|NCT02288572|insulin resistance
944085|NCT02288572|dyslipidemia
944086|NCT02288572|probiotic bacteria
944087|NCT02288546|nutritional status
944088|NCT02288546|pesticides
944089|NCT02288546|nitrate
944090|NCT02288533|Minimally Conscious State
944091|NCT02288533|tDCS
944092|NCT02288520|Methotrexate
944093|NCT02288520|Therapeutic strategy
944094|NCT02288507|sorafenib, yttrium-90 radioembolization
944095|NCT02288494|hypoalbuminemia
944096|NCT02288494|-acid base balance
944097|NCT02288494|acid base disorders
944098|NCT02288494|critical ill
944099|NCT02288494|Stewart approach
944100|NCT02288494|human albumin infusion
944101|NCT02288481|Tuberculosis
944102|NCT02288481|TBA-354
944103|NCT02288481|Pulmonary Tuberculosis
944104|NCT02288481|TB
944105|NCT02288468|Parkinson's Disease
944106|NCT02288455|SUI, incontinence, sphincter
944107|NCT02288429|pharmacokinetics
944108|NCT02288429|cystic fibrosis
944109|NCT02288429|critical illness
944110|NCT02288403|Aerobic Exercise
944111|NCT02288403|Oxygen Consumption
944112|NCT02288403|Blood Pressure
944113|NCT02288390|VAP
944114|NCT02288390|Oral care
944115|NCT02288390|Chlorhexidine
944116|NCT02288390|Miswak (Sewak)
944117|NCT02288377|Lanreotide
944118|NCT02288377|Duodeno-pancreatic neuroendocrine tumours
944119|NCT02288377|Maintenance treatment
944120|NCT02288351|Roux-en-Y gastric bypass
944121|NCT02288325|Fetzima
944122|NCT02288325|Relapse-prevention
944123|NCT02288325|Placebo-controlled
944124|NCT02288299|Instrumental cough assistance
944125|NCT02288299|positive pressure insufflation maneuver
944126|NCT02288299|home mechanical ventilation
944127|NCT02288299|prospective evaluation
944128|NCT02288260|Acute Coronary Syndrome
944129|NCT02288260|Russian ACS Registry
944130|NCT02288260|ticagrelor
944131|NCT02288247|Metastatic
944132|NCT02288247|Castration-resistant
944133|NCT02288247|Docetaxel
944134|NCT02288247|Chemotherapy- Naïve
944135|NCT02288247|Enzalutamide
944136|NCT02288247|Prostate Cancer
944137|NCT02288247|Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
944138|NCT02288247|Prednisolone
944139|NCT02288247|Xtandi
944140|NCT02288247|Metastatic Castration Resistant Prostate Cancer
944141|NCT02288234|Registry
944142|NCT02288195|Neoadjuvant Chemotherapy
944143|NCT02288195|Preoperative radiotherapy
944144|NCT02288195|Chemoradiotherapy
944145|NCT02288195|Capecitabine
944146|NCT02288195|Oxaliplatin
944147|NCT02288182|Sinus augmentation procedure
944148|NCT02288169|Symptom management
944149|NCT02288169|palliative care
944150|NCT02288117|PMCF
944151|NCT02288117|Post Market Clinical Follow up
944152|NCT02288117|SP-CL
944153|NCT02288117|anatomic stem
944154|NCT02288104|Interventional Radiology
944155|NCT02288104|Liver
944156|NCT02288104|Kidney
944157|NCT02288104|Confocal endomicroscopy
944158|NCT02288104|Optical Biopsy
944159|NCT02288104|Scanner
944160|NCT02288104|Fluoroscopy
944161|NCT02288104|CT
944162|NCT02288104|Computed Tomography
944163|NCT02288104|Radiofrequency Ablation
944164|NCT02288104|Fluorescein
944165|NCT02288091|ALS
944166|NCT02288091|Inosine
944167|NCT02288091|Uric acid
944168|NCT02288091|Urate
944169|NCT02288091|Glutathione
944170|NCT02288091|Biomarker
944171|NCT02288091|Oxidative stress
944172|NCT02288091|Oxidative damage
944173|NCT02288091|proof-of-concept
944174|NCT02288078|unresectable colorectal cancer
944175|NCT02288078|regorafenib
944176|NCT02288078|Steroid
944177|NCT02288078|fatigue and malaise
944178|NCT02288078|Phase 2 randomized, controlled trial (RCT)
944179|NCT02288052|Handwriting
944180|NCT02288052|Motor learning
944181|NCT02288039|Pulmonary
944182|NCT02288026|Carcinoma, Non-Small-Cell Lung
944183|NCT02288026|Lung Neoplasms
944184|NCT02288026|Carcinoma, Bronchogenic
944185|NCT02288026|Bronchial Neoplasms
944186|NCT02288013|Cesarean section
944187|NCT02288013|uterine closure technique
944188|NCT02288013|materials used
944189|NCT02288000|Alzheimer
944190|NCT02288000|Memantine
944191|NCT02288000|biomarkers
944192|NCT02288000|battery
944193|NCT02288000|cognition
944194|NCT02288000|imaging
944195|NCT02288000|neuropsychology
944196|NCT02287987|Renal function
944197|NCT02287987|Off-clamp
944198|NCT02287987|Partial nephrectomy
944199|NCT02287987|Robotic
944200|NCT02287987|Hylar clamping
944201|NCT02287948|Balance
944202|NCT02287948|Multiple Sclerosis
944203|NCT02287948|Nintendo Wii Fit
944204|NCT02287935|Karydakis procedure
944205|NCT02287935|Limberg flap
944206|NCT02287935|recurrent pilonidal sinus
944207|NCT02287896|RhD-negative pregnant woman
944208|NCT02287896|anti-RhD antibody
944209|NCT02287883|Patient activation and engagement
944210|NCT02287883|Patient reported outcomes
944211|NCT02287883|Accountable Care Organizations
944212|NCT02287883|Chronic illness
944213|NCT02287883|Vulnerable population
944214|NCT02287883|Comparison of approaches
944215|NCT02287870|Epidural anesthesia
944216|NCT02287870|Chloroprocaine
944217|NCT02287870|Lidocaine
944218|NCT02287844|Xylo-oligosaccharides
944219|NCT02287844|Immunonutrition
944220|NCT02287844|Prebiotics
944221|NCT02287844|Lipopolysaccharides
944222|NCT02287844|Cytokines
944223|NCT02287805|craniosynostosis
944224|NCT02287805|simple form
944225|NCT02287805|complex form
944226|NCT02287805|diagnostic
944227|NCT02287805|announcement
944228|NCT02287805|impacts
944229|NCT02287792|Infective endocarditis
944230|NCT02287792|18-FDG PET/CT
944231|NCT02287792|Impact
944232|NCT02287792|Patient's managment
944233|NCT02287792|Diagnostic
944234|NCT02287753|vascular occlusion test
944235|NCT02287753|near infrared spectroscopy
944236|NCT02287740|Exercise
944237|NCT02287714|Instep plantar fasciotomy
944238|NCT02287701|bladder cancer
944239|NCT02287701|MRI
944240|NCT02287701|PET
944241|NCT02287688|safety of Meningococcal quadrivalent CRM-197 conjugate vaccine
944242|NCT02287688|Children 2-23 months of age
944243|NCT02287675|Sentinel Node
944244|NCT02287662|Transcatheter Aortic Valve Replacement
944245|NCT02287649|Immune thrombocytopenia
944246|NCT02287649|Fc gamma RIIIA V/F158 polymorphism
944247|NCT02287649|Rituximab
944248|NCT02287649|autoreactive B and T cells
944249|NCT02287649|ITP
944250|NCT02287610|RA
944251|NCT02287610|Delayed-release prednisone
944252|NCT02287610|Immediate-release prednisone
944253|NCT02287610|Non-interventional
944254|NCT02287571|comfort
944255|NCT02287571|satisfaction
944256|NCT02287558|HHT
944257|NCT02287558|CASE4Z14
944258|NCT02287558|Pomalidomide
944259|NCT02287545|open angle glaucoma
944260|NCT02287545|corneal biomechanics
944261|NCT02287545|trabeculectomy
944262|NCT02287506|diagnosis, strategy
944263|NCT02287480|Ebolavirus Vaccines
944264|NCT02287467|Antiviral
944265|NCT02287467|IVIG
944266|NCT02287467|Hemagglutination inhibition (HAI)
944267|NCT02287467|Antibody
944268|NCT02287454|Multiple Sclerosis, cognitive rehabilitation, REHACOP
944269|NCT02287376|Migraine with and without aura
944270|NCT02287350|pain
944271|NCT02287350|moderate pain
944272|NCT02287350|mild pain
944273|NCT02287350|acute pain
944274|NCT02287350|mild acute pain
944275|NCT02287350|moderate acute pain
944276|NCT02287350|mild or moderate acute pain
944277|NCT02287350|NSAID
944278|NCT02287350|nonsteroidal anti-inflammatory drug
944279|NCT02287337|Neck pain
944280|NCT02287324|Cervicalgia
944281|NCT02287311|EBV positive diseases
944282|NCT02287311|cytotoxic T lymphocytes
944283|NCT02287285|Type 2 Diabetes Mellitus
944284|NCT02287285|Gastric Bypass Surgery
944285|NCT02287285|Exendin9
944286|NCT02287272|COPD- cimetidine- drug-drug interaction
944287|NCT02287233|Myelogenous Leukemia
944288|NCT02287233|Untreated AML
944289|NCT02287233|Treatment Naive AML
944290|NCT02287220|Non-Contact Oximetry
944291|NCT02287220|video plethysmography
944292|NCT02287220|oxygen desaturation
944293|NCT02287168|Peritoneal lavage
944294|NCT02287168|Dissemination
944295|NCT02287168|Gastrectomy
944296|NCT02287168|Cytology
944297|NCT02287168|Lavage
944298|NCT02287155|Health Promotion
944299|NCT02287155|Intervention Study
944300|NCT02287155|Occupational Therapy
944301|NCT02287155|Rural Population
944302|NCT02287155|Quality of life
944303|NCT02287155|Sense of coherence
944304|NCT02287129|Potentially R0 - resectable AEG and primary tumor category
944305|NCT02287129|Histologically confirmed AEG I-III
944306|NCT02287129|Functional operability
944307|NCT02287129|Intense FDG tracer uptake of the tumor
944308|NCT02287116|preterm infants
944309|NCT02287116|CPAP
944310|NCT02287116|BPD
944311|NCT02287116|invasive mechanical ventilation
944312|NCT02287116|we aimed determine that affect the rate of BPD and death of NCPAP therapy with nasal prongs or nasal mask as the initial treatment for RDS.
944313|NCT02287103|Skipping Breakfast
944314|NCT02287038|PTSD
944315|NCT02287038|ADHD
944316|NCT02287038|Comorbidity
944317|NCT02287038|Combat Trauma
944318|NCT02287038|Cognitive Deficit
944319|NCT02286986|Epilepsy
944320|NCT02286986|Dravet syndrome
944321|NCT02286986|Seizures
944322|NCT02286986|Intractable Epilepsy
944323|NCT02286986|Medically Refractory Epilepsy
944324|NCT02286973|Tranexamic acid
944325|NCT02286947|DMD
944326|NCT02286947|exon 51
944327|NCT02286947|dystrophin
944328|NCT02286947|dystrophy
944329|NCT02286947|Eteplirsen
944330|NCT02286947|Duchenne
944331|NCT02286934|Carvedilol
944332|NCT02286934|CYP2D6
944333|NCT02286934|Isoproterenol Sensitivity Test
944334|NCT02286921|Testosterone
944335|NCT02286921|Enzalutamide
944336|NCT02286921|Abiraterone
944337|NCT02286921|Androgen Ablative Therapies
944338|NCT02286921|Bipolar Androgen Therapy
944339|NCT02286908|Ejection fraction, Global Strain, Mechanical dispersion
944340|NCT02286895|rotavirus
944341|NCT02286895|rotavirus vaccine
944342|NCT02286895|Mali
944343|NCT02286895|EPI vaccines
944344|NCT02286882|Single Ascending Dose
944345|NCT02286882|healthy subjects
944346|NCT02286869|mechanical ventilation
944347|NCT02286869|autonomic nervous system
944348|NCT02286869|heart rate variability
944349|NCT02286869|cardioventilatory coupling
944350|NCT02286856|malnutrition, diet intervention, Nutritional Assessment
944351|NCT02286843|89Zr-trastuzumab
944352|NCT02286843|PET/CT
944353|NCT02286843|14-156
944354|NCT02286830|osteolysis
944355|NCT02286830|zoledronic acid
944356|NCT02286830|osteonecrosis
944357|NCT02286830|bone markers
944358|NCT02286830|low-dose CT
944359|NCT02286791|Prevention of dementia
944360|NCT02286791|Mindful awareness program
944361|NCT02286791|Mild cognitive impairment
944362|NCT02286791|Mindfulness
944363|NCT02286791|Elderly
944364|NCT02286791|Cognitive decline
944365|NCT02286765|Ulthera System
944366|NCT02286765|Ultherapy
944367|NCT02286739|Total Knee Arthroplasty
944368|NCT02286739|Rotational Alignment
944369|NCT02286739|Intraoperative Sensors
944370|NCT02286739|Patient Outcomes
944371|NCT02286739|Soft Tissue Balance
944372|NCT02286726|Leukemia
944373|NCT02286726|Acute myeloid leukemia
944374|NCT02286726|AML
944375|NCT02286726|CPX-351
944376|NCT02286726|Phone call
944377|NCT02286713|Lung Cancer Screening
944378|NCT02286713|heavy smokers
944379|NCT02286713|state-based smoking cessation quitlines
944380|NCT02286713|patient decision aid
944381|NCT02286713|low-dose computed tomography
944382|NCT02286713|LDCT
944383|NCT02286713|standard educational information
944384|NCT02286700|dermatitis, eczema, itch, moisturizer, amino acid
944385|NCT02286687|Advanced Cancers
944386|NCT02286687|Germline mutations
944387|NCT02286687|Metastatic cancer
944388|NCT02286687|Talazoparib Tosylate
944389|NCT02286687|BMN 673
944390|NCT02286687|Phone call
944391|NCT02286674|mYpas
944392|NCT02286674|anxiety
944393|NCT02286674|distraction
944394|NCT02286674|inhalation induction
944395|NCT02286648|clinical signs
944396|NCT02286648|child
944397|NCT02286648|pulpotomy
944398|NCT02286583|RTM
944399|NCT02286583|Female breast cancer
944400|NCT02286557|Methylphenidate
944401|NCT02286557|Multiple Sclerosis
944402|NCT02286557|Cognitive Fatigue
944403|NCT02286544|Myocardial Infarction
944404|NCT02286544|Oxygen
944405|NCT02286544|Inflammation
944406|NCT02286544|Acute coronary syndrome (ACS)
944407|NCT02286544|ST-segment elevation myocardial infarction (STEMI)
944408|NCT02286544|Reperfusion injury (IR-injury)
944409|NCT02286544|Biomarkers
944410|NCT02286544|Normoxemia
944411|NCT02286544|Salmonella typhi
944412|NCT02286544|Vaccine-induced inflammation
944413|NCT02286544|Soluble markers of apoptosis
944414|NCT02286544|Leukocyte subset distribution
944415|NCT02286544|Matrix metalloproteinase (MMP)
944416|NCT02286544|Biological Markers
944417|NCT02286531|: Low grade glioma
944418|NCT02286531|PET
944419|NCT02286531|FET
944420|NCT02286531|MRI
944421|NCT02286531|Standardized uptake value
944422|NCT02286453|Osteoarthritis of The knee
944423|NCT02286453|Benjakul
944424|NCT02286453|Alternative Medicine
944425|NCT02286440|Depression
944426|NCT02286440|Genotyping
944427|NCT02286440|Pharmacokinetic
944428|NCT02286440|Pharmacodynamic
944429|NCT02286414|Oral anticoagulants, Geriatrics, General Practitioner, Safety, Misuse
944430|NCT02286401|myocardial perfusion
944431|NCT02286401|coronary atherosclerosis
944432|NCT02286401|coronary blood flow
944433|NCT02286401|fractional flow reserve
944434|NCT02286401|coronary flow reserve
944435|NCT02286388|Deep carious lesion
944436|NCT02286388|incomplete caries removal
944437|NCT02286388|antibacterial adhesive system
944438|NCT02286388|dental composite resin
944439|NCT02286388|pulp vitality preservation
944440|NCT02286388|randomized controlled trial
944441|NCT02286375|health-social partnership
944442|NCT02286375|self-efficacy
944443|NCT02286349|Neuromodulation Attention Deficit Hyperactivity Disorder
944444|NCT02286336|minimum effective concentration
944445|NCT02286336|ropivacaine
944446|NCT02286336|ultrasound-guided supraclavicular block
944447|NCT02286323|Intubation, Endotracheal
944448|NCT02286310|Exercise
944449|NCT02286310|Kinematics
944450|NCT02286297|Intubation
944451|NCT02286284|Early severe preeclampsia
944452|NCT02286284|Angiogenic factor
944453|NCT02286284|Apheresis
944454|NCT02286271|Seizure detection
944455|NCT02286258|Inulin
944456|NCT02286258|Ca-EDTA
944457|NCT02286258|Gd-DOTA
944458|NCT02286258|Chronic kidney disease
944459|NCT02286258|glomerular filtration rate measurement
944460|NCT02286245|Triage
944461|NCT02286245|Hotline
944462|NCT02286245|Primary Health Care
944463|NCT02286245|Emergency Medical Service Communication Systems
944464|NCT02286232|Chronic low back pain
944465|NCT02286232|stretching exercises
944466|NCT02286206|Clozapine
944467|NCT02286206|Psychotropic Drugs
944468|NCT02286206|Antipsychotic Agents
944469|NCT02286206|Psychotic Disorders
944470|NCT02286206|Schizophrenia
944471|NCT02286206|Adverse Effects
944472|NCT02286206|Drug Monitoring
944473|NCT02286180|near infrared spectroscopy
944474|NCT02286180|NIRS
944475|NCT02286180|intern
944476|NCT02286167|modified-Atkins diet
944477|NCT02286167|ketogenic diet
944478|NCT02286167|central nervous system malignancy
944479|NCT02286167|glioma
944480|NCT02286154|Hydroxyurea
944481|NCT02286154|Sickle Cell
944482|NCT02286154|Pharmacokinetics
944483|NCT02286154|dynamics
944484|NCT02286154|genomics
944485|NCT02286128|Type 2 diabetes
944486|NCT02286128|RAGE
944487|NCT02286128|osteoblast
944488|NCT02286115|Chronic Pelvic Pain
944489|NCT02286115|Interstitial Cystitis
944490|NCT02286115|Vulvodynia
944491|NCT02286115|Dyspareunia
944492|NCT02286115|Pelvic Floor Dysfunction
944493|NCT02286115|Emotional Processing
944494|NCT02286089|dry-AMD
944495|NCT02286089|Geographic Atrophy
944496|NCT02286076|endometrioma
944497|NCT02286076|laparoscopy
944498|NCT02286076|ovarian reserve
944499|NCT02286037|Secondary Hyperalgesia
944500|NCT02286037|Method
944501|NCT02286037|Pin-prick
944502|NCT02286037|Monofilament
944503|NCT02285998|Influenza
944504|NCT02285985|Adipose tissue
944505|NCT02285985|Inflammation
944506|NCT02285985|.Obesity
944507|NCT02285933|stroke
944508|NCT02285933|physical therapy specialty
944509|NCT02285933|exercise therapy
944510|NCT02285933|virtual reality
944511|NCT02285933|man-machine systems
944512|NCT02285933|randomized control trial
944513|NCT02285933|inpatients
944514|NCT02285933|rehabilitation
944515|NCT02285920|hemodialysis
944516|NCT02285920|spironolactone
944517|NCT02285920|cardiac fibrosis
944518|NCT02285920|diastolic function
944519|NCT02285881|diabetes treatment
944520|NCT02285881|personalized medicine
944521|NCT02285881|shared decision making
944522|NCT02285881|goal setting
944523|NCT02285868|Orthopedic rehabilitation
944524|NCT02285868|Rehabilitation outcomes
944525|NCT02285868|Physical therapy
944526|NCT02285868|Physical therapy outcomes
944527|NCT02285855|Lung Cancer
944528|NCT02285855|Non small cell lung cancer
944529|NCT02285855|Stereotactic body radiotherapy
944530|NCT02285855|SBRT
944531|NCT02285855|XRT
944532|NCT02285855|Radiation therapy
944533|NCT02285855|Metformin
944534|NCT02285855|Metformin ER
944535|NCT02285855|Placebo
944536|NCT02285855|Sugar pill
944537|NCT02285855|Lung adenocarcinoma
944538|NCT02285855|Genotypes
944539|NCT02285855|Genetic mutations
944548|NCT02285751|high on treatment platelet reactivity
944549|NCT02285751|acetylsalicylic acid
944550|NCT02285751|clopidogrel
944551|NCT02285751|prasugrel
944552|NCT02285751|ticagrelor
944553|NCT02285751|critically ill
944554|NCT02285751|pharmacokinetic
944555|NCT02285751|pharmacodynamics
944556|NCT02285738|solid tumor, cancer, simvastatin, aspirin, blood clot, VTE, venous thromboembolism
944557|NCT02285712|Peripheral venous catheter
944558|NCT02285712|ultrasound
944559|NCT02285712|nurse
944560|NCT02285712|Intensive Care Units
944561|NCT02285699|Selective Serotonin Reuptake Inhibitors
944562|NCT02285686|troponin
944563|NCT02285686|biomarkers
944564|NCT02285686|myocardial infarction
944565|NCT02285686|critical illness
944566|NCT02285673|umbilical cord, mesenchymal stem cell
944567|NCT02285621|Scoliosis
944568|NCT02285621|Spine deformity
944569|NCT02285621|Brace
944570|NCT02285621|3D
944571|NCT02285608|Medication adherence
944572|NCT02285608|Patient education
944573|NCT02285608|Mood disorders
944574|NCT02285608|Economic assessment
944575|NCT02285608|Mixed methods
944576|NCT02285556|drug carving changes during rehabilitation
944577|NCT02285556|community
944578|NCT02285556|DNA
944579|NCT02285543|TPF induction chemotherapy, randomized, trial,OSCC
944580|NCT02285530|head and neck squamous cell carcinoma, GDF15, TPF
944581|NCT02285504|Postpartum depression
944582|NCT02285465|Healthy volunteers
944583|NCT02285465|Pharmacokinetics
944584|NCT02285465|Pharmacodynamics
944585|NCT02285465|ASP3700
944586|NCT02285452|physiologcal phenomena
944587|NCT02285452|.HRV Parameters
944588|NCT02285452|respiratory activity
944589|NCT02285452|thorax wraps
944590|NCT02285439|Pediatric Oncology
944591|NCT02285439|Ras/Raf pathway
944592|NCT02285439|Low-Grade Glioma
944593|NCT02285439|MEK inhibitor
944594|NCT02285426|i-scan
944595|NCT02285426|histology
944596|NCT02285413|Melanoma
944597|NCT02285413|Dendritic cells
944598|NCT02285413|Cisplatin
944599|NCT02285413|Vaccine
944600|NCT02285413|Immunotherapy
944601|NCT02285400|COPD
944602|NCT02285400|CPAP
944603|NCT02285400|Central Drive
944604|NCT02285348|Ataxia Telangiectasia
944605|NCT02285348|cerebrospinal fluid
944606|NCT02285348|inflammation
944607|NCT02285348|proteomic analysis
944608|NCT02285309|Cardiac Surgery
944609|NCT02285309|Diastolic Dysfunction
944610|NCT02285309|Enoximone
944611|NCT02285296|geriatric assessment
944612|NCT02285296|Caregivers
944613|NCT02285296|Needs Assessment
944614|NCT02285296|oncology nursing
944615|NCT02285296|frail elderly
944616|NCT02285296|Medical, psychologic and sociologic approach
944617|NCT02285270|Circadian rhythm
944618|NCT02285270|Adipose tissue, brown
944619|NCT02285270|Metabolism
944620|NCT02285257|Sepsis, Severe sepsis, septic shock, epidemiology, outcome
944621|NCT02285231|Anti-hyperglycemic effect
944622|NCT02285192|18F-FDG Injection
944623|NCT02285192|Positron Lymphography
944624|NCT02285192|Lymphatic Mapping
944625|NCT02285192|sentinel lymph nodes
944626|NCT02285192|PET/CT
944627|NCT02285192|14-222
944628|NCT02285179|GDC-0032
944629|NCT02285179|Pi3K inhibitor
944630|NCT02285179|tamoxifen
944631|NCT02285179|hormone receptor positive
944632|NCT02285179|dose escalation
944633|NCT02285179|RECIST
944634|NCT02285179|pharmacodynamic
944635|NCT02285166|Pharmaocological therapy
944636|NCT02285153|acetylsalicylic acid
944637|NCT02285153|intensive care unit
944638|NCT02285153|mortality
944639|NCT02285153|Post mortem examination
944640|NCT02285153|bleeding
944654|NCT02285101|arginine auxotrophic tumors
944655|NCT02285101|PEG-BCT-100
944656|NCT02285101|arginase
944657|NCT02285075|temocillin
944658|NCT02285075|PD/PD
944659|NCT02285075|T>MIC
944668|NCT02285049|Chronic urticaria
944669|NCT02285049|Urticaria Control Test
944670|NCT02285023|Chronic urticaria
944671|NCT02285023|CU-Q2oL
944672|NCT02285010|pregabalin
944673|NCT02285010|postoperative pain
944674|NCT02285010|abdominal hysterectomy
944675|NCT02284984|Antibodies, Monoclonal
944676|NCT02284984|mabthera
944677|NCT02284984|benlysta
944678|NCT02284984|Antinuclear Antibodies
944679|NCT02284958|walking
944680|NCT02284958|pedometer
944681|NCT02284932|COPD
944682|NCT02284932|atrophy
944683|NCT02284932|muscle
944684|NCT02284906|Drug therapy
944685|NCT02284867|uterine natural killer cells
944686|NCT02284867|CD16
944687|NCT02284867|CD56
944688|NCT02284867|Preterm labour
944689|NCT02284815|Gluten
944690|NCT02284815|T1D
944691|NCT02284815|Remission
944692|NCT02284789|Hemophilia
944693|NCT02284776|Therapeutic education
944694|NCT02284750|Bifurcation lesion
944695|NCT02284750|Percutaneous coronary intervention
944696|NCT02284737|Pulmonary arterial hypertension
944697|NCT02284711|salpingectomy, ovarian reserve, coagulation technique
944698|NCT02284685|Mental Health Services
944699|NCT02284646|Ankylosing spondylitis
944700|NCT02284646|Physical training program
944701|NCT02284633|EGFR mutation
944702|NCT02284633|Liquid biopsies
944703|NCT02284633|Lung cancer
944704|NCT02284633|erlotinib
944705|NCT02284620|anesthesia
944706|NCT02284620|nerve block
944707|NCT02284620|infltration
944708|NCT02284581|MBC
944709|NCT02284581|metastatic
944710|NCT02284581|breast
944711|NCT02284581|observational
944712|NCT02284581|disease management
944713|NCT02284529|high-risk stage-Ⅱ Colorectal Cancer,Orectalip,oxaliplatin
944714|NCT02284503|MI reduction
944715|NCT02284503|intensive statin treatment
944716|NCT02284503|NSTE-ACS
944717|NCT02284490|Brain Metastases
944718|NCT02284477|Insulin resistance
944719|NCT02284477|Pulmonary function
944720|NCT02284477|Phthalates
944721|NCT02284464|Kidney transplant
944722|NCT02284464|Immunosuppression
944723|NCT02284464|Steroid withdrawal
944724|NCT02284464|Donor specific antibodies
944725|NCT02284451|HIV/AIDS and HIV Testing Knowledge
944726|NCT02284438|ETT
944727|NCT02284438|Biofilm
944728|NCT02284438|Mechanical ventilation
944729|NCT02284438|Critical illness
944730|NCT02284438|Ventilator-associated pneumonia
944731|NCT02284412|Neostigmine
944732|NCT02284412|Sugammadex
944733|NCT02284399|aneuploidy
944734|NCT02284399|Trisomy 21
944735|NCT02284399|NIPT
944736|NCT02284386|Total knee arthroplasty
944737|NCT02284360|wound healing
944738|NCT02284360|APOSEC™
944739|NCT02284360|Safety
944740|NCT02284334|mitochondrial diseases
944741|NCT02284334|nutrition
944742|NCT02284334|glycemic index
944743|NCT02283255|Fontan
944744|NCT02283255|Exercise
944745|NCT02283255|Pulmonary Function
944746|NCT02283255|Aerobic Capacity
944747|NCT02283255|Skeletal Muscle
944748|NCT02283242|Cholinergic Antagonists
944749|NCT02283242|Inflammation
944750|NCT02283242|Oxidative Stress
944751|NCT02283229|Plagiocephaly
944752|NCT02283229|torticollis
944753|NCT02283229|occlusal defect
944754|NCT02283216|neuromodulation
944755|NCT02283216|noninvasive
944756|NCT02283216|plasticity
944757|NCT02283216|transcranial magnetic stimulation
944758|NCT02283216|hearing
944759|NCT02283216|hyperacusis
944760|NCT02283203|Paracetamol
944761|NCT02283203|Management of fever
944762|NCT02283203|Infections
944763|NCT02283190|Asparaginase
944764|NCT02283190|Glutamine
944765|NCT02283164|Occupational health
944766|NCT02283164|Hazardous material handling
944767|NCT02283151|Very Low Carbohydrate Diet
944768|NCT02283151|Overweight/obese
944769|NCT02283138|FLV, VOCAL, PA-RI, preterm fetuses, RDS
944770|NCT02282098|Atrial fibrillation
944771|NCT02282098|Arrhythmias, Cardiac
944772|NCT02282098|Stroke
944773|NCT02282098|agents, anti inflammatory
944774|NCT02282098|D-dimer
944775|NCT02282098|C-reactive protein
944776|NCT02282085|Medication Non-Adherence
944777|NCT02282085|Antipsychotic
944778|NCT02284308|NSCLC
944779|NCT02284295|chronic obstructive pulmonary disease
944780|NCT02284295|silica dust
944781|NCT02284295|aromatic hydrocarbons
944782|NCT02284295|genetic
944783|NCT02284295|occupational
944784|NCT02284282|Spinal Morphine
944785|NCT02284282|Laparoscopic GI-surgery
944786|NCT02284282|Post-operative pain
944787|NCT02284243|Bunion
944788|NCT02284243|Bunionectomy
944789|NCT02284243|Pain
944790|NCT02284243|Analgesia
944791|NCT02284243|dexmedetomidine
944792|NCT02284243|intranasal
944793|NCT02284191|Radiology
944794|NCT02284191|Acute Medicine
944795|NCT02284191|Emergency Medicine
944796|NCT02284191|Cardiology
944797|NCT02284178|mechanical ventilation
944798|NCT02284178|aspiration
944799|NCT02284178|suctioning
944800|NCT02284178|secretions
944801|NCT02284178|ventilator-associated events
944802|NCT02284152|bottle feeding
944803|NCT02284152|feeding behavior
944804|NCT02284152|infants
944805|NCT02284152|mothers
944806|NCT02284152|responsive feeding
944807|NCT02284152|maternal feeding practices
944808|NCT02284152|maternal feeding styles
944809|NCT02284139|EGF ointment
944810|NCT02284139|EGFR inhibitor
944811|NCT02284139|Skin side effect
944812|NCT02284126|Vancomycin
944813|NCT02284126|Anti-Infective Agents, Local
944814|NCT02284126|Craniotomy
944815|NCT02284126|surgical site infection
944816|NCT02284126|wound prophylaxis
944817|NCT02284126|Anti-Bacterial Agents
944818|NCT02284126|Neurosurgical Procedures
944819|NCT02284126|Administration, Topical
944820|NCT02284126|Antibiotic Prophylaxis
944821|NCT02284126|antibiotics
944822|NCT02284126|prophylaxis
944823|NCT02284126|neurosurgery
944824|NCT02284126|Bacterial Infections
944825|NCT02284126|Central Nervous System Infections
944826|NCT02284087|transcranial magnetic stimulation
944827|NCT02284087|movement disorders
944828|NCT02284074|Lipopolysaccharide (LPS)
944829|NCT02284074|Biomarkers
944830|NCT02284074|Chemokines
944831|NCT02284074|Cytokines
944832|NCT02284074|Gene Expression
944833|NCT02284074|Nasal Challenge
944834|NCT02284074|Inflammation
944835|NCT02284074|Nasal
944836|NCT02284074|Nasosorption
944837|NCT02284074|Respiratory
944838|NCT02284048|Ticagrelor
944839|NCT02284048|Coronary Flow Reserve
944840|NCT02284009|New-onset type 1 diabetes mellitus
944841|NCT02284009|Albiglutide
944842|NCT02283905|amphotericin-B
944843|NCT02283905|continuously infused
944844|NCT02283905|voriconazole
944845|NCT02283892|respiratory complaints
944846|NCT02283892|dyspnea
944847|NCT02283892|cough
944848|NCT02283892|checklist
944849|NCT02283879|Human Umbilical Cord Mesenchymal Stem Cell
944850|NCT02283879|Mesenchymal Stem Cell
944851|NCT02283879|Cerebral hemorrhage
944852|NCT02283853|Pediatrics
944853|NCT02283749|NCSLC
944854|NCT02283749|lung cancer
944855|NCT02283749|non small cell lung cancer
944856|NCT02283749|bone metastases
944857|NCT02283749|maintenance
944858|NCT02283736|Chronic periodontitis
944859|NCT02283736|Probiotics
944860|NCT02283736|Non- surgical treatment
944861|NCT02283723|older adults, goal attainment, optimal aging
944862|NCT02283710|Pentoxifylline
944863|NCT02283710|Aminotransferase
944864|NCT02283710|Steatohepatitis
944865|NCT02283697|hypertension
944866|NCT02283697|high blood pressure
944867|NCT02283697|sodium
944868|NCT02283697|prevention
944869|NCT02283697|dietary sodium
944870|NCT02283697|salt
944871|NCT02283684|LASER
944872|NCT02283684|PROSTATE
944873|NCT02283684|BIPOLAR
944874|NCT02283684|HYPERPLASIA
944875|NCT02283684|VAPORIZATION
944876|NCT02283580|COPD
944877|NCT02283580|Healthy adults
944878|NCT02283580|Resistance training
944879|NCT02283580|Elastic bands
944880|NCT02283580|Limb muscle function
944881|NCT02283580|Volunteers
944882|NCT02283554|Periodontal Surgery
944883|NCT02283554|Periodontal Regeneration
944884|NCT02283554|Growth factors
944885|NCT02283554|Clinical trials
944886|NCT02283541|Gait
944887|NCT02283541|late life depression
944888|NCT02283541|mind-body therapies
944889|NCT02283515|chronic periodontitis
944890|NCT02283515|local drug delivery
944891|NCT02283515|rosuvastatin
944892|NCT02283515|osseo-differentiation
944893|NCT02283502|Uterine fibroid
944894|NCT02283502|magnetic resonance imaging
944895|NCT02283502|ultrasound
944896|NCT02283502|non-invasive therapy
944897|NCT02283489|Recombinant Human Endostatin Adenovirus
944898|NCT02283489|Head and Neck Malignant Tumor
944899|NCT02283489|clinical trial
944900|NCT02283489|randomized
944901|NCT02283489|Endostatin
944902|NCT02283489|gene therapy
944903|NCT02283476|efficacy and safety
944904|NCT02283437|Bibliotherapy
944905|NCT02283437|Problem-solving
944906|NCT02283437|Randomized Controlled Trial
944907|NCT02283437|Schizophrenia Spectrum Disorders
944908|NCT02283437|Family Caregivers
944909|NCT02283385|Elder abuse
944910|NCT02283385|Intervention
944911|NCT02283385|Treatment
944912|NCT02283385|Detection
944913|NCT02283359|Distal Esophagus
944914|NCT02283359|Esophageal
944915|NCT02283359|Gastric
944916|NCT02283359|Carcinoma
944917|NCT02283359|Adenocarcinoma
944918|NCT02283359|Stomach
944919|NCT02283359|Gastro-esophageal junction
944920|NCT02283359|Recurrent
944921|NCT02283359|Metastatic
944922|NCT02283359|Unresectable
944923|NCT02283346|Prostate Cancer
944924|NCT02283346|HDR brachytherapy
944925|NCT02283346|hypo fractionated external beam radiotherapy
944926|NCT02283346|toxicity
944927|NCT02283346|biochemical control
944928|NCT02283333|Behavioral Activation
944929|NCT02283333|Therapeutic Exposure
944930|NCT02283333|Mental Health
944931|NCT02283333|Veterans
944932|NCT02283333|Complicated Grief
944933|NCT02283333|Military
944934|NCT02283333|Treatment
944935|NCT02283333|Cognitive Therapy
944936|NCT02283333|Bereavement
944937|NCT02283333|Complicated Bereavement
944938|NCT02283099|Ebola virus, vaccination, phase I, healthy volunteers
944939|NCT02283086|Quality Improvement
944940|NCT02283086|Physician Feedback
944941|NCT02283073|Diagnosis
944942|NCT02283060|Atripla
944943|NCT02283060|Stribild
944944|NCT02283060|HIV
944945|NCT02283060|Sleep architecture
944946|NCT02283060|Neuropsychological performance
944948|NCT02283021|expression of L-type calcium subunits
944949|NCT02282995|Functional dyspepsia
944950|NCT02282995|symptom response
944951|NCT02282982|Immunoprophylaxis
944952|NCT02282982|Palivizumab
944953|NCT02282969|Cancer Prevention
944954|NCT02282969|Smokers
944955|NCT02282969|Quit smoking
944956|NCT02282969|Interviews
944957|NCT02282969|Questionnaires
944958|NCT02282969|Surveys
944959|NCT02282969|Lung cancer screening
944960|NCT02282969|Patient decision aid
944961|NCT02282943|endometriosis
944962|NCT02282943|CO2 laser vapourisation
944963|NCT02282943|Harmonic scalpel
944964|NCT02282943|AFS stage I-III
944965|NCT02282930|ACTH
944966|NCT02282930|Acthar
944967|NCT02282930|IgA
944968|NCT02282930|Progressive
944969|NCT02282930|Nephropathy
944970|NCT02282930|renal function
944971|NCT02282917|NF2
944972|NCT02282917|Vestibular Schwannoma
944973|NCT02282917|Schwannoma
944974|NCT02282917|Meningioma
944975|NCT02282904|Bone Marrow Transplant
944976|NCT02282904|Subablative Conditioning
944977|NCT02282904|Graft Versus Host Disease
944978|NCT02282904|Non-Myeloablative
944979|NCT02282904|Reduced Intensity
944980|NCT02282891|propofol
944981|NCT02282891|ketofol
944982|NCT02282878|High Sodium Diet
944983|NCT02282878|Low Sodium Diet
944984|NCT02282878|MS
944985|NCT02282865|Emergence agitation, Heart rate variability (HRV)
944986|NCT02282839|Head and neck cancer
944987|NCT02282839|Glutamine
944988|NCT02282839|Oral mucositis
944989|NCT02282839|Quality of life
944990|NCT02282813|Parathyroid Diseases
944991|NCT02282813|Renal Insufficiency
944992|NCT02282813|Kidney Failure, Chronic
944993|NCT02282813|Hyperparathyroidism, Secondary
944994|NCT02282813|Vitamin D
944995|NCT02282813|Hyperparathyroidism
944996|NCT02282813|Kidney Diseases
944997|NCT02282813|Kidney Failure
944998|NCT02282813|Renal Insufficiency, Chronic
944999|NCT02282787|local anesthesia
945000|NCT02282787|peribulbar anesthesia
945001|NCT02282787|DEXMEDETOMIDINE
945002|NCT02282787|vitreoretinal surgery
945003|NCT02282774|Vitreoretinal surgery
945004|NCT02282735|neuroblastoma
945005|NCT02282735|end-of-life
945006|NCT02282735|decision-making
945007|NCT02282735|parent
945008|NCT02282735|child
945009|NCT02282735|prognosis
945010|NCT02282735|preferences
945011|NCT02282735|childhood cancer
945012|NCT02282735|oncology
945013|NCT02282722|cancer
945014|NCT02282722|palliative
945015|NCT02282722|chemotherapy
945016|NCT02282722|metastatic
945017|NCT02282722|colorectal
945018|NCT02282722|communication
945019|NCT02282722|informed consent
945020|NCT02282722|video
945021|NCT02282722|education
945022|NCT02282722|oncology
945023|NCT02282722|patient-centered
945024|NCT02282722|outcomes research
945025|NCT02282709|Immunity
945026|NCT02282657|extracorporreal
945027|NCT02282657|CO2 removal
945028|NCT02282657|ARDS
945029|NCT02282657|lung
945030|NCT02282657|Protective ventilation
945031|NCT02282631|active school travel
945032|NCT02282631|active travel
945033|NCT02282631|incentive scheme
945034|NCT02282631|children
945035|NCT02282631|school
945036|NCT02282631|behaviour change
945037|NCT02282618|Cardiac Sympathetic Blockade
945038|NCT02282592|Metabolic syndrome
945039|NCT02282592|case-control study
945040|NCT02282592|Breast cancer
945041|NCT02282566|Muscle protein synthesis
945042|NCT02282514|autoimmune diseases
945043|NCT02282514|stem cells
945044|NCT02282514|autologous hematopoietic stem cell transplantation
945045|NCT02282514|Stiff Person Syndrome (SPS)
945046|NCT02282501|leptin levels
945047|NCT02282501|ghrelin levels
945048|NCT02282462|Chest tube
945049|NCT02282449|Venous access device
945050|NCT02282449|Port catheters
945051|NCT02282449|Chemotherapy
945052|NCT02282410|severe hemophilia A
945053|NCT02282410|moderately severe hemophilia A
945054|NCT02282410|Recombinant Human Coagulation Factor VIII
945055|NCT02282410|standard prophylaxis
945056|NCT02282397|Diabetes Mellitus
945057|NCT02282371|Cetuximab
945058|NCT02282371|BYL719
945059|NCT02282371|IMRT (Intensity-Modulated Radiation Therapy)
945060|NCT02282371|14-116
945061|NCT02282358|Mocetinostat
945062|NCT02282358|14-106
945063|NCT02282345|Breast cancer
945064|NCT02282345|BRCA deleterious mutation
945065|NCT02282345|Invasive adenocarcinoma of the breast
945066|NCT02282345|BMN 673
945067|NCT02282345|Talazoparib tosylate
945068|NCT02282319|spinal or intravenous dexmedetomidine
945069|NCT02282293|Chemoprevention
945070|NCT02282293|Malaria
945071|NCT02282293|Uganda
945072|NCT02282293|Dihydroartemisinin-piperaquine
945073|NCT02282293|Trimethoprim-sulfamethoxazole
945074|NCT02282293|Human Immunodeficiency Virus
945075|NCT02282267|Epidermal growth factor receptor
945076|NCT02282267|Droplet digital PCR
945077|NCT02282254|Type 1 diabetes
945078|NCT02282254|Hypoglycemia unawareness
945079|NCT02282254|Nocturnal hypoglycemia
945080|NCT02282254|Closed-loop strategy
945081|NCT02282254|Artificial pancreas
945082|NCT02282254|Glucagon
945083|NCT02282254|Hypoglycemia
945084|NCT02282254|Insulin
945085|NCT02282241|Melatonin
945086|NCT02282241|Sleep
945087|NCT02282241|Delirium
945088|NCT02282215|Fever
945089|NCT02282215|Induction chemotherapy
945090|NCT02282215|Infection
945091|NCT02282215|Leukemia
945092|NCT02282215|Myeloid progenitor cells
945093|NCT02282215|Neutropenia
945094|NCT02282202|Sputum
945095|NCT02282202|Bronchiectasis
945096|NCT02282202|Chronic Obstructive Pulmonary Disease
945097|NCT02282202|Airway clearance therapy
945098|NCT02282202|Oscillatory Positive Expiratory Pressure
945099|NCT02282189|Sputum
945100|NCT02282189|Airway clearance therapy
945101|NCT02282189|Oscillatory Positive Expiratory Pressure
945102|NCT02282189|Chronic Obstructive Pulmonary Disease
945103|NCT02282176|Neonates
945104|NCT02282176|Preterm
945105|NCT02282176|Azithromycin
945106|NCT02282176|Ureaplasma
945107|NCT02282176|Chronic Lung disease
945108|NCT02282176|Bronchopulmonary dysplasia
945109|NCT02282150|Fatigue
945110|NCT02282150|Quality of Life
945111|NCT02282150|Hydrocortisone
945112|NCT02282150|Ecological Momentary Assessments
945113|NCT02282124|weight
945114|NCT02282124|self-management
945115|NCT02282124|exercise
945116|NCT02282046|type 2 diabetes mellitus
945117|NCT02282046|dental implant
945118|NCT02282020|BRCA, ovarian, platinum, chemotherapy,
945119|NCT02282007|Quality of life
945120|NCT02281994|PEMF
945121|NCT02281994|odontoid fracture
945122|NCT02281994|IDE
945123|NCT02281994|prospective
945124|NCT02281955|Human Papillomavirus
945125|NCT02281955|Oropharynx
945126|NCT02281955|Oropharyngeal Squamous Cell Carcinoma
945127|NCT02281955|Squamous Cell Carcinoma
945128|NCT02281955|Radiation Therapy
945129|NCT02281955|Chemotherapy
945130|NCT02281955|p16
945131|NCT02281929|Alcoholic hepatitis
945132|NCT02281929|corticotherapy
945133|NCT02281929|antibiotherapy
945134|NCT02281929|survival
945135|NCT02281929|infection
945136|NCT02281929|hepato renal syndrome
945137|NCT02281916|Crohn disease
945138|NCT02281916|Immunotherapy
945139|NCT02281916|Helminth antigen
945140|NCT02281890|neurodevelopmental disability
945141|NCT02281877|Total Knee Arthroplasty (TKA)
945142|NCT02281877|Gene Expression
945143|NCT02281851|Endogenous antioxidants
945144|NCT02281851|Antioxidant supplements
945145|NCT02281851|Vitamin Supplements
945146|NCT02281851|Exercise adaptations
945147|NCT02281851|Oxidative stress
945148|NCT02281851|Redox regulation
945149|NCT02281851|Cycling - exercise
945150|NCT02281838|Stroke
945151|NCT02281838|Hypertension
945152|NCT02281825|Attention-Deficit and Hyperactivity Disorder
945153|NCT02281825|Anxiety
945154|NCT02281825|Impulsivity
945155|NCT02281825|Computer Games
945156|NCT02281825|Depression
945157|NCT02281812|Ablation Technique
945158|NCT02281812|Breast cancer
945159|NCT02281812|Stage 1
945160|NCT02281812|Lumpectomy
945161|NCT02281799|Azathioprine (AZA)
945162|NCT02281799|6-mercaptopurine (6-MP)
945163|NCT02281799|Thiopurine-S-methyltransferase (TPMT)
945164|NCT02281799|Xanthine oxidase (XO)
945165|NCT02281799|6-thioguanine (6-TGN)
945166|NCT02281799|6-methyl-mercaptopurine (6-MMP)
945167|NCT02281799|inflammatory bowel disease (IBD)
945168|NCT02281799|acute pancreatitis (AP)
945169|NCT02281799|inosine triphosphate pyrophosphohydrolase (ITPA)
945170|NCT02281799|rheumatoid arthritis (RA)
945171|NCT02281799|systemic lupus erythematosis (SLE)
945172|NCT02281799|Crohn's disease (CD)
945173|NCT02281799|ulcerative colitis (UC)
945174|NCT02281760|Histiocytosis
945175|NCT02281760|Non Langerhans Cell Histiocytosis
945176|NCT02281760|BRAF Inhibitor
945177|NCT02281747|Biologic Therapy
945178|NCT02281747|Rheumatoid Arthritis
945179|NCT02281747|Arthroplasty
945180|NCT02281708|normogram
945181|NCT02281708|recurrence
945182|NCT02281708|adjuvant chemotherapy
945183|NCT02281708|disease free survival
945184|NCT02281708|Quality of life
945185|NCT02281682|Keratosis, Actinic
945186|NCT02281682|Treatment Outcome
945187|NCT02281682|cost-effectiveness
945188|NCT02281682|economic evaluation
945189|NCT02281682|imiquimod
945190|NCT02281682|photodynamic therapy
945191|NCT02281682|topical fluorouracil
945192|NCT02281682|ingenol mebutate
945193|NCT02281643|Coinfection
945194|NCT02281643|Buruli ulcer
945195|NCT02281643|Tuberculosis
945196|NCT02281643|Mansonella perstans
945197|NCT02281630|Chronic Constipation
945198|NCT02281630|CC
945199|NCT02281578|Sex Workers
945200|NCT02281578|Prevention
945201|NCT02281565|attitudes
945202|NCT02281565|blood donation
945203|NCT02281565|blood shortage
945337|NCT02280824|AMPLATZER(R) Occluder
945204|NCT02281552|Tofacitinib, CP-690,550, Janis kinase, JAK inhibitor, modified release, Xeljanz
945205|NCT02281539|Phantom Limb Pain
945206|NCT02281539|Augmented Reality
945207|NCT02281539|Myoelectric control
945208|NCT02281539|Virtual reality
945209|NCT02281539|electromyography
945210|NCT02281539|pattern recognition
945211|NCT02281539|neurorehabilitation
945212|NCT02281513|Nutrition
945213|NCT02281487|tubal carcinoma
945214|NCT02281487|ovarian carcinoma
945215|NCT02281487|tubectomy
945216|NCT02281487|hysterectomy
945217|NCT02281487|dysplastic changes
945218|NCT02281487|Anti Mullerian Hormone
945219|NCT02281487|Tubal Intraepithelial Carcinoma
945220|NCT02281487|Salpingectomy
945221|NCT02281461|PrePex
945222|NCT02281461|Infants
945223|NCT02281461|Early infants
945224|NCT02281461|Children
945225|NCT02281461|Circumcision
945226|NCT02281461|HIV
945227|NCT02281461|AIDS
945228|NCT02281461|Non surgical
945229|NCT02281435|Male Circumcision
945230|NCT02281435|HIV Prevention
945231|NCT02281435|Screen Failure Subjects
945232|NCT02281435|PrePex with Incision
945233|NCT02281409|Mogamulizumab (KW-0761)
945234|NCT02281409|14-135
945235|NCT02281396|safety
945236|NCT02281396|rabies vaccine
945237|NCT02281396|MRC-5 cell
945238|NCT02281383|Bacillus Calmette-Guérin (BCG)
945239|NCT02281383|14-174
945240|NCT02281370|eltrombopag
945241|NCT02281370|cyclosporine
945242|NCT02281370|drug-drug interaction
945243|NCT02281370|pharmacokinetics
945244|NCT02281370|SB-497115
945250|NCT02281344|induced blood stage malaria infection
945251|NCT02281318|Asthma control
945252|NCT02281318|Lung function
945253|NCT02281318|Health-related quality of life
945254|NCT02281318|Mepolizumab
945255|NCT02281318|Severe Eosinophilic asthma
945256|NCT02281292|Diabetic Macular Edema
945257|NCT02281292|Intravitreal
945258|NCT02281292|Retina
945259|NCT02281292|Ophthalmology
945260|NCT02281292|Lucentis
945261|NCT02281292|OCT
945262|NCT02281253|L-carnitine
945263|NCT02281253|fibre
945264|NCT02281253|bakery product
945265|NCT02281253|insulin resistance
945266|NCT02281240|Hematopoietic Stem Cell Transplantation
945270|NCT02281175|Benzodiazepine withdrawal
945271|NCT02281175|PASSE-65+ program
945272|NCT02281175|Psychosocial (non-pharmacological) intervention
945273|NCT02281175|Cognitive-Behavioral Therapy (CBT)
945274|NCT02281175|Older adults
945275|NCT02281149|breast cancer
945276|NCT02281149|radiotherapy
945277|NCT02281149|intensity modulation
945278|NCT02281149|toxicity
945279|NCT02281136|Actinic keratosis
945280|NCT02281110|Diagnostic coronary catheterization
945281|NCT02281110|Multi-vessel coronary disease
945282|NCT02281110|Percutaneous Coronary Intervention
945283|NCT02281110|Instantaneous wave free ratio
945284|NCT02281110|Fractional flow reserve
945285|NCT02281097|Postural Orthostatic Tachycardia Syndrome
945286|NCT02281097|POTS
945287|NCT02281097|Vagal Stimulation
945288|NCT02281084|myelodysplastic syndromes
945289|NCT02281084|MDS
945290|NCT02281084|azacitidine
945291|NCT02281084|oral azacitidine (CC-486)
945292|NCT02281084|decitabine
945293|NCT02281084|intermediate-1
945294|NCT02281084|intermediate-2 and high risk myelodysplastic syndromes (MDS)
945295|NCT02281084|proliferative chronic myelomonocytic leukemia (CMML)
945296|NCT02281084|Durvalumab
945297|NCT02281084|MEDI4736
945298|NCT02281084|hronic, Durvalumab, MEDI4736
945299|NCT02281084|iHMA (injectable hypomethylating agents)
945300|NCT02281084|PD-L1
945301|NCT02281032|Palliative Care
945302|NCT02281032|Nursing Homes
945303|NCT02281032|interRAI Palliative Care instrument
945304|NCT02281032|Older adults
945305|NCT02280980|Stroke
945306|NCT02280980|Postural Balance
945307|NCT02280980|Oculomotor and Gaze Stability Exercises
945308|NCT02280980|Rehabilitation
945309|NCT02280980|Physical therapy
945310|NCT02280980|Outpatient
945311|NCT02280967|Adolescent
945312|NCT02280967|Attitude
945313|NCT02280967|Condom
945314|NCT02280967|Human Papillomavirus Vaccines
945315|NCT02280967|Primary prevention
945316|NCT02280967|School Health
945317|NCT02280954|Solid Tumor
945318|NCT02280915|female
945319|NCT02280915|subjects
945320|NCT02280902|auto-immune diseases
945321|NCT02280902|inflammatory diseases
945322|NCT02280902|risk factors
945323|NCT02280902|infections
945324|NCT02280902|cohort study
945325|NCT02280889|quality of life
945326|NCT02280889|nevus or scar
945327|NCT02280889|stigmatization
945328|NCT02280889|scar
945329|NCT02280876|MS
945330|NCT02280876|Demyelinating Autoimmune Diseases
945331|NCT02280876|CNS
945332|NCT02280876|Nervous System Diseases
945333|NCT02280850|Angina
945334|NCT02280837|GLP-1
945335|NCT02280824|Transcaval
945336|NCT02280824|TAVR
945338|NCT02280811|HPV positive
945339|NCT02280811|Metastatic
945340|NCT02280811|Diet
945341|NCT02280811|Screening
945342|NCT02280811|Risk Factors
945343|NCT02280811|Colorectal adenoma
945344|NCT02280811|Refractory
945345|NCT02280811|Immunotherapy
945346|NCT02280811|Reproductive Cancers
945347|NCT02280798|ERA
945348|NCT02280772|glucomannan
945349|NCT02280772|obesity
945350|NCT02280772|children
945351|NCT02280772|overweight
945352|NCT02280772|adolescents
945353|NCT02280772|treatment
945354|NCT02280759|diarrhea, gelatin tannate, acute gastroenteritis
945355|NCT02280733|Qualified Clinical Data Registry
945356|NCT02280733|Quality Measures
945357|NCT02280733|Meaningful Use Stage 2
945358|NCT02280733|Electronic Health Records
945359|NCT02280733|Clinical Data Research Network
945360|NCT02280733|Real world data
945361|NCT02280720|titanium-nitride-oxide-coated stent
945362|NCT02280720|everolimus-eluting stent
945363|NCT02280720|optical coherence tomography
945364|NCT02280720|strut coverage
945365|NCT02280681|reproductive medicine
945366|NCT02280681|artificial gametes
945367|NCT02280681|patient preference
945368|NCT02280681|decision making
945369|NCT02280668|muscle
945370|NCT02280668|muscle repair
945371|NCT02280668|tissue repair
945372|NCT02280668|eccentric exercise
945373|NCT02280668|force loss
945374|NCT02280668|icing
945375|NCT02280668|cold therapy
945376|NCT02280668|DOMS
945377|NCT02280668|soreness
945378|NCT02280668|recovery
945379|NCT02280655|Blood Transfusions
945380|NCT02280642|Human papillomavirus
945381|NCT02280642|Cervical cancer
945382|NCT02280642|Genital warts
945383|NCT02280642|Vaccine
945384|NCT02280642|Immunogenicity
945385|NCT02280564|motivational interviewing
945386|NCT02280564|problem solving skills
945387|NCT02280564|family communication
945388|NCT02280564|technology support
945389|NCT02280564|cell phone system
945390|NCT02280551|adolescent
945391|NCT02280551|alcohol
945392|NCT02280551|parent
945393|NCT02280551|epidemiology
945394|NCT02280538|Knee Osteoarthritis
945395|NCT02280538|Intra-Articular Hyaluronic Acid
945396|NCT02280538|disease modifying
945397|NCT02280525|Leukemia
945398|NCT02280525|Chronic Lymphocytic Leukemia
945399|NCT02280525|CLL
945400|NCT02280525|Natural Killer Cells
945401|NCT02280525|NK
945402|NCT02280525|Umbilical Cord Blood
945403|NCT02280525|UCB
945404|NCT02280525|Lenalidomide
945405|NCT02280525|CC-5013
945406|NCT02280525|Revlimid
945407|NCT02280525|Rituximab
945408|NCT02280525|Rituxan
945409|NCT02280525|Fludarabine
945410|NCT02280525|Fludarabine phosphate
945411|NCT02280525|Fludara
945412|NCT02280525|Cyclophosphamide
945413|NCT02280525|Cytoxan
945414|NCT02280525|Neosar
945415|NCT02280512|noninvasive cardiac output measurement(NICOM)
945416|NCT02280512|Leg fractures
945417|NCT02280512|Near-Infrared Spectroscopy (NIRS)
945418|NCT02280512|Intensive care unit(ICU)
945419|NCT02280486|saxagliptin
945420|NCT02280486|glimepiride
945421|NCT02280486|metformin monotherapy
945422|NCT02280421|HSV
945423|NCT02280421|Herpes
945424|NCT02280421|volunteers
945425|NCT02280421|drug-drug interaction
945426|NCT02280421|transplant
945427|NCT02280382|splinting
945428|NCT02280369|posture detection
945429|NCT02280369|healthy subjects
945430|NCT02280356|Radiation Therapy
945431|NCT02280356|Brachytherapy
945432|NCT02280356|14-163
945433|NCT02280343|forced oscillation tecnique
945434|NCT02280343|lung function
945435|NCT02280343|asbestosis
945436|NCT02280330|Iodine Deficiency
945437|NCT02280330|Micronutrient Powder
945438|NCT02280330|Hypothyroidism
945439|NCT02280304|Stress Disorders, Post-Traumatic
945440|NCT02280304|Concussion, Mild
945441|NCT02280304|Brain Injuries
945442|NCT02280304|Community Integration
945443|NCT02280304|Meditation
945444|NCT02280304|Magnetic Resonance Imaging
945445|NCT02280278|colon cancer
945446|NCT02280278|cytokine-induced killer cell immunotherapy
945447|NCT02280265|hemophilia A
945448|NCT02280265|standard prophylaxis
945449|NCT02280265|Recombinant Human Coagulation Factor VIII for injection
945450|NCT02280265|ADVATE
945451|NCT02280265|Pediatric
945452|NCT02280252|Locally-advanced Breast Cancer
945453|NCT02280252|LABC
945454|NCT02280252|breast cancer
945455|NCT02280252|breast
945456|NCT02280252|cancer
945457|NCT02280252|metastasis
945458|NCT02280252|metastatic
945459|NCT02280252|tumor
945460|NCT02280252|radiation
945461|NCT02280252|radiation therapy
945462|NCT02280252|radiotherapy
945463|NCT02280252|paclitaxel
945464|NCT02280239|Fever
945465|NCT02280239|Acetaminophen
945466|NCT02280239|Body Temperature Regulation
945467|NCT02280239|Critical Illness
945468|NCT02280239|Hypotension
945469|NCT02280200|claudication
945470|NCT02280200|ankle foot orthoses
945471|NCT02280200|community walking exercise
945472|NCT02280187|InductOs
945473|NCT02280187|rhBMP-2
945474|NCT02280187|Retrospective
945475|NCT02280187|France
945476|NCT02280187|Fusion
945477|NCT02280187|real world use
945478|NCT02280174|Apo B-48
945479|NCT02280174|TRL
945480|NCT02280174|Linagliptin
945481|NCT02280148|Propofol
945482|NCT02280148|gastroscopy and colonoscopy
945483|NCT02280148|driving simulator
945484|NCT02280148|driving ability
945485|NCT02280148|cognitive function
945486|NCT02280148|patients
945487|NCT02280122|activated matrix metalloproteinase 8
945488|NCT02280122|untreated moderate/severe chronic periodontitis
945489|NCT02280122|saliva
945490|NCT02280122|sensitivity/specificity
945491|NCT02280109|Tenofovir
945492|NCT02280109|Healthy Volunteers
945493|NCT02280109|HIV
945494|NCT02280109|pharmacokinetics of tenofovir gel and film
945495|NCT02280096|Cognitive function
945496|NCT02280096|Multiple sclerosis
945497|NCT02280096|4-aminopyridine
945498|NCT02280096|Fatigue
945499|NCT02280083|Spasticity, Post-Stroke
945500|NCT02280083|Botulinum toxin type A for Injection
945501|NCT02280083|upper limb spasticity
945502|NCT02280070|resectable rectal cancer
945503|NCT02280070|SOX
945504|NCT02280070|mFOLFOX6
945505|NCT02280070|neoadjuvant
945506|NCT02280057|PCOS
945507|NCT02280057|metformin
945508|NCT02280057|obesity
945509|NCT02280057|randomized controlled trial
945510|NCT02280044|Campylobacter jejuni
945511|NCT02280044|rifaximin
945512|NCT02280044|antibiotic prophylaxis
945513|NCT02280044|dysentery
945514|NCT02280044|diarrhea
945515|NCT02280031|Twin Pregnancy
945516|NCT02280031|Pregnancy Complications
945517|NCT02280018|Healthy
945518|NCT02280018|JNJ-49122944
945519|NCT02280018|Placebo
945520|NCT02280005|Dialysis
945521|NCT02280005|Renal Failure
945522|NCT02280005|Wearable
945523|NCT02280005|Artificial Kidney
945524|NCT02280005|Hemodialysis
945525|NCT02279992|Malignant Glioma
945526|NCT02279992|Brain Neoplasms, Malignant
945527|NCT02279992|Brain metastasis
945528|NCT02279979|PHP
945529|NCT02279979|Cardiogenic Shock
945530|NCT02279979|Percutaneous
945531|NCT02279979|Ventricular Assist
945532|NCT02279979|Heart Pump
945533|NCT02279979|Catheter
945534|NCT02279979|Thoratec Corporation
945535|NCT02279940|rivaroxaban
945536|NCT02279940|stroke
945537|NCT02279940|transient ischemic attack
945538|NCT02279940|ischemia
945539|NCT02279927|Ureteroscopy
945540|NCT02279901|Obstructive Sleep Apnea
945541|NCT02279901|CPAP
945542|NCT02279901|Continuous positive airway pressure
945543|NCT02279901|CPAP compliance
945544|NCT02279901|Telemedicine
945545|NCT02279901|Automated response mechanisms
945546|NCT02279901|Patient engagement
945547|NCT02279901|OSA
945548|NCT02279888|Pulmonary Artery Pressure Monitoring
945549|NCT02279888|Implantable Hemodynamic Monitor
945550|NCT02279875|Tuberculosis
945551|NCT02279875|Drug-Sensitive Tuberculosis
945552|NCT02279875|Linezolid
945553|NCT02279875|HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol)
945554|NCT02279875|Pulmonary Tuberculosis
945555|NCT02279875|TB
945556|NCT02279849|multi-level intervention
945557|NCT02279849|price discounts
945558|NCT02279849|communication
945559|NCT02279849|low income population
945560|NCT02279849|dietary intervention
945561|NCT02279849|obesity prevention
945562|NCT02279849|store-based intervention
945563|NCT02279836|Patients with any indication for colonoscopy in the U.S.A.
945564|NCT02279823|androgen
945565|NCT02279823|alopecia
945566|NCT02279823|CB-03-01
945567|NCT02279823|solution
945568|NCT02279823|topical
945569|NCT02279810|organ shortage
945570|NCT02279810|attitudes to organ transplantation
945571|NCT02279797|bone marrow
945572|NCT02279797|attitude
945573|NCT02279771|colorectal anastomosis
945574|NCT02279771|anastomotic leak
945575|NCT02279771|ileostomy
945576|NCT02279771|complications
945577|NCT02279758|Neuroendocrine Tumors
945578|NCT02279758|The Mammalian Target of Rapamycin (mTOR)
945579|NCT02279758|metformin
945582|NCT02279654|Lenalidomide
945583|NCT02279654|Revlimid
945584|NCT02279654|Transfusion-dependent
945585|NCT02279654|international Prognostic Scoring System (IPSS) low
945586|NCT02279654|Intermediate-1-risk
945587|NCT02279654|MDS
945588|NCT02279654|Isolated del(5q)
945589|NCT02279654|Prospective
945590|NCT02279654|Non-interventional
945591|NCT02279654|Post-authorization safety study (PASS)
945592|NCT02279654|Disease registry
945593|NCT02279628|cesarean section
945594|NCT02279628|spinal anesthesia
945595|NCT02279628|continuous wound infiltration
945596|NCT02279628|intrathecal morphine
945597|NCT02279628|oral morphine
945598|NCT02279615|Overactive Bladder
945599|NCT02279615|Benign Prostatic Hyperplasia
945600|NCT02279615|Combination Therapy
945601|NCT02279615|β3-Adrenoceptor Agonist
945602|NCT02279615|Mirabegron
945603|NCT02279615|Myrbetriq
945604|NCT02279615|α-Adrenoceptor Antagonist
945605|NCT02279615|Tamsulosin
945606|NCT02279615|Flomax
945607|NCT02279602|Pancreatic
945608|NCT02279602|Gastrointestional
945609|NCT02279589|hyporesponsiveness
945610|NCT02279589|vaccination
945611|NCT02279589|recommendations
945612|NCT02279589|improvement
945613|NCT02279589|schedule
945614|NCT02279589|fractional dose
945615|NCT02279589|conjugate polysaccharide vaccine
945616|NCT02279576|Penile squamous cell carcinoma
945617|NCT02279576|Pazopanib
945618|NCT02279576|Weekly paclitaxel
945619|NCT02279550|hip fracture, elderly
945620|NCT02279537|Wet age-related macular Degeneration (Wet-AMD)
945621|NCT02279537|Naïve patients
945622|NCT02279537|Real life
945623|NCT02279537|Aflibercept
945624|NCT02279524|NASH
945625|NCT02279511|Alzheimer
945626|NCT02279485|Healthy Subjects
945627|NCT02279485|Bioequivalence
945628|NCT02279485|Fasted
945629|NCT02279485|Fed
945630|NCT02279433|Neoplasms
945631|NCT02279433|Lung Neoplasms
945632|NCT02279433|Colorectal Neoplasms
945633|NCT02279433|Neuroendocrine Tumors
945634|NCT02279433|Pancreatic Neoplasms
945635|NCT02279407|omega-3 carboxylic acid
945636|NCT02279394|Smoldering myeloma
945637|NCT02279394|Smoldering Multiple Myeloma
945638|NCT02279381|Chlorhexidine
945639|NCT02279381|Kangaroo mother care
945640|NCT02279381|RCT
945641|NCT02279342|Coronary artery disease
945642|NCT02279342|hyperuricemia
945643|NCT02279342|coronary plaque volume
945644|NCT02279342|IVUS
945645|NCT02279316|Dalcroze eurhythmics
945646|NCT02279316|home exercise
945647|NCT02279316|vitamin D
945648|NCT02279316|mild cognitive impairment
945649|NCT02279316|MCI
945650|NCT02279316|mild dementia
945651|NCT02279290|Childhood trauma
945652|NCT02279264|ph
945653|NCT02279264|RightSpot Infant
945654|NCT02279264|Feeding Tube
945655|NCT02279264|RightBio Metrics
945656|NCT02279264|placement
945657|NCT02279264|Nasogastric Tube
945658|NCT02279264|NG
945659|NCT02279264|infant
945660|NCT02279251|Anxiety
945661|NCT02279251|adolescents
945662|NCT02279251|school-based
945663|NCT02279251|low-intensity CBT
945664|NCT02279225|Phototherapy
945665|NCT02279225|Laser
945666|NCT02279225|Fibromyalgia
945667|NCT02279225|DTM/ TMD
945668|NCT02279225|Pain
945669|NCT02279212|Critical illness
945670|NCT02279212|pain
945671|NCT02279212|quality of life
945672|NCT02279199|hemophilia
945673|NCT02279199|joint health
945674|NCT02279199|motor development
945675|NCT02279199|motor proficiency
945676|NCT02279173|Pediatric
945677|NCT02279173|Immune Thrombocytopenia (ITP)
945678|NCT02279173|Amgen
945679|NCT02279147|Systemic Inflammatory Response Syndrome
945680|NCT02279147|Jaundice, Obstructive
945681|NCT02279147|anti-inflammatory
945682|NCT02279134|StageⅡB-Ⅲ esophageal cancer
945683|NCT02279134|adjuvant radiotherapy
945684|NCT02279134|adjuvant chemoradiotherapy
945685|NCT02279121|central venous catheter
945686|NCT02279121|Taurolidine
945687|NCT02279121|lock-therapy
945693|NCT02279095|Open-label extension study
945694|NCT02279095|Clinical trial Phase 2
945695|NCT02279095|Efficacy and safety
945696|NCT02279095|Heterotopic ossification
945697|NCT02279095|Fibrodysplasia Ossificans Progressiva
945698|NCT02279095|Flare-up
945699|NCT02279095|Palovarotene
945700|NCT02279095|Retinoic acid receptor agonist
945701|NCT02279095|Retinoic acid receptor gamma agonist
945702|NCT02279095|Clementia
945703|NCT02279095|Myositis Ossificans Progressiva
945704|NCT02279095|Munchmeyer's Disease
945705|NCT02279095|FOP
945706|NCT02279069|stroke
945707|NCT02279069|walking
945708|NCT02279069|rehabilitation
945709|NCT02279043|IUD
945710|NCT02279043|IUC
945711|NCT02279043|birth control
945712|NCT02279043|contraception
945713|NCT02279043|online
945714|NCT02279030|ablation
945715|NCT02279017|Mobile Technology
945716|NCT02279017|Diet and Fitness
945717|NCT02279004|Plasma Genotyping
945718|NCT02279004|NSCLC
945719|NCT02279004|Melanoma
945720|NCT02278978|urothelial carcinoma
945721|NCT02278978|BIBF1120
945722|NCT02278965|Breast Cancer
945723|NCT02278965|Early Stage
945724|NCT02278939|diabetes prevention
945725|NCT02278939|Filipinos
945726|NCT02278939|lifestyle intervention
945727|NCT02278926|Ultrasound
945728|NCT02278926|Lypo-hypertrophy
945729|NCT02278913|inpatient
945730|NCT02278913|hospital
945731|NCT02278913|randomized trial
945732|NCT02278913|diabetes
945733|NCT02278913|analogs
945734|NCT02278913|human insulin
945735|NCT02278900|communication
945736|NCT02278900|shared decision-making
945737|NCT02278887|melanoma
945738|NCT02278887|TIL treatment
945739|NCT02278887|tumor infiltrating lymphocytes
945740|NCT02278887|ipilimumab
945741|NCT02278887|interleukin 2
945742|NCT02278887|non-myeloablative
945743|NCT02278887|randomization
945744|NCT02278874|Trisomy 13
945745|NCT02278874|Trisomy 18
945746|NCT02278874|Trisomy 21
945747|NCT02278874|Sex Chromosome Abnormalities
945748|NCT02278874|Monosomy X
945749|NCT02278874|XXX
945750|NCT02278874|XXY
945751|NCT02278874|XYY
945752|NCT02278861|actinic keratosis
945753|NCT02278861|tretinoin
945754|NCT02278861|isotretinoin
945755|NCT02278861|cryotherapy
945756|NCT02278861|sun protection factor
945757|NCT02278861|clinical clearance
945758|NCT02278848|Computerised gait analysis
945759|NCT02278848|Ultrasound measurement of cerebral pulsatility
945760|NCT02278848|MRI flow
945761|NCT02278848|Urinary incontinence scale
945762|NCT02278848|Subtractive lumbar puncture
945763|NCT02278835|Cardiac valve
945764|NCT02278809|physical activity
945765|NCT02278809|screen time
945766|NCT02278809|vegetables
945767|NCT02278809|fruit
945768|NCT02278809|snacks
945769|NCT02278809|softdrink
945770|NCT02278809|water
945771|NCT02278809|fruit juice
945772|NCT02278809|parenting practices
945773|NCT02278809|online videos
945774|NCT02278809|intervention mapping protocol
945775|NCT02278796|Diffuse large B-cell lymphomas (DLBC)
945776|NCT02278796|Follicular lymphomas (FL)
945777|NCT02278796|Mantle cell lymphomas (MCL)
945778|NCT02278770|diverticular disease
945779|NCT02278770|MRI
945780|NCT02278770|visceral and subcutaneous fat
945781|NCT02278770|adipokines
945782|NCT02278757|Metabolic syndrome
945783|NCT02278757|Weight loss
945784|NCT02278757|Obesity
945785|NCT02278757|Hypertension
945786|NCT02278757|Dyslipidemia
945787|NCT02278744|Single-Fraction Stereotactic Radiosurgery
945788|NCT02278744|Salvage Re-Irradiation
945789|NCT02278744|14-054
945790|NCT02278731|Physical activity
945791|NCT02278731|Rehabilitation
945792|NCT02278731|Older adults
945793|NCT02278731|Pilates
945794|NCT02278731|Proprioceptive neuromuscular facilitation
945795|NCT02278705|childhood obesity
945796|NCT02278705|childhood overweight
945797|NCT02278705|primary care
945798|NCT02278705|weight management
945799|NCT02278692|Vitamin K
945800|NCT02278692|Calciphylaxis
945801|NCT02278692|Calcific uremic arteriolopathy
945802|NCT02278692|Dialysis
945803|NCT02278692|End-stage renal disease
945804|NCT02278653|Restaging
945805|NCT02278653|Watchful Waiting
945806|NCT02278653|Quality of Life
945807|NCT02278653|Manometry
945808|NCT02278601|Breakthrough pain
945809|NCT02278575|antithrombin, Atenativ, preeclampsia, blood flow.
945810|NCT02278549|Spinal kinematics
945811|NCT02278536|Trisomy 13
945812|NCT02278536|Trisomy 18
945813|NCT02278536|Trisomy 21
945814|NCT02278536|Sex Chromosome Abnormalities
945815|NCT02278536|Monosomy X
945816|NCT02278536|XXX
945817|NCT02278536|XXY
945818|NCT02278536|XYY
945819|NCT02278510|topotecan
945820|NCT02278510|convection-enhanced delivery
945821|NCT02278510|CED
945822|NCT02278510|High Grade Glioma
945823|NCT02278484|sinus infections
945824|NCT02278484|sinusitis
945825|NCT02278484|chronic sinusitis
945826|NCT02278484|rhinosinusitis
945827|NCT02278484|allergic sinusitis
945828|NCT02278484|allergic rhinitis
945829|NCT02278484|chronic rhinosinusitis
945830|NCT02278484|sinus disease in children
945831|NCT02278484|sinus balloon dilation
945832|NCT02278484|balloon dilatation
945833|NCT02278484|sinus disease
945834|NCT02278484|pediatric
945835|NCT02278471|combination pill
945836|NCT02278471|polypill
945837|NCT02278471|primary prevention
945838|NCT02278445|Systemic Sclerosis
945839|NCT02278445|Pulmonary hypertension
945840|NCT02278445|Lung Doppler Signals
945841|NCT02278432|risk assessment
945842|NCT02278432|pharmacovigilance
945843|NCT02278432|pharmacoepidemiology
945844|NCT02278432|drug toxicity
945845|NCT02278432|adverse drug reaction reporting system
945846|NCT02278432|omeprazole
945847|NCT02278419|Hepatitis C
945848|NCT02278419|Simeprevir
945849|NCT02278419|Sofosbuvir
945850|NCT02278419|Healthy
945851|NCT02278406|Parkinson's Disease
945852|NCT02278406|Deep brain stimulator
945853|NCT02278406|dbs
945854|NCT02278393|Japanese healthy volunteers
945855|NCT02278393|High LDL-C
945856|NCT02278393|dairy drinks
945857|NCT02278393|phytosterols
945869|NCT02278328|dose titration study
945870|NCT02278328|electrophysiology
945871|NCT02278315|Multiple Myeloma
945872|NCT02278315|Radiopharmaceutical
945873|NCT02278315|Therapy
945874|NCT02278315|Phase 1
945875|NCT02278263|tranexamic acid
945876|NCT02278263|enhanced recovery
945877|NCT02278263|arthroplasty
945878|NCT02278263|perioperative care
945879|NCT02278198|thyroid cancer
945880|NCT02278172|vitamin D
945881|NCT02278172|athletes
945882|NCT02278172|fitness
945883|NCT02278159|end-stage kidney disease
945884|NCT02278159|peritoneal dialysis
945885|NCT02278159|home hemodialysis
945886|NCT02278159|technique survival
945887|NCT02278159|patient survival
945888|NCT02278133|metastatic,
945889|NCT02278133|Colorectal cancer,
945890|NCT02278133|WNT974,
945891|NCT02278133|LGX818,
945892|NCT02278133|cetuximab,
945893|NCT02278133|BRAF-mutant,
945894|NCT02278133|mCRC,
945895|NCT02278133|BRAFV600-mutant,
945896|NCT02278133|KRAS
945912|NCT02278094|OSAS
945913|NCT02278094|Adult
945914|NCT02278094|Home-based
945915|NCT02278094|Genioglossus
945916|NCT02278094|Inspiratory muscle
945917|NCT02278094|Exercise
945918|NCT02278081|Rhinitis (nasal obstruction) and GERD
945919|NCT02278068|Type 2 diabetes
945920|NCT02278055|Radium-223
945921|NCT02278055|14-098
945922|NCT02278055|Prostate Cancer Clinical Trials Consortium
945923|NCT02278016|procalcitonin
945924|NCT02278016|interleukin-6
945925|NCT02278016|agiotensininⅡ
945926|NCT02278003|Amnesic
945927|NCT02278003|Propofol
945928|NCT02278003|12-006
945929|NCT02277977|sepsis
945930|NCT02277977|septic shock
945931|NCT02277977|contrast-enhanced ultrasound
945932|NCT02277977|microcirculation
945933|NCT02277964|RRMS
945934|NCT02277964|Natalizumab
945935|NCT02277964|Fingolimod
945936|NCT02277964|Treatment Change
945937|NCT02277964|Disease Activity
945941|NCT02277912|ICH
945942|NCT02277912|Stroke
945943|NCT02277912|Navigated
945944|NCT02277912|Placebo
945945|NCT02277912|TMS
945946|NCT02277899|childhood obesity
945947|NCT02277899|overweight
945948|NCT02277899|communication
945949|NCT02277899|primary care
945950|NCT02277899|weight management
945951|NCT02277899|communication methods
945952|NCT02277899|patient-centered communication
945953|NCT02277886|sodium alginate
945954|NCT02277886|esomeprazole
945955|NCT02277886|GERD
945956|NCT02277873|moon
945957|NCT02277873|parturition
945958|NCT02277873|moon phases
945959|NCT02277860|Exercise
945960|NCT02277847|Idarubicin
945961|NCT02277847|Cytosine arabinoside
945962|NCT02277847|Efficacy
945963|NCT02277847|Safety
945964|NCT02277821|Essential Hypertension
945965|NCT02277821|Central Blood Pressure
945966|NCT02277821|Microcirculation
945967|NCT02277821|Endothelium Stimulation
945968|NCT02277808|Pneumocystis
945969|NCT02277808|Nebulizer
945970|NCT02277808|Pentamidine
945971|NCT02277795|Early infant male circumcision
945972|NCT02277795|HIV
945973|NCT02277795|Prevention
945974|NCT02277795|AccuCirc
945975|NCT02277795|Kenya
945976|NCT02277795|Providers
945977|NCT02277795|Parents
945978|NCT02277782|Labor
945979|NCT02277782|Analgesia
945980|NCT02277756|high functioning autism
945981|NCT02277756|endogenous modulation systems
945982|NCT02277730|Hypotension
945983|NCT02277717|cancer
945984|NCT02277717|metastasis
945985|NCT02277717|HER2
945986|NCT02277717|trastuzumab
945987|NCT02277717|duocarmycin
945988|NCT02277717|SYD985
945989|NCT02277717|antibody-drug conjugate
945990|NCT02277717|ADC
945991|NCT02277717|trastuzumab vc-seco-DUBA
945992|NCT02277704|PTSD
945993|NCT02277704|Military-related PTSD and other related conditions
945994|NCT02277691|Pharmacological therapy
945995|NCT02277678|Pruritus
945996|NCT02277665|Cannabis Use Disorder
945997|NCT02277665|Tobacco Use
945998|NCT02277665|Treatment
945999|NCT02277639|Transplant related mortality
946000|NCT02277639|Graft versus host disease
946001|NCT02277639|Bone marrow transplant
946002|NCT02277613|stem cells
946011|NCT02277574|Rheumatoid arthritis
946012|NCT02277574|Arthritis
946013|NCT02277574|Joint diseases
946014|NCT02277574|Musculoskeletal diseases
946015|NCT02277548|chemotherapy
946016|NCT02277548|radiation therapy
946138|NCT02276781|PAD
946017|NCT02277535|Malnutrition in the ICU (caloric deficit >4000 kcal or 150 g protein deficit) or >48hrs of admission without receiving nutrition
946018|NCT02277470|pharmacokinetics, Golimumab, IBD
946019|NCT02277444|Methotrexate
946020|NCT02277444|Anti-TNFα Antibody
946021|NCT02277444|Golimumab
946022|NCT02277444|Pediatric Participants
946023|NCT02277379|cardiac surgery ; hemorrhage ; transfusion requirements
946024|NCT02277366|Lung Neoplasms
946025|NCT02277366|Bronchoscopy
946026|NCT02277366|Early Detection of Cancer
946027|NCT02277353|Fluid responsiveness
946028|NCT02277353|NICOM
946029|NCT02277353|Prone Position
946030|NCT02277353|Stroke Volume Variation
946031|NCT02277327|Hospitalization
946032|NCT02277327|Readmissions
946033|NCT02277327|Medical complexity
946034|NCT02277301|Pilot study
946035|NCT02277301|Randomised Controlled Trial
946036|NCT02277301|Parenting
946037|NCT02277301|Paediatrics
946038|NCT02277301|Mental Health
946039|NCT02277275|Branched chain amino acid, high protein diet, weight loss
946040|NCT02277262|peritonitis patients
946041|NCT02277236|sarcopenia
946042|NCT02277236|aging
946043|NCT02277236|insulin resistance
946044|NCT02277236|screening
946045|NCT02277184|Intermediate Risk HNSCC
946046|NCT02277184|High Risk HNSCC
946047|NCT02277184|Previously Untreated, Locally Advanced HNSCC
946048|NCT02277184|Undifferentiated carcinoma
946049|NCT02277184|Poorly differentiated carcinoma of the oral cavity
946050|NCT02277184|Poorly differentiated carcinoma of the oropharynx
946051|NCT02277184|Poorly differentiated carcinoma of the larynx
946052|NCT02277184|Poorly differentiated carcinoma of the hypopharynx
946053|NCT02277158|Rectal cancer
946054|NCT02277158|S-1
946055|NCT02277158|Chemoradiotherapy
946056|NCT02277158|Phase I
946057|NCT02277145|radiation-induced pulmonary fibrosis
946058|NCT02277145|MSCs
946059|NCT02277132|Fetal growth restriction
946060|NCT02277132|Sildenafil
946061|NCT02277080|Pain, opioids, immune system, endocrine system, quality of life
946062|NCT02277067|PPH
946063|NCT02277041|PPH
946064|NCT02277002|Cabin Air Filtration
946065|NCT02277002|Particulate Matter
946066|NCT02277002|Commuter Exposure
946067|NCT02277002|Traffic Related Air Pollution
946068|NCT02276989|Chronic Pain
946069|NCT02276989|Compliance Marker
946070|NCT02276989|Narcotic Abuse
946071|NCT02276989|Opioid related disorders
946072|NCT02276989|Opiate substitution treatment
946073|NCT02276989|Buprenorphrine
946074|NCT02276989|Suboxone
946075|NCT02276989|Lyrica
946076|NCT02276989|Pregabalin
946077|NCT02276989|Acetazolamide
946078|NCT02276989|Quinine
946079|NCT02276989|Compliance
946080|NCT02276976|crebral white matter lesions
946081|NCT02276976|brain networks
946082|NCT02276976|MRI
946083|NCT02276976|DTI
946084|NCT02276976|fMRI
946085|NCT02276976|cognitive impairment
946086|NCT02276976|gene
946087|NCT02276963|Transverse myelitis, optic neuritis, neuromyelitis optica
946088|NCT02276950|Cardiac Surgery
946089|NCT02276950|Epidemiologic Methods
946090|NCT02276950|Blood Transfusions
946091|NCT02276937|Recombinant Sendai virus
946092|NCT02276937|fibroblast growth factor-2
946093|NCT02276937|treadmill
946094|NCT02276924|Laser Confocal Microscopy
946095|NCT02276924|Superior Urinary Tract Tumors
946096|NCT02276898|pediatric
946097|NCT02276898|lung clearance index
946098|NCT02276898|Multiple Breath Washout
946099|NCT02276898|Hypertonic Saline
946100|NCT02276885|breast
946101|NCT02276885|cancer
946102|NCT02276885|breast cancer
946103|NCT02276885|prone
946104|NCT02276885|partial breast irradiation
946105|NCT02276885|PBI
946106|NCT02276872|pediatric
946107|NCT02276872|treprostinil
946108|NCT02276872|transition
946109|NCT02276872|Remodulin
946110|NCT02276859|dual-wave bolus
946111|NCT02276859|square bolus
946112|NCT02276859|normal bolus
946113|NCT02276859|standard bolus
946114|NCT02276859|high-protein meal
946115|NCT02276859|prandial insulin requirement
946116|NCT02276846|Palpitate-Eluting Balloon
946117|NCT02276846|Bifurcation
946118|NCT02276846|OCT
946119|NCT02276846|Transluminal
946120|NCT02276820|Adenovirus
946121|NCT02276820|Virus specific T cells
946122|NCT02276820|Viral infections
946123|NCT02276807|Depression
946124|NCT02276807|Behavioral Symptoms
946125|NCT02276807|Mental Disorders
946126|NCT02276807|Depressive Disorder
946127|NCT02276807|suicidal ideation
946128|NCT02276807|primary health care
946129|NCT02276807|Veterans
946130|NCT02276794|Low back pain
946131|NCT02276794|Thrust manipulation
946132|NCT02276794|Spinal manipulation
946133|NCT02276794|Joint mobilization
946134|NCT02276794|Non-thrust manipulation
946135|NCT02276794|proprioception
946136|NCT02276794|Postural stability
946137|NCT02276794|Baropodometry
946139|NCT02276781|Peripheral Arterial Disease
946140|NCT02276781|Biomarkers
946141|NCT02276768|rectal distension
946142|NCT02276768|rectal compliance
946143|NCT02276768|visceral pain
946144|NCT02276768|pain intensity
946145|NCT02276768|barostat
946146|NCT02276768|distender
946147|NCT02276768|VAS (Visual Analog Scale)
946148|NCT02276768|rectal sensory threshold
946149|NCT02276768|analgesia
946150|NCT02276768|trimebutine
946151|NCT02276768|pain management
946152|NCT02276768|peripheral
946153|NCT02276768|colon cancer
946154|NCT02276768|H2S (hydrogen sulfide)
946155|NCT02276729|Upper limb
946156|NCT02276729|Rehabilitation
946157|NCT02276729|Occupational Therapy
946158|NCT02276729|Mirror Box Therapy
946159|NCT02276690|iron deficiency
946160|NCT02276690|dosage of hepcidin
946161|NCT02276690|usual biomarker (ferritin and transferrin saturation)
946162|NCT02276690|mass spectrometry
946163|NCT02276690|immuno-detection
946164|NCT02276690|anaemia in intensive care unit
946165|NCT02276664|lung cancer prevention
946166|NCT02276560|main tumor ranging from less than 3cm (T1 up to 7cm (T3)
946167|NCT02276547|Mitral
946168|NCT02276547|Regurgitation
946169|NCT02276547|Heart valve
946170|NCT02276547|Transcatheter
946171|NCT02276547|Transapical
946172|NCT02276547|Functional
946173|NCT02276547|Degenerative
946174|NCT02276547|Symptomatic, severe mitral valve regurgitation, high risk for open mitral valve surgery
946175|NCT02276495|pain management for total knee arthroplasty
946176|NCT02276469|severe mental illness
946177|NCT02276443|Breast Cancer
946178|NCT02276443|Triple-negative breast cancer
946179|NCT02276443|TNBC
946180|NCT02276443|Molecular testing
946181|NCT02276443|Standard chemotherapy
946182|NCT02276443|Ultrasound
946183|NCT02276430|Testicular cancer
946184|NCT02276430|Survivor
946185|NCT02276430|Cardiovascular disease
946186|NCT02276430|Risk factors
946187|NCT02276417|Sepsis
946188|NCT02276417|Surgical ICU
946189|NCT02276313|Peripheral
946190|NCT02276313|Infrainguinal
946191|NCT02276313|Drug Releasing Balloon
946192|NCT02276313|Drug Eluting Balloon
946193|NCT02276287|Adherence
946194|NCT02276287|HAART
946195|NCT02276287|HIV
946196|NCT02276287|Illness Perception
946197|NCT02276287|IPQ-R
946198|NCT02276235|catgut embedding
946199|NCT02276235|obese women
946200|NCT02276235|obesity-related hormones
946201|NCT02276222|Chronic Obstructive Pulmonary Disease
946202|NCT02276222|COPD
946203|NCT02276157|cholangioscopy
946204|NCT02276105|Carpal Tunnel Syndrome
946205|NCT02276105|Quality of Life
946206|NCT02276105|EQ-5D
946207|NCT02276105|SF-12
946208|NCT02276105|Michigan Hand Questionnaire
946209|NCT02276092|Community-acquired pneumonia
946210|NCT02276092|Pragmatic study
946211|NCT02276092|Multi-center
946212|NCT02276092|Time-dependent bias
946213|NCT02276092|antimicrobial stewardship
946214|NCT02276092|prospective audit and feedback
946215|NCT02276079|Mild Traumatic Brain Injury
946216|NCT02276079|Aerobic Exercise
946217|NCT02276079|Brain-Derived Neurotrophic Factor
946218|NCT02276066|kidney dysfunction
946219|NCT02276066|chronic critical illness
946220|NCT02276066|sepsis
946221|NCT02276066|Glomerular filtration rate
946222|NCT02276053|Epilepsy
946223|NCT02276053|Brain tumor
946224|NCT02276053|lacosamide (LCM)
946225|NCT02276053|Anti-Epileptic Drugs (AEDs)
946226|NCT02276040|Arthroplasty
946227|NCT02276040|Knee Replacement
946228|NCT02276040|Analgesia
946229|NCT02276040|pain
946230|NCT02276027|adenocarcinoma lung cancer,squamous cell lung carcinoma, NSCLC
946231|NCT02276014|Beta carotene
946232|NCT02276014|Retinol
946233|NCT02276001|Adult Volunteers
946234|NCT02275988|Adult Volunteers
946235|NCT02275975|Adult Volunteers
946236|NCT02275962|Adult Volunteers
946237|NCT02275949|SAH (Subarachnoid Hemorrhage)
946238|NCT02275949|Cerebral Vasospasm
946239|NCT02275949|Acupuncture
946240|NCT02275936|N91115
946241|NCT02275936|Cavosonstat
946244|NCT02275897|Lower Segmental Caesarean Section (LSCS)
946245|NCT02275897|Speed of Injection
946246|NCT02275897|Spinal Anaesthesia
946247|NCT02275897|Anesthesia
946248|NCT02275884|Parkinson Disease
946249|NCT02275884|Cacao
946250|NCT02275884|Biogenic amines
946251|NCT02275884|Xanthines
946252|NCT02275884|Neurodegenerative Diseases
946253|NCT02275871|Breast Cancer
946254|NCT02275858|balloon assisted enteroscopy
946255|NCT02275858|terminal ileum intubation
946256|NCT02275845|metformin
946257|NCT02275845|prevention
946258|NCT02275819|Heart Failure
946259|NCT02275819|Exercise
946260|NCT02275819|Echocardiography
946261|NCT02275741|Vaccine
946262|NCT02275741|Antibody response
946263|NCT02275741|relaps rate
946264|NCT02275741|expanded disability status scale
946265|NCT02275728|Menopause
946266|NCT02275728|Stress Urinary Incontinence
946267|NCT02275728|EMG Biofeedback
946268|NCT02275728|Pelvic Floor Muscle Training
946269|NCT02275728|Quality of life
946270|NCT02275728|Physical Therapie
946271|NCT02275715|autism spectrum disorder (ASD)
946272|NCT02275715|feeding problems
946273|NCT02275702|Dexamethasone
946274|NCT02275702|Quality of recovery questionnaire
946275|NCT02275702|QoR-40
946276|NCT02275702|Lung cancer
946277|NCT02275702|Video-assisted thoracoscopic
946278|NCT02275689|Rotator cuff
946279|NCT02275689|Tendinosis
946280|NCT02275689|Impingement
946281|NCT02275689|radiofrequency
946282|NCT02275676|Inflammatory bowel disease
946283|NCT02275676|Nutritional Status
946284|NCT02275676|Malnutrition
946285|NCT02275676|Resting Energy Expenditure
946286|NCT02275663|relapsed AML
946287|NCT02275663|refractory AML
946288|NCT02275663|azacytidine
946289|NCT02275650|calcidiol
946290|NCT02275650|25(oh)d
946291|NCT02275650|nbUVB
946292|NCT02275650|cyp27A1
946293|NCT02275650|cyp27B1
946294|NCT02275650|vitamin D
946295|NCT02275637|Implantable Cardioverter-Defibrillators
946296|NCT02275637|Ventricular Fibrillation
946297|NCT02275637|ventricular Tachycardia
946298|NCT02275611|oxytocin
946299|NCT02275611|alcohol withdrawal
946300|NCT02275611|alcohol dependence
946301|NCT02275611|alcoholism
946302|NCT02275585|Portal vein
946303|NCT02275585|Thrombosis
946304|NCT02275585|Cirrhosis
946305|NCT02275481|Chronic obstructive pulmonary disease
946306|NCT02275481|COPD
946307|NCT02275481|Emphysema
946308|NCT02275481|Chronic bronchitis
946309|NCT02275468|Chronic Kidney Disease
946310|NCT02275468|eGFR slope
946311|NCT02275468|Herbal medicine Fu-zheng-qu-zhuo Oral liquid
946312|NCT02275442|EPICES scale
946313|NCT02275442|Precarious situation
946314|NCT02275442|Rural parturient women
946315|NCT02275442|Access to care
946316|NCT02275442|Global Initiative for Sentinel E-health Network on Grid
946317|NCT02275442|General practice
946318|NCT02275429|Metabolic Diseases
946319|NCT02275429|Athletes
946320|NCT02275429|Running
946321|NCT02275429|Selenium
946322|NCT02275429|Zinc
946323|NCT02275429|Iron Metabolism Disorders
946324|NCT02275429|Water-Electrolyte Imbalance
946325|NCT02275429|Hyperkalemia
946326|NCT02275429|Hypernatremia
946327|NCT02275429|Selenium levels before and after the race
946328|NCT02275429|Levels of other electrolytes and markers
946329|NCT02275390|mental illness
946330|NCT02275390|psychoeducation
946331|NCT02275390|nurse-led clinic
946332|NCT02275390|randomized controlled trial
946333|NCT02275377|Breathing Exercises; Autonomic Control; Blood Pressure.
946334|NCT02275351|alopecia
946335|NCT02275351|topical
946336|NCT02275351|Samumed
946337|NCT02275325|Posture
946338|NCT02275325|Unilateral vestibular deafferentation
946339|NCT02275325|Medical management
946340|NCT02275325|Preoperative vestibular rehabilitation
946341|NCT02275325|Neural plasticity
946342|NCT02275286|sarcoma
946343|NCT02275273|Adnexal Masses
946344|NCT02275273|Magnetic Resonance Imaging
946345|NCT02275273|Anatomopathology
946346|NCT02275247|Stellate ganglion block
946347|NCT02275247|Aneurysm surgery
946348|NCT02275247|Cognitive recovery
946349|NCT02275247|Cerebral vasospasm
946350|NCT02275234|cardiac arrest
946351|NCT02275234|psychological intervention
946352|NCT02275221|Hepatitis B (HBV)
946353|NCT02275221|Hepatitis C (HCV)
946354|NCT02275195|hepatitis
946355|NCT02275195|alcohol
946356|NCT02275182|Dexmedetomidine
946357|NCT02275169|follicle stimulating hormone treatment
946358|NCT02275169|azoospermia nonobstructive
946359|NCT02275169|male infertility
946360|NCT02275169|follicle stimulating hormone
946361|NCT02275156|Subjects with normal renal function or severe renal impairment (RI) or end stage renal disease (ESRD) receiving hemodialysis
946362|NCT02275143|Computed Tomography of Thorax, Abdomen and Pelvis
946363|NCT02275143|cancer patients
946364|NCT02275143|coronary angiogram evaluation
946365|NCT02275130|glottic insufficiency
946366|NCT02275130|calcium hydroxyapatite
946367|NCT02275130|augmentation of vocal cords with injection technique
946368|NCT02275117|Migraine Disorders
946369|NCT02275117|ALD403
946370|NCT02275104|Ventricular arrhythmias
946371|NCT02275104|Persistent atrial fibrillation
946372|NCT02275104|Ablation guidance
946373|NCT02275104|Software
946374|NCT02275104|MRI (Magnetic resonance imaging)
946375|NCT02275091|Children
946376|NCT02275091|Cholesterol
946377|NCT02275078|COPD
946378|NCT02275078|Action Plan
946379|NCT02275078|Telesystem
946380|NCT02275078|New technology
946381|NCT02275065|HIV-1 Infected
946382|NCT02275065|Adults
946383|NCT02275065|Treatment Naive
946384|NCT02275052|shuttle walk test
946385|NCT02275052|umeclidinium
946386|NCT02275052|beta2-agonist
946387|NCT02275052|exercise endurance time
946388|NCT02275052|anticholinergic
946389|NCT02275052|combination product
946390|NCT02275052|vilanterol
946391|NCT02275052|exercise
946392|NCT02275052|COPD
946393|NCT02275026|General Anesthesia, Postoperative Delirium, Recovery
946394|NCT02274974|incisional
946395|NCT02274974|infiltration
946396|NCT02274974|cs
946397|NCT02274974|lidocaine
946398|NCT02274974|epinephrine
946399|NCT02274974|Adverse Reaction to Topical or Infiltrative Lidocaine
946400|NCT02274922|Campylobacter diagnosis,
946401|NCT02274922|immuno-chromatographic test, ELISA, PCR, culture, stool
946402|NCT02274922|ELISA,
946403|NCT02274922|PCR,
946404|NCT02274922|culture, stool
946405|NCT02274909|electromyography
946406|NCT02274909|aged
946407|NCT02274909|muscle strength
946408|NCT02274909|wavelet analysis
946409|NCT02274909|pilates
946410|NCT02274909|proprioceptive neuromuscular facilitation
946411|NCT02274857|FIRMap
946412|NCT02274857|Rotor
946413|NCT02274857|FIRM-guided procedure
946414|NCT02274857|REAFFIRM
946415|NCT02274805|Brown adipose tissue
946416|NCT02274805|Neck surgery
946417|NCT02274779|Prostate Cancer,Oligometastasis,Radiotherapy,Hormonotherapy
946418|NCT02274766|Levodopa-Induced Dyskinesia
946419|NCT02274766|LID
946420|NCT02274766|Parkinsonism
946421|NCT02274766|Parkinson's Disease
946422|NCT02274727|Biomarker
946423|NCT02274727|Stroke
946424|NCT02274727|Etiology
946425|NCT02274727|Outcome
946426|NCT02274675|Stroke
946427|NCT02274675|Robot-assisted therapy
946428|NCT02274675|Rehabilitation
946429|NCT02274623|Bone Neoplasms
946430|NCT02274623|Hypocalcemia
946431|NCT02274623|Hyperparathyroidism, Secondary
946432|NCT02274610|docetaxel
946433|NCT02274610|Pharmacokinetic
946434|NCT02274597|hypothermia
946435|NCT02274597|pre-hospital
946436|NCT02274597|epitympanic
946437|NCT02274597|temperature
946438|NCT02274584|Hodgkin's lymphoma
946439|NCT02274584|Anaplastic large cell lymphoma
946440|NCT02274584|CD30 positive lymphoma
946441|NCT02274584|Peripheral T/Natural Killer (NK) cell lymphoma
946442|NCT02274519|multiple myeloma
946443|NCT02274519|plasma cell disorder
946444|NCT02274519|autologous stem cell transplant
946445|NCT02274506|Blood And Marrow Transplantation
946446|NCT02274506|Leukemia
946447|NCT02274506|Lymphoma
946448|NCT02274506|CD19-specific T cells
946449|NCT02274506|Acute lymphoblastic leukemia
946450|NCT02274506|ALL
946451|NCT02274506|Biphenotypic leukemia
946452|NCT02274506|Non-Hodgkin's Lymphoma
946453|NCT02274506|NHL
946454|NCT02274506|Diffuse large B-cell lymphoma
946455|NCT02274506|Small lymphocytic lymphoma
946456|NCT02274506|Follicular lymphoma
946457|NCT02274506|Mantle cell lymphoma
946458|NCT02274506|Chronic lymphocytic leukemia
946459|NCT02274506|CLL
946460|NCT02274493|da Vinci® robotic surgical system
946461|NCT02274493|latissimus dorsi muscle flap harvest procedures
946462|NCT02274493|breast reconstruction
946463|NCT02274493|scalp reconstruction
946464|NCT02274493|upper extremity reconstruction
946465|NCT02274493|lower extremity reconstruction
946466|NCT02274480|MRI
946467|NCT02274480|Diffusion Weighted Imaging
946468|NCT02274480|14-191
946469|NCT02274467|Tsui Test
946470|NCT02274467|Labour
946471|NCT02274467|Epidural catheter
946472|NCT02274454|Uterine contraction
946473|NCT02274454|Oxytocin desensitization
946474|NCT02274428|intraventricular hemorrhage
946475|NCT02274415|Streptococcus pneumoniae
946476|NCT02274415|Sickle cell disease
946477|NCT02274415|Immunogenicity
946478|NCT02274415|Antibody response
946479|NCT02274402|Prednisone
946480|NCT02274402|Glucocorticoids
946481|NCT02274402|pharmacokinetics
946482|NCT02274389|Pulmonary Multi-drug Resistant Tuberculosis
946483|NCT02274389|Bedaquiline
946484|NCT02274389|Sirturo
946485|NCT02274389|Observational
946486|NCT02274389|Prospective
946487|NCT02274363|Psoriasis
946488|NCT02274363|Plaque
946489|NCT02274363|Chronic
946490|NCT02274350|prostate cancer
946491|NCT02274350|radiation therapy
946492|NCT02274350|sexual side effects
946493|NCT02274337|Epidermal Growth Factor Receptor
946494|NCT02274337|Tyrosine Kinase Inhibitor
946495|NCT02274337|T790M mutation
946496|NCT02274324|parkinson
946497|NCT02274324|duodopa
946498|NCT02274324|diet
946499|NCT02274324|proteins
946500|NCT02274324|amino acids
946501|NCT02274311|Acromegaly
946502|NCT02274311|SERM
946503|NCT02274311|Clomiphene
946510|NCT02274272|lactobacillus reuteri
946511|NCT02274272|type 2 diabetes
946512|NCT02274246|Segmentation
946513|NCT02274246|GIMIAS® program
946514|NCT02274246|Atrial fibrillation
946515|NCT02274246|Left atrial fibrosis
946516|NCT02274246|Healthy volunteers
946517|NCT02274233|Chelation
946518|NCT02274233|Iron Overload
946519|NCT02274233|Thalassemia
946520|NCT02274233|Transfusion
946521|NCT02274233|Iron Chelation
946522|NCT02274220|systemic inflammation
946523|NCT02274220|glucose metabolism
946524|NCT02274220|glucose-insulin ratio
946525|NCT02274207|Silver dressing
946526|NCT02274207|NPWT
946527|NCT02274207|DMF
946528|NCT02274207|foot
946529|NCT02274194|CPAP
946530|NCT02274194|Nasal mask
946531|NCT02274194|Oronasal mask
946532|NCT02274194|Mucociliary clearance
946533|NCT02274194|breathing route
946534|NCT02274155|Head and Neck Cancer
946535|NCT02274155|anti-OX40 antibody
946536|NCT02274155|MEDI6469
946537|NCT02274155|Immunotherapy
946538|NCT02274142|dentinal caries
946539|NCT02274142|occlusal
946540|NCT02274142|occluso-proximal
946541|NCT02274116|acute intermittent hypoxia
946542|NCT02274116|walking
946543|NCT02274116|spasticity
946544|NCT02274116|incomplete spinal cord injury
946545|NCT02274116|breathing
946546|NCT02274116|strength
946547|NCT02274090|Metformin
946548|NCT02274090|Pocket depth
946549|NCT02274090|moderate periodontitis
946550|NCT02274090|severe periodontitis
946551|NCT02274077|length of stay
946552|NCT02274077|nausea
946553|NCT02274077|emesis
946554|NCT02274077|bowel function
946555|NCT02274077|pain scores
946556|NCT02274077|narcotic pain medication
946557|NCT02274077|post operative period
946558|NCT02274064|Retention
946559|NCT02274064|Blood Donor Motivation
946560|NCT02274025|Patient diagnosed with lung cancer
946561|NCT02274012|Gastric
946562|NCT02274012|Gastroesophageal Junction
946563|NCT02274012|Gastroesophageal Cancer
946564|NCT02274012|Esophageal Cancer
946565|NCT02274012|Metastatic
946566|NCT02274012|HER2 amplified
946567|NCT02274012|Afatinib
946568|NCT02273999|pulsed electromagnetic fields
946569|NCT02273999|post operative morbidity
946570|NCT02273999|third molar
946571|NCT02273999|extraction
946572|NCT02273999|pain
946573|NCT02273986|Adult Volunteers
946574|NCT02273934|Home-based rehabilitation
946575|NCT02273934|Activities of daily living
946576|NCT02273934|Restorative care
946577|NCT02273934|Reablement
946578|NCT02273934|Everyday rehabilitation
946579|NCT02273921|Dementia, Diagnosis, Electroencephalography
946580|NCT02273908|Low-Back Pain
946581|NCT02273908|Neuropathic Pain
946582|NCT02273908|Pregabalin
946583|NCT02273895|Scopolamine, AD, EEG, MCI
946584|NCT02273882|RSV
946585|NCT02273882|RSVH
946586|NCT02273882|Infant
946587|NCT02273882|Gestational Age
946588|NCT02273882|wGA
946589|NCT02273882|PRETERM
946590|NCT02273856|Chronic Lymphocytic Leukaemia (CLL)
946591|NCT02273856|Indolent Non Hodgkin's Lymphoma (iNHL)
946592|NCT02273843|Preterm
946593|NCT02273843|late-onset sepsis
946594|NCT02273843|Vitamin D
946595|NCT02273843|Dose
946596|NCT02273843|Interleukin-6
946597|NCT02273843|Tumor necrosis factor-alpha
946598|NCT02273830|oxygen therapy
946599|NCT02273830|COPD
946600|NCT02273830|exercise
946601|NCT02273804|Topiramate
946602|NCT02273804|Obesity
946603|NCT02273804|Children
946604|NCT02273804|Adolescents
946605|NCT02273791|Frozen-thawed embryo transfer
946606|NCT02273791|FET protocols
946607|NCT02273739|solid tumor
946608|NCT02273739|intrahepatic cholangiocarcinoma
946609|NCT02273739|ICC
946610|NCT02273739|chondrosarcoma
946611|NCT02273739|angioimmunoblastic T-cell lymphoma
946612|NCT02273739|AITL
946613|NCT02273739|IDH
946614|NCT02273739|glioma
946615|NCT02273739|solid tumor, including intrahepatic cholangiocarcinoma and chondrosarcoma
946616|NCT02273726|Anemia
946617|NCT02273726|Chronic Kidney Disease
946618|NCT02273726|Dialysis
946619|NCT02273726|hemodialysis
946620|NCT02273726|peritoneal dialysis
946621|NCT02273726|hemoglobin
946622|NCT02273726|End stage renal disease
946623|NCT02273726|Stable Dialysis
946624|NCT02273726|erythropoietins
946625|NCT02273726|erythropoiesis stimulating agent
946626|NCT02273713|Esophageal cancer
946627|NCT02273713|Metastasized
946628|NCT02273713|Nab-paclitaxel
946629|NCT02273713|Toxicity
946630|NCT02273713|First line treatment
946631|NCT02273713|Phase Ib/II
946632|NCT02273700|Xarelto®
946633|NCT02273700|protein/peptide profiles
946634|NCT02273687|diaphragm movement
946635|NCT02273687|ultrasound
946636|NCT02273687|emergency room
946637|NCT02273674|Borderline Personality Disorder
946638|NCT02273674|Transcranial Magnetic Stimulation, Repetitive
946639|NCT02273648|national
946640|NCT02273648|multicenter
946641|NCT02273648|observational registry
946642|NCT02273648|Orsiro Drug Eluting Stent
946643|NCT02273648|Stenting Treatment of coronary artery disease
946644|NCT02273648|coronary revascularization
946645|NCT02273648|PCI
946646|NCT02273648|STEMI
946647|NCT02273648|NSTEMI
946648|NCT02273648|Ischemia
946649|NCT02273648|Angina
946650|NCT02273648|Acute Myocardial Infarction
946651|NCT02273648|Small Vessels
946652|NCT02273648|Chronic Total Occlusion
946653|NCT02273622|hydroxytyrosol
946654|NCT02273622|dietary supplement
946655|NCT02273622|gene expression regulation
946656|NCT02273609|Atrial fibrillation
946657|NCT02273609|Anticoagulation
946658|NCT02273609|Vitamin K antagonists
946659|NCT02273609|INR control
946660|NCT02273583|of the extremity
946661|NCT02273570|Hyperparathyroidism, Secondary
946662|NCT02273570|Anemia
946663|NCT02273570|Vascular Stiffness
946664|NCT02273570|Vascular Calcification
946665|NCT02273323|Flow mediated dilation
946666|NCT02273323|tea
946667|NCT02273323|blood pressure
946668|NCT02273297|Body composition
946669|NCT02273297|Body size
946670|NCT02273284|Pain, Pediatrics, Botulinum Toxin injections, Buzzy
946671|NCT02273271|FLT-PET
946672|NCT02273271|DWI-MRI
946673|NCT02273232|Peripheral Arterial Disease
946674|NCT02273232|Peripheral Vascular Disease
946675|NCT02273232|Claudication
946676|NCT02273232|Remote Ischemic Preconditioning
946677|NCT02273232|EQ-5D
946678|NCT02273232|Symptoms free distance
946679|NCT02273232|ABI
946680|NCT02273232|micro vessel formation
946681|NCT02273219|Uveal
946682|NCT02273219|Melanoma
946683|NCT02273219|Advanced uveal melanoma
946684|NCT02273206|Depression
946685|NCT02273206|Breast Cancer Screening
946686|NCT02273206|Cervical Cancer Screening
946687|NCT02273206|Colorectal Cancer Screening
946688|NCT02273154|major depressive disorder
946689|NCT02273154|Efficacy and safety of buspirone add-one treatment in patients with major depression disorder
946690|NCT02273154|buspirone
946691|NCT02273154|paroxetine
946692|NCT02273154|anxiety
946693|NCT02273128|Osteoporosis
946694|NCT02273128|Chronic Periodontitis
946695|NCT02273128|Calcitonin gene Polymorphism
946696|NCT02273115|induction
946697|NCT02273115|Foley catheter
946698|NCT02273115|oxytocin
946699|NCT02273102|Acute Myelogenous Leukemia
946700|NCT02273102|AML
946701|NCT02273102|Myelodysplastic Syndromes
946702|NCT02273102|MDS
946703|NCT02273102|Tranylcypromine
946704|NCT02273102|TCP
946705|NCT02273102|ATRA
946706|NCT02273102|Tretinoin
946707|NCT02273089|Obstructive sleep apnea
946708|NCT02273089|arterial stiffness
946709|NCT02273089|CPAP
946710|NCT02273089|excessive daytime sleepiness
946711|NCT02273089|pulse wave velocity
946712|NCT02273063|PTSD
946713|NCT02273063|MDD
946714|NCT02273063|TMS
946715|NCT02273063|5Hz
946716|NCT02273050|Type 2 Diabetes Mellitus, Dipeptidyl-Peptidase 4 Inhibitors, Saxagliptin, Metformin, Endocrine System Diseases
946717|NCT02273037|Labour
946718|NCT02273037|Birth asphyxia
946719|NCT02273037|Fetal Heart Rate Monitor
946720|NCT02273037|Doppler Fetal Heart Rate Monitor
946721|NCT02273037|Pinard Horn
946722|NCT02273037|Pediatrics
946723|NCT02273037|Uganda
946724|NCT02273024|Exercise
946725|NCT02273024|Quality of Life
946726|NCT02273024|Fatigue
946727|NCT02273024|Symptoms
946728|NCT02273024|Prehabilitation
946729|NCT02273024|Aerobic Capacity
946730|NCT02272998|FGFR, RET, KIT
946731|NCT02272985|cerebral blood flow
946732|NCT02272985|hemodialysis
946733|NCT02272972|"fluoroscopy[MeSH], education, medical[MeSH]"
946734|NCT02272959|Anxiety/Anxiety disorders, Clinical trials, treatment, cognition, computer/Internet technology
946735|NCT02272907|Bariatric Surgery
946736|NCT02272907|Laparoscopy
946737|NCT02272907|Weight Loss Surgery
946738|NCT02272907|Staple Line Reinforcement
946739|NCT02272894|Gastric Cancer
946740|NCT02272894|D2 Lymphadenectomy
946741|NCT02272894|Superior Mesenteric Vein Lymph Node
946742|NCT02272855|HF10
946743|NCT02272855|HSV-1
946744|NCT02272855|Ipilimumab
946745|NCT02272855|Oncolytic virus
946746|NCT02272855|Phase II
946747|NCT02272855|Stage IIIB melanoma
946748|NCT02272855|Stage IIIC melanoma
946749|NCT02272855|Stage IV melanoma
946750|NCT02272855|Unresectable malignant melanoma
946751|NCT02272855|Metastatic malignant melanoma
946752|NCT02272855|Combination treatment
946753|NCT02272855|Intratumoral injection
946754|NCT02272842|Nepal
946755|NCT02272842|Cobalamin
946756|NCT02272842|Neurodevelopment
946757|NCT02272842|Stunting
946758|NCT02272842|Growth
946759|NCT02272790|Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
946760|NCT02272777|Myelogenous
946761|NCT02272777|Chronic
946762|NCT02272777|BCR-ABL Positive
946763|NCT02272751|cancer survivorship
946764|NCT02272751|exercise
946765|NCT02272751|relaxation
946766|NCT02272751|mindfulness
946767|NCT02272725|ultramarathon
946768|NCT02272725|ibuprofen
946769|NCT02272725|acute kidney injury
946770|NCT02272725|exercise-associated hyponatremia
946771|NCT02272725|exertion
946772|NCT02272712|cancer survivor
946773|NCT02272712|computerized treatment
946774|NCT02272712|symptom management
946775|NCT02272699|Esophageal Squamous Cell Carcinoma
946776|NCT02272699|Nimotuzumab
946777|NCT02272699|Neoadjuvant treatment
946778|NCT02272686|Lymphoma
946779|NCT02272686|Blood And Marrow Transplantation
946780|NCT02272686|Post Autologous Stem Cell Transplantation
946781|NCT02272686|SCT
946782|NCT02272686|B-cell lymphoma
946783|NCT02272686|Ibrutinib
946784|NCT02272686|PCI-32765
946785|NCT02272686|Imbruvica
946786|NCT02272660|preemptive analgesia
946787|NCT02272660|parecoxib sodium
946788|NCT02272660|total knee arthroplasty
946789|NCT02272660|total hip arthroplasty
946790|NCT02272647|Normal Healthy Volunteers
946791|NCT02272634|COPD
946792|NCT02272595|Biologic Markers
946793|NCT02272595|Molecular testing
946794|NCT02272595|Advanced cancers
946795|NCT02272595|Molecular information
946796|NCT02272595|Molecular profiling
946797|NCT02272595|Genetic Mutation
946798|NCT02272569|glaucoma
946799|NCT02272569|glaucoma drainage device
946800|NCT02272569|glaucoma shunt
946801|NCT02272530|Endothelial NO-synthase
946802|NCT02272530|red blood cell
946803|NCT02272530|erythrocytes
946804|NCT02272530|Peripheral Blood Mononuclear Cell
946805|NCT02272530|cardiovascular disease
946806|NCT02272517|Vortioxetine
946807|NCT02272517|Cognition
946808|NCT02272504|HCC
946809|NCT02272504|AFP
946810|NCT02272504|AFP-L3
946811|NCT02272504|DCP
946812|NCT02272504|Surveillance
946813|NCT02272504|biomarkers
946814|NCT02272478|AML
946815|NCT02272478|MDS
946816|NCT02272465|pre-hospital resuscitation, helicopter, trauma
946817|NCT02272452|High resolution magic angle spinning Nuclear magnetic resonance
946818|NCT02272452|Nuclear magnetic resonance
946819|NCT02272452|Spectroscopy
946820|NCT02272452|Primary brain tumors
946821|NCT02272452|Gliomas
946822|NCT02272452|extemporaneous analysis
946823|NCT02272439|Bisphenol A
946824|NCT02272439|phthalates
946825|NCT02272439|infertility
946826|NCT02272439|human
946827|NCT02272426|Stroke
946828|NCT02272426|Exercise Training
946829|NCT02272426|Cognitive Training
946830|NCT02272426|Quality of Life
946831|NCT02272400|image guided radiation therapy
946832|NCT02272400|partial breast irradiation
946833|NCT02272400|breast cancer
946834|NCT02272400|breast
946835|NCT02272400|cancer
946836|NCT02272400|breast preservation
946837|NCT02272400|IGRT
946838|NCT02272400|PBI
946839|NCT02272374|Hemodialysis
946840|NCT02272374|Arteriovenous fistula
946841|NCT02272374|Tunneled cuffed catheter
946842|NCT02272374|Arteriovenous graft
946843|NCT02272374|Elderly
946844|NCT02272374|Very elderly
946845|NCT02272348|Therapeutic education
946846|NCT02272348|Functional insulin therapy
946847|NCT02272335|Breast Cancer
946848|NCT02272335|Health Disparities
946849|NCT02272335|Psychosocial Intervention
946850|NCT02272335|Cancer Survivors
946851|NCT02272322|Anterior prolapse
946852|NCT02272296|Injections, Jet
946853|NCT02272296|pharmacology
946854|NCT02272296|Insulin Aspart
946855|NCT02272296|Equipment and Supplies
946856|NCT02272283|PCI optimization
946857|NCT02272283|Coronary Remodeling
946858|NCT02272283|Drug-Eluting Stent
946859|NCT02272283|Optical Coherence Tomography
946860|NCT02272283|Intravascular Ultrasound
946861|NCT02272283|Strut Coverage
946862|NCT02272283|Strut Apposition
946863|NCT02272283|Vascular Healing Pattern
946864|NCT02272257|Musculoskeletal Pain
946865|NCT02272257|Physical Therapists
946866|NCT02272257|Drug Prescriptions
946867|NCT02272257|Humans
946868|NCT02272257|Physical Therapy Modalities
946869|NCT02272257|Referral and Consultation
946870|NCT02272257|Workers' Compensation
946871|NCT02272257|United States
946872|NCT02272257|Primary Care
946873|NCT02272257|Health Services Research
946874|NCT02272257|Triage
946875|NCT02272257|Acute
946876|NCT02272257|Cost
946877|NCT02272257|Occupational Health
946878|NCT02272244|Colorectal Cancer
946879|NCT02272244|Cancer Screening
946880|NCT02272244|Decision Support
946881|NCT02272244|Navigation
946882|NCT02272231|women's health
946883|NCT02272231|vaginosis, bacterial
946884|NCT02272231|african americans
946885|NCT02272205|Hip replacement
946886|NCT02272205|Knee replacement
946887|NCT02272205|Knee infection
946888|NCT02272205|Hip infection
946889|NCT02272205|Antibiotic prophylaxis
946890|NCT02272192|autism
946891|NCT02272192|autism spectrum disorder
946892|NCT02272192|intensive intervention
946893|NCT02272192|early intervention
946894|NCT02272192|Early Start Denver Model
946895|NCT02272179|adolescence
946896|NCT02272179|suicidality
946897|NCT02272179|depression
946898|NCT02272127|EGFR tyrosine kinase inhibitor
946899|NCT02272088|physical activity
946900|NCT02272088|energy expenditure
946901|NCT02272088|compensatory mechanisms
946902|NCT02272088|adolescent
946903|NCT02272075|screeening
946904|NCT02272062|Coronary artery disease
946905|NCT02272062|Angina
946906|NCT02272062|Shared decision-making
946907|NCT02272062|Patient preferences
946908|NCT02272062|Percutaneous coronary intervention
946909|NCT02272062|Coronary artery bypass graft
946910|NCT02272049|Respiratory
946911|NCT02272036|Colonoscopy
946912|NCT02272036|Colonoscopy preparation
946913|NCT02272036|screening
946914|NCT02272036|New media
946915|NCT02272036|SMS
946916|NCT02272036|Short message service
946917|NCT02272023|alcohol
946918|NCT02272023|women
946919|NCT02272023|motivational interviewing
946920|NCT02271984|Healthy
946921|NCT02271984|Praziquantel
946922|NCT02271984|L-PZQ
946923|NCT02271984|PZQ
946924|NCT02271984|MSC2499550A
946925|NCT02271984|Bioavailability
946926|NCT02271984|Pharmacokinetics
946927|NCT02271971|Psoriasis
946928|NCT02271971|Vitamin D
946929|NCT02271971|Metabolic syndrome
946930|NCT02271971|Insulin resistance
946931|NCT02271971|Cholesterol
946932|NCT02271971|Methotrexate
946933|NCT02271971|Dyslipidemia
946934|NCT02271971|PASI
946935|NCT02271971|Psoriasis Area Severity Index
946936|NCT02271958|Mifepristone
946937|NCT02271958|Endometriosis
946938|NCT02271945|aggressive lymphoma, DLBCL, NHL
946939|NCT02271932|appendicitis
946940|NCT02271932|non-operative management
946941|NCT02271932|children
946942|NCT02271932|pediatric
946943|NCT02271919|Cancer Prevention
946944|NCT02271919|Tobacco Use Cessation
946945|NCT02271919|Nicotine replacement therapy
946946|NCT02271919|NRT
946947|NCT02271919|Varenicline
946948|NCT02271919|Chantix
946949|NCT02271919|Nicotine lozenge
946950|NCT02271919|Placebo tablet
946951|NCT02271919|Placebo patch
946952|NCT02271919|Questionnaire
946953|NCT02271919|Survey
946954|NCT02271919|Counseling
946955|NCT02271906|Lung Cancer
946956|NCT02271906|Non small cell lung cancer
946957|NCT02271906|NSCLC
946958|NCT02271906|Adenocarcinoma
946959|NCT02271906|Squamous cell carcinoma
946960|NCT02271906|BIBW 2992
946961|NCT02271906|Afatinib
946962|NCT02271893|Chemotherapy-induced peripheral neuropathy
946963|NCT02271880|Medication nonadherence
946964|NCT02271802|Butyrate
946965|NCT02271802|Interorgan metabolism
946966|NCT02271802|Short-chain fatty acids
946967|NCT02271802|Gut production
946968|NCT02271776|Insulin Sensitivity
946969|NCT02271763|cricothyroid membrane
946970|NCT02271763|ultrasound
946971|NCT02271750|IGF, Neurotrophic factors, Dementia, spinal fluid
946972|NCT02271737|Newborn
946973|NCT02271737|infection
946974|NCT02271737|community health
946975|NCT02271724|CIDP
946976|NCT02271724|MMN
946977|NCT02271724|Spinal fluid
946978|NCT02271724|CD163
946979|NCT02271724|CD19
946980|NCT02271711|Brain Cancer
946981|NCT02271711|Brain tumor
946982|NCT02271711|Recurrent posterior fossa tumors
946983|NCT02271711|Central nervous system
946984|NCT02271711|CNS
946985|NCT02271711|Artificial antigen- presenting cells
946986|NCT02271711|aAPC
946987|NCT02271711|Natural killer cells
946988|NCT02271711|NK
946989|NCT02271711|Ommaya reservoir
946990|NCT02271698|Knee arthroplasty
946991|NCT02271698|Dexamethasone
946992|NCT02271698|Acute pain
946993|NCT02271698|Chronic pain
946994|NCT02271685|Diagnostic Information
946995|NCT02271685|Risk Perception
946996|NCT02271659|Prostate
946997|NCT02271659|external beam radiotherapy
946998|NCT02271659|brachytherapy boost
946999|NCT02271659|economical evaluation
947000|NCT02271646|paravertebral block
947001|NCT02271646|ultrasound guided
947002|NCT02271633|Nitrate
947003|NCT02271633|Bioavailability
947004|NCT02271633|Sports
947005|NCT02271620|1 prevalence
947006|NCT02271620|2 children
947007|NCT02271620|3 local allergic rhinitis
947008|NCT02271607|moxibustion
947009|NCT02271555|electroconvulsive therapy
947010|NCT02271555|sevoflurane
947011|NCT02271555|remifentanil
947012|NCT02271542|Propofol
947013|NCT02271542|Polymorphism
947014|NCT02271542|UGT1A9
947015|NCT02271542|CYP2B6
947016|NCT02271529|Peripheral Vascular Disease
947017|NCT02271529|Femoral Artery
947018|NCT02271529|Drug-Eluting Stent
947019|NCT02271490|Assisted Reproductive Technique
947020|NCT02271490|ICSI
947021|NCT02271490|Acrosome Reaction
947022|NCT02271490|Pregnancy outcome
947023|NCT02271477|Fluid replacement
947024|NCT02271477|Trans-Thoracic Echocardiography
947025|NCT02271477|Spinal Anesthesia
947026|NCT02271477|Empirical Volemic Repletion
947027|NCT02271464|Metastatic colorectal cancer
947028|NCT02271464|Ist line therapy
947029|NCT02271464|metronimic therapy
947030|NCT02271464|bevacizumab
947031|NCT02271451|concussion
947032|NCT02271438|Healthy
947033|NCT02271438|Ibrutinib
947034|NCT02271438|Moxifloxacin
947035|NCT02271438|Cardiac Repolarization
947036|NCT02271438|Electrocardiogram
947037|NCT02271438|QTc interval
947038|NCT02271399|venous thromboembolism
947039|NCT02271399|total knee arthroplasty
947040|NCT02271386|Evidence-Based Practice
947041|NCT02271386|Provider Education
947042|NCT02271373|Vision, Ocular
947043|NCT02271373|Physical activity
947044|NCT02271373|Schoolchildren
947045|NCT02271373|Intervention Studies
947046|NCT02271360|infertility ICSI OHSS Calcium Dobesilate Cabergoline
947047|NCT02271334|Asthma
947048|NCT02271334|Albuterol
947049|NCT02271321|dementia
947050|NCT02271321|white noise
947051|NCT02271321|agitation
947052|NCT02271321|saliva cortisol
947053|NCT02271308|elastic band resistance training
947054|NCT02271308|nursing home residents
947055|NCT02271308|muscle strength
947056|NCT02271308|flexibility
947057|NCT02271308|quality of life
947058|NCT02271308|ease of care
947059|NCT02271295|Cirrhosis
947060|NCT02271295|Child B
947061|NCT02271295|decompensation
947062|NCT02271295|mortality
947063|NCT02271295|portal thrombosis
947064|NCT02271295|anticoagulation
947065|NCT02271269|glaucoma
947066|NCT02271269|medication adherence
947067|NCT02271269|financial incentives
947068|NCT02271269|behavioral economics
947069|NCT02271256|Functional intimate apparel
947070|NCT02271256|Adolescent Idiopathic scoliosis
947071|NCT02271243|Central line-associated bloodstream infections
947072|NCT02271243|mucosal barrier injury
947073|NCT02271243|laboratory-confirmed bloodstream infection
947074|NCT02271217|Post stroke
947075|NCT02271217|Ischemic stroke
947076|NCT02271126|ECMO
947077|NCT02271126|Heparin
947078|NCT02271126|Thromboelastography
947079|NCT02271126|Bleeding complications
947080|NCT02271074|HIV
947081|NCT02271074|Care
947082|NCT02271074|Treatment
947083|NCT02271074|Retention
947084|NCT02271074|Implementation Science
947085|NCT02271048|telemedicine
947086|NCT02271048|ultrasonography
947087|NCT02271048|echocardiography
947088|NCT02271035|VUR
947089|NCT02271022|ACS, Acute Coronary Syndromes
947090|NCT02271022|NSTEMI
947091|NCT02271022|MI, Myocardial Infarction
947092|NCT02270996|antibiotic, antimicrobial, stewardship, child
947093|NCT02270983|Opioid-Induced Constipation
947094|NCT02270983|Linaclotide
947095|NCT02270983|Linzess
947096|NCT02270944|Group B Strep
947097|NCT02270944|GBS
947098|NCT02270944|vaccine comparability
947099|NCT02270918|Xa inhibitor
947100|NCT02270918|Prothrombin complex concentrate
947101|NCT02270918|anticoagulation
947102|NCT02270905|meniscus
947103|NCT02270905|meniscectomy
947104|NCT02270905|decellularised
947105|NCT02270905|xenograft
947106|NCT02270892|Ulthera, Ulthera System, Ultherapy
947107|NCT02270866|aphasia
947108|NCT02270866|stroke
947109|NCT02270853|ApneaLink
947110|NCT02270853|bronchial carcinoma
947111|NCT02270853|sleep apnea screening
947112|NCT02270840|cardiac resynchronization therapy
947113|NCT02270801|recombinant human thrombopoietin
947114|NCT02270801|immune thrombocytopenia
947115|NCT02270801|pregnancy
947116|NCT02270775|Questionnaire
947117|NCT02270775|Translation
947118|NCT02270762|Early Physical Exercise
947119|NCT02270762|Early Passive Exercise
947120|NCT02270762|Alveolar Recruitment
947121|NCT02270762|Electrical Impedance Tomography
947122|NCT02270762|Oxygenation
947123|NCT02270762|Ventilation
947124|NCT02270684|Total Knee Arthroplasty
947125|NCT02270684|Home monitoring
947126|NCT02270671|Social Anxiety
947127|NCT02270671|Social Phobia
947128|NCT02270671|Depression
947129|NCT02270671|Attention Bias Modification Training
947130|NCT02270658|continuous positive airway pressure
947131|NCT02270658|hypertension
947132|NCT02270658|sleep apnea
947133|NCT02270606|Rectum
947134|NCT02270541|Telemedicine
947135|NCT02270541|Prehospital
947136|NCT02270541|Emergency Medicine
947137|NCT02270541|Stroke
947138|NCT02270515|Patient-Centered Care
947139|NCT02270515|Medical Home
947140|NCT02270502|critically illness
947141|NCT02270502|intensive care unit
947142|NCT02270502|outcome
947143|NCT02270502|frailty
947144|NCT02270476|Cystic Fibrosis
947145|NCT02270476|Infant
947146|NCT02270476|Toddler
947147|NCT02270476|Children
947148|NCT02270476|Newborn screening
947149|NCT02270437|total knee arthroplasty
947150|NCT02270437|cocktail analgesia
947151|NCT02270437|morphine consumption
947152|NCT02270424|Pulmonary Disease, Chronic Obstructive
947153|NCT02270424|Medicine, Chinese Traditional
947154|NCT02270424|Humans
947155|NCT02270424|Treatment Outcome
947156|NCT02270398|Exercise
947157|NCT02270398|Balance
947158|NCT02270398|Gait
947159|NCT02270398|Community
947160|NCT02270398|Rehabilitation
947161|NCT02270398|Dual-task
947162|NCT02270385|pressure ulcer
947163|NCT02270385|nursing home
947164|NCT02270372|Advanced breast carcinoma
947165|NCT02270372|Advanced ovarian carcinoma
947166|NCT02270372|MUC1
947167|NCT02270372|vaccine
947168|NCT02270372|Phase 1b
947169|NCT02270359|Myocardial Infarction
947170|NCT02270359|CAD
947171|NCT02270346|Allogeneic HSCT, Inspiratory Muscle Training, Exercise Capacity
947172|NCT02270333|sarcoidosis
947173|NCT02270333|inspiratory muscle strength
947174|NCT02270333|exercise capacity
947175|NCT02270333|quality of life
947176|NCT02270320|Tai Chi Chuan
947177|NCT02270320|cognitive function
947178|NCT02270320|motor function
947179|NCT02270320|MRI
947180|NCT02270294|Ischemic stroke
947181|NCT02270294|Thai traditional massage
947182|NCT02270294|Vascular function
947183|NCT02270294|Cerebral blood flow
947436|NCT02269150|Recipients
947184|NCT02270294|Cerebrovascular reactivity
947185|NCT02270268|Irritable bowel syndrome
947186|NCT02270268|Gut microbiota
947187|NCT02270268|Soluble dietary fiber
947188|NCT02270255|embolization
947189|NCT02270255|analgesia
947190|NCT02270242|PCI
947191|NCT02270242|DAPT
947192|NCT02270242|ticagrelor
947193|NCT02270242|aspirin
947194|NCT02270216|isolated systolic hypertension
947195|NCT02270216|exercise pressor responses
947196|NCT02270203|si joint
947197|NCT02270203|si joint injury
947198|NCT02270203|si joint treatment
947199|NCT02270203|si joint inflammation
947200|NCT02270203|si joint problems
947201|NCT02270203|si joint symptoms
947202|NCT02270203|hypermobile joint
947203|NCT02270203|si joint arthritis
947204|NCT02270203|si joint pain treatment
947205|NCT02270203|inflamed si joint
947206|NCT02270203|si joint sclerosis
947207|NCT02270203|locked si joint
947208|NCT02270203|si joint injuries
947209|NCT02270203|si joint disease
947210|NCT02270203|si joint infection
947211|NCT02270203|sacroiliac joint pelvic pain
947212|NCT02270203|sacroiliac joint arthritis treatment
947213|NCT02270203|si joint pain
947214|NCT02270203|si joint injections
947215|NCT02270177|Headache
947216|NCT02270177|Telemedicine
947217|NCT02270177|Videoconsultation
947218|NCT02270177|Headache-referrals
947219|NCT02270164|Lipids
947220|NCT02270164|Cholesterol
947221|NCT02270164|Dietary Supplements
947222|NCT02270164|Cynara scolymus
947223|NCT02270164|Safety
947224|NCT02270151|Atrial fibrillation
947225|NCT02270151|Screening
947226|NCT02270151|Primary care
947227|NCT02270151|Diagnostic
947228|NCT02270138|physical activity
947229|NCT02270138|music
947230|NCT02270138|sedentary lifestyle
947231|NCT02270125|nasal mucosa
947232|NCT02270125|chronic hypertrophic rhinosinusitis
947233|NCT02270125|mucotomy
947234|NCT02270125|nanoparticles
947235|NCT02270125|scanning electron microscopy
947236|NCT02270125|Raman microspectroscopy
947237|NCT02270125|nasal polyposis
947238|NCT02270112|atrial fibrillation
947239|NCT02270112|atrial electrophysiology
947240|NCT02270112|stroke
947241|NCT02270112|vascular stiffness
947242|NCT02270073|Psychotherapy process
947243|NCT02270073|Change mechanisms
947244|NCT02270073|Mindfulness
947245|NCT02270073|Micro-interventions
947246|NCT02270073|Mindfulness interventions
947247|NCT02270073|Progressive muscle relaxation
947248|NCT02270060|Music Therapy
947249|NCT02270060|Sickle Cell Disease
947250|NCT02270060|Pain
947251|NCT02270047|Ad libitum energy intake
947252|NCT02270047|Appetite sensation
947253|NCT02270021|Pap smear
947254|NCT02270021|Screening
947255|NCT02270021|Women
947256|NCT02270021|Human papillomavirus
947257|NCT02270021|Cervical precancer
947258|NCT02270021|Guideline adherence
947259|NCT02270008|anal incontinence
947260|NCT02270008|pregnancy-associated pelvic floor disorders
947261|NCT02269995|Hepatocellular
947262|NCT02269995|Carcinoma
947263|NCT02269969|Aminoglycoside
947264|NCT02269969|Pharmacokinetics
947265|NCT02269969|Once daily dosing
947266|NCT02269943|Metastatic nasopharyngeal carcinoma
947267|NCT02269943|oral azacitidine
947268|NCT02269943|oral AZA
947269|NCT02269943|CC-486
947270|NCT02269943|metastatic
947271|NCT02269943|recurrent
947272|NCT02269943|nasopharyngeal carcinoma
947273|NCT02269943|nasal
947274|NCT02269943|solid tumors
947275|NCT02269943|locally advanced
947276|NCT02269943|rare head and neck cancer
947277|NCT02269943|nasopharynx
947278|NCT02269943|single chemotherapy agent
947279|NCT02269943|Epstein-Barr Virus (EBV) + nasopharyngeal carcinoma
947280|NCT02269943|EBV-DN
947281|NCT02269943|Celgene
947282|NCT02269943|Sponsor-study
947283|NCT02269943|oral chemotherapy
947284|NCT02269943|phase 2
947285|NCT02269943|oral Vidaza
947286|NCT02269943|EBV promoter methylation
947287|NCT02269943|hypomethylation
947288|NCT02269943|tumor infiltrating lymphocytes (TILs)
947289|NCT02269943|EBV gene expression
947290|NCT02269943|neoplasms
947291|NCT02269917|Human Immunodeficiency Virus Type 1
947292|NCT02269917|Emerald
947293|NCT02269917|Darunavir
947294|NCT02269917|Cobicistat
947295|NCT02269917|Emtricitabine
947296|NCT02269917|Tenofovir Alafenamide
947297|NCT02269891|Menopausal symptoms
947298|NCT02269891|Peri-menopause
947299|NCT02269891|Nu Femme
947300|NCT02269891|Labisia pumila
947301|NCT02269891|Eurycoma longifolia
947302|NCT02269891|Hot flash
947303|NCT02269891|Joint pain
947304|NCT02269852|seasonal trivalent inactivated influenza vaccine
947305|NCT02269852|immunogenicity
947306|NCT02269852|safety
947307|NCT02269852|cross-reactivity
947308|NCT02269852|Northern hemisphere 2013-2014 formulation
947309|NCT02269839|Tinnitus
947310|NCT02269839|rTMS
947311|NCT02269813|MammaPrint
947312|NCT02269813|BluePrint
947313|NCT02269813|TargetPrint
947314|NCT02269774|Atrial Fibrillation
947315|NCT02269774|Obstructive Sleep Apnea
947316|NCT02269774|Atrial Premature Complexes
947317|NCT02269774|Pulmonary Vein Isolation
947318|NCT02269774|Mueller Manoeuvre
947319|NCT02269761|Emergency Departments
947320|NCT02269761|Chest
947321|NCT02269761|Lung
947322|NCT02269761|Cough
947323|NCT02269761|Dyspnea
947324|NCT02269761|Wheezing
947325|NCT02269761|Ultrasound
947326|NCT02269761|Ultrasonography
947327|NCT02269657|Scoliosis
947328|NCT02269657|Postural balance
947329|NCT02269657|Lordosis
947330|NCT02269657|Kyphosis
947331|NCT02269657|X-rays
947332|NCT02269631|Weight loss
947333|NCT02269631|Epidemiology
947334|NCT02269631|Nutrition
947335|NCT02269618|Telehealth, Home-based, rehabilitation
947336|NCT02269605|HIV reservoir
947337|NCT02269605|Bryostatin
947338|NCT02269592|MGUS
947339|NCT02269592|Smoldering Myeloma
947340|NCT02269592|Chronic Lymphocytic leukemia
947341|NCT02269592|Acute Myeloid Leukemia
947342|NCT02269592|Myeloproliferative neoplasms
947343|NCT02269592|Waldenstrom Macroglobulinemia
947344|NCT02269592|Monoclonal Gammopathy of Undermined Significance
947345|NCT02269592|Monoclonal B cell lymphocytosis
947346|NCT02269592|Smoldering Multiple Myeloma
947347|NCT02269592|Myelodysplastic syndromes
947348|NCT02269579|Newly Diagnosed AML
947349|NCT02269579|Secondary AML
947350|NCT02269579|Relapsed/Refractory AML
947351|NCT02269579|Relapsed/Refractory ALL
947352|NCT02269566|allergic rhinitis
947353|NCT02269566|immunotherapy
947354|NCT02269553|Migraine
947355|NCT02269553|Headache
947356|NCT02269514|adoption
947357|NCT02269514|electronic cigarettes
947358|NCT02269514|e-cigarettes
947359|NCT02269514|combustible cigarettes
947360|NCT02269514|nicotine polacrilex
947361|NCT02269514|own brand cigarette
947362|NCT02269514|subjective measures
947363|NCT02269514|pharmacokinetics
947364|NCT02269514|pharmacodynamics
947365|NCT02269488|Safety
947366|NCT02269488|Tolerability
947367|NCT02269488|MEDI3250
947368|NCT02269488|Japanese children
947369|NCT02269475|Efficacy
947370|NCT02269475|Safety
947371|NCT02269475|Tolerability
947372|NCT02269475|MEDI3250
947373|NCT02269475|Japanese children
947374|NCT02269449|transradial intervention
947375|NCT02269449|radial artery
947376|NCT02269410|Bariatric Surgery
947377|NCT02269410|Nitrogen Balance
947378|NCT02269410|Body composition
947379|NCT02269410|Protein supplementation
947380|NCT02269410|Satiety
947381|NCT02269410|Adherence
947382|NCT02269397|Epilepsy
947383|NCT02269397|Seizures
947384|NCT02269397|Diagnosis
947385|NCT02269397|Diagnostic
947386|NCT02269397|Inflammation
947387|NCT02269384|Pain
947388|NCT02269384|Memory
947389|NCT02269384|Pressure Pain Threshold
947390|NCT02269384|Electromyography
947391|NCT02269384|Heart Rate Variability
947392|NCT02269319|ABSSSI
947393|NCT02269319|MRX-I
947394|NCT02269319|Acute Bacterial Skin and Skin Structure Infections
947395|NCT02269306|PCOS
947396|NCT02269306|clomiphene citrate
947397|NCT02269306|AMH
947398|NCT02269306|visceral fat area
947399|NCT02269306|HOMA-IR
947400|NCT02269293|Selinexor (KPT-330)
947401|NCT02269293|Paclitaxel
947402|NCT02269293|Carboplatin
947403|NCT02269293|14-110
947404|NCT02269280|Leukemia
947405|NCT02269280|Myelodysplastic syndrome
947406|NCT02269280|MDS
947407|NCT02269280|Low or intermediate-1 risk
947408|NCT02269280|Transfusion-dependent
947409|NCT02269280|Transfusion-independent
947410|NCT02269280|Best supportive care
947411|NCT02269280|BSC
947412|NCT02269280|Azacitidine
947413|NCT02269280|5-Azacytidine
947414|NCT02269280|5-AZA
947415|NCT02269280|Vidaza
947416|NCT02269280|5-AZC
947417|NCT02269280|AZA-CR
947418|NCT02269280|Ladakamycin
947419|NCT02269280|NSC-102816
947420|NCT02269280|Azacytidine
947421|NCT02269280|Decitabine
947422|NCT02269280|Dacogen
947423|NCT02269254|Comparative Study
947424|NCT02269254|Knee Prosthesis
947425|NCT02269254|Prosthesis Design
947426|NCT02269254|Treatment Outcome
947427|NCT02269254|Follow-Up Studies
947428|NCT02269254|Arthroplasty, Replacement, Knee/methods
947429|NCT02269241|contraception
947430|NCT02269241|hormonal oral contraceptive agents
947431|NCT02269241|hormonal oral contraceptive
947432|NCT02269241|oral contraceptive
947433|NCT02269241|drospirenone
947434|NCT02269241|LF111
947435|NCT02269241|birth control
947437|NCT02269150|Transplantation
947438|NCT02269137|status epileptics
947439|NCT02269137|prognosis
947440|NCT02269137|risk factor
947441|NCT02269137|outcome
947442|NCT02269098|type 2 diabetes
947443|NCT02269098|hyperglycemia
947444|NCT02269098|Emergency Department
947445|NCT02269098|Patient Education as Topic
947446|NCT02269098|Drug Therapy
947447|NCT02269085|Lymphoma
947448|NCT02269085|Mantle cell lymphoma
947449|NCT02269085|MCL
947450|NCT02269085|Relapsed or refractory
947451|NCT02269085|Ibrutinib
947452|NCT02269085|PCI-32765
947453|NCT02269085|Imbruvica
947454|NCT02269085|Carfilzomib
947455|NCT02269072|Natriuretic Peptide
947456|NCT02269046|acupuncture
947457|NCT02269046|moxibustion
947458|NCT02269046|hyperlipidemias
947459|NCT02269046|effectiveness
947460|NCT02269033|Breast cancer
947461|NCT02269033|Patient Navigation
947462|NCT02269033|Health Disparities
947463|NCT02269033|Latinas
947464|NCT02269033|Breast Imaging Reporting and Data System, BI-RADS
947465|NCT02269033|underserved
947466|NCT02269020|Squamous Cell Carcinoma of the Epi-larynx
947467|NCT02269007|safety, tolerance, quadrivalent influenza vaccine
947468|NCT02268994|ferric citrate
947469|NCT02268994|Chronic kidney disease
947470|NCT02268994|Anemia
947471|NCT02268981|Oxymizer
947472|NCT02268981|Oxygen conserving device
947473|NCT02268981|Conventional nasal cannula (CNC)
947474|NCT02268981|Idiopathic pulmonary fibrosis
947475|NCT02268968|Topical Lidocaine
947476|NCT02268968|Nasal CPAP
947477|NCT02268968|Pain
947478|NCT02268968|Preterm Infants
947479|NCT02268968|Salivary cortisol
947480|NCT02268955|Biliary Colic
947481|NCT02268955|Abdominal pain
947482|NCT02268955|Intravenous Ibuprofen
947483|NCT02268916|diabetes
947484|NCT02268916|physical activity
947485|NCT02268916|participation
947486|NCT02268903|Pulmonary Embolism
947487|NCT02268903|Right Ventricle failure
947488|NCT02268903|Diuretics
947489|NCT02268890|Multiple Myeloma
947490|NCT02268890|Bortezomib
947491|NCT02268890|Velcade
947492|NCT02268877|ultrasonography
947493|NCT02268877|emergency department
947494|NCT02268864|Hepatitis C Chronic
947495|NCT02268864|Simeprevir
947496|NCT02268864|Daclatasvir
947497|NCT02268851|Mantle Cell Lymphoma
947498|NCT02268851|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
947499|NCT02268838|E6007
947500|NCT02268838|Healthy Japanese male subjects
947501|NCT02268812|Pain Management
947502|NCT02268812|Europe
947503|NCT02268812|Intrathecal
947504|NCT02268799|Cardioversion
947505|NCT02268799|High Sensitivity Troponin T (Hs-Trop T)
947506|NCT02268799|Brain Natriuretic Peptide (BNP)
947507|NCT02268799|Neutrophil Gelatinase-associated Lipocalin (NGAL)
947508|NCT02268786|Preimplantation Genetic Screening
947509|NCT02268786|Blastocyst
947510|NCT02268786|Vitrification
947511|NCT02268786|In vitro fertilization
947512|NCT02268786|non-invasive prenatal testing
947513|NCT02268786|next generation sequencing
947514|NCT02268747|skin squamous cell cancer panHER inhibitor Dacomitinib
947515|NCT02268734|Sporadic Medullary Thyroid Cancer Vandetanib miRNA
947516|NCT02268721|Pilot study
947517|NCT02268721|Frail elderly
947518|NCT02268721|Malnutrition
947519|NCT02268721|Functionality
947520|NCT02268721|Life quality
947521|NCT02268721|Health care technology
947522|NCT02268708|COPD
947523|NCT02268708|Surgery, Thoracic
947524|NCT02268695|Recurrent/Metastatic HNSCC
947525|NCT02268695|Taxanes
947526|NCT02268682|Educator-Guided
947527|NCT02268682|Patient-Guided
947528|NCT02268682|Standard of Care (Control)
947529|NCT02268669|primary angioplasty
947530|NCT02268669|post-thrombolysis angioplasty
947531|NCT02268669|ST elevation acute myocardial infarction
947532|NCT02268643|breast cancer
947533|NCT02268643|screening
947534|NCT02268643|ultrasound
947535|NCT02268643|risk model
947536|NCT02268630|Post-thrombotic syndrome
947537|NCT02268630|Chronic thromboembolic pulmonary hypertension
947538|NCT02268630|Anticoagulation
947539|NCT02268630|Rivaroxaban
947540|NCT02268617|Treadmill
947541|NCT02268617|Walking
947542|NCT02268617|Gait
947543|NCT02268617|Exercise
947544|NCT02268578|Transcranial Direct Current Stimulation
947545|NCT02268578|TDCS
947546|NCT02268578|Memory Dysfunction
947547|NCT02268578|Depression
947548|NCT02268565|sleep, insomnia, inflammation, pain
947549|NCT02268565|Insomnia symptom induction/placebo
947550|NCT02268565|Insomnia symptom induction/aspirin
947551|NCT02268552|Type 1 Spinal Muscular Atrophy
947552|NCT02268539|pilot study
947553|NCT02268539|atrial fibrillation
947554|NCT02268539|ablation
947555|NCT02268539|implanted loop recorder
947556|NCT02268526|Safety, efficacy, pharmacokinetics, CSJ148, HCMV, HCMV viral load,
947557|NCT02268526|immunogenicity
947558|NCT02268513|Cardiovascular Disease
947559|NCT02268513|Social network
947560|NCT02268513|South Asians
947561|NCT02268487|Early Improvement
947562|NCT02268487|Depression
947563|NCT02268487|Antidepressant
947564|NCT02268474|532nm
947565|NCT02268474|Excel V
947566|NCT02268474|Cutera
947567|NCT02268474|Laser
947568|NCT02268474|Laser Light
947569|NCT02268474|PDL
947570|NCT02268474|595nm
947571|NCT02268474|Flash Lamp
947573|NCT02268448|itch atopic dermatitis
947574|NCT02268422|Healthy volunteer
947575|NCT02268422|crossover
947576|NCT02268422|open-label
947577|NCT02268422|randomised
947578|NCT02268422|bioequivalence
947579|NCT02268422|pharmacokinetic study
947580|NCT02268357|Dental Anxiety
947581|NCT02268357|Tooth Extraction
947582|NCT02268357|Propranolol
947583|NCT02268344|nerve regeneration
947584|NCT02268344|spinal accessory nerve
947585|NCT02268344|shoulder function
947586|NCT02268344|head neck cancer
947587|NCT02268344|electrical stimulation
947588|NCT02268318|Japanese Subjects, High LDL-C, fermented-dairy products, phytosterols
947589|NCT02268292|Metabolic syndrome
947590|NCT02268292|Diabetes
947591|NCT02268292|Muscle strength
947592|NCT02268292|Aerobic exercise
947593|NCT02268292|Bicycle
947594|NCT02268292|Brain-derived neurotrophic factor
947595|NCT02268266|brain injury, early rehabilitation, tilt table
947596|NCT02268214|Dapagliflozin
947597|NCT02268214|Efficacy
947598|NCT02268214|Safety
947599|NCT02268214|Add on to insulin
947600|NCT02268214|Oral Antidiabetic
947601|NCT02268214|Type 1 diabetes
947602|NCT02268201|immunosuppressive therapy
947603|NCT02268201|tacrolimus
947604|NCT02268188|Cancer Survivors
947605|NCT02268175|prostate adenocarcinoma
947606|NCT02268175|advanced prostate cancer
947607|NCT02268175|high risk prostate cancer
947608|NCT02268162|Lung Neoplasms
947609|NCT02268162|Bronchoscopy
947610|NCT02268162|Virtual Bronchoscopic Navigation(VBN)
947611|NCT02268162|Fluoroscopy
947612|NCT02268162|Endobronchial Ultrasonography with a Guide Sheath(EBUS-GS)
947613|NCT02268162|Diagnosis
947614|NCT02268123|Male Infertility
947615|NCT02268123|Sperm DNA Fragmentation
947616|NCT02268123|Sperm Abnormality
947617|NCT02268110|diastasis recti
947618|NCT02268110|physiotherapy
947619|NCT02268110|exercise therapy
947620|NCT02268110|abdominal binding
947621|NCT02268097|patella
947622|NCT02268097|total knee arthroplasty
947623|NCT02268097|resection
947624|NCT02268084|PTSD
947625|NCT02268084|TMS
947626|NCT02268084|EEG
947627|NCT02268071|Hypertension
947628|NCT02268071|Stopping antihypertensive treatment
947629|NCT02268071|Primary care
947630|NCT02268071|White coat hypertension
947631|NCT02268071|Masked Hypertension
947632|NCT02268045|Non-Hodgkin Lymphoma
947633|NCT02268045|DLBCL
947634|NCT02268045|Diffuse large b-cell lymphoma
947635|NCT02268032|hormone replacement therapy
947636|NCT02268019|hypospadias
947637|NCT02268019|dehiscence
947638|NCT02268019|urethral stricture
947639|NCT02268019|side effects
947640|NCT02268006|rectal carcinoma
947641|NCT02268006|preoperative radiochemotherapy
947642|NCT02268006|IMRT
947643|NCT02268006|SIB
947644|NCT02267980|Electroconvulsive therapy; sevoflurane; ketamine
947645|NCT02267954|Calories
947646|NCT02267954|Fast Food Literacy
947647|NCT02267928|Symptom Assessment
947648|NCT02267915|Relapsed or refractory patients with mantle-cell lymphoma
947649|NCT02267915|Progression after high-dose chemotherapy and autologous HPT
947650|NCT02267902|Volunteers
947651|NCT02267889|Ganglionated plexi
947652|NCT02267850|Photobiomodulation
947653|NCT02267850|Orthodontic treatment
947654|NCT02267850|Malocclusion
947655|NCT02267850|OrthoPulse™
947656|NCT02267837|Alignment phase
947657|NCT02267837|Photobiomodulation
947658|NCT02267837|Orthodontic treatment
947659|NCT02267837|Malocclusion
947660|NCT02267837|OrthoPulse™
947661|NCT02267824|Alignment phase
947662|NCT02267824|Photobiomodulation
947663|NCT02267824|Orthodontic treatment
947664|NCT02267824|Malocclusion
947665|NCT02267824|OrthoPulse™
947666|NCT02267811|Photobiomodulation
947667|NCT02267811|Orthodontic treatment
947668|NCT02267811|Malocclusion
947669|NCT02267811|OrthoPulse™
947670|NCT02267798|Stroke
947671|NCT02267798|Rehabilitation
947672|NCT02267798|Arm motor recovery
947673|NCT02267798|biological biomarkers
947674|NCT02267785|exercise
947675|NCT02267785|mild cognitive impairment
947676|NCT02267785|Parkinson's Disease
947677|NCT02267720|Dental Atraumatic Restorative Treatment
947678|NCT02267720|Glass ionomer cement
947679|NCT02267720|Occlusal-proximal leasons
947680|NCT02267720|Primary molars
947681|NCT02267707|nab®-paclitaxel
947682|NCT02267707|ABI-007
947683|NCT02267707|Abraxane
947684|NCT02267707|Advanced Pancreatic Cancer
947685|NCT02267707|Cholestatic Hyperbilirubinemia
947686|NCT02267707|Bile Duct Obstruction
947687|NCT02267707|Pancreatic Cancer
947688|NCT02267668|concussion
947689|NCT02267668|sports concussion
947690|NCT02267668|exercise therapy
947691|NCT02267655|Inhaled Nitric Oxide (iNO)
947692|NCT02267655|Pulmonary Hypertension (PH)
947693|NCT02267655|Chronic Obstructive Pulmonary Disease (COPD)
947694|NCT02267655|Long Term Oxygen Therapy (LTOT)
947695|NCT02267655|Idiopathic Pulmonary Fibrosis (IPF)
947696|NCT02267629|OCD
947697|NCT02267616|Levonorgestrel intrauterine device (LNG IUD)
947698|NCT02267616|Etonogestrel (ENG) Implant
947699|NCT02267616|Contraception
947700|NCT02267564|patellar dislocation
947701|NCT02267564|medial patellofemoral ligament
947702|NCT02267564|tibial tubercle transfer
947703|NCT02267551|robotic surgery
947704|NCT02267551|simulation
947705|NCT02267538|Delirium
947706|NCT02267538|Cardiac Surgical Procedures
947707|NCT02267538|Postoperative Complications
947708|NCT02267538|Dexmedetomidine
947709|NCT02267538|Prevention
947710|NCT02267525|Gastroparesis
947711|NCT02267525|Diabetic
947712|NCT02267525|Idiopathic
947713|NCT02267512|Kidney Transplant Patients
947714|NCT02267512|ATG-F
947715|NCT02267499|cognitive training
947716|NCT02267499|physical training
947717|NCT02267499|exercise games
947718|NCT02267499|novelty serious games
947719|NCT02267499|computer training
947720|NCT02267499|mild cognitive impairment
947721|NCT02267499|mild dementia
947722|NCT02267499|healthy elderly
947723|NCT02267486|Alzheimer Dementia, AD
947724|NCT02267486|patients
947725|NCT02267486|cognitive
947726|NCT02267460|Peyronie's disease
947727|NCT02267460|penile plaque
947728|NCT02267460|penile curvature
947729|NCT02267447|Cardiovascular diseases
947730|NCT02267447|Clinical prediction rule
947731|NCT02267447|Population projection
947732|NCT02267447|Risk stratification
947733|NCT02267447|Health behavior
947734|NCT02267408|Heart valve prosthesis
947735|NCT02267408|Anticoagulation
947736|NCT02267408|Warfarin
947737|NCT02267395|Musicians, Injuries
947738|NCT02267369|online
947739|NCT02267369|social media
947740|NCT02267369|online social network
947741|NCT02267369|physical activity
947742|NCT02267369|message
947743|NCT02267330|Gonadal Radiation Exposure
947744|NCT02267330|Fluoroscopic Imaging
947745|NCT02267330|Trauma Surgery
947746|NCT02267330|Pelvis fractures
947747|NCT02267330|Femur fractures
947748|NCT02267317|Insulin signaling and glucose disposal in muscle
947749|NCT02267317|Hepatic insulin sensitivity
947750|NCT02267317|TLR4 signaling and inflammatory gene expression
947751|NCT02267317|Plasma cytokine concentration
947752|NCT02267317|Intramyocellular diacylglycerol and ceramide content
947753|NCT02267304|volunteers
947754|NCT02267291|Cardiac Catheterization
947755|NCT02267291|Echocardiography
947756|NCT02267291|Noninvasive Ventilation
947757|NCT02267291|Positive-Pressure Respiration
947758|NCT02267291|Ventricular Function
947759|NCT02267278|Myeloproliferative Diseases
947760|NCT02267278|Myelofibrosis
947761|NCT02267278|MF
947762|NCT02267278|Primary or post essential thrombocythemia/polycythemia vera
947763|NCT02267278|Ruxolitinib
947764|NCT02267278|Jakafi
947765|NCT02267278|INCB018424
947766|NCT02267278|INC424
947767|NCT02267278|Pracinostat
947768|NCT02267278|Questionnaire
947769|NCT02267278|Survey
947770|NCT02267265|educational intervention
947771|NCT02267265|language development
947772|NCT02267265|universal newborn hearing screening
947773|NCT02267265|postpartum
947774|NCT02267265|parental attachment
947775|NCT02267265|loss to follow-up
947776|NCT02267265|hearing loss
947777|NCT02267265|achievement gap
947778|NCT02267265|language gap
947779|NCT02267265|school readiness
947780|NCT02267239|essential oils
947781|NCT02267239|chlorhexidine
947782|NCT02267239|microscopy, confocal
947783|NCT02267239|immersion
947784|NCT02267239|antiseptic
947785|NCT02267200|biomarkers，pulmonary arterial hypertension
947786|NCT02267187|Craniomaxillofacial (CMF)
947787|NCT02267187|Battle-injured (BI)
947788|NCT02267187|Facial Trauma
947789|NCT02267187|Fat Grafts
947790|NCT02267187|Autogenous Fat Transfers (AFT)
947791|NCT02267187|Wounded Warriors
947792|NCT02267174|Implementation
947793|NCT02267174|quality improvement
947794|NCT02267174|patient safety
947795|NCT02267174|handoffs
947796|NCT02267174|intensive care unit
947797|NCT02267174|postoperative care
947798|NCT02267174|simulation
947799|NCT02267161|agenesis
947800|NCT02267161|corpus callosum
947801|NCT02267161|prenatal diagnosis
947802|NCT02267148|Non-alcoholic fatty liver disease
947803|NCT02267148|Fatty liver
947804|NCT02267148|Steatosis
947805|NCT02267148|Fibrosis
947806|NCT02267148|Liver Stiffness
947807|NCT02267148|Cirrhosis
947808|NCT02267148|Genetics
947809|NCT02267148|Single Nucleotide Polymorphism
947810|NCT02267135|scalp psoriasis, plaque psoriasis, secukinumab, AIN457, biologic, monoclonal antibody, psoriasis, AIN457A
947811|NCT02267096|lung cancer screening
947812|NCT02267083|soft tissue sarcoma
947813|NCT02267070|cognitive training
947814|NCT02267070|aerobic exercise
947815|NCT02267070|neurotrophic factors
947816|NCT02267070|randomized controlled trial
947817|NCT02267057|Pain measurement
947818|NCT02267057|Pain assessment
947819|NCT02267057|Pain management
947820|NCT02267057|Analgesia
947821|NCT02267057|Analgesics
947822|NCT02267057|Depressive symptoms
947823|NCT02267057|Alzheimer disease
947824|NCT02267057|Vascular dementia
947825|NCT02267057|Multi-infarct dementia
947826|NCT02267057|Frontotemporal lobar degeneration
947827|NCT02267057|Lewy body disease
947828|NCT02267031|cognitive dysfunction
947829|NCT02267031|mechanical ventilation
947830|NCT02267031|hyperoxia
947831|NCT02267031|hypocapnia
947832|NCT02267018|nCPAP
947833|NCT02267018|High-Frequency Oscillator Ventilation
947834|NCT02267018|Diaphragm Electrical Activity
947835|NCT02266979|peritoneal dialysis
947836|NCT02266979|nursing staff
947837|NCT02266979|nursing activities
947838|NCT02266979|Personnel Downsizing
947839|NCT02266953|Dietary services
947840|NCT02266953|Public Health Nursing
947841|NCT02266953|Preschool child
947842|NCT02266940|pharmacokinetics
947843|NCT02266901|leaks after bariatric surgery
947844|NCT02266901|fistulae after bariatric surgery
947845|NCT02266901|abdominal abcesses and bariatric surgery
947846|NCT02266901|endoscopic drainage of abcesses
947847|NCT02266901|percutaneous drainage of abcesses
947848|NCT02266901|gastric bypass
947849|NCT02266901|sleeve gastrectomy
947850|NCT02266901|necrotic collection and bariatric surgery
947851|NCT02266888|B cells
947852|NCT02266888|lung transplant recipient
947853|NCT02266888|rituximab
947854|NCT02266888|placebo
947855|NCT02266888|standard of care
947856|NCT02266836|Stroke
947857|NCT02266836|Cerebrovascular accident
947858|NCT02266836|Upper Extremity
947859|NCT02266836|Cerebral Infarction
947860|NCT02266836|Brain Infarction
947861|NCT02266836|Brain Ischemia
947862|NCT02266836|Cerebrovascular Disorders
947863|NCT02266836|Cardiovascular Diseases
947864|NCT02266836|Nervous System Diseases
947865|NCT02266836|Central Nervous System Diseases
947866|NCT02266784|smoking, smoking cessation, contingency management, ADHD
947867|NCT02266771|Negative Pressure Wound Therapy, Wound VAC, Instillation
947871|NCT02266719|Aortic Aneurysm, Abdominal [C14.907.055.239.075]
947872|NCT02266693|Cognitive Behavioural Therapy
947873|NCT02266693|Internet Based
947874|NCT02266693|CBT
947875|NCT02266693|Transdiagnostic
947876|NCT02266693|MDD
947877|NCT02266693|PD
947878|NCT02266693|SAD
947879|NCT02266693|GAD
947880|NCT02266693|iCBT
947881|NCT02266680|Social Anxiety
947882|NCT02266680|Yoga
947883|NCT02266667|NEMOT device
947884|NCT02266667|pediatrics
947885|NCT02266667|surgery
947886|NCT02266667|progressive scoliosis
947887|NCT02266654|Emergency Medical Services
947888|NCT02266654|Lactic Acid
947889|NCT02266654|Sepsis
947890|NCT02266641|one-carbon metabolism
947891|NCT02266641|folate
947892|NCT02266641|choline
947893|NCT02266641|DNA methylation
947894|NCT02266641|imprint marker
947895|NCT02266641|cancer risks
947896|NCT02266602|IORT
947897|NCT02266602|Breast Cancer
947898|NCT02266589|coagulopathy
947899|NCT02266589|hydrocortisone
947900|NCT02266589|organ failure
947901|NCT02266589|hemodynamic improvement induced by hydrocortisone
947902|NCT02266563|Traumatic Brain Injury
947903|NCT02266563|Chronic Traumatic Encephalopathy
947904|NCT02266563|Mild Cognitive Impairment
947905|NCT02266563|PET imaging
947906|NCT02266563|tauopathy
947907|NCT02266563|amyloid
947908|NCT02266446|anxiety disorders
947909|NCT02266446|cognitive bias modification
947910|NCT02266446|primary care
947911|NCT02266446|attention
947912|NCT02266446|interpretation
947913|NCT02266446|computer
947914|NCT02266433|DeQuervains Tenosynovitis
947915|NCT02266433|Lateral Epicondylitis
947916|NCT02266433|Tennis Elbow
947917|NCT02266433|Trigger Finger
947918|NCT02266433|Tenosynovitis
947919|NCT02266433|Inflammatory Disease
947920|NCT02266433|Dexamethasone
947921|NCT02266433|Ketorolac
947922|NCT02266433|Toradol
947923|NCT02266420|Triple negative breast cancer
947924|NCT02266420|immuno-histochemistery
947925|NCT02266420|genomic profiles
947926|NCT02266407|Revision TKA
947927|NCT02266407|Septic
947928|NCT02266407|Aseptic
947929|NCT02266407|Transfusion
947930|NCT02266407|Blood Loss
947931|NCT02266381|PCNL
947932|NCT02266381|MPCNL
947933|NCT02266381|guidance
947934|NCT02266381|puncture
947935|NCT02266368|Ureteral stents
947936|NCT02266368|Double J stent
947937|NCT02266368|Antimicoreal coated stent
947938|NCT02266368|USSQ
947939|NCT02266368|UTI
947940|NCT02266355|Oxaliplatin
947941|NCT02266355|Omalizumab
947942|NCT02266329|controlled clinical trial
947943|NCT02266329|randomized controlled clinical trial
947944|NCT02266290|ADHESIVE TAPE
947945|NCT02266290|ANKLE INJURY
947946|NCT02266290|POSTURAL BALANCE
947947|NCT02266290|FUNCTIONAL ANKLE INSTABILITY
947948|NCT02266277|electronic health record, utilization
947949|NCT02266277|randomized controlled trial
947950|NCT02266277|pragmatic clinical trial
947951|NCT02266277|influenza, prevention and control
947952|NCT02266277|pneumococcal vaccines
947953|NCT02266277|qualitative research
947954|NCT02266225|Chronic disease management
947955|NCT02266225|Physical activity
947956|NCT02266225|Fall prevention
947957|NCT02266225|Strength and balance exercise
947958|NCT02266199|questionnaire
947959|NCT02266199|quality assurance
947960|NCT02266199|qualitative Verification
947961|NCT02266199|conservative patients
947962|NCT02266199|interview
947963|NCT02266160|tinnitus
947964|NCT02266160|local anaesthetic
947965|NCT02266160|EMLA cream 5%
947966|NCT02266147|Low Grade B-cell Lymphoma
947967|NCT02266134|implementation
947968|NCT02266134|measurement based care
947969|NCT02266134|standardized
947970|NCT02266134|tailored
947971|NCT02266121|Multiple Sclerosis
947972|NCT02266121|MS
947973|NCT02266121|Cognitive deficits
947974|NCT02266121|Motor deficits
947975|NCT02266121|Fatigue
947976|NCT02266121|Nervous System Diseases
947977|NCT02266121|Brain Diseases
947978|NCT02266121|Brain stimulation
947979|NCT02266121|Working memory
947980|NCT02266121|Motor learning
947981|NCT02266121|Central Nervous System Diseases
947982|NCT02266121|Neuropsychological rehabilitation
947983|NCT02266108|Sexually Transmitted Infections
947984|NCT02266108|Female Sex Workers
947985|NCT02266095|Osteoarthritis
947986|NCT02266095|Thumb spica splint
947987|NCT02266095|Oval-8 splint
947988|NCT02266095|Tee-Pee splint
947989|NCT02266069|implementation
947990|NCT02266069|anticipatory care planning
947991|NCT02266069|symptom assessment
947992|NCT02266069|interdisciplinary collaboration
947993|NCT02266056|deep neuromuscular block
947994|NCT02266056|sugammadex
947995|NCT02266056|laparoscopic colorectal surgery
947996|NCT02266056|hemodynamic change
947997|NCT02266043|Upper airway obstruction
947998|NCT02266017|pain
947999|NCT02266017|coping
948000|NCT02266017|mhealth
948001|NCT02266017|cancer
948002|NCT02266004|transcranial direct current stimulation
948003|NCT02266004|neuromodulation
948004|NCT02265978|Emotional Self-Awareness
948005|NCT02265978|Positive Coping
948006|NCT02265978|Help-Seeking
948007|NCT02265926|filtering facepiece respirators
948008|NCT02265926|N95 masks
948009|NCT02265926|pandemic response
948010|NCT02265926|pregnant healthcare workers
948011|NCT02265900|Positron Emission Tomography
948012|NCT02265900|Dopamine
948013|NCT02265900|Parkinson's Disease
948014|NCT02265887|Pulmonary Hypertension
948015|NCT02265887|Africa
948016|NCT02265887|Heart Disease
948017|NCT02265887|Echocardiography
948018|NCT02265861|Polycystic ovary syndrome; Vascular endothelial growth factor; Angiotensin-Ⅱ; Ovarian hyperstimulation syndrome
948019|NCT02265848|Spinal cord stimulation
948020|NCT02265848|Chronic pain
948021|NCT02265848|Chronic low back pain
948022|NCT02265848|Radiculopathy
948023|NCT02265848|Complex Regional Pain Syndrome (CRPS)
948024|NCT02265848|High Frequency stimulation
948025|NCT02265822|melatonin
948026|NCT02265822|midazolam
948027|NCT02265822|children
948028|NCT02265809|Interleukin 2
948029|NCT02265809|Type 1 diabetes
948030|NCT02265809|T regulatory cells
948031|NCT02265809|Adaptive trial
948032|NCT02265796|deferred percutaneous coronary intervention
948033|NCT02265796|fractional flow reserve
948034|NCT02265783|Focus of Study: Healthy Volunteers
948035|NCT02265757|Behavioral Intervention
948036|NCT02265757|Mild Cognitive Impairment
948037|NCT02265757|HABIT
948038|NCT02265757|Cognitive Rehabilitation
948039|NCT02265757|Multi-Component Intervention
948040|NCT02265731|acute myeloid leukemia
948041|NCT02265731|small lymphocytic lymphoma
948042|NCT02265731|relapsed chronic lymphocytic leukemia
948043|NCT02265731|refractory multiple myeloma
948044|NCT02265731|refractory small lymphocytic lymphoma
948045|NCT02265731|relapsed multiple myeloma
948046|NCT02265731|Lymphoma, Non-Hodgkin
948047|NCT02265731|refractory chronic lymphocytic leukemia
948048|NCT02265731|Lymphoproliferative Disorders
948049|NCT02265731|relapsed small lymphocytic lymphoma
948050|NCT02265731|Lymphatic Diseases
948051|NCT02265718|Healthy
948052|NCT02265718|elderly volunteers
948053|NCT02265614|PGS
948054|NCT02265614|blastocyst
948055|NCT02265614|human
948056|NCT02265614|IVF
948057|NCT02265614|vitrification
948058|NCT02265614|single embryo transfer
948059|NCT02265601|advance care planning
948060|NCT02265601|living wills
948061|NCT02265601|end of life
948062|NCT02265601|cancer
948063|NCT02265588|Inflammatory bowel disease (IBD)
948064|NCT02265588|Ulcerative colitis
948065|NCT02265588|Crohn's disease
948066|NCT02265588|Children
948067|NCT02265588|Adolescents
948068|NCT02265588|Anxiety
948069|NCT02265588|Depression
948070|NCT02265588|Cognitive behavioral therapy
948071|NCT02265562|Hysterectomy
948072|NCT02265562|Misoprostol
948073|NCT02265562|Blood loss
948074|NCT02265549|Metastases,
948075|NCT02265549|Neoplasm
948076|NCT02265549|Cerebral
948077|NCT02265523|Arthroplasties, Replacement, Knee
948078|NCT02265458|Respiratory failure
948079|NCT02265458|NIV
948080|NCT02265458|Musical intervention
948081|NCT02265445|Carbapenems therapy/ESBL infections/Deescalation
948082|NCT02265445|due to ESBL-PE
948083|NCT02265432|Physical activity
948084|NCT02265432|Sedentary behavior
948085|NCT02265419|hyperinflammation, Cytosorb
948086|NCT02265354|Tobacco Smoking Cessation
948087|NCT02265354|Computer tailored health communication
948088|NCT02265354|messaging
948089|NCT02265354|collective intelligence
948090|NCT02265354|recommender systems
948091|NCT02265354|machine learning
948092|NCT02265328|Severe Alcoholic Hepatitis in 'Extremis'
948093|NCT02265328|Bovine Colostrum
948094|NCT02265328|Glucocorticoids
948095|NCT02265276|NAFLD, Diabetes, Glitazone
948096|NCT02265250|magnetic resonance imaging
948097|NCT02265250|positron emission tomography
948098|NCT02265237|Compensated Cirrhosis
948099|NCT02265237|Hepatitis C
948100|NCT02265237|Hepatitis C Genotype 4
948101|NCT02265237|Chronic Hepatitis C
948102|NCT02265198|Pulmonary Contusion
948103|NCT02265198|ARDS
948104|NCT02265198|Respiratory Failure
948105|NCT02265172|Physiotherapy
948106|NCT02265172|Orthopaedic
948107|NCT02265172|Primary care
948108|NCT02265146|Lipid Core Plaques (LCPs)
948109|NCT02265146|Vulnerable Plaque
948110|NCT02265146|Near Infrared Spectroscopy
948111|NCT02265107|endothelial function
948112|NCT02265107|physical training
948113|NCT02265107|exercise
948114|NCT02265107|coronary artery bypass
948115|NCT02265094|Autism Spectrum Disorder
948116|NCT02265094|Development
948117|NCT02265094|Memory
948118|NCT02265094|ERD
948119|NCT02265068|Acute coronary syndrome (ACS), Ticagrelor
948120|NCT02265029|fibromyalgia
948121|NCT02265029|rheumatism
948122|NCT02265029|fatigue syndrom
948123|NCT02265029|pain
948124|NCT02265029|spa treatment in rheumatology
948125|NCT02265016|coronary artery disease
948126|NCT02265016|acute coronary syndrome
948127|NCT02265016|angina pectoris
948128|NCT02265016|non-ST-segment elevation myocardial infarction
948129|NCT02265016|red blood cells
948130|NCT02265016|erythrocytes
948131|NCT02265003|red blood cells
948132|NCT02265003|endothelial function
948133|NCT02265003|nitric oxide pool in red blood cells
948134|NCT02265003|nitric oxide poll in blood plasma
948135|NCT02265003|nitric oxide synthase III - expression
948136|NCT02265003|oxidative status
948137|NCT02265003|nitric oxide signalling
948138|NCT02264990|cisplatin
948139|NCT02264990|paclitaxel
948140|NCT02264990|Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP)
948141|NCT02264990|Non-squamous
948142|NCT02264990|Non-small cell lung cancer
948143|NCT02264990|pemetrexed
948144|NCT02264990|carboplatin
948145|NCT02264990|Metastatic
948146|NCT02264990|veliparib
948147|NCT02264964|Hemodialysis
948148|NCT02264964|End-Stage Kidney Disease
948149|NCT02264964|Central Venous Catheterization
948150|NCT02264964|Digital Subtraction Angiography
948151|NCT02264951|Short fatty acids
948152|NCT02264951|2-oleoyl glycerol
948153|NCT02264951|GLP-1 secretion
948154|NCT02264951|C8-diet oil
948155|NCT02264951|GIP secretion
948156|NCT02264925|Essential tremor
948157|NCT02264925|Deep brain stimulation (DBS)
948158|NCT02264925|Ventral intermediate Thalamus (VIM)
948159|NCT02264925|Local field potentials (LFPs)
948160|NCT02264925|Closed loop therapy
948161|NCT02264912|antiplatelet drugs, percutanous coronary intervention, acute coronary syndromes, laboratory efficacy
948162|NCT02264899|Alzheimer's disease
948163|NCT02264899|Mild Cognitive Impairment
948164|NCT02264873|Relapse
948165|NCT02264873|Autologous stem cell transplant
948166|NCT02264847|Clomiphene Citrate
948167|NCT02264847|Ovulation trigger
948168|NCT02264847|Human chorionic gonadotrophin
948169|NCT02264834|epidural
948170|NCT02264834|primiparous patient
948171|NCT02264834|deambulation
948172|NCT02264821|analgesia
948173|NCT02264821|caesarean
948174|NCT02264821|wound infiltration
948175|NCT02264821|intrathecal morphine.
948176|NCT02264795|Cesarean section
948177|NCT02264795|Lidocaine
948178|NCT02264769|pregnancy
948179|NCT02264769|postpartum hemorrhage
948180|NCT02264769|Cesarean delivery
948181|NCT02264769|carbetocin
948182|NCT02264756|Community-acquired pneumonia
948183|NCT02264756|Pragmatic clinical trial
948184|NCT02264756|Antimicrobial stewardship
948185|NCT02264756|length of stay
948186|NCT02264756|stepped-wedge design
948187|NCT02264756|time-dependent bias
948188|NCT02264704|MS
948189|NCT02264704|Exercise
948190|NCT02264704|Training
948191|NCT02264704|Multiple sclerosis
948192|NCT02264704|Immune response
948193|NCT02264704|Neurotrophin
948194|NCT02264704|Cytokine
948195|NCT02264704|Fatigue
948196|NCT02264678|ATM deficient, ATM proficient, HER2 negative, Breast, Gastric, Head & Neck, Lung
948197|NCT02264652|Refractory
948198|NCT02264652|Partial
948199|NCT02264652|Epilepsy
948200|NCT02264626|acute respiratory failure
948201|NCT02264626|noninvasive ventilation
948202|NCT02264626|sedation
948203|NCT02264626|patient/ventilator interaction
948204|NCT02264600|Restless Legs Syndrome, Apelin, Oxidative Stress
948205|NCT02264535|Allergy
948206|NCT02264535|Skin test
948207|NCT02264535|Ginkgolides Meglumine Injection
948208|NCT02264509|Arterial Insufficiency
948209|NCT02264509|Human Immunodeficiency Virus
948210|NCT02264509|Atherosclerosis
948211|NCT02264509|Ankle-brachial index
948212|NCT02264509|HAART
948213|NCT02264496|Colorectal cancer
948214|NCT02264496|Exercise
948215|NCT02264496|CPEX
948216|NCT02264496|Exercise, Physical
948217|NCT02264496|Exercise, Aerobic
948218|NCT02264496|Surgery
948219|NCT02264483|Pneumonia in COPD exacerbation
948220|NCT02264470|Prediction
948221|NCT02264470|Falls
948222|NCT02264470|Stroke
948223|NCT02264457|Lenses, Intraocular
948224|NCT02264444|Cholecystectomy, visualization, single incision
948225|NCT02264431|Obesity
948226|NCT02264431|Obstructive Sleep Apnea
948227|NCT02264431|Sleep Habits
948228|NCT02264431|Bariatric Surgery
948229|NCT02264431|Cohort
948230|NCT02264418|Solid tumours
948231|NCT02264405|Autoimmune diseases
948232|NCT02264405|Systemic sclerosis
948233|NCT02264405|Autologous Hematopoietic stem cell transplant
948234|NCT02264379|Oligometastases
948235|NCT02264379|Prostate Cancer
948236|NCT02264379|Stereotactic Radiotherapy
948237|NCT02264379|Hypo fractionation
948238|NCT02264379|Normal fractionation
948239|NCT02264353|Obstructive
948240|NCT02264353|Sleep Apnea
948241|NCT02264353|Arousal threshold
948242|NCT02264353|Donepezil
948243|NCT02264340|Tension-type headache
948244|NCT02264340|relaxation techniques
948245|NCT02264340|physiotherapy
948246|NCT02264327|Motivational Interviewing
948247|NCT02264327|Evidence Based Practice
948248|NCT02264327|Online Simulation
948249|NCT02264327|Workforce development
948250|NCT02264327|Training
948251|NCT02264314|Aged
948252|NCT02264314|Hearing Aids
948253|NCT02264314|Rehabilitation
948254|NCT02264288|Peripheral Arterial Disease
948255|NCT02264288|Diabetic Foot
948256|NCT02264275|Aerobic Exercise
948257|NCT02264275|Exercise
948258|NCT02264275|Exergame
948259|NCT02264275|Behavior
948260|NCT02264275|Video Game
948261|NCT02264275|Inflammatory Bowel Disease
948262|NCT02264275|Children
948263|NCT02264275|Adolescents
948264|NCT02264275|Pediatric
948265|NCT02264275|Physical Fitness
948266|NCT02264223|Bioavailability
948267|NCT02264223|Isoflavones
948268|NCT02264223|Plasma
948269|NCT02264223|Human
948270|NCT02264223|Processing
948271|NCT02264223|Cross-over
948272|NCT02263950|Cancer
948273|NCT02263950|Malignant Neoplasm
948274|NCT02263950|Artemether
948275|NCT02263950|Sublingual
948276|NCT02263950|Neoplastic disease
948277|NCT02263950|Solid Tumour
948278|NCT02263950|Anti-cancer drug
948279|NCT02263950|Chemotherapy
948280|NCT02263950|LON002
948281|NCT02263885|Parkinson's Disease
948282|NCT02263885|ExAblate
948283|NCT02263885|MRgFUS
948284|NCT02263859|Obstructive Sleep Apnea
948285|NCT02263846|Breast cancer
948286|NCT02263846|Menopause
948287|NCT02263846|Estradiol
948288|NCT02263846|Follicle stimulating hormone
948289|NCT02263820|Acute Kidney Injury
948290|NCT02263820|Acute Renal Failure
948291|NCT02263807|Patella luxation
948292|NCT02263794|Bronchial Thermoplasty
948293|NCT02263755|CHB, cohort, fibroscan
948294|NCT02263742|Healthcare choice and outcomes
948295|NCT02263742|Peer-led whole health
948296|NCT02263742|Mental Illness
948297|NCT02263742|Peer Health Navigation
948298|NCT02263742|Health care Coordination
948299|NCT02263716|Physical Activity
948300|NCT02263716|Intensive Care
948301|NCT02263716|Activities of Daily Living
948302|NCT02263716|Delirium
948303|NCT02263716|Sepsis
948304|NCT02263716|Mechanical Ventilation
948305|NCT02263716|Critical Care
948306|NCT02263716|Critical Illness
948307|NCT02263716|Aging
948308|NCT02263716|Accelerometery
948309|NCT02263703|HPV vaccine, children, immunocompromised
948310|NCT02263677|diabetes
948311|NCT02263677|fatty liver
948312|NCT02263664|microcirculation
948313|NCT02263664|esophagectomy
948314|NCT02263664|side stream dark field
948315|NCT02263664|microcirculatory derangements
948316|NCT02263651|Breast cancer
948317|NCT02263651|Mastectomy
948318|NCT02263651|Seroma
948319|NCT02263651|Quilting suture
948320|NCT02263638|hereditary haemochromatosis
948321|NCT02263638|rheumatism
948322|NCT02263638|anakinra
948323|NCT02263625|Indication
948324|NCT02263625|Differences
948325|NCT02263612|Incisional Hernia
948326|NCT02263612|Complications
948327|NCT02263612|Long-term
948328|NCT02263586|Ironman
948329|NCT02263586|Triathlon
948330|NCT02263573|PEP'C-R
948331|NCT02263573|Endurance parameters
948332|NCT02263573|Maximal cardio-respiratory function
948333|NCT02263573|Older seniors
948334|NCT02263573|Over 70
948335|NCT02263547|teriflunomide
948336|NCT02263547|colestipol hcl
948337|NCT02263534|stress urinary incontinence
948338|NCT02263534|tension free vaginal tape
948339|NCT02263534|single incision minisling
948340|NCT02263534|midurethral sling
948345|NCT02263495|HER2-Negative
948346|NCT02263482|muscle training
948347|NCT02263482|walking test
948348|NCT02263482|chronic heart failure
948349|NCT02263482|functional capacity
948350|NCT02263443|bowel preparation
948351|NCT02263443|gynecologic surgery
948352|NCT02263443|laparotomy
948353|NCT02263391|transmission
948354|NCT02263391|prevention
948355|NCT02263391|women
948356|NCT02263391|childbearing age
948357|NCT02263391|HIV testing
948358|NCT02263391|testing strategy
948359|NCT02263378|HPV, L-SIL
948360|NCT02263352|Diabetes, Periodontitis, Oxidative stress, Antioxidant
948361|NCT02263339|Exercise
948362|NCT02263339|MRI
948363|NCT02263313|Safety and efficacy
948364|NCT02263313|Combo stent
948365|NCT02263313|Late loss thrombosis
948366|NCT02263313|Late loss catch up
948367|NCT02263300|Fiberoptic Intubation
948368|NCT02263300|Medical student
948369|NCT02263300|Virtual larynx
948370|NCT02263300|Didactic Training
948371|NCT02263300|Medical Education
948372|NCT02263287|Alzheimer Disease
948373|NCT02263287|Lewy Body Disease
948374|NCT02263261|dermal matrix
948375|NCT02263235|Alzheimer disease (AD)
948376|NCT02263235|diagnosis biomarkers
948377|NCT02263235|cerebrospinal fluid (CSF)
948378|NCT02263235|targeted quantitative proteomics
948379|NCT02263235|mass spectrometry
948380|NCT02263235|stable isotope-labelled leucine
948381|NCT02263183|Metabolic risk
948382|NCT02263183|Abdominally overweight
948383|NCT02263131|Influenza
948384|NCT02263131|Influenza vaccine
948385|NCT02263131|Split influenza vaccine
948386|NCT02263131|Seasonal influenza vaccine
948387|NCT02263118|breastfeeding
948388|NCT02263118|rural
948389|NCT02263118|m-health
948390|NCT02263118|mHealth
948391|NCT02263118|Patojitos
948392|NCT02263118|Guatemala
948393|NCT02263118|exclusive breastfeeding
948394|NCT02263118|mobile
948395|NCT02263118|eHealth
948396|NCT02263118|e-health
948397|NCT02263105|recurrent high-grade gliomas
948398|NCT02263105|cisplatin (CDDP)
948399|NCT02263105|temozolomide (TMZ)
948400|NCT02263092|Cortical excitability
948401|NCT02263092|Plasticity
948402|NCT02263092|Healthy subjects
948403|NCT02263040|influenza vaccine
948404|NCT02263040|adult
948405|NCT02263040|immunogenicity
948406|NCT02263040|reactogenicity
948407|NCT02263027|influenza vaccine
948408|NCT02263027|adult
948409|NCT02263027|safety
948410|NCT02263027|reactogenicity
948411|NCT02263014|Breast Cancer
948412|NCT02263014|Contralateral Prophylactic Mastectomy
948413|NCT02263014|Questionnaires
948414|NCT02263014|Surveys
948415|NCT02263014|Psychosocial
948416|NCT02263001|Auricular therapy
948417|NCT02263001|Acupuncture
948418|NCT02263001|Acute, sub-acute pain
948419|NCT02263001|Auricular Acupuncture Needles
948420|NCT02262988|knee
948421|NCT02262988|joint replacement
948422|NCT02262988|total knee
948423|NCT02262988|cell therapy
948424|NCT02262975|Alzheimer's disease
948425|NCT02262936|Aged
948426|NCT02262936|Deamino Arginine Vasopressin
948427|NCT02262936|Fesoterodine
948428|NCT02262936|Randomized Controlled Trial
948429|NCT02262910|metastatic castration-resistant prostate cancer
948430|NCT02262910|CRPC
948431|NCT02262897|small cell lung cancer
948432|NCT02262897|chemotherapy
948433|NCT02262897|Nab-paclitaxel
948434|NCT02262871|Cystic fibrosis
948435|NCT02262871|High-flow nasal oxygen cannula
948436|NCT02262871|Non-invasive ventilation
948437|NCT02262871|Respiratory distress
948438|NCT02262871|Oxygen therapy
948439|NCT02262832|Diabetes
948440|NCT02262832|Leptin
948441|NCT02262832|Lipodystrophy
948442|NCT02262832|Hypertriglyceridemia
948448|NCT02262806|Lipodystrophy
948449|NCT02262806|Leptin
948450|NCT02262806|Hypertriglyceridemia
948451|NCT02262806|Diabetes
948452|NCT02262767|Phase 1, Randomized, Double Blind, Placebo-Controlled, Single-Dose Escalation, Safety, Tolerability, Pharmacokinetic, PF-06649751, Trimethobenzamide
948453|NCT02262728|Hepatitis C, Chronic
948454|NCT02262728|Simeprevir
948455|NCT02262728|Daclatasvir
948456|NCT02262728|Sofosbuvir
948457|NCT02262728|Decompensated Liver Disease
948458|NCT02262715|Oseltamivir
948459|NCT02262715|VX-787
948460|NCT02262689|GSK2256294
948461|NCT02262689|normoxic
948462|NCT02262689|hypoxic
948463|NCT02262689|Pulmonary artery systolic pressure (PASP)
948464|NCT02262676|Stroke prevention on Atrial Fibrillation
948465|NCT02262676|Prevention and Control
948466|NCT02262676|Stroke
948467|NCT02262507|Brain
948468|NCT02262507|Hearing
948469|NCT02262507|MTBI
948470|NCT02262468|retrospective analysis
948471|NCT02262455|Serous tumor
948472|NCT02262455|Granulosa tumor
948473|NCT02262455|Clear Cell tumor
948474|NCT02262455|Endometrial cancer
948475|NCT02262455|Advanced solid tumors
948476|NCT02262455|Adenocarcinoma
948477|NCT02262455|Prostate cancer
948478|NCT02262455|Head and Neck cancer
948479|NCT02262455|Lung cancer
948480|NCT02262455|Non-small cell lung cancer
948481|NCT02262455|Small cell lung cancer
948482|NCT02262455|Gastric cancer
948483|NCT02262455|Kidney cancer
948484|NCT02262455|Pancreatic cancer
948485|NCT02262455|Breast cancer
948486|NCT02262455|Colorectal cancer
948487|NCT02262455|Bladder cancer
948488|NCT02262455|Esophagus cancer
948489|NCT02262455|Liver cancer
948490|NCT02262455|Hepatobiliary cancer
948491|NCT02262455|Skin cancer
948492|NCT02262442|flexible bronchoscopy
948493|NCT02262442|anaesthetics
948494|NCT02262442|transcutaneous pCO2
948495|NCT02262442|capillary pCO2
948496|NCT02262442|special atomizing set
948497|NCT02262416|GnRH agonist
948498|NCT02262416|IVF
948499|NCT02262403|Hookworm
948500|NCT02262403|Helminths
948501|NCT02262403|Treg
948502|NCT02262403|Immune regulation
948503|NCT02262403|Vietnam
948504|NCT02262403|Allergic diseases
948505|NCT02262377|Group Medical Visits
948506|NCT02262377|Integrative Medicine
948507|NCT02262377|Chronic Pain
948508|NCT02262377|Depression
948509|NCT02262377|MBSR
948510|NCT02262377|Mindfulness Based Stress Reduction
948511|NCT02262377|Web based
948512|NCT02262377|Virtual Patient Advocate
948513|NCT02262377|Internet Based
948514|NCT02262351|Atrial Fibrillation
948515|NCT02262351|Screening
948516|NCT02262351|Family Practice
948517|NCT02262351|Novel screening technologies
948518|NCT02262338|MPS II
948519|NCT02262338|Hunter Syndrome
948520|NCT02262325|Non-small cell
948521|NCT02262325|Lung Cancer
948522|NCT02262325|Chemoradiation
948523|NCT02262286|Brain Injury
948524|NCT02262273|women
948525|NCT02262273|platinum sensitive
948526|NCT02262273|recurrent
948527|NCT02262273|serous
948528|NCT02262273|ovarian cancer
948529|NCT02262273|BRCA
948530|NCT02262273|PARP
948531|NCT02262273|Olaparib
948532|NCT02262260|Diabetic macular edema, DME, ranibizumab, wait and extend
948533|NCT02262247|Transoral
948534|NCT02262247|Oropharynx
948535|NCT02262247|Hypopharynx
948536|NCT02262247|Endoscopic
948537|NCT02262247|TORS
948538|NCT02262247|Endoscopic Transoral
948539|NCT02262247|Larynx
948540|NCT02262234|Spinal cord injury
948541|NCT02262234|Chronic pain
948542|NCT02262234|Education
948543|NCT02262208|Glycemic variability, exercise, diabetes
948544|NCT02262182|Atelectasis, Respiratory physiotherapy, end expiratory pressure, EzPAP®, cardiac surgery
948545|NCT02262169|Non-Bleeding Peptic Ulcers, DLBS2411, Ulcer Healing
948546|NCT02262156|Cognitive Behavioral Therapy
948547|NCT02262156|Selective serotonin reuptake inhibitor
948548|NCT02262156|depression
948549|NCT02262156|epilepsy
948550|NCT02262130|Omalizumab
948551|NCT02262130|Efficacy
948552|NCT02262130|Safety
948553|NCT02262117|IVF, pregnancy, immune endometrial profile, personalization of treatment
948554|NCT02262104|Exercise
948555|NCT02262104|dementia
948556|NCT02262104|nursing home
948557|NCT02262078|Preserved Ejection Fraction
948558|NCT02262065|implant
948559|NCT02262065|allergy
948560|NCT02262065|particle
948561|NCT02262065|cytokine
948562|NCT02262052|Deep vein thrombosis
948563|NCT02262052|Diagnostic management
948564|NCT02262052|Recurrent
948565|NCT02262052|MRI
948566|NCT02262052|Ipsilateral
948567|NCT02262039|living
948568|NCT02262039|kidney
948569|NCT02262039|donors
948570|NCT02262013|Pediatric Obesity
948571|NCT02262013|Lifestyle Intervention
948572|NCT02262013|Family-based Intervention
948573|NCT02262013|Motivational Interviewing
948574|NCT02262000|Non Small Cell Lung Cancer
948575|NCT02262000|Surgically inoperable
948576|NCT02262000|Radiation Therapy
948577|NCT02261987|Autogenic drainage
948578|NCT02261987|Resistive inspiratory manoeuvre
948579|NCT02261987|Computerized respiratory sounds
948580|NCT02261987|Airway clearance techniques
948581|NCT02261987|Mucus clearances
948582|NCT02261974|Vaginal laxity
948583|NCT02261961|resistance exercise
948584|NCT02261961|Juven
948585|NCT02261961|exercise training
948586|NCT02261961|interleukin-1
948587|NCT02261961|insulin-like growth factor
948588|NCT02261948|Cardiac Failure
948589|NCT02261948|Severe Heart Failure
948590|NCT02261935|Family caregiver
948591|NCT02261935|Home care nursing practice
948592|NCT02261935|Palliative care
948593|NCT02261935|End of life care
948594|NCT02261935|Family caregiver quality of life
948595|NCT02261935|Family caregiver grief symptoms
948596|NCT02261935|Family caregiver burden
948597|NCT02261935|Family caregiver preparedness for caregiving
948598|NCT02261935|Family caregiver perceived social supports
948599|NCT02261935|Family caregiver health status
948600|NCT02261935|Family caregiver satisfaction with healthcare provided
948601|NCT02261909|Emergency Medicine
948602|NCT02261909|diagnosis
948603|NCT02261896|cyst
948604|NCT02261896|pancreatic cyst
948605|NCT02261896|EUS-FNA
948606|NCT02261896|antibiotic prophylaxis
948608|NCT02261870|MRI, T2 quantification
948616|NCT02261844|Hepatocellular carcinoma
948617|NCT02261844|Metastatic colorectal cancer
948618|NCT02261844|Metabolism
948619|NCT02261844|Hepatic function
948620|NCT02261831|bacterial
948621|NCT02261831|gut
948622|NCT02261831|type 2 diabetes.
948623|NCT02261831|16S rDNA gene
948624|NCT02261831|intestinal crypt
948625|NCT02261818|depression
948626|NCT02261818|aging
948627|NCT02261818|health services
948628|NCT02261792|Postural headache treatment
948629|NCT02261792|Spontaneous intracranial hypotension
948630|NCT02261792|Epidural blood patch
948631|NCT02261792|Trendelenburg position
948632|NCT02261792|Head-Down Tilt
948633|NCT02261792|Blood Patch, Epidural
948634|NCT02261753|epilepsy surgery, outcome, ketogenic diet, ortical dysplasia
948635|NCT02261740|Pelvic Pain
948636|NCT02261740|Genital Pain
948637|NCT02261727|COPD
948638|NCT02261727|Theophylline
948639|NCT02261727|Oral corticosteroids
948640|NCT02261727|COPD exacerbations
948641|NCT02261714|Pancreatic cancer, resected
948642|NCT02261714|Vaccine
948643|NCT02261714|KRAS
948644|NCT02261701|shoulder surgery
948645|NCT02261701|rotator cuff injury
948646|NCT02261701|rehabilitation
948647|NCT02261701|function
948648|NCT02261701|pain
948649|NCT02261701|quality of life
948650|NCT02261675|dexmedetomidine
948651|NCT02261675|sevoflurane
948652|NCT02261675|MAC bar
948653|NCT02261675|drug interaction
948654|NCT02261675|anesthesia
948655|NCT02261649|Cerebellar tumor
948656|NCT02261649|Non-malignant low-grade cerebellar astrocytomas
948657|NCT02261610|PCT algorithm
948658|NCT02261610|Antibiotic
948659|NCT02261610|Pulmonary embolism
948660|NCT02261597|insomnia, inflammation, stress
948661|NCT02261545|n-3 fatty acid
948662|NCT02261545|Sirt-1
948663|NCT02261545|AdipoR1
948664|NCT02261545|AdipoR2
948665|NCT02261545|MCP-1
948666|NCT02261545|Adiponectin
948667|NCT02261545|Resistin
948668|NCT02261545|T2DM
948669|NCT02261506|Intensive care
948670|NCT02261506|bacteremia
948671|NCT02261506|bloodstream infection
948672|NCT02261506|antimicrobial
948673|NCT02261506|mortality
948674|NCT02261506|antimicrobial stewardship
948675|NCT02261480|Parvovirus B19 Infection
948676|NCT02261454|postoperative ileus
948677|NCT02261454|gum chewing
948678|NCT02261454|postoperative care
948679|NCT02261454|abdominal surgery
948680|NCT02261454|child
948681|NCT02261441|Cardiovascular disease
948682|NCT02261441|Hypertension
948683|NCT02261441|Diabetes
948684|NCT02261441|Smoking
948685|NCT02261441|Hypercholesterolemia
948686|NCT02261441|Cardiovascular risk factor
948687|NCT02261428|Nasotracheal suction, tracheal access
948688|NCT02261415|blood transfusion
948689|NCT02261415|blood loss
948690|NCT02261415|feasibility
948691|NCT02261415|outcome
948692|NCT02261415|liver resection
948693|NCT02261402|Adherence
948694|NCT02261402|Morisky Medication Adherence Scale
948695|NCT02261402|Beliefs about Medicines Questionnaire
948696|NCT02261402|Medication Possession Ratio
948697|NCT02261402|Medication-Related Problems
948698|NCT02261402|Pharmacist
948699|NCT02261402|Pharmacist Intervention
948700|NCT02261402|Pharmacy
948701|NCT02261402|Pharmacy Service
948702|NCT02261402|Pharmacy Practice
948703|NCT02261402|Hypertension
948704|NCT02261402|Antihypertensive Agents
948705|NCT02261402|Anticoagulants
948706|NCT02261402|Statins
948707|NCT02261402|Dyslipidemia
948711|NCT02261376|pharmacokinetics
948712|NCT02261337|Sarcopenia
948713|NCT02261324|Percutaneous coronary intervention
948714|NCT02261311|Breast
948715|NCT02261194|depression
948716|NCT02261194|age-related macular degeneration
948717|NCT02261194|self-care
948718|NCT02261194|self-help
948719|NCT02261181|head neck cancer XONRID radiation induced dermatitis
948720|NCT02261168|Circadian Rhythm
948721|NCT02261051|Palliative Care
948722|NCT02261051|Hospice
948723|NCT02261051|End of Life
948724|NCT02261051|Health Service Utilization
948725|NCT02261051|Quality of Life
948726|NCT02261038|total knee arthroplasty
948727|NCT02261038|total knee prothesis
948728|NCT02261038|X-Ray
948729|NCT02261038|Kanekasu radiographs
948730|NCT02261038|femoral component rotation
948731|NCT02261038|effects
948732|NCT02261025|aspirin
948733|NCT02260908|Trauma
948734|NCT02260908|Thromboprophylaxis
948735|NCT02260908|Intracranial haemorrhage
948736|NCT02260908|Deep vein thrombosis
948737|NCT02260856|RCT
948738|NCT02260856|Epiphysiodesis
948739|NCT02260856|Tantalum beads
948740|NCT02260856|Patient centered outcome data
948741|NCT02260856|Cost effective analysis
948742|NCT02260843|Insomnia
948743|NCT02260843|Sleeping
948744|NCT02260843|Quality
948745|NCT02260817|Prostate Cancer
948746|NCT02260817|11C Choline
948747|NCT02260817|PET Imaging
948748|NCT02260791|Rheumatoid
948749|NCT02260791|Arthritis
948750|NCT02260778|Learning Collaborative
948751|NCT02260778|Treat-to-Target
948752|NCT02260778|Arthritis, Rheumatoid
948753|NCT02260765|Treatment as Usual = TAU
948754|NCT02260726|femoroacetabular impingement
948755|NCT02260726|morphometry
948756|NCT02260726|dynamic
948757|NCT02260726|magnetic resonance imaging
948758|NCT02260726|ultrasound
948759|NCT02260726|screening
948760|NCT02260726|diagnosis
948761|NCT02260700|Healthy
948762|NCT02260700|Bioavailability
948763|NCT02260700|Alzheimer's Disease
948764|NCT02260700|JNJ-54861911
948765|NCT02260687|Aflibercept
948766|NCT02260687|Anti-VEGF
948767|NCT02260674|Alzheimer's Disease
948768|NCT02260674|JNJ-54861911
948769|NCT02260674|Placebo
948770|NCT02260661|AZD8835
948771|NCT02260661|Fulvestrant
948772|NCT02260661|Breast Cancer
948773|NCT02260661|PIK3CA Gene Mutation
948774|NCT02260622|Restenosis
948775|NCT02260622|Critical Limb Ischemia
948776|NCT02260622|Infrainguinal Percutaneous Transluminal Angioplasty
948777|NCT02260622|Rivaroxaban
948778|NCT02260622|Clopidogrel
948779|NCT02260609|Complex Wound
948780|NCT02260609|Diabetic Foot Ulcer
948781|NCT02260609|DFU
948782|NCT02260609|GrafixCORE
948783|NCT02260609|Exposed tendon
948784|NCT02260609|Exposed bone
948785|NCT02260609|Allograft tissue
948786|NCT02260570|tolcapone
948787|NCT02260570|traumatic brain injury
948788|NCT02260570|MRI
948789|NCT02260570|memory
948790|NCT02260557|Systemic Sclerosis
948791|NCT02260557|Raynaud's Phenomenon
948914|NCT02259582|Phase 2
948792|NCT02260531|Metastatic breast cancer and brain metastases
948793|NCT02260531|HER-2 Positive Breast Cancer
948794|NCT02260531|ER-Positive PR-Positive HER-2 Negative Breast Cancer
948795|NCT02260531|ER-Negative PR-Negative HER2-Negative Breast Cancer
948796|NCT02260518|Gestational weight gain
948797|NCT02260518|Lifestyle intervention
948798|NCT02260518|Pregnancy
948799|NCT02260518|Postpartum
948800|NCT02260518|Physical activity
948801|NCT02260518|Nutrition
948802|NCT02260505|Gastrointestinal Stromal Tumors
948803|NCT02260505|Non-metastatic
948804|NCT02260505|KIT +
948805|NCT02260505|Imatinib
948806|NCT02260505|Adjuvant treatment
948807|NCT02260505|High risk of recurrence
948808|NCT02260505|Tyrosine kinase inhibitor
948809|NCT02260505|Disease Free Survival
948810|NCT02260505|Overall survival
948811|NCT02260505|Time To Secondary Resistance
948812|NCT02260505|Safety profile
948813|NCT02260505|Quality of Life during treatment
948814|NCT02260479|skin disinfection
948815|NCT02260479|bacterial colonization
948816|NCT02260479|perioperative
948817|NCT02260479|chlorehexidine
948818|NCT02260466|Amyloidosis
948819|NCT02260466|echocardiography
948820|NCT02260466|magnetic resonance imaging
948821|NCT02260466|radionuclide imaging
948822|NCT02260427|elective surgery
948823|NCT02260427|undergoing general anesthesia
948824|NCT02260427|elderly adult patients
948825|NCT02260414|Endogenous Thrombin Potential
948826|NCT02260414|Lymphoma
948827|NCT02260414|Multiple Myeloma
948828|NCT02260414|tinzaparin
948829|NCT02260414|thrombin generation
948830|NCT02260414|Thromboplastin generation tests
948831|NCT02260388|CSPN
948832|NCT02260388|neuropathy
948833|NCT02260388|pain
948834|NCT02260388|pain management
948835|NCT02260375|Mesenchymal stromal cells; liver transplantation; tolerance.
948836|NCT02260349|Prostatic Neoplasms
948837|NCT02260349|Prostate cancer
948838|NCT02260349|surgical margins
948839|NCT02260349|indocyanine green
948840|NCT02260349|characterization
948841|NCT02260349|prostatectomy
948842|NCT02260349|peroperative
948843|NCT02260349|detection
948844|NCT02260297|Actigraphy
948845|NCT02260297|overweight and obese adults
948846|NCT02260297|sleep disorders
948847|NCT02260258|Cardiac Arrest, NMB, Neuromuscular Blockade, Rocuronium
948848|NCT02260219|Ahmed implant
948849|NCT02260219|Neovascular Glaucoma
948850|NCT02260219|Intraocular pressure
948851|NCT02260206|Pericardial Effusion
948852|NCT02260206|Colchicine
948853|NCT02260206|arrhythmia Recurrence
948854|NCT02260206|pericardiocentesis
948855|NCT02260193|anemia
948856|NCT02260193|end stage renal disease
948857|NCT02260193|chronic kidney disease
948858|NCT02260193|CKD
948859|NCT02260193|dialysis
948860|NCT02260193|chronic renal insufficiency
948861|NCT02260193|renal impairment
948862|NCT02260193|erythropoietin
948863|NCT02260193|kidney
948864|NCT02260193|oral anemia treatment
948865|NCT02260193|hemoglobin
948866|NCT02260193|hypoxia-inducible factor
948867|NCT02260193|HIF
948868|NCT02260193|hypoxia-inducible factor propyl-hydroxylase inhibitor
948869|NCT02260193|HIF-PHI
948870|NCT02260193|pharmacokinetics
948871|NCT02260154|Duspatalin
948872|NCT02260154|mebeverine
948873|NCT02260154|cholecystectomy
948874|NCT02260154|gastrointestinal spasm
948875|NCT02260154|abdominal pain
948876|NCT02260154|dyspepsia
948877|NCT02260154|antispasmodics
948878|NCT02260128|postoperative ileus
948879|NCT02260128|chewing gum
948880|NCT02259712|Women
948881|NCT02259712|Pelvic floor disorders
948882|NCT02259712|Urinary incontinence
948883|NCT02259712|Fecal incontinence
948884|NCT02259712|Physical Therapy Modalities
948885|NCT02259699|Ovarian Cancer
948886|NCT02259699|Intraperitoneal chemotherapy
948887|NCT02259699|Intravenous chemotherapy
948888|NCT02259699|decision making
948889|NCT02259686|Apelin
948890|NCT02259686|volunteers
948891|NCT02259660|obstructive sleep apnea
948892|NCT02259660|osa
948893|NCT02259660|breathing
948894|NCT02259660|snoring
948895|NCT02259660|respiratory
948896|NCT02259660|exercise
948897|NCT02259660|inspiratory muscle strength training
948898|NCT02259660|expiratory muscle strength training
948899|NCT02259634|Patient Navigation
948900|NCT02259634|Motivational Interviewing
948901|NCT02259634|Formerly Incarcerated
948902|NCT02259634|Health Education
948903|NCT02259634|Quality of Life
948904|NCT02259634|Healthcare Utilization
948905|NCT02259608|Trained innate immunity
948906|NCT02259608|Heterologous effects of BCG on immunity
948907|NCT02259595|Hearing Loss
948908|NCT02259595|Sensorineural Hearing Loss
948909|NCT02259595|Noise-Induced Hearing Loss
948910|NCT02259595|Antioxidant
948911|NCT02259595|NAC
948912|NCT02259595|N-acetylcysteine
948913|NCT02259595|HPN-07
948915|NCT02259582|histologically
948916|NCT02259582|confirmed
948917|NCT02259582|malignancy
948918|NCT02259582|metastatic
948919|NCT02259582|pemetrexed
948920|NCT02259582|carboplatin
948921|NCT02259582|carcinoma
948922|NCT02259582|non small cell lung
948923|NCT02259582|lung neoplasms
948924|NCT02259582|lung diseases
948925|NCT02259569|Gastric insufflation
948926|NCT02259569|I-gel
948927|NCT02259569|Peak airway pressure
948928|NCT02259569|Pressure-controlled ventilation
948929|NCT02259569|Volume-Controlled Ventilation
948930|NCT02259569|pediatric patient
948931|NCT02259543|gingival recession
948932|NCT02259543|soft tissue
948933|NCT02259543|root biomodification
948934|NCT02259543|root coverage
948935|NCT02259543|citric acid
948936|NCT02259543|tetracycline
948937|NCT02259517|ADHD
948938|NCT02259517|Intuniv
948939|NCT02259517|Non-stimulant
948940|NCT02259517|Guanfacine extended-release
948941|NCT02259517|Vyvanse
948942|NCT02259517|Stimulant
948943|NCT02259517|Lisdexamfetamine
948944|NCT02259504|aneurysms
948945|NCT02259491|Wound Healing
948946|NCT02259491|Honey
948947|NCT02259491|Skin Grafts
948948|NCT02259491|Free tissue transfer
948949|NCT02259478|Intravenous Immunoglobulin (IVIG)
948950|NCT02259478|Hemolysis
948951|NCT02259478|Transfusion Medicine
948952|NCT02259478|Pharmacovigilance
948953|NCT02259465|microbiota
948954|NCT02259465|FODMAP
948955|NCT02259465|oligofructose
948956|NCT02259465|Magnetic Resonance Imaging
948957|NCT02259465|Metabolomics
948958|NCT02259465|Diet
948959|NCT02259452|Radiation Therapy
948960|NCT02259413|Hemodialysis
948961|NCT02259413|End-stage renal disease
948962|NCT02259413|Exercise
948963|NCT02259413|Symptom Burden
948964|NCT02259400|NIV
948965|NCT02259400|NSIPPV
948966|NCT02259400|BiPAP
948967|NCT02259348|Hematological malignancies
948968|NCT02259348|Allogeneic hematopoietic cell transplant
948969|NCT02259348|Refractory hematologic malignancy
948970|NCT02259348|Relapsed hematologic malignancy
948971|NCT02259335|weaning from mechanical ventilation
948972|NCT02259335|extracorporeal CO2 removal
948973|NCT02259335|post-extubation failure
948974|NCT02259322|Bariatric surgery
948975|NCT02259322|Weight loss surgery
948976|NCT02259322|Behavioral weight loss treatment
948977|NCT02259322|Cognitive behavioral therapy
948978|NCT02259322|Behavioral treatment
948979|NCT02259322|Obesity
948980|NCT02259322|Morbid obesity
948981|NCT02259322|Binge eating
948982|NCT02259322|Binge eating disorder
948983|NCT02259322|Loss of control eating
948984|NCT02259322|Overeating
948985|NCT02259309|misoprostol
948986|NCT02259309|mucosal
948987|NCT02259309|cervical
948988|NCT02259309|immune
948989|NCT02259309|buccal
948990|NCT02259309|vaginal
948991|NCT02259283|achalasia
948992|NCT02259283|per oral endoscopic myotoymy
948993|NCT02259283|endoscopy
948994|NCT02259270|Acid suppressive therapy
948995|NCT02259270|Appropriateness
948996|NCT02259270|Long term treatment
948997|NCT02259270|Risk factors
948998|NCT02259270|Hospitalisation
948999|NCT02259270|Non-critically ill
949000|NCT02259270|Adult
949001|NCT02259257|carotid arteriosclerosis
949002|NCT02259257|contrast-enhanced ultrasound
949003|NCT02259257|neovascularization
949004|NCT02259257|quantitative analysis
949005|NCT02259257|3D/4D imaging
949006|NCT02259257|CEUS
949007|NCT02259257|Vasa vasorum
949008|NCT02259231|RTA 408
949009|NCT02259231|RTA 408 Capsules
949010|NCT02259231|Myeloid-derived suppressor cells (MDSDs)
949011|NCT02259231|iNOS
949012|NCT02259231|Melanoma
949013|NCT02259231|Checkpoint inhibitor
949014|NCT02259231|omaveloxolone
949015|NCT02259218|Biomarker
949016|NCT02259218|Radiation
949017|NCT02259205|platelet activating factor
949018|NCT02259205|inflammatory markers
949019|NCT02259205|yogurt
949020|NCT02259205|olive oil
949021|NCT02259205|platelet aggregation
949022|NCT02259205|oxidative stress
949023|NCT02259205|endothelial damage
949024|NCT02259205|bioactive lipids
949025|NCT02259192|deaf adult
949026|NCT02259192|single-sided
949027|NCT02259192|cochlear implant
949028|NCT02259179|Obesity
949029|NCT02259179|Overweight
949030|NCT02259179|Contrave
949031|NCT02259179|Antiobesity agents
949032|NCT02259179|Antiobesity drugs
949033|NCT02259179|Weight loss drug
949034|NCT02259179|Bioequivalence
949035|NCT02259179|Pharmacokinetic
949036|NCT02259153|Lipids
949037|NCT02259153|Non Cholesterol Sterols
949038|NCT02259153|Oxysterols
949039|NCT02259153|Cholesterol Metabolism
949040|NCT02259140|cerebral palsy
949041|NCT02259140|randomized controlled trial
949042|NCT02259140|hip dislocation
949043|NCT02259140|hip subluxation
949044|NCT02259140|patient centered outcomes
949045|NCT02259140|cost effectiveness analysis
949046|NCT02259088|DME, macular edema, vision impairment, Chinese, diabetes
949047|NCT02259075|Migraine with aura
949048|NCT02259075|Migraine without aura
949049|NCT02259075|Headache disorders
949050|NCT02259075|Botulinum Toxin Type A
949051|NCT02259075|Sphenopalatine Ganglion Block
949052|NCT02259075|Autonomic Nerve Block
949053|NCT02259036|child anxiety
949054|NCT02259036|worries
949055|NCT02259036|fears
949056|NCT02259036|talk therapy
949057|NCT02259023|Stress Perception
949058|NCT02259023|Discretionary Calories
949059|NCT02259023|Health
949060|NCT02258997|sickle cell disease
949061|NCT02258958|venous thromboembolism prophylaxis
949062|NCT02258958|deep venous thrombosis
949063|NCT02258958|pulmonary embolus
949064|NCT02258958|thoracic surgery
949065|NCT02258958|lung resection
949066|NCT02258958|incidence
949067|NCT02258945|Type 1 diabetes
949068|NCT02258945|CSII
949069|NCT02258945|Continuous subcutaneous insulin infusion
949070|NCT02258945|Insulin pump
949071|NCT02258945|Nutrition
949072|NCT02258945|Eating behaviours
949073|NCT02258945|Quality of life
949074|NCT02258945|Cardiometabolic risks
949075|NCT02258945|Liverpool
949076|NCT02258945|NHS
949077|NCT02258945|Metabolomics
949078|NCT02258945|Observational
949079|NCT02258945|Lipoproteins
949080|NCT02258945|Lipids
949081|NCT02258945|Food
949082|NCT02258945|Food diary
949083|NCT02258945|Cross-Sectional
949084|NCT02258932|Type 1 diabetes
949085|NCT02258932|CSII
949086|NCT02258932|Continuous subcutaneous insulin infusion
949087|NCT02258932|Insulin pump
949088|NCT02258932|Nutrition
949089|NCT02258932|Eating behaviours
949090|NCT02258932|Quality of life
949091|NCT02258932|Cardiometabolic risks
949092|NCT02258932|Liverpool
949093|NCT02258932|NHS
949094|NCT02258932|Metabolomics
949095|NCT02258932|Observational
949096|NCT02258932|Lipoproteins
949097|NCT02258932|Lipids
949098|NCT02258932|Food
949099|NCT02258932|Food diary
949100|NCT02258932|Longitudinal
949101|NCT02258919|Intracerebral hemorrhage
949102|NCT02258919|Decompressive craniectomy
949103|NCT02258919|Randomized controlled trial
949104|NCT02258919|Acute stroke
949105|NCT02258893|Nitrogen Dioxide
949106|NCT02258893|Parts per billion
949107|NCT02258880|Acute Stroke
949108|NCT02258880|Outcome Measures
949109|NCT02258880|Physical Performance
949110|NCT02258867|Uveitis
949111|NCT02258867|Behcet's Disease Uveitis
949112|NCT02258867|Behcet's Disease
949113|NCT02258854|Uveitis
949114|NCT02258854|Non-infectious Uveitis
949115|NCT02258854|Intermediate Uveitis
949116|NCT02258854|Posterior Uveitis
949117|NCT02258854|Panuveitis
949118|NCT02258854|Behçet's disease uveitis
949119|NCT02258841|domestic violence
949120|NCT02258841|mental health
949121|NCT02258841|safety planning
949122|NCT02258815|pediatric
949123|NCT02258815|haploidentical
949124|NCT02258815|stem cell transplantation
949125|NCT02258802|psychoeducational intervention
949126|NCT02258802|nutrition intervention
949127|NCT02258802|malnutrition
949128|NCT02258802|micronutrient deficiency
949129|NCT02258802|nutrition transition
949130|NCT02258789|Stroke, rehabilitation, spatial neglect
949131|NCT02258763|Pneumonia
949132|NCT02258763|Child
949133|NCT02258763|Outcome
949134|NCT02258763|Antibiotics
949135|NCT02258763|Etiology
949136|NCT02258737|Case management
949137|NCT02258737|psychiatric hospitalization
949138|NCT02258737|discharge
949139|NCT02258724|Adult
949140|NCT02258724|Registry
949141|NCT02258724|Grown-up congenital heart disease
949142|NCT02258711|Bipolar disorder
949143|NCT02258711|Psychoeducation
949144|NCT02258711|Smart-phone monitoring
949145|NCT02258685|Gut microbiota composition
949146|NCT02258672|Preoperative rehabilitation
949147|NCT02258672|Minimally invasive surgery
949148|NCT02258672|Functional capacity
949149|NCT02258646|Exercise
949150|NCT02258646|Rehabilitation
949151|NCT02258646|Telemedicine
949152|NCT02258646|Treatment Outcome
949153|NCT02258646|Costs and Cost Analysis
949154|NCT02258646|Physical Therapists
949155|NCT02258646|Adaptation, Psychological
949156|NCT02258568|Cigarette Smoking
949157|NCT02258568|Pregnancy
949158|NCT02258568|Postpartum smoking relapse
949159|NCT02258568|Romania
949160|NCT02258555|Chronic lymphocytic leukemia (CLL)
949161|NCT02258555|Follicular lymphoma (FL)
949162|NCT02258555|Small Lymphocytic Lymphoma (SLL)
949163|NCT02258555|Phosphatidylinositol 3 kinase (PI3K)
949164|NCT02258555|Marginal Zone Lymphoma (MZL)
949165|NCT02258542|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
949166|NCT02258529|Cancer
949167|NCT02258529|Indolent Non-Hodgkin Lymphoma
949168|NCT02258529|FL
949169|NCT02258529|SLL
949170|NCT02258503|Numerical scale
949171|NCT02258503|Pain in elderly patients admitted in emergency department
949172|NCT02258490|chronic myeloid leukemia
949173|NCT02258490|myelodysplastic syndrome
949174|NCT02258490|acute myeloid leukemia
949175|NCT02258490|CD34+ cell mobilization therapy
949176|NCT02258490|graft versus host disease
949177|NCT02258490|allogeneic hematopoietic stem cell
949178|NCT02258490|G-CSF
949179|NCT02258464|Breast Cancer
949180|NCT02258451|Breast Cancer
949181|NCT02258438|Sedentary Behavior
949182|NCT02258425|Homeless Women
949183|NCT02258425|Parolees
949184|NCT02258425|Probationers
949185|NCT02258425|Community Drug Treatment
949186|NCT02258425|Recidivism
949187|NCT02258412|antimicrobial
949188|NCT02258412|efficacy
949189|NCT02258412|hand
949190|NCT02258412|hygiene
949191|NCT02258412|bacteria
949192|NCT02258373|Diabetes Mellitus
949193|NCT02258373|Continuous Glucose Monitoring
949194|NCT02258360|Thromboelastometry
949195|NCT02258360|Haemostasis
949196|NCT02258360|Hypothermia
949197|NCT02258360|Heart Arrest
949198|NCT02258334|Influenza
949199|NCT02258334|Fluzone® Quadrivalent, Influenza Vaccine
949200|NCT02258334|Fluzone® Intradermal, Influenza Vaccine
949201|NCT02258334|Fluzone® High-Dose, Influenza Vaccine
949202|NCT02258295|Lateral Humeral Epicondylitis
949203|NCT02258295|Tendinitis
949204|NCT02258295|Tendinosis
949205|NCT02258295|Athletic Injuries
949206|NCT02258295|Elbow Joint
949207|NCT02258295|Sports Medicine
949208|NCT02258204|Cerebral Infarct
949209|NCT02258204|Thrombolysis
949210|NCT02258204|Tissue-type plasminogen activator
949211|NCT02258204|Neuroprotection
949212|NCT02258204|Anesthetic agent
949213|NCT02258204|Magnetic resonance imaging
949214|NCT02258191|NIV
949215|NCT02258191|COPD
949216|NCT02258191|telemonitoring
949217|NCT02258165|ovarian cancer
949218|NCT02258165|imaging
949219|NCT02258165|gated PET/CT scan
949220|NCT02258152|PDD
949221|NCT02258152|Parkinson's Disease Dementia
949222|NCT02258152|patients taking a cholinesterase inhibitor.
949223|NCT02258126|overweight children
949224|NCT02258126|hepatic fat
949225|NCT02258126|exercise
949226|NCT02258126|nutritional education program
949227|NCT02258126|cardiometabolic risk
949228|NCT02258087|Prostate, Cancer, Brachytherapy, HDR, LDR, monotherapy
949229|NCT02258048|Cirrhosis
949230|NCT02258035|vitamin D binding protein (DBP)
949231|NCT02258022|Wounds and Injuries
949232|NCT02258022|Sepsis
949233|NCT02257996|Psychoanalytic Psychotherapy
949234|NCT02257996|Telepsychology
949235|NCT02257996|Online Therapy
949236|NCT02257996|Web conferencing
949237|NCT02257996|RCT
949238|NCT02257996|HIPAA
949239|NCT02257983|hearing
949240|NCT02257983|noise
949241|NCT02257983|oxidative stress
949242|NCT02257970|Lymphedema
949243|NCT02257970|edema
949244|NCT02257970|swelling
949245|NCT02257931|infection
949246|NCT02257931|bacteria
949247|NCT02257931|gram-negative
949248|NCT02257931|HSCT
949249|NCT02257931|allogeneic
949250|NCT02257931|autologous
949251|NCT02257931|recipients, of all ages, for any indications
949252|NCT02257918|antibiotic
949253|NCT02257918|antimicrobial
949254|NCT02257918|AZD0914
949255|NCT02257918|Ceftriaxone
949256|NCT02257918|drug-resistant
949257|NCT02257918|sexually transmitted infection
949258|NCT02257918|urogenital gonorrhoea
949259|NCT02257905|AL Amyloidosis
949260|NCT02257905|Amyloidosis
949261|NCT02257905|allogeneic
949262|NCT02257905|HSCT
949263|NCT02257892|CTLA4
949264|NCT02257892|PI3KCD
949265|NCT02257892|MAG T1
949266|NCT02257892|Rare Immune Disorders
949267|NCT02257892|Genetic Testing
949268|NCT02257879|Midazolam
949269|NCT02257879|CYP3A
949270|NCT02257879|Loperamide
949271|NCT02257866|Autoimmunity
949272|NCT02257866|Adult and Pediatric Disease
949273|NCT02257866|Vasculitis
949274|NCT02257866|Rheumatic Disease
949275|NCT02257853|Caregiver Stress
949276|NCT02257853|Cancer Caregivers
949277|NCT02257853|Yoga-Based Stress Reduction Intervention
949278|NCT02257853|HSCT Caregivers
949279|NCT02257827|Hypofractionated schedule
949280|NCT02257827|Intensity Modulated Radiotherapy
949281|NCT02257827|Conformal radiotherapy
949282|NCT02257801|Memory
949283|NCT02257801|Cognition
949284|NCT02257801|Execute Function
949285|NCT02257801|Attention
949286|NCT02257801|Mood
949287|NCT02257762|Ready-to-use supplementary food (RUSF)
949288|NCT02257762|Lipid-based nutrient supplement (LNS)
949289|NCT02257762|Multiple micronutrients (MMN)
949290|NCT02257762|Complementary feeding
949291|NCT02257762|Home fortification
949292|NCT02257762|Efficacy/impact
949293|NCT02257762|Infant and young child feeding (IYCF)
949294|NCT02257762|Cambodia
949295|NCT02257762|Cluster randomised controlled trial
949296|NCT02257749|Concussion
949297|NCT02257749|Persistent Symptoms
949298|NCT02257749|Children
949299|NCT02257749|Exercise
949300|NCT02257749|Adolescents
949301|NCT02257749|Active Rehabilitation
949302|NCT02257749|Education
949303|NCT02257736|Prostatic neoplasms
949304|NCT02257736|JN56021927
949305|NCT02257736|ZYTIGA
949306|NCT02257736|Prednisone
949307|NCT02257736|Abiraterone acetate
949308|NCT02257736|Apalutamide
949309|NCT02257723|Inpatient care
949310|NCT02257723|Complementary and alternative medicine
949311|NCT02257723|Integrated medicine
949312|NCT02257710|national
949313|NCT02257710|Multicenter
949314|NCT02257710|Observational registry
949315|NCT02257710|Orsiro Drug Eluting Stent (DES)
949316|NCT02257710|Stenting
949317|NCT02257710|Treatment of coronary artery disease
949318|NCT02257710|Coronary revascularization
949319|NCT02257710|Coronary Intervention
949320|NCT02257710|STEMI
949321|NCT02257710|NSTEMI
949322|NCT02257710|Ischemia
949323|NCT02257710|Angina
949324|NCT02257710|Acute Myocardial Infarction (AMI)
949325|NCT02257710|Small Vessels
949326|NCT02257710|Chronic Total Occlusion
949327|NCT02257684|ALL
949328|NCT02257684|LBL
949329|NCT02257658|Men who have Sex with Men
949330|NCT02257658|HIV-positive
949331|NCT02257658|Syphilis
949332|NCT02257658|Contingency Management
949333|NCT02257619|Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
949334|NCT02257593|macronutrient
949335|NCT02257593|malnutrition
949336|NCT02257593|birth weight
949337|NCT02257593|protein leverage
949338|NCT02257580|E-Aminocaproic Acid
949339|NCT02257580|Bilateral Varus Rotational Osteotomy
949340|NCT02257580|Blood Loss and Transfusion
949341|NCT02257580|Complications
949342|NCT02257580|Safety
949343|NCT02257554|expectations
949344|NCT02257541|BGJ398
949345|NCT02257541|Imatinib Mesylate
949346|NCT02257541|14-140
949347|NCT02257502|aflibercept
949348|NCT02257502|iodiopathic choroidal neovascularization
949349|NCT02257502|young patient
949350|NCT02257476|carfilzomib
949351|NCT02257476|advanced solid malignancies
949352|NCT02257476|advanced solid cancers
949353|NCT02257476|prostate
949354|NCT02257476|bladder
949355|NCT02257476|colon
949356|NCT02257476|breast
949357|NCT02257476|lung
949358|NCT02257463|COPD
949359|NCT02257463|inspiratory muscle training
949360|NCT02257463|dyspnea
949361|NCT02257463|Quality of Life
949362|NCT02257450|Primary Aldosteronism
949363|NCT02257450|Hyperaldosteronism
949364|NCT02257437|Ready-to-use supplementary food (RUSF)
949365|NCT02257437|Lipid-based nutrient supplement (LNS)
949366|NCT02257437|Multiple micronutrients (MMN)
949367|NCT02257437|Complementary feeding
949368|NCT02257437|Home fortification
949369|NCT02257437|Acceptability
949370|NCT02257437|Infant and young child feeding (IYCF)
949371|NCT02257437|Cambodia
949372|NCT02257437|Cross-over studies
949373|NCT02257411|child
949374|NCT02257411|ear based
949375|NCT02257411|Proseal LMA
949376|NCT02257398|TQTc
949377|NCT02257398|Moxifloxacin
949378|NCT02257398|GSK2140944
949379|NCT02257385|indacaterol
949380|NCT02257385|efficacy
949381|NCT02257385|FEV1
949382|NCT02257385|ELLIPTA
949383|NCT02257385|non inferiority
949384|NCT02257385|vilanterol
949385|NCT02257385|COPD
949386|NCT02257385|safety
949387|NCT02257385|tiotropium
949388|NCT02257385|umeclidinium bromide
949389|NCT02257385|GSK573719
949390|NCT02257372|FEV1
949391|NCT02257372|DPI
949392|NCT02257372|ICS/LABA
949393|NCT02257372|UMEC
949394|NCT02257372|COPD
949395|NCT02257359|Epelsiban
949396|NCT02257359|Healthy Female Volunteers
949397|NCT02257359|Safety
949398|NCT02257359|Tolerability
949399|NCT02257359|Oxytocin
949400|NCT02257359|Pharmacokinetics
949401|NCT02257346|Pregnancy
949402|NCT02257346|Lidocaine
949403|NCT02257346|Quality
949404|NCT02257346|Recovery
949405|NCT02257333|Retinal Vein Occlusion
949406|NCT02257333|Atherosclerosis
949407|NCT02257333|Risk Factors
949408|NCT02257333|Major Adverse Cardiovascular Events
949409|NCT02257307|ROP
949410|NCT02257307|retinopathy
949411|NCT02257307|Referral warranted retinopathy
949412|NCT02257281|Sodium lauryl sulfate
949413|NCT02257281|Skin irritants
949414|NCT02257281|inflammation
949415|NCT02257281|therapeutic ultrasound
949416|NCT02257268|health behavior; risk factors;
949417|NCT02257255|cesarean section
949418|NCT02257255|pain, postoperative/diagnosis
949419|NCT02257255|pain measurement/methods
949420|NCT02257242|Bendamustine
949421|NCT02257242|Rituximab
949422|NCT02257242|Vincristine sulfate
949423|NCT02257242|Vincristine sulfate liposome injection
949424|NCT02257242|Phase I
949425|NCT02257242|Escalation With Overdose Control
949426|NCT02257229|Feet, deformity, correction, management, gait
949427|NCT02257203|Dietary sucrose
949428|NCT02257190|Glycemic control
949429|NCT02257190|Exercise
949430|NCT02257164|anterior cruciate ligament reconstruction
949431|NCT02257164|femoral nerve block
949432|NCT02257164|articular injection and obturator nerve block
949433|NCT02257151|Volunteers
949434|NCT02257138|Leukemia
949435|NCT02257138|Myeloproliferative Diseases
949436|NCT02257138|Acute Myeloid Leukemia
949437|NCT02257138|AML
949438|NCT02257138|Ruxolitinib
949439|NCT02257138|Jakafi
949440|NCT02257138|INCB018424
949441|NCT02257138|INC424
949442|NCT02257138|Decitabine
949443|NCT02257138|Dacogen
949444|NCT02257138|Post myeloproliferative neoplasm
949445|NCT02257138|Post MPN-AML
949446|NCT02257125|rehabilitation
949447|NCT02257125|virtual reality
949448|NCT02257125|stroke
949449|NCT02257125|upper extremity
949450|NCT02257125|arm
949451|NCT02257125|feedback
949452|NCT02257125|reward
949453|NCT02257060|Endocardial Ablation
949454|NCT02257060|Atrial Flutter
949455|NCT02257060|Cavotricuspid Isthmus
949456|NCT02256995|Pregnancy
949457|NCT02256995|Preeclampsia
949458|NCT02256995|Eclampsia
949459|NCT02256995|Proteinuria
949460|NCT02256982|unresectable intrahepatic cholangiocarcinoma
949461|NCT02256982|resectable intrahepatic cholangiocarcinoma
949462|NCT02256956|Pharmacogenetics of Amitriptyline
949463|NCT02256943|Pharmacogenetics of Amitriptyline
949464|NCT02256904|Alignment
949465|NCT02256904|Kinematic
949466|NCT02256904|knee
949467|NCT02256904|satisfaction
949468|NCT02256904|function
949469|NCT02256904|survivorship
949470|NCT02256891|Rotator cuff tear
949471|NCT02256891|Rotator cuff injury
949472|NCT02256891|Shoulder pain
949473|NCT02256891|Shoulder injury
949474|NCT02256865|Sleep Restriction
949475|NCT02256865|Insulin Resistance
949476|NCT02256865|Testosterone
949477|NCT02256865|Cortisol
949478|NCT02256839|Tuberculosis
949479|NCT02256839|TB
949480|NCT02256683|atrial fibrillation
949481|NCT02256683|atrial flutter
949482|NCT02256683|Atrial-Appendage Thrombus
949483|NCT02256683|Thrombus resolution
949484|NCT02256683|Dabigatran
949485|NCT02256683|Phenprocoumon
949486|NCT02256683|Transesophageal Echocardiography
949487|NCT02256670|Hormone Receptor Positive
949488|NCT02256618|neonatal encephalopathy
949489|NCT02256618|hypoxic-ischemic encephalopathy
949490|NCT02256618|newborn infants
949491|NCT02256618|neonates
949492|NCT02256618|umbilical cord blood cells
949493|NCT02256592|inflammation
949494|NCT02256592|microbiome
949495|NCT02256592|immune activation
949496|NCT02256592|fecal microbiota transplantation
949497|NCT02256592|dysbiosis
949498|NCT02256579|TDF:Tenofovir, Urine beta2microglobulin
949499|NCT02256566|cognitive training
949500|NCT02256566|depression
949501|NCT02256566|bipolar depression
949502|NCT02256566|anxiety
949503|NCT02256566|ptsd
949504|NCT02256566|generalized anxiety
949505|NCT02256566|social phobia
949506|NCT02256514|therapeutic vaccine
949507|NCT02256501|Dilated cardiomyopathy pediatric heart failure cell therapy
949508|NCT02256449|Coronary artery disease; angioplasty; bioresorbable device
949509|NCT02256436|P-D1
949510|NCT02256436|PD-1
949511|NCT02256436|PD1
949512|NCT02256436|P-DL1
949513|NCT02256436|PD-L1
949514|NCT02256436|PDL-1
949515|NCT02256436|PDL1
949516|NCT02256436|Bladder cancer
949517|NCT02256423|Ibuprofen
949518|NCT02256423|healthy volunteer study
949519|NCT02256423|pharmacokinetics
949520|NCT02256410|low back pain
949521|NCT02256410|chronic pain
949522|NCT02256410|sensitization
949523|NCT02256410|treatment
949524|NCT02256410|trigger points
949525|NCT02256397|Asthma
949526|NCT02256384|Respiration Rate
949527|NCT02256384|Respiratory Acoustic Monitor
949528|NCT02256384|postoperative
949532|NCT02256358|child, ketamine, midazolam
949533|NCT02256319|Deep brain stimulation
949534|NCT02256319|Dexmedetomidine
949535|NCT02256319|Propofol
949536|NCT02256293|Type 1 Diabetes
949537|NCT02256280|Neuromuscular blockade
949538|NCT02256280|Thoracic surgery
949539|NCT02256254|Oxidative stress
949540|NCT02256254|Simvastatin
949541|NCT02256228|Analgesia
949542|NCT02256228|Local infiltration analgesia
949543|NCT02256228|Pain, relief
949544|NCT02256228|Pain, Postoperative
949545|NCT02256228|Intra-peritoneal analgesia
949546|NCT02256228|Ropivacaine
949547|NCT02256228|Saline
949548|NCT02256228|Therapeutic Uses
949549|NCT02256228|Analgesics, Non-Narcotic
949550|NCT02256228|Analgesics
949551|NCT02256228|Opioids
949552|NCT02256228|Morphine
949553|NCT02256228|Pain
949554|NCT02256228|Postoperative Complications
949555|NCT02256228|Physiological Effects of Drugs
949556|NCT02256228|Anesthetics, Local
949557|NCT02256228|Anesthetic
949558|NCT02256228|Cytoreductive
949559|NCT02256228|Surgery
949560|NCT02256228|Cancer
949561|NCT02256215|Vitamin D
949562|NCT02256163|Thoracic Aortic Aneurysm (TAA)
949563|NCT02256163|gene
949564|NCT02256163|familial TAA
949565|NCT02256163|blood collection
949566|NCT02256137|Frailty phenotype
949567|NCT02256137|Physical fitness
949568|NCT02256137|Childhood cancer
949569|NCT02256137|Late onset of chronic health conditions
949570|NCT02256137|Physical frailty
949578|NCT02256098|Comparative Study
949579|NCT02256098|Knee Prosthesis
949580|NCT02256098|Prosthesis Design
949581|NCT02256098|Treatment Outcome
949582|NCT02256098|Follow-Up Studies
949583|NCT02256098|Arthroplasty, Replacement, Knee/methods
949584|NCT02256085|Dissociative
949585|NCT02256085|Dissociation
949586|NCT02256085|Depersonalization
949587|NCT02256085|Depersonalization Disorder
949588|NCT02256085|Transcranial Magnetic Stimulation
949589|NCT02256085|TMS
949590|NCT02256085|DPD
949591|NCT02256085|rTMS
949592|NCT02256085|Behavioral Symptoms
949593|NCT02256072|aging, geriatrics, aging in place, home services
949594|NCT02256033|Mild hepatic impairment
949595|NCT02256033|Healthy volunteer
949596|NCT02256033|Istradefylline
949597|NCT02256020|Wheel-chair dependent, music aerobic exercise, depression, insomnia
949598|NCT02256007|Videogames; stroke
949599|NCT02255981|macular, degeneration, acupuncture, visual acuity, OCT
949600|NCT02255968|Normal Volunteers
949601|NCT02255968|Safety
949602|NCT02255968|Pharmacokinetics
949603|NCT02255955|naproxen sodium codeine
949604|NCT02255955|paracetamol codeine
949605|NCT02255955|disk surgery
949606|NCT02255929|Benign Essential Tremor
949607|NCT02255929|Tremor
949608|NCT02255929|Neurologic Manifestations
949609|NCT02255929|Nervous System Diseases
949610|NCT02255929|Movement Disorders
949611|NCT02255929|Central Nervous System Diseases
949612|NCT02255916|oncology
949613|NCT02255916|psychology
949614|NCT02255916|cancer
949615|NCT02255916|music
949616|NCT02255916|sound-bed
949617|NCT02255877|Bi lateral knee surgery
949618|NCT02255877|uni compartmental
949619|NCT02255864|Stents
949620|NCT02255864|Angioplasty
949621|NCT02255864|Coronary Vessels
949622|NCT02255864|Coronary Artery Disease
949623|NCT02255864|Angina Pectoris
949624|NCT02255864|Myocardial Ischemia
949625|NCT02255864|Myocardial Infarction
949626|NCT02255864|Myocardial Revascularization
949627|NCT02255851|selected for TAVR by heart team consensus
949628|NCT02255851|treated with CE-Marked TAVR devices
949629|NCT02255799|traumatic brain injury
949630|NCT02255799|TBI
949631|NCT02255799|brain injury
949632|NCT02255799|memory
949633|NCT02255799|verbal memory deficits
949634|NCT02255799|memory problems
949635|NCT02255799|cognition
949636|NCT02255799|cognitive impairment
949637|NCT02255799|neuropsychiatric symptoms
949638|NCT02255799|donepezil
949639|NCT02255799|acetylcholinesterase inhibitor
949640|NCT02255786|Group Therapy
949641|NCT02255786|Parents
949642|NCT02255786|Autism
949643|NCT02255786|Quality of Life
949644|NCT02255773|Head and Neck Cancer
949645|NCT02255773|HNC
949646|NCT02255773|Moderate to severe fatigue
949647|NCT02255773|Computerized tasks
949648|NCT02255773|Questionnaires
949649|NCT02255773|Surveys
949650|NCT02255773|Disease-free adult males
949651|NCT02255773|Cancer survivors
949652|NCT02255760|MEDI3902, Safety, Pharmacokinetics
949653|NCT02255747|infants and children with constipation
949654|NCT02255734|Volunteers
949655|NCT02255695|posture
949656|NCT02255695|child
949657|NCT02255695|prevention
949658|NCT02255695|muscle strength
949787|NCT02255032|panuveitis
949659|NCT02255695|muscle stretching exercises
949660|NCT02255695|exercise therapy
949661|NCT02255695|disease management
949662|NCT02255695|musculoskeletal pain
949663|NCT02255695|adolescent
949664|NCT02255695|spinal curvatures
949665|NCT02255682|physical activity
949666|NCT02255682|statin therapy
949667|NCT02255682|diabetes mellitus
949668|NCT02255682|cardiovascular disease
949669|NCT02255682|Q10-supplementation
949670|NCT02255643|motor cortex stimulation
949671|NCT02255643|chronic neuropathic pain
949672|NCT02255630|salbutamol
949673|NCT02255630|exercise-induced bronchoconstriction
949674|NCT02255630|anaerobic power
949675|NCT02255604|Allergic Rhinitis
949676|NCT02255604|Allergen immunotherapy
949677|NCT02255591|Hip surgery anesthesia
949678|NCT02255591|Perioperative analgesia
949679|NCT02255565|Quillivant
949680|NCT02255552|DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
949681|NCT02255500|Total knee arthroplasty
949682|NCT02255487|surgical device
949683|NCT02255487|surgical irrigation device
949684|NCT02255487|surgical site infection prophylaxis
949685|NCT02255474|pediatrics
949686|NCT02255474|refractive error - myopia
949687|NCT02255474|contact lenses
949688|NCT02255474|intervention
949694|NCT02255422|omaveloxolone
949695|NCT02255422|RTA 408 capsules
949696|NCT02255422|mitochondrial myopathies
949697|NCT02255383|Osteoarthritis
949698|NCT02255383|Rheumatoid Arthritis
949699|NCT02255383|Traumatic Arthritis
949700|NCT02255383|Polyarthritis
949701|NCT02255383|Total Knee Arthroplasty
949702|NCT02255370|Curcumin. Crohn's disease. Post-operative recurrence. Thiopurines . Rutgeerts endoscopic score
949703|NCT02255357|Oxytocin
949704|NCT02255357|Vasopressin
949705|NCT02255357|Cocaine
949706|NCT02255344|Acute Coronary Syndromes
949707|NCT02255344|Risk Model
949708|NCT02255344|National Registry
949709|NCT02255344|Comprehensive Care Program
949710|NCT02255344|Major Cardiovascular Events
949711|NCT02255331|Arthroplasty
949712|NCT02255331|Replacement
949713|NCT02255331|Hip
949714|NCT02255318|Taurolock®
949715|NCT02255318|infections related to chambers implantable catheter
949716|NCT02255318|patients with cancer receiving parenteral nutrition
949717|NCT02255305|CDI
949718|NCT02255305|C difficile
949719|NCT02255305|C diff
949720|NCT02255305|Clostridium difficile
949721|NCT02255253|Telmisartan
949722|NCT02255253|Hydrochlorothiazide
949723|NCT02255253|Efficacy
949724|NCT02255253|hypertension
949725|NCT02255253|high sodium intake
949726|NCT02255240|breast cancer
949727|NCT02255240|cancer
949728|NCT02255240|survivorship
949729|NCT02255240|cancer survivor
949730|NCT02255240|physical activity
949731|NCT02255240|video game
949732|NCT02255240|women
949733|NCT02255240|women's health
949734|NCT02255227|vaccination
949735|NCT02255227|randomized
949736|NCT02255227|anti-pneumococcal
949737|NCT02255227|Pneumo 23
949738|NCT02255227|Prevenar 13
949739|NCT02255227|Chronic Inflammatory Bowel Disease
949740|NCT02255188|Haemostas, prosthesis
949741|NCT02255175|Reproductive Affective Disorder
949742|NCT02255175|Depression
949743|NCT02255175|Perimenopause
949744|NCT02255175|Estrogen
949745|NCT02255175|Estradiol treatment
949746|NCT02255175|Mood Disorders
949747|NCT02255175|Estrogen Replacement Therapy
949748|NCT02255175|Sex Steroids
949749|NCT02255175|Depressive disorder
949750|NCT02255175|Mental Disorders
949751|NCT02255175|Estradiol
949752|NCT02255175|Hormones
949753|NCT02255175|Physiological effects of drugs
949754|NCT02255175|Reproductive Control Agents
949755|NCT02255162|Acute Myeloid Leukemia (AML)
949756|NCT02255162|Acute Myelocytic Leukemia
949757|NCT02255162|Acute Myelogenous Leukemia
949758|NCT02255162|Acute Granulocytic Leukemia
949759|NCT02255162|Acute Non-Lymphocytic Leukemia
949760|NCT02255136|Interleukin
949761|NCT02255136|Immunoglobulin
949762|NCT02255136|Homeopathy
949763|NCT02255136|Allergic Rhinitis
949764|NCT02255136|Asthma
949765|NCT02255110|Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
949766|NCT02255110|TH-302
949767|NCT02255110|Doxorubicin
949768|NCT02255110|Evofosfamide
949769|NCT02255097|PD-1
949770|NCT02255097|PD1
949771|NCT02255097|PD-L1
949772|NCT02255097|PDL1
949773|NCT02255084|Cervical cancer screening
949774|NCT02255084|High Risk Human papillomavirus Infection
949775|NCT02255084|vaginal self-sampling
949776|NCT02255084|pap smear
949777|NCT02255084|general practitioner
949778|NCT02255071|GERD
949779|NCT02255071|Neiguan
949780|NCT02255071|Acupressure
949781|NCT02255071|P6
949782|NCT02255032|uveitis
949783|NCT02255032|macular edema
949784|NCT02255032|UME
949785|NCT02255032|posterior uveitis
949786|NCT02255032|anterior uveitis
949788|NCT02255032|intermediate uveitis
949789|NCT02255032|noninfectious uveitis
949790|NCT02255032|triamcinolone acetonide
949791|NCT02255032|suprachoroidal space
949792|NCT02255032|injection
949793|NCT02255032|microneedle
949794|NCT02255032|intravitreal injection
949795|NCT02255032|corticosteroid
949796|NCT02255032|CME
949797|NCT02255032|choroid
949798|NCT02255032|retina
949799|NCT02255032|microinjection
949800|NCT02255032|SCS
949801|NCT02255006|volunteer
949802|NCT02255006|BMI(25 kg/m2)
949803|NCT02254980|Total hip arthroplasty
949804|NCT02254980|Cemented acetabular cup
949805|NCT02254980|Vitamin-E
949806|NCT02254980|Radiostereometry
949807|NCT02254980|Fixation of cemented acetabular component in total hip arthroplasty
949808|NCT02254967|Aged
949809|NCT02254967|Fidaxomicin
949810|NCT02254967|Clostridium Difficile
949811|NCT02254967|Vancomycin
949812|NCT02254954|glioblastoma
949813|NCT02254941|Metastatic Colon Cancer
949814|NCT02254941|Monoclonal antibodies
949815|NCT02254941|Chemotherapy
949816|NCT02254941|First line
949817|NCT02254928|poor ovarian response
949818|NCT02254928|controlled ovarian stimulation
949819|NCT02254928|randomised clinical trial
949820|NCT02254928|corifollitropin alfa
949821|NCT02254928|recombinant follicle-stimulating hormone (rFSH)
949822|NCT02254928|human menopausal gonadotropin (HMG)
949823|NCT02254915|Synergo
949824|NCT02254915|RITE
949825|NCT02254915|SHTC
949826|NCT02254915|Non Muscle Invasive Bladder Cancer
949827|NCT02254915|NMIBC
949828|NCT02254915|Superficial Bladder Cancer
949829|NCT02254915|Urothelial Cell Cancer
949830|NCT02254915|Transitional Cell Cancer
949831|NCT02254915|Mitomycin
949832|NCT02254902|sedentary lifestyle
949833|NCT02254902|physical activity
949834|NCT02254902|Somali women
949835|NCT02254902|prevention
949836|NCT02254876|Stroke
949837|NCT02254876|Hemiplegia
949838|NCT02254876|Painful shoulder Syndrome
949839|NCT02254876|NeuroMuscolar Taping
949840|NCT02254863|Adrenoleukodystrophy
949841|NCT02254863|Batten Disease
949842|NCT02254863|Hunter Syndrome
949843|NCT02254863|Krabbe
949844|NCT02254863|Metachromatic Leukodystrophy
949845|NCT02254863|ALD
949846|NCT02254863|MLD
949847|NCT02254863|PMD
949848|NCT02254850|Mesoglycan
949849|NCT02254850|Metabolic Syndrome
949850|NCT02254850|Flow Mediated Dilation
949851|NCT02254824|Xuezhikang
949852|NCT02254824|atorvastatin
949853|NCT02254785|poor prognosis
949854|NCT02254785|castrate-resistant prostate cancer
949855|NCT02254785|cabazitaxel
949856|NCT02254785|abiraterone
949857|NCT02254785|enzalutamide
949858|NCT02254733|CBSST
949859|NCT02254733|Schizoaffective Disorder
949860|NCT02254733|Psychotic Disorder
949861|NCT02254733|Cognitive Behavioral Therapy
949862|NCT02254733|Social Skills Training
949863|NCT02254733|Assertive Community Treatment
949864|NCT02254694|sagittal balance
949865|NCT02254694|posture
949866|NCT02254694|lumbar lordosis
949867|NCT02254694|high heeled shoes
949868|NCT02254681|low-dose radiotherapy
949869|NCT02254681|gemcitabine
949870|NCT02254681|cisplatin
949871|NCT02254681|cholangiocarcinoma
949872|NCT02254668|intima
949873|NCT02254668|thickness
949874|NCT02254668|transplantation
949875|NCT02254668|cardiology
949876|NCT02254668|immunosuppression
949877|NCT02254655|puerarin
949878|NCT02254655|rheumatoid arthritis
949879|NCT02254655|atherosclerosis
949880|NCT02254655|carotid intima-media thickness
949881|NCT02254629|Fecal microflora
949882|NCT02254629|IBS
949883|NCT02254629|Sequential treatment
949884|NCT02254629|Probiotic
949885|NCT02254629|Laxative
949886|NCT02254616|Stroke Rehabilitation
949887|NCT02254616|Hybrid therapy
949888|NCT02254616|Mirror Therapy
949889|NCT02254616|Transcranial Direct Current Stimulation
949890|NCT02254603|Obesity, ayuveda yoga exercise, acupuncture.
949891|NCT02254590|IEDL
949892|NCT02254590|irrigation endoscopic decompressive laminotomy
949893|NCT02254590|irrigation endoscopic decompression
949894|NCT02254590|minimally invasive spine surgery
949895|NCT02254590|endoscopic decompression
949896|NCT02254590|spinal stenosis
949904|NCT02254551|relapsed multiple myeloma
949905|NCT02254551|refractory multiple myeloma
949906|NCT02254551|LDE225
949907|NCT02254551|Sonidegib
949908|NCT02254551|bortezomib
949909|NCT02254551|smoothened (SMO) inhibitors
949910|NCT02254551|Velcade
949911|NCT02254473|Knee
949912|NCT02254473|Osteoarthritis
949913|NCT02254447|relative bio-availability
949914|NCT02254447|fasting
949915|NCT02254447|GW615775
949916|NCT02254447|Candesartan cilexetil
949917|NCT02254447|ATACAND
949918|NCT02254434|single-dose
949919|NCT02254434|fasting
949920|NCT02254434|eltrombopag 50 mg
949921|NCT02254434|pharmacokinetic
949922|NCT02254434|healthy volunteers
949923|NCT02254434|Open-label
949924|NCT02254421|Respiratory Syncytial Virus (RSV)
949925|NCT02254421|Antiviral
949926|NCT02254421|Hematopoietic Cell Transplant (HCT)
949927|NCT02254421|Lower respiratory tract infection
949928|NCT02254408|Respiratory Syncytial Virus (RSV)
949929|NCT02254408|Antiviral
949930|NCT02254408|Hematopoietic Cell Transplant (HCT)
949931|NCT02254408|Upper respiratory tract infection
949932|NCT02254382|diastolic heart failure
949933|NCT02254356|drug-eluting stent, paclitaxel-eluting stent, peripheral artery disease, peripheral vascular disease, superficial femoral artery, popliteal artery
949934|NCT02254343|stroke rehabilitation
949935|NCT02254343|robot-assisted therapy
949936|NCT02254330|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
949937|NCT02254317|Impaired Glucose Tolerance
949938|NCT02254317|Oral Glucose Tolerance Test
949939|NCT02254317|Grape Seed Extract
949940|NCT02254304|Relapsing multiple sclerosis
949941|NCT02254304|Clinically isolated syndrome
949942|NCT02254304|RMS
949943|NCT02254304|CIS
949944|NCT02254304|RebiSmart™
949945|NCT02254304|Rebif®
949946|NCT02254304|Interferon beta-1a
949947|NCT02254252|Slow coronary flow phenomenon
949948|NCT02254252|Angina pectoris
949949|NCT02254252|chest pain
949950|NCT02254252|nicroandil
949951|NCT02254213|Intra-individual stability, EEG
949952|NCT02254200|exercise
949953|NCT02254200|fat oxidation
949954|NCT02254200|indirect calorimetry
949955|NCT02254200|insulin sensitivity
949956|NCT02254200|weight management
949957|NCT02253810|Dysplasia, Congenital Hip
949958|NCT02253810|Osteotomy
949959|NCT02253810|Blood Transfusion
949960|NCT02253810|Tranexamic Acid
949961|NCT02253758|Magnetic Resonance Imaging
949962|NCT02253758|Electroencephalography
949963|NCT02253758|Conscious Sedation
949964|NCT02253758|Deep Sedation
949965|NCT02253758|Arousal
949966|NCT02253758|Consciousness
949967|NCT02253745|ADHD
949968|NCT02253745|Attention Deficit/ Hyperactivity Disorder
949969|NCT02253732|MicroRNAs
949970|NCT02253732|exercise
949971|NCT02253732|skeletal muscle
949972|NCT02253732|metabolism
949973|NCT02253719|cervical neoplasia
949974|NCT02253719|cervical cancer'
949975|NCT02253719|visual inspection acetic acid
949976|NCT02253719|cryotherapy
949977|NCT02253706|bronchoscopy
949978|NCT02253706|hypoxia
949979|NCT02253706|oxygen supplementation
949980|NCT02253706|safety
949981|NCT02253693|Hemophilia A
949982|NCT02253693|Hemophilic arthropathy
949983|NCT02253693|Accelerometry
949984|NCT02253680|Osteoarthritis
949985|NCT02253680|Total knee replacement
949986|NCT02253680|Enhanced recovery
949987|NCT02253680|Compression bandages
949988|NCT02253667|Palliative care
949989|NCT02253667|Lung disease
949990|NCT02253667|Acute Respiratory Distress Syndrome
949991|NCT02253667|High-flow oxygen nasal cannula
949992|NCT02253667|Dyspnoea
949993|NCT02253667|Opioids
949994|NCT02253654|Chronic Kidney Disease
949995|NCT02253654|Anemia
949996|NCT02253654|Hemodialysis
949997|NCT02253654|Red Blood Cell Transfusion
949998|NCT02253641|African American, Women
949999|NCT02253641|Weight Loss
950000|NCT02253628|Coffee
950001|NCT02253628|Gastrin
950002|NCT02253628|Alpha-amylase
950003|NCT02253628|Cortisol
950004|NCT02253628|Self-reported gastrointestinal symptoms
950005|NCT02253628|Self-reported stress
950006|NCT02253628|Blood pressure
950007|NCT02253615|Aging
950008|NCT02253615|Resistance training
950009|NCT02253615|Muscle strength
950010|NCT02253615|Functional performance
950011|NCT02253615|Postural balance
950012|NCT02253602|Esophageal Neoplasms
950013|NCT02253602|Lymph Nodes
950014|NCT02253602|USPIO
950015|NCT02253602|Magnetic Resonance Imaging
950016|NCT02253576|infant
950017|NCT02253576|bronchiolitis
950018|NCT02253576|hypertonic saline
950019|NCT02253537|Tuberculosis
950020|NCT02253537|TB
950021|NCT02253524|Metoclopramide
950022|NCT02253524|Dimenhydrinate
950023|NCT02253524|emergency medicine
950024|NCT02253511|Hepatocellular carcinoma
950025|NCT02253511|Hepotectomy
950026|NCT02253511|Recurrence-free survival
950027|NCT02253511|Overall survival
950028|NCT02253485|Mother-to-child transmission
950029|NCT02253446|Dysmenorrhea
950030|NCT02253446|Piroxicam
950031|NCT02253446|Diclofenac Sodium
950032|NCT02253446|Emergency department
950033|NCT02253433|asthma
950034|NCT02253433|environmental triggers
950035|NCT02253433|home-based intervention
950036|NCT02253433|asthma home visits
950037|NCT02253420|Phase 1
950038|NCT02253420|Advanced solid tumor
950039|NCT02253420|PI3 Kinase inhibitor
950040|NCT02253420|Drug-drug Interaction
950041|NCT02253394|Pulmonary Arterial Hypertension (PAH)
950042|NCT02253394|Ambrisentan
950043|NCT02253394|Spironolactone
950044|NCT02253394|Selective Endothelin A (ETA) inhibition
950045|NCT02253394|Aldosterone antagonism
950046|NCT02253394|Cardiac output (CO)
950047|NCT02253394|Right ventricular (RV) function
950048|NCT02253394|Heart failure
950049|NCT02253394|Quality of life
950050|NCT02253394|Pro-inflammatory cytokine
950051|NCT02253394|Interleukin-6 (IL-6)
950052|NCT02253394|Troponin-I
950053|NCT02253394|N-terminal pro-brain natriuretic peptide (NT-BNP)
950054|NCT02253394|Collagen metabolism
950055|NCT02253394|N-terminal procollagen type I
950056|NCT02253394|Collagen III
950057|NCT02253394|Echocardiography
950058|NCT02253394|WHO Functional Class
950059|NCT02253394|Cardiopulmonary Exercise Test with Innocor
950060|NCT02253394|Peak oxygen consumption (pVO2)
950061|NCT02253394|Liver function markers (AST/ALT)
950062|NCT02253394|Renal function markers (creatinine and potassium)
950063|NCT02253381|lateral decubitus position
950064|NCT02253381|hypotension
950065|NCT02253381|cesarean section
950066|NCT02253329|Neuromuscular electrical stimulation
950067|NCT02253329|Ageing
950068|NCT02253329|Protein ingestion
950074|NCT02253277|CML, Ph+ ALL
950075|NCT02253251|Breast Cancer
950076|NCT02253251|Cancer Risk
950077|NCT02253251|Family Breast and Ovarian Cancer
950078|NCT02253251|Genetic Cancer Risk
950079|NCT02253251|Cancer Treatment
950080|NCT02253251|Familial multiple primary cancer risk
950081|NCT02253238|Head and Neck Cancer
950082|NCT02253238|Dehydration
950083|NCT02253238|Sensor-based home monitoring
950084|NCT02253238|Radiation therapy
950085|NCT02253238|RT
950086|NCT02253238|XRT
950087|NCT02253238|Oropharyngeal cancer
950088|NCT02253238|Hypopharyngeal cancer
950089|NCT02253238|Nasopharyngeal cancer
950090|NCT02253238|Salivary gland cancer
950091|NCT02253238|Oral cavity cancer
950092|NCT02253238|Questionnaires
950093|NCT02253238|Surveys
950094|NCT02253238|Quality of life
950095|NCT02253238|QOL
950096|NCT02253238|Phone calls
950097|NCT02253238|Self-monitoring devices
950098|NCT02253238|CYberinfrastructure for COmparative effectiveness REsearch
950099|NCT02253238|CYCORE
950100|NCT02253238|Emergency room visits
950101|NCT02253238|ER
950102|NCT02253238|Emergency room visits with hospitalization
950103|NCT02253238|ERHV
950104|NCT02253225|Bipolar Disorder
950105|NCT02253225|Major Depression
950106|NCT02253225|Rumination
950107|NCT02253225|Self Processing
950108|NCT02253173|VVA
950109|NCT02253173|Painful Sex
950110|NCT02253173|Postmenopausal
950111|NCT02253160|MNCs
950112|NCT02253160|Mononuclear Cells
950113|NCT02253160|Apheresis
950114|NCT02253160|Spectra Optia
950115|NCT02253134|Syncopal events
950116|NCT02253134|Palpitation events
950117|NCT02253121|COPD
950118|NCT02253121|acute exacerbation
950119|NCT02253121|glucocorticoid therapy
950120|NCT02253121|hyperglycemia
950121|NCT02253108|DES
950122|NCT02253108|Angina pectoris
950123|NCT02253108|Stent
950124|NCT02253108|Optical coherence tomography
950125|NCT02253108|Stent thrombosis
950126|NCT02253056|Fasting
950127|NCT02253056|Caloric Restriction
950128|NCT02253056|Focus is to observe effects of fasting in healthy volunteers.
950129|NCT02253043|Alzheimer's Disease
950130|NCT02253030|AMD
950131|NCT02253030|OCT
950132|NCT02253030|Angiography
950133|NCT02253030|Macular degeneration
950134|NCT02253017|Therapeutic strategies
950135|NCT02253017|Pediatrics
950136|NCT02253017|Cataract
950137|NCT02253017|Surgery
950138|NCT02253017|Intra-ocular lens
950139|NCT02252991|Breast cancer
950140|NCT02252991|Fatigue
950141|NCT02252991|Physical activity
950142|NCT02252965|Diabetes Mellitus, Type 2
950143|NCT02252965|Metformin XR
950144|NCT02252965|Metformin IR
950145|NCT02252952|Sugar Sweetened Beverages, Diet Beverages, ectopic fat, Functional MRI
950146|NCT02252926|Anesthetics, Local
950147|NCT02252926|Bupivacaine
950148|NCT02252926|Lozenge
950149|NCT02252926|Administration, Topical
950150|NCT02252900|Brain damages
950151|NCT02252900|MRI
950152|NCT02252900|infectious endocarditis
950153|NCT02252887|Gemcitabine,
950154|NCT02252887|Trastuzumab
950155|NCT02252887|Pertuzumab
950156|NCT02252887|14-124
950157|NCT02252874|balance
950158|NCT02252874|visual function
950159|NCT02252874|community-dwelling older adults
950160|NCT02252874|action video-game
950161|NCT02252822|Eating Disorders
950162|NCT02252822|Self Help
950163|NCT02252822|Anonymous CBT
950164|NCT02252809|inflammation endotoxin anti-TNF corticosteroids
950165|NCT02252796|Non-small Cell Lung Cancer
950166|NCT02252796|Radiotherapy Therapy
950167|NCT02252783|Coronary Artery Disease
950168|NCT02252783|Myocardial Ischemia
950169|NCT02252783|Coronary Disease
950170|NCT02252783|Heart Diseases
950171|NCT02252783|Cardiovascular Diseases
950172|NCT02252783|Arteriosclerosis
950173|NCT02252783|Arterial Occlusive Diseases
950174|NCT02252783|Vascular Diseases
950175|NCT02252770|ASA
950176|NCT02252770|ASLD
950177|NCT02252770|UCD
950178|NCT02252757|mHealth, hypertension, atherosclerotic disease, diabetes, obesity, metabolic syndrome, cardiotoxins, cardiomyopathy, dsypnea
950179|NCT02252744|dry eye disease
950180|NCT02252744|rheumatoid arthritis
950181|NCT02252731|Phase I
950182|NCT02252731|FG-4592
950183|NCT02252731|Warfarin
950184|NCT02252731|Pharmacokinetics
950185|NCT02252731|Pharmacodynamics
950186|NCT02252705|Pulmonary arterial hypertension
950187|NCT02252705|Mortality
950188|NCT02252705|Survival
950189|NCT02252692|Bioavailability
950190|NCT02252692|pharmacokinetics
950191|NCT02252692|enalapril
950192|NCT02252692|enalaprilat
950193|NCT02252679|Bone Turnover Markers
950194|NCT02252679|Calcium Isotopes
950195|NCT02252666|MS
950196|NCT02252666|balance
950197|NCT02252666|standing
950198|NCT02252666|control
950199|NCT02252666|movement
950200|NCT02252653|Cardiomyopathy
950201|NCT02252653|Heart Failure
950202|NCT02252653|FAC
950203|NCT02252653|Amyloid
950204|NCT02252653|Transthyretin (TTR)
950205|NCT02252640|Plasmodium Falciparum
950206|NCT02252640|Malaria
950207|NCT02252640|Vaccine
950208|NCT02252640|Plasmodium
950209|NCT02252640|Falciparum
950210|NCT02252614|naproxen sodium+codein, paracetamol+codein,lumbar disc surgery
950211|NCT02252601|Cystic Fibrosis
950212|NCT02252601|Hearing Loss
950213|NCT02252601|High Frequency Digit Triplet Test
950216|NCT02252562|Hand hygiene
950217|NCT02252562|Hospital acquired infections (HAI)
950218|NCT02252562|Healthcare acquired infections (HCAI)
950219|NCT02252536|alcohol use disorder
950220|NCT02252536|alcoholism
950221|NCT02252536|alcohol dependence
950222|NCT02252536|drinking alcohol
950223|NCT02252523|Feasibility study
950224|NCT02252497|hip arthroplasty
950225|NCT02252497|Tranexamic acid
950226|NCT02252497|randomized control trial
950227|NCT02252484|prostate cancer
950228|NCT02252484|prostatectomy
950229|NCT02252484|weight loss
950230|NCT02252484|prevent weight gain
950231|NCT02252471|alcohol-exposed pregnancy
950232|NCT02252471|nicotine-exposed pregnancy
950233|NCT02252471|tobacco-exposed pregnancy
950234|NCT02252471|alcohol
950235|NCT02252471|contraception
950236|NCT02252471|smoking
950237|NCT02252471|pregnancy
950238|NCT02252471|HIV
950239|NCT02252471|prevention
950240|NCT02252458|Opioid induced hyperalgesia
950241|NCT02252458|Fentanyl
950242|NCT02252432|KETAMINE
950243|NCT02252432|METHADONE
950244|NCT02252432|POSTOPERATIVE PAIN
950245|NCT02252432|OPIOID REQUIREMENTS
950246|NCT02252432|Length of hospital stay
950247|NCT02252432|Perioperative outcomes
950248|NCT02252419|Postoperative Period
950249|NCT02252419|Anesthesia, General
950250|NCT02252419|Intubation, Intratracheal
950251|NCT02252419|Dexamethasone
950252|NCT02252419|Acetaminophen
950253|NCT02252406|Stable Angina
950254|NCT02252406|Metabolic Syndrome
950255|NCT02252406|Women
950256|NCT02252406|Biomarkers
950257|NCT02252367|Phosphodiesterase 5 Inhibitors
950258|NCT02252367|BPH/LUTS
950259|NCT02252354|Drug therapy
950260|NCT02252341|smoking
950261|NCT02252341|inflammation
950262|NCT02252341|oxidative stress
950263|NCT02252341|NAC
950264|NCT02252341|treatment
950265|NCT02252328|Uveitis
950266|NCT02252328|Simvastatin
950267|NCT02252328|Visual acuity
950268|NCT02252328|Corticosteroids
950269|NCT02252328|Immunosuppression
950270|NCT02252302|Exercise-induced bronchoconstriction
950271|NCT02252302|Air pollution
950272|NCT02252302|Exercise
950273|NCT02252302|Inhaled beta-2-agonist
950274|NCT02252302|Cognitive Function
950275|NCT02252289|Asthma
950276|NCT02252289|children
950277|NCT02252289|fluctuation analysis
950278|NCT02252289|exacerbations
950279|NCT02252276|Manual therapy
950280|NCT02252276|proprioception
950281|NCT02252276|exercises
950282|NCT02252276|ankle sprain
950283|NCT02252250|rectal cancer
950284|NCT02252250|laparoscopic
950285|NCT02252250|NOTES
950286|NCT02252237|Prednisone
950287|NCT02252237|Prednisolone
950288|NCT02252237|Methylprednisolone
950289|NCT02252237|Glucocorticoids
950290|NCT02252237|pharmacokinetics
950291|NCT02252211|EphA2 positive cancer
950292|NCT02252211|DS-8895a monoclonal antibody
950298|NCT02252159|Polycythemia
950299|NCT02252159|Polycythemia Vera
950300|NCT02252159|Hematologic Diseases
950301|NCT02252159|Myeloproliferative Disorders
950302|NCT02252159|Bone Marrow Diseases
950303|NCT02252159|Hydroxyurea
950304|NCT02252159|Antineoplastic Agents
950305|NCT02252159|Therapeutic Uses
950306|NCT02252159|Pharmacologic Actions
950307|NCT02252159|Antisickling Agents
950308|NCT02252159|Hematologic Agents
950309|NCT02252159|Enzyme Inhibitors
950310|NCT02252159|Molecular Mechanisms of Pharmacological Action
950311|NCT02252159|Nucleic Acid Synthesis Inhibitors
950312|NCT02252146|DLBCL
950313|NCT02252146|MYD88 L265P
950314|NCT02252146|Lymphoma
950315|NCT02252146|Diffuse Large B Cell Lymphoma
950316|NCT02252146|Idera
950317|NCT02252146|IMO 8400
950318|NCT02252133|Contact lenses
950319|NCT02252133|Myopia
950320|NCT02252107|Decitabine
950321|NCT02252107|Hematopoietic stem cell transplantation (HSCT)
950322|NCT02252107|Conditioning
950323|NCT02252107|AML
950324|NCT02252081|metformin
950325|NCT02252081|cardiovascular disease
950326|NCT02252081|Chronic Kidney Disease
950327|NCT02252081|Metabolic Syndrome
950328|NCT02252042|Squamous cell carcinoma
950329|NCT02252042|Head and neck carcinoma
950330|NCT02252042|PD1
950331|NCT02252042|PD-1
950332|NCT02252042|PDL1
950333|NCT02252042|PD-L1
950334|NCT02252029|Rotavirus
950335|NCT02252029|Vaccine
950336|NCT02252003|Children
950337|NCT02252003|Pain
950338|NCT02252003|Pain scale evaluation
950339|NCT02251964|IMID
950340|NCT02251964|Interstitial Pneumonitis
950341|NCT02251964|rituximab
950342|NCT02251964|Immuno PET
950343|NCT02251964|PET/CT
950344|NCT02251951|Cancer
950345|NCT02251951|Stomach
950346|NCT02251951|Gastro-Esophageal Junction
950347|NCT02251951|Salvage treatment
950348|NCT02251951|Nab-paclitaxel
950349|NCT02251925|infertility froze emberyo transfer hormone replacement
950350|NCT02251912|Alcohol dependence
950351|NCT02251912|Alcohol withdrawal
950352|NCT02251912|Alcohol
950353|NCT02251912|Alcoholism
950354|NCT02251912|Oxytocin
950355|NCT02251912|OT
950356|NCT02251912|Intranasal administration
950357|NCT02251847|cholesterol
950358|NCT02251834|Healthcare Disparities
950359|NCT02251834|stroke
950360|NCT02251834|Hispanic Americans
950361|NCT02251834|community health worker
950362|NCT02251834|Mobile Health
950363|NCT02251834|Transient Ischemic Attack (TIA)
950364|NCT02251834|hypertension
950365|NCT02251834|Randomized Controlled Trial
950366|NCT02251834|high cholesterol
950367|NCT02251834|behavioral
950368|NCT02251834|exercise
950369|NCT02251834|diabetes
950370|NCT02251834|diet
950371|NCT02251808|Parkinson's Disease, Deep brain stimulation
950372|NCT02251743|ADHD
950373|NCT02251743|Attention-Deficit/Hyperactivity Disorder
950374|NCT02251743|neurofeedback
950375|NCT02251743|EEG
950376|NCT02251730|radiation therapy,Smoking pattern,head and neck cancer
950377|NCT02251717|renal transplant
950378|NCT02251704|Malaria
950379|NCT02251704|MTI
950380|NCT02251704|Surveillance study
950381|NCT02251704|Africa
950382|NCT02251704|RTSS, adjuvant
950383|NCT02251704|Epidemiology
950384|NCT02251691|Compliance
950385|NCT02251678|Plaque
950386|NCT02251678|Psoriasis
950387|NCT02251678|Biomarkers
950388|NCT02251678|CRP
950389|NCT02251678|αTNF
950390|NCT02251678|Interleuken
950391|NCT02251665|Acute ischemic stroke
950392|NCT02251665|Acute intracerebral hemorrhage
950393|NCT02251665|Transient ischemic attack
950394|NCT02251652|Actinic
950395|NCT02251639|Oral cancer
950396|NCT02251639|Pre-cancer
950397|NCT02251639|Widefield Fluorescence Imaging
950398|NCT02251639|VELScope
950399|NCT02251639|Point Spectroscopy System
950400|NCT02251639|Oral brush biopsy
950401|NCT02251639|Questionnaire
950402|NCT02251639|Survey
950403|NCT02251639|Diagnostic aid
950404|NCT02251639|Screening
950405|NCT02251626|MGH
950406|NCT02251626|Burn patient
950407|NCT02251626|Adult
950408|NCT02251626|CoQ10
950409|NCT02251626|Ubiquinol
950410|NCT02251600|Pediatric
950411|NCT02251600|Adolescent
950412|NCT02251600|Deflazacort
950413|NCT02251561|contact lenses
950414|NCT02251561|contact lens solution
950415|NCT02251561|corneal staining
950416|NCT02251561|fluorescein
950417|NCT02251548|Chronic lymphocytic leukemia
950418|NCT02251548|Leukemia
950419|NCT02251535|kinematic analysis
950420|NCT02251535|femoral rollback
950421|NCT02251535|mobile bearing
950422|NCT02251535|cruciate retaining Primary Total Knee Arthroplasty
950423|NCT02251496|Malnutrition
950424|NCT02251496|Chronic obstructive pulmonary disease
950425|NCT02251496|Nutrition Therapy
950426|NCT02251496|Oral Nutrition Supplement
950427|NCT02251496|Food
950428|NCT02251483|DIBS
950429|NCT02251483|SIBO
950430|NCT02251470|stroke
950431|NCT02251470|balance
950432|NCT02251470|exer-gaming
950433|NCT02251470|home-based exercises
950434|NCT02251470|Wii
950435|NCT02251470|postural balance
950436|NCT02251470|Nintendo
950437|NCT02251470|balance board
950438|NCT02251470|Wii-Fit
950439|NCT02251470|home
950440|NCT02251470|feasibility
950441|NCT02251457|Myotonia Congenita
950442|NCT02251457|ranolazine
950443|NCT02251457|Ohio State
950444|NCT02251457|Open Label
950445|NCT02251457|Paramyotonia Congenita
950446|NCT02251457|Myotonic Dystrophy 1
950447|NCT02251431|diabetes mellitus
950448|NCT02251431|chronic kidney disease
950449|NCT02251431|diastolic function
950450|NCT02251431|cardiac fibrosis
950451|NCT02251431|cardiac strain
950452|NCT02251431|cardiac biomarker
950453|NCT02251431|renal biomarker
950454|NCT02251418|Foot ulcer, diabetic
950455|NCT02251418|ESWT (Extracorporeal Shockwave Therapy)
950456|NCT02251418|Endocrinology
950457|NCT02251418|Dermatology
950458|NCT02251418|Wound healing
950459|NCT02251418|Ischemia
950460|NCT02251418|Neovascularization, Physiologic
950461|NCT02251418|Pain management
950462|NCT02251405|Melamine
950463|NCT02251405|Melamine tableware
950464|NCT02251392|chamomilla
950465|NCT02251392|matricaria
950466|NCT02251392|chamomile
950467|NCT02251392|chamomila
950468|NCT02251392|recutita
950469|NCT02251392|Breast Neoplasms
950470|NCT02251392|head and neck neoplasms
950471|NCT02251392|radiotherapy
950472|NCT02251366|Age-Related Macular Degeneration
950473|NCT02251353|breast cancer, intervention to metastasis
950474|NCT02251314|BRAF mutant melanoma
950475|NCT02251314|circulation tumour DNA
950476|NCT02251314|tumour heterogeneity
950477|NCT02251314|liquid biopsy
950478|NCT02251288|H7N9 pandemic
950479|NCT02251288|inactivated influenza vaccine (pIIV)
950480|NCT02251288|live attenuated influenza vaccine (pLAIV)
950481|NCT02251288|MF59 adjuvant
950483|NCT02251262|Pacemaker
950484|NCT02251262|Endocarditis
950485|NCT02251262|18FDG-PET-CT
950486|NCT02251262|Diagnostic accuracy
950487|NCT02251262|Pacing or defibrillation lead
950488|NCT02251236|Stribild
950489|NCT02251236|Genvoya
950490|NCT02251236|elvitegravir
950491|NCT02251236|Cerebrospinal Fluid
950492|NCT02251236|HIV
950493|NCT02251093|mycosis
950494|NCT02251093|vulvovaginal candidiasis
950495|NCT02251093|lcr35
950496|NCT02251093|Lcr Regenerans®
950497|NCT02251080|adherence
950498|NCT02251080|internet-based
950499|NCT02251054|Overactive Bladder
950500|NCT02251054|Multimedia
950501|NCT02251054|Behavioral Therapy
950502|NCT02251041|Liver
950503|NCT02251041|Transplantation
950504|NCT02251041|Ischemia-reperfusion
950505|NCT02251041|Effectiveness
950506|NCT02251028|whiplash, prevention, pain, cognitive-behavioural therapy
950507|NCT02251015|Postural balance
950508|NCT02251015|Temporomandibular disorders
950509|NCT02251015|splints
950510|NCT02250989|Endothelial disfunction
950511|NCT02250989|Intercellular Adhesion Molecule-1
950512|NCT02250989|Vascular Cell Adhesion Molecule-1
950513|NCT02250989|8-epi-prostaglandin F2alpha
950514|NCT02250989|Nitric Oxide
950515|NCT02250989|Plasminogen Activator Inhibitor 1
950516|NCT02250989|Endothelin-1
950517|NCT02250989|Tumor Necrosis Factor-alpha
950518|NCT02250989|Glucose
950519|NCT02250989|Insulin
950520|NCT02250989|C-peptide
950521|NCT02250989|C-reactive protein
950522|NCT02250989|3-nitrotyrosine
950523|NCT02250963|Dobutamine Stress Echocardiography
950524|NCT02250963|Computed tomography coronary angiography
950525|NCT02250950|self-determination theory
950526|NCT02250950|motivational interviewing
950527|NCT02250950|exercise
950528|NCT02250950|physical activity
950529|NCT02250937|Acute Myeloid Leukemia
950530|NCT02250937|AML
950531|NCT02250937|Myelodysplastic Syndrome
950532|NCT02250937|MDS
950533|NCT02250937|Stem Cell Transplantation
950534|NCT02250937|Busulfan
950535|NCT02250937|Busulfex
950536|NCT02250937|Myleran
950537|NCT02250937|Fludarabine
950538|NCT02250937|Fludarabine Phosphate
950539|NCT02250937|Fludara
950540|NCT02250937|Cladribine
950541|NCT02250937|Leustatin
950542|NCT02250937|2-CdA
950543|NCT02250937|G-CSF
950544|NCT02250937|Filgrastim
950545|NCT02250937|Neupogen
950546|NCT02250937|Methotrexate
950547|NCT02250911|Caregivers of patients
950548|NCT02250911|CCC = Care for the Cancer Caregivers
950549|NCT02250911|MCP-C = Meaning-Centered Psychotherapy for Cancer Caregivers
950550|NCT02250911|14-208
950551|NCT02250898|Post Breast Surgery
950552|NCT02250898|Myofascial Massage
950553|NCT02250898|Pain
950554|NCT02250898|Mobility Limitations
950555|NCT02250885|Selinexor
950556|NCT02250885|phase 2
950557|NCT02250885|Gabrail
950558|NCT02250872|Cisplatin
950559|NCT02250872|Nephrotoxicity
950560|NCT02250872|Gemigliptin
950561|NCT02250872|DPP4 inhibitor
950562|NCT02250846|EGFR mutations
950563|NCT02250846|asymptomatic brain metastases
950564|NCT02250846|EGFR-TKI
950565|NCT02250846|Erlotinib
950566|NCT02250833|Hypertension
950567|NCT02250833|CKD-828
950568|NCT02250833|Telmisartan
950569|NCT02250833|S-amlodipine
950570|NCT02250833|Pharmacokinetic
950571|NCT02250820|Pediatric
950572|NCT02250820|Sedation
950573|NCT02250820|Transthoracic echocardiography
950574|NCT02250820|TTE
950575|NCT02250820|Dexmedetomidine
950576|NCT02250820|Pentobarbital
950577|NCT02250807|Chronic hepatitis C
950578|NCT02250807|Genotype 4 chronic hepatitis C
950579|NCT02250807|Simeprevir
950580|NCT02250807|Sofosbuvir
950581|NCT02250794|diabetes mellitus
950582|NCT02250794|inpatient management
950583|NCT02250794|metformin
950584|NCT02250794|sitagliptin
950585|NCT02250768|GM-CSF, repeated implantation failure
950586|NCT02250755|MRI perfusion
950587|NCT02250755|therapeutic response
950588|NCT02250755|chemotherapy
950589|NCT02250755|brain metastases
950590|NCT02250742|ultrasound imaging
950591|NCT02250742|acupuncture
950592|NCT02250742|back muscles
950593|NCT02250742|spine
950594|NCT02250742|muscle strength
950595|NCT02250729|anaphylaxis
950596|NCT02250729|pholcodine
950597|NCT02250729|neuromuscular blocking agents
950598|NCT02250716|CIN1
950599|NCT02250716|HIV seropositive women
950600|NCT02250716|Cryotherapy
950601|NCT02250703|Premedication
950602|NCT02250690|idiopathic PD
950603|NCT02250690|Hoehn and Yahr stage I to III
950604|NCT02250690|stable medication usage
950605|NCT02250690|age 40 to 80 years
950606|NCT02250690|absence of cognitive impairment
950607|NCT02250677|physical activity
950608|NCT02250677|Statin therapy
950609|NCT02250677|cardiovascular disease
950610|NCT02250677|diabetes mellitus
950611|NCT02250664|Biomarkers of exposure
950612|NCT02250664|Compensatory smoking
950613|NCT02250664|Nicotine dependence
950614|NCT02250664|Reduced nicotine cigarettes
950615|NCT02250664|Tobacco withdrawal
950616|NCT02250664|Women
950617|NCT02250664|Health disparities
950618|NCT02250664|Vulnerable populations
950619|NCT02250612|SYL040012
950620|NCT02250612|bamosiran
950621|NCT02250612|siRNA
950622|NCT02250612|RNAi
950623|NCT02250612|Glaucoma
950624|NCT02250612|Ocular hypertension
950625|NCT02250599|Metastatic Nasopharyngeal Carcinoma
950626|NCT02250599|treatment
950627|NCT02250586|concerned significant other
950628|NCT02250586|internet-delivered cognitive-behavioral therapy,
950629|NCT02250586|treatment-refusing problem gambler
950630|NCT02250534|Biomarkers of exposure
950631|NCT02250534|Compensatory smoking
950632|NCT02250534|Nicotine dependence
950633|NCT02250534|Reduced nicotine cigarettes
950634|NCT02250534|Tobacco withdrawal
950635|NCT02250534|Women
950636|NCT02250534|Health disparities
950637|NCT02250534|Vulnerable populations
950638|NCT02250521|BMI < 50 kg/m2
950639|NCT02250521|Mallampatti class: III-IV
950640|NCT02250521|Reduced mouth opening < 4 cm
950641|NCT02250521|Neck circumference > 40 cm for females and > 43 cm for males
950642|NCT02250521|Thyromental distance < 6 cm
950643|NCT02250521|Ratio of the patient's height to thyromental distance ≥ 23.5
950644|NCT02250521|Sternomental distance < 12 cm
950645|NCT02250443|Inclusion Body Myositis (IBM)
950646|NCT02250430|acne
950647|NCT02250365|stroke, acute
950648|NCT02250365|upper extremity
950649|NCT02250365|rehabilitation
950650|NCT02250365|electric stimulation therapy
950651|NCT02250339|Child Mental Health
950652|NCT02250339|Parenting
950653|NCT02250339|Family Issues
950654|NCT02250326|Cancer of the lung
950655|NCT02250326|lung neoplasm
950656|NCT02250326|NSCLC - non-small cell lung cancer
950657|NCT02250326|Nonsquamou
950658|NCT02250326|squamous
950659|NCT02250326|squamous NSCLC
950660|NCT02250326|Tumor
950661|NCT02250326|locally advanced NSCLC
950662|NCT02250326|metastatic NSCLC
950663|NCT02250326|advanced lung cancer
950664|NCT02250326|metastatic lung cancer
950665|NCT02250326|non-squamous NSCLC
950666|NCT02250326|lung cancer
950667|NCT02250326|Abraxane
950668|NCT02250326|ABI-007
950669|NCT02250326|nab-paclitaxel
950670|NCT02250326|albumin-bound paclitaxel
950671|NCT02250326|taxanes
950672|NCT02250326|CC-486
950673|NCT02250326|oral azacitidine
950674|NCT02250326|azacitidine
950675|NCT02250326|second line treatment of lung cancer
950676|NCT02250326|second line treatment
950677|NCT02250326|Celgene
950678|NCT02250326|abound.2L
950679|NCT02250326|third line treatment
950680|NCT02250326|durvalumab
950681|NCT02250326|immunotherapy
950682|NCT02250326|MEDI4736
950683|NCT02250313|prostate cancer
950684|NCT02250287|autosomal dominant polycystic kidney disease
950685|NCT02250287|magnetic resonance imaging parameters
950686|NCT02250287|magnetic resonance elastography
950687|NCT02250287|apparent diffusion coefficient
950688|NCT02250287|blood oxygen level determinations
950689|NCT02250287|diffusion weighted imaging
950690|NCT02250274|Immune response to influenza vaccine
950691|NCT02250274|PCR confirmed Influenza A virus
950692|NCT02250274|PCR confirmed Influenza B virus
950693|NCT02250261|walking
950694|NCT02250261|cycling
950695|NCT02250261|intervention
950696|NCT02250261|physical activity
950697|NCT02250261|environment
950698|NCT02250261|promotion
950699|NCT02250248|Degenerative disc disease
950700|NCT02250248|Lumbar spine
950701|NCT02250209|Gastric Cancer
950702|NCT02250209|HER2-positive
950703|NCT02250209|Trastuzumab
950704|NCT02250209|XELOX
950705|NCT02250209|Stage III
950706|NCT02250209|D2 Gastrectomy
950707|NCT02250196|Bowel preparation
950708|NCT02250196|Polyethylene glycol with ascorbic acid
950709|NCT02250196|Sodium picosulfate with magnesium citrate
950710|NCT02250183|Medihoney
950711|NCT02250183|Santyl
950712|NCT02250183|Burns
950713|NCT02250144|Patellofemoral pain syndrome
950714|NCT02250144|Feet orthoses
950715|NCT02250144|KOOS
950716|NCT02250131|cardiopulmonary bypass
950717|NCT02250118|pleural
950718|NCT02250118|effusion
950719|NCT02250118|breast
950720|NCT02250118|cancer
950721|NCT02250092|Cerebral Palsy
950722|NCT02250092|Hemiparesis
950723|NCT02250092|Stroke
950724|NCT02250092|Non-Invasive Brain Stimulation
950725|NCT02250092|Transcranial Direct Current Stimulation
950726|NCT02250092|Constraint-Induced Movement Therapy
950727|NCT02250092|Diffusion Tensor Imaging
950728|NCT02250092|Congenital Hemiparesis
950729|NCT02250053|stage II and stage III colon cancer survivors, who have completed curative treatment i.e., surgical resection and chemotherapy for their colon cancer
950730|NCT02250040|Stroke
950731|NCT02250040|Rehabilitation
950732|NCT02250040|Physiotherapy
950733|NCT02250040|Functional Recovery
950734|NCT02250027|acute bronchitis
950735|NCT02250027|acute exacerbations of chronic bronchitis
950736|NCT02250001|HCV
950737|NCT02249962|prospective
950738|NCT02249962|cohort
950739|NCT02249936|Volunteers
950740|NCT02249923|Pulmonary Arterial Hypertension (PAH)
950741|NCT02249923|Pulmonary Vascular Disease (PVD)
950742|NCT02249923|Registry
950743|NCT02249923|Pediatric
950744|NCT02249884|radiodermatitis
950745|NCT02249884|head and neck neoplasms
950746|NCT02249884|Breast Neoplasms
950747|NCT02249884|Urea
950748|NCT02249884|Matricaria
950749|NCT02249884|chamomilla
950750|NCT02249884|chamomile
950751|NCT02249858|cervical spine
950752|NCT02249858|OMT
950753|NCT02249858|HVLA
950754|NCT02249858|ultrasound
950755|NCT02249845|dehydration
950756|NCT02249845|children
950757|NCT02249845|gastroenteritis
950758|NCT02249832|stroke
950759|NCT02249832|CVA
950760|NCT02249832|cerebrovascular accident
950761|NCT02249832|cerebral stroke
950762|NCT02249832|robotic therapy
950763|NCT02249832|anklebot
950764|NCT02249832|physical therapy
950765|NCT02249819|stroke
950766|NCT02249819|aphasia
950767|NCT02249819|CVA
950768|NCT02249819|apraxia
950769|NCT02249819|cerebrovascular accident
950770|NCT02249819|cerebral stroke
950771|NCT02249819|speech therapy
950772|NCT02249819|aphasia therapy
950773|NCT02249819|non-invasive brain stimulation
950774|NCT02249819|transcranial direct current stimulation
950775|NCT02249819|tDCS
950776|NCT02249806|Pulmonary Hypertension
950777|NCT02249806|Chronic thromboembolic pulmonary hypertension
950778|NCT02249806|Pulmonary arterial hypertension
950779|NCT02249806|Outcome
950780|NCT02249793|circadian
950781|NCT02249793|oscillation
950782|NCT02249793|clock
950783|NCT02249793|human
950784|NCT02249793|social behavior
950785|NCT02249793|cell phone with internet access (so-called smartphone)
950786|NCT02249793|social sensing
950787|NCT02249793|behavioral feature
950788|NCT02249793|Ginger.io
950789|NCT02249793|blood pressure
950790|NCT02249793|metabolism
950791|NCT02249793|metabolomics
950792|NCT02249793|gut bacteria
950793|NCT02249793|microbiome
950794|NCT02249780|Parathyroid gland angiography
950795|NCT02249780|Parathyroid gland indocyanine green angiography
950796|NCT02249780|Parathyroid gland indocyanine green fluoroscopy
950797|NCT02249754|Nutrition education
950798|NCT02249754|Maternal counselling
950799|NCT02249754|Complementary feeding
950800|NCT02249754|Infant growth
950801|NCT02249754|Micronutrients
950802|NCT02249754|Tanzania
950803|NCT02249715|Parkinson
950804|NCT02249715|TMS
950805|NCT02249715|BNA
950806|NCT02249702|trabectedin
950807|NCT02249702|uterine leiomyosarcoma
950808|NCT02249676|Autologous mesenchymal stem cells
950809|NCT02249676|neuromyelitis optica
950810|NCT02249676|treatment
950811|NCT02249663|Bioequivalence
950812|NCT02249650|metastatic colorectal cancer
950813|NCT02249650|TSB-9-W1
950814|NCT02249624|Twin to twin transfusion syndrome
950815|NCT02249624|Developmental disabilities
950816|NCT02249624|Magnetic resonance imaging
950817|NCT02249611|Physical activity
950818|NCT02249611|mobile activity sensor and feedback system
950819|NCT02249611|self-management of health
950820|NCT02249572|Vestibular schwannoma
950821|NCT02249572|Radiosurgery
950822|NCT02249572|Neurosurgery
950823|NCT02249572|Randomized
950824|NCT02249533|Spot Light
950825|NCT02249533|High School RIO
950826|NCT02249533|Concussion
950827|NCT02249533|Injury Prevention
950828|NCT02249533|Football
950829|NCT02249533|Pop Warner
950830|NCT02249533|High School
950831|NCT02249533|Middle School
950832|NCT02249520|Magnetic Resonance Imaging
950833|NCT02249520|MRI
950834|NCT02249520|Positron Emission Tomography
950835|NCT02249520|PET
950836|NCT02249520|PET-MR
950837|NCT02249520|mMR
950838|NCT02249507|Resistant Hypertension
950839|NCT02249507|Aerobic Exercise
950840|NCT02249494|Nutritional Knowledge
950841|NCT02249494|Nutritional Counseling
950842|NCT02249481|Anaesthetic
950843|NCT02249481|total knee replacement
950844|NCT02249481|Femoral nerve catheter
950845|NCT02249481|Adductor canal catheter
950846|NCT02249429|Non Hodgkin Lymphoma
950847|NCT02249377|Baker's Cyst
950848|NCT02249325|group B Streptococcus colonization
950849|NCT02249325|Probiotic
950850|NCT02249325|Pregnancy
950851|NCT02249299|ADHD,
950852|NCT02249299|Cannabis,
950853|NCT02249299|Sativex,
950854|NCT02249299|Endocannabinoid,
950855|NCT02249299|Cognition
950856|NCT02249286|Child Centered Counseling
950857|NCT02249286|Home based food production
950858|NCT02249286|Nutrition
950859|NCT02249286|Health
950860|NCT02249286|IYCF
950861|NCT02249260|Exercise, cardiac rehabilitation, quality of life
950862|NCT02249234|Scrotal pain
950863|NCT02249234|Botox
950864|NCT02249221|Influenza vaccine
950865|NCT02249221|Vaccination
950866|NCT02249221|cell-culture based influenza vaccine
950867|NCT02249221|cell culture derived influenza vaccine
950868|NCT02249221|CCIV
950869|NCT02249208|Breast Cancer
950870|NCT02249208|Sentinel Lymph Node
950871|NCT02249208|Neoadjuvant Chemotherapy
950872|NCT02249208|Clinically Node-Positive with biopsy-proven cN1
950873|NCT02249208|False-negative Rate
950874|NCT02249195|ECG loop recorder, pregnant women, arrhythmias
950875|NCT02249169|IBS
950876|NCT02249156|Health economics
950877|NCT02249156|Financial incentives
950878|NCT02249156|Health care spending
950879|NCT02249143|Continuous positive airway pressure
950880|NCT02249143|Prematurity
950881|NCT02249143|Respiratory distress syndrome
950882|NCT02249143|Bronchopulmonary dysplasia
950883|NCT02249078|Crohn's Disease
950884|NCT02249013|Ovarian Cancer
950885|NCT02248974|End-Stage Heart Failure
950886|NCT02248974|Left Ventricular Assist Device
950887|NCT02248974|Decision Aid
950888|NCT02248974|Medical Decision-Making
950889|NCT02248948|Omega-3
950890|NCT02248948|ADHD
950891|NCT02248948|Quality of Life
950892|NCT02248948|Inattention
950893|NCT02248948|Hyperactivity
950894|NCT02248935|Robotic Assisted Laparoscopic Sacrocolpopexy
950895|NCT02248935|Y Mesh
950896|NCT02248935|Pelvic Organ Prolapse
950898|NCT02248909|COPD, Primary Care, Spirometry, Risk factors
950899|NCT02248870|femoral neck
950900|NCT02248857|UMS
950901|NCT02248857|medication schedule
950902|NCT02248857|diabetes
950903|NCT02248857|drug labeling
950904|NCT02248831|Dyspnea
950905|NCT02248831|Acute decompensated heart failure
950906|NCT02248831|Doppler ultrasound
950907|NCT02248831|Lung Doppler signals
950908|NCT02248805|colon cancer
950909|NCT02248805|colorectal carcinoma
950910|NCT02248805|stage IV colorectal cancer
950911|NCT02248779|Diabetes Risk
950912|NCT02248779|14-202
950913|NCT02248753|Atrial fibrillation
950914|NCT02248753|Electrical cardioversion
950915|NCT02248753|Pharmacological cardioversion
950916|NCT02248753|Rhythm control
950917|NCT02248753|Rate control
950918|NCT02248740|chronic venous insufficiency
950919|NCT02248740|varicose vein
950920|NCT02248740|small saphenous vein
950921|NCT02248701|Testosterone
950922|NCT02248701|Testosterone enanthate
950923|NCT02248701|Testosterone undecanoate
950924|NCT02248701|Testosterone 17 beta-cypionate
950925|NCT02248701|Methyltestosterone
950926|NCT02248701|Androgens
950927|NCT02248701|Hormones
950928|NCT02248701|Hormone Substitutes, and Hormone Antagonists
950929|NCT02248701|Physiologic Effects of Drugs
950930|NCT02248701|Pharmacologic Actions
950931|NCT02248701|Antineoplastic Agents, Hormonal
950932|NCT02248701|Antineoplastic Agents
950933|NCT02248701|Therapeutic Uses
950934|NCT02248701|Anabolic Agents
950935|NCT02248701|Testosterone Replacement Therapy
950936|NCT02248701|Dual Energy X ray Absorptiometry
950937|NCT02248701|Lean Tissue Mass
950938|NCT02248701|Body Composition
950939|NCT02248701|Lipid and Glucose profile
950940|NCT02248701|Muscle Strength
950941|NCT02248701|5-alpha Reductase
950942|NCT02248701|Muscle Mass
950943|NCT02248701|Bone Mineral Density
950944|NCT02248701|Adipose Tissue
950945|NCT02248701|Body Fat
950946|NCT02248701|Density, Bone
950947|NCT02248701|Bone Formation
950948|NCT02248701|Bone Resorption
950949|NCT02248701|Bone Density Conservation Agents
950950|NCT02248701|Magnetic Resonance Imaging
950951|NCT02248701|Muscle, Skeletal
950952|NCT02248701|Bone and Bones
950953|NCT02248701|Gait
950954|NCT02248701|Walking
950955|NCT02248701|Locomotion
950956|NCT02248701|Motor Activity
950957|NCT02248688|Bariatric Embolization
950958|NCT02248688|Gastric Artery Emboliziation
950959|NCT02248688|Left Gastric Artery Embolization
950960|NCT02248688|Morbid Obesity
950961|NCT02248688|Obesity
950962|NCT02248688|Weight Loss
950963|NCT02248688|Ghrelin
950964|NCT02248688|Embolization
950965|NCT02248675|sleep disorders
950966|NCT02248675|insomnia
950967|NCT02248675|suicidal ideation
950968|NCT02248675|Depression
950969|NCT02248675|Depressive disorders
950970|NCT02248675|PTSD
950971|NCT02248675|anxiety disorders
950972|NCT02248675|suicide
950973|NCT02248675|cognitive behavioral therapy
950974|NCT02248662|DCIS
950975|NCT02248662|PCORI
950976|NCT02248662|ductal carcinoma in situ
950977|NCT02248662|radiation
950978|NCT02248662|oncology
950979|NCT02248662|patient-centered
950980|NCT02248662|decision aid
950981|NCT02248662|decision-making
950982|NCT02248649|Parkinson's disease
950983|NCT02248649|Exercise therapy
950984|NCT02248649|Mild cognitive impairment
950985|NCT02248636|Alzheimer's disease
950986|NCT02248636|Cholinesterase inhibitor
950987|NCT02248636|Discontinuation
950988|NCT02248623|Anaesthesia
950989|NCT02248623|Isolated forearm test
950990|NCT02248623|Responsiveness
950991|NCT02248623|Laryngoscopy
950992|NCT02248623|Intubation
950993|NCT02248610|Pulmonary embolism
950994|NCT02248610|PE
950995|NCT02248610|Deep vein thrombosis
950996|NCT02248610|DVT
950997|NCT02248610|Rivaroxaban
950998|NCT02248610|Venous thromboembolism
950999|NCT02248610|Chronic thromboembolic pulmonary hypertension
951000|NCT02248610|Post thrombotic limb syndrome
951001|NCT02248610|Root cause analysis
951002|NCT02248571|breast cancer
951003|NCT02248571|advanced
951004|NCT02248571|inoperable
951005|NCT02248571|metastatic
951006|NCT02248571|HER2/neu-negative
951007|NCT02248571|hormone receptor positive
951008|NCT02248571|HR+
951009|NCT02248571|female
951010|NCT02248571|postmenopausal
951011|NCT02248558|Contest
951012|NCT02248558|Crowdsourcing
951013|NCT02248558|Innovation
951014|NCT02248558|Randomized controlled trial
951015|NCT02248558|China
951016|NCT02248558|Social entrepreneurship
951017|NCT02248545|Non-Celiac Wheat Sensitivity
951018|NCT02248545|Autoimmune diseases
951019|NCT02248545|Anti-nuclear antibodies
951020|NCT02248545|Celiac disease
951021|NCT02248545|Irritable bowel syndrome
951022|NCT02248519|Gastric cancer
951023|NCT02248519|Gastrectomy
951024|NCT02248519|Laparoscopy
951025|NCT02248506|Candidiasis
951026|NCT02248493|Pain, Postoperative
951027|NCT02248493|Paracetamol
951028|NCT02248493|Administration, Intravenous
951029|NCT02248493|Anti-Inflammatory Agents, Non-Steroidal
951030|NCT02248493|Child
951031|NCT02248493|Adolescent
951032|NCT02248467|Testosterone replacement therapy
951033|NCT02248428|multiple myeloma
951034|NCT02248428|Clarithromycin
951035|NCT02248428|CTd
951036|NCT02248415|Cardioplegic Solutions
951037|NCT02248415|Myocardial Ischemia
951038|NCT02248389|carcinoma, renal cell
951039|NCT02248389|ablation
951040|NCT02248389|laparoscopic surgery
951041|NCT02248389|high intensity focused ultrasound
951042|NCT02248376|Uterine synechiae Scraping surgery Natural miscarriage
951043|NCT02248363|Rehabilitation
951044|NCT02248363|Effectiveness
951045|NCT02248363|Determinants
951046|NCT02248363|Prediction
951047|NCT02248350|prostate cancer
951048|NCT02248350|physical activity
951049|NCT02248350|exercise
951050|NCT02248350|intervention
951051|NCT02248350|side effects
951052|NCT02248350|androgen deprivation therapy
951053|NCT02248337|Colon preparation; Colonoscopy; Inflammatory bowel disease
951179|NCT02247713|overall survival
951054|NCT02248324|Age-related macular degeneration, genetic polymorphisms
951055|NCT02248298|Ablative fractional laser
951056|NCT02248298|Actinic keratosis
951057|NCT02248298|Efficacy
951058|NCT02248298|Photodynamic therapy
951059|NCT02248298|Short incubation time
951060|NCT02248285|multiplex
951061|NCT02248285|polymerase chain reaction
951062|NCT02248285|PCR
951063|NCT02248285|BioFire Diagnostics
951064|NCT02248285|Infectious gastroenteritis
951065|NCT02248285|Diarrheal disease
951066|NCT02248285|Emergency department
951067|NCT02248285|rapid diagnostics
951068|NCT02248285|FilmArray
951069|NCT02248285|FilmArray GI Panel
951070|NCT02248272|Polycystic ovary syndrome
951071|NCT02248272|Type 2 Diabetes
951072|NCT02248272|Hyperinsulinemia
951073|NCT02248272|Meal frequency
951074|NCT02248246|Hemostasis
951075|NCT02248246|Harmonic ACE®+7 Shears
951076|NCT02248246|Laparoscopic
951077|NCT02248246|Inferior mesenteric artery
951078|NCT02248246|Inferior mesenteric vein
951079|NCT02248246|Observational
951080|NCT02248233|nimodipine
951081|NCT02248233|acute massive cerebral infarction
951082|NCT02248233|Cerebral Infarction
951083|NCT02248233|optimal therapeutic time window
951084|NCT02248233|optimal dose
951085|NCT02248233|multi-center
951086|NCT02248194|Dysfunction uterine bleeding
951087|NCT02248194|Hysteroscopic endometrial ablation
951088|NCT02248194|Tactile endometrial ablation
951089|NCT02248194|Hysteroscopic difficulties
951090|NCT02248194|Quality of life
951091|NCT02248194|Satisfaction
951092|NCT02248090|Phase 1
951093|NCT02248090|Safety
951094|NCT02248090|Tolerability
951095|NCT02248090|Pharmacokinetics
951096|NCT02248090|Ascending Doses
951097|NCT02248090|Estrogen Receptor Positive
951098|NCT02248090|Her2 Negative
951099|NCT02248090|Advanced Breast Cancer
951100|NCT02248064|Chronic obstructive pulmonary disease
951101|NCT02248064|Long term oxygen therapy
951102|NCT02248064|Auto-titrating oxygen system
951103|NCT02248064|Intelligent oxygen therapy
951104|NCT02248064|Idiopathic pulmonary fibrosis
951105|NCT02248025|Fluid responsiveness
951106|NCT02248025|capillary refill time
951107|NCT02248025|microcirculation
951108|NCT02248025|circulatory failure
951109|NCT02248025|passive leg raising
951110|NCT02248012|Gastroenteropancreatic
951111|NCT02248012|Neuroendocrine carcinoma
951112|NCT02248012|Chemotherapy
951113|NCT02247999|Cervical Cancer
951114|NCT02247999|HIV/AIDS
951115|NCT02247999|HPV
951116|NCT02247999|Biomarkers
951117|NCT02247999|Screening
951118|NCT02247986|Conduct Disorder
951119|NCT02247986|Methylphenidate
951120|NCT02247986|Disruptive Behavior Disorders
951121|NCT02247947|CPR
951122|NCT02247934|Primary sclerosing cholangitis
951123|NCT02247934|PSC
951124|NCT02247921|caregiver delivered rehabilitation
951125|NCT02247921|nurse-organized service
951126|NCT02247921|disabled stroke patients
951127|NCT02247908|Cigarette smoking
951128|NCT02247908|Smoke
951129|NCT02247908|Smoking
951130|NCT02247908|Tobacco Use
951131|NCT02247895|ICU Acquired weakness
951132|NCT02247895|Critical illness
951133|NCT02247895|Mechanical ventilation
951134|NCT02247882|Osteoarthritis
951135|NCT02247882|Patient Education
951136|NCT02247882|Aquatic Exercise
951137|NCT02247882|kinetic
951138|NCT02247869|HL
951139|NCT02247869|Hodgkin Lymphoma
951140|NCT02247869|First line therapy
951141|NCT02247856|nebulizers,
951142|NCT02247856|noninvasive ventilation
951143|NCT02247856|COPD
951144|NCT02247856|scintigraphy,
951145|NCT02247856|aerosol
951146|NCT02247843|Sickle Cell Disease (SCD)
951147|NCT02247843|Gene Therapy
951148|NCT02247843|Lentiviral Vector
951149|NCT02247843|Beta Globin
951150|NCT02247830|Radiodermatitis
951151|NCT02247830|Head and neck neoplasms
951152|NCT02247830|Radiotherapy
951153|NCT02247830|Urea
951154|NCT02247830|Matricaria
951155|NCT02247830|Breast Neoplasms
951156|NCT02247830|chamomilla
951157|NCT02247830|chamomile
951158|NCT02247778|clavicle
951159|NCT02247778|surgical intervention
951160|NCT02247778|mini-incision
951161|NCT02247778|plate osteosynthesis
951162|NCT02247752|hepatitis
951163|NCT02247752|HBV
951164|NCT02247752|chronic hepatitis
951165|NCT02247752|HCC
951166|NCT02247752|cirrhosis
951167|NCT02247752|quantitative HBsAg
951168|NCT02247752|HBsAg inactive carriers
951169|NCT02247739|HAE
951170|NCT02247739|Hereditary Angioedema
951171|NCT02247739|Prophylaxis
951172|NCT02247726|RSV
951173|NCT02247726|Third Trimester
951174|NCT02247726|Maternal Immunization
951175|NCT02247713|PET
951176|NCT02247713|radiotherapy
951177|NCT02247713|international
951178|NCT02247713|NSCLC
951180|NCT02247713|low and middle income countries
951181|NCT02247700|Pediatrics
951182|NCT02247700|ARDS
951183|NCT02247700|ARF
951184|NCT02247700|ALI
951185|NCT02247700|Respiratory
951186|NCT02247700|Mechanical ventilation
951187|NCT02247700|Ventilation
951188|NCT02247700|Noninvasive monitoring
951189|NCT02247700|electrical impedance tomography
951190|NCT02247700|EIT
951191|NCT02247687|HIV-1
951192|NCT02247687|antiretroviral treatment
951193|NCT02247687|viral load
951194|NCT02247674|Stroke, Cerebrovascular accident, Rehabilitation, Upper extremity
951195|NCT02247661|Femoral neck fracture,surgical approach, limp, abductor strenght, trochanteric pain
951196|NCT02247648|tramadol
951197|NCT02247648|shoulder surgery
951198|NCT02247648|pain
951199|NCT02247648|interscalen block
951200|NCT02247648|BUPRENORPHINE/HYDROMORPHONE [VA Drug Interaction]
951201|NCT02247635|Treatment adherence
951202|NCT02247635|Behavioral model of health care
951203|NCT02247635|Healthy lifestyle
951204|NCT02247635|Chronic metabolic diseases
951205|NCT02247635|Metabolic syndrome
951206|NCT02247635|Obesity
951207|NCT02247622|telomeres
951208|NCT02247622|PSC
951209|NCT02247609|B cell lymphoma
951210|NCT02247609|non-Hodgkin's lymphoma
951211|NCT02247609|Burkitt lymphoma
951212|NCT02247609|diffused large B cell lymphoma
951213|NCT02247609|B cell malignancy
951214|NCT02247596|Resveratrol
951215|NCT02247596|obesity
951216|NCT02247596|insulin resistance
951217|NCT02247596|energy expenditure
951218|NCT02247596|diabetes
951219|NCT02247570|Vestibular Rehabilitation
951220|NCT02247570|PTSD
951221|NCT02247570|DSM-IV
951222|NCT02247557|IC/PBS
951223|NCT02247557|VAS
951224|NCT02247557|Botulinum Toxin A
951225|NCT02247557|Lipotoxin
951226|NCT02247544|STS, leiomyosarcoma, liposarcoma, trabectedin
951227|NCT02247518|Male
951228|NCT02247518|Volunteers
951229|NCT02247492|International
951230|NCT02247492|Multicenter
951231|NCT02247492|Observational registry
951232|NCT02247492|Orsiro Drug Eluting Stent (DES)
951233|NCT02247492|Stenting
951234|NCT02247492|Treatment of coronary artery disease
951235|NCT02247492|Coronary revascularization
951236|NCT02247492|Percutaneous Coronary Intervention (PCI)
951237|NCT02247492|STEMI
951238|NCT02247492|NSTEMI
951239|NCT02247492|Ischemia
951240|NCT02247492|Angina
951241|NCT02247492|Acute Myocardial Infarction (AMI)
951242|NCT02247492|Small Vessels
951243|NCT02247492|Chronic Total Occlusion (CTO
951244|NCT02247466|Neuromuscular Blockade
951245|NCT02247466|Laparoscopy
951246|NCT02247453|lung cancer
951247|NCT02247453|clinical trial
951248|NCT02247453|screening
951249|NCT02247453|microRNA
951250|NCT02247453|biomarkers
951251|NCT02247440|HCV
951252|NCT02247440|HIV
951253|NCT02247440|Thailand
951254|NCT02247440|pegylated interferon
951255|NCT02247440|ribavirin
951256|NCT02247427|Heart failure
951257|NCT02247427|Super responder
951258|NCT02247414|Cirrhosis
951259|NCT02247414|Hypertension
951260|NCT02247414|venous thrombosis
951261|NCT02247414|Warfarin
951262|NCT02247414|Splenectomy
951263|NCT02247414|Azygoportal Disconnection
951264|NCT02247414|Laparoscopy
951265|NCT02247401|non-responder
951266|NCT02247401|Egypt
951267|NCT02247401|HCV
951268|NCT02247401|null responder
951269|NCT02247401|Genotype 4
951270|NCT02247401|compensated cirrhosis
951271|NCT02247401|naive
951272|NCT02247401|treatment experienced
951273|NCT02247401|hepatitis c
951274|NCT02247401|relapser
951275|NCT02247401|hepatitis infection
951276|NCT02247401|partial responder
951277|NCT02247401|Cirrhosis
951278|NCT02247388|Alcohol Dependence
951279|NCT02247388|Alcoholism
951280|NCT02247388|AB-CASI
951281|NCT02247388|Emergency Department
951282|NCT02247362|Safety
951283|NCT02247362|Immunogenicity
951284|NCT02247336|colorectal cancer
951285|NCT02247336|early detection of cancer
951286|NCT02247297|Pancreatic stone protein (PSP)
951287|NCT02247297|premature rupture of membranes (PPROM)
951288|NCT02247297|amniotic infection syndrome (AIS)
951289|NCT02247297|hemolysis, elevated liver enzymes, and low platelets (HELLP)
951290|NCT02247297|preeclampsia
951291|NCT02247297|pregnancy
951292|NCT02247271|peer coaches
951293|NCT02247245|CHF
951294|NCT02247245|AF
951295|NCT02247245|SR
951296|NCT02247245|HFREF
951297|NCT02247245|CRT
951298|NCT02247219|Health education
951299|NCT02247219|Health services research
951300|NCT02247206|Tourette Syndrome
951301|NCT02247206|tic disorders
951302|NCT02247206|behavior therapy
951303|NCT02247206|web-based videoconferencing
951304|NCT02247206|VoIP
951305|NCT02247193|Botulinum Toxin
951306|NCT02247193|Botox
951307|NCT02247193|Craniofacial deformity
951308|NCT02247167|obstructive sleep apnoea, oxidative stress, FMD
951309|NCT02247128|Transcatheter Aortic Valve Implantation (TAVI)
951310|NCT02247128|Transcatheter Aortic Valve Replacement (TAVR)
951311|NCT02247128|Aortic Valve Disease
951312|NCT02247128|Aortic Stenosis
951313|NCT02247128|Myocardial Infarction
951314|NCT02247128|Ischemic stroke
951315|NCT02247128|Bleeding
951316|NCT02247128|Thrombosis
951317|NCT02247128|Myocardial Ischemia
951318|NCT02247128|Heart Diseases
951319|NCT02247128|Cardiovascular Diseases
951320|NCT02247128|Vascular Diseases
951321|NCT02247128|Embolism and Thrombosis
951322|NCT02247128|Aspirin
951323|NCT02247128|Clopidogrel
951324|NCT02247128|Prasugrel
951325|NCT02247128|Ticagrelor
951326|NCT02247128|Antithrombotic treatment
951327|NCT02247128|Oral anticoagulation
951328|NCT02247128|Warfarin
951329|NCT02247128|Platelet Aggregation Inhibitors
951330|NCT02247128|Genetic Testing
951331|NCT02247128|Cytochrome P450 2C19 (CYP2C19)
951332|NCT02247128|Prostaglandin-endoperoxide synthase 2(PTGS2)
951333|NCT02247115|endoscopic ultrasound
951334|NCT02247115|endoscopic retrograde cholangiopancreatography
951335|NCT02247115|competency
951336|NCT02247089|Night Shift work
951337|NCT02247089|Stress
951338|NCT02247089|Autonomic nervous system (ANS)
951339|NCT02247089|Heart rate variability (HRV)
951340|NCT02247089|Pre-ejection period (PEP)
951341|NCT02247089|Inflammation
951342|NCT02247089|Pro-inflammatory cytokines
951343|NCT02247089|Massage Therapy
951344|NCT02247050|Costs and Cost Analysis
951345|NCT02247050|Professional Practice
951346|NCT02247050|Attitude of Health Personnel
951347|NCT02247050|Health Knowledge, Attitudes, and Practice
951348|NCT02247050|Decision Making
951349|NCT02247050|Practice Guidelines as Topic
951350|NCT02247050|Physician-Patient Relations
951351|NCT02247050|Physician's Role
951352|NCT02247050|Health Care
951353|NCT02247050|Quality of Health Care
951354|NCT02247050|Quality Assurance
951355|NCT02247050|Physicians, Primary Care
951356|NCT02247050|Evidence-Based Medicine
951357|NCT02247050|Evidence-Based Practice
951358|NCT02247050|Decision Support Systems, Clinical
951359|NCT02247050|Reminder Systems
951360|NCT02247050|Judgment
951361|NCT02247050|Cognition
951362|NCT02247050|Patient Care
951363|NCT02247050|Health Services Misuse
951364|NCT02247050|Unnecessary Procedures
951365|NCT02247050|Prescribing Patterns, Physician
951366|NCT02247050|Inappropriate Prescribing
951367|NCT02247050|Over Prescribing
951368|NCT02247050|Low Back Pain
951369|NCT02247050|Sinusitis
951370|NCT02247050|Infections, Upper Respiratory
951371|NCT02247050|Generalized Headache
951372|NCT02247050|Imaging, Diagnostic
951373|NCT02247050|Antibiotics
951374|NCT02247050|Humans
951375|NCT02247050|Overuse of Low-Value Services
951376|NCT02247050|Pragmatic Trial
951377|NCT02247050|Stepped Wedge Design
951378|NCT02247050|Cluster Randomized Trial
951379|NCT02247050|Choosing Wisely
951380|NCT02247037|Triple Negative Breast Cancer
951381|NCT02247037|Patient Derived Xenograft
951382|NCT02247037|Neoadjuvant Chemotherapy
951383|NCT02247037|Therapeutic Resistance
951384|NCT02247011|bone mineral density
951385|NCT02247011|25(OH)D
951386|NCT02246985|Processed foods
951387|NCT02246985|Carotenoids in plasma, urine and faeces
951388|NCT02246985|alpha-carotene
951389|NCT02246985|beta-carotene
951390|NCT02246985|Vitamin A
951391|NCT02246985|Lycopene
951392|NCT02246985|Gut absorption
951393|NCT02246985|Bread
951394|NCT02246985|Mayonnaise
951395|NCT02246985|Bioavailability
951396|NCT02246985|Fruits and Vegetables
951397|NCT02246985|Inflammation
951398|NCT02246985|Oxidative Stress
951404|NCT02246946|pleural effusion
951405|NCT02246946|chest tube
951406|NCT02246946|respiratory therapy
951407|NCT02246946|intermittent positive-pressure breathing
951408|NCT02246946|lung function
951409|NCT02246946|pulmonary complications
951410|NCT02246920|Bioequivalence
951411|NCT02246920|Allergic Rhinitis
951412|NCT02246907|Health related quality of life
951413|NCT02246855|Subjects
951414|NCT02246842|Volunteers
951415|NCT02246829|wet AMD, SD-OCT, intravitreal injection, central retinal thickness,
951416|NCT02246816|Short Bowel Syndrome
951417|NCT02246816|SBS
951418|NCT02246816|Chronic Diarrhea
951419|NCT02246816|Short Bowel
951420|NCT02246816|Short Gut
951421|NCT02246816|Short Gut Syndrome
951422|NCT02246816|Anti-Diarrheal
951423|NCT02246816|Opium Tincture
951424|NCT02246816|loperamide
951425|NCT02246816|diphenoxylate
951426|NCT02246816|ileostomies
951427|NCT02246816|tincture of opium
951428|NCT02246816|DTO
951429|NCT02246816|codeine
951430|NCT02246816|morphine
951431|NCT02246816|opiate
951432|NCT02246803|paroxysmal atrial fibrillation, CABG, pulmonary vein isolation
951433|NCT02246790|ablation, CABG
951434|NCT02246790|Long-standing persistent Atrial Fibrillation
951435|NCT02246777|Glaucoma
951436|NCT02246764|Ocular hypertension.
951437|NCT02246764|Glaucoma
951438|NCT02246751|postural control
951439|NCT02246751|Targeted Training
951440|NCT02246751|cerebral palsy
951441|NCT02246751|sensorimotor control
951442|NCT02246751|trunk segments
951443|NCT02246725|Colorectal Neoplasms
951444|NCT02246725|Depression
951445|NCT02246725|Intestinal Neoplasms
951446|NCT02246725|Gastrointestinal Neoplasms
951447|NCT02246725|Digestive System Neoplasms
951448|NCT02246725|Digestive System Diseases
951449|NCT02246725|Gastrointestinal Diseases
951450|NCT02246725|Intestinal Diseases
951451|NCT02246725|Palliative chemotherapy
951452|NCT02246725|Palliative care
951453|NCT02246725|Palliative treatment
951454|NCT02246725|Quality of life
951455|NCT02246725|Quality of life for relatives
951456|NCT02246725|Survival
951457|NCT02246712|tramadol
951458|NCT02246712|pharmacokinetics
951459|NCT02246712|enantiomers
951460|NCT02246712|metabolism
951461|NCT02246712|diabetes
951462|NCT02246699|obesity
951463|NCT02246699|overweight
951464|NCT02246699|chitosan
951465|NCT02246699|fungal chitosan
951466|NCT02246699|weight management
951467|NCT02246686|Iberogast N
951468|NCT02246686|Mild to moderate ulcerative colitis
951469|NCT02246686|add-on therapy
951470|NCT02246686|efficacy
951471|NCT02246660|Peripheral Artery Disease
951472|NCT02246660|Peripheral Arterial Disease
951473|NCT02246660|PAD
951474|NCT02246634|Colorectal Neoplasms
951475|NCT02246634|Neoplasm Metastases
951476|NCT02246634|Magnetic Resonance Imaging
951477|NCT02246634|Diffusion Weighted MRI
951478|NCT02246634|Hepatic Neoplasms
951479|NCT02246634|Tumors
951480|NCT02246634|Neoplasms, Rectal
951481|NCT02246621|MONARCH 3
951482|NCT02246595|Sepsis
951483|NCT02246595|Severe Sepsis
951484|NCT02246595|Septic Shock
951485|NCT02246595|Systemic Inflammatory Response Syndrome
951486|NCT02246595|Organ Dysfunction
951487|NCT02246582|Type 1 Diabetes
951488|NCT02246582|Type 2 Diabetes
951489|NCT02246582|Enlite 3
951490|NCT02246569|Chronic obstructive pulmonary disease (COPD)
951491|NCT02246569|endoscopic lung volume reduction
951492|NCT02246569|RePneu®Coils
951493|NCT02246569|physical capacity
951494|NCT02246569|quality of life
951495|NCT02246556|Amblyopia
951496|NCT02246556|Dichoptic
951497|NCT02246556|Virtual reality
951498|NCT02246556|Stereopsis
951499|NCT02246556|Stereo vision
951500|NCT02246556|Visual acuity
951501|NCT02246556|Binocular
951502|NCT02246543|Appetite
951503|NCT02246543|Gut Hormones
951504|NCT02246543|Protein
951505|NCT02246543|Energy Density
951506|NCT02246543|Gastric Emptying
951507|NCT02246465|Hypertrophic scar
951508|NCT02246465|Cicatrix
951509|NCT02246465|Scar prevention
951510|NCT02246465|Scar revision
951511|NCT02246452|Children and adolescents
951512|NCT02246452|Cancer
951513|NCT02246452|Malnutrition
951514|NCT02246452|BMI percentile
951515|NCT02246452|BMI-SDS
951516|NCT02246439|Gastroenteritis
951517|NCT02246439|Gastritis
951518|NCT02246439|Vomiting
951519|NCT02246439|Nausea
951520|NCT02246439|Diarrhea
951521|NCT02246413|BMI
951522|NCT02246413|Depressive symptoms
951523|NCT02246413|Integrated therapy
951524|NCT02246413|Cardiometabolic risk
951525|NCT02246413|Self-regulation
951526|NCT02246413|Behavior change
951527|NCT02246413|Precision medicine
951528|NCT02246413|Lifestyle
951529|NCT02246400|eCMP
951530|NCT02246400|eHealth
951531|NCT02246400|mHealth
951532|NCT02246400|Lifestyle intervention
951533|NCT02246400|Cardiometabolic risk reduction
951534|NCT02246400|PAMF
951535|NCT02246387|Pelvic Organ Prolapse
951536|NCT02246387|Gynecologic Surgery Procedures
951537|NCT02246387|Treatment Outcome
951538|NCT02246374|Parkinson's Disease
951539|NCT02246374|ExAblate
951540|NCT02246374|MRgFUS
951541|NCT02246361|Ankle sprain
951542|NCT02246361|Infectious colitis
951543|NCT02246361|Diverticulitis
951544|NCT02246361|Pyelonephritis
951545|NCT02246361|Prostatitis
951546|NCT02246361|Pneumonitis
951547|NCT02246361|Patient Information Leaflet (PIL)
951548|NCT02246361|Doctor Patient Communication
951549|NCT02246361|Adherence
951550|NCT02246361|Satisfaction
951551|NCT02246361|Scale
951552|NCT02246361|Doctor Patient Communication scale
951553|NCT02246361|Adherence scale
951554|NCT02246361|Satisfaction scale
951555|NCT02246348|Systemic Sclerosis
951556|NCT02246348|Pulmonary hypertension
951557|NCT02246348|Lung Doppler signals
951558|NCT02246322|Pancreatic cancer
951559|NCT02246322|Neuroendocrine tumors
951560|NCT02246322|Lymphadenopathies
951561|NCT02246322|GIST
951562|NCT02246322|Gastrointestinal wall neoplasia
951563|NCT02246309|Infertility
951564|NCT02246309|Embryo Culture
951565|NCT02246309|Laboratory Technique
951566|NCT02246296|severe acute malnutrition
951567|NCT02246296|wasting
951568|NCT02246296|kwashiorkor
951569|NCT02246296|nutrition
951570|NCT02246296|feeding
951571|NCT02246296|milk
951572|NCT02246283|schizophrenia
951573|NCT02246283|elderly
951574|NCT02246283|lifelong
951575|NCT02246283|quality of life
951576|NCT02246283|register
951577|NCT02246283|questionaire
951578|NCT02246218|Urea Cycle Disorder
951579|NCT02246218|UCD
951580|NCT02246218|GT4P
951581|NCT02246218|Buphenyl
951582|NCT02246218|Glycerol Phenylbutyrate
951583|NCT02246218|Ravicti
951584|NCT02246218|Hyperammonemia
951585|NCT02246218|Sodium Phenylbutyrate
951586|NCT02246218|GPB
951587|NCT02246218|HPN-100
951588|NCT02246205|pancreaticoduodenectomy
951589|NCT02246205|delayed gastric emptying
951590|NCT02246205|Roux en-Y reconstruction
951591|NCT02246179|Fractional laser
951592|NCT02246179|Topical anesthesia
951593|NCT02246179|Drug delivery
951594|NCT02246153|Laparoscopic gastrectomy
951595|NCT02246153|Advanced gastric cancer
951596|NCT02246153|Elderly patients
951597|NCT02246153|Morbidity
951598|NCT02246153|Mortality
951599|NCT02246127|advanced pNET
951600|NCT02246127|everolimus
951601|NCT02246127|STZ-5FU
951602|NCT02246127|treatment sequence
951603|NCT02246114|Pregnancy
951604|NCT02246114|Smoking
951605|NCT02246114|Smoking cessation
951606|NCT02246101|cardiac disease
951607|NCT02246101|cardiopulmonary disease
951608|NCT02246101|renal disease
951609|NCT02246101|albuminuria
951610|NCT02246101|cardiovascular disease
951611|NCT02246101|CVD
951612|NCT02246101|particulate matter
951613|NCT02246088|Osteoarthritis, Central Nervous System Sensitization
951614|NCT02246075|Alzheimer's disease
951615|NCT02246075|Cognition
951616|NCT02246075|Alpha-7 nAChR
951617|NCT02246062|Anxiety
951618|NCT02246062|Anesthesia
951619|NCT02246062|Evaluation
951620|NCT02246062|Preoperative care
951621|NCT02246062|Child
951622|NCT02246049|Metastatic colorectal cancer, bevacizumab, FOLFOXIRI
951623|NCT02246010|diarrhea
951624|NCT02246010|developing world
951625|NCT02246010|lactose-free diet
951626|NCT02246010|Clinical trial
951627|NCT02245997|Reduced-dose Radiotherapy
951628|NCT02245997|14-186
951629|NCT02245984|clinical competence, nursing process, nursing student
951630|NCT02245945|HIV
951631|NCT02245945|prevention
951632|NCT02245932|Pulmonary disease, Chronic Obstructive
951633|NCT02245932|Cardiovascular diseases
951634|NCT02245932|Metabolism
951635|NCT02245932|Resveratrol
951636|NCT02245919|Low Back Pain
951637|NCT02245919|Chronic Pain
951638|NCT02245919|Cognitive Behavioral Therapy
951639|NCT02245919|Primary Health Care
951640|NCT02245919|Physical Therapy
951641|NCT02245906|Brazilian fruit peel
951642|NCT02245906|Functional food
951643|NCT02245906|Cardiometabolic risk
951644|NCT02245906|Metabolic syndrome
951645|NCT02245906|Inflammation
951646|NCT02245906|Appetite
951647|NCT02245906|Gut hormone
951648|NCT02245880|cervical spine
951649|NCT02245880|intubating laryngeal mask airway
951650|NCT02245880|Glidescope videolaryngoscope
951651|NCT02245880|collar
951652|NCT02245867|Amyloidosis
951653|NCT02245867|Relapse
951654|NCT02245867|Refractory
951655|NCT02245854|diminutive polyps
951656|NCT02245854|small polyps
951657|NCT02245854|cold snare polypectomy
951658|NCT02245854|complications
951659|NCT02245854|bleeding
951660|NCT02245841|dermatomyositis
951661|NCT02245841|Acthar gel
951662|NCT02245828|healthy subjects, inhaled
951663|NCT02245815|Necrotizing enterocolitis
951664|NCT02245815|Probiotics
951665|NCT02245815|Secreting IgA
951666|NCT02245815|Preterm newborns
951667|NCT02245802|Bleeding peptic ulcer
951668|NCT02245802|Prediction model
951669|NCT02245802|Mortality
951670|NCT02245802|Prediction of in-hospital mortality for bleeding peptic ulcer
951671|NCT02245776|Incurable Neurological Disorders
951672|NCT02245776|Autologous mononuclear cell therapy
951673|NCT02245776|Stem cells
951674|NCT02245750|hysteroscopy - recurrent implantation failure
951684|NCT02245724|Mental retardation
951685|NCT02245724|Autologous mononuclear cell therapy
951686|NCT02245724|Stem cell
951687|NCT02245711|Limb Girdle Muscular Dystrophy
951688|NCT02245711|Autologous Bone Marrow Mononuclear cell therapy
951689|NCT02245711|Stem Cell
951690|NCT02245698|Chronic Stroke
951691|NCT02245698|Subacute stroke
951692|NCT02245698|Autologous Bone Marrow Mononuclear Cell therapy
951693|NCT02245698|Stem cell
951694|NCT02245685|Substitution Therapy
951695|NCT02245685|Specialized Care Center for Addicts
951696|NCT02245672|Asthma
951697|NCT02245672|fluticasone
951698|NCT02245672|salmeterol
951699|NCT02245672|CRC749
951700|NCT02245672|Diskus
951701|NCT02245672|Advair
951702|NCT02245672|FEV1
951703|NCT02245672|MGR001
951704|NCT02245620|Skeletal muscle dysfunction, MTP-131, Bendavia™
951705|NCT02245620|elamipretide
951706|NCT02245607|Psychotic Disorders
951707|NCT02245607|Cognitive Training
951708|NCT02245607|Mental Disorders
951709|NCT02245607|Schizophrenia and Disorders with Psychotic Features
951710|NCT02245594|Gastrointestinal motility
951711|NCT02245594|Motility Tracking System (MTS)
951712|NCT02245594|Transit time
951713|NCT02245594|Sleep pattern
951714|NCT02245568|Dementia
951715|NCT02245568|Alzheimer Disease
951716|NCT02245568|bvFTD
951717|NCT02245568|Frontotemporal Dementia
951718|NCT02245568|Neurodegenerative Diseases
951719|NCT02245568|Brain Diseases
951720|NCT02245568|Cognitive Disorders
951721|NCT02245516|Intraretinal Fluid
951722|NCT02245516|Subretinal Fluid
951723|NCT02245516|Retinal Vein Occlusion
951724|NCT02245516|Diabetic Macular Edema
951725|NCT02245477|Serum VEGF, FGR
951726|NCT02245425|Neck pain
951727|NCT02245425|Thoracic spine manipulation
951728|NCT02245425|Range of Motion
951729|NCT02245425|Disability
951730|NCT02245399|Weight loss
951731|NCT02245399|Diabetes
951732|NCT02245399|Cardiovascular disease (CVD) risk
951733|NCT02245399|Weight loss diet
951734|NCT02245399|mediterranean type diet
951735|NCT02245399|Canola oil
951736|NCT02245399|Low-carbohydrate diet
951737|NCT02245399|Glycemic index
951738|NCT02245373|Depression
951739|NCT02245373|Primary Care
951740|NCT02245373|Cost-effectiveness
951741|NCT02245373|Pharmacological treatment
951742|NCT02245373|Watchful-waiting or Active Monitoring.
951743|NCT02245360|GRAZAX
951744|NCT02245347|TB
951745|NCT02245347|Tuberculosis
951746|NCT02245347|MDR TB
951747|NCT02245347|Drug resistant TB
951748|NCT02245321|hemoglobin recovery
951749|NCT02245321|iron recovery
951750|NCT02245321|iron supplements
951751|NCT02245308|Tobacco use cessation
951752|NCT02245308|Homelessness
951753|NCT02245308|Veterans
951754|NCT02245295|Bronchial endoscopy
951755|NCT02245295|ultrasound
951756|NCT02245295|EBUS
951757|NCT02245295|anesthesia
951758|NCT02245295|lung cancer
951759|NCT02245295|diagnosis including staging
951760|NCT02245256|delirium
951761|NCT02245256|incidence
951762|NCT02245256|dexmedetomidine
951763|NCT02245243|Hepatic Impairment, single dose, intravenous
951764|NCT02245230|Hypertension
951765|NCT02245230|Autonomic Nervous System
951766|NCT02245230|Renin-Angiotensin System
951767|NCT02245230|Angiotensin (1-7)
951768|NCT02245230|Ganglionic Blockers
951769|NCT02245230|Trimethaphan
951770|NCT02245230|Blood Pressure
951771|NCT02245230|Hemodynamics
951772|NCT02245191|Vasopressor
951773|NCT02245191|Cesarian delivery
951774|NCT02245191|Hypotension
951775|NCT02245191|Maternal cardiac output
951776|NCT02245191|Uteroplacental blood flow
951777|NCT02245191|Cerebral fetal blood flow
951778|NCT02245191|Preeclampsia
951779|NCT02245165|Nitric oxide
951780|NCT02245165|Nitric oxide synthase
951781|NCT02245165|Gastrointestinal motility
951782|NCT02245165|Gut peptide hormones
951783|NCT02245152|child acute malnutrition
951784|NCT02245152|prevention
951785|NCT02245152|behavior change communication
951786|NCT02245152|lipid-based nutrient supplement
951787|NCT02245152|screening coverage
951788|NCT02245139|diarrhea
951789|NCT02245139|vomiting
951790|NCT02245139|fever
951791|NCT02245139|abdominal pain
951792|NCT02245139|oliguria
951793|NCT02245126|Pain, Visual analogue scale
951794|NCT02245087|atorvastatin
951795|NCT02245087|coronary artery disease
951796|NCT02245087|myocardial infarction
951797|NCT02245087|stroke
951798|NCT02245087|revascularization
951799|NCT02245074|Infantile asthma
951800|NCT02245074|Induced sputum
951801|NCT02245074|Phenotypes
951802|NCT02245074|Eosinophils
951803|NCT02245074|Neutrophils
951804|NCT02245061|pharmacoresistant focal epilepsy
951805|NCT02245061|cortical excitability
951806|NCT02245061|paired pulses
951807|NCT02245061|TMS
951808|NCT02245061|SEEG
951809|NCT02245061|DES
951810|NCT02245048|Cardiovascular Risk Stratification
951811|NCT02245048|Carotid intima-media thickness (CIMT)
951812|NCT02245048|Stress echocardiography (SE)
951813|NCT02245035|Glutathione
951814|NCT02245035|Dairy consumption
951815|NCT02245035|Brain
951816|NCT02245035|Humans
951817|NCT02245022|HIV
951818|NCT02245022|Prevention of mother to child transmission
951819|NCT02245022|Africa
951820|NCT02245022|Uganda
951821|NCT02245022|Pharmacokinetics
951822|NCT02245022|Pregnancy
951823|NCT02245022|Breastfeeding
951824|NCT02244996|Retinitis pigmentosa
951825|NCT02244996|Lycium barbarum
951826|NCT02244996|Antioxidation
951827|NCT02244996|Visual field
951828|NCT02244996|Electroretinogram
951829|NCT02244970|Mindfulness
951830|NCT02244970|Depressive mood
951831|NCT02244970|anxiety
951832|NCT02244970|early psychosis
951833|NCT02244944|nonalcoholic fatty liver disease
951834|NCT02244944|NAFLD
951835|NCT02244931|Spinal cord injuries, paraplegic, manual wheelchairs, assisting propelling device
951836|NCT02244905|Positive Deviance
951837|NCT02244905|Infection Control
951838|NCT02244905|Healthcare-Associated Infections
951839|NCT02244905|Staff Engagement
951840|NCT02244905|Cluster Randomized Controlled Trial
951841|NCT02244892|Disability glare
951842|NCT02244892|Corneal scar
951843|NCT02244892|Corneal haze
951844|NCT02244892|Scheimpflug densitometry
951845|NCT02244892|Contrast sensitivity
951846|NCT02244879|resveratrol
951847|NCT02244879|type 2 diabetes mellitus
951848|NCT02244879|inflammation
951849|NCT02244879|insulin resistance
951850|NCT02244879|body composition
951851|NCT02244879|bone mass
951852|NCT02244866|IVF
951853|NCT02244866|LH supplementation
951854|NCT02244866|ovarian stimulation
951855|NCT02244866|poor responder
951856|NCT02244840|Bidet, Sitz bath, Anal resting pressure
951857|NCT02244814|glucose
951858|NCT02244814|insulin resistance
951859|NCT02244814|dietary carbohydrate
951860|NCT02244814|dietary fat
951861|NCT02244814|adiposity
951862|NCT02244814|Air displacement plethysmography
951863|NCT02244814|Dual X-ray Absorptiometry
951864|NCT02244814|continuous glucose monitoring
951865|NCT02244775|osteo-arthritis
951866|NCT02244775|post traumatic arthritis
951867|NCT02244736|Arterial stiffness
951868|NCT02244736|Endothelial glycocalyx
951869|NCT02244736|Coronary flow reserve
951870|NCT02244723|Ventilator-Associated Pneumonia
951871|NCT02244723|diagnosis
951872|NCT02244710|Circulating Endothelial Cells
951873|NCT02244710|Endothelial Progenitor Cells
951874|NCT02244710|Acute coronary syndrome (ACS)
951875|NCT02244710|Ticagrelor
951876|NCT02244697|Stridor
951877|NCT02244697|Vocal Cord Paralysis (VCP)
951878|NCT02244697|Ultrasound (US)
951879|NCT02244684|Folate
951880|NCT02244684|Folic Acid
951881|NCT02244684|One-Carbon Nutrients
951882|NCT02244684|Epigenetics
951883|NCT02244684|Pregnancy
951884|NCT02244684|Fetal Health
951885|NCT02244658|chemotherapy-induced thrombocytopenia
951886|NCT02244658|recombinant human thrombopoietin
951887|NCT02244658|acute myelocytic leukemia
951888|NCT02244645|Low back pain, physical therapy, yoga.
951889|NCT02244632|Colorectal cancer
951890|NCT02244632|Colorectal carcinoma
951891|NCT02244632|Colorectal tumors
951892|NCT02244632|Intestinal Neoplasm
951893|NCT02244632|Gastrointestinal Neoplasm
951894|NCT02244632|Gastrointestinal disease
951895|NCT02244632|5,10-methylenetetrahydrofolate
951896|NCT02244632|Tetrahydrofolates
951897|NCT02244632|Therapeutic uses
951898|NCT02244632|Pharmacokinetics
951899|NCT02244632|Pharmacodynamics
951900|NCT02244632|Safety assessments
951901|NCT02244619|Hip replacement
951902|NCT02244619|Knee replacement
951903|NCT02244619|randomized trial
951904|NCT02244619|acetaminophen
951905|NCT02244619|post-op pain management
951906|NCT02244606|Invasive Candidiasis
951907|NCT02244606|Invasive Candida infections
951908|NCT02244606|Candidemia
951909|NCT02244606|SCY-078
951910|NCT02244606|Micafungin
951911|NCT02244606|Fluconazole
951912|NCT02244606|Echinocandin
951913|NCT02244593|breast cancer survivors
951914|NCT02244593|FAST MRI
951915|NCT02244593|mammography screening
951916|NCT02244580|Subtyping of Invasive breast cancer
951917|NCT02244567|PCOS
951918|NCT02244554|tattoo removal
951919|NCT02244554|Q-switched laser
951920|NCT02244554|Nd:YAG laser
951921|NCT02244554|nanosecond laser
951922|NCT02244554|picosecond laser
951923|NCT02244554|laser therapy
951924|NCT02244554|tattoo
951925|NCT02244554|pulsed-laser
951926|NCT02244554|laser treatment
951927|NCT02244554|remove tattoo
951928|NCT02244554|tattoo clearing
951929|NCT02244554|tattoo lightening
951930|NCT02244554|tattoo lighten
951931|NCT02244554|resistant tattoo
951932|NCT02244515|children
951933|NCT02244502|Ovarian Carcinoma
951934|NCT02244502|Treatment
951935|NCT02244502|Minimal toxicity
951936|NCT02244502|TTFields
951937|NCT02244502|Tumor Treating Fields
951938|NCT02244502|Novocure
951939|NCT02244502|Paclitaxel
951940|NCT02244502|Weekly paclitaxel
951941|NCT02244476|mouth feel
951942|NCT02244476|acoustic tribology
951943|NCT02244476|vibration spectrum
951944|NCT02244476|sensory perception
951945|NCT02244463|Anaplastic Thyroid Cancer
951946|NCT02244463|Thyroid Cancer
951947|NCT02244450|Neonatal screening
951948|NCT02244450|severe combined immunodeficiency
951949|NCT02244450|T-cell Receptor Excision Circle
951950|NCT02244437|altitude, altitude illnesses, headache
951951|NCT02244424|Infant
951952|NCT02244424|Obesity
951953|NCT02244424|Adolescent
951954|NCT02244424|Social media
951955|NCT02244424|Prevention
951956|NCT02244411|EQUAL
951957|NCT02244411|Exercise
951958|NCT02244411|Diet
951959|NCT02244411|Physical activity
951960|NCT02244411|14-164
951961|NCT02244385|vascular disease
951962|NCT02244385|pregnancy
951963|NCT02244385|chronic hypertension
951964|NCT02244385|diabetes
951965|NCT02244385|obesity
951966|NCT02244372|Cordyceps sinensis mycelium culture extract(Paecilomyces hepiali, CBG-CS-2)
951967|NCT02244372|immunity
951968|NCT02244359|Shared Decision making
951969|NCT02244359|Patient Centred care
951970|NCT02244359|Interprofessionalism
951971|NCT02244359|Home care
951972|NCT02244359|Frail elderly
951973|NCT02244164|Type 2 Diabetes
951974|NCT02244164|Incretinomimetics
951975|NCT02244164|DPP-4 inhibitors
951976|NCT02244164|Pancreas
951977|NCT02244164|PanIN
951978|NCT02244164|RMN
951979|NCT02244164|Lipasemia
951980|NCT02244151|ovulation induction,oocyte maturation timing and collection
951981|NCT02244138|Adolescent
951982|NCT02244138|Screening
951983|NCT02244138|Primary Care
951984|NCT02244138|Computer Decision Support Systems
951985|NCT02244125|Myeloma
951986|NCT02244125|Multiple Myeloma
951987|NCT02244125|Relapse
951988|NCT02244125|Refractory
951989|NCT02244125|PCD
951990|NCT02244125|IFM/DFCI 2009
951991|NCT02244125|Transplantation
951992|NCT02244125|Autologous
951993|NCT02244125|Pomalidomide
951994|NCT02244125|Immunoglobulin
951995|NCT02244125|Ig
951996|NCT02244125|Free light Chain
951997|NCT02244099|Controlled substance prescribing
951998|NCT02244099|Controlled substance treatment agreements
951999|NCT02244099|Opioid use
952000|NCT02244086|obstetric pain, bupivacaine, analgesic efficacy
952001|NCT02244073|blood glucose target
952002|NCT02244073|ICU
952003|NCT02244073|insulin
952004|NCT02244073|hypoglycemia
952005|NCT02244073|hyperglycemia
952006|NCT02244073|glycated hemoglobin
952007|NCT02244060|Vignette
952008|NCT02244060|Priming effect
952009|NCT02244021|HD
952010|NCT02244021|Hodgkin's Lymphoma
952011|NCT02244021|RELAPSED-REFRACTORY
952012|NCT02244008|Mobilization
952013|NCT02244008|Joint Range of Motion
952014|NCT02244008|Ankle
952015|NCT02244008|Manual Therapy
952016|NCT02243995|Training program
952017|NCT02243995|Resistance training
952018|NCT02243995|Endurance training
952019|NCT02243995|Muscle strength
952020|NCT02243995|Exercise capacity
952021|NCT02243995|Fatigue
952022|NCT02243995|Quality of life
952023|NCT02243982|Parkinson, dementia, FDDNP, tau, beta-amyloid
952024|NCT02243969|n-3 polyunsaturated fatty acids
952025|NCT02243969|Alpha-linolenic acid
952026|NCT02243969|Blood pressure
952027|NCT02243969|Vascular function
952028|NCT02243943|Neuromuscular block
952029|NCT02243943|neuromuscular reversal
952030|NCT02243943|postoperative conditions
952031|NCT02243943|respiratory failure
952032|NCT02243930|Sigmoidoscopy with or without cap
952033|NCT02243930|Pain during sigmoidoscopy
952034|NCT02243930|Sigmoidoscopy and time
952035|NCT02243904|Autonomic nervous function
952036|NCT02243904|Blood pressure
952037|NCT02243904|Cardiovascular regulation
952038|NCT02243904|Lead
952039|NCT02243904|Occupational exposure
952040|NCT02243904|Renal function
952041|NCT02243852|Growth Hormone Deficiency (GHD)
952042|NCT02243852|Growth Hormone Replacement Therapy
952043|NCT02243852|Fibroblast Growth Factor 21 (FGF21)
952044|NCT02243852|Visceral Fat
952045|NCT02243852|Subcutaneous Fat
952046|NCT02243839|Prosthetic valve
952047|NCT02243839|Thrombosis
952048|NCT02243839|Surgery
952049|NCT02243839|Thrombolytic therapy
952050|NCT02243839|Transesophageal echocardiography
952051|NCT02243826|Lumbar puncture
952052|NCT02243826|Adults
952053|NCT02243826|Nitrous oxide
952054|NCT02243826|Procedural pain
952055|NCT02243826|Procedural anxiety
952056|NCT02243813|Psilocybin
952057|NCT02243813|Pharmacologic Actions
952058|NCT02243813|Psychotropic Drugs
952059|NCT02243800|Vitamin D
952060|NCT02243800|Rheumatoid arthritis
952061|NCT02243800|Cholecalciferol
952062|NCT02243774|Vaccination
952063|NCT02243774|Immunization
952064|NCT02243774|Randomized Controlled Trial
952065|NCT02243774|Prevention & Control
952066|NCT02243774|Preventive Measures
952067|NCT02243774|Health Promotion
952068|NCT02243774|Medicare
952069|NCT02243774|Intention Prompts
952070|NCT02243774|Letters
952071|NCT02243761|Concurrent Disorders
952072|NCT02243761|Mental Health
952073|NCT02243761|Addictions
952074|NCT02243761|Caregiver Burden
952075|NCT02243722|laryngeal electromyography
952076|NCT02243722|intrinsic laryngeal muscles
952077|NCT02243722|recurrent laryngeal nerve
952078|NCT02243722|superior laryngeal nerve
952079|NCT02243722|laryngeal sensation
952080|NCT02243722|tone language
952081|NCT02243709|Stress, alcohol craving, alcohol use disorders
952082|NCT02243670|opioid addiction
952083|NCT02243670|opioid substitution therapy
952084|NCT02243670|addiction
952085|NCT02243670|buprenorphine maintenance treatment
952086|NCT02243670|opioid dependence
952087|NCT02243670|substitution treatment
952088|NCT02243670|noncompliance
952089|NCT02243670|opiate addiction
952090|NCT02243670|Zubzolv® maintenance
952091|NCT02243670|adherence monitoring
952092|NCT02243670|directly observed therapy
952093|NCT02243670|medication adherence
952094|NCT02243670|adherence
952095|NCT02243670|mobile
952096|NCT02243670|electronic monitoring
952097|NCT02243670|wireless
952098|NCT02243670|mobile device
952099|NCT02243670|artificial intelligence
952100|NCT02243670|facial recognition
952101|NCT02243670|computer vision
952102|NCT02243670|visual confirmation
952103|NCT02243670|sublingual buprenorphine/naloxone
952104|NCT02243670|nonadherence
952105|NCT02243657|ASP3652
952106|NCT02243657|Age
952107|NCT02243657|Gender
952108|NCT02243657|Pharmacokinetics
952109|NCT02243657|Pharmacodynamics
952110|NCT02243657|Phase 1
952111|NCT02243657|Multiple Ascending Doses (MAD)
952112|NCT02243644|parenchymal neurocysticercosis upto five lesions
952113|NCT02243631|ATP
952114|NCT02243631|Probenecid
952115|NCT02243631|Chondrocalcinosis
952116|NCT02243527|Exercise
952117|NCT02243514|Hypertension
952118|NCT02243514|Heart failure
952119|NCT02243514|Sympathetic hyperactivity
952120|NCT02243514|Renal nerve
952121|NCT02243514|Remodeling
952122|NCT02243514|Nerve remodeling
952123|NCT02243488|Menstruation
952124|NCT02243488|MHM
952125|NCT02243488|Menstrual Hygiene Management
952126|NCT02243488|Girls Education
952127|NCT02243488|Absenteeism
952128|NCT02243488|Access to Education
952129|NCT02243488|Menstrual Health Education
952130|NCT02243488|Reusable Sanitary Product
952131|NCT02243462|Shivering
952132|NCT02243462|Hypothermia
952133|NCT02243462|Postoperative
952134|NCT02243462|Temperature
952135|NCT02243462|Forced air warmer
952136|NCT02243449|mechanical ventilation
952137|NCT02243449|weaning
952138|NCT02243449|elderly
952139|NCT02243449|critically ill
952140|NCT02243449|screening
952141|NCT02243449|spontaneous breathing trial
952142|NCT02243449|invasive ventilation
952143|NCT02243436|CLASSICAL HODGKIN LYMPHOMA
952144|NCT02243436|HODGKIN LYMPHOMA
952145|NCT02243436|LYMPHOMA
952146|NCT02243436|HL
952147|NCT02243423|Aortocaval compression
952148|NCT02243423|Cesarean Section
952149|NCT02243423|Spinal Anesthesia
952150|NCT02243423|Phenylephrine
952151|NCT02243384|Early Hepatocellular Carcinoma
952152|NCT02243384|Laparoscopic Hepatectomy
952153|NCT02243384|Radiofrequency Ablation
952154|NCT02243384|Micrometastases
952155|NCT02243358|Pancreatic, cancer
952156|NCT02243345|decompression
952157|NCT02243345|recompression
952158|NCT02243345|delayed
952159|NCT02243345|late
952168|NCT02243306|pharmacokinetics
952169|NCT02243306|Chronic kidney disease
952170|NCT02243306|peritoneal dialysis
952171|NCT02243306|hemoglobin
952172|NCT02243306|Anemia
952173|NCT02243306|GSK1278863
952174|NCT02243306|Prolyl hydroxylase inhibitor
952175|NCT02243306|erythropoiesis stimulating agents
952176|NCT02243293|Hepatitis C Virus
952177|NCT02243293|Hepatitis C Genotype 4
952178|NCT02243293|Hepatitis C
952179|NCT02243293|HCV
952180|NCT02243293|Hepatitis C Genotype 5
952181|NCT02243293|interferon free
952182|NCT02243293|Hepatitis C Genotype 2
952183|NCT02243293|Hepatitis C Genotype 3
952184|NCT02243293|Hepatitis C Genotype 6
952185|NCT02243293|Chronic Hepatitis C
952186|NCT02243280|HCV GT4
952187|NCT02243280|Hepatitis C virus
952188|NCT02243280|HCV GT1
952189|NCT02243280|HCV
952190|NCT02243280|Compensated Cirrhosis
952191|NCT02243280|HCV GT6
952192|NCT02243280|Hepatitis C Genotype 4 (GT 4)
952193|NCT02243280|Hepatitis C Genotype 1 (GT1)
952194|NCT02243280|RBV
952195|NCT02243280|Cirrhotic
952196|NCT02243280|Hepatitis C
952197|NCT02243280|Interferon (IFN) Free
952198|NCT02243280|IFN free
952199|NCT02243280|HCV GT5
952200|NCT02243280|Chronic Hepatitis C
952201|NCT02243280|Ribavirin
952202|NCT02243280|Child Pugh A
952203|NCT02243280|Hepatitis C Genotype 5 (GT 5)
952204|NCT02243280|Hepatitis C Genotype 6 (GT 6)
952205|NCT02243280|ABT-493
952206|NCT02243280|ABT-530
952207|NCT02243280|glecaprevir
952208|NCT02243280|pibrentasvir
952209|NCT02243267|Colon Cancer Colon Cancer Prevention
952210|NCT02243241|Healthy volunteers
952211|NCT02243241|Opioid
952212|NCT02243241|ECG
952213|NCT02243241|QTcI
952214|NCT02243228|granulocyte-macrophage colony stimulating factor(GM-CSF)
952215|NCT02243228|Autoimmune pulmonary alveolar proteinosis (PAP)
952216|NCT02243215|Laparoscopy
952217|NCT02243215|Training
952218|NCT02243215|Off-site
952219|NCT02243215|Box trainer
952220|NCT02243215|Virtual Reality Simulator
952221|NCT02243202|Obesity
952222|NCT02243202|Overweight
952223|NCT02243202|Canagliflozin
952224|NCT02243202|Phentermine
952225|NCT02243202|INVOKANA®
952226|NCT02243189|Healthy
952227|NCT02243189|Asthma
952228|NCT02243189|JNJ-43260295
952229|NCT02243189|Nasal Allergen Challenge
952230|NCT02243176|Saxagliptin
952231|NCT02243176|Acarbose
952232|NCT02243176|Type 2 Diabetes
952233|NCT02243176|Metformin
952234|NCT02243124|Anemia
952235|NCT02243124|Transfusion
952236|NCT02243124|AML
952237|NCT02243124|MDS
952238|NCT02243124|CLL
952239|NCT02243124|p53
952240|NCT02243124|erythropoiesis
952241|NCT02243111|Systemic sclerosis, pulmonary hypertension
952242|NCT02243072|Insulin Dependent Diabetes Mellitus
952243|NCT02243072|family therapy
952244|NCT02243072|adolescents
952245|NCT02243072|regimen adherence
952246|NCT02243072|metabolic control
952247|NCT02243059|Magnetic Resonance Imaging
952248|NCT02243059|Gadofosveset trisodium
952249|NCT02243059|Nodal imaging
952250|NCT02243033|Prostate cancer
952251|NCT02243033|Focal therapy
952252|NCT02243033|Laser therapy
952253|NCT02243033|Transrectal
952254|NCT02243033|MRI-guided
952255|NCT02243007|Resectable pancreatic cancer
952256|NCT02243007|Pancreatic Ductal Carcinoma
952257|NCT02242968|Licensed Vaccines
952258|NCT02242968|Blood Draw
952259|NCT02242968|Investigational Vaccines
952260|NCT02242968|Healthy Volunteers
952261|NCT02242968|Eligibility Screening
952262|NCT02242955|Alcohol-dependence
952263|NCT02242955|Relapse
952264|NCT02242955|Detoxification
952265|NCT02242955|Diazepam
952266|NCT02242955|Benzodiazepines
952267|NCT02242955|Anxiety
952268|NCT02242929|Nodular Basal Cell Carcinoma
952269|NCT02242929|Treatment
952270|NCT02242929|Imiquimod
952271|NCT02242929|Curettage
952272|NCT02242929|Surgery
952273|NCT02242916|reccurent Head and Neck tumors
952274|NCT02242916|re-irradiation
952275|NCT02242916|photon
952276|NCT02242916|proton
952277|NCT02242916|carbon-ion
952278|NCT02242890|intrauterine contraception (IUC)
952279|NCT02242890|social networks
952280|NCT02242890|social influence
952281|NCT02242890|diffusion of innovation
952282|NCT02242890|intrauterine device (IUD)
952283|NCT02242890|LARC
952284|NCT02242799|Malaria
952285|NCT02242799|HIV
952286|NCT02242799|Dolutegravir
952287|NCT02242799|Artemisinin
952288|NCT02242799|Pharmacokinetics
952289|NCT02242799|Interactions
952290|NCT02242773|Prostate Cancer
952291|NCT02242773|Active Surveillance
952292|NCT02242773|MRI-Guided Biopsy
952293|NCT02242773|Multi-parametric MRI
952294|NCT02242773|MP-MRI
952295|NCT02242760|acne
952296|NCT02242747|actinic keratosis
952297|NCT02242747|field cancerization
952298|NCT02242747|ingenol mebutate
952299|NCT02242747|5-fluorouracil
952300|NCT02242747|tolerability
952301|NCT02242747|safety
952302|NCT02242695|vulvovaginal candidiasis
952303|NCT02242695|vulvovaginal candidosis
952304|NCT02242695|mycotic vaginal infection
952305|NCT02242695|dequalinium chloride
952306|NCT02242695|Fluomizin
952307|NCT02242695|clotrimazole
952308|NCT02242695|canesten
952309|NCT02242656|Short Bowel Syndrome
952310|NCT02242656|SBS
952311|NCT02242656|Chronic Diarrhea
952312|NCT02242656|Short Bowel
952313|NCT02242656|Short Gut
952314|NCT02242656|Short Gut Syndrome
952315|NCT02242656|Anti-Diarrheal
952316|NCT02242656|Opium Tincture
952317|NCT02242656|loperamide
952318|NCT02242656|diphenoxylate
952319|NCT02242656|ileostomies
952320|NCT02242656|tincture of opium
952321|NCT02242656|DTO
952322|NCT02242656|codeine
952323|NCT02242656|morphine
952324|NCT02242656|opiate
952325|NCT02242643|Fluzone Quadrivalent
952326|NCT02242643|Comparator
952327|NCT02242643|Children
952328|NCT02242643|Seasonal influenza
952329|NCT02242643|Safety
952330|NCT02242643|Immunogenicity
952331|NCT02242630|Subacromial bursitis
952332|NCT02242630|Triamcinolone
952333|NCT02242630|Methylprednisolone
952334|NCT02242630|Shoulder pain
952335|NCT02242617|Adherence
952336|NCT02242617|CPAP
952337|NCT02242617|Oral Appliance
952338|NCT02242617|Mandibular Advancement Splints
952339|NCT02242617|Preference
952340|NCT02242591|Knee surgery
952341|NCT02242591|Saphenous nerve
952342|NCT02242591|Perineural block
952343|NCT02242591|Adductor Canal Block
952344|NCT02242591|Postoperative Pain
952345|NCT02242591|Mobilization
952346|NCT02242578|Negative symptoms
952347|NCT02242565|HIV prevention
952348|NCT02242565|ShangRing
952349|NCT02242565|adverse events
952350|NCT02242565|wound healing
952351|NCT02242565|voluntary medical male circumcision (VMMC)
952352|NCT02242565|medical device
952353|NCT02242565|Zambia
952354|NCT02242526|hiatal hernia, recurrence, biologic mesh, synthetic mesh
952355|NCT02242513|Pulsed mode radiofrequency
952356|NCT02242513|Plantar Fasciitis
952357|NCT02242513|Ultrasound-guided
952358|NCT02242500|Gingival recession/surgery
952359|NCT02242500|Collagen/therapeutic use
952360|NCT02242500|Root coverage
952361|NCT02242500|Treatment outcome
952362|NCT02242487|Parkinson's Disease
952363|NCT02242487|Motor fluctuations
952364|NCT02242487|levodopa
952365|NCT02242487|inhaled drugs
952366|NCT02242487|OFF episodes
952367|NCT02242474|Rheumatoid arthritis
952368|NCT02242474|Surgical Wound Infection
952369|NCT02242474|Surgical Site Infection
952370|NCT02242474|Antirheumatic Agents
952371|NCT02242474|Perioperative Care
952372|NCT02242474|Anti-TNF
952373|NCT02242474|Anti-TNF-alpha
952374|NCT02242461|COPD, Rhodiola L., clinical trial, biomarkers, spirometry
952375|NCT02242448|Healthy Volunteer
952376|NCT02242448|Contrast
952377|NCT02242409|Metastatic pancreatic cancer
952378|NCT02242409|Second Line treatment
952379|NCT02242409|Gemcitabine
952380|NCT02242409|Nab-paclitaxel
952381|NCT02242188|Breastfeeding
952382|NCT02242188|Iron supplementation
952383|NCT02242188|Psychomotor development
952384|NCT02242188|Safety
952385|NCT02242188|infants
952386|NCT02242162|phrenic nerves magnetic stimulations
952387|NCT02242149|Fat liver
952388|NCT02242149|Diabetes
952389|NCT02242149|Diacerein
952390|NCT02242149|Transient elastography
952391|NCT02242149|Treatment
952392|NCT02242136|Posttraumatic Stress Disorder
952393|NCT02242136|Aggressive Behavior
952394|NCT02242136|Appetitive Aggression
952395|NCT02242136|Treatment
952396|NCT02242136|FORNET
952397|NCT02242123|Celiac Disease
952398|NCT02242123|Gluten-free diet
952399|NCT02242123|EmA assay
952400|NCT02242123|Duodenal culture medium
952401|NCT02242110|Nightmares
952402|NCT02242110|Sleep
952403|NCT02242110|PTSD
952404|NCT02242110|Exposure, Relaxation, and Rescripting Therapy
952405|NCT02242071|Motor Neuron Disease
952406|NCT02242071|Amyotrophic Lateral Sclerosis
952407|NCT02242071|Autologous Mononuclear Cell therapy
952408|NCT02242071|Stem cells
952409|NCT02242032|dry eye disease
952410|NCT02241993|glucose sensor
952411|NCT02241993|Inter-sensor distance
952412|NCT02241967|total knee arthroplasty
952413|NCT02241967|pain
952414|NCT02241967|post-surgical pain
952415|NCT02241967|opioid
952416|NCT02241967|transcranial direct current stimulation
952417|NCT02241967|tDCS
952418|NCT02241967|brain stimulation
952419|NCT02241967|total hip arthroplasty
952420|NCT02241967|TKA
952421|NCT02241967|THA
952422|NCT02241928|Muscular Dystrophy
952423|NCT02241928|Autologous Mononuclear cell therapy
952424|NCT02241928|Stem Cell
952425|NCT02241889|diabetes
952426|NCT02241889|closed-loop
952427|NCT02241889|bi-hormonal
952428|NCT02241889|exercise
952429|NCT02241863|bipolar disorders
952430|NCT02241863|medication adherence
952431|NCT02241863|psychological intervention
952432|NCT02241863|multifaceted intervention
952433|NCT02241850|High Intensity Training
952434|NCT02241850|Genetic Polymorphisms
952435|NCT02241850|Genome Wide association study
952436|NCT02241850|Single Nucleotide Polymorphism genotype
952437|NCT02241850|Subjects
952446|NCT02241824|Lumbar Orthosis
952447|NCT02241824|Lumbar brace
952448|NCT02241811|Diabetic
952449|NCT02241811|Foot
952450|NCT02241811|Wound
952451|NCT02241811|Sodium pentaborate pentahydrate
952452|NCT02241811|Hydrogel
952453|NCT02241798|epilepsy
952454|NCT02241798|oxygen saturation
952455|NCT02241798|transcutaneous carbon dioxide
952456|NCT02241798|sudep
952457|NCT02241798|pre-oxygenation
952458|NCT02241733|exercise
952459|NCT02241733|pulmonary rehabilitation
952460|NCT02241733|dynamic hyperinflation
952461|NCT02241707|Varicose vein
952462|NCT02241707|Endovenous ablation
952463|NCT02241707|Compression
952464|NCT02241681|Medium Chain Triglycerides
952465|NCT02241681|Medium Chain Triglycerides metabolites
952466|NCT02241681|Peptamen 1.5
952467|NCT02241668|Brain tumor
952468|NCT02241668|3'-Deoxy-3'-18f-Fluorothymidine
952469|NCT02241668|Fluoro-L-Thymidine Positron Emission Tomography
952470|NCT02241668|FLT PET
952471|NCT02241668|Magnetic resonance imaging
952472|NCT02241668|MRI
952473|NCT02241655|Anesthesia
952474|NCT02241655|Electroencephalography
952475|NCT02241655|Burst suppression
952476|NCT02241655|Surgery
952477|NCT02241655|Delirium
952478|NCT02241655|Falls
952479|NCT02241655|Health related quality of life
952480|NCT02241642|Percutaneous vascular closure device
952481|NCT02241642|vascular closure device
952482|NCT02241642|Large hole closure device
952483|NCT02241629|motion sickness
952484|NCT02241603|Insulin resistance
952485|NCT02241603|Consummatory Reward
952486|NCT02241577|peri-implantitis
952487|NCT02241577|dental implants
952488|NCT02241577|randomized controlled trial
952489|NCT02241577|non-surgical periodontal treatment
952490|NCT02241577|will be defined by the presence of alveolar bone loss of at least 3mm, pocket depth of at least 5mm and bleeding on probing.
952491|NCT02241564|Immunosuppression
952492|NCT02241551|Borderline
952493|NCT02241551|Resectable
952494|NCT02241551|Pancreatic
952495|NCT02241551|Cancer
952496|NCT02241551|Neoadjuvant
952497|NCT02241551|Chemotheraphy
952498|NCT02241551|Gemcitabine
952499|NCT02241551|Nab-Paclitaxel
952500|NCT02241551|mFOFIRINOX
952501|NCT02241551|Sterotatic Body Radiation Therapy
952502|NCT02241538|Pilates-based exercises
952503|NCT02241525|Pulmonary
952504|NCT02241525|Thromboembolic
952505|NCT02241525|Lung
952506|NCT02241512|post-ERCP pancreatitis
952507|NCT02241512|pediatric
952508|NCT02241512|ibuprofen
952509|NCT02241499|Digestive System Diseases
952510|NCT02241499|Esophageal cancer
952511|NCT02241499|Intestinal Neoplasms
952512|NCT02241499|Gastrointestinal Neoplasms
952513|NCT02241499|Digestive System Neoplasms
952514|NCT02241499|Endoscopic response
952515|NCT02241499|Fluorouracil
952516|NCT02241499|Metabolic response
952517|NCT02241499|Oxaliplatin
952518|NCT02241499|Radiotherapy
952519|NCT02241486|Burn pain
952520|NCT02241486|Procedural pain
952521|NCT02241486|Sublingual fentanyl
952522|NCT02241486|Morphine
952523|NCT02241473|gait
952524|NCT02241473|physical activity
952525|NCT02241473|energy cost
952526|NCT02241473|efficiency
952527|NCT02241460|Premature Ejaculation
952528|NCT02241460|Lidocaine
952529|NCT02241447|aortic valve Stenosis
952530|NCT02241447|Echo
952531|NCT02241447|TAVI
952532|NCT02241447|SAVR
952533|NCT02241447|referral
952534|NCT02241434|Duchenne muscular dystrophy
952535|NCT02241434|Autologous Bone marrow Mononuclear cell therapy
952536|NCT02241434|Stem Cells
952537|NCT02241421|Impaired glucose tolerance
952538|NCT02241421|Glucose Metabolism Disorders
952539|NCT02241421|Metabolic Diseases
952540|NCT02241421|Endocrine System Diseases
952541|NCT02241421|Hyperinsulinism
952542|NCT02241421|Lipid metabolism
952543|NCT02241421|Anti Bacterial Agents
952544|NCT02241421|Gastro Intestinal Tract
952545|NCT02241395|Cerebral Palsy
952546|NCT02241395|autologous bone marrow mononuclear cells
952547|NCT02241395|stem cell
952548|NCT02241369|Aerodigestive Lesions and Malignancies
952549|NCT02241369|Human Papillomavirus
952550|NCT02241369|Squamous Cell Carcinoma
952551|NCT02241356|Down syndrome
952552|NCT02241356|visual functions
952553|NCT02241356|bifocals
952554|NCT02241356|children
952555|NCT02241356|visual acuity at near
952556|NCT02241343|Artificially and reversibly achieved with a blood pressure cuff
952557|NCT02241330|Zinc
952558|NCT02241330|deficiency
952559|NCT02241330|biofortification
952560|NCT02241330|wheat
952561|NCT02241317|Diabetes mellitus
952562|NCT02241317|Hypoglycaemia
952563|NCT02241317|staff training
952564|NCT02241317|Education
952565|NCT02241317|blood glucose
952566|NCT02241304|electromyography
952567|NCT02241304|neuromuscular blockade
952568|NCT02241291|Percutaneous Coronary Intervention
952569|NCT02241291|Registries
952570|NCT02241278|colon surgery
952571|NCT02241278|ketamine
952572|NCT02241278|patient-controlled-analgesia
952573|NCT02241278|preemptive analgesia
952574|NCT02241265|asthma
952575|NCT02241265|thermoplasty
952576|NCT02241252|ECG
952577|NCT02241252|QT interval
952578|NCT02241252|Sotalol
952579|NCT02241252|Dofetilide
952580|NCT02241252|iPhone
952581|NCT02241226|wellbeing
952582|NCT02241226|meditation
952583|NCT02241226|Ayurveda
952584|NCT02241226|yoga
952585|NCT02241226|herbs
952586|NCT02241226|health
952587|NCT02241226|longevity
952588|NCT02241226|individuals
952589|NCT02241213|Stroke
952590|NCT02241213|Aphasia
952591|NCT02241213|Broca
952592|NCT02241187|PEGPH20
952593|NCT02241187|Cetuximab
952594|NCT02241187|14-039
952595|NCT02241174|Atopic Dermatitis
952596|NCT02241161|skin eythema
952597|NCT02241161|rejuvenating cream
952598|NCT02241161|rejuvenating serum
952599|NCT02241161|antioxidant serum
952600|NCT02241135|Rav G protein
952601|NCT02241135|rabies
952602|NCT02241135|VNT
952603|NCT02241135|immunogenicity
952604|NCT02241135|PrEP vaccination
952605|NCT02241135|mRNA
952606|NCT02241135|CV7201
952607|NCT02241122|prostate cancer
952608|NCT02241122|PSA
952609|NCT02241122|MRI
952610|NCT02241122|biopsy
952611|NCT02241122|biomarker
952612|NCT02241109|aortic stenosis progression
952613|NCT02241109|aortic valve sclerosis progression
952614|NCT02241109|calcification propensity
952615|NCT02241070|mindfulness meditation
952616|NCT02241070|mental health promotion
952617|NCT02241070|worker
952618|NCT02241057|temperature profile
952619|NCT02241057|air activated 3-cell patch
952620|NCT02241057|adhesion
952621|NCT02241044|argon plasma coagulation, bleeding peptic ulcer
952622|NCT02241031|Megakaryocytic Progenitor Products
952623|NCT02241031|Hematological Diseases
952624|NCT02241031|Thrombocytopenia
952625|NCT02241018|Hematopoietic Stem Cell Transplantation
952626|NCT02241018|Mesenchymal Stem Cells
952627|NCT02241018|CD25 Monoclonal Antibody
952628|NCT02241018|Acute Graft-versus-host disease
952629|NCT02241005|Health-care associated infection
952630|NCT02241005|Skin integrity
952631|NCT02241005|Antimicrobial resistance
952632|NCT02240992|Poor Graft Function
952633|NCT02240992|Delayed platelet engraftment
952634|NCT02240992|Peripheral Blood Stem Cell
952635|NCT02240992|Mesenchymal Stem Cells
952636|NCT02240992|Allogeneic hematopoietic stem cell transplantation
952637|NCT02240979|arterial waveform
952638|NCT02240979|cardiac magnetic resonance imaging
952639|NCT02240979|echocardiography
952640|NCT02240979|intrinsic frequency measures of cardiac function
952641|NCT02240966|Testicular Neoplasms
952642|NCT02240966|Hypogonadism
952643|NCT02240966|Metabolic Syndrome
952644|NCT02240966|Treatment related late effects
952645|NCT02240953|Anticoagulation
952646|NCT02240953|Prosthetic Heart Valves
952647|NCT02240953|Acetylsalicylic acid
952648|NCT02240953|Warfarin
952649|NCT02240953|Thrombosis
952655|NCT02240927|Anticoagulation
952656|NCT02240927|Prosthetic Heart Valves
952657|NCT02240927|Pregnancy
952658|NCT02240927|Warfarin
952659|NCT02240927|Thrombosis
952660|NCT02240914|Iliac Vein Obstruction
952661|NCT02240914|May-Thurner Syndrome
952662|NCT02240914|Cockett Syndrome
952663|NCT02240914|Vascular Ultrasound
952664|NCT02240914|IVUS
952665|NCT02240901|Laryngeal mask airway
952666|NCT02240901|endotracheal intubation
952667|NCT02240901|postoperative pulmonary complications
952668|NCT02240901|elderly patients
952669|NCT02240888|pneumococcal
952670|NCT02240888|vaccination
952671|NCT02240888|antibody
952672|NCT02240888|response
952673|NCT02240888|immunosuppressive
952674|NCT02240888|treatment
952675|NCT02240888|inflammatory
952676|NCT02240888|rheumatic
952677|NCT02240888|disease
952680|NCT02240849|Neck pain
952681|NCT02240849|functional pillow
952682|NCT02240849|sleep
952683|NCT02240849|cervical lordosis
952684|NCT02240823|Erectile Function
952685|NCT02240823|Mesenchymal Stromal Cells
952686|NCT02240823|Stem Cell
952687|NCT02240797|Anorexia Nervosa
952688|NCT02240797|Neuroimaging
952689|NCT02240797|Positron emission tomography (PET)
952690|NCT02240797|[11C]PKAB
952691|NCT02240784|Porphyria
952692|NCT02240784|AIP
952693|NCT02240784|VP
952694|NCT02240784|HCP
952695|NCT02240784|Variegate
952696|NCT02240784|Coproporphyria
952697|NCT02240771|Transarterial chemotherapy
952698|NCT02240771|Thalidomide
952699|NCT02240771|Capecitabine
952700|NCT02240758|glioma, confocal laser endomicroscopy
952701|NCT02240745|Echocardiography, Stress
952702|NCT02240745|Echocardiography, Three-Dimensional
952703|NCT02240745|Coronary Artery Disease
952704|NCT02240745|Fractional Flow Reserve, Myocardial
952705|NCT02240745|Coronary Circulation
952706|NCT02240615|Epiphora
952707|NCT02240615|Lacrimal Stent
952708|NCT02240615|Lacrimal System
952709|NCT02240602|acute pain
952710|NCT02240602|postoperative
952711|NCT02240602|surgery
952712|NCT02240589|Traumatic Brain Injury
952713|NCT02240589|Memantine
952714|NCT02240589|Memory
952715|NCT02240576|surgery for nasal fracture
952716|NCT02240563|autoimmune thyroiditis
952717|NCT02240563|LLLT
952718|NCT02240563|safety
952719|NCT02240563|ultrasound
952720|NCT02240550|Open Inguinal Hernia
952721|NCT02240537|AML
952722|NCT02240537|MM
952723|NCT02240537|MDS
952724|NCT02240537|sMM
952725|NCT02240524|Gastric adenocarcinoma
952726|NCT02240524|HIPEC
952727|NCT02240524|Paclitaxel
952728|NCT02240524|Oxaliplatin
952729|NCT02240524|Capecitabine
952730|NCT02240511|Body Composition
952731|NCT02240511|Amino Acids Supplementation
952732|NCT02240511|Resistance Exercise
952733|NCT02240498|Abscess
952734|NCT02240498|Drainage
952735|NCT02240485|Pathological gambling
952736|NCT02240485|Treatment
952737|NCT02240485|Marital relationship
952738|NCT02240472|sentinel node biopsy, lymph node metastasis, survival
952739|NCT02240459|crossover study
952740|NCT02240459|placebo controlled
952741|NCT02240459|double blind
952742|NCT02240459|overactive bladder
952743|NCT02240420|Type 2 diabetes prevention in the post-partum
952744|NCT02240420|Behavior change among Latinas,
952745|NCT02240420|Health Coaching, Motivational interviewing techniques
952746|NCT02240407|Pompe Disease
952747|NCT02240407|Gene Therapy
952748|NCT02240407|Repeated dosing
952749|NCT02240407|Immune modulation
952750|NCT02240394|TCD Traumatic brain injury increased intracranial pressure
952751|NCT02240368|Depth anesthesia monitors
952752|NCT02240368|Children anesthesia
952753|NCT02240368|Bispectral monitor
952754|NCT02240368|Entropy monitor
952755|NCT02240342|Ovarian reserve
952756|NCT02240342|Poor response
952757|NCT02240342|Follicle recruitment
952758|NCT02240342|Bone marrow transplant
952759|NCT02240329|respiratory
952760|NCT02240329|cough
952761|NCT02240303|pain
952762|NCT02240303|mobility
952763|NCT02240303|brain
952764|NCT02240303|cognition
952765|NCT02240290|C14
952766|NCT02240290|Dosimetry
952767|NCT02240290|Mass balance
952768|NCT02240290|ADME
952769|NCT02240277|Septic Shock
952770|NCT02240277|Meropenem
952771|NCT02240277|Ciprofloxacin
952772|NCT02240277|Pharmacokinetics
952773|NCT02240264|Omega-3 fatty acids
952774|NCT02240264|Cognitive function
952775|NCT02240264|Academic performance
952776|NCT02240264|Mental health
952777|NCT02240264|Eye tracking
952778|NCT02240264|Krill oil
952779|NCT02240264|LCPUFA
952780|NCT02240251|Inferior Vena Cava Filter
952781|NCT02240251|IVC Filter
952782|NCT02240251|IVC filter removal
952783|NCT02240251|Excimer Laser
952784|NCT02240225|COPD;SRI;Reliability;validity;
952785|NCT02240212|second line treatment
952786|NCT02240212|oncology
952787|NCT02240212|AKT inhibitor
952788|NCT02240212|paclitaxel
952789|NCT02240212|HER2 (ErbB2) negative advanced gastric cancer
952790|NCT02240212|Afuresertib
952791|NCT02240186|Microprocessor-controlled knee
952792|NCT02240186|prosthesis
952793|NCT02240186|amputation
952794|NCT02240173|antipsychotic Jobelyn schizophrenia sorghum bicolor
952795|NCT02240160|Sativex
952796|NCT02240160|Pharmacokinetics
952797|NCT02240160|Oral pH
952798|NCT02240147|adult congenital heart disease
952799|NCT02240147|exercise capacity
952800|NCT02240147|exercise training
952801|NCT02240147|physical activity
952802|NCT02240121|Crohn's Disease
952803|NCT02240121|Rifaximin
952804|NCT02240121|Clinical remission with endoscopic response
952805|NCT02240121|Inflammatory Bowel Disease
952806|NCT02240108|Crohn's Disease
952807|NCT02240108|Rifaximin
952808|NCT02240108|Clinical remission with endoscopic response
952809|NCT02240108|Inflammatory Bowel Disease
952810|NCT02240082|Shiftwork
952811|NCT02240082|Sleep disruption
952812|NCT02240082|Stress
952813|NCT02240030|Parkinson's Disease
952814|NCT02240030|Motor fluctuations
952815|NCT02240030|levodopa
952816|NCT02240030|inhaled drugs
952817|NCT02240030|OFF episodes
952818|NCT02240017|Urothelial cancer, renal function impaired.
952819|NCT02239991|Point of care
952820|NCT02239991|perioperative hemostasis
952821|NCT02239991|thromboelastometry
952822|NCT02239991|bleeding risk
952823|NCT02239991|end-stage liver disease
952824|NCT02239991|hepatic coagulopathy
952825|NCT02239991|whole blood coagulation
952826|NCT02239978|Parkinson Disease
952827|NCT02239978|Posture Balance
952828|NCT02239978|Learning
952829|NCT02239978|Dopamine
952830|NCT02239965|Neuromuscular blockade
952831|NCT02239965|Neuromuscular monitoring
952832|NCT02239965|Focus group interview
952833|NCT02239965|Clinical observation
952834|NCT02239939|older adults, body composition, weight loss, muscle mass
952835|NCT02239926|IBS-D
952836|NCT02239913|Cocaine
952837|NCT02239913|Pharmacotherapy
952838|NCT02239913|Phentermine
952839|NCT02239913|Topiramate
952840|NCT02239913|Self-Administration
952853|NCT02239887|LAA occlusion
952854|NCT02239887|Non-valvular Atrial Fibrillation
952855|NCT02239887|Percutaneous
952856|NCT02239887|Oral Anticoagulation
952857|NCT02239887|Occluder
952858|NCT02239887|WAVECREST
952859|NCT02239874|mammographic breast density, breast disease, breast tissue
952860|NCT02239861|Bladder cancer
952861|NCT02239861|Breast cancer
952862|NCT02239861|Colorectal cancer
952863|NCT02239861|Endometrial cancer
952864|NCT02239861|Gastric cancer
952865|NCT02239861|Head and neck cancer
952866|NCT02239861|HCC
952867|NCT02239861|Lung cancer
952868|NCT02239861|Melanoma
952869|NCT02239861|Neuroblastoma
952870|NCT02239861|Sarcoma (osteo-, synovial, rhabdomyo-, etc)
952871|NCT02239861|Pancreatic cancer
952872|NCT02239861|Prostate cancer
952873|NCT02239861|Renal cell carcinoma
952874|NCT02239861|Thyroid cancer
952875|NCT02239861|cytotoxic T lymphocytes
952876|NCT02239822|Electrodes, Implanted
952877|NCT02239822|Electric Stimulation Therapy
952878|NCT02239809|Electrodes, Implanted
952879|NCT02239809|Electric Stimulation Therapy
952880|NCT02239796|transcutaneous posterior tibial nerve stimulation
952881|NCT02239796|Randomised controlled trial
952882|NCT02239796|Feasibility
952891|NCT02239770|Nicotine
952892|NCT02239770|Random Delivery
952893|NCT02239770|Smoking Cessation
952894|NCT02239770|Plasma Nicotine
952895|NCT02239770|Oral Film
952896|NCT02239757|Transradial Approach, Primary PCI, ST-segment elevation myocardial infarction
952897|NCT02239744|air pollution
952898|NCT02239744|air purification
952899|NCT02239744|intervention
952900|NCT02239744|randomized controlled trial
952901|NCT02239744|cardiovascular health
952902|NCT02239744|pulmonary health
952903|NCT02239731|EGFRI
952904|NCT02239731|Epidermal Growth Factor Receptor Inhibition
952905|NCT02239731|Skin toxicity
952906|NCT02239731|Topical
952907|NCT02239731|Doxycycline
952908|NCT02239731|Foam
952909|NCT02239731|Phase II
952910|NCT02239731|Cetuximab
952911|NCT02239731|Panitumumab
952912|NCT02239731|Vectibix
952913|NCT02239731|Erbitux
952914|NCT02239731|Rash
952915|NCT02239718|Resin bonded bridges
952916|NCT02239718|Clinical trial
952917|NCT02239718|Prospective
952918|NCT02239718|Survival
952919|NCT02239718|Oral health related quality of life
952920|NCT02239705|Trans pulmonary thermodilution
952921|NCT02239705|Hemodynamic
952922|NCT02239679|Actinic Keratosis
952923|NCT02239666|Dermatology, plaque psoriasis, biologic treatment, biologic naive
952924|NCT02239614|dengue fever
952925|NCT02239614|dengue
952926|NCT02239601|Physical Therapy
952927|NCT02239601|Physiotherapy
952928|NCT02239601|Breast Cancer
952929|NCT02239601|Chemotherapy Induced Peripheral Neuropathy (CIPN)
952930|NCT02239601|Nerve gliding exercises
952931|NCT02239601|Nerve Entrapment
952932|NCT02239575|Assorted cancers (oncology)
952933|NCT02239562|sPIF
952934|NCT02239562|synthetic PreImplantation Factor
952935|NCT02239562|Autoimmune
952936|NCT02239562|Liver
952937|NCT02239562|Hepatitis
952938|NCT02239549|Colonic Polyps
952939|NCT02239549|Polypectomy
952940|NCT02239536|neoplastic colorectal polyp
952941|NCT02239536|hot snare polypectomy
952942|NCT02239536|hot snare polypectomy after saline injection
952943|NCT02239523|Pathologic fracture
952944|NCT02239523|Insufficiency fracture
952945|NCT02239523|Secondary fracture
952946|NCT02239523|Fracture with bone fragility
952947|NCT02239523|Osteoporosis
952948|NCT02239523|Bone loss
952949|NCT02239523|Osteopenia
952950|NCT02239523|Metabolic Bone Disease
952951|NCT02239523|Fragility fracture
952952|NCT02239510|constipation
952953|NCT02239510|bowel habits
952954|NCT02239497|postoperatory pain
952955|NCT02239497|orthopaedic surgery
952956|NCT02239497|femoral block
952957|NCT02239432|Adenocarcinoma of the Lung
952958|NCT02239432|Adenocarcinoma, Bronchiolo-Alveolar
952959|NCT02239419|Critical Limb Ischemia
952960|NCT02239419|Limb Ischemia
952961|NCT02239419|Wound Care
952962|NCT02239419|Hemodialysis
952963|NCT02239419|Dialysis
952964|NCT02239419|Skin Ulceration
952965|NCT02239406|metal on metal total hip
952966|NCT02239406|avasuclar necrosis
952967|NCT02239406|acetabular revision
952968|NCT02239406|bone vascularity
952969|NCT02239393|Multiple Sclerosis
952970|NCT02239393|Mesenchymal Stem Cells
952971|NCT02239393|MSC
952972|NCT02239380|Lorazepam
952973|NCT02239380|Status Epilepticus
952974|NCT02239341|hospitalized
952975|NCT02239341|activity restriction
952976|NCT02239341|bed rest
952977|NCT02239341|antepartum
952978|NCT02239341|pregnant
952979|NCT02239341|high risk
952980|NCT02239328|Lung cancer
952981|NCT02239328|esophageal cancer
952982|NCT02239315|Breast cancers
952983|NCT02239315|Neoadjuvant chemotherapy
952984|NCT02239315|RNA Disruption Assay™ (RDA) score
952985|NCT02239315|Pathological Complete Response (pCR)
952986|NCT02239315|Fine Needle Aspiration Biopsy
952987|NCT02239302|Obstructed defaecation syndrome
952988|NCT02239302|Transperineal Ultrasound
952989|NCT02239302|Endovaginal Ultrasound
952990|NCT02239302|Evacuation Proctography
952991|NCT02239289|Low back pain
952992|NCT02239289|Rehabilitation
952993|NCT02239289|Biofeedback
952994|NCT02239289|Electromyography
952995|NCT02239289|Kinematic
952996|NCT02239276|Stiripentol
952997|NCT02239276|Dravet syndrome
952998|NCT02239276|Epilepsy
952999|NCT02239276|Epileptic Encephalopathies
953000|NCT02237300|Bulimia nervosa
953001|NCT02237300|Binge eating disorder
953002|NCT02237300|Food craving
953003|NCT02237300|Anxiety
953004|NCT02237300|Bingeing
953005|NCT02237300|Cue Exposure Therapy
953006|NCT02237300|Virtual Reality
953007|NCT02237274|Fontan circulation
953008|NCT02237274|High altitude exposure
953009|NCT02237261|Newly diagnosed symptomatic multiple myeloma
953010|NCT02239250|Child health
953011|NCT02239250|Pneumonia
953012|NCT02239250|Diarrhoea
953013|NCT02239250|Household air pollution
953014|NCT02239250|PM2.5
953015|NCT02239250|Stove intervention
953016|NCT02239250|Biomass fuel
953017|NCT02239250|Monitoring and evaluation
953018|NCT02239250|Water filter
953019|NCT02239250|Compliance
953020|NCT02239250|Thermotolerant coliforms
953021|NCT02239250|Rwanda
953022|NCT02239224|FSHD
953023|NCT02239211|BUTEO
953024|NCT02239211|Primary sclerosing cholangitis
953025|NCT02239211|PSC
953026|NCT02239211|VAP-1
953027|NCT02239211|BTT1023
953028|NCT02239211|Human monoclonal antibody
953029|NCT02239198|HDL
953030|NCT02239198|nutrition bar
953031|NCT02239185|Laparoscopy
953032|NCT02239185|purse string
953033|NCT02239185|hernial sac
953034|NCT02239159|transcutaneous electric acupoint stimulation
953035|NCT02239159|elderly patients
953036|NCT02239133|Pelvic Organ Prolapse
953037|NCT02239133|POP
953038|NCT02239107|polycystic ovary syndrome
953039|NCT02239107|laparoscopic drilling
953040|NCT02239107|clomiphene citrate
953041|NCT02239107|n acetyl cysteine
953042|NCT02239107|insulin resistance
953043|NCT02239094|Bipolar Disorder
953044|NCT02239094|depression
953045|NCT02239094|Bipolar depression
953046|NCT02239081|Pharmacokinetics
953047|NCT02239081|Safety
953048|NCT02239068|CT, sedation, oral contrast
953049|NCT02239055|Borderline Personality Disorder
953050|NCT02239055|Mentalization Based Treatment
953051|NCT02239055|MBT Skills Training
953052|NCT02239055|Staff Nurse Perceptions
953053|NCT02239055|Acute Mental Health
953054|NCT02239042|Gingival recessions
953055|NCT02239029|Platelet rich plasma
953056|NCT02239029|Osteoarthritis of knee
953057|NCT02239029|Balance
953058|NCT02239029|Strength
953059|NCT02239016|Sickle cell disease
953060|NCT02239016|Hgb SS
953061|NCT02239016|Hgb SC
953062|NCT02239016|Sβ-Thalassemia
953063|NCT02238977|depression
953064|NCT02238977|ESRD
953065|NCT02238977|hemodialysis
953066|NCT02238951|care coordination, mobile health, chemotherapy, technology
953067|NCT02238938|piecemeal polypectomy
953068|NCT02238938|piecemeal endoscopic mucosal resection (EMR)
953069|NCT02238938|endoscopic submucosal dissection (ESD)
953070|NCT02238938|endoscopic en-bloc resection
953071|NCT02238925|Newly Diagnosed AML
953072|NCT02238925|Secondary AML
953073|NCT02238925|Relapsed/Refractory AML
953074|NCT02238925|Relapsed/Refractory ALL
953075|NCT02238925|MDS
953076|NCT02238912|tinea
953077|NCT02238886|Quality of Life
953078|NCT02238886|Enteral nutrition
953079|NCT02238886|Nutrition Therapy
953080|NCT02238886|Parenteral nutrition, total
953081|NCT02238873|lymphoma
953082|NCT02238873|neutropenia
953083|NCT02238873|pegfilgrastim
953084|NCT02238860|Hepatitis B
953085|NCT02238860|cirrhosis
953086|NCT02238860|Entacavir
953087|NCT02238860|enofovir
953088|NCT02238847|Pancreatic
953089|NCT02238847|Pancreatic Cancer
953090|NCT02238847|Preoperative Biliary Drainage
953091|NCT02238847|Neoadjuvant Therapy
953092|NCT02238834|Phase I
953093|NCT02238834|Safety and tolerability
953094|NCT02238834|Pharmacokinetic
953095|NCT02238834|Randomized
953096|NCT02238834|Double Blind
953097|NCT02238834|Placebo-Controlled
953098|NCT02238834|Single- & Multiple Dose Escalation
953099|NCT02238834|FP-025
953100|NCT02238834|MMP-12 inhibitor
953101|NCT02238821|resectable colorectal cancer
953102|NCT02238808|ER+ breast cancer
953103|NCT02238808|Luminal A
953104|NCT02238808|Estradiol
953105|NCT02238795|Purpura fulminans, Sepsis, Epidemiology, Morbidity, Therapy
953106|NCT02238782|bioavailability
953107|NCT02238782|pharmacokinetics
953108|NCT02238782|I phase
953109|NCT02238782|AZD6244
953110|NCT02238782|cancer
953111|NCT02238769|Hepatocellular Carcinoma, 18F-FluoroethylCholine PET
953112|NCT02238730|Depression
953113|NCT02238730|Depressive Disorder
953114|NCT02238730|Treatment Resistant Depressive Disorder
953115|NCT02238730|Bipolar Disorder
953116|NCT02238730|Major Depressive Disorder
953117|NCT02238730|Electroconvulsive therapy
953118|NCT02238717|Pain
953119|NCT02238717|evoked pain
953120|NCT02238717|healthy volunteer
953121|NCT02238717|pharmacodynamics
953122|NCT02238704|Adherence
953123|NCT02238704|Calcium supplementation
953124|NCT02238704|Prevention of preeclampsia
953125|NCT02238704|Adherence to calcium supplementation
953126|NCT02238691|PEEP
953127|NCT02238691|Air insufflation
953128|NCT02238691|Mask ventilation
953129|NCT02238691|Esophageal manometry
953130|NCT02238691|Esophageal impedance
953131|NCT02238652|Nursing homes
953132|NCT02238652|Dementia
953133|NCT02238652|Quality of Life
953134|NCT02238652|Geriatrics
953135|NCT02238652|Aged
953136|NCT02238652|Activities of Daily Living
953137|NCT02238652|Pain
953138|NCT02238652|Pain management
953139|NCT02238652|Advance Care Planning
953140|NCT02238652|Patient Safety
953141|NCT02238652|Costs and Cost Analysis
953142|NCT02238652|Medication Errors
953143|NCT02238652|Medical Order Entry Systems
953144|NCT02238652|Medication Reconciliation
953145|NCT02238652|Medication Therapy Management
953146|NCT02238652|Depression
953147|NCT02238652|Psychotropic Drugs
953148|NCT02238652|Informed Consent
953149|NCT02238652|Presumed Consent
953150|NCT02238652|Anxiety
953151|NCT02238652|Apathy
953152|NCT02238652|Hospitalization
953153|NCT02238652|Mortality
953154|NCT02238639|Venous thromboembolism
953155|NCT02238639|COPD exacerbations
953156|NCT02238639|Anticoagulation
953157|NCT02238639|Mortality
953158|NCT02238626|amyotrophic lateral sclerosis
953159|NCT02238626|pharmacotherapy
953160|NCT02238626|intervention
953161|NCT02238626|prospective
953162|NCT02238626|safety endpoint
953163|NCT02238626|preliminary efficacy
953164|NCT02238626|ibudilast
953165|NCT02238613|Radioactive stents
953166|NCT02238613|Brachytherapy
953167|NCT02238613|Biliary obstruction
953168|NCT02238613|Intrahepatic Cholangiocarcinoma
953169|NCT02238613|Cholangiocarcinoma of the Extrahepatic Bile Duct
953170|NCT02238613|ampullary carcinoma
953171|NCT02238587|Gandoerma Spores Powder Capsules, head-and-neck cancer.
953172|NCT02238561|non-invasive
953173|NCT02238561|measurement of oxygen
953174|NCT02238561|consumption
953175|NCT02238561|delivery
953176|NCT02238561|post-operative complications
953177|NCT02238548|immunity
953178|NCT02238548|vaccination
953179|NCT02238548|milk
953180|NCT02238522|Chronic lymphocytic leukemia
953181|NCT02238522|B-prolymphocytic leukemia
953182|NCT02238522|Non-Hodgkin's lymphoma
953183|NCT02238522|follicular lymphoma
953184|NCT02238522|mantle cell lymphoma
953185|NCT02238522|marginal zone lymphoma
953186|NCT02238522|small lymphocytic lymphoma
953187|NCT02238522|diffuse large B-cell lymphoma
953188|NCT02238522|unclassifiable lymphoma
953189|NCT02238522|T-cell lymphoma
953190|NCT02238522|Richter's syndrome
953191|NCT02238522|Waldenström's macroglobulinemia
953192|NCT02238509|Breast cancer
953193|NCT02238509|HER2 Positive
953194|NCT02238509|HER2+
953195|NCT02238509|MBC
953196|NCT02238509|Metastatic
953197|NCT02238509|Metastatic breast cancer
953198|NCT02238509|Chemotherapy
953199|NCT02238509|Lapatinib
953200|NCT02238509|Trastuzumab
953201|NCT02238509|anti HER2 therapies
953202|NCT02238496|Glioblastoma
953203|NCT02238496|Anaplastic Astrocytoma
953204|NCT02238496|Anaplastic Oligodendroglioma
953205|NCT02238496|Mixed Glioma
953206|NCT02238496|akt-Oncogene Protein
953207|NCT02238496|mTOR Protein
953208|NCT02238496|Glioma
953209|NCT02238496|Brain Neoplasms
953210|NCT02238496|Brain Tumor, Recurrent
953211|NCT02238483|Chronic Obstructive Pulmonary Disease
953212|NCT02238483|COPD patients
953213|NCT02238483|Exacerbations
953214|NCT02238483|ICS
953215|NCT02238483|LABA
953216|NCT02238470|Ischemic stroke
953217|NCT02238470|Intracerebral hemorrhage
953218|NCT02238470|Subdural hemorrhage
953219|NCT02238470|Microbleed
953220|NCT02238470|Leukoaraiosis
953221|NCT02238470|Oral anticoagulants
953222|NCT02238457|Heart failure
953223|NCT02238457|Losartan
953224|NCT02238444|Warfarin
953225|NCT02238444|Portal Vein
953226|NCT02238444|Anticoagulants
953227|NCT02238444|Cirrhosis
953228|NCT02238444|Hypertension
953229|NCT02238444|Venous Thrombosis
953230|NCT02238444|Splenectomy
953231|NCT02238431|Lucrin depot,
953232|NCT02238431|frozen embryo transfer,
953233|NCT02238431|artificial cycle,
953234|NCT02238431|pregnancy,
953235|NCT02238431|cancellation
953236|NCT02238418|Vitamin D, Calciuria, Paediatrics, Nephrology
953237|NCT02238392|paroxysmal atrial fibrillation
953238|NCT02238392|pulmonary vein isolation
953239|NCT02238392|adenosine
953240|NCT02238392|AF terminatin
953241|NCT02238379|Intranasal oxytocin
953242|NCT02238379|Social perception
953243|NCT02238379|EEG/ERP
953244|NCT02238340|Postoperatory pain
953245|NCT02238340|Oxycodone
953246|NCT02238327|Antiretroviral therapy
953247|NCT02238327|pulmonary function
953248|NCT02238327|biomarkers
953249|NCT02238301|Intrauterine growth restriction
953250|NCT02238301|BOLD effect
953251|NCT02238288|anticoagulation
953252|NCT02238288|extraction
953253|NCT02238288|epsilon amino caproic
953257|NCT02237235|Schizophrenia
953258|NCT02237235|Schizoaffective disorder
953259|NCT02237235|Cognition
953260|NCT02237235|Magnesium
953261|NCT02237235|Imaging
953262|NCT02237235|Negative symptoms
953263|NCT02237222|Outcome Assessment
953264|NCT02237222|Gait
953265|NCT02237222|Neuromuscular Diseases
953266|NCT02237222|Psychometrics
953267|NCT02237222|Clinical Assessment Tools
953268|NCT02238054|Cardiology
953269|NCT02238054|Intracoronary angioplasty
953270|NCT02238054|Bioresorbable stent
953271|NCT02238041|Glucose monitoring
953272|NCT02238041|Intensive care unit
953273|NCT02238028|Heart rate variability
953274|NCT02238028|Blood pressure
953275|NCT02238028|Circulating biomarkers
953276|NCT02238028|Respirator
953277|NCT02238028|Fine particulate matter
953278|NCT02238015|cataract ,tear film,SS-OCT
953279|NCT02238002|shallow anterior chamber
953280|NCT02238002|narrow angle
953281|NCT02238002|SS-OCT
953282|NCT02237989|knee osteoarthritis, native collagen type 2, paracetamol
953283|NCT02237937|Depression, Affective Disorder
953284|NCT02237924|nasopharyngeal carcinoma
953285|NCT02237924|endostar
953286|NCT02237924|IMRT
953287|NCT02237924|chemoradiation
953288|NCT02237911|total knee replacement
953289|NCT02237911|rehabilitation
953290|NCT02237911|exercise program
953291|NCT02237911|total knee arthroplasty
953292|NCT02237898|Tobacco cessation
953293|NCT02237885|Military Veterans
953294|NCT02237872|Brown Adipose Tissue
953295|NCT02237859|cdiff
953296|NCT02237859|vancomycin
953297|NCT02237859|infection
953298|NCT02237859|clostridium difficile
953299|NCT02237846|osteoarthritis
953300|NCT02237846|knee
953301|NCT02237846|stem cells
953302|NCT02237846|mesenchymal
953303|NCT02237846|umbilical cord
953304|NCT02237833|septic shock
953305|NCT02237833|cerebral oximetry
953306|NCT02237833|vasopressor
953307|NCT02237833|norepinephrine
953308|NCT02237807|Fed Conditions
953309|NCT02237781|AMH
953310|NCT02237781|IVF
953311|NCT02237781|ovarian stimulation
953312|NCT02237768|Fasting conditions
953313|NCT02237755|Clomiphene citrate
953314|NCT02237755|IVF
953315|NCT02237755|Pregnancy Rates
953316|NCT02237755|Ovarian Reserve
953317|NCT02237729|healthy subjects
953318|NCT02237729|immunology
953319|NCT02237729|PK
953320|NCT02237729|Phase 1
953321|NCT02237729|bioequivalence
953322|NCT02237729|biosimilarity
953323|NCT02237729|adalimumab
953324|NCT02237729|single dose.
953325|NCT02237703|Post-traumatic Stress Disorder (PTSD)
953326|NCT02237703|Positron emission tomography (PET)
953327|NCT02237703|Neuroimaging
953328|NCT02237703|Kappa opioid receptor (KOR)
953329|NCT02237677|Post-traumatic stress disorder (PTSD)
953330|NCT02237677|Trauma
953331|NCT02237677|Neuroimaging
953332|NCT02237677|Positron emission tomography (PET)
953333|NCT02237677|[11C]OMAR
953334|NCT02237677|Endocannabinoid
953335|NCT02237664|Thoracoscopy
953336|NCT02237664|Patient-controlled analgesia
953337|NCT02237664|Paravertebral analgesia
953338|NCT02237651|anesthesia
953339|NCT02237651|bronchosocopy
953340|NCT02237651|lung transplantation
953341|NCT02237638|VEGF
953342|NCT02237638|Vaccine
953343|NCT02237638|Angiogenesis
953344|NCT02237625|Hypophosphatasia
953345|NCT02237625|HPP
953346|NCT02237599|SSEP
953347|NCT02237599|neuropraxia
953348|NCT02237599|intraoperative
953349|NCT02237599|automated
953350|NCT02237586|Plasmodium falciparum malaria
953351|NCT02237586|Malaria
953352|NCT02237586|PfSPZ Challenge
953353|NCT02237586|Controlled Human Malaria Infection (CHMI)
953354|NCT02237586|Sickle Cell Trait
953355|NCT02237586|Sporozoites
953356|NCT02237573|general practice
953357|NCT02237573|viral infections
953358|NCT02237573|consultation reports
953359|NCT02237573|drug prescription
953360|NCT02237560|MCI
953361|NCT02237560|Exergaming
953362|NCT02237560|Cognition
953363|NCT02237560|Exercise
953364|NCT02237560|Older Adults
953365|NCT02237547|spinal cord injury
953366|NCT02237547|mesenchymal
953367|NCT02237547|bone marrow
953368|NCT02237547|mononuclear cells
953369|NCT02237547|stem cells
953370|NCT02237547|umbilical cord
953371|NCT02237534|Lanthanum
953372|NCT02237534|Calcium Carbonate
953373|NCT02237534|Vascular Calcification
953374|NCT02237521|Incretin hormones
953375|NCT02237521|End-stage renal disease
953376|NCT02237521|ESRD
953377|NCT02237521|GLP-1
953378|NCT02237521|GIP
953379|NCT02237521|Insulin
953380|NCT02237521|Glucagon
953381|NCT02237469|Breast cancer
953382|NCT02237469|Breast conserving surgery.
953383|NCT02237469|Radiotherapy.
953384|NCT02237469|Treatment planning.
953385|NCT02237469|Prone.
953386|NCT02237456|Myocardial infarction
953387|NCT02237456|Atherosclerosis
953388|NCT02237456|PCI
953389|NCT02237456|OCT
953390|NCT02237456|Optical coherence tomography
953391|NCT02237456|Stent
953392|NCT02237456|Bioresorbable stents
953393|NCT02237443|Patient Safety
953394|NCT02237430|Coronary angiography (CAG)
953395|NCT02237417|MRI
953396|NCT02237417|Imaging
953397|NCT02237417|Antipsychotic
953398|NCT02237404|Follow-Up studies
953399|NCT02237404|Biological Pacemakers
953400|NCT02237404|Telemedicine
953401|NCT02237404|Efficiency
953402|NCT02237391|High Frequency Emergency Department Visits
953403|NCT02237391|Healthcare Utilization
953404|NCT02237391|Chronic Pain
953405|NCT02237391|Interdisciplinary
953406|NCT02237378|FDG lung and RV uptake
953407|NCT02237365|neurological disability
953408|NCT02237365|tuberculous meningitis (TBM)
953409|NCT02237365|safety
953410|NCT02237365|aspirin
953411|NCT02237365|efficacy
953412|NCT02237352|Diabetes mellitus
953413|NCT02237352|Diabetic nephropathy
953414|NCT02237352|Social Factors
953415|NCT02237352|Biological Factors
953416|NCT02237352|VEGF-A
953417|NCT02237352|Tenascin C
953418|NCT02237352|Disease characterization
953419|NCT02237352|Mechanisms
953420|NCT02237352|Kidney
953421|NCT02237352|Chronic kidney disease
953422|NCT02237352|Secondary nephropathy
953423|NCT02237352|South America
953424|NCT02237352|Hispanics
953425|NCT02237352|Ecuador
953426|NCT02237352|Biomarkers
953427|NCT02237339|Allopurinol
953428|NCT02237339|Cardiac MRI (CMR)
953429|NCT02237339|Flow mediated dilatation (FMD)
953430|NCT02237339|Pulse wave analysis (PWA)
953431|NCT02237339|Endothelial function
953432|NCT02237339|Scar
953433|NCT02237339|Hypertrophy
953434|NCT02237339|Hypertension
953435|NCT02237326|Visual Inspection with Acetic Acid
953436|NCT02237326|Visual Inspection with Lugol's Iodine
953437|NCT02237326|Cervical Intraepithelial neoplasia
953438|NCT02237326|Cervical Cancer Screening
953439|NCT02237326|HIV infected women
953440|NCT02237313|psychological support
953441|NCT02237313|therapeutic education
953442|NCT02237313|vulnerability of patients
953443|NCT02237196|cat-allergic
953444|NCT02237196|cat immunotherapy
953445|NCT02237196|anti-thymic stromal lymphopoietin (anti-TSLP)
953446|NCT02237170|Sipuleucel-T
953447|NCT02237170|Castration Resistant Prostate Cancer
953448|NCT02237170|Provenge
953449|NCT02237157|pancreatic cancer
953450|NCT02237157|unresectable
953451|NCT02237157|gemcitabine
953452|NCT02237157|device
953453|NCT02237157|local delivery
953454|NCT02237157|chemoembolization
953455|NCT02237131|Endometriosis
953456|NCT02237131|Oral contraceptives
953457|NCT02237131|Laparoscopy
953458|NCT02237118|Acute
953459|NCT02237118|wound
953460|NCT02237118|management
953461|NCT02237118|measured
953462|NCT02237118|Visual analoge scale
953463|NCT02237066|OCT
953464|NCT02237066|PTA
953465|NCT02237066|Balloon
953466|NCT02237053|Energy expenditure
953467|NCT02237053|Glucagon
953468|NCT02237053|Octreotide
953469|NCT02237053|Weight loss
953470|NCT02237040|Children
953471|NCT02237040|mandible
953472|NCT02237040|condylar fracture
953473|NCT02237040|conservative treatment
953474|NCT02237040|functional treatment
953475|NCT02237027|HIV
953476|NCT02237027|Early treatment as prevention (TasP)
953477|NCT02237027|Pre-exposure prophylaxis (PrEP)
953478|NCT02237027|antiretroviral treatment
953479|NCT02237027|prevention
953480|NCT02237027|feasibility
953481|NCT02237027|female sex workers
953482|NCT02237027|Benin
953483|NCT02237027|West Africa
953484|NCT02237001|meniscal
953485|NCT02237001|meniscus
953486|NCT02237001|repair
953487|NCT02237001|knee
953488|NCT02237001|arthroscopy knee
953489|NCT02237001|horizontal
953490|NCT02236988|Apremilast
953491|NCT02236988|Healthy male subjects
953492|NCT02236988|Pharmacokinetics
953493|NCT02236949|pediatric pain
953494|NCT02236949|intervention sustainability
953495|NCT02236936|Squamous Cell Carcinoma
953496|NCT02236936|Head and neck
953497|NCT02236936|SCCHN
953498|NCT02236936|Parenteral nutrition
953499|NCT02236936|Larynx
953500|NCT02236936|Hypopharynx
953501|NCT02236936|Cavum oris
953502|NCT02236936|Radiotherapy
953503|NCT02236936|Cetuximab
953504|NCT02236936|Cisplatin
953505|NCT02236923|cardiovascular
953506|NCT02236923|surgery
953507|NCT02236923|ascending aorta
953508|NCT02236923|aortic dissection
953509|NCT02236910|somatostatin receptor positive tumour
953510|NCT02236884|rectal cancer
953511|NCT02236884|no scar
953512|NCT02236884|NOTES
953513|NCT02236884|TaTME
953514|NCT02236884|feasibility
953515|NCT02236884|safety
953516|NCT02236871|Adolescents
953517|NCT02236871|Dairy
953518|NCT02236871|Bone
953519|NCT02236858|COPD
953520|NCT02236845|Insomnia, medical device, sleep latency
953521|NCT02236806|Breast cancer
953522|NCT02236806|Adjuvant chemotherapy
953523|NCT02236806|Neoadjuvant chemotherapy
953524|NCT02236806|Cardioprotection
953525|NCT02236806|Anthracyclines
953526|NCT02236780|in vitro fertilisation
953527|NCT02236780|environmental conditions
953528|NCT02236780|pregnancy
953529|NCT02236780|live birth rate
953530|NCT02236754|dihydrotetrabenazine
953531|NCT02236754|beta cell mass
953532|NCT02236754|diabetes mellitus
953533|NCT02236702|Major Depressive Disorder
953534|NCT02236702|Anhedonia
953535|NCT02236702|Positron Emission Tomography (PET)
953536|NCT02236702|Kappa Opioid Receptor (KOR)
953537|NCT02236676|motor learning TBI
953538|NCT02236663|Intimate Partner Violence
953539|NCT02236663|Dating Violence
953540|NCT02236663|Relationships
953541|NCT02236663|Safety Planning
953542|NCT02236663|College
953543|NCT02236663|Student
953544|NCT02236663|App
953545|NCT02236650|Parental Resilience
953546|NCT02236650|Parental Stress
953547|NCT02236650|Family Adaptation
953548|NCT02236650|Autistic Disorder
953549|NCT02236650|Behavior
953550|NCT02236650|Child Behavior
953551|NCT02236650|Child Development Disorders
953552|NCT02236650|Pervasive Developmental Disabilities
953553|NCT02236650|Caregivers
953554|NCT02236650|Parents
953555|NCT02236650|Parenting
953556|NCT02236650|Primary Health Care
953557|NCT02236637|Adenocarcinoma of the Prostate
953558|NCT02236637|Registry
953559|NCT02236637|metastatic castration-resistant prostate cancer
953560|NCT02236611|COPD
953561|NCT02236611|inhaler ease of use
953562|NCT02236611|glycopyrronium
953563|NCT02236611|umeclidinium
953564|NCT02236611|novel dry powder inhaler
953565|NCT02236611|long-acting muscarinic antagonist
953566|NCT02236611|inhaler errors
953567|NCT02236598|borderline hypokalemia
953568|NCT02236598|glucose tolerance
953569|NCT02236598|insulin secretion
953570|NCT02236598|insulin sensitivity
953571|NCT02236598|fasting glucose
953572|NCT02236598|African American
953573|NCT02236585|uterine artery embolization, epidural , patient-controlled analgesia
953574|NCT02236572|Postmenopausal
953575|NCT02236572|ER-positive, PR-positive, HER2-negative
953576|NCT02236572|Low and intermediate risk
953577|NCT02236559|high flow therapy
953578|NCT02236559|high flow nasal cannula
953579|NCT02236559|acute respiratory failure
953580|NCT02236559|noninvasive ventilation
953581|NCT02236546|fluorodeoxyglucose
953582|NCT02236546|FDG
953583|NCT02236546|PET/CT
953584|NCT02236546|melanoma
953585|NCT02236546|imaging biomarkers
953586|NCT02236546|cancer imaging
953587|NCT02236520|Na+ MRI
953588|NCT02236520|salt stores
953589|NCT02236494|alcoholism
953590|NCT02236494|dangerous behavior
953591|NCT02236494|aged
953592|NCT02236494|emergency medicine
953593|NCT02236455|complementary medicine
953594|NCT02236455|state anxiety
953595|NCT02236455|acute pain
953596|NCT02236455|self-efficacy
953597|NCT02236455|surgery
953598|NCT02236455|medical music intervention
953599|NCT02236455|nature therapy
953600|NCT02236455|relaxation technique
953601|NCT02236442|Cephalalgia
953602|NCT02236442|Headache
953603|NCT02236442|Migraine
953604|NCT02236442|Pain
953605|NCT02236442|Global
953606|NCT02236442|Treatment
953607|NCT02236442|Oxygen
953608|NCT02236442|Emergency
953609|NCT02236442|Treatment of cephalalgia in emergency department
953610|NCT02236429|bacterial vaginitis
953611|NCT02236429|vaginal flora
953612|NCT02236429|microbiome
953613|NCT02236416|Dementia
953614|NCT02236416|Prevention
953615|NCT02236416|Physical Activity
953616|NCT02236403|Blepharitis , Demodex, Ivermectin, Metronidazole
953617|NCT02236390|Nightmare
953618|NCT02236390|PTSD
953619|NCT02236390|Sleep
953620|NCT02236390|Emotion Regulation
953621|NCT02236390|Exposure Relaxation and Rescripting Therapy
953622|NCT02236390|Cognitive Processing Therapy
953623|NCT02236377|ERRT
953624|NCT02236377|Nightmares
953625|NCT02236377|Sleep
953626|NCT02236377|Trauma
953627|NCT02236377|PTSD
953628|NCT02236351|patching
953629|NCT02236351|pediatric ophthalmology
953630|NCT02236338|chronic venous insufficiency
953631|NCT02236338|varicose vein
953632|NCT02236338|greater saphenous vein
953633|NCT02236299|Right Coronary Artery
953634|NCT02236299|Percutaneous Coronary Intervention
953635|NCT02236299|Diastolic Dysfunction
953636|NCT02236299|Glucagon-like peptide-1
953637|NCT02236299|GLP-1
953638|NCT02236299|Stunning
953639|NCT02236299|Cardioprotection
953640|NCT02236286|freezing of gait (FOG)
953641|NCT02236286|balance
953642|NCT02236286|gait
953643|NCT02236286|exercise
953644|NCT02236273|Human papillomavirus
953645|NCT02236273|vaccination
953646|NCT02236273|text message
953647|NCT02236273|reminder
953648|NCT02236247|ivabradine
953649|NCT02236247|heart rate
953650|NCT02236247|heart failure
953651|NCT02236234|HIV
953652|NCT02236234|HPV
953653|NCT02236234|Clinical trial
953654|NCT02236234|outcome
953655|NCT02236195|Urothelial
953656|NCT02236195|Bladder
953657|NCT02236195|HDAC
953658|NCT02236195|MGCD0103
953659|NCT02236195|Mocetinostat
953660|NCT02236195|CREBBP
953661|NCT02236195|EP300
953662|NCT02236195|Mirati
953663|NCT02236195|MethylGene
953664|NCT02236143|Healthy
953665|NCT02236130|pediatric regional
953666|NCT02236117|heart rate variability
953667|NCT02236117|children
953668|NCT02236117|progressive test
953669|NCT02236104|neuromuscular disorders
953670|NCT02236104|mechanical insufflation-exsufflation
953671|NCT02236104|respiratory parameters
953672|NCT02236104|plethysmography opto electronic
953673|NCT02236104|Vital capacity
953674|NCT02236091|cerebral palsy
953675|NCT02236091|stroke
953676|NCT02236091|traumatic brain injury
953677|NCT02236065|Umbilical cord blood
953678|NCT02236065|Granulocyte-colony stimulating factor
953679|NCT02236065|Brain injury
953680|NCT02236065|Neurodegenerative disorder
953681|NCT02236065|Efficacy
953682|NCT02236065|Safety
953683|NCT02236052|Influenza
953684|NCT02236052|Human
953685|NCT02236052|RNA Virus Infections
953686|NCT02236052|Immunologic
953687|NCT02236052|Immunogenic Factors
953688|NCT02236052|Physiological Effects of Drugs
953689|NCT02236052|Virus diseases
953690|NCT02236052|Orthomyxoviridae Infections
953691|NCT02236052|Infection
953692|NCT02236039|Diesel exhaust
953693|NCT02236039|Air pollution
953694|NCT02236039|Airway responsivness
953695|NCT02236026|Nestorone use as an IV solution on heart rate;
953696|NCT02236026|Abnormality in Heart Rate or Rhythm, Unspecified as to Time of Onset
953697|NCT02236013|ASP2215
953698|NCT02236013|Acute Myeloid Leukemia
953699|NCT02236013|Idarubicin
953700|NCT02236013|Cytarabine
953701|NCT02236000|NSABP
953702|NCT02236000|Trastuzumab Emtansine
953703|NCT02236000|T DM1
953704|NCT02236000|Neratinib
953705|NCT02236000|Metastatic Breast Cancer
953706|NCT02236000|HER2 positive
953707|NCT02236000|Dose Escalation
953708|NCT02235974|stroke
953709|NCT02235974|critical periods
953710|NCT02235974|sensitive periods
953711|NCT02235974|hemiparesis
953712|NCT02235974|upper extremity
953713|NCT02235974|physical rehabilitation
953714|NCT02235974|arm therapy
953715|NCT02235974|occupational therapy
953716|NCT02235974|physical therapy
953717|NCT02235974|task oriented training
953718|NCT02235974|patient focused
953719|NCT02235974|arm function
953720|NCT02235974|hand function
953721|NCT02235974|neurorehabilitation
953722|NCT02235974|motor learning
953723|NCT02235974|motor control
953724|NCT02235974|motor function
953725|NCT02235974|motor recovery
953726|NCT02235974|skill acquisition
953727|NCT02235974|skill training
953728|NCT02235948|arsenic induced health problem
953729|NCT02235948|modifying effects
953730|NCT02235948|folic acid
953731|NCT02235948|oxidative damage
953732|NCT02235948|clinical trial
953733|NCT02235922|Aged
953734|NCT02235922|Exercise
953735|NCT02235922|Cognition
953736|NCT02235922|Functional capacity
953737|NCT02235909|Pediatric Hypertension
953738|NCT02235909|High Blood Pressure
953739|NCT02235909|Hypertension
953740|NCT02235909|Pediatric
953741|NCT02235909|Primary Hypertension
953742|NCT02235909|Secondary Hypertension
953743|NCT02235896|risk factors, African American, lipids, blood pressure
953744|NCT02235883|Coronary artery disease
953745|NCT02235883|FFR
953746|NCT02235883|diagnosis
953747|NCT02235883|computational model
953748|NCT02235883|non-invasive
953749|NCT02235870|Weight Loss
953750|NCT02235870|Obesity
953751|NCT02235870|BMI
953752|NCT02235857|pediatric, renal transplantation, recurrence, drug-resistant
953753|NCT02235844|Mesenchymal
953754|NCT02235844|Stem Cells
953755|NCT02235844|Umbilical Cord
953756|NCT02235844|Duchenne's
953757|NCT02235844|Muscular Dystrophy
953758|NCT02235831|DACP MF
953759|NCT02235831|DAILIES AquaComfort Plus® Multifocal
953760|NCT02235831|presbyopia
953761|NCT02235831|visual performance
953762|NCT02235818|tennis elbow, treatment, lateral epicondylitis, immediate effects
953763|NCT02235805|Metabolic Syndrome
953764|NCT02235805|Obesity
953765|NCT02235805|Magnesium Supplementation
953766|NCT02235805|Vascular Stiffness
953767|NCT02235805|Vascular Function
953768|NCT02235779|ILD
953769|NCT02235779|Pulmonary fibrosis
953770|NCT02235779|Cryobiopsy
953771|NCT02235779|Transbronchial
953772|NCT02235766|Cardiac Resynchronization Therapy
953773|NCT02235766|Satellite Tele-Echocardiography
953774|NCT02235740|Open label
953775|NCT02235740|carfilzomib
953776|NCT02235740|Phase I
953777|NCT02235740|clinical activity
953778|NCT02235740|pharmacokinetics
953779|NCT02235740|afuresertib
953780|NCT02235740|relapsed
953781|NCT02235740|refractory
953782|NCT02235740|safety
953783|NCT02235740|multiple myeloma
953784|NCT02235714|Airway inflammation
953785|NCT02235714|Tetraplegia
953786|NCT02235714|Asthma
953787|NCT02235714|Exhaled breath condensate
953788|NCT02235714|Spirometry
953789|NCT02235714|Pulmonary Function Testing
953790|NCT02235701|soft tissue sarcoma
953791|NCT02235701|aldoxorubicin
953792|NCT02235701|ifosfamide
953793|NCT02235701|mesna
953794|NCT02235701|phase 1
953795|NCT02235701|INNO-206
953796|NCT02235688|aldoxorubicin
953797|NCT02235688|INNO-206
953798|NCT02235688|solid tumors
953799|NCT02235688|gemcitabine
953800|NCT02235688|phase 1
953801|NCT02235675|Angioplasty
953802|NCT02235675|Peripheral Artery Disease
953803|NCT02235675|Critical Limb Ischemia
953804|NCT02235675|CLI
953805|NCT02235675|PAD
953806|NCT02235662|HIV
953807|NCT02235662|LNG
953808|NCT02235662|IVR
953809|NCT02235662|Contraception
953810|NCT02235662|Prevention
953811|NCT02235623|Laparoscopic Surgery
953812|NCT02235623|Orchiopexy
953813|NCT02235610|Lung Transplantation
953814|NCT02235610|Ex Vivo Lung Perfusion
953815|NCT02235610|EVLP
953816|NCT02235597|patient access
953817|NCT02235597|patient centered care
953818|NCT02235597|scheduling
953819|NCT02235597|access barriers
953820|NCT02235597|improve efficiency
953821|NCT02235597|decision making tools
953822|NCT02235597|underserved
953823|NCT02235584|Incretin hormones
953824|NCT02235584|GLP-1
953825|NCT02235584|GIP
953826|NCT02235584|Dexamethasone
953827|NCT02235558|Acute Ischemic Stoke
953828|NCT02235558|Thrombectomy
953829|NCT02235558|Intraarterial Pharmacotherapy
953830|NCT02235558|Neuroprotection
953831|NCT02235545|HV Lead
953832|NCT02235545|ICD
953833|NCT02235545|CRT-D System
953834|NCT02235545|Treatment of Heart Failure
953835|NCT02235545|Treamtent of life-threatening ventricular tachyarrhythmia
953836|NCT02235545|Optisure
953837|NCT02235532|clinical trial
953838|NCT02235532|oral hygiene
953839|NCT02235532|Gingivitis
953840|NCT02235532|Aloevera
953841|NCT02235532|Toothpaste
953842|NCT02235532|anti-inflammatory agents
953843|NCT02235493|HPP
953844|NCT02235493|Soft Bones
953845|NCT02235493|low Alkaline Phosphatase
953846|NCT02235493|genetic metabolic disorder
953847|NCT02235493|alkaline phosphatase
953848|NCT02235493|tissue non-specific alkaline phosphatase
953849|NCT02235493|rickets
953850|NCT02235493|osteomalacia
953851|NCT02235467|autism
953852|NCT02235467|videomodeling
953853|NCT02235467|behavioral therapy
953854|NCT02235467|parental training
953855|NCT02235454|glaucoma
953856|NCT02235454|OCT
953857|NCT02235454|spectral domain optical coherence tomography
953858|NCT02235441|Gastrointestinal malignancy
953859|NCT02235441|Cardiopulmonary fitness
953860|NCT02235441|Chemoradiation therapy
953861|NCT02235376|Critical Care
953862|NCT02235376|Brain injured patients
953863|NCT02235376|Mechanical Ventilation
953864|NCT02235376|Weaning
953865|NCT02235376|Extubation
953866|NCT02235376|Prognostic score
953867|NCT02235376|Clinical examination
953868|NCT02235363|face lift
953869|NCT02235363|thread lift
953870|NCT02235363|retaining ligament
953871|NCT02235363|SMAS
953872|NCT02235350|Adult
953873|NCT02235350|Male
953874|NCT02235350|Female
953875|NCT02235350|Neuronal Plasticity
953876|NCT02235350|Imitative Behavior/physiology
953877|NCT02235350|Magnetic Resonance Imaging
953878|NCT02235350|Psychomotor Disorders/rehabilitation
953879|NCT02235350|Follow-up Studies
953880|NCT02235350|Video Recording
953881|NCT02235350|Physical Therapy Modalities
953882|NCT02235350|Recovery of Function
953883|NCT02235350|Action Observation Treatment
953884|NCT02235350|Mirror Neuron System
953885|NCT02235350|Stroke/rehabilitation
953886|NCT02235350|Upper Limb
953887|NCT02235337|Concussion
953888|NCT02235337|Sports related concussion
953889|NCT02235337|mTBI
953890|NCT02235337|Vitamin B
953891|NCT02235337|Riboflavin
953892|NCT02235311|Proton pump inhibitor
953893|NCT02235311|Upper gastrointestinal bleed
953894|NCT02235311|Ulcer healing
953895|NCT02235298|epicardial fat
953896|NCT02235298|diabetes
953897|NCT02235298|dapagliflozin
953898|NCT02235285|capsular contracture
953899|NCT02235285|reoperation
953900|NCT02235285|breast augmentation
953901|NCT02235246|perioperative intravenous magnesium
953902|NCT02235246|endoscopic submucosal dissection
953903|NCT02235220|Bruxism
953904|NCT02235207|sedentary work
953905|NCT02235207|musculoskeletal pain
953906|NCT02235207|neuromuscular exercise
953907|NCT02235207|physical fitness
953908|NCT02235207|quality of life
953909|NCT02235207|work ability
953910|NCT02235181|Twin Pregnancy
953911|NCT02235181|Prevention of Preterm birth
953912|NCT02235181|Short Cervix
953913|NCT02235181|Arabin cervical pessary
953914|NCT02235116|Number of patients
953915|NCT02235116|full body skin exam
953916|NCT02235116|Survey
953917|NCT02235116|preferences
953918|NCT02235090|Spinal muscular atrophy
953919|NCT02235090|Neuromuscular disorders
953920|NCT02235090|Outcome measures
953921|NCT02235090|Visit-free clinical trial design
953922|NCT02235077|Heart Failure
953923|NCT02235077|Heart Diseases
953924|NCT02235077|Cardiovascular Diseases
953925|NCT02235077|Spironolactone
953926|NCT02235077|Aldactone
953927|NCT02235025|mild COPD
953928|NCT02235025|dyspnea
953929|NCT02235025|exercise
953930|NCT02235025|respiratory mechanics
953931|NCT02235012|Schizophrenia
953932|NCT02235012|Ketamine
953933|NCT02235012|Cognitive biases
953934|NCT02235012|Uncertainty
953935|NCT02234999|Pharmacokinetics, Healthy Subjects
953936|NCT02234986|Advanced Fibrolamellar Carcinoma
953937|NCT02234947|type 1 diabetes
953938|NCT02234947|pancreas volume
953939|NCT02234934|Gene Therapy
953940|NCT02234934|X-Linked Chronic Granulomatous Disease (X-CGD)
953941|NCT02234934|Lentiviral Vector
953942|NCT02234921|Prostate
953943|NCT02234921|Adenocarcinoma
953944|NCT02234921|Metastatic
953945|NCT02234921|DRibble
953946|NCT02234921|Immunotherapy
953947|NCT02234921|Microbiome
953948|NCT02234908|Tuberculosis
953949|NCT02234908|Drug-resistant tuberculosis
953950|NCT02234908|Incentives
953951|NCT02234908|Symptom screening
953952|NCT02234895|osteoarthritis
953953|NCT02234895|knee
953954|NCT02234895|biomechanics
953955|NCT02234895|treatment
953956|NCT02234895|symptoms
953957|NCT02234869|Peginterferon Beta-1a
953958|NCT02234869|Relapsing Multiple Sclerosis
953959|NCT02234869|RMS
953960|NCT02234869|flu-like symptoms
953961|NCT02234856|Hysterectomy
953962|NCT02234856|Laparoscopy
953963|NCT02234856|Surgical assessment
953964|NCT02234856|Education
953965|NCT02234843|Pediatric
953966|NCT02234830|PCI
953967|NCT02234804|Coronary angiography (CAG)
953968|NCT02234804|Percutaneous coronary intervention (PCI)
953969|NCT02234804|OCT
953970|NCT02234804|Stent
953971|NCT02234778|critical limb ischemia
953972|NCT02234778|autologous stromal vascular fraction
953973|NCT02234765|OSA
953974|NCT02234765|OSAS
953975|NCT02234765|Sleep apnea
953976|NCT02234765|Management
953977|NCT02234765|Primary Care
953978|NCT02234765|Sleep Unit
953979|NCT02234765|Cost-Effectiveness
953980|NCT02234765|ESS
953981|NCT02234752|Schizophrenia
953982|NCT02234752|Schizoaffective Disorder
953983|NCT02234752|Cognition
953984|NCT02234752|Cognitive Impairment
953985|NCT02234752|Galantamine
953986|NCT02234752|Memantine
953987|NCT02234739|voriconazole
953988|NCT02234739|COPD
953989|NCT02234739|invasive pulmonary aspergillosis
953990|NCT02234739|efficacy
953991|NCT02234739|safety
953992|NCT02234726|child health
953993|NCT02234726|child development
953994|NCT02234726|malnutrition
953995|NCT02234726|stunting
953996|NCT02234726|community-based health services
953997|NCT02234687|post-traumatic stress disorder
953998|NCT02234674|Pulsating suit
953999|NCT02234674|lymphedema
954000|NCT02234674|leg volume
954001|NCT02234661|Low income
954002|NCT02234661|Education
954003|NCT02234661|Poverty
954004|NCT02234661|Children
954005|NCT02234661|Parents
954006|NCT02234661|Head Start
954007|NCT02234648|Vascular Function
954008|NCT02234648|tart Montmorency cherries
954009|NCT02234648|Arterial Stiffness
954010|NCT02234648|Blood Flow
954011|NCT02234635|visual acuity
954012|NCT02234635|objective visual quality
954013|NCT02234635|multifocal intraocular lens
954014|NCT02234635|tear-film quality dynamics
954015|NCT02234622|Stress Disorders, Post-Traumatic
954016|NCT02234622|Yoga
954017|NCT02234622|Veterans
954018|NCT02234609|dentistry
954019|NCT02234609|dental caries
954020|NCT02234609|atraumatic restorative Treatment
954021|NCT02234609|effectiveness
954022|NCT02234596|Nintedanib
954023|NCT02234596|14-094
954024|NCT02234583|pain
954025|NCT02234583|fibromyalgia
954026|NCT02234570|neurocysticercosis
954027|NCT02234570|pork tapeworm
954028|NCT02234570|Taenia solium
954029|NCT02234557|Motor Control
954030|NCT02234557|Attention
954031|NCT02234557|Cognitive Control
954032|NCT02234544|vitamin D
954033|NCT02234544|absorption
954034|NCT02234544|ezetimibe
954035|NCT02234531|Virtual Reality,
954036|NCT02234531|Enhanced Feedback,
954037|NCT02234531|Stroke,
954038|NCT02234531|Rehabilitation,
954039|NCT02234531|Motor Learning
954040|NCT02234505|prosthetics
954041|NCT02234505|amputation
954042|NCT02234505|gait stability
954043|NCT02234505|step variability
954044|NCT02234505|load cell
954045|NCT02234492|Human immunodeficiency virus (HIV)
954046|NCT02234492|Statin therapy
954047|NCT02234492|Cardiovascular disease (CVD)
954048|NCT02234492|Coronary Flow Reserve (CFR)
954049|NCT02234492|Positron Emission Tomography (PET)
954050|NCT02234492|Myocardial contrast echocardiography (MCE)
954051|NCT02234479|Breast Cancer
954052|NCT02234479|Radiation Dermatitis
954053|NCT02234466|Quality of Recovery (QOR40)
954054|NCT02234466|Breast Surgery
954055|NCT02234466|Clinically significant Nausea and Vomiting
954056|NCT02234466|Postoperative Nausea and Vomiting
954057|NCT02234453|cancer
954058|NCT02234453|chemotherapy
954059|NCT02234453|home
954060|NCT02234453|blood count
954061|NCT02234453|remote
954062|NCT02234427|aspirin, atherosclerosis
954063|NCT02234414|vertebral fracture assessment (vfa)
954064|NCT02234414|vitamin D
954065|NCT02234401|Cystic Fibrosis
954066|NCT02234401|Noninvasive ventilation
954067|NCT02234401|Non invasive ventilation
954068|NCT02234401|Acute respiratory exacerbation
954069|NCT02234401|Bi level pressure support
954070|NCT02234388|connective tissue disease
954071|NCT02234388|registry
954072|NCT02234388|hospital for special surgery
954073|NCT02234375|Pulmonary embolism
954074|NCT02234375|Contrast
954075|NCT02234375|Computed tomography
954076|NCT02234375|Gadolinium
954077|NCT02234349|bile acids
954078|NCT02234349|pancreas kidney transplantation
954079|NCT02234349|incretins
954080|NCT02234349|intestinal flora
954081|NCT02234336|Echocardiography
954082|NCT02234336|hypertrophic cardiomyopathy
954083|NCT02234336|cardiomyopathy
954084|NCT02234336|magnetic resonance imaging
954085|NCT02234336|contrast
954086|NCT02234323|prophylaxis treatment
954087|NCT02234323|Hemophilia A
954088|NCT02234323|Hemophilia
954089|NCT02234323|episodic treatment
954090|NCT02234310|prophylaxis treatment
954091|NCT02234310|episodic treatment
954092|NCT02234297|Glioma
954093|NCT02234297|Tumor Paint
954094|NCT02234297|BLZ100
954095|NCT02234284|Chronic Obstructive Pulmonary Disease
954096|NCT02234284|Health Coaching
954097|NCT02234284|Health Disparities
954098|NCT02234284|Self-management
954099|NCT02234284|Chronic Disease Model
954100|NCT02234245|Follow-Up studies
954101|NCT02234245|Biological Pacemakers
954102|NCT02234245|Telemedicine
954103|NCT02234245|Efficiency
954104|NCT02234232|Hemodialysis
954105|NCT02234232|Exercise, aerobic
954106|NCT02234232|Exercise, resistance
954107|NCT02234232|Intradialytic
954108|NCT02234232|Randomized Controlled Trial
954109|NCT02234232|Safety
954110|NCT02234232|Quality of life
954111|NCT02234232|Physical performance
954112|NCT02234206|Hypospermatogenesis, Low Sperm Count, Oligozoospermia
954113|NCT02234193|wound healing
954114|NCT02234128|Ex Vivo Lung Perfusion
954115|NCT02234128|EVLP
954116|NCT02234128|Lung Transplant
954117|NCT02234128|Lung Transplantation
954118|NCT02234128|Toronto EVLP System™
954119|NCT02234128|PERFUSIX
954120|NCT02234115|Prostate Neoplasm Cancer Carcinoma
954121|NCT02234076|Posttraumatic Stress Disorder
954122|NCT02234076|Depression
954123|NCT02234076|Treatment
954124|NCT02234076|VRET
954125|NCT02234063|Hypertension
954126|NCT02234063|Chronic Kidney Disease
954127|NCT02234063|End Stage Renal Disease
954128|NCT02234063|APOL1
954129|NCT02234063|Genomics
954130|NCT02234063|Genetics
954131|NCT02234063|Community-engaged
954132|NCT02234050|Grade 2 Chordoid meningioma
954133|NCT02234050|Grade 2 Clear cell meningioma
954134|NCT02234050|Grade 2 Atypical meningioma
954135|NCT02234050|Grade 3 Papillary meningioma
954136|NCT02234050|Grade 3 Rhabdoid meningioma
954137|NCT02234050|Grade 3 Anaplastic meningioma
954138|NCT02234050|Grade 3 Malignant meningioma
954139|NCT02234037|AML
954140|NCT02233998|Plaque
954141|NCT02233998|Bleeding
954142|NCT02233998|Gums
954143|NCT02233998|Gingiva
954144|NCT02233998|Gingival Inflammation
954145|NCT02233998|Gingival Bleeding
954146|NCT02233985|bronchiolitis
954147|NCT02233985|hypertonic
954148|NCT02233985|saline
954149|NCT02233985|salbutamol
954150|NCT02233972|Pharmacokinetics
954151|NCT02233972|Ginkgolides Meglumine Injection
954152|NCT02233946|Substance Abuse
954153|NCT02233946|Prevention
954154|NCT02233946|Youth
954155|NCT02233946|Alcohol
954156|NCT02233946|Drugs
954157|NCT02233933|radiation proctitis
954158|NCT02233933|bleeding
954159|NCT02233933|therapy
954160|NCT02233868|Imaging Studies
954161|NCT02233868|Alcoholism
954162|NCT02233868|Inflammation
954163|NCT02233855|Seizures
954164|NCT02233855|Cestode
954165|NCT02233855|Hydrocephalus
954166|NCT02233855|Taenia Solium
954167|NCT02233855|Helminth
954168|NCT02233842|Qualitative Data
954169|NCT02233842|Questionnaire
954170|NCT02233829|C-11 Raclopride
954171|NCT02233829|015 PET
954172|NCT02233829|Circadian Rhythm
954173|NCT02233816|Influenza
954174|NCT02233816|Human
954175|NCT02233816|RNA Virus Infections
954176|NCT02233816|Immunologic
954177|NCT02233816|Immunogenic Factors
954178|NCT02233816|Physiological Effects of Drugs
954179|NCT02233816|Virus diseases
954180|NCT02233816|Orthomyxoviridae Infections
954181|NCT02233816|Infection
954182|NCT02233803|tolerability
954183|NCT02233803|NEUMOTEROL
954184|NCT02233803|efficacy
954185|NCT02233803|budesonide/formoterol fumarate 400/12 mcg
954186|NCT02233803|safety
954187|NCT02233803|Asthma
954188|NCT02233803|pharmacodynamics
954189|NCT02233790|Myocardial infarction
954190|NCT02233790|No-Reflow Phenomenon
954191|NCT02233790|Ticagrelor
954192|NCT02233790|Clopidogrel
954193|NCT02233790|Single-Photon Emission Computerized Tomography
954194|NCT02233777|Pregabalin
954195|NCT02233777|Bioequivalence
954196|NCT02233777|Bioavailability
954197|NCT02233777|Pharmacokinetic
954198|NCT02233777|Antiepileptic
954199|NCT02233764|iron
954200|NCT02233764|zinc
954201|NCT02233764|pearl millet
954202|NCT02233764|India
954203|NCT02233764|children
954204|NCT02233764|trial
954205|NCT02233764|randomized
954206|NCT02233751|Healthy Adult Males
954207|NCT02233738|Alcoholism
954208|NCT02233738|Substance-related disorders
954209|NCT02233738|Dual Diagnosis
954210|NCT02233725|Prostatic Neoplasms
954211|NCT02233725|Magnetic Resonance Imaging
954212|NCT02233725|MRI / Ultrasound Fusion
954213|NCT02233725|Contrast-Enhanced Ultrasound (CEUS)
954214|NCT02233712|gastric cancer, stomach neoplasms,
954215|NCT02233673|Obesity
954216|NCT02233673|Pregnancy
954217|NCT02233647|cocaine
954218|NCT02233647|phendimetrazine
954219|NCT02233647|pharmacotherapy
954220|NCT02233634|Coronary Angiography
954221|NCT02233634|Magnetic Resonance Imaging
954222|NCT02233634|Oxygen
954223|NCT02233634|Hyperoxia
954224|NCT02233634|Carbon Dioxide
954225|NCT02233634|Apnea
954226|NCT02233634|Hyperventilation
954227|NCT02233608|Prostate cancer
954228|NCT02233608|Radical prostatectomy
954229|NCT02233608|Pelvic floor muscle exercises
954230|NCT02233608|Pfilates
954231|NCT02233608|Hypopressives
954232|NCT02233608|Urinary Incontinence
954233|NCT02233595|MRI
954234|NCT02233595|PET
954235|NCT02233595|rectal cancer
954236|NCT02233595|adjuvant chemotherapy
954237|NCT02233582|altitude
954238|NCT02233582|mountain sickness
954239|NCT02233582|ibuprofen
954240|NCT02233582|hypoxia
954241|NCT02233569|Laparoscopic hernia repair
954242|NCT02233569|Ventral hernia
954243|NCT02233569|Incisional hernia
954244|NCT02233569|IPOM
954245|NCT02233556|event-related potential
954246|NCT02233556|mismatch negativity
954247|NCT02233556|NMDA
954248|NCT02233556|Glutamate
954249|NCT02233543|COPD
954250|NCT02233543|QVA149
954251|NCT02233543|nocturnal oxygen levels
954252|NCT02233543|combination bronchodilator
954253|NCT02233530|Dementia
954254|NCT02233530|Cognitive Stimulation Therapy
954255|NCT02233530|Quality of life
954256|NCT02233530|Cognitive impairment
954257|NCT02233530|Africa
954258|NCT02233530|Tanzania
954259|NCT02233530|Nigeria
954260|NCT02233530|Low- and Middle-income countries
954261|NCT02233530|Non-pharmacological intervention
954262|NCT02233530|Task-shifting
954263|NCT02233530|Cognitive screening
954264|NCT02233517|Veterans
954265|NCT02233517|Cognitive-Behavioral Therapy
954266|NCT02233517|Aggression
954267|NCT02233517|Anger
954268|NCT02233517|Posttraumatic Stress Disorder
954269|NCT02233517|Combat Disorders
954270|NCT02233491|PTDM
954271|NCT02233491|kidney transplant
954272|NCT02233491|lifestyle intervention
954273|NCT02233491|diet
954274|NCT02233491|exercise
954275|NCT02233478|Pomegranate polyphenols
954276|NCT02233478|Soy Protein
954277|NCT02233478|Ellagitannins
954278|NCT02233465|parastomal
954279|NCT02233465|hernia
954280|NCT02233465|mesh
954281|NCT02233465|parastomal hernia-repair with mesh
954282|NCT02233452|Neuropathic pain
954283|NCT02233452|Methadone
954284|NCT02233452|Ketamine
954285|NCT02233452|Multimodal analgesia
954286|NCT02233439|galactagogues
954287|NCT02233439|herbs
954288|NCT02233439|breastfeeding
954289|NCT02233439|supplements
954290|NCT02233439|Silybum marianum
954291|NCT02233439|Galega officinalis
954292|NCT02233426|allergic rhinitis
954293|NCT02233426|nasal steroid
954294|NCT02233426|hypertonic saline
954295|NCT02233426|eosinophil
954296|NCT02233426|symptom score
954297|NCT02233413|Traumatic brain injury
954298|NCT02233413|TBI
954299|NCT02233413|Low-level light therapy
954300|NCT02233413|LLLT
954301|NCT02233413|LLLT helmet
954302|NCT02233400|Acetaminophen
954303|NCT02233400|Gastric Bypass
954304|NCT02233400|Sleeve Gastrectomy
954305|NCT02233400|Pain
954306|NCT02233400|Cost
954307|NCT02233387|cervix cancer
954308|NCT02233387|[18F] HX4 PET imaging
954309|NCT02233387|hypoxia
954310|NCT02233387|phase II trial
954311|NCT02233374|Rectal Cancer
954312|NCT02233374|Magnetic Resonance Imaging
954313|NCT02233374|Positron Emission Tomography
954314|NCT02233374|pathologic complete response
954315|NCT02233374|Diffusion-weighted magnetic resonance imaging
954316|NCT02233374|Microstructural Imaging
954317|NCT02233374|FDG PET
954318|NCT02233361|Hearing rehabilitation
954319|NCT02233361|Elderly
954320|NCT02233361|Hearing aid use
954321|NCT02233322|ADHR
954322|NCT02233322|Rickets
954323|NCT02233322|Hypophosphatemia
954324|NCT02233296|pharmacokinetics
954325|NCT02233283|LH pulsatility
954326|NCT02233283|Insulin sensitivity
954327|NCT02233283|Metabolism
954328|NCT02233283|hypercaloric feeding
954329|NCT02233257|Adrenoleukodystrophy
954330|NCT02233257|Lorenzo's oil
954331|NCT02233257|erucic acid
954332|NCT02233244|Drug Interaction
954333|NCT02233205|microbubble
954334|NCT02233205|chemotherapy
954335|NCT02233205|alimentary
954336|NCT02233192|PrEP
954337|NCT02233192|conception
954338|NCT02233192|HIV
954339|NCT02233192|serodiscordant
954340|NCT02233179|Diabetic foot ulcer
954341|NCT02233153|Senior
954342|NCT02233153|Elderly
954343|NCT02233153|Acute Care
954344|NCT02233153|Emergency Surgery
954345|NCT02233140|Diabetes
954346|NCT02233140|Ankle equinus
954347|NCT02233140|ankle dorsiflexion
954348|NCT02233140|dynamic plantar pressure
954349|NCT02233140|shockwave therapy
954350|NCT02233127|Birth cohort
954351|NCT02233127|Pakistan
954352|NCT02233127|Child mortality
954353|NCT02233088|Prediabetic State
954354|NCT02233088|Hypertension
954355|NCT02233088|Enlarged Waist Elevated Triglycerides
954356|NCT02233088|HDL Cholesterol, Low Serum
954357|NCT02233062|Crohn's Disease
954358|NCT02233062|semen quality
954359|NCT02233062|enteral nutrition
954360|NCT02233062|CDAI score higher than 150
954361|NCT02233049|Children
954362|NCT02233049|adolescents
954363|NCT02233049|young adults
954364|NCT02233049|newly diagnosed
954365|NCT02233036|Young Adults
954366|NCT02233036|Transfer
954367|NCT02233036|Chronic Disease
954368|NCT02232997|Chronic kidney disease
954369|NCT02232997|contrast induced nephropathy
954370|NCT02232997|diabetes mellitus
954371|NCT02232997|congestive heart failure
954372|NCT02232997|hypertension
954373|NCT02232984|Heart Failure
954374|NCT02232984|Cardiac Resynchronization Therapy
954375|NCT02232984|CRT-D
954376|NCT02232984|Quadripolar pacing
954377|NCT02232971|glucagon
954378|NCT02232971|insulin pump
954379|NCT02232971|artificial pancreas
954380|NCT02232971|closed-loop
954381|NCT02232958|Hyperbaric Oxygen
954382|NCT02232958|Small Vessel Disease of the Brain
954383|NCT02232958|Impaired Brain Circuit Connections
954384|NCT02232945|influenza A (H1N1,H3N2)
954385|NCT02232945|influenza B virus
954386|NCT02232932|Hilar cholangiocarcinoma
954387|NCT02232932|Liver transplantation
954388|NCT02232932|Radiochemotherapy
954389|NCT02232919|Deep Brain Stimulation
954390|NCT02232906|Chronic kidney disease
954391|NCT02232906|CKD
954392|NCT02232906|non-dialysis-dependent
954393|NCT02232906|ND-CKD
954394|NCT02232906|Erythropoiesis-stimulating agent
954395|NCT02232906|Ferric carboxymaltose
954396|NCT02232906|Iron
954402|NCT02232880|hypertension
954403|NCT02232880|inflammation
954404|NCT02232867|rehabilitation
954405|NCT02232867|stroke
954406|NCT02232867|walking
954407|NCT02232867|interlimb connections
954408|NCT02232854|Depression
954409|NCT02232841|Electrical impedance tomography
954410|NCT02232841|lung imaging
954411|NCT02232789|Mephedrone
954412|NCT02232789|3,4-methylenedioxymethamphetamine
954413|NCT02232789|Abuse liability
954414|NCT02232789|Human Pharmacology
954415|NCT02232776|Losartan
954416|NCT02232776|Ig A nephropathy
954417|NCT02232776|children
954418|NCT02232776|proteinuria
954419|NCT02232763|Losartan
954420|NCT02232763|children
954421|NCT02232763|proteinuria
954422|NCT02232737|Biomarkers of exposure
954423|NCT02232737|Compensatory smoking
954424|NCT02232737|Nicotine dependence
954425|NCT02232737|Reduced nicotine cigarettes
954426|NCT02232737|Tobacco withdrawal
954427|NCT02232737|Women
954428|NCT02232737|Health disparaties
954429|NCT02232737|Vulnerable populations
954430|NCT02232724|Prostate Cancer
954431|NCT02232724|Staging
954432|NCT02232724|PET/CT
954433|NCT02232711|multiplex, polymerase chain reaction, PCR, BioFire, respiratory infection, infectious disease, point of care, CLIA waived, rapid diagnostics
954434|NCT02232698|Sensing Technology
954435|NCT02232698|Type 1 Diabetes,
954436|NCT02232685|Prostate cancer
954437|NCT02232685|Staging
954438|NCT02232685|PET/CT
954439|NCT02232672|Prostate Cancer
954440|NCT02232672|Staging
954441|NCT02232672|PET/CT
954442|NCT02232659|SynCardia
954443|NCT02232659|Total Artificial Heart
954444|NCT02232659|Biventricular heart failure
954445|NCT02232659|Ineligible for cardiac transplant
954446|NCT02232568|Patient blood management
954447|NCT02232568|RBC transfusion
954448|NCT02232568|Restrictive transfusion strategy
954449|NCT02232529|modified release formulation
954450|NCT02232529|pharmacokinetics
954451|NCT02232490|AFP
954452|NCT02232490|alpha-fetoprotein
954453|NCT02232490|cancer vaccine
954454|NCT02232490|cirrhosis
954455|NCT02232490|hepatitis
954456|NCT02232490|HCC
954457|NCT02232490|hepatocellular carcinoma
954458|NCT02232490|immunotherapy
954459|NCT02232490|liver tumor
954460|NCT02232490|Cholangiocarcinoma
954461|NCT02232464|Adult ADHD
954462|NCT02232464|diffusion spectrum imaging
954463|NCT02232464|resting-state fMRI
954464|NCT02232464|frontostriatal circuitries
954465|NCT02232464|frontoparietal circuitries
954466|NCT02232464|executive function
954467|NCT02232451|loop
954468|NCT02232451|ERCP
954469|NCT02232451|cannulation
954470|NCT02232451|biliary
954471|NCT02232451|wire
954472|NCT02232438|Depression
954473|NCT02232438|Psychotherapy
954474|NCT02232438|Anxiety
954475|NCT02232438|Cancer
954476|NCT02232412|Anemia
954477|NCT02232412|NIRS
954478|NCT02232412|Near Infrared Spectroscopy
954479|NCT02232412|RBC transfusion
954480|NCT02232412|critical ill
954481|NCT02232412|regional cerebral oxygen saturation
954482|NCT02232412|tissue oxygenation
954483|NCT02232386|Chronic lymphocyte leukemia
954484|NCT02232386|Adults
954485|NCT02232386|Ibrutinib
954486|NCT02232373|FODMAPs
954487|NCT02232373|microbiota
954488|NCT02232373|oligofructose
954489|NCT02232373|IBS
954490|NCT02232373|Irritable bowel syndrome
954491|NCT02232360|Atherosclerotic plaque
954492|NCT02232360|Virtual histology intravascular ultrasound
954493|NCT02232360|Plaque composition
954494|NCT02232360|Rosuvastatin
954495|NCT02232360|Fenofibrate
954496|NCT02232360|Coronary artery disease
954497|NCT02232347|traumatic brain injury
954498|NCT02232347|ketamine
954499|NCT02232347|microdialysis
954500|NCT02232347|PtiO2
954501|NCT02232347|glutamate
954502|NCT02232334|Idiopathic Gastroparesis, Nausea, Vomiting, Abdominal Pain, Gastrectomy, Osteopathy, Gastroparesis Cardinal Symptom Index, GCSI
954503|NCT02232295|Upper extremity, motor imagery, mirror therapy
954504|NCT02232282|Painful Bladder Syndrome
954505|NCT02232282|Interstitial Cystitis
954506|NCT02232282|Suprapubic Pain
954507|NCT02232282|Urinary Urgency
954508|NCT02232269|Coffee
954509|NCT02232269|Grapefruit Juice
954510|NCT02232269|Felodipine
954511|NCT02232269|Calcium Channel Blocker
954512|NCT02232269|Hemodynamics
954513|NCT02232269|CYP3A4
954514|NCT02232256|Chronic non-cancer pain
954515|NCT02232256|Insomnia
954516|NCT02232256|California poppy
954517|NCT02232256|Eschscholzia californica
954518|NCT02232256|Pain
954519|NCT02232256|Sleep quality
954520|NCT02232243|Cancer
954521|NCT02232243|Surgery
954522|NCT02232243|Hydroxychloroquine
954523|NCT02232217|Children
954524|NCT02232217|Sleep
954525|NCT02232217|Obesity
954526|NCT02232204|insomnia
954527|NCT02232204|implantable cardioverter defibrillator
954528|NCT02232204|cardiac arrhythmia
954529|NCT02232204|cognitive behavioral treatment
954530|NCT02232178|unilateral inguinal hernioplasty
954531|NCT02232165|acute spinal cord injury
954532|NCT02232165|hemodynamic therapy
954533|NCT02232165|functional outcome
954534|NCT02232126|Hospital readmissions
954535|NCT02232126|Randomized controlled trial
954536|NCT02232126|Older adults
954537|NCT02232126|Care transitions
954538|NCT02232126|Social work
954539|NCT02232113|malnutrition, inflammation, and anemia (MIA) syndrome,
954540|NCT02232113|hemodialysis,
954541|NCT02232113|erythropoietin stimulating agent (ESA),
954542|NCT02232113|cost-effectiveness,
954543|NCT02232113|pharmacokinetics,
954544|NCT02232113|endothelial dysfunction
954545|NCT02232100|Attentional bias modification
954546|NCT02232100|Chronic pain
954547|NCT02232100|Visual-probe task
954548|NCT02232100|Internet-delivered therapy
954549|NCT02232087|long-acting beta agonist (LABA)
954550|NCT02232087|corticosteroid
954551|NCT02232087|pMDI
954552|NCT02232087|inhaler
954553|NCT02232074|Patient Navigation
954554|NCT02232074|Medical Legal Partnership
954555|NCT02232074|Healthcare Disparities
954556|NCT02232061|multiple sclerosis, fingolimod,
954557|NCT02232035|diazepam
954558|NCT02232035|active phase
954564|NCT02232009|Neonate
954565|NCT02232009|Infant
954566|NCT02231983|Clinical Characteristics
954567|NCT02231983|Genetic Profiles
954568|NCT02231970|Obesity
954569|NCT02231970|Endoscopic sleeve gastroplasty
954570|NCT02231970|Weight loss
954571|NCT02231892|Repetitive TMS (rTMS)
954572|NCT02231892|Parameter Development
954573|NCT02231892|Cognitive Tasks
954574|NCT02231892|MRI (Magnetic Resonance Imaging)
954575|NCT02231879|Infections
954576|NCT02231879|Hypogammaglobulinemia
954577|NCT02231879|CXCR4
954578|NCT02231879|Myelokathexis
954579|NCT02231879|Warts
954580|NCT02231866|Filovirus
954581|NCT02231866|Healthy
954582|NCT02231866|Ebola Hemorrhagic Fever
954583|NCT02231866|Immunity
954584|NCT02231866|Ebola Virus
954590|NCT02231840|Phenotypes
954591|NCT02231840|Alcohol Use
954592|NCT02231840|Alcohol
954593|NCT02231840|Alcohol Dependence
954594|NCT02231840|Genetics
954595|NCT02231827|subjects
954596|NCT02231814|Crohn's disease
954597|NCT02231814|Mild to moderate Crohn's Disease
954598|NCT02231814|Diet
954599|NCT02231814|Enteral Nutrition
954600|NCT02231801|Preterm
954601|NCT02231801|Kangaroo Care
954602|NCT02231801|Skin-to-Skin
954603|NCT02231801|Vital Sign
954604|NCT02231801|Heart Rate
954605|NCT02231801|Respiratory Rate
954606|NCT02231801|Oxygen Saturation
954607|NCT02231788|Telminuvo
954608|NCT02231788|Telmitrend
954609|NCT02231788|Hypertension
954610|NCT02231788|24hr ABPM
954611|NCT02231788|Telmisartan
954612|NCT02231788|S-amlodipine
954613|NCT02231775|Neoadjuvant
954614|NCT02231775|Dabrafenib
954615|NCT02231775|Tafinlar
954616|NCT02231775|GSK2118436
954617|NCT02231775|Trametinib
954618|NCT02231775|GSK1120212
954619|NCT02231775|Combination therapy
954620|NCT02231775|Surgery
954621|NCT02231775|Adjuvant therapy
954622|NCT02231775|Melanoma
954623|NCT02231736|Type 2 Diabetes
954624|NCT02231736|Chromosomal damage
954625|NCT02231736|Micronuclei
954626|NCT02231736|DNA damage
954627|NCT02231736|HbA1c
954628|NCT02231736|Comet Assay
954629|NCT02231736|Glycemic control
954630|NCT02231723|Digestive System Neoplasms
954631|NCT02231723|Endocrine Gland Neoplasms
954632|NCT02231723|Pancreatic neoplasms
954633|NCT02231723|Pancreatic cancer, adult
954634|NCT02231723|Pancreatic cancer
954635|NCT02231723|Pancreas cancer
954636|NCT02231723|Pancreatic diseases
954637|NCT02231723|Adenoma, Islet Cell
954638|NCT02231723|Carcinoma, Islet Cell
954639|NCT02231723|Carcinoma, Pancreatic Ductal
954640|NCT02231723|Gemcitabine
954641|NCT02231723|Gemzar
954642|NCT02231723|Nab-paclitaxel
954643|NCT02231723|Paclitaxel
954644|NCT02231723|Abraxane
954645|NCT02231723|Oxaliplatin
954646|NCT02231723|Leucovorin
954647|NCT02231723|Irinotecan
954648|NCT02231723|Fluorouracil
954649|NCT02231723|5-FU
954650|NCT02231723|MM-398
954651|NCT02231710|Severe Combined Immune Deficiency
954652|NCT02231710|Congenital T-cell Defect
954653|NCT02231710|Congenital T-cell Deficiency
954654|NCT02231710|Chronic Granulomatous Disease
954655|NCT02231710|Shwachman Diamond Syndrome
954656|NCT02231710|Diamond Blackfan Anemia
954657|NCT02231710|Dyskeratosis Congenita
954658|NCT02231710|Fanconi Anemia
954659|NCT02231710|Sickle Cell Disease
954660|NCT02231710|Thalassemia
954661|NCT02231710|Mucopolysaccharidosis
954662|NCT02231710|Sphingolipidoses
954663|NCT02231697|XLMTM
954664|NCT02231645|Parkinson's disease
954665|NCT02231645|Deep brain stimulation
954666|NCT02231645|Subthalamic nucleus
954667|NCT02231645|decision-making
954668|NCT02231645|cognition
954669|NCT02231645|behavior
954670|NCT02231632|Poliomyelitis
954671|NCT02231632|Vaccine
954672|NCT02231632|Safety
954673|NCT02231632|efficacy
954674|NCT02231619|feasibility
954675|NCT02231619|self assessment
954676|NCT02231619|medical abortion
954677|NCT02231619|low sensitivity urine pregnancy test
954678|NCT02231619|South Africa
954679|NCT02231606|Myopia Prevalence
954680|NCT02231606|Proportion of Purchase of free Spectacles
954681|NCT02231606|Proportion of Purchase of update Spectacles
954682|NCT02231606|Proportion of Wearing Spectacles
954683|NCT02231580|Neurodegenerative genetic disorder
954684|NCT02231567|hip replacement
954685|NCT02231567|neurocognitive rehabilitation
954686|NCT02231567|WOMAC questionnaire
954687|NCT02231554|low back pain
954688|NCT02231554|quality of life
954689|NCT02231554|rehabilitation
954690|NCT02231554|exercise
954691|NCT02231541|Fibromylgia
954692|NCT02231541|Magnetic Fields
954693|NCT02231541|Pain
954694|NCT02231541|Visual Analogue scale
954695|NCT02231528|anesthesia
954696|NCT02231528|central venous catheter
954697|NCT02231528|jugular vein
954698|NCT02231528|ultrasound guidance
954699|NCT02231502|Bioavailability in healthy individuals
954700|NCT02231489|Healthy
954701|NCT02231489|JNJ-42756493
954702|NCT02231489|JNJ-61818549
954703|NCT02231463|ultrasound
954704|NCT02231450|AE58054
954705|NCT02231450|Hepatic impairment
954706|NCT02231411|Delayed Cord Clamping
954707|NCT02231411|Pulmonary Ventilation
954708|NCT02231398|Cardiovascular disease
954709|NCT02231398|Pregnant women
954710|NCT02231398|Nulliparity
954711|NCT02231398|Pregnancy outcomes
954712|NCT02231398|Pregnancy complications
954713|NCT02231398|Sleep disordered breathing
954714|NCT02231385|Colorectal cancer
954715|NCT02231385|Serrated adenomas
954716|NCT02231385|Screening
954717|NCT02231385|Adenoma detection rate
954718|NCT02231385|Polypectomy
954719|NCT02231307|sublingual immunotherapy
954720|NCT02231307|birch pollen
954721|NCT02231307|allergic rhinitis / rhinoconjunctivitis
954722|NCT02231307|efficacy
954723|NCT02231281|HIV Infections
954724|NCT02231281|Acquired Immunodeficiency Syndrome
954725|NCT02231281|Immunologic Deficiency Syndromes
954726|NCT02231281|Immune System Diseases
954727|NCT02231281|Lentivirus Infections
954728|NCT02231281|Retroviridae Infections
954729|NCT02231281|Virus Diseases
954730|NCT02231281|RNA Virus Infections
954731|NCT02231281|Sexually Transmitted Diseases, Viral
954732|NCT02231281|Slow Virus Diseases
954733|NCT02231281|Therapeutic Uses
954734|NCT02231281|Pharmacologic Actions
954735|NCT02231281|Antiretroviral therapy
954736|NCT02231281|Early therapy
954737|NCT02231242|brain
954738|NCT02231242|children
954739|NCT02231242|cerebral palsy
954740|NCT02231242|bone marrow stem cells
954741|NCT02231242|intrathecal autologous total nucleated cells
954742|NCT02231242|quadriparesis
954743|NCT02231229|Pulmonary tuberculosis
954744|NCT02231229|Mycobacterium tuberculosis (MTB)
954745|NCT02231229|Drug Resistance (DR)
954746|NCT02231229|Isoniazid (INH or H)
954747|NCT02231229|Rifampicin (RIF or RMP or R)
954748|NCT02231229|Pyrazinamide (PZA or Z)
954749|NCT02231229|Ethambutol (EMB or E)
954750|NCT02231229|Fast-TB
954751|NCT02231229|Isoniazid, Rifampicin, Pyrazinamide (HRZ)
954752|NCT02231229|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
954753|NCT02231229|drug susceptibility testing (DST)
954754|NCT02231229|Acid-Fast Bacilli (AFB+)
954755|NCT02231229|Polymerase Chain Reaction (PCR)
954756|NCT02231216|rhinoseptoplasty
954757|NCT02231203|fish oil
954758|NCT02231203|omega-3 fatty acids
954759|NCT02231203|postoperative inflammatory response
954760|NCT02231203|erythrocyte function
954761|NCT02231190|muscle soreness
954762|NCT02231190|Muscle damage and recovery
954763|NCT02231190|muscle function
954764|NCT02231190|eccentric exercise
954765|NCT02231151|CPR quality assessment
954766|NCT02231151|Visual CPR assessment
954767|NCT02231151|Position relative to patient
954768|NCT02231138|Abelmoschus manihot
954769|NCT02231138|Chronic Kidney Disease
954770|NCT02231138|proteinuria
954771|NCT02231138|efficacy
954772|NCT02231138|safety
954773|NCT02231125|Abelmoschus manihot
954774|NCT02231125|IgA Nephropathy
954775|NCT02231125|proteinuria
954776|NCT02231125|efficacy
954777|NCT02231125|safety
954778|NCT02231112|Korean
954779|NCT02231112|Left side
954780|NCT02231099|recurrent pelvic organ prolapse
954781|NCT02231099|mesh
954782|NCT02231086|Chemotherapy, Adjuvant
954783|NCT02231086|Laparoscopy
954784|NCT02231086|Peritoneal Lavage
954785|NCT02231086|HIPEC
954786|NCT02231073|Freezing of gait
954787|NCT02231073|Idiopathic Parkinson's disease
954788|NCT02231073|Exercise
954789|NCT02231073|parkinsonism
954790|NCT02231060|Outcome Prediction
954791|NCT02231060|Anoxic-Ischemic Encephalopathy
954792|NCT02231060|Coma
954793|NCT02231060|Vegetative State
954794|NCT02231060|Minimally Conscious State
954795|NCT02231060|Chronic Disorders of Consciousness
954796|NCT02231047|Diarrhea
954797|NCT02231047|Pneumonia
954798|NCT02231047|Child, Preschool
954799|NCT02231047|Infant
954800|NCT02231047|Dietary Supplements
954801|NCT02231047|Colostrums
954802|NCT02231047|Developing Countries
954803|NCT02231021|Diabetes Mellitus, Type 2
954804|NCT02231021|alogliptin
954805|NCT02231021|pioglitazone
954806|NCT02231021|DPP4 inhibitor
954807|NCT02231021|thiazolidinedione
954808|NCT02231008|SMS
954809|NCT02230969|peginterferon
954810|NCT02230969|relapsing
954811|NCT02230969|pegylated
954812|NCT02230969|Subcutaneous
954813|NCT02230969|Injectable
954814|NCT02230969|Multiple Sclerosis
954815|NCT02230943|rheumatoid
954816|NCT02230943|arthritis
954817|NCT02230943|osteoarthritis
954818|NCT02230943|gout
954819|NCT02230930|Parkinson's disease
954820|NCT02230930|Apomorphine
954821|NCT02230930|Infusion
954822|NCT02230930|Skin reactions
954823|NCT02230930|Subcutaneous nodules
954824|NCT02230930|Hydrocortisone
954825|NCT02230930|Massage
954826|NCT02230930|Dilution
954827|NCT02230904|Rotigotine patch
954828|NCT02230904|Neupro
954829|NCT02230904|Parkinson's Disease
954830|NCT02230891|heart failure
954831|NCT02230891|biomarkers
954832|NCT02230891|troponin
954833|NCT02230891|BNP
954834|NCT02230891|carvedilol
954835|NCT02230891|spironolactone
954836|NCT02230891|prevention
954837|NCT02230878|JNJ-42847922
954838|NCT02230878|Phase 1
954839|NCT02230878|Healthy
954840|NCT02230878|Placebo
954841|NCT02230865|Funnel chest (Pectus excavatum)
954842|NCT02230852|Telemedicine
954843|NCT02230852|Prehospital
954844|NCT02230852|Emergency Medicine
954845|NCT02230852|Stroke
954846|NCT02230839|insulin resistance
954847|NCT02230839|muscle
954848|NCT02230839|health education
954849|NCT02230839|exercise
954850|NCT02230826|Arthroplasty
954851|NCT02230826|Hip Replacement
954852|NCT02230826|Acetabular cup
954853|NCT02230826|Femoral stem
954854|NCT02230813|Cohort Study,
954855|NCT02230813|Cellulitis,
954856|NCT02230813|Skin and Soft Tissue Infection,
954857|NCT02230813|Emergency Department,
954858|NCT02230813|Clinical Prediction Rule
954859|NCT02230787|Pilot study
954860|NCT02230787|randomized clinical trial
954861|NCT02230787|periodontal disease
954862|NCT02230787|gingival recession
954863|NCT02230787|Emdogain
954864|NCT02230787|connective tissue
954865|NCT02230787|wound healing
954866|NCT02230787|inflammation
954867|NCT02230774|hydration
954868|NCT02230774|cognitive function
954869|NCT02230774|doctors
954870|NCT02230774|nurses
954871|NCT02230774|Nurses and Doctors oncall
954872|NCT02230761|steatoblepharon
954873|NCT02230761|blepharoptosis
954874|NCT02230761|dermatochalasis
954875|NCT02230761|blepharoplasty
954876|NCT02230761|periorbital
954877|NCT02230761|orbital
954878|NCT02230761|eyelid
954879|NCT02230761|eyebags
954880|NCT02230761|eye bags
954881|NCT02230748|LAA
954882|NCT02230748|LAA-Occluder
954883|NCT02230748|Atrial Fibrillation
954884|NCT02230748|AF
954885|NCT02230735|Robotic
954886|NCT02230735|Hysterectomy
954887|NCT02230735|Uterosacral
954888|NCT02230735|Bupivacaine
954889|NCT02230735|Robotic hysterectomy pain control
954890|NCT02230722|opioids
954891|NCT02230722|chronic pain
954892|NCT02230722|collaborative care
954893|NCT02230709|Neck pain
954894|NCT02230709|Myofascial pain syndrome
954895|NCT02230709|Soreness
954896|NCT02230683|Liver Cirrhosis
954897|NCT02230683|Hepatic Cirrhosis
954898|NCT02230683|Portal Hypertension
954899|NCT02230670|Liver Cirrhosis
954900|NCT02230670|Hepatic Cirrhosis
954901|NCT02230605|Delirium
954902|NCT02230605|Post Operative Delirium
954903|NCT02230605|PD
954904|NCT02230605|POD
954905|NCT02230605|Anesthesia
954906|NCT02230605|Anesthesiology
954907|NCT02230605|Post Operative Recovery
954908|NCT02230605|Post Anesthesia Care Unit
954909|NCT02230605|PACU
954910|NCT02230605|Cognition
954911|NCT02230605|Cognitive Impairment
954912|NCT02230605|Memory
954913|NCT02230605|Thinking
954914|NCT02230605|Confusion Assessment Method
954915|NCT02230605|CAM
954916|NCT02230605|Neurobics
954917|NCT02230605|Neuroplasticity
954918|NCT02230605|Lumosity
954919|NCT02230605|Brain Games
954920|NCT02230605|Cognitive Exercise
954921|NCT02230605|Cognitive Training
954922|NCT02230605|Perioperative Cognitive Protection
954923|NCT02230605|Cognitive Reserve
954924|NCT02230605|Neurobics Trial
954925|NCT02230605|Surgery
954926|NCT02230605|Elderly Patients
954927|NCT02230592|PET
954928|NCT02230592|Metabolic Glutamate Receptors
954929|NCT02230592|Brain Imaging
954930|NCT02230579|safety
954931|NCT02230579|tolerability
954932|NCT02230579|malaria
954933|NCT02230566|MPS 7
954934|NCT02230566|Sly Syndrome
954935|NCT02230566|Mucopolysaccharidosis
954936|NCT02230566|MPS VII
954937|NCT02230566|Enzyme Replacement Therapy
954938|NCT02230566|Mucopolysaccharidosis type 7
954939|NCT02230566|rare disease
954940|NCT02230566|lysosomal storage disease
954941|NCT02230566|metabolic disorder
954942|NCT02230514|Nonunion fracture
954943|NCT02230514|Long bones
954944|NCT02230514|Pseudoarthrosis
954945|NCT02230514|Cell therapy
954946|NCT02230514|Tissue engineering
954947|NCT02230514|Mesenchymal stromal cells
954948|NCT02230488|Inpatient Diabetes Management
954949|NCT02230488|Prevent <31 day readmission in patients with Diabetes
954950|NCT02230488|CDEs role in transition of care of inpatients with diabetes
954951|NCT02230475|Allergic Rhinitis
954952|NCT02230475|NMR
954953|NCT02230462|patient satisfaction
954954|NCT02230462|Mohs surgery
954955|NCT02230436|Pancreatectomy
954956|NCT02230436|Time of drain removal
954957|NCT02230423|Functional nasal surgery
954958|NCT02230423|Empty Nose Syndrome (ENS)
954959|NCT02230410|Barrett's
954960|NCT02230410|high grade dysplasia
954961|NCT02230410|ablation
954962|NCT02230410|cyrotherapy
954963|NCT02230397|skin aging
954964|NCT02230397|anti-aging cream
954965|NCT02230397|wrinkles
954966|NCT02230384|Attempt at Smoking Cessation
954967|NCT02230384|Schizophrenia or Schizoaffective disorder
954968|NCT02230384|Novel nicotinergic drug
954969|NCT02230371|Myofascial pain
954970|NCT02230371|TMD
954971|NCT02230371|5-HT3
954972|NCT02230371|Granisetron
954973|NCT02230371|Placebo-controlled
954974|NCT02230371|Patients
954975|NCT02230371|Randomized
954976|NCT02230371|Double-blind
954977|NCT02230358|carotid endarterectomy
954978|NCT02230358|cardiac output
954979|NCT02230358|trans-cranial Doppler
954980|NCT02230358|CEA
954981|NCT02230358|regional anesthesia
954982|NCT02230358|general anesthesia
954983|NCT02230345|Probiotic
954984|NCT02230345|Yoghourt
954985|NCT02230345|Inflammation
954986|NCT02230345|Metabolomics
954987|NCT02230319|Cryotherapy
954988|NCT02230319|Cold therapy
954989|NCT02230319|Peripheral Neuropathy
954990|NCT02230319|Paclitaxel
954991|NCT02230319|Breast Cancer
954992|NCT02230319|Symptom management
954993|NCT02230319|Prevention
954994|NCT02230293|ambulatory care,
954995|NCT02230293|hypertension,
954996|NCT02230293|health personnel,
954997|NCT02230293|clinical trial
954998|NCT02230280|Mobile health technology
954999|NCT02230280|Multiple chronic conditions
955000|NCT02230280|Older adults
955001|NCT02230280|Home and community care
955002|NCT02230280|Effectiveness
955003|NCT02230280|Cost analysis
955004|NCT02230280|Interprofessional Stroke Rehabilitation
955005|NCT02230267|boot camp
955006|NCT02230267|exercise
955007|NCT02230267|balance training
955008|NCT02230267|fall prevention
955009|NCT02230267|falling
955010|NCT02230267|strength training
955011|NCT02230254|Coronary Artery Disease
955012|NCT02230241|Dyslipidaemia
955013|NCT02230241|LDL-C goals
955014|NCT02230241|Guidelines
955015|NCT02230215|Total Knee Replacement
955016|NCT02230215|Visionaire
955017|NCT02230189|Asthma
955018|NCT02230189|Allergen challenge
955019|NCT02230163|Chikungunya virus
955020|NCT02230163|Human anti-CHIKV hyperimmune intravenous immunoglobulins
955021|NCT02230163|Neonates
955022|NCT02230150|Adhesion, Knowledge, Nursing
955023|NCT02230137|adolescents
955024|NCT02230137|type 1 diabetes
955025|NCT02230137|poorly controlled
955026|NCT02230137|SMS
955027|NCT02230137|Improve glycaemic control
955028|NCT02230137|HbA1c reduction
955029|NCT02230137|poorly controlled type 1 diabetic adolescents
955030|NCT02230124|Hydrocephalus
955031|NCT02230111|Women
955032|NCT02230111|Caloric restriction
955033|NCT02230111|Cognitive dietary restraint
955034|NCT02230111|Eating behaviours
955035|NCT02230111|Food habits
955036|NCT02230111|Appetite sensations
955037|NCT02230111|Stress
955038|NCT02230111|Weight management
955039|NCT02230098|remote ischemic conditioning
955040|NCT02230098|ischemic heart disease
955041|NCT02230059|Prostatic Neoplasms
955042|NCT02230059|observational Study
955043|NCT02230059|Metastatic castration-resistant prostate cancer
955044|NCT02230046|Healthy,
955045|NCT02230046|Abiraterone Acetate,
955046|NCT02230046|Bioequivalence.
955047|NCT02230033|JNJ-56021927
955048|NCT02230033|Itraconazole
955049|NCT02230033|Gemfibrozil
955050|NCT02229994|Dyspnea
955051|NCT02229994|Self-administered questionnaire
955052|NCT02229994|Chronic respiratory disease
955053|NCT02229994|COPD
955054|NCT02229994|Diffuse interstitial lung diseases
955055|NCT02229994|Pulmonary arterial hypertension
955056|NCT02229994|Cystic fibrosis
955057|NCT02229981|Lymphoma
955058|NCT02229981|B-cell Lymphomas
955059|NCT02229981|Diffuse Large B-cell Lymphoma
955060|NCT02229981|Lymphosarcoma
955061|NCT02229981|Kaposi's Sarcoma-associated Herpesvirus
955062|NCT02229981|KHSV
955063|NCT02229981|Human Immunodeficiency Virus
955064|NCT02229981|HIV
955065|NCT02229981|Epstein-Barr Virus
955066|NCT02229981|EBV
955067|NCT02229981|Kaposi sarcoma
955068|NCT02229968|craniosynostosis
955069|NCT02229968|craniofacial
955070|NCT02229968|amicar
955071|NCT02229968|epsilon aminocaproic acid
955072|NCT02229968|ε-aminocaproic acid
955073|NCT02229955|Dry Eye Syndromes
955074|NCT02229942|Chronic Fatigue Syndrome (CFS)
955075|NCT02229942|Myalgic Encephalitis (ME)
955076|NCT02229942|Rituximab
955077|NCT02229942|B-lymphocyte depletion
955078|NCT02229942|B-cell depletion
955079|NCT02229929|Pruritus
955080|NCT02229929|uremic pruritus
955081|NCT02229929|kappa opioid
955082|NCT02229929|CR845
955083|NCT02229916|Testicular Neoplasms
955084|NCT02229916|Testicular Cancer
955085|NCT02229916|Cohort Study
955086|NCT02229903|OCD
955087|NCT02229864|Absorb™ BVS
955088|NCT02229864|Angioplasty
955089|NCT02229864|Bioabsorbable
955090|NCT02229864|BVS
955091|NCT02229864|Coronary Artery Disease
955092|NCT02229864|Coronary Artery Endothelial Responsiveness
955093|NCT02229864|Coronary artery restenosis
955094|NCT02229864|Coronary artery stenosis
955095|NCT02229864|Coronary scaffold
955096|NCT02229864|Coronary Stent
955097|NCT02229864|Drug eluting stents
955098|NCT02229864|Everolimus
955099|NCT02229864|Myocardial ischemia
955100|NCT02229864|Stent thrombosis
955101|NCT02229864|Stents
955102|NCT02229708|Pregnancy
955103|NCT02229708|Weight control
955104|NCT02229708|Behavioral
955105|NCT02229708|technology-based intervention
955106|NCT02229695|Trauma
955107|NCT02229695|Sepsis
955108|NCT02229695|Temporary abdominal closure
955109|NCT02229695|Bogota bag
955110|NCT02229695|Vacuum assisted closure
955111|NCT02229682|extranodal NK/T-cell lymphoma,nasal-type,
955112|NCT02229682|radiotherapy,
955113|NCT02229682|intensity-modulated radiation treatment,
955114|NCT02229682|asparaginase-based chemotherapy,
955115|NCT02229682|loco-regional control,
955116|NCT02229682|survival
955117|NCT02229656|olaparib
955118|NCT02229656|radiotherapy
955119|NCT02229656|Laryngeal SCC
955120|NCT02229656|oropharyngeal SCC
955121|NCT02229643|Traumatic brain injury
955122|NCT02229643|Neuroglobin
955123|NCT02229643|Nogo-A
955124|NCT02229643|Prognosis
955125|NCT02229630|intra-uterine growth restriction
955126|NCT02229630|MRI
955127|NCT02229630|apparent diffusion coefficient
955128|NCT02229617|Intramuscular testosterone
955129|NCT02229617|Subcutaneous testosterone
955130|NCT02229604|electroacupuncture
955131|NCT02229604|diminished ovarian reserve
955132|NCT02229604|cohort study
955133|NCT02229578|Burn pain
955134|NCT02229578|lidocaine
955135|NCT02229578|donor site pain
955136|NCT02229578|Narcotic use
955137|NCT02229565|prostate cancer
955138|NCT02229565|prostate biopsy
955139|NCT02229565|prostatectomy
955140|NCT02229526|Fish oil supplementation
955141|NCT02229526|RCT
955142|NCT02229526|High risk pregnancies
955143|NCT02229526|Twin pregnancy
955144|NCT02229526|Preterm birth
955145|NCT02229526|Intrauterine growth retardation
955146|NCT02229526|Pregnancy induced hypertension
955147|NCT02229513|postpartum hemorrhage
955148|NCT02229513|uterine atony
955149|NCT02229513|cesarean section
955150|NCT02229513|cesarean hysterectomy
955151|NCT02229513|acute blood loss anemia
955152|NCT02229513|uterotonics
955153|NCT02229513|obstetric hemorrhage
955154|NCT02229513|severe hemorrhage
955155|NCT02229513|blood transfusion
955156|NCT02229513|obstetric emergencies
955157|NCT02229513|obstetrics
955158|NCT02229513|massive hemorrhage
955159|NCT02229513|hemorrhage
955160|NCT02229513|uterine cooling
955161|NCT02229500|Propionate
955162|NCT02229500|Microbiome
955163|NCT02229500|Dietary Fibre
955164|NCT02229500|Short chain fatty acids
955165|NCT02229487|Prediabetes
955166|NCT02229487|Short sleepers
955167|NCT02229487|GLP-1
955168|NCT02229474|Dementia
955169|NCT02229474|Cognitive Stimulation Therapy
955170|NCT02229474|Quality of life
955171|NCT02229474|Cognitive impairment
955172|NCT02229474|Africa
955173|NCT02229474|Tanzania
955174|NCT02229474|Nigeria
955175|NCT02229474|Low- and Middle-income countries
955176|NCT02229474|Non-pharmacological intervention
955177|NCT02229474|Task-shifting
955178|NCT02229474|Cognitive screening
955179|NCT02229448|Immunoglobulin G
955180|NCT02229448|focus
955181|NCT02229448|study
955182|NCT02229448|detect
955183|NCT02229448|patients
955184|NCT02229435|Chronic kidney disease
955185|NCT02229435|Urological care
955186|NCT02229435|Nephrological care
955187|NCT02229409|adults
955188|NCT02229396|Diabetes Mellitus
955189|NCT02229396|Exenatide
955190|NCT02229396|Dapagliflozin
955191|NCT02229396|Diabetes medication
955192|NCT02229396|Treatment efficacy
955193|NCT02229396|Placebo
955194|NCT02229396|Metabolism
955195|NCT02229396|Cardiovascular metabolic
955196|NCT02229383|Diabetes Mellitus
955197|NCT02229383|Exenatide
955198|NCT02229383|Diabetes drug
955199|NCT02229383|Treatment efficacy
955200|NCT02229383|Placebo
955201|NCT02229383|Metabolism
955202|NCT02229383|Cardiovascilar metabolic
955203|NCT02229370|extracranial
955204|NCT02229370|carotid
955205|NCT02229370|artery
955206|NCT02229370|aneurysm
955207|NCT02229370|registry
955208|NCT02229370|CAR
955209|NCT02229357|H5N2 Vaccine
955210|NCT02229344|colitis, ulcerative
955211|NCT02229344|MOSAIK
955212|NCT02229344|REMICADE
955213|NCT02229344|Infliximab
955214|NCT02229331|haemophilia
955215|NCT02229331|arthropathy
955216|NCT02229331|pediatrics
955217|NCT02229331|ankle
955218|NCT02229331|biomechanics
955219|NCT02229305|Anxiety
955220|NCT02229305|Trauma
955221|NCT02229305|Depression
955222|NCT02229305|Problem Behavior
955223|NCT02229305|evidence-based treatments
955224|NCT02229279|Surgical Procedures, Operative
955225|NCT02229266|AML
955226|NCT02229266|high-risk AML
955227|NCT02229266|acute myeloid leukemia
955228|NCT02229266|NK cells
955229|NCT02229266|haploidentical natural killer cells
955230|NCT02229266|immunotherapy
955231|NCT02229240|Albiglutide
955232|NCT02229240|Add-on to basal-bolus insulin therapy
955233|NCT02229240|Glucagon-like peptide-1 receptor agonist
955234|NCT02229240|Type 2 diabetes mellitus
955235|NCT02229227|switch study
955236|NCT02229227|albiglutide
955237|NCT02229227|glucagon-like peptide-1 receptor agonist
955238|NCT02229227|Type 2 diabetes mellitus
955239|NCT02229227|basal-bolus insulin therapy
955240|NCT02229214|Renal function
955241|NCT02229214|Glomerular Filtration Rate
955242|NCT02229214|Kidney function
955243|NCT02229214|Qsymia
955244|NCT02229214|Iohexol
955245|NCT02229214|Serum Creatinine
955246|NCT02229214|Creatinine clearance
955247|NCT02229214|Renal Clearance
955248|NCT02229214|VI-0521
955249|NCT02229214|Healthy volunteers
955250|NCT02229201|propofol
955251|NCT02229201|sevoflurane
955252|NCT02229201|Interleukin 6
955253|NCT02229201|Interleukin 10
955254|NCT02229188|Depression; mood; cognitive training
955255|NCT02229175|Diabetic Macular Edema
955256|NCT02229175|Diabetic Retinopathy
955257|NCT02229175|Type 1 Diabetes
955258|NCT02229175|Type 2 Diabetes
955259|NCT02229175|Macular Edema
955260|NCT02229175|bevacizumab
955261|NCT02229175|intravitreal injection
955262|NCT02229175|Avastin
955263|NCT02229175|PASCAL Endpoint Management (EpM) system
955264|NCT02229175|Subthreshold focal laser treatments
955265|NCT02229162|umbilical cord
955266|NCT02229162|cesarean section
955267|NCT02229162|Blood Loss, Surgical
955268|NCT02229149|breast cancer
955269|NCT02229149|metastatic breast cancer
955270|NCT02229149|HER2+ breast cancer
955271|NCT02229136|Mouth sores from chemotherapy
955272|NCT02229136|mouth sores
955273|NCT02229136|hormone receptor-positive metastatic breast cancer
955274|NCT02229136|metastatic breast cancer
955275|NCT02229123|seizures
955276|NCT02229123|neonates
955277|NCT02229123|anticonvulsants treatment
955278|NCT02229123|levetiracetam
955279|NCT02229123|hypoxic-ischemic encephalopathy
955280|NCT02229123|electroencephalography
955281|NCT02229110|type 2 diabetes mellitus
955282|NCT02229110|e-Health
955283|NCT02229110|allocation of care
955284|NCT02229110|clinical inertia
955285|NCT02229110|quality of care
955286|NCT02229110|patient satisfaction
955287|NCT02229097|type 1 diabetes
955288|NCT02229071|Donafenib
955289|NCT02229071|HCC
955290|NCT02229071|Advanced
955291|NCT02229071|inoperable
955292|NCT02229071|Phase 1B
955293|NCT02229058|Gastric Cancer
955294|NCT02229058|Albumin Bound Paclitaxel
955295|NCT02229058|S-1
955296|NCT02229058|First Line
955297|NCT02229045|gastric caner
955298|NCT02229045|Albumin Bound Paclitaxel
955299|NCT02229045|5-FU/CF
955300|NCT02229045|taxanes naive
955301|NCT02229032|Dravet Syndrome
955302|NCT02229032|cannabidiol therapy
955303|NCT02229032|Charlotte's Web
955304|NCT02229019|Volunteers
955305|NCT02229019|Mealtime assistance
955306|NCT02229019|Older adults
955307|NCT02229019|Nutrition
955308|NCT02229019|Nursing
955309|NCT02229006|Aortic aneurysm, abdominal
955310|NCT02229006|Sodium Fluoride
955311|NCT02229006|Positron Emission Tomography
955312|NCT02228980|Influenza
955313|NCT02228980|Trivalent influenza vaccine
955314|NCT02228980|Sanofi Pasteur Shenzhen trivalent influenza vaccine
955315|NCT02228967|Alcohol Use
955316|NCT02228967|SBIRT
955317|NCT02228967|Military
955318|NCT02228967|Health Behavior
955319|NCT02228967|Emergency Room
955320|NCT02228967|Health Promotion
955321|NCT02228967|Formative Research
955322|NCT02228967|Randomized Trial
955323|NCT02228954|Clear-cell metastatic renal cell carcinoma
955324|NCT02228954|Positron-Emission Tomography
955325|NCT02228928|Peripheral Nerve Injury
955326|NCT02228928|Postherpetic Neuralgia
955327|NCT02228889|Hernia
955328|NCT02228889|Abdominal wall reconstruction
955329|NCT02228889|Abdominal wall defect
955330|NCT02228889|Porcine mesh
955331|NCT02228889|Component separation
955332|NCT02228889|Abdominal wall tumor
955333|NCT02228889|Desmoid
955334|NCT02228863|Stroke
955335|NCT02228863|Spasticity
955336|NCT02228850|Secondary Raynaud's Phenomenon
955337|NCT02228850|Secondary Raynaud's Disease
955338|NCT02228850|Scleroderma
955339|NCT02228850|Raynaud's Disease secondary to systemic sclerosis
955340|NCT02228850|CREST
955341|NCT02228850|Apricus Biosciences
955342|NCT02228850|laser doppler
955343|NCT02228850|thermography
955344|NCT02228824|Smoking
955345|NCT02228824|Non-daily smokers
955346|NCT02228824|Ecological Momentary Assessment
955347|NCT02228824|Biomarkers
955348|NCT02228798|anticoagulant
955349|NCT02228798|atrial fibrillation
955350|NCT02228798|surgery
955351|NCT02228798|oral anticoagulant
955352|NCT02228798|discontinue
955353|NCT02228798|DOAC
955354|NCT02228798|NOAC
955355|NCT02228798|blood thinner
955356|NCT02228798|interruption
955357|NCT02228772|Acute lymphoblastic Leukemia
955358|NCT02228772|Lymphoblastic lymphoma
955359|NCT02228772|B-cell Adult Acute Lymphoblastic Leukemia
955360|NCT02228772|T-cell Adult Acute Lymphoblastic Leukemia
955361|NCT02228759|Ambulatory home regional
955362|NCT02228759|adductor canal block
955363|NCT02228759|Postoperative pain
955364|NCT02228759|total knee arthroplasty
955365|NCT02228759|Home regional
955366|NCT02228759|Fast track arthroplasty
955367|NCT02228694|ADC
955368|NCT02228694|Pre installation
955369|NCT02228694|Post installation
955370|NCT02228694|Safety
955371|NCT02228694|Time
955372|NCT02228668|AVANT
955373|NCT02228668|GERCOR
955374|NCT02228668|Follow up
955375|NCT02228668|Colon cancer
955376|NCT02228668|Bevacizumab
955377|NCT02228668|Overall survival
955378|NCT02228655|Chronic Kidney Disease
955379|NCT02228655|CKD
955380|NCT02228655|Anemia of Chronic Illness
955381|NCT02228642|Type 1 diabetes
955382|NCT02228642|Type 2 diabetes
955383|NCT02228642|Hypoglycemia
955384|NCT02228642|Cognition disorders
955385|NCT02228642|Inpatient
955386|NCT02228629|Diabetes
955387|NCT02228629|Foot complications
955388|NCT02228629|plantar keratoma
955389|NCT02228629|plantar pressure
955390|NCT02228616|Constipation
955391|NCT02228616|Chronic constipation
955392|NCT02228616|Prucalopride
955393|NCT02228616|Women
955394|NCT02228603|exercise therapy
955395|NCT02228603|rehabilitation
955396|NCT02228590|Parkinson's Disease
955520|NCT02228083|procedure
955397|NCT02228551|Augmented renal clearance
955398|NCT02228551|non-critically ill
955399|NCT02228551|surgery
955400|NCT02228551|prevalence
955401|NCT02228551|risk factors
955402|NCT02228538|total knee arthroplasty
955403|NCT02228538|osteoarthritis
955404|NCT02228525|Selinexor (KPT-330)
955405|NCT02228525|Selective Inhibitor of Nuclear Export (SINE)
955406|NCT02228525|14-005
955407|NCT02228512|HHV8
955408|NCT02228512|PEL
955409|NCT02228512|Immune Modulation
955410|NCT02228512|CC-4047
955411|NCT02228512|IMiD
955412|NCT02228499|asthma
955413|NCT02228499|academics
955414|NCT02228499|GPA
955415|NCT02228499|attendance
955416|NCT02228447|Adolescent
955417|NCT02228447|Randomized controlled trial
955418|NCT02228447|Eating behavior
955419|NCT02228447|Physical Activity
955420|NCT02228447|Sedentary lifestyle
955421|NCT02228434|Childhood obesity, intervention, effectiveness, comparison
955422|NCT02228408|hemodialysis
955423|NCT02228408|ESRD
955424|NCT02228408|Cardiovascular Disease
955425|NCT02228408|Isosorbide Dinitrate
955426|NCT02228408|Hydralazine
955427|NCT02228395|Single ascending doses
955428|NCT02228395|pharmacokinetics
955429|NCT02228395|safety
955430|NCT02228395|tolerability
955431|NCT02228395|healthy volunteers
955432|NCT02228395|cognitive impairment associated with schizophrenia (CIAS)
955433|NCT02228382|Bosutinib
955434|NCT02228382|Chronic Myeloid Leukemia
955435|NCT02228382|CML
955436|NCT02228382|Leukemia
955437|NCT02228382|Myelogenous
955438|NCT02228382|Chronic
955439|NCT02228382|BC-ABL Positive
955440|NCT02228369|Non Small Cell Lung Cancer, EGFR, Tyrosine kinase inhibitor,EGFR mutation positive, Brain Metastasis, Leptomeningeal Metastasis
955441|NCT02228356|Neoplasm Metastasis
955442|NCT02228356|oligometastatic cancer
955443|NCT02228356|Stereotactic Body Radiation Therapy
955444|NCT02228356|SBRT
955445|NCT02228356|Real-time Tumor Tracking (RTTT)
955446|NCT02228356|ITV
955447|NCT02228356|Internal Target Volume
955448|NCT02228356|Respiratory Motion Management
955449|NCT02228356|Image-guided Radiotherapy
955450|NCT02228356|IGRT
955451|NCT02228330|Transurethral resection of bladder tumors
955452|NCT02228330|Obturator nerve reflex
955453|NCT02228330|Obturator nerve block
955454|NCT02228317|Emergency Medical Dispatch
955455|NCT02228317|Telemedicine
955456|NCT02228317|Emergency Medical Services
955457|NCT02228317|Pre-hospital
955458|NCT02228304|Wet AMD
955459|NCT02228304|Wet Age Related Macular Degeneration
955460|NCT02228304|Recurrent CNV Secondary to AMD
955461|NCT02228304|Active subfoveal CNV
955462|NCT02228291|Polyphenols
955463|NCT02228291|Endothelial function
955464|NCT02228291|Gut barrier function
955465|NCT02228278|Pediatric
955466|NCT02228278|Obesity
955467|NCT02228278|Overweight
955468|NCT02228278|Texting
955469|NCT02228278|Text message
955470|NCT02228278|SMS
955471|NCT02228278|Diet
955472|NCT02228278|Weight Loss
955473|NCT02228278|Nutrition
955474|NCT02228278|Physical activity
955475|NCT02228278|BMI z-score
955476|NCT02228278|BMI
955477|NCT02228252|Proteins
955478|NCT02228252|Postprandial lipemia
955479|NCT02228252|Pre-meal
955480|NCT02228252|Metabolic syndrome
955481|NCT02228239|Healthy
955482|NCT02228239|Esketamine
955483|NCT02228239|Mirtazapine
955484|NCT02228239|Psychomotor.
955485|NCT02228226|Arthroscopic Bankart repair
955486|NCT02228226|Bone hole
955487|NCT02228226|Ossification
955488|NCT02228226|Suture anchor
955489|NCT02228226|Shoulder dislocation
955490|NCT02228213|multiple sclerosis
955491|NCT02228213|SPMS
955492|NCT02228200|Oncology Nursing
955493|NCT02228200|Advanced Practice Nursing
955494|NCT02228200|Nurse-led care
955495|NCT02228200|Chemotherapy
955496|NCT02228174|Abnormal Uterine Bleeding associated with fibroids
955497|NCT02228174|AUB-L
955498|NCT02228174|Fibroids
955499|NCT02228174|Heavy menstrual bleeding
955500|NCT02228174|HMB
955501|NCT02228174|Myoma
955502|NCT02228174|Menorrhagia
955503|NCT02228161|Yoga
955504|NCT02228161|Work-related Stress,
955505|NCT02228161|Stress Adaptation.
955506|NCT02228148|Post linguistically deafness, severe to profound deafness
955507|NCT02228122|Chronic wounds
955508|NCT02228122|Biofilms
955509|NCT02228122|Bacteria
955510|NCT02228096|Chronic myeloid leukemia and relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukemia
955511|NCT02228096|Pharmaceuticals
955512|NCT02228096|Philadelphia chromosome positive
955513|NCT02228096|Acute Lymphoid Leukemia (ALL)
955514|NCT02228096|Acute Lymphocytic Leukemia (ALL)
955515|NCT02228083|dental
955516|NCT02228083|epinephrine
955517|NCT02228083|local anesthetic
955518|NCT02228083|lidocaine
955519|NCT02228083|cardiac arrhythmias
955521|NCT02228070|strabismus
955522|NCT02228070|oculomotor palsy
955523|NCT02228070|abducens palsy
955524|NCT02228070|trochlear palsy
955525|NCT02228057|arterial patency
955526|NCT02228057|upper extremity
955527|NCT02228057|anastomosis
955528|NCT02228057|sensibility
955529|NCT02228057|pain
955530|NCT02228057|cold intolerance
955531|NCT02228044|suicide
955532|NCT02228044|alcohol
955533|NCT02228044|marijuana
955534|NCT02228044|HIV
955535|NCT02228044|prevention
955536|NCT02228044|adolescent
955537|NCT02228031|Mirror neurons
955538|NCT02228031|Imitation
955539|NCT02228031|Oxytocin
955543|NCT02227966|Mild Cognitive Impairment
955544|NCT02227966|MCI
955545|NCT02227966|tDCS
955546|NCT02227966|transcranial Direct Current Stimulation
955547|NCT02227953|Alzheimer's Disease
955548|NCT02227953|AD
955549|NCT02227953|tDCS
955550|NCT02227953|transcranial direct current stimulation
955551|NCT02227927|Gastroesophageal Reflux Disease
955552|NCT02227927|GERD
955553|NCT02227927|Gastroparesis
955554|NCT02227927|Domperidone
955555|NCT02227888|CF
955556|NCT02227888|F508Del
955557|NCT02227888|Cavosonstat
955558|NCT02227888|N91115
955559|NCT02227849|insulin resistance
955560|NCT02227836|Allergy Patch testing
955561|NCT02227836|Eosinophilic Esophagitis
955562|NCT02227836|EoE
955563|NCT02227823|spinal muscular atrophy type 3
955564|NCT02227823|electromyography
955565|NCT02227823|fatigability
955566|NCT02227823|decrement
955567|NCT02227810|Prolong mechanical ventilator,
955568|NCT02227810|Electrical stimulation,
955569|NCT02227810|Activities of daily life,
955570|NCT02227810|Hospitalization outcomes.
955571|NCT02227797|stem cell transplant
955572|NCT02227797|hematopoietic stem cell transplant
955573|NCT02227797|fungal infection
955574|NCT02227797|voriconazole
955575|NCT02227797|pediatric
955576|NCT02227719|after augmentation
955577|NCT02227719|procedure
955581|NCT02227693|Thrombocytopenia
955582|NCT02227693|Chronic Liver Disease
955583|NCT02227680|music therapy
955584|NCT02227680|massage therapy
955585|NCT02227667|MEDI4736
955586|NCT02227667|14-109
955587|NCT02227654|Ovary
955588|NCT02227654|Cancer
955589|NCT02227654|Morphology
955590|NCT02227654|Surgery
955591|NCT02227641|CMV
955592|NCT02227641|Cytomegalovirus
955593|NCT02227641|EBV
955594|NCT02227641|Epstein Barr Virus
955595|NCT02227641|virus
955596|NCT02227641|T cell
955597|NCT02227641|adoptive transfer
955598|NCT02227641|transplantation
955599|NCT02227641|allogeneic
955600|NCT02227589|adolescent,
955601|NCT02227589|alcohol abuse
955602|NCT02227589|depression,
955603|NCT02227589|cognitive behavior therapy
955604|NCT02227589|cannabis abuse
955605|NCT02227576|glioblastoma, thrombocytopenia, temozolomide, chemotherapy
955606|NCT02227563|dorsolateral prefrontal cortex
955607|NCT02227563|left superior temporal gyrus
955608|NCT02227563|auditory hallucinations
955609|NCT02227563|transcranial direct current stimulation (tDCS)
955610|NCT02227550|Atrilal fibrillation
955611|NCT02227550|anticoagulation
955612|NCT02227550|prevention of peri-procedural complication
955613|NCT02227550|catheter ablation
955614|NCT02227537|Adolescence Idiopathic Scoliosis
955615|NCT02227537|nighttime Bracing
955616|NCT02227537|Providence
955617|NCT02227524|Multiple Sclerosis
955618|NCT02227524|Walking
955619|NCT02227524|Gait
955620|NCT02227511|fruit, nuts, liver fat, insulin, glucose
955621|NCT02227511|Focus of the study is to compare the often given advice to eat fruit, containing large amount of glucose and fructose, with nuts that are more rich in fat.
955622|NCT02227485|Gingivitis
955623|NCT02227485|Diabetes mellitus
955624|NCT02227485|Medicine, Traditional
955625|NCT02227485|Herbal medicine
955626|NCT02227485|Punica granatum
955627|NCT02227446|Surgical site infection risk prevention
955628|NCT02227446|Bacterial species type and antibacterial sensitives
955629|NCT02227433|Hodgkin Lymphoma, Elderly Patients, brentuximab vedotin (BV)
955630|NCT02227407|SCI
955631|NCT02227407|SMA
955632|NCT02227407|Paralysis
955633|NCT02227394|Asthma
955634|NCT02227394|Functional Respiratory Imaging
955635|NCT02227394|Computational Fluid Dynamic
955636|NCT02227368|Myocardial Infarction
955637|NCT02227368|Peripheral Arterial disease
955638|NCT02227368|Mycardial Ischemia
955639|NCT02227368|Heart Diseases
955640|NCT02227368|Cardiovascular Diseases
955641|NCT02227368|Vascular Diseases
955642|NCT02227368|Altherosclerosis
955643|NCT02227368|Arteriosclerosis
955644|NCT02227368|Arterial Occlusive Diseases
955645|NCT02227368|Peripheral Vascular Diseases
955646|NCT02227368|Ticagrelor
955647|NCT02227368|Ticlopidine
955648|NCT02227368|Platelet Aggregation inhibitors
955649|NCT02227368|Hematologic Agents
955650|NCT02227368|Therapeutic Uses
955651|NCT02227368|Pharmacologic Actions
955652|NCT02227368|Purinegic P2Y Receptor Antagonists
955653|NCT02227368|Purinegic P2 Receptor Antagonists
955654|NCT02227368|Purinergic Antagonists
955655|NCT02227368|Purinergic Agents
955656|NCT02227368|Neurotransmitter Agents
955657|NCT02227368|Molecular Mechanisms of Pharmacological Actions
955658|NCT02227368|Physiological Effects of Drugs
955659|NCT02227368|Fibrinolytic Agents
955660|NCT02227368|Crardiovascular Agents
955661|NCT02227355|Parkinson's Disease
955662|NCT02227355|Neupro®
955663|NCT02227355|Rotigotine
955664|NCT02227355|Transdermal patch
955665|NCT02227355|NEUPART
955666|NCT02227355|Levodopa
955667|NCT02227355|Noninterventional
955668|NCT02227355|Combination therapy
955669|NCT02227329|Home parenteral Nutrition
955670|NCT02227329|Quality of Life
955671|NCT02227329|infection prevention
955672|NCT02227329|CRBSI
955673|NCT02227329|Ethanol lock therapy
955674|NCT02227316|Uterine Fibroid Embolization
955675|NCT02227316|Pain
955676|NCT02227316|UFE
955677|NCT02227316|Fibroids
955678|NCT02227316|Adenomyosis
955679|NCT02227316|Bleeding
955680|NCT02227316|IV Acetaminophen
955681|NCT02227316|IV Ibuprofen
955682|NCT02227316|Menorrhagia
955683|NCT02227316|Leiomyoma
955684|NCT02227316|Patient Satisfaction
955685|NCT02227290|Tinea Corporis
955686|NCT02227290|Ringworm
955687|NCT02227277|HIV
955688|NCT02227277|HIV-1
955689|NCT02227277|Pegintron
955690|NCT02227277|Peg-IFN-α2b
955691|NCT02227277|Viral suppression
955692|NCT02227277|ART cessation
955693|NCT02227277|Immune function
955694|NCT02227277|Innate immunity
955695|NCT02227277|Toxicity
955696|NCT02227277|Immune-based therapy
955697|NCT02227277|Treatment interruption
955698|NCT02227277|HIV Cure
955699|NCT02227277|HIV Eradication
955700|NCT02227277|BEAT-HIV
955701|NCT02227277|HIV Cure Trial
955702|NCT02227277|Cure Trial
955703|NCT02227264|Primary hyperparathyroidism
955704|NCT02227264|Calcimimetic Agents
955705|NCT02227264|Parathyroid adenomectomy
955706|NCT02227251|Diffuse large B-cell Lymphoma
955707|NCT02227251|DLBCL
955708|NCT02227251|Karyopharm
955709|NCT02227251|KPT-330
955710|NCT02227251|selinexor
955711|NCT02227238|integrase inhibitor
955712|NCT02227238|non-inferiority
955713|NCT02227238|dolutegravir
955714|NCT02227238|lopinavir/ritonavir
955715|NCT02227238|second-line treatment
955716|NCT02227238|HIV-1
955717|NCT02227238|antiretroviral therapy-experienced
955718|NCT02227225|Postoperative Delirium
955719|NCT02227186|Influenza vaccination rates
955720|NCT02227147|Neurotrophic Keratitis
955721|NCT02227108|pediatric cancer,pediatric acute lymphoblastic leukemia, lymphoblastic lymphoma, B-cell leukemia, ALL, moxetumomab pasudotox, CD22
955722|NCT02227082|radiotherapy
955723|NCT02227082|olaparib
955724|NCT02227082|breast cancer
955725|NCT02227082|locally advanced breast cancer
955726|NCT02227056|Acquired pediatric brain injury
955727|NCT02227056|Methylphenidate
955728|NCT02227056|Traumatic brain injury
955729|NCT02227056|Cerebrovascular event
955730|NCT02227056|Hypoxic ischemic brain injury
955731|NCT02227056|Function (ecologic)
955732|NCT02227004|MRI
955733|NCT02227004|Magnetic Resonance Imaging
955734|NCT02227004|pacemakers
955735|NCT02227004|ICD
955736|NCT02226965|PNT2258
955737|NCT02226965|DLBCL
955738|NCT02226965|Diffuse Large B-cell Lymphoma
955739|NCT02226965|NHL
955740|NCT02226965|Non-Hodgkin's Lymphoma
955741|NCT02226965|Lymphoma
955742|NCT02226913|Buffered
955743|NCT02226913|inferior alveolar nerve block
955744|NCT02226913|irreversible pulpitis
955745|NCT02226913|local anesthesia
955746|NCT02226913|sodium bicarbonate
955747|NCT02226900|Multivessel Coronary Artery Disease
955748|NCT02226900|Hybrid Revascularization
955749|NCT02226887|Loop ileostomy
955750|NCT02226887|Eventration
955751|NCT02226874|Dose Estimation
955752|NCT02226874|Dose Reconstruction
955753|NCT02226874|Methods
955754|NCT02226874|Fallout
955755|NCT02226874|Radiation Exposure
955756|NCT02226861|Acute Lymphoblastic Leukemia (ALL)
955757|NCT02226861|MDS
955758|NCT02226861|Chronic Myelogenous Leukemia (CML)
955759|NCT02226861|Chronic Lymphocytic Leukemia (CLL)
955760|NCT02226861|Acute Myelogenous Leukemia (AML)
955761|NCT02226848|Endothelial Progenitor Cells
955762|NCT02226848|Angiogenesis
955763|NCT02226848|Traumatic Brain Injury
955764|NCT02226835|OCT
955765|NCT02226835|Alzheimer's Disease
955766|NCT02226835|Age-Related Macular Degeneration (AMD)
955767|NCT02226822|Type 2 diabetes mellitus
955768|NCT02226809|Muscle relaxants
955769|NCT02226809|Postoperative complications, respiratory
955770|NCT02226809|General anesthesia
955771|NCT02226809|Postanesthesia care unit
955772|NCT02226809|Neuromuscular block reversal
955773|NCT02226796|Broca's Aphasia
955774|NCT02226796|Transcranial Direct Current Stimulation
955775|NCT02226783|Phase I
955776|NCT02226783|Healthy subjects
955777|NCT02226783|PK
955778|NCT02226783|PD
955779|NCT02226757|NSCLC
955780|NCT02226757|HER2-expression
955781|NCT02226757|EGFR-mutation
955782|NCT02226757|Trastuzumab
955783|NCT02226757|Paclitaxel
955784|NCT02226744|breathing
955785|NCT02226744|mind-body practices
955786|NCT02226744|yoga
955787|NCT02226744|meditation
955788|NCT02226731|Immediate postpartum hemorrhage
955789|NCT02226731|Intrauterine balloon tamponade
955790|NCT02226705|Rhinocerebral Mucormycosis
955791|NCT02226705|Surgery
955792|NCT02226705|Fungal Infection
955793|NCT02226705|Survival
955794|NCT02226692|chronic low back pain
955795|NCT02226692|prognostic factors
955796|NCT02226692|disabling low back pain
955797|NCT02226692|lumbar muscle activity
955798|NCT02226692|start back screening tool
955799|NCT02226692|physical evaluation
955800|NCT02226679|crossover
955801|NCT02226679|rollover study
955802|NCT02226679|open label
955803|NCT02226666|MRI
955804|NCT02226666|Eovist
955805|NCT02226666|MultiHance
955806|NCT02226601|drowsiness
955807|NCT02226601|loopiness
955808|NCT02226601|nausea
955809|NCT02226575|Sense of coherence
955810|NCT02226549|hepatitis C
955811|NCT02226549|Gilead
955812|NCT02226549|GS-9451
955813|NCT02226536|Posture
955814|NCT02226536|Vertigo
955815|NCT02226536|glucose metabolism
955816|NCT02226536|diet
955817|NCT02226536|scales
955818|NCT02226536|dinamic posturography
955819|NCT02226523|immunomagnetic reduction
955820|NCT02226523|acute coronary syndrome
955821|NCT02226523|serum biomarkers
955822|NCT02226484|Gastroesophageal reflux disease
955823|NCT02226484|GERD
955824|NCT02226484|Acid reflux
955825|NCT02226484|Reflux
955826|NCT02226484|Quercetin
955827|NCT02226458|Autism
955828|NCT02226458|Mitochondrial Disorders
955829|NCT02226458|EPI-743
955830|NCT02226458|EPI743
955831|NCT02226458|Rett syndrome
955832|NCT02226458|Angelman syndrome
955833|NCT02226445|Adults
955834|NCT02226445|Outpatients
955842|NCT02226419|Fatty acid oxidation disorder
955843|NCT02226419|Primary carnitine deficiency
955844|NCT02226419|Exercise
955845|NCT02226419|L-carnitine treatment
955846|NCT02226419|Stable isotopes
955847|NCT02226419|Carnitine transporter deficiency
955848|NCT02226406|Early Physical Exercise
955849|NCT02226406|Alveolar Recruitment
955850|NCT02226406|Electrical Impedance Tomography
955851|NCT02226406|Oxygenation
955852|NCT02226406|Ventilation
955853|NCT02226393|Toddlers; Preschoolers; PTSD
955854|NCT02226367|prazosin
955855|NCT02226367|alcohol use disorders
955856|NCT02226367|posttraumatic stress disorder
955857|NCT02226367|PTSD
955858|NCT02226367|combat trauma
955859|NCT02226367|military
955860|NCT02226367|alpha-1 adrenoreceptor antagonist
955861|NCT02226354|Dietary vegetable oil
955862|NCT02226354|Stearidonic acid
955863|NCT02226354|Tissue
955864|NCT02226354|Fatty Acid
955865|NCT02226354|composition
955866|NCT02226341|Lupus
955867|NCT02226341|Lupus Nephritis
955868|NCT02226341|ACTHar
955869|NCT02226341|Columbia
955870|NCT02226341|Rheumatology
955871|NCT02226341|CUMC
955872|NCT02226341|Autoimmune
955873|NCT02226341|SLE
955874|NCT02226341|Proliferative Lupus Nephritis
955875|NCT02226315|noninvasive prenatal testing
955876|NCT02226302|Endometrial cancer
955877|NCT02226302|Obesity
955878|NCT02226289|bevacizumab
955879|NCT02226289|refractory
955880|NCT02226289|colorectal cancer
955881|NCT02226289|metastatic
955882|NCT02226263|Necrotizing enterocolitis
955883|NCT02226263|Probiotics
955884|NCT02226263|Preterm newborns
955885|NCT02226250|sugar-based beverage
955886|NCT02226250|Time Influence
955887|NCT02226237|urinary incontinence
955888|NCT02226237|erectile dysfunction
955889|NCT02226237|Retropubic Prostatectomy
955890|NCT02226237|Physiotherapy
955891|NCT02226224|gastrointestinal neoplasms
955892|NCT02226224|endosonography
955893|NCT02226224|in vitro
955894|NCT02226224|Staging
955895|NCT02226198|LDL-C
955896|NCT02226198|HoFH
955897|NCT02226198|Hyperlipidemia
955898|NCT02226172|Primary myelofibrosis
955899|NCT02226172|Secondary myelofibrosis
955900|NCT02226172|PMF
955901|NCT02226172|PET-MF
955902|NCT02226172|PPV-MF
955903|NCT02226172|Ruxolitinib resistant or intolerant
955904|NCT02226172|previously treated myelofibrosis
955905|NCT02226172|smoothened inhibitor
955906|NCT02226172|oral
955907|NCT02226172|single agent.
955908|NCT02226159|cervical
955909|NCT02226159|radicular pain
955910|NCT02226159|transforaminal epidural steroid injections
955911|NCT02226146|Pemphigoid Bullous
955912|NCT02226146|Bullous
955913|NCT02226146|Blisters
955914|NCT02226146|SKIN DISEASES
955915|NCT02226146|BP
955916|NCT02226120|LCZ696, chronic heart failure, open-label study, ARNI
955917|NCT02226107|Lay health worker
955918|NCT02226107|Patient navigation
955919|NCT02226107|Screening colonoscopy
955920|NCT02226107|Colon cancer
955921|NCT02226107|Training
955922|NCT02226107|Hispanic
955923|NCT02226107|Latino
955924|NCT02226094|intra-ocular pressure
955925|NCT02226094|primary open-angle glaucoma
955926|NCT02226094|intra ocular pressure
955927|NCT02226094|primary open angle glaucoma
955928|NCT02226094|glaucoma
955929|NCT02226094|deep wave trabeculoplasty
955930|NCT02226094|ocular hypertension
955931|NCT02226081|breast lesion
955932|NCT02226081|ultrasound
955933|NCT02226081|BI-RADS
955934|NCT02226081|women
955935|NCT02226081|malignancy
955936|NCT02226068|Atopic dermatitis
955937|NCT02226068|Ciclosporine
955938|NCT02226068|Extracorporal photopheresis
955939|NCT02226055|Chronic kidney disease of unknown origin
955940|NCT02226055|Chronic kidney disease of unknown aetiology
955941|NCT02226055|Sri Lanka
955942|NCT02226055|CKDu
955943|NCT02226055|Arterial stiffness
955944|NCT02226055|Cardiovascular risk
955945|NCT02226055|North Central Province
955946|NCT02226029|MRI, fat fraction, stomach, lipid emulsion
955947|NCT02226016|ptosis
955948|NCT02226016|blepharochalasis
955949|NCT02226016|dermatochalasis
955950|NCT02225990|stroke
955951|NCT02225990|stroke rehabilitation
955952|NCT02225990|stroke therapy
955953|NCT02225964|APOEε4
955954|NCT02225938|Intensive Care
955955|NCT02225938|Recovery
955956|NCT02225938|Long term outcome
955957|NCT02225938|Function
955958|NCT02225925|brachytherapy
955959|NCT02225886|Renal anaemia
955960|NCT02225886|Intravenous ascorbic acid
955961|NCT02225886|Intravenous iron administration
955962|NCT02225860|ADPKD
955963|NCT02225860|Copeptin
955964|NCT02225860|Vasopressin
955965|NCT02225860|Diet
955966|NCT02225860|Water
955967|NCT02225847|Gardening
955968|NCT02225847|Therapeutic Horticulture
955969|NCT02225847|Functional Magnetic Resonance Imaging
955970|NCT02225847|Psychometric Assessment
955971|NCT02225847|Stress
955972|NCT02225847|Depression
955973|NCT02225847|Anxiety
955974|NCT02225847|Quality of Life
955975|NCT02225847|Wellness
955976|NCT02225834|Atorvastatin, ischemic stroke, cytokines
955977|NCT02225821|Implant Removal
955978|NCT02225821|Antibiotic Prophylaxis
955979|NCT02225821|Postoperative wound infection
955980|NCT02225821|Orthopedics
955981|NCT02225808|CBT
955982|NCT02225808|autism
955983|NCT02225808|anxiety
955984|NCT02225808|treatment
955985|NCT02225808|fMRI
955986|NCT02225795|Crohn's Disease
955987|NCT02225795|Hematopoietic stem cell transplantation
955988|NCT02225795|Children
955989|NCT02225795|Young Adults
955990|NCT02225782|Alteplase; Hemodialysis Catheter; Occlusion; Renal Failure
955991|NCT02225769|fever
955992|NCT02225769|point-of-care tests
955993|NCT02225769|clinical algorithms
955994|NCT02225769|electronic support
955995|NCT02225769|host biomarkers
955996|NCT02225756|Drug therapy
955997|NCT02225756|Prevention and control
955998|NCT02225756|Healing
955999|NCT02225756|Tissue regeneration
956000|NCT02225756|Therapy
956001|NCT02225743|Hypothermia
956002|NCT02225743|Total Hip Joint Prosthesis
956003|NCT02225743|Total Knee Joint Prosthesis
956004|NCT02225717|Preterm labor
956005|NCT02225717|cervicovaginal secretions
956006|NCT02225717|markers of fetal membranes remodelling
956007|NCT02225717|Multiplex test
956008|NCT02225691|type 1 diabetes
956009|NCT02225691|type 2 diabetes
956010|NCT02225691|paired testing
956011|NCT02225678|healthy volunteers
956012|NCT02225678|asthma
956013|NCT02225678|sputum eosinophils
956014|NCT02225639|ADHD
956015|NCT02225639|Adult
956016|NCT02225613|Cruciate ligament injury
956017|NCT02225613|Balance control
956018|NCT02225613|Rehabilitation
956019|NCT02225613|Spa therapy
956020|NCT02225613|Sport
956021|NCT02225600|Borderline Personality Disorder
956022|NCT02225600|BPD
956023|NCT02225600|Intranasal oxytocin
956024|NCT02225574|Leukemia
956025|NCT02225574|Advanced phase chronic myeloid leukemia
956026|NCT02225574|refractory chronic phase chronic myeloid leukemia
956027|NCT02225574|CML
956028|NCT02225574|Accelerated phase
956029|NCT02225574|(AP)
956030|NCT02225574|Blast phase
956031|NCT02225574|(BP)
956032|NCT02225574|Philadelphia-positive acute leukemia
956033|NCT02225574|MEK-162
956034|NCT02225574|Nilotinib
956035|NCT02225574|AMN107
956036|NCT02225574|Tasigna
956037|NCT02225574|Questionnaires
956038|NCT02225574|Surveys
956039|NCT02225561|Cardiopulmonary resuscitation
956040|NCT02225561|Nitroprusside
956041|NCT02225561|Transthoracic
956042|NCT02225561|Impedances
956043|NCT02225535|low back pain
956044|NCT02225535|telehealth
956045|NCT02225535|videoconferencing
956046|NCT02225535|access to physical therapy
956047|NCT02225535|interprofessional care
956048|NCT02225535|rural health
956052|NCT02225509|Thyroid cancer
956053|NCT02225509|Thyroid cancer diagnostic
956054|NCT02225509|Thyroid nodule
956055|NCT02225509|Fine needle aspiration biopsy
956056|NCT02225509|Indeterminate cytological result
956057|NCT02225509|Molecular diagnostic
956058|NCT02225509|Transcriptomics
956059|NCT02225509|Molecular signature
956060|NCT02225496|Oropharyngeal cancer
956061|NCT02225496|Oropharynx
956062|NCT02225496|Human papilloma virus
956063|NCT02225496|HPV positive
956064|NCT02225496|Squamous cell carcinoma
956065|NCT02225496|SCC
956066|NCT02225496|Transoral robotic surgery
956067|NCT02225496|TORS
956068|NCT02225496|Intuitive Surgical da Vinci Surgical System
956069|NCT02225496|Modified barium swallow
956070|NCT02225496|MBS
956071|NCT02225496|Questionnaires
956072|NCT02225496|Surveys
956073|NCT02225496|Speech and swallowing function
956074|NCT02225470|Locally Recurrent or Metastatic Breast Cancer
956075|NCT02225457|insulin resistance
956076|NCT02225457|type 2 diabetes
956077|NCT02225457|obesity
956078|NCT02225457|polyphenols
956079|NCT02225457|adipose tissue
956080|NCT02225457|overfeeding
956081|NCT02225444|degenerative lumbosacral spine disease
956082|NCT02225444|posterolateral fusion evaluation
956083|NCT02225444|OsteoAMP growth factor
956084|NCT02225444|autograft
956085|NCT02225431|Contrast-induced nephropathy
956086|NCT02225431|Contrast-Induced acute kidney injury
956087|NCT02225431|Contrast media
956088|NCT02225431|Angiography
956089|NCT02225431|Coronary percutaneous intervention
956090|NCT02225418|Laparoscopic
956091|NCT02225418|Cholecystectomy
956092|NCT02225418|Postoperative
956093|NCT02225418|Pain
956094|NCT02225418|Quadratus lumborum
956095|NCT02225418|Ultrasound
956096|NCT02225405|Lung Cancer
956097|NCT02225405|Non-small Cell Lung Cancers
956098|NCT02225405|NCLC
956099|NCT02225405|Chemotherapy
956100|NCT02225405|Nintedanib
956101|NCT02225405|BIBF 1120
956102|NCT02225405|Cisplatin
956103|NCT02225405|Platinol-AQ
956104|NCT02225405|Platinol
956105|NCT02225405|CDDP
956106|NCT02225405|Docetaxel
956107|NCT02225405|Taxotere
956108|NCT02225392|Bronchial thermoplasty
956109|NCT02225392|Severe asthma
956110|NCT02225379|Type 1 Diabetes
956111|NCT02225379|Hypoglycemia detection
956112|NCT02225379|Non-invasive sensor
956113|NCT02225379|Nocturnal hypoglycemia
956119|NCT02225353|Cervical Pessaries
956120|NCT02225353|Progesterone
956121|NCT02225314|Parkinson's Disease
956122|NCT02225314|Mild Cognitive Impairment
956123|NCT02225301|Child maltreatment
956124|NCT02225301|Child Care
956125|NCT02225301|Knowledge
956126|NCT02225301|Attitude
956127|NCT02225288|Healthy Subjects
956128|NCT02225288|Japanese
956129|NCT02225288|Males
956130|NCT02225275|Leukemia
956131|NCT02225275|Chronic Lymphocytic Leukemia
956132|NCT02225275|CLL
956133|NCT02225275|Small Lymphocytic Lymphoma
956134|NCT02225275|SLL
956135|NCT02225275|Recurrent
956136|NCT02225275|Lenalidomide
956137|NCT02225275|CC-5013
956138|NCT02225275|Revlimid
956139|NCT02225275|Obinutuzumab
956140|NCT02225275|GA101
956141|NCT02225275|Gazyva
956142|NCT02225262|Prostate cancer
956143|NCT02225262|CyberKnife
956144|NCT02225262|Stereotactic
956145|NCT02225262|Radiation
956146|NCT02225236|executive functioning
956147|NCT02225236|metacognition
956148|NCT02225236|self-regulation
956149|NCT02225236|preschoolers
956150|NCT02225223|metastatic lesions
956151|NCT02225223|vertebral body
956152|NCT02225223|ablation
956153|NCT02225223|radiation
956154|NCT02225223|targeted radio-frequency ablation
956155|NCT02225223|radio-frequency targeted vertebral augmentation
956156|NCT02225223|radiofrequency kyphoplasty
956157|NCT02225223|spine
956158|NCT02225223|vertebral augmentation
956159|NCT02225223|kyphoplasty
956160|NCT02225223|spinal ablation
956161|NCT02225223|pain
956162|NCT02225223|quality of life
956163|NCT02225223|spinal tumors
956164|NCT02225210|Dexmedetomidine ,Delirium ,Haemodynamic, Mechanical ventilation
956165|NCT02225197|Perioptic
956166|NCT02225197|Stereotactic
956167|NCT02225197|Radiation
956168|NCT02225197|Benign brain tumor
956169|NCT02225197|Optic apparatus
956170|NCT02225184|Opioid Dependence
956171|NCT02225184|OPRM1
956172|NCT02225184|Outcome
956173|NCT02225184|Treatment
956174|NCT02225171|Genetic Knowledge
956175|NCT02225171|Genetic Testing
956176|NCT02225158|Immunity
956177|NCT02225158|Co-Infection
956178|NCT02225158|Parasite
956179|NCT02225158|Mycobacteria
956180|NCT02225145|Bone Marrow Transplant
956181|NCT02225145|Fertility
956182|NCT02225145|Ovary
956186|NCT02225119|Retinal Images
956187|NCT02225119|Retinal Pigment Epithelium
956203|NCT02225067|Patients
956204|NCT02225067|Volunteers
956205|NCT02225054|duration of analgesia
956211|NCT02225028|physical activity
956212|NCT02225028|physical fitness
956213|NCT02225028|exercise program
956214|NCT02225028|telephone coaching
956215|NCT02225028|motivational counseling
956216|NCT02225028|stretching
956217|NCT02225028|fitness improvement
956218|NCT02225028|exercise coaching
956219|NCT02225028|toning
956220|NCT02225028|SCI
956221|NCT02225028|spinal cord injury
956222|NCT02225028|home-based
956223|NCT02225028|home exercise
956224|NCT02225015|Cancer
956225|NCT02225015|Breast cancer
956226|NCT02225015|Ovarian cancer
956227|NCT02225015|BRCA Mutation
956228|NCT02225015|BRCA1 Gene Mutation
956229|NCT02225015|BRCA2 Gene Mutation
956230|NCT02225015|Telephone genetic counselling
956231|NCT02225015|Cancer prevention
956232|NCT02225002|relapsed
956233|NCT02225002|refractory to standard therapy
956234|NCT02225002|no effective therapy exists
956235|NCT02224976|exercise training
956236|NCT02224963|Aging,
956237|NCT02224963|Macular Degeneration,
956238|NCT02224963|Preparation for Future Care,
956239|NCT02224963|Psychological Well-being,
956240|NCT02224963|Problem Solving
956241|NCT02224963|Prevention
956242|NCT02224963|Mental Health Promotion
956243|NCT02224950|Atopic dermatitis
956244|NCT02224950|eczema
956245|NCT02224950|alternative therapy
956246|NCT02224950|complementary therapy
956247|NCT02224950|moisturizer
956248|NCT02224937|Melatonin
956249|NCT02224937|Cognitive parameters
956250|NCT02224937|pharmacodynamic
956251|NCT02224937|pharmacokinetics
956252|NCT02224924|Experimental: autologous blood patch injection (ABPI)
956253|NCT02224924|Experimental: BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug
956254|NCT02224924|14-141
956255|NCT02224911|focal therapy
956256|NCT02224911|prostate cancer treatment
956257|NCT02224911|laser treatment
956258|NCT02224885|Interventional radiology
956259|NCT02224885|Lung
956260|NCT02224885|Liver
956261|NCT02224885|Confocal endomicroscopy
956262|NCT02224885|Optical biopsy
956263|NCT02224885|Scanner
956264|NCT02224885|Fluoroscopy
956265|NCT02224885|CT
956266|NCT02224885|Computed Tomography
956267|NCT02224885|Radiofrequency Ablation
956268|NCT02224885|Fluorescein
956269|NCT02224872|bone marrow transplant
956270|NCT02224872|thymoglobulin
956271|NCT02224872|cyclophosphamide
956272|NCT02224872|fludarabine
956273|NCT02224872|tacrolimus
956274|NCT02224872|Mycophenolic Acid Mofetil
956275|NCT02224872|chemotherapy
956276|NCT02224872|GVHD
956277|NCT02224872|haploidentical
956278|NCT02224833|appropriateness
956279|NCT02224833|elderly
956280|NCT02224833|polypharmacy
956281|NCT02224833|primary care
956282|NCT02224820|transplantation
956283|NCT02224820|sensitised patients
956284|NCT02224820|HLA-antibodies
956285|NCT02224807|breast cancer
956286|NCT02224807|diet
956287|NCT02224807|exercise
956288|NCT02224807|weight loss
956289|NCT02224794|abdominal
956290|NCT02224794|aortic
956291|NCT02224794|aneurysm
956292|NCT02224755|Heart Failure
956293|NCT02224755|Left Ventricular Assist Device
956294|NCT02224755|Ventricular Dysfunction
956295|NCT02224755|Cardiomyopathy
956296|NCT02224755|Heart Disease
956297|NCT02224755|Cardiovascular Disease
956298|NCT02224755|Heart-assist devices
956299|NCT02224755|Thoratec Corporation
956300|NCT02224703|Cannabidiol
956301|NCT02224703|CBD
956302|NCT02224703|GWP42003-P
956303|NCT02224690|Cannabidiol
956304|NCT02224690|CBD
956305|NCT02224690|Epidiolex
956306|NCT02224690|GWP42003-P
956307|NCT02224677|CFM
956308|NCT02224677|facial asymmetry
956309|NCT02224677|skin tag
956310|NCT02224677|facial tag
956311|NCT02224677|missing ear
956312|NCT02224677|small ear
956313|NCT02224677|anotia
956314|NCT02224677|microtia
956315|NCT02224677|epibulbar dermoid
956316|NCT02224677|coloboma
956317|NCT02224677|macrostomia
956318|NCT02224677|lateral cleft
956319|NCT02224677|infant
956320|NCT02224677|toddler
956321|NCT02224677|baby
956322|NCT02224677|neurodevelopment
956323|NCT02224677|cognition
956324|NCT02224677|socialization
956325|NCT02224638|skin ulcers
956326|NCT02224612|Pediatric Face Masks
956327|NCT02224612|children
956328|NCT02224573|Cannabidiol
956329|NCT02224573|CBD
956330|NCT02224573|GWP42003-P
956331|NCT02224560|Cannabidiol
956332|NCT02224560|CBD
956333|NCT02224560|Epidiolex
956334|NCT02224560|GWP42003-P
956335|NCT02224547|non-small cell lung cancer
956336|NCT02224547|lung carcinoma
956337|NCT02224547|NSCLC
956338|NCT02224534|ST elevation myocardial infarction.
956339|NCT02224534|Ticagrelor
956340|NCT02224534|Left ventricular remodeling
956341|NCT02224534|Platelet reactivity
956342|NCT02224521|FLAP inhibitor
956343|NCT02224521|Chronic Obstructive Pulmonary Disease (COPD)
956344|NCT02224521|COPD
956345|NCT02224521|Bioavailability
956346|NCT02224469|Brain-Computer Interface
956347|NCT02224469|Motor Cortex
956348|NCT02224469|Dorsolateral Prefrontal Cortex
956349|NCT02224469|Quality of Life
956350|NCT02224456|Tenofovir disoproxil fumarate
956351|NCT02224456|hepatocellular carcinoma
956352|NCT02224456|chronic hepatitis B
956353|NCT02224456|Cirrhosis
956354|NCT02224443|Dexmedetomidine,postoperative cognitive dysfunction
956355|NCT02224430|biomarker of relapse
956356|NCT02224430|schizophrenia
956357|NCT02224430|schizoaffective disorder
956358|NCT02224430|on-body sensors
956359|NCT02224430|smartphone
956360|NCT02224430|observational
956361|NCT02224417|Diabetes
956362|NCT02224417|Treatment medication adherence
956363|NCT02224417|Physical activity
956364|NCT02224417|Financial incentives
956365|NCT02224417|Outcome incentives
956366|NCT02224417|Process incentives
956367|NCT02224417|HbA1c
956368|NCT02224391|Smoking Cessation
956369|NCT02224391|Attentional bias modification
956370|NCT02224391|ABM
956371|NCT02224391|Smartphone
956372|NCT02224391|Nicotine replacement therapy
956373|NCT02224391|Nicotine patch
956374|NCT02224391|NRT
956375|NCT02224391|Questionnaires
956376|NCT02224391|Surveys
956377|NCT02224391|Saliva collection
956378|NCT02224391|Cotinine level
956379|NCT02224391|Counseling sessions
956380|NCT02224391|Electroencephalography
956381|NCT02224391|EEG
956382|NCT02224378|fluid responsiveness
956383|NCT02224378|atrial fibrillation
956384|NCT02224378|passive leg raising
956385|NCT02224378|central venous pressure
956386|NCT02224378|valvular heart surgery
956387|NCT02224365|Diabetes
956388|NCT02224365|Arterial Stiffness
956389|NCT02224365|Blood Pressure
956390|NCT02224365|Endothelial Function
956391|NCT02224365|Body Composition
956392|NCT02224365|Glycemic Control
956393|NCT02224365|Apples
956394|NCT02224365|Functional Foods
956395|NCT02224365|Polyphenols
956396|NCT02224365|Fiber
956397|NCT02224352|Electric Stimulation
956398|NCT02224352|Respiration
956399|NCT02224352|Abdominal wall
956400|NCT02224352|Lung Diseases
956401|NCT02224352|Respiratory Tract Diseases
956402|NCT02224352|COPD
956403|NCT02224339|Atherosclerosis
956404|NCT02224339|carotid plaque
956405|NCT02224339|Contrast-enhanced ultrasound
956406|NCT02224339|Major Adverse Cardiovascular Events
956407|NCT02224326|Alzheimer´s disease
956408|NCT02224326|early diagnosis
956409|NCT02224326|evoked potentials
956410|NCT02224326|near-infrared spectroscopy
956411|NCT02224313|vaginal cytokine
956412|NCT02224287|Urolithiasis
956413|NCT02224287|Kidney Stones
956414|NCT02224287|Ureteroscopy
956415|NCT02224287|Fluoroscopy
956416|NCT02224274|Antiplatelet Therapy
956417|NCT02224274|Cardiac Arrest
956418|NCT02224274|Therapeutic hypothermia
956419|NCT02224274|Myocardial infarction (STEMI and NSTEMI)
956420|NCT02224261|Axillary web syndrome
956421|NCT02224261|cording
956422|NCT02224261|physical therapy
956423|NCT02224261|breast cancer
956424|NCT02224248|cardiorespiratory fitness
956425|NCT02224248|exercise tolerance
956426|NCT02224248|exercise test
956427|NCT02224248|health behavior
956428|NCT02224248|motor activity
956429|NCT02224248|motivation
956430|NCT02224248|intention
956431|NCT02224248|self-rated health
956432|NCT02224235|Stable angina
956433|NCT02224235|PCI
956434|NCT02224235|Percutaneous Coronary Intervention
956435|NCT02224209|Carotid artery stenosis
956436|NCT02224209|High risk of hyperperfusion
956437|NCT02224209|Staged angioplasty
956438|NCT02224209|Routine single-stage stenting
956439|NCT02224196|manual ventilation
956440|NCT02224196|pressure-controlled ventilation
956441|NCT02224196|peak airway pressure
956442|NCT02224196|antral area
956443|NCT02224183|low back pain
956444|NCT02224183|yoga
956445|NCT02224183|education
956446|NCT02224183|Veterans
956447|NCT02224183|cost-effectiveness
956448|NCT02224183|military
956449|NCT02224183|back pain
956450|NCT02224170|Dexamethasone
956451|NCT02224170|Lidocaine
956452|NCT02224170|Quality of Recovery
956453|NCT02224170|Laparoscopic cholecystectomy
956454|NCT02224144|Kidney Transplantation
956455|NCT02224144|Calcitriol
956456|NCT02224144|Bone Mineral Density
956457|NCT02224144|Bone Mass and Strength
956458|NCT02224144|Vascular Calcifications
956459|NCT02224144|Hyperparathyroidism
956460|NCT02224144|Parathyroid Hormone
956461|NCT02224131|platelet function test
956462|NCT02224131|stent;
956463|NCT02224118|Healthy
956464|NCT02224118|Diabetes Mellitus, Type 2
956465|NCT02224118|CNTO 3649
956466|NCT02224092|heart health
956467|NCT02224092|general well-being
956468|NCT02224066|Aortic stenosis
956469|NCT02224066|TAVI
956470|NCT02224066|TAVR
956471|NCT02224066|Transcatheter aortic valve implantation
956472|NCT02224066|Ticagrelor
956473|NCT02224066|Antiplatelet reactivity
956474|NCT02224053|oncology, cancer, non small cell lung cancer, anticancer druge, omeprazole, healthy volunteer
956475|NCT02224001|tip plasty
956476|NCT02224001|septal cartilage
956477|NCT02223988|Patients
956478|NCT02223988|mechanical
956479|NCT02223988|ventilation
956480|NCT02223988|tracheostomy
956481|NCT02223975|Spectrum Analysis, vibrational
956482|NCT02223975|Spectrum Analysis, infrared
956483|NCT02223975|Spectrum Analysis, Raman
956484|NCT02223975|Spectrum Analysis
956485|NCT02223975|Fourier transform infrared spectroscopy
956486|NCT02223975|Raman probe
956487|NCT02223975|Optical
956488|NCT02223975|Diagnosis
956489|NCT02223975|Cancer
956490|NCT02223975|Multivariate analysis
956491|NCT02223975|Vulval Intraepithelial Neoplasia
956492|NCT02223975|Vulvar Neoplasm
956493|NCT02223975|Vulva
956494|NCT02223975|Vulvar Diseases
956495|NCT02223962|physical activity
956496|NCT02223962|COPD
956497|NCT02223962|activity monitors
956498|NCT02223949|Obesity
956499|NCT02223949|Labor complications
956500|NCT02223949|Induction of labor
956501|NCT02223949|Mechanical cervical ripening
956502|NCT02223936|nuchal translucency, neurological developpment, anxiety, depression, prenatal diagnosis, normal karyotype
956503|NCT02223923|Phase 1
956504|NCT02223923|Maximimum tolerated dose
956505|NCT02223923|ATR Inhibitor
956506|NCT02223923|Radiotherapy
956507|NCT02223910|brain computer interface
956508|NCT02223910|neurofeedback
956509|NCT02223910|functional connectivity
956510|NCT02223897|Liver transplantation
956511|NCT02223897|Biliary complication
956512|NCT02223897|mesenchymal stem cells
956513|NCT02223884|Malignant melanoma, second-line treatment, docetaxel, carboplatin
956514|NCT02223871|Malaria
956515|NCT02223871|ACT-451840
956516|NCT02223858|Health Status Disparities
956517|NCT02223858|Arthritis
956518|NCT02223858|Psychology
956519|NCT02223858|Pain Management
956520|NCT02223858|Affect
956521|NCT02223845|Music, Anxiety, IVF
956522|NCT02223832|ACT-128800
956523|NCT02223832|Safety
956524|NCT02223832|Tolerability
956525|NCT02223832|Pharmacokinetics
956526|NCT02223819|Crizotinib
956527|NCT02223819|14-063
956528|NCT02223806|Postpartum hemorrhage
956529|NCT02223806|Uterine tonus assessment
956530|NCT02223806|Active management of third stage of labor
956531|NCT02223793|Vascular screening
956532|NCT02223793|Cardiovascular risk factors
956533|NCT02223793|Blood pressure
956534|NCT02223793|Lipids
956535|NCT02223793|Lifestyle
956536|NCT02223793|Identifying unknown risk
956537|NCT02223793|Low socioeconomic status
956538|NCT02223793|low threshold
956539|NCT02223780|COPD
956540|NCT02223780|palliative care
956541|NCT02223767|TMS
956542|NCT02223767|VR
956543|NCT02223767|Exposure therapy
956544|NCT02223767|TMS augmentations of exposure therapy
956545|NCT02223741|Cerebral palsy
956546|NCT02223741|GMFM-66
956547|NCT02223741|PEDI
956548|NCT02223702|Aggressive periodontitis
956549|NCT02223702|amoxicillin
956550|NCT02223702|metronidazole
956551|NCT02223702|moxifloxacin
956552|NCT02223702|nonsurgical periodontal debridement.
956553|NCT02223689|SkinAffix
956554|NCT02223676|Pharmacy
956555|NCT02223676|Length-of-stay
956556|NCT02223676|Emergency Department
956557|NCT02223650|Intermittent Exotropia
956558|NCT02223650|IXT
956559|NCT02223650|overminus
956560|NCT02223624|eccentric
956561|NCT02223624|exercise
956562|NCT02223624|heart disease
956563|NCT02223624|chronic heart failure
956564|NCT02223624|rehabilitation
956565|NCT02223611|Stage Ⅱ-ⅢA NSCLC S1 capsule Completely resection
956566|NCT02223598|Lymphoid Hematological Malignancies
956567|NCT02223585|Gut microbial
956568|NCT02223585|response
956569|NCT02223585|to protein-based
956570|NCT02223585|diet
956571|NCT02223585|challenges
956572|NCT02223585|population
956573|NCT02223533|analgesia
956574|NCT02223533|post-operative
956575|NCT02223533|wound catheter infusion
956576|NCT02223533|laparoscopic colon surgery
956577|NCT02223520|Staphylococcus aureus
956578|NCT02223520|Infection
956579|NCT02223520|Colonization
956580|NCT02223520|Transmission
956581|NCT02223520|Neonate
956582|NCT02223468|Intestinal Microbiota
956583|NCT02223468|Liver Transplant
956584|NCT02223468|Acute Rejection
956585|NCT02223468|Infection
956586|NCT02223455|Methicillin-resistant Staphylococcus aureus (MRSA)
956587|NCT02223455|Infection Control (IC)
956588|NCT02223455|Hospital-associated infections (HAI)
956589|NCT02223455|Hand Hygiene (HH)
956590|NCT02223455|Compliance
956591|NCT02223455|Health Care Workers (HCWs)
956592|NCT02223442|chronic pain
956593|NCT02223442|central analgesic drugs
956594|NCT02223442|adherence to therapy
956595|NCT02223442|side effects
956596|NCT02223442|quality of life
956597|NCT02223442|MOR-NRI drugs
956598|NCT02223429|Paternal nurturance
956599|NCT02223429|Oxytocin
956600|NCT02223429|Vasopressin
956601|NCT02223429|fMRI
956602|NCT02223429|Neurobiology
956603|NCT02223416|female
956604|NCT02223416|volunteers
956605|NCT02223403|Nitrate-rich beetroot juice
956606|NCT02223403|heart failure
956607|NCT02223403|exercise performance
956608|NCT02223403|oxygen consumption
956609|NCT02223390|South Africa
956610|NCT02223390|HIV
956611|NCT02223390|Mental health
956612|NCT02223390|Trauma
956613|NCT02223390|Women
956614|NCT02223351|HSV
956615|NCT02223351|HIV
956616|NCT02223351|Herpes
956617|NCT02223351|volunteers
956618|NCT02223351|drug-drug interaction
956619|NCT02223325|Elderly
956620|NCT02223325|Prognosis
956621|NCT02223299|Depression
956622|NCT02223299|SSRI
956623|NCT02223299|Nutritional Supplements
956624|NCT02223299|Beck Depression Scale
956625|NCT02223299|L-tyrosine
956626|NCT02223299|L-tryptophan
956627|NCT02223273|stroke,
956628|NCT02223273|quality improvement
956629|NCT02223247|solid tumors
956630|NCT02223247|cancer
956631|NCT02223221|In Vitro Fertilization
956632|NCT02223221|Intracytoplasmic Sperm Injections
956633|NCT02223221|Infertility, Female
956634|NCT02223221|Abortion, Habitual
956635|NCT02223221|recurrent pregnancy loss
956636|NCT02223221|comprehensive chromosome screening
956637|NCT02223221|preimplantation genetic screening
956638|NCT02223221|SNP array
956639|NCT02223208|PTCL
956640|NCT02223208|PTCL-NOS
956641|NCT02223208|AITL
956642|NCT02223208|ALCL
956643|NCT02223195|Juvenile Idiopathic Arthritis
956644|NCT02223195|Saliva
956645|NCT02223182|Milk Allergy,
956646|NCT02223182|Viaskin Milk,
956647|NCT02223182|Specific Immunotherapy,
956648|NCT02223182|Epicutaneous ImmunoTherapy (EPIT)
956649|NCT02223182|IgE-Mediated Cow's Milk Allergy
956650|NCT02223169|Blood Pressure
956651|NCT02223169|Hypertension
956652|NCT02223169|Cardiovascular disease
956653|NCT02223143|Lipid lowering therapy
956654|NCT02223130|HIV
956655|NCT02223130|Discrimination
956656|NCT02223130|Coping
956657|NCT02223130|Medical Mistrust
956658|NCT02223130|HIV Outcomes
956659|NCT02223130|Cognitive Behavioral Therapy
956660|NCT02223091|complementary therapies
956661|NCT02223091|consultants
956662|NCT02223091|medical oncology
956663|NCT02223091|breast-cancer
956664|NCT02223091|education
956708|NCT02223039|Psoriasis
956709|NCT02223039|Dermatology
956710|NCT02223039|Monoclonal antibody
956711|NCT02222935|Balance training
956712|NCT02222935|low back pain
956713|NCT02222935|balance test
956714|NCT02222935|routine back exercise
956715|NCT02222922|ADC
956716|NCT02222922|PF-06647020
956717|NCT02222922|solid tumors
956718|NCT02222922|tumors
956719|NCT02222922|neoplasm metastasis
956720|NCT02222922|TNBC
956721|NCT02222922|triple negative breast cancer
956722|NCT02222922|NSCLC
956723|NCT02222922|non small cell lung cancer
956724|NCT02222922|advanced metastatic breast cancer
956725|NCT02222922|ovarian cancer
956726|NCT02222922|OVCA
956727|NCT02222909|Community Based Organization
956728|NCT02222909|Reverse Innovation
956729|NCT02222909|Social Services
956730|NCT02222909|Referral
956731|NCT02222909|Chronic disease
956732|NCT02222870|Influenza
956733|NCT02222870|Influenza virus vaccine
956734|NCT02222870|Quadrivalent Influenza Virus Vaccine (No Preservative)
956735|NCT02222870|Fluzone®
956736|NCT02222857|Acute retinal necrosis
956737|NCT02222857|Retinal detachment
956738|NCT02222857|Laser photocoagulation
956739|NCT02222857|Vitrectomy
956740|NCT02222844|Cancer
956741|NCT02222844|Colorectal Neoplasms
956742|NCT02222844|Colon, Sigmoid
956743|NCT02222844|Magnetic Resonance Imaging
956744|NCT02222844|General Surgery
956745|NCT02222844|Postoperative Complications
956746|NCT02222831|IVF
956747|NCT02222831|Embryo Quality
956748|NCT02222831|Time Lapse Culture
956749|NCT02222831|Preimplantation factor
956750|NCT02222805|Cord clamping
956751|NCT02222805|Iron deficiency
956752|NCT02222805|Anemia
956753|NCT02222805|Iron
956754|NCT02222805|Hyperbilirubinemia
956755|NCT02222805|Jaundice
956756|NCT02222805|Neurodevelopment
956757|NCT02222792|Staphylococci, Streptococci, P acnes and Gram-negative bacteria
956758|NCT02222740|Safety
956759|NCT02222740|Tolerability
956760|NCT02222740|Pharmacokinetics
956761|NCT02222714|ischemic stroke
956762|NCT02222714|stroke
956763|NCT02222714|APC
956764|NCT02222714|3K3A
956765|NCT02222714|3K3A-APC
956766|NCT02222714|activated protein C
956767|NCT02222714|RHAPSODY
956768|NCT02222701|composite
956769|NCT02222701|dental
956770|NCT02222701|longevity
956771|NCT02222688|cancer
956772|NCT02222688|CLL
956773|NCT02222662|Massage
956774|NCT02222662|effectiveness
956775|NCT02222662|autism
956776|NCT02222662|parent stress
956777|NCT02222649|Elderly
956778|NCT02222649|vitamin D insufficiency
956779|NCT02222649|High dose vitamin D3 supplementation
956780|NCT02222649|Polymorphism of the VDR gene
956781|NCT02222636|The efficacy and safety of intranasal dexmedetomidine
956782|NCT02222623|insulin
956783|NCT02222623|basal
956784|NCT02222623|diabetes
956785|NCT02222623|hospital
956786|NCT02222623|glucose
956787|NCT02222623|hypoglycemia
956788|NCT02222623|glargine
956789|NCT02222623|NPH
956790|NCT02222623|neutral protamine hagedorn
956791|NCT02222610|Radiation Retinopathy
956792|NCT02222597|head injury
956793|NCT02222597|infrascanner
956794|NCT02222597|intracranial hemorrhage
956795|NCT02222584|inflammatory bowel disease
956796|NCT02222584|physical activity
956797|NCT02222584|disease activity
956798|NCT02222584|quality of life
956799|NCT02222558|hypogonadism
956800|NCT02222558|Gonadal Disorders
956801|NCT02222558|Endocrine System Diseases
956802|NCT02222558|Testosterone
956803|NCT02222558|Testosterone enanthate
956804|NCT02222558|Testosterone undecanoate
956805|NCT02222558|Testosterone 17 beta-cypionate
956806|NCT02222558|Methyltestosterone
956807|NCT02222558|Androgens
956808|NCT02222558|Hormones
956809|NCT02222558|Hormones,
956810|NCT02222558|Hormone Substitutes,
956811|NCT02222558|Hormone Antagonists
956812|NCT02222558|Physiological Effects of Drugs
956813|NCT02222558|Pharmacologic Actions
956814|NCT02222558|Therapeutic Uses
956815|NCT02222558|Anabolic Agents
956816|NCT02222558|dihydrotestosterone
956817|NCT02222545|TMA, aHUS, HSCT-associated TMA, TTP
956818|NCT02222532|tetronine
956819|NCT02222532|congenital heart disease
956820|NCT02222532|cardiopulmonary bypass
956821|NCT02222532|euthyroid sick syndrome
956822|NCT02222519|statins
956823|NCT02222519|nondepolarizing muscle relaxants
956824|NCT02222519|rocuronium
956825|NCT02222519|myalgia
956829|NCT02222480|Patients
956830|NCT02222480|with mild
956831|NCT02222480|moderate
956832|NCT02222480|essential
956833|NCT02222441|Palbociclib
956834|NCT02222441|Modafinil
956835|NCT02222441|Pioglitazone
956836|NCT02222441|Pharmacokinetics
956837|NCT02222441|Drug-Drug Interaction Study
956838|NCT02222441|Healthy Volunteers
956839|NCT02222441|CYP3A Inducers
956840|NCT02222415|Muscle mass
956841|NCT02222415|Strength
956842|NCT02222415|Cross-sectional area
956843|NCT02222415|Protein
956844|NCT02222402|Quality of Life
956845|NCT02222402|Exercise
956846|NCT02222402|Functional Capacity
956847|NCT02222376|Diabetic ulcer, diabetic foot
956848|NCT02222363|Phase I
956849|NCT02222363|Iron chelator
956850|NCT02222363|Refractory advanced solid tumors
956851|NCT02222363|Dose escalation study
956852|NCT02222363|Safety and tolerability
956853|NCT02222363|Tumor response by RECIST 1.1
956854|NCT02222363|Progression-free survival
956855|NCT02222363|Overall survival Pharmacokinetics
956856|NCT02222350|type 2 diabetes mellitus
956857|NCT02222337|behavioral intervention
956858|NCT02222337|quality of life
956859|NCT02222337|breast cancer
956860|NCT02222337|Latina
956861|NCT02222337|caregiver
956862|NCT02222337|PCORI
956863|NCT02222324|QTc Interval
956864|NCT02222324|Healthy Subjects
956865|NCT02222272|cml
956866|NCT02222272|chronic myeloid leukemia
956867|NCT02222272|dasatinib
956868|NCT02222272|nilotinib
956869|NCT02222272|tki
956870|NCT02222272|second generation tki
956871|NCT02222272|2nd generation tki
956872|NCT02222259|Geriatric Oncology
956873|NCT02222259|Quality of Life
956874|NCT02222259|Comprehensive Geriatric Assessment
956875|NCT02222259|Functional Status
956876|NCT02222259|Chemotherapy
956877|NCT02222259|Older Adults
956878|NCT02222246|Sickle Cell Disease
956879|NCT02222246|Emergency Department
956880|NCT02222246|Vaso-occlusive Crisis
956881|NCT02222246|Pain Management
956882|NCT02222246|Pilot Project
956883|NCT02222207|neovascular Age-related Macular Degeneration
956884|NCT02222194|Lung cancer
956885|NCT02222194|Surgery
956886|NCT02222194|Videomediastinoscopy
956887|NCT02222181|elderly, medication adherence,pharmaceutical care
956888|NCT02222155|ANCA-associated vasculitis
956889|NCT02222155|complement
956890|NCT02222155|vasculitis
956891|NCT02222155|C5aR
956892|NCT02222142|Ischemic heart disease
956893|NCT02222142|Off pump coronary artery bypass graft
956894|NCT02222142|Isoflurane
956895|NCT02222142|Propofol
956896|NCT02222129|Randomized controlled trial
956897|NCT02222129|anesthetics-local
956898|NCT02222129|bupivacaine
956899|NCT02222129|analgesia
956900|NCT02222129|Pain, Postoperative
956901|NCT02222116|STEMI
956902|NCT02222116|BMS
956903|NCT02222116|DES
956904|NCT02222116|mesh
956905|NCT02222090|patients with atrial fibrillation (AF) recommend the use of novel oral anticoagulants (NOACs) in patients with non-valvular AF
956906|NCT02222077|Central blood pressure
956907|NCT02222077|Ambulatory blood pressure monitoring
956908|NCT02222077|Target-organ damage
956909|NCT02222077|Adolescents and young adults
956910|NCT02222051|neck pain
956911|NCT02222051|chronic pain
956912|NCT02221986|Interdisciplinary rehabilitation
956913|NCT02221986|Neurooncology
956914|NCT02221986|Physiotherapy
956915|NCT02221986|Occupational therapy
956916|NCT02221986|Neurorehabilitation
956917|NCT02221986|Glioma
956919|NCT02221947|Alzheimer's
956920|NCT02221947|bryostatin
956921|NCT02221947|PKC epsilon
956922|NCT02221934|Pain
956923|NCT02221934|Chronic
956924|NCT02221934|Amputation
956925|NCT02221934|Phantom Pain
956926|NCT02221934|Stump Pain
956927|NCT02221908|Systolic Blood pressure < 100 mm Hg
956928|NCT02221895|postpartum appointment
956929|NCT02221895|breastfeeding
956930|NCT02221895|postpartum contraception
956931|NCT02221895|postpartum cervical cancer screening
956932|NCT02221895|postpartum depression screening
956933|NCT02221856|Conventional orthodontic treatment
956934|NCT02221856|Motion View
956935|NCT02221843|sun behavior
956936|NCT02221843|immunosuppression
956937|NCT02221843|skin neoplasms
956938|NCT02221843|sunbit
956939|NCT02221843|uv sensor
956940|NCT02221843|uv dosimeter
956941|NCT02221843|solar radiation
956942|NCT02221843|uv exposition
956943|NCT02221843|uv index
956944|NCT02221804|Physical Inactivity
956945|NCT02221804|Skeletal Muscle
956946|NCT02221804|Cachexia
956947|NCT02221791|Flavan-3-ol
956948|NCT02221791|Flavonoids
956949|NCT02221791|Epicatechin
956950|NCT02221791|Cocoa
956951|NCT02221791|Chocolate
956952|NCT02221791|Endothelial function
956953|NCT02221791|Bioavailability
956954|NCT02221778|Carcinoma, Hepatocellular
956955|NCT02221778|SBRT
956956|NCT02221765|Obesity
956957|NCT02221765|Overnutrition
956958|NCT02221765|Nutrition Disorders
956959|NCT02221765|Overweight
956960|NCT02221765|Body Weight
956961|NCT02221765|Signs and Symptoms
956962|NCT02221752|iron deficiency
956963|NCT02221752|iron deficiency anemia
956964|NCT02221752|infant
956965|NCT02221752|pregnancy
956966|NCT02221739|lung cancer
956967|NCT02221739|NSCLC
956968|NCT02221739|lung
956969|NCT02221739|cancer
956970|NCT02221739|radiation
956971|NCT02221739|immunotherapy
956972|NCT02221739|metastatic
956973|NCT02221726|Healthy
956974|NCT02221726|JNJ-35685-AAA-G-023
956975|NCT02221726|Placebo
956976|NCT02221726|Transdermal delivery device system
956977|NCT02221713|diverticulitis
956978|NCT02221713|diverticulosis
956979|NCT02221713|diverticular disease
956988|NCT02221687|synbiotic formula
956989|NCT02221687|infant formula
956990|NCT02221687|diarrhea
956991|NCT02221674|Post-surgical pain
956992|NCT02221674|Opioid
956993|NCT02221661|Alzheimer
956994|NCT02221661|cognitive impairment
956995|NCT02221661|blood test
956996|NCT02221648|Back
956997|NCT02221648|Pain
956998|NCT02221648|Muscle
956999|NCT02221635|Schizoaffective Disorder
957000|NCT02221635|Repetitive transcranial magnetic stimulation (rTMS)
957001|NCT02221622|Alzheimer's disease
957002|NCT02221622|Mild Cognitive Impairment
957003|NCT02221622|Dementia
957004|NCT02221622|Regenerative therapeutic
957005|NCT02221609|Low Back Pain, Mechanical Low Back Pain, Low Back Ache, Low Backache, Lower Back Pain, Lumbago
957006|NCT02221596|Vitamin D
957007|NCT02221596|25(OH)D
957008|NCT02221596|Aerobic training
957009|NCT02221596|Near-infrared spectroscopy
957010|NCT02221596|Diffuse correlation spectroscopy
957011|NCT02221596|MRS
957012|NCT02221583|End stage renal disease
957013|NCT02221583|Renal transplant candidate
957014|NCT02221583|Laparoscopic sleeve gastrectomy
957015|NCT02221583|Immunosuppressants
957016|NCT02221544|Parkinson's disease, rTMS, Freezing of Gait
957017|NCT02221518|OCD
957018|NCT02221518|Functional Magnetic Resonance Imaging (fMRI)
957019|NCT02221505|LOP628,
957020|NCT02221505|cKit,
957021|NCT02221505|ADC,
957022|NCT02221505|Antibody drug conjugates,
957023|NCT02221505|maytansine
957024|NCT02221466|diabetes
957025|NCT02221466|foot
957026|NCT02221466|wounds
957027|NCT02221466|nitric oxide
957028|NCT02221466|endothelium
957029|NCT02221466|infection
957030|NCT02221466|biological markers
957031|NCT02221466|observational study
957032|NCT02221466|hyperbaric oxygen
957033|NCT02221466|ulcers
957034|NCT02221466|cytokines
957035|NCT02221466|inflammation
957036|NCT02221453|Diabetic Macular Edema
957037|NCT02221453|Ocular Cytokines
957038|NCT02221453|Triamcinolone Acetonide
957039|NCT02221427|First time mothers
957040|NCT02221427|Labour progression
957041|NCT02221427|Prolonged labour
957042|NCT02221427|Oxytocin
957043|NCT02221427|Mode of delivery
957044|NCT02221427|Maternal birth outcome
957045|NCT02221427|Neonatal birth outcome
957046|NCT02221349|Sensitivity
957047|NCT02221336|Bipolar disorder
957048|NCT02221336|Daily electronic monitoring
957049|NCT02221336|Smartphones
957050|NCT02221336|Subjective and objective smartphone data
957051|NCT02221336|Feedback loop
957052|NCT02221310|targeted therapy
957053|NCT02221310|leukemia
957054|NCT02221310|MDS
957055|NCT02221310|immune therapy
957056|NCT02221284|Pharmacological therapy
957057|NCT02221258|Rheumatoid Arthritis
957058|NCT02221258|Rheumatic Disease
957059|NCT02221258|RA
957060|NCT02221258|Stem cell
957061|NCT02221258|Cell therapy
957062|NCT02221258|furestem
957063|NCT02221258|Umbilical cord Blood
957064|NCT02221258|hUCB-MSC
957065|NCT02221258|UCB-MSC
957066|NCT02221245|Esophageal cancer
957067|NCT02221245|Cancer Stem Cell
957068|NCT02221245|CSC
957069|NCT02221245|Wnt
957070|NCT02221245|Hegdehog
957071|NCT02221245|Notch
957072|NCT02221245|Signaling
957073|NCT02221245|Pathway
957074|NCT02221245|Chemo-naive
957075|NCT02221232|ZuraPrep
957076|NCT02221232|Antimicrobial
957077|NCT02221232|Bio-Science Laboratories
957078|NCT02221232|Zurex Pharma
957079|NCT02221232|Surgical/Patient preoperative skin preparation
957080|NCT02221219|infant
957081|NCT02221219|brain injury
957082|NCT02221219|renal
957083|NCT02221219|indomethacin
957084|NCT02221206|Mini-Screw implant anchorage
957085|NCT02221206|retraction of maxillary incisors
957086|NCT02221180|Bioequivalence
957087|NCT02221180|Metformin
957088|NCT02221180|Canagliflozin
957089|NCT02221180|Healthy
957090|NCT02221167|breastfeeding
957091|NCT02221167|donor milk
957092|NCT02221167|formula
957093|NCT02221167|exclusive breastfeeding
957094|NCT02221167|newborn
957095|NCT02221154|in vitro fertilization
957096|NCT02221154|ovarian hyperstimulation
957097|NCT02221154|pregnancy
957098|NCT02221115|Google Glass device
957099|NCT02221115|Evaluation
957100|NCT02221115|patient's
957101|NCT02221115|response
957102|NCT02221115|to new technology
957103|NCT02221115|clinical setting
957104|NCT02221102|edoxaban
957105|NCT02221102|aspirin
957106|NCT02221102|new oral anticoagulant
957107|NCT02221102|TIA
957108|NCT02221102|acute minor ischemic stroke
957109|NCT02221089|Effect of Retaron on imparied retinal vascular reactivity after LPS administration in healthy subjects
957110|NCT02221076|Cellvizio
957111|NCT02221076|Endomicroscopy
957112|NCT02221076|Robot-assisted procedure
957113|NCT02221076|Cervix cancer
957114|NCT02221076|Endocervix cancer
957115|NCT02221076|Endometrium cancer
957116|NCT02221076|Ovarian cancer
957117|NCT02221076|Tubal cancer
957118|NCT02221076|Colposcopy
957119|NCT02221076|Hysteroscopy
957120|NCT02221063|thiamin
957121|NCT02221063|thiamin diphosphate
957122|NCT02221063|beriberi
957123|NCT02221063|Cambodia
957124|NCT02221063|fish sauce
957125|NCT02221063|fortification
957126|NCT02221063|pregnancy
957127|NCT02221063|breastfeeding
957128|NCT02221063|childbearing age
957129|NCT02221037|PaO2/FiO2
957130|NCT02221037|Peri-operative lung injury
957131|NCT02221037|EVLWI
957132|NCT02221037|ARDS
957133|NCT02221037|PVPI
957134|NCT02221037|SOFA scores
957135|NCT02221037|GSK2862277
957136|NCT02221037|Oesophagectomy
957137|NCT02221024|Peripheral intravenous catheter
957138|NCT02221024|Peripheral intravenous lock
957139|NCT02221024|Normal saline
957140|NCT02221024|Patency
957141|NCT02221024|Management
957142|NCT02221024|of peripheral
957143|NCT02221024|intravenous catheter
957144|NCT02221011|Shock wave
957145|NCT02221011|Spasticity
957146|NCT02221011|Effect
957147|NCT02220998|Hepatitis C
957148|NCT02220998|HCV
957149|NCT02220998|cirrhosis
957150|NCT02220998|Sofosbuvir
957151|NCT02220998|Sovaldi
957152|NCT02220998|SOF/VEL
957153|NCT02220998|GS-5816
957154|NCT02220998|GS-7977
957155|NCT02220998|liver
957156|NCT02220998|Treatment naive
957157|NCT02220998|Treatment Experience
957158|NCT02220998|genotype 2
957159|NCT02220972|Epilepsy
957160|NCT02220972|Partial Onset Seizures
957161|NCT02220972|Insomnia
957162|NCT02220959|morbid obesity surgery
957163|NCT02220959|walk test
957164|NCT02220959|exercise
957165|NCT02220946|Vaginal Electrical Stimulation
957166|NCT02220933|Multiple Sclerosis
957167|NCT02220933|MS
957168|NCT02220933|EDSS
957169|NCT02220920|insulin resistance
957170|NCT02220907|MT-2412
957171|NCT02220907|MP-513
957172|NCT02220907|TA-7284
957173|NCT02220907|Teneligliptin
957174|NCT02220907|Canagliflozin
957175|NCT02220894|PD-1
957176|NCT02220894|PD1
957177|NCT02220894|PD-L1
957178|NCT02220894|PDL1
957179|NCT02220881|Hallux valgus, Mold making silicone toe separator, Toe separator
957180|NCT02220868|HIV
957181|NCT02220868|HCV
957182|NCT02220868|DAA
957183|NCT02220829|alpha-blocker
957184|NCT02220829|symptomatic urinary problems
957185|NCT02220829|radiation therapy
957186|NCT02220829|prostate cancer
957187|NCT02220816|Attention
957188|NCT02220816|Competitive
957189|NCT02220816|Training
957190|NCT02220803|Acetazolamide
957191|NCT02220803|Zonegran
957192|NCT02220803|Obstructive Sleep apnea
957193|NCT02220803|Apnea
957194|NCT02220803|Respiration Disorders
957195|NCT02220803|Sleep Disorders
957196|NCT02220803|Cardiovascular
957197|NCT02220803|Hypertension
957198|NCT02220803|Carbonic Anhydrase
957199|NCT02220803|Carbonic Anhydrase Inhibitors
957200|NCT02220803|Enzyme Inhibitors
957201|NCT02220803|Sulfonamides
957202|NCT02220803|Therapeutic Uses
957203|NCT02220803|Pharmacologic Actions
957204|NCT02220803|Vascular stifness
957211|NCT02220777|MTD (Maximum Tolerated Dose)
957212|NCT02220777|Food effect
957213|NCT02220777|Postmenopausal subjects
957214|NCT02220777|Vasectomized subjects
957215|NCT02220777|FIH (First In Humans)
957216|NCT02220777|SAD (Single Ascending Dose)
957217|NCT02220777|DDI (Drug-Drug Interaction)
957218|NCT02220764|prospective study
957219|NCT02220764|chipping
957220|NCT02220764|survival rate
957221|NCT02220764|fracture resistance
957222|NCT02220764|zirconia
957223|NCT02220751|Periodontal Attachment Loss
957224|NCT02220751|Genes
957225|NCT02220751|Saliva
957226|NCT02220751|Diagnosis
957227|NCT02220738|Alzheimer's Disease
957228|NCT02220725|Andexanet alpha
957229|NCT02220725|Anticoagulation
957230|NCT02220725|Antidote
957231|NCT02220725|Rivaroxaban
957232|NCT02220725|Anti-fXa inhibitor
957233|NCT02220725|PRT4445
957234|NCT02220725|Xarelto
957235|NCT02220725|Reversal agent
957236|NCT02220712|Aripiprazole
957237|NCT02220712|Deltoid
957238|NCT02220699|Ostoporosis
957239|NCT02220699|Primary Prevention
957240|NCT02220699|Health Promotion
957241|NCT02220699|General Practice
957242|NCT02220699|Secondary screening
957243|NCT02220699|Patients at increased risk of osteoporosis
957244|NCT02220686|VAPOR
957245|NCT02220686|smoking cessation
957246|NCT02220686|PAD
957247|NCT02220621|Intrauterine adhesion
957248|NCT02220621|crosslinked hyaluronan gel
957249|NCT02220621|hysteroscopy
957250|NCT02220621|clinical trial
957251|NCT02220608|Multiple Myeloma
957252|NCT02220608|G-CSF
957253|NCT02220608|Bortezomib
957254|NCT02220595|Stenting
957255|NCT02220595|Endarterectomy
957256|NCT02220595|Cognition
957257|NCT02220582|Cardiac Magnetic Resonance (CMR)
957258|NCT02220582|Cardiovascular Diseases
957259|NCT02220582|socio-environmental factors
957260|NCT02220582|Contextual factors
957261|NCT02220543|Cognitive behavioral therapy
957262|NCT02220543|Primary health care
957263|NCT02220543|Physical Therapy
957264|NCT02220530|Sedation.
957265|NCT02220530|Colonoscopy quality.
957266|NCT02220530|Scientific and technical quality.
957267|NCT02220530|Perceived quality (patient's satisfaction).
957268|NCT02220530|Safety
957269|NCT02220517|MRI/US fusion-guided prostate biopsy
957270|NCT02220517|MR-guided in-bore prostate biopsy
957271|NCT02220517|prostate cancer
957272|NCT02220504|Treatment
957273|NCT02220504|Maintenance
957274|NCT02220478|hip
957275|NCT02220478|Signature
957276|NCT02220465|sedentary
957277|NCT02220465|smoking
957278|NCT02220465|cue reactivity
957279|NCT02220465|physical activity
957280|NCT02220439|rotavirus
957281|NCT02220439|immunogenicity
957282|NCT02220439|enteric vaccine
957283|NCT02220439|vaccine immunogenicity
957284|NCT02220439|rotavirus vaccine
957285|NCT02220439|gut microbiome
957286|NCT02220439|microbiome
957287|NCT02220426|Brown adipose tissue
957288|NCT02220426|Hyperpolarized xenon gas MRI
957289|NCT02220413|Breastmilk
957290|NCT02220413|Lactogenesis
957291|NCT02220413|Obesity
957292|NCT02220400|Postoperative cognitive dysfunction
957293|NCT02220400|Ketamine
957294|NCT02220400|Surgery
957295|NCT02220387|occupational COPD
957296|NCT02220387|phenotype
957297|NCT02220387|genetic
957298|NCT02220374|Osteoarthritis
957299|NCT02220374|Finger
957300|NCT02220374|Supportive
957301|NCT02220374|Tape
957302|NCT02220374|Pain
957303|NCT02220374|Function
957304|NCT02220374|Trial
957305|NCT02220335|pulmonary hypertension
957306|NCT02220335|pulmonary arterial denervation
957307|NCT02220335|left heart failure
957308|NCT02220335|6-min walk distance
957309|NCT02220322|cortical thickness
957310|NCT02220322|age
957311|NCT02220309|anxiety
957312|NCT02220309|depression
957313|NCT02220309|SAD
957314|NCT02220309|bipolar disorder II
957315|NCT02220309|PTSD
957316|NCT02220309|GAD
957317|NCT02220309|Phobia
957318|NCT02220283|Acute kidney injury,aortic dissection
957319|NCT02220257|diabetes mellitus type 1
957320|NCT02220257|remission, honeymoon
957321|NCT02220257|microangiopathy
957322|NCT02220244|multiple sclerosis (MS)
957323|NCT02220244|optic neuritis
957324|NCT02220244|visual defect
957325|NCT02220244|visual loss
957326|NCT02220244|relapsing remitting multiple sclerosis (RRMS)
957327|NCT02220244|primary progressive multiple sclerosis (PPMS)
957328|NCT02220244|secondary progressive multiple sclerosis (SPMS)
957329|NCT02220231|mediastinal mass, one-lung ventilation, capnothorax, transesophageal echocardiography
957330|NCT02220218|Healthy
957331|NCT02220218|Metformin
957332|NCT02220218|Canagliflozin
957333|NCT02220218|JNJ-28431754
957334|NCT02220205|IUD
957335|NCT02220205|training
957336|NCT02220205|simulation
957337|NCT02220192|cervical neoplasia
957338|NCT02220192|cervix
957339|NCT02220192|high-grade dysplasia
957340|NCT02220192|LEEP (loop electrosurgical excision procedure)
957341|NCT02220192|precancerous cells
957342|NCT02220192|colposcopy
957343|NCT02220166|Celiac Disease
957344|NCT02220166|Gluten
957345|NCT02220166|Gluten free diet
957346|NCT02220166|Triticum monococcum
957347|NCT02220153|Monoclonal antibody
957348|NCT02220153|subjects
957349|NCT02220153|First in human
957350|NCT02220127|Brain
957351|NCT02220127|Neoplasm Micrometastasis
957352|NCT02220127|Gamma Knife Radiosurgery
957353|NCT02220114|Infantile spasms
957354|NCT02220114|vigabatrin
957355|NCT02220114|soluble tablets
957356|NCT02220114|acceptability
957357|NCT02220114|adherence
957358|NCT02220114|pharmacokinetics
957359|NCT02220101|hypothermia
957360|NCT02220101|core temperature
957361|NCT02220101|temperature measurement methods
957362|NCT02220088|Hepatocellular Carcinoma
957363|NCT02220088|TACE
957364|NCT02220088|TACE failure
957365|NCT02220088|TACE refractoriness
957366|NCT02220088|BCLC B
957367|NCT02220075|fiberoptic, LMA, caudal block
957368|NCT02220036|Diabetic nephropathy
957369|NCT02220036|Renal function
957370|NCT02220036|Insulin resistance
957371|NCT02220036|Metabolic profile
957372|NCT02220036|Serum magnesium level
957373|NCT02220010|Post operative pancreatic fistulas
957374|NCT02220010|Pancreatic stenting
957375|NCT02219997|Cataract
957376|NCT02219997|Intraocular lens (IOL)
957377|NCT02219997|AcrySof
957378|NCT02219984|Anticoagulation
957379|NCT02219984|vitamin K antagonists
957380|NCT02219984|Warfarin
957381|NCT02219984|low molecular weight heparin
957382|NCT02219984|fondaparinux
957383|NCT02219984|antithrombotics
957384|NCT02219984|Direct oral anticoagulants
957385|NCT02219984|dabigatran
957386|NCT02219984|rivaroxaban
957387|NCT02219984|apixaban
957388|NCT02219984|edoxaban
957389|NCT02219984|atrial fibrillation
957390|NCT02219984|venous thromboembolism
957391|NCT02219971|Healthy
957392|NCT02219958|Hypertension
957393|NCT02219945|pulmonary tuberculosis; electronic nose; diagnostic accuracy
957394|NCT02219932|Fampridine
957395|NCT02219919|Carpal Tunnel Syndrome
957396|NCT02219919|Pain
957397|NCT02219919|Sensitivity
957398|NCT02219919|Pain Thresholds
957399|NCT02219919|Sensitization
957400|NCT02219919|Physical Therapy
957401|NCT02219893|Peritoneal Carcinomatosis
957402|NCT02219893|Peritoneal Metastasis
957403|NCT02219893|Colorectal Cancer
957404|NCT02219893|Cytoreductive surgery
957405|NCT02219893|HIPEC
957406|NCT02219893|Intraperitoneal treatment
957407|NCT02219893|Immunotoxin
957408|NCT02219893|MOC31PE
957409|NCT02219880|Kava
957410|NCT02219880|Anxiety
957411|NCT02219880|Generalized Anxiety Disorder
957412|NCT02219880|Psychiatric
957413|NCT02219880|Anxiolytic
957414|NCT02219880|GABA
957415|NCT02219880|Kavalactones
957416|NCT02219867|ketamine
957417|NCT02219867|MDD
957418|NCT02219841|Obesity, low-calorie diet, exercise, atrial fibrillation
957419|NCT02219828|pericarditis
957420|NCT02219828|recurrent pericarditis
957421|NCT02219828|corticosteroids
957422|NCT02219828|anakinra
957423|NCT02219815|Preoperative Care
957424|NCT02219815|Exercise Therapy
957425|NCT02219815|Cardiac Surgery
957426|NCT02219815|Frailty
957427|NCT02219802|Coronary artery disease
957428|NCT02219802|Acute myocardial infarction
957429|NCT02219802|Drug-coated balloon
957430|NCT02219802|Drug-eluting stent
957431|NCT02219776|Infection,
957432|NCT02219776|Proprionbacterium Acne,
957433|NCT02219776|Shoulder,
957434|NCT02219776|skin preparation
957435|NCT02219750|premix insuiln, basal-plus insulin
957436|NCT02219711|MGCD516
957437|NCT02219711|MET
957438|NCT02219711|AXL
957439|NCT02219711|RET
957440|NCT02219711|TRK
957441|NCT02219711|NTRK
957442|NCT02219711|DDR2
957443|NCT02219711|KDR
957444|NCT02219711|VEGFR
957445|NCT02219711|PDGFRA
957446|NCT02219711|KIT
957447|NCT02219711|Tyrosine kinase inhibitor
957448|NCT02219711|NSCLC
957449|NCT02219711|Non-small cell lung cancer
957450|NCT02219711|Head and neck cancer
957451|NCT02219711|Renal cell carcinoma
957452|NCT02219711|Prostate cancer
957453|NCT02219711|Phase 1
957454|NCT02219711|CBL
957455|NCT02219672|Triptolide wilfordii HIV-1 reservoir acute hiv infection
957456|NCT02219659|sedation strategy
957457|NCT02219659|mechanical ventilation
957458|NCT02219659|ventilator weaning
957459|NCT02219646|T2DM
957460|NCT02219646|ED
957461|NCT02219620|creative arts
957462|NCT02219620|older adults
957463|NCT02219620|intervention study
957464|NCT02219594|gemstone CT
957465|NCT02219594|320-detector row spiral CT
957466|NCT02219594|optical coherence tomography(OCT)
957467|NCT02219594|in-stent restenosis
957468|NCT02219594|coronary heart disease
957469|NCT02219581|Osteoarthritis
957470|NCT02219581|Postoperative pain
957471|NCT02219581|Total knee arthroplasty
957472|NCT02219581|Orthopaedics
957473|NCT02219581|Inflammation
957474|NCT02219568|obscure gastrointestinal bleeding, CT enterography
957475|NCT02219555|Carpal tunnel
957476|NCT02219542|cytokine Transversus Abdominis Plane Block
957477|NCT02219503|Hepatitis C
957478|NCT02219503|Chronic Hepatitis C
957479|NCT02219503|Compensated Cirrhosis
957480|NCT02219503|Cirrhotic
957481|NCT02219503|Hepatitis C Genotype 1b
957482|NCT02219503|Hepatitis C Virus
957483|NCT02219503|Interferon-Free
957484|NCT02219503|Child Pugh A
957485|NCT02219503|Ribavirin-Free
957486|NCT02219490|Non responder
957487|NCT02219490|Null responder
957488|NCT02219490|Treatment-Experienced
957489|NCT02219490|Cirrhosis
957490|NCT02219490|Relapser
957491|NCT02219490|Hepatitis C Genotype 1
957492|NCT02219490|Compensated Cirrhosis
957493|NCT02219490|Naive
957494|NCT02219477|Hepatitis C Genotype 1
957495|NCT02219477|Chronic Hepatitis C
957496|NCT02219477|Decompensated Cirrhosis
957497|NCT02219477|Interferon-Free
957498|NCT02219477|Hepatitis C
957499|NCT02219477|Hepatitis C Virus
957500|NCT02219477|Child-Pugh B
957501|NCT02219477|Cirrhosis
957502|NCT02219477|Hepatitis C Genotype 4
957503|NCT02219464|nasopharyngeal catheter
957504|NCT02219464|nasal cannula
957505|NCT02219451|Chronic heart failure
957506|NCT02219451|exercise training
957507|NCT02219451|Sympathetic modulation
957508|NCT02219451|arterial baroreflex control
957509|NCT02219425|Infertility
957510|NCT02219425|Endometrium
957511|NCT02219425|Endometrial biopsy
957512|NCT02219425|Gene expression
957513|NCT02219412|ticagrelor
957514|NCT02219412|platelet aggregation rate
957515|NCT02219412|ADP antagonist
957516|NCT02219412|antiplatelet therapy
957517|NCT02219399|Pregnancy
957518|NCT02219399|DHA
957519|NCT02219399|Gestational Length
957520|NCT02219399|Cognitive Development
957644|NCT02218840|smoking
957521|NCT02219386|Myofascial pain syndromes,physiotherapy,muscle stretching exercises,neck pain,dry needling
957522|NCT02219360|acute
957523|NCT02219360|exacerbation
957524|NCT02219360|chronic obstructive pulmonary disease
957525|NCT02219347|rheumatoid arthritis
957526|NCT02219347|biological markers
957527|NCT02219347|remission
957528|NCT02219347|ultrasonography
957529|NCT02219347|microarray
957530|NCT02219347|survival analysis
957531|NCT02219347|T cell
957532|NCT02219334|Children
957533|NCT02219334|Nasal suction devices
957534|NCT02219334|Suctioning
957535|NCT02219321|Pain, Opioid dependence, Lidocaine infusion
957536|NCT02219308|Contraception
957537|NCT02219308|Pain
957538|NCT02219308|Intrauterine Device
957539|NCT02219308|Paracervical Block
957540|NCT02219295|SGLT1 (sodium dependent glucose transporter)
957541|NCT02219295|Glut-transporters
957542|NCT02219295|taste receptors genes
957543|NCT02219295|sweet taste receptor T1R2T1R3
957544|NCT02219295|bitter taste receptors of the hTAS2gene family
957545|NCT02219282|laryngeal mask airway, edentulate geriatric patients
957546|NCT02219269|contraception
957547|NCT02219269|family planning
957548|NCT02219269|complex medical conditions
957549|NCT02219256|Drug therapy
957550|NCT02219243|Social Anxiety Disorder
957551|NCT02219243|Cognitive Training
957552|NCT02219243|Interpretation Modification Program
957553|NCT02219204|Acupuncture
957554|NCT02219204|Herbal treatment
957555|NCT02219191|Puerarin tablet
957556|NCT02219191|rheumatoid arthritis
957557|NCT02219191|metabolism syndrome
957558|NCT02219165|Paediatrics
957559|NCT02219165|Toxic Shock Syndrome
957560|NCT02219165|Intravenous human immunoglobulin
957561|NCT02219165|feasibility
957562|NCT02219139|Edentulous
957563|NCT02219139|Roxolid
957564|NCT02219139|SLAclive surface
957565|NCT02219139|Titanium/zirconium
957566|NCT02219113|Damage of articular cartilage
957567|NCT02219113|Cartilage degeneration
957568|NCT02219113|Intraarticular injection
957569|NCT02219113|ADRC
957570|NCT02219113|Adipose-derived regenerative cells
957571|NCT02219113|Adipose tissue
957572|NCT02219113|Stem cells
957573|NCT02219087|Total knee arthroplasty
957574|NCT02219087|Total joint arthroplasty
957575|NCT02219087|Knee replacement
957576|NCT02219087|Osteoarthritis of the knee
957577|NCT02219061|Measles
957578|NCT02219061|Meningitis C
957579|NCT02219061|waning
957580|NCT02219061|Geometric Mean Titer
957581|NCT02219061|China
957582|NCT02219048|Asthma
957583|NCT02219048|Staged withdrawal of background therapy
957584|NCT02219035|presentation with
957585|NCT02219022|Rheumatoid arthritis
957586|NCT02219022|Progressive resistance exercise
957587|NCT02219022|Pain
957588|NCT02219022|Functional capacity
957589|NCT02219022|Quality of life
957590|NCT02219022|Muscle strength
957591|NCT02219009|OPC-14597 Digital
957592|NCT02219009|Aripiprazole
957593|NCT02219009|Medical Information Device #1 System (MIND1)
957594|NCT02219009|Treatment Adherence
957595|NCT02219009|Ingestible Event Marker
957596|NCT02218996|Anxiety
957597|NCT02218996|Children
957598|NCT02218996|Adolescent
957599|NCT02218996|Effectiveness
957600|NCT02218996|Outpatient
957601|NCT02218983|trauma
957602|NCT02218983|echo
957603|NCT02218983|echocardiogram
957604|NCT02218983|ultrasound
957605|NCT02218983|inferior vena cava collapsibility
957606|NCT02218970|rehabilitation
957607|NCT02218970|strength training
957608|NCT02218970|muscle strength
957609|NCT02218970|physical fitness
957610|NCT02218957|Bariatric surgery
957611|NCT02218957|Roux-en-Y Gastric Bypass
957612|NCT02218931|Pre-eclampsia
957613|NCT02218931|Gestational diabetes
957614|NCT02218931|Stillbirth
957615|NCT02218931|Small for gestational age
957616|NCT02218931|Admission to neonatal intensive care unit
957617|NCT02218931|Obesity
957618|NCT02218931|Raised Lipids
957619|NCT02218931|High Blood Pressure
957620|NCT02218931|Cardiovascular risk
957621|NCT02218931|Insulin resistance
957622|NCT02218931|Mediterranean dietary pattern
957623|NCT02218931|Dietary interventions
957624|NCT02218918|Ground walk
957625|NCT02218918|treadmill walk
957626|NCT02218918|Functional walk capacity
957627|NCT02218918|COPD
957628|NCT02218918|Quality of Life
957629|NCT02218905|Correlation
957630|NCT02218905|Sit to stand repetitions
957631|NCT02218905|Anthropometric variables
957632|NCT02218905|Age
957633|NCT02218905|Height
957634|NCT02218905|weight
957635|NCT02218905|Gender
957636|NCT02218905|Regression
957637|NCT02218866|Bariatric surgery
957638|NCT02218866|Obesity
957639|NCT02218866|Neuropathy
957640|NCT02218853|Bipolar disorder
957641|NCT02218853|Psychosis
957642|NCT02218853|Schizophrenia
957643|NCT02218840|cigar smoker
957645|NCT02218840|behavioral pharmacology
957646|NCT02218840|smoking topography
957647|NCT02218827|Dry Eye
957648|NCT02218827|Inflammatory reaction
957649|NCT02218827|steroids
957650|NCT02218814|Femoral Nerve Block
957651|NCT02218814|Adductor Canal Nerve Block
957652|NCT02218801|Liver metastasis
957653|NCT02218801|Colorectal carcinoma
957654|NCT02218801|Unresectable
957655|NCT02218801|Borderline resectable
957656|NCT02218801|Initially unresectable
957657|NCT02218788|Nasolabial folds
957658|NCT02218788|Marionette lines
957659|NCT02218788|Cheek bones
957660|NCT02218788|Jaw lines
957661|NCT02218775|Kappa opioid receptor
957662|NCT02218775|Mu opioid receptor
957663|NCT02218775|LY2456302
957664|NCT02218775|Anhedonia
957665|NCT02218775|Mood and Anxiety Spectrum Disorders
957666|NCT02218762|Fluticasone propionate/salmeterol in a capsule-based inhaler
957667|NCT02218762|replicated cross-over design
957668|NCT02218762|Respiratory
957669|NCT02218762|asthma
957670|NCT02218762|safety
957671|NCT02218762|pharmacokinetics
957672|NCT02218762|Fluticasone propionate/salmeterol
957673|NCT02218762|pharmacodynamics
957674|NCT02218762|Fluticasone propionate/salmeterol in a multi-dose dry powder inhaler
957675|NCT02218736|Anhedonia
957676|NCT02218736|Mood and Anxiety Spectrum Disorders
957677|NCT02218736|CERC-501 (investigational product)
957678|NCT02218736|Kappa Opioid Receptor (KOR)
957679|NCT02218723|healthy volunteer
957680|NCT02218723|Asthma
957681|NCT02218723|inhaled corticosteroid
957682|NCT02218723|UD-DPI
957683|NCT02218723|ELLIPTA DPI
957684|NCT02218723|Fluticasone furoate
957685|NCT02218697|Immunogenicity
957686|NCT02218697|Influsplit Tetra (Fluarix Tetra) 2014/2015 season
957687|NCT02218697|Safety
957688|NCT02218697|Adults
957689|NCT02218697|Pneumovax 23/Pneumovax
957690|NCT02218697|Co-administration
957691|NCT02218697|Elderly
957692|NCT02218697|Seasonal influenza
957693|NCT02218697|Pneumococcal infection
957694|NCT02218632|Galactosaemia
957695|NCT02218632|Dysglycosylation
957696|NCT02218632|Diet
957697|NCT02218619|type 1 diabetes (T1D)
957698|NCT02218619|endoplasmic reticulum (ER) stress
957699|NCT02218619|induced pluripotential stem (iPS) cells
957700|NCT02218619|Tauroursodeoxycholic Acid (TUDCA)
957701|NCT02218606|Abiraterone Acetate
957702|NCT02218606|CABAZITAXEL
957703|NCT02218606|CASTRATION RESISTANT
957704|NCT02218606|14-046
957705|NCT02218606|Prostate Cancer Clinical Trials Consortium
957706|NCT02218580|massage therapy
957707|NCT02218580|juvenile arthritis
957708|NCT02218580|pain
957709|NCT02218554|BRONJ
957710|NCT02218528|subjects
957711|NCT02218515|Autogenous bone graft
957712|NCT02218515|Chronic periodontitis
957713|NCT02218515|Enamel matrix derivatives
957714|NCT02218515|Gingival crevicular fluid
957715|NCT02218515|Periodontal flap surgery
957716|NCT02218502|Ovarian cancer
957717|NCT02218502|Diagnosis
957718|NCT02218502|Risk of Malignancy Index
957719|NCT02218502|RMI
957720|NCT02218502|Ultrasound
957721|NCT02218502|Simple ultrasound-based rules
957722|NCT02218502|DW-MRI
957723|NCT02218502|Subjective assessment
957724|NCT02218489|Pain
957725|NCT02218489|Corticosteroid
957726|NCT02218489|Meibomian Gland Disease
957727|NCT02218489|Blepharitis
957728|NCT02218489|Eyelid
957729|NCT02218489|Ocular Discomfort
957730|NCT02218463|Vulvar disease, adhesions, topical therapy
957731|NCT02218463|Labial adhesions prepubertal girls
957732|NCT02218463|Labial agglutination
957733|NCT02218463|Labial fusion
957734|NCT02218437|Mesenchymal Stem Cells (MSC)
957735|NCT02218437|Umbilical Cord
957736|NCT02218437|thymocyte globulin (ATG)
957737|NCT02218437|Severe Aplastic Anemia (SAA)
957738|NCT02218398|airway resistance
957739|NCT02218398|lung compliance
957740|NCT02218398|Duration of mechanical ventilation
957741|NCT02218385|Nipple Aspirate Fluid
957742|NCT02218385|Breast Health Screening
957743|NCT02218385|Cytology
957744|NCT02218372|Clostridium difficile-associated Diarrhea (CDAD)
957745|NCT02218372|vancomycin
957746|NCT02218372|Clostridium difficile infection
957747|NCT02218372|fidaxomicin
957748|NCT02218359|Gram-negative pneumonia
957749|NCT02218359|Aerosol antibiotics
957750|NCT02218359|Mechanical ventilation
957751|NCT02218359|Amikacin
957752|NCT02218359|Fosfomycin
957753|NCT02218359|Pneumonia, Bacterial
957754|NCT02218359|Pneumonia
957755|NCT02218359|Bacterial Infections
957756|NCT02218359|Lung Diseases
957757|NCT02218359|Respiratory Tract Diseases
957758|NCT02218359|Respiratory Tract Infections
957759|NCT02218359|Anti-Bacterial Agents
957760|NCT02218359|Anti-Infective Agents
957761|NCT02218359|Therapeutic Uses
957762|NCT02218359|Pharmacologic Actions
957763|NCT02218359|MRSA
957764|NCT02218346|Healthy volunteers
957765|NCT02218320|HIV
957766|NCT02218320|Gut-associated lymphoid tissue
957767|NCT02218320|raltegravir
957768|NCT02218320|Isentress
957769|NCT02218320|dolutegravir
957770|NCT02218320|Tivicay
957771|NCT02218320|pharmacodynamics
957772|NCT02218294|BCX4161
957773|NCT02218294|BioCryst
957774|NCT02218294|hereditary angioedema
957775|NCT02218294|mass balance
957776|NCT02218294|kallikrein inhibitor
957777|NCT02218294|ADME
957778|NCT02218268|type I diabetes
957779|NCT02218268|healthy
957780|NCT02218268|children
957781|NCT02218268|adolescents
957782|NCT02218268|young adults
957783|NCT02218255|In Vitro Fertilization
957784|NCT02218242|Lung
957785|NCT02218242|Cancer
957786|NCT02218242|Ultrasound
957787|NCT02218242|Staging
957788|NCT02218229|shock wave
957789|NCT02218229|carpal tunnel syndrome
957790|NCT02218216|Mild Traumatic Brain Injury
957791|NCT02218203|chronic pain
957792|NCT02218203|central neuropathic pain
957793|NCT02218203|spinal cord injury
957794|NCT02218203|dextromethorphan
957795|NCT02218203|lidocaine
957796|NCT02218203|combination therapy
957797|NCT02218203|analgesia
957798|NCT02218190|Alvimopan
957799|NCT02218190|Ileus
957800|NCT02218190|Posterior spinal fusion
957801|NCT02218177|wet Age Related Macular Degeneration
957802|NCT02218177|Ranibizumab
957803|NCT02218177|Aflibercept
957804|NCT02218177|Combination Photodynamic Therapy
957805|NCT02218177|Cytokine analysis
957806|NCT02218164|metastatic
957807|NCT02218164|cutaneous
957808|NCT02218164|skin cancer
957809|NCT02218151|Hematopoietic
957810|NCT02218151|Stem Cell
957811|NCT02218151|Transplant
957812|NCT02218151|patient-centered
957813|NCT02218151|Microbiota
957814|NCT02218151|GVHD
957815|NCT02218138|Adolescent
957816|NCT02218138|Diabetes
957817|NCT02218138|Depression
957818|NCT02218138|Obesity
957819|NCT02218138|Stress
957820|NCT02218125|Healthy
957821|NCT02218125|Human immunodeficiency virus type 1 (HIV-1) infection
957822|NCT02218125|Acquired immunodeficiency syndrome (AIDS)
957823|NCT02218125|recombinant adenovirus (rAd) vector-based vaccines
957824|NCT02218125|Vaccination
957825|NCT02218125|Ad26.ENVA.01
957826|NCT02218125|Recombinant
957827|NCT02218125|Modified Vaccinia Ankara (MVA) vector-based vaccines
957828|NCT02218112|Blood pressure
957829|NCT02218112|Obesity
957830|NCT02218112|Glomerular filtration rate
957831|NCT02218112|Renal Sodium handling
957832|NCT02218099|Phase 1
957833|NCT02218099|ASP8232
957834|NCT02218099|Single dose
957835|NCT02218099|Multiple doses
957836|NCT02218086|postural control
957837|NCT02218086|postural balance
957838|NCT02218086|slackline
957839|NCT02218073|Healthy
957840|NCT02218073|JNJ-42756493
957841|NCT02218073|JNJ-61818549
957842|NCT02218073|Isotope
957843|NCT02218047|Pegylated-Proline-interferon alpha-2b (AOP2014)
957844|NCT02218047|Polycythemia Vera
957845|NCT02218047|PROUD-PV
957846|NCT02218047|CONTINUATION-PV
957847|NCT02218047|AOP Orphan
957848|NCT02218047|Polycythemia
957849|NCT02218047|Hematologic Diseases
957850|NCT02218047|Myeloproliferative Disorders
957851|NCT02218047|Bone Marrow Diseases
957852|NCT02218047|Interferon-alpha
957853|NCT02218047|Peginterferon alfa-2b
957854|NCT02218021|Alkermes
957855|NCT02218021|ALKS 33
957856|NCT02218021|ALKS 5461
957857|NCT02218021|Samidorphan
957858|NCT02218008|Major depressive disorder (MDD)
957859|NCT02218008|depression
957860|NCT02218008|Alkermes
957861|NCT02218008|ALKS 5461
957862|NCT02218008|samidorphan
957863|NCT02217995|Mindfulness-Based Cognitive Therapy
957864|NCT02217995|Mindfulness
957865|NCT02217969|Anesthesia
957866|NCT02217969|Hypotension
957867|NCT02217930|TQT
957868|NCT02217917|Healthy subjects
957869|NCT02217917|Randomized
957870|NCT02217917|Double-blind
957871|NCT02217917|Single ascending dose
957872|NCT02217917|Multiple ascending dose
957873|NCT02217878|ST-segment elevation myocardial infarction
957874|NCT02217878|non-ST-segment elevation myocardial infarction
957875|NCT02217878|ticagrelor
957876|NCT02217878|morphine
957877|NCT02217878|pharmacokinetics
957878|NCT02217878|pharmacodynamics
957879|NCT02217878|drug interactions
957880|NCT02217878|VASP assay
957881|NCT02217878|Multiple Electrode Aggregometry
957882|NCT02217878|VerifyNow
957883|NCT02217865|Colorectal Cancer
957884|NCT02217865|CRC
957885|NCT02217865|Curative resection of colorectal cancer
957886|NCT02217865|Caregivers
957887|NCT02217865|Interviews
957888|NCT02217865|Focus groups
957889|NCT02217865|Questionnaires
957890|NCT02217865|Surveys
957891|NCT02217852|hypertension
957892|NCT02217852|Tibetan
957893|NCT02217852|Nitrendipine
957894|NCT02217852|hydrochlorothiazide
957895|NCT02217852|captopril
957896|NCT02217852|Beijing hypotensive No.0
957897|NCT02217774|Computer-Aided Design/instrumentation
957898|NCT02217774|Cone-Beam Computed Tomography
957899|NCT02217774|Dental Implant
957900|NCT02217774|MGuide
957901|NCT02217761|Pharmacokinetics
957902|NCT02217761|Antifungal Agents
957903|NCT02217735|Parkinson's Disease
957904|NCT02217735|Caregivers
957905|NCT02217735|Expressive Writing
957906|NCT02217735|Complementary Medicine
957907|NCT02217735|Cortisol
957908|NCT02217696|Electroencephalography (EEG)
957909|NCT02217696|Magnetic Resonance Imaging (MRI)
957910|NCT02217696|Multimodal Neuroimaging
957911|NCT02217696|Development
957912|NCT02217696|Prediction
957913|NCT02217696|Intervention
957914|NCT02217683|Catheterization, Swan-Ganz
957915|NCT02217683|Cardiac Surgical Procedures
957916|NCT02217683|Blood Transfusion
957917|NCT02217683|Nitric Oxide
957918|NCT02217657|Smart-Touch
957919|NCT02217657|Contact force
957920|NCT02217605|NAFLD
957921|NCT02217605|Oral Fructose Challenge
957922|NCT02217605|31P MRS
957923|NCT02217605|Liver
957924|NCT02217605|Subjects
957925|NCT02217579|Weight loss
957926|NCT02217579|Appetite
957927|NCT02217579|Overweight
957928|NCT02217579|Obesity
957929|NCT02217579|Dietary fiber
957930|NCT02217579|Dietary protein
957931|NCT02217566|Prostatic neoplasms
957932|NCT02217566|Diethylstilbestrol therapy
957933|NCT02217566|Abiraterone acetate
957934|NCT02217566|Prednisone
957935|NCT02217566|Androgen deprivation therapy
957936|NCT02217553|platelet
957937|NCT02217553|P-selectin
957938|NCT02217553|platelet-fibrinogen binding
957939|NCT02217553|platelet-monocye aggregate formation
957940|NCT02217553|vitamin D
957941|NCT02217540|Shoulder, disability evaluation, physiotherapy modalities
957942|NCT02217527|crossover
957943|NCT02217501|peripheral arterial disease, antiplatelet therapy
957944|NCT02217462|pregnancy
957945|NCT02217462|gestational weight gain
957946|NCT02217462|dietary intake
957947|NCT02217462|food reward
957948|NCT02217423|Physical Therapy Modalities
957949|NCT02217423|Respiration Disorders
957950|NCT02217423|Respiratory Therapy
957951|NCT02217410|renal, de novo,
957952|NCT02217397|Apnea-hyponea Index, CPAP, Obstructive Sleep Apnea, Oral Appliance
957953|NCT02217384|Microbiome
957954|NCT02217384|DNA sequencing
957955|NCT02217384|Leptin
957956|NCT02217384|Adiponectin
957957|NCT02217384|Insulin
957958|NCT02217384|IGF-I
957959|NCT02217371|ADHD Patient
957960|NCT02217371|Healthy subjects
957961|NCT02217371|Sleepiness
957962|NCT02217371|PSG
957963|NCT02217371|MWT
957964|NCT02217371|EEG
957965|NCT02217371|cognitive tests
957966|NCT02217358|squamous cell carcinoma of the head and neck
957967|NCT02217358|NBI endoscopy
957968|NCT02217358|videoendoscopy
957969|NCT02217358|white light endoscopy
957970|NCT02217358|magnifying endoscopy
957971|NCT02217358|direct laryngoscopy
957972|NCT02217332|Sinusitis
957973|NCT02217332|Rhinosinusitis
957974|NCT02217332|CRS
957975|NCT02217332|CRSwNP
957976|NCT02217332|CSNP-E
957977|NCT02217332|Nasal polyps
957978|NCT02217332|Nasal polyposis
957979|NCT02217332|Eosinophilia
957980|NCT02217332|Asthma
957981|NCT02217319|Volatile Anesthetic
957982|NCT02217319|Cardioprotection
957983|NCT02217319|Lung surgery
957984|NCT02217319|non cardiac surgery
957985|NCT02217293|Pulsed radiofrequency
957986|NCT02217293|Ultrasound-guided
957987|NCT02217293|Carpal tunnel syndrome
957988|NCT02217280|Cervical Radiculopathy
957989|NCT02217267|Peripheral neuropathy
957990|NCT02217215|Spectroscopy
957991|NCT02217215|HPV
957992|NCT02217202|knee replacement
957993|NCT02217202|knee arthroplasty
957994|NCT02217202|revision
957995|NCT02217202|high risk
957996|NCT02217189|Zinc supplementation.
957997|NCT02217189|Oxidative stress.
957998|NCT02217189|Superoxide radical scavengers.
957999|NCT02217189|Asthenospermia.
958000|NCT02217189|Oxido-sensitive index.
958001|NCT02217137|Dry Eye
958002|NCT02217137|Rheumatoid Arthritis
958003|NCT02217137|Systemic Lupus Erythematosus
958004|NCT02217137|Tear cytokines and immune response
958005|NCT02217124|apple
958006|NCT02217124|high fiber
958007|NCT02217124|body composition
958008|NCT02217124|children
958009|NCT02217111|vocal fold nodules
958010|NCT02217111|pediatric
958011|NCT02217111|voice therapy
958012|NCT02217111|acoustic
958013|NCT02217111|aerodynamic
958014|NCT02217111|quality of life
958015|NCT02217111|Adventures in Voice
958016|NCT02217098|ART
958017|NCT02217098|Occlusal
958018|NCT02217098|Occlusoproximal
958019|NCT02217098|Primary teeth
958020|NCT02217085|Colorectal Cancer Screening
958021|NCT02217085|Colon Cancer Screening
958022|NCT02217085|Polyps
958023|NCT02217085|Colonoscopy
958024|NCT02217072|academic performance
958025|NCT02217072|cognitive development
958026|NCT02217072|children in care
958027|NCT02217072|prevention of school failure
958028|NCT02217059|Emergency Medical Services
958029|NCT02217059|Emergency Care
958030|NCT02217059|Hypertension
958031|NCT02217059|BpTRU
958032|NCT02217059|Blood pressure
958033|NCT02217046|Infection
958034|NCT02217046|prevention
958035|NCT02217046|cardiac devices
958036|NCT02217033|Breast Cancer
958037|NCT02217033|Stage I breast cancer
958038|NCT02217033|Stage II breast cancer
958039|NCT02217033|Water study
958040|NCT02217033|'R'
958041|NCT02217033|Electro-kinetically altered beverage
958042|NCT02217033|altered beverage
958043|NCT02217033|Insomnia
958044|NCT02217033|Fatigue
958045|NCT02217033|Depression
958046|NCT02217033|Adjuvant chemotherapy
958047|NCT02217020|Rectal Cancer
958048|NCT02217020|Locally advanced rectal cancer
958049|NCT02217020|Neoadjuvant
958050|NCT02217020|chemotherapy
958051|NCT02217020|FOLFOXIRI
958052|NCT02217007|Tourette
958053|NCT02217007|Tourette's
958054|NCT02217007|tic
958055|NCT02216994|Intestinal dysganglinosis
958056|NCT02216994|Hirschsprung disease
958057|NCT02216994|Hirschsprung disease allied disorders
958058|NCT02216994|diagnostic scoring system
958059|NCT02216994|Prospective study
958060|NCT02216981|Obsessive Compulsive Disorder (OCD)
958061|NCT02216981|Cognitive Behavioural Therapy (CBT)
958062|NCT02216981|Intensive therapy
958063|NCT02216981|Intensive treatment
958064|NCT02216981|Treatment Resistant
958065|NCT02216968|vegetables
958066|NCT02216968|Head Start
958067|NCT02216968|preschool
958068|NCT02216968|children
958069|NCT02216968|theater
958070|NCT02216968|puppet
958071|NCT02216942|Endodontics
958072|NCT02216942|Deciduous teeth
958073|NCT02216942|Iodoform pastes
958074|NCT02216942|Treatment Refusal
958075|NCT02216929|intubation
958076|NCT02216929|intensive care
958077|NCT02216929|withholding treatment
958078|NCT02216929|cancer
958079|NCT02216929|terminal care
958080|NCT02216929|APACHE
958081|NCT02216903|Atrial fibrillation, sleep apnea
958082|NCT02216890|Renal Cell Carcinoma
958083|NCT02216890|Mantle-Cell Lymphoma
958084|NCT02216890|Diffuse, Large B-Cell, Lymphoma
958085|NCT02216890|Follicular Lymphoma, Grade 3
958086|NCT02216890|Antibody-Drug Conjugate
958087|NCT02216890|CD70 Antigen
958088|NCT02216890|Drug Therapy
958089|NCT02216877|Chronic Kidney Disease
958090|NCT02216877|Hypomagnesemia
958091|NCT02216851|hyaluronic acid
958092|NCT02216851|no-treatment control
958093|NCT02216851|enhancement
958094|NCT02216812|Finger stiffness
958095|NCT02216812|Range of motion
958096|NCT02216812|Distal radius fracture
958097|NCT02216812|Vitamin C
958098|NCT02216799|Parenteral nutrition
958099|NCT02216799|Hyperglycemia
958100|NCT02216799|Glargine insulin
958101|NCT02216799|Regular insulin
958102|NCT02216773|Liver hypertrophy
958103|NCT02216773|Liver resection
958104|NCT02216773|Liver metastases
958105|NCT02216773|Portal vein ligation
958106|NCT02216773|Portal vein embolization
958107|NCT02216773|Radiofrequency splitting
958108|NCT02216760|Monomorphic Ventricular Tachycardia
958109|NCT02216760|Myocardial infarction
958110|NCT02216760|Dilated cardiomyopathy
958111|NCT02216760|Catheter ablation
958112|NCT02216760|Substrate mapping
958113|NCT02216760|Ripple Conduction channels
958114|NCT02216747|Idiopathic Nephrotic syndrome relapse
958115|NCT02216734|HIV/AIDS
958116|NCT02216734|Prevention of mother-to-child transmission
958117|NCT02216734|Mother support groups
958118|NCT02216734|Retention-in-care
958119|NCT02216734|Male participation
958120|NCT02216734|Anti-retroviral treatment
958121|NCT02216734|Infants
958122|NCT02216721|bone mineral density
958123|NCT02216721|bone turnover markers
958124|NCT02216721|primary aldosteronism treatment
958125|NCT02216708|Severe malnutrition
958126|NCT02216708|severe dehydration
958127|NCT02216708|cholera
958128|NCT02216695|acute kidney injury
958129|NCT02216695|epidemiology
958130|NCT02216695|mortality
958131|NCT02216682|Acetaminophen
958132|NCT02216682|Total knee replacement
958133|NCT02216682|Numeric rating scale
958134|NCT02216669|Solid tumors
958135|NCT02216669|Head and Neck Neoplasms
958136|NCT02216643|Stroke
958137|NCT02216643|Ischemic Stroke
958138|NCT02216643|Thrombectomy
958139|NCT02216643|Reperfusion Therapy
958140|NCT02216643|Treatment
958141|NCT02216630|COPD
958142|NCT02216604|Exercise
958143|NCT02216604|Pediatric oncology
958144|NCT02216604|Physical Performance
958145|NCT02216604|Quality of Life
958146|NCT02216604|Feasibility
958147|NCT02216604|during primary
958148|NCT02216604|anticancer treatment
958149|NCT02216591|HIV
958150|NCT02216591|Medication Adherence
958151|NCT02216591|Working Memory
958152|NCT02216578|tyrosine kinase inhibitor
958153|NCT02216578|progressed
958154|NCT02216578|(GIST)
958155|NCT02216565|Stroke
958156|NCT02216565|Endovascular treatment
958157|NCT02216565|Tandem carotid occlusions
958158|NCT02216565|Fibrinolysis
958159|NCT02216552|Pediatrics
958160|NCT02216552|Adolescents
958161|NCT02216552|NAFLD
958162|NCT02216552|Spectroscopy
958163|NCT02216552|Type 2 diabetes
958164|NCT02216539|All terminal
958165|NCT02216539|leading
958166|NCT02216539|indication
958167|NCT02216539|lung transplantation
958168|NCT02216526|Skin health
958169|NCT02216526|Nursing
958170|NCT02216526|Long-term care
958171|NCT02216513|subarachnoid hemorrhage
958172|NCT02216513|SAH
958173|NCT02216513|DFO
958174|NCT02216513|cerebral autoregulation
958175|NCT02216513|delayed cerebral ischemia
958176|NCT02216500|Ketogenic Therapy
958177|NCT02216500|Ketogenic Diet
958178|NCT02216487|mCRC
958179|NCT02216487|colorectal cancer
958180|NCT02216448|Arthroscopy skills
958181|NCT02216448|Knee
958182|NCT02216448|Virtual reality
958183|NCT02216448|Simulator
958184|NCT02216422|Chronic Hepatitis C
958185|NCT02216422|Hepatitis C
958186|NCT02216422|Hepatitis C Virus
958187|NCT02216422|Hepatitis C Genotype 1b
958188|NCT02216422|Interferon-Free
958189|NCT02216396|dementia
958190|NCT02216396|care home
958191|NCT02216396|agitation
958192|NCT02216396|coping
958193|NCT02216383|Post partum haemorrhage
958194|NCT02216383|Active Management of Third Stage of Labour
958195|NCT02216383|Carbetocin
958196|NCT02216383|Syntocinon
958197|NCT02216383|Syntometrine
958198|NCT02216383|Birth experience
958199|NCT02216383|Labour
958200|NCT02216370|Cryptogenic stroke /TIA
958201|NCT02216370|Atrial Fibrillation
958202|NCT02216370|Implantable Loop Recorder
958203|NCT02216370|Genetic Mutation
958204|NCT02216357|Samster's triad
958205|NCT02216357|Acetylsalicylic acid triad
958206|NCT02216357|Widal's triad
958207|NCT02216357|Francis' triad
958208|NCT02216357|Aspirin triad
958209|NCT02216357|Aspirin-induced asthma and rhinitis (AIAR)
958210|NCT02216344|Patient safety monitors
958211|NCT02216331|tuberculosis
958212|NCT02216331|PK
958213|NCT02216331|TMC207
958214|NCT02216331|bedaquiline
958215|NCT02216331|rifapentine
958216|NCT02216331|rifampicin
958217|NCT02216331|drug drug interaction
958218|NCT02216318|sleep
958219|NCT02216318|circadian
958220|NCT02216318|melatonine
958221|NCT02216318|pupil response
958222|NCT02216305|HAL-RAR
958223|NCT02216305|Hemorrhoids
958224|NCT02216305|Hemorrhoid artery ligation
958225|NCT02216305|Anal repair
958226|NCT02216305|Quality of Life
958227|NCT02216305|Postoperative Complications
958228|NCT02216292|preterm single donor milk
958229|NCT02216292|human milk
958230|NCT02216292|very lo birth weight infants
958231|NCT02216292|enteral feedings
958232|NCT02216292|NEC
958233|NCT02216279|Pulmonary
958234|NCT02216279|Hypertension
958235|NCT02216279|PH
958236|NCT02216279|PulmoBind
958237|NCT02216279|Imaging
958238|NCT02216266|Delirium
958239|NCT02216266|CAM-ICU
958240|NCT02216253|Urinary tract infection
958241|NCT02216253|Pelvic organ prolapse
958242|NCT02216253|Urinary incontinence
958243|NCT02216253|Stress urinary incontinence
958244|NCT02216253|Mixed Urinary incontinence
958245|NCT02216253|L-methionine
958246|NCT02216253|Placebo
958247|NCT02216227|MRSA
958248|NCT02216227|surgical site infection
958252|NCT02216175|Cow's milk allergy
958253|NCT02216175|Desensitisation
958254|NCT02216175|Safety
958255|NCT02216162|oncogeriatrics
958256|NCT02216162|adjuvant endocrine therapy
958257|NCT02216162|compliance
958258|NCT02216162|elderly
958259|NCT02216162|Taï Chi
958260|NCT02216162|Physical training
958261|NCT02216149|fluoropyrimidine
958262|NCT02216149|S-1
958263|NCT02216149|Teysuno
958264|NCT02216149|oxaliplatin
958265|NCT02216149|coronary artery flow
958266|NCT02216149|coronary artery dysfunction
958267|NCT02216149|gastrointestinal tract cancer
958268|NCT02216136|Mastectomy
958269|NCT02216136|Breast Cancer
958270|NCT02216136|Reconstruction
958271|NCT02216136|Lumpectomy
958272|NCT02216136|Breast Conservation Therapy
958273|NCT02216123|Tafenoquine
958274|NCT02216123|Plasmodium vivax
958275|NCT02216123|Hemolysis
958276|NCT02216123|Primaquine
958277|NCT02216123|Chloroquine
958278|NCT02216123|Glucose-6-phosphate dehydrogenase (G6PD)
958279|NCT02216123|Relapse
958280|NCT02216110|Endoscopic submucosal dissection
958281|NCT02216110|Gastrectomy
958282|NCT02216110|Survival
958283|NCT02216110|Outcome
958284|NCT02216045|Hepatitis C ,Chronic Hepatitis C ,camel milk
958285|NCT02216019|cardiac surgery
958286|NCT02216019|infectious complication
958287|NCT02216006|Atelectasis
958288|NCT02216006|Fresh gas flow
958289|NCT02216006|Prevention
958290|NCT02216006|Oxygenation
958291|NCT02216006|Anaesthesia
958292|NCT02215993|Ticagrelor
958293|NCT02215993|Prasugrel
958294|NCT02215993|VerifyNow
958295|NCT02215993|Acute coronary syndrome
958296|NCT02215980|Multiple myeloma
958297|NCT02215980|Diagnosis
958298|NCT02215980|Elderly and unfit patients
958299|NCT02215980|Lenalidomide plus steroids
958300|NCT02215967|Immunotherapy
958301|NCT02215967|Anti-BCMA-CAR
958302|NCT02215967|Gene Therapy
958303|NCT02215967|Adoptive T Cell Therapy
958304|NCT02215967|Plasma Cell Malignancy
958305|NCT02215915|Percutaneous coronary intervention
958306|NCT02215915|Drug-eluting stent
958307|NCT02215915|Intravascular ultrasound
958308|NCT02215902|ESRD
958309|NCT02215902|Hepatitis C
958310|NCT02215889|Liver metastases
958311|NCT02215889|Transplantation
958312|NCT02215876|Her 2-negative breast cancer
958313|NCT02215876|neoadjuvant doxorubicin/cyclophosphamide followed by Eribulin chemotherapy
958314|NCT02215863|Immunogenicity, Safety, MF59, Influenza vaccine, Pneumococcal vaccine
958315|NCT02215837|Gastric cancer
958316|NCT02215837|D-CIK
958317|NCT02215837|Autologous tumor lysate
958318|NCT02215811|Extracorporeal membrane oxygenation
958319|NCT02215785|Funtional constipation
958320|NCT02215785|Kiwifruit
958321|NCT02215785|Health promotion
958322|NCT02215707|PfSPZ Vaccine
958323|NCT02215707|Plasmodium falciparum
958324|NCT02215707|Malaria
958325|NCT02215707|Controlled Human Malaria Infection (CHMI)
958326|NCT02215694|Apolipoprotein A-V
958327|NCT02215694|LDL particle size
958328|NCT02215694|probiotic
958329|NCT02215694|triglyceride
958330|NCT02215681|otitis media with effusion
958331|NCT02215681|acupuncture
958332|NCT02215681|inflammatory markers
958333|NCT02215655|phosphate binder adherence
958334|NCT02215655|autonomous motivation
958335|NCT02215629|Leukemia
958336|NCT02215629|Acute Leukemia
958337|NCT02215629|Relapsed Leukemia
958338|NCT02215629|Refractory Leukemia
958339|NCT02215629|Acute Myeloid Leukemia
958340|NCT02215629|B-Cell Acute Lymphoblastic Leukemia
958341|NCT02215590|Postural balance
958342|NCT02215590|Motor Learning and Motor Control
958343|NCT02215590|Community integration
958344|NCT02215590|Quality of life
958345|NCT02215590|Functional ambulation
958346|NCT02215577|cancer, colorectal
958347|NCT02215577|hepatectomy
958348|NCT02215577|portal vein
958349|NCT02215577|embolization
958350|NCT02215577|two-stage
958351|NCT02215564|Bordetella pertussis
958352|NCT02215564|Carriage rates in young adults
958353|NCT02215551|laminectomy
958354|NCT02215538|ADHD
958355|NCT02215538|adult
958356|NCT02215538|WRAADDS
958357|NCT02215538|OROS MPH
958358|NCT02215538|emotional dysregulation
958359|NCT02215525|HCV
958360|NCT02215525|UVA
958361|NCT02215525|Herbal therapy
958362|NCT02215499|JZP-386, Xyrem, sodium oxybate
958363|NCT02215486|Head massage therapy
958364|NCT02215486|Massage therapy
958365|NCT02215486|Autonomic nervous system (ANS)
958366|NCT02215486|Heart rate variability (HRV)
958367|NCT02215486|Pre-ejection period (PEP)
958368|NCT02215473|gingivitis
958369|NCT02215473|periodontitis
958370|NCT02215473|mouth rinse
958371|NCT02215473|bacteremia
958372|NCT02215447|NAB-paclitaxel
958373|NCT02215447|Gastrointestinal Neuroendocrine Carcinomas
958374|NCT02215447|phase II
958375|NCT02215447|carboplatin
958376|NCT02215434|Libido; Sexual Dysfunction; testosterone
958377|NCT02215421|vegetables
958378|NCT02215421|dietary intake
958379|NCT02215421|preschoolers
958380|NCT02215421|parents
958381|NCT02215421|video game
958382|NCT02215408|Diabetes
958383|NCT02215408|Hyperlipidemia
958384|NCT02215408|Hypertension
958385|NCT02215408|Cardiovascular Disease
958386|NCT02215395|Nestorone
958387|NCT02215395|miconazole nitrate
958388|NCT02215382|two reversal methods
958389|NCT02215382|changes in IOP
958390|NCT02215382|heart rate
958391|NCT02215382|blood pressure
958392|NCT02215382|tracheal extubation
958393|NCT02215330|Central serous chorioretinopathy
958394|NCT02215330|Eplerenone
958395|NCT02215330|Photodynamic Therapy
958396|NCT02215330|Macula
958397|NCT02215330|Retina
958398|NCT02215317|Sleep Apnea
958399|NCT02215317|Stent
958400|NCT02215317|Coronary Artery Disease
958401|NCT02215317|Percutaneous Coronary Intervention
958402|NCT02215304|Dietary supplementation
958403|NCT02215304|Probiotics
958404|NCT02215304|Safety/Efficiency
958405|NCT02215304|Healthy infants
958406|NCT02215291|Undergoing Esophagogastroduodenoscopy (EGD) or endoscopy
958407|NCT02215278|iron biofortification
958408|NCT02215278|lpa bean
958409|NCT02215278|stable iron isotope study
958410|NCT02215278|phytic acid
958411|NCT02215265|Human papillomavirus HPV positive oropharyngeal cancer
958412|NCT02215239|health lifestyle
958413|NCT02215239|health promotion
958414|NCT02215239|occupational health
958415|NCT02215239|Work site health promotion
958416|NCT02215226|Group B Streptococcus, early onset disease, late onset disease, anticapsular antibodies, serotype specific
958417|NCT02215213|Vitamin D
958418|NCT02215213|pregnancy
958419|NCT02215213|Pakistan
958420|NCT02215200|Type 1 Diabetes TrialNet
958421|NCT02215174|Rosuvastatin
958422|NCT02215174|PK
958423|NCT02215174|Interethnic
958424|NCT02215174|Morbid obese
958425|NCT02215135|Corifollitropin alfa
958426|NCT02215135|polycystic ovarian syndrome (PCOS)
958427|NCT02215135|controlled ovarian hyperstimulation (COS)
958428|NCT02215135|GnRH antagonist protocol
958429|NCT02215135|Ovarian hyperstimulation syndrome (OHSS)
958430|NCT02215122|Fluticasone Propionate
958431|NCT02215122|Salmeterol
958432|NCT02215122|Pharmacokinetics
958433|NCT02215122|Healthy Subjects
958434|NCT02215122|MGR001
958435|NCT02215122|CRC749
958436|NCT02215122|Dry Powder Inhaler
958437|NCT02215122|generic
958438|NCT02215122|Advair Diskus
958439|NCT02215122|Seretide Accuhaler
958440|NCT02215096|enzalutamide
958441|NCT02215096|metastatic castration-resistant prostate cancer
958442|NCT02215096|GSK2636771
958443|NCT02215096|PI3K-beta
958444|NCT02215096|PTEN deficiency
958445|NCT02215083|peripheral neuropathy
958446|NCT02215083|breast cancer
958447|NCT02215083|taxane induced peripheral neuropathy
958448|NCT02215083|chemotherapy induced peripheral neuropathy
958449|NCT02215070|Allogeneic Stem Cell Transplantation
958450|NCT02215070|Acute Myeloid Leukemia
958451|NCT02215070|Acute Lymphoid Leukemia
958452|NCT02215070|Acute Non-Lymphocytic Leukemia
958453|NCT02215070|Myelodysplastic Syndrome
958454|NCT02215070|Chronic Myeloid Leukemia
958455|NCT02215070|Lymphoma
958456|NCT02215057|topical anesthesia
958457|NCT02215057|intracameral lidocaine
958458|NCT02215057|implantable collamer lens
958459|NCT02214875|Retention
958460|NCT02214862|Unclassifiable Parkinsonism, [F18]-FDDNP-PET, Tauopathy, PSP,MSA
958461|NCT02214849|Breastfeeding
958462|NCT02214849|Breastfeeding peer counseling
958463|NCT02214849|Exclusive breastfeeding
958464|NCT02214849|Formula supplementation
958465|NCT02214849|Mobile health
958466|NCT02214849|WIC program
958467|NCT02214836|kidney stones
958468|NCT02214836|ultrasound imaging
958469|NCT02214836|ureter stones
958470|NCT02214810|Bupivacaine
958471|NCT02214810|multimodal
958472|NCT02214810|exparel
958473|NCT02214810|open reduction
958474|NCT02214810|internal fixation
958475|NCT02214810|post-surgical pain control
958476|NCT02214797|Presbyopia
958477|NCT02214797|Refractive Error
958478|NCT02214797|Contact Lenses
958479|NCT02214784|Stress urinary Incontinence
958480|NCT02214784|SUI
958481|NCT02214784|Continence
958482|NCT02214771|Clostridium difficile infection CDI
958483|NCT02214771|Observational
958484|NCT02214771|Fidaxomicin recurrence
958485|NCT02214771|France
958486|NCT02214758|Home care clients, nutrition, oral health, medication
958487|NCT02214745|Israeli Arab population
958488|NCT02214745|Israeli/ethnology
958489|NCT02214732|Pregnancy
958490|NCT02214732|Postpartum
958491|NCT02214732|Mindfulness Based Cognitive Therapy
958492|NCT02214732|Depression
958493|NCT02214732|Anxiety
958494|NCT02214732|Stress
958495|NCT02214732|MBCT
958496|NCT02214732|Actigraphy
958497|NCT02214719|type 1 diabetes, insulin therapy, bolus calculator
958498|NCT02214693|patients
958499|NCT02214680|Pupil diameter
958500|NCT02214680|Brimonidine
958501|NCT02214680|Timolol
958502|NCT02214680|Combigan
958503|NCT02214667|Jail
958504|NCT02214667|co-occurring disorders
958505|NCT02214667|implementation
958506|NCT02214667|acceptability
958507|NCT02214667|feasibility
958508|NCT02214667|fidelity
958509|NCT02214628|Wet AMD
958510|NCT02214628|Choroidal neovascularization
958511|NCT02214628|Fovista®
958512|NCT02214628|E10030
958513|NCT02214628|Avastin®
958514|NCT02214628|Eylea®
958515|NCT02214602|non muscle invasive bladder cancer
958516|NCT02214602|intermediate and high risk
958517|NCT02214602|immediate single instillation
958518|NCT02214602|Intravesical chemotherapy
958519|NCT02214602|Disease prevention
958644|NCT02214160|C7
958520|NCT02214576|Respiratory Distress Syndrome, Adult
958521|NCT02214576|intubation, intratracheal
958522|NCT02214576|Oxygen Inhalation Therapy
958523|NCT02214576|Positive-Pressure Respiration
958524|NCT02214576|laryngoscopy
958525|NCT02214563|Vitamin D
958526|NCT02214563|Cholecalciferol
958527|NCT02214563|Hepcidins
958528|NCT02214563|Renal Dialysis
958529|NCT02214550|Cystitis, Interstitial
958530|NCT02214550|Dysmenorrhea
958531|NCT02214550|Migraine Disorders
958532|NCT02214550|Cross Organ Sensitization
958533|NCT02214550|Pelvic Pain
958534|NCT02214550|Endometriosis
958535|NCT02214550|Contraceptives, Oral
958536|NCT02214550|Birth Control Pills
958537|NCT02214550|Painful Bladder Syndrome
958538|NCT02214550|Visceral Pain
958539|NCT02214550|Chronic Pain
958540|NCT02214524|perioperative hypothermia
958541|NCT02214524|Tympanic temperature
958542|NCT02214524|Blood loss
958543|NCT02214524|Blood Coagulation Disorders
958544|NCT02214524|Major surgery
958545|NCT02214511|major depressive disorder
958546|NCT02214511|social rejection
958547|NCT02214511|rapid facial reaction
958548|NCT02214511|facial mimicry
958549|NCT02214511|prosocial behavior
958550|NCT02214511|inflammation
958551|NCT02214511|self esteem
958552|NCT02214498|Dipper
958553|NCT02214498|Non-dipper
958554|NCT02214498|Chronopharmacology
958555|NCT02214485|frailty
958556|NCT02214485|exercise
958557|NCT02214485|intervention
958558|NCT02214472|Rumination síndrome
958559|NCT02214472|Regurgitation
958560|NCT02214472|Vomiting
958561|NCT02214472|Biofeedback
958562|NCT02214472|Electromyography
958563|NCT02214472|Abdominal accommodation
958564|NCT02214459|mHealth
958565|NCT02214459|Hypertension
958566|NCT02214459|Mobile
958567|NCT02214459|smartphone
958568|NCT02214459|diet
958569|NCT02214459|lifestyle
958570|NCT02214459|bluetooth
958571|NCT02214459|physical acitvity
958572|NCT02214459|behavior change
958573|NCT02214459|motivational interviewing
958574|NCT02214446|truth telling
958575|NCT02214446|hope
958576|NCT02214446|quality of life
958577|NCT02214446|care burden
958578|NCT02214446|children with cancer
958579|NCT02214433|Antibiotic
958580|NCT02214433|Antibiotic Resistant Bacterial Infection
958581|NCT02214381|breast cancer
958582|NCT02214381|elderly
958583|NCT02214329|Postural Balance
958584|NCT02214329|Gait
958585|NCT02214329|Fall risk
958586|NCT02214303|Allergic asthma
958587|NCT02214303|Allergic rhinitis
958588|NCT02214303|Healthy subjects
958589|NCT02214290|Cardiovascular
958590|NCT02214290|Caffeine
958591|NCT02214290|L-citrulline
958592|NCT02214290|Arterial Function
958593|NCT02214290|Hemodynamics
958594|NCT02214290|Blood Pressure
958595|NCT02214290|Pulse Wave Velocity
958596|NCT02214290|Pulse Wave Analysis
958597|NCT02214277|Embolic Protection
958598|NCT02214277|Edwards SAPIEN THV
958599|NCT02214277|Edwards SAPIEN XT
958600|NCT02214277|TAVR
958601|NCT02214277|Transfemoral
958602|NCT02214277|Transapical
958603|NCT02214277|Heart Valve Diseases
958604|NCT02214277|Heart Diseases
958605|NCT02214277|TAVI
958606|NCT02214277|Aortic Stenosis
958607|NCT02214277|Aortic Valve
958608|NCT02214277|Transcatheter Heart Valve
958609|NCT02214251|Parkinson's disease
958610|NCT02214251|freezing of gait
958611|NCT02214251|movement disorders
958612|NCT02214251|neuroscience
958613|NCT02214251|neural
958614|NCT02214251|mechanism
958615|NCT02214212|traumatic brain injury
958616|NCT02214212|TBI
958617|NCT02214212|Sleep
958618|NCT02214212|Bright White Light Therapy
958619|NCT02214212|Red Light Therapy
958620|NCT02214212|Recovery
958621|NCT02214212|Central Nervous System Diseases
958622|NCT02214212|Brain Diseases
958623|NCT02214212|Nervous System Diseases
958624|NCT02214212|Signs and Symptoms
958625|NCT02214212|Rehabilitation
958626|NCT02214212|Actigraphy
958627|NCT02214199|Shoulder Pain
958628|NCT02214199|Shoulder Impingement Syndrome
958629|NCT02214199|Exercise therapy
958630|NCT02214199|Randomized Controlled Trial
958631|NCT02214186|Pre-Eclampsia
958632|NCT02214186|Acute Kidney Injury
958633|NCT02214186|Fluid Therapy
958634|NCT02214186|Anesthesia, Spinal
958635|NCT02214173|HIV, BRM4, hydrolyzed rice bran, metabolic syndrome
958636|NCT02214160|Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
958637|NCT02214160|carnitine palmitoyltransferase (CPT I or CPT II) deficiency
958638|NCT02214160|very long chain acyl-CoA dehydrogenase (VLCAD) deficiency
958639|NCT02214160|long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency
958640|NCT02214160|trifunctional protein (TFP) deficiency
958641|NCT02214160|carnitine-acylcarnitine translocase (CACT) deficiency
958642|NCT02214160|Triheptanoin
958643|NCT02214160|UX007
958645|NCT02214147|Alisertib
958646|NCT02214147|MLN8237
958647|NCT02214147|Relapsed/refractory lymphoma
958648|NCT02214134|Lung cancer
958649|NCT02214134|Malignant pleural mesothelioma
958650|NCT02214134|Thymic malignancy
958651|NCT02214134|Biomarkers
958652|NCT02214134|Screening
958653|NCT02214121|sickle cell anemia
958654|NCT02214121|paediatric
958655|NCT02214108|BMI
958656|NCT02214108|Obesity
958657|NCT02214108|overweight
958658|NCT02214108|child
958659|NCT02214108|Physical activity
958660|NCT02214095|Cytokines
958661|NCT02214095|interleukin-1β
958662|NCT02214095|chronic periodontitis
958663|NCT02214095|host modulation
958664|NCT02214095|glucosamine sulphate.
958665|NCT02214056|mobile screening team
958666|NCT02214056|feasibility
958667|NCT02214030|Femoral compression device
958668|NCT02214030|manual compression
958669|NCT02214030|arterial hemostasis
958670|NCT02214030|coronary intervention
958671|NCT02214030|coronary artery disease
958672|NCT02214017|diabetes
958673|NCT02214017|telemedicine
958674|NCT02214017|glycemia
958675|NCT02214017|lipids
958676|NCT02214017|blood pressure
958677|NCT02214004|Breast cancer
958678|NCT02214004|HER2
958679|NCT02214004|ER
958680|NCT02214004|Postmenopausal
958681|NCT02214004|Trastuzumab
958682|NCT02214004|Letrozole
958683|NCT02214004|Neoadjuvant endocrine treatment
958684|NCT02213991|Breast Cancer
958685|NCT02213991|Breast Conservative Surgery
958686|NCT02213991|Intraoperative Radiotherapy
958687|NCT02213991|Local Toxicity
958688|NCT02213991|Whole breast radiotherapy
958689|NCT02213965|Intravenous Catheter
958690|NCT02213965|Vasofix safety
958691|NCT02213965|Introcan safety
958692|NCT02213952|Ulcer
958693|NCT02213952|Platelet-Rich Plasma
958694|NCT02213939|Myocardial revascularization
958695|NCT02213939|Cytosorb
958696|NCT02213939|Inflammatory response
958697|NCT02213939|Cardiopulmonary bypass
958698|NCT02213926|Bruton tyrosine kinase inhibitor
958699|NCT02213926|Btk
958700|NCT02213926|Mantle Cell Lymphoma
958701|NCT02213926|MCL
958702|NCT02213926|ACP-196
958703|NCT02213926|Acalabrutinib
958704|NCT02213926|ACE-LY-004
958705|NCT02213900|delirium
958706|NCT02213900|confusion
958707|NCT02213900|surgery
958708|NCT02213900|cognitive Impairment
958709|NCT02213900|post-traumatic Stress disorder
958710|NCT02213900|depression
958711|NCT02213900|anxiety
958712|NCT02213887|Drug Interactions
958713|NCT02213887|Pantoprazole
958714|NCT02213887|Proton Pump Inhibitors
958715|NCT02213887|Psychotropic Drugs
958716|NCT02213887|Antipsychotic Agents
958717|NCT02213887|Aripiprazole
958718|NCT02213887|Asenapine
958719|NCT02213887|Clozapine
958720|NCT02213887|Lurasidone
958721|NCT02213887|Olanzapine
958722|NCT02213887|9-hydroxy-risperidone
958723|NCT02213887|Quetiapine
958724|NCT02213887|Risperidone
958725|NCT02213887|Ziprasidone
958726|NCT02213887|Valproic Acid
958727|NCT02213887|Lithium
958728|NCT02213887|Gastrins
958729|NCT02213887|Psychotic Disorders
958730|NCT02213887|Gastroesophageal Reflux
958731|NCT02213874|Pregnant Women
958732|NCT02213874|Women's Health
958733|NCT02213874|Contraception
958734|NCT02213874|Trust in Health Care
958735|NCT02213861|CTCL
958736|NCT02213861|Cutaneous T-Cell Lymphoma
958737|NCT02213861|Early-stage
958738|NCT02213861|SHAPE
958739|NCT02213861|SHP-141
958740|NCT02213861|topical
958741|NCT02213861|Histone deacetylase inhibitor
958742|NCT02213861|CAILS
958743|NCT02213861|mSWAT
958744|NCT02213861|mycosis fungoides
958745|NCT02213848|Neuromuscular blockade reversal
958746|NCT02213848|TOF ratio
958747|NCT02213848|Calcium chloride
958748|NCT02213835|Crohn's disease and Ulcerative colitis
958749|NCT02213822|genome
958750|NCT02213822|transcriptome
958751|NCT02213822|molecular
958752|NCT02213822|proteome
958753|NCT02213822|oncogenic mutations
958754|NCT02213822|sequencing
958755|NCT02213822|solid tumor
958756|NCT02213822|hematological malignancy
958757|NCT02213822|cancer
958758|NCT02213822|analysis
958759|NCT02213822|genetic
958760|NCT02213822|mutation
958761|NCT02213796|meropenem, early phase, severe sepsis and septic shock, critically ill, population pharmacokinetics
958762|NCT02213783|Imipenem
958763|NCT02213783|Febrile neutropenia
958764|NCT02213783|Gram-negative infection
958765|NCT02213783|Pharmacodynamic
958766|NCT02213783|Monte Carlo Simulation
958767|NCT02213757|Hematuria
958768|NCT02213757|Menopause
958769|NCT02213757|Urinalysis
958770|NCT02213744|HER2-positive
958771|NCT02213744|HER2+
958772|NCT02213744|HER2
958773|NCT02213744|Locally Advanced Breast Cancer
958774|NCT02213744|Metastatic Breast Cancer
958775|NCT02213744|trastuzumab
958776|NCT02213744|Herceptin
958777|NCT02213744|pertuzumab
958778|NCT02213744|ado-trastuzumab emtansine
958779|NCT02213744|TDM-1
958780|NCT02213744|Perjeta
958781|NCT02213744|Kadcyla
958782|NCT02213731|Atrial Fibrillation
958783|NCT02213731|Persistent Atrial Fibrillation
958784|NCT02213731|Cryoablation
958785|NCT02213731|Cryoballoon
958786|NCT02213731|Pulmonary Vein Isolation
958787|NCT02213718|Desflurane
958788|NCT02213718|myocardial function
958789|NCT02213718|Coronary Artery Bypass Surgery
958790|NCT02213705|SYSTEMIC SCLERODERMA
958791|NCT02213705|TRANSPLANTATION
958792|NCT02213705|ALLOGENEIC MESENCHYMAL STEM CELLS
958793|NCT02213705|ADULT
958794|NCT02213692|Liver Resection
958795|NCT02213692|Harmonic Scalpel
958796|NCT02213692|Crush-clamping
958797|NCT02213692|A Prospective Randomized Study
958798|NCT02213679|Creatine
958799|NCT02213679|Guanidinoacetic acid
958800|NCT02213679|Intervention
958801|NCT02213679|Fatigue
958802|NCT02213679|Muscle strength
958803|NCT02213666|Atrial fibrillation ablation
958804|NCT02213666|Intracardiac echocardiography
958805|NCT02213666|Thrombus
958806|NCT02213666|Left atrial appendage
958807|NCT02213666|Right atrial appendage
958808|NCT02213653|Functional iron deficiency
958809|NCT02213653|Metastatic
958810|NCT02213640|Neurologic neglect syndrome
958811|NCT02213640|post stroke
958812|NCT02213640|transcranial direct current stimulation (tDCS)
958813|NCT02213640|prismatic adaptation
958814|NCT02213627|Corifollitropin alfa, recombinant FSH, HP-hMG, apoptosis, oocyte donation
958815|NCT02213601|Yoga
958816|NCT02213601|Complementary and Alternative Medicine Interventions
958817|NCT02213601|Treatment
958818|NCT02213601|Postpartum Depression
958819|NCT02213588|Antioxidant
958820|NCT02213575|Resistent Hypertension
958821|NCT02213536|Metastatic brain cancer
958822|NCT02213536|Whole brain radiotherapy
958949|NCT02213029|pharmacokinetics
958823|NCT02213536|Scalp sparing whole brain radiotherapy
958824|NCT02213536|Prophylactic whole brain radiotherapy
958825|NCT02213523|antioxidant
958826|NCT02213510|pacemaker
958827|NCT02213510|implantable cardioverter defibrillator
958828|NCT02213510|ICD
958829|NCT02213510|surgical wound closure
958830|NCT02213510|sutures
958831|NCT02213510|Zipline
958832|NCT02213510|Zips
958833|NCT02213510|CIED
958834|NCT02213510|cardiovascular implantable electronic devices
958835|NCT02213510|arrhythmia
958836|NCT02213497|Patients with esophageal cancer to be treated with concurrent preoperative chemoradiation with carboplatin and paclitaxel.
958837|NCT02213484|aortopathy syndrome
958838|NCT02213484|aortic aneurysm
958839|NCT02213484|aortic dissection
958840|NCT02213484|connective tissue disorder
958841|NCT02213458|Pragmatic Clinical Trial
958842|NCT02213458|Family Caregivers
958843|NCT02213458|Patient Care Management
958844|NCT02213432|influenza vaccine
958845|NCT02213432|cancer
958846|NCT02213419|Cystic Tumors of the Pancreas
958847|NCT02213419|Endoscopic Ultrasound
958848|NCT02213419|Ethanol
958849|NCT02213393|undernutrition
958850|NCT02213393|nutritional status
958851|NCT02213393|elderly patients
958852|NCT02213393|protein
958853|NCT02213393|enriched products
958854|NCT02213393|recovery
958855|NCT02213393|physical function
958856|NCT02213393|quality of life
958857|NCT02213393|activities of daily living
958858|NCT02213380|delirium
958859|NCT02213380|general anesthesia
958860|NCT02213380|regional anesthesia
958861|NCT02213380|elderly patient
958862|NCT02213380|hip fracture
958863|NCT02213354|Influenza, H7N9, Elderly, Vaccine, MF59 Adjuvant
958864|NCT02213341|Milk Allergy
958865|NCT02213341|Egg Allergy
958866|NCT02213341|Peanut Allergy
958867|NCT02213341|Infant Vaccination
958868|NCT02213315|Healthy Volunteers, Rheumatoid Arthritis, mavrilimumab
958869|NCT02213302|premedication
958870|NCT02213302|preoperative anxiety
958871|NCT02213302|salivary cortisol level
958872|NCT02213302|anxiety visual analog scale
958873|NCT02213289|Gastric
958874|NCT02213289|Esophagogastric
958875|NCT02213276|Glucose infusion
958876|NCT02213276|Bone markers
958877|NCT02213276|Inflammatory markers
958878|NCT02213263|rituximab
958879|NCT02213263|follicular lymphoma
958880|NCT02213263|Non-Hodgkin lymphoma
958881|NCT02213263|Non-Hodgkin's lymphoma
958882|NCT02213224|Perindopril,Telmisartan, Efficacy, NAFLD
958883|NCT02213211|Malawi
958884|NCT02213211|Case management
958885|NCT02213211|Rapid diagnostic tests
958886|NCT02213211|Artemether lumefantrine
958887|NCT02213211|School children
958888|NCT02213211|School health services
958889|NCT02213211|Attendance
958890|NCT02213211|Anaemia
958891|NCT02213211|Parasitic diseases
958892|NCT02213198|Serious mental illness transitions shared decision making
958893|NCT02213185|Sterile water injections
958894|NCT02213185|Pain
958895|NCT02213185|VAS
958896|NCT02213185|Complementary method
958897|NCT02213172|IBS
958898|NCT02213172|Probiotic
958899|NCT02213172|Constipation
958900|NCT02213172|Bifidobacterium longum
958901|NCT02213172|Lactobacillus paracasei
958902|NCT02213172|Lallemand Health Solutions
958903|NCT02213159|Dexmedetomidine
958904|NCT02213159|bariatric surgery
958905|NCT02213159|postoperative pain
958906|NCT02213159|morphine consumption
958907|NCT02213159|Quality of recovery
958908|NCT02213133|Squamous
958909|NCT02213133|SCC
958910|NCT02213133|Carcinoma
958911|NCT02213133|KPT-330
958912|NCT02213133|SINE
958913|NCT02213133|Selinexor
958914|NCT02213133|Karyopharm
958915|NCT02213133|Karyopharm Therapeutics
958916|NCT02213133|Lung
958917|NCT02213133|Head
958918|NCT02213133|Neck
958919|NCT02213133|Esophageal
958920|NCT02213120|Vertigo, Dizziness
958921|NCT02213107|prostate
958922|NCT02213094|preeclampsia
958923|NCT02213094|pregnancy-induced hypertension
958924|NCT02213094|nicotinamide
958925|NCT02213081|Endometriosis
958926|NCT02213081|chronic pelvic pain
958927|NCT02213081|dysmenorrhea
958928|NCT02213081|dyschezia
958929|NCT02213081|bleeding
958930|NCT02213081|ulipristal
958931|NCT02213081|progesterone
958932|NCT02213068|Kidney
958933|NCT02213068|Renal
958934|NCT02213068|Transplant
958935|NCT02213068|EBV
958936|NCT02213068|Immunosuppressants
958937|NCT02213068|Belatacept
958938|NCT02213055|Lice
958948|NCT02213029|epelsiban
958950|NCT02213029|patient reported pain / discomfort
958951|NCT02213029|pharmacodynamics
958952|NCT02213029|oxytocin infusions
958953|NCT02213029|Uterine contractions
958954|NCT02213016|Stimulation magnetic transcranial, major depression, cognitive impairment
958955|NCT02213003|islet transplantation
958956|NCT02212990|Fever
958957|NCT02212990|Antipyretics
958958|NCT02212990|Acetaminophen
958959|NCT02212990|Ibuprofen
958960|NCT02212990|Influenza vaccine
958961|NCT02212990|Influenza
958962|NCT02212990|Body temperature changes
958963|NCT02212990|Signs and symptoms
958964|NCT02212977|Port Catheter
958965|NCT02212977|Octyl 2-cyanoacrylate
958966|NCT02212977|2-octylcyanoacrylate
958967|NCT02212964|Radiation Injury
958968|NCT02212964|Radiation Necrosis
958969|NCT02212964|Ultra-high field MRI
958970|NCT02212964|Susceptibility Weighted Imaging
958971|NCT02212964|Post-treatment radiographic imaging change
958972|NCT02212912|acute ischemic stroke, performance measure, acute treatment
958973|NCT02212899|Spinal Surgery
958974|NCT02212899|Spinal Fusion
958975|NCT02212899|Deformity Correction
958976|NCT02212899|Spinal Instrumentation
958977|NCT02212886|Glatiramer acetate
958978|NCT02212886|Copaxone
958979|NCT02212886|Multiple sclerosis
958980|NCT02212886|Relapsing remitting multiple sclerosis
958981|NCT02212886|RRMS
958982|NCT02212886|GA Depot
958983|NCT02212886|Monthly injection
958984|NCT02212873|school based intervention
958985|NCT02212873|overweight
958986|NCT02212873|obese
958987|NCT02212873|BMI z score
958988|NCT02212873|fat mass
958989|NCT02212860|neoadjuvant
958990|NCT02212860|radiation
958991|NCT02212860|breast
958992|NCT02212860|cancer
958993|NCT02212860|hypofractionation
958994|NCT02212860|stereotactic
958995|NCT02212860|preoperative
958996|NCT02212834|Breast
958997|NCT02212834|Cancer
958998|NCT02212834|Surveillance
958999|NCT02212834|Imaging
959000|NCT02212834|Comparative
959001|NCT02212834|Effectiveness
959002|NCT02212808|Cluster-randomized crossover trial
959003|NCT02212808|Antimicrobial stewardship
959004|NCT02212808|Community hospitals
959005|NCT02212808|Feasibility
959006|NCT02212795|healthy
959007|NCT02212782|Healthy
959008|NCT02212769|healthy
959009|NCT02212756|healthy
959010|NCT02212717|Acute cholecystitis
959011|NCT02212717|EUS-guided gallbladder drainage
959012|NCT02212717|Percutaneous cholecystostomy
959013|NCT02212704|vestibular
959014|NCT02212704|proprioception
959015|NCT02212704|spatial orientation
959016|NCT02212704|bayesian
959017|NCT02212691|Sickle Cell
959018|NCT02212652|Bariatric surgery
959019|NCT02212652|Vitamin D deficiency
959020|NCT02212652|Vitamin D insufficiency
959021|NCT02212652|Adverse surgical outcomes
959022|NCT02212652|Clinical outcomes
959023|NCT02212639|Kaposi' s sarcoma
959024|NCT02212639|Digoxin
959025|NCT02212613|Major Depressive Disorder
959026|NCT02212613|Mental Disorders, nonpsychotic episode, antipsychotic
959027|NCT02212613|Mood Disorder, psychotic disorder
959028|NCT02212587|inhaled antibiotics
959029|NCT02212574|Wnt
959030|NCT02212574|Medulloblastoma
959031|NCT02212574|Chemotherapy
959032|NCT02212548|SpaceOAR Hydrogel Image Guided Modulated Radiotherapy
959033|NCT02212535|Sickle cell disease
959034|NCT02212535|Open monocenter study
959035|NCT02212535|Phase I/II
959036|NCT02212535|hematopoietic stem cells
959037|NCT02212535|Plerixafor
959038|NCT02212522|Diabetes Mellitus
959039|NCT02212522|Insulin-Dependent
959040|NCT02212522|Genome-Wide Association Study
959041|NCT02212522|Environment-Wide Association Study
959042|NCT02212522|Predisposition
959043|NCT02212522|Complications
959044|NCT02212483|Asthma
959045|NCT02212483|Medical Indoor Environment Counselors
959046|NCT02212483|Pediatric
959047|NCT02212483|Environment
959048|NCT02212483|Clinical effectiveness
959049|NCT02212483|Economical impact
959050|NCT02212444|plantar fasciitis
959051|NCT02212444|dynamic elastomeric fabric orthoses (DEFO)
959052|NCT02212444|feasibility
959053|NCT02212444|Physiotherapy
959054|NCT02212444|Musculoskeletal
959055|NCT02212431|Cystic Fibrosis
959056|NCT02212431|Cysteamine
959057|NCT02212431|Pharmacokinetics
959058|NCT02212405|Deep rTMS
959059|NCT02212405|Insular cortex
959060|NCT02212405|PET
959061|NCT02212405|[11C]-PHNO
959062|NCT02212392|acute pancreatitis
959063|NCT02212379|Raltegravir
959064|NCT02212379|Etravirine
959065|NCT02212379|aged, 45 and over
959066|NCT02212379|Viral load
959067|NCT02212379|Efficacy
959068|NCT02212379|Safety
959069|NCT02212366|TDCS
959070|NCT02212366|Depression
959071|NCT02212366|Brain Stimulation
959072|NCT02212366|Memory
959073|NCT02212366|Cognition
959074|NCT02212366|EEG
959075|NCT02212340|propofol
959076|NCT02212340|desflurane
959077|NCT02212340|quality of recovery
959078|NCT02212340|vitrectomy
959079|NCT02212327|Na+ MRI
959080|NCT02212327|salt stores
959081|NCT02212314|Response Inhibition, Williams Syndrome
959082|NCT02212275|ASD
959083|NCT02212275|autism
959084|NCT02212275|typical development
959085|NCT02212275|sensory testing
959086|NCT02212275|the cortical metric
959087|NCT02212249|soluble VE-cadherin
959088|NCT02212249|antibody
959089|NCT02212249|systemic slerosis
959090|NCT02212236|Distress
959091|NCT02212236|Depression
959092|NCT02212236|Anxiety
959093|NCT02212236|Stress
959094|NCT02212236|Coping
959095|NCT02212236|Illness perceptions
959096|NCT02212236|Stem cell transplantation
959097|NCT02212236|Bone marrow transplantation
959098|NCT02212223|Vitamin D
959099|NCT02212223|Serum 25-hydroxyvitamin D (25OHD)
959100|NCT02212223|Dietary supplement
959101|NCT02212223|Ethnicity
959102|NCT02212223|Immigrant
959103|NCT02212197|prostate cancer
959104|NCT02212197|leuprolide
959105|NCT02212184|Diaphragm
959106|NCT02212184|COPD
959107|NCT02212184|Musculoskeletal Manipulations
959108|NCT02212184|Ultrasonography
959109|NCT02212184|Optoelectronic Plethysmography.
959110|NCT02212158|Type 1 diabetes
959111|NCT02212158|adolescents
959112|NCT02212158|HA1c
959113|NCT02212158|psychological intervention
959114|NCT02212145|prevention
959115|NCT02212145|cardiovascular disease
959116|NCT02212145|risk factors
959117|NCT02212132|metamemory
959118|NCT02212132|memory complaints
959119|NCT02212132|performance mnemonic
959120|NCT02212132|cancer
959121|NCT02212119|Dementia
959122|NCT02212119|Paratonia
959123|NCT02212119|Caregiver Burden
959124|NCT02212119|Botulinum toxin
959125|NCT02212093|Pneumonia, mechanical ventilation, ICU, mortality
959126|NCT02212041|electronic cigarettes
959127|NCT02212041|smoking
959128|NCT02212041|schizophrenia
959129|NCT02212041|serious mental illness
959130|NCT02212028|ST-elevation myocardial infarction
959131|NCT02212028|prasugrel
959132|NCT02212028|pharmacodynamic
959133|NCT02212028|pharmacokinetic
959134|NCT02212002|Group B Streptococcus
959135|NCT02212002|Intrapartum Antibiotic Prophylaxis
959136|NCT02212002|term infants
959137|NCT02212002|vaginal delivery
959138|NCT02212002|gut microbiota
959139|NCT02212002|feeding
959140|NCT02212002|molecular analysis
959141|NCT02212002|real-time PCR
959142|NCT02211846|Pharmacokinetics
959143|NCT02211846|Mirabegron
959144|NCT02211846|Neurogenic detrusor overactivity (NDO)
959145|NCT02211846|Overactive bladder (OAB)
959146|NCT02211820|Encephalopathy
959147|NCT02211820|Imaging Studies
959148|NCT02211820|Dementia
959149|NCT02211820|Cerebellar Cortical Atrophy
959150|NCT02211794|Total Knee Arthroplasty
959151|NCT02211794|degenerative joint disease
959152|NCT02211781|Tribal Communities
959153|NCT02211781|Radiation
959154|NCT02211781|Cancer
959155|NCT02211768|Genetic Analysis
959156|NCT02211768|Biopsy
959157|NCT02211768|FDG-PET
959158|NCT02211768|FLT-PET
959159|NCT02211755|Purine Nucleoside Inhibitor
959160|NCT02211755|Proteasome Inhibitor
959161|NCT02211755|Combination Treatment
959162|NCT02211755|Solid Tumors
959163|NCT02211742|dapagliflozin
959164|NCT02211742|fasting glucose
959165|NCT02211742|postprandial glucose excursion
959166|NCT02211742|euglycemic hyperinsulinemic clamp
959167|NCT02211742|euglycemic oral glucose tolerance test
959168|NCT02211703|perioperative hypothermia
959169|NCT02211703|Epidemiology
959170|NCT02211703|Tympanic temperature
959171|NCT02211651|adipose tissue
959172|NCT02211651|placenta
959173|NCT02211651|pregnancy
959174|NCT02211651|umbilical cord
959175|NCT02211638|Drug Therapy
959176|NCT02211625|Healthy
959177|NCT02211625|Pharmacodynamics (PD)
959178|NCT02211625|Pharmacokinetics (PK)
959179|NCT02211612|Overfeeding
959180|NCT02211612|Weight gain
959181|NCT02211612|Liver fat
959182|NCT02211612|Pancreatic fat
959183|NCT02211612|Ectopic fat
959184|NCT02211612|Skeletal muscle
959185|NCT02211612|Adipose tissue
959186|NCT02211612|Gene expression
959187|NCT02211612|DNA methylation
959188|NCT02211612|Palmitate
959189|NCT02211612|Linoleic acid
959190|NCT02211612|Saturated fat
959191|NCT02211612|Polyunsaturated fat
959192|NCT02211612|Metabolism
959193|NCT02211612|Insulin sensitivity
959194|NCT02211599|protein
959195|NCT02211599|carbohydrate
959196|NCT02211599|lipid
959197|NCT02211599|oxidation
959198|NCT02211599|fat
959199|NCT02211599|sugar
959200|NCT02211599|juice
959201|NCT02211599|obesity
959202|NCT02211586|insulin glargine
959203|NCT02211586|subcutaneous injections
959204|NCT02211586|sleep respiratory quotient
959205|NCT02211573|Autonomic Nervous System, Body composition, Oxygen Uptake,
959206|NCT02211573|Water Based Physical Training.
959207|NCT02211534|Pulsed Electromagnetic Energy Fields
959208|NCT02211534|Total Knee Arthroplasty
959209|NCT02211534|Pain Intensity
959210|NCT02211521|Osteoarthritis, platelet-rich plasma, hyaluronic acid
959211|NCT02211508|fibromyalgia
959212|NCT02211508|pain
959213|NCT02211508|stimulation
959214|NCT02211482|HIV-1 infected patients
959215|NCT02211482|dual therapy
959216|NCT02211456|Endocardial pacing
959217|NCT02211456|Multi site pacing
959218|NCT02211443|Full human anti-EGFR monoclonal antibody (SCT200) ;
959219|NCT02211443|metastatic colorectal cancer （mCRC）;
959220|NCT02211443|Escalating doses ;
959221|NCT02211443|single dose and multiple doses;
959222|NCT02211443|safety, tolerability and pharmacokinetics.
959223|NCT02211430|smoking cessation
959224|NCT02211430|pregnancy
959225|NCT02211430|postpartum
959226|NCT02211430|intervention
959227|NCT02211391|Nighttime Eating
959228|NCT02211391|Protein
959229|NCT02211391|Obesity
959230|NCT02211391|Lipolysis
959231|NCT02211391|Metabolism
959232|NCT02211378|stress
959233|NCT02211378|performance
959234|NCT02211378|cortisol
959235|NCT02211365|Hypertension
959236|NCT02211365|CVD
959237|NCT02211352|blood pressure, ginseng
959238|NCT02211339|Social skills
959239|NCT02211339|Social communication
959240|NCT02211339|Cognitive communication
959241|NCT02211339|Traumatic brain injury
959242|NCT02211339|Acquired brain injury
959243|NCT02211339|Communication partner training
959244|NCT02211339|Peer partner training
959245|NCT02211339|Peer mentoring
959246|NCT02211339|Rating scales
959247|NCT02211339|Rehabilitation
959248|NCT02211326|AF or DVT
959249|NCT02211326|Age Over 18 Years, Acquired
959250|NCT02211300|glucose monitoring
959251|NCT02211300|OptiScanner
959252|NCT02211287|Dementia
959253|NCT02211287|Decision-making
959254|NCT02211287|Communication
959255|NCT02211287|Advance Care Planning
959256|NCT02211274|Quality of Life
959257|NCT02211274|Nursing Homes
959258|NCT02211274|Housing for the Elderly
959259|NCT02211274|Homes for the Aged
959260|NCT02211261|first in human
959261|NCT02211261|single dose
959262|NCT02211261|multiple dose
959263|NCT02211261|escalation
959264|NCT02211261|safety study
959265|NCT02211261|Type 2 Diabetes Mellitus
959266|NCT02211248|Cardiac Frequency Variability
959267|NCT02211248|multidisciplinary care
959268|NCT02211248|clinical trial
959269|NCT02211235|Cystic Fibrosis
959270|NCT02211235|Healthy Controls
959271|NCT02211235|Diabetes
959272|NCT02211235|Cystic Fibrosis Related Diabetes (CFRD)
959273|NCT02211235|CFRD
959274|NCT02211222|Thyroid Cancer
959275|NCT02211222|Radioiodine-Refractory
959276|NCT02211222|Differentiated
959277|NCT02211183|Massive Rotator Cuff Tear
959278|NCT02211183|Sub-acromial spacer
959279|NCT02211183|Best repair of rotator cuff
959280|NCT02211105|GastroEsophageal Reflux Disease
959281|NCT02211105|Transoral Incisionless Fundoplication
959282|NCT02211105|Laparoscopic Nissen Fundoplication
959283|NCT02211092|Family Caregivers
959284|NCT02211092|Advanced Cancer
959285|NCT02211092|Palliative Care
959286|NCT02211092|Support
959287|NCT02211092|Self Care
959288|NCT02211092|Physical Activity
959289|NCT02211079|Healthy
959290|NCT02211079|JNJ-54861911
959291|NCT02211079|Caffeine
959292|NCT02211079|Midazolam
959293|NCT02211079|Tolbutamide
959294|NCT02211079|Cytochrome P450 3A4
959295|NCT02211079|Cytochrome P450 2C9
959296|NCT02211079|Cytochrome P450 1A2
959297|NCT02211079|Alzheimer's disease
959298|NCT02211053|Organ donation
959299|NCT02211053|Brain dead
959300|NCT02211053|Levothyroxine
959301|NCT02211040|Intervention Mapping Protocol
959302|NCT02211040|physical activity
959303|NCT02211040|fruit intake
959304|NCT02211040|vegetable intake
959305|NCT02211040|computer tailoring
959306|NCT02211040|eHealth
959307|NCT02211040|self-regulation
959308|NCT02211040|goal setting
959309|NCT02211040|problem solving
959310|NCT02211040|general practice
959311|NCT02211027|Squamous Cell Carcinoma
959312|NCT02211027|Head & Neck Cancer
959313|NCT02211027|Vaccine
959314|NCT02211027|Carcinoma
959315|NCT02211027|Immunization
959316|NCT02211027|Autologous Tumor
959317|NCT02211014|Bruton tyrosine kinase inhibitor
959318|NCT02211014|Btk
959319|NCT02211014|Multiple Myeloma
959320|NCT02211014|MM
959321|NCT02211014|ACP-196
959322|NCT02211014|acalabrutinib
959323|NCT02211001|Exercise Movement Techniques
959324|NCT02211001|Exercise Therapy
959325|NCT02211001|Physical Therapy Modalities.
959450|NCT02210429|Pediatric Anesthesia
959326|NCT02210988|Acupuncture therapy, Acute stroke, Randomized controlled trials
959327|NCT02210975|GERD
959328|NCT02210975|LES
959329|NCT02210975|Sleeve Gastrectomy
959330|NCT02210975|Electrical Stimulation Therapy
959331|NCT02210962|early psychosis
959332|NCT02210962|chronic schizophrenia
959333|NCT02210962|first episode psychosis
959334|NCT02210962|omega-3 and omega-6 essential fatty acids
959335|NCT02210962|relapse prevention
959336|NCT02210962|efficacy
959337|NCT02210949|Blood transfusion
959338|NCT02210949|Erythropoietin
959339|NCT02210949|Iron suppletion
959340|NCT02210923|Baroreflex
959341|NCT02210923|Electrical stimulation
959342|NCT02210923|Carotid body
959343|NCT02210923|Chemoreceptors
959344|NCT02210923|Resistant hypertension
959345|NCT02210910|Massive Rotator Cuff Tear, Sub-acromial spacer, Best repair of rotator cuff
959346|NCT02210884|Vitamin D supplementation
959347|NCT02210884|Lactation
959348|NCT02210884|25 hydroxyvitamin D
959349|NCT02210884|Breast feeding
959350|NCT02210845|Diabetes
959351|NCT02210845|Supervised Exercise
959352|NCT02210845|Weight loss
959353|NCT02210832|smoking
959354|NCT02210832|pregnancy
959355|NCT02210832|cessation
959356|NCT02210832|incentives
959357|NCT02210819|Thromboembolism
959358|NCT02210819|Embolism and Thrombosis
959359|NCT02210819|Vascular Diseases
959360|NCT02210819|Cardiovascular Diseases
959361|NCT02210819|Thrombosis
959362|NCT02210806|Asthma
959363|NCT02210806|Mild-to-moderate persistent asthma
959364|NCT02210806|Mild asthma
959365|NCT02210806|Moderate asthma
959366|NCT02210806|Persistent asthma
959367|NCT02210793|Transepithelial PRK
959368|NCT02210793|Dry eye
959369|NCT02210793|Schirmer test
959370|NCT02210793|Tear break up time
959371|NCT02210793|Dry eye after advanced surface ablation technique
959372|NCT02210754|Nicotine
959373|NCT02210754|Pharmacokinetics
959374|NCT02210754|Pharmacodynamics
959375|NCT02210754|blu e-cigs
959376|NCT02210754|Tolerability
959377|NCT02210754|Safety
959378|NCT02210754|Smoke urge
959379|NCT02210741|immune repertoire
959380|NCT02210741|Graves' disease
959381|NCT02210728|cognitive behavioral therapy
959382|NCT02210728|stimulant medication
959383|NCT02210728|efficacy
959384|NCT02210728|symptoms
959385|NCT02210728|functional outcomes
959386|NCT02210663|Breast cancer
959387|NCT02210663|PARP
959388|NCT02210663|Primary peritoneal cancer
959389|NCT02210663|Fallopian tube
959390|NCT02210663|Ovarian cancer
959391|NCT02210663|veliparib
959392|NCT02210663|ABT-888
959393|NCT02210663|BRCA
959394|NCT02210650|kidney stone
959395|NCT02210637|Appointments and Schedules
959396|NCT02210637|Outpatient Clinics, Hospital/Economics
959397|NCT02210637|Emergency Department
959398|NCT02210637|Hospitalization
959399|NCT02210637|Mortality
959400|NCT02210624|Anoxic Brain Injury
959401|NCT02210624|Autologous bone marrow derived stem cell
959402|NCT02210624|stoke
959403|NCT02210598|labor, induced
959404|NCT02210598|catheter
959405|NCT02210598|oxytocin
959406|NCT02210598|Cesarean section
959407|NCT02210572|Intestinal microbiota
959408|NCT02210572|Intestinal gas
959409|NCT02210572|Dietary intervention
959410|NCT02210572|Low-FODMAPs diet
959411|NCT02210572|Prebiotics
959412|NCT02210559|locally
959413|NCT02210559|advanced
959414|NCT02210559|pancreatic
959415|NCT02210559|cancer
959416|NCT02210559|unresectable
959417|NCT02210559|pancreatic cancer
959418|NCT02210546|breast cancer
959419|NCT02210546|intermediate risk
959420|NCT02210507|vitamin A
959421|NCT02210507|retinol
959422|NCT02210507|carotenoids
959423|NCT02210481|vitrectomy,
959424|NCT02210481|macular thinning,
959425|NCT02210481|retinal detachment,
959426|NCT02210481|epimacular membrane,
959427|NCT02210481|intravitreal glucose,
959428|NCT02210481|OCT
959429|NCT02210468|Osteoarthritis
959430|NCT02210468|Protease Inhibitors
959431|NCT02210468|Alpha-2-macroglobulin
959432|NCT02210468|Autologous treatment
959433|NCT02210468|APIC-CF
959434|NCT02210468|Pain due to Mild to Moderate osteoarthritis (OA) of the knee
959435|NCT02210455|FASD
959436|NCT02210455|pFAS
959437|NCT02210455|ARND
959438|NCT02210455|Fetal Alcohol Syndrome
959439|NCT02210455|Partial Fetal Alcohol Syndrome
959440|NCT02210455|Alcohol Related Neurodevelopmental Disorder
959441|NCT02210455|Static Encephalopathy (Alcohol Exposed)
959442|NCT02210455|Neurobehavioural Disorder (Alcohol Exposed)
959443|NCT02210442|educational games
959444|NCT02210442|clinical practice guideline
959445|NCT02210442|family medicine
959446|NCT02210442|primary health care
959447|NCT02210442|cluster clinical trial
959448|NCT02210429|Supraclavicular Block
959449|NCT02210429|Supraclavicular Catheter
959451|NCT02210429|Regional Anesthesia
959452|NCT02210429|Supracondylar Elbow Fracture
959453|NCT02210390|Psycho-education, Bipolar , cultural adaptation, Pakistan
959454|NCT02210377|Auto-moxibusition, intra-dialytic hypotension, hemodialysis
959455|NCT02210325|gonorrhea
959456|NCT02210325|chlamydia
959457|NCT02210325|solithromycin
959458|NCT02210299|Healthy young children (2-6 months ; 12-18 months)
959459|NCT02210286|dementia
959460|NCT02210286|magnesium
959461|NCT02210286|learning
959462|NCT02210286|memory
959463|NCT02210286|Alzheimer's disease
959464|NCT02210273|Stress Urinary Incontinence
959465|NCT02210273|SUI
959466|NCT02210260|Cancer
959467|NCT02210260|Colorectal
959468|NCT02210260|Pain relief
959469|NCT02210234|wheat bran
959470|NCT02210234|healthy immunity
959471|NCT02210234|T cells
959472|NCT02210221|TBI
959473|NCT02210195|Cannabis Treatment
959474|NCT02210195|Alcohol Treatment
959475|NCT02210195|Alcohol-Related Disorders
959476|NCT02210195|Cannabis-Related Disorders
959477|NCT02210195|Substance-Related Disorders
959478|NCT02210195|Emend
959479|NCT02210195|NK1 receptor antagonist
959480|NCT02210195|Alcohol
959481|NCT02210195|Cannabis
959482|NCT02210195|aprepitant
959483|NCT02210182|Hepatocellular carcinoma
959484|NCT02210182|Oral Pentamidine
959485|NCT02210182|Endo-exonuclease
959486|NCT02210156|Respiratory tract infection
959487|NCT02210156|Incidence
959488|NCT02210156|Dietary supplements
959489|NCT02210156|Micronutrients
959490|NCT02210156|Plant extracts
959491|NCT02210117|Kidney Cancer
959492|NCT02210117|Metastatic Renal Cell Carcinoma
959493|NCT02210117|mRCC
959494|NCT02210117|Cytoreductive Nephrectomy
959495|NCT02210117|Presurgical therapy
959496|NCT02210117|Nivolumab
959497|NCT02210117|BMS-936558
959498|NCT02210117|Bevacizumab
959499|NCT02210117|Avastin
959500|NCT02210117|Anti-VEGF monoclonal antibody
959501|NCT02210117|fhuMab-VEGF
959502|NCT02210117|Ipilimumab
959503|NCT02210117|Yervoy
959504|NCT02210117|BMS-734016
959505|NCT02210117|MDX010
959506|NCT02210104|Melanoma
959507|NCT02210104|Sarcoma
959508|NCT02210104|Mixed round cell liposarcoma
959509|NCT02210104|Advanced
959510|NCT02210104|Metastatic
959511|NCT02210104|Immunotherapy
959512|NCT02210104|Ipilimumab
959513|NCT02210104|Yervoy
959514|NCT02210104|BMS-734016
959515|NCT02210104|MDX010
959516|NCT02210104|Cyclophosphamide
959517|NCT02210104|Cytoxan
959518|NCT02210104|Neosar
959519|NCT02210104|CD4+T Cells
959520|NCT02210078|Blood And Marrow Transplantation
959521|NCT02210078|Infection
959522|NCT02210078|Cytomegalovirus
959523|NCT02210078|CMV
959524|NCT02210078|Stem cell transplant
959525|NCT02210078|Hematopoietic stem cell transplantation
959526|NCT02210078|HSCT
959527|NCT02210078|Human Leukocyte Antigen
959528|NCT02210078|HLA
959529|NCT02210078|Cytotoxic T-Lymphocytes
959530|NCT02210078|CTL
959531|NCT02210065|Leukemia
959532|NCT02210065|Lymphoma
959533|NCT02210065|Blood And Marrow Transplantation
959534|NCT02210065|Hematological malignancies
959535|NCT02210065|Cytotoxic T cells
959536|NCT02210065|CTL
959537|NCT02210065|Cytomegalovirus
959538|NCT02210065|CMV
959539|NCT02210065|Allogeneic hematopoietic stem cell transplantation
959540|NCT02210065|HSCT
959541|NCT02210052|radiofrequency ablation
959542|NCT02210039|SECM
959543|NCT02210039|Esophagus
959544|NCT02210039|Imaging
959545|NCT02210026|bubble nasal continuous positive airway pressure (Bn-CPAP)
959546|NCT02210026|work of breathing
959547|NCT02210026|pressure-rate products
959548|NCT02210013|AMH, AFC, aging, ethnicity
959549|NCT02210000|repeat dose
959550|NCT02210000|phase II
959551|NCT02210000|GCSI-DD
959552|NCT02210000|pharmacodynamics
959553|NCT02210000|gastroparesis
959554|NCT02210000|type 1 and type 2 diabetes mellitus
959555|NCT02210000|camicinal
959556|NCT02210000|GSK962040
959557|NCT02210000|symptoms
959558|NCT02210000|gut motility
959559|NCT02209974|emphysema
959560|NCT02209974|CRP
959561|NCT02209974|interleukin-8
959562|NCT02209974|dynamic hyperinflation
959563|NCT02209935|pediatric
959564|NCT02209935|acute neurologic disease
959565|NCT02209935|critical care
959566|NCT02209935|rehabilitation
959567|NCT02209935|outcome
959568|NCT02209922|tDCS, stroke, postural control
959569|NCT02209909|preoperative aspirin use
959570|NCT02209909|platelet activation
959571|NCT02209909|off pump coronary artery bypass
959572|NCT02209896|Peripheral Neuropathic Pain
959573|NCT02209896|PNP
959574|NCT02209883|sevoflurane, anesthesia, washout time,COPD
959575|NCT02209870|Cardiopulmonary resuscitation
959576|NCT02209870|Teamwork
959577|NCT02209870|electronic checklist
959578|NCT02209857|Breastcancer
959579|NCT02209857|Adjuvant chemotherapy
959580|NCT02209857|70-gene expression profile
959581|NCT02209857|MammaPrint
959582|NCT02209818|Low level laser therapy
959583|NCT02209818|Elastomeric separator
959584|NCT02209818|Placebo
959585|NCT02209818|Visual analog scale
959586|NCT02209818|Laser irradiation
959587|NCT02209766|Safety
959588|NCT02209766|Tolerability
959589|NCT02209766|Pharmacokinetics
959590|NCT02209766|Pharmacodynamics
959591|NCT02209766|D5884
959592|NCT02209766|Japanese
959593|NCT02209766|Caucasian
959594|NCT02209740|renal toxicity, HIV, antiretroviral, outcome
959595|NCT02209675|hepatitis C recurrence
959596|NCT02209675|Rejection
959597|NCT02209675|Liver Transplantation
959598|NCT02209675|Liver biopsy
959599|NCT02209662|APIC-PRP
959600|NCT02209662|Chronic Wounds
959601|NCT02209662|Diabetic foot ulcer
959602|NCT02209636|hyperphosphatemia
959603|NCT02209636|vascular dysfunction
959604|NCT02209636|chronic kidney disease
959605|NCT02209636|cardiovascular disease
959606|NCT02209636|endothelial dysfunction
959607|NCT02209610|Heart Failure
959608|NCT02209597|Major Depressive Disorder
959609|NCT02209597|MDD
959610|NCT02209597|bupropion XL
959611|NCT02209597|Wellbutrin XL
959612|NCT02209571|Breath Tests
959613|NCT02209545|fibroids, leiomyomata, blood loss, misoprostol
959618|NCT02209519|bacterial vaginosis
959619|NCT02209519|recurrence
959620|NCT02209519|male partner
959621|NCT02209506|MLN3126
959622|NCT02209493|Dietary intervention
959623|NCT02209493|Hypercholesterolemic adults
959624|NCT02209493|Vegetable intake
959625|NCT02209493|Functional food
959626|NCT02209493|Prevention
959627|NCT02209467|walking
959628|NCT02209467|postural balance
959629|NCT02209467|falls
959630|NCT02209454|Dexketoprofen
959631|NCT02209454|Bioavailability
959632|NCT02209454|Comparative
959633|NCT02209454|Pharmacokinetic
959634|NCT02209441|sorafenib, gastric cancer, FOLFOX4
959635|NCT02209428|Temozolomide
959636|NCT02209428|IDH mutation
959637|NCT02209428|Low grade glioma
959638|NCT02209389|breast cancer
959639|NCT02209389|cancer associated auto antibodies
959640|NCT02209389|breast cancer blood test
959641|NCT02209363|Parkinson's disease
959642|NCT02209363|OSA
959643|NCT02209363|CPAP
959644|NCT02209363|cognition
959645|NCT02209311|Alveolar Bone Loss
959646|NCT02209311|Alveolar Bone Atrophy
959647|NCT02209311|Dental Implantation
959648|NCT02209311|Bone Tissue Reconstruction
959649|NCT02209311|Sinus Lift
959650|NCT02209311|Autologous Multipotent Mesenchymal Stem Cell
959651|NCT02209311|Autologous MMSCs
959652|NCT02209311|Synthetic Tricalcium Phosphate
959653|NCT02209311|Tissue Engineered Construction
959654|NCT02209311|Oral Mucosa
959655|NCT02209285|Older adults
959656|NCT02209285|Home and community care
959657|NCT02209285|Effectiveness
959658|NCT02209285|Cost analysis
959659|NCT02209285|Stroke
959660|NCT02209285|TIA
959661|NCT02209285|Hypertension
959662|NCT02209285|Cardiovascular disease
959663|NCT02209220|Obstructive sleep apnea
959664|NCT02209220|Treatment compliance
959665|NCT02209220|Automatic positive airway pressure
959666|NCT02209220|Continuous positive airway pressure
959667|NCT02209220|Bariatric surgery
959668|NCT02209207|chronic obstructive pulmonary disease
959669|NCT02209207|endurance training
959670|NCT02209207|interval training
959671|NCT02209207|continuous training
959672|NCT02209207|walking training
959673|NCT02209194|aneurysms
959674|NCT02209194|vascular disease
959675|NCT02209194|E-liac Stent Graft
959676|NCT02209194|E-liac Stent Graft System
959677|NCT02209194|iliac aneurysm
959678|NCT02209194|branched stent graft
959679|NCT02209194|self expanding stent graft
959680|NCT02209181|dental pain
959681|NCT02209181|post-surgical dental pain
959682|NCT02209168|AMH, ACF, VIT D, Ethnicity
959683|NCT02209142|Major depression
959684|NCT02209129|digital breast tomosynthesis
959685|NCT02209116|ADHD
959686|NCT02209116|QB Test
959687|NCT02209116|Activity
959688|NCT02209116|Attention
959689|NCT02209116|Children
959690|NCT02209116|Clinical Decision Making
959691|NCT02209103|Polyphenols
959692|NCT02209103|Orange
959693|NCT02209103|Sleep
959694|NCT02209103|Fatigue
959695|NCT02209090|occiput-posterior
959696|NCT02209090|occipitoposterior
959697|NCT02209090|labour
959698|NCT02209064|Subxiphoid
959699|NCT02209064|Access
959700|NCT02209051|Diabetic Foot Ulcers
959701|NCT02209051|AMNIOEXCEL
959702|NCT02209051|Wagner Grade 1 or 2 foot ulcers
959703|NCT02209051|Wound
959704|NCT02209051|Foot health
959705|NCT02209051|Ulcer
959706|NCT02209051|Foot Ulcer
959707|NCT02209051|Diabetic Foot
959708|NCT02209051|Foot Diseases
959709|NCT02209051|Skin Diseases
959710|NCT02209051|Leg Ulcer
959711|NCT02209051|Skin Ulcer
959712|NCT02209051|Diabetic Angiopathies
959713|NCT02209051|Vascular Diseases
959714|NCT02209051|Cardiovascular Diseases
959715|NCT02209051|Diabetes Complications
959716|NCT02209051|Diabetes Mellitus
959717|NCT02209051|Endocrine System Diseases
959718|NCT02209051|Diabetic Neuropathies
959719|NCT02209038|end stage renal disease
959720|NCT02209038|hemodialysis
959721|NCT02209038|dialysis
959722|NCT02209025|Atherosclerosis
959723|NCT02209025|Cholesterol
959724|NCT02209025|Cholesterol, HDL
959725|NCT02209025|Apolipoprotein A-I
959726|NCT02209025|Theobromine
959727|NCT02209012|Actinic Keratosis
959728|NCT02208999|medullary neurostimulation
959729|NCT02208999|pain
959730|NCT02208999|Precision
959731|NCT02208999|rechargeable
959732|NCT02208999|implantable
959733|NCT02208986|GnRH antagonist
959734|NCT02208986|GnRH agonist trigger
959735|NCT02208986|Oocyte donor
959736|NCT02208973|Adenosine A1 receptor antagonist
959737|NCT02208973|adenosine receptor modulator
959738|NCT02208973|Asthma
959739|NCT02208973|COPD
959740|NCT02208960|Neurodevelopment
959741|NCT02208960|Neonatal kit
959742|NCT02208960|Kenya
959743|NCT02208960|Cluster Randomized Controlled Trial
959744|NCT02208960|Chlorhexidine
959745|NCT02208960|ThermoSpot
959746|NCT02208947|advance care planning
959747|NCT02208947|decision making
959748|NCT02208947|patient engagement
959749|NCT02208947|patient education
959750|NCT02208947|financial incentives
959751|NCT02208947|behavioral economics
959752|NCT02208934|PDE10 inhibitor
959753|NCT02208934|Huntington's disease
959754|NCT02208934|phosphodiesterase 10 inhibitor
959755|NCT02208934|psychiatric disorders
959756|NCT02208921|Type 2 Diabetes
959757|NCT02208908|Oral care
959758|NCT02208908|cancer
959759|NCT02208908|palliative
959760|NCT02208908|training
959761|NCT02208895|pleural
959762|NCT02208895|glucose
959763|NCT02208895|glucometer
959764|NCT02208895|i-STAT
959765|NCT02208869|familial hypercholesterolemia
959766|NCT02208869|cholesterol
959767|NCT02208869|prevention
959768|NCT02208869|registry
959769|NCT02208869|atherosclerosis
959770|NCT02208869|treatment
959771|NCT02208869|prevalence
959772|NCT02208830|bronchiectasis
959773|NCT02208830|functional capacity
959774|NCT02208830|lung functional
959775|NCT02208817|capillary refill
959776|NCT02208817|paediatric early warning score
959777|NCT02208817|photoplethysmography
959778|NCT02208804|Colorectal Cancer Liver Metastases
959779|NCT02208791|Kidney Transplantation
959780|NCT02208791|Graft Rejection
959781|NCT02208791|Immunossupression
959782|NCT02208778|Osteoarthritis
959783|NCT02208778|Chronic Pain
959784|NCT02208778|Pain relief
959785|NCT02208765|Coronary Circulation
959786|NCT02208765|Coronary Artery Disease
959787|NCT02208765|Myocardial perfusion imaging
959788|NCT02208765|Prognosis
959789|NCT02208752|rotator cuff tears
959790|NCT02208752|ultrasound measure
959791|NCT02208752|pain
959792|NCT02208752|range of motion
959793|NCT02208752|muscle force
959794|NCT02208739|Chronic periodontitis
959795|NCT02208739|periodontal pathogens
959796|NCT02208739|inflammatory mediators
959797|NCT02208739|Non surgical periodontal therapy
959798|NCT02208739|Oral hygiene instructions
959799|NCT02208739|Polymerase chain reaction
959800|NCT02208739|Elisa
959801|NCT02208726|anxiety
959802|NCT02208726|students
959803|NCT02208726|examinations
959804|NCT02208726|Homeopathy
959805|NCT02208713|FSHD muscle derived stem cell adipose derived mesenchymal stem cell intramuscular injection
959806|NCT02208687|Social Participation
959807|NCT02208687|Fatigue
959808|NCT02208687|Self-Management
959809|NCT02208687|Rehabilitation
959810|NCT02208687|Physical therapy
959811|NCT02208687|Occupational therapy
959812|NCT02208687|Group intervention
959813|NCT02208687|Exercise
959814|NCT02208674|chronic kidney disease
959815|NCT02208674|albuminuria
959816|NCT02208674|hypertension
959817|NCT02208674|dyslipidemia
959818|NCT02208674|cardiovascular disease
959819|NCT02208674|pragmatic trial
959820|NCT02208674|cluster randomized trial
959821|NCT02208661|Morquio A syndrome
959822|NCT02208661|Mucopolysaccharidosis IV A
959823|NCT02208661|Psychological health
959824|NCT02208648|coronary calcification
959825|NCT02208648|Computed Tomography
959826|NCT02208648|Coronary artery calcium
959827|NCT02208648|calcium scores
959828|NCT02208648|post-operative mortality
959829|NCT02208635|Zinc Absorption
959830|NCT02208635|Biofortification
959831|NCT02208635|Maize
959832|NCT02208635|Zambia
959833|NCT02208635|Stable isotopes of Zn
959834|NCT02208622|Zinc absorption
959835|NCT02208622|Iron Absorption
959836|NCT02208622|Whey Protein
959837|NCT02208622|Mexico
959838|NCT02208622|Stable isotopes
959839|NCT02208609|Zinc Absorption
959840|NCT02208609|Maize
959841|NCT02208609|Amaranth
959842|NCT02208609|Guatemala
959843|NCT02208609|Stable isotopes of Zn
959844|NCT02208583|Molecular phenotypic；CRPC; personalized treatment
959845|NCT02208570|Hypotension during anesthesia induction
959846|NCT02208557|Incisional hernia
959847|NCT02208557|prevention
959848|NCT02208557|laparotomy closure
959849|NCT02208557|absorbable mesh
959850|NCT02208544|Thyroid Nodule
959851|NCT02208544|Indeterminate Cytology
959852|NCT02208544|FDG-PET/CT
959853|NCT02208544|Diagnostic Thyroid Surgery
959854|NCT02208544|Efficacy
959855|NCT02208544|Cost-Effectiveness
959856|NCT02208544|Quality-of-Life
959857|NCT02208544|Thyroidectomy
959858|NCT02208531|Early Childhood Development (ECD)
959859|NCT02208531|Psychosocial stimulation
959860|NCT02208531|Malnutrition
959861|NCT02208531|Bangladesh
959862|NCT02208531|Scaling up ECD
959863|NCT02208518|Endoscopic Ultrasound elastography
959864|NCT02208518|Quantitative elastography
959865|NCT02208518|Qualitative elastography
959866|NCT02208518|Endoscopic Ultrasound
959867|NCT02208518|Elastography
959868|NCT02208492|Levetiracetam, Carabamazepine
959869|NCT02208479|cardiac surgery
959870|NCT02208479|diaphragm dysfunction
959871|NCT02208479|mechanical ventilation weaning
959872|NCT02208479|respiratory paralysis
959873|NCT02208479|muscle weakness
959874|NCT02208479|cardiac bypass
959875|NCT02208479|valvular surgery
959876|NCT02208479|respiratory insufficiency
959877|NCT02208466|repetitive transcranial magnetic stimulation
959878|NCT02208466|rTMS
959879|NCT02208466|TMS
959880|NCT02208466|fluoxetine
959881|NCT02208453|Massive Rotator Cuff Tear
959882|NCT02208453|Local anesthesia
959883|NCT02208453|Sub-acromial spacer
959884|NCT02208440|Massive Rotator Cuff Tear, Sub-acromial spacer, Best repair of rotator cuff
959885|NCT02208427|isoniazid, LTBI, rifapentine, TST
959886|NCT02208414|Food Allergies
959889|NCT02208375|Breast Cancer
959890|NCT02208375|Malignant Female Reproductive System Neoplasm
959891|NCT02208375|Recurrent endometrial cancer
959892|NCT02208375|Recurrent endometrial adenocarcinoma
959893|NCT02208375|Triple negative breast cancer
959894|NCT02208375|Ovarian cancer
959895|NCT02208375|Primary peritoneal cancer
959896|NCT02208375|Fallopian tube cancer
959897|NCT02208375|Olaparib
959898|NCT02208375|AZD2014
959899|NCT02208375|AZD5363
959900|NCT02208349|intubation, video laryngoscopy, direct laryngoscopy, prehospital, emergency medical services
959901|NCT02208323|Hypoxia
959902|NCT02208323|Respiratory Distress
959903|NCT02208310|Crohn's disease
959904|NCT02208310|Vitamin D deficiency
959905|NCT02208284|Single Ascending Dose
959906|NCT02208284|healthy subjects
959907|NCT02208284|Hyperlipidemia
959908|NCT02208284|Lipid Metabolism Disorders
959909|NCT02208284|Metabolic Diseases
959910|NCT02208271|tissue necrosis
959911|NCT02208271|metal on metal total hip
959912|NCT02208271|biomarker
959913|NCT02208258|fecal incontinence, consure medical, semi formed stool, stool management system
959914|NCT02208232|IOL rotation
959915|NCT02208219|Stroke
959916|NCT02208219|Paresis
959917|NCT02208219|Upper extremity
959918|NCT02208219|Motor deficits
959919|NCT02208219|Music Therapy
959920|NCT02208219|Neurorehabilitation
959921|NCT02208206|Neuropathic pain
959922|NCT02208206|Phenotype
959923|NCT02208206|Genotype
959924|NCT02208206|Biomarkers
959925|NCT02208206|HIV
959926|NCT02208206|Diabetes mellitus
959927|NCT02208206|Breast cancer
959928|NCT02208206|Genomics
959929|NCT02208206|Quantitative sensory testing
959930|NCT02208193|Alzheimer disease Art Healing gardens Discourse analysis
959931|NCT02208180|Return of results
959932|NCT02208180|Genomics
959933|NCT02208167|Antigen Expanded Specific T Cell Therapy
959934|NCT02208167|HXTC
959935|NCT02208167|Antiretroviral Therapy
959936|NCT02208167|Acute HIV infection
959937|NCT02208167|Chronic HIV infection
959938|NCT02208167|Leukapheresis
959939|NCT02208154|ICU acquired bacteraemia
959940|NCT02208154|colonization
959941|NCT02208154|decolonization
959942|NCT02208154|selective decontamination
959943|NCT02208154|multidrug resistant bacteria
959944|NCT02208141|children
959945|NCT02208141|obesity
959946|NCT02208141|adipose tissue dysfunction
959947|NCT02208141|inflammation
959948|NCT02208141|macrophage infiltration
959949|NCT02208141|insulin resistance
959950|NCT02208141|dyslipidemia
959951|NCT02208128|Renal cell carcinoma
959952|NCT02208128|Biomarkers
959953|NCT02208128|Molecular modifications
959954|NCT02208115|Type 1 Diabetes Mellitus
959955|NCT02208115|Exercise
959956|NCT02208115|Appetite
959957|NCT02208102|atrial fibrillation, catheter ablation, blood-biomarkers
959958|NCT02208089|Keratoconus
959959|NCT02208089|Corneal collagen cross-linking
959960|NCT02208089|Photorefractive keratectomy
959961|NCT02208076|Growth disorders
959962|NCT02208076|Saizen
959963|NCT02208076|Easypod
959964|NCT02208076|Growth hormone
959965|NCT02208076|Pediatric subject
959966|NCT02208063|Bacteremia
959967|NCT02208063|Staphylococcus aureus
959968|NCT02208050|Secondary Progressive Multiple Sclerosis
959969|NCT02208050|Primary Progressive Multiple Sclerosis
959970|NCT02208050|Multiple Sclerosis
959971|NCT02208050|Upper limb function
959972|NCT02208050|Mobility
959973|NCT02208050|Fampridine
959974|NCT02208050|DASH
959975|NCT02208050|AMSQ
959976|NCT02208050|MSWS-12
959977|NCT02208050|MSIS-29
959978|NCT02208050|SF-36
959979|NCT02208050|9HPT
959980|NCT02208050|25FTW
959981|NCT02208050|JTT
959982|NCT02208037|Acute Lymphoblastic Leukemia/Lymphoma
959983|NCT02208037|Acute Myelogenous Leukemia
959984|NCT02208037|Mantel-Cell Lymphoma
959985|NCT02208037|Hematopoietic Transplant
959986|NCT02208037|GVHD Prophylaxis
959987|NCT02207998|osteoarthritis, physiotherapy, homeopathy, complex
959988|NCT02207985|Pancreatic adenocarcinoma
959989|NCT02207985|Hematopoietic stem cell transplantation
959990|NCT02207972|Pregnant
959991|NCT02207972|labor
959992|NCT02207972|Epidural
959993|NCT02207959|Gastric cancer
959994|NCT02207959|Neoplasia
959995|NCT02207959|Endoscopic imaging
959996|NCT02207959|In vivo imaging
959997|NCT02207933|anterioposterior
959998|NCT02207933|weight
959999|NCT02207933|shifting
960000|NCT02207933|training
960001|NCT02207933|patient
960002|NCT02207894|Haemophilia A, factor VIII, development of inhibitor
960003|NCT02207881|herpes labialis
960004|NCT02207881|cold sore
960005|NCT02207829|COPD
960006|NCT02207829|inhaler critical errors
960007|NCT02207829|double-dummy
960008|NCT02207829|novel dry powder inhaler
960009|NCT02207829|inhaler preference
960010|NCT02207829|tiotropium
960011|NCT02207829|umeclidinium
960012|NCT02207829|long-acting muscarinic antagonist
960023|NCT02207803|Brain Injuries
960024|NCT02207803|Caregivers
960025|NCT02207803|Intervention Studies
960026|NCT02207803|Latin America
960027|NCT02207790|Clinical Trial, Phase I
960028|NCT02207790|Healthy Volunteers
960029|NCT02207777|Obesity
960030|NCT02207777|Roux-en-Y gastric bypass (RYGB)
960031|NCT02207777|Type 2 Diabetes
960032|NCT02207777|Sleeve Gastrectomy (SG)
960033|NCT02207777|Biliopancreatic Diversion with Duodenal switch (BPD)
960034|NCT02207777|Laparoscopic Adjustable Gastric Banding (LAGB)
960035|NCT02207751|Chronic Kidney Disease
960036|NCT02207751|Peritoneal Dialysis Access
960037|NCT02207751|Peritoneal Dialysis Catheter
960038|NCT02207751|Catheter Function
960039|NCT02207738|acne
960040|NCT02207738|acne scar
960041|NCT02207738|microneedling radiofrequency
960042|NCT02207738|bipolar radiofrequency
960043|NCT02207725|Andexanet alpha
960044|NCT02207725|Anticoagulation
960045|NCT02207725|Antidote
960046|NCT02207725|Apixaban
960047|NCT02207725|Anti-fXa inhibitor
960048|NCT02207725|PRT4445
960049|NCT02207725|Eliquis
960050|NCT02207725|Reversal agent
960051|NCT02207712|Diabetes
960052|NCT02207712|Macular Oedema
960053|NCT02207712|Diabetic retinopathy
960054|NCT02207712|Noctura
960055|NCT02207686|CNS hemangioblastoma
960056|NCT02207686|Renal Cell Carcinoma
960057|NCT02207686|VHL germline mutation
960058|NCT02207686|VHL somatic mutation
960059|NCT02207686|Tumor development
960060|NCT02207673|epilepsy surgery
960061|NCT02207673|biomarker
960062|NCT02207673|high frequency oscillations (HFOs)
960063|NCT02207673|acute electrocorticography (aECoG)
960064|NCT02207660|cisplatin
960065|NCT02207660|Cervical cancer
960066|NCT02207660|metastasis
960067|NCT02207660|recurrence
960073|NCT02207621|Glaucoma
960074|NCT02207608|BCG
960075|NCT02207608|hyaluronic acid
960076|NCT02207608|non-muscle invasive bladder cancer
960077|NCT02207608|non bacterial cystitis
960078|NCT02207582|depression; trns
960079|NCT02207556|AL amyloidosis
960080|NCT02207556|amyloidosis
960081|NCT02207556|light chain amyloidosis
960082|NCT02207543|Cancer
960083|NCT02207543|Palliative care
960084|NCT02207543|home
960085|NCT02207530|Head and neck cancer; SCCHN
960086|NCT02207517|convergence insufficiency
960087|NCT02207517|vision therapy
960088|NCT02207517|reading
960089|NCT02207517|attention
960090|NCT02207504|Castration-resistant Prostate Cancer
960091|NCT02207491|Glaucoma
960092|NCT02207478|Electromagnetic navigation bronchoscopy with a guide sheath
960093|NCT02207478|Transbronchial lung biopsy
960094|NCT02207478|Peripheral lung lesions
960095|NCT02207478|Solitary pulmonary nodule
960099|NCT02207426|Healthy volunteers
960100|NCT02207413|Quadrivalent influenza vaccine
960101|NCT02207413|Safety
960102|NCT02207413|Children
960103|NCT02207413|Adults
960104|NCT02207413|Immunogenicity
960105|NCT02207322|Hematopoietic stem cell transplantation (HSCT)
960106|NCT02207322|autologous stem cell transplant
960107|NCT02207322|allogeneic stem cell transplant
960108|NCT02207309|high-risk soft tissue sarcoma
960109|NCT02207309|pazopanib
960110|NCT02207309|retroperitoneal soft tissue sarcoma
960111|NCT02207309|visceral soft tissue sarcoma
960112|NCT02207309|votrient
960113|NCT02207270|Angina
960114|NCT02207270|Coronary artery disease
960115|NCT02207270|Costs
960116|NCT02207270|Cost minimization
960117|NCT02207270|Percutaneous coronary intervention
960118|NCT02207270|Randomized trial
960119|NCT02207270|Risk score
960120|NCT02207270|Same day discharge
960121|NCT02207270|Unstable angina
960122|NCT02207257|PER977
960123|NCT02207257|anticoagulation reversal
960124|NCT02207257|pharmacokinetics
960125|NCT02207257|edoxaban
960126|NCT02207257|whole blood clotting time
960127|NCT02207257|D-dimer
960128|NCT02207257|prothrombin fragments 1 and 2
960129|NCT02207257|tissue factor pathway inhibitor
960130|NCT02207257|prothrombin time
960131|NCT02207244|Psoriasis
960132|NCT02207244|Plaque-type psoriasis
960133|NCT02207244|Guselkumab
960134|NCT02207244|Adalimumab
960135|NCT02207244|CNTO 1959
960136|NCT02207244|Monoclonal antibody
960137|NCT02207231|Psoriasis
960138|NCT02207231|Plaque-type psoriasis
960139|NCT02207231|Guselkumab
960140|NCT02207231|Adalimumab
960141|NCT02207231|CNTO 1959
960142|NCT02207231|Monoclonal antibody
960143|NCT02207192|obesity, lung volumes, postural changes
960144|NCT02207179|Intraoperative
960145|NCT02207179|Cancer margin
960146|NCT02207179|Spectroscopy
960147|NCT02207179|Polarization
960148|NCT02207166|hypertension
960149|NCT02207166|device
960150|NCT02207166|errors
960151|NCT02207166|human factor engineering
960152|NCT02207166|usability engineering
960153|NCT02207153|Chronic Hemodialysis
960154|NCT02207153|Chronic Peritoneal Dialysis
960155|NCT02207127|obstructive sleep apnea
960156|NCT02207127|sleep apnea
960157|NCT02207114|Sepsis, Systemic inflammatory response syndrome (SIRS), antibiotic use, intensive care unit
960158|NCT02207101|Young athletes
960159|NCT02207101|Cardiac endurance
960160|NCT02207101|Herbal
960161|NCT02207101|Ejection Fraction
960162|NCT02207101|Basic Research
960163|NCT02207101|Cardiovascular Injury
960164|NCT02207088|Compensated Cirrhosis
960165|NCT02207088|dialysis
960166|NCT02207088|Hepatitis C Virus
960167|NCT02207088|Severe Renal Impairment
960168|NCT02207088|Renal impairment
960169|NCT02207088|cirrhosis
960170|NCT02207088|Chronic Hepatitis C
960171|NCT02207088|Hepatitis C
960172|NCT02207088|End-stage renal disease
960173|NCT02207088|Hepatitis C Genotype 1
960174|NCT02207088|renal disease
960175|NCT02207075|SPMS
960176|NCT02207075|Myelin Water Fraction
960177|NCT02207075|activated microglia
960178|NCT02207036|Tobacco
960179|NCT02207036|cigarettes
960180|NCT02207036|cessation
960181|NCT02207036|intervention
960182|NCT02207036|young adults
960183|NCT02207036|Internet
960184|NCT02207036|social media
960185|NCT02207036|mobile health
960186|NCT02207023|Stroke
960187|NCT02207023|Telehealth
960188|NCT02207023|Rehabilitation
960189|NCT02207023|Stroke Coach
960190|NCT02207023|Randomized controlled trial
960191|NCT02207023|Lifestyle behaviours
960192|NCT02207023|Secondary prevention
960193|NCT02207023|Chronic disease self-management
960194|NCT02207010|Glioblastoma
960195|NCT02207010|GBM
960196|NCT02207010|first recurrence
960197|NCT02206997|perioperative hypothermia
960198|NCT02206997|prewarming
960199|NCT02206997|treatment guideline
960200|NCT02206958|Toileting disability
960201|NCT02206958|Functional urinary incontinence
960202|NCT02206958|Urinary incontinence
960203|NCT02206958|Frailty
960204|NCT02206958|Physical activity
960205|NCT02206932|Hepatitis C
960206|NCT02206932|HIV
960207|NCT02206932|Simeprevir
960208|NCT02206932|Sofosbuvir
960209|NCT02206919|Flow mediated dilation
960210|NCT02206919|Magnetic Resonance Imaging MRI
960211|NCT02206919|Diabetes
960212|NCT02206919|Endothelial dysfunction
960213|NCT02206919|Popliteal artery
960214|NCT02206919|Atherosclerosis
960215|NCT02206919|Cardiovascular disease
960216|NCT02206919|Vascular disease
960217|NCT02206906|Medication Adherence
960218|NCT02206906|Incentives
960219|NCT02206906|Real-time Medication Monitoring
960220|NCT02206880|Thoracic Surgery
960221|NCT02206880|Delirium
960222|NCT02206880|Cardiopulmonary Bypass
960223|NCT02206880|Intensive Care
960224|NCT02206854|Pharmakokinetic
960225|NCT02206854|capsules
960226|NCT02206854|R-Flurbiprofen
960227|NCT02206841|fibrosis
960228|NCT02206841|markers
960229|NCT02206828|HERNIA
960230|NCT02206828|SYMCHRO
960231|NCT02206828|SOFRADIM
960232|NCT02206828|REGISTRY
960233|NCT02206828|SYMBOTEX
960234|NCT02206802|Alopecia
960235|NCT02206802|Androgenetic Alopecia
960236|NCT02206802|Female Pattern Hair Loss
960237|NCT02206802|Hair Loss
960238|NCT02206802|Minoxidil
960239|NCT02206802|Hair Thinning
960240|NCT02206776|OCD
960241|NCT02206750|Controlled Human exposure study
960242|NCT02206750|Air Pollution
960243|NCT02206750|Cardiovascular
960244|NCT02206750|Social factors
960245|NCT02206750|Cognitive function
960246|NCT02206724|Metastatic prostate cancer
960247|NCT02206698|Intraabdominal Injury
960248|NCT02206698|CT Abdomen and Pelvis
960249|NCT02206698|Pediatric trauma
960250|NCT02206698|blunt abdominal injury
960251|NCT02206698|blunt trauma
960252|NCT02206698|clinical prediction model
960253|NCT02206633|dehydration
960254|NCT02206607|Phase 1
960255|NCT02206607|bioavailability
960256|NCT02206607|type 2 diabetes mellitus
960257|NCT02206607|PF-04937319
960258|NCT02206581|dehydration
960259|NCT02206568|diabetes mellitus
960260|NCT02206568|phase 1
960261|NCT02206568|insulin lispro
960262|NCT02206568|male subjects
960263|NCT02206555|HIV
960264|NCT02206555|prevention
960265|NCT02206555|prophylaxis
960266|NCT02206555|antiretroviral
960267|NCT02206555|biomedical
960268|NCT02206555|bio-behavioural
960269|NCT02206555|evaluation
960270|NCT02206555|demonstration study
960271|NCT02206542|acupuncture,frozen shoulder,robot,sonography,MRI
960272|NCT02206529|obesity
960273|NCT02206529|child
960274|NCT02206529|weight management
960275|NCT02206529|behavioral
960276|NCT02206529|social networks
960277|NCT02206529|social support
960278|NCT02206503|LENALIDOMIDE
960279|NCT02206503|BIOCHEMICAL PROGRESSION
960280|NCT02206503|RELAPSED/REFRACTORY MM
960281|NCT02206503|WITHOUT CRAB
960282|NCT02206490|Gulf War Illness
960283|NCT02206490|treatment
960284|NCT02206490|dextromethorphan
960285|NCT02206490|naltrexone
960286|NCT02206477|breast capsular contructure
960287|NCT02206477|dimethyl sulfoxide
960288|NCT02206477|radiotherapy
960289|NCT02206477|breast reconstruction
960290|NCT02206464|A/Anhui/1/2013 (H7N9)
960291|NCT02206464|Antibody Response
960292|NCT02206464|Avian Influenza
960293|NCT02206464|A/Shanghai/2/2013 (H7N9)
960294|NCT02206464|Immunogenicity
960295|NCT02206451|Assay
960296|NCT02206451|Infection
960297|NCT02206451|Direct Skin Feed
960298|NCT02206451|Midgut
960299|NCT02206451|Parasite
960300|NCT02206438|supraglottic airway devices
960424|NCT02205814|Osteoarthritis, Knee
960301|NCT02206438|the classic laryngeal mask airway
960302|NCT02206438|the self-pressurised air-Q intubating laryngeal airway in adult patients
960303|NCT02206438|elective surgery of short duration (less than 2 hr) undergoing general anesthesia using supraglottic airway in adult patients
960304|NCT02206425|multiple myeloma
960305|NCT02206425|Relapsed/refractory
960306|NCT02206425|Ixazomib
960307|NCT02206425|Proteasome inhibitor
960308|NCT02206425|Oral
960309|NCT02206412|high mobility group box 1
960310|NCT02206412|prognostic biomarker
960311|NCT02206412|off-pump coronary artery bypass graft
960312|NCT02206412|patients
960313|NCT02206373|creatinine
960314|NCT02206373|glomerular filtration rate
960315|NCT02206373|renal insufficiency, chronic
960316|NCT02206360|Pancreatic Cancer
960317|NCT02206360|Pancreatic Cancer Screening
960318|NCT02206360|Pancreas Cancer
960319|NCT02206360|Pancreatic Adenocarcinoma
960320|NCT02206360|Pancreatic Adenocarcinoma screening
960321|NCT02206360|Familial Pancreatic Cancer
960322|NCT02206360|BRCA 1/2
960323|NCT02206360|HNPCC
960324|NCT02206360|Lynch Syndrome
960325|NCT02206360|Hereditary Pancreatitis
960326|NCT02206360|FAMMM
960327|NCT02206360|Familial atypical multiple mole melanoma
960328|NCT02206360|Peutz Jeghers Syndrome
960329|NCT02206360|MRI
960330|NCT02206360|Magnetic Resonance Imaging
960331|NCT02206360|EUS
960332|NCT02206360|Endoscopic Ultrasound
960333|NCT02206360|Early detection
960334|NCT02206360|Screening
960335|NCT02206308|Chimeric anti-CD20 monoclonal antibody(SCT400)
960336|NCT02206308|escalating doses
960337|NCT02206308|safety
960338|NCT02206308|pharmacokinetics and pharmacodynamics
960339|NCT02206295|selexipag
960340|NCT02206295|ACT-333679
960341|NCT02206243|Benign prostatic hyperplasia
960342|NCT02206243|BPH
960343|NCT02206230|glioblastoma
960344|NCT02206230|radiotherapy
960345|NCT02206230|hypofractionated radiotherapy
960346|NCT02206204|Selexipag
960347|NCT02206204|ACT-333679
960348|NCT02206152|Diabetes
960349|NCT02206152|Hypoglycemia
960350|NCT02206152|Unawareness
960351|NCT02206152|HAAF
960352|NCT02206126|Obstructive sleep apnea
960353|NCT02206126|Weight loss
960354|NCT02206126|Obesity
960355|NCT02206126|Sympathetic activity
960356|NCT02206126|Metabolic profile
960357|NCT02206126|Endothelial function
960358|NCT02206113|Standing workstation
960359|NCT02206100|PER977
960360|NCT02206100|enoxaparin
960361|NCT02206100|anticoagulation reversal
960362|NCT02206100|whole blood clotting time
960363|NCT02206087|PER977
960364|NCT02206087|heparin
960365|NCT02206087|anticoagulation reversal
960366|NCT02206087|whole blood clotting time
960367|NCT02206048|Cervix Carcinoma
960368|NCT02206048|Cervical adenocarcinoma in situ
960369|NCT02206048|AIS
960370|NCT02206048|Cervical intraepithelial neoplasia
960371|NCT02206048|CIN
960372|NCT02206048|microinvasive carcinoma of the cervix
960373|NCT02206048|cold knife cone of the cervix
960374|NCT02206048|CKC
960375|NCT02206048|High-Resolution Microendoscopy
960376|NCT02206048|HRME
960377|NCT02206048|Proflavine
960378|NCT02206022|Central Venous Catheter
960379|NCT02206022|Remifentanil
960380|NCT02206022|local anesthesia
960381|NCT02206022|pain
960382|NCT02205996|Type 2 diabetes
960383|NCT02205996|Hypoglycaemia
960384|NCT02205996|Platelets
960385|NCT02205996|Inflammation
960386|NCT02205983|enrolling
960387|NCT02205983|adult
960388|NCT02205983|volunteers
960389|NCT02205970|TENS
960390|NCT02205970|Dysmenorrhea
960391|NCT02205970|analgesia
960392|NCT02205970|interactive
960393|NCT02205957|anesthesiology and intensive care, quality, training
960394|NCT02205944|chronic kidney disease
960395|NCT02205944|hemodialysis
960396|NCT02205944|vascular access
960397|NCT02205944|arteriovenous fistula
960398|NCT02205944|forearm exercise
960399|NCT02205931|Epilepsy
960400|NCT02205931|Ketogenic diet
960401|NCT02205931|Antiepileptic drugs
960402|NCT02205931|Randomised controlled trial
960403|NCT02205905|PER977
960404|NCT02205905|metabolic disposition
960405|NCT02205905|mass balance
960406|NCT02205905|metabolites
960407|NCT02205905|radiolabeled
960408|NCT02205892|natural product
960409|NCT02205892|clinical trial
960410|NCT02205879|pregabalin
960411|NCT02205879|patients
960412|NCT02205879|treatment
960413|NCT02205853|Oncology Service Hospital
960414|NCT02205853|Patient-centred
960415|NCT02205853|Exercise
960416|NCT02205853|Neoplasms
960417|NCT02205853|Rehabilitation
960418|NCT02205853|Qualitative Research
960419|NCT02205853|Health Plan Implementation
960420|NCT02205853|Quality of Health Care
960421|NCT02205853|Guidelines
960422|NCT02205853|Quality of Life
960423|NCT02205827|whole blood clotting time
960425|NCT02205814|Arthritis
960426|NCT02205814|WOMAC
960427|NCT02205814|Injections, intra-articular
960428|NCT02205814|Fasitibant
960429|NCT02205814|MEN 16132
960430|NCT02205762|Langerhans cell histiocytosis
960431|NCT02205749|biobanks
960432|NCT02205749|informed consent
960433|NCT02205749|health literacy
960434|NCT02205736|Breast health education
960435|NCT02205736|Latino women
960436|NCT02205736|Group education
960437|NCT02205736|Breast cancer
960438|NCT02205723|Asthma
960439|NCT02205723|Asthma exacerbations
960440|NCT02205723|Pediatric
960441|NCT02205697|Fruit
960442|NCT02205697|Vegetable
960443|NCT02205684|Physical activity
960444|NCT02205684|Exercise
960445|NCT02205684|High intensity training
960446|NCT02205684|Schizophrenia
960447|NCT02205684|Symptoms
960448|NCT02205684|Well-being
960449|NCT02205684|Cognition
960450|NCT02205684|Hippocampal volume
960451|NCT02205684|Neuroplasticity
960452|NCT02205684|Smoking
960453|NCT02205684|Substance use
960454|NCT02205684|Metabolic indices
960455|NCT02205671|caregiving
960456|NCT02205671|chronic illness
960457|NCT02205671|patient education
960458|NCT02205671|self management
960459|NCT02205658|Sensory Processing
960460|NCT02205658|Autism
960461|NCT02205645|medial
960462|NCT02205645|meniscus
960463|NCT02205645|scaffold
960464|NCT02205645|repair
960465|NCT02205645|tear
960466|NCT02205645|injury
960467|NCT02205619|Residual cementum
960468|NCT02205619|root surface instrumentation
960469|NCT02205619|ultrasonic scaling
960470|NCT02205619|air polishing with glycine
960471|NCT02205593|psoriasis
960472|NCT02205593|atopic dermatitis
960473|NCT02205593|eczema
960474|NCT02205593|patient education
960475|NCT02205593|stress reduction
960476|NCT02205593|quality of life
960477|NCT02205554|Analgesia
960478|NCT02205554|Pharmacokinetics
960479|NCT02205554|Treatment
960480|NCT02205541|Eculizumab
960481|NCT02205541|Shiga-toxin
960482|NCT02205541|hemolytic and uremic syndrome
960483|NCT02205541|pediatric
960484|NCT02205476|Phase 2
960485|NCT02205476|open-label
960486|NCT02205476|safety
960487|NCT02205476|hypertrophic scar revision surgery
960488|NCT02205463|Esophagus
960489|NCT02205463|Gastroesophageal Junction
960490|NCT02205463|Stomach
960491|NCT02205463|Gastric
960492|NCT02205463|Cancer
960493|NCT02205463|HER2
960494|NCT02205463|Metastatic
960495|NCT02205463|Adenocarcinoma
960496|NCT02205450|Prader-Willi Syndrome
960497|NCT02205450|Growth Hormone
960498|NCT02205450|Children
960499|NCT02205437|Schizophrenia
960500|NCT02205437|Psychosis
960501|NCT02205437|Antipsychotics
960502|NCT02205437|Treatment response
960503|NCT02205437|Metabolic side effects
960504|NCT02205437|Gene expression
960505|NCT02205437|RNA
960506|NCT02205437|Genes
960507|NCT02205424|Ischaemic stroke
960508|NCT02205424|Alzheimer's disease
960509|NCT02205424|Brain volume
960510|NCT02205424|Cortical thickness
960511|NCT02205424|Magnetic Resonance Imaging
960512|NCT02205411|heart assist device
960513|NCT02205411|ventricular assist device
960514|NCT02205398|INC280
960515|NCT02205398|c-MET inhibitor
960516|NCT02205398|cetuximab
960517|NCT02205398|metastatic colorectal cancer
960518|NCT02205398|head and neck
960519|NCT02205398|squamous cell carcinoma
960520|NCT02205398|resistance to cetuximab/panitumumab
960521|NCT02205385|Neuroma
960522|NCT02205385|Amputee
960523|NCT02205385|Amputation Stump
960524|NCT02205385|Assessment, Pain
960525|NCT02205372|Diabetic Nephropathy
960526|NCT02205359|AdaptivCRT
960527|NCT02205359|aCRT
960528|NCT02205346|obstructive sleep apnea
960529|NCT02205333|Advanced Solid tumors
960530|NCT02205333|Diffuse Large B-cell Lymphoma
960531|NCT02205333|programmed death 1
960532|NCT02205333|programmed dealth ligand 1
960533|NCT02205333|cytotoxic T-lymphocyte-associated antigen-4
960534|NCT02205333|OX40 ligand
960535|NCT02205320|Pegfilgrastim
960536|NCT02205320|Pharmacokinetics
960537|NCT02205320|Pharmacodynamics
960538|NCT02205320|Healthy volunteers
960543|NCT02205294|Osteopathic treatment
960544|NCT02205294|Deep Vein Thrombosis
960545|NCT02205294|Proximal Leg DVT
960546|NCT02205281|Overweight
960547|NCT02205281|Obese
960548|NCT02205281|Pregnancy
960549|NCT02205281|Weight Gain
960550|NCT02205281|Weight Loss
960551|NCT02205268|Attention Deficit Disorder with Hyperactivity
960552|NCT02205268|Attention Deficit Hyperactivity Disorder
960553|NCT02205268|Biofeedback
960554|NCT02205268|Neurofeedback Training
960555|NCT02205268|Prefrontal Cortex
960556|NCT02205268|Near infrared spectroscopy
960557|NCT02205255|AECOPD
960558|NCT02205255|Chronic Obstructive Pulmonary Disease
960559|NCT02205255|Acute exacerbation
960560|NCT02205255|Hospitalization
960561|NCT02205255|Azithromycin
960562|NCT02205255|Macrolides
960563|NCT02205255|Randomized Controlled Trial
960564|NCT02205255|Placebo
960565|NCT02205255|Economic Impact
960566|NCT02205255|Cost-effectiveness
960567|NCT02205255|EQ5D
960568|NCT02205242|AECOPD
960569|NCT02205242|Chronic Obstructive Pulmonary Disease
960570|NCT02205242|Acute exacerbation
960571|NCT02205242|Hospitalization
960572|NCT02205242|Azithromycin
960573|NCT02205242|Macrolides
960574|NCT02205242|Randomized Controlled Trial
960575|NCT02205242|Placebo
960576|NCT02205242|Physical Activity
960577|NCT02205242|PRO-Active
960578|NCT02205242|Activity Monitor
960579|NCT02205216|tDCS
960580|NCT02205216|FOG
960581|NCT02205216|Freezing of Gait
960582|NCT02205216|Parkinson
960583|NCT02205216|Rehabilitation
960584|NCT02205203|Anxiety
960585|NCT02205203|Social Anxiety
960586|NCT02205203|Social Phobia
960587|NCT02205203|Separation Anxiety
960588|NCT02205203|Generalized Anxiety
960589|NCT02205203|GAD
960590|NCT02205203|Phobia
960591|NCT02205203|Panic
960592|NCT02205203|Agoraphobia
960593|NCT02205203|Obsessive Compulsive Disorder
960594|NCT02205203|OCD
960595|NCT02205203|Child
960596|NCT02205203|Adolescent
960597|NCT02205203|Smartphone
960598|NCT02205203|Teen
960599|NCT02205203|Youth
960600|NCT02205190|Fimasartan
960601|NCT02205177|Anxiety
960602|NCT02205177|Social Anxiety
960603|NCT02205177|Social Phobia
960604|NCT02205177|Separation Anxiety
960605|NCT02205177|Generalized Anxiety
960606|NCT02205177|GAD
960607|NCT02205177|Phobia
960608|NCT02205177|Panic
960609|NCT02205177|Agoraphobia
960610|NCT02205177|Obsessive Compulsive Disorder
960611|NCT02205177|OCD
960612|NCT02205177|Child
960613|NCT02205177|Adolescent
960614|NCT02205177|Smartphone
960615|NCT02205177|Teen
960616|NCT02205177|Youth
960617|NCT02205164|palonosetron
960618|NCT02205164|aprepitant
960619|NCT02205164|CINV
960620|NCT02205164|AML
960621|NCT02205164|multiple-days
960622|NCT02205151|Fimasartan
960623|NCT02205138|Spinal Fusion
960624|NCT02205138|Lumbar Interbody Fusion
960625|NCT02205138|Degenerative Disc Disease
960626|NCT02205138|Cell Therapy
960627|NCT02205138|Bone Graft
960628|NCT02205125|polyp
960629|NCT02205125|colon
960630|NCT02205125|polypectomy
960631|NCT02205125|snare
960632|NCT02205112|intravenous nemonoxacin
960633|NCT02205112|community-acquired pneumonia
960634|NCT02205099|Schizophrenia
960635|NCT02205047|Neoadjuvant chemotherapy
960636|NCT02205034|Prader Willi
960637|NCT02205008|advanced gastric cancer
960638|NCT02205008|serosal invasion
960639|NCT02205008|peritoneal recurrence
960640|NCT02205008|intraperitoneal chemotherapy
960641|NCT02204995|Osteoarthritis
960642|NCT02204995|Thumb
960643|NCT02204995|LRTI
960644|NCT02204995|Trapeziectomy
960645|NCT02204982|Phase 3, Follicular Lymphoma, FL, PI3K
960646|NCT02204956|Smoking cessation
960647|NCT02204956|Tobacco use cessation
960648|NCT02204956|Psychiatric comorbidity
960649|NCT02204930|Haemostat
960650|NCT02204930|Liver surgery
960651|NCT02204930|Primary liver cancer
960652|NCT02204930|Metastatic liver cancer
960653|NCT02204930|Benign liver disease such as adenoma
960654|NCT02204930|Hepatitis-related or alcoholic-related liver cirrhosis
960655|NCT02204930|Living donation for liver transplant
960656|NCT02204917|Ultrasound
960657|NCT02204917|Ultrasound Contrast Agents
960658|NCT02204917|Optison
960659|NCT02204917|contrast enhanced Voiding Urosonography
960660|NCT02204917|ceVUS
960661|NCT02204917|Vesicoureteral Reflux
960662|NCT02204917|Children
960663|NCT02204917|Kidney
960664|NCT02204917|Bladder
960665|NCT02204917|Urethra
960666|NCT02204917|Voiding Cystourethrography
960667|NCT02204917|VCUG
960668|NCT02204917|Safety
960669|NCT02204917|Urinary tract
960670|NCT02204904|X-linked Adrenoleukodystrophy
960671|NCT02204904|Hematopoietic Stem Cells
960672|NCT02204891|Abdominal pain
960673|NCT02204891|Abdominal discomfort
960674|NCT02204891|Flatulence
960675|NCT02204891|Diarrhea
960676|NCT02204891|Bacterial overgrowth
960677|NCT02204891|Cytokines
960678|NCT02204865|Sleep-Disordered Breathing
960679|NCT02204865|Sleep Apnoea
960680|NCT02204865|Heart failure
960681|NCT02204839|T1DM, Exercise, Hypoglycaemia
960682|NCT02204826|Effects of Korean Red Ginseng on semen parameters in male infertility patients: a randomized, placebo-controlled, double-blind clinical study
960683|NCT02204813|Gastric Bypass
960684|NCT02204813|RYGB
960685|NCT02204813|GLP-1
960686|NCT02204813|Xenin
960687|NCT02204813|Insulin Secretion
960688|NCT02204813|Glucose Homeostasis
960689|NCT02204813|Vertical Sleeve
960690|NCT02204813|Lap Band
960691|NCT02204800|Tumor growth rate in maximal dimension, biomarker assessment based on driver gene alterations (specifically CRG)
960692|NCT02204774|aortic aneurysm
960693|NCT02204774|obstructive sleep apnea
960694|NCT02204735|Meal Time
960695|NCT02204735|Weight Loss
960696|NCT02204735|Circadian Rhythm
960697|NCT02204709|obese
960698|NCT02204709|obesity
960699|NCT02204709|metabolic syndrome
960700|NCT02204709|omega-3 fatty acids
960701|NCT02204709|fish
960702|NCT02204696|sleep apnea
960703|NCT02204696|obstructive sleep apnea
960704|NCT02204696|sleepiness
960705|NCT02204696|quality of life
960706|NCT02204683|AMD
960707|NCT02204683|Neovascularization
960708|NCT02204683|macular degeneration
960709|NCT02204683|wet macular degeneration
960710|NCT02204683|vitrectomy
960711|NCT02204670|Irisin
960712|NCT02204670|Obesity
960713|NCT02204670|Exercise
960714|NCT02204670|Myokine
960715|NCT02204670|Impaired Glucose Tolerance
960716|NCT02204657|Continuous glucose monitoring in GDM
960717|NCT02204631|Head and Neck Cancer
960718|NCT02204618|single sided deafness
960719|NCT02204618|Asymmetrical hearing loss
960720|NCT02204618|Cost-utility
960721|NCT02204618|Tinnitus
960722|NCT02204618|Cochlear implants
960723|NCT02204618|Bone conduction device
960724|NCT02204618|Dichotic hearing
960725|NCT02204618|Squelch effect.
960726|NCT02204605|patients
960727|NCT02204605|puzzling
960728|NCT02204605|conditions
960729|NCT02204579|Autosomal Dominant Hypocalcemia
960730|NCT02204579|Hypocalcemia
960731|NCT02204579|ADH
960732|NCT02204579|Hypoparathyroidism
960733|NCT02204566|OFDI
960734|NCT02204566|RF Ablation
960735|NCT02204566|Atrial Fibrillation
960736|NCT02204566|Imaging
960737|NCT02204566|Esophagus
960738|NCT02204553|Multiple Myeloma
960739|NCT02204553|Panobinostat
960740|NCT02204553|LBH589
960741|NCT02204553|Expanded Access
960742|NCT02204553|EAP, ETP
960743|NCT02204553|Expanded Treatment
960744|NCT02204553|Bortezomib
960745|NCT02204553|HDAC
960746|NCT02204553|histone deacetylace inhibitor
960747|NCT02204540|Webcams, video monitoring, compliance, adherence
960748|NCT02204527|hypertension
960749|NCT02204527|diabetes mellitus
960750|NCT02204527|vitamin D
960751|NCT02204501|Aviragen Therapeutics, Inc.
960752|NCT02204501|Aviragen Therapeutics
960753|NCT02204501|Aviragen
960754|NCT02204488|Osteoarthritis
960755|NCT02204488|Thumb
960756|NCT02204488|Total joint arthroplasty
960757|NCT02204488|Trapeziectomy
960758|NCT02204462|PET
960759|NCT02204462|Positron Emission Tomography
960760|NCT02204462|Breast Cancer
960761|NCT02204462|Imaging
960762|NCT02204449|cardiac rehabilitation
960763|NCT02204449|peer mentorship
960764|NCT02204449|healthcare utilization
960765|NCT02204449|continuity of cardiac care
960766|NCT02204436|hyperpigmentation
960767|NCT02204436|depigmenting treatment
960768|NCT02204436|hand
960769|NCT02204423|Upper extremity dysfunction
960770|NCT02204423|Trans-Radial Percutaneous Coronary Interventions
960771|NCT02204410|ADHD
960772|NCT02204410|Attention Deficit Hyperactivity Disorder
960773|NCT02204410|DESR
960774|NCT02204410|Deficient Emotional Self-Regulation
960775|NCT02204410|Emotional Dysregulation
960776|NCT02204410|Omega-3 Fatty Acids
960777|NCT02204410|Fish Oil
960778|NCT02204397|Type 1 Diabetes mellitus
960779|NCT02204397|INGAP
960780|NCT02204397|Ustekinumab
960781|NCT02204384|Dietary fiber
960782|NCT02204384|Dietary Supplements
960783|NCT02204384|Type 2 diabetes
960784|NCT02204384|Postprandial Period
960785|NCT02204384|Plasma insulin
960786|NCT02204384|Plasma glucose
960787|NCT02204384|Area Under Curve
960788|NCT02204384|Soluble fiber
960789|NCT02204371|Pazopanib
960790|NCT02204371|hereditary haemorrhagic telangiectasia
960791|NCT02204371|bleeding
960792|NCT02204319|provoked or non-provoked vulvar vestibulitis
960793|NCT02204319|low level laser light device
960794|NCT02204293|Adult-Onset Still´s Disease
960795|NCT02204293|Canakinumab
960796|NCT02204293|Joint involvement
960797|NCT02204293|AOSD
960798|NCT02204280|UbA52;diabetic nephropathy ;diabetic;ELISA
960799|NCT02204267|Stroke
960800|NCT02204267|atrial fibrillation
960801|NCT02204267|ECG
960802|NCT02204241|Multiple myeloma
960803|NCT02204241|Diagnosis
960804|NCT02204241|CCyd
960805|NCT02204228|osteoarthritis
960806|NCT02204228|rheumatoid arthritis
960807|NCT02204228|post traumatic arthritis
960808|NCT02204228|avascular necrosis
960809|NCT02204228|severe fractures
960810|NCT02204215|Weakness
960811|NCT02204215|Mechanical Ventilation
960812|NCT02204215|Acupuncture Therapy
960813|NCT02204202|acute lung transplant rejection
960814|NCT02204202|neutrophilic lung inflammation
960815|NCT02204202|positron emission tomography imaging
960816|NCT02204202|[18F] fluorodeoxyglucose
960817|NCT02204202|[18F] ISO-1
960818|NCT02204189|acute pancreatitis
960819|NCT02204189|gastrointestinal dysfunction
960820|NCT02204189|TongFuSan
960821|NCT02204189|ShenQue acupoint
960822|NCT02204150|Optical Coherence Tomography
960823|NCT02204150|Barrett's Esophagus
960824|NCT02204150|Esophagus
960825|NCT02204150|Imaging
960826|NCT02204124|Whipple procedure
960827|NCT02204111|Palliative Treatment
960828|NCT02204111|Trabectedin
960829|NCT02204111|Patient Reported Outcome
960830|NCT02204085|Refractory acute myeloid leukemia
960831|NCT02204085|Relapsed acute myeloid leukemia
960832|NCT02204020|Acute Myeloid Leukemia (AML)
960833|NCT02204020|Myelodysplastic Syndrome (MDS)
960834|NCT02204020|allogeneic
960835|NCT02204020|5-azacytidine (5-aza)
960836|NCT02204020|hematopoietic
960837|NCT02204020|transplantation
960838|NCT02204020|transplant
960839|NCT02204020|graft-versus-tumor
960840|NCT02204020|graft-versus-host disease (GVHD)
960841|NCT02204020|epigenetic
960842|NCT02204020|maintenance
960843|NCT02204020|hypomethylation
960844|NCT02204020|relapse
960845|NCT02204007|Acetabular Shell
960846|NCT02204007|Total Hip Arthroplasty
960847|NCT02204007|3D imaging
960848|NCT02203994|extracorporal shock wave therapy (ESWT)
960849|NCT02203994|spasticity
960850|NCT02203994|spinal cord injury
960851|NCT02203981|normal Eyes
960852|NCT02203968|Fibrinogen replacement
960853|NCT02203968|Trauma coagulopathy
960854|NCT02203968|Hypofibrinogenemia
960855|NCT02203968|Early trauma coagulopathy
960856|NCT02203968|Haemorrhage
960857|NCT02203968|Fibrinogen concentrate
960858|NCT02203968|Feasibility trial
960859|NCT02203968|Clinical trials
960860|NCT02203942|Bacterial Vaginosis
960861|NCT02203942|Vulvovaginal Candidiasis
960862|NCT02203942|Trichomoniasis
960863|NCT02203929|Macular Holes
960864|NCT02203929|Progression
960865|NCT02203916|Drug therapy
960866|NCT02203890|Growth
960867|NCT02203890|Hematology
960868|NCT02203890|Hydration
960869|NCT02203890|Oxidation
960870|NCT02203890|Infection
960871|NCT02203890|Inflammation
960872|NCT02203890|Guatemalan children
960873|NCT02203851|BI 655066
960874|NCT02203851|risankizumab
960875|NCT02203838|Schizophrenia
960876|NCT02203838|Schizophrenic
960877|NCT02203838|Schizophrenias
960878|NCT02203838|Risperidone
960879|NCT02203838|Long-acting Risperidone
960880|NCT02203838|Atrigel
960881|NCT02203838|Subcutaneous
960882|NCT02203825|Acute Myeloid Leukemia
960883|NCT02203825|NKG2D
960884|NCT02203825|Multiple Myeloma
960885|NCT02203825|Cell Therapy
960886|NCT02203799|Peanut Allergy
960887|NCT02203799|Anaphylaxis
960888|NCT02203799|Desensitization
960889|NCT02203799|Food Allergy
960890|NCT02203799|Oral Immunotherapy
960891|NCT02203786|amphetamine
960892|NCT02203786|d1 and d2 receptors
960893|NCT02203786|dopamine antagonists
960894|NCT02203786|pathological gambling
960895|NCT02203786|priming
960896|NCT02203786|reinforcement
960897|NCT02203773|AML
960898|NCT02203773|ABT-199
960899|NCT02203773|Untreated AML
960900|NCT02203773|Acute Myelogenous Leukemia
960901|NCT02203773|Treatment Naive AML
960902|NCT02203773|GDC-0199
960903|NCT02203773|Myelogenous Leukemia
960904|NCT02203760|Relapsed or metastatic uterine leiomyosarcomas or carcinosarcomas
960905|NCT02203734|Pregnancy
960906|NCT02203734|Depression
960907|NCT02203734|Massage
960908|NCT02203708|BPD (Borderline Personality Disorder)
960909|NCT02203708|Mother/child
960910|NCT02203695|Salvage Radiation Therapy (SRT)
960911|NCT02203695|Enzalutamide
960912|NCT02203682|Graves' orbitopathy
960913|NCT02203682|Graves´ ophthalmopathy
960914|NCT02203682|Thyroid eye disease
960915|NCT02203682|Thyroid-associated ophthalmopathy
960916|NCT02203682|Doxycycline
960917|NCT02203682|EUGOGO
960918|NCT02203682|CAS
960919|NCT02203669|breast reconstruction
960920|NCT02203669|occupational therapy
960921|NCT02203669|physical therapy
960922|NCT02203669|upper extremity morbidity
960923|NCT02203656|intervention studies
960924|NCT02203656|nutrition
960925|NCT02203656|exercise
960926|NCT02203656|testosterone
960927|NCT02203656|patient readmission
960928|NCT02203630|Septic shock
960929|NCT02203630|Vasopressor Agents
960930|NCT02203630|Phenylephrine
960931|NCT02203630|Norepinephrine
960932|NCT02203630|Tachycardia
960933|NCT02203630|Heart Rate
960934|NCT02203630|Arrhythmia
960935|NCT02203630|Catecholamine
960936|NCT02203617|anticipatory guidance
960937|NCT02203617|baby books
960938|NCT02203617|safety
960939|NCT02203591|surgical skin prep
960940|NCT02203591|CHG
960941|NCT02203591|IPA
960942|NCT02203552|Breast Cancer
960943|NCT02203539|circadian rhythm
960944|NCT02203539|light exposure
960945|NCT02203539|exercise capacity
960946|NCT02203539|endurance
960947|NCT02203539|strength
960948|NCT02203539|reaction
960949|NCT02203526|Tyrosine Kinase Inhibitor
960950|NCT02203526|ABC DLBCL
960951|NCT02203526|Lymphoma in Brain and CNS
960952|NCT02203526|Diffuse Large B-Cell Lymphomas in CNS
960958|NCT02203461|ART, HIV, insulin resistance
960959|NCT02203435|code blue
960960|NCT02203435|Cardiopulmonary Resuscitation
960961|NCT02203435|APACHE
960962|NCT02203422|Immune Thrombocytopenia
960963|NCT02203422|Recombinant Human Thrombopoietin
960964|NCT02203422|Cyclosporin A
960965|NCT02203409|liver tumor
960966|NCT02203409|Two stage hepatectomy
960967|NCT02203409|Hypertrophy
960968|NCT02203409|laparoscopy
960969|NCT02203409|ALPPS
960970|NCT02203396|SAA
960971|NCT02203396|Immunosuppressive treatment
960972|NCT02203396|ATG
960973|NCT02203396|Cyclosporine
960974|NCT02203396|Levamisole
960975|NCT02203383|Cardiac Resynchronization Therapy
960976|NCT02203383|Central Sleep Apnoea
960977|NCT02203383|Sleep Disordered Breathing
960978|NCT02203383|Heart Failure
960979|NCT02203383|Hypercapnic Ventilatory Response
960980|NCT02203357|hepatitis B
960981|NCT02203357|hepatitis B vaccine
960982|NCT02203357|immunogenicity
960983|NCT02203357|adults
960984|NCT02203318|cryptorchidism, undescended testis, hypertrophy of contralateral testis
960985|NCT02203305|Unilateral hearing loss
960986|NCT02203305|Single Sided Deafness
960987|NCT02203305|Asymmetric hearing loss
960988|NCT02203292|Traumatic Brain Injury
960989|NCT02203292|Blood Transfusion
960990|NCT02203279|Chair-side hard relining
960991|NCT02203279|complete denture
960992|NCT02203279|patients' satisfaction
960993|NCT02203279|supporting tissues
960994|NCT02203279|autopolymerized reline resins
960995|NCT02203279|heat cured relining material
960996|NCT02203266|Medication Adherence
960997|NCT02203266|Patient Compliance
960998|NCT02203253|solid tumor
960999|NCT02203253|chemotherapy-induced delayed nausea and vomiting
961000|NCT02203253|thalidomide
961001|NCT02203253|prevention
961002|NCT02203240|Cacao
961003|NCT02203240|Polyphenols
961004|NCT02203240|Prediabetic State
961005|NCT02203240|Blood Glucose
961006|NCT02203240|Glucose Intolerance
961007|NCT02203240|Diabetes Mellitus, Type 2
961008|NCT02203240|Obesity
961009|NCT02203240|Muscle, Skeletal
961010|NCT02203240|Endotoxins
961011|NCT02203240|Gut Permeability
961012|NCT02203240|Incretins
961013|NCT02203240|Metabolic Flexibility
961014|NCT02203227|Dietary supplements
961015|NCT02203227|Cotinine level
961016|NCT02203227|Malondialdehyde
961017|NCT02203227|Chronic smokers
961018|NCT02203227|Hyperlipidemia
961019|NCT02203214|Ligamys
961020|NCT02203214|ACL
961021|NCT02203214|healing
961022|NCT02203201|Not-celiac gluten sensitivity
961023|NCT02203201|Celiac Disease
961024|NCT02203201|Gluten-free diet
961025|NCT02203201|EMA assay
961026|NCT02203201|Duodenal culture medium
961027|NCT02203175|propofol
961028|NCT02203175|pretreatment
961029|NCT02203175|mixture
961030|NCT02203162|cough
961031|NCT02203162|cough reflex sensitivity
961032|NCT02203162|electronic cigarette
961033|NCT02203162|capsaicin
961034|NCT02203136|Bladder cancer
961035|NCT02203136|Muscle invasive bladder cancer
961036|NCT02203136|MIBC
961037|NCT02203136|Biopsy specimen molecular profiling
961038|NCT02203136|Bladder surgery
961039|NCT02203136|Magnetic resonance imaging
961040|NCT02203136|MRI
961041|NCT02203136|Trans urethral resection of bladder
961042|NCT02203110|simultaneous bacterial and viral pneumonia
961043|NCT02203097|Target controlled infusion
961044|NCT02203097|propofol
961045|NCT02203097|cerebral vasoreactivity
961046|NCT02203097|arterial stiffness
961047|NCT02203097|Transcranial Doppler
961048|NCT02203097|SphygmoCor
961049|NCT02203084|Cystic Fibrosis
961050|NCT02203084|Diabetes Mellitus Type I
961051|NCT02203084|Chronic Renal Insufficiency
961052|NCT02203084|The influence of socioeconomic variables upon outcome in children with three chronic medical diseases.
961053|NCT02203071|sports
961054|NCT02203071|injury
961055|NCT02203071|knee
961056|NCT02203071|pain
961057|NCT02203071|cartilage
961058|NCT02203058|Inspiratory capacity
961059|NCT02203058|Positive-pressure respiration
961060|NCT02203058|Exercise
961061|NCT02203058|Activities of daily living
961062|NCT02203058|COPD.
961063|NCT02203045|Total Knee Arthroplasty
961064|NCT02203032|Psoriasis
961065|NCT02203032|Plaque-type psoriasis
961066|NCT02203032|Guselkumab
961067|NCT02203032|Ustekinumab
961068|NCT02203032|CNTO 1959
961069|NCT02203032|Monoclonal antibody
961075|NCT02203006|HIV,
961076|NCT02203006|infection,
961077|NCT02203006|cohort
961078|NCT02202967|Aspirin
961079|NCT02202967|Intestinal bleeding
961080|NCT02202967|Misoprostol
961081|NCT02202967|NSAIDs
961082|NCT02202967|Small intestine
961083|NCT02202967|Video capsule endoscopy
961087|NCT02202928|Colorectal cancer
961088|NCT02202928|DC-CIK
961089|NCT02202928|Autologous tumor lysate
961090|NCT02202902|Cushing's syndrome
961091|NCT02202902|cardiac steatosis
961092|NCT02202902|intramyocardial triglyceride content
961093|NCT02202902|1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging
961094|NCT02202902|Left Ventricularly hypertrophy
961095|NCT02202889|Adolescents
961096|NCT02202889|Bone mass
961097|NCT02202889|Calcium
961098|NCT02202889|Perceived milk intolerance
961099|NCT02202889|lactose maldigestion
961100|NCT02202863|Dietary intervention
961101|NCT02202863|Wine grape pomace flour
961102|NCT02202863|Metabolic Syndrome
961103|NCT02202863|Oxidative stress
961104|NCT02202863|Antioxidants
961105|NCT02202863|Fiber
961106|NCT02202785|Drug therapy
961107|NCT02202772|Urothelial
961108|NCT02202772|Cisplatin
961109|NCT02202772|Gemcitabine
961110|NCT02202772|Cabazitaxel
961111|NCT02202772|Bladder
961112|NCT02202772|Carcinoma
961113|NCT02202772|Bacillus Calmette-Guerin
961114|NCT02202772|Intravesical
961115|NCT02202772|Recurrent
961116|NCT02202772|Non-muscle
961117|NCT02202772|Invasive
961118|NCT02202772|Cancer
961119|NCT02202759|Drug therapy
961120|NCT02202746|Breast cancer
961121|NCT02202746|Metastatic breast cancer
961122|NCT02202746|MBC
961123|NCT02202746|HER2 positive
961124|NCT02202746|HER2+
961125|NCT02202746|Estrogen receptor positive
961126|NCT02202746|ER+
961127|NCT02202746|Triple negative
961128|NCT02202746|FGFR1
961129|NCT02202746|11q
961130|NCT02202746|FGF aberrant
961131|NCT02202746|Biomarker negative
961132|NCT02202746|FGF non-aberrant
961133|NCT02202733|cooking skills
961134|NCT02202733|eating out
961135|NCT02202733|foods prepared away from home
961136|NCT02202720|Sevoflurane
961137|NCT02202720|RASS score
961138|NCT02202720|Sedation
961139|NCT02202720|Minimal alveolar concentration (MAC)
961140|NCT02202694|CBT, Psychosis, cultural adaptation, Pakistan
961141|NCT02202681|Duodenum
961142|NCT02202681|Optical Frequency Domain Imaging (OFDI)
961143|NCT02202681|Optical Coherence Tomography
961144|NCT02202681|Imaging
961145|NCT02202681|Celiac Disease
961146|NCT02202668|Foot ulcer, diabetic
961147|NCT02202668|Spectrum analysis, Raman
961148|NCT02202655|non- small cell lung cancer;
961149|NCT02202655|lymphocyte subsets
961150|NCT02202616|COPD,
961151|NCT02202616|QVA149,
961152|NCT02202616|Tiotropium,
961153|NCT02202616|FDC,
961154|NCT02202616|GlycOpyrronium With IndacatERol,
961155|NCT02202616|POWER
961156|NCT02202590|SECM
961157|NCT02202590|Esophagus
961158|NCT02202590|Eosinophilic Esophagitis
961159|NCT02202590|Allergy
961160|NCT02202577|Surgical site infection
961161|NCT02202577|Surgical site antisepsis
961162|NCT02202577|Cesarean Delivery
961163|NCT02202564|hepatocellular carcinoma
961164|NCT02202564|liver transplantation
961165|NCT02202564|adenovirus-thymidine kinase
961166|NCT02202564|gene therapy
961167|NCT02202551|Levodopa Induced Dyskinesia
961168|NCT02202551|LID
961169|NCT02202551|Parkinsonism
961170|NCT02202551|Parkinson's Disease
961171|NCT02202538|SCI
961172|NCT02202538|Indego
961173|NCT02202538|Walking
961174|NCT02202499|pharmacotherapy
961175|NCT02202473|Oxymatrine Capsules, lamivudine, chronic Hepatitis B
961176|NCT02202447|EC1169
961177|NCT02202447|prostate cancer
961178|NCT02202447|EC0652
961179|NCT02202421|Autism
961180|NCT02202421|Applied Behavior Analysis
961181|NCT02202395|Hydroxytriptolide
961182|NCT02202395|Rheumatoid Arthritis
961183|NCT02202395|Methotrexate
961184|NCT02202395|T8
961185|NCT02202395|LTS
961186|NCT02202369|Multimodal Analgesia
961187|NCT02202369|Pain Management
961188|NCT02202356|RSV
961189|NCT02202356|Respiratory Syncytial Virus
961190|NCT02202343|Nutrition
961191|NCT02202343|Food
961192|NCT02202343|Security
961193|NCT02202343|School
961194|NCT02202343|Health
961195|NCT02202317|Liver Cancer
961196|NCT02202317|Hepatic Tumors
961197|NCT02202317|Primary Liver Tumors
961198|NCT02202317|Metastastic Liver Tumors
961199|NCT02202317|Yttrium-90
961200|NCT02202317|Y-90
961201|NCT02202291|Raynaud's phenomenon, Vasospasm, Genetics
961202|NCT02202278|ovarian hyperstimulation
961203|NCT02202278|Oxidative Stress
961204|NCT02202278|IMA
961205|NCT02202278|OHSS
961206|NCT02202278|ICSI
961207|NCT02202278|long agonist protocol
961208|NCT02202278|TAC
961209|NCT02202278|TOS
961210|NCT02202278|OSI
961211|NCT02202278|MDA
961212|NCT02202265|Heart Diseases
961213|NCT02202252|Patient comfort
961214|NCT02202252|Drains
961215|NCT02202252|Breast cancer
961216|NCT02202252|Modified radical mastectomy
961217|NCT02202252|Seroma
961218|NCT02202200|Melanoma
961219|NCT02202200|BRAF mutated
961220|NCT02202174|supraglottic airway
961221|NCT02202174|children
961222|NCT02202174|safety
961223|NCT02202174|efficacy
961224|NCT02202161|pharmacokinetic
961225|NCT02202161|intestinal bile acid transporter inhibitor
961226|NCT02202161|metformin
961227|NCT02202161|sitagliptin
961228|NCT02202161|GSK2330672
961229|NCT02202161|pharmacodynamic
961230|NCT02202148|Fibroscan
961231|NCT02202148|alcohol dependence
961232|NCT02202148|alcohol withdrawal
961233|NCT02202148|controlled attenuation parameter
961234|NCT02202148|BDNF
961235|NCT02202135|complicated skin and soft tissue infections (cSSTI)
961236|NCT02202135|skin infection
961237|NCT02202135|ceftaroline
961238|NCT02202135|wound infection
961239|NCT02202135|cellulitis
961240|NCT02202135|burn infection
961241|NCT02202135|bacterial infection
961242|NCT02202135|vancomycin
961243|NCT02202122|Femoral Neck Fractures
961244|NCT02202122|Obstructive Sleep Apnea
961245|NCT02202122|Perioperative Complications
961254|NCT02202083|Oxytocin
961255|NCT02202083|Cook Balloon
961256|NCT02202070|onabotulinumtoxinA
961257|NCT02202070|Temporomandibular Joint Disorders
961258|NCT02202070|Bruxism
961259|NCT02202070|Temporomandibular Joint Dysfunction Syndrome
961260|NCT02202070|Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint
961261|NCT02202057|respiratory sensation
961262|NCT02202057|somatosensation
961263|NCT02202057|resistive load
961264|NCT02202057|magnitude estimation
961265|NCT02202044|Bladder Cancer
961266|NCT02202018|Knowledge Translation
961267|NCT02202018|Chronic Kidney Disease
961268|NCT02202018|Dialysis
961269|NCT02202018|Home dialysis
961270|NCT02202018|Cluster randomized trial
961271|NCT02202005|Bioequivalence
961272|NCT02201979|breast
961273|NCT02201979|ptosis
961274|NCT02201979|sagging
961275|NCT02201979|implant
961276|NCT02201979|lift
961277|NCT02201966|low back pain
961278|NCT02201966|pediatric
961279|NCT02201966|gymnasts
961280|NCT02201953|Sofosbuvir
961281|NCT02201953|Velpatasvir
961282|NCT02201953|SOF/VEL
961283|NCT02201953|GS-5816
961284|NCT02201953|Hepatitis C
961285|NCT02201953|HCV
961286|NCT02201953|Cirrhosis
961287|NCT02201953|Genotype 3
961288|NCT02201940|Sofosbuvir
961289|NCT02201940|SOF/VEL
961290|NCT02201940|Velpatasvir
961291|NCT02201940|Hepatitis C
961292|NCT02201940|HCV
961293|NCT02201940|cirrhosis
961294|NCT02201927|galvanic vestibular stimulation
961295|NCT02201927|right parietal lobe lesion
961296|NCT02201927|egocentric space
961297|NCT02201901|Sofosbuvir
961298|NCT02201901|Velpatasvir
961299|NCT02201901|SOF/VEL
961300|NCT02201901|GS-5816
961301|NCT02201901|Hepatitis C
961302|NCT02201901|HCV
961303|NCT02201901|Cirrhosis
961304|NCT02201901|CPT-B
961305|NCT02201888|Schizophrenia
961306|NCT02201888|Rehabilitation
961307|NCT02201888|Cognition
961308|NCT02201875|hypoxia
961309|NCT02201875|exercise
961310|NCT02201875|periodic breathing
961311|NCT02201875|hypercapnia
961312|NCT02201875|apneas
961313|NCT02201875|cardiac failure
961314|NCT02201862|Aneuploidy
961315|NCT02201862|Down Syndrome
961316|NCT02201862|amniocentesis
961317|NCT02201862|chronic villus sampling
961318|NCT02201862|Trisomy
961319|NCT02201862|non-invasive prenatal testing
961320|NCT02201862|Chromosome disorders
961321|NCT02201849|Alkermes
961322|NCT02201849|ALKS 8700
961323|NCT02201810|smoking cessation
961324|NCT02201810|quit line
961325|NCT02201810|nicotine replacement therapy
961326|NCT02201810|tobacco intervention
961327|NCT02201797|Reproducibility of Results
961328|NCT02201797|Liver neoplasm
961329|NCT02201797|Neoplasm metastasis
961330|NCT02201797|Regional Perfusion
961331|NCT02201797|Perfusion Magnetic Resonance Imaging
961332|NCT02201784|Subarachnoid block
961333|NCT02201784|intrathecal
961334|NCT02201784|spinal anesthesia
961335|NCT02201784|isobaric
961336|NCT02201784|levobupivacaine
961337|NCT02201784|ropivacaine
961472|NCT02201303|CD11b
961341|NCT02201758|Inflammatory Bowel Disease (IBD), ulcerative colitis (UC), flaxseed lignan-enriched complex (FLC)
961346|NCT02201719|Adenomyosis
961347|NCT02201719|Dysmenorrhea
961348|NCT02201719|Chronic pelvic pain
961349|NCT02201719|Infertility
961350|NCT02201719|Sensitivity histology
961351|NCT02201719|womens health
961352|NCT02201719|junction zone
961353|NCT02201706|Retinal detachment
961354|NCT02201706|silicone oil
961355|NCT02201706|retinectomy
961356|NCT02201693|Crohn's disease,
961357|NCT02201693|pediatric GETAID (Therapeutic study group of inflammatory bowel diseases of the child),
961358|NCT02201693|enteral nutrition,
961359|NCT02201693|randomized multicenter study
961360|NCT02201680|anxiety
961361|NCT02201680|preoperative
961362|NCT02201667|non-ST elevation acute coronary syndrome
961363|NCT02201667|myocardial perfusion
961364|NCT02201667|magnetic Resonance Imaging
961365|NCT02201667|antiplatelet
961366|NCT02201641|Indirect pulp capping
961367|NCT02201641|reversible pulpitis
961368|NCT02201641|periapical radiolucency
961369|NCT02201641|periapical radiographs
961370|NCT02201641|cone beam computed tomography
961371|NCT02201641|calcium silicate cements
961372|NCT02201641|glass ionomer cements
961373|NCT02201641|caries
961374|NCT02201628|Oesophageal
961375|NCT02201628|Nasopharyngeal
961376|NCT02201628|temperature
961377|NCT02201628|Intubation, endotracheal
961378|NCT02201628|Pediatric
961379|NCT02201628|Anesthesia
961380|NCT02201628|Hypothermia
961381|NCT02201615|Perineal Massage; Episiotomy; Perineal Laceration
961382|NCT02201602|sulphonylureas
961383|NCT02201602|gliclazide
961384|NCT02201602|glibenclamide
961385|NCT02201589|Lesions in the ascending thoracic aorta
961386|NCT02201576|Chronic antibody-mediated rejection,
961387|NCT02201576|transplant rejection, kidney transplantation,
961388|NCT02201576|proteasome inhibitor,
961389|NCT02201576|anti-HLA antibodies,
961390|NCT02201576|immunosuppressive agents
961395|NCT02201537|Ultrasound functional imaging
961396|NCT02201537|Chronic kidney Nephropathy
961397|NCT02201524|Phase 2
961398|NCT02201524|randomized
961399|NCT02201524|double-blind
961400|NCT02201524|placebo
961401|NCT02201524|plaque
961402|NCT02201524|psoriasis
961403|NCT02201524|safety
961404|NCT02201524|efficacy
961405|NCT02201524|JAK
961406|NCT02201524|janus kinase
961407|NCT02201524|moderate
961408|NCT02201524|severe
961409|NCT02201511|relative bioavailbility
961410|NCT02201511|food effect
961411|NCT02201511|pharmacokinetics
961412|NCT02201511|ALTERATION OF COGNITIVE FUNCTIONS
961413|NCT02201485|Budd-Chiari syndrome
961414|NCT02201485|percutaneous recanalization
961415|NCT02201485|treatment
961416|NCT02201485|reocclusion
961417|NCT02201485|patency
961418|NCT02201472|liver
961419|NCT02201472|mre
961420|NCT02201472|mri
961421|NCT02201472|neonatal
961422|NCT02201472|mr touch
961423|NCT02201459|Peg-IFN, nilotinib, MR4.5, CML, chronic phase, first-line
961424|NCT02201433|breastfeeding
961425|NCT02201433|fathers
961426|NCT02201433|preterm newborns
961427|NCT02201433|partner influence
961428|NCT02201394|Antiplatelet
961429|NCT02201394|Ticagrelor
961430|NCT02201394|Platelets
961431|NCT02201394|Thrombosis
961432|NCT02201394|Coronary artery disease
961433|NCT02201394|Coronary artery disease.
961434|NCT02201381|Cancer
961435|NCT02201381|Cancer Treatments
961436|NCT02201381|Cancer Palliative Care
961437|NCT02201381|Metabolic
961438|NCT02201381|Metabolism
961439|NCT02201381|Existing Medicines
961440|NCT02201381|Licensed Medicines
961441|NCT02201381|Real World
961442|NCT02201381|Breast Cancer
961443|NCT02201381|Triple Negative Breast Cancer
961444|NCT02201381|Colon Cancer
961445|NCT02201381|Prostrate Cancer
961446|NCT02201381|Brain Cancer
961447|NCT02201381|Ovarian Cancer
961448|NCT02201381|Pancreatic Cancer
961449|NCT02201381|AML
961450|NCT02201381|CML
961451|NCT02201381|Leukemea
961452|NCT02201381|Metformin
961453|NCT02201381|Statins
961454|NCT02201381|Mebendazole
961455|NCT02201381|Doxycycline
961456|NCT02201381|Ibuprofen
961457|NCT02201381|Metastatic
961580|NCT02200744|adults
961458|NCT02201368|Triglycerides; Lipid Metabolism; Fatty Acids.
961459|NCT02201355|Head and Neck cancer
961460|NCT02201342|Fontan
961461|NCT02201342|Pharmacokinetics
961462|NCT02201342|Pharmacodynamics
961463|NCT02201342|Exercise capacity
961464|NCT02201342|Maximal Oxygen Consumption
961465|NCT02201342|Vascular function
961466|NCT02201342|EndoPAT
961467|NCT02201342|Myocardial performance
961468|NCT02201316|Healthy adult human subjects
961469|NCT02201316|Mosapride citrate anhydrous
961470|NCT02201316|Bioequivalence
961471|NCT02201316|Dyspepsia
961473|NCT02201303|Neutrophils
961474|NCT02201303|CXCL1
961475|NCT02201303|Danirixin
961476|NCT02201303|Respiratory Syncytial Virus
961477|NCT02201303|Children
961478|NCT02201303|CXCR2
961479|NCT02201290|Chronic immune thrombocytopenic purpura, ITP, eltrombopag olamine, thrombopoietin receptor agonist, pediatrics
961480|NCT02201277|IVC
961481|NCT02201277|IVC Filter
961482|NCT02201277|Filter
961483|NCT02201277|Option
961484|NCT02201277|Denali
961485|NCT02201277|filter tilt
961486|NCT02201277|filter migration
961487|NCT02201277|filter fracture
961488|NCT02201277|filter thrombus
961489|NCT02201277|filter penetration
961490|NCT02201264|myocardial infarction
961491|NCT02201264|Angioplasty
961492|NCT02201264|Stent
961493|NCT02201251|Epilepsy
961494|NCT02201251|Topiramate
961495|NCT02201251|Levetiracetam
961496|NCT02201251|Pediatric
961497|NCT02201212|TSC1
961498|NCT02201212|TSC2
961499|NCT02201212|Tuberous Sclerosis Complex
961500|NCT02201212|MTOR
961501|NCT02201186|honey enema for pouchitis
961502|NCT02201160|NAFLD
961503|NCT02201160|Fatty acid composition
961504|NCT02201160|Omega 3 supplementation
961505|NCT02201160|Metabolism
961506|NCT02201134|Cardiac arrest
961507|NCT02201134|Therapeutic hypothermia
961508|NCT02201134|Sevoflurane
961509|NCT02201134|Sedation
961510|NCT02201134|Patient resuscitated from cardiac arrest
961511|NCT02201134|Requiring sedation
961512|NCT02201134|Adult patients
961513|NCT02201134|Patient covered by french health care system
961514|NCT02201095|caesarean section
961515|NCT02201095|perioperative hypothermia
961516|NCT02201095|active warming
961517|NCT02201095|forced air warming
961518|NCT02201095|conduction mattress warming
961519|NCT02201095|thermal comfort
961520|NCT02201095|Prevention of
961521|NCT02201069|nutrition
961522|NCT02201069|physical activity
961523|NCT02201069|sleep
961524|NCT02201069|weight loss
961525|NCT02201056|Drug Therapy
961526|NCT02201043|ankylosing spondylitis
961527|NCT02201043|thalidomide
961528|NCT02200952|OHSS
961529|NCT02200952|Oocytes triggering
961530|NCT02200952|GnRh agonist triggering
961531|NCT02200952|Luteal phase supplementation
961532|NCT02200952|recombinant LH
961533|NCT02200900|High flow nasal cannula
961534|NCT02200900|Continuous Positive Airway Pressure
961535|NCT02200900|Respiratory physiology
961536|NCT02200887|Dyskinesia
961537|NCT02200887|Slow Wave Sleep
961538|NCT02200874|disease related malnutrition
961539|NCT02200874|influence of Nutrition Support Team
961540|NCT02200874|length of hospital stay
961541|NCT02200874|quality of life
961542|NCT02200874|body composition
961543|NCT02200874|health care costs
961544|NCT02200861|sedation,
961545|NCT02200861|tooth extraction,
961546|NCT02200848|Lenalidomide
961547|NCT02200848|Ibrutinib
961548|NCT02200848|Rituximab
961549|NCT02200848|CLL
961550|NCT02200848|SLL
961551|NCT02200835|aortic dissection
961552|NCT02200835|Chinese patients
961553|NCT02200835|gender differences
961554|NCT02200822|neurohumoral blocker therapy
961555|NCT02200822|renin-angiotensin-aldosterone system (RAAS)
961556|NCT02200822|RAAS-blocker
961557|NCT02200822|beta blocker
961558|NCT02200822|spironolactone
961559|NCT02200822|angiotensin converting enzyme inhibitor (ACE-I)
961560|NCT02200822|angiotensin receptor blocker (ARB)
961561|NCT02200822|cardiac resynchronization therapy (CRT)
961562|NCT02200822|heart failure
961563|NCT02200822|dyssynchrony
961564|NCT02200822|left bundle branch block
961565|NCT02200809|MR-guided therapy
961566|NCT02200809|Focal laser ablation
961567|NCT02200809|Prostate cancer
961568|NCT02200796|Dietary Protein
961569|NCT02200796|Satiety
961570|NCT02200796|Food Intake
961571|NCT02200796|Thermic Effect of Food
961572|NCT02200796|Diet Induced Thermogenesis
961573|NCT02200783|Cardiac catheterization
961574|NCT02200783|Radiation Protection
961575|NCT02200783|Radial artery
961576|NCT02200783|Femoral artery
961577|NCT02200770|NMO, NMOSD, Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders, autoimmune, demyelination, MEDI-551, monoclonal antibody, Devic's syndrome, B-cell
961578|NCT02200744|Procedural sedation
961579|NCT02200744|emergency department
961581|NCT02200744|propofol
961582|NCT02200744|recall assessment
961583|NCT02200731|Childhood cancer
961584|NCT02200731|Psychosocial intervention
961585|NCT02200731|Family
961586|NCT02200731|Siblings
961587|NCT02200731|Childhood cancer survivors
961588|NCT02200731|Cogntive Behavioural
961589|NCT02200731|Manualized
961590|NCT02200718|Multiple Sclerosis Pediatric MS NeuroVax Vaccine Therapeutic
961591|NCT02200705|cryoablation, cryotherapy, breast cancer
961592|NCT02200692|plasma transfusion
961593|NCT02200692|allergic transfusion reaction
961594|NCT02200692|transfusion reaction
961595|NCT02200692|blood transfusion
961596|NCT02200692|Solvent detergent plasma
961597|NCT02200679|Autism spectrum disorders
961598|NCT02200679|Prevalence
961599|NCT02200679|Diagnosis
961600|NCT02200679|Screen
961601|NCT02200679|Risk Factor
961602|NCT02200679|SRS
961603|NCT02200679|ASRS
961608|NCT02200627|Type 2 diabetes mellitus
961609|NCT02200627|Diabetes
961610|NCT02200627|Forxiga
961611|NCT02200627|Elderly
961612|NCT02200601|Seipher Wellness
961613|NCT02200601|algorithm
961614|NCT02200601|secure samples of SGC waveform
961615|NCT02200601|volunteers
961616|NCT02200601|validation
961617|NCT02200601|heart health algorithm
961618|NCT02200588|psychosis
961619|NCT02200588|schizophrenia
961620|NCT02200549|pulmonary rehabilitation
961621|NCT02200549|inspiratory muscle training
961622|NCT02200549|exercise training
961623|NCT02200523|EEG
961624|NCT02200523|electrode
961625|NCT02200510|Anemia, Sickle Cell
961626|NCT02200510|Transition to Adult Care
961627|NCT02200510|Self Care
961628|NCT02200510|Personal Electronic Health Records
961629|NCT02200510|Adolescent
961630|NCT02200510|Young Adult
961631|NCT02200510|Disease Management
961632|NCT02200510|Physician-Patient Relations
961633|NCT02200484|obesity
961634|NCT02200484|adolescents, females
961635|NCT02200484|child development
961636|NCT02200484|weight loss programs
961637|NCT02200484|child rearing
961638|NCT02200484|parenting
961639|NCT02200471|Cosmetic dermatology
961640|NCT02200471|near-infrared
961641|NCT02200471|patient preference
961642|NCT02200471|physician preference
961651|NCT02200432|Smoking Cessation
961652|NCT02200432|Persuasive Communication Tailoring
961653|NCT02200432|Health Behavior Change
961654|NCT02200432|Patient decision support
961655|NCT02200419|Rotem
961656|NCT02200419|Point of care coagulation tests
961657|NCT02200419|Cardiac surgery
961658|NCT02200419|Vascular surgery
961659|NCT02200419|Cardiopulmonary bypass
961660|NCT02200419|Blood products
961661|NCT02200419|Transfusion
961662|NCT02200419|Viscoelastic coagulation
961663|NCT02200406|Desvenlafaxine
961664|NCT02200406|Opioid-dependent
961665|NCT02200406|Addiction
961666|NCT02200406|Depression
961667|NCT02200406|Methadone
961668|NCT02200406|Comorbidity
961669|NCT02200393|Spinal cord injury
961670|NCT02200393|Tetraplegia
961671|NCT02200393|Ventilator
961672|NCT02200367|Primary health care
961673|NCT02200367|Computer communication network
961674|NCT02200367|Depression
961675|NCT02200328|Clostridium difficile infection
961676|NCT02200328|Diarrhea
961677|NCT02200328|Flagyl
961678|NCT02200328|Metronidazole
961679|NCT02200315|Stomach neoplasms
961680|NCT02200315|Surgical site infection
961681|NCT02200315|Laparoscopic gastrectomy
961682|NCT02200315|Antimicrobial prophylaxis
961683|NCT02200289|Birth cohort
961684|NCT02200289|Ghana
961685|NCT02200289|Biomass
961686|NCT02200289|Cook stove
961687|NCT02200289|Oxidative stress
961688|NCT02200289|Lung development
961689|NCT02200263|ocular albinism (OA)
961690|NCT02200263|oculocutaneous albinism (OCA)
961691|NCT02200263|macular pigment
961692|NCT02200263|visual function
961693|NCT02200237|EV71 Vaccine
961694|NCT02200211|Amblyopia
961695|NCT02200198|undernutrition
961696|NCT02200198|abdominal surgery
961697|NCT02200198|respiratory muscles
961698|NCT02200198|muscles strength
961699|NCT02200198|pulmonary complication
961700|NCT02200198|perioperative care
961701|NCT02200185|post traumatic pain
961702|NCT02200185|titrated morphine
961703|NCT02200185|nebulised morphine
961704|NCT02200172|Cancer
961705|NCT02200172|Melatonin
961706|NCT02200172|Delirium
961707|NCT02200172|Feasibility Studies
961708|NCT02200172|Palliative Care
961709|NCT02200159|Sedation
961710|NCT02200159|Dexmedetomidine
961711|NCT02200159|ICU
961712|NCT02200159|Delirium
961713|NCT02200146|sarcoidosis
961714|NCT02200146|treatment
961715|NCT02200146|lung
961716|NCT02200146|glucocorticoids
961717|NCT02200146|hydroxychloroquine
961718|NCT02200133|Hematopoietic cell transplant (HCT) survivors
961719|NCT02200133|Survivorship Care Plan
961720|NCT02200107|Osteoarthritis Knee
961721|NCT02200107|Self Care
961722|NCT02200107|Treatment Outcome
961723|NCT02200107|Patient Education as Topic
961724|NCT02200107|Physical Therapy Modalities
961725|NCT02200081|Extensive disease
961726|NCT02200081|After first line therapy
961727|NCT02200081|Immuno therapy
961728|NCT02200068|Perceived Efficacy of Patient Physician Interactions
961729|NCT02200068|Patient Reported Outcomes
961730|NCT02200068|Personal Health Record
961731|NCT02200055|Electrical Bioimpedance
961732|NCT02200055|Major Intra-abdominal Surgical Procedures
961733|NCT02200055|Total Body Volume
961734|NCT02200055|Fluid Resuscitation
961735|NCT02200029|Intrahepatic Cholestasis
961736|NCT02200016|Postoperative pain
961737|NCT02200016|Regional anesteshia
961738|NCT02200016|Nerve catheters
961739|NCT02200016|Sciatic nerve catheters
961740|NCT02200003|attention bias modification, anxiety, event-related potentials
961741|NCT02199990|cognitive function; propofol; etomidate;
961742|NCT02199977|Malaria
961743|NCT02199977|Antimalarial subsidy
961744|NCT02199977|Malaria rapid diagnostic test (RDT)
961745|NCT02199977|public-private partnership
961746|NCT02199964|Dry eye
961747|NCT02199964|environmental stress
961748|NCT02199964|artificial tears
961749|NCT02199964|cyclosporin
961750|NCT02199964|Restasis
961751|NCT02199951|Uncomplicated Malaria
961752|NCT02199951|dihydroartemisinin
961753|NCT02199951|piperaquine
961754|NCT02199925|Autism
961755|NCT02199925|Autism spectrum
961756|NCT02199925|Autism children
961757|NCT02199912|cachexia
961758|NCT02199912|nutrition
961759|NCT02199912|cancer
961760|NCT02199912|colorectal tumor
961761|NCT02199834|diabetes
961762|NCT02199834|peer support
961763|NCT02199834|personalized feedback report
961764|NCT02199795|stroke
961765|NCT02199795|hemiplegia
961766|NCT02199795|footdrop
961767|NCT02199795|electrical stimulation
961768|NCT02199769|Clinical decision support
961769|NCT02199769|Diabetes screening
961770|NCT02199756|Uterine contractions
961771|NCT02199756|Indomethacin
961772|NCT02199756|Nanovectors
961773|NCT02199743|schizophrenia
961774|NCT02199743|schizoaffective
961775|NCT02199743|cognition
961776|NCT02199743|lurasidone
961777|NCT02199743|Latuda
961778|NCT02199717|Physical Activity
961779|NCT02199717|Accelerometer
961780|NCT02199717|Exercise
961781|NCT02199717|Obesity
961782|NCT02199717|BMI
961783|NCT02199704|Parenting
961784|NCT02199704|Psychosis
961785|NCT02199704|Schizophrenia
961786|NCT02199704|Delusions
961787|NCT02199704|Hallucinations
961788|NCT02199691|Meningitis
961789|NCT02199691|Meningococcal Meningitis
961790|NCT02199691|MenACYW conjugate vaccine
961791|NCT02199691|MENVEO vaccine
961792|NCT02199691|Adacel®
961793|NCT02199691|GARDASIL®
961794|NCT02199639|Haemophilia
961795|NCT02199639|Arthropathy
961796|NCT02199639|Range of Movement
961797|NCT02199639|Strength
961798|NCT02199639|Proprioception
961799|NCT02199639|Gait
961800|NCT02199639|Quality of Life
961801|NCT02199613|HIV
961802|NCT02199613|antiretroviral therapy
961803|NCT02199587|Medical clown
961804|NCT02199587|Growth hormone
961805|NCT02199587|Precocious puberty
961806|NCT02199548|Adolescent
961807|NCT02199548|Decision-making
961808|NCT02199548|Social network
961809|NCT02199535|operating room,
961810|NCT02199535|risk factors
961811|NCT02199535|anesthesiologists
961812|NCT02199509|Levetiracetam
961813|NCT02199509|Cranial Dystonia
961814|NCT02199509|Oromandibular Dystonia
961820|NCT02199483|Energy Expenditure
961821|NCT02199483|Behavioral Weight Loss Treatment
961822|NCT02199483|Neurocognitive Function
961823|NCT02199483|Weight Loss
961824|NCT02199470|β-CELLS,
961825|NCT02199470|MIXED MEAL TEST,
961826|NCT02199470|C-PEPTİDE
961827|NCT02199431|Lu AF11167
961828|NCT02199431|Interaction
961829|NCT02199405|Spondylosis, Massage Therapy, Exercise Therapy ,Treatment Efficacy
961830|NCT02199392|P-glycoprotein
961831|NCT02199392|Healthy Volunteers
961832|NCT02199379|renal impairment
961833|NCT02199379|disease severity
961834|NCT02199366|Cardiac MRI
961835|NCT02199366|Radiation
961836|NCT02199366|Proton Radiation
961837|NCT02199366|Breast Cancer
961838|NCT02199353|Activities of daily living, Occupational Therapy, Dementia
961839|NCT02199340|Exercise testing
961840|NCT02199340|Children
961841|NCT02199340|Exercise capacity
961842|NCT02199327|Conjunctival-corneal intraepithelial neoplasia
961843|NCT02199327|Mitomycin C
961844|NCT02199327|Interferon alfa 2b
961845|NCT02199314|intra
961846|NCT02199314|operative
961847|NCT02199314|neurophysiologic
961848|NCT02199314|monitoring
961849|NCT02199314|transcranial
961850|NCT02199314|motor
961851|NCT02199314|evoked
961852|NCT02199314|potential
961853|NCT02199314|anesthesia
961854|NCT02199314|pulses
961855|NCT02199301|Kidney transplantation
961856|NCT02199301|Tolerance induction
961857|NCT02199301|Immunosuppression withdrawal
961858|NCT02199301|Bone marrow transplantation
961859|NCT02199301|Transplantation conditioning
961860|NCT02199301|Hematopoietic stem cell transplantation
961861|NCT02199301|Living donor
961862|NCT02199301|Haplotype
961863|NCT02199301|Immune tolerance
961864|NCT02199275|Non-urgent surgery
961865|NCT02199275|General anesthesia
961866|NCT02199275|Enterocyte damage
961867|NCT02199275|Intestinal fatty acid-binding protein
961868|NCT02199262|Intensive care unit
961869|NCT02199262|Incidents
961870|NCT02199262|prevention
961871|NCT02199262|music
961872|NCT02199262|reflexology
961873|NCT02199249|open anatomic reduction
961874|NCT02199249|syndesmosis screw fixation, syndesmosis Tightrope fixation
961875|NCT02199236|High-Dose-Rate Brachytherapy
961876|NCT02199236|oral capecitabine
961877|NCT02199236|infusional 5-FU
961878|NCT02199236|Questionnaires
961879|NCT02199236|14-104
961880|NCT02199210|Massive transfusion protocols
961881|NCT02199210|Self-regulatory learning
961882|NCT02199210|Forethought
961883|NCT02199210|Clinical expertise
961884|NCT02199210|Simulation
961885|NCT02199210|Education
961886|NCT02199184|Leukemia
961887|NCT02199184|Burkitt leukemia
961888|NCT02199184|Burkitt-like leukemia/lymphoma
961889|NCT02199184|Newly diagnosed
961890|NCT02199184|Relapsed/refractory
961891|NCT02199184|Ofatumumab
961892|NCT02199184|Arzerra
961893|NCT02199184|Etoposide
961894|NCT02199184|VePesid
961895|NCT02199184|Doxorubicin
961896|NCT02199184|Doxorubicin Hydrochloride
961897|NCT02199184|Adriamycin PFS
961898|NCT02199184|Adriamycin RDF
961899|NCT02199184|Adriamycin
961900|NCT02199184|Rubex
961901|NCT02199184|Vincristine
961902|NCT02199184|Cyclophosphamide
961903|NCT02199184|Cytoxan
961904|NCT02199184|Neosar
961905|NCT02199184|Prednisone
961906|NCT02199184|Rituximab
961907|NCT02199184|Rituxan
961908|NCT02199184|DA-EPOCH
961909|NCT02199184|Pegfilgrastim
961910|NCT02199184|Neulasta
961911|NCT02199184|PEG-G-CSF
961912|NCT02199184|G-CSF
961913|NCT02199184|Filgrastim
961914|NCT02199184|Neupogen
961915|NCT02199184|Phone calls
961916|NCT02199171|hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin
961917|NCT02199171|intraperitoneal (IP) chemotherapy
961918|NCT02199171|cytoreductive surgery
961919|NCT02199158|iridoplasty
961920|NCT02199158|angle
961921|NCT02199158|glaucoma
961922|NCT02199158|anterior chamber
961923|NCT02199158|laser treatment
961924|NCT02199132|Nasopharyngeal Carcinoma
961925|NCT02199119|children
961926|NCT02199119|television
961927|NCT02199119|exercise
961928|NCT02199119|food intake
961929|NCT02199119|appetite
961930|NCT02199119|satiation
961931|NCT02199093|MeSH terms:
961932|NCT02199093|Apraxias
961933|NCT02199093|Apraxia, Ideomotor
961934|NCT02199093|Stroke
961935|NCT02199093|Cerebral Stroke
961936|NCT02199093|Rehabilitation
961937|NCT02199093|Occupational therapy
961938|NCT02199093|Treatment Outcome
961939|NCT02199093|Activities of Daily Living
961940|NCT02199054|Snack Foods
961941|NCT02199054|Safflower Oil
961942|NCT02199054|Soy
961943|NCT02199054|Postmenopausal women
961944|NCT02199054|Metabolic Syndrome
961945|NCT02199041|Cord Blood
961946|NCT02199041|Haploidentical
961947|NCT02199041|Reduced Intensity Regimen
961948|NCT02199028|hyaluronidase
961949|NCT02199028|infusion sets
961950|NCT02199028|insulin pump
961951|NCT02199028|Continuous glucose monitor
961952|NCT02199015|Dysarthria
961953|NCT02199015|Electrical Stimulation
961954|NCT02199015|Lateral Cord Stimulation
961955|NCT02199015|Spasticity
961956|NCT02199015|Treatment
961957|NCT02199002|acid pocket
961958|NCT02199002|GERD
961959|NCT02199002|Barrett
961960|NCT02198963|Skin irritation potential of RUT058-60.
961961|NCT02198950|sepsis
961962|NCT02198950|diagnosis
961963|NCT02198950|biomarker
961964|NCT02198937|smokers
961965|NCT02198937|non-smokers
961966|NCT02198924|sequential administration
961967|NCT02198924|pain control
961968|NCT02198924|inflammation control
961969|NCT02198924|function recovery
961970|NCT02198911|Habituation
961971|NCT02198911|Orosensory cues
961972|NCT02198911|Satiation
961973|NCT02198885|FAST
961974|NCT02198885|Thoracoabdominal Trauma
961975|NCT02198885|Prehospital care
961976|NCT02198885|ultrasound
961977|NCT02198885|NanoMaxx Ultrasound
961978|NCT02198885|RP-Xpress
961979|NCT02198872|Autonomic Nervous System, Body composition, Oxygen Uptake,
961980|NCT02198872|Water Based Physical Training, Land Based Physical Training.
961981|NCT02198859|Prostate Cancer
961982|NCT02198859|Lithium
961983|NCT02198859|Androgen
961984|NCT02198859|PSA
961985|NCT02198833|Urinary Tract Infection
961986|NCT02198833|Bacteriuria
961987|NCT02198833|Transurethral Foley Catheter
961988|NCT02198833|Suprapubic Foley Catheter
961989|NCT02198833|Spinal Cord injury
961990|NCT02198820|Femoral Neck Fractures
961991|NCT02198820|Perioperative Care
961992|NCT02198820|Perioperative Period
961993|NCT02198820|Postoperative Complications
961994|NCT02198794|Dyskinesias
961995|NCT02198794|Movement Disorders
961996|NCT02198794|Central Nervous System Diseases
961997|NCT02198794|Nervous System Diseases
961998|NCT02198794|Neurologic Manifestations
961999|NCT02198794|Signs and Symptoms
962000|NCT02198781|atrial fibrilation
962001|NCT02198781|atrial-ventricula
962002|NCT02198781|right ventricle
962003|NCT02198781|left ventricle
962004|NCT02198781|surrogate marker
962005|NCT02198781|ventricular dysfunction
962006|NCT02198781|pacing
962007|NCT02198768|ankle fracture
962008|NCT02198768|ankle fracture-dislocation
962009|NCT02198768|prospective
962010|NCT02198768|observational
962011|NCT02198755|high resolution ultrasound
962012|NCT02198755|osteomyelitis
962013|NCT02198716|Percutaneous coronary intervention
962014|NCT02198716|Elderly
962015|NCT02198716|Angina
962016|NCT02198703|Probiotics
962017|NCT02198703|AB-Life
962018|NCT02198703|LDL-cholesterol
962019|NCT02198703|Hypercholesterolemia
962020|NCT02198690|Mammography, Older women, decision making
962021|NCT02198664|Characterized Peanut Allergen
962022|NCT02198664|Peanut
962023|NCT02198664|OIT
962024|NCT02198664|Oral Desensitization
962025|NCT02198664|Peanut Allergen
962026|NCT02198664|Peanut-Allergic Children
962027|NCT02198664|Children
962028|NCT02198664|Peanut-Allergic Adults
962029|NCT02198651|Magnetic Resonance Imaging
962030|NCT02198651|Taper
962031|NCT02198651|Anti-rheumatic drugs
962032|NCT02198651|Arthritis
962033|NCT02198651|Rheumatoid Arthritis
962034|NCT02198651|Drug Level
962035|NCT02198651|Flare
962036|NCT02198651|Ultrasound
962037|NCT02198651|Reduced dose
962038|NCT02198651|Remission
962039|NCT02198651|Adalimumab
962040|NCT02198651|Biomarker
962041|NCT02198638|Influenza
962042|NCT02198638|Vaccination rate
962043|NCT02198638|Hospital acquired infection
962044|NCT02198625|Moderate FiO2
962045|NCT02198625|Protective lung ventilation
962046|NCT02198625|Postoperative pulmonary complications
962047|NCT02198625|Positive end-expiratory pressure
962048|NCT02198625|recruitment maneuvers
962049|NCT02198599|Multiple sclerosis
962050|NCT02198599|Stroke
962051|NCT02198599|Nursing
962052|NCT02198599|Mobility
962053|NCT02198599|Rehabilitation
962054|NCT02198586|Alzheimer's, MRI, APOE
962055|NCT02198573|malaria
962056|NCT02198573|K13
962057|NCT02198573|pfmrp1
962058|NCT02198573|Myanmar
962059|NCT02198560|Normal (Eyes without pathologies)
962060|NCT02198547|Local anesthetic adjuvant,
962061|NCT02198547|Magnesium solfatus,
962062|NCT02198547|Sciatic block
962063|NCT02198534|visual acuity
962064|NCT02198534|Landolt C
962065|NCT02198534|ETDRS charts
962066|NCT02198534|Freiburg Visual Acuity Test
962067|NCT02198534|FrACT
962068|NCT02198534|Comparison
962069|NCT02198534|acceptance
962070|NCT02198534|Test retest reliability
962071|NCT02198534|duration
962072|NCT02198534|questionnaire
962073|NCT02198521|Patients undergoing staged bilateral open Carpal Tunnel Release (CTR) have no difference in overall pain intensity of pain between sides.
962074|NCT02198482|Acute Myeloid Leukemia (AML)
962075|NCT02198482|Volasertib
962076|NCT02198482|High-risk Myelodysplastic Syndrome (MDS)
962077|NCT02198469|actinic cheilitis
962078|NCT02198469|Er:YAG ablative fractional laser
962079|NCT02198469|methyl aminolevulinate photodynamic therapy
962207|NCT02197780|Cohort Study
962080|NCT02198456|pulmonary arterial hypertension
962081|NCT02198430|Haemophilia
962082|NCT02198430|Arthropathy
962083|NCT02198430|Range of motion
962084|NCT02198430|Strength
962085|NCT02198430|Proprioception
962086|NCT02198430|Gait
962087|NCT02198430|Quality of Life.
962088|NCT02198417|Polycystic Ovary Syndrome
962089|NCT02198417|PCOS
962090|NCT02198417|Acne
962091|NCT02198417|Infertility
962092|NCT02198417|Irregular menses
962093|NCT02198417|Irregular period
962094|NCT02198417|Mitochondria
962095|NCT02198417|Metabolism
962096|NCT02198378|premixed nitrous oxide and oxygen
962097|NCT02198378|pain
962098|NCT02198378|prehospital setting
962099|NCT02198378|acute coronary syndrome
962100|NCT02198365|mRNA,
962101|NCT02198365|DNA,
962102|NCT02198365|integrated HPV DNA
962103|NCT02198365|human papillomavirus,
962104|NCT02198365|cervical neoplasia
962105|NCT02198300|dedicated bifurcation stent
962106|NCT02198300|sirolimus eluting stent
962107|NCT02198261|alopecia
962108|NCT02198261|androgenetic alopecia
962109|NCT02198261|hair loss
962110|NCT02198261|minoxidil
962111|NCT02198261|5% minoxidil foam
962112|NCT02198261|male pattern hair loss
962113|NCT02198209|liraglutide
962114|NCT02198209|GLP-1
962115|NCT02198209|liver glucokinase
962116|NCT02198170|Healthy Volunteers
962117|NCT02198157|duration of second stage
962118|NCT02198157|urinary catheterization
962119|NCT02198157|epidural anaesthesia
962120|NCT02198144|Hypertension
962121|NCT02198144|High Blood Pressure
962122|NCT02198144|African American Men
962123|NCT02198144|Black Men
962124|NCT02198118|breast cancer
962125|NCT02198118|physiotherapy
962126|NCT02198118|radiotherapy
962127|NCT02198105|PAD
962128|NCT02198105|femoropoliteal stenosis/occlusion
962129|NCT02198105|cutting-balloon
962130|NCT02198105|drug-coated-balloon
962131|NCT02198092|familial adenomatous polyposis
962132|NCT02198092|multiple adenomatous polyposis
962133|NCT02198092|lynch syndrome
962134|NCT02198092|hnpcc
962135|NCT02198092|colorectal cancer
962136|NCT02198092|genetic syndrome
962137|NCT02198092|epigenomics
962138|NCT02198092|septin9
962139|NCT02198079|non-tuberculous mycobacteria
962140|NCT02198079|Pediatrics
962141|NCT02198079|Cystic Fibrosis
962142|NCT02198066|Sternotomy incision
962143|NCT02198066|Silver dressing
962144|NCT02198066|Sternal wound infection
962145|NCT02198040|Elbow
962146|NCT02198040|Joint disease
962147|NCT02198040|Hemophilia
962148|NCT02198040|Physiotherapy modalities
962149|NCT02198027|Percutaneous nephrolithotomy
962150|NCT02198027|postoperative analgesia
962151|NCT02198027|peritubal block
962152|NCT02198027|pain
962153|NCT02198027|Visual Analog Pain Scale
962154|NCT02198014|Knee
962155|NCT02198014|Joint disease
962156|NCT02198014|Haemophilia
962157|NCT02198014|Physiotherapy modalities
962158|NCT02198001|Platelets
962159|NCT02198001|fibrin
962160|NCT02198001|growth factors
962161|NCT02198001|bisphosphonates
962162|NCT02198001|tooth extraction
962163|NCT02197988|Surgery
962164|NCT02197988|Abdominal
962165|NCT02197988|Epidural Anesthesia
962166|NCT02197988|Transversus Abdominis Plane Block
962167|NCT02197988|TAP block
962168|NCT02197975|Healthy Volunteers
962169|NCT02197962|Osteoarthritis
962170|NCT02197962|Radial shockwaves
962171|NCT02197936|Peristalsis
962172|NCT02197936|ultrasound
962173|NCT02197923|Menorrhagia
962174|NCT02197923|Dysmenorrhea
962175|NCT02197923|Pelvic pain
962176|NCT02197923|expression profiling
962177|NCT02197923|uterine biopsies
962178|NCT02197923|serum hormones
962181|NCT02197884|Healthy
962182|NCT02197884|JNJ-54861911
962183|NCT02197884|Cytochrome P450 3A4 inhibitor
962184|NCT02197884|Itraconazole
962185|NCT02197884|Clarithromycin
962186|NCT02197884|Alzheimer's disease
962187|NCT02197871|COPD
962188|NCT02197871|malnutrition
962189|NCT02197871|nutrition supplementation
962190|NCT02197858|invasive arterial pressure
962191|NCT02197858|extended hemodynamic monitoring
962192|NCT02197858|propofol
962193|NCT02197858|remifentanil
962194|NCT02197845|sickle cell disease
962195|NCT02197845|hydroxyurea
962196|NCT02197845|patient navigator
962197|NCT02197845|community health worker
962198|NCT02197845|public health worker
962199|NCT02197845|fetal hemoglobin
962200|NCT02197845|health services research
962201|NCT02197832|Frozen thawed embryo transfer
962202|NCT02197832|Endometrial injury
962203|NCT02197832|Ongoing pregnancy rates
962204|NCT02197780|Diagnostic accuracy
962205|NCT02197780|Fecal biomarker
962206|NCT02197780|Clinical Decision Rule
962208|NCT02197767|fibrillary GN
962209|NCT02197767|rituximab
962210|NCT02197767|Rituxan
962211|NCT02197767|MabThera
962212|NCT02197767|Zytux
962213|NCT02197754|pharmacokinetics
962214|NCT02197754|polyphenol metabolites
962215|NCT02197754|lean individuals
962216|NCT02197754|obese individuals
962217|NCT02197728|hysterectomy, uterine manipulator, thermal damage, laparoscopy, colpotomy
962218|NCT02197715|Pregnancy
962219|NCT02197715|Contraceptive Methods
962220|NCT02197715|Family Planning Services
962221|NCT02197702|RCT
962222|NCT02197702|asthma
962223|NCT02197702|pediatric
962224|NCT02197702|virus
962225|NCT02197702|corticosteroid
962226|NCT02197689|Personalized Medication Management
962227|NCT02197689|Medication Adherence
962228|NCT02197689|SMS Medication Reminder
962229|NCT02197663|acupuncture
962230|NCT02197663|stroke
962231|NCT02197663|Randomized Controlled Trial
962232|NCT02197650|ALL l-asparaginase encapsulated erythrocytes
962233|NCT02197624|Non-heme iron absorption; HFE
962234|NCT02197611|Haemophilia
962235|NCT02197611|Adherence of Treatment
962236|NCT02197611|Knowledge of Illness
962237|NCT02197611|Medical-patient Relationship
962238|NCT02197611|Illness Behavior
962239|NCT02197611|Treatment Difficulties.
962240|NCT02197598|nalmefene, alcohol consumption, liver effects
962241|NCT02197585|Male patients
962242|NCT02197585|Age > 18 year
962243|NCT02197585|Primary hernia
962244|NCT02197585|glue
962245|NCT02197572|Drug therapy
962246|NCT02197559|Ischemic Stroke, restenosis,bare-metal stents, drug -eluting stents
962247|NCT02197546|Injection pain
962248|NCT02197546|local anesthesia
962249|NCT02197546|acupuncture
962250|NCT02197481|BiClamp forceps hepatectomy
962251|NCT02197481|Clamp crushing technique
962252|NCT02197481|Liver parenchyma transection
962253|NCT02197481|Randomized controlled trial
962254|NCT02197468|Gut microbiome
962255|NCT02197468|Necrotizing enterocolitis
962256|NCT02197468|Antibiotics
962257|NCT02197429|Vulvodynia
962258|NCT02197429|Acupuncture
962259|NCT02197429|Provoked Vestibulodynia
962260|NCT02197429|Vulvar Vestibulitis
962261|NCT02197429|Vulvar Pain
962262|NCT02197429|Dyspareunia
962263|NCT02197429|Female Sexual Function
962264|NCT02197403|Dexmedetomidine
962265|NCT02197403|Sedation
962266|NCT02197403|Paradoxical excitement response
962267|NCT02197403|Alcohol drinkers
962268|NCT02197390|Childhood obesity
962269|NCT02197390|Latino
962270|NCT02197390|Hispanic
962271|NCT02197377|Laryngeal mask airway, edentulous geriatric patient
962272|NCT02197364|Interstitial Lung Disease
962273|NCT02197364|Diagnosis
962274|NCT02197364|Krebs Von Den Lungen-6
962275|NCT02197351|stomach neoplasms
962276|NCT02197351|narrow band imaging
962277|NCT02197351|gastroscopy
962278|NCT02197338|cholangiopancreatography, endoscopic retrograde
962279|NCT02197325|NSTEMI and STEMI
962280|NCT02197312|yttrium-oxide
962281|NCT02197312|Y-TZP
962282|NCT02197312|bridge
962283|NCT02197312|NobelProcera
962284|NCT02197312|Shaded Zirconia
962285|NCT02197273|Total knee arthroplasty
962286|NCT02197273|Total shoulder arthroplasty
962287|NCT02197273|Total hip arthroplasty
962288|NCT02197273|Total joint arthroplasty
962289|NCT02197273|Hip replacement
962290|NCT02197273|Knee replacement
962291|NCT02197273|Shoulder replacement
962292|NCT02197260|Periodontitis
962293|NCT02197260|amoxicillin
962294|NCT02197260|metronidazole
962295|NCT02197260|case management
962296|NCT02197247|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, rifampicin, CYP P450 inducer, EGFR genes
962297|NCT02197234|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, simvastatin, EGFR genes
962298|NCT02197208|Frozen-thawed embryo transfer
962299|NCT02197208|natural cycle
962300|NCT02197208|spontaneous ovulation
962301|NCT02197208|hCG induced natural cycles
962302|NCT02197182|Bacterial Vaginosis (BV)
962303|NCT02197182|Amsel's criteria
962304|NCT02197182|Pap smear
962305|NCT02197169|Brain
962306|NCT02197169|Brain Cancer
962307|NCT02197169|Brain Neoplasms
962308|NCT02197169|Central Nervous System Diseases
962309|NCT02197169|Central Nervous System Neoplasms
962310|NCT02197169|CNS
962311|NCT02197169|Conditionally Replication-Competent Adenovirus
962312|NCT02197169|DNX-2401
962313|NCT02197169|Delta-24-RGD
962314|NCT02197169|Glioma
962315|NCT02197169|Glioblastoma
962316|NCT02197169|Gliosarcoma
962317|NCT02197169|Interferon gamma
962318|NCT02197169|Malignant brain tumor
962319|NCT02197169|Neoplasms, Neuroepithelial
962320|NCT02197169|Neuroectodermal Tumors
962321|NCT02197169|Neoplasms, Germ Cell and Embryonal
962322|NCT02197169|Neoplasms by Histologic Type
962323|NCT02197169|Neoplasms, Glandular and Epithelial
962324|NCT02197169|Neoplasms, Nerve Tissue
962325|NCT02197169|Nervous System Diseases
962326|NCT02197169|Alcyone Lifesciences
962327|NCT02197169|AMC™
962328|NCT02197169|Cannula
962329|NCT02197169|Alcyone MEMS Cannula (AMC™) System
962330|NCT02197143|esomeprazole
962331|NCT02197143|ranitidine
962332|NCT02197143|hydrotalcid
962333|NCT02197143|treatment of dyspepsia
962334|NCT02197143|emergancy medicine
962335|NCT02197130|Huntington; chorea; total motor score; CAG repeat: total functional capacity; motor cognitive and behavioral symptoms
962336|NCT02197117|ST-segment elevation myocardial infarction (STEMI); thrombolysis, remote ischemic conditioning, myocardial infarct size, cardioprotection
962337|NCT02197065|hip fracture
962338|NCT02197065|myocardial ischemia
962339|NCT02197065|statin
962340|NCT02197065|surgery
962341|NCT02197065|troponin
962342|NCT02197065|complication
962343|NCT02197065|arthroplasty
962344|NCT02197065|hip
962345|NCT02197065|knee
962346|NCT02197065|orthopedic
962347|NCT02197065|atorvastatin
962348|NCT02197065|cardiovascular
962349|NCT02197039|Peptic ulcer hemorrhage, second-look endoscopy
962350|NCT02197000|BRCA mutation
962351|NCT02197000|Breast cancer
962352|NCT02197000|Estrogen metabolism
962353|NCT02197000|3,3-Diindolylmethane
962354|NCT02197000|Breast density
962355|NCT02196987|Pain
962356|NCT02196987|Catheter
962357|NCT02196987|Urethra
962358|NCT02196987|Urination
962359|NCT02196974|bronchoscopy
962360|NCT02196974|lung nodule
962361|NCT02196974|diagnosis
962362|NCT02196974|cryobiopsy
962363|NCT02196961|Merkel cell carcinoma
962364|NCT02196961|Ipilimumab
962365|NCT02196961|Adjuvant
962366|NCT02196948|Supraspinatus, tendinopathy, pain, disability, EPTE
962367|NCT02196935|Cholangitis
962368|NCT02196935|Choledocholithiasis
962369|NCT02196935|Gastrointestinal Neoplasms
962370|NCT02196935|Medically underserved area
962371|NCT02196935|Anesthesia
962372|NCT02196922|Chronic Heart Failure
962373|NCT02196922|Telehealth
962374|NCT02196922|Self Management
962375|NCT02196909|HIBM
962376|NCT02196909|GNE
962377|NCT02196870|Airway pressure stress index
962378|NCT02196870|Transpulmonary pressure stress index
962379|NCT02196870|Acute Respiratory Failure
962380|NCT02196870|Chest wall elastance
962381|NCT02196870|Lung stress
962382|NCT02196857|Leukemia
962383|NCT02196857|Acute myeloid leukemia
962384|NCT02196857|AML
962385|NCT02196857|High risk myelodysplastic syndrome
962386|NCT02196857|MDS
962387|NCT02196857|FLT3-ITD mutation
962388|NCT02196857|Azacytidine
962389|NCT02196857|5-Azacytidine
962390|NCT02196857|5-AZA
962391|NCT02196857|Vidaza
962392|NCT02196857|5-AZC
962393|NCT02196857|AZA-CR
962394|NCT02196857|Ladakamycin
962395|NCT02196857|NSC-102816
962396|NCT02196857|Sorafenib
962397|NCT02196857|Nexavar
962398|NCT02196857|BAY 43-9006
962399|NCT02196844|Lung cancer
962400|NCT02196844|Hatha Yoga
962401|NCT02196844|Questionnaires
962402|NCT02196844|Surveys
962403|NCT02196844|Walk Test
962404|NCT02196844|Caregiver
962405|NCT02196831|Human immunodeficiency virus (HIV)
962406|NCT02196831|Nonalcoholic fatty liver disease (NAFLD)
962407|NCT02196831|Nonalcoholic steatohepatitis (NASH)
962408|NCT02196831|Growth hormone releasing hormone
962409|NCT02196831|tesamorelin
962410|NCT02196805|bioequivalence
962411|NCT02196805|imported PROBUCOL table
962412|NCT02196805|Lorelco
962413|NCT02196805|marketed PROBUCOL tablet
962414|NCT02196805|Chang Tai
962415|NCT02196792|Joint Diseases
962416|NCT02196792|Musculoskeletal Diseases
962417|NCT02196792|radiostereometric analysis
962418|NCT02196779|Abdominoplasty
962419|NCT02196779|circulation
962420|NCT02196779|skin
962421|NCT02196779|dissection
962422|NCT02196779|laser
962423|NCT02196779|fluorescence
962424|NCT02196779|imaging
962425|NCT02196753|Positron emission tomography combined with computed tomography
962426|NCT02196753|PET CT
962427|NCT02196753|Cardiovascular Implantable Electronic Device
962428|NCT02196753|Infective endocarditis
962429|NCT02196753|Generator pocket infection
962430|NCT02196753|Fever of unknown origin
962431|NCT02196740|periapical periodontitis,primary teeth
962432|NCT02196727|Postoperative pain
962433|NCT02196727|Multimodal analgesia
962434|NCT02196727|Bascom Cleft Lift
962435|NCT02196727|Day-case.
962436|NCT02196714|Japanese Healthy Volunteers
962437|NCT02196701|methotrexate
962438|NCT02196701|adalimumab
962439|NCT02196701|biologic
962440|NCT02196701|psoriasis
962441|NCT02196701|Tumor necrosis factor (TNF)-α inhibitor
962442|NCT02196688|subjects with mCRC who failed at least 2nd line therapy
962443|NCT02196610|End-Stage Renal Disease,
962444|NCT02196610|arterial or vascular stiffness,
962445|NCT02196610|hemodialysis,
962446|NCT02196610|Pulse wave velocity
962447|NCT02196610|Renal insufficiency,
962448|NCT02196610|tonometry
962449|NCT02196597|anorectal manometry
962450|NCT02196571|GDM
962451|NCT02196571|Exercise
962452|NCT02196571|Diabetes
962453|NCT02196571|Pregnancy
962454|NCT02196558|Rheumatoid Arthritis
962455|NCT02196558|Japanese subjects
962456|NCT02196532|retinal nerve fiber layer thickness
962457|NCT02196532|optical coherence tomography
962458|NCT02196532|migraine
962459|NCT02196506|OPC-34712
962460|NCT02196506|brexpiprazole
962461|NCT02196506|Major Depressive Disorder
962462|NCT02196506|Adjunctive Treatment
962463|NCT02196506|Anxious Distress
962464|NCT02196493|Productive
962465|NCT02196493|Cough
962466|NCT02196493|Bronchitis
962467|NCT02196493|Azithromycin
962468|NCT02196467|myoblast
962469|NCT02196467|transplantation
962470|NCT02196467|strength
962471|NCT02196467|tacrolimus
962472|NCT02196467|immunosuppression
962479|NCT02196441|deep topical fornix nerve block
962480|NCT02196441|topical anesthesia
962481|NCT02196441|implantable contact lens procedure
962482|NCT02196428|Ambient Assisted Living (AAL)
962483|NCT02196428|Telemonitoring
962484|NCT02196428|Teleconsultation
962485|NCT02196415|Hindfoot Alignment
962486|NCT02196415|Rearfoot
962487|NCT02196415|Malalignment
962488|NCT02196415|biplanar radiography
962489|NCT02196415|3D measurement
962490|NCT02196376|Postural orthostatic syndrome
962491|NCT02196376|orthostatic intolerance
962492|NCT02196376|autonomic dysfunction
962493|NCT02196350|personalized treatment
962494|NCT02196350|prevention
962495|NCT02196350|improved diagnosis
962496|NCT02196337|Iodine deficiency
962497|NCT02196324|Prurigo Nodularis
962498|NCT02196324|Atopic Dermatitis
962499|NCT02196324|Lichen-simplex chronicus
962500|NCT02196311|Supracondylar humerus fractures, external fixation, open reduction, and internal fixation.
962501|NCT02196298|physical therapy
962502|NCT02196298|gait
962503|NCT02196298|pediatric rehabilitation
962504|NCT02196298|gross motor function
962505|NCT02196298|participation
962506|NCT02196285|Double
962507|NCT02196285|Viral
962508|NCT02196285|Vaccine
962509|NCT02196285|Measles
962510|NCT02196285|Rubella
962511|NCT02196285|Safety
962512|NCT02196285|Efficacy
962513|NCT02196285|Imunogenicity
962514|NCT02196259|Pre-Post
962515|NCT02196233|Trigger Finger
962516|NCT02196233|Prospective Clinical Research
962517|NCT02196233|Randomized
962518|NCT02196233|Questionnaires
962519|NCT02196233|Transverse
962520|NCT02196233|Longitudinal
962521|NCT02196207|Severe Hemophilia A
962522|NCT02196207|Previously Untreated Patients
962523|NCT02196207|Hemophilia Inhibitor Formation
962524|NCT02196207|Long-Acting Factor VIII
962525|NCT02196207|Prophylaxis
962526|NCT02196155|plantar fasciitis
962527|NCT02196155|Botulinum toxin A
962528|NCT02196155|Cortisone
962529|NCT02196155|RCT
962530|NCT02196142|Cortisol
962531|NCT02196142|Alcohol Craving
962532|NCT02196142|Alcohol Dependence
962533|NCT02196129|low back pain
962534|NCT02196129|pharmacoacupuncture
962535|NCT02196129|sinbaro-3
962536|NCT02196116|Alzheimer disease
962537|NCT02196116|amyloid load
962538|NCT02196116|educational level
962539|NCT02196116|cognitive performances
962540|NCT02196103|TOLAC
962541|NCT02196103|PROM
962542|NCT02196103|Previous Cesarian section
962543|NCT02196103|Mechanical cervical ripening
962544|NCT02196090|OCD, Exposure and Response Prevention, Vagal Stimulation
962545|NCT02196077|Budesonide and formoterol inhalation aerosol
962546|NCT02196064|HIV HCV antiretroviral
962547|NCT02196051|Insulin resistance
962548|NCT02196051|Exercise
962549|NCT02196051|de novo lipogenesis
962550|NCT02196051|NAFLD
962551|NCT02196051|Magnetic Resonance Spectroscopy
962552|NCT02196038|heart failure
962553|NCT02196025|Insomnia
962554|NCT02196012|overweight
962555|NCT02196012|obesity
962556|NCT02196012|Technology
962557|NCT02196012|College Students
962558|NCT02195986|vaginal dryness
962559|NCT02195986|vaginal and/or vulvar irritation/itching
962560|NCT02195986|dysuria
962561|NCT02195986|vaginal pain and bleeding associated with sexual activity
962562|NCT02195986|vaginal atrophy
962563|NCT02195973|ovarian cancer
962564|NCT02195973|platinum resistant
962565|NCT02195973|LED225
962566|NCT02195973|Sonidegib
962567|NCT02195973|Paclitaxel
962568|NCT02195960|skin toxicity, radiotherapy, antioxidants
962569|NCT02195947|Growth hormone
962570|NCT02195947|IVF/ICSI
962571|NCT02195947|Poor responder
962572|NCT02195947|Antagonist protocol
962573|NCT02195934|Cardiovascular disease, blood orange juice, anthocyanins
962574|NCT02195895|Teriparatide
962575|NCT02195895|Alendronate
962576|NCT02195895|Alendronic Acid
962577|NCT02195895|Osteoporosis
962578|NCT02195895|Bone Fracture
962579|NCT02195895|Bone Loss
962580|NCT02195895|Spinal Cord Injury
962581|NCT02195895|Bone Diseases
962582|NCT02195895|Metabolic Bone Diseases
962583|NCT02195895|Musculoskeletal Diseases
962584|NCT02195895|Spinal Cord Diseases
962585|NCT02195895|Central Nervous System Diseases
962586|NCT02195895|Nervous System Diseases
962587|NCT02195895|Nervous System
962588|NCT02195895|Wounds and Injuries
962589|NCT02195895|Bone Density Conservation Agents
962590|NCT02195895|Physiological Effects of Drugs
962591|NCT02195895|Pharmacologic Actions
962592|NCT02195882|strength training
962593|NCT02195882|scapular stabilization
962594|NCT02195882|kayakers.
962595|NCT02195869|PCYC1129
962596|NCT02195869|PCYC1129CA
962597|NCT02195869|1129
962598|NCT02195869|Ibrutinib
962599|NCT02195869|PCI32765
962600|NCT02195869|IMBRUVICA
962601|NCT02195869|Pharmacyclics
962602|NCT02195869|PCYC
962603|NCT02195869|GVHD
962604|NCT02195869|Steroid dependent
962605|NCT02195869|refractory
962606|NCT02195869|chronic
962607|NCT02195869|graft versus host disease
962608|NCT02195869|chronic graft versus host disease
962609|NCT02195869|immunology
962610|NCT02195856|Diabetes
962611|NCT02195856|Nitrate
962612|NCT02195856|Nitrite
962613|NCT02195856|Hepatic
962614|NCT02195856|MRI
962615|NCT02195856|Incretin
962616|NCT02195856|Insulin
962617|NCT02195856|Glucose
962618|NCT02195843|CRT-D
962619|NCT02195843|Heart Failure
962620|NCT02195843|Middle East
962621|NCT02195843|Quadripolar
962622|NCT02195830|Sepsis
962623|NCT02195830|ultrasound
962624|NCT02195830|inferior vena cava collapsibility
962625|NCT02195778|Health Literacy
962626|NCT02195778|Adult
962627|NCT02195778|UAE
962628|NCT02195778|Disease
962629|NCT02195778|Age
962630|NCT02195765|Chronic Periodontitis
962631|NCT02195765|Periodontal disease
962632|NCT02195752|Compounded pain cream
962633|NCT02195752|Ordinary care
962634|NCT02195752|Compounding
962635|NCT02195752|Topical treatment
962636|NCT02195752|Analgesia
962637|NCT02195739|smoking
962638|NCT02195739|smoking cessation
962639|NCT02195739|cardiovascular disease
962640|NCT02195739|pharmacological intervention
962641|NCT02195739|UK primary care population
962642|NCT02195739|nicotine replacement therapy
962643|NCT02195700|Dyskinesias
962644|NCT02195700|Movement Disorders
962645|NCT02195700|Central Nervous System Diseases
962646|NCT02195700|Nervous System Diseases
962647|NCT02195700|Neurologic Manifestations
962648|NCT02195700|Signs and Symptoms
962649|NCT02195661|Epilepsy
962650|NCT02195661|Electroencephalogram
962651|NCT02195661|children
962652|NCT02195661|sedation
962653|NCT02195648|Tension-Type Headache
962654|NCT02195648|Physical Therapy Modalities
962655|NCT02195648|Musculoskeletal Manipulations
962656|NCT02195648|Sub-occipital muscle inhibition technique
962657|NCT02195609|Vasomotor Symptoms Associated With Menopause
962658|NCT02195609|Menopause
962659|NCT02195609|Hot Flashes
962660|NCT02195609|Postmenopausal Women
962661|NCT02195596|Alzheimer disease, exercise, cognition
962662|NCT02195570|contingency management
962663|NCT02195570|smoking cessation
962664|NCT02195570|prenatal tobacco exposure
962665|NCT02195570|maternal smoking
962666|NCT02195531|Adherence
962667|NCT02195518|Chronic Hepatitis B
962668|NCT02195518|Tenofovir disoproxil fumarate
962669|NCT02195518|Failure of multiple NAs treatment
962670|NCT02195479|Multiple Myeloma
962671|NCT02195479|Bortezomib
962672|NCT02195479|Velcade
962673|NCT02195479|Melphalan
962674|NCT02195479|Prednisone
962675|NCT02195479|Daratumumab
962676|NCT02195453|Non-small cell lung cancer
962677|NCT02195453|FACT-L scale
962678|NCT02195453|Yangzhengxiaoji
962679|NCT02195440|Hepatitis C virus, cirrhosis
962680|NCT02195414|NeoVas
962681|NCT02195414|Bioresorbable scaffold
962682|NCT02195414|Sirolimus
962683|NCT02195414|First-in-Man
962684|NCT02195401|autism, cleanroom, immune dysregulation, toxins
962685|NCT02195388|Arterial stiffness,
962686|NCT02195388|endothelial function,
962687|NCT02195388|autonomic nervous system,
962688|NCT02195388|acute coronary syndrome,
962689|NCT02195388|arterial hypertension,
962690|NCT02195388|pulse wave velocity,
962691|NCT02195388|augmentation index,
962692|NCT02195388|arterial stiffness index,
962693|NCT02195388|heart rate variability,
962694|NCT02195388|heart rate turbulence,
962695|NCT02195388|vascular endothelial growth factor,
962696|NCT02195388|asymmetric dimethylarginine
962697|NCT02195375|Chronic Obstructive Pulmonary Disease
962698|NCT02195375|FEV1 ≤ 50%
962699|NCT02195349|Tuberculin Purified Protein Derivative
962700|NCT02195349|Delayed Type Hypersensitivity
962701|NCT02195349|Biopsy
962702|NCT02195349|Induration
962703|NCT02195349|First time in human
962704|NCT02195349|T-cells
962705|NCT02195349|LAG-3
962706|NCT02195349|safety
962707|NCT02195349|GSK2831781
962708|NCT02195349|psoriasis
962709|NCT02195323|autologous bone marrow mesenchymal stem cells chronic kidney disease
962710|NCT02195310|Sternotomy
962711|NCT02195310|Surgical site Occurences
962712|NCT02195310|Negative Pressure Wound Therapy
962713|NCT02195310|Surgical Site Infection
962714|NCT02195297|cellulitis
962715|NCT02195297|anticellulitis
962716|NCT02195284|Inhaler preference
962717|NCT02195284|Overall inhaler error
962718|NCT02195284|DISKUS/ACCUHALER
962719|NCT02195284|MDI
962720|NCT02195284|TURBUHALER
962721|NCT02195284|ELLIPTA
962722|NCT02195284|Ease of use
962723|NCT02195284|Critical inhaler error
962724|NCT02195271|Melatonin
962725|NCT02195271|Transcranial Direct Current Stimulation
962726|NCT02195271|Neuroplasticity
962727|NCT02195271|Analgesia
962728|NCT02195271|Pain
962729|NCT02195245|CO2 filter
962730|NCT02195245|anesthesia
962731|NCT02195245|device
962732|NCT02195232|Venous Thromboembolic Events in Cancer Patients
962733|NCT02195232|Thromboembolism of Vein in Colorectal Cancer
962734|NCT02195232|Thromboembolism of Vein in Pancreatic Cancer
962735|NCT02195232|Thromboembolism of Vein in Non-small Cell Lung Cancer
962736|NCT02195219|conservative
962737|NCT02195219|treatment
962738|NCT02195219|surgical
962739|NCT02195219|Acromioclavicular
962740|NCT02195219|Joint
962741|NCT02195219|dislocation
962742|NCT02195206|Hyperpolarized gas magnetic resonance imaging
962743|NCT02195206|Hyperpolarized Xenon-129 magnetic resonance imaging
962744|NCT02195206|Lung Imaging
962745|NCT02195206|Healthy Adults
962746|NCT02195193|Health Services Research
962747|NCT02195193|Acute Coronary Syndromes
962748|NCT02195193|Depression
962749|NCT02195193|Integrated care
962750|NCT02195180|Pancreas
962751|NCT02195180|adenocarcinoma
962752|NCT02195180|cancer
962753|NCT02195180|asparaginase
962754|NCT02195180|erythrocytes
962755|NCT02195180|red blood cell
962756|NCT02195180|Encapsulation
962757|NCT02195180|folfox
962758|NCT02195180|gemcitabine
962759|NCT02195154|18F-DTBZ
962760|NCT02195141|Preoperative Chemoradiotherapy
962761|NCT02195141|Locally Advanced Rectal Cancer
962762|NCT02195141|boost
962763|NCT02195141|IMRT
962764|NCT02195102|transcatheter aortic valve Replacement
962765|NCT02195089|Treatment of Cervical Intraepithelial Neoplasia(CIN3)
962766|NCT02195076|Lung cancer
962767|NCT02195076|Breast Cancer
962768|NCT02195076|Biosensors
962769|NCT02195076|Volatile Organic Compounds
962770|NCT02195076|Odor
962771|NCT02195076|Urine Sample
962772|NCT02195076|Exhaled Breath Samples
962773|NCT02195063|Pain management
962774|NCT02195063|Scar care
962775|NCT02195063|Wound care
962776|NCT02195063|UDT
962777|NCT02195063|Urinary drug testing
962778|NCT02195037|Delayed Cord Clamping
962779|NCT02195024|pacemaker
962780|NCT02195024|magnetic resonance imaging
962781|NCT02195024|MRI conditional
962782|NCT02195024|pacemaker leads
962783|NCT02195011|Regorafenib
962784|NCT02195011|90Y
962785|NCT02195011|Radioembolization
962786|NCT02195011|SIR-Spheres Microspheres
962787|NCT02195011|Metastatic Colorectal Cancer
962788|NCT02195011|Liver Metastases
962789|NCT02195011|SIRT
962790|NCT02195011|Refractory
962791|NCT02194985|Fabry disease
962792|NCT02194985|Lysosomal storage disease
962793|NCT02194985|migalastat HCl
962794|NCT02194985|AT1001
962795|NCT02194972|constipation
962796|NCT02194972|colon transit time
962797|NCT02194972|gut microbiota
962798|NCT02194972|soluble dietary fiber
962799|NCT02194972|disturbance of gut microbiota in constipation
962800|NCT02194959|Patient Navigation
962801|NCT02194959|Screening Colonoscopy
962802|NCT02194959|Colorectal Cancer Screening
962803|NCT02194959|African Americans
962804|NCT02194946|Chronic Kidney Disease,
962805|NCT02194946|End-Stage Renal Disease,
962806|NCT02194946|Traditional Chinese Medicine,
962807|NCT02194946|dialysis initiation.
962808|NCT02194933|Schizophrenia
962809|NCT02194933|Mental Disorders, Antipsychotic,
962810|NCT02194933|Psychotic disorder, Impulsivity
962811|NCT02194907|Emotional Aging
962812|NCT02194907|Neurofeedback
962813|NCT02194894|Acetaminophen, Non-alcoholic Fatty Liver Disease (NAFLD)
962814|NCT02194881|Cystic fibrosis
962815|NCT02194881|CFTR
962816|NCT02194881|G551D mutation
962817|NCT02194881|Novel treatments
962818|NCT02194881|Potentiator
962819|NCT02194881|Ivacaftor
962820|NCT02194868|Allogeneic hematopoietic stem cell transplantation,
962821|NCT02194868|Immunoregulatory T lymphocytes,
962822|NCT02194868|acute graft versus host disease
962823|NCT02194855|rocuronium
962824|NCT02194855|cisatracurium
962825|NCT02194855|pharmacokinetic
962826|NCT02194842|metastatic
962827|NCT02194842|prostate cancer
962828|NCT02194816|Parkinson's Disease
962829|NCT02194816|PD
962830|NCT02194816|Complementary and Alternative
962831|NCT02194816|CAM
962832|NCT02194790|Chronic Kidney Disease
962833|NCT02194790|Diabetic Nephropathy
962834|NCT02194790|Integrated Chronic Kidney Disease Care
962835|NCT02194725|Stress and Coping Model
962836|NCT02194725|Coping
962837|NCT02194712|circulating anodic antigen
962838|NCT02194686|cilostazol
962839|NCT02194686|progenitor cells
962840|NCT02194686|cardiovascular disease
962841|NCT02194686|risk factors
962842|NCT02194686|angiogenesis
962843|NCT02194686|biological markers
962844|NCT02194686|endothelial function
962845|NCT02194660|Fractures Liaison Service
962846|NCT02194660|Osteoporosis
962847|NCT02194660|Fracture
962848|NCT02194660|Medication adherence
962849|NCT02194647|Osteoporosis
962850|NCT02194647|Medication Monitoring
962851|NCT02194647|Education
962852|NCT02194647|Adherence
962853|NCT02194647|Management
962854|NCT02194595|type 2 diabetes
962855|NCT02194595|beta-cell function
962856|NCT02194595|GLP-1
962857|NCT02194595|insulin
962858|NCT02194582|FSGS
962859|NCT02194582|NS
962860|NCT02194582|Kidney disease
962861|NCT02194582|Kidney failure
962862|NCT02194582|Renal disease
962863|NCT02194582|nephrotic syndrome
962864|NCT02194582|focal segmental glomerulosclerosis
962865|NCT02194582|familial kidney disease
962866|NCT02194582|minimal change disease
962867|NCT02194582|proteinuria
962868|NCT02194543|Cataract
962869|NCT02194543|HD 3D
962870|NCT02194543|Microscope
962871|NCT02194530|Peanut allergy
962872|NCT02194530|Allergic/atopic individuals
962873|NCT02194530|Non allergic individuals
962874|NCT02194530|Allergic individuals receiving xolair therapy
962875|NCT02194517|diabetes
962876|NCT02194517|diet control toolset
962877|NCT02194517|food exchanges
962878|NCT02194517|CHO
962879|NCT02194517|FP
962880|NCT02194504|Metabolic health
962881|NCT02194504|Phenotyping
962882|NCT02194504|Abdominal obesity
962883|NCT02194504|Abdominal adiposity
962884|NCT02194504|Liver fat
962885|NCT02194504|Belly fat
962886|NCT02194491|[11C]AS2471907
962887|NCT02194491|ASP3662
962888|NCT02194491|Positron Emission Tomography (PET)
962889|NCT02194491|Brain enzyme occupancy
962890|NCT02194478|Stress
962891|NCT02194478|Meditation
962892|NCT02194478|Mind body
962893|NCT02194439|Acute Graft Versus Host Disease
962894|NCT02194439|Affect
962895|NCT02194439|Anti-inflammatory
962896|NCT02194439|Anti-inflammatory Agents
962897|NCT02194439|Antigen-Presenting Cells
962898|NCT02194439|Alloantigen
962899|NCT02194439|Allogeneic
962900|NCT02194439|Allograft rejection
962901|NCT02194439|Allograft Tolerance
962902|NCT02194439|Antigens
962903|NCT02194439|Autoimmunity
962904|NCT02194439|Biomarkers
962905|NCT02194439|Biospecimen Repository
962906|NCT02194439|BMT
962907|NCT02194439|Bone Marrow Transplantation
962908|NCT02194439|Cell Transplantation
962909|NCT02194439|Cells
962910|NCT02194439|Clonal Expansion
962911|NCT02194439|Complex
962912|NCT02194439|Cytokine
962913|NCT02194439|Data
962914|NCT02194439|Development
962915|NCT02194439|Environment
962916|NCT02194439|Failure (biologic function)
962917|NCT02194439|Genomics
962918|NCT02194439|Graft-vs-Host Disease
962919|NCT02194439|Graft-vs-Leukemia
962920|NCT02194439|GVHD
962921|NCT02194439|GVL
962922|NCT02194439|Hematopoietic
962923|NCT02194439|Hematopoietic Stem Cell Transplantation
962924|NCT02194439|HCT
962925|NCT02194439|HSCT
962926|NCT02194439|IL-33 Receptor
962927|NCT02194439|Immune Reconstitution
962928|NCT02194439|Immune Response
962929|NCT02194439|Inflammatory
962930|NCT02194439|Modeling
962931|NCT02194439|Novel
962932|NCT02194439|Novel therapeutics
962933|NCT02194439|Outcome
962934|NCT02194439|Pathway interactions
962935|NCT02194439|Peptides
962936|NCT02194439|Prevent
962937|NCT02194439|Process
962938|NCT02194439|Production
962939|NCT02194439|Proteomics
962940|NCT02194439|Regulatory T-Lymphocyte
962941|NCT02194439|Response
962942|NCT02194439|Role
962943|NCT02194439|Signal
962944|NCT02194439|ST2
962945|NCT02194439|Transduction
962946|NCT02194439|T-cell response
962947|NCT02194439|T-cell Activation
962948|NCT02194439|T-Lymphocytes
962949|NCT02194439|Tissues
962950|NCT02194400|RSLV-132
962951|NCT02194400|Systemic Lupus Erythematosus
962952|NCT02194400|Lupus
962953|NCT02194400|SLE
962954|NCT02194400|Resolve
962955|NCT02194387|Breast Cancer
962956|NCT02194387|Ovarian Cancer
962957|NCT02194387|Triple negative breast cancer
962958|NCT02194387|TNBC
962959|NCT02194387|BRCA-positive survivor
962960|NCT02194387|High-grade serous ovarian cancer
962961|NCT02194387|HGSOC
962962|NCT02194387|Female biological relative of a BRCA positive TNBC or HGSOC survivor
962963|NCT02194387|Cancer survivors
962964|NCT02194387|Employees at MD Anderson
962965|NCT02194387|Multi-phase Optimization Strategy
962966|NCT02194387|MOST
962967|NCT02194387|Energy balance interventions
962968|NCT02194387|EB
962969|NCT02194387|Telephone Coaching
962970|NCT02194387|Text Messaging
962971|NCT02194387|Resistance Training
962972|NCT02194387|Daily Self-Monitoring
962973|NCT02194387|Weekly Self-Monitoring
962974|NCT02194387|Email Coaching
962975|NCT02194387|Questionnaires
962976|NCT02194387|Surveys
962977|NCT02194374|Leukemia
962978|NCT02194374|Chronic lymphocytic leukemia
962979|NCT02194374|CLL
962980|NCT02194374|Small lymphocytic lymphoma
962981|NCT02194374|SLL
962982|NCT02194374|B cell
962983|NCT02194374|ROR1-specific T cells
962984|NCT02194374|Fludarabine
962985|NCT02194374|Fludarabine Phosphate
962986|NCT02194374|Fludara
962987|NCT02194374|Cyclophosphamide
962988|NCT02194374|Cytoxan
962989|NCT02194374|Neosar
962990|NCT02194374|Rituximab
962991|NCT02194374|Rituxan
962992|NCT02194374|Bendamustine
962993|NCT02194374|Bendamustine Hydrochloride
962994|NCT02194374|Bendamustine HCL
962995|NCT02194374|CEP-18083
962996|NCT02194374|SDX-105
962997|NCT02194374|Treanda
962998|NCT02194231|Mesothelioma
962999|NCT02194231|MPM
963000|NCT02194231|Trabectedin
963001|NCT02194192|prevention of hypotension
963002|NCT02194192|spinal anesthesia
963003|NCT02194192|cesarean section
963004|NCT02194192|ephedrine
963005|NCT02194192|ondansetron
963006|NCT02194140|ultrasound
963007|NCT02194140|iodinated contrast material
963008|NCT02194140|computed tomography
963009|NCT02194114|Chronic Renal Failure
963010|NCT02194114|End-Stage Renal Disease
963011|NCT02194114|Nitrogen Balance
963012|NCT02194114|Dietary Protein Intake
963013|NCT02194101|oxygen delivery
963014|NCT02194101|proximal femoral fracture
963015|NCT02194101|goal-directed therapy
963016|NCT02194062|Chronic rhinosinusitis with polyps
963017|NCT02194062|Nasal steroids
963018|NCT02194062|Functional endoscopic sinus surgery
963019|NCT02194062|SNOT-22
963020|NCT02194062|Lund-Kennedy
963021|NCT02194036|Ownership of body
963022|NCT02194036|Bodily and mental balance
963023|NCT02194036|Learning
963024|NCT02194036|Body image
963025|NCT02194036|Sensations
963026|NCT02194036|Expectations
963027|NCT02194023|chlorhexidine digluconate
963028|NCT02194023|gingivitis
963029|NCT02194023|cetylpyridinium chloride
963030|NCT02194023|mouthrinse
963031|NCT02194023|dental plaque
963032|NCT02194023|de novo
963033|NCT02194023|in vivo
963034|NCT02194010|Outcome Measure
963035|NCT02194010|Patient Reported Questionnaires
963036|NCT02193984|Diabetes
963037|NCT02193984|Peer support
963038|NCT02193984|Hispanic
963039|NCT02193984|Latino
963040|NCT02193971|Acute coronary syndrome
963041|NCT02193971|Drug eluting stent
963042|NCT02193971|Everolimus
963043|NCT02193971|Prasugrel
963044|NCT02193958|Acute Myeloid Leukemia
963045|NCT02193958|Chronic Myelomonocytic Leukemia
963046|NCT02193958|Myelodysplastic Syndrome
963047|NCT02193932|EEG triggered
963048|NCT02193932|fMRI
963049|NCT02193932|epilepsy
963050|NCT02193932|intractable
963051|NCT02193919|psoriasis
963052|NCT02193906|Cognitive training
963053|NCT02193906|Multiple sclerosis
963054|NCT02193906|Cognitive deficits
963055|NCT02193893|cell-based therapy
963056|NCT02193893|autologous bone marrow-derived stem/progenitor cells
963057|NCT02193893|stem cell infusion, stem cell transplantation
963058|NCT02193893|biological therapy with neurotrophic factors
963059|NCT02193893|bioactive neurotrophic factors
963060|NCT02193867|LIPA
963061|NCT02193867|Wolman Disease
963062|NCT02193867|Wolman Phenotype
963063|NCT02193867|Acid Lipase Deficiency
963064|NCT02193867|Acid Cholesteryl Hydrolase
963065|NCT02193867|Acid Lipase Disease Deficiency, type 2
963066|NCT02193867|Cholesteryl Ester Storage Disease (CESD)
963067|NCT02193867|Cholesteryl Ester Hydrolase Deficiency
963068|NCT02193867|Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
963069|NCT02193867|LAL Deficiency
963070|NCT02193867|Late Onset Lysosomal Acid Lipase Deficiency (CESD)
963071|NCT02193867|Wolman Disease (early onset LAL Deficiency)
963072|NCT02193867|Related Disorders:
963073|NCT02193867|Non-alcoholic Fatty Liver Disease (NAFLD)
963074|NCT02193867|Non-alcoholic Steatohepatitis (NASH)
963075|NCT02193867|Alcoholic Liver Disease
963076|NCT02193867|Cryptogenic Cirrhosis
963077|NCT02193867|Niemann-Pick Disease (NPD) Type C
963078|NCT02193867|Chanarin Dorfman Syndrome
963079|NCT02193854|Telemedicine
963080|NCT02193854|Mobile phone
963081|NCT02193854|Rural physicians
963082|NCT02193854|Mongolia
963083|NCT02193841|Simple bone cyst
963084|NCT02193841|Unicameral bone cyst
963085|NCT02193828|Dupuytren's nodules
963086|NCT02193815|psoriasis
963087|NCT02193815|plaque
963088|NCT02193815|vulgaris
963089|NCT02193815|phase 1
963090|NCT02193815|randomized
963091|NCT02193815|double-blind
963092|NCT02193815|topical
963093|NCT02193815|safety
963094|NCT02193802|Crohn's disease
963095|NCT02193802|small bowel (SB)
963096|NCT02193802|capsule endoscopy
963097|NCT02193802|ileocolonoscopy
963098|NCT02193802|anti-TNF-alpha antibodies
963099|NCT02193789|Anastomosis site structure
963100|NCT02193789|Stent insertion
963101|NCT02193789|Stent migration
963102|NCT02193776|Tuberculosis
963103|NCT02193776|Multi Drug-Resistant Tuberculosis
963104|NCT02193776|Drug-Sensitive Tuberculosis
963105|NCT02193776|Pa-824
963106|NCT02193776|Bedaquiline
963107|NCT02193776|Moxifloxacin
963108|NCT02193776|Pyrazinamide
963109|NCT02193776|Nitroimidazole
963110|NCT02193776|Quinolone
963111|NCT02193776|Pretomanid
963112|NCT02193776|NC-005
963113|NCT02193763|pediatric
963114|NCT02193763|lumbar puncture
963115|NCT02193763|ultrasonography
963116|NCT02193763|efficacy
963117|NCT02193750|Crohn's Disease
963118|NCT02193724|Heritable Retinoblastoma
963119|NCT02193724|Familial Retinoblastoma
963120|NCT02193724|Pluripotent Stem Cells
963121|NCT02193698|POEMS syndrome
963122|NCT02193698|lenalidomide
963123|NCT02193685|(HAEC) Hirschsprung Associated Entrocolistis
963124|NCT02193685|(HD) Hirschsprung Disease
963125|NCT02193685|(IBD) Inflammatory Bowel Disease
963126|NCT02193685|Children
963127|NCT02193672|Advanced cancers
963128|NCT02193672|PET/CT
963129|NCT02193672|Positron emission tomography / computed tomography
963130|NCT02193672|[18F]Fluciclatide
963131|NCT02193672|Chemotherapy
963132|NCT02193672|Phone calls
963133|NCT02193659|breakfast cereal
963134|NCT02193659|omega-3
963135|NCT02193659|cholesterol
963136|NCT02193659|lipidic profile
963137|NCT02193659|consumption
963138|NCT02193659|acceptability
963139|NCT02193646|Colonoscopy
963140|NCT02193646|Adenoma
963141|NCT02193646|ADR
963142|NCT02193646|Screening Colon Cancer
963143|NCT02193620|Analgesic
963144|NCT02193620|Narcotics
963145|NCT02193620|Opioids
963146|NCT02193620|Pain relief after surgery
963147|NCT02193607|Occult stress incontinence
963148|NCT02193607|Pelvic Organ Prolapse
963149|NCT02193607|Surgical Intervention
963150|NCT02193607|TVT-O(Tension-free vaginal tape-obturator)
963151|NCT02193607|Improved Reconstructive Pelvic Surgery
963152|NCT02193607|Combined Surgery
963153|NCT02193607|Two-step Approach
963154|NCT02193607|Prophylactic Incontinence Procedure
963155|NCT02193607|Randomized Controlled Trial
963156|NCT02193594|Preoperative concurrent chemoradiotherapy
963157|NCT02193594|Neoadjuvant chemoradiotherapy
963158|NCT02193594|Gastroesophageal junction adenocarcinoma
963159|NCT02193568|Supratentorial Glioma
963160|NCT02193568|Craniotomy
963161|NCT02193555|Presbyopia
963162|NCT02193555|Refractive error correction
963163|NCT02193555|Contact lenses
963164|NCT02193542|regional anesthesia
963165|NCT02193542|general anesthesia
963166|NCT02193542|obstetric
963167|NCT02193529|sleeve gastrectomy, dietary intake, morbid obesity.
963168|NCT02193503|cancer
963169|NCT02193503|solid tumors
963170|NCT02193503|gene therapy
963171|NCT02193503|cell therapy
963172|NCT02193503|encapsulation
963173|NCT02193490|DNase, Pulmozyme, dry eye disease, treatment
963174|NCT02193464|inflammatory bowel disease, registry, incidence, Korea
963175|NCT02193451|Lower urinary tract symptoms
963176|NCT02193451|Male LUTS
963177|NCT02193451|Voiding dysfunction
963178|NCT02193451|Benign prostate obstruction
963179|NCT02193451|Detrusor underactivity
963180|NCT02193438|Heart rate variability
963181|NCT02193438|Resting energy expenditure
963182|NCT02193438|Facial thermography
963183|NCT02193438|Blood pressure
963184|NCT02193438|Spices ingestion
963185|NCT02193425|Brain
963186|NCT02193425|Connectivity
963187|NCT02193425|PET
963188|NCT02193425|fcMRI
963189|NCT02193425|18FDG
963190|NCT02193412|analgesia nociception index
963191|NCT02193412|heart rate variability
963192|NCT02193412|autonomic nervous system
963193|NCT02193412|specificity
963194|NCT02193412|systemic venous return
963195|NCT02193412|pulse pressure variation
963196|NCT02193412|Intraoperative Monitoring
963197|NCT02193399|Stem cell transplantation
963198|NCT02193399|Fatigue
963199|NCT02193399|Physiotherapy
963200|NCT02193399|Quality of Life
963201|NCT02193399|Cancer
963202|NCT02193399|Psychosocial aspects
963203|NCT02193386|Cerebral Palsy
963204|NCT02193386|Physical Therapy
963205|NCT02193386|gait analysis
963206|NCT02193386|gross motor function
963207|NCT02193373|Osteopathic Manipulative Medicine
963208|NCT02193373|Autonomic Nervous System
963209|NCT02193373|Heart Rate Variability
963210|NCT02193373|Sub-Occipital Release
963211|NCT02193373|Rib-Raising
963212|NCT02193373|Stellate Ganglion Release
963213|NCT02193360|Inflammation
963214|NCT02193360|PBC
963215|NCT02193347|Immunotherapy
963216|NCT02193347|Adult
963217|NCT02193334|Hepatocyte Growth Factor
963218|NCT02193334|HGF
963219|NCT02193334|KP-100IT
963220|NCT02193334|Intrathecal injection
963221|NCT02193321|Atrial Fibrillation
963222|NCT02193321|Amniotic Membrane
963223|NCT02193295|Weight Reduction
963224|NCT02193295|Caloric Restriction
963225|NCT02193295|Euglycemic Hyperinsulinemic Clamp
963226|NCT02193295|Magnetic Resonance Spectroscopy
963227|NCT02193269|Abstinent cocaine users
963228|NCT02193269|minocycline
963229|NCT02193269|antibiotic
963230|NCT02193256|varenicline
963231|NCT02193256|prazosin
963232|NCT02193256|cigarette smoking
963233|NCT02193256|alcohol drinking
963234|NCT02193256|sleep
963235|NCT02193256|dreams
963236|NCT02193243|Congenital Heart Disease
963237|NCT02193243|Six Minute Walk Test
963238|NCT02193243|Exercise Testing
963239|NCT02193243|Peak oxygen uptake
963240|NCT02193230|Atopic dermatitis, Feasibility, Adherence to treatment
963241|NCT02193204|Alcohol dependence
963242|NCT02193204|Stress
963243|NCT02193204|Cytokines
963244|NCT02193204|Depressive Symptomatology
963245|NCT02193191|Plerixafor
963246|NCT02193191|13-229
963247|NCT02193152|Advanced Non-Small Cell Lung Cancer
963248|NCT02193152|NSCLC
963249|NCT02193152|Pazopanib
963250|NCT02193126|Long term foster care
963251|NCT02193126|child abuse and neglect
963252|NCT02193126|trauma
963253|NCT02193113|Diabetic Macular Edema
963254|NCT02193113|DME
963255|NCT02193113|Plasma Kallikrein inhibitor
963256|NCT02193113|KVD001
963257|NCT02193113|KVD001-001
963258|NCT02193113|Intravitreal
963259|NCT02193113|IVT
963260|NCT02193113|Diabetes mellitus
963261|NCT02193087|Drug therapy
963262|NCT02193074|Spinal Muscular Atrophy
963263|NCT02193074|SMA
963264|NCT02193074|SMN
963265|NCT02193074|SMNRx
963266|NCT02193074|ISIS-SMNRx
963267|NCT02193074|ISIS-SMN Rx
963268|NCT02193074|ISIS 396443
963269|NCT02193074|IONIS-SMNRx
963270|NCT02193074|IONIS-SMN Rx
963271|NCT02193074|Spinraza
963272|NCT02193074|ENDEAR
963273|NCT02193061|Rotavirus
963274|NCT02193061|immunological behavior
963275|NCT02193061|Rotarix
963276|NCT02193061|RotaTeq
963277|NCT02193061|vaccine interchangeability
963278|NCT02193035|Microparticles
963279|NCT02193035|Severe aortic stenosis
963280|NCT02193035|Calcified aortic stenosis
963281|NCT02193035|transcatheter aortic valve replacement
963282|NCT02193022|Bangladesh, PKDL, Visceral Leishmaniasis, Children, Miltefosine
963283|NCT02192996|VLBW preterm
963284|NCT02192996|GUT microbiota
963285|NCT02192996|probiotics supplementation
963286|NCT02192996|immune compounds
963287|NCT02192970|Retinal detachment
963288|NCT02192970|Proliferative vitreoretinopathy
963289|NCT02192957|cardioversion
963290|NCT02192957|electrical cardioversion
963291|NCT02192957|atrial fibrillation
963292|NCT02192957|cardioversion protocol
963293|NCT02192944|ECG
963294|NCT02192944|Pharmacokinetic profile
963295|NCT02192892|Young children
963296|NCT02192892|Acceptability
963297|NCT02192892|Food intake
963298|NCT02192892|Energy dense porridge
963299|NCT02192879|thoracic epidural
963300|NCT02192879|continuous paravertebral catheter
963301|NCT02192879|PCA
963302|NCT02192879|liver resection
963303|NCT02192879|pain management
963304|NCT02192853|Diabetes Mellitus
963305|NCT02192853|Glucagon-like peptide 1
963306|NCT02192853|Dipeptidyl peptidase 4
963307|NCT02192853|Dipeptidyl peptidase 4 inhibitor
963308|NCT02192853|sitagliptin
963309|NCT02192853|Enzyme activity
963310|NCT02192840|provisional T stenting
963311|NCT02192840|dedicated bifurcation stent
963312|NCT02192827|Pediatric
963313|NCT02192827|Asthma
963314|NCT02192827|Exacerbation
963315|NCT02192827|Dexamethasone
963316|NCT02192827|Peak flow
963317|NCT02192814|Lacosamide
963318|NCT02192814|LCM
963319|NCT02192814|Epilepsy
963320|NCT02192814|Partial-onset seizures
963321|NCT02192814|iv
963322|NCT02192801|Classic Bladder Exstrophy
963323|NCT02192801|Renal function
963324|NCT02192801|GFR
963325|NCT02192801|Proteinuria
963326|NCT02192788|SBRT
963327|NCT02192788|Oligometastases
963328|NCT02192788|Prostate Cancer
963329|NCT02192775|Measles virus
963330|NCT02192775|Sodium Iodide Symporter
963331|NCT02192775|Cyclophosphamide
963332|NCT02192775|Refractory multiple myeloma
963333|NCT02192749|autism
963334|NCT02192749|umbilical cord
963335|NCT02192749|mesenchymal
963336|NCT02192749|stem cells
963337|NCT02192736|asthma
963338|NCT02192736|umbilical cord
963339|NCT02192736|mesenchymal
963340|NCT02192736|stem cells
963341|NCT02192736|trophic factors
963342|NCT02192710|outpatient surgery
963343|NCT02192710|anaesthesia
963344|NCT02192710|midazolam
963345|NCT02192710|electronic tab
963346|NCT02192697|safety
963347|NCT02192697|pharmacokinetics
963348|NCT02192697|tolerability
963349|NCT02192697|ASP8273
963350|NCT02192697|Non-small Cell Lung Cancer
963351|NCT02192697|T790M resistance mutation
963352|NCT02192697|NSCLC
963353|NCT02192697|Epidermal Growth Factor Receptor mutations
963354|NCT02192697|irreversible EGFR inhibitor
963355|NCT02192697|antitumor activity
963356|NCT02192697|EGFR
963357|NCT02192684|obstructive sleep apnea
963358|NCT02192684|insulin sensitivity
963359|NCT02192684|cardiovascular risk
963360|NCT02192684|positive airway pressure therapy
963361|NCT02192671|hepatocellular carcinoma
963362|NCT02192671|radiofrequency ablation
963363|NCT02192671|hepatic resection
963364|NCT02192671|portal hypertension
963365|NCT02192671|Milan criteria
963366|NCT02192671|randomized critical trial
963367|NCT02192619|APL
963368|NCT02192619|acute promyelocytic leukemia
963369|NCT02192619|AML M3
963370|NCT02192606|Laparoscopy
963371|NCT02192606|3D Visual System
963372|NCT02192606|Total Hysterectomy
963373|NCT02192567|Advanced solid malignant tumor
963374|NCT02192567|phase 1
963375|NCT02192567|oncology
963376|NCT02192554|OPC-34712
963377|NCT02192554|brexpiprazole
963378|NCT02192554|Dementia
963379|NCT02192554|Alzheimer's Disease
963380|NCT02192554|Cognitive Disorders
963381|NCT02192554|Memory
963382|NCT02192554|Agitation
963383|NCT02192541|Urothelial Carcinomas
963384|NCT02192541|Non-Squamous Non-Small Cell Lung Carcinomas
963385|NCT02192541|Refractory Gastrointestinal Carcinomas
963386|NCT02192541|Hsp90 Inhibitor
963387|NCT02192541|Sarcomas
963388|NCT02192528|vitamin D
963389|NCT02192528|25-hydroxyvitamin D
963390|NCT02192528|1,25-dihydroxyvitamin D
963391|NCT02192528|MACCE
963392|NCT02192528|mortality
963393|NCT02192528|cardiac
963394|NCT02192528|cerebrovascular
963395|NCT02192515|Healthy Subjects
963396|NCT02192515|Japanese Adult
963397|NCT02192489|Chronic Cutaneous Sarcoidosis
963398|NCT02192489|Cutaneous Sarcoidosis
963399|NCT02192489|Skin Sarcoidosis
963400|NCT02192489|Sarcoidosis
963401|NCT02192476|Stroke, subluxation
963402|NCT02192450|Diabetes Mellitus
963403|NCT02192450|Hypoglycaemia
963404|NCT02192450|Glucose Metabolism Disorders
963405|NCT02192450|Metabolic Diseases
963406|NCT02192450|Endocrine System Diseases
963407|NCT02192450|Autoimmune Diseases
963408|NCT02192450|Insulin
963409|NCT02192450|Hypoglycaemic Agents
963410|NCT02192450|Physiological Effetcs of Drugs
963411|NCT02192437|methionine
963412|NCT02192437|cysteine
963413|NCT02192437|sulfur amino acid restriction
963414|NCT02192424|beta-cell function,
963415|NCT02192424|type 2 diabetes,
963416|NCT02192424|intermittent insulin
963417|NCT02192411|lidocaine
963418|NCT02192411|tumescent
963419|NCT02192411|endovenous
963420|NCT02192411|laser
963421|NCT02192411|pain
963422|NCT02192398|Pain
963423|NCT02192398|Pain management
963424|NCT02192398|Neck
963425|NCT02192398|Back
963426|NCT02192372|creatinine
963427|NCT02192372|glomerular filtration rate
963428|NCT02192372|metabolic syndrome
963429|NCT02192346|metastatic
963430|NCT02192346|refractory
963431|NCT02192346|progressive
963432|NCT02192320|Atorvastatin
963433|NCT02192320|Atorvastatin and Dexamethasone
963434|NCT02192320|Chronic Subdural Hematoma
963435|NCT02192320|conservative treatment
963436|NCT02192307|Sensitivity
963437|NCT02192294|Bosutinib
963438|NCT02192294|absolute bioavailability
963439|NCT02192281|Physical activity
963440|NCT02192281|Recess
963441|NCT02192281|Accelerometer
963442|NCT02192281|Play
963443|NCT02192255|diabetes type 2
963444|NCT02192255|primary care
963445|NCT02192255|chronic disease care improvement
963446|NCT02192255|adherence, randomized trial
963447|NCT02192255|BP control
963448|NCT02192255|lipid control
963449|NCT02192255|glucose control
963450|NCT02192255|natural language processing.
963451|NCT02192242|acute ischemic pain
963452|NCT02192242|model
963453|NCT02192242|S100
963454|NCT02192242|interleukine 6
963455|NCT02192216|Body composition
963456|NCT02192216|Chemotherapy
963457|NCT02192216|Muscle mass
963458|NCT02192216|Muscle function
963459|NCT02192216|Exercise
963460|NCT02192177|Apoptosis
963461|NCT02192177|intrahepatic cholestasis
963462|NCT02192177|obstetric outcomes
963463|NCT02192164|plaque psoriasis
963464|NCT02192164|smoking
963465|NCT02192164|etanercept
963466|NCT02192151|Analgesic
963467|NCT02192151|Narcotics
963468|NCT02192151|Opioids
963469|NCT02192151|Non-scheduled substanse
963470|NCT02192138|Pleural effusion
963471|NCT02192138|Pleural fluid
963472|NCT02192138|Thoracentesis
963473|NCT02192138|Intrapleural pressure
963474|NCT02192138|Pleural manometry
963475|NCT02192125|stroke
963476|NCT02192125|rehabilitation
963477|NCT02192125|balance
963478|NCT02192125|training
963479|NCT02192125|posture
963480|NCT02192086|Kidney transplantation
963481|NCT02192060|Biofilm
963482|NCT02192060|Triclosan
963483|NCT02192060|Crossover
963484|NCT02192060|Clinical trial
963485|NCT02192034|Colonoscopy
963486|NCT02192034|Colon cancer
963487|NCT02192034|screening
963488|NCT02192034|navigation
963489|NCT02192021|CTCL
963490|NCT02192021|Cutaneous T-cell Lymphoma
963491|NCT02192021|Mycosis Fungoides
963492|NCT02192008|Challenge
963493|NCT02192008|Re-challenge
963494|NCT02192008|Controlled Infection
963495|NCT02192008|Enteric fever
963496|NCT02191982|Cancer
963497|NCT02191982|Chemotherapy
963498|NCT02191982|Fatigue
963499|NCT02191982|Elderly
963500|NCT02191982|Geriatric
963501|NCT02191982|Any Cancer
963502|NCT02191982|Cancer Treatment
963503|NCT02191982|Weakness
963504|NCT02191982|Tiredness
963505|NCT02191969|Chemotherapy
963506|NCT02191969|Adjuvant Chemotherapy
963507|NCT02191969|Cancer Therapy
963508|NCT02191969|Fatigue
963509|NCT02191969|Physical Activity
963510|NCT02191969|Physical Function
963511|NCT02191969|Tiredness
963512|NCT02191969|Colon Cancer
963513|NCT02191969|Rectal Cancer
963514|NCT02191969|Walk With Ease
963515|NCT02191969|Colorectal Cancer
963516|NCT02191969|Geriatric Assessment
963517|NCT02191969|Geriatric
963518|NCT02191969|Elderly
963519|NCT02191956|Disruptive behavior disorders
963520|NCT02191956|Early Onset
963521|NCT02191956|Young Children
963522|NCT02191956|Parenting
963523|NCT02191956|Behavioral Parent Training
963524|NCT02191943|caries
963525|NCT02191943|proximal
963526|NCT02191943|non-cavitated
963527|NCT02191943|fluoridation
963528|NCT02191878|Liver Cancer
963529|NCT02191878|Liver Neoplasms
963530|NCT02191878|Liver Epithelial Neoplasms
963531|NCT02191878|Liver Cancer, malignant
963532|NCT02191839|cardiac surgery
963533|NCT02191839|alpha 1 antitrypsin
963534|NCT02191839|inflammation
963535|NCT02191839|post operative bleeding
963536|NCT02191839|organ function
963537|NCT02191826|Transthyretin
963538|NCT02191826|TTR
963539|NCT02191826|Amyloidosis
963540|NCT02191826|SOM0226
963541|NCT02191826|Familiar Amyloid Polyneuropathy
963542|NCT02190747|Intervention study
963543|NCT02190747|Clinical trial Phase 2
963544|NCT02190747|Efficacy and safety
963545|NCT02190747|Heterotopic ossification
963546|NCT02190747|Flare-up
963547|NCT02190747|Palovarotene
963548|NCT02190747|Retinoic acid receptor agonist
963549|NCT02190747|Retinoic acid receptor gamma agonist
963550|NCT02190747|Clementia
963551|NCT02190747|Myositis Ossificans Progressiva
963552|NCT02190747|Munchmeyer's Disease
963553|NCT02190747|FOP
963554|NCT02190734|Stroke
963555|NCT02190734|Pusher Syndrome
963556|NCT02190734|Lateropulsion
963557|NCT02190734|Pushing Behaviors
963558|NCT02190734|Burke Lateropulsion Scale
963559|NCT02190721|Neutropenia
963560|NCT02190708|PQ912
963561|NCT02190708|Midazolam
963562|NCT02190708|Omeprazole
963563|NCT02190708|Pharmacokinetics
963564|NCT02190708|Drug Interaction
963565|NCT02191774|Medical abortion
963566|NCT02191774|Home abortion
963567|NCT02191683|Anaemia
963568|NCT02191683|Pregnancy
963569|NCT02191683|Foetal programming
963570|NCT02191683|Epigenetics
963571|NCT02191683|Non-communicable diseases
963572|NCT02191683|Tanzania
963573|NCT02191657|HIV
963574|NCT02191657|deferiprone
963575|NCT02191657|iron chelation
963576|NCT02191631|OCD
963577|NCT02191631|adolescents
963578|NCT02191631|pediatric
963579|NCT02191631|internet
963580|NCT02191631|online
963581|NCT02191631|CBT
963582|NCT02191618|Aneurysm
963583|NCT02191618|Intracranial Aneurysm
963584|NCT02191618|Vascular Diseases
963585|NCT02191618|Cardiovascular Diseases
963586|NCT02191618|Intracranial Arterial Diseases
963587|NCT02191618|Cerebrovascular Disorders
963588|NCT02191618|Brain Diseases
963589|NCT02191618|Central Nervous System Diseases
963590|NCT02191618|Nervous System Diseases
963591|NCT02191605|Computerized Brief Intervention
963592|NCT02191592|Tinnitus
963593|NCT02191592|EMA
963594|NCT02191592|Bothersome
963595|NCT02191566|Stomach Cancer
963596|NCT02191553|mindfulness meditation
963597|NCT02191553|alpha rhythm
963598|NCT02191553|EEG
963599|NCT02191553|brain mapping
963600|NCT02191553|emotion
963601|NCT02191553|attention
963602|NCT02191527|PMTCT
963603|NCT02191527|HIV
963604|NCT02191527|Syphilis
963605|NCT02191527|Anemia during pregnancy
963606|NCT02191527|Point of care diagnostics
963607|NCT02191514|Prehospital
963608|NCT02191514|EMS
963609|NCT02191514|EMD
963610|NCT02191514|Stroke
963611|NCT02191514|Dispatch
963612|NCT02191501|Obesity Treatment
963613|NCT02191501|Endoscopy
963614|NCT02191501|Pyloric Suturing
963615|NCT02191501|Pyloric restriction
963616|NCT02191488|Fluorescence
963617|NCT02191488|Brain Tumors
963618|NCT02191488|Brain Metastases
963619|NCT02191488|Malignant Glioma
963620|NCT02191488|Brain Lesions
963621|NCT02191475|sepsis shock
963622|NCT02191475|Tigecycline
963623|NCT02191475|Piperacillin / tazobactam
963624|NCT02191475|Abdominal infection
963625|NCT02191462|Pharmacokinetics
963626|NCT02191462|Niagen
963627|NCT02191462|Nicotinamide riboside
963628|NCT02191436|Haemophilia
963629|NCT02191436|Adherence
963630|NCT02191436|Family Functioning
963631|NCT02191436|Quality of Life
963632|NCT02191436|Anxiety
963633|NCT02191436|Illness Behavior
963634|NCT02191436|Coping Strategies
963635|NCT02191423|postpartum Depression
963636|NCT02191423|Diadic psychotherapy
963637|NCT02191423|Oxytocin
963638|NCT02191423|fMRI
963639|NCT02191423|attachment
963640|NCT02191423|empathy
963641|NCT02191410|Video-assisted thoracoscopic surgery
963642|NCT02191410|one-lung ventilation
963643|NCT02191410|continuous positive-airway ventilation
963644|NCT02191410|high-frequency positive-pressure ventilation
963645|NCT02191410|stroke volume variation
963646|NCT02191410|fluid responsiveness
963647|NCT02191397|Escitalopram
963648|NCT02191397|Major depressive disorder
963649|NCT02191397|Non-inferiority
963650|NCT02191397|Bupropion
963651|NCT02191371|oxygenation
963652|NCT02191371|microcirculation
963653|NCT02191371|one-lung ventilation
963654|NCT02191371|thoracic surgery
963655|NCT02191358|Cytochrome drug interactions
963656|NCT02191358|Drug-drug interaction
963657|NCT02191358|Drug-gene interaction
963658|NCT02191358|Drug-drug-gene interaction
963659|NCT02191358|Drug Metabolism
963660|NCT02191358|Elderly
963661|NCT02191358|Geriatric medicine
963662|NCT02191358|Geriatrics
963663|NCT02191358|Personalized medicine
963664|NCT02191358|Pharmacist
963665|NCT02191358|Pharmacogenetics
963666|NCT02191358|Pharmacogenomics
963667|NCT02191358|Pharmacokinetics
963668|NCT02191358|Polymorphism
963669|NCT02191358|Polypharmacy
963670|NCT02191358|Precision medicine
963671|NCT02191358|Seniors
963672|NCT02191358|YouScript
963673|NCT02191358|CYP2C9
963674|NCT02191358|CYP2C19
963675|NCT02191358|CYP2D6
963676|NCT02191358|CYP3A4
963677|NCT02191358|CYP3A5
963678|NCT02191358|VKORC1
963679|NCT02191358|Amitriptyline
963680|NCT02191358|Aripiprazole
963681|NCT02191358|Atomoxetine
963682|NCT02191358|Carvedilol
963683|NCT02191358|Celecoxib
963684|NCT02191358|Citalopram
963685|NCT02191358|Clobazam
963686|NCT02191358|Clomipramine
963687|NCT02191358|Clopidogrel
963688|NCT02191358|Clozapine
963689|NCT02191358|Codeine
963690|NCT02191358|Desipramine
963691|NCT02191358|Dextromethorphan
963692|NCT02191358|Diazepam
963693|NCT02191358|Doxepin
963694|NCT02191358|Escitalopram
963695|NCT02191358|Esomeprazole
963696|NCT02191358|Fesoterodine
963697|NCT02191358|Flecainide
963698|NCT02191358|Fluoxetine
963699|NCT02191358|Flurbiprofen
963700|NCT02191358|Fluvoxamine
963701|NCT02191358|Haloperidol
963702|NCT02191358|Hydrocodone
963703|NCT02191358|Ibuprofen
963704|NCT02191358|Iloperidone
963705|NCT02191358|Imipramine
963706|NCT02191358|Indomethacin
963707|NCT02191358|Meloxicam
963708|NCT02191358|Metoprolol
963709|NCT02191358|Mexiletine
963710|NCT02191358|Nortriptyline
963711|NCT02191358|Omeprazole
963712|NCT02191358|Oxycodone
963713|NCT02191358|Paroxetine
963714|NCT02191358|Perphenazine
963715|NCT02191358|Phenobarbital
963716|NCT02191358|Phenytoin
963717|NCT02191358|Pimozide
963718|NCT02191358|Piroxicam
963719|NCT02191358|Proguanil
963720|NCT02191358|Propafenone
963721|NCT02191358|Propranolol
963722|NCT02191358|Risperidone
963723|NCT02191358|Sertraline
963724|NCT02191358|Tetrabenazine
963725|NCT02191358|Thioridazine
963726|NCT02191358|Timolol
963727|NCT02191358|Tolterodine
963728|NCT02191358|Torsemide
963729|NCT02191358|Tramadol
963730|NCT02191358|Trimipramine
963731|NCT02191358|Venlafaxine
963732|NCT02191358|Voriconazole
963733|NCT02191358|Vortioxetine
963734|NCT02191345|guided imagery
963735|NCT02191345|burnout
963736|NCT02191345|compassion fatigue
963737|NCT02191345|state anxiety
963738|NCT02191267|CTE
963739|NCT02191267|Positron Emission Topography
963740|NCT02191267|Tau
963741|NCT02191267|Beta-amyloid
963742|NCT02191267|Magnetic Resonance Imaging
963743|NCT02191267|Magnetic Resonance Spectroscopy
963744|NCT02191267|Diffusion Tensor Imaging
963745|NCT02191150|Anaemia, Chronic Kidney Disease, Switching, Aranesp, Darbepoetin Alfa, Epoetin Alfa Biosimilars, Haemodialysis.
963870|NCT02190448|galactogogue
963871|NCT02190448|lactation
963746|NCT02191137|Pulmonary Hypertension,Riociguat,Living with Pulmonary Hypertension Questionnaire
963747|NCT02191124|Measurement-based care
963748|NCT02191124|Unipolar depression
963749|NCT02191124|Outpatients
963750|NCT02191111|Pharmacist
963751|NCT02191111|Pharmacy practice
963752|NCT02191111|Patient care
963753|NCT02191111|Community pharmacy
963754|NCT02191111|Hypertension
963755|NCT02191111|Diabetes
963756|NCT02191111|Dyslipidemia
963757|NCT02191111|Pharmaceutical care
963758|NCT02191098|HIV
963759|NCT02191098|ART
963760|NCT02191072|urticaria,omalizumab
963761|NCT02191059|Non Small Cell Lung Cancer
963762|NCT02191059|Wild Type EGFR
963763|NCT02191059|Icotinib
963764|NCT02191059|Second-line Treatment
963765|NCT02191046|nasal irrigation
963766|NCT02191046|sinusitis
963767|NCT02191046|children
963768|NCT02191046|buffered hypertonic saline
963769|NCT02191046|nasal irrigation device
963770|NCT02191033|cigarette smoking
963771|NCT02191033|tobacco use cessation products
963772|NCT02191020|Total Glucosides of Paeony(TGP)
963773|NCT02191020|Acitretin Capsules
963774|NCT02191020|Psoriasis Vulgaris
963775|NCT02190994|Hydrocortisone
963776|NCT02190994|Pituitary adenomas
963777|NCT02190994|Replacement therapy
963778|NCT02190981|Small bowel obstruction
963779|NCT02190981|Ultrasound
963780|NCT02190981|Emergency department
963781|NCT02190968|Mindfulness Based Cognitive Therapy
963782|NCT02190968|Internet interventions
963783|NCT02190968|Residual depressive symptoms
963784|NCT02190968|Depressive relapse prevention
963785|NCT02190903|delirium
963786|NCT02190903|hip fracture
963787|NCT02190903|general anesthesia
963788|NCT02190903|spinal anesthesia
963789|NCT02190903|postoperative complications
963790|NCT02190877|Heart Failure
963791|NCT02190877|Impedance
963792|NCT02190877|Fluids
963793|NCT02190851|urinary disorders
963794|NCT02190851|Parkinson's disease
963795|NCT02190838|Melanoma
963796|NCT02190838|Melatonin
963797|NCT02190838|Metformin
963798|NCT02190838|Dacarbazine
963799|NCT02190812|wrist muscle strength
963800|NCT02190799|Corona Virus
963801|NCT02190799|Convalescent plasma
963802|NCT02190799|Serology
963803|NCT02190786|Hyperuricemia
963804|NCT02190773|Chronic Periodontitis, Aggressive Periodontitis, RANKL/OPG ratio, Gingival crevicular fluid
963805|NCT02190682|postoperative
963806|NCT02190682|chronic
963807|NCT02190682|pain
963808|NCT02190682|software
963809|NCT02190656|Rectal cancer
963810|NCT02190656|Anterior Resection Syndrome
963811|NCT02190656|Functional outcomes
963812|NCT02190643|Smoking
963813|NCT02190643|HIV
963814|NCT02190643|Latino
963815|NCT02190643|Cessation
963816|NCT02190643|Nicotine patch
963817|NCT02190617|Asthma
963818|NCT02190617|Guidelines
963819|NCT02190617|Community Health Worker
963820|NCT02190604|FEV1- Forced Expiratory volume
963821|NCT02190604|LCI - Lung Clearance Index
963822|NCT02190604|CFTR - cystic fibrosis transmembrane conductance regulator
963823|NCT02190591|epidural
963824|NCT02190591|pregnant
963825|NCT02190591|Cesarean Section
963826|NCT02190591|forceps
963827|NCT02190591|vaginal
963828|NCT02190565|pregnancy, lactation, food supplement, anaemia
963829|NCT02190552|Brain
963830|NCT02190552|Brain Clot
963831|NCT02190552|Brain Diseases
963832|NCT02190552|Brain Infarction
963833|NCT02190552|Cerebral Ischemia
963834|NCT02190552|Cerebrovascular Disorders
963835|NCT02190552|EmboTrap® Revascularization Device
963836|NCT02190552|EmboTrap
963837|NCT02190552|Ischemia
963838|NCT02190552|Ischemic
963839|NCT02190552|Ischemic Stroke
963840|NCT02190552|Mechanical Thrombectomy
963841|NCT02190552|Neurovascular Intervention
963842|NCT02190552|Revascularization
963843|NCT02190552|Stent Retriever
963844|NCT02190552|Stroke
963845|NCT02190552|Vascular Diseases
963846|NCT02190539|Breast cancer
963847|NCT02190539|complementary medicine
963848|NCT02190539|homeopathy
963849|NCT02190539|quality of life
963850|NCT02190526|mesalamine
963851|NCT02190526|amitriptyline
963852|NCT02190526|Severity of Illness Index
963853|NCT02190500|stroke
963854|NCT02190500|tpa
963855|NCT02190500|emergency medical service
963856|NCT02190500|ems
963857|NCT02190500|mobile
963858|NCT02190500|ct scan
963859|NCT02190474|fibromyalgia
963860|NCT02190474|juvenile fibromyalgia
963861|NCT02190474|juvenile primary fibromyalgia syndrome (JPFS)
963862|NCT02190474|adolescent pain
963863|NCT02190474|mindfulness
963864|NCT02190474|MBSR
963865|NCT02190461|Early Respiratory Rehabilitation
963866|NCT02190461|Chronic Obstructive Pulmonary Disease
963867|NCT02190461|Re-admitted patients
963868|NCT02190461|Open clinical trial
963869|NCT02190461|Exacerbations
963872|NCT02190448|milk production
963873|NCT02190448|breastfeeding
963874|NCT02190435|Computer-assisted navigation
963875|NCT02190435|ADAPT
963876|NCT02190435|Intramedullary nail
963877|NCT02190435|Intertrochanteric femur fracture
963878|NCT02190422|reproductive technologies, assisted
963879|NCT02190422|echocardiography
963880|NCT02190422|cardiology
963881|NCT02190422|pediatrics
963882|NCT02190409|Dental Implant,
963883|NCT02190396|Calcium
963884|NCT02190396|Vitamin D
963885|NCT02190396|Placental calcification.
963886|NCT02190383|Tic-Disorder, Tourette-Disorder, Habit Reversal Training
963887|NCT02190370|Tic-Disorder, Tourette-Disorder, Resources activation
963888|NCT02190357|Cirrhosis
963889|NCT02190344|Eight
963890|NCT02190344|Channel
963891|NCT02190344|Paddle
963892|NCT02190344|Coil
963893|NCT02190344|MRI
963894|NCT02190344|Prostate
963895|NCT02190344|Healthy Male
963896|NCT02190331|Detraining
963897|NCT02190331|Neck
963898|NCT02190331|Exercise
963899|NCT02190331|Posture
963900|NCT02190331|Rehabilitation
963901|NCT02190318|peritoneal dialysis；
963902|NCT02190318|residual renal function；
963903|NCT02190318|RAAS
963904|NCT02190279|Prostate Specific Membrane Antigen
963905|NCT02190279|Radiolabeled PET Agent
963906|NCT02190279|Imaging
963907|NCT02190279|NaF
963908|NCT02190266|Extrapulmonary
963909|NCT02190266|Immunodeficiency
963910|NCT02190266|Genetics
963911|NCT02190266|Infection
963912|NCT02190266|Fungal
963913|NCT02190253|Renal Threshold
963914|NCT02190253|Liver Transplant
963915|NCT02190253|Transplantation
963916|NCT02190253|Hepatitis E
963917|NCT02190240|Complementary and Alternative Medicine
963918|NCT02190240|Integrative Medicine
963919|NCT02190240|Pain Management
963920|NCT02190227|Breast Cancer
963921|NCT02190227|Chemotherapy
963922|NCT02190227|Neoadjuvant
963923|NCT02190227|RNA Disruption Assay
963924|NCT02190227|Biopsies
963925|NCT02190227|Response
963926|NCT02190214|Hyperthyroidism
963927|NCT02190214|Hypothyroidism
963928|NCT02190214|Autoimmune thyroid disorders
963929|NCT02190214|Iodine deficiency
963930|NCT02190214|Genetic susceptibility
963931|NCT02190201|videolaryngoscope
963932|NCT02190201|double lumen intubation
963933|NCT02190188|wedge insoles,
963934|NCT02190188|knee brace,
963935|NCT02190188|orthotic device
963936|NCT02190188|goal
963937|NCT02190162|Patients undergoing tonsillectomy with or without adenoidectomy
963938|NCT02190149|Factor VIII Deficiency
963939|NCT02190149|Factor FIX Deficiency
963940|NCT02190136|obesity
963941|NCT02190136|protein-rich whole foods diet
963942|NCT02190136|aerobic fitness
963943|NCT02190136|resistance training
963944|NCT02190136|stretching/yoga training
963945|NCT02190136|glycemia
963946|NCT02190136|mood state
963947|NCT02190123|Acute Coronary Syndrome (ACS)
963948|NCT02190123|Oral antiplatelets (ticagrelor, prasugrel, clopidogrel) (OAP)
963949|NCT02190123|Treatment persistence.
963950|NCT02190110|Pulmonary embolism
963951|NCT02190110|diagnosis
963952|NCT02190110|emergency medicine
963953|NCT02190110|ultrasonography
963954|NCT02190097|PCOS
963955|NCT02190097|insulin sensitivity
963956|NCT02190097|paleolithic diet
963957|NCT02190084|apathy
963958|NCT02190084|Alzheimer's
963959|NCT02190084|executive function
963960|NCT02190071|EUS-FNA
963961|NCT02190071|cytopathology
963962|NCT02190071|slide smear
963963|NCT02190058|safety
963964|NCT02190058|pharmacokinetics
963965|NCT02190058|DS-1971a
963966|NCT02190045|Balance
963967|NCT02190045|gait
963968|NCT02190045|Wii-Fit
963969|NCT02190019|Mild Cognitive Impairment
963970|NCT02190019|apathy
963971|NCT02190019|executive function
963972|NCT02190006|Polycystic ovarian syndrome
963973|NCT02190006|Follicle output rate
963974|NCT02190006|preovulatory count
963975|NCT02190006|ICSI
963976|NCT02189993|Mortality
963977|NCT02189993|Long term follow-up
963978|NCT02189993|Parenteral Nutrition, Total
963979|NCT02189980|Nausea
963980|NCT02189980|Post-operative
963981|NCT02189967|non-small cell lung cancer
963982|NCT02189967|radiotherapy
963983|NCT02189967|accelerated fractionation
963984|NCT02189967|conventional fractionation
963985|NCT02189967|postoperative
963986|NCT02189954|elderly; laryngeal masks; postoperative complications
963987|NCT02189941|Deferiprone
963988|NCT02189941|Deferiprone sustained-release tablets
963989|NCT02189941|Pharmacokinetics
963990|NCT02189902|Vitamin D
963991|NCT02189889|Active preoperative anemia management
963992|NCT02189889|Erythrocyte transfusion
963993|NCT02189889|RBC transfusion
963994|NCT02189889|Red cell transfusion
963995|NCT02189889|Transfusion in cardiac surgery
963996|NCT02189889|Anemia treatment with erythropoietin
963997|NCT02189889|Anemic cardiac surgery patients
963998|NCT02189889|Erythrocyte stimulating agent (ESA)
963999|NCT02189889|Iron deficiency anemia
964000|NCT02189889|EPO
964001|NCT02189889|Feraheme
964002|NCT02189876|HIV Prevention
964003|NCT02189876|Behavioral Intervention
964004|NCT02189876|Condom Use
964005|NCT02189876|African American
964006|NCT02189876|Sexually Transmitted Disease
964007|NCT02189876|Sexually Transmitted Infection
964008|NCT02189876|Internet
964009|NCT02189863|Driving Simulator
964010|NCT02189863|Air Optix Aqua
964011|NCT02189863|AOAMF
964012|NCT02189850|colonoscopy
964013|NCT02189850|pediatric
964014|NCT02189837|Raised cholesterol
964015|NCT02189837|Cholesterol
964016|NCT02189837|Elevated Cholesterol
964017|NCT02189837|Hyperlipidemias
964018|NCT02189837|Dyslipidemias
964019|NCT02189837|Lipid Metabolism Disorders
964020|NCT02189837|Metabolic Diseases
964021|NCT02189811|IPV
964022|NCT02189811|OPV
964023|NCT02189811|tOPV
964024|NCT02189811|bOPV
964025|NCT02189811|Polio
964026|NCT02189811|Endgame
964027|NCT02189811|Pakistan
964028|NCT02189798|Cochlear Implant
964029|NCT02189798|HiRes™ 90K Advantage implant
964030|NCT02189798|Cochlear Implantation
964031|NCT02189798|HiFocus™ Mid-Scala electrode
964032|NCT02189798|Listening Benefits
964033|NCT02189798|Adults
964034|NCT02189798|Cochlear Implant Benefit
964035|NCT02189798|Electrical Stimulation
964036|NCT02189798|Electro-Acoustic Stimulation (EAS)
964037|NCT02189785|social
964038|NCT02189785|rejection
964039|NCT02189785|acceptance
964040|NCT02189785|PET
964041|NCT02189785|opioid
964042|NCT02189785|fMRI
964043|NCT02189785|reward
964044|NCT02189785|exclusion
964045|NCT02189772|ADHD
964046|NCT02189772|Inattention
964047|NCT02189772|MDX
964048|NCT02189759|Hypothermia
964049|NCT02189759|Hyperthermia
964050|NCT02189759|Kangaroo Mother Care
964051|NCT02189759|Newborn
964052|NCT02189746|Hypothermia
964053|NCT02189746|Newborn
964054|NCT02189746|Hyperthermia
964055|NCT02189746|Kangaroo mother care
964056|NCT02189720|Amifampridine Phosphate
964057|NCT02189720|Amifampridine
964058|NCT02189720|3,4-Diaminopyridine Phosphate
964059|NCT02189720|3,4-Diaminopyridine
964060|NCT02189720|3,4-DAP
964061|NCT02189720|LEMS
964062|NCT02189720|CMS
964063|NCT02189720|Lambert-Eaton Myasthenic Syndrome
964064|NCT02189720|Congenital Myasthenic Syndrome
964065|NCT02189720|Neuromuscular disorders
964066|NCT02189720|Neuromuscular
964067|NCT02189720|eye movement
964068|NCT02189720|electromyography
964069|NCT02189720|EMG
964070|NCT02189720|Expanded Access
964071|NCT02189720|Firdapse®
964072|NCT02189720|Downbeat Nystagmus
964073|NCT02189707|Gastrointestinal disorder
964074|NCT02189707|Constipation
964075|NCT02189707|Probiotics
964076|NCT02189707|Dietary supplement
964077|NCT02189694|Type 1 diabetes
964078|NCT02189694|Hypoglycemia
964079|NCT02189694|Insulin
964080|NCT02189694|Glucagon
964081|NCT02189694|Closed-loop system
964082|NCT02189694|Artificial pancreas
964083|NCT02189681|spinal anaesthesia
964084|NCT02189681|ultrasound
964085|NCT02189681|paramedian
964086|NCT02189668|Appendicitis
964087|NCT02189668|Non-operative
964088|NCT02189668|Children
964089|NCT02189668|Appendicolith
964090|NCT02189668|fecalith
964091|NCT02189668|Pediatrics
964092|NCT02189655|shivering spinal anesthesia
964093|NCT02189629|Acne vulgaris
964094|NCT02189629|Safety
964095|NCT02189629|Face
964096|NCT02189629|Trunk
964097|NCT02189616|asthma management
964098|NCT02189616|SMS reminder
964099|NCT02189616|SMS consultation
964100|NCT02189603|hepatitis E
964101|NCT02189603|Immunogenicity
964102|NCT02189603|vaccine
964103|NCT02189603|safety
964104|NCT02189590|supraglottic airway
964105|NCT02189590|children
964106|NCT02189590|fiberoptic guided tracheal intubation
964107|NCT02189590|air-Q
964108|NCT02189590|i-gel
964109|NCT02189577|Chronic Obstructive Pulmonary disease
964110|NCT02189577|COPD
964111|NCT02189538|Infections, Enteral nutrition, SIRS, critically ill
964112|NCT02189525|traumatic brain injury
964113|NCT02189525|sports head injury
964114|NCT02189525|sports concussion
964115|NCT02189512|brain-death organ donors
964116|NCT02189512|intestinal manipulation
964117|NCT02189512|monocytes
964118|NCT02189499|Stents
964119|NCT02189499|Angioplasty
964120|NCT02189499|Coronary Vessels
964121|NCT02189499|Coronary Artery Disease
964122|NCT02189499|Angina Pectoris
964123|NCT02189499|Myocardial Ischemia
964124|NCT02189499|Myocardial Infarction
964125|NCT02189499|Myocardial Revascularization
964126|NCT02189486|Prostate Cancer
964127|NCT02189486|Radical Prostatectomy
964128|NCT02189486|Prostate biopsy
964129|NCT02189486|Upgrading
964130|NCT02189486|Upgrading Reference set
964131|NCT02189473|metastatic epidural spinal cord compression
964132|NCT02189473|motor function
964133|NCT02189473|ambulatory status
964134|NCT02189473|pain
964135|NCT02189473|quality of life
964136|NCT02189473|overall survival
964137|NCT02189473|local control
964138|NCT02189473|toxicity
964139|NCT02189460|Cognition
964140|NCT02189447|Keratoconus
964141|NCT02189447|Ectasia
964142|NCT02189447|Corneal Cross-linking
964143|NCT02189421|peroral cholangioscopy
964144|NCT02189421|ultra-slim upper endoscope
964145|NCT02189421|multibending endoscope
964146|NCT02189408|Platelet rich plasma
964147|NCT02189408|Autologous conditioned plasma
964148|NCT02189408|Outerbridge
964149|NCT02189395|Type 2 diabetes
964150|NCT02189395|Uncontrolled blood glucose
964151|NCT02189395|insulin
964152|NCT02189395|glargine
964153|NCT02189395|NPH
964154|NCT02189382|Sensitivity
964155|NCT02189356|Pregnancy-related low back and pelvic pain
964156|NCT02189356|exercise program
964157|NCT02189356|nurse
964158|NCT02189343|Multiple Myeloma
964159|NCT02189343|Relapsed and Refractory
964160|NCT02189343|Refractory Disease
964161|NCT02189343|Progressive Disease
964162|NCT02189343|Pomalidomide
964163|NCT02189343|Dexamethasone
964164|NCT02189343|Proteasome Inhibitor
964165|NCT02189343|Ricolinostat
964166|NCT02189304|Healthy volunteers
964167|NCT02189291|Indwelling catheter
964168|NCT02189291|Hospital stay
964169|NCT02189291|Urinary tract infection
964170|NCT02189291|Sacrocolpopexy
964171|NCT02189278|Breast Cancer
964172|NCT02189278|Surveillance
964173|NCT02189278|Mammography
964174|NCT02189278|Adherence
964175|NCT02189265|Live birth [MeSH]
964176|NCT02189265|Infant [MeSH]
964177|NCT02189265|Infant, newborn [MeSH]
964178|NCT02189265|Second-hand smoke
964179|NCT02189265|Tobacco smoke pollution [MeSH]
964180|NCT02189265|Smoke-free
964181|NCT02189265|Smoke-free policy [MeSH]
964182|NCT02189226|probe-based confocal laser endomicroscopy (pCLE), early gastric cancer (EGC), endoscopic submucosal dissection (ESD), margin
964183|NCT02189213|anxiety
964184|NCT02189213|SSRI
964185|NCT02189213|biomarker
964186|NCT02189213|sleep
964187|NCT02189213|children
964188|NCT02189213|adolescents
964189|NCT02189213|young adults
964190|NCT02189200|nutritional counseling
964191|NCT02189200|oat bran
964192|NCT02189200|dyslipidemia
964193|NCT02189200|cardiovascular disease
964194|NCT02189187|Weight Loss
964195|NCT02189187|Body Weight Changes
964196|NCT02189187|Body Weight
964197|NCT02189187|Magnetic Resonance Imaging
964198|NCT02189187|Emotions
964199|NCT02189187|Emotion regulation
964200|NCT02189187|Health Behavior
964201|NCT02189187|Eating behavior
964202|NCT02189174|Solid tumor,
964203|NCT02189174|breast cancer,
964204|NCT02189174|lung cancer,
964205|NCT02189174|endometrial cancer
964206|NCT02189161|anal intraepithelial neoplasia
964207|NCT02189161|AIN
964208|NCT02189161|Radiofrequency Ablation
964209|NCT02189161|RFA
964210|NCT02189148|Prediction
964211|NCT02189148|Preeclampsia
964212|NCT02189148|Preterm birth
964213|NCT02189148|Pregnancy
964214|NCT02189148|Placenta
964215|NCT02189148|Intra-uterine growth restriction
964216|NCT02189148|fetal growth restriction
964217|NCT02189148|Ultrasound
964218|NCT02189148|Doppler
964219|NCT02189148|Biomarkers
964220|NCT02189148|PAPP-A
964221|NCT02189148|Placental growth factor (PlGF)
964222|NCT02189109|glioblastoma
964223|NCT02189109|multiforme
964224|NCT02189109|radiation
964225|NCT02189109|radiation therapy
964226|NCT02189096|Sepsis
964227|NCT02189096|National Early Warning Score
964228|NCT02189096|Lactate
964229|NCT02189083|Leiomyoma
964230|NCT02189083|Medicine, Chinese Traditional
964231|NCT02189083|Randomized Controlled Trial
964232|NCT02189070|Follow-up
964233|NCT02189070|Percutaneous coronary intervention
964234|NCT02189070|Patient preference
964235|NCT02189070|DUTCH PEERS
964236|NCT02189070|TWENTE
964237|NCT02189057|Bipolar
964238|NCT02189057|Unipolar
964239|NCT02189057|Genotyping
964240|NCT02189057|Pharmacokinetic
964241|NCT02189057|Pharmacodynamic
964242|NCT02189044|aged;
964243|NCT02189044|breathing exercises;
964244|NCT02189044|muscle strength.
964245|NCT02189031|Upper limb Amputee
964246|NCT02189031|Targeted Muscle Reinnervation
964247|NCT02189031|Prosthetic
964248|NCT02189018|Peripheral arterial disease
964249|NCT02189018|Endovascular
964250|NCT02189018|Exercise
964251|NCT02189018|Perfusion
964252|NCT02189018|Functional capacity
964253|NCT02189005|High blood sugar
964254|NCT02189005|High HbA1C
964255|NCT02189005|hyperglycemia
964256|NCT02189005|Pre-Diabetes
964257|NCT02189005|Natural Supplement for Diabetes
964258|NCT02188992|Sepsis
964259|NCT02188992|Immune activation
964260|NCT02188992|Systemic Inflammation
964261|NCT02188992|Emergency Medicine
964262|NCT02188992|Critical Care
964263|NCT02188979|airway
964264|NCT02188979|equipment - laryngoscopes
964265|NCT02188979|intubation - tracheal
964266|NCT02188979|obesity.
964267|NCT02188966|Geographic Information System
964268|NCT02188966|Emergency Care Information Systems
964269|NCT02188966|Telemedicine
964270|NCT02188966|Emergency Hospital Service
964271|NCT02188953|aflatoxin
964272|NCT02188953|Kenya
964273|NCT02188940|Asthma
964274|NCT02188940|Obesity
964275|NCT02188940|Clinical control
964276|NCT02188940|Exercise
964277|NCT02188940|Weight-loss
964278|NCT02188927|Advanced notification letter
964279|NCT02188927|Standard invitation
964280|NCT02188927|Participation rate
964281|NCT02188927|Colonoscopy
964282|NCT02188927|Screening
964283|NCT02188927|Colorectal Neoplasms
964284|NCT02188927|Digestive System Diseases
964285|NCT02188914|Inhalant use disorder
964286|NCT02188914|Positron emission tomography
964287|NCT02188914|Magnetic Resonance Imaging
964288|NCT02188914|Executive functions assessment
964289|NCT02188914|Transcriptome
964290|NCT02188901|HCC
964291|NCT02188901|Sonazoid
964292|NCT02188901|Ultrasonography
964293|NCT02188901|Screening
964294|NCT02188888|septic shock
964295|NCT02188888|esmolol
964296|NCT02188888|tachycardia
964297|NCT02188888|betablockers
964298|NCT02188875|Fitbit One
964299|NCT02188875|wearable sensor
964300|NCT02188875|wearable device
964301|NCT02188875|web-based intervention
964302|NCT02188875|SMS text messages
964303|NCT02188875|randomized controlled trial
964304|NCT02188875|physical activity
964305|NCT02188875|behavioral intervention
964306|NCT02188875|text message prompts
964307|NCT02188875|text messaging
964308|NCT02188875|technology
964309|NCT02188875|exercise
964310|NCT02188862|Rheumatic heart disease
964311|NCT02188862|Acute rheumatic fever
964312|NCT02188862|Group A streptococcal disease
964313|NCT02188862|Streptococcus pyogenes
964314|NCT02188862|Genetics
964315|NCT02188862|Oceania
964316|NCT02188849|creatine
964317|NCT02188849|resistance training
964318|NCT02188849|older women
964319|NCT02188849|muscle strength
964320|NCT02188823|prediabetes
964321|NCT02188823|obesity
964322|NCT02188823|mindful eating
964323|NCT02188823|positive affect
964324|NCT02188823|low carbohydrate
964325|NCT02188823|ketogenic
964326|NCT02188823|diet
964327|NCT02188810|PAL
964328|NCT02188810|fluviral
964329|NCT02188810|healthy volunteer
964330|NCT02188810|adjuvant
964331|NCT02188810|TH1 immune response
964332|NCT02188797|homeless
964333|NCT02188797|young adults
964334|NCT02188797|substance use
964335|NCT02188797|HIV risk
964336|NCT02188797|sexual risk behavior
964337|NCT02188797|group motivational interviewing
964338|NCT02188771|Moderate to Severe OA
964339|NCT02188771|VAS score of ≥ 5
964340|NCT02188771|grade III-IV Kellgren Lawrence of OA
964341|NCT02188771|subjects who failed conservative treatment
964342|NCT02188771|subjects who candidates for total knee replacement (TKR)
964343|NCT02188771|subject 45 and 75 years old
964344|NCT02188771|subject is experiencing pain in the intended study knee with a VAS score of ≥ 5
964345|NCT02188771|subject has a Body Mass Index (BMI) between 18.5 and 35
964346|NCT02188758|iron
964347|NCT02188758|hepcidin-25
964348|NCT02188758|pulmonary exacerbation
964349|NCT02188758|interleukin-6
964350|NCT02188745|metastatic
964351|NCT02188745|locally advanced
964352|NCT02188745|ER+
964353|NCT02188745|Estrogen therapy
964354|NCT02188745|Estradiol therapy
964355|NCT02188732|Community Mental Health
964356|NCT02188732|Serious Mental Illness
964357|NCT02188732|Medical Comorbidity
964358|NCT02188732|Self-Management
964359|NCT02188732|Automated Telehealth
964360|NCT02188732|Early Mortality
964361|NCT02188719|Donor-Alloantigen-Reactive Regulatory T Cell Therapy
964362|NCT02188719|Tregs
964363|NCT02188719|Cell- and Tissue-Based Therapy
964364|NCT02188719|Immunotherapy, Adoptive
964365|NCT02188719|Liver Transplantation
964366|NCT02188706|Leukemia
964367|NCT02188706|Acute myeloid leukemia
964368|NCT02188706|AML
964369|NCT02188706|Myelodysplastic syndrome
964370|NCT02188706|MDS
964371|NCT02188706|Relapsed or refractory
964372|NCT02188706|Decitabine
964373|NCT02188706|Dacogen
964374|NCT02188706|Carboplatin
964375|NCT02188706|Paraplatin
964376|NCT02188706|Arsenic Trioxide
964377|NCT02188706|ATO
964378|NCT02188706|Trisenox
964379|NCT02188680|fructose test
964380|NCT02188667|Chronic Noncancer Pain
964381|NCT02188667|Musculoskeletal Pain
964382|NCT02188667|Neuropathic Pain
964383|NCT02188667|Headache Pain
964384|NCT02188654|psoriatic arthritis
964385|NCT02188654|inflammation
964386|NCT02188654|metabolic syndrome
964387|NCT02188654|metformin
964388|NCT02188641|Psoriatic arthritis
964389|NCT02188641|inflammation
964390|NCT02188641|obesity
964391|NCT02188641|diet
964392|NCT02188641|exercise
964393|NCT02188628|Motor recovery, robotics, stroke rehabilitation
964394|NCT02188615|Squamous Cell Esophageal Carcinoma
964395|NCT02188615|minimally invasive esophagectomy
964396|NCT02188615|laparoscopy
964397|NCT02188615|thoracoscopy
964398|NCT02188576|Craniofacial Surgery
964399|NCT02188576|tranexamic acid
964400|NCT02188576|Antifibrinolytic
964401|NCT02188563|Smoking cessation
964402|NCT02188563|Head and neck neoplasms
964403|NCT02188563|Lung neoplasms
964404|NCT02188563|Thoracic neoplasms
964405|NCT02188563|Radiation
964406|NCT02188550|relapse or refractory or persistent epithelial ovarian fallopian tube
964407|NCT02188550|primary peritoneal carcinoma or endometrial cancer
964408|NCT02188537|Myeloma
964409|NCT02188537|proteasome inhibitor-nonresponsive myeloma
964410|NCT02188537|Nelfinavir
964411|NCT02188537|bortezomib
964412|NCT02188537|bortezomib-sensitizing drug
964413|NCT02188524|balance, exercise, compensatory stepping, tai chi
964414|NCT02188511|E-Cigarettes
964415|NCT02188511|Lung
964416|NCT02188511|Non-Smokers
964417|NCT02188511|Lung Biology
964418|NCT02188472|Oxidative Stress
964419|NCT02188472|antibiotics
964420|NCT02188446|Radical cystectomy
964421|NCT02188446|Bladder cancer
964422|NCT02188446|Smoking cessation
964423|NCT02188446|Alcohol cessation
964424|NCT02188446|Postoperative complications
964425|NCT02188433|Effectiveness of quit immediately (QI) and cut down to quit (CDTQ) interventions in achieving smoking abstinence
964426|NCT02188420|PAS
964427|NCT02188420|TMS
964428|NCT02188420|Stroke
964429|NCT02188420|Paired Associative Stimulation
964430|NCT02188420|Transcranial Magnetic Stimulation
964431|NCT02188407|thoracotomy
964432|NCT02188407|one-lung ventilation (OLV)
964433|NCT02188407|total intravenous anaesthesia (TIVA)
964434|NCT02188407|volatile induced and maintained anaesthesia (VIMA)
964435|NCT02188407|cytokines
964436|NCT02188407|interleukine (IL)
964437|NCT02188394|migraine,
964438|NCT02188394|pressure pain,
964439|NCT02188394|anesthetic blocks
964440|NCT02188394|patients
964441|NCT02188381|Resistant Hypertension
964442|NCT02188381|Uncontrolled Hypertension
964443|NCT02188368|Pomalidomide
964444|NCT02188368|Lenalidomide refractory
964445|NCT02188368|multiple myeloma
964446|NCT02188355|Ultimaster
964447|NCT02188355|registry
964448|NCT02188355|DES
964449|NCT02188355|DAPT
964450|NCT02188329|Early care and education
964451|NCT02188329|ECE
964452|NCT02188329|workforce
964453|NCT02188329|child care
964454|NCT02188329|caregivers
964455|NCT02188329|home-based providers
964456|NCT02188329|center-based providers
964457|NCT02188316|Cold forceps polypectomy
964458|NCT02188316|Diminutive colorectal polyp
964459|NCT02188316|Hot biopsy forceps electrocauterization
964460|NCT02188316|Jumbo forceps.
964461|NCT02188290|Haploidentical donor
964462|NCT02188290|Unrelated donor
964463|NCT02188290|Umbilical cord blood
964464|NCT02188290|Graft versus host disease
964465|NCT02188290|Transplant-related mortality
964466|NCT02188290|Hematologic malignancy
964467|NCT02188290|Hematopoietic Stem Cell Transplantation
964468|NCT02188251|Activamp
964469|NCT02188251|Gynostemma pentaphyllum
964470|NCT02188251|Body weight
964471|NCT02188251|Fat Loss
964472|NCT02188251|Metabolic markers
964473|NCT02188251|Overweight participants
964474|NCT02188251|DXA
964475|NCT02188251|AMPK
964476|NCT02188238|saliva
964477|NCT02188238|protein
964478|NCT02188238|oral health
964479|NCT02188238|film
964480|NCT02188238|pellicle
964481|NCT02188225|Hot flash
964482|NCT02188225|Acupuncture
964483|NCT02188225|Fluoxetine
964484|NCT02188225|Quality of life
964485|NCT02188199|Hip
964486|NCT02188199|Knee
964487|NCT02188199|Hip replacement
964488|NCT02188199|Knee replacement
964489|NCT02188199|Total Joint
964490|NCT02188186|triple combination
964491|NCT02188186|metformin
964492|NCT02188186|sitagliptin
964493|NCT02188186|thiazolidinedione
964494|NCT02188160|Pain
964495|NCT02188160|Corticosteroid
964496|NCT02188160|Dry Eye
964497|NCT02188160|Hyperemia
964498|NCT02188160|Ocular Discomfort
964499|NCT02188147|Syncope
964500|NCT02188147|Sudden Cardiac Arrest
964501|NCT02188147|Sudden Cardiac Death
964502|NCT02188147|Cardiac Arrest
964503|NCT02188147|Emergency Service
964504|NCT02188147|Emergency Department
964505|NCT02188147|Ambulatory Electrocardiography
964506|NCT02188147|Holter
964507|NCT02188147|Holter Electrocardiography
964508|NCT02188147|Holter Monitoring
964509|NCT02188134|Adverse events,
964510|NCT02188134|adverse drug reactions,
964511|NCT02188134|medication error,
964512|NCT02188134|noncompliance
964513|NCT02188108|quality of life
964514|NCT02188108|QOL
964515|NCT02188108|urolithiasis
964516|NCT02188108|nephrolithiasis
964517|NCT02188108|kidney stones
964518|NCT02188108|patient-reported outcomes
964519|NCT02188069|Non-atherosclerotic Coronary Artery Disease
964520|NCT02188056|Venous
964521|NCT02188056|Thromboembolic
964522|NCT02188056|Pulmonary embolism
964523|NCT02188043|Alcohol use disorder
964524|NCT02188043|Motivational Intervention
964525|NCT02188043|Health expenditures
964526|NCT02188043|efficacy study
964527|NCT02188030|musculoskeletal symptom
964528|NCT02188030|industrial workers
964529|NCT02188030|physical-activity program
964530|NCT02188030|resistance training
964531|NCT02188030|randomized controlled trial
964532|NCT02188017|prednisone, methotrexate, sarcoidosis, azathioprine
964533|NCT02188004|HPV
964534|NCT02188004|genital warts
964535|NCT02187991|metastatic breast cancer
964536|NCT02187991|Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer
964537|NCT02187991|Estrogen Receptor-positive (ER+) breast cancer
964538|NCT02187991|Triple Negative breast cancer
964539|NCT02187991|alisertib
964540|NCT02187991|paclitaxel
964541|NCT02187978|Early total enteral feeding (ETEF)
964542|NCT02187978|Conventional enteral feeding (CEF)
964543|NCT02187978|VLBW infants
964544|NCT02187978|NEC
964545|NCT02187978|Preterm infants
964546|NCT02187926|Drug therapy
964547|NCT02187900|Tripterygium Wilfordii HOOK. f.
964548|NCT02187900|Mycophenolate mofetil
964549|NCT02187887|alcohol
964550|NCT02187887|young adult veterans
964551|NCT02187887|brief intervention
964552|NCT02187887|online
964553|NCT02187887|perceived norms
964554|NCT02187835|complexity
964555|NCT02187835|electroencephalogram
964556|NCT02187835|entropy
964557|NCT02187835|negative symptoms
964558|NCT02187835|schizophrenia.
964559|NCT02187822|Brain
964560|NCT02187822|Advanced solid tumors
964561|NCT02187822|Fractionated Stereotactic Radiotherapy (FSRT)
964562|NCT02187822|Brain lesions
964563|NCT02187822|Primary solid malignancy
964564|NCT02187796|HIV
964565|NCT02187796|Dementia
964566|NCT02187796|HAND
964567|NCT02187796|COGNISION System
964568|NCT02187796|ERP
964569|NCT02187796|event-related potentials
964570|NCT02187783|Solid malignancy,
964571|NCT02187783|Hematologic malignancy,
964572|NCT02187783|Mutations,
964573|NCT02187783|Amplifications,
964574|NCT02187783|Signature,
964575|NCT02187783|CDK4,
964576|NCT02187783|CDK6,
964577|NCT02187783|CDK4/6,
964578|NCT02187783|Cyclin D1,
964579|NCT02187783|CCND1,
964580|NCT02187783|Cyclin D3,
964581|NCT02187783|CCND3,
964582|NCT02187783|p16 mutation,
964583|NCT02187783|CDKN2A,
964584|NCT02187783|LEE011,
964585|NCT02187783|Breast cancer,
964586|NCT02187783|Ovarian cancer,
964587|NCT02187783|Lymphoma,
964588|NCT02187783|Mesothelioma,
964589|NCT02187783|Pancreatic neuroendocrine,
964590|NCT02187783|Leukemia
964591|NCT02187783|Tumor
964592|NCT02187757|Dyslipidemia
964593|NCT02187757|High cholesterol
964594|NCT02187757|High LDL
964595|NCT02187757|Triglycerides
964596|NCT02187744|Biosimilars
964597|NCT02187744|Non-inferiority
964598|NCT02187744|Neoadjuvant Setting
964599|NCT02187744|Early Breast Cancer
964600|NCT02187744|PK
964601|NCT02187744|Phase 3
964602|NCT02187744|Trastuzumab
964603|NCT02187744|Herceptin
964604|NCT02187744|HER2 Positive
964605|NCT02187731|Multiple Myeloma
964606|NCT02187731|Functional Imaging
964607|NCT02187731|PET/CT
964608|NCT02187731|Diffusion Weighted MRI
964609|NCT02187718|Sentinel Lymph Node Biopsy
964610|NCT02187718|Local Anaesthesia
964611|NCT02187692|schizophrenia;
964612|NCT02187692|meta-cognition;
964613|NCT02187692|general functioning;
964614|NCT02187692|positive symptoms;
964615|NCT02187692|insight;
964616|NCT02187679|Tourette Syndrome
964617|NCT02187679|Tourette's Syndrome
964618|NCT02187679|Chronic Vocal Tic
964619|NCT02187679|Vocal Tic
964620|NCT02187666|Cervical
964621|NCT02187666|Lumbar
964622|NCT02187666|Spine
964623|NCT02187666|Spinal Disease
964624|NCT02187653|IOM
964625|NCT02187653|IONM
964626|NCT02187653|Intraoperative Monitoring
964627|NCT02187653|Intraoperative Neuromonitoring
964628|NCT02187653|Spine
964629|NCT02187653|Lumbar
964630|NCT02187653|Cervical
964631|NCT02187640|Acupressure
964632|NCT02187640|Self-administration
964633|NCT02187640|Psychiatric in-patients
964634|NCT02187640|Constipation
964635|NCT02187640|Self-administered acupressure program
964636|NCT02187640|Sham control group
964637|NCT02187614|Acute Renal colic
964638|NCT02187614|Acute Ureteric Colic
964639|NCT02187614|Renal or Ureteral Calculi
964640|NCT02187614|Urolithiasis
964641|NCT02187614|Kidney or Ureteral stones
964642|NCT02187601|CLD
964643|NCT02187549|Hyaluronic Acid
964644|NCT02187549|Osteoarthritis
964645|NCT02187549|Knee
964646|NCT02187549|Hyaluronan
964647|NCT02187549|Viscoelastic
964648|NCT02187549|Hydrogel
964649|NCT02187510|Hemodynamics
964650|NCT02187510|Premature Infant
964651|NCT02187510|Umbilical cord
964652|NCT02187510|Milking
964653|NCT02187510|Delayed clamping
964654|NCT02187471|pain
964655|NCT02187471|fibromyalgia
964656|NCT02187445|Sickle Cell Disease
964657|NCT02187445|Budesonide inhalation suspension
964658|NCT02187445|Acute Chest Syndrome
964659|NCT02187419|Sleep
964660|NCT02187419|Menopause
964661|NCT02187419|Hypnosis
964662|NCT02187419|Relaxation
964663|NCT02187419|Hypnotic Relaxation Therapy
964664|NCT02187419|Hot Flash
964665|NCT02187406|athletic tape
964666|NCT02187406|tennis
964667|NCT02187406|warm-up exercise
964668|NCT02187393|Epithelial cell function of cells from individuals with various genotypes
964669|NCT02187302|nanopharmaceutical,
964670|NCT02187289|NCSG
964671|NCT02187289|Compression bandages
964672|NCT02187289|devices
964673|NCT02187289|Night time compression
964674|NCT02187289|Breast cancer treatment side effects
964675|NCT02187289|Compression therapy
964676|NCT02187289|Reid Sleeve
964677|NCT02187289|Comprefit
964678|NCT02187289|Medassist
964679|NCT02187289|Tribute
964680|NCT02187289|Comprilan
964681|NCT02187276|Predictive factors of response
964682|NCT02187276|mild and moderate
964683|NCT02187276|Alzheimer disease
964684|NCT02187276|mixed dementia
964685|NCT02187276|APOE
964686|NCT02187276|polymorphisms of CYP 2D6
964687|NCT02187263|hereditary cardiomyopathy,
964688|NCT02187263|inflammatory cardiomyopathy,
964689|NCT02187263|registry,
964690|NCT02187263|biomaterial,
964691|NCT02187263|clinical trial
964692|NCT02187263|Patients
964693|NCT02187250|PCOS
964694|NCT02187250|PDE-4 inhibitor
964695|NCT02187250|roflumilast
964696|NCT02187250|liraglutide
964697|NCT02187250|metformin
964698|NCT02187250|obesity
964699|NCT02187224|Alcohol Dependence
964700|NCT02187224|Post-Traumatic stress disorder (PTSD)
964701|NCT02187224|Progesterone
964702|NCT02187211|Alcohol Dependence
964703|NCT02187211|Minocycline
964704|NCT02187198|Opioid Dependence
964705|NCT02187198|Buprenorphine
964706|NCT02187185|Inflammatory biomarkers
964707|NCT02187185|Periodontitis
964708|NCT02187172|Psoriasis
964709|NCT02187172|Cardiovascular Disease
964710|NCT02187172|Vascular Inflammation
964711|NCT02187172|Lipid Biomarkers
964712|NCT02187172|FDG-PET/CT
964713|NCT02187159|pain
964714|NCT02187159|fibromyalgia
964715|NCT02187146|Vitamin D
964716|NCT02187146|Infertility
964717|NCT02187146|IVF
964718|NCT02187146|ART
964719|NCT02187133|Relapsed
964720|NCT02187133|Refractory
964721|NCT02187120|Wounds and Injuries
964722|NCT02187120|Acute Coagulopathy
964723|NCT02187120|Tranexamic Acid
964724|NCT02187120|Emergency Medical Services
964725|NCT02187107|HIV
964726|NCT02187107|AIDS
964727|NCT02187107|TMC114
964728|NCT02187107|Ritonavir
964729|NCT02187107|Norvir
964730|NCT02187107|Darunavir
964731|NCT02187081|HCC
964732|NCT02187081|RFA
964733|NCT02187081|Sorafenib
964734|NCT02187081|Tumor recurrence
964735|NCT02187081|Overall survival
964736|NCT02187068|Anaesthetics iv
964737|NCT02187068|Dexmedetomidine
964738|NCT02187068|Pharmacokinetic
964739|NCT02187042|sunitinib
964740|NCT02187042|call center
964741|NCT02187042|management of patients
964742|NCT02187042|nurses
964743|NCT02187042|metastatic renal carcinoma
964744|NCT02187029|Hyperuricemia
964745|NCT02187029|gout
964746|NCT02187029|serum uric acid
964747|NCT02187016|Gingivitis
964748|NCT02187016|plaque
964749|NCT02187016|interproximal cleaning
964750|NCT02187016|dental floss
964761|NCT02186977|immunogenicity
964762|NCT02186977|safety
964763|NCT02186977|proof of concept
964764|NCT02186951|ventilator-associated pneumonia
964765|NCT02186951|cardiac arrests with shockable rhythm
964766|NCT02186951|Mild therapeutic hypothermia
964767|NCT02186951|preventive antibiotics
964768|NCT02186938|head and neck cancer
964769|NCT02186938|patients requiring a free flap surgery
964770|NCT02186925|Kidney Cancer
964771|NCT02186925|Prostate Cancer
964772|NCT02186925|Bladder Cancer
964773|NCT02186912|edentulous
964774|NCT02186912|Nobel Active
964775|NCT02186912|Nobel Procera
964776|NCT02186912|IBO
964777|NCT02186912|CAD/CAM
964778|NCT02186886|Ulcerative Colitis
964779|NCT02186886|Golimumab
964780|NCT02186886|Physiological Intermolecular Modification Spectroscopy
964781|NCT02186886|PIMS
964782|NCT02186873|Ankylosing Spondylitis
964783|NCT02186873|Golimumab
964784|NCT02186873|SIMPONI
964785|NCT02186834|Relapsed
964786|NCT02186834|Refractory
964787|NCT02186834|Myeloma
964788|NCT02186821|hematological malignancy
964789|NCT02186821|solid tumor malignancy
964790|NCT02186821|mutation
964791|NCT02186821|translocation
964792|NCT02186821|rearrangement
964793|NCT02186821|amplification
964794|NCT02186821|ALK
964795|NCT02186821|ROS1
964796|NCT02186821|NSCLC
964797|NCT02186821|B-cell lymphoma
964798|NCT02186795|Arthroplasty
964799|NCT02186795|Replacement, Hip
964800|NCT02186782|Clomiphene citrate
964801|NCT02186782|Estradiol
964802|NCT02186782|Endometrial thickness
964803|NCT02186756|Fibromyalgia
964804|NCT02186756|Complementary Therapies
964805|NCT02186756|Biofeedback
964806|NCT02186756|Randomized controlled trial
964807|NCT02186756|Relaxation Therapy
964808|NCT02186743|Irritable Bowel Syndrome
964809|NCT02186743|IBS
964810|NCT02186743|Diet
964811|NCT02186743|Food sensitivity
964812|NCT02186730|Computerised Cognitive Behaviour Therapy
964813|NCT02186730|Adolescents
964814|NCT02186730|Depression
964815|NCT02186730|Low Mood
964816|NCT02186704|Atrial Fibrillation
964817|NCT02186704|Implantable Defibrillators
964818|NCT02186704|Implanted Electrodes
964819|NCT02186691|pulmonary valve replacement
964820|NCT02186691|tetralogy of Fallot
964826|NCT02186639|exhaled breath
964827|NCT02186639|volatile organic compounds (VOCs)
964828|NCT02186639|SESI-MS
964829|NCT02186626|West Nile Virus, vaccine
964830|NCT02186613|Breast Feeding
964831|NCT02186613|Telephone
964832|NCT02186613|Education
964833|NCT02186613|Primary Health Care
964834|NCT02186600|Low bone mass
964835|NCT02186600|Post-menopausal women
964836|NCT02186600|Bone mineral density
964837|NCT02186600|Bone structure
964838|NCT02186600|Bone turnover
964839|NCT02186600|Bone-loading exercises
964840|NCT02186600|Optimal calcium and vitamin D
964841|NCT02186600|risedronate
964842|NCT02186574|Non-Hodgkin
964843|NCT02186574|Lymphoma
964844|NCT02186574|Hepatitis B
964845|NCT02186574|Tenofovir
964846|NCT02186574|Viread
964847|NCT02186561|intracranial aneurysm
964848|NCT02186561|brain aneurysm
964849|NCT02186522|Sepsis
964850|NCT02186522|Septic shock
964851|NCT02186522|Critical care
964852|NCT02186522|Immune dysfunction
964853|NCT02186522|Inflammatory markers
964854|NCT02186522|Neutrophil
964855|NCT02186522|Monocyte
964856|NCT02186522|Tregs
964857|NCT02186470|Breast Cancer
964858|NCT02186470|Early Stage Breast Cancer
964859|NCT02186457|Pancreatoduodenectomy
964860|NCT02186457|Whipple
964861|NCT02186444|newly diagnosed prostate cancer
964862|NCT02186444|prostate
964863|NCT02186431|Contact lenses
964864|NCT02186418|sickle cell disease
964865|NCT02186418|sickle cell anemia
964866|NCT02186418|hemoglobinopathies
964867|NCT02186418|hematopoietic stem cell
964868|NCT02186418|gene transfer
964869|NCT02186418|gene therapy
964870|NCT02186392|Depression
964871|NCT02186392|Anxiety
964872|NCT02186392|Stroke
964873|NCT02186392|Cerebral Infarction
964874|NCT02186392|Sleep disorders
964875|NCT02186392|Circadian Rhythm disorders
964876|NCT02186392|Circadian Light
964877|NCT02186392|Light therapy
964878|NCT02186392|Melatonin
964879|NCT02186392|Sleep
964880|NCT02186392|Sleep apnea
964881|NCT02186392|Coagulation disturbances
964882|NCT02186392|Bone metabolism
964883|NCT02186392|Rehabilitation
964884|NCT02186392|Mood disorders
964885|NCT02186392|Mental disorders
964886|NCT02186392|Neurologic Manifestations
964887|NCT02186392|Signs and Symptoms Cerebrovascular Disorders
964888|NCT02186392|Brain Diseases
964889|NCT02186392|Vascular Disease
964890|NCT02186392|Brain Infarction
964891|NCT02186392|Brain Ischemia
964892|NCT02186379|Obesity
964893|NCT02186379|Obesity Prevention
964894|NCT02186379|Childhood obesity prevention
964895|NCT02186379|Rapid Eating Style
964896|NCT02186366|Anxiety Disorders, Massage Therapy, Treatment Efficacy
964897|NCT02186353|Whole grains
964898|NCT02186353|Food processing
964899|NCT02186353|Cardiometabolic risk factors
964900|NCT02186327|Integrative Health Coaching
964901|NCT02186314|atrial fibrillation, heart failure, pacemaker
964902|NCT02186301|cancer
964903|NCT02186301|metastatic
964904|NCT02186301|locally advanced
964905|NCT02186301|lung
964906|NCT02186301|non-small cell lung cancer
964907|NCT02186301|NSCLC
964908|NCT02186301|epidermal growth factor receptor
964909|NCT02186301|EGFR
964910|NCT02186301|T790M
964911|NCT02186301|CO-1686
964912|NCT02186301|unresectable
964913|NCT02186301|recurrent
964914|NCT02186301|EGFR-directed therapy
964915|NCT02186301|irreversible EGFR inhibitor
964916|NCT02186301|TIGER
964917|NCT02186301|rociletinib
964918|NCT02186288|Critical Care
964919|NCT02186288|High-flow nasal cannula oxygen
964920|NCT02186288|Electrical impedance tomography
964921|NCT02186288|End expiratory lung volume
964922|NCT02186288|End expiratory lung impedance
964923|NCT02186288|Diaphragmatic ultrasound
964924|NCT02186275|Crohn
964925|NCT02186275|vitamin D
964926|NCT02186275|remission
964927|NCT02186275|inflammation
964928|NCT02186275|tolerance
964929|NCT02186262|Glioma
964930|NCT02186262|MRI
964931|NCT02186262|Rotating frame relaxation
964932|NCT02186262|DWI
964933|NCT02186262|treatment response
964934|NCT02186236|Detection of Oncogenic Tumor Mutations
964935|NCT02186236|blood
964936|NCT02186236|urine
964937|NCT02186236|14-114
964938|NCT02186223|Pulmonary Embolism
964939|NCT02186223|PE
964940|NCT02186223|DVT
964941|NCT02186223|Deep Vein Thrombosis
964942|NCT02186223|VTE
964943|NCT02186223|Venous Thromboembolism
964944|NCT02186223|prophylaxis
964945|NCT02186223|thromboprophylaxis
964946|NCT02186223|contraindications to thromboprophylaxis
964947|NCT02186223|prophylactic
964948|NCT02186223|prevention
964949|NCT02186223|Inferior vena cava filter
964950|NCT02186223|IVC filter
964951|NCT02186223|filter
964952|NCT02186223|prevention of pulmonary embolism
964953|NCT02186223|trauma
964954|NCT02186223|critically-ill
964955|NCT02186210|microcirculation
964956|NCT02186210|off-pump coronary artery bypass surgery
964957|NCT02186210|tissue oxygen saturation
964958|NCT02186210|vascular occlusion test
964959|NCT02186210|recovery slope
964960|NCT02186197|Volume Responsiveness
964961|NCT02186184|Myopia progression
964962|NCT02186184|Orthokeratology
964963|NCT02186171|Osteoporosis in men
964964|NCT02186158|Pneumonia
964965|NCT02186158|Elderly
964966|NCT02186158|Ascorbic acid
964967|NCT02186158|Vitamin C
964968|NCT02186158|Hospitalized patient
964969|NCT02186132|heart rate
964970|NCT02186132|neostigmine
964971|NCT02186132|atropine
964972|NCT02186132|dosage
964973|NCT02186093|Coronary Artery Disease
964974|NCT02186093|Angina, Stable
964975|NCT02186093|Fractional Flow Reserve, Myocardial
964976|NCT02186093|Coronary Angiography
964977|NCT02186080|diabetes mellitus
964978|NCT02186080|metabolic endotoxemia
964979|NCT02186080|gemigliptin
964980|NCT02186080|DPP-4 inhibitor
964981|NCT02186067|Hypertension
964982|NCT02186067|Uncontrolled Hypertension
964983|NCT02186054|Abdominal-Pelvic MRI (magnetic resonance image)
964984|NCT02186054|T2W (T2 weighted)
964985|NCT02186054|FSE Flex (recently developed MRI pulse sequence)
964986|NCT02186054|Enhanced single shot FSE (fast spin echo).
964987|NCT02186028|oral daily supplementation with vitamin D for 6 months
964988|NCT02186015|Metastatic Breast Cancer
964989|NCT02186015|MBC
964990|NCT02186015|Vitamin D Supplementation
964991|NCT02186015|Symptom Management
964992|NCT02186002|ACT-451840
964993|NCT02186002|Safety
964994|NCT02186002|Tolerability
964995|NCT02186002|Pharmacokinetics
964996|NCT02185989|Critical Illness/*rehabilitation
964997|NCT02185989|Humans
964998|NCT02185989|*Intensive Care Units
964999|NCT02185989|Muscle Weakness/diagnosis/*etiology/physiopathology/prevention & control
965000|NCT02185989|Polyneuropathies/diagnosis/*etiology/physiopathology
965001|NCT02185976|preoperative anxiety
965002|NCT02185976|paediatric patients
965003|NCT02185976|Cartoon
965004|NCT02185963|Diabetes
965005|NCT02185963|Dyslipidemia
965006|NCT02185963|HDL function
965007|NCT02185963|Cholesterol efflux
965008|NCT02185963|MCA assay
965009|NCT02185963|MCP-1
965010|NCT02185950|Burn
965011|NCT02185950|Skin graft
965012|NCT02185950|Elasticity
965013|NCT02185950|Skin
965014|NCT02185950|Physical therapy modalities
965015|NCT02185937|imatinib
965016|NCT02185937|gastrectomy
965017|NCT02185937|gastrointestinal stromal tumor
965018|NCT02185937|pharmacokinetics
965019|NCT02185924|PARECOXIB
965020|NCT02185924|CONTINUOUS FEMORAL BLOCK
965021|NCT02185911|chronic kidney disease,
965022|NCT02185911|anaemia correction/maintenance,
965023|NCT02185911|non dialysis,
965024|NCT02185898|electronic cigarettes
965025|NCT02185898|e-cigarettes
965026|NCT02185898|combustible cigarettes
965027|NCT02185898|second-hand smoke
965028|NCT02185898|environmental tobacco smoke
965029|NCT02185898|tobacco-burning
965030|NCT02185885|Ischemic stroke
965031|NCT02185885|Embolic stroke
965032|NCT02185885|Postoperative Cognitive Dysfunction
965033|NCT02185885|Cardiac Bypass Surgery
965034|NCT02185885|Cardiac Anaesthesia
965035|NCT02185872|Exercise
965036|NCT02185872|Physical Fitness
965037|NCT02185872|Body Composition, Beneficial
965038|NCT02185859|Lidocaine
965039|NCT02185859|Magnesium
965040|NCT02185859|Mastectomy
965041|NCT02185859|Functional Recovery
965042|NCT02185846|Fed condition
965043|NCT02185833|Fasting condition
965044|NCT02185820|Multiple myeloma
965045|NCT02185820|Relapsed and/or refractory
965046|NCT02185820|CPD
965047|NCT02185807|cataract
965048|NCT02185807|surgery
965049|NCT02185807|consent process
965050|NCT02185807|video-assisted
965051|NCT02185794|HCV genotype 1 (GT-1)
965052|NCT02185794|HCV genotype 2 (GT-2)
965053|NCT02185794|HCV genotype 3 (GT-3)
965054|NCT02185794|HCV genotype 4 (GT-4)
965055|NCT02185794|HCV
965056|NCT02185794|Sustained Virologic Response
965057|NCT02185794|Direct Acting Antiviral
965058|NCT02185794|Combination Therapy
965059|NCT02185794|Open Label
965060|NCT02185794|Hepatitis
965061|NCT02185794|Hepatitis, Chronic
965062|NCT02185794|Hepatitis C
965063|NCT02185794|Hepatitis C, Chronic
965064|NCT02185794|Liver Diseases
965065|NCT02185794|Digestive System Diseases
965066|NCT02185794|Hepatitis, Viral, Human
965067|NCT02185794|Virus Diseases
965068|NCT02185794|Enterovirus Infections
965069|NCT02185794|Picornaviridae Infections
965070|NCT02185794|RNA Virus Infections
965071|NCT02185794|Flaviviridae Infections
965072|NCT02185794|Antiviral Agents
965073|NCT02185794|Anti-Infective Agents
965074|NCT02185794|Therapeutic Uses
965075|NCT02185794|Pharmacologic Actions
965076|NCT02185794|Antimetabolites
965077|NCT02185794|Molecular Mechanisms of Pharmacological Action
965078|NCT02185781|Phase I
965079|NCT02185781|Adoptive immunotherapy
965080|NCT02185781|Enriched and expanded autologous natural killer (NK) cells
965081|NCT02185781|Ph+ acute lymphoblastic leukemia
965082|NCT02185781|≥60 years
965083|NCT02185781|Not eligible for other post-CHR treatment modalities
965084|NCT02185768|Liver cancer
965085|NCT02185755|Internet-Based Glucose Monitoring System
965086|NCT02185755|Type 2 Diabetes
965087|NCT02185742|HIV
965088|NCT02185742|jail
965089|NCT02185742|detainee
965090|NCT02185742|Linkage and Retention
965091|NCT02185742|Treatment as Prevention
965092|NCT02185742|Strength Based Case Management
965093|NCT02185742|releases
965094|NCT02185729|Intravenous Feeding
965095|NCT02185729|Lipid Emulsions, Intravenous
965096|NCT02185716|Transversus abdominis plane block
965097|NCT02185716|levobupivacaine
965098|NCT02185690|Lung cancer
965099|NCT02185690|Non small cell lung cancer
965100|NCT02185690|non squamous
965101|NCT02185690|pemetrexed
965102|NCT02185690|carboplatin
965103|NCT02185690|binimetinib
965104|NCT02185690|chemotherapy
965105|NCT02185690|combination chemotherapy
965106|NCT02185690|Phase 1
965107|NCT02185690|Princess Margaret Cancer Centre
965108|NCT02185690|carcinoma
965109|NCT02185677|dysexecutive syndrome
965110|NCT02185677|multiple system atrophy
965111|NCT02185677|imaging study
965112|NCT02185664|internal jugular vein
965113|NCT02185664|landmark
965114|NCT02185664|ultrasound
965115|NCT02185664|static
965116|NCT02185664|cardiac surgery
965117|NCT02185651|Pompe Disease
965118|NCT02185651|Enzyme Replacement Therapy
965119|NCT02185651|Infusion Associated Reaction
965120|NCT02185638|obesity
965121|NCT02185638|herbal bioactive compounds
965122|NCT02185638|appetite
965123|NCT02185638|GLP-1
965124|NCT02185638|ghrelin
965125|NCT02185638|CCK
965126|NCT02185599|colposcopy
965127|NCT02185599|CIN
965128|NCT02185599|cervical neoplasia
965129|NCT02185599|cervical dysplasia
965130|NCT02185599|cervical cancer
965131|NCT02185599|CIN2+
965132|NCT02185573|Bulk fill
965133|NCT02185573|SonicFill
965134|NCT02185573|resin composite application
965135|NCT02185573|class II restoration
965141|NCT02185547|women
965142|NCT02185534|Clopidogrel, Zyllt, Plavix, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence
965143|NCT02185521|Hemodynamics
965144|NCT02185521|Medical Informatics
965145|NCT02185508|IONM
965146|NCT02185508|Lumbar Disk Disease
965147|NCT02185508|Degenerative Spine Disease
965148|NCT02185508|Radiculopathy
965149|NCT02185508|Intraoperative Neurophysiological Monitoring
965150|NCT02185508|Somatosensory Evoked Potentials
965151|NCT02185508|Electromyography
965152|NCT02185482|Psychological counselling
965153|NCT02185482|Randomized single blind study
965154|NCT02185482|Depression
965155|NCT02185482|Diabetes
965156|NCT02185469|Corneal Endothelial Cell Loss
965157|NCT02185469|pneumatic retinopexy
965158|NCT02185469|vitrectomy
965159|NCT02185443|SBRT
965160|NCT02185443|radiation
965161|NCT02185443|Neoplasm Metastasis
965162|NCT02185443|Colorectal Neoplasms
965163|NCT02185443|Anal Canal
965164|NCT02185443|Neuroendocrine Tumors
965169|NCT02185391|Coronary Disease
965170|NCT02185391|Audience Response System
965171|NCT02185365|T1-rho MRI
965172|NCT02185365|dGEMRIC MRI
965173|NCT02185365|DDH
965174|NCT02185365|Developmental dysplasia of the hip
965175|NCT02185352|Bevacizumab
965176|NCT02185352|Brain Metastases
965177|NCT02185352|Breast Cancer
965178|NCT02185352|Chemotherapy
965179|NCT02185352|Whole Brain Radiotherapy
965180|NCT02185339|Respiratory mechanics
965181|NCT02185339|Respiratory function test
965182|NCT02185339|Hemodynamics
965183|NCT02185326|Poor responders
965184|NCT02185326|Poor ovarian response
965185|NCT02185326|IVF/ICSI
965186|NCT02185326|Microflare protocol
965187|NCT02185326|Growth hormone
965188|NCT02185326|Oral contraceptive pills
965189|NCT02185300|GSK1349572
965190|NCT02185300|granule
965191|NCT02185300|pediatric
965192|NCT02185300|CONTREX mineral water
965193|NCT02185300|free-acid
965194|NCT02185300|chelating
965195|NCT02185300|cations
965196|NCT02185300|divalent
965197|NCT02185300|dolutegravir
965198|NCT02185300|dispersible tablet
965199|NCT02185300|relative bioavailability
965200|NCT02185274|Transsexualism
965201|NCT02185274|Cross-sex hormone treatment
965202|NCT02185274|Sex hormones
965203|NCT02185274|Mood
965204|NCT02185274|Stress
965205|NCT02185274|Cortisol
965206|NCT02185274|Cardiovascular
965207|NCT02185274|Metabolome
965208|NCT02185261|Relapse
965209|NCT02185261|Minimal residual disease
965210|NCT02185261|Graft-versus-host disease
965211|NCT02185261|Acute leukemia
965212|NCT02185261|Interferon Alfa-2b
965213|NCT02185248|Pediatric Obesity
965214|NCT02185248|Body Mass Index
965215|NCT02185248|Weight Perception
965216|NCT02185248|Counseling
965217|NCT02185248|Health Behavior
965218|NCT02185235|Electrical stimulation
965219|NCT02185235|Biofeedback
965220|NCT02185222|Vitamin D
965221|NCT02185222|Cholecalciferol
965222|NCT02185222|25-hydroxyvitamin D
965223|NCT02185222|Memory complaint
965224|NCT02185222|Subjective memory complaint
965225|NCT02185222|Mild cognitive impairment
965226|NCT02185222|Preventive therapy
965227|NCT02185222|Cognitive disorders
965228|NCT02185196|Vitamin D,
965229|NCT02185196|Severe pneumonia,
965230|NCT02185196|Under-five children,
965231|NCT02185196|Randomised
965232|NCT02185196|Controlled
965233|NCT02185196|Trial (RCT)
965234|NCT02185196|Morbidity
965235|NCT02185170|Prostate
965236|NCT02185170|Cancer
965237|NCT02185170|Medical Device
965238|NCT02185170|Fluorescence
965239|NCT02185157|elderly
965240|NCT02185157|dual-task training
965241|NCT02185157|aerobic training
965242|NCT02185157|gait
965243|NCT02185157|cognition
965244|NCT02185144|HIV, mental health, substance abuse
965245|NCT02185131|Major Depressive Disorder
965246|NCT02185131|Alcohol Use Disorder
965247|NCT02185092|exacerbations
965248|NCT02185092|COPD
965249|NCT02185092|pneumonia
965250|NCT02185092|probiotic
965251|NCT02185079|labor
965252|NCT02185079|epidural
965253|NCT02185040|Lupus, Systemic Lupus, SLE
965254|NCT02185027|Oral anticoagulants
965255|NCT02185027|Surgery
965256|NCT02185027|Haemorrhage
965257|NCT02185027|Emergency
965258|NCT02185014|Crohn's Disease
965259|NCT02185001|Medial patellofemoral ligament
965260|NCT02185001|MPFL
965261|NCT02185001|Repair
965262|NCT02185001|Patellar dislocation
965263|NCT02185001|Knee
965264|NCT02184988|Glabellar Lines
965265|NCT02184988|Botulinum purifies neurotoxin, Type A (DWP-450)
965266|NCT02184975|cold knife conization
965267|NCT02184975|lateral hemostatic sutures
965268|NCT02184975|cervix
965269|NCT02184949|PCI
965270|NCT02184949|Coronary angioplasty
965271|NCT02184949|Percutaneous transluminal coronary angioplasty
965272|NCT02184949|PTCA
965273|NCT02184936|CT Angiography, CT Perfusion, Ischemic Stroke, Collaterals
965274|NCT02184910|atrophic gastritis, pepsinogen, Helicobacter pylori
965275|NCT02184884|off-pump coronary artery bypass surgery, clopidogrel responsiveness, ischemic outcome
965276|NCT02184871|intrahepatic cholangiocarcinoma
965277|NCT02184871|RNAseq
965278|NCT02184871|risk factors
965279|NCT02184871|asbestos
965280|NCT02184845|single tooth implant
965281|NCT02184845|supported restoration(s)
965282|NCT02184845|maxillary lateral incisor
965283|NCT02184845|mandibular central incisor
965284|NCT02184845|lateral incisor
965285|NCT02184845|areas of the mouth
965286|NCT02184819|coronary artery bypass graft
965287|NCT02184819|left ventricular dysfunction
965288|NCT02184819|low cardiac output syndrome
965289|NCT02184819|levosimendan
965290|NCT02184819|mortality
965291|NCT02184819|inotropic agents
965292|NCT02184819|cardiac mechanical assist devices
965293|NCT02184819|renal replacement therapy
965294|NCT02184819|mechanical ventilation duration
965295|NCT02184819|ICU stay
965296|NCT02184806|Ovarian tissue transplantation
965297|NCT02184806|Cryopreserved ovarian tissue
965298|NCT02184793|mechanical ventilation
965299|NCT02184793|semirecumbent position
965300|NCT02184793|electronic monitoring device
965301|NCT02184780|Neurodevelopment
965302|NCT02184780|General Anaesthesia
965303|NCT02184780|Infants
965304|NCT02184780|Epidural
965305|NCT02184780|Spinal
965306|NCT02184780|Anxiety and depression
965307|NCT02184754|Magnetic endoscope imaging
965308|NCT02184754|single-balloon-enteroscopy
965309|NCT02184741|IVIG
965310|NCT02184741|Unexplained Recurrent miscarriage
965311|NCT02184741|Recurrent abortion
965312|NCT02184741|Intravenous immunoglobulin
965313|NCT02184728|end-tidal CO2
965314|NCT02184728|capnometer
965315|NCT02184715|virtual reality system, children, developmental delay
965316|NCT02184676|Type 1 diabetes
965317|NCT02184676|risk assessment
965318|NCT02184676|immunological marker
965319|NCT02184676|children
965320|NCT02184676|relatives
965321|NCT02184676|autoantibodies
965322|NCT02184676|lymphocytes
965323|NCT02184676|T cells
965324|NCT02184676|epitopes
965325|NCT02184676|Children born to mother/father with type 1 diabetes and their parents
965326|NCT02184663|Unresectable
965327|NCT02184663|Pancreatic cancer
965328|NCT02184663|GERCOR
965329|NCT02184663|Adapted physical activity (APA)
965330|NCT02184663|Quality of life
965331|NCT02184663|Fatigue
965332|NCT02184650|Premature infants
965333|NCT02184650|Nutritional status
965334|NCT02184650|Polyunsaturated fatty acids status
965335|NCT02184637|Malaria
965336|NCT02184637|Artemisinin-based Combination Therapies (ACT)
965337|NCT02184624|BREEZHALER
965338|NCT02184624|DISKUS/ACCUHALER
965339|NCT02184624|MDI
965340|NCT02184624|Inhaler preference
965341|NCT02184624|Overall inhaler error
965342|NCT02184624|HANDIHALER
965343|NCT02184624|Ease of use
965344|NCT02184624|TURBUHALER
965345|NCT02184624|ELLIPTA
965346|NCT02184624|Critical inhaler error
965354|NCT02184598|ADHD
965355|NCT02184598|Cognitive training
965356|NCT02184598|fMRI
965357|NCT02184598|Cognitive function
965358|NCT02184585|bioavailability
965359|NCT02184585|crossover design
965360|NCT02184585|healthy male volunteers
965361|NCT02184585|tamsulosin hydrochloride
965362|NCT02184585|Dutasteride
965363|NCT02184572|Rubella
965364|NCT02184572|Healthy children
965365|NCT02184572|Measles
965366|NCT02184572|Safety
965367|NCT02184572|Mumps
965368|NCT02184572|12 to 15 months
965369|NCT02184572|Immunogenicity
965370|NCT02184507|insulin resistance
965371|NCT02184507|blood glucose
965372|NCT02184507|CABG
965373|NCT02184507|oxidative stress
965374|NCT02184494|Parkinson's Disease
965375|NCT02184494|Multiple Sclerosis
965376|NCT02184494|Fatigue
965377|NCT02184494|Resting Energy Expenditure
965378|NCT02184494|Whole Body Vibration
965379|NCT02184494|Exercise
965380|NCT02184494|Blood Lactate
965381|NCT02184481|Depression
965382|NCT02184481|Anxiety
965383|NCT02184481|Working memory
965384|NCT02184481|Rumination
965385|NCT02184481|Cognitive training
965386|NCT02184481|Executive functioning
965387|NCT02184468|Cardiac Arrest
965388|NCT02184468|Out-of-Hospital Cardiac Arrest
965389|NCT02184468|Firefighters
965390|NCT02184468|Police
965391|NCT02184468|Defibrillators
965392|NCT02184468|Survival
965393|NCT02184455|Diabetic
965394|NCT02184455|Chronic Ulcer
965395|NCT02184455|Wound Healing
965396|NCT02184455|Leg
965397|NCT02184442|SAPIEN
965398|NCT02184442|TAVR
965399|NCT02184442|THV
965400|NCT02184442|Aortic Stenosis
965401|NCT02184442|Heart Valve Disease
965402|NCT02184442|Aortic Valve
965403|NCT02184442|Retroflex
965404|NCT02184442|Ascendra
965405|NCT02184429|First in human
965406|NCT02184429|single ascending dose study
965407|NCT02184429|multiple ascending dose study
965408|NCT02184429|safety and tolerability
965409|NCT02184429|pharmacokinetics
965410|NCT02184429|food effect
965411|NCT02184429|Parkinson's Disease
965412|NCT02184416|Inlyta
965413|NCT02184416|axitinib
965414|NCT02184416|Sutent
965415|NCT02184416|sunitinib
965416|NCT02184416|renal
965417|NCT02184390|Internet
965418|NCT02184390|Education
965419|NCT02184377|quantitative laryngeal electromyography
965420|NCT02184377|cricothyroid muscle
965421|NCT02184377|unilateral vocal fold paralysis
965422|NCT02184377|superior laryngeal nerve
965423|NCT02184377|lexical tone
965424|NCT02184377|Mandarin
965425|NCT02184221|Deep-brain magnetic stimulation
965426|NCT02184221|Brain derived neurotropic factor
965427|NCT02184221|Effectiveness
965428|NCT02184221|Safety
965429|NCT02184208|ARDS
965430|NCT02184208|ALI
965431|NCT02184208|mechanical ventilation
965432|NCT02184195|BRCA, metastatic adenocarcinoma pancreas, maintenance olaparib monotherapy, first line platinum chemotherapy, pancreatic cancer, PARP inhibitor
965433|NCT02184169|hemodynamics
965434|NCT02184169|neonatal
965435|NCT02184169|cardiac disease
965436|NCT02184169|congenital heart disease
965437|NCT02184169|volumetric oxygen consumption
965438|NCT02184117|Fractional Flow Reserve, Myocardial
965439|NCT02184117|Adenosine
965440|NCT02184117|Contrast Media
965441|NCT02184104|caffeine
965442|NCT02184104|pharmacokinetics
965443|NCT02184104|pharmacodynamics
965444|NCT02184026|nightmare
965445|NCT02184026|PTSD
965446|NCT02184026|trauma
965447|NCT02184026|children
965448|NCT02184026|Children Age 8 to 13
965449|NCT02184013|Atrial fibrillation
965450|NCT02184013|Catheter ablation
965451|NCT02184013|Delayed gadolinium enhanced MRI
965452|NCT02184013|C-metahydroxyepherdrine (HED) PET scan
965453|NCT02184013|ECGI mapping
965454|NCT02184013|Atrial Fibrosis
965455|NCT02184013|Atrial sympathetic denervation
965456|NCT02184000|strain elastography
965457|NCT02184000|hepatopathy
965458|NCT02184000|liver fibrosis
965459|NCT02183987|Knowledge Translation
965460|NCT02183987|Chronic Kidney Disease
965461|NCT02183987|Dialysis
965462|NCT02183987|Intent-to-defer
965463|NCT02183987|Early dialysis
965464|NCT02183987|Cluster randomized trial
965465|NCT02183974|otitis media with effusion
965466|NCT02183974|Laryngopharyngeal Reflux
965467|NCT02183961|otitis media with effusion
965468|NCT02183961|peptest
965469|NCT02183961|restech
965470|NCT02183961|oropharyngeal pH monitoring
965471|NCT02183961|laryngopharyngeal reflux
965472|NCT02183948|treatment
965473|NCT02183948|mask face exoressions
965474|NCT02183948|genier
965475|NCT02183935|Obesity
965476|NCT02183935|Diabetes
965477|NCT02183935|Metabolic syndrome
965478|NCT02183935|Gut hormones
965479|NCT02183935|Adipokines
965480|NCT02183935|Appetite
965481|NCT02183935|Adolescent
965482|NCT02183896|Femoroacetabular impingement (FAI)
965483|NCT02183896|Chondral lesions
965484|NCT02183896|Hip
965485|NCT02183896|Microfracture
965486|NCT02183896|Platelet-rich plasma (PRP)
965487|NCT02183883|Non-small cell lung cancer
965488|NCT02183883|NSCLC
965489|NCT02183883|Afatinib
965490|NCT02183883|Intra-tumour heterogeneity
965491|NCT02183883|Clonal dominance
965492|NCT02183883|Drug resistance
965493|NCT02183883|EGFR
965494|NCT02183883|HER2
965495|NCT02183883|Phase 2
965496|NCT02183870|lung cancer
965497|NCT02183870|adenocarcinoma
965498|NCT02183870|NSCLC
965499|NCT02183870|ROS1
965500|NCT02183870|ROS1 translocation
965501|NCT02183870|crizotinib
965502|NCT02183870|phase II
965503|NCT02183857|children
965504|NCT02183857|congenital heart disease
965505|NCT02183844|Medical Informatics
965506|NCT02183844|Patient-Centered
965507|NCT02183844|Healthcare Preferences
965508|NCT02183844|Health Education
965509|NCT02183844|Quality Improvement
965510|NCT02183844|Weight Loss
965511|NCT02183844|Personal Satisfaction
965512|NCT02183844|Humans
965513|NCT02183844|Cognition
965514|NCT02183844|Body Weight
965515|NCT02183818|Smoking
965516|NCT02183818|COPD
965517|NCT02183818|Non-Smokers
965518|NCT02183818|Smokers
965519|NCT02183805|triple negative breast cancer
965520|NCT02183805|autologous hematopoietic stem-cell transplantation
965521|NCT02183779|post-occlusive hyperaemia
965522|NCT02183779|laser-speckle contrast imaging
965523|NCT02183779|epoxyeicosatrienoic acid
965524|NCT02183779|nitrous oxide
965525|NCT02183753|LAIV
965526|NCT02183753|Flumist
965527|NCT02183753|wood smoke
965528|NCT02183740|Education
965529|NCT02183740|Nurses
965530|NCT02183740|Nursing homes
965531|NCT02183740|Fecal incontinence
965532|NCT02183740|Cluster-randomized controlled trial
965533|NCT02183727|ACL
965534|NCT02183727|knee injury
965535|NCT02183727|anterior cruciate ligament
965536|NCT02183597|Magnetic Resonance Imaging
965537|NCT02183597|Data Accuracy
965538|NCT02183597|Reproducibility of Results
965539|NCT02183597|Diagnosis
965540|NCT02183558|PCOS
965541|NCT02183558|GDM
965542|NCT02183558|OGTT
965543|NCT02183558|Glucose metabolism
965544|NCT02183519|Cough
965545|NCT02183519|Reflex
965546|NCT02183519|Voluntary
965547|NCT02183519|Healthy older adults
965548|NCT02183519|Parkinson's disease
965549|NCT02183519|Respiratory kinematics
965550|NCT02183519|Cueing
965551|NCT02183454|intracoronary stent
965552|NCT02183454|drug eluting stent
965553|NCT02183454|sirolimus
965554|NCT02183454|endothelial progenitor cells
965555|NCT02183272|Depression
965556|NCT02183272|Suicidal Ideation
965557|NCT02183272|Ketamine
965558|NCT02183272|Emergency Department
965559|NCT02183207|percutaneous endoscopic gastrostomy
965560|NCT02183207|Introducer method
965561|NCT02182999|Hallux valgus surgery
965562|NCT02182999|wound infiltration
965563|NCT02182999|pain
965564|NCT02182986|Biomarkers
965565|NCT02182986|Post-Transplant Lymphoproliferative Disorders (PTLDs)
965566|NCT02182973|neonatal abstinence syndrome, infant opiate withdrawal
965567|NCT02182947|Pediatric
965568|NCT02182947|Inflammatory Bowel Disease
965569|NCT02182947|capsule endoscopy
965570|NCT02182947|MRI
965571|NCT02182947|Crohn's Disease
965572|NCT02182947|Indeterminant Colitis
965573|NCT02182947|Small bowel Crohn's Disease
965574|NCT02182908|Aneurysm of abdominal aorta
965575|NCT02182908|18F-fluorodesoxyglucose (FDG-F18)
965576|NCT02182843|Cellentra ACDF
965577|NCT02182817|General Anaesthesia
965578|NCT02182817|Neurocognitive Development
965579|NCT02182817|Behaviour
965580|NCT02182804|Confocal Laser Endomicroscopy
965581|NCT02182804|Narrow Band Imaging
965582|NCT02182804|Lugol Chromoendoscopy
965583|NCT02182804|Esophageal Neoplasm
965584|NCT02182804|Head and Neck Cancer
965585|NCT02182687|Hepatocellular carcinoma (HCC)
965586|NCT02182687|Orthotopic liver transplant
965587|NCT02182687|Bridge to transplant
965717|NCT02181361|aspirin
965588|NCT02182687|stereotactic body radiation therapy (SBRT)
965589|NCT02182687|trans-arterial chemoembolization (TACE)
965590|NCT02182596|Acute Myeloid Leukemia
965591|NCT02182596|First relapsing AML
965592|NCT02182466|Colon capsule endoscopy
965593|NCT02182466|Colonoscopy
965594|NCT02182466|Screening colonoscopy
965600|NCT02182167|Drug Induced Hepatitis (DIH)
965601|NCT02182167|Toxic Liver
965602|NCT02182167|Drug Induced Liver Injury (DILI)
965603|NCT02182115|Staphylococcus aureus infection
965604|NCT02182115|Decolonization
965605|NCT02182115|Surgical site infection
965606|NCT02181894|Infant
965607|NCT02181894|Newborn
965608|NCT02181894|Neonate
965609|NCT02181894|Intubation
965610|NCT02181894|Neonatal resuscitation
965611|NCT02181842|Pharmacological therapy
965612|NCT02181829|Whole Lung IMRT
965613|NCT02181829|14-075
965614|NCT02181816|Pharmacological therapy
965615|NCT02181790|psoriasis
965616|NCT02181790|palmoplantar
965617|NCT02181790|acitretin
965618|NCT02181790|retinoids
965619|NCT02181790|laser treatment
965620|NCT02181777|Psychosis
965621|NCT02181777|Schizophrenia
965622|NCT02181777|Social Skills
965623|NCT02181777|Therapy
965624|NCT02181764|XLH
965625|NCT02181751|Child Sexual Abuse
965626|NCT02181751|CSA
965627|NCT02181751|Treatment
965628|NCT02181751|Prevention
965629|NCT02181751|PTSD
965630|NCT02181751|Post Traumatic Stress Disorder
965631|NCT02181751|Depression
965632|NCT02181751|Anxiety
965633|NCT02181751|Quality of Life
965634|NCT02181751|Attachment
965635|NCT02181751|Cognitive Behavioural Therapy
965636|NCT02181751|Group Therapy
965637|NCT02181725|Chronic Pain
965638|NCT02181725|Adolescent
965639|NCT02181725|Graded Exposure
965640|NCT02181712|Bronchiolitis obliterans
965641|NCT02181712|lung transplant
965642|NCT02181712|mesenchymal stem cell
965643|NCT02181712|cell therapy
965644|NCT02181686|Heart Failure
965645|NCT02181686|Iperia ICD family
965646|NCT02181686|Sentus QP left ventricular lead
965647|NCT02181686|Quadripolar CRT-D system
965648|NCT02181673|Psoriatic arthritis
965649|NCT02181673|Golimumab
965650|NCT02181673|Simponi
965651|NCT02181660|AML
965652|NCT02181660|Acute myeloid leukemia
965653|NCT02181660|ASP2215
965654|NCT02181634|Advanced Cholangiocarcinoma
965655|NCT02181634|Metastatic Cholangiocarcinoma
965656|NCT02181634|CCA
965657|NCT02181634|Bile Duct Cancer
965658|NCT02181634|Nab-Paclitaxel
965659|NCT02181634|Abraxane®
965660|NCT02181634|Gemcitabine
965661|NCT02181634|Gemzar®
965662|NCT02181608|Alcohol Dependence
965663|NCT02181608|Fear Conditioning
965664|NCT02181608|Stress
965665|NCT02181608|Alcohol
965666|NCT02181595|Reading
965667|NCT02181595|FACIT-SP
965668|NCT02181595|Primary Ovarian Insufficiency
965669|NCT02181582|Health Humans
965670|NCT02181582|Receptor Occupancy
965671|NCT02181569|Addiction Severity Index
965672|NCT02181569|Addiction
965673|NCT02181569|Sleep Measures
965674|NCT02181569|Sleep Disorders
965675|NCT02181556|colorectal cancer
965676|NCT02181556|Metastatic
965677|NCT02181543|Clonidine
965678|NCT02181543|Psychomotor agitation
965679|NCT02181543|Anesthesia recovery period
965680|NCT02181543|Tonsillectomy
965681|NCT02181543|Child, preschool
965682|NCT02181478|Total Body Irradiation
965683|NCT02181478|Human Mesenchymal Stromal Cells
965684|NCT02181478|hMSC
965685|NCT02181478|Cyclophosphamide
965686|NCT02181478|Fludarabine
965687|NCT02181478|Dimethyl Sulfoxide
965688|NCT02181478|DMSO
965689|NCT02181478|Cyclosporine
965690|NCT02181478|Mycophenolate Mofetil
965691|NCT02181478|MMF
965692|NCT02181478|Granulocyte- Colony Stimulating Factor
965693|NCT02181478|G-CSF
965694|NCT02181478|GVHD
965695|NCT02181478|Cancer
965696|NCT02181478|feasibility
965697|NCT02181452|liver
965698|NCT02181452|fibrosis
965699|NCT02181452|ShearWave Elastography
965700|NCT02181452|ultrasound
965701|NCT02181426|Knee Arthroscopy
965702|NCT02181413|Drug therapy
965703|NCT02181413|TOURMALINE
965704|NCT02181413|ixazomib
965705|NCT02181400|diabetic retinopathy
965706|NCT02181400|diabetic macular edema
965707|NCT02181400|diabetic macular oedema
965708|NCT02181400|near infrared light therapy
965709|NCT02181387|labor pain
965710|NCT02181387|acetaminophen
965711|NCT02181374|atrial fibrillation
965712|NCT02181374|NT-proBNP
965713|NCT02181374|Cardioembolic Stroke
965714|NCT02181361|atrial fibrillation
965715|NCT02181361|cardioembolic stroke
965716|NCT02181361|Hirudin
965718|NCT02181361|warfarin
965719|NCT02181348|Vitamin E, Hemoglobin, mild anemia
965720|NCT02181296|Shoulder arthroscopy
965721|NCT02181296|Interscalene block
965722|NCT02181296|Drug concentration
965723|NCT02181296|0.1% ropivacaine or 0.2% ropivacaine
965727|NCT02181270|NAFLD
965728|NCT02181270|obesity
965729|NCT02181270|ck18
965730|NCT02181270|blood lipids
965731|NCT02181270|high intensity exercise training
965732|NCT02181270|individuals
965733|NCT02181270|>5% liver fat
965734|NCT02181257|Bronchiolitis Obliterans Syndrome
965735|NCT02181257|Lung Transplantation
965736|NCT02181257|Extracorporeal Photopheresis
965737|NCT02181257|Methoxsalen
965738|NCT02181244|egg
965739|NCT02181244|oatmeal
965740|NCT02181244|atherogenic dyslipidemia
965741|NCT02181244|glycosylated hemoglobin
965742|NCT02181244|inflammatory markers
965743|NCT02181231|depression
965744|NCT02181231|older adult
965745|NCT02181231|buprenorphine
965746|NCT02181231|Effexor XR
965747|NCT02181231|treatment resistant
965748|NCT02181231|venlafaxine
965749|NCT02181231|Saint Louis
965750|NCT02181231|late life
965751|NCT02181231|major depression
965752|NCT02181192|biochemical recurrence
965753|NCT02181192|prostate carcinoma
965754|NCT02181192|prostate cancer
965755|NCT02181192|PSA
965756|NCT02181192|postoperative
965757|NCT02181192|radiotherapy
965758|NCT02181192|imaging diagnostic
965759|NCT02181192|PET/CT
965760|NCT02181192|social economic aspects
965761|NCT02181192|quality of life
965762|NCT02181179|yoga
965763|NCT02181179|exercise intervention
965764|NCT02181179|smoking
965765|NCT02181179|stress
965766|NCT02181179|mind-body
965767|NCT02181179|intervention
965768|NCT02181166|Breast Neoplasms
965769|NCT02181166|Mastectomy
965770|NCT02181166|Myofascial pain syndromes
965771|NCT02181166|Physical Therapy Modalities
965772|NCT02181153|inflammatory bowel disease
965773|NCT02181153|siblings
965774|NCT02181140|fine needle aspiration
965775|NCT02181140|core biopsy
965776|NCT02181140|endoscopic ultrasound
965777|NCT02181140|space occupying process mediastinal, perigastral, perihilar
965778|NCT02181140|suspect lymph nodes mediastinal, perigastral or perihilar
965779|NCT02181140|diagnostic accuracy of EUS guided core biopsy
965780|NCT02181127|bionic pancreas
965781|NCT02181127|artificial pancreas
965782|NCT02181127|insulin
965783|NCT02181127|glucagon
965784|NCT02181127|continuous glucose monitoring (CGM)
965785|NCT02181127|outpatient
965786|NCT02181127|insulin pump
965787|NCT02181127|glucagon pump
965788|NCT02181114|Coaching
965789|NCT02181114|Educational Materials
965790|NCT02181114|Expert System
965791|NCT02181114|Living Donor Kidney Transplant
965792|NCT02181088|Malaria
965793|NCT02181088|Plasmodium falciparum
965794|NCT02181088|RH5
965795|NCT02181075|ThermoDox
965796|NCT02181075|High Intensity Focused Ultrasound
965797|NCT02181075|Lyso thermosensitive Liposomal
965798|NCT02181075|Non invasive drug delivery
965799|NCT02181075|Hepatic metastatic disease
965800|NCT02181075|Liver tumour(s)
965801|NCT02181075|Targeted Release of Chemotherapy
965802|NCT02181062|Stroke
965803|NCT02181062|Stroke prevention
965804|NCT02181062|older adults
965805|NCT02181062|self efficacy
965806|NCT02181062|walking
965807|NCT02181062|minorities
965808|NCT02181062|minority older adults
965809|NCT02181062|hypertension
965810|NCT02181062|high blood pressure
965811|NCT02181062|elderly
965812|NCT02181062|sedentary lifestyle
965813|NCT02181049|Childhood cancer survivors
965814|NCT02181049|Cardiac
965815|NCT02181049|Vascular
965816|NCT02181049|Cardiovascular
965817|NCT02181049|Late-sequelae
965818|NCT02181036|Family work shop
965819|NCT02181036|speech developmental delays
965820|NCT02181036|children
965821|NCT02181023|COPD
965822|NCT02181023|Hyperinflation
965823|NCT02181023|Aclidinium
965824|NCT02181023|Glycopyrronium
965825|NCT02181023|Volume distribution
965826|NCT02181023|Anticholinergic
965827|NCT02181023|Pharmacokinetics
965828|NCT02181023|Single Breath Nitrogen Test
965829|NCT02181023|Phase III
965830|NCT02181010|African American
965831|NCT02181010|Adolescents
965832|NCT02181010|Urban
965833|NCT02181010|Food Desert
965834|NCT02181010|Food Insecurity
965835|NCT02181010|Obesity
965836|NCT02181010|Baltimore City
965837|NCT02181010|Peer mentors
965838|NCT02181010|Multi level
965839|NCT02181010|Policy
965840|NCT02181010|Caregivers
965841|NCT02181010|Systems
965842|NCT02181010|Agent Based Model
965843|NCT02181010|Systems Dynamic Model
965844|NCT02181010|Corner Store
965845|NCT02181010|Carryout
965846|NCT02181010|Recreation Center
965847|NCT02181010|Text Messaging
965848|NCT02181010|Social Media
965849|NCT02181010|Mapping
965850|NCT02180997|α1-blockers
965851|NCT02180997|antimuscarinic agent
965852|NCT02180984|Binge Eating
965853|NCT02180984|Obesity
965854|NCT02180984|TMS
965855|NCT02180984|Neuroimage
965856|NCT02180984|Neuromodulation
965857|NCT02180984|Biomarkers
965858|NCT02180984|Eating Disorders
965859|NCT02180984|Cognition
965860|NCT02180984|Endocrine
965861|NCT02180984|Hormones
965862|NCT02180984|BDNF
965863|NCT02180984|Inflammatory biomarkers
965864|NCT02180971|Multi-detector computed tomography angiography
965865|NCT02180971|Coronary vessel distensibility
965866|NCT02180971|Coronary spasm
965867|NCT02180958|cerebral arteriovenous malformations
965868|NCT02180958|cAVM
965869|NCT02180958|ONYX
965870|NCT02180945|dAVF
965871|NCT02180945|Arteriovenous fistula
965872|NCT02180945|ONYX
965873|NCT02180919|Telemonitoring
965874|NCT02180919|COPD
965875|NCT02180919|Heart failure
965876|NCT02180919|Exacerbation
965877|NCT02180919|Respiratory failure
965878|NCT02180919|Prevention
965879|NCT02180919|Self monitoring
965880|NCT02180906|Fasciitis
965881|NCT02180906|Gangrene
965882|NCT02180906|Fasciitis, Necrotizing
965883|NCT02180906|Soft Tissue Infections
965884|NCT02180906|Fournier's Gangrene
965885|NCT02180906|Streptococcal septic shock syndrome
965886|NCT02180906|Flesh eating bacteria
965887|NCT02180906|Meleneys ulcer
965888|NCT02180906|Wounds and Injuries
965889|NCT02180906|Streptococcus pyogenes
965890|NCT02180906|Staphylococcus aureus
965891|NCT02180906|Immunopathogenesis
965892|NCT02180906|Soft Tissue Infections/blood
965893|NCT02180906|Necrosis/blood
965894|NCT02180906|Necrosis/diagnosis
965895|NCT02180906|Necrosis/mortality
965896|NCT02180906|Necrosis/surgery
965897|NCT02180906|Prognosis
965898|NCT02180906|Risk Factors
965899|NCT02180906|Bacterial Infections
965900|NCT02180906|Infection
965901|NCT02180906|Skin Diseases, Bacterial
965902|NCT02180906|Observational study
965903|NCT02180906|Biological markers
965904|NCT02180880|Neuralgia
965905|NCT02180880|Spinal cord
965906|NCT02180880|Oxcarbazepine
965907|NCT02180880|Pregabalin
965908|NCT02180880|Drug therapy
965909|NCT02180880|Algorithms
965910|NCT02180854|Early warning score
965911|NCT02180854|Rapid response systems
965912|NCT02180854|Medical emergency team
965913|NCT02180841|soy
965914|NCT02180841|hypertension
965915|NCT02180841|HDL-C
965916|NCT02180841|cholesterol efflux
965917|NCT02180841|cardiovascular disease
965918|NCT02180815|Obstructive Sleep Apnea
965919|NCT02180815|Obstructive Sleep Apnea due to primary tongue base closure
965920|NCT02180815|Minimally invasive surgery
965921|NCT02180815|ReVENT Sleep Apnea System
965922|NCT02180815|Tongue implants
965923|NCT02180802|obese adolescents
965924|NCT02180802|BMI ≥ 95th percentile for age and gender
965925|NCT02180789|tamsulosin,
965926|NCT02180789|benign prostatic hyperplasia,
965927|NCT02180789|α1-adrenoceptor antagonists
965928|NCT02180763|Primary Immunodeficiency, PID
965929|NCT02180750|Children
965930|NCT02180750|HIV
965931|NCT02180750|orphans
965932|NCT02180737|dexmedetomedine
965933|NCT02180737|sedation
965934|NCT02180737|interventional radiology
965935|NCT02180724|Bruton tyrosine kinase inhibitor
965936|NCT02180724|Btk
965937|NCT02180724|Waldenström Macroglobulinemia
965938|NCT02180724|WM
965939|NCT02180724|Waldenström
965940|NCT02180724|Macroglobulinemia
965941|NCT02180711|Bruton tyrosine kinase inhibitor
965942|NCT02180711|Btk
965943|NCT02180711|Follicular Lymphoma
965944|NCT02180711|FL
965945|NCT02180711|acalabrutinib
965946|NCT02180711|ACP-196
965947|NCT02180672|Obstructive sleep apnea syndrome
965948|NCT02180672|OSA
965949|NCT02180672|sleep apnea
965950|NCT02180672|nasal steroids
965951|NCT02180672|corticosteroids
965952|NCT02180646|GLP-1
965953|NCT02180646|GIP
965954|NCT02180646|second meal phenomena
965955|NCT02180646|type 2 diabetes
965956|NCT02180633|Idiopathic Macular Hole
965957|NCT02180620|GIP
965958|NCT02180620|GLP-1
965959|NCT02180620|exercise timing
965960|NCT02180620|resistance exercise
965961|NCT02180620|glucose concentrations
965962|NCT02180607|depression
965963|NCT02180607|social
965964|NCT02180607|rejection
965965|NCT02180607|acceptance
965966|NCT02180607|fMRI
965967|NCT02180607|reward
965968|NCT02180607|exclusion
965969|NCT02180581|Infections
965970|NCT02180581|Allergy
965971|NCT02180581|Immune function
965972|NCT02180581|Microbiota
965973|NCT02180581|Infant
965974|NCT02180568|Ground-glass-opacity (GGO)
965975|NCT02180568|Lung localization
965976|NCT02180568|Lipiodol
965977|NCT02180568|Hook wire
965978|NCT02180568|Video assisted thoracic surgery (VATS)
965979|NCT02180542|stroke
965980|NCT02180542|Ischemic stroke
965981|NCT02180542|Cerebral infarction
965982|NCT02180542|recurrent stroke
965983|NCT02180542|atrial fibrillation
965984|NCT02180542|premature atrial complexes
965985|NCT02180542|heart rhythm monitoring
965986|NCT02180542|left atrial function
965987|NCT02180542|carotid artery
965988|NCT02180542|plaque morphology
965989|NCT02180529|methylphenidate, elderly, mild cognitive impairment
965990|NCT02180464|psoriasis, topical
965991|NCT02180438|HIV-2
965992|NCT02180425|acne
965993|NCT02180425|lipid
965994|NCT02180425|tretinoin
965995|NCT02180425|isotretinoin
965996|NCT02180412|Acute porphyria
965997|NCT02180412|Hemin
965998|NCT02180399|Sepsis
965999|NCT02180399|Capillary blood lactate
966000|NCT02180399|Serial measurement of capillary
966001|NCT02180386|Audiovisual distraction
966002|NCT02180386|Pediatric dentistry
966003|NCT02180360|Capoeira training
966004|NCT02180360|Range of motion
966005|NCT02180360|Flexibility
966006|NCT02180360|beginners
966007|NCT02180347|Pediatrics
966008|NCT02180347|Contact lenses
966009|NCT02180334|Gastric Emptying
966010|NCT02180334|Gastrointestinal Motility
966011|NCT02180334|Incretins
966012|NCT02180334|Glucagon-Like Peptide 1
966013|NCT02180334|Diabetes Mellitus
966014|NCT02180321|Tranexamic acid
966015|NCT02180321|pharmacokinetics
966016|NCT02180321|craniosynostosis
966017|NCT02180308|Head cancer
966018|NCT02180308|Neck cancer
966019|NCT02180308|MRI
966020|NCT02180308|PET
966021|NCT02180282|Acne Treatment
966022|NCT02180269|Healthy
966023|NCT02180269|JNJ-54861911
966024|NCT02180269|Alzheimer's disease
966025|NCT02180256|IVF
966026|NCT02180256|ICSI
966027|NCT02180256|Embryo transfer
966028|NCT02180256|Assisted reproduction
966029|NCT02180256|Endometrial injury
966030|NCT02180256|Endometrial scratching
966031|NCT02180243|meditation
966032|NCT02180243|acupuncture
966033|NCT02180243|Gulf War Veterans' Illness
966034|NCT02180243|Gulf War health education
966035|NCT02180243|iRest yoga
966036|NCT02180230|Short implants
966037|NCT02180230|prospective multicenter study
966038|NCT02180230|maxilla & mandible
966041|NCT02180204|Cerebral Infarction
966042|NCT02180204|Ischemic Stroke
966043|NCT02180204|Thrombolysis
966044|NCT02180191|Gut microbiota
966045|NCT02180178|microvascular disease
966046|NCT02180178|coronary artery disease
966047|NCT02180178|Coronary artery disease, with or without microvascular dysfuntion
966048|NCT02180152|Perinatal outcomes
966049|NCT02180113|Cirrhotic patients
966050|NCT02180113|Fibroscan
966051|NCT02180113|Liver Stiffness Measurement
966052|NCT02180113|Oesophageal Varices
966053|NCT02180113|Portal Hypertension
966054|NCT02180113|Spleen Stiffness Measurement
966055|NCT02180087|Cardiac surgery
966056|NCT02180087|Post-operative pain
966057|NCT02180087|Kétoprofène
966058|NCT02180087|Minimum analgesic dose
966059|NCT02180087|Morphin consumption
966060|NCT02180087|Morphin secondary effects
966061|NCT02180087|Patient comfort and satisfaction
966062|NCT02180087|Renal fonction
966063|NCT02180074|Hydrogen Sulfide Pools,
966064|NCT02180061|PD1
966065|NCT02180061|PD-1
966066|NCT02180061|PDL1
966067|NCT02180061|PD-L1
966068|NCT02180035|diet therapy
966069|NCT02180035|symbiotic
966070|NCT02180035|dyslipidemia
966071|NCT02180035|gastrointestinal symptoms
966072|NCT02180035|body composition
966073|NCT02180035|adherence
966074|NCT02180035|HIV
966075|NCT02180035|HAART
966076|NCT02180022|Quercetin
966077|NCT02180022|Endothelial function
966078|NCT02180022|Onion peel extract
966079|NCT02180022|volunteers
966080|NCT02179996|Vaccination
966081|NCT02179996|Very preterm-born infants
966082|NCT02179996|Hib immunisation
966083|NCT02179996|Pertussis immunisation
966084|NCT02179983|Bronchiectasis
966085|NCT02179983|rehabilitation
966086|NCT02179983|exercise
966087|NCT02179983|exacerbations
966088|NCT02179970|Advanced pancreatic cancer
966089|NCT02179970|Advanced ovarian cancer
966090|NCT02179970|Advanced colorectal cancer
966091|NCT02179970|Metastatic pancreatic cancer
966092|NCT02179970|Metastatic ovarian cancer
966093|NCT02179970|Metastatic colorectal cancer
966094|NCT02179957|Stenoses
966095|NCT02179957|Ischaemia
966096|NCT02179957|haemodynamics
966097|NCT02179957|fractional flow reserve (FFR)
966222|NCT02179307|exercise
966098|NCT02179957|computed tomography (CT)
966099|NCT02179957|cardiac
966100|NCT02179944|medication abortion
966101|NCT02179944|serum hCG
966102|NCT02179918|Advanced Solid Tumors
966103|NCT02179905|MRI
966104|NCT02179905|Heart rate variability
966105|NCT02179905|Fatty acid
966106|NCT02179892|anesthesia
966107|NCT02179892|surgery
966108|NCT02179892|pain
966109|NCT02179879|labor,epidural,analgesia
966110|NCT02179853|Kawasaki disease
966111|NCT02179853|Anakinra
966112|NCT02179853|IL-1
966113|NCT02179840|Cerebral microvascular circulation
966114|NCT02179840|Cerebral autoregulation
966115|NCT02179814|bulimia nervosa
966116|NCT02179814|dopamine
966117|NCT02179814|reward
966118|NCT02179814|catechol-O-methyltransferase
966119|NCT02179814|gene
966120|NCT02179814|catecholamines
966121|NCT02179814|alpha-methyl-para-tyrosine
966122|NCT02179814|magnetic resonance imaging
966123|NCT02179801|Abdominal aortic aneurysm
966124|NCT02179801|AAA
966125|NCT02179801|Screening
966126|NCT02179788|lactation
966127|NCT02179788|breastfeeding
966128|NCT02179788|human milk
966129|NCT02179788|insulin
966130|NCT02179788|metformin
966131|NCT02179788|prediabetes
966132|NCT02179788|pre-diabetes
966133|NCT02179788|insulin resistance
966134|NCT02179762|cancer survivor
966135|NCT02179762|prostate cancer
966136|NCT02179762|exercise
966137|NCT02179762|Active surveillance
966138|NCT02179762|EASE
966139|NCT02179749|Alcohol-Related Disorders
966140|NCT02179749|Substance-Related Disorders
966141|NCT02179749|Mental Disorders
966142|NCT02179749|Mifepristone
966143|NCT02179749|Glucocorticoid Antagonists
966144|NCT02179749|Alcohol Treatment
966145|NCT02179749|Alcohol
966146|NCT02179736|Correction of moderate to severe nasolabial folds
966147|NCT02179723|wound healing
966148|NCT02179723|cosmetic results
966149|NCT02179723|trocar incision
966150|NCT02179710|adherence
966151|NCT02179710|cystic fibrosis
966152|NCT02179710|adolescents
966153|NCT02179710|adults
966154|NCT02179697|Groups:
966155|NCT02179697|Group 1 (2 Treatment Arms (Randomized between 2 treatments))
966156|NCT02179697|Treatment 1: Surgery + Bracing
966157|NCT02179697|Treatment 2: Bracing Alone
966158|NCT02179697|Group 2
966159|NCT02179697|The patient will decide which group is best for themselves.
966160|NCT02179684|Cranial Nerve fascial paresis
966161|NCT02179671|Lung cancer; NSCLC
966162|NCT02179658|Clostridium
966163|NCT02179658|Infections
966164|NCT02179658|Difficile
966165|NCT02179658|Vancomycin
966166|NCT02179658|Fidaxomicin
966167|NCT02179632|disclosure
966168|NCT02179632|conflicts of interest
966169|NCT02179632|trust
966170|NCT02179632|patient doctor relationship
966171|NCT02179593|Maxillary expansion
966172|NCT02179593|Orthognathic surgery
966173|NCT02179593|Symmetry
966174|NCT02179593|Palatal expansion technique
966175|NCT02179593|Maxilla abnormality
966176|NCT02179580|Traditional Chinese Medicine
966177|NCT02179580|Clinical trial
966178|NCT02179580|Good Clinical Practice
966179|NCT02179567|Metastatic NSCLC
966180|NCT02179567|Elderly
966181|NCT02179567|1st Line
966182|NCT02179567|Bevacizumab-based treatment
966183|NCT02179541|Otitis media with effusion, viscosity, RGB (red-green-blue).
966184|NCT02179515|Immune Response
966185|NCT02179515|Maximum Tolerated Dose
966186|NCT02179515|Vaccine Therapy
966187|NCT02179515|Increased Expression of Brachyury
966188|NCT02179515|Immunotherapy
966189|NCT02179489|Peritoneal carcinomatosis
966190|NCT02179489|HIPEC
966191|NCT02179489|controlled clinical trial
966192|NCT02179489|colorectal cancer
966193|NCT02179476|Facet joint
966194|NCT02179476|facet joint pain
966195|NCT02179476|facet joint disease
966196|NCT02179476|lumbar pain
966197|NCT02179476|back pain
966198|NCT02179463|Gastric Cancer
966199|NCT02179463|Neoadjuvant chemotherapy
966200|NCT02179463|Response Evaluation
966201|NCT02179437|TIVA
966202|NCT02179437|Propofol
966203|NCT02179437|Postoperative pain
966204|NCT02179437|Liver resection surgery
966205|NCT02179437|Retrospective study
966206|NCT02179424|smoking cessation interventions
966207|NCT02179398|Fever without source
966208|NCT02179398|Antibiotic prescription
966209|NCT02179398|Serious bacterial infection
966210|NCT02179385|Type 2 diabetes
966211|NCT02179385|Type II diabetes
966212|NCT02179359|Stem Cell Transplant
966213|NCT02179346|cartilage defect
966214|NCT02179346|hip
966215|NCT02179346|impingement
966216|NCT02179320|Myofascial Pain Syndrome
966217|NCT02179320|Dry needling
966218|NCT02179320|Clinical Trial
966219|NCT02179307|muscle hypertrophy
966220|NCT02179307|strength
966221|NCT02179307|resistance training
966223|NCT02179307|physical fitness
966224|NCT02179307|health
966225|NCT02179307|physical conditioning
966226|NCT02179294|Pain relief
966227|NCT02179294|Labour
966228|NCT02179294|Child birth
966229|NCT02179294|Anaesthetics
966230|NCT02179268|Antidepressants
966231|NCT02179268|bone mineral density
966232|NCT02179268|bone turnover markers
966233|NCT02179255|DOR
966234|NCT02179255|Premature Ovarian Failure (POF)
966235|NCT02179255|Ovarian Failure
966236|NCT02179255|Human Growth Hormone
966237|NCT02179242|cardiac rehab
966238|NCT02179242|heart failure
966239|NCT02179242|KCCQ
966240|NCT02179242|6 minute walk test
966241|NCT02179242|readmission
966242|NCT02179229|Kidney transplantation
966243|NCT02179229|pCresol
966244|NCT02179229|Immunosuppressant drugs
966245|NCT02179216|Orthostatic hypotension in the elderly
966246|NCT02179216|Efficacity of Hydration
966247|NCT02179216|Difference between hydratation and venous contention
966248|NCT02179177|Vaso-occlusive crisis
966249|NCT02179177|Reduction in hospitalizations
966250|NCT02179177|Sickle Cell Disease
966251|NCT02179151|Prader-Willi Syndrome
966252|NCT02179151|Obesity
966253|NCT02179151|Hyperphagia
966256|NCT02179112|Surgery
966257|NCT02179112|Specialties, Surgical
966258|NCT02179112|Geography, Medical
966259|NCT02179112|Developing Countries
966260|NCT02179112|Developed Countries
966261|NCT02179112|Laparotomy
966262|NCT02179112|Outcome and Process Assessment (Health Care)
966263|NCT02179112|Treatment Outcome
966264|NCT02179112|Quality of Health Care
966265|NCT02179099|overactive bladder
966266|NCT02179099|OAB
966267|NCT02179099|urgency
966268|NCT02179099|botulinum toxin
966269|NCT02179099|BTX
966270|NCT02179099|botox
966271|NCT02179099|intravesical
966272|NCT02179099|TheraCoat
966273|NCT02179099|TCGel
966274|NCT02179099|TC-3 Gel
966275|NCT02179060|Sudden cardiac arrest, RhinoChill -cooling, MRI
966276|NCT02179047|SYNTAX ,NGAL,Cystatin C,Galectin-3,Copeptin.MR-ProANP,sST2.
966277|NCT02179034|tobacco
966278|NCT02179034|electronic cigarettes
966279|NCT02179034|menthol
966280|NCT02179034|flavors
966281|NCT02179021|Thromboelastometry
966282|NCT02179021|Haemostasis
966283|NCT02179021|Hypothermia
966284|NCT02179021|Heart arrest
966285|NCT02179008|Santen
966286|NCT02179008|Eye
966287|NCT02179008|Glaucoma
966288|NCT02179008|Ocular hypertension
966289|NCT02178982|mechanical ventilation
966290|NCT02178982|ARDS
966291|NCT02178982|Ventilator strategy
966292|NCT02178982|outcome
966293|NCT02178943|Molecular Diagnostics
966294|NCT02178943|Heart Transplantation
966295|NCT02178943|Risk Factors
966296|NCT02178943|Prognosis
966297|NCT02178930|HIV
966298|NCT02178930|cardiovascular disease
966299|NCT02178930|self-management
966300|NCT02178930|HIV co-morbidities
966301|NCT02178930|self-efficacy
966302|NCT02178930|coronary heart disease risk
966303|NCT02178930|quality of life
966304|NCT02178904|Ischemia
966305|NCT02178904|Dual Energy Computed Tomography
966306|NCT02178904|Computed Tomographic Perfusion
966307|NCT02178904|Fractional Flow Rate
966308|NCT02178904|Invasive Coronary Angiography
966309|NCT02178904|Coronary Artery Stenosis
966310|NCT02178891|short implants
966311|NCT02178891|Nobel Biocare
966312|NCT02178891|partially edentulous
966313|NCT02178891|maxilla or mandible
966314|NCT02178878|Labor pain and progress, variation, genetic
966315|NCT02178865|translocation
966316|NCT02178839|Non Alcoholic Fatty Liver Disease(NAFLD)
966317|NCT02178839|β- glucan
966318|NCT02178839|Appetite
966319|NCT02178839|Insulin Resistance
966320|NCT02178826|Nocturnal Enuresis
966321|NCT02178826|Rapid Maxillary Expansion
966322|NCT02178826|Orthodontics
966323|NCT02178826|Polysomnography
966324|NCT02178826|Quality of life
966325|NCT02178813|Minocycline
966326|NCT02178813|Neuroprotection
966327|NCT02178813|Stroke
966328|NCT02178787|cerebral blood flow
966329|NCT02178787|near infrared spectroscopy
966330|NCT02178787|transcranial Doppler
966331|NCT02178787|diabetes mellitus
966332|NCT02178787|cerebral autoregulation
966333|NCT02178774|Near-Infrared Spectroscopy (NIRS)
966334|NCT02178774|spinal anesthesia
966335|NCT02178774|cesarean section
966336|NCT02178761|Erectile dysfunction
966337|NCT02178761|Lower Urinary Tract Symptoms
966338|NCT02178761|Peripheral Arterial Disease
966339|NCT02178761|Angioplasty
966340|NCT02178761|Multidetector Computed Tomography
966341|NCT02178748|Tuberculosis
966342|NCT02178748|Phase II
966343|NCT02178748|MVA85A
966344|NCT02178748|Schistosoma mansoni
966345|NCT02178735|pelvic organ prolapse, vaginal mesh, urodynamic studies
966346|NCT02178709|Pancreatic
966347|NCT02178709|Cancer
966348|NCT02178709|Resectable
966349|NCT02178683|TACROLIMUS
966350|NCT02178683|MYCOPHENOLATE MOFETIL
966351|NCT02178683|FLUDARABINE
966352|NCT02178683|HLA-MATCHED
966353|NCT02178683|MIS-MATCHED
966354|NCT02178657|Stroke
966355|NCT02178657|Cell therapy
966356|NCT02178657|Bone marrow
966357|NCT02178605|rhBMP-2
966358|NCT02178605|arthrodesis
966359|NCT02178605|cervical
966360|NCT02178592|integrase inhibitor
966361|NCT02178592|Mycobacterium tuberculosis
966362|NCT02178592|rifampicin-sensitive
966363|NCT02178592|dolutegravir
966364|NCT02178592|antiretroviral therapy-naïve
966365|NCT02178592|HIV-1 infection
966366|NCT02178592|efavirenz
966367|NCT02178592|co-infection
966368|NCT02178579|Heart Failure
966369|NCT02178579|Cardiac Toxicity
966370|NCT02178579|Multiple Myeloma
966371|NCT02178579|Bortezomib
966372|NCT02178579|Carfilzomib
966373|NCT02178566|COPD
966374|NCT02178566|Trepostinil
966375|NCT02178566|Pulmonary Rehabilitation
966376|NCT02178553|Thoracotomy
966377|NCT02178553|Pain
966378|NCT02178540|Human factors, TOBI® Podhaler™, Instructions For use, IFU, CF patients
966379|NCT02178527|Geriatrics
966380|NCT02178527|Accidental Falls
966381|NCT02178527|Podiatry
966382|NCT02178527|Exercise Therapy
966383|NCT02178527|Orthotic Devices
966384|NCT02178527|Foot
966385|NCT02178501|OMEGA-3 PUFA
966386|NCT02178501|type 2 diabetes
966387|NCT02178501|cardiovascular diseases
966388|NCT02178475|NHL
966389|NCT02178475|Breast Cancer
966390|NCT02178423|children, ultrasound, central catheter
966391|NCT02178410|Atrial Fibrillation
966392|NCT02178410|Vitamin D3
966393|NCT02178410|Omega-3 fatty acids
966394|NCT02178410|Fish oil
966395|NCT02178397|erlotinib
966396|NCT02178397|lung cancer
966397|NCT02178397|EGFR mutation
966398|NCT02178384|Loading Forces
966399|NCT02178384|Removable partial dentures
966400|NCT02178384|Bilateral distal extension
966401|NCT02178371|Upper extremity
966402|NCT02178371|Physical therapy modalities
966403|NCT02178358|transforming growth factor beta (TGF-β)
966404|NCT02178345|MRI
966405|NCT02178345|14-126
966406|NCT02178332|Children
966407|NCT02178332|socio-emotional
966408|NCT02178332|socio-emotional skills
966409|NCT02178332|psychiatric symptoms
966410|NCT02178332|SDQ
966411|NCT02178332|Finland
966412|NCT02178332|School
966413|NCT02178332|School community
966414|NCT02178332|Teacher
966415|NCT02178332|Whole school approach
966416|NCT02178332|Intervention
966417|NCT02178332|Effectiveness study
966418|NCT02178332|Cluster randomised trial
966419|NCT02178319|portal hypertension
966420|NCT02178319|Randomized clinical trial
966421|NCT02178319|laparoscopic
966422|NCT02178319|open
966423|NCT02178267|Newborn, preterm, probiotic, resistant microorganisms
966424|NCT02178254|Pseudomonas aeruginosa, ZTI-101, phosphonic acid derivative, Monurol, fosfomycin tromethamine
966425|NCT02178228|Anastomotic Leaks
966426|NCT02178228|Bowel Resection
966427|NCT02178228|Postoperative Complication
966428|NCT02178215|atopic dermatitis
966429|NCT02178215|skin barrier function
966430|NCT02178215|transepidermal water loss
966431|NCT02178215|skin pH
966432|NCT02178215|stratum corneum hydration
966433|NCT02178215|sebum
966434|NCT02178215|wrinkle
966435|NCT02178202|Harmonic technique, Low Back Pain, McKenzie exercise, Pain, Disability
966436|NCT02178189|prenatal opioid exposure
966437|NCT02178189|infant
966438|NCT02178189|weight gain
966439|NCT02178189|infant formula
966440|NCT02178150|Magnesium
966441|NCT02178150|Insulin Resistance
966442|NCT02178150|Lipid profile
966443|NCT02178150|Sex hormones
966444|NCT02178150|Inflammatory factors
966445|NCT02178111|episiotomy, vaginal delivery, randomized, perineum
966446|NCT02178098|LDL
966447|NCT02178098|Cholesterol
966448|NCT02178085|glaucoma
966449|NCT02178085|phase-contrast MRI
966450|NCT02178085|blood flow
966451|NCT02178085|cerebrospinal fluid
966452|NCT02178072|HNSCC
966453|NCT02178059|Healthy volunteers, pharmacokinetic, inhalation
966454|NCT02178046|Gingivitis
966455|NCT02178033|adenoma detection rate, screening colonoscopy
966456|NCT02178020|Knee Arthroplasty
966457|NCT02178020|Osteolysis
966458|NCT02178020|Radiolucent Lines
966459|NCT02177994|Elective Cesarean Section
966460|NCT02177994|Antibiotic prophylaxis
966461|NCT02177994|Timing of Antibiotic prophylaxis
966462|NCT02177994|post cesarean section infection
966463|NCT02177981|Remote Ischemic Preconditioning
966464|NCT02177981|Coronary Artery Bypass Grafting
966465|NCT02177981|Diffusion Weighted Magnetic Resonance Imaging
966466|NCT02177981|Resting State Functional Magnetic Resonance Imaging
966467|NCT02177981|Postoperative Cognitive Dysfunction
966468|NCT02177968|fall
966469|NCT02177968|elderly
966470|NCT02177968|characteristics
966471|NCT02177955|Third Molar
966472|NCT02177955|Anty-anxiety drugs
966473|NCT02177955|hemodynamic
966474|NCT02177955|Benzodiazepines
966475|NCT02177929|Spinal cord injury,
966476|NCT02177929|adaptive sport,
966477|NCT02177929|dynamometry,
966478|NCT02177929|electromyography,
966479|NCT02177929|force platform.
966480|NCT02177916|lung transplantation
966481|NCT02177903|hypothermia
966482|NCT02177903|surgical site infection
966483|NCT02177903|opioid usage
966484|NCT02177903|blood loss
966485|NCT02177903|pain severity
966486|NCT02177903|anxiety
966487|NCT02177903|Length of Stay
966488|NCT02177877|Epilepsy
966489|NCT02177877|Seizures
966490|NCT02177877|Wrist accelerometer
966491|NCT02177877|Epilepsy diary
966492|NCT02177877|Seizure detection
966493|NCT02177877|Biosensor
966494|NCT02177851|Iron bio-availability
966495|NCT02177851|Hepcidin
966496|NCT02177851|Iron absorption
966497|NCT02177812|Oncology
966498|NCT02177812|LSD1
966499|NCT02177812|GSK2879552
966500|NCT02177812|Acute myeloid leukemia
966501|NCT02177799|Gastroenteritis
966502|NCT02177799|Hospitalized
966503|NCT02177799|Children
966504|NCT02177786|Diabetic Kidney Disease
966505|NCT02177786|Gilead
966506|NCT02177760|SCID
966507|NCT02177760|severe combined immunodeficiency
966508|NCT02177760|maternal engraftment
966509|NCT02177760|aGVHD prophylaxis
966510|NCT02177760|sirolimus
966511|NCT02177734|Adjuvant
966512|NCT02177734|Safety
966513|NCT02177734|Influenza
966514|NCT02177734|H7N9
966515|NCT02177734|Immunogenicity
966516|NCT02177734|Adults
966517|NCT02177721|Raxibacumab
966518|NCT02177721|anthrax
966519|NCT02177721|anti-toxin
966520|NCT02177695|Bladder Cancer
966521|NCT02177695|Neoadjuvant Chemotherapy
966522|NCT02177695|Coexpression Extrapolation
966523|NCT02177695|COXEN
966524|NCT02177695|S1314
966525|NCT02177695|SWOG
966526|NCT02177682|AKT inhibitor
966527|NCT02177682|Afuresertib
966528|NCT02177682|multiple myeloma
966529|NCT02177669|Normal, healthy individuals without ocular disease
966530|NCT02177669|Ages 20-89
966531|NCT02177669|English speaking
966532|NCT02177669|Visual acuity better than 20/25
966533|NCT02177656|heart failure
966534|NCT02177656|self-care
966535|NCT02177656|self-care maintenance
966536|NCT02177656|self-care management
966537|NCT02177656|self-efficacy
966538|NCT02177656|quality of life
966539|NCT02177656|symptoms
966540|NCT02177643|Diabetes
966541|NCT02177643|Diacerein
966542|NCT02177630|myocarditis, myocardial inflammation, imaging, magnetic resonance
966543|NCT02177617|Cervical Dystonia
966544|NCT02177617|Botox
966545|NCT02177578|Subventricular Zone
966546|NCT02177578|progenitor cell
966547|NCT02177578|radiation therapy
966548|NCT02177578|temozolomide
966549|NCT02177565|Non-union
966550|NCT02177565|fracture
966551|NCT02177565|bone marrow stem cells
966552|NCT02177552|Esophageal cancer
966553|NCT02177552|Gastric cancer
966554|NCT02177539|cycloplegia
966555|NCT02177539|refraction in children
966556|NCT02177539|cycloplegic agents
966557|NCT02177539|cycloplegic schemes
966558|NCT02177539|cyclopentolate
966559|NCT02177526|CT
966560|NCT02177526|MRI
966561|NCT02177513|Cannabis
966562|NCT02177513|Pharmacodynamics
966563|NCT02177513|Marijuana
966564|NCT02177513|Cannabinoids
966565|NCT02177513|Vaporized
966566|NCT02177474|depressive symptoms
966567|NCT02177474|perceived social support
966568|NCT02177474|coronary heart disease
966569|NCT02177474|peer support
966570|NCT02177474|women
966571|NCT02177279|Wheat bran cereals, bran phytochemicals, phytochemicals bioavailability
966572|NCT02177240|GlideScope®
966573|NCT02177240|GlideRite®
966574|NCT02177240|Flex-it®
966575|NCT02177240|Difficult intubation
966576|NCT02177227|Total Knee Arthroplasty (TKA)
966577|NCT02177227|Attune
966578|NCT02177227|Primary Total Knee Prosthesis
966579|NCT02177227|TruMatch
966580|NCT02177188|Hypovolaemic shock
966581|NCT02177188|Monitoring
966582|NCT02177188|Haemorrhage
966583|NCT02177188|Transthoracic Echocardiography
966584|NCT02177175|Carvedilol
966585|NCT02177175|Anthracycline
966586|NCT02177175|HER2
966587|NCT02177175|14-099
966588|NCT02177136|PSC
966589|NCT02177123|glaucoma shunt
966590|NCT02177123|glaucoma drainage device
966591|NCT02177110|advanced melanoma
966592|NCT02177110|metastatic melanoma
966593|NCT02177110|fresh frozen tissue
966594|NCT02177110|FFPE tissue
966595|NCT02177097|Pain
966596|NCT02177097|Infection
966597|NCT02177097|Inflammation
966598|NCT02177097|Prosthesis
966599|NCT02177084|PTNS
966600|NCT02177084|rectal cancer
966601|NCT02177084|low anterior resection syndrome
966602|NCT02177071|CROHN DISEASE
966603|NCT02177071|INFLIXIMAB
966604|NCT02177071|COMBINATION THERAPY
966605|NCT02177071|steroid free remission
966606|NCT02177071|anti-metabolites
966607|NCT02177058|Nursing homes
966608|NCT02177058|Hospitalizations
966609|NCT02177032|Rabies vaccines
966610|NCT02177032|intradermal
966611|NCT02177032|human rabies immunoglobulins
966612|NCT02177019|frequent headaches
966613|NCT02177019|personalized health plan
966614|NCT02176993|Acute stroke
966615|NCT02176993|Therapeutic Hypothermia
966616|NCT02176980|HCV
966617|NCT02176980|hepatitis C
966618|NCT02176980|alcohol
966619|NCT02176980|integrated care
966620|NCT02176941|Telomere Length
966621|NCT02176941|Arterial Aging
966622|NCT02176941|Endothelial Progenitor Cells
966623|NCT02176941|Inflammation
966624|NCT02176941|Atherosclerosis
966625|NCT02176889|Lactospore
966626|NCT02176889|Bacillus coagulans
966627|NCT02176889|Safety
966628|NCT02176889|Probiotic
966629|NCT02176889|Healthy Adults
966630|NCT02176889|Tolerability
966631|NCT02176876|rheumatoid arthritis
966632|NCT02176876|RA
966633|NCT02176876|GS-5745
966634|NCT02176876|MMP9
966635|NCT02176876|phase 1
966636|NCT02176863|FORCE
966637|NCT02176863|post-polio syndrome
966638|NCT02176863|Flebogamma
966639|NCT02176863|Immune Globulin Intravenous
966640|NCT02176863|IGIV
966641|NCT02176837|subarachnoid hemorrhage
966642|NCT02176837|vasospasm
966643|NCT02176837|nitrite
966644|NCT02176837|sodium nitrite
966645|NCT02176811|Non-alcoholic Fatty Liver Disease
966646|NCT02176811|Betatrophin
966647|NCT02176785|Sleep
966648|NCT02176785|Transcranial Electric Stimulation
966649|NCT02176720|Glioma
966650|NCT02176720|Glioblastoma
966651|NCT02176720|Glioblastoma multiforme
966652|NCT02176720|GBM
966653|NCT02176720|Recurrence
966654|NCT02176720|PET
966655|NCT02176720|FDOPA
966656|NCT02176707|Lung Function
966657|NCT02176707|Exercise Capacity
966658|NCT02176694|persistent asthma
966659|NCT02176694|adherence
966660|NCT02176694|text message reminders
966661|NCT02176655|Delayed Alcohol Induced Headache
966662|NCT02176642|Urinary Urge Incontinence
966663|NCT02176642|Posterior Tibial Nerve Stimulation
966664|NCT02176642|PTNS
966665|NCT02176642|Neuromodulation
966666|NCT02176642|Oxybutynin
966667|NCT02176642|Anticholinergic Medication
966668|NCT02176629|Virtual Reality
966669|NCT02176629|mild cognitive impairment
966670|NCT02176629|Alzheimer's disease
966671|NCT02176603|phenylketonuria, endothelial dysfunction, CKD
966672|NCT02176590|PATHS Social Emotional Learning
966673|NCT02176590|Coping Power
966674|NCT02176590|Power PATH
966675|NCT02176590|Head Start
966676|NCT02176486|Drug therapy
966677|NCT02176473|Depression
966678|NCT02176460|Knee Osteoarthritis
966679|NCT02176460|Double-blind
966680|NCT02176460|placebo-controlled
966681|NCT02176460|randomized
966682|NCT02176460|colchicine
966683|NCT02176434|End stage renal disease
966684|NCT02176434|Transplantation
966685|NCT02176434|Tolerance
966686|NCT02176408|Major Depressive Disorder
966687|NCT02176408|Depression
966688|NCT02176408|MDD
966689|NCT02176408|Exercise
966690|NCT02176408|Physical Activity
966691|NCT02176408|Treatment
966692|NCT02176408|Behavioral Activation
966693|NCT02176395|Acute Ischemic Stroke
966694|NCT02176395|Randomized Controlled Trial
966695|NCT02176395|Traditional Chinese Medicine
966696|NCT02176395|Proteomics
966697|NCT02176369|Non small cell lung cancer (NSCLC)
966698|NCT02176369|Lung tumor in advanced phase
966699|NCT02175277|Myelodysplastic Syndrome (MDS)
966700|NCT02175277|Darbepoetin alfa
966701|NCT02175277|low risk MDS
966702|NCT02175277|intermediate-1 risk MDS
966703|NCT02175277|International Prognostic Scoring System (IPSS)
966704|NCT02176330|Randomised Controlled Trial
966705|NCT02176330|Virtual Clinic
966706|NCT02176330|ePAQ-PF
966707|NCT02176330|Pelvic Floor Disorders
966708|NCT02176330|Economic Analysis
966709|NCT02176317|Autism Spectrum Disorder
966710|NCT02176317|ASD
966711|NCT02176317|Umbilical cord blood
966712|NCT02176317|Autologous cord blood
966713|NCT02176317|cord blood
966714|NCT02176304|knee
966715|NCT02176304|arthritis
966716|NCT02176304|injections
966717|NCT02176304|corticosteroids
966718|NCT02176291|Buprenorphine
966719|NCT02176291|Receptors, opioid
966720|NCT02176291|Receptors, opioid kappa and mu
966721|NCT02176278|Diabetic Kidney Disease
966722|NCT02176278|Diabetes
966723|NCT02176278|Asian
966724|NCT02176278|Joint Asia Diabetes Evaluation (JADE) Program
966725|NCT02176265|CAD
966726|NCT02176265|PCI
966727|NCT02176265|bioactive coronary stent
966728|NCT02176265|OCT
966729|NCT02176226|Major Depressive Disorder
966730|NCT02176226|Anxiety Disorders
966731|NCT02176226|Behavior Therapy
966732|NCT02176226|Technology Assisted
966733|NCT02176226|Mobile Phone
966734|NCT02176226|Cellular Phone
966735|NCT02176226|Smartphone
966736|NCT02176226|App
966737|NCT02176213|Relapsed
966738|NCT02176213|Refractory
966739|NCT02176213|Multiple Myeloma
966740|NCT02176213|Pomalidomide
966741|NCT02176213|Cyclophosphamide
966742|NCT02176213|Dexamethasone
966743|NCT02176174|Ethnic group
966744|NCT02176174|Cardiovascular disease
966745|NCT02176174|Atherosclerosis
966746|NCT02176161|Prostate Cancer
966747|NCT02176161|Prostate Cancer Recurrent
966748|NCT02176148|cutaneous lupus
966749|NCT02176148|systemic lupus
966750|NCT02176148|systemic therapy
966751|NCT02176148|medication
966752|NCT02176135|HIV
966753|NCT02176135|HAART suppressed
966754|NCT02176135|Auranofin
966755|NCT02176135|HIV latent reservoir
966756|NCT02176057|trachoma
966757|NCT02176044|Nitric Oxide
966758|NCT02176044|Sodium Nitroprusside
966759|NCT02176044|Spatial Working Memory
966760|NCT02176044|Psychosis
966761|NCT02176044|Schizophrenia
966762|NCT02176031|Graft Versus Host Disease
966763|NCT02176018|Episodic Migraine
966764|NCT02176018|Migraine
966765|NCT02176018|Headache
966766|NCT02175979|postoperative ileus
966767|NCT02175979|anastomotic leak
966768|NCT02175979|colorectal surgery
966769|NCT02175979|inflammation
966770|NCT02175953|caregiver burden
966771|NCT02175953|stress
966772|NCT02175953|depression
966773|NCT02175953|dementia
966774|NCT02175927|Helicobacter pylori
966775|NCT02175927|Treatment Failure
966776|NCT02175927|second-line therapy
966777|NCT02175914|Erythromycin
966778|NCT02175914|Familial Adenomatous Polyposis (FAP).
966779|NCT02175914|APC gene
966780|NCT02175914|nonsense mutations
966781|NCT02175901|helicobacter pylori eradication
966782|NCT02175901|antibiotic
966783|NCT02175888|Iron bio availability
966784|NCT02175888|Hepcidin
966785|NCT02175888|Iron absorption
966786|NCT02175875|ticagrelor
966787|NCT02175875|platelet function test
966788|NCT02175875|comatose
966789|NCT02175875|PCI
966790|NCT02175875|naso-gastric tube
966791|NCT02175862|Helicopter Emergency Medical Service
966792|NCT02175862|Trauma
966793|NCT02175862|Early retirement
966794|NCT02175862|ISS
966795|NCT02175862|Quality of life
966796|NCT02175849|Multi-Drug Resistant Tuberculosis
966797|NCT02175849|Social Network Analysis
966798|NCT02175836|Arrhythmic Sudden Cardiac Death
966799|NCT02175836|Heart Failure
966800|NCT02175836|Risk Stratification
966801|NCT02175836|Autonomic Nervous System
966802|NCT02175836|Heart Rate
966803|NCT02175836|Repolarization
966804|NCT02175823|Cancer survivors
966805|NCT02175823|circadian rhythm
966806|NCT02175823|Elderly Patients
966807|NCT02175823|frailty
966808|NCT02175810|Obesity
966809|NCT02175810|Bariatric surgery
966810|NCT02175810|physical activity
966811|NCT02175810|cardiopulmonary exercise test
966812|NCT02175797|Pacemaker, leads and MRI exam
966813|NCT02175784|Blood glucose
966814|NCT02175784|insulin
966815|NCT02175784|ipragliflozin
966816|NCT02175784|SGLT2 inhibitor
966817|NCT02175732|Type 1 Diabetes
966818|NCT02175732|Distress
966819|NCT02175719|Torticollis
966820|NCT02175719|rimabotulinumtoxinB
966821|NCT02175693|Torticollis
966822|NCT02175693|rimabotulinumtoxinB
966823|NCT02175680|HIV-1
966824|NCT02175680|HIV
966825|NCT02175680|Treatment Substitution
966826|NCT02175680|PRO 140
966827|NCT02175680|PRO140
966828|NCT02175680|CytoDyn
966829|NCT02175680|Amarex
966830|NCT02175667|Global postural reeducation
966831|NCT02175667|Stabilometry
966832|NCT02175667|Postural Sway
966833|NCT02175667|Range of motion
966834|NCT02175667|Personality traits
966835|NCT02175654|metastatic colorectal cancer
966836|NCT02175654|RAS/BRAF mutation
966837|NCT02175654|Regorafenib
966838|NCT02175654|FOLFOXIRI
966839|NCT02175654|Bevacizumab
966840|NCT02175641|Healthy lifestyle Intervention
966841|NCT02175641|Serious Mental Illness
966842|NCT02175641|Effectiveness trial
966843|NCT02175641|Supportive housing
966844|NCT02175641|Racial and Ethnic Health Disparities
966845|NCT02175628|Ultrasound
966846|NCT02175628|Breast
966847|NCT02175628|Angiography
966848|NCT02175615|CYCLOSPORINE
966849|NCT02175615|ACUTE GRAFT VERSUS HOST DISEASE
966850|NCT02175615|PROPHYLAXIS
966851|NCT02175615|CHILDREN
966852|NCT02175615|HAEMATOPOIETIC STEM CELL TRANSPLANT
966853|NCT02175589|Familial Mediterranean Fever
966854|NCT02175589|Monozygous
966855|NCT02175589|MEFV
966856|NCT02175589|Colchicine
966857|NCT02175589|Serum Amyloid A
966858|NCT02175563|Chest
966859|NCT02175563|Compression
966860|NCT02175550|partially edentulous
966861|NCT02175550|maxilla
966862|NCT02175550|implants
966863|NCT02175550|Conical connection
966864|NCT02175550|Nobel Biocare
966865|NCT02175550|NobelReplace
966866|NCT02175550|Immediate loading
966867|NCT02175550|One- stage surgery
966868|NCT02175550|Two- stage surgery
966869|NCT02175550|supported restoration
966870|NCT02175550|patients
966871|NCT02175537|Diabetes Mellitus, Type II
966872|NCT02175537|Disease management
966873|NCT02175537|Obesity
966874|NCT02175537|Social Network
966875|NCT02175537|Chronic disease
966876|NCT02175537|Prevention and control
966877|NCT02175537|Education
966878|NCT02175524|nut chewing
966879|NCT02175511|Home Blood Pressure
966880|NCT02175511|Computerized physician order entry (CPOE)
966881|NCT02175511|Telemonitoring
966882|NCT02175511|Hypertension
966883|NCT02175498|Homoeopathy Similimum female infertility
966884|NCT02175472|Parkinson's disease
966885|NCT02175472|Light therapy
966886|NCT02175472|Circadian rhythm
966887|NCT02175446|Breast cancer
966888|NCT02175446|HER2Negative
966889|NCT02175446|Second line treatment
966890|NCT02175446|HER2-
966891|NCT02175446|MBC
966892|NCT02175446|Metastatic
966893|NCT02175446|Metastatic breast cancer
966894|NCT02175446|bevacizumab
966895|NCT02175446|eribulin
966896|NCT02175446|Human Epidermal Growth Factor Receptor 2-Negative
966897|NCT02175433|Refractory or relapsed chronic lymphocytic leukemia (CLL) prolymphocytic leukemia (PLL)
966898|NCT02175433|Relapsed lymphoid malignancy
966899|NCT02175433|Refractory lymphoid malignancy
966900|NCT02175433|Pharmacokinetics of AGS67E
966901|NCT02175433|hairy cell leukemia (HCL)
966902|NCT02175433|AGS67C
966903|NCT02175433|non-Hodgkin lymphoma (NHL)
966904|NCT02175433|AGS67E
966905|NCT02175420|BCG
966906|NCT02175420|Salmonella
966907|NCT02175420|Trained immunity
966908|NCT02175420|Non-specific effect vaccines
966909|NCT02175407|Healthy subjects
966910|NCT02175407|ASP1707
966911|NCT02175407|Itraconazole
966912|NCT02175381|Metastatic NSCLC
966913|NCT02175381|Elderly
966914|NCT02175381|1st Line
966915|NCT02175381|Platinum-based treatment
966916|NCT02175368|total etch protocol
966917|NCT02175368|direct filling therapy
966918|NCT02175329|CAD/CAM, three-unit posterior bridges, zirconia framework
966919|NCT02175264|Isolated non syndromic CDH
966920|NCT02175251|rTMS
966921|NCT02175251|Schizophrenia
966922|NCT02175251|high frequency rTMS
966923|NCT02175251|low frequency rTMS
966924|NCT02175251|AHRS
966925|NCT02175251|SAPS SANS PANSS
966926|NCT02175251|GAF
966927|NCT02175251|UKU
966928|NCT02175225|Brain hemorrhage
966929|NCT02175225|Cerebral hemorrhage
966930|NCT02175225|Bleeding in the brain
966931|NCT02175225|Deferoxamine
966932|NCT02175225|iDEF trial
966933|NCT02175212|Patients with prostate adenocarcinoma
966934|NCT02175199|Contact lens
966935|NCT02175199|Vision care
966936|NCT02175199|Daily wear
966937|NCT02175199|Color contact lens
966938|NCT02175186|Gastritis
966939|NCT02175186|Gastroduodenal Ulcer
966940|NCT02175186|Percutaneous Coronary Revascularization
966941|NCT02175186|Dual Antiplatelet Therapy
966942|NCT02175173|Epileptic encephalopathy, Lennox-Gastaut type
966943|NCT02175160|Driver reaction time
966944|NCT02175134|tuberculosis
966945|NCT02175134|peritonitis
966946|NCT02175134|laparoscopy
966947|NCT02175108|Cerebral palsy
966948|NCT02175108|Adolescents
966949|NCT02175108|Adults
966950|NCT02175108|Diet
966951|NCT02175108|Activity
966952|NCT02175108|Metabolic Syndrome
966953|NCT02175095|regorafenib
966954|NCT02175095|fluorothymidine
966955|NCT02175095|positron emission tomography
966956|NCT02175095|metastatic colorectal cancer
966957|NCT02175082|Parkinson Disease
966958|NCT02175082|Exercise
966959|NCT02175082|Rehabilitation
966960|NCT02175082|Physical Therapy
966961|NCT02175082|Cycling
966962|NCT02175069|Shoulder surgery
966963|NCT02175056|First In Human
966964|NCT02175056|CAPS, SoJIA, AOSD, Bechet Disease, Rheumatoid arthritis
966965|NCT02175043|atrial fibrillation, catheter ablation, recurrence
966966|NCT02175030|Emergency contraception
966967|NCT02175030|Levonorgestrel IUD
966968|NCT02175030|Copper IUD
966969|NCT02175017|ONO-4538
966970|NCT02175017|Advanced non-small cell lung cancer
966971|NCT02175004|FAP
966972|NCT02175004|Familial Amyloid Polyneuropathy
966973|NCT02175004|TTR
966974|NCT02175004|Transthyretin
966975|NCT02175004|Amyloidosis
966976|NCT02174978|Malaria vaccine
966977|NCT02174952|Parenting interventions
966978|NCT02174952|ADHD
966979|NCT02174952|Family functioning
966980|NCT02174952|Parent Training
966981|NCT02174939|cilostazol
966982|NCT02174939|progenitor cells
966983|NCT02174939|coronary artery disease
966984|NCT02174939|myocardial infarction
966985|NCT02174939|angiogenesis
966986|NCT02174939|biological markers
966987|NCT02174939|endothelial function
966988|NCT02174913|Awakening time
966989|NCT02174913|Bispectral index
966990|NCT02174913|clinical signs
966991|NCT02174913|neurophysiologic monitoring
966992|NCT02174913|spine surgery
966993|NCT02174900|G6PD deficiency
966994|NCT02174900|safety
966995|NCT02174900|transmission
966996|NCT02174887|pancreatic adenocarcinoma
966997|NCT02174887|liver metastases
966998|NCT02174861|Chronic Migraine
966999|NCT02174848|Pantothenate Kinase-Associated Neurodegeneration
967000|NCT02174848|PKAN
967001|NCT02174848|Neurodegeneration with Brain Iron Accumulation
967002|NCT02174848|NBIA
967003|NCT02174848|Deferiprone
967004|NCT02174848|Ferriprox
967005|NCT02174835|Pharmacokinetics
967006|NCT02174835|Healthy Volunteers
967007|NCT02174835|deuterated dextromethorphan
967008|NCT02174835|deuterated dextromethorphan with quinidine
967009|NCT02174822|Drug-drug interaction
967010|NCT02174822|Pharmacokinetics
967011|NCT02174822|Healthy Volunteers
967012|NCT02174822|deuterated dextromethorphan
967013|NCT02174822|deuterated dextromethorphan with quinidine
967014|NCT02174809|Pregnancy
967015|NCT02174809|Gestational Weight Gain
967016|NCT02174809|Primary Care
967017|NCT02174809|Guidelines
967018|NCT02174796|Pectus excavatum
967019|NCT02174796|cardiac output
967020|NCT02174796|transthoracic impedancemetry
967021|NCT02174783|Weight Loss
967022|NCT02174783|Diet, Mediterranean
967023|NCT02174783|Diet, Reducing
967024|NCT02174783|protein sparing modified diet
967025|NCT02174744|Pain in elderly patients having communication disorders
967026|NCT02174744|Numerical scale
967027|NCT02174744|Algoplus® scale
967028|NCT02174744|Doloplus® scale
967035|NCT02174718|Cholecalciferol
967036|NCT02174718|Transdermal patch
967037|NCT02174705|vaccination
967038|NCT02174705|pain management
967039|NCT02174705|sucrose
967040|NCT02174705|rotavirus
967041|NCT02174666|Aglycones
967042|NCT02174666|Isoflavones
967043|NCT02174666|Red clover
967044|NCT02174666|Osteopenia
967045|NCT02174666|Menopause
967046|NCT02174666|Bone turnover
967047|NCT02174666|Bone mineral density
967048|NCT02174640|Coffee
967049|NCT02174640|Polyphenolics
967050|NCT02174627|Renal,
967051|NCT02174627|CKD,
967052|NCT02174627|Roxadustat,
967053|NCT02174627|anemia,
967054|NCT02174627|non-dialysis
967055|NCT02174614|Cocaine use disorder
967056|NCT02174601|bowel preparation
967057|NCT02174601|coolprep
967058|NCT02174601|colonoscopy
967059|NCT02174601|prediction model
967060|NCT02174588|sedation, propofol, midazolam
967061|NCT02174575|Hepatectomy
967062|NCT02174562|Type 2 diabetes
967063|NCT02174562|Mild Cognitive Impairment
967064|NCT02174549|Hypoxia
967065|NCT02174549|Embolization
967066|NCT02174549|Tirapazamine
967067|NCT02174549|Hepatocellular carcinoma
967068|NCT02174523|pharmacokinetic
967069|NCT02174523|lurasidone
967070|NCT02174523|multiple dose
967071|NCT02174510|pharmacokinetic
967072|NCT02174510|lurasidone
967073|NCT02174510|single dose
967074|NCT02174497|Pediatric Colonoscopy
967075|NCT02174497|Bowel Preparation
967076|NCT02174497|Safety
967077|NCT02174497|Tolerability
967078|NCT02174484|Pacemaker
967079|NCT02174484|Remote monitoring
967080|NCT02174484|Remote follow-up
967081|NCT02174484|Home monitoring
967082|NCT02174484|Periodic IEGM
967083|NCT02174484|Intracardiac electrogram
967084|NCT02174471|Aortic Stenosis
967085|NCT02174471|Aortic Valve Replacement
967086|NCT02174471|T1 Mapping
967087|NCT02174471|Extracellular Volume Fraction
967088|NCT02174471|Cardiovascular Magnetic Resonance
967089|NCT02174471|Diffuse Myocardial Fibrosis
967090|NCT02174458|Bariatric surgery; Body contouring; Quality of life
967091|NCT02174445|Patients with CML in chronic phase
967092|NCT02174445|Imatinib
967093|NCT02174445|Nilotinib
967094|NCT02174432|Itch
967095|NCT02174432|Chronic Itch
967096|NCT02174432|Nalbupine
967097|NCT02174419|Itch
967098|NCT02174419|Chronic Itch
967099|NCT02174419|nalbuphine
967100|NCT02174406|Ultrasound
967101|NCT02174406|Digital Breast Tomosynthesis
967102|NCT02174406|14-119
967103|NCT02174367|Chronic plaque psoriasis
967104|NCT02174367|Liver fibrosis
967105|NCT02174367|Fatty liver disease
967106|NCT02174367|Non-alcoholic fatty liver disease
967107|NCT02174367|Transient elastography
967108|NCT02174367|Fibroscan
967109|NCT02174367|Procollagen-3 N-Terminal peptide
967110|NCT02174367|Alanine aminotransferase
967111|NCT02174367|Liver function tests
967112|NCT02174354|Psoriasis
967113|NCT02174354|Methotrexate
967114|NCT02174354|Methotrexate Polyglutamates
967115|NCT02174354|Injury of Liver
967116|NCT02174341|Chikungunya fever
967117|NCT02174341|Chikungunya Virus
967118|NCT02174328|See incidence of Pre-Eclampsia in acetylsalicylic acid group
967119|NCT02174328|See incidence of Pre-Eclampsia in placebo group
967120|NCT02174289|Heart Failure
967121|NCT02174289|Cardiac Resynchronisation Therapy
967122|NCT02174289|Transseptal left ventricular endocardial lead
967123|NCT02174250|PD
967124|NCT02174237|Phase 1, safety, tolerability, PK, PD
967125|NCT02174224|Violence
967126|NCT02174224|At-risk youth
967127|NCT02174224|Intentional Injury
967128|NCT02174224|Violence Intervention
967129|NCT02174224|Youth
967130|NCT02174224|recidivism
967131|NCT02174198|Immediate implant
967132|NCT02174198|bone graft
967133|NCT02174198|immediate restoration
967134|NCT02174185|bladder cancer
967135|NCT02174185|conduit diversion
967136|NCT02174185|orthotopic neobladder
967137|NCT02174185|health-related quality of life
967138|NCT02174185|validated questionnaire
967139|NCT02174146|leptin
967140|NCT02174146|visfatin
967141|NCT02174146|chronic periodontitis
967142|NCT02174146|diabetes mellitus
967143|NCT02174146|non-surgical periodontal therapy
967144|NCT02174133|left ventricular assist device
967145|NCT02174133|endothelial function
967146|NCT02174133|microvascular perfusion
967147|NCT02174133|microparticles
967148|NCT02174107|Health economics
967149|NCT02174107|Percutaneous vertebroplasty
967150|NCT02174107|Radiation therapy
967151|NCT02174107|Painful spine metastases
967152|NCT02174081|mechanical ventilation, ARDS, Ventilator strategy, outcome
967153|NCT02174068|Paracetamol
967154|NCT02174068|Nefopam
967155|NCT02174068|Pharmacokinetic
967156|NCT02174068|Drug interaction
967157|NCT02174055|Depression
967158|NCT02174055|14-101
967159|NCT02174029|Atrophy
967160|NCT02174029|Ventilator
967161|NCT02174029|Induced
967162|NCT02174029|Diaphragm
967163|NCT02174029|Dysfunction
967164|NCT02174016|Intensive Care Units
967165|NCT02174016|Pediatric
967166|NCT02174003|whole body hyperthermia
967167|NCT02174003|depression
967168|NCT02174003|fibromyalgia
967169|NCT02174003|rheumatoid arthritis
967170|NCT02174003|perimenopausal symptoms
967171|NCT02174003|open treatment
967172|NCT02173990|adenocarcinoma
967173|NCT02173990|colon and/or rectum
967174|NCT02173977|GnRH Agonist
967175|NCT02173977|GnRH Antagonist
967176|NCT02173977|OHSS
967177|NCT02173964|fluorodeoxyglucose
967178|NCT02173964|positron emission tomography
967179|NCT02173964|computed tomography
967180|NCT02173964|bowel
967181|NCT02173964|pinaverium bromide
967182|NCT02173951|young minimally transfused beta thalassemia major
967183|NCT02173951|labile plasma iron (LPI)
967184|NCT02173951|Transferrin saturation (TSAT)
967185|NCT02173951|Deferiprone
967186|NCT02173951|Transfusional iron loading rate
967187|NCT02173951|Transfusion units
967188|NCT02173938|Smokers
967189|NCT02173938|outpatient
967190|NCT02173938|Tobacco Dependence Treatment Program
967191|NCT02173873|Age related macular degeneration
967192|NCT02173873|central retinal vein occlusion
967193|NCT02173860|Coronary artery disease
967194|NCT02173860|Valvular heart disease
967195|NCT02173860|Fractional flow reserve
967196|NCT02173860|Coronary artery bypass surgery
967197|NCT02173860|Coronary graft failure or patency
967198|NCT02173847|anvil-shaped corneal graft
967199|NCT02173847|penetrating keratoplasty
967200|NCT02173847|femtosecond laser
967201|NCT02173847|laser welding
967202|NCT02173834|Brown Adipose Tissue
967203|NCT02173834|Weight
967204|NCT02173834|Sympathetic Nervous System
967205|NCT02173756|chemotherapy
967206|NCT02173756|mucositis
967207|NCT02173756|systemic opioids
967208|NCT02173756|morphine
967210|NCT02173704|Meningitis
967211|NCT02173704|Infants
967212|NCT02173704|Meningococcal B Recombinant Vaccine
967213|NCT02173626|Mindfulness
967214|NCT02173613|infection lung elderly patients
967215|NCT02173600|Cardiovascular risk
967216|NCT02173600|Primary prevention
967217|NCT02173600|Intensive dietary counselling
967218|NCT02173600|Physical exercise
967219|NCT02173587|Anti-inflammation, Rheumatoid arthritis, Thick shell mussel lipid extract, Chinese
967339|NCT02173002|Integrated care
967220|NCT02173574|Hepatitis C Virus, Viral, Antiviral, Infection, Infectious disease, alisporivir, EDP239, DEB025
967221|NCT02173561|Posttraumatic Stress Disorder
967222|NCT02173561|Cognitive Processing Therapy
967223|NCT02173561|combat
967224|NCT02173561|military
967225|NCT02173561|CPT
967226|NCT02173561|group therapy
967227|NCT02173548|heart failure
967228|NCT02173548|HFpEF
967229|NCT02173548|diastole
967230|NCT02173548|diastolic heart failure
967231|NCT02173548|inflammation
967232|NCT02173548|interleukin-1
967233|NCT02173548|C-reactive protein
967237|NCT02173496|Wet age-related macular degeneration
967238|NCT02173496|Assessment modalities for preclinical, pre-symptomatic ARMD
967239|NCT02173457|Chiglitazar
967240|NCT02173457|Sitagliptin
967241|NCT02173457|diabetes
967242|NCT02173457|type 2 diabetes
967243|NCT02173444|in-vitro fertilization
967244|NCT02173444|ovarian stimulation
967245|NCT02173431|BMI
967246|NCT02173431|Pressure
967247|NCT02173431|Bedsore
967248|NCT02173418|Postoperative pain
967249|NCT02173418|Acute postoperative pain
967250|NCT02173418|Chronic postoperative pain
967251|NCT02173418|Shoulder pain
967252|NCT02173418|Thoracotomy
967253|NCT02173418|Thoracoscopy
967254|NCT02173405|Myofascial Pain Syndromes
967255|NCT02173405|Pelvic pain
967256|NCT02173405|Trigger points + injections
967257|NCT02173405|Myofascial Trigger Point Pain
967258|NCT02173405|Trigger Point Pain, Myofascial
967259|NCT02173405|Botulinum Toxins, Type A
967260|NCT02173405|Botulinum Neurotoxin A
967261|NCT02173405|Botulinum Toxin Type A
967262|NCT02173405|Clostridium botulinum A Toxin
967263|NCT02173405|Clostridium Botulinum Toxin Type A
967264|NCT02173405|Oculinum
967265|NCT02173379|Absorb™ BVS
967266|NCT02173379|Angioplasty
967267|NCT02173379|Bioabsorbable
967268|NCT02173379|BVS
967269|NCT02173379|Coronary Artery Disease
967270|NCT02173379|Coronary Artery Endothelial Responsiveness
967271|NCT02173379|Coronary artery restenosis
967272|NCT02173379|Coronary artery stenosis
967273|NCT02173379|Coronary scaffold
967274|NCT02173379|Coronary Stent
967275|NCT02173379|Drug eluting stents
967276|NCT02173379|Everolimus
967277|NCT02173379|Myocardial ischemia
967278|NCT02173379|Stent thrombosis
967279|NCT02173379|Stents
967280|NCT02173353|Ultrasound use during radiation therapy for Pancreas cancer
967281|NCT02173314|Long term foster care
967282|NCT02173314|child abuse and neglect
967283|NCT02173262|Breast
967284|NCT02173236|Dental Implant Platform Switching
967285|NCT02173236|Early Dental Implant Loading
967286|NCT02173210|Premature birth
967287|NCT02173210|Premature delivery
967288|NCT02173210|Metabolomics
967289|NCT02173210|Microbiota
967290|NCT02173210|Genetics
967291|NCT02173210|17 hydroxyprogesterone caproate
967292|NCT02173197|Occupational Therapy
967293|NCT02173197|Complex patients
967294|NCT02173197|Occupational performance problem
967295|NCT02173197|Rehabilitation Complexity Scale
967296|NCT02173184|bacterial vaginosis
967297|NCT02173184|Gynevac Lactobacillus vaccine
967298|NCT02173171|Melanoma
967299|NCT02173145|idiopathic pulmonary fibrosis
967300|NCT02173145|cough
967301|NCT02173145|immunomodulation
967302|NCT02173145|macrolide
967303|NCT02173119|Hepatocellular
967304|NCT02173119|Carcinoma
967305|NCT02173119|HCC
967306|NCT02173119|lipiodol
967307|NCT02173093|Neuroblastoma
967308|NCT02173093|Osteosarcoma
967309|NCT02173093|Solid tumor
967310|NCT02173093|Immunotherapy targeting GD2
967311|NCT02173093|Bispecific antibodies
967312|NCT02173093|Activated T cells
967313|NCT02173080|autosomal dominant polycystic liver disease
967314|NCT02173080|autosomal dominant polycystic kidney disease
967315|NCT02173080|quality of life
967316|NCT02173080|patient reported outcome tool
967317|NCT02173067|Diabetes mellitus
967318|NCT02173067|Epinephrine
967319|NCT02173067|Anesthesia, Dental
967320|NCT02173067|lidocaine
967321|NCT02173067|Ambulatory Surgical Procedures
967322|NCT02173054|Acne
967323|NCT02173054|Moisturizer
967324|NCT02173054|Efficacy
967325|NCT02173054|Irritation
967326|NCT02173041|Prevention and Awareness Groups (PAG),
967327|NCT02173041|Substance Use Disorder,
967328|NCT02173041|Community based intervention
967329|NCT02173028|Beta Blocker Intolerance;
967330|NCT02173028|Remote Patient Management system;
967331|NCT02173028|Cardiac Resynchronization Therapy
967332|NCT02173015|accidental falls
967333|NCT02173015|older adults
967334|NCT02173015|long-term care
967335|NCT02173015|nursing home
967336|NCT02173015|postural balance
967337|NCT02173002|Telemedicine
967338|NCT02173002|Patient empowerment
967340|NCT02172989|Near-infrared fluorescence
967341|NCT02172989|Indocyanine green, ICG
967342|NCT02172989|Radio-guided surgery
967343|NCT02172989|breast cancer
967344|NCT02172976|pancreas cancer
967345|NCT02172976|neoadjuvant chemotherapy
967346|NCT02172976|Folfirinox
967347|NCT02172976|gemcitabine
967348|NCT02172963|Stem Cell Transplantation
967349|NCT02172963|Decidual Stromal Cells
967350|NCT02172937|Stem Cell Transplantation
967351|NCT02172937|Decidual Stromal Cells
967352|NCT02172924|Stem Cell Transplantation
967353|NCT02172924|Decidual Stromal Cells
967354|NCT02172911|Cervical cancer
967355|NCT02172911|Papillomavirus
967356|NCT02172911|Chemoradiation
967357|NCT02172911|Recurrent cervical cancer
967358|NCT02172911|Persistent cervical cancer
967359|NCT02172885|Mesenchymal stem cell based therapy
967360|NCT02172885|cell infusion
967361|NCT02172872|Newly diagnosed
967362|NCT02172872|AML
967363|NCT02172872|Elderly
967364|NCT02172872|Decitabine
967365|NCT02172872|Transplant
967366|NCT02172859|lumiVida™, cognition, mood, sleep, tryptophane
967367|NCT02172820|cardiac rehabilitation
967368|NCT02172820|contingency management
967369|NCT02172768|pharmacokinetics
967370|NCT02172768|alternate dosing
967371|NCT02172768|micafungin
967372|NCT02172755|Eslicarbazepine acetate
967373|NCT02172755|BIA 2-093
967374|NCT02172742|Eslicarbazepine acetate
967375|NCT02172742|BIA 2-093
967376|NCT02172729|adductor canal block
967377|NCT02172729|healthy volunteers
967378|NCT02172729|US-guided peripheral nerve block
967379|NCT02172729|lower limb
967380|NCT02172729|duration
967381|NCT02172729|Muscle Strength
967382|NCT02172729|Anesthetics, Local
967383|NCT02172729|Sensation
967384|NCT02172703|TBI
967385|NCT02172703|SAH
967386|NCT02172703|ICP
967387|NCT02172703|non invasive measurement
967388|NCT02172690|Gastric Cancer
967389|NCT02172690|Laparoscopic Staging
967390|NCT02172690|Cytology
967391|NCT02172690|Peritoneal Metastases
967392|NCT02172664|noncarious cervical lesions
967393|NCT02172664|dental adhesive
967394|NCT02172664|retention
967395|NCT02172664|enamel margin discoloration
967396|NCT02172664|self etch
967397|NCT02172664|selective etch procedures
967398|NCT02172651|Vitamin D
967399|NCT02172651|Stage I-III colon cancer
967400|NCT02172651|Stage IV colon cancer
967401|NCT02172651|Resectable liver metastases
967402|NCT02172638|Enhanced Recovery After Surgery
967403|NCT02172638|ERAS
967404|NCT02172638|Fast-Track
967405|NCT02172638|Ovarian cancer
967406|NCT02172638|Gynecologic surgery
967407|NCT02172638|Gynecology oncology
967408|NCT02172638|Median length of stay
967409|NCT02172638|Readmission rate
967410|NCT02172638|Surgery related complications
967411|NCT02172638|Cost
967412|NCT02172625|Athletic performance
967413|NCT02172625|Running
967414|NCT02172625|Dietary supplementation
967415|NCT02172625|Quality of life
967416|NCT02172625|Running performance
967417|NCT02172625|oxidative damage
967418|NCT02172612|Anticholinergic drugs
967419|NCT02172599|sit-stand workstation
967420|NCT02172599|workplace
967421|NCT02172599|multi-component intervention
967422|NCT02172599|randomised control trial design
967423|NCT02172599|physical activity
967424|NCT02172599|sitting
967425|NCT02172599|sedentary behaviour
967426|NCT02172599|process evaluation
967427|NCT02172599|health
967428|NCT02172365|Chronic myeloid leukemia
967429|NCT02172365|Allogeneic hematopoietic cell transplantation
967430|NCT02172365|Tyrosine kinase inhibitor
967431|NCT02172365|TKI failure
967432|NCT02172183|cognitive-behavioral therapy, adolescents, ADHD.
967433|NCT02172092|Diabetes
967434|NCT02172092|Ketoacidosis
967435|NCT02172092|fluid shift
967436|NCT02172079|shoulder impingement, manual therapy, pain, motion.
967437|NCT02172066|Posttraumatic Stress Disorder
967438|NCT02172066|Childhood maltreatment
967439|NCT02172053|Workplace
967440|NCT02172053|Industrial workers
967441|NCT02172053|Resistance exercise
967442|NCT02172053|Fatigue
967443|NCT02172053|Occupational risk
967444|NCT02172053|Physical therapy
967445|NCT02172040|High blood pressure
967446|NCT02172040|Systolic blood pressure
967447|NCT02172040|Diastolic blood pressure
967448|NCT02172040|Antihypertensive
967449|NCT02172014|Mechanical Ventilation
967450|NCT02172014|Sedation
967451|NCT02172014|Fentanyl
967452|NCT02172014|Midazolam
967453|NCT02172014|Comfort behavior scale
967454|NCT02172001|IDA
967455|NCT02172001|Iron deficiency
967456|NCT02172001|iron deficiency anemia and who are intolerant or unresponsive to oral iron therapy
967457|NCT02171988|Postural Orthostatic Tachycardia Syndrome
967458|NCT02171988|propranolol
967459|NCT02171988|bisoprolol
967460|NCT02171988|pyridostigmine
967461|NCT02171975|Spinal anaesthesia
967462|NCT02171975|Ultrasound pre-procedure guided
967463|NCT02171975|Paramedian spinal
967464|NCT02171962|Zilver® PTX® Drug-Eluting Peripheral Stent
967465|NCT02171962|Above-the-Knee Femoropopliteal Artery
967466|NCT02171962|Chinese patient
967467|NCT02171949|Chronic hepatitis
967468|NCT02171949|Hepatic cirrhosis
967469|NCT02171936|Pain
967470|NCT02171936|Precariousness
967471|NCT02171936|EPICES Score
967472|NCT02171936|CETD
967473|NCT02171923|depression
967474|NCT02171910|Cholangiopancreatography, Endoscopic Retrograde
967475|NCT02171910|Sedation
967476|NCT02171871|EFFECTS,
967477|NCT02171871|PASSIVE SMOKING ,
967478|NCT02171871|RESPIRATORY SYSTEM MECHANICS,
967479|NCT02171871|DIFFERENT BODY POSITIONS.
967480|NCT02171858|Stroke
967481|NCT02171858|National Institutes of Health Stroke Scale
967482|NCT02171858|Serum high sensitivity C-Reactive Protein
967483|NCT02171845|Male foetuses of 10 to 37 weeks
967484|NCT02171819|Influenza
967485|NCT02171819|Avian
967486|NCT02171819|H5N1
967487|NCT02171819|Vaccine
967488|NCT02171390|Hypogonadism
967489|NCT02171390|Endothelial dysfunction
967490|NCT02171390|Insulin resistance
967491|NCT02171390|Inflammation
967492|NCT02171390|Testosterone replacement therapy
967493|NCT02171377|COPD
967494|NCT02171377|electrical stimulation
967495|NCT02171377|Rehabilitation
967496|NCT02171377|exercise test
967497|NCT02171364|Atrial fibrillation, Virtual ablation, electrocardiography, electroanatomical mapping data
967498|NCT02171351|sympathetic nerve reactivity
967499|NCT02171351|neuromuscular electrostimulation
967500|NCT02171338|Procalcitonin
967501|NCT02171338|Antibiotic therapy
967502|NCT02171338|Lower respiratory tract diseases
967503|NCT02171325|irinotecan
967504|NCT02171325|Small Cell Lung Cancer
967505|NCT02171312|Dizziness
967506|NCT02171312|Imbalance
967507|NCT02171286|KRAS
967508|NCT02171286|EGFR
967509|NCT02171286|BRAF
967510|NCT02171286|NRAS and HRAS
967511|NCT02171286|PIK3CA
967512|NCT02171286|RAS-RAF-MEK-MAPK
967513|NCT02171286|HER2
967514|NCT02171286|IDH1 and IDH2
967515|NCT02171286|ALK
967516|NCT02171286|TP53
967517|NCT02171286|c-KIT
967518|NCT02171286|STAT1&3
967519|NCT02171286|PDGFRA
967520|NCT02171286|Metastatic colorectal cancer
967521|NCT02171286|Advanced non-small cell lung cancer
967522|NCT02171286|Advanced melanoma
967523|NCT02171286|Gastrointestingal Struma Tumor
967524|NCT02171286|Candidate genes implicated as potential prognostic and predictive biomarkers in patients with solid tumours
967525|NCT02171286|Circulating Tumor DNA
967526|NCT02171273|Sleep
967527|NCT02171273|Aging
967528|NCT02171273|Metabolism
967529|NCT02171273|Circadian
967530|NCT02171273|Genetic
967531|NCT02171273|Alertness
967532|NCT02171260|Tumors
967533|NCT02171260|Lymphomas
967534|NCT02171260|Solid Tumors
967535|NCT02171260|Pediatric
967536|NCT02171247|coronary computed tomographic angiography
967537|NCT02171247|contrast
967538|NCT02171234|Epilepsy
967539|NCT02171234|BIA 2-093
967540|NCT02171234|Eslicarbazepine acetate
967541|NCT02171221|Refractory or relapsed tumors
967542|NCT02171221|Antimetabolites, Antineoplastic
967543|NCT02171221|Fluorouracil
967544|NCT02171195|Eslicarbazepine acetate
967545|NCT02171195|BIA 2-093
967546|NCT02171195|Epilepsy
967547|NCT02171182|Qutenza
967548|NCT02171182|8% capsaicin patch
967549|NCT02171182|Non-interventional
967550|NCT02171182|Post-operative peripheral neuropathic pain
967551|NCT02171182|Observational
967552|NCT02171182|Czech Republic
967553|NCT02171143|ASP2409
967554|NCT02171143|Rheumatoid Arthritis
967555|NCT02171143|methotrexate
967556|NCT02171130|Diabetes Mellitus
967557|NCT02171130|Hypoglycemia
967558|NCT02171130|Glucagon
967559|NCT02171130|Anti-glucagon Antibody
967560|NCT02171130|Immunogenicity
967561|NCT02171117|Acute Myeloid Leukemia
967562|NCT02171117|microtransplantation
967563|NCT02171117|elderly patients
967564|NCT02171117|HLA-mismatched
967565|NCT02171117|donor
967566|NCT02171117|Peripheral
967567|NCT02171117|stem cell
967568|NCT02171117|infusion
967569|NCT02171104|allogeneic hematopoietic cell transplantation
967570|NCT02171104|bone marrow transplantation
967571|NCT02171104|IMD
967572|NCT02171104|AMACRD
967573|NCT02171104|MNGIE
967574|NCT02171104|HDLS
967575|NCT02171104|OP
967576|NCT02171104|ALD
967577|NCT02171091|endotracheal
967578|NCT02171091|intubation
967579|NCT02171091|airway
967580|NCT02171091|inflammation
967581|NCT02171078|Breast Cancer
967582|NCT02171078|Breast Neoplasms
967583|NCT02171078|Health Services Research
967584|NCT02171078|Surveillance
967585|NCT02171078|Diagnostic Imaging
967586|NCT02171078|Magnetic Resonance Imaging
967587|NCT02171078|Mammography
967588|NCT02171078|Toxicity
967589|NCT02171078|Adverse Effects
967590|NCT02171078|Side Effects
967591|NCT02171078|Recurrence
967592|NCT02171065|NIRS/IVUS
967593|NCT02171065|multimodality imaging
967594|NCT02171065|PROSPECT
967595|NCT02170961|Acute heart failure
967596|NCT02170961|RAAS
967597|NCT02170961|MMP3
967598|NCT02170961|MMP12
967599|NCT02170961|Polymorphysm
967600|NCT02170948|ultrasound-guided regional anesthesia
967601|NCT02170948|nerve block
967602|NCT02170948|ankle block
967603|NCT02170948|dexmedetomidine
967604|NCT02170948|Precedex
967605|NCT02170948|ankle surgery
967606|NCT02170948|forefoot surgery
967607|NCT02170948|duration
967608|NCT02170948|anesthetic duration following ankle block for forefoot surgery
967609|NCT02170883|asthma
967610|NCT02170883|mHealth
967611|NCT02170883|cluster randomized controlled trial
967612|NCT02170883|pharmacy practice
967613|NCT02170883|pharmacist
967614|NCT02170857|Hyaluronic acid
967615|NCT02170857|infra-bony defects
967616|NCT02170857|chronic periodontitis
967617|NCT02170857|experimental
967618|NCT02170857|radiographic
967619|NCT02170857|clinical
967620|NCT02170857|periodontal surgical treatment
967621|NCT02170857|open flap curettage
967622|NCT02170818|Education
967623|NCT02170818|Curriculum
967624|NCT02170818|Anesthesiology
967625|NCT02170818|Operating Rooms
967626|NCT02170779|multiple sclerosis
967627|NCT02170779|spasticity
967628|NCT02170779|stretching
967629|NCT02170779|exercise
967630|NCT02170779|rehabilitation
967631|NCT02170714|Acute severe colitis
967632|NCT02170714|Children
967633|NCT02170714|Infliximab
967634|NCT02170714|colectomy
967635|NCT02170688|IV contrast
967636|NCT02170688|contrast dosing
967637|NCT02170662|male pattern hair loss
967638|NCT02170662|androgenetic alopecia
967639|NCT02170662|bimatoprost
967640|NCT02170649|BIA 2-093
967641|NCT02170649|Eslicarbazepine acetate
967642|NCT02170558|Trabecular Metal
967643|NCT02170558|Metal reduction CT
967644|NCT02170558|TM- Ardis
967645|NCT02170545|avascular necrosis
967646|NCT02170545|humeral head fracture
967647|NCT02170545|proximal arm fracture
967648|NCT02170545|arthroplasty
967649|NCT02170532|asthma
967650|NCT02170519|pulmonary hypertension
967651|NCT02170493|Insole Sensor
967652|NCT02170493|Optimial Limb Loading
967653|NCT02170493|42IIIB
967654|NCT02170493|IIIC
967655|NCT02170493|Lower Extremity Fractures
967656|NCT02170467|Intestinal permeability - Anorexia nervosa- Re feeding - auto-antibodies α-MSH
967657|NCT02170454|neuromodulation
967658|NCT02170454|swallowing
967659|NCT02170454|magnetic stimulation
967660|NCT02170454|healthy subjects
967661|NCT02170441|Tuberculosis
967662|NCT02170441|Multi-drug resistant tuberculosis
967663|NCT02170441|Extensively drug-resistant tuberculosis
967664|NCT02170441|Drug-resistant tuberculosis
967665|NCT02170441|Mycobacterial Growth Indicator Tube Drug Susceptibility Test
967666|NCT02170441|Line Probe Assay
967667|NCT02170441|Microscopic Observation Drug Susceptibility Assay
967668|NCT02170441|Pyrosequencing
967669|NCT02170428|growth,
967670|NCT02170428|infancy,
967671|NCT02170428|children,
967672|NCT02170428|diet,
967673|NCT02170428|breastfeeding
967674|NCT02170428|complementary feeding
967675|NCT02170428|early life programming
967676|NCT02170428|tracking
967677|NCT02170428|physical activity
967678|NCT02170415|Persistent post-surgical pain
967679|NCT02170415|Breast surgery
967680|NCT02170415|Complex intervention
967681|NCT02170415|Pain treatment
967682|NCT02170376|Parkinson's disease (PD)
967683|NCT02170376|BIA 9-1067
967684|NCT02170376|Opicapone
967685|NCT02170363|Heart Failure
967686|NCT02170363|Ventricular Dysfunction
967687|NCT02170363|Cardiomyopathies
967688|NCT02170363|Heart Disease
967689|NCT02170363|Cardiovascular Disease
967690|NCT02170363|Heart-assist devices
967691|NCT02170311|Z-213, Ferric carboxymaltose, Iron, Iron-deficiency-anemia
967696|NCT02170285|perinatal stroke
967697|NCT02170285|hemiparetic cerebral palsy
967698|NCT02170285|brain stimulation
967699|NCT02170285|tDCS
967700|NCT02170285|constraint-induced movement therapy
967701|NCT02170285|hand arm bimanual intensive therapy
967702|NCT02170259|Tension-type headache
967703|NCT02170259|Depression
967704|NCT02170259|Anxiety
967705|NCT02170259|Manual therapy
967706|NCT02170259|Spinal manipulation
967707|NCT02170259|Patients diagnosed with tension-type headache
967708|NCT02170246|Acute HIV infection
967709|NCT02170246|Central nervous system
967710|NCT02170246|Antiretroviral therapy
967711|NCT02170246|Telmisartan
967712|NCT02170246|Cerebrospinal fluid
967713|NCT02170220|Drug therapy
967714|NCT02170207|Pharmacological therapy
967715|NCT02170194|smart phone apps
967716|NCT02170194|subthreshold PTSD
967717|NCT02170194|resilience enhancement
967718|NCT02170194|military veterans
967719|NCT02170194|natural disasters
967720|NCT02170194|terrorism
967721|NCT02170194|shootings
967722|NCT02170194|fMRI
967723|NCT02170194|physiology
967724|NCT02170181|SBRT
967725|NCT02170181|prostate cancer
967726|NCT02170181|lung cancer
967727|NCT02170181|bladder cancer
967728|NCT02170181|kidney cancer
967729|NCT02170181|oligometastatic disease
967730|NCT02170168|Community health services
967731|NCT02170168|Models, organizational
967732|NCT02170168|Referral and consultation
967733|NCT02170168|Palliative medicine
967734|NCT02170168|Terminal care
967735|NCT02170142|MRI
967736|NCT02170142|perinatal brain
967737|NCT02170142|development, neonates
967738|NCT02170103|segment elevation myocardial infarctions (STEMIs),
967739|NCT02170103|sonothrombolysis
967740|NCT02170103|reperfusion
967741|NCT02170103|percutaneous intervention (PCI),
967742|NCT02170103|antithrombotic therapy,
967743|NCT02170103|antiplatelet therapy,
967744|NCT02170090|adjuvant chemotherapy
967745|NCT02170090|cholangiocarcinoma
967746|NCT02170090|muscle invasive gall bladder carcinoma
967747|NCT02170090|translational research
967748|NCT02170090|multidisciplinary
967749|NCT02170090|AIO, DGAV, DGVS
967750|NCT02170077|Epilepsy
967751|NCT02170077|BIA 2-093
967752|NCT02170064|Epilepsy
967753|NCT02170064|BIA 2-093
967754|NCT02170051|negative symptoms
967755|NCT02170051|cognition
967756|NCT02170051|functioning
967757|NCT02170051|defeatist attitudes
967758|NCT02170051|psychosocial treatment
967759|NCT02170038|Drug Kinetics
967760|NCT02170025|Cystic fibrosis
967761|NCT02170025|delta F508
967762|NCT02170025|Safety
967763|NCT02170025|Tolerability
967764|NCT02170025|Sweat Chloride
967765|NCT02170025|Pharmacokinetics
967766|NCT02170012|Multiple dose
967767|NCT02170012|safety
967768|NCT02170012|tolerability
967769|NCT02170012|PK
967770|NCT02169973|Healthy
967771|NCT02169973|Positron Emission Tomography
967772|NCT02169973|11C-MK-3168
967773|NCT02169973|JNJ-42165279
967774|NCT02169973|Human Brain
967775|NCT02169895|Parkinson's disease (PD)
967776|NCT02169895|Opicapone
967777|NCT02169895|Bia 9-1067
967778|NCT02169882|Tuberculous meningitis
967779|NCT02169882|Rifampicin
967780|NCT02169882|Dose finding study
967781|NCT02169882|Pharmacokinetics
967782|NCT02169869|intrauterine device, postpartum, contraception, Mirena, Paragard, intrauterine system
967783|NCT02169856|Cholecystectomy
967784|NCT02169856|Laparoscopic
967785|NCT02169856|Postoperative Nausea and Vomiting
967786|NCT02169843|Dexmedetomidine,
967787|NCT02169843|agitation,
967788|NCT02169843|AFPS,
967789|NCT02169843|NRS,
967790|NCT02169843|mean arterial pressure
967791|NCT02169843|heart rate(HR)
967792|NCT02169830|vestibular migraines, nortriptyline and topiramate
967793|NCT02169791|hematologic malignancies
967794|NCT02169778|Weight loss
967795|NCT02169778|Intermittent energy restriction
967796|NCT02169778|Metabolic compensation
967797|NCT02169778|Diet therapy
967798|NCT02169765|Hepatocellular Carcinoma
967799|NCT02169765|Liver Cancer
967800|NCT02169752|Pre-Pulmonary Atrial Hypertension
967801|NCT02169739|ischemic preconditioning
967802|NCT02169739|remote ischemic preconditioning
967803|NCT02169739|ischemic stroke
967804|NCT02169739|white matter disease
967805|NCT02169739|cerebral small vessel disease
967806|NCT02169739|cognitive decline
967807|NCT02169739|leukoaraiosis
967808|NCT02169739|diffusion tensor imaging
967809|NCT02169739|white matter hyper intensity score
967810|NCT02169739|European scale of age-related white matter change
967811|NCT02169713|Healthy subjects
967812|NCT02169713|Mirabegron
967813|NCT02169713|Solifenacin
967814|NCT02169713|Tamsulosin HCl
967815|NCT02169700|Ischemic compression
967816|NCT02169700|Myofascial trigger points
967817|NCT02169700|Post-needling soreness
967818|NCT02169687|Thyroid, HIFU, hyperfunctioning, autonomous
967819|NCT02169674|Hepatitis B
967820|NCT02169674|Vaccine
967821|NCT02169674|Immunogenicity
967822|NCT02169661|Oxidative stress
967823|NCT02169661|Lipid peroxides
967824|NCT02169661|Phytochemicals
967825|NCT02169661|Ready meals
967826|NCT02169661|Beetroot
967827|NCT02169661|Blood pressure
967828|NCT02169648|macular edema
967829|NCT02169648|branch retinal vein occlusion
967830|NCT02169648|central retinal vein occlusion
967831|NCT02169648|ranibizumab
967832|NCT02169648|cytokines
967833|NCT02169648|visual acuity
967834|NCT02169648|central macular thickness
967835|NCT02169635|macular buckle
967836|NCT02169635|high myopia
967837|NCT02169635|posterior staphyloma
967838|NCT02169609|Neuroblastoma
967839|NCT02169609|Immunotherapy
967840|NCT02169609|Dinutuximab
967841|NCT02169596|Acute Coronary Syndrome
967842|NCT02169596|Nitric oxide
967843|NCT02169596|Ticagrelor
967844|NCT02169596|Antiplatelet agents
967845|NCT02169596|Endothelial function
967846|NCT02169583|GSK1325756
967847|NCT02169583|Safety
967848|NCT02169583|Bioavailability
967849|NCT02169583|Pharmacokinetics
967850|NCT02169570|Type 2 Diabetes Mellitus
967851|NCT02169570|Pulmonary Tuberculosis
967852|NCT02169570|Vitamin D
967853|NCT02169570|Calcium
967854|NCT02169531|Diabetes Mellitus Type 2
967855|NCT02169531|Hyperglycemia
967856|NCT02169531|Immunotherapy
967857|NCT02169531|Autologous
967858|NCT02169518|PON1 activity
967859|NCT02169518|HDL functionality
967860|NCT02169518|LDL oxidation
967861|NCT02169518|Type 1 diabetes
967862|NCT02169518|Type 2 diabetes
967863|NCT02169518|Obesity
967864|NCT02169518|Bariatric surgery
967865|NCT02169505|Lymphoma
967866|NCT02169505|Hodgkin lymphoma
967867|NCT02169505|HL
967868|NCT02169505|CD30 positive Hodgkin Lymphoma
967869|NCT02169505|Anaplastic large cell lymphoma
967870|NCT02169505|ALCL
967871|NCT02169505|Allogeneic Stem Cell Transplantation
967872|NCT02169505|ASCT
967873|NCT02169505|Graft-versus-host disease
967874|NCT02169505|GVHD
967875|NCT02169505|Brentuximab Vedotin
967876|NCT02169505|SGN-35
967877|NCT02169505|Adcetris
967878|NCT02169492|Thrombectomy
967879|NCT02169492|Stroke
967880|NCT02169492|ReVive SE
967881|NCT02169479|Parkinson's disease (PD)
967882|NCT02169479|Opicapone
967883|NCT02169479|BIA 9-1067
967884|NCT02169466|Parkinson's disease (PD)
967885|NCT02169466|Opicapone
967886|NCT02169466|BIA 9-1067
967887|NCT02169453|Parkinson's disease (PD)
967888|NCT02169453|BIA 9-1067
967889|NCT02169453|Opicapone
967890|NCT02169440|Parkinson's disease (PD)
967891|NCT02169440|BIA 9-1067
967892|NCT02169440|Opicapone
967893|NCT02169427|Parkinson's disease (PD)
967894|NCT02169427|BIA 9-1067
967895|NCT02169427|Opicapone
967896|NCT02169414|Parkinson's disease (PD)
967897|NCT02169414|BIA 9-1067
967898|NCT02169414|Opicapone
967899|NCT02169388|Gut microflora
967900|NCT02169388|colorectal cancer
967901|NCT02169388|Chemotherapy
967902|NCT02169388|Immunity
967903|NCT02169388|Nutrition
967904|NCT02169362|Burns
967905|NCT02169362|Thermal burns
967906|NCT02169362|Second degree burns
967907|NCT02169362|Partial thickness burns
967908|NCT02169362|Deep partial thickness burns
967909|NCT02169362|Acute burns
967910|NCT02169362|Burn wounds
967911|NCT02169336|Bunion
967912|NCT02169336|Bunionectomy
967913|NCT02169336|Pain
967914|NCT02169336|Analgesia
967915|NCT02169336|dexmedetomidine
967916|NCT02169336|intranasal
967917|NCT02169323|Non-eosinophilic Asthma
967918|NCT02169323|Inhaled corticosteroids
967919|NCT02169323|Step-down
967920|NCT02169310|Traumatic Brain Injury
967921|NCT02169310|Decision-Making
967922|NCT02169310|Dopaminergic Network
967923|NCT02169310|Brain Imaging
967924|NCT02169310|Non-Invasive Brain Stimulation
967925|NCT02169297|Pain Management
967926|NCT02169297|Anesthesia: Nerve Block
967927|NCT02169258|coronary artery disease
967928|NCT02169258|peripheral artery disease
967929|NCT02169258|percutaneous transluminal angioplasty
967930|NCT02169258|coronary angiography
967931|NCT02169258|revascularization
967932|NCT02169258|gene polymorphisms
967933|NCT02169258|microRNAs
967934|NCT02169232|Awake intubation
967935|NCT02169232|Videolaryngoscope
967936|NCT02169232|Fiberoptic
967937|NCT02169206|Frozen shoulder
967938|NCT02169206|scapulothoracic angle
967939|NCT02169206|scapulohumeral angle
967940|NCT02169206|acromiohumeral distance
967941|NCT02169206|center equator distance
967942|NCT02169206|shoulder radiography
967943|NCT02169193|microaspiration
967944|NCT02169193|mechanical ventilation
967945|NCT02169193|enteral feeding
967946|NCT02169193|99m technetium
967947|NCT02169193|pepsin
967948|NCT02169180|Ibrutinib
967949|NCT02169180|IMBRUVICA
967950|NCT02169180|PCI-32765
967951|NCT02169180|JNJ-54179060
967952|NCT02169180|Lymphoma, Mantle-cell
967953|NCT02169167|Diabetes complications
967954|NCT02169167|Diabetic foot
967955|NCT02169167|Foot ulcer
967956|NCT02169167|Wound healing
967957|NCT02169167|Wound infection
967958|NCT02169141|pharmacokinetics
967959|NCT02169141|pharmacodynamics
967960|NCT02169141|MDR-TB
967961|NCT02169141|Levofloxacin
967962|NCT02169141|Capreomycin
967963|NCT02169102|Low power laser
967964|NCT02169102|Pulpitis
967965|NCT02169102|Pain
967966|NCT02169076|Ventricular Assist Device, Cardiac Resynchronization Therapy
967967|NCT02169050|Vitamin D deficiency
967968|NCT02169050|Inflammation
967969|NCT02169050|Obesity
967970|NCT02169037|Rotor
967971|NCT02169037|FIRM
967972|NCT02169037|Paroxysmal Atrial Fibrillation
967973|NCT02169037|Atrial tachyarrhythmia
967974|NCT02169037|Ablation
967975|NCT02169037|Contact mapping
967976|NCT02169037|Clinical trial
967977|NCT02169037|Signal processing.
967978|NCT02169024|prenatal care
967979|NCT02169024|group care
967980|NCT02169024|Expect With Me
967981|NCT02169024|evaluation studies
967982|NCT02169024|group prenatal care
967983|NCT02169011|Breast reconstruction
967984|NCT02169011|Breast cancer
967985|NCT02168998|Medical clown
967986|NCT02168998|Pediatric emergency medicine
967987|NCT02168985|Child violence
967988|NCT02168985|HIV AIDS conflicted couples
967989|NCT02168985|Intimate partner violence
967990|NCT02168985|Tanzania
967991|NCT02168985|Marriage counseling
967992|NCT02168985|Child maltreatment
967993|NCT02168985|Couples communication
967994|NCT02168972|atrial fibrillation
967995|NCT02168972|global
967996|NCT02168972|radiofrequency RF ablation
967997|NCT02168972|left atrium anatomical and electrophysiological mapping
967998|NCT02168959|Femoral Nerve Block
967999|NCT02168959|Pain Control
968000|NCT02168959|Tibial Plateau Fracture
968001|NCT02168959|Prospective
968002|NCT02168959|Randomized
968003|NCT02168933|psoriasis
968004|NCT02168933|nail
968005|NCT02168933|laser
968006|NCT02168933|excimer
968007|NCT02168933|treatment
968008|NCT02168920|Alzeheimer
968009|NCT02168894|Peripheral neuropathy
968010|NCT02168894|Chemotherapy-Induced Peripheral Neuropathy
968011|NCT02168894|Cancer Survivors
968012|NCT02168894|Acupuncture
968013|NCT02168894|Electrical stimulation
968014|NCT02168894|Nerve function tests
968015|NCT02168894|Hand function tests
968016|NCT02168894|Balance tests
968017|NCT02168894|Questionnaires
968018|NCT02168894|Surveys
968019|NCT02168881|labour
968020|NCT02168881|induction
968021|NCT02168881|misoprostol
968022|NCT02168881|dinoprostone
968023|NCT02168868|Autoimmune Diseases
968024|NCT02168868|Child Development Disorders, Pervasive
968025|NCT02168868|Inflammation
968026|NCT02168868|Risk Factors
968027|NCT02168855|Smoking cessation
968028|NCT02168855|Non-daily smokers
968029|NCT02168855|Ecological Momentary Assessment
968030|NCT02168855|nicotine replacement therapy
968031|NCT02168842|Parkinson
968032|NCT02168842|Parkinson Disease
968033|NCT02168842|Parkinson's Disease
968034|NCT02168829|AF ablation
968035|NCT02168829|Anticoagulation AF ablation
968036|NCT02168829|Stroke prevention
968037|NCT02168816|Osteomyelitis
968038|NCT02168816|Diabetes
968039|NCT02168816|Foot Infection
968040|NCT02168803|abnormal cholesterol
968041|NCT02168790|amniotic membrane holder, aminiotic membrane transplantation
968042|NCT02168777|Patients with Cancer
968043|NCT02168751|one lung ventilation
968044|NCT02168751|inflammatory response
968045|NCT02168751|thoracic surgery
968046|NCT02168738|nutrition
968047|NCT02168725|briciclib
968048|NCT02168725|Dose escalation
968049|NCT02168725|Maximum tolerated dose
968050|NCT02168712|Coronary Heart Disease
968051|NCT02168712|Interval exercise training
968052|NCT02168712|Continuous exercise training
968053|NCT02168712|Quality of life
968054|NCT02168712|Safety
968055|NCT02168699|children
968056|NCT02168699|infants
968057|NCT02168699|musculocutaneous nerve
968058|NCT02168699|ultrasonography
968059|NCT02168686|alpha1-antitrypsin deficiency
968060|NCT02168686|alpha1AT
968061|NCT02168686|A1AT
968062|NCT02168686|ADVM-043
968063|NCT02168686|gene therapy
968064|NCT02168686|gene transfer vector
968065|NCT02168673|COPD
968066|NCT02168673|Cigarette Smoke
968067|NCT02168673|Smoker
968068|NCT02168673|Nonsmoker
968069|NCT02168673|ODF2
968070|NCT02168673|Cilia
968071|NCT02168660|Obesity
968072|NCT02168660|Insulin Resistance
968073|NCT02168660|Vitamin D Deficiency
968074|NCT02168660|Children
968075|NCT02168660|Adolescents
968076|NCT02168647|Excessive gestational weight gain
968077|NCT02168647|Insulin resistance
968078|NCT02168647|Physical activity
968079|NCT02168647|Behavioral prenatal lifestyle intervention
968080|NCT02168647|Reduced carbohydrate intake
968081|NCT02168647|Self-determination theory
968082|NCT02168647|Motivational interviewing
968083|NCT02168621|Chronic periodontitis
968084|NCT02168621|Non-surgical therapy
968085|NCT02168621|Ultrasonic debridement
968086|NCT02168621|Scaling and root planing
968087|NCT02168608|hepatic ischemia reperfusion injury
968088|NCT02168608|ischemia precondition
968089|NCT02168608|remote ischemia precondition
968090|NCT02168608|anti-inflammation
968091|NCT02168595|healthy volunteers, GMI-1271
968092|NCT02168582|Physical Therapy Modalities
968093|NCT02168582|Prognosis
968094|NCT02168582|Patient Selection
968095|NCT02168569|treatment
968096|NCT02168569|artemisin-based combinations
968097|NCT02168569|children
968098|NCT02168556|Urodynamics, Anxiety
968099|NCT02168517|Obesity
968100|NCT02168517|Pain
968101|NCT02168517|Fertility
968102|NCT02168478|Neo-Synalar
968103|NCT02168478|Patch Test
968104|NCT02168478|Sodium lauryl sulfate
968105|NCT02168478|Saline
968106|NCT02168478|Presensitization
968107|NCT02168465|self-efficacy
968108|NCT02168465|self-management
968109|NCT02168465|web-based intervention research
968110|NCT02168452|Neoadjuvant chemotherapy
968111|NCT02168452|Indocyanine green (ICG)
968112|NCT02168452|Radioisotope (RI)
968113|NCT02168452|Near infrared fluorescence camera
968114|NCT02168439|Dexmedetomidine
968115|NCT02168439|Midazolam
968116|NCT02168413|cortical excitability
968117|NCT02168413|robotized TMS
968118|NCT02168413|EEG
968119|NCT02168413|EMG
968120|NCT02168387|atelectasis
968121|NCT02168387|continuous high frequency oscillator
968122|NCT02168387|acetylcysteine
968123|NCT02168387|dornase alfa
968124|NCT02168374|Glass ionomer cement
968125|NCT02168374|Indirect pulp therapy
968126|NCT02168361|cirrhosis
968127|NCT02168322|growth factors
968128|NCT02168322|periodontal regeneration
968129|NCT02168322|modefied perforated membranes
968130|NCT02168296|Pharmacokinetics
968131|NCT02168296|Blood glucose
968132|NCT02168296|subjects
968133|NCT02168283|cardiovascular disease
968134|NCT02168283|hypertension
968135|NCT02168257|Nasal Cannula
968136|NCT02168244|psoriasis
968137|NCT02168244|biologics
968138|NCT02168244|subcutaneous
968139|NCT02168244|pain
968140|NCT02168244|heat
968141|NCT02168244|ice
968142|NCT02168231|Complex abdominal wall hernia
968143|NCT02168231|Biologic mesh
968144|NCT02168231|Strattice
968145|NCT02168218|protein synthesis
968146|NCT02168218|intrahepatic fat
968147|NCT02168218|lean body mass
968148|NCT02168218|IGF1
968149|NCT02168218|energy metabolism
968150|NCT02168205|Healthy volunteer
968151|NCT02168205|Pharmacokinetics
968152|NCT02168205|Pomalyst
968153|NCT02168205|Pomalidomide
968154|NCT02168205|Food effect
968155|NCT02168205|smoker
968156|NCT02168192|Breaking bad news skills
968157|NCT02168192|Communications skills
968158|NCT02168192|Medical education
968159|NCT02168192|Obstetrics
968160|NCT02168192|Simulation
968161|NCT02168166|Neurological Disorders
968162|NCT02168166|Neuroscience
968163|NCT02168166|Neuropsychology
968164|NCT02168166|EEG
968165|NCT02168166|Cognitive remediation
968166|NCT02168166|Cognitive Response
968167|NCT02168153|Chiropractic Manipulative Therapy
968168|NCT02168153|Reaction Times
968169|NCT02168153|Response Times
968170|NCT02168153|Special Forces
968171|NCT02168153|Biomechanical Assessments
968172|NCT02168114|Duchenne Muscular Dystrophy
968173|NCT02168114|Exercise
968174|NCT02168114|Optical Imaging
968175|NCT02168114|Magnetic Resonance
968176|NCT02168101|MLN9708
968177|NCT02168101|allogeneic stem cell transplant
968178|NCT02168101|multiple myeloma
968179|NCT02168101|ixazomib
968180|NCT02168101|autologous stem cell transplant
968181|NCT02168088|Sudden unexplained death
968182|NCT02168062|Supportive Therapy
968183|NCT02168062|Androgen Deprivation Therapy
968184|NCT02168049|cardiac, respiratory, monitoring
968185|NCT02168036|lung disease
968186|NCT02168036|mediastinal lymph node
968187|NCT02168036|bronchoscopy
968188|NCT02168036|Endobronchial-Guided Transbronchial Needle Aspiration
968189|NCT02168023|surgical site infection
968190|NCT02168023|dialkylcarbamoylchloride impregnated dressing
968191|NCT02168023|caesarean section
968192|NCT02168023|wound dehiscence
968193|NCT02167984|esophageal swallow
968194|NCT02167984|gastroesophageal reflux
968195|NCT02167984|esophageal impedance
968196|NCT02167984|newborn
968197|NCT02167984|preterm
968198|NCT02167971|traumatic brain injury
968199|NCT02167971|diffuse axonal injury
968200|NCT02167971|repetitive transcranial magnetic stimulation
968201|NCT02167971|neuromodulation
968202|NCT02167971|cognitive rehabilitation
968203|NCT02167945|Naïve
968204|NCT02167945|Hepatitis C
968205|NCT02167945|Non responder
968206|NCT02167945|Relapser
968207|NCT02167945|Null responder
968208|NCT02167945|Treatment-Experienced
968209|NCT02167945|Cirrhosis
968210|NCT02167945|Hepatitis C Genotype 1
968211|NCT02167945|Compensated Cirrhosis
968212|NCT02167945|Hepatitis C Virus
968213|NCT02167932|Breast Cancer
968214|NCT02167932|Walk With Ease
968215|NCT02167932|Physical Activity
968216|NCT02167932|Walking
968217|NCT02167932|Younger Women
968218|NCT02167932|Cancer
968219|NCT02167932|p16
968220|NCT02167932|Aging
968221|NCT02167932|Biomarkers
968222|NCT02167932|Biomarkers of Aging
968223|NCT02167932|Chemotherapy
968224|NCT02167932|Chemotherapy Treatment
968225|NCT02167932|Adjuvant Chemotherapy
968226|NCT02167932|Neoadjuvant Chemotherapy
968227|NCT02167919|Prostate
968228|NCT02167919|Men
968229|NCT02167919|Hyperplasia
968230|NCT02167893|Pharmacological therapy
968231|NCT02166827|TMS
968232|NCT02166827|Cognitive Stimulation
968233|NCT02166827|NeuroAD
968234|NCT02166801|Cerebral palsy
968235|NCT02166801|Children
968236|NCT02166801|Early Intervention
968237|NCT02166801|Communication
968238|NCT02166801|Gross motor function
968239|NCT02166801|Hand function
968240|NCT02166788|metastatic melanoma
968241|NCT02166788|groin lymph nodes
968242|NCT02166788|surgery
968243|NCT02166788|lymphadenectomy
968244|NCT02166762|Cardiac Resynchronization Therapy
968245|NCT02166762|Biventricular implantable cardioverter defibrillators
968246|NCT02166762|Heart failure
968247|NCT02166762|Cardiomyopathy
968248|NCT02166762|QLV
968249|NCT02166762|LV lead placement
968250|NCT02166762|Arrhythmia
968251|NCT02166749|Hysterectomy, long term follow up, subjective outcome
968252|NCT02166736|Instantaneous wave Free Ratio
968253|NCT02166736|Fractional Flow Reserve
968254|NCT02166723|persistent atrial fibrillation
968255|NCT02166723|Cryoballoon ablation
968256|NCT02166710|Knee arthroplasty
968257|NCT02166710|Adductor canal block
968258|NCT02166710|Quadriceps strength
968259|NCT02166697|Pharmacological therapy
968260|NCT02166684|Do-it-yourself devices
968261|NCT02166684|User-experiences
968262|NCT02166684|Health behavior
968263|NCT02166684|Self-measurement
968264|NCT02166684|Methodology, Evaluation
968265|NCT02166684|Personal health records
968266|NCT02166684|Blood Glucose Self-Monitoring
968267|NCT02166684|Self Blood Pressure Monitoring
968268|NCT02167867|body contouring
968269|NCT02167867|circumference reduction
968270|NCT02167867|body shaping
968271|NCT02167867|low level laser
968272|NCT02167854|LJM716
968273|NCT02167854|BYL719 [Alpelisib]
968274|NCT02167854|TRASTUZUMAB
968275|NCT02167854|HER2+
968276|NCT02167854|14-057
968277|NCT02167841|Breech presentation,
968278|NCT02167841|External cephalic version,
968279|NCT02167841|Maternal posture,
968280|NCT02167841|Pregnancy,
968281|NCT02167841|Caesarean section.
968282|NCT02167828|HIV
968283|NCT02167828|AIDS
968284|NCT02167828|treatment adherence
968285|NCT02167828|social network
968286|NCT02167802|severe infection, pediatrics, sub-optimal care, term care
968287|NCT02167789|HF, diagnosis
968288|NCT02167763|contraception
968289|NCT02167763|IUD
968290|NCT02167763|copper
968291|NCT02167750|cognitive
968292|NCT02167750|phytochmicals
968293|NCT02167750|caffeine
968294|NCT02167750|cognitive performance after ingestion of test beverage
968295|NCT02167737|Accident Prevention
968296|NCT02167737|Accidental Falls
968297|NCT02167737|Geriatric Health Services
968298|NCT02167737|Gender Differences
968299|NCT02167698|Pediatric acute respiratory distress syndrome
968300|NCT02167698|Mechanical ventilation
968301|NCT02167698|Airway pressure release ventilation
968302|NCT02167698|Conventional low-tidal volume ventilation
968303|NCT02167672|total abdominal hysterectomy, total laparoscopic hysterectomy, vaginal hysterectomy
968308|NCT02167646|Soft tissue defect
968309|NCT02167646|dorsal branch of the digital nerve
968310|NCT02167646|dorsal branch of the digital artery
968311|NCT02167646|dorsal digital flap
968312|NCT02167633|Radiosurgery
968313|NCT02167633|Laminectomy
968314|NCT02167633|Radiotherapy
968315|NCT02167633|Spinal Cord Compression
968316|NCT02167633|Neoplasm Metastasis
968317|NCT02167633|Randomized Controlled Trial
968318|NCT02167607|Purple Potatoes
968319|NCT02167607|Polyphenolics
968320|NCT02167581|Maxillofacial surgery
968321|NCT02167581|Epithelial odontogenic tumours
968322|NCT02167568|corpus callosum agenesis/dysgenesis
968323|NCT02167568|mental deficiency/ Intellectual deficiency
968324|NCT02167568|genetic and phenotypic characterization
968325|NCT02167555|Wild Blueberries
968326|NCT02167555|Polyphenolics
968327|NCT02167542|Severe hypoxemic respiratory failure
968328|NCT02167542|Fiberoptic bronchoscopy
968329|NCT02167542|Noninvasive possitive pressure ventilation
968330|NCT02167542|Continuous positive airway pressure
968331|NCT02167529|Quality of life-Thyroidectomy-Morbidity
968332|NCT02167516|Xinfeng capsule
968333|NCT02167516|Knee osteoarthritis
968334|NCT02167516|Randomized controlled trials
968335|NCT02167516|Double-blind
968336|NCT02167490|BC; conservative surgery; SNB; AD; axillary US imaging
968337|NCT02167477|Intubation, Endotracheal
968338|NCT02167464|Hypertension
968339|NCT02167451|stem cell transplant
968340|NCT02167451|GVHD prevention
968341|NCT02167438|Cesarean
968342|NCT02167438|Section
968343|NCT02167438|second
968344|NCT02167438|stage
968345|NCT02167438|labor
968346|NCT02167425|People who Inject Drugs
968347|NCT02167425|HIV
968348|NCT02167425|Methadone
968349|NCT02167425|Sub Saharan Africa
968350|NCT02167425|Tanzania
968351|NCT02167425|Implementation Science
968352|NCT02167412|POTS
968353|NCT02167412|Syncope
968354|NCT02167386|Men who have sex with men (MSM)
968355|NCT02167386|Black/African-American
968356|NCT02167360|adult patients
968357|NCT02167360|B-cell ALL
968358|NCT02167360|chemo-refractory
968359|NCT02167360|relapsed after allogeneic SCT
968360|NCT02167360|ineligible for allogeneic SCT
968361|NCT02167347|CBT, Psychosis, cultural adaptation, Pakistan
968362|NCT02167334|panendoscopy
968363|NCT02167334|preoxygenation
968364|NCT02167334|non invasive ventilation
968365|NCT02167295|betel nut
968366|NCT02167295|dependence
968367|NCT02167295|withdraw
968368|NCT02167295|deprivation test
968369|NCT02167269|enclosed afferent reservoir
968370|NCT02167269|Jackson Rees system
968371|NCT02167269|anesthesia breathing circuit
968372|NCT02167269|spontaneous breathing
968373|NCT02167269|pediatric anesthesia
968374|NCT02167230|Coronary Artery Disease
968375|NCT02167230|Percutaneous Coronary Intervention
968376|NCT02167230|Bifurcation
968377|NCT02167230|Jailed-balloon technique
968378|NCT02167217|Duchenne Muscular Dystrophy
968379|NCT02167217|Corticosteroids
968380|NCT02167217|Infants
968381|NCT02167217|Young Children
968382|NCT02167217|Toddlers
968383|NCT02167165|Atrial Fibrillation
968384|NCT02167165|Digoxin
968385|NCT02167165|SNP
968386|NCT02167139|Rheumatoid Arthritis, Adalimumab
968387|NCT02167126|Athletic Performance;
968388|NCT02167126|Muscle Strength;
968389|NCT02167126|Isometric Contraction;
968390|NCT02167126|Kinesio Taping
968391|NCT02167100|HIV
968392|NCT02167100|Highly Active Antiretroviral Therapy
968393|NCT02167100|Patient Care
968394|NCT02167100|Patient Care Management
968395|NCT02167100|Lost to Follow-Up
968396|NCT02167087|Sentinel node mapping
968397|NCT02167087|lymphatic mapping
968398|NCT02167087|lymphatic metastasis
968399|NCT02167087|Aberrant lymphatic drainage
968400|NCT02167087|indocyanine green
968401|NCT02167087|ICG
968402|NCT02167087|near infrared
968403|NCT02167087|colon cancer
968404|NCT02167087|laparoscopic surgery
968405|NCT02167074|Diagnostic accuracy
968406|NCT02167074|Endoscopic Ultrasound-Guided Fine Needle Aspiration
968407|NCT02167074|EUS-FNA
968408|NCT02167074|Endoscopic Ultrasound-Guided Fine Needle Biopsy
968409|NCT02167074|EUS-FNB
968410|NCT02167074|Pancreatic mass
968411|NCT02167074|Lymph node
968412|NCT02167048|Attention Deficit Hyperactivity Disorders
968413|NCT02167048|Executive Function
968414|NCT02167048|Methylphenidate
968415|NCT02167048|Psychostimulants
968416|NCT02167048|Adolescent
968417|NCT02167048|Child
968418|NCT02167048|Working Memory
968419|NCT02167048|Prefrontal Cortex
968420|NCT02167048|Attention
968421|NCT02167048|Cognitive Function
968422|NCT02167048|Inhibition
968423|NCT02167035|Open-Angle Glaucoma
968424|NCT02167035|Ocular Hypertension
968425|NCT02167022|intense therapy
968426|NCT02167022|brain plasticity
968427|NCT02167022|Perception-Action approach
968428|NCT02167009|ARTERY EMBOLIZATION
968429|NCT02167009|BPH
968430|NCT02166970|Hilar tumor
968431|NCT02166970|Metal stent
968432|NCT02166970|Single
968433|NCT02166970|Multiple
968434|NCT02166957|Esophageal disruption
968435|NCT02166957|anterograde-retrograde endoscopy
968436|NCT02166957|rendez-vous technique
968437|NCT02166957|NOTES
968438|NCT02166957|recanalization
968439|NCT02166957|dilatations
968440|NCT02166957|Stenting
968441|NCT02166957|radiation therapy
968442|NCT02166957|head and neck carcinoma
968443|NCT02166944|amyotrophic lateral sclerosis
968444|NCT02166944|ALS functional ration scale
968445|NCT02166944|TAR-DNA-binding protein-43
968446|NCT02166944|tamoxifen
968447|NCT02166944|mTOR
968448|NCT02166931|Essence of Chicken
968449|NCT02166931|stress
968450|NCT02166931|cognitive function
968451|NCT02166918|Schizophrenia
968452|NCT02166918|Real-Life Functioning
968453|NCT02166918|Schizophrenia Endophenotypes
968454|NCT02166892|Childhood obesity
968455|NCT02166892|Plate
968456|NCT02166892|Food consumption
968457|NCT02166879|Obstructive Sleep Apnea-Hypopnea Syndrome
968458|NCT02166879|Obstructive sleep apnea
968459|NCT02166879|OSA
968460|NCT02166879|Chart review
968461|NCT02166879|Questionnaire
968462|NCT02166879|Survey
968463|NCT02166853|Acute respiratory distress syndrome (ARDS)
968464|NCT02166853|Sevoflurane
968465|NCT02166853|Mechanical ventilation
968466|NCT02166853|Intensive Care Unit (ICU)
968467|NCT02166853|Prospective study
968468|NCT02166853|Lung injury
968469|NCT02166853|Gas exchange
968470|NCT02166853|Inflammation
968471|NCT02166853|Receptor for advanced glycation end-produts (RAGE)
968472|NCT02166853|sRAGE
968475|NCT02166645|patient positioning
968476|NCT02166645|premature infant
968477|NCT02166645|mechanical ventilation
968478|NCT02166645|airway extubation
968479|NCT02166632|Knee arthroplasty
968480|NCT02166632|Exparel
968481|NCT02166632|Bupivacaine liposome
968482|NCT02166632|Total knee replacement
968483|NCT02166632|Pain control
968484|NCT02166619|Stroke
968485|NCT02166619|Rehabilitation
968486|NCT02166619|Electric stimulation therapy
968487|NCT02166619|Neuroplasticity
968488|NCT02166567|intracytoplasmic sperm injection
968489|NCT02166567|Male infertility
968490|NCT02166567|apoptosis
968491|NCT02166567|flow cytometry and sorting
968492|NCT02166567|DNA fragmentation
968493|NCT02166554|Adhesions
968494|NCT02166554|Hyaluronan
968495|NCT02166554|Gynaecological surgery
968496|NCT02166554|Clinical outcomes
968497|NCT02166541|cerebral palsy, spastic, diplegic,
968498|NCT02166541|children,
968499|NCT02166541|intervention study,
968500|NCT02166541|manipulation, spinal
968501|NCT02166541|randomized controlled trial
968502|NCT02166528|female pelvic floor dysfunction
968503|NCT02166528|pelvic organ prolaps
968504|NCT02166528|urinary incontinence
968505|NCT02166528|massively parallel sequencing
968506|NCT02166515|cervical cancer
968507|NCT02166515|ovarian cancer
968508|NCT02166515|endometrial cancer
968509|NCT02166515|high-throughput sequencing
968510|NCT02166502|pediatric
968511|NCT02166502|HIV
968512|NCT02166502|prevention
968513|NCT02166502|prophylaxis
968514|NCT02166502|nevirapine
968515|NCT02166489|autologous mesenchymal stem cells
968516|NCT02166489|polycystic kidney disease
968517|NCT02166489|intravenous injection
968518|NCT02166489|CRF
968519|NCT02166450|Denture stomatitis
968520|NCT02166450|Dentures
968521|NCT02166450|Denture wearers
968522|NCT02166437|osteoporosis
968523|NCT02166437|BMD
968524|NCT02166437|teriparatide
968525|NCT02166437|bisphosphonate
968526|NCT02166437|denosmab
968527|NCT02166424|Pregnancy
968528|NCT02166424|Depression
968529|NCT02166424|omega-3 fatty acids
968530|NCT02166411|Myomectomy ,Laparoscopy , Barbed sutures
968531|NCT02166398|Amlodipine basylate, Losartan potassium
968532|NCT02166359|Icodextrin
968533|NCT02166359|Triglyceride
968534|NCT02166346|Transverse myelitis
968535|NCT02166333|vitamin D
968536|NCT02166333|falls
968537|NCT02166333|high risk of falling
968538|NCT02166333|insufficient or deficient serum vitamin D levels
968539|NCT02166333|10-29 ng/ml
968540|NCT02166307|formaldehyde; Maillard Reaction; cross-linkage; human aging
968546|NCT02166281|Insomnia
968547|NCT02166281|Anxiety
968548|NCT02166281|Depression
968549|NCT02166281|Restless leg syndrome
968550|NCT02166281|Aromatase inhibitor
968551|NCT02166281|Body composition
968552|NCT02166268|Allergic rhinoconjunctivitis
968553|NCT02166268|Allergic rhinitis
968554|NCT02166268|Allergy
968555|NCT02166268|Grass pollen
968556|NCT02166242|non-small cell lung cancer
968557|NCT02166242|thioredoxin reductase
968558|NCT02166216|Prolonged high intensity exercise
968559|NCT02166216|Healthy subjects
968560|NCT02166216|Cardiovascular risk markers
968561|NCT02166216|Troponin
968562|NCT02166216|Leisure sports athletes
968563|NCT02166216|Cycling
968564|NCT02166216|CT coronary angiography
968565|NCT02166216|Outcomes
968566|NCT02166190|Pancreatic
968567|NCT02166190|cholangiocarcinoma
968568|NCT02166190|radiofrequency ablation
968569|NCT02166164|Pain
968570|NCT02166164|Secondary hyperalgesia
968571|NCT02166164|thermal sensitization
968572|NCT02166164|Catastrophization
968573|NCT02166164|Anxiety
968574|NCT02166125|gastric bypass
968575|NCT02166125|sleeve gastrectomy
968576|NCT02166125|esophageal stent
968577|NCT02166125|suturing
968578|NCT02166112|Hernia of Abdominal Wall
968579|NCT02166112|Biologic implant
968580|NCT02166112|Infected Hernioplasty Mesh
968581|NCT02166047|Hepatitis B
968582|NCT02166047|HBV
968583|NCT02166047|GS-9620
968584|NCT02166047|TLR-7 Agonist
968585|NCT02166034|children
968586|NCT02166034|fruit
968587|NCT02166034|vegetable
968588|NCT02166034|diet
968589|NCT02166034|school
968590|NCT02166034|garden
968591|NCT02166021|Multiple Sclerosis (MS)
968592|NCT02166021|Stem Cells
968593|NCT02166008|Repamipide
968594|NCT02166008|Dual antiplatelet
968595|NCT02166008|Peptic ulcer
968596|NCT02165995|Brain Tumor
968597|NCT02165995|Glioma
968598|NCT02165995|Tumor resection
968599|NCT02165995|Navigated Transcranial Magnetic Stimulation
968600|NCT02165995|nTMS
968601|NCT02165995|Brain mapping
968602|NCT02165995|Motor function
968603|NCT02165995|Speech function
968604|NCT02165995|Speech mapping
968605|NCT02165969|tumor
968606|NCT02165969|inflammatory process
968607|NCT02165969|fracture
968608|NCT02165969|defect
968609|NCT02165956|Cereals
968610|NCT02165956|Obesity
968611|NCT02165956|Complementary Feeding
968612|NCT02165930|Bioavailability
968613|NCT02165930|oxycodone
968614|NCT02165930|ethanol interaction
968615|NCT02165930|healthy volunteers
968616|NCT02165917|Endometriosis
968617|NCT02165917|Adhesions
968618|NCT02165917|Hyalobarrier®
968619|NCT02165917|Hyaluronic acid
968620|NCT02165917|Antiadhesion agent
968621|NCT02165917|Adhesionbarrier
968622|NCT02165917|Pregnancy rate
968623|NCT02165904|Analyze clinical efficacy of subarachnoid administration of
968624|NCT02165904|"autologous BMSC expanded in vitro"
968625|NCT02165878|Chronic kidney disease(CKD)
968626|NCT02165865|hand transplantation
968627|NCT02165865|hand allotransplantation
968628|NCT02165865|upper extremity transplantation
968629|NCT02165865|upper extremity amputation
968630|NCT02165865|hand amputation
968631|NCT02165865|vascularized composite allotransplantation
968632|NCT02165865|composite tissue allotransplantation
968633|NCT02165865|variance component analysis (VCA)
968634|NCT02165865|composite tissue allograft (CTA)
968635|NCT02165852|ampulla of Vater
968636|NCT02165852|adenoma
968637|NCT02165852|papillectomy
968638|NCT02165852|injection
968639|NCT02165852|non-injection
968640|NCT02165826|Drug therapy
968641|NCT02165774|sacral neuromodulation, neurogenic lower urinary tract dysfunction
968642|NCT02165761|Hemodialysis
968643|NCT02165761|End Stage Renal Disease
968644|NCT02165761|Vascular Graft
968645|NCT02165722|Influenza
968646|NCT02165722|HPV
968647|NCT02165722|Tdap
968648|NCT02165722|MCV
968649|NCT02165722|vaccination
968650|NCT02165722|adolescents
968651|NCT02165696|compression bandage, manual lymphatic drainage, lymphedema, breast cancer, qualitative research.
968655|NCT02165670|Ischemic heart disesase
968656|NCT02165670|Myocardial infarction
968657|NCT02165670|Angina pectoris
968658|NCT02165657|Excimer laser
968659|NCT02165657|UVB
968660|NCT02165657|Psoriasis
968661|NCT02165644|Subarachnoid Hemorrhage
968662|NCT02165644|Vasospasm
968663|NCT02165644|Acetazolamide
968664|NCT02165618|frailty
968665|NCT02165618|geriatric, elderly
968666|NCT02165618|polypharmacy
968667|NCT02165605|external beam radiotherapy
968668|NCT02165605|breast cancer
968669|NCT02165592|Hemophilia
968670|NCT02165592|Arthropathy
968671|NCT02165592|Range of Motion
968672|NCT02165592|Strength
968673|NCT02165592|Proprioception
968674|NCT02165592|Gait
968675|NCT02165592|Quality of Life
968676|NCT02165579|procalcitonin
968677|NCT02165579|biomarkers
968678|NCT02165579|Osteomyelitis
968679|NCT02165579|diabetes
968680|NCT02165579|foot ulcer(s)
968681|NCT02165579|Infectious Disease Society of America stage 3 infection
968682|NCT02165566|intensive insulin therapy
968683|NCT02165566|critical care patients
968684|NCT02165566|blood glucose concentration>180 mg/dl
968685|NCT02165553|Hibiscus sabdariffa calyces
968686|NCT02165553|Blood Pressure
968687|NCT02165553|Vascular Function
968688|NCT02165553|Inflammation
968689|NCT02165553|Cardiometabolic risk markers
968690|NCT02165553|Systemic antioxidant capacity
968691|NCT02165540|Doula
968692|NCT02165540|Pain management
968693|NCT02165540|Miscarriage
968694|NCT02165540|Abortion
968695|NCT02165514|spinal curvatures
968696|NCT02165488|ketamine
968697|NCT02165488|abuse
968698|NCT02165488|abdominal discomfort
968699|NCT02165488|cholangiopathy
968700|NCT02165462|Haemophilia
968701|NCT02165462|Arthropathy
968702|NCT02165462|Bilateral deficit phenomenon
968703|NCT02165462|Proprioception
968704|NCT02165449|ketamine
968705|NCT02165449|major depression
968706|NCT02165449|imaging
968707|NCT02165449|gene expression
968708|NCT02165423|pediatric
968709|NCT02165423|solid organ transplant
968710|NCT02165423|parents
968711|NCT02165423|heart
968712|NCT02165423|kidney
968713|NCT02165423|liver
968714|NCT02165410|Autism, mental retardation, Magnetic Resonance Imaging
968715|NCT02165397|Ibrutinib
968716|NCT02165397|Pharmacyclics
968717|NCT02165397|PCYC
968718|NCT02165397|Lymphoma
968719|NCT02165397|Btk inhibitor
968720|NCT02165397|WM
968721|NCT02165397|Rituximab
968722|NCT02165397|Rituxan
968723|NCT02165397|Waldenström's
968724|NCT02165397|Waldenstrom Macroglobulinemia
968725|NCT02165397|non-Hodgkin lymphoma
968726|NCT02165397|NHL
968727|NCT02165384|tympanostomy
968728|NCT02165384|myringotomy
968729|NCT02165384|otitis media
968730|NCT02165384|ear tubes
968731|NCT02165384|ear infection
968732|NCT02165358|BMD
968733|NCT02165358|LGMD2I
968734|NCT02165358|Calf enlargement
968735|NCT02165358|Muscular dystrophy
968736|NCT02165358|MRI
968737|NCT02165306|epilepsy
968738|NCT02165280|Pelvic Organ Prolapse
968739|NCT02165280|Surgery
968740|NCT02165254|physical activity
968741|NCT02165254|coronary heart disease
968742|NCT02165254|exercise
968743|NCT02165254|affect
968744|NCT02165254|mind/body therapies
968745|NCT02165254|stress, psychological
968746|NCT02165241|Hypertension
968747|NCT02165241|Cardiac remodeling
968748|NCT02165241|Immune system
968749|NCT02165202|HIV Pre-exposure Prophylaxis;
968750|NCT02165202|long-acting injectable;
968751|NCT02165202|HIV PrEP;
968752|NCT02165202|biomedical HIV prevention research
968753|NCT02165189|Simeprevir
968754|NCT02165189|Sofosbuvir
968755|NCT02165189|Ribavirin
968756|NCT02165189|Hepatitits C
968757|NCT02165189|Hepatitis C virus ribonucleic acid
968758|NCT02165176|cannabis
968759|NCT02165176|toxicology
968760|NCT02165176|intoxication
968761|NCT02165150|Elastic Band
968762|NCT02165150|Institutional Elders
968763|NCT02165150|Functional Fitness
968764|NCT02165150|Sleep Quality
968765|NCT02165150|Depression
968766|NCT02165137|trauma
968767|NCT02165137|major trauma
968768|NCT02165137|multiple trauma
968769|NCT02165137|outcome
968770|NCT02165137|quality
968771|NCT02165137|process Management
968772|NCT02165137|emergency room
968773|NCT02165137|trauma center
968774|NCT02165124|Obesity
968775|NCT02165124|Morbid Obesity
968776|NCT02165124|Bariatric Surgery
968777|NCT02165124|Embolization
968778|NCT02165124|Minimally Invasive
968779|NCT02165124|Weight Loss
968780|NCT02165111|Scleroderma, Systemic
968781|NCT02165111|Raynaud Disease
968782|NCT02165111|Botulinum Toxins, Type A
968783|NCT02165085|Biomarkers
968784|NCT02165085|Ehlers-Danlos syndrome, vascular type
968785|NCT02165085|Pathophysiology
968786|NCT02165072|Inferior vena cava
968787|NCT02165072|Kidney injury
968788|NCT02165072|Ultrasound
968789|NCT02165059|Nausea
968790|NCT02165059|Vomiting
968791|NCT02165059|Functional dyspepsia
968792|NCT02165059|Bloating
968793|NCT02165059|Regurgitation
968794|NCT02165059|Retching
968795|NCT02165020|Prostate
968796|NCT02165020|Hypofractionated radiotherapy
968797|NCT02165020|Hyaluronic acid
968798|NCT02165020|Spacer
968799|NCT02165020|Rectum toxicity
968800|NCT02165020|Rectal toxicities after hypofractionated irradiation and injection of hyaluronic acid in patients with low- to intermediate-risk Prostate Cancer
968801|NCT02164994|Astigmatism, arcuate incisions, astigmatic keratotomy
968802|NCT02164968|Device investigation
968803|NCT02164955|Pomalidomide
968804|NCT02164955|Multiple Myeloma
968805|NCT02164955|Relapsed, Refractory
968806|NCT02164955|Observational
968807|NCT02164955|Imnovid
968808|NCT02164955|Registry
968809|NCT02164955|Post-approval
968810|NCT02164955|Safety
968811|NCT02164929|TAP block
968812|NCT02164929|Paravertebral block
968813|NCT02164929|Epidural
968814|NCT02164929|Laparoscopic colectomy
968815|NCT02164916|BRAF Mutant
968816|NCT02164916|Metastatic
968817|NCT02164903|Quality of Life
968818|NCT02164903|Chronic Myeloid Leukemia
968819|NCT02164903|Imatinib
968820|NCT02164903|Dasatinib
968821|NCT02164877|Dietary fiber
968822|NCT02164851|shock, emergencies, inflammation, infection
968823|NCT02164851|pathologic process
968824|NCT02164799|Shock
968825|NCT02164799|Predicting diagnosis
968826|NCT02164799|Predicting adverse outcomes
968827|NCT02164786|Acute severe disease
968828|NCT02164786|Intensive care unit
968829|NCT02164786|adult
968830|NCT02164786|cohort study
968831|NCT02164786|metabolomics
968832|NCT02164786|NMR
968833|NCT02164786|High Performance Liquid Chromatography
968834|NCT02164773|sevoflurane
968835|NCT02164773|pediatric
968836|NCT02164773|lower abdominal surgery
968837|NCT02164773|caudal
968838|NCT02164773|magnesium sulfate
968839|NCT02164773|Magnesium Sulfate Causing Adverse Effects in Therapeutic Use
968840|NCT02164773|Agitation States as Acute Reaction to Exceptional Stress
968841|NCT02164760|burns
968842|NCT02164760|dermal substitute
968843|NCT02164760|scar quality
968844|NCT02164760|reconstruction
968845|NCT02164760|wound healing
968846|NCT02164760|wound closure
968848|NCT02164721|Heart failure
968849|NCT02164721|Chemotherapy-induced cardiomyopathy
968850|NCT02164721|Cardiac resynchronization therapy
968851|NCT02164708|mindfulness meditation, mental health, self-criticism
968852|NCT02164682|Hypospadias repair
968853|NCT02164682|Caudal block
968854|NCT02164682|Postoperative complications
968855|NCT02164669|Inflammation
968856|NCT02164669|Coronary artery bypass graft
968857|NCT02164669|Magnetic Resonance Imaging
968858|NCT02164643|Alzheimer's disease
968859|NCT02164643|Mild Cognitive Impairment
968860|NCT02164630|Temporomandibular Joint Disorder
968861|NCT02164630|TMD
968862|NCT02164630|Hope
968863|NCT02164630|Resilience
968864|NCT02164630|Cognitive Behavior Therapy
968865|NCT02164617|Dementia
968866|NCT02164617|Wheelchair-bound seniors
968867|NCT02164617|Long-term care facilities
968868|NCT02164617|Elastic band exercise
968869|NCT02164617|Functional fitness
968870|NCT02164617|Daily life function
968871|NCT02164617|Depression
968872|NCT02164617|Problem behaviors
968873|NCT02164604|ranibizumab
968874|NCT02164604|intravitreal therapy
968875|NCT02164604|ROP
968876|NCT02164604|Plus disease
968877|NCT02164604|stage 3 plus
968878|NCT02164591|gastroparesis
968879|NCT02164591|gastric electrical stimulator
968880|NCT02164591|GES
968881|NCT02164591|vomiting
968882|NCT02164591|nausea
968883|NCT02164591|bloating
968884|NCT02164591|postprandial fullness
968885|NCT02164591|epigastric pain
968886|NCT02164552|PCOS
968887|NCT02164552|vitamin D
968888|NCT02164552|insulin resistance
968889|NCT02164552|glycemic control
968890|NCT02164539|GSK573719
968891|NCT02164539|asthma
968892|NCT02164539|UMEC
968893|NCT02164539|FF
968894|NCT02164539|GSK2829332
968895|NCT02164539|persistent obstruction
968896|NCT02164539|GW685698
968897|NCT02164539|Fluticasone Furoate
968898|NCT02164539|COPD
968899|NCT02164539|umeclidinium bromide
968900|NCT02164526|Pulmonary Hypertension
968901|NCT02164526|Left Heart Disease
968902|NCT02164526|Heart failure
968903|NCT02164526|Registry
968904|NCT02164526|China
968911|NCT02164487|B1 adolescents Eating disorders Thaimine
968912|NCT02164461|Adenocarcinoma
968913|NCT02164461|Carcinoma
968914|NCT02164461|Carcinoma, Squamous Cell
968915|NCT02164461|Uterine Cervical Neoplasms
968916|NCT02164461|Small Cell Lung Carcinoma
968917|NCT02164461|Carcinoma, Small Cell
968918|NCT02164461|Carcinoma, Adenosquamous
968919|NCT02164461|Neoplasms, Glandular and Epithelial
968920|NCT02164461|Neoplasms by Histologic Type
968921|NCT02164461|Neoplasms
968922|NCT02164461|Neoplasms, Squamous Cell
968923|NCT02164461|Uterine Neoplasms
968924|NCT02164461|Genital Neoplasms, Female
968925|NCT02164461|Urogenital Neoplasms
968926|NCT02164461|Neoplasms by Site
968927|NCT02164461|Uterine Cervical Diseases
968928|NCT02164461|Uterine Diseases
968929|NCT02164461|Genital Diseases, Female
968930|NCT02164448|dexmedetomidine
968931|NCT02164448|postoperative bowel movement
968932|NCT02164448|laparoscopic gastrectomy
968933|NCT02164435|Uncontrolled hypertension
968934|NCT02164435|Renal denervation
968935|NCT02164435|Renal artery
968939|NCT02164383|Smoking Cessation
968940|NCT02164383|Smoking
968941|NCT02164383|Nicotine
968942|NCT02164357|Ischaemic Stroke
968943|NCT02164357|Main artery occlusion
968944|NCT02164357|Endovascular treatment
968945|NCT02164357|Intravenous Thrombolytic Therapy
968946|NCT02164344|HIV
968947|NCT02164344|Gut
968948|NCT02164344|probiotics
968949|NCT02164344|immune activation
968950|NCT02164305|Rotator cuff muscle
968951|NCT02164305|Excitability
968952|NCT02164305|Proprioception
968953|NCT02164305|Kinematics
968954|NCT02164305|Muscle activity
968955|NCT02164305|Electromyography
968956|NCT02164292|Liver tumor
968957|NCT02164292|ALPPS
968958|NCT02164292|Two-stage hepatectomy
968959|NCT02164292|Morbidity
968960|NCT02164292|Hypertrophy
968961|NCT02164279|Microalbuminuria
968962|NCT02164279|diabetic nephropathy
968963|NCT02164279|type I diabetes
968964|NCT02164279|early predictive urinary biomarkers
968965|NCT02164240|Gastrointestinal Stromal Tumor
968966|NCT02164227|anxiety
968967|NCT02164227|breathing exercise
968968|NCT02164227|labour
968969|NCT02164201|Type A Aortic Dissection (where the use of BioFoam is limited to the anastomotic site)
968970|NCT02164188|Stress
968971|NCT02164188|Well-being
968972|NCT02164188|Functional magnetic resonance imaging
968973|NCT02164188|Positive psychology
968974|NCT02164175|HeRO Graft
968975|NCT02164162|Parkinson's disease, Lokomat, gait training, rehabilitation.
968976|NCT02164149|Colon cancer
968977|NCT02164149|Quality of surgery
968978|NCT02164149|Length of tumour feeding artery
968979|NCT02164123|Autonomic effects
968980|NCT02164123|spinal mobilization
968981|NCT02164123|clinical trial
968982|NCT02164097|ICE
968983|NCT02164097|ODSH
968984|NCT02164097|platelet recovery
968985|NCT02164097|recurrent solid tumor
968986|NCT02164084|acne
968987|NCT02164071|Haematological malignancy
968988|NCT02164071|Elderly
968989|NCT02164071|Health Status
968990|NCT02164071|Scale validation
968991|NCT02164058|Myocardial infarction
968992|NCT02164058|STEMI
968993|NCT02164058|ST elevation MI
968994|NCT02164058|Acute MI
968995|NCT02164019|Pathologic Fractures
968996|NCT02164019|hip replacements
968997|NCT02164019|12-287
968999|NCT02163980|dexmedetomidine
969000|NCT02163980|caudal block
969001|NCT02163980|children
969002|NCT02163980|children (1-6 years) undergoing ambulatory orchipexy
969003|NCT02163967|cranial electrical stimulation
969004|NCT02163967|CES
969005|NCT02163967|heart rate variability
969006|NCT02163967|parasympathetic
969007|NCT02163967|Vagal
969008|NCT02163954|platelet
969009|NCT02163954|ticagrelor
969010|NCT02163954|clopidogrel
969011|NCT02163954|end stage renal disease
969012|NCT02163954|hemodialysis
969013|NCT02163941|PTSD
969014|NCT02163941|empathy
969015|NCT02163941|meditation
969016|NCT02163941|compassion
969017|NCT02163941|inflammation
969018|NCT02163941|oxytocin
969019|NCT02163941|fMRI
969020|NCT02163928|Antioxidants
969021|NCT02163928|Carotenoids
969022|NCT02163928|Diet
969023|NCT02163915|Drug therapy
969024|NCT02163889|Candida
969025|NCT02163889|Blood culture
969026|NCT02163889|Antifungal therapy
969027|NCT02163889|Sepsis
969028|NCT02163876|spine
969029|NCT02163876|injury
969030|NCT02163876|trauma
969031|NCT02163876|spine injury
969032|NCT02163876|cervical spine injury
969033|NCT02163876|cervical spine
969034|NCT02163876|stemcells transplantation
969035|NCT02163863|Peripheral arterial disease (PAD)
969036|NCT02163863|Peripheral vascular disease (PVD)
969037|NCT02163863|Biomimetic stent
969038|NCT02163863|Helical centerline
969039|NCT02163837|sleep quality
969040|NCT02163837|physical activity
969041|NCT02163837|daytime sleepiness
969042|NCT02163837|actigraphy
969043|NCT02163837|quality of life
969044|NCT02163824|postsurgical
969045|NCT02163824|postoperative
969046|NCT02163824|ocular
969047|NCT02163824|cataract
969048|NCT02163824|inflammation
969049|NCT02163824|pain
969050|NCT02163824|corticosteroid
969051|NCT02163811|Self-management
969052|NCT02163811|Functional status
969053|NCT02163811|Depression
969054|NCT02163798|Tai Chi
969055|NCT02163798|Walking
969056|NCT02163798|Physical activity
969057|NCT02163798|Randomized controlled trial
969058|NCT02163798|Chinese population
969059|NCT02163798|Exercise
969060|NCT02163798|Body composition
969061|NCT02163798|Cardiovascular risk factor
969062|NCT02163798|Energy expenditure
969063|NCT02163798|Fitness
969064|NCT02163798|SF-12
969065|NCT02163785|Inferior rectal cancer
969066|NCT02163785|Abdominoperineal resection
969067|NCT02163785|Miles operation
969068|NCT02163785|Supine Miles operation
969069|NCT02163785|Prone Miles operation
969070|NCT02163785|Total mesorectal excision
969071|NCT02163785|Circumferential radial margin
969072|NCT02163746|Hidradenitis suppurativa
969073|NCT02163733|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, EGFR sensitivity mutation, food effect
969074|NCT02163720|ovarian cancer
969075|NCT02163720|fallopian tube or primary peritoneal
969076|NCT02163720|relapse
969077|NCT02163720|platinum-sensitive
969078|NCT02163720|Yondelis®-Caelyx®
969079|NCT02163707|Psilocybin
969080|NCT02163707|Pharmacokinetics
969081|NCT02163694|Breast Cancer
969082|NCT02163694|Carboplatin
969083|NCT02163694|BRCA2
969084|NCT02163694|BRCA Mutation
969085|NCT02163694|BRCA1
969086|NCT02163694|ABT-888
969087|NCT02163694|Paclitaxel
969088|NCT02163694|Metastatic Breast Cancer
969089|NCT02163694|PARP
969090|NCT02163694|Genetic breast cancer
969091|NCT02163694|Veliparib
969092|NCT02163694|Locally recurrent
969093|NCT02163694|PARP Inhibitor
969094|NCT02163694|HER2-negative
969095|NCT02163668|Yoga
969096|NCT02163668|Bone turnover markers
969097|NCT02163668|Bone strength
969098|NCT02163668|Bone mineral density
969099|NCT02163655|preeclampsia, very high blood pressure, diuretics
969100|NCT02163642|Bronchiectasis
969101|NCT02163642|Immunity
969102|NCT02163629|Psychotherapeutic intervention
969103|NCT02163629|stress management
969104|NCT02163629|cardiac transplantation
969105|NCT02163629|quality of life
969106|NCT02163616|Primary postpartum hemorrhage
969107|NCT02163616|PPH
969108|NCT02163616|uterine atony
969109|NCT02163616|high fever
969110|NCT02163616|hyperpyrexia
969111|NCT02163616|shock index
969112|NCT02163590|Spinal mobilisation
969113|NCT02163590|Pressure pain threshold
969114|NCT02163590|Thoracic spine
969115|NCT02163577|X-linked hypophosphatemia
969116|NCT02163577|XLH
969117|NCT02163577|FGF23
969118|NCT02163577|KRN23
969119|NCT02163564|Adolescent
969120|NCT02163564|Depression
969121|NCT02163564|Insomnia
969122|NCT02163551|dyspnea
969123|NCT02163551|respiratory sensation
969124|NCT02163551|event-related potentials
969125|NCT02163551|spinal cord injury
969126|NCT02163538|energy device
969127|NCT02163538|laparoscopic
969128|NCT02163538|hysterectomy
969129|NCT02163538|enseal
969130|NCT02163538|ligasure
969131|NCT02163538|raw tlx
969132|NCT02163525|Fibroids
969133|NCT02163525|Myomas
969134|NCT02163525|leiomyomata
969135|NCT02163525|menorrhagia
969136|NCT02163525|Acessa Procedure
969137|NCT02163525|Radiofrequency Ablation (RFA)
969138|NCT02163525|GFA
969139|NCT02163525|Acessa
969140|NCT02163512|Hepatic cirrhosis
969141|NCT02163512|Ascites
969142|NCT02163512|Beta blockers treatment
969143|NCT02163486|I-gel
969144|NCT02163486|oropharyngeal leak pressure
969145|NCT02163486|head position
969146|NCT02163460|ventral hernia
969147|NCT02163460|seroma
969148|NCT02163460|drainage
969149|NCT02163460|infection
969150|NCT02163447|Chemoprevention
969151|NCT02163447|Malaria
969152|NCT02163447|Uganda
969153|NCT02163447|Sulfadoxine-pyrimethamine
969154|NCT02163447|Dihydroartemisinin-piperaquine
969155|NCT02163434|pregnancy
969156|NCT02163434|nausea
969157|NCT02163434|vomiting
969158|NCT02163434|hyperemesis
969159|NCT02163434|treatment
969160|NCT02163434|gabapentin
969161|NCT02163434|metoclopramide
969162|NCT02163434|safety
969163|NCT02163421|Drug therapy
969164|NCT02163408|MRI
969165|NCT02163408|Plaque Characterization
969166|NCT02163395|Ceramic implant
969167|NCT02163382|Nava
969168|NCT02163382|Non Invasive Ventilation
969169|NCT02163356|neuroblastoma
969170|NCT02163356|recurrent
969171|NCT02163356|resistant
969172|NCT02163343|Serum metal ion levels
969173|NCT02163343|Cathcart/Corail hemiarthroplasty
969174|NCT02163343|Hip replacement
969175|NCT02163291|advanced gastric cancer
969176|NCT02163291|neoadjuvant chemotherapy
969177|NCT02163291|safety
969178|NCT02163291|feasibility
969179|NCT02163278|DBPR108
969180|NCT02163278|DPP4
969181|NCT02163278|Diabetes
969182|NCT02163278|Glucagon-like peptide-1 (GLP-1)
969183|NCT02163278|Incretins
969184|NCT02163239|FloShield
969185|NCT02163239|MID
969186|NCT02163239|Minimally invasive surgery
969187|NCT02163239|Minimally Invasive devices
969188|NCT02163239|Robot-assisted Laparoscopic Surgery
969189|NCT02163239|Single-site Laparoscopic Surgery
969190|NCT02163239|Single Incision Laparoscopic Surgery
969191|NCT02163239|Cannula
969192|NCT02163239|Blunt Obturator
969193|NCT02163239|Cholecystectomy
969194|NCT02163239|Benign hysterectomy
969195|NCT02163239|Salpingo-oophorectomy
969196|NCT02163226|Bone metastases
969197|NCT02163226|Hypofractionated Radiation Therapy
969198|NCT02163226|Standard Radiation Therapy
969199|NCT02163226|XRT
969200|NCT02163226|Pain control
969201|NCT02163226|Palliation of symptoms
969202|NCT02163226|Questionnaire
969203|NCT02163226|Survey
969204|NCT02163213|diarrhea
969205|NCT02163213|irritable bowel syndrome
969206|NCT02163200|Bedsores
969207|NCT02163200|pressure
969208|NCT02163200|hip
969209|NCT02163187|Neuromodulation (SNM)
969210|NCT02163187|sphincter preservation
969211|NCT02163187|rectal polyp
969212|NCT02163187|InterStimTM
969213|NCT02163187|14-100
969214|NCT02163174|neonatal
969215|NCT02163174|pentoxifylline
969216|NCT02163174|randomized controlled trial
969217|NCT02163161|Phase I
969218|NCT02163161|Open Label
969219|NCT02163161|Single dose
969220|NCT02163161|Crossover
969221|NCT02163161|Bioavailability
969222|NCT02163161|Fasting
969223|NCT02163161|Fed
969224|NCT02163161|PF-04965842
969225|NCT02163161|Healthy
969226|NCT02163122|Cat Allergy
969227|NCT02163122|Feld1
969228|NCT02163109|Oxygen consumption
969229|NCT02163109|Pulmonary gas exchange
969230|NCT02163109|Cardiac output
969231|NCT02163070|whey protein
969232|NCT02163070|malnutrition
969233|NCT02163070|oxidative stress
969234|NCT02163070|hemodialysis
969235|NCT02163057|Head and neck squamous cell cancer
969236|NCT02163057|Papillomavirus
969237|NCT02163031|heart transplant
969238|NCT02163031|radial approach
969239|NCT02163031|catheterization
969240|NCT02163005|GDL contrast agent
969241|NCT02162992|Antibodies, Antinuclear
969242|NCT02162992|SS-A antigen
969243|NCT02162992|Lupus Erythematosus, Systemic
969244|NCT02162992|Atrioventricular Block
969245|NCT02162992|Sudden death
969246|NCT02162979|Parkinson's disease
969247|NCT02162979|PD
969248|NCT02162979|dyskinesia
969249|NCT02162979|treatment
969250|NCT02162979|motor complications
969251|NCT02162966|colistin
969252|NCT02162966|ICU
969253|NCT02162966|critical care
969254|NCT02162953|eye disease
969255|NCT02162953|retinal
969256|NCT02162953|best1
969257|NCT02162940|low back pain
969258|NCT02162940|epidural steroid injection
969259|NCT02162940|statin
969260|NCT02162940|quality of life
969261|NCT02162927|muscular strength
969262|NCT02162927|muscular endurance
969263|NCT02162927|muscular power
969264|NCT02162927|rowing
969265|NCT02162927|CrossFit
969266|NCT02162927|dietary nitrate
969267|NCT02162914|Intra-hepatic
969268|NCT02162914|Hilar
969269|NCT02162914|Locally Advanced
969270|NCT02162914|Non Resectable
969271|NCT02162914|Metastatic
969272|NCT02162914|Regorafenib
969273|NCT02162914|Placebo
969274|NCT02162901|Diabetes prevention
969275|NCT02162875|Schistosoma mansoni
969276|NCT02162875|treatment
969277|NCT02162875|school children
969278|NCT02162875|adults
969279|NCT02162862|Inflammatory Bowel Disease
969280|NCT02162862|Physical Illness
969281|NCT02162862|Wellbutrin
969297|NCT02162836|Prostatic Neoplasms, Castration-Resistant
969298|NCT02162836|Metastatic Castration-Resistant Prostate Cancer
969299|NCT02162836|Prostate Cancer
969300|NCT02162836|Androgen Receptor
969301|NCT02162836|JNJ-56021927
969302|NCT02162823|The MeSH name is Carcinoma, Pancreatic Ductal
969303|NCT02162810|hypospadias
969304|NCT02162797|HIV
969305|NCT02162797|AIDS
969306|NCT02162797|zinc
969307|NCT02162797|zinc supplement
969308|NCT02162797|immunological deficiency
969310|NCT02162758|Drug therapy
969311|NCT02162745|Bronchiolitis
969312|NCT02162745|Normal saline solution
969313|NCT02162745|Hypertonic solution
969314|NCT02162745|Nasal irrigation
969315|NCT02162680|local anesthesia
969316|NCT02162680|intravenous catheter
969317|NCT02162654|neuroprotection
969318|NCT02162654|ischemic preconditioning
969319|NCT02162654|cerebral aneurysm
969320|NCT02162628|Pelvic Floor Disorder
969321|NCT02162628|Pelvic Organ Prolapse
969322|NCT02162628|Sexual Dysfunction
969323|NCT02162628|Mesh
969324|NCT02162628|POP
969325|NCT02162628|Transvaginal
969326|NCT02162628|Total Repair
969327|NCT02162628|Uterine Prolapse
969328|NCT02162628|Cystocele
969329|NCT02162628|Rectocele
969330|NCT02162628|Enterocele
969331|NCT02162628|Vaginal Vault Prolapse
969332|NCT02162628|Native Tissue Repair
969333|NCT02162628|Repair Augmented with Mesh
969334|NCT02162628|Pathological Conditions, Anatomical
969335|NCT02162628|Exair Prolapse Repair System
969336|NCT02162628|Vaginal Mesh
969337|NCT02162628|Transvaginal Mesh
969338|NCT02162615|Pelvic Floor Disorder
969339|NCT02162615|Pelvic Organ Prolapse
969340|NCT02162615|Sexual Dysfunction
969341|NCT02162615|Mesh
969342|NCT02162615|POP
969343|NCT02162615|Transvaginal
969344|NCT02162615|Anterior
969345|NCT02162615|Posterior
969346|NCT02162615|Apical
969347|NCT02162615|Uterine Prolapse
969348|NCT02162615|Cystocele
969349|NCT02162615|Rectocele
969350|NCT02162615|Enterocele
969351|NCT02162615|Vaginal Vault Prolapse
969352|NCT02162615|Native Tissue Repair
969353|NCT02162615|Repair Augmented with Mesh
969354|NCT02162615|Pathological Conditions, Anatomical
969355|NCT02162615|Restorelle Direct Fix
969356|NCT02162615|Vaginal Mesh
969357|NCT02162615|Transvaginal Mesh
969358|NCT02162576|asthma
969359|NCT02162576|asthma control
969360|NCT02162576|healthcare utilization costs
969361|NCT02162576|community hotspots
969362|NCT02162576|public health research
969363|NCT02162563|Colorectal cancer
969364|NCT02162563|Chemotherapy
969365|NCT02162563|Anti-EGFR
969366|NCT02162563|Liver metastases
969367|NCT02162563|R0 R1 liver resection
969368|NCT02162563|Resectability of liver
969369|NCT02162563|Liver expert panel
969370|NCT02162550|Type 2 Diabetes
969371|NCT02162550|Cardiovascular Disease
969372|NCT02162550|Hyperglycemia
969373|NCT02162550|Carotid Plaque
969374|NCT02162550|Endothelial function
969375|NCT02162550|Incretins
969376|NCT02162550|Atherosclerosis
969377|NCT02162537|Strategy
969378|NCT02162537|Radiotherapy
969379|NCT02162537|Chemotherapy
969380|NCT02162537|Cisplatin
969381|NCT02162524|aerobic exercise
969382|NCT02162524|obesity
969383|NCT02162524|energy balance
969384|NCT02162511|Haplocompatible
969385|NCT02162511|Stem cell transplant
969386|NCT02162511|Borderline organ function
969387|NCT02162511|Alternative donor stem cell transplant
969388|NCT02162498|Peer support
969389|NCT02162498|Adherence
969390|NCT02162498|Exclusive breastfeeding
969391|NCT02162498|Early infant diagnosis
969392|NCT02162498|Stigma and disclosure
969393|NCT02162472|videocapillaroscopy, psoriasis, systemic agent
969394|NCT02162459|Adolescent
969395|NCT02162459|supplements
969396|NCT02162459|strength
969397|NCT02162459|whey protein
969398|NCT02162459|bench press strength
969399|NCT02162459|squat strength
969400|NCT02162420|severe aplastic anemia
969401|NCT02162420|Hematopoietic Stem Cell Transplant
969402|NCT02162381|Humphrey visual fields
969403|NCT02162381|methylphenidate
969404|NCT02162381|attention deficit disorder
969405|NCT02162381|MoCa questionnaire
969406|NCT02162368|laryngeal mask, prone position, spine surgery
969407|NCT02162342|upper extremity
969408|NCT02162342|muscle activity
969409|NCT02162342|kinematics
969410|NCT02162342|motion capture
969411|NCT02162342|Electromyography
969412|NCT02162329|Breast Cancer
969413|NCT02162329|Cognitive function
969414|NCT02162329|Questionnaires
969415|NCT02162329|Surveys
969416|NCT02162329|Electroencephalography
969417|NCT02162329|EEG
969418|NCT02162329|Magnetic resonance imaging
969419|NCT02162329|fMRI
969420|NCT02162329|Tibetan meditation
969421|NCT02162329|Quality of life
969422|NCT02162329|QOL
969423|NCT02162303|Atherosclerosis
969424|NCT02162303|Vascular
969425|NCT02162303|Cardiovascular
969426|NCT02162303|Coronary artery disease
969427|NCT02162303|Imaging
969428|NCT02162303|PET
969429|NCT02162303|Scan
969430|NCT02162303|anti-inflammatory
969431|NCT02162277|To decrease
969432|NCT02162277|number
969433|NCT02162277|osteoporotic
969434|NCT02162277|patients in
969435|NCT02162277|Kami-Ina area
969436|NCT02162277|Nagano prefecture
969437|NCT02162264|Alzheimer's Disease
969438|NCT02162264|donepezil hydrochloride
969439|NCT02162251|Alzheimer's Disease
969440|NCT02162251|donepezil hydrochloride
969441|NCT02162238|zinc
969442|NCT02162238|diet
969443|NCT02162238|water
969444|NCT02162238|morbidity
969445|NCT02162238|growth
969446|NCT02162225|Erythrocyte Deformability
969447|NCT02162225|Platelet Activation
969448|NCT02162225|Platelet Aggregation
969449|NCT02162225|Nitrite
969450|NCT02162225|Sickle Cell Anemia
969451|NCT02162225|Diet Therapy
969452|NCT02162199|Antibiotic
969453|NCT02162199|Antibiotic Resistant Bacterial Infection
969454|NCT02162186|Arthroplasty, Replacement, Hip/methods
969455|NCT02162186|Hip Joint/physiopathology
969456|NCT02162186|Hip Joint/radiography
969457|NCT02162186|Hip Joint/surgery
969458|NCT02162186|Hip Prosthesis
969459|NCT02162186|Outcome Assessment (Health Care)
969460|NCT02162186|Female
969461|NCT02162186|Male
969462|NCT02162186|Adult
969463|NCT02162173|Familial adenomatous polyposis syndrome
969464|NCT02162173|Non-ampullary polyp
969465|NCT02162173|Ampullary polyp
969466|NCT02162173|Narrow band imaging endoscopy
969467|NCT02162173|Confocal laser endomicroscopy
969468|NCT02162160|probiotic
969469|NCT02162160|post-menopausal
969470|NCT02162160|atrophic vaginitis
969471|NCT02162147|patient safety
969472|NCT02162147|pediatrics
969473|NCT02162147|emergency medicine
969474|NCT02162134|cholecystectomy
969475|NCT02162134|laparoscopic
969476|NCT02162134|postoperative
969477|NCT02162134|ileus
969478|NCT02162134|chewing gum
969479|NCT02162095|Chronic obstructive pulmonary disease
969480|NCT02162095|Coronary artery disease
969481|NCT02162095|Coronary calcium score
969482|NCT02162043|Glaucoma
969483|NCT02162043|Perimetry
969484|NCT02162043|Diagnostic self-evaluation
969485|NCT02162043|Screening
969486|NCT02162043|Visual fields
969487|NCT02162017|Acute ischemic stroke
969488|NCT02162017|Acute intracerebral haemorrhage
969489|NCT02162017|Head position
969490|NCT02162017|Lying flat head position
969491|NCT02162017|Sitting up head position
969492|NCT02162017|Death
969493|NCT02162017|Disability
969494|NCT02162017|Clinical trial
969495|NCT02162004|Type 1 diabetes
969496|NCT02162004|Continuous Glucose Monitoring
969497|NCT02162004|Insulin pump
969498|NCT02162004|Sensor-augmented pump
969499|NCT02162004|Continuous correction of high blood glucose
969500|NCT02161991|aprepitant
969501|NCT02161991|non-small cell lung cancer
969502|NCT02161978|antiangiogenic
969503|NCT02161978|cancer
969504|NCT02161978|vascular
969505|NCT02161978|biomarker
969506|NCT02161978|tyrosine kinase inhibitor
969507|NCT02161965|Anticoagulation
969508|NCT02161965|Coronary and peripheral calcification
969509|NCT02161965|Arterial stiffness
969510|NCT02161965|Biomarker
969511|NCT02161952|Fibrosis, necroinflammation, hepatitis C chronic
969512|NCT02161926|Obesity
969513|NCT02161926|dietary restrictions
969514|NCT02161926|metabolism
969515|NCT02161926|nutrition
969516|NCT02161926|elderly
969517|NCT02161874|edentulism
969518|NCT02161874|dental implants
969519|NCT02161874|clinical study
969520|NCT02161874|endosseous
969521|NCT02161874|randomized
969522|NCT02161874|crestal bone level
969523|NCT02161874|T3
969524|NCT02161874|Nanotite Certain
969525|NCT02161874|Nanotite Certain Prevail
969526|NCT02161874|Tapered
969527|NCT02161861|tripeptide FEE
969528|NCT02161861|fertilization rates
969529|NCT02161861|embryos
969530|NCT02161861|oocytes
969531|NCT02161835|Congenital myotonia
969532|NCT02161835|Myotonia congenita
969533|NCT02161835|Thomsons disease
969534|NCT02161835|Becker type
969535|NCT02161835|Training
969536|NCT02161835|Exercise
969537|NCT02161822|locally advanced rectal cancer, neoadjuvant chemoradiation
969538|NCT02161809|MVPA
969539|NCT02161809|Healthy Eating
969540|NCT02161809|children
969541|NCT02161809|childhood obesity
969542|NCT02161796|Phase 1
969543|NCT02161796|FG-4592
969544|NCT02161796|Age/gender comparison
969545|NCT02161783|Hematopoietic stem cell transplant
969546|NCT02161770|oncology, cancer, neoplasm, anticancer drug, pharmacokinetics, area under curve, AZD9291, solid tumour, mild hepatic impairment, moderate hepatic impairment
969547|NCT02161757|Asthma
969548|NCT02161757|Reactive Airways
969549|NCT02161757|Respiratory Tract Disease
969550|NCT02161757|Obstructive Lung Disease
969551|NCT02161757|Lung Diseases
969552|NCT02161744|Adipose derived stem cells
969553|NCT02161744|Stromal vascular fraction cells
969554|NCT02161744|Pulmonary Function Tests
969555|NCT02161744|Chronic Obstructive Pulmonary Disease
969556|NCT02161718|Alkermes
969557|NCT02161718|Schizophrenia
969558|NCT02161718|Alcohol Use Disorder
969559|NCT02161718|ALKS 3831
969560|NCT02161705|Immediate breast reconstruction
969561|NCT02161705|pain control
969562|NCT02161705|post mastectomy pain control
969563|NCT02161679|Antibody drug conjugate
969564|NCT02161679|IMMU-132
969565|NCT02161679|Triple-negative breast cancer
969566|NCT02161679|Safety and tolerability
969567|NCT02161679|Progression Free Survival (PFS)
969568|NCT02161666|Obesity
969569|NCT02161666|Gastric Bypass
969570|NCT02161666|Bariatric Surgery
969571|NCT02161666|Incretin Function
969572|NCT02161666|Islet Function
969573|NCT02161653|Severe alcoholic hepatitis
969574|NCT02161653|survival
969575|NCT02161653|oxidative stress
969576|NCT02161627|spinal cord stimulation
969577|NCT02161627|automatic control
969578|NCT02161614|hormone replacement therapy
969579|NCT02161614|Dopplervelocimetry
969580|NCT02161614|Flow-mediated dilation
969581|NCT02161614|menopause
969582|NCT02161614|Estradiol valerate
969583|NCT02161601|Cricoid pressure
969584|NCT02161601|Rapid Sequence Induction
969585|NCT02161562|chronic spontaneous urticaria, CSU, chronic idiopathic urticaria, CIU, hives, angioedema, itch
969586|NCT02161523|mast cells, lung cancer, cancer associated fibroblasts (CAF)
969587|NCT02161497|Medical History Taking
969588|NCT02161497|Electronic Health Records
969589|NCT02161497|Pediatrics
969590|NCT02161497|Parents
969591|NCT02161484|Peripheral Nerve Block
969592|NCT02161484|Total Hip Replacement
969593|NCT02161471|Atria, Heart
969594|NCT02161471|Function, Atrial
969595|NCT02161471|Heart Defects, Congenital
969596|NCT02161471|Cardiovascular Abnormalities
969597|NCT02161471|Congenital Abnormalities
969598|NCT02161471|Tetralogy, Fallot
969599|NCT02161471|Transposition of Great Arteries
969600|NCT02161471|Coarctation of the Aorta
969601|NCT02161458|Escitalopram
969602|NCT02161458|Amyloid Beta
969603|NCT02161458|Cerebrospinal Fluid
969604|NCT02161445|impedance
969605|NCT02161445|pep
969606|NCT02161445|tevg
969607|NCT02161445|dyspnea
969608|NCT02161445|AHF
969609|NCT02161445|BNP
969610|NCT02161419|Small Cell Lung Carcinoma,
969611|NCT02161419|First line
969612|NCT02161419|Extensive disease
969613|NCT02161419|Small cell lung cancer
969614|NCT02161406|Scleroderma
969615|NCT02161393|Physical Activity
969616|NCT02161393|Pulmonary Rehabilitation
969617|NCT02161393|Chronic obstructive pulmonary disease
969618|NCT02161380|Gene therapy
969619|NCT02161380|Mitochondrial Genes
969620|NCT02161380|Leber's
969621|NCT02161380|AAV2 Viral vectors
969622|NCT02161367|colorectal surgery
969623|NCT02161367|postoperative ileus
969624|NCT02161367|simethicone
969625|NCT02161367|randomized controlled trial
969626|NCT02161367|double blind
969627|NCT02161367|pilot study
969628|NCT02161367|anti-foaming agent
969629|NCT02161367|abdominal pain
969630|NCT02161367|abdominal distention
969631|NCT02161367|nausea vomiting
969632|NCT02161367|flatus
969633|NCT02161367|bowel movement
969634|NCT02161367|placebo
969635|NCT02161367|postoperative complications
969636|NCT02161367|polydimethylsiloxane
969637|NCT02161367|hydrated silica gel
969638|NCT02161367|gas bubbles
969639|NCT02161367|intestinal tract
969644|NCT02161341|Bacterial microbiome
969645|NCT02161341|Gene expression
969646|NCT02161315|SAID, Progestogens, nSAID-resistanced, LSBC
969647|NCT02161302|Endometriosis
969648|NCT02161302|Transcranial Direct Current Stimulation
969649|NCT02161302|tDCS
969650|NCT02161302|Near Infrared Spectroscopy
969651|NCT02161302|NIRS
969652|NCT02161302|Chronic Pelvic Pain
969653|NCT02161289|100 HIV-negagtve MSM
969654|NCT02161263|LASIK
969655|NCT02161263|Satisfaction
969656|NCT02161237|Acute rejection
969657|NCT02161237|Advagraf
969658|NCT02161237|Renal function
969659|NCT02161224|Phase 1
969660|NCT02161224|FG-4592
969661|NCT02161224|Single dose
969662|NCT02161224|Moderate hepatic impairment
969663|NCT02161211|alcohol
969664|NCT02161211|anxiety
969665|NCT02161198|Panax ginseng CA
969666|NCT02161198|ginsan
969667|NCT02161198|polysaccharide
969668|NCT02161198|immunity
969669|NCT02161198|natural killer cell
969670|NCT02161185|Epilepsy
969671|NCT02161185|seizure cluster
969672|NCT02161185|acute repetitive seizures
969673|NCT02161185|open-label
969674|NCT02161185|intranasal Midazolam
969675|NCT02161185|USL261
969676|NCT02161185|Upsher-Smith
969677|NCT02161172|Mild traumatic brain injury
969678|NCT02161172|Cognitive outcome
969679|NCT02161172|Psychological outcome
969680|NCT02161133|Veterans
969681|NCT02161133|neuropsychology
969682|NCT02161133|fatigue
969683|NCT02161133|Chronic Multisymptom Illness
969684|NCT02161133|Gulf War Illness
969685|NCT02161133|behavioral treatment
969686|NCT02161120|IBS, irritable bowel syndrome, functional gastrointestinal disorder, diet, bread, rye, FODMAP, microbiota
969687|NCT02161107|Grass
969688|NCT02161107|Allergy
969689|NCT02161107|rhinoconjunctivitis
969690|NCT02161107|rhinitis
969691|NCT02161107|asthma
969692|NCT02161094|Community management incentives
969693|NCT02161081|Myocardial ischemia
969694|NCT02161081|Coronary artery disease
969695|NCT02161081|Myocardial CT perfusion
969696|NCT02161081|Modified scan protocol
969697|NCT02161081|Diagnostic performance
969698|NCT02161081|Radiation dose
969699|NCT02161068|ADPKD
969700|NCT02161068|Chart Review
969701|NCT02161068|PKD Genotyping
969702|NCT02161055|Insulin
969703|NCT02161055|Hyperglycemia
969704|NCT02161055|Postoperative Mortality
969705|NCT02161055|Intensive insulin therapy
969706|NCT02161055|Non-intensive insulin therapy
969707|NCT02161055|Brain Injuries
969708|NCT02161055|Wounds and Injuries
969709|NCT02161055|Craniocerebral Trauma
969710|NCT02161055|Trauma, Nervous System
969711|NCT02161042|Blood transfusion
969712|NCT02161042|Storage Lesion
969713|NCT02161042|Endothelial dysfunction
969714|NCT02161042|Nitric Oxide
969715|NCT02161029|Gastric tumor
969716|NCT02161003|Fecal Incontinence
969717|NCT02161003|Posterior Sagittal Ano-rectoplasty
969718|NCT02161003|Mesenchymal Stem Cell
969719|NCT02160990|Obesity
969720|NCT02160977|Surgical procedures
969721|NCT02160977|Minimally invasive
969722|NCT02160977|Arthroplasty
969723|NCT02160977|Knee
969724|NCT02160964|Inferior Vena Cava
969725|NCT02160951|Multiple Myeloma,
969726|NCT02160951|Phase I,
969727|NCT02160951|PIM,
969728|NCT02160951|Japanese patients,
969729|NCT02160951|LGH447
969730|NCT02160938|microarray
969731|NCT02160938|prenatal
969732|NCT02160938|copy number variant
969733|NCT02160938|CNV
969734|NCT02160938|microdeletion
969735|NCT02160938|microduplication
969736|NCT02160938|genetic
969737|NCT02160899|High Lipoprotein(a)
969738|NCT02160847|children
969739|NCT02160847|pediatric obesity
969740|NCT02160847|parent training
969741|NCT02160847|home-based
969742|NCT02160847|nutrition
969743|NCT02160847|physical activity
969744|NCT02160847|parent-child interaction
969745|NCT02160847|parenting
969746|NCT02160834|Sedentary behavior
969747|NCT02160834|Physical activity
969748|NCT02160834|Obesity
969749|NCT02160834|Mobile health
969750|NCT02160834|Smartphone
969751|NCT02160834|Time spent sedentary
969752|NCT02160821|Transversus Abdominis Plane Block
969753|NCT02160821|Caudal Epidural
969754|NCT02160821|Pediatric Pain control
969755|NCT02160821|Pain control for Lower Abdominal Surgery
969756|NCT02160795|Periconceptional
969757|NCT02160795|Folic Acid
969758|NCT02160795|Leukemia
969759|NCT02160795|Childhood Cancer
969760|NCT02160769|Tear Lipid Thickness
969761|NCT02160769|Pterygium surgery
969762|NCT02160756|Healthy
969763|NCT02160756|JNJ-56021927
969764|NCT02160756|JNJ-56142060
969765|NCT02160756|ARN-509
969766|NCT02160730|Cushings disease
969767|NCT02160730|R-roscovitine
969768|NCT02160717|Turner Syndrome
969769|NCT02160717|Diabetes
969770|NCT02160704|Sperm density
969771|NCT02160704|Testosterone
969772|NCT02160704|Hypogonadism
969773|NCT02160652|Ureteral Obstruction
969774|NCT02160652|HYDRONEPHROSIS
969775|NCT02160652|nephrostomy tube
969776|NCT02160639|diabetes self management education
969777|NCT02160639|diabetes self management support
969778|NCT02160639|type 2 diabetes
969779|NCT02160626|Seborrheic keratosis
969780|NCT02160626|A101
969781|NCT02160613|Osteoprotegerin
969782|NCT02160613|Biomarker
969783|NCT02160613|Chronic periodontitis
969784|NCT02160613|Open flap debridement
969785|NCT02160561|mechanical
969786|NCT02160561|ventilation
969787|NCT02160561|acute
969788|NCT02160561|respiratory
969789|NCT02160561|failure
969790|NCT02160548|Organophosphate, insectiside, Salbutamol, Atropine
969791|NCT02160535|Mild Traumatic Brain Injury
969792|NCT02160535|Concussion
969793|NCT02160535|Post Concussive Headache
969794|NCT02160522|Intubation
969795|NCT02160522|cuff
969796|NCT02160522|cuffed
969797|NCT02160522|endotracheal
969798|NCT02160522|tube
969799|NCT02160522|pressure
969800|NCT02160522|pediatric
969801|NCT02160522|child
969802|NCT02160522|children
969803|NCT02160522|emergency
969804|NCT02160509|real time, ultrasonography, handheld
969805|NCT02160496|Weight Loss
969806|NCT02160496|Obesity
969807|NCT02160496|Overweight
969808|NCT02160496|Diet, Reducing
969809|NCT02160496|Lipids
969810|NCT02160483|Chronic pelvic pain
969811|NCT02160483|Endometriosis
969812|NCT02160457|Cerebral palsy
969813|NCT02160457|Instrumented gait analysis
969814|NCT02160457|Gait Deviation Index
969815|NCT02160444|CBT
969816|NCT02160444|Parent Training
969817|NCT02160444|Anxiety Disorders in Children
969818|NCT02160431|Children
969819|NCT02160431|OCD
969820|NCT02160431|CBT
969821|NCT02160431|Neuropsychological profiles
969822|NCT02160405|Iron levels
969823|NCT02160392|HIV
969824|NCT02160392|female
969825|NCT02160392|genital tract
969826|NCT02160379|roux-en-Y-gastric bypass
969827|NCT02160379|brain responses to food
969828|NCT02160379|gastrointestinal hormones
969829|NCT02160379|bile acids
969830|NCT02160366|Advanced Cancers
969831|NCT02160366|Molecular profiling
969832|NCT02160366|Biomarker data
969833|NCT02160366|Data analysis
969834|NCT02160366|Tumor marker
969835|NCT02160340|Posterior Vitreous Detachment
969836|NCT02160340|Vitreomacular Traction
969837|NCT02160340|Vitreous
969838|NCT02160314|stress urinary incontinence, SUI, pessary
969839|NCT02160301|pain
969840|NCT02160301|postoperative
969841|NCT02160301|multimodal
969842|NCT02160301|satisfaction
969843|NCT02160301|narcotic
969844|NCT02160288|Botox
969845|NCT02160288|obstructed defecation syndrome
969846|NCT02160288|ODS
969847|NCT02160288|Outlet-Type Constipation
969848|NCT02160288|injection
969849|NCT02160275|Artificial pancreas
969850|NCT02160275|Bi-hormonal closed loop
969851|NCT02160275|Diabetes Type 1
969852|NCT02160249|Schizophrenia
969853|NCT02160249|Psychotic disorders
969854|NCT02160249|Schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder or schizophreniform disorder) using DSM-IV criteria
969855|NCT02160236|dexketoprofen trometamol
969856|NCT02160236|tenoxicam
969857|NCT02160236|postoperative pain
969858|NCT02160223|sugammadex
969859|NCT02160223|neostigmine
969860|NCT02160223|obstructive sleep apnea
969861|NCT02160197|Ankle Fractures
969862|NCT02160197|Fracture Fixation
969863|NCT02160197|Early Ambulation
969864|NCT02160197|Fracture Healing
969865|NCT02160197|Return to Work
969866|NCT02160171|Decision Support Algorithm
969867|NCT02160171|Neonatal Seizures
969868|NCT02160171|EEG
969869|NCT02160158|Fesoterodine
969870|NCT02160158|SR3
969871|NCT02160158|SR4
969872|NCT02160158|bioavailability
969873|NCT02160158|pharmacokinetics
969874|NCT02160158|sprinkle
969875|NCT02160158|applesauce
969876|NCT02160145|Chronic Kidney Disease
969877|NCT02160145|Autosomal Dominant Polycystic Kidney Disease
969878|NCT02160119|Autism Spectrum Disorders
969879|NCT02160119|Emotion
969880|NCT02160119|Attention
969881|NCT02160119|Event-related potential
969882|NCT02160119|Functional neuroimaging
969883|NCT02160119|Diffusion Tensor Imaging
969884|NCT02160119|Development
969885|NCT02160106|Cancer
969886|NCT02160106|advanced solid tumors
969887|NCT02160106|metastatic
969888|NCT02160106|phase I
969889|NCT02160106|transforming growth factor beta
969890|NCT02160106|TGF-β
969891|NCT02160106|first-in-human
969892|NCT02160106|TEW-7197
969893|NCT02160106|activin receptor-like kinase 5
969894|NCT02160106|ALK5
969895|NCT02160106|Smad2
969896|NCT02160106|Smad3
969897|NCT02160106|phospho-Smad
969898|NCT02160106|phospho Smad
969899|NCT02160106|psmad
969900|NCT02160106|serine / threonine kinase inhibitor
969901|NCT02160106|pharmacokinetics
969902|NCT02160106|MedPacto
969903|NCT02160106|National OncoVenture
969904|NCT02160093|sarcopenia
969905|NCT02160093|frailty
969906|NCT02160093|chronic disease control
969907|NCT02160093|aging psychology
969908|NCT02160080|Boceprevir;
969909|NCT02160080|Liver pre-transplant
969910|NCT02160067|Healthy Volunteers
969911|NCT02160067|Pharmacokinetics
969912|NCT02160054|tacrolimus
969913|NCT02160054|cyclosporine
969914|NCT02160054|Graceptor®
969915|NCT02160054|kidney transplantation
969916|NCT02160041|Solid tumor malignancy
969917|NCT02160041|hematologic malignancy
969918|NCT02160041|mutation
969919|NCT02160041|translocations
969920|NCT02160041|amplifications,
969921|NCT02160041|fusions
969922|NCT02160041|signature
969923|NCT02160041|FGFR
969924|NCT02160041|ligand
969925|NCT02160041|BGJ398
969926|NCT02160028|Information
969927|NCT02160028|Pain
969928|NCT02160028|Stress
969929|NCT02160028|Fear
969930|NCT02160028|Placebo analgesia
969931|NCT02160002|Incubator Weaning
969932|NCT02160002|Moderately Preterm Infants
969933|NCT02160002|Growth Velocity
969934|NCT02159976|Helicobacter pylori
969935|NCT02159963|FSHD
969936|NCT02159963|HIT
969937|NCT02159963|Training
969938|NCT02159963|Exercise
969939|NCT02159963|10-20-30 interval training
969940|NCT02159937|cancer
969941|NCT02159937|in vitro
969942|NCT02159937|peptides
969943|NCT02159937|dendritic cells
969944|NCT02159924|Smartphone measurements
969945|NCT02159924|Orientation
969946|NCT02159924|Range of motion
969947|NCT02159924|Median nerve neurodynamic test
969948|NCT02159924|Posture
969949|NCT02159924|Thoracic spine
969950|NCT02159924|Shoulder girdle
969951|NCT02159911|Cervical
969952|NCT02159911|Hysteroscopy
969953|NCT02159911|Misoprostol
969954|NCT02159911|Oral
969955|NCT02159898|Esophageal Cancer
969956|NCT02159898|Dysphagia
969957|NCT02159898|Regurgitation
969958|NCT02159885|obstructive sleep apnea
969959|NCT02159885|adherence
969960|NCT02159885|telemedicine
969961|NCT02159885|auto-titrating continuous positive airway pressure
969962|NCT02159872|Leukemia
969963|NCT02159872|Myelodysplastic Syndrome
969964|NCT02159872|MDS
969965|NCT02159872|Omacetaxine
969966|NCT02159872|Synribo
969967|NCT02159872|Homoharringtonine
969968|NCT02159859|ertapenem
969969|NCT02159859|pharmacokinetic
969970|NCT02159859|pharmacodynamics
969971|NCT02159859|hemodialysis
969972|NCT02159859|requires hemodialysis three times a week
969973|NCT02159846|Herbs
969974|NCT02159846|Diabetes Mellitus
969975|NCT02159846|HbA1c
969976|NCT02159846|Lipid Profile
969977|NCT02159833|Food allergy
969978|NCT02159833|Diagnosis
969979|NCT02159807|Pain control
969980|NCT02159807|labor
969981|NCT02159807|epidural
969982|NCT02159807|pregnant
969983|NCT02159794|Transcatheter Aortic Valve Replacement
969984|NCT02159794|Aortic valve stenosis
969985|NCT02159794|Severe aortic stenosis
969986|NCT02159768|tracheal intubation
969987|NCT02159742|Adult subjects
969988|NCT02159742|history
969989|NCT02159742|treatment
969990|NCT02159742|photodynamic therapy
969992|NCT02159703|T1-2 N2 M0,
969993|NCT02159703|stage IVa SCCA
969994|NCT02159703|oropharynx
969995|NCT02159703|negative for PNI,
969996|NCT02159703|negative surgical margins
969997|NCT02159690|prostate cancer
969998|NCT02159690|prostatectomy
969999|NCT02159690|localized prostate cancer
970000|NCT02159677|EIM
970001|NCT02159664|didgeridoo
970002|NCT02159664|sleep apnea
970003|NCT02159664|drug induced sleep endoscopy
970004|NCT02159651|tacrolimus
970005|NCT02159651|interstitial pneumonia
970006|NCT02159651|prograf
970007|NCT02159638|Diabetes Mellitus
970008|NCT02159638|Diabetes Mellitus, Type 1
970009|NCT02159638|Diabetes Mellitus, Insulin-Dependent
970010|NCT02159638|Endocrine System Diseases
970011|NCT02159638|Blood glucose
970012|NCT02159638|Blood Glucose, Self-Monitoring
970013|NCT02159625|Abdominal Compression Elastic Support
970014|NCT02159625|Hemodialysis
970015|NCT02159625|hypotension
970016|NCT02159625|occurrence rate
970017|NCT02159612|FSHD
970018|NCT02159612|MRI
970019|NCT02159612|Disease progression
970020|NCT02159586|gastroparesis
970021|NCT02159586|gastric electrical stimulator
970022|NCT02159586|GES
970023|NCT02159586|vomiting
970024|NCT02159586|nausea
970025|NCT02159586|bloating
970026|NCT02159586|postprandial fullness
970027|NCT02159586|epigastric pain
970028|NCT02159547|migraine, emergency department, dexketoprofen, placebo
970029|NCT02159521|deep vein thrombosis
970030|NCT02159521|post-thrombotic syndrome
970031|NCT02159521|chronic deep vein thrombosis
970032|NCT02159508|nutritional status
970033|NCT02159508|nutritional intervention
970034|NCT02159508|handgrip strength
970035|NCT02159508|patient-generated subjective global assessment
970036|NCT02159508|chemoradiotherapy
970037|NCT02159508|survival
970038|NCT02159469|Hypogonadism
970039|NCT02159469|Testosterone enanthate
970040|NCT02159443|Hu14.18K322A
970041|NCT02159443|Human anti-human antibodies (HAHA)
970042|NCT02159443|Pretreatment anti-therapeutic antibodies (PATA)
970043|NCT02159417|Evolution of the sport, HbA1C, IMC
970044|NCT02159391|Accident Prevention
970045|NCT02159391|Alcohol Drinking
970046|NCT02159391|Substance-Related Disorders
970047|NCT02159391|Motivational Interviewing
970048|NCT02159391|Adult
970049|NCT02159391|Humans
970050|NCT02159391|Intervention Studies
970051|NCT02159391|Recurrence
970052|NCT02159391|Risk Factors
970053|NCT02159391|Trauma Centers
970054|NCT02159391|Wounds and Injuries/epidemiology
970055|NCT02159391|Wounds and Injuries/etiology*
970056|NCT02159391|Wounds and Injuries/prevention & control*
970057|NCT02159378|Gestational Diabetes
970058|NCT02159378|Fructosamines
970059|NCT02159378|Insulin treatment
970060|NCT02159339|DNA methylation
970061|NCT02159313|Biological Availability
970062|NCT02159300|Fibromyalgia
970063|NCT02159300|Pain
970064|NCT02159287|ischemic stroke
970065|NCT02159287|atrial fibrillation
970066|NCT02159287|bridging therapy
970067|NCT02159274|Late symptoms
970068|NCT02159274|Shoulder function
970069|NCT02159274|Cosmetic results
970070|NCT02159274|EORTC
970071|NCT02159274|Lymphoedema
970072|NCT02159261|Personal Satisfaction
970073|NCT02159248|pancreatic, gemcitabine, radiation, tolfenamic acid
970074|NCT02159235|cadmium
970075|NCT02159235|lead
970076|NCT02159235|mercury
970077|NCT02159235|zinc
970078|NCT02159235|endostatin
970079|NCT02159235|angiostatin
970080|NCT02159235|VEGF
970081|NCT02159235|CAD
970082|NCT02159235|osteopontin
970083|NCT02159209|Acute Kidney Injury
970084|NCT02159209|Adverse Drug Reaction
970085|NCT02159209|Acute Kidney Failure
970086|NCT02159209|Kidney
970087|NCT02159209|Kidneys
970088|NCT02159196|mechanical ventilation
970089|NCT02159196|nebulisation
970090|NCT02159196|respiratory failure
970091|NCT02159170|Use of NGF injection as a model of non-inflammatory neuropathic pain in healthy subjects
970092|NCT02159157|breast cancer, exercise
970093|NCT02159144|Brown adipose tissue
970094|NCT02159144|Subcutaneous white adipose tissue
970095|NCT02159144|White adipose tissue
970096|NCT02159131|ethinyl estradiol
970097|NCT02159131|GSK1265744
970098|NCT02159131|pharmacokinetics
970099|NCT02159131|oral contraceptive
970100|NCT02159131|oral contraceptive containing levonorgestrel and ethinyl estradiol
970101|NCT02159131|levonorgestrel
970102|NCT02159118|bone marrow aspiration
970103|NCT02159118|bone marrow biopsy
970104|NCT02159118|OnControl
970230|NCT02158585|Anticonvulsant
970105|NCT02159118|powered bone marrow aspiration and biopsy device
970106|NCT02159118|standard manual bone marrow aspiration and biopsy device
970107|NCT02159105|postpartum hemorrhage
970108|NCT02159105|postsurgical bleeding
970109|NCT02159105|abdominal ultrasound
970110|NCT02159105|FAST scan
970111|NCT02159105|non-invasive hemoglobin measurement
970112|NCT02159092|Waterpipe
970113|NCT02159092|Smoking cessation
970114|NCT02159092|Contingency management
970115|NCT02159092|Dependence
970116|NCT02159079|Sepsis
970117|NCT02159079|Severe Sepsis
970118|NCT02159079|Septic Shock
970119|NCT02159079|Conservative Fluid Management
970120|NCT02159079|Fluid Balance
970121|NCT02159079|Fluid Restriction
970122|NCT02159066|Melanoma
970123|NCT02159053|AIN457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, secukinumab, self-injection
970124|NCT02159040|Int-2 MDS
970125|NCT02159027|Human Immunodeficiency Virus
970126|NCT02159027|AIDS Dementia Complex
970127|NCT02159014|Physical activity intervention
970128|NCT02159014|Aerobic dance
970129|NCT02159014|Nutritional intervention
970130|NCT02159014|Online participation
970131|NCT02159014|Primary Care settings
970132|NCT02159014|General Practice Physical Activity Questionnaire GPPAQ
970133|NCT02159014|Qrisk2
970134|NCT02159014|QDS Diabetes
970135|NCT02159001|clozapine
970136|NCT02159001|ECT
970137|NCT02159001|PANSS
970138|NCT02159001|schizoaffective disorder
970139|NCT02159001|schizophrenia
970140|NCT02159001|treatment
970141|NCT02158988|Gastric cancer
970142|NCT02158988|cancer of the esophagogastric junction
970143|NCT02158988|peritoneal carcinomatosis
970144|NCT02158988|hyperthermic intraperitoneal chemotherapy
970145|NCT02158988|HIPEC
970146|NCT02158962|Partner abuse
970147|NCT02158962|Abuse African Caribbean women
970148|NCT02158962|Intimate Partner Violence
970149|NCT02158949|alcohol
970150|NCT02158949|mHealth
970151|NCT02158949|SBIRT
970152|NCT02158936|thrombocytopenia
970153|NCT02158936|myelodysplastic syndromes (MDS)
970154|NCT02158936|thrombopoietin
970155|NCT02158936|azacitidine
970156|NCT02158936|Eltrombopag
970157|NCT02158923|ventilation
970158|NCT02158923|lung
970159|NCT02158923|lung complications
970160|NCT02158923|postoperative complications
970161|NCT02158923|perioperative lung protective ventilation
970162|NCT02158910|Alzheimer's disease
970163|NCT02158884|Major extremity trauma
970164|NCT02158884|wounded warriors
970165|NCT02158884|IDEO
970166|NCT02158884|return to run
970167|NCT02158871|Education
970168|NCT02158871|Early intervention
970169|NCT02158871|Workplace
970170|NCT02158871|Stigma
970171|NCT02158871|Mental Health Literacy
970172|NCT02158858|Phase 1
970173|NCT02158858|Oncology
970174|NCT02158858|BET Inhibitor
970175|NCT02158845|endometriosis
970176|NCT02158845|blood coagulation
970177|NCT02158845|levonorgestrel
970178|NCT02158845|GnRH agonist
970179|NCT02158845|progesterone-releasing intrauterine device
970180|NCT02158832|Lymphoedema
970181|NCT02158832|Edema
970182|NCT02158832|Oedema
970183|NCT02158832|Cancer
970184|NCT02158832|Breast Cancer
970185|NCT02158819|Visionaire
970186|NCT02158819|Health Economics
970187|NCT02158819|Degenerative arthritis
970188|NCT02158819|total knee arthroplasty
970189|NCT02158806|Venous ulcer, varicose ulcer, gravitational ulcer, aspirin
970190|NCT02158793|face transplant
970191|NCT02158793|Craniomaxillofacial Allotransplantation
970192|NCT02158793|facial disfigurement
970193|NCT02158793|facial trauma
970194|NCT02158754|coronary artery disease
970195|NCT02158754|gene expression score
970196|NCT02158754|Corus CAD
970197|NCT02158754|coronary artery disease diagnosis
970198|NCT02158754|coronary artery disease economics
970199|NCT02158741|Self-Management
970200|NCT02158741|Home Visits
970205|NCT02158689|Poor responders
970206|NCT02158689|letrozole
970207|NCT02158689|human menopausal gonadotropin
970208|NCT02158676|Roux-en-y gastric bypass
970209|NCT02158676|Inflammatory markers
970210|NCT02158676|Nutritional status
970211|NCT02158676|Fatty acids
970212|NCT02158676|Glucose
970213|NCT02158676|Prebiotic
970214|NCT02158676|Synbiotic
970215|NCT02158663|Transcranial Magnetic Stimulation
970216|NCT02158663|TMS
970217|NCT02158663|PTSD
970218|NCT02158650|informed consent
970219|NCT02158650|video-based
970220|NCT02158637|PRO-CTCAE
970221|NCT02158637|Patient-Reported Outcomes
970222|NCT02158637|Common Terminology Criteria for Adverse Events
970223|NCT02158637|Questionnaire
970224|NCT02158637|Adverse Events
970225|NCT02158637|Symptoms
970226|NCT02158611|Individual Counseling service
970227|NCT02158611|Group Counseling service
970228|NCT02158585|Lamotrigine
970229|NCT02158585|Lamictal
970231|NCT02158585|Ménière's disease
970232|NCT02158585|Vertigo attack
970233|NCT02158585|Dizziness
970234|NCT02158585|Vestibular disorder
970235|NCT02158572|prevention of pregnancy
970236|NCT02158546|Major Depressive Disorder
970237|NCT02158546|Depression
970238|NCT02158546|Alkermes
970239|NCT02158546|ALKS 5461
970240|NCT02158546|Samidorphan
970241|NCT02158533|Major Depressive Disorder
970242|NCT02158533|Depression
970243|NCT02158533|Alkermes
970244|NCT02158533|ALKS 5461
970245|NCT02158533|Samidorphan
970246|NCT02158507|metastatic
970247|NCT02158507|triple negative breast cancer (TNBC)
970248|NCT02158507|Veliparib
970249|NCT02158507|Lapatinib
970250|NCT02158507|estrogen receptor (ER) negative
970251|NCT02158507|progesterone receptor (PR) negative
970252|NCT02158507|human epidermal growth factor receptor 2 (HER-2-Neu) negative
970253|NCT02158494|Cranial Nerve Noninvasive Neuromodulation
970254|NCT02158494|Portable Neuromodulation Stimulator (PoNS)
970255|NCT02158494|Balance and Gait Training
970256|NCT02158494|Breathing Awareness Training
970257|NCT02158481|Vascular function
970258|NCT02158481|Dietary ingredients
970259|NCT02158481|Acute glucose load
970260|NCT02158481|Oxidative stress
970261|NCT02158468|STEMI, reperfusion, preconditioning, postconditioning, reperfusion injury, myocardial salvage
970262|NCT02158455|CABG
970263|NCT02158455|Saphenous vein
970264|NCT02158455|Radial artery
970265|NCT02158442|Diabetes
970266|NCT02158442|Lower limb infection
970267|NCT02158442|Significant wound infections
970268|NCT02158442|Intravenous antibiotics
970269|NCT02158442|Timentin
970270|NCT02158429|substance use disorders
970271|NCT02158429|pregnancy
970272|NCT02158429|maternal attachment
970273|NCT02158429|paternal attachment
970274|NCT02158429|three dimensional ultrasound
970275|NCT02158416|platelet
970276|NCT02158416|transfusion
970277|NCT02158416|ThromboLUX
970278|NCT02158416|corrected count increment
970279|NCT02158416|thrombocytopenic
970280|NCT02158403|HeartMate II
970281|NCT02158403|heart assist device
970282|NCT02158403|pump thrombosis
970283|NCT02158403|hypercoagulable disorder
970284|NCT02158403|thrombus
970285|NCT02158403|Thoratec Corporation
970286|NCT02158390|Down syndrome
970287|NCT02158390|Language intervention
970288|NCT02158390|Communication intervention
970289|NCT02158377|Dental implants
970290|NCT02158377|Trabecular Metal dental implants
970291|NCT02158377|TSV dental implants
970292|NCT02158377|Zimmer Dental
970293|NCT02158377|Implant stability
970294|NCT02158377|Implant stability quotient (ISQ)
970295|NCT02158377|Resonance Frequency Analysis (RFA)
970296|NCT02158364|Pharmacological therapy
970297|NCT02158351|Simple steatosis (SS)
970298|NCT02158351|Non-alcoholic steatohepatitis (NASH)
970299|NCT02158351|Gut microbiota (GM)
970300|NCT02158351|Non alcoholic fatty liver disease (NAFLD)
970301|NCT02158338|asthma
970302|NCT02158338|maternal bonding
970303|NCT02158338|maternal bonding disruptions
970304|NCT02158338|mother-infant interaction
970305|NCT02158312|neuroplasticity
970306|NCT02158273|Alcohol
970307|NCT02158273|Relapse
970308|NCT02158260|Capsule endoscopy
970309|NCT02158260|Patient position changing
970310|NCT02158234|squamous cell carcinoma
970311|NCT02158234|head and neck cancer
970312|NCT02158234|paranasal sinuses
970313|NCT02158234|nasal cavity
970314|NCT02158234|nasopharynx
970315|NCT02158234|oropharynx
970316|NCT02158234|oral cavity
970317|NCT02158234|larynx
970318|NCT02158234|hypopharynx
970319|NCT02158234|salivary glands
970320|NCT02158234|cervical lymph nodes
970321|NCT02158208|before any treatment
970322|NCT02158208|at the diagnosis
970323|NCT02158182|Hepatic Encephalopathy
970324|NCT02158182|Acute Variceal Bleeding
970325|NCT02158182|Cirrhosis
970326|NCT02158130|Physical Inactivity
970327|NCT02158130|Aerobic Exercise Detraining
970328|NCT02158130|Body Weight
970329|NCT02158130|Energy Expenditure
970330|NCT02158130|Metabolic Syndrome
970331|NCT02158117|Emergency Treatment
970332|NCT02158117|Morphine Derivates
970333|NCT02158117|Heroin
970334|NCT02158117|Antidotes
970335|NCT02158117|Administration, Intranasal
970336|NCT02158091|Chronic Lymphocytic Leukemia
970337|NCT02158078|Diabetes Mellitus
970338|NCT02158078|Diabetes Mellitus, Type 2
970339|NCT02158078|Glucose Metabolism Disorders
970340|NCT02158078|Metabolic Diseases
970341|NCT02158078|Endocrine System Diseases
970342|NCT02158078|Insulin
970343|NCT02158078|Continuous subcutaneous insulin infusion (CSII)
970344|NCT02158078|Insulin pumps
970345|NCT02158065|Chronic obstructive pulmonary disease (COPD)
970346|NCT02158065|physical activity
970347|NCT02158065|PROactive
970348|NCT02158065|telecoaching
970349|NCT02158052|HLA matched
970350|NCT02158052|bone marrow transplantation
970351|NCT02158052|kidney transplantation
970352|NCT02158039|Intraductal Papillary Mucinous Neoplasm
970353|NCT02158039|Mucinous Cystic Neoplasm
970354|NCT02158039|Endoscopic Ultrasound
970355|NCT02158039|Ethanol
970356|NCT02158026|Follicular sensitivity index
970357|NCT02158026|ICSI
970358|NCT02158026|IVF
970359|NCT02157987|telangietasia hereditary hemorragic
970360|NCT02157987|epistaxis
970361|NCT02157987|safety
970362|NCT02157987|quality of life
970363|NCT02157987|bevacizumab
970364|NCT02157987|spray
970365|NCT02157948|postmenopausal osteoporosis
970366|NCT02157948|osteoporosis
970367|NCT02157948|postmenopausal
970368|NCT02157948|denosumab
970369|NCT02157948|women
970370|NCT02157935|COPD, turbuhaler, pMDI
970371|NCT02157922|Cystic fibrosis
970372|NCT02157922|mucolytic
970373|NCT02157922|mucociliary clearance
970374|NCT02157922|lung clearance
970375|NCT02157909|Lens fit
970376|NCT02157909|contact lenses
970377|NCT02157909|myopia
970378|NCT02157896|Acute ischemic stroke
970379|NCT02157896|Vascular endothelial growth factor
970380|NCT02157896|Endostatin
970381|NCT02157883|oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, intraconazole, EGFR sensitivity mutation
970382|NCT02157870|Ovary
970383|NCT02157870|ovarian cancer
970384|NCT02157870|biologic therapy
970385|NCT02157870|platinum-resistant
970386|NCT02157870|platinum-refractory ovarian cancer
970387|NCT02157870|platinum-resistant ovarian cancer
970388|NCT02157870|paclitaxel
970389|NCT02157870|tgDCC-E1A
970390|NCT02157870|E1A
970391|NCT02157870|Taxol
970392|NCT02157857|NSCLC, SCLC, lung cancer, EBUS-TBNA
970393|NCT02157844|Obstructive Sleep Apnea
970394|NCT02157844|Chronic Obstructive Pulmonary Disease
970395|NCT02157844|Obesity
970396|NCT02157844|Hepatic fat metabolism
970397|NCT02157844|fat digestion
970398|NCT02157844|whole body protein synthesis
970399|NCT02157844|protein digestion
970400|NCT02157844|amino acid metabolism
970401|NCT02157844|adipose tissue fat metabolism
970402|NCT02157844|lipolysis
970403|NCT02157831|Subjects with Clinical Benefit After a Single Infusion of CP - 870, 893
970404|NCT02157805|Meat processes
970405|NCT02157805|Amino acids bioavailability
970406|NCT02157805|Digestion rate
970407|NCT02157805|Protein synthesis
970408|NCT02157805|Aging
970409|NCT02157805|Sarcopenia
970410|NCT02157792|Solid Tumor
970411|NCT02157792|Advanced Solid Tumor
970412|NCT02157779|Veterans
970413|NCT02157779|Anger
970414|NCT02157779|Cognitive Behavioral Therapy
970415|NCT02157779|Treatment
970416|NCT02157766|Mental Health
970417|NCT02157766|Asthma
970418|NCT02157766|Mindfulness
970419|NCT02157766|Compassion
970420|NCT02157766|Meditation
970421|NCT02157753|Osteoporotic fracture
970422|NCT02157753|treatment for osteoporosis
970423|NCT02157753|adherence and compliance
970424|NCT02157701|Dietary herbs
970425|NCT02157701|Polyherbal capsule
970426|NCT02157701|Functional exercise capacity
970427|NCT02157701|Joint health
970428|NCT02157688|folliculitis decalvans
970429|NCT02157688|Staphylococcus Aureus
970430|NCT02157688|antibiotics
970431|NCT02157675|Delayed onset muscle soreness
970432|NCT02157675|Muscle damage
970433|NCT02157675|Eccentric exercise
970434|NCT02157636|Phase 1
970435|NCT02157636|Oncology
970436|NCT02157636|BET Inhibitor
970437|NCT02157623|Basal Cell Nevus Syndrome
970438|NCT02157623|Gorlin's Syndrome
970439|NCT02157610|Cervical Cancer
970440|NCT02157610|Cervical Cancer Survivors
970441|NCT02157610|Smoking Cessation
970442|NCT02157610|Motivation And Problem-Solving
970443|NCT02157610|MAPS
970444|NCT02157610|Saliva test
970445|NCT02157610|Self help materials
970446|NCT02157610|Pamphlets
970447|NCT02157610|Texas Quitline
970448|NCT02157610|Nicotine patch
970449|NCT02157610|Questionnaires
970450|NCT02157610|Surveys
970451|NCT02157610|Telephone counseling sessions
970452|NCT02157571|prulifloxacin
970453|NCT02157571|AECB
970454|NCT02157571|Levofloxacin
970455|NCT02157545|muscle relaxants
970456|NCT02157545|pyridostigmine
970457|NCT02157545|pharmacodynamics
970458|NCT02157545|potency
970459|NCT02157532|Severe stroke
970460|NCT02157532|IV tPA
970461|NCT02157532|mechanical thrombectomy
970462|NCT02157519|Oral Chemotherapy
970463|NCT02157519|Cancer
970464|NCT02157506|Acute Heart failure
970465|NCT02157506|Hemodynamics
970466|NCT02157506|Pharmacokinetics
970467|NCT02157506|Renal Function
970468|NCT02157493|American Indian
970469|NCT02157493|Adolescents
970470|NCT02157493|Entrepreneurship
970471|NCT02157493|Paraprofessional
970472|NCT02157493|Life skills
970473|NCT02157480|glucose profile
970474|NCT02157480|continuous glucose monitoring
970475|NCT02157480|electrostimulation
970476|NCT02157441|Postpartum Hemorrhage
970477|NCT02157441|Placenta Previa
970478|NCT02157441|uterine cavity
970479|NCT02157402|Adolescent
970480|NCT02157376|SUP
970481|NCT02157376|Upper GI bleeding
970482|NCT02157376|Seriously ill patients
970483|NCT02157350|Eye Diseases
970484|NCT02157350|Proliferative Diabetic Retinopathy
970485|NCT02157350|Retinal Vessel Geometry
970486|NCT02157350|Retinal Oxymetry
970487|NCT02157350|Retina Ischemia
970488|NCT02157350|Panretinal Photocoagulation
970489|NCT02157350|Lasers, Semiconductor
970490|NCT02157350|Fluorescein Angiography
970491|NCT02157337|aortic surgery
970492|NCT02157337|postoperative acute kidney injury
970493|NCT02157337|statin
970494|NCT02157337|the patient undergoing aortic surgery
970495|NCT02157324|Bruton tyrosine kinase inhibitor
970496|NCT02157324|Btk
970497|NCT02157311|HIV-1
970498|NCT02157311|simplification,
970499|NCT02157311|treatment discontinuation
970500|NCT02157311|virological success
970501|NCT02157311|four days a week
970502|NCT02157298|Japanese patients with type 2 diabetes with inadequate glycemic control on insulin
970503|NCT02157285|Unintended pregnancy in adolescence
970504|NCT02157285|LARC
970505|NCT02157285|contraception
970506|NCT02157272|Antiphospholipid
970507|NCT02157272|Syndrome
970508|NCT02157272|Rivaroxaban
970509|NCT02157272|Warfarin
970510|NCT02157272|Thrombosis
970511|NCT02157272|Treatment
970512|NCT02157246|hypoxia
970513|NCT02157246|rectal cancer
970514|NCT02157207|antioxidants
970515|NCT02157207|Caucasians
970516|NCT02157207|healthy
970517|NCT02157207|African Americans
970518|NCT02157207|vascular
970519|NCT02157207|aging
970520|NCT02157207|racial differences
970521|NCT02157181|HCL variant
970522|NCT02157181|HCL relapse
970523|NCT02157181|Risk stratified
970524|NCT02157168|Affordable Care Act
970525|NCT02157168|Medically underserved minorities
970526|NCT02157168|Community health workers
970527|NCT02157168|Health disparities among Mexican origin
970528|NCT02157142|Severe aortic stenosis
970529|NCT02157142|Aortic valve stenosis
970530|NCT02157142|Transcatheter aortic valve replacement
970531|NCT02157129|Tracheostomy
970532|NCT02157129|inflammation
970533|NCT02157129|mucous congestion
970534|NCT02157129|inhalation therapy
970535|NCT02157129|phospholipids
970536|NCT02157116|Dose-Dense Chemotherapy
970537|NCT02157103|GBM
970538|NCT02157103|Glioblastoma
970539|NCT02157103|Bevacizumab
970540|NCT02157103|Avastin
970541|NCT02157103|Subcutaneous
970542|NCT02157090|HSL of lips
970543|NCT02157090|perioral skin
970544|NCT02157090|duration of HSL symptoms not more than three days
970545|NCT02157090|not acyclovir or other cold sore therapies
970546|NCT02157077|Eye diseases
970547|NCT02157077|Vision Impairment and Blindness
970548|NCT02157077|Eyes and Vision
970549|NCT02157077|Seniors
970550|NCT02157077|Neovascular Age-Related Macular Degeneration (AMD)
970551|NCT02157077|Retinal Disease
970552|NCT02157038|whiplash
970553|NCT02157038|neck pain
970554|NCT02157038|chronic pain
970555|NCT02157038|motor vehicle accident
970556|NCT02157038|car accident
970557|NCT02157038|MRI
970558|NCT02157038|DNA
970559|NCT02157038|RNA
970560|NCT02157025|Humphrey visual fields
970561|NCT02157025|perimetry
970562|NCT02157025|pediatrics
970563|NCT02156973|cardiac computed tomography
970564|NCT02156973|Image quality
970565|NCT02156947|Power Doppler sonography
970566|NCT02156947|cholecystitis, adhesion
970567|NCT02156934|autologous stress urinary incontinence muscle derived cells
970568|NCT02156908|cognitive remediation
970569|NCT02156895|Korean PMS of Axitinib
970570|NCT02156895|Metastatic RCC ; 2nd line only
970571|NCT02156882|TB
970572|NCT02156882|Tuberculosis
970573|NCT02156882|MaTuTU - Maputo Tuberculosis Trial Unit
970574|NCT02156882|Clinical Trial Capacity Development
970575|NCT02156869|Prostate cancer
970576|NCT02156869|Screening
970577|NCT02156869|Decision aids
970578|NCT02156856|hemodynamic monitoring
970579|NCT02156856|cardiac output
970580|NCT02156856|cardiac surgery
970581|NCT02156843|Diabetic Kidney Disease
970582|NCT02156843|Nephropathy
970583|NCT02156843|Diabetic Nephropathy
970584|NCT02156843|Kidney Disease
970585|NCT02156843|Type 2 Diabetes
970586|NCT02156817|Amplitude integrated electroencephalogram
970587|NCT02156817|Heart rate variability
970588|NCT02156817|Respiratory rate variability
970589|NCT02156817|Preterm Infants
970590|NCT02156817|Length of Hospital Stay
970591|NCT02156791|Seasonal allergic rhinoconjunctivitis
970592|NCT02156791|Grass pollen
970593|NCT02156791|Allergen specific immunotherapy
970594|NCT02156778|Post-Stroke Disease Management
970595|NCT02156778|Post-Stroke Complication
970596|NCT02156778|Risk Factor Control
970597|NCT02156778|Quality-of-Life
970598|NCT02156765|Atrial Fibrillation
970599|NCT02156765|Screening
970600|NCT02156765|Stroke patients
970601|NCT02156739|Liver Neoplasms
970602|NCT02156739|Liver lesions
970603|NCT02156739|Benign liver lesions
970604|NCT02156739|Malignant liver lesions
970605|NCT02156739|Contrast-Enhanced Magnetic Resonance Imaging
970606|NCT02156739|MRI
970607|NCT02156739|Gadoxetate
970608|NCT02156739|Eovist
970609|NCT02156739|Gadopentetate Dimeglumine
970610|NCT02156739|Magnevist
970611|NCT02156726|chronic lymphocytic leukemia
970612|NCT02156726|fludarabine
970613|NCT02156726|rituximab
970614|NCT02156726|elderly
970615|NCT02156726|comorbid
970616|NCT02156726|FCR
970617|NCT02156726|CIRS
970618|NCT02156713|Hemiparesis
970619|NCT02156713|Occupational Therapy
970620|NCT02156700|shear wave elastography
970621|NCT02156700|haemangiomas
970622|NCT02156700|metastases
970623|NCT02156700|hepatocellular carcinoma
970624|NCT02156700|focal nodular hyperplasia
970625|NCT02156700|cholangiocellular carcinoma
970626|NCT02156674|Maroteaux-Lamy Syndrome
970627|NCT02156674|mucopolysaccharide VI
970628|NCT02156674|MPS VI
970629|NCT02156648|Invasive ductal
970630|NCT02156648|HER2-neu positive
970631|NCT02156635|Rehabilitation
970632|NCT02156635|Direct Current Stimulation
970633|NCT02156635|Acute Stroke
970634|NCT02156622|HIV
970635|NCT02156622|Depression
970636|NCT02156622|Measurement-based care
970637|NCT02156622|Outcomes
970638|NCT02156622|Viral load
970639|NCT02156609|HeartMate PHP
970640|NCT02156609|HeartMate PHP CE Mark
970641|NCT02156609|Percutaneous coronary intervention
970642|NCT02156609|PCI
970643|NCT02156609|Percutaneous ventricular assist
970644|NCT02156609|Thoratec Corporation
970645|NCT02156596|renal colic
970646|NCT02156596|nebulised morphine
970647|NCT02156596|Intravenous NSAID
970648|NCT02156583|Ventricular Assist Device
970649|NCT02156583|Skeletal Muscle
970650|NCT02156583|Frailty
970651|NCT02156583|Older adults
970652|NCT02156570|Hepatitis C
970653|NCT02156570|Acute/early chronic
970654|NCT02156570|Recently acquired
970655|NCT02156570|Directly acting antiviral therapy
970656|NCT02156570|Sofosbuvir
970657|NCT02156570|Ribavirin
970658|NCT02156531|Anxiety
970659|NCT02156531|Youth Anxiety
970660|NCT02156531|CBM
970661|NCT02156531|Cognitive Bias Modification
970662|NCT02156531|Adolescents
970663|NCT02156505|stent
970664|NCT02156505|gastric outlet obstruction
970665|NCT02156505|restenosis
970666|NCT02156479|CMV
970667|NCT02156479|T-Track CMV
970668|NCT02156479|allo-HSCT
970669|NCT02156479|CMI
970670|NCT02156466|Psoriasis
970671|NCT02156466|MSB0010841
970672|NCT02156466|Anti-IL17A/F Nanobody
970673|NCT02156466|M1095
970674|NCT02156453|Functional recovery
970675|NCT02156453|Total knee arthroplasty
970676|NCT02156440|Ostearthritis
970677|NCT02156440|Knee
970678|NCT02156440|SierraSil
970679|NCT02156414|Prostatectomy
970680|NCT02156414|Extended Lymphadenectomy
970681|NCT02156414|Pelvic lymph node dissection
970682|NCT02156414|Prostatic Neoplasm
970683|NCT02156414|Prospective Studies
970684|NCT02156401|Venous thromboembolism
970685|NCT02156401|Deep vein thrombosis
970686|NCT02156401|Pulmonary embolism
970687|NCT02156401|Cohort study/epidemiology
970688|NCT02156401|Outcome
970689|NCT02156401|Prognosis
970690|NCT02156375|Healthy
970691|NCT02156375|Ustekinumab
970692|NCT02156375|STELARA®
970693|NCT02156362|Thyroid carcinoma
970694|NCT02156362|predictive factors
970695|NCT02156362|refractory
970696|NCT02156362|Differentiated
970697|NCT02156362|follicular origin
970698|NCT02156349|Diabetes
970699|NCT02156336|Diabetic Peripheral Neuropathic Pain
970700|NCT02156336|Ranexa
970701|NCT02156336|Ranolazine
970702|NCT02156336|Neurology
970826|NCT02155764|extraction
970703|NCT02156284|Fear; Thoracic Surgery; Nursing Care; Preoperative Care
970704|NCT02156271|Insomnia
970705|NCT02156258|Imaging
970706|NCT02156258|Mammography
970707|NCT02156232|hepatic encephalopathy (HE)
970708|NCT02156232|vericeal bleeding
970709|NCT02156232|spontaneous portosystemic shunts (SPSS)
970710|NCT02156232|transjugular intrahepatic portosystemic shunt (TIPS)
970711|NCT02156232|embolization
970712|NCT02156180|exhaled breath
970713|NCT02156180|volatile organic compounds
970714|NCT02156180|surgery
970715|NCT02156180|chemotherapy
970716|NCT02156180|radiotherapy
970717|NCT02156167|Otosclerosis, cochlear implant, acoustic stimulation
970718|NCT02156141|Kennedy's disease
970719|NCT02156141|Spinal and bulbar muscular atrophy
970720|NCT02156141|High Intensity Training
970721|NCT02156141|High Intensity Interval Training
970722|NCT02156141|HIT
970723|NCT02156141|HIIT
970724|NCT02156141|Training
970725|NCT02156141|Exercise
970726|NCT02156141|10-20-30
970727|NCT02156128|Cognitive therapy
970728|NCT02156115|Lymphangiomatosis
970729|NCT02156115|Lymphangiogenesis
970730|NCT02156115|Smooth Muscle Cell
970731|NCT02156115|Vascular Anomalies
970732|NCT02156102|Genetic Disorders
970733|NCT02156102|Sickle Cell Disease
970734|NCT02156102|African American
970735|NCT02156102|Leg Ulcers
970736|NCT02156102|Skin
970737|NCT02156089|fMRI
970738|NCT02156089|Reward Processing
970739|NCT02156089|Nutrition
970740|NCT02156089|Omega-3 Fatty Acids
970741|NCT02156089|ADHD
970742|NCT02156063|Recurrent Pregnancy Loss
970743|NCT02156063|Recurrent Miscarriage
970744|NCT02156063|Miscarriage
970745|NCT02156063|Pregnancy Loss
970746|NCT02156063|Repeated Pregnancy Loss
970747|NCT02156037|Hispanic
970748|NCT02156037|clinical decision support
970749|NCT02156037|diabetes
970750|NCT02156037|Hba1c
970751|NCT02156037|psychosocial
970752|NCT02156024|clinical trials
970753|NCT02156024|Gastrodia and Uncaria Drink
970754|NCT02156011|In vivo knee joint kinematics
970755|NCT02156011|In vivo knee joint loading
970756|NCT02156011|Video-fluoroscopy
970757|NCT02156011|Instrumented implants
970758|NCT02156011|Optical motion capture
970759|NCT02156011|Ground reaction forces
970760|NCT02156011|Electromyography
970761|NCT02155998|prostate adenocarcinoma, locally advanced prostate cancer with high and very high risk of recurrence, adjuvant endocrine treatment, prostate specific antigen
970762|NCT02155972|Bipolar
970763|NCT02155972|Depression
970764|NCT02155972|Probiotic
970765|NCT02155972|ALIGN
970766|NCT02155972|HAMD
970767|NCT02155972|STAI
970768|NCT02155972|YMRS
970769|NCT02155972|CGI
970770|NCT02155972|SDS
970771|NCT02155972|WHOQOL-BREF
970772|NCT02155972|C-SSRS
970773|NCT02155972|TSES
970774|NCT02155959|astigmatism
970775|NCT02155959|cataract
970776|NCT02155959|toric
970777|NCT02155959|lens
970778|NCT02155946|Aging
970779|NCT02155946|Alzheimer's Disease/Dementia
970780|NCT02155946|Cognitive Disorders
970781|NCT02155946|Imaging
970782|NCT02155946|Magnetic Resonance Imaging (MRI)
970783|NCT02155946|Neurology
970784|NCT02155946|Physical Medicine & Rehabilitation
970785|NCT02155946|transcranial direct current stimulation
970786|NCT02155920|Ependymoma
970787|NCT02155920|Anaplastic Ependymoma
970788|NCT02155894|Rheumatoid arthritis, treat to target, telemedicine
970789|NCT02155881|Drug therapy
970790|NCT02155868|Cerebral near-infrared spectroscopy monitoring
970791|NCT02155868|Postoperative complications
970792|NCT02155868|Cardiac surgery
970793|NCT02155855|type 1 diabetes, home glucose monitor, upload, cloud
970794|NCT02155842|exercise therapy
970795|NCT02155829|PTSD
970796|NCT02155829|TBI
970797|NCT02155829|Riluzole
970798|NCT02155829|Rilutek
970799|NCT02155829|augmentation
970800|NCT02155829|supplement
970801|NCT02155829|double blinded
970802|NCT02155829|clinical trial
970803|NCT02155829|placebo
970804|NCT02155829|RCT
970805|NCT02155829|Randomized Control Trial
970806|NCT02155816|inflammation
970807|NCT02155816|lipoproteins
970808|NCT02155816|omega 3
970809|NCT02155816|omega 7
970810|NCT02155803|Sarcoidosis-Associated Calcium Dysregulation
970811|NCT02155803|Sarcoidosis-Associated hypercalciuria
970812|NCT02155803|hypercalcemia
970813|NCT02155803|hypercalciuria
970814|NCT02155803|nephrocalcinosis
970815|NCT02155803|nephrolithiasis
970816|NCT02155803|interstitial nephritis
970817|NCT02155803|glomerulonephritis
970818|NCT02155803|acute kidney disease
970819|NCT02155803|chronic kidney disease
970820|NCT02155790|safety, performance, hypertension, renal denervation
970821|NCT02155777|BRCA1
970822|NCT02155777|BRCA2
970823|NCT02155777|Risk-reducing surgery
970824|NCT02155777|Oral Contraceptives
970825|NCT02155764|tooth
970827|NCT02155764|alveolar socket
970828|NCT02155764|socket preservation
970829|NCT02155764|ridge preservation
970830|NCT02155764|bone graft
970831|NCT02155764|tricalcium phosphate
970832|NCT02155764|octacalcium phosphate
970833|NCT02155764|xenograft
970834|NCT02155764|bio oss
970835|NCT02155751|Obesity prevention
970836|NCT02155751|Nutrition and exercise in pregnancy
970837|NCT02155751|Postpartum
970838|NCT02155751|Maternal obesity risk
970839|NCT02155738|IV acetaminophen
970840|NCT02155738|Postoperative pain
970841|NCT02155738|Pelvic organ prolapse surgery
970842|NCT02155738|Pelvic organ prolapse repair
970843|NCT02155725|PPH
970844|NCT02155725|fibrinogen
970845|NCT02155725|vaginal delivery
970846|NCT02155699|UHR, Remediation, Exercise, Intervention, Psychosis
970847|NCT02155686|Elderly
970848|NCT02155686|Prevention
970849|NCT02155686|Multiple chronic disease
970850|NCT02155686|Telemonitoring
970851|NCT02155686|Geriatric teleexpertise
970852|NCT02155686|Home heath care
970853|NCT02155686|Medico-economics
970854|NCT02155660|Obstructive Lung Diseases
970855|NCT02155660|Chronic Obstructive Pulmonary Disease
970856|NCT02155660|Lung Disease
970857|NCT02155660|Bronchial Diseases
970858|NCT02155660|COPD Exacerbation
970859|NCT02155660|Respiratory Tract Diseases
970860|NCT02155647|Carcinoma, Merkel Cell
970861|NCT02155647|MSB0010718C
970862|NCT02155647|avelumab
970863|NCT02155647|Bavencio
970864|NCT02155647|anti PD-L1
970865|NCT02155647|JAVELIN Merkel 200
970866|NCT02155634|Newly Diagnosed Multiple Myeloma
970867|NCT02155634|Multiple Myeloma
970868|NCT02155634|Lenalidomide
970869|NCT02155634|Revlimid
970870|NCT02155634|Phase III
970871|NCT02155634|Phase IIIb
970872|NCT02155634|Plasma Cell Dyscrasia
970873|NCT02155621|cancer genomics
970874|NCT02155621|precision medicine
970875|NCT02155621|metastatic cancer
970876|NCT02155621|clinical decision-making
970877|NCT02155608|ADHD
970878|NCT02155608|neuromodulation
970879|NCT02155608|trigeminal nerve stimulation
970880|NCT02155608|cognition
970881|NCT02155582|Solid tumors
970882|NCT02155569|Cesarean, extraperitoneal
970883|NCT02155569|Cesarean
970884|NCT02155569|Pain
970885|NCT02155517|TCI,Schnider Model, Cortinez Model, BIS, Cardiac Output.
970886|NCT02155504|Healthy volunteers
970887|NCT02155504|Pharmacokinetics
970888|NCT02155504|ASP3700
970889|NCT02155504|Itraconazole
970890|NCT02155504|Drug-drug interaction
970891|NCT02155491|venous, thromboembolism, embolism, DVT, Pulmonary Embolism, thrombosis
970892|NCT02155465|Ruxolitinib
970893|NCT02155465|Erlotinib
970894|NCT02155465|EGFR-mutant
970895|NCT02155465|14-043
970896|NCT02155452|ALA
970897|NCT02155452|Malignant gliomas
970898|NCT02155439|Prospective, randomized controlled trial - pilot study
970899|NCT02155413|Acute pain
970900|NCT02155413|Audit
970901|NCT02155413|Safety
970902|NCT02155413|Tolerability
970903|NCT02155400|perioperative hypothermia
970904|NCT02155400|thermal compression
970905|NCT02155400|forced air warming
970906|NCT02155387|EVLW
970907|NCT02155387|EVLWI
970908|NCT02155387|PVPI
970909|NCT02155387|MICS
970910|NCT02155374|Glucocorticoid induced hyperglycemia, insulin, chemotherapy
970911|NCT02155361|Diabetes mellitus
970912|NCT02155361|Diabetes complications
970913|NCT02155361|Pain
970914|NCT02155309|scopolamine
970915|NCT02155309|motion
970916|NCT02155309|sickness
970917|NCT02155296|positive youth development
970918|NCT02155296|restorative practices
970919|NCT02155296|school climate
970920|NCT02155296|social competency
970921|NCT02155283|Chronic Low Back Pain
970922|NCT02155283|Mild-to-Moderate Chronic Low Back Pain
970923|NCT02155283|Continuous Passive Motion Devices
970924|NCT02155270|Cataract
970925|NCT02155270|Incision
970926|NCT02155270|Precut
970927|NCT02155270|Corneal
970928|NCT02155270|OCT
970929|NCT02155270|Intraoperative OCT
970930|NCT02155270|Imaging
970931|NCT02155270|Astigmatism
970932|NCT02155270|Clear corneal incision
970933|NCT02155257|Osteoarthritis
970934|NCT02155244|CBDS
970935|NCT02155244|ERCP
970936|NCT02155244|Dindo-Clavien classification
970937|NCT02155231|Male with history of anal sex with men or previous participants of the MSM VCT study
970938|NCT02155218|Magnetic Resonance Angiography
970939|NCT02155218|Contrast Media
970940|NCT02155192|CNTO1959PSO2001
970941|NCT02155192|C0743T08
970942|NCT02155192|C0743T09
970943|NCT02155192|C0743T12
970944|NCT02155192|Psoriasis
970945|NCT02155192|Pharmacogenomics
970946|NCT02155166|Levonorgestrel-releasing intrauterine system
970947|NCT02155166|anesthesia
970948|NCT02155166|pain
970949|NCT02155166|nulliparous
970950|NCT02155140|enteral feeding
970951|NCT02155140|Discharged
970952|NCT02155140|surgical resection of an upper gastrointestinal malignancy
970953|NCT02155140|Nutritional supplementation via a jejunostomy
970954|NCT02155127|chronic kidney disease
970955|NCT02155127|physical function
970956|NCT02155114|Hepcidins
970957|NCT02155114|Homeostasis
970958|NCT02155114|Iron/administration & dosage
970959|NCT02155114|Biological Markers/blood
970960|NCT02155101|Efficacy
970961|NCT02155101|Safety
970962|NCT02155101|Darunavir
970963|NCT02155101|HIV-1 RNA level
970964|NCT02155101|Cameroon
970965|NCT02155088|Locally Advanced
970966|NCT02155088|Metastatic
970967|NCT02155088|Recurrent
970968|NCT02155088|Pancreas
970969|NCT02155075|Breast neoplasm
970970|NCT02155075|Breast implants
970971|NCT02155075|Mammography
970972|NCT02155075|Breast imaging
970973|NCT02155075|Imaging augmented breast
970974|NCT02155062|Nutritional biomarker
970975|NCT02155062|Dietary assessment
970976|NCT02155062|Whole grain
970977|NCT02155062|Wheat
970978|NCT02155062|Rye
970979|NCT02155062|Alkylresorcinol
970980|NCT02155062|Urine
970981|NCT02155049|TED
970982|NCT02155049|Prostaglandin Analogues
970983|NCT02155036|exercise
970984|NCT02155036|rehabilitation
970985|NCT02155036|kidney function
970986|NCT02155036|cardiovascular disease risk
970987|NCT02155010|Dexmedetomidine
970988|NCT02155010|Spinal anesthesia
970989|NCT02154971|HIV Seropositivity
970990|NCT02154971|Audiometry
970991|NCT02154971|Hearing Loss
970992|NCT02154958|Follicular output rate
970993|NCT02154958|IVF
970994|NCT02154958|ICSI
970995|NCT02154932|Myomectomy, Misoprostol
970996|NCT02154906|periodontal disease
970997|NCT02154906|periodontitis
970998|NCT02154893|Ultrasound
970999|NCT02154893|Laser
971000|NCT02154893|Therapeutic exercise
971001|NCT02154893|Rehabilitation
971002|NCT02154893|Osteoarthritis
971003|NCT02154880|HIV
971004|NCT02154880|lung
971005|NCT02154880|aging
971006|NCT02154867|IBS-D
971007|NCT02154867|FMT
971008|NCT02154867|metagenomics
971009|NCT02154867|gut microbiome
971010|NCT02154854|Renal
971011|NCT02154854|Transplantation
971012|NCT02154854|Tacrolimus
971013|NCT02154854|Arterial stiffness
971014|NCT02154854|Vascular fibrose plasma markers
971015|NCT02154841|Postoperative
971016|NCT02154841|nutrition
971017|NCT02154841|taste
971018|NCT02154841|perception
971019|NCT02154841|preference
971020|NCT02154841|choice
971021|NCT02154828|Children
971022|NCT02154828|aged
971023|NCT02154828|3 to 6 years
971024|NCT02154815|End Stage Renal Disease
971025|NCT02154815|Renal transplantation
971026|NCT02154815|Dialysis
971027|NCT02154815|Pre-emptive transplantation
971028|NCT02154815|Psychological adjustment
971029|NCT02154815|Quality of life.
971030|NCT02154776|LEE011,
971031|NCT02154776|buparlisib,
971032|NCT02154776|letrozole,
971033|NCT02154776|HR +,
971034|NCT02154776|HER2 - negative,
971035|NCT02154776|post-menopausal,
971036|NCT02154776|breast cancer,
971037|NCT02154776|CDK 4/6,
971038|NCT02154776|PI3K,
971039|NCT02154776|MTD
971040|NCT02154763|Bariatric surgery
971041|NCT02154763|Bariatrics
971042|NCT02154763|Local anesthetic
971043|NCT02154763|Ropivacaine
971044|NCT02154763|Intraperitoneal
971045|NCT02154750|Atrioventricular delay
971046|NCT02154750|AV delay
971047|NCT02154750|Pacemaker
971048|NCT02154750|Sick Sinus Syndrome
971049|NCT02154750|Bradycardia
971050|NCT02154750|PR interval
971051|NCT02154750|Atrioventricular block
971052|NCT02154750|AV block
971053|NCT02154750|Echocardiography
971054|NCT02154750|Arrhythmia
971055|NCT02154750|AV optimization
971056|NCT02154737|Pancreatic
971057|NCT02154737|Gemcitabine
971058|NCT02154737|Gemzar
971059|NCT02154737|erlotinib
971060|NCT02154737|Tarceva
971061|NCT02154711|mitochondrial disease
971062|NCT02154711|magnetic resonance imaging
971063|NCT02154711|magnetic resonance spectroscopy
971064|NCT02154711|creatine
971065|NCT02154711|phosphocreatine
971066|NCT02154685|Smoking
971067|NCT02154685|Nicotine
971068|NCT02154685|Addiction
971069|NCT02154685|Cessation
971070|NCT02154620|Distal radius fracture
971071|NCT02154620|wrist fracture
971072|NCT02154620|volar plate
971073|NCT02154620|surgical treatment
971074|NCT02154620|plaster immobilisation
971075|NCT02154607|oral lichen planus
971076|NCT02154607|recurrence
971077|NCT02154607|Treatment
971078|NCT02154607|cancer
971079|NCT02154607|Primary disease Management
971080|NCT02154594|Acacia
971081|NCT02154594|Chlorhexidine
971082|NCT02154594|Gingivitis
971083|NCT02154594|Orthodontic appliances.
971084|NCT02154581|Dental implants
971085|NCT02154581|Esthetic score
971086|NCT02154581|Immediate implants
971087|NCT02154581|Gingival biotype
971088|NCT02154568|Hyperpolarized gas MRI
971089|NCT02154542|Nava
971090|NCT02154542|Mechanical ventilation
971092|NCT02154464|Morphine-sparing
971093|NCT02154464|Paracetamol
971094|NCT02154464|Obesity
971095|NCT02154464|Gastric banding
971096|NCT02154425|Cimzia®
971097|NCT02154425|CZP
971098|NCT02154425|Breastfeeding
971099|NCT02154425|Nursing
971100|NCT02154425|Autoimmune diseases and pregnancy
971101|NCT02154412|Respiration
971102|NCT02154412|Motor control
971103|NCT02154412|Blood Pressure
971104|NCT02154412|Orthostatic Hypotension
971105|NCT02154386|bone augmentation
971106|NCT02154386|tooth extraction
971107|NCT02154386|dental implant
971108|NCT02154360|HIV infection
971109|NCT02154360|NK-1R antagonists
971110|NCT02154360|aprepitant
971111|NCT02154360|ritonavir boosting
971112|NCT02154347|Type 2 Diabetes Mellitus
971113|NCT02154347|HbA1c
971114|NCT02154334|Allergic Rhinitis
971115|NCT02154334|Healthy
971116|NCT02154334|Esketamine
971117|NCT02154334|Mometasone
971118|NCT02154334|Oxymetazoline
971119|NCT02154334|Phase 1
971120|NCT02154308|Influenza
971121|NCT02154308|Influenza vaccine
971122|NCT02154308|Split influenza vaccine
971123|NCT02154308|Seasonal influenza vaccine
971124|NCT02154282|hepatic encephalopathy
971125|NCT02154282|covert hepatic encephalopathy
971126|NCT02154282|cirrhosis
971127|NCT02154269|Chagas disease
971128|NCT02154269|G-CSF
971129|NCT02154269|Cell therapy
971130|NCT02154256|walking
971131|NCT02154256|incentives
971132|NCT02154256|exercise
971133|NCT02154256|habits
971134|NCT02154230|weight loss
971135|NCT02154230|sulphate-bicarbonate-calcium water
971136|NCT02154230|gut microbiota
971137|NCT02154230|body composition
971138|NCT02154230|bile salts
971139|NCT02154191|Lumbosacral Region
971140|NCT02154191|Sedentary Lifestyle
971141|NCT02154191|Surgical Procedure, Operative
971142|NCT02154178|empiric antifungal therapy
971143|NCT02154178|biomarkers
971144|NCT02154178|invasive fungal infection
971145|NCT02154178|Candida
971146|NCT02154165|Neonatal hyperbilirubinemia
971147|NCT02154165|Phototherapy
971148|NCT02154165|Light emitting diodes
971149|NCT02154165|Blue light
971150|NCT02154165|Turquoise light
971151|NCT02154152|Bed wetting
971152|NCT02154152|Primary Enuresis
971153|NCT02154152|Frequency
971154|NCT02154152|Efficacy
971155|NCT02154152|Homoeopathic Medicine
971156|NCT02154152|Causticum 200c
971157|NCT02154139|Pharmacological therapy
971158|NCT02154113|Syneron
971159|NCT02154113|Velashape
971160|NCT02154113|ELOS
971161|NCT02154113|Ultrashape
971162|NCT02154100|Metabolic Syndrome
971163|NCT02154100|Arterial Stiffness
971164|NCT02154100|Blood Pressure
971165|NCT02154100|Endothelial Function
971166|NCT02154100|Tart Cherries
971167|NCT02154087|Venous leg ulcer
971168|NCT02154087|Ulcer
971169|NCT02154087|Venous stasis
971170|NCT02154087|Compression
971171|NCT02154074|Dexmedetomidine perioperative blood glucose and insulin
971172|NCT02154061|Flu Vaccine, Intestinal Microbiome, Antibiotics
971173|NCT02154035|Viral Suppression
971174|NCT02154035|Functional Cure
971175|NCT02154022|PK
971181|NCT02153996|Malaria Immunity Longevity
971182|NCT02153983|Obesity
971183|NCT02153983|Colchicine
971184|NCT02153983|Inflammation
971185|NCT02153983|Metabolic Syndrome
971186|NCT02153983|Dyslipidemia
971187|NCT02153970|Clinical Outcomes Measures
971188|NCT02153970|Proxy Reported Outcome
971189|NCT02153970|Pediatric
971190|NCT02153970|Neuromuscular Disease
971191|NCT02153970|Cerebral Palsy
971192|NCT02153957|Exercise
971193|NCT02153957|Memory
971194|NCT02153957|BDNF
971195|NCT02153957|Zamzee
971196|NCT02153957|QOL
971197|NCT02153944|Startle
971198|NCT02153944|Induced-Threat
971199|NCT02153944|Memory
971200|NCT02153944|Stimulant
971201|NCT02153944|Cognitive Interference
971202|NCT02153931|Children's Tumor Foundation
971203|NCT02153931|Social Support
971204|NCT02153931|Online
971205|NCT02153931|Anxiety
971206|NCT02153931|Depression
971207|NCT02153918|Surgery
971208|NCT02153918|Neoadjuvant
971209|NCT02153918|CD8 Cell Infiltrate Response
971459|NCT02152722|oxidative stress
971210|NCT02153918|CD4 Cell Infiltrate Response
971211|NCT02153918|Vaccine
971212|NCT02153905|Adoptive Cell Therapy
971213|NCT02153905|Metastatic Melanoma
971214|NCT02153905|Metastatic Cancer
971215|NCT02153905|Renal Cancer
971216|NCT02153892|Functional Mitral Regurgitation
971217|NCT02153892|Heart Failure
971218|NCT02153892|Ventricular Reshaping
971219|NCT02153879|HDL
971220|NCT02153879|Niacin
971221|NCT02153879|Fenofibrate
971222|NCT02153879|Diabetes
971223|NCT02153879|Metabolomics
971224|NCT02153866|rotavirus vaccine
971225|NCT02153840|Stable Plaque Psoriasis
971226|NCT02153827|Shoulder
971227|NCT02153827|Eccentric Training
971228|NCT02153827|Subacromial Impingement Syndrome
971229|NCT02153814|Infertility
971230|NCT02153814|In vitro fertilization
971231|NCT02153814|Endometrial injury
971232|NCT02153801|High Ligation, Low ligation, Genito-urinary function, laparoscopy, rectal cancer, aterior resection, Total mesorectal Excision, anastomotic leak.
971233|NCT02153788|Insomnia
971234|NCT02153788|HIV
971235|NCT02153775|Progressive muscle relaxation
971236|NCT02153775|Cigarette
971237|NCT02153775|Smoking
971238|NCT02153775|Craving
971239|NCT02153762|Atopic Dermatitis
971240|NCT02153762|AD
971241|NCT02153723|Treatment trial
971242|NCT02153710|Aphasia
971243|NCT02153710|Anomia
971244|NCT02153697|solar lentigines
971245|NCT02153697|Q-switches Laser
971246|NCT02153697|bleaching cream
971247|NCT02153684|smoking
971248|NCT02153684|small airway dysfunction
971249|NCT02153684|mild COPD
971250|NCT02153684|dyspnea
971251|NCT02153684|exercise
971252|NCT02153684|clinical outcomes
971253|NCT02153671|LAIV H5N2
971254|NCT02153671|Influenza vaccine
971255|NCT02153671|Russia
971256|NCT02153658|PrePex
971257|NCT02153658|Odor
971258|NCT02153658|Cleaning technique
971259|NCT02153658|Male Circumcision
971260|NCT02153658|HIV
971261|NCT02153658|AIDS
971262|NCT02153658|Chlorhexidine
971263|NCT02153658|Soap
971264|NCT02153645|Parkinson's Disease
971265|NCT02153645|Levodopa Induced Dyskinesias (LID)
971266|NCT02153645|Dyskinesias
971267|NCT02153645|Parkinsonism
971268|NCT02153632|Parkinson's Disease
971269|NCT02153632|Levodopa Induced Dyskinesia (LID)
971270|NCT02153632|LID
971271|NCT02153632|Parkinsonism
971272|NCT02153632|Dyskinesia
971273|NCT02153619|Grief
971274|NCT02153619|bereavement
971275|NCT02153619|questionnaires
971276|NCT02153619|therapy sessions
971277|NCT02153619|14-102
971278|NCT02153606|Glycerin Suppositories
971279|NCT02153606|Enteral Nutrition
971280|NCT02153606|Enterocolitis, Necrotizing
971281|NCT02153606|Infant, Premature
971282|NCT02153606|Meconium
971283|NCT02153593|Clinical trial
971284|NCT02153593|Randomized
971285|NCT02153593|Fibrin glue
971286|NCT02153593|Tranexamic acid
971287|NCT02153593|Blood loss
971288|NCT02153567|Functional dyspepsia
971289|NCT02153567|symptom response
971290|NCT02153567|postprandial fullness
971291|NCT02153567|Anxiety
971292|NCT02153567|Depression
971293|NCT02153528|Bangladesh
971294|NCT02153528|Rimfapicin
971295|NCT02153515|Finger prick with diabetic lancet
971296|NCT02153515|Fingerprick
971297|NCT02153515|Fresh
971298|NCT02153515|Your own blood
971299|NCT02153515|autologous blood
971300|NCT02153515|Dry eyes
971301|NCT02153515|Sjogren's disease with dry eyes
971302|NCT02153515|Persistent corneal epithelial defects
971303|NCT02153515|Chronic corneal ulcers
971304|NCT02153463|Tourette Syndrome
971305|NCT02153463|Persistent Tic Disorder
971306|NCT02153463|Physical Activity
971307|NCT02153463|Quality of Life
971308|NCT02153450|pancreatic cancer
971309|NCT02153450|Radiation
971310|NCT02153450|Metformin
971311|NCT02153450|Pancreatic Adenocarcinomas
971312|NCT02153411|Asthma control
971313|NCT02153398|Gastric ulcer (GU)
971314|NCT02153398|Duodenal ulcer (DU)
971315|NCT02153398|Anastomotic ulcer (AU)
971316|NCT02153398|Non-erosive reflux esophagitis disease (NERD)
971317|NCT02153398|Reflux esophagitis (RE)
971318|NCT02153398|Zollinger-Ellison syndrome
971319|NCT02153385|Yoga, heart rate variability, stress, mood, women
971320|NCT02153372|large bone defect, bone marrow-derived mononuclear cells
971321|NCT02153359|asthma
971322|NCT02153359|HEPA
971323|NCT02153359|air pollutants
971324|NCT02153359|lung function
971325|NCT02153359|home environment
971326|NCT02153359|respiratory symptoms
971327|NCT02153359|diet
971328|NCT02153346|indirect cost
971329|NCT02153346|asthma
971330|NCT02153333|Human rotavirus (HRV) vaccine
971331|NCT02153333|Serologic response
971332|NCT02153333|Porcine circovirus type 1 (PCV-1)
971333|NCT02153333|Laboratory evaluations
971334|NCT02153320|HBsAg
971335|NCT02153320|Persistence of the immune response
971336|NCT02153320|Adjuvants
971337|NCT02153294|low tidal volume
971338|NCT02153294|high tidal volume
971339|NCT02153294|protective ventilation
971340|NCT02153294|ARDS
971341|NCT02153281|Depression
971342|NCT02153281|Positron Emission Tomography (PET)
971343|NCT02153281|MAO-B
971344|NCT02153268|Safety
971345|NCT02153268|efficacy
971346|NCT02153268|BonoFill
971347|NCT02153268|bone filler
971348|NCT02153268|autologous adipose tissue derived cells (HATDCs)
971349|NCT02153268|Bone augmentation
971350|NCT02153268|sinus augmentation
971351|NCT02153268|Bone grafting after removal of cysts from jaws
971352|NCT02153255|Morquio
971353|NCT02153255|Mucopolysaccharidosis
971354|NCT02153255|Galactosamine-6-Sulfatase
971355|NCT02153255|GALNS
971356|NCT02153242|Pacing
971357|NCT02153242|Haemodynamics
971358|NCT02153242|Pilot
971359|NCT02153229|Histological diagnosis of MPM
971360|NCT02153229|epitheliod subtype
971361|NCT02153229|limited to the hemithorax
971362|NCT02153229|macroscopically complete resection of the tumor
971363|NCT02153203|Autism spectrum disorder
971364|NCT02153203|Problem behavior
971365|NCT02153190|Type 1 Diabetes,
971366|NCT02153190|T1DM,
971367|NCT02153190|Artificial Pancreas
971368|NCT02153177|Randomized Controlled Trial (RCT)
971369|NCT02153177|RCT
971370|NCT02153177|rotator cuff tear
971371|NCT02153177|NSAIDs
971372|NCT02153177|non-steroidal anti-inflammatory drugs
971373|NCT02153177|rotator cuff repair
971374|NCT02153164|Enthalpy
971375|NCT02153164|Trendelenberg position
971376|NCT02153164|Mechanical ventilation
971377|NCT02153138|vegetarian diet
971378|NCT02153138|vegan
971379|NCT02153138|cardiovascular diseases
971380|NCT02153138|endothelial function
971381|NCT02153138|carotid intima-media thickness
971382|NCT02153112|Drug therapy
971383|NCT02153099|Drug therapy
971384|NCT02153086|Pharmacological therapy
971385|NCT02153073|Pharmacological therapy
971386|NCT02153060|immune thrombocytopenia
971387|NCT02153060|dexamethasone
971388|NCT02153060|efficacy
971389|NCT02153060|safety
971390|NCT02153047|Smoking cessation
971391|NCT02153047|Spirometry
971392|NCT02153047|Primary health care
971393|NCT02153034|Buruli ulcer
971394|NCT02153034|Mycobacterium ulcerans disease
971395|NCT02153034|M. ulcerans disease
971396|NCT02153021|anthropometric parameters;
971397|NCT02153021|biochemical parameters;
971398|NCT02153021|inflammatory markers
971399|NCT02153021|neuropeptide markers
971400|NCT02153021|phototherapy
971401|NCT02153008|Strep throat
971402|NCT02152956|AML
971403|NCT02152956|leukemia
971404|NCT02152956|myelogenous
971405|NCT02152956|myeloid
971406|NCT02152956|refractory
971407|NCT02152956|MDS
971408|NCT02152956|Myelodysplastic
971409|NCT02152943|Breast Cancer
971410|NCT02152943|Advanced Metastatic Breast Cancer
971411|NCT02152943|Solid Tumors
971412|NCT02152943|Advanced Solid Tumors
971413|NCT02152943|Everolimus
971414|NCT02152943|Afinitor
971415|NCT02152943|Zortress
971416|NCT02152943|RAD001
971417|NCT02152943|Trastuzumab
971418|NCT02152943|Herceptin
971419|NCT02152943|Letrozole
971420|NCT02152943|Femara
971421|NCT02152930|Fish oil supplements
971422|NCT02152930|Supervised Exercise Training
971423|NCT02152930|Walking distance
971424|NCT02152930|Hemorheological factors
971425|NCT02152930|Cardiovascular risk
971426|NCT02152904|Peptic ulcer bleeding
971427|NCT02152904|rebleeding
971428|NCT02152904|mortality
971429|NCT02152904|nationwide
971430|NCT02152891|Emergency Medical Services
971431|NCT02152891|Elderly
971432|NCT02152878|transcranial direct current stimulation
971433|NCT02152878|non invasive brain stimulation
971434|NCT02152878|bipolar disorder
971435|NCT02152878|depression
971436|NCT02152865|medication
971437|NCT02152852|Type 2 Diabetes
971438|NCT02152826|Sensitivity
971439|NCT02152813|Electrical stimulation, exercise, stroke , rehabilitation
971440|NCT02152787|emergence agitation
971441|NCT02152787|propofol
971442|NCT02152787|strabismus surgery
971443|NCT02152787|children
971444|NCT02152787|elective strabismus surgery
971445|NCT02152761|bimagrumab,
971446|NCT02152761|BYM338,
971447|NCT02152761|hip fracture,
971448|NCT02152761|elderly,
971449|NCT02152761|controlled clinical trial,
971450|NCT02152761|randomized,
971451|NCT02152761|muscle wasting (atrophy)
971452|NCT02152748|glioblastoma
971453|NCT02152748|morphological and molecular changes
971454|NCT02152748|progression
971455|NCT02152748|therapy-resistance
971456|NCT02152722|Breath test
971457|NCT02152722|Volatile Organic Compounds
971458|NCT02152722|VOC
971460|NCT02152722|radiation biodosimetry
971461|NCT02152722|metabolomics
971462|NCT02152722|GCxGC TOF-MS
971463|NCT02152709|Safety
971464|NCT02152709|Immunogenicity
971465|NCT02152709|Vaccine
971466|NCT02152709|Hepatitis B
971467|NCT02152657|Spinal cord injury
971468|NCT02152657|Stem cell transplantation
971469|NCT02152657|Mesenchymal stem cell
971470|NCT02152644|amyloidosis-carpal tunnel
971471|NCT02152631|Therapy, Platinum, Kras +
971472|NCT02152618|Serious emotional disturbance
971473|NCT02152618|foster care
971474|NCT02152618|child protective services
971475|NCT02152605|SGRQ
971476|NCT02152605|vilanterol
971477|NCT02152605|long-acting beta2-agonist
971478|NCT02152605|long-acting muscarinic antagonist
971479|NCT02152605|COPD
971480|NCT02152605|umeclidinium
971481|NCT02152592|Postoperative pain
971482|NCT02152592|Ambulatory surgery
971483|NCT02152592|NSAIDS
971484|NCT02152592|CR Oxycodone
971485|NCT02152592|Compliance to study medication
971486|NCT02152579|Stable Angina
971487|NCT02152553|Biomarker
971488|NCT02152553|Glucocorticoids
971489|NCT02152553|Metabolism
971490|NCT02152553|Pharmacology
971491|NCT02152553|Metabolomics
971492|NCT02152540|TBI
971493|NCT02152540|Transcranial Magnetic Stimulation, Repetitive
971494|NCT02152540|magnetic resonance imaging functional
971495|NCT02152540|Quality of life
971496|NCT02152540|Executive Function
971497|NCT02152540|Veterans
971498|NCT02152501|obese
971499|NCT02152501|overweight
971500|NCT02152501|exercise
971501|NCT02152501|energy expenditure differences
971502|NCT02152501|relative reinforcing values (RRV)
971503|NCT02152501|food
971504|NCT02152501|physical activity
971505|NCT02152501|biological
971506|NCT02152501|neurobehavioral
971507|NCT02152501|behavioral
971508|NCT02152488|cerebral blood flow
971509|NCT02152488|position
971510|NCT02152488|cervical spine
971511|NCT02152475|Blue-LED
971512|NCT02152475|Curcumin
971513|NCT02152475|PDT
971514|NCT02152475|Oral disinfection
971515|NCT02152462|exergaming
971516|NCT02152462|breast cancer
971517|NCT02152462|African American women
971518|NCT02152462|obesity
971519|NCT02152423|enoxaparin
971520|NCT02152423|Enoxamed
971521|NCT02152423|lovenox
971522|NCT02152423|anti Xa
971523|NCT02152423|acute coronary syndrome
971524|NCT02152410|acupuncture
971525|NCT02152410|renal colic
971526|NCT02152358|Cytomegalovirus
971527|NCT02152358|Herpes simplex virus
971528|NCT02152358|ICU
971529|NCT02152358|mechanical ventilation
971530|NCT02152358|mortality
971531|NCT02152358|ventilator-free days
971532|NCT02152358|PCR
971533|NCT02152345|kidney
971534|NCT02152345|renal
971535|NCT02152345|transplant
971536|NCT02152345|belatacept
971537|NCT02152345|delayed graft function
971538|NCT02152345|thymoglobulin
971539|NCT02152345|tacrolimus
971540|NCT02152345|kidney function
971541|NCT02152345|immunosuppression
971542|NCT02152345|NGAL
971543|NCT02152332|JNJ-54861912
971544|NCT02152332|RSC-385896
971545|NCT02152332|MTS-0385896A
971546|NCT02152332|Phase 1
971547|NCT02152332|Moxifloxacin
971548|NCT02152332|Placebo
971549|NCT02152332|Healthy
971550|NCT02152319|Parkinson's disease
971551|NCT02152319|Telemedicine
971552|NCT02152319|Telehealth
971553|NCT02152319|Kinesia
971554|NCT02152319|Tremor
971555|NCT02152319|Bradykinesia
971556|NCT02152319|Dyskinesia
971557|NCT02152306|Fimasartan
971558|NCT02152306|Fimasartan and Amlodipine
971559|NCT02152306|Antihypertension
971560|NCT02152267|Temporomandibular
971561|NCT02152267|Musculoskeletal Diseases
971562|NCT02152267|Electrical Stimulation of the Brain
971563|NCT02152267|Prefrontal Cortex
971564|NCT02152254|Metastatic Cancer
971565|NCT02152254|Molecular Profiling
971566|NCT02152254|Genomic alteration analysis of the tumor
971567|NCT02152254|Advanced Cancer Therapy
971568|NCT02152254|Gene mutations
971569|NCT02152254|Tumor biopsy
971570|NCT02152254|Personalized medicine
971571|NCT02152241|IBD
971572|NCT02152241|Crohn
971573|NCT02152241|Colitis
971574|NCT02152241|Function
971575|NCT02152176|pain
971576|NCT02152176|analgesia
971577|NCT02152176|morphine
971578|NCT02152176|PCA
971579|NCT02152176|Nurse
971580|NCT02152163|Assessing the efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients
971581|NCT02152150|iron
971582|NCT02152150|anemia
971583|NCT02152150|bio-fortification
971584|NCT02152150|children
971585|NCT02152150|India
971586|NCT02152124|Acromegaly
971587|NCT02152124|Acromegaly treatment
971588|NCT02152124|Long-acting somatostatin analogs
971589|NCT02152124|Pegvisomant
971590|NCT02152124|Insulin sensitivity
971591|NCT02152124|Gut hormones
971592|NCT02152124|Lipid metabolism
971593|NCT02152124|Adipokines
971594|NCT02152111|Obesity
971595|NCT02152111|Coconut flour
971596|NCT02152111|Diet quality
971597|NCT02152111|Cardiovascular risk factor
971598|NCT02152085|Walking
971599|NCT02152085|Mobility
971600|NCT02152085|Neuromuscular electrical stimulation
971601|NCT02152085|Multiple sclerosis
971602|NCT02152059|Small cell lung cancer
971603|NCT02152059|BIBF1120
971604|NCT02152059|nintedanib
971605|NCT02152059|platinum-sensitive
971606|NCT02152033|Substance Abuse
971607|NCT02152033|Continuing Care
971608|NCT02152033|Recovery
971609|NCT02152033|Substance Abuse Treatment
971610|NCT02152033|Parent
971611|NCT02152033|Family
971612|NCT02152033|Young Adult
971613|NCT02152007|pachyonychia congenita
971614|NCT02151994|BIA 5-1058
971615|NCT02151994|hypertension
971616|NCT02151994|chronic heart failure
971617|NCT02151994|cardiovascular disorders
971618|NCT02151981|Advanced Non-Small Cell Lung Cancer; T790M Mutation Positive
971619|NCT02151942|elective endovascular AAA repair
971620|NCT02151929|myocardial infarction
971621|NCT02151929|primary PCI
971622|NCT02151929|stent
971623|NCT02151916|dental caries
971624|NCT02151916|early childhood caries
971625|NCT02151916|topical fluorides
971626|NCT02151916|fluoride varnish
971627|NCT02151903|NHL
971628|NCT02151903|Immunocytokine
971629|NCT02151903|Lymphoma
971630|NCT02151903|Non-Hodgkin
971631|NCT02151903|B-cell
971632|NCT02151903|IL (interleukin)
971633|NCT02151890|POF
971634|NCT02151890|ESS
971635|NCT02151890|stem cell
971637|NCT02151864|liver cancer
971638|NCT02151864|cirrhosis
971639|NCT02151864|Child-Pugh A
971640|NCT02151864|Hedgehog
971641|NCT02151851|Rheumatoid Arthritis
971642|NCT02151851|TNFα antagonist
971643|NCT02151851|Certolizumab Pegol
971644|NCT02151851|Chinese patients
971645|NCT02151838|HIV-infected pregnant women who request HAART from the TRCSPMTCT
971646|NCT02151825|Gut microbiota
971647|NCT02151825|Probiotics
971648|NCT02151825|Prebiotics
971649|NCT02151825|Synbiotic
971650|NCT02151825|Bifidobacterium lactis BB-12
971651|NCT02151825|Lactobacillus acidophilus LA-5
971652|NCT02151825|Lactobacillus casei 431
971653|NCT02151825|Inulin
971654|NCT02151825|GOS
971655|NCT02151825|Body Weight
971656|NCT02151825|Overweight
971657|NCT02151825|Adiposity
971658|NCT02151825|Obesity
971659|NCT02151825|ANGPTL4
971660|NCT02151786|Pharmacological therapy
971661|NCT02151773|Pharmacological therapy
971662|NCT02151760|Metastatic Prostate Cancer
971663|NCT02151747|breast neoplasms, BRCA1, Sanger, NGS, Next generation sequencing
971664|NCT02151721|Vorinostat
971665|NCT02151721|Gefitinib
971666|NCT02151721|BIM polymorphism
971667|NCT02151721|EGFR-TKI resistance
971668|NCT02151708|accommodation, emptying,motilitone
971669|NCT02151682|chronic pain
971670|NCT02151682|opioid
971671|NCT02151669|Mediterranean diet
971672|NCT02151669|Smoking/tobacco
971673|NCT02151669|Spirometry
971674|NCT02151656|Schizophrenia
971675|NCT02151656|Mental disorders
971676|NCT02151656|Antipsychotic Drugs
971677|NCT02151643|Dialysis Dependent Chronic Kidney Disease
971678|NCT02151630|wart
971679|NCT02151630|verruca vulgaris
971680|NCT02151630|topical therapy
971681|NCT02151630|pyruvic acid
971682|NCT02151630|salicylic acid
971683|NCT02151617|Multiple dose
971684|NCT02151617|safety
971685|NCT02151617|tolerability
971686|NCT02151617|PK
971687|NCT02151591|Quit smoking
971688|NCT02151591|Quit drinking
971689|NCT02151578|Impact of home management of malaria and pneumonia on child mortality
971690|NCT02151578|home management of malaria and pneumonia
971691|NCT02151565|back pain
971692|NCT02151565|sciatica
971693|NCT02151565|electrotherapy
971694|NCT02151565|HTEMS
971695|NCT02151565|TENS
971696|NCT02151552|lung inflammation
971697|NCT02151552|positron emission tomography
971698|NCT02151552|inducible nitric oxide synthase
971699|NCT02151513|Cancer-associated pain
971700|NCT02151513|Immune function
971701|NCT02151500|Medically Unexplained Symptoms (MUPS)
971702|NCT02151500|Somatoform disorders
971703|NCT02151500|Chronic pain
971704|NCT02151500|Somatic symptoms
971705|NCT02151500|Emotional processing
971706|NCT02151500|Primary Care
971707|NCT02151487|Supraclavicular block
971708|NCT02151487|Ropivacaine
971709|NCT02151487|Dexamethasone
971710|NCT02151487|Clonidine
971711|NCT02151461|Diabetes
971712|NCT02151461|Type 2 Diabetes
971713|NCT02151435|Idiopathic Pulmonary Fibrosis
971714|NCT02151435|Biomarkers
971715|NCT02151435|Forced Vital Capacity
971716|NCT02151435|Diffusion Capacity for Carbon Monoxide
971717|NCT02151435|Prognosis
971718|NCT02151422|Adults
971719|NCT02151422|age 18-65
971720|NCT02151422|physician-diagnosed
971721|NCT02151422|persistent asthma
971722|NCT02151396|ADHD, hyperactivity, inattention, working memory
971723|NCT02151383|Acute heart failure,
971724|NCT02151383|RELAX−AHF−PEDIATRIC PK
971725|NCT02151357|first in man
971726|NCT02151357|dose escalating
971727|NCT02151357|MTD
971728|NCT02151357|DLT
971729|NCT02151331|Chronic care model
971730|NCT02151331|Mood disorders
971731|NCT02151331|Adaptive implementation
971732|NCT02151279|Shrimp allergy
971733|NCT02151279|Chitosan
971734|NCT02151279|fining agent
971735|NCT02151266|Heart failure
971736|NCT02151266|Exercise
971737|NCT02151266|Cognitive training
971738|NCT02151253|Nocturia
971739|NCT02151253|Daytime sleepiness
971740|NCT02151240|herpes zoster, Foscarnet Sodium, Acyclovir, Postherpetic neuralgia
971741|NCT02151227|Meta-Analysis
971742|NCT02151227|Metabolic Syndrome
971743|NCT02151227|Magnesium
971744|NCT02151227|Dose Response Effect
971745|NCT02151227|Systematic Review
971746|NCT02151214|Palliative Phase of Cancer
971747|NCT02151214|Quality of life
971748|NCT02151214|Parenteral nutrition
971749|NCT02151214|Undernutrition
971750|NCT02151201|pregnancy vaccination influenza education
971751|NCT02151149|NSCLC advanced non-small cell lung cancer squamous adenocarcinoma large cell carcinoma lung cancer elderly first line treatment abraxane carbo nab-paclitaxel
971752|NCT02151136|Sucrose
971753|NCT02151136|Pain
971754|NCT02151123|Colonic Neoplasms
971755|NCT02151123|Colon Cancer
971756|NCT02151123|Microbiome
971757|NCT02151110|Healthy Male
971758|NCT02151110|Healthy Female of non child bearing potential
971759|NCT02151097|Prostatectomy
971760|NCT02151097|Prostate cancer
971761|NCT02151097|Cerenkov Luminescence Imaging
971762|NCT02151084|randomized
971763|NCT02151084|selumetinib
971764|NCT02151084|tablets
971765|NCT02151084|cisplatin
971766|NCT02151084|gemcitabine
971767|NCT02151084|non-resectable
971768|NCT02151084|recurrent
971769|NCT02151084|metstatic
971770|NCT02151071|Breast Cancer
971771|NCT02151071|Mastectomy, Segmental
971772|NCT02151071|Breast Conserving Surgery
971773|NCT02151071|Cerenkov Luminescence Imaging
971774|NCT02151071|Beta particle detection
971775|NCT02151058|Staining
971776|NCT02151058|Intensity
971777|NCT02151058|Area
971778|NCT02151045|Epidural infiltration of Corticoids
971779|NCT02151045|L3-L4 stage
971780|NCT02151045|On contact of disco radicular conflict
971781|NCT02151045|Scan control
971782|NCT02151032|Colorectal Cancer
971783|NCT02151032|Colorectal cancer screening
971784|NCT02151032|Multimedia
971785|NCT02151032|Booklet
971786|NCT02151032|Pamphlet
971787|NCT02151032|Audio CD
971788|NCT02151032|Video with animated images
971789|NCT02151032|Video with non-moving images
971790|NCT02151032|Questionnaires
971791|NCT02151032|Surveys
971792|NCT02151006|DHEA
971793|NCT02151006|IVF
971794|NCT02151006|ICSI
971795|NCT02150993|Africa
971796|NCT02150993|Antiretroviral Treatment
971797|NCT02150993|HIV-2
971798|NCT02150993|firsts line ART
971799|NCT02150993|Adults
971800|NCT02150980|Fractures
971801|NCT02150980|burden of fractures
971802|NCT02150980|orthopaedic fractures
971803|NCT02150980|orthopaedic injuries
971804|NCT02150980|orthopaedic trauma
971805|NCT02150980|observational study
971806|NCT02150980|outcomes of fracture care
971807|NCT02150980|epidemiology
971808|NCT02150967|cholangiocarcinoma,
971809|NCT02150967|FGFR2 gene fusion,
971810|NCT02150967|FGFR genetic alteration
971811|NCT02150954|induction of labor
971812|NCT02150954|pitocin
971813|NCT02150954|foley bulb
971814|NCT02150941|Upper gastrointestinal tract
971815|NCT02150941|Endoscopy
971816|NCT02150941|Endoscopic Hemostasis
971817|NCT02150915|Acupoints
971818|NCT02150915|Acupuncture therapy
971819|NCT02150915|Median nerve
971820|NCT02150915|Biomechanics
971821|NCT02150902|Catheter ablation for atrial fibrillation
971822|NCT02150902|treatment for atrial fibrillation
971823|NCT02150902|comparison of catheter ablation techniques for atrial fibrillation
971824|NCT02150889|insulin resistance
971825|NCT02150889|lipid metabolism
971826|NCT02150889|diabetes
971827|NCT02150876|DES
971828|NCT02150876|SDF
971829|NCT02150876|MACE
971830|NCT02150876|SYNERGY
971831|NCT02150863|actinic keratosis
971832|NCT02150863|field cancerization
971833|NCT02150863|organ transplant patients
971834|NCT02150850|Femoral Fractures
971835|NCT02150850|Subtrochanteric Fractures
971836|NCT02150850|Osteoporotic Fractures
971837|NCT02150850|Fractures, Spontaneous
971838|NCT02150850|Stress Fractures
971839|NCT02150850|Bone Fractures
971840|NCT02150850|Hip Fractures
971841|NCT02150850|Osteoporosis
971842|NCT02150837|Obesity
971843|NCT02150837|Weight Loss
971844|NCT02150837|Meal replacements
971845|NCT02150837|Weight maintenance
971846|NCT02150798|Diet Therapy
971847|NCT02150798|Diet, Carbohydrate Restricted
971848|NCT02150798|Fatty Acids, Omega 3
971849|NCT02150798|Oximetry
971850|NCT02150798|phase angle
971851|NCT02150798|Triglycerides, blood
971852|NCT02150798|Lipids, blood
971853|NCT02150798|Hand Strength
971854|NCT02150798|Body Composition
971855|NCT02150798|Electric Impedance
971856|NCT02150785|Thrombolysis
971857|NCT02150785|Safety of Streptokinase
971858|NCT02150785|tissue plasminogen activator tPA
971859|NCT02150785|Stroke treatment
971860|NCT02150759|Dexmedetomidine
971861|NCT02150759|Ketamine
971862|NCT02150759|Pain
971863|NCT02150746|Pancreatic ductal adenocarcinoma
971864|NCT02150746|Pancreatic cancer
971865|NCT02150746|PDAC
971866|NCT02150746|Circulating tumor cells
971867|NCT02150720|Hip fractures
971868|NCT02150720|Clinical Trial
971869|NCT02150720|Randomized
971870|NCT02150720|Fibrin glue
971871|NCT02150720|Tranexamic acid
971872|NCT02150720|Blood loss
971873|NCT02150681|preconception
971874|NCT02150681|pregnancy
971875|NCT02150681|postpartum
971876|NCT02150681|women
971877|NCT02150668|ADHD
971878|NCT02150668|Homework
971879|NCT02150668|School
971880|NCT02150668|Organization
971881|NCT02150668|Time-management
971882|NCT02150616|Pulmonary hypertension
971883|NCT02150616|Interstitial lung disease
971884|NCT02150616|Pulmonary fibrosis
971885|NCT02150603|Heart defects, congenital
971886|NCT02150603|Patient-reported outcomes
971887|NCT02150603|Health status
971888|NCT02150603|Factors, psychosocial
971889|NCT02150603|Health behavior
971890|NCT02150603|Quality of life
971891|NCT02150603|Sense of coherence
971892|NCT02150603|Illness perceptions
971893|NCT02150603|Depression
971894|NCT02150603|Anxiety
971895|NCT02150590|airway disease
971896|NCT02150590|bronchitis
971897|NCT02150590|emphysema
971898|NCT02150590|lung
971899|NCT02150577|Screening
971900|NCT02150577|Mood Stabilizers
971901|NCT02150577|Computer delivered psychotherapy
971902|NCT02150577|Peer Support
971903|NCT02150577|Telepsychiatry
971904|NCT02150577|Implementation
971905|NCT02150577|Rural
971906|NCT02150564|Malignant gliomas
971907|NCT02150564|Sono RCT
971908|NCT02150551|Crohn disease
971909|NCT02150551|ulcerative colitis
971910|NCT02150551|mesenchymal stromal cells
971911|NCT02150551|inflammatory bowel diseases
971912|NCT02150538|Cardiac Resynchronization therapy
971913|NCT02150538|Minimized Right ventricular pacing
971914|NCT02150538|Prolonged AV conduction
971915|NCT02150525|breast cancer
971916|NCT02150525|vaginal dryness
971917|NCT02150525|dyspareunia
971918|NCT02150525|genital irritation
971919|NCT02150512|Septic shock
971920|NCT02150512|Critically ill patients
971921|NCT02150512|Transpulmonary thermodilution
971922|NCT02150512|Fluid resuscitation
971923|NCT02150499|Acute Asthma exacerbation
971924|NCT02150473|rheumatoid Arthritis
971925|NCT02150460|ophthalmic surgery, peribulbar local anaesthesia
971926|NCT02150447|Gastric cancer bleeding
971927|NCT02150447|Proton pump inhibitor
971928|NCT02150434|Oxygen therapy
971929|NCT02150434|Hypoxemia
971930|NCT02150434|COPD
971931|NCT02150434|Closed-loop
971932|NCT02150434|Automated titration,
971933|NCT02150382|hypertension
971934|NCT02150382|rural
971935|NCT02150382|China
971936|NCT02150382|protocol-based treatment
971937|NCT02150343|Cat allergy
971938|NCT02150343|Rhinoconjunctivitis
971939|NCT02150330|Dehydroepiandrosterone
971940|NCT02150330|DHEAS
971941|NCT02150330|Gene expression of cumulus cells.
971942|NCT02150330|Folliculogenesis.
971943|NCT02150330|Oocyte maturation.
971944|NCT02150330|Ovarian hyper-stimulation protocol.
971945|NCT02150330|Artificial reproduction technology.
971946|NCT02150317|Carcinoma, Hepatocellular
971947|NCT02150317|Chemoembolization, Therapeutic
971948|NCT02150317|Sorafenib
971949|NCT02150278|Driving
971950|NCT02150278|Alcohol consumption
971951|NCT02150278|Risk perception
971952|NCT02150252|Clinical trial
971953|NCT02150252|Ischemic stroke
971954|NCT02150252|Bu-Yang-Huan-Wu Tang (BYHWT）
971955|NCT02150252|Gait parameter
971956|NCT02150252|Quality of life
971957|NCT02150239|pain
971958|NCT02150239|postoperative
971959|NCT02150213|Adrenocortical Adenoma,
971960|NCT02150213|Endometrial Stromal sarcomas
971961|NCT02150213|BGG492
971962|NCT02150187|Androgenetic Alopecia
971963|NCT02150187|Male
971964|NCT02150187|Baldness
971965|NCT02150187|hair loss pattern
971966|NCT02150174|Schizophrenia
971967|NCT02150174|Episodic memory deficits
971968|NCT02150148|breast cancer
971969|NCT02150148|prostate cancer
971970|NCT02150148|colorectal cancer
971971|NCT02150148|small intestine cancer
971972|NCT02150148|thyroid cancer
971973|NCT02150148|Hodgkin lymphoma
971974|NCT02150148|non-Hodgkin lymphoma
971975|NCT02150148|endometrial cancer
971976|NCT02150148|kidney cancer
971977|NCT02150148|cervical cancer
971978|NCT02150148|diet
971979|NCT02150148|exercise
971980|NCT02150148|physical activity
971981|NCT02150148|garden
971982|NCT02150135|Pancreatic cancer
971983|NCT02150135|Quality of life
971984|NCT02150135|Pain
971985|NCT02150122|Vitamin D
971986|NCT02150122|Serum 25-hydroxyvitamin D (25OHD)
971987|NCT02150122|Adolescents
971988|NCT02150096|chronic non-specific low back pain
971989|NCT02150096|clinical trial
971990|NCT02150096|disability
971991|NCT02150096|women
971992|NCT02150083|midurethral sling
971993|NCT02150083|voiding study
971994|NCT02150083|voiding trial
971995|NCT02150083|retrograde voiding trial
971996|NCT02150070|Healthy subjects
971997|NCT02150070|ASP2408
971998|NCT02150070|Rheumatoid arthritis
971999|NCT02150070|Safety and Tolerability
972000|NCT02150070|Pharmacokinetics
972001|NCT02150057|knee osteoarthritis unicompartmental unloading brace
972002|NCT02150031|prevention and control
972003|NCT02150031|chlorhexidine
972004|NCT02150031|therapeutic irrigation
972005|NCT02150031|mouthwashes
972006|NCT02150031|culture
972007|NCT02150018|- Critical Care
972008|NCT02150018|Non invasive ventilation
972009|NCT02150018|Electrical impedance tomography
972010|NCT02150018|End expiratory lung volume
972011|NCT02150018|End expiratory lung impedance
972012|NCT02150005|periodontal diseases
972013|NCT02150005|cardiovascular diseases
972014|NCT02150005|periodontitis treatment
972015|NCT02149992|gestational diabetes
972016|NCT02149992|myoinositol
972017|NCT02149979|Incision
972018|NCT02149979|Wound Closure
972019|NCT02149979|Laser Tissue Soldering
972020|NCT02149966|safety and tolerability
972021|NCT02149966|pharmacokinetic study
972022|NCT02149953|Pregnancy
972023|NCT02149953|Glycine requirements
972024|NCT02149953|Indicator Amino Acid Oxidation (IAAO) method
972025|NCT02149953|Stable isotopes
972026|NCT02149940|Elderly
972027|NCT02149940|Frailty
972028|NCT02149940|Polypharmacy
972029|NCT02149940|Medication review
972030|NCT02149940|Clinical pharmacy services
972031|NCT02149927|EEG
972032|NCT02149927|fMRI
972033|NCT02149927|connectivity
972034|NCT02149927|sevoflurane
972035|NCT02149914|Ryodoraku
972036|NCT02149914|Meridian energy
972037|NCT02149914|Heart rate variability
972038|NCT02149914|Autonomic Nervous System
972039|NCT02149914|GERD
972040|NCT02149901|Pure Autonomic Failure
972041|NCT02149901|Multiple System Atrophy
972042|NCT02149901|Pseudoephedrine
972043|NCT02149901|Water
972044|NCT02149901|Osmopressor
972045|NCT02149888|HIV
972046|NCT02149888|Pre-Exposure Prophylaxis
972047|NCT02149888|PrEP
972048|NCT02149888|Human Immunodeficiency Virus
972049|NCT02149875|Acute ischemic stroke
972050|NCT02149875|Dl-3-n-butylphthalide
972051|NCT02149875|Cerebrolysin
972052|NCT02149862|Bladder cancer
972053|NCT02149862|Diagnostic
972054|NCT02149862|Infrared
972055|NCT02149862|Spectrum
972056|NCT02149862|Urina
972057|NCT02149862|Patients with an indication of partial or total bladder resection
972058|NCT02149862|or
972059|NCT02149862|"Lithiasic patients should be operated a urinary calculation, without catheter double J"
972060|NCT02149849|Ipsilateral shoulder pain
972061|NCT02149849|Surgical positioning
972062|NCT02149849|Lung cancer
972063|NCT02149849|Thoracotomy
972064|NCT02149849|Video assisted thoracic surgery
972065|NCT02149836|major depressive disorder
972066|NCT02149836|depression
972067|NCT02149836|treatment resistent depression
972068|NCT02149823|Oxytocin, Social Cognition
972069|NCT02149823|Borderline Personality Disorder
972070|NCT02149823|Schizotypal Personality Disorder
972071|NCT02149823|Social Cognition
972072|NCT02149823|BPD
972073|NCT02149823|SPD
972074|NCT02149823|MASC
972075|NCT02149810|MDD
972076|NCT02149784|Metastasis colorectal cancer
972077|NCT02149784|Chemotherapy
972078|NCT02149784|Resection of primary tumor
972079|NCT02149771|hepatocellular carcinoma
972080|NCT02149771|portal vein tumor thrombosis
972081|NCT02149771|stents
972082|NCT02149771|chemoembolization
972083|NCT02149758|Cyclooxygenase two inhibitors
972084|NCT02149758|Etoricoxib
972085|NCT02149758|Periodontitis
972086|NCT02149758|Superoxide dismutase
972087|NCT02149758|Saliva
972088|NCT02149732|Limbal stem cell deficiency
972089|NCT02149732|Cultivated oral mucosal cell sheet transplantation
972090|NCT02149732|Ocular surface reconstruction
972091|NCT02149719|Peanut allergy
972092|NCT02149719|Desensitisation
972093|NCT02149719|Safety
972094|NCT02149706|Secondary Progress Multiple Sclerosis
972095|NCT02149706|SPMS
972096|NCT02149706|Multiple Sclerosis
972097|NCT02149706|NeuroVax
972098|NCT02149693|Flipped classroom
972099|NCT02149693|High-fidelity simulation
972100|NCT02149693|Medical education reform
972101|NCT02149693|Medical teamwork
972102|NCT02149693|Resuscitation training
972103|NCT02149680|Post-dural puncture headache
972104|NCT02149680|epidural blood patch
972105|NCT02149680|labour analgesia
972106|NCT02149680|epidural analgesia
972115|NCT02149654|Transcatheter aortic valve implantation
972116|NCT02149654|Transcatheter aortic valve replacement
972117|NCT02149654|Engager transcatheter aortic valve implantation system
972118|NCT02149654|Engager bioprosthesis
972119|NCT02149615|idiopathic intracranial hypertension
972120|NCT02149615|optic disc swelling
972121|NCT02149615|antiacne medication
972122|NCT02149615|isotretinoin
972123|NCT02149602|involvement of bilateral parapharyngeal spaces
972124|NCT02149589|ARDS
972125|NCT02149589|PEEP
972126|NCT02149589|Recruitment manoeuvres
972127|NCT02149589|Lung Morphology
972128|NCT02149576|Retrospective Review
972129|NCT02149576|Pilot Study
972130|NCT02149576|Early Stage NSCLC
972131|NCT02149576|Post-Surgical Surveillance
972132|NCT02149576|Re-intervention Rates
972133|NCT02149550|Plasmodium falciparum
972134|NCT02149550|malaria
972135|NCT02149537|sickle cell disease
972136|NCT02149537|sickle cell anemia
972137|NCT02149537|hydroxyurea
972138|NCT02149537|Nigeria
972139|NCT02149537|low income country
972140|NCT02149537|middle income country
972141|NCT02149537|developing country
972142|NCT02149524|HER2 Positive Breast Cancer
972143|NCT02149524|Trastuzumab
972144|NCT02149524|Biosimilar
972145|NCT02149498|Parkinson
972146|NCT02149498|EEG
972147|NCT02149498|BNA
972148|NCT02149485|PGD,
972149|NCT02149485|follow up
972150|NCT02149459|Radiotherapy
972151|NCT02149459|Ketosis
972152|NCT02149459|Metformin
972153|NCT02149459|Magnetic Resonance Imaging
972154|NCT02149459|Metabolome
972155|NCT02149459|Insulin
972156|NCT02149459|recurrent brain tumors
972157|NCT02149459|gliomas
972158|NCT02149459|glioblastomas
972159|NCT02149459|astrocytomas
972160|NCT02149446|Left sided pancreatic resections
972161|NCT02149446|Distal pancreatic resections
972162|NCT02149446|Reinforced staple line
972163|NCT02149446|Post operative pancreatic fistula
972164|NCT02149433|Pneumocystis Jiroveci
972165|NCT02149433|Steroids
972166|NCT02149433|Infants
972167|NCT02149420|primary Sjögren's syndrome, pharmacodynamics
972168|NCT02149394|Thirst
972169|NCT02149394|Ice
972170|NCT02149394|Water
972171|NCT02149394|Perioperative Nursing
972172|NCT02149394|Recovery Room
972173|NCT02149381|Depression
972174|NCT02149381|treatment as usual
972175|NCT02149381|CBASP
972176|NCT02149381|befriending
972177|NCT02149355|teeth position
972178|NCT02149355|jaw alignment
972179|NCT02149342|Actinic keratoses
972180|NCT02149342|Daylight-PDT
972181|NCT02149342|Hexylaminolaevulinate
972182|NCT02149342|HAL
972183|NCT02149342|Methylaminolaevulinate
972184|NCT02149342|MAL
972185|NCT02149342|Hyperspectral imaging
972186|NCT02149329|fever
972187|NCT02149329|neutropenia
972188|NCT02149329|febrile neutropenia
972189|NCT02149329|carbapenem
972190|NCT02149329|imipenem
972191|NCT02149329|meropenem
972192|NCT02149329|antibiotic stewardship
972193|NCT02149329|hematology
972194|NCT02149329|oncology
972195|NCT02149290|Heart Failure
972196|NCT02149290|Six minute walk test
972197|NCT02149277|Infertility
972198|NCT02149277|IVF
972199|NCT02149277|Embryo transfer
972200|NCT02149251|Pre-genetic diagnosis
972201|NCT02149251|ICSI
972202|NCT02149238|flavanols
972203|NCT02149238|cardiovascular effects
972204|NCT02149238|nutrition-nutrition interaction
972205|NCT02149225|Actively personalized peptide vaccinations
972206|NCT02149225|Newly diagnosed Glioblastoma
972207|NCT02149225|Concurrent to first line temozolomide maintenance therapy
972208|NCT02149212|Iliac
972209|NCT02149212|Vein
972210|NCT02149212|Stent
972211|NCT02149160|Histone deacetylase inhibitor
972212|NCT02149160|Frontotemporal dementia
972213|NCT02149160|Granulin
972214|NCT02149147|physical activity
972215|NCT02149147|environmental factors
972216|NCT02149147|variety
972217|NCT02149147|MVPA
972218|NCT02149095|treprostinil
972219|NCT02149082|Intracranial hematoma
972220|NCT02149082|traumatic brain injury
972221|NCT02149082|Near infrared spectroscopy
972222|NCT02149082|NIRS
972223|NCT02149056|Platelets/Lymphocytes Rate;Serological Index;
972224|NCT02149043|inflammatory bowel disease
972225|NCT02149043|ulcerative colitis
972226|NCT02149043|thermography
972227|NCT02149043|endoscopy
972228|NCT02149043|CRP
972229|NCT02149017|amyloid plaque
972230|NCT02149017|Positron-Emission Tomography
972231|NCT02149017|radiopharmaceuticals
972232|NCT02149004|Human immunodeficiency virus (HIV)
972233|NCT02149004|Prevention
972234|NCT02149004|Long-term life
972235|NCT02149004|Cure
972236|NCT02149004|Cohort
972237|NCT02148965|motor activity
972238|NCT02148965|clinical trials
972239|NCT02148965|pregnancy
972240|NCT02148965|hypertension
972241|NCT02148965|cohort studies
972242|NCT02148952|Maternal Health
972243|NCT02148952|Maternal Death
972244|NCT02148952|Maternal Morbidity
972245|NCT02148952|Stillbirth
972246|NCT02148952|Neonatal Mortality
972247|NCT02148952|Quality Improvement
972248|NCT02148952|Resource Limited Settings
972249|NCT02148952|Checklist
972250|NCT02148952|Safe Childbirth
972251|NCT02148939|ischemic stroke
972252|NCT02148939|Antiplatelet Effects
972253|NCT02148939|aspirin
972254|NCT02148939|metamizole
972255|NCT02148939|dipyrone
972256|NCT02148900|Marfan syndrome
972257|NCT02148900|blood test
972258|NCT02148900|aortic root size
972259|NCT02148900|Marfan related disorders
972260|NCT02148874|pregnant
972261|NCT02148874|flu shot
972262|NCT02148874|influenza
972263|NCT02148874|vaccine
972264|NCT02148848|Osteoporosis
972265|NCT02148848|Femoral neck fracture
972266|NCT02148848|hemiarthroplasty
972267|NCT02148835|Omega-3 Index
972268|NCT02148835|Bioavailability
972269|NCT02148835|Eicosapentaenoic acid
972270|NCT02148835|Docosahexaenoic acid
972271|NCT02148835|Fortified food
972272|NCT02148822|Visceral leishmaniasis
972273|NCT02148822|kala azar
972274|NCT02148822|malnutrition
972275|NCT02148822|stunting
972276|NCT02148822|thinness
972277|NCT02148822|Leishmania donovani
972278|NCT02148796|Wheezing
972279|NCT02148796|Lower respiratory tract illness
972280|NCT02148796|Asthma
972281|NCT02148796|Atopy
972282|NCT02148783|Traumatic brain injury
972283|NCT02148783|Attention deficit and memory problems
972284|NCT02148783|Methylphenidate
972285|NCT02148783|Dopamine receptor imaging
972286|NCT02148783|Motivation and reward
972287|NCT02148783|Positron emission tomography
972288|NCT02148783|Transcranial magnetic stimulation
972289|NCT02148770|rt-fmri
972290|NCT02148770|self-control
972291|NCT02148770|eating behaviour
972292|NCT02148770|overweight
972293|NCT02148770|neurofeedback
972294|NCT02148757|DVT
972295|NCT02148731|Colon cancer
972296|NCT02148731|Elderly patients
972297|NCT02148718|Crohn's Disease
972298|NCT02148705|fire/flame
972299|NCT02148705|scalds
972300|NCT02148705|contact
972301|NCT02148679|Heart Failure
972302|NCT02148679|Diet
972303|NCT02148653|Cardiometabolic risk
972304|NCT02148653|Diet
972305|NCT02148653|Dietary prevention
972306|NCT02148653|Functional diet
972307|NCT02148653|Functional foods
972308|NCT02148653|Metabolic Syndrome
972309|NCT02148653|Overweight
972310|NCT02148627|antibody
972311|NCT02148627|autoimmune
972312|NCT02148601|Fecal microbiota transplantation
972313|NCT02148601|Recurrent C. difficile infection
972314|NCT02148601|Colonoscopy
972315|NCT02148601|Randomized clinical trial
972316|NCT02148588|Central Post Stroke Pain
972317|NCT02148588|Nerve block
972318|NCT02148575|Palliative Care
972319|NCT02148575|Self-management
972320|NCT02148575|Breast Cancer
972321|NCT02148549|Borderline resectable pancreatic cancer
972322|NCT02148549|R0 resection
972323|NCT02148549|Resection rate
972324|NCT02148549|Optimal schedule
972325|NCT02148523|Medication Adherence
972326|NCT02148523|High Blood Pressure
972327|NCT02148523|Diabetes
972328|NCT02148523|Statins
972329|NCT02148510|human
972330|NCT02148510|sleep apnea
972331|NCT02148510|adults
972332|NCT02148510|oral appliance
972333|NCT02148510|efficacy
972334|NCT02148510|safety
972335|NCT02148510|polygraphy
972336|NCT02148510|bruxism
972337|NCT02148510|cost
972338|NCT02148497|volunteers
972339|NCT02148484|PTSD
972340|NCT02148484|Cognitive Behavioral Treatment
972341|NCT02148484|Child Sexual Abuse
972342|NCT02148471|Nonalcoholic fatty liver disease
972343|NCT02148471|Steatosis
972344|NCT02148471|Nonalcoholic steatohepatitis
972345|NCT02148458|Intermittent fasting
972346|NCT02148458|Mediterranean diet
972347|NCT02148458|overweight
972348|NCT02148458|Calorie restriction
972349|NCT02148445|smoking cessation
972350|NCT02148445|tobacco use cessation products
972351|NCT02148445|nicotine
972352|NCT02148432|sleep apnea syndrome, fiberoptic bronchoscopy, IV sedation
972353|NCT02148419|quality of life
972354|NCT02148419|maltreatment
972355|NCT02148419|neglect
972356|NCT02148419|childhood
972357|NCT02148406|Yoga
972358|NCT02148406|Mind-body therapies
972359|NCT02148406|Fatigue
972360|NCT02148406|Colorectal cancer
972361|NCT02148406|Depressive symptoms
972362|NCT02148380|Lung adenocarcinoma,EGFR mutation, chemotherapy, gefitinib
972363|NCT02148367|Traumatic brain injury
972364|NCT02148367|Endothelial progenitor cells
972365|NCT02148367|Cerebrovascular reactivity
972366|NCT02148367|Angiogenesis
972367|NCT02148354|Depression
972368|NCT02148354|Self-applied treatment
972369|NCT02148354|Internet
972370|NCT02148354|Support by the therapist
972371|NCT02148354|Cognitive-Behavioural Treatment
972372|NCT02148354|Positive Psychology
972373|NCT02148354|Behavioral Activation
972374|NCT02148328|Healthy participants
972375|NCT02148328|Immunogenicity
972376|NCT02148328|Influenza
972377|NCT02148328|Prevention
972378|NCT02148328|Safety
972379|NCT02148315|physical activity
972380|NCT02148315|children
972381|NCT02148315|school
972382|NCT02148315|garden
972383|NCT02148302|Venous Leg Ulcerations
972384|NCT02148302|Epidermal Grafts
972385|NCT02148302|Chronic wounds
972386|NCT02148302|Clinical trial
972387|NCT02148302|Protease levels in chronic wounds
972388|NCT02148289|COPD, beetroot, dietary nitrate, nitric oxide
972389|NCT02148276|Social harm detection
972390|NCT02148276|Instrument development
972391|NCT02148276|HIV-related clinical trials
972392|NCT02148276|Substance abuse
972393|NCT02148276|Research participation
972394|NCT02148263|Contact Lenses
972395|NCT02148263|Neophytes
972396|NCT02148263|Contact Lens Adaptation
972397|NCT02148263|Randomized
972398|NCT02148250|Type 2 diabetes
972399|NCT02148250|Insulin resistance
972400|NCT02148250|High insulin requirements
972401|NCT02148250|U 500
972402|NCT02148237|Breastfeeding duration
972403|NCT02148237|Puerto Rican mothers
972404|NCT02148237|WIC program
972405|NCT02148237|Home-based individual breastfeeding consultation
972406|NCT02148224|glycemic index
972407|NCT02148224|body composition
972408|NCT02148211|Fluarix Quadrivalent
972409|NCT02148211|Fluarix
972410|NCT02148211|FluLaval
972411|NCT02148211|FluLaval Quadrivalent
972412|NCT02148211|Pregnancy Registry
972413|NCT02148211|Pregnancy outcome
972414|NCT02148185|Crohn's disease
972415|NCT02148172|Knee
972416|NCT02148172|plyometrics
972417|NCT02148172|motor learning
972418|NCT02148172|psychological factors
972425|NCT02148146|short bowel syndrome
972426|NCT02148146|intestinal failure
972427|NCT02148146|total parenteral nutrition associated cholestasis
972428|NCT02148133|Thrombocytopenia
972429|NCT02148133|Eltrombopag
972430|NCT02148133|Aplastic Anemia (AA)
972431|NCT02148133|Thrombopoietin
972432|NCT02148094|HIV
972433|NCT02148094|AIDS
972434|NCT02148094|India
972435|NCT02148094|Prevention
972436|NCT02148094|Female sex workers
972437|NCT02148094|PrEP
972438|NCT02148094|Pre-exposure prophylaxis
972439|NCT02148094|Truvada
972440|NCT02148094|Tenofovir
972441|NCT02148081|pediatrics, critical illness, recovery, function, health
972442|NCT02148068|Obesity
972443|NCT02148068|Bariatric Surgery
972444|NCT02148068|Roux-en-y Gastric Bypass
972445|NCT02148068|Sleeve Gastrectomy
972446|NCT02148055|spontaneous intrauterine death
972447|NCT02148055|fetal MRI
972448|NCT02148055|autopsy
972449|NCT02148042|Anorexia
972450|NCT02148042|Generalized anxiety
972451|NCT02148042|Fear
972452|NCT02148029|Deep vein thrombosis
972453|NCT02148029|Post thrombotic syndrome
972454|NCT02148029|Thrombus resolution
972455|NCT02148016|Corneal disorders
972456|NCT02148016|Chemical injury
972457|NCT02148016|Pterygium
972458|NCT02148016|Refractive error
972459|NCT02148016|Myopia
972460|NCT02148016|Hyperopia
972461|NCT02148016|Cornea
972462|NCT02148016|Monocular
972463|NCT02148016|Transparent
972464|NCT02148016|Transplantation
972465|NCT02148016|Visual function
972466|NCT02147990|cancer
972467|NCT02147990|metastatic
972468|NCT02147990|locally advanced
972469|NCT02147990|lung
972470|NCT02147990|non-small cell lung cancer
972471|NCT02147990|NSCLC
972472|NCT02147990|epidermal growth factor receptor
972473|NCT02147990|EGFR
972474|NCT02147990|T790M
972475|NCT02147990|CO-1686
972476|NCT02147990|unresectable
972477|NCT02147990|recurrent
972478|NCT02147990|EGFR-directed therapy
972479|NCT02147990|irreversible EGFR inhibitor
972480|NCT02147990|TIGER
972481|NCT02147990|Rociletinib
972482|NCT02147977|Renal Dialysis
972483|NCT02147977|Arrhythmias Cardiac
972484|NCT02147977|Death Sudden Cardiac
972485|NCT02147977|Fatty Acids Omega 3
972486|NCT02147964|intratesticular androgens
972487|NCT02147964|testosterone
972488|NCT02147964|dutasteride
972489|NCT02147964|gonadotropin suppression
972490|NCT02147964|male contraception
972491|NCT02147964|spermatogenesis
972492|NCT02147951|Melanoma
972493|NCT02147938|France
972494|NCT02147938|Tacrolimus
972495|NCT02147938|Prograf
972496|NCT02147938|Observational
972497|NCT02147938|Advagraf
972498|NCT02147925|Non-alcoholic fatty liver disease
972499|NCT02147925|Glucagon-like peptide-1 receptor agonists
972500|NCT02147925|Diabetes mellitus, type 2
972501|NCT02147912|Depression
972502|NCT02147912|COPD
972503|NCT02147912|Aerobic Exercise
972504|NCT02147912|Anxiety
972505|NCT02147912|Quality of life
972506|NCT02147912|neurocognitive functioning
972507|NCT02147886|Bioblast, Randomized, parallel-group, and dose-controlled
972508|NCT02147873|MDS
972509|NCT02147873|CMML
972510|NCT02147873|myelodysplastic syndrome
972511|NCT02147873|chronic myelomonocytic leukemia
972512|NCT02147873|TL32711
972513|NCT02147873|TL32711-0094
972514|NCT02147873|azacitidine
972515|NCT02147873|birinapant
972516|NCT02147873|higher risk
972517|NCT02147873|naive
972518|NCT02147873|double blind
972519|NCT02147873|placebo
972520|NCT02147873|placebo controlled
972521|NCT02147873|randomized
972522|NCT02147860|Diabetes Mellitus, Type 1
972523|NCT02147860|Artificial Pancreas Project (APP)
972524|NCT02147860|Diabetes Assistant (DiAs)
972525|NCT02147860|Closed-Loop Control (CLC)
972526|NCT02147860|Continuous Glucose Monitor (CGM)
972527|NCT02147860|Insulin Pump
972528|NCT02147847|Presbycusis
972529|NCT02147847|Hearing In Noise
972530|NCT02147847|Hearing Impairment
972531|NCT02147847|Hearing Loss
972532|NCT02147847|Aging
972533|NCT02147847|Plasticity
972534|NCT02147847|Video Games
972535|NCT02147847|Perceptual Learning
972536|NCT02147834|deferred percutaneous coronary intervention
972537|NCT02147834|fractional flow reserve
972538|NCT02147795|Patient Blood Management
972539|NCT02147795|Red Blood Cell Transfusion Practice
972540|NCT02147795|Patient Safety
972541|NCT02147795|Anemia
972542|NCT02147795|Clinical Outcome
972543|NCT02147795|perioperative care
972544|NCT02147782|chronic renal insufficient, renal osteodystrophy, bone mineral density, bone turnover, kidney function
972545|NCT02147769|cerebral autoregulation
972546|NCT02147769|preterm
972547|NCT02147769|near-infrared spectroscopy
972548|NCT02147756|Skin pigmentation, skin texture disorders, fractional laser, CO2, fractional CO2, Syneron, Solta.
972549|NCT02147743|Adolescents
972550|NCT02147743|Family-Based treatment
972551|NCT02147743|Multidimensional Family Therapy
972552|NCT02147730|chronic pain
972553|NCT02147717|preterm newborns
972554|NCT02147717|Transfontanellar ultrafast doppler
972555|NCT02147717|Acupuncture
972556|NCT02147717|perioperative pain
972557|NCT02147717|surgery of the ductus arteriosus
972558|NCT02147665|Hookah
972559|NCT02147665|waterpipe
972560|NCT02147665|smoking
972561|NCT02147665|sympathetic
972562|NCT02147652|moderate dementia
972563|NCT02147652|severe dementia
972564|NCT02147652|Alzheimer's disease
972565|NCT02147652|Vascular dementia
972566|NCT02147652|agitation
972567|NCT02147652|personalized music therapy
972568|NCT02147626|preeclampsia
972569|NCT02147626|cardiovascular disease
972570|NCT02147626|health behaviors
972571|NCT02147626|behavioral intervention
972572|NCT02147626|web-based
972573|NCT02147626|Hypertension
972574|NCT02147626|Post-partum Weight Retention
972575|NCT02147600|adalimumab
972576|NCT02147600|biologicals
972577|NCT02147600|immunogenicity
972578|NCT02147574|slow-transit constipation
972579|NCT02147574|laparoscope Sub-total Colectomy
972580|NCT02147574|anti-peristaltic anastomosis
972581|NCT02147522|community health worker
972582|NCT02147522|promotoras
972583|NCT02147522|self-care behaviors activation
972584|NCT02147522|depression
972585|NCT02147522|low-income patients
972586|NCT02147522|safety-net care
972587|NCT02147509|Dry eye
972588|NCT02147509|Therapeutic bandage contact lenses
972589|NCT02147509|The quality of life
972590|NCT02147496|Food intake
972591|NCT02147496|Appetite
972592|NCT02147496|Blood glucose
972593|NCT02147496|Insulin
972594|NCT02147496|Dairy
972595|NCT02147496|Milk
972596|NCT02147483|Mindfulness
972597|NCT02147483|Alcohol use disorders
972598|NCT02147470|cirrhosis of the liver
972599|NCT02147470|Acute kidney injury
972600|NCT02147457|Prematurity
972601|NCT02147457|Extremely low birth weight
972602|NCT02147457|Phenotyping
972603|NCT02147444|Rivaroxaban
972604|NCT02147444|Non-valvular atrial fibrillation
972605|NCT02147444|NOAC
972606|NCT02147444|Xa inhibitor
972607|NCT02147418|Head and neck cancer
972608|NCT02147418|Throat cancer
972609|NCT02147418|Human papillomavirus
972610|NCT02147418|HPV
972611|NCT02147418|Exosome
972612|NCT02147418|Diagnostic
972613|NCT02147418|Early Detection
972614|NCT02147405|FDG PET/CT Scan
972615|NCT02147405|Lymph Node Biopsy
972616|NCT02147405|Apheresis
972617|NCT02147392|PET Imaging
972618|NCT02147379|Bipolar Disorder
972619|NCT02147379|Cognition
972620|NCT02147379|Euthymic
972621|NCT02147379|Lurasidone
972622|NCT02147366|Hypertension,ambulatory pressure,autonomic function,music
972623|NCT02147353|External Genital Warts
972624|NCT02147353|Sinecatechins
972625|NCT02147353|Cryotherapy
972626|NCT02147340|Heart Failure patients
972627|NCT02147340|Remote Patient Management
972628|NCT02147340|External Sensors
972629|NCT02147327|vitamin D
972630|NCT02147327|cord blood
972631|NCT02147327|neonatal sepsis
972632|NCT02147327|neonatal morbidity
972633|NCT02147314|diabetes
972634|NCT02147314|glucometer
972635|NCT02147314|Yofimeter
972636|NCT02147314|diabetes monitoring
972637|NCT02147275|hypertension
972638|NCT02147275|cerebral oxygen saturation
972639|NCT02147275|near-infrared spectroscopy
972640|NCT02147275|cognitive function
972641|NCT02147262|chronic atrophic acrodermatitis
972642|NCT02147262|Lyme borreliosis
972643|NCT02147262|molecular characteristics
972644|NCT02147262|outcome
972645|NCT02147249|erythema migrans
972646|NCT02147249|Lyme borreliosis
972647|NCT02147249|inflammation
972648|NCT02147249|outcome
972649|NCT02147236|autism
972650|NCT02147236|pervasive developmental disorders
972651|NCT02147236|social skills intervention
972652|NCT02147223|flavanols
972653|NCT02147223|sex-related cardiovascular effects
972654|NCT02147210|Chronic transplant glomerulopathy
972655|NCT02147210|antibody mediated rejection
972656|NCT02147210|Ephrin-B1
972657|NCT02147184|SSRI
972658|NCT02147184|serotonin transporter
972659|NCT02147184|DXA
972660|NCT02147184|pQCT
972661|NCT02147184|bone mass
972662|NCT02147184|adolescents
972663|NCT02147171|Retinal ageing, macular pigment, visual function
972664|NCT02147145|GIST
972665|NCT02147145|endoscopy
972666|NCT02147145|endoscopic ultrasound
972667|NCT02147132|Cigarette
972668|NCT02147132|Methadone
972669|NCT02147132|Smoking
972670|NCT02147132|Cessation
972671|NCT02147132|Varenicline
972672|NCT02147132|Nicotine
972673|NCT02147106|Neuroendocrine tumor
972674|NCT02147106|Videoconsultation
972675|NCT02147106|Feasibility
972676|NCT02147080|prevention or control
972677|NCT02147067|microvascular angina
972678|NCT02147067|coronary microvascular disease
972679|NCT02147067|coronary physiology
972680|NCT02147067|ranolazine
972681|NCT02147054|Organophosphate poisoning
972682|NCT02147054|Intermediate syndrome
972683|NCT02147054|Rocuronium
972684|NCT02147041|diabetes mellitus
972685|NCT02147041|hyperlipidemia
972686|NCT02147041|green tea
972687|NCT02147041|epigallocatechin gallate
972688|NCT02147028|whole brain RT
972689|NCT02147028|hippocampal sparing
972690|NCT02147028|neurocognitive function
972691|NCT02147015|Acute Exacerbations
972692|NCT02147015|Corticosteroids
972693|NCT02147015|Chronic Obstructive Pulmonary Disease
972694|NCT02147015|Doses
972695|NCT02147002|Chronic Kidney Disease
972696|NCT02147002|Cardiovascular Complications
972697|NCT02146989|Cerebral Palsy
972698|NCT02146989|child
972699|NCT02146989|upper extremity
972700|NCT02146989|strength, reproducibility
972701|NCT02146976|postoperative
972702|NCT02146976|sleep quality
972703|NCT02146976|propofol
972704|NCT02146976|sevoflurane
972705|NCT02146950|LCS-12
972706|NCT02146950|Intrauterine Device (IUD)
972707|NCT02146950|Intrauterine System (IUS)
972708|NCT02146950|Levonorgestrel
972709|NCT02146950|Pearl Index
972710|NCT02146950|Hormonal Contraception
972711|NCT02146937|active surveillance
972712|NCT02146937|MRI/transrectal ultrasound fusion guided biopsy
972713|NCT02146937|biopsy
972714|NCT02146911|Smoking Cessation Medication
972715|NCT02146911|Smoking Treatment
972716|NCT02146911|Tobacco Treatment
972717|NCT02146911|Quitting Smoking
972718|NCT02146911|Bupropion
972719|NCT02146911|Varenicline
972720|NCT02146911|Efficacy
972721|NCT02146911|Pharmacogenetics of Smoking Treatment
972722|NCT02146911|Genetics analysis
972723|NCT02146911|Smoking Personality
972724|NCT02146911|Dependence
972725|NCT02146911|Addiction
972726|NCT02146911|Cigarettes
972727|NCT02146911|Primary Care Physicians
972728|NCT02146911|Biochemical Confirmation
972729|NCT02146898|spinal anesthesia
972730|NCT02146898|hypotension
972731|NCT02146898|pregnancy
972732|NCT02146872|Coronary Artery Disease
972733|NCT02146872|Myocardial Infarction
972734|NCT02146872|Atherosclerosis
972735|NCT02146872|High-Throughput Nucleotide Sequencing
972736|NCT02146872|Sequence Analysis, DNA
972737|NCT02146872|Genetic Testing
972738|NCT02146872|Genetic Linkage
972739|NCT02146859|residual neuromuscular blockade
972740|NCT02146846|cml
972741|NCT02146833|castrate-resistant prostate cancer
972742|NCT02146833|prostate cancer
972743|NCT02146833|Karyopharm
972744|NCT02146833|KPT-330
972745|NCT02146833|selinexor
972746|NCT02146820|Pigmented Lesions, Skin Pigment, Picosecond Laser, Syneron
972747|NCT02146807|Tattoos, Picosecond Laser, Syneron
972748|NCT02146742|ASP1707
972749|NCT02146742|Japanese subjects
972750|NCT02146742|Safety
972751|NCT02146742|Pharmacokinetics
972752|NCT02146742|Pharmacodynamics
972753|NCT02146729|Randomized
972754|NCT02146729|Thoracolumbar fractures
972755|NCT02146729|Spine Trauma
972756|NCT02146729|Percutaneous Pedicle Screw Fixation
972757|NCT02146729|Functional Outcome
972758|NCT02146716|RESC, alcohol withdrawal syndrome
972759|NCT02146703|biliary tract neoplasm
972760|NCT02146703|gemcitabine
972761|NCT02146703|S-1
972762|NCT02146690|pathology
972763|NCT02146690|newborn
972764|NCT02146690|osteopathic manipulative treatment
972765|NCT02146690|pain
972766|NCT02146677|prematurity
972767|NCT02146677|newborns
972768|NCT02146677|pain
972769|NCT02146677|cost
972770|NCT02146664|Acute NSTEMI
972771|NCT02146664|DLBS1033
972772|NCT02146664|SPECT
972773|NCT02146664|Infarct size
972774|NCT02146664|Left ventricular function
972775|NCT02146638|post operative analgesia, morphine, fentanyl
972776|NCT02146573|Intensive Care Units, Pediatric
972777|NCT02146573|Communication
972778|NCT02146573|Health personnel
972779|NCT02146573|Decision making
972780|NCT02146573|Critical Care
972781|NCT02146573|Length of Stay
972782|NCT02146573|Iatrogenic Disease
972783|NCT02146560|Surgery
972784|NCT02146560|Non-cardiac
972785|NCT02146560|Elective
972786|NCT02146560|Adult
972787|NCT02146560|Patients
972788|NCT02146560|Troponin
972789|NCT02146560|Myocardial
972790|NCT02146560|Injury
972791|NCT02146560|Postoperative
972792|NCT02146560|Recovery
972793|NCT02146560|Outcome
972794|NCT02146547|depot, oral, antipsychotics, paliperidone, aripiprazole
972795|NCT02146521|z-axis limited CT
972796|NCT02146521|computed tomography
972797|NCT02146521|CT
972798|NCT02146521|abdominal non-traumatic pain and tenderness
972799|NCT02146521|emergency patients
972800|NCT02146508|Esophageal cancer
972801|NCT02146508|Radiofrequency, catheter ablation
972802|NCT02146508|Endoscopic mucosal resection
972803|NCT02146508|Esophageal squamous dysplasia
972804|NCT02146508|Cancer prevention
972805|NCT02146482|back pain
972806|NCT02146482|low back pain
972807|NCT02146482|sit-stand workstation
972808|NCT02146482|standing desk
972809|NCT02146469|varicella vaccination
972810|NCT02146443|Manual dexterity
972811|NCT02146443|hand to eye coordination
972812|NCT02146443|stress
972813|NCT02146443|fatigue
972814|NCT02146430|pain
972815|NCT02146430|fibromyalgia
972816|NCT02146417|Low pressure pneumoperitoneum
972817|NCT02146417|Deep neuromuscular block
972818|NCT02146404|Type 1 Diabetes Mellitus
972819|NCT02146404|Hypoglycemia unawareness
972820|NCT02146404|1H MRS
972821|NCT02146404|Lactate
972822|NCT02146352|Pancreatic pseudocyst
972823|NCT02146339|nutrition
972824|NCT02146339|milk
972825|NCT02146339|polar lipids
972826|NCT02146339|cardiometabolic risk
972827|NCT02146300|birch pollen
972828|NCT02146300|allergy
972829|NCT02146300|breathing
972830|NCT02146300|pattern
972831|NCT02146300|exposure
972832|NCT02146287|cycled light
972833|NCT02146287|preterm infants
972834|NCT02146287|infant neurodevelopment
972835|NCT02146287|infant sleep
972836|NCT02146274|PROSPER
972837|NCT02146274|Stroke
972838|NCT02146274|Ischemic Stroke
972839|NCT02146261|Volunteers
972840|NCT02146261|Japanese
972841|NCT02146261|Males
972842|NCT02146248|hysterosalpingography, DMPA, combined oral contraceptive, tubal patency
972843|NCT02146235|Music Therapy
972844|NCT02146235|Pulmonary Disease
972845|NCT02146235|COPD
972846|NCT02146235|Music Visualization
972847|NCT02146235|Therapeutic Singing
972848|NCT02146235|Wind-playing
972849|NCT02146235|Lung Condition
972850|NCT02146196|Heart failure
972851|NCT02146196|robotic assisted gait therapy
972852|NCT02146183|Stevio glycosides
972853|NCT02146183|sport
972854|NCT02146183|glycogen
972855|NCT02146170|Sample Acquisition
972856|NCT02146170|Generic and Epigenetic Alterations
972857|NCT02146170|Mig6 Expression
972858|NCT02146170|Proteomic Analysis
972859|NCT02146170|Genomic Analysis
972860|NCT02146144|Idiopathic epimacular membrane
972861|NCT02146144|internal limiting membrane peeling
972862|NCT02146144|microscotomas
972863|NCT02146131|Peripheral pulmonary lesions
972864|NCT02146131|Solitary pulmonary lesions
972865|NCT02146131|Multiple pulmonary lesions
972866|NCT02146118|Erlotinib
972867|NCT02146118|Silybin-phytosome
972868|NCT02146118|EGFR mutant lung adenocarcinoma
972869|NCT02146092|lung resection
972870|NCT02146092|incentive spirometry
972871|NCT02146092|physiotherapy
972872|NCT02146092|quality improvement
972873|NCT02146092|outcomes
972874|NCT02146092|post operative complications
972875|NCT02146066|GBM
972876|NCT02146066|Brain tumor
972877|NCT02146066|glioblastoma
972878|NCT02146066|Brain tumor WHO grade IV
972879|NCT02146053|healthy participants
972880|NCT02146053|gastrointestinal side-effects associated with oral iron
972881|NCT02146040|anticoagulation
972882|NCT02146040|atrial fibrillation
972883|NCT02146040|cardioversion
972884|NCT02146040|complications
972885|NCT02146040|hemorrhage
972886|NCT02146040|medications
972887|NCT02146040|thromboembolism
972888|NCT02146040|TIA
972889|NCT02146040|stroke
972890|NCT02146040|treatment
972891|NCT02146027|HIV
972892|NCT02146027|Lactobacillus casei Shirota
972893|NCT02146027|NK cell
972894|NCT02146027|CD4
972895|NCT02146027|Lymphocyte
972896|NCT02146027|Cell activation
972897|NCT02146027|Antiretroviral therapy
972898|NCT02146027|Immune discordants
972899|NCT02146014|cigarette smoking, smoking
972900|NCT02146001|sedentary behavior
972901|NCT02146001|physical activity
972902|NCT02146001|older adults
972906|NCT02145975|Severe postoperative pain
972907|NCT02145975|Morphine
972908|NCT02145975|Fentanyl
972909|NCT02145975|Time to titration of pain
972910|NCT02145975|Pain and PACU
972911|NCT02145975|Anesthesiology
972912|NCT02145962|diabetic foot ulcer healing
972913|NCT02145962|magnetic therapy
972914|NCT02145962|safety and efficacy
972915|NCT02145962|wound care
972916|NCT02145949|aging
972917|NCT02145949|clinical
972918|NCT02145949|translational
972919|NCT02145949|functional mobility
972920|NCT02145949|total knee arthroplasty
972921|NCT02145936|fatty acid
972922|NCT02145923|Hodgkin Lymphoma
972923|NCT02145923|Non-Hodgkin's Lymphomas
972924|NCT02145923|Allogeneic Mesenchymal Stem Cell Transplantation
972925|NCT02145923|Autologous Peripheral Blood Stem Cell Transplantation
972926|NCT02145923|Neutropenic Enterocolitis
972927|NCT02145923|Myeloablative Chemotherapy
972928|NCT02145923|Bone Marrow Aplasia
972929|NCT02145897|CLI
972930|NCT02145884|hemangioma
972931|NCT02145884|birthmark
972932|NCT02145884|strawberry hemangioma
972933|NCT02145884|timolol
972934|NCT02145871|Radical Cystectomy
972935|NCT02145871|Perioperative Fluid Management
972936|NCT02145871|EV1000
972937|NCT02145871|14-069
972938|NCT02145858|Chest tube, chest drainage, chest tube clogging, retained blood complications, hemothorax, tamponade, heart surgery, pleural effusion, intensive care
972939|NCT02145845|critical limb ischemia
972940|NCT02145845|wound healing
972941|NCT02145845|amputation
972942|NCT02145832|TINN
972943|NCT02145832|Pharmacokinetic
972944|NCT02145832|Neonates
972945|NCT02145832|Antifungal
972946|NCT02145832|Fluconazole
972947|NCT02145832|Micafungin
972948|NCT02145806|Urinary incontinence
972949|NCT02145806|Validation study
972950|NCT02145806|Pregnant women
972951|NCT02145806|Postpartum period
972952|NCT02145793|primary care
972953|NCT02145793|pediatrics
972954|NCT02145793|parenting
972955|NCT02145793|education
972956|NCT02145780|Overfeeding
972957|NCT02145780|Fat distribution
972958|NCT02145780|Subcutaneous and visceral adipose tissue
972959|NCT02145780|Insulin sensitivity
972960|NCT02145780|Insulin resistance
972961|NCT02145780|Peripheral and hepatic insulin sensitivity
972962|NCT02145780|Stable isotopes
972963|NCT02145780|Lipid oxidation
972964|NCT02145780|Energy expenditure
972965|NCT02145780|Muscle and subcutaneous adipose tissue gene expression
972966|NCT02145754|erythema migrans
972967|NCT02145754|Lyme borreliosis
972968|NCT02145754|Borrelia burgdorferi
972969|NCT02145754|skin culture
972970|NCT02145754|culture media
972971|NCT02145728|Non-specific chronic low back pain
972972|NCT02145728|Cognitive functional therapy
972973|NCT02145728|Exercise classes
972974|NCT02145702|ESRD
972975|NCT02145702|Kidney Failure
972976|NCT02145702|Exercise
972977|NCT02145702|Cognitive impairment
972978|NCT02145637|Cancer, Lung cancer, Head and neck squamous cell carcinoma, Afatinib, Ruxolitinib, EGFR, JAK, STAT
972979|NCT02145624|pertussis
972980|NCT02145624|maternal vaccination
972981|NCT02145624|maternal immunisation
972982|NCT02145624|immune response
972983|NCT02145611|hypertension, diabetes, endothelial function
972984|NCT02145598|Multiple Myeloma
972985|NCT02145598|Revlimid
972986|NCT02145598|Lenalidomide maintenance
972987|NCT02145585|Cardiac surgery
972988|NCT02145585|Robotic pharmacological anesthesia
972989|NCT02145585|Anesthesia
972990|NCT02145546|Pacing dependent
972991|NCT02145546|Atrial Fibrillation
972992|NCT02145546|Amiodarone
972993|NCT02145546|Propafenone
972994|NCT02145546|Sotalol
972995|NCT02145546|AF burden
972996|NCT02145533|MMP
972997|NCT02145533|NGAL
972998|NCT02145533|Arterial Aneurysms
972999|NCT02145520|bronchiolitis
973000|NCT02145507|Leukoreduction
973001|NCT02145507|Red Blood Cell post-leukoreduction recovery
973002|NCT02145507|Packed red blood cell post storage hemolysis
973003|NCT02145507|Red blood cell recovery
973004|NCT02145507|Plasma clotting factors
973005|NCT02145507|2,3-DPG rejuvenation
973006|NCT02145494|SBRT (stereotactic body radiotherapy)
973007|NCT02145494|Focal boost
973008|NCT02145494|Prostate
973009|NCT02145481|coronary artery disease
973010|NCT02145481|decision quality
973011|NCT02145481|decision making
973012|NCT02145481|survey
973013|NCT02145481|measure development
973014|NCT02145481|patient-centered care
973015|NCT02145481|cardiology
973016|NCT02145481|heart disease
973017|NCT02145468|Myocardial infarction
973018|NCT02145468|Acute coronary syndrome
973019|NCT02145468|Cardiovascular disease
973020|NCT02145468|p38 mitogen-activated protein kinase (MAPK) inhibitor
973021|NCT02145468|NSTEMI
973022|NCT02145468|Losmapimod
973023|NCT02145468|STEMI
973024|NCT02145455|Arthroplasty, Replacement, Knee/methods
973025|NCT02145455|Knee Joint/physiopathology
973026|NCT02145455|Knee Joint/radiography
973027|NCT02145455|Knee Joint/surgery
973028|NCT02145455|Knee Prosthesis
973029|NCT02145455|Outcome Assessment (Health Care)
973030|NCT02145455|Female
973031|NCT02145455|Male
973032|NCT02145455|Adult
973033|NCT02145442|Impaired fasting glucose
973034|NCT02145442|Prediabetes
973035|NCT02145442|Obesity
973036|NCT02145442|Overweight
973037|NCT02145442|Insulin sensitivity
973038|NCT02145442|Weight loss
973039|NCT02145442|Nutritional supplement
973040|NCT02145442|Waist
973041|NCT02145442|Body composition
973042|NCT02145429|Prevention of depression and anxiety disorder
973043|NCT02145429|Depression Prevention
973044|NCT02145416|Imaging
973045|NCT02145416|Chemoradiotherapy
973046|NCT02145403|Allogeneic Transplantation
973047|NCT02145403|Carfilzomib
973048|NCT02145403|Relapse
973049|NCT02145403|Graft-Versus-Host Disease
973050|NCT02145403|Multiple Myeloma
973051|NCT02145403|Lymphoma
973052|NCT02145403|Leukemia
973053|NCT02145390|Bladder Cancer
973054|NCT02145390|Bladder Carcinoma
973055|NCT02145390|Transition Cell Cancer
973056|NCT02145390|TCC
973057|NCT02145390|Muscle Invasive Bladder Carcinoma
973058|NCT02145377|Cholera
973059|NCT02145377|Vaccine
973060|NCT02145377|Mali
973061|NCT02145364|Ulthera System®
973062|NCT02145364|Ultherapy®
973063|NCT02145364|Ulthera, Inc.
973064|NCT02145351|HFpEF
973065|NCT02145351|Heart failure
973066|NCT02145351|Heart failure with preserved ejection fraction
973067|NCT02145351|Chronotropic incompetence
973068|NCT02145338|Urinary tract infection
973069|NCT02145338|Clean intermittent self-catheterisation
973070|NCT02145338|Antibiotic prophylaxis
973071|NCT02145325|Kidney transplant
973072|NCT02145325|Regulatory T cells
973073|NCT02145325|Leukopheresis
973074|NCT02145325|Immune cells
973075|NCT02145325|Stem Cells
973076|NCT02145325|Tolerance
973077|NCT02145273|Maternal Depression
973078|NCT02145273|Interpersonal Psychotherapy
973079|NCT02145273|School Readiness
973080|NCT02145260|Hemodialysis
973081|NCT02145260|Hypotension
973082|NCT02145260|Hospitalization
973083|NCT02145208|BPH
973084|NCT02145195|Vitamin D
973085|NCT02145195|Children
973086|NCT02145195|Supplements
973087|NCT02145195|Cardiometabolic markers
973088|NCT02145195|Immune defense
973089|NCT02145195|Bone turnover
973090|NCT02145195|Muscle strength
973091|NCT02145182|DGF
973092|NCT02145182|Dialysis
973093|NCT02145182|Kidney
973094|NCT02145182|Kidney Transplantation
973095|NCT02145182|eGFR
973096|NCT02145182|Complement
973097|NCT02145182|Eculizumab
973098|NCT02145169|procedural sedation
973099|NCT02145169|emergence reaction
973100|NCT02145169|nitrous oxide
973101|NCT02145169|ketamine
973102|NCT02145156|HPV vaccination
973103|NCT02145156|Tailored health messaging
973104|NCT02145143|Radioiodine (RAI) Incorporation
973105|NCT02145143|Vemurafenib
973106|NCT02145143|14-031
973107|NCT02145130|Skin
973108|NCT02145130|Tissue-engineering
973109|NCT02145130|Autologous
973110|NCT02145130|Dermis
973111|NCT02145130|Epidermis
973112|NCT02145117|MBSR
973113|NCT02145117|fMRI
973114|NCT02145117|PTH
973115|NCT02145091|Psilocybin
973116|NCT02145091|Hallucinogens
973117|NCT02145091|Pharmacologic Actions
973118|NCT02145091|Central Nervous System Agents
973119|NCT02145091|Therapeutic Uses
973120|NCT02145091|Psychotropic Drugs
973121|NCT02145065|paclitaxel coated balloon
973122|NCT02145065|restenosis
973123|NCT02145065|Femoropopliteal artery disease
973124|NCT02145052|Fascial closure
973125|NCT02145052|Interrupted suture
973126|NCT02145052|Running suture
973127|NCT02145052|Continuous suture
973249|NCT02144454|Endothelial activation
973128|NCT02145039|Acute Lymphoblastic Leukemia (ALL)
973129|NCT02145039|Acute Myelogenous Leukemia (AML)
973130|NCT02145039|Burkitt's lymphoma
973131|NCT02145039|Natural killer cell malignancies
973132|NCT02145039|Chronic myelogenous leukemia
973133|NCT02145039|Myelodysplastic syndrome
973134|NCT02145039|Large-cell lymphoma
973135|NCT02145039|Hodgkin lymphoma
973136|NCT02145039|Multiple myeloma
973137|NCT02145039|Chronic lymphocytic leukemia (CLL)
973138|NCT02145039|Small lymphocytic lymphoma (SLL)
973139|NCT02145039|Marginal zone B-cell lymphoma
973140|NCT02145039|Follicular lymphoma
973141|NCT02145039|Lymphoplasmacytic lymphoma
973142|NCT02145039|Mantle-cell lymphoma
973143|NCT02145039|Prolymphocytic leukemia
973144|NCT02145039|Refractory leukemia
973145|NCT02145039|MDS
973146|NCT02145039|Bone marrow failure syndromes
973147|NCT02145039|Myeloproliferative syndromes
973148|NCT02145013|portal hypertension, hepatocellular carcinoma, resection
973149|NCT02145000|Rotavirus
973150|NCT02145000|Gastroenteritis
973151|NCT02145000|Diarrhea
973152|NCT02145000|Vaccine
973153|NCT02145000|Niger
973154|NCT02144974|Total pelvic exenteration.
973155|NCT02144961|breast reconstruction
973156|NCT02144961|Deep Inferior Epigastric Artery Perforator (DIEP)
973157|NCT02144961|Indocyanine Green Angiography (IGA)
973158|NCT02144961|autologous tissue transfer
973159|NCT02144948|diabetes
973160|NCT02144935|pediatrics
973161|NCT02144922|Hypertension
973162|NCT02144922|Statin
973163|NCT02144909|Diabetes self management
973164|NCT02144909|support group
973165|NCT02144909|semi structured support group
973166|NCT02144883|telephone counseling
973167|NCT02144870|Tic-Disorder, Tourette-Disorder, Habit Reversal Training, Resources activation
973168|NCT02144844|Antepartum depressive symptoms
973169|NCT02144844|Antepartum depression
973170|NCT02144844|Cognitive behavioral intervention
973171|NCT02144844|Feasibility
973172|NCT02144844|randomized clinical trial
973173|NCT02144831|TIA
973174|NCT02144831|stroke prevention
973175|NCT02144831|ASA
973176|NCT02144831|clopidogrel
973177|NCT02144831|dual antiplatelet treatment
973178|NCT02144753|IBS-C
973179|NCT02144753|Constipation
973180|NCT02144753|IBS
973181|NCT02144740|Flow-mediated dilation
973182|NCT02144688|Human Immunodeficiency Virus
973183|NCT02144688|HIV
973184|NCT02144688|Cognitive symptoms
973185|NCT02144688|Cognitive evaluation
973186|NCT02144688|Neuropsychological testing
973187|NCT02144688|Quality of life
973188|NCT02144688|Anxiety
973189|NCT02144688|Viral load
973190|NCT02144688|Antiretroviral
973191|NCT02144688|Cerebrospinal fluid
973192|NCT02144688|Lumbar puncture
973193|NCT02144688|Magnetic resonance imaging
973194|NCT02144688|MRI
973195|NCT02144649|Prostate Cancer
973196|NCT02144649|Tangerine Juice
973197|NCT02144649|Tomato Juice
973198|NCT02144623|Chronic Lymphocytic Leukemia
973199|NCT02144623|Valproate
973200|NCT02144623|Cluster of differentiation antigen 20
973201|NCT02144623|Lymphomas
973202|NCT02144623|B-cell lymphomas
973203|NCT02144623|Translational research
973204|NCT02144623|Monoclonal antibodies
973205|NCT02144610|CLI
973206|NCT02144597|morbid obesity
973207|NCT02144597|gastric bypass
973208|NCT02144597|bariatrics
973209|NCT02144597|diet
973210|NCT02144597|caloric restriction
973211|NCT02144597|liver fat
973212|NCT02144597|appetite
973213|NCT02144584|ischemic stroke
973214|NCT02144584|memantine
973215|NCT02144584|upper extremity weakness
973216|NCT02144584|motor recovery
973217|NCT02144558|Sperm parameters
973218|NCT02144558|Spinal cord injuries
973219|NCT02144558|Oxidative stress
973220|NCT02144558|Inflammatory syndrome
973221|NCT02144545|Surgery
973222|NCT02144545|Morbid Obesity
973223|NCT02144545|Bariatric surgery
973224|NCT02144545|Sleeve gastrectomy
973225|NCT02144545|Bougie Size
973226|NCT02144545|Distance from pylorus
973227|NCT02144545|Hormones
973228|NCT02144545|Gastric remanent
973229|NCT02144532|Ehlers-Danlos syndrome
973230|NCT02144532|hypermobility
973231|NCT02144532|Compression garment
973232|NCT02144532|pain
973233|NCT02144532|isokinetic evaluation
973234|NCT02144506|Elderly, home-based exercises programm
973235|NCT02144493|common bile duct stones
973236|NCT02144493|diverticulum
973237|NCT02144480|coronary bypass surgery
973238|NCT02144480|rehabilitation
973239|NCT02144480|exercise training
973240|NCT02144480|platelet activation
973241|NCT02144480|cardiopulmonary fitness
973242|NCT02144467|Multiple-MRI, Gene, Cognition
973243|NCT02144454|Cardiovascular disease
973244|NCT02144454|Fatty acids
973245|NCT02144454|Vascular function
973246|NCT02144454|Blood pressure
973247|NCT02144454|Plasma lipids
973248|NCT02144454|Insulin resistance
973250|NCT02144441|Diabetes Mellitus
973251|NCT02144441|Insulin
973252|NCT02144441|Self Administration
973253|NCT02144441|Patient Satisfaction
973254|NCT02144441|Glucose
973255|NCT02144441|Hypoglycemia
973256|NCT02144441|Hyperglycemia
973257|NCT02144415|abuse liability
973258|NCT02144415|recreational drug user
973259|NCT02144415|stimulant
973260|NCT02144415|d-amphetamine
973261|NCT02144415|ADHD
973262|NCT02144389|Arachidonic acid
973263|NCT02144389|Bilharzia
973264|NCT02144389|Mansoni
973265|NCT02144389|Schistosomiasis
973266|NCT02144389|Polyunsaturated fatty acid
973267|NCT02144376|Constipation
973268|NCT02144376|psyllium
973269|NCT02144376|ispaghula
973270|NCT02144376|Magnetic Resonance Imaging
973271|NCT02144376|MRI
973272|NCT02144376|microbiota
973273|NCT02144363|Preterm
973274|NCT02144363|RDS
973275|NCT02144363|Mechanical Ventilation
973276|NCT02144363|Extubation failure
973277|NCT02144350|hyperbaric oxygen
973278|NCT02144337|Physical activity
973279|NCT02144337|Type 1 Diabetes Mellitus
973280|NCT02144337|Children
973281|NCT02144337|Intervention
973282|NCT02144324|Maxillary protraction
973283|NCT02144324|Modified Tandem Appliance
973284|NCT02144324|Face mask therapy
973285|NCT02144324|Class III malocclusion
973286|NCT02144324|Maxillary deficiency
973287|NCT02144311|MRI
973288|NCT02144311|FDG PET/CT
973289|NCT02144311|histologic heterogeneity
973290|NCT02144311|14-061
973291|NCT02144298|microcirculation
973292|NCT02144298|coronary artery bypass grafting
973293|NCT02144298|cold blood cardioplegia
973294|NCT02144298|cristalloid cardioplegia
973295|NCT02144285|Renal dialysis
973296|NCT02144272|Antibody
973297|NCT02144272|Tumor Necrosis Factor alpha
973298|NCT02144272|Interleukin-17
973299|NCT02144233|Pain
973300|NCT02144233|Temporomandibular joint disorders
973301|NCT02144233|Occlusal adjustment
973302|NCT02144233|Therapy
973303|NCT02144233|Randomized clinical trial
973304|NCT02144233|Mastication
973305|NCT02144233|Habitual chewing side
973306|NCT02144233|Handedness preference
973307|NCT02144233|Hemimandibular retrognathia
973308|NCT02144220|Telemedicine
973309|NCT02144220|Virtual care visit
973310|NCT02144220|Remote visit
973311|NCT02144220|Video-conferencing
973312|NCT02144194|Oral Vinorelbine
973313|NCT02144194|Oral Chemotherapy
973314|NCT02144194|Metastatic Breast Cancer
973315|NCT02144194|Advanced Breast Cancer
973316|NCT02144194|Maintenance treatment
973317|NCT02144181|Ulthera® System
973318|NCT02144181|Ultherapy® Treatment
973319|NCT02144181|Ulthera, Inc.
973320|NCT02144168|Prebiotics
973321|NCT02144168|diarrhoea
973322|NCT02144168|Enteral nutrition
973323|NCT02144168|Fibre
973324|NCT02144168|Bifidobacteria
973325|NCT02144168|SCFA
973326|NCT02144155|Oxytocin
973327|NCT02144142|Microbiome
973328|NCT02144142|Atopic dermatitis
973329|NCT02144142|Eczema
973330|NCT02144142|Bacteriotherapy
973331|NCT02144129|Whole Body Electromyostimulation
973332|NCT02144129|Inflammatory Bowel Disease
973333|NCT02144129|Lean Body Mass
973334|NCT02144129|Muscle Strength
973335|NCT02144116|dance-movement therapy
973336|NCT02144116|balance
973337|NCT02144116|Fibromyalgia
973338|NCT02144103|Glaucomatous Neurodegeneration
973339|NCT02144103|Retinal Degeneration
973340|NCT02144103|Primary Open-Angle Glaucoma
973341|NCT02144103|Optic Neuropathy
973342|NCT02144103|Intraocular pressure
973343|NCT02144103|Retinal ganglion cell degeneration
973344|NCT02144103|Optic nerve atrophy
973345|NCT02144103|Subtenon injection
973346|NCT02144103|Glaucomatous damage
973347|NCT02144103|ADRC
973348|NCT02144103|Adipose-derived regenerative cells
973349|NCT02144103|Fat tissue
973350|NCT02144103|Stem cells
973351|NCT02144090|Angiography
973352|NCT02144090|Angioplasty
973353|NCT02144090|Coronary artery disease
973354|NCT02144090|Diagnostic
973355|NCT02144090|Fractional flow reserve
973356|NCT02144077|Photodynamic Therapy
973357|NCT02144077|PDT
973358|NCT02144077|non-aggressive BCC
973359|NCT02144064|Aspirin, heparin, pregnancy, recurrent pregnancy loss
973360|NCT02144051|solid tumor, prostate cancer, breast cancer, bladder cancer, ovarian cancer, gastric cancer, salivary duct cancer
973361|NCT02144038|multiple myeloma,
973362|NCT02144038|relapsed and refractory,
973363|NCT02144038|LGH447,
973364|NCT02144038|pan-PIM inhibitor,
973365|NCT02144038|PIM Kinase,
973366|NCT02144038|BYL719,
973367|NCT02144038|PI3K inhibitor
973368|NCT02144025|Ocular Graft-Versus-Host-Disease
973369|NCT02144025|Topical Cyclosporine
973370|NCT02143986|sepsis
973371|NCT02143986|Macrophagic activation syndrome
973372|NCT02143986|Ferritin
973373|NCT02143986|Still's disease
973374|NCT02143973|Uremic
973375|NCT02143973|Pruritus
973376|NCT02143973|Itch
973377|NCT02143973|Chronic Itch
973378|NCT02143973|Nalbuphine
973379|NCT02143960|Syneron
973380|NCT02143960|Velashape
973381|NCT02143960|ELOS
973382|NCT02143960|Zeltiq
973383|NCT02143960|Cryolipolysis
973384|NCT02143947|Orthoses
973385|NCT02143947|Foot
973386|NCT02143947|Kinematics
973387|NCT02143947|EMG
973388|NCT02143947|Biomechanics
973389|NCT02143934|Plasmodium vivax
973390|NCT02143934|Hypnozoites
973391|NCT02143934|Primaquine
973392|NCT02143934|Liver-stage
973393|NCT02143934|Blood-stage
973394|NCT02143934|Plasmodium falciparum
973395|NCT02143921|NGO zinc scale
973396|NCT02143921|compliance with WHO zinc treatment recommendations
973397|NCT02143908|Diarrhea
973398|NCT02143908|L-lysine supplementation
973399|NCT02143908|immune status
973400|NCT02143908|adults
973401|NCT02143908|Bangladesh
973402|NCT02143908|aged 18-45 years
973403|NCT02143908|urban community
973404|NCT02143882|Live attenuated influenza vaccine
973405|NCT02143882|fluenz
973406|NCT02143882|pandemrix
973407|NCT02143882|pandemic influenza vaccine
973408|NCT02143882|immunogenicity
973409|NCT02143869|Gastrointestinal cancer
973410|NCT02143869|Lung cancer
973411|NCT02143869|Bioelectrical Impedance analysis
973412|NCT02143869|Body composition
973413|NCT02143869|Perioperative
973414|NCT02143830|marrow aplasia
973415|NCT02143830|cytopenia
973416|NCT02143830|myelodysplasia
973417|NCT02143830|AML
973418|NCT02143830|bone marrow transplant
973419|NCT02143830|cytoreductive regimen
973420|NCT02143830|T-cell reduction
973421|NCT02143817|whole body vibration training
973422|NCT02143817|L-citrulline
973423|NCT02143817|hypertension
973424|NCT02143817|obesity
973425|NCT02143817|arterial function
973426|NCT02143817|arterial stiffness
973427|NCT02143817|autonomic function
973428|NCT02143817|endothelial function
973429|NCT02143804|Oncolytic virus
973430|NCT02143804|GMCSF
973431|NCT02143804|pRb
973432|NCT02143804|PDL1
973433|NCT02143804|Immunotherapy
973434|NCT02143804|Adenovirus
973435|NCT02143791|SCS
973436|NCT02143791|Burst stimulation
973437|NCT02143778|MBT
973438|NCT02143778|CSPH
973439|NCT02143778|HVPG
973440|NCT02143765|Mitiglinide
973441|NCT02143765|Acarbose
973442|NCT02143765|Type 2 Diabetes Mellitus
973443|NCT02143752|Smoking
973444|NCT02143752|Tobacco
973445|NCT02143752|Addiction
973446|NCT02143752|Mindfulness
973447|NCT02143752|Meditation
973448|NCT02143739|asthma
973449|NCT02143713|Dyspareunia
973450|NCT02143713|Endometriosis-associated pain
973451|NCT02143713|Dysmenorrhea (DYS)
973452|NCT02143713|Elagolix
973453|NCT02143713|Gonadotropin-releasing Hormone Antagonist
973454|NCT02143713|Non-menstrual Pelvic Pain (NMPP)
973455|NCT02143700|exacerbation
973456|NCT02143700|cognitive
973457|NCT02143700|chronic obstructive pulmonary disease
973458|NCT02143687|Pulmonary hypertension
973459|NCT02143687|Interstitial lung disease
973460|NCT02143687|Pulmonary fibrosis
973461|NCT02143674|Stretching exercise muscle
973462|NCT02143674|Elderly
973463|NCT02143674|Techniques and exercise
973464|NCT02143674|Physiotherapy
973465|NCT02143648|uremic
973466|NCT02143648|pruritus
973467|NCT02143648|itch
973468|NCT02143648|chronic itch
973469|NCT02143648|nalbuphine
973470|NCT02143635|HDM201,TP53wt, p53, MDM2, HDM2, advanced tumors, BLRM (Bayesian logistic regression model)
973471|NCT02143622|Head and neck cancer
973472|NCT02143609|airway disease
973473|NCT02143609|bronchitis
973474|NCT02143609|emphysema
973475|NCT02143609|lung
973476|NCT02143596|stroke
973477|NCT02143596|dehydration
973478|NCT02143596|prognosis
973479|NCT02143583|rhinoconjunctivitis
973480|NCT02143583|birch pollen
973481|NCT02143583|desensitization
973482|NCT02143583|allergen immunotherapy
973483|NCT02143570|Urinary Bladder, Overactive
973484|NCT02143570|Darifenacin
973485|NCT02143570|Physiotherapy
973486|NCT02143570|Quality of Life
973487|NCT02143557|breast milk
973488|NCT02143557|infants
973489|NCT02143557|chylothorax
973490|NCT02143557|cardiac surgery
973491|NCT02143557|modified breast milk
973492|NCT02143544|Intra-aortic balloon counterpulsation
973493|NCT02143544|Cardiac surgery
973494|NCT02143544|High-risk patients
973495|NCT02143518|Human Hookworm
973496|NCT02143518|Necator americanus
973497|NCT02143518|Hookworm
973498|NCT02143518|Hookworm Disease
973499|NCT02143518|Iron-deficiency anemia
973500|NCT02143518|Soil-transmitted helminth infection
973501|NCT02143518|Neglected Tropical Disease
973502|NCT02143518|Na-GST-1
973503|NCT02143518|CpG
973509|NCT02143466|Phase I
973510|NCT02143466|Safety
973511|NCT02143466|Tolerability
973512|NCT02143466|Efficacy
973513|NCT02143466|Anti-tumour
973514|NCT02143466|AZD9291
973515|NCT02143466|AZD6094
973516|NCT02143466|MEDI4736
973517|NCT02143466|Osimertinib
973518|NCT02143466|Savolitinib
973519|NCT02143466|Selumetinib
973520|NCT02143466|Durvalumab
973521|NCT02143466|Ascending Doses
973522|NCT02143466|Expansion cohorts
973523|NCT02143466|EGFR
973524|NCT02143466|Advanced Non-Small Cell Lung Cancer
973525|NCT02143466|Tyrosine Kinase Inhibitors
973526|NCT02143453|exercise
973527|NCT02143453|overweight
973528|NCT02143453|children
973529|NCT02143427|social skills training,
973530|NCT02143427|computer based,
973531|NCT02143427|social competence training,
973532|NCT02143427|Oppositional Defiant Disorder
973533|NCT02143427|peer related aggressive behavior
973534|NCT02143427|randomized controlled trial
973535|NCT02143388|Local advanced
973536|NCT02143388|high risk
973537|NCT02143388|nasopharyngeal carcinoma
973538|NCT02143362|Intraoperative wake up
973539|NCT02143362|Closed loop of target controlled infusion
973540|NCT02143362|Dexmedetomidine
973541|NCT02143362|Propofol
973542|NCT02143349|obesity
973543|NCT02143349|herbal remedies
973544|NCT02143349|metabolic disorders
973545|NCT02143336|Surgical site infections
973546|NCT02143336|Skin closure techniques
973547|NCT02143336|Colorectal surgery
973548|NCT02143323|GST, DILI, biomarker
973549|NCT02143297|Sleep Apnea/Hypopnea Syndrome
973550|NCT02143297|Pulse Oximetry
973551|NCT02143297|Nonlinear Dynamics
973552|NCT02143297|Fourier Analysis
973553|NCT02143297|Neural Networks (Computer)
973554|NCT02143271|Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
973555|NCT02143258|stenting venous sinus
973556|NCT02143258|intracranial hypertension
973557|NCT02143258|quality of life
973558|NCT02143258|headache
973559|NCT02143258|visual impairment
973560|NCT02143232|knee replacement
973561|NCT02143232|hip replacement
973562|NCT02143232|patient monitor
973563|NCT02143219|Pancreatic metastatic cancer
973564|NCT02143219|FOLFIRINOX
973565|NCT02143219|toxicity
973566|NCT02143219|efficacy
973567|NCT02143206|Chronic Obstructive Pulmonary Disease
973568|NCT02143206|Pain
973569|NCT02143206|Arthritis
973570|NCT02143206|Dyspnea
973571|NCT02143206|Exercise
973572|NCT02143206|Aerobic
973573|NCT02143193|Breastfeeding
973574|NCT02143193|Newborn
973575|NCT02143193|Formula
973576|NCT02143193|Temperature
973577|NCT02143193|Initial Bath
973578|NCT02143180|real-time tissue elastography
973579|NCT02143180|hepatic fibrosis
973580|NCT02143154|vancomycin, GBS
973581|NCT02143141|postoperative pain
973582|NCT02143141|narcotic side effects
973583|NCT02143128|score
973584|NCT02143128|postoperative
973585|NCT02143128|pain
973586|NCT02143128|nausea
973587|NCT02143128|mental status
973588|NCT02143128|tool
973589|NCT02143115|Colorectal cancer surveillance
973590|NCT02143089|CCSWI
973591|NCT02143076|Medication Adherence
973592|NCT02143076|Hydroxyurea
973593|NCT02143050|Unresectable melanoma Stage IIIC and Stage IV BRAF V600E+
973594|NCT02143024|depression
973595|NCT02143024|family
973596|NCT02143024|primary health care
973597|NCT02143011|sugar
973598|NCT02143011|sucrose
973599|NCT02143011|fruit juice
973600|NCT02143011|orange juice
973601|NCT02143011|metabolism
973602|NCT02143011|immune cell aging
973603|NCT02143011|lipids
973604|NCT02142998|GERD
973605|NCT02142998|Laparoscopic
973606|NCT02142998|sleeve
973607|NCT02142998|gastrectomy
973608|NCT02142972|Low back pain
973609|NCT02142972|Oswestry questionnaire
973610|NCT02142972|Post-partum Depression
973611|NCT02142972|Pelvic pain
973612|NCT02142959|RTA 408
973613|NCT02142959|RTA 408 Lotion
973614|NCT02142959|Breast cancer
973615|NCT02142959|Radiation therapy
973616|NCT02142959|Radiation dermatitis
973617|NCT02142959|Oxidative stress
973618|NCT02142959|Inflammation
973619|NCT02142959|omaveloxolone
973620|NCT02142933|colonization
973621|NCT02142933|screening
973622|NCT02142933|group B streptococci
973623|NCT02142933|extended-spectrum beta-lactamase
973624|NCT02142933|enterobacteriaceae
973625|NCT02142920|Healthy Volunteers
973626|NCT02142907|Breast conservative surgery
973627|NCT02142907|boost radiation
973628|NCT02142907|acute toxicity
973629|NCT02142907|cosmesis
973630|NCT02142907|local control
973631|NCT02142894|Tuberculosis
973632|NCT02142894|TB
973633|NCT02142868|Expanded Access
973634|NCT02142868|Advanced Breast Cancer
973635|NCT02142855|volunteers
973636|NCT02142855|young (18-30 y)
973637|NCT02142855|older (65-75 y)
973638|NCT02142855|age groups
973639|NCT02142842|Adipose stem cell
973640|NCT02142842|Platelet rich plasma
973641|NCT02142842|Knee Osteoarthritis
973642|NCT02142842|Injured cartilage
973643|NCT02142829|bariatric surgery, postoperative pain
973644|NCT02142777|S-equol
973645|NCT02142777|COX activity
973646|NCT02142764|Multiple Sclerosis
973647|NCT02142764|CD8+ T-cells
973648|NCT02142764|Class I Major Histocompatibility Complex (MHC)
973649|NCT02142764|pentamers
973650|NCT02142751|Escherichia coli
973651|NCT02142751|Extended-spectrum β-lactamases (ESBLs)
973652|NCT02142751|Bacteremia
973653|NCT02142751|Urinary tract infection
973654|NCT02142751|Bloodstream infection
973655|NCT02142751|Fosfomycin
973656|NCT02142751|Meropenem
973657|NCT02142751|Pharmacokinetics
973658|NCT02142751|intestinal colonization
973659|NCT02142751|Recurrence
973660|NCT02142751|multidrug resistance E.coli
973661|NCT02142751|Ceftriaxone
973662|NCT02142738|PD-1
973663|NCT02142738|PD1
973664|NCT02142738|PD-L1
973665|NCT02142738|PDL1
973666|NCT02142712|Ischemic Stroke
973667|NCT02142712|Brain Edema
973668|NCT02142712|Diphenhydramine
973669|NCT02142712|Dextromethorphan
973670|NCT02142712|Famotidine
973671|NCT02142699|Acute kidney injury
973672|NCT02142699|Cardiac surgery
973673|NCT02142699|Ischaemia reperfusion injury
973674|NCT02142699|hemearginate
973675|NCT02142686|Hysteroscopy
973676|NCT02142686|Filling pressures
973677|NCT02142673|Operative hysteroscopy
973678|NCT02142673|Filling pressure
973679|NCT02142660|Adhesion barrier system
973680|NCT02142660|Bariatric surgery
973681|NCT02142647|infant growth
973682|NCT02142647|dietary protein
973683|NCT02142647|body composition
973684|NCT02142647|gut microbiome
973685|NCT02142608|Prostate cancer
973686|NCT02142608|Ultrasound Imaging
973687|NCT02142595|dexmedetomidine
973688|NCT02142595|midazolam
973689|NCT02142595|sleep quality
973690|NCT02142595|delirium
973691|NCT02142582|Home Parenteral Nutrition
973692|NCT02142582|Compliance
973693|NCT02142582|Short Bowel Syndrome
973694|NCT02142582|Oral Rehydration Solution
973695|NCT02142569|Monacolin K
973696|NCT02142569|Cholesterol
973697|NCT02142569|Tocotrienol-enriched fraction of palm oil (TRF)
973698|NCT02142569|Chinese Red Yeast Rice (CRYR
973705|NCT02142517|pancreaticoduodenectomy, pancreatic fistula
973706|NCT02142504|Drug therapy
973707|NCT02142491|Egg allergy
973708|NCT02142491|live attenuated influenza vaccine
973709|NCT02142478|physical activity
973710|NCT02142478|behaviour change
973711|NCT02142478|exercise referral
973712|NCT02142478|self-determination theory
973713|NCT02142478|mixed-method
973714|NCT02142478|evaluation
973715|NCT02142478|qualitative
973716|NCT02142452|Pregnancy
973717|NCT02142452|Obesity/Overweight
973718|NCT02142452|postpartum
973719|NCT02142452|mobile health
973720|NCT02142452|cardiovascular disease
973721|NCT02142439|Anorexia
973722|NCT02142439|Bulimia
973723|NCT02142439|Physical activity
973724|NCT02142439|Treatment
973725|NCT02142426|wound chronic
973726|NCT02142413|Stroke
973727|NCT02142413|Atrial fibrillation
973728|NCT02142413|Holter ECG
973729|NCT02142413|cardiac MRI
973730|NCT02142335|B-Raf, inoperable stage III melanoma, metastatic stage IV melanoma,
973731|NCT02142296|Pigment Epithelial Detachment
973732|NCT02142296|Age-related Macular degeneration
973733|NCT02142283|Mechanical thrombectomy
973734|NCT02142283|Acute ischemic stroke
973735|NCT02142283|Wake up stroke
973736|NCT02142283|Late presenting stroke
973737|NCT02142257|Obesity
973738|NCT02142257|Gastric Bypass
973739|NCT02142257|Aspiration Therapy
973740|NCT02142257|AspireAssist
973741|NCT02142244|Sentinel node biopsy
973742|NCT02142244|Near infra red light
973743|NCT02142244|Indocyanine green
973744|NCT02142244|micrometastasis
973745|NCT02142231|acupuncture
973746|NCT02142231|test anxiety
973747|NCT02142231|neuroenhancer
973748|NCT02142231|placebo
973749|NCT02142179|Asthma
973750|NCT02142179|Knowledge
973751|NCT02142179|School-Based Service
973752|NCT02142179|Adolescents
973753|NCT02142166|aneurysmal subarachnoid hemorrhage (ASH)
973754|NCT02142166|biomarker
973755|NCT02142153|First in man
973756|NCT02142153|Antifungal
973757|NCT02142153|Intravenous infusion
973758|NCT02142153|Healthy volunteers
973759|NCT02142140|Treatment of ADHD
973760|NCT02142140|Long-term treatment follow-up
973761|NCT02142127|GFT505
973762|NCT02142127|Mass balance
973763|NCT02142127|Pharmacokinetics
973764|NCT02142127|Metabolites
973765|NCT02142127|Healthy subjects
973766|NCT02142127|Healthy male volunteers
973767|NCT02142114|Intravitreal injection
973768|NCT02142114|Needle size
973769|NCT02142114|Pain
973770|NCT02142114|Intraocular pressure
973771|NCT02142114|Pain following an Intravitreal injection
973772|NCT02142101|Gut Microbiota
973773|NCT02142101|Polycystic kidney disease
973774|NCT02142101|Chronic kidney disease
973775|NCT02142101|Uremic metabolites
973776|NCT02142088|Glycaemic Control
973777|NCT02142088|Glucose Monitoring
973778|NCT02142088|Intravascular Glucose Monitoring
973779|NCT02142075|Pharmacokinetics
973780|NCT02142062|Venous outflow obstruction
973781|NCT02142062|Iliac Vein
973782|NCT02142062|Common Femoral Vein
973783|NCT02142062|Iliac Compression
973784|NCT02142049|DLBCL
973785|NCT02142049|ABC
973786|NCT02142049|GCB
973787|NCT02142049|Primary Mediastinal B-cell lymphoma
973788|NCT02142049|Pharmacyclics
973789|NCT02142049|Lenalidomide
973790|NCT02142049|lymphoma
973791|NCT02142049|Rituximab
973792|NCT02142049|EPOCH
973793|NCT02142036|Metastatic disease
973794|NCT02142036|Metastasis
973795|NCT02142036|Targeted therapy
973796|NCT02142036|Solid tumor
973797|NCT02142036|Personalized medicine
973798|NCT02142036|N-of-1 trial
973799|NCT02141204|HRV
973800|NCT02141204|Liquid vaccine
973801|NCT02141204|Human rotavirus vaccine
973802|NCT02141997|efficacy
973803|NCT02141997|Methotrexate
973804|NCT02141997|safety
973805|NCT02141984|Korean regulatory required Postmarketing Surveillance
973806|NCT02141971|Down syndrome
973807|NCT02141971|Alzheimer's disease
973808|NCT02141971|biomarkers
973809|NCT02141971|amyloid
973810|NCT02141971|tau
973811|NCT02141945|Cancer
973812|NCT02141945|Colon Cancer
973813|NCT02141945|Colorectal Cancer
973814|NCT02141945|Neoplasm
973815|NCT02141945|Colorectal Neoplasm
973816|NCT02141945|Intestinal Neoplasms
973817|NCT02141945|Gastrointestinal Neoplasms
973818|NCT02141945|Digestive System Neoplasms
973819|NCT02141945|Neoplasms by Site
973820|NCT02141945|Neoplasms
973821|NCT02141945|Colonic Diseases
973822|NCT02141945|Digestive System Diseases
973823|NCT02141945|Gastrointestinal Diseases
973824|NCT02141945|Intestinal Diseases
973825|NCT02141945|Rectal Diseases
973826|NCT02141932|Hand-held
973827|NCT02141932|Ultrasound
973828|NCT02141932|Diagnosis
973829|NCT02141932|Cardiovascular
973830|NCT02141932|Carotid artery stenosis
973831|NCT02141919|renal cancer
973832|NCT02141880|Obesity
973833|NCT02141867|Surgery
973834|NCT02141867|Mortality
973835|NCT02141841|intrathecal;
973836|NCT02141841|bupivacaine;
973837|NCT02141841|concentration;
973838|NCT02141828|Leukemia
973839|NCT02141828|Advanced hematologic malignancies
973840|NCT02141828|Epizyme
973841|NCT02141828|Phase 1b
973842|NCT02141828|MLL gene
973843|NCT02141828|11q23
973844|NCT02141828|Ambiguous lineage
973845|NCT02141828|ALL
973846|NCT02141828|AML
973847|NCT02141828|Acute leukemias
973848|NCT02141828|MLL-r
973849|NCT02141763|Psoriatic Arthritis
973850|NCT02141724|Neuromuscular
973851|NCT02141724|Wheelchair
973852|NCT02141724|Pain
973853|NCT02141724|Bedsore
973854|NCT02141724|Trouble postural
973855|NCT02141711|Drug therapy
973856|NCT02141698|Drug therapy
973857|NCT02141685|in vitro fertilization
973858|NCT02141685|assisted reproduction techniques
973859|NCT02141685|noninvasive imaging of embryos
973860|NCT02141685|time lapse imaging of embryos
973861|NCT02141685|traditional morphological grading of embryos
973862|NCT02141685|prediction of blastocysts
973863|NCT02141685|infertility
973864|NCT02141685|preimplantation genetic diagnosis
973865|NCT02141685|array-Comparative Genomic Hybridization
973866|NCT02141672|lupus nephritis
973867|NCT02141672|calcineurin inhibitors
973868|NCT02141672|voclosporin
973869|NCT02141646|adolescent risky sexual behavior, MI, BST
973870|NCT02141633|smokers
973871|NCT02141633|airway blood flow
973872|NCT02141633|fluticasone
973873|NCT02141633|echocardiogram
973874|NCT02141607|shock
973875|NCT02141607|heart failure
973876|NCT02141607|inflammation
973877|NCT02141607|biomarkers
973878|NCT02141607|cardiovascular instability
973879|NCT02141607|metabolic pathways
973880|NCT02141607|proteolysis
973881|NCT02141581|Intramuscular inactivated trivalent influenza vaccine
973882|NCT02141581|Intradermal inactivated trivalent influenza vaccine
973883|NCT02141581|Live, attenuated influenza vaccine
973884|NCT02141581|Young adults
973885|NCT02141568|Cost-effective
973886|NCT02141568|Unexplained Medical Symptoms
973887|NCT02141568|Frequent Attenders
973888|NCT02141555|misoprostol, early pregnancy loss, missed abortion
973889|NCT02141542|Metastatic Melanoma
973890|NCT02141529|Intraarticular
973891|NCT02141529|pulsed radiofrequency
973892|NCT02141529|osteoarthritis
973893|NCT02141516|Meningitis
973894|NCT02141516|vaccination
973895|NCT02141516|complement deficiency
973896|NCT02141516|asplenia
973897|NCT02141516|splenic dysfunction
973898|NCT02141503|Biomarkers
973899|NCT02141503|Alpha-Manosidosis
973900|NCT02141490|Lymph Node
973901|NCT02141490|Biopsy
973902|NCT02141490|Metastatic Nodes
973903|NCT02141490|Imaging Agent
973904|NCT02141477|Leukemia
973905|NCT02141477|Acute Myelogenous Leukemia
973906|NCT02141477|AML
973907|NCT02141477|High Risk Myelodysplastic Syndrome
973908|NCT02141477|MDS
973909|NCT02141477|Omacetaxine
973910|NCT02141477|Synribo
973911|NCT02141477|Homoharringtonine
973912|NCT02141477|Decitabine
973913|NCT02141477|Dacogen
973914|NCT02141451|DLBCL
973920|NCT02141425|Healthy volunteers
973921|NCT02141425|ASP015K
973922|NCT02141412|optimal dose of dexmedetomidine
973923|NCT02141412|prevent shivering
973924|NCT02141412|improve quality of emergence
973925|NCT02141412|anesthesia
973926|NCT02141412|without delay
973927|NCT02141412|recovery
973928|NCT02141386|Multiple Sclerosis
973929|NCT02141386|Cognitive remediation
973930|NCT02141386|Plasticity-based, adaptive, computerized cognitive remediation
973931|NCT02141386|Cognitive impairment
973932|NCT02141373|seroma
973933|NCT02141373|axillary
973934|NCT02141373|dissection
973935|NCT02141360|Mild Traumatic Brain Injury
973936|NCT02141321|IUD
973937|NCT02141321|Misoprostol
973938|NCT02141321|Rectal administration
973939|NCT02141308|Retina
973940|NCT02141308|Optical coherence tomography
973941|NCT02141308|Imaging
973942|NCT02141282|Oncology
973943|NCT02141282|Cancer of the blood and bone marrow
973944|NCT02141282|Chronic Lymphocytic Leukemia
973945|NCT02141269|Transthoracic echocardiogram
973946|NCT02141269|Hand-held Echocardiography
973947|NCT02141256|elderly
973948|NCT02141256|protein enrichment
973949|NCT02141256|undernutrition
973950|NCT02141217|Odontogenic (Dental) Infections
973951|NCT02141217|Dental infections, periapical abscess
973952|NCT02141217|Bacterial infection
973953|NCT02141191|cystic fibrosis
973954|NCT02141191|hypertonic saline
973955|NCT02141191|nebulizer
973956|NCT02141191|nasal cannula
973957|NCT02141165|sleep apnea
973958|NCT02141165|portable monitor
973959|NCT02141165|primary care
973960|NCT02141165|cost-effectiveness
973961|NCT02141165|OSAS
973962|NCT02141139|Anti-Inflammatory Agents, Non-Steroidal
973963|NCT02141139|Inflammation
973964|NCT02141139|Perioperative Period
973965|NCT02141126|Older adults
973966|NCT02141126|Strength training
973967|NCT02141126|Muscle mass
973968|NCT02141126|Function
973969|NCT02141126|Inpatients
973970|NCT02141100|thioguanine
973971|NCT02141100|mercaptopurine
973972|NCT02141100|methotrexate
973973|NCT02141048|Parenting programme
973974|NCT02141048|Randomised controlled trial
973975|NCT02141048|South Africa
973976|NCT02141048|Positive parenting
973977|NCT02141048|Child behaviour problems
973978|NCT02141048|Implementation fidelity
973979|NCT02141048|Low- and middle-income country
973980|NCT02141035|Acetyl-l-carnitine
973981|NCT02141035|Carpal tunnel syndrome
973982|NCT02141035|Motor unit number estimation
973983|NCT02141035|Compression neuropathy
973984|NCT02141022|Multiple Sclerosis
973985|NCT02141022|Cognition
973986|NCT02141022|Cognitive Remediation
973987|NCT02141022|Gilenya
973988|NCT02141022|Computerized Cognitive Exercise
973989|NCT02141009|Vaccination, prevnar, PCV13
973990|NCT02140996|MUC-1 vector vaccine; epithelial cancers; immunotherapy; safety; antigen specific vaccine, dendritic cell activation
973991|NCT02140983|Insulin Resistance
973992|NCT02140983|Family History of Dementia
973993|NCT02140983|Cognition
973994|NCT02140970|ureteral stent
973995|NCT02140970|stent pain
973996|NCT02140970|ureteral spasm
973997|NCT02140970|NSAID
973998|NCT02140970|ibuprofen
973999|NCT02140970|placebo
974000|NCT02140970|ureteropelvic junction obstruction
974001|NCT02140970|urolithiasis
974002|NCT02140957|Toddler Bottle Use
974003|NCT02140957|Educational Intervention
974004|NCT02140957|Pediatrics
974005|NCT02140957|Iron Deficiency
974006|NCT02140944|Cord blood transplantation
974007|NCT02140944|CCR5Δ32
974008|NCT02140944|HIV cure
974009|NCT02140931|Cell therapy
974010|NCT02140931|Autologous
974011|NCT02140918|Fludrocortisone
974012|NCT02140918|Mineralocorticoids
974013|NCT02140918|Hemodynamics
974014|NCT02140918|Pharmacokinetics
974015|NCT02140905|Hemodialysis
974016|NCT02140905|Heart failure
974017|NCT02140905|Impedance
974018|NCT02140905|Fluids
974019|NCT02140879|pregnancy
974020|NCT02140879|inflammation
974021|NCT02140879|infant assessment
974022|NCT02140853|MDR gram-negative bacilli
974023|NCT02140853|Mortality
974024|NCT02140853|Therapy
974025|NCT02140840|TMTB
974026|NCT02140840|Mekinist
974027|NCT02140840|Trametinib
974028|NCT02140840|relapse
974029|NCT02140840|refractory
974030|NCT02140840|response rate
974031|NCT02140827|bowel preparation
974032|NCT02140827|instant messaging program
974033|NCT02140814|PKD
974034|NCT02140814|niacinamide
974035|NCT02140814|Vitamin B3
974036|NCT02140814|Vitamin B
974037|NCT02140801|Percutaneous coronary intervention
974038|NCT02140801|Drug-eluting stent
974039|NCT02140801|Thrombosis
974040|NCT02140788|schizophrenia
974041|NCT02140788|schizo-affective disorder
974042|NCT02140775|HIV
974043|NCT02140775|AIDS
974044|NCT02140775|Fatigue
974045|NCT02140775|armodafinil
974046|NCT02140775|Unemployment
974047|NCT02140762|Meningitis ABCWY
974048|NCT02140762|adolescents
974049|NCT02140762|accination
974050|NCT02140762|meningococcal disease
974051|NCT02140749|Bifidobacteria
974052|NCT02140749|Bristol Stool Scale
974053|NCT02140749|Constipation
974054|NCT02140749|Diet
974055|NCT02140749|Fructooligosacchardes
974056|NCT02140749|Microbiota
974057|NCT02140749|Oligofructose
974058|NCT02140736|Chemotherapy-induced anemia
974059|NCT02140736|Epoetin biosimilar
974060|NCT02140723|preoperative short course radiotherapy
974061|NCT02140723|delay of surgery
974062|NCT02140723|rectal cancer
974063|NCT02140723|TP53
974064|NCT02140723|predictive marker
974065|NCT02140723|MRT imaging
974066|NCT02140710|premature infant
974067|NCT02140710|visceral osteopathy
974068|NCT02140710|alternative medicine
974069|NCT02140710|meconium passage
974070|NCT02140710|enteral feedings
974071|NCT02140710|hospital stay
974072|NCT02140684|Real-world
974073|NCT02140684|observational
974074|NCT02140684|Nitric oxide
974075|NCT02140684|Inhaled corticosteroid
974076|NCT02140684|UK
974077|NCT02140671|asthma management
974078|NCT02140671|anti-inflammatory therapy
974079|NCT02140671|compliance
974080|NCT02140671|hospital admission
974081|NCT02140671|educations
974082|NCT02140671|self-management
974083|NCT02140671|guidelines
974084|NCT02140671|exacerbations
974085|NCT02140671|diagnostic accuracy
974086|NCT02140671|symptom control
974087|NCT02140658|ischemic stroke
974088|NCT02140658|Statins Medication Compliance
974089|NCT02140658|outcome
974090|NCT02140632|Carpal tunnel syndrome
974091|NCT02140632|Local steroid injection
974092|NCT02140632|Wrist splinting
974093|NCT02140619|ischemic stroke
974094|NCT02140619|Medication Compliance
974095|NCT02140619|outcome
974096|NCT02140606|AML
974097|NCT02140606|phase1
974098|NCT02140606|MTD
974099|NCT02140606|Cafusertib
974100|NCT02140580|Minimally-invasive surfactant therapy
974101|NCT02140541|Asthma
974102|NCT02140541|Blood eosinophils
974103|NCT02140541|Sputum eosinophils
974104|NCT02140541|Clinical predictor
974105|NCT02140541|UK primary care
974106|NCT02140541|Global Initiative for Asthma (GINA)
974107|NCT02140528|Allogenic adipose derived mesenchymal stem cell tibial fracture
974108|NCT02140515|Gonal-F Luveris Assisted Reproductive Technology Hypogonadotropic Hypogonadism
974109|NCT02140502|Enterobacterial Infections
974110|NCT02140502|Prostate cancer
974111|NCT02140502|Biopsy
974112|NCT02140502|Incidence of fluoroquinolone resistant enteric bacteria
974113|NCT02140476|Thyroid goiter
974114|NCT02140476|Papillary thyroid cancer
974115|NCT02140476|Bipolar device
974116|NCT02140476|Sealing and cutting device
974117|NCT02140476|Thyroidectomy
974118|NCT02140450|intraocular pressure, intravitreal injection, short term
974119|NCT02140437|Fulvestrant
974120|NCT02140437|Anastrozole
974121|NCT02140437|Luminal A-like
974122|NCT02140437|Postmenopausal
974123|NCT02140437|Advanced breast cancer
974124|NCT02140424|type 1 diabetes
974125|NCT02140424|osteoporosis
974126|NCT02140424|children
974127|NCT02140398|infertility
974128|NCT02140398|PCOS
974129|NCT02140398|scratching
974130|NCT02140398|endometrial receptivity
974131|NCT02140372|colchicine
974132|NCT02140372|platelet activity
974133|NCT02140372|neutrophil
974134|NCT02140359|homelessness
974135|NCT02140359|housing first
974136|NCT02140359|social networks
974137|NCT02140359|drug abuse
974138|NCT02140359|alcohol use
974139|NCT02140359|HIV
974140|NCT02140333|erlotinib
974141|NCT02140333|EGFR mutation
974142|NCT02140307|Health Promotion
974143|NCT02140307|Prevention
974144|NCT02140307|Relaxation Response
974145|NCT02140307|Meditation
974146|NCT02140307|Cortisol
974147|NCT02140281|Phase I, Healthy Volunteers
974148|NCT02140268|Phase I
974149|NCT02140268|Healthy
974150|NCT02140268|Pharmacokinetics
974151|NCT02140255|HIV Remission
974152|NCT02140242|AML
974153|NCT02140242|leukemia
974154|NCT02140242|induction treatment
974155|NCT02140242|daunorubicin
974156|NCT02140242|7+3
974157|NCT02140229|Rheumatoid Arthritis
974158|NCT02140229|Remission,
974159|NCT02140229|DAS28,
974160|NCT02140229|ACR/EULAR,
974161|NCT02140229|RAPID, Randomized study,
974162|NCT02140229|Longitudinal follow-up
974163|NCT02140216|Blood transfusion
974164|NCT02140216|Immune
974165|NCT02140216|Surgery
974166|NCT02140203|Metabolic Syndrome
974167|NCT02140203|Waist circumference
974168|NCT02140203|blood pressure
974169|NCT02140203|triglyceride
974170|NCT02140203|HDL
974171|NCT02140177|Screening
974172|NCT02140177|Adults
974173|NCT02140177|Medical Inpatients
974174|NCT02140177|Suicide
974175|NCT02140164|Cystoid Macular Edema
974176|NCT02140164|Minocycline
974177|NCT02140164|Microglia
974178|NCT02140164|Retinitis Pigmentosa
974179|NCT02140151|amd
974180|NCT02140151|non-exudative macular degeneration
974181|NCT02140151|exudative macular degeneration
974182|NCT02140151|age-related macular degeneration
974183|NCT02140151|ranibizumab
974184|NCT02140151|anti-VEGF
974185|NCT02140125|ASP2408
974186|NCT02140112|T. suis ova
974187|NCT02140112|Trichuris suis ova
974188|NCT02140112|Autism Spectrum Disorder
974189|NCT02140112|ASD
974190|NCT02140099|Mental health
974191|NCT02140099|Violence
974192|NCT02140099|Substance use
974193|NCT02140099|Adolescent
974194|NCT02140099|Prevention
974195|NCT02140086|asthma
974196|NCT02140086|Buteyko
974197|NCT02140086|remedial breathing
974198|NCT02140086|children
974199|NCT02140073|GERD
974200|NCT02140073|Omez
974201|NCT02140073|Omez DSR
974202|NCT02140073|heartburn
974203|NCT02140073|esophagitis
974204|NCT02140073|omeprazole
974205|NCT02140073|omeprazole+domperidone
974206|NCT02140060|Glaucoma
974207|NCT02140060|Ocular
974208|NCT02140060|Hypertension
974209|NCT02140060|OAG
974210|NCT02140060|POAG
974211|NCT02140060|OHT
974212|NCT02140047|Haemophilus influenza type b
974213|NCT02140047|Hib
974214|NCT02140034|Extensive Peritoneal Lavage
974215|NCT02140034|Overall Survival
974216|NCT02140034|Disease Free Survival
974217|NCT02140034|Peritoneal Recurrence Rate
974218|NCT02140034|T3 and T4 Gastric Cancer
974219|NCT02140021|Malignant Female Reproductive System Neoplasm
974220|NCT02140021|Gynecological Cancer
974221|NCT02140021|High-grade dysplasia
974222|NCT02140021|Carcinoma of the cervix
974223|NCT02140021|Carcinoma of the vagina
974224|NCT02140021|Carcinoma of the vulva
974225|NCT02140021|Invasive squamous cell carcinoma
974226|NCT02140021|Anal pap test
974227|NCT02140021|Anoscopy
974228|NCT02140008|supraglottic airway devices
974229|NCT02140008|the i-gel
974230|NCT02140008|the self-pressurised air-Q intubating laryngeal airway,
974231|NCT02140008|children
974232|NCT02139995|transfusion
974233|NCT02139995|trigger
974234|NCT02139995|critically-ill
974235|NCT02139982|hemodynamics
974236|NCT02139982|anaesthetics
974237|NCT02139982|brachial plexus
974238|NCT02139982|peripheral nerves
974239|NCT02139982|skin temperature
974240|NCT02139982|sympathetic nervous system
974241|NCT02139982|dose-response relationship
974242|NCT02139943|Diabetes Mellitus, Type 1
974243|NCT02139943|Canagliflozin
974244|NCT02139943|Continuous Glucose Monitoring
974245|NCT02139930|smoking
974246|NCT02139930|nicotine reduction
974247|NCT02139917|transitional palliative care
974248|NCT02139917|end stage renal failure
974249|NCT02139904|Mesothelioma
974250|NCT02139904|Vinorelbine
974251|NCT02139904|BRCA1
974252|NCT02139891|Cardiac Resynchronization Therapy
974253|NCT02139891|non responders
974254|NCT02139891|MultiPoint Pacing (MPP)
974255|NCT02139813|Obesity -
974256|NCT02139813|Bariatric surgery
974257|NCT02139813|Gastric bypass
974258|NCT02139800|Neonatal resuscitation
974259|NCT02139800|Extreme Low Gestational Age Newborn (ELGAN)
974260|NCT02139800|Delivery Room
974261|NCT02139800|Continuous positive airway pressure (CPAP)
974262|NCT02139800|Positive pressure ventilation (PPV)
974263|NCT02139800|Sustained inflation
974264|NCT02139787|Hypertension, obesity
974265|NCT02139787|Dietary behaviors
974266|NCT02139787|Physical activity behaviors
974267|NCT02139787|Radio story, entertainment health education
974268|NCT02139787|Immigrants
974269|NCT02139787|Somali, Latino, Hmong
974270|NCT02139787|Families with 3-18 year old children
974271|NCT02139774|Prostate Cancer
974272|NCT02139774|Elderly
974273|NCT02139774|Geriatric
974274|NCT02139774|Radiation
974275|NCT02139774|Arthritis
974276|NCT02139774|Exercise
974277|NCT02139774|Walking
974278|NCT02139774|Endocrine Therapy
974279|NCT02139774|Androgen Deprivation Therapy
974280|NCT02139774|Active Surveillance
974281|NCT02139774|Men
974282|NCT02139761|Cocaine
974283|NCT02139761|Treatment
974284|NCT02139748|Dental Implants
974285|NCT02139748|Alveolar Bone Grafting
974286|NCT02139748|Acellular Dermis
974287|NCT02139735|Temporomandibular Joint Disorders,
974288|NCT02139735|Ultrasonics,
974289|NCT02139735|Electromyography,
974290|NCT02139735|Pain Measurement,
974291|NCT02139735|Muscle Stretching Exercise
974292|NCT02139722|hepatitis B
974293|NCT02139722|hepatitis C
974294|NCT02139722|screening
974295|NCT02139722|Asian Americans
974296|NCT02139722|mobile technology
974297|NCT02139657|Rabies
974298|NCT02139657|Rabies virus
974299|NCT02139657|Rhabdoviridae
974300|NCT02139657|Rabies immune globulin
974301|NCT02139657|Rabies antibodies
974302|NCT02139657|Passive rabies immunization
974303|NCT02139644|fluticasone propionate
974304|NCT02139644|multidose dry powder inhaler
974305|NCT02139631|hemodynamic
974306|NCT02139631|mechanical ventilation
974307|NCT02139631|respiration with positive pressure
974308|NCT02139618|Randomized-controlled-trial
974309|NCT02139618|Methyl-Aminolevulinate
974310|NCT02139618|Daylight
974311|NCT02139618|Photodynamic-therapy
974312|NCT02139605|D2 versus D3 Lymphadenectomy
974313|NCT02139592|Pharmacological therapy
974314|NCT02139579|chemotherapy
974315|NCT02139579|EGFR-TKI resistance
974316|NCT02139579|Bevacizumab
974317|NCT02139553|Rhythmic versus discrete movements
974318|NCT02139553|Rehabilitation
974319|NCT02139540|Treatment
974320|NCT02139527|arthroplasty
974321|NCT02139527|spinal
974322|NCT02139527|CHARITE
974323|NCT02139527|PRODISC-L
974324|NCT02139527|PRODISC
974325|NCT02139527|disc
974326|NCT02139527|replacement
974327|NCT02139527|lumbar
974328|NCT02139514|Social Skills
974329|NCT02139514|Adults
974330|NCT02139501|Recombinant Human Thrombopoietin
974331|NCT02139501|Dose and frequency
974332|NCT02139501|Immune Thrombocytopenia
974333|NCT02139488|Esophageal cancer
974334|NCT02139488|Chemoradiation
974335|NCT02139475|bowel cleansing, colorectal cancer surgery
974336|NCT02139462|FBT, fidelity, training
974337|NCT02139449|CRT, heart failure, ICD
974338|NCT02139423|Congenital cytomegalovirus infection
974339|NCT02139423|newborn universal hearing screening
974340|NCT02139410|sarcopenia
974341|NCT02139410|mortality
974342|NCT02139384|procalcitonin
974343|NCT02139384|community acquired pneumonia
974344|NCT02139384|pneumonia score
974345|NCT02139371|Positron Emission Tomography
974346|NCT02139371|Uroplasminogen Plasminogen Activator Receptor
974347|NCT02139371|Breast cancer
974348|NCT02139371|Prostate cancer
974349|NCT02139371|Urinary bladder cancer
974350|NCT02139371|Biodistribution
974351|NCT02139371|Radiation exposure
974352|NCT02139358|Breast - Female
974353|NCT02139358|Metastatic
974354|NCT02139358|HER2+
974355|NCT02139345|Osteoarthritis
974356|NCT02139345|Rheumatoid arthritis
974357|NCT02139345|Post-traumatic arthritis
974358|NCT02139345|Avascular necrosis
974359|NCT02139345|AVN
974360|NCT02139332|Attachment theory
974361|NCT02139332|Parent- child relationship
974362|NCT02139332|Child mental health
974363|NCT02139332|Behavioral health
974364|NCT02139293|vagus nerve stimulation effects on heart rate variability and peripheral blood perfusion
974365|NCT02139280|Cyclophosphamide
974366|NCT02139280|Hematopoietic
974367|NCT02139280|Stem Cell
974368|NCT02139280|Mobilization
974369|NCT02139280|Hematologic Malignancy
974370|NCT02139267|CIN3
974371|NCT02139267|Cervical Intraepithelial Neoplasia
974372|NCT02139267|High-Risk HPV
974373|NCT02139267|HPV Infection
974374|NCT02139267|Neoplasm
974375|NCT02139267|Precancerous Diseases
974376|NCT02139267|Uterine Diseases
974377|NCT02139267|Genital Diseases, Female
974378|NCT02139254|Gestational Diabetes
974379|NCT02139254|HbA1c
974380|NCT02139254|Glucose
974381|NCT02139254|First Trimenon
974382|NCT02139228|Haemophilus influenzae type b
974383|NCT02139228|persistency
974384|NCT02139228|children
974385|NCT02139228|CRM197
974386|NCT02139228|anti-PRP antibody
974387|NCT02139202|Acute
974388|NCT02139202|Myocardial
974389|NCT02139202|Infarction
974390|NCT02139202|AMI
974391|NCT02139176|couple HIV testing and counseling
974392|NCT02139176|disclosure
974393|NCT02139176|discordant
974394|NCT02139176|HIV
974395|NCT02139176|Malawi
974396|NCT02139163|Community acquired pneumonia
974397|NCT02139163|CAP
974398|NCT02139163|CAPNETZ
974399|NCT02139163|age ≥18
974400|NCT02139163|infiltrate on chest X-ray
974401|NCT02139163|cough or production of purulent sputum
974402|NCT02139163|pathologic lung auscultation
974403|NCT02139163|fever
974404|NCT02139150|FLT PET Imaging
974405|NCT02139150|3'deoxy-3' [18F] fluorothymidine ([18F] FLT)
974406|NCT02139150|CT
974407|NCT02139150|scans
974408|NCT02139150|14-050
974409|NCT02139098|sleep architecture
974410|NCT02139098|conditioning of pharmacological responses
974411|NCT02139098|insomnia
974412|NCT02139085|varicose veins
974413|NCT02139085|catheter ablation
974414|NCT02139085|Catheter Ablation, Electrical
974415|NCT02139085|Catheter Ablation, Radiofrequency
974416|NCT02139072|Anticoagulation
974417|NCT02139072|International normalized ratio
974418|NCT02139072|Warfarin
974419|NCT02139059|anuria
974420|NCT02139059|children
974421|NCT02139059|ureteroscopy
974422|NCT02139059|initial urinary drainage
974423|NCT02139059|ureteric stones
974424|NCT02139046|Drug therapy
974425|NCT02139033|Dry Eye, Dry Eye Syndrome, Retaine, KCS, Keratoconjunctivitis sicca
974426|NCT02139020|Targeted therapies
974427|NCT02139020|Plasma samples
974428|NCT02138981|Hepatocellular Carcinoma
974429|NCT02138981|Milan Criteria
974430|NCT02138968|Pre-frailty
974431|NCT02138968|Frail
974432|NCT02138968|Exercise
974433|NCT02138968|Nutritional assessment
974434|NCT02138968|Functional capacity
974435|NCT02138942|automated vascular filling
974436|NCT02138942|Learning Intravenous Resuscitator (LIR)
974437|NCT02138942|General Surgery
974438|NCT02138942|Fluid Therapy
974439|NCT02138929|Esophageal Cancer
974440|NCT02138929|Advanced adenocarcinoma of the esophagus
974441|NCT02138929|Advanced adenocarcinoma of the gastroesophageal junction
974442|NCT02138929|GEJ
974443|NCT02138929|Metastatic
974444|NCT02138929|Everolimus
974445|NCT02138929|Afinitor
974446|NCT02138929|Zortress
974447|NCT02138929|RAD001
974448|NCT02138929|LDE 225
974449|NCT02138916|Obstructive Lung Diseases
974450|NCT02138916|Chronic Obstructive Pulmonary Disease
974451|NCT02138916|Lung Disease
974452|NCT02138916|Bronchial Diseases
974453|NCT02138916|COPD Exacerbation
974454|NCT02138916|Respiratory Tract Diseases
974455|NCT02138903|weaning
974456|NCT02138903|Cardiac
974457|NCT02138903|Echocardiography
974458|NCT02138903|Mechanical Ventilation
974459|NCT02138890|Autologous Protein Solution
974460|NCT02138890|APS
974461|NCT02138890|Osteoarthritis
974462|NCT02138890|Intra Articular Injection
974463|NCT02138877|Pelviureteric junction obstruction
974464|NCT02138877|pyeloplasty
974465|NCT02138877|Neonate affected by hydronephrosis
974466|NCT02138877|obstructive uropathy
974467|NCT02138877|urinary stent
974468|NCT02138864|carbon monoxide intoxication
974469|NCT02138864|Parkinsonism
974470|NCT02138864|18F-DTBZ AV-133
974471|NCT02138838|Chronic Kidney Disease, Secondary Hyperparathyroidism, Dialysis, Pediatric
974472|NCT02138812|Phase 1
974473|NCT02138812|Solid tumors
974474|NCT02138812|Breast cancer
974475|NCT02138812|Paclitaxel
974476|NCT02138812|MPS-1 inhibitor
974477|NCT02138812|Taxanes
974478|NCT02138799|Phase I
974479|NCT02138799|Pharmacokinetics
974480|NCT02138799|Safety
974481|NCT02138799|Drug-drug interactions
974482|NCT02138799|Enzalutamide
974483|NCT02138799|Rifampin
974484|NCT02138799|CYP3A4
974485|NCT02138799|CYP2D8
974486|NCT02138799|Enzyme induction
974487|NCT02138786|Richter's Transformation
974488|NCT02138786|Richter's Syndrome
974489|NCT02138786|Karyopharm
974490|NCT02138786|selinexor
974491|NCT02138786|KPT-330
974492|NCT02138786|SIRRT
974493|NCT02138786|CLL
974494|NCT02138773|prolonged release formulation
974495|NCT02138773|adrenergic blocker
974496|NCT02138773|Bioequivalence
974497|NCT02138760|prostate cancer
974498|NCT02138760|prostate biopsy
974499|NCT02138760|magnetic resonance imaging guidance
974500|NCT02138760|detection rates
974501|NCT02138760|performance
974502|NCT02138747|Overactive bladder (OAB)
974503|NCT02138747|tolterodine ER
974504|NCT02138747|mirabegron
974505|NCT02138734|antitumor
974506|NCT02138734|BCG
974507|NCT02138734|bladder cancer
974508|NCT02138734|cancer
974509|NCT02138734|immunotherapy
974510|NCT02138734|instillation
974511|NCT02138734|interleukin-15
974512|NCT02138734|intravesical
974513|NCT02138734|naive
974514|NCT02138734|non-muscle invasive
974515|NCT02138734|transitional cell carcinoma
974516|NCT02138721|Metastatic Prostate Cancer
974517|NCT02138721|Prostatectomy
974518|NCT02138708|Pulmonary arterial hypertension,
974519|NCT02138708|congenital heart disease,
974520|NCT02138708|heart shunt,
974521|NCT02138708|acetylcholine
974522|NCT02138708|Pharmacological test of pulmonary vascular reactivity (acetylcholine) in
974523|NCT02138695|atrial fibrillation
974524|NCT02138695|catheter ablation
974525|NCT02138695|recurrence
974526|NCT02138682|DaT-SPECT scan
974527|NCT02138682|Parkinson's
974528|NCT02138682|Diagnostic
974529|NCT02138669|Cornea
974530|NCT02138669|Keratoconus
974531|NCT02138669|Steep cornea
974532|NCT02138656|Crying
974533|NCT02138656|Chiropractic
974534|NCT02138656|Infant
974535|NCT02138656|pediatric
974536|NCT02138656|Infantile colic
974537|NCT02138656|Clinical Trial
974538|NCT02138643|Achalasia
974539|NCT02138643|Megaesophagus
974540|NCT02138643|Peropal endoscopic myotomy(POEM)
974541|NCT02138643|Laparoscopic Heller myotomy
974542|NCT02138630|Exercise
974543|NCT02138617|Colon Cancer
974544|NCT02138617|Irinotecan
974545|NCT02138617|FOLFIRI
974546|NCT02138617|Genotyping
974547|NCT02138617|UGT1A1
974548|NCT02138604|chest pain
974549|NCT02138604|myocardial ischemia
974550|NCT02138604|acute myocardial dysfunction
974551|NCT02138604|plethesmography
974552|NCT02138604|non invasive dP/dt
974553|NCT02138591|vitamin d deficiency
974554|NCT02138591|cathelicidin antimicrobial peptide
974555|NCT02138591|resistin, human
974556|NCT02138591|protein, human
974557|NCT02138591|1,25-dihydroxy-16,23-diene vitamin D3
974558|NCT02138591|Cholecalciferol
974559|NCT02138591|Nutritional Status
974560|NCT02138591|length of stay
974561|NCT02138539|hyperpigmentation
974562|NCT02138539|melasma
974563|NCT02138539|sun spots
974564|NCT02138539|dark spots
974565|NCT02138526|cancer
974566|NCT02138526|pazopanib
974567|NCT02138526|food
974568|NCT02138526|pharmacokinetics
974569|NCT02138513|Mindfulness
974570|NCT02138513|MBCT
974571|NCT02138513|Cancer
974572|NCT02138513|Oncology
974573|NCT02138513|E-health
974574|NCT02138513|Cost-effectiveness
974575|NCT02138500|PF-06372865
974576|NCT02138500|phase 1
974577|NCT02138500|open-label
974578|NCT02138500|GABA-A receptor occupancy
974579|NCT02138500|positron emission tomography
974580|NCT02138500|healthy subjects
974581|NCT02138487|pelvic organ prolapse
974582|NCT02138487|reconstructive pelvic surgery
974583|NCT02138487|postoperative restrictions
974584|NCT02138487|patient satisfaction
974585|NCT02138474|Lacticum acidum homaccord
974586|NCT02138474|homeopathy
974587|NCT02138474|chronic tension-type headaches
974588|NCT02138461|glaucoma
974589|NCT02138461|bimatoprost
974590|NCT02138461|latanoprost
974591|NCT02138461|tolerability
974592|NCT02138448|Cancer Screenings
974593|NCT02138448|Health Information Technology
974594|NCT02138448|Patient Health Record
974595|NCT02138448|Preventive Services
974597|NCT02138383|advanced pancreatic cancer
974598|NCT02138383|pancreas
974599|NCT02138383|malignant neoplasm
974600|NCT02138383|endocrine system
974601|NCT02138357|Restless Legs Syndrome
974602|NCT02138357|Willis Ekbom Disease
974603|NCT02138357|Twitchy Legs
974604|NCT02138357|Periodic Limb Movements
974605|NCT02138357|Leg Movements
974606|NCT02138357|Augmentation
974607|NCT02138357|Requip
974608|NCT02138357|ropinirole
974609|NCT02138357|Mirapex
974610|NCT02138357|pramipexole
974611|NCT02138357|gabapentin
974612|NCT02138357|Horizant
974613|NCT02138357|Neupro
974614|NCT02138357|rotigotine
974615|NCT02138331|Diabetes Mellitus Type 1
974616|NCT02138331|Microvesicles
974617|NCT02138331|Exosomes
974618|NCT02138331|Cord Blood
974619|NCT02138331|Mesenchymal Stem Cells
974620|NCT02138305|Fractional Flow Reserve (FFR)
974621|NCT02138305|Instantaneous Wave Free Ratio (iFR)
974622|NCT02138305|Coronary Flow Reserve (CFR)
974623|NCT02138305|Hyperemic Stenosis Resistance Index (HSR)
974624|NCT02138305|Hyperemic microvascular resistance (HMR)
974625|NCT02138305|Wave intensity analysis (WIA)
974626|NCT02138305|Myocardial Perfusion
974627|NCT02138305|SPY NIRF Regional Myocardial Perfusion Analysis
974628|NCT02138253|liver transplant
974629|NCT02138253|hepatitis C
974630|NCT02138253|liver fibrosis
974631|NCT02138253|hepatic fibrosis
974632|NCT02138253|liver cirrhosis
974633|NCT02138253|hepatic cirrhosis
974634|NCT02138227|Organ donation request
974635|NCT02138227|Family decision makers
974636|NCT02138227|Communication
974637|NCT02138201|diffusion tensor imaging fiber tracking
974638|NCT02138201|magnetic resonance Imaging
974639|NCT02138201|spinal cord injury
974640|NCT02138201|neurogenic lower urinary tract dysfunction
974641|NCT02138175|bleeding
974642|NCT02138175|blood loss
974643|NCT02138175|hemoglobin
974644|NCT02138175|hemoglobin monitoring
974645|NCT02138175|noninvasive monitoring
974646|NCT02138162|Phase 1
974647|NCT02138162|Pharmacokinetics
974648|NCT02138162|Safety
974649|NCT02138162|Severe hepatic impairment
974650|NCT02138162|Enzalutamide
974651|NCT02138149|spinal cord injury
974652|NCT02138149|neurogenic lower urinary tract dysfunction
974653|NCT02138149|nerve growth factor
974654|NCT02138149|neurogenic detrusor overactivity
974655|NCT02138149|urodynamics
974656|NCT02138123|dense cataract
974657|NCT02138123|phacoemulsification
974658|NCT02138123|lens-shell technique
974659|NCT02138123|intraocular lens
974660|NCT02138110|Spinal Cord Injury (SCI)
974661|NCT02138110|Complete (AIS A) Traumatic Acute Spinal Cord Injury
974662|NCT02138071|low back pain
974663|NCT02138071|lumbar pain
974664|NCT02138058|compulsive buying, compulsive shopping, topiramate
974665|NCT02138045|Diabetes Mellitus, Type 1
974666|NCT02138045|Diabetic Neuropathy
974667|NCT02138045|Liraglutide
974668|NCT02138032|message framing
974669|NCT02138032|smoking cessation
974670|NCT02138032|peripheral artery disease
974671|NCT02138019|corneal ulcers
974672|NCT02138019|conjunctival closure in strabismus surgery
974673|NCT02138019|surgery for retinal detachment
974674|NCT02138019|cataract surgery
974675|NCT02138019|mucous membrane grafting
974676|NCT02137954|cancer
974677|NCT02137954|pain
974678|NCT02137941|Stress
974679|NCT02137941|occupations
974680|NCT02137941|biomarkers
974681|NCT02137941|firefighters
974682|NCT02137928|Retinoblastoma
974683|NCT02137928|carboplatin
974684|NCT02137915|AMD
974685|NCT02137902|Tobacco dependence
974686|NCT02137902|Cardiovascular disease
974687|NCT02137902|Risk behaviors
974688|NCT02137902|Smoking
974689|NCT02137902|Physical activity
974690|NCT02137902|Alaska Native people
974691|NCT02137889|CLL
974692|NCT02137876|B cells
974693|NCT02137876|Thymoglubulin
974694|NCT02137876|humoral rejections
974695|NCT02137876|transplant
974696|NCT02137876|rATG
974697|NCT02137863|Contrast induced nephropathy
974698|NCT02137863|Diabetes Mellitus
974699|NCT02137863|Dexmedetomidine
974700|NCT02137837|Metastatic breast cancer
974701|NCT02137837|Invasive breast carcinoma
974702|NCT02137837|estrogen receptor-positive breast cancer
974703|NCT02137837|HER2-negative breast cancer
974704|NCT02137837|Stage IV breast cancer
974705|NCT02137837|progesterone receptor-positive breast cancer
974706|NCT02137811|cancer
974707|NCT02137811|CorrectChemo
974708|NCT02137811|assay
974709|NCT02137811|lab test
974710|NCT02137811|MICK assay
974711|NCT02137811|apoptosis
974712|NCT02137811|increase survival
974713|NCT02137811|increase response rates
974714|NCT02137811|decrease time to progression
974715|NCT02137811|chemotherapy
974716|NCT02137811|cancer treatment
974717|NCT02137798|fluoroscopy exposure
974718|NCT02137798|paroxysmal atrial fibrillation Ablation
974719|NCT02137798|fluoroscopy
974720|NCT02137798|Atrial Fibrillation Ablation
974721|NCT02137785|Actinic Keratosis
974722|NCT02137759|Glioblastoma
974723|NCT02137746|Prostate Cancer
974724|NCT02137746|Radical Prostatectomy
974725|NCT02137720|Diabetes
974726|NCT02137720|Treatment Adherence
974727|NCT02137720|Self-management
974728|NCT02137720|Emotional Distress
974729|NCT02137720|Diabetes-related Distress
974730|NCT02137707|Multiple Sclerosis, Relapsing-Remitting
974731|NCT02137707|Gilenya
974732|NCT02137707|Fingolimod
974733|NCT02137694|Papillomavirus
974734|NCT02137694|Vaginal auto-takings
974735|NCT02137694|Urinary test
974736|NCT02137681|immune thrombocytopenia
974737|NCT02137681|rituximab
974738|NCT02137681|efficacy
974739|NCT02137681|safety
974740|NCT02137642|constipation
974741|NCT02137629|Myelodysplastic syndromes
974742|NCT02137629|Vidaza
974743|NCT02137629|Observational study
974744|NCT02137629|Korea
974745|NCT02137616|psychosis
974746|NCT02137616|syndrome
974747|NCT02137616|risk
974748|NCT02137616|antipsychotic
974749|NCT02137603|Suppurative appendicitis, appendicitis, pediatric
974750|NCT02137590|Spanish Black Radish
974751|NCT02137590|Phase I detoxification enzymes
974752|NCT02137590|Phase II detoxification enzymes
974753|NCT02137590|Acetaminophen
974754|NCT02137577|drug eluting balloon catheter
974755|NCT02137551|adherence
974756|NCT02137551|healthcare costs
974757|NCT02137551|appointment based model
974758|NCT02137551|accountable care organization
974759|NCT02137512|Artificial Pancreas
974760|NCT02137486|stable angina
974761|NCT02137486|high angulated bifurcation
974762|NCT02137486|SYNTAX
974763|NCT02137486|DES
974764|NCT02137486|BMS
974765|NCT02137460|Alzheimer's disease
974766|NCT02137460|Early diagnosis
974767|NCT02137460|Prediction
974768|NCT02137460|Biomarker
974769|NCT02137460|Imaging
974770|NCT02137447|Prevena
974771|NCT02137447|faster healing time
974772|NCT02137447|surgical site infection
974773|NCT02137434|Acute calcium
974774|NCT02137434|Dietary calcium
974775|NCT02137434|Supplementary calcium
974776|NCT02137434|Postprandial metabolism
974777|NCT02137421|Coronary artery disease
974778|NCT02137421|Metabolic syndrome
974779|NCT02137421|Resveratrol
974780|NCT02137421|β-catenin
974781|NCT02137421|Wnt signaling
974782|NCT02137421|FOXO
974783|NCT02137421|MnSOD
974784|NCT02137408|Chronic hypertension in pregnancy
974785|NCT02137408|Pre-term delivery
974786|NCT02137408|Preeclampsia
974787|NCT02137408|Endothelial Health
974788|NCT02137408|Docosahexaenoic acid (DHA)
974789|NCT02137395|Children, Dexamethasone, Sugammadex,
974790|NCT02137382|maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in Cystic Fibrosis
974791|NCT02137369|MDD
974792|NCT02137369|Major Depressive Disorder
974793|NCT02137369|Treatment
974794|NCT02137369|Antidepressants
974795|NCT02137369|Lexapro
974796|NCT02137369|Talk therapy
974797|NCT02137356|rectal cancer
974798|NCT02137356|rectal adenocarcinoma
974799|NCT02137356|Selinexor
974800|NCT02137356|capecitabine
974801|NCT02137356|chemoradiation
974802|NCT02137356|radiation
974803|NCT02137356|radiotherapy
974804|NCT02137356|neoadjuvant
974805|NCT02137356|locally advanced rectal cancer
974806|NCT02137343|Gastric Cancer
974807|NCT02137343|First Line Treatment Gastroesophageal Junction (GEJ)
974808|NCT02137343|Gastroesophageal Junction Cancer (GEJ)
974809|NCT02137343|GEJ Cancer
974810|NCT02137330|Obalon swallowable intragastric balloons
974811|NCT02137330|Severe obesity
974812|NCT02137330|Children
974813|NCT02137317|Pesticides
974814|NCT02137317|Personal protective equipment
974815|NCT02137317|Developing countries
974816|NCT02137317|Tropical Climate
974817|NCT02137304|cough help
974818|NCT02137304|in-exsufflation
974819|NCT02137304|neuromuscular disease
974820|NCT02137304|cough assistance optimization
974821|NCT02137304|efficient cough flow
974822|NCT02137291|Video-assisted thoracoscopic surgery (VATS)
974823|NCT02137291|Lung isolation device
974824|NCT02137291|One-lung ventilation
974825|NCT02137291|Double lumen endotracheal tube
974826|NCT02137291|Bronchial blocker
974827|NCT02137278|Syncope
974828|NCT02137278|Presyncope
974829|NCT02137278|Vasoactive drugs
974830|NCT02137278|Hypotension
974831|NCT02137278|Carotid sinus massage
974832|NCT02137278|Tilt table test
974833|NCT02137265|Azoospermia
974834|NCT02137265|Hypogonadism
974835|NCT02137265|Clomiphene
974836|NCT02137252|Invasive Breast Cancer (Stage I-III)
974837|NCT02137252|Ductal Carcinoma in Situ
974838|NCT02137252|Lobular Carcinoma in Situ
974839|NCT02137252|Lobular Carcinoma
974840|NCT02137252|Fatigue Related to Cancer Treatment
974841|NCT02137213|Opioid-induced constipation
974842|NCT02137213|Methadone
974843|NCT02137213|Naloxone
974844|NCT02137187|Atrial fibrillation
974845|NCT02137187|Heart failure
974846|NCT02137187|Catheter ablation
974847|NCT02137187|Cardiac resynchronization therapy
974848|NCT02137187|Implantable defibrillator
974849|NCT02137148|Vascular Access
974850|NCT02137148|Sonic Window
974851|NCT02137148|Ultrasound
974852|NCT02137135|chronic postoperative pain
974853|NCT02137135|menstrual cycle
974854|NCT02137122|Volunteers
974855|NCT02137109|Pediatric
974856|NCT02137096|Recurrent nasopharynx carcinoma
974857|NCT02137083|Chemotherapy
974858|NCT02137083|Endocrine therapy
974859|NCT02137083|Docetaxel
974860|NCT02137083|Fulvestrant
974861|NCT02137070|Weightloss and brain function
974862|NCT02137070|Effects of bariatric surgery on brain function
974863|NCT02137070|Reduced glucose insulin changes and brain function
974864|NCT02137057|Heart Rate Variability
974865|NCT02137057|spinal anesthesia
974866|NCT02137057|DM
974867|NCT02137057|cardiac autonomic dysfunction
974868|NCT02137044|multiple sclerosis
974869|NCT02137044|pain
974870|NCT02137044|depression
974871|NCT02137018|hernia
974872|NCT02137018|incisional hernia
974873|NCT02137018|device
974874|NCT02137018|pig
974881|NCT02136953|Obsessive-Compulsive Disorder
974882|NCT02136953|Exercise
974883|NCT02136953|Cognitive Behavior Therapy
974884|NCT02136953|Cognitive Behavioral Therapy
974885|NCT02136953|Treatment Efficacy
974886|NCT02136953|Brain-Derived Neurotrophic Factor
974887|NCT02136914|Levodopa Induced Dyskinesia
974888|NCT02136914|LID
974889|NCT02136914|Parkinsonism
974890|NCT02136901|NuSurface
974891|NCT02136901|Meniscus
974892|NCT02136901|Prosthesis
974893|NCT02136901|KOOS
974894|NCT02136888|Ponesimod
974895|NCT02136888|Safety
974896|NCT02136875|COPD
974897|NCT02136875|COPD exacerbation
974898|NCT02136862|Alport syndrome
974899|NCT02136862|kidney disease
974900|NCT02136849|severe intellectual disability, genetic, de novo exome
974901|NCT02136836|Genes, erbB-2
974902|NCT02136836|Prognosis
974903|NCT02136823|Spinal Cord Injury
974904|NCT02136810|Hypertension
974905|NCT02136810|Perioperative Care
974906|NCT02136797|CMVpp65 Specific T-cells
974907|NCT02136797|Allogeneic Hematopoietic Stem Cell Transplantation
974908|NCT02136797|14-070
974909|NCT02136784|pain
974910|NCT02136784|cold presser test
974911|NCT02136784|buprenorphine
974912|NCT02136784|opioids
974913|NCT02136758|lifestyle modification
974914|NCT02136758|diet
974915|NCT02136758|exercise
974916|NCT02136758|cardiovascular disease
974917|NCT02136758|gene expression
974918|NCT02136758|obesity
974919|NCT02136745|Irritable Bowel Syndrome
974920|NCT02136745|Inflammatory Bowel Disease
974921|NCT02136745|mind body
974922|NCT02136745|intervention
974923|NCT02136745|group
974924|NCT02136745|Relaxation Response
974925|NCT02136745|genomic effects
974926|NCT02136732|chronic conditions
974927|NCT02136732|multimorbid
974928|NCT02136719|Uterine massage
974929|NCT02136719|vaginal birth
974930|NCT02136719|postpartum haemorrhage
974931|NCT02136706|Stable coronary artery disease
974932|NCT02136693|obstructed defecation
974933|NCT02136693|STARR
974934|NCT02136693|constipation
974935|NCT02136693|incontinence
974936|NCT02136693|psyllium
974937|NCT02136680|HIV disease
974938|NCT02136680|palliative care
974939|NCT02136680|educational intervention
974940|NCT02136667|Preeclampsia
974941|NCT02136667|Cardiovascular disease (CVD) risk
974942|NCT02136654|diabetes
974943|NCT02136654|ethnicity
974944|NCT02136654|South Asian
974945|NCT02136654|diabetes management
974946|NCT02136641|Anesthesia
974947|NCT02136641|Spinal Anesthesia
974948|NCT02136641|Conscious Sedation
974949|NCT02136641|Operating Rooms.
974950|NCT02136628|RTL Technique
974951|NCT02136615|hyperbaric oxygenation
974952|NCT02136615|insulin sensitivity
974953|NCT02136615|human
974954|NCT02136615|inflammation
974955|NCT02136615|adipose tissue
974956|NCT02136563|Chronic kidney disease
974957|NCT02136563|Erythropoiesis stimulating agent response index
974958|NCT02136563|Hyporesponsive anemia to erythropoiesis stimulating agent
974959|NCT02136563|Observational study
974960|NCT02136550|smoking
974961|NCT02136550|smoking cessation
974962|NCT02136550|mucociliary clearance
974963|NCT02136550|proteomics
974964|NCT02136550|miRNA
974965|NCT02136498|smoking cessation
974966|NCT02136498|varenicline
974967|NCT02136498|adherence
974968|NCT02136472|Subfertility
974969|NCT02136472|Metabolic syndrome
974970|NCT02136472|Plasma volume
974971|NCT02136472|Intima media thickness
974972|NCT02136472|Flow mediated dilatation
974973|NCT02136459|Thyroidectomy
974974|NCT02136459|Endotracheal tube
974975|NCT02136459|Voice
974976|NCT02136459|Complications
974977|NCT02136459|Patients undergoing elective thyroidectomy
974978|NCT02136446|Paravertebral block
974979|NCT02136446|Mastectomy
974980|NCT02136446|Post-operative pain
974981|NCT02136446|Echogenic
974982|NCT02136446|Peripheral nerve block catheter
974983|NCT02136433|Hand
974984|NCT02136433|Rehabilitation
974985|NCT02136433|Stroke
974986|NCT02136433|Brain-injury
974987|NCT02136433|Tablet
974988|NCT02136407|Vitamin D
974989|NCT02136407|vitamin D deficiency
974990|NCT02136407|parathyroid hormone
974991|NCT02136381|Lifestyle, interventions, retirement
974992|NCT02136368|older adults
974993|NCT02136368|multiple-modality exercise
974994|NCT02136368|mind-motor exercise
974995|NCT02136368|self-reported cognitive complaints
974996|NCT02136368|global cognitive functioning
974997|NCT02136368|mobility
974998|NCT02136368|vascular function
974999|NCT02136368|sensorimotor function
975000|NCT02136368|brain imaging
975001|NCT02136368|community-based research
975002|NCT02136368|subjective cognitive complaints
975003|NCT02136342|no available effective treatment
975004|NCT02136316|Healthy volunteers
975005|NCT02136316|ASP7962
975006|NCT02136316|pharmacokinetics
975007|NCT02136290|Weight loss
975008|NCT02136277|colorectal surgery
975009|NCT02136277|cardiac output
975010|NCT02136264|hypertension
975011|NCT02136264|dietary intervention
975012|NCT02136264|personalized nutrition
975013|NCT02136264|randomized controlled trial
975014|NCT02136251|Total Shoulder Arthroplasty
975015|NCT02136251|Glenoid anchor peg component fixation
975016|NCT02136251|Autologous bone grafting
975017|NCT02136238|amputation
975018|NCT02136238|transradial
975019|NCT02136238|prosthesis
975020|NCT02136238|terminal device
975021|NCT02136225|youth
975022|NCT02136225|gun
975023|NCT02136225|access
975024|NCT02136225|home
975025|NCT02136186|home telemonitoring
975026|NCT02136186|readmission
975027|NCT02136186|high risk
975028|NCT02136160|elementary school
975029|NCT02136160|children
975030|NCT02136160|health promotion
975031|NCT02136160|teachers
975032|NCT02136160|prevention
975033|NCT02136147|Attention Deficit Disorder with Hyperactivity
975034|NCT02136147|Neuropsychiatry
975035|NCT02136147|Drug therapy
975036|NCT02136147|Pharmacogenetics
975037|NCT02136147|Child Psychiatry
975038|NCT02136134|Multiple Myeloma
975039|NCT02136134|Plasmacytoma
975040|NCT02136134|Refractory Multiple Myeloma
975041|NCT02136134|Relapsed Multiple Myeloma
975042|NCT02136134|Daratumumab
975043|NCT02136134|VELCADE
975044|NCT02136108|Chronic pain
975045|NCT02136108|Complementary and alternative therapies
975046|NCT02136108|Mobile health
975047|NCT02136108|Medicaid
975048|NCT02136108|Patient navigation
975049|NCT02136095|Fluorescent cholangiography
975050|NCT02136095|Laparoscopic cholecystectomy
975051|NCT02136082|HIV
975052|NCT02136082|Women
975053|NCT02136082|Children
975054|NCT02136082|Nutrition
975055|NCT02136056|Sick-leave
975056|NCT02136056|Return to work
975057|NCT02136056|Self-management
975058|NCT02136056|Self-efficacy
975059|NCT02136056|Quality of Life and Well-being
975060|NCT02136056|Motivation
975061|NCT02136030|Cryptococcal meningitis
975062|NCT02136017|AEFI
975063|NCT02136017|influenza vaccine
975064|NCT02136004|arteriotomy
975065|NCT02136004|vessel closure
975066|NCT02136004|femoral access site
975067|NCT02135978|Spinal Cord Injury
975068|NCT02135978|Shoulder Pain
975069|NCT02135978|Exercise
975070|NCT02135952|Periodontitis
975071|NCT02135952|Diabetes
975072|NCT02135926|Cerebral Stroke, Stroke, Acute, Brain Infarction
975073|NCT02135913|Obese
975074|NCT02135913|Children
975075|NCT02135913|Vitamin D deficiency
975076|NCT02135913|Low HDL
975077|NCT02135900|Heliox
975078|NCT02135900|Obstructive Sleep Apnea
975079|NCT02135887|Stage III Colorectal Cancer
975080|NCT02135887|Grade 4 Neutropenia
975081|NCT02135887|MB-6
975082|NCT02135874|Leukemia
975083|NCT02135874|Mixed Phenotype Acute Leukemia
975084|NCT02135874|MPAL
975085|NCT02135874|Newly Diagnosed
975086|NCT02135874|Relapsed
975087|NCT02135874|Clofarabine
975088|NCT02135874|Clofarex
975089|NCT02135874|Clolar
975090|NCT02135874|Idarubicin
975091|NCT02135874|Idamycin
975092|NCT02135874|Cytarabine
975093|NCT02135874|Ara-C
975094|NCT02135874|Cytosar
975095|NCT02135874|DepoCyt
975096|NCT02135874|Cytosine arabinosine hydrochloride
975097|NCT02135874|Vincristine
975098|NCT02135874|Rituximab
975099|NCT02135874|Rituxan
975100|NCT02135874|Dexamethasone
975101|NCT02135874|Decadron
975102|NCT02135861|Acute decompensated heart failure
975103|NCT02135861|heart failure
975104|NCT02135861|MRI
975105|NCT02135861|trpV4 channel inhibitors
975106|NCT02135861|pulmonary oedema
975107|NCT02135822|nanoparticle albumin-bound paclitaxel
975108|NCT02135822|gemcitabine
975109|NCT02135822|advanced pancreatic cancer
975110|NCT02135796|Septic Shock
975111|NCT02135796|Severe Sepsis
975112|NCT02135796|ICU
975113|NCT02135770|heparin
975114|NCT02135770|sepsis
975115|NCT02135770|inflammation
975116|NCT02135744|Chronic Obstructive Pulmonary Disease
975117|NCT02135744|COPD
975118|NCT02135744|Readmissions
975119|NCT02135718|ELLIPTA
975120|NCT02135718|Asthma
975121|NCT02135718|Inhaler preference
975122|NCT02135718|Fluticasone furoate
975123|NCT02135718|ELLIPTA inhaler
975124|NCT02135718|Dry Powder Inhaler
975125|NCT02135692|Severe eosinophilic asthma
975126|NCT02135692|Extension study
975127|NCT02135692|Expanded access
975128|NCT02135692|Safety
975129|NCT02135692|Mepolizumab
975130|NCT02135692|Eosinophils
975131|NCT02135666|Twinrix
975132|NCT02135666|Long-term follow-up
975133|NCT02135666|Persistence
975134|NCT02135666|Hepatitis A
975135|NCT02135666|Antibody
975136|NCT02135666|Immunity
975137|NCT02135666|Hepatitis B
975138|NCT02135666|Combination vaccine
975139|NCT02135666|Adult
975140|NCT02135601|colonoscopy
975141|NCT02135601|water
975142|NCT02135601|adenoma
975143|NCT02135601|pain
975144|NCT02135575|premenopausal
975145|NCT02135575|postmenopausal
975146|NCT02135575|cardiovascular
975147|NCT02135575|exercise training
975148|NCT02135575|vascular function
975149|NCT02135575|cardiac function
975150|NCT02135575|cardiac morphology
975151|NCT02135575|health
975152|NCT02135562|endometrial cancer
975153|NCT02135562|survivor
975154|NCT02135562|obesity
975155|NCT02135562|diet
975156|NCT02135562|high protein
975157|NCT02135562|protein-sparing modified fast intervention
975158|NCT02135562|PSMF
975159|NCT02135523|ovarian cancer
975160|NCT02135523|involved-field radiation therapy
975161|NCT02135523|progression free survival
975162|NCT02135484|Prostate Cancer
975163|NCT02135484|Adenocarcinoma of the prostate
975164|NCT02135484|Castrate resistant prostate cancer
975165|NCT02135484|CRPC
975166|NCT02135484|Skeletal metastases
975167|NCT02135484|Alpharadin
975168|NCT02135484|Xofigo
975169|NCT02135484|Radium-223 chloride
975170|NCT02135484|Radium-223 dichloride
975171|NCT02135471|gingival recession
975172|NCT02135471|dental enamel proteins
975173|NCT02135471|acellular dermal matrix graft
975174|NCT02135471|tobacco
975175|NCT02135458|Heart failure
975176|NCT02135458|Telemonitoring
975177|NCT02135458|therapeutic education
975178|NCT02135458|care network
975179|NCT02135458|hospitalization
975180|NCT02135445|Drug therapy
975181|NCT02135432|Chronic Obstructive pulmonary disease, Ivacaftor
975182|NCT02135406|Adult
975183|NCT02135406|18 years or older
975184|NCT02135406|multiple myeloma
975185|NCT02135406|poor prognosis
975186|NCT02135406|relapsed/progressive disease
975187|NCT02135406|within one year of first autologous stem cell transplantation
975188|NCT02135367|PRP
975189|NCT02135367|growth factors
975190|NCT02135367|Viscosupplementation
975191|NCT02135367|injections
975192|NCT02135367|chondropathy
975193|NCT02135367|randomized controlled trial
975194|NCT02135354|AECOPD
975195|NCT02135354|Chronic Obstructive Pulmonary Disease
975196|NCT02135354|Acute exacerbation
975197|NCT02135354|Hospitalization
975198|NCT02135354|Azithromycin
975199|NCT02135354|Macrolides
975200|NCT02135354|Randomized Controlled Trial
975201|NCT02135354|Placebo
975202|NCT02135341|Detrusor Overactivity
975203|NCT02135341|Impaired Contractility
975204|NCT02135341|Botulinum Toxin A (BoNT-A)
975205|NCT02135328|Type 2 diabetes
975206|NCT02135328|Dietary behaviors
975207|NCT02135328|Physical activity behaviors
975208|NCT02135328|Radio story, entertainment health education
975209|NCT02135328|Immigrants
975210|NCT02135328|Somali, Latino, Hmong
975211|NCT02135328|Families with 3-18 year old children
975212|NCT02135315|Acute Coronary Syndrome, arterial pressure
975213|NCT02135302|hepatic
975214|NCT02135250|Traditional Chinese Medicine
975215|NCT02135211|non-small cell lung cancer (NSCLC)
975216|NCT02135211|multiple risk factor
975217|NCT02135211|lifestyle intervention
975218|NCT02135211|health behavior
975219|NCT02135211|lifestyle risk reduction
975220|NCT02135211|health related quality of life
975221|NCT02135198|GABA modulator
975222|NCT02135198|AZD7325
975223|NCT02135198|Short interval intracortical inhibition
975224|NCT02135198|volunteers
975225|NCT02135146|Hypotension
975226|NCT02135146|Kidney injury
975227|NCT02135133|Chronic Lymphocytic Leukemia
975228|NCT02135133|Small Lymphocytic Lymphoma
975229|NCT02135107|Gastroesophageal reflux disease
975230|NCT02135094|trapezius
975231|NCT02135094|upper back
975232|NCT02135094|muscle pain
975233|NCT02135094|pain relief
975234|NCT02135094|ultrasound
975235|NCT02135094|double blind
975236|NCT02135094|Sam
975237|NCT02135094|ZetrOZ
975238|NCT02135094|muscle
975239|NCT02135094|LITUS
975240|NCT02135094|low intensity therapeutic ultrasound
975241|NCT02135081|Single ventricle
975242|NCT02135081|Hypoplastic Left Heart Syndrome
975243|NCT02135081|Congenital heart lesion
975244|NCT02135081|Right or left ventricle
975245|NCT02135081|Cerebral blood flow
975246|NCT02135081|Pulmonary blood flow
975247|NCT02135081|Staged Fontan reconstruction
975248|NCT02135081|hemi Fontan/bidirectional Glenn stages
975249|NCT02135068|type 1 diabetes
975250|NCT02135068|closed loop insulin delivery systems
975251|NCT02135068|exercise
975252|NCT02135068|hypoglycemia
975253|NCT02135055|organ function
975254|NCT02135055|sedation
975255|NCT02135029|Hyperlipidemia
975256|NCT02135029|statin intolerance
975257|NCT02135016|effect-site concentration
975258|NCT02135016|propofol
975259|NCT02135016|thoracic epidural anesthesia
975260|NCT02134990|Carcinoma, Non-Small-Cell Lung
975261|NCT02134990|Docetaxel
975262|NCT02134977|Pharmacological therapy
975263|NCT02134964|Safety
975264|NCT02134964|Tolerability
975265|NCT02134964|Pharmacokinetics
975266|NCT02134964|Dose escalation
975267|NCT02134964|Randomized
975268|NCT02134964|Healthy volunteers
975269|NCT02134964|OLT1177
975270|NCT02134964|Olatec
975271|NCT02134899|Autosomal dominant polycystic kidney disease
975272|NCT02134899|cyst
975273|NCT02134899|kidney
975274|NCT02134899|liver
975275|NCT02134899|kidney transplantation
975276|NCT02134899|IF/TA
975277|NCT02134899|fibrosis
975278|NCT02134899|DSA
975279|NCT02134899|mTOR inhibitors
975280|NCT02134899|calcineurin inhibitors
975281|NCT02134873|Pain
975282|NCT02134873|Pain management
975283|NCT02134873|Hospitalized
975284|NCT02134873|Infants
975285|NCT02134873|Sucrose
975286|NCT02134847|Resident
975287|NCT02134847|Fatigue
975288|NCT02134847|Sleep deprivation
975289|NCT02134847|medical errors
975290|NCT02134808|Major Depressive Disorder
975291|NCT02134808|Creatine
975292|NCT02134808|Brain Chemistry
975293|NCT02134808|Magnetic Resonance Spectroscopy
975294|NCT02134808|Treatment Resistance
975295|NCT02134808|Selective Serotonin Reuptake Inhibitor (SSRI) Resistance
975296|NCT02134795|Parkinson's disease
975297|NCT02134782|Randomized Controlled Trial, yoga, children, chemotherapy, haematopoietic stem cell transplantation, fatigue, quality of life
975298|NCT02134769|catheter-related bloodstream infections
975299|NCT02134756|Supplement impact
975300|NCT02134756|Performance
975301|NCT02134756|Fatigue
975302|NCT02134743|dental implant
975303|NCT02134743|Surface energy
975304|NCT02134743|Hydrophilicity
975305|NCT02134743|Contact angle
975306|NCT02134743|Titanium implant roughness
975307|NCT02134743|Surface conditioning
975308|NCT02134730|FRIENDS for life
975309|NCT02134730|universal prevention
975310|NCT02134730|school children
975311|NCT02134730|anxiety
975312|NCT02134717|sarcoidosis
975313|NCT02134717|CCR5 inhibition
975314|NCT02134717|maraviroc
975315|NCT02134691|Posttraumatic Stress Disorder (PTSD)
975316|NCT02134691|Prolonged Exposure (PE)
975317|NCT02134678|self-system therapy
975318|NCT02134678|cognitive therapy
975319|NCT02134678|depression
975320|NCT02134678|psychotherapy
975321|NCT02134678|mechanisms of action
975322|NCT02134665|Vancomycin
975323|NCT02134665|severe acute pancreatitis
975324|NCT02134665|Creatinine clearance
975325|NCT02134652|Ultrasonography
975326|NCT02134652|World Health
975327|NCT02134626|Portal Hypertension
975328|NCT02134626|Hepatic Venous Pressure Gradient
975329|NCT02134626|Esophageal Varices
975330|NCT02134626|Liver Cirrhosis
975331|NCT02134626|Simvastatin
975332|NCT02134626|Nitric oxide
975333|NCT02134626|HVPG
975334|NCT02134613|99mTc-anti-TNF
975335|NCT02134613|Inflammation
975336|NCT02134613|Psoriatic arthritis
975337|NCT02134613|Rheumatoid arthritis
975338|NCT02134600|Omega-3 fatty acids
975339|NCT02134600|DHA
975340|NCT02134600|EPA
975341|NCT02134600|Docosahexaenoic acid
975342|NCT02134600|Eicosapentaenoic acid
975343|NCT02134600|Childhood cancer
975344|NCT02134600|Body composition
975345|NCT02134600|Inflammation
975346|NCT02134600|Neuropsychiatric symptoms
975347|NCT02134587|Health knowledge, attitudes, practices.
975348|NCT02134587|Adverse drug reaction reporting systems.
975349|NCT02134587|Pharmacovigilance. Product Surveillance, Postmarketing.
975350|NCT02134587|Drug-related side effects and adverse reactions.
975351|NCT02134574|Lymphoma,
975352|NCT02134574|leukemia,
975353|NCT02134574|multiple myeloma,
975354|NCT02134574|hodgkin disease
975355|NCT02134522|non alcoholic fatty liver
975356|NCT02134522|childhood obesity
975357|NCT02134522|Sleep Apnea
975358|NCT02134509|Cigarette smoking
975359|NCT02134496|hip
975360|NCT02134496|knee
975361|NCT02134496|arthroplasty
975362|NCT02134496|spinal
975363|NCT02134496|anesthesia
975364|NCT02134483|Parathyroid
975365|NCT02134483|Permanent hypocalcemia
975366|NCT02134483|Transplantation
975367|NCT02134470|saliva
975368|NCT02134470|blood
975369|NCT02134470|urine
975370|NCT02134444|Dizziness
975371|NCT02134444|Vertigo
975372|NCT02134444|Vestibular Diseases
975373|NCT02134444|Vestibular Neuritis
975374|NCT02134444|Labyrinth Diseases
975375|NCT02134444|Ear Diseases
975376|NCT02134444|Vestibular rehabilitation
975377|NCT02134444|Telerehabilitation
975378|NCT02134444|Gaze control
975379|NCT02134444|Balance
975380|NCT02134431|HIV
975381|NCT02134431|tenofovir
975382|NCT02134431|miocrobicide
975383|NCT02134431|endoscopy (colonoscopy, sigmoidoscopy)
975384|NCT02134431|adolescents
975385|NCT02134431|pediatrics
975386|NCT02134418|Schizophrenia
975387|NCT02134418|Irony
975388|NCT02134418|Hemispheric processing
975389|NCT02134418|Theory of mind
975390|NCT02134405|functional dyspepsia
975391|NCT02134405|symptoms
975392|NCT02134405|proton pump inhibitor
975393|NCT02134405|gastritis
975394|NCT02134392|C-diff
975395|NCT02134392|Clostridium difficile
975396|NCT02134392|Fecal Transplant
975397|NCT02134392|FMT
975398|NCT02134392|Fecal Microbiota Transplant
975399|NCT02134379|Thoracic Impedance
975400|NCT02134379|Diagnostic Marker
975401|NCT02134379|Bed Rest Test
975402|NCT02134379|Transthoracic Impedance
975403|NCT02134379|Heart Failure
975404|NCT02134379|HF
975405|NCT02134366|Epilepsia Partialis Continua
975406|NCT02134366|Kojewnikov's Epilepsy
975407|NCT02134366|Epilepsy
975408|NCT02134366|Clobazam
975409|NCT02134366|Focal Motor Epilepsy
975410|NCT02134366|Partial Motor Seizure
975411|NCT02134340|IGF1R
975412|NCT02134314|ESRD
975413|NCT02134314|CKD
975414|NCT02134314|Kidney Transplant
975415|NCT02134314|ECD
975416|NCT02134314|delayed graft function
975417|NCT02134301|oritavancin
975418|NCT02134301|pediatrics
975419|NCT02134301|gram positive
975420|NCT02134301|bacterial infection
975421|NCT02134301|Confirmed
975422|NCT02134301|Suspected
975423|NCT02134288|Dialysis
975424|NCT02134288|Kidney Transplant
975425|NCT02134288|immunosuppressive therapy
975426|NCT02134288|Delayed Graft Function
975427|NCT02134288|Belatacept
975428|NCT02134275|whole body vibration training
975429|NCT02134275|young adult
975430|NCT02134275|weight gain
975431|NCT02134275|obesity
975432|NCT02134275|randomized clinical trial
975433|NCT02134262|Anti-CD19 CAR Expressing T cells Therapy
975434|NCT02134262|CD19 CAR Gene-Transduced Lymphocyte
975435|NCT02134262|Adoptive Immunotherapy
975436|NCT02134262|Genetically Engineered Lymphocyte Therapy
975437|NCT02134262|Retroviral Vector
975438|NCT02134262|Burkitt Lymphoma
975439|NCT02134262|Lymphoma
975440|NCT02134262|Lymphoma, Follicular
975441|NCT02134262|Lymphoma, Non-Hodgkin
975442|NCT02134262|Lymphomatoid Granulomatosis
975443|NCT02134262|Lymphoma, B-Cell
975444|NCT02134262|Lymphoma, Large B-Cell, Diffuse
975445|NCT02134262|Lymphoma, Large-Cell, Immunoblastic
975446|NCT02134262|Lymphoma, B-Cell, Marginal Zone
975447|NCT02134262|Lymphoma, Extranodal NK-T-Cell
975448|NCT02134262|Lymphoma, Mantle-Cell
975449|NCT02134262|Neoplasms by Histologic Type
975450|NCT02134262|Neoplasms
975451|NCT02134262|Neoplasms, Experimental
975452|NCT02134262|Immune System Diseases
975453|NCT02134249|infertility
975454|NCT02134249|ICSI
975455|NCT02134249|OHSS
975456|NCT02134249|Diosmin
975457|NCT02134249|Cabergoline
975458|NCT02134210|PsO
975459|NCT02134197|Oncology
975460|NCT02134197|Solid tumors
975461|NCT02134197|Antibody drug conjugate
975462|NCT02134197|Maximum tolerated dose
975463|NCT02134171|Thrombotic microangiopathy,
975464|NCT02134171|haemolytic uremic syndrome,
975465|NCT02134171|thrombotic thrombocytopenic purpura,
975466|NCT02134171|ADAMTS13,
975467|NCT02134171|troponin,
975468|NCT02134171|plasma exchange.
975469|NCT02134158|tDCS, gait disorders, equilibrium, hemiplegic, stroke
975470|NCT02134145|Mobile Health
975471|NCT02134145|mHealth
975472|NCT02134145|Technology
975473|NCT02134132|Platelet gel
975474|NCT02134132|diabetic foot ulcer
975475|NCT02134132|umbilical cord blood
975476|NCT02134119|dietary supplement
975477|NCT02134119|endurance athletes
975478|NCT02134119|VO2max
975479|NCT02134119|red blood cells
975480|NCT02134106|Multicenter
975481|NCT02134106|Open-label
975482|NCT02134106|Randomized
975483|NCT02134106|Controlled
975484|NCT02134106|RCT
975485|NCT02134106|antibiotic
975486|NCT02134106|drug-resistant
975487|NCT02134106|Gram-negative
975488|NCT02134106|bacteria
975489|NCT02134080|Tourette Syndrome
975490|NCT02134080|FAAH-Inhibitor
975491|NCT02134080|Tics
975492|NCT02134080|Tic Disorders
975493|NCT02134067|advanced solid tumors
975494|NCT02134067|tumor
975495|NCT02134067|Dose Escalation
975496|NCT02134067|TAS-119
975497|NCT02134067|Taxane
975498|NCT02134067|Paclitaxel
975499|NCT02134067|Aurora A kinase inhibitor
975500|NCT02134067|AurA
975501|NCT02134054|Therapeutic drug monitoring
975502|NCT02134054|Biological treatment
975503|NCT02134054|IBD
975504|NCT02134041|traumatic brain injury
975505|NCT02134041|Alzheimer disease
975506|NCT02134015|Carcinoma
975507|NCT02134015|Non-Small-Cell Lung
975508|NCT02134015|Lung Neoplasms
975509|NCT02134015|Bronchogenic
975510|NCT02134015|Bronchial Neoplasms
975511|NCT02134015|Respiratory Tract Neoplasms
975512|NCT02134015|Thoracic Neoplasms
975513|NCT02134015|Neoplasms by Site
975514|NCT02134015|Neoplasms
975515|NCT02134015|Lung Diseases
975516|NCT02134015|Respiratory Tract Diseases
975517|NCT02134015|Erlotinib
975518|NCT02134015|Therapeutic Uses
975519|NCT02134015|Pharmacologic Actions
975520|NCT02134015|Molecular Mechanisms of Pharmacological Action
975521|NCT02134002|cocaine
975522|NCT02134002|disulfiram
975523|NCT02134002|beta-dopamine hydroxylase
975524|NCT02133989|Carotid stenosis
975525|NCT02133989|Stenting
975526|NCT02133989|Clopidogrel resistance
975527|NCT02133989|Stroke, ischemic
975528|NCT02133976|chronic low back pain
975529|NCT02133976|psychosocial interventions
975530|NCT02133976|mechanisms
975531|NCT02133963|depression
975532|NCT02133963|postpartum depression
975533|NCT02133963|pregnancy
975534|NCT02133963|perinatal depression
975535|NCT02133963|sleep
975536|NCT02133963|life stress
975537|NCT02133950|preimplantation genetic diagnosis
975538|NCT02133950|cryopreservation
975539|NCT02133950|pregnancy
975540|NCT02133924|Graft vs Host Disease
975541|NCT02133924|Graft vs Host Reaction
975542|NCT02133924|allogeneic bone marrow transplantation
975543|NCT02133924|allogeneic hematopoietic stem cell transplantation
975544|NCT02133924|adverse effects
975545|NCT02133898|Depression
975546|NCT02133898|MTHFR
975547|NCT02133898|L-methylfolate
975548|NCT02133885|Resistent Hypertension
975549|NCT02133885|Systolic Blood Pressure
975550|NCT02133872|Resistent Hypertension
975551|NCT02133846|4RT, CBS, PSP, CBD, TPI-287
975552|NCT02133820|Healthy Volunteer
975553|NCT02133820|Pharmacokinetics
975554|NCT02133807|Lipoprotein(a);
975555|NCT02133807|Lp(a) immunoadsorption;
975556|NCT02133807|Apheresis;
975557|NCT02133807|Coronary atherosclerosis;
975558|NCT02133807|Carotid Atherosclerosis;
975559|NCT02133807|Intima-media thickness;
975560|NCT02133807|Regression;
975561|NCT02133807|Quantitative Coronary Angiography;
975562|NCT02133807|Intravascular Ultrasound;
975563|NCT02133807|Virtual Histology;
975564|NCT02133807|Plaque;
975565|NCT02133807|Atorvastatin;
975566|NCT02133794|Hip fracture
975567|NCT02133794|Tomosynthesis
975568|NCT02133794|X-ray
975569|NCT02133794|Emergency room
975570|NCT02133781|Inactivated influenza vaccine
975571|NCT02133781|Live, attenuated influenza vaccine
975572|NCT02133781|Child identical twins
975573|NCT02133781|Young and elderly adults
975574|NCT02133742|Axitinib and MK-3475
975575|NCT02133742|patients with advanced Renal Cell Cancer.
975576|NCT02133716|pain
975577|NCT02133716|premature infant
975578|NCT02133716|sucrose
975579|NCT02133716|breastfeeding
975580|NCT02133716|expressed breast milk
975581|NCT02133716|PIPP
975582|NCT02133703|Genetic counseling
975583|NCT02133703|genetic testing
975584|NCT02133703|BRCA1
975585|NCT02133703|BRCA2
975586|NCT02133703|Hereditary breast cancer
975587|NCT02133703|Hereditary ovarian cancer
975588|NCT02133690|rotavirus
975589|NCT02133690|rotavirus vaccine
975590|NCT02133690|BRV-PV
975591|NCT02133677|lung cancer and breast cancer patients with brain metastases
975592|NCT02133664|multiple sclerosis
975593|NCT02133664|cognition
975594|NCT02133664|clinical trial
975595|NCT02133664|thiotic acid
975596|NCT02133664|Omega-3 fatty acids
975597|NCT02133651|Clostridium difficile
975598|NCT02133651|Intestinal Microbiota Transplantation
975599|NCT02133651|Diarrhea
975600|NCT02133651|Fecal Microbiota Transplant
975601|NCT02133638|Delirium
975602|NCT02133638|Hypoxic Brain Damage
975603|NCT02133638|Propofol
975604|NCT02133638|S100b protein
975605|NCT02133638|Sevoflurane
975606|NCT02133625|Advanced solid tumor
975607|NCT02133625|Metastatic solid tumor
975608|NCT02133612|esophageal cancer
975609|NCT02133612|adjuvant chemotherapy
975610|NCT02133612|esophageal surgery
975611|NCT02133612|paclitaxel
975612|NCT02133612|cisplatin
975613|NCT02133586|Air pollution
975614|NCT02133586|Ozone
975615|NCT02133586|Nitrogen dioxide
975616|NCT02133586|Lung function
975617|NCT02133586|Cytokines
975618|NCT02133573|progesterone
975619|NCT02133573|congenital heart disease
975620|NCT02133573|periventricular leucomalacia
975621|NCT02133573|brain development
975622|NCT02133573|cardiac surgery
975623|NCT02133573|neurodevelopmental disability
975624|NCT02133573|fetus
975625|NCT02133573|fetal neuroprotection
975626|NCT02133560|Sickle cell
975627|NCT02133560|Thalassemia
975628|NCT02133560|Adherence
975629|NCT02133547|Nitric Oxide
975630|NCT02133547|Nose
975631|NCT02133547|Healthy Volunteers
975632|NCT02133547|Kartagener Syndrome
975633|NCT02133547|Primary Ciliary Dyskinesia
975634|NCT02133534|Chronic kidney disease
975635|NCT02133534|High cholesterol
975636|NCT02133521|DLBS1033
975637|NCT02133521|Acute ischemic stroke
975638|NCT02133521|NIHSS
975639|NCT02133521|Barthel Index
975640|NCT02133495|lower eyelid
975641|NCT02133495|retraction
975642|NCT02133469|Effectiveness
975643|NCT02133469|Prevenar
975644|NCT02133469|nasopharyngeal carriage
975645|NCT02133469|vaccine serotype
975646|NCT02133456|safety
975647|NCT02133456|influenza vaccine
975648|NCT02133456|post-marketing
975649|NCT02133443|Mechanical ventilation
975650|NCT02133443|Acute respiratory failure
975651|NCT02133443|Weaning
975652|NCT02133443|Pressure support ventilation
975653|NCT02133443|Neurally adjusted ventilatory assist
975654|NCT02133430|Postoperative delirium
975655|NCT02133417|Quantitative Transmission Ultrasound
975656|NCT02133417|QTUS
975657|NCT02133404|secondary hyperparathyroidism(SHPT)
975658|NCT02133404|Chronic kidney disease(CKD)
975659|NCT02133404|Mineral bone disease(MBD)
975660|NCT02133391|Accountable Care Organization
975661|NCT02133391|Comparative Effectiveness Research
975662|NCT02133391|Immunization/statistics & numerical data
975663|NCT02133391|Medicaid
975664|NCT02133391|Reminder Systems/economics
975665|NCT02133391|Reminder Systems/statistics & numerical data
975666|NCT02133378|Bleeding
975667|NCT02133378|Hemostatic
975668|NCT02133352|pulmonary hypertension
975669|NCT02133352|diastolic dyfunction
975670|NCT02133326|Analgesia
975671|NCT02133326|Third Molar Extraction
975672|NCT02133326|Ibuprofen
975673|NCT02133326|Acetaminophen
975674|NCT02133326|Pain Medicine
975675|NCT02133326|Nonsteroidal
975676|NCT02133326|Anti-inflammatory
975677|NCT02133313|Peritoneal Dialysis
975678|NCT02133313|Peritoneal Fibrosis
975679|NCT02133313|Glucose Transporters
975680|NCT02133274|Neoplasms
975681|NCT02133274|Early Palliative Care
975682|NCT02133274|Psychosocial Intervention
975683|NCT02133274|Symptoms
975684|NCT02133274|Quality of life
975685|NCT02133274|Depression
975686|NCT02133248|donor specific antibodies
975687|NCT02133248|B cells
975688|NCT02133248|antibody mediated rejection
975689|NCT02133248|kidney transplant
975690|NCT02133248|desensitization
975691|NCT02133235|endobronchial blocker
975692|NCT02133235|lung separation
975693|NCT02133235|vedio-assisted thoracic operation
975694|NCT02133209|migraine
975695|NCT02133209|headache
975696|NCT02133209|meditation
975697|NCT02133209|mindfulness based stress reduction
975698|NCT02133209|MBSR
975699|NCT02133196|Metastatic
975700|NCT02133196|Non-Small Cell Lung Cancer
975701|NCT02133196|NSCLC
975702|NCT02133196|Lung Cancer
975703|NCT02133170|BIPOLAR DISORDER
975704|NCT02133170|DEPRESSIVE SYMPTOMS
975705|NCT02133170|MINDFULNESS
975706|NCT02133170|PSYCHOEDUCATION
975707|NCT02133170|BIPOLAR PATIENTS WITH DEPRESSIVE SYMPTOMS
975708|NCT02133157|tumor
975709|NCT02133144|NAFLD
975710|NCT02133144|insulin resistance
975711|NCT02133144|metabolic syndrome
975712|NCT02133144|de novo lipogenesis
975713|NCT02133144|overfeeding
975714|NCT02133118|Type 2 diabetes
975715|NCT02133118|New-user design
975716|NCT02133118|Weight trajectory
975717|NCT02133118|Add-on therapy
975718|NCT02133118|Sulphonylureas.
975719|NCT02133105|Heart failure
975720|NCT02133105|Renal failure
975721|NCT02133105|Inotropic drugs
975722|NCT02133105|Levosimendan
975723|NCT02133105|Dobutamine
975724|NCT02133092|Respiratory syncytial virus
975725|NCT02133092|RSV
975726|NCT02133092|Lower respiratory tract infection
975727|NCT02133092|LRTI
975728|NCT02133092|Acute respiratory infection
975729|NCT02133092|Belgian children
975730|NCT02133066|Ultrasound
975731|NCT02133066|Lumbar Puncture
975732|NCT02133066|Spinal Tap
975733|NCT02133066|Pediatric
975734|NCT02133066|Infant
975735|NCT02133066|Bedside Ultrasonography
975736|NCT02133053|Allergic Rhinitis
975737|NCT02133053|Ectoine
975738|NCT02133053|bitop
975739|NCT02133053|Ectoin
975740|NCT02133040|Brown Adipose Tissue
975741|NCT02133027|Laparoscopic cholecystectomy
975742|NCT02133014|pancreatitis
975743|NCT02133014|laparoscopic
975744|NCT02133014|drainage
975745|NCT02133014|surgery
975746|NCT02133001|Major Depressive Disorder
975747|NCT02133001|Esketamine
975748|NCT02133001|Intranasal esketamine
975749|NCT02133001|Placebo
975750|NCT02132975|prostate
975751|NCT02132975|cancer
975752|NCT02132923|Respiratory syncytial virus
975753|NCT02132923|RSV
975754|NCT02132923|Lower respiratory tract infection
975755|NCT02132923|LRTI
975756|NCT02132923|Acute respiratory infection
975757|NCT02132923|Japanese children
975758|NCT02132897|Antiepileptic
975759|NCT02132897|Carbamazepine
975760|NCT02132897|Bio-equivalence
975761|NCT02132897|Fed
975762|NCT02132897|Crossover
975763|NCT02132832|marijuana
975764|NCT02132832|attentional bias
975765|NCT02132832|stress
975766|NCT02132832|buspirone
975767|NCT02132819|transfusion
975768|NCT02132819|feeding
975769|NCT02132819|TRAGI
975770|NCT02132819|NEC
975771|NCT02132806|class II furcation involvement
975772|NCT02132806|piezoelectric surgery
975773|NCT02132806|regeneration
975774|NCT02132806|biomaterial
975775|NCT02132793|technology
975776|NCT02132793|mobile
975777|NCT02132793|anger management
975778|NCT02132793|anger
975779|NCT02132793|PTSD
975780|NCT02132793|veterans
975781|NCT02132767|Heart surgery
975782|NCT02132767|Cardiac surgery
975783|NCT02132767|Coronary artery bypass
975784|NCT02132767|Mitral valve surgery
975785|NCT02132767|Aortic valve surgery
975786|NCT02132767|Atrial fibrillation
975787|NCT02132767|Atrial flutter
975788|NCT02132767|Cardiac arrhythmia
975789|NCT02132767|Valve surgery
975790|NCT02132741|OCT; hypertension; CKD
975791|NCT02132728|flaxseed
975792|NCT02132728|lignans
975793|NCT02132728|inflammation
975794|NCT02132728|Nutrition
975795|NCT02132728|enterolactone
975796|NCT02132728|enterodiol
975797|NCT02132689|Moderate Risk Acute Pulmonary Embolism
975798|NCT02132676|Self-Management
975799|NCT02132676|Patient Care Management
975800|NCT02132676|Peer Group
975801|NCT02132676|Disease Management
975802|NCT02132676|Health Plan Implementation
975803|NCT02132676|Diabetes Mellitus
975804|NCT02132650|Rehabilitation
975805|NCT02132650|Walking
975806|NCT02132650|Motor skills disorders
975807|NCT02132650|Electromyography
975808|NCT02132598|Lung Cancer
975809|NCT02132598|Non Small Cell
975810|NCT02132598|Brain metastases
975811|NCT02132598|c-MET
975812|NCT02132520|Hemiparesis
975813|NCT02132520|Stroke
975814|NCT02132520|Rehabilitation
975815|NCT02132520|Transcranial Magnetic Stimulation, Repetitive
975816|NCT02132520|Electroencephalography
975817|NCT02132520|Functional Neuroimaging
975818|NCT02132520|Brain-Computer Interface
975819|NCT02132507|epilepsy
975820|NCT02132507|fMRI
975821|NCT02132507|EEG
975822|NCT02132507|ICA
975823|NCT02132481|Smartphones
975824|NCT02132481|Mobile phones
975825|NCT02132481|Substance use disorder
975826|NCT02132481|Recovery Support Services
975827|NCT02132481|Ecological Momentary Assessment (EMA)
975828|NCT02132481|Ecological Momentary Intervention (EMI)
975829|NCT02132481|Randomized field experiment
975830|NCT02132481|Effectiveness
975831|NCT02132481|Post-Discharge
975832|NCT02132468|PNET
975833|NCT02132468|GI-NET
975834|NCT02132468|neuroendocrine
975835|NCT02132468|carcinoid
975836|NCT02132455|Screening colonoscopy
975837|NCT02132455|Surveillance colonoscopy
975838|NCT02132442|Children
975839|NCT02132442|Adolescents
975840|NCT02132442|Adults
975841|NCT02132442|Type 2 diabetes
975842|NCT02132442|Nonalcoholic fatty liver disease
975843|NCT02132442|Vitamin D deficiency
975844|NCT02132429|Migraine
975845|NCT02132416|Prospective study
975846|NCT02132416|Surgical management
975847|NCT02132416|Unstable thoracic cage injuries
975848|NCT02132416|Trauma
975849|NCT02132416|Ventilator support
975850|NCT02132403|pancreatic cancer
975851|NCT02132403|adenocarcinoma of the pancreas (PDAC)
975852|NCT02132403|mixed adenocarcinoma of the pancreas
975853|NCT02132403|locally advanced
975854|NCT02132403|recurrent
975855|NCT02132403|metastatic
975856|NCT02132390|Breast cancer
975857|NCT02132390|Chemotherapy induced amenorrhea
975858|NCT02132390|Goserelin
975859|NCT02132364|stroke
975860|NCT02132364|hypertension
975861|NCT02132364|secondary prevention
975862|NCT02132364|educational program
975863|NCT02132338|Type 2 Diabetes Mellitus
975864|NCT02132338|Prevention
975865|NCT02132338|Health Education
975866|NCT02132325|Pancreatic Cancer
975867|NCT02132325|Dignity Therapy
975868|NCT02132325|Palliative Care
975869|NCT02132325|Advanced Lung Cancer
975870|NCT02132325|Non-Small-Cell Lung Cancer
975871|NCT02132312|Cataract
975872|NCT02132312|Lens replacement
975873|NCT02132312|pediatric
975874|NCT02132299|Malaria
975875|NCT02132299|Plasmodium falciparum malaria
975876|NCT02132299|PfSPZ Vaccine
975877|NCT02132299|PfSPZ Challenge
975878|NCT02132299|Controlled human malaria infection (CHMI)
975879|NCT02132286|Functional magnetic resonance neuroimaging
975880|NCT02132286|Serotonin transporter gene polymorphism
975881|NCT02132286|Amygdala
975882|NCT02132286|Antidepressant
975883|NCT02132286|Quetiapine
975884|NCT02132286|Citalopram
975885|NCT02132286|imaging biomarker
975886|NCT02132260|Naftifine
975887|NCT02132260|Naftin®
975888|NCT02132260|Tinea pedis
975889|NCT02132247|Minor athletic injuries
975890|NCT02132247|Pain
975891|NCT02132247|Diclofenac
975892|NCT02132247|Topical
975893|NCT02132221|Chronic non cancer pain
975894|NCT02132221|Long term opioid therapy
975895|NCT02132221|Side effects
975896|NCT02132221|risks
975897|NCT02132221|function
975898|NCT02132221|negative benefit/risk ratio
975899|NCT02132143|Lung adenocarcinoma
975900|NCT02132143|Concurrent chemoradiotherapy
975901|NCT02132143|Sequential chemoradiotherapy
975902|NCT02132143|Progression-free survival
975903|NCT02132130|gene therapy
975904|NCT02132130|hearing loss
975905|NCT02132130|balance
975906|NCT02132130|vestibular
975907|NCT02132130|cochlear implant
975908|NCT02132104|Intrauterine adhesions
975909|NCT02132104|Asherman Syndrome
975910|NCT02132104|Amnion graft
975911|NCT02132091|Sirtuins
975912|NCT02132091|Calorie Restriction
975913|NCT02132091|Intermittent Fasting
975914|NCT02132091|Antioxidant
975915|NCT02132091|Aging
975916|NCT02132091|Metabolism
975917|NCT02132091|Mitochondria
975918|NCT02132091|Oxidative Stress
975919|NCT02132078|Lung transplant recipients
975920|NCT02132078|diverticulitis
975921|NCT02132078|immunosuppression
975922|NCT02132052|Essential Tremor
975923|NCT02132052|Multiple System Atrophy
975924|NCT02132052|Corticobasal Degeneration
975925|NCT02132052|Supranuclear Palsy, Progressive
975926|NCT02132052|Parkinson's Disease
975927|NCT02132052|PD
975928|NCT02132039|Tai Chi, dementia, caregivers
975929|NCT02132026|Aortic Stenosis
975930|NCT02132026|Denosumab
975931|NCT02132026|Alendronic Acid
975932|NCT02132026|Osteoporosis
975933|NCT02131987|Dislocation
975934|NCT02131987|Hemiarthroplasty
975935|NCT02131987|Femoral neck fracture
975936|NCT02131987|Femoral offset
975937|NCT02131987|Leg length difference
975938|NCT02131987|Wiberg angle
975939|NCT02131974|intubation, pediatric, endotracheal, cuffed ETT
975940|NCT02131961|diabetic foot
975941|NCT02131961|foot ulcer
975942|NCT02131961|foot wound
975943|NCT02131961|plantar ulcer
975944|NCT02131961|plantar wound
975945|NCT02131961|contact cast
975946|NCT02131961|collagenase
975947|NCT02131948|Insulin resistance
975948|NCT02131948|Brain insulin action
975949|NCT02131948|Type 2 Diabetes
975950|NCT02131909|unilateral cerebral palsy
975951|NCT02131909|children
975952|NCT02131909|upper-limb
975953|NCT02131909|mirror therapy
975954|NCT02131909|bimanual coordination
975955|NCT02131909|kinematics analysis
975956|NCT02131896|Type 1 Diabetes
975957|NCT02131896|Newly diagnosed
975958|NCT02131896|Lipid profile
975959|NCT02131896|Mediterranean diet
975960|NCT02131883|Health Anxiety
975961|NCT02131883|Hypochondriasis
975962|NCT02131883|Illness Anxiety Disorder
975963|NCT02131883|Somatic Symptom Disorder
975964|NCT02131883|Personality Disorders
975965|NCT02131883|Cognitive Behavioral Therapy
975966|NCT02131883|Group-CBT
975967|NCT02131883|Illness Perception
975968|NCT02131883|Cost-effectiveness
975969|NCT02131870|iron absorption
975970|NCT02131870|healthy females
975971|NCT02131870|child bearing age
975972|NCT02131857|Mindfulness
975973|NCT02131857|stress reduction
975974|NCT02131844|colorectal surgery
975975|NCT02131844|postoperative recovery
975976|NCT02131844|early mobilization
975977|NCT02131831|telomere
975978|NCT02131831|telomerase
975979|NCT02131831|cirrhosis
975980|NCT02131818|amoxicillin
975981|NCT02131818|postpartum infections
975982|NCT02131818|puerperal infection
975983|NCT02131805|skin
975984|NCT02131805|Brachytherapy
975985|NCT02131805|14-001
975986|NCT02131779|prostate cancer disparities
975987|NCT02131779|African American
975988|NCT02131779|Spiritually based intervention
975989|NCT02131779|Men's Health
975990|NCT02131779|Informed Decision Making
975991|NCT02131779|Community Based Participatory Research
975992|NCT02131779|Health Communication
975993|NCT02131779|Health Information Technology
975994|NCT02131779|Community Health Advisors
975995|NCT02131766|Diabetes Mellitus, Type 1
975996|NCT02131766|Artificial Pancreas Project (APP)
975997|NCT02131766|Diabetes Assistant (DiAs)
975998|NCT02131766|Closed-Loop Control (CLC)
975999|NCT02131753|hairy cell leukemia
976000|NCT02131753|untreated
976001|NCT02131753|cladribine subcutaneous
976002|NCT02131740|corneal
976003|NCT02131740|eye rubbing
976004|NCT02131727|hand hygiene
976005|NCT02131727|communicable diseases
976006|NCT02131727|respiratory tract infections
976007|NCT02131727|primary prevention
976008|NCT02131727|employees
976009|NCT02131714|pressure pain threshold
976010|NCT02131714|temporomandibular disorder syndrome
976011|NCT02131714|therapeutic exercise
976012|NCT02131714|conservative treatment
976013|NCT02131714|facial pain
976014|NCT02131701|Physical fitness
976015|NCT02131701|Family history of type 2 diabetes
976016|NCT02131701|Prescription of exercise
976017|NCT02131688|safety;malignant lymphoma;
976018|NCT02131675|C-peptide
976019|NCT02131675|type 1 diabetes
976020|NCT02131662|Uterine fibroids
976021|NCT02131649|Prostate Cancer
976022|NCT02131649|PET
976023|NCT02131649|MRI
976024|NCT02131649|Fluorocholine
976025|NCT02131649|Radiotherapy
976026|NCT02131649|Prostatectomy
976027|NCT02131610|Sleep apnea
976028|NCT02131610|Obstructive sleep apnea
976029|NCT02131610|Subclinical atherosclerosis
976030|NCT02131610|Epigenetics
976031|NCT02131610|T cells
976032|NCT02131597|Leukemia
976033|NCT02131597|Myelodysplastic syndrome
976034|NCT02131597|MDS
976035|NCT02131597|Higher risk
976036|NCT02131597|SGI-110
976037|NCT02131584|Leukemia
976038|NCT02131584|Chronic Lymphocytic Leukemia
976039|NCT02131584|CLL
976040|NCT02131584|Fatigue
976041|NCT02131584|Brief Fatigue Inventory
976042|NCT02131584|BFI
976043|NCT02131584|Questionnaires
976044|NCT02131584|Surveys
976045|NCT02131584|Ruxolitinib
976046|NCT02131584|Jakafi
976047|NCT02131584|INCB018424
976048|NCT02131584|INC424
976049|NCT02131571|HIV
976050|NCT02131571|bone
976051|NCT02131571|fractures
976052|NCT02131571|vitamin D
976053|NCT02131571|biomarkers
976054|NCT02131558|Endometrial cancer
976055|NCT02131558|Sentinel lymph node
976056|NCT02131558|Indocyanine green
976057|NCT02131558|Near infrared imaging
976058|NCT02131545|quetiapine
976059|NCT02131545|pharmacokinetics
976060|NCT02131545|dementia
976061|NCT02131545|delirium
976062|NCT02131545|palliative care
976063|NCT02131532|Post-stroke fatigue
976064|NCT02131532|Psychological intervention
976065|NCT02131532|Feasibility
976066|NCT02131506|Advanced HER2 positive Breast Cancer
976067|NCT02131506|pretreated breast cancer
976068|NCT02131506|advanced disease
976069|NCT02131454|asthma and COPD treatment
976070|NCT02131454|inhalation techniques
976071|NCT02131454|training of inhalation
976072|NCT02131428|Heart Failure
976073|NCT02131428|Depression
976074|NCT02131428|BNP
976075|NCT02131415|schizophrenia
976076|NCT02131415|real-life
976077|NCT02131415|long-acting injectable
976078|NCT02131415|Reliam
976079|NCT02131389|Hip
976080|NCT02131389|Arthroplasty
976081|NCT02131389|Arthroplasties
976082|NCT02131389|Prosthesis
976083|NCT02131389|Iconacy
976084|NCT02131389|Osteoarthritis
976085|NCT02131389|Arthritis
976086|NCT02131389|THA
976087|NCT02131389|THR
976088|NCT02131389|DJD
976089|NCT02131376|carcinoma, renal cell
976090|NCT02131376|partial nephrectomy
976091|NCT02131376|kidney function test
976092|NCT02131376|robotics
976093|NCT02131324|Psoriasis
976094|NCT02131311|single use
976095|NCT02131311|disposable
976096|NCT02131311|pessary
976097|NCT02131311|stress urinary incontinence
976098|NCT02131311|sui
976099|NCT02131298|Palbociclib
976100|NCT02131298|Itraconazole
976101|NCT02131298|Pharmacokinetics
976102|NCT02131298|Drug-Drug Interaction Study
976103|NCT02131298|Healthy Volunteers
976104|NCT02131285|Rehabilitation,
976105|NCT02131285|Balance,
976106|NCT02131285|Sensory strategies,
976107|NCT02131285|Multiple Sclerosis,
976108|NCT02131285|Postural control
976109|NCT02131220|No-Reflow Phenomenon
976110|NCT02131194|Cataract
976111|NCT02131194|Nutritional Supplement
976112|NCT02131181|Delirium, postoperative delirium, elderly
976113|NCT02131142|ischemic heart disease
976114|NCT02131142|CAD
976115|NCT02131129|schizophrenia
976116|NCT02131129|schizophreniform disorder
976117|NCT02131129|schizoaffective disorder
976118|NCT02131129|first episode
976119|NCT02131129|psychosis
976120|NCT02131129|cognition
976121|NCT02131116|schizophrenia
976122|NCT02131116|schizophreniform disorder
976123|NCT02131116|schizoaffective disorder
976124|NCT02131116|cognition
976125|NCT02131116|metacognition
976126|NCT02131116|insight
976127|NCT02131116|first episode psychosis
976128|NCT02131116|psychosis
976129|NCT02131103|Pharmacoinvasive strategy
976130|NCT02131090|Epidural
976131|NCT02131090|Catheter
976132|NCT02131090|Fixation
976133|NCT02131090|Device
976134|NCT02131090|Intrapartum
976135|NCT02131077|Lateral Epicondylitis
976136|NCT02131051|ectoine
976137|NCT02131051|allergic rhinitis
976138|NCT02131051|bitop
976139|NCT02131038|Ectoine
976140|NCT02131038|bitop
976141|NCT02131038|Allergic Rhinitis
976142|NCT02131012|Macular edema
976143|NCT02130999|Non-24
976144|NCT02130999|absolute bioavailability
976145|NCT02130999|tasimelteon
976146|NCT02130999|Hetlioz™
976147|NCT02130986|procalcitonin (PCT)
976148|NCT02130986|lower respiratory tract infection (LRTI)
976149|NCT02130986|antibiotic exposure
976150|NCT02130986|antibiotic decision making
976151|NCT02130986|community acquired pneumonia (CAP)
976152|NCT02130986|chronic obstructive pulmonary disease (COPD) exacerbation
976153|NCT02130986|acute asthma exacerbation
976154|NCT02130986|acute bronchitis
976155|NCT02130986|procalcitonin guideline
976156|NCT02130973|teriparatide
976157|NCT02130973|Forteo
976158|NCT02130973|Denosumab
976159|NCT02130973|Prolia
976160|NCT02130973|bone density
976161|NCT02130973|treatment
976162|NCT02130960|RMR
976163|NCT02130960|Reliability
976164|NCT02130960|Obese
976165|NCT02130960|Energy Expenditure
976166|NCT02130960|Resting Energy Expenditure
976167|NCT02130960|Resting Metabolic Rate
976168|NCT02130947|Metastatic Castration Resistant Prostate Cancer
976169|NCT02130947|Prostate Cancer
976170|NCT02130947|mCRPC
976171|NCT02130947|Pilot Study
976172|NCT02130947|UNC Lineberger
976173|NCT02130947|Exercise
976174|NCT02130934|Childhood cancer
976175|NCT02130934|anthracyclines
976176|NCT02130934|cardiotoxicity
976177|NCT02130934|cardiac MRI
976178|NCT02130934|cumulative does of at least 150 mg/m2 of anthracyclines
976179|NCT02130934|Ventricular function
976180|NCT02130921|Stigma
976181|NCT02130921|HIV
976182|NCT02130921|CHWs
976183|NCT02130921|PLH
976184|NCT02130921|Injecting Drug Users
976185|NCT02130921|FM
976186|NCT02130895|prescribing
976187|NCT02130895|STOPP Criteria
976188|NCT02130895|potentially inappropriate prescribing
976189|NCT02130895|clinical decision support
976190|NCT02130895|Electronic Medical Records
976191|NCT02130895|primary care
976192|NCT02130882|Interleukin-5
976193|NCT02130882|Monoclonal Antibody
976194|NCT02130882|Treatment
976195|NCT02130869|Autologous stem cell transplantation
976196|NCT02130869|Natural killer cells
976197|NCT02130856|Neonatal mortality
976198|NCT02130856|Neonatal kit
976199|NCT02130856|Pakistan
976200|NCT02130856|Randomized Control Trial
976201|NCT02130856|Chlorhexidine
976202|NCT02130856|ThermoSpot
976203|NCT02130856|Birth
976204|NCT02130843|URINARY INCONTINENCE
976205|NCT02130843|URODYNAMICS
976206|NCT02130843|URINARY RETENTION
976207|NCT02130843|URINARY CATHETERIZATION
976208|NCT02130830|hemorrhoids
976209|NCT02130830|Rubber band ligation
976210|NCT02130830|pain
976211|NCT02130817|Renal Transplant
976212|NCT02130817|Kidney Transplant
976213|NCT02130817|Mean flourescent Intensity
976214|NCT02130817|Delayed Graft Function
976215|NCT02130817|Antagonist of Thymocyte Cell Activation
976216|NCT02130804|Obesity
976217|NCT02130804|Adipose tissue inflammation
976218|NCT02130804|Salsalate
976219|NCT02130804|Hispanics
976220|NCT02130765|Monomorphic Ventricular Tachycardia
976221|NCT02130765|Ischemic
976222|NCT02130765|Non-ischemic
976223|NCT02130765|Catheter Ablation
976224|NCT02130752|Stomach Neoplasms
976225|NCT02130752|Operative Time
976226|NCT02130752|Gastrectomy
976227|NCT02130752|Surgical Hemorrhage
976228|NCT02130752|Mortality
976229|NCT02130752|Morbidity
976230|NCT02130739|Anesthesia
976231|NCT02130739|Epidural
976232|NCT02130739|Thoracic Nerves
976233|NCT02130739|Horner syndrome
976234|NCT02130726|Gastric cancer
976235|NCT02130726|Minimally-invasive
976236|NCT02130726|Oncological quality of resection
976237|NCT02130700|mCRPC
976238|NCT02130700|metastatic
976239|NCT02130700|castration-resistant prostate cancer
976240|NCT02130687|Type 2 Diabetes Mellitus
976241|NCT02130687|Hypertension
976242|NCT02130687|Angiotensin Converting Enzyme Inhibitors
976243|NCT02130687|Dipeptidyl Peptidase IV Inhibitors
976244|NCT02130687|Sitagliptin
976245|NCT02130687|Aprepitant
976246|NCT02130687|Ramipril
976247|NCT02130674|traumatic brain injury
976248|NCT02130674|glutamine
976249|NCT02130674|microdialysis
976250|NCT02130674|metabolism
976251|NCT02130661|drug interaction
976252|NCT02130661|healthy volunteer
976253|NCT02130661|rilapladib
976254|NCT02130661|SB-659032
976255|NCT02130661|Alzheimer's disease
976256|NCT02130661|itraconazole
976257|NCT02130648|Non-invasive Prenatal Diagnosis (NIPD)
976258|NCT02130648|Cystic Fibrosis
976259|NCT02130648|Quantitative real time MEMO-PCR
976260|NCT02130635|PI3Kd
976261|NCT02130635|Pharmacodynamics
976262|NCT02130635|dry powder inhaler
976263|NCT02130635|GSK2269557
976264|NCT02130635|safety
976265|NCT02130635|COPD subjects
976266|NCT02130622|Diabetic Gastroparesis
976267|NCT02130622|Promethazine
976268|NCT02130570|Adverse events
976269|NCT02130570|Readmissions
976270|NCT02130570|Patient Centered Medical Home (PCMH)
976271|NCT02130570|Accountable Care Organizations (ACO)
976272|NCT02130570|Medication reconciliation
976273|NCT02130570|Discharge Advocate
976274|NCT02130570|Patient engagement
976275|NCT02130570|Transitions of care
976276|NCT02130570|Transitions coach
976277|NCT02130570|Pharmacist intervention
976278|NCT02130557|Leukemia
976279|NCT02130557|Myelogenous
976280|NCT02130557|Chronic
976281|NCT02130557|BCR-ABL Positive
976282|NCT02130557|Bosutinib
976283|NCT02130557|Leukemia, Myeloid
976284|NCT02130557|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
976285|NCT02130557|Philadelphia Chromosome
976286|NCT02130557|Neoplasms by Histologic Type
976287|NCT02130557|Bone Marrow Diseases
976288|NCT02130557|Hematologic Diseases
976289|NCT02130557|Translocation, Genetic
976290|NCT02130557|Pathologic Processes
976291|NCT02130557|Imatinib
976292|NCT02130557|Therapeutic Uses
976293|NCT02130557|Pharmacologic Actions
976294|NCT02130557|Molecular Mechanisms of Pharmacological Action
976295|NCT02130466|PD1
976296|NCT02130466|PD-1
976297|NCT02130466|PDL1
976298|NCT02130466|PD-L1
976299|NCT02130453|Ischemia
976300|NCT02130453|Coronary artery disease
976301|NCT02130453|Nuclear stress test
976302|NCT02130453|Stress Echocardiogram
976303|NCT02130453|Echocardiography strain measurement
976304|NCT02130453|Ultrasound cardiac imaging
976305|NCT02130453|ReSTE
976306|NCT02130453|SPECT
976307|NCT02130453|Regadenoson
976308|NCT02130440|nasal obstruction
976309|NCT02130440|sneezing
976310|NCT02130440|itching
976311|NCT02130440|rhinorrhea
976312|NCT02130440|respiratory infections
976313|NCT02130440|wheezing
976314|NCT02130427|Adult subjects
976315|NCT02130427|NSCLC
976316|NCT02130414|Cyclosporine
976317|NCT02130414|Healthy Volunteers
976318|NCT02130414|Immunosuppressive Agents
976319|NCT02130414|CyCol
976320|NCT02130414|Pharmacokinetics
976321|NCT02130401|neuromodulation
976322|NCT02130401|caloric vestibular stimulation
976323|NCT02130401|Type 2 Diabetes
976324|NCT02130362|Adalimumab
976325|NCT02130362|Crohn's
976326|NCT02130362|Crohn's Disease
976327|NCT02130362|Registry
976328|NCT02130362|Gastrointestinal Diseases
976329|NCT02130362|Inflammatory Bowel Diseases
976330|NCT02130349|IBD
976331|NCT02130349|Crohns Disease
976332|NCT02130349|Ulcerative Colitis
976333|NCT02130349|Cohort
976334|NCT02130349|Biobank
976335|NCT02130349|Population based
976336|NCT02130349|IBDSL
976337|NCT02130336|Metabolic syndrome
976338|NCT02130336|Metabolic risk factors
976339|NCT02130336|High-intensity interval training
976340|NCT02130336|Moderate-intensity exercise
976341|NCT02130323|Cervical intraepithelial neoplasia, Imiquimod
976342|NCT02130310|Chronic ulcers
976343|NCT02130310|Venous ulcers
976344|NCT02130297|Mohs
976345|NCT02130297|scar
976346|NCT02130297|post excision
976347|NCT02130297|CO2 laser
976348|NCT02130297|laser
976349|NCT02130297|skin cancer
976350|NCT02130297|resurfacing
976351|NCT02130271|Sciatica
976352|NCT02130271|PET scan
976353|NCT02130271|MRI
976354|NCT02130271|Inflammation
976355|NCT02130271|Epidural Steroid Injection (ESI)
976356|NCT02130258|Radicular
976357|NCT02130258|Pain
976358|NCT02130258|Epidural Steroid Injection
976359|NCT02130245|Laparoscopic cholecystectomy
976360|NCT02130245|Acute cholecystitis
976361|NCT02130245|Early
976362|NCT02130245|Delayed
976363|NCT02130232|Gestational weight gain
976364|NCT02130232|Lifestyle
976365|NCT02130232|Intervention
976366|NCT02130219|ICP, intracranial hypertension, Vittamed 205
976367|NCT02130206|Plaque, Saliva, Cavities
976368|NCT02130193|Efficacy
976369|NCT02130193|Danirixin
976370|NCT02130193|EXACT-PRO
976371|NCT02130193|COPD
976372|NCT02130193|Safety
976373|NCT02130193|RD
976374|NCT02130193|CXCR2 inhibitor
976375|NCT02130193|EXACT-RS
976376|NCT02130193|PK
976377|NCT02130193|HCRU exacerbations
976378|NCT02130193|PD
976379|NCT02130167|Myopia progression
976380|NCT02130167|Low concentration atropine
976381|NCT02130154|Brown adipose Tissue
976382|NCT02130154|Ageing
976383|NCT02130154|Sympathetic Nervous Stimulation
976384|NCT02130154|Obesity
976385|NCT02130141|cocoa
976386|NCT02130141|dark chocolate
976387|NCT02130141|hypertension
976388|NCT02130141|blood pressure monitoring, ambulatory
976389|NCT02130141|flavanols
976390|NCT02130102|technology acceptance
976391|NCT02130102|ambient assisted living
976392|NCT02130102|independent living
976393|NCT02130102|quality of life
976394|NCT02130102|socioeconomic impact
976395|NCT02130102|usability of information and communication technologies
976396|NCT02130063|IDA
976397|NCT02130063|Iron deficiency
976398|NCT02130063|iron deficiency anaemia and who are intolerant or unresponsive to oral iron therapy
976399|NCT02130050|Obstructive Sleep Apnea
976400|NCT02130050|Continuous Positive Airway Pressure
976401|NCT02130050|Cardiovascular disease
976402|NCT02130050|Polysomnography
976403|NCT02130050|Metabolomic
976404|NCT02130037|APPLICATION
976405|NCT02130037|SMARTPHONE
976406|NCT02130037|BULIMIA
976407|NCT02130037|B.E.D
976408|NCT02130037|BINGE EATING DISORDER
976409|NCT02130024|Age-related macular degeneration, ranibizumab, aflibercept, geographic atrophy, inject and extend
976410|NCT02129998|Infertility
976411|NCT02129998|IVF/ICSI
976412|NCT02129998|Progesterone
976413|NCT02129998|Preimplantation Factor (PIF)
976414|NCT02129985|the newly onset type 2 diabetes
976415|NCT02129985|short-term insulin treatment
976416|NCT02129985|exenatide sequential therapy
976417|NCT02129985|beta cell function
976418|NCT02129985|glycaemic remission
976419|NCT02129972|Inflammatory Bowel Disease, colon lesions, colon capsule endoscopy
976420|NCT02129959|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic
976421|NCT02129959|assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
976422|NCT02129946|Type 2 Diabetes
976423|NCT02129946|Resistant Starch
976424|NCT02129946|Postprandial Glucose
976425|NCT02129946|Postprandial Insulin
976426|NCT02129946|Satiety
976427|NCT02129933|EAC
976428|NCT02129933|HGD
976429|NCT02129933|Esophagus
976430|NCT02129920|Stroke
976431|NCT02129920|Cerebral Infarction
976432|NCT02129920|Atrial Fibrillation
976433|NCT02129920|Arrhythmias, Cardiac
976434|NCT02129920|Heart Diseases
976435|NCT02129920|Cardiovascular Diseases
976436|NCT02129920|Cerebrovascular Disorders
976437|NCT02129920|Brain Diseases
976438|NCT02129920|Central Nervous System Diseases
976439|NCT02129920|Nervous System Diseases
976440|NCT02129920|Vascular Diseases
976441|NCT02129920|Brain Infarction
976442|NCT02129920|Brain Ischemia
976443|NCT02129920|Anticoagulants
976444|NCT02129920|Hematologic Agents
976445|NCT02129920|Therapeutic Uses
976446|NCT02129907|Anemias
976447|NCT02129907|Iron-Deficiency
976448|NCT02129907|thrombin
976449|NCT02129894|cesarean section
976450|NCT02129894|postoperative pain
976451|NCT02129894|pregnancy
976452|NCT02129894|abdominal binder
976453|NCT02129868|Type 1 diabetes
976454|NCT02129868|Closed-loop glucose control
976455|NCT02129868|Artificial Pancreas
976456|NCT02129868|Continuous subcutaneous insulin infusion
976457|NCT02129868|Continuous glucose monitoring
976458|NCT02129842|AFib
976459|NCT02129842|AF
976460|NCT02129842|ablation
976461|NCT02129842|EndoPAT
976462|NCT02129842|Endothelial dysfunction
976463|NCT02129842|PAT
976464|NCT02129829|Cirrhosis
976465|NCT02129829|HBV
976466|NCT02129829|HIV
976467|NCT02129829|HCV
976468|NCT02129816|Female
976469|NCT02129816|Postmenopause
976470|NCT02129803|Cystic Fibrosis, high flow 20 liters per minute (LPM) humidification therapy
976471|NCT02129790|Bipolar Disorder
976472|NCT02129790|Suicidal
976473|NCT02129790|Depression
976474|NCT02129790|Self-harm
976475|NCT02129790|Psychosocial intervention
976476|NCT02129777|Drug therapy
976477|NCT02129751|able to swallow medications without difficulty
976478|NCT02129751|bupropion hydrobromide
976479|NCT02129699|NSCLC
976480|NCT02129699|stage IV
976481|NCT02129686|Chemotherapy-induced peripheral neuropathy (CIPN)
976482|NCT02129686|Acupuncture
976483|NCT02129686|Early-Stage Breast Carcinoma
976484|NCT02129686|Stage I Breast Cancer
976485|NCT02129686|Stage II Breast Cancer
976486|NCT02129686|Stage III Breast Cancer
976487|NCT02129673|Glaucoma
976488|NCT02129673|Intra-ocular pressure
976489|NCT02129673|Slow Release
976490|NCT02129673|Controlled release
976491|NCT02129647|Neurofibromatosis Type 2
976492|NCT02129647|Vestibular Schwannomas
976493|NCT02129647|Axitinib
976494|NCT02129634|Percutaneous Transluminal Angioplasty
976495|NCT02129634|Limb-salvage
976496|NCT02129634|Randomized Controlled Trial
976497|NCT02129634|Paclitaxel
976498|NCT02129621|Lipocalin
976499|NCT02129621|mineralocorticoid receptor
976500|NCT02129608|overweight
976501|NCT02129608|obese
976502|NCT02129608|central adiposity
976503|NCT02129608|Laser
976504|NCT02129608|lorcaserin
976505|NCT02129608|low level laser therapy
976506|NCT02129608|belviq
976507|NCT02129595|Resveratrol
976508|NCT02129595|Diabetes Mellitus
976509|NCT02129595|Diabetes Mellitus, Type 2
976510|NCT02129595|Insulin Resistance
976511|NCT02129595|Glucose Metabolism Disorders
976512|NCT02129595|Metabolic Diseases
976513|NCT02129595|Endocrine System Diseases
976514|NCT02129595|Hyperinsulinism
976515|NCT02129595|Anti-Inflammatory Agents, Non-Steroidal
976516|NCT02129595|Analgesics, Non-Narcotic
976517|NCT02129595|Analgesics
976518|NCT02129595|Sensory System Agents
976519|NCT02129595|Peripheral Nervous System Agents
976520|NCT02129595|Physiological Effects of Drugs
976521|NCT02129595|Pharmacologic Actions
976522|NCT02129595|Anti-Inflammatory Agents
976523|NCT02129595|Therapeutic Uses
976524|NCT02129595|Antirheumatic Agents
976525|NCT02129595|Antineoplastic Agents, Phytogenic
976526|NCT02129595|Antineoplastic Agents
976527|NCT02129595|Antioxidants
976528|NCT02129595|Molecular Mechanisms of Pharmacological Action
976529|NCT02129595|Protective Agents
976530|NCT02129595|Enzyme Inhibitors
976531|NCT02129595|Platelet Aggregation Inhibitors
976532|NCT02129595|Hematologic Agents
976533|NCT02129595|Antimutagenic Agents
976534|NCT02129595|Anticarcinogenic Agents
976535|NCT02129595|Central Nervous System Agents
976536|NCT02129595|Brown Adipose Tissue
976537|NCT02129556|Metastatic
976538|NCT02129556|Breast
976539|NCT02129556|trastuzumab-resistant
976540|NCT02129556|PD-L1 expressing
976541|NCT02129556|HER2-positive
976542|NCT02129543|SCT
976543|NCT02129543|Stem Cell Transplantation
976544|NCT02129543|Stem Cell Transplant
976545|NCT02129530|Community Mobilization
976546|NCT02129530|HIV
976547|NCT02129530|Intimate Partner Violence
976548|NCT02129530|Gender Norms
976549|NCT02129504|root coverage
976550|NCT02129504|gingival recession
976551|NCT02129504|periodontal surgery
976552|NCT02129491|stroke
976553|NCT02129491|Congenital stroke
976554|NCT02129491|neonatal
976555|NCT02129491|hemiplegia
976556|NCT02129478|olanzapine
976557|NCT02129478|pediatrics
976558|NCT02129478|chemotherapy-induced nausea
976559|NCT02129478|chemotherapy-induced vomiting
976560|NCT02129465|Cytomegalovirus
976561|NCT02129465|CMV
976562|NCT02129465|pregnancy
976563|NCT02129465|transmission
976564|NCT02129452|Alzheimer disease
976565|NCT02129452|Dementia
976566|NCT02129452|Neurodegenerative Diseases
976567|NCT02129452|Tauopathies
976568|NCT02129452|Amyloid beta Peptides
976569|NCT02129452|Amyloid Plaque
976570|NCT02129452|MicroRNAs
976571|NCT02129452|Early Diagnosis
976572|NCT02129439|Antisense oligonucleotide
976573|NCT02129439|Colitis Ulcerosa
976574|NCT02129439|Ulcerative colitis
976575|NCT02129439|Phase II
976576|NCT02129439|Transcription factor GATA-3
976577|NCT02129439|intrarectal application
976578|NCT02129439|proof-of-concept
976579|NCT02129426|Sedation
976580|NCT02129426|MRI
976581|NCT02129413|Aneurysmal subarachnoid hemorrhage
976582|NCT02129413|Subarachnoid hemorrhage
976583|NCT02129413|Cerebral vasospasm
976584|NCT02129413|Ruptured aneurysm
976585|NCT02129413|Delayed Cerebral Ischemia
976586|NCT02129413|Delayed Ischemic Deficit
976587|NCT02129413|Delayed ischemic neurological deficit
976588|NCT02129413|Neurostimulation
976589|NCT02129413|Carotid body
976590|NCT02129400|Xenon-inhalation
976591|NCT02129400|Erythropoetin
976592|NCT02129400|Pharmakokinetic
976593|NCT02129400|Pharmacodynamic
976594|NCT02129400|Hemodynamic parameters
976595|NCT02129400|Inflammatory parameters
976596|NCT02129400|Growth factors
976597|NCT02129400|Oxidative stress parameters
976598|NCT02129387|Nicotine
976599|NCT02129387|Smoking Progression
976600|NCT02129387|EEG
976601|NCT02129387|Young adults
976602|NCT02129387|Light smokers
976603|NCT02129387|rs1051730 genotype
976604|NCT02129374|Spondylolysis
976605|NCT02129374|Lumbar spine
976606|NCT02129374|Young population
976607|NCT02129374|Direct repair
976608|NCT02129374|Union rate
976609|NCT02129374|Functional outcome
976610|NCT02129361|traumatic brain injury
976611|NCT02129348|Alzheimer's disease
976612|NCT02129348|psychosis
976613|NCT02129348|agitation
976614|NCT02129348|aggression
976615|NCT02129348|Lithium
976616|NCT02129348|delusions
976617|NCT02129348|hallucinations
976618|NCT02129335|glioblastoma
976619|NCT02129335|partner
976620|NCT02129335|stress
976621|NCT02129335|exercise
976622|NCT02129335|outcome
976623|NCT02129309|COPD
976624|NCT02129309|Apelin
976625|NCT02129309|agonist
976626|NCT02129309|antagonist
976627|NCT02129296|Morbid obesity
976628|NCT02129296|Gastric balloon
976629|NCT02129296|Weight loss
976630|NCT02129296|Tolerance
976631|NCT02129296|Safety
976632|NCT02129283|physicians, nurses, ICU, end-of-life, simulation training
976633|NCT02129270|Fractures of the distal radius
976634|NCT02129270|Hematoma block
976635|NCT02129270|Lidocaine
976636|NCT02129244|MDR-TB
976637|NCT02129244|HIV
976638|NCT02129244|Nurse Case Management (NCM)
976639|NCT02129231|ezetimibe/simvastatin
976640|NCT02129231|rosuvastatin
976641|NCT02129231|diabetic polyneuropathy
976642|NCT02129231|oxidative stress
976643|NCT02129231|mitochondrial dysfunction
976644|NCT02129205|solid tumors
976645|NCT02129205|triple negative breast cancer
976646|NCT02129205|PF-06650808
976647|NCT02129205|Phase 1
976648|NCT02129153|Randomized controlled trial
976649|NCT02129153|Population, School Age
976650|NCT02129140|hernia repair
976651|NCT02129140|ventral incisional hernia
976652|NCT02129140|biologic mesh
976653|NCT02129140|hernia graft
976654|NCT02129088|Healthy
976655|NCT02129088|Esketamine
976656|NCT02129088|Phase 1
976657|NCT02129088|Placebo
976658|NCT02129088|Elderly
976659|NCT02129088|Adult
976660|NCT02129036|Ovarian cancer
976661|NCT02129036|Clear cell carcinoma
976662|NCT02129036|Paclitaxel-platinum
976663|NCT02129036|Chemotherapy
976664|NCT02129036|response to chemotherapy
976665|NCT02129036|survival of clear cell ovarian carcinoma
976666|NCT02129036|Prognostic factors
976667|NCT02129023|Exergame
976668|NCT02129023|user health
976669|NCT02129023|exercise
976670|NCT02129010|subarachnoid hemorrhage
976671|NCT02129010|terson syndrome
976672|NCT02129010|CSF-proteines
976673|NCT02129010|phospho-tau
976674|NCT02129010|beta-amyloid
976675|NCT02128997|obesity, cesarean section, wound complication
976676|NCT02128984|Malnutrition
976677|NCT02128984|Dietary supplement
976678|NCT02128984|Nutritional supplement
976679|NCT02128984|Symbiotic formula
976680|NCT02128984|DHA
976681|NCT02128984|Cystic Fibrosis
976682|NCT02128984|Failure to Thrive
976683|NCT02128971|Iron supplement study
976684|NCT02128958|Hepatocellular Carcinoma
976685|NCT02128958|Child-Pugh Class B Cirrhosis
976686|NCT02128945|PET
976687|NCT02128945|Chronic lymphocytic Leukemia (CLL)
976688|NCT02128945|Diffuse Large B Cells Lymphoma (DLBCL)
976689|NCT02128945|Fludarabine
976690|NCT02128919|Schizophrenia
976691|NCT02128919|Cigarette smoking
976692|NCT02128919|Cognition
976693|NCT02128919|Craving
976694|NCT02128919|MATRICS
976695|NCT02128906|ERCC1
976696|NCT02128906|squamous cell carcinoma
976697|NCT02128906|oropharynx
976698|NCT02128906|larynx
976699|NCT02128906|hypopharynx
976700|NCT02128906|p16
976701|NCT02128906|radiotherapy
976702|NCT02128906|docetaxel
976703|NCT02128906|cetuximab
976704|NCT02128906|cisplatin
976705|NCT02128906|EGFR
976706|NCT02128906|Biomarker
976707|NCT02128906|efficacy
976708|NCT02128906|head and neck
976709|NCT02128906|tongue
976710|NCT02128906|throat
976711|NCT02128893|Isavuconazole
976712|NCT02128893|Esomeprazole
976713|NCT02128893|BAL4815
976714|NCT02128893|BAL8728
976715|NCT02128893|Healthy Subjects
976716|NCT02128880|AEP, drinking, contraception, FASD, Internet interventions
976717|NCT02128867|gastro-esophageal reflux
976718|NCT02128867|GOR
976719|NCT02128867|GER
976720|NCT02128867|airway clearance techniques
976721|NCT02128854|Diabetes Mellitus, Type 2
976722|NCT02128854|Diabetes Mellitus, Adult-Onset
976723|NCT02128854|Diabetes Mellitus, Non-Insulin-Dependent
976724|NCT02128854|Diabetes Mellitus, Noninsulin Dependent
976725|NCT02128854|Diabetes Mellitus, Type II
976726|NCT02128854|African Americans
976727|NCT02128854|Blacks
976728|NCT02128854|Non-Hispanic Blacks
976729|NCT02128854|Randomized Control Trial
976730|NCT02128854|Controlled Clinical Trial
976731|NCT02128854|Behavioral Research
976732|NCT02128854|Behavioral Medicine
976733|NCT02128841|rivaroxaban
976734|NCT02128841|Heart Valve Prosthesis Implantation
976735|NCT02128841|anticoagulants
976736|NCT02128841|Factor Xa/antagonists & inhibitors
976737|NCT02128828|AIDS Dementia Complex
976738|NCT02128828|HIV-1-Associated Cognitive Motor Complex
976739|NCT02128828|Human Immunodeficiency Virus
976740|NCT02128815|adults
976741|NCT02128815|coaching
976742|NCT02128815|type 2 diabetes
976743|NCT02128802|Obesity
976744|NCT02128802|Renal failure
976745|NCT02128802|Gastric bypass
976746|NCT02128789|Older Adults
976747|NCT02128789|Caregivers
976748|NCT02128789|Aging
976749|NCT02128789|Support
976750|NCT02128776|Children
976751|NCT02128776|Chronic illnesses
976752|NCT02128724|Lung cancer
976753|NCT02128724|BKM120
976754|NCT02128724|Hypoxia
976755|NCT02128724|Misonidazole
976756|NCT02128724|Radiotherapy
976757|NCT02128711|lung
976758|NCT02128711|cystic fibrosis
976759|NCT02128711|bacteria
976760|NCT02128711|positive diagnosis of CF,
976761|NCT02128698|Bariatric surgery
976762|NCT02128698|Protein supplementation
976763|NCT02128698|Physical activity
976764|NCT02128698|Muscle mass
976765|NCT02128698|Weight loss
976766|NCT02128698|Physical fitness
976767|NCT02128698|Muscle strength
976768|NCT02128685|Threatened miscarriage
976769|NCT02128685|Dydrogesterone
976770|NCT02128685|Randomized controlled trial
976771|NCT02128646|Pain Management
976772|NCT02128646|Exparel
976773|NCT02128646|Abdominal Hernia Repair
976774|NCT02128646|Laparoscopic Surgery
976775|NCT02128633|Dentin hypersensitivity
976776|NCT02128633|Dentin Sensitivities
976777|NCT02128620|Sexually transmitted diseases
976778|NCT02128620|Internet
976779|NCT02128620|Education
976780|NCT02128620|Appointments and Schedules
976781|NCT02128607|low back pain
976782|NCT02128607|manual therapy
976783|NCT02128607|Mulligan
976784|NCT02128607|sustained natural apophyseal glide (SNAG)
976785|NCT02128607|Kinematic spine model
976786|NCT02128568|Depression/therapy;
976787|NCT02128568|Developing Countries;
976788|NCT02128568|Interpersonal Relations;
976789|NCT02128568|Life Change Events;
976790|NCT02128568|Psychotherapy, Group;
976791|NCT02128568|Resilience, Psychological;
976792|NCT02128568|Sierra Leone;
976793|NCT02128568|Survivors/psychology;
976794|NCT02128568|Social Adjustment;
976795|NCT02128568|Social Behavior;
976796|NCT02128568|War
976797|NCT02128555|ankle arthritis
976798|NCT02128555|osteoarthritis
976799|NCT02128555|total ankle replacement
976800|NCT02128555|arthrodesis
976801|NCT02128555|quality of life
976802|NCT02128555|musculoskeletal
976803|NCT02128542|Veterans HCV
976804|NCT02128529|COPD
976805|NCT02128490|Drug therapy
976806|NCT02128477|Myocardial infarction
976807|NCT02128477|Repolarization instability
976808|NCT02128477|Ventricular fibrillation
976809|NCT02128464|Knee Osteoarthritis
976810|NCT02128464|Total Knee Arthroplasty
976811|NCT02128464|Customized Cutting Block
976812|NCT02128464|Conventional Intramedullary Cutting Guide
976813|NCT02128451|meperdine ,fentanyl, clonidine, orthopedic surgery .
976814|NCT02128425|Colorectal cancer
976815|NCT02128425|Metastatic colorectal cancer
976816|NCT02128425|FOLFOXIRI
976817|NCT02128425|FOLFOX
976818|NCT02128425|Oxaliplatin
976819|NCT02128425|irinotecan
976820|NCT02128425|Leucovorin
976821|NCT02128425|5-FU
976822|NCT02128412|Patients scheduled to undergo coronary angioplasty and stenting because of symptoms related to a single de novo coronary artery stenoses
976823|NCT02128399|antimicrobial stewardship
976824|NCT02128360|Low ovarian reserve
976825|NCT02128360|Poor responder
976826|NCT02128360|Infertility
976827|NCT02128347|Hemodialysis, Home
976828|NCT02128347|Peritoneal Dialysis
976829|NCT02128347|Telemedicine
976830|NCT02128334|Uro-Oncologists
976831|NCT02128334|PSA
976832|NCT02128334|Eligard
976833|NCT02128334|prostate carcinoma
976834|NCT02128321|Isavuconazole
976835|NCT02128321|Repaglinide
976836|NCT02128321|Caffeine
976837|NCT02128321|BAL4815
976838|NCT02128321|BAL8728
976839|NCT02128321|Healthy Subjects
976840|NCT02128308|Antituberculosis agents
976841|NCT02128308|Pharmacokinetics
976842|NCT02128295|Breast pumps, breast milk, expression, term infants
976843|NCT02128282|Cholangiocarcinoma
976844|NCT02128282|Bile duct cancer
976845|NCT02128282|Biliary tract cancer
976846|NCT02128269|Antiphospholipid (aPL)-positive
976847|NCT02128269|Antiphospholid syndrome (APS)
976848|NCT02128256|Osteomyelitis
976849|NCT02128256|Bone substitute
976850|NCT02128256|Ceramic
976851|NCT02128256|Gentamicin
976852|NCT02128230|High risk
976853|NCT02128230|Carfilzomib
976854|NCT02128191|Patent ductus arteriosus
976855|NCT02128191|Ibuprofen
976856|NCT02128191|Bronchopulmonary dysplasia
976857|NCT02128178|Morbid obesity
976858|NCT02128178|Laparoscopic surgery
976859|NCT02128178|Compression ultrasonography
976860|NCT02128178|Pulmonary embolism
976861|NCT02128178|Bleeding
976862|NCT02128165|gastric balloon
976863|NCT02128165|morbid obesity
976864|NCT02128152|stroke
976865|NCT02128152|exoskeleton
976866|NCT02128152|Ekso
976867|NCT02128152|ambulation
976868|NCT02128152|robotics
976869|NCT02128139|Infective endocarditis
976870|NCT02128139|Developing country
976871|NCT02128139|Global health
976872|NCT02128139|Cardiac surgery
976873|NCT02128139|Heart valve disease
976874|NCT02128139|Bacteremia
976875|NCT02128126|Advanced or recurrent cervical cancer
976876|NCT02128126|HPV16 positive
976877|NCT02128126|No curative treatment options
976878|NCT02128113|RTA 408
976879|NCT02128113|Cataract surgery
976880|NCT02128113|Corneal Endothelial Cells
976881|NCT02128113|omaveloxolone
976882|NCT02128100|Pancreatic Cancer
976883|NCT02128087|HIV
976884|NCT02128087|Antiretroviral (ARV)
976885|NCT02128087|co-trimoxazole
976886|NCT02128087|SMS
976887|NCT02128087|mobile Health (mHealth)
976888|NCT02128087|Adolescents
976889|NCT02128087|Uganda
976890|NCT02128087|Adherence
976891|NCT02128035|radiation protection
976892|NCT02128035|interventional cardiologist
976893|NCT02128035|percutaneous coronary intervention (PCI)
976894|NCT02128035|angiography
976895|NCT02128035|lead shield
976896|NCT02128022|Glucagon-Like Peptide 1
976897|NCT02128022|Angina Pectoris
976898|NCT02128022|Percutaneous Coronary Intervention
977022|NCT02127463|MC-1101
976899|NCT02128022|Ischemic Preconditioning
976900|NCT02128022|Myocardial Reperfusion Injury
976901|NCT02127996|Angina Pectoris
976902|NCT02127996|Percutaneous Coronary Intervention
976903|NCT02127996|Myocardial Infarction
976904|NCT02127996|Glucagon-Like Peptide 1
976905|NCT02127996|Reperfusion Injury
976906|NCT02127983|TB, HIV, case finding, access, informal providers
976907|NCT02127957|cystic fibrosis
976908|NCT02127957|exercise
976909|NCT02127957|Cystic fibrosis related diabetes
976910|NCT02127918|Electrical status epilepticus in sleep
976911|NCT02127918|Continuous spikes and waves during sleep
976912|NCT02127918|Children
976913|NCT02127918|Electroencephalogram
976914|NCT02127918|Neuropsychology
976915|NCT02127918|Development
976916|NCT02127918|Antiepileptic drugs
976917|NCT02127918|Clobazam
976918|NCT02127918|Seizures
976919|NCT02127905|Fanconi Anemia
976920|NCT02127905|compassionate treatment
976921|NCT02127905|BMT
976922|NCT02127905|HSCT
976923|NCT02127905|unrelated
976924|NCT02127905|bone marrow transplantation
976925|NCT02127905|PBSC
976926|NCT02127905|peripheral blood
976927|NCT02127905|CD34+
976928|NCT02127892|Severe Combined Immune Deficiency
976929|NCT02127892|SCID
976930|NCT02127892|HLA-matched unrelated donor
976931|NCT02127892|unrelated
976932|NCT02127892|MUD
976933|NCT02127892|bone marrow
976934|NCT02127892|cord blood
976935|NCT02127892|haplo-identical
976936|NCT02127892|peripheral blood
976937|NCT02127892|CD34+ selection
976938|NCT02127892|T cell depletion
976939|NCT02127892|HSCT
976940|NCT02127892|BMT
976941|NCT02127892|CliniMACS
976942|NCT02127879|Repetitive Transcranial Magnetic Stimulation
976943|NCT02127879|Schizophrenia
976944|NCT02127879|Negative symptoms
976945|NCT02127879|Intensive
976946|NCT02127879|Transcranial Magnetic Stimulation, Repetitive
976947|NCT02127866|Asthma, anticholinergics
976948|NCT02127853|serial cataract surgery
976949|NCT02127853|hyperalgesia
976950|NCT02127853|gabapentin
976951|NCT02127853|central sensitization
976952|NCT02127840|primary aldosteronism
976953|NCT02127840|adrenal adenoma
976954|NCT02127840|arterial hypertension
976955|NCT02127814|induced diarrhea
976956|NCT02127814|Clostridium difficile toxicity
976957|NCT02127788|Haematology
976958|NCT02127788|Micafungin
976959|NCT02127788|Observational study
976960|NCT02127788|Prophylaxis
976961|NCT02127788|Invasive Fungal Infection
976962|NCT02127788|France
976963|NCT02127762|Pain
976964|NCT02127762|Quality of Life
976965|NCT02127762|Glycemic Control
976966|NCT02127762|diabetic neuropathy
976967|NCT02127762|mindfulness
976968|NCT02127762|stress reduction
976969|NCT02127762|adult
976970|NCT02127762|chronic pain
976971|NCT02127762|depression
976972|NCT02127762|cortisol
976973|NCT02127749|antibiotics
976974|NCT02127749|gut microbiota
976975|NCT02127749|endotoxemia
976976|NCT02127749|innate immunity
976977|NCT02127723|cellulite
976978|NCT02127710|AZD6094
976979|NCT02127710|Savolitinib
976980|NCT02127710|Papillary Renal Cell Cancer
976981|NCT02127697|Asthma, poorly controlled asthma, LAMA, Long-Acting Muscarinic Antagonist, Glycopyrronium, Glycopyrronium bromide, Anticholinergic
976982|NCT02127684|diabetic macular edema
976983|NCT02127645|RADIOTHERAPY
976984|NCT02127645|TRANSANAL ENDOSCOPIC MICROSURGERY
976985|NCT02127645|LOCAL EXCISION
976986|NCT02127632|laryngeal mask Supreme
976987|NCT02127632|laparoscopic gynecologic surgery
976988|NCT02127632|Laryngeal mask during surgery
976989|NCT02127619|knee prosthesis
976990|NCT02127619|total knee replacement
976991|NCT02127619|total knee arthroplasty
976992|NCT02127619|prospective study
976993|NCT02127619|Therapeutic level IV
976994|NCT02127593|Norgestimate
976995|NCT02127593|Ethinyl estradiol
976996|NCT02127593|Norgestrel
976997|NCT02127593|Norelgestromin
976998|NCT02127593|Ortho cyclen
976999|NCT02127593|Phase 1
977000|NCT02127593|Healthy Women
977001|NCT02127580|THV
977002|NCT02127580|BAV
977003|NCT02127580|pre-dilation
977004|NCT02127580|Aortic valve stenosis
977005|NCT02127567|medical writing, reporting, randomized controlled trial
977006|NCT02127541|Localisation of Insulinoma
977007|NCT02127541|beta-cell imaging
977008|NCT02127541|exendin-4
977009|NCT02127541|68Ga-DOTA-exendin-4 PET/CT
977010|NCT02127541|111In-DOTA-exendin-4 SPECT/CT
977011|NCT02127515|Down, trisomy 21
977012|NCT02127515|NIPT
977013|NCT02127515|Amniocentesis
977014|NCT02127515|miscarriage
977015|NCT02127515|invasive
977016|NCT02127515|prenatal
977017|NCT02127515|screening.
977018|NCT02127489|Bupivacaine, caudal, rectal midazolam, children
977019|NCT02127463|AMD
977020|NCT02127463|Dry AMD
977021|NCT02127463|Non-Exudative AMD
977023|NCT02127450|Enterobacteriaceae
977024|NCT02127450|non-susceptible to carbapenem
977025|NCT02127450|carbapenemases
977026|NCT02127450|prevalence
977027|NCT02127450|screening algorithm
977028|NCT02127437|Autosomal dominant polycystic kidney disease,
977029|NCT02127437|Glomerular filtration rate,
977030|NCT02127437|Somatostatin,
977031|NCT02127437|lanreotide
977032|NCT02127424|Nurse
977033|NCT02127424|Nursing
977034|NCT02127424|Screening
977035|NCT02127424|HIV
977036|NCT02127424|Emergency Service Hospital
977037|NCT02127411|Mindfulness
977038|NCT02127411|Benzodiazepines
977039|NCT02127411|Sleep
977040|NCT02127411|Dependence
977041|NCT02127411|Relapse Prevention
977042|NCT02127398|C. difficile colitis
977043|NCT02127398|fecal microbiota transplantation
977044|NCT02127372|non-small cell
977045|NCT02127372|lung cancer
977046|NCT02127359|Metastatic
977047|NCT02127346|Chronic Periodontitis
977048|NCT02127346|Vitamin D concentration
977049|NCT02127346|Calcium concentration
977050|NCT02127333|chronic obstructive pulmonary disease
977051|NCT02127333|Coronary artery disease
977052|NCT02127333|Endothelial function
977053|NCT02127307|Myocardial sympathetic innervation
977054|NCT02127307|Heart failure (HF)
977055|NCT02127307|Nuclear imaging
977056|NCT02127307|Radiopharmaceutical
977057|NCT02127294|Foramen Ovale, Patent
977058|NCT02127294|migraine
977059|NCT02127294|transcatheter patent foramen ovale closure
977060|NCT02127294|contrast-enhanced transcranial Doppler
977061|NCT02127294|Transthoracic Echocardiography
977062|NCT02127281|Revision total knee arthroplasty
977063|NCT02127281|Revision total hip arthroplasty
977064|NCT02127281|Negative pressure wound therapy system (NPWT)
977065|NCT02127281|Drainage
977066|NCT02127255|chemotherapy
977067|NCT02127255|nausea
977068|NCT02127255|vomiting
977069|NCT02127255|cancer
977070|NCT02127242|hepatolithiasis
977071|NCT02127242|ureteroscope
977072|NCT02127242|air-pressure ballistic lithotripsy
977073|NCT02127242|hepatectomy
977074|NCT02127229|endoscopic retrograde cholangiopancreatography
977075|NCT02127229|disposable accessory cost
977076|NCT02127229|endoscopy cost analysis
977077|NCT02127216|Mobile Health
977078|NCT02127216|Diabetes
977079|NCT02127216|Self-Care of Diabetes
977080|NCT02127203|oxidative stress
977081|NCT02127203|periodontal disease
977082|NCT02127203|nitric oxide
977083|NCT02127190|nitro-fatty acids
977084|NCT02127190|anti-inflammatory
977085|NCT02127190|Nrf2 activation
977086|NCT02127190|contrast induced AKI
977087|NCT02127177|obstructive sleep apnea
977088|NCT02127177|coronary heart disease
977089|NCT02127177|continuous positive airway pressure
977090|NCT02127177|lipid profiles
977091|NCT02127177|high-sensitivity C-reactive protein
977092|NCT02127138|unprotected distal left main bifurcation lesion
977093|NCT02127138|Percutaneous coronary intervention
977094|NCT02127138|clinical study
977095|NCT02127138|Active Transfer of Plaque （ATP）
977096|NCT02127138|Provisional T Stenting
977097|NCT02127112|Ridge Augmentation
977098|NCT02127112|Bone regeneration
977099|NCT02127112|Guided Bone Regeneration
977100|NCT02127112|Partially Edentulous
977101|NCT02127099|OSA
977102|NCT02127099|obstructive
977103|NCT02127099|sleep
977104|NCT02127099|apnea
977105|NCT02127099|operation
977106|NCT02127086|Acute pain severity
977107|NCT02127086|Non-communicative patients
977108|NCT02127086|PAIN algorithm
977109|NCT02127086|Multi-dimensional Pain Assessment Tool (MOPAT)
977110|NCT02127073|Breast cancer
977111|NCT02127073|Ductal carcinoma in situ (DCIS)
977112|NCT02127073|Oxytocin
977113|NCT02127060|vitamin C
977114|NCT02127060|effectiveness
977115|NCT02127060|pain management
977116|NCT02127060|posterior lumbar interbody fusion
977117|NCT02127034|Healthy subjects
977118|NCT02127034|Mirabegron
977119|NCT02127034|Solifenacin
977120|NCT02127034|Digoxin
977121|NCT02127021|Pancreaticoduodenectomy
977122|NCT02127021|Nutritional Status
977123|NCT02127021|Quality of Life
977124|NCT02127021|Biochemical Marker
977125|NCT02127008|epidural fat
977126|NCT02127008|resection
977127|NCT02127008|spinal stenosis
977128|NCT02127008|lumbar spine
977129|NCT02126995|Fragile X Syndrome, Fra(X) Syndrome, FRAXA Syndrome
977130|NCT02126982|clopidogrel besylate
977131|NCT02126982|clopidogrel hydrogen sulfate
977132|NCT02126982|Generic clopidogrel
977133|NCT02126982|Coronary Artery Disease
977134|NCT02126969|Cancer
977135|NCT02126969|Low dose radiation
977136|NCT02126956|ACT-128800
977137|NCT02126943|PAH
977138|NCT02126943|pulmonary arterial hypertension
977139|NCT02126930|anti-infectious treatment
977140|NCT02126930|observance
977141|NCT02126930|pharmaceutical consultation
977142|NCT02126917|Phase 1
977143|NCT02126917|Alcohol
977144|NCT02126917|Hydrocodone Bitartrate
977145|NCT02126917|Pharmacokinetics
977146|NCT02126891|Cardiac functions
977147|NCT02126891|Endurance training
977148|NCT02126891|Senior athletes
977149|NCT02126852|residual paralysis,neuromuscular blockade,acceleromyography,electromyography
977150|NCT02126813|Postoperative urinary retention
977151|NCT02126813|Fast-track total hip (THA) and knee arthroplasty (TKA)
977152|NCT02126813|Urinary bladder volume
977153|NCT02126800|breast cancer
977154|NCT02126787|Anxiety disorders
977155|NCT02126787|Depressive disorders
977156|NCT02126787|Personality disorders
977157|NCT02126787|Psychodynamic psychotherapy
977158|NCT02126787|Cognitive-behavioral psychotherapy
977159|NCT02126787|Group psychotherapy
977160|NCT02126787|Day treatment
977161|NCT02126774|epilepsy
977162|NCT02126774|focal epilepsy
977163|NCT02126761|Influenza
977164|NCT02126761|elderly
977165|NCT02126761|adjuvant
977166|NCT02126748|bronchiolitis
977167|NCT02126748|Wang score
977168|NCT02126748|Sa02
977169|NCT02126748|airway clearance techniques
977170|NCT02126748|intrapulmonary percussive ventilation
977171|NCT02126748|assisted autogenic drainage
977172|NCT02126722|Helicobacter pylori
977173|NCT02126722|Gastritis
977174|NCT02126709|Povidone Iodine
977175|NCT02126709|Safety
977176|NCT02126709|Efficacy
977177|NCT02126709|Acne treatment
977178|NCT02126696|Anti-retroviral Therapy
977179|NCT02126696|Lesotho
977180|NCT02126696|Southern Africa
977181|NCT02126696|Comorbidity
977182|NCT02126696|Virologic failure
977183|NCT02126683|Hashimoto's thyroiditis
977184|NCT02126683|Plaquenil
977185|NCT02126657|Acne scars
977186|NCT02126657|70% Glycolic acid peel
977187|NCT02126644|Photoaging
977188|NCT02126644|70% glycolic acid peel
977189|NCT02126618|Lower urinary tract symptoms
977190|NCT02126618|urodynamic studies
977191|NCT02126618|diuresis
977192|NCT02126605|diabetes alert dogs
977193|NCT02126605|hypoglycemia
977194|NCT02126579|melanoma
977195|NCT02126579|neoplasms
977196|NCT02126579|Poly ICLC
977197|NCT02126579|Freund's Adjuvant
977198|NCT02126579|Metastatic melanoma
977199|NCT02126579|resiquimod
977200|NCT02126579|adjuvants
977201|NCT02126579|peptide vaccine
977202|NCT02126566|striae distensiae
977203|NCT02126553|Leukemia
977204|NCT02126553|Acute myeloid leukemia
977205|NCT02126553|AML
977206|NCT02126553|Remission
977207|NCT02126553|Lenalidomide
977208|NCT02126553|CC-5013
977209|NCT02126553|Revlimid
977210|NCT02126540|Peripheral Arterial Disease
977211|NCT02126540|Atherectomy
977212|NCT02126540|Optical Coherence Tomography
977213|NCT02126514|Beta secretase inhibitor
977214|NCT02126514|Alzheimer disease
977215|NCT02126501|weaning
977216|NCT02126501|NCPAP
977217|NCT02126501|Preterm
977218|NCT02126501|sudden wean
977219|NCT02126501|gradual pressure off wean
977220|NCT02126488|treadmill training
977221|NCT02126488|generalization
977222|NCT02126488|retention
977223|NCT02126475|"parkinson patients ON"
977224|NCT02126475|"parkinson patients OFF"
977225|NCT02126475|time estimation
977226|NCT02126475|anticipation
977227|NCT02126462|Human Hookworm
977228|NCT02126462|Necator americanus
977229|NCT02126462|Hookworm
977230|NCT02126462|Hookworm Disease
977231|NCT02126462|Iron-deficiency anemia
977232|NCT02126462|Soil-transmitted helminth infection
977233|NCT02126462|Neglected Tropical Disease
977234|NCT02126462|Na-APR-1
977235|NCT02126462|Na-GST-1
977236|NCT02126436|phantom limb pain
977237|NCT02126436|phantom limb sensation
977238|NCT02126436|acupuncture
977239|NCT02126436|randomised controlled trial
977240|NCT02126423|Drug Resistance, Microbial
977241|NCT02126410|sarcopenia
977242|NCT02126410|sleep duration
977243|NCT02126410|body composition
977244|NCT02126410|skeletal muscle
977245|NCT02126397|endometrial polyp
977246|NCT02126397|resection of endometrial polyps
977247|NCT02126397|hysteroscopy
977248|NCT02126397|bipolar electrode Versapoint
977249|NCT02126397|Laser Diode
977250|NCT02126384|Immunology
977251|NCT02126384|human
977252|NCT02126384|B-lymphocytes subsets
977253|NCT02126384|Antibody-Producing Cells
977254|NCT02126384|23 valent pneumococcal capsular polysaccharide vaccine
977255|NCT02126332|Severe acute pancreatitis
977256|NCT02126332|Epidural analgesia
977257|NCT02126332|Acute respiratory failure
977258|NCT02126332|Mechanical ventilation
977259|NCT02126332|Intensive Care Unit (ICU)
977260|NCT02126319|Cognitive-affective preparation
977261|NCT02126319|prostate cancer counseling
977262|NCT02126280|proinflammatory cytokines
977263|NCT02126280|anti-inflammatory cytokines
977264|NCT02126280|human monocytes
977265|NCT02126280|activation
977266|NCT02126280|biomarkers
977267|NCT02126280|asymptomatic atherosclerosis
977268|NCT02126267|periodontal disease
977269|NCT02126267|therapy
977270|NCT02126267|anti-bacterial agents
977271|NCT02126267|Randomized Controlled Trials
977272|NCT02126241|Heart Failure
977273|NCT02126241|Cardiac Resyncronization Therapy
977274|NCT02126241|Optimization
977275|NCT02126241|Non-invasive cardiac system
977276|NCT02126241|Impedance measured cardiac output
977277|NCT02126228|antibiotics, cesarean
977278|NCT02126215|magnetic resonance imaging
977279|NCT02126215|carbon dioxide
977280|NCT02126215|abdominal aortic aneurysm
977281|NCT02126215|post-op delirium
977282|NCT02126202|Elderly
977283|NCT02126202|Octogenarians
977284|NCT02126202|PCI
977285|NCT02126202|Myocardial infarction
977286|NCT02126202|NSTEMI
977287|NCT02126202|Unstable angina pectoris
977288|NCT02126189|Head and Neck Squamous Cell Carcinoma
977289|NCT02126189|Human Papillomavirus
977290|NCT02126189|Aetiology
977291|NCT02126189|prevalence
977292|NCT02126189|risk factors
977293|NCT02126189|clinical outcome
977294|NCT02126163|Excessive Drinking
977295|NCT02126163|Hazardous Drinking
977296|NCT02126137|HCV
977297|NCT02126137|Ezetimibe
977298|NCT02126137|Cholesterol
977299|NCT02126137|Host
977300|NCT02126124|Brainsway, dTMS, Deep Transcranial Magnetic Stimulation, Smoking Cessation
977301|NCT02126098|ANCA-associated vasculitis
977302|NCT02126098|Granulomatosis with polyangiitis
977303|NCT02126098|Microscopic polyangiitis
977304|NCT02126098|Wegner's granulomatosis
977305|NCT02126098|Eosinphilic granulomatosis with polyangiitis
977306|NCT02126085|ischemic stroke
977307|NCT02126085|recanalisation
977308|NCT02126085|sedation
977309|NCT02126072|Ethanol
977310|NCT02126072|Alcohol
977311|NCT02126072|Consumption
977312|NCT02126072|Gut wall integrity
977313|NCT02126072|Endotoxemia
977314|NCT02126059|dementia
977315|NCT02126059|behavioral and psychological symptoms
977316|NCT02126059|quality of life
977317|NCT02126046|Cord Blood Transplant
977318|NCT02126046|Haploidentical HSCT
977319|NCT02126046|Thalassemia major
977320|NCT02126033|celiac
977321|NCT02126033|telomere
977322|NCT02126033|telomerase
977323|NCT02126020|Keratoprosthesis
977324|NCT02126020|corneal melt
977325|NCT02126020|keratolysis
977326|NCT02126020|Tumor necrosis factor alpha
977327|NCT02126020|infliximab
977328|NCT02126020|matrix metalloproteinase
977329|NCT02126007|fatigue
977330|NCT02126007|HIV
977331|NCT02126007|behavioral intervention
977332|NCT02126007|sleep
977333|NCT02125981|limaprost alfadex
977334|NCT02125981|cervical myelopathy
977335|NCT02125981|surgery
977336|NCT02125968|chronic low back pain
977337|NCT02125968|video game
977338|NCT02125968|therapeutic effects
977339|NCT02125955|Pediatric
977340|NCT02125955|Overweight
977341|NCT02125955|Obesity
977342|NCT02125955|Gut microbiota
977343|NCT02125955|Adiposity
977344|NCT02125955|Prebiotic
977345|NCT02125955|Dietary fiber
977346|NCT02125942|Borderline Personality Disorder
977347|NCT02125877|Iron overload
977348|NCT02125877|Chelation
977349|NCT02125877|Thalassemia
977350|NCT02125877|Myelodysplastic syndrome (MDS)
977351|NCT02125877|Transfusional hemisiderosis
977352|NCT02125877|Deferasirox
977353|NCT02125877|ICL670
977354|NCT02125877|Dispersible tablet
977355|NCT02125877|Film-coated tablet
977356|NCT02125864|AMD
977357|NCT02125864|VEGF
977358|NCT02125864|Aflibercept
977359|NCT02125851|slurry
977360|NCT02125851|splenda
977361|NCT02125851|sucralose
977362|NCT02125851|budesonide
977363|NCT02125851|mucosal contact time
977364|NCT02125838|laryngeal mask Supreme
977365|NCT02125838|laparoscopic gynecologic surgery
977366|NCT02125838|Laryngeal mask during surgery
977367|NCT02125812|Aggressive Periodontitis
977368|NCT02125812|antimicrobial(s)
977369|NCT02125812|microbiology
977370|NCT02125773|PrEP
977371|NCT02125773|Risk score
977372|NCT02125773|Self-perception
977373|NCT02125760|Respiratory muscle training
977374|NCT02125760|stroke
977375|NCT02125760|rehabilitation
977376|NCT02125747|Respiratory muscle training; high-intensity training
977377|NCT02125721|cystinuria
977378|NCT02125721|D-penicillamine (Cuprimine®)
977379|NCT02125721|tiopronin (Thiola®)
977380|NCT02125708|preterm prelabor rupture of membranes
977381|NCT02125708|Ovula Ring
977382|NCT02125708|body-core-temperature
977383|NCT02125708|biomarkers
977384|NCT02125708|Single pregnancies
977385|NCT02125708|PPROM
977386|NCT02125708|gestation week 22 and 27
977387|NCT02125682|HDL
977388|NCT02125682|Hyperlipidemia
977389|NCT02125682|Diabetes
977390|NCT02125682|Inflammation
977391|NCT02125669|basal cell carcinoma
977392|NCT02125669|laser surgery
977393|NCT02125669|pulsed dye laser
977394|NCT02125669|randomized controlled trial
977395|NCT02125643|Exercise-induced muscle damage
977396|NCT02125643|Caffeine
977397|NCT02125643|Maximal voluntary strength
977398|NCT02125630|Metastatic breast carcer
977399|NCT02125630|Bone metastasis
977400|NCT02125630|surgery
977401|NCT02125617|Castration-resistant prostate cancer
977402|NCT02125617|Abiraterone
977403|NCT02125617|Biomarker
977404|NCT02125617|Urokinase Plasminogen Activator Receptor
977405|NCT02125617|Plasma
977406|NCT02125617|Predictive markers
977407|NCT02125604|Gastrointestinal event
977408|NCT02125591|Mild Traumatic Brain Injury
977409|NCT02125565|Arterial
977410|NCT02125565|Blood
977411|NCT02125565|Gas
977412|NCT02125565|Needle
977413|NCT02125565|Pain
977414|NCT02125565|Local
977415|NCT02125565|Anaesthesia
977416|NCT02125565|Anaesthetic
977417|NCT02125552|vascular access device
977418|NCT02125552|ultrasonography
977419|NCT02125539|Online adolescent substance abuse relapse prevention program
977420|NCT02125526|Acute myocardial infarction
977421|NCT02125526|Persisting ischemia
977422|NCT02125526|No reflow
977423|NCT02125526|Intra-aortic balloon pump
977424|NCT02125526|Exhausted autoregulation
977425|NCT02125513|neoadjuvant chemotherapy
977426|NCT02125513|ovarian cancer
977427|NCT02125513|fallopian tube carcinoma
977428|NCT02125513|peritoneal carcinoma
977429|NCT02125513|randomized study
977432|NCT02125487|Clinical Breast Examination
977433|NCT02125487|Breast Cancer detection
977434|NCT02125487|Breast Simulator
977435|NCT02125487|Hybrid Simulation
977436|NCT02125487|Patient Simulation
977437|NCT02125487|Standardized Patient
977438|NCT02125487|Medical student education
977439|NCT02125487|Health Communication
977440|NCT02125487|Communication Barriers
977441|NCT02125487|Cultural competency
977442|NCT02125487|Cultural
977443|NCT02125487|Middle East
977444|NCT02125487|Lebanon
977445|NCT02125474|Neuroendocrine Tumors
977446|NCT02125474|Lutetium
977447|NCT02125474|Treatment Outcome
977455|NCT02125448|Esophageal cancer
977456|NCT02125448|MRI
977457|NCT02125448|PET-CT
977458|NCT02125448|Response assessment
977459|NCT02125435|Healthy subjects
977460|NCT02125435|ASP2408
977461|NCT02125435|pharmacokinetics
977462|NCT02125396|hepatocellular carcinoma
977463|NCT02125396|liver cancer
977464|NCT02125396|transarterial chemoembolization
977465|NCT02125396|radiotherapy
977466|NCT02125396|adjuvant therapy
977467|NCT02125383|Parkinson's disease
977468|NCT02125383|Transcranial direct current stimulation
977469|NCT02125357|sequencing
977470|NCT02125357|abiraterone
977471|NCT02125357|enzalutamide
977472|NCT02125357|metastatic castration-resistant prostate cancer
977473|NCT02125357|randomized
977474|NCT02125331|Blood Pressure
977475|NCT02125318|myeloproliferative neoplasm
977476|NCT02125318|chronic myelogenous leukemia
977477|NCT02125318|polycythemia vera
977478|NCT02125318|primary myelofibrosis
977479|NCT02125318|essential thrombocythemia
977480|NCT02125318|anagrelide
977481|NCT02125318|thrombocytosis
977482|NCT02125318|GALE-401
977483|NCT02125305|Metformin
977484|NCT02125305|Pharmacokinetics/ Pharmacodynamics
977485|NCT02125214|consciousness, anesthesia, electroencephalogram, microstate, long-range dependency
977486|NCT02125201|intranasal fentanyl
977487|NCT02125201|newborn
977488|NCT02125162|BCX4161
977489|NCT02125162|BioCryst
977490|NCT02125162|hereditary angioedema
977491|NCT02125162|relative bioavailability
977492|NCT02125162|kallikrein inhibitor
977495|NCT02125136|unresectable
977496|NCT02125136|borderline resectable
977497|NCT02125110|neurotoxicants
977498|NCT02125110|MRI
977499|NCT02125110|developing brain
977500|NCT02125097|Intracranial Aneurysm Treatment
977501|NCT02125097|Endovascular Therapy
977502|NCT02125084|Metastatic Prostate Cancer
977503|NCT02125084|Castrate-resistant
977504|NCT02125084|Enzalutamide
977505|NCT02125084|Everolimus
977506|NCT02125058|intracutaneous sutures
977507|NCT02125058|transcutaneous sutures
977508|NCT02125058|dermatological surgery
977509|NCT02125058|facial area
977510|NCT02125045|GSH
977511|NCT02125045|cardiovascular risk factors
977512|NCT02125045|endothelial dysfunction
977513|NCT02125045|oxidative stress
977514|NCT02125019|Breast Cancer
977515|NCT02125019|Taxane
977516|NCT02125019|Gait
977517|NCT02125019|Men
977518|NCT02125019|Women
977519|NCT02125006|Mindfulness
977520|NCT02125006|Breast Cancer
977521|NCT02125006|Painful Neuropathy
977522|NCT02125006|Chronic Pain
977523|NCT02125006|fMRI
977524|NCT02125006|Disability
977525|NCT02125006|Quality of Life
977526|NCT02125006|Cytokines
977527|NCT02125006|Cortisol
977528|NCT02124993|Gastrectomy
977529|NCT02124980|Opioid Substitution Treatment
977530|NCT02124980|Cognitive Behavioral Therapy
977531|NCT02124980|Mobile Health
977532|NCT02124928|stroke
977533|NCT02124928|biomarkers
977534|NCT02124928|vulnerable plaque
977535|NCT02124928|carotid endarterectomy
977536|NCT02124928|carotid artery disease
977537|NCT02124915|prosthetic socket
977538|NCT02124915|amputee
977539|NCT02124889|bariatric surgery
977540|NCT02124889|multivitamin
977541|NCT02124889|weight loss
977542|NCT02124889|adherence
977543|NCT02124876|amputee
977544|NCT02124876|prosthetics
977545|NCT02124837|lunch breaks, recovery, nature, park walking, relaxation
977546|NCT02124811|Schizophrenia
977547|NCT02124811|Clozapine
977548|NCT02124811|Minocycline
977549|NCT02124798|Subcutaneous
977550|NCT02124798|Autoinjector
977551|NCT02124798|Belimumab
977552|NCT02124798|Real-Life Use Study
977553|NCT02124798|Reliability
977554|NCT02124785|Long-term persistence
977555|NCT02124785|Havrix
977556|NCT02124785|Hepatitis A
977562|NCT02124746|Primary Myelofibrosis
977563|NCT02124746|Post Polycythemia Vera Myelofibrosis
977564|NCT02124746|Post Essential Thrombocythemia Myelofibrosis
977565|NCT02124746|Polycythemia Vera
977566|NCT02124746|Essential Thrombocythemia
977567|NCT02124746|blood disorders
977568|NCT02124733|Actinic Keratosis
977569|NCT02124733|Actinic Keratoses
977570|NCT02124733|AK
977571|NCT02124733|PDT
977572|NCT02124733|Photodynamic Therapy
977573|NCT02124733|Blue Light Therapy
977574|NCT02124733|ALA
977575|NCT02124733|aminolevulinic acid
977576|NCT02124733|Levulan
977577|NCT02124720|Autism spectrum disorders
977578|NCT02124720|Stereotypy
977579|NCT02124720|Repetitive behavior
977580|NCT02124707|Head and neck cancer
977581|NCT02124707|Squamous cell carcinoma
977582|NCT02124707|Metastatic
977583|NCT02124707|Recurrent
977584|NCT02124707|Phase II
977585|NCT02124707|Carboplatin
977586|NCT02124707|Paclitaxel
977587|NCT02124707|Cetuximab
977588|NCT02124694|historical trauma and unresolved grief
977589|NCT02124694|complicated grief
977590|NCT02124694|prolonged grief
977591|NCT02124694|interpersonal conflicts
977592|NCT02124694|depression
977593|NCT02124694|American Indians
977594|NCT02124694|interpersonal psychotherapy
977595|NCT02124694|traumatic grief
977596|NCT02124694|posttraumatic stress disorder
977597|NCT02124668|Xtandi
977598|NCT02124668|MDV3100
977599|NCT02124668|Progressive Castration-Resistant Prostate Cancer
977600|NCT02124668|Enzalutamide
977601|NCT02124655|Biofilms
977602|NCT02124655|Chlorhexidine
977603|NCT02124655|Microscopy, confocal
977604|NCT02124655|Dental plaque
977605|NCT02124655|Mouthwashes
977606|NCT02124642|Folate requirements
977607|NCT02124642|Pregnancy
977608|NCT02124642|Folic acid
977609|NCT02124642|DNA methylation
977610|NCT02124642|Folate biomarkers
977611|NCT02124616|spinal muscular atrophy
977612|NCT02124616|Muscular dystrophy
977613|NCT02124616|Muscle diseases
977614|NCT02124616|myasthenic syndromes
977615|NCT02124616|Polyneuropathies
977616|NCT02124616|Myopathies
977617|NCT02124603|cataract
977618|NCT02124603|prophylaxis
977619|NCT02124603|susceptibility
977620|NCT02124590|Carnitine
977621|NCT02124590|Acylcarnitine
977622|NCT02124590|Exercise
977623|NCT02124590|Exercise Intensity
977624|NCT02124590|Insulin Sensitivity
977625|NCT02124564|Lacosamide
977626|NCT02124564|Epilepsy
977627|NCT02124564|Focal, Partial-Onset Seizures with or without secondary generalization
977628|NCT02124564|Monotherapy
977629|NCT02124551|Goal-directed fluid therapy
977630|NCT02124512|obese
977631|NCT02124512|insulin resistance
977632|NCT02124512|metabolic syndrome
977633|NCT02124499|anesthesia recovery period
977634|NCT02124499|postoperative complications
977635|NCT02124499|pain
977636|NCT02124499|pain measurement
977637|NCT02124499|postoperative nausea and vomiting
977638|NCT02124499|quality of life
977639|NCT02124499|genetic association study
977640|NCT02124486|IIH
977641|NCT02124486|Weight loss
977642|NCT02124486|Bariatric surgery
977643|NCT02124473|Resistant hypertension
977644|NCT02124473|Homeopathy
977645|NCT02124473|Blood pressure
977646|NCT02124473|Ambulatory blood pressure monitoring
977647|NCT02124460|Pediatric
977648|NCT02124460|Obesity
977649|NCT02124460|Overweight
977650|NCT02124460|Intervention
977651|NCT02124434|Laparoscopic Sleeve Gastrectomy surgery
977652|NCT02124421|Ovarian cancer
977653|NCT02124421|Cytoreductive surgery
977654|NCT02124421|Hyperthermic Intraperitoneal chemotherapy
977655|NCT02124421|Systemic chemotherapy
977656|NCT02124421|Primary peritoneal carcinoma
977657|NCT02124421|Fallopian Tube cancer
977658|NCT02124421|Intraperitoneal chemotherapy
977659|NCT02124421|IV/IP chemotherapy
977660|NCT02124421|IV chemotherapy
977661|NCT02124382|liver failure
977662|NCT02124382|liver malignancy
977663|NCT02124382|metabolic diseases
977664|NCT02124382|Pediatric liver transplanted recipients and their healthy donors
977665|NCT02124369|Pancreatic cancer
977666|NCT02124369|locally advanced
977667|NCT02124369|unresectable
977668|NCT02124343|Neutrophil
977669|NCT02124343|Exercise
977670|NCT02124343|COPD
977671|NCT02124343|Pulmonary Rehabilitation
977672|NCT02124330|Montmorillonite, proteic diet, in vitro and in vivo models
977673|NCT02124317|nanoparticle albumin-bound paclitaxel
977674|NCT02124317|S-1
977675|NCT02124317|advanced pancreatic cancer
977676|NCT02124317|objective response rate
977677|NCT02124304|Sternocleidomastoid
977678|NCT02124304|Neck pain
977679|NCT02124304|EMG
977680|NCT02124304|Perceived Exertion
977681|NCT02124304|Thera-Band
977682|NCT02124304|Cervical Paraspinals
977683|NCT02124291|In Vitro Fertilization
977684|NCT02124291|Vitrification
977685|NCT02124291|Frozen Embryo
977686|NCT02124291|Assisted Hatching
977687|NCT02124291|Pregnancy Rate
977688|NCT02124278|Single ascending dose
977689|NCT02124278|Safety and tolerability in healthy subjects
977690|NCT02124265|Oral Rehydration Therapy
977691|NCT02124252|cervical cancer screening
977692|NCT02124252|human papillomavirus testing
977693|NCT02124252|Kenya
977694|NCT02124252|implementation science
977695|NCT02124226|Chronic severe asthma, immunomodulation, methotrexate, steroids, omalizumab
977696|NCT02124213|Receptor Occupancy
977697|NCT02124213|PET
977698|NCT02124213|D1 Receptor Agonist
977699|NCT02124174|acute myelogenous leukemia (AML)
977700|NCT02124174|myelodysplastic syndrome (MDS)
977701|NCT02124161|Pneumococcal polysaccharide vaccine
977702|NCT02124161|13-valent pneumococcal conjugate vaccine
977703|NCT02124161|invasive pneumococcal disease
977704|NCT02124161|flu vaccine
977705|NCT02124148|cancer
977706|NCT02124135|Nutrition
977707|NCT02124122|Focus
977708|NCT02124122|safety
977709|NCT02124109|Rheumatic Fever
977710|NCT02124109|Acquired Heart Disease
977711|NCT02124109|Rheumatic Heart Disease
977712|NCT02124109|Endomyocardial Fibrosis
977713|NCT02124096|Zoonotic
977714|NCT02124096|Influenza
977715|NCT02124096|Infections
977716|NCT02124096|Ohio
977717|NCT02124096|Fairs
977718|NCT02124083|Niemann Pick Disease, Type C1
977719|NCT02124083|Phase I, Phase 2
977720|NCT02124083|Vorinostat
977721|NCT02124070|Cystinosis
977722|NCT02124070|Myopathy
977723|NCT02124070|Recombiant Growth Hormone
977724|NCT02124057|Liver
977725|NCT02124057|Motor Neuron Disease
977726|NCT02124044|Coinfection
977727|NCT02124044|HCV Genotype 1b
977728|NCT02124044|Interferon Free therapy
977729|NCT02124044|Liver Biopsy
977730|NCT02124044|Virological Response
977731|NCT02124031|Osteoarthritis
977732|NCT02124031|Rheumatoid Arthritis
977733|NCT02124031|Disability
977734|NCT02124031|Joint function
977735|NCT02124018|Myocardial infarction
977736|NCT02124018|Risk stratification
977737|NCT02124018|Sudden cardiac death
977738|NCT02124018|Preserved ejection fraction
977739|NCT02124018|Programmed ventricular stimulation
977740|NCT02124005|Knee surgery
977741|NCT02124005|Femoral block
977742|NCT02124005|Bupivacaine
977743|NCT02124005|Ultrasound
977744|NCT02123966|Chronic Graft-versus-Host-Disease
977745|NCT02123966|Oral mucosal disease
977746|NCT02123953|Drug therapy
977747|NCT02123940|Weaning from mechanical ventilation
977748|NCT02123940|Lung ultrasound
977749|NCT02123940|Nasal humidified high flow therapy
977750|NCT02123940|Weaning failure
977751|NCT02123940|Postextubation distress
977752|NCT02123927|Drug therapy
977753|NCT02123914|Exercise training
977754|NCT02123914|Allergic rhinitis
977755|NCT02123914|Vitamin C
977756|NCT02123914|Cytokine
977757|NCT02123914|Rhinitis symptoms
977758|NCT02123901|Mind and body Exercise
977759|NCT02123901|Flow mediated dilation
977760|NCT02123901|Diabetes
977761|NCT02123888|Prostate
977762|NCT02123888|Lung
977763|NCT02123862|Prostate Cancer
977764|NCT02123862|Breast Cancer
977765|NCT02123862|Colorectal Cancer
977766|NCT02123862|Colon Cancer
977767|NCT02123862|Rectal Cancer
977768|NCT02123862|Cancer
977769|NCT02123862|Solid Tumor
977770|NCT02123862|Metastatic
977771|NCT02123862|Circulating Tumor Cells
977772|NCT02123810|fatigue
977773|NCT02123810|motor skills
977774|NCT02123810|cardiopulmonary resuscitation
977775|NCT02123784|Rotator Cuff Tear
977776|NCT02123784|Rotator Cuff Repair
977777|NCT02123784|Biomarker
977778|NCT02123784|Predictive factors
977779|NCT02123784|Skeletal Muscle
977780|NCT02123784|Tendon
977781|NCT02123784|Subacromial Bursa
977782|NCT02123771|Focus of Study : HELICOBACTER PYLORI INFECTIONS
977783|NCT02123758|Prostatic Neoplasms
977784|NCT02123758|Metastatic Castration-Resistant Prostate Cancer (mCRPC)
977785|NCT02123758|Prostate cancer
977786|NCT02123758|Abiraterone Acetate (ZYTIGA)
977787|NCT02123758|Prednisone
977788|NCT02123758|JNJ-56021927
977789|NCT02123745|infiltration
977790|NCT02123745|extravasation
977791|NCT02123745|peripheral intravenous therapy
977792|NCT02123732|Diabetes
977793|NCT02123732|Diabetes Mellitus
977794|NCT02123732|Herbal
977795|NCT02123732|food supplement
977796|NCT02123693|Osteopathic manipulative treatment
977797|NCT02123693|Low back pain
977798|NCT02123693|Dynamic MRI
977799|NCT02123680|expectation
977800|NCT02123680|chronic illness
977801|NCT02123680|trajectory
977802|NCT02123628|diabetic foot osteomyelitis, antibiotic treatment duration
977803|NCT02123615|Primary Immunodeficiency
977804|NCT02123615|Subdermal bloodless space
977805|NCT02123615|Subdermal injection
977806|NCT02123615|Subcutaneous injection
977807|NCT02123615|Injectable electromyography needle
977808|NCT02123615|Electrical stimulation
977809|NCT02123615|MRI with Gadolinium
977810|NCT02123602|patellofemoral pain syndrome
977811|NCT02123602|abdominal muscles
977812|NCT02123576|Hepatorenal syndrome
977813|NCT02123576|Renal failure
977814|NCT02123576|Pentoxyfylline
977815|NCT02123576|Liver transplantation
977816|NCT02123576|Cirrhosis
977817|NCT02123550|deep
977818|NCT02123550|venous
977819|NCT02123550|thrombosis
977820|NCT02123550|Doppler
977821|NCT02123550|ultrasound
977822|NCT02123550|plastic
977823|NCT02123550|surgery
977824|NCT02123550|thromboembolism
977825|NCT02123550|prevention
977826|NCT02123537|Bioness L300 Foot Drop System
977827|NCT02123537|Functional electrical stimulation
977828|NCT02123524|Superficial Vein Thrombosis
977829|NCT02123498|ear pressure
977830|NCT02123498|ear fullness
977831|NCT02123498|ear pain
977832|NCT02123498|ETD
977833|NCT02123498|laryngopharyngeal reflux
977834|NCT02123498|LPR
977835|NCT02123498|gastroesophageal reflux disease
977836|NCT02123498|GERD
977837|NCT02123498|nasopharyngeal reflux
977838|NCT02123498|acid reflux
977839|NCT02123485|Depression,
977840|NCT02123485|ECT,
977841|NCT02123485|rTMS,
977842|NCT02123485|Right prefrontal,
977843|NCT02123485|antidepressive efficacy
977844|NCT02123485|Inflammation markers
977845|NCT02123433|HIV
977846|NCT02123433|Streptococcus pneumoniae
977847|NCT02123433|13-valent conjugate pneumococcal vaccine
977848|NCT02123433|Vaccine
977849|NCT02123433|Immunological Response
977850|NCT02123433|Pneumococcal Carriage
977851|NCT02123420|Platform Switching vs Regular Platform
977852|NCT02123407|Advanced Gastric Cancer
977853|NCT02123407|Carbon Nanoparticles
977854|NCT02123407|Lymph Nodes
977855|NCT02123394|Low Back Pain
977856|NCT02123394|Mechanical Low Back Pain
977857|NCT02123394|Low Back Ache
977858|NCT02123394|Low Backache
977859|NCT02123394|Lower Back Pain
977860|NCT02123394|Lumbago
977861|NCT02123381|tumor tissue and serum biomarkers
977862|NCT02123381|cetuximab
977863|NCT02123381|preoperative radiotherapy
977864|NCT02123381|esophageal squamous cell carcinoma
977865|NCT02123368|Osteoarthritis
977866|NCT02123368|Mesenchimal stem cell
977867|NCT02123368|Knee
977868|NCT02123342|health
977869|NCT02123342|older adults
977870|NCT02123342|mobile phone
977871|NCT02123329|Qatar
977872|NCT02123329|Pharmacy
977873|NCT02123329|Pharmacist
977874|NCT02123329|Smoking cessation
977875|NCT02123316|local allergic rhinitis
977876|NCT02123316|subcutaneous immunotherapy
977877|NCT02123316|house dust mite allergy
977878|NCT02123316|Dermatophagoides pteronyssinus allergy
977879|NCT02123303|Hypotension, Orthostatic Hypotension
977880|NCT02123290|Plasmodium
977881|NCT02123290|falciparum
977882|NCT02123290|malaria
977883|NCT02123290|vivax
977884|NCT02123290|DSM265
977885|NCT02123290|pharmacokinetics
977886|NCT02123290|adult
977887|NCT02123251|Incentives,
977888|NCT02123251|Diabetes,
977889|NCT02123251|Medicaid,
977890|NCT02123251|Health behavior,
977891|NCT02123251|Cost effectiveness
977892|NCT02123225|STOP-BANG
977893|NCT02123225|Obstructive sleep apnea (OSA)
977894|NCT02123225|total knee arthroplasty (TKA)
977895|NCT02123225|portable monitoring
977896|NCT02123225|sleep medicine
977897|NCT02123225|unattended sleep study
977898|NCT02123225|postoperative sleep study
977899|NCT02123212|Hepatitis C
977900|NCT02123212|Chronic Hepatitis C
977901|NCT02123212|Screening
977902|NCT02123199|COPD
977903|NCT02123186|Newborn Screening , spinal muscular atrophy
977904|NCT02123173|one lung ventilation,
977905|NCT02123173|cardiac output
977906|NCT02123173|fluid responsiveness
977907|NCT02123160|Depression
977908|NCT02123160|Dyadic therapy
977909|NCT02123160|Behavioral Problems
977910|NCT02123160|Child parent therapy
977911|NCT02123160|Affect regulation
977912|NCT02123160|Immune markers
977913|NCT02123160|Cortisol
977914|NCT02123121|Aging
977915|NCT02123121|Biogenesis
977916|NCT02123121|Cell Respiration
977917|NCT02123121|Elderly
977918|NCT02123121|Enzymes
977919|NCT02123121|Mitochondria
977920|NCT02123121|Mitochondrial DNA
977921|NCT02123121|Muscle Fatigue
977922|NCT02123121|Physical Function
977923|NCT02123121|Resveratrol
977924|NCT02123108|Simulect, Myfortic, OLT, Renal Dysfunction, Liver Transplant, Orthotopic Liver Transplantation
977925|NCT02123082|Urolithiasis
977926|NCT02123082|Kidney stones
977927|NCT02123082|Ureteral Obstruction
977928|NCT02123082|Ureteroscopes
977929|NCT02123082|Ureteroscopies
977930|NCT02123069|Autonomic nervous system
977931|NCT02123069|Blood pressure
977932|NCT02123069|Blood vessels
977933|NCT02123069|Physiological effects of drugs
977934|NCT02123069|Vascular stiffness
977935|NCT02123056|reflex fainting
977936|NCT02123056|vasovagal syncope
977937|NCT02123056|metoprolol
977938|NCT02123056|randomized clinical trial
977939|NCT02123056|quality of life
977940|NCT02123043|rehabilitation
977941|NCT02123043|wheelchair
977942|NCT02123043|older adults
977943|NCT02123043|manual wheelchair
977944|NCT02123043|motor learning
977945|NCT02123043|biomechanics
977946|NCT02123043|gross mechanical efficiency
977947|NCT02123030|Lung cancer
977948|NCT02123030|pulmonary disease
977949|NCT02123017|Bowel Evacuation
977950|NCT02123017|Colonoscopy Preparation
977951|NCT02123004|ST-Segment Elevation Myocardial Infarction
977952|NCT02123004|Percutaneous Coronary Intervention
977953|NCT02122991|spinal cord injury
977954|NCT02122991|autonomic dysreflexia
977955|NCT02122991|baroreceptor integrity
977956|NCT02122991|sympathetic integrity
977957|NCT02122991|vagal integrity
977958|NCT02122991|autonomic integrity
977959|NCT02122991|arterial stiffness
977960|NCT02122991|cognitive function
977961|NCT02122991|traumatic brain injury
977962|NCT02122991|cerebral blood flow
977963|NCT02122978|psoriasis
977964|NCT02122978|dermatology
977965|NCT02122978|mindfulness
977966|NCT02122978|self-compassion
977967|NCT02122952|Gene Transfer
977968|NCT02122952|Gene Therapy
977969|NCT02122952|Adeno-associated virus
977970|NCT02122952|Survival Motor Neuron
977971|NCT02122952|SMN
977972|NCT02122952|AAV9
977973|NCT02122926|Transitions in care
977974|NCT02122926|discharge intervention
977975|NCT02122926|RCT
977976|NCT02122926|readmission rates
977977|NCT02122926|medication adherence
977978|NCT02122926|glycemic control
977979|NCT02122926|ED visits
977980|NCT02122926|medication reconciliation
977981|NCT02122926|Coleman Transitions Coach
977982|NCT02122926|telemonitoring; hypoglycemic events
977983|NCT02122913|TRK
977984|NCT02122913|TRKA
977985|NCT02122913|TRKB
977986|NCT02122913|TRKC
977987|NCT02122913|NTRK1
977988|NCT02122913|NTRK2
977989|NCT02122913|NTRK3
977990|NCT02122913|larotrectinib
977991|NCT02122913|NTRK fusion positive
977992|NCT02122913|NTRK gene rearrangements
977993|NCT02122913|NTRK1 fusion
977994|NCT02122913|NTRK2 fusion
977995|NCT02122913|NTRK3 fusion
977996|NCT02122913|NTRK1 gene rearrangement
977997|NCT02122913|NTRK2 gene rearrangement
977998|NCT02122913|NTRK3 gene rearrangement
977999|NCT02122913|ETV6-NTRK3
978000|NCT02122913|fusion
978001|NCT02122913|tumors
978002|NCT02122913|solid tumors
978003|NCT02122913|CNS tumors
978004|NCT02122913|central nervous system tumors
978005|NCT02122913|TRK fusion
978006|NCT02122913|ETV6
978007|NCT02122913|ETV6 fusion
978008|NCT02122913|ETV6 gene rearrangement
978009|NCT02122913|solid CNS tumor
978010|NCT02122913|Advanced CNS tumor
978011|NCT02122913|Primary CNS tumor
978012|NCT02122913|Metastatic CNS tumor
978013|NCT02122913|LOXO-101
978014|NCT02122887|jewish, arab, israel, teenagers
978015|NCT02122874|Percutaneous neurostimulation; dermatome T7, type 2 diabetes
978016|NCT02122861|Melanoma
978017|NCT02122848|Heart failure
978018|NCT02122848|Exercise tolerance
978019|NCT02122848|Noninvasive ventilation
978020|NCT02122835|exercise
978021|NCT02122835|aerobic exercise
978022|NCT02122822|supratentoria glioma
978023|NCT02122809|Chiauranib, advanced solid tumors, phase 1 study
978024|NCT02122796|Breast Cancer
978025|NCT02122796|Mastectomy
978026|NCT02122796|Acupuncture
978027|NCT02122770|Drug Therapy
978028|NCT02122731|antihypertensive therapy
978029|NCT02122731|amiloride
978030|NCT02122731|add-on
978031|NCT02122731|resistant hypertension
978032|NCT02122731|blood pressure control
978033|NCT02122731|type 2 diabetes mellitus,
978034|NCT02122731|microalbuminuria.
978035|NCT02122705|Remifentanil
978036|NCT02122705|Labour analgesia
978037|NCT02122666|Metabolic Syndrome
978038|NCT02122666|Pre-diabetes
978039|NCT02122666|impaired glucose tolerance
978040|NCT02122666|Phospholipids
978041|NCT02122653|Fatigue
978042|NCT02122653|aging
978043|NCT02122653|transcranial magnetic stimulation
978044|NCT02122653|interpolated
978045|NCT02122653|twitch technique
978046|NCT02122627|Vitamin D, COPD, immunomodulation, physical function, pulmonary function
978047|NCT02122614|Chronic obstructive pulmonary disease
978048|NCT02122614|COPD
978049|NCT02122614|Pulmonary rehabilitation
978050|NCT02122614|Physical activity
978051|NCT02122614|Exercise
978052|NCT02122588|serous and endometrioid ovarian, peritoneal, fallopian tube cancer, hereditary ovarian cancer, BRCA (breast cancer gene) mutation, genetic testing
978053|NCT02122575|Inflammasome
978054|NCT02122575|Fasting
978055|NCT02122575|Sirt3
978056|NCT02122562|Ketamine
978057|NCT02122562|Major Depression
978058|NCT02122562|Alcohol
978059|NCT02122562|Alcohol Clamp
978060|NCT02122562|NMDA Antagonist
978061|NCT02122549|In-Hospital Cardiac Arrest
978062|NCT02122549|Telemetry
978063|NCT02122523|Image guided surgery
978064|NCT02122510|Analgesia, casarean section, TAP block
978065|NCT02122497|abdominal aortic aneurysm
978066|NCT02122497|aortic occlusive disease
978067|NCT02122497|cardiovascular biomarkers
978068|NCT02122497|open surgical repair
978069|NCT02122497|endovascular aortic repair
978070|NCT02122484|reperfusion damage
978071|NCT02122471|CIC
978072|NCT02122471|Constipation
978073|NCT02122471|Chronic Constipation
978074|NCT02122471|Synergy
978075|NCT02122471|Plecanatide
978076|NCT02122458|hearing impairment
978077|NCT02122458|post-traumatic stress disorder
978078|NCT02122458|traumatic brain injury
978079|NCT02122458|auditory processing disorder
978080|NCT02122445|Gluteus Maximum
978081|NCT02122445|Gluteus Medius
978082|NCT02122445|TFL
978083|NCT02122445|EMG
978084|NCT02122445|Flexion-Response Phenomenon
978085|NCT02122445|Thera-Band
978086|NCT02122445|kinesiology tape
978087|NCT02122432|teledermatology
978088|NCT02122432|dermatology
978089|NCT02122432|general practice
978090|NCT02122432|organization of care
978091|NCT02122406|Rheumatoid Arthritis
978092|NCT02122406|Depression
978093|NCT02122406|Anxiety
978094|NCT02122406|DAS28
978095|NCT02122406|HADS
978096|NCT02122380|Growth Hormone
978097|NCT02122380|Dipeptidyl Peptidase 4
978098|NCT02122380|Polycystic Ovary Syndrome
978099|NCT02122328|Twin twin transfusion syndrome
978100|NCT02122328|Sequential laser photocoagulation of communicating vessels
978101|NCT02122302|Altered gastrointestinal anatomy
978102|NCT02122302|Chronic pancreatic disease
978103|NCT02122302|Chronic pancreatic pain
978104|NCT02122302|Patient self-assessment
978105|NCT02122302|Online assessment
978106|NCT02122289|Exacerbation, QoL
978107|NCT02122276|Spinal cord injury
978108|NCT02122276|Passive motion
978109|NCT02122276|Fatigue index
978110|NCT02122276|Hypertonia
978111|NCT02122250|Diabetes
978112|NCT02122250|Health literacy
978113|NCT02122250|web intervention
978114|NCT02122224|satiety
978115|NCT02122224|satiation
978116|NCT02122224|diet quality
978117|NCT02122224|memory
978118|NCT02122224|obesity
978119|NCT02122224|protein
978120|NCT02122224|fiber
978121|NCT02122211|Sperm motility
978122|NCT02122198|Cognitive impairment
978123|NCT02122198|Executive function
978124|NCT02122198|Arterial stiffness
978125|NCT02122198|Endothelial function
978126|NCT02122198|Menopause
978127|NCT02122198|Women's health
978128|NCT02122198|Hormone therapy
978129|NCT02122198|functional MRI
978130|NCT02122159|safety
978131|NCT02122159|tolerability
978132|NCT02122159|RPE cellular therapy
978133|NCT02122159|MMD
978134|NCT02122146|ADC
978135|NCT02122146|PF-06664178
978136|NCT02122146|solid tumors
978137|NCT02122146|tumors
978138|NCT02122146|neoplasm metastasis
978139|NCT02122146|NSCLC
978140|NCT02122146|non small cell lung cancer
978141|NCT02122146|OVCA
978142|NCT02122146|ovarian cancer
978143|NCT02122146|Phase 1
978144|NCT02122146|breast cancer
978145|NCT02122133|IC aneurysms, coil embolization, PC 400, radiation exposure,
978146|NCT02122120|enteral nutrition, tube feeding, nutritional support
978147|NCT02122107|Treatment Exposure
978148|NCT02122107|Smoking History
978149|NCT02122107|14-071
978150|NCT02122068|Meditation
978151|NCT02122068|Mindfulness
978152|NCT02122068|Caregiver
978153|NCT02122068|Dementia
978154|NCT02122068|Depression
978155|NCT02122055|combined sedation
978156|NCT02122029|Lifestyle intervention
978157|NCT02122029|Bariatric surgery
978158|NCT02122029|Weight management
978159|NCT02122029|Physical activity
978160|NCT02122016|Ventilator weaning
978161|NCT02122016|Protocols
978162|NCT02122016|Computer driven weaning
978163|NCT02122016|Decision Making, Computer-Assisted
978164|NCT02122016|Therapy, Computer-Assisted
978165|NCT02122016|Respiration, Artificial
978166|NCT02122003|sorafenib
978167|NCT02122003|pazopanib
978168|NCT02122003|cross-resistance
978169|NCT02122003|TKI
978170|NCT02122003|mRCC
978171|NCT02121990|(IP) Cisplatin
978172|NCT02121990|IV/IP Paclitaxel
978173|NCT02121990|IV Bevacizumab
978174|NCT02121990|Oral Olaparib (AZD2281)
978175|NCT02121990|Optimally Debulked
978176|NCT02121990|Stage II/III
978177|NCT02121990|Ovary
978178|NCT02121990|Pertoneum
978179|NCT02121990|10-220
978180|NCT02121964|unilateral primary total hip arthroplasty
978181|NCT02121964|bilateral primary total hip arthroplasty
978182|NCT02121964|Arthritis
978183|NCT02121964|Orthopedic Disorders
978184|NCT02121964|Orthopedics
978185|NCT02121964|Surgery,
978186|NCT02121964|Orthopedic
978187|NCT02121964|arthroplasty
978188|NCT02121964|hip
978189|NCT02121964|osteoarthritis
978190|NCT02121964|capsulectomy
978191|NCT02121964|capsulotomy
978192|NCT02121951|Percutaneous Nephrostomy
978193|NCT02121951|Quadtatus Lumborum Block
978194|NCT02121951|Cancer
978195|NCT02121951|Monitored Anaesthesia Care
978196|NCT02121938|Very Low Birth Weight (VLBW)
978197|NCT02121938|Microbiome
978198|NCT02121925|Registry
978199|NCT02121899|Registry
978200|NCT02121873|breast cancer, nipple aspirate, ductal lavage, hyperplasia
978201|NCT02121860|Hepatic Impairment
978202|NCT02121860|Pharmacokinetics
978203|NCT02121860|Pharmacodynamics
978204|NCT02121808|Morbid Obesity
978205|NCT02121808|Bariatric Surgery Candidate
978206|NCT02121808|Pre-Oxygenation
978207|NCT02121808|Functional Residual Capacity
978208|NCT02121795|HIV
978209|NCT02121795|HIV-1 Positive
978210|NCT02121795|Virologically-suppressed
978211|NCT02121782|QIV
978212|NCT02121782|Quadrivalent Influenza Vaccine
978213|NCT02121782|Influenza vaccine
978214|NCT02121782|Vaccination
978215|NCT02121769|cholestasis
978216|NCT02121769|short bowel syndrome
978217|NCT02121756|Dipyridamole
978218|NCT02121756|HIV
978219|NCT02121756|Immune Markers
978220|NCT02121756|Immune Activation
978221|NCT02121756|Inflammation
978222|NCT02121743|strattice
978223|NCT02121743|colostomy
978224|NCT02121743|parastomal hernia
978225|NCT02121730|grafting kidney
978226|NCT02121730|Cancer
978227|NCT02121717|Chiglitazar,diabetes,type 2 diabetes
978228|NCT02121704|Sedation
978229|NCT02121704|Colonoscopy
978230|NCT02121704|Propofol
978231|NCT02121704|Scope guide
978232|NCT02121691|Cancer
978233|NCT02121691|Obesity
978234|NCT02121691|Body Mass Index
978235|NCT02121678|Resistance training
978236|NCT02121678|Aerobic exercise
978237|NCT02121678|Isokinetic muscle strength
978238|NCT02121678|Bicycle ergometry test
978239|NCT02121678|Subcutaneous immunoglobulin
978240|NCT02121652|lung cancer survivors
978241|NCT02121652|insomnia treatment
978242|NCT02121652|cognitive behavioral therapy
978243|NCT02121639|Metastatic Castration Resistant Prostate Cancer
978244|NCT02121639|AZD5363
978245|NCT02121639|Docetaxel
978246|NCT02121639|Prednisolone
978247|NCT02121626|Cancer
978248|NCT02121626|Chemotheraphy
978249|NCT02121626|Small Bowel Bacterial Overgrowth
978250|NCT02121626|Bile Acid Malabsorption
978251|NCT02121626|Pancreatic Insufficiency
978252|NCT02121626|Carbohydrate Malabsorption
978253|NCT02121626|Anorexia
978254|NCT02121626|Borborygmi
978255|NCT02121626|Bloating
978256|NCT02121626|Constipation
978257|NCT02121626|Diarrhoea
978258|NCT02121626|Mucositis
978259|NCT02121626|Dysphagia
978260|NCT02121626|Early satiety
978261|NCT02121626|Frequency of defaecation
978262|NCT02121626|Incontinence
978263|NCT02121626|Mucus discharge
978264|NCT02121626|Nausea
978265|NCT02121626|Nocturnal defaecation
978266|NCT02121626|Pain
978267|NCT02121626|Reflux
978268|NCT02121626|Regurgitation
978269|NCT02121626|Steatorrhoea
978270|NCT02121626|Tenesmus
978271|NCT02121626|Urgency of defaecation
978272|NCT02121626|Vomiting
978273|NCT02121626|Weight loss
978274|NCT02121626|Wind.
978275|NCT02121600|Fluorocholine (FCH)
978276|NCT02121600|Positron Emission Tomography (PET)
978277|NCT02121600|Magnetic Resonance Imaging (MRI)
978278|NCT02121587|Musculoskeletal Pain, Osteopathy, Mindfulness
978279|NCT02121574|Surgery
978280|NCT02121574|thermometers
978281|NCT02121574|Hypothermia
978282|NCT02121574|anesthesia
978283|NCT02121574|temperature
978284|NCT02121561|Shame
978285|NCT02121548|Screen
978286|NCT02121548|cervical, cancer
978287|NCT02121548|HPV
978288|NCT02121548|women
978289|NCT02121548|community health workers
978290|NCT02121548|Hispanic/ Latinas
978291|NCT02121548|Haitian
978292|NCT02121496|Depression
978293|NCT02121496|Development
978294|NCT02121496|Infant sleep
978295|NCT02121470|AKI
978296|NCT02121470|Acute Kidney Injury
978297|NCT02121470|Renal failure
978298|NCT02121470|NGAL
978299|NCT02121470|neutrophil gelatinase-associated lipocalin
978300|NCT02121470|lipocalin-2
978301|NCT02121470|siderocalin
978302|NCT02121470|Intensive care
978303|NCT02121470|ICU
978304|NCT02121470|Critical care
978305|NCT02121457|cognitive performance
978306|NCT02121457|selenium
978307|NCT02121457|brazil nuts
978308|NCT02121457|oxidative stress
978309|NCT02121444|RRMS
978310|NCT02121444|CIS
978311|NCT02121366|Endoscopic Ultrasound-Guided Fine Needle Aspiration
978312|NCT02121366|Insulinoma
978313|NCT02121366|Ethanol
978314|NCT02121366|Ablation Techniques
978315|NCT02121353|Age related macular degeneration
978316|NCT02121353|AMD
978317|NCT02121353|Wet AMD
978318|NCT02121353|Eye conditions
978319|NCT02121353|CFT
978320|NCT02121353|OCT
978321|NCT02121353|CNV
978322|NCT02121353|FA
978323|NCT02121353|Ocular
978324|NCT02121353|Eye
978325|NCT02121353|Disorder of the eye
978326|NCT02121340|Depression
978327|NCT02121340|Health disparities
978328|NCT02121340|African American
978329|NCT02121340|Geriatric
978330|NCT02121327|stroke, disease management programs, self-management
978331|NCT02121314|TB
978332|NCT02121314|bioavailability
978333|NCT02121314|HRZE
978334|NCT02121314|fasting
978335|NCT02121314|fed
978336|NCT02121301|Dry Eye
978337|NCT02121301|Dry Eye Syndrome
978338|NCT02121301|SkQ1
978339|NCT02121301|KCS
978340|NCT02121301|Keratoconjunctivitis
978341|NCT02121288|Peripheral Artery Disease
978342|NCT02121288|Myocardial Blood Flow
978343|NCT02121288|Cardiac Blood Flow
978344|NCT02121236|CBCT
978345|NCT02121236|Ultrasonic diagnosis
978346|NCT02121236|Benign radiolucent lesions
978347|NCT02121236|Histopathology
978348|NCT02121223|acute ST segment elevated myocardial infarction
978349|NCT02121223|primary percutaneous intervention
978350|NCT02121223|Stent Incomplete Apposition
978351|NCT02121197|Macular Diabetic Edema
978352|NCT02121197|Ozurdex
978353|NCT02121197|Retrospective
978354|NCT02121197|European
978355|NCT02121197|Intra-vitreal injections
978356|NCT02121184|Oxytocin
978357|NCT02121184|Labor, Obstetric
978358|NCT02121184|Non-reassuring fetal heart rate
978359|NCT02121184|Epidural
978360|NCT02121158|CSP 592
978361|NCT02121158|ICD
978362|NCT02121158|cardiovascular
978363|NCT02121158|heart
978364|NCT02121158|aging
978365|NCT02121158|chronic diseases
978366|NCT02121158|multi-site trial
978367|NCT02121158|phase 3
978368|NCT02121158|investigational device
978369|NCT02121158|cardiomyopathy
978370|NCT02121158|coronary artery disease
978371|NCT02121158|congestive heart failure
978372|NCT02121158|myocardial infarction
978373|NCT02121158|I-70
978374|NCT02121158|I70
978375|NCT02121158|elderly
978376|NCT02121158|defibrillator
978377|NCT02121145|Vivotif
978378|NCT02121145|Typherix
978379|NCT02121145|Salmonella Typhi
978380|NCT02121145|non-typhoid Salmonella
978381|NCT02121145|Salmonella Paratyphi
978382|NCT02121145|enzyme-linked immunospot assay
978383|NCT02121145|Plasmablast
978384|NCT02121132|Overweight
978385|NCT02121132|Obesity
978386|NCT02121119|Peripheral nerve block
978387|NCT02121119|Lidocaine
978388|NCT02121119|Bupivacaine
978389|NCT02121093|vibration
978390|NCT02121093|physiotherapy
978391|NCT02121093|cortex
978392|NCT02121093|muscles
978393|NCT02121067|postpartum
978394|NCT02121067|contraception
978395|NCT02121067|intrauterine device
978396|NCT02121067|intrauterine system
978397|NCT02121067|mirena
978398|NCT02121067|uterine involution
978399|NCT02121054|Antiplatelet Agents
978400|NCT02121054|Drug Resistance
978401|NCT02121041|Hypertension
978402|NCT02121041|Blood Pressure
978403|NCT02121041|Ambulatory Blood Pressure Monitoring
978404|NCT02121028|Intracranial Atherosclerotic Disease
978405|NCT02121028|Stroke
978406|NCT02121028|Transient Ischemic Attack
978407|NCT02121028|Imaging
978408|NCT02121015|Postpartum Depression
978409|NCT02121015|Depression Prevention
978410|NCT02121015|Supportive Accountability
978411|NCT02121015|Individual Internet Interventions (IIIs)
978412|NCT02121015|Internet Support Groups (ISGs)
978413|NCT02121002|Knee
978414|NCT02120989|insomnia
978415|NCT02120989|cognitive behavioral therapy for insomnia (CBT-I)
978416|NCT02120989|partner-assisted
978417|NCT02120976|Safety
978418|NCT02120976|Tolerability
978419|NCT02120976|Pharmacokinetics
978420|NCT02120976|Food-effect
978421|NCT02120976|Diabetes
978422|NCT02120963|Fatigue
978423|NCT02120963|Rheumatoid Arthritis
978424|NCT02120963|Physical Therapy
978425|NCT02120963|Person-Centred Care
978426|NCT02120950|PCV
978427|NCT02120937|amygdala
978428|NCT02120937|mindfulness
978429|NCT02120937|mood
978430|NCT02120937|emotion
978431|NCT02120937|bipolar disorder
978432|NCT02120937|parental bipolar disorder
978433|NCT02120937|adolescence
978434|NCT02120924|Moderate facial rosacea
978435|NCT02120924|Azelaic acid
978436|NCT02120924|Rosacea
978437|NCT02120911|Her2+
978438|NCT02120911|Resectable esophageal carcinoma
978439|NCT02120911|Pertuzumab
978440|NCT02120911|Trastuzumab
978441|NCT02120898|Actinic Keratosis
978442|NCT02120898|Imiquimod
978443|NCT02120898|Zyclara
978444|NCT02120885|Gastric cancer
978445|NCT02120885|minimally invasive gastrectomy
978446|NCT02120885|Physical activity intervention
978447|NCT02120859|PCI
978448|NCT02120859|Drug-eluting balloon (DEB)
978577|NCT02120352|TMC278
978449|NCT02120859|Fractional flow reserve (FFR)
978450|NCT02120846|Stroke
978451|NCT02120846|Flywheel resistance exercise
978452|NCT02120846|Muscle function
978453|NCT02120846|Cognitive function
978454|NCT02120833|Atopic Dermatitis
978455|NCT02120820|massage
978456|NCT02120820|multisensory environment
978457|NCT02120820|challenging behaviours
978458|NCT02120820|relaxation
978459|NCT02120807|Certolizumab
978460|NCT02120807|Cisplatin
978461|NCT02120807|Pemetrexed
978462|NCT02120807|thoracic
978463|NCT02120807|13-063
978464|NCT02120794|Type 1 diabetes
978465|NCT02120794|Pediatric
978466|NCT02120794|Threshold Suspend
978467|NCT02120794|Sensor augmented pump
978468|NCT02120768|Barrier resection
978469|NCT02120768|Local recurrence
978470|NCT02120768|Complication
978471|NCT02120742|Road traffic injury prevention
978472|NCT02120742|Helmet use
978473|NCT02120742|mHealth intervention
978474|NCT02120729|Pharmacogenetics
978475|NCT02120729|CYP2D6 Mutations
978476|NCT02120729|Major Depressive Disorder
978477|NCT02120729|Psychiatric Inpatients
978478|NCT02120729|Length of Stay
978479|NCT02120729|30 Day Readmission Rate
978480|NCT02120729|Psychiatric hospital inpatients
978481|NCT02120716|HIV
978482|NCT02120716|STIs
978483|NCT02120716|Health Check Up
978484|NCT02120716|Intervention
978485|NCT02120703|Pregabalin
978486|NCT02120703|gabapentin
978487|NCT02120703|microdiscectomy
978488|NCT02120703|pain
978489|NCT02120690|pain
978490|NCT02120690|fibromyagia
978491|NCT02120690|TNS
978492|NCT02120677|skin cancer
978493|NCT02120677|basal cell carcinoma
978494|NCT02120651|Fibrin monomer
978495|NCT02120651|Tympanoplasty
978496|NCT02120651|Hemostatic sponge
978497|NCT02120638|Multidrug Resistant Tuberculosis
978498|NCT02120638|Pyrazinamide
978499|NCT02120625|radiofrequency ablation
978500|NCT02120625|neurotomy
978501|NCT02120625|facet joint
978502|NCT02120625|medial branch
978503|NCT02120625|low back pain
978504|NCT02120612|Opioid Dependence
978505|NCT02120612|Addiction
978506|NCT02120612|Naloxone
978507|NCT02120612|Naloxone Education
978508|NCT02120612|Opiate Overdose Knowledge Scale
978509|NCT02120612|OOKS
978510|NCT02120586|Elderly
978511|NCT02120586|Institutionalization
978512|NCT02120586|Sarcopenia
978513|NCT02120586|Strength training
978514|NCT02120586|Muscle mass
978515|NCT02120586|Muscle strength
978516|NCT02120586|Physical performance
978517|NCT02120573|Cardiac Arrest
978518|NCT02120573|Cardiopulmonary Resuscitation
978519|NCT02120573|Training
978520|NCT02120560|Atrial Fibrillation Ablation
978521|NCT02120560|Cerebrothromboemboli
978522|NCT02120560|Neurocognitive Function
978523|NCT02120547|Liver Insufficiency
978524|NCT02120547|Hepatic impairment
978525|NCT02120534|soluble CD14 ,serum CD88,sepsis , SIRS.
978526|NCT02120521|Sepsis and SIRS, ICU
978527|NCT02120508|stroke
978528|NCT02120508|aphasia
978529|NCT02120508|rTMS
978530|NCT02120508|Functional MRI
978531|NCT02120508|Speech training
978532|NCT02120495|condylectomy
978533|NCT02120495|TMJ function
978534|NCT02120495|intraoral approach
978535|NCT02120482|ABO isoagglutinins
978536|NCT02120482|ABO incompatible transplantation
978537|NCT02120482|immunoadsorption
978538|NCT02120482|membrane filtration
978539|NCT02120482|plasmapheresis
978540|NCT02120443|infiltration
978541|NCT02120443|extravasation
978542|NCT02120443|peripheral intravenous therapy
978543|NCT02120430|Early childhood
978544|NCT02120430|Audiovisual materials
978545|NCT02120430|Parent-child interaction
978546|NCT02120430|Parenting programs
978547|NCT02120430|Timing
978548|NCT02120417|Breast Cancer
978550|NCT02120378|miscarriage
978551|NCT02120378|fetal viability
978552|NCT02120378|prematurity
978553|NCT02120365|Alcoholism
978554|NCT02120365|Heavy Drinking
978555|NCT02120365|Perampanel
978556|NCT02120352|bi-monthly
978557|NCT02120352|GSK744
978558|NCT02120352|injectable
978559|NCT02120352|long acting
978560|NCT02120352|maintenance
978561|NCT02120352|abacavir
978562|NCT02120352|every other month
978563|NCT02120352|rilpivirine
978564|NCT02120352|HIV-1 infection
978565|NCT02120352|integrase inhibitor
978566|NCT02120352|TMC278 LA
978567|NCT02120352|RPV
978568|NCT02120352|non-nucleoside reverse transcriptase inhibitor
978569|NCT02120352|LA
978570|NCT02120352|once monthly
978571|NCT02120352|GSK1265744
978572|NCT02120352|induction
978573|NCT02120352|treatment satisfication
978574|NCT02120352|once daily
978575|NCT02120352|lamivudine
978576|NCT02120352|adherence
978578|NCT02120352|therapy-naive
978579|NCT02120339|Hypertension
978580|NCT02120339|PAH
978581|NCT02120326|Chronic migraine, tDCS, Transcranial direct current stimulation
978582|NCT02120313|rehabilitation
978583|NCT02120313|total knee arthroplasty
978593|NCT02120274|RNA Virus Infections
978594|NCT02120274|Flaviviridae Infections
978595|NCT02120274|Hepatitis C
978596|NCT02120274|Hepatitis C, Chronic
978597|NCT02120274|Vitamin D
978598|NCT02120274|Cholecalciferol
978599|NCT02120274|Vitamin B 12
978600|NCT02120261|Myofascial Pain Syndrome
978601|NCT02120261|trigger point injection
978602|NCT02120248|WIC
978603|NCT02120248|Oregon
978604|NCT02120248|Breastfeeding
978605|NCT02120248|Peer Counseling
978606|NCT02120248|Exclusive Breastfeeding
978607|NCT02120235|Lysosomal storage disorders
978608|NCT02120235|LSD
978609|NCT02120235|Gaucher disease
978610|NCT02120235|Fabry disease
978611|NCT02120235|Pompe disease
978612|NCT02120235|Niemann-Pick disease
978613|NCT02120222|melanoma
978614|NCT02120209|assessment; falls; older adults; prediction scale; standardized declaration
978615|NCT02120183|Caregivers
978616|NCT02120183|Quality of life
978617|NCT02120183|Neoplasms
978618|NCT02120183|Psychotherapy, group
978619|NCT02120183|Family
978620|NCT02120183|Adaptation, psychological
978621|NCT02120183|Psycho-educational support group therapy
978622|NCT02120183|Cancer patients
978623|NCT02120170|Hemoclip, Heparin bridging therapy, colon polypectomy, warfarin
978624|NCT02120157|Acute lymphoblastic leukemia
978625|NCT02120157|Acute myeloid leukemia
978626|NCT02120157|Juvenile myelomonocytic leukemia
978627|NCT02120157|Treatment related leukemia
978628|NCT02120157|Biphenotypic leukemia
978629|NCT02120131|third molar surgery, periodontal probing depth , flap design
978630|NCT02120118|Treatment failure
978631|NCT02120105|Renal aminoaciduria
978632|NCT02120105|cystinuria
978633|NCT02120105|D-penicillamine
978634|NCT02120105|renal tubular transport
978635|NCT02120105|inborn errors
978636|NCT02120105|tiopronin
978637|NCT02120105|urolithiasis
978638|NCT02120092|ACS, Acute coronary syndrome
978639|NCT02120079|Dry Eye
978640|NCT02120066|Submacular hemorrhage
978641|NCT02120066|Vitrectomy
978642|NCT02120066|tissue- plasminogen activator
978643|NCT02120053|Immediate complete denture
978644|NCT02120053|Alveolar ridge resorption
978645|NCT02120053|Alveolar bone loss
978646|NCT02120053|Bone substitute material
978647|NCT02120053|Edentulism
978648|NCT02120027|Irritable Bowel Syndrome
978649|NCT02120027|Colon, irritable
978650|NCT02120027|Bowel disease
978651|NCT02120027|Diarrhea
978652|NCT02120014|Heart Failure
978653|NCT02120014|Heart Failure Reduced Ejection Fraction
978654|NCT02120014|Heart Failure Preserved Ejection Fraction
978655|NCT02120014|Venous Plethysmography
978656|NCT02120014|Blood Volume Study
978657|NCT02120001|Medical Devices
978658|NCT02120001|Ventilator-Associated Pneumonia (VAP)
978659|NCT02120001|Ventilator-Associated Events (VAE)
978660|NCT02120001|Endotracheal Tube
978661|NCT02120001|Microbial Diversity
978662|NCT02120001|Drug-Resistance
978663|NCT02120001|biofilms
978664|NCT02120001|endotracheal intubation
978665|NCT02120001|mechanical ventilation
978666|NCT02119988|TIPS
978667|NCT02119988|Embolization
978668|NCT02119988|Variceal rebleeding
978669|NCT02119975|Rumination
978670|NCT02119975|Working memory
978671|NCT02119975|Depression
978672|NCT02119975|Anxiety
978673|NCT02119975|Working memory training
978674|NCT02119975|Overgeneral memories
978675|NCT02119962|burnout
978676|NCT02119962|working memory
978677|NCT02119962|working memory training
978678|NCT02119962|cognitive behavioral therapy
978679|NCT02119962|executive control
978680|NCT02119949|Substance abuse
978681|NCT02119949|Addiction
978682|NCT02119949|Working memory
978683|NCT02119949|Craving
978684|NCT02119949|Impulsivity
978685|NCT02119949|Attention control
978686|NCT02119936|Stress
978687|NCT02119936|Anxiety
978688|NCT02119936|Mental Health
978689|NCT02119936|Mental Health Services
978690|NCT02119936|Maternal Mental Health
978691|NCT02119923|Depression
978692|NCT02119923|Anxiety
978693|NCT02119923|Working memory
978694|NCT02119923|Rumination
978695|NCT02119923|Cognitive training
978696|NCT02119923|Executive functioning
978697|NCT02119910|pediatric feeding disorders
978698|NCT02119910|behavioral intervention
978699|NCT02119910|treatment manual
978700|NCT02119910|feeding
978701|NCT02119910|food refusal
978702|NCT02119910|diet
978703|NCT02119897|Oropharyngeal Mucositis
978704|NCT02119897|Myeloablative Hematopoietic Cell Transplantation
978705|NCT02119897|Low Level Light Therapy
978706|NCT02119884|Gastric and Esophageal Varices
978707|NCT02119884|Hepatic Venous Pressure Gradient
978708|NCT02119884|Terlipressin
978709|NCT02119884|Octreotide
978710|NCT02119871|Cerebral air emboli, heart surgery
978711|NCT02119845|Chronic kidney disease
978712|NCT02119845|Arteriovenous fistula (AVF)
978713|NCT02119845|Hemodialysis
978714|NCT02119845|Vascular access
978715|NCT02119845|Endovascular AVF (EndoAVF)
978716|NCT02119832|Chronic kidney disease
978717|NCT02119832|Arteriovenous fistula
978718|NCT02119832|Hemodialysis
978719|NCT02119832|Vascular access
978720|NCT02119819|Weight loss
978721|NCT02119806|cardiac surgery, benzodiazepines, delirium
978722|NCT02119767|Atherosclerosis
978723|NCT02119754|Wound
978724|NCT02119754|Ulcer
978725|NCT02119754|Infected
978726|NCT02119754|Infection
978727|NCT02119741|Interdental papilla
978728|NCT02119741|hyaluronic acid
978729|NCT02119741|esthetic zone
978730|NCT02119741|black triangles
978731|NCT02119715|Breast Cancer
978732|NCT02119715|Neutropenia
978733|NCT02119715|Febrile Neutropenia
978734|NCT02119702|HIV/AIDS, perinatal HIV infection
978735|NCT02119689|Diabetes
978736|NCT02119689|Retinopathy
978737|NCT02119676|Metastatic Colorectal Cancer
978738|NCT02119676|Colon Cancer
978739|NCT02119676|Ruxolitinib
978740|NCT02119676|adenocarcinoma
978741|NCT02119676|regorafenib
978742|NCT02119676|Jakavi ®
978743|NCT02119676|Jakafi ®
978744|NCT02119676|Stivarga ®
978745|NCT02119663|Metastatic pancreatic cancer
978746|NCT02119650|Non small cell lung cancer
978747|NCT02119637|Emotion
978748|NCT02119637|Tactile Discrimination
978749|NCT02119637|Transcranial Magnetic Stimulation (TMS)
978750|NCT02119637|Somatosensory
978751|NCT02119637|Somatosensory Cortex
978752|NCT02119624|Neural Networks
978753|NCT02119624|Alcoholism
978754|NCT02119624|fMRI
978755|NCT02119624|Reward
978756|NCT02119624|Addiction
978757|NCT02119611|Deep Brain Stimulation
978758|NCT02119611|Movement Disorders
978759|NCT02119611|Parkinson's Disease
978760|NCT02119611|Dystonia
978761|NCT02119611|Essential Tremor
978762|NCT02119598|Prehospital care
978763|NCT02119598|Telemedicine
978764|NCT02119598|Ambulance-based telemedicine
978765|NCT02119585|orthotopic liver transplantation
978766|NCT02119585|ischemia reperfusion syndrome
978767|NCT02119585|cytokines
978768|NCT02119585|respiratory system elastance
978769|NCT02119585|lung elastance
978770|NCT02119585|chest wall elastance
978771|NCT02119585|shunt
978772|NCT02119585|dead space
978773|NCT02119585|acute respiratory failure
978774|NCT02119585|atelectasis
978775|NCT02119585|pleural effusion
978776|NCT02119572|diabetes,peer support
978777|NCT02119559|Circulating Tumor Cells
978778|NCT02119559|Treatment Efficiency
978779|NCT02119559|Biomarker
978780|NCT02119546|Mild CognitIve impairment
978781|NCT02119546|Alzheimer's disease
978782|NCT02119546|Cognitive function
978783|NCT02119546|Exercise training
978784|NCT02119533|brain injury
978785|NCT02119533|concussion
978786|NCT02119533|post traumatic stress
978787|NCT02119520|Periodontitis
978788|NCT02119520|Surgery
978789|NCT02119520|Growth Factors
978790|NCT02119520|Statins
978791|NCT02119507|Dental caries
978792|NCT02119507|Curodont Repair
978793|NCT02119507|P11-4
978794|NCT02119494|chronic obstructive pulmonary disease
978795|NCT02119494|phenotypes
978796|NCT02119494|categories
978797|NCT02119494|stage
978798|NCT02119494|GOLD
978799|NCT02119494|treatment
978800|NCT02119481|Mindfulness stress reduction training
978801|NCT02119481|Expressive writing condition
978802|NCT02119481|Waiting list control condition
978803|NCT02119442|Eisenmenger Syndrome, Pulmonary Arterial Hyptertension
978804|NCT02119429|Blood pressure
978805|NCT02119429|Pre-menopausal
978806|NCT02119429|Supplementation
978807|NCT02119416|Cardiovascular influences
978808|NCT02119416|caffeine
978809|NCT02119416|healthy children
978810|NCT02119403|Minimal Sedation nitrous oxide
978811|NCT02119390|adolescents
978812|NCT02119390|young adults
978813|NCT02119390|medication adherence
978814|NCT02119377|trans
978815|NCT02119377|transsexual
978816|NCT02119377|transgender
978817|NCT02119377|sistergirl
978818|NCT02119377|brotherboy
978819|NCT02119377|androgynous
978820|NCT02119377|genderqueer
978821|NCT02119364|cerebral palsy
978822|NCT02119364|working memory
978823|NCT02119364|cognitive training
978824|NCT02119351|peripheral intravenous catheters
978825|NCT02119351|blood exposure
978826|NCT02119351|blood control
978827|NCT02119351|IV catheter insertion
978828|NCT02119338|5-ala
978829|NCT02119338|5-aminolevulinic acid
978830|NCT02119338|fluorescence-guided surgery
978831|NCT02119338|glioma
978832|NCT02119338|astrocytoma
978833|NCT02119338|glioblastoma
978834|NCT02119338|oligodendroglioma
978835|NCT02119338|recurrence of glioma
978836|NCT02119325|fibre
978837|NCT02119325|overweight
978838|NCT02119325|impaired fasting glucose
978839|NCT02119312|Malaria
978840|NCT02119312|Plasmodium
978841|NCT02119312|Plasmodium falciparum
978842|NCT02119312|Clinical Trials
978843|NCT02119312|Vaccine Study
978844|NCT02119312|Drug Study
978845|NCT02119312|Malaria Clinical Trials Center
978846|NCT02119312|Seattle BioMed
978847|NCT02119312|Center for Infectious Disease Research
978848|NCT02119286|long acting beta2- receptor agonist
978849|NCT02119286|long acting muscarininc receptor antagonist
978850|NCT02119286|dry powder inhaler
978851|NCT02119286|safety
978852|NCT02119286|COPD
978853|NCT02119286|inhaled corticosteroid
978854|NCT02119286|efficacy
978855|NCT02119286|fluticasone furoate/vilanterol
978856|NCT02119286|umeclidinium bromide
978857|NCT02119273|CRSsNP
978858|NCT02119273|Steroids
978859|NCT02119273|Corticosteroids
978860|NCT02119273|Endoscopic
978861|NCT02119273|Surgery
978862|NCT02119273|Perioperative
978863|NCT02119260|First Time in Human
978864|NCT02119260|TRPV4 inhibitor
978865|NCT02119260|Heart failure
978866|NCT02119247|systemic availability , pharmacokinetics, COPD
978867|NCT02119195|composite
978868|NCT02119195|sealant
978869|NCT02119195|longevity
978870|NCT02119182|Traumatic Brain Injury
978871|NCT02119182|Biomarkers
978872|NCT02119182|Neuroimaging
978873|NCT02119182|Psychological Health
978874|NCT02119182|Comparative Effectiveness Research
978875|NCT02119156|treatment holiday
978876|NCT02119156|PGA
978877|NCT02119156|belimumab
978878|NCT02119156|Lymphostat-B
978879|NCT02119156|rebound
978880|NCT02119156|SELENA SLEDAI
978881|NCT02119156|Systemic Lupus Erythematosus
978882|NCT02119156|immunogenicity
978883|NCT02119143|common cold, immunity, oxidative stress
978884|NCT02119130|cluster randomized trial
978885|NCT02119130|interferon-gamma
978886|NCT02119130|tuberculin test
978887|NCT02119130|operational comparison
978888|NCT02119130|cost effectiveness
978889|NCT02119130|qualitative evaluation
978890|NCT02119117|mtDNA
978891|NCT02119117|aneuploidy
978892|NCT02119117|IVF
978893|NCT02119117|blastocyst
978894|NCT02119117|COQ10
978895|NCT02119091|QT prolongation
978896|NCT02119091|Chinese
978897|NCT02119091|Caucasian
978898|NCT02119091|Moxifloxacin
978899|NCT02119078|Geriatrics
978900|NCT02119078|Acute Care for Elders
978901|NCT02119078|Geriatric syndromes
978902|NCT02119078|Delirium
978903|NCT02119078|Falls
978904|NCT02119078|Polypharmacy
978905|NCT02119065|Yttrium-90 Radioembolization
978906|NCT02119065|hepatic malignancy
978907|NCT02119065|hepatic metastatic disease
978908|NCT02119039|Cross-linking
978909|NCT02119039|RGTA OTR4120 (CACICOL20)
978910|NCT02119026|metastatic colorectal cancer
978911|NCT02119026|Patients with metastatic colorectal cancer who did not receive
978912|NCT02119026|systemic treatment for their metastatic disease
978913|NCT02118987|Drug Desensitization
978914|NCT02118987|Hypersensitivity reactions to chemotherapeutic agents
978915|NCT02118974|Hysterectomy
978916|NCT02118974|Robot-assisted
978917|NCT02118974|Laparoscopy
978918|NCT02118961|Diphtheria
978919|NCT02118961|Tetanus
978920|NCT02118961|Pertussis
978921|NCT02118961|DTaP vaccine
978922|NCT02118961|Adolescents
978923|NCT02118948|abuse
978924|NCT02118948|sexual behavior
978925|NCT02118948|sexual risk reduction
978926|NCT02118948|behavioral intervention
978927|NCT02118896|Tacrolimus
978928|NCT02118896|FK506E
978929|NCT02118896|MR4
978930|NCT02118896|Advagraf
978931|NCT02118896|Kidney Transplantation
978932|NCT02118896|Renal Transplantation
978933|NCT02118896|Heart Transplantation
978934|NCT02118883|exercise
978935|NCT02118883|hydration
978936|NCT02118883|dehydration
978937|NCT02118883|rehydration
978938|NCT02118883|alkaline water
978939|NCT02118883|blood viscosity
978940|NCT02118883|plasma osmolality
978941|NCT02118883|bioimpedance
978942|NCT02118870|ACS patients
978943|NCT02118870|Older than 18 years
978944|NCT02118870|PCI
978945|NCT02118870|Combo stent
978946|NCT02118857|Microorganisms and foods
978947|NCT02118857|Fecal microbiota
978948|NCT02118857|Salivary microbiota
978949|NCT02118844|bariatric surgery
978950|NCT02118844|surgical conditions
979324|NCT02117076|Restless leg syndrome
978951|NCT02118844|deep neuromuscular blockade
978952|NCT02118831|macular degeneration
978953|NCT02118831|diabetic macular edema
978954|NCT02118831|vein occlusion
978955|NCT02118831|vascular endothelial growth factor
978956|NCT02118805|ALS
978957|NCT02118805|Myasthenia Gravis
978958|NCT02118805|Myopathy
978959|NCT02118805|Stroke
978960|NCT02118805|Parkinson's Disease
978961|NCT02118805|Bulbar
978962|NCT02118805|Orofacial
978963|NCT02118805|Ultrasound
978964|NCT02118805|Electrical Impedance Myography
978965|NCT02118792|atopic dermatitis
978966|NCT02118779|Myotonic Dystrophy Type 1
978967|NCT02118779|DM1
978968|NCT02118779|Physical Exercise
978969|NCT02118779|Cognitive Behavioural Therapy
978970|NCT02118779|Biomarkers
978971|NCT02118766|atopic dermatitis
978972|NCT02118753|ischemia-reperfusion injury
978973|NCT02118740|Autologous Stem Cells
978974|NCT02118740|Spinal Cord Injury
978975|NCT02118740|Preclinical
978976|NCT02118727|ALS
978977|NCT02118727|FTD
978978|NCT02118727|Tau
978979|NCT02118727|pNF-H/C3
978980|NCT02118714|Kidney Diseases
978981|NCT02118714|Urologic Diseases
978982|NCT02118714|Diabetes Complications
978983|NCT02118714|Diabetes Mellitus
978984|NCT02118714|Endocrine System Diseases
978985|NCT02118714|Diabetic Nephropathies
978986|NCT02118701|Shared decision making
978987|NCT02118701|Dementia
978988|NCT02118701|Long-term care
978989|NCT02118701|Nursing home
978990|NCT02118701|Care plan
978991|NCT02118636|Joint pain
978992|NCT02118636|Hormone receptor positive breast cancer
978993|NCT02118636|Estrogen
978994|NCT02118636|Androgen
978995|NCT02118623|Bipolar Disorder
978996|NCT02118623|Bipolar
978997|NCT02118623|Online intervention
978998|NCT02118623|Internet intervention
978999|NCT02118623|Self help
979000|NCT02118545|vWF
979001|NCT02118545|Liver Resection
979002|NCT02118545|Liver Dysfunction
979003|NCT02118545|Liver Regeneration
979004|NCT02118545|Postoperative Outcome
979005|NCT02118532|Atherosclerosis
979006|NCT02118532|Superficial Femoral Artery
979007|NCT02118532|Proximal Popliteal Artery
979008|NCT02118519|Bone marrow derived Mesenchymal Stem Cells
979009|NCT02118519|Knee articular cartilage injury
979010|NCT02118519|Chondrogenesis
979011|NCT02118519|orthopedics
979012|NCT02118506|Primary Parkinsonism.
979013|NCT02118506|Rehabilitation.
979014|NCT02118506|Biomechanics.
979015|NCT02118506|Neurological gait disorders.
979016|NCT02118493|Benign Biliary Stenosis
979017|NCT02118493|Laser Excision
979018|NCT02118480|Parkinson disease, cognitive rehabilitation, REHACOP
979019|NCT02118467|Shock
979020|NCT02118467|Vasopressor agents
979021|NCT02118467|Norepinephrine
979022|NCT02118467|Epinephrine
979023|NCT02118467|Phenylephrine
979024|NCT02118467|Vasopressin
979025|NCT02118467|Atrial fibrillation
979026|NCT02118467|Tachyarrhythmia
979027|NCT02118454|Medication adherence
979028|NCT02118454|Self-management
979029|NCT02118454|Depression
979030|NCT02118454|Coping
979031|NCT02118454|Social support
979032|NCT02118454|Mobile health
979033|NCT02118454|Antiretroviral treatment
979034|NCT02118428|whole blood
979035|NCT02118428|transfusion
979036|NCT02118428|Plasmodium
979037|NCT02118428|Malaria
979038|NCT02118428|Pathogen Reduction Technology
979039|NCT02118428|Whole blood transfusion
979040|NCT02118415|not eligible for surgery
979041|NCT02118415|efficacy of immunotherapy following RCTx
979042|NCT02118376|obesity; fat distribution; inflammation
979043|NCT02118363|upper limb
979044|NCT02118363|lower limb
979045|NCT02118363|monitoring
979046|NCT02118363|assessment
979047|NCT02118363|sensor
979048|NCT02118337|select advanced malignancies
979049|NCT02118324|Acute Lymphoblastic Leukemia
979050|NCT02118324|ALL
979051|NCT02118324|fitness intervention
979052|NCT02118311|Acute Leukemias
979053|NCT02118311|Burkitt's Lymphoma
979054|NCT02118311|Natural Killer Cell Malignancies
979055|NCT02118311|Chronic Myelogenous Leukemia
979056|NCT02118311|Myelodysplastic Syndrome
979057|NCT02118311|Large-Cell Lymphoma
979058|NCT02118311|Hodgkin Lymphoma
979059|NCT02118311|Multiple Myeloma
979060|NCT02118311|Chronic Lymphocytic Leukemia
979061|NCT02118311|Small Lymphocytic Lymphoma
979062|NCT02118311|Marginal Zone B-Cell Lymphoma
979063|NCT02118311|Follicular Lymphoma:
979064|NCT02118311|Lymphoplasmacytic Lymphoma
979065|NCT02118311|Mantle-Cell Lymphoma
979066|NCT02118311|Prolymphocytic Leukemia
979067|NCT02118285|Ovarian cancer
979068|NCT02118285|Fallopian cancer
979069|NCT02118285|Primary peritoneal cancer
979070|NCT02118259|Multidisciplinary review of drug prescriptions
979071|NCT02118259|Adverse drug events geriatric risk score
979072|NCT02118259|Residence for dependent elderly
979073|NCT02118246|Knee pain,Dry Needling, kinesioTape,Trigger point
979074|NCT02118233|carotid
979075|NCT02118233|stenosis
979076|NCT02118233|surgery
979077|NCT02118233|cognitive
979078|NCT02118233|unilateral
979079|NCT02118207|SCUBA diving
979080|NCT02118207|Exercise
979081|NCT02118207|Microparticles
979082|NCT02118207|Repetitive diving
979083|NCT02118207|Endothelial function
979084|NCT02118194|paraplegia
979085|NCT02118194|paralysis
979086|NCT02118194|robotics
979087|NCT02118194|walking
979088|NCT02118194|immobilization
979089|NCT02118168|HIV
979090|NCT02118168|HAART
979091|NCT02118168|Tat Protein
979092|NCT02118129|Vitamin D
979093|NCT02118129|Intervention
979094|NCT02118129|Behaviour
979095|NCT02118129|Mobile app
979096|NCT02118116|ASIST, gatekeeper, suicide, intervention, First Nations, Aboriginal, educational, prevention, safety
979097|NCT02118103|Lumbosacral Region
979098|NCT02118103|Psychomotor Performance
979099|NCT02118103|Manipulation, Spinal
979100|NCT02118090|malaria
979101|NCT02118090|Plasmodium vivax
979102|NCT02118090|drug resistance
979103|NCT02118090|chloroquine
979104|NCT02118090|Cambodia
979105|NCT02118064|G17DT
979106|NCT02118064|irinotecan
979107|NCT02118064|Colorectal Cancer
979108|NCT02118051|Infertility
979109|NCT02118051|IVF
979110|NCT02118051|Corifollitropin Alfa treatment
979111|NCT02118051|Ovarian stimulation
979112|NCT02118038|Postpartum haemorrhage
979113|NCT02118038|Sulprostone
979114|NCT02118038|Cardiac impact
979115|NCT02118038|Emotional impact
979116|NCT02118038|Cardiac magnetic imaging resonance
979117|NCT02118025|Off-pump bypass graft surgery
979118|NCT02118025|Mini extracorporeal circulation bypass surgery
979119|NCT02118012|Chlorcyclizine HCL
979120|NCT02118012|Direct Acting Antivirals
979121|NCT02118012|Ribavirin
979122|NCT02118012|Hepatitis C
979123|NCT02117999|corneal cross-linking
979124|NCT02117999|transepithelial corneal cross-linking
979125|NCT02117999|iontophoresis
979126|NCT02117999|progressive keratoconus
979127|NCT02117986|critically ill patients
979128|NCT02117986|colistin dosing
979129|NCT02117986|multidrug resistant bacteria
979130|NCT02117960|atherosclerotic
979131|NCT02117960|BMP-4
979132|NCT02117960|YKL40
979133|NCT02117960|HSP70
979134|NCT02117960|HSP27
979135|NCT02117947|child secondhand smoke
979136|NCT02117947|maternal smoking
979137|NCT02117947|tobacco
979138|NCT02117947|nicotine
979139|NCT02117947|behavioral counseling
979140|NCT02117947|low-income
979141|NCT02117947|underserved
979142|NCT02117934|HBV vaccine
979143|NCT02117934|HEPLISAV-B
979144|NCT02117934|Hepatitis B vaccine
979145|NCT02117934|Hepatitis B
979146|NCT02117934|Hepatitis
979147|NCT02117934|Hepatitis B virus (HBV)
979148|NCT02117934|Prevention and Control
979149|NCT02117934|Healthy
979150|NCT02117934|Healthy volunteers
979151|NCT02117921|Mind Body Syndrome
979152|NCT02117921|MBS
979153|NCT02117921|Chronic Pain
979157|NCT02117895|Distal Pancreatectomy
979158|NCT02117895|Celiac Plexus
979159|NCT02117895|Resection
979160|NCT02117895|Pancreatic Cancer
979161|NCT02117895|Body and Tail
979162|NCT02117882|lateral approach, bone augmentation , sinus floor elevation
979163|NCT02117869|Grapefruit juice
979164|NCT02117856|Implant-Supported Denture
979165|NCT02117856|Single-Implant Denture
979166|NCT02117856|Patient Satisfaction
979167|NCT02117856|Edentulous Mandible
979168|NCT02117856|Dental Implants
979169|NCT02117856|Standard of Care
979170|NCT02117856|Randomized Clinical Trial
979171|NCT02117830|To determine
979172|NCT02117830|effects
979173|NCT02117830|once
979174|NCT02117830|daily
979175|NCT02117830|oral doses
979176|NCT02117830|Androxal
979177|NCT02117804|Discharge Planning
979178|NCT02117804|Decision Support
979179|NCT02117791|Riociguat, Adempas, sGC stimulator, CTEPH, Japan, PMS
979180|NCT02117765|T1D
979181|NCT02117765|ustekinumab
979182|NCT02117765|new-onset
979183|NCT02117765|diabetes
979184|NCT02117726|Sedation;
979185|NCT02117726|ARDS;
979186|NCT02117726|Mechanical ventilation
979187|NCT02117726|Hypnotics
979188|NCT02117726|Antianxiety Drugs
979189|NCT02117726|Causing
979190|NCT02117726|Adverse Effects
979191|NCT02117726|Therapeutic Use
979192|NCT02117700|fatty liver
979193|NCT02117700|obesity
979194|NCT02117700|children
979195|NCT02117700|oxidative stress
979196|NCT02117700|antioxidants
979197|NCT02117674|colonoscopy
979198|NCT02117674|adenoma detection rate
979199|NCT02117674|full spectrum colonoscopy
979200|NCT02117674|right colon retroflexion
979201|NCT02117674|feasibility
979202|NCT02117661|L-carnitine
979203|NCT02117661|Metabolic syndrome
979204|NCT02117661|Atherosclerosis
979205|NCT02117661|Coronary artery disease
979206|NCT02117661|Carotid
979207|NCT02117661|Plaque
979208|NCT02117661|Cardiovascular disease
979209|NCT02117661|Heart disease
979210|NCT02117661|Vascular disease
979211|NCT02117648|advanced cancer
979212|NCT02117648|metastatic cancer
979213|NCT02117635|Efficacy
979214|NCT02117635|Non comparative
979215|NCT02117635|Neural stem cells
979216|NCT02117635|Intracranial administration
979217|NCT02117609|Elderly
979218|NCT02117609|Nursing home
979219|NCT02117609|Functional impairment
979220|NCT02117609|High-protein oral supplement
979221|NCT02117596|Pediatric
979222|NCT02117596|Renal
979223|NCT02117596|Transplant
979224|NCT02117583|pharmacokinetics
979225|NCT02117583|relative bioavailability
979226|NCT02117583|food effects
979227|NCT02117583|oxycodone
979228|NCT02117570|Clostridium difficile
979229|NCT02117570|vaccine
979230|NCT02117557|Single-incision
979231|NCT02117557|Laparoscopy
979232|NCT02117557|Colorectal Cancer
979233|NCT02117544|Contact lens
979234|NCT02117544|Presbyopia
979235|NCT02117544|Multifocal
979236|NCT02117518|type 1 diabetes
979237|NCT02117518|autoreactive T cells
979238|NCT02117518|beta cell peptides
979239|NCT02117518|genetically modified T cells
979240|NCT02117518|mRNA electroporation
979241|NCT02117505|Biological Availability
979242|NCT02117505|JNJ-39220675
979243|NCT02117505|Healthy
979244|NCT02117505|Phase 1
979247|NCT02117479|Metastatic pancreatic cancer
979248|NCT02117479|Metastatic pancreatic adenocarcinoma that is recurrent
979249|NCT02117466|cetuximab
979250|NCT02117466|PET-imaging
979251|NCT02117453|ANCA vasculitis
979252|NCT02117453|Statin
979253|NCT02117453|Subclinical markers of atherosclerosis
979254|NCT02117453|Cardiovascular events
979255|NCT02117453|Myocardial infarction
979256|NCT02117453|Stroke
979257|NCT02117453|Arterial revascularization
979258|NCT02117453|Unstable angina
979259|NCT02117453|Death
979260|NCT02117440|Lung Cancer
979261|NCT02117440|Lung Neoplasms
979262|NCT02117414|Magnetic Resonance Imaging (MRI)
979263|NCT02117388|Older adults
979264|NCT02117388|insomnia
979265|NCT02117388|CBT-I (cognitive behavioral therapy-insomnia)
979266|NCT02117388|Behavioral Therapy
979267|NCT02117388|SRT (sleep restriction therapy)
979268|NCT02117388|Cognitive Therapy
979269|NCT02117375|multiple sclerosis
979270|NCT02117375|spinal cord
979271|NCT02117375|MRI
979272|NCT02117375|longitudinal study
979273|NCT02117375|disability
979274|NCT02117362|Melanoma
979275|NCT02117362|Ipilimumab
979276|NCT02117362|Yervoy
979277|NCT02117362|Galectin
979278|NCT02117362|GR-MD-02
979279|NCT02117362|galactoarabino-rhamnogalacturonate
979280|NCT02117362|galectin-3 inhibitor
979281|NCT02117362|Providence Health & Services
979282|NCT02117362|Earle A. Chiles Research Institute
979283|NCT02117362|Robert W. Franz Cancer Center
979284|NCT02117362|Immunotherapy
979285|NCT02117349|surgical hemostasis
979286|NCT02117349|bleeding
979287|NCT02117349|fibrin sealant
979288|NCT02117349|fibrinogen
979289|NCT02117349|thrombin
979290|NCT02117349|spray dried
979291|NCT02117323|corneal opacities
979292|NCT02117323|Optical coherence tomography
979293|NCT02117284|positron emission tomography (PET)
979294|NCT02117284|Rubidium-82
979295|NCT02117284|myocardial perfusion imaging
979296|NCT02117284|automated elution system
979297|NCT02117284|controlled radioactivity delivery
979298|NCT02117271|obstructive sleep apnea
979299|NCT02117271|treatment
979300|NCT02117271|placebo
979301|NCT02117271|appearance
979302|NCT02117271|skin quality
979303|NCT02117258|Z-360, Pancreatic cancer, Pancreatic Adenocarcinoma
979304|NCT02117245|Food effect on MGCD265 bioavailability in healthy volunteers
979305|NCT02117232|colonoscopy
979306|NCT02117232|cecal intubation
979307|NCT02117232|carbon dioxide insufflation
979308|NCT02117219|Myelodysplastic syndrome
979309|NCT02117219|MDS
979310|NCT02117206|L-arginine
979311|NCT02117180|functional gastrointestinal disorders
979312|NCT02117180|FGID
979313|NCT02117180|children
979314|NCT02117180|FODMAP
979315|NCT02117154|Continuous Glucose Monitoring System
979316|NCT02117154|HbA1c
979317|NCT02117154|Diabetes Mellitus, Type 2
979318|NCT02117141|Food Effect
979319|NCT02117141|Pharmacokinetics
979320|NCT02117128|Tranexamic Acid
979321|NCT02117128|Antifibrinolytic
979322|NCT02117128|Blood transfusion
979323|NCT02117128|Total knee arthroplasty
979325|NCT02117076|RLS
979326|NCT02117076|gabapentin
979327|NCT02117076|gabapentin enacarbil
979328|NCT02117076|Neurontin
979329|NCT02117076|Horizant
979330|NCT02117050|Multiple Sclerosis
979331|NCT02117050|Rebif ®
979332|NCT02117050|Tecfidera ™
979333|NCT02117050|treatment change
979334|NCT02117024|lung
979335|NCT02117024|cancer
979336|NCT02117024|gp96
979337|NCT02117024|vaccine
979338|NCT02117024|immunotherapy
979339|NCT02117024|Heat Biologics
979340|NCT02117024|cyclophosphamide
979341|NCT02117024|vinorelbine
979342|NCT02117024|erlotinib
979343|NCT02117024|gemcitabine
979344|NCT02117024|paclitaxel
979345|NCT02117024|docetaxel
979346|NCT02117024|pemetrexed
979347|NCT02116998|GEN-004
979348|NCT02116998|Aluminum hydroxide
979349|NCT02116998|Vaccine
979350|NCT02116998|Streptococcus pneumoniae
979351|NCT02116998|Pneumococcal Infections
979352|NCT02116998|Strep pneumoniae
979353|NCT02116998|Pneumonia
979354|NCT02116985|Dual-Loop TCI
979355|NCT02116985|NI
979356|NCT02116985|Laparoscopic Cholecystectomy
979357|NCT02116972|Osteoarthritis
979358|NCT02116972|Knee
979359|NCT02116972|pain
979360|NCT02116972|steroid
979361|NCT02116972|intra-articular
979362|NCT02116972|injection
979363|NCT02116959|Systemic
979364|NCT02116959|Chemotherapy
979365|NCT02116959|Melphalan
979366|NCT02116933|Autologous Fat Grafting
979367|NCT02116933|Breast Augmentation
979368|NCT02116933|Stromal Vascular Fraction
979369|NCT02116933|Adipose Derived Stem Cell
979370|NCT02116920|CIN
979371|NCT02116920|HPV DNA
979372|NCT02116920|mRNA E6/E7
979373|NCT02116920|CIN triage
979374|NCT02116920|Cervix Biopsy
979375|NCT02116920|VIA
979376|NCT02116920|Cervix Cancer
979377|NCT02116907|Healthy
979378|NCT02116907|Male Subjects
979379|NCT02116894|Colorectal cancer
979380|NCT02116894|PF-03446962
979381|NCT02116894|regorafenib
979382|NCT02116881|Incisional hernia
979383|NCT02116881|colorectal surgery
979384|NCT02116881|bowel obstruction
979385|NCT02116868|Pupillometry
979386|NCT02116868|Pupillary reflex
979387|NCT02116868|Analgesia
979388|NCT02116868|Laparoscopic surgery
979389|NCT02116868|Total intravenous anesthesia
979390|NCT02116868|Target controlled infusion
979391|NCT02116803|solid tumors,
979392|NCT02116803|TKI258
979393|NCT02116790|acute
979394|NCT02116790|pain
979395|NCT02116764|Hematopoietic (Stem) Cell Transplantation
979396|NCT02116764|Primary Immune Deficiency Consortium
979397|NCT02116751|HIV, antiretroviral, toxicity, eGFR, tubular disease, BMD
979398|NCT02116738|flap
979399|NCT02116738|pilonidal sinus
979400|NCT02116738|vas
979401|NCT02116738|recurrence
979402|NCT02116712|LAM
979403|NCT02116712|saracatinib
979404|NCT02116712|Lymphangioleiomyomatosis
979405|NCT02116699|oropharyngeal
979406|NCT02116699|colostrum
979407|NCT02116699|mother's milk
979408|NCT02116699|premature
979409|NCT02116699|neonate
979410|NCT02116699|infection
979411|NCT02116699|necrotizing enterocolitis
979412|NCT02116699|ventilator-associated pneumonia
979413|NCT02116699|breastmilk
979414|NCT02116699|human milk
979415|NCT02116699|late-onset sepsis
979416|NCT02116699|microbiome
979417|NCT02116699|antioxidant
979418|NCT02116699|enteral feeds
979419|NCT02116686|chronic heart failure
979420|NCT02116686|Polysomnography
979421|NCT02116686|Sleep Apnea Syndromes
979422|NCT02116686|Electrocardiogram
979423|NCT02116673|Head injury
979424|NCT02116673|Concussion
979425|NCT02116673|Cognitive rest
979426|NCT02116673|Emergency department
979427|NCT02116647|Gender discrimination
979428|NCT02116647|Psychoanalysis
979429|NCT02116647|Randomized controlled trial
979430|NCT02116621|Musculoskeletal pain
979431|NCT02116621|Chronic pain
979432|NCT02116621|Patient centered outcomes research
979433|NCT02116621|Physician patient relationship
979434|NCT02116621|Mobile applications
979435|NCT02116595|volunteers
979436|NCT02116582|MDV3100
979437|NCT02116582|Xtandi
979438|NCT02116582|Abiraterone
979439|NCT02116582|Metastatic Castration-Resistant Prostate Cancer
979440|NCT02116582|Enzalutamide
979441|NCT02116569|Multiple Myeloma
979442|NCT02116569|Daratumumab
979443|NCT02116569|JNJ-54767414
979444|NCT02116569|Phase 1
979445|NCT02116569|Relapse
979446|NCT02116569|Refractory
979447|NCT02116556|Alcoholic Hepatitis
979448|NCT02116556|Bacterial Infections
979449|NCT02116556|Acute-on-Chronic Liver Failure
979450|NCT02116543|Hepatitis C
979451|NCT02116543|HCV
979452|NCT02116517|obese women
979453|NCT02116517|high LDL-C
979454|NCT02116504|Rheumatoid arthritis
979455|NCT02116504|Juvenile Idiopathic Arthritis
979456|NCT02116504|Biopharmaceutical
979457|NCT02116504|Immunogenicity
979458|NCT02116504|Anti-Drug Antibody
979459|NCT02116504|Prediction
979460|NCT02116478|plantar fasciitis
979461|NCT02116478|gastrocnemius recession
979462|NCT02116439|Violence
979463|NCT02116426|copeptin
979464|NCT02116426|troponin HS
979465|NCT02116413|fluid challenge
979466|NCT02116413|fluid resuscitation
979467|NCT02116400|Suicidal ideation
979468|NCT02116387|Proprioception
979469|NCT02116348|Cerebral palsy children
979470|NCT02116348|Cerebrolysin
979471|NCT02116348|Sleep questionnaire
979472|NCT02116348|Quality of life
979473|NCT02116348|Bayley III scale
979474|NCT02116335|arterial stiffness
979475|NCT02116335|flow-mediated dilation
979476|NCT02116335|endothelial function
979477|NCT02116335|pulse wave velocity
979478|NCT02116335|inflammation
979479|NCT02116335|oxidative stress
979480|NCT02116335|Nitric Oxide
979481|NCT02116335|Cold Pressor Test
979482|NCT02116335|physio flow
979483|NCT02116335|Bosentan
979484|NCT02116335|Endothelin Receptor
979485|NCT02116335|Endothelin-1
979486|NCT02116335|BMI
979487|NCT02116335|stress
979488|NCT02116335|blood pressure
979489|NCT02116283|smoking
979490|NCT02116283|healthy
979491|NCT02116283|smartphone
979492|NCT02116270|Renal Failure
979493|NCT02116270|Dialysis
979494|NCT02116270|Biological Aging
979495|NCT02116257|Nausea
979496|NCT02116257|Vomiting
979497|NCT02116244|Dry Eye
979498|NCT02116244|Civamide
979499|NCT02116244|Zucapsaicin
979500|NCT02116244|Neuropeptides
979501|NCT02116244|TRPV-1
979502|NCT02116231|Nasopharyngeal neoplasm;IMRT; Concurrent chemotherapy
979503|NCT02116218|Traditional Chinese Medicine
979504|NCT02116218|acupuncture
979505|NCT02116218|complementary alternative medicine
979506|NCT02116218|cancer pain
979507|NCT02116218|emergency department
979508|NCT02116205|Hantaan virus
979509|NCT02116205|Puumala virus
979510|NCT02116205|HFRS
979511|NCT02116192|Non-alcoholic Fatty Liver Disease
979512|NCT02116192|Adolescent
979513|NCT02116179|Human Immunodeficiency Virus
979514|NCT02116179|Acquired Immunodeficiency Syndrome
979515|NCT02116179|Hepatitis C
979516|NCT02116179|Hispanic
979517|NCT02116179|Criminal Justice
979518|NCT02116166|aging
979519|NCT02116166|sarcopenia
979520|NCT02116166|mitochondria
979521|NCT02116166|skeletal muscle
979522|NCT02116166|inflammation
979523|NCT02116153|Cardiac Troponin T
979524|NCT02116153|Micro-RNA
979525|NCT02116153|Sensitivity
979526|NCT02116153|Specificity
979527|NCT02116140|positron emission tomography
979528|NCT02116140|[11C]hydroxyephedrine (HED)
979529|NCT02116140|[11C]acetate
979530|NCT02116140|Adaptive Servoventilation (ASV)
979531|NCT02116140|Myocardial Energetics
979532|NCT02116140|work-metabolic index (WMI)
979533|NCT02116140|Myocardial sympathetic neuron (SN) presynaptic function continuous positive airway pressure
979534|NCT02116140|heart rate variability
979535|NCT02116140|overnight polysomnogram
979536|NCT02116140|Plasma Norepinephrine
979537|NCT02116140|Urine Normetanephrine
979538|NCT02116140|Quality of Life
979539|NCT02116127|Depression
979540|NCT02116127|Pregnancy
979541|NCT02116127|Transcranial Direct Current Stimulation
979542|NCT02116114|Pulmonary Disease, Chronic Obstructive
979543|NCT02116101|Intestinal Health
979544|NCT02116101|Prebiotics
979545|NCT02116101|Blood Lipid
979546|NCT02116088|Externalizing problem behavior, teacher training, teacher coaching, primary school, elementary school, continuing professional development, advanced training
979547|NCT02116049|Disclosure, intervention
979548|NCT02116049|HIV
979549|NCT02116049|prevention
979550|NCT02116049|Disclosure Intervention
979673|NCT02115594|HDAC inhibitors
979551|NCT02116049|Attention Control Case Management
979552|NCT02116036|Antiphospholipid Antibody Syndrome
979553|NCT02116036|Rivaroxaban
979554|NCT02116036|Thromboembolism
979555|NCT02116036|Bleeding
979556|NCT02116036|Feasibility
979557|NCT02116023|Satiety, beverage, crossover
979558|NCT02116010|Wound Infection in burned patient
979559|NCT02115971|chronic
979560|NCT02115971|functional
979561|NCT02115971|instability
979562|NCT02115971|ankle
979563|NCT02115945|chronic postoperative pain
979564|NCT02115945|total knee arthroplasty
979565|NCT02115945|femoral block
979566|NCT02115945|We aimed to compare the effects of epidural and femoral block on acute and chronic postoperative pain.
979567|NCT02115932|Diabetes Mellitus
979568|NCT02115932|Diabetes Mellitus, Type 2
979569|NCT02115932|Diabetes Complications
979570|NCT02115932|Diabetic Foot
979571|NCT02115932|Diabetic Neuropathies
979572|NCT02115932|Gait
979573|NCT02115932|Balance, Postural
979574|NCT02115932|Muscle Strength
979575|NCT02115932|Exercise Therapy
979576|NCT02115932|Physical Therapy Modalities
979577|NCT02115932|Endocrine System Diseases
979578|NCT02115932|Peripheral Nervous System Diseases
979579|NCT02115932|Metabolic Diseases
979580|NCT02115932|Glucose Metabolism Diseases
979581|NCT02115932|Quality of Life
979582|NCT02115932|Training
979583|NCT02115919|condyloma
979584|NCT02115919|HIV
979585|NCT02115893|Nitrate
979586|NCT02115893|Performance
979587|NCT02115893|Sports
979588|NCT02115880|Depression
979589|NCT02115880|Prevention
979590|NCT02115880|Adolescent
979591|NCT02115880|Child
979592|NCT02115880|Randomised Controlled Trial
979593|NCT02115880|Risk
979594|NCT02115880|Cognitive behavioural therapy
979595|NCT02115880|Group-based therapy
979596|NCT02115867|diverticular disease
979597|NCT02115867|diverticulitis
979598|NCT02115867|diverticulosis
979599|NCT02115854|usefullness of labial biopsy to distinguish between tuberculosis and sarcoidosis
979600|NCT02115841|Transcutaneous Nerve Stimulation
979601|NCT02115841|serial reaction time task
979602|NCT02115841|functional near infrared spectroscopy
979603|NCT02115841|transcranial magnetic stimulation
979604|NCT02115828|Vismodegib
979605|NCT02115828|Metastatic Castration-Resistant Prostate Cancer
979606|NCT02115828|Accessible Metastatic Lesions for Tumor Biopsy
979607|NCT02115815|Respiratory Syncytial Virus (RSV)
979608|NCT02115815|MEDI7510
979609|NCT02115789|cicatrix
979610|NCT02115789|Demonstrate
979611|NCT02115789|that there
979612|NCT02115789|is no perception of superiority
979613|NCT02115776|bacteremia
979614|NCT02115776|prophylaxis
979615|NCT02115776|antibiotics
979616|NCT02115776|dentistry
979617|NCT02115763|physically active,
979618|NCT02115763|18-35 year old men
979619|NCT02115750|CHS-0214
979620|NCT02115750|Enbrel
979621|NCT02115750|RA
979622|NCT02115750|Biosimilar
979623|NCT02115750|Etanercept
979624|NCT02115724|Low childhood SES
979625|NCT02115724|Early Life Stress
979626|NCT02115724|Endothelial function
979627|NCT02115724|Flow mediated dilation
979628|NCT02115724|Cardiovascular disease
979629|NCT02115724|Subcutaneous adipose arterioles
979630|NCT02115711|India
979631|NCT02115711|Cardiovascular risk factors
979632|NCT02115711|Community health workers
979633|NCT02115711|Hypertension
979634|NCT02115711|Diabetes
979635|NCT02115711|Smoking
979636|NCT02115698|Sarcopenia
979637|NCT02115698|Frailty
979638|NCT02115698|Ageing
979639|NCT02115698|Protein supplementation
979640|NCT02115698|Protein quality
979641|NCT02115698|Exercise training
979642|NCT02115698|Muscle protein turnover
979643|NCT02115685|spinal cord injury
979644|NCT02115685|sympathetic nervous system
979645|NCT02115685|locomotor training
979646|NCT02115685|exercise
979647|NCT02115672|Chronic myeloid leukemia
979648|NCT02115672|imatinib
979649|NCT02115672|CXCR4 antagonist
979650|NCT02115672|BL-8040
979651|NCT02115659|ADPKD
979652|NCT02115659|triptolide
979653|NCT02115646|burn
979654|NCT02115646|scar
979655|NCT02115620|Heart failure
979656|NCT02115620|Cardiac failure
979657|NCT02115620|Congestive Heart Failure
979658|NCT02115620|Cardiomyopathy
979659|NCT02115620|Myocardial Failure
979660|NCT02115620|Telemedicine
979661|NCT02115620|Telehealth
979662|NCT02115620|Remote Consultation
979663|NCT02115607|Breast cancer
979664|NCT02115607|Interstitial fluid pressure
979665|NCT02115607|Angiogenesis
979666|NCT02115607|Contrast enhanced ultrasound imaging
979667|NCT02115607|Subharmonic imaging
979668|NCT02115607|Subharmonic pressure estimation
979669|NCT02115594|metastatic breast cancer
979670|NCT02115594|estrogen receptor
979671|NCT02115594|Histone Deacetylase Inhibitors
979672|NCT02115594|Histone Deacetylases
979674|NCT02115594|selective estrogen receptor modulator
979675|NCT02115594|estrogen receptor modulator, selective
979676|NCT02115594|Estrogen receptor modulators, selective
979677|NCT02115581|Coenzyme O10
979678|NCT02115581|Children
979679|NCT02115581|Idiopathic Dilated Cardiomyopathy
979680|NCT02115555|type 1
979681|NCT02115555|diabetes
979682|NCT02115555|adolescents
979683|NCT02115555|heath information technology
979684|NCT02115542|biliary
979685|NCT02115542|liver
979686|NCT02115542|Refractory Advanced Biliary Cancers
979687|NCT02115542|gallbladder cancer
979688|NCT02115542|carcinoma
979689|NCT02115542|intra-hepatic biliary system
979690|NCT02115542|extra-hepatic biliary system
979691|NCT02115542|gall bladder
979692|NCT02115542|unresectable
979693|NCT02115542|locally advanced
979694|NCT02115542|metastatic disease
979695|NCT02115542|Bile Duct Diseases
979696|NCT02115542|Gallbladder Diseases
979697|NCT02115542|regorafenib
979698|NCT02115542|stivarga
979699|NCT02115542|Bay 73-4506
979700|NCT02115542|multikinase inhibitor
979701|NCT02115516|Malaria
979702|NCT02115516|Plasmodium falciparum malaria
979703|NCT02115516|Antimalarial chemoprophylaxis
979704|NCT02115516|PfSPZ Challenge
979705|NCT02115516|Cryopreserved Plasmodium Falciparum Sporozoites
979706|NCT02115516|PfSPZ-CVac
979707|NCT02115490|Alveolar bone
979708|NCT02115490|Bisphosphonates
979709|NCT02115490|Cone-beam CT
979710|NCT02115490|Osteoporosis
979711|NCT02115477|Uterus cancer
979712|NCT02115477|Hysterectomy
979713|NCT02115477|Lymphadenectomy
979714|NCT02115477|Lymphedema
979715|NCT02115464|Metformin
979716|NCT02115464|Non-small cell lung cancer
979717|NCT02115464|Locally advanced
979718|NCT02115464|Chemo-radiotherapy
979719|NCT02115464|Lung cancer treatment
979720|NCT02114476|GDM
979721|NCT02114476|implant
979722|NCT02114476|diabetes mellitus
979723|NCT02114476|metabolic syndrome
979724|NCT02114463|Local analgesia system
979725|NCT02114463|Ropivacaine
979726|NCT02114463|Analgesic efficacy after operation
979727|NCT02114463|Postoperative
979728|NCT02114450|Stroke
979729|NCT02114450|Paresis
979730|NCT02114450|Gait rehabilitation
979731|NCT02114450|Human-Machine Interaction
979732|NCT02114450|Wearable Robotic Devices
979733|NCT02114437|Closed-Loop TCI
979734|NCT02114437|NI
979735|NCT02114437|Laparoscopic Cholecystectomy
979736|NCT02114424|Positional Obstructive sleep apnea syndrome (POSAS)
979737|NCT02114424|Obstructive sleep apnea syndrome (OSAS)
979738|NCT02114424|Apnea-Hypnea Index (AHI)
979739|NCT02114424|Sleep questionnaire
979740|NCT02114424|Positional sleep apnea belt
979741|NCT02114424|Adverse events
979742|NCT02114424|Compliance
979743|NCT02114385|Prevention
979744|NCT02114372|Alzheimer's disease
979745|NCT02114372|Asymptomatic at risk for Alzheimer's disease
979746|NCT02114372|Retinal diagnosis for Alzheimer's disease
979747|NCT02114359|gastric cancer, elderly, chemotherapy
979748|NCT02114346|Computed Tomography Angiogram
979749|NCT02114346|Side Effects
979750|NCT02114346|Contrast-Induced Nephropathy
979751|NCT02114346|Prevention
979752|NCT02114333|Shingles vaccine
979753|NCT02114333|Immune response
979754|NCT02114333|Zoster vaccine
979755|NCT02114320|Endoscopic ultrasonography
979756|NCT02114320|Biliary drainage
979757|NCT02114320|Metal stent
979758|NCT02114307|electrical stimulation
979759|NCT02114307|venous insufficiency
979760|NCT02114307|post thrombotic syndrome
979761|NCT02114307|varicose veins
979762|NCT02115399|Dermatitis
979763|NCT02115399|Staphylococcus
979764|NCT02115399|Staphylococcus aureus
979765|NCT02115399|Dermatitis, Atopic
979766|NCT02115399|Non-atopic controls
979767|NCT02115386|Ph+ CML, chronic myeloid leukemia
979768|NCT02115373|Hepatocellular Carcinoma
979769|NCT02115373|c-Met inhibitor
979770|NCT02115373|Phase 1b
979771|NCT02115373|Sorafenib
979772|NCT02115373|MSC2156119J
979773|NCT02115360|epidural calcitonin
979774|NCT02115360|amputation
979775|NCT02115360|postoperative pain
979776|NCT02115360|Later Complication
979777|NCT02115334|Developmental delay
979778|NCT02115334|Early Intervention
979779|NCT02115334|Home programs
979780|NCT02115334|Preschool activities
979800|NCT02115269|Indoprocaf
979801|NCT02115269|Indomethacin
979802|NCT02115269|Caffeine
979803|NCT02115269|Prochlorperazine
979804|NCT02115269|Migraine with Aura
979805|NCT02115269|Migraine without Aura
979806|NCT02115269|Tension-Type Headache
979807|NCT02115256|External Cephalic Version
979808|NCT02115256|breech
979809|NCT02115230|Heart Failure
979810|NCT02115230|Heart Failure, Diastolic
979811|NCT02115230|Hypertension
979812|NCT02115230|Renal Denervation
979813|NCT02115230|Irrigated Radiofrequency Catheter
979814|NCT02115217|Kinestiotaping
979815|NCT02115217|Basketball players
979816|NCT02115217|Effect of kinesiotaping
979817|NCT02115217|on postural stability
979818|NCT02115191|2-octylcyanoacrylate
979819|NCT02115191|Urethrocutaneous fistulas.
979820|NCT02115191|Closure.
979821|NCT02115191|Recurrence.
979822|NCT02115178|Hemodynamic changes
979823|NCT02115178|Spinal anesthesia
979824|NCT02115178|Patient position
979825|NCT02115178|Impedance cardiography
979826|NCT02115152|Capecitabine
979827|NCT02115152|Neoadjuvant therapy
979828|NCT02115152|Early Breast Cancer
979829|NCT02115139|melanoma
979830|NCT02115139|brain
979831|NCT02115139|metastases
979832|NCT02115139|Patients with melanoma and brain metastases
979833|NCT02115113|Liver transplantation, everolimus, CNI-minimization, CNI-elimination, renal function
979834|NCT02115100|Paroxysmal atrial fibrillation
979835|NCT02115100|Persistent atrial fibrillation
979836|NCT02115100|Out of range hypertension
979837|NCT02115100|Signs of sympathetic overdrive
979838|NCT02115087|laparotomy
979839|NCT02115087|levobupivacaine
979840|NCT02115087|patient controlled analgesia
979841|NCT02115074|Low-grade gliomas
979842|NCT02115074|high-grade gliomas
979843|NCT02115074|optico-chiasmatic
979844|NCT02115074|relapsed
979845|NCT02115074|refractory
979846|NCT02115061|Gastric varices,coil,cyanoacrylate,treating gastric varices.
979847|NCT02115035|Multiple Myeloma
979848|NCT02115022|pancreatic cancer
979849|NCT02115022|resectability
979850|NCT02115022|endosonography (EUS)
979851|NCT02115022|multidetection computer tomography (MDCT)
979852|NCT02115022|staging
979853|NCT02115009|sacroiliac joint lumbopelvic ,chronic low back pain
979854|NCT02114996|mechanical ventilation
979855|NCT02114996|ischemic stroke
979856|NCT02114983|deep vein thrombosis
979857|NCT02114983|diagnostic accuracy
979858|NCT02114983|general practitioner
979859|NCT02114983|test
979860|NCT02114983|compression ultrasonography
979861|NCT02114983|ultrasound
979862|NCT02114970|Older Adults
979863|NCT02114970|Informed Consent
979864|NCT02114970|Technology
979865|NCT02114970|Tablet-delivered
979866|NCT02114957|bio-availability
979867|NCT02114957|decursin
979868|NCT02114957|decursinol angelate
979869|NCT02114957|decursinol
979870|NCT02114957|subjects
979871|NCT02114944|Do-not-intubate
979872|NCT02114944|DNI
979873|NCT02114944|Palliative treatment
979874|NCT02114944|Acute respiratory failure
979875|NCT02114944|Acute on chronic respiratory failure
979876|NCT02114944|Hypoxia
979877|NCT02114944|Respiratory acidosis
979878|NCT02114944|Hypercarbia
979879|NCT02114944|Non invasive ventilation
979880|NCT02114944|NIV
979881|NCT02114944|CPAP
979882|NCT02114944|Oxygen-therapy
979883|NCT02114944|High-flow oxygen therapy
979884|NCT02114931|arthritis
979885|NCT02114931|rheumatoid
979886|NCT02114918|obsessive compulsive disorder
979887|NCT02114918|children
979888|NCT02114918|adolescents
979889|NCT02114918|attention bias modification
979890|NCT02114905|Tourette's
979891|NCT02114905|Tic Disorder
979892|NCT02114905|CBIT
979893|NCT02114905|Dissemination
979894|NCT02114905|Occupational Therapist
979895|NCT02114892|metabolic syndrome
979896|NCT02114892|central obesity
979897|NCT02114892|resveratrol
979898|NCT02114892|insulin secretion
979899|NCT02114892|insulin sensitivity
979900|NCT02114879|Physical Therapy
979901|NCT02114879|Occupational Therapy
979902|NCT02114879|Rehabilitation
979903|NCT02114879|Older adults
979904|NCT02114879|Depression
979905|NCT02114879|Physical Functioning
979906|NCT02114827|Multiple Myeloma
979907|NCT02114814|Diabetes
979908|NCT02114814|Hispanic
979909|NCT02114814|Adult
979910|NCT02114814|Family Member
979911|NCT02114801|Cerebral Palsy;
979912|NCT02114801|Toothbrushing;
979913|NCT02114801|Dental Plaque
979914|NCT02114775|mild traumatic brain injury
979915|NCT02114775|growth hormone
979916|NCT02114775|fatigue
979917|NCT02114775|sildenafil
979918|NCT02114775|neurology
979919|NCT02114762|otitis media
979920|NCT02114762|eustachian tube
979921|NCT02114762|eustachian tube dysfunction
979922|NCT02114762|eustachian tube function testing
979923|NCT02114749|Healthy volunteers
979924|NCT02114749|Physiological variables : respiration and circulation
979925|NCT02114736|Stroke
979926|NCT02114736|Muscle spasticity
979927|NCT02114736|Stiff knee gait
979928|NCT02114736|Botulinum toxin
979929|NCT02114736|Tenotomy
979930|NCT02114723|Mediacal Taping concept
979931|NCT02114723|Neuromuscular bandage
979932|NCT02114723|Physiotherapy techniques
979933|NCT02114723|Kinesio Tape
979934|NCT02114710|coagulopathy
979935|NCT02114710|hydrocortisone
979936|NCT02114710|organ failure
980186|NCT02113657|Yervoy
979937|NCT02114697|Cancer survivorship, cardiovascular disease, stroke, TIA
979938|NCT02114658|Anaplastic and medullary thyroid carcinoma
979939|NCT02114658|Thyroid Neoplasms
979940|NCT02114645|Luteal phase support,GnRH agonist,ART cycles
980069|NCT02114086|early and late effects of radiation
980070|NCT02114086|cosmesis and quality of life
979941|NCT02114632|ADHD, attention deficit/hyperactivity disorder, attention deficit disorder, inattention, cognitive skills, children, polyunsaturated fatty acids, PUFA
979942|NCT02114619|radioiodine therapy
979943|NCT02114619|Graves' disease
979944|NCT02114619|Hyperthyroidism
979945|NCT02114619|calculated dose
979946|NCT02114606|Eosinophilic Esophagitis
979947|NCT02114606|EoE
979948|NCT02114606|Cytosponge
979949|NCT02114593|Mental Health
979950|NCT02114593|Children
979951|NCT02114593|Parent support program
979952|NCT02114593|Somali families
979953|NCT02114593|Sweden
979954|NCT02114580|mild cognitive impairment
979955|NCT02114580|exercise
979956|NCT02114580|brain plasticity
979957|NCT02114580|FMRI
979958|NCT02114567|AECOPD
979959|NCT02114567|work of breathing
979960|NCT02114567|patient-ventilator synchrony
979961|NCT02114554|MELAS
979962|NCT02114554|MIDD
979963|NCT02114554|Heteroplasmy
979964|NCT02114528|Ventricular Tachycardia
979965|NCT02114528|Ventricular Arrhythmia
979966|NCT02114528|Anti-arrhythmic drugs
979967|NCT02114528|Catheter Ablation
979968|NCT02114528|ICD Shocks
979969|NCT02114515|Patient Navigators
979970|NCT02114515|Readmissions
979971|NCT02114515|Peer Coaching
979972|NCT02114502|Myeloma
979973|NCT02114502|Multiple myeloma
979974|NCT02114502|MM
979975|NCT02114502|Refractory
979976|NCT02114502|Relapsed
979977|NCT02114502|Stem Cell Transplant
979978|NCT02114502|SCT
979979|NCT02114502|Carfilzomib
979980|NCT02114502|SAHA
979981|NCT02114502|Vorinostat
979982|NCT02114502|Suberoylanilide Hydroxamic Acid
979983|NCT02114502|MSK-390
979984|NCT02114502|Zolinza
979985|NCT02114502|Gemcitabine
979986|NCT02114502|Gemcitabine Hydrochloride
979987|NCT02114502|Gemzar
979988|NCT02114502|Busulfan
979989|NCT02114502|Busulfex
979990|NCT02114502|Myleran
979991|NCT02114502|Palifermin
979992|NCT02114502|Kepivance
979993|NCT02114502|Dexamethasone
979994|NCT02114502|Decadron
979995|NCT02114502|Melphalan
979996|NCT02114502|Alkeran
979997|NCT02114502|Caphosol
979998|NCT02114502|Glutamine
979999|NCT02114502|Enterex
980000|NCT02114502|Glutapak-10
980001|NCT02114502|NutreStore
980002|NCT02114502|Resource
980003|NCT02114502|GlutaSolve
980004|NCT02114502|Sympt-X G.I.
980005|NCT02114502|Sympt-X
980006|NCT02114502|Pyridoxine
980007|NCT02114489|AOH
980008|NCT02114489|ibandronate
980009|NCT02114294|Patellofemoral pain syndrome
980010|NCT02114294|Anterior knee pain
980011|NCT02114294|Randomised controlled trial
980012|NCT02114294|Exercise intervention
980013|NCT02114294|Hip strengthening
980014|NCT02114294|Quadriceps based training
980015|NCT02114294|Anterior knee pain score
980016|NCT02114281|Oral Health
980017|NCT02114281|Periodontitis
980018|NCT02114281|Tooth cavities
980019|NCT02114281|Saliva
980020|NCT02114281|Halitosis
980021|NCT02114281|Mucosa
980022|NCT02114281|Chronic kidney disease
980023|NCT02114281|Inflammation
980024|NCT02114281|Nutrition
980025|NCT02114268|Respiratory Syncytial Virus, RSV
980026|NCT02114255|Influenza
980027|NCT02114255|Trained immunity
980028|NCT02114255|BCG
980029|NCT02114242|Parkinson's disease
980030|NCT02114242|multiple system atrophy
980031|NCT02114242|progressive supranuclear palsy
980032|NCT02114242|alpha-synuclein
980033|NCT02114229|Alisertib
980034|NCT02114229|MLN8237
980035|NCT02114229|AT/RT
980036|NCT02114229|MRT
980037|NCT02114190|Overweight Adolescents
980038|NCT02114190|Mindful Eating and Living
980039|NCT02114190|Family Systems
980040|NCT02114190|Body-Mass Index
980041|NCT02114190|Mindfulness
980042|NCT02114177|Hepatitis C Virus Infection
980043|NCT02114177|Simeprevir
980044|NCT02114177|Sofosbuvir
980045|NCT02114177|HCV
980046|NCT02114177|Cirrhosis
980047|NCT02114164|AirSeal
980048|NCT02114164|Trocar
980049|NCT02114164|Carbon Dioxide Exchange and Absorption
980050|NCT02114151|Hepatitis C Virus Infection
980051|NCT02114151|Simeprevir
980052|NCT02114151|Sofosbuvir
980053|NCT02114151|HCV
980054|NCT02114151|Cirrhosis
980055|NCT02114138|postoperative acute kidney injury
980056|NCT02114138|pAKI
980057|NCT02114138|stress injury on the kidney
980058|NCT02114138|chronic kidney disease
980059|NCT02114138|CKD
980060|NCT02114125|Physical activity
980061|NCT02114125|Cognitive training
980062|NCT02114112|Bronchopulmonary dysplasia
980063|NCT02114112|Continuous positive airway pressure pressure
980064|NCT02114112|Preterms
980065|NCT02114099|Kawasaki Disease
980066|NCT02114099|Aneurysm, Coronary
980067|NCT02114086|Observational Study
980068|NCT02114086|intraoperative Radiation of Breast Cancer
980071|NCT02114073|glaucoma
980072|NCT02114073|trabeculectomy
980073|NCT02114073|cyclosporine
980074|NCT02114073|betamethasone
980075|NCT02114060|HSV
980076|NCT02114060|Herpes
980077|NCT02114060|genital infection
980078|NCT02114060|vaccine
980079|NCT02114034|Severe asthma,
980080|NCT02114034|child,
980081|NCT02114034|outcome,
980082|NCT02114021|Syndrome incidence after intubation
980083|NCT02114021|Betamethasone gel
980084|NCT02114021|lidocaine jelly
980085|NCT02114021|sore throat
980086|NCT02114021|cough
980087|NCT02114021|hoarseness of voice
980088|NCT02114008|Gastric emptying.
980089|NCT02114008|Residual gastric volume.
980090|NCT02114008|Preoperative fasting.
980091|NCT02114008|Morbid Obesity.
980092|NCT02114008|Diabetes.
980093|NCT02113995|Obesity, Morbid
980094|NCT02113995|Insulin Resistance
980095|NCT02113995|Acute-Phase Reaction
980096|NCT02113995|Gastroplasty
980097|NCT02113995|Length of Stay
980098|NCT02113995|Protocols
980099|NCT02113995|Randomized Controlled Trial.
980100|NCT02113969|Pelvic Organ Prolapse
980101|NCT02113969|Quality of Life
980102|NCT02113969|Symptoms
980103|NCT02113969|Pessary
980104|NCT02113969|Treatment
980105|NCT02113956|HIV Prevention
980106|NCT02113956|Adolescent Men who Have Sex with Men (AMSM)
980107|NCT02113956|Text-Messaging
980108|NCT02113956|Information-Motivation-Behavioral Skills(IMB)Model
980109|NCT02113917|infant, adolescent and adult Hemophagocytic Syndrome
980110|NCT02113917|Hemophagocytic lymphohistiocytosis
980111|NCT02113904|Netherton syndrome
980112|NCT02113904|Adalimumab
980113|NCT02113904|TNF-alpha
980114|NCT02113904|Orphan genetic syndrome
980115|NCT02113891|Antibody-mediated rejection
980116|NCT02113891|Complement blockade
980117|NCT02113891|Eculizumab
980118|NCT02113891|Kidney transplantation
980119|NCT02113878|Carcinoma, Squamous Cell of Head and Neck
980120|NCT02113878|Human Papillomavirus Positive Oropharyngeal Carcinoma
980121|NCT02113878|Hypopharyngeal Cancer
980122|NCT02113878|Early Invasive Cervical Squamous Cell Carcinoma
980123|NCT02113878|Carcinoma of Larynx
980124|NCT02113878|Cancer of Nasopharynx
980125|NCT02113852|Non small cell Lung Cancer
980126|NCT02113852|Heavy smokers
980127|NCT02113852|Treatment naive patients
980128|NCT02113839|Dyspnea perception
980129|NCT02113839|COPD
980130|NCT02113839|Exacerbations
980131|NCT02113839|CO2 rebreathing test
980132|NCT02113826|Pazopanib
980133|NCT02113826|Alveolar soft part sarcoma
980134|NCT02113813|irreversible EGFR inhibitor
980135|NCT02113813|Non-Small-Cell Lung Cancer
980136|NCT02113813|Midazolam
980137|NCT02113813|T790M resistance mutation
980138|NCT02113813|EGFR
980139|NCT02113813|NSCLC
980140|NCT02113813|Epidermal Growth Factor Receptor mutations
980141|NCT02113813|ASP8273
980142|NCT02113787|epilepsy
980143|NCT02113787|anticonvulsants
980144|NCT02113787|generic drugs
980145|NCT02113748|Pulmonary disease, chronic obstructive
980146|NCT02113748|Downhill walking
980147|NCT02113748|exercise
980148|NCT02113735|ARDS
980149|NCT02113735|Acute Respiratory Distress Syndrome
980150|NCT02113735|Acthar
980151|NCT02113735|ACTH
980152|NCT02113735|H.P. Acthar Gel
980153|NCT02113722|Sudden cardiac death
980154|NCT02113722|Ganglionectomy
980155|NCT02113722|Ventricular arrhythmia
980156|NCT02113722|Cardiac surgery
980157|NCT02113722|Implanted cardiac defibrillator
980158|NCT02113709|Amblyopia
980159|NCT02113709|Strabismus
980160|NCT02113709|Occlusion therapy
980161|NCT02113709|Visual improvement
980162|NCT02113696|morbid obesity
980163|NCT02113696|BMI at or above 4O kg/m2
980164|NCT02113696|ingestion of omega 3
980165|NCT02113696|inflammatory cytokines
980166|NCT02113696|biochemical factors
980167|NCT02113696|anthropometric factors
980168|NCT02113683|colo-rectal cancer
980169|NCT02113683|stomach cancer
980170|NCT02113683|melanoma
980171|NCT02113683|MMS test
980172|NCT02113683|therapy monitoring
980173|NCT02113683|Sarcoma
980174|NCT02113670|stress urinary incontinence
980175|NCT02113670|abdominal leak point pressure
980176|NCT02113670|urodynamic study
980177|NCT02113657|Prostate cancer
980178|NCT02113657|Castration-resistant prostate cancer
980179|NCT02113657|CRPC
980180|NCT02113657|Metastatic
980181|NCT02113657|Hormone therapy treatment
980182|NCT02113657|Androgen deprivation therapy
980183|NCT02113657|gonadotropin-releasing hormone
980184|NCT02113657|GnRH
980185|NCT02113657|Ipilimumab
980187|NCT02113657|BMS-734016
980188|NCT02113657|MDX010
980189|NCT02113631|Hepatitis C treatment,
980190|NCT02113631|Boceprevir,
980191|NCT02113631|Telaprevir,
980192|NCT02113631|Safety
980193|NCT02113631|Effectiveness
980194|NCT02113631|Head-to-head trial
980195|NCT02113618|Cognitive function, alcohol dependence, working memory
980196|NCT02113605|Functional gastrointestinal disorders
980197|NCT02113605|FGID
980198|NCT02113605|Recurrent abdominal pain
980199|NCT02113605|Abdominal pain
980200|NCT02113605|pain-predominant functional gastrointestinal disorders
980201|NCT02113605|Pediatric pain
980202|NCT02113592|Pain management
980203|NCT02113592|Opioid use
980204|NCT02113592|Pragmatic
980205|NCT02113592|Collaborative care
980206|NCT02113592|Primary care
980207|NCT02113579|Tooth Sensitivity
980208|NCT02113566|Delayed onset muscle soreness
980209|NCT02113566|DOMS
980210|NCT02113540|coronary angiography
980211|NCT02113540|chronic stable angina
980212|NCT02113540|CIN
980213|NCT02113527|Electrogastrography
980214|NCT02113527|Functional dyspepsia
980215|NCT02113527|Gastric emptying
980216|NCT02113527|Gastrointestinal peptides
980217|NCT02113527|Rome III criteria
980218|NCT02113514|Appalachian
980219|NCT02113514|abnormal pap test
980220|NCT02113501|HGT1
980221|NCT02113501|high risk bladder cancer
980222|NCT02113501|substaging
980223|NCT02113501|repeat transurethral resection (reTUR)
980224|NCT02113501|lamina propria
980225|NCT02113475|CDT
980226|NCT02113475|PCDT
980227|NCT02113475|DVT
980228|NCT02113475|PTS
980229|NCT02113475|Quality of Life
980230|NCT02113462|Chronic kidney disease
980231|NCT02113462|Endothelial dysfunction
980232|NCT02113462|Inflammation
980233|NCT02113462|Insulin resistance
980234|NCT02113462|Tg/hdl ratio
980235|NCT02113449|Carbon Dioxide, Allergy symptoms
980236|NCT02113436|FP/SLM
980237|NCT02113436|Asthma
980238|NCT02113436|Infant
980239|NCT02113436|Efficacy
980240|NCT02113436|Safety
980241|NCT02113423|superiority, re-irradiation, IMRT, recurrent T1-2 NPC
980242|NCT02113410|osteoarthritis
980243|NCT02113410|Older adults
980244|NCT02113410|Sit 'N' Chair Yoga
980245|NCT02113410|Pain
980246|NCT02113410|Physical Function
980247|NCT02113410|Balance
980248|NCT02113410|Fatigue
980249|NCT02113410|Depression
980250|NCT02113410|Life Satisfaction
980251|NCT02113397|Cystic fibrosis
980252|NCT02113397|Microbiome
980253|NCT02113397|Sputum
980254|NCT02113397|Tobramycin
980255|NCT02113397|Colistimethate
980256|NCT02113384|Rectal cancer
980257|NCT02113384|Locally advanced rectal cancer
980258|NCT02113384|Peritoneal carcinomatosis
980259|NCT02113384|Exfoliated peritoneal cells
980260|NCT02113384|Peritoneal lavage
980261|NCT02113371|Injury Prevention
980262|NCT02113371|Health Promotion
980263|NCT02113371|Well being
980264|NCT02113371|Safety
980265|NCT02113371|Nutrition
980266|NCT02113371|Physical Activity
980267|NCT02113371|Sleep
980268|NCT02113371|Stress
980269|NCT02113358|fluid therapy
980270|NCT02113358|neurosurgery
980271|NCT02113345|metamemory
980272|NCT02113345|memory
980273|NCT02113345|mild cognitive impairment
980274|NCT02113332|Insulin injections
980275|NCT02113332|Overweight
980276|NCT02113332|Inadequate glycaemic control
980277|NCT02113319|Core Binding Factors
980278|NCT02113319|Acute Myelogenous Leukemia refractory to conventional chemotherapy
980279|NCT02113319|molecular relapse
980280|NCT02113293|phase I study
980281|NCT02113293|tolerability
980282|NCT02113293|safety
980283|NCT02113293|CyclASol®
980284|NCT02113293|eye drops
980285|NCT02113267|esophagitis
980286|NCT02113267|eosinophils
980287|NCT02113267|allergy
980288|NCT02113267|inflammation
980289|NCT02113267|corticosteroids
980290|NCT02113254|corn
980291|NCT02113254|macular pigment
980292|NCT02113254|lutein
980293|NCT02113254|zeaxanthin
980294|NCT02113254|Age Macular Degeneration
980295|NCT02113254|AMD
980296|NCT02113241|metabolic syndrome
980297|NCT02113241|forxiga
980298|NCT02113241|dapagliflozin
980299|NCT02113241|insulin secretion
980300|NCT02113241|insulin sensitivity
980301|NCT02113228|Energy metabolism
980302|NCT02113228|Stable isotopes
980303|NCT02113228|Short bowel syndrome
980304|NCT02113228|Doubly labeled water
980305|NCT02113215|aging
980306|NCT02113215|lipid metabolism
980307|NCT02113215|very low density lipoproteins
980308|NCT02113202|Optical imaging
980309|NCT02113202|Fluorescence endoscopy
980310|NCT02113202|Near infrared fluorescence
980311|NCT02113202|Familial Adenomatous Polyposis
980312|NCT02113202|IRDye800CW
980313|NCT02113202|Vascular Endothelial Growth Factor A
980314|NCT02113202|Gastrointestinal endoscopy
980315|NCT02113189|gait
980316|NCT02113189|Parkinson's disease
980317|NCT02113176|SAH
980318|NCT02113163|Type 2 diabetes
980319|NCT02113163|T2DM
980320|NCT02113163|hypertriglyceridemia
980321|NCT02113163|severe hypertriglyceridemia
980322|NCT02113163|dyslipidemia
980323|NCT02113163|triglycerides
980324|NCT02113163|lipids
980325|NCT02113163|omega-3 fatty acids
980326|NCT02113163|EPA
980327|NCT02113163|ethyl-EPA
980328|NCT02113163|Metformin
980329|NCT02113163|Glucophage
980330|NCT02113163|Lovaza
980331|NCT02113163|Vascepa
980332|NCT02113163|Epanova
980333|NCT02113163|Astra Zeneca
980334|NCT02113163|Amarin
980335|NCT02113163|GSK
980336|NCT02113150|troponin t,cystatin-c,ketamine,remifentanil
980337|NCT02113137|halitosis
980338|NCT02113137|chlorine dioxide
980339|NCT02113137|tongue cleaning
980340|NCT02113124|Chronic Brain Injury
980341|NCT02113124|Traumatic brain injury (TBI)
980342|NCT02113124|Amino Acids
980343|NCT02113124|Microbiome
980344|NCT02113098|Stroke
980345|NCT02113098|Gait
980346|NCT02113098|Rehabilitation
980347|NCT02113085|Adolescents, foster care, self-determination
980348|NCT02113072|wheezing, immune system, cytokines, probiotics, infants.
980349|NCT02113059|Liver regeneration
980350|NCT02113059|liver dysfunction
980351|NCT02113059|platelets
980352|NCT02113059|plasma
980353|NCT02113059|serum
980354|NCT02113059|platelet activation
980355|NCT02113059|morbidity
980356|NCT02113059|mortality
980357|NCT02113059|Growth factors
980358|NCT02113059|Postoperative clinical outcome
980359|NCT02113046|pancreas
980360|NCT02113046|pancreatico-jejunal anastomosis
980361|NCT02113046|postoperative pancreatic fistulae
980362|NCT02113007|Lymphoma; CNS; rituximab; temozolomide
980363|NCT02112994|Enzyme Replacement Therapy (ERT)
980364|NCT02112994|Lysosomal Storage Disease
980365|NCT02112994|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
980366|NCT02112994|Acid cholesteryl ester hydrolase deficiency, type 2
980367|NCT02112994|Acid lipase disease
980368|NCT02112994|Cholesterol ester hydrolase deficiency
980369|NCT02112994|LAL Deficiency
980370|NCT02112994|LIPA Deficiency
980371|NCT02112994|Wolman disease
980372|NCT02112994|Additional relevant MeSH terms:
980373|NCT02112994|Cholesterol Ester Storage Disease
980374|NCT02112994|Metabolic Diseases
980375|NCT02112994|Lipidoses
980376|NCT02112994|Lipid Metabolism, Inborn Errors
980377|NCT02112994|Metabolism, Inborn Errors
980378|NCT02112994|Genetic Diseases, Inborn
980379|NCT02112994|Lysosomal Storage Diseases
980380|NCT02112994|Lipid Metabolism Disorders
980381|NCT02112994|Infant, Newborn, Diseases
980382|NCT02112981|CORONARY ARTERIOSCLEROSIS
980383|NCT02112968|Myopia
980384|NCT02112968|Hyperopia
980385|NCT02112968|Presbyopia
980386|NCT02112968|Supracor
980387|NCT02112968|Zyoptix
980388|NCT02112968|Proscan
980389|NCT02112968|LASIK
980390|NCT02112955|Stroke
980391|NCT02112955|Disease management
980392|NCT02112955|Self efficacy
980393|NCT02112955|Quality of life
980394|NCT02112955|Community integration
980395|NCT02112942|Hepatitis C virus
980396|NCT02112942|HCV
980397|NCT02112929|Magnetic Resonance Imaging
980398|NCT02112929|Lung Diseases
980399|NCT02112890|Mexico
980400|NCT02112890|Adolescents
980401|NCT02112890|Hepatitis
980402|NCT02112890|Seroprevalence
980403|NCT02112890|Pertussis
980404|NCT02112890|Young adults
980405|NCT02112877|iliofemoral vein
980406|NCT02112877|venous
980407|NCT02112877|venous obstruction
980408|NCT02112838|IGA Glomerulonephritis
980409|NCT02112838|Nephritis, IGA Type
980410|NCT02112825|Exercise
980411|NCT02112825|blood pressure
980412|NCT02112825|chronic kidney disease
980413|NCT02112812|Parkinsons disease
980414|NCT02112812|Helicobacter pylori
980415|NCT02112812|Eradication
980416|NCT02112812|Levodopa response
980417|NCT02112812|Motor outcomes
980418|NCT02112812|Quality of Life
980419|NCT02112812|Open label
980420|NCT02112799|Hepatitis B
980421|NCT02112786|Overactive Bladder
980422|NCT02112773|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
980423|NCT02112760|specific stabilization exercise
980424|NCT02112760|ultrasound
980425|NCT02112760|low back pain
980426|NCT02112747|Colorectal Cancer Prevention
980427|NCT02112747|Colorectal Cancer Screening
980428|NCT02112747|ACCS
980429|NCT02112747|Lynch Syndrome
980430|NCT02112747|LS
980431|NCT02112734|vitamin D
980432|NCT02112734|food allergy
980433|NCT02112734|eczema
980434|NCT02112708|Psychotherapy, Rational-Emotive
980435|NCT02112708|Depression
980436|NCT02112708|Social Work
980437|NCT02112708|Primary Health Care
980438|NCT02112695|endurance sportswomen
980439|NCT02112695|addiction
980440|NCT02112695|undernutrition
980441|NCT02112695|[11C]diprenorphine Pet
980442|NCT02112695|pituitary region
980443|NCT02112682|Sentinel lymph node metastasis
980444|NCT02112682|Completion axillary lymph node dissection
980445|NCT02112682|Axillary radiotherapy
980462|NCT02112643|Thyroid eye disease
980463|NCT02112643|Thyroid orbitopathy
980464|NCT02112643|Graves' orbitopathy
980465|NCT02112643|Graves' ophthalmopathy
980466|NCT02112630|Hepatitis C Infection
980467|NCT02112630|HCV, genotype 1
980468|NCT02112630|End Stage Renal Disease
980469|NCT02112630|ESRD
980470|NCT02112630|Boceprevir
980471|NCT02112630|Pegylated Interferon
980472|NCT02112630|Ribavirin
980473|NCT02112617|Neuroblastoma
980474|NCT02112617|Childhood neuroblastoma
980475|NCT02112617|Ganglioneuroblastoma
980476|NCT02112617|Pediatric neuroblastoma
980477|NCT02112604|critically ill, OSA, mechanical ventilation
980478|NCT02112591|Stress urinary incontinence
980479|NCT02112591|mesh
980480|NCT02112591|tape
980481|NCT02112591|micturition dysfunction
980482|NCT02112591|urinary obstruction
980483|NCT02112591|TOT
980484|NCT02112578|Vertigo, Meclizine, dimenhydrinate, Peripheral Origin
980485|NCT02112526|de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
980486|NCT02112526|Diffuse Large B-Cell Lymphoma
980487|NCT02112526|Novo Activated B-cell (ABC)
980488|NCT02112526|Novo Activated B-cell
980489|NCT02112526|ABC DLBCL
980490|NCT02112526|DLBCL
980491|NCT02112526|Lymphoma
980492|NCT02112526|B-Cell
980493|NCT02112526|Immunoproliferative Disorders
980494|NCT02112526|Immune System Diseases
980495|NCT02112487|pulmonary arterial hypertension
980496|NCT02112487|PAH-SYMPACT
980497|NCT02112487|PAH
980498|NCT02112487|psychometric instrument
980499|NCT02112474|Failed Back Surgery Syndrome
980500|NCT02112474|Neuropathic pain
980501|NCT02112474|Leg Pain
980502|NCT02112474|Chronic Pain
980503|NCT02112474|Spinal Cord Stimulation
980504|NCT02112474|Neurostimulation
980505|NCT02112461|end of life care
980506|NCT02112448|congenital heart disease, pediatric cardiothoracic surgery
980507|NCT02112435|obstructive sleep apnea
980508|NCT02112435|mandibular advancement splint
980509|NCT02112435|active mandibular advancement splint
980510|NCT02112435|oral appliance
980511|NCT02112422|Parturients
980512|NCT02112409|Adolescent idiopathic scoliosis
980513|NCT02112409|scoliosis corrective surgery
980514|NCT02112409|autologous blood transfusion
980515|NCT02112409|cell salvage
980516|NCT02112409|acute normovolemic hemodilution
980517|NCT02112409|hemoglobin level
980518|NCT02112396|CRAFT
980519|NCT02112396|Concerned Significant Others
980520|NCT02112396|Contingency management
980521|NCT02112396|Reinforcement
980522|NCT02112396|Family Intervention
980523|NCT02112383|Procrastination
980524|NCT02112383|Cognitive behavior therapy
980525|NCT02112383|Internet interventions
980526|NCT02112383|Group intervention
980527|NCT02112383|Students
980528|NCT02112383|Randomized controlled trial
980529|NCT02112370|Ropivacaine
980530|NCT02112370|Epinephrine
980531|NCT02112370|Endoscopy
980532|NCT02112370|Robotics
980533|NCT02112370|Thyroidectomy
980534|NCT02112357|molecular profiling
980535|NCT02112357|genetic sequencing
980536|NCT02112357|personalised medicine
980537|NCT02112357|gastrointestinal cancer
980538|NCT02112331|Preterm newborns
980539|NCT02112331|Gastric lipolysis
980540|NCT02112331|Physical treatments
980541|NCT02112331|Human milk
980542|NCT02112305|Magnesium sulphate nebulized
980543|NCT02112279|Microbiota
980544|NCT02112279|c-difficile
980545|NCT02112279|colonoscopy
980546|NCT02112279|stool transplant
980547|NCT02112266|depression
980548|NCT02112266|online therapy
980549|NCT02112266|cognitive behavioural therapy
980550|NCT02112266|quality of life
980551|NCT02112266|alexithymia
980552|NCT02112266|therapy expectation and satisfaction
980553|NCT02112253|Tourette's syndrome
980554|NCT02112253|Deep brain stimulation
980555|NCT02112253|Stereotactic surgery
980556|NCT02112253|Globus pallidus interna
980557|NCT02112253|Tics
980558|NCT02112240|sentinel lymph node
980559|NCT02112240|lymphatic mapping
980560|NCT02112240|rectal tumor
980561|NCT02112227|Heart Failure
980562|NCT02112227|Transitional Care
980563|NCT02112227|Knowledge Translation
980564|NCT02112227|Outcomes
980565|NCT02112214|Helicobacter pylori treatment
980566|NCT02112214|Gastric cancer
980567|NCT02112214|Screening
980568|NCT02112175|Multiple Myeloma
980569|NCT02112175|Lenalidomide
980570|NCT02112175|Revlimid
980571|NCT02112175|MPV
980572|NCT02112175|Melphalan
980573|NCT02112175|Prednisone
980574|NCT02112175|Velcade
980575|NCT02112175|Placebo
980576|NCT02112149|Body Composition
980577|NCT02112149|Exercise
980578|NCT02112149|Survivorship
980579|NCT02112136|Autosomal Dominant Polycystic Kidney Disease (ADPKD)
980580|NCT02112136|Renal cysts
980581|NCT02112136|Chronic Kidney Diseases
980582|NCT02112136|Genetic
980583|NCT02112123|icariin
980584|NCT02112123|pharmacokinetics
980585|NCT02112123|healthy participants
980586|NCT02112097|Plaque Psoriasis.
980587|NCT02112097|Subdermal bloodless space
980588|NCT02112097|Subdermal injection
980589|NCT02112097|Subcutaneous injection
980590|NCT02112097|Injectable electromyography needle
980591|NCT02112097|Electrical stimulation
980592|NCT02112097|MRI with Gadolinium
980593|NCT02112071|Exercise
980594|NCT02112071|Diabetic kidney disease
980595|NCT02112071|vascular function
980596|NCT02112071|physical function
980597|NCT02112032|melanoma
980598|NCT02112032|advanced
980599|NCT02112019|Sjögren's Syndrome
980600|NCT02112019|Sialoendoscopy
980601|NCT02112019|Saliva
980602|NCT02112019|Dry Mouth
980603|NCT02112006|hand surgery
980604|NCT02112006|wrist surgery
980605|NCT02112006|finger surgery
980606|NCT02112006|anesthesia
980607|NCT02112006|regional anesthesia
980608|NCT02112006|postoperative pain
980609|NCT02111993|Defibrillation testing
980610|NCT02111993|Upper Limit of Vulnerability
980611|NCT02111993|ULV
980612|NCT02111993|DFT
980613|NCT02111993|ICD
980614|NCT02111993|implantable cardioverter defibrillator
980615|NCT02111993|cardiomyopathy
980616|NCT02111993|cardiac arrhythmia
980617|NCT02111993|cardiac device testing
980618|NCT02111980|CIED
980619|NCT02111980|pacemaker
980620|NCT02111980|implantable cardioverter defibrillator
980621|NCT02111980|ICD
980622|NCT02111980|radiofrequency
980623|NCT02111980|cardiac device programming
980624|NCT02111980|RF sponge detection
980625|NCT02111980|RF assure
980626|NCT02111980|cardiac internal electronic devices
980627|NCT02111980|temporary pacing
980628|NCT02111980|pulmonary thromboendarterectomy
980629|NCT02111980|pacing interference
980630|NCT02111980|Arrhythmia
980631|NCT02111954|prostate cancer
980632|NCT02111954|primary
980633|NCT02111954|recurrence
980634|NCT02111954|F-18-FCH PET/CT
980635|NCT02111954|Ga-68-NODAGA-MJ9 PET/CT
980636|NCT02111915|Maternal depression
980637|NCT02111902|Cardiovascular Disease
980638|NCT02111902|Obesity
980639|NCT02111902|Physical Activity
980640|NCT02111902|Vitamin D deficiency
980641|NCT02111902|African Americans
980642|NCT02111876|ICU, COPD, OHS, OSA, heart failure
980643|NCT02111863|Skin Cancer
980644|NCT02111863|Metastatic Melanoma
980645|NCT02111863|Adoptive Cell Therapy
980646|NCT02111863|Immunotherapy
980647|NCT02111863|Clinical Response
980648|NCT02111850|Gene Therapy
980649|NCT02111850|Tumor Regression
980650|NCT02111850|Immunotherapy
980651|NCT02111850|Adoptive Cell Therapy
980652|NCT02111824|Lung Cancer
980653|NCT02111824|Peripheral lung lesions
980654|NCT02111824|Lung biopsy
980655|NCT02111824|Minimally invasive
980656|NCT02111824|multimodality image-guided intervention system
980657|NCT02111824|MIMIG
980658|NCT02111824|Indocyanine green
980659|NCT02111824|ICG
980660|NCT02111811|Depression
980661|NCT02111811|Treatment Outcome
980662|NCT02111811|Delivery of Healthcare, Integrated
980663|NCT02111811|Employment
980664|NCT02111811|Rehabilitation
980665|NCT02111798|substance abuse treatment
980666|NCT02111798|cocaine dependence
980667|NCT02111798|contingency management; abstinence incentives
980668|NCT02111798|medication-enhanced behavioral therapy
980669|NCT02111785|Dexamethasone
980670|NCT02111785|Burr hole craniostomy
980671|NCT02111785|Chronic subdural hematoma
980672|NCT02111746|Postoperative pain
980673|NCT02111746|sternotomy
980674|NCT02111746|laparotomy
980675|NCT02111746|thoracotomy
980676|NCT02111746|mini-thoracotomy
980677|NCT02111746|truncal surgical incisions
980678|NCT02111746|local anaesthetics
980679|NCT02111746|bupivacaine
980680|NCT02111720|HIV
980681|NCT02111720|Disclosure
980682|NCT02111720|Family
980683|NCT02111720|Intervention
980684|NCT02111694|infant
980685|NCT02111694|intake
980686|NCT02111694|satiation
980687|NCT02111694|mother
980688|NCT02111694|feeding practices
980689|NCT02111694|bottle feeding
980690|NCT02111694|formula feeding
980691|NCT02111694|maternal responsiveness
980692|NCT02111694|infant cues
980693|NCT02111681|Calypso-based Deep Inspiration Breath Hold (DIBH)
980694|NCT02111681|radiation treatments
980695|NCT02111681|13-174
980696|NCT02111668|Aorta
980697|NCT02111668|Dilatation
980698|NCT02111668|Marfan syndrome
980699|NCT02111668|Genetic
980700|NCT02111668|Fbn1
980701|NCT02111655|Thrombosis
980702|NCT02111655|Arteriovenous fistulae
980703|NCT02111655|Hemodialysis
980704|NCT02111655|Doppler ultrasound
980705|NCT02111655|Vascular access blood flow
980706|NCT02111655|Surveillance
980707|NCT02111642|Pelvic organ prolapse
980708|NCT02111642|Stress urinary incontinence
980709|NCT02111642|Midurethral sling
980710|NCT02111642|Patient satisfaction
980711|NCT02111629|Vaginosis, bacterial; Candidiasis, vulvovaginal
980712|NCT02111616|cancer survivorship care
980713|NCT02111616|provider communication
980714|NCT02111616|provider care coordination
980715|NCT02111590|Immunoglobulins, Intravenous
980716|NCT02111590|Immunoglobulins, Subcutaneous
980717|NCT02111577|Immunotherapy
980718|NCT02111577|Metastatic
980719|NCT02111577|Castrate Resistant
980720|NCT02111577|Prostate Cancer
980721|NCT02111577|Biological
980722|NCT02111577|Vaccine
980723|NCT02111564|Heart Failure
980724|NCT02111564|Respiratory Insufficiency
980725|NCT02111564|Stroke Acute
980726|NCT02111564|Infectious Diseases
980727|NCT02111564|Rheumatic Diseases
980728|NCT02111564|Medically ill Patient
980729|NCT02111564|Rivaroxaban
980730|NCT02111564|Thromboembolism
980731|NCT02111564|Prophylactic Anti-Coagulation
980732|NCT02111551|Autism
980733|NCT02111551|Nicotinic agonist
980734|NCT02111551|Cognition
980735|NCT02111551|P50
980736|NCT02111551|Alpha 7
980737|NCT02111499|psoriasis plaque test
980738|NCT02111499|topical application
980739|NCT02111499|atrophy measure
980740|NCT02111486|Breakfast
980741|NCT02111486|Satiety
980742|NCT02111486|Fibre
980743|NCT02111486|Glucose
980744|NCT02111486|Gastric emptying
980745|NCT02111473|endothelial dysfunction
980746|NCT02111473|bone mineral metabolism
980747|NCT02111473|testosteron replacement treatment
980748|NCT02111460|Initially
980749|NCT02111460|Untreated
980750|NCT02111460|Distant metastatic
980751|NCT02111447|children
980752|NCT02111447|sevoflurane
980753|NCT02111447|isoflurane
980754|NCT02111447|propofol
980755|NCT02111447|anesthesia
980756|NCT02111447|MRI
980757|NCT02111447|delirium
980758|NCT02111434|visceral adiposity index
980759|NCT02111434|triglycerides / hdl cholesterol ratio
980760|NCT02111434|testosterone
980761|NCT02111421|dexmedetomidine
980762|NCT02111421|parturient
980763|NCT02111421|nonpregnant women
980764|NCT02111421|sedation
980765|NCT02111408|Sleep apnea syndromes
980766|NCT02111408|Autonomic nervous system +/- disease
980767|NCT02111408|Depression
980768|NCT02111408|Peripheral arterial disease
980769|NCT02111382|Low back pain
980770|NCT02111382|osteopathic manipulations
980771|NCT02111382|electroencephalography
980772|NCT02111369|Essential Tremor
980773|NCT02111369|Essential Vocal Tremor
980774|NCT02111369|Essential Voice Tremor
980775|NCT02111343|auditory processing disorder
980776|NCT02111343|central auditory processing disorder
980777|NCT02111343|auditory processing
980778|NCT02111343|auditory training
980779|NCT02111330|Adenosine A2a receptor antagonist
980780|NCT02111330|adenosine receptor modulator
980781|NCT02111330|Cancer
980782|NCT02111317|ASP015K
980783|NCT02111317|Pharmacokinetics
980784|NCT02111317|Healthy Subjects
980785|NCT02111304|cholera
980786|NCT02111304|diarrhea
980787|NCT02111304|secretory diarrhea
980788|NCT02111304|ORS
980789|NCT02111304|V. cholerae O1
980790|NCT02111304|iOWH032
980791|NCT02111304|children
980792|NCT02111304|pharmacokinetic
980793|NCT02111304|Bangladesh
980794|NCT02111291|Diabetic Foot Ulcers
980795|NCT02111278|Manipulation
980796|NCT02111278|Lumbar
980797|NCT02111278|Low Back Pain
980798|NCT02111278|Manual Therapy
980799|NCT02111278|Adolescents
980800|NCT02111252|Drug Therapy
980801|NCT02111239|DIEP
980802|NCT02111239|DIEP flap
980803|NCT02111239|Breast reconstruction
980804|NCT02111239|Breast Cancer
980805|NCT02111239|CTA
980806|NCT02111239|MRA
980807|NCT02111226|hypertension
980808|NCT02111226|cardiovascular disease
980809|NCT02111226|diabetes
980810|NCT02111226|chronic disease management
980811|NCT02111213|physical activity
980812|NCT02111213|Intervention
980813|NCT02111213|Attitude to Computers
980814|NCT02111200|UCD
980815|NCT02111187|LDE225
980816|NCT02111187|High risk localized prostate cancer
980817|NCT02111187|Pre-surgical
980818|NCT02111174|Neuropathy
980819|NCT02111174|Peripheral neuropathy
980820|NCT02111174|Chemotherapy-induced peripheral neuropathy
980821|NCT02111161|Randomised controlled trial (RCT)
980822|NCT02111161|Immunoglobulin
980823|NCT02111161|Patient Reported Outcome
980824|NCT02111161|Health-Related Quality of Life
980825|NCT02111161|Short Form-36 (SF-36)
980826|NCT02111148|rupture of membranes, nitrazine, urea, creatinine
980827|NCT02111122|excessive daytime sleepiness
980828|NCT02111122|Parkinson`s Disease
980829|NCT02111122|sleep-wake disturbances
980830|NCT02111122|Sodium Oxybate
980831|NCT02111109|Microcirculation
980832|NCT02111109|Trauma
980833|NCT02111109|Haemorrhage
980834|NCT02111109|Shock
980835|NCT02111070|Influenza
980836|NCT02111070|Influenza vaccine
980837|NCT02111070|Split influenza vaccine
980838|NCT02111057|Rheumatoid Arthritis
980839|NCT02111057|Total Hip Replacement
980840|NCT02111057|Flare
980841|NCT02111057|Perioperative Outcomes
980842|NCT02111044|de novo or partial responder to somatostatin analogues
980843|NCT02111031|CELLSEARCH
980844|NCT02111031|CTC
980845|NCT02111031|metastatic breast cancer
980846|NCT02111031|Registry
980847|NCT02111031|mBC
980848|NCT02111005|apoptosis
980849|NCT02111005|periodontal disease
980850|NCT02111005|smoking
980851|NCT02110979|Patient Decision Aid
980852|NCT02110979|Shared Decision Making
980853|NCT02110966|Anaesthetic effect
980854|NCT02110966|Inferior alveolar nerve block
980855|NCT02110966|Local tramadol
980856|NCT02110966|Mepivacaine
980857|NCT02110966|Symptomatic irreversible pulpitis.
980858|NCT02110927|Abdominal fat
980859|NCT02110927|Metabolic syndrome
980860|NCT02110927|Microcurrent
980861|NCT02110927|Aerobic exercise
980862|NCT02110927|Lipolysis
980863|NCT02110914|Feasibility study
980864|NCT02110914|Coaching
980865|NCT02110914|Health related quality of life
980866|NCT02110914|Adherence
980867|NCT02110901|radiocephalic
980868|NCT02110901|arteriovenous fistula
980869|NCT02110901|AVF
980870|NCT02110901|hemodialysis
980871|NCT02110901|PRT-201
980872|NCT02110901|vascular access
980873|NCT02110901|kidney
980874|NCT02110901|renal
980875|NCT02110901|vonapanitase
980876|NCT02110901|PATENCY-1
980877|NCT02110875|Healthy Volunteers
980878|NCT02110849|Prostate
980879|NCT02110849|Proton Therapy
980880|NCT02110849|Cancer
980881|NCT02110810|post-ERCP Acute Pancreatitis
980882|NCT02110810|Indomethacin
980883|NCT02110810|NSAIDs
980884|NCT02110797|RETT syndrome
980885|NCT02110797|MECP2
980886|NCT02110797|Osteoporosis
980887|NCT02110797|RANK-ligand
980888|NCT02110797|osteoprotegerin
980889|NCT02110784|Artemisinin based Combination Therapies
980890|NCT02110784|eurartesim
980891|NCT02110784|Dihydroartemisinin/Piperaquine
980892|NCT02110771|schizophrenia
980893|NCT02110771|social cognition
980894|NCT02110771|facial affects recognition
980895|NCT02110771|cognitive remediation
980896|NCT02110758|Patient Care Management
980897|NCT02110758|Patient Care Planning
980898|NCT02110758|Patient-Centered Care
980899|NCT02110758|Patient Care Team
980900|NCT02110758|Advance Care Planning
980901|NCT02110758|Delivery of Health Care
980902|NCT02110758|Evidence-based Practice
980903|NCT02110758|Health Care Costs
980904|NCT02110758|Health Care Quality, Access, and Evaluation
980905|NCT02110758|Quality of Health Care
980906|NCT02110758|Neoplasms
980907|NCT02110758|Medical Oncology
980908|NCT02110719|narcotic use
980909|NCT02110719|pain
980910|NCT02110719|constipation
980911|NCT02110719|nausea
980912|NCT02110706|Myasthenia Gravis
980913|NCT02110706|Rituximab
980914|NCT02110693|Substance Use
980915|NCT02110693|Substance Use Disorder
980916|NCT02110693|Screening
980917|NCT02110693|Brief Assessment
980918|NCT02110680|overactive bladder
980919|NCT02110680|transcutaneous electric stimulation
980920|NCT02110680|posterior tibial nerve stimulation
980921|NCT02110667|Prostate cancer
980922|NCT02110667|Prostatectomy
980923|NCT02110667|Ultrasound
980924|NCT02110667|TPUS
980925|NCT02110654|chronic rhinosinusitis
980926|NCT02110654|asthma
980927|NCT02110654|montelukast
980928|NCT02110654|surgery
980929|NCT02110654|treatment outcomes
980930|NCT02110641|Breast Cancer
980931|NCT02110641|Survivorship
980932|NCT02110641|Weight Loss
980933|NCT02110628|total gastrectomy
980934|NCT02110628|pouch
980935|NCT02110628|roux-en-y
980936|NCT02110628|quality of life
980937|NCT02110602|Nutrition
980938|NCT02110589|seizures
980939|NCT02110550|endocrown
980940|NCT02110550|marginal adaptation
980941|NCT02110550|anatomic form
980942|NCT02110550|retention loss
980943|NCT02110550|IPS.emmax crowns
980944|NCT02110537|Atrial fibrillation
980945|NCT02110537|Acupuncture
980946|NCT02110537|Recurrence
980947|NCT02110537|Electrical cardioversion
980948|NCT02110524|Peripheral Arterial Disease
980949|NCT02110498|Pancreatic cyst
980950|NCT02110498|IPMN
980951|NCT02110498|SCA
980952|NCT02110498|SPN
980953|NCT02110498|MCN
980954|NCT02110498|pancreatic cystic neoplasm
980955|NCT02110485|Appendicitis
980956|NCT02110485|Pediatric
980957|NCT02110485|Children
980958|NCT02110485|Non-operative
980959|NCT02110485|Antibiotics alone
980960|NCT02110472|Emmetropic presbyopes
980961|NCT02110472|Presbyopic
980962|NCT02110459|POL7080
980963|NCT02110459|Pharmacokinetics
980964|NCT02110446|Sjögren's syndrome
980965|NCT02110446|SS-1
980966|NCT02110446|Gan-Lu-Yin
980967|NCT02110446|Sang-Ju-Yin
980968|NCT02110446|Xuefu-Zhuyu-Decoction
980969|NCT02110433|chronic heart failure
980970|NCT02110433|BNP
980971|NCT02110433|telemedicine
980972|NCT02110433|telemonitoring
980973|NCT02110433|weight
980974|NCT02110433|education
980975|NCT02110433|self management
980976|NCT02110433|cost effectiveness
980977|NCT02110420|Safety
980978|NCT02110420|Pharmacokinetics
980979|NCT02110420|Healthy Subjects
980980|NCT02110420|First-in-Human
980981|NCT02110407|healthy young adults
980982|NCT02110407|tDCS
980983|NCT02110407|LOCATO task
980984|NCT02110407|visual-spatial learning
980985|NCT02110394|observational
980986|NCT02110394|chronic lymphocytic leukemia
980987|NCT02110394|bendamustine
980988|NCT02110381|High blood pressure
980989|NCT02110355|Metastatic melanoma
980990|NCT02110342|PF-04449913
980991|NCT02110342|[14C]PF-04449913
980992|NCT02110342|Human ADME
980993|NCT02110342|Radiolabel
980994|NCT02110342|Mass Balance
980995|NCT02110342|Pharmacokinetics
980996|NCT02110329|colorectal cancer
980997|NCT02110329|stage II and III
980998|NCT02110329|somatic quantitative molecular alterations
980999|NCT02110329|Qantitative Multiplex Pcr of Short fluorescent Fragments method (QMPSF)
981000|NCT02110290|quality of life
981001|NCT02110290|adaptive sports
981002|NCT02110290|therapeutic recreation
981003|NCT02110290|mental health
981004|NCT02110277|Ovarian Cancer
981005|NCT02110277|Epithelial ovarian cancer
981006|NCT02110264|Opioid Use
981007|NCT02110264|Incarceration
981008|NCT02110264|Vivitrol
981009|NCT02110264|Patient Navigator
981010|NCT02110264|Drug Education
981011|NCT02110238|osteoarthritis
981012|NCT02110238|knee pain
981013|NCT02110238|Supartz
981014|NCT02110238|Euflexxa
981015|NCT02110238|HA
981016|NCT02110238|hyaluronic acid
981017|NCT02110225|Cone-Rod Degenerations
981018|NCT02110225|Cone-Rod Dystrophy
981019|NCT02110225|Cone-Rod Dystrophy 2
981020|NCT02110225|Cone-Rod Retinal Dystrophy
981021|NCT02110225|Pigmentary Retinopathy
981022|NCT02110225|Retinal Cone-Rod Dystrophy
981023|NCT02110225|Rod Cone Dystrophies
981024|NCT02110225|Rod-Cone Dystrophy
981025|NCT02110225|Tapetoretinal Degeneration
981026|NCT02110212|Cataract
981027|NCT02110212|Surgery, cataract extraction
981028|NCT02110212|Optical devices, laser
981029|NCT02110186|lumbar disc herniation
981030|NCT02110186|dynamic stabilization
981031|NCT02110186|discectomy with posterior dynamic stabilization
981032|NCT02110186|discectomy alone
981033|NCT02110186|discectomy with internal fixation and fusion
981034|NCT02110069|KHE
981035|NCT02110069|Vascular anomaly
981036|NCT02110069|Kasabach-Merritt Syndrome
981037|NCT02110069|Tufted angioma
981038|NCT02110069|hemangioendothelioma
981039|NCT02110056|healthy older adults
981040|NCT02110056|tDCS
981041|NCT02110056|LOCATO task
981042|NCT02110056|visual-spatial learning
981043|NCT02110043|mild cognitive impairment (MCI)
981044|NCT02110043|tDCS
981045|NCT02110043|LOCATO task
981046|NCT02110043|visual-spatial learning
981047|NCT02110030|Transcutaneous electrical nerve stimulation (TENS)
981048|NCT02110030|Ultrasound
981049|NCT02110030|Interferential current therapy
981050|NCT02110030|Rehabilitation
981051|NCT02110030|Shoulder pain
981052|NCT02110017|Ecological task
981053|NCT02110017|fMRI
981054|NCT02110017|Schizophrenia
981055|NCT02110017|Social Cognition
981056|NCT02109978|Diabetes
981057|NCT02109978|Type 2 diabetes
981058|NCT02109978|Diabetes therapy response
981059|NCT02109978|Diabetes progression
981060|NCT02109939|MDD
981061|NCT02109939|Pharmacogenomic
981062|NCT02109939|Pharmacogenomic Testing
981063|NCT02109939|Pharmacogenomics
981064|NCT02109939|Genetic Testing
981065|NCT02109939|Genetics
981066|NCT02109939|Major Depressive Disorder
981067|NCT02109939|GeneSight
981068|NCT02109939|Assurex
981069|NCT02109939|AssureRx
981070|NCT02109939|Psychotropic
981071|NCT02109939|Randomized
981072|NCT02109939|Double Blind
981073|NCT02109939|Placebo Controlled
981074|NCT02109913|Breast Cancer
981075|NCT02109913|metastatic
981076|NCT02109913|hormone receptor positive
981077|NCT02109913|everolimus
981078|NCT02109913|biomarker
981079|NCT02109887|Pneumocystis jiroveci, cytomegalovirus, co-infection
981080|NCT02109861|Multiple Myeloma
981081|NCT02109861|Phase 0 study
981082|NCT02109861|Microdose study
981083|NCT02109861|Micro array
981084|NCT02109861|Gene expression profiling
981085|NCT02109848|keratoconus
981086|NCT02109848|post-keratoplasty
981087|NCT02109835|Diabetes
981088|NCT02109835|coronary artery disease
981089|NCT02109835|Cardiac computed tomography
981090|NCT02109835|Computed tomographics coronary angiography
981091|NCT02109835|Plaque progression
981092|NCT02109822|Cystic Fibrosis
981093|NCT02109822|Pulmonary Exacerbation
981094|NCT02109822|Lung Infection
981095|NCT02109822|Cystic Fibrosis Foundation
981096|NCT02109822|Cystic Fibrosis Foundation National Patient Registry
981097|NCT02109796|tDCS
981098|NCT02109796|Stroke
981099|NCT02109796|Force
981100|NCT02109796|Spasticity
981101|NCT02109796|Gait
981102|NCT02109796|EMG
981103|NCT02109796|Isokinetic
981104|NCT02109783|Athletes
981105|NCT02109783|Ergogenic aids
981106|NCT02109783|Caffeine
981107|NCT02109783|Nutrigenomics
981108|NCT02109783|Genotype
981109|NCT02109770|22q
981110|NCT02109770|DiGeorge
981111|NCT02109770|Angelman
981112|NCT02109770|Cri du chat
981113|NCT02109770|Miller Dieker
981114|NCT02109770|1p36
981115|NCT02109770|Phelan McDermid
981116|NCT02109770|Prader Willi
981117|NCT02109770|Wolf Hirschorn
981118|NCT02109770|Smith Magenis
981119|NCT02109770|Trisomy 21
981120|NCT02109770|Down syndrome
981121|NCT02109770|Trisomy 18
981122|NCT02109770|Edwards syndrome
981123|NCT02109770|Trisomy 13
981124|NCT02109770|Patau syndrome
981125|NCT02109770|Monosomy X
981126|NCT02109770|Turner syndrome
981127|NCT02109770|XXY
981128|NCT02109770|Klinefelter syndrome
981129|NCT02109770|XXX
981130|NCT02109770|XYY
981131|NCT02109757|Hearing conservation
981132|NCT02109757|Personal attenuation rating
981133|NCT02109757|earplug
981134|NCT02109731|Obstructive Sleep Apnea Syndrome (OSAS)
981135|NCT02109731|Sleep Apnea
981136|NCT02109718|Burns
981137|NCT02109718|Dressings
981138|NCT02109718|Outpatient Management
981139|NCT02109718|Petrolatum Jelly
981140|NCT02109718|Superficial Partial Thickness Burns
981141|NCT02109718|Less than or equal to 10% Total Body Surface Area
981142|NCT02109692|dystrophinopathies
981143|NCT02109692|muscle dystrophies
981144|NCT02109692|dystromirs
981145|NCT02109692|longitudinal study
981146|NCT02109692|miRNA
981147|NCT02109653|NSCLC,
981148|NCT02109653|Non-Small Cell Lung Cancer,
981149|NCT02109653|BRAF V600,
981150|NCT02109653|LGX818
981151|NCT02109640|Colorectal
981152|NCT02109640|Surgery
981153|NCT02109640|Laparoscopic
981154|NCT02109640|Analgesia
981155|NCT02109640|Enhanced Recovery
981156|NCT02109640|Targinact
981157|NCT02109627|Acute Myeloid Leukemia
981158|NCT02109627|Ficlatuzumab
981159|NCT02109627|High Dose Cytarabine
981160|NCT02109627|antibody
981161|NCT02109614|lipoprotein(a)
981162|NCT02109614|aortic stenosis
981163|NCT02109601|Patient Portals
981164|NCT02109601|Personal Health Records
981165|NCT02109601|Patient Engagement
981166|NCT02109601|Mobile Health
981167|NCT02109601|Tablet Computers
981168|NCT02109575|Acute Rejection
981169|NCT02109575|Cardiac Biomarkers
981170|NCT02109575|Cardiac Catheterization
981171|NCT02109575|Cardiomyopathy
981172|NCT02109575|Cell-Free DNA
981173|NCT02109575|Congenital Heart Defect
981174|NCT02109575|Congenital Heart Disease
981175|NCT02109575|Coronary Angiogram
981176|NCT02109575|Donor Specific DNA
981177|NCT02109575|Donor Specific Cell-Free DNA
981178|NCT02109575|Endomyocardial Biopsy
981179|NCT02109575|Heart Failure
981180|NCT02109575|Heart Transplant Failure
981181|NCT02109575|Heart Transplant
981182|NCT02109575|Heart Transplant Rejection
981183|NCT02109562|Schizophrenia
981184|NCT02109562|Schizophrenic
981185|NCT02109562|Schizophrenias
981186|NCT02109562|Risperidone
981187|NCT02109536|Colonoscopy
981188|NCT02109536|Looping
981189|NCT02109536|Loop recognition
981190|NCT02109536|magnetic endoscopic imager
981191|NCT02109471|corneal opacities
981192|NCT02109471|Optical coherence tomography
981193|NCT02109458|Lung nodule biopsy
981194|NCT02109432|Pedal Desk
981195|NCT02109432|Physical Activity
981196|NCT02109432|Workplace
981197|NCT02109432|Energy Expenditure
981198|NCT02109419|computerized assessments
981199|NCT02109419|mood
981200|NCT02109419|life space
981201|NCT02109419|cognition
981202|NCT02109393|Rehabilitation
981203|NCT02109393|Robot-assisted walking training
981204|NCT02109393|Treadmill
981205|NCT02109393|Lokomat
981206|NCT02109367|ovarian cancer
981207|NCT02109367|ovarian mass
981208|NCT02109367|CA-125
981209|NCT02109367|HE4
981210|NCT02109367|culdocentesis
981211|NCT02109367|biomarker(s)
981212|NCT02109354|HIV infection
981213|NCT02109354|Vaccine
981214|NCT02109341|mPC
981215|NCT02109328|Bladder cancer
981216|NCT02109328|Urothelial cancer
981217|NCT02109328|Alisertib
981218|NCT02109328|Phase 2
981219|NCT02109328|Advanced disease
981220|NCT02109289|Anti-Tumor necrosis factor alpha
981221|NCT02109289|18-FluoroDeoxyGlucose Positron Emission Tomography
981222|NCT02109289|High-sensitivity C- Reactive protein
981223|NCT02109276|Fuch's endothelial dystrophy
981224|NCT02109276|Aspheric intraocular lens
981225|NCT02109276|Higher Order Aberrations
981226|NCT02109276|Contrast Sensitivity
981227|NCT02109263|Breast-feeding
981228|NCT02109263|Saccharose
981229|NCT02109263|Breast-feeding newborn
981230|NCT02109263|cortical pain responses
981231|NCT02109263|near infrared spectroscopy (NIRS)
981232|NCT02109263|Salivary rate cortisol
981233|NCT02109263|heel lance
981234|NCT02109250|Medullary Thyroid Cancer (MTC) vandetanib caprelsa
981235|NCT02109237|Lung transplantation
981236|NCT02109237|Bronchiolitis obliterans
981237|NCT02109198|Mild Traumatic Brain Injury
981238|NCT02109185|seasonal allergic rhinitis
981239|NCT02109185|grass/tree/ragweed allergies
981240|NCT02109185|nasal congestion/stuffiness
981241|NCT02109185|rhinnorea
981242|NCT02109185|nasal itching
981243|NCT02109185|sneezing
981244|NCT02109172|Chronic Obstructive Pulmonary Disease
981245|NCT02109172|COPD
981246|NCT02109146|TACE
981247|NCT02109146|Postoperation
981248|NCT02109133|deep neuromuscular blockade
981249|NCT02109133|intraocular pressure
981250|NCT02109107|body contouring
981251|NCT02109107|body shaping
981252|NCT02109107|circumference reduction
981253|NCT02109094|insulin
981254|NCT02109094|metabolomics
981255|NCT02109081|dexamethasone
981256|NCT02109081|delirium
981257|NCT02109081|postoperative cognitive dysfunction
981258|NCT02109081|postoperative
981259|NCT02109081|elderly
981260|NCT02109068|Breast Cancer
981261|NCT02109068|Survivorship
981262|NCT02109068|Weight Loss
981263|NCT02109055|Cardiovascular Diseases
981264|NCT02109055|Thoracic Surgery
981265|NCT02109055|Exercise Therapy
981266|NCT02109016|FGFR1 amplification
981267|NCT02109016|FGF alteration
981268|NCT02109016|VEGF alteration
981269|NCT02109016|PDGF alteration
981270|NCT02109016|Tyrosine kinase inhibitor
981271|NCT02109016|VEGFR inhibitor
981272|NCT02109016|FGFR inhibitor
981273|NCT02109016|PDGFR inhibitor
981274|NCT02109016|VEGFR-FGFR inhibitor
981275|NCT02109003|tracheal cuff
981276|NCT02109003|cuff overinflation
981277|NCT02109003|cuff underinflation
981278|NCT02108990|borderline personality disorder
981279|NCT02108990|rejection
981280|NCT02108990|social pain
981281|NCT02108977|Remote Consultation
981282|NCT02108977|Teleconsultation
981283|NCT02108977|Videoconferencing
981284|NCT02108977|Genetic Counseling
981285|NCT02108977|Costs and Cost Analysis
981286|NCT02108977|Comparative Effectiveness Research
981287|NCT02108977|Telehealth
981288|NCT02108964|NSCLC
981289|NCT02108964|Non-small Cell Lung Cancer EGFRmut
981290|NCT02108964|EGFR TKIs (EGF816)
981291|NCT02108964|acquired T790M mutation
981292|NCT02108964|de novo T790M mutation
981293|NCT02108964|EGFR TKI activating mutation (i.e. L858R or ex19del)
981294|NCT02108964|Treatment naive advanced NSCLC with EGFR activating mutations
981295|NCT02108964|Locally advanced NSCLC (Stage IIIB NSCLC not amenable to definitive multi-modality therapy including surgery)
981296|NCT02108964|Metastatic NSCLC refers to Stage IV NSCLC
981297|NCT02108964|1st line
981298|NCT02108951|CML
981299|NCT02108951|Ph-CML
981300|NCT02108951|leukaemia
981301|NCT02108951|leukemia
981302|NCT02108951|chronic myeloid leukemia
981303|NCT02108951|chronic myeloid leukaemia
981304|NCT02108951|TKI intolerance
981305|NCT02108951|tyrosine kinase inhibitor
981306|NCT02108951|tyrosine kinase inhibitor intolerance
981310|NCT02108899|Schizophrenia
981311|NCT02108899|Episodic memory deficits
981312|NCT02108886|preterm labor
981313|NCT02108886|montelukast
981314|NCT02108886|uterine contractions
981315|NCT02108873|Appointments and Schedules
981316|NCT02108873|Outpatient Clinics, Hospital/economics
981317|NCT02108860|Granulomatosis with polyangiitis (Wegener's)
981318|NCT02108860|Granulomatosis with polyangiitis
981319|NCT02108860|GPA
981320|NCT02108860|Wegener's granulomatosis
981321|NCT02108860|Wegener granulomatosis
981322|NCT02108860|Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
981323|NCT02108860|ANCA Associated Vasculitis
981324|NCT02108860|AAV
981325|NCT02108860|Vasculitis
981326|NCT02108860|Systemic vasculitis
981327|NCT02108860|Systemic inflammatory disease
981328|NCT02108860|Lung Diseases
981329|NCT02108860|Respiratory Tract Diseases
981330|NCT02108860|Vascular Diseases
981331|NCT02108860|Abatacept
981332|NCT02108860|CTLA4-Ig
981333|NCT02108860|Immunosuppressive agent
981334|NCT02108860|Prednisone
981335|NCT02108860|Glucocorticoids
981336|NCT02108860|Glucocorticoid
981337|NCT02108860|Corticosteroid
981338|NCT02108860|Corticosteroids
981339|NCT02108860|Treatment
981340|NCT02108860|Pharmacologic Actions
981341|NCT02108860|Therapeutic Uses
981342|NCT02108860|Anti Inflammatory Agents
981343|NCT02108847|Arthroplasty, Replacement, Hip
981344|NCT02108847|Pain, Postoperative
981345|NCT02108847|Nerve Block
981346|NCT02108847|Anesthesia, Regional
981347|NCT02108847|Fascia Iliaca Block
981348|NCT02108847|Ultrasound Guided
981349|NCT02108834|chronic postsurgery pain
981350|NCT02108834|acute pain
981351|NCT02108821|Inflammatory Bowel Diseases (IBD)
981352|NCT02108821|Crohn's Disease (CD)
981353|NCT02108821|Ulcerative Colitis (UC)
981354|NCT02108808|FFR
981355|NCT02108808|adenosine
981356|NCT02108808|Ticagrelor
981357|NCT02108769|Yoga
981358|NCT02108769|Yogic breathing
981359|NCT02108769|Saliva
981360|NCT02108769|Proteomics
981361|NCT02108769|Lipdomics
981362|NCT02108769|Nerve growth factor
981363|NCT02108769|Thirumanthiram
981364|NCT02108717|Telemedicine
981365|NCT02108717|appendicitis
981366|NCT02108717|remote consultation
981367|NCT02108704|Parkinson's Disease
981368|NCT02108704|Helicobacter pylori infection
981369|NCT02108678|Acceptance and Commitment Therapy (ACT)
981370|NCT02108678|Depression
981371|NCT02108678|Illness Management
981372|NCT02108678|Behavioral Treatment
981373|NCT02108678|Impairment
981374|NCT02108652|anti-PD-L1
981375|NCT02108652|PD-L1
981376|NCT02108652|MPDL3280A
981377|NCT02108652|PD-1
981378|NCT02108652|bladder cancer
981379|NCT02108652|atezolizumab
981380|NCT02108652|Tecentriq
981381|NCT02108626|Electronic Cigarettes
981382|NCT02108626|Lozenge
981383|NCT02108626|Nicotine
981384|NCT02108626|Tobacco
981385|NCT02108626|Dependence
981386|NCT02108626|Withdrawal
981387|NCT02108613|Androgen deprivation therapy
981388|NCT02108613|Supportive care
981389|NCT02108613|Quality of life
981390|NCT02108600|Kidney transplantation
981391|NCT02108600|Inflammation
981392|NCT02108561|Breast Cancer Heterogeneity Her2
981393|NCT02108548|ASP7657
981394|NCT02108548|Pharmacokinetics
981395|NCT02108548|Pharmacodynamics
981396|NCT02108548|Healthy Subjects
981397|NCT02108548|First in man
981398|NCT02108548|Safety
981399|NCT02108535|burns
981400|NCT02108535|dressings
981401|NCT02108535|silver sulfadiazine
981402|NCT02108535|silver compounds
981403|NCT02108535|cost
981404|NCT02108522|CMV infection
981405|NCT02108522|EBV infection
981406|NCT02108522|HHV6 virus infection
981407|NCT02108522|BK virus infection
981408|NCT02108522|Adenovirus infection
981409|NCT02108522|JC virus infection
981410|NCT02108522|allogeneic stem cell transplant
981411|NCT02108522|Virus Specific T cells
981412|NCT02108509|Chronic Pancreatitis
981413|NCT02108509|Osteopenia
981414|NCT02108509|Osteoporosis
981415|NCT02108509|Hypogonadism
981416|NCT02108509|Opioid medications
981417|NCT02108470|Oral Health Related Quality of Life (OHRQoL)
981418|NCT02108470|Oral Health Impact Profile (OHIP)
981419|NCT02108470|Dentist-Patient Relations
981420|NCT02108470|patients' participation.
981421|NCT02108470|patients' satisfaction with the consultation.
981422|NCT02108457|concurrent chemotherapy
981423|NCT02108444|hepatitis
981424|NCT02108444|hepatitis B
981425|NCT02108444|lymphoma
981426|NCT02108444|Hematologic Diseases
981427|NCT02108431|urinary diversion
981428|NCT02108431|urethral catheter
981429|NCT02108431|suprapubic tube
981430|NCT02108431|radical prostatectomy
981431|NCT02108431|robotic surgery
981432|NCT02108431|discomfort
981433|NCT02108431|pain
981434|NCT02108405|critically ill patient.
981435|NCT02108392|PXE
981436|NCT02108392|phenotype
981437|NCT02108392|eye
981438|NCT02108392|biomarkers
981439|NCT02108366|severe
981440|NCT02108366|influenza A
981441|NCT02108366|celecoxib
981442|NCT02108353|Type 2 Diabetes
981443|NCT02108353|metabolic control
981444|NCT02108353|Metabolomics
981445|NCT02108353|Circadian Rhythm
981446|NCT02108353|Melatonin
981447|NCT02108353|Biomarker
981448|NCT02108353|Clock Gene
981449|NCT02108353|PBMC
981450|NCT02108353|Cardiovascular function
981451|NCT02108353|Epigenetic modification
981452|NCT02108353|Lifestyle Intervention
981453|NCT02108340|Appendicitis
981454|NCT02108340|Diagnosis
981455|NCT02108340|Microwave radiometry
981456|NCT02108340|Ultrasonography
981457|NCT02108327|Blood loss
981458|NCT02108327|total knee arthroplasty
981459|NCT02108327|hot knife
981460|NCT02108327|cold knife
981461|NCT02108327|unipolar electrocautery
981462|NCT02108327|surgical blade
981463|NCT02108301|chronic hepatitis C-virus infection
981464|NCT02108301|renal transplantation
981465|NCT02108301|glucose tolerance
981466|NCT02108301|immunosuppression
981467|NCT02107222|COPD
981468|NCT02107222|Exacerbation
981469|NCT02107222|invasive ventilation
981470|NCT02107222|CO2-Removal
981471|NCT02107196|Irritable Bowel Syndrome
981472|NCT02107196|Colon, irritable
981473|NCT02107196|Bowel disease
981474|NCT02107196|Diarrhea
981475|NCT02107183|Oxygen therapy
981476|NCT02107183|Extubation
981477|NCT02107183|Weaning
981478|NCT02107183|Reintubation
981479|NCT02107183|Acute respiratory failure
981480|NCT02107144|trimetazidine
981481|NCT02107144|microcirculation
981482|NCT02107144|stenting
981483|NCT02107144|pressure wire
981484|NCT02108236|acupuncture
981485|NCT02108236|chinese traditional medicine
981486|NCT02108223|ICSI
981487|NCT02108223|Suboptimal Ovarian Response
981488|NCT02108223|rLH
981489|NCT02108210|Chronic fatigue syndrome
981490|NCT02108210|Cytokines
981491|NCT02108210|Interleukin-1
981492|NCT02108210|Fatigue
981493|NCT02108210|Anakinra
981494|NCT02108184|helicobacter eradication rates
981495|NCT02108171|intranasal
981496|NCT02108171|dexmedetomidine
981497|NCT02108171|early recovery
981498|NCT02108171|suspension laryngoscopy
981499|NCT02108145|cholangiocarcinoma
981500|NCT02108145|jaundice
981501|NCT02108145|metal stent
981502|NCT02108145|PTBS
981503|NCT02108132|hemophilia
981504|NCT02108132|mesenchymal stem cells
981505|NCT02108132|in-vitro transdifferentiation
981506|NCT02108106|safety and tolerability
981507|NCT02108106|pharmacokinetic study
981508|NCT02108080|Alcohol
981509|NCT02108080|Adolescents
981510|NCT02108080|Adults
981511|NCT02108054|fMRI
981512|NCT02108054|Alcoholism
981513|NCT02108054|Phenotype
981514|NCT02108054|Imaging
981515|NCT02108041|Physicians
981516|NCT02108041|Pharmacogenetic Testing
981517|NCT02108041|Decision-Making
981518|NCT02108041|Communicative Behaviors
981521|NCT02108015|Transmembrane AMPA Receptor Regulatory Protein
981522|NCT02108015|Glutamate Receptors
981523|NCT02108015|Healthy Volunteers
981524|NCT02108002|Missense Mutations
981525|NCT02108002|Hemangioblastoma
981526|NCT02108002|Histone Deacytelase Inhibitors
981527|NCT02108002|Von Hippel-Lindau Disease
981528|NCT02107989|Epilepsy
981529|NCT02107989|MRI
981530|NCT02107989|fMRI
981531|NCT02107989|MEG
981532|NCT02107976|Diabetes
981533|NCT02107976|Red Blood Cells
981534|NCT02107976|Vitamin C
981535|NCT02107976|Plasma Vitamin C Levels
981536|NCT02107963|GD2-Expressing Tumors
981537|NCT02107963|Anti-GD2 Chimeric Antigen Receptor
981538|NCT02107963|Osteosarcoma
981539|NCT02107963|Adoptive Immunotherapy
981540|NCT02107963|Sarcomas
981541|NCT02107950|Ovarian
981542|NCT02107950|Platinum Sensitive
981543|NCT02107950|Epithelial
981544|NCT02107937|serous
981545|NCT02107937|endometrioid
981546|NCT02107937|mucinous
981547|NCT02107937|epithelial ovarian cancer
981548|NCT02107924|Total
981549|NCT02107924|Knee
981550|NCT02107924|Replacment
981551|NCT02107924|Infection
981552|NCT02107924|Stimulan
981553|NCT02107911|men who have sex with men
981554|NCT02107911|non-occupational post exposure prophylaxis
981555|NCT02107911|HIV infection
981556|NCT02107859|Cystic fibrosis
981557|NCT02107859|Nonsense mutation
981558|NCT02107859|Premature stop codon
981559|NCT02107859|PTC124
981560|NCT02107859|Ataluren
981561|NCT02107820|Bladder training
981562|NCT02107820|Percutaneous Tibial nerve stimulation
981563|NCT02107820|Overactive bladder
981564|NCT02107820|Randomised controlled study
981565|NCT02107807|Influenza,
981566|NCT02107807|H5N1
981567|NCT02107807|aH5N1
981568|NCT02107807|H5N1 vaccine
981569|NCT02107807|Pandemic Influenza vaccine
981570|NCT02107807|MF59
981571|NCT02107807|Adjuvant
981572|NCT02107807|Avian flu
981573|NCT02107807|Underlying Immunosuppressive
981574|NCT02107807|immunosuppressive conditions
981575|NCT02107807|Pandemic vaccine
981576|NCT02107807|Adjuvanted vaccine
981577|NCT02107794|Grave's
981578|NCT02107794|Disease
981579|NCT02107794|Thyroid
981580|NCT02107794|Hyperthyroidism
981581|NCT02107794|Thyroidectomy
981582|NCT02107794|Radioactive
981583|NCT02107794|Iodine
981584|NCT02107794|Antithyroid
981585|NCT02107794|Shared
981586|NCT02107794|Decision
981587|NCT02107794|Making
981588|NCT02107794|Aid
981589|NCT02107794|Evidence
981590|NCT02107794|Based
981591|NCT02107794|Endocrinology
981592|NCT02107794|Mayo
981593|NCT02107794|Clinic
981594|NCT02107781|Open abdomen
981595|NCT02107781|abdominal compartment pressure
981596|NCT02107768|Stroke
981597|NCT02107768|Exercise
981598|NCT02107768|Randomized trial
981599|NCT02107768|Quality of Life
981600|NCT02107755|oligometastatic melanoma
981601|NCT02107755|melanoma
981602|NCT02107742|Injections
981603|NCT02107742|Time factors
981604|NCT02107742|Pain
981605|NCT02107742|Healthy volunteers
981606|NCT02107742|Lidocaine
981607|NCT02107729|Injections
981608|NCT02107729|Pain
981609|NCT02107729|Healthy volunteers
981610|NCT02107729|Lidocaine
981611|NCT02107716|Pain
981612|NCT02107716|Injections
981613|NCT02107716|Lidocaine
981614|NCT02107716|Healthy volunteers
981615|NCT02107703|MONARCH 2
981616|NCT02107690|Injections
981617|NCT02107690|Temperature
981618|NCT02107690|Pain
981619|NCT02107690|Healthy volunteers
981620|NCT02107690|Lidocaine
981621|NCT02107664|Radiotherapy
981622|NCT02107664|Cachexia
981623|NCT02107664|Inflammation
981624|NCT02107664|Depression
981625|NCT02107651|Bleeding
981626|NCT02107651|Anticoagulation
981627|NCT02107638|Parkinson's Disease
981628|NCT02107638|Osteopathic Manipulative Medicine
981629|NCT02107638|Falls
981630|NCT02107638|Balance
981631|NCT02107638|Motor function
981632|NCT02107625|Defecation
981633|NCT02107625|Abdominal pain
981634|NCT02107612|Mini-Dental Implant
981635|NCT02107612|Implant-Supported Dental Prosthesis
981636|NCT02107612|Minimally Invasive Surgical procedures
981637|NCT02107612|Overdentures
981638|NCT02107612|Aged
981639|NCT02107586|biceps tenodesis
981640|NCT02107586|biceps tenotomy
981641|NCT02107586|biceps tendonitis
981642|NCT02107586|biceps inflammation
981643|NCT02107586|shoulder surgery
981644|NCT02107573|Randomized Controlled Trial
981645|NCT02107573|Rotator Cuff Tear
981646|NCT02107573|Suprascapular Nerve
981647|NCT02107573|Decompression
981648|NCT02107573|Shoulder Surgery
981649|NCT02107560|Cholangitis
981650|NCT02107560|Bacteremia
981651|NCT02107560|Endotoxemia
981652|NCT02107560|Blood
981653|NCT02107560|Bile
981654|NCT02107547|Randomized Controlled Trial (RCT)
981655|NCT02107547|Type 2 SLAP lesions
981656|NCT02107547|labral tear
981657|NCT02107547|biceps tenodesis
981658|NCT02107547|shoulder surgery
981659|NCT02107547|RCT
981660|NCT02107547|Comparison between two alternative surgical procedures
981661|NCT02107534|parent training
981662|NCT02107534|homework
981663|NCT02107534|parenting stress
981664|NCT02107521|sperm morphology
981665|NCT02107521|ICSI
981666|NCT02107521|IMSI
981667|NCT02107521|implantation
981668|NCT02107521|pregnancy
981669|NCT02107508|activity energy expenditure
981670|NCT02107508|body composition
981671|NCT02107495|CHF
981672|NCT02107469|Diabetic Polyneuropathy
981673|NCT02107469|Diabetic
981674|NCT02107469|Polyneuropathy
981675|NCT02107469|Ayurvedic
981676|NCT02107469|Ayurveda
981677|NCT02107469|Neuralgia
981678|NCT02107469|Diabetic Neuralgia
981679|NCT02107469|Sida cordifolia
981680|NCT02107469|Phyllanthus Niruri
981681|NCT02107469|Phyllanthus Amarus
981682|NCT02107469|Extracts
981683|NCT02107469|Extract
981684|NCT02107469|Crude Herb
981685|NCT02107469|Crude
981686|NCT02107469|Herb
981687|NCT02107469|Herbal
981688|NCT02107469|Herbal Extract
981689|NCT02107469|Decoction
981690|NCT02107469|Churna
981691|NCT02107469|Powder
981692|NCT02107469|Bala
981693|NCT02107469|Bhumyamalaki
981694|NCT02107469|Tamalaki
981695|NCT02107456|Dry Needling, Myofascial trigger point, Upper trapezius
981696|NCT02107430|Immunotherapy
981697|NCT02107430|Prostate Cancer
981698|NCT02107430|Biological, Vaccine
981699|NCT02107417|chemotherapy
981700|NCT02107417|pain
981701|NCT02107417|paresthesia
981702|NCT02107417|Physiotherapy
981703|NCT02107417|Transcutaneous Electrical Nerve Stimulation
981704|NCT02107404|Immunotherapy
981705|NCT02107404|Prostate Cancer
981706|NCT02107404|Biological
981707|NCT02107404|Vaccine
981708|NCT02107391|Immunotherapy
981709|NCT02107391|Prostate Cancer
981710|NCT02107391|Biological
981711|NCT02107391|Vaccine
981712|NCT02107391|Androgen Deprivation Therapy
981713|NCT02107378|Immunotherapy
981714|NCT02107378|Serous
981715|NCT02107378|Relapsed
981716|NCT02107378|Platinum resistant (pt)
981717|NCT02107378|Ovarian Cancer (OvCa)
981718|NCT02107378|Biological
981719|NCT02107378|Vaccine
981720|NCT02107365|Hepatitis C
981721|NCT02107365|HCV infection
981722|NCT02107365|HCV genotype 4
981723|NCT02107365|Non-responders HCV infected patients
981724|NCT02107365|Asunaprevir
981725|NCT02107365|Daclatasvir
981726|NCT02107365|Pegylated Interferon
981727|NCT02107365|Ribavirin
981728|NCT02107352|Anti-craving medication
981729|NCT02107352|Inhibition
981730|NCT02107352|Attentional Bias
981731|NCT02107352|Event-Related Potentials
981732|NCT02107352|Relapse
981733|NCT02107339|methadone
981734|NCT02107339|hydromorphone
981735|NCT02107339|acute postoperative pain
981736|NCT02107339|chronic persistent surgical pain
981737|NCT02107326|Type 1 diabetes
981738|NCT02107326|HbA1C
981739|NCT02107326|Quality of Life
981740|NCT02107326|Hypoglycaemia
981741|NCT02107326|Self-management
981742|NCT02107326|Telemedicine
981743|NCT02107300|Obstructive Sleep Apnea Syndrome
981744|NCT02107274|Azithromycin
981745|NCT02107274|Bronchiectasis
981746|NCT02107274|Macrolide
981747|NCT02107274|Inflammation
981748|NCT02107274|Pulmonary
981749|NCT02107261|Musician's Dystonia
981750|NCT02107248|Arthroplasty
981751|NCT02107248|Replacement
981752|NCT02107248|Hip
981753|NCT02107248|Posterolateral surgery
981754|NCT02107248|Precautions
981757|NCT02107118|Stem cells
981758|NCT02107118|cardiovascular disease
981759|NCT02107118|erectile dysfunction
981760|NCT02107105|Rectal cancer
981761|NCT02107105|Adenocarcinoma of the rectum
981762|NCT02107105|Quality of Life
981763|NCT02107105|QOL
981764|NCT02107105|Post surgery
981765|NCT02107105|Pre-surgery
981766|NCT02107105|Questionnaires
981767|NCT02107105|Surveys
981768|NCT02107079|melatonin
981769|NCT02107079|bioavailability
981770|NCT02107079|pharmacokinetics
981771|NCT02107066|exercise
981772|NCT02107066|physical activity
981773|NCT02107066|ovarian cancer
981774|NCT02107066|quality of life
981775|NCT02107066|fatigue
981776|NCT02107066|weight
981777|NCT02107053|Oxidative stress,
981778|NCT02107053|hemodialysis,
981779|NCT02107053|pomegranate juice,
981780|NCT02107053|dietary supplement
981781|NCT02107053|patients
981782|NCT02107001|Lung ultrasound
981783|NCT02107001|Community acquired p neumonia (CAP)
981784|NCT02107001|Pleuritis
981785|NCT02107001|Pulmonary embolism
981786|NCT02107001|Lung Cancer
981787|NCT02106988|Lymphoma
981788|NCT02106988|NK cell lymphoma-nasal type
981789|NCT02106988|Radiation therapy
981790|NCT02106988|XRT
981791|NCT02106988|Dexamethasone
981792|NCT02106988|Decadron
981793|NCT02106988|Etoposide
981794|NCT02106988|VePesid
981795|NCT02106988|Ifosfamide
981796|NCT02106988|Ifex
981797|NCT02106988|Mesna
981798|NCT02106988|Mesnex
981799|NCT02106988|Carboplatin
981800|NCT02106988|Paraplatin
981801|NCT02106962|hemodialysis
981802|NCT02106962|fistula
981803|NCT02106962|clotting
981804|NCT02106962|tranexamic acid
981805|NCT02106962|bacitracin
981806|NCT02106949|suicide attempt, SMS monitoring, recurrence, phone, prevention control, tertiary healthcare
981812|NCT02106910|Barrett's Esophagus
981813|NCT02106910|Radiofrequency Ablation
981814|NCT02106884|Pancreatic cancer
981815|NCT02106884|Locally advanced
981816|NCT02106884|Metastatic
981817|NCT02106871|cancer
981818|NCT02106871|pancreas
981819|NCT02106871|cholangiocarcinoma
981820|NCT02106871|fatigue
981821|NCT02106871|sildenafil
981822|NCT02106871|lean mass
981823|NCT02106871|muscle
981824|NCT02106858|Stivarga / Regorafenib / Metastatic Colorectal Cancer / Metastatic or unresectable locally advanced GIST (Gastrointestinal stromal tumors)
981825|NCT02106845|Regorafenib
981826|NCT02106845|Probe substrates
981827|NCT02106845|Pharmacokinetics
981828|NCT02106845|Cancer
981829|NCT02106845|Safety
981830|NCT02106845|Advanced solid malignant tumors
981831|NCT02106832|Ciprofloxacin
981832|NCT02106832|Dry Powder for Inhalation
981833|NCT02106832|Exacerbation
981834|NCT02106832|Bronchiectasis
981835|NCT02106819|Cerebellar Ataxia
981836|NCT02106819|Emotions
981837|NCT02106819|Affective Prosody
981838|NCT02106819|Facial Expression
981839|NCT02106819|Magnetic Resonance Imaging
981840|NCT02106806|Oxidative stress
981841|NCT02106806|Zinc
981842|NCT02106806|Chemotherapy
981843|NCT02106806|Colorectal cancer
981844|NCT02106793|Chronic Rhinosinusitis
981845|NCT02106793|Mitomicin C
981846|NCT02106793|Postoperative nasal synerchia
981847|NCT02106780|Phase 1
981848|NCT02106780|Healthy subjects
981849|NCT02106780|Excretion
981850|NCT02106780|14C-labeled ASP1707
981851|NCT02106767|rosuvastatin
981852|NCT02106767|rifampin
981853|NCT02106767|pharmacokinetics
981854|NCT02106767|drug interaction
981855|NCT02106767|healthy volunteer
981856|NCT02106767|drug transporter
981857|NCT02106767|Asian
981858|NCT02106767|White
981859|NCT02106741|Pain
981860|NCT02106741|Acupressure
981861|NCT02106741|Symptoms
981862|NCT02106741|Fatigue
981863|NCT02106741|Self-administered
981864|NCT02106728|Eating Disorders
981865|NCT02106728|Family Therapy
981866|NCT02106728|Multi-Family Therapy
981867|NCT02106728|Bulimia Nervosa
981868|NCT02106728|Eating Disorder Not Otherwise Specified
981869|NCT02106702|HIV
981870|NCT02106702|detention
981871|NCT02106702|substance abuse
981872|NCT02106689|infertility, superovulation, gonadotropins, needle free injection system
981873|NCT02106676|polycystic ovary Syndrome
981874|NCT02106676|hyperandrogenism
981875|NCT02106676|cordblood
981876|NCT02106676|androgens
981877|NCT02106663|atrial fibrillation
981878|NCT02106663|paroxysmal atrial fibrillation
981879|NCT02106663|PAF
981880|NCT02106663|arrhythmia
981881|NCT02106663|atrial fibrillation ablation
981882|NCT02106663|circumferential ablation
981883|NCT02106663|CPVA
981884|NCT02106663|segmental ablation
981885|NCT02106663|PVI
981886|NCT02106663|pulmonary vein isolation
981887|NCT02106650|Relapsed PTCL
981888|NCT02106650|Refractory PTCL
981889|NCT02106637|ACS
981890|NCT02106637|Cessation
981891|NCT02106624|mechanical ventilation
981892|NCT02106611|MRI
981893|NCT02106611|stress echo
981894|NCT02106611|Clinical Assessment
981895|NCT02106611|14-017
981896|NCT02106598|Sentinel Lymph Node Mapping
981897|NCT02106598|Intraoperative Sentinel
981898|NCT02106598|Head and Neck Melanoma
981899|NCT02106598|Targeted Silica Nanoparticles
981900|NCT02106598|cRGDY-PEG-Cy5.5-C dots
981901|NCT02106598|13-249
981902|NCT02106585|Safety
981903|NCT02106585|Tolerability
981904|NCT02106585|Pharmacokinetics
981905|NCT02106585|Food-effect
981906|NCT02106585|Diabetes
981907|NCT02106572|superficial bladder cancer
981908|NCT02106572|viscum album extract
981909|NCT02106572|mistletoe extract
981910|NCT02106572|abnobaVISCUM
981911|NCT02106572|recurrence rate
981912|NCT02106559|Pleural Photodynamic Therapy
981913|NCT02106559|Pleural Malignancy
981914|NCT02106559|PDT
981915|NCT02106546|carboplatin
981916|NCT02106546|Randomized
981917|NCT02106546|veliparib
981918|NCT02106546|Advanced
981919|NCT02106546|Metastatic
981920|NCT02106546|Overall Survival
981921|NCT02106546|Squamous
981922|NCT02106546|placebo controlled
981923|NCT02106546|ABT-888
981924|NCT02106546|Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP)
981925|NCT02106546|non-small cell lung cancer
981926|NCT02106546|paclitaxel
981927|NCT02106533|Coronary artery disease
981928|NCT02106533|Exercise
981929|NCT02106533|Ventilatory efficiency
981930|NCT02106520|Epistaxis
981931|NCT02106520|Bevacizumab
981932|NCT02106507|Apalutamide
981933|NCT02106507|RAD001
981934|NCT02106507|Everolimus
981935|NCT02106507|Castration-resistant
981936|NCT02106507|13-025
981937|NCT02106507|ARN-509
981938|NCT02106494|Highly emetogenic chemotherapy (HEC)
981939|NCT02106494|Chemotherapy-Induced Nausea and Vomiting (CINV)
981940|NCT02106481|TKA
981941|NCT02106481|TKR
981942|NCT02106481|Knee OA
981943|NCT02106481|pain management
981944|NCT02106481|Femoral Nerve Catheter
981945|NCT02106481|Single Shot Femoral Nerve Blocks
981946|NCT02106468|Oral Lichen Planus
981947|NCT02106468|Corticosteroid
981948|NCT02106468|Omega -3
981950|NCT02106442|Pharmacological therapy
981951|NCT02106429|Vascular Surgery
981952|NCT02106416|prostate cancer
981953|NCT02106416|bladder cancer
981954|NCT02106416|MRI
981955|NCT02106416|PET
981956|NCT02106416|perfusion
981957|NCT02106390|Central Nervous System Diseases
981958|NCT02106390|Nervous System Diseases
981959|NCT02106390|Meningitis
981960|NCT02106377|(DES)
981961|NCT02106338|follow-up to 10-0008, Clostridium difficile, dose-escalating, CRS3123
981962|NCT02106325|Ketamine
981963|NCT02106325|Ketlar
981964|NCT02106325|Depression
981965|NCT02106325|Antidepressants
981966|NCT02106325|Treatment
981967|NCT02106325|Acute
981968|NCT02106312|Radiotherapy
981969|NCT02106312|Myxoid liposarcoma
981970|NCT02106312|Soft tissue sarcoma
981971|NCT02106286|Cardiopulmonary exercise test
981972|NCT02106286|surgery
981973|NCT02106286|abdominal aortic aneurysm
981974|NCT02106286|anaerobic threshold
981975|NCT02106286|fitness
981976|NCT02106286|beta-blockers
981977|NCT02106273|LMA
981978|NCT02106273|Bronchial blocker
981979|NCT02106260|safety
981980|NCT02106260|pharmacokinetics (PK)
981981|NCT02106260|pharmacodynamics (PD)
981982|NCT02106260|CLS003
981983|NCT02106234|contrast induced nephropathy
981984|NCT02106234|prophylactic intravenous hydration
981985|NCT02106234|intravenous normal saline
981986|NCT02106234|acute kidney injury
981987|NCT02106221|Care coordination
981988|NCT02106221|nurse care management
981989|NCT02106221|practice facilitation
981990|NCT02106221|health information technology
981991|NCT02106182|Benign prostatic hyperplasia
981992|NCT02106182|Nocturia
981993|NCT02106182|Silodosin
981994|NCT02106182|Thrupas
981995|NCT02106169|Food allergy
981996|NCT02106169|Children and families
981997|NCT02106169|Therapeutic education
981998|NCT02106169|Quality of life
981999|NCT02106130|Mosapride citrate
982000|NCT02106130|Rebamipide
982001|NCT02106130|pharmacokinetic drug drug interaction
982002|NCT02106130|oral administration
982003|NCT02106130|healthy male subjects
982004|NCT02106104|Type 2 diabetes mellitus
982005|NCT02106104|Diabetic kidney disease
982006|NCT02106104|Diabetic nephropathy
982007|NCT02106104|Renoprotection
982008|NCT02106104|DPP-4 inhibitors
982009|NCT02106104|Linagliptin
982010|NCT02106104|SU derivatives
982011|NCT02106104|Glimepiride
982012|NCT02106078|Bipolar Disorder
982013|NCT02106078|Bipolar
982014|NCT02106078|Online Intervention
982015|NCT02106078|Internet intervention
982016|NCT02106078|Self-Help
982017|NCT02106065|Dementia
982018|NCT02106065|Caregivers
982019|NCT02106065|Neurodegenerative Diseases
982020|NCT02106065|Brain Diseases
982021|NCT02106065|Cost of Illness
982022|NCT02106065|Stress, Psychological
982023|NCT02106065|Depression
982024|NCT02106065|Vital Statistics
982025|NCT02106065|Mortality
982026|NCT02106065|Behavioral Symptoms
982027|NCT02106065|Residential Facilities
982028|NCT02106065|Emergency Medical Services
982029|NCT02106065|Long-Term Care
982030|NCT02106052|cognitive function
982031|NCT02106052|cognitive impairment
982032|NCT02106052|cognitive intervention
982033|NCT02106052|cognitive improvement
982034|NCT02106052|information processing speed
982035|NCT02106052|exercise training program
982036|NCT02106052|aerobic exercise
982037|NCT02106052|stretching and toning
982038|NCT02106052|Multiple sclerosis
982039|NCT02106052|executive function
982040|NCT02106039|diabetes mellitus
982041|NCT02106039|tuberculosis
982042|NCT02106039|management
982043|NCT02106039|randomized controlled trial
982044|NCT02106026|Breastfeeding
982045|NCT02106026|Nursing
982046|NCT02106026|Patient Education as Topic
982047|NCT02106026|Health Knowledge, Attitudes, Practice
982048|NCT02106026|Hispanic Americans.
982049|NCT02106013|HDL
982050|NCT02106013|Carotid artery intima-media thickness
982051|NCT02106013|Cholesterol efflux capacity
982052|NCT02106013|Antioxidant effect of HDL
982053|NCT02106013|Susceptibility to oxidation of HDL
982054|NCT02106013|Anti-inflammatory effect of HDL
982055|NCT02106013|Platelet aggregation inhibition by HDL
982056|NCT02106000|Post Partum
982057|NCT02106000|Inhaled Oxytocin
982058|NCT02106000|Inhalation Profiles
982059|NCT02105987|Abacavir/dolutegravir/lamivudine
982060|NCT02105987|Fixed-dose combination
982061|NCT02105987|Once daily
982062|NCT02105987|Trii
982063|NCT02105987|Single-tablet regimen
982064|NCT02105974|COPD
982065|NCT02105974|Fluticasone Furoate (FF)
982066|NCT02105974|Vilanterol (VI)
982067|NCT02105974|Dry Powder Inhaler
982068|NCT02105961|Chronic Obstructive Pulmonary Disease
982069|NCT02105961|exacerbations
982070|NCT02105961|SB240563
982071|NCT02105961|mepolizumab
982072|NCT02105961|eosinophils
982073|NCT02105948|eosinophils
982074|NCT02105948|SB240563
982075|NCT02105948|exacerbations
982076|NCT02105948|Chronic Obstructive Pulmonary Disease
982077|NCT02105948|mepolizumab
982078|NCT02105922|Frailty
982079|NCT02105922|Ageing
982080|NCT02105922|Protein supplementation
982081|NCT02105922|Protein quality
982082|NCT02105922|Exercise training
982083|NCT02105922|Sarcopenia
982084|NCT02105896|dental bonding
982085|NCT02105857|knee mobilazation
982086|NCT02105857|TKA
982087|NCT02105857|joint replacement
982088|NCT02105857|rehabilitation
982089|NCT02105844|atrial fibrillation
982090|NCT02105844|dementia
982091|NCT02105844|cognitive dysfunction
982092|NCT02105844|stroke
982093|NCT02105844|Magnetic resonance imaging
982094|NCT02105831|left ventricular assist device
982095|NCT02105831|contrast ultrasound
982096|NCT02105831|perfusion imaging
982097|NCT02105818|Self-reported questionnaire
982098|NCT02105818|Swallowing disorders
982099|NCT02105818|Systemic sclerosis
982100|NCT02105818|Drug therapy
982101|NCT02105818|Adherence to medication regime
982102|NCT02105818|Coping strategy
982103|NCT02105818|Pharmaceutical care
982104|NCT02105818|Patient safety
982105|NCT02105818|Patient oriented care
982106|NCT02105805|intention weight loss
982107|NCT02105805|heart failure
982108|NCT02105805|6-minute walk test
982109|NCT02105792|Diabetes
982110|NCT02105792|Type 2 diabetes
982111|NCT02105792|Diabetes therapy response
982112|NCT02105792|Diabetes progression
982118|NCT02105740|BEHAVIORAL
982119|NCT02105740|HYPNOSIS
982120|NCT02105740|ANXIETY
982121|NCT02105740|DEPRESSION
982122|NCT02105727|Dietary sodium
982123|NCT02105727|Urinary sodium excretion
982124|NCT02105727|Urinary iodine excretion
982125|NCT02105714|Diarrhoea
982126|NCT02105714|Abdominal pain
982127|NCT02105714|Bacterial
982128|NCT02105714|Protozoal
982129|NCT02105714|Helminth
982130|NCT02105675|Immunotherapy
982131|NCT02105675|Metastatic
982132|NCT02105675|Castrate Resistant
982133|NCT02105675|Prostate Cancer
982134|NCT02105675|Biological
982135|NCT02105675|Vaccine
982136|NCT02105649|cerebral palsy
982137|NCT02105649|standing
982138|NCT02105649|strengthening
982139|NCT02105623|Coronary Arteriosclerosis
982140|NCT02105623|rosuvastatin
982150|NCT02105597|Diabetes mellitus
982151|NCT02105597|Medication adherence
982152|NCT02105597|Compliance
982153|NCT02105597|Mobile health
982154|NCT02105571|Body Weight
982155|NCT02105571|Nutrition
982156|NCT02105571|Physical Activity
982157|NCT02105571|Sleep
982158|NCT02105571|Health Promotion
982159|NCT02105571|Stress
982160|NCT02105571|Safety
982161|NCT02105558|trial of labor after cesarean
982162|NCT02105558|vaginal birth after cesarean
982163|NCT02105558|epidural vs combined spinal epidural
982164|NCT02105545|cancer
982165|NCT02105545|oncology
982166|NCT02105545|malignant
982167|NCT02105545|malignancy
982168|NCT02105545|genetics
982169|NCT02105545|genomics
982170|NCT02105545|exome
982171|NCT02105545|DNA
982172|NCT02105545|RNA
982173|NCT02105545|sequencing
982174|NCT02105545|epigenetic
982175|NCT02105545|clinically actionable findings
982176|NCT02105545|CAF
982177|NCT02105545|secondary findings
982178|NCT02105545|SF
982179|NCT02105545|single nucleotide variants
982180|NCT02105545|SNV
982181|NCT02105545|bioinformatics
982182|NCT02105545|genotype
982183|NCT02105545|The American College of Medical Genetics and Genomics
982184|NCT02105545|ACMG
982185|NCT02105532|Transfusion in gastrointestinal bleeding
982186|NCT02105519|trivalent influenza vaccine, chronic kidney disease
982187|NCT02105506|Esophagus
982188|NCT02105506|Stomach
982189|NCT02105506|Resection
982190|NCT02105506|Esophageal disease requiring surgery
982191|NCT02105506|Gastric disease requiring surgery
982192|NCT02105493|Nitroglycerin
982193|NCT02105493|Radial Artery Occlusion
982194|NCT02105493|Transradial Catheterization
982195|NCT02105480|Computer aided auscultation (CAA)
982196|NCT02105480|Phonocardiogram analysis
982197|NCT02105480|Murmur detection
982198|NCT02105480|Heart auscultation
982199|NCT02105441|cochlear implant
982200|NCT02105428|Polycystic Ovarian Syndrome (PCOS)
982201|NCT02105428|Insulin Resistance
982202|NCT02105428|Overweight, Obese Women
982203|NCT02105428|Protein Metabolism
982204|NCT02105428|Post Translational Modifications
982205|NCT02105415|Critical care
982206|NCT02105415|Emergent
982207|NCT02105415|Etomidate
982208|NCT02105415|Hemodynamics
982209|NCT02105415|Intensive care unit
982210|NCT02105415|Intubation
982211|NCT02105415|Ketamine-Propofol admixture
982212|NCT02105402|Speech sound disorders
982213|NCT02105402|Randomized Controlled Trial
982214|NCT02105402|Speech intelligibility
982215|NCT02105402|PROMPT treatment
982216|NCT02105402|Developmental motor speech disorders
982217|NCT02105402|Children
982218|NCT02105402|Functional outcomes
982219|NCT02105402|Treatment efficacy
982220|NCT02105389|fatigue
982221|NCT02105389|quality of life
982222|NCT02105389|chemotherapy
982223|NCT02105389|haematopoietic stem cell transplantation
982224|NCT02105389|children
982225|NCT02105389|pilot
982226|NCT02105389|yoga
982227|NCT02105376|depression
982228|NCT02105376|cranial nerve stimulation
982229|NCT02105376|trigeminal stimulation
982230|NCT02105350|MEK162
982231|NCT02105350|Gemcitabine
982232|NCT02105350|Oxaliplatin
982233|NCT02105350|Non-resectable
982234|NCT02105350|Recurrent or metastatic
982235|NCT02105324|bionic pancreas
982236|NCT02105324|artificial pancreas
982237|NCT02105324|insulin
982238|NCT02105324|glucagon
982239|NCT02105324|continuous glucose monitoring (CGM)
982240|NCT02105324|outpatient
982241|NCT02105324|insulin pump
982242|NCT02105324|pediatrics
982243|NCT02105324|children
982244|NCT02105324|camp
982245|NCT02105324|summer camp
982246|NCT02105311|Intraocular pressure
982247|NCT02105311|Selective laser trabeculoplasty
982248|NCT02105311|Travoprost
982249|NCT02105311|Ocular surface disease
982250|NCT02105311|Glaucoma symptom scale
982251|NCT02105298|Fluids
982252|NCT02105298|Intraoperative
982253|NCT02105298|Respiratory
982254|NCT02105298|Outcomes
982255|NCT02105298|Surgery
982256|NCT02105298|Anesthesia
982257|NCT02105259|Test
982258|NCT02105259|psychodynamic
982259|NCT02105259|Internet-delivered psychodynamic treatment
982260|NCT02105259|patients with social anxiety disorder
982261|NCT02105246|Cardiac rehabilitation
982262|NCT02105246|home based care
982263|NCT02105246|secondary prevention
982264|NCT02105246|efficacy
982265|NCT02105246|6 minute walk rates.
982266|NCT02105233|ultrasonography
982267|NCT02105233|ultrasonics
982268|NCT02105233|brain
982269|NCT02105233|surgery
982270|NCT02105220|Respiratory mechanics
982271|NCT02105220|Esophageal pressure
982272|NCT02105220|Functional residual capacity
982273|NCT02105220|positive end-expiratory pressure
982274|NCT02105194|cerebral decompression illness
982275|NCT02105181|benign biliary stricture
982276|NCT02105181|anastomotic biliary stricture after liver transplantation
982277|NCT02105181|chronic pancreatitis
982278|NCT02105181|biliary surgical procedure
982279|NCT02105181|fully covered metal stent
982280|NCT02105155|Liver transplantation,
982281|NCT02105155|Conversion (Prograf® to Advagraf®),
982282|NCT02105155|Prograf® ,
982283|NCT02105155|Advagraf® ,
982284|NCT02105155|acute rejection,
982285|NCT02105155|GFR
982286|NCT02105142|Attention deficit hyperactivity disorder
982287|NCT02105142|Interventions
982288|NCT02105142|Primary care
982289|NCT02105142|Pediatric
982290|NCT02105090|Upper gastrointestinal tract
982291|NCT02105090|Endoscopy
982292|NCT02105090|Lozenge
982293|NCT02105090|Articaine
982294|NCT02105090|Dyspepsia
982295|NCT02105090|Hematemesis
982296|NCT02105090|Abdominal pain
982297|NCT02105090|Heartburn
982298|NCT02105077|xenon
982299|NCT02105077|doping
982300|NCT02105077|anesthesia
982301|NCT02105077|mass spectrometry
982302|NCT02105077|surgery
982303|NCT02105038|distal radius fracture
982304|NCT02105038|steering
982305|NCT02105038|steering wheel spinner knob
982306|NCT02105025|insertion time
982307|NCT02105012|Mild
982308|NCT02105012|moderate persistent
982309|NCT02105012|Adult
982310|NCT02104986|non seminomateous malignant germ cell tumour (NSMGCT)
982311|NCT02104986|Dose De-escalation
982312|NCT02104986|Chemotherapy
982313|NCT02104960|Skin Surface Microscopy
982314|NCT02104960|Skin Aging
982315|NCT02104960|PROOF
982316|NCT02104895|Breast cancer
982317|NCT02104895|Early breast cancer
982318|NCT02104895|Adjuvant breast cancer
982319|NCT02104895|Accelerated partial breast irradiation
982320|NCT02104895|Intensity modulated radiotherapy
982321|NCT02104882|Glioblastoma Multiforme
982322|NCT02104882|High-Grade Glioma
982323|NCT02104882|Malignant Glioma
982324|NCT02104882|IORT
982325|NCT02104869|Influenza vaccine
982326|NCT02104856|Asthma
982327|NCT02104856|Bronchial Thermoplasty
982328|NCT02104856|Registry
982329|NCT02104856|Device
982330|NCT02104856|Alair
982331|NCT02104830|empegfilgrastim
982332|NCT02104830|pegylated filgrastim
982333|NCT02104830|neutropenia
982334|NCT02104830|febrile neutropenia
982335|NCT02104830|chemotherapy-associated neutropenia
982336|NCT02104830|breast cancer
982337|NCT02104830|docetaxel
982338|NCT02104830|doxorubicin
982339|NCT02104817|omega-3 carboxylic acid
982340|NCT02104804|Type 2 Diabetes Mellitus, Insulin, Dipeptidyl-Peptidase 4 Inhibitors, Metformin,saxagliptin,Endocrine System Diseases
982341|NCT02104791|Procalcitonin
982342|NCT02104791|intra-amniotic subclinical infection.
982343|NCT02104752|Curcumin
982344|NCT02104752|Turmeric
982345|NCT02104752|Schizophrenia
982346|NCT02104752|Cognition
982347|NCT02104752|Psychosis
982348|NCT02104739|prediabetes
982349|NCT02104739|diabetes mellitus type 2
982350|NCT02104739|exenatide
982351|NCT02104739|saxagliptin
982352|NCT02104739|exenatide ER
982353|NCT02104713|Skin Burn Degree Second
982354|NCT02104713|Second degree Burn
982355|NCT02104713|Burn wound
982356|NCT02104700|HIV
982357|NCT02104687|GTD, goal-directed haemodynamic therapy
982358|NCT02104687|CI, cardiac index
982359|NCT02104687|MAP, mean arterial pressure
982360|NCT02104687|CVP, central venous pressure
982361|NCT02104622|spinal cord injury
982362|NCT02104622|exoskeleton
982363|NCT02104622|ambulation
982364|NCT02104622|walking
982365|NCT02104622|robotics
982366|NCT02104609|Obesity
982367|NCT02104609|Emergency contraception
982368|NCT02104609|Levonorgestrel emergency contraception
982369|NCT02104583|VT
982370|NCT02104583|VF
982371|NCT02104583|Ventricular Tachycardia
982372|NCT02104583|Ventricular Fibrillation
982373|NCT02104583|shock
982374|NCT02104583|ATP
982375|NCT02104570|Fatigue
982376|NCT02104570|Proprioception
982377|NCT02104570|Shoulder
982378|NCT02104557|Sayana
982379|NCT02104557|Pregnancy
982380|NCT02104557|Contraception
982381|NCT02104557|Endometriosis-associated pain
982382|NCT02104557|PMS
982383|NCT02104557|Post Marketing Surveillance
982384|NCT02104544|DHA intake;
982385|NCT02104544|Plasma;
982386|NCT02104544|Erythrocyte;
982387|NCT02104544|Breast milk.
982388|NCT02104518|glucose-6-phosphate dehydrogenase
982389|NCT02104518|point-of-care diagnostic testing
982390|NCT02104492|multiple sclerosis
982391|NCT02104492|respiratory muscle strength
982392|NCT02104492|maximal inspiratory pressure (MIP)
982393|NCT02104492|maximal expiratory pressure (MEP)
982394|NCT02104492|respiratory muscle endurance
982395|NCT02104492|quality of life
982396|NCT02104492|qualitative research
982397|NCT02104466|acupuncture
982398|NCT02104466|pain
982399|NCT02104466|neuropathy
982400|NCT02104453|airway maneuver
982401|NCT02104440|Cytopenia
982402|NCT02104414|Liposomal Bupivacaine
982403|NCT02104414|Exparel
982404|NCT02104375|wave reflection
982405|NCT02104375|augmentation Index
982406|NCT02104375|heart rate variability
982407|NCT02104375|arterial stiffness
982408|NCT02104349|spine surgery
982409|NCT02104349|post op pain management
982410|NCT02104336|Pearson
982411|NCT02104336|EPI743
982412|NCT02104336|EPI-743
982413|NCT02104336|Vincerinone
982414|NCT02104336|Mitochondrial disorder
982415|NCT02104336|Mitochondrial disease
982416|NCT02104323|Neurofibromatosis Type 2
982417|NCT02104323|Vestibular Schwannoma
982418|NCT02104323|Other NF2-related tumors
982419|NCT02104310|malignant glioma
982420|NCT02104310|FDOPA
982421|NCT02104310|PET CT
982422|NCT02104310|radiation therapy
982423|NCT02104297|Nasal septum operation
982424|NCT02104297|agitation
982425|NCT02104284|Bronchial provocation test
982426|NCT02104284|Mannitol
982427|NCT02104284|Methacholine
982428|NCT02104284|Bronchial hyperreactivity
982429|NCT02104284|Sensitivity and specificity
982430|NCT02104271|chronic radiation proctitis
982431|NCT02104271|argon plasma coagulation
982432|NCT02104271|rectal bleeding
982433|NCT02104258|Hamstring
982434|NCT02104258|Muscle
982435|NCT02104258|Injury
982436|NCT02104258|Treatment
982437|NCT02104258|Rehabilitation
982438|NCT02104245|Non Cystic Fibrosis Bronchiectasis, Pulmaquin, Ciprofloxacin, Pseudomonas aeruginosa
982439|NCT02104232|Maternal depression
982440|NCT02104219|Hypophosphatasia
982441|NCT02104219|HPP
982442|NCT02104219|bone disease
982443|NCT02104219|Soft Bones
982444|NCT02104219|low Alkaline Phosphatase
982445|NCT02104219|genetic metabolic disorder
982446|NCT02104219|alkaline phosphatase
982447|NCT02104219|tissue non-specific alkaline phosphatase
982448|NCT02104219|rickets
982449|NCT02104219|osteomalacia
982450|NCT02104193|brain metastases
982451|NCT02104193|simvastatin
982452|NCT02104193|radiation therapy
982453|NCT02104180|non-inferiority
982454|NCT02104180|randomized
982455|NCT02104180|TulleGras
982456|NCT02104180|Urgotul
982457|NCT02104180|pain
982458|NCT02104180|venous leg ulcer
982459|NCT02104180|healing
982460|NCT02104167|DDD
982461|NCT02104167|degenerative disc disease
982462|NCT02104167|cervical spine
982463|NCT02104167|fusion rate
982464|NCT02104141|DDD
982465|NCT02104141|lumbar spine
982466|NCT02104141|fusion rate
982467|NCT02104141|degenerative disc disease
982468|NCT02104128|Anhedonia
982469|NCT02104128|Dopamine
982470|NCT02104128|Bupropion
982471|NCT02104128|fMRI
982472|NCT02104128|emotional processing
982473|NCT02104128|reward
982474|NCT02104115|Stomach
982475|NCT02104115|Small bowel
982476|NCT02104115|Colon
982477|NCT02104115|MRI
982478|NCT02104115|Function
982479|NCT02104115|Gastrointestinal volumes
982480|NCT02104102|Elderly
982481|NCT02104102|mirror therapy
982482|NCT02104102|hands
982483|NCT02104089|Thoracoabdominal aortic aneurysm
982484|NCT02104089|Endovascular
982485|NCT02104089|Fenestration
982486|NCT02104089|Branch
982487|NCT02104089|Off-the-shelf
982488|NCT02104076|Bile Duct Obstructions
982489|NCT02104076|Biliary Stases
982490|NCT02104076|Biliary Tract
982491|NCT02104076|Stents
982492|NCT02104024|Kidney
982493|NCT02104024|Pancreas
982494|NCT02104024|Transplant
982495|NCT02104024|Contrast Enhanced Ultrasound
982496|NCT02104011|Angiomyolipomas in tuberous sclerosis
982497|NCT02104011|Beta-blockers
982498|NCT02104011|Anti-angiogenic therapies
982499|NCT02103998|extremely low gestational age neonate
982500|NCT02103998|hypothyroxinemia of prematurity
982501|NCT02103998|brain development
982502|NCT02103998|cerebral palsy
982503|NCT02103998|cognitive dealy
982504|NCT02103985|Healthy
982505|NCT02103985|JNJ-39823277
982506|NCT02103985|JNJ-40917006
982507|NCT02103985|Pharmacokinetics
982508|NCT02103972|All subjects of any ethnicity aged from 4 to 30 months with atopic dermatitis skin symptoms with a SCORAD equal or above 20
982509|NCT02103946|serratus
982510|NCT02103946|paravertebral
982511|NCT02103946|breast
982512|NCT02103946|cancer
982513|NCT02103946|axilla
982514|NCT02103907|balance
982515|NCT02103907|knee
982516|NCT02103907|osteoarthritis
982517|NCT02103907|physical function
982518|NCT02103894|Alzheimer's disease (AD)
982519|NCT02103894|Parkinson's disease (PD)
982520|NCT02103894|Progressive supranuclear palsy (PSP)
982521|NCT02103894|Chronic traumatic encephalopathy (CTE)
982522|NCT02103894|Frontal temporal dementia (FTD)
982523|NCT02103894|Pick's disease
982524|NCT02103894|tauopathies
982525|NCT02103881|Agitation
982526|NCT02103881|Ketamine
982527|NCT02103881|Haloperidol
982528|NCT02103881|Emergency Medical Services
982529|NCT02103881|Feeling of restlessness
982530|NCT02103881|Increased motor activity
982531|NCT02103868|Tobacco cessation
982532|NCT02103868|Zari worker
982533|NCT02103868|Behavior therapy
982534|NCT02103868|Qualitative Research
982535|NCT02103868|Mumbai
982536|NCT02103855|pancreas transplantation
982537|NCT02103855|immunosuppression
982538|NCT02103855|belatacept
982539|NCT02103829|Cigarette smoking
982540|NCT02103829|Tobacco smoking
982541|NCT02103829|Smoking, Tobacco
982542|NCT02103803|concussion
982543|NCT02103803|sports-related concussion
982544|NCT02103803|mild traumatic brain injury (mTBI)
982545|NCT02103803|eye tracking
982546|NCT02103803|oculometrics
982547|NCT02103777|high dose of caffeine
982548|NCT02103777|low dose of caffeine
982549|NCT02103777|prevention
982550|NCT02103764|Anovulatory Dysfunctional Uterine Bleeding
982551|NCT02103764|cyclic desogestrel
982552|NCT02103764|cyclic medroxyprogesterone acetate
982553|NCT02103764|lipid metabolism
982554|NCT02103764|glucose metabolism
982555|NCT02103764|endometrial histology changing
982556|NCT02103751|biomarkers
982557|NCT02103751|HPHCs
982558|NCT02103751|CVD
982559|NCT02103751|smoking
982560|NCT02103751|Smokers
982561|NCT02103751|non-smokers
982562|NCT02103738|Lucentis
982563|NCT02103738|Ranibizumab
982564|NCT02103738|Treat and Extend
982565|NCT02103738|wetAMD
982566|NCT02103738|Age related macular degeneration
982567|NCT02103699|Hepatitis C virus
982568|NCT02103699|Simeprevir
982569|NCT02103699|Ribonucleic acid
982570|NCT02103699|Sustained virologic response
982571|NCT02103686|Neuropathic pain
982572|NCT02103686|pregabalin
982573|NCT02103660|contraceptive implant
982574|NCT02103660|Depo-Medroxyprogesterone Acetate
982575|NCT02103660|Hormonal Contraception
982576|NCT02103660|progestin
982577|NCT02103647|Neuropathic pain
982578|NCT02103647|pregabalin
982579|NCT02103634|breast cancer
982580|NCT02103634|FDG PET/CT
982581|NCT02103634|MRI
982582|NCT02103634|NaF PET/MRI
982583|NCT02103634|NaF PET/CT
982584|NCT02103608|at Home Photo depilation device, Silk'n.
982585|NCT02103556|Constipation
982586|NCT02103556|Rome III criteria
982587|NCT02103556|Hemodialysis
982588|NCT02103491|Half-ironman
982589|NCT02103491|Triathlon
982590|NCT02103491|Salt
982591|NCT02103491|Exercise
982592|NCT02103491|Performance
982593|NCT02103478|Myelodysplastic Syndrome
982594|NCT02103478|MDS
982595|NCT02103465|Parkinson's Disease
982596|NCT02103465|treatment
982597|NCT02103465|old patients
982598|NCT02103465|Rotigotine
982599|NCT02103439|Hepatitis C
982600|NCT02103439|Cepeginterferon alfa
982601|NCT02103439|Peginterferon
982602|NCT02103439|Treatment
982603|NCT02103426|Cytomegalovirus
982604|NCT02103426|ASP0113
982605|NCT02103426|CMV-seropositive
982606|NCT02103426|Healthy subjects
982607|NCT02103426|CMV-seronegative
982608|NCT02103426|Dialysis
982609|NCT02103374|weaned tobacco
982610|NCT02103374|Has not submitted an exacerbation in the past 3 months
982611|NCT02103361|autoimmune disease
982612|NCT02103361|pregnancy
982613|NCT02103361|psoriasis
982614|NCT02103361|Stelara
982615|NCT02103361|ustekinumab
982616|NCT02103361|birth outcome
982617|NCT02103361|malformation
982618|NCT02103361|birth defect
982619|NCT02103361|psoriatic arthritis
982620|NCT02103361|Crohn's Disease
982621|NCT02103348|Severe asthma
982622|NCT02103348|Sputum
982623|NCT02103348|Mucolysis
982624|NCT02103335|Myeloma
982625|NCT02103335|Multiple Myeloma
982626|NCT02103335|Pomalidomide
982627|NCT02103335|Marizomib
982628|NCT02103335|Low dose Dexamethasone
982629|NCT02103335|Relapsed
982630|NCT02103335|Refractory
982631|NCT02103309|Soft contact lenses
982632|NCT02103309|DACP
982633|NCT02103283|Diabetic Macular Edema
982634|NCT02103244|pharmacokinetics
982635|NCT02103244|safety
982636|NCT02103231|Preterm birth
982637|NCT02103231|Hypertension
982638|NCT02103231|Exercise capacity
982639|NCT02103231|Cardiovascular risk
982640|NCT02103218|HIV
982641|NCT02103218|risky sex prevention
982642|NCT02103218|intervention
982643|NCT02103205|Lactoferrin
982644|NCT02103205|Infant formula
982645|NCT02103205|Iron
982646|NCT02103179|Extrahepatic cholangiocarcinoma
982647|NCT02103179|ECC
982648|NCT02103179|VEGF signaling
982649|NCT02103140|Breast Cancer
982650|NCT02103140|Obesity
982651|NCT02103140|African American female
982652|NCT02103140|exergaming
982653|NCT02103101|polymorphism
982654|NCT02103101|ABCB1
982655|NCT02103101|P-glycoprotein
982656|NCT02103101|oral anticoagulant
982657|NCT02103101|dabigatran
982658|NCT02103101|apixaban
982659|NCT02103101|rivaroxaban
982660|NCT02103101|hemorrhagic complication
982661|NCT02103101|thrombo-embolism
982662|NCT02103101|serious adverse event
982663|NCT02103088|Prostate cancer
982664|NCT02103088|Intervention
982665|NCT02103088|Rehabilitation
982666|NCT02103088|Couple
982667|NCT02103088|Sexology
982668|NCT02103088|Urology
982669|NCT02103088|Late effects
982670|NCT02103075|spinocerebellar ataxia (SCA)
982671|NCT02103075|motor evoked potential (MEP)
982672|NCT02103075|Neuromuscular electrical stimulation (NMES)
982673|NCT02103075|silent period
982674|NCT02103075|cerebellum
982675|NCT02103062|Metastatic Colorectal Cancer
982676|NCT02103062|nab®Paclitaxel
982677|NCT02103062|Response Evaluation in Solid Tumors
982678|NCT02103062|Progression Free Survival
982679|NCT02103062|Overall Survival
982680|NCT02103062|Duration of Response
982681|NCT02103062|RAS
982682|NCT02103036|Low Back Pain
982683|NCT02103036|Core stability exercise
982684|NCT02103036|Back school
982685|NCT02103036|TENS
982686|NCT02103036|Infra- red light
982687|NCT02102997|DTS
982688|NCT02102997|Stents
982689|NCT02102997|Stent
982690|NCT02102997|DES
982691|NCT02102997|Drug eluting
982692|NCT02102997|Drug Eluting Stent (DES)
982693|NCT02102997|Drug eluting stents
982694|NCT02102997|Endothelial Progenitor Cell (EPC)
982695|NCT02102997|Endothelial progenitor cell capturing
982696|NCT02102997|Sirolimus
982697|NCT02102997|Sirolimus eluting
982698|NCT02102997|Percutaneous Coronary Intervention (PCI)
982699|NCT02102997|PCI
982700|NCT02102997|Registry
982701|NCT02102997|Registries
982702|NCT02102997|Multi center
982703|NCT02102997|Multi centre
982704|NCT02102984|distal malignancy of the extra-hepatic biliary tract
982705|NCT02102984|metallic biliary stents
982706|NCT02102984|covered biliary stents
982707|NCT02102984|uncovered biliary stents
982708|NCT02102971|liver
982709|NCT02102971|ischemia
982710|NCT02102971|reperfusion
982711|NCT02102958|diabetes
982712|NCT02102958|visual impairment
982713|NCT02102958|foot care
982714|NCT02102958|diabetes self-management education
982715|NCT02102945|Computed tomography
982716|NCT02102945|Perfusion imaging
982717|NCT02102945|Coma
982718|NCT02102945|Heart arrest
982719|NCT02102945|Brain death
982720|NCT02102906|Adult
982721|NCT02102906|Humans
982722|NCT02102906|Conversion disorder
982723|NCT02102906|Somatoform Disorders/therapy
982724|NCT02102906|Nervous System Disorders/therapy
982725|NCT02102893|for Gastroentero-Pancreatic Neuroendocrine Tumors in Taiwan
982726|NCT02102880|Genetic Association Studies
982727|NCT02102867|HIV
982728|NCT02102867|STI
982729|NCT02102867|Primary Prevention
982730|NCT02102867|Topical Microbicides
982731|NCT02102867|User Experience
982732|NCT02102867|Drug Delivery Systems
982733|NCT02102854|kidney transplantation
982734|NCT02102854|acute rejection
982735|NCT02102854|rabbit antithymocyte globulin
982736|NCT02102828|DVT
982737|NCT02102828|Total Knee Arthroplasty
982738|NCT02102815|total knee arthroplasty
982739|NCT02102815|pain control
982740|NCT02102815|dexamethasone
982741|NCT02102815|steroids
982742|NCT02102802|PTSD
982743|NCT02102802|MDMA
982744|NCT02102802|Brain activity
982745|NCT02102802|fMRI
982746|NCT02102802|Heart rate variability
982747|NCT02102802|Physiological correlate
982748|NCT02102776|Primary Pterygium
982749|NCT02102776|Mitomycin C
982750|NCT02102776|Amniotic membrane transplantation
982751|NCT02102776|Conjunctival autograft
982752|NCT02102776|Multi-center randomized clinical trial
982753|NCT02102763|Overweight
982754|NCT02102763|Obesity
982755|NCT02102763|Dietary intake
982756|NCT02102763|Physical activity levels
982757|NCT02102763|Blood pressure levels
982758|NCT02102763|Family perceptions
982759|NCT02102737|insulin resistance
982760|NCT02102737|Scintigraphy
982761|NCT02102737|Hyperinsulinemic euglycemic clamp
982762|NCT02102724|African Americans
982763|NCT02102724|Older Adults
982767|NCT02102698|Tourette's Syndrome
982768|NCT02102698|Ecopipam
982769|NCT02102698|D1 Receptor
982770|NCT02102698|Phase 2
982771|NCT02102685|VAC Therapy
982772|NCT02102685|Neck Abscess
982773|NCT02102685|Traditional Therapy
982774|NCT02102685|Wound Healing
982775|NCT02102659|Nutritional Assessment
982776|NCT02102659|Oral Epithelial Cell
982777|NCT02102659|Apoptosis
982778|NCT02102633|bosutinib
982779|NCT02102633|dabigatran
982780|NCT02102633|drug interaction
982781|NCT02102633|p-glycoprotein
982782|NCT02102633|pharmacokinetics
982783|NCT02102620|intra-articular injection
982784|NCT02102620|corticosteroid
982785|NCT02102620|osteoarthritis
982786|NCT02102620|Interphalangeal joint
982787|NCT02102607|intrathecal; ropivacaine; motor blockade; local anesthetics
982788|NCT02102594|Myasthenia Gravis
982789|NCT02102594|Systemic Lupus Erythematosus
982790|NCT02102594|Rheumatoid Arthritis
982791|NCT02102594|proteasome inhibitor
982792|NCT02102594|Bortezomib
982793|NCT02102594|Velcade
982794|NCT02102594|antibody-mediated autoimmune disease
982795|NCT02102581|Tourniquet
982796|NCT02102581|Total knee arthroplasty
982797|NCT02102581|Blood loss
982798|NCT02102581|Limb swelling
982799|NCT02102581|Limb circumference
982800|NCT02102542|glycopyrrolate
982801|NCT02102542|efficacy
982802|NCT02102542|antisialagogue
982803|NCT02102529|pain
982804|NCT02102529|quality of life
982805|NCT02102516|Post operative pain management
982806|NCT02102490|Endocrine Therapy, Taxane, MONARCH 1
982807|NCT02102477|Prostatic neoplasms
982808|NCT02102477|Locally advanced
982809|NCT02102477|Radiotherapy
982810|NCT02102477|Surgery
982811|NCT02102477|Mortality
982812|NCT02102451|Interferon-free
982813|NCT02102451|Direct acting antiviral (DAA)
982814|NCT02102451|Treatment as prevention
982815|NCT02102451|Surveillance
982816|NCT02102451|Feasibility
982817|NCT02102438|Elderly patients
982818|NCT02102438|Localized HER2+ Breast Cancer
982819|NCT02102438|Omission of anthracyclines
982820|NCT02102438|Neoadjuvant chemotherapy
982821|NCT02102438|Adjuvant chemotherapy
982822|NCT02102438|Safety information
982823|NCT02102425|Peritoneal Dialysis
982824|NCT02102425|Exit site infection
982825|NCT02102425|Exit site care
982826|NCT02102425|Bandage
982827|NCT02102425|Prevention
982828|NCT02102425|Guidelines
982829|NCT02102412|crc
982830|NCT02102412|colonoscopy
982831|NCT02102412|colon cancer
982832|NCT02102399|Voice training
982833|NCT02102399|Education
982834|NCT02102399|Voice
982835|NCT02102399|Faculty
982836|NCT02102386|elective
982837|NCT02102386|carotid endarterectomy surgery
982838|NCT02102373|colonoscopy, pediatric, preparation, diet
982839|NCT02102360|microsurgery, furcation defects, periodontal disease, enamel matrix proteins, bone substitutes
982840|NCT02102347|Physical Therapy Modalities
982841|NCT02102347|osteoarthritis
982842|NCT02102334|Osteoarthritis, hip,
982843|NCT02102334|radiograpghic measurements
982844|NCT02102334|femoral offset
982845|NCT02102334|leg length discrepancy
982846|NCT02102334|cup anteversion
982847|NCT02102334|cup inclination
982848|NCT02102321|hookworm
982849|NCT02102321|albendazole
982850|NCT02102321|iron supplementation
982851|NCT02102321|democratic republic of congo
982852|NCT02102321|subsistence farmers
982853|NCT02102321|randomized control trial
982854|NCT02102321|neglected tropical disease
982855|NCT02102321|helminths
982856|NCT02102295|Gingivitis
982857|NCT02102295|antioxidant
982858|NCT02102295|dentifrice
982859|NCT02102295|Ascorbic Acid Derivative
982860|NCT02102295|L ascorbic acid 2 phosphate magnesium salt
982861|NCT02102282|Pregnancy
982862|NCT02102282|Breast Cancer
982863|NCT02102282|Chemotherapy
982864|NCT02102282|Surgery
982865|NCT02102282|Obstetric managment
982866|NCT02102256|deafness
982867|NCT02102256|congenital
982868|NCT02102256|pediatric
982869|NCT02102256|device
982870|NCT02102243|hypertension
982871|NCT02102243|blood pressure
982872|NCT02102243|sympathetic nerve activity
982873|NCT02102243|vascular oxidative stress
982874|NCT02102243|nitric oxide
982875|NCT02102243|nitric oxide synthase (eNOS)
982876|NCT02102243|endothelium
982877|NCT02102243|endothelial dysfunction
982878|NCT02102243|endothelial cell protein expression
982879|NCT02102243|microvascular blood flow
982880|NCT02102243|flow mediated dilation
982881|NCT02102243|endothelial cell collection
982882|NCT02102243|microbubbles
982883|NCT02102243|Definity
982884|NCT02102230|Sleep Initiation and Maintenance Disorders
982885|NCT02102230|marijuana abuse
982886|NCT02102230|Veterans
982887|NCT02102217|Major Abdominal Surgery
982888|NCT02102217|C-reactive protein
982889|NCT02102217|Computed Tomography
982890|NCT02102217|Quality Control
982891|NCT02102217|Postoperative complications
982893|NCT02102178|oncological pain
982894|NCT02102178|therapeutic activities
982895|NCT02102178|occupational therapy.
982896|NCT02102165|Aurora
982897|NCT02102165|breast cancer
982898|NCT02102165|metastatic
982899|NCT02102165|molecular screening
982900|NCT02102165|targeted gene sequencing
982901|NCT02102165|molecular aberrations
982902|NCT02102165|exploratory
982903|NCT02102165|biomarker
982904|NCT02102152|Tobramycin Podhaler
982905|NCT02102152|bronchiectasis
982906|NCT02102152|chronic infection
982907|NCT02102152|Pseudomonas Aeruginosa
982908|NCT02102126|Renal denervation therapy
982909|NCT02102126|Aortic blood pressure
982910|NCT02102126|Blood pressure variability
982911|NCT02102126|Arterial stiffness
982912|NCT02102126|Target organ damage
982913|NCT02102126|Biomarker
982914|NCT02102100|menthol, electronic cigarette, nicotine, smoking, tobacco
982915|NCT02102074|colon and rectal tumors
982916|NCT02102074|colon cancer markers
982917|NCT02102061|overweight
982918|NCT02102061|exercise
982919|NCT02102061|nutrition
982920|NCT02102061|philosophy
982921|NCT02102048|HIV
982922|NCT02102048|diabetes
982923|NCT02102048|glucose metabolism
982924|NCT02102048|antiretroviral therapy
982925|NCT02102048|ritonavir
982926|NCT02102048|atazanavir
982927|NCT02102035|defect
982928|NCT02102035|dorsal branch of the proper digital nerve
982929|NCT02102035|dorsal digital island flap
982930|NCT02102035|sensory reconstruction.
982931|NCT02102022|argininosuccinate synthetase
982932|NCT02102022|arginine
982933|NCT02102022|arginine deiminase
982934|NCT02102009|Malnutrition
982935|NCT02102009|Dietary supplement
982936|NCT02102009|Nutritional supplement
982937|NCT02102009|Complete enteral formula
982938|NCT02102009|COPD
982939|NCT02101996|stable isotopes
982940|NCT02101996|triacylglycerol
982941|NCT02101983|Acute myeloid leukemia
982942|NCT02101983|outpatient consolidation treatment
982943|NCT02101970|Breast cancer risk
982944|NCT02101970|DHA
982945|NCT02101970|Omega-3 Fatty Acids
982946|NCT02101970|EPA
982947|NCT02101970|Weight Loss
982948|NCT02101931|Bladder Cancer
982949|NCT02101931|Laser Diagnosis
982950|NCT02101931|Amino levulinic Acid
982951|NCT02101931|Photodynamic Detection
982952|NCT02101931|spectra of urine
982953|NCT02101892|migraine
982954|NCT02101892|Amitriptyline
982955|NCT02101892|pain modulation
982956|NCT02101892|pain psychophysics
982957|NCT02101892|pain neurophysiology
982958|NCT02101892|preventive treatment
982959|NCT02101866|Bioavailability Study
982960|NCT02101866|Aviragen Therapeutics, Inc.
982961|NCT02101866|Aviragen Therapeutics
982962|NCT02101866|Aviragen
982963|NCT02101840|Substance-Related Disorders
982964|NCT02101840|Prescription Drug Misuse
982965|NCT02101840|Analgesics, Opioid
982966|NCT02101840|Oxycodone
982967|NCT02101840|Randomized Controlled Trial
982968|NCT02101840|Cross-Over Studies
982969|NCT02101840|Placebo
982970|NCT02101840|Healthy Volunteers
982971|NCT02101801|environment, recycled wastewater, carbamazepine
982972|NCT02101762|Foley
982973|NCT02101762|Catheters
982974|NCT02101762|CAUTI
982975|NCT02101762|ERASE CAUTI
982976|NCT02101749|trivalent inactivated influenza vaccine
982977|NCT02101736|Ages 16 or greater
982978|NCT02101736|Cabozantinib
982979|NCT02101736|XL184
982980|NCT02101736|Plexiform Neurofibromas
982981|NCT02101736|Neurofibromatosis
982982|NCT02101736|Pathogenetic NF1 Mutations
982983|NCT02101736|Cometriq
982984|NCT02101736|NF1
982985|NCT02101723|Zinc absorption
982986|NCT02101723|Micronutrient supplement
982987|NCT02101723|Microbiome
982988|NCT02101723|Kenya
982989|NCT02101723|Complementary foods
982990|NCT02101723|Home fortification
982991|NCT02101710|Bioequivalence
982992|NCT02101710|Isosorbide 5-mononitrate
982993|NCT02101710|Elantan
982994|NCT02101710|Imdur
982995|NCT02101710|Korean
982996|NCT02101710|Healthy
982997|NCT02101697|reduce
982998|NCT02101697|Indian health providers
982999|NCT02101684|Orteronel, Granulosa Cell Tumour
983000|NCT02101671|agitation
983001|NCT02101671|anaesthesia
983002|NCT02101671|laparoscopy
983003|NCT02101671|surgery
983004|NCT02101671|delirium
983005|NCT02101671|sedation
983006|NCT02101671|emergence
983007|NCT02101671|steep
983008|NCT02101671|trendelemburg
983009|NCT02101671|position
983010|NCT02101671|delayed
983011|NCT02101671|Confusion
983012|NCT02101671|Disorientation
983013|NCT02101645|Bioimpedance
983014|NCT02101645|Venous ulcer
983015|NCT02101645|Edema
983016|NCT02101645|LIDC
983017|NCT02101645|Electrical stimulation
983018|NCT02101632|TMD
983019|NCT02101632|bee venom
983020|NCT02101632|muscle tension
983021|NCT02101632|muscle pain
983022|NCT02101619|aortic stenosis
983023|NCT02101619|myocardial tissue
983024|NCT02101619|echocardiography
983025|NCT02101619|MRI
983026|NCT02101606|Acute Stroke
983027|NCT02101606|Cerebral Stroke
983028|NCT02101606|Brain Ischemia
983029|NCT02101606|Perfusion Imaging
983030|NCT02101606|MRI, Diffusion Weighted
983031|NCT02101606|MRI, Perfusion Weighted
983032|NCT02101593|argininosuccinate synthetase
983033|NCT02101593|arginine
983034|NCT02101593|arginine deiminase
983035|NCT02101580|argininosuccinate synthetase
983036|NCT02101580|arginine
983037|NCT02101580|arginine deiminase
983038|NCT02101567|Postpartum hemorrhage, Cesarean section, Uterotonics
983042|NCT02101541|Atrial fibrillation
983043|NCT02101541|Arrhythmias, Cardiac
983044|NCT02101541|Heart diseases
983045|NCT02101541|Cardiovascular diseases
983046|NCT02101541|Pathological processes
983047|NCT02101528|Strength in PD patients
983048|NCT02101528|Isokinetic muscle strength
983049|NCT02101515|randomized controlled trial
983050|NCT02101515|labor complications
983051|NCT02101515|cesarean section
983052|NCT02101515|second stage
983053|NCT02101502|Healthcare,educational effectiveness, institutional capacity
983054|NCT02101489|TVT
983055|NCT02101489|Stress urinary incontinence
983056|NCT02101476|Pain
983057|NCT02101463|aortic
983058|NCT02101463|sm-FBSG
983059|NCT02101463|aneurysms
983060|NCT02101463|fenestrated
983061|NCT02101463|stent-grafts
983062|NCT02101463|Vascular
983063|NCT02101463|Endovascular
983064|NCT02101450|extra-abdominal
983065|NCT02101450|intra-abdominal
983066|NCT02101450|removal of placenta
983067|NCT02101450|cesarean section
983068|NCT02101450|bleeding
983069|NCT02101424|Overdose
983070|NCT02101424|Emergency Department
983071|NCT02101424|Supplemental Oxygen
983072|NCT02101424|Pulse Oximeter
983073|NCT02101424|Capnography
983074|NCT02101398|tDCS
983075|NCT02101398|Stroke
983076|NCT02101398|Aphasia
983077|NCT02101398|Naming
983078|NCT02101385|Genomically-Directed Therapy
983079|NCT02101385|DNA Sequencing
983080|NCT02101385|RNA Sequencing
983081|NCT02101372|first episode psychosis
983082|NCT02101372|psychoeducation
983083|NCT02101372|group therapy
983084|NCT02101333|TAKAYASU ARTERITIS
983085|NCT02101333|STEROID SPARING
983086|NCT02101333|TOCILIZUMAB
983087|NCT02101333|EFFICACY
983088|NCT02101333|SAFETY
983089|NCT02101320|surgery
983090|NCT02101320|nuclear medicine
983091|NCT02101320|Lymphoscintigraphy
983092|NCT02101320|Gamma Camera
983093|NCT02101320|SNOLL
983094|NCT02101320|breast cancer
983095|NCT02101294|carpal tunnel syndrome
983096|NCT02101294|repetitive stress disorder
983097|NCT02101281|Dry Eye
983098|NCT02101255|Dental caries
983099|NCT02101255|Curodont Repair
983100|NCT02101255|P11-4
983101|NCT02101242|Near-infrared-Spectroscopy
983102|NCT02101229|Glycemic control algorithm
983103|NCT02101229|closed loop
983104|NCT02101229|artificial pancreas
983105|NCT02101216|bioequivalence
983106|NCT02101216|pharmacokinetics
983107|NCT02101216|psoriasis
983108|NCT02101203|HSDD
983109|NCT02101190|BIA 9-1067
983110|NCT02101190|Opicapone
983111|NCT02101190|catechol-O-methyltransferase (COMT)
983112|NCT02101177|Viral Hepatitis C
983113|NCT02101177|Genotype 4
983114|NCT02101177|SVR
983115|NCT02101177|Egyptian National Program
983116|NCT02101151|Type 2 diabetes mellitus
983117|NCT02101151|vitamin D
983118|NCT02101151|cholecalciferol
983119|NCT02101151|obesity
983120|NCT02101138|Corticosteroids
983121|NCT02101138|Eosinophilia
983122|NCT02101099|Colonoscopy
983123|NCT02101099|Force
983124|NCT02101099|Monitor
983125|NCT02101099|Endoscopist
983126|NCT02101099|Conscious
983127|NCT02101099|Sedation
983128|NCT02101099|Propofol
983129|NCT02101086|umbilical cord blood
983130|NCT02101086|premature
983131|NCT02101086|autologous transfusion
983132|NCT02101086|allogeneic transfusion
983133|NCT02101060|exercise
983134|NCT02101060|aging
983135|NCT02101060|aerobic capacity
983136|NCT02101060|cardiac function
983137|NCT02101060|inflammation
983138|NCT02101047|cesarean section
983139|NCT02101047|hypotension
983140|NCT02101047|phenylephrine
983145|NCT02100969|MG
983146|NCT02100969|Hizentra
983147|NCT02100969|autoimmune neuromuscular disorder
983148|NCT02100956|chronic pain
983149|NCT02100956|neuropathic pain
983150|NCT02100943|Obstructive Sleep Apnea
983151|NCT02100930|Anti-GD2 3F8 Monoclonal Antibody
983152|NCT02100930|oral isotretinoin
983153|NCT02100930|GM-CSF
983154|NCT02100930|Sargramostim
983155|NCT02100930|13-260
983156|NCT02100917|Bioequivalence
983157|NCT02100917|Biosimilarity
983158|NCT02100917|Similarity
983159|NCT02100917|Pharmacokinetics
983160|NCT02100917|Phase I
983161|NCT02100917|Trastuzumab
983162|NCT02100917|Healthy Male Volunteers
983163|NCT02100917|Single-dose
983164|NCT02100917|HER-2
983165|NCT02100917|Oncology
983166|NCT02100904|Fibroids
983167|NCT02100904|Radiofrequency ablation
983168|NCT02100891|Ewing Sarcoma
983169|NCT02100891|Neuroblastoma
983170|NCT02100891|Rhabdomyosarcoma
983171|NCT02100891|Osteosarcoma
983172|NCT02100891|CNS tumors
983173|NCT02100891|Brain Tumors
983174|NCT02100839|hypercholesterolemia
983175|NCT02100839|apolipoprotein E
983176|NCT02100839|First in Human
983177|NCT02100839|Apolipoprotein E (ApoE)
983178|NCT02100839|Apolipoprotein E Mimetic (AEM)
983179|NCT02100800|COPD
983180|NCT02100800|Emphysema
983181|NCT02100800|MRI
983182|NCT02100800|UTE
983183|NCT02100800|Quantification
983184|NCT02100800|CT
983185|NCT02100787|tear osmolarity
983186|NCT02100787|keratitis sicca
983187|NCT02100787|ocular surface disease
983188|NCT02100787|TheraTears
983189|NCT02100774|bioavailability
983190|NCT02100774|postprandial period
983191|NCT02100774|genetic variants
983192|NCT02100774|single nucleotide polymorphisms
983193|NCT02100774|vitamin
983194|NCT02100774|carotenoid
983195|NCT02100774|lutein
983196|NCT02100774|lycopene
983197|NCT02100774|tocopherol
983198|NCT02100774|cholecalciferol
983199|NCT02100761|Voriconazole
983200|NCT02100761|Invasive pulmonary aspergillosis
983201|NCT02100761|Therapeutic drug monitoring
983202|NCT02100761|CYP genetic polymorphism
983203|NCT02100761|Efficacy
983204|NCT02100761|Safety
983205|NCT02100748|moderate to severe acute pain
983206|NCT02100748|bunionectomy
983207|NCT02100735|sedatives
983208|NCT02100735|analgesics
983209|NCT02100735|protocol
983210|NCT02100735|mechanical ventilation
983211|NCT02100735|analgosedation
983212|NCT02100683|Occluder
983213|NCT02100657|multiple myeloma
983214|NCT02100657|plitidepsin
983215|NCT02100657|APLIDIN
983216|NCT02100618|Adolescents
983217|NCT02100618|Adults
983218|NCT02100618|Immunogenicity
983219|NCT02100618|6.5 years
983220|NCT02100618|Safety
983221|NCT02100618|Antibody persistence
983222|NCT02100618|Human Papillomavirus (HPV) vaccine
983223|NCT02100605|Nasal
983224|NCT02100605|Congestion
983225|NCT02100605|Decongestion
983226|NCT02100605|Hypertonic
983227|NCT02100605|Saline solution
983228|NCT02100592|brain injury
983229|NCT02100592|coma
983230|NCT02100592|intensive care
983231|NCT02100592|early rehabilitation
983232|NCT02100566|Advance Directive
983233|NCT02100553|Postmenopausal Women
983234|NCT02100553|Obese
983235|NCT02100553|Non-obese
983236|NCT02100553|Drug Interaction with Itraconazole
983237|NCT02100553|Pharmacokinetic
983238|NCT02100540|PMS
983239|NCT02100540|hot flashes
983240|NCT02100527|safety
983241|NCT02100527|tolerability
983242|NCT02100527|pharmacokinetics
983243|NCT02100527|oral dosing
983244|NCT02100527|moderate to severe acne vulgaris
983245|NCT02100514|Primary hyperlipidemia or mixed dyslipidemia
983246|NCT02100514|high risk of cardiovascular events
983247|NCT02100514|multiple cardiovascular disease risk factors.
983248|NCT02100501|Seizure control through dietary therapy in pediatric intractable epilepsy patients.
983249|NCT02100488|Closed-loop insulin infusion
983250|NCT02100488|Postprandial glucose control
983251|NCT02100488|Glucose variability
983252|NCT02100462|Hypertension
983253|NCT02100462|Platelet activation
983254|NCT02100462|Platelet aggregation
983255|NCT02100462|Chlorthalidone
983256|NCT02100449|Atelectasis
983257|NCT02100449|Pneumonia
983258|NCT02100449|Lung ultrasound
983259|NCT02100449|Doppler
983260|NCT02100436|children
983261|NCT02100436|H3N2
983262|NCT02100436|H3N2v
983263|NCT02100436|influenza
983264|NCT02100436|pediatric
983265|NCT02100436|unadjuvanted
983266|NCT02100436|vaccine
983267|NCT02100410|Contact Lens
983268|NCT02100410|Toric
983269|NCT02100397|Enteric fever
983270|NCT02100397|Paratyphoid
983271|NCT02100397|Salmonella Paratyphi
983272|NCT02100397|Challenge study
983273|NCT02100397|Human model of infection
983274|NCT02100384|peri implant
983275|NCT02100384|Maintenance
983276|NCT02100384|Ultrasonic
983277|NCT02100384|Scalers
983278|NCT02100371|BMS-833923
983279|NCT02100371|CA194002
983280|NCT02100358|acute cholecystitis
983281|NCT02100332|Drug Therapy
983282|NCT02100319|Pharmacological therapy
983283|NCT02100293|magnesium sulfate, rocuronium
983284|NCT02100280|Neuromuscular blockade
983285|NCT02100280|Sugammadex
983286|NCT02100280|Laparoscopic surgery
983287|NCT02100280|IL-6
983288|NCT02100241|Young adult
983289|NCT02100241|Muscle Stretching Exercises
983290|NCT02100241|Range of Motion, Articular
983291|NCT02100228|apixaban
983292|NCT02100228|oral anticoagulant
983293|NCT02100228|non-valvular atrial fibrillation
983294|NCT02100228|cardioversion
983295|NCT02100215|simulation
983296|NCT02100215|competence
983297|NCT02100215|self-efficacy
983298|NCT02100215|novice nurses
983299|NCT02100202|Dietary supplements
983300|NCT02100202|Cotinine level
983301|NCT02100202|Malondialdehyde
983302|NCT02100202|Chronic smokers
983303|NCT02100202|Hyperlipidemia
983304|NCT02100176|Rehabilitation treatment
983305|NCT02100163|Ortho trauma
983306|NCT02100150|Concussion
983307|NCT02100124|reproductive life planning
983308|NCT02100124|action planning
983309|NCT02100124|contraceptive use
983310|NCT02100124|unintended pregnancy
983311|NCT02100098|Ankle fracture
983312|NCT02100098|Nerve block
983313|NCT02100098|Postoperative pain
983314|NCT02100098|Pain profile
983315|NCT02100098|Rebound pain
983316|NCT02100085|Phase 1 follow up
983317|NCT02100085|Cervical Intraepithelial Neoplasia
983318|NCT02100085|Adult
983319|NCT02100085|Safety
983320|NCT02100085|Efficacy
983321|NCT02100059|meniscectomy
983322|NCT02100059|arthroscopic partial meniscectomy
983323|NCT02100059|meniscus
983324|NCT02100046|Ethosuximide
983325|NCT02100046|Neuropathic pain
983326|NCT02100046|Pain
983327|NCT02100046|Quality of life
983328|NCT02100046|Neuropathic Pain diagnostic questionnaire ≥ 4
983329|NCT02100046|Analgesic treatment failure for at least 3 months
983330|NCT02100020|physical activity
983331|NCT02100020|exercise guidelines
983332|NCT02100020|multiple sclerosis
983333|NCT02100007|solid tumors
983334|NCT02100007|relapsed
983335|NCT02100007|advanced
983336|NCT02100007|metastatic
983337|NCT02100007|small cell lung cancer
983338|NCT02100007|ovarian cancer
983339|NCT02100007|refractory
983340|NCT02099994|HIV
983341|NCT02099994|vaccine
983342|NCT02099981|Diabetes
983343|NCT02099981|Diabetic
983344|NCT02099981|Retinopathy
983345|NCT02099981|Ophthalmology
983346|NCT02099981|Eye
983347|NCT02099981|Eyes
983348|NCT02099955|spinal cord injury
983349|NCT02099955|vitamin D deficiency
983350|NCT02099955|pulmonary function
983351|NCT02099955|metabolic diseases
983352|NCT02099942|Balloon Aortic Valvuloplasty
983353|NCT02099942|Valvuloplasty
983354|NCT02099942|Transcatheter Aortic Valve Replacement
983355|NCT02099942|Surgical Aortic Valve Replacement
983356|NCT02099929|Coffee
983357|NCT02099929|Glucose
983358|NCT02099929|Insulin
983359|NCT02099929|Diabetes
983360|NCT02099929|Type 2 Diabetes Mellitus
983361|NCT02099916|DHEA, pregnancy, ovarian reserve, AMH
983362|NCT02099903|Heart Failure
983363|NCT02099903|Heart Failure, Systolic
983364|NCT02099903|Chagas Disease
983365|NCT02099903|Chagas Cardiomyopathy
983366|NCT02099903|Renal Denervation
983367|NCT02099903|Irrigated Radiofrequency Catheter
983368|NCT02099890|Chronic Inflammation
983369|NCT02099890|Spinal Cord Injury
983370|NCT02099890|Anti-inflammatory Diet
983371|NCT02099890|Neuropathic Pain
983372|NCT02099890|Depression
983373|NCT02099890|Cognitive Impairment
983374|NCT02099890|Somatic Nerve Function
983375|NCT02099890|Autonomic Nerve Function
983376|NCT02099877|µ-opioid receptor polymorphism
983377|NCT02099877|Opioids
983378|NCT02099877|Opioid analgesia
983379|NCT02099877|Labor analgesia
983380|NCT02099838|Pioglitazone
983381|NCT02099838|Metformin
983382|NCT02099838|Type 2 Diabetes Mellitus
983383|NCT02099825|adult male
983384|NCT02099825|anxiety
983385|NCT02099825|public speaking
983386|NCT02099825|healthy controls
983387|NCT02099825|exposure therapy
983388|NCT02099825|social anxiety
983389|NCT02099825|mifepristone
983390|NCT02099825|d-cycloserine
983391|NCT02099799|Physical Activity
983392|NCT02099799|COPD Self-Management
983393|NCT02099799|Internet
983394|NCT02099799|6-Minute Walk Test
983395|NCT02099799|COPD Exacerbation
983396|NCT02099799|Health-related Quality of Life
983397|NCT02099786|hearing
983398|NCT02099786|cisplatin
983399|NCT02099786|Ototoxicity
983400|NCT02099786|Veterans
983401|NCT02099773|AAC
983402|NCT02099773|support worker
983403|NCT02099773|direct care staff
983404|NCT02099773|intellectual disability
983405|NCT02099773|learning disability
983406|NCT02099773|communication
983407|NCT02099773|adults
983408|NCT02099760|gonorrhea
983409|NCT02099760|chlamydia
983410|NCT02099760|trichomonas
983411|NCT02099747|Aplastic Anaemia
983412|NCT02099747|Eltrombopag
983413|NCT02099747|HATG
983414|NCT02099747|ATGAM
983415|NCT02099734|14-016
983416|NCT02099721|Sudden Cardiac Arrest (SCA)
983417|NCT02099721|Syncope
983418|NCT02099721|NSVT
983419|NCT02099721|PVC
983420|NCT02099721|LVEF
983421|NCT02099721|Primary Prevention
983422|NCT02099721|Secondary Prevention
983423|NCT02099721|ATP
983424|NCT02099721|shock
983425|NCT02099721|appropriate therapy
983426|NCT02099708|Pharmacological therapy
983427|NCT02099695|Hyperhidrosis
983428|NCT02099695|Oxybutynin
983429|NCT02099682|Pharmacological therapy
983430|NCT02099604|Hepatitis C - Genotype 4
983431|NCT02099604|SVR (Sustained Virological Response)
983432|NCT02099604|Vitamin D
983433|NCT02099604|Treatment Naïve
983434|NCT02099591|Constipation
983435|NCT02099591|Colonic Inertia
983436|NCT02099591|Dyschezia
983437|NCT02099591|Pharmacokinetics
983438|NCT02099591|Naloxegol
983439|NCT02099591|Paediatric
983440|NCT02099591|Opioids
983441|NCT02099591|Opioid induced constipation
983442|NCT02099591|OIC
983443|NCT02099591|Phase 1
983444|NCT02099578|Blood pressure
983445|NCT02099578|Arterial stiffness
983446|NCT02099578|Pulse wave velocity
983447|NCT02099578|Strawberries
983448|NCT02099578|Endothelial function
983449|NCT02099578|Oxidative stress
983450|NCT02099578|Postmenopausal women
983451|NCT02099565|Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
983452|NCT02099565|Statins
983453|NCT02099565|LDL-cholesterol
983454|NCT02099565|Inflammatory markers
983455|NCT02099565|Percutaneous Coronary Intervention (PCI)
983456|NCT02099552|X-Linked hypohidrotic ectodermal dysplasia
983457|NCT02099552|XLHED
983458|NCT02099552|Hypohidrotic ectodermal dysplasia
983459|NCT02099552|HED
983460|NCT02099552|Christ-Siemens-Touraine syndrome
983461|NCT02099539|absolute lymphocyte count
983462|NCT02099539|antitumor
983463|NCT02099539|cancer
983464|NCT02099539|immunotherapy
983465|NCT02099539|immunochemotherapy
983466|NCT02099539|interleukin-15
983467|NCT02099539|multiple myeloma
983468|NCT02099539|NK cell
983469|NCT02099539|refractory
983470|NCT02099539|relapsed
983471|NCT02099539|T cell
983472|NCT02099539|white blood cell count
983473|NCT02099526|cancer
983474|NCT02099526|caregiver
983475|NCT02099526|caregiving
983476|NCT02099526|care give
983477|NCT02099526|elderly
983478|NCT02099526|older adults
983479|NCT02099526|unmet needs
983480|NCT02099526|post-discharge
983481|NCT02099526|cancer symptoms
983482|NCT02099513|Mobile Technology
983483|NCT02099513|Chronic illness
983484|NCT02099513|Wireless blood pressure device
983485|NCT02099513|Wireless scale
983486|NCT02099513|Pedometer
983487|NCT02099500|Critical Limb Ischemia
983488|NCT02099500|Peripheral Vascular Disease
983489|NCT02099500|Lower Limb Ulcer
983490|NCT02099500|Gangrene
983491|NCT02099500|Amputation
983492|NCT02099500|Lower Limb Wound
983493|NCT02099487|HGG
983494|NCT02099474|HIV-1
983495|NCT02099474|HIV mother to child prevention
983496|NCT02099474|Raltegravir
983497|NCT02099474|Pharmacokinetic
983498|NCT02099435|Gastriointestinal
983499|NCT02099435|Lower gastriointestinal
983500|NCT02099435|Digestive
983501|NCT02099435|Hemostasis
983502|NCT02099435|Recurrent bleeding
983503|NCT02099435|Hemospray
983504|NCT02099409|Type 1 diabetes mellitus
983505|NCT02099409|children
983506|NCT02099409|closed loop
983507|NCT02099409|cross over
983508|NCT02099409|overnight
983509|NCT02099409|FLORENCED2
983510|NCT02099409|DANA Diabecare R pump
983511|NCT02099409|FreeStyle Navigator II
983512|NCT02099409|Dexcom G4
983513|NCT02099396|PFS,efficacy and safety,lobaplatin and gemcitabine in combination, second-line treatments on advanced osteosarcoma
983517|NCT02099370|Multiple Sclerosis
983518|NCT02099370|Tecfidera(R)
983519|NCT02099370|Oral medication
983520|NCT02099370|Adherence
983521|NCT02099331|Atrial Fibrillation
983522|NCT02099331|Reactive Oxygen Species
983523|NCT02099331|Cardiac Surgery
983524|NCT02099318|Rehearsal Platform
983525|NCT02099305|Adolescent; Depression
983526|NCT02099305|Early intervention (education)
983527|NCT02099305|Randomized Controlled Trial
983528|NCT02099305|Primary Prevention
983529|NCT02099305|schools
983530|NCT02099305|Health Literacy
983531|NCT02099305|Discrimination (Psychology)
983532|NCT02099305|Mental Health Services
983533|NCT02099292|lymphoma
983534|NCT02099292|high dose therapy
983535|NCT02099292|DexaBEAM
983536|NCT02099292|Rituximab
983537|NCT02099292|role of alternative salvage treatment - dexaBEAM
983538|NCT02099266|Umbilical Cord Blood (UCB) Stem Cell Transplant
983539|NCT02099266|Hyperbaric oxygen
983540|NCT02099266|Leukemia
983541|NCT02099266|Lymphoma
983542|NCT02099266|MDS
983543|NCT02099253|Age
983544|NCT02099253|Pharmacodynamics
983545|NCT02099253|dexmedetomidine
983546|NCT02099240|Osteomyelitis
983547|NCT02099240|IV Antibiotics
983548|NCT02099240|Oral Antibiotics
983549|NCT02099227|pediatric
983550|NCT02099227|soft tissue infections
983551|NCT02099227|ultrasonography
983552|NCT02099227|effectiveness
983553|NCT02099214|myocardial iron overload
983554|NCT02099214|HFE-Associated Hereditary Hemochromatosis
983555|NCT02099214|3 Tesla MRI
983556|NCT02099214|cardiological strategy in haemochromatosis
983557|NCT02099214|congestive heart failure
983558|NCT02099201|ACT-389949
983559|NCT02099162|OCT
983560|NCT02099162|Coronary
983561|NCT02099162|Stenting
983562|NCT02099149|Group B Streptococcus
983563|NCT02099149|early onset disease
983564|NCT02099149|late onset disease
983565|NCT02099149|anticapsular antibodies
983566|NCT02099149|serotype specific
983567|NCT02099123|Survival
983568|NCT02099123|Functional Disability
983569|NCT02099123|Cardiovascular Disease
983570|NCT02099123|Diabetes
983571|NCT02099123|Dementia
983572|NCT02099123|Cancer
983573|NCT02099097|3D Coping Skills Game
983574|NCT02099097|Quit smoking
983575|NCT02099097|14-062
983576|NCT02099071|ACT-389949
983577|NCT02099058|Advanced Solid Tumor
983578|NCT02099058|Neoplasm
983579|NCT02099058|Cancer
983580|NCT02099032|nutrition
983581|NCT02099032|milk
983582|NCT02099032|polar lipids
983583|NCT02099032|cardiometabolic risk
983584|NCT02099019|Coronary CT angiography; Revascularization; Decision-making
983585|NCT02098993|Sickle cell disease
983586|NCT02098993|Acute chest syndrome
983587|NCT02098993|Hemoglobinopathy
983588|NCT02098993|Hemolytic anemia
983589|NCT02098993|Heparin
983590|NCT02098993|Anticoagulant
983591|NCT02098954|TKI
983592|NCT02098954|resistance
983593|NCT02098954|erlotinib
983594|NCT02098954|combined chemotherapy
983595|NCT02098941|topiramate
983596|NCT02098941|oxcarbazepine
983597|NCT02098941|levetiracetam
983598|NCT02098941|retention rate
983599|NCT02098928|Acupuncture
983600|NCT02098928|Electro acupuncture
983601|NCT02098928|Menopause
983602|NCT02098915|gastroschisis
983603|NCT02098915|intestinal motility
983604|NCT02098915|prokinetic agents
983605|NCT02098915|intravenous metoclopramide
983606|NCT02098915|time to full enteral feeding
983607|NCT02098902|Overweight
983608|NCT02098902|Obesity
983609|NCT02098902|Overnutrition
983610|NCT02098902|Weight Loss
983611|NCT02098902|Body Weight
983612|NCT02098902|Nutrition Disorders
983613|NCT02098889|Cervix, active phase of labor, Hyoscine-N-Butylbromide (HBB)
983614|NCT02098876|neointimal tissue area
983615|NCT02098876|angulated coronary vessels
983616|NCT02098876|wall shear stress
983617|NCT02098876|zotarolimus eluting stent
983618|NCT02098876|everolimus eluting stent
983619|NCT02098863|Sickle Cell Anemia
983620|NCT02098863|Sickle Cell Disease
983621|NCT02098863|Survival
983622|NCT02098863|Mortality
983623|NCT02098863|End-Order Dysfunction
983624|NCT02098850|Staphylococcus aureus
983625|NCT02098850|bloodstream infection
983626|NCT02098850|bacteremia
983627|NCT02098837|HIV
983628|NCT02098824|vascular cognitive impairment
983629|NCT02098824|treatment
983630|NCT02098824|cerebrovascular lesions
983631|NCT02098824|memory impairment
983632|NCT02098824|executive dysfunction
983633|NCT02098824|neuronal networks
983634|NCT02098824|white matter tracts
983635|NCT02098824|monoaminergic systems
983636|NCT02098824|cholinergic systems
983637|NCT02098824|DTI
983638|NCT02098824|rs-fMRI
983639|NCT02098798|Dysplasia, Inflammatory Bowel Disease
983640|NCT02098785|VAP
983641|NCT02098785|liver
983642|NCT02098785|hepatology
983643|NCT02098785|caffeine
983644|NCT02098772|aortic valve disease
983645|NCT02098772|coronary bypass surgery
983646|NCT02098772|cardioplegic solutions
983647|NCT02098759|TSC
983648|NCT02098759|tuberous sclerosis complex
983649|NCT02098759|epilepsy
983650|NCT02098746|Pharmacological therapy
983651|NCT02098733|Pharmacological therapy
983652|NCT02098707|Stabilometric Platform
983653|NCT02098707|Rehabilitation
983654|NCT02098707|Balance Disorders
983655|NCT02098707|Falls
983656|NCT02098694|Physiotherapy
983657|NCT02098694|Outpatient clinic
983658|NCT02098681|Pectus Excavatum
983659|NCT02098668|menstrual cycle dynamics
983660|NCT02098668|PCOS
983661|NCT02098668|hyperprolactinemia
983662|NCT02098668|endometriosis
983663|NCT02098668|infertility
983664|NCT02098655|Stabilometric Platform
983665|NCT02098655|Postural instability
983666|NCT02098642|Gait Disturbances
983667|NCT02098642|Metatarsophalangeal joint
983668|NCT02098629|Myocardial infarction
983669|NCT02098629|myocardial ischemia
983670|NCT02098629|reperfusion injury
983671|NCT02098616|Hepatitis
983672|NCT02098616|Hepatitis, Chronic
983673|NCT02098616|Hepatitis C
983674|NCT02098616|Hepatitis C, Chronic
983675|NCT02098616|Liver Diseases
983676|NCT02098616|Digestive System Diseases
983677|NCT02098616|Hepatitis, Viral, Human
983678|NCT02098616|RNA Virus Infections
983679|NCT02098616|Antiviral Agents
983680|NCT02098616|Drug Resistance, Viral
983681|NCT02098590|Malaria
983682|NCT02098590|Plasmodium falciparum
983683|NCT02098577|Balance
983684|NCT02098564|hand therapy
983685|NCT02098564|activity-based training
983686|NCT02098564|hand related injuries
983687|NCT02098564|sense of coherence
983688|NCT02098551|atopic dermatitis
983689|NCT02098551|bet v 1
983690|NCT02098551|bet v 1 fragments
983691|NCT02098551|allergy
983692|NCT02098538|Regorafenib
983693|NCT02098538|13-244
983694|NCT02098525|Cryptococcal meningitis
983695|NCT02098525|HIV/AIDS
983696|NCT02098525|Antiretroviral therapy
983697|NCT02098525|Prognosis
983698|NCT02098525|Thailand
983699|NCT02098512|Brentuximab Vedotin
983700|NCT02098512|Immunotherapy
983701|NCT02098512|Relapsed Hodgkin Lymphoma
983702|NCT02098512|Refractory Hodgkin Lymphoma
983703|NCT02098512|Reduced Intensity Conditioning
983704|NCT02098512|Allogeneic Stem Cell Transplantation
983705|NCT02098486|Bile duct obstruction
983706|NCT02098486|Cholangitis
983707|NCT02098486|Moxifloxacin
983708|NCT02098486|Ceftriaxone
983709|NCT02098486|Sepsis
983710|NCT02098460|the Achilles tendon
983711|NCT02098460|intima-media thickness
983712|NCT02098447|vagus nerve stimulation effects on heart rate variability and peripheral blood perfusion
983713|NCT02098421|Induction of Labor
983714|NCT02098421|Pitocin
983715|NCT02098421|Oxytocin
983716|NCT02098421|Foley bulb
983717|NCT02098408|Ultra-high risk psychosis
983718|NCT02098408|Schizophrenia prodrome
983719|NCT02098408|Cognitive remediation
983720|NCT02098382|Cervical ripening
983721|NCT02098369|Chronic obstructive pulmonary disease (COPD)
983722|NCT02098369|Supplemental oxygen
983723|NCT02098369|Adherence
983724|NCT02098369|Telephonic education
983725|NCT02098369|Peer coaching
983726|NCT02098356|hemodialysis
983727|NCT02098356|dialysis
983728|NCT02098356|acidosis
983729|NCT02098356|bicarbonate
983730|NCT02098343|Ovarian cancer
983731|NCT02098343|Ovarian carcinoma
983732|NCT02098343|High Grade Serous Ovarian Cancer
983733|NCT02098343|Recurrent Cancer
983734|NCT02098343|Resistant Cancer
983735|NCT02098330|Vestibular neuritis
983736|NCT02098330|Vertigo
983737|NCT02098330|Head impulse test
983738|NCT02098330|Steroid
983739|NCT02098317|NAFLD
983740|NCT02098317|NASH
983741|NCT02098317|DHA
983742|NCT02098317|VITAMIN D
983743|NCT02098317|OBESITY
983744|NCT02098317|CHILDREN
983745|NCT02098304|Caries
983746|NCT02098304|ICDAS
983747|NCT02098304|Lesion activity
983748|NCT02098304|Demineralisation
983749|NCT02098304|Imaging
983750|NCT02098265|aneurysm
983751|NCT02098265|transient ischemic attack
983752|NCT02098252|brain arteriovenous malformation
983753|NCT02098252|Arteriovenous Malformations
983754|NCT02098252|AVM
983755|NCT02098252|BAVM
983756|NCT02098252|Stroke
983757|NCT02098252|Intracranial Hemorrhage
983758|NCT02098252|Congenital Abnormalities
983759|NCT02098252|Aneurysm
983760|NCT02098252|Vascular Malformations
983761|NCT02098252|Cardiovascular Abnormalities
983762|NCT02098252|Cardiovascular Diseases
983763|NCT02098252|Vascular Diseases
983764|NCT02098213|plaque psoriasis
983765|NCT02098213|DLQI
983766|NCT02098213|VQ Dermato
983767|NCT02098213|PASI
983768|NCT02098213|PASI change
983769|NCT02098213|phototherapy
983770|NCT02098213|balneotherapy
983771|NCT02098213|hydrotherapy
983772|NCT02098213|Euroquol EQ 5d scale
983773|NCT02098213|Visual analogic scale
983774|NCT02098213|SPA treatment Scale
983775|NCT02098213|PSS
983776|NCT02098200|tricuspid
983777|NCT02098200|regurgitation
983778|NCT02098200|repair
983779|NCT02098200|outcomes
983780|NCT02098187|Glomerular Filtration Rate
983781|NCT02098187|Acute Kidney Injury
983782|NCT02098174|Glomerular Filtration Rate
983783|NCT02098174|Acute kidney injury
983784|NCT02098161|Leukemia
983785|NCT02098161|Primary Myelofibrosis
983786|NCT02098161|PMF
983787|NCT02098161|Post-Polycythemia Vera Myelofibrosis
983788|NCT02098161|Post-PV MF
983789|NCT02098161|Post-Essential Thrombocytosis Myelofibrosis
983790|NCT02098161|Post-ET MF
983791|NCT02098161|LCL-161
983792|NCT02098161|Questionnaire
983793|NCT02098161|Survey
983794|NCT02098161|Phone Call
983795|NCT02098096|knee
983796|NCT02098096|arthritis
983797|NCT02098096|Veterans
983798|NCT02098096|strength
983799|NCT02098096|exercise
983800|NCT02098096|muscle
983801|NCT02098083|acute
983802|NCT02098083|stroke
983803|NCT02098083|gait
983804|NCT02098070|Knee Pain
983805|NCT02098070|Community Study
983806|NCT02098070|Knee Osteoarthritis
983807|NCT02098070|Risk Factors
983808|NCT02098057|IBS-diarrhea
983809|NCT02098044|knee osteoarthritis
983810|NCT02098044|epidemiology
983811|NCT02098044|risk factors
983812|NCT02098044|prevalence
983813|NCT02098044|professional football
983814|NCT02098031|Child Nutrition Sciences
983815|NCT02098031|Growth and Development
983816|NCT02098031|Developing Countries
983817|NCT02097992|COPD
983818|NCT02097992|airway blood flow
983819|NCT02097979|glaucoma
983820|NCT02097979|adherence
983821|NCT02097979|medication possession ratio
983822|NCT02097979|intervention
983823|NCT02097953|Daptomycin
983824|NCT02097953|Rifampin
983825|NCT02097953|P-glycoprotein
983826|NCT02097953|Pharmacokinetic
983827|NCT02097940|Postural balance
983828|NCT02097940|Athletes
983829|NCT02097940|Sports
983830|NCT02097940|Soccer
983831|NCT02097940|Physiotherapy
983832|NCT02097927|Appetite
983833|NCT02097927|Satiety
983834|NCT02097927|Energy intake
983835|NCT02097927|Saliva
983836|NCT02097927|Biomarkers
983837|NCT02097914|Secondhand smoke exposure
983838|NCT02097914|Secondhand smoke
983839|NCT02097914|Environmental Tobacco Smoke
983840|NCT02097914|Smoke-free homes
983841|NCT02097914|Smoke-free homes ban
983842|NCT02097901|Rotator Cuff
983843|NCT02097901|Injury
983844|NCT02097901|Repair
983845|NCT02097901|Microfracture
983846|NCT02097901|Healing
983847|NCT02097875|Skin cancer
983848|NCT02097875|Basal cell carcinoma
983849|NCT02097875|Squamous cell carcinoma
983850|NCT02097875|Melanoma
983851|NCT02097862|Degenerative Disc Disease
983852|NCT02097862|Disc Disease
983853|NCT02097862|Back pain
983854|NCT02097862|stem cells
983855|NCT02097862|adipose stem cells
983856|NCT02097862|ADSCs
983857|NCT02097849|vaccine
983858|NCT02097849|pneumococcal
983859|NCT02097849|meningococcal
983860|NCT02097849|tetanus diphtheria
983861|NCT02097849|immune response
983862|NCT02097836|postural control
983863|NCT02097836|Targeted Training
983864|NCT02097836|cerebral palsy
983865|NCT02097836|trunk segments
983866|NCT02097823|olanzapine
983867|NCT02097823|Nausea and vomiting
983868|NCT02097823|aprepitant
983869|NCT02097823|pediatrics
983870|NCT02097797|Inflammatory bowel disease
983871|NCT02097797|Crohn's disease
983872|NCT02097797|microbiota
983873|NCT02097797|fecal transplantation
983874|NCT02097784|cirrhosis
983875|NCT02097784|hepatorenal syndrome
983876|NCT02097784|acute kidney injury
983877|NCT02097784|diastolic function
983878|NCT02097771|laryngeal mask airway ventilation
983879|NCT02097732|Metastatic melanoma
983880|NCT02097732|Brain metastases
983881|NCT02097732|Radiation therapy
983882|NCT02097732|Immune therapy
983883|NCT02097706|Boderline Personality Disorder
983884|NCT02097706|Mental Illness
983885|NCT02097706|Cognition
983886|NCT02097693|DBS
983887|NCT02097693|quality of life
983888|NCT02097693|dystonia
983889|NCT02097693|dyskinetic cerebral palsy
983890|NCT02097680|with disturbed glucose metabolism
983891|NCT02097680|without disturbed glucose metabolism
983892|NCT02097667|Severe early onset Fetal Growth Restrictions
983893|NCT02097654|Hospital acquired
983894|NCT02097654|Elderly
983895|NCT02097641|Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells
983896|NCT02097641|Acute Respiratory Distress Syndrome
983897|NCT02097628|volume controlled ventilation
984024|NCT02097082|Cardiovascular Diseases
983898|NCT02097628|pressure controlled ventilation
983899|NCT02097615|soft
983900|NCT02097615|tissue
983901|NCT02097615|infections
983902|NCT02097602|Reticulated platelets
983903|NCT02097602|noncardiac surgery
983904|NCT02097602|MACCEs
983905|NCT02097602|major adverse cardiac and cerebrovascular events
983906|NCT02097602|outcome
983907|NCT02097602|High-risk or intermediate-risk noncardiac surgery
983908|NCT02097589|Health Controls
983909|NCT02097576|Chronic Rhinosinusitis
983910|NCT02097563|Mood Disorders
983911|NCT02097563|Psychosis
983912|NCT02097563|Subthreshold
983913|NCT02097563|Bipolar Disorder
983914|NCT02097550|Renal Insufficiency, Chronic
983915|NCT02097550|Kidney Failure, Chronic
983916|NCT02097550|Self Care
983917|NCT02097550|Consumer Participation
983918|NCT02097550|Patient Participation
983919|NCT02097550|Marketing
983920|NCT02097550|Consumer Health Information
983921|NCT02097511|Drug-drug interaction
983922|NCT02097511|Pharmacokinetics
983923|NCT02097511|Pharmacodynamics
983924|NCT02097498|Simulation
983925|NCT02097498|Enhance
983926|NCT02097498|Safety
983927|NCT02097498|Proficiency
983928|NCT02097498|Paramedics.
983929|NCT02097498|Airway Management
983930|NCT02097498|Intubation
983931|NCT02097459|Breast cancer
983932|NCT02097459|Endocrine therapy
983933|NCT02097459|Perimenopausal and recently postmenopausal patients
983934|NCT02097459|Early-stage hormone receptor-positive
983935|NCT02097446|cystectomy
983936|NCT02097433|Dacomitinib
983937|NCT02097433|PF299804
983938|NCT02097433|pharmacokinetics
983939|NCT02097433|healthy
983940|NCT02097433|Chinese
983941|NCT02097420|Mitral valve
983942|NCT02097381|HIV infection
983943|NCT02097381|GUT
983944|NCT02097381|microbial translocation
983945|NCT02097381|chronic inflammation
983946|NCT02097381|antiretroviral therapy
983947|NCT02097381|cART
983948|NCT02097381|HAART
983949|NCT02097381|Th17
983950|NCT02097381|Th1
983951|NCT02097381|CD4+
983952|NCT02097368|Tongue strength
983953|NCT02097368|neuromuscular
983954|NCT02097368|swallowing
983955|NCT02097355|chronic disease
983956|NCT02097355|patient portal
983957|NCT02097355|health information technology
983958|NCT02097355|patient provider communication
983959|NCT02097355|quality improvement
983960|NCT02097342|Type 2 Diabetes Mellitus
983961|NCT02097342|Insulin sensitivity- hyperinsulinemic euglycemic clamp
983962|NCT02097342|Pancreatic beta cell function
983963|NCT02097342|Linagliptin
983964|NCT02097342|Voglibose
983965|NCT02097342|Mixed meal test
983966|NCT02097342|GLP-1 response
983967|NCT02097329|bioavailability
983968|NCT02097329|antacid
983969|NCT02097329|rabeprazole
983970|NCT02097329|famotidine
983971|NCT02097329|palbociclib
983972|NCT02097316|Glycemic control
983973|NCT02097316|JewelPump accuracy
983974|NCT02097303|Prostate Cancer
983975|NCT02097303|Bone Metastasis
983976|NCT02097303|Symptomatic
983977|NCT02097303|Androgen Independent
983978|NCT02097303|Hormone Refractory
983979|NCT02097303|Castrate Resistant
983980|NCT02097303|AIPC
983981|NCT02097303|pre-chemotherapy
983982|NCT02097303|Post-chemotherapy
983983|NCT02097290|Threshold algorithms
983984|NCT02097290|CRT-D
983985|NCT02097251|Mucopolysaccharidosis Type 7
983986|NCT02097251|Sly syndrome
983987|NCT02097251|UX003
983988|NCT02097251|Enzyme Replacement Therapy
983989|NCT02097251|rare disease
983990|NCT02097251|Lysosomal Storage Disease
983991|NCT02097251|metabolic disorder
983992|NCT02097212|Tracheobronchomalacia
983993|NCT02097212|TBM
983994|NCT02097212|HyperDynamic Airway Collapse
983995|NCT02097212|HDAC
983996|NCT02097212|Obstructive Sleep Apnea
983997|NCT02097212|OSA
983998|NCT02097199|activity, osteoprotegerin, endocan, atherosclerosis, biomarker
983999|NCT02097186|Vascular disease
984000|NCT02097186|Open aortic aneurysm repair
984001|NCT02097186|Endovascular aneurysm repair
984002|NCT02097186|Carotid endartrectomy
984003|NCT02097186|Lower limb surgical revascularisation
984004|NCT02097186|Major lower limb amputation
984005|NCT02097160|childhood
984006|NCT02097160|healthy
984007|NCT02097160|vitamin D
984008|NCT02097160|bone
984009|NCT02097160|dairy products
984010|NCT02097147|Viibryd
984011|NCT02097108|HIV infection
984012|NCT02097108|Raltegravir
984013|NCT02097108|Switch
984014|NCT02097108|Hyperlipidemia
984015|NCT02097108|Women
984016|NCT02097095|Correlates of risk
984017|NCT02097095|TB
984018|NCT02097095|Tuberculosis
984019|NCT02097095|Sub-study
984020|NCT02097095|TB-018
984021|NCT02097082|Peripheral Arterial Disease
984022|NCT02097082|Intermittent Claudication
984023|NCT02097082|Vascular Diseases
984025|NCT02097082|Superficial Femoral Artery
984026|NCT02097069|Gestational diabetes mellitus
984027|NCT02097069|Myo-inositol
984028|NCT02097069|D-chiro-inositol
984029|NCT02097069|Insulin resistance
984030|NCT02097056|Alzheimer's disease
984031|NCT02097017|lidocaine
984032|NCT02097017|laminaria
984033|NCT02097017|dilatation and evacuation
984034|NCT02097017|pain
984035|NCT02097004|chronic hepatitis B
984036|NCT02097004|Pegasys
984037|NCT02097004|Euvax B
984038|NCT02097004|Baracrude
984039|NCT02096978|Implant
984040|NCT02096978|Stability
984041|NCT02096978|placement
984042|NCT02096978|Osteotome
984043|NCT02096965|Calcium oxalate
984044|NCT02096965|Calcium phosphate
984045|NCT02096965|Kidney stone
984046|NCT02096952|Attention-deficit/hyperactivity disorder
984047|NCT02096952|ADHD
984048|NCT02096952|Autism spectrum disorder
984049|NCT02096952|ASD
984050|NCT02096952|High-functioning ASD
984051|NCT02096952|Asperger's disorder
984052|NCT02096952|Asperger's
984053|NCT02096926|Third Molar Extraction
984054|NCT02096913|Rho-Inhibition
984055|NCT02096913|Plasticity
984056|NCT02096913|Neurological Function
984057|NCT02096913|RhoA
984058|NCT02096913|Ibuprofen
984059|NCT02096913|NSAIDs
984060|NCT02096900|Pre-medication
984061|NCT02096900|Pre-operative anxiety
984062|NCT02096887|education
984063|NCT02096887|compliance
984064|NCT02096887|risk factors
984065|NCT02096874|Peripheral retinal ischemia
984066|NCT02096874|ultra wide field fluorescein angiography
984067|NCT02096874|Bevacizumab
984068|NCT02096848|otitis media
984069|NCT02096848|microbiology
984070|NCT02096848|vaccines
984071|NCT02096835|Postoperative nausea and vomiting
984072|NCT02096835|Transcutaneous electrical acupoint stimulation
984073|NCT02096835|Gynecological laparoscopic surgery
984074|NCT02096835|Tropisetron
984075|NCT02096835|Dexamethasone
984076|NCT02096822|Facilitated tucking
984077|NCT02096822|Non nutritive sucking
984078|NCT02096822|Preterm
984079|NCT02096822|Pain relief
984080|NCT02096809|Bone Conduction
984081|NCT02096809|Hearing loss - conductive
984082|NCT02096809|Osseointegration
984083|NCT02096809|Prostheses and Implants
984084|NCT02096757|Claudication
984085|NCT02096757|Critical Limb Ischemia
984086|NCT02096757|Endovascular procedure
984087|NCT02096757|Atherosclerosis
984088|NCT02096679|Phase I, healthy, pharmacokinetics, Mass balance
984089|NCT02096666|MET Amplified Gastric/ Gastroesophageal Junction/ Esophageal Adenocarcinomas, or other solid tumors
984090|NCT02096653|sacroiliac joint
984091|NCT02096653|low back pain
984092|NCT02096653|steroid injection
984093|NCT02096627|Cataract, femtosecond laser, FLACS
984094|NCT02096614|Adoptive cell transfer
984095|NCT02096614|Cell therapy
984096|NCT02096614|Immunotherapy
984097|NCT02096614|MAGE-A4
984098|NCT02096614|Esophageal cancer
984099|NCT02096614|Melanoma
984100|NCT02096614|Head and neck cancer
984101|NCT02096614|Ovarian cancer
984102|NCT02096614|TCR gene therapy
984103|NCT02096601|Motor fluctuations
984104|NCT02096601|levodopa pharmacokinetics
984105|NCT02096601|levodopa and carbidopa solution
984106|NCT02096601|continuous subcutaneous delivery
984107|NCT02096588|Breast cancer
984108|NCT02096588|Adriamycin
984109|NCT02096588|Simvastatin
984110|NCT02096588|Statin
984111|NCT02096588|Echocardiogram
984112|NCT02096575|nitrous oxide
984113|NCT02096575|pain
984114|NCT02096562|knee welling outpatient compression stockings
984120|NCT02096536|Neonate
984121|NCT02096536|Vancomycin
984122|NCT02096536|LC/MS-MS
984123|NCT02096536|protein binding
984124|NCT02096523|inherited platelet disorders
984125|NCT02096523|proteome
984126|NCT02096510|Addison Disease
984127|NCT02096510|Adrenal Hyperplasia Congenital
984128|NCT02096484|Metacognitive therapy
984129|NCT02096484|mindfulness meditation therapy
984130|NCT02096484|group therapy
984131|NCT02096484|generalized anxiety disorder
984132|NCT02096484|Group Based Metacognitive Therapy
984133|NCT02096484|Group Based Mindfulness Meditation Therapy
984134|NCT02096471|Neurofibromatosis Type 1 (Neurofibromas)
984135|NCT02096471|PD-0325901
984136|NCT02096471|Radiographic Response
984137|NCT02096471|Inoperable Plexiform Neurofibromas
984138|NCT02096458|Drug therapy
984139|NCT02096445|stroke
984140|NCT02096445|acute
984141|NCT02096445|rehabilitation
984142|NCT02096445|robot therapy
984143|NCT02096445|hand function
984144|NCT02096445|fine motor skills
984145|NCT02096445|neurocognitive
984146|NCT02096445|sensory
984147|NCT02096445|Perfetti
984148|NCT02096445|haptics
984149|NCT02096419|clopidogrel
984150|NCT02096419|platelet reactivity
984151|NCT02096419|acute coronary syndrome
984152|NCT02096419|tailoring therapy
984153|NCT02096419|outcome
984154|NCT02096406|Coronary artery disease
984155|NCT02096406|Coronary artery bypass grafting
984156|NCT02096406|angiotensin converting enzyme inhibitor
984157|NCT02096406|angiotensin receptor blocker
984158|NCT02096406|Surgical valve repair
984159|NCT02096406|Valve Replacement
984160|NCT02096380|Nasopharyngeal Carcinoma
984161|NCT02096380|cycle
984162|NCT02096380|induction chemotherapy
984163|NCT02096380|docetaxel
984164|NCT02096367|vibrations
984165|NCT02096367|stroke
984166|NCT02096367|posture
984167|NCT02096367|gait
984168|NCT02096367|readaptation
984169|NCT02096328|Ventilator Associated Pneumonia (VAP)
984170|NCT02096328|Lower respiratory infection
984171|NCT02096328|POL7080
984172|NCT02096328|Pseudomonas aeruginosa
984173|NCT02096328|Nosocomial pneumonia
984174|NCT02096315|POL7080
984175|NCT02096315|Pseudomonas aeruginosa
984176|NCT02096315|Non cystic fibrosis bronchiectasis
984177|NCT02096315|Exacerbation
984178|NCT02096302|Probiotics
984179|NCT02096302|Infant Formula
984180|NCT02096302|Microbiota
984181|NCT02096302|Bifidobacterium longum biovar infantis CECT7210
984182|NCT02096302|Growth
984183|NCT02096289|Relapsed Acute Myeloid Leukemia
984184|NCT02096289|Refractory Acute Myeloid Leukemia
984185|NCT02096289|Thioridazine
984186|NCT02096289|Phase I
984187|NCT02096289|Clinical Trial
984188|NCT02096276|Pregnancy Registry
984189|NCT02096276|Boostrix
984190|NCT02096276|Women
984191|NCT02096276|Cohort
984192|NCT02096276|Prospective
984193|NCT02096276|Pregnancy outcome
984194|NCT02096276|Exploratory
984195|NCT02096263|Healthy
984196|NCT02096263|Infanrix Hexa
984197|NCT02096263|Immunogenicity
984198|NCT02096263|Infants
984199|NCT02096263|Safety
984200|NCT02096237|asthma, bronchial
984201|NCT02096237|immunoadsorbents
984202|NCT02096237|apheresis
984203|NCT02096237|immunoglobulin E
984208|NCT02096198|Total Hip Replacement
984209|NCT02096198|Total Hip Arthroplasty
984210|NCT02096198|Hip Joint Replacement
984211|NCT02096198|Hip Prosthesis Replacement
984212|NCT02096185|Breast cancer
984213|NCT02096185|Surgery
984214|NCT02096185|Specimen imaging
984215|NCT02096159|Hypospadias
984216|NCT02096159|Anti-Bacterial Agents
984217|NCT02096146|Plate
984218|NCT02096146|Hallux valgus
984219|NCT02096146|Foot deformity
984220|NCT02096146|Screw
984221|NCT02096146|Tarsometatarsal angle
984222|NCT02096146|Cost effectiveness
984223|NCT02096133|Multiple sclerosis, vitamin D, HPA-axis, cortisol
984224|NCT02096120|Periodontitis
984225|NCT02096107|Everolimus
984226|NCT02096107|Graft dysfunction
984227|NCT02096107|Interstitial fibrosis
984228|NCT02096094|Antiseptics
984229|NCT02096094|Administration cutaneously
984230|NCT02096094|Chlorine compounds
984231|NCT02096094|Infection control
984232|NCT02096094|Anti-infecting agents, local
984233|NCT02096081|Glabellar Frown Lines
984234|NCT02096081|Frown Lines
984235|NCT02096081|Facial Wrinkles
984236|NCT02096068|Neuroprotection
984237|NCT02096055|Leukemia
984238|NCT02096055|Acute Myeloid Leukemia
984239|NCT02096055|AML
984240|NCT02096055|Elderly
984241|NCT02096055|SGI-110
984242|NCT02096055|Idarubicin
984243|NCT02096055|Idamycin
984244|NCT02096055|Leustatin
984245|NCT02096055|2-CdA
984246|NCT02096042|Leukemia
984247|NCT02096042|Acute Myeloid Leukemia
984248|NCT02096042|AML
984249|NCT02096042|CD30-Positive
984250|NCT02096042|Relapsed
984251|NCT02096042|Refractory
984252|NCT02096042|Brentuximab Vedotin
984253|NCT02096042|SGN-35
984254|NCT02096042|Adcetris
984255|NCT02096042|5-Azacytidine
984256|NCT02096042|Azacytidine
984257|NCT02096042|Azacitidine
984258|NCT02096042|5-aza
984259|NCT02096042|Vidaza
984260|NCT02096042|5-AZC
984261|NCT02096042|AZA-CR
984262|NCT02096042|Ladakamycin
984263|NCT02096042|NSC-102816
984264|NCT02096029|smoking
984265|NCT02096029|smoking cessation
984266|NCT02096029|nicotine replacement therapy
984267|NCT02096029|primary care
984268|NCT02096029|comparative effectiveness
984269|NCT02096016|Surveillance
984270|NCT02096016|Follow up
984271|NCT02096003|Intrathecal hydromorphone
984272|NCT02096003|Intrathecal morphine
984273|NCT02096003|Primary cesarean section
984274|NCT02096003|Analgesia
984275|NCT02095990|Facial Melasma
984276|NCT02095977|St. Jude Riata lead failure
984277|NCT02095977|implantable cardioverter-defibrillator (ICD)
984278|NCT02095977|externalized conductors
984279|NCT02095977|ventricular tachyarrythmia
984280|NCT02095977|electrophysiology
984281|NCT02095964|cardiac syndrome X
984282|NCT02095964|inflammation
984283|NCT02095964|dyslipidemia
984284|NCT02095938|schizophrenia
984285|NCT02095938|brain structure
984286|NCT02095938|treatment response
984287|NCT02095938|solian
984288|NCT02095938|gene
984289|NCT02095938|mri
984290|NCT02095912|Squamous Cell Carcinoma
984291|NCT02095899|Thoracic Surgical Procedures
984292|NCT02095873|Oral glucose tolerance test
984293|NCT02095873|Flow mediated dilatation
984294|NCT02095873|Aortal pulse wave velocity
984295|NCT02095873|Finger-fold capillary density by capillaroscopy
984296|NCT02095847|Uterine Cancer
984297|NCT02095847|Endometrial cancer
984298|NCT02095847|Hysterectomy
984299|NCT02095847|Hysteroscopy
984300|NCT02095847|High-resolution microendoscopy
984301|NCT02095847|HRME
984302|NCT02095847|Hysteroscopic-guided resection
984303|NCT02095847|Proflavine
984304|NCT02095834|Myeloma
984305|NCT02095834|Multiple Myeloma
984306|NCT02095834|Relapsed
984307|NCT02095834|Refractory
984308|NCT02095834|Carfilzomib
984309|NCT02095834|Bendamustine
984310|NCT02095834|Bendamustine Hydrochloride
984311|NCT02095834|Bendamustine HCL
984312|NCT02095834|CEP-18083
984313|NCT02095834|SDX-105
984314|NCT02095834|Treanda
984315|NCT02095834|Dexamethasone
984316|NCT02095834|Decadron
984317|NCT02095795|Exercise Therapy
984318|NCT02095782|non-small cell lung cancer
984319|NCT02095782|erlotinib
984320|NCT02095782|chemotherapy
984321|NCT02095769|Pharmacogenomics
984322|NCT02095769|Adverse Drug Reactions
984323|NCT02095743|Early breast cancer
984324|NCT02095743|Chemotherapy
984325|NCT02095743|PICC line
984326|NCT02095743|Implanted port
984327|NCT02095730|crosslinking
984328|NCT02095730|cornea
984329|NCT02095730|keratoconus
984330|NCT02095730|ectasia
984331|NCT02095730|irradiance
984332|NCT02095730|riboflavin
984333|NCT02095691|Renal Sympathetic Denervation
984334|NCT02095678|Hepatocellular Carcinoma
984335|NCT02095678|Hepatoma
984336|NCT02095678|Liver Cancer, Adult
984337|NCT02095678|Liver Cell Carcinoma
984338|NCT02095678|Liver Cell Carcinoma, Adult
984339|NCT02095678|HCC
984340|NCT02095665|ureteric stents
984341|NCT02095665|LUTS
984342|NCT02095665|lower urinary tract symptoms
984343|NCT02095587|Phase 1
984344|NCT02095587|hepatic impairment
984345|NCT02095574|GDC-0199
984346|NCT02095574|ADME
984347|NCT02095574|Relapsed
984348|NCT02095574|Refractory
984349|NCT02095574|ABT-199
984350|NCT02095574|Non-Hodgkin's Lymphoma
984351|NCT02095561|HPV self testing
984352|NCT02095561|screening uptake
984353|NCT02095561|cervical cáncer
984354|NCT02095561|cervical intraepithelial neoplasia
984355|NCT02095535|obstetric patients
984356|NCT02095535|chloraprep
984357|NCT02095535|chlorhexidine
984358|NCT02095535|drying time
984359|NCT02095522|colchicine NSTEMI endothelial function inflammation
984360|NCT02095496|sleep
984361|NCT02095496|intensive care
984362|NCT02095496|mechanical ventilation
984363|NCT02095470|Laryngoscopy
984364|NCT02095470|Equipment
984365|NCT02095470|Video Laryngoscope
984366|NCT02095457|Routine Outcome Monitoring
984367|NCT02095457|Psychotherapy
984368|NCT02095457|Alliance
984369|NCT02095457|Feedback Informed Treatment
984370|NCT02095457|Mental Health Outpatients
984371|NCT02095431|patients undergoing the liver transplantation
984372|NCT02095431|acute kidney injury
984373|NCT02095418|New-onset diabetes after transplantation (NODAT)
984374|NCT02095418|Liver transplantation
984375|NCT02095405|Supraventricular Tachycardia
984376|NCT02095405|Atrial Fibrillation
984377|NCT02095405|Electrophysiology Study
984378|NCT02095405|Programmed Electrical Stimulation
984379|NCT02095392|soluble phosphate
984380|NCT02095392|phosphorus metabolism
984381|NCT02095392|calcium metabolism
984382|NCT02095392|bone metabolism
984383|NCT02095392|human study
984384|NCT02095379|oligosecretary multiple myeloma
984385|NCT02095366|Acute Pain
984386|NCT02095366|Traumatic Pain
984387|NCT02095366|Emergency setting
984388|NCT02095366|Prehospital setting
984389|NCT02095366|Analgesia
984390|NCT02095366|Intranasal device
984391|NCT02095366|Intra veinous injection
984392|NCT02095366|Sufentanil citrate
984393|NCT02095366|Morphine Sulfate
984394|NCT02095353|Brain tumor
984395|NCT02095353|extraaxial
984396|NCT02095353|metastasis
984397|NCT02095353|glioma
984398|NCT02095353|primary brain tumor
984399|NCT02095353|secondary brain tumor
984400|NCT02095353|MRI
984401|NCT02095353|perfusion
984402|NCT02095353|dynamic contrast enhancement
984403|NCT02095353|CBV
984404|NCT02095353|CBF
984405|NCT02095353|ktrans
984406|NCT02095314|DTP-HB-Hib
984407|NCT02095314|Pentavalen
984408|NCT02095314|Pentabio
984409|NCT02095314|Booster
984410|NCT02095288|lipidomics
984411|NCT02095288|in vitro human whole blood assay
984412|NCT02095288|anti-inflammatory drugs
984413|NCT02095288|Lipidomics screening of anti-inflammatory drugs
984414|NCT02095275|BNP, acute kidney injury, fluid status
984415|NCT02095249|prostate cancer
984416|NCT02095249|radical prostatectomy
984417|NCT02095223|Knee injury
984418|NCT02095223|Meniscus injury
984419|NCT02095223|Anterior cruciate ligament injury
984420|NCT02095223|Knee ligament injury
984421|NCT02095210|PET scan
984422|NCT02095210|HER2
984423|NCT02095210|breast cancer
984424|NCT02095184|Breast Cancer
984425|NCT02095184|Postmenopausal
984426|NCT02095184|Hormone-Receptor Positive
984427|NCT02095119|Uterine cervical cancer
984428|NCT02095119|Palliative
984429|NCT02095119|Treatment
984430|NCT02095119|Monoclonal antibody
984431|NCT02095119|Nimotuzumab
984432|NCT02095106|forearm fractures
984433|NCT02095106|pediatric fractures
984434|NCT02095106|distal radius
984435|NCT02095093|Total Hip Arthroplasty
984436|NCT02095093|Navigation
984437|NCT02095093|Imageless
984438|NCT02095093|THA
984439|NCT02095093|Computer navigated
984440|NCT02095080|Leucine
984441|NCT02095080|Upper Intake Level (UL)
984442|NCT02095080|Elderly
984443|NCT02095080|Amino acids
984444|NCT02095080|Protein
984445|NCT02095067|Telemedicine
984446|NCT02095067|Emergency medical dispatch
984447|NCT02095067|Prehospital care
984448|NCT02095067|Video conference
984449|NCT02095054|Advanced Cancers
984450|NCT02095054|Advanced malignancy
984451|NCT02095054|Metastatic cancer
984452|NCT02095054|Advanced solid tumor
984453|NCT02095054|Regorafenib
984454|NCT02095054|Stivarga
984455|NCT02095054|Cetuximab
984456|NCT02095054|C225
984457|NCT02095054|Erbitux
984458|NCT02095054|IMC-C225
984459|NCT02095054|MOAB C225
984460|NCT02095054|Questionnaire
984461|NCT02095054|Survey
984462|NCT02095041|Oxygen saturation.
984463|NCT02095041|Term infants.
984464|NCT02095041|Saturation trend.
984465|NCT02095041|Histogram.
984466|NCT02095041|Public health nurse.
984467|NCT02095041|congenital heart disease screening.
984468|NCT02095015|MPS
984469|NCT02095015|Mucopolysaccharidosis
984470|NCT02095015|MPS I
984471|NCT02095015|Mucopolysaccharidosis I
984472|NCT02095015|Hurler, Hurler-Scheie, or Scheie syndrome
984473|NCT02095015|MPS II
984474|NCT02095015|Mucopolysaccharidosis II
984475|NCT02095015|Hunter syndrome
984476|NCT02095015|MPS VI
984477|NCT02095015|Mucopolysaccharidosis VI
984478|NCT02095015|Maroteaux-Lamy syndrome
984479|NCT02095015|iduronate-2-sulfatase
984480|NCT02095015|ENT
984481|NCT02095015|ear, nose and throat
984482|NCT02095002|modified valsalva maneuver, internal jugular vein
984483|NCT02094989|electrocardiogram
984484|NCT02094989|vectorcardiogram
984485|NCT02094989|telecardiology
984486|NCT02094989|linear regression
984487|NCT02094989|individual transformation matrix
984488|NCT02094989|posture
984489|NCT02094976|Prone position
984490|NCT02094976|Intra-abdominal pressure
984491|NCT02094976|Respiratory system compliance
984492|NCT02094976|Jackson table
984493|NCT02094976|Wilson frame
984494|NCT02094976|Chest roll
984498|NCT02094950|concurrent chemotherapy
984499|NCT02094950|concurrent radiation
984500|NCT02094937|fluticasone propionate
984501|NCT02094937|step-down regimen
984502|NCT02094937|well-controlled subjects
984503|NCT02094937|adults
984504|NCT02094937|switching regimen
984505|NCT02094937|asthma
984506|NCT02094937|fluticasone furoate
984507|NCT02094937|fluticasone furoate/Vilanterol
984508|NCT02094924|Candesartan cilexetil
984509|NCT02094924|Hypertension
984510|NCT02094924|Hydrochlorothiazide
984511|NCT02094924|Healthy adult human subjects
984512|NCT02094924|Bioequivalence
984513|NCT02094911|Prevention
984514|NCT02094911|Combined lifestyle intervention
984515|NCT02094911|Primary health care
984516|NCT02094898|Depression
984517|NCT02094898|Unipolar
984518|NCT02094898|Bipolar
984519|NCT02094898|Suicidal
984520|NCT02094859|Glucose Monitoring
984521|NCT02094846|Cellular phones
984522|NCT02094846|Type 2 diabetes
984523|NCT02094846|Glycated hemoglobin
984524|NCT02094846|glycemic control
984525|NCT02094833|Diphtheria
984526|NCT02094833|Tetanus
984527|NCT02094833|Pertussis
984528|NCT02094833|Haemophilus influenzae type b infection
984529|NCT02094833|Hepatitis B
984530|NCT02094833|DTaP-IPV-Hep - PRP-T vaccine
984531|NCT02094807|prospective study
984532|NCT02094807|surgical management
984533|NCT02094807|rib fractures
984534|NCT02094807|trauma
984535|NCT02094755|critical limb ischemia, High on-treatment platelet reactivity, HPR, aspirin, clopidogrel
984536|NCT02094742|screening program
984537|NCT02094742|metastatic breast cancer
984538|NCT02094742|molecular profile
984539|NCT02094742|gene sequencing
984540|NCT02094729|mild cognitive impairment
984541|NCT02094729|Alzheimer's disease
984542|NCT02094716|Sarcoptes
984543|NCT02094716|Scabiei
984544|NCT02094716|Scabies
984545|NCT02094716|ectoparasite
984546|NCT02094716|parasite
984547|NCT02094716|infestation
984548|NCT02094716|Renaissance
984549|NCT02094703|female
984550|NCT02094703|age 18-65 years
984551|NCT02094703|storage symptoms
984552|NCT02094703|clinical urinary tract infection
984553|NCT02094703|non complicated
984554|NCT02094690|head and neck neoplasms
984555|NCT02094690|radiotherapy
984556|NCT02094690|physical therapy
984557|NCT02094690|trismus
984558|NCT02094664|Heat
984559|NCT02094664|Humidification
984560|NCT02094664|Oxygen
984561|NCT02094651|Abnormal EEGs
984562|NCT02094638|Traditional Chinese Medicine Injection
984563|NCT02094625|Cisplatin
984564|NCT02094625|N-acetylcysteine
984565|NCT02094625|Hearing Loss
984566|NCT02094625|Otoprotection
984567|NCT02094612|Attention Deficit and Disruptive Behavior Disorders
984568|NCT02094612|Attention Deficit Disorder with Hyperactivity
984569|NCT02094612|Pediatrics
984570|NCT02094612|Patient Outcome Assessment
984571|NCT02094573|Non-small cell lung cancer
984572|NCT02094573|Non-small cell lung carcinoma
984573|NCT02094573|Epithelial lung cancer
984574|NCT02094573|Squamous cell carcinoma
984575|NCT02094573|Large cell carcinoma
984576|NCT02094573|Adenocarcinoma
984577|NCT02094573|Anaplastic lymphoma kinase (ALK)
984578|NCT02094573|Advanced Malignancies
984579|NCT02094573|Carcinoma
984580|NCT02094573|Advanced Cancers
984581|NCT02094573|AP26113
984582|NCT02094560|therapy refractory
984583|NCT02094560|endstage
984584|NCT02094560|solid tumours
984585|NCT02094547|Infant Formula
984586|NCT02094547|Cognition
984587|NCT02094547|Neurodevelopment
984588|NCT02094547|Immunity
984589|NCT02094547|Microbiota
984590|NCT02094534|Diabetes type 1
984591|NCT02094534|Oral Insulin
984592|NCT02094534|Safety
984593|NCT02094534|Tolerability
984594|NCT02094534|Phase 2a
984595|NCT02094534|Randomized
984596|NCT02094534|Blinded
984597|NCT02094534|Parallel
984598|NCT02094508|Parasitemia
984599|NCT02094508|HIV-Exposed
984600|NCT02094508|HIV-Unexposed
984601|NCT02094508|Liver Stage
984602|NCT02094508|Randomized
984603|NCT02094495|Tamoxifen
984604|NCT02094495|Breast cancer
984605|NCT02094495|Knowkedge
984606|NCT02094469|Treatment for vasospastic angina
984607|NCT02094456|diverticular disease
984608|NCT02094456|diverticular bleeding
984609|NCT02094456|endoscopic clipping
984610|NCT02094456|endoscopy
984611|NCT02094456|lower gastrointestinal bleeding
984612|NCT02094443|Chronic hepatitis C genotype 2
984613|NCT02094443|Chronic hepatitis C genotype 3
984614|NCT02094443|Cyclophilin inhibitor
984615|NCT02094443|Interferon intolerant
984616|NCT02094417|Anemia, Aplastic
984617|NCT02094417|Thrombopoietin
984618|NCT02094417|Thrombocytopenia
984619|NCT02094404|Emergency Department
984620|NCT02094404|Pediatric Early Warning Score
984621|NCT02094404|Manchester Triage System
984622|NCT02094378|Healthy
984623|NCT02094378|Esketamine
984624|NCT02094378|Cognitive functioning
984625|NCT02094352|Complex Regional Pain Syndrome
984626|NCT02094352|Pain management
984627|NCT02094352|Ketamine infusion
984628|NCT02094339|Local analgesia system
984629|NCT02094339|Ropivacaine
984630|NCT02094339|Analgesic efficacy after operation
984631|NCT02094339|Postoperative
984632|NCT02094313|Atorvastatin
984633|NCT02094313|Human Spermatozoa
984634|NCT02094313|Seminal fluid
984635|NCT02094313|Accessory Glands
984636|NCT02094313|Cholesterol
984637|NCT02094313|Gonadotropins,
984638|NCT02094313|Testosterone
984639|NCT02094300|Aorta
984640|NCT02094300|Thoracic
984641|NCT02094300|Aortic dissection
984642|NCT02094300|Rupture
984643|NCT02094300|Type B
984644|NCT02094300|DeBakey type III
984645|NCT02094300|Endovascular
984646|NCT02094261|Phase II, open label study; safety and efficacy of AZD9291; diagnosis of Epidermal Growth Factor Receptor mutation positive and T790M mutation positive NSCLC
984647|NCT02094235|Dermatitis
984648|NCT02094235|Atopic
984649|NCT02094235|Pediatric
984650|NCT02094235|Adolescent
984651|NCT02094235|Child
984652|NCT02094209|External Fixation
984653|NCT02094209|Tibial fracture
984654|NCT02094209|Fracture healing
984655|NCT02094196|Reward- based learning
984656|NCT02094196|Pavlovian-to-instrumental transfer
984657|NCT02094196|Relapse Risk
984658|NCT02094196|Positron emission tomography (PET)
984659|NCT02094196|Magnetic resonance spectroscopy (MRS)
984660|NCT02094196|Dopamine receptor availability
984661|NCT02094196|Glutamate
984662|NCT02094157|Atrial fibrillation
984663|NCT02094157|Mechanical heart valve
984664|NCT02094157|Stroke
984665|NCT02094157|Venous thromboembolism
984666|NCT02094157|Hemorrhage
984667|NCT02094144|Sedentary
984668|NCT02094144|Physical activity
984669|NCT02094144|Brisk walking
984670|NCT02094144|Postmenopausal women
984671|NCT02094144|Body composition
984672|NCT02094144|Balance
984673|NCT02094144|Muscle strength
984674|NCT02094144|Depression, bone density
984675|NCT02094144|Nutrition
984676|NCT02094144|Biological effects
984677|NCT02094131|incentive spirometry
984678|NCT02094131|flow-oriented spirometer
984679|NCT02094131|volume-oriented spirometer
984680|NCT02094131|physical therapy
984681|NCT02094131|respiratory muscle training
984682|NCT02094118|Transfusion
984683|NCT02094118|RBC
984684|NCT02094118|cardiac
984685|NCT02094118|surgery
984686|NCT02094118|transfusion related acute lung injury (TRALI)
984687|NCT02094118|transfusion associated circulatory overload (TACO)
984688|NCT02094105|esophageal cancer
984689|NCT02094105|screening
984690|NCT02094105|endoscopy
984691|NCT02094105|prevention
984692|NCT02094092|L.reuteri ProTectis DSM 17938
984693|NCT02094092|Infantile colic
984694|NCT02094092|Maternal mental health.
984695|NCT02094092|Infant crying/fussing
984696|NCT02094092|Edinburgh Postnatal Depression Scale (EPDS)
984697|NCT02094079|hypothyroidism
984698|NCT02094079|pregnancy
984699|NCT02094066|tranexamic acid
984700|NCT02094066|total hip arthroplasty
984701|NCT02094053|Down syndrome
984702|NCT02094053|regression symptoms
984703|NCT02094053|disabled activities of daily living
984704|NCT02094040|frailty
984705|NCT02094040|readmission
984706|NCT02094040|transition
984707|NCT02094040|discharge
984708|NCT02094040|primary care
984709|NCT02094027|Obesity
984710|NCT02094027|Bariatric surgery
984711|NCT02094027|Binge eating
984712|NCT02094027|Self help
984713|NCT02094014|Perceptual masking
984714|NCT02094014|Auditory stimulation
984715|NCT02094014|Speech
984716|NCT02094014|Language
984717|NCT02094014|Verbal Fluency Disorders
984718|NCT02093962|TH-302
984719|NCT02093962|TH-CR-415
984720|NCT02093962|Pemetrexed
984721|NCT02093962|Non-small cell lung cancer
984722|NCT02093962|Lung cancer
984723|NCT02093962|Evofosfamide
984724|NCT02093936|airway inflammation
984725|NCT02093936|induced sputum
984726|NCT02093936|normal values
984727|NCT02093936|lymphocyte
984728|NCT02093936|eosinophil
984729|NCT02093936|neutrophil
984730|NCT02093923|HAE
984731|NCT02093910|multiple myeloma
984732|NCT02093910|peripheral neuropathy
984733|NCT02093910|prophylaxis
984734|NCT02093884|Pregnancy
984735|NCT02093884|Pregnancy, unplanned
984736|NCT02093884|Reproductive behavior
984737|NCT02093884|Pregnancy in Adolescence
984738|NCT02093884|Text messaging
984739|NCT02093871|Ovarian cancer
984740|NCT02093871|Therapeutic hyperthermia
984741|NCT02093871|HEATT
984742|NCT02093871|whole body hyperthermia
984743|NCT02093871|hyperthermia
984744|NCT02093871|PISH
984745|NCT02093871|Verthermia
984746|NCT02093871|Phase 1 clinical trial
984747|NCT02093871|stage 3 ovarian cancer
984748|NCT02093871|stage 4 ovarian cancer
984749|NCT02093871|stage III ovarian cancer
984750|NCT02093871|stage IV ovarian cancer
984751|NCT02093871|late stage ovarian cancer
984752|NCT02093871|Core HFC
984753|NCT02093871|Lilja
984754|NCT02093871|Vertrees
984755|NCT02093871|Bastidas
984756|NCT02093871|total body hyperthermia
984757|NCT02093858|Metabolic Syndrome
984758|NCT02093845|Percutaneous coronary intervention
984759|NCT02093845|DES
984760|NCT02093845|Angina pectoris
984761|NCT02093845|Stent
984762|NCT02093832|femoral head size
984763|NCT02093832|cup size
984764|NCT02093832|Total hip arthroplasty
984765|NCT02093767|prebiotics
984766|NCT02093767|Synergy1
984767|NCT02093728|Phase I, healthy, pharmacokinetics
984768|NCT02093715|Bronchiolitis
984769|NCT02093715|FeNO
984770|NCT02093715|Asthma
984771|NCT02093715|wheezing, RSV
984772|NCT02093676|diabetes
984773|NCT02093676|type 1
984774|NCT02093676|adolescents
984775|NCT02093676|parents counselling
984776|NCT02093663|Mild
984777|NCT02093663|Moderate
984778|NCT02093650|Menopausal symptoms
984779|NCT02093650|menopause related quality of life
984780|NCT02093650|black cohosh
984781|NCT02093650|cimicifuga racemosa
984782|NCT02093650|MENQOL
984783|NCT02093650|Kupperman index
984784|NCT02093650|KI
984785|NCT02093650|liver function tests
984786|NCT02093598|pharmacokinetic
984787|NCT02093598|pharmacodynamic
984788|NCT02093598|Carcinoma, Endometrioid
984789|NCT02093598|mTOR protein
984790|NCT02093598|temsirolimus
984791|NCT02093598|torisel
984792|NCT02093598|biological marker
984793|NCT02093598|phase II
984794|NCT02093585|HIV-1
984795|NCT02093585|Abacavir
984796|NCT02093585|Platelet activation
984797|NCT02093585|Thromboelastography
984798|NCT02093585|Coagulation
984799|NCT02093572|Clock genes
984800|NCT02093572|Metabolism
984801|NCT02093572|Insulin sensitivity
984802|NCT02093559|Clinical Trial
984803|NCT02093559|Naloxone
984804|NCT02093559|Motivational Interviewing
984805|NCT02093546|Endometrial cancer
984806|NCT02093546|Endometrioid adenocarcinoma
984807|NCT02093546|Serous adenocarcinoma
984808|NCT02093546|Undifferentiated carcinoma
984809|NCT02093546|Mixed epithelial carcinoma
984810|NCT02093546|Adenocarcinoma not otherwise specified
984811|NCT02093546|NOS
984812|NCT02093546|Companion Protocol to GOG229O
984813|NCT02093546|Biomarkers
984814|NCT02093546|Circulating tumor cells
984815|NCT02093546|CTCs
984816|NCT02093546|Blood draw
984817|NCT02093546|Biopsy
984818|NCT02093533|Membranoproliferative glomerulonephritis
984819|NCT02093533|Nephrotic syndrome
984820|NCT02093533|Proteinuria
984821|NCT02093533|Alternative complement pathway
984822|NCT02093533|Complement inhibition
984823|NCT02093533|Eculizumab
984824|NCT02093520|Lumbar Spinal Stenosis
984825|NCT02093520|Spinal Stenosis
984826|NCT02093520|Neurogenic Claudication
984827|NCT02093507|newborn
984828|NCT02093507|foot deformity congenital
984829|NCT02093494|Septicemia
984830|NCT02093494|Blood culture
984831|NCT02093494|Contamination
984832|NCT02093468|Acute limb ischemia
984833|NCT02093468|ALI
984834|NCT02093468|Acute lower extremity arterial occlusion
984835|NCT02093455|Endothelial function
984836|NCT02093416|Obesity
984837|NCT02093416|Leptin
984838|NCT02093403|AML
984839|NCT02093403|Acute Myeloid Leukemia
984840|NCT02093403|Adult Acute Myeloid Leukemia with T(8;21)(Q22;Q22)
984841|NCT02093403|adult Acute Myeloid Leukemia with 11q23 (MLL) abnormalities
984842|NCT02093403|adult Acute Myeloid Leukemia with del(5q)
984843|NCT02093403|adult Acute Myeloid Leukemia with inv(16)(p13;q22)
984844|NCT02093377|acute myocardial infarction
984845|NCT02093377|sleep apnea
984846|NCT02093377|adaptive servo-ventilation
984847|NCT02093351|oncology, cancer, tumour, neoplasm, anticancer drug, pharmacokinetics, olaparib, anastrozole, tamoxifen, letrozole,
984848|NCT02093338|breast pain
984849|NCT02093338|probiotic
984850|NCT02093338|mastitis
984851|NCT02093338|lactobacillus fermentun
984852|NCT02093338|Staphylococcus
984853|NCT02093325|eltrombopag , thrombocytopenia, gynecologic cancer
984854|NCT02093312|Cancer
984855|NCT02093312|Food-delivery
984856|NCT02093312|Nutritional Intervention
984857|NCT02093312|Quality of life
984858|NCT02093312|Outpatients
984859|NCT02093286|Pentabio Vaccine
984860|NCT02093286|Safety
984861|NCT02093286|Infants
984862|NCT02093286|Booster Dose
984863|NCT02093286|DTwP/HepB/Hib
984864|NCT02093273|tOPV
984865|NCT02093273|Antibody response
984866|NCT02093273|Safety
984867|NCT02093260|Flubio Vaccine (Influenza HA)
984868|NCT02093260|Infants
984869|NCT02093260|Children
984870|NCT02093260|Safety
984871|NCT02093260|Immunogenicity
984872|NCT02093234|self care of diabetes type 2 patients
984873|NCT02093234|mobile health cell phone application impact on health
984874|NCT02093234|community health workers impact on health
984875|NCT02093221|Type 1 Diabetes Mellitus
984876|NCT02093221|Alpha1-Proteinase Inhibitor
984877|NCT02093221|Beta Cell
984878|NCT02093221|Alpha1-Antitrypsin
984879|NCT02093195|Treatment, COPD, bosentan
984880|NCT02093156|bowel preparation
984881|NCT02093156|Ottawa Score
984882|NCT02093143|Diagnostic panendoscopy of the upper airway
984883|NCT02093143|Total intravenous general anesthesia
984884|NCT02093143|Remifentanil
984885|NCT02093143|Propofol
984886|NCT02093143|Target controlled infusion
984887|NCT02093143|Direct laryngoscopy
984888|NCT02093143|Tracheoscopy
984889|NCT02093143|Oesophagoscopy
984890|NCT02093143|Ear Nose and Throat (ENT) tumor
984891|NCT02093143|Ear Nose and Throat (ENT) cancer
984892|NCT02093130|Double-blind Trial
984893|NCT02093130|Placebo-controlled
984894|NCT02093130|Pomegranate
984895|NCT02093130|Memory
984896|NCT02093130|Memory Impairment
984897|NCT02093130|Cognition
984898|NCT02093130|Ages 50-75
984899|NCT02093117|Supratentorial neurosurgery
984900|NCT02093117|Recruitment maneuver
984901|NCT02093117|Subdural pressure
984902|NCT02093117|Brain relaxation
984903|NCT02093117|Cerebral perfusion pressure
984904|NCT02093104|unresectable hepatocellular carcinoma
984905|NCT02093104|(undergoing chemoembolization and radioembolization)
984906|NCT02093091|nano-filled resin modified glass ionomer
984907|NCT02093091|clinical performance
984908|NCT02093091|class I
984909|NCT02093091|primary teeth
984910|NCT02093091|dentin bond strength
984911|NCT02093091|Filling of class I
984912|NCT02093065|severe hemophilia A
984913|NCT02093065|coated platelets
984914|NCT02093065|bleeding
984915|NCT02093052|Parenting
984916|NCT02093052|Parent child relations
984917|NCT02093052|Middle childhood outcomes
984918|NCT02093039|breast cancer screening
984919|NCT02093039|patient decision aids
984920|NCT02093039|informed decision
984921|NCT02093039|empowerment
984922|NCT02093039|randomized control trial
984923|NCT02093039|From 50 to 74 years old
984924|NCT02093039|invited to national breast cancer screening
984925|NCT02093013|asthma
984926|NCT02093013|intervention
984927|NCT02093013|medication adherence
984928|NCT02093013|inhaled corticosteroids
984929|NCT02093013|asthma control
984930|NCT02093013|integrated care
984931|NCT02092987|Hispanic
984932|NCT02092987|Dementia
984933|NCT02092987|Caregivers
984934|NCT02092987|Depressive symptoms
984935|NCT02092987|Burden
984936|NCT02092987|Pragmatic randomized trial
984937|NCT02092974|transcranial direct current stimulation (tDCS)
984938|NCT02092974|selective serotonin reuptake inhibitor (SSRI)
984939|NCT02092974|young
984940|NCT02092974|older adults
984941|NCT02092961|Rheumatoid Arthritis
984942|NCT02092961|OSKIRA
984943|NCT02092961|fostamatinib
984944|NCT02092961|CE-MRI
984945|NCT02092961|DCE-MRI
984946|NCT02092948|metastatic
984947|NCT02092948|PSCA
984948|NCT02092948|minibody
984949|NCT02092948|PET/CT
984950|NCT02092935|CDAD
984951|NCT02092935|Clostridium Difficile
984952|NCT02092896|Diabetes Mellitus
984953|NCT02092896|Diabetes Mellitus, Type 1
984954|NCT02092896|Glucose Metabolism Disorders
984955|NCT02092896|Metabolic Diseases
984956|NCT02092896|Cognitive performance
984957|NCT02092896|Hypoglycemia
984958|NCT02092896|Insulin
984959|NCT02092896|Glucagon-Like Peptide 1
984960|NCT02092896|Hypoglycemic Agents
984961|NCT02092896|Physiological Effects of Drugs
984962|NCT02092896|Pharmacologic Actions
984963|NCT02092896|Incretins
984964|NCT02092896|Hormones
984965|NCT02092883|Infantile Spasms
984966|NCT02092883|Neuroinflammation
984967|NCT02092883|PK11195
984968|NCT02092883|PET
984969|NCT02092883|ACTH
984970|NCT02092870|Chronic Wounds
984971|NCT02092870|Diabetes
984972|NCT02092870|Adipose Derived Stem Cells
984973|NCT02092870|Diabetic Foot
984974|NCT02092857|nutrient
984975|NCT02092857|nutrition
984976|NCT02092857|arachidonic acid
984977|NCT02092857|essential fatty acids
984978|NCT02092844|Menopause
984979|NCT02092844|Insomnia
984980|NCT02092844|Hot Flashes
984981|NCT02092805|VAS
984982|NCT02092805|VDS
984983|NCT02092805|HAM-D
984984|NCT02092805|Visceral pain
984985|NCT02092805|Malignancy
984986|NCT02092805|rTMS
984987|NCT02092805|Motor cortex
984988|NCT02092805|Analgesia
984989|NCT02092805|Dynorphin
984990|NCT02092766|malaria
984991|NCT02092766|anaemia
984992|NCT02092766|artesunate
984993|NCT02092753|Ketogenic diet, logi diet, breast cancer, rehabilitation
984994|NCT02092740|Testicular cancer
984995|NCT02092727|Dialysis facilities
984996|NCT02092727|African Americans
984997|NCT02092727|Racial disparity
984998|NCT02092727|Kidney Transplantation
984999|NCT02092727|Community-based Participatory Research
985000|NCT02092727|Coalition
985001|NCT02092727|Georgia
985002|NCT02092688|time to delivery
985003|NCT02092688|PROM
985004|NCT02092688|PTL
985005|NCT02092688|positive predictive value
985006|NCT02092675|Chronic obstructive pulmonary disease
985007|NCT02092675|frequent exacerbator
985008|NCT02092675|endothelial dysfunction
985009|NCT02092675|Flow mediated dilatation
985010|NCT02092675|Systemic inflammation
985011|NCT02092649|Omega-3
985012|NCT02092649|Resting metabolic rate
985013|NCT02092649|Eicosapentaenoic acid
985014|NCT02092649|Docosahexaenoic acid
985015|NCT02092636|Hybrid NIR/US imaging technique
985016|NCT02092636|NIR/US imaging
985017|NCT02092636|US imaging
985018|NCT02092636|US imaging technique
985019|NCT02092623|Female
985020|NCT02092623|Prolapse surgery with transvaginal mesh
985021|NCT02092623|Subjective outcome
985022|NCT02092584|atherosclerotic
985023|NCT02092584|IGF-1
985024|NCT02092584|IGFBP-3
985025|NCT02092558|metaplasia, dysfunction, urinary bladder, children
985026|NCT02092545|Obesity
985027|NCT02092519|EUSFNA
985028|NCT02092519|endoscopic ultrasound
985029|NCT02092519|pancreatic masses
985030|NCT02092506|H pylori
985031|NCT02092506|therapy
985032|NCT02092493|ScopeGuide
985033|NCT02092493|Colonoscopy
985034|NCT02092493|Mental workload
985035|NCT02092480|Feasibility Trial
985036|NCT02092480|Educational Intervention
985037|NCT02092480|Teenage Pregnancy
985038|NCT02092480|Boys
985039|NCT02092480|Gender sensitive interventions
985040|NCT02092480|Unintended pregnancy
985041|NCT02092480|Parents
985042|NCT02092480|Process evaluation
985043|NCT02092480|Economic costing
985044|NCT02092467|Post-marketing
985045|NCT02092467|Phase 4
985046|NCT02092467|Open-label
985047|NCT02092467|Safety Surveillance
985048|NCT02092467|CP690550
985049|NCT02092467|Xeljanz
985050|NCT02092467|oral treatment
985051|NCT02092441|Nausea
985052|NCT02092441|Vomiting
985053|NCT02092441|Antiemetic
985054|NCT02092428|Coronary Magnetic Resonance Imaging
985055|NCT02092428|CAD
985056|NCT02092428|Coronary Magnetic Resonance Angiography
985057|NCT02092428|MRA
985058|NCT02092428|3 Tesla MRI
985059|NCT02092415|Tourniquet
985060|NCT02092415|Muscle perfusion
985061|NCT02092415|Contrast ultrasound
985062|NCT02092402|Fecal transplantation
985063|NCT02092402|microbiota transplantation
985064|NCT02092402|irritable bowel syndrome
985065|NCT02092402|IBS
985066|NCT02092389|Ulcerative Colitis
985067|NCT02092389|Inflammatory Bowel Syndrome
985068|NCT02092389|Adalimumab
985069|NCT02092389|Tumor necrosis factor (TNF) alpha Antibody
985070|NCT02092389|Calprotectin
985071|NCT02092376|Bariatric surgery
985072|NCT02092376|vitamin D
985073|NCT02092376|supplementation
985074|NCT02092363|Platinum-Sensitive Ovarian Cancer
985075|NCT02092337|CAST, Hearing aids, Speech recognition, Cochlear implants
985076|NCT02092311|varicocele
985077|NCT02092311|varicocelectomy
985078|NCT02092311|complications of varicocelectomy
985079|NCT02092311|Recurrence of varicocele
985080|NCT02092311|Post-varicocelectomy testicular atrophy
985081|NCT02092311|Post-varicocelectomy hydrocele
985082|NCT02092298|Gastrointestinal cancer
985083|NCT02092298|Hyperthermic Intraperitoneal Chemoperfusion
985084|NCT02092298|HIPEC
985085|NCT02092298|Gastric carcinomatosis
985086|NCT02092298|Gastroesophageal cancer
985087|NCT02092298|Mitomycin C
985088|NCT02092298|Mitomycin
985089|NCT02092298|Cisplatin
985090|NCT02092298|Platinol-AQ
985091|NCT02092298|Platinol
985092|NCT02092298|CDDP
985093|NCT02092298|Sodium Thiosulfate
985094|NCT02092298|Tinver
985095|NCT02092233|ARIES HSV 1&2
985096|NCT02092220|Bionic Pancreas
985097|NCT02092220|Insulin
985098|NCT02092220|Glucagon
985099|NCT02092220|Continuous Glucose Monitor
985100|NCT02092194|beta 2-Microglobulin
985101|NCT02092194|Hemodiafiltration
985102|NCT02092194|convective volume
985103|NCT02092168|Opicapone
985104|NCT02092168|BIAL
985105|NCT02092142|Q fever
985106|NCT02092142|Coxiella burnetii
985107|NCT02092129|Acromegaly, surgery, histopathology, hyperprolactinaemia,
985108|NCT02092103|Premature Birth
985109|NCT02092103|Umbilical Cord Clamping
985110|NCT02092090|salt substitute
985111|NCT02092090|sodium reduction
985112|NCT02092090|stroke
985113|NCT02092090|cluster randomized trial
985114|NCT02092090|China
985115|NCT02092077|Growth Hormone-Deficient
985116|NCT02092077|recombinant human growth hormone
985117|NCT02092064|basal proteinuria
985118|NCT02092064|FMF
985119|NCT02092064|pregnancy
985120|NCT02092051|Continuous glucose monitoring
985121|NCT02092051|Type 1 diabetes
985122|NCT02092051|Insulin injections
985123|NCT02092051|Cross-over
985124|NCT02092038|glioblastoma
985125|NCT02092038|temozolomide
985126|NCT02092038|radiation therapy
985127|NCT02092038|radiotherapy
985128|NCT02092038|surgery
985129|NCT02092038|pre-operative
985130|NCT02092038|neoadjuvant
985131|NCT02092025|Pharmacological therapy
985132|NCT02092012|postoperative pain
985133|NCT02092012|dexketoprofen trometamol
985134|NCT02092012|dexmedetomidine
985143|NCT02091986|asthma, children, budesonide pMDI
985144|NCT02091973|everolimus
985145|NCT02091973|tacrolimus
985146|NCT02091973|kidney transplantation
985147|NCT02091973|microRNA
985154|NCT02091947|FMS
985155|NCT02091947|Urine incontinence
985156|NCT02091934|Alcon
985157|NCT02091934|Wavelight
985158|NCT02091934|PRK
985159|NCT02091934|Wavefront-guided
985160|NCT02091934|Wavefront-optimized
985161|NCT02091934|Myopia
985162|NCT02091934|Astigmatism
985163|NCT02091921|Critical Limb Ischemia, ticagrelor, Brilinta
985164|NCT02091908|Influenza
985165|NCT02091908|H5N1
985166|NCT02091908|aH5N1
985167|NCT02091908|H5N1 vaccine
985168|NCT02091908|Pandemic Influenza vaccine
985169|NCT02091908|MF59, Adjuvant, Avian flu
985170|NCT02091908|Underlying medical conditions
985171|NCT02091908|Underlying cardiovascular medical condition
985172|NCT02091908|Pandemic vaccine
985173|NCT02091908|Charlson Comorbidity Index (CCI)
985174|NCT02091908|Adjuvanted vaccine
985175|NCT02091895|probe-based confocal laser endomicroscopy, lower gastrointestinal disorders
985176|NCT02091882|OPC-14597 Digital
985177|NCT02091882|Aripiprazole
985178|NCT02091882|Medical Information Device #1 System (MIND1)
985179|NCT02091882|Ingestible Event Marker
985180|NCT02091869|Adolescents
985181|NCT02091869|Asthma
985182|NCT02091869|Asthma Symptoms
985183|NCT02091817|oxytocin
985184|NCT02091817|face
985185|NCT02091817|memory
985186|NCT02091804|Attachment theory
985187|NCT02091804|Parent- child relationship
985188|NCT02091804|Child mental health
985189|NCT02091804|Behavioral health
985190|NCT02091791|acute lumbar sciatica, lumbar traction, traction force, radicular pain, lumbar functional parameters, disc herniation
985191|NCT02091765|Sexual dysfunction.
985192|NCT02091765|Intimacy problems.
985193|NCT02091765|Breast cancer survivors.
985194|NCT02091765|Internet-based.
985195|NCT02091765|Cognitive behavioral therapy.
985196|NCT02091752|Primary Myelofibrosis
985197|NCT02091752|Hematologic Diseases
985198|NCT02091752|Myeloproliferative Disorders
985199|NCT02091752|INC424
985200|NCT02091752|Ruxolitinib
985201|NCT02091726|Circumcision
985202|NCT02091726|HIV prevention
985203|NCT02091726|Surgical device
985204|NCT02091726|Cyanoacrylate
985205|NCT02091726|Tissue Adhesive
985206|NCT02091726|voluntary
985207|NCT02091713|FMS
985208|NCT02091713|functional movement screen
985209|NCT02091700|Normal
985210|NCT02091700|Healthy
985211|NCT02091700|Normal healthy patient
985212|NCT02091674|ankle sprain
985213|NCT02091674|hyaluronic acid
985214|NCT02091661|Clinically localized prostate cancer
985215|NCT02091661|Radical retropubic prostatectomy
985216|NCT02091661|External beam radiotherapy
985217|NCT02091661|Efficacy
985218|NCT02091661|Quality of life
985219|NCT02091661|adverse events
985220|NCT02091648|Asthma
985221|NCT02091648|Stress
985222|NCT02091648|Children
985223|NCT02091648|Psychosocial Factors
985224|NCT02091648|Relaxation
985225|NCT02091648|Stress management
985226|NCT02091635|accommodation, emptying, motilitone
985227|NCT02091609|plaque removal around dental implants
985228|NCT02091596|Wound
985229|NCT02091596|Ulcer
985230|NCT02091596|Infected
985231|NCT02091596|Infection
985232|NCT02091583|Metabolic syndrome
985233|NCT02091583|Cardiovascular disease
985234|NCT02091583|High Oleic Canola Oil
985235|NCT02091583|DHA
985236|NCT02091583|β-glucan
985237|NCT02091583|Barley
985238|NCT02091583|Cholesterol
985239|NCT02091583|Lipoproteins
985240|NCT02091583|Lipids
985241|NCT02091583|Inflammation
985242|NCT02091583|Glucose
985243|NCT02091583|Insulin
985244|NCT02091583|Satiety
985245|NCT02091583|Body composition
985246|NCT02091583|Blood pressure
985247|NCT02091570|Hunger
985248|NCT02091570|Fullness
985249|NCT02091570|Satiety
985250|NCT02091570|Nutrition bar
985251|NCT02091570|Crossover
985252|NCT02091557|GnRH-a
985253|NCT02091557|endometriosis
985254|NCT02091557|chronic pelvic pain
985255|NCT02091557|VAS score
985256|NCT02091557|diagnostic accuracy
985257|NCT02091544|overweight
985258|NCT02091544|obesity
985259|NCT02091544|children
985260|NCT02091544|lifestyle intervention
985261|NCT02091531|mTOR Inhibitor MLN0128
985262|NCT02091531|PSA
985263|NCT02091531|13-143
985264|NCT02091518|MRI
985265|NCT02091518|13-239
985266|NCT02091518|volunteers
985267|NCT02091518|patients
985268|NCT02091492|Proximal humerus fracture, teriparatide
985269|NCT02091479|hæmorrhage, thrombosis
985270|NCT02091466|Hypothermia
985271|NCT02091466|Perioperative Care
985272|NCT02091466|Anesthesia
985273|NCT02091466|Spinal
985274|NCT02091466|Rewarming
985275|NCT02091453|Brain injury
985276|NCT02091453|stroke
985277|NCT02091453|cognitive rehabilitation
985278|NCT02091440|Medical Device
985279|NCT02091440|Thoracic Surgical Procedure
985280|NCT02091440|Pumps Heart Assist
985281|NCT02091440|Ventricular Assist Device
985282|NCT02091401|magnesium sulfate
985283|NCT02091375|cannabidiol
985284|NCT02091336|gestational diabetes
985285|NCT02091336|metformin
985286|NCT02091336|glyburide
985287|NCT02091336|fetal growth
985288|NCT02091336|capillar glucose
985289|NCT02091323|T2DM, gastric bypass surgery, BMI<35, obesity
985290|NCT02091310|GFT505
985291|NCT02091310|TQT
985292|NCT02091310|QT/QTc
985293|NCT02091310|Pharmacokinetic
985294|NCT02091310|Healthy subjects
985295|NCT02091310|Moxifloxacin
985296|NCT02091297|Buprenorphine
985297|NCT02091297|Suboxone
985298|NCT02091297|Subutex
985299|NCT02091297|Buprenex
985300|NCT02091297|Caesarean Delivery
985301|NCT02091284|alcoholism
985302|NCT02091284|tDCS
985303|NCT02091284|dlPFC
985304|NCT02091284|craving
985305|NCT02091284|cognition
985306|NCT02091271|Evaluation
985307|NCT02091271|Research
985308|NCT02091271|Healthy Volunteers
985309|NCT02091245|Relapsed acute lymphoblastic leukemia (ALL)
985310|NCT02091245|Refractory acute lymphoblastic leukemia (ALL)
985311|NCT02091245|Relapsed acute myelogenous leukemia (AML)
985312|NCT02091245|Refractory acute myelogenous leukemia (AML)
985313|NCT02091245|Relapsed childhood leukemia
985314|NCT02091245|Relapsed mixed lineage leukemia
985315|NCT02091245|Refractory mixed lineage leukemia
985316|NCT02091245|Relapsed biphenotypic leukemia
985317|NCT02091245|Refractory biphenotypic leukemia
985318|NCT02091245|Chronic myelogenous leukemia (CML) in blast crisis
985319|NCT02091219|Hypovitaminosis D
985320|NCT02091219|Free 25-hydroxyvitamin D
985321|NCT02091219|Total 25-hydroxyvitamin D
985322|NCT02091206|Cannabidiol
985323|NCT02091193|Krill Oil
985324|NCT02091193|Endothelial Function
985325|NCT02091193|Type II Diabetes Mellitus
985326|NCT02091180|Anesthesia
985327|NCT02091180|Recovery
985328|NCT02091180|laparoscopy
985329|NCT02091180|cholecystectomy
985330|NCT02091167|crack-cocaine addiction
985331|NCT02091167|tDCS
985332|NCT02091167|dlPFC
985333|NCT02091167|craving
985334|NCT02091167|cognition
985335|NCT02091154|Food Intake Regulation
985336|NCT02091154|Fruit
985337|NCT02091154|Vegetable
985338|NCT02091115|Constipation
985339|NCT02091115|ROMA III criteria
985340|NCT02091115|Scale Bristol
985341|NCT02091076|Silk fibroin with bioactive coating layer dressing
985342|NCT02091076|Wound healing
985343|NCT02091076|Skin graft donor
985344|NCT02091063|hematologic malignancies
985345|NCT02091063|hodgkin
985346|NCT02091063|hodgkins
985347|NCT02091063|non-hodgkin
985348|NCT02091063|non-hodgkins
985349|NCT02091063|mantle cell lymphoma
985350|NCT02091063|follicular
985351|NCT02091063|lymphoma
985352|NCT02091063|lymphoid malignancies
985353|NCT02091050|3D Brachytherapy
985354|NCT02091050|cervical cancer
985355|NCT02091050|endometrial cancer
985356|NCT02091050|vaginal vault brachytherapy
985357|NCT02091037|Atopic dermatitis
985358|NCT02091037|Bacterial colonization
985359|NCT02091011|This study is designed to efficiently provide device and battery longevity data on market released
985360|NCT02091011|Boston Scientific ICD and CRT-D (Cardiac Resynchronization Therapy Defibrillator) devices. In addition, the data collected will allow for
985361|NCT02091011|comparisons of device survival probability estimated in the Product Performance Report versus
985362|NCT02091011|those collected in the study. The data collected will also provide a better understanding on the
985363|NCT02091011|potential predictors of pulse generator battery longevity.
985364|NCT02090998|Migraine Headache
985365|NCT02090998|Menstrual Migraine
985366|NCT02090998|Vascular Headache
985367|NCT02090998|Temporal Lobe Seizure
985368|NCT02090985|Stoma
985369|NCT02090985|Peri-stomal
985370|NCT02090985|Lipomodelling
985371|NCT02090959|Duchenne muscular dystrophy
985372|NCT02090959|Dystrophinopathy
985373|NCT02090959|Nonsense mutation
985374|NCT02090959|Premature stop codon
985375|NCT02090959|Becker muscular dystrophy
985376|NCT02090959|DMD/BMD
985377|NCT02090959|PTC124
985378|NCT02090959|Ataluren
985379|NCT02090946|children with physical disabilities
985380|NCT02090946|home activity programs
985381|NCT02090946|home programmes
985382|NCT02090946|learning
985383|NCT02090946|therapeutic relationship
985384|NCT02090946|phenomenology
985385|NCT02090946|physiotherapy
985386|NCT02090946|clinicians who teach
985387|NCT02090946|parent perspective
985388|NCT02090946|parent-professional relationships
985389|NCT02090946|Parents/carers
985390|NCT02090946|long term physiotherapy needs
985391|NCT02090907|Subclinical hypothyroidism
985392|NCT02090907|Atherosclerosis
985393|NCT02090907|Cardiovascular disease
985394|NCT02090907|Endothelial function
985395|NCT02090907|Prevention
985396|NCT02090868|Non-Invasive Ventilation
985397|NCT02090868|Bi-Level Positive Airway Pressure
985398|NCT02090868|Continuous Positive Airway Pressure
985399|NCT02090868|Critical Care
985400|NCT02090868|Nutrition
985401|NCT02090868|Malnutrition
985402|NCT02090868|Staff attitudes, knowledge and beliefs
985403|NCT02090842|Milk proteins
985404|NCT02090842|Blood pressure
985405|NCT02090842|Vascular function
985406|NCT02090829|Autism
985407|NCT02090829|Oxytocin
985408|NCT02090829|Syntocinon
985409|NCT02090790|dexamethasone
985410|NCT02090790|femoral block
985411|NCT02090790|total knee arthroplasty
985412|NCT02090751|Retinal Rod Photoreceptor Cells
985413|NCT02090751|Dark Adaptation
985414|NCT02090725|fluctuating muscle weakness
985415|NCT02090725|hyporeflexia
985416|NCT02090725|autonomic Dysfunction
985417|NCT02090712|myocardial infarction
985418|NCT02090712|acute coronary syndrome
985419|NCT02090712|coronary disease
985420|NCT02090699|thalassemia major
985421|NCT02090699|chronic blood transfusion related iron overload
985422|NCT02090699|magnetic resonance imaging
985423|NCT02090699|myocardium
985424|NCT02090699|fibrosis
985425|NCT02090647|dental implant, aesthetic, implant abutment
985426|NCT02090634|HIV
985427|NCT02090634|Bipolar Disorder
985428|NCT02090634|Medication Adherence
985429|NCT02090621|Liver
985430|NCT02090621|transplantation
985431|NCT02090621|Immunosuppression
985432|NCT02090621|photopheresis
985433|NCT02090621|extracorporeal
985434|NCT02090595|bipolar disorder
985435|NCT02090595|anxiety
985436|NCT02090595|mindfulness
985437|NCT02090595|high risk
985438|NCT02090595|cognitive behavioral
985439|NCT02090569|Functional micro-Doppler Sonography, fmDS, dysplasia, epilepsy, neurosurgery, cerebral blood volume, echography, hemodynamics
985440|NCT02090530|Cancer Genomics
985441|NCT02090530|Tumor Sequencing
985442|NCT02090517|Nasal telangiectasis
985443|NCT02090504|alcohol withdrawal syndrome
985444|NCT02090504|treatment
985445|NCT02090504|sodium oxybate
985446|NCT02090504|oxazepam
985447|NCT02090491|autism
985448|NCT02090465|Actinic Keratosis
985449|NCT02090452|Telemedicine
985450|NCT02090452|Mobile
985451|NCT02090452|Vital signs
985452|NCT02090452|Prehospital care
985453|NCT02090452|Emergency medicine
985454|NCT02090413|multiple sclerosis
985455|NCT02090413|flushing
985456|NCT02090413|aspirin
985457|NCT02090400|Women
985458|NCT02090400|Osteoporosis, Postmenopausal
985459|NCT02090400|Bazedoxifene
985460|NCT02090400|BMD
985461|NCT02090374|Allergy
985462|NCT02090374|Asthma
985463|NCT02090374|Biomarkers
985464|NCT02090374|Chemokines
985465|NCT02090374|Cytokines
985466|NCT02090374|Eosinophil
985467|NCT02090374|Gene Expression
985468|NCT02090374|Grass pollen
985469|NCT02090374|Hay Fever
985470|NCT02090374|Human Challenge Study
985471|NCT02090374|Inflammation
985472|NCT02090374|Innate Immune Response
985473|NCT02090374|Lipopolysaccharide
985474|NCT02090374|Mucosal Lining Fluid
985475|NCT02090374|Nasal
985476|NCT02090374|Nasorption
985477|NCT02090374|Respiratory
985478|NCT02090374|Respiratory Tract Infection
985479|NCT02090374|T cells
985480|NCT02090374|Tuberculosis
985481|NCT02090374|Virus
985482|NCT02090361|collagen -elastin matrix
985483|NCT02090361|skin graft
985484|NCT02090361|loss of cutaneous substance
985485|NCT02090335|community mental health
985486|NCT02090335|health coach
985487|NCT02090335|weight loss
985488|NCT02090335|fitness
985489|NCT02090335|serious mental illness
985490|NCT02090335|health promotion
985491|NCT02090322|ROP
985492|NCT02090322|Bevacizumab
985493|NCT02090322|No inferiority
985494|NCT02090283|Epidermolysis Bullosa
985495|NCT02090283|Simplex
985496|NCT02090283|Recessive Dystrophic
985497|NCT02090283|Junctional non-Herlitz
985498|NCT02090270|hair cortisol
985499|NCT02090270|stroke
985500|NCT02090257|Heart transplant recipients who are entering into adult care.
985501|NCT02090244|PTH
985502|NCT02090244|Spinal stenosis
985503|NCT02090244|Teriparatide
985504|NCT02090231|stroke
985505|NCT02090231|dysphagia
985506|NCT02090231|rTMS
985507|NCT02090205|cardio-pulmonary bypass
985508|NCT02090205|cardiac surgery
985509|NCT02090205|lung injury prevention
985510|NCT02090205|mechanical ventilation
985511|NCT02090205|pulmonary insufficiency
985512|NCT02090192|Whole-body vibration;
985513|NCT02090192|Frail Elderly;
985514|NCT02090192|Blood flow;
985515|NCT02090192|Bone density
985516|NCT02090192|Mobility;
985517|NCT02090192|Balance;
985518|NCT02090192|Muscle strength;
985519|NCT02090192|Lower Extremity;
985520|NCT02090192|Musculoskeletal System;
985521|NCT02090192|Health Status;
985522|NCT02090192|Exercise;
985523|NCT02090192|Mechanical Oscillation
985524|NCT02090179|MPS IIIB
985525|NCT02090179|Mucopolysaccharidosis
985526|NCT02090179|Mucopolysaccharidosis type IIIB
985527|NCT02090179|Sanfilippo Syndrome
985528|NCT02090179|Metabolism, Inborn Errors
985529|NCT02090179|Metabolic Diseases
985530|NCT02090179|Genetic Diseases, Inborn
985531|NCT02090153|Advance Gastric Cancer,
985532|NCT02090153|S-1 plus leucovorin,
985533|NCT02090153|ORR,
985534|NCT02090153|OS,
985535|NCT02090153|TTP,
985536|NCT02090153|TTF,
985537|NCT02090153|Adverse events,
985538|NCT02090153|Pharmacokinetics
985539|NCT02090140|cartilage/transplantation
985540|NCT02090140|cartilage, articular/injuries
985541|NCT02090140|cartilage, articular/surgery
985542|NCT02090140|chondrocytes/cytology
985543|NCT02090140|knee injuries/surgery
985544|NCT02090140|knee joint/surgery
985545|NCT02090140|orthopedic procedures/methods
985546|NCT02090140|tissue engineering
985547|NCT02090140|tissue scaffolds
985548|NCT02090140|arthroscopy/methods
985549|NCT02090140|chondrocytes/transplantation
985550|NCT02090140|adipose tissue/cytology
985551|NCT02090140|cartilage, articular/cytology
985552|NCT02090140|chondrogenesis/physiology
985553|NCT02090140|osteogenesis/physiology
985554|NCT02090140|stem cell transplantation/methods
985555|NCT02090140|stem cells
985556|NCT02090140|tissue engineering/methods
985557|NCT02090140|cartilage, articular/pathology
985558|NCT02090140|chondrocytes/pathology
985559|NCT02090140|knee joint/pathology
985560|NCT02090140|platelet-rich plasma
985561|NCT02090114|Bipolar Androgen Therapy
985562|NCT02090114|Testosterone
985563|NCT02090114|Enzalutamide
985564|NCT02090114|Abiraterone
985565|NCT02090114|Androgen Ablative Therapies
985566|NCT02090075|cardiac Computed tomography
985567|NCT02090075|coronary calcification
985568|NCT02090075|intervention
985569|NCT02090075|warfarin
985570|NCT02090075|apixaban
985571|NCT02090062|endoscopic resection
985572|NCT02090062|H. pylori infection
985573|NCT02090049|Appetite
985574|NCT02090049|Satiety
985575|NCT02090049|Bread
985576|NCT02090049|Dietary fiber
985577|NCT02090049|Gastrointestinal hormones
985578|NCT02090049|Glycemia
985579|NCT02090049|Insulinemia
985580|NCT02090036|Efficacy
985581|NCT02090036|Safety
985582|NCT02090036|Primaquine
985583|NCT02090036|Artemether-lumefantrine
985584|NCT02090036|Gametocytes
985585|NCT02090023|Obstructive sleep apnea
985586|NCT02090023|National Health Insurance Research Database in Taiwan
985587|NCT02090023|Survival Analysis
985588|NCT02090023|Validation Studies
985589|NCT02090023|Cohort Studies
985590|NCT02089997|Pharmacological therapy
985591|NCT02089984|Cognitive Behavior Therapy
985592|NCT02089984|On-line training
985593|NCT02089958|Lapraoscopy, incisional hernia repair, mesh
985594|NCT02089945|transcatheter aortic valve implantation
985595|NCT02089945|severe aortic stenosis
985596|NCT02089945|cognition
985597|NCT02089945|functional capacity
985598|NCT02089945|quality of life
985599|NCT02089932|femoral nerve block
985600|NCT02089932|peri-neural dexmedetomidine
985601|NCT02089867|Ezetimibe
985602|NCT02089867|Plant sterol
985603|NCT02089867|Hydroxymethylglutaryl coenzyme A Reductase Inhibitors
985604|NCT02089867|Coronary artery disease
985605|NCT02089867|LDL-cholesterol
985606|NCT02089854|triple negative breast cancer
985607|NCT02089854|estrogen receptor-beta
985608|NCT02089854|endocrine therapy
985609|NCT02089841|Efficacy
985610|NCT02089841|Artemether/lumefantrine
985611|NCT02089841|Malaria
985612|NCT02089841|Children
985613|NCT02089802|RCC
985614|NCT02089789|Natural History
985615|NCT02089789|Glycosylation
985616|NCT02089789|Genetic Disorders
985617|NCT02089776|Stroke
985618|NCT02089776|fMRI
985619|NCT02089776|Real Time fMRI Feedback
985620|NCT02089763|Hepatocellular carcinoma
985621|NCT02089763|HCC
985622|NCT02089763|Pegylated recombinant human arginase
985623|NCT02089763|PEG-BCT-100
985624|NCT02089763|ASS
985625|NCT02089763|OTC
985626|NCT02089750|Low Back Pain
985627|NCT02089750|Chiropractic
985628|NCT02089750|Shoe Orthotics
985629|NCT02089711|Normal subjects
985630|NCT02089698|Kelman tip
985631|NCT02089698|Mini-flared
985632|NCT02089698|phacoemulsification
985633|NCT02089698|cataract
985634|NCT02089633|hepatocellular carcinoma
985635|NCT02089633|HCC
985636|NCT02089633|pegylated recombinant human arginase
985637|NCT02089633|PEG-BCT-100
985638|NCT02089633|oxaliplatin
985639|NCT02089633|capecitabine
985640|NCT02089620|Premenstrual syndrome
985641|NCT02089620|Oral contraceptive pills
985642|NCT02089620|Calcium Supplements
985643|NCT02089594|Hyperbaric Oxygen Treatment
985644|NCT02089594|Mild Traumatic Brain Injury
985645|NCT02089594|Persistent Post-Concussion Syndrome
985646|NCT02089581|Healthy Volunteer
985647|NCT02089581|Pharmacokinetics
985648|NCT02089581|Bioequivalence
985649|NCT02089568|Living donation
985650|NCT02089568|Antibiotics
985651|NCT02089568|Laparoscopic surgery
985652|NCT02089542|thyroidectomy
985653|NCT02089542|parathyroid surgery
985654|NCT02089542|parathyroid identification
985655|NCT02089542|methylene blue
985656|NCT02089542|near infrared fluorescence
985657|NCT02089542|intraoperative imaging
985658|NCT02089529|Axial Spondyloarthritis
985659|NCT02089529|Pain
985660|NCT02089529|NSAIDs
985661|NCT02089529|Placebo
985662|NCT02089529|Placebo intervention
985663|NCT02089529|Stress
985664|NCT02089529|Conditioning
985665|NCT02089516|Frailty
985666|NCT02089516|Accelerometry
985667|NCT02089516|Physical activity
985668|NCT02089516|validity
985669|NCT02089477|Type 2 diabetes, InterWalk, Individual Support, Motivation
985670|NCT02089412|Healthy Subjects
985671|NCT02089412|Absorption
985672|NCT02089412|High-Fat Meal
985673|NCT02089360|Advanced glycation end product
985674|NCT02089360|coronary
985675|NCT02089360|atherosclerosis
985676|NCT02089360|inflammation
985677|NCT02089360|outcome
985678|NCT02089347|Tetanus
985679|NCT02089347|Diphtheria
985680|NCT02089347|Pertussis
985681|NCT02089347|TdaP vaccine
985682|NCT02089347|DT vaccine
985683|NCT02089334|renal cell carcinoma
985684|NCT02089334|clear cell
985685|NCT02089334|renal cancer
985686|NCT02089334|metastatic renal cancer
985687|NCT02089334|Carcinoma, Renal Cell*/therapy
985688|NCT02089334|Humans
985689|NCT02089334|Kidney Neoplasms*/therapy
985690|NCT02089321|low back pain
985691|NCT02089321|lumbopelvic assessment
985692|NCT02089321|active straight leg raise
985693|NCT02089321|active hip abduction
985694|NCT02089308|Smoking cessation
985695|NCT02089308|Nicotine
985696|NCT02089308|Tobacco Use Disorder
985697|NCT02089308|Central Nervous System Agents
985698|NCT02089295|dose proportionality
985699|NCT02089295|oxycodone
985700|NCT02089269|pancreatic neoplasms
985701|NCT02089269|neoplasms
985702|NCT02089269|registry
985703|NCT02089269|advanced pancreatic cancer
985704|NCT02089269|health services research
985705|NCT02089269|epidemiology
985706|NCT02089269|Germany
985707|NCT02089269|palliative treatment
985708|NCT02089269|palliative care
985709|NCT02089243|Epilepsy,Temporal Lobe
985710|NCT02089243|Brain Diseases
985711|NCT02089230|Leukemia
985712|NCT02089230|Acute Myeloid Leukemia
985713|NCT02089230|AML
985714|NCT02089230|Advanced leukemias
985715|NCT02089230|Myelodysplastic syndrome
985716|NCT02089230|MDS
985717|NCT02089230|Acute lymphoblastic leukemia
985718|NCT02089230|ALL
985719|NCT02089230|Relapsed
985720|NCT02089230|Refractory
985721|NCT02089230|MEK 162
985722|NCT02089217|asymptomatic
985723|NCT02089217|carotid
985724|NCT02089217|stent
985725|NCT02089217|endarterectomy
985726|NCT02089217|embolic protection
985727|NCT02089217|medical management
985728|NCT02089217|hypertension
985729|NCT02089217|hyperlipidemia
985730|NCT02089217|cognition
985731|NCT02089217|risk factor control
985732|NCT02089204|Hypoxia Imaging -Guided Radiotherapy
985733|NCT02089204|PET/CT
985734|NCT02089204|simultaneous modulated accelerated radiation therapy (SMART)
985735|NCT02089191|DACP
985736|NCT02089191|DAILIES® AquaComfort Plus
985737|NCT02089191|Tear film stability
985738|NCT02089191|NIK-BUT
985739|NCT02089178|total intravenous anesthesia, inhalation anesthesia, cancer cell cytotoxicity, breast tumor
985740|NCT02089152|Diabetes
985741|NCT02089152|Melioidosis
985742|NCT02089152|stepped wedge trial
985743|NCT02089152|behaviour change
985744|NCT02089152|Education program
985745|NCT02089139|Back pain
985746|NCT02089139|Discogel
985747|NCT02089087|Rheumatoid arthritis, RA, first-in-human, single ascending dose, safety, tolerability
985748|NCT02089074|Secondary Prevention
985749|NCT02089074|Pharmacists
985750|NCT02089074|Directive Counseling
985751|NCT02089074|Medication Adherence
985752|NCT02089074|Patient Compliance
985753|NCT02089048|Amebiasis
985754|NCT02089048|auranofin
985755|NCT02089048|pharmacodynamics
985756|NCT02089048|pharmokinetics
985757|NCT02089035|Milk fatty acids
985758|NCT02089035|Total cholesterol
985759|NCT02089035|Vascular function
985760|NCT02089035|Blood pressure
985761|NCT02089022|Ice
985762|NCT02089022|Heat
985763|NCT02089022|Ground reaction forces
985764|NCT02089022|Electromyography
985765|NCT02089022|Lower Limb
985766|NCT02089022|Center of pressure
985767|NCT02088970|Infectious keratitis
985768|NCT02088970|Corneal cross linking
985769|NCT02088970|Topical antibiotics
985770|NCT02088957|Brivaracetam
985771|NCT02088957|Phenytoin
985772|NCT02088957|Nonconvulsive electrographic seizures
985773|NCT02088931|Tregs
985774|NCT02088931|Kidney transplantation
985775|NCT02088905|PCIT, autism, parent training, noncompliance
985776|NCT02088892|BCG challenge study
985777|NCT02088866|Tinnitus
985778|NCT02088866|Otolaryngology
985779|NCT02088853|intestinal
985780|NCT02088853|metabolic control
985781|NCT02088853|mucosa
985782|NCT02088853|human
985783|NCT02088853|diet
985784|NCT02088840|SIGNB
985785|NCT02088840|severe infections gram negative bacteria
985786|NCT02088840|stem cell transplant
985787|NCT02088827|Exercise
985788|NCT02088827|Sedentary Behaviour
985789|NCT02088827|Type 2 Diabetes
985790|NCT02088827|Older Adults
985791|NCT02088814|posttraumatic stress
985792|NCT02088814|burns
985793|NCT02088814|injuries
985794|NCT02088814|children
985795|NCT02088801|Intubation; Difficult
985796|NCT02088788|radiation
985797|NCT02088788|radiation injury
985798|NCT02088788|occupational risk
985799|NCT02088762|margin of safety
985800|NCT02088749|obesity
985801|NCT02088749|weight loss
985802|NCT02088749|treatment
985803|NCT02088749|lifestyle
985804|NCT02088723|Sleep Apnea, Obstructive
985805|NCT02088723|Sleep Apnea Syndromes
985806|NCT02088723|Polysomnography
985807|NCT02088723|Sleep
985808|NCT02088723|Patient Positioning
985809|NCT02088710|Patients´ Expectations
985810|NCT02088710|Breast Cancer
985811|NCT02088710|Adjuvant Endocrine Treatment
985812|NCT02088710|Nocebo
985813|NCT02088710|Psycho-oncology
985814|NCT02088710|Satisfaction with information
985815|NCT02088684|Hormone receptor positive, HER2 negative
985816|NCT02088671|NeuroSENSE
985817|NCT02088671|Anesthesia
985818|NCT02088671|Hypnosis
985819|NCT02088671|Desflurane
985820|NCT02088671|Propofol
985821|NCT02088658|Diabetes Mellitus, Type 2
985822|NCT02088658|Diabetes Mellitus, Adult-Onset
985823|NCT02088658|Diabetes Mellitus, Non-Insulin-Dependent
985824|NCT02088658|Diabetes Mellitus, Noninsulin Dependent
985825|NCT02088658|Diabetes Mellitus, Type II
985826|NCT02088658|African Americans
985827|NCT02088658|Blacks
985828|NCT02088658|non-Hispanic Blacks
985829|NCT02088658|Randomized Control Trial
985830|NCT02088658|Controlled Clinical Trial
985831|NCT02088658|Behavioral Research
985832|NCT02088658|Behavioral Medicine
985833|NCT02088645|Calcitonin
985834|NCT02088645|Medullary thyroid carcinoma
985835|NCT02088645|Peptide receptor radionuclide therapy
985836|NCT02088645|Gastrin
985837|NCT02088645|Cholecystokinin-2 receptor
985838|NCT02088619|psychological wellbeing
985839|NCT02088619|anxiety
985840|NCT02088619|depression
985841|NCT02088619|autonomic functioning
985842|NCT02088606|Atrial fibrillation
985843|NCT02088593|Medical Students
985844|NCT02088541|Relapsed/Refractory Acute Myeloid Leukemia
985845|NCT02088541|Acute Myeloid Leukemia
985846|NCT02088541|AML
985847|NCT02088541|Karyopharm
985848|NCT02088541|Selinexor
985849|NCT02088541|KPT-330
985850|NCT02088515|Nedaplatin
985851|NCT02088515|lung squamous cell carcinoma
985852|NCT02088502|Coronary Angiography
985853|NCT02088502|Side Effects
985854|NCT02088502|Contrast-Induced Nephropathy
985855|NCT02088502|Prevention
985856|NCT02088489|Atrial flutter
985857|NCT02088489|Thermocool catheter
985858|NCT02088489|Thermocool SF catheter
985859|NCT02088476|candidemia
985860|NCT02088476|children
985861|NCT02088476|mortality
985862|NCT02088476|risk factors
985863|NCT02088463|Mechanical LBP
985864|NCT02088463|Mobilization
985865|NCT02088463|Postpartum
985866|NCT02088450|Cardiovascular complications
985867|NCT02088450|Clinical trial
985868|NCT02088450|Elderly
985869|NCT02088450|Isolated systolic hypertension
985870|NCT02088450|Stroke
985871|NCT02088398|relative bioavailability
985872|NCT02088398|food-effect
985873|NCT02088359|cycled light, near darkness, growth
985874|NCT02088346|Stroke
985875|NCT02088346|Thrombolysis
985876|NCT02088346|Tissue plasminogen activator
985877|NCT02088346|Urokinase
985878|NCT02088346|Telemedicine
985879|NCT02088333|colorectal cancer screening
985880|NCT02088333|computer-assisted instruction
985881|NCT02088333|mHealth
985882|NCT02088333|text message
985883|NCT02088307|cardiovascular supplement
985884|NCT02088307|cardiovascular disease
985885|NCT02088307|coronary artery disease
985886|NCT02088294|obesity
985887|NCT02088294|stress
985888|NCT02088294|intuitive eating
985889|NCT02088294|guided imagery
985890|NCT02088294|adolescents
985891|NCT02088294|insulin resistance
985892|NCT02088294|latinos
985893|NCT02088294|minorities
985894|NCT02088281|Indigo naturalis, indirubin, Th1 cells, Th17 cells
985895|NCT02088255|Rehabilitation
985896|NCT02088255|Gait
985897|NCT02088255|Stroke
985898|NCT02088255|Biomechanics
985899|NCT02088229|Diabetic Macular Edema
985900|NCT02088216|N-acetylcysteine；
985901|NCT02088216|Bronchiectasis；
985902|NCT02088216|Acute exacerbations；
985903|NCT02088216|Antioxidant；
985904|NCT02088216|Anti-inflammatory
985905|NCT02088177|Cannabis
985906|NCT02088177|Cannabis Dependence
985907|NCT02088177|Cannabis Use Disorder
985908|NCT02088177|Marijuana
985909|NCT02088177|Naltrexone
985910|NCT02088177|Long Acting Injectable Naltrexone
985911|NCT02088177|Treatment
985912|NCT02088164|PSA,
985913|NCT02088164|asian men,
985914|NCT02088164|survival
985915|NCT02088151|selective laser therapy
985916|NCT02088151|retinal pigment epithelium
985917|NCT02088151|macular edema
985918|NCT02088151|diabetic retinopathy
985919|NCT02088151|central serous chorioretinopathy
985920|NCT02088151|age-related macular degeneration
985921|NCT02088151|retinal vein occlusion
985922|NCT02088138|Thoracic Surgery
985923|NCT02088138|Electrical Stimulation
985924|NCT02088138|Rehabilitation
985925|NCT02088138|Quality of Life
985926|NCT02088125|Stroke
985927|NCT02088125|Incentive Spirometry
985928|NCT02088125|Breath Stacking
985929|NCT02088125|Optoelectronic Plethysmography
985930|NCT02088112|NSCLC
985931|NCT02088099|Traumatic brain injury
985932|NCT02088099|Telehealth
985933|NCT02088099|ehealth
985934|NCT02088099|Mobile Health
985935|NCT02088099|social participation
985936|NCT02088099|patient participation
985937|NCT02088099|consumer participation
985938|NCT02088099|Patient Outcome Assessment
985939|NCT02088086|Pediatric obesity
985940|NCT02088086|Overweight
985941|NCT02088086|Body mass index
985942|NCT02088086|Primary schools
985943|NCT02088086|Secondary schools
985944|NCT02088047|Autism
985945|NCT02088047|Self-Stimulating behaviors
985946|NCT02088047|Autism Spectrum Disorders
985947|NCT02087995|Diabetes Mellitus
985948|NCT02087956|Women
985949|NCT02087956|Depression
985950|NCT02087956|Socioeconomically Disadvantaged
985951|NCT02087956|Navigation
985952|NCT02087943|Atopic Dermatitis
985953|NCT02087943|Atopic Eczema
985954|NCT02087917|hypercholesterolemia
985955|NCT02087917|cholesterol absorption inhibitor
985956|NCT02087917|placebo-controlled trial
985957|NCT02087904|Pain
985958|NCT02087904|Osteoarthritis
985959|NCT02087904|Synovitis
985960|NCT02087904|Knee
985961|NCT02087878|Hepatosplenic T-Cell Lymphoma
985962|NCT02087852|Questionnaire
985963|NCT02087852|DNA
985964|NCT02087852|saliva
985965|NCT02087852|kidney cancer
985966|NCT02087852|13-218
985967|NCT02087839|Non-Small Cell Lung Cancer
985968|NCT02087839|Lung Cancer
985969|NCT02087839|NSCLC
985970|NCT02087839|ZD6474
985971|NCT02087839|ZACTIMA
985972|NCT02087839|Vandetanib
985973|NCT02087839|Inoperable NSCLC
985974|NCT02087839|Unresectable NSCLC
985975|NCT02087839|Radiation Therapy
985976|NCT02087839|Palliative radiation therapy
985977|NCT02087839|Angiogenesis
985978|NCT02087813|neuromyelitis optica
985979|NCT02087813|optic neuritis
985980|NCT02087813|longitudinally extensive transverse myelitis
985981|NCT02087800|smoking cessation
985982|NCT02087800|smoking abstinence
985983|NCT02087800|allopregnanolone
985984|NCT02087787|bone marrow transplant
985985|NCT02087787|hematologic malignancies
985986|NCT02087761|ARIES Flu
985987|NCT02087748|DOMS
985988|NCT02087735|Cranberry
985989|NCT02087735|Proanthocyanidins
985990|NCT02087735|Urinary catabolites
985991|NCT02087722|Primary Insomnia
985992|NCT02087696|Arthritis, Rheumatoid
985993|NCT02087696|methotrexate
985994|NCT02087696|intolerance
985995|NCT02087696|poor compliance
985996|NCT02087696|contraindication
985997|NCT02087696|Tocilizumab
985998|NCT02087696|monotherapy
985999|NCT02087683|heart failure
986000|NCT02087683|vitamin D deficiency
986001|NCT02087683|ventricular function
986002|NCT02087683|cytokines
986003|NCT02087670|chronic heart failure
986004|NCT02087670|cardiac rehabilitation
986005|NCT02087670|exercise
986006|NCT02087670|Natriuretic Brain Pro-peptid
986007|NCT02087657|Peripheral Blood Stem Cell (PBSC) Transplant
986008|NCT02087657|Hyperbaric oxygen
986009|NCT02087657|Lymphoma
986010|NCT02087657|Myeloma
986011|NCT02087631|multiple sclerosis
986012|NCT02087631|quetiapine
986013|NCT02087631|remyelination
986014|NCT02087618|MCI
986015|NCT02087618|Alzheimer's
986016|NCT02087618|Dementia
986017|NCT02087618|Tablet
986018|NCT02087618|Non-Pharmacological Intervention
986019|NCT02087618|Cognition
986020|NCT02087605|Vascular stiffness, retinal vessels, target organ damage
986021|NCT02087592|hereditary breast and ovarian cancer (HBOC)
986022|NCT02087592|BRCA1/2 mutation carriers
986023|NCT02087592|Mediterranean diet
986024|NCT02087592|Structured exercise training
986025|NCT02087592|prevention
986026|NCT02087579|Psychotic Disorders
986027|NCT02087579|Schizophrenia
986028|NCT02087579|Bipolar Disorder
986029|NCT02087579|Depressive Disorder
986030|NCT02087579|Antipsychotics
986031|NCT02087579|Aripiprazole
986032|NCT02087579|Olanzapine
986033|NCT02087579|Paliperidone
986034|NCT02087579|Quetiapine
986035|NCT02087579|Risperidone
986036|NCT02087579|Capillary Concentration
986037|NCT02087566|Linezolid
986038|NCT02087566|Pharmacokinetics
986039|NCT02087566|Haemodialysis
986040|NCT02087566|Dosing adjustment
986041|NCT02087566|Eligible subjects were classified into three groups depending on their 24-h urinary creatinine clearance (CLcr) values or HD status.
986042|NCT02087566|Group 1, included 6 healthy subjects with normal renal function (CLcr ˃80 ml/min);
986043|NCT02087566|Group 2, included 6 patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine);
986044|NCT02087566|Group 3, included 6 patients on long term haemodialysis (minimum period of dialysis was 40 month while maximum period were 130 month)
986045|NCT02087553|Blood Transfusion
986046|NCT02087553|Iron
986047|NCT02087553|Packed Red Blood Cells
986048|NCT02087553|PRBC
986049|NCT02087553|NTBI
986050|NCT02087527|Cellulitis
986051|NCT02087527|Soft Tissue Infections
986052|NCT02087527|Skin Diseases, Infectious
986053|NCT02087527|Corticosteroids
986054|NCT02087527|Glucocorticoids
986055|NCT02087527|Dexamethasone
986056|NCT02087514|Blood Transfusion
986057|NCT02087514|Iron
986058|NCT02087514|Red Blood Cells
986059|NCT02087501|Abdominal Aortic Aneurysm
986060|NCT02087501|AAA
986061|NCT02087501|Abdominal Aortoiliac Aneurysm
986062|NCT02087501|Endovascular Aortic Repair
986063|NCT02087501|EVAR
986064|NCT02087488|primary insomnia
986065|NCT02087488|auricular acupuncture
986066|NCT02087462|Sciatica
986067|NCT02087462|Electroacupuncture
986068|NCT02087462|Intervertebral disc displacement
986069|NCT02087423|Locally advanced, metastatic, Non-Small Cell Lung Cancer, MEDI4736, PD-L1
986070|NCT02087397|Stem Cell
986071|NCT02087397|Erectile Dysfunction
986072|NCT02087384|Anal intraepithelial neoplasia
986073|NCT02087384|HIV
986074|NCT02087384|HPV
986075|NCT02087384|Vaccination
986076|NCT02087384|Gardasil
986077|NCT02087384|Prophylactic
986078|NCT02087358|alcohol dependence
986079|NCT02087358|Stress- correlation
986080|NCT02087358|genetic
986081|NCT02087358|CRHR1
986082|NCT02087332|Kidney damage hypertension cardiovascular diseases, congestive heart failure renal function natriuresis natriuresis monitoring
986083|NCT02087306|Adenovirus Infection
986084|NCT02087241|Stage IV Lung Cancer
986085|NCT02087228|Endometrial ablation, menorrhagia
986086|NCT02087215|diabetes mellitus
986087|NCT02087215|foot ulcer
986088|NCT02087215|boron
986089|NCT02087215|wound care
986090|NCT02087202|pain
986091|NCT02087189|ICD, CRT-D, lead
986092|NCT02087176|NSCLC
986093|NCT02087137|aging
986094|NCT02087137|memory
986095|NCT02087137|memory training
986096|NCT02087124|Whey protein
986097|NCT02087124|Postprandial lipaemia
986098|NCT02087124|Pre-meal
986099|NCT02087124|Metabolic syndrome
986100|NCT02087111|Telaprevir
986101|NCT02087111|Genotype 3 HCV
986102|NCT02087098|overactive bladder
986103|NCT02087098|solifenacin
986104|NCT02087098|quality of life
986105|NCT02087072|home visits
986106|NCT02087072|transitions of care
986107|NCT02087072|pharmacist
986108|NCT02087059|Post-Polycythemia Vera (PV) MF
986109|NCT02087059|Post-Essential Thrombocythemia (ET) MF
986110|NCT02087033|supraventricular ectopic beats
986111|NCT02087020|Joint Prosthesis
986112|NCT02087020|Prosthesis-Related Infections
986113|NCT02087020|Joint Diseases
986114|NCT02087020|Therapeutic Irrigation
986115|NCT02087020|Prostheses and Implants
986116|NCT02087020|Arthroplasty Replacement
986117|NCT02087007|Treatment for vasospastic angina
986118|NCT02086994|carbetocin, misoprostol, pre-eclampsia, pph
986119|NCT02086955|Diabetes
986120|NCT02086955|Nursing counseling
986121|NCT02086955|Foot ulceration
986122|NCT02086955|Outpatient
986123|NCT02086955|Advanced Practice Nurse
986124|NCT02086929|Trazodone
986125|NCT02086929|Venlafaxine
986126|NCT02086929|Major depressive disorder
986127|NCT02086916|Clostridium difficile
986128|NCT02086916|Prediction
986129|NCT02086916|Treatment
986130|NCT02086916|Failure
986131|NCT02086903|Ticagrelor
986132|NCT02086903|Clopidogrel
986133|NCT02086903|Platelet function test
986134|NCT02086890|retinitis pigmentosa
986135|NCT02086890|acupuncture
986136|NCT02086890|electroacupuncture
986137|NCT02086890|transcorneal electrical stimulation
986138|NCT02086890|microcurrent
986139|NCT02086864|Attention Deficit Hyperactivity Disorder
986140|NCT02086864|ADHD
986141|NCT02086864|Homeopathy
986142|NCT02086851|pediatric obesity
986143|NCT02086851|motivational interviewing
986144|NCT02086851|lifestyle intervention
986145|NCT02086838|Iron deficiency anemia
986146|NCT02086838|Pregnancy
986147|NCT02086838|Iron therapy
986148|NCT02086799|asthma
986149|NCT02086799|thyroid hormones
986150|NCT02086799|treatment
986151|NCT02086799|asthma exacerbation
986152|NCT02086773|Acute Leukemia
986153|NCT02086773|Red Cell Transfusion
986154|NCT02086760|hydronephrosis
986155|NCT02086747|Abdominal Hysterectomy, Acetaminophen, chronic pain
986156|NCT02086734|Perfusion-CT
986157|NCT02086734|mRCC
986158|NCT02086734|antiangiogenic therapy
986159|NCT02086734|response assessment
986160|NCT02086708|Sonoelastography,
986161|NCT02086708|Diffuse liver disease,
986162|NCT02086708|chronic liver disease,
986163|NCT02086708|NASH,
986164|NCT02086708|NAFLD,
986165|NCT02086708|Elevated Transaminases,
986166|NCT02086708|Liver Biopsy,
986167|NCT02086708|Fibrosis,
986168|NCT02086708|METAVIR
986169|NCT02086695|Chemotherapy
986170|NCT02086695|Cardiotoxicity
986171|NCT02086682|hemodialysis
986172|NCT02086682|dialysis
986173|NCT02086682|renal dialysis
986174|NCT02086682|clotting
986175|NCT02086682|coagulation
986176|NCT02086682|blood lines
986177|NCT02086656|liver metastases
986178|NCT02086656|colorectal cancer
986179|NCT02086656|perioperative treatment
986180|NCT02086643|Infraclavicular block
986181|NCT02086643|Brachial Plexus
986182|NCT02086643|Retroclavicular Approach
986183|NCT02086643|Complications of retroclavicular approach
986184|NCT02086643|Success of retroclavicular approach
986185|NCT02086643|Obese Patients
986186|NCT02086643|Obesity and Anesthesia
986187|NCT02086630|disparities
986188|NCT02086630|antiretroviral
986189|NCT02086630|HIV
986190|NCT02086630|barriers
986191|NCT02086630|access
986192|NCT02086630|delay
986193|NCT02086630|decline
986194|NCT02086630|discontinue
986195|NCT02086630|African American
986196|NCT02086630|Black
986197|NCT02086630|Latino
986198|NCT02086630|Hispanic
986199|NCT02086630|care continuum
986200|NCT02086630|Heart to Heart Behavioral intervention
986201|NCT02086630|Treatment as Usual
986202|NCT02086591|Non Hodgkin Lymphoma
986203|NCT02086591|Doxycycline
986204|NCT02086578|multi-beam Intensity-Modulated Radiation Therapy (IMRT)
986205|NCT02086578|14-028
986206|NCT02086565|asthma,
986207|NCT02086565|asthma control,
986208|NCT02086565|asthma-related quality of life
986209|NCT02086565|electronic health record,
986210|NCT02086565|portal,
986211|NCT02086565|health literacy
986212|NCT02086513|Graft versus Host Disease
986213|NCT02086513|Allogeneic Stem Cell Transplantation
986214|NCT02086500|Tranexamic acid
986215|NCT02086500|randomized
986216|NCT02086500|hemorrhage
986217|NCT02086500|blinded
986218|NCT02086487|NIlotinib , Suboptimal Response , Imatinib
986219|NCT02086435|Myomectomy
986220|NCT02086435|Laparoscopic myomectomy
986221|NCT02086435|Morcellation
986222|NCT02086435|Risk of dissemination
986223|NCT02086435|Uterine Sarcoma
986224|NCT02086435|Parasitic myoma
986225|NCT02086396|obesity
986226|NCT02086396|cardiovascular risk factors
986227|NCT02086396|pumpkin seed
986228|NCT02086396|diet quality
986229|NCT02086383|Pulmonary Rehabilitation
986230|NCT02086383|Self-Efficacy
986231|NCT02086383|Physical Activity
986232|NCT02086370|PBS
986233|NCT02086370|Prophylactic bilateral salpingectomy
986234|NCT02086370|Ovarian cancer prevention
986235|NCT02086370|Ovarian reserve
986236|NCT02086370|Permanent contraception
986237|NCT02086370|Surgical sterilization
986238|NCT02086344|Total Laparoscopic Hysterectomy
986239|NCT02086344|TLH
986240|NCT02086344|Ovarian reserve
986241|NCT02086344|Prophylactic bilateral salpingectomy
986242|NCT02086344|Ovarian cancer prevention
986243|NCT02086344|Ovarian cancer
986244|NCT02086344|Fallopian Tubes
986245|NCT02086318|Ovarian reserve
986246|NCT02086318|Ovarian age
986247|NCT02086318|Fertility
986248|NCT02086318|Reproductive prognosis
986249|NCT02086318|Distance to menopause
986250|NCT02086305|Transitional care
986251|NCT02086305|Supportive and palliative care
986252|NCT02086292|Injections
986253|NCT02086292|Lidocaine
986254|NCT02086292|Pain
986255|NCT02086292|Healthy volunteers
986256|NCT02086279|AMH levels
986257|NCT02086279|Ovarian reserve
986258|NCT02086279|GnRH analogue
986259|NCT02086279|Ovarian reserve after GnRH analogue
986260|NCT02086279|Ovarian reserve modification
986261|NCT02086279|Antral follicle count
986262|NCT02086279|Antral follicle count after GnRH analogue
986263|NCT02086266|Prostatectomy
986264|NCT02086266|Urinary Continence
986265|NCT02086266|Physical Therapy Modalities
986266|NCT02086266|Pelvic Floor
986267|NCT02086266|Randomized Trial.
986268|NCT02086253|Endothelin, endothelium, flow-mediated dilatation
986269|NCT02086227|Bioequivalence
986270|NCT02086214|Upper limb
986271|NCT02086214|Proprioceptive pressure therapy
986272|NCT02086214|Children
986273|NCT02086214|Assisting Hand Assessment performance
986274|NCT02086201|major depression
986275|NCT02086201|depression
986276|NCT02086201|depressive disorder
986277|NCT02086201|mental health
986278|NCT02086201|mental disorder
986279|NCT02086188|Multiple Sclerosis
986280|NCT02086188|Overactive Bladder
986281|NCT02086188|Incontinence
986282|NCT02086188|Voiding
986283|NCT02086188|Bladder Urgency
986284|NCT02086188|Pelvic Floor Exercises
986286|NCT02086162|Schizophrenia
986287|NCT02086162|Smoking
986288|NCT02086162|Tobacco
986289|NCT02086162|Motivation
986290|NCT02086162|Cessation Treatment
986291|NCT02086149|Quit smoking
986292|NCT02086149|Exercise
986293|NCT02086149|Tobacco
986294|NCT02086149|Smoking
986295|NCT02086136|aortic dissection
986296|NCT02086136|diagnosis
986297|NCT02086136|emergency medicine
986298|NCT02086136|d-dimer
986299|NCT02086123|Analgesia
986300|NCT02086123|Epidural Analgesia
986301|NCT02086123|Narcotic Analgesia
986302|NCT02086123|Patient Controlled Analgesia
986303|NCT02086123|Anesthesia and Analgesia
986304|NCT02086123|Anti inflammatory Analgesics
986305|NCT02086123|NSAIDS
986306|NCT02086110|probiotic
986307|NCT02086110|prebiotic
986308|NCT02086110|autism
986309|NCT02086110|oligosaccharides
986310|NCT02086110|Bifidobacterium infantis
986311|NCT02086097|pain
986312|NCT02086097|symptomatic irreversible pulpitis
986313|NCT02086097|postoperative dental pain
986314|NCT02086084|Acute Exacerbation Chronic Obstructive Pulmonary Disease
986315|NCT02086084|AECOPD
986316|NCT02086084|Non invasive ventilation
986317|NCT02086084|NIV
986318|NCT02086084|Extracorporeal carbon dioxide removal
986319|NCT02086084|ECCO2R
986320|NCT02086071|REBIOP re-biopsies advanced or metastatic NSCLC
986321|NCT02086058|overactive bladder
986322|NCT02086058|daytime urinary incontinence
986323|NCT02086058|children
986324|NCT02086058|gene expression
986325|NCT02086045|Coronary artery disease
986326|NCT02086032|Sleeping quality
986327|NCT02086032|menopause
986328|NCT02086032|climacteric
986329|NCT02086032|progestin
986330|NCT02086032|dydrogesterone
986331|NCT02086032|micronized progesterone
986332|NCT02086019|Revascularisation, octogenarian,acute coronary syndromes
986333|NCT02086006|Coronary artery disease
986334|NCT02085993|romiplostim,
986335|NCT02085993|Nplate,
986336|NCT02085993|immune thrombocytopenic purpura
986337|NCT02085967|Healthy
986338|NCT02085967|Metabolism
986339|NCT02085967|Drug-Drug Interactions
986340|NCT02085941|Head and Neck Neoplasms
986341|NCT02085941|Malignant Neoplasm of Vertebral Column
986342|NCT02085928|Tennis elbow
986343|NCT02085928|Lateral epicondylitis
986344|NCT02085928|Intratissue percutaneous electrolysis
986345|NCT02085928|Eccentric exercise
986346|NCT02085928|Ultrasonography
986347|NCT02085876|patients
986348|NCT02085876|present
986349|NCT02085876|undergo bariatric surgery
986350|NCT02085811|Kyphoplasty
986351|NCT02085811|at a single level
986352|NCT02085811|(between T11 and L5)
986353|NCT02085811|associated surgery
986354|NCT02085798|Leukemia, Myelomonocytic, Chronic, myelodysplastic syndrome, Prospective, Treatment strategy, epidemiologic data
986355|NCT02085785|weight loss
986356|NCT02085785|exercise
986357|NCT02085785|home-based
986358|NCT02085785|lower extremity amputation
986359|NCT02085785|pilot study
986360|NCT02085759|Healthy
986361|NCT02085733|Arthritis, Septic
986362|NCT02085681|Diabetic Retinopathy
986363|NCT02085681|Screening
986364|NCT02085681|Tele-medicine
986365|NCT02085681|Retinal Imaging
986366|NCT02085681|Remote diagnosis
986367|NCT02085668|Chronic Heart Failure
986368|NCT02085668|Cardio-Renal Syndrome
986369|NCT02085668|Renal Denervation
986370|NCT02085668|Symplicity
986371|NCT02085668|Sympathetic activation
986372|NCT02085655|Extranodal NK/T-cell lymphoma
986373|NCT02085655|PA-Gemox regimen
986374|NCT02085655|thalidomide
986375|NCT02085642|Stroke
986376|NCT02085642|Acupuncture
986377|NCT02085642|Gait
986378|NCT02085642|Spasticity
986379|NCT02085629|renal failure, end stage
986380|NCT02085629|renal transplantation
986381|NCT02085629|cell therapy
986382|NCT02085629|macrophages, monocyte derived
986383|NCT02085629|immune tolerance
986384|NCT02085629|ONE Study
986385|NCT02085629|immunotherapy
986386|NCT02085616|Smoking cessation
986387|NCT02085616|Tobacco cessation
986388|NCT02085616|Quitline
986389|NCT02085616|Telephone counselling
986390|NCT02085616|Intensity
986391|NCT02085603|advanced solid malignancies
986392|NCT02085590|BCG vaccine
986393|NCT02085590|Sepsis
986394|NCT02085590|Immunity
986395|NCT02085577|Morphine consumption
986396|NCT02085577|Postoperative pain
986397|NCT02085577|Ketamine
986398|NCT02085577|Side effects
986399|NCT02085577|Spine surgery
986400|NCT02085577|Chronic pain
986401|NCT02085564|Gastroesophageal-junction cancer
986402|NCT02085564|neoadjuvant chemotherapy
986403|NCT02085551|peripheral arterial occlusion
986404|NCT02085551|visceral emboli
986405|NCT02085551|limb ischemia
986406|NCT02085551|adverse events
986407|NCT02085551|Indigo System
986408|NCT02085551|aspiration
986409|NCT02085551|mechanical thrombectomy
986410|NCT02085538|renal impairment
986411|NCT02085538|AUC
986412|NCT02085538|Cmax
986413|NCT02085538|palbociclib
986414|NCT02085538|normal matched subjects
986415|NCT02085512|Post Traumatic Stress Disorder (PTSD)
986416|NCT02085512|Major Depression
986417|NCT02085512|Secondary Prevention
986418|NCT02085512|Neurocognitive Retraining
986419|NCT02085512|Randomized Controlled Trial
986420|NCT02085499|nasal ventilation
986421|NCT02085499|premature infants
986422|NCT02085499|synchronized ventilation
986428|NCT02085447|Homelessness
986429|NCT02085447|Antipsychotic Drugs
986430|NCT02085447|Antipsychotics
986431|NCT02085447|Injectables
986432|NCT02085447|Long Acting Injectable Antipsychotic
986433|NCT02085447|Psychotic Disorders
986434|NCT02085447|Schizophrenia
986435|NCT02085447|Schizoaffective Disorder
986436|NCT02085447|Medication Adherence
986437|NCT02085447|Medication Non-Adherence
986438|NCT02085447|Community Mental Health Centers
986439|NCT02085421|tdcs, neuromodulation, CRT, psychosis, schizophrenia
986440|NCT02085395|Actinic Keratosis, AK, Bowen's Disease, Bowen
986441|NCT02085382|Kangaroo Mother Care(KMC), Low-birth weight, neonates
986442|NCT02085369|bariatric surgery
986443|NCT02085369|cognitive function
986444|NCT02085369|gene expression
986445|NCT02085356|HIV
986446|NCT02085356|PMTCT
986447|NCT02085356|South Africa
986448|NCT02085356|Couples
986449|NCT02085356|Male involvement
986450|NCT02085343|Exposure therapy
986451|NCT02085343|Specific phobia
986452|NCT02085343|Fear of heights
986453|NCT02085343|Acrophobia
986454|NCT02085343|Safety behavior fading
986455|NCT02085343|Anti-phobic Actions
986456|NCT02085317|Microcirculation
986457|NCT02085317|Leprosy
986458|NCT02085317|Nervous system
986459|NCT02085317|Orthogonal polarization spectral (OPS) imaging
986460|NCT02085317|Laser Doppler flowmetry
986461|NCT02085317|Iontophoresis.
986462|NCT02085304|Glioblastoma
986463|NCT02085304|GBM
986464|NCT02085304|Radiation
986465|NCT02085304|GammaKnife(R)
986466|NCT02085304|Radiosurgery
986467|NCT02085304|Gliadel(R)
986468|NCT02085304|Temozolomide
986469|NCT02085304|Temodar(R)
986470|NCT02085291|septic shock, microcirculation, fluid
986471|NCT02085278|arteriovenous malformation
986472|NCT02085278|Brain
986473|NCT02085278|AVM
986474|NCT02085278|Onyx
986475|NCT02085278|Micro catheter
986476|NCT02085278|catheter entrapment,
986477|NCT02085278|Embolization
986478|NCT02085278|Vein Of Galen
986479|NCT02085265|Alzheimer's Disease
986480|NCT02085265|Hypertension
986481|NCT02085265|Perindopril
986482|NCT02085265|Telmisartan
986483|NCT02085265|Brain atrophy
986484|NCT02085252|Drug Therapy
986485|NCT02085239|Breast Biopsy
986486|NCT02085239|Ultrasound
986487|NCT02085239|Lidocaine
986488|NCT02085239|Ropivacaine
986489|NCT02085239|Breast Lesion
986490|NCT02085226|Stroke
986491|NCT02085226|Rehabilitation
986492|NCT02085226|Creative Engagement
986493|NCT02085226|Psychosocial
986494|NCT02085226|Art
986495|NCT02085213|Retained placenta
986496|NCT02085213|Manual Removal of Placenta
986497|NCT02085213|Glyceryl Trinitrate
986498|NCT02085200|glenohumeral internal rotation deficit
986499|NCT02085200|overhead athlete
986500|NCT02085200|shoulder exercise
986501|NCT02085200|posterior glenohumeral capsule
986502|NCT02085200|posteroinferior glenohumeral ligament
986503|NCT02085200|posterior rotator cuff
986504|NCT02085187|Pulmonary rehabilitation
986505|NCT02085187|Training
986506|NCT02085187|Counselling
986507|NCT02085187|Telemedicine
986508|NCT02085187|Videoconference
986509|NCT02085187|COPD
986510|NCT02085187|Chronic disease
986511|NCT02085187|Internet.
986512|NCT02085148|Pediatric cancer
986513|NCT02085135|depression
986514|NCT02085135|major depressive disorder
986515|NCT02085135|Alkermes
986516|NCT02085135|ALKS 5461
986517|NCT02085135|samidorphan
986518|NCT02085135|buprenorphine
986519|NCT02085109|Cardiovascular Diseases
986520|NCT02085109|HDL metabolism
986521|NCT02085109|ApoA-I
986522|NCT02085109|High fat
986523|NCT02085109|Theobromine
986524|NCT02085096|Caregivers
986525|NCT02085096|Coping Skills
986526|NCT02085083|Inflammatory Bowel Disease
986527|NCT02085083|Transition
986528|NCT02085083|Adolescent
986529|NCT02085083|Chronic Disease
986530|NCT02085083|Colitis, Ulcerative
986531|NCT02085044|malnutrition
986532|NCT02085044|children's health
986533|NCT02085044|prevention
986534|NCT02085044|ready-to-use supplementary food
986535|NCT02085044|lipid based nutrient supplement
986536|NCT02085044|chad
986537|NCT02085044|children
986538|NCT02085031|Roux-en-Y Anastomosis
986539|NCT02085031|laparoscopic surgery
986540|NCT02085031|minilaparotomy
986541|NCT02085031|stomach neoplasms
986542|NCT02085018|omeprazole, idiopathic pulmonary fibrosis
986543|NCT02084992|Congestive Heart Failure
986544|NCT02084992|Disease management
986545|NCT02084992|Hospitalization
986546|NCT02084979|Primary care mental health consultation
986547|NCT02084979|Telepsychiatry
986548|NCT02084979|Asynchronous telepsychiatry
986549|NCT02084966|Kidney
986550|NCT02084966|Transplantation
986551|NCT02084966|Imaging
986552|NCT02084966|Renal function
986553|NCT02084966|Optical Coherence Tomography
986554|NCT02084940|PCOS
986555|NCT02084940|OHSS
986556|NCT02084940|GnRH antagonist
986557|NCT02084940|IVF
986558|NCT02084940|COH
986559|NCT02084914|endometrial scratching
986560|NCT02084914|pipelle
986561|NCT02084914|pregnancy rate
986562|NCT02084914|unexplained infertility
986563|NCT02084901|Biodegradable stents
986564|NCT02084901|converage
986565|NCT02084901|OCT
986566|NCT02084875|Food effect
986567|NCT02084875|pharmacokinetic
986568|NCT02084875|healthy volunteer
986569|NCT02084862|Tracheostomy
986570|NCT02084862|Ultrasound
986571|NCT02084836|fMRI obesity adolescents
986572|NCT02084797|arginine vasopressin
986573|NCT02084797|sweat sodium
986574|NCT02084797|V2 antagonist
986575|NCT02084797|running
986576|NCT02084784|Near-infrared fluorescence
986577|NCT02084784|Image guided surgery
986578|NCT02084784|Breast cancer;
986579|NCT02084784|Sentinel lymph node biopsy
986580|NCT02084784|Indocyanine green
986581|NCT02084784|Methylene blue
986582|NCT02084771|contrast nephropathy
986583|NCT02084771|contrast induced acute kidney injury
986584|NCT02084771|acute kidney injury
986585|NCT02084771|prophylaxis
986586|NCT02084771|randomized trial
986587|NCT02084758|COPD
986588|NCT02084758|nitrate supplementation
986589|NCT02084758|metabolic efficiency
986590|NCT02084745|Boston keratoprosthesis
986591|NCT02084745|Glaucoma drainage device
986592|NCT02084745|Ahmed tube shunt
986593|NCT02084732|Sorafenib, thyroid neoplasms, salicylic acid
986594|NCT02084680|Prenatal
986595|NCT02084680|Newborn care
986596|NCT02084680|mobile phones
986597|NCT02084654|prediabetes
986598|NCT02084654|exenatide
986599|NCT02084654|weight loss
986600|NCT02084654|insulin resistance
986601|NCT02084654|acute insulin response
986602|NCT02084654|insulin secretion
986603|NCT02084641|ectopic fat
986604|NCT02084641|obesity
986605|NCT02084641|triglyceride storage
986606|NCT02084641|adipocyte
986607|NCT02084641|overfeeding
986608|NCT02084641|intrahepatic fat
986609|NCT02084641|adipocyte proliferation
986610|NCT02084641|inflammation
986611|NCT02084641|macrophage
986612|NCT02084615|Aspirin
986613|NCT02084615|Postoperative hemorrhage
986614|NCT02084615|Inguinal hernia
986615|NCT02084602|artesunate
986616|NCT02084602|mefloquine
986617|NCT02084602|falciparum
986618|NCT02084602|peruvian amazon
986619|NCT02084589|PCEA, labor analgesia, background infusion, ropivacaine
986620|NCT02084576|Cystoid macular edema
986621|NCT02084576|nonsteroidal anti-inflammatory drug
986622|NCT02084576|OCT
986623|NCT02084576|phacoemulsification.
986624|NCT02084563|Acute Myeloid Leukemia
986625|NCT02084563|Myeloproliferative Neoplasms
986626|NCT02084563|Myelodysplastic Syndromes
986627|NCT02084563|Myeloproliferative/Myelodysplastic Neoplasm
986628|NCT02084563|Leukemia
986629|NCT02084563|MDS
986630|NCT02084563|MPN
986631|NCT02084563|AML
986632|NCT02084563|Chronic myelomonocytic leukemia (CMML)
986633|NCT02084563|Polycythemia Vera (PV)
986634|NCT02084563|Essential Thrombocythemia (ET)
986635|NCT02084563|Myelofibrosis (MF)
986636|NCT02084537|symptomatic
986637|NCT02084537|infected
986638|NCT02084537|necrotic collection
986639|NCT02084524|vulnerable
986640|NCT02084524|nutrition
986641|NCT02084524|cancer
986642|NCT02084524|colorectal
986643|NCT02084524|tumor
986644|NCT02084498|Automated bolus calculator (ABC)
986645|NCT02084498|Advanced carbohydrate counting (ACC)
986646|NCT02084498|Patient empowerment
986647|NCT02084485|COPD
986648|NCT02084485|LPS
986649|NCT02084472|atopic eczema
986650|NCT02084472|moisturisers
986651|NCT02084472|alternatives
986652|NCT02084472|affordable
986653|NCT02084459|Chronic pain
986654|NCT02084459|Supportive care
986655|NCT02084459|Psychosocial Circumstances
986656|NCT02084459|Autonomy support
986657|NCT02084459|Nursing intervention
986658|NCT02084446|Everolimus
986659|NCT02084446|Tacrolimus
986660|NCT02084446|Sodium Mycophenolate
986661|NCT02084446|CMV
986662|NCT02084446|Graft function
986663|NCT02084446|Acute rejection
986664|NCT02084433|MIH of the first permanent molar
986665|NCT02084407|DM1
986666|NCT02084407|Cardiopathy
986667|NCT02084407|Adult
986668|NCT02084394|CBF autoregulation, rSO2,doppler, TCD, delirium,
986669|NCT02084381|CKD5, dialysis, high porous membranes
986670|NCT02084368|combined lumbar plexus and sciatic nerve block，
986671|NCT02084368|combined spinal and epidural anesthesia
986672|NCT02084355|Significant cancer pain
986673|NCT02084355|at least numeric rating scale 4
986674|NCT02084342|desmopressin
986675|NCT02084342|tranexamic acid
986676|NCT02084342|blood loss
986677|NCT02084342|transfusion need
986678|NCT02084342|posterior scoliosis orthopedics
986679|NCT02084329|Physiotherapy
986680|NCT02084329|Physical therapy
986681|NCT02084329|neurotrauma rehabilitation
986682|NCT02084329|Rehabilitation
986683|NCT02084329|Balance
986684|NCT02084329|Balance Confidence
986685|NCT02084329|concussion
986686|NCT02084329|Post-Concussion
986687|NCT02084329|Mild Traumatic Brain Injury
986688|NCT02084316|China CDC
986689|NCT02084316|One4All testing algorithm
986690|NCT02084316|Guangxi Autonomous Region
986691|NCT02084316|Testing and Linkage to HIV Care in China
986692|NCT02084290|Crohn's disease
986693|NCT02084290|Shared Decision Making
986694|NCT02084290|Decision Aid
986695|NCT02084277|Oral health-related quality of life (OHRQoL)
986696|NCT02084277|Self-ligating brackets (SLB)
986697|NCT02084277|Conventional brackets (CB)
986698|NCT02084277|Oral Health Impact Profile-14 (OHIP-14)
986699|NCT02084277|Short Form-36 (SF-36)
986700|NCT02084264|Adolescent Idiopathic Scoliosis
986701|NCT02084264|Pediatric Scoliosis
986702|NCT02084251|safety,
986703|NCT02084251|pharmacokinetics,
986704|NCT02084251|Long acting GLP-1 analogue
986705|NCT02084238|SLE, IL-2
986706|NCT02084225|low resource
986707|NCT02084225|conflict setting
986708|NCT02084225|ultrasound guided regional anesthesia
986709|NCT02084225|acute injuries
986710|NCT02084225|pain management
986711|NCT02084225|education
986712|NCT02084225|ultrasound
986713|NCT02084225|trauma
986714|NCT02084225|emergency department
986715|NCT02084173|alcohol
986716|NCT02084173|60+ years
986717|NCT02084173|treatment
986718|NCT02084173|met
986719|NCT02084173|cra
986720|NCT02084173|multi site
986721|NCT02084173|multi country
986722|NCT02084173|questionnaire
986723|NCT02084173|random
986724|NCT02084134|pituitary adenoma
986725|NCT02084134|Pituitary Tumor
986726|NCT02084134|transsphenoidal resection
986727|NCT02084134|pituitary cyst
986728|NCT02084121|metachromatic leukodystrophy
986729|NCT02084108|Frail and dependent older adults
986730|NCT02084108|Integrated care
986731|NCT02084108|Home care
986732|NCT02084108|Multidimensional geriatric assessment
986733|NCT02084108|RAI-HC (resident assessment instrument- Home care)
986734|NCT02084108|Palliative care.
986735|NCT02084043|aerosol delivery
986736|NCT02084043|vibrating mesh nebulizer
986737|NCT02084043|breath-actuated nebulizer
986738|NCT02084043|non invasive ventilation
986739|NCT02084043|bilevel ventilator
986740|NCT02084043|single limb circuit ventilator
986741|NCT02084043|Amikacin
986742|NCT02084030|cardiac surgery
986743|NCT02084030|POCD
986744|NCT02084030|GWAS
986745|NCT02084030|Susceptibility gene
986746|NCT02084017|Surgical Site Infection
986747|NCT02084017|Vascular Surgery
986748|NCT02084017|Negative Pressure Wound Therapy
986749|NCT02084004|Type 2 diabetes mellitus
986750|NCT02084004|Berberine Hydrochloride
986751|NCT02084004|Bifidobacterium
986752|NCT02083991|NODAT
986753|NCT02083991|Renal transplantation
986754|NCT02083991|Corticosteroids avoidance
986755|NCT02083991|CNI minimization
986756|NCT02083978|Bipolar Disorder
986757|NCT02083978|Magnetic Resonance Imaging (MRI) scanning
986758|NCT02083939|Inguinal hernia
986759|NCT02083939|Mesh repair
986760|NCT02083939|Prophylactic Antibiotics
986761|NCT02083939|Herniorrhaphy
986762|NCT02083939|Laparoscopic Inguinal Hernia Repair
986763|NCT02083926|Social Anxiety Disorder
986764|NCT02083926|SAD
986765|NCT02083926|Ketamine
986766|NCT02083913|Severely obese
986767|NCT02083913|Bariatric surgery
986768|NCT02083913|Physical activity
986769|NCT02083913|Physical fitness
986770|NCT02083913|Telehealth
986771|NCT02083913|Quality of life
986772|NCT02083887|Immune response
986773|NCT02083887|Vaccine
986774|NCT02083887|Malaria
986775|NCT02083874|cannabidiol
986776|NCT02083874|CBD
986777|NCT02083874|marijuana
986778|NCT02083874|withdrawal
986779|NCT02083874|treatment
986780|NCT02083861|osteoarthritis
986781|NCT02083861|arthritis
986782|NCT02083861|musculoskeletal
986783|NCT02083861|connective tissue disease
986784|NCT02083861|ultrasound
986785|NCT02083861|pain
986786|NCT02083861|mobility
986787|NCT02083861|heat
986788|NCT02083861|strength
986789|NCT02083861|ZetrOZ
986790|NCT02083861|LITUS
986791|NCT02083861|Sam
986792|NCT02083861|grade 1
986793|NCT02083861|grade 2
986794|NCT02083848|Locoregional invasion
986795|NCT02083848|Stage IB1, IB2, IIA or IIB
986796|NCT02083835|post-operative pain
986797|NCT02083822|premature baby
986798|NCT02083822|MRI : conventional and advanced images
986799|NCT02083822|Executive function testing at 5 years of age
986800|NCT02083796|manual therapy
986801|NCT02083796|rehabilitation
986802|NCT02083796|shoulder
986803|NCT02083796|spine
986804|NCT02083770|Hispanics
986805|NCT02083770|Patient Participation
986806|NCT02083770|Refusal to Participate
986807|NCT02083770|Education
986808|NCT02083770|Clinical Trials
986809|NCT02083757|Fluid responsiveness; Passive leg raising
986810|NCT02083744|Congestive Heart Failure
986811|NCT02083744|Self-care
986812|NCT02083744|Spanish
986813|NCT02083731|CMV infection
986814|NCT02083731|Mesenchymal Stem Cells
986815|NCT02083731|Allogeneic hematopoietic stem cell transplantation
986816|NCT02083718|Poor Graft Function
986817|NCT02083718|Peripheral Blood Stem Cell
986818|NCT02083718|Mesenchymal Stem Cells
986819|NCT02083718|Allogeneic hematopoietic stem cell transplantation
986820|NCT02083705|Chest compression, Delivery Room, NICU,
986821|NCT02083679|Carcinoma, Non-Small-Cell Lung
986822|NCT02083679|Sym004
986823|NCT02083666|Phase I
986824|NCT02083666|Dose cohorts
986825|NCT02083666|Escalating dose
986826|NCT02083666|Single dose
986827|NCT02083666|Multiple dose
986828|NCT02083666|Safety
986829|NCT02083666|Tolerability
986830|NCT02083666|Pharmacokinetics
986831|NCT02083666|Pharmacodynamics
986832|NCT02083666|volunteers
986838|NCT02083640|healthy volunteer
986839|NCT02083640|bioavailability
986840|NCT02083640|palbociclib
986841|NCT02083640|formulation
986842|NCT02083627|Pharmacokinetics
986843|NCT02083627|Drug-Drug Interaction
986844|NCT02083627|Intestinal Absorption
986845|NCT02083627|Fidaxomicin
986846|NCT02083627|Rosuvastatin
986847|NCT02083627|Multiple Doses
986848|NCT02083627|Single Doses
986849|NCT02083601|Caregivers
986850|NCT02083601|Spinal Cord Injuries
986851|NCT02083601|Psychology, Educational
986852|NCT02083601|Counseling
986853|NCT02083601|Outcome Assessment (Health Care)
986854|NCT02083588|Fibromyalgia
986855|NCT02083588|dTMS
986856|NCT02083588|pain
986857|NCT02083588|PFC
986858|NCT02083588|Subjects with Fibromyalgia
986859|NCT02083575|vitamin c
986860|NCT02083575|thalassemia major
986861|NCT02083575|iron chelation
986862|NCT02083562|Bronchopulmonary dysplasia, preterm infant
986863|NCT02083549|Massive Transfusion Protocol
986864|NCT02083536|Low Dose Fractionated Whole Abdominal Radiation Therapy
986865|NCT02083536|LDFWART
986866|NCT02083536|Docetaxel
986867|NCT02083536|Ovarian Cancer
986868|NCT02083536|Ovarian Carcinoma
986869|NCT02083536|Platinum-Resistant
986870|NCT02083523|Motivational Interview, normative feedback, adolescents
986871|NCT02083510|Colchicine
986872|NCT02083510|Hypertriglyceridemia
986873|NCT02083510|Apolipoprotein CIII
986874|NCT02083497|kick
986875|NCT02083497|taping
986876|NCT02083497|dynamic equilibrium
986877|NCT02083458|critical care
986878|NCT02083458|catheterization
986879|NCT02083458|axillary vein
986880|NCT02083445|Traumatic brain injury
986881|NCT02083445|Exercise
986882|NCT02083445|Psychology
986883|NCT02083445|Physiology
986884|NCT02083445|Progenitor cells
986885|NCT02083445|Hypoxia
986886|NCT02083432|intra-oral injections
986887|NCT02083432|CBT
986888|NCT02083432|Blood-Injury-Injection-phobia
986889|NCT02083432|DSM-IV. 300.29
986890|NCT02083419|Left Ventricular Assist Devices (LVAD)
986891|NCT02083419|Cardiac Resynchronization Devices (CRT)
986892|NCT02083406|Malaria
986893|NCT02083406|Bio-availability
986894|NCT02083393|dendritic cell
986895|NCT02083380|Plasmodium falciparum malaria
986896|NCT02083380|malaria
986897|NCT02083380|OZ439
986898|NCT02083380|piperaquine
986899|NCT02083380|PQP
986900|NCT02083354|melanoma
986901|NCT02083354|dabrafenib
986902|NCT02083354|trametinib
986903|NCT02083328|heart rate variability
986904|NCT02083328|exercise performance
986905|NCT02083315|acute pain, analgesia, respiratory drive, ventilator response to hypercapnia, pupillometry
986906|NCT02083302|campus sexual assault
986907|NCT02083302|bystander intervention
986908|NCT02083289|ONO-9054
986909|NCT02083289|ocular hypertension (OHT)
986910|NCT02083289|Open angle-glaucoma (OAG)
986911|NCT02083289|Glaucoma
986912|NCT02083289|Eye Diseases
986913|NCT02083289|Mild to moderate
986914|NCT02083276|Chlamydia trachomatis
986915|NCT02083276|Urethritis
986916|NCT02083276|Genital Diseases, Male
986917|NCT02083263|Lung function
986918|NCT02083250|Leukemia
986919|NCT02083250|Blood And Marrow Transplantation
986920|NCT02083250|Acute lymphoblastic leukemia
986921|NCT02083250|ALL
986922|NCT02083250|Acute myeloid leukemia
986923|NCT02083250|AML
986924|NCT02083250|Myelodysplastic syndrome
986925|NCT02083250|MDS
986926|NCT02083250|Allogeneic stem cell transplant
986927|NCT02083250|SCT
986928|NCT02083250|Thymoglobulin
986929|NCT02083250|ATG
986930|NCT02083250|Antithymocyte Globulin
986931|NCT02083250|Fludarabine
986932|NCT02083250|Fludarabine Phosphate
986933|NCT02083250|Fludara
986934|NCT02083250|Clofarabine
986935|NCT02083250|Clofarex
986936|NCT02083250|Clolar
986937|NCT02083250|Busulfan
986938|NCT02083250|Busulfex
986939|NCT02083250|Myleran
986940|NCT02083250|SAHA
986941|NCT02083250|Vorinostat
986942|NCT02083250|Suberoylanilide Hydroxamic Acid
986943|NCT02083250|MSK-390
986944|NCT02083250|Zolinza
986945|NCT02083237|mild cognitive impairment
986946|NCT02083237|memory training
986947|NCT02083237|healthy lifestyle
986948|NCT02083237|psychosocial support
986949|NCT02083211|Cervical cancer
986950|NCT02083211|Recurrent or persistent tumor
986951|NCT02083211|Monoclonal antibody
986955|NCT02083172|USCOM (UltraSound Cardiac Output Monitor)
986956|NCT02083172|2D echocardiography
986957|NCT02083172|agreement
986958|NCT02083172|pediatrics
986959|NCT02083133|Diabetes
986960|NCT02083133|Renal Failure
986961|NCT02083133|Dialysis
986962|NCT02083133|End Stage Renal Disease
986963|NCT02083133|Hypoglycemia
986964|NCT02083120|high flow
986965|NCT02083120|COPD
986966|NCT02083120|AIRVO
986967|NCT02083107|Postpartum hemorrhage
986968|NCT02083107|Intrapartum blood loss
986969|NCT02083107|Misoprostol
986970|NCT02083081|tobacco
986971|NCT02083081|smoking
986972|NCT02083068|Malaria, vaccine, P. vivax
986973|NCT02083055|dexmedetomidine
986974|NCT02083055|controlled hypotensive anesthesia
986975|NCT02083042|CMV
986976|NCT02083042|T-Track CMV
986977|NCT02083042|kidney transplantation
986978|NCT02083029|Asthma
986979|NCT02083029|Death
986980|NCT02083029|Mechanism
986981|NCT02083029|Syncope
986982|NCT02083029|Dive reflex
986983|NCT02083003|Pain
986984|NCT02083003|Polyamine
986985|NCT02083003|Cholecystectomy
986986|NCT02082990|Alcohol-related disorders
986987|NCT02082990|Alcohol Drinking
986988|NCT02082990|e-health
986989|NCT02082990|Alcohol Use Disorder Test
986990|NCT02082990|Quality of Life
986991|NCT02082977|Refractory
986992|NCT02082977|Phase I study, dose escalation study
986993|NCT02082977|diffuse large B cell lymphoma
986994|NCT02082977|Relapsed
986995|NCT02082977|Solid tumors
986996|NCT02082977|transformed follicular lymphoma
986997|NCT02082977|Multiple myeloma
986998|NCT02082977|GSK2816126
986999|NCT02082977|Non-Hodgkin's lymphoma
987000|NCT02082938|stroke,
987001|NCT02082938|rehabilitation,
987002|NCT02082938|hemiparesis,
987003|NCT02082938|gait training
987004|NCT02082925|Exercise training
987005|NCT02082925|Dyspnea threshold
987006|NCT02082925|6MWT
987007|NCT02082899|Allergic Conjunctivitis
987008|NCT02082899|Interleukin 1 Receptor Inhibitor
987009|NCT02082899|Environmental Exposure Chamber
987010|NCT02082899|Conjunctival Allergen Provocation Test
987011|NCT02082886|Metastasis
987012|NCT02082886|Carcinomatosis
987013|NCT02082886|Carcinosis
987014|NCT02082886|Sarcomatosis
987015|NCT02082886|CRS
987016|NCT02082886|Cytoreductive surgery
987017|NCT02082886|HIPEC
987018|NCT02082886|Heated Intraperitoneal Chemotherapy
987019|NCT02082886|Intra-abdominal
987020|NCT02082886|Sugarbaker technique
987021|NCT02082886|Mitomycin C
987022|NCT02082886|Cisplatin
987023|NCT02082886|Doxorubicin
987024|NCT02082886|Oxaliplatin
987025|NCT02082886|Melphalan
987026|NCT02082873|Quantitative EEG
987027|NCT02082873|Nonconvulsive seizures
987028|NCT02082873|ICU EEG monitoring
987029|NCT02082860|Porphyria
987030|NCT02082860|Gene therapy
987031|NCT02082860|AAV
987032|NCT02082860|Liver gene transfer
987033|NCT02082834|Endovascular aneurysm repair EVAR
987034|NCT02082834|Endoleak/diagnosis
987035|NCT02082834|VEOTM
987036|NCT02082834|Model-based iterative reconstruction (MBIR)
987037|NCT02082834|Adaptive statistical iterative reconstruction (ASIR)
987038|NCT02082834|Aortic Aneurysm
987039|NCT02082834|Low dose
987040|NCT02082834|Prospective
987041|NCT02082834|CTA
987042|NCT02082808|Dolutegravir
987043|NCT02082808|healthy volunteer
987044|NCT02082808|pharmacokinetics
987045|NCT02082808|daclatasvir
987046|NCT02082808|drug interaction
987047|NCT02082795|Breech presentation
987048|NCT02082795|External cephalic version
987049|NCT02082795|Anaesthesia
987050|NCT02082795|Qualitative
987051|NCT02082795|Pregnancy
987052|NCT02082782|Colorectal liver metastases (CRLM)
987053|NCT02082782|Tumor ablation
987054|NCT02082782|Irreversible electroporation (IRE)
987055|NCT02082782|Interventional oncology
987056|NCT02082782|NanoKnife
987057|NCT02082782|Colorectal liver metastasis, unresectable and not-thermally ablative due to location near vulnerable structures like vessels or bile ducts
987058|NCT02082769|Gout
987059|NCT02082769|Uric Acid
987060|NCT02082769|Xanthine oxidase
987061|NCT02082769|Febuxostat
987062|NCT02082756|Prediabetes
987063|NCT02082756|Berberine Hydrochloride
987064|NCT02082756|Bifidobacterium
987065|NCT02082743|Myopia
987066|NCT02082743|Outdoor activity
987067|NCT02082743|Recess outside classroom
987068|NCT02082730|CFS/ME, Chronic fatigue syndrome, Pediatric, remote mobile technology
987069|NCT02082704|Diabetes
987070|NCT02082704|Education, Patient
987071|NCT02082704|Educational Technology
987072|NCT02082691|G-202
987073|NCT02082691|Hepatocellular
987074|NCT02082678|Bipolar Disorder
987075|NCT02082678|BPD
987076|NCT02082678|Alcohol Use Disorder
987077|NCT02082678|Alcohol Abuse
987078|NCT02082678|Alcohol Dependence
987079|NCT02082678|Ondansetron
987080|NCT02082678|Cognition
987081|NCT02082678|Mood
987082|NCT02082665|rosuvastatin
987083|NCT02082665|BRAF V600
987084|NCT02082665|Melanoma
987085|NCT02082665|dabrafenib
987086|NCT02082665|midazolam
987087|NCT02082652|Etonogestrel
987088|NCT02082652|Efavirenz
987089|NCT02082652|Nevirapine
987090|NCT02082652|Pharmacokinetics
987091|NCT02082639|Adolescents
987092|NCT02082639|Havrix
987093|NCT02082639|Immunogenicity
987094|NCT02082639|Cervarix
987095|NCT02082639|Safety
987096|NCT02082626|Phase I
987097|NCT02082626|Pediatric
987098|NCT02082626|Cancer
987099|NCT02082626|Lymphoma
987100|NCT02082626|Eribulin
987101|NCT02082613|Testicular hydrocele
987102|NCT02082613|Hydrocele
987103|NCT02082613|Sclerotherapy
987104|NCT02082613|Surgery
987105|NCT02082613|Complications
987106|NCT02082587|brain metastases
987107|NCT02082587|brain mets
987108|NCT02082587|WBRT
987109|NCT02082561|transdiagnostic treatment
987110|NCT02082561|cognitive behavior therapy
987111|NCT02082561|anxiety
987112|NCT02082561|panic disorder
987113|NCT02082561|generalized anxiety disorder
987114|NCT02082561|social anxiety disorder
987115|NCT02082548|atrial fibrillation
987116|NCT02082548|anticoagulation
987117|NCT02082548|education
987118|NCT02082548|educational intervention
987119|NCT02082535|Premature Birth
987120|NCT02082535|Brain Injuries
987121|NCT02082535|Leukomalacia Periventricular
987122|NCT02082535|S100B protein human
987123|NCT02082535|Glial Fibrillary Acidic Protein
987124|NCT02082535|Magnetic Resonance Imaging
987125|NCT02082535|Developmental Disabilities
987126|NCT02082522|Cholangiocarcinoma
987127|NCT02082522|Unresectable perihilar cholangiocarcinoma
987128|NCT02082522|Klatskin tumor
987129|NCT02082522|Photodynamic therapy
987130|NCT02082522|Porfimer sodium
987131|NCT02082522|Photofrin
987132|NCT02082522|Gemcitabine
987133|NCT02082522|Cisplatin
987134|NCT02082522|Stents
987135|NCT02082522|CCA
987136|NCT02082522|PDT
987137|NCT02082522|Bile duct cancer
987138|NCT02082522|Bile duct tumor
987139|NCT02082522|Bile duct adenocarcinoma
987140|NCT02082522|Chemotherapy
987141|NCT02082509|Traumatic Brain Injury
987142|NCT02082509|Post-Concussive Symptoms
987143|NCT02082509|Brain Imaging
987144|NCT02082509|Cognition
987145|NCT02082496|Obesity
987146|NCT02082496|Obesity Genetics
987147|NCT02082496|GLP-1
987148|NCT02082496|GLP-1 Receptor Agonists
987149|NCT02082483|Kidney Transplant
987150|NCT02082483|Screening
987151|NCT02082457|Irritable Bowel Syndrome
987152|NCT02082457|Constipation
987153|NCT02082457|C-IBS
987154|NCT02082431|Sensorineural hearing loss
987155|NCT02082431|Long QT Syndrome
987156|NCT02082418|Mild cognitive impairment
987157|NCT02082418|Protein digestion
987158|NCT02082418|Tryptophan digestion
987159|NCT02082418|Cognitive function
987160|NCT02082418|Mood
987161|NCT02082418|Muscle function
987162|NCT02082418|Alpha-lactalbumin
987163|NCT02082379|Interface, aerosol, child, acceptance
987164|NCT02082366|Atrial fibrillation
987165|NCT02082366|CPVI
987166|NCT02082366|TCD
987167|NCT02082366|nMARQ
987168|NCT02082366|MES
987169|NCT02082366|microembolic signals
987170|NCT02082353|Granulomatous Disease, Chronic
987171|NCT02082353|Hematopoietic Stem Cell Transplantation
987172|NCT02082340|Tuberculosis
987173|NCT02082340|Armenia
987174|NCT02082340|Clinical trial
987175|NCT02082340|Directly Observed Therapy (DOT)
987176|NCT02082340|Self-administered drug intake
987177|NCT02082327|Fabry Disease
987178|NCT02082327|Fabry
987179|NCT02082327|Lysosomal storage disorders
987180|NCT02082327|LSD
987181|NCT02082327|Amicus
987182|NCT02082327|migalastat HCl
987183|NCT02082327|migalastat
987184|NCT02082327|AT1001
987185|NCT02082314|radiofrequency ablation
987186|NCT02082314|bone metastases
987187|NCT02082288|ICSI outcome
987188|NCT02082275|Prenatal Care
987189|NCT02082275|Obstetrics
987190|NCT02082249|carbidopa
987191|NCT02082249|Tolerability
987192|NCT02082249|levodopa
987193|NCT02082249|levodopa-carbidopa intestinal gel
987194|NCT02082249|Efficacy
987195|NCT02082249|Advanced Parkinson's Disease
987196|NCT02082249|Safety
987197|NCT02082236|Plasma concentrations
987198|NCT02082223|Quality of life
987199|NCT02082223|Deficits
987200|NCT02082223|Complex gastrointestinal surgery
987201|NCT02082197|low testosterone
987202|NCT02082184|Sensing Technology
987203|NCT02082184|Type 2 Diabetes,
987204|NCT02082171|older adults
987205|NCT02082171|physical disability
987206|NCT02082171|multidomain intervention
987207|NCT02082171|prevention
987208|NCT02082171|pilot study
987209|NCT02082171|frailty
987210|NCT02082171|mobility
987211|NCT02082171|comprehensive geriatric assessment
987212|NCT02082106|alpine skiing
987213|NCT02082106|cross country skiing
987214|NCT02082106|indoor cycling
987215|NCT02082106|physical fitness
987216|NCT02082106|training status
987217|NCT02082106|metabolic equivalent
987218|NCT02082093|Chronic Kidney Disease
987219|NCT02082093|telemedicine
987220|NCT02082054|rhinitis
987221|NCT02082054|seasonal
987222|NCT02082054|allergic
987223|NCT02082015|Neuronal plasticity
987224|NCT02082015|Transcranial magnetic stimulation
987225|NCT02082015|Stroke
987226|NCT02082015|Upper extremity
987227|NCT02082015|Function
987228|NCT02082015|Recovery
987229|NCT02082002|Multiple scerlosis
987230|NCT02082002|Fatigue
987231|NCT02082002|Sleep
987232|NCT02082002|Somnolence
987233|NCT02082002|Depression
987234|NCT02082002|Cognitive disorders
987235|NCT02081989|Diabetes
987236|NCT02081989|Renal denervation
987237|NCT02081963|Nebulized amikacin;
987238|NCT02081963|Non-Cystic Fibrosis Bronchiectasis;
987239|NCT02081963|Bacterial clearance rate of sputum；
987240|NCT02081963|Acute exacerbation.
987241|NCT02081937|chimeric antigen receptor
987242|NCT02081937|immunotherapy
987243|NCT02081937|T lymphocyte
987244|NCT02081937|mantle cell lymphoma
987245|NCT02081924|Infertility
987246|NCT02081924|Kisspeptin
987247|NCT02081924|Reproductive hormones
987248|NCT02081911|adductor canal
987249|NCT02081911|femoral
987250|NCT02081911|quadriceps
987251|NCT02081898|low calorie diet
987252|NCT02081898|BMI
987253|NCT02081898|sphingomyelin
987254|NCT02081898|L-leucine
987255|NCT02081898|L-phenylalanine
987256|NCT02081885|Tricalcium phosphate
987257|NCT02081885|Chitosan
987258|NCT02081885|Grafting, Bone
987259|NCT02081885|Mandibular Fractures
987260|NCT02081872|Pharmacogenomics
987261|NCT02081872|Target Drug Related Adverse Events (TDAE)
987262|NCT02081846|transitions of care
987263|NCT02081846|reutilization
987264|NCT02081846|home nurse visit
987265|NCT02081846|focus groups
987266|NCT02081846|quality improvement
987267|NCT02081833|acute respiratory infections
987268|NCT02081833|acute gastrointestinal infections
987269|NCT02081833|children
987270|NCT02081833|child
987271|NCT02081833|symptom diary
987272|NCT02081833|nasal swabs
987273|NCT02081833|stool samples
987274|NCT02081820|hyperglycemia
987275|NCT02081820|aneurysmal subarachnoid hemorrhage
987276|NCT02081820|glycated hemoglobin
987277|NCT02081820|outcome
987278|NCT02081820|DCI
987279|NCT02081768|Rathke's cleft cyst
987280|NCT02081768|cystic craniopharyngiomas
987281|NCT02081755|Immunosuppressive Agents
987282|NCT02081755|Liver Transplantation
987283|NCT02081742|Colonoscopy, CT colonography, Colon capsule
987284|NCT02081703|Postsurgical pain
987285|NCT02081703|Total knee arthroplasty
987286|NCT02081703|Total knee replacement
987287|NCT02081690|PAH-SYMPACT
987288|NCT02081690|psychometric instrument
987289|NCT02081664|Amalgam attributed health complaints
987290|NCT02081664|feasibility pilot study
987291|NCT02081664|integrated medical care program
987292|NCT02081664|lifestyle
987294|NCT02081625|Duchenne muscular dystrophy
987295|NCT02081625|NS-065/NCNP-01
987296|NCT02081625|exon 53 skipping
987297|NCT02081625|morpholino
987298|NCT02081599|insulin resistance
987299|NCT02081586|CBT
987300|NCT02081586|Type 2 Diabetes
987301|NCT02081586|Diabetes Distress
987302|NCT02081586|Adherence
987303|NCT02081586|Smartphone App
987304|NCT02081586|Self-management
987305|NCT02081573|Brief CBT
987306|NCT02081573|smartphone app
987307|NCT02081573|mHealth
987308|NCT02081573|diabetes distress
987309|NCT02081573|adherence
987310|NCT02081560|pharmacokinetics
987311|NCT02081560|antibiotic
987312|NCT02081560|Gram negative
987313|NCT02081560|continuous renal replacement therapy
987314|NCT02081547|rectal carcinoma
987315|NCT02081547|recurrence
987316|NCT02081547|pathology
987317|NCT02081547|cytology
987318|NCT02081547|free cancer cells
987319|NCT02081547|survival
987320|NCT02081534|S-phosphate, hyperphosphatemia, hemodialysis, ESRD
987321|NCT02081521|behaviour change
987322|NCT02081521|diarrhoeal disease
987323|NCT02081521|handwashing
987324|NCT02081521|breastfeeding
987325|NCT02081521|diarrhoea management
987326|NCT02081508|Memory
987327|NCT02081495|Neoplasms
987328|NCT02081495|Neoplasms, Ovarian
987329|NCT02081495|Ovarian Cancer
987330|NCT02081495|Advanced or Refractory Solid Malignancies
987331|NCT02081495|Doxorubicin
987332|NCT02081495|DOXIL
987333|NCT02081495|CAELYX
987334|NCT02081469|Chronic hepatitis B
987335|NCT02081469|HBV
987336|NCT02081469|Chemotherapy
987337|NCT02081469|Reactivation
987338|NCT02081469|Prophylaxis
987339|NCT02081443|coronary artery disease
987340|NCT02081443|platelet function
987341|NCT02081443|ticagrelor
987342|NCT02081443|cangrelor
987343|NCT02081417|Trauma
987344|NCT02081417|Post traumatic stress disorder
987345|NCT02081417|substance use disorders
987346|NCT02081417|peer-delivered trauma treatment
987347|NCT02081404|Non-erosive Reflux Disease
987348|NCT02081391|Acute Pain
987349|NCT02081391|Post-operative
987350|NCT02081391|Tapentadol
987351|NCT02081391|Opioid Treatment
987352|NCT02081391|Pediatric Participants
987353|NCT02081378|CML
987354|NCT02081378|Ph+ ALL
987355|NCT02081352|Dermis
987356|NCT02081352|Diabetic foot ulcers
987357|NCT02081352|Skin substitutes
987358|NCT02081352|Decellularized
987359|NCT02081326|Diabetes Mellitus, Type One
987360|NCT02081326|Diabetes Mellitus, Type I
987361|NCT02081326|Autoimmune Diabetes
987362|NCT02081326|Insulin Dependent Diabetes Mellitus 1
987363|NCT02081326|IDDM
987364|NCT02081313|Netherton syndrome
987365|NCT02081313|Immune system
987366|NCT02081313|Skin barrier
987367|NCT02081300|Testosterone
987368|NCT02081300|Male hypogonadism
987369|NCT02081300|Low testosterone
987370|NCT02081300|LPCN 1021
987371|NCT02081300|Androgel
987372|NCT02081300|Testim
987373|NCT02081300|Testopel
987374|NCT02081300|Fortesta
987375|NCT02081300|Axiron.
987376|NCT02081300|Hypogonadism
987377|NCT02081300|Eunuchism
987378|NCT02081300|Gonadal Disorders
987379|NCT02081300|Endocrine System Diseases
987380|NCT02081300|Testosterone enanthate
987381|NCT02081300|Testosterone undecanoate
987382|NCT02081300|Testosterone 17 beta-cypionate
987383|NCT02081300|Methyltestosterone
987384|NCT02081300|Androgens
987385|NCT02081300|Hormones
987386|NCT02081300|Hormones, Hormone Substitutes, and Hormone Antagonists
987387|NCT02081300|Physiological Effects of Drugs
987388|NCT02081300|Pharmacologic Actions
987389|NCT02081300|Antineoplastic Agents, Hormonal
987390|NCT02081300|Antineoplastic Agents
987391|NCT02081300|Anabolic Agents
987392|NCT02081287|Bipolar Disorder
987393|NCT02081287|Depression
987394|NCT02081287|Inositol
987395|NCT02081287|Inositol Hexaphosphate
987396|NCT02081287|Phytic Acid
987397|NCT02081287|IP6
987398|NCT02081287|Lithium
987399|NCT02081287|Lamotrigine
987400|NCT02081274|tidal volume
987401|NCT02081274|congenital heart disease
987402|NCT02081274|mortality
987403|NCT02081261|coronary artery bypass surgery
987404|NCT02081261|acute kidney injury
987405|NCT02081261|creatinine
987406|NCT02081261|mortality
987407|NCT02081235|congenital heart disease
987408|NCT02081235|acute kidney injury
987409|NCT02081235|risk factor
987410|NCT02081235|anesthesia
987411|NCT02081222|congenital heart disease
987412|NCT02081222|rotational thromboelastometry
987413|NCT02081222|blood loss
987414|NCT02081222|transfusion requirements
987421|NCT02081144|Standard Care Condition
987422|NCT02081144|Texting + NRT Condition
987423|NCT02081131|periampullary cancer
987424|NCT02081131|pancreatic cancer
987425|NCT02081131|randomized controlled trial
987426|NCT02081131|Whipple's operation
987427|NCT02081131|laparoscopy
987428|NCT02081105|ARDS,
987429|NCT02081105|PEEP,
987430|NCT02081105|lung recruitment,
987431|NCT02081105|lung recruitability,
987432|NCT02081105|Chest-X-Ray,
987433|NCT02081105|lung imaging,
987434|NCT02081105|Pressure/Volume (PV) curve,
987435|NCT02081105|compliance,
987436|NCT02081105|respiratory mechanics
987437|NCT02081092|PAP
987438|NCT02081092|Pulmonary Alveolar Proteinosis
987439|NCT02081092|Pulmonary
987440|NCT02081092|Patients
987441|NCT02081079|HCV GT 4
987442|NCT02081079|HCV GT 5
987443|NCT02081053|metastatic lesions
987444|NCT02081053|vertebral body
987445|NCT02081053|ablation
987446|NCT02081053|targeted radio-frequency ablation
987447|NCT02081053|radio-frequency targeted vertebral augmentation
987448|NCT02081053|radiofrequency kyphoplasty
987449|NCT02081053|spine
987450|NCT02081053|vertebral augmentation
987451|NCT02081053|kyphoplasty
987452|NCT02081053|spinal ablation
987453|NCT02081053|pain
987454|NCT02081053|quality of life
987455|NCT02081040|brainstem
987456|NCT02081040|diaphragm
987457|NCT02081040|deglutition disorder
987458|NCT02081040|sonography
987459|NCT02081014|Hypoglycemia
987460|NCT02081014|Glucagon
987461|NCT02081014|Diabetes
987462|NCT02081001|Hypoglycemia
987463|NCT02081001|Glucagon
987464|NCT02081001|Artificial Pancreas
987465|NCT02080988|stroke
987466|NCT02080988|deglutition disorders
987467|NCT02080988|cough
987468|NCT02080988|aspiration pneumonia
987469|NCT02080988|diaphragm
987470|NCT02080988|respiratory function
987471|NCT02080962|non-melanoma skin cancer, radiotherapy, orthovoltage
987472|NCT02080949|brain metastases, hypofractionated stereotactic radiotherapy
987473|NCT02080936|Experimental approaches
987474|NCT02080936|Peripheral muscle Keyword
987475|NCT02080936|Rehabilitation
987493|NCT02080910|Caregiver
987494|NCT02080910|stroke
987495|NCT02080910|psychoeducation
987496|NCT02080910|problem-solving
987497|NCT02080897|non-surgical
987498|NCT02080897|palliative surgery
987499|NCT02080871|PAD
987500|NCT02080871|Stent
987501|NCT02080871|Claudication
987502|NCT02080871|Viabahn
987503|NCT02080871|Gore
987504|NCT02080871|Endoprosthesis
987505|NCT02080871|Vascular Diseases
987506|NCT02080871|Cardiovascular Diseases
987507|NCT02080871|Iliac Occlusive Disease
987508|NCT02080871|Balloon Expandable
987509|NCT02080871|Stent-graft
987510|NCT02080871|VBX
987511|NCT02080858|Apixaban
987512|NCT02080858|Ticagrelor
987513|NCT02080858|ASA
987514|NCT02080858|shed blood
987515|NCT02080858|perfusion chamber
987516|NCT02080845|Caffeine
987517|NCT02080845|MRI
987518|NCT02080845|Brain blood flow
987519|NCT02080845|Cognition
987520|NCT02080845|Perfusion
987521|NCT02080845|Resting functional magnetic resonance imaging (fMRI)
987522|NCT02080832|substance abuse
987523|NCT02080832|cocaine
987524|NCT02080832|impulsivity
987525|NCT02080832|serotonin
987526|NCT02080832|MRI
987527|NCT02080819|drug abuse
987528|NCT02080819|cocaine
987529|NCT02080819|impulsivity
987530|NCT02080819|dopamine
987531|NCT02080806|stroke, dysphagia, cough, mechanical insufflation exsufflation
987532|NCT02080754|Crush induction
987533|NCT02080754|Cricoid pressure
987534|NCT02080754|Sellick maneuver
987535|NCT02080754|Lung aspiration
987536|NCT02080754|Aspiration pneumonia
987537|NCT02080715|Sleep-wake
987538|NCT02080715|regulation
987539|NCT02080715|volunteers
987540|NCT02080702|GIT, Monosyn, anastomoses leakage
987541|NCT02080676|Cannabis
987542|NCT02080676|Intra ocular pressure
987543|NCT02080676|Ocular perfusion
987544|NCT02080676|Blood pressure
987545|NCT02080663|carpectomy, proximal row, long-term, wrist, arthritis
987546|NCT02080637|Single ventricle
987547|NCT02080585|Inactivity
987548|NCT02080546|Vaginal cuff dehiscence
987549|NCT02080546|Thermal Injury
987550|NCT02080546|Total laparoscopic hysterectomy
987551|NCT02080533|pulmonary arterial hypertension
987552|NCT02080533|symptoms
987553|NCT02080533|dyspnea
987554|NCT02080533|fatigue
987555|NCT02080533|sleep
987556|NCT02080520|Prevention
987557|NCT02080520|Soy
987558|NCT02080520|Fermented soy
987559|NCT02080520|Nattokinase
987560|NCT02080520|Randomized controlled trial
987561|NCT02080520|Carotid artery
987562|NCT02080520|Cognition
987563|NCT02080520|Atherothrombosis
987564|NCT02080507|rTMS
987565|NCT02080507|depression
987566|NCT02080507|ECT
987567|NCT02080494|tranexamic acid
987568|NCT02080494|orthopaedic trauma
987569|NCT02080494|pelvic fracture
987570|NCT02080494|hip fracture
987571|NCT02080494|femur fracture
987572|NCT02080494|blood loss
987573|NCT02080468|Effect
987574|NCT02080468|Ethinyl Estradiol/Norgestimate
987575|NCT02080468|Pharmacokinetics
987576|NCT02080468|Lomitapide.
987577|NCT02080442|COPD
987578|NCT02080442|Balance
987579|NCT02080442|Pulmonary Rehabilitation
987580|NCT02080416|EBV
987581|NCT02080416|KSHV
987582|NCT02080416|malignancy
987583|NCT02080416|lymphoma
987584|NCT02080416|sarcoma
987585|NCT02080416|virus-associated
987586|NCT02080403|Peri-Implantitis
987587|NCT02080403|Periodontal Diseases
987588|NCT02080403|Chlorhexidine gluconate
987589|NCT02080403|PerioChip
987590|NCT02080403|Anti-Infective Agents
987591|NCT02080403|Mouth Diseases
987592|NCT02080403|Antiseptics
987593|NCT02080390|Her 2 Positive Breast Cancer
987594|NCT02080390|Trastuzumab
987595|NCT02080390|Herceptin
987596|NCT02080390|Heart Failure
987597|NCT02080390|Echocardiography
987598|NCT02080377|Pregnancy
987599|NCT02080377|Gestational diabetes
987600|NCT02080377|Glycaemic control
987601|NCT02080377|Metformin
987602|NCT02080364|Alzheimer's disease
987603|NCT02080364|RAGE
987604|NCT02080364|ADAS-cog
987605|NCT02080364|CDR-sb
987606|NCT02080338|Orthodontic, Bracket slot, Effective, Randomized, Duration
987607|NCT02080325|weight loss
987608|NCT02080325|high protein diet
987609|NCT02080325|plant protein
987610|NCT02080325|satiety
987611|NCT02080325|soy
987612|NCT02080312|Meniere's disease
987613|NCT02080312|endolymphatic hydrops
987614|NCT02080286|spatial neglect
987615|NCT02080286|rehabilitation
987616|NCT02080286|brain stimulation
987617|NCT02080286|tDCS
987618|NCT02080286|prism adaptation
987619|NCT02080234|Lymphoma, Extranodal NK-T-Cell
987620|NCT02080234|asparaginase
987621|NCT02080234|GELOX
987622|NCT02080234|concurrent chemoradiotherapy
987623|NCT02080234|sIL-2R
987624|NCT02080221|metastatic pancreatic cancer
987625|NCT02080221|pancreatic cancer
987626|NCT02080221|metastatic
987627|NCT02080208|hypoxemia
987628|NCT02080208|high flow oxygen therapy
987629|NCT02080208|respiratory failure
987630|NCT02080182|Acute Pyelonephritis
987631|NCT02080182|Acetylcysteine
987632|NCT02080182|Pediatric
987633|NCT02080169|Intensive care unit
987634|NCT02080169|Mechanical ventilation
987635|NCT02080169|Combined sedation
987636|NCT02080156|Obstructive Sleep Apnea
987637|NCT02080156|Percutaneous Coronary Intervention
987638|NCT02080156|Coronary Artery Bypass Graft
987639|NCT02080156|Mortality
987640|NCT02080156|Questionnaire
987641|NCT02080156|Biomarker
987642|NCT02080143|Skin temperature measurements
987643|NCT02080143|Heat patch adhesion
987644|NCT02080143|Dermal irritation
987645|NCT02080130|Gastroenteritis
987646|NCT02080130|diarrhea
987647|NCT02080117|kidney transplantation
987648|NCT02080117|delayed graft function
987649|NCT02080117|creatinine
987650|NCT02080117|graft survival
987651|NCT02080104|postpartum hemorrhage
987652|NCT02080104|oxytocin
987653|NCT02080104|vaginal delivery
987654|NCT02080104|prophylactic
987655|NCT02080078|Erlotinib
987656|NCT02080078|Theophylline
987657|NCT02080078|Diarrhea
987658|NCT02080065|risk factor
987659|NCT02080065|acute kidney injury
987660|NCT02080065|liver transplantation
987661|NCT02080065|postoperative renal function
987662|NCT02080039|Spinal Cord Injury
987663|NCT02080039|Denervation
987664|NCT02080039|Electrical Stimulation
987665|NCT02080026|malaria
987666|NCT02080026|Plasmodium falciparum
987667|NCT02080000|Heart Failure
987668|NCT02080000|Cardiac Resynchronisation Therapy
987669|NCT02080000|Biventricular Pacemaker
987670|NCT02080000|Optimisation
987671|NCT02079987|Health Literacy
987672|NCT02079987|Care Transition Intervention
987673|NCT02079987|Emergency Department Population
987674|NCT02079987|Access to Care
987675|NCT02079974|endometriosis
987676|NCT02079974|pain
987677|NCT02079974|fertility
987678|NCT02079961|anemia
987679|NCT02079961|children
987680|NCT02079961|iron-fortified product
987681|NCT02079961|value chain
987682|NCT02079948|Aging
987683|NCT02079948|Cognitive Function
987684|NCT02079948|Physical Function
987685|NCT02079948|Systematic Inflammation
987686|NCT02079948|Methotrexate
987687|NCT02079948|Pain Symptoms
987688|NCT02079935|BN
987689|NCT02079935|Binge
987690|NCT02079935|overconsumption of food
987691|NCT02079935|purging
987692|NCT02079935|purge
987693|NCT02079922|Multiple Ascending Dose
987694|NCT02079922|healthy subjects
987695|NCT02079922|Hypercholesterolemia
987696|NCT02079922|Hyperlipidemias
987697|NCT02079922|Dyslipidemias
987698|NCT02079922|Lipid Metabolism Disorders
987699|NCT02079922|Metabolic Diseases
987700|NCT02079909|Alzheimer's Disease
987701|NCT02079909|Alzheimer's
987702|NCT02079896|Dialysis
987703|NCT02079844|Drug therapy
987704|NCT02079831|Adolescent obesity
987705|NCT02079831|childhood obesity
987706|NCT02079831|anthropometry
987707|NCT02079831|body weights and measures
987708|NCT02079818|visceral artery aneurysms
987709|NCT02079818|arteriovenous malformations
987710|NCT02079818|Penumbra Ruby Coil System
987711|NCT02079792|Budesonide
987712|NCT02079792|Mucosal Atomization Device
987713|NCT02079792|Head Position
987714|NCT02079779|Robotic-assisted therapy
987715|NCT02079779|Acute Stroke
987716|NCT02079779|International Classification of Functioning, Disability and Health
987717|NCT02079753|COPD, portable concentrator, oxygen sources
987718|NCT02079727|Condrosulf
987719|NCT02079727|Chondroitin sulfate
987720|NCT02079727|Celebrex
987721|NCT02079727|Knee OA
987722|NCT02079727|Knee osteoarthritis
987723|NCT02079714|Orthopaedic Trauma
987724|NCT02079714|Injury
987725|NCT02079701|pneumonia
987726|NCT02079701|pneumococcus
987727|NCT02079701|vaccine
987728|NCT02079701|23-valent pneumococcal vaccine
987729|NCT02079701|military recruits
987730|NCT02079688|Antisense oligonucleotide
987731|NCT02079688|atopic eczema
987732|NCT02079688|atopic dermatitis
987733|NCT02079688|Phase II
987734|NCT02079688|Transcription factor GATA-3
987735|NCT02079688|dermal application
987736|NCT02079688|Proof-of-Concept
987737|NCT02079662|Breast Cancer
987738|NCT02079662|Radiation Therapy
987739|NCT02079662|Radiotherapy
987740|NCT02079662|XRT
987741|NCT02079662|Aerobic Activity
987742|NCT02079662|Dietician Counseling
987743|NCT02079662|Dietary Assessment
987744|NCT02079662|Yoga
987745|NCT02079662|Cognitive Behavior Therapy
987746|NCT02079662|Smoking Cessation Counseling
987747|NCT02079662|Questionnaires
987748|NCT02079662|Surveys
987749|NCT02079662|Saliva Samples
987750|NCT02079662|Blood Samples
987751|NCT02079649|Allergic conjunctivitis
987752|NCT02079649|Red eyes
987753|NCT02079649|Eyelid swelling
987754|NCT02079649|Ragweed
987755|NCT02079649|Allergies
987756|NCT02079649|Itchy eyes
987757|NCT02079649|Ocular redness
987758|NCT02079649|Chemosis
987759|NCT02079649|Tearing
987760|NCT02079649|Watery eyes
987761|NCT02079623|Pancreatic cancer
987762|NCT02079623|Electroporation
987763|NCT02079623|Nano knife treatment
987764|NCT02079610|Depression
987765|NCT02079610|Neurofeedback
987766|NCT02079610|Amygdala
987767|NCT02079597|SIRS
987768|NCT02079597|Ninj1
987769|NCT02079597|Sepsis
987770|NCT02079597|Healthy
987771|NCT02079584|Patient Compliance
987772|NCT02079584|Target Specific Anticoagulant
987773|NCT02079584|Quality of Life
987774|NCT02079558|prevention
987775|NCT02079558|cesarean section
987776|NCT02079545|Healthy
987777|NCT02079545|Bioavailability
987778|NCT02079545|Pharmacokinetics
987779|NCT02079545|Sirukumab
987780|NCT02079545|Subcutaneous
987781|NCT02079545|Male
987782|NCT02079493|osteoarthritis
987783|NCT02079493|knee replacement
987784|NCT02079493|functional testing
987785|NCT02079467|Arthroplasty, Hip
987786|NCT02079467|Replacement, Hip
987787|NCT02079467|Postoperative Care
987788|NCT02079467|Rehabilitation
987789|NCT02079441|Anti- TNF
987790|NCT02079441|inflammatory bowel disease
987791|NCT02079441|pregnancy
987792|NCT02079441|infant
987793|NCT02079441|immunity
987794|NCT02079441|Immune function
987795|NCT02079428|Heart Failure
987796|NCT02079428|Registry
987797|NCT02079428|China
987798|NCT02079415|NICU
987799|NCT02079402|sepsis
987800|NCT02079402|septic
987801|NCT02079402|shock
987802|NCT02079402|ICU
987803|NCT02079402|intensive
987804|NCT02079402|critical
987805|NCT02079402|resuscitation
987806|NCT02079402|fluid
987807|NCT02079402|IV
987808|NCT02079402|crystalloid
987809|NCT02079402|balance
987810|NCT02079389|colon cancer
987811|NCT02079389|rectum cancer
987812|NCT02079389|laparoscopic ultrasound
987813|NCT02079389|LUS
987814|NCT02079389|Contrast enhanced ultrasound
987815|NCT02079389|CEUS
987816|NCT02079389|Peroperative TNM staging
987817|NCT02079389|screening for liver metastases
987818|NCT02079376|diabetes
987819|NCT02079363|Pancreatic Diseases
987820|NCT02079363|Pancreatic Neoplasms
987821|NCT02079363|Pancreatitis
987822|NCT02079363|DNA promoter hypermethylation
987823|NCT02079363|DNA methylation
987824|NCT02079363|Cell-free DNA
987825|NCT02079363|Plasma
987826|NCT02079324|head and neck cancer
987827|NCT02079324|gene therapy
987828|NCT02079324|stem cell therapy
987829|NCT02079324|immunotherappy
987830|NCT02079311|Patient warming
987831|NCT02079311|Active warming
987832|NCT02079311|Forced Air Warming
987833|NCT02079311|Warming blanket
987834|NCT02079272|Tomotherapy
987835|NCT02079272|Breast Cancer
987836|NCT02079272|Heart
987837|NCT02079272|Subclinical cardiac lesions
987838|NCT02079272|Myocardial lesions
987839|NCT02079272|Coronary lesions
987840|NCT02079272|Circulating biomarkers
987841|NCT02079272|Ionizing radiation
987842|NCT02079272|Heart absorbed doses
987843|NCT02079233|Basic Science
987844|NCT02079233|Safety
987845|NCT02079233|Tolerability
987846|NCT02079233|Efficacy of CLP
987847|NCT02079220|Colorectal Cancer
987848|NCT02079220|Metastatic Colorectal Cancer
987849|NCT02079194|Drug-eluting stents
987850|NCT02079194|aspirin
987851|NCT02079194|P2Y12 antagonist monotherapy
987852|NCT02079168|Keloid
987853|NCT02079168|Cicatrix
987854|NCT02079168|Keloid prevention
987855|NCT02079168|Keloid revision/excision
987856|NCT02079168|Keloidectomy
987857|NCT02079129|agreement between cMRI PVL grading and TTE PVL grading
987858|NCT02079129|Edwards Sapien TAVR
987859|NCT02079116|Obesity
987860|NCT02079116|Lipids
987861|NCT02079116|Single Photon Emission Computed Tomography
987862|NCT02079116|Functional Neuroimaging
987863|NCT02079103|Virtual reality
987864|NCT02079103|Stroke
987865|NCT02079103|Arm motor function
987866|NCT02079103|Neurorehabilitation
987867|NCT02079090|Propofol
987868|NCT02079090|Ketamine
987869|NCT02079090|Fentanyl
987870|NCT02079090|Procedural sedation
987871|NCT02079090|children
987872|NCT02079090|Emergency Department
987874|NCT02079064|Splenectomy
987875|NCT02079064|Desflurane
987876|NCT02079064|Propofol
987877|NCT02079064|TCI
987878|NCT02079064|ROTEM
987879|NCT02079051|Obesity Physical Performance Weight loss Optifast
987880|NCT02079025|Prostate Biopsy
987881|NCT02079025|Ultrasound guided biopsy of the prostate
987882|NCT02079025|High-resolution ultrasound
987883|NCT02079012|Walking Program
987884|NCT02079012|Mental Disorders
987885|NCT02079012|Physical Activity
987886|NCT02079012|Physical Fitness
987887|NCT02079012|Anxiety
987888|NCT02079012|Depression
987889|NCT02079012|Self Determination
987890|NCT02078999|Mechanical ventilation, procalcitonin, c-reactive protein
987891|NCT02078986|Whole-Body-Electromyostimulation
987892|NCT02078986|High Intensity Resistance Exercise Training (HIT)
987893|NCT02078986|Lean Body Mass
987894|NCT02078986|Muscle Strength
987895|NCT02078973|Tolvaptan
987896|NCT02078973|L-NMMA
987897|NCT02078973|Healthy subjects
987898|NCT02078973|Nephrology
987899|NCT02078960|Chronic Phase
987900|NCT02078960|Accelerated Phase
987901|NCT02078960|CML
987902|NCT02078960|Chronic Myeloid Leukemia
987903|NCT02078947|Diastolic heart failure, Heart failure with preserved ejection fraction, exercise
987904|NCT02078934|Surgical Endoscopy
987905|NCT02078934|Morbid Obesity
987906|NCT02078934|Weight Loss
987907|NCT02078934|Bariatrics
987908|NCT02078934|Complex incisional hernia with mesh
987909|NCT02078908|Central blood pressure
987910|NCT02078908|Peripheral (brachial) blood pressure
987911|NCT02078908|Renal variables
987912|NCT02078908|Vasoactive hormones
987913|NCT02078908|Pharmacology
987914|NCT02078908|Pharmacokinetics
987915|NCT02078895|Lower Urinary tract discomfort , ureteral stent pain
987920|NCT02078843|NET
987921|NCT02078843|Gallium-68-DOTATATE
987922|NCT02078843|PET/CT
987923|NCT02078843|Indium-111-pentetreotide scintigraphy
987924|NCT02078843|octreoscan
987925|NCT02078843|GEP-NET
987926|NCT02078843|gastroenteropancreatic neuroendocrine tumors
987927|NCT02078830|Wound Contamination
987928|NCT02078817|Treatment-resistant
987929|NCT02078804|Colorectal cancer
987930|NCT02078804|Mortality
987931|NCT02078804|Incidence
987932|NCT02078804|Screening
987933|NCT02078804|Health-economy
987934|NCT02078791|Fibromyalgia
987935|NCT02078791|Group Problem Solving Technique
987936|NCT02078791|infiltration
987937|NCT02078778|Continuous airway pressure
987938|NCT02078778|Hypertension
987939|NCT02078778|Obstructive sleep apnea
987940|NCT02078765|hypertension
987941|NCT02078765|chronic kidneys disease
987942|NCT02078765|obstructive sleep apnea
987943|NCT02078765|24-h blood pressure
987944|NCT02078765|central blood pressure
987945|NCT02078765|peripheral blood pressure
987946|NCT02078752|ADC
987947|NCT02078752|PF-06647263
987948|NCT02078752|solid tumors
987949|NCT02078752|tumors
987950|NCT02078752|neoplasm metastasis
987951|NCT02078752|TNBC
987952|NCT02078752|Triple negative breast cancer
987953|NCT02078739|Yoga
987954|NCT02078739|COPD
987955|NCT02078739|Congestive Heart Failure
987956|NCT02078726|glucagon, screening colonoscopy
987957|NCT02078713|contraception
987958|NCT02078713|patient decision support
987959|NCT02078713|patient decision aid
987960|NCT02078713|shared decision making
987961|NCT02078713|Decision Making, Shared
987962|NCT02078713|Patient-Centered Outcomes Research
987963|NCT02078700|cancer
987964|NCT02078700|early palliative care
987965|NCT02078700|feasibility
987966|NCT02078687|very preterm
987967|NCT02078687|nutrition
987968|NCT02078687|6 year follow-up
987969|NCT02078687|growth
987970|NCT02078687|metabolic syndrome
987971|NCT02078687|allergy
987972|NCT02078687|dexa
987973|NCT02078674|H7N9
987974|NCT02078661|Keratoconjunctivitis sicca
987975|NCT02078661|Dry eye
987976|NCT02078648|Glioma Associated Antigen
987977|NCT02078648|Vaccine
987978|NCT02078648|Adult
987979|NCT02078648|Recurrent Glioblastoma
987980|NCT02078648|Immunotherapy
987981|NCT02078635|Arterial plaque
987982|NCT02078635|portfolio diet
987983|NCT02078635|dietary modification
987984|NCT02078635|dietary trials
987985|NCT02078635|Canadian Network
987986|NCT02078635|knowledge synthesis and translation
987987|NCT02078635|Magnetic resonance imaging
987988|NCT02078622|COPD
987989|NCT02078622|Respiratory Therapist
987990|NCT02078622|Case Management
987991|NCT02078622|Education
987992|NCT02078609|AML,
987993|NCT02078609|MDS,
987994|NCT02078609|PIM,
987995|NCT02078609|LGH447,
987996|NCT02078609|acute myelod leukemia,
987997|NCT02078609|myelodysplastic syndrome,
987998|NCT02078609|midostaurin,
987999|NCT02078609|PKC412
988000|NCT02078596|temper outbursts
988001|NCT02078596|pediatric aggression
988002|NCT02078596|irritability
988003|NCT02078544|Cancer in Gynaecologic Oncology
988004|NCT02078505|Change in gut microbial population
988005|NCT02078505|polycystic ovary syndrome
988006|NCT02078505|gut microbiome
988007|NCT02078505|diet
988008|NCT02078479|Malignancy
988009|NCT02078479|VAS
988010|NCT02078479|LANSS
988011|NCT02078479|VDS
988012|NCT02078479|Neuropathic pain
988013|NCT02078479|rTMS
988014|NCT02078479|motor cortex
988015|NCT02078479|analgesia
988016|NCT02078466|Functional assessment
988017|NCT02078466|readmission
988018|NCT02078466|acute care
988019|NCT02078466|older medical patients
988020|NCT02078453|Dental caries
988021|NCT02078453|Diagnosis
988022|NCT02078453|Visual inspection
988023|NCT02078453|Radiographic examination
988024|NCT02078440|Type 2 Diabetes
988025|NCT02078440|Children
988026|NCT02078440|Adolescents
988027|NCT02078440|Bioavailability
988028|NCT02078440|Cycloset
988029|NCT02078440|Bromocriptine Mesylate
988030|NCT02078401|Optic pathway glioma
988031|NCT02078401|Ophthalmological screening
988032|NCT02078375|Rheumatoid Arthritis
988035|NCT02078310|Dementia,
988036|NCT02078310|Healthy
988037|NCT02078310|geriatric
988038|NCT02078310|volunteers
988039|NCT02078310|patients
988040|NCT02078297|IL-23
988041|NCT02078297|IL-17A
988042|NCT02078297|Skin biopsies
988043|NCT02078284|platelet transfusion
988044|NCT02078258|depression，adolescent，attention bias，modification
988045|NCT02078245|Familial pancreatic cancer
988046|NCT02078245|Surveillance
988047|NCT02078245|Screening
988048|NCT02078232|fine needle aspiration under ultrasound endoscopy
988049|NCT02078232|solid pancreatic tumors
988050|NCT02078232|head of pancreas
988051|NCT02078232|19G Flex needle
988052|NCT02078232|22G standard needle
988053|NCT02078206|Critical illness
988054|NCT02078206|Neurocognition
988055|NCT02078206|Neurocognitive stimulation
988056|NCT02078206|Delirium
988057|NCT02078206|Virtual Reality
988058|NCT02078206|cognitive
988059|NCT02078206|rehabilitation
988060|NCT02078206|ICU
988061|NCT02078167|ipercholesterolemia not familiarity
988062|NCT02078154|D-Dimer
988063|NCT02078154|DVT
988064|NCT02078154|Wells score
988065|NCT02078141|18F-deoxyglucose (FDG) PET, idiopathic Dilated Cardiomyopathy
988066|NCT02078128|burn, wound healing, skin graft
988067|NCT02078089|Refractory cancer pain
988068|NCT02078076|MRI
988069|NCT02078076|free-breathing acquisitions
988070|NCT02078076|myopathy
988071|NCT02078076|fibrosis assessment
988072|NCT02078076|function
988073|NCT02078037|Intracerebral hemorrhage
988074|NCT02078037|Perihematomal edema
988075|NCT02078037|hemorrhage
988076|NCT02078037|normothermia
988077|NCT02078024|Onchocerciasis
988078|NCT02077985|autism
988079|NCT02077985|electrodermal activity
988080|NCT02077985|cooperation
988081|NCT02077985|anxiety
988082|NCT02077985|distress
988083|NCT02077985|stress
988084|NCT02077985|oral care
988085|NCT02077985|sensory processing
988086|NCT02077985|behavior
988087|NCT02077985|occupational therapy
988088|NCT02077972|PTSD
988089|NCT02077972|Military service
988090|NCT02077972|depression
988091|NCT02077972|Whole Body Hyperthermia (WBH)
988092|NCT02077959|Relapsed Multiple Myeloma
988093|NCT02077959|Refractory Multiple Myeloma
988094|NCT02077933|Solid tumors
988095|NCT02077933|renal cell carcinoma
988096|NCT02077933|pancreatic neuroendocrine tumors
988097|NCT02077933|breast cancer
988098|NCT02077933|PI3K inhibitor
988099|NCT02077933|BYL719
988100|NCT02077933|alpelisib
988101|NCT02077933|everolimus
988102|NCT02077933|exemestane
988103|NCT02077920|Ventilator-associated pneumonia VAP
988104|NCT02077920|Chlorhexidine
988105|NCT02077920|Oropharyngeal decontamination
988106|NCT02077920|Subglottic secretion drainage
988109|NCT02077881|metastatic
988110|NCT02077881|metastasis
988111|NCT02077881|Pancreatic
988112|NCT02077881|Pancreas
988113|NCT02077881|Cancer
988114|NCT02077881|adenocarcinoma
988122|NCT02077855|Sensitivity and Sensitivity
988123|NCT02077829|Implementation process
988124|NCT02077829|implementation strategy
988125|NCT02077829|Implementation research
988126|NCT02077829|evidence based practice
988127|NCT02077829|recovery
988128|NCT02077829|Illness management and recovery
988129|NCT02077816|body temperature
988130|NCT02077816|Thermometry
988131|NCT02077816|Infrared Rays
988132|NCT02077816|catheter related infection
988133|NCT02077803|Healthy
988134|NCT02077803|Canagliflozin
988135|NCT02077803|Metformin
988136|NCT02077803|Type 2 diabetes mellitus
988137|NCT02077803|Bioequivalence
988138|NCT02077803|GLUMETZA®
988139|NCT02077777|mesalazine
988140|NCT02077777|colon
988141|NCT02077777|cancer
988142|NCT02077764|heart transplantation,
988143|NCT02077764|rejection
988144|NCT02077764|cardiac vasculopathy
988145|NCT02077764|optical coherence tomography
988146|NCT02077764|speckle tracking
988147|NCT02077764|Positron Emission Tomography .
988148|NCT02077764|exercise capacity
988149|NCT02077738|effectiveness
988150|NCT02077738|elderly
988151|NCT02077738|high frequency chest wall oscillation
988152|NCT02077738|mechanical ventilation
988153|NCT02077738|pneumonia
988154|NCT02077738|randomized controlled trial
988155|NCT02077725|drug related problems
988156|NCT02077725|comprehensive medication review
988157|NCT02077725|quality of life
988158|NCT02077699|Lactobacillus casei DG
988159|NCT02077699|Irritable Bowel Syndrome
988160|NCT02077686|diabetes
988161|NCT02077686|education
988162|NCT02077686|randomized
988163|NCT02077686|prospective
988164|NCT02077673|GEJ-cancer
988165|NCT02077673|surgery
988166|NCT02077673|gastroesophageal resection
988167|NCT02077673|gastroesophageal anastomosis
988168|NCT02077673|anastomotic leakage
988169|NCT02077660|Green tea, aging, oxidation, anthropometrics.
988170|NCT02077647|Knee osteoarthritis
988171|NCT02077647|knee osteonecrosis
988172|NCT02077647|osteotomy
988173|NCT02077621|cancer-related fatigue
988174|NCT02077621|Palliative Abdominal Surgery
988175|NCT02077621|HRQL
988176|NCT02077608|In vitro fertilization
988177|NCT02077608|Embryotransfer
988178|NCT02077608|Hyaluronan
988179|NCT02077608|Pregnancy rate
988180|NCT02077608|Implantation rate
988181|NCT02077595|transcutaneous electrical nerve stimulation
988182|NCT02077595|transcranial magnetic stimulation
988183|NCT02077582|acute ischemic stroke
988184|NCT02077569|AKT inhibitor
988185|NCT02077569|AZD5363
988186|NCT02077569|Anti-tumour activity
988187|NCT02077569|Breast cancer
988188|NCT02077569|ER positive
988189|NCT02077569|Oestrogen positive
988190|NCT02077569|post menopausal
988191|NCT02077569|chemotherapy required
988192|NCT02077569|no prior cancer treatment
988193|NCT02077556|tacrolimus, everolimus, pharmacokinetics, drug interaction
988194|NCT02077530|Patients with metabolic syndrome age between 30 to 64: Central obesity (Men ≥ 90 cm Women ≥ 85 cm), Plasma triglycerides ≥ 150 mg/dL
988195|NCT02077530|HDL cholesterol Men < 40 mg/dL, Women < 50 mg/dL, Blood pressure ≥130/85 mm Hg (or treatment for hypertension),
988196|NCT02077530|Fasting plasma glucose ≥ 100 mg/dL
988197|NCT02077517|Roux en Y Gastric Bypass
988198|NCT02077517|Postoperative complications
988199|NCT02077517|Hand sewn anastomosis
988200|NCT02077517|Stapled anastomosis
988201|NCT02077491|Aged
988202|NCT02077491|Systemic Inflammatory Response Syndrome
988203|NCT02077491|Body Composition
988204|NCT02077491|Dietary Protein
988205|NCT02077465|COPD, chronic obstructive pulmonary disease; Phase 1b, Safety, Pharmacokinetics
988206|NCT02077452|Glucokinase activator
988207|NCT02077452|Phase I
988208|NCT02077452|Type 2 diabetes mellitus
988209|NCT02077439|Stroke
988210|NCT02077439|Hand
988211|NCT02077439|Upper Extremity
988212|NCT02077439|Robotics
988213|NCT02077426|Functional Capacity
988214|NCT02077426|Exercise Independence
988215|NCT02077426|Peripheral
988216|NCT02077426|Strength
988217|NCT02077413|muscle
988218|NCT02077413|eccentric exercise
988219|NCT02077413|T2 MRI
988220|NCT02077387|Inhibitory control
988221|NCT02077387|executive functioning
988222|NCT02077387|childhood obesity
988223|NCT02077387|preschool
988224|NCT02077387|snack foods
988225|NCT02077387|caloric intake
988226|NCT02077374|NAFLD
988227|NCT02077374|NASH
988228|NCT02077361|choroideremia
988229|NCT02077361|gene therapy
988230|NCT02077361|gene transfer
988231|NCT02077348|Diabetes Mellitus type I
988232|NCT02077348|Ketoacidosis
988233|NCT02077348|Insulin withdrawal
988234|NCT02077348|Growth hormone injection
988235|NCT02077348|Lipolysis and ATGL
988236|NCT02077335|Brachytherapy
988237|NCT02077335|Monotherapy
988238|NCT02077335|HDR
988239|NCT02077322|Merocel Middle Meatus Spacers
988240|NCT02077322|Silastic Middle Meatus Spacers
988241|NCT02077322|Functional Endoscopic Sinus Surgery
988242|NCT02077309|T2DM,
988243|NCT02077309|vascular inflammation,
988244|NCT02077309|18-FDG-PET,
988245|NCT02077309|plaque morphology,
988246|NCT02077309|MRI,
988247|NCT02077309|DPP-4 Inhibition
988248|NCT02077296|cytokines
988249|NCT02077296|predictive value
988250|NCT02077296|preoperative chemoradiotherapy
988251|NCT02077296|rectal cancer
988252|NCT02077283|NAFLD (non-alcoholic fatty liver disease, NAFLD)
988253|NCT02077283|urinary metabonomics
988254|NCT02077283|TCM pattern
988255|NCT02077283|"liver depression and spleen deficiency pattern,"
988256|NCT02077283|"damp-heat in the interior pattern"
988257|NCT02077270|colonoscopy
988258|NCT02077270|acupuncture
988259|NCT02077270|pain
988260|NCT02077244|patient
988261|NCT02077244|intensive care
988262|NCT02077244|follow up
988263|NCT02077244|post traumatic stress symptoms
988264|NCT02077244|randomized controlled trial
988265|NCT02077205|Diagnostic and Statistical Manual of Mental Disorders-IV/-5: Anxiety Disorders in children
988266|NCT02077179|Postpartum
988267|NCT02077179|Preeclampsia
988268|NCT02077179|Gestational Hypertension
988269|NCT02077179|Gestational Diabetes
988270|NCT02077179|Exercise Intervention
988271|NCT02077179|Dietary Intervention
988272|NCT02077179|Behavioral Intervention
988273|NCT02077179|Mobile Website
988274|NCT02077179|Mobile Application
988275|NCT02077166|DLBCL
988276|NCT02077101|HIV
988277|NCT02077101|Therapeutic vaccine
988278|NCT02077101|acceptability
988279|NCT02077101|representations
988280|NCT02077088|interventional
988281|NCT02077088|doubleblind
988282|NCT02077088|randomised
988283|NCT02077088|pediatric
988284|NCT02077088|prebiotic
988285|NCT02077088|atopic
988286|NCT02077088|dermatitis
988287|NCT02077088|infant
988288|NCT02077075|weight loss
988289|NCT02077075|healthy weight
988290|NCT02077075|overweight
988291|NCT02077075|body mass index greater that 25 kg/m2
988292|NCT02077062|hepatectomy,
988293|NCT02077062|liver regeneration
988294|NCT02077062|mediators
988295|NCT02077049|elderly
988296|NCT02077049|exercise program
988297|NCT02077049|self-training
988298|NCT02077049|mobility
988299|NCT02077049|computer-based learning games
988300|NCT02077049|serious game
988301|NCT02077049|balance
988302|NCT02077049|training adherence
988303|NCT02077049|training compliance
988304|NCT02077049|Kinect ®
988305|NCT02077049|Fit Bit ®
988306|NCT02077023|Stroke
988307|NCT02077023|Heart Attack
988308|NCT02077023|Asymptomatic Carotid Artery Disease
988309|NCT02077023|Atrial Fibrillation
988310|NCT02077010|milrinone
988311|NCT02077010|heart failure
988312|NCT02077010|cardiomyopathy
988313|NCT02077010|inhaled
988314|NCT02076997|Cancer
988315|NCT02076997|High Dose Methotrexate
988316|NCT02076984|Ventral hernia
988317|NCT02076984|Incisional hernia
988318|NCT02076984|Patient affected by ventral or incisional hernias
988319|NCT02076971|Lung transplant
988320|NCT02076971|Quantiferon
988321|NCT02076971|Immuknow
988322|NCT02076958|Implementation
988323|NCT02076958|Cancer
988324|NCT02076958|Early detection
988325|NCT02076958|Faith-based
988326|NCT02076958|Community health advisor
988327|NCT02076945|Regional anesthesia
988328|NCT02076945|Diabetic neuropathy
988329|NCT02076945|Ultrasound
988330|NCT02076919|LHA510
988331|NCT02076919|First in human
988332|NCT02076919|Safety
988333|NCT02076919|Tolerability
988334|NCT02076919|Pharmacokinetics
988335|NCT02076919|Elderly
988336|NCT02076919|Age-Related Macular Degeneration
988337|NCT02076919|AMD
988338|NCT02076919|Ocular
988339|NCT02076919|Eye drop
988340|NCT02076906|relapsed pediatric solid tumors
988341|NCT02076906|refractory pediatric solid tumors
988342|NCT02076906|high intensity focused ultrasound
988343|NCT02076906|rhabdomyosarcoma
988344|NCT02076906|Ewing's sarcoma
988345|NCT02076906|osteosarcoma
988346|NCT02076906|neuroblastoma
988347|NCT02076906|Wilms' tumor
988348|NCT02076906|hepatic tumors
988349|NCT02076906|germ cell tumors
988350|NCT02076906|desmoid tumor
988351|NCT02076893|Tonsillectomy
988352|NCT02076893|Pain management
988353|NCT02076893|Pediatrics
988354|NCT02076880|Type 2 diabetes
988355|NCT02076880|Obesity
988356|NCT02076880|Sleeve gastrectomy
988357|NCT02076880|Insulin
988358|NCT02076880|GLP-1
988359|NCT02076867|somatic symptoms and related disorders
988360|NCT02076867|somatic symptoms
988361|NCT02076867|psychodynamic psychotherapy
988362|NCT02076854|eating disorders
988363|NCT02076854|anorexia nervosa
988364|NCT02076854|treatment
988365|NCT02076854|technology
988366|NCT02076828|anemia
988367|NCT02076828|iron polymaltose complexes
988368|NCT02076828|iron zinc
988369|NCT02076815|myeloproliferative neoplasm
988370|NCT02076815|essential thrombocythemia
988371|NCT02076815|high risk patients
988372|NCT02076815|anagrelide
988373|NCT02076802|prehypertension
988374|NCT02076802|coronary atherosclerosis
988375|NCT02076802|cardiovascular disease
988376|NCT02076789|Device Replacement
988377|NCT02076789|Device Upgrade
988378|NCT02076789|Long-term Postoperative Complications
988379|NCT02076789|Resource consumption and associated costs after device replacement/upgrade
988380|NCT02076776|Stroke
988381|NCT02076776|Exercise
988382|NCT02076776|Rehabilitation
988383|NCT02076776|Neuroplasticity
988384|NCT02076776|Task Practice
988385|NCT02076763|Observational
988386|NCT02076763|Porphyria
988387|NCT02076750|Inflammatory Bowel Diseases
988388|NCT02076750|Vitamin D
988389|NCT02076750|Cholecalciferol
988390|NCT02076750|Skin Pigmentation
988391|NCT02076737|Model-based iterative reconstruction MB-IR
988392|NCT02076737|VEOTM
988393|NCT02076737|Ultra low-dose
988394|NCT02076737|Abdominal CT
988395|NCT02076737|Dose reduction
988396|NCT02076737|Adaptative statistical iterative reconstruction ASIR
988397|NCT02076737|Acute renal colic
988398|NCT02076724|Abdominal donor-site
988399|NCT02076724|Breast reconstruction
988400|NCT02076724|Synthetic mesh
988401|NCT02076724|Biological mesh
988402|NCT02076711|Aortic Stenosis
988403|NCT02076711|Myocardial efficiency
988404|NCT02076698|Deep Brain Stimulation
988405|NCT02076698|Anterior Nucleus of thalamus
988406|NCT02076698|Treatment refractory
988407|NCT02076698|Pharmacoresistant partial epilepsy
988408|NCT02076698|vagus nerve stimulation therapy
988409|NCT02076685|pharmacogenetics
988410|NCT02076685|anti-tuberculosis drug
988411|NCT02076685|genetic polymorphism
988412|NCT02076685|isoniazid
988413|NCT02076672|prevention
988414|NCT02076672|non-malignant asbestos-related disease
988415|NCT02076672|benign pleural disease
988416|NCT02076672|asbestosis
988417|NCT02076659|F8
988418|NCT02076659|IL10
988419|NCT02076659|Interleukin
988420|NCT02076659|monoclonal
988421|NCT02076659|antibody
988422|NCT02076659|Rheumatoid Arthritis
988423|NCT02076646|Interleukin
988424|NCT02076646|IL2
988425|NCT02076646|monoclonal
988426|NCT02076646|antibody
988427|NCT02076646|cytokine
988428|NCT02076646|Dacarbazine
988429|NCT02076646|metastatic
988430|NCT02076646|melanoma
988431|NCT02076646|tumor targeting
988432|NCT02076646|Dose definition
988433|NCT02076646|L19
988434|NCT02076633|L19
988435|NCT02076633|monoclonal
988436|NCT02076633|antibody
988437|NCT02076633|IL-2
988438|NCT02076633|TNFα
988439|NCT02076633|Interleukin
988440|NCT02076633|Phase II
988441|NCT02076633|metastatic melanoma
988442|NCT02076633|clinical stage III
988443|NCT02076633|Clinical stage IV M1a
988444|NCT02076620|L19
988445|NCT02076620|monoclonal
988446|NCT02076620|antibody
988447|NCT02076620|doxorubicin
988448|NCT02076620|TNFα
988449|NCT02076620|solid tumour
988450|NCT02076620|sarcoma, breast cancer, lung carcinomas, gynecological cancer
988451|NCT02076620|anthracycline
988452|NCT02076607|vertebra
988453|NCT02076607|column
988454|NCT02076607|lumbar
988455|NCT02076607|toracica
988456|NCT02076607|fracture
988457|NCT02076607|burst
988458|NCT02076568|diabetes
988459|NCT02076568|education
988460|NCT02076568|randomized
988461|NCT02076568|prospective
988462|NCT02076555|diabetes
988463|NCT02076555|education
988464|NCT02076555|randomized
988465|NCT02076555|prospective
988466|NCT02076542|diabetes
988467|NCT02076542|education
988468|NCT02076542|randomized
988469|NCT02076542|prospective
988470|NCT02076529|chemotherapy induced nausea vomiting
988471|NCT02076516|Drug-eluting Stent,Coronary Artery Disease
988472|NCT02076503|Neoplasm Staging
988473|NCT02076503|Positron-Emission Tomography
988474|NCT02076503|Magnetic Resonance Imaging
988475|NCT02076503|1-amino-3-fluorocyclobutane-1-carboxylic acid
988476|NCT02076490|Telerehabilitation, mirror therapy, phantom limb pain
988477|NCT02076477|intervention time
988478|NCT02076477|radiotherapy
988479|NCT02076477|oligometastatic
988480|NCT02076477|non-small cell lung cancer
988481|NCT02076438|antibiotics
988482|NCT02076438|diarrhea
988483|NCT02076438|c diff
988484|NCT02076438|Hospitalized patients
988485|NCT02076425|Depressive Disorder, Major
988486|NCT02076425|Child Psychiatry
988487|NCT02076425|Parent-Child Relationship
988488|NCT02076425|Therapy
988489|NCT02076399|Persistent Immune Thrombocytopenic Purpura
988490|NCT02076399|Chronic Immune Thrombocytopenic Purpura
988491|NCT02076360|Preoperative counseling
988492|NCT02076360|Patient satisfaction
988493|NCT02076360|Prolapse
988494|NCT02076360|Sacrocolpopexy
988495|NCT02076347|Metformin
988496|NCT02076347|Vitamin B12 Deficiency
988497|NCT02076347|Population Management
988498|NCT02076347|Pharmacist
988499|NCT02076334|compression, isokinetic, far-infrared
988500|NCT02076308|Acupuncture, ultrasound
988501|NCT02076295|Cognition
988502|NCT02076295|Cholinergic nicotinic receptors
988503|NCT02076295|Positron Emission Tomography
988504|NCT02076282|Stage III non-small cell lung cancer
988505|NCT02076282|Optimization
988506|NCT02076282|MRI
988507|NCT02076282|Radiotherapy
988508|NCT02076269|HRCT
988509|NCT02076269|Dry Powder Inhaler
988510|NCT02076269|COPD
988511|NCT02076269|Pharyngometry
988512|NCT02076269|Inhalation Profiles
988513|NCT02076256|helping relationships, healthy lifestyle, quality of life
988514|NCT02076243|cutaneous squamous cell carcinoma
988515|NCT02076243|SCC
988516|NCT02076243|abraxane
988517|NCT02076243|nab-paclitaxel
988518|NCT02076243|unresectable
988519|NCT02076243|metastatic
988520|NCT02076230|14C-TH-302
988521|NCT02076230|Advanced or Metastatic Solid Tumors
988522|NCT02076230|Evofosfamide
988523|NCT02076217|Highly Effective Contraception
988524|NCT02076217|Emergency Contraception
988525|NCT02076217|Birth Control
988526|NCT02076217|LARC (Long Acting Reversible Contraception)
988527|NCT02076217|HERC (Highly Effective Contraception)
988528|NCT02076204|Pregnancy
988529|NCT02076204|Postpartum programs
988530|NCT02076204|Infant health services
988531|NCT02076191|Ruxolitinib
988532|NCT02076191|Decitabine
988533|NCT02076191|Myeloproliferative Neoplasms
988534|NCT02076191|Combination Therapy
988535|NCT02076178|Pre-Exposure Prophylaxis
988536|NCT02076178|HIV integrase
988537|NCT02076178|Intramuscular Injection
988538|NCT02076178|GSK1265744
988539|NCT02076165|insomnia
988540|NCT02076165|women
988542|NCT02076139|tuberculosis
988543|NCT02076139|treg
988544|NCT02076139|tolerance
988545|NCT02076139|probiotic
988546|NCT02076139|mycobacteria
988547|NCT02076126|Lung maturity
988548|NCT02076126|RDS
988549|NCT02076126|Prematurity
988550|NCT02076126|Lecithin-sphingomyelin ratio
988551|NCT02076126|Spectroscopy
988552|NCT02076126|Chemometrics
988553|NCT02076113|cervical spondylotic myelopathy
988554|NCT02076113|degenerative cervical spondylosis
988555|NCT02076113|spinal fusion
988556|NCT02076087|Subcutaneous adipose tissue
988557|NCT02076087|Lipectomy
988558|NCT02076061|COPD
988559|NCT02076061|Primary Care
988560|NCT02076061|Smoking
988561|NCT02076061|Smokers
988562|NCT02076061|ex-Smokers
988563|NCT02076061|Lung Cancer
988564|NCT02076061|Cardiovascular Disease
988565|NCT02076061|Proteomics
988566|NCT02076061|Biomarkers
988567|NCT02076061|Biobank
988568|NCT02076061|Disease Staging
988569|NCT02076061|Gold Stage
988570|NCT02076048|LCPUFA supplementation
988571|NCT02076048|Brain Imaging
988572|NCT02076048|MRI
988573|NCT02076048|MEG
988574|NCT02076035|low back pain
988575|NCT02076035|periduroscopy
988576|NCT02076035|genetic
988577|NCT02076035|genomic
988578|NCT02076035|inflammation
988579|NCT02076022|Fat Grafting
988580|NCT02076022|Pain at amputation site
988581|NCT02076022|prosthetic
988582|NCT02076009|Multiple Myeloma
988583|NCT02076009|Relapsed Multiple Myeloma
988584|NCT02076009|Refractory Multiple Myeloma
988585|NCT02076009|Daratumumab
988586|NCT02076009|Lenalidomide
988587|NCT02076009|Dexamethasone
988712|NCT02075463|GSK1278863
988713|NCT02075463|hemodialysis
988588|NCT02075996|pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,
988589|NCT02075983|HIV
988590|NCT02075983|Vaccine
988591|NCT02075983|Immunisation
988592|NCT02075983|DNA
988593|NCT02075983|Adverse events
988594|NCT02075983|Electroporation
988595|NCT02075983|Transcutaneous
988596|NCT02075983|GTU MultiHIV B Clade
988597|NCT02075983|Antibody
988598|NCT02075983|Intramuscular
988599|NCT02075983|Immunogenicity
988600|NCT02075970|Neonatal
988601|NCT02075970|Anemia
988602|NCT02075970|Transfusion
988603|NCT02075970|Erythropoetin
988604|NCT02075970|Epoetin Alpha
988605|NCT02075970|Red Blood Cell
988606|NCT02075970|Survival
988607|NCT02075970|Pharmacodynamics
988608|NCT02075970|Model
988609|NCT02075957|Non-small cell lung cancer, adjuvant chemo-therapy, DNA chip
988610|NCT02075944|Aerobic exercise
988611|NCT02075944|Cognitive function
988612|NCT02075944|Executive function
988613|NCT02075944|Brain-derived neurotrophic factor
988614|NCT02075905|Barrett's Esophagus
988615|NCT02075905|Esophageal Adenocarcinoma
988616|NCT02075892|cordyceps, aerobic capacity, exercise performance, fatigue
988617|NCT02075853|Cerebral palsy
988618|NCT02075853|Pes planus
988619|NCT02075853|Calcaneal lengthening
988620|NCT02075827|Appetite, metabolism, sedentary behaviour, stress response
988621|NCT02075801|Sealant, Margins Defect, Amalgam
988622|NCT02075775|instability
988623|NCT02075749|irradiation
988624|NCT02075749|mucositis
988625|NCT02075749|triamcinolone acetonide
988626|NCT02075749|licorice
988627|NCT02075749|mucoadhesive film
988628|NCT02075710|Diet
988629|NCT02075710|Sugar
988630|NCT02075710|Cardiovascular
988631|NCT02075710|Lipid
988632|NCT02075697|psoriasis
988633|NCT02075697|biologic therapy
988634|NCT02075697|infliximab
988635|NCT02075697|etanercept
988636|NCT02075697|efalizumab
988637|NCT02075697|adalimumab
988638|NCT02075697|ustekinumab
988639|NCT02075697|methotrexate
988640|NCT02075697|cyclosporine
988641|NCT02075697|acitretin
988642|NCT02075671|Rosacea
988643|NCT02075671|Photodynamic Therapy
988644|NCT02075671|Aminolevulinic Acid
988645|NCT02075671|Papulopustular Rosacea
988646|NCT02075671|Blue Light
988647|NCT02075658|renal cell carcinoma
988648|NCT02075658|minimally invasive procedures
988649|NCT02075658|robotic nephrectomy
988650|NCT02075658|laparoscopic nephrectomy
988651|NCT02075658|pneumoperitoneum
988652|NCT02075658|trocars
988653|NCT02075658|AirSeal® IFS
988654|NCT02075632|Alclometasone dipropionate
988655|NCT02075632|Eczema
988656|NCT02075632|Psoriasis
988657|NCT02075632|Itch
988658|NCT02075619|Amlodipine
988659|NCT02075619|Healthy volunteers
988660|NCT02075619|Rosuvastatin
988661|NCT02075619|Dyslipidaemia
988662|NCT02075619|Pharmacokinetics
988663|NCT02075619|Hypertension
988664|NCT02075606|NET
988665|NCT02075606|Symptomatic response
988666|NCT02075606|Functioning NeuroEndocrine Tumours
988667|NCT02075606|midgut region
988668|NCT02075593|dolutegravir/abacavir/lamivudine fixed dose combination
988669|NCT02075593|pregnant women
988670|NCT02075593|once daily
988671|NCT02075593|antiretroviral therapy-naive
988672|NCT02075593|HIV-1 Infection
988673|NCT02075593|integrase inhibitor
988674|NCT02075580|cancer, quality of life, body-image, subcutaneous-implant
988675|NCT02075567|Diabetes Mellitus Type 1
988676|NCT02075567|Exercise
988677|NCT02075567|Insulin Reduction
988678|NCT02075567|Glucose
988679|NCT02075567|Hypoglycemia
988680|NCT02075567|Continuous Glucose Monitoring System
988681|NCT02075541|Immunogenicity
988682|NCT02075541|Observer-blind
988683|NCT02075541|Reactogenicity
988684|NCT02075541|Chronic Obstructive Pulmonary Disease
988685|NCT02075541|Safety
988686|NCT02075528|Paliperidone
988687|NCT02075528|Treatment response
988688|NCT02075528|Schizophrenia
988689|NCT02075528|Early prediction
988690|NCT02075528|Pharmacokinetics
988691|NCT02075515|Safety
988692|NCT02075515|Zoster
988693|NCT02075515|Immunogenicity
988694|NCT02075515|Adults
988695|NCT02075515|Consistency
988696|NCT02075502|claudication
988697|NCT02075502|community walking exercise
988698|NCT02075502|community-based participatory research
988699|NCT02075502|exercise adherence
988700|NCT02075502|endovascular therapy
988701|NCT02075489|Acupressure
988702|NCT02075489|Reiki
988703|NCT02075489|EEG
988704|NCT02075489|EMG
988705|NCT02075489|fatigue relief
988706|NCT02075489|veterans
988707|NCT02075476|Fracture-luxation
988708|NCT02075476|humeral proximal extremity
988709|NCT02075476|Hemiarthroplasty
988710|NCT02075476|reverse Arthroplasty
988711|NCT02075463|recombinant human erythropoietin
988714|NCT02075463|anemia
988715|NCT02075463|Hemoglobin
988716|NCT02075463|chronic rhEPO hyporesponsiveness
988717|NCT02075463|chronic kidney disease
988718|NCT02075463|erythropoiesis stimulating agents
988719|NCT02075463|pharmacokinetics
988720|NCT02075450|Cardiac
988721|NCT02075450|Arrest
988722|NCT02075450|Simulation
988723|NCT02075450|Feedback
988724|NCT02075437|Functional Abdominal Pain, Children
988725|NCT02075437|Finding a treatment or intervention for children
988726|NCT02075424|stress
988727|NCT02075424|cortisol
988728|NCT02075424|emergency call center
988729|NCT02075424|hospital staff
988730|NCT02075411|anterior cruciate ligament reconstruction
988731|NCT02075411|transplantation allografts
988732|NCT02075411|adolescent
988733|NCT02075411|nerve block
988734|NCT02075411|pain
988735|NCT02075398|Portable pulse oximeter
988741|NCT02075372|Chronic Total Occlusion of Coronary Artery
988742|NCT02075372|Percutaneous Coronary Intervention
988743|NCT02075372|Hybrid
988744|NCT02075372|Angioplasty
988745|NCT02075359|Total Energy Expenditure
988746|NCT02075359|Physical Activity Levels
988747|NCT02075359|Body Mass Index
988748|NCT02075359|Children
988749|NCT02075346|Patient safety monitors
988750|NCT02075320|CT
988751|NCT02075320|Chest
988752|NCT02075320|Lung
988753|NCT02075307|insulin
988754|NCT02075307|diabetes
988755|NCT02075307|obesity
988756|NCT02075307|DNA damage
988757|NCT02075307|metabolic syndrome
988758|NCT02075294|Aged
988759|NCT02075294|Hepatitis B, Chronic
988760|NCT02075294|Antiviral Agents
988761|NCT02075268|Korean
988762|NCT02075268|Healthy
988763|NCT02075268|Male
988764|NCT02075255|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases, OCS, Oral Corticosteroids
988765|NCT02075242|HBV
988766|NCT02075229|Cochlear Implant
988767|NCT02075229|Post-lingual onset hearing loss
988768|NCT02075229|Profound hearing loss
988769|NCT02075229|Low Frequency hearing loss
988770|NCT02075229|Profound sensorineural hearing loss
988771|NCT02075229|High frequency hearing loss
988772|NCT02075229|CMS-eligible patients
988773|NCT02075216|Urinary Incontinence
988774|NCT02075216|Children
988775|NCT02075216|Bladder Exstrophy
988776|NCT02075216|Extrophy -Epispadias complex,
988777|NCT02075216|Modern staged repair,
988778|NCT02075216|Bladder neck reconstruction
988779|NCT02075203|BCG Vaccinated
988780|NCT02075177|neuroblastoma
988781|NCT02075164|Non-alcoholic Fatty Liver Disease
988782|NCT02075164|Non-alcoholic steatohepatitis
988783|NCT02075164|NAFLD
988784|NCT02075164|NASH
988785|NCT02075151|Bronchial Thermoplasty
988786|NCT02075125|Korea
988787|NCT02075125|Platelet inhibition
988788|NCT02075125|Prasugrel
988789|NCT02075125|Ticagrelor
988790|NCT02075125|ST-segment elevation myocardial infarction
988791|NCT02075112|Soy
988792|NCT02075112|Isoflavone
988793|NCT02075112|Radiation Therapy
988794|NCT02075112|Cisplatin
988795|NCT02075099|whole blood donation
988796|NCT02075099|donation water drink
988797|NCT02075099|isotonic drink
988798|NCT02075099|presyncopal and syncopal reactions
988799|NCT02075086|angiogenic switch
988800|NCT02075086|plasma cytokines
988801|NCT02075086|Colon cancer
988802|NCT02075073|Pharmacokinetics
988803|NCT02075060|low-grade
988804|NCT02075060|NMIBC
988813|NCT02075021|relapsed
988814|NCT02075021|refractory
988815|NCT02075021|multiple myeloma
988816|NCT02075021|revlimid
988817|NCT02075021|lenalidomide
988818|NCT02075021|abraxane
988819|NCT02075021|n-paclitaxel
988820|NCT02075008|asthma
988821|NCT02075008|allergic asthma
988822|NCT02075008|QGE031
988823|NCT02075008|open-label
988824|NCT02075008|IgE
988825|NCT02075008|long-term safety
988826|NCT02074995|Burn, Severe burn, Lean body mass, Cachexia, Hypermetabolism, Catabolism, Wound healing
988827|NCT02074982|chronic plaque type psoriasis, secukinumab, ustekinumab, inflammatory skin disease, scaling
988828|NCT02074969|re-operation rate
988829|NCT02074969|pertrochanteric fractures
988830|NCT02074969|GammaNail
988831|NCT02074969|PFNA
988832|NCT02074969|Tip-Apex-Distance
988833|NCT02074969|Parkers-Ratio
988834|NCT02074956|BCG Vaccinated
988835|NCT02074956|HIV Negative
988836|NCT02074943|Androgenetic Alopecia
988837|NCT02074917|anterior cruciate ligament
988838|NCT02074917|ACL
988839|NCT02074917|anterior cruciate ligament reconstruction
988840|NCT02074917|outcome assessment
988841|NCT02074917|outcome assessment, patient
988842|NCT02074917|treatment outcome
988843|NCT02074917|exercise test
988844|NCT02074917|anatomic
988845|NCT02074917|anatomical
988846|NCT02074917|single-bundle
988847|NCT02074917|force platform
988848|NCT02074917|postural balance
988849|NCT02074917|biomechanics
988850|NCT02074917|CT scan
988851|NCT02074917|X-ray computed tomography
988852|NCT02074917|tomography
988853|NCT02074917|diagnostic imaging
988854|NCT02074917|knee
988855|NCT02074917|knee injuries
988856|NCT02074917|joint instability
988857|NCT02074917|reconstructive surgical procedures
988858|NCT02074917|knee surgery
988859|NCT02074917|arthroscopy
988860|NCT02074917|athletes
988861|NCT02074917|sports medicine
988862|NCT02074917|humans
988863|NCT02074917|prospective studies
988864|NCT02074917|Randomized Controlled Trial
988865|NCT02074891|preexposure prophylaxis
988866|NCT02074891|PrEP
988867|NCT02074891|HIV
988868|NCT02074878|Breast Cancer
988869|NCT02074878|Metastatic
988870|NCT02074878|Crizotinib
988871|NCT02074878|Sunitinib
988872|NCT02074878|Xalcori
988873|NCT02074878|Sutent
988874|NCT02074839|acute myeloid leukemia
988875|NCT02074839|AML
988876|NCT02074839|myelodysplastic syndrome
988877|NCT02074839|MDS
988878|NCT02074839|hematologic malignancies
988879|NCT02074839|IDH
988880|NCT02074839|Untreated AML
988881|NCT02074839|IDH1
988882|NCT02074839|relapsed AML
988883|NCT02074839|refractory AML
988884|NCT02074813|Inspiratory muscle training
988885|NCT02074813|COPD
988886|NCT02074813|dyspnea
988887|NCT02074813|Multidimensional Dyspnea Profile questionnaire (MDP).
988888|NCT02074813|pulmonary rehabilitation
988889|NCT02074800|Healthy
988890|NCT02074800|CNTO 328
988891|NCT02074800|Sp2/0-derived CNTO 328
988892|NCT02074800|CHO-derived CNTO 328
988893|NCT02074800|Safety
988894|NCT02074800|Pharmacokinetics
988895|NCT02074774|nasal cannula, high flow oxygen therapy, pulse oximetry
988896|NCT02074761|sacroiliac joint fusion
988897|NCT02074761|SIJ fusion
988898|NCT02074761|SI joint
988899|NCT02074761|SIJ
988900|NCT02074748|Bunion
988901|NCT02074748|Foot Arch
988902|NCT02074748|Instability
988903|NCT02074735|alcohol dependence
988904|NCT02074735|alcohol abuse
988905|NCT02074709|Pain, Liposomal bupivacaine, Wound infiltration
988906|NCT02074696|brain derived neurotrophic factor
988907|NCT02074657|Immunotherapy
988908|NCT02074657|NKAEs
988909|NCT02074657|Expanded haploidentical natural killer cells
988910|NCT02074657|Activated natural killer cells
988911|NCT02074644|Prostatism
988912|NCT02074644|Randomized Controlled Trial
988913|NCT02074644|Embolization, Therapeutic
988914|NCT02074644|Hyperplasia
988915|NCT02074644|Prostatic Diseases
988916|NCT02074644|Genital Diseases, Male
988917|NCT02074631|bone mineral content
988918|NCT02074631|bone mineral density
988919|NCT02074631|bone formation
988920|NCT02074631|bone resorption
988921|NCT02074631|pamidronate
988922|NCT02074631|children
988923|NCT02074631|DXA
988924|NCT02074631|bone marrow transplant
988925|NCT02074618|Physical Therapy.
988926|NCT02074618|Exercise.
988927|NCT02074618|Rehabilitation.
988928|NCT02074618|Renal Insufficiency.
988929|NCT02074618|Quality of life.
988930|NCT02074605|Melanoma
988931|NCT02074605|Interferon
988932|NCT02074605|Cognition
988933|NCT02074592|Self assessment
988934|NCT02074592|Audit
988935|NCT02074592|Feedback
988936|NCT02074592|Quality
988937|NCT02074592|Ultrasound
988938|NCT02074592|Fetal
988939|NCT02074592|Biometry
988940|NCT02074579|Irritable Bowel Syndrome
988941|NCT02074579|Rome III criteria
988942|NCT02074579|abdominal bloating
988943|NCT02074579|natural
988944|NCT02074579|herbal
988945|NCT02074579|Kampo
988946|NCT02074579|Adult ages 18 to 65
988947|NCT02074579|Female subjects
988948|NCT02074566|Pulmonary Vein Isolation
988949|NCT02074566|Atrial fibrillation
988950|NCT02074566|Cryoballoon therapy
988951|NCT02074566|Duration
988952|NCT02074527|congenital heart disease
988953|NCT02074527|cardiac catheterization
988954|NCT02074527|brazilian electronic registration
988955|NCT02074501|stroke
988956|NCT02074501|elderly
988957|NCT02074501|caregivers
988958|NCT02074501|empowerment
988959|NCT02074501|self-care
988960|NCT02074501|pilot study
988961|NCT02074488|balance
988962|NCT02074488|gait
988963|NCT02074462|Voriconazole
988964|NCT02074462|CRP
988965|NCT02074462|Inflammation
988966|NCT02074462|Pharmacokinetics
988967|NCT02074449|Pulmonary Arterial Hypertension
988968|NCT02074449|Right Ventricular Performance
988969|NCT02074449|Treprostinil
988970|NCT02074449|Remodulin
988971|NCT02074436|hematological malignancies
988972|NCT02074436|thrombocytopenia
988973|NCT02074436|aminocaproic acid
988974|NCT02074423|Cinnamon extract
988975|NCT02074423|Postprandial glycemia
988976|NCT02074423|Glycemic index
988977|NCT02074423|Pre-diabetes
988978|NCT02074423|Metabolic syndrome
988979|NCT02074371|coronary artery bypass surgery
988980|NCT02074371|cardiopulmonary bypass
988981|NCT02074371|ICU
988982|NCT02074371|postoperative respiratory depression
988983|NCT02074345|Drug therapy
988984|NCT02074345|Safety and immunogenicity of Hib vaccine
988985|NCT02074332|Obesity
988986|NCT02074332|Physical activity
988987|NCT02074332|Schoolchildren
988988|NCT02074332|Intervention Studies
988989|NCT02074319|Schizophrenia
988990|NCT02074319|Anti-Inflammatory
988991|NCT02074319|Methotrexate
988992|NCT02074319|Psychosis Not Otherwise Specified
988993|NCT02074306|endotracheal intubation
988994|NCT02074306|low energy ultrasound
988995|NCT02074306|sputum culture
988996|NCT02074293|Subdermal bloodless space
988997|NCT02074293|Subdermal injection
988998|NCT02074293|injectable EMG needle
988999|NCT02074293|electrical stimulation
989000|NCT02074293|MRI with Gadolinium
989001|NCT02074293|Cervical Dystonia
989002|NCT02074293|intramuscular injection
989003|NCT02074293|cervical dystonia,
989004|NCT02074280|rifaximin
989005|NCT02074280|endotoxemia
989006|NCT02074280|cirrhosis
989007|NCT02074280|advanced cirrhosis
989008|NCT02074228|Attention-deficit/hyperactivity disorder,
989009|NCT02074228|symptomatology,
989010|NCT02074228|neurocognitive endophenotype,
989011|NCT02074228|medication response
989012|NCT02074215|Mild Cognitive Impairment
989013|NCT02074215|Alzheimer's disease
989014|NCT02074215|Aerobic exercise
989015|NCT02074202|18F fluorocholine
989016|NCT02074202|18F fluorodeoxyglucose
989017|NCT02074202|hepatocellular carcinoma
989018|NCT02074202|PET CT scan
989019|NCT02074176|Attention-deficit/hyperactivity disorder
989020|NCT02074176|orexin A
989021|NCT02074176|mRNA
989022|NCT02074163|Subdermal bloodless space
989023|NCT02074163|Subdermal injection
989024|NCT02074163|injectable EMG needle
989025|NCT02074163|electrical stimulation
989026|NCT02074163|MRI with Gadolinium
989027|NCT02074163|Chronic Migraine
989028|NCT02074163|intramuscular injection
989029|NCT02074150|Subdermal bloodless space
989030|NCT02074150|Subdermal injection
989031|NCT02074150|injectable EMG needle
989032|NCT02074150|electrical stimulation
989033|NCT02074150|MRI with Gadolinium
989034|NCT02074150|Upper Limb Spasticity
989035|NCT02074150|intramuscular injection
989036|NCT02074111|Moyamoya disease
989037|NCT02074111|Intracranial atherosclerotic stroke
989038|NCT02074111|Intracranial steno-occlusive disease
989039|NCT02074111|ring finger 213 (RNF213) gene mutation
989040|NCT02074111|high-resolution MRI
989041|NCT02074098|intubation
989042|NCT02074098|Cardiopulmonary resuscitation
989043|NCT02074098|Manikin study
989044|NCT02074072|Endotracheal intubation
989045|NCT02074072|Left lateral tilt wedge
989046|NCT02074072|Maternal Cardiopulmonary Resuscitation
989047|NCT02074072|Manikin Study
989048|NCT02074020|SLE
989049|NCT02074020|Lupus
989050|NCT02074020|Lupus Erythematosus, Systemic
989051|NCT02074020|Autoimmune Diseases
989052|NCT02074020|A-623
989053|NCT02074020|Blisibimod
989054|NCT02074020|Nephritis
989055|NCT02074007|Acute Otitis Media
989056|NCT02074007|Pain
989057|NCT02074007|Ear Pain
989058|NCT02074007|Ear Ache
989059|NCT02074007|Ear infection
989060|NCT02074007|middle ear infection
989061|NCT02073994|chondrosarcoma
989062|NCT02073994|cholangiocarcinoma
989063|NCT02073994|glioma
989064|NCT02073994|advanced solid tumors
989065|NCT02073994|IDH1
989066|NCT02073994|AG-120
989067|NCT02073981|Parkinson Disease
989068|NCT02073955|Stroke
989069|NCT02073955|Validation
989070|NCT02073955|Community Health workers
989071|NCT02073955|stroke symptom questionnaire
989072|NCT02073916|Breast Cancer
989073|NCT02073916|HER2 positive Breast Cancer
989074|NCT02073903|dual handset interpreter phones
989075|NCT02073903|communication
989076|NCT02073903|14-042
989077|NCT02073890|traumatic Subarachnoid Haemorrhage
989078|NCT02073890|Head Trauma
989079|NCT02073890|Computed Tomography
989080|NCT02073877|Peri-implant dermatitis
989081|NCT02073864|Aortic valve stenosis, stenosis, intervention
989082|NCT02073851|TAVR
989083|NCT02073825|Computer-assisted interventions
989084|NCT02073825|Alcohol use disorders
989085|NCT02073825|At-risk drinking
989086|NCT02073825|Spouses
989087|NCT02073825|Military
989088|NCT02073825|Brief Intervention
989089|NCT02073773|stroke, virtual reality based therapy
989090|NCT02073760|Healthcare acquired infections
989091|NCT02073760|Cardiac Surgery
989092|NCT02073760|Sternal Superficial Wound Infection
989093|NCT02073760|Deep Sternal Infection
989094|NCT02073760|Mediastinitis
989095|NCT02073760|Thoracotomy
989096|NCT02073760|Conduit harvest or cannulation site
989097|NCT02073760|Sepsis
989098|NCT02073760|Pneumonia
989099|NCT02073747|Albuterol
989100|NCT02073747|Serum Lactate
989101|NCT02073747|Lactic Acidosis
989102|NCT02073747|Asthma
989103|NCT02073734|pelvic organ prolapse surgery
989104|NCT02073734|dexamethasone
989105|NCT02073734|postoperative nausea and vomiting
989106|NCT02073734|peroperative administration
989107|NCT02073695|Proximal humeral fracture
989108|NCT02073695|Shoulder
989109|NCT02073695|Orthopaedics
989110|NCT02073695|Neutral rotation brace
989111|NCT02073695|Polysling
989112|NCT02073669|latent tuberculosis
989113|NCT02073669|tuberculin skin test
989114|NCT02073669|Interferon gamma release assay
989115|NCT02073669|immigration
989116|NCT02073656|genotype 1
989117|NCT02073656|genotype 4
989118|NCT02073656|HIV
989119|NCT02073630|magnetoencephalography
989120|NCT02073630|non invasive brain stimulation
989121|NCT02073630|cerebellum
989122|NCT02073630|gamma rhythms
989123|NCT02073617|DynaCT
989124|NCT02073617|Aortic valve and root measurements
989125|NCT02073617|TAVR
989126|NCT02073604|Congenital mirror movements
989127|NCT02073604|SMA
989128|NCT02073604|Movement preparation
989129|NCT02073604|Movement lateralization
989130|NCT02073604|MRI
989131|NCT02073604|Transcranial magnetic stimulation
989132|NCT02073591|Children
989133|NCT02073591|Atopic Dermatitis
989134|NCT02073591|Ceradan
989135|NCT02073591|PEST
989136|NCT02073591|SCORAD
989137|NCT02073578|achalasia
989138|NCT02073578|POEM
989139|NCT02073578|peroral endoscopic myotomy
989140|NCT02073578|myotomy
989141|NCT02073578|Heller myotomy
989142|NCT02073565|intracoronary stent
989143|NCT02073565|drug eluting stent
989144|NCT02073565|sirolimus
989145|NCT02073565|endothelial progenitor cells
989146|NCT02073552|colon cleansing, bowel preparations; polyethyleneglycol
989147|NCT02073539|Chest compression
989148|NCT02073539|One accelerometer
989149|NCT02073539|Manikin Study
989150|NCT02073526|Antibodies, Monoclonal
989151|NCT02073526|Anti-TNF
989152|NCT02073526|TNF-alpha
989153|NCT02073526|Trough level
989154|NCT02073526|Drug concentration
989155|NCT02073526|ELISA
989156|NCT02073513|Spasticity, Hand Function, Cerebral Palsy, Kinesiotape
989157|NCT02073500|Peritoneal carcinomatosis
989158|NCT02073500|Peritoneal surface malignancy
989159|NCT02073500|Cytoreductive surgery
989160|NCT02073500|Hyperthermic intraperitoneal chemotherapy
989161|NCT02073500|CRS
989162|NCT02073500|HIPEC
989163|NCT02073500|Prognostic biomarker
989164|NCT02073500|Predictive biomarker
989165|NCT02073487|Neoadjuvant Breast Cancer
989166|NCT02073487|HER2 positive Breast Cancer
989167|NCT02073474|cannabinoids
989168|NCT02073474|Sativex
989169|NCT02073474|THC
989170|NCT02073474|delta-9-tetrahydrocannabinol
989171|NCT02073474|cannabidiol
989172|NCT02073474|CBD
989173|NCT02073474|Registry
989174|NCT02073474|Safety
989175|NCT02073474|MS
989176|NCT02073461|Acne Vulgaris
989177|NCT02073448|Acne Vulgaris
989178|NCT02073435|liver transplantation
989179|NCT02073435|living donor
989180|NCT02073435|Safety
989181|NCT02073422|Magnetic resonance imaging
989182|NCT02073422|Myocardial stress perfusion magnetic resonance imaging
989183|NCT02073422|Fractional flow reserve
989184|NCT02073422|Relaxometry
989185|NCT02073422|Coronary artery disease
989186|NCT02073409|Nontuberculous Mycobacteria
989187|NCT02073383|Axillary brachial plexus block
989188|NCT02073383|Ultrasound
989189|NCT02073383|Bupivacaine
989190|NCT02073344|obstructive sleep apnea
989191|NCT02073344|overhydration
989192|NCT02073344|end stage renal disease
989193|NCT02073344|renal transplantation
989194|NCT02073344|polysomnography
989195|NCT02073344|bioimpedance
989196|NCT02073344|leg fluid shift
989197|NCT02073344|neck circumference
989198|NCT02073331|Open heart surgery, cardiac repair
989199|NCT02073305|obstructive sleep apnea
989200|NCT02073305|end stage renal disease
989201|NCT02073305|cardiovascular events
989202|NCT02073240|Tuberculosis
989203|NCT02073240|Infection Control
989204|NCT02073227|Healthy Volunteers
989205|NCT02073227|Canagliflozin
989206|NCT02073227|Metformin
989207|NCT02073227|Type 2 diabetes mellitus
989208|NCT02073175|Postpartum
989209|NCT02073175|Dietary Supplements
989210|NCT02073175|Mood Symptoms
989211|NCT02073149|Iron
989212|NCT02073149|Anemia
989213|NCT02073149|Sodium Fe(III)-ethylenediaminetetraacetic acid (NaFeEDTA)
989214|NCT02073149|Ferrous compounds
989215|NCT02073149|Child, preschool
989216|NCT02073149|Kenya
989217|NCT02073123|Metastatic melanoma
989218|NCT02073123|Stage III melanoma
989219|NCT02073123|Stage IV melanoma
989220|NCT02073123|unresectable
989221|NCT02073110|Kidney cancer
989222|NCT02073110|Renal mass
989223|NCT02073110|Small renal mass
989224|NCT02073110|Optical Coherence Tomography
989225|NCT02073110|OCT
989226|NCT02073110|Diffuse Reflectance Spectroscopy
989227|NCT02073110|DRS
989228|NCT02073110|Optical Biopsy
989229|NCT02073110|OB
989230|NCT02073058|Subjects with Type 1 or Type 2 Diabetes Requiring Multiple daily Insulin Injection (MDI) or Continuous Subcutaneous Insulin Infusion (CSII)
989231|NCT02073032|Refeeding syndrome, risk factors, head and neck cancer
989232|NCT02073006|Chronic
989233|NCT02073006|Functional
989234|NCT02073006|Constipation
989235|NCT02073006|less than 3 bowel movements per week
989236|NCT02072993|Phase I, healthy, pharmacokinetics
989237|NCT02072980|DT1
989238|NCT02072980|DAILIES TOTAL1®
989239|NCT02072980|Lubricity
989240|NCT02072967|Relapsed
989241|NCT02072967|Refractory
989242|NCT02072967|Non-Hodgkin Lymphoma
989243|NCT02072967|Bendamustine
989244|NCT02072941|Advance care planning
989245|NCT02072941|Latino Health
989246|NCT02072941|Medical decision making
989247|NCT02072941|Health Literacy
989248|NCT02072941|Limited English proficiency
989249|NCT02072941|Aging
989250|NCT02072902|Cohort
989251|NCT02072902|Historical
989252|NCT02072902|Prospective
989253|NCT02072902|Medications
989254|NCT02072902|Observational
989255|NCT02072902|Glucose
989256|NCT02072902|Control
989257|NCT02072889|Cardiac Surgery
989258|NCT02072889|Internal Jugular Cannulation
989259|NCT02072889|Optimal Neck Angle
989260|NCT02072876|Stroke
989261|NCT02072876|Asymptomatic Intracranial Atherosclerotic Disease
989262|NCT02072876|Lifestyle and socio-economic risk factors
989263|NCT02072876|Clinical predictors
989264|NCT02072850|Myocardial infarction
989265|NCT02072850|Primary percutaneous coronary intervention (PCI)
989266|NCT02072850|Thrombolysis
989267|NCT02072850|Rescue PCI
989268|NCT02072850|Electrocardiogram
989269|NCT02072850|Magnetic resonance imaging
989270|NCT02072850|Area-at-risk
989271|NCT02072850|Myocardial salvage
989272|NCT02072850|Infarct size
989273|NCT02072850|Pressure wire
989274|NCT02072850|Coronary thermodilution
989275|NCT02072850|Coronary microvascular function
989276|NCT02072850|Index of microvascular resistance
989277|NCT02072850|Heart failure
989278|NCT02072850|Prognosis
989279|NCT02072837|hemodialysis, dyslipidemia, cardiovascular disease
989280|NCT02072824|Partial Onset Seizures
989281|NCT02072824|Epilepsy
989282|NCT02072824|Safety
989283|NCT02072824|Efficacy
989284|NCT02072824|Tolerability
989285|NCT02072824|Pregabalin
989286|NCT02072824|Lyrica
989287|NCT02072824|Adjunctive treatment
989288|NCT02072824|Placebo controlled
989289|NCT02072824|blinded
989290|NCT02072824|Eligibility Criteria
989291|NCT02072811|AML
989292|NCT02072798|Randomized Controlled Trial
989293|NCT02072798|Caesarean Section
989294|NCT02072798|Surgical Site Infections
989295|NCT02072798|Wound Infections
989296|NCT02072798|Infectious Morbidity
989297|NCT02072785|Adult Acute Lymphoblastic Leukemia
989298|NCT02072785|Vincristine Sulfate Liposome
989299|NCT02072785|Vincristine Sulfate
989300|NCT02072759|Insulin sensitivity
989301|NCT02072759|Metabolic flexibility
989302|NCT02072746|cirrhosis
989303|NCT02072746|alcohol
989304|NCT02072733|frailty
989305|NCT02072733|oncogeriatrics
989306|NCT02072733|Multidisciplinary intervention
989307|NCT02072733|multimorbidity
989308|NCT02072733|Comprehensive geriatric assessment
989309|NCT02072733|patients
989310|NCT02072720|Radiotherapy
989311|NCT02072720|VEGF
989312|NCT02072720|esophagus carcinoma
989313|NCT02072720|bevacizumab
989314|NCT02072707|Ventricular Tachycardia
989315|NCT02072707|RF ablation
989316|NCT02072707|Epicardial Access
989317|NCT02072707|Contact Sensor Irrigated tip catheter
989318|NCT02072694|Obesity
989319|NCT02072694|Single Photon Emission Computed Tomography
989320|NCT02072694|Functional Neuroimaging
989321|NCT02072668|sickle cell anemia
989322|NCT02072668|sickle cell disease
989323|NCT02072668|rivaroxaban
989324|NCT02072668|direct Xa inhibition
989325|NCT02072668|coagulation
989326|NCT02072668|anticoagulation
989327|NCT02072629|Antimalarials
989328|NCT02072629|Antibiotics
989329|NCT02072629|ORS Zn
989330|NCT02072629|Village Health Volunteers
989331|NCT02072629|Integrated Community Case Management
989332|NCT02072616|Circulating Tumor Cells
989333|NCT02072616|pancreatic adenocarcinoma
989334|NCT02072616|circulating tumor DNA (KRAS)
989335|NCT02072616|CA 19.9
989336|NCT02072603|Infant HIV
989337|NCT02072603|Kenya
989338|NCT02072603|HITSystem
989339|NCT02072603|EID care
989340|NCT02072603|Early Infant Diagnosis
989341|NCT02072590|Celiac disease
989342|NCT02072590|Eosinophilic esophagitis
989343|NCT02072590|Endomysial antibodies
989344|NCT02072590|Transglutaminase antibodies
989345|NCT02072590|Small-bowel
989346|NCT02072577|Nursing care, oral health, educational video, oral hygiene.
989347|NCT02072538|Stress testing
989348|NCT02072538|Troponin T
989349|NCT02072538|GRACE score
989350|NCT02072538|Outcome
989351|NCT02072525|Pertussis
989352|NCT02072525|Healthy adults
989353|NCT02072525|Tetanus
989354|NCT02072525|Human serum samples
989355|NCT02072525|Streptococcus
989356|NCT02072525|Diphtheria
989357|NCT02072525|Plasma
989358|NCT02072525|Meningococcus
989359|NCT02072512|pre- and perimenopausal HR+ advanced breast cancer
989360|NCT02072473|Re-entrant Atrioventricular Node Tachycardia
989361|NCT02072473|Unsuccessful right-sided slow pathway ablation
989362|NCT02072473|Coronary sinus / left-sided slow pathway ablation
989363|NCT02072447|absolute bioavailability,
989364|NCT02072447|microdose,
989365|NCT02072447|AMS
989366|NCT02072434|Atrial fibrillation
989367|NCT02072434|anti-coagulant
989368|NCT02072434|warfarin
989369|NCT02072434|edoxaban
989370|NCT02072434|electrical cardioversion
989371|NCT02072395|morbid obesity
989372|NCT02072395|bariatric surgery
989373|NCT02072395|gastric banding
989374|NCT02072395|gastric plication
989375|NCT02072382|Hypertension
989376|NCT02072382|Metformin
989377|NCT02072382|Ambulatory blood pressure monitor
989383|NCT02072356|Humanitarian Device
989384|NCT02072356|Carcinoma
989385|NCT02072356|Hepatocellular Carcinoma
989386|NCT02072356|TheraSphere®
989387|NCT02072356|HUD
989388|NCT02072343|Capnography
989389|NCT02072343|Catheters
989390|NCT02072343|Intubation
989391|NCT02072330|Hypertension, Drug therapy
989392|NCT02072317|PFS
989393|NCT02072304|mood disorder
989394|NCT02072304|depressive disorder
989395|NCT02072304|mental disorders
989396|NCT02072304|program acceptability
989397|NCT02072304|behavioral symptoms
989398|NCT02072304|suicidal ideation
989399|NCT02072304|patient adherence
989400|NCT02072265|infrared thermal image
989401|NCT02072265|wound healing
989402|NCT02072265|wound infection
989403|NCT02072252|Depression
989404|NCT02072252|Anxiety
989405|NCT02072252|Mobile Phone
989406|NCT02072252|Cellular Phone
989407|NCT02072252|Mobile Application
989408|NCT02072252|Mobile Intervention
989409|NCT02072252|App
989410|NCT02072252|mHealth
989411|NCT02072252|eHealth
989412|NCT02072252|Technology Assisted
989413|NCT02072252|Internet
989414|NCT02072252|Cognitive Behavioral Therapy
989415|NCT02072252|LGBT
989416|NCT02072252|Sexual Minorities
989417|NCT02072252|Gay
989418|NCT02072252|Bisexual
989419|NCT02072252|Same Sex Attraction
989420|NCT02072252|Males
989421|NCT02072252|Men
989422|NCT02072252|Youth
989423|NCT02072252|Adolescents
989424|NCT02072252|Young Adults
989425|NCT02072239|CABG
989426|NCT02072239|Intimal Hyperplasia
989427|NCT02072239|Atherosclerosis
989428|NCT02072239|Myocardial Infarction
989429|NCT02072213|Tamsulosin,controlled release formulation
989430|NCT02072200|RA, MS, Safety, Efficacy, MR prednisone
989431|NCT02072187|Depression
989432|NCT02072187|Vitamin D
989433|NCT02072187|Complementary and Alternative Medicine
989434|NCT02072187|Supplements
989435|NCT02072187|Non Remitted Depression
989436|NCT02072161|Statin
989437|NCT02072161|LDL
989438|NCT02072161|Cholesterol
989439|NCT02072148|Human Papilloma Virus
989440|NCT02072148|Oropharyngeal Squamous Cell Carcinoma
989441|NCT02072148|Transoral Robotic Surgery
989442|NCT02072122|dry eye
989443|NCT02072122|fertility treatment
989444|NCT02072122|Meibomian gland dysfunction
989445|NCT02072122|supra physiologic estrogen level
989446|NCT02072109|Near infrared spectroscopy
989447|NCT02072109|Bolus nutrition
989448|NCT02072109|Continuous nutrition
989449|NCT02072109|Mesenteric circulation
989450|NCT02072083|dexmedetomidine
989451|NCT02072083|intranasal
989452|NCT02072083|strabismus surgery
989453|NCT02072083|premedication
989454|NCT02072083|oculocardiac reflex
989455|NCT02072070|chondrocyte cells, Osteoarthritis, gene therapy
989456|NCT02072044|Renal Cell Carcinoma（RCC）
989457|NCT02072044|Anlotinib
989458|NCT02072031|Anlotinib
989459|NCT02072031|Sunitinib
989460|NCT02072031|Renal Cell Carcinoma（RCC）
989461|NCT02072018|Peyronie's
989462|NCT02072018|Peyronie's disease
989463|NCT02072018|Treatment
989464|NCT02072018|Clinical Study
989465|NCT02071979|Chronic
989466|NCT02071979|Non-healing
989467|NCT02071979|Wounds
989468|NCT02071966|Micro-RNA, Microparticles, Ticagrelor, NSTE-ACS
989469|NCT02071940|Acral Melanoma subtypes
989470|NCT02071940|Mucosal Melanoma subtypes
989471|NCT02071927|leukemia
989472|NCT02071927|glutaminase
989473|NCT02071927|glutamine
989474|NCT02071888|Non-Hodgkin's lymphoma
989475|NCT02071888|Waldenstrom's macroglobulinemia
989476|NCT02071888|Multiple myeloma
989477|NCT02071888|glutaminase
989478|NCT02071888|glutamine
989479|NCT02071875|Vasospasm
989480|NCT02071875|Aneurysm
989481|NCT02071875|SAH
989482|NCT02071875|Nautilus NeuroWave
989483|NCT02071862|Tumor metabolism
989484|NCT02071862|Glutaminase
989485|NCT02071862|Glutamine
989486|NCT02071862|Tricarboxylic acid (TCA) cycle
989487|NCT02071849|Aortic Insufficiency
989488|NCT02071849|Aortic Regurgitation
989489|NCT02071836|web application
989490|NCT02071836|DWI intervention
989491|NCT02071836|DUI intervention
989492|NCT02071836|Experimental group: Right Turns + treatment as usual
989493|NCT02071836|Control group: Treatment as usual
989494|NCT02071823|Opicapone,
989495|NCT02071823|Parkinson,
989496|NCT02071823|Bial,
989497|NCT02071823|BIA 9-1067
989498|NCT02071810|Parkinson's disease (PD)
989499|NCT02071810|Opicapone
989500|NCT02071810|Bial
989501|NCT02071810|BIA 9-1067
989502|NCT02071797|Therapeutic Hypothermia
989503|NCT02071797|Cardiac Arrest
989504|NCT02071797|Randomised Controlled trial
989505|NCT02071797|Pilot study
989506|NCT02071771|DACP Toric
989507|NCT02071771|DAILIES® AquaComfort Plus®
989508|NCT02071771|Astigmatism
989509|NCT02071771|Toric
989510|NCT02071758|Leishmaniasis
989511|NCT02071758|Visceral leishmaniasis
989512|NCT02071758|Vaccine
989513|NCT02071758|Adjuvant
989514|NCT02071758|GLA
989515|NCT02071758|SLA
989516|NCT02071693|subthalamic nucleus
989517|NCT02071693|deep brain stimulation
989518|NCT02071693|cognition
989519|NCT02071693|white matter hyperintensities
989520|NCT02071680|atrial fibrillation
989521|NCT02071680|atrial cardiac innervation
989522|NCT02071680|catheter ablation of atrial fibrillation
989523|NCT02071680|High Frequency Stimulation
989524|NCT02071680|ganglionated plexuses
989525|NCT02071680|123I-mIBG
989526|NCT02071680|nuclear imaging
989527|NCT02071667|Chronic sinusitis
989528|NCT02071667|Nasal Polyps
989529|NCT02071654|Venus P-valve
989530|NCT02071615|Brain Activity
989531|NCT02071602|Heart attack
989532|NCT02071602|Myocardial Infarction
989533|NCT02071602|STEMI
989534|NCT02071576|Myopia
989535|NCT02071576|Hyperopia
989536|NCT02071576|Proscan
989537|NCT02071576|LASIK
989538|NCT02071576|TENEO
989539|NCT02071576|Excimer
989540|NCT02071550|laparoscopic cholecystectomy, near infrared spectroscopy, positive end expiratory pressure
989541|NCT02071498|Pillbox
989542|NCT02071498|Non-adherence
989543|NCT02071498|Applications
989544|NCT02071498|Patient safety
989545|NCT02071498|Elderly
989546|NCT02071459|L-threo DOPS (DroxiDopa)
989547|NCT02071459|Orthostatic Hypotension
989548|NCT02071459|Multiple system atrophy
989549|NCT02071446|Deep Brain Stimulation
989550|NCT02071446|Local Field Potential
989551|NCT02071446|Subthalamic Nucleus
989552|NCT02071433|Saphenous nerve block
989553|NCT02071433|Adductor canal block
989554|NCT02071433|Anterior cruciate ligament
989555|NCT02071433|Pain management
989556|NCT02071433|Day care
989557|NCT02071407|traumatic brain injury
989558|NCT02071407|sedation
989559|NCT02071407|midazolam
989560|NCT02071394|Xenon
989561|NCT02071394|Hypothermia
989562|NCT02071394|Hypoxic Ischemic Encephalopathy
989563|NCT02071394|Newborn
989564|NCT02071394|Neonate
989565|NCT02071394|Term
989566|NCT02071394|Neuroprotection
989567|NCT02071394|Cooling
989568|NCT02071394|HIE
989569|NCT02071368|Healthy
989570|NCT02071368|Canagliflozin
989571|NCT02071368|Metformin
989572|NCT02071368|JNJ-28431754
989573|NCT02071368|GLUMETZA®
989574|NCT02071368|Bioequivalence
989575|NCT02071368|Fixed Dose Combination
989576|NCT02071355|Healthy
989577|NCT02071355|Chinese participants
989578|NCT02071355|TMC435
989579|NCT02071355|Multiple oral doses
989580|NCT02071355|Pharmacokinetics
989581|NCT02071355|Safety
989582|NCT02071355|Tolerability
989583|NCT02071342|acute myocardial infarction
989584|NCT02071342|bioresorbable vascular scaffold
989585|NCT02071342|percutaneous coronary intervention
989586|NCT02071329|FP-01.1
989587|NCT02071329|Influenza A
989588|NCT02071329|Flu
989589|NCT02071329|Vaccine
989590|NCT02071329|Virus
989591|NCT02071329|H1N1
989592|NCT02071329|Challenge
989593|NCT02071316|upper gastrointestinal bleeding
989594|NCT02071316|Hexacapron
989595|NCT02071316|hemostasis
989596|NCT02071303|Pain
989597|NCT02071303|Hysteroscopy
989598|NCT02071303|Tramadol
989599|NCT02071303|Celecoxib
989600|NCT02071290|Hemorrhagic Shock
989601|NCT02071290|Remote Ischemic Conditioning
989602|NCT02071277|Mechanical ventilation
989603|NCT02071277|Airway pressure release ventilation
989604|NCT02071277|Biphasic intermittent positive airway pressure
989605|NCT02071277|Pressure-controlled ventilation
989606|NCT02071277|Lung protective ventilation
989607|NCT02071277|Spontaneous breathing
989608|NCT02071264|HIV/AIDS
989609|NCT02071264|sex work
989610|NCT02071264|reproductive health
989611|NCT02071264|human rights
989612|NCT02071264|ethics
989613|NCT02071251|Wound complications
989614|NCT02071251|Wound infection
989615|NCT02071251|Wound separation
989616|NCT02071238|Carpal tunnel
989617|NCT02071238|Carpal tunnel release
989618|NCT02071238|Risk Recall
989619|NCT02071238|Patient satisfaction
989620|NCT02071238|Pamphlet
989621|NCT02071238|Brochure
989622|NCT02071199|Gingivitis
989623|NCT02071199|Periodontitis
989624|NCT02071199|ACCS
989625|NCT02071160|HIE
989626|NCT02071160|hypothermia
989627|NCT02071160|encephalopathy
989628|NCT02071160|anti oxidants
989629|NCT02071160|MRI
989630|NCT02071147|Follow-up
989631|NCT02071147|No follow-up
989632|NCT02071147|removal
989633|NCT02071147|Randomised Controlled Trial
989634|NCT02071147|6 Weeks
989635|NCT02071134|Deep brain stimulation
989636|NCT02071134|Parkinson's disease
989637|NCT02071134|Vercise
989638|NCT02071121|BIIB061
989639|NCT02071121|Healthy
989640|NCT02071095|Human immunodeficiency virus 1
989641|NCT02071095|Combined Antiretroviral Therapy
989642|NCT02071095|Poly-ICLC
989643|NCT02071095|Adjuvant
989644|NCT02071082|HIV
989645|NCT02071082|HBV
989646|NCT02071082|Coinfection
989647|NCT02071069|Incurable colorectal cancer
989648|NCT02071069|maintenance therapy
989649|NCT02071069|Cetuximab
989650|NCT02071043|neo-adjuvant chemotherapy
989651|NCT02071043|advanced gastric cancer patients
989652|NCT02071043|para-aortic lymph node metastasis
989653|NCT02071030|CBCT
989654|NCT02071030|Third molar removal
989655|NCT02071030|Inferior alveolar nerve injury
989656|NCT02071004|acute ischemic stroke
989657|NCT02070991|pre- and post-capillary pulmonary hypertension
989658|NCT02070991|CpcPH
989659|NCT02070978|Lupus Erythematosus, Systemic
989660|NCT02070978|Atacicept 75 and 150 mg
989661|NCT02070978|LTE
989662|NCT02070952|CyberKnife
989663|NCT02070952|Stereotactic Body Radiation Therapy
989664|NCT02070952|Low and Intermediate Risk Prostate Cancer
989665|NCT02070939|Phase 1
989666|NCT02070939|Randomized
989667|NCT02070939|Double Blind
989668|NCT02070939|Placebo-Controlled
989669|NCT02070939|Single and Multiple Dose Escalation
989670|NCT02070939|Safety Tolerability
989671|NCT02070939|PK
989672|NCT02070939|PD
989673|NCT02070939|PF-06460414
989674|NCT02070913|Hypothermia
989675|NCT02070913|Acute Myocardial Infarction
989676|NCT02070913|Percutaneous Coronary Intervention
989677|NCT02070913|AMI
989678|NCT02070913|PCI
989679|NCT02070913|Therapeutic Hypothermia
989680|NCT02070900|Prevention of Mother to Child Transmission
989681|NCT02070900|PMTCT
989682|NCT02070900|Option B+
989683|NCT02070900|ART
989684|NCT02070900|Retention
989685|NCT02070900|Loss to Follow Up
989686|NCT02070900|Time to initiation
989687|NCT02070900|POC CD4
989688|NCT02070900|Clinical mentoring
989689|NCT02070900|Costing
989690|NCT02070900|HIV
989691|NCT02070900|AIDS
989692|NCT02070900|Zimbabwe
989693|NCT02070874|pain and symptom management
989694|NCT02070861|Cardiac output
989695|NCT02070861|Endtidal CO2
989696|NCT02070861|Nexfin
989697|NCT02070861|Esophageal Doppler
989698|NCT02070848|red blood cell
989699|NCT02070848|knee extension exercise
989700|NCT02070835|Diabetic Foot Ulcer
989701|NCT02070835|ReCell
989702|NCT02070822|Hepatocellular carcinoma
989703|NCT02070822|Transarterial chemoembolization
989704|NCT02070822|Magnetic resonance imaging
989705|NCT02070809|wound
989706|NCT02070809|tissue-engineered skin
989707|NCT02070796|Rotigotine
989708|NCT02070796|Transdermal Patch
989709|NCT02070796|Bioequivalence
989710|NCT02070783|depression
989711|NCT02070783|cognition
989712|NCT02070783|emotion perception
989713|NCT02070783|information processing
989714|NCT02070757|Ventilator-associated bacterial pneumonia
989715|NCT02070757|Hospital-acquired bacterial pneumonia
989716|NCT02070757|Pneumonia
989717|NCT02070757|Lung Diseases
989718|NCT02070757|Respiratory Tract Diseases
989719|NCT02070757|Respiratory Tract Infections
989720|NCT02070757|Infection
989721|NCT02070757|Ventilator-Induced Lung Injury
989722|NCT02070757|Lung Injury
989723|NCT02070744|CF
989724|NCT02070731|TAVR
989725|NCT02070731|TAVI
989726|NCT02070731|Aortic Valve Stenosis
989727|NCT02070718|hot flashes
989728|NCT02070718|menopause
989729|NCT02070718|kappa agonist
989730|NCT02070692|Contraceptive implant
989731|NCT02070692|Irregular vaginal bleeding
989732|NCT02070692|Etonogestrel implant
989733|NCT02070679|Alpha-tocopherol
989734|NCT02070679|Vitamin E
989735|NCT02070679|Contrast-Induced Acute Kidney Injury
989736|NCT02070679|Coronary angiography
989737|NCT02070666|ARDS
989738|NCT02070666|Prevention
989739|NCT02070666|Protective mechanical ventilation
989740|NCT02070666|low tidal volumes
989741|NCT02070653|Aorta
989742|NCT02070653|Aneurysm
989743|NCT02070653|Antiplatelet
989744|NCT02070640|cholecystectomy
989745|NCT02070640|cholecystitis
989746|NCT02070627|acute cholecystitis
989747|NCT02070627|acute cholangitis
989748|NCT02070627|cholecystectomy
989749|NCT02070614|sufentanil
989750|NCT02070614|metabolism
989751|NCT02070614|cytochrome P450 3A4
989752|NCT02070614|gene polymorphism
989753|NCT02070588|TBI
989754|NCT02070588|mTBI
989755|NCT02070588|MR
989756|NCT02070588|MRI
989757|NCT02070588|Pulse Sequences
989758|NCT02070588|NFL
989759|NCT02070575|PSA
989760|NCT02070575|Human Kallikrein 2
989761|NCT02070575|locally resected prostate cancer
989762|NCT02070575|biochemical recurrence
989763|NCT02070575|14-041
989764|NCT02070562|breast milk, dietary survey
989765|NCT02070536|Acute Respiratory Distress Syndrome (ARDS)
989766|NCT02070536|Receptor for advanced glycation end products (RAGE)
989767|NCT02070536|Soluble RAGE (sRAGE)
989768|NCT02070536|Gene polymorphisms
989769|NCT02070536|Biomarker
989770|NCT02070484|NuCel
989771|NCT02070484|Lumbar Spine
989772|NCT02070484|Degenerative Disease
989773|NCT02070484|Efficacy
989774|NCT02070484|Fusion
989775|NCT02070445|CABG
989776|NCT02070445|pilot
989777|NCT02070445|ultrasound
989778|NCT02070445|perioperative
989779|NCT02070445|low tidal volume ventilation
989780|NCT02070432|LUZ11
989781|NCT02070432|head and neck cancer
989782|NCT02070432|photodynamic therapy
989783|NCT02070432|Redaporfin
989784|NCT02070393|Hodgkins Disease in Young Females
989785|NCT02070393|Breast Sparing Radiation Treatments
989786|NCT02070380|confirmed brain disease
989787|NCT02070380|highly suspected brain disease
989788|NCT02070367|allodynia
989789|NCT02070367|complex regional pain syndrome
989790|NCT02070367|peripheral nerve injuries
989791|NCT02070367|clinical measurement properties
989792|NCT02070354|Obesity
989793|NCT02070354|Bariatric surgery
989794|NCT02070354|Physical Activity
989795|NCT02070354|Nutrition
989796|NCT02070354|Weight Loss
989797|NCT02070341|patient tolerability
989798|NCT02070341|quality
989799|NCT02070328|Proton Therapy
989800|NCT02070328|Registry
989801|NCT02070315|heart failure
989802|NCT02070315|liver failure
989803|NCT02070315|post liver transplant
989804|NCT02070289|Multiple dose
989805|NCT02070289|safety
989806|NCT02070289|tolerability
989807|NCT02070289|PK
989808|NCT02070276|Spinal anesthesia
989809|NCT02070276|Systemic hypotension
989810|NCT02070276|Total fluid amount
989811|NCT02070276|Non-invasive fluid responsiveness
989812|NCT02070276|Passive Leg Raising Test
989813|NCT02070263|Food allergy
989814|NCT02070263|Tree nuts
989815|NCT02070250|Stress management
989816|NCT02070250|Coping skills
989817|NCT02070250|Recently diagnosed cancer patients
989818|NCT02070250|Intervention, Psychological
989819|NCT02070237|Obesity
989820|NCT02070237|Obesity, Morbid
989821|NCT02070237|Pregnancy
989822|NCT02070237|Cesarean
989823|NCT02070237|Venous thromboembolism
989824|NCT02070237|Deep venous thrombosis
989825|NCT02070237|Pulmonary embolism
989826|NCT02070211|Psychotic Disorder
989827|NCT02070211|22q11 Deletion Syndrome
989828|NCT02070211|Fatty Acids, Omega-3
989829|NCT02070198|Poor responders, IVF, GnRH agonist, GnRH antagonist, recombinant FSH
989830|NCT02070185|caloric adjustment,liking, flavour nutrient learning, children
989831|NCT02070172|headache diagnosis
989832|NCT02070172|flexion rotation test
989833|NCT02070172|range of motion
989834|NCT02070172|upper cervical
989835|NCT02070159|coronary artery disease
989836|NCT02070159|prasugrel
989837|NCT02070159|platelet function tests
989838|NCT02070133|Chronic Bronchitis
989839|NCT02070133|Statins
989840|NCT02070133|Endothelial dysfunction
989841|NCT02070133|Systemic inflammation
989842|NCT02070133|BODE index
989843|NCT02070133|Uric acid
989844|NCT02070133|Vascular growth factors
989845|NCT02070120|Nonmuscle invasive bladder cancer (NMIBC)
989846|NCT02070120|Mitomycin C
989847|NCT02070120|Chemoresection
989848|NCT02070081|Obesity
989849|NCT02070081|Bariatric surgery
989850|NCT02070055|Maximal Rate of Fat Oxidation
989851|NCT02070055|Substrate Oxidation
989852|NCT02070055|Fat oxidation
989853|NCT02070055|Respiratory Exchange Ratio (RER)
989854|NCT02070055|Exercise
989855|NCT02070055|indirect calorimetry
989856|NCT02070055|substrate crossover
989857|NCT02070042|Overactive Bladder
989858|NCT02070042|Oxybutynin
989859|NCT02070042|Omega -3 Fatty Acid
989860|NCT02070029|Female Sexual Dysfunction (FSD)
989861|NCT02070029|Hypoactive Sexual Desire Disorder (HSDD)
989862|NCT02070029|Low libido
989863|NCT02070029|Acupuncture
989864|NCT02069977|Autism
989865|NCT02069977|Aripiprazole
989866|NCT02069977|Abilify
989867|NCT02069951|Laparoscopy
989868|NCT02069951|Training
989869|NCT02069951|Simulator
989870|NCT02069938|Subjects
989871|NCT02069912|Major Depression
989872|NCT02069912|Heart Disease
989873|NCT02069912|Hispanics
989874|NCT02069912|Collaborative Depression Care Management
989876|NCT02069886|Endocrine complications
989877|NCT02069886|transfusion dependent thalassemia
989878|NCT02069873|Post Traumatic Stress Disorder
989879|NCT02069873|Group
989880|NCT02069873|Treatment
989881|NCT02069873|Cognitive, Exposure, Skills
989882|NCT02069873|Women
989883|NCT02069873|Veterans
989884|NCT02069860|bona anchored
989885|NCT02069860|haemodialysis
989886|NCT02069860|Mastoid bone
989887|NCT02069860|nephrology
989888|NCT02069860|retroauricular anchored devices
989889|NCT02069860|permanent central venous access devices.
989890|NCT02069847|Esophageal stricture formation
989891|NCT02069847|Endoscopic mucosal resection
989892|NCT02069847|Endoscopic submucosal dissection
989893|NCT02069847|Budesonide
989894|NCT02069847|Radical endoscopic mucosal resection
989895|NCT02069847|EMR
989896|NCT02069847|ESD
989897|NCT02069834|Dolutegravir
989898|NCT02069834|Rilpivirine
989899|NCT02069834|PI- and NRTI- sparing ART regimen
989900|NCT02069834|switch study
989901|NCT02069795|concussion, athlete, speech analysis
989902|NCT02069782|Pregnancy
989903|NCT02069782|postpartum programs
989904|NCT02069782|infant health services
989905|NCT02069769|Hospice Care
989906|NCT02069769|Head and Neck cancer
989907|NCT02069769|Gynecological Oncology
989908|NCT02069769|Sarcoma
989909|NCT02069769|Melanoma
989910|NCT02069756|Duchenne
989911|NCT02069756|Becker
989912|NCT02069756|Muscular Dystrophy
989913|NCT02069743|cancer pain
989914|NCT02069730|molecular profiling
989915|NCT02069730|selinexor
989916|NCT02069730|tumor tissue
989917|NCT02069704|colorectal cancer
989918|NCT02069704|metastatic
989919|NCT02069704|first-line treatment
989920|NCT02069704|comparability
989921|NCT02069691|stroke,
989922|NCT02069691|rehabilitation,
989923|NCT02069691|leg cycling,
989924|NCT02069691|feedback,
989925|NCT02069691|virtual reality
989926|NCT02069665|pneumonia
989927|NCT02069665|pediatrics
989928|NCT02069665|viral
989929|NCT02069613|Mild traumatic injury to extremity (for controls)
989930|NCT02069613|mTBI
989931|NCT02069613|concussion
989932|NCT02069613|MEG
989933|NCT02069613|EEG
989934|NCT02069613|Blood
989935|NCT02069613|MRI
989936|NCT02069613|DTI
989937|NCT02069613|biomarkers
989938|NCT02069600|Elderly
989939|NCT02069600|CPAP
989940|NCT02069600|clinical trial
989941|NCT02069600|obstructive sleep apnea
989942|NCT02069587|PPROM
989943|NCT02069587|PREGNANCY
989944|NCT02069587|POMEGRANATE
989945|NCT02069587|OXIDATIVE STRESS
989946|NCT02069535|Cupressus arizonica
989947|NCT02069509|Friedreich's Ataxia
989948|NCT02069509|EFACTS
989949|NCT02069509|FRDA
989950|NCT02069483|smoking
989951|NCT02069483|smoker
989952|NCT02069483|text
989953|NCT02069483|smartphone
989954|NCT02069483|motivation
989955|NCT02069483|quitting
989956|NCT02069483|cessation
989957|NCT02069483|feedback
989958|NCT02069483|messages
989959|NCT02069470|Stepped wedged design
989960|NCT02069470|Early cancer diagnosis
989961|NCT02069470|Continuing medical education
989962|NCT02069431|inflammation
989963|NCT02069431|physical function
989964|NCT02069431|cognitive function
989965|NCT02069392|schizophrenia
989966|NCT02069392|cognition
989967|NCT02069392|cognitive remediation
989968|NCT02069392|nicotine
989969|NCT02069379|Metabolic syndrome
989970|NCT02069379|Insulin resistance
989971|NCT02069379|Mu-opioid system
989972|NCT02069379|Depression
989973|NCT02069379|Emotion regulation
989974|NCT02069366|Post-Traumatic Stress Disorders
989975|NCT02069366|Dronabinol
989976|NCT02069366|Extinction
989977|NCT02069366|fMRI
989978|NCT02069353|Cardiac arrest
989979|NCT02069353|Neurological injury
989980|NCT02069353|Seizures
989981|NCT02069353|Spreading depolarizations
989982|NCT02069353|Cerebral hypoperfusion
989983|NCT02069353|Brain tissue hypoxia
989984|NCT02069327|Femur
989985|NCT02069327|Fat
989986|NCT02069327|Emboli
989987|NCT02069327|Bone
989988|NCT02069327|Marrow
989989|NCT02069327|proteomic
989990|NCT02069327|proteomics
989991|NCT02069327|metabolomics
989992|NCT02069327|metabolomic
989993|NCT02069327|inflammatory
989994|NCT02069327|cytokine
989995|NCT02069327|chemokine
989996|NCT02069327|anaphlylatoxin
989997|NCT02069327|Thromboelastography
989998|NCT02069327|Medical Center of the Rockies
989999|NCT02069327|Fat Embolism Syndrome
990000|NCT02069327|Injury
990001|NCT02069327|Fracture
990002|NCT02069327|Metabolite
990003|NCT02069327|MCR
990004|NCT02069327|TEG
990005|NCT02069327|FES
990006|NCT02069301|Behavior Activation
990007|NCT02069301|Problem solving therapy
990008|NCT02069301|Depression Treatment
990009|NCT02069301|depression care integration
990010|NCT02069301|microfinance
990011|NCT02069301|livelihood
990012|NCT02069288|fludrocortisone
990013|NCT02069288|pharmacology
990014|NCT02069288|septic shock
990015|NCT02069275|Immediate mobilization
990016|NCT02069275|Bedrest
990017|NCT02069275|Coronary angiography
990018|NCT02069275|Coronary percutaneous intervention
990019|NCT02069275|Vascular access complications
990020|NCT02069275|Patients comfort
990021|NCT02069262|obscure gastrointestinal bleeding
990022|NCT02069262|laparoscopy
990023|NCT02069262|angiography
990024|NCT02069249|Preschool children
990025|NCT02069249|Sleep problems
990026|NCT02069249|Nutrition problems
990027|NCT02069249|Online intervention
990028|NCT02069249|Psychological functioning
990029|NCT02069236|Glucose-6 phosphate dehydrogenase deficiency
990030|NCT02069236|capillary
990031|NCT02069236|venous
990032|NCT02069236|genotype phenotype correlation
990033|NCT02069223|Biliopancreatic Diversion with Duodenal Switch
990034|NCT02069223|Gastrectomy
990035|NCT02069197|ketogenic diet
990036|NCT02069197|obesity
990037|NCT02069197|diabetes
990038|NCT02069197|obstructive sleep apnea
990039|NCT02069184|opioid usage requirements
990040|NCT02069184|pain
990041|NCT02069184|IV acetaminophen
990042|NCT02069184|opioid usage
990043|NCT02069184|c-section
990044|NCT02069171|Lower extremity edema
990045|NCT02069171|Lower leg lymphedema
990046|NCT02069171|Lower leg edema
990047|NCT02069171|Lymphedema
990048|NCT02069171|Pelvic lymph node dissection
990049|NCT02069171|Gynecologic Cancer Lymphedema Questionnaire
990050|NCT02069158|Advanced solid tumor
990051|NCT02069145|Hepatocellular Cancer
990052|NCT02069145|Liver Cancer
990053|NCT02069132|Warfarin
990054|NCT02069132|International Warfarin Pharmacogenetics Consortium algorithm
990055|NCT02069132|Atrial Fibrillation
990056|NCT02069132|Heart Valve Prosthesis Implantation
990057|NCT02069132|elderly
990058|NCT02069132|comorbidity
990059|NCT02069106|low density lipoprotein cholesterol
990060|NCT02069106|triglycerides
990061|NCT02069106|mixed hyperlipoproteinemia
990062|NCT02069106|Dehydroascorbic Acid
990063|NCT02069106|Eicosapentaenoic Acid
990064|NCT02069106|Fish oil
990065|NCT02069080|Positron Emission Tomograhy
990066|NCT02069080|Metastasis
990067|NCT02069067|breakthrough cancer pain
990068|NCT02069067|pain
990069|NCT02069067|neuropathic pain
990070|NCT02069067|intractable pain
990071|NCT02069067|cancer
990072|NCT02069054|asthma
990073|NCT02069054|COPD
990074|NCT02069054|airway inflammation
990075|NCT02069054|remodeling
990076|NCT02069054|cytokines
990077|NCT02069054|airway wall thickness
990078|NCT02069028|surviving sepsis campaign
990079|NCT02069028|sepsis
990080|NCT02069028|septic
990081|NCT02069028|septicemia
990082|NCT02069028|mortality
990083|NCT02069028|compliance
990084|NCT02069015|Patient education
990085|NCT02069015|Hypertension
990086|NCT02069015|Patient activation
990087|NCT02069002|Indoor Air
990088|NCT02069002|Medically unexplained symptoms
990089|NCT02069002|Randomized controlled trial
990090|NCT02069002|Cognitive-Behavioral Therapy
990091|NCT02069002|Applied relaxation
990092|NCT02068950|Head and neck cancer
990093|NCT02068950|Concurrent chemoradiotherapy
990094|NCT02068950|Progressive resistance training
990095|NCT02068950|Exercise
990096|NCT02068950|Feasibility
990097|NCT02068950|Weight loss
990098|NCT02068950|LBM
990099|NCT02068950|Body composition
990100|NCT02068937|Heart Failure
990101|NCT02068937|Therapy
990102|NCT02068937|Diuretics
990103|NCT02068937|Algorithms
990104|NCT02068924|Slow freezing
990105|NCT02068924|Vitrification
990106|NCT02068924|Single embryo transfer
990107|NCT02068911|Neuromuscular disease
990108|NCT02068911|Home ventilation
990109|NCT02068911|End tidal CO2
990110|NCT02068911|Transcutaneous CO2
990111|NCT02068911|Monitoring
990112|NCT02068885|Low carbohydrate diet
990113|NCT02068885|Low fat diet
990114|NCT02068885|Glycemic index
990115|NCT02068885|Weight loss maintenance
990116|NCT02068872|Obesity
990117|NCT02068872|Transplant
990118|NCT02068872|Sleeve Gastrectomy
990119|NCT02068872|Liver Transplantation
990120|NCT02068872|Weight Loss
990121|NCT02068846|HIV
990122|NCT02068846|Salivary Gland Disease
990123|NCT02068846|Benign Lymphoepithelial Lesion
990124|NCT02068846|BK Polyomavirus
990125|NCT02068833|Microalbuminuria
990126|NCT02068833|Gastrectomy
990127|NCT02068833|Biliopancreatic Diversion With Duodenal Switch
990128|NCT02068820|Sentinel lymph nodes
990129|NCT02068820|da Vinci
990130|NCT02068820|Firefly
990131|NCT02068820|Sentinel lymph node mapping
990132|NCT02068820|Fluorescence Imaging
990133|NCT02068820|SLN
990134|NCT02068820|SLN mapping
990135|NCT02068768|fusion
990136|NCT02068768|lateral interbody fusion system
990137|NCT02068768|lumbar spine
990138|NCT02068768|degenerative disc disease
990139|NCT02068755|anemia
990140|NCT02068755|renal impairment
990141|NCT02068755|thrombocytopenia
990142|NCT02068755|anticoagulation
990143|NCT02068755|Coronary bypass
990144|NCT02068755|Aortic valve surgery
990145|NCT02068755|Mitral valve surgery
990146|NCT02068755|red blood cell
990147|NCT02068755|platelet
990148|NCT02068755|fresh frozen plasma
990149|NCT02068755|octaplas
990150|NCT02068742|post-operative cognitive dysfunction
990151|NCT02068742|elderly
990152|NCT02068742|Mini Mental State Examination
990153|NCT02068742|Geriatric Index of Comorbidity
990154|NCT02068742|Geriatric Depression Scale
990155|NCT02068742|Trail Making Test B-A
990156|NCT02068742|Digit Span
990157|NCT02068742|Digit Symbol Substitution Test
990158|NCT02068729|degenerative disc disease
990159|NCT02068729|DDD
990160|NCT02068729|Grade 1 spondylolisthesis
990161|NCT02068729|spondylolisthesis
990162|NCT02068729|L2-S1
990163|NCT02068716|Healthcare acquired infections
990164|NCT02068716|Cardiovascular Surgery
990165|NCT02068716|Mediastinitis
990166|NCT02068716|Thoracotomy
990167|NCT02068716|Conduit harvest or cannulation site
990168|NCT02068703|survey
990169|NCT02068664|spatial neglect
990170|NCT02068664|aphasia
990171|NCT02068651|End-of-life care
990172|NCT02068651|Treatment decision making
990173|NCT02068651|Advance care planning
990174|NCT02068638|exercise
990175|NCT02068638|isotope labeling, stable
990176|NCT02068638|spectroscopy, magnetic resonance
990177|NCT02068638|monitoring, home blood glucose
990178|NCT02068638|hormones
990179|NCT02068625|retinal detachment
990180|NCT02068625|rasagiline
990181|NCT02068625|optical coherence tomography
990182|NCT02068625|visual acuity
990183|NCT02068625|neuroprotection
990184|NCT02068625|azilect
990185|NCT02068612|Executive function,
990186|NCT02068612|cardiovascular fitness,
990187|NCT02068612|cognitive function
990188|NCT02068599|Osteoarthritis
990189|NCT02068599|OA
990190|NCT02068599|Arthritis pain
990191|NCT02068573|Childhood Asthma
990192|NCT02068573|Allergy
990193|NCT02068573|House dust mites
990194|NCT02068573|Indoor air quality
990195|NCT02068547|posterior cervical fusion
990196|NCT02068547|posterior cervical decompression
990197|NCT02068534|in-depth individual interview
990198|NCT02068534|charcoal-burning suicide
990199|NCT02068521|Growth Hormone Deficiency
990200|NCT02068521|Pediatric Growth Hormone Deficiency
990201|NCT02068521|GHD
990202|NCT02068521|PGHD
990203|NCT02068521|VRS-317
990204|NCT02068521|Versartis
990205|NCT02068521|Growth disorder
990206|NCT02068521|Long acting growth hormone
990207|NCT02068521|Growth hormone
990208|NCT02068521|Weekly growth hormone dosing
990209|NCT02068521|Semi-monthly growth hormone dosing
990210|NCT02068521|Monthly growth hormone dosing
990211|NCT02068521|IGF-I
990212|NCT02068521|Short stature
990213|NCT02068521|Height velocity
990214|NCT02068521|Annual height velocity
990215|NCT02068521|Growth rate
990216|NCT02068521|Somavaratan
990217|NCT02068508|Drug therapy
990218|NCT02068495|Drug therapy
990219|NCT02068482|Uncomplicated
990220|NCT02068482|Symptomatic
990222|NCT02068443|Drug therapy
990223|NCT02068430|Corneal Ulcers
990224|NCT02068430|cross-linking
990225|NCT02068430|UVA
990226|NCT02068430|Riboflavin
990227|NCT02068417|IIEF score
990228|NCT02068417|ED
990229|NCT02068404|Tocolysis
990230|NCT02068404|Preterm labor
990231|NCT02068404|Nifedipine
990232|NCT02068404|Pharmacokinetics
990233|NCT02068391|covert stroke
990234|NCT02068391|cerebral blood flow
990235|NCT02068391|grey matter
990236|NCT02068391|attention
990237|NCT02068391|executive function
990238|NCT02068391|aerobic exercise
990239|NCT02068352|Atopic Dermatitis, Eczema
990240|NCT02068326|Mentalization-based Treatment
990241|NCT02068326|Adolescence
990242|NCT02068326|Borderline Personality Disorder
990243|NCT02068300|1,5-anhydro-D-glucitol, hypoglycemia, surrogate marker
990244|NCT02068287|Septic Shock
990245|NCT02068287|Hemodynamic
990246|NCT02068287|Inflammatory status
990247|NCT02068287|Beta adrenergic modulation
990248|NCT02068287|Esmolol
990249|NCT02068235|Ponesimod
990250|NCT02068235|Bioavailability
990251|NCT02068235|Pharmacokinetics
990252|NCT02068235|Safety
990253|NCT02068222|Hepatitis C
990254|NCT02068222|HCV
990255|NCT02068222|Interferon Free
990256|NCT02068222|Chronic Hepatitis C
990257|NCT02068222|Hepatitis C virus
990258|NCT02068222|Hepatitis C Genotype 3
990259|NCT02068209|Outpatient hysteroscopy
990260|NCT02068209|Tramadol
990261|NCT02068196|Cancer
990262|NCT02068196|Malignant Melanoma
990263|NCT02068196|Ipilimumab
990264|NCT02068183|World Trade Center exposure
990265|NCT02068183|cardiovascular risk
990266|NCT02068183|insulin resistance
990267|NCT02068183|post-traumatic stress
990268|NCT02068183|pulmonary disease
990269|NCT02068170|QT-prolongation
990270|NCT02068170|Torsade de Pointes
990271|NCT02068170|QT-prolonging drugs
990272|NCT02068144|Cranberry Extract
990273|NCT02068131|Metastatic Colorectal Cancer
990274|NCT02068131|Novaferon
990275|NCT02068131|Recombinant anti-tumor and anti-virus protein for injection
990276|NCT02068131|xeloda
990277|NCT02068118|E health
990278|NCT02068118|Telecardiology program
990279|NCT02068118|Heart failure
990280|NCT02068105|ALKS 5461
990281|NCT02068105|samidorphan
990282|NCT02068066|Physical work requirements
990283|NCT02068066|Energy expenditure
990284|NCT02068066|Physical activity
990285|NCT02068066|Different occupational categories
990286|NCT02068066|Aerobic capacity
990287|NCT02068040|with preserved ejection fraction of >55%
990288|NCT02068027|Diabetes Mellitus
990289|NCT02068027|Pain
990290|NCT02068027|Foot pain
990291|NCT02068027|Neuropathy
990292|NCT02068014|stapplers- obesity- stomach
990293|NCT02067988|Radioembolization
990294|NCT02067988|Somatostatin receptor treatment
990295|NCT02067988|Neuroendocrine tumors
990296|NCT02067988|Liver metastases
990297|NCT02067975|tryptophan
990298|NCT02067975|kynurenic acid
990299|NCT02067975|schizophrenia
990300|NCT02067962|Juvenile idiopathic arhtritis
990301|NCT02067962|JIA
990302|NCT02067962|Gene identification
990303|NCT02067962|Whole exome sequencing
990304|NCT02067962|Next generation sequencing
990305|NCT02067962|Identification of molecular basis
990306|NCT02067962|Acceptation of both parents to participate to the study
990307|NCT02067923|T1D
990308|NCT02067923|type 1 diabetes
990309|NCT02067923|type 1 diabetes mellitus
990310|NCT02067923|juvenile diabetes
990311|NCT02067923|autoimmune diabetes
990312|NCT02067923|autoimmune
990313|NCT02067923|anti-CD3 mAb
990314|NCT02067923|mAb hOKT3g1(Ala-Ala)
990315|NCT02067923|teplizumab
990316|NCT02067910|Abatacept
990317|NCT02067910|Subcutaneous
990318|NCT02067910|Sjögren's syndrome
990319|NCT02067910|Treatment
990320|NCT02067910|Safety
990321|NCT02067910|Efficacy
990322|NCT02067897|Nails, Ingrown
990323|NCT02067897|Children
990324|NCT02067897|Ambulatory Surgical Procedures
990325|NCT02067871|neuromuscular electrical stimulation
990326|NCT02067871|low-level laser therapy
990327|NCT02067871|knee osteoarthritis
990328|NCT02067871|muscle architecture
990329|NCT02067871|functionality
990330|NCT02067871|neuromuscular parameters
990331|NCT02067845|Lesbian, queer, bisexual women
990332|NCT02067845|HIV and STI prevention
990333|NCT02067845|Resilient coping
990334|NCT02067845|Sexual stigma
990335|NCT02067845|Depression
990336|NCT02067845|Safer-sex practices
990337|NCT02067845|Safer sex self-efficacy
990338|NCT02067845|HIV/STI knowledge and testing
990339|NCT02067845|Pilot-testing
990340|NCT02067819|Tourette's
990341|NCT02067819|Tic Disorder
990342|NCT02067819|Dental Appliance
990343|NCT02067819|Oral Orthotic
990344|NCT02067819|Mouthguard
990345|NCT02067806|PASS
990346|NCT02067806|TNS
990347|NCT02067806|CES
990348|NCT02067806|CHLOROPROCAINE
990349|NCT02067793|NRX-1074
990350|NCT02067793|NMDA Receptor Modulator
990351|NCT02067793|Major Depressive Disorder
990352|NCT02067793|Glycine site modulator
990353|NCT02067767|HIV-1 infection
990354|NCT02067767|Nevirapine
990355|NCT02067767|Dolutegravir
990356|NCT02067767|Anti-retroviral agents
990357|NCT02067754|The mutation profiling of circulating free DNA
990358|NCT02067741|Post-menopausal women
990359|NCT02067741|topical application CR1447
990360|NCT02067741|endocrine responsive-HER2neg breast cancer
990361|NCT02067741|triple negative-androgen receptor positive breast cancer
990362|NCT02067728|obesity prevention
990363|NCT02067715|Tooth Discoloration
990364|NCT02067715|Bleaching Agents
990365|NCT02067715|Tooth Bleaching
990366|NCT02067689|Normal cognition in healthy adults
990367|NCT02067689|Cognitive function
990368|NCT02067689|Transcranial direct current stimulation
990369|NCT02067689|Structural Magnetic Resonance Imaging
990370|NCT02067689|Functional Magnetic Resonance Imaging
990371|NCT02067676|Campylobacter jejuni
990372|NCT02067663|Postplacental IUD placement
990373|NCT02067663|LNG-IUS
990374|NCT02067637|cancer therapy, cancer treatment
990375|NCT02067611|Phase 2, Efficacy, Safety, Osteoarthritis
990376|NCT02067598|Scapular exercises
990377|NCT02067572|oral health
990378|NCT02067572|mouthwash
990379|NCT02067572|salvia
990380|NCT02067572|hospice
990381|NCT02067572|xerostomia
990382|NCT02067572|mouth sores
990383|NCT02067559|Post Traumatic Stress Disorder
990384|NCT02067559|PTSD
990385|NCT02067559|Intensive Care Unit
990386|NCT02067559|ICU
990387|NCT02067546|constipation
990388|NCT02067520|Post C/S pain relief
990389|NCT02067507|Human Papillomavirus
990390|NCT02067507|Immunization
990391|NCT02067507|Oncogenic viruses
990392|NCT02067507|Cervical Cancer
990393|NCT02067507|Health Disparities
990394|NCT02067494|Low Back Pain
990395|NCT02067494|Chronic Pain
990396|NCT02067494|Manual Therapy
990397|NCT02067494|Randomized Clinical Trial
990398|NCT02067494|Bandages
990399|NCT02067481|Breast cancer
990400|NCT02067481|Survivors
990401|NCT02067481|Weight loss
990402|NCT02067481|Diet
990403|NCT02067481|Physical activity
990404|NCT02067468|Human Papillomavirus
990405|NCT02067468|cervical cancer
990406|NCT02067468|health services research
990407|NCT02067468|Colombia
990408|NCT02067468|Cervical Intraepithelial Neoplasia
990409|NCT02067455|Right ventricular function
990410|NCT02067455|echocardiography
990411|NCT02067455|left ventricular assist device
990412|NCT02067455|exercise
990413|NCT02067442|acetaminophen intravenous oral pain scores opioids
990414|NCT02067416|neoadjuvant
990415|NCT02067416|mammostrat
990416|NCT02067416|TLE3
990417|NCT02067416|DDR
990418|NCT02067416|breast cancer
990419|NCT02067403|Pressure-support
990420|NCT02067403|Asynchrony
990421|NCT02067377|GOLD, COPD, cachexia, BMI
990422|NCT02067364|hydrocephalus
990423|NCT02067364|CSF shunt
990424|NCT02067299|Depressive Disorder, Major
990425|NCT02067299|Major Depressive Disorder
990426|NCT02067299|Insomnia
990427|NCT02067299|JNJ-42847922
990428|NCT02067299|Placebo
990429|NCT02067221|percutaneous nephrolithotomy
990430|NCT02067221|renal calculi
990431|NCT02067221|ureteroscopy
990432|NCT02067208|Osteoarthritis
990433|NCT02067208|Cartilage
990434|NCT02067208|Musculoskeletal
990435|NCT02067208|Biomechanics
990436|NCT02067208|Subtype
990437|NCT02067208|Footwear
990438|NCT02067208|Orthotics
990439|NCT02067208|Joint Loading
990440|NCT02067195|acute myocardial infarction,contrast,coronary intervention
990441|NCT02067169|Transplantation
990442|NCT02067169|CMV infection
990443|NCT02067169|antiviral resistance
990444|NCT02067156|glioblastoma
990445|NCT02067143|Untreated philadelphia positive acute lymphoblastic leukemia
990446|NCT02067143|De novo
990447|NCT02067143|Secondary
990448|NCT02067143|Low-dose corticosteroids pretreatment
990449|NCT02067143|Pegylated asparaginase
990450|NCT02067143|Lineage-targeted risk and minimal residual disease
990451|NCT02067130|Beta Thalassemia Major
990452|NCT02067117|influenza
990453|NCT02067091|STEMI
990454|NCT02067091|Coronary
990455|NCT02067091|Bioresorbable scaffold
990456|NCT02067091|Drug eluting stent
990457|NCT02067091|Optical coherence tomography
990458|NCT02067091|Multislice computed tomography
990459|NCT02067078|nerve block
990460|NCT02067078|total knee arthroplasty
990461|NCT02067078|saphenous nerve block
990462|NCT02067078|obturator nerve block
990463|NCT02067078|pain
990464|NCT02067078|opioid consumption
990465|NCT02067065|Colonoscopy
990466|NCT02067065|Sedation
990467|NCT02067065|Propofol
990468|NCT02067065|Non-anesthesiologist propofol administration
990469|NCT02067052|Vulvar neoplasm
990470|NCT02067052|sentinel nodes
990471|NCT02067052|chemotherapy
990472|NCT02067052|radiotherapy
990473|NCT02067039|HIV testing
990474|NCT02067039|Rapid HIV test
990475|NCT02067039|HIV self-testing
990476|NCT02067039|Men who have sex with men (MSM)
990477|NCT02067039|HIV diagnosis
990478|NCT02067039|Sexual behavior
990479|NCT02067026|overweight
990480|NCT02067013|Tractional retinal detachment
990481|NCT02067013|Exudative retinal detachment
990482|NCT02067013|Macular hole
990483|NCT02067013|Neovascular glaucoma
990484|NCT02066987|Action planning, Implementation intention
990485|NCT02066974|hepatocellular carcinoma
990486|NCT02066974|genomic expression
990487|NCT02066974|radiotherapy
990488|NCT02066961|metastatic prostate cancer
990489|NCT02066961|castration-resistant prostate cancer
990490|NCT02066961|prostate cancer
990491|NCT02066948|DXA
990492|NCT02066948|MRI
990493|NCT02066948|Fitness assessment
990494|NCT02066948|Meal tolerance test
990495|NCT02066935|immunosuppression
990496|NCT02066935|medication nonadherence
990497|NCT02066935|kidney transplantation
990498|NCT02066922|Contact lenses
990499|NCT02066922|Nearsightedness
990500|NCT02066922|Corneal curvature
990501|NCT02066922|K-reading
990502|NCT02066922|High minus
990503|NCT02066922|Spectacle refraction
990504|NCT02066909|pharmacokinetics
990505|NCT02066909|safety
990506|NCT02066909|tolerability
990507|NCT02066909|healthy volunteers
990508|NCT02066909|steady state
990509|NCT02066909|multiple doses
990510|NCT02066909|Japanese subjects
990511|NCT02066896|Sjogrens Syndrome
990512|NCT02066896|Syndrome, Sjogren's
990513|NCT02066896|Sjogren Syndrome
990514|NCT02066896|Sicca Syndrome
990515|NCT02066896|Syndrome, Sicca
990516|NCT02066870|Icotinib
990517|NCT02066870|Arsenic Trioxide
990518|NCT02066870|Resistance
990519|NCT02066870|Non-small cell lung cancer
990520|NCT02066857|Wrist fracture
990521|NCT02066857|Radius fracture
990522|NCT02066857|Elderly
990523|NCT02066857|Splint
990524|NCT02066857|Cast
990525|NCT02066844|Hip Pain
990526|NCT02066844|Hip Injection
990527|NCT02066844|Hip Fracture
990528|NCT02066844|Hip Bursitis
990529|NCT02066844|Hip Arthritis
990530|NCT02066844|Hip Sciatica
990531|NCT02066818|local anesthetic
990532|NCT02066818|incision and drainage
990533|NCT02066818|pain
990534|NCT02066818|cutaneous abscess
990535|NCT02066792|Social Phobia
990536|NCT02066753|Cardiac arrest
990537|NCT02066753|Therapeutic Hypothermia
990538|NCT02066753|Cardioprotectiveness
990539|NCT02066753|Hemodynamics
990540|NCT02066740|Superficial Femoral Artery
990541|NCT02066740|Proximal Popliteal Artery
990542|NCT02066740|Everflex
990543|NCT02066740|Entrust
990544|NCT02066740|stent
990545|NCT02066727|Dexmedetomidine
990546|NCT02066727|obturator nerve block
990547|NCT02066727|lidocaine
990548|NCT02066727|EC50
990549|NCT02066714|Enterovirus Infections
990550|NCT02066714|Hand, Foot and Mouth Disease
990551|NCT02066714|Coxsackievirus Infections
990552|NCT02066714|Herpangina
990553|NCT02066714|Cognition
990554|NCT02066714|Neurocognitive
990555|NCT02066714|Sequelae
990556|NCT02066714|Outcomes
990557|NCT02066701|Barrett's esophagus
990558|NCT02066675|Metastatic
990559|NCT02066675|Locally advanced
990560|NCT02066675|Soft tissue tumors
990561|NCT02066662|Coronary or Valvular Calcification
990562|NCT02066662|Agatston Score
990563|NCT02066662|Rivaroxaban
990564|NCT02066662|Coumarin
990565|NCT02066662|Oral Anticoagulation Therapy (OAT)
990566|NCT02066662|Atrial Fibrillation
990567|NCT02066662|Pulmonary Embolism
990568|NCT02066649|portal hypertension
990569|NCT02066649|esophageal varices
990570|NCT02066649|variceal bleed
990571|NCT02066649|carvedilol
990572|NCT02066649|variceal band ligation
990574|NCT02066597|Deep vein thrombosis
990575|NCT02066597|thrombectomy
990576|NCT02066597|percutaneuos
990577|NCT02066584|sibling oocytes
990578|NCT02066584|glucose
990579|NCT02066584|culture media
990580|NCT02066571|Parkinson's disease
990581|NCT02066571|Freezing of gait
990582|NCT02066571|Gait
990583|NCT02066558|Carbon monoxide
990584|NCT02066558|Headache
990585|NCT02066558|Migraine
990586|NCT02066532|Breast Neoplasms
990587|NCT02066532|Breast Cancer
990588|NCT02066532|Breast Carcinoma
990589|NCT02066532|Breast tumors
990590|NCT02066532|Cancer of the Breast
990591|NCT02066532|Malignant tumor of the breast
990592|NCT02066532|HER2 positive
990593|NCT02066532|erythroblastosis virus oncogene B-2 (erbB-2)
990594|NCT02066532|Metastatic Breast Cancer
990595|NCT02066532|Secondary Breast Cancer
990596|NCT02066519|Myasthenia gravis
990597|NCT02066519|physical exercise
990598|NCT02066519|quality of life
990599|NCT02066519|muscular performance
990600|NCT02066519|fatigability
990601|NCT02066506|systemic right ventricle
990602|NCT02066506|cardiac magnetic resonance imaging
990603|NCT02066506|congenital heart disease
990604|NCT02066493|giant intracranial aneurysm, cerebrovascular bypass, flow diverter
990605|NCT02066467|Phrenic Nerve Stimulation
990606|NCT02066467|Heartfailure treatment
990607|NCT02066467|CRT-D therapy
990608|NCT02066467|Quadripolar lead
990609|NCT02066467|Lead related complication free rate
990610|NCT02066454|myeloma
990611|NCT02066454|antiXa anticoagulant
990612|NCT02066454|venous thromboembolic disease
990613|NCT02066454|iMiDs
990614|NCT02066441|Vitamin D
990615|NCT02066441|bone formation
990616|NCT02066441|resorption
990617|NCT02066441|mineral density
990618|NCT02066441|inflammation
990619|NCT02066441|flexibility
990620|NCT02066441|balance
990621|NCT02066441|elderly
990622|NCT02066428|BCG Vaccinated
990623|NCT02066428|HIV Negative
990624|NCT02066415|Chronic Migraine
990625|NCT02066389|anti-inflammatory agents
990626|NCT02066389|Joint Diseases
990627|NCT02066389|Arthritis
990628|NCT02066389|Musculoskeletal Disease
990629|NCT02066389|antirheumatic agents
990630|NCT02066363|Bioelectrical impedance
990631|NCT02066363|Parenteral nutrition
990632|NCT02066363|Malnutrition
990633|NCT02066363|Quality of life.
990634|NCT02066363|Cancer cachexia
990635|NCT02066363|Body composition
990636|NCT02066350|Diabetes type 1
990637|NCT02066350|Endothelial dysfunction
990638|NCT02066350|Pancreas transplantation
990639|NCT02066337|Ozone gel
990640|NCT02066337|Antioxidants
990641|NCT02066337|Chronic periodontitis
990642|NCT02066337|Superoxide dismutase
990643|NCT02066311|lupus
990644|NCT02066311|SLE
990645|NCT02066298|Asthma
990646|NCT02066298|Mometasone
990647|NCT02066298|Tiotropium
990648|NCT02066285|Solitary fibrous tumor
990649|NCT02066285|Extraskeletal myxoid chondrosarcoma
990650|NCT02066285|Unresectable
990651|NCT02066285|Locally advanced
990652|NCT02066285|Metastatic disease
990653|NCT02066272|IBD
990654|NCT02066272|anti-TNF
990655|NCT02066272|biosimilars
990656|NCT02066272|safety
990657|NCT02066259|colon cancer
990658|NCT02066259|cancer associated auto antibodies
990659|NCT02066259|colon cancer blood test
990660|NCT02066246|laparoscopic robot-assisted surgery
990661|NCT02066246|in steep trendelenburg position
990662|NCT02066233|Barrett's
990663|NCT02066233|esophagus
990664|NCT02066233|reflux
990665|NCT02066233|heartburn
990666|NCT02066233|screening
990667|NCT02066220|pediatric brain tumor
990668|NCT02066220|medulloblastoma
990669|NCT02066220|event-free survival (EFS)
990670|NCT02066220|progression-free survival (PFS)
990671|NCT02066220|overall survival (OS)
990672|NCT02066220|PNET
990673|NCT02066220|posterior fossa
990674|NCT02066220|chemotherapy
990675|NCT02066220|radiotherapy
990676|NCT02066220|biological profile
990677|NCT02066220|ß-catenin
990678|NCT02066155|diabetes self-management support
990679|NCT02066155|diabetes-related distress
990680|NCT02066155|parish nurses
990681|NCT02066155|peer support
990682|NCT02066129|Asthma
990683|NCT02066129|Fluticasone
990684|NCT02066090|acupuncture
990685|NCT02066090|obesity
990686|NCT02066090|metabolomics
990687|NCT02066077|Major Depressive Disorder
990688|NCT02066077|Modified Electroconvulsive Therapy
990689|NCT02066077|Cognition
990690|NCT02066077|Memory
990691|NCT02066064|Colorectal Cancer
990692|NCT02066064|Adenoma
990693|NCT02066064|Standard Colonoscopy
990694|NCT02066064|G-EYE(TM) Colonoscopy
990695|NCT02066038|chemotherapy
990696|NCT02066038|maintenance therapy
990697|NCT02066038|erlotinib
990698|NCT02066025|breast cancer
990699|NCT02066025|cancer associated auto antibodies
990700|NCT02066025|breast cancer blood test
990701|NCT02066012|Dysmetabolic Iron Overload Syndrome
990702|NCT02066012|Metabolic Syndrome X
990703|NCT02066012|Iron
990704|NCT02066012|Monocyte
990705|NCT02066012|Macrophage
990706|NCT02066012|Polarization
990707|NCT02065999|Hepatitis C, chronic
990708|NCT02065986|HIV
990709|NCT02065986|Prevention
990710|NCT02065986|Truvada
990711|NCT02065960|Feasibility study
990712|NCT02065960|Early breast cancer
990713|NCT02065960|Stereotactic body radiotherapy
990714|NCT02065960|Cyberknife
990715|NCT02065960|Pre-operative radiotherapy
990716|NCT02065947|paravertebral block, mastectomy, efficiency
990717|NCT02065934|in hospital cardiac arrest
990718|NCT02065934|in situ simulation
990719|NCT02065934|clinical audit
990720|NCT02065934|education
990721|NCT02065921|COPD cohort
990722|NCT02065921|COPD management
990723|NCT02065921|exacerbation
990724|NCT02065908|breast cancer
990725|NCT02065908|anthracyclines
990726|NCT02065908|cardiotoxicity
990727|NCT02065908|circulating microRNA
990728|NCT02065908|biomarker
990729|NCT02065908|serum
990730|NCT02065908|anthracyclines based chemotherapy
990731|NCT02065895|Physiologic Insulin Delivery (PID)
990732|NCT02065895|Closed Loop
990733|NCT02065895|Sensor
990734|NCT02065895|Insulin sensitivity
990735|NCT02065882|fibrinogen, bleeding,
990736|NCT02065869|ALL
990737|NCT02065869|AML
990738|NCT02065869|hematologic neoplasms
990739|NCT02065869|hematologic malignancies
990740|NCT02065869|primary immune deficiences
990741|NCT02065843|Anxiety
990742|NCT02065843|Third molar surgery
990743|NCT02065843|Blood pressure
990744|NCT02065843|Heart rate
990745|NCT02065843|Oxygen saturation
990746|NCT02065830|Robot
990747|NCT02065830|Spinal Cord Injury
990748|NCT02065830|Gait
990749|NCT02065830|Quality of life
990750|NCT02065830|Rehabilitation
990751|NCT02065830|Lower Limb
990752|NCT02065817|Lipid
990753|NCT02065817|Apolipoproteins
990754|NCT02065817|Cardiovascular disease risks
990755|NCT02065804|Herniorrhaphy
990756|NCT02065804|Surgical Equipment
990757|NCT02065804|Chronic Pain
990758|NCT02065804|Inguinal Herniorrhaphy
990759|NCT02065804|Laparoscopy
990760|NCT02065804|Surgical Outcome
990761|NCT02065791|Diabetes Mellitus, Type 2
990762|NCT02065791|Diabetic Nephropathies
990763|NCT02065791|Canagliflozin
990764|NCT02065791|JNJ-28431754
990765|NCT02065791|End-Stage Kidney Disease
990766|NCT02065791|Chronic Kidney Disease
990767|NCT02065791|Macroalbuminuria
990768|NCT02065752|Healthy Volunteers
990769|NCT02065752|Canagliflozin
990770|NCT02065752|Metformin
990771|NCT02065752|Type 2 diabetes mellitus
990772|NCT02065739|Healthy
990773|NCT02065739|JNJ-42165279
990774|NCT02065739|Itraconazole
990775|NCT02065739|Pharmacokinetics
990776|NCT02065713|Psoriatic arthritis, dactylitis, enthesitis
990777|NCT02065700|Methotrexate
990778|NCT02065700|insufficient responders
990779|NCT02065674|type II Diabetes mellitus
990780|NCT02065674|FBS
990781|NCT02065674|PPBS
990782|NCT02065674|HbA1c%
990783|NCT02065648|MRA
990784|NCT02065648|Syngo Native
990785|NCT02065648|Gadolinium
990786|NCT02065648|Non contrast
990787|NCT02065622|Ulcerative Colitis
990788|NCT02065609|Trastuzumab
990789|NCT02065596|Sickle Cell Disease
990790|NCT02065596|Sickle Cell Anemia
990791|NCT02065596|GvHD
990792|NCT02065596|fludarabine
990793|NCT02065583|Ileus
990794|NCT02065583|Equipment and Supplies
990795|NCT02065583|Technology
990796|NCT02065583|Acoustics
990797|NCT02065570|Crohn's Disease
990798|NCT02065557|Ulcerative Colitis
990799|NCT02065557|adalimumab
990800|NCT02065544|Type 2 diabetes mellitus
990801|NCT02065544|behavioral weight loss
990802|NCT02065544|exercise training
990803|NCT02065544|hemoglobin A1c
990804|NCT02065531|Low Back Pain
990805|NCT02065531|Chronic Pain
990806|NCT02065531|Manipulation
990807|NCT02065531|Manual Therapy
990808|NCT02065531|Randomized Controlled Trial
990809|NCT02065518|Muscle strength
990810|NCT02065518|Electrical muscle stimulation
990811|NCT02065518|Strength training
990812|NCT02065505|Spastic hemiparesis
990813|NCT02065505|Posture
990814|NCT02065505|Pilates
990815|NCT02065505|Respiratory Capacity
990822|NCT02065479|Coronary Artery Disease
990823|NCT02065479|Percutaneous Coronary Intervention
990824|NCT02065479|Genetic Polymorphism
990825|NCT02065479|Pharmacodynamic
990826|NCT02065453|lap hysterectomy
990827|NCT02065453|Women in need of a lap hysterectomy for benign disease.
990828|NCT02065440|Ebastine/Pseudoephedrine
990829|NCT02065440|subacute cough
990830|NCT02065440|upper airway cough syndrome
990831|NCT02065427|Caregiver
990832|NCT02065427|Burden
990833|NCT02065427|Social support
990834|NCT02065427|Primary health Care
990835|NCT02065427|Home Care
990836|NCT02065427|Intervention
990837|NCT02065414|Gums
990838|NCT02065414|Gingiva
990839|NCT02065414|Gingival Inflammation
990840|NCT02065414|Gingival Bleeding
990841|NCT02065375|RTA 408
990842|NCT02065375|Ocular surgery
990843|NCT02065375|Cataract surgery
990844|NCT02065375|Ocular inflammation
990845|NCT02065375|Ocular pain
990846|NCT02065375|Eye inflammation
990847|NCT02065362|EBV positive
990848|NCT02065362|TGFbeta
990849|NCT02065362|Nasopharyngeal carcinoma
990850|NCT02065362|cytotoxic T lymphocytes
990851|NCT02065349|peripheral neuropathy
990852|NCT02065349|PDPN
990853|NCT02065349|PHN
990854|NCT02065349|pain
990857|NCT02065323|Prostate Cancer
990858|NCT02065323|Metastatic
990859|NCT02065323|Hormone-sensitive
990860|NCT02065323|Androgen Deprivation Therapy (ADT)
990861|NCT02065323|Castration-Resistant Prostate Cancer (CRPC)
990862|NCT02065323|Dovitinib
990863|NCT02065323|TKI258
990864|NCT02065323|Circulating Tumor Cells
990865|NCT02065310|AGE
990866|NCT02065310|Diabetes Biomarkers
990867|NCT02065310|CEdG
990868|NCT02065284|MS
990869|NCT02065284|Ambulation
990870|NCT02065258|Asthma, Clinical control, Exercise
991258|NCT02063555|TB Vaccines
990871|NCT02065245|Aging Frailty, Frailty, Cardiovascular, stem cells
990872|NCT02065219|Chronic Pain
990873|NCT02065219|Inguinal Hernia
990874|NCT02065219|Outcome
990875|NCT02065219|Surgical Procedure, Operative
990876|NCT02065206|Focus groups
990877|NCT02065206|Underrepresented Minorities
990878|NCT02065206|Social Media
990879|NCT02065206|Clinical Research Careers
990880|NCT02065167|avascular necrosis of femoral head
990881|NCT02065167|cell therapy
990882|NCT02065167|Mesenchymal stem cells
990883|NCT02065154|acute myeloid leukemia
990884|NCT02065154|AML
990885|NCT02065154|acute lymphoblastic leukemia
990886|NCT02065154|ALL
990887|NCT02065154|chronic myeloid leukemia
990888|NCT02065154|CML
990889|NCT02065154|chronic lymphocytic leukemia
990890|NCT02065154|CLL
990891|NCT02065154|non-Hodgkin lymphoma
990892|NCT02065154|NHL
990893|NCT02065154|Hodgkin lymphoma
990894|NCT02065154|HL
990895|NCT02065154|myelodysplastic syndrome
990896|NCT02065154|MDS
990897|NCT02065154|myelofibrosis
990898|NCT02065154|severe aplastic anemia
990899|NCT02065141|digestion
990900|NCT02065141|absorption
990901|NCT02065141|protein
990902|NCT02065141|amino acids
990903|NCT02065141|heart failure
990904|NCT02065141|COPD
990905|NCT02065115|ice
990906|NCT02065115|cryotherapy
990907|NCT02065115|puncture
990908|NCT02065115|pain
990909|NCT02065102|Rotational atherectomy
990910|NCT02065102|Angina
990911|NCT02065102|Optical coherence tomography
990912|NCT02065102|Intravascular ultrasound
990913|NCT02065102|Coronary stent
990914|NCT02065076|Sodium Polystyrene Sulfonate
990915|NCT02065076|Kayexalate
990916|NCT02065076|Pre-dialysis
990917|NCT02065076|Outpatients
990918|NCT02065076|Hyperkalemia
990919|NCT02065076|Chronic kidney failure
990920|NCT02065076|Potassium
990921|NCT02065063|MEK inhibitor
990922|NCT02065063|PD-0332991
990923|NCT02065063|CDK4/6 inhibitor
990924|NCT02065063|palbociclib
990925|NCT02065063|NRAS wild type
990926|NCT02065063|cutaneous melanoma
990927|NCT02065063|GSK1120212
990928|NCT02065063|trametinib
990929|NCT02065063|NRAS mutant
990930|NCT02065063|BRAFV600 wild type
990931|NCT02065050|Diabetes mellitus
990932|NCT02065050|Team approach
990933|NCT02065037|Insufflation
990934|NCT02065037|Carbon Dioxide
990935|NCT02065037|Colonic Polyps
990936|NCT02065037|Colonoscopy
990937|NCT02065037|Randomized Controlled Trial
990938|NCT02065024|b-cryptoxanthin
990939|NCT02065024|plant sterols
990940|NCT02065024|serum Cholesterol
990941|NCT02065024|bone turnover markers
990942|NCT02064998|Randomized Controlled Trial
990943|NCT02064998|Alcohol
990944|NCT02064998|Internet
990945|NCT02064998|Mobile phone
990946|NCT02064998|Screening
990947|NCT02064998|Brief intervention
990948|NCT02064972|Graft vs Host Disease
990949|NCT02064972|Hematopoietic Stem Cell Transplant
990950|NCT02064972|Biological Marker
990951|NCT02064972|Circulating Endothelial Cells
990952|NCT02064972|Endothelial Dysfunction
990953|NCT02064959|Subdural Hematoma
990954|NCT02064959|Traumatic Brain Injury
990955|NCT02064959|Hypothermia
990956|NCT02064946|prostate cancer
990957|NCT02064946|bone density
990958|NCT02064946|vitamin D
990959|NCT02064946|micronutrients
990960|NCT02064946|pharmacologic actions
990961|NCT02064933|Wiskott-Aldrich Syndrome
990962|NCT02064933|Hematopoietic Stem Cell Transplantation
990963|NCT02064933|Genetic Therapy
990964|NCT02064907|Drug therapy
990965|NCT02064894|children
990966|NCT02064894|analgesia
990967|NCT02064894|musculoskeletal injury
990968|NCT02064894|emergency
990969|NCT02064894|opioids
990970|NCT02064881|Postprandial lipemia
990971|NCT02064881|Diabetes
990972|NCT02064881|Metformin glycinate
990973|NCT02064881|oxidized LDL
990974|NCT02064868|AHF,
990975|NCT02064868|RLX030,
990976|NCT02064868|SOC,
990977|NCT02064868|WHF,
990978|NCT02064868|RELAX-AHF-EU
990979|NCT02064868|Renal Impairment
990980|NCT02064855|Spinal stenosis
990981|NCT02064855|Spondylolisthesis
990982|NCT02064855|Degenerative disc disease
990983|NCT02064855|Spinal fusion
990984|NCT02064855|Allograft
990985|NCT02064855|Interbody fusion
990986|NCT02064842|Healthy
990987|NCT02064842|TMC647055
990988|NCT02064842|TMC435
990989|NCT02064842|Simeprevir
990990|NCT02064842|Sovriad
990991|NCT02064842|Ritonavir (RTV)
990992|NCT02064829|Metastatic breast cancer
990993|NCT02064829|Locally recurrent breast cancer
990994|NCT02064829|Bioequivalence
990995|NCT02064829|IG-001
990996|NCT02064829|nab-paclitaxel
990997|NCT02064829|Paclitaxel
990998|NCT02064829|Pharmacokinetics
991385|NCT02062944|Rapamune
990999|NCT02064816|Multiple Sclerosis, Relapsing-Remitting
991000|NCT02064816|Interferon beta 1a
991001|NCT02064816|Rebif®
991002|NCT02064790|Gabapentin
991003|NCT02064790|Pregabalin
991004|NCT02064790|Lyrica
991005|NCT02064790|Neurontin
991006|NCT02064790|lumbar
991007|NCT02064790|cervical
991008|NCT02064738|Omega-3 fatty acids
991009|NCT02064738|Omega-6 fatty acids
991010|NCT02064738|aspirin exacerbated respiratory disease
991011|NCT02064738|AERD
991012|NCT02064738|Samter's Triad
991013|NCT02064738|nasal polyp
991014|NCT02064738|aspirin
991015|NCT02064738|diet
991016|NCT02064738|leukotriene
991017|NCT02064725|Endometrial cancer
991018|NCT02064725|Recurrent or persistent endometrial carcinoma
991019|NCT02064725|Progesterone Receptor Negative
991020|NCT02064725|Sodium cridanimod
991021|NCT02064725|Virexxa
991022|NCT02064712|Continuous Positive Airway Pressure
991023|NCT02064699|Renal transplant
991024|NCT02064699|CMV
991025|NCT02064699|Test QuantiFERON-CMV
991026|NCT02064673|prostate cancer
991027|NCT02064673|radical prostatectomy
991028|NCT02064660|Myopia
991029|NCT02064660|Children
991030|NCT02064660|Acupressure
991031|NCT02064660|Refractive error
991032|NCT02064660|Axial length
991033|NCT02064660|Korean medicine
991034|NCT02064647|Insulin Infusion Systems
991035|NCT02064647|Blood Glucose
991036|NCT02064634|Shinbaro Capsule
991037|NCT02064634|Celecoxib
991038|NCT02064634|Osteoarthritis
991039|NCT02064634|GCSB-5
991040|NCT02064634|Discontinuation rate
991041|NCT02064634|Gastrointestinal adverse event
991042|NCT02064634|NSAIDs
991043|NCT02064634|OASIS
991044|NCT02064608|Prostate
991045|NCT02064608|Cancer
991046|NCT02064608|Prostate Cancer
991047|NCT02064608|High Risk
991048|NCT02064608|Intermediate Risk
991049|NCT02064608|Early disease
991050|NCT02064608|Neoadjuvant treatment
991051|NCT02064608|Radical Prostatectomy
991052|NCT02064595|Tibial fractures.
991053|NCT02064595|Fracture fixation.
991054|NCT02064595|External fixators.
991055|NCT02064595|Intramedullary.
991056|NCT02064595|Quality of life.
991057|NCT02064582|prostate cancer, enzalutamide, radiation, hormone therapy
991058|NCT02064543|Parkinson's disease
991059|NCT02064543|gait
991060|NCT02064530|TAP block
991061|NCT02064530|dexmedetomidine
991062|NCT02064530|bupivacaine
991063|NCT02064530|postoperative analgesia
991064|NCT02064517|Necrosed Immature monoradicular Teeth , Revascularisation pulpar, MTA apical barrier, Clinical and radiographic success
991065|NCT02064504|Respiratory
991066|NCT02064504|GSK961081 (MABA)
991067|NCT02064504|healthy subjects
991068|NCT02064504|pharmacokinetics
991069|NCT02064504|GW685698 (fluticasone furoate)
991074|NCT02064478|Bone anchored hearing implant
991075|NCT02064478|Bone anchored hearing device
991076|NCT02064452|behavior problems
991077|NCT02064452|children
991078|NCT02064452|prevention
991079|NCT02064452|parenting
991080|NCT02064452|online
991081|NCT02064452|pediatric
991082|NCT02064439|deep vein thrombosis
991083|NCT02064439|pulmonary embolism
991084|NCT02064439|long-term prevention of recurrent symptomatic VTE
991085|NCT02064426|Anemia of CKD on dialysis
991086|NCT02064413|Birth control
991087|NCT02064400|Rheumatoid arthritis
991088|NCT02064400|Ultrasound
991089|NCT02064400|Remission
991090|NCT02064400|Qualitative
991091|NCT02064387|Multiple Myeloma
991092|NCT02064387|BCMA expressing Lymphomas
991093|NCT02064374|Dolutegravir
991094|NCT02064374|drug interaction
991095|NCT02064374|metformin
991096|NCT02064374|pharmacokinetics
991097|NCT02064374|healthy volunteers
991098|NCT02064361|SCUBA diving
991099|NCT02064361|exercise,
991100|NCT02064361|microparticles
991101|NCT02064361|neutrophil activation,
991102|NCT02064361|high intensity exercise
991103|NCT02064335|physical activity coach, diabetic persons, health, behaviour
991104|NCT02064322|sacroiliac joint fusion
991105|NCT02064322|SIJ fusion
991106|NCT02064322|SI joint
991107|NCT02064296|Fibromyalgia Chronic Pain
991108|NCT02064270|incision care
991109|NCT02064270|Total Hip Arthroplasty
991110|NCT02064270|Total Knee Arthroplasty
991111|NCT02064270|Knee surgery
991112|NCT02064270|Hip surgery
991113|NCT02064257|autonomic nervous system
991114|NCT02064257|auditory processing disorder
991115|NCT02064257|social behavior
991116|NCT02064244|renal
991117|NCT02064244|kidney
991118|NCT02064244|creatinine
991119|NCT02064244|Inferior Vena Cava (IVC)
991120|NCT02064244|Acute Renal Failure (ARF)
991121|NCT02064244|Acute Kidney Injury (AKI)
991122|NCT02064205|pre-load
991123|NCT02064205|satiety
991124|NCT02064205|energy intake
991125|NCT02064205|appetite
991512|NCT02062346|endothelin;
991126|NCT02064192|defibrillator, implantable cardioverter
991127|NCT02064192|sudden cardiac death
991128|NCT02064192|primary prophylaxis
991129|NCT02064192|risk stratification
991130|NCT02064179|Congenital heart disease
991131|NCT02064179|Antiplatelet therapy
991132|NCT02064179|Aspirin
991133|NCT02064166|Parkinson disease
991134|NCT02064166|Multiple system atrophy
991135|NCT02064166|Intranasal
991136|NCT02064166|Insulin
991137|NCT02064153|Dialysate temperature
991138|NCT02064153|Spent dialysate
991139|NCT02064153|Toxin removal
991140|NCT02064153|Intra-dialytic hypotension
991141|NCT02064153|Inter-compartmental resistance
991142|NCT02064140|ARDS
991143|NCT02064140|Mechanical Ventilation
991144|NCT02064140|Tidal volume
991145|NCT02064140|NMBA
991146|NCT02064114|BMI >40
991147|NCT02064101|Scoliosis
991148|NCT02064101|EMG
991149|NCT02064101|Pedicle screw
991150|NCT02064101|Neuromonitoring
991151|NCT02064088|Regional anesthesia
991152|NCT02064088|TAP block
991153|NCT02064088|Pediatric anesthesia
991154|NCT02064088|analgesic effects
991155|NCT02064088|pharmacokinetics
991156|NCT02064075|Subarachnoid hemorrhage
991157|NCT02064075|vasospasm
991158|NCT02064075|Lactated Ringer's solution
991159|NCT02064075|Hydroxyethyl starch solution
991160|NCT02064062|Achilles Tendinopathy
991161|NCT02064062|Autologous Stem Cells
991162|NCT02064062|Musculoskeletal
991163|NCT02064049|Hepatitis C virus
991164|NCT02064049|People who inject drugs
991165|NCT02064049|Drug users
991166|NCT02064049|Direct acting antiviral (DAA)
991167|NCT02064049|Infectious diseases
991168|NCT02064049|Prisoners
991172|NCT02064023|insulin pump
991173|NCT02064023|CSII
991174|NCT02064023|multiple daily injections
991175|NCT02064023|MDI
991176|NCT02064023|type 1 diabetes
991177|NCT02064023|type 2 diabetes
991178|NCT02064023|pregnancy
991179|NCT02063971|Skin aging
991180|NCT02063971|Soothing activity
991181|NCT02063971|Hyaluronic acid injections
991182|NCT02063958|Neuroendocrine tumor
991183|NCT02063958|Hsp90
991184|NCT02063945|ADHA
991185|NCT02063945|ODD
991186|NCT02063945|Conduct disorder
991187|NCT02063945|Aggression
991188|NCT02063945|Treatment
991189|NCT02063945|Methylphenidate
991190|NCT02063945|Risperidone
991191|NCT02063932|mucosal microbiome
991192|NCT02063932|H.pylori
991193|NCT02063932|intestinal metaplasia
991194|NCT02063932|gastric neoplasia
991195|NCT02063932|endomicroscopy
991196|NCT02063880|HIV-1
991197|NCT02063880|IRIS
991198|NCT02063867|HAI
991199|NCT02063867|MRSA
991200|NCT02063867|VRE
991201|NCT02063854|Drug Therapy
991202|NCT02063802|pediatric obesity
991203|NCT02063802|conjugated linoleic acid
991204|NCT02063802|CLA
991205|NCT02063802|metformin
991206|NCT02063789|Immune Thrombocytopenia
991207|NCT02063789|Immune Thrombocytopenic Purpura
991208|NCT02063789|Idiopathic Thrombocytopenic Purpura
991209|NCT02063789|Human Immunoglobulin
991210|NCT02063789|ITP
991211|NCT02063789|IVIg
991212|NCT02063789|IgIV
991213|NCT02063789|IV-Globulin SN Inj.
991214|NCT02063776|Haemodiafiltration (HDF)
991215|NCT02063776|Haemodialysis (HD)
991216|NCT02063776|Children
991217|NCT02063776|Carotid intima media thickness
991218|NCT02063776|Pulse wave velocity
991219|NCT02063776|Height standard deviation score
991220|NCT02063763|Adult patients
991221|NCT02063763|Immune primary thrombocytopenia
991222|NCT02063763|Splenectomy
991223|NCT02063763|TPO-mimetics
991224|NCT02063763|Eltrombopag
991225|NCT02063763|Romiplostim
991226|NCT02063750|Fibromyalgia
991227|NCT02063750|Muscle strength exercises
991228|NCT02063750|Pain
991229|NCT02063750|Quality of life
991230|NCT02063737|Shift work
991231|NCT02063737|Fatigue
991232|NCT02063737|Sleepiness
991233|NCT02063737|Injury
991234|NCT02063724|Invasive Breast Cancer
991235|NCT02063724|Breast Cancer
991236|NCT02063724|Immunotherapy
991237|NCT02063724|Vaccine
991238|NCT02063724|Dendritic Cell
991239|NCT02063711|Prenatal Yoga
991240|NCT02063711|Yoga, Pregnancy
991241|NCT02063711|Yoga, Fetal Response
991242|NCT02063646|polyphenols
991243|NCT02063646|memory
991244|NCT02063646|elderly
991245|NCT02063633|Thoracic malignancy, irradiation, respiratory gating system PET
991246|NCT02063620|IVRA, ketamine, lidocaine, ECG
991247|NCT02063607|Hepatitis C naive
991248|NCT02063594|Iodixanol
991249|NCT02063594|Iodinated Contrast
991250|NCT02063594|Liposome
991251|NCT02063594|Computed Tomography
991252|NCT02063594|X-ray Imaging
991253|NCT02063594|Blood pool agent
991254|NCT02063594|Biomarker
991255|NCT02063555|Tuberculosis
991256|NCT02063555|BCG
991257|NCT02063555|HIV
991259|NCT02063542|Postoperative cognitive changes
991260|NCT02063542|Acetylcholine in CSF
991261|NCT02063542|Surgery
991262|NCT02063529|Colorectal cancer
991263|NCT02063529|Metastatic colorectal cancer
991264|NCT02063529|Liver metastases
991265|NCT02063529|Liver resection
991266|NCT02063529|Liver ablation
991267|NCT02063529|Conversion therapy
991268|NCT02063529|FOLFOXIRI
991269|NCT02063529|Cetuximab
991270|NCT02063529|Oxaliplatin
991271|NCT02063529|Irinotecan
991272|NCT02063529|Leucovorin
991273|NCT02063516|Airway Cuff
991274|NCT02063516|Guardian
991275|NCT02063516|Proseal
991276|NCT02063516|Cuff Pressure
991277|NCT02063516|laryngeal Mask Airway
991278|NCT02063503|clinical prediction rule
991279|NCT02063503|nonspecific
991280|NCT02063503|chronic
991281|NCT02063503|low back pain
991282|NCT02063503|Non specific chronic low back pain
991283|NCT02063490|Adherence
991284|NCT02063490|dialysis
991285|NCT02063490|intervention
991286|NCT02063490|nurse-led
991287|NCT02063490|phosphate binders
991288|NCT02063490|trial
991289|NCT02063464|Tumorcidal
991290|NCT02063464|Monocytes
991291|NCT02063464|Interferons Alpha and Gamma
991292|NCT02063451|Obesity [C18.654.726.500]
991293|NCT02063451|Receptor, Opioid, mu [D12.776.543.750.100.620.550]
991294|NCT02063451|Brain [A08.186.211]
991295|NCT02063451|Affect [F01.470.047]
991296|NCT02063438|Thoracotomy
991297|NCT02063438|Pain
991298|NCT02063438|Intracostal Suture
991299|NCT02063438|Pericostal Suture
991300|NCT02063425|Motor recovery
991301|NCT02063425|Fluoxetine
991302|NCT02063425|Transcranial magnetic stimulation
991303|NCT02063425|stroke
991304|NCT02063399|NPC
991305|NCT02063399|Cancer screening
991306|NCT02063399|Plasma EBV DNA
991307|NCT02063347|innate collateral supply
991308|NCT02063347|collateral
991309|NCT02063347|coronary collateral
991310|NCT02063347|renal collateral
991311|NCT02063347|peripheral collateral
991312|NCT02063347|coronary artery disease
991313|NCT02063334|vitamin D3
991314|NCT02063334|cholecalciferol
991315|NCT02063334|calcidiol
991316|NCT02063334|25-hydroxyvitamin D
991317|NCT02063334|gene expression
991318|NCT02063334|vitamin D receptor
991319|NCT02063334|randomized controlled trial
991320|NCT02063334|men
991321|NCT02063334|adults
991322|NCT02063321|DME, diabetic retinopathy, diabetes mellitus, epidemiology
991323|NCT02063308|Oxaloacetate
991324|NCT02063308|OAA
991325|NCT02063308|AD
991326|NCT02063308|Alzheimer's Disease
991327|NCT02063295|Beloranib
991328|NCT02063295|ZGN-440
991329|NCT02063295|ZGN-440 for injectable suspension
991330|NCT02063295|ZGN-433
991331|NCT02063282|Asymptomatic
991332|NCT02063282|Carriage
991333|NCT02063282|Colonization
991334|NCT02063282|Clostridium difficile
991335|NCT02063282|Colitis
991336|NCT02063282|Rectal swab
991337|NCT02063269|rivastigmine, butyrylcholinesterase, MRI, PET
991338|NCT02063256|sperm count
991339|NCT02063256|sperm concentration
991340|NCT02063256|mobility
991341|NCT02063256|diet
991342|NCT02063256|PUFA (polyunsaturated fatty acids)
991343|NCT02063243|Keloid, hypertrophic scar
991344|NCT02063230|Phase I, healthy, pharmacokinetic, hepatic impairment
991345|NCT02063204|Phase I, healthy, pharmacokinetics, renal impairment
991346|NCT02063191|Atrial Fibrillation
991347|NCT02063191|Bundle Branch Block
991348|NCT02063165|Safflower Oil
991349|NCT02063165|Linoleic Acid
991350|NCT02063165|Dyslipidemia
991351|NCT02063165|Hypertension
991352|NCT02063139|Knemometry
991353|NCT02063126|Coenzyme Q10 plus NADH
991354|NCT02063126|maximum Heart Rate
991355|NCT02063126|Fatigue
991356|NCT02063126|Pain
991357|NCT02063126|Sleep
991358|NCT02063113|Multiple myeloma,
991359|NCT02063113|Older patient,
991360|NCT02063113|Treatment,
991361|NCT02063113|Geriatric assessment
991362|NCT02063100|Glomerulonephritis
991363|NCT02063100|proteinuria
991364|NCT02063100|shenyankangfu tablets
991365|NCT02063100|Losartan Potassium
991366|NCT02063100|efficacy
991367|NCT02063100|safety
991368|NCT02063087|Head CT
991369|NCT02063087|Head Injury
991370|NCT02063087|Pediatric
991371|NCT02063087|Emergency Department
991372|NCT02063087|Decision Aids
991373|NCT02063087|Shared Decision Making
991374|NCT02063061|extracorporeal shock wave therapy ESWT
991375|NCT02063061|erectile dysfunction
991376|NCT02063048|weight loss
991377|NCT02063048|Text Messaging
991378|NCT02063048|Short Message Service
991379|NCT02063048|Text Messages
991380|NCT02063035|lumbar spine surgery
991381|NCT02063035|thoracic spine surgery
991382|NCT02063022|Non metastatic Ewing's Sarcoma
991383|NCT02062944|Liver Transplant
991384|NCT02062944|Sirolimus
991386|NCT02062944|Immunosuppressant Therapy
991387|NCT02062944|Withdrawal
991388|NCT02062931|Primary Infertility
991389|NCT02062931|Primary Amenorrhea
991390|NCT02062931|Sex Steroid Deficiency
991391|NCT02062931|Premature Ovarian Failure (POF)
991392|NCT02062918|Abdominal belt
991393|NCT02062918|Chronic low back pain
991394|NCT02062918|Pain
991395|NCT02062918|Functional capacity
991396|NCT02062892|everolimus
991397|NCT02062892|sirolimus
991398|NCT02062892|tacrolimus
991399|NCT02062892|vascular endothelial function
991400|NCT02062892|kidney
991401|NCT02062892|Transplantation
991402|NCT02062892|biomarkers
991403|NCT02062879|pain
991404|NCT02062879|trauma
991405|NCT02062840|Whole Body Hyperthermia
991406|NCT02062840|Functional Magnetic Resonance Imaging
991407|NCT02062840|EEG
991408|NCT02062827|Glioma
991409|NCT02062801|Combined spinal epidural analgesia, labor, fetal bradycardia
991410|NCT02062788|Early Recovery After Surgery
991411|NCT02062788|Oral rehydration solution
991412|NCT02062788|Insulin resistance
991413|NCT02062788|Postoperative complication
991414|NCT02062749|Colorectal cancer
991415|NCT02062749|Colon Cancer
991416|NCT02062749|Pediatric
991417|NCT02062749|Adolescent
991418|NCT02062749|Hyperthermic Intraperitoneal Chemotherapy
991419|NCT02062749|HIPEC
991420|NCT02062749|Oxaliplatin
991421|NCT02062749|Eloxatin
991422|NCT02062736|methadone
991423|NCT02062736|heroin addiction
991424|NCT02062736|methadone maintenance treatment
991425|NCT02062736|adequate dosage of methadone
991426|NCT02062723|methadone
991427|NCT02062723|heroin addiction
991428|NCT02062723|methadone maintenance treatment
991429|NCT02062723|adequate dosage of methadone
991430|NCT02062710|cough
991431|NCT02062710|cough reflex
991432|NCT02062710|capsaicin
991433|NCT02062710|diphenhydramine
991434|NCT02062710|phenylephrine
991435|NCT02062710|dextromethorphan
991436|NCT02062710|placebo
991437|NCT02062697|Neoplasms
991438|NCT02062697|Glandular and Epithelial
991439|NCT02062697|Ovarian Neoplasms
991440|NCT02062697|Ovarian cancer
991441|NCT02062684|IgAN
991442|NCT02062684|IgA Nephropathy
991443|NCT02062684|A-623
991444|NCT02062684|Blisibimod
991445|NCT02062684|Kidney Disease
991446|NCT02062684|Persistent proteinuria
991447|NCT02062671|ADPKD
991448|NCT02062671|denervation
991449|NCT02062671|renal denervation
991450|NCT02062658|OCD
991451|NCT02062645|essential hypertension
991452|NCT02062619|Stroke
991453|NCT02062619|Aphasia
991454|NCT02062619|Acquired reading disorders
991455|NCT02062619|Central alexia
991456|NCT02062619|Computer based rehabilitation
991457|NCT02062619|Transcranial direct current stimulation
991458|NCT02062619|tDCS
991459|NCT02062619|Magnetoencephalography
991460|NCT02062619|MEG
991461|NCT02062619|Magnetic Resonance Imaging
991462|NCT02062619|MRI
991463|NCT02062606|Scoliosis
991464|NCT02062606|Spinal Curvatures
991465|NCT02062606|Spinal Diseases
991466|NCT02062606|Adolescent Idiopathic Scoliosis
991467|NCT02062606|Spinal Deformity
991468|NCT02062593|Stable angina
991469|NCT02062593|Percutaneous coronary intervention
991470|NCT02062593|Optimal medical therapy
991471|NCT02062593|Sham-control
991472|NCT02062580|Vaccine immunogenicity
991473|NCT02062580|Immune activation
991474|NCT02062554|Myocardial infarction
991475|NCT02062554|Clinical outcome
991476|NCT02062554|Flow-mediated dilation
991477|NCT02062554|Inflammation
991478|NCT02062541|functional assessment
991479|NCT02062541|rehabilitation
991480|NCT02062541|cross-sectorial cooperation
991481|NCT02062528|EPA
991482|NCT02062489|breast cancer,
991483|NCT02062489|tamoxifen,
991484|NCT02062489|ER/PR negative, ER-beta positive
991485|NCT02062463|Asthma
991486|NCT02062450|Arthroplasty
991487|NCT02062450|Hip Replacement
991488|NCT02062450|Acetabular cup
991489|NCT02062450|Dual mobility
991490|NCT02062450|Hip revision surgery
991491|NCT02062437|Arthroplasty
991492|NCT02062437|Hip Replacement
991493|NCT02062437|Ceramic
991494|NCT02062437|Acetabular cup
991495|NCT02062437|Femoral stem
991496|NCT02062424|ischemic heart disease, dietary guidelines
991497|NCT02062411|attention deficit disorder (ADHD)
991498|NCT02062411|cognitive behavioral therapy (CBT)
991499|NCT02062411|adult
991500|NCT02062398|PNP
991501|NCT02062398|Stimulation
991502|NCT02062398|Peripheral neurostimulation
991503|NCT02062372|7 T MRI
991504|NCT02062372|Radiotherapy
991505|NCT02062372|Glioblastoma
991506|NCT02062372|Biopsy
991507|NCT02062359|Malignant Melanoma
991508|NCT02062359|Metastatic Cancer
991509|NCT02062359|Gene Therapy
991510|NCT02062359|Immunotherapy
991511|NCT02062359|Tumor Regression
991513|NCT02062346|blood pressure;
991514|NCT02062346|vasculitis
991515|NCT02062333|dexmedetomidine
991516|NCT02062333|esmolol
991517|NCT02062333|stapes reflex
991518|NCT02062320|Acute Pain Service
991519|NCT02062320|postoperative analgesia
991520|NCT02062320|Caesarean Section
991521|NCT02062320|non-opioid analgesia
991522|NCT02062320|opioid analgesia
991523|NCT02062320|epidural analgesia
991524|NCT02062307|Hypogonadism
991525|NCT02062307|Asymmetric Dimethyl Arginine
991526|NCT02062307|Osteoprotegerin
991527|NCT02062307|Fibroblast Growth Factor
991528|NCT02062307|Vitamin D
991529|NCT02062281|Safety
991530|NCT02062281|Immunogenicity
991531|NCT02062281|vaccine
991532|NCT02062281|pneumococcal
991533|NCT02062281|influenza
991534|NCT02062268|KAP
991535|NCT02062268|drink driving
991536|NCT02062268|public
991537|NCT02062268|Jiangsu province
991538|NCT02062268|China
991539|NCT02062255|Asprin
991540|NCT02062255|Omega-3 Free Fatty Acids
991541|NCT02062255|Obesity
991542|NCT02062255|COX-2 inhibitor
991543|NCT02062242|Pelvic Floor
991544|NCT02062242|Physical Therapy Specialty
991545|NCT02062242|Awareness
991546|NCT02062242|Electric Stimulation
991547|NCT02062242|Palpation
991548|NCT02062229|oxidative stress
991549|NCT02062229|oxysterols
991550|NCT02062229|fatty acids
991551|NCT02062229|seminal fluid
991552|NCT02062216|Coronary artery disease
991553|NCT02062216|Percutaneous coronary intervention
991554|NCT02062216|Inflammatory receptors
991555|NCT02062203|Akebia
991556|NCT02062203|QT interval
991557|NCT02062203|TQT
991558|NCT02062203|pharmacokinetic
991559|NCT02062203|anemia
991560|NCT02062203|chronic kidney disease
991561|NCT02062203|CKD
991562|NCT02062203|chronic renal insufficiency
991563|NCT02062203|renal impairment
991564|NCT02062203|safety
991565|NCT02062164|psychosocial, healthcare, co-morbidities, extremely obese adolescents
991566|NCT02062138|rehabilitation
991567|NCT02062138|total knee arthroplasty
991568|NCT02062138|range of motion
991569|NCT02062138|continuous passive motion
991570|NCT02062138|controlled active motion
991571|NCT02062138|postoperative physical therapy
991572|NCT02062125|scleroderma
991573|NCT02062125|calcinosis
991574|NCT02062112|Bowel preparation solutions
991575|NCT02062112|Colonoscopy
991576|NCT02062112|Polyethylene glycol
991577|NCT02062086|Sarcopenia
991578|NCT02062086|Mass muscle
991579|NCT02062086|Quality of life
991580|NCT02062073|head lice
991581|NCT02062073|Hatchtech
991582|NCT02062060|Head Lice
991583|NCT02062060|Hatchtech
991584|NCT02062047|Diabetes Mellitus
991585|NCT02062047|Chronic Periodontitis
991586|NCT02062047|Root Planing
991587|NCT02062047|Cytokines
991588|NCT02062047|microbiology
991589|NCT02062047|Glycated hemoglobin
991590|NCT02062047|diabetic subjects
991591|NCT02062034|Oxidative stress
991592|NCT02062034|Mitochondrial dysfunction
991593|NCT02062034|Ubiquinone
991594|NCT02062034|Antioxidant combined therapy
991595|NCT02062034|Diabetic retinopathy
991596|NCT02062008|Positron Emission Tomography-Magnetic Resonance Imaging
991597|NCT02062008|Cardiac Disease
991598|NCT02061995|Bone Diseases
991599|NCT02061995|Metabolic Bone Diseases
991600|NCT02061995|Osteoporosis
991601|NCT02061995|Bone Fractures
991602|NCT02061995|Osteoporotic Fractures
991603|NCT02061995|Musculoskeletal Diseases
991604|NCT02061982|Do It Yourself (DIY)
991605|NCT02061982|Caffeine
991606|NCT02061982|Cognition
991607|NCT02061969|nursing home facility
991608|NCT02061969|long-term care facility
991609|NCT02061969|older patients
991610|NCT02061969|elderly patients
991611|NCT02061969|hyperglycemia
991612|NCT02061969|type 2 diabetes
991613|NCT02061943|Spasmodic dysphonia
991614|NCT02061943|Laryngeal dystonia
991615|NCT02061943|Dystonia
991616|NCT02061943|Severity
991617|NCT02061930|single tooth
991618|NCT02061930|dental implant
991619|NCT02061930|aesthetics outcome
991620|NCT02061930|long term
991621|NCT02061930|soft tissue recession
991622|NCT02061930|pink esthetic score
991623|NCT02061930|white esthetic score
991624|NCT02061917|Biomarkers
991625|NCT02061917|Tobacco
991626|NCT02061917|Tobacco-heating
991627|NCT02061917|Smokeless Tobacco
991628|NCT02061917|Snus
991629|NCT02061917|Smoking
991630|NCT02061917|Exposure
991631|NCT02061917|Quality of Life
991632|NCT02061891|Coronary Stenosis
991633|NCT02061891|Coronary Artery Disease
991634|NCT02061891|Acute coronary syndrome
991635|NCT02061891|Percutaneous Coronary Intervention
991636|NCT02061891|Multidetector Computed Tomography
991637|NCT02061878|ApoE
991638|NCT02061878|beta-amyloid
991639|NCT02061813|Hatchtech
991640|NCT02061800|Unrelated donor transplant
991641|NCT02061800|Allogenic Stem Cell Transplant
991642|NCT02061800|Adult Bone Marrow Transplant
991643|NCT02061800|Pediatric Bone Marrow Transplant
991644|NCT02061800|Related donor transplant
991645|NCT02061800|Haploidentical donor transplant
991646|NCT02061800|Peripheral blood stem cell transplantation
991647|NCT02061800|Non-malignant disease
991648|NCT02061800|Malignant disease
991649|NCT02061800|Bone marrow failure syndrome
991650|NCT02061800|Severe Aplastic Anemia
991651|NCT02061800|Severe Congenital Neutropenia
991652|NCT02061800|Amegakaryocytic Thrombocytopenia
991653|NCT02061800|Diamond-Blackfan Anemia
991654|NCT02061800|Schwachman Diamond Syndrome
991655|NCT02061800|Primary Immunodeficiency Syndrome
991656|NCT02061800|Acquired Immunodeficiency Syndrome
991657|NCT02061800|Histiocytic Syndrome
991658|NCT02061800|Familial Hemophagocytic Lymphocytosis
991659|NCT02061800|Lymphohistiocytosis
991660|NCT02061800|Macrophage Activation Syndrome
991661|NCT02061800|Langerhans Cell Histiocytosis (LCH)
991662|NCT02061800|Hemoglobinopathies
991663|NCT02061800|Reduced-Intensity Conditioning
991664|NCT02061800|Sickle Cell Disease
991665|NCT02061800|Sickle Cell-beta-thalassemia
991667|NCT02061735|skin imaging
991668|NCT02061735|image analysis
991669|NCT02061735|infrared thermography
991670|NCT02061735|infantile hemangioma
991671|NCT02061735|three dimensional imaging
991672|NCT02061735|color imaging and analysis
991673|NCT02061735|propranolol
991674|NCT02061735|timolol
991675|NCT02061735|ontogeny
991676|NCT02061709|Rhinoconjunctivitis
991677|NCT02061709|Rhinitis
991678|NCT02061709|Seasonal
991679|NCT02061709|Ragweed
991680|NCT02061709|Allergy
991681|NCT02061696|Coronary Artery Disease
991682|NCT02061696|Coronary Disease
991683|NCT02061696|Heart disease
991684|NCT02061696|Cardiovascular Diseases
991685|NCT02061696|Arteriosclerosis
991686|NCT02061696|Atherosclerosis
991687|NCT02061696|Manual Compression
991688|NCT02061670|Ragweed
991689|NCT02061670|Allergy
991690|NCT02061670|rhinoconjunctivitis
991691|NCT02061670|rhinitis
991692|NCT02061670|asthma
991693|NCT02061618|South Asian
991694|NCT02061605|Laparoscopic partial nephrectomy
991695|NCT02061605|Surgical hemostasis
991696|NCT02061605|Laser tissue welding
991697|NCT02061605|Tissue sealant
991698|NCT02061579|Physical Activity
991699|NCT02061566|Acute kidney injury
991700|NCT02061553|traumatic brain injury
991701|NCT02061553|TBI
991702|NCT02061553|head injury
991703|NCT02061553|brain injury
991704|NCT02061553|depression
991705|NCT02061553|anxiety
991706|NCT02061527|ADM
991707|NCT02061527|Strattice
991708|NCT02061527|Breast reconstruction
991709|NCT02061527|Immediate breast reconstruction
991710|NCT02061527|IBR
991711|NCT02061527|Acellular dermal matrix
991712|NCT02061527|Biological mesh
991713|NCT02061527|Randomized controlled trial
991714|NCT02061527|RCT
991715|NCT02061527|Breast cancer
991716|NCT02061527|Implants
991717|NCT02061527|Mastectomy
991718|NCT02061527|Direct-to-implant
991719|NCT02061501|visual cognitive deficits
991720|NCT02061488|Artificial pancreas, closed loop glucose control, model predictive control
991721|NCT02061475|Lidocaine patches
991722|NCT02061475|Pain
991723|NCT02061475|Intravenous cannulation
991724|NCT02061449|Toll-like receptor agonist
991725|NCT02061449|immunostimulation
991726|NCT02061436|chronic total occlusion, percutaneous coronary intervention
991727|NCT02061423|Invasive Breast Cancer
991728|NCT02061423|Breast Cancer
991729|NCT02061423|Immunotherapy
991730|NCT02061423|Vaccine
991731|NCT02061423|Dendritic Cell
991732|NCT02061423|Neoadjuvant
991733|NCT02061410|Elderly
991734|NCT02061397|lymphangioleiomyomatosis (LAM)
991735|NCT02061397|tuberous sclerosis complex (TSC)
991736|NCT02061397|simvastatin
991737|NCT02061397|sirolimus
991738|NCT02061397|everolimus
991739|NCT02061384|Infertility
991740|NCT02061371|stroke
991741|NCT02061371|spasticity
991742|NCT02061371|physiotherapy
991743|NCT02061371|virtual reality
991744|NCT02061358|Dengue
991745|NCT02061358|Arbovirus Infections
991746|NCT02061358|Flaviviridae Infections
991747|NCT02061358|Flavivirus Infections
991748|NCT02061358|Hemorrhagic Fevers, Viral
991749|NCT02061358|RNA Virus Infections
991750|NCT02061358|Virus Diseases
991751|NCT02061358|Pharmaceutical Solutions
991752|NCT02061358|Pharmacologic Actions
991753|NCT02061358|Therapeutic Uses
991754|NCT02061345|Prostate cancer
991755|NCT02061345|Androgen Deprivation Therapy
991756|NCT02061345|Mild Cognitive Impairment
991757|NCT02061332|Breast Cancer
991758|NCT02061332|DCIS
991759|NCT02061332|Immunotherapy
991760|NCT02061332|Vaccine
991761|NCT02061332|Dendritic Cell
991762|NCT02061306|Celiac disease
991763|NCT02061306|coeliac disease
991764|NCT02061306|microbiome
991765|NCT02061306|gluten
991766|NCT02061306|infants
991767|NCT02061306|pregnancy
991768|NCT02061306|genetic
991769|NCT02061280|Asthma
991770|NCT02061280|Clinical Trial Design
991771|NCT02061280|Electronic Data Entry
991772|NCT02061280|Mobile Devices
991773|NCT02061280|Home Spirometry
991774|NCT02061267|Metabolic Syndrome
991775|NCT02061267|Olive Oil
991776|NCT02061267|Niacin
991777|NCT02061254|Venous insufficiency
991778|NCT02061254|Lymphedema
991779|NCT02061254|Elastograph
991780|NCT02061254|Ultrasonography
991781|NCT02061254|Fibrosis
991782|NCT02061254|Dermis
991783|NCT02061254|Hypodermis
991784|NCT02061254|Skin
991785|NCT02061241|Cardiac resynchronisation therapy
991786|NCT02061241|Pacing
991787|NCT02061215|CYTOF
991788|NCT02061215|CMV
991789|NCT02061215|PCR
991790|NCT02061215|HLA
991791|NCT02061202|Sickle Cell Disease
991792|NCT02061202|Pain Crisis
991793|NCT02061202|Painful Crisis
991794|NCT02061202|Sickle Pain
991795|NCT02061189|neuromuscular disease, Spinal Muscular Atrophy, Infantile,
991796|NCT02061189|motor function measure, Hammersmith scale,
991797|NCT02061189|rehabilitation program, physical exercise
991798|NCT02061176|Hemorrhoids
991799|NCT02061176|Haemorrhoids
991800|NCT02061176|Transanal Haemorrhoidal Dearterialization
991801|NCT02061176|Transanal Hemorrhoidal Dearterialisation
991802|NCT02061176|Open Haemorrhoidectomy
991803|NCT02061176|Open Hemorrhoidectomy
991804|NCT02061150|Early onset GBS sepsis
991805|NCT02061150|Prevention
991806|NCT02061150|Maternal risk factors
991807|NCT02061137|Rett Syndrome (Mecp2 positive)
991808|NCT02061137|Fingolimod (FTY 720)
991809|NCT02061137|BDNF
991810|NCT02061137|Brain Atrophy
991811|NCT02061111|Mitochondria Function
991812|NCT02061111|TPO-antibodies
991813|NCT02061111|Subclinical Thyroid Disease
991814|NCT02061111|Thyroid Disease In Pregnancy
991815|NCT02061111|Children´s Development
991816|NCT02061098|Pomegranate
991817|NCT02061098|Cardiovascular
991818|NCT02061098|Urolithins
991819|NCT02061098|Microbiota
991820|NCT02061098|Polyphenols
991821|NCT02061098|Nutraceutical
991822|NCT02061098|Dietary supplement
991823|NCT02061085|Breast Neoplasm Metastasis
991824|NCT02061085|Receptor,HER-2
991825|NCT02061085|Eribulin
991826|NCT02061085|Furans, quetones
991827|NCT02061085|Antimitotic agent
991828|NCT02061072|pharmacokinetics
991829|NCT02061072|population pharmacokinetics
991830|NCT02061072|hemophilia
991831|NCT02061072|factor VIII
991832|NCT02061072|factor IX
991833|NCT02061046|Gait
991834|NCT02061046|Dual task
991835|NCT02061033|Hemophilia A
991836|NCT02061033|Hemophilia B
991837|NCT02061033|Von Willebrand's Disease
991838|NCT02061033|Endogen thrombin potential
991839|NCT02061033|Overall hemostatic potential
991840|NCT02061033|Microparticles
991841|NCT02061033|Fibrin clot
991964|NCT02060448|CBT
991842|NCT02061020|delta-9-tetrahydrocannabinol, volunteers, cannabis users
991843|NCT02061007|skin cancer
991844|NCT02060981|Randomized controlled trial
991845|NCT02060981|Primary medication adherence
991846|NCT02060981|Decision-support tool
991847|NCT02060981|Patient-centered outcomes research
991848|NCT02060981|Antihypertensive medications
991849|NCT02060981|One-on-one patient interviews
991850|NCT02060968|Promus PREMIER
991851|NCT02060968|Routine Clinical Practice
991852|NCT02060955|Glioblastoma multiforme
991853|NCT02060955|Immunotherapy
991854|NCT02060955|Bevacizumab/Irinotecan
991855|NCT02060955|ALECSAT
991856|NCT02060955|recurrent
991857|NCT02060942|Volume responsiveness mean systemic filling pressure
991858|NCT02060929|Healthy
991859|NCT02060929|Esketamine
991860|NCT02060929|Intranasal
991861|NCT02060929|Nasal Guide
991862|NCT02060929|Pharmacokinetics
991863|NCT02060903|Head Lice
991864|NCT02060903|Hatchtech
991865|NCT02060890|Glioblastoma
991866|NCT02060877|suspected lung cancer
991867|NCT02060877|diagnostic work-up
991868|NCT02060864|enzyme
991869|NCT02060864|gluten
991870|NCT02060864|food intolerance
991871|NCT02060851|EPO
991872|NCT02060851|Intravenous iron
991873|NCT02060851|iron storage
991874|NCT02060851|preterm anemia
991875|NCT02060812|ultrasound guided axillary nerve block
991876|NCT02060812|arthroscopic rotator cuff repair
991877|NCT02060812|ultrasound guided suprascapular nerve block
991878|NCT02060812|rebound phenomenon of pain
991879|NCT02060799|Dyspnea
991880|NCT02060799|Emergency Service, Hospital
991881|NCT02060799|prognosis
991882|NCT02060799|Fatal Outcome
991883|NCT02060799|Epidemiology
991884|NCT02060786|Antiplatelet; clopidogrel; acute coronary syndrome
991885|NCT02060773|Septic shock
991886|NCT02060773|Early goal directed therapy
991887|NCT02060773|Fluid resuscitation
991888|NCT02060773|Hepatic perfusion
991889|NCT02060773|Indocyanine Green
991890|NCT02060760|Prospective cohort study
991891|NCT02060760|Diagnostic accuracy
991892|NCT02060760|High sensitivity versus contemporary troponin I assay
991893|NCT02060760|Gender
991894|NCT02060760|Renal Function
991895|NCT02060734|Whiplash,
991896|NCT02060734|injection,
991897|NCT02060734|lidocaine,
991898|NCT02060734|sham needling
991900|NCT02060695|Parkinson disease
991901|NCT02060682|Fractional Flow Reserve
991902|NCT02060682|Rapid Exchange
991903|NCT02060682|Catheter
991904|NCT02060656|Relapsed or refractory Diffuse Large B-Cell Lymphoma after R-CHOP chemotherapy
991914|NCT02060617|low back pain
991915|NCT02060617|physical therapy
991916|NCT02060617|manual therapy
991917|NCT02060617|manipulation
991918|NCT02060617|exercise
991919|NCT02060617|motor control
991920|NCT02060617|regional interdependence
991921|NCT02060604|ketorolac
991922|NCT02060604|NSAIDs
991923|NCT02060604|wet macular degeneration
991924|NCT02060604|choroidal neovascularization
991925|NCT02060578|Cancer palliative care
991926|NCT02060578|Dead child
991927|NCT02060565|diagnosis
991928|NCT02060565|survival
991929|NCT02060565|non-invasive method
991930|NCT02060565|cirrhosis
991931|NCT02060565|FibroScan
991932|NCT02060526|sulfoglucosamine sulfohydrolase (SGSH)
991933|NCT02060526|recombinant human heparan N-sulfatase (rhHNS)
991934|NCT02060526|Hunter's Syndrome
991935|NCT02060526|Shire HGT
991936|NCT02060526|Lysosomal Storage Disease (LSD)
991937|NCT02060526|Sanfilippo Syndrome Type A (Sanfilippo A)
991938|NCT02060526|enzyme replacement therapy (ERT)
991939|NCT02060513|Wounded warriors
991940|NCT02060513|Battlefield infection
991941|NCT02060513|Acinetobacter
991942|NCT02060513|ESBL
991943|NCT02060513|MRSA
991944|NCT02060513|KPC
991945|NCT02060500|GERD
991946|NCT02060500|fundoplication
991947|NCT02060500|cardiaplication
991948|NCT02060500|reflux
991954|NCT02060474|Allan-Herndon-Dudley Syndrome
991955|NCT02060474|MCT8
991956|NCT02060474|Triac
991957|NCT02060474|Therapeutic Trial
991958|NCT02060448|Non-suicidal self-injury
991959|NCT02060448|Self-injurious behavior
991960|NCT02060448|NSSI
991961|NCT02060448|Anxiety
991962|NCT02060448|Depression
991963|NCT02060448|Transdiagnostic
991965|NCT02060448|Unified Protocol
991966|NCT02060435|diffuse large B-cell lymphoma
991967|NCT02060435|Ebstein-Barr Virus
991968|NCT02060422|Epilepsy
991969|NCT02060422|Drug-resistant epilepsy
991970|NCT02060422|Seizure
991971|NCT02060422|Mindfulness
991972|NCT02060422|Stress
991973|NCT02060422|Psychotherapy
991974|NCT02060409|myelodysplastic syndrome
991975|NCT02060409|decitabine
991976|NCT02060409|spliceosome mutation
991977|NCT02060383|Cushing's disease
991978|NCT02060383|acromegaly
991979|NCT02060383|pasireotide
991980|NCT02060383|hyperglycemia
991981|NCT02060370|Genitourinary Cancer
991982|NCT02060370|Kidney Cancer
991983|NCT02060370|Metastatic Renal Cell Carcinoma
991984|NCT02060370|mRCC
991985|NCT02060370|Sunitinib
991986|NCT02060370|Sunitinib malate
991987|NCT02060370|SUO11248
991988|NCT02060370|Sutent
991989|NCT02060370|Questionnaire
991990|NCT02060370|Survey
991991|NCT02060357|Diabetes Mellitus
991992|NCT02060357|PCI
991993|NCT02060357|Drug eluting stent
991994|NCT02060357|OCT
991995|NCT02060344|Cardiovascular Disease
991996|NCT02060344|Hispanic
991997|NCT02060344|Latinos
991998|NCT02060331|Nocturia
991999|NCT02060331|Pelvic Organ Prolapse
992000|NCT02060331|Nocturnal Polyuria
992001|NCT02060331|Post-obstructive Diuresis
992002|NCT02060318|Crohn Disease
992003|NCT02060318|Regulatory T-cells
992004|NCT02060318|Infliximab
992005|NCT02060292|COPD
992006|NCT02060292|Cognitive Function
992007|NCT02060292|MRI Brain
992008|NCT02060292|Aortic Stiffness
992009|NCT02060292|Cerebrovascular disease
992010|NCT02060279|Obesity
992011|NCT02060279|Diabetes Mellitus
992012|NCT02060279|Diabetes Mellitus, Type 2
992013|NCT02060279|Prevention
992014|NCT02060279|Behavioral research
992015|NCT02060279|Metabolic Syndrome
992016|NCT02060279|Metabolic Disease
992017|NCT02060279|Overnutrition
992018|NCT02060279|Nutrition Disorders
992019|NCT02060279|Overweight
992020|NCT02060279|Body weight
992021|NCT02060279|Insulin resistance
992022|NCT02060279|Carotenoids
992023|NCT02060279|Dietary Supplement
992024|NCT02060279|Physical fitness
992025|NCT02060279|Sedentary lifestyle
992026|NCT02060240|Obesity
992027|NCT02060240|Prediabetic State
992028|NCT02060240|Sedentary Lifestyle
992029|NCT02060240|Insulin Resistance
992030|NCT02060240|Endothelium
992031|NCT02060240|Eicosanoids
992032|NCT02060240|Nitric Oxide
992033|NCT02060240|Regional Blood Flow
992034|NCT02060175|Optical coherence tomography, Drug-eluting stent, Strut coverage
992035|NCT02060162|antiretroviral therapy
992036|NCT02060162|Hepatitis C virus
992037|NCT02060149|Extensively Drug Resistant A. Baumannii
992038|NCT02060136|Electronic micturition chart, validation
992039|NCT02060123|Qigong
992040|NCT02060123|Telomerase
992041|NCT02060123|Perceived stress
992042|NCT02060123|RCT
992043|NCT02060123|Chinese
992044|NCT02060123|Abused women
992045|NCT02060123|intervention
992046|NCT02060123|Depression
992047|NCT02060110|CRT
992048|NCT02060110|HEART FAILURE
992049|NCT02060097|Anti-aging
992050|NCT02060097|High-flavanol cocoa
992051|NCT02060084|preterm;
992052|NCT02060084|Intestinal flora;
992053|NCT02060084|early Micro-feeding
992054|NCT02060084|Feeding intolerance
992055|NCT02060071|aortic stenosis
992056|NCT02060058|hepatitis C virus
992057|NCT02060058|hepatitis B virus
992058|NCT02060058|boceprevir
992059|NCT02060058|null responder
992060|NCT02060058|partial responder
992061|NCT02060058|relapser
992062|NCT02060045|bundle
992063|NCT02060045|prevention
992064|NCT02060045|Disturbance; Heart, Functional, Postoperative, Cardiac Surgery
992065|NCT02060032|Chronic periodontitis, Local drug delivery,
992066|NCT02060019|Pharmacokinetics
992067|NCT02060019|Pharmacodynamics
992068|NCT02060019|Safety
992069|NCT02060019|Tolerability
992070|NCT02060006|TB
992071|NCT02060006|IRIS
992072|NCT02059993|continuous positive airway pressure
992073|NCT02059993|hypertension
992074|NCT02059993|coronary heart disease
992075|NCT02059993|metabolic disorder
992076|NCT02059993|obstructive sleep apnea
992077|NCT02059980|OCD
992078|NCT02059980|Trichotillomania
992079|NCT02059980|Response inhibition
992080|NCT02059980|Cognitive training
992081|NCT02059967|Lung
992082|NCT02059954|Hysterectomy
992083|NCT02059941|Severe traumatic brain injury, ICP, Latin America, outcomes
992084|NCT02059928|fluid resuscitation
992085|NCT02059928|invasive pressure monitoring
992086|NCT02059915|pharmacokinetics
992087|NCT02059915|bioequivalence
992088|NCT02059915|bioavailability
992089|NCT02059915|oxycodone
992090|NCT02059902|Pain management
992091|NCT02059902|Narcotic consumption
992092|NCT02059902|Skin graft
992093|NCT02059889|Lung
992094|NCT02059876|breast cancer
992095|NCT02059876|dose dense
992096|NCT02059876|neoadjuvant treatment
992097|NCT02059876|pathologic complete response
992098|NCT02059863|cluster randomised trial
992099|NCT02059863|low and middle income countries
992100|NCT02059863|community based intervention
992101|NCT02059863|complex intervention
992102|NCT02059824|Eyelid sensation, aesthesiometer
992103|NCT02059811|Kidney Diseases
992104|NCT02059811|Renal Insufficiency, Chronic
992105|NCT02059811|Diet
992106|NCT02059811|DASH diet
992107|NCT02059811|Hypertension
992108|NCT02059811|Vascular diseases
992109|NCT02059811|Cardiovascular Diseases
992110|NCT02059811|Blood pressure
992111|NCT02059798|Myelopathy
992112|NCT02059785|Pinocembrin for Injection
992113|NCT02059785|Placebo
992114|NCT02059785|mRS
992115|NCT02059759|low-dose interleukin 2
992116|NCT02059746|cesarean section
992117|NCT02059746|vaginal birth
992118|NCT02059746|twins
992119|NCT02059746|urinary incontinence
992120|NCT02059746|sexuality
992121|NCT02059746|quality of life
992122|NCT02059733|18F-DTBZ
992123|NCT02059720|acute myeloid leukemia
992124|NCT02059720|allogeneic hematopoietic stem cell transplantation
992125|NCT02059720|autologous hematopoietic stem cell transplantation
992126|NCT02059720|maintenance treatment
992127|NCT02059720|hematopoietic stem cell transplantation
992128|NCT02059694|Eyelid surgery
992129|NCT02059694|local block/anesthesia
992130|NCT02059694|hyaluronidase
992131|NCT02059694|Bilateral upper eyelid surgery
992132|NCT02059694|Duke Eye Centre
992133|NCT02059694|Duke Aesthetic Center
992134|NCT02059668|locally advanced head and neck cancer
992135|NCT02059668|biomarkers
992136|NCT02059668|definitive treatment
992137|NCT02059668|adjuvant treatment
992138|NCT02059668|radiochemotherapy
992139|NCT02059655|Graves' disease
992140|NCT02059629|Heart failure
992141|NCT02059629|Eluna pacemaker family
992142|NCT02059629|Sentus OTW BP L left ventricular lead
992143|NCT02059629|Bradycardia
992144|NCT02059629|SADE-free rate
992145|NCT02059603|Electroacupuncture
992146|NCT02059603|Fast track program
992147|NCT02059603|Postoperative ileus
992148|NCT02059603|Laparoscopic surgery
992149|NCT02059603|Colorectal surgery
992150|NCT02059603|Randomized controlled trial
992151|NCT02059603|Hospital stay
992152|NCT02059590|14C-labeled isavuconazonium sulfate
992153|NCT02059590|Pyridinylmethyl-14C-labeled isavuconazonium sulfate
992154|NCT02059590|Healthy Subjects
992155|NCT02059590|BAL8728
992156|NCT02059590|BAL4815
992157|NCT02059577|vitamins
992158|NCT02059577|minerals
992159|NCT02059577|essential fatty acids
992160|NCT02059577|Epsom salts
992161|NCT02059577|carnitine
992162|NCT02059577|digestive enzymes
992163|NCT02059577|gluten-free casein-free diet
992164|NCT02059564|Diabetes Mellitus
992165|NCT02059564|Diabetes Mellitus, Type 2
992166|NCT02059564|Glucose Metabolism Disorders
992167|NCT02059564|Metabolic Diseases
992168|NCT02059564|Endocrine System Diseases
992169|NCT02059564|Exendin-4
992170|NCT02059551|pulmonary embolism
992171|NCT02059551|magnetic resonance imaging
992172|NCT02059551|venous ultrasonography of the legs
992173|NCT02059551|diagnostic performances
992174|NCT02059538|Obesity
992175|NCT02059538|Type 2 diabetes
992176|NCT02059538|Coronary artery diseases
992177|NCT02059538|Microbiota
992178|NCT02059538|Omics (ie transcriptomics, metabolomics, metagenomics, lipidomics)
992179|NCT02059525|observational
992180|NCT02059525|Belgium
992181|NCT02059512|ischemic heart disease,
992182|NCT02059512|autologous bone marrow mononuclear cells
992183|NCT02059512|coronary artery bypass grafting
992184|NCT02059460|Terlipressin
992185|NCT02059460|Acute kidney injury
992186|NCT02059460|Liver transplantation
992187|NCT02059460|NGAL
992188|NCT02059447|Controlled trial
992189|NCT02059447|Active control
992190|NCT02059447|Waiting, non treatment, period
992191|NCT02059447|Mindfulness Based Cognitive Therapy
992192|NCT02059447|Relaxation Therapy
992193|NCT02059421|Johrei therapy
992194|NCT02059421|Sleep
992195|NCT02059421|CBT-I
992196|NCT02059421|Critical illness
992197|NCT02059382|daily physical activity
992198|NCT02059382|exercise
992199|NCT02059382|social support
992200|NCT02059382|online social network
992201|NCT02059369|Atrial fibrillation
992202|NCT02059369|Recurrence
992203|NCT02059369|CFAE
992204|NCT02059369|linear ablation
992205|NCT02059356|Dementia
992206|NCT02059356|Alzheimer's
992207|NCT02059356|Alzheimers
992208|NCT02059356|Cognitive decline
992209|NCT02059356|Cognitive impairment
992210|NCT02059356|Memory loss
992211|NCT02059356|Memory disorder
992212|NCT02059356|Forgetfulness
992213|NCT02059356|Confusion
992214|NCT02059356|Senile
992215|NCT02059356|Demented
992216|NCT02059356|Developmental delay
992217|NCT02059356|Portal systemic shunting
992218|NCT02059356|High ammonia level
992219|NCT02059356|Elevated ammonia level
992220|NCT02059343|pharmacokinetics
992221|NCT02059343|pharmacodynamics
992222|NCT02059343|safety
992223|NCT02059343|dexmedetomidine
992224|NCT02059343|cardiopulmonary bypass
992225|NCT02059343|children
992226|NCT02059330|Japanese PK-Bridging Study
992227|NCT02059330|dose-proportionality study
992228|NCT02059330|Palbociclib
992229|NCT02059330|PD-0332991
992230|NCT02059330|healthy volunteers
992231|NCT02059304|cervical length
992232|NCT02059304|prediction of preterm delivery
992233|NCT02059291|Canakinumab, interleukin-1, Hereditary Periodic Fevers, auto-inflammatory diseases
992234|NCT02059278|Primary open angle glaucoma
992235|NCT02059278|Ocular hypertension
992236|NCT02059239|NHL
992237|NCT02059239|HL
992238|NCT02059239|Lymphoma
992239|NCT02059200|Randomised controlled trial
992240|NCT02059200|Recurrent depression
992241|NCT02059200|Mindfulness training
992242|NCT02059200|Compassion training (MBCL)
992243|NCT02059200|Fear of Compassion
992244|NCT02059200|Added value Compassion
992245|NCT02059135|Preeclampsia
992246|NCT02059135|Preterm preeclampsia
992247|NCT02059135|Pregnancy
992248|NCT02059109|Belmont
992249|NCT02059109|Rapid
992250|NCT02059109|Infuser
992251|NCT02059109|proficiency
992252|NCT02059109|proficient
992253|NCT02059109|training
992254|NCT02059096|Multiple Sclerosis
992255|NCT02059096|Repetitive transcranial magnetic stimulation (rTMS)
992256|NCT02059096|Chronic neuropathic pain
992257|NCT02059096|Cortical excitability
992258|NCT02059083|adolescent
992259|NCT02059083|cannabis
992260|NCT02059083|biofeedback
992261|NCT02059070|Nerve Block/adverse effects
992262|NCT02059070|Phrenic Nerve
992263|NCT02059070|Respiratory function
992264|NCT02059070|Pain measurement
992265|NCT02059044|patient safety
992266|NCT02059044|pharmacoepidemiology
992267|NCT02059044|health services research
992268|NCT02059044|adherence
992269|NCT02059044|information technology
992270|NCT02059031|integrase inhibitor
992271|NCT02059031|pharmacokinetics
992272|NCT02059031|HIV
992273|NCT02059031|relative bioavailability
992274|NCT02059031|food
992275|NCT02059031|GSK1265744
992276|NCT02059005|Addiction
992277|NCT02059005|Substance Use Disorder
992278|NCT02059005|Rehospitalization
992279|NCT02059005|Community Disease Management
992280|NCT02059005|Behavioral Health
992281|NCT02059005|Community Health Worker
992282|NCT02058992|Drug therapy
992283|NCT02058966|Entacapone
992284|NCT02058966|COMT val158met
992285|NCT02058966|Methamphetamine
992286|NCT02058953|Melanoma
992287|NCT02058953|skin cancer
992288|NCT02058953|brain metastases
992289|NCT02058953|craniotomy
992290|NCT02058927|HIV
992291|NCT02058927|ART
992292|NCT02058927|children
992293|NCT02058914|Sugar sweetened beverages
992294|NCT02058914|metabolism
992295|NCT02058914|endocrine
992296|NCT02058914|lipids
992297|NCT02058914|blood glucose
992298|NCT02058901|sunitinib
992299|NCT02058901|solid tumors
992300|NCT02058888|metagenomics
992301|NCT02058888|antimicrobial resistance
992302|NCT02058888|multidrug resistance
992303|NCT02058849|Mucositis
992304|NCT02058849|Beetroot
992305|NCT02058849|Head and neck cancer
992306|NCT02058836|Chronic testicular pain
992307|NCT02058836|Orchialgia
992308|NCT02058836|Botulinum toxin
992309|NCT02058836|Botox
992310|NCT02058836|Urology
992311|NCT02058823|Hypoxia
992312|NCT02058823|Sleep apnea
992313|NCT02058823|Valsartan
992314|NCT02058823|Amlodipine
992315|NCT02058823|Healthy subjects
992316|NCT02058823|Randomized
992317|NCT02058823|Cross-over
992318|NCT02058823|International
992319|NCT02058823|Sympathetic nervous system
992320|NCT02058810|nasal high flow oxygen
992321|NCT02058810|cardio-renal syndrom
992322|NCT02058810|heartfailure
992323|NCT02058797|Procrastination
992324|NCT02058797|Coherence Therapy
992325|NCT02058797|Cognitive Behavioral Therapy
992326|NCT02058797|Repertory Grid Technique
992327|NCT02058797|Cognitive Conflicts
992328|NCT02058797|Personal Dilemmas
992329|NCT02058771|Action potential duration restitution
992330|NCT02058771|Ventricular arrhythmia
992331|NCT02058771|Sudden cardiac death
992332|NCT02058771|Body-surface potential mapping
992333|NCT02058771|Electrocardiogram
992334|NCT02058758|Breast cancer
992335|NCT02058758|Magnetic resonance spectroscopy
992336|NCT02058758|Diffusion weighted imaging
992337|NCT02058745|Neuro-oncology
992338|NCT02058745|Caregivers
992339|NCT02058745|Intervention Research
992340|NCT02058745|Representational Approach
992341|NCT02058745|Cognitive Behavioral Therapy
992342|NCT02058745|Family
992343|NCT02058745|Internet
992344|NCT02058680|prostate specific antigen (PSA)
992345|NCT02058667|Breast Cancer
992346|NCT02058667|Paclitaxel
992347|NCT02058667|Helical Tomotherapy
992348|NCT02058667|Chest wall
992352|NCT02058641|cellular accumulation
992353|NCT02058641|macrophage phenotype
992354|NCT02058641|cantharidin blister
992355|NCT02058641|M1/M2
992356|NCT02058641|inflammatory mediators
992357|NCT02058641|Type 2 diabetes mellitus
992358|NCT02058641|darapladib
992359|NCT02058641|cytokines
992360|NCT02058628|azelaic acid
992361|NCT02058628|Clindamycin
992362|NCT02058628|Benzoyl peroxide
992363|NCT02058628|Acne vulgaris
992364|NCT02058615|Male caregivers
992365|NCT02058615|Breast cancer
992366|NCT02058615|Intervention
992367|NCT02058615|Online toolkit
992368|NCT02058602|HRCT
992369|NCT02058602|Airway morphometry
992370|NCT02058602|Resistivity
992371|NCT02058602|Inhalation Profiles
992372|NCT02058602|Inhaler
992373|NCT02058602|Pharyngometry
992374|NCT02058602|Idiopathic Pulmonary Fibrosis (IPF)
992375|NCT02058589|Immunocompromised
992376|NCT02058589|Safety
992377|NCT02058589|≥ 18 years of age
992378|NCT02058589|Renal transplant
992379|NCT02058589|Adults
992380|NCT02058589|Immunosuppressed
992381|NCT02058589|Immunogenicity
992382|NCT02058589|Herpes zoster
992383|NCT02058576|combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
992384|NCT02058576|Tamsulosin
992385|NCT02058576|healthy subject
992386|NCT02058576|bioequivalence
992387|NCT02058576|GI198745
992388|NCT02058576|dutasteride
992389|NCT02058576|tamsulosin hydrochloride
992390|NCT02058563|Measles, mumps and rubella diseases
992391|NCT02058563|Safety
992392|NCT02058563|Immunogenicity
992393|NCT02058524|Ulcerative Colitis
992394|NCT02058524|Fecal Microbiota Transplantation
992395|NCT02058498|Liver transplant
992396|NCT02058498|Physical Activity
992397|NCT02058498|Quality of Life
992398|NCT02058485|hypertension
992399|NCT02058485|dexmedetomidine
992400|NCT02058485|midazolam
992401|NCT02058485|premedication
992402|NCT02058459|Chronic obstructive pulmonary disease, targeted lung denervation, intervention, device, safety, lung function, Holaira
992403|NCT02058433|Chemotherapy
992404|NCT02058433|Individual Paclitaxel dose
992405|NCT02058433|pharmacokinetics
992406|NCT02058420|bone health
992407|NCT02058407|food effect
992408|NCT02058407|pharmacokinetics
992409|NCT02058407|GSK2793660
992410|NCT02058407|FTIH
992411|NCT02058407|pharmacodynamics
992412|NCT02058407|safety
992413|NCT02058394|Retained nuclear lens fragments
992414|NCT02058394|Phacoemulsification
992415|NCT02058394|Cataract Surgery
992416|NCT02058368|Benign Prostatic Hyperplasia
992417|NCT02058368|Quality of Life
992418|NCT02058342|Prader Willi syndrome
992419|NCT02058342|Obesity
992420|NCT02058342|Childhood
992421|NCT02058342|Family
992422|NCT02058342|Interactive games
992423|NCT02058342|Playground games
992424|NCT02058342|Exercise routine
992425|NCT02058329|Hip fracture
992426|NCT02058329|postoperative complications
992427|NCT02058329|Depression
992428|NCT02058329|Environmental Hazards
992429|NCT02058329|FIM scores
992430|NCT02058329|Falls
992431|NCT02058303|hand surgery
992432|NCT02058303|wrist surgery
992433|NCT02058303|finger surgery
992434|NCT02058303|anesthesia
992435|NCT02058303|regional anesthesia
992436|NCT02058303|postoperative pain
992437|NCT02058290|laparoscopic colectomy
992438|NCT02058277|bosutinib
992439|NCT02058277|aprepitant
992440|NCT02058277|drug interaction
992441|NCT02058277|healthy volunteers
992442|NCT02058277|pharmacokinetics
992443|NCT02058277|chronic myelogenous leukemia
992444|NCT02058251|Alcohol
992445|NCT02058251|Oxytocin
992446|NCT02058251|Stress reactivity
992447|NCT02058238|Robotic-guided spinal fusions
992448|NCT02058238|Scoliosis
992449|NCT02058238|Kyphoscoliosis
992450|NCT02058238|Spinal deformity
992451|NCT02058238|Spondylosis
992457|NCT02058212|ICSI
992458|NCT02058212|antioxidants
992459|NCT02058212|ROS
992460|NCT02058212|endometriosis
992461|NCT02058199|gastric bypass
992462|NCT02058199|rivaroxaban
992463|NCT02058199|pharmacodynamics
992464|NCT02058186|Atopic dermatitis, vitamin D supplementation, cathelicidin, Staphylococcus aureus colonization, SCORAD score
992465|NCT02058121|Eating disorders
992466|NCT02058121|Acceptance and Commitment Therapy
992467|NCT02058121|Body image
992468|NCT02058108|Chronic hepatitis B, pediatrics, antiviral treatment, telbivudine
992469|NCT02058082|Failure to Conceive Due to Infertility of Male Partner
992470|NCT02058082|DNA Damage
992471|NCT02058056|Early prophylactic
992472|NCT02058056|cranial irradiation
992473|NCT02058056|hippocampal avoidance
992474|NCT02058056|limited disease small-cell lung cancer
992475|NCT02058030|ProSeal laryngeal mask airway
992476|NCT02058030|Insertion success
992477|NCT02058030|complication
992478|NCT02058004|Microaspiration
992479|NCT02058004|ARDS
992480|NCT02058004|Hospital acquired pneumonia
992481|NCT02058004|Cricoid pressure
992482|NCT02057978|Late Lumen Loss
992483|NCT02057978|MACE
992484|NCT02057978|Death
992485|NCT02057978|TLF
992486|NCT02057978|Thrombosis(definite or probable )
992487|NCT02057965|Mesenchymal Stromal Cells
992488|NCT02057965|Allograft rejection
992489|NCT02057965|Fibrosis
992490|NCT02057952|Weight Management
992491|NCT02057952|Diabetes
992492|NCT02057952|Exercise
992493|NCT02057952|Portion Control
992494|NCT02057952|Multiple Chronic Conditions
992495|NCT02057939|Prostate cancer
992496|NCT02057939|enzalutamide
992497|NCT02057939|ADT
992498|NCT02057939|radiation
992499|NCT02057926|Membrane degradation
992500|NCT02057926|Collagen membrane bio-durability
992501|NCT02057913|Penile neoplasms
992502|NCT02057913|Chemotherapy
992503|NCT02057913|Vinflunine
992504|NCT02057913|Phase II
992505|NCT02057900|Postinfarction heart failure
992506|NCT02057900|Transplantation of human embryonic stem cell-derived cardiac progenitors
992507|NCT02057900|Tissue-engineered cellular graft
992508|NCT02057900|Fibrin hydrogel
992509|NCT02057861|diabetes mellitus
992510|NCT02057861|neuromuscular blockade
992511|NCT02057861|sugammadex
992512|NCT02057848|carbohydrate, hypoglycemia
992513|NCT02057822|Vernal keratoconjunctivitis
992514|NCT02057822|Cytokines
992515|NCT02057822|Mediators
992516|NCT02057822|Tears
992517|NCT02057809|Developmental Disabilities
992518|NCT02057809|Family-centered services
992519|NCT02057809|Pediatric rehabilitation
992520|NCT02057796|HIV-1
992521|NCT02057796|Tuberculosis
992522|NCT02057796|Systematic empiric TB treatment
992523|NCT02057796|ART
992524|NCT02057796|TB diagnosis
992525|NCT02057796|Xpert MTB/RIF®
992526|NCT02057796|Urine LAM
992527|NCT02057744|Robotic-guided surgery
992528|NCT02057744|Minimally invasive spinal surgery
992529|NCT02057744|Spinal fusion
992530|NCT02057744|Pedicle screws
992531|NCT02057705|MTM
992532|NCT02057705|myotubular myopathy
992533|NCT02057705|X-linked centronuclear myopathy
992534|NCT02057705|inherited myopathies
992535|NCT02057705|neuromuscular diseases
992536|NCT02057705|hypotonia
992537|NCT02057705|genetic mutation
992538|NCT02057679|Acute cholecystitis.
992539|NCT02057679|Amoxicillin clavulanic
992540|NCT02057653|Goal-directed fluid management
992541|NCT02057601|Local anaesthetic infiltration
992542|NCT02057601|Fractured neck of femur
992543|NCT02057601|Postoperative pain
992544|NCT02057588|ablation
992545|NCT02057575|Open Angle Glaucoma
992546|NCT02057575|Ocular Hypertension
992547|NCT02057575|Intraocular Pressure
992548|NCT02057575|AR13324
992549|NCT02057575|PG324
992550|NCT02057562|Adenoma
992551|NCT02057562|Diverticular disease
992552|NCT02057562|Diverticulosis
992553|NCT02057562|Colorectal carcinoma
992554|NCT02057562|Polyp
992555|NCT02057536|estrogen receptor positive, aromatase inhibitors, exercise,
992556|NCT02057510|Head and Neck Cancer
992557|NCT02057510|Radiation Therapy
992558|NCT02057484|long-term follow-up
992559|NCT02057484|liver transplant
992560|NCT02057484|kidney transplant
992561|NCT02057484|Advagraf
992562|NCT02057471|Adenocarcinoma
992563|NCT02057471|Anemia
992564|NCT02057471|Blood Transfusion
992565|NCT02057471|Colorectal surgery
992566|NCT02057471|Preoperative care
992567|NCT02057471|Perioperative care
992568|NCT02057471|Postoperative care
992569|NCT02057471|Iron
992570|NCT02057471|Hematinics
992571|NCT02057471|Hepcidin
992572|NCT02057471|Quality of life
992573|NCT02057471|Postoperative complications
992574|NCT02057458|arterial stiffness
992575|NCT02057458|flow-mediated dilation
992576|NCT02057458|endothelial function
992577|NCT02057458|pulse wave velocity
992578|NCT02057458|inflammation
992579|NCT02057458|oxidative stress
992580|NCT02057458|pulmonary function test
992581|NCT02057458|Cystic Fibrosis
992582|NCT02057458|Lung Disease
992583|NCT02057458|Nitric Oxide
992584|NCT02057458|Exercise Capacity
992585|NCT02057458|CF
992586|NCT02057458|Muscle Function
992587|NCT02057458|Sildenafil
992588|NCT02057458|Viagra
992589|NCT02057458|Revatio
992590|NCT02057445|cellular therapy
992591|NCT02057445|lymphoma
992592|NCT02057445|lymphoproliferative disorder
992593|NCT02057432|I-II Breast Cancer
992594|NCT02057419|contraception
992595|NCT02057419|contraceptive methods
992596|NCT02057419|sexual lubricant
992597|NCT02057419|user experience
992598|NCT02057419|adherence
992599|NCT02057419|User experience: impact on use of contraceptive methods
992600|NCT02057419|User experience: impact on use of sexual lubricants
992601|NCT02057393|Melanoma
992602|NCT02057393|Sentinel node biopsy
992603|NCT02057393|Indocyanine green
992604|NCT02057393|Real time lymphangiography
992605|NCT02057380|Paclitaxel
992606|NCT02057380|Linsitinib
992607|NCT02057380|OSI-774
992608|NCT02057380|Advanced Solid Tumor
992609|NCT02057380|Tarceva
992610|NCT02057380|Erlotinib
992611|NCT02057380|OSI-906
992612|NCT02057367|supratentorial brain tumour
992613|NCT02057367|craniotomy
992614|NCT02057354|Brain
992615|NCT02057354|Brain-Derived Neurotrophic Factor
992616|NCT02057354|Brain Mapping
992617|NCT02057354|Cognition
992618|NCT02057354|Exercise
992619|NCT02057354|Hippocampus
992620|NCT02057354|Hydrocortisone
992621|NCT02057354|Learning
992622|NCT02057354|Memory
992623|NCT02057354|Magnetic Resonance Imaging
992624|NCT02057354|Nerve Growth Factors
992625|NCT02057354|Neuroimaging
992626|NCT02057354|Physical Endurance
992627|NCT02057354|Physical Fitness
992628|NCT02057354|Resistance Training
992629|NCT02057354|Walking
992630|NCT02057341|laminopathy
992631|NCT02057315|Migraine headache
992632|NCT02057315|Photophobia
992633|NCT02057315|Phonophobia
992634|NCT02057315|Aura
992635|NCT02057315|Topical treatment
992636|NCT02057302|Xuezhikang Dyslipidemia chinese medicine RCT
992637|NCT02057289|pediatric
992638|NCT02057289|antifungal
992639|NCT02057289|bone marrow
992640|NCT02057289|AML or relapsed ALL
992641|NCT02057263|Vaccine
992642|NCT02057263|Adjuvant
992643|NCT02057263|Bisphosphonates
992644|NCT02057263|Alendronate
992645|NCT02057263|Hepatitis B vaccine
992646|NCT02057224|Renal denervation
992647|NCT02057224|Hypertension
992648|NCT02057224|Insulin resistance
992649|NCT02057224|Adipose tissue function
992650|NCT02057185|Chronic Hematological Diseases
992651|NCT02057185|work
992652|NCT02057185|job
992653|NCT02057172|glycaemic control
992654|NCT02057172|HM11260C
992655|NCT02057172|placebo
992656|NCT02057172|safety
992657|NCT02057172|tolerability
992658|NCT02057172|type 2 diabetes mellitus
992659|NCT02057172|efficacy
992660|NCT02057172|T2DM
992661|NCT02057172|glycated haemoglobin (HbA1c)
992662|NCT02057172|glycosylated haemoglobin (HbA1c)
992663|NCT02057172|Glucagon-Like Peptide-1 (GLP-1) agonists
992664|NCT02057172|blood sugar levels
992665|NCT02057172|fasting plasma glucose (FPG)
992666|NCT02057159|Secondary Progress Multiple Sclerosis
992667|NCT02057159|SPMS
992668|NCT02057159|Multiple Sclerosis
992669|NCT02057159|NeuroVax
992670|NCT02057146|PSC
992671|NCT02057146|mother-baby endoscopy
992672|NCT02057146|ERCP
992673|NCT02057146|IPMN
992674|NCT02057120|Kinesio Taping, Soccer, Hop Test, Electromyography, Athletic Performance, Muscle Strength Dynamometer
992675|NCT02057081|Stress Disorders, Post-traumatic
992676|NCT02057081|Mild Traumatic Brain Injury
992677|NCT02057081|Veterans Health
992678|NCT02057081|Veterans
992679|NCT02057081|Spouses
992680|NCT02057081|Couples
992681|NCT02057081|Psychotherapy, Group
992682|NCT02057081|Depression
992683|NCT02057081|Couples Therapy
992684|NCT02057081|Family Therapy
992685|NCT02057081|PTSD
992686|NCT02057081|posttraumatic stress disorder
992687|NCT02057068|Caregivers
992688|NCT02057068|Telemedicine
992689|NCT02057068|Sleep Disorders
992690|NCT02057068|Meditation
992691|NCT02057068|Dementia
992692|NCT02057068|Cognitive Behavioral Therapy
992693|NCT02057068|Exercise
992694|NCT02057068|Technology
992695|NCT02057055|Antibacterial soaps
992696|NCT02057055|Microbiome
992697|NCT02057055|Commensal bacteria
992698|NCT02057055|Pyrosequencing
992699|NCT02057055|Innate immunity
992700|NCT02057042|Peer Support
992701|NCT02057042|cCBT
992702|NCT02057042|primary care
992703|NCT02057029|Estrogen Receptor (ER) Positive
992704|NCT02057029|Early Stage Breast Cancer
992705|NCT02057029|Breast Cancer Index
992706|NCT02057003|HIV
992707|NCT02057003|hepatitis C virus
992708|NCT02057003|sustained virologic response
992709|NCT02057003|telaprevir
992710|NCT02057003|boceprevir
992711|NCT02057003|simeprevir
992712|NCT02057003|sofosbuvir
992713|NCT02057003|daclatasvir
992714|NCT02057003|paritaprevir
992715|NCT02057003|pegylated interferon
992716|NCT02057003|ribavirin
992717|NCT02057003|direct-acting antivirals
992718|NCT02057003|dasabuvir
992719|NCT02057003|ombitasvir
992720|NCT02057003|ledipasvir
992721|NCT02057003|velpatasvir
992722|NCT02057003|grazoprevir
992723|NCT02057003|elbasvir
992724|NCT02056990|Athletes
992725|NCT02056977|Acute Respiratory Distress Syndrome
992726|NCT02056977|Cardiac Surgical Procedure
992727|NCT02056977|Mechanical Ventilation
992728|NCT02056977|Postoperative Complications
992729|NCT02056977|Positive End-Expiratory Pressure
992730|NCT02056977|Lung Collapse
992731|NCT02056977|Respiratory Failure
992732|NCT02056977|Electrical Impedance Tomography
992733|NCT02056964|Acute Coronary Syndrome
992734|NCT02056964|Chest Pain
992735|NCT02056964|Risk Stratification
992736|NCT02056964|Clinical Decision Aid
992737|NCT02056964|Emergency Department
992738|NCT02056964|Low Risk Chest Pain
992739|NCT02056964|Non Cardiac Chest Pain
992740|NCT02056951|Rehabilitation
992741|NCT02056951|Treatment Outcome
992742|NCT02056951|Interprofessional Relations
992743|NCT02056951|Interdisciplinary Communication
992744|NCT02056951|Behavioural Exercise Therapy
992745|NCT02056951|Cognitive Therapy
992746|NCT02056951|Health Education
992747|NCT02056951|Workplace related information
992748|NCT02056951|Multicenter Study
992749|NCT02056938|Transplantation
992750|NCT02056938|kidney
992751|NCT02056938|delayed graft function
992752|NCT02056938|induction therapy
992753|NCT02056938|personalized medicine
992754|NCT02056938|First kidney transplantation
992755|NCT02056938|No anti HLA immunization prior transplantation
992756|NCT02056938|Risk of DGF higher than 40% calculated byt he score DGFS
992757|NCT02056912|lipodystrophy
992758|NCT02056912|gene
992759|NCT02056912|inborn error of metabolism
992760|NCT02056899|Preterm labor, premature birth, gabapentin
992761|NCT02056886|breast cancer, sentinel lymph node, extemporaneous, OSNA
992762|NCT02056873|deep brain stimulation
992763|NCT02056873|DBS
992764|NCT02056873|tourette
992765|NCT02056873|tourette's
992766|NCT02056873|tourette syndrome
992767|NCT02056873|TS
992768|NCT02056860|cystic fibrosis
992769|NCT02056847|Livalo, pitavastatin, hyperlipidemia, IFG
992770|NCT02056821|stroke
992771|NCT02056821|transcranial doppler
992772|NCT02056821|cerebral blood flow
992773|NCT02056821|cardiac output
992774|NCT02056821|non-invasive hemodynamic monitoring
992775|NCT02056782|Acute Myeloid Leukemia
992776|NCT02056782|AML
992777|NCT02056782|ODSH
992778|NCT02056782|ODSH-AML
992779|NCT02056782|Cantex
992780|NCT02056756|REFRACTORY OR RELAPSED
992781|NCT02056756|CBD
992782|NCT02056730|chronic hemodialysis patients
992783|NCT02056730|Hyperparathyroidism
992784|NCT02056730|Regpara
992785|NCT02056730|FGF 23
992786|NCT02056704|Dialysis Fistula
992787|NCT02056704|Dialysis Graft
992788|NCT02056704|Stenosis
992789|NCT02056704|Intravascular Ultrasound
992790|NCT02056704|Angiography
992791|NCT02056691|Resectable
992792|NCT02056691|non-metastatic
992793|NCT02056691|colorectal
992794|NCT02056691|carcinoma
992795|NCT02056691|cancer
992796|NCT02056691|neoplasm
992797|NCT02056691|exercise
992798|NCT02056691|effects
992799|NCT02056691|program
992800|NCT02056691|pre-operative
992801|NCT02056691|proliferation
992802|NCT02056691|diagnosed
992803|NCT02056691|surgery
992804|NCT02056691|biopsy
992805|NCT02056691|muscle
992806|NCT02056691|signalling
992807|NCT02056691|IGF1
992808|NCT02056691|ki67
992809|NCT02056691|p53
992810|NCT02056691|response
992811|NCT02056691|training
992812|NCT02056691|biochemical
992813|NCT02056691|pathways
992814|NCT02056691|glucose
992815|NCT02056678|cholecystitis
992816|NCT02056678|cholelithiasis
992817|NCT02056678|obstructive sleep apnea
992818|NCT02056678|acetaminophen
992819|NCT02056665|Angelman Syndrome
992820|NCT02056665|EFFICACY
992821|NCT02056665|SAFETY
992822|NCT02056665|MINOCYCLINE
992823|NCT02056665|Pediatrics population
992824|NCT02056665|Rare diseases
992825|NCT02056652|Preterm birth
992826|NCT02056652|Preterm delivery
992827|NCT02056652|short cervix
992828|NCT02056652|pessary
992829|NCT02056639|Premature birth
992830|NCT02056639|Premature delivery
992831|NCT02056639|Short cervix
992832|NCT02056639|Pessary
992833|NCT02056626|hypertension
992834|NCT02056613|Blood Donation
992835|NCT02056613|Tissue Procurement
992836|NCT02056613|Cellular Therapies
992837|NCT02056587|renal cell carcinoma
992838|NCT02056587|kidney cancer
992839|NCT02056587|bevacizumab failure
992840|NCT02056587|everolimus
992841|NCT02056574|Endovascular repair
992842|NCT02056574|Subarachnoid hemorrhage
992843|NCT02056574|Ruptured intracranial aneurysm
992844|NCT02056574|Stroke
992845|NCT02056574|Coiling
992846|NCT02056574|NA-1
992847|NCT02056561|Anesthesia
992848|NCT02056561|Oxidants
992849|NCT02056561|Antioxidants
992850|NCT02056548|preemptive antiviral treatment
992851|NCT02056548|lymphoma
992852|NCT02056548|chronic hepatitis B
992853|NCT02056535|Alcohol
992854|NCT02056535|SBIRT (Screening, Brief Intervention, Referral to Treatment)
992855|NCT02056522|Melanoma
992856|NCT02056522|Skin Cancer
992857|NCT02056509|cardiopulmonary resuscitation,Ventilation
992858|NCT02056496|Pomegranate
992859|NCT02056496|Ellagic acid
992860|NCT02056496|Pharmacokinetics
992861|NCT02056496|Urolithins
992862|NCT02056496|Bioavailability
992863|NCT02056483|neoplasms
992864|NCT02056483|rehabilitation
992865|NCT02056483|anxiety
992866|NCT02056483|depression
992867|NCT02056483|adverse effects
992868|NCT02056483|health behavior
992869|NCT02056457|Responsible fatherhood
992870|NCT02056457|Healthy marriage
992871|NCT02056457|Healthy relationships
992872|NCT02056457|Parenting
992873|NCT02056457|Economic self-sufficiency
992874|NCT02056444|Blood conservation
992875|NCT02056444|Tranexamic acid
992876|NCT02056444|Total hip arthroplasty
992877|NCT02056431|Diabetes
992878|NCT02056431|Neuropathy
992879|NCT02056431|Patient-Reported Outcomes
992880|NCT02056405|Postoperative Ileus
992881|NCT02056405|Mosapride
992882|NCT02056405|Colorectal laparoscopic surgery
992883|NCT02056405|Prolonged postoperative ileus
992884|NCT02056392|Phase I, healthy, pharmacokinetics
992885|NCT02056379|stridor
992886|NCT02056379|laryngitis
992887|NCT02056379|budesonide
992888|NCT02056379|dexamethasone
992889|NCT02056379|children
992890|NCT02056366|Cardiac Autonomic Neuropathy
992891|NCT02056353|Software
992892|NCT02056353|Algorithm
992893|NCT02056353|Cardiac surgery
992894|NCT02056327|Oral Appliance
992895|NCT02056262|Bacteria
992896|NCT02056262|microbial community
992897|NCT02056262|hygiene
992898|NCT02056249|hypoglycemia
992899|NCT02056249|Positron Emission Tomography
992900|NCT02056249|norepinephrine transporter
992901|NCT02056236|Cardiac arrest
992902|NCT02056236|Postanoxic encephalopathy
992903|NCT02056236|Electroencephalographic status epilepticus
992904|NCT02056236|EEG monitoring
992905|NCT02056236|Anti-epileptic drugs
992910|NCT02056210|Stem cells
992911|NCT02056210|Bone marrow
992912|NCT02056171|delirium
992913|NCT02056171|pediatrics
992914|NCT02056171|critical care
992915|NCT02056171|quetiapine
992916|NCT02056158|HIV
992917|NCT02056158|COPD
992918|NCT02056158|Emphysema
992919|NCT02056158|Smoking
992920|NCT02056119|Ventilators, mechanical
992921|NCT02056119|Aerosol Drug Therapy
992922|NCT02056119|Nebulizers
992923|NCT02056119|Equipment Contamination
992924|NCT02056119|vibrating mesh nebulizer
992925|NCT02056119|jet nebulizer
992926|NCT02056119|mechanical ventilation
992927|NCT02056119|ventilator associated event
992928|NCT02056119|ventilator associated tracheobronchitis
992929|NCT02056106|depression, Uganda, HIV, task-shifting, condom use, adherence
992930|NCT02056093|NAVA - PAV- Breathing Variability - Asynchrony
992931|NCT02056080|Breast Neoplasm
992932|NCT02056080|Receptor,HER2
992933|NCT02056080|Antineoplastic agent
992934|NCT02056080|Antibodies, monoclonal
992935|NCT02056080|Trastuzumab, Lapatinib
992936|NCT02056080|Protein kinase inhibitors
992937|NCT02056080|quinazolines
992938|NCT02056054|Autoimmune hepatitis
992939|NCT02056054|Liver transplantation
992940|NCT02056054|Hepatitis C
992941|NCT02056002|Peer-driven intervention
992942|NCT02056002|Interactive voice response system
992943|NCT02056002|Continuous Positive Airway Pressure therapy and adherence
992944|NCT02055976|PF-04950615
992945|NCT02055976|Japan
992946|NCT02055963|Head And Neck Cancer
992947|NCT02055963|Postsurgical symptom reduction
992948|NCT02055963|Minocycline
992949|NCT02055963|Dynacin
992950|NCT02055963|Minocin
992951|NCT02055963|Minocin PAC
992952|NCT02055963|Myrac
992953|NCT02055963|Solodyn
992954|NCT02055963|Placebo
992955|NCT02055963|Sugar pill
992956|NCT02055963|Questionnaires
992957|NCT02055963|Surveys
992958|NCT02055950|Kidney transplant
992959|NCT02055950|Marginal donors
992960|NCT02055950|Pulse perfusion
992961|NCT02055950|Graft function
992962|NCT02055937|mastectomy, reconstruction
992963|NCT02055924|Bruton's tyrosine kinase (BTK) Inhibition in B-cell Lymphomas
992964|NCT02055911|diabetic macular edema
992965|NCT02055911|intravitreal ranibizumab
992966|NCT02055911|f retinal ganglion cell
992967|NCT02055872|Edema
992968|NCT02055872|Hypoproteinemia
992969|NCT02055872|Albumin
992970|NCT02055872|Diuresis
992971|NCT02055872|Critical illness
992972|NCT02055859|acoustic neuromas
992973|NCT02055859|radiosurgery
992974|NCT02055859|hearing preservation
992975|NCT02055846|Androgen-independent prostate cancer
992976|NCT02055807|Atelectasis
992977|NCT02055807|Ultrasound
992978|NCT02055807|Recruitment maneuver
992979|NCT02055807|Positive end-expiratory pressure
992980|NCT02055794|perineal wound
992981|NCT02055794|perineal tear
992982|NCT02055794|perineum
992983|NCT02055794|pain
992984|NCT02055794|childbirth
992985|NCT02055781|Myelofibrosis
992986|NCT02055781|Post-Polycythemia Vera Myelofibrosis
992987|NCT02055781|Post-Essential Thrombocythemia Myelofibrosis
992988|NCT02055781|Primary Myelofibrosis
992989|NCT02055781|Polycythemia
992990|NCT02055781|Polycythemia Vera
992991|NCT02055781|Thrombocythemia, Essential
992992|NCT02055781|Thrombocythemia
992993|NCT02055781|Myeloproliferative Disorders
992994|NCT02055781|Bone Marrow Disease
992995|NCT02055781|Hematologic Diseases
992996|NCT02055781|Blood Platelet Disorders
992997|NCT02055781|Hemorrhagic Disorders
992998|NCT02055781|Splenomegaly
992999|NCT02055781|Pacritinib
993000|NCT02055781|MPN-SAF
993001|NCT02055781|MPN-SAF TSS
993002|NCT02055781|Anemia
993003|NCT02055781|Myeloproliferative
993004|NCT02055781|Myeloproliferative Neoplasm
993005|NCT02055781|Spleen
993006|NCT02055781|Spleen volume
993007|NCT02055781|Thrombocytopenia
993008|NCT02055781|SB1518
993009|NCT02055755|Diabetes
993010|NCT02055755|Wounds
993011|NCT02055755|Wound Healing
993012|NCT02055755|Diabetic Foot Ulcer
993013|NCT02055755|DFU
993014|NCT02055755|Clinical Decision Support
993015|NCT02055729|bedsore
993016|NCT02055729|bacteria
993017|NCT02055729|colonization
993018|NCT02055729|ecology
993019|NCT02055703|Healthy Subjects
993020|NCT02055690|Advanced Recurrent Ovarian Cancer
993021|NCT02055690|Pazopanib
993022|NCT02055690|Votrient
993023|NCT02055690|Fosbretabulin
993024|NCT02055677|personality profiles
993025|NCT02055677|values
993026|NCT02055677|empathy
993027|NCT02055677|quality of life
993028|NCT02055677|vegetarians
993029|NCT02055677|vegans
993030|NCT02055651|Worksite
993031|NCT02055651|Cardiovascular
993032|NCT02055651|Epidemiology
993033|NCT02055651|Risk factors
993034|NCT02055638|Intermittent Explosive Disorder
993035|NCT02055638|IED
993036|NCT02055638|Aggression
993037|NCT02055638|SRX246
993038|NCT02055638|Vasopressin 1a Receptor Antagonist
993039|NCT02055638|V1a
993040|NCT02055625|Graft-versus-host-disease
993041|NCT02055625|Immune system diseases
993042|NCT02055625|Oral
993043|NCT02055612|wet AMD
993044|NCT02055612|epidemiology
993045|NCT02055599|Wound
993046|NCT02055599|Wound Healing
993047|NCT02055599|Pressure Ulcers
993048|NCT02055599|Chronic Wounds
993049|NCT02055599|Clinical Decision Support
993050|NCT02055573|Abusive Head Trauma
993051|NCT02055573|Early Literacy
993052|NCT02055573|Parental Education
993053|NCT02055573|Low Income
993054|NCT02055560|colorectal
993055|NCT02055560|OnDose
993056|NCT02055560|MyCare
993057|NCT02055560|5-FU
993058|NCT02055560|pharmacokinetics
993059|NCT02055560|exposure
993060|NCT02055560|optimization
993061|NCT02055560|dose adjustment
993062|NCT02055521|Composite tissue allograft
993063|NCT02055521|operational tolerance
993064|NCT02055521|skin rejection
993065|NCT02055521|Hand and Face allotransplantation
993066|NCT02055508|Exercise
993067|NCT02055508|Physical Activity
993068|NCT02055508|Palliative Care
993069|NCT02055508|Lung Cancer
993070|NCT02055508|NSCLC
993071|NCT02055495|Painful flatfeet
993072|NCT02055495|Planovagus feet
993073|NCT02055495|Subtalar arthroeresis
993074|NCT02055495|Lateral column lengthening
993075|NCT02055495|Kinematic motion analysis
993076|NCT02055482|Anemia on CKD
993077|NCT02055469|Achalasia
993078|NCT02055456|Hormones
993079|NCT02055456|Androgens
993080|NCT02055456|Aplastic Anemia
993081|NCT02055456|Bone Marrow Failure Syndromes
993082|NCT02055456|Idiopathic Pulmonary Fibrosis
993083|NCT02055456|Telomere
993084|NCT02055456|Telomere Shortening
993085|NCT02055443|nuclear cardiology
993086|NCT02055443|chest pain
993087|NCT02055443|cardiac ischemia
993088|NCT02055443|shortness of breath
993089|NCT02055443|ECG
993090|NCT02055443|EKG
993091|NCT02055443|electrocardiogram
993092|NCT02055430|anuria
993093|NCT02055430|children
993094|NCT02055430|nephrostomy
993095|NCT02055430|stents
993096|NCT02055430|urinary calculi
993097|NCT02055404|astigmatism
993098|NCT02055404|toric
993099|NCT02055404|contact lenses
993100|NCT02055404|daily disposable contact lenses
993101|NCT02055404|molded mark
993102|NCT02055404|rotation mark
993103|NCT02055378|myopia
993104|NCT02055378|atropine
993105|NCT02055378|anterior chamber depth
993106|NCT02055378|auricular acupoint
993107|NCT02055378|axial length
993108|NCT02055365|Hepatitis B vaccine
993109|NCT02055326|Smoking
993110|NCT02055326|yoga
993111|NCT02055326|men
993112|NCT02055326|intervention
993113|NCT02055313|Exceptional patient
993114|NCT02055313|Cancer care
993115|NCT02055313|Lung cancer
993116|NCT02055313|Pancreatic cancer
993117|NCT02055313|Stomach cancer
993118|NCT02055313|Unexplained survival
993119|NCT02055313|still alive from 2001-2008
993120|NCT02055287|schizophrenia
993121|NCT02055287|schizoaffective disorder
993122|NCT02055274|Parkinsons
993123|NCT02055248|Genetic Counseling
993124|NCT02055248|Mobius Syndrome
993125|NCT02055248|Birth Defects
993126|NCT02055248|Congenital Malformations
993127|NCT02055248|Gene Identification
993128|NCT02055235|Brain
993129|NCT02055235|Pain
993130|NCT02055235|Yoga
993131|NCT02055222|COPD
993132|NCT02055222|Smoking
993133|NCT02055222|Idiopathic Pulmonary Fibrosis
993134|NCT02055209|Coronary Artery Calcification
993135|NCT02055209|African American
993136|NCT02055209|African-American Families
993137|NCT02055183|Registry
993138|NCT02055183|Botulinum toxin
993139|NCT02055183|Botulism Antitoxin Heptavalent- (Equine)
993140|NCT02055183|BAT®
993141|NCT02055157|Achondroplasia
993142|NCT02055157|Dwarfism
993143|NCT02055157|Bone Diseases, Developmental
993144|NCT02055157|Bone Diseases
993145|NCT02055144|NSCLC
993146|NCT02055144|VeriStrat
993147|NCT02055144|chemotherapy
993148|NCT02055144|circulating tumor cells
993149|NCT02055131|vascular access
993150|NCT02055131|hemodialysis
993151|NCT02055131|aspirin resistance
993152|NCT02055131|PFA-100
993153|NCT02055118|hunters disease
993154|NCT02055118|MPS II
993155|NCT02055118|lysosomal storage disorder
993156|NCT02055118|hunters syndrome
993157|NCT02055118|ert treatment
993158|NCT02055118|hunter's disease
993159|NCT02055118|iduronate sulfatase
993160|NCT02055118|MPS society
993161|NCT02055118|mps 2
993162|NCT02055118|enlarged adenoids
993163|NCT02055118|hunter's syndrome
993164|NCT02055118|iduronate 2 sulfatase
993165|NCT02055118|chronic ear infection
993166|NCT02055118|mucopolysaccharides
993167|NCT02055118|hunter syndrome therapy
993168|NCT02055118|hunter's syndrome treatment
993169|NCT02055118|enzyme replacement therapy
993170|NCT02055118|hunter syndrome treatment
993171|NCT02055118|elaprase
993172|NCT02055118|MPSII
993173|NCT02055118|lysosomal storage disease
993174|NCT02055118|mps diagnosis
993175|NCT02055118|mps symptoms
993176|NCT02055118|idursulfase
993177|NCT02055118|hunter disease
993178|NCT02055118|hunter's disease treatment
993179|NCT02055118|MPS2
993180|NCT02055105|Pediatric Sepsis
993181|NCT02055092|Young onset dementia
993182|NCT02055092|Quality of life
993183|NCT02055092|Specific needs
993184|NCT02055092|Healthcare resources in dementia
993185|NCT02055092|Frontotemporal dementia
993186|NCT02055092|Alzheimer's disease
993187|NCT02055092|Healthcare services
993188|NCT02055079|ADPKD
993189|NCT02055079|PKD
993190|NCT02055079|Polycystic kidney disease
993191|NCT02055079|Mammalian target of rapamycin
993192|NCT02055079|mTOR-I
993193|NCT02055079|Sirolimus
993194|NCT02055066|cancer
993195|NCT02055066|c-MET
993196|NCT02055053|Post Operative Pain
993197|NCT02055053|hernia repair
993198|NCT02055027|Sleep Apnea, Obstructive
993199|NCT02055027|Continuous Positive Airway Pressure
993200|NCT02055027|Perioperative Period
993201|NCT02055014|Endobarrier
993202|NCT02055014|Duodenal-jejunal bypass liner
993203|NCT02055014|Glucagon-like peptide-1 receptor agonist
993204|NCT02055014|Liraglutide
993205|NCT02055014|Diabesity
993206|NCT02055014|Type 2 diabetes
993207|NCT02055014|Obesity
993208|NCT02055001|gender medicine
993209|NCT02055001|platelet function
993210|NCT02055001|sex hormones
993211|NCT02055001|antiplatelet drugs
993212|NCT02055001|haemostasis
993213|NCT02054975|asthma, children, vitamin D deficiency, clinical trial
993214|NCT02054962|Pain
993215|NCT02054949|N-acetyl cysteine
993216|NCT02054949|Refractory Seizures
993217|NCT02054923|colonoscopy
993218|NCT02054923|videorecording
993219|NCT02054923|quality indicators
993220|NCT02054923|screening
993221|NCT02054923|colorectal cancer
993222|NCT02054884|Interleukin, IL2, F16, monoclonal, antibody, cytokine Paclitaxel, Merkel cell carcinoma
993223|NCT02054871|Peripheral Angioplasty
993224|NCT02054871|Remote Ischaemic Preconditioning
993225|NCT02054871|Contrast Induced Nephropathy
993226|NCT02054858|Computerized Tomography
993227|NCT02054858|Contrast enhanced
993228|NCT02054858|Acute Kidney Injury
993229|NCT02054858|Remote ischaemic preconditioning
993230|NCT02054858|RIPC
993231|NCT02054845|Body awareness therapy
993232|NCT02054845|Physical therapy
993233|NCT02054819|lung cancer
993234|NCT02054819|NSCLC
993235|NCT02054806|PD1
993236|NCT02054806|PD-1
993237|NCT02054806|PDL1
993238|NCT02054806|PD-L1
993239|NCT02054793|metastatic disease
993240|NCT02054793|non-metastatic disease
993241|NCT02054793|prostate cancer
993242|NCT02054793|castration-resistant prostate cancer
993243|NCT02054767|articaine
993244|NCT02054767|lidocaine
993245|NCT02054767|mepivacaine
993246|NCT02054767|inferior alveolar nerve block
993247|NCT02054767|irreversible pulpitis
993248|NCT02054754|Dexanabinol
993249|NCT02054754|Oral
993250|NCT02054754|Safety
993251|NCT02054754|Tolerability
993252|NCT02054754|Pharmacokinetics
993253|NCT02054728|right-heart catheterization
993254|NCT02054728|respiratory muscle training
993255|NCT02054728|inspiratory resistance
993256|NCT02054728|hemodynamics
993257|NCT02054702|Schizophrenia
993258|NCT02054702|Mental Disorders
993259|NCT02054702|Psychotic Disorders
993260|NCT02054702|Antipsychotic
993261|NCT02054702|Cognitive testing
993262|NCT02054676|mandible
993263|NCT02054676|alveolar nerve inferior
993264|NCT02054676|anatomy
993265|NCT02054676|cross-sectional
993266|NCT02054676|dental implants
993267|NCT02054676|classification
993268|NCT02054676|reliability
993269|NCT02054676|validity
993270|NCT02054663|Acute coronary syndrome
993271|NCT02054663|Coronary artery disease
993272|NCT02054663|Antiplatelet therapy
993273|NCT02054663|Ticagrelor
993274|NCT02054663|Clopidogrel
993275|NCT02054650|Chronic low back pain
993276|NCT02054650|Type 2 diabetes mellitus
993277|NCT02054650|Back pain
993278|NCT02054650|Diabetes
993279|NCT02054650|Osteopathic manual treatment
993280|NCT02054650|Osteopathic manipulative treatment
993281|NCT02054650|OMT
993282|NCT02054650|Biomarkers
993283|NCT02054650|Glycemic control
993284|NCT02054650|Kidney function
993285|NCT02054637|Bile reflux
993286|NCT02054637|Reflux esophagitis
993287|NCT02054637|Lanreotide autogel
993288|NCT02054637|Somatuline
993289|NCT02054637|Endoscopy
993290|NCT02054637|Impedancemetry
993291|NCT02054624|Obesity
993292|NCT02054624|Rural Health
993293|NCT02054624|Exercise
993294|NCT02054624|Weight loss
993295|NCT02054624|Behavior change
993296|NCT02054611|ARDS
993297|NCT02054611|Chest radiographs
993298|NCT02054611|Vignettes
993299|NCT02054611|Online educational video
993300|NCT02054585|dehydration
993301|NCT02054585|pediatric
993302|NCT02054585|glucose
993303|NCT02054585|IV fluid
993304|NCT02054572|AMG 416, ESRD, hemodialysis
993305|NCT02054559|localized
993306|NCT02054559|diffuse large B-cell lymphoma
993307|NCT02054559|R-CHOP chemotherapy
993308|NCT02054559|radiotherapy
993309|NCT02054533|Crohn's disease
993310|NCT02054533|Ulcerative colitis
993311|NCT02054533|Inflammatory bowel disease
993312|NCT02054533|Surgery
993313|NCT02054533|Anti-Tumor Necrosis Factor
993314|NCT02054533|Infection
993315|NCT02054520|Stage IV
993316|NCT02054520|metastatic melanoma
993317|NCT02054507|Children
993318|NCT02054507|Cognitive outcome
993319|NCT02054507|Prematurity
993320|NCT02054507|Care Network
993321|NCT02054507|Outpatient follow-up of cognitive development
993322|NCT02054507|Care resources
993323|NCT02054468|Muscle relaxant, Rocuronium, TIVA, Propofol
993324|NCT02054455|PPI
993325|NCT02054455|SIBO
993326|NCT02054455|LP-F19
993327|NCT02054442|cetuximab
993328|NCT02054442|methotrexate
993329|NCT02054442|squamous cell carcinoma head neck
993330|NCT02054442|palliative chemotherapy
993331|NCT02054416|non-traumatic lower limb amputation
993332|NCT02054416|AKA
993333|NCT02054416|BKA
993334|NCT02054390|Angiotensin converting enzyme inhibitor
993335|NCT02054390|inflammation
993336|NCT02054390|metabolic syndrome
993337|NCT02054390|myonecrosis
993338|NCT02054390|percutaneous coronary intervention
993339|NCT02054390|periprocedural myocardial injury
993340|NCT02054377|cystic fibrosis
993341|NCT02054377|tai chi
993342|NCT02054364|Eating Disorder
993343|NCT02054364|Anorexia Nervosa
993344|NCT02054364|Eating Disorder Not Otherwise Specified
993345|NCT02054364|Maudsley
993346|NCT02054364|Family-Based Therapy
993347|NCT02054364|FBT
993348|NCT02054364|Family Therapy
993349|NCT02054364|Cognitive Remediation Therapy
993350|NCT02054364|CRT
993351|NCT02054351|Advanced ovarian cancer
993352|NCT02054351|CLDN6 positive
993353|NCT02054325|Sclerotherapy
993354|NCT02054325|varicose veins
993355|NCT02054325|veins
993356|NCT02054273|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
993357|NCT02054247|Carpal tunnel syndrome,ultrasound,pulsed ultrasound
993358|NCT02054234|Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test
993359|NCT02054221|hypertrophic cardiomyopathy
993360|NCT02054221|mitral valve
993361|NCT02054208|human umbilical cord blood derived mesenchymal stem cells
993362|NCT02054208|stem cells
993363|NCT02054208|alzheimer's disease
993364|NCT02054208|cognitive ability
993365|NCT02054208|mesenchymal stem cells
993366|NCT02054208|cord blood
993367|NCT02054182|vitamin D supplementation, pneumonia, bronchiolitis
993368|NCT02054156|Cystic fibrosis (CF)
993369|NCT02054156|Azithromycin
993370|NCT02054156|Tobramycin solution for inhalation (TIS)
993371|NCT02054156|Pseudomonas aeruginosa (Pa)
993372|NCT02054156|Early Pseudomonas aeruginosa infection
993373|NCT02054156|Pulmonary exacerbation
993374|NCT02054156|Standardized anti-pseudomonal therapy
993375|NCT02054143|sevoflurane
993376|NCT02054143|cerebral vasoreactivity
993377|NCT02054143|arterial stiffness
993378|NCT02054143|Transcranial Doppler
993379|NCT02054143|SphygmoCor
993380|NCT02054130|Asthma
993381|NCT02054117|Hemorrhage
993382|NCT02054117|Intracerebral hemorrhage (ICH)
993383|NCT02054104|Lung Cancer
993384|NCT02054104|Cancer Vaccine
993385|NCT02054104|Immunotherapy
993386|NCT02054104|Adjuvant Therapy
993387|NCT02054104|Surgical Intervention
993388|NCT02054091|Preterm infants
993389|NCT02054091|Bovine colostrum
993390|NCT02054091|Feeding intolerance
993391|NCT02054091|Postnatal growth
993392|NCT02054091|Intestinal maturation
993393|NCT02054091|Necrotizing enterocolitis
993394|NCT02054065|Urinary Catheter
993395|NCT02054065|urinary tract infection
993396|NCT02054052|non-small cell lung cancer
993397|NCT02054052|malignant pleural effusion
993398|NCT02054052|bevacizumab
993399|NCT02054052|intrapleural injection
993400|NCT02054052|pericardial effusion
993401|NCT02054039|Cardiac surgery
993402|NCT02054039|Spirometry
993403|NCT02054039|Physical Therapy Modalities
993404|NCT02054039|Postoperative Complications
993405|NCT02054000|No-reflow phenomenon, tirofiban, intracoronary
993406|NCT02053974|Anthracycline
993407|NCT02053974|spironolactone
993408|NCT02053974|cardiotoxicity
993409|NCT02053948|Reversal
993410|NCT02053948|Surgical technique
993411|NCT02053948|Pursestring Wound Closure
993412|NCT02053948|Gunsight Skin Incision and Closure Technique
993413|NCT02053935|Dopamine
993414|NCT02053935|hyperglycemic clamp
993415|NCT02053935|sepsis
993416|NCT02053935|hyperglycemia
993417|NCT02053935|insulin secretion
993418|NCT02053922|caesarean section, ecbolics, postpartum hemorrhage
993419|NCT02053909|Saphenous vein graft disease
993420|NCT02053909|Coronary artery bypass graft surgery
993421|NCT02053909|Antiplatelet therapy
993422|NCT02053909|Coronary artery disease
993423|NCT02053909|Secondary prevention
993424|NCT02053909|Graft patency
993425|NCT02053896|Type I Gaucher
993426|NCT02053896|ISU302
993427|NCT02053896|Imiglucerase
993428|NCT02053883|SCI
993429|NCT02053883|spinal cord injury
993430|NCT02053883|biologic drug
993431|NCT02053883|rho
993432|NCT02053883|paralysis
993433|NCT02053883|paraplegia
993434|NCT02053883|tetraplegia
993435|NCT02053883|quadriplegia
993436|NCT02053883|trauma
993437|NCT02053883|central nervous system
993438|NCT02053883|fibrin sealant
993439|NCT02053883|neurosurgery
993440|NCT02053883|cervical
993441|NCT02053883|regeneration
993442|NCT02053883|neurotrauma
993443|NCT02053870|Adventitious lung sounds
993444|NCT02053870|Crackles
993445|NCT02053870|Wheezes
993446|NCT02053870|Sputum location
993447|NCT02053857|severe acute malnutrition
993448|NCT02053857|polyunsaturated fatty acids
993449|NCT02053857|ready-to-use therapeutic food
993450|NCT02053844|health care costs
993451|NCT02053844|quality of health care
993452|NCT02053831|plastic surgery
993453|NCT02053818|Cognitive dysfunction
993454|NCT02053818|Cardioprotection
993455|NCT02053818|Recovery
993456|NCT02053818|Renal function
993457|NCT02053818|ICU discharge
993458|NCT02053805|prostate cancer
993459|NCT02053805|BRCA1 Syndrome
993460|NCT02053805|BRCA germ-line mutation
993461|NCT02053805|Lynch syndrome
993462|NCT02053805|BRCA2 Syndrome
993463|NCT02053779|GnRH agonist
993464|NCT02053779|GnRH antagonist
993465|NCT02053779|Luteal phase
993466|NCT02053766|Mitochondrial Diseases
993467|NCT02053766|Sevoflurane
993468|NCT02053766|Dexmedetomidine (Precedex®)
993469|NCT02053766|Propofol
993470|NCT02053753|denosumab, bioequivalence
993471|NCT02053727|Rheumatoid Arthritis
993472|NCT02053727|Hepatitis B
993473|NCT02053727|Abatacept
993474|NCT02053727|Orencia
993475|NCT02053727|entecavir
993476|NCT02053701|magnetic resonance spectroscopy
993477|NCT02053701|quantification precision
993478|NCT02053701|brain
993479|NCT02053701|brain metabolites
993480|NCT02053675|septic shock
993481|NCT02053675|vasopressin
993482|NCT02053675|microcirculation
993483|NCT02053675|tissue oxygenation
993484|NCT02053675|vasopressors
993485|NCT02053675|hemodynamics
993486|NCT02053662|Bladder Cancer
993487|NCT02053649|depression
993488|NCT02053649|major depressive disorder
993489|NCT02053649|postpartum depression
993490|NCT02053649|antenatal depression
993491|NCT02053649|sleep
993492|NCT02053649|circadian
993493|NCT02053649|bright light
993494|NCT02053597|Primary breast cancer
993495|NCT02053597|Young women
993496|NCT02053597|Ovarian function
993497|NCT02053597|Sexual function
993498|NCT02053597|Eligible for adjuvant or neoadjuvant chemotherapy
993499|NCT02053597|Negative hormone-receptor status
993500|NCT02053558|Anesthesiology
993501|NCT02053558|Pain
993502|NCT02053558|TAP block
993503|NCT02053558|Gynecology
993504|NCT02053558|Postoperative
993505|NCT02053558|Analgesia
993506|NCT02053532|Trauma
993507|NCT02053532|Post-traumatic stress disorder (PTSD)
993508|NCT02053532|Imaging
993509|NCT02053532|Neuroimaging
993510|NCT02053532|F-18-fluorodeoxyglucose (FDG)
993511|NCT02053493|Heart Failure
993512|NCT02053493|Preserved Ejection Fraction
993513|NCT02053480|pyruvate kinase deficiency
993514|NCT02053480|hemolytic anemia
993515|NCT02053480|anemia
993516|NCT02053480|enzymopathy
993517|NCT02053480|jaundice
993518|NCT02053480|splenectomy
993519|NCT02053480|health-related quality of life
993520|NCT02053480|Hematologic diseases
993521|NCT02053467|eConsultation
993522|NCT02053467|Specialist care
993523|NCT02053467|Primary health care
993524|NCT02053467|Reducing wait times for specialist care
993525|NCT02053467|Reducing referral rates
993526|NCT02053454|RNAi therapeutic
993527|NCT02053441|Muscle Protein Synthesis
993528|NCT02053441|Muscle Protein Breakdown
993529|NCT02053428|Head and neck cancer
993530|NCT02053428|Percutaneous image-guided gastrostomy
993531|NCT02053428|Pain
993532|NCT02053428|Quality of life
993533|NCT02053428|Complication
993534|NCT02053415|krill oil
993535|NCT02053415|omega-3 index
993536|NCT02053415|plasma lipid profile
993537|NCT02053415|tolerance
993538|NCT02053415|young adults
993539|NCT02053402|vitamin D supplementation, persistent asthma, control
993540|NCT02053389|Patient-Physician communication
993541|NCT02053389|Decision Support Techniques
993542|NCT02053389|Health Communication
993543|NCT02053389|Physician-Patient Relationship
993544|NCT02053389|Decision Making
993545|NCT02053376|gallbladder cancer, biliary cancer, bile duct cancer, hepatobiliary cancer, Biliary Tract Carcinoma
993546|NCT02053376|Cholangiocarcinoma
993547|NCT02053363|tranexamic acid, reconstructive spine surgery
993552|NCT02053324|AvidinOX
993553|NCT02053311|adenocarcinoma of the prostate
993554|NCT02053311|metastatic castration-resistant prostate cancer
993555|NCT02053311|maintenance therapy
993556|NCT02053311|orteronel
993557|NCT02053311|TAK-700
993558|NCT02053298|Glaucoma
993559|NCT02053272|Diabetes
993560|NCT02053272|Glycaemic control
993561|NCT02053272|Delta-9-tetrahydrocannabivarin
993562|NCT02053272|Cannabinoids
993563|NCT02053233|stroke
993564|NCT02053233|robot-assisted therapy
993565|NCT02053233|conventional therapy
993566|NCT02053233|motor function
993573|NCT02053194|Inappropriate prescribing
993574|NCT02053194|Health Education
993575|NCT02053194|Community Pharmacy Services
993576|NCT02053194|Medication Therapy Management
993577|NCT02053194|Preventive Health Services
993578|NCT02053194|Polypharmacy
993579|NCT02053194|Inappropriate prescriptions
993580|NCT02053194|Aged
993581|NCT02053181|Cadazolid
993582|NCT02053181|ACT-179811
993583|NCT02053181|Pharmacokinetics
993584|NCT02053181|Safety
993585|NCT02053181|Tolerability
993586|NCT02053155|Smoking cessation
993587|NCT02053155|perioperative complication
993588|NCT02053155|Smokerlyzer
993589|NCT02053155|smokers help line
993590|NCT02053142|Pharmacokinetics
993591|NCT02053142|Herpes simplex virus
993592|NCT02053142|Genital herpes ulcers
993593|NCT02053129|tuberculosis
993594|NCT02053129|HIV
993595|NCT02053129|pregnancy
993596|NCT02053090|Fibromyalgia
993597|NCT02053090|Group Acupuncture
993598|NCT02053090|Group Education with Stretching
993599|NCT02053090|Nociceptive Reflex Testing
993600|NCT02053090|Pain
993601|NCT02053090|Sleep
993602|NCT02053090|Fatigue
993609|NCT02053025|appetite
993610|NCT02053025|overweight
993611|NCT02053025|energy intake
993612|NCT02053025|obesity
993613|NCT02053025|gut hormones
993614|NCT02052986|Fatty Acids, Omega-3
993615|NCT02052986|Omega-3 fatty acids
993616|NCT02052986|Docosahexaenoic acid (DHA)
993617|NCT02052986|Eicosapentaenoic acid (EPA)
993618|NCT02052986|Docosapentaenoic acid (DPA)
993619|NCT02052986|Omega Index
993620|NCT02052986|Omega Score
993621|NCT02052986|Cardiac Rehab
993622|NCT02052973|Streptococcus mutans
993623|NCT02052973|Natural products
993624|NCT02052947|Alzheimer's disease
993625|NCT02052947|cerebrovascular disease
993626|NCT02052947|Lewy body disease
993627|NCT02052947|MRI
993628|NCT02052947|SPECT
993629|NCT02052947|CSF
993630|NCT02052947|biomarkers
993631|NCT02052947|disability
993632|NCT02052947|Multicenter and prospective cohort study
993633|NCT02052934|Escherichia coli Infections
993634|NCT02052934|ETEC Candidate Vaccine
993635|NCT02052934|Immunogenicity
993636|NCT02052921|Observation
993637|NCT02052921|Rectal Resection
993638|NCT02052921|complete clinical response
993639|NCT02052921|neoadjuvant chemoradiotherapy.
993640|NCT02052895|Presepsin
993641|NCT02052895|Sepsis
993642|NCT02052895|SIRS
993643|NCT02052882|Romiplostim
993644|NCT02052882|Thrombocytopenia
993645|NCT02052882|13-132
993646|NCT02052869|endotracheal intubation
993647|NCT02052869|esophageal intubation
993648|NCT02052856|Tunnel Widening
993649|NCT02052856|All-Inside Suspensory Method
993650|NCT02052856|Biointerference Screw Fixation
993651|NCT02052791|Spinal Muscular Atrophy
993652|NCT02052791|SMA
993653|NCT02052791|SMN
993654|NCT02052791|SMNRx
993655|NCT02052791|ISIS-SMNRx
993656|NCT02052791|ISIS 396443
993657|NCT02052791|IONIS-SMNRx
993658|NCT02052791|IONIS-SMN Rx
993659|NCT02052791|Spinraza
993660|NCT02052778|Breast Cancer
993661|NCT02052778|Non Small Cell Lung Cancer
993662|NCT02052778|Gastric Cancer
993663|NCT02052778|Multiple Myeloma
993664|NCT02052778|FGF
993665|NCT02052778|FGFR
993666|NCT02052778|FGFR abnormality
993667|NCT02052778|TAS-120
993668|NCT02052778|Dose Escalation
993669|NCT02052739|Status Epilepticus
993670|NCT02052739|Refractory status epilepticus
993671|NCT02052739|Super-refractory status epilepticus
993672|NCT02052739|SAGE-547
993673|NCT02052739|SAGE
993674|NCT02052739|Sage Therapeutics
993675|NCT02052713|dutasteride
993676|NCT02052713|tamsulosin
993677|NCT02052713|healthy subject
993678|NCT02052713|dutasteride and tamsulosin combination
993679|NCT02052713|combination capsule of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
993680|NCT02052687|Healthy volunteer
993681|NCT02052674|Precursor to CAUTI
993682|NCT02052661|Infanrix™ hexa
993683|NCT02052661|Hepatitis B antibodies
993684|NCT02052661|Immunogenicity
993685|NCT02052661|Hepatitis B
993686|NCT02052661|Adolescents
993687|NCT02052661|Infancy
993688|NCT02052661|Engerix™-B Kinder
993689|NCT02052661|Safety
993690|NCT02052648|glioblastoma multiforme
993691|NCT02052648|glioma
993692|NCT02052648|gliosarcoma
993693|NCT02052648|malignant brain tumor
993694|NCT02052635|Percutaneous Coronary Intervention
993695|NCT02052622|submental fat reduction
993696|NCT02052596|Boostrix
993697|NCT02052596|Herpes zoster
993698|NCT02052596|Immunogenicity
993699|NCT02052596|Co-administration
993700|NCT02052596|Adults
993701|NCT02052596|Safety
993702|NCT02052583|Cardiac arrest
993703|NCT02052583|Oxymetry
993704|NCT02052583|Hypothermia
993705|NCT02052570|School Reentry after pediatric HSCT
993706|NCT02052557|Exparel
993707|NCT02052557|liposomal bupivicaine
993708|NCT02052557|post operative pain control
993709|NCT02052557|local anesthetic after surgery
993710|NCT02052557|colorectal surgery
993711|NCT02052557|marcaine
993712|NCT02052557|long acting local anesthetic
993713|NCT02052557|pain medication use after surgery
993714|NCT02052544|determination of heparin levels
993715|NCT02052544|Patients
993716|NCT02052544|requiring
993717|NCT02052544|unfractionated
993718|NCT02052518|Childhood obesity
993719|NCT02052518|Breastfeeding
993720|NCT02052518|Introduction of solids
993721|NCT02052518|Introduction of juice
993722|NCT02052505|inappropriate prescribing
993723|NCT02052505|psychiatry
993724|NCT02052505|medication quality
993725|NCT02052505|patient safety
993726|NCT02052505|medication errors
993727|NCT02052479|Polycystic Ovary Syndrome
993728|NCT02052479|PCOS
993729|NCT02052479|Secondary Amenorrhea
993730|NCT02052479|Hirsutism
993731|NCT02052479|Hyperandrogenism
993732|NCT02052479|Insulin Resistance
993733|NCT02052466|Shoulder Joint
993734|NCT02052466|Computed tomography
993735|NCT02052453|Pacemaker
993736|NCT02052453|ICD
993737|NCT02052453|Surgery
993738|NCT02052453|Electrocautery
993739|NCT02052453|Electromagnetic interference
993740|NCT02052427|Ischemic heart disease
993741|NCT02052427|Coronary artery disease
993742|NCT02052427|Chronic Heart Failure
993743|NCT02052427|Cardiovascular disease
993744|NCT02052427|adult stem cells
993745|NCT02052427|adipose derived regenerative cells
993746|NCT02052414|side effects
993747|NCT02052414|safety
993748|NCT02052414|efficacy
993749|NCT02052414|Gralise
993750|NCT02052414|Fibromyalgia
993751|NCT02052414|gabapentin
993752|NCT02052401|OLD AGE
993753|NCT02052401|Elderly
993754|NCT02052401|Domiciliary Intervention
993755|NCT02052401|Occupational Therapy
993756|NCT02052401|Rehospitalization
993757|NCT02052388|Skin Infection
993758|NCT02052388|Staph aureus
993759|NCT02052388|MRSA
993760|NCT02052388|MSSA
993761|NCT02052388|Cellulitis/Erysipelas
993762|NCT02052388|Wound Infection
993763|NCT02052388|Abscess
993764|NCT02052375|Rheumatoid Arthritis
993765|NCT02052375|ASP2408
993766|NCT02052375|methotrexate
993767|NCT02052362|absolute bioavailability
993768|NCT02052362|healthy volunteers
993769|NCT02052349|relative bioavailability
993770|NCT02052349|healthy volunteers
993771|NCT02052336|Drug-Drug interaction
993772|NCT02052336|Pharmacokinetics
993773|NCT02052323|P.f Malaria, Artemisinin resistance, ACT treatment failure
993774|NCT02052310|Anemia
993775|NCT02052310|Chronic Kidney Disease
993776|NCT02052310|Hemoglobin
993777|NCT02052310|End-Stage Renal Disease
993778|NCT02052310|Incident-Dialysis
993779|NCT02052310|Erythropoieitin
993780|NCT02052310|Erythropoieisis stimulating-agent
993781|NCT02052310|Roxadustat
993782|NCT02052310|AZD9941
993783|NCT02052310|ASP1517
993784|NCT02052297|Idiopathic Pulmonary Fibrosis (IPF)
993785|NCT02052297|dosimetry
993786|NCT02052297|Positron Emission Tomograph (PET)
993787|NCT02052284|ELBW
993788|NCT02052284|premature
993789|NCT02052284|neonate
993790|NCT02052284|skin
993791|NCT02052284|water loss
993792|NCT02052271|essential tremor
993793|NCT02052271|cerebellum
993794|NCT02052271|transcranial direct current stimulation
993795|NCT02052271|electrophysiology
993796|NCT02052258|oxytocin
993797|NCT02052219|Blisibimod
993798|NCT02052219|IgA nephropathy
993799|NCT02052219|BAFF
993800|NCT02052219|BLyS
993801|NCT02052206|osteoarthritis
993802|NCT02052206|complexe proximal humeral fracture
993803|NCT02052206|shoulder
993804|NCT02052206|shoulder replacement
993805|NCT02052206|accuracy
993806|NCT02052206|computer-assisted
993807|NCT02052206|3D
993808|NCT02052180|Carpalmetacarpal arthroplasty
993809|NCT02052180|Proximal row carpectomy
993810|NCT02052180|Post-operative pain control
993811|NCT02052180|Exparel
993812|NCT02052180|Marcaine
993813|NCT02052154|Pneumococcal infection
993814|NCT02052154|Splenectomized
993815|NCT02052154|vaccination
993816|NCT02052141|Pediatric
993817|NCT02052141|C1 inhibitor
993818|NCT02052141|HAE
993819|NCT02052141|Cinryze
993820|NCT02052141|C1 INH
993821|NCT02052141|Prevention
993822|NCT02052128|endometrial cancer
993823|NCT02052128|ovarian cancer
993824|NCT02052128|breast cancer
993825|NCT02052128|uterine sarcoma
993826|NCT02052128|uterine endometrioid adenocarcinoma
993827|NCT02052115|breast cancer
993828|NCT02052115|exercise
993829|NCT02052115|weight loss
993830|NCT02052115|executive function
993831|NCT02052115|breast cancer survivor
993832|NCT02052102|Deep inspiration breath hold
993833|NCT02052102|radiation therapy
993834|NCT02052102|Cardiac toxicity
993835|NCT02052102|Left-sided breast cancer
993836|NCT02052089|Tennis Elbow
993837|NCT02052089|lateral epicondylosis
993838|NCT02052089|lateral epicondylitis
993839|NCT02052089|Platelet-Rich Plasma
993840|NCT02052089|Extracorporeal Shockwave Therapy
993841|NCT02052089|Prolotherapy
993842|NCT02052089|Physiotherapy
993843|NCT02052076|Energy balance
993844|NCT02052076|meal pattern
993845|NCT02052076|metabolic syndrome
993846|NCT02052063|rectocele
993847|NCT02052063|intussusception
993848|NCT02052063|surgery
993849|NCT02052050|colorectal-neoplasms,deep-muscles of the back,rehabilitation
993850|NCT02052037|Type 2 Diabetes
993851|NCT02052037|Egg
993852|NCT02052037|Glycemic Control
993853|NCT02052037|Insulin sensitivity
993854|NCT02052037|Diet quality
993855|NCT02052024|Spasticity
993856|NCT02052024|Modified Ashworth Scale
993857|NCT02052024|MYOBLOC
993858|NCT02052024|Botox
993859|NCT02052024|Muscle Atrophy
993860|NCT02052011|Chest Pain
993861|NCT02052011|Microvascular Angina
993862|NCT02052011|Ranolazine
993863|NCT02052011|Emergency department
993864|NCT02052011|PET
993865|NCT02051998|Geographic atrophy
993866|NCT02051998|Age-related macular degeneration
993867|NCT02051998|Retina
993868|NCT02051998|Retinal pigment epithelium
993869|NCT02051998|Optical coherence tomography
993870|NCT02051998|Scanning laser ophthalmoscopy
993871|NCT02051985|Chronic heart failure
993872|NCT02051985|Heart decompensation
993873|NCT02051985|Aerobic exercise training
993874|NCT02051985|Functional capacity
993875|NCT02051985|Dyspnea
993876|NCT02051985|Beta-adrenergic receptor signaling
993877|NCT02051959|Phantom Limb Pain
993878|NCT02051959|Transcranial Direct Current Stimulation
993879|NCT02051959|Amputation
993880|NCT02051959|Diabetes Mellitus
993881|NCT02051946|novel drug delivery technique for glaucoma patients
993882|NCT02051933|pilon
993883|NCT02051933|tibial plafond
993884|NCT02051933|botox
993885|NCT02051933|ankle dorsiflexion
993886|NCT02051933|ankle functionality
993887|NCT02051933|ankle range of motion
993888|NCT02051920|Elastography
993889|NCT02051894|Neonates
993890|NCT02051894|Dobutamine
993891|NCT02051894|Superior Vena Cana Flow
993892|NCT02051894|Hypoxic Ischemic Encephalopathy
993893|NCT02051894|Pleth Variability Index
993894|NCT02051868|Squamous cell carcinoma of the anus
993895|NCT02051868|Anal cancer
993896|NCT02051868|Cancer of the anus
993897|NCT02051868|SCCA
993898|NCT02051868|Cisplatin-5FU
993899|NCT02051868|Carboplatin-Paclitaxel
993900|NCT02051868|inoperable
993901|NCT02051868|locally recurrent
993902|NCT02051868|metastatic
993903|NCT02051855|Neonates
993904|NCT02051855|Superior Vena Cava Flow
993905|NCT02051855|Pleth Variability Index
993906|NCT02051855|Dobutamine
993907|NCT02051855|Intensive Care
993908|NCT02051842|NAFLD
993909|NCT02051842|oxidative stress
993910|NCT02051842|malondialdehyde
993911|NCT02051816|Endotracheal Intubation
993912|NCT02051816|Apneic Oxygenation
993913|NCT02051816|Respiratory failure
993914|NCT02051803|smoking cessation
993915|NCT02051803|women
993916|NCT02051751|Solid tumors, Head and neck non squamous cell carcinoma, breast cancer, PI3K inhibitor, BYL719, paclitaxel
993917|NCT02051738|Healthy
993918|NCT02051738|Mebendazole
993919|NCT02051738|Fast-Disintegrating Chewable Formulation
993920|NCT02051738|Bioavailability
993921|NCT02051712|chronic heart failure
993922|NCT02051712|exercise training
993923|NCT02051712|preferred training
993924|NCT02051712|prevention
993925|NCT02051699|Osteoarthritis of the knee
993926|NCT02051699|Weight bearing radiograph
993927|NCT02051699|Kellgren-Lawrence classification
993928|NCT02051699|Joint space width
993929|NCT02051699|One-leg standing view
993930|NCT02051686|Acetabulum Fractures
993931|NCT02051686|Pelvic Ring Injuries
993932|NCT02051686|Tranexamic Acid
993933|NCT02051673|Kidney Transplantation
993934|NCT02051647|medical students
993935|NCT02051647|Basel University
993936|NCT02051634|Aging
993937|NCT02051634|Papaya
993938|NCT02051634|Fermented Papaya
993939|NCT02051634|Inflammation
993940|NCT02051634|Phytochemicals
993941|NCT02051634|Physical function
993942|NCT02051634|Quality of life
993943|NCT02051634|Fatigue
993944|NCT02051634|Health
993945|NCT02051621|pulmonary vein isolation
993946|NCT02051621|isthmus ablation
993947|NCT02051621|recurrence
993948|NCT02051595|heart lung machine
993949|NCT02051595|blood pump
993950|NCT02051595|cardiac surgery
993951|NCT02051595|cardiopulmonary bypass
993952|NCT02051595|circulation
993953|NCT02051556|Parkinson's disease
993954|NCT02051556|Freezing of gait
993955|NCT02051556|Asymmetry
993956|NCT02051556|Rehabilitation
993957|NCT02051556|Physical therapy
993958|NCT02051530|mood
993959|NCT02051530|empathy
993960|NCT02051530|mimicry
993961|NCT02051530|emotional reactivity
993962|NCT02051530|prosody
993963|NCT02051517|Virectomy
993964|NCT02051504|Type 1 diabetes
993965|NCT02051504|Glycated hemoglobin
993966|NCT02051504|Muscle Oxygenation
993967|NCT02051504|Exercise
993968|NCT02051504|Maximal Oxygen uptake
993969|NCT02051504|Mitochondrial respiration
993970|NCT02051504|Endocannabinoid system
993971|NCT02051504|Oxidative stress
993972|NCT02051478|manipulation
993973|NCT02051478|mobilization
993974|NCT02051478|spine
993975|NCT02051478|pressure pain
993976|NCT02051439|Varicose Veins
993977|NCT02051439|Venous Insufficiency
993978|NCT02051439|Doppler
993979|NCT02051439|Duplex
993980|NCT02051439|Valsava
993981|NCT02051426|neuropsychiatric effects
993982|NCT02051413|Major depression
993983|NCT02051413|Antidepressant drug
993984|NCT02051413|Beta-arrestin
993985|NCT02051413|Biomarker
993986|NCT02051413|Predictive factor
993987|NCT02051400|Intubation
993988|NCT02051400|Laryngoscopes
993989|NCT02051361|DAT = Dual Antiplatelet Treatment
993990|NCT02051361|Major Cardiac Adverse Events
993991|NCT02051348|Helicobacter pylori
993992|NCT02051348|Mild Indigestion
993993|NCT02051335|Drug therapy
993998|NCT02051283|Hepatocellular carcinoma
993999|NCT02051283|RFA
994000|NCT02051283|MRI
994001|NCT02051270|Elderly
994002|NCT02051270|Nursing homes
994003|NCT02051270|Mild cognitive impairment
994004|NCT02051244|Alzheimer's Disease
994005|NCT02051244|Retinal Nerve Fiber Layer
994006|NCT02051244|Ocular Computerized Tomography
994007|NCT02051244|Minimal Cognitive Impairment
994008|NCT02051244|Subjective Memory Loss
994009|NCT02051244|Asymptomatic Preclinical Alzheimer's Disease
994010|NCT02051231|Uterine contraction
994011|NCT02051231|Oxytocin receptors
994012|NCT02051231|Oxytocin desensitization
994013|NCT02051218|metastatic breast cancer
994014|NCT02051218|castration resistant metastatic prostate cancer
994015|NCT02051218|bone metastases
994016|NCT02051218|Denosumab
994017|NCT02051218|XGEVA
994018|NCT02051218|de-escalation
994019|NCT02051205|Parkinson's disease, risk factors, epidemiology
994020|NCT02051192|obsessive-compulsive disorder
994021|NCT02051192|Social phobia
994022|NCT02051192|Generalized anxiety disorder
994023|NCT02051192|Specific phobia
994024|NCT02051192|Separation anxiety disorder
994025|NCT02051192|Selective Mutism
994026|NCT02051192|Anxiety Disorder, Not Otherwise Specified
994027|NCT02051192|Counseling
994028|NCT02051192|Behavioral therapy
994029|NCT02051192|Psychotherapy
994030|NCT02051192|Exposure
994031|NCT02051192|Young Children
994032|NCT02051179|Repair
994033|NCT02051179|Replacement
994034|NCT02051179|Dental Amalgam
994035|NCT02051153|Modafinil
994036|NCT02051153|Cognitive
994037|NCT02051153|Performance
994038|NCT02051140|Postural Balance
994039|NCT02051140|Walking
994040|NCT02051140|Giat
994041|NCT02051140|Cognition
994042|NCT02051140|Learning
994043|NCT02051140|Memory
994044|NCT02051140|Antioxidants
994045|NCT02051140|Anti-Inflammatory Agents
994046|NCT02051140|Brain
994047|NCT02051140|Strawberry
994048|NCT02051127|Exercise
994049|NCT02051127|Physical Fitness
994050|NCT02051127|Stress, Psychological
994051|NCT02051127|Cognition
994052|NCT02051127|Psychophysiology
994053|NCT02051127|Ergometry
994054|NCT02051127|Exercise Test
994055|NCT02051127|Sedentary Lifestyle
994056|NCT02051114|Rheumatoid arthritis
994057|NCT02051088|Critical limb ischemia
994058|NCT02051088|Intermittent claudication
994059|NCT02051088|endovascular treatment
994060|NCT02051088|drug-elution
994061|NCT02051075|IVF
994062|NCT02051075|ICSI
994063|NCT02051075|Asthenospermia
994064|NCT02051075|pentoxyphylline
994065|NCT02051075|Spermatozoa
994066|NCT02051062|Pharmacokinetics
994067|NCT02051062|BAT
994068|NCT02051062|Pediatric
994069|NCT02051049|CN
994070|NCT02051049|UCD
994071|NCT02051036|moxibustion
994072|NCT02051023|keratoconjunctivitis sicca
994073|NCT02051023|dry eye
994074|NCT02051023|dry eye syndrome
994075|NCT02051023|dry eye disease
994076|NCT02051023|steroids
994077|NCT02050984|Obesity
994078|NCT02050984|Hypertension
994079|NCT02050984|Bariatric Surgery
994080|NCT02050984|Diabetes
994081|NCT02050971|Umbilical Cord Blood
994082|NCT02050971|Autologous Umbilical Cord Blood Transfusion
994083|NCT02050971|Prematurity Complications
994084|NCT02050971|Infant, Premature, Diseases
994085|NCT02050971|Infant, Newborn, Diseases
994086|NCT02050971|Hematologic Diseases
994087|NCT02050971|Lung Diseases
994088|NCT02050971|Central Nervous System Diseases
994089|NCT02050971|Gastrointestinal Tract Diseases
994090|NCT02050971|Vascular Diseases
994091|NCT02050971|Retinopathies, Neonates
994092|NCT02050971|Prevention,Treatment
994093|NCT02050932|hepcidin
994094|NCT02050932|iron bioavailability
994095|NCT02050932|iron supplementation
994096|NCT02050906|IDEA-P
994097|NCT02050906|Androgen Deprivation Therapy
994098|NCT02050893|septic shock
994099|NCT02050893|sepsis
994100|NCT02050893|fluid responsiveness
994101|NCT02050893|Midazolam
994102|NCT02050893|Propofol
994103|NCT02050893|haemodynamics
994104|NCT02050880|Normal Eyes
994105|NCT02050880|Eye; Disorder with Glaucoma
994106|NCT02050880|Eye; Disorder with Retinal Disease
994107|NCT02050880|Eye; Disorder Corneal Disease incl kerato-refractive group
994110|NCT02050854|Aripiprazole
994111|NCT02050854|Treatment Adherence
994112|NCT02050841|Pediatric
994113|NCT02050841|patients
994114|NCT02050841|replacement
994115|NCT02050841|coagulation factors
994116|NCT02050841|plasma
994117|NCT02050841|s/d plasma
994118|NCT02050841|Octaplas
994119|NCT02050841|plasma replacement
994120|NCT02050815|MEK162
994121|NCT02050815|Hepatic impairment
994122|NCT02050815|Healthy subjects
994123|NCT02050802|Macitentan
994124|NCT02050802|Pharmacokinetics
994125|NCT02050802|Pharmacodynamics
994126|NCT02050763|HIV
994127|NCT02050763|Intimate partner violence
994128|NCT02050763|Community based prevention intervention
994129|NCT02050763|Uganda
994130|NCT02050763|Cluster randomized trial
994131|NCT02050750|Must have registered with the ICORG 06-31 TAILORx trial
994132|NCT02050737|Curative resection
994133|NCT02050737|Adjuvant chemotherapy
994134|NCT02050724|Solitary Pulmonary Nodule
994135|NCT02050724|Thoracoscopy
994136|NCT02050724|Thoracic Surgery
994137|NCT02050724|Video-Assisted
994138|NCT02050724|Radioactive Tracers
994139|NCT02050724|Radioguided surgery
994140|NCT02050724|Handheld-SPECT
994141|NCT02050711|Chronic obstructive pulmonary disease (COPD)
994142|NCT02050711|Pulmonary rehabilitation
994143|NCT02050711|Computerized respiratory sounds
994144|NCT02050698|fift metatarsal avulsion fracture
994145|NCT02050698|hard-soled shoe
994146|NCT02050698|short leg walking cast
994147|NCT02050698|protected weightbearing
994148|NCT02050672|Myoinositol
994149|NCT02050672|ART
994150|NCT02050672|EMBRYO QUALITY
994151|NCT02050646|Autoimmune hepatitis
994152|NCT02050646|Liver dysfunction
994153|NCT02050646|Elevated serum auto antibodies
994154|NCT02050633|Craniocerebral Trauma
994155|NCT02050633|Long term outcome
994156|NCT02050633|Activities of Daily Living
994157|NCT02050633|Cognitive Deficiency
994158|NCT02050633|Health Care Quality, Access, and Evaluation
994159|NCT02050633|Burden of care
994160|NCT02050620|Breast cancer, exercise and quality of life
994161|NCT02050581|Platelets are a part of the blood hat helps with clotting
994162|NCT02050581|ITP idiopathic thrombocytopenia purpura low platelet count
994163|NCT02050568|Genital prolapse
994164|NCT02050568|Genital prolapse surgery
994165|NCT02050568|Stress urinary incontinence
994166|NCT02050568|Urethral Pressure Reflectometry
994167|NCT02050542|cancer
994168|NCT02050542|prostate
994169|NCT02050542|PSA
994170|NCT02050542|biopsies
994171|NCT02050542|ultrasound
994172|NCT02050542|MRI
994173|NCT02050542|fusion of images
994174|NCT02050529|Hypertension, Pregnancy induced
994175|NCT02050529|Pre-eclampsia
994176|NCT02050529|Eclampsia
994177|NCT02050529|Labetalol
994178|NCT02050529|Hydralazine
994179|NCT02050516|Blastocyst, micro-well group culture dish
994180|NCT02050503|Mucositis
994181|NCT02050503|Breakthrough pain
994182|NCT02050503|Head Nad neck cancer
994183|NCT02050503|Intranasal transmucosal fentanyl in pectin
994184|NCT02050477|Obesity
994185|NCT02050477|Bariatric
994186|NCT02050477|Surgery
994187|NCT02050477|Sleeve
994188|NCT02050477|Gastroplasty
994189|NCT02050477|Laparoscopy
994190|NCT02050464|Alzheimer Disease
994191|NCT02050464|Frontotemporal Dementia
994192|NCT02050464|Dementia, Vascular
994193|NCT02050464|Mild Cognitive Impairment
994194|NCT02050464|Diagnosis
994195|NCT02050464|Risk factors
994196|NCT02050464|Biomarkers
994197|NCT02050464|AD
994198|NCT02050464|FTD
994199|NCT02050464|VAD
994200|NCT02050464|MCI
994201|NCT02050451|radical cystectomy
994202|NCT02050451|urinary diversion
994203|NCT02050451|nutrition
994204|NCT02050451|oral supplementation
994205|NCT02050451|enteral nutrition
994206|NCT02050438|Osteoarthritis Knee
994207|NCT02050438|Total Knee Arthroplasty
994208|NCT02050438|Quality of Life
994209|NCT02050425|OSA
994210|NCT02050425|CPAP
994211|NCT02050425|exhaled breath
994212|NCT02050399|Isometric Exercise
994213|NCT02050399|Arterial Pressure
994214|NCT02050399|Autonomic Nervous System
994215|NCT02050399|Cardiovascular system
994216|NCT02050399|Posture
994217|NCT02050386|Brain arousal systems
994218|NCT02050386|Aging
994219|NCT02050386|MRI
994220|NCT02050386|fMRI
994221|NCT02050386|Cognition
994222|NCT02050373|Mucositis
994223|NCT02050373|Stomatitis
994224|NCT02050373|Chemotherapy
994225|NCT02050373|Hematopoietic stem cell transplant
994226|NCT02050373|Laser therapy
994227|NCT02050373|Inflammatory cytokines
994228|NCT02050360|Raynaud's phenomenon
994229|NCT02050360|Sildenafil
994230|NCT02050360|Systemic Sclerosis
994231|NCT02050360|Local cooling
994232|NCT02050360|Microcirculation
994233|NCT02050347|CD19.CAR-CD28zeta
994234|NCT02050347|chimeric antigen receptor
994235|NCT02050347|hematopoietic stem cell transplant
994236|NCT02050334|Phase 1
994237|NCT02050334|Healthy Volunteer
994238|NCT02050334|Safety
994239|NCT02050334|Healthy Volunteer Safety Study
994240|NCT02050282|Dyspnea
994241|NCT02050282|Prehospital
994242|NCT02050282|Biomarker
994243|NCT02050282|Heart failure
994244|NCT02050282|Triage
994245|NCT02050282|Randomized, controlled study
994246|NCT02050256|Palliative care
994247|NCT02050256|Continuing medical education
994248|NCT02050256|General practitioner
994249|NCT02050256|Electronic decision support
994250|NCT02050243|pediatrics
994251|NCT02050243|brain tumor
994252|NCT02050243|CNS
994253|NCT02050243|fluorescence
994254|NCT02050243|5ALA
994255|NCT02050230|transfusion
994256|NCT02050230|pulmonary hypertension
994257|NCT02050230|intensive care medicine
994258|NCT02050217|Helmet
994259|NCT02050217|Neurally Adjusted Ventilatory Assist
994260|NCT02050217|Children
994261|NCT02050217|Respiratory Failure
994262|NCT02050204|work to family conflict
994263|NCT02050204|supervisor support
994264|NCT02050204|long work hours
994265|NCT02050204|cardiometabolic risk
994266|NCT02050204|sleep duration
994267|NCT02050204|insomnia symptoms
994268|NCT02050178|Pancreatic Cancer
994269|NCT02050178|Stage IV Pancreatic Cancer
994270|NCT02050165|obesity
994271|NCT02050165|snacks
994272|NCT02050165|satiety
994273|NCT02050165|hunger
994274|NCT02050152|Amnesia
994275|NCT02050152|Memory
994276|NCT02050152|Implicit
994277|NCT02050152|Explicit
994278|NCT02050152|Nitrous Oxide
994279|NCT02050139|L-Cysteine
994280|NCT02050139|Peritoneal dialysis
994281|NCT02050139|Diuresis
994282|NCT02050139|Glomerular filtration rate
994283|NCT02050139|Peritoneal function
994284|NCT02050139|Inflammation
994285|NCT02050113|Complex Aortic Aneurysms
994286|NCT02050113|Thoracoabdominal Aneurysms
994287|NCT02050113|Pararenal Aortic Aneurysms
994288|NCT02050113|Juxtarenal Renal Aneurysms
994289|NCT02050113|Endovascular Branch Graft
994290|NCT02050113|Fenestrated Stent Graft
994291|NCT02050113|Abdominal Aortic Aneurysm
994292|NCT02050113|Endovascular
994293|NCT02050100|primary lung adenocarcinoma Stages I, II, IIIA, IIIB
994294|NCT02050100|squamous cell carcinoma Stages I, II, IIIA, IIIB
994295|NCT02050100|benign non-calcified pulmonary nodules
994296|NCT02050100|early detection
994297|NCT02050087|Rotator cuff
994298|NCT02050087|Rehabilitation
994299|NCT02050048|Pancreatitis
994300|NCT02050048|Endoscopic retrograde cholangiopancreatography
994301|NCT02050048|Cholangiopancreatography, Endoscopic Retrograde
994302|NCT02050048|ERCP
994303|NCT02050048|High Volume
994304|NCT02050048|Lactated Ringer
994305|NCT02050048|Intravenous Administration
994306|NCT02050048|Sphincterotomy, Endoscopic
994307|NCT02050048|Pancreas
994308|NCT02050035|Exercise Therapy
994309|NCT02050035|Endothelium, vascular
994310|NCT02050035|Blood Vessels
994311|NCT02050022|Biomarkers
994312|NCT02050022|Genomics
994313|NCT02050022|Proteomics
994314|NCT02050022|Diagnostics
994315|NCT02050022|Prognostics
994316|NCT02049996|Quality of life
994317|NCT02049996|Robotic surgery
994318|NCT02049996|Vaginal surgery
994319|NCT02049996|Prolapse repair
994320|NCT02049996|Vaginal hysterectomy
994321|NCT02049970|Supraclavicular block
994322|NCT02049957|MLN0128
994323|NCT02049944|Antibiotic Prophylaxis
994324|NCT02049944|Obesity
994325|NCT02049944|Obesity, Morbid
994326|NCT02049944|Pregnancy
994327|NCT02049944|Infection; Cesarean Section
994328|NCT02049931|osteoporosis, compression fracture, brace
994329|NCT02049918|Respiratory viruses
994330|NCT02049905|soft tissue sarcoma
994331|NCT02049905|unresectable
994332|NCT02049905|metastatic
994333|NCT02049905|locally advanced
994334|NCT02049905|sarcoma
994335|NCT02049892|Total Hip Replacement
994336|NCT02049892|Metal Ion
994337|NCT02049892|2-5 years after surgery
994338|NCT02049892|Asymptomatic
994339|NCT02049866|osteoporosis
994340|NCT02049866|premenopausal
994341|NCT02049866|denosumab
994342|NCT02049866|idiopathic
994343|NCT02049866|Idiopathic Osteoporosis in Premenopausal Women
994344|NCT02049853|acute dyspnea
994345|NCT02049853|heart failure
994346|NCT02049853|diagnostics
994347|NCT02049853|POCT analysis
994348|NCT02049853|preclinical area
994349|NCT02049840|Female sling
994350|NCT02049840|Stress Urinary Incontinence
994351|NCT02049840|Urination Disorders
994352|NCT02049840|Urologic Diseases
994353|NCT02049827|Renal transplant, BK virus
994354|NCT02049814|Drug therapy
994355|NCT02049762|novel P2Y12 inhibitors
994356|NCT02049762|aspirin
994357|NCT02049762|platelet reactivity
994358|NCT02049762|acute coronary syndrome
994359|NCT02049749|Child Behavior Problems
994360|NCT02049749|Parent Training Program
994361|NCT02049723|Gastroesophageal reflux disease
994362|NCT02049723|Knowledge
994363|NCT02049697|Healthy
994364|NCT02049697|Healthy male participants
994365|NCT02049697|14C-JNJ -39823277
994366|NCT02049697|TPI 1062
994367|NCT02049697|Tianeptine
994368|NCT02049697|Absorption
994369|NCT02049697|Metabolism
994370|NCT02049697|Excretion
994371|NCT02049697|Pharmacokinetics
994372|NCT02049658|tumor
994373|NCT02049658|cancer
994374|NCT02049645|lung cancer
994375|NCT02049645|breast cancer
994376|NCT02049632|Breast cancer
994377|NCT02049632|Sentinel Node Biopsy
994378|NCT02049632|Micrometastasis
994379|NCT02049632|Axillary lymph node dissection
994380|NCT02049619|Pharyngeal pack
994381|NCT02049619|Nausea
994382|NCT02049619|Vomiting
994383|NCT02049619|orthognathic surgery
994384|NCT02049619|maxillary osteotomy
994385|NCT02049606|LAYLA
994386|NCT02049606|Non-inferiority
994387|NCT02049606|100mm pain VAS
994388|NCT02049593|protocol specific
994389|NCT02049580|lymphoma
994390|NCT02049567|cataract, presbyopia
994391|NCT02049554|preconception care
994392|NCT02049554|women's health
994393|NCT02049541|BKM120
994394|NCT02049541|B-Cell Lymphoma
994395|NCT02049541|PI3K inhibitor
994396|NCT02049528|Food Effect
994397|NCT02049528|Pharmacokinetic
994398|NCT02049528|Healthy
994399|NCT02049528|Male
994400|NCT02049515|Phase 3
994401|NCT02049515|CLL/SLL
994402|NCT02049515|PI3K
994403|NCT02049502|ulcerative colitis
994404|NCT02049502|fecal microbiota transplantation
994405|NCT02049489|ICT-121
994406|NCT02049489|glioblastoma
994407|NCT02049489|immunotherapy
994408|NCT02049489|dendritic cell vaccine
994409|NCT02049489|CD133
994410|NCT02049476|Uveitis, Intermediate
994411|NCT02049476|Uveitis, Posterior
994412|NCT02049476|Dexamethasone
994413|NCT02049476|Immunosuppressive Agents
994414|NCT02049476|Eye Abnormalities
994415|NCT02049476|Eye Diseases
994416|NCT02049476|Ophthalmology
994417|NCT02049476|Ophthalmologic Surgical Procedures
994418|NCT02049476|Vision Disorders
994419|NCT02049476|Inflammation
994420|NCT02049463|carotid artery
994421|NCT02049463|sound
994422|NCT02049463|stenosis
994423|NCT02049463|wall
994424|NCT02049463|stroke
994425|NCT02049450|thalassemia
994426|NCT02049450|thalassemia major
994427|NCT02049450|spleen enlargement
994428|NCT02049450|INC424
994429|NCT02049450|ruxolitinib
994430|NCT02049437|HIV
994431|NCT02049437|Immune failure
994432|NCT02049437|Tocilizumab
994433|NCT02049437|ACTEMRA
994434|NCT02049437|Antiretroviral therapy
994435|NCT02049437|HAART
994436|NCT02049411|Ketamine
994437|NCT02049411|acute cognitive dysfunction
994438|NCT02049411|geriatric patients
994439|NCT02049398|Microbiome
994440|NCT02049398|Saliva
994441|NCT02049398|Reliability
994442|NCT02049398|Oral Cavity
994443|NCT02049385|Glutamate
994444|NCT02049385|Pathophysiology
994445|NCT02049385|Depression
994446|NCT02049385|Treatment
994447|NCT02049372|complications
994448|NCT02049372|tonsillectomy
994449|NCT02049372|tonsillotomy
994450|NCT02049359|Diabetes
994451|NCT02049346|Anemia
994452|NCT02049346|Hemodialysis
994453|NCT02049346|Erythropoetin Stimulating Agents
994454|NCT02049346|Comparison
994455|NCT02049294|Prednisone
994456|NCT02049294|Eosinophils
994457|NCT02049294|Immunoglobin E (IgE)
994458|NCT02049294|Asthma
994459|NCT02049294|Bronchitis
994460|NCT02049294|Inflammation
994461|NCT02049294|Allergy
994462|NCT02049268|alcohol
994463|NCT02049268|nicotine
994464|NCT02049268|addiction
994465|NCT02049268|functional MRI
994466|NCT02049268|functional connectivity
994467|NCT02049268|brain circuits
994468|NCT02049255|All
994469|NCT02049242|Hemorrhage
994470|NCT02049242|Leiomyoma
994471|NCT02049242|Myofibroma
994472|NCT02049242|Uterine Myomectomy
994473|NCT02049242|Tourniquet
994474|NCT02049229|Stent
994475|NCT02049229|Titanium
994476|NCT02049229|drug eluting stent
994477|NCT02049229|myocardial infarction
994478|NCT02049229|stent thrombosis
994479|NCT02049216|knee
994480|NCT02049216|osteoarthritis
994481|NCT02049216|tape
994482|NCT02049216|exercise
994483|NCT02049216|rocktape
994484|NCT02049190|Advanced Prostate Cancer
994485|NCT02049190|Castration-resistant Prostate Cancer
994486|NCT02049190|Prostatic Neoplasms
994487|NCT02049190|Genital Neoplasms, Male
994488|NCT02049190|Urogenital Neoplasms
994489|NCT02049190|Neoplasms by Site
994490|NCT02049190|Neoplasms
994491|NCT02049190|Genital Diseases, Male
994492|NCT02049190|Prostatic Diseases
994493|NCT02049190|onapristone
994494|NCT02049177|Cancer
994495|NCT02049177|Epidemiology
994496|NCT02049177|Head and Neck
994497|NCT02049177|HPV
994498|NCT02049164|AR08, Vasomotor Symptoms
994499|NCT02049151|Carcinoma, Non-Small-Cell Lung
994500|NCT02049151|Tecemotide
994501|NCT02049151|Placebo
994502|NCT02049151|NSCLC
994503|NCT02049151|L-BLP25
994504|NCT02049138|Joint Diseases
994505|NCT02049138|Musculoskeletal Disease
994506|NCT02049138|Anti-inflammatory Agents
994507|NCT02049138|Antirheumatic agents
994508|NCT02049138|Arthritis
994509|NCT02049125|NGAL
994510|NCT02049125|Acute kidney injury
994511|NCT02049125|Cirrhosis
994512|NCT02049125|Hepatorenal syndrome
994513|NCT02049112|Cross-over
994514|NCT02049112|Salivary equivalent
994515|NCT02049112|Dry mouth
994516|NCT02049112|Medical device
994517|NCT02049086|SBIRT
994518|NCT02049086|Screening
994519|NCT02049086|Brief Intervention
994520|NCT02049086|Referral to Treatment
994521|NCT02049086|Pain-Management
994522|NCT02049086|Veterans
994523|NCT02049073|hearing loss
994524|NCT02049073|noise induced hearing loss
994525|NCT02049073|zonisamide
994526|NCT02049060|MPM
994527|NCT02049060|NSCLC
994528|NCT02049047|thymoma thymic carcinoma
994529|NCT02049034|GLP-1 agonist
994530|NCT02049034|Lixisenatide
994531|NCT02049034|Postprandial glucose metabolism
994532|NCT02049034|Postprandial lipid metabolism
994533|NCT02049034|Gastric emptying
994534|NCT02049034|Lipoprotein lipase activity
994535|NCT02049021|schizophrenia
994536|NCT02049021|electroconvulsive therapy
994537|NCT02049021|refractory Schizophrenia
994538|NCT02049021|super refractory schizophrenia
994539|NCT02049021|clozapine
994540|NCT02048995|Bipolar Disorder
994541|NCT02048995|Depression
994542|NCT02048995|Light Therapy
994543|NCT02048995|Contrast Sensitivity
994544|NCT02048995|Visual Evoked Potential
994545|NCT02048995|Visual or Neural Responses
994546|NCT02048995|Biomarker
994547|NCT02048982|physician prescribing
994548|NCT02048982|behavioral economics
994549|NCT02048982|primary care practice
994550|NCT02048969|hepatic encephalopathy
994551|NCT02048969|flumazenil
994552|NCT02048969|liver cirrhosis
994553|NCT02048956|knee osteoarthritis
994554|NCT02048956|hydrotherapy
994555|NCT02048930|GPRD
994556|NCT02048930|effectiveness
994557|NCT02048930|cost-effectiveness
994558|NCT02048930|Easyhaler
994559|NCT02048930|Primary care
994560|NCT02048930|DPI
994561|NCT02048917|Smoking
994562|NCT02048917|Cessation
994563|NCT02048917|Bupropion
994564|NCT02048917|Varenicline
994565|NCT02048917|Nicotine
994566|NCT02048917|Counseling
994567|NCT02048917|Tobacco
994568|NCT02048904|microalbuminuria
994569|NCT02048904|type 2 diabetes
994570|NCT02048878|Insomnia
994571|NCT02048865|VTE Cancer
994572|NCT02048852|menthol
994573|NCT02048852|nicotine
994574|NCT02048826|stroke
994575|NCT02048800|Treosulfan pharmacokinetics
994576|NCT02048800|Children
994577|NCT02048800|Any condition that requires an allogeneic HSCT
994578|NCT02048787|Renal impairment
994579|NCT02048787|Healthy volunteers
994580|NCT02048787|Clinical pharmacology study
994581|NCT02048748|Home Care Services
994582|NCT02048748|Telemedicine
994583|NCT02048696|Exercise training
994584|NCT02048696|High intensity interval training
994585|NCT02048696|left ventricular systolic function
994586|NCT02048696|G-protein related kinase 2
994587|NCT02048696|heart failure
994588|NCT02048696|myocardial infarction
994589|NCT02048696|coronary artery disease
994590|NCT02048696|beta adrenergic receptor
994591|NCT02048683|Pharmacokinetics
994592|NCT02048683|Sevoflurane
994593|NCT02048683|Burn
994594|NCT02048683|Sedation
994595|NCT02048670|Pilot study
994596|NCT02048670|Assessment of sway phase
994597|NCT02048670|Therapy trial phase
994598|NCT02048657|LMA, Foley Airway Stylet Tool (FAST), introducer-tool (I-Tool)
994599|NCT02048644|Platelets adhesion
994600|NCT02048631|oral cancer,Quality of life,Sensory
994601|NCT02048618|Active Crohn's Disease
994602|NCT02048618|GLPG0634
994603|NCT02048592|cystic fibrosis, immunonutrition, oxidative stress
994604|NCT02048566|Echocardiography, Transesophageal
994605|NCT02048566|Monitoring, Physiologic
994606|NCT02048566|Shock
994607|NCT02048553|ventriculostomy; complications in neurosurgery;catheter accuracy;
994608|NCT02048514|Aortic Aneurysm, Abdominal
994609|NCT02048514|Endovascular Procedures
994610|NCT02048501|Weight regain
994611|NCT02048501|Sustain weight loss
994612|NCT02048501|Weight loss
994613|NCT02048501|Gut hormones
994614|NCT02048488|non small cell lung cancer
994615|NCT02048488|NSCLC
994616|NCT02048488|Anaplastic lymphoma kinase
994617|NCT02048488|ALK tyrosine kinase receptor
994618|NCT02048488|ALK+
994619|NCT02048488|TRK+
994620|NCT02048488|ALK inhibitor
994621|NCT02048488|TRK inhibitor
994622|NCT02048488|tropomyosin receptor kinase
994623|NCT02048488|TRKA
994624|NCT02048488|TRKB
994625|NCT02048488|TRKC
994626|NCT02048488|advanced malignancy
994627|NCT02048475|desflurane
994628|NCT02048475|electroencephalogram
994629|NCT02048449|Reflux finding score, interrater reliability
994630|NCT02048436|Respiratory Rate
994631|NCT02048423|suicidal
994632|NCT02048397|Bronchiectasis.
994633|NCT02048384|rapamycin
994634|NCT02048384|metformin
994635|NCT02048384|pancreatic cancer
994636|NCT02048384|adenocarcinoma
994637|NCT02048384|metastatic
994638|NCT02048358|Healthy volunteers
994639|NCT02048358|first in human
994640|NCT02048358|2B3-201
994641|NCT02048358|methylprednisolone
994642|NCT02048358|CNS-targeting
994643|NCT02048358|liposomal
994644|NCT02048358|crossover
994645|NCT02048358|placebo controlled
994646|NCT02048358|active controlled
994647|NCT02048358|multiple sclerosis
994648|NCT02048358|multiple sclerosis relapse
994649|NCT02048345|ten mL suspension of posaconazol (Noxafil) together with 240mL water will be taken by the volunteer in a fasted state
994650|NCT02048345|ten mL suspension of posaconazol (Noxafil) together with 240mL water will be taken by the volunteer in a fed state
994651|NCT02048345|two point six mL of suspension that is dissolved in 247mL water will be administered to the volunteer by the stomach catheter in a fasted state
994652|NCT02048345|two point six mL of suspension that is dissolved in 247mL water will be administered to the volunteer by the stomach catheter in a fed state
994653|NCT02048332|Epstein-Barr Virus (EBV)
994654|NCT02048332|Adenovirus (ADV)
994655|NCT02048332|t-cells
994656|NCT02048332|donor
994657|NCT02048332|transplant
994658|NCT02048332|children
994659|NCT02048332|cytomegalovirus (CMV)
994660|NCT02048319|Liver cyst
994661|NCT02048319|Hepatic cyst
994662|NCT02048319|Symptomatic
994663|NCT02048319|Aspiration sclerotherapy
994664|NCT02048306|Chronic obstructive pulmonary disease (COPD)
994665|NCT02048306|Pulmonary rehabilitation
994666|NCT02048306|Family
994667|NCT02048306|Integrated care
994668|NCT02048306|Mixed methods
994669|NCT02048293|remifentanil
994670|NCT02048293|propofol
994671|NCT02048293|pharmacodynamic
994672|NCT02048293|total intravenous anesthesia
994673|NCT02048293|orotracheal intubation
994674|NCT02048293|heart rate
994675|NCT02048293|mean arterial pressure
994676|NCT02048293|Cooper intubation condition score
994677|NCT02048267|Alcoholic
994678|NCT02048267|Non alcoholic
994679|NCT02048267|Idiopathic
994680|NCT02048267|Tropical
994681|NCT02048267|Exocrine dysfunction
994682|NCT02048267|Endocrine dysfunction
994683|NCT02048267|Pain control
994684|NCT02048267|Frey's procedure
994685|NCT02048267|Duodenum preserving pancreatic head resection
994686|NCT02048254|inoperable salivary gland cancer
994687|NCT02048254|brachytherapy
994688|NCT02048254|intensity-modulated radiation therapy
994689|NCT02048241|childhood
994690|NCT02048241|temper
994691|NCT02048241|explosive
994692|NCT02048241|aggression
994693|NCT02048241|tantrums
994694|NCT02048241|oppositional
994695|NCT02048241|defiant
994696|NCT02048241|conduct
994697|NCT02048241|disruptive
994698|NCT02048241|emotional dysregulation
994699|NCT02048241|special education
994700|NCT02048228|Clopidogrel,
994701|NCT02048228|Pharmacogenetics,
994702|NCT02048228|Platelet reactivity,
994703|NCT02048228|CYP2C19,
994704|NCT02048228|point-of-care
994705|NCT02048215|thermogenesis
994706|NCT02048215|low-calorie diet
994707|NCT02048215|uncoupling-protein 3
994708|NCT02048215|beta-3 adrenoceptors
994709|NCT02048215|thermogenic drugs
994710|NCT02048202|clown
994711|NCT02048202|neonate
994712|NCT02048202|premature
994713|NCT02048176|Mutism
994714|NCT02048163|Meropenem
994715|NCT02048163|Nausea
994716|NCT02048163|Pharmacokinetics
994717|NCT02048124|25d ProCor needle
994718|NCT02048124|22 gauge
994719|NCT02048124|endoscopic ultrasonography
994720|NCT02048124|fine needle biopsies
994721|NCT02048124|Patients
994722|NCT02048124|presenting
994723|NCT02048111|Hemophilia B
994724|NCT02048111|Hemophilia A
994725|NCT02048111|Blood Coagulation Disorders, Inherited
994726|NCT02048111|Blood Coagulation Disorders
994727|NCT02048111|Hematologic Diseases
994728|NCT02048111|Coagulation Protein Disorders
994729|NCT02048111|Hemorrhagic Disorders
994730|NCT02048111|Genetic Diseases, Inborn
994731|NCT02048111|Genetic Diseases, X-Linked
994732|NCT02048098|misoprostol
994733|NCT02048098|Labor, Induced
994734|NCT02048098|Pregnancy Trimester, Second
994735|NCT02048098|Abortion, Induced
994736|NCT02048085|ACS
994737|NCT02048085|STEMI
994738|NCT02048085|Fibrinolysis
994739|NCT02048085|Pharmacodynamics
994740|NCT02048085|Pharmacokinetics
994741|NCT02048085|Plavix
994742|NCT02048085|Brilinta
994743|NCT02048085|Ticagrelor
994744|NCT02048085|Clopidogrel
994745|NCT02048072|relapsing remitting
994746|NCT02048072|multiple sclerosis
994747|NCT02048072|fingolimod
994748|NCT02048072|Gilenya
994749|NCT02048072|autonomic nervous system
994750|NCT02048059|ANG1005
994751|NCT02048059|GRN1005
994752|NCT02048059|LRP-1
994753|NCT02048059|Targeted therapy
994754|NCT02048059|Breast cancer
994755|NCT02048059|Brain metastases
994756|NCT02048059|Brain tumor
994757|NCT02048059|Blood-brain barrier
994758|NCT02048059|Trastuzumab
994759|NCT02048059|Herceptin
994760|NCT02048059|Paclitaxel
994761|NCT02048059|Taxol
994762|NCT02048059|Breast cancer with brain metastases
994763|NCT02048059|Triple Negative
994764|NCT02048059|TNBC
994765|NCT02048059|HER2-positive
994766|NCT02048059|HER2-negative
994767|NCT02048059|Metastatic brain tumors
994768|NCT02048046|ECMO
994769|NCT02048046|Nutrition therapy
994770|NCT02048033|Obesity
994771|NCT02048033|Endogastric suturing
994772|NCT02048033|Jujenal anastomosis
994773|NCT02048033|weight regain
994774|NCT02048007|Childhood mortality
994775|NCT02048007|Azithromycin
994776|NCT02048007|Mass treatment
994777|NCT02048007|Infection
994778|NCT02048007|Bacterial infections
994779|NCT02048007|Trachoma
994780|NCT02048007|Chlamydia infections
994781|NCT02048007|Malaria
994782|NCT02048007|Diarrhea
994783|NCT02048007|Respiratory Infections
994784|NCT02048007|Antibiotic resistance
994785|NCT02048007|Verbal Autopsy
994786|NCT02048007|Microbiome
994787|NCT02047994|Gastric cancer
994788|NCT02047994|Gastric cancer mortality
994789|NCT02047994|Helicobacter pylori treatment
994790|NCT02047994|Pepsinogen testing
994791|NCT02047994|Endoscopy
994792|NCT02047994|Volatile marker
994793|NCT02047981|Childhood mortality
994794|NCT02047981|Azithromycin
994795|NCT02047981|Mass treatment
994796|NCT02047981|Infection
994797|NCT02047981|Verbal Autopsy
994798|NCT02047968|Wake therapy
994799|NCT02047968|Sleep deprivation
994800|NCT02047968|Light therapy
994801|NCT02047968|Bipolar depression
994802|NCT02047968|Sleep-wake cycle
994803|NCT02047968|Major depression
994804|NCT02047968|Depression
994805|NCT02047968|Depressive Disorder
994806|NCT02047968|Major Behavioural Symptoms
994807|NCT02047968|Mood Disorders
994808|NCT02047968|Mental Disorders
994809|NCT02047968|Dyssomnias
994810|NCT02047968|Sleep Disorders
994811|NCT02047968|Affective Disorders
994812|NCT02047929|Asthma
994813|NCT02047929|Shared decision making
994814|NCT02047929|Participatory methods
994815|NCT02047929|Practice facilitator
994816|NCT02047929|Health coach
994817|NCT02047916|Neonates
994818|NCT02047916|Superior Vena Cava Flow
994819|NCT02047916|Pleth variabilty index
994820|NCT02047890|CDK inhibitor
994821|NCT02047890|BAY1000394
994822|NCT02047890|Advanced malignancies
994823|NCT02047890|Japanese
994824|NCT02047877|Respiratory Secretions
994825|NCT02047877|Tracheal Secretions
994826|NCT02047877|Bronchial Secretions
994827|NCT02047877|NonBronchoscopic BAL
994828|NCT02047877|Interleukin 10
994829|NCT02047877|Interleukin 12p70
994830|NCT02047864|Osteoporosis
994831|NCT02047864|Sarcopenia
994832|NCT02047864|Strength
994833|NCT02047864|Bone
994834|NCT02047864|Muscle
994835|NCT02047864|Creatine
994836|NCT02047825|Multiple sclerosis
994837|NCT02047825|Dexterity
994838|NCT02047825|Upper limbs
994839|NCT02047812|Laparotomy
994840|NCT02047812|General Surgery
994841|NCT02047812|Hospitals,General
994842|NCT02047812|Hospitals,High-Volume
994843|NCT02047812|Hospitals,Low-Volume
994844|NCT02047812|Outcome Assessment (Health Care)
994845|NCT02047799|elderly people, blood pressure, hypertension, vitamin D.
994846|NCT02047786|Outcome Assessment (Health Care)
994847|NCT02047786|Appendectomy
994848|NCT02047786|Child
994849|NCT02047786|Hospitals, Pediatric
994850|NCT02047786|Hospitals, General
994851|NCT02047773|bronchiectasis
994852|NCT02047773|intravenous antibiotics
994853|NCT02047773|duration of antibiotic course
994854|NCT02047773|side effects
994855|NCT02047773|bacterial load
994856|NCT02047747|Brain
994857|NCT02047747|Metastasis
994858|NCT02047747|human epidermal receptor (HER)
994859|NCT02047695|migraine with aura
994860|NCT02047695|migraine
994861|NCT02047695|case-control study
994862|NCT02047695|magnetic resonance imaging
994863|NCT02047695|brain diseases
994864|NCT02047656|Healthy volunteers, hypertension
994865|NCT02047643|Type 1 diabetes
994866|NCT02047643|Hypoglycemia
994867|NCT02047643|Accelerometer
994868|NCT02047630|Primary open angle glaucoma
994869|NCT02047630|Ocular hypertension
994870|NCT02047630|latanoprost
994871|NCT02047630|generic
994872|NCT02047630|intraocular pressure
994873|NCT02047617|Muscle Weakness
994874|NCT02047617|Exercise therapy
994875|NCT02047617|Physiotherapy
994876|NCT02047617|Critical illness
994877|NCT02047617|Intensive care
994878|NCT02047617|Mechanical ventilation
994879|NCT02047617|Rehabilitation
994880|NCT02047604|Phase 2a multiple ascending dose, Anti-Very Late Antigen-1
994881|NCT02047578|hematopoietic stem cell transplantation
994882|NCT02047565|punch biopsy
994883|NCT02047552|trauma
994884|NCT02047552|iron
994885|NCT02047552|anemia
994886|NCT02047552|red blood cell transfusion
994887|NCT02047526|Heart Failure
994888|NCT02047526|Cardiovascular disease
994889|NCT02047526|Congestive Heart Failure
994890|NCT02047500|TH-302
994891|NCT02047500|Nab-paclitaxel
994892|NCT02047500|Gemcitabine
994893|NCT02047500|Evofosfamide
994894|NCT02047461|Molybdenum cofactor deficiency (MoCD)
994895|NCT02047461|molybdenum cofactor (MoCo) biosynthesis
994896|NCT02047461|sulfite oxidase (SO)
994897|NCT02047461|xanthine dehydrogenase
994898|NCT02047461|aldehyde oxidase
994899|NCT02047461|S sulfocysteine (SSC)
994900|NCT02047448|transition of care
994901|NCT02047448|care transitions
994902|NCT02047448|readmission
994903|NCT02047448|medication
994904|NCT02047448|adherence
994905|NCT02047448|medication management
994906|NCT02047448|medication reconciliation
994907|NCT02047448|patient counseling
994908|NCT02047448|pharmacist
994909|NCT02047435|Social participation
994910|NCT02047435|Loneliness
994911|NCT02047435|General practice
994912|NCT02047435|Cultural institutions
994913|NCT02047422|Heart failure, diuretics, kidney, glomerular filtration rate
994914|NCT02047383|respiratory infection
994915|NCT02047383|physical variables
994916|NCT02047370|stretching, diaphragm, asthma, manual therapy
994917|NCT02047357|Maternal depression
994918|NCT02047357|Mother
994919|NCT02047357|Child
994920|NCT02047357|LTP
994921|NCT02047357|Learning Through Play
994922|NCT02047357|Healthy thinking
994923|NCT02047344|NSCLC
994924|NCT02047331|periarticular drug injection
994925|NCT02047331|fascia iliaca block
994926|NCT02047331|knee arthroplasty
994927|NCT02047305|ESCN
994928|NCT02047305|RFA
994929|NCT02047292|Gait analysis
994930|NCT02047292|3D videofluoroscopy
994931|NCT02047292|Femoroacetabular impingement
994932|NCT02047292|Neck-cup impingement
994933|NCT02047292|Head-neck ratio
994934|NCT02047292|Hip scores
994935|NCT02047292|Functional assessment
994936|NCT02047292|Cup size
994937|NCT02047292|Range of motion
994938|NCT02047292|Unilateral Primary
994939|NCT02047292|Secondary
994940|NCT02047279|Atrial fibrillation
994941|NCT02047279|Mitral valve
994942|NCT02047266|MICS CABG OPCABG ONCABG CAD
994947|NCT02047240|liver cirrhosis
994948|NCT02047240|glomerular filtration
994949|NCT02047240|cystatin C
994950|NCT02047227|ESPART
994951|NCT02047227|Reproductive Techniques, Assisted
994952|NCT02047227|Infertility
994953|NCT02047227|Pergoveris®
994954|NCT02047227|GONAL-f®
994955|NCT02047214|Glioblastoma multiforme
994956|NCT02047214|Glioblastoma
994957|NCT02047214|Radiotherapy
994958|NCT02047214|Temozolomide
994959|NCT02047214|TPI 287
994960|NCT02047214|Taxoid
994961|NCT02047214|Avastin
994962|NCT02047214|Bevacizumab
994963|NCT02047201|Head and neck cancer
994964|NCT02047201|PET/CT
994965|NCT02047201|induction chemotherapy
994966|NCT02047201|IMRT
994967|NCT02047188|narrow band imaging,microvessels,matrix metalloproteinase-7
994968|NCT02047162|diarrhea
994969|NCT02047162|gastroenteritis
994970|NCT02047162|antimicrobial drug resistance
994971|NCT02047162|antimicrobial agents
994972|NCT02047162|Pakistan
994973|NCT02047162|ambulatory care
994974|NCT02047162|bismuth
994975|NCT02047149|Myelogenous Leukemia
994976|NCT02047123|commercial flaxseed
994977|NCT02047123|cholesterol
994978|NCT02047123|lipidic profile
994979|NCT02047123|yoghurt
994980|NCT02047123|consumption
994981|NCT02047110|ABBV-066
994982|NCT02047110|BI 655066
994983|NCT02047110|risankizumab
994984|NCT02047071|Obstructive sleep apnea
994985|NCT02047071|Female gender
994986|NCT02047071|Continuous Positive Airway Pressure
994987|NCT02047058|biomarker
994988|NCT02047058|Q cell
994989|NCT02047058|Overall survival
994990|NCT02047058|Progression-free survival
994991|NCT02047045|severe chronic constipation
994992|NCT02047045|randomized controlled
994993|NCT02047045|electro-acupuncture
994994|NCT02047045|prucalopride
994995|NCT02047032|electroacupuncture
994996|NCT02047032|urinary incontinence
994997|NCT02047032|PFMT
994998|NCT02047032|Solifenacin
994999|NCT02047019|Drug combination
995000|NCT02047019|Nifedipine GITS
995001|NCT02047019|Candesartan Cilexetil
995002|NCT02047019|Hypertension
995003|NCT02047019|Combination therapy
995004|NCT02047006|Hemodialysis
995005|NCT02047006|Rivaroxaban
995006|NCT02047006|AUC
995007|NCT02046993|Hypertension
995008|NCT02046993|self blood pressure monitoring
995009|NCT02046993|smartphone based telemonitoring
995010|NCT02046993|primary care
995011|NCT02046967|endovenous laser ablation
995012|NCT02046967|endovenous steam ablation
995013|NCT02046967|great saphenous veins
995014|NCT02046967|quality of life
995015|NCT02046954|transesophageal echocardiography
995016|NCT02046954|tee
995017|NCT02046954|toe
995018|NCT02046954|cardiac surgery
995019|NCT02046941|aphasia
995020|NCT02046941|stroke
995021|NCT02046941|Magnetic Resonance Imaging
995022|NCT02046941|Diffusion Magnetic Resonance Imaging
995023|NCT02046928|Leukemia
995024|NCT02046928|Lymphoma
995025|NCT02046902|coronary artery disease
995026|NCT02046902|cardiac stent
995027|NCT02046902|PCI procedure
995028|NCT02046902|Patient preference
995029|NCT02046876|neck pain
995030|NCT02046876|physiotherapy
995031|NCT02046876|adapted swimming
995032|NCT02046876|therapeutic exercises
995033|NCT02046876|health education
995034|NCT02046863|Parkinson's disease
995035|NCT02046863|Tremor
995036|NCT02046863|Bradykinesia
995037|NCT02046863|Deep brain stimulation
995038|NCT02046863|Kinesia
995039|NCT02046850|Phase I, healthy, pharmacokinetics,
995040|NCT02046837|Prostate cancer
995041|NCT02046837|Exercise
995042|NCT02046837|Elderly
995043|NCT02046837|Quality of life
995044|NCT02046837|Fatigue
995045|NCT02046837|Physical fitness
995046|NCT02046837|Adherence
995047|NCT02046837|Cost-effectiveness
995048|NCT02046811|Skin neoplasms
995049|NCT02046811|Radiation
995050|NCT02046811|Screening
995051|NCT02046811|Self-examination
995052|NCT02046811|Comparative effectiveness research
995053|NCT02046811|Dermoscopy
995054|NCT02046798|Pharmacokinetics
995055|NCT02046798|ASP3652
995056|NCT02046798|14C radio-labeled
995057|NCT02046798|Phase 1
995058|NCT02046785|Fluid administration
995059|NCT02046785|Cardiac output
995060|NCT02046785|Right atrial pressure
995061|NCT02046785|Resuscitation
995062|NCT02046772|hemorrhoidectomy
995063|NCT02046772|analgesia
995064|NCT02046772|anaesthetic
995065|NCT02046772|bupivacaine
995066|NCT02046772|morphine chloride
995067|NCT02046733|SCLC
995068|NCT02046733|CTLA-4
995069|NCT02046694|acute lymphoblastic leukemia
995070|NCT02046694|ALL
995071|NCT02046694|pediatric
995072|NCT02046694|maintenance
995073|NCT02046694|allopurinol
995074|NCT02046694|6-MP
995075|NCT02046694|6-mercaptopurine
995076|NCT02046681|Medication Adherence
995077|NCT02046681|Medication Compliance
995078|NCT02046681|Medication Therapy Management
995079|NCT02046681|Side effects
995080|NCT02046681|Analgesics
995081|NCT02046681|Emergency Medicine
995082|NCT02046681|Home care
995083|NCT02046681|Aged
995084|NCT02046681|Acetaminophen
995085|NCT02046681|codeine
995086|NCT02046681|ibuprofen
995087|NCT02046681|Oxycodone
995088|NCT02046668|Osteoarthritis of knee
995089|NCT02046642|Amniotic fluid index;
995090|NCT02046642|amniotic fluid volume;
995091|NCT02046642|intervention studies;
995092|NCT02046642|maternal care patterns;
995093|NCT02046642|mother-fetus relationships;
995094|NCT02046642|rest;
995095|NCT02046642|sonography;
995096|NCT02046642|transplacental exposure
995097|NCT02046590|Propofol
995098|NCT02046590|remifentanil
995099|NCT02046590|safety
995100|NCT02046590|gastro-intestinal
995101|NCT02046590|ERCP
995102|NCT02046590|minimally invasive
995103|NCT02046590|intubation
995104|NCT02046590|ventilation
995105|NCT02046577|Acute respiratory tract infections
995106|NCT02046577|vitamin D
995107|NCT02046577|cholecalciferol
995108|NCT02046577|children
995109|NCT02046577|bronchiolitis
995110|NCT02046577|pneumonia
995111|NCT02046577|prevention
995112|NCT02046551|nicotine
995113|NCT02046551|smoking
995114|NCT02046551|atomoxetine
995115|NCT02046551|stress
995116|NCT02046525|Fecal microbiota therapy
995117|NCT02046512|Probiotics
995118|NCT02046499|Prevention, post partum haemorrhage
995119|NCT02046486|ticagrelor
995120|NCT02046486|ST elevation myocardial infarction
995121|NCT02046486|liquid formulation
995122|NCT02046447|dystonia
995123|NCT02046447|cervical dystonia
995124|NCT02046447|DYT1
995125|NCT02046447|DYT 1
995126|NCT02046447|DYT-1
995127|NCT02046447|Dystonia 1
995128|NCT02046447|fMRI
995129|NCT02046447|healthy
995130|NCT02046447|trihexyphenidyl
995131|NCT02046447|Artane
995132|NCT02046447|Apo-Trihex
995133|NCT02046447|Parkin
995134|NCT02046447|Pacitane
995135|NCT02046447|Benzhexol
995136|NCT02046447|Trihex
995137|NCT02046408|Smoking
995138|NCT02046408|5A's for smoking cessation
995139|NCT02046408|tailored health messages
995140|NCT02046408|Patient-facing information technology
995141|NCT02046408|Mobile health
995142|NCT02046408|behavioral health
995143|NCT02046395|Type 2 Diabetes
995144|NCT02046395|Hypertension
995145|NCT02046382|IV Acetaminophen
995146|NCT02046382|Cesarean Section
995147|NCT02046382|Pain, Postoperative
995148|NCT02046369|Lurasidone, Latuda, Bipolar Depression
995149|NCT02046356|hepatocellular carcinoma
995150|NCT02046356|radiofrequency ablation
995151|NCT02046356|Milan Criteria
995152|NCT02046356|recurrence
995153|NCT02046356|risk factor
995154|NCT02046343|physical activity
995155|NCT02046343|prevention
995156|NCT02046343|health disparities
995157|NCT02046343|behavior
995158|NCT02046343|community based intervention
995159|NCT02046330|Deep Brain Stimulation
995160|NCT02046330|Treatment Resistant Depression
995161|NCT02046330|Major Depressive Disorder
995162|NCT02046330|Depression
995163|NCT02046330|ECT
995164|NCT02046330|TNS
995165|NCT02046304|Sarcoma
995166|NCT02046304|Soft Tissue Sarcomas
995167|NCT02046304|STS
995168|NCT02046304|Extremity and Trunk
995169|NCT02046304|Gemcitabine
995170|NCT02046304|Gemcitabine Hydrochloride
995171|NCT02046304|Gemzar
995172|NCT02046304|External beam radiation therapy
995173|NCT02046304|EBRT
995174|NCT02046304|Radiotherapy
995175|NCT02046304|XRT
995176|NCT02046291|umbilical cord transplant
995177|NCT02046291|acute leukemia
995178|NCT02046291|UCBT
995179|NCT02046291|Hodgkin's Lymphoma
995180|NCT02046291|Lymphoid Leukemia
995181|NCT02046291|Multiple Myeloma
995182|NCT02046291|Myeloid and Monocytic Leukemia
995183|NCT02046291|Non-Hodgkin's Lymphoma
995184|NCT02046291|Hematopoietic malignancies
995185|NCT02046265|Cervical cancer prevention
995186|NCT02046226|Critical Limb Ischemia
995187|NCT02046226|Non Healing Wounds
995188|NCT02046226|Diabetic Wounds
995189|NCT02046226|Foot Ulcers
995190|NCT02046213|Metabolism and Excretion
995191|NCT02046200|ivermectin, alcoholism, alcohol use disorder, treatment
995192|NCT02046187|Ketogenic Diet
995193|NCT02046187|Brain tumor
995194|NCT02046187|Glioma
995195|NCT02046187|Glioblastoma
995196|NCT02046187|Radiation
995197|NCT02046187|Chemotherapy
995198|NCT02046187|temozolomide
995199|NCT02046174|colon
995200|NCT02046174|colorectal
995201|NCT02046174|rectal
995202|NCT02046174|cancer
995203|NCT02046174|macrobead
995204|NCT02046174|stage IV
995205|NCT02046174|metastatic
995206|NCT02046174|biological
995207|NCT02046174|mouse cells
995208|NCT02046174|new york
995209|NCT02046174|new jersey
995210|NCT02046174|clinical research
995211|NCT02046161|colon preparation
995212|NCT02046148|Maternal vaccine
995213|NCT02046148|IgG
995214|NCT02046148|IgA
995215|NCT02046148|GBS
995216|NCT02046148|pregnant women
995217|NCT02046135|Pediatric
995218|NCT02046135|Sodium bicarbonate
995219|NCT02046135|Acute kidney injury
995220|NCT02046135|Cardiac surgery
995221|NCT02046109|Repair
995222|NCT02046109|Replace
995223|NCT02046109|Composite
995224|NCT02046109|restoration
995225|NCT02046109|failing dental restoration
995226|NCT02046109|filling
995227|NCT02046109|dental
995228|NCT02046109|dentistry
995229|NCT02046096|Venous thrombosis
995230|NCT02046096|pulmonary embolism
995231|NCT02046096|vena cava, inferior
995232|NCT02046096|vena cava filters
995233|NCT02046096|venous thromboembolism
995234|NCT02046083|Teenager
995235|NCT02046083|Peanut
995236|NCT02046083|OIT (Oral Induction Tolerance)
995237|NCT02046070|MLN9708
995238|NCT02046070|Newly diagnosed
995239|NCT02046070|NDMM
995240|NCT02046070|IXAZOMIB
995241|NCT02046070|RRMM
995242|NCT02046057|Sentinel Lymph Node
995243|NCT02046057|Ultrasound Guided Needle Core Biopsy
995244|NCT02046044|Heart failure
995245|NCT02046044|Digoxin
995246|NCT02046044|Ivabradine
995247|NCT02046031|Ischemic stroke
995248|NCT02046031|safety
995249|NCT02046031|Pharmacokinetics
995250|NCT02046031|Ginkgolides Meglumine Injection
995251|NCT02046018|Maternal and Child Health
995252|NCT02046018|Rural Uganda
995253|NCT02046005|Family History
995254|NCT02046005|RA
995255|NCT02046005|Rheumatoid Arthritis
995256|NCT02046005|Genetics
995257|NCT02046005|Rheumatoid Factor
995258|NCT02046005|Shared Epitope
995259|NCT02046005|Anti-CCP
995260|NCT02045953|Healthy Subjects
995261|NCT02045953|SERETIDE
995262|NCT02045953|Pharmocokinetics
995263|NCT02045953|FLIXOTIDE
995264|NCT02045953|VENTOLIN Mini-Spacer
995265|NCT02045940|FTIH
995266|NCT02045940|pharmacokinetics
995267|NCT02045940|SARM
995268|NCT02045940|safety
995269|NCT02045927|sedation
995270|NCT02045927|BIS
995271|NCT02045927|monitoring
995272|NCT02045914|calcium ionophore
995273|NCT02045914|fertilization rate
995274|NCT02045914|poor ovarian reserve
995275|NCT02045901|Nausea
995276|NCT02045901|Vomiting
995277|NCT02045901|Pregnancy
995278|NCT02045901|Adolescent
995279|NCT02045901|Diclegis
995280|NCT02045901|Morning
995281|NCT02045901|Sickness
995282|NCT02045888|Hamstring
995283|NCT02045888|Tear
995284|NCT02045888|Muscle
995285|NCT02045888|Grade
995286|NCT02045888|adipose
995287|NCT02045888|cells
995288|NCT02045888|regenerative
995289|NCT02045888|Celution
995290|NCT02045888|stem
995291|NCT02045888|cell
995292|NCT02045888|liposuction
995293|NCT02045888|fat
995294|NCT02045875|Adherence monitoring
995295|NCT02045875|Motivational Interviewing Adherence strategies
995296|NCT02045862|Solifenacin Succinate
995297|NCT02045862|Mirabegron
995298|NCT02045862|Urinary Incontinence
995299|NCT02045862|Combination Therapy
995300|NCT02045862|Urgency
995301|NCT02045862|Nocturia
995302|NCT02045862|Overactive Bladder
995303|NCT02045849|pharmacokinetics
995304|NCT02045849|GSK2140944
995305|NCT02045849|tolerability
995306|NCT02045849|drug interaction
995307|NCT02045849|safety
995308|NCT02045849|itraconazole
995309|NCT02045849|elderly healthy subjects
995310|NCT02045849|food effect
995311|NCT02045849|relative bioavailability
995312|NCT02045836|Pneumovax 23
995313|NCT02045836|Co-administration
995314|NCT02045836|Herpes zoster
995315|NCT02045836|Immunogenicity
995316|NCT02045836|Safety
995317|NCT02045836|Adults
995318|NCT02045810|Measurement
995319|NCT02045810|nosiseption
995320|NCT02045797|Dose ranging
995321|NCT02045797|Intravenous
995322|NCT02045797|Adaptive design
995323|NCT02045797|suspected or confirmed gram-positive acute bacterial skin and skin structure infection
995324|NCT02045797|Subjects
995325|NCT02045797|infection
995326|NCT02045797|Oral
995327|NCT02045797|GSK2140944
995328|NCT02045771|Depression
995329|NCT02045771|Behavioral Activation
995330|NCT02045745|Postoperative air leaks in risk patients.
995331|NCT02045732|Multiple Sclerosis
995332|NCT02045732|MRI
995333|NCT02045719|cat´s claw
995334|NCT02045719|uncaria tomentosa
995335|NCT02045719|quality of life
995336|NCT02045719|no further therapeutic options
995337|NCT02045706|Community Health Workers
995338|NCT02045706|Service
995339|NCT02045706|Volunteerism
995340|NCT02045706|Health Behaviors
995341|NCT02045680|colorectal cancer
995342|NCT02045680|laparoscopy
995343|NCT02045680|neuromuscular block
995344|NCT02045680|oxygen delivery
995345|NCT02045667|Becker's myotonia congenita (BMC)
995346|NCT02045667|Thomson's myotonia congenita (TMC)
995347|NCT02045667|Paramyotonia Congenita (PMC)
995348|NCT02045667|Sodium Channel Myotonia (SCM)
995349|NCT02045641|cardiac surgery
995350|NCT02045641|postoperative treatment
995351|NCT02045641|pleural effusion
995352|NCT02045641|physical performance
995353|NCT02045628|Bariatric Surgery
995354|NCT02045628|Health Psychology
995355|NCT02045602|Cancer
995356|NCT02045602|Solid Tumors
995357|NCT02045602|Gemcitabine
995358|NCT02045602|Oncolytic virus
995359|NCT02045602|Metastatic
995360|NCT02045602|Pancreatic cancer
995361|NCT02045589|Cancer
995362|NCT02045589|Pancreatic adenocarcinoma
995363|NCT02045589|Locally advanced
995364|NCT02045589|Metastatic
995365|NCT02045589|Gemcitabine
995366|NCT02045589|Oncolytic virus
995367|NCT02045589|Abraxane®
995368|NCT02045576|Obstructive Sleep Apnea
995369|NCT02045576|sleep position trainer
995370|NCT02045576|oral appliance therapy
995371|NCT02045576|mandibular advancement device or splint
995372|NCT02045537|HIV
995373|NCT02045498|cpr
995374|NCT02045498|feedback
995375|NCT02045498|capnography
995376|NCT02045498|outcome
995377|NCT02045498|quality
995378|NCT02045498|resuscitation
995379|NCT02045472|Influenza
995380|NCT02045472|Monoclonal antibody
995381|NCT02045459|Microvascular Disease
995382|NCT02045459|Exercise
995383|NCT02045459|Angina
995384|NCT02045459|Chest pain
995385|NCT02045420|Idiopathic Parkinson's Disease
995386|NCT02045420|Magnetic Resonance Imaging
995387|NCT02045420|MR Venography
995388|NCT02045420|Flow Quantification
995389|NCT02045420|Susceptibility Weighted Imaging
995390|NCT02045407|Brain Death
995391|NCT02045407|Neurological Death
995392|NCT02045407|Cerebral circulatory arrest
995393|NCT02045407|Computed Tomography Angiography
995394|NCT02045394|haemoptysis
995395|NCT02045394|hemoptysis
995396|NCT02045394|airway bleeding
995397|NCT02045381|Cancer
995398|NCT02045381|MRI
995399|NCT02045368|refractory
995400|NCT02045368|intolerant
995401|NCT02045368|solid tumors
995402|NCT02045329|Staphylococcus aureus, mupirocin, decolonization
995403|NCT02045316|Preeclampsia
995404|NCT02045316|Aquaporins
995405|NCT02045316|Placenta
995406|NCT02045303|Sub-acute wound
995407|NCT02045303|Chronic wound
995408|NCT02045303|wound
995409|NCT02045303|MIST
995410|NCT02045303|Soring
995411|NCT02045303|Contact Ultrasound
995412|NCT02045303|Noncontact ultrasound
995413|NCT02045303|Wound Care
995414|NCT02045303|VIP Ultrasound Protocol
995415|NCT02045303|Ultrasound
995416|NCT02045264|Firazyr
995417|NCT02045264|Angioedema
995418|NCT02045264|Angioedemas, Hereditary
995419|NCT02045264|Vascular Diseases
995420|NCT02045264|Cardiovascular Diseases
995421|NCT02045264|Urticaria
995422|NCT02045264|Skin Diseases, Vascular
995423|NCT02045264|Skin Diseases
995424|NCT02045264|Hypersensitivity, Immediate
995425|NCT02045264|Hypersensitivity
995426|NCT02045264|Immune System Diseases
995427|NCT02045264|Genetic Diseases, Inborn
995428|NCT02045264|Icatibant
995429|NCT02045264|Anti-Inflammatory Agents, Non-Steroidal
995430|NCT02045264|Analgesics, Non-Narcotic
995431|NCT02045264|Analgesics
995432|NCT02045264|Sensory System Agents
995433|NCT02045264|Peripheral Nervous System Agents
995434|NCT02045264|Physiological Effects of Drugs
995435|NCT02045264|Pharmacologic Actions
995436|NCT02045264|Anti-Inflammatory Agents
995437|NCT02045264|Therapeutic Uses
995438|NCT02045264|Antirheumatic Agents
995439|NCT02045264|Adrenergic beta-Antagonists
995440|NCT02045264|Adrenergic Antagonists
995441|NCT02045264|Adrenergic Agents
995442|NCT02045264|Neurotransmitter Agents
995443|NCT02045264|Molecular Mechanisms of Pharmacological Action
995444|NCT02045264|Central Nervous System Agents
995445|NCT02045251|Helicobacter pylori
995446|NCT02045251|H. pylori
995447|NCT02045251|Pylera
995448|NCT02045238|Bronchiolitis
995449|NCT02045238|Therapeutics
995450|NCT02045238|Saline Solution, Hypertonic
995451|NCT02045225|social anxiety in sexual situations
995452|NCT02045212|Ischemic Optic Neuropathy
995453|NCT02045212|Traumatic Neuropathy
995454|NCT02045212|Non Arteritic Ischemic Neuropathy (NAION)
995455|NCT02045199|Diabetic Neuropathies
995456|NCT02045199|Diabetes Mellitus
995457|NCT02045199|Diabetic Foot
995458|NCT02045199|Diabetes Complications
995459|NCT02045186|Human Papilloma Virus
995460|NCT02045186|Oropharynx
995461|NCT02045186|Oropharyngeal Squamous Cell Carcinoma
995462|NCT02045186|Squamous Cell Carcinoma
995463|NCT02045186|Radiation Therapy
995464|NCT02045186|Chemotherapy
995465|NCT02045173|Sleep apnea, Arrhythmias, Heart Failure, ICD, CRT-D, Apneascan
995466|NCT02045147|Home Bound Care Transitions
995467|NCT02045134|Post Operative Atrial Fibrillation after a cardiac surgery
995468|NCT02045082|Flocked swab
995469|NCT02045082|Traditional fiber swab
995470|NCT02045082|Herpes simplex epithelial keratitis
995471|NCT02045082|Quantitative PCR
995472|NCT02045056|Alzheimer disease
995473|NCT02045056|mild cognitive impairment
995474|NCT02045056|normal cognition
995475|NCT02045043|Sudden Cardiac Death
995476|NCT02045043|Arrhythmias
995477|NCT02045043|Congestive Heart Failure
995478|NCT02045043|Cardiomyopathy
995479|NCT02045043|Single Nucleotide Polymorphisms
995480|NCT02045043|Genomics
995481|NCT02045030|metastatic
995482|NCT02045030|colorectal
995483|NCT02045030|cancer
995484|NCT02045030|aflibercept
995485|NCT02045030|FOLFIRI
995486|NCT02045017|Multiple Myeloma
995487|NCT02045017|Relapsed Multiple Myeloma
995488|NCT02045017|Refactory Multiple Myeloma
995489|NCT02045017|Renal Insufficiency
995490|NCT02045017|Pomalidomide
995491|NCT02045017|Dexamethasone
995492|NCT02045004|Anesthesia
995493|NCT02045004|Surgery
995494|NCT02045004|Geriatrics
995495|NCT02045004|Postoperative cognitive dysfunction
995496|NCT02045004|Postoperative delirium
995497|NCT02045004|Dementia
995498|NCT02045004|Postoperative complications
995499|NCT02045004|Neurological complications
995500|NCT02045004|Psychological complications
995501|NCT02044991|Sciatica
995502|NCT02044991|Pelvic girdle pain
995503|NCT02044965|urinary tract infection
995504|NCT02044965|antibiotic prophylaxis
995505|NCT02044965|probiotics
995506|NCT02044965|neurogenic bladder
995507|NCT02044965|clean intermittent catheterization
995508|NCT02044952|Crohn's Disease
995509|NCT02044952|mesalazine
995510|NCT02044952|Tripterygium Glycosides
995511|NCT02044952|induction remission
995512|NCT02044939|Sarcoidosis, pulmonary rehabilitation
995513|NCT02044900|obstructive sleep apnea
995514|NCT02044900|polysomnography
995515|NCT02044900|heart rate variability
995516|NCT02044900|mathematical biomarker
995517|NCT02044887|Physical activity
995518|NCT02044887|dementia
995519|NCT02044887|relative caregivers
995520|NCT02044887|podometer
995521|NCT02044887|cardiovascular risk
995522|NCT02044848|type 1 diabetes mellitus
995523|NCT02044835|atherosclerotic renal artery stenosis, herbal medicine
995524|NCT02044822|Chronic Lymphocytic Leukemia
995525|NCT02044822|CLL
995526|NCT02044783|Adults
995527|NCT02044783|Elderly
995528|NCT02044770|laparoscopic
995529|NCT02044770|colectomy
995530|NCT02044770|ENSEAL
995531|NCT02044757|Caffeine
995532|NCT02044757|Addiction
995533|NCT02044757|Withdrawal symptoms
995534|NCT02044757|Pediatric
995535|NCT02044757|Adolescent
995536|NCT02044757|Overweight
995537|NCT02044744|Obesity
995538|NCT02044744|Pediatric Obesity
995539|NCT02044744|Physical Activity
995540|NCT02044744|Physical Fitness
995541|NCT02044744|Primary Health Care
995542|NCT02044744|Referral and Consultation
995543|NCT02044731|Schools
995544|NCT02044731|Pediatrics
995545|NCT02044731|Obesity
995546|NCT02044731|Overweight
995547|NCT02044731|Intervention Studies
995548|NCT02044731|African Americans
995549|NCT02044731|Family
995550|NCT02044731|Body mass index
995551|NCT02044718|adverse events
995552|NCT02044718|unplanned admission intensive care
995553|NCT02044718|chart review
995554|NCT02044705|Primary Health Care
995555|NCT02044705|Pediatrics
995556|NCT02044705|Obesity
995557|NCT02044705|Overweight
995558|NCT02044705|Clinical trial
995559|NCT02044705|Hispanic Americans
995560|NCT02044705|Family
995561|NCT02044705|Body mass index
995562|NCT02044692|Hunter syndrome
995563|NCT02044692|Mucopolysaccharidosis II
995564|NCT02044692|Hunterase
995565|NCT02044666|Critical Limb Ischemia
995566|NCT02044666|Amputation
995567|NCT02044653|Phase 2
995568|NCT02044614|Hemodialysis/Peritoneal Dialysis
995569|NCT02044614|functionally anuric
995570|NCT02044614|Icodextrin
995571|NCT02044614|Kidney Disease Quality of Life
995572|NCT02044601|Lung Cancer
995573|NCT02044601|Non-small cell lung cancer
995574|NCT02044601|NSCLC
995575|NCT02044601|Squamous cell carcinoma of the lung
995576|NCT02044601|Adenocarcinoma of the lung
995577|NCT02044601|Radiation therapy
995578|NCT02044601|Proton therapy
995579|NCT02044601|XRT
995580|NCT02044601|Carboplatin
995581|NCT02044601|Paraplatin
995582|NCT02044601|Paclitaxel
995583|NCT02044601|Taxol
995584|NCT02044601|Onartuzumab
995585|NCT02044601|Erlotinib
995586|NCT02044601|Erlotinib hydrochloride
995587|NCT02044601|OSI-774
995588|NCT02044601|CP358774
995589|NCT02044601|Tarceva
995590|NCT02044588|HBsAg(+) donor
995591|NCT02044588|HBsAg(-) donor
995592|NCT02044588|Anti-hepatitis B antibody
995593|NCT02044588|Kidney allograft
995594|NCT02044575|Clock genes, circadian regulation
995595|NCT02044562|dietary nitrate
995596|NCT02044562|radiotherapy
995597|NCT02044562|nasopharyngeal carcinoma
995598|NCT02044549|Carbetocin
995599|NCT02044549|syntometrine
995600|NCT02044549|postpartum hemorrhage
995601|NCT02044549|cesarean section
995602|NCT02044536|biopsy; endoscopy; neoplasms
995603|NCT02044523|Chronic liver disease
995604|NCT02044523|Fibrosis
995605|NCT02044523|Elastography
995606|NCT02044523|Ultrasound
995607|NCT02044523|Magnetic resonance elastography
995608|NCT02044523|Diagnostic performance
995609|NCT02044523|Sensitivity and specificity
995610|NCT02044510|Multiple Sclerosis
995611|NCT02044510|Spinal Cord Injuries
995612|NCT02044510|mirabegron
995613|NCT02044510|Urodynamics
995614|NCT02044497|pharmacokinetics
995615|NCT02044497|pharmacogenomics
995616|NCT02044497|oral oxycodone
995617|NCT02044497|pediatric surgical patients
995618|NCT02044484|HIV
995619|NCT02044484|AIDS
995620|NCT02044484|Viral load
995621|NCT02044484|Primary care
995622|NCT02044471|left ventricular assist device
995623|NCT02044471|continuous flow
995624|NCT02044471|remote ischemic conditioning
995625|NCT02044471|hypertension
995626|NCT02044471|sympathetic tone
995627|NCT02044471|endothelial dysfunction
995628|NCT02044458|Foley Catheterization
995629|NCT02044458|Induction of Labor
995630|NCT02044458|5 French Stylette
995631|NCT02044445|IVF, hCG, oocyte retrieval, time interval
995632|NCT02044419|Comparative
995633|NCT02044419|Bioavailability
995634|NCT02044419|lomitapide
995635|NCT02044341|Acute Otitis Media
995636|NCT02044341|Pain
995637|NCT02044341|Ear Pain
995638|NCT02044341|Ear Ache
995639|NCT02044341|Ear infection
995640|NCT02044341|middle ear infection
995641|NCT02044302|pain
995642|NCT02044302|breast cancer
995643|NCT02044302|breast implant
995644|NCT02044302|breast reconstruction
995645|NCT02044289|depression
995646|NCT02044289|electroconvulsive therapy (ECT)
995647|NCT02044289|magnetic resonance imaging (MRI)
995648|NCT02044276|Neutropenia
995649|NCT02044276|NHL
995650|NCT02044276|Non-Hodgkin lymphomas
995651|NCT02044276|R-CHOP-21
995652|NCT02044263|Cognitive therapy
995653|NCT02044263|Behavior therapy
995654|NCT02044263|Waiting lists
995655|NCT02044263|Therapy, computer-assisted
995656|NCT02044263|Internet
995657|NCT02044250|Aspirin
995658|NCT02044250|Clopidogrel
995659|NCT02044250|Antiplatelet monotherapy
995660|NCT02044250|Drug-eluting stent
995661|NCT02044237|trichotillomania
995662|NCT02044237|online therapy
995663|NCT02044211|Heart Failure, Systolic
995664|NCT02044211|Depressive Disorder
995665|NCT02044211|Depressive Disorder, Major
995666|NCT02044211|Mood Disorder
995667|NCT02044198|Plasmodium Falciparum
995668|NCT02044198|Malaria
995669|NCT02044198|Vaccine
995670|NCT02044198|Plasmodium
995671|NCT02044198|Falciparum
995672|NCT02044185|HMGB1 Protein
995673|NCT02044185|Graft versus Host Disease
995674|NCT02044185|Immunosuppressive Agents
995675|NCT02044185|oral mucositis
995676|NCT02044172|Prostate cancer
995677|NCT02044172|Treatment
995678|NCT02044172|Screening
995679|NCT02044172|Surgery
995680|NCT02044172|Radiotherapy
995681|NCT02044172|Active monitoring
995682|NCT02044159|Hydrocortisone
995683|NCT02044159|Pediatrics
995684|NCT02044159|Adrenal Insufficiency
995685|NCT02044107|Diarrhea,
995686|NCT02044107|Pneumonia,
995687|NCT02044107|Zinc treatment,
995688|NCT02044107|Patient Compliance.
995689|NCT02044094|Opioid dependent
995690|NCT02044094|Buprenorphine
995691|NCT02044094|Suboxone Film
995692|NCT02044094|Opioid blockade
995693|NCT02044094|Hydromorphone challenge
995694|NCT02044016|Achilles tendon rupture, lengthening, validity, goniometer.
995695|NCT02044003|angioplasty
995696|NCT02044003|dissections
995697|NCT02043990|NAVA
995698|NCT02043990|noninvasive ventilation
995699|NCT02043990|infants
995700|NCT02043977|Propofol
995701|NCT02043977|Insomnia
995702|NCT02043977|Sleep disorder
995703|NCT02043977|Sleep deprivation
995704|NCT02043977|Chronic insomnia
995705|NCT02043977|Refractory insomnia
995706|NCT02043977|Primary insomnia
995707|NCT02043964|Multiple Sclerosis
995708|NCT02043964|Clinically Isolated Syndrome
995709|NCT02043964|Tears
995710|NCT02043964|Isoelectric focusing
995711|NCT02043964|Oligoclonal profile
995712|NCT02043925|QT-prolongation
995713|NCT02043925|Torsade de Pointes
995714|NCT02043925|drug interactions
995715|NCT02043925|psychiatry
995716|NCT02043912|QT-prolongation
995717|NCT02043912|Torsade de Pointes
995718|NCT02043912|Haloperidol
995719|NCT02043912|Drug interactions
995720|NCT02043899|Neuroblastoma
995721|NCT02043899|Positron emission tomography
995722|NCT02043899|124-iodine
995723|NCT02043899|Meta-Iodobenzylguanidine
995725|NCT02043873|Clinical Trial
995726|NCT02043873|Composite Restorations
995727|NCT02043873|Restorations Repair
995728|NCT02043873|Replacement Restorations
995729|NCT02043873|Operative Dentistry.
995730|NCT02043860|Multiple Myeloma
995731|NCT02043860|High Risk
995732|NCT02043860|Intermediate Risk
995733|NCT02043860|Symptomatic
995734|NCT02043847|Multiple Myeloma
995735|NCT02043847|Relapsed
995736|NCT02043847|Refractory
995737|NCT02043847|Progressive Disease
995738|NCT02043847|Symptomatic
995739|NCT02043795|Bioresorbable Vascular Scaffold System
995740|NCT02043795|Percutaneous Transluminal Angioplasty
995741|NCT02043795|Stent
995742|NCT02043769|South Africa
995743|NCT02043769|Eastern Cape
995744|NCT02043769|Child ARV
995745|NCT02043769|CLWHIV
995746|NCT02043756|Mitoxantrone Hydrochloride Liposome Injection
995747|NCT02043730|pancreatic cancer
995748|NCT02043730|locally advanced
995749|NCT02043730|unresectable cancer
995753|NCT02043704|IV Acetaminophen
995754|NCT02043704|Vaginal Reconstruction
995755|NCT02043704|Pain, Postoperative
995756|NCT02043691|Endovascular
995757|NCT02043691|Aortic
995758|NCT02043691|Aneurysm
995759|NCT02043691|Thoracoabdominal
995760|NCT02043691|Juxtarenal
995761|NCT02043691|Suprarenal
995762|NCT02043691|Endograft
995763|NCT02043691|Fenestrated
995764|NCT02043691|Branched
995765|NCT02043691|Complex
995766|NCT02043691|Abdominal
995767|NCT02043691|Thoracic
995768|NCT02043691|Stent
995769|NCT02043691|Stentgraft
995777|NCT02043665|CAVATAK
995778|NCT02043665|KEYNOTE-200
995779|NCT02043665|pembrolizumab
995780|NCT02043665|lung cancer
995781|NCT02043665|bladder cancer
995782|NCT02043639|rotation
995783|NCT02043639|shoulder
995784|NCT02043639|joint
995785|NCT02043639|ROM
995786|NCT02043639|abduction,
995787|NCT02043639|internal rotation,
995788|NCT02043639|external rotation,
995789|NCT02043639|flexion
995790|NCT02043639|normal
995791|NCT02043639|joint movement
995792|NCT02043639|physical examination
995793|NCT02043626|childhood nutrition
995794|NCT02043626|physical activity
995795|NCT02043626|school wellness
995796|NCT02043626|school health
995797|NCT02043626|nutritional policies
995798|NCT02043626|childhood obesity
995799|NCT02043613|Joint pain
995800|NCT02043613|Context effects
995801|NCT02043613|Placebo effect
995802|NCT02043613|Exercise treatment
995803|NCT02043600|Colitis, ulcerative
995804|NCT02043600|Yoga
995805|NCT02043587|Acute lymphoblastic leukemia
995806|NCT02043587|Lymphoblastic leukemia
995807|NCT02043587|Lymphoblastic lymphoma
995811|NCT02043548|dermatomyositis
995812|NCT02043548|polymyositis
995813|NCT02043548|tocilizumab
995814|NCT02043548|Actemra
995815|NCT02043535|myocardial perfusion imaging
995816|NCT02043535|myocardial blood flow
995817|NCT02043535|pharmacologic stress agents
995818|NCT02043535|carbon dioxide
995819|NCT02043535|rubidium 82 radioisotope
995820|NCT02043535|positron emission tomography
995821|NCT02043522|123I-mIBG
995822|NCT02043522|SPECT Imaging
995823|NCT02043522|Phantom imaging
995824|NCT02043522|Heart failure
995825|NCT02043522|Coronary artery disease
995826|NCT02043522|Heart to mediastinum ratios
995827|NCT02043522|heart to calibration ratios
995828|NCT02043522|Myocardial blood flow
995829|NCT02043522|Myocardial blood flow researve
995830|NCT02043509|smoking cessation
995831|NCT02043509|pregnancy
995832|NCT02043509|cessation support
995833|NCT02043509|tailored text messages
995834|NCT02043509|self-help
995835|NCT02043509|MiQuit
995836|NCT02043496|Binge Eating Disorder
995837|NCT02043496|Binge Eating
995838|NCT02043496|Eating Disorders
995839|NCT02043496|Obesity
995840|NCT02043496|Psychotherapy
995841|NCT02043496|Cognitive Behavioral Therapy
995842|NCT02043483|CPAP
995843|NCT02043483|OSAS
995844|NCT02043483|CEDOC (Centro de Estudos de Doenças Crónicas)
995845|NCT02043483|FCM (Faculdade de Ciências Médicas)
995846|NCT02043483|UNL (Universidade Nova de Lisboa
995847|NCT02043483|NOVA MEDICAL SCHOOL
995848|NCT02043483|FCT (Fundação para a Ciência e Tecnologia)
995849|NCT02043470|Sinus/nasal cancer
995850|NCT02043431|Heart failure
995851|NCT02043431|Electronic medical records
995852|NCT02043431|Genomics
995853|NCT02043431|Biobank
995854|NCT02043418|HIV
995855|NCT02043418|ARV
995856|NCT02043418|Pediatric
995857|NCT02043418|Cameroon
995858|NCT02043392|intestinal anastomosis
995859|NCT02043392|non-emergent
995860|NCT02043392|intestinal revision
995861|NCT02043392|magnetic compression
995862|NCT02043392|anastomotic leak
995863|NCT02043379|congenital heart disease
995864|NCT02043379|Cardiopulmonary Bypass
995865|NCT02043379|Hypogammaglobulinemia
995866|NCT02043366|Remifentanil
995867|NCT02043366|Opioid-induced hyperalgesia
995868|NCT02043366|Postoperative pain
995869|NCT02043366|Pain Intensity
995870|NCT02043340|Periodontitis
995871|NCT02043340|Bacterial viability
995872|NCT02043340|Lactate dehydrogenase levels
995873|NCT02043340|Indocyanine green
995874|NCT02043340|Scaling and root planing
995875|NCT02043340|Antimicrobial photodynamic therapy.
995876|NCT02043327|Colonoscopy
995877|NCT02043327|assessment
995878|NCT02043327|certification,
995879|NCT02043327|simulation,
995880|NCT02043327|standard setting
995881|NCT02043301|pharmacokinetics
995882|NCT02043301|bioavailability
995883|NCT02043301|PF-04950615
995884|NCT02043288|Pancreatic cancer
995885|NCT02043288|Platinum
995886|NCT02043288|Micelle
995887|NCT02043275|resistance training
995888|NCT02043262|Elderly
995889|NCT02043262|Home-based rehabilitation
995890|NCT02043262|Activities of daily living
995891|NCT02043262|Restorative care
995892|NCT02043262|Reablement
995893|NCT02043262|Everyday rehabilitation
995894|NCT02043249|DELAYED CORD CLAMPING
995895|NCT02043249|MILKING OF CORD
995896|NCT02043249|PREMATURE INFANTS
995897|NCT02043249|LEVEL OF IgG IN NEONATES
995898|NCT02043236|Prostate cancer
995899|NCT02043236|Androgen deprivation therapy
995900|NCT02043236|Bone health
995901|NCT02043236|Bone mineral density
995902|NCT02043223|Vitamin A
995903|NCT02043223|Breast milk
995904|NCT02043223|Postpartum vitamin A supplementation
995905|NCT02043223|Infant vaccine response
995907|NCT02043197|Depression,
995908|NCT02043197|depressive symptoms,
995909|NCT02043197|major depressive disorder,
995910|NCT02043197|Fevarine,
995911|NCT02043197|fluvoxamine,
995912|NCT02043197|cognitive function,
995913|NCT02043197|neurological disorders,
995914|NCT02043197|sleep state
995915|NCT02043184|Neoplasms
995916|NCT02043184|Medication Adherence
995917|NCT02043184|Administration, Oral
995918|NCT02043184|Symptom Assessment
995919|NCT02043184|Neurobehavioral Manifestations
995920|NCT02043184|Depression
995921|NCT02043184|Behavioral Symptoms
995922|NCT02043184|Utilization
995923|NCT02043158|Ovarian Cancer
995924|NCT02043158|Short term survivors
995925|NCT02043158|Long term survivors
995926|NCT02043158|Biobehavioral characteristics
995927|NCT02043158|Sociodemographic characteristics
995928|NCT02043158|Questionnaire
995929|NCT02043158|Survey
995930|NCT02043158|Interview
995931|NCT02043132|reverse shoulder arthroplasty
995932|NCT02043132|Rotator cuff
995933|NCT02043132|Orthopedic joint surgery
995934|NCT02043132|Total shoulder
995935|NCT02043132|Perioperative bleeding
995936|NCT02043132|Tranexamic acid
995937|NCT02043132|Orthopedic complications
995938|NCT02043132|Hemorrhage
995939|NCT02043132|Postoperative Hemorrhage
995940|NCT02043132|Pathologic Processes
995941|NCT02043132|Arthritis
995942|NCT02043132|Joint Diseases
995943|NCT02043132|Musculoskeletal Diseases
995944|NCT02043132|Postoperative Complications
995945|NCT02043132|Antifibrinolytic Agents
995946|NCT02043132|Fibrin Modulating Agents
995947|NCT02043132|Molecular Mechanisms of Pharmacological Action
995948|NCT02043132|Pharmacologic Actions
995949|NCT02043132|Hemostatics
995950|NCT02043132|Coagulants
995951|NCT02043132|Hematologic Agents
995952|NCT02043132|Therapeutic Uses
995953|NCT02043093|Adolescent suicide prevention
995954|NCT02043093|Peer Leader prevention model
995955|NCT02043093|Universal school-based prevention
995956|NCT02043080|Tuberculosis
995957|NCT02043080|HIV
995958|NCT02043080|Xpert MTB/RIF
995959|NCT02043080|Determine TB-LAM
995960|NCT02043080|UNC
995961|NCT02043080|Zambia
995962|NCT02043080|Cost Effectiveness Analysis Curve
995963|NCT02043080|Centre for Infectious Disease Research in Zambia
995964|NCT02043067|TB
995965|NCT02043067|HIV
995966|NCT02043067|Extensively resistant TB
995967|NCT02043067|Extra pulmonary TB
995968|NCT02043054|Type 2 Diabetes Mellitus (T2DM)
995969|NCT02043054|Young Adults
995970|NCT02043054|Cardiovascular Disease (CVD)
995971|NCT02043054|GLP1 Analogue
995972|NCT02043054|DPP IV Inhibitor
995973|NCT02043054|Obesity
995974|NCT02043054|Cardiometabolic Effects
995975|NCT02043054|Cardiac MRI
995976|NCT02043028|Cardiopulmonary resuscitation
995977|NCT02043028|Chest compression
995978|NCT02043028|Advanced cardiac life support
995979|NCT02043028|Posture
995980|NCT02043015|voluntary counseling and testing (VCT)
995981|NCT02043015|couples voluntary counseling and testing (CVCT)
995982|NCT02043015|pre-exposure prophylaxis (PrEP)
995983|NCT02043015|homosexuality
995984|NCT02043015|male
995985|NCT02043015|South Africa
995986|NCT02042989|Advanced Cancers
995987|NCT02042989|Advanced solid tumor
995988|NCT02042989|Advanced p53 Mutant Malignancies
995989|NCT02042989|MLN9708
995990|NCT02042989|Vorinostat
995991|NCT02042989|SAHA
995992|NCT02042989|Suberoylanilide Hydroxamic Acid
995993|NCT02042989|MSK-390
995994|NCT02042989|Zolinza
995995|NCT02042976|Chronic obstructive pulmonary disease (COPD)
995996|NCT02042976|Mindfulness-based cognitive therapy (MBCT)
995997|NCT02042976|Behavioural intervention
995998|NCT02042976|Quality-of-life
995999|NCT02042976|Anxiety
996000|NCT02042976|Depression
996001|NCT02042976|Physical health status
996002|NCT02042963|The cohort of Asian kidney transplant recipients
996003|NCT02042963|The cohort of metabolic complication after kidney transplant
996004|NCT02042963|The biorepository of Asian kidney transplant recipients
996005|NCT02042950|Lymphoma
996006|NCT02042950|Mantle Cell Lymphoma
996007|NCT02042950|MCL
996008|NCT02042950|Relapsed
996009|NCT02042950|Refractory
996010|NCT02042950|Carfilzomib
996011|NCT02042937|Knee
996012|NCT02042937|Hip
996013|NCT02042937|Muscle Strength
996014|NCT02042937|Electromyography
996015|NCT02042937|Biomechanical Phenomena
996016|NCT02042924|Leukemia
996017|NCT02042924|Lymphoma
996018|NCT02042924|Myeloma
996019|NCT02042924|Myelodysplastic Syndrome
996020|NCT02042898|Cardiac Surgery
996021|NCT02042898|Transfusion
996022|NCT02042885|Prostate cancer
996023|NCT02042872|Spinal Cord Injury
996024|NCT02042872|Disuse Osteoporosis
996025|NCT02042872|Zoledronic acid
996026|NCT02042872|Bisphosphonates
996027|NCT02042872|Dual Energy X-ray Absorptiometry
996028|NCT02042859|EndoHPB
996029|NCT02042820|Dry Eye
996030|NCT02042781|PG545
996031|NCT02042781|Phase I
996032|NCT02042781|Progen
996033|NCT02042781|antimetastatic
996034|NCT02042781|antiangiogenic
996035|NCT02042781|advanced cancer patients
996036|NCT02042781|solid tumors
996037|NCT02042781|solid tumours
996038|NCT02042781|tumor microenvironment
996039|NCT02042768|Glucose
996040|NCT02042768|Dialysate
996041|NCT02042768|Peritoneal Dialysis
996042|NCT02042768|patients
996043|NCT02042768|non-diabetic
996044|NCT02042755|cataract
996045|NCT02042755|IOL
996046|NCT02042755|trifocal
996047|NCT02042755|FineVision
996048|NCT02042742|Cross-over studies
996049|NCT02042742|Antioxidants
996050|NCT02042742|Hydroxytyrosol
996051|NCT02042742|Punicalagin
996052|NCT02042742|Treatment outcome
996053|NCT02042742|Inflammatory markers
996054|NCT02042742|Endothelial function
996055|NCT02042742|Humans
996056|NCT02042742|Adults
996057|NCT02042742|volunteers
996058|NCT02042729|volunteer
996059|NCT02042716|preterm and term newborns
996060|NCT02042716|diagnosis of cerebral white matter damage
996061|NCT02042716|quantitative brain elasticity
996062|NCT02042716|Transfontanel ultrafast doppler
996063|NCT02042690|Acute Lymphoblastic Leukemia
996064|NCT02042690|hematopoietic stem cell transplantation
996065|NCT02042690|chemotherapy
996066|NCT02042677|ileostomy
996067|NCT02042677|1-piece
996068|NCT02042677|assessment
996069|NCT02042677|Nova
996070|NCT02042677|NovaLife
996071|NCT02042677|Dansac
996072|NCT02042651|ESWT
996073|NCT02042651|Chronic pelvic pain
996074|NCT02042651|randomized
996075|NCT02042651|sham controlled
996076|NCT02042612|Pharmacokinetics
996077|NCT02042612|Sevoflurane
996078|NCT02042612|Obesity
996079|NCT02042612|Sedation
996080|NCT02042612|ICU patients
996081|NCT02042599|Pharmacokinetics
996082|NCT02042599|Sevoflurane
996083|NCT02042599|Acute kidney injury
996084|NCT02042599|Sedation
996085|NCT02042599|ICU patients
996086|NCT02042534|stroke
996087|NCT02042534|TIA
996088|NCT02042521|Cigarette
996089|NCT02042521|Withdrawal
996090|NCT02042521|Nicotine
996091|NCT02042482|Ultra coenzyme Q10
996092|NCT02042482|L-carnitine
996093|NCT02042469|awareness, clinical research, Saudi arabia
996094|NCT02042456|breast cancer
996095|NCT02042456|dense breasts
996096|NCT02042456|mammography screening
996097|NCT02042456|Screening techniques
996098|NCT02042456|women
996099|NCT02042404|Hearing impairment
996100|NCT02042404|Hearing loss
996101|NCT02042391|PTLD
996102|NCT02042391|CD20-positive
996103|NCT02042391|solid organ transplantation
996104|NCT02042378|BRCA
996105|NCT02042378|BRCA mutation
996106|NCT02042378|germline BRCA
996107|NCT02042378|somatic BRCA
996108|NCT02042378|PARP inhibitor
996109|NCT02042378|rucaparib
996110|NCT02042378|CO-338
996111|NCT02042378|PF 01367338
996112|NCT02042378|AG 14699
996113|NCT02042378|Clovis
996114|NCT02042378|Clovis Oncology
996115|NCT02042378|RucaPanc
996116|NCT02042365|Enhanced recovery,
996117|NCT02042365|sleeve gastrectomy,
996118|NCT02042339|Hyperbaric Oxygen
996119|NCT02042339|Diabetic ulcer
996120|NCT02042339|Wound healing
996121|NCT02042339|3-D life-viz- system
996122|NCT02042339|Indocyanine green video angiography
996123|NCT02042339|Transcutaneous oxygen pressure
996124|NCT02042339|Endothelial progenitor cells
996125|NCT02042326|Arteriovenous Malformations
996126|NCT02042326|Sirolimus
996127|NCT02042326|Maxillofacial Surgery
996131|NCT02042287|Bacterial Infections and Mycoses
996132|NCT02042287|Pharmaceutical Preparations
996133|NCT02042287|Health Occupations
996134|NCT02042274|Fish oil
996135|NCT02042274|EPA
996136|NCT02042274|DHA
996137|NCT02042274|fatty acids
996138|NCT02042274|genetic variation
996139|NCT02042274|gene expression
996140|NCT02042248|HIV
996141|NCT02042248|Acute HIV Infection
996142|NCT02042248|Chronic HIV Infection
996143|NCT02042248|AGS-004
996144|NCT02042248|Phase 1
996145|NCT02042248|Antiretroviral Therapy
996146|NCT02042248|ART
996147|NCT02042248|UNC
996148|NCT02042248|Argos Therapeutics
996149|NCT02042248|The CARE Collaboratory of AIDS
996150|NCT02042248|Immunization
996151|NCT02042248|vaccination
996152|NCT02042235|prematurity
996153|NCT02042235|language
996154|NCT02042235|parent-implemented intervention
996155|NCT02042235|speech therapy
996156|NCT02042235|neurodevelopment
996157|NCT02042222|Sickle cell
996158|NCT02042222|Hydroxyurea
996159|NCT02042222|Dose prediction
996160|NCT02042222|Maximum tolerated dose
996161|NCT02042209|acute coronary syndrome
996162|NCT02042209|thoracic pain
996163|NCT02042209|prehospital
996164|NCT02042209|diagnostic score
996165|NCT02042196|endothelial function
996166|NCT02042196|women
996167|NCT02042196|estrogen deficiency
996168|NCT02042196|sex hormones
996169|NCT02042196|adiposity
996170|NCT02042196|oxidative stress
996171|NCT02042196|antioxidants
996172|NCT02042157|Quality of Life
996173|NCT02042157|Caregivers
996174|NCT02042157|Caregiver burden
996175|NCT02042157|Urinary Tract Infections
996176|NCT02042157|Bidet
996177|NCT02042157|Women's health
996178|NCT02042157|Toileting
996179|NCT02042157|Hygiene
996180|NCT02042157|Activities of Daily Living
996181|NCT02042157|Functional impairment
996182|NCT02042157|Geriatrics
996183|NCT02042144|Neoplasms, Colorectal
996184|NCT02042131|suicide
996185|NCT02042131|suicidal ideation
996186|NCT02042131|ambivalence
996187|NCT02042131|suicide ambivalence
996188|NCT02042131|reasons for living
996189|NCT02042131|reasons for dying
996190|NCT02042131|military
996191|NCT02042131|veteran
996192|NCT02042131|clinical trial
996193|NCT02042131|cognitive behavioral therapy
996194|NCT02042131|psychotherapy
996195|NCT02042131|crisis
996196|NCT02042131|Treatment As Usual (TAU)
996197|NCT02042131|Crisis Response Plan (CRP)
996198|NCT02042131|Enhanced Crisis Response Plan (E-CRP)
996199|NCT02042118|Neonatal resuscitation
996200|NCT02042118|Laryngeal Mask Airway (LMA)
996201|NCT02042118|Face mask ventilation (FMV)
996202|NCT02042118|Uganda
996203|NCT02042118|Africa
996204|NCT02042105|non-small-cell lung cancer
996205|NCT02042105|anaplastic lymphoma kinase
996206|NCT02042105|immunohistochemistry
996207|NCT02042092|Ultrasound
996208|NCT02042092|MRA
996209|NCT02042092|Large Vessel Vasculitis
996210|NCT02042092|Giant Cell Arteritis
996211|NCT02042092|Takayasu Arteritis
996212|NCT02042092|Immunological abnormalities
996213|NCT02042079|Endoscopic full-thickness resection
996214|NCT02042079|gastric subepithelial tumor
996215|NCT02042079|hybrid-NOTES
996216|NCT02042066|Resistant Hypertension
996217|NCT02042066|RH
996218|NCT02042066|RHT
996219|NCT02042066|Blood Pressure
996220|NCT02042066|Kidney
996221|NCT02042066|Shockwave
996222|NCT02042053|imaging
996223|NCT02042053|diagnostic
996224|NCT02042053|castration resistant
996225|NCT02042053|metastatic prostate cancer
996226|NCT02042053|immunotherapy
996227|NCT02042027|corneal neovascularization
996228|NCT02042027|Gamunex-C
996229|NCT02042027|IVI-g
996230|NCT02042027|anterior segment inflammation
996231|NCT02042014|Pulmonary arterial hypertension, QTI571, open label study
996232|NCT02041988|premedication
996233|NCT02041988|oral morphine
996234|NCT02041988|preemptive analgesia
996235|NCT02041975|Prebiotics
996236|NCT02041975|Gut health
996237|NCT02041975|Satisfaction
996238|NCT02041962|Care Management
996239|NCT02041962|Chronic Care Model
996240|NCT02041962|Mood Disorders
996241|NCT02041936|irreversible electroporation
996242|NCT02041936|Nanoknife
996243|NCT02041936|pancreatic cancer
996244|NCT02041923|preterm infant
996245|NCT02041923|stable infant
996246|NCT02041923|mother-infant interaction
996247|NCT02041923|health care cost
996248|NCT02041923|H-HOPE intervention
996249|NCT02041923|mother outcomes
996250|NCT02041923|infant behavioral organization
996251|NCT02041923|infant growth
996252|NCT02041897|EUS-FNA
996253|NCT02041897|Pancreatic cystic lesion
996254|NCT02041897|Diagnosis
996255|NCT02041884|Cognitive Behavioral Therapy
996256|NCT02041884|Dialectical Behavioral Therapy
996257|NCT02041884|Applied Relaxation
996258|NCT02041884|Stress-reduction
996259|NCT02041884|Smartphone application
996260|NCT02041884|ADHD
996261|NCT02041884|Randomized controlled trial
996262|NCT02041884|Psychological treatment
996263|NCT02041884|Efficacy
996264|NCT02041871|Liver Surgery
996265|NCT02041871|Hepatectomy
996266|NCT02041871|Immunonutrition
996267|NCT02041871|Cancer
996268|NCT02041871|Morbidity
996269|NCT02041871|Postoperative complication
996270|NCT02041858|Alarms
996271|NCT02041858|Physiologic Monitoring
996272|NCT02041858|Critical Care
996273|NCT02041858|Alarm fatigue
996274|NCT02041858|Adverse Events
996275|NCT02041845|Radiotherapy
996276|NCT02041845|Radiotherapy dosage
996277|NCT02041845|Dose fractionation
996278|NCT02041845|Radiotherapy, image-guided
996279|NCT02041845|Thorax
996280|NCT02041819|Neoadjuvant chemotherapy
996281|NCT02041819|Nimotuzumab
996282|NCT02041819|Nab-Paclitaxel
996283|NCT02041819|Carcinoma of Esophagus
996284|NCT02041793|Acute pancreatitis
996285|NCT02041793|Pseudocyst
996286|NCT02041780|Diagnostic
996287|NCT02041780|Liver fibrosis
996288|NCT02041780|Ishak score
996289|NCT02041780|Fibrotest
996290|NCT02041780|ShearWave elastography
996291|NCT02041780|Liver biopsies
996292|NCT02041767|Ertapenem; prostatic diffusion; antibioprophylaxy; pharmacokinetics; benign prostatic hyperplasia
996293|NCT02041741|happiness
996294|NCT02041741|well-being
996295|NCT02041741|distress
996296|NCT02041741|positive psychology
996297|NCT02041715|Virus Diseases
996298|NCT02041715|Hemorrhagic Fever, Ebola
996299|NCT02041715|Hemorrhagic Fevers, Viral
996300|NCT02041715|RNA Virus Infections
996301|NCT02041715|Filoviridae Infections
996302|NCT02041715|Mononegavirales Infections
996303|NCT02041702|Bradycardia
996304|NCT02041702|Pacemaker
996305|NCT02041702|Magnetic
996306|NCT02041702|Conditional
996307|NCT02041702|St Jude
996308|NCT02041702|Accent
996309|NCT02041702|Tendril
996310|NCT02041689|Children
996311|NCT02041689|Cancer
996312|NCT02041689|Learning
996313|NCT02041689|Education
996314|NCT02041689|Qualitative
996315|NCT02041676|Chest
996316|NCT02041676|Physiotherapy
996317|NCT02041676|Increased Inspiratory Flow Technique
996318|NCT02041676|Prematurity
996319|NCT02041676|Non Invasive Ventilation
996320|NCT02041663|brain natriuretic peptide
996321|NCT02041663|cardiac function
996322|NCT02041663|meningococcal infections
996323|NCT02041663|septic shock
996324|NCT02041663|severe sepsis
996325|NCT02041637|liver failure
996326|NCT02041637|etiology
996327|NCT02041637|liver transplantation
996328|NCT02041624|allergic
996329|NCT02041624|rhinitis
996330|NCT02041624|conjunctivitis
996331|NCT02041624|grass pollen
996332|NCT02041624|Allergen ImmunoTherapy (AIT)
996333|NCT02041624|grass mix
996334|NCT02041611|WHO grade III and IV
996335|NCT02041585|Hospital Readmission
996336|NCT02041585|Social Isolation and Hospital Readmission
996337|NCT02041585|Age and Hospital Readmission
996338|NCT02041585|Functional Status and Hospital Readmission
996339|NCT02041585|Charlson Score and Hospital Readmission
996340|NCT02041585|Length of Stay and Hospital Readmission
996341|NCT02041546|Lung lavage,
996342|NCT02041546|Surfactant,
996343|NCT02041546|Duration of mechanical
996344|NCT02041546|ventilation
996345|NCT02041520|Seropositive HIV
996346|NCT02041520|Omega 3 fatty acids
996347|NCT02041520|Oxidative stress
996348|NCT02041507|Water-aided colonoscopy
996349|NCT02041507|Water Immersion
996350|NCT02041507|Water Exchange
996351|NCT02041507|On-demand sedation
996352|NCT02041507|Unsedated colonoscopy
996353|NCT02041507|Adenoma detection rate
996354|NCT02041507|Mean adenomas per procedure
996355|NCT02041494|Hernia
996356|NCT02041494|Ventral
996357|NCT02041494|Incisional
996358|NCT02041494|Abdominal
996359|NCT02041494|Herniorrhaphy
996360|NCT02041494|Recurrence
996361|NCT02041494|Infection
996362|NCT02041494|Mesh
996363|NCT02041494|Biologic
996364|NCT02041494|Synthetic
996365|NCT02041468|ALK-positive
996366|NCT02041455|Fibromyalgia
996367|NCT02041455|Melatonin
996368|NCT02041455|Amitriptylin
996369|NCT02041455|Imune-pineal axis
996370|NCT02041442|overactive bladder
996371|NCT02041442|cystoscopy
996372|NCT02041429|Recurrent Breast Cancer
996373|NCT02041429|Advanced Breast Cancer
996374|NCT02041429|Metastatic Breast Cancer
996375|NCT02041416|Geriatric assessment
996376|NCT02041416|REDCap
996377|NCT02041416|touchscreen
996378|NCT02041416|age 65
996379|NCT02041364|Fatigue
996380|NCT02041364|Biomarkers
996381|NCT02041364|Breast Cancer
996382|NCT02041351|metastatic breast cancer
996383|NCT02041351|taxanes
996384|NCT02041351|heavily pretreated
996385|NCT02041312|Cholesterol
996386|NCT02041312|Gastric cancer
996387|NCT02041312|Stage
996388|NCT02041299|sickle cell disease
996389|NCT02041299|Iron overload
996390|NCT02041299|Deferiprone
996391|NCT02041299|Ferriprox
996392|NCT02041299|deferoxamine
996393|NCT02041299|Chelation
996394|NCT02041273|bioavailability
996395|NCT02041273|bioequivalence
996396|NCT02041273|AUC
996397|NCT02041273|Cmax
996398|NCT02041260|Adult
996399|NCT02041260|differentiated thyroid cancer (DTC),
996400|NCT02041260|poorly differentiated thyroid cancer
996401|NCT02041260|not anaplastic thyroid cancer
996402|NCT02041234|Diabetes
996403|NCT02041234|surgical treatment
996404|NCT02041234|medical treatment
996405|NCT02041221|pharmacokinetics, pharmacodynamics, asthma
996406|NCT02041208|Chronic renal anemia
996407|NCT02041208|Hemoglobin
996408|NCT02041208|Kidney transplant
996409|NCT02041195|Overweight
996410|NCT02041182|youth violence
996411|NCT02041182|doctor-patient communication
996412|NCT02041182|health risk behaviors
996413|NCT02041182|pre-visit questionnaires
996414|NCT02041130|Heart Failure
996415|NCT02041130|Heart Failure with Preserved Ejection Fraction
996416|NCT02041104|Metabolic syndrome
996417|NCT02041104|Two month intervention
996418|NCT02041104|Randomised placebo controlled parallel study
996419|NCT02041104|Beta-glucans
996420|NCT02041104|Abdominal fat
996421|NCT02041104|Dyslipidemia
996422|NCT02041104|Insulin resistance
996423|NCT02041104|Hypertension
996424|NCT02041104|Gut Microbiota Composition
996425|NCT02041104|Oral Glucose Tolerance Test
996426|NCT02041104|Lipid Profile
996427|NCT02041104|Real-Time Polymerase Chain Reaction
996428|NCT02041104|Denaturating Gradient Gel Electrophoresis
996429|NCT02041078|Liver surgery
996430|NCT02041078|Blood loss
996431|NCT02041078|CUSA
996432|NCT02041078|Hepatic transection
996433|NCT02041065|Liver transection
996434|NCT02041065|Bloodloss
996435|NCT02041065|Operation time
996436|NCT02041065|Safety
996437|NCT02041065|feasibility
996438|NCT02041026|probiotic
996439|NCT02041026|Yoghurt
996440|NCT02041026|NN20
996441|NCT02041013|Asthma
996442|NCT02041013|Health Literacy
996443|NCT02041000|COPD
996444|NCT02041000|pulmonary
996445|NCT02041000|stem cells
996446|NCT02041000|emphysema
996447|NCT02041000|lungs
996448|NCT02040987|Thorough QT study
996449|NCT02040974|immunotherapy, house dust mites, pollens, allergic rhinitis
996450|NCT02040961|Patients
996451|NCT02040961|Undergoing
996452|NCT02040961|Elective
996453|NCT02040961|Thoracic
996454|NCT02040961|Surgery
996455|NCT02040922|Antibiotics
996456|NCT02040922|Campylobacter
996457|NCT02040922|Diarrhoea
996458|NCT02040922|Enteritis
996459|NCT02040922|Microbiota
996460|NCT02040922|Calprotectin
996461|NCT02040909|sedation
996462|NCT02040909|quality of intubation
996463|NCT02040909|hypotension
996464|NCT02040909|pharmacodynamics
996465|NCT02040909|pharmacokinetics
996466|NCT02040896|computed tomography
996467|NCT02040896|emergency
996468|NCT02040896|CT scan
996469|NCT02040896|ordering behavior
996470|NCT02040896|diagnosis
996471|NCT02040896|radiation
996472|NCT02040883|Schizophrenia
996473|NCT02040883|Tandospirone
996474|NCT02040883|Cognitive Therapy
996475|NCT02040870|Non-Small Cell lung Cancer, NSCLC, ALK, LDK378
996476|NCT02040857|Breast Cancer
996477|NCT02040805|compulsive hoarding
996478|NCT02040805|clutter
996479|NCT02040805|hoarding disorder
996480|NCT02040792|COPD
996481|NCT02040792|Chronic Obstructive Pulmonary Disease
996482|NCT02040779|asthma
996483|NCT02040779|breath-actuated inhaler
996484|NCT02040779|beclomethasone
996485|NCT02040766|asthma
996486|NCT02040766|breath-actuated inhaler
996487|NCT02040766|metered dose inhaler
996488|NCT02040753|Lifestyle intervention
996489|NCT02040753|Change of body composition
996490|NCT02040753|Physical activity
996491|NCT02040753|Weight loss maintenance
996492|NCT02040727|Myokines
996493|NCT02040727|Osteokines
996494|NCT02040727|Glucose homeostasis
996495|NCT02040727|Puberty
996496|NCT02040714|femur head necrosis
996497|NCT02040714|hip
996498|NCT02040714|pediatric orthopedics
996499|NCT02040714|MRI
996500|NCT02040714|Osteonecrosis
996501|NCT02040714|Bone diseases
996502|NCT02040714|Legg Calve Perthes Syndrome
996503|NCT02040662|paravertebral block
996504|NCT02040662|thoracic epidural analgesia
996505|NCT02040662|videothoracoscopic surgery
996506|NCT02040662|lung lobectomy
996507|NCT02040649|Critical care
996508|NCT02040649|Respiration, artificial
996509|NCT02040636|Pertussis
996510|NCT02040636|Tetanus
996511|NCT02040636|Diphtheria
996512|NCT02040636|Poliomyelitis
996513|NCT02040636|Hepatitis B
996514|NCT02040636|Acellular Pertussis Vaccines
996515|NCT02040623|Chronic Graft versus Host Disease
996516|NCT02040623|Keratoconjunctivitis Sicca
996517|NCT02040610|Low Risk Prostate Cancer
996518|NCT02040610|Intermediate Risk Prostate Cancer
996519|NCT02040610|Hypofractionated
996520|NCT02040610|Image Guided Proton Therapy
996521|NCT02040584|De Novo Liver Transplant Recipients, Tacrolimus Minimisation, Everolimus, Renal Function
996522|NCT02040545|Infertility
996523|NCT02040545|In Vitro Fertilization (IVF)
996524|NCT02040545|Venopuncture-free treatment
996525|NCT02040545|Needle-free treatment
996526|NCT02040519|Overactive bladder
996527|NCT02040519|Non obstructive urinary retention
996528|NCT02040519|Sacral neuromodulation
996529|NCT02040506|Acute Myelogenous Leukemia
996530|NCT02040506|Acute Myeloid Leukemia
996531|NCT02040506|Drug therapy
996532|NCT02040506|CD98
996533|NCT02040506|Relapsed
996534|NCT02040506|Refractory
996535|NCT02040506|Monoclonal antibody
996536|NCT02040493|breast cancer
996537|NCT02040493|IORT
996538|NCT02040493|brachytherapy
996539|NCT02040480|bioavailability
996540|NCT02040480|food effect
996541|NCT02040480|formulation
996542|NCT02040480|GSK2110183
996543|NCT02040480|afuresertib
996544|NCT02040480|AKT inhibitor
996545|NCT02040441|Proteomics
996546|NCT02040441|Diabetes
996547|NCT02040441|Chronic kidney disease
996548|NCT02040441|Diabetic nephropathy
996549|NCT02040441|Diabetic retinopathy
996550|NCT02040441|Mineralocorticoid receptor antagonists
996551|NCT02040441|Spironolactone
996552|NCT02040441|Microalbuminuria
996553|NCT02040428|Cardiovascular Diseases
996554|NCT02040428|Fibrin Sealant
996555|NCT02040428|Hemostatics
996556|NCT02040428|Coagulants
996557|NCT02040402|Comparison of pneumococcal conjugated vaccine regimes
996558|NCT02040389|children
996559|NCT02040389|penile
996560|NCT02040389|inguinal
996561|NCT02040389|kidney parents
996562|NCT02040389|anxiety
996563|NCT02040376|Paediatrics
996564|NCT02040376|Medulloblastoma
996565|NCT02040376|Metformin
996566|NCT02040363|COPD
996567|NCT02040363|skeletal muscle
996568|NCT02040363|angiogenesis
996569|NCT02040363|exercise training
996570|NCT02040363|intensity
996571|NCT02040350|Pralidoxime, atropine, organophosphorous poisoning.
996572|NCT02040285|CT colonography
996573|NCT02040259|ischemic stroke
996574|NCT02040259|mechanical thrombectomy device
996575|NCT02040259|Retriever
996576|NCT02040220|CRVO, Macular edema, Aflibercept, anti-VEGF
996577|NCT02040181|renal function, creatinine clearance
996578|NCT02040168|Ventilation
996579|NCT02040168|PTSD
996580|NCT02040168|sedation
996581|NCT02040142|Hyperthermic Intraperitoneal Mitomycin c
996582|NCT02040142|HIPEC
996583|NCT02040142|Cytoreduction
996584|NCT02040116|Rapid Infusion Rituximab
996585|NCT02040103|Deep Vein Thrombosis
996586|NCT02040103|Pulmonary Embolism
996587|NCT02040103|Intermittent Pneumatic Compression
996588|NCT02040103|Pharmacologic DVT
996589|NCT02040103|Prophylaxis
996590|NCT02040103|Critically Ill Patients.
996591|NCT02040077|opioid
996592|NCT02040077|overdose
996593|NCT02040077|OD
996594|NCT02040077|opiate
996595|NCT02040077|prescription opioids
996596|NCT02040077|prescription pain medication
996597|NCT02040077|heroin
996598|NCT02040077|detoxification
996599|NCT02040077|prevention
996600|NCT02040051|intensive care units
996601|NCT02040051|mechanical ventilation
996602|NCT02040051|music therapy
996603|NCT02040038|Diabetes
996604|NCT02040038|Virtual Environment
996605|NCT02040038|Self-Management
996606|NCT02040025|hypertension
996607|NCT02040025|diabetes mellitus
996608|NCT02040025|hemoglobin A1C
996609|NCT02040025|peripheral vascular resistance
996610|NCT02040025|EECP
996611|NCT02040025|Blood pressure
996612|NCT02040025|angiogenesis
996613|NCT02040025|Coronary Artery Disease
996614|NCT02040025|Coronary Disease
996615|NCT02040025|Heart Diseases
996616|NCT02040025|Cardiovascular Diseases
996617|NCT02040012|Type 2 Diabetes Mellitus
996618|NCT02039999|chronic
996619|NCT02039999|cough
996620|NCT02039999|challenge
996621|NCT02039999|ATP
996622|NCT02039999|hypersensitivity
996623|NCT02039999|TRPA1
996624|NCT02039986|cystic fibrosis
996625|NCT02039986|CF
996626|NCT02039986|cystic fibrosis related diabetes
996627|NCT02039986|CFRD
996628|NCT02039986|kalydeco
996629|NCT02039986|ivacaftor
996630|NCT02039973|HIV
996631|NCT02039973|AIDS
996632|NCT02039973|Tanzania
996633|NCT02039973|depression
996634|NCT02039973|perinatal
996635|NCT02039973|psychotherapy
996636|NCT02039973|task-sharing
996637|NCT02039973|problem-solving
996638|NCT02039960|Epidemiology
996639|NCT02039960|Drug Abuse Warning Network (DAWN)
996640|NCT02039960|bupropion
996641|NCT02039960|abuse
996642|NCT02039947|BRAF V600K mutation
996643|NCT02039947|Metastatic Melanoma
996644|NCT02039947|BRAF V600R mutation
996645|NCT02039947|BRAF V600D mutation
996646|NCT02039947|BRAF V600E mutation
996647|NCT02039947|Brain metastases BRAF inhibitor
996648|NCT02039947|Intracranial
996649|NCT02039934|type 2 diabetes
996650|NCT02039934|exercise intervention
996651|NCT02039934|high intensity interval training
996652|NCT02039908|Tolerance to stimulant medication
996653|NCT02039895|Cutaneous T-cell lymphoma
996654|NCT02039895|Helical irradiation of the total skin
996655|NCT02039895|Refractory
996656|NCT02039895|Total skin electron beam therapy
996657|NCT02039882|Acute Coronary Syndrome (ACS)
996658|NCT02039882|Percutaneous Coronary Intervention PCI
996659|NCT02039882|Normals
996660|NCT02039882|Myocardial Infarction MI
996661|NCT02039882|Point of Care POC
996662|NCT02039882|Hypoxanthine
996663|NCT02039882|Inosine
996664|NCT02039882|HPLC High Pressure Liquid Chromatography
996665|NCT02039869|NERD
996666|NCT02039869|Non erosive reflux disease
996667|NCT02039869|functional dyspepsia
996668|NCT02039869|erosive esophagitis
996669|NCT02039869|confocal endomicroscopy
996670|NCT02039869|cell visio
996671|NCT02039869|proton pump inhibitor
996672|NCT02039869|sucralfate
996673|NCT02039856|Patient-centered medical homes
996674|NCT02039856|Primary care
996675|NCT02039856|Women's health
996676|NCT02039856|Veterans
996677|NCT02039830|female
996678|NCT02039830|aging
996679|NCT02039830|physiotherapy
996680|NCT02039830|pelvic floor
996681|NCT02039830|rehabilitation
996682|NCT02039817|pharmacokinetics
996683|NCT02039817|pharmacodynamics
996684|NCT02039817|renal impairment
996685|NCT02039778|Glioblastoma
996686|NCT02039778|High-grade Glioma
996687|NCT02039778|Brain Tums
996688|NCT02039778|Temozolomide
996689|NCT02039778|Stem cell radiation therapy
996690|NCT02039778|IMRT
996691|NCT02039778|Proton beam radiotherapy
996692|NCT02039778|Conventional external beam radiotherapy
996693|NCT02039778|Quality of Life
996694|NCT02039778|Neurocognition
996695|NCT02039765|Ocular Redness
996697|NCT02039739|Orsiro
996698|NCT02039739|Drug Eluting Stent
996699|NCT02039739|Routine Clinical Practice
996700|NCT02039739|Angioplasty, Transluminal, Percutaneous Coronary
996701|NCT02039739|Coronary Artery Disease
996702|NCT02039726|Acute Myeloid Leukemia
996703|NCT02039726|AML
996704|NCT02039726|FMS-like tyrosine kinase 3
996705|NCT02039726|FLT3-ITD
996706|NCT02039726|Quizartinib
996707|NCT02039726|Leukemia
996708|NCT02039726|Tablets
996709|NCT02039713|DeSyne
996710|NCT02039713|Angioplasty, Transluminal, Percutaneous Coronary
996711|NCT02039713|Coronary Artery Disease
996712|NCT02039687|neuropathy
996713|NCT02039687|sarcoidosis
996714|NCT02039674|PD-1
996715|NCT02039674|PD1
996716|NCT02039674|Programmed Cell Death-1
996717|NCT02039674|Programmed Cell Death 1
996718|NCT02039661|Curettage;
996719|NCT02039661|Pain Score
996720|NCT02039648|Periodontitis
996721|NCT02039648|Porphyromonas gingivalis
996722|NCT02039648|Rumex acetosa L.
996723|NCT02039648|Proanthocyanidins
996724|NCT02039635|cancer
996725|NCT02039635|cancer related fatigue
996726|NCT02039635|Korean red ginseng
996727|NCT02039635|chemotherapy
996728|NCT02039583|live birth
996729|NCT02039583|infant
996730|NCT02039583|infant, newborn
996731|NCT02039583|second-hand smoke
996732|NCT02039583|tobacco smoke pollution
996733|NCT02039583|smoke-free
996734|NCT02039583|smoke-free policy
996735|NCT02039570|haemorrhoids
996736|NCT02039570|pelvic reflux
996737|NCT02039531|Knee
996738|NCT02039531|osteoarthritis
996739|NCT02039531|plasma rich in growth factors
996740|NCT02039531|platelet rich plasma
996741|NCT02039531|hyaluronic acid
996742|NCT02039518|Progression free Survival
996743|NCT02039505|Drug therapy
996744|NCT02039479|anti-suicide
996745|NCT02039479|Lithium
996746|NCT02039479|Depression
996747|NCT02039479|suicidal Ideation/behavior
996748|NCT02039453|Colonoscopy
996749|NCT02039453|sedation
996750|NCT02039453|propofol
996751|NCT02039453|fentanyl
996752|NCT02039453|pethidine
996753|NCT02039427|Sore throat
996754|NCT02039427|Hoarseness
996755|NCT02039427|Intubation
996756|NCT02039427|Thyroidectomy
996757|NCT02039427|Ketorolac
996758|NCT02039427|Dexamethasone
996759|NCT02039414|Obesity
996760|NCT02039414|Physical Inactivity
996761|NCT02039414|Lipid Oxidation
996762|NCT02039414|Oxidative stress
996763|NCT02039414|pregnancy
996764|NCT02039414|neonatal adiposity
996765|NCT02039414|neonatal insulin sensitivity
996766|NCT02039401|ALS
996767|NCT02039401|Lou Gehrig's disease
996768|NCT02039401|neurodegenerative disease
996769|NCT02039388|Ovarian Epithelial Cancer
996770|NCT02039388|Serous Intraepithelial Carcinoma (STIC)
996771|NCT02039388|BRCA1 gene
996772|NCT02039388|BRCA2 gene
996773|NCT02039388|Mutation
996774|NCT02039388|Neoplasms
996775|NCT02039388|Glandular and Epithelial
996776|NCT02039388|Ovarian Neoplasms
996777|NCT02039388|Ovarian cancer
996778|NCT02039388|Carcinoma in situ
996779|NCT02039388|family history breast cancer
996780|NCT02039388|family history ovarian cancer
996781|NCT02039375|IV tPA
996782|NCT02039375|Thrombolysis
996783|NCT02039375|Stroke
996784|NCT02039375|Ischemic
996785|NCT02039375|Monitoring
996786|NCT02039349|Alcoholism
996787|NCT02039349|Ghrelin
996788|NCT02039349|Ghrelin Antagonism
996789|NCT02039323|Tenofovir
996790|NCT02039323|Tenofovir disoproxil
996791|NCT02039323|Maraviroc
996792|NCT02039323|Pharmacologic Actions
996793|NCT02039323|Anti-HIV agents
996794|NCT02039323|Pharmacodynamics
996795|NCT02039297|AWARE, Checklist, ICU, Outcome, Adults
996796|NCT02039284|Cerebral palsy
996797|NCT02039284|novel intervention
996798|NCT02039284|sensory electrical stimulation
996799|NCT02039284|virtual reality
996800|NCT02039284|cycling training
996801|NCT02039284|constraint-induced therapy
996802|NCT02039284|biomechanical
996803|NCT02039284|physiology
996804|NCT02039284|outcome
996805|NCT02039271|music
996806|NCT02039271|total knee replacement
996807|NCT02039271|Pain management
996808|NCT02039258|Healthy Volunteers
996809|NCT02039258|Canagliflozin
996810|NCT02039258|Metformin
996811|NCT02039258|INVOKANA®
996812|NCT02039258|Type 2 diabetes mellitus
996813|NCT02039245|Healthy Volunteers
996814|NCT02039245|Canagliflozin
996815|NCT02039245|Metformin
996816|NCT02039245|INVOKANA®
996817|NCT02039245|Type 2 Diabetes Mellitus
996818|NCT02039206|Machado Joseph disease
996819|NCT02039206|Deep TMS
996820|NCT02039206|TMS
996821|NCT02039206|Transcranial Magnetic Stimulation
996822|NCT02039206|SCA3
996823|NCT02039206|Magnetic Stimulation
996824|NCT02039206|Brainsway
996825|NCT02039193|Generalized anxiety disorder
996826|NCT02039193|cognitive behavior therapy
996827|NCT02039193|adherence
996828|NCT02039180|phase I
996829|NCT02039180|healthy volunteers
996830|NCT02039180|AZD3293
996831|NCT02039180|bioavailability
996832|NCT02039180|Pharmacokinetics
996833|NCT02039154|Exercise
996834|NCT02039154|Exercise tolerance
996835|NCT02039154|Aging
996836|NCT02039154|Physical activity
996837|NCT02039141|diabetes prevention program
996838|NCT02039141|community based interventions
996839|NCT02039141|childhood obesity
996840|NCT02039141|insulin resistance
996841|NCT02039141|glucose tolerance
996842|NCT02039141|quality of life
996843|NCT02039141|Latino youth
996844|NCT02039141|physical activity
996845|NCT02039141|nutrition
996846|NCT02039102|hormonal contraceptives
996847|NCT02039102|combined pills
996848|NCT02039102|progesterone-only contraceptives
996849|NCT02039102|body mass index
996850|NCT02039102|asthma
996851|NCT02039102|Scotland
996852|NCT02039102|women
996853|NCT02039076|Healthy
996854|NCT02039063|Crohn's Disease
996855|NCT02039050|Pulmonary Disease, Chronic Obstructive
996856|NCT02039050|Long-acting muscarinic antagonists
996857|NCT02039050|Impulse oscillometry
996858|NCT02039024|18F-DTBZ
996859|NCT02039011|Asthma
996860|NCT02039011|Long acting beta-agonists
996861|NCT02039011|Long acting muscarinic antagonists
996862|NCT02039011|Mannitol challenge
996863|NCT02038998|stroke
996864|NCT02038998|periodic acceleration
996865|NCT02038998|endothelium release
996866|NCT02038998|ischemic penumbra
996867|NCT02038998|shear stress
996868|NCT02038998|adrenomedullin
996869|NCT02038985|Endometriosis
996870|NCT02038985|Robotic Surgery
996871|NCT02038985|Diagnostic Imaging
996872|NCT02038959|Parkinson disease
996873|NCT02038959|Parkinson's
996874|NCT02038959|Parkinson's disease
996875|NCT02038959|telemedicine
996876|NCT02038959|virtual visits
996877|NCT02038959|video calls
996878|NCT02038959|video conferencing
996879|NCT02038959|virtual house calls
996880|NCT02038920|Drug Therapy
996881|NCT02038907|Norovirus, vaccination
996882|NCT02038894|Anesthetic
996883|NCT02038894|Pediatric
996884|NCT02038894|Esophagogastroduodenoscopies
996885|NCT02038894|Eosinophilic esophagitis
996886|NCT02038894|Gastroesophageal reflux disease (GERD)
996887|NCT02038894|Abdominal Pain
996888|NCT02038894|Vomiting
996889|NCT02038894|Sevofluorane
996890|NCT02038894|Propofol
996891|NCT02038894|Nasal cannula
996892|NCT02038894|Intubation
996893|NCT02038894|Endotracheal tube
996894|NCT02038868|BPH
996895|NCT02038868|ASP4901
996896|NCT02038855|Dual-diagnosis
996897|NCT02038855|Latino
996898|NCT02038855|Mental health
996899|NCT02038855|Substance use
996900|NCT02038855|HIV risk
996901|NCT02038829|COPD
996902|NCT02038803|Cystic Fibrosis Medication Adherence
996903|NCT02038790|opioid dependence
996904|NCT02038790|buprenorphine/naloxone
996905|NCT02038790|Opioid-Related Disorders
996906|NCT02038777|Hematologic Malignancies
996907|NCT02038764|Phase 1
996908|NCT02038764|RN168
996909|NCT02038764|Adults
996910|NCT02038764|Type 1 Diabetes
996911|NCT02038764|T1D
996912|NCT02038751|Genotyping
996913|NCT02038751|Phenotyping
996914|NCT02038751|Sleep Apnea
996915|NCT02038751|Genetic Association Studies
996916|NCT02038751|Phenotype
996917|NCT02038738|gallium
996918|NCT02038738|Ga
996919|NCT02038738|PET Scan
996920|NCT02038725|Risks
996921|NCT02038725|Risk Factors
996922|NCT02038725|ABCD2 score
996923|NCT02038725|Predictive Value of Tests
996924|NCT02038725|Risk Assessment
996925|NCT02038725|Severity of Illness Index
996926|NCT02038725|Decision Support Techniques
996927|NCT02038712|Obesity
996928|NCT02038712|Binge eating disorder
996929|NCT02038712|fMRI
996930|NCT02038712|gut hormones
996931|NCT02038686|Hip fracture
996932|NCT02038686|Unstable (31A2 and 31A3)
996933|NCT02038686|Proximal femoral nail
996934|NCT02038673|ASP5878
996935|NCT02038673|FGFR 1,2,3 and 4 inhibitor
996938|NCT02038647|Drug therapy
996939|NCT02038634|wrist
996940|NCT02038634|tendonitis
996941|NCT02038634|dequervain's
996942|NCT02038634|tenosynovitis
996943|NCT02038608|Parkinson
996944|NCT02038608|serotonin
996945|NCT02038608|dopamine
996946|NCT02038608|non motor
996947|NCT02038608|progression
996948|NCT02038608|PET
996949|NCT02038595|brown adipose tissue
996950|NCT02038582|HIV
996951|NCT02038582|HIV Counseling and Testing
996952|NCT02038582|Linkages to Care
996953|NCT02038582|Point of Care CD4
996954|NCT02038582|Point of Care Viral Load
996955|NCT02038543|Hyperoxaluria
996956|NCT02038543|Oxalate
996957|NCT02038543|Primary Hyperoxaluria
996958|NCT02038543|PH
996959|NCT02038530|Deep Vein Thrombosis
996960|NCT02038517|Insulin secretion
996961|NCT02038517|Insulin sensitivity
996962|NCT02038517|Orthotopic liver transplantation
996963|NCT02038517|Type 2 diabetes
996964|NCT02038517|Metabolic syndrome
996965|NCT02038517|Cardiovascular disease
996966|NCT02038504|gastrointestinal fistula
996967|NCT02038504|enteral nutrition
996968|NCT02038504|thyroid function
996969|NCT02038491|Epidural anesthesia
996970|NCT02038491|Spinal anesthesia
996971|NCT02038491|nerve blocks
996972|NCT02038491|complications
996973|NCT02038478|Sickle Cell Disease
996974|NCT02038478|Thalassemia
996975|NCT02038452|hand
996976|NCT02038452|wrist
996977|NCT02038452|carpal
996978|NCT02038452|tunnel
996979|NCT02038452|syndrome
996980|NCT02038452|pragmatic
996981|NCT02038452|randomised
996982|NCT02038452|steroid
996983|NCT02038452|splint
996984|NCT02038439|Evidence-Based Medicine
996985|NCT02038439|Evidence Retrieval
996986|NCT02038439|Knowledge Translation
996987|NCT02038439|Medical Education
996988|NCT02038413|NSCLC
996989|NCT02038413|cT1/cT2aN0M0
996990|NCT02038413|Stereotactic lung treatment
996991|NCT02038413|MAASTRO
996992|NCT02038413|age >18 years
996993|NCT02038335|immune cells
996994|NCT02038335|contraception
996995|NCT02038335|intrauterine device
996996|NCT02038335|IUD
996997|NCT02038335|copper
996998|NCT02038335|microbiota
996999|NCT02038335|DMPA
997000|NCT02038335|etonogestrel
997001|NCT02038335|subdermal implant
997002|NCT02038335|NET-EN
997003|NCT02038335|Jadelle
997004|NCT02038335|Implanon
997005|NCT02038335|Cyclofem
997006|NCT02038322|OTC Home Use Conception Aid Cervical Cap Insemination
997007|NCT02038309|Acute coronary syndrome
997008|NCT02038309|persistent platelet reactivity
997009|NCT02038296|Hepatocellular carcinoma
997010|NCT02038296|Transarterial chemoembolization
997011|NCT02038296|Gemcitabine
997012|NCT02038283|Colorectal Neoplasms
997013|NCT02038283|Early Detection of Cancer
997014|NCT02038283|Quality of Life
997015|NCT02038283|Quality-Adjusted Life Years
997016|NCT02038283|Direct Service Costs
997017|NCT02038283|Cost-Benefit Analysis
997018|NCT02038231|Adolescence
997019|NCT02038231|Substance abuse
997020|NCT02038231|Mindfulness
997021|NCT02038218|DM-CHOC-PEN
997022|NCT02038218|CNS
997023|NCT02038218|brain
997024|NCT02038218|melanoma
997025|NCT02038218|lung cancer
997026|NCT02038218|breast cancer
997027|NCT02038218|glioblastoma multiforme
997028|NCT02038218|primary brain tumors
997029|NCT02038192|Caregiver
997030|NCT02038192|Dementia
997031|NCT02038192|Long Term Care
997032|NCT02038192|Hope
997033|NCT02038192|Quality of Life
997034|NCT02038192|Intervention
997035|NCT02038179|Pre-hypertension
997036|NCT02038179|JNC 7 stage I hypertension
997037|NCT02038140|Primary Ankle Replacement
997038|NCT02038140|Total Ankle Arthroplasty
997039|NCT02038140|Total Ankle Replacement
997040|NCT02038140|Trabecular Metal Total Ankle
997041|NCT02038114|Odette Cancer Centre at Sunnybrook Health Sciences Centre
997042|NCT02038114|Toronto
997043|NCT02038114|Ontario
997044|NCT02038088|Need general anesthesia
997045|NCT02038075|suicide
997046|NCT02038075|suicidal ideation
997047|NCT02038075|military
997048|NCT02038075|veteran
997049|NCT02038075|cognitive behavioral therapy
997050|NCT02038075|behavioral therapy
997051|NCT02038075|psychotherapy
997052|NCT02038075|Brief Cognitive Behavioral Therapy (BCBT)
997053|NCT02038075|Treatement As Usual (TAU)
997054|NCT02038049|Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Magnetic Resonance Imaging, VAY736, monoclonal antibody, gadolinium [Gd]-enhancing lesions, B-Cell
997055|NCT02038036|Polycythemia Vera
997056|NCT02038036|Hematologic Diseases
997057|NCT02038036|Myeloproliferative Disorders
997058|NCT02038036|Bone Marrow Diseases
997059|NCT02038036|Hydroxyurea
997060|NCT02038036|INC424
997061|NCT02038036|Ruxolitinib
997062|NCT02038023|Iv iron in pregnant women
997063|NCT02038023|second and third trimester
997064|NCT02037997|PFS
997065|NCT02037971|Systemic Lupus Erythematosus
997066|NCT02037971|Lupus
997067|NCT02037971|Sleep disorders
997068|NCT02037971|Sleep disturbed
997069|NCT02037971|Physical exercise
997070|NCT02037971|Aerobic exercise
997071|NCT02037945|18F-Fluorocholine (18F-FCho)
997072|NCT02037945|Pet Scan
997073|NCT02037945|MRI
997074|NCT02037945|13-199
997075|NCT02037932|Aneurysm
997076|NCT02037932|Brain Aneurysm
997077|NCT02037906|Renal stones
997078|NCT02037906|SWL
997079|NCT02037880|Mucopolysaccharidosis
997080|NCT02037880|MPS
997081|NCT02037880|Sanfilippo
997082|NCT02037867|alcohol
997083|NCT02037867|type 2 diabetes
997084|NCT02037867|ALT
997085|NCT02037867|abnormal liver enzymes
997086|NCT02037867|hepatic fibrosis
997087|NCT02037867|cirrhosis
997088|NCT02037841|Asthma
997089|NCT02037841|Nursing
997090|NCT02037841|Protocol
997091|NCT02037841|PRAM
997092|NCT02037841|Length of Stay
997093|NCT02037841|Weaning
997094|NCT02037841|Clinical pathway
997095|NCT02037841|Asthma exacerbation
997096|NCT02037828|COPD
997097|NCT02037828|biomarker
997098|NCT02037828|EBC
997099|NCT02037828|FEV1
997100|NCT02037815|hyperosmolar drugs
997101|NCT02037815|mannitol
997102|NCT02037815|hypertonic saline
997103|NCT02037815|serum osmolality
997104|NCT02037815|correlation
997105|NCT02037802|caudal
997106|NCT02037802|epidural
997107|NCT02037802|pediatric
997108|NCT02037802|renal
997109|NCT02037802|transplant
997110|NCT02037802|hemodynamics
997111|NCT02037789|pain
997112|NCT02037789|low back pain
997113|NCT02037789|GWAS
997114|NCT02037789|glycomics
997115|NCT02037789|activomics
997116|NCT02037776|Rikkunshito
997117|NCT02037776|Double blind
997118|NCT02037776|Functional dyspepsia (FD)
997119|NCT02037763|Low back pain
997120|NCT02037763|GWAS
997121|NCT02037763|Glycomics
997122|NCT02037763|Activomics
997123|NCT02037763|Epigenetics
997124|NCT02037750|foster care
997125|NCT02037750|school adjustment
997126|NCT02037711|Laparoscopic
997127|NCT02037711|Levobupivacaine
997128|NCT02037711|Pediatric
997129|NCT02037711|Anesthesia
997130|NCT02037711|Instillation
997131|NCT02037711|surgeries
997132|NCT02037698|CTO
997133|NCT02037698|CT
997134|NCT02037698|Revascularization
997135|NCT02037685|Statins
997136|NCT02037685|Cholesterol lowering medications
997137|NCT02037685|Adherence
997138|NCT02037685|Motivational interviewing
997139|NCT02037685|Minority populations
997140|NCT02037672|PCOS
997141|NCT02037672|PDE-4 inhibitor
997142|NCT02037672|roflumilast
997143|NCT02037672|metformin
997144|NCT02037672|obesity
997145|NCT02037646|Colorectal cancer
997146|NCT02037646|Screening
997147|NCT02037646|Fecal occult blood
997148|NCT02037646|Fecal immunochemical test
997149|NCT02037646|Qualitative
997150|NCT02037646|Quantitative
997151|NCT02037620|Epidural Stimulation
997152|NCT02037607|Deep vein thrombosis
997153|NCT02037607|Children
997154|NCT02037607|Pediatric
997155|NCT02037607|Anti-coagulant
997156|NCT02037607|Neurosurgical procedures
997157|NCT02037607|Blood Clot
997158|NCT02037594|HIV
997159|NCT02037594|Pre-exposure prophylaxis
997160|NCT02037594|PrEP
997161|NCT02037594|MSM
997162|NCT02037594|Demonstration Project
997163|NCT02037581|integrated care
997164|NCT02037581|hometreatment
997165|NCT02037581|assertive community treatment (ACT)
997166|NCT02037581|psychosis
997167|NCT02037581|schizophrenia
997168|NCT02037581|bipolar disorder
997169|NCT02037581|first episode
997170|NCT02037568|depression
997171|NCT02037568|stress
997172|NCT02037568|caregiving
997173|NCT02037568|anxiety
997174|NCT02037568|psychoeducation intervention
997175|NCT02037568|psycho-oncology
997176|NCT02037568|allogeneic hematopoietic stem cell transplant
997177|NCT02037555|Antithrombin
997178|NCT02037555|Cardiopulmonary bypass
997179|NCT02037542|BMI, Lipid profile
997180|NCT02037529|Breast Cancer
997181|NCT02037529|Metastatic
997182|NCT02037529|Locally Recurrent
997183|NCT02037516|residual muscle weakness, respiratory events
997184|NCT02037490|Infants
997185|NCT02037490|Mothers
997186|NCT02037490|Social media
997187|NCT02037490|Obesity prevention
997188|NCT02037464|Prostate Cancer
997189|NCT02037464|Active Surveillance
997190|NCT02037464|Radical Prostatectomy
997191|NCT02037451|Parkinson's disease
997192|NCT02037451|Auditory Cueing
997193|NCT02037438|Clinical sleep medicine
997194|NCT02037438|New methodology for healthcare delivery
997195|NCT02037438|Diagnosis and treatment of sleep disorders
997196|NCT02037438|Electronic health records
997197|NCT02037438|Clinical informatics
997198|NCT02037438|Evidence-based comparative effectiveness research
997199|NCT02037438|Sleep specialists
997200|NCT02037438|Primary care providers
997201|NCT02037438|Allied health professionals
997202|NCT02037438|Patient-centered care
997203|NCT02037425|Chronic Migraine
997204|NCT02037425|onabotulinumtoxinA
997205|NCT02037425|Headache
997206|NCT02037425|Migraine
997207|NCT02037425|Neuronal regrowth
997208|NCT02037425|Botox
997209|NCT02037412|Ticagrelor
997210|NCT02037412|strut coverage
997211|NCT02037412|DES
997212|NCT02037412|ACS
997213|NCT02037412|OCT
997214|NCT02037399|Endoscopic submucosal dissection
997215|NCT02037399|early gastric cancer
997216|NCT02037399|pain relief
997217|NCT02037399|intravenous dexamethasone
997218|NCT02037399|present pain intensity
997219|NCT02037386|Side branch stent
997220|NCT02037386|Coronary bifurcation lesion
997221|NCT02037373|intra and post-op coagulopathy in patients undergoing OLT
997222|NCT02037360|Smoking
997223|NCT02037360|Cessation
997224|NCT02037334|Preterm delivery
997225|NCT02037334|Diagnostics
997226|NCT02037334|Biomechanics
997227|NCT02037321|Systematic review and meta-analysis
997228|NCT02037308|Glu298Asp polymorphism
997229|NCT02037308|Blood pressure
997230|NCT02037308|Plasma NOx
997231|NCT02037308|Beetroot
997236|NCT02037282|HAI Titer
997237|NCT02037282|Hemagglutination Inhibition Assays
997238|NCT02037282|Immunogenicity
997239|NCT02037282|Serum Antibody Response
997240|NCT02037269|Cerenkov Luminescence Imaging, CLI, margin status
997241|NCT02037243|behavior change
997242|NCT02037243|handwashing
997243|NCT02037243|water treatment
997244|NCT02037243|disgust
997245|NCT02037243|shame
997246|NCT02037243|neighbour
997247|NCT02037243|willingness to pay
997248|NCT02037204|IMPACT
997249|NCT02037204|Chondrons
997250|NCT02037204|Mesenchymal stem cells
997251|NCT02037204|Allogeneic MSCs
997252|NCT02037204|single-stage
997253|NCT02037204|Cartilage repair
997254|NCT02037204|Safety
997255|NCT02037204|Efficacy
997256|NCT02037191|ALOPECIA AREATA
997257|NCT02037191|TREATMENT METHOTREXATE
997258|NCT02037178|Peripheral Obliterative Arteriopathy of the legs
997259|NCT02037178|Screening by generalists
997260|NCT02037178|Ultrasound
997261|NCT02037152|Chronic pain
997262|NCT02037152|Mobile applications
997263|NCT02037152|Mindfulness
997264|NCT02037152|Meditation
997265|NCT02037152|Telemedicine
997266|NCT02037152|Cellular phone
997267|NCT02037152|Pain Management
997268|NCT02037152|Therapy, computer-assisted
997269|NCT02037139|Hearing loss
997270|NCT02037139|Tinnitus
997271|NCT02037139|Screening
997272|NCT02037139|Primary Care
997277|NCT02037087|Short Message Service
997278|NCT02037087|newborn health
997279|NCT02037087|maternal behavior
997280|NCT02037087|good household pregnancy practice
997281|NCT02037087|care seeking
997282|NCT02037074|Phosphodiesterase 10 inhibitor
997283|NCT02037022|Autism Spectrum Disorder (ASD)
997284|NCT02037022|Autism
997285|NCT02036983|Ultrasound guided
997286|NCT02036983|Bilateral Transversus abdominis Plane Block
997287|NCT02036983|Dexamethasone
997288|NCT02036983|Preperitoneal Instillation
997289|NCT02036983|Local Analgesic
997290|NCT02036983|Efficacy
997291|NCT02036983|Total Extraperitoneal Bilateral Inguinal hernia repair
997299|NCT02036957|capecitabine
997300|NCT02036957|dermatologic toxicity
997301|NCT02036944|Celiac Disease
997302|NCT02036944|Celiac Sprue
997303|NCT02036944|Iron-Deficiency Anemia
997304|NCT02036931|Joint
997305|NCT02036931|Osteoarthritis
997306|NCT02036931|Avascular Necrosis
997307|NCT02036918|castrate resistant prostate cancer
997308|NCT02036918|metastatic
997309|NCT02036918|sipuleucel-T
997310|NCT02036918|lymphadenectomy
997311|NCT02036918|Excisional lymph node biopsy
997312|NCT02036905|neck pain, orthopedic manual therapy
997313|NCT02036892|Diabetes
997314|NCT02036879|Cystic Fibrosis
997315|NCT02036879|Loestrin
997316|NCT02036879|Hormone
997317|NCT02036866|knee osteoarthritis
997318|NCT02036866|grade I and II knee osteoarthritis
997319|NCT02036866|arthritis
997320|NCT02036853|Triheptanoin
997321|NCT02036853|Glut1 DS
997322|NCT02036853|Epilepsy
997323|NCT02036853|Seizures
997324|NCT02036827|Pain, Postoperative
997325|NCT02036827|Neuromuscular Blocking Agents
997326|NCT02036827|Laparoscopy
997327|NCT02036814|Hypertension
997328|NCT02036814|Nursing
997329|NCT02036814|Therapeutic compliance
997330|NCT02036814|Quality of life
997331|NCT02036814|Health education
997332|NCT02036801|ARDS
997333|NCT02036801|Lung
997334|NCT02036801|Specific Elastance
997335|NCT02036801|Pediatric patients
997336|NCT02036788|Esophageal pressure, Mechanical ventilation
997337|NCT02036762|Chronic Obstructive Pulmonary Disease
997338|NCT02036762|Thoracoabdominal Mechanics
997339|NCT02036762|Functional capacity
997340|NCT02036762|Quality of life
997341|NCT02036736|Orthopedic Surgery
997342|NCT02036736|Total hip prosthesis
997343|NCT02036736|Total knee replacement
997344|NCT02036736|Intraoperative anesthetic strategy
997345|NCT02036736|Propofol
997346|NCT02036736|Desflurane
997347|NCT02036723|Macular Degeneration
997348|NCT02036723|Eye Diseases
997349|NCT02036723|Neovascular Macular Degeneration
997350|NCT02036723|Choroidal Neovascularization
997351|NCT02036723|Geographic Atrophy
997352|NCT02036710|GLP-1
997353|NCT02036710|PYY
997354|NCT02036710|Leptin
997355|NCT02036710|Duodenal Switch
997356|NCT02036697|Cesarean section
997357|NCT02036697|spinal anesthesia
997358|NCT02036697|low dose spinal
997359|NCT02036697|bupivacaine
997360|NCT02036697|hemodynamics
997361|NCT02036697|blood pressure
997362|NCT02036697|cardiac output
997363|NCT02036684|Prostate cancer
997364|NCT02036684|Radical prostatectomy
997365|NCT02036684|Prehabilitation
997366|NCT02036684|Pelvic floor muscle exercises
997367|NCT02036671|Arteriovenous fistula
997368|NCT02036671|Fistula
997369|NCT02036671|Chronic kidney disease
997370|NCT02036671|Percutaneous
997371|NCT02036671|Kidney Disease
997372|NCT02036671|Kidney Failure, Chronic
997373|NCT02036671|Urologic Diseases
997374|NCT02036671|Renal Insufficiency, Chronic
997375|NCT02036671|Renal Insufficiency
997376|NCT02036671|CKD
997377|NCT02036671|hemodialysis
997378|NCT02036658|social anxiety
997379|NCT02036658|treatment
997380|NCT02036619|gestational diabetes
997381|NCT02036619|pregestational diabetes
997382|NCT02036619|screening
997383|NCT02036619|diagnostic criteria
997384|NCT02036619|IADPSG
997385|NCT02036593|Cardiovascular Risk Factors
997386|NCT02036580|Japan
997387|NCT02036580|Phase2
997388|NCT02036580|Safety
997389|NCT02036580|Tolerability
997390|NCT02036580|Idiopathic Pulmonary Fibrosis
997391|NCT02036580|IPF
997392|NCT02036580|CAT-354
997393|NCT02036580|Tralokinumab
997394|NCT02036541|Glaucoma Implant
997395|NCT02036541|Trabeculectomy
997396|NCT02036541|POAG
997397|NCT02036541|Primary Open Angle Glaucoma
997398|NCT02036541|Pseudoexfoliation Glaucoma
997399|NCT02036541|Pigmentary Glaucoma
997400|NCT02036528|Foot Ulcer
997401|NCT02036528|Diabetic Foot
997402|NCT02036528|Gentamicins
997403|NCT02036528|infection
997404|NCT02036502|PD1
997405|NCT02036502|PD-1
997406|NCT02036502|PDL1
997407|NCT02036502|PD-L1
997408|NCT02036476|Merkel Cell Carcinoma
997409|NCT02036476|Skin Cancer
997410|NCT02036463|Duchenne Muscular Dystrophy
997411|NCT02036463|Corticosteroids
997412|NCT02036450|atrial fibrillation
997413|NCT02036450|cardiac arrhythmia
997414|NCT02036450|stroke
997415|NCT02036450|implantable loop recorder
997416|NCT02036450|bleeding
997417|NCT02036450|anticoagulation
997418|NCT02036450|hypertension
997419|NCT02036450|diabetes
997420|NCT02036450|heart failure
997421|NCT02036450|mortality
997422|NCT02036437|Induction of Labor
997423|NCT02036437|Misoprostol
997424|NCT02036411|clomiphene citrate
997425|NCT02036411|amh
997426|NCT02036411|inhibin b
997427|NCT02036398|Percutaneous Nephrolithotomy (PCNL)
997428|NCT02036398|Nephrostomy
997429|NCT02036398|Double J stent
997430|NCT02036398|PleuraL Effusion
997431|NCT02036398|Pain
997432|NCT02036372|glucose
997433|NCT02036372|diabetes mellitus
997434|NCT02036372|perioperative
997435|NCT02036359|Non-small Cell Lung Cancer(NSCLC)
997436|NCT02036346|ileostomy
997437|NCT02036346|colorectal resection
997438|NCT02036346|dehydration
997439|NCT02036346|nutritional status
997440|NCT02036333|near infrared spectroscopy
997441|NCT02036333|pediatrics
997442|NCT02036307|Fish oils
997443|NCT02036307|Triglycerides
997444|NCT02036307|Blood pressure
997445|NCT02036294|Patient self-care behaviors
997446|NCT02036294|Patient activation
997447|NCT02036294|Family caregiver support
997448|NCT02036294|Patient-centered care
997449|NCT02036281|Terminally ill , histologically-confirmed advanced cancer
997450|NCT02036281|Pain unrelieved by opioids
997451|NCT02036268|Ostomy education
997452|NCT02036268|Education
997453|NCT02036268|care of ostomy site
997454|NCT02036255|Prevention, Thrombosis, Hemodialysis, Vascular access device
997455|NCT02036242|Opioid
997456|NCT02036242|Local anesthetic
997457|NCT02036242|Labor delivery
997458|NCT02036242|Safety
997459|NCT02036229|demodex
997460|NCT02036229|demodicidosis
997461|NCT02036229|rosacea
997462|NCT02036229|ivermectin
997463|NCT02036216|Hepatocellular Carcinoma；cell free tumor DNA; Mutation;
997464|NCT02036190|COPD, chronic obstructive pulmonary disease, emphysema
997465|NCT02036164|Locally advanced cervical cancer
997466|NCT02036164|Concurrent chemoradiation
997467|NCT02036164|Adjuvant chemotherapy
997468|NCT02036151|Xylitol
997469|NCT02036151|prevention
997470|NCT02036151|Mutans streptococci
997471|NCT02036151|caries
997472|NCT02036151|plaque
997473|NCT02036151|children
997474|NCT02036125|Corticosteroid
997475|NCT02036125|Ultrasound
997476|NCT02036125|Guided injection
997477|NCT02036112|Advanced Lower rectal cancer
997478|NCT02036112|Extralevator abdominoperineal excision
997479|NCT02036112|Circumferential resection margin
997480|NCT02036112|Morbidity
997481|NCT02036112|Survival
997482|NCT02036099|Dementia
997483|NCT02036099|Automobile driving
997484|NCT02036099|Accidents, traffic
997485|NCT02036086|Melanoma stage IIIB or C with BRAF mutation
997486|NCT02036086|Recurrent regional lymphadenopathy not suitable for surgery
997734|NCT02034838|ritonavir
997487|NCT02036086|Eligible for neoadjuvant vemurafenib and cobimetinib
997488|NCT02036073|erythropoietin
997489|NCT02036073|preterm
997490|NCT02036073|brain injury
997491|NCT02036073|cerebral palsy
997492|NCT02036073|PVL
997495|NCT02036021|pediatric anesthesia
997496|NCT02036021|perioperative respiratory events
997497|NCT02036021|days of hospitalization
997498|NCT02036021|cost of hospitalization
997499|NCT02036008|Liver metastases
997500|NCT02036008|MRI
997501|NCT02036008|Contrast Agents
997502|NCT02035995|gestational diabetes mellitus; optical coherence tomography; pregnancy; retinal nerve fiber layer.
997503|NCT02035956|IVAC MUTANOME
997504|NCT02035956|IVAC
997505|NCT02035956|personalized therapy
997506|NCT02035956|personalized immuno therapy
997507|NCT02035956|RB_0004-01
997508|NCT02035956|Ribological
997509|NCT02035956|Melanoma
997510|NCT02035956|cancer vaccine
997511|NCT02035930|Bispectral Index Monitor, Menstrual Cycle, Dexmedetomidine
997512|NCT02035891|colchicine
997513|NCT02035891|urinary albumin-to-creatinine ratio
997514|NCT02035891|carotid Intima-Media Thickness
997515|NCT02035891|overt nephropathy
997516|NCT02035891|Type 2 diabetes
997517|NCT02035878|anxiety
997518|NCT02035878|depression
997519|NCT02035878|probiotics
997520|NCT02035878|adult
997521|NCT02035878|human
997522|NCT02035878|depression anxiety stress scale
997523|NCT02035878|anxiety sensitivity index
997524|NCT02035865|Psychiatric morbidity
997525|NCT02035865|Cognitive function
997526|NCT02035865|Heart transplantation
997527|NCT02035865|Mortality
997528|NCT02035865|Cardiac allograft vasculopathy
997529|NCT02035839|Target Temperature Management
997530|NCT02035839|Cooling comatose survivors from OHCA
997531|NCT02035839|Good neurological outcome at modified Rankin Score (mRS) ≤ 3
997532|NCT02035813|metastatic breast cancer
997533|NCT02035813|circulating tumor cells
997534|NCT02035813|everolimus
997535|NCT02035813|eribulin
997536|NCT02035800|Rheumatoid Arthritis
997537|NCT02035800|Adalimumab
997538|NCT02035800|Humira
997539|NCT02035787|metformin
997540|NCT02035787|endometrial cancer
997541|NCT02035787|Lineberger Comprehensive Cancer Center
997542|NCT02035787|complex atypical hyperplasia
997543|NCT02035774|Brachial plexus block
997544|NCT02035774|Suprascapular nerve block
997545|NCT02035761|MSA
997546|NCT02035761|Shy-Dragers Syndrome
997547|NCT02035761|Possible or Probable
997548|NCT02035748|Vitreomacular traction
997549|NCT02035748|Symptomatic vitreomacular adhesion
997550|NCT02035748|Ocriplasmin
997551|NCT02035748|JETREA
997552|NCT02035735|NBI,
997553|NCT02035735|squamous cell carcinoma,
997554|NCT02035735|pharynx, larynx, surgical margins.
997555|NCT02035709|Therapy
997556|NCT02035696|influenza
997557|NCT02035696|children
997558|NCT02035696|safety
997559|NCT02035696|tolerability
997560|NCT02035696|immunogenicity
997561|NCT02035683|metabolic response
997562|NCT02035683|chemotherapy
997563|NCT02035670|diagnostic strategy
997564|NCT02035670|effectiveness
997565|NCT02035670|fever of unknown origin
997566|NCT02035657|Merkel cell carcinoma
997567|NCT02035657|MCC
997568|NCT02035631|Breast Neoplasms
997569|NCT02035631|Recurrence
997570|NCT02035631|Motor Activity
997571|NCT02035631|Diet
997572|NCT02035631|Quality of Life
997573|NCT02035579|concussion
997574|NCT02035579|mild traumatic brain injury
997575|NCT02035579|post-concussion syndrome
997576|NCT02035579|adolescents
997577|NCT02035579|sports injury
997578|NCT02035579|aerobic training
997579|NCT02035579|stretching training
997580|NCT02035566|Minority Health
997581|NCT02035566|Health Status Disparities
997582|NCT02035566|Health Care Disparities
997583|NCT02035566|Rural Health
997584|NCT02035566|Telemedicine
997585|NCT02035566|Health Services Research
997586|NCT02035566|Social Determinants of Health
997587|NCT02035566|Ecological Theory of Health
997588|NCT02035527|squamous cell carcinoma
997589|NCT02035527|head and neck
997590|NCT02035514|multiple sclerosis
997591|NCT02035514|mesenchymal stem cells
997592|NCT02035514|autologous transplantation
997593|NCT02035514|MRI efficacy
997594|NCT02035514|clinical safety
997595|NCT02035488|Dry powder inhalation
997596|NCT02035488|Bronchiectasis
997597|NCT02035488|Tobramycin
997598|NCT02035475|Prevention
997599|NCT02035475|Pelvic Lymph Node Dissection
997600|NCT02035475|Lymphoceles
997601|NCT02035475|Prostate Malignancies
997602|NCT02035475|daVinci
997603|NCT02035475|Vessel Sealer
997604|NCT02035475|EndoWrist One
997605|NCT02035449|Video laryngoscope
997606|NCT02035449|Pre-hospital
997607|NCT02035449|Endotracheal intubation
997608|NCT02035449|Difficult endotracheal intubation
997609|NCT02035449|Pre hospital Critical care
997610|NCT02035449|McGrath MAC
997611|NCT02035449|Airway device
997612|NCT02035436|Respiration, artificial
997613|NCT02035436|Critcal care
997614|NCT02035423|Vitamin D Deficiency
997615|NCT02035423|Compliance
997616|NCT02035423|Milk
997617|NCT02035410|cardiac devices
997618|NCT02035410|prevention
997619|NCT02035410|infection
997620|NCT02035397|botulinum toxin
997621|NCT02035397|Endoscopy
997622|NCT02035397|Satiation
997623|NCT02035397|Diet
997624|NCT02035397|Weight Loss
997625|NCT02035358|Metastatic
997626|NCT02035358|Recurrent
997627|NCT02035358|Refractory
997628|NCT02035358|Renal Cell Carcinoma
997629|NCT02035358|Kidney
997630|NCT02035358|clear-cell renal cancer
997631|NCT02035358|Cancer
997632|NCT02035345|Recurrent Ovarian Cancer
997633|NCT02035345|Platinum Sensitive Ovarian Cancer
997634|NCT02035332|Excessive Uterine Bleeding
997635|NCT02035332|Menorrhagia
997636|NCT02035332|Endometrial Ablation
997637|NCT02035293|COPD Exacerbation
997638|NCT02035293|Pulmonary embolism
997639|NCT02035293|Standardized and consensus diagnostic strategy
997640|NCT02035280|Spine
997641|NCT02035280|Deformity
997642|NCT02035280|Fusion
997643|NCT02035280|Elderly
997644|NCT02035280|SRS-22r
997645|NCT02035241|Spices
997646|NCT02035241|Herbs
997647|NCT02035241|Functional food
997648|NCT02035241|Cardiometabolic risk
997649|NCT02035241|Metabolic syndrome
997650|NCT02035241|Inflammation
997651|NCT02035241|Appetite
997652|NCT02035241|Gut hormone
997653|NCT02035228|Chronic Obstructive Pulmonary Disease
997654|NCT02035228|Lung Hyperinflation
997655|NCT02035228|Abdominal Muscle
997656|NCT02035228|Functional Electrical Stimulation
997657|NCT02035215|Hyperlipidemia, Familial Combined
997658|NCT02035215|Omega 3 acids ethylesters 90
997659|NCT02035215|Atorvastatin
997660|NCT02035176|autism
997661|NCT02035176|ADHD
997662|NCT02035176|attention deficit hyperactivity disorder
997663|NCT02035176|behavioral assessment
997664|NCT02035176|behavior
997665|NCT02035163|Atrial fibrillation
997666|NCT02035163|coronary artery bypass graft
997667|NCT02035163|cryoablation
997668|NCT02035163|ganglionic plexi
997669|NCT02035150|breakfast
997670|NCT02035150|oatmeal
997671|NCT02035150|appetite
997672|NCT02035150|cholesterol
997673|NCT02035124|Prostate
997674|NCT02035124|Metastatic
997675|NCT02035124|Refractory
997676|NCT02035124|mCRPC
997677|NCT02035111|Migraine
997678|NCT02035111|Tianshu capsule
997679|NCT02035098|cancer, pain, cluster trial, quality improvement
997680|NCT02035085|19F MRI
997681|NCT02035059|Oral Glucose Tolerance Test
997682|NCT02035059|Fibronectin
997683|NCT02035059|Adiponectin
997684|NCT02035059|Copeptin
997685|NCT02035059|Cortisol
997686|NCT02035046|Gitelman
997687|NCT02035046|Heterozygous SLC12A3 mutation
997688|NCT02035046|Blood pressure
997689|NCT02035046|Hypokalemia
997690|NCT02035020|frataxin, gamma interferon, Friedreich ataxia
997691|NCT02034994|school-based intervention
997692|NCT02034994|after school physical activity
997693|NCT02034994|sugar sweetened beverages
997694|NCT02034994|sedentary behavior
997695|NCT02034994|schoolchildren
997696|NCT02034981|metastatic or unresectable locally advanced malignancies.
997697|NCT02034981|genomic alterations.
997698|NCT02034981|biological crizotinib targets (ALK, MET, ROS1, RON, AXL).
997699|NCT02034968|Nimotuzumab
997700|NCT02034968|Nab-Paclitaxel
997701|NCT02034968|Carcinoma of Esophagus
997702|NCT02034955|Prostate Cancer
997703|NCT02034955|Adaptive Radiotherapy
997704|NCT02034955|Prostatectomy
997705|NCT02034955|Patients who had a prostatectomy
997706|NCT02034942|non-sedation
997707|NCT02034929|colon cancer
997708|NCT02034929|adenoma
997709|NCT02034929|colon polyps
997710|NCT02034916|Breast cancer
997711|NCT02034916|BRCA mutation
997712|NCT02034916|PARP inhibitor
997713|NCT02034916|BRCA 1
997714|NCT02034916|BRCA 2
997715|NCT02034903|Enteral Feeding
997716|NCT02034903|Infant, Premature
997717|NCT02034890|orthotopic neobladder
997718|NCT02034890|urinary tract infection
997719|NCT02034890|intravesical instillation
997720|NCT02034890|hyaluronic acid
997721|NCT02034877|13-valent pneunococcal conjugate vaccine
997722|NCT02034877|pneumococcal disease prevention; safety and immunogenicity study
997723|NCT02034851|Acute pyelonephritis
997724|NCT02034851|Renal scarring
997725|NCT02034851|Dexamethasone
997726|NCT02034851|Children
997727|NCT02034851|Corticoids
997728|NCT02034851|Complementary treatment
997729|NCT02034851|Prevention strategy
997730|NCT02034838|PK
997731|NCT02034838|pharmacokinetic
997732|NCT02034838|HIV-infected
997733|NCT02034838|atazanavir
997735|NCT02034786|Mesenchymal stem cell
997736|NCT02034786|Hyaluronic acid
997737|NCT02034786|Adipose Tissue
997738|NCT02034786|Filler Agent
997739|NCT02034773|Safety, Pharmacokinetics, Pharmacodynamics, Healthy Subjects
997740|NCT02034760|Frailty
997741|NCT02034760|Ageing
997742|NCT02034760|Protein supplementation
997743|NCT02034760|Protein quality
997744|NCT02034760|Gut microbiota
997745|NCT02034760|Metabolome
997746|NCT02034760|Exercise training
997747|NCT02034760|Sarcopenia
997748|NCT02034747|Advagraf
997749|NCT02034747|kidney transplant
997750|NCT02034747|Corticosteroid
997751|NCT02034747|Immunosuppressive regimen
997752|NCT02034734|Phase 1
997753|NCT02034734|ASP3652
997754|NCT02034734|Cerebrospinal fluid (CSF)
997755|NCT02034734|Multiple doses
997756|NCT02034721|Muscle damage
997757|NCT02034721|Muscle soreness
997758|NCT02034721|Muscle function
997759|NCT02034721|Innate immune function
997760|NCT02034721|Inflammation
997761|NCT02034708|Primary brain tumor
997762|NCT02034695|Diabetes mellitus
997763|NCT02034669|Acute Spinal cord Injury, Adipose derived stem cells
997764|NCT02034656|imatinib resistance
997765|NCT02034656|mutation
997766|NCT02034630|hematopoietic stem cell transplantation
997767|NCT02034617|Cognition
997768|NCT02034617|Family nursing
997769|NCT02034617|Infant, premature
997770|NCT02034617|Object attachment
997771|NCT02034617|Stress, physiological
997772|NCT02034617|Stress, psychological
997773|NCT02034604|Naftopidil
997774|NCT02034604|safety
997775|NCT02034539|peripheral artery disease
997776|NCT02034539|critical limb ischemia
997777|NCT02034539|VADOplex
997778|NCT02034539|intermittent foot compression
997779|NCT02034526|Sinus node disease
997780|NCT02034526|Atrial fibrillation
997781|NCT02034526|Pacing
997782|NCT02034500|prevention
997783|NCT02034500|Shigella sonnei
997784|NCT02034487|Delayed Puberty
997785|NCT02034487|Boys
997786|NCT02034487|Hormones
997787|NCT02034487|Polymorphism, Genetic
997788|NCT02034461|Micro-Electrodes
997789|NCT02034461|Peripheral Nerve Injury
997790|NCT02034461|Amputation
997791|NCT02034461|Spinal Cord Injury
997792|NCT02034448|CRRT
997793|NCT02034448|Renal
997794|NCT02034448|Kidney
997795|NCT02034448|adults
997796|NCT02034448|registry
997797|NCT02034448|AKI
997798|NCT02034422|Exercise
997799|NCT02034409|Knee Osteoarthritis
997800|NCT02034409|Pulsed Low Intensity Ultrasound
997801|NCT02034396|Ulcers, venous, unna's boot
997802|NCT02034370|Interscalene nerve block
997803|NCT02034370|Shoulder surgery
997804|NCT02034370|Obstructive Sleep Apnea
997805|NCT02034370|Sleep Disordered Breathing
997806|NCT02034357|Parkinson Disease
997807|NCT02034357|Sleep Disordered Breathing
997808|NCT02034357|Sleep Obstructive Apnea
997809|NCT02034357|Polysomnography
997810|NCT02034357|CPAP (continuous positive airway pressure) titration
997811|NCT02034357|CPAP (continuous positive airway pressure) treatment
997812|NCT02034344|Lupus Erythematosus, Cutaneous
997813|NCT02034344|Lupus Erythematosus, Systemic
997814|NCT02034344|Lupus Erythematosus, Discoid
997815|NCT02034344|Healthy
997816|NCT02034344|Active Cutaneous Lupus Erythematosus
997817|NCT02034344|Longitudinal Study
997818|NCT02034344|Biomarkers
997819|NCT02034344|Subacute Cutaneous Lupus Erythematosus
997820|NCT02034344|Skin Biopsy
997821|NCT02034331|Insulin Sensitivity
997822|NCT02034331|Microvascular permeability
997823|NCT02034331|Sympathetic nervous system
997824|NCT02034318|Fatigue
997825|NCT02034318|Cardiac Sympathetic Denervation
997826|NCT02034318|Parkinson Disease
997827|NCT02034305|Airway Clearance
997828|NCT02034305|Duchenne Muscular Dystrophy
997829|NCT02034305|Peak Cough Flow
997830|NCT02034279|cirrhosis
997831|NCT02034266|Type one diabetes
997832|NCT02034266|nerve damage
997833|NCT02034266|neuropathy
997834|NCT02034266|omega-3 fatty acid
997835|NCT02034266|supplementation
997836|NCT02034266|nutrition
997837|NCT02034253|duration of untreated psychosis
997838|NCT02034253|glutamate
997839|NCT02034253|functional connectivity
997840|NCT02034253|structural connectivity
997841|NCT02034253|schizophrenia
997842|NCT02034253|psychosis
997843|NCT02034227|leukemia
997844|NCT02034214|HIV
997845|NCT02034214|adolescents
997846|NCT02034188|multiple sclerosis
997847|NCT02034188|umbilical cord
997848|NCT02034188|mesenchymal
997849|NCT02034188|stem cells
997850|NCT02034175|apnea
997851|NCT02034175|hypopnea
997852|NCT02034175|polysomnography
997853|NCT02034175|respiratory
997854|NCT02034175|cheyne
997855|NCT02034162|Helminth infections
997856|NCT02034162|Helminths
997857|NCT02034162|Pediatric
997858|NCT02034162|Preschool aged
997859|NCT02034162|School aged
997860|NCT02034162|Mebendazole
997861|NCT02034162|Vermox
997862|NCT02034162|Placebo
997863|NCT02034149|chronic kidney disease
997864|NCT02034149|high risk
997865|NCT02034149|intervention
997866|NCT02034149|hypertension
997867|NCT02034149|hyperglycemia
997868|NCT02034149|hyperlipidemia
997869|NCT02034123|First time in humans
998246|NCT02031419|CC-122
997870|NCT02034123|Small cell lung carcinoma
997871|NCT02034123|Oncology
997872|NCT02034123|GSK2879552
997873|NCT02034123|LSD1 inhibitor
997874|NCT02034110|solid tumors
997875|NCT02034110|efficacy
997876|NCT02034110|BRAF V600E mutation
997877|NCT02034110|trametinib
997878|NCT02034110|safety
997879|NCT02034110|Dabrafenib
997880|NCT02034097|ROS1
997881|NCT02034097|erlotinib
997882|NCT02034097|EGFR
997883|NCT02034097|non-small cell lung cancer
997884|NCT02034097|foretinib
997885|NCT02034084|Transradial approach,
997886|NCT02034084|Coronary angiography
997887|NCT02034071|Prader-Willi syndrome
997894|NCT02034032|Osteoarthritis
997895|NCT02034032|Knee
997896|NCT02034032|Arthritis
997897|NCT02034032|TKA
997898|NCT02034032|Total Knee Arthroplasty
997899|NCT02034006|pathological myopia
997900|NCT02034006|choroidal neovascularization
997901|NCT02034006|ranibizumab
997902|NCT02034006|mono-bilateral
997903|NCT02034006|poor visual acuity
997904|NCT02034006|retinal disease
997905|NCT02034006|eye disease
997906|NCT02034006|Angiogenesis Inhibitors
997907|NCT02034006|Angiogenesis Modulating Agents
997908|NCT02033980|narrow band imaging(NBI)
997909|NCT02033980|NICE classification
997910|NCT02033980|colorectal lesions
997911|NCT02033980|predicting histology
997912|NCT02033967|liver donor
997913|NCT02033967|hepatectomy
997914|NCT02033967|vasodilator
997915|NCT02033967|central venous pressure
997916|NCT02033967|stroke volume variation
997917|NCT02033954|Embolization
997918|NCT02033954|Hemorrhage
997919|NCT02033954|TIPS
997920|NCT02033954|GI Bleeding
997921|NCT02033954|AV Fistula
997922|NCT02033954|AV Malformation
997923|NCT02033954|Traumatic Vascular Injury
997924|NCT02033941|Alzheimer's Disease
997925|NCT02033941|Grapeseed Extract
997926|NCT02033941|Clinical Trial
997927|NCT02033941|Meganatural-AZ
997928|NCT02033941|anti-oligomerization
997929|NCT02033941|Phase 2
997930|NCT02033941|Dietary Supplement
997931|NCT02033941|Nutraceutical
997932|NCT02033928|Myeloma
997933|NCT02033928|MGUS (monoclonal gammopathy of undetermined significance)
997934|NCT02033928|amyloidosis
997935|NCT02033928|stem cell transplant
997936|NCT02033915|Suicide risk assessment
997937|NCT02033915|interactive discussion group
997938|NCT02033915|suicide attempt
997939|NCT02033915|self-harm
997940|NCT02033915|randomized control study
997941|NCT02033915|identifying high risk group for suicide
997942|NCT02033902|Epilepsy
997943|NCT02033863|Varicocele
997944|NCT02033863|Pelvic Congestion Syndrome
997945|NCT02033863|Pelvic Venous Incompetence
997946|NCT02033863|Ovarian Varices
997947|NCT02033850|small vessel disease
997948|NCT02033850|cognition
997949|NCT02033850|treatment
997950|NCT02033850|rehabilitation
997951|NCT02033850|attention
997952|NCT02033850|fMRI
997953|NCT02033850|vascular dementia
997954|NCT02033837|Coronary artery disease
997955|NCT02033837|Cardiac CT
997956|NCT02033837|Appropriate Use Criteria (AUC)
997957|NCT02033811|mitral regurgitation
997958|NCT02033811|MitraClip system
997959|NCT02033811|percutaneous mitral valve repair
997960|NCT02033798|Urodynamics
997961|NCT02033798|Glomerular Filtration Rate
997962|NCT02033785|Prostatic hyperplasia
997963|NCT02033759|Lymphedema
997964|NCT02033733|Post cardiac arrest
997965|NCT02033733|Postcardiac arrest therapeutic hypothermia
997966|NCT02033733|Therapeutic hypothermia protocol
997967|NCT02033733|Neuromuscular blocking agents
997968|NCT02033733|Muscle relaxants
997969|NCT02033733|Hypothermia-induced increased muscle tone
997970|NCT02033733|Microshivering
997971|NCT02033720|postcardiac arrest
997972|NCT02033720|post cardiac arrest syndrome
997973|NCT02033720|post cardiac arrest hypothermia
997974|NCT02033720|pulseless electrical activity
997975|NCT02033720|asystole
997976|NCT02033720|therapeutic hypothermia
997977|NCT02033720|therapeutic hypothermia after cardiac arrest
997978|NCT02033720|therapeutic hypothermia neurologic outcome
997979|NCT02033707|Hallucinogen
997980|NCT02033707|Cognitive effects
997981|NCT02033707|Subjective effects
997982|NCT02033694|Lipid
997983|NCT02033694|Vulnerable Plaque
997984|NCT02033694|Plaque
997985|NCT02033694|Cholesterol
997986|NCT02033694|Near Infrared Spectroscopy
997987|NCT02033694|NIRS-IVUS
997988|NCT02033694|Intravascular Ultrasound
997989|NCT02033694|Angiography
997990|NCT02033694|Coronary Imaging
997991|NCT02033681|epinephrine
997992|NCT02033681|hand
997993|NCT02033681|ischemia
997994|NCT02033681|lidocaine
997995|NCT02033681|upper extremity
997996|NCT02033668|bioavailability
997997|NCT02033668|Pharmacokinetics
997998|NCT02033668|intravenous
998247|NCT02031419|CC-223
997999|NCT02033668|subcutaneous and intramuscular administration
998000|NCT02033668|amyloid beta
998001|NCT02033668|monoclonal antibody
998005|NCT02033629|Anesthesia
998006|NCT02033629|remifentanil
998007|NCT02033629|propofol
998008|NCT02033629|target-controlled infusion
998009|NCT02033629|cardiac surgery
998010|NCT02033603|Total knee arthroplasty
998011|NCT02033603|Total knee replacement
998012|NCT02033603|Femoral Nerve Block
998013|NCT02033603|Adductor Canal Block
998014|NCT02033564|Sore Throat
998015|NCT02033564|Intubation
998016|NCT02033564|Laryngoscopy
998017|NCT02033564|Anesthesiology
998018|NCT02033564|Perioperative
998019|NCT02033564|Airway Management
998020|NCT02033551|Gastric Cancer
998021|NCT02033551|Lung Cancer
998022|NCT02033551|PARP Inhibitor
998023|NCT02033551|Ovarian Cancer
998024|NCT02033551|Solid Tumors
998025|NCT02033551|Breast Cancer
998026|NCT02033551|Colon Cancer
998027|NCT02033538|Neoadjuvant chemotherapy
998028|NCT02033538|Nab-Paclitaxel
998029|NCT02033538|Carcinoma of Esophagus
998030|NCT02033525|Chronic Meniscal Injury
998031|NCT02033525|Degenerative meniscus
998032|NCT02033525|Meniscus injury
998033|NCT02033525|Meniscal injury
998034|NCT02033525|Mesenchymal stromal cells
998035|NCT02033525|Mesenchymal stem cells
998036|NCT02033525|Advanced Therapy
998037|NCT02033525|Bone marrow
998038|NCT02033512|Post-menopause
998039|NCT02033512|Hormone Replacement Therapy
998040|NCT02033512|Nanotechnology
998041|NCT02033512|Biolipid B2
998042|NCT02033499|Blood Glucose Self-Monitoring
998043|NCT02033499|Self-Monitoring, Blood Glucose
998044|NCT02033499|Diabetes Mellitus, Type 2
998045|NCT02033499|Quality of Life
998046|NCT02033486|diffuse optical tomography
998047|NCT02033486|digital breast tomosynthesis
998048|NCT02033486|breast cancer
998049|NCT02033486|solid benign lesions
998050|NCT02033486|cysts
998051|NCT02033486|malignant lesions
998052|NCT02033473|Apelin
998053|NCT02033473|insulin
998054|NCT02033473|volunteers
998055|NCT02033460|Manual therapy
998056|NCT02033460|Exercise
998057|NCT02033460|Education
998058|NCT02033447|Prostate Cancer
998059|NCT02033434|intranasal
998060|NCT02033434|ketamine
998061|NCT02033434|analgesia
998062|NCT02033434|mountain medicine
998063|NCT02033434|pre-hospital care
998064|NCT02033434|patient transport
998065|NCT02033434|pilot study
998066|NCT02033434|mountain environment
998067|NCT02033421|Infective endocarditis
998068|NCT02033421|Therapeutic drug monitoring
998069|NCT02033408|IBD: Inflammatory Bowel Diseases
998070|NCT02033408|CD: Crohn's Disease
998071|NCT02033408|UC: Ulcerative Colitis
998072|NCT02033408|ASC: Acute Severe Colitis
998073|NCT02033408|FMT: Fecal Microbiota Transplantation
998074|NCT02033408|PUCAI: Pediatric Ulcerative Colitis Activity Index
998075|NCT02033408|Ciprofloxacin, Doxycycline, Gentamycin, amoxicillin, vancomycin, metronidazole,ciprofloxacin
998076|NCT02033369|Major depressive disorder
998077|NCT02033369|MDD
998078|NCT02033369|depression
998079|NCT02033369|pramipexole
998080|NCT02033356|adductor canal block
998081|NCT02033356|volunteers
998082|NCT02033356|US-guided peripheral nerve block
998083|NCT02033356|lower limb
998084|NCT02033356|MRI
998085|NCT02033343|Prostate Cancer
998086|NCT02033343|Real-time tracking
998087|NCT02033343|Radiotherapy
998088|NCT02033343|Dynamic Multileaf Collimator
998089|NCT02033330|phenolics
998090|NCT02033330|orange peel
998091|NCT02033330|bioavailability
998092|NCT02033304|Cesarean section
998093|NCT02033304|Pain
998094|NCT02033304|Wound hyperalgesia
998095|NCT02033291|Cerebral Small Vessel Disease
998096|NCT02033291|Blood-Brain Barrier permeability
998097|NCT02033291|Dynamic contrast enhanced Magnetic Resonance Imaging
998098|NCT02033291|Pharmacokinetic modeling
998099|NCT02033291|Reproducibility
998100|NCT02033265|Ultrasound-guided Axillary Brachial Plexus Block
998101|NCT02033265|Obesity
998102|NCT02033265|Performance time
998103|NCT02033265|Failure rate
998104|NCT02033265|Acute complications
998105|NCT02033226|Periodontitis
998106|NCT02033226|Periodontal Regeneration
998107|NCT02033226|Amniotic membrane
998108|NCT02033226|Guided tissue regeneration
998109|NCT02033226|Anti-inflammatory
998110|NCT02033226|Periodontal Therapy.
998111|NCT02033213|intraoperative
998112|NCT02033213|fluid management
998113|NCT02033213|esophageal carcinoma
998114|NCT02033213|surgery
998115|NCT02033213|gas exchange
998116|NCT02033213|tissue perfusion
998117|NCT02033200|vision
998118|NCT02033200|Stendra
998119|NCT02033200|avanafil
998120|NCT02033200|PDE5 inhibitor
998121|NCT02033200|visual acuity
998122|NCT02033200|intraocular pressure
998123|NCT02033200|pupillometry
998124|NCT02033200|color vision discrimination
998125|NCT02033200|healthy males
998126|NCT02033174|alcohol, inflammation, oxidation.
998127|NCT02033161|Functional gastrointestinal disorders
998128|NCT02033161|FGID
998129|NCT02033161|Recurrent abdominal pain
998130|NCT02033161|Abdominal pain
998131|NCT02033161|pain-related functional gastrointestinal disorders
998132|NCT02033135|Atherosclerosis
998133|NCT02033135|Intermittent claudication
998134|NCT02033135|Angioplasty
998135|NCT02033122|exercise, bronchial hyperresponsiveness, inflammation
998136|NCT02033096|stannsoporfin
998137|NCT02033096|hyperbilirubinemia
998138|NCT02033096|heme oxygenase
998139|NCT02033083|abortion
998140|NCT02033083|cervical dilation
998141|NCT02033070|RFA
998142|NCT02033057|Muscular electrostimulation, mechanically ventilated, critically ill patients, muscular weakness.
998143|NCT02033044|borderline personality disorder
998144|NCT02033044|cognitive rehabilitation
998145|NCT02033044|psychoeducation
998146|NCT02033044|psychosocial functioning
998147|NCT02033031|branch retinal vein occlusion
998148|NCT02033031|central retinal thickness
998149|NCT02033031|visual acuity
998150|NCT02033031|central reintal sensitivity
998151|NCT02033018|Aflibercept
998152|NCT02033018|Myopia
998153|NCT02033018|Complications
998154|NCT02033018|Neovascularization
998155|NCT02033018|OCT
998156|NCT02033005|Body Composition
998157|NCT02033005|Adipose Tissue
998158|NCT02033005|Intrahepatocellular Lipid
998159|NCT02033005|Infant
998160|NCT02033005|Magnetic Resonance Imaging
998161|NCT02033005|Magnetic Resonance Spectroscopy
998162|NCT02032966|outcomes
998163|NCT02032966|surgical
998164|NCT02032966|non-surgical
998165|NCT02032966|ankle
998166|NCT02032966|malleolus
998167|NCT02032966|fracture
998168|NCT02032966|tibia
998169|NCT02032966|fibula
998170|NCT02032966|bimalleolar
998171|NCT02032966|trimalleolar
998172|NCT02032953|colorectal cancer
998173|NCT02032953|protein recovery
998174|NCT02032953|perioperative nutrition
998175|NCT02032953|hyperinsulinemia
998176|NCT02032953|normoglycemia
998177|NCT02032953|hyperinsulinemic-normoglycemic clamp
998178|NCT02032953|anabolism
998179|NCT02032940|MRI, Angiography, Pulse Sequence
998180|NCT02032927|osteoarthritis
998181|NCT02032927|pain
998182|NCT02032927|opioids
998183|NCT02032914|pyogenic liver abscess
998184|NCT02032914|colon cancer
998185|NCT02032862|menopause, hot flushes, hot flashes, salvia, sage, sweating
998186|NCT02032849|ventilator associated pneumonia
998187|NCT02032849|subglottic secretion drainage
998188|NCT02032849|manual air-impingement operation
998189|NCT02032849|prolonged intubation
998190|NCT02032823|Breast Cancer
998191|NCT02032823|Adjuvant
998192|NCT02032823|Olaparib
998193|NCT02032823|BRCA 1/2
998194|NCT02032823|HER2
998195|NCT02032810|Stage III Melanoma
998196|NCT02032810|Stage IV Melanoma
998197|NCT02032810|HDAC Inhibitor
998198|NCT02032758|Occupational; Cramp(s)
998199|NCT02032719|Hypertension, Systolic, Uncontrolled
998200|NCT02032706|obstructive sleep apnea
998201|NCT02032706|position therapy
998202|NCT02032706|snoring
998203|NCT02032706|positional
998204|NCT02032693|Everycell
998205|NCT02032693|DNA damage
998206|NCT02032693|DNA inflammation
998207|NCT02032693|DNA stress
998208|NCT02032667|physical activity
998209|NCT02032667|exergames
998210|NCT02032654|antibiotics
998211|NCT02032654|flucloxacillin
998212|NCT02032654|therapy duration
998213|NCT02032654|cellulitis
998214|NCT02032654|erysipelas
998215|NCT02032654|skin infections
998216|NCT02032654|hospital
998217|NCT02032641|Non-ablative laser
998218|NCT02032641|Scar revision
998219|NCT02032641|direct brow lift
998220|NCT02032628|epigenetics
998221|NCT02032628|cancer
998222|NCT02032628|exercise
998223|NCT02032628|intensity
998224|NCT02032628|duration
998225|NCT02032615|anemia
998226|NCT02032602|Myofascial Pain Syndromes
998227|NCT02032602|Trigger Point
998228|NCT02032602|Shoulder Pain
998229|NCT02032602|Aged
998230|NCT02032576|major depressive episode, electroconvulsive therapy
998231|NCT02032563|neoadjuvant therapy
998232|NCT02032550|Localized prostate cancer
998233|NCT02032550|Patient preference
998234|NCT02032550|Treatment choice
998235|NCT02032550|Decision making
998236|NCT02032550|Patient centered outcomes
998237|NCT02032537|callmax cream
998238|NCT02032537|uremic pruritus
998239|NCT02031523|endometriosis
998240|NCT02031523|dysmenorrhea
998241|NCT02031523|Sanjie analgesic capsule
998242|NCT02031523|effect/safety
998243|NCT02031497|Sweetener, insulin, body mass index, physical activity
998244|NCT02031432|cancer-related pain
998245|NCT02031432|cebranopadol
998248|NCT02031419|CC-292
998249|NCT02031419|Rituximab
998250|NCT02031419|Lymphoma
998251|NCT02031419|Diffuse Large B-Cell Lymphoma
998252|NCT02031380|Glaucoma
998253|NCT02031380|Open angle glaucoma
998254|NCT02031380|ocular hypertension
998255|NCT02031380|compliance
998256|NCT02031354|Lysine Chloride
998257|NCT02031328|prostate
998258|NCT02031328|radiation
998259|NCT02031328|stereotactic body radiation
998260|NCT02031315|sudden death
998261|NCT02031315|sudden cardiac arrest
998262|NCT02031302|Lotus
998263|NCT02031302|Valve
998264|NCT02031302|Real world
998265|NCT02031302|Aortic stenosis
998266|NCT02031302|High risk
998267|NCT02032498|sentinel lymph nodes
998268|NCT02032498|radiocolloids
998269|NCT02032498|Indocyanine Green
998270|NCT02032498|complementarity
998271|NCT02032498|axillary lymph node dissection
998272|NCT02032485|colorectal cancer
998273|NCT02032485|Indocyanine Green
998274|NCT02032485|visualization of peritoneal metastases
998275|NCT02032472|Blood Pressure Monitoring, Ambulatory
998276|NCT02032472|Arterial Pressure
998277|NCT02032472|Hypertension Controlled
998278|NCT02032472|Pharmacies
998279|NCT02032459|Pregnancy
998280|NCT02032459|Minority Women
998281|NCT02032459|Preterm delivery
998282|NCT02032459|Fetal growth restriction
998283|NCT02032459|Preeclampsia
998284|NCT02032459|Gestational Diabetes
998285|NCT02032459|Vitamin D
998286|NCT02032433|extended-release naltrexone (Vivitrol)
998287|NCT02032433|buprenorphine-naloxone (Suboxone)
998288|NCT02032433|comparative effective
998289|NCT02032433|relapse prevention
998290|NCT02032394|Chlorhexidine
998291|NCT02032394|Povidone-iodine
998292|NCT02032394|bacteriuria
998293|NCT02032394|Urinary Catheterization
998294|NCT02032394|Urinary tract infection
998295|NCT02032381|non infectious pulmonary complications after hematopoietic cell transplant
998296|NCT02032381|functional respiratory test and exercise test
998297|NCT02032381|thoracic tomodensitometry
998298|NCT02032368|circulating tumour cell;
998299|NCT02032368|transarterial chemoembolization;
998300|NCT02032368|hepatocellular carcinoma;
998301|NCT02032368|recurrence
998302|NCT02032329|Functional Electrical Stimulation (FES)
998303|NCT02032316|Renal Stone
998304|NCT02032316|Ureteroscopy
998305|NCT02032316|Ureteral Stent
998306|NCT02032316|post-uncomplicated ureteroscopy
998307|NCT02032316|UURS
998308|NCT02032277|Oncology
998309|NCT02032277|United States Oncology - 12152
998310|NCT02032277|Alliance - AFT-04
998311|NCT02032277|Triple negative breast cancer
998312|NCT02032277|National Surgical Adjuvant Breast and Bowel Project - B-56-I
998313|NCT02032277|Grupo Español de Investigación en Cáncer de Mama - GEICAM/2014-02
998314|NCT02032277|German Breast Group - GBG 81
998315|NCT02032264|Next generation sequencing
998316|NCT02032264|Embryonic aneuploidy
998317|NCT02032251|Sperm DNA damage ejaculated spermatozoa Ginger Herbal Drug Herbal medicine
998318|NCT02032199|Gastric bypass
998319|NCT02032199|Health-related quality of life
998320|NCT02032199|SF-36
998321|NCT02032199|Questionnaire
998322|NCT02032199|Treatment guidelines
998323|NCT02032186|magnesium
998324|NCT02032186|prematurity
998325|NCT02032173|Ranibizumab
998326|NCT02032173|Diabetic Macular Edema
998327|NCT02032160|ADITEC
998328|NCT02032160|Immunology
998329|NCT02032160|Vaccines
998330|NCT02032160|Hepatitis B
998331|NCT02032160|Investigational study
998332|NCT02032160|innate and adaptive immune responses
998333|NCT02032160|Hepatitis B vaccinations
998334|NCT02032134|Cryopreserved platelets, thrombocytopenia, DMSO
998335|NCT02032121|Cancer survivors
998336|NCT02032121|Long-term cancer survivor
998337|NCT02032108|Diabetes lifestyle intervention Rwanda
998338|NCT02032095|IVIG
998339|NCT02032095|Renal transplantation
998340|NCT02032095|desensitization
998341|NCT02032056|Infections
998342|NCT02032056|Allergy
998343|NCT02032056|Immune function
998344|NCT02032056|Microbiota
998345|NCT02032056|infant
998346|NCT02032043|Filariasis
998347|NCT02032043|Onchocerciasis
998348|NCT02032043|Albendazole
998349|NCT02032043|Ivermectin
998350|NCT02032043|STH Soil Transmitted Helminth infections
998351|NCT02032043|MDA Mass Drug Administration
998352|NCT02032030|quality of Life
998353|NCT02032030|pain
998354|NCT02032030|nausea
998355|NCT02032030|falls
998356|NCT02032030|intraoperative awareness
998357|NCT02032030|anesthesia awareness
998358|NCT02032030|cognition
998359|NCT02032030|activities of daily living
998360|NCT02032030|major morbidity
998361|NCT02032030|all-cause mortality
998362|NCT02032017|Total Hip Arthroplasty
998363|NCT02032017|Gluteus medius
998364|NCT02032017|Approach
998365|NCT02032017|Rehabilitation
998366|NCT02032017|Functional outcome
998367|NCT02032004|Chronic Heart Failure
998368|NCT02032004|CHF
998369|NCT02032004|Left Ventricular Systolic Dysfunction
998370|NCT02032004|Ischemic Heart Failure
998371|NCT02032004|Nonischemic Heart Failure
998372|NCT02032004|Stem Cells
998373|NCT02032004|Allogeneic Mesenchymal Precursor Cells
998374|NCT02031991|Bioequivalence
998375|NCT02031991|Biosimilarity
998376|NCT02031991|Similarity
998377|NCT02031991|PK
998378|NCT02031991|Phase 1
998379|NCT02031991|Bevacizumab
998380|NCT02031991|Healthy Volunteers
998381|NCT02031991|Single-Dose
998382|NCT02031991|Oncology
998383|NCT02031978|Breast Feeding
998384|NCT02031978|Infant Nutrition
998385|NCT02031978|Childhood Obesity
998386|NCT02031978|Infant feeding patterns
998387|NCT02031978|WIC
998388|NCT02031952|hepatocellular carcinoma
998389|NCT02031952|hepatectomy
998390|NCT02031952|lymphadenectomy
998391|NCT02031952|complication
998392|NCT02031952|prognosis
998393|NCT02031939|Rectal cancer
998394|NCT02031939|neoadjuvant chemoradiotherapy
998395|NCT02031939|optimization
998396|NCT02031913|Chronic hepatitis B
998397|NCT02031913|Hepatic fibrosis
998398|NCT02031913|Steatosis
998399|NCT02031887|starter formula
998400|NCT02031887|stool microbiota
998401|NCT02031887|infants
998402|NCT02031887|caesarean section delivery
998403|NCT02031874|H1N1
998404|NCT02031874|HIV
998405|NCT02031874|Immunogenecity
998406|NCT02031848|weight loss
998407|NCT02031848|diet
998417|NCT02031809|Thoracic Surgery, Video-Assisted
998418|NCT02031770|vascular endothelial cells
998419|NCT02031757|Balance control
998420|NCT02031757|Aging
998421|NCT02031757|Balance reactions
998422|NCT02031757|Perturbation
998423|NCT02031705|Fibrillation
998424|NCT02031705|Catheter ablation
998425|NCT02031692|Benign paroxysmal positional vertigo
998426|NCT02031692|Vitamin D
998427|NCT02031692|Calcium
998428|NCT02031692|Prevention
998429|NCT02031679|Chronic Idiopathic Urticaria
998430|NCT02031666|Healthy
998431|NCT02031666|JNJ-56021927
998432|NCT02031666|ARN-509
998433|NCT02031666|Bioavailability
998434|NCT02031653|Penile Cuff Test
998435|NCT02031640|asthma
998436|NCT02031640|breath-actuated inhaler
998437|NCT02031640|metered-dose inhaler
998438|NCT02031627|lymphedema
998439|NCT02031627|lymphoedema
998440|NCT02031627|leg lymphoedema
998441|NCT02031627|lower extremity lymphoedema
998442|NCT02031627|pneumatic compression device
998443|NCT02031614|anemia
998444|NCT02031614|blood withdrawal
998445|NCT02031614|phlebotomy
998446|NCT02031614|innate immunity
998447|NCT02031614|Immune reponse
998448|NCT02031588|Study of commensal flora
998449|NCT02031588|Fluoroquinolones
998450|NCT02031575|Reproductive Health
998451|NCT02031575|Contraception
998452|NCT02031575|Public Health
998453|NCT02031575|Sexual Health
998454|NCT02031575|Adolescents
998455|NCT02031575|Mobile Health
998456|NCT02031562|Balance
998457|NCT02031562|Falls
998458|NCT02031562|Low back pain
998459|NCT02031562|Geriatric
998460|NCT02031289|Anemia
998461|NCT02031289|Iron deficiency
998462|NCT02031289|Cardiac surgery
998463|NCT02031289|Perioperative Care
998464|NCT02031276|ABBV-066
998465|NCT02031276|BI 655066
998466|NCT02031276|risankizumab
998467|NCT02031224|Chronic Kidney Disease
998468|NCT02031224|Restricted protein diets
998469|NCT02031224|Nutritional status
998470|NCT02031198|Alzheimer's disease
998471|NCT02031198|tau
998472|NCT02031198|dementia
998473|NCT02031198|elderly
998474|NCT02031198|cognitive
998475|NCT02031198|disease modifying
998476|NCT02031198|treatment
998477|NCT02031198|immunization
998478|NCT02031198|vaccine
998479|NCT02031172|Dry Eye Disease
998480|NCT02031172|Sjogren's Syndrome
998481|NCT02031172|Tear Film
998482|NCT02031172|Ocular Surface
998483|NCT02031172|Aqueous Tear Deficiency
998484|NCT02031159|perioperative hypothermia
998485|NCT02031159|zero heat flux
998486|NCT02031159|non-invasive measurement of body core temperature
998487|NCT02031133|Antisense
998488|NCT02031133|miR-122 antagonist
998489|NCT02031133|host factor
998490|NCT02031133|Chronic hepatitis C
998491|NCT02031133|Hepatitis C
998492|NCT02031107|stroke
998493|NCT02031107|brain stimulation
998494|NCT02031107|electroencephalography
998495|NCT02031107|functional magnetic resonance imaging
998496|NCT02031107|functional connectivity
998497|NCT02031068|active rehabilitation
998498|NCT02031068|exercise
998499|NCT02031068|concussion
998500|NCT02031055|Advanced solid tumors
998501|NCT02031042|neoadjuvant chemotherapy
998502|NCT02031042|breast cancer
998503|NCT02031042|sentinel lymph node biopsy
998504|NCT02031042|false negative rate
998505|NCT02031042|identification rate
998506|NCT02031029|personality scores
998507|NCT02031016|Chronic thoracic pain
998508|NCT02031016|Remifentanil
998509|NCT02031016|Fentanyl
998510|NCT02031016|sternotomy
998511|NCT02030990|photorefractive keratectomy
998512|NCT02030990|corneal haze
998513|NCT02030990|mitomycin-C
998514|NCT02030990|postoperative steroids
998515|NCT02030951|preterm infant behavior
998516|NCT02030951|tube feeding
998517|NCT02030951|feeding efficiency
998518|NCT02030938|breast implant
998519|NCT02030938|revision augmentation
998520|NCT02030938|stretch deformity
998521|NCT02030938|fold malposition
998522|NCT02030938|bottoming out
998523|NCT02030912|The impact of a number of different types of antibiotics
998524|NCT02030912|The emergence and persistence of antibiotic resistance
998525|NCT02030899|Cervical vertebrae
998526|NCT02030899|single
998527|NCT02030899|degenerative disease
998528|NCT02030899|Fusion
998529|NCT02030899|Sagittal angle
998530|NCT02030873|virtual simulation
998531|NCT02030873|temporal bone
998532|NCT02030873|surgical training
998533|NCT02030873|medical education
998534|NCT02030873|self-directed learning
998535|NCT02030873|final product assessment
998536|NCT02030873|cognitive load
998537|NCT02030873|reaction time
998538|NCT02030873|skills training
998539|NCT02030873|simulator metrics
998540|NCT02030808|Thoracic surgery
998541|NCT02030808|non-muscle relaxant
998542|NCT02030808|target-controlled infusion
998543|NCT02030808|remifentanil
998544|NCT02030808|surgical conditions
998545|NCT02030795|Thoracic surgery
998546|NCT02030795|Arndt® blocker
998547|NCT02030795|lung deflation
998548|NCT02030795|Disconnection technique
998549|NCT02030795|Continuous suction
998550|NCT02030795|Elective video-assisted thoracoscopic
998551|NCT02030782|depression
998552|NCT02030782|quality improvement
998553|NCT02030782|treatment
998554|NCT02030782|adolescents
998555|NCT02030769|Esophageal Neoplasms
998556|NCT02030769|Lugol's solution
998557|NCT02030769|Pronase
998558|NCT02030769|Endoscopy, Digestive System
998559|NCT02030769|Pretreatment method
998560|NCT02030756|constipation
998561|NCT02030743|Falls
998562|NCT02030743|Older adults
998563|NCT02030743|Balance
998564|NCT02030743|Mobility
998565|NCT02030743|Visual attention
998566|NCT02030730|Brief Parenting Training
998567|NCT02030730|Early Intervention
998568|NCT02030730|Child Behavior
998569|NCT02030730|Greece
998570|NCT02030717|Spinal anesthesia
998571|NCT02030717|Epidural anesthesia
998572|NCT02030717|Klonidin
998573|NCT02030717|renal cell carcinoma
998574|NCT02030691|Neonatal respiratory distress
998575|NCT02030691|nHFPV
998576|NCT02030691|nCPAP
998577|NCT02030691|cerebral tissue oxygenation
998578|NCT02030691|NIRS
998579|NCT02030665|Marijuana Dependence
998580|NCT02030665|Individualized treatment
998581|NCT02030665|Motivational Enhancement Treatment
998582|NCT02030665|Cognitive-Behavioral Treatment
998583|NCT02030665|Contingency Management
998584|NCT02030652|premature newborn
998585|NCT02030652|nasal ventilation
998586|NCT02030652|noninvasive ventilation
998587|NCT02030652|continuous positive airway pressure
998588|NCT02030626|Neuropathic pain
998589|NCT02030626|lumbar radiculopathy
998590|NCT02030626|rTMS
998591|NCT02030626|tDCS
998592|NCT02030626|placebo controlled study
998593|NCT02030613|juvenile idiopathic arthritis
998594|NCT02030613|etanercept
998595|NCT02030587|Hyperaldosteronism
998596|NCT02030587|Adrenocortical adenoma
998597|NCT02030587|Adrenalectomy
998598|NCT02030587|Catheter ablation
998599|NCT02030561|NK cells
998600|NCT02030561|trastuzumab
998601|NCT02030561|immunotherapy
998602|NCT02030548|CABG
998603|NCT02030548|dual antiplatelet therapy
998604|NCT02030548|aspirin
998605|NCT02030548|clopidogrel
998606|NCT02030548|prasugrel
998607|NCT02030548|ticagrelor
998608|NCT02030522|Post-traumatic stress disorder
998609|NCT02030522|PTSD
998610|NCT02030522|Accelerated Resolution Therapy
998611|NCT02030522|Military
998612|NCT02030522|Veterans
998613|NCT02030522|Exposure therapy
998614|NCT02030522|Eye movements
998615|NCT02030509|cancer diagnosis
998616|NCT02030496|distal radius fractures
998617|NCT02030496|Closed reduction
998618|NCT02030496|Open reduction internal fixation
998619|NCT02030496|Volar plate
998620|NCT02030496|Redislocation
998621|NCT02030496|Unstable fracture
998622|NCT02030496|Extra-articular fracture
998623|NCT02030496|Colles fracture
998624|NCT02030496|Barton fracture
998625|NCT02030470|Periodontitis, treatment, photodynamic, mid-term, bacteria
998626|NCT02030444|Neoplasms Staging
998627|NCT02030444|Bronchoscopy
998628|NCT02030444|Nuclear Medicine
998629|NCT02030444|Radiology
998630|NCT02030392|Functional abdominal pain
998631|NCT02030392|psychological intervention
998632|NCT02030392|quality of life
998633|NCT02030392|Randomized controlled trial
998634|NCT02030392|children
998635|NCT02030379|Cancer
998636|NCT02030353|Lifestyle intervention
998637|NCT02030353|Internet intervention
998638|NCT02030353|Breast neoplasms
998639|NCT02030353|Body weight
998640|NCT02030353|Body weight changes
998641|NCT02030340|urodynamic investigation
998642|NCT02030340|lower urinary tract dysfunction
998643|NCT02030340|catheter
998644|NCT02030340|air-charged
998645|NCT02030340|water filled
998646|NCT02030327|proteomics
998647|NCT02030327|multiple trauma
998648|NCT02030327|organ dysfunction
998649|NCT02030314|Chlorthalidone
998650|NCT02030314|Resistant Hypertension
998651|NCT02030314|Kidney Transplant Patients
998652|NCT02030301|Herpes Simplex Virus, Type 2
998653|NCT02030301|Herpes
998654|NCT02030301|HSV-2
998655|NCT02030288|alcohol
998656|NCT02030288|substance use
998657|NCT02030288|eHealth
998658|NCT02030275|Hypertrophic scar
998659|NCT02030275|Cicatrix
998660|NCT02030275|Scar prevention
998661|NCT02030275|Scar revision
998662|NCT02030249|Pre-diabetes
998663|NCT02030249|Obesity
998664|NCT02030249|Low calorie diet
998665|NCT02030249|Diet - reducing
998666|NCT02030249|Appetite
998667|NCT02030249|Visual analogue scale
998668|NCT02030249|Ghrelin
998669|NCT02030249|Peptide YY
998670|NCT02030249|Bone mass
998671|NCT02030249|Bone turnover
998672|NCT02030249|Muscle strength
998673|NCT02030236|hypothermia, induced
998674|NCT02030236|rewarming
998675|NCT02030236|therapeutic
998676|NCT02030236|heart arrest
998677|NCT02030236|asystole
998678|NCT02030236|frostbite
998679|NCT02030223|transversus abdominis plane block
998680|NCT02030223|inguinal hernia repair
998681|NCT02030223|acute postoperative pain
998682|NCT02030223|neuropathic pain
998683|NCT02030210|Quality improvement
998684|NCT02030210|STEMI
998685|NCT02030210|Belgium
998686|NCT02030184|Lung cancer
998687|NCT02030184|Small cell lung cancer
998688|NCT02030184|Neuroendocrine tumor
998689|NCT02030184|Rhenium
998690|NCT02030184|Re 188-P2045
998691|NCT02030171|Chronic low back pain
998692|NCT02030158|Severe sepsis
998693|NCT02030158|Septic shock
998694|NCT02030158|Early goal directed therapy
998695|NCT02030158|Individual patient data meta-analysis
998696|NCT02030145|COPD
998697|NCT02030145|Pulmonary
998698|NCT02030132|Physical activity
998699|NCT02030132|Sedentary lifestyle
998700|NCT02030132|Pedometers
998701|NCT02030132|Walking
998702|NCT02030132|Financial Incentives
998703|NCT02030132|Behavioral Economics
998704|NCT02030119|Sedentary lifestyle
998705|NCT02030119|Pedometers
998706|NCT02030119|Obesity
998707|NCT02030119|Physical Activity
998708|NCT02030119|Financial Incentives
998709|NCT02030119|Behavioral Economics
998710|NCT02030106|Cervicovaginal microbiome
998711|NCT02030106|Microbiome
998712|NCT02030106|Preterm Birth
998713|NCT02030106|Cervical Remodeling
998714|NCT02030106|Preterm delivery
998715|NCT02030106|Microbiota
998716|NCT02030093|Alcohol dependence
998717|NCT02030093|Telephone-based continuing care
998718|NCT02030093|Outcome monitoring
998719|NCT02030080|Pedometers
998720|NCT02030080|Walking
998721|NCT02030080|Financial incentives
998722|NCT02030080|Sedentary lifestyle
998723|NCT02030080|Behavioral economics
998724|NCT02030067|oncology
998725|NCT02030067|tumor
998726|NCT02030067|metastatic
998727|NCT02030041|simvastatin
998728|NCT02030041|cardiorespiratory fitness
998729|NCT02030041|vitamin D
998730|NCT02030041|exercise
998731|NCT02030041|mitochondria
998732|NCT02030028|Rheumatoid Arthritis
998733|NCT02030028|ACTH gel
998734|NCT02030015|infantile Tay-Sachs disease
998735|NCT02030015|juvenile Tay-Sachs disease
998736|NCT02030015|infantile GM1 gangliosidosis
998737|NCT02030015|juvenile GM1 gangliosidosis
998738|NCT02030015|infantile GM2 gangliosidosis
998739|NCT02030015|juvenile GM2 gangliosidosis
998740|NCT02030015|Sandhoff disease
998741|NCT02030015|gangliosidoses
998742|NCT02030015|miglustat
998743|NCT02030015|ketogenic diet
998744|NCT02030015|SYNER-G regimen
998745|NCT02030015|Syner-G
998746|NCT02030015|Zavesca
998747|NCT02030015|Tay-Sachs disease
998748|NCT02030015|Tay Sachs disease
998749|NCT02029989|Metabolic Syndrome
998750|NCT02029989|Antipsychotics
998751|NCT02029989|Schizophrenia
998752|NCT02029989|Bipolar Disorder
998753|NCT02029989|Diabetes
998754|NCT02029989|Dyslipidemia
998755|NCT02029989|Hyperlipidemia
998756|NCT02029989|Hypertension
998757|NCT02029989|Obesity
998758|NCT02029989|Medication Therapy Management
998759|NCT02029989|MTM
998760|NCT02029989|Pharmacist
998761|NCT02029989|Comprehensive Medication Management
998762|NCT02029989|CMM
998763|NCT02029989|Health Disparity
998764|NCT02029989|Monitoring
998765|NCT02029989|Point of Care Testing
998766|NCT02029989|Chronic Persistent Mental Illness
998767|NCT02029937|Squamous cell neoplasia
998768|NCT02029937|Proflavine
998769|NCT02029937|Lugol's chromoendoscopy
998770|NCT02029911|Menorrhagia
998771|NCT02029911|Excessive uterine bleeding
998772|NCT02029911|Endometrial Ablation
998773|NCT02029898|cesarean section
998774|NCT02029898|anesthesia
998775|NCT02029898|children
998776|NCT02029885|Hypertension
998777|NCT02029885|Renal Denervation
998778|NCT02029872|MRSA
998779|NCT02029872|colonization
998780|NCT02029872|decolonization
998781|NCT02029859|pregnancy (after 30 weeks of amenorhea)
998782|NCT02029859|obesity (BMI>35)
998783|NCT02029859|sleep apnea syndrom
998784|NCT02029859|preeclampsy
998785|NCT02029859|intrauterine growth restriction
998786|NCT02029820|Contrast Nephropathy
998787|NCT02029820|Prevention
998788|NCT02029820|Renalguard
998789|NCT02029794|Cervical Cancer
998790|NCT02029794|Cervical Cancer Screening
998791|NCT02029794|Low Resource setting
998792|NCT02029794|HPV
998793|NCT02029794|Self-Collection
998794|NCT02029794|VIA
998795|NCT02029781|Appendicitis
998796|NCT02029781|Laparoscopy
998797|NCT02029781|Appendectomy
998798|NCT02029781|Negative appendectomy
998799|NCT02029781|Morbidity
998801|NCT02029755|transversus abdominis plane block
998802|NCT02029755|local infiltration
998803|NCT02029755|ropivacaine
998804|NCT02029755|heart rate variability
998805|NCT02029755|postoperative analgesia
998806|NCT02029742|Sickle cell disease
998807|NCT02029742|Medication adherence
998808|NCT02029742|Hydroxyurea
998809|NCT02029742|Community health worker intervention
998810|NCT02029742|Sickle Cell Treatment
998811|NCT02029729|RTA 408
998812|NCT02029729|RTA 408 Capsules
998813|NCT02029729|Non-small cell lung cancer
998814|NCT02029729|Metastatic non-small cell lung cancer
998815|NCT02029729|Incurable non-small cell lung cancer
998816|NCT02029729|Refractory melanoma
998817|NCT02029729|Relapsed melanoma
998818|NCT02029716|RTA 408
998819|NCT02029716|RTA 408 Lotion
998820|NCT02029716|Oxidative stress
998821|NCT02029716|Inflammation
998822|NCT02029716|Volunteers
998823|NCT02029703|Knee Osteoarthritis
998824|NCT02029703|Knee Pain
998825|NCT02029703|Synvisc-One
998826|NCT02029690|argininosuccinate synthetase
998827|NCT02029690|arginine
998828|NCT02029690|arginine deiminase
998829|NCT02029651|Stroke
998830|NCT02029651|Hand
998831|NCT02029651|Rehabilitation
998832|NCT02029651|Game
998833|NCT02029638|Kidney Transplantation
998834|NCT02029638|Renal Transplantation
998835|NCT02029612|Tobacco Use Cessation
998836|NCT02029612|Cancer Prevention
998837|NCT02029612|HIV/AIDS
998838|NCT02029612|Questionnaires
998839|NCT02029612|Surveys
998840|NCT02029612|Nicotine patch
998841|NCT02029612|Breath test
998842|NCT02029612|Cell Phone Calls for Smoking Cessation Counseling
998843|NCT02029612|Text Message Smoking Cessation Support
998844|NCT02029573|Phase II
998845|NCT02029573|Atorvastatin
998846|NCT02029573|Temozolomide
998847|NCT02029573|Radiotherapy
998848|NCT02029573|Glioblastoma Multiforme (GBM)
998849|NCT02029534|post-operative atrial fibrillation
998850|NCT02029534|POAF
998851|NCT02029534|A-Fib
998852|NCT02029521|cystic fibrosis
998853|NCT02029521|growth Failure
998854|NCT02029521|glutathione
998979|NCT02028832|oncology
998855|NCT02029508|PSCC(Posterior semicircular canal)
998856|NCT02029508|BPPV(Bening paroxysmal positional vertigo)
998857|NCT02029508|Vertigo
998858|NCT02029508|Otorhinolaryngologic Diseases
998859|NCT02029495|Psoriatic Arthritis
998860|NCT02029495|Brodalumab
998861|NCT02029495|AMG 827
998862|NCT02029482|ACT-128800
998863|NCT02029469|Humeral Resurfacing
998864|NCT02029469|Humeral Resurfacing Arthroplasty
998865|NCT02029456|Massive Pulmonary embolism
998866|NCT02029456|thrombolytic therapy
998867|NCT02029456|high risk
998868|NCT02029456|elderly
998869|NCT02029443|Bruton's tyrosine kinase inhibitor
998870|NCT02029430|HIV +
998871|NCT02029430|HIV positive
998872|NCT02029430|AIDS
998873|NCT02029430|Kaposi's sarcoma
998874|NCT02029430|Sarcoma
998875|NCT02029430|tumor
998876|NCT02029430|cancer
998877|NCT02029391|Myofascial pain syndrome
998878|NCT02029391|taping
998879|NCT02029391|manual therapies
998880|NCT02029365|Infertility
998881|NCT02029365|desire for children
998882|NCT02029365|eating disorder
998883|NCT02029365|anorexia nervosa
998884|NCT02029365|bulimia nervosa
998885|NCT02029365|eating disorders not otherwise specified
998886|NCT02029352|Treatment
998887|NCT02029352|Sinecatechins
998888|NCT02029339|Negative pressure wound therapy
998889|NCT02029339|Acute wound infection
998890|NCT02029339|complicated abdominal infection
998891|NCT02029339|Cytokines
998892|NCT02029339|Matrix metalloproteinase
998893|NCT02029326|colorectal cancer, cetuximab, biomarker, prometheus
998894|NCT02029300|pediatrics
998895|NCT02029300|fiberoptic intubation
998896|NCT02029300|oral intubation
998897|NCT02029300|nasal intubation
998898|NCT02029300|children under the age of 2
998899|NCT02029287|Chronic heart failure
998900|NCT02029287|telemedicine
998901|NCT02029287|health service platform
998902|NCT02029274|Dermatomyositis
998903|NCT02029261|Burn
998904|NCT02029248|Anorectal malformation
998905|NCT02029248|fecal incontinence
998906|NCT02029248|quality of life
998907|NCT02029248|child
998908|NCT02029235|Adult
998909|NCT02029235|soft-tissue hand surgery
998910|NCT02029183|stroke, SAHS, BiPAP
998911|NCT02029170|ankle fracture
998912|NCT02029170|weightbearing
998913|NCT02029170|cast
998914|NCT02029118|Acupoint Application,Stable Angina Pectoris,herbal medicine
998915|NCT02029105|Mesothelioma,
998916|NCT02029105|Pleural diseases,
998917|NCT02029105|Mesothelin,
998918|NCT02029105|Osteopontin,
998919|NCT02029105|Hyaluronan,
998920|NCT02029105|Syndecan-1
998921|NCT02029092|International
998922|NCT02029092|Multicenter
998923|NCT02029092|Observational registry
998924|NCT02029092|Orsiro Drug Eluting Stent (DES)
998925|NCT02029092|Stenting
998926|NCT02029092|Treatment of coronary artery disease
998927|NCT02029092|Coronary revascularization
998928|NCT02029092|Percutaneous Coronary Intervention (PCI)
998929|NCT02029092|STEMI
998930|NCT02029092|NSTEMI
998931|NCT02029092|Ischemia
998932|NCT02029092|Angina
998933|NCT02029092|Acute Myocardial Infarction (AMI)
998934|NCT02029092|Small Vessels
998935|NCT02029092|Chronical Total Occlusion (CTO)
998936|NCT02029079|Malnutrition
998937|NCT02029066|actinic keratosis
998938|NCT02029066|SR-T100
998939|NCT02029066|pharmacokinetics
998940|NCT02029053|Vaginal dryness
998941|NCT02029053|Vaginal lubrication
998942|NCT02029053|Post-menopausal symptoms
998943|NCT02029053|Peri-menopausal symptoms
998944|NCT02029053|Urogenital atrophy
998945|NCT02029053|Dyspareunia
998946|NCT02029053|Painful intercourse
998947|NCT02029040|Bronchiolitis
998948|NCT02029040|Hypertonic saline
998949|NCT02029040|Emergency Department
998950|NCT02029027|Urinary Stress Incontinence
998951|NCT02029027|Urinary Mixed Incontinence
998952|NCT02029014|LAmbre
998953|NCT02029001|Solid tumor
998954|NCT02029001|Recurrent/metastatic
998955|NCT02029001|Personalized medicine
998956|NCT02029001|Genomic alteration
998957|NCT02029001|Targeted therapy
998958|NCT02029001|Nilotinib
998959|NCT02029001|Everolimus
998960|NCT02029001|Sorafenib
998961|NCT02029001|Lapatinib
998962|NCT02029001|Pazopanib
998963|NCT02028988|Intermediate Risk Prostate Cancer
998964|NCT02028962|Smoking cessation
998965|NCT02028962|Romanian adults
998966|NCT02028923|topical morphine
998967|NCT02028910|gastroenteritis
998968|NCT02028910|pediatrics
998969|NCT02028910|vomiting
998970|NCT02028897|In vitro fertilization
998971|NCT02028897|IVF
998972|NCT02028897|Embryo culture
998973|NCT02028897|Blastocyst transfer
998974|NCT02028832|pain
998975|NCT02028832|nausea/vomiting
998976|NCT02028832|anxiety
998977|NCT02028832|complementary and alternative medicine
998978|NCT02028832|pediatric
998980|NCT02028832|cost-effectiveness
998981|NCT02028793|Pharmaceutical Care, Taiwan, pharmacist, Workload, pressure
998982|NCT02028741|neck pain
998983|NCT02028741|transverse vertebral pressures
998984|NCT02028741|thoracic mobilization
998985|NCT02028728|International
998986|NCT02028728|Multicenter
998987|NCT02028728|Observational registry
998988|NCT02028728|Orsiro Drug Eluting Stent (DES)
998989|NCT02028728|Stenting
998990|NCT02028728|Treatment of coronary artery disease
998991|NCT02028728|Coronary revascularization
998992|NCT02028728|Percutaneous Coronary Intervention (PCI)
998993|NCT02028728|STEMI
998994|NCT02028728|NSTEMI
998995|NCT02028728|Ischemia
998996|NCT02028728|Angina
998997|NCT02028728|Acute Myocardial Infarction (AMI)
998998|NCT02028728|Small Vessels
998999|NCT02028728|Chronic Total Occlusion (CTO)
999000|NCT02028715|IV Acetaminophen
999001|NCT02028715|Ofirmev
999002|NCT02028715|Post-operative pain
999003|NCT02028702|red clover
999004|NCT02028702|menopause
999005|NCT02028702|bioactive compounds
999006|NCT02028702|isoflavones
999007|NCT02028702|phytoestrogen
999008|NCT02028676|HIV
999009|NCT02028676|Africa
999010|NCT02028676|children
999011|NCT02028676|antiretroviral therapy
999012|NCT02028676|laboratory monitoring
999013|NCT02028676|toxicity
999014|NCT02028676|CD4
999015|NCT02028676|induction maintenance
999016|NCT02028676|cotrimoxazole
999017|NCT02028676|prophylaxis
999018|NCT02028676|abacavir
999019|NCT02028676|lamivudine
999020|NCT02028676|once daily
999021|NCT02028663|P-CAB
999022|NCT02028663|APA(Acid Pump Antagonist)
999023|NCT02028650|relapse leukemia
999024|NCT02028650|DSI
999025|NCT02028637|asthma
999026|NCT02028637|toll like receptor
999027|NCT02028637|innate immunity
999028|NCT02028624|Rheumatoid arthritis
999029|NCT02028624|Mediterranean diet
999030|NCT02028624|Lifestyle intervention
999031|NCT02028624|Adiponectin
999032|NCT02028624|Telephone counseling
999033|NCT02028611|Rib fracture
999034|NCT02028611|Inverted grayscale
999035|NCT02028598|Clomipramine
999036|NCT02028598|Premature ejaculation
999037|NCT02028585|low-fat milk
999038|NCT02028585|metabolic syndrome
999039|NCT02028585|lipid profile
999040|NCT02028585|inflammation
999041|NCT02028585|oxidative stress
999042|NCT02028585|endothelial function
999043|NCT02028572|Structure function correlation
999044|NCT02028572|Optical coherence tomography
999045|NCT02028572|Retinal Nerve fibre layer thickness
999046|NCT02028572|Visual fields
999047|NCT02028572|Primary open angle glaucoma
999048|NCT02028559|stones
999049|NCT02028559|kidney
999050|NCT02028559|stone fragments
999051|NCT02028559|lithotripsy
999052|NCT02028546|atopic dermatitis, skin cleansing, cleanser, moisturizer, skin hydration
999053|NCT02028533|addiction
999054|NCT02028533|oxytocin
999055|NCT02028533|tolerability
999056|NCT02028507|Palbociclib
999057|NCT02028507|Capecitabine
999058|NCT02028507|Hormonal Receptor positive
999059|NCT02028507|HER2 negative
999060|NCT02028507|Metastatic Breast Cancer
999061|NCT02028507|Resistance to non-steroidal Aromatase inhibitors
999062|NCT02028507|Fulvestrant
999063|NCT02028507|Exemestane
999064|NCT02028481|Macular hole
999065|NCT02028481|Vitreoretinal surgery
999066|NCT02028481|Macular surgery
999067|NCT02028481|Air tamponade
999068|NCT02028468|Femoral Neck Fracture
999069|NCT02028468|Anterolateral approach
999070|NCT02028468|Trans-gluteal approach
999071|NCT02028468|Watson Jones approach
999072|NCT02028468|Hardinge approach
999073|NCT02028455|pediatric
999074|NCT02028455|young adult
999075|NCT02028455|acute lymphoblastic leukemia
999076|NCT02028455|CD19
999077|NCT02028455|leukemia
999078|NCT02028455|Chimeric Antigen Receptor
999079|NCT02028455|T cell
999080|NCT02028429|Minimal Hepatic Encephalopathy (MHE)
999081|NCT02028429|Psychometric Hepatic Encephalopathy Score (PHES)
999082|NCT02028429|Sickness Impact Profile (SIP)
999083|NCT02028429|Model for End-stage Liver Disease (MELD)
999084|NCT02028429|Child-Turcotte-Pugh score (CTP)
999085|NCT02028416|pancytopenia
999086|NCT02028416|aplastic anemia
999087|NCT02028416|ATG
999088|NCT02028416|Cyclosporin
999089|NCT02028390|wounds
999090|NCT02028390|thermal
999091|NCT02028390|temperature
999092|NCT02028390|periwound
999093|NCT02028390|camera
999094|NCT02028390|imaging
999095|NCT02028377|Adenocarcinoma
999096|NCT02028377|imaging
999097|NCT02028377|PET
999098|NCT02028377|MRI
999099|NCT02028364|Locally advanced breast cancer
999100|NCT02028364|HER2 negative
999101|NCT02028364|NSAI refractory
999102|NCT02028364|Metastatic breast cancer
999103|NCT02028364|Estrogen-receptor positive (ER+)
999104|NCT02028351|visual acuity
999105|NCT02028351|contrast sensitivity
999106|NCT02028351|cataract
999107|NCT02028351|maculopathy
999108|NCT02028312|Dry Eye
999109|NCT02028299|Pulmonary Arterial Hypertension
999110|NCT02028299|Pulmonary Vascular Resistance
999111|NCT02028299|Right Heart Catheterization
999112|NCT02028286|Rosacea
999113|NCT02028273|Neurogenesis
999114|NCT02028273|Addiction
999115|NCT02028273|Cocaine
999116|NCT02028273|MRI
999117|NCT02028273|MRS
999118|NCT02028247|Autism spectrum disorders
999119|NCT02028247|Autism
999120|NCT02028247|Asperger's syndrome
999121|NCT02028247|Pervasive developmental disability - not otherwise specified
999122|NCT02028247|obsessive-compulsive disorder
999123|NCT02028247|Social phobia
999124|NCT02028247|Generalized anxiety disorder
999125|NCT02028247|Specific phobia
999126|NCT02028247|Separation anxiety disorder
999127|NCT02028247|Counseling
999128|NCT02028247|Cognitive-behavioral therapy
999129|NCT02028247|Psychotherapy
999130|NCT02028221|Breast cancer prevention
999131|NCT02028221|metformin
999132|NCT02028221|Breast cancer risk reduction
999133|NCT02028208|Patch Test
999134|NCT02028208|Allergy Testing
999135|NCT02028208|Contact Dermatitis
999136|NCT02028208|Mercury, Aluminum or Palladium skin allergy
999137|NCT02028195|Health check
999138|NCT02028195|Health promotion
999139|NCT02028195|prevention diabetes
999140|NCT02028195|prevention cardiovascular disease
999141|NCT02028195|mental health
999142|NCT02028182|Patch Test
999143|NCT02028182|Allergy Testing
999144|NCT02028182|Contact dermatitis
999145|NCT02028182|Lyral allergen
999146|NCT02028182|Fragrance Mix allergen
999147|NCT02028169|Work Productivity
999148|NCT02028169|Anti-TNFs
999149|NCT02028169|Psoriatic Arthritis
999150|NCT02028143|Atrial Fibrillation
999151|NCT02028130|Atrial fibrillation
999152|NCT02028130|Ablation
999153|NCT02028130|Left atrial appendage occlusion
999154|NCT02028130|Stroke prevention
999155|NCT02028091|Pulse walve arrival time differences
999156|NCT02028078|Endogenous glucose production
999157|NCT02028078|Type 1 diabetes mellitus
999158|NCT02028078|hypoglycaemic clamp
999159|NCT02028078|tracer to technique
999160|NCT02028078|pharmacodynamics
999161|NCT02028078|pharmacokinetics
999162|NCT02028065|reversal of neuromuscular blockade
999163|NCT02028052|enlarged mediastinal nodes
999164|NCT02028052|enlarged hilar lymph nodes
999165|NCT02028039|Leukemia
999166|NCT02028039|Refractory Acute Lymphoblastic Leukemia
999167|NCT02028039|ALL
999168|NCT02028039|Burkitt's lymphoma
999169|NCT02028039|Lymphoblastic lymphoma
999170|NCT02028039|IPI-145
999171|NCT02028026|Depressive Disorder
999172|NCT02028026|Anxiety
999173|NCT02028026|Comorbidity
999174|NCT02028026|Magnetic Resonance Imaging
999175|NCT02028026|Magnetic Resonance Spectroscopy
999176|NCT02028026|Citalopram
999177|NCT02028026|Vilazodone
999178|NCT02028026|Serotonin Uptake Inhibitors
999179|NCT02028026|Receptor, Serotonin, 5-HT1A
999180|NCT02028013|Erectile dysfunction, sexual dysfunction, bioresonance
999181|NCT02028000|Pregnancy
999182|NCT02028000|Pregnant
999183|NCT02028000|Cesarean Section Delivery
999184|NCT02027987|valproate acid
999185|NCT02027987|traumatic brain injury
999186|NCT02027987|brain protection
999187|NCT02027987|epilepsy
999188|NCT02027974|Hip
999189|NCT02027974|Arthroplasty
999190|NCT02027974|Arthroplasties
999191|NCT02027974|Prosthesis
999192|NCT02027974|Iconacy
999193|NCT02027974|Osteoarthritis
999194|NCT02027974|Arthritis
999195|NCT02027974|THA
999196|NCT02027974|THR
999197|NCT02027974|DJD
999198|NCT02027961|Metastatic or Unresectable Melanoma, MEDI4736, dafrafenib, trametinib, BRAF-mutation positive, wild-type BRAF, PD-L1, PD-1
999199|NCT02027948|nutritional management algorithm
999200|NCT02027948|nutritional and functional assessments
999201|NCT02027948|13-264
999202|NCT02027935|Melanoma
999203|NCT02027935|Metastatic
999204|NCT02027935|CD8+ T cells
999205|NCT02027935|White blood cell
999206|NCT02027935|Leukapheresis
999207|NCT02027935|Cyclophosphamide
999208|NCT02027935|Cytoxan
999209|NCT02027935|Neosar
999210|NCT02027935|Interleukin-2
999211|NCT02027935|Aldesleukin
999212|NCT02027935|IL-2
999213|NCT02027935|Proleukin
999214|NCT02027935|Ipilimumab
999215|NCT02027935|Yervoy
999216|NCT02027935|BMS-734016
999217|NCT02027935|MDX010
999218|NCT02027922|white spot lesion
999219|NCT02027922|caries
999220|NCT02027909|Sinus Node Dysfunction
999221|NCT02027896|Perioperative outcomes
999222|NCT02027883|Defibrillators
999223|NCT02027883|Ventricular Fibrillation Induction Testing
999224|NCT02027870|DES
999225|NCT02027870|CAD
999226|NCT02027870|EXCEL-II
999227|NCT02027870|JWMS
999228|NCT02027870|PCI
999229|NCT02027857|brain electrical impedance;
999230|NCT02027857|traumatic brain injury;
999231|NCT02027857|brain edema;
999232|NCT02027857|intracranial pressure
999233|NCT02027831|lymph nodes
999234|NCT02027818|margins
999235|NCT02027818|tumorectomy
999236|NCT02027805|Steroid-resistant
999237|NCT02027805|Graft vs Host Disease
999238|NCT02027805|Refractory acute Graft vs Host Disease
999239|NCT02027805|Hematopoietic Stem Cell Transplantation
999240|NCT02027805|Stem Cell Transplantation
999241|NCT02027805|Allogeneic Stem Cell Transplantation
999242|NCT02027805|Immune System Diseases
999243|NCT02027805|Antibodies, monoclonal
999244|NCT02027805|Immunotoxins
999245|NCT02027805|Immunosuppressive agents
999246|NCT02027779|GreenGene™ F, Previously Treated Patients
999247|NCT02027727|inflammatory bowel disease
999248|NCT02027727|infliximab
999249|NCT02027727|trough level
999250|NCT02027727|crohn's disease
999251|NCT02027727|ulcerative colitis
999252|NCT02027714|Discordant
999253|NCT02027714|Lesotho
999254|NCT02027714|Couples
999255|NCT02027714|Enhanced Prevention Package (EPP)
999256|NCT02027714|ART
999257|NCT02027714|Counseling
999258|NCT02027714|Male Circumcision
999259|NCT02027688|Oral feeding
999260|NCT02027688|Premature
999261|NCT02027688|Infants
999262|NCT02027688|Neonatal Intensive Care Unit
999263|NCT02027675|exercise
999264|NCT02027675|immune function
999265|NCT02027675|inflammation
999266|NCT02027675|immunity
999267|NCT02027675|diet
999268|NCT02027675|obesity
999269|NCT02027675|asthma
999270|NCT02027649|Bladder cancer
999271|NCT02027649|Keratin 14
999272|NCT02027649|Pronostic marker
999273|NCT02027649|Diagnostic marker
999274|NCT02027649|Noninvasive technique
999275|NCT02027636|Depression
999276|NCT02027636|Latinos
999277|NCT02027636|Mental Health
999278|NCT02027636|Disparities
999279|NCT02027623|Mechanical low back pain
999280|NCT02027623|Non-specific low back pain
999281|NCT02027623|Exercise
999282|NCT02027623|Motor skill training
999283|NCT02027610|Infant
999284|NCT02027610|Bangladesh
999285|NCT02027610|vitamin A
999286|NCT02027610|microbiota
999287|NCT02027610|vaccine
999288|NCT02027610|immunity
999289|NCT02027597|video games
999290|NCT02027597|oral health
999291|NCT02027597|social cognitive theory
999292|NCT02027597|behavior change
999293|NCT02027597|randomized trial
999294|NCT02027597|growth modeling
999295|NCT02027597|minority
999296|NCT02027597|gender
999297|NCT02027584|infant, premature
999298|NCT02027584|infant, newborn
999299|NCT02027584|choline
999300|NCT02027571|Diabetes
999301|NCT02027571|Race/Ethnicity
999302|NCT02027571|Offspring Cohort
999303|NCT02027571|African Americans
999304|NCT02027571|Prediabetes Reversal
999305|NCT02027571|Lifestyle Intervention
999306|NCT02027571|Insulin Sensitivity
999307|NCT02027571|Beta-cell Function
999308|NCT02027571|Diabetes Prevention
999309|NCT02027558|cognitive behavioral therapy
999310|NCT02027558|insomnia
999311|NCT02027558|apnea
999312|NCT02027545|cancer screening
999313|NCT02027545|decision making
999314|NCT02027519|Self-testing
999315|NCT02027519|Home-based testing
999316|NCT02027519|Lesotho
999317|NCT02027519|Discordant
999318|NCT02027506|ECG
999319|NCT02027506|aVL
999320|NCT02027506|CHRONIC STABLE ANGINA
999321|NCT02027506|T WAVE
999322|NCT02027493|Children
999323|NCT02027493|Chronic hepatitis C
999324|NCT02027493|Hansenula polymorpha
999325|NCT02027493|Pegylated interferon
999326|NCT02027493|Response rate
999327|NCT02027493|Ribavirin
999328|NCT02027493|Treatment
999329|NCT02027480|Antiretroviral Therapy (ART)
999330|NCT02027480|Biomarkers
999331|NCT02027480|Nyanza Province
999332|NCT02027480|Kenya
999333|NCT02027467|Hematopoietic stem cells
999334|NCT02027467|Herbal
999335|NCT02027467|Dietary
999336|NCT02027467|CD cells
999337|NCT02027467|Basic research
999338|NCT02027454|GSK1265744
999339|NCT02027454|HIV
999340|NCT02027454|placebo
999341|NCT02027454|cardiac repolarization
999342|NCT02027454|12-lead ECG
999343|NCT02027454|moxifloxacin
999344|NCT02027454|QTc
999345|NCT02027441|Serodiscordant
999346|NCT02027441|Lesotho
999347|NCT02027441|Home-based testing
999361|NCT02027415|air pollution
999362|NCT02027415|food
999363|NCT02027415|nitrites
999364|NCT02027415|nitrates
999365|NCT02027415|breath tests/methods
999366|NCT02027389|MSSA, MRSA
999367|NCT02027376|Advanced Breast Cancer
999368|NCT02027376|LDE225
999369|NCT02027376|Triple Negative
999370|NCT02027376|Hormonal Receptor negative
999371|NCT02027376|Her2 negative
999372|NCT02027363|Metastasis colorectal cancer
999373|NCT02027363|Maintenance
999374|NCT02027363|First-line treatment
999375|NCT02027363|Capecitabine
999376|NCT02027337|combined oral contraceptives
999377|NCT02027337|drospirenone
999378|NCT02027337|cyproterone
999379|NCT02027337|hemostasis
999380|NCT02027337|antioxidants
999381|NCT02027324|Surgical site infection
999382|NCT02027324|Cesarean delivery
999383|NCT02027324|Antisepsis
999384|NCT02027324|Povidone iodine
999385|NCT02027324|Chlorhexidine alcohol
999386|NCT02027324|Endometritis
999387|NCT02027311|Endoscopic Retrograde Cholangiopancreatography (ERCP)
999388|NCT02027311|Conscious Sedation
999389|NCT02027311|etomidate
999390|NCT02027311|midazolam
999391|NCT02027298|Abatacept
999392|NCT02027298|Sjogren's Syndrome
999393|NCT02027298|Rheumatoid Arthritis
999394|NCT02027285|fortified milk, aging, health status
999395|NCT02027272|Eclampsia
999396|NCT02027259|Diabetes
999397|NCT02027259|Depression
999398|NCT02027259|Group
999399|NCT02027246|spinal cord injury
999400|NCT02027246|autologous bone marrow mononuclear cells
999401|NCT02027246|stem cell therapy
999402|NCT02027233|Prevention
999403|NCT02027233|Influenza
999404|NCT02027233|Adults hospitalized
999405|NCT02027233|Vaccines
999406|NCT02027233|Effectiveness
999407|NCT02027207|Cholera
999408|NCT02027207|Oral cholera vaccine
999409|NCT02027207|Shanchol
999410|NCT02027207|Protective efficacy
999411|NCT02027207|Bangladesh
999412|NCT02027194|Allergic Rhinitis
999413|NCT02027194|Chinese herbal medicine
999414|NCT02027194|Adolescents
999415|NCT02027194|Double-blinded
999416|NCT02027194|Randomized controlled trial
999417|NCT02027168|infertility
999418|NCT02027168|elevated FSH
999419|NCT02027168|alternative treatment
999420|NCT02027168|Clear Passage Approach
999421|NCT02027168|Clear Passage Physical Therapy
999422|NCT02027155|healthy volunteers
999423|NCT02027129|Respiratory Distress Syndrome, Adult
999424|NCT02027129|Cor Pulmonale
999425|NCT02027129|High Frequency Ventilaiton
999426|NCT02027116|chronic hepatitis C
999427|NCT02027116|DNA Vaccine
999428|NCT02027116|Electroporation
999429|NCT02027116|Intramuscular (IM) Injection
999430|NCT02027103|Fetuin-A
999431|NCT02027103|OPG
999432|NCT02027103|Metformin
999433|NCT02027103|Pioglitazone
999434|NCT02027077|physical activity
999435|NCT02027077|diet
999436|NCT02027077|small change
999437|NCT02027077|behavior change
999438|NCT02027051|population genetics
999439|NCT02027025|Spasticity, Multiple sclerosis
999440|NCT02026934|Graft-Versus-Host Disease(GVHD)
999441|NCT02026934|Hematopoietic Stem Cell Transplantation.
999442|NCT02026934|Graft failure
999443|NCT02026934|Graft exhaustion
999444|NCT02026921|Phase II study,
999445|NCT02026921|Recurrent platinum-sensitive ovarian cancer
999446|NCT02026921|docetaxel
999447|NCT02026921|Carboplatin
999448|NCT02026921|Toxicity
999449|NCT02026908|Prostate Artery Embolization
999450|NCT02026908|PAE
999451|NCT02026908|Benign Prostatic Hyperplasia
999452|NCT02026908|BPH
999453|NCT02026908|Lower Urinary Tract Symptoms
999454|NCT02026908|LUTS
999455|NCT02026882|Airway, Caesarean
999456|NCT02026869|Vaginal administration, PCOS, Metformin
999457|NCT02026856|oxidative stress, sepsis, selenium
999458|NCT02026830|Diabetic foot infections
999459|NCT02026830|microorganisms
999460|NCT02026791|Supraglottic airway device
999461|NCT02026791|I-gel
999462|NCT02026791|SupremeLMA
999463|NCT02026791|Elderly patient
999464|NCT02026739|minimally invasive esophagectomy; pulmonary function
999465|NCT02026674|urineflow
999466|NCT02026674|luts
999467|NCT02026674|urine flow
999468|NCT02026674|uroflometry
999469|NCT02026674|bph
999470|NCT02026635|heart failure
999471|NCT02026635|Optivol® cardiac device
999472|NCT02026635|Medtronic CareLink
999473|NCT02026622|major depressive disorder
999474|NCT02026622|cerebrovascular reactivity
999475|NCT02026622|emotional reactivity
999476|NCT02026609|TIPS
999477|NCT02026609|Hepatic encephalopathy
999478|NCT02026609|Oral glutamine challenge
999479|NCT02026609|Psychometric tests
999480|NCT02026609|Portal hypertension
999481|NCT02026609|Cirrhosis
999482|NCT02026596|subrachnoid hemorrhage
999483|NCT02026596|secondary brain injury
999484|NCT02026570|Prosthesis
999485|NCT02026570|Falls
999486|NCT02026570|Training
999487|NCT02026544|low frequency ultrasound
999488|NCT02026544|glomerular filtration rate
999489|NCT02026492|exercise-induced bronchoconstriction
999490|NCT02026492|exercise-induced asthma
999491|NCT02026492|cold chamber
999492|NCT02026492|exercise challenge
999493|NCT02026492|cold air challenge
999494|NCT02026492|combined exercise- and cold-air challenge
999495|NCT02026492|methacholine challenge
999496|NCT02026479|full-frequency sudden hearing loss
999497|NCT02026479|post auricular injection
999498|NCT02026479|glucocorticoid
999499|NCT02026479|multi-center
999500|NCT02026466|Coronary Artery Disease
999501|NCT02026466|Chronic Total Occlusion
999502|NCT02026453|Adverse drug events
999503|NCT02026440|oral fluid collection device cotinine detection
999504|NCT02026414|PrimaVie
999505|NCT02026414|Herbal Supplement
999506|NCT02026414|Muscle biopsy
999507|NCT02026414|Energy
999508|NCT02026414|Exercise
999509|NCT02026414|Human skeletal muscle adaptation
999510|NCT02026414|Muscle function
999511|NCT02026388|PH
999512|NCT02026388|primary hyperoxaluria
999513|NCT02026388|hyperoxaluria
999514|NCT02026388|primary oxalosis
999515|NCT02026388|Primary Hyperoxaluria Type 1
999516|NCT02026388|Primary Hyperoxaluria Type 2
999517|NCT02026388|Primary Hyperoxaluria Type 3
999518|NCT02026388|Dent
999519|NCT02026388|Dents
999520|NCT02026388|Dent Disease
999521|NCT02026388|Dent 1
999522|NCT02026388|Dent 2
999523|NCT02026388|Cystinuria
999524|NCT02026388|APRT
999525|NCT02026388|APRT deficiency
999526|NCT02026388|Biobank
999527|NCT02026362|HCC
999528|NCT02026362|DC
999529|NCT02026362|CTL
999530|NCT02026349|influenza
999531|NCT02026349|flu
999532|NCT02026349|fever
999533|NCT02026349|cough
999534|NCT02026349|body aches
999535|NCT02026349|headache
999536|NCT02026349|nasal congestion
999537|NCT02026349|body pains
999538|NCT02026349|sore throat
999539|NCT02026349|fatigue
999540|NCT02026349|T-705
999541|NCT02026349|favipiravir
999542|NCT02026349|favor
999543|NCT02026349|flu symptoms
999544|NCT02026336|asthma; inflammation; electronic nose
999545|NCT02026310|glimepiride
999546|NCT02026310|metformin
999547|NCT02026310|basal insulin
999548|NCT02026310|Hemoglobin A, Glycosylated
999549|NCT02026310|glucose fluctuation
999550|NCT02026310|hypoglycemia
999551|NCT02026297|postpartum hemorrhage
999552|NCT02026297|estimated blood loss
999553|NCT02026297|coagulation
999554|NCT02026297|thromboelastography
999555|NCT02026297|tranexamic acid
999556|NCT02026284|Caesarean section
999557|NCT02026284|Anaesthesia
999558|NCT02026284|Questionnaires
999559|NCT02026245|Arthritis
999560|NCT02026245|rheumatoid
999561|NCT02026245|joints
999562|NCT02026245|swelling
999563|NCT02026245|measurement
999564|NCT02026245|movement
999565|NCT02026245|electronic
999566|NCT02026245|data
999567|NCT02026245|glove
999568|NCT02026245|goniometry
999569|NCT02026245|outcome
999570|NCT02026245|stiffness
999571|NCT02026232|Type 2 Diabetes
999572|NCT02026232|Overweight
999573|NCT02026206|Primary Dysmenorrhea
999574|NCT02026206|Pain
999575|NCT02026167|Chronic Pain
999576|NCT02026167|Mood
999577|NCT02026167|Physical Activity
999578|NCT02026154|hypertension, biomarkers, echocardiography, heart failure
999579|NCT02026128|Uveitis
999580|NCT02026128|Inflammation
999581|NCT02026128|OCT
999582|NCT02026128|Grading
999583|NCT02026115|cancer
999584|NCT02026115|hospice
999585|NCT02026115|pain
999586|NCT02026102|decision aid
999587|NCT02026102|patient decision making
999588|NCT02026102|heart failure
999589|NCT02026102|ejection fraction
999590|NCT02026102|primary prevention
999591|NCT02026102|implantable cardioverter defibrillator
999592|NCT02026102|ICD
999593|NCT02026102|pilot trial
999594|NCT02026102|patient centered health care
999595|NCT02026076|low back pain
999596|NCT02026076|traction
999597|NCT02026076|unloading
999598|NCT02026050|dexamethasone
999599|NCT02026050|intraarticular injection
999600|NCT02026050|interscalene brachial plexus block
999601|NCT02026037|Stress Disorders
999602|NCT02026037|Post-Traumatic
999603|NCT02026037|Burns
999604|NCT02026037|Brief Psychotherapy
999605|NCT02026037|Cognitive Behavior Therapy
999606|NCT02026011|alcohol use disorder
999607|NCT02026011|naltrexone
999608|NCT02026011|Asian American
999609|NCT02026011|pharmacogenetics
999610|NCT02026011|OPRM1 gene
999611|NCT02025998|ibudilast, alcoholism
999612|NCT02025985|Karyopharm
999613|NCT02025985|KPT-330
999614|NCT02025985|Selinexor
999615|NCT02025985|SIGN
999616|NCT02025985|ovarian cancer
999617|NCT02025985|endometrial cancer
999618|NCT02025985|cervical cancer
999619|NCT02025985|SINE™
999620|NCT02025985|breast cancer
999621|NCT02025985|HER2 negative
999622|NCT02025972|Cerebral palsy
999623|NCT02025972|Umbilical cord blood
999624|NCT02025972|Rehabilitation
999625|NCT02025972|Cytokine
999626|NCT02025972|Outcome
999627|NCT02025959|staff empowerment
999628|NCT02025959|Sleep Apnea
999629|NCT02025959|educational intervention
999630|NCT02025933|Children
999631|NCT02025933|Age 9-12 years
999632|NCT02025933|Overweight (iso-BMI > 25)
999633|NCT02025907|Diabetes Mellitus, Type 2
999634|NCT02025907|Canagliflozin
999635|NCT02025907|Hemoglobin A1c
999636|NCT02025907|Metformin
999637|NCT02025907|Sitagliptin
999638|NCT02025907|T2DM
999639|NCT02025907|JNJ-28431754
999640|NCT02025894|neoplastic solid tumour
999641|NCT02025894|PCVC
999642|NCT02025894|thromboembolic complications
999643|NCT02025894|infectious complications
999644|NCT02025894|risk factors
999645|NCT02025868|Africa
999646|NCT02025868|Antiretroviral Treatment
999647|NCT02025868|Adherence reinforcement
999648|NCT02025868|Third line ART
999649|NCT02025868|Second line ART
999650|NCT02025868|Virologic failure
999651|NCT02025868|Adults
999652|NCT02025855|Iatrogenic opioid abstinence syndrome
999653|NCT02025855|Methadone
999654|NCT02025855|Mechanical ventilation
999655|NCT02025855|ICU delirium
999656|NCT02025855|Continuous sedation
999657|NCT02025842|Hepatocellular carcinoma
999658|NCT02025842|Hepatitis B
999659|NCT02025829|cystic fibrosis
999660|NCT02025829|IL-17 neutrophils
999661|NCT02025803|Advanced solid tumors
999662|NCT02025790|Achalasia
999663|NCT02025790|POEM
999664|NCT02025790|Pneumatic dilatation
999665|NCT02025790|Eckardt score
999666|NCT02025777|Ulcerative Colitis
999667|NCT02025777|PillCam
999668|NCT02025777|IBD
999669|NCT02025751|Diabetes
999670|NCT02025751|Gastroparesis
999671|NCT02025751|Delayed gastric emptying
999672|NCT02025751|Nausea
999673|NCT02025751|Vomiting
999674|NCT02025751|Bloating
999675|NCT02025751|Abdominal pain
999676|NCT02025751|Early Satiety
999677|NCT02025751|Gastric stasis
999678|NCT02025751|Gastropathy
999679|NCT02025725|Gastroparesis
999680|NCT02025725|Diabetic
999681|NCT02025725|Delayed gastric emptying
999682|NCT02025725|Gastric stasis
999683|NCT02025725|Nausea
999684|NCT02025725|Vomiting
999685|NCT02025725|Bloating
999686|NCT02025725|Abdominal pain
999687|NCT02025725|Early satiety
999688|NCT02025725|Gastropathy
999689|NCT02025686|Pain
999690|NCT02025686|Inflammation
999691|NCT02025686|Hyperalgesia
999692|NCT02025686|burn injury
999693|NCT02025686|Hyperbaric Oxygen
999694|NCT02025660|Mw
999695|NCT02025660|Mycobacterium indicum prannii
999696|NCT02025660|Mycobacterium w
999697|NCT02025660|Severe sepsis
999698|NCT02025660|Septic shock
999699|NCT02025647|Mood disorders
999700|NCT02025647|Anxiety disorders
999701|NCT02025647|Eating concerns
999702|NCT02025647|Pain concerns
999703|NCT02025647|Alcohol abuse
999704|NCT02025647|Self harm
999705|NCT02025647|Mental health
999706|NCT02025647|Clinical Decision Support
999707|NCT02025634|Pain, Postoperative
999708|NCT02025634|Ofirmev
999709|NCT02025634|Acetaminophen
999710|NCT02025634|Analgesics, Non-Narcotic
999711|NCT02025634|Arthroscopy
999712|NCT02025621|coronary artery bypass grafting
999713|NCT02025621|CABG
999714|NCT02025621|mitral valve
999715|NCT02025621|LCOS
999716|NCT02025621|low cardiac output syndrome
999717|NCT02025621|levosimendan
999718|NCT02025608|Restless legs syndrome
999719|NCT02025595|Brain
999720|NCT02025595|Genes
999721|NCT02025595|Environment
999722|NCT02025595|Etiology
999723|NCT02025595|Reward
999724|NCT02025595|Satiety Response
999725|NCT02025595|Central Nervous System
999726|NCT02025595|Magnetic Resonance Imaging
999727|NCT02025595|Twins, Monozygotic
999728|NCT02025595|Overweight
999729|NCT02025595|Obesity
999730|NCT02025582|idiopathic toe walking
999731|NCT02025582|gait disorder
999732|NCT02025582|gait analysis
999733|NCT02025582|kinesio taping
999734|NCT02025582|ultrasound elastography
999735|NCT02025582|pediatric
999736|NCT02025582|children
999737|NCT02025582|muscle stiffness
999738|NCT02025582|muscle elasticity
999739|NCT02025569|chronic ankle instability
999740|NCT02025569|lateral ankle sprain
999741|NCT02025569|manual therapy
999742|NCT02025569|star excursion balance test
999743|NCT02025569|strain and counterstrain
999744|NCT02025556|High Frequency Episodic Migraine Headache
999745|NCT02025556|Episodic Migraine Headache
999746|NCT02025556|Migraine Headache
999747|NCT02025543|MRI
999748|NCT02025543|Iron overload
999749|NCT02025530|Stillbirth
999750|NCT02025530|Modifiable risk factors
999751|NCT02025517|Parkinson's disease
999752|NCT02025517|rehabilitation
999753|NCT02025517|kinematics
999754|NCT02025517|cognition
999755|NCT02025504|Colonoscopy, Looping, Sigmoid Looping, ColoWrap, Binder, Patient Satisfaction
999756|NCT02025491|Disseminated leishmaniasis
999757|NCT02025491|Liposomal Amphotericin B
999758|NCT02025491|Leishmania braziliensis
999759|NCT02025478|children
999760|NCT02025478|bone marrow transplant
999761|NCT02025478|autologous
999762|NCT02025478|allogeneic
999763|NCT02025478|breastmilk
999764|NCT02025478|hematopoietic stem cell transplantation (HSCT)
999765|NCT02025465|Atrial Fibrillation
999766|NCT02025465|Atrial Flutter
999767|NCT02025465|Metoprolol
999768|NCT02025465|Diltiazem
999769|NCT02025452|diarrhoea
999770|NCT02025452|gastroenteritis
999771|NCT02025452|rapid diagnostics
999772|NCT02025452|probiotics
999773|NCT02025452|sub-Saharan Africa
999774|NCT02025439|Traumatic Brain Injury
999775|NCT02025439|Transcranial Magnetic Stimulation
999776|NCT02025439|Amantadine
999777|NCT02025439|Vegetative State
999778|NCT02025439|Minimally Conscious State
999779|NCT02025426|Cesarean delivery
999780|NCT02025426|Spinal Anesthesia
999781|NCT02025400|Rehabilitation
999782|NCT02025400|eRehab
999783|NCT02025400|Physical Therapy
999784|NCT02025400|e-Health
999785|NCT02025400|Telemedicine
999786|NCT02025400|Telerehabilitation
999787|NCT02025400|Patient-Centered
999788|NCT02025374|spinal anesthesia
999789|NCT02025374|cesarean section
999790|NCT02025374|hyperbaric levobupivacaine
999791|NCT02025361|prostate biopsy, local anesthesia, cancer detection rate.
999792|NCT02025322|HIV/AIDS
999793|NCT02025322|Peer Mentoring
999794|NCT02025322|Medication Adherence
999795|NCT02025322|Medication Non-adherent
999796|NCT02025322|Newly diagnosed
999797|NCT02025322|HIV-positive individuals
999798|NCT02025322|HIV viral load
999799|NCT02025322|CD4 lymphocyte cell counts
999800|NCT02025322|Treatment adherence
999801|NCT02025322|Health literacy
999802|NCT02025322|Self-efficacy
999803|NCT02025309|train of four
999804|NCT02025309|neuromuscular recovery
999805|NCT02025309|sugammadex
999806|NCT02025296|Telemedicine
999807|NCT02025296|Clinical decision support system
999808|NCT02025296|Ubiquitous healthcare
999809|NCT02025296|Diabetes Care
999810|NCT02025296|Multifactorial Intervention
999811|NCT02025283|Intervertebral disc disease
999812|NCT02025283|Radiculopathy
999813|NCT02025283|Chronic pain
999814|NCT02025283|Thermocoagulation
999815|NCT02025270|Azoospermia, Spermatogonial Arrest, Maturation Arrest.
999816|NCT02025257|coronary artery disease
999817|NCT02025257|elderly
999818|NCT02025257|exercise
999819|NCT02025257|exercise-based cardiac rehabilitation
999820|NCT02025244|Key hole biopsy
999821|NCT02025244|Upper Gastrointestinal Submucosal Tumors
999822|NCT02025244|EUS-FNA
999823|NCT02025244|Mitototic Activity
999824|NCT02025244|GIST
999825|NCT02025231|reirradiation
999826|NCT02025231|recurrent glioma
999827|NCT02025231|positron emission tomography
999828|NCT02025231|amino acid tracer
999829|NCT02025218|NSCLC
999830|NCT02025218|EGFR
999831|NCT02025218|TKI
999832|NCT02025218|Re-challenge
999833|NCT02025218|Lung Cancer
999834|NCT02025218|Resistance
999835|NCT02025192|ONT-380
999836|NCT02025192|Capecitabine
999837|NCT02025192|Trastuzumab
999838|NCT02025192|Xeloda
999839|NCT02025192|Herceptin
999840|NCT02025192|HER2 positive breast cancer
999841|NCT02025192|Breast cancer
999842|NCT02025192|ARRY-380
999843|NCT02025192|Tucatinib
999844|NCT02025179|Teriparatide
999845|NCT02025179|Osteoporosis
999846|NCT02025179|Spinal Cord Injury
999847|NCT02025179|Bone Diseases
999848|NCT02025179|Metabolic Bone Diseases
999849|NCT02025179|Musculoskeletal Diseases
999850|NCT02025179|Spinal Cord Diseases
999851|NCT02025179|Central Nervous System Diseases
999852|NCT02025179|Nervous System Diseases
999853|NCT02025179|Nervous System
999854|NCT02025179|Wounds and Injuries
999855|NCT02025179|Bone Density Conservation Agents
999856|NCT02025179|Physiological Effects of Drugs
999857|NCT02025179|Pharmacologic Actions
999858|NCT02025179|Vibration
999859|NCT02025166|Pain
999860|NCT02025166|abortion
999861|NCT02025166|paracetamol
999862|NCT02025166|lornoxicam
999863|NCT02025140|Computer controlled anesthesia (CCLAD)
999864|NCT02025140|pain perception
999865|NCT02025140|Effectiveness
999866|NCT02025140|primary molars
999867|NCT02025140|Behavior
999868|NCT02025127|septic shock
999869|NCT02025127|mechanical ventilation
999870|NCT02025127|enteral nutrition
999871|NCT02025127|trophic feeding
999872|NCT02025114|NSCLC, EGFR mutation
999873|NCT02025101|Slow Coronary Flow
999874|NCT02025075|Tomography
999875|NCT02025075|Oximetry
999876|NCT02025075|Echocardiography
999877|NCT02025062|head and neck squamous cell carcinomas (HNSCCs)
999878|NCT02025062|elderly
999879|NCT02025062|cancer
999880|NCT02025062|comprehensive geriatric assessment
999881|NCT02025062|functional status
999882|NCT02025062|malnutrition
999883|NCT02025062|survival
999884|NCT02025049|pancreatitis
999885|NCT02025036|Chemoradiotherapy， Esophageal Squamous Cancer
999886|NCT02025023|Size
999887|NCT02025023|Pain
999888|NCT02025023|Resolution
999889|NCT02025023|Complications
999890|NCT02025023|Swelling
999891|NCT02025010|castration-resistant prostate cancer
999892|NCT02024997|Pancreatic malignancy
999893|NCT02024997|Radiation Therapy
999894|NCT02024984|LPFPCCPCOS
999895|NCT02024971|Drug therapy
999896|NCT02024958|Adult ICU patients
999897|NCT02024958|spontaneous breathing
999898|NCT02024958|invasive ventilation
999899|NCT02024958|non-invasive ventilation
999900|NCT02024945|Drug therapy
999901|NCT02024906|isoflavone
999902|NCT02024906|CVD
999903|NCT02024906|soy intake
999904|NCT02024906|subclinical hypothyroid
999905|NCT02024893|Humeral retroversion
999906|NCT02024893|dynamic control ratio
999907|NCT02024893|GIRD
999908|NCT02024880|in vitro fertilization
999909|NCT02024880|embryo transfer
999910|NCT02024880|transfer catheter
999911|NCT02024867|Methicillin resistent Staphylococcus aureus
999912|NCT02024867|Staphylococcus aureus
999913|NCT02024854|Kangaroo-Mother Care Method
999914|NCT02024854|Stress, Physiological
999915|NCT02024841|Gastric cancer
999916|NCT02024841|Peritoneal carcinomatosis
999917|NCT02024841|Intraperitoneal docetaxel
999918|NCT02024841|Cisplatin
999919|NCT02024841|TS-ONE
999920|NCT02024828|Infant feeding
999921|NCT02024802|Pain
999922|NCT02024802|Pain Cream
999923|NCT02024802|Nociceptive pain
999924|NCT02024802|neurologic pain
999925|NCT02024802|transdermal
999926|NCT02024802|compounding
999927|NCT02024802|compound
999928|NCT02024776|Training
999929|NCT02024776|Wellness
999930|NCT02024776|Aerobic capacity
999931|NCT02024776|Information and communication technology, surgical risk
999932|NCT02024776|Abdominal surgery
999933|NCT02024763|Energy Expenditure
999934|NCT02024763|Physical Education
999935|NCT02024763|Children
999936|NCT02024763|Randomized Controlled Trial
999937|NCT02024750|Family centered care
999938|NCT02024750|Patient centered care
999939|NCT02024750|Diabetes Mellitus, Type 1
999940|NCT02024750|Problem Recognition in Illness Self-Management (PRISM)
999941|NCT02024711|Cataract
999942|NCT02024711|Intraocular Lens
999943|NCT02024711|IOL
999944|NCT02024711|Aphakia
999945|NCT02024685|Prostate
999946|NCT02024685|Localized Prostate Cancer
999947|NCT02024685|Decision making
999948|NCT02024672|Intrauterine devices
999949|NCT02024672|IUDs
999950|NCT02024672|postpartum
999951|NCT02024672|contraception
999952|NCT02024659|nasal polyps
999953|NCT02024659|remodeling
999954|NCT02024659|inflammatory cells
999955|NCT02024659|budesonide
999956|NCT02024646|Psoriatic Arthritis
999957|NCT02024646|Brodalumab
999958|NCT02024646|AMG 827
999959|NCT02024620|depression
999960|NCT02024620|technology
999961|NCT02024620|psychotherapy
999962|NCT02024620|behavioral activation
999963|NCT02024594|Nitrous Oxide-Oxygen conscious sedation
999964|NCT02024594|Cognitive Behavioral Therapy
999965|NCT02024594|Children, Preschool
999966|NCT02024594|dental anxiety
999967|NCT02024594|Patient Cooperation
999968|NCT02024581|pediatric
999969|NCT02024581|dermatology
999970|NCT02024581|East Indian sandalwood oil
999971|NCT02024581|pox virus
999972|NCT02024568|Pregabalin
999973|NCT02024568|Arthralgia Myalgia Syndrome
999974|NCT02024568|Paclitaxel
999975|NCT02024568|Pain management
999976|NCT02024568|Breast cancer
999977|NCT02024542|Bariatric Surgery, Obesity, White Adipose Tissue
999978|NCT02024516|Type 2 diabetes
999979|NCT02024516|Pomegranate
999980|NCT02024516|Inflammation
999981|NCT02024516|lipid profiles
999982|NCT02024503|stroke
999983|NCT02024503|fMRI
999984|NCT02024503|DTI
999985|NCT02024490|vitamin D, prematurity, RDS, BPD, maternal, neonatal
999989|NCT02024464|Primary open angle glaucoma
999990|NCT02024464|POAG
999991|NCT02024464|Pseudoexfoliative glaucoma
999992|NCT02024464|PXG
999993|NCT02024464|Pigmentary dispersion glaucoma
999994|NCT02024464|PDG
999995|NCT02024464|Hydrus
999996|NCT02024451|Radial shock wave
999997|NCT02024451|Acupuncture
999998|NCT02024438|metastatic gastric cancer
999999|NCT02024438|neurotoxicity
1000000|NCT02024438|mFOLFOX6
1000001|NCT02024438|monosialotetrahexosylganglioside Sodium Injection
1000002|NCT02024425|Clinical trials
1000003|NCT02024425|Adult
1000004|NCT02024425|Women
1000005|NCT02024425|Functional food
1000006|NCT02024425|Dietary Supplements
1000007|NCT02024425|Overweight
1000008|NCT02024425|Obese
1000009|NCT02024425|Absorptiometry, Dual X-Ray
1000010|NCT02024425|Rosmarinus
1000011|NCT02024425|Oligosaccharides
1000012|NCT02024425|Lactulose
1000013|NCT02024425|Bioactive peptide
1000014|NCT02024412|metastatic colorectal cancer
1000015|NCT02024412|neurotoxicity
1000016|NCT02024412|mFOLFOX6
1000017|NCT02024412|monosialotetrahexosylganglioside Sodium Injection
1000018|NCT02024399|Pediatric Overweight/Obesity, DEXA, Fitness
1000019|NCT02024386|Guanylate Cyclase
1000020|NCT02024386|Pulmonary Edema of Mountaineers
1000021|NCT02024386|Mountaineering
1000022|NCT02024386|Performance-Enhancing Substances
1000023|NCT02024386|Athletic Performance
1000024|NCT02024373|chronic subdural hematoma
1000025|NCT02024373|Atorvastatin
1000026|NCT02024373|oral administration therapy
1000027|NCT02024360|obesity
1000028|NCT02024360|overweight
1000029|NCT02024360|children
1000030|NCT02024360|prevention
1000031|NCT02024334|JIA
1000032|NCT02024334|LEFLUNOMIDE
1000033|NCT02024334|EFFICACY
1000034|NCT02024321|abdominal surgery
1000035|NCT02024321|TPN
1000036|NCT02024321|blood glucose
1000037|NCT02024308|acute myeloid leukemia,
1000038|NCT02024308|AML1-ETO fusion protein,
1000039|NCT02024308|Fludarabine,
1000040|NCT02024308|recurrence
1000041|NCT02024269|macular degeneration
1000042|NCT02024269|stem cells
1000043|NCT02024269|adipose stem cells
1000044|NCT02024256|Vaginal delivery
1000045|NCT02024256|Perineal swelling
1000046|NCT02024256|Perineal pain
1000047|NCT02024256|MgSo4
1000048|NCT02024256|Magnesium sulfate
1000049|NCT02024256|Cold water
1000050|NCT02024243|Micro RNA
1000051|NCT02024243|Wound
1000052|NCT02024243|Chronic Venous Leg Ulcer
1000053|NCT02024243|VLU
1000054|NCT02024243|miR210
1000055|NCT02024243|OSU Comprehensive Wound Center
1000056|NCT02024204|World Trade Center Disaster
1000057|NCT02024204|Environmental Exposure
1000058|NCT02024204|Respiratory Physiology
1000059|NCT02024204|Inflammation
1000060|NCT02024204|Gastrointestinal Diseases
1000061|NCT02024204|Sinus Symptoms
1000062|NCT02024204|PTSD
1000063|NCT02024204|Anxiety
1000064|NCT02024204|Depression
1000065|NCT02024204|Hypersensitivity
1000066|NCT02024204|Spirometry
1000067|NCT02024204|Oscillometry
1000068|NCT02024191|glutamine
1000069|NCT02024191|oxaliplatin
1000070|NCT02024191|peripheral neuropathy
1000071|NCT02024178|Prostate Cancer
1000072|NCT02024178|Radical Prostatectomy
1000073|NCT02024178|Ultrasound Imaging
1000074|NCT02024165|Ultrasound
1000075|NCT02024165|FSE
1000076|NCT02024165|IUPC
1000077|NCT02024139|Orthodontic pain
1000078|NCT02024139|Chewing gum
1000079|NCT02024126|Knee osteoarthritis
1000080|NCT02024126|Exercise therapy
1000081|NCT02024126|RCT
1000082|NCT02024126|Intervention
1000083|NCT02024126|Knee pain
1000084|NCT02024126|Muticenter
1000085|NCT02024126|Knee function
1000086|NCT02024113|validation
1000087|NCT02024113|model
1000088|NCT02024113|metabolic profile
1000089|NCT02024113|positron emission tomography
1000090|NCT02024061|Adolescents
1000091|NCT02024061|Obesity
1000092|NCT02024061|Physical activity
1000093|NCT02024061|Sedentary behavior
1000094|NCT02024061|Psychosocial health
1000095|NCT02024048|Pregnancy
1000096|NCT02024048|OCT
1000097|NCT02024048|Enhanced depth imaging
1000098|NCT02024048|Choroid
1000099|NCT02024035|Tomotherapy
1000100|NCT02024035|Head and neck squamous celle carcinoma
1000101|NCT02024035|Health economic evaluation
1000102|NCT02024022|colonoscopy
1000103|NCT02024022|bowel cleansing
1000104|NCT02024022|polyethylene glycol
1000105|NCT02024022|sodium picosulphate / magnesium citrate
1000106|NCT02024009|chemoradiotherapy
1000107|NCT02024009|nelfinavir
1000108|NCT02024009|abraxane
1000109|NCT02024009|gemcitabine
1000110|NCT02024009|radiotherapy
1000111|NCT02024009|capecitabine
1000112|NCT02023996|HER2 positive
1000113|NCT02023996|PET Imaging
1000114|NCT02023996|89Zr-DFO-trastuzumab
1000115|NCT02023996|13-165
1000116|NCT02023983|ST-segment elevation myocardial infarction
1000117|NCT02023983|Primary percutaneous coronary intervention
1000118|NCT02023983|Low risk
1000119|NCT02023983|Early discharge
1000120|NCT02023970|Bioprosthetic heart valves, immune response, structural valve deterioration, valvular disease.
1000121|NCT02023957|Interactive Health-risk assessment
1000122|NCT02023957|Primary Care
1000123|NCT02023957|Randomized
1000124|NCT02023957|Open Label
1000125|NCT02023957|Efficacy Study
1000126|NCT02023944|Memory
1000127|NCT02023944|Aging
1000128|NCT02023944|Healthy People
1000129|NCT02023944|Intervention
1000130|NCT02023931|Oral mucosa
1000131|NCT02023931|Nrf2 pathway
1000132|NCT02023931|Broccoli Sprout Extract
1000133|NCT02023931|Head and Neck Cancer
1000134|NCT02023918|Growth hormone antagonism
1000135|NCT02023866|Leigh Syndrome
1000136|NCT02023866|Leber's hereditary optic neuropathy
1000137|NCT02023866|myoclonic epilepsy
1000138|NCT02023866|mitochondrial encephalomyopathy
1000139|NCT02023866|Kearn-Sayre syndrome
1000140|NCT02023866|POLG-related disorders
1000141|NCT02023866|Neurogastrointestinal encephalopathy
1000142|NCT02023840|periodontitis
1000143|NCT02023840|pockets
1000144|NCT02023827|Transtheoretical Model
1000145|NCT02023827|Stages of change
1000146|NCT02023827|Computer-tailored intervention
1000147|NCT02023827|Delinquency
1000148|NCT02023827|Substance abuse
1000149|NCT02023827|Juvenile offender
1000150|NCT02023827|Juvenile justice
1000151|NCT02023827|Rise Above Your Situation (RAYS) program
1000152|NCT02023801|Menorrhagia
1000153|NCT02023801|Dysfunctional Uterine Bleeding
1000154|NCT02023801|Endometrial Ablation
1000155|NCT02023788|human umbilical cord blood-derived mesenchymal stem cells
1000156|NCT02023788|bronchopulmonary dysplasia
1000157|NCT02023788|respiratory tract infection
1000158|NCT02023788|Premature infants
1000159|NCT02023762|mitral regurgitation
1000160|NCT02023762|local anaesthesia
1000161|NCT02023762|percutaneous repair
1000162|NCT02023749|nuts
1000163|NCT02023749|metabolic syndrome
1000164|NCT02023749|lipid profile
1000165|NCT02023749|inflammation
1000166|NCT02023749|oxidative stress
1000167|NCT02023749|endothelial function
1000168|NCT02023723|Energy Drink
1000169|NCT02023723|Electrocardiograph
1000170|NCT02023723|Hemodynamic
1000171|NCT02023710|mucosal melanoma
1000172|NCT02023710|Bevacizumab
1000173|NCT02023710|Carboplatin
1000174|NCT02023710|Paclitaxel
1000175|NCT02023684|Sleeve Gastrectomy
1000176|NCT02023684|Lidocaine
1000177|NCT02023684|ropivacaine
1000178|NCT02023658|HIV
1000179|NCT02023658|pMTCT
1000180|NCT02023645|lutein
1000181|NCT02023645|cognition
1000182|NCT02023645|neural efficiency
1000183|NCT02023645|aging
1000184|NCT02023632|older adults
1000185|NCT02023632|physical activity
1000186|NCT02023632|self-categorization
1000187|NCT02023632|group dynamics
1000188|NCT02023632|self-identity
1000189|NCT02023619|Keratoconus
1000190|NCT02023619|Astigmatism
1000191|NCT02023619|Cornea
1000192|NCT02023619|SD-OCT
1000193|NCT02023606|Impulsive Aggression
1000194|NCT02023606|ADHD
1000195|NCT02023580|Viral suppression
1000196|NCT02023580|Sexual risk
1000197|NCT02023554|azithromycin
1000198|NCT02023554|theophylline
1000199|NCT02023554|CYP3A4
1000200|NCT02023515|weight loss
1000201|NCT02023515|metabolic syndrome
1000202|NCT02023515|stress
1000203|NCT02023515|obesity
1000204|NCT02023502|female stress urinary incontinence
1000205|NCT02023502|proteomics
1000206|NCT02023502|biomarker
1000207|NCT02023424|BDNF
1000208|NCT02023424|GLATIRAMER ACETATE
1000209|NCT02023424|RETT SYNDROME
1000210|NCT02023424|COPAXONE
1000211|NCT02023424|Bruria Ben-Zeev
1000212|NCT02023411|Teriparatide
1000213|NCT02023411|Inactive Charcot's neuroarthropathy
1000214|NCT02023398|High Frequency
1000215|NCT02023398|Waist circumferential reduction
1000216|NCT02023385|Low Level Laser Therapy
1000217|NCT02023385|LLLT
1000218|NCT02023385|Waist circumferential reduction
1000219|NCT02023372|NuCel
1000220|NCT02023372|Lumbar Spine
1000221|NCT02023372|Degenerative Disease
1000222|NCT02023372|Efficacy
1000223|NCT02023372|Fusion
1000224|NCT02023359|Advanced breast cancer
1000225|NCT02023359|Everolimus
1000226|NCT02023346|Patient-Physician Communication
1000227|NCT02023346|Brain cancer
1000228|NCT02023346|13-253
1000229|NCT02023333|Regorafenib
1000230|NCT02023333|Performance Status
1000231|NCT02023333|13-211
1000232|NCT02023281|Depression
1000233|NCT02023281|Exercise
1000234|NCT02023281|Neurotransmitters
1000235|NCT02023281|Catecholimines
1000236|NCT02023281|EEG
1000237|NCT02023255|Healthy
1000238|NCT02023255|JNJ-39393406
1000239|NCT02023255|Safety
1000240|NCT02023255|Tolerability
1000241|NCT02023255|Pharmacokinetics
1000242|NCT02023242|Primary open angle glaucoma
1000243|NCT02023242|POAG
1000244|NCT02023242|Pseudoexfoliative glaucoma
1000245|NCT02023242|PXG
1000246|NCT02023242|Pigmentary glaucoma
1000247|NCT02023242|PG
1000248|NCT02023242|Hydrus
1000249|NCT02023229|Branched chain aminoacids
1000250|NCT02023229|Nutritional status
1000251|NCT02023229|Hepatic encephalopathy
1000252|NCT02023216|Preterm infants
1000253|NCT02023216|Non-nutritive sucking
1000254|NCT02023216|Pacifier
1000255|NCT02023216|Gastro-esophageal reflux
1000256|NCT02023216|pH-multiple intraluminal impedance
1000257|NCT02023216|Apneas
1000258|NCT02023216|Bradycardias
1000259|NCT02023216|Hypoxic episodes
1000260|NCT02023216|Polysomnographic monitoring
1000261|NCT02023190|liver cirrhosis
1000262|NCT02023190|liver transplant
1000263|NCT02023190|nutritional status
1000264|NCT02023190|bioelectrical impedance vector analysis
1000265|NCT02023177|phase angle
1000266|NCT02023177|liver cirrhosis
1000267|NCT02023177|mortality
1000268|NCT02023177|malnutrition
1000269|NCT02023138|Clinical practice guideline
1000270|NCT02023138|Brain injury
1000271|NCT02023138|Acceptability
1000272|NCT02023138|Feasibility
1000273|NCT02023138|Effectiveness
1000274|NCT02023112|Japanese
1000275|NCT02023112|Hepatitis C
1000276|NCT02023112|Treatment naive
1000277|NCT02023112|Treatment experienced
1000278|NCT02023112|Genotype 2
1000279|NCT02023112|Ombitasvir
1000280|NCT02023112|Paritaprevir
1000281|NCT02023112|Ritonavir
1000282|NCT02023112|Ribavirin
1000283|NCT02023112|VIEKIRAX Combination Tablets
1000284|NCT02023099|Hepatitis C
1000285|NCT02023099|Genotype 1b
1000286|NCT02023099|Cirrhotic
1000287|NCT02023099|Treatment Experienced
1000288|NCT02023099|Treatment Naive
1000289|NCT02023099|Japanese
1000290|NCT02023099|ombitasvir
1000291|NCT02023099|paritaprevir
1000292|NCT02023099|ritonavir
1000293|NCT02023099|VIEKIRAX Combination Tablets
1000294|NCT02023086|Visual field defect
1000295|NCT02023086|Blood oxygenation
1000296|NCT02023086|Optic nerve Head
1000297|NCT02023047|Anal Fissure
1000298|NCT02023047|Nifedipine
1000299|NCT02023034|Parkinson's disease, Physical Therapy, Fatigue, Quality of Life
1000300|NCT02023021|Pancreatic Cancer; Pancreatic Adenocarcinoma; Nab-paclitaxel; Gemcitabine; Adjuvant Therapy
1000301|NCT02022995|EGFR
1000302|NCT02022995|cetuximab
1000303|NCT02022995|colon cancer
1000304|NCT02022982|KRAS mutant Non-Small Cell Lung Cancer
1000305|NCT02022982|Solid Tumors
1000306|NCT02022969|atelectasis
1000307|NCT02022969|SPO2 - oscillations
1000308|NCT02022943|Alzheimer's
1000309|NCT02022943|prevention
1000310|NCT02022930|Osteoarthritis
1000311|NCT02022930|Knee
1000312|NCT02022917|ovarian cancer.
1000313|NCT02022917|tubal cancer
1000314|NCT02022917|peritoneal cancer
1000315|NCT02022904|prostate cancer
1000316|NCT02022904|metastatic
1000317|NCT02022904|castrate resistant
1000318|NCT02022891|Sickle cell disease
1000319|NCT02022891|psychological support
1000320|NCT02022891|quality of life
1000321|NCT02022878|Chronic total occlusion
1000322|NCT02022878|Percutaneous coronary intervention
1000323|NCT02022878|Coronary computed tomography angiography
1000324|NCT02022878|Coronary angiography
1000325|NCT02022865|periodontitis
1000326|NCT02022865|cytokines
1000327|NCT02022865|adverse pregnancy outcome
1000328|NCT02022852|Rectal Cancer
1000329|NCT02022852|Concurrent Chemoradiotherapy
1000330|NCT02022852|Sequential Therapy
1000331|NCT02022839|mechanical ventilation, weaning
1000332|NCT02022839|ultrasonography
1000333|NCT02022826|Gastroparesis
1000334|NCT02022826|SmartPill Monitoring System (SPM)
1000335|NCT02022826|Gastric Emptying Scintigraphy (GES)
1000336|NCT02022813|Energy requirements, Glucose turnover, Protein turnover
1000337|NCT02022787|RCC
1000338|NCT02022787|Chemokines
1000339|NCT02022787|nephrectomy
1000340|NCT02022787|partial nephrectomy
1000341|NCT02022761|Mild or moderate asthmatics
1000342|NCT02022761|Adults
1000343|NCT02022761|Laninamivir
1000344|NCT02022735|Deep Brain Stimulation
1000345|NCT02022722|Pelvic Floor Myalgia
1000346|NCT02022722|Trigger Point Injections
1000347|NCT02022722|Pelvic Rehabilitation
1000348|NCT02022722|Dyspareunia
1000349|NCT02022709|Cognitive Behavior Therapy
1000350|NCT02022709|Exposure and Response/Ritual Prevention
1000351|NCT02022709|Selective Serotonin Reuptake Inhibitors
1000352|NCT02022709|Psychotherapy
1000353|NCT02022709|Pharmacotherapy
1000354|NCT02022709|Citalopram
1000355|NCT02022709|Fluoxetine
1000356|NCT02022709|Paroxetine
1000357|NCT02022709|Sertraline
1000358|NCT02022709|Fluvoxamine
1000359|NCT02022709|fMRI
1000360|NCT02022709|Stop Signal Task
1000361|NCT02022696|Adenosine Deaminase Deficiency
1000362|NCT02022696|Gene Therapy
1000363|NCT02022696|Lentiviral Vectors
1000364|NCT02022683|Endoscopic lung volume reduction
1000365|NCT02022683|Endobronchial valves
1000366|NCT02022670|endothelial function
1000367|NCT02022670|arterial stiffness
1000368|NCT02022670|flow-mediated dilation
1000369|NCT02022670|pulse wave velocity
1000370|NCT02022670|sodium nitrite
1000371|NCT02022670|aging
1000372|NCT02022670|vascular diseases
1000373|NCT02022657|Pre exposure prophylaxis
1000374|NCT02022657|Dried blood spots
1000375|NCT02022618|Hypertension
1000376|NCT02022618|Target organ damage
1000377|NCT02022618|polymorphism
1000378|NCT02022618|Hypertensive patients
1000379|NCT02022605|ERCP, trainning, trainees, EMS
1000385|NCT02022566|Osteoarthritis knee
1000386|NCT02022566|Osteoarthritis hip
1000387|NCT02022566|Physical activity
1000388|NCT02022566|accelerometer
1000389|NCT02022553|rectal cancer
1000390|NCT02022553|RACHEL
1000391|NCT02022553|oil chemoembolization
1000392|NCT02022540|Neovascular Age-Related Macular Degeneration
1000393|NCT02022540|AMD
1000394|NCT02022540|Macular Degeneration
1000395|NCT02022540|Age-Related Macular Degeneration
1000396|NCT02022540|wet AMD
1000397|NCT02022540|neovascular AMD
1000398|NCT02022540|exudative AMD
1000399|NCT02022527|Cost-Effectiveness,
1000400|NCT02022527|Heart valve prosthesis
1000401|NCT02022527|Warfarin,
1000402|NCT02022527|Aspirin,
1000403|NCT02022527|Egypt
1000404|NCT02022501|Macular Degeneration
1000405|NCT02022488|Child
1000406|NCT02022488|Sevoflurane
1000407|NCT02022488|Emergence delirium
1000408|NCT02022488|General anesthesia
1000409|NCT02022488|Premedication.
1000410|NCT02022475|vitamin D
1000411|NCT02022475|fatigue
1000412|NCT02022462|Serious mental illnesses
1000413|NCT02022462|peer navigator
1000414|NCT02022462|integrated health care
1000415|NCT02022449|Maternal depression
1000416|NCT02022449|Maternal psychosocial stress and distress
1000417|NCT02022449|Maternal health outcomes
1000418|NCT02022449|Social support
1000419|NCT02022449|Pediatric cancer
1000420|NCT02022410|CAS
1000421|NCT02022410|Length of stay
1000422|NCT02022410|Rehabilitation localisation
1000423|NCT02022410|TKA
1000424|NCT02022397|tracheal intubation
1000425|NCT02022397|predicting difficult intubation
1000426|NCT02022397|general anesthesia
1000427|NCT02022397|difficult ventilation
1000428|NCT02022384|Malignant glioma
1000429|NCT02022384|Anaplastic astrocytoma
1000430|NCT02022384|Glioblastoma multiforme
1000431|NCT02022384|Immune
1000432|NCT02022384|Immunophenotyping
1000433|NCT02022384|Immune cells
1000434|NCT02022384|activation state
1000435|NCT02022384|Quality of live
1000436|NCT02022384|translational research
1000437|NCT02022358|Osteosarcoma
1000438|NCT02022358|Methotrexate
1000439|NCT02022358|Glucarpidase
1000440|NCT02022358|Mucositis
1000441|NCT02022345|Percutaneous Coronary Intervention
1000442|NCT02022345|Coronary Artery Disease
1000443|NCT02022345|Angioplasty
1000444|NCT02022345|Offsite cardiac surgery
1000445|NCT02022345|Heart disease
1000446|NCT02022345|Ischemic Heart Disease
1000447|NCT02022306|Hepatitis C
1000448|NCT02022293|Nasopharyngeal Carcinoma
1000449|NCT02022293|Radiotherapy
1000450|NCT02022293|Carotid Stenosis
1000451|NCT02022293|Atorvastatin
1000452|NCT02022267|clubfoot
1000453|NCT02022267|gait analysis
1000454|NCT02022267|outcome questionaire
1000455|NCT02022267|Ponseti method
1000456|NCT02022241|Ovarian Hyperstimulation Syndrome
1000457|NCT02022241|Luteinizing Hormone
1000458|NCT02022241|Polycystic Ovarian Syndrome
1000459|NCT02022241|Ovarian Yield
1000460|NCT02022241|Ovarian Maturity
1000461|NCT02022228|Ovarian Hyperstimulation Syndrome
1000462|NCT02022228|Luteinizing Hormone
1000463|NCT02022228|Polycystic Ovarian Syndrome
1000464|NCT02022228|Ovarian Yield
1000465|NCT02022228|Ovarian Maturity
1000466|NCT02022228|Gonadotropin Releasing Hormone Agonist
1000467|NCT02022228|Human Chorionic Gonadotropin
1000468|NCT02022189|Dent
1000469|NCT02022189|Dents
1000470|NCT02022189|Dent Disease
1000471|NCT02022189|Renal Biopsy
1000472|NCT02022189|Kidney Biopsy
1000473|NCT02022189|Clinical Biopsy
1000474|NCT02022176|Nitrate
1000475|NCT02022176|Nitrite
1000476|NCT02022176|Nitric oxide
1000477|NCT02022176|Resting metabolic rate
1000478|NCT02022176|Glucose uptake
1000479|NCT02022176|Insulin sensitivity
1000480|NCT02022176|Reactive oxygen species production
1000481|NCT02022176|inorganic nitrate
1000482|NCT02022176|Sodium nitrite infusion
1000483|NCT02022163|Influenza, Human
1000484|NCT02022163|RNA Virus Infections
1000485|NCT02022163|Respiratory Tract Diseases
1000486|NCT02022163|Respiratory Tract Infections
1000487|NCT02022163|Aluminum Hydroxide
1000488|NCT02022163|Adjuvants, Immunologic
1000489|NCT02022163|Immunogenic Factors
1000490|NCT02022163|Physiological Effects of Drugs
1000491|NCT02022163|Virus Diseases
1000492|NCT02022163|Orthomyxoviridae Infections
1000493|NCT02022163|Infection
1000494|NCT02022150|Paracentesis
1000495|NCT02022150|Liver Cirrhosis
1000496|NCT02022150|ascites
1000497|NCT02022150|body composition
1000498|NCT02022137|Minimal hepatic encephalopathy
1000499|NCT02022137|Hepatic encephalopathy
1000500|NCT02022124|chronic low back pain
1000501|NCT02022124|open-label placebo
1000502|NCT02022046|chronic kidney disease
1000503|NCT02022046|cardiovascular disease
1000504|NCT02022046|nitric oxide
1000505|NCT02022046|homocysteine
1000506|NCT02022046|asymmetric dimethylarginine
1000507|NCT02022046|methylation
1000508|NCT02022033|Pancreatic Cancer
1000509|NCT02022033|Adjuvant
1000510|NCT02022033|Pancreas
1000511|NCT02022033|Resected
1000512|NCT02022033|Invasive adenocarcinoma
1000513|NCT02022033|adenosquamous cancer
1000514|NCT02022033|Intraductal papillary mucinous neoplasm
1000515|NCT02022007|PCOS
1000516|NCT02022007|IGT
1000517|NCT02022007|DPP-4 inhibitor
1000518|NCT02021981|Quality Improvement
1000519|NCT02021981|Primary Care
1000520|NCT02021981|Blood Pressure, High
1000521|NCT02021981|Feedback
1000522|NCT02021981|Knowledge
1000523|NCT02021955|randomized controlled trial
1000524|NCT02021955|quality of life
1000525|NCT02021955|patient readmission
1000526|NCT02021955|mortality
1000527|NCT02021955|patient satisfaction
1000528|NCT02021955|intervention studies
1000529|NCT02021955|multicenter study
1000530|NCT02021942|primary inoperable thymoma
1000531|NCT02021942|local recurrent thymoma
1000532|NCT02021942|reduction of tumor size
1000533|NCT02021942|SOM230 LAR
1000534|NCT02021929|Randomized Controlled Trial
1000535|NCT02021929|Clinical Trial
1000536|NCT02021929|sorafenib
1000537|NCT02021929|Hepatopulmonary Syndrome
1000538|NCT02021903|arterial hypotension
1000539|NCT02021903|postprandial sleepiness
1000540|NCT02021903|orthostatic hypotension
1000541|NCT02021903|synucleinopathies
1000542|NCT02021903|hyperglycemia
1000543|NCT02021890|Dance
1000544|NCT02021890|Physical activity
1000545|NCT02021890|Physical fitness
1000546|NCT02021890|Weight loss
1000547|NCT02021877|Brain trauma
1000548|NCT02021877|ICP measurement
1000549|NCT02021877|cranial CT / MRI
1000550|NCT02021877|Glasgow Coma Score
1000551|NCT02021877|acute TBI
1000552|NCT02021877|EEG
1000553|NCT02021877|metabolic, proteomic, and genetic biomarkers of TBIs
1000554|NCT02021877|injury mechanism
1000555|NCT02021864|hypocalcemia, pregnancy, vitamin D
1000556|NCT02021851|Dexamethasone,
1000557|NCT02021851|Ondansetron
1000558|NCT02021851|Aprepitant
1000559|NCT02021851|PONV
1000560|NCT02021851|Laparoscopic surgery
1000561|NCT02021838|domestic violence homicide prevention
1000562|NCT02021825|mitoxantrone
1000563|NCT02021825|neuromyelitis optica
1000564|NCT02021825|relapse
1000565|NCT02021799|Gut microbiome
1000566|NCT02021799|Vaginal microbiome
1000567|NCT02021799|Oral microbiome
1000568|NCT02021799|Human milk microbiome
1000569|NCT02021799|Nutritional Status
1000570|NCT02021773|Headache
1000571|NCT02021773|Migraine
1000572|NCT02021773|Chronic Migraine
1000573|NCT02021682|Aβ
1000574|NCT02021682|ABeta
1000575|NCT02021682|ABeta kinetics
1000576|NCT02021682|Alzheimer's Disease
1000577|NCT02021682|Alzheimer's
1000578|NCT02021682|amyloid beta
1000579|NCT02021682|biomarker
1000580|NCT02021682|dementia
1000581|NCT02021682|PET/PIB
1000582|NCT02021669|Antidepressive agents
1000583|NCT02021669|Coronary disease
1000584|NCT02021669|Depression
1000585|NCT02021669|Depressive disorder
1000586|NCT02021669|Fatty Acids, Omega-3
1000587|NCT02021630|Obesity
1000588|NCT02021630|Bariatric Surgery
1000589|NCT02021630|Weight Loss
1000590|NCT02021630|Physical Activity
1000591|NCT02021630|Body Composition
1000592|NCT02021617|Intraosseous Access
1000593|NCT02021617|EZ-IO
1000594|NCT02021604|Congenital Hyperinsulinism
1000595|NCT02021604|HI
1000596|NCT02021604|Hypoglycemia
1000597|NCT02021591|Diabetes
1000598|NCT02021591|Chronic disease
1000599|NCT02021591|problem solving
1000600|NCT02021591|self management
1000601|NCT02021578|Depression
1000602|NCT02021578|Mood disorder
1000603|NCT02021565|Caregivers
1000604|NCT02021565|Activities of Daily Living
1000605|NCT02021565|Dementia
1000606|NCT02021565|Veterans
1000607|NCT02021565|Self-Help Devices
1000608|NCT02021565|Telemedicine
1000609|NCT02021552|Trauma
1000610|NCT02021552|Sepsis
1000611|NCT02021539|Elastography of the cervix
1000612|NCT02021539|Cervical elastography
1000613|NCT02021539|Predicting delivery
1000614|NCT02021526|G1D
1000615|NCT02021526|Glut1 Deficiency
1000616|NCT02021526|Glucose Transporter Type 1 Deficiency
1000617|NCT02021526|Glucose Transporter Type I Deficiency
1000618|NCT02021513|SLE
1000619|NCT02021513|Fish Oil
1000620|NCT02021513|Omega-3
1000621|NCT02021448|OHS
1000622|NCT02021422|metastatic pancreatic ductal adenocarcinoma (PDAC)
1000623|NCT02021422|pancreatic cancer
1000624|NCT02021422|pancreas cancer
1000625|NCT02021422|pancreatic adenocarcinoma
1000626|NCT02021422|metastatic pancreas cancer
1000627|NCT02021422|metastatic pancreatic cancer
1000628|NCT02021409|Anemia on CKD
1000629|NCT02021396|Rescue splenic trauma patients at high risk of splenectomy
1000630|NCT02021383|Weight loss
1000631|NCT02021383|Weight maintenance
1000632|NCT02021383|Contingency Management
1000633|NCT02021383|College students
1000634|NCT02021383|Financial incentives
1000635|NCT02021370|Anemia of CKD
1000636|NCT02021357|Facial Pain
1000637|NCT02021357|Physical Therapy Modalities
1000638|NCT02021357|Temporomandibular Joint Disorders
1000639|NCT02021357|Exercise Therapy
1000640|NCT02021331|jaw, edentulous, partially
1000641|NCT02021318|Non-dialysis
1000642|NCT02021318|Roxadustat
1000643|NCT02021318|ASP1517
1000644|NCT02021318|Chronic Kidney Disease (CKD)
1000645|NCT02021318|Anemia
1000646|NCT02021318|Hemoglobin
1000647|NCT02021305|Toll like Receptors
1000648|NCT02021305|TLR 4
1000649|NCT02021305|Urinary track infections in children
1000650|NCT02021305|TLR 4 polymorphisms
1000651|NCT02021305|Innate immunity
1000652|NCT02021305|Defence mechanisms
1000653|NCT02021305|Immune responses
1000654|NCT02021292|Chronic thromboembolic pulmonary hypertension (CTEPH)
1000655|NCT02021279|pelvic organ prolapse
1000656|NCT02021279|MatriStem
1000657|NCT02021279|pelvic floor matrix
1000658|NCT02021279|ACell
1000659|NCT02021279|native tissue repair
1000660|NCT02021253|Endotoxemia
1000661|NCT02021253|Probiotic
1000662|NCT02021253|Leaky gut
1000663|NCT02021253|Gut permeability
1000664|NCT02021253|Liver cirrhosis
1000665|NCT02021253|Liver fibrosis
1000666|NCT02021253|Hepatocellular carcinoma
1000667|NCT02021227|Acute respiratory failure
1000668|NCT02021227|Mechanical ventilation
1000669|NCT02021227|Rehabilitation
1000670|NCT02021227|Exercise chair sitting
1000671|NCT02021227|Weaning
1000672|NCT02021227|Chronic respiratory failure
1000673|NCT02021214|Methylphenidate
1000674|NCT02021214|Fear extinction
1000675|NCT02021214|fMRI
1000676|NCT02021214|mPFC
1000677|NCT02021188|Vascular inflammation
1000678|NCT02021188|Atherosclerosis
1000679|NCT02021188|Positron Emission Tomography
1000680|NCT02021188|Molecular Imaging
1000681|NCT02021188|68Ga-DOTATATE
1000682|NCT02021175|Smoking Cessation
1000683|NCT02021175|Korean
1000684|NCT02021175|Youth
1000685|NCT02021175|Adolescent
1000686|NCT02021175|Dependence
1000687|NCT02021175|Teen Smoking
1000688|NCT02021175|Smoking and Youth
1000689|NCT02021175|Youth and Tobacco
1000690|NCT02021175|Cognitive-Behavioral Motivational Enhancement
1000691|NCT02021175|Technology
1000692|NCT02021175|Nicotine Dependence
1000693|NCT02021175|Cell Phone
1000694|NCT02021175|Smart Phone
1000695|NCT02021175|Internet
1000696|NCT02021175|Web
1000697|NCT02021162|Multiple sclerosis
1000698|NCT02021162|Gilenya
1000699|NCT02021162|Healthy controls
1000700|NCT02021162|Thalamic atrophy
1000701|NCT02021162|MRI
1000702|NCT02021149|Major Depressive Disorder
1000703|NCT02021149|Whole Body Hyperthermia
1000704|NCT02021149|Psychotherapy
1000705|NCT02021149|Therapist and patient alliance
1000706|NCT02021123|Anidulafungin
1000707|NCT02021123|Gastric bypass
1000708|NCT02021123|Morbidly obese
1000709|NCT02021123|Pharmacokinetics
1000710|NCT02021123|Prophylaxis
1000711|NCT02021123|Yeast infection
1000712|NCT02021097|Levonorgestrel；
1000713|NCT02021097|Ethinyl Estradiol；
1000714|NCT02021097|Oral Contraceptive
1000715|NCT02021084|Familial Mediterranean Fever (FMF), probiotics
1000716|NCT02021032|BPH
1000722|NCT02020993|Nt-proBNP, newborn, preterm
1000723|NCT02020928|Oral Mucositis
1000724|NCT02020928|chemotherapy
1000725|NCT02020928|Bone Marrow Transplantation
1000726|NCT02020889|eosinophils
1000727|NCT02020889|SB 240563
1000728|NCT02020889|Churg-Strauss Syndrome
1000729|NCT02020889|quality of life
1000730|NCT02020889|mepolizumab
1000731|NCT02020889|safety
1000732|NCT02020889|biomarkers
1000733|NCT02020889|efficacy
1000734|NCT02020889|corticosteroids
1000735|NCT02020889|Eosinophilic granulomatosis with polyangiitis
1000736|NCT02020850|Toe-Brachial Index
1000737|NCT02020850|Ankle-Brachial Index
1000738|NCT02020850|Systolic blood pressure
1000739|NCT02020824|Acrophobia
1000740|NCT02020785|proteinuria
1000741|NCT02020772|primary health care
1000742|NCT02020772|Physical Therapy Specialty
1000743|NCT02020772|General Practitioners
1000744|NCT02020772|General Practice
1000745|NCT02020733|Hysterosalpingography
1000746|NCT02020733|balloon catheter
1000747|NCT02020733|metal cannula
1000748|NCT02020733|pain assessment
1000749|NCT02020694|Obesity
1000750|NCT02020694|Insulin resistance
1000751|NCT02020694|Vitamin D
1000752|NCT02020694|Cardiovascular risk factors
1000753|NCT02020681|Dental caries
1000754|NCT02020681|Curodont Repair
1000755|NCT02020681|P11-4
1000756|NCT02020668|Pain
1000757|NCT02020668|Functional capacity
1000758|NCT02020668|Quality of Life
1000759|NCT02020655|IL-1 alpha, Sebutape, shear- force
1000760|NCT02020642|polysomnography
1000761|NCT02020642|bioimpedance
1000762|NCT02020642|leg fluid shift
1000763|NCT02020642|neck circumference
1000764|NCT02020642|Sleep Apnea Syndromes
1000765|NCT02020642|Sleep Apnea, Obstructive
1000766|NCT02020642|Sleep Disorders, Intrinsic
1000767|NCT02020642|Sleep Disorders
1000768|NCT02020642|Apnea
1000769|NCT02020642|Kidney Diseases
1000770|NCT02020642|Kidney Failure, Chronic
1000771|NCT02020642|Renal Insufficiency, Chronic
1000772|NCT02020642|Renal Insufficiency
1000773|NCT02020642|Dyssomnias
1000774|NCT02020629|Glucagon
1000775|NCT02020629|Hypoglycemia
1000776|NCT02020629|Counterregulation
1000777|NCT02020603|peptic ulcer bleeding
1000778|NCT02020603|hemostatic forceps
1000779|NCT02020603|soft coagulation
1000780|NCT02020603|argon plasma coagulation
1000781|NCT02020590|Delayed-Union Fractures
1000782|NCT02020590|Impaired Healing
1000783|NCT02020590|Fractures
1000784|NCT02020590|Orthopedics
1000785|NCT02020590|Bone
1000786|NCT02020590|Musculoskeletal Disorders
1000787|NCT02020564|Processing Speed
1000788|NCT02020564|Cognition
1000789|NCT02020564|Intervention
1000790|NCT02020564|Traumatic Brain Injury
1000791|NCT02020564|Mild Cognitive Impairment
1000792|NCT02020551|Scores During IUD insertion.
1000793|NCT02020538|Thoracic surgery
1000794|NCT02020538|cardiac surgery
1000795|NCT02020538|acute kidney injury
1000796|NCT02020538|hyperchloremia
1000797|NCT02020538|intravenous fluid
1000798|NCT02020486|Healthy
1000799|NCT02020473|Informed consents
1000800|NCT02020473|Withholding/withdrawing life support (WLS)
1000801|NCT02020473|Intensive care unit (ICU)
1000802|NCT02020460|post-laminectomy pain syndrome,
1000803|NCT02020460|refractory,
1000804|NCT02020460|refractory chronic neuropathic pain,
1000805|NCT02020460|failed back surgery syndrome.
1000806|NCT02020421|ischemic stroke
1000807|NCT02020421|rehabilitation
1000808|NCT02020421|aphasia
1000809|NCT02020421|non-invasive brain stimulation
1000810|NCT02020382|microRNAs
1000811|NCT02020382|IBD
1000812|NCT02020382|Crohn's disease
1000813|NCT02020382|Ulcerative colitis
1000814|NCT02020382|colonic polyps screening
1000815|NCT02020382|controls
1000816|NCT02020356|Alzheimer's disease
1000817|NCT02020356|Neuroleptics
1000818|NCT02020356|Music therapy
1000819|NCT02020330|falciparum, malaria
1000820|NCT02020317|drug interactions
1000821|NCT02020317|Drug Monitoring
1000822|NCT02020317|Potassium
1000823|NCT02020317|Hyperkalemia
1000824|NCT02020304|Combined spinal epidural duration
1000825|NCT02020304|labor pain
1000826|NCT02020291|Foxy-5
1000827|NCT02020291|Wnt-5A
1000828|NCT02020278|Hyponatremia
1000829|NCT02020278|Euvolemic
1000830|NCT02020278|Hypervolemic
1000831|NCT02020278|Serum sodium
1000832|NCT02020278|Dilutional hyponatremia
1000833|NCT02020278|Electrolyte abnormality
1000834|NCT02020278|Electrolyte imbalance
1000835|NCT02020278|Metabolic disease
1000836|NCT02020278|Water-Electrolyte Imbalance
1000837|NCT02020265|stress and depression related symptoms
1000838|NCT02020239|physical activity
1000839|NCT02020239|females
1000840|NCT02020239|body composition
1000841|NCT02020226|TH-302
1000842|NCT02020226|Solid Tumors
1000843|NCT02020226|QTc
1000844|NCT02020226|Cardiac
1000845|NCT02020226|Evofosfamide
1000846|NCT02020213|successful percentage
1000847|NCT02020200|Bipolar Disorder
1000848|NCT02020200|Methylphenidate
1000849|NCT02020200|Cognitive Function
1000850|NCT02020187|Congenital myopathy
1000851|NCT02020187|Exercise
1000852|NCT02020174|Preeclampsia
1000853|NCT02020174|Eclampsia
1000854|NCT02020174|HELLP
1000855|NCT02020174|HELLP Syndrome
1000856|NCT02020174|Toxemia
1000857|NCT02020174|Hypertensive Disorder of Pregnancy
1000858|NCT02020174|Registry
1000859|NCT02020174|Pregnancy Complication
1000860|NCT02020174|Pregnancy
1000861|NCT02020174|Maternal Death
1000862|NCT02020174|Premature
1000863|NCT02020174|High Blood Pressure
1000864|NCT02020174|Hypertension
1000865|NCT02020148|pregnancy
1000866|NCT02020148|oxytocin
1000867|NCT02020148|postpartum depression
1000868|NCT02020148|depression
1000869|NCT02020148|pregnant women
1000870|NCT02020148|mood
1000871|NCT02020148|anxiety
1000872|NCT02020148|hormones
1000873|NCT02020148|women's health
1000874|NCT02020148|mental health
1000875|NCT02020148|baby blues
1000876|NCT02020148|mood disorders
1000877|NCT02020122|endogenous pain modulation
1000878|NCT02020122|coronary artery bypass grafting
1000879|NCT02020122|quantitative sensory testings
1000880|NCT02020122|duloxetine
1000881|NCT02020122|pregabalin
1000882|NCT02020122|preemptive treatment
1000883|NCT02020096|Lumbar plexus block
1000884|NCT02020096|Ultrasound guidance
1000885|NCT02020096|Nerve stimulator
1000886|NCT02020083|VIH ; Placental transfer ; Tenofovir ; Emtricitabine ; Membrane transporter
1000887|NCT02020070|Ipilimumab
1000888|NCT02020070|Degarelix
1000889|NCT02020070|Radical Prostatectomy
1000890|NCT02020070|13-134
1000891|NCT02020031|Revision knee joint
1000892|NCT02020005|menthol cigarettes
1000893|NCT02020005|smoking cessation
1000894|NCT02019992|sepsis
1000895|NCT02019992|mitochondrial DNA
1000896|NCT02019992|systemic inflammation
1000897|NCT02019992|outcome
1000898|NCT02019979|non squamous
1000899|NCT02019979|non small cell
1000900|NCT02019979|lung cancer
1000901|NCT02019979|metformin
1000902|NCT02019927|NAION
1000903|NCT02019927|Decreased vision
1000904|NCT02019927|Eye trauma
1000905|NCT02019927|TES
1000906|NCT02019927|Electrical stimulation
1000907|NCT02019927|Multiple Sclerosis
1000908|NCT02019927|Optic Neuritis
1000909|NCT02019914|PTSD
1000910|NCT02019914|CPAP
1000911|NCT02019914|OSA
1000912|NCT02019901|Rheumatoid arthritis
1000913|NCT02019901|Person-centered care
1000914|NCT02019901|Tight control
1000915|NCT02019888|Ear, Middle
1000916|NCT02019888|Ear, Inner
1000917|NCT02019888|Audiometry
1000918|NCT02019888|Acoustic impedance tests
1000919|NCT02019875|Vitamin D
1000920|NCT02019875|CYP3A4
1000921|NCT02019875|Calcium
1000922|NCT02019862|Total hip arthroplasty
1000923|NCT02019862|TRJ
1000924|NCT02019862|PMCF
1000925|NCT02019862|Hip stem
1000926|NCT02019849|THA, Plasmafit®
1000927|NCT02019836|vit D; sepsis; newborn; maternal; neonatal
1000928|NCT02019823|SMS-text
1000929|NCT02019823|mobile health
1000930|NCT02019823|mHealth
1000931|NCT02019823|treatment
1000932|NCT02019823|adherence
1000933|NCT02019797|aortic valve replacement
1000934|NCT02019784|Cirrhosis
1000935|NCT02019784|Hepatic encephalopathy
1000936|NCT02019771|HIV Infection
1000937|NCT02019771|Men who have sex with men
1000938|NCT02019771|Chlamydia
1000939|NCT02019771|Gonorrhea
1000940|NCT02019745|Live attenuated influenza virus (LAIV)
1000941|NCT02019745|Flu vaccine
1000942|NCT02019745|FluMist
1000943|NCT02019745|Smokers
1000944|NCT02019745|New and emerging tobacco products
1000945|NCT02019732|Mild outcomes
1000946|NCT02019732|Database
1000947|NCT02019732|Influenza-attributable
1000948|NCT02019732|Retrospective
1000949|NCT02019732|Influenza
1000950|NCT02019732|United States of America (USA)
1000951|NCT02019719|Hemodialysis
1000952|NCT02019719|GSK1278863
1000953|NCT02019719|Pharmacokinetics
1000954|NCT02019719|Erythropoiesis Stimulating Agents
1000955|NCT02019719|Chronic Kidney Disease
1000956|NCT02019719|Hemoglobin
1000957|NCT02019719|Recombinant Erythropoietin
1000958|NCT02019719|Prolyl Hydroxylase Inhibitor
1000959|NCT02019719|Anemia
1000960|NCT02019706|Cushing Syndrome
1000961|NCT02019706|Ectopic ACTH Secretion
1000962|NCT02019706|Imaging
1000963|NCT02019693|MET Inhibitor
1000964|NCT02019693|Sporadic
1000965|NCT02019693|Hereditary
1000966|NCT02019693|Multifocal
1000967|NCT02019693|HGF/MET Pathway
1000968|NCT02019680|Endothelial Function
1000969|NCT02019680|Biomarkers
1000970|NCT02019680|Atherosclerosis
1000971|NCT02019680|Blood Flow
1000972|NCT02019680|Blood Pressure
1000973|NCT02019667|GABA
1000974|NCT02019667|Seizures
1000975|NCT02019667|Neurotransmitters
1000976|NCT02019654|Post -Traumatic Stress Disorder (PTSD)
1000977|NCT02019654|Traumatic Brain Injury
1000978|NCT02019654|Neuroendocrine
1000979|NCT02019654|Epigenetics
1000983|NCT02019628|NK cells cytotoxicity, dietary supplementation
1000984|NCT02019615|disorders of consciousness
1000985|NCT02019615|minimally conscious state
1000986|NCT02019615|traumatic brain injury
1000987|NCT02019615|stroke
1000988|NCT02019615|transcranial direct current stimulation
1000989|NCT02019602|Cimzia®
1000990|NCT02019602|CZP
1000991|NCT02019602|Placental transfer
1000992|NCT02019602|Autoimmune diseases and pregnancy
1000993|NCT02019589|Secondary Amenorrhea
1000994|NCT02019589|SPRY Trial
1000995|NCT02019576|Metastatic renal cell carcinoma
1000996|NCT02019576|mRCC
1000997|NCT02019576|Clear cell
1000998|NCT02019563|pediatrics
1000999|NCT02019563|dental caries
1001000|NCT02019563|dental pulp exposure
1001001|NCT02019563|incisor
1001002|NCT02019550|Multiple Sclerosis, Relapsing-Remitting
1001003|NCT02019550|Rebif®Rebidose®
1001004|NCT02019550|Rebiject II®
1001005|NCT02019524|Stage I breast cancer
1001006|NCT02019524|Stage II breast cancer
1001007|NCT02019524|Stage IIIA, IIIB, and IIIC breast cancer
1001008|NCT02019524|Male breast cancer
1001009|NCT02019524|Ovarian cancer
1001010|NCT02019511|Orthopedic surgery
1001011|NCT02019511|Infections
1001012|NCT02019511|Steroid
1001013|NCT02019511|Fast-track
1001014|NCT02019511|Total knee arthroplasty
1001015|NCT02019511|Safety
1001016|NCT02019498|low back pain
1001017|NCT02019498|relaxation
1001018|NCT02019485|Healthy
1001019|NCT02019485|Tapentadol
1001020|NCT02019485|Tapentadol extended-release tamper-resistant formulation
1001021|NCT02019485|Tapentadol extended-release prolonged-release formulation
1001022|NCT02019485|Bioequivalence
1001023|NCT02019485|Fasted Conditions
1001024|NCT02019472|Rheumatoid arthritis
1001025|NCT02019472|CNTO 136
1001026|NCT02019472|Sirukumab
1001027|NCT02019472|Adalimumab
1001028|NCT02019472|HUMIRA®
1001029|NCT02019446|type 2 diabetes mellitus
1001030|NCT02019446|onychomycosis
1001031|NCT02019446|laser treatment
1001032|NCT02019446|antifungal
1001033|NCT02019433|THA, augment, revision, pelvis
1001037|NCT02019407|atrial fibrillation
1001038|NCT02019407|atrial flutter
1001039|NCT02019407|catheter ablation
1001040|NCT02019407|cavo-tricuspid isthmus block
1001041|NCT02019342|blood pressure
1001042|NCT02019342|mean arterial pressure
1001043|NCT02019342|MAP
1001044|NCT02019342|intraoperative
1001045|NCT02019342|postoperative
1001046|NCT02019342|anesthesia
1001047|NCT02019316|Supplementation
1001048|NCT02019316|Performance
1001049|NCT02019316|Cognitive Function
1001050|NCT02019316|Muscular Endurance
1001051|NCT02019316|BioSteel
1001052|NCT02019316|BCAA
1001053|NCT02019316|Branched Chain Amino Acids
1001054|NCT02019316|Sprint Interval Exercise
1001055|NCT02019264|Diabetes
1001056|NCT02019264|Cardiovascular Disease
1001057|NCT02019264|Multiple Cardiovascular Risk Factors
1001058|NCT02019264|Obesity
1001059|NCT02019264|Overweight
1001060|NCT02019264|MACE
1001061|NCT02019264|Conversion to Diabetes
1001067|NCT02019212|99mTc-tetrofosmin
1001068|NCT02019212|myocardial perfusion imaging
1001069|NCT02019212|SPECT
1001070|NCT02019212|radiation
1001071|NCT02019186|type 1 diabetes
1001072|NCT02019186|endothelial function
1001073|NCT02019186|adolescents
1001074|NCT02019186|vitamin C
1001075|NCT02019186|vitamin E
1001076|NCT02019173|exercise therapy
1001077|NCT02019173|brain injury
1001078|NCT02019173|postural balance
1001079|NCT02019160|silver nitrate
1001080|NCT02019160|sodium fluoride
1001081|NCT02019160|silver diamine fluoride
1001082|NCT02019160|caries
1001083|NCT02019160|non-inferiority trial
1001084|NCT02019147|HIE
1001085|NCT02019147|Biomarker
1001086|NCT02019134|chronic neck pain
1001087|NCT02019134|relaxation technique
1001088|NCT02019134|comparative effectiveness research
1001089|NCT02019108|osteoarthritis
1001090|NCT02019108|knee
1001091|NCT02019108|walking
1001092|NCT02019108|toeout
1001093|NCT02019108|gait modification
1001094|NCT02019095|Pneumonia, Ventilator-Associated
1001095|NCT02019095|Respiratory Distress Syndrome, Adult
1001096|NCT02019095|Pulmonary Surfactant-Associated Proteins
1001097|NCT02019095|activin A
1001098|NCT02019030|benign prostatic hyperplasia
1001099|NCT02019030|Transurethral vaporization of prostate
1001100|NCT02019017|Cluster Headache
1001101|NCT02019017|Botulinum Toxin Type A
1001102|NCT02019017|Sphenopalatine Ganglion Block
1001103|NCT02019017|Autonomic Nerve Block
1001104|NCT02018978|HIV prevention
1001105|NCT02018978|Behavioral intervention
1001106|NCT02018978|Community-randomized trial
1001107|NCT02018965|HIV
1001108|NCT02018965|Extended-release Niacin
1001109|NCT02018965|Immune activation
1001110|NCT02018952|Septic arthritis
1001111|NCT02018952|Ultrasonography
1001112|NCT02018952|Prognosis parameters
1001113|NCT02018939|pharmacokinetics, doripenem, renal replacement therapy, MARS, organ replacement therapy
1001114|NCT02018926|Mocetinostat
1001115|NCT02018926|Azacitidine
1001116|NCT02018926|Vidaza
1001117|NCT02018926|Myelodysplastic syndrome
1001118|NCT02018926|HDAC
1001119|NCT02018926|HMA
1001120|NCT02018926|MDS
1001121|NCT02018900|Synbiotics
1001122|NCT02018900|Intestinal permeability
1001123|NCT02018900|Microbiota
1001124|NCT02018900|Immune response
1001125|NCT02018848|Obsessive-Compulsive Disorder
1001126|NCT02018848|Attention Training
1001127|NCT02018848|Attention Bias Modification
1001128|NCT02018848|Dot-Probe Task
1001129|NCT02018848|Randomized Controlled Trial
1001130|NCT02018848|Online Treatment
1001131|NCT02018848|Washing
1001132|NCT02018848|Checking
1001133|NCT02018822|restorative material
1001134|NCT02018809|Medication Adherence
1001135|NCT02018809|High Blood Pressure
1001136|NCT02018809|Diabetes
1001137|NCT02018809|Statins
1001138|NCT02018770|Temporomandibular Disorders, Electromyogram,
1001139|NCT02018770|Modalities of physiotherapy,
1001140|NCT02018770|Temporomandibular dysfunction syndrome,
1001141|NCT02018770|Lasers.
1001142|NCT02018757|Carcinoma, Hepatocellular
1001143|NCT02018757|primary liver cancer
1001144|NCT02018757|primary hepatocellular carcinoma
1001145|NCT02018757|transarterial chemoembolization
1001146|NCT02018757|Chemoembolization, Therapeutic
1001147|NCT02018757|arsenic trioxide
1001148|NCT02018757|arsenous anhydride
1001149|NCT02018757|diarsenic trioxide
1001150|NCT02018757|randomized controlled trial
1001151|NCT02018757|multicenter study
1001152|NCT02018757|HCC
1001153|NCT02018757|TACE
1001154|NCT02018731|Becker's Muscular dystrophy
1001155|NCT02018731|BMD
1001156|NCT02018731|Metformin
1001157|NCT02018731|L-citrulline
1001158|NCT02018718|Skeletal muscle
1001159|NCT02018718|Marathon
1001160|NCT02018718|MRI
1001161|NCT02018705|POEM
1001162|NCT02018705|LHM
1001163|NCT02018705|Achalasia treatment
1001164|NCT02018705|LES sphincter myotomy
1001165|NCT02018679|Nodular basal cell carcinoma
1001166|NCT02018679|Er:YAG
1001167|NCT02018679|AFL-assisted
1001168|NCT02018679|MAL-PDT
1001169|NCT02018653|Cancer
1001170|NCT02018653|Diarrhea
1001171|NCT02018653|Calcium Alumina-Silicate
1001172|NCT02018653|CASAD
1001173|NCT02018653|Calcium Aluminosilicate anti-diarrheal
1001174|NCT02018653|Placebo
1001175|NCT02018653|Sugar pill
1001176|NCT02018653|Questionnaire
1001177|NCT02018653|Survey
1001178|NCT02018640|cancer
1001179|NCT02018640|tobacco use
1001180|NCT02018640|pregnancy
1001181|NCT02018627|bionic pancreas
1001182|NCT02018627|artificial pancreas
1001183|NCT02018627|insulin
1001184|NCT02018627|glucagon
1001185|NCT02018627|clamp
1001186|NCT02018614|Pain
1001187|NCT02018614|elderly
1001188|NCT02018614|aged 65 or above 65
1001189|NCT02018614|communication disorders
1001190|NCT02018614|Algoplus® scale
1001191|NCT02018588|requirements
1001192|NCT02018588|amino acid
1001193|NCT02018588|tryptophan
1001194|NCT02018575|lysine
1001195|NCT02018575|bioavailability
1001196|NCT02018575|amino acids
1001197|NCT02018575|corn
1001198|NCT02018562|Quality of Life
1001199|NCT02018562|Talking Tracheostomy Tube
1001200|NCT02018562|Speech
1001201|NCT02018562|Mechanically ventilated patients
1001202|NCT02018549|COPD
1001203|NCT02018549|placebo
1001204|NCT02018549|inhalatory profile
1001205|NCT02018536|Healthy
1001206|NCT02018536|TMC435
1001207|NCT02018536|GSK2336805
1001208|NCT02018536|Pharmacokinetic
1001209|NCT02018536|Safety
1001210|NCT02018536|Tolerability
1001211|NCT02018523|Carcinoma, Non-Small-Cell Lung
1001212|NCT02018523|Stage 3B/4
1001213|NCT02018523|Maintenance Therapy
1001214|NCT02018523|Lenalidomide
1001215|NCT02018510|Healthy Volunteers
1001216|NCT02018510|HIV
1001217|NCT02018497|Essential arterial hypotension
1001218|NCT02018497|Arterial hypotension
1001219|NCT02018497|Low blood pressure
1001220|NCT02018497|Hypotension
1001221|NCT02018497|Essential arterial hypertension
1001222|NCT02018497|Syncope
1001223|NCT02018497|Dysautonomia
1001224|NCT02018497|Stress
1001225|NCT02018497|Adaptability
1001226|NCT02018497|Reactivity
1001227|NCT02018497|Homeostasis
1001228|NCT02018497|Allostasis
1001229|NCT02018497|Allostatic load
1001230|NCT02018497|Distress
1001231|NCT02018497|Epigenetic
1001232|NCT02018497|Plasticity
1001233|NCT02018484|Surgery / Knee / Replacement / MRI / Specific cutting guides
1001234|NCT02018471|anxiety
1001235|NCT02018471|psychoeducational training
1001236|NCT02018471|coping
1001237|NCT02018471|relaxation
1001238|NCT02018458|Dendritic cell vaccine
1001239|NCT02018458|Breast Cancer
1001240|NCT02018458|Doxorubicin
1001241|NCT02018458|Paclitaxel
1001242|NCT02018458|Cyclophosphamide
1001243|NCT02018458|Carboplatin
1001244|NCT02018406|Hematopoietic Growth Factors (EPO, G-CSF),
1001245|NCT02018406|Neurological Diseases,
1001246|NCT02018406|Neurorehabilitation,
1001247|NCT02018406|Neurotrophic and Neuroprotective Effects
1001248|NCT02018393|FEIBA®
1001249|NCT02018367|Barrett's esophagus
1001250|NCT02018367|proflavine
1001251|NCT02018367|Microscopic imaging
1001252|NCT02018354|Orthopaedics
1001253|NCT02018354|Anterior cruciate ligament (ACL) reconstruction
1001254|NCT02018354|Anterolateral ligament
1001255|NCT02018354|Lateral Extra-articular Tenodesis (LET)
1001256|NCT02018341|Assessment of biologic activity of a homeopathic remedy
1001257|NCT02018315|G1D
1001258|NCT02018315|Glut1 Disorder
1001259|NCT02018315|Glucose Transporter Type 1 Disorder
1001260|NCT02018315|Glucose Transporter Type I Disorder
1001261|NCT02018302|G1D
1001262|NCT02018302|Glut1 Deficiency
1001263|NCT02018302|Glucose Transporter Type 1 Deficiency
1001264|NCT02018302|Glucose Transporter Type I Deficiency
1001265|NCT02018289|Triclosan coated suture
1001266|NCT02018289|Surgical site infection
1001267|NCT02018289|Fecal peritonitis
1001268|NCT02018289|Superficial
1001269|NCT02018289|incisional
1001270|NCT02018276|Lidocaine
1001271|NCT02018276|Magnesium
1001272|NCT02018276|Functional recovery
1001273|NCT02018237|Obesity
1001274|NCT02018237|Nonalcoholic fatty liver disease
1001275|NCT02018237|High fructose corn syrup
1001276|NCT02018224|Achilles tendon rupture, operative treatment, elongation, long-term follow up.
1001277|NCT02018211|delayed onset muscle soreness
1001278|NCT02018211|muscle damage
1001279|NCT02018211|muscle function
1001280|NCT02018211|inflammation
1001281|NCT02018146|Laryngeal Masks
1001282|NCT02018146|Airway Management
1001283|NCT02018133|CKD
1001284|NCT02018133|chronic
1001285|NCT02018133|kidney
1001286|NCT02018133|vitamin D
1001287|NCT02018120|multiple gingival recession
1001288|NCT02018120|platelet rich fibrin
1001289|NCT02018120|connective tissue graft
1001290|NCT02018120|microsurgery
1001291|NCT02018120|periodontal diseases
1001292|NCT02018120|gingival recession
1001293|NCT02018107|Liver Tumor Ablation
1001294|NCT02018107|Liver Neoplasms
1001295|NCT02018107|Positron Emission Tomography
1001296|NCT02018107|Computed Tomography
1001297|NCT02018094|Amputation
1001298|NCT02018094|Infection
1001299|NCT02018094|Skin Preparation
1001300|NCT02018094|SSI
1001301|NCT02018094|Stump
1001302|NCT02018094|Wound
1001303|NCT02018081|pharmacokinetic study : open, prospective, monocentric
1001304|NCT02018068|Patient-controlled Perineural analgesia
1001305|NCT02018068|Postoperative
1001306|NCT02018068|Orthopedic surgery
1001307|NCT02018068|"Remote Control versus at bedside care"
1001308|NCT02018068|Comparative medico-economic evaluation
1001309|NCT02018042|Alopecia Areata
1001310|NCT02018042|AA
1001311|NCT02018029|Heart failure
1001312|NCT02018029|Cardiac Resynchronisation Therapy
1001313|NCT02018029|collagen peptides
1001314|NCT02018029|MIBG scintigraphy
1001315|NCT02018016|Appendectomy
1001316|NCT02018016|Hospitals,General
1001317|NCT02018016|Hospitals,High-Volume
1001318|NCT02018016|Hospitals,Low-Volume
1001319|NCT02018016|Outcome Assessment (Health Care)
1001320|NCT02017990|Renal transplantation
1001321|NCT02017990|n-3 polyunsaturated fatty acids
1001322|NCT02017990|Mortality
1001323|NCT02017990|Graft loss
1001324|NCT02017990|Rejection
1001325|NCT02017977|Laparotomy
1001326|NCT02017977|General Surgery
1001327|NCT02017977|Hospitals,General
1001328|NCT02017977|Hospitals,Rural
1001329|NCT02017977|Hospitals,Urban
1001330|NCT02017977|Rural Health Services
1001331|NCT02017977|Geography, Medical
1001332|NCT02017977|Outcome Assessment (Health Care)
1001333|NCT02017951|Appendectomy
1001334|NCT02017951|Hospitals,General
1001335|NCT02017951|Hospitals,Rural
1001336|NCT02017951|Hospitals,Urban
1001337|NCT02017951|Rural Health Services
1001338|NCT02017951|Geography, Medical
1001339|NCT02017951|Outcome Assessment (Health Care)
1001340|NCT02017938|Fatigue
1001341|NCT02017938|electromyography (EMG)
1001342|NCT02017938|central fatigue
1001343|NCT02017938|cycling training
1001344|NCT02017925|Pulmonary Rehabilitation
1001345|NCT02017925|Non-Small Cell Lung Cancer
1001346|NCT02017925|NSCLC
1001347|NCT02017912|Mesenchymal Stromal cells
1001348|NCT02017912|MSC-NTF
1001349|NCT02017912|Cell therapy
1001350|NCT02017912|ALS
1001351|NCT02017899|prevention
1001352|NCT02017899|Shigella sonnei
1001353|NCT02017886|Probiotics
1001354|NCT02017886|Oral health
1001355|NCT02017886|Innate immunity
1001356|NCT02017873|bleaching
1001357|NCT02017873|smokers
1001358|NCT02017873|effectiveness
1001359|NCT02017873|pain
1001360|NCT02017860|RAD001, everolimus, roll-over
1001361|NCT02017847|oxygen consumption
1001362|NCT02017847|activity monitors
1001363|NCT02017847|METs
1001364|NCT02017847|intensity
1001365|NCT02017834|oral cavity squamous cell carcinoma
1001366|NCT02017834|head and neck cancer
1001367|NCT02017834|oral cancer
1001368|NCT02017821|Exercise
1001369|NCT02017821|Oxygen Consumption
1001370|NCT02017821|mental health
1001371|NCT02017808|OCT
1001372|NCT02017808|Copaxone
1001373|NCT02017808|Multiple sclerosis
1001374|NCT02017808|relapsing-remitting
1001375|NCT02017795|asthma, mixed asthma, telehealth, action plan, exacerbation
1001376|NCT02017782|Dust
1001377|NCT02017782|Ozone
1001378|NCT02017782|Indoor air quality
1001379|NCT02017782|Indoor environment
1001380|NCT02017782|Indoor climate
1001381|NCT02017782|Cardiovascular diseases
1001382|NCT02017782|Full body exposure
1001383|NCT02017782|Exposure experiment with dust and ozone
1001384|NCT02017782|Acute exposure to ozone and dust
1001385|NCT02017782|Respiratory outcomes
1001386|NCT02017782|Cardiovascular outcomes
1001387|NCT02017782|Acoustic rhinometry
1001388|NCT02017782|Body inflammatory markers
1001389|NCT02017782|Cytokines
1001390|NCT02017782|Exhaled FeNO
1001391|NCT02017782|Nasal Lavage
1001392|NCT02017782|Heart rate variability
1001393|NCT02017782|Blood biomarkers
1001394|NCT02017782|Subjective discomfort
1001395|NCT02017782|General mucosal irritation
1001396|NCT02017769|Subcutaneous immunoglobulin
1001397|NCT02017769|Magnetic resonance imaging
1001398|NCT02017756|Carotid artery
1001399|NCT02017756|Atherosclerosis
1001400|NCT02017756|Vulnerable plaque
1001401|NCT02017756|Magnetic resonance imaging
1001402|NCT02017756|Arterial wall
1001403|NCT02017704|Endorectal Brachytherapy Radiation Therapy
1001404|NCT02017704|Intensity Modulated Radiation Therapy and Capecitabine
1001405|NCT02017678|JX-594
1001406|NCT02017678|Ovarian cancer
1001407|NCT02017678|Peritoneal
1001408|NCT02017678|Carcinomatosis
1001409|NCT02017678|Vaccinia virus
1001410|NCT02017678|Oncolytic virus
1001411|NCT02017665|encephalitis
1001412|NCT02017665|viral infections
1001413|NCT02017665|central nervous system
1001414|NCT02017652|bowel motility
1001415|NCT02017652|cerebral perfusion
1001416|NCT02017652|intestinal perfusion
1001417|NCT02017626|Fish allergy
1001418|NCT02017626|immunotherapy
1001419|NCT02017626|hypoallergen
1001420|NCT02017613|CLL, SLL, NHL, SLL, PTCL, CTCL, MM, AML
1001421|NCT02017574|Stroke
1001422|NCT02017574|Cerebral Infarction
1001423|NCT02017561|Diastolic dysfunction
1001424|NCT02017561|Metabolic syndrome
1001425|NCT02017561|Metformin
1001681|NCT02016456|Neuronavigation
1001426|NCT02017548|advance directives, advance care planning
1001427|NCT02017522|PET
1001428|NCT02017522|Cardiac sarcoidosis
1001429|NCT02017522|FDG
1001430|NCT02017522|Cardiac MRI
1001431|NCT02017509|Immunophenotype
1001432|NCT02017509|Immunoscore
1001433|NCT02017509|MRI
1001434|NCT02017509|RNA Later
1001435|NCT02017496|Breast cancer
1001436|NCT02017496|locally advanced
1001437|NCT02017496|neoadjuvant treatment
1001438|NCT02017496|breast conserving surgery
1001439|NCT02017483|ADHD,
1001440|NCT02017483|emotion recognition
1001441|NCT02017483|attention
1001442|NCT02017470|Women Heart Health
1001443|NCT02017470|Cardiovascular Disease
1001444|NCT02017470|focus group
1001445|NCT02017470|advisory board
1001446|NCT02017470|one-on-one interview
1001447|NCT02017457|Hematology
1001448|NCT02017457|Acute Myelogenous Leukemia
1001449|NCT02017457|Myelodysplasic syndrome
1001450|NCT02017457|Allogeneic stem cell transplantation
1001451|NCT02017457|Donor lymphocyte infusion
1001452|NCT02017457|DLI
1001453|NCT02017457|Azacytidine
1001454|NCT02017457|Vidaza
1001455|NCT02017457|Overall response rate
1001456|NCT02017457|Relapse
1001457|NCT02017444|Pseudotumor Cerebri
1001458|NCT02017444|Benign Intracranial Hypertension
1001459|NCT02017444|Headaches
1001460|NCT02017444|Tinnitus
1001461|NCT02017444|Papilledema
1001462|NCT02017444|Blindness
1001463|NCT02017444|Optic Disk
1001464|NCT02017444|Intracranial Hypertension
1001465|NCT02017444|Clinical Trial, Phase 2
1001466|NCT02017444|11beta-Hydroxysteroid Dehydrogenase Type 1
1001467|NCT02017444|Obesity
1001468|NCT02017431|Diesel exhaust
1001469|NCT02017431|Particle depleted diesel exhaust
1001470|NCT02017431|Air pollution
1001471|NCT02017431|Airway responsiveness
1001472|NCT02017431|Allergies
1001473|NCT02017418|zeaxanthin
1001474|NCT02017418|visual function
1001475|NCT02017418|reaction time
1001476|NCT02017418|processing speed
1001477|NCT02017405|Digestibility
1001478|NCT02017405|Healthy volunteers
1001479|NCT02017405|serum-derived bovine immunoglobulin protein isolate
1001480|NCT02017405|bovine IgG
1001481|NCT02017405|adults
1001482|NCT02017392|postoperative agitation
1001483|NCT02017392|endotracheal intubation
1001484|NCT02017392|general anesthesia
1001485|NCT02017379|upper gastrointestinal bleeding
1001486|NCT02017379|melena
1001487|NCT02017379|hematemesis
1001488|NCT02017366|Surgery
1001489|NCT02017366|Malnutrition
1001490|NCT02017366|Nutrition, Enteral
1001491|NCT02017340|Alzheimer's Disease
1001618|NCT02016755|Vascular Disease
1001492|NCT02017340|Investigator-driven clinical trial
1001493|NCT02017340|Nilvadipine
1001494|NCT02017340|Calcium Channel blocker
1001495|NCT02017340|Elderly
1001496|NCT02017340|Therapeutic Intervention
1001497|NCT02017314|morbid obesity
1001498|NCT02017314|postoperative pain
1001499|NCT02017301|Liver Cirrhosis,Infection, Impedance, Body Composition
1001500|NCT02017288|Head and Neck Cancers
1001501|NCT02017288|Larynx
1001502|NCT02017288|Oropharynx
1001503|NCT02017288|Oral Cavity
1001504|NCT02017262|Self-care
1001505|NCT02017262|Patient education
1001506|NCT02017236|Food Effect
1001507|NCT02017236|Health subjects
1001508|NCT02017223|Physical activity
1001509|NCT02017197|Therapeutic Equivalency
1001510|NCT02017197|Warfarin
1001511|NCT02017197|Drugs, Generic
1001512|NCT02017197|Anticoagulants
1001513|NCT02017197|Anticoagulants [Pharmacological Action]
1001514|NCT02017197|Coumarins
1001515|NCT02017184|Body Temperature Regulation Sensor Noninvasive
1001516|NCT02017171|Kidney Diseases
1001517|NCT02017171|Diabetic Nephropathies
1001518|NCT02017171|Diabetes Mellitus
1001519|NCT02017171|Diabetes Complications
1001520|NCT02017171|Uric acid
1001521|NCT02017171|Allopurinol
1001522|NCT02017171|Glomerular filtration rate
1001523|NCT02017171|Coronary artery disease
1001524|NCT02017158|Obesity
1001525|NCT02017158|Nutrition
1001526|NCT02017158|Children
1001527|NCT02017145|infection
1001528|NCT02017145|chloraprep
1001529|NCT02017145|chlorhexidine
1001530|NCT02017145|lower extremity surgery
1001531|NCT02017145|antiseptic
1001532|NCT02017145|bacterial colonization
1001533|NCT02017132|Pomegranate
1001534|NCT02017132|Blood pressure
1001535|NCT02017132|Body composition
1001536|NCT02017132|Weight-loss
1001537|NCT02017132|Fat mass
1001538|NCT02017132|Polyphenols
1001539|NCT02017132|Quality of Life
1001540|NCT02017106|Varicose Veins
1001541|NCT02017093|CVA, rehabilitation
1001542|NCT02017080|fetal thyroid ultrasound
1001543|NCT02017080|fetal fT4
1001544|NCT02017080|antithyroid antibodies
1001545|NCT02017080|pregnancy
1001546|NCT02017080|autoimmune thyroid disease
1001547|NCT02017067|Resistance training
1001548|NCT02017067|musculoskeletal conditions
1001549|NCT02017067|RFD
1001550|NCT02017041|opioid dependence, buprenorphine, smartphone, suboxone
1001551|NCT02017015|Pancreatic cancer
1001552|NCT02017015|Metastatic pancreatic cancer
1001553|NCT02017015|treatment for pancreatic cancer
1001554|NCT02017015|Abraxane clinical research trials
1001555|NCT02017015|Celgene clinical research trials
1001556|NCT02017002|Esophageal cancer
1001557|NCT02017002|minimally invasive
1001558|NCT02017002|Surgical Procedures
1001559|NCT02017002|Esophagectomy
1001560|NCT02016989|Bacterial keratitis
1001561|NCT02016989|OTR4120
1001562|NCT02016989|Matrix therapy
1001563|NCT02016963|Monoclonal Antibody
1001564|NCT02016963|Safety
1001565|NCT02016963|Raxibacumab
1001566|NCT02016963|HGS1021
1001567|NCT02016963|Immunogenicity
1001568|NCT02016937|Anesthesia , lactation, birth
1001574|NCT02016898|Primary open angle glaucoma
1001575|NCT02016898|trabeculectomy
1001576|NCT02016898|mitomycin-C
1001577|NCT02016898|express mini-shunt
1001578|NCT02016872|PET/CT
1001579|NCT02016872|18F-FMISO
1001580|NCT02016872|tumor hypoxia
1001581|NCT02016872|13-186
1001582|NCT02016859|IPF Immature platelet fraction
1001583|NCT02016859|ICU neutropenic fever
1001584|NCT02016859|hip fracture
1001585|NCT02016859|critically ill
1001586|NCT02016833|Ovarian Cancer
1001587|NCT02016833|Cervical Cancer
1001588|NCT02016833|Leukemia
1001589|NCT02016833|Immunity
1001590|NCT02016833|WT-1
1001591|NCT02016833|Survivin
1001592|NCT02016833|HPV
1001593|NCT02016820|Clostridium Difficile Infection
1001594|NCT02016820|Proton Pump Inhibitors
1001595|NCT02016820|Histamine-2 Receptor Antagonists
1001596|NCT02016820|Gastroesophageal Reflux Disease
1001597|NCT02016807|Mucositis
1001598|NCT02016807|Sucralfate
1001599|NCT02016807|Prothelial
1001600|NCT02016807|High potency sucralfate
1001601|NCT02016807|Ulcerations
1001602|NCT02016807|Chemotherapy induced diarrhea
1001603|NCT02016807|Radiation induced mucositis
1001604|NCT02016807|Chemotherapy colitis
1001605|NCT02016807|Radiation colitis
1001606|NCT02016807|Mucosal erosions
1001607|NCT02016794|cervical
1001608|NCT02016794|interbody
1001609|NCT02016794|spacer
1001610|NCT02016794|degenerative
1001611|NCT02016794|pain
1001612|NCT02016794|neck
1001613|NCT02016794|decompression
1001614|NCT02016794|fusion
1001615|NCT02016794|implant
1001616|NCT02016781|Myelodysplastic Syndrome
1001617|NCT02016755|Peripheral Arterial Disease
1001619|NCT02016755|CLI
1001620|NCT02016755|Critical Limb Ischemia
1001621|NCT02016755|PAD
1001622|NCT02016755|AnGes
1001623|NCT02016755|HGF Plasmid
1001624|NCT02016755|HGF
1001625|NCT02016755|Hepatocyte Growth Factor Plasmid
1001626|NCT02016755|gene therapy
1001627|NCT02016742|Pharmacokinetics
1001628|NCT02016729|AML
1001629|NCT02016716|Postmenopausal Osteoporosis
1001630|NCT02016703|erythritol
1001631|NCT02016703|polyol
1001632|NCT02016703|laxation
1001633|NCT02016703|gastrointestinal
1001634|NCT02016703|tolerance
1001635|NCT02016703|soft drinks
1001636|NCT02016703|child
1001637|NCT02016703|diarrhoea
1001638|NCT02016690|Prevention of severe RSV infection
1001639|NCT02016690|Respiratory syncytial virus (RSV) infection
1001640|NCT02016690|Down Syndrome
1001641|NCT02016690|Immunocompromised
1001642|NCT02016690|Effectiveness of palivizumab
1001643|NCT02016677|Breast reduction
1001644|NCT02016677|Mastopexy
1001645|NCT02016677|Sagging
1001646|NCT02016664|Chronic Pain, Ketamine, Safety
1001647|NCT02016638|Obstructive Sleep Apnea in pregnancy
1001648|NCT02016638|Pregnancy induced hypertension
1001649|NCT02016638|Restless leg syndrome
1001650|NCT02016638|Sleep
1001651|NCT02016612|Recurrent
1001652|NCT02016612|Ptosis
1001653|NCT02016612|Reduction
1001654|NCT02016612|Mammoplasty
1001655|NCT02016612|Mastopexy
1001656|NCT02016599|Hypotension
1001657|NCT02016599|Low blood pressure
1001658|NCT02016599|Neonate
1001659|NCT02016599|Extremely Low Birth Weight Infant
1001660|NCT02016573|renal denervation
1001661|NCT02016573|blood pressure
1001662|NCT02016573|cardiovascular risk
1001663|NCT02016573|target organ damage
1001664|NCT02016573|sympathetic activity
1001665|NCT02016547|Stroke
1001666|NCT02016547|Middle Cerebral Artery
1001667|NCT02016547|Thrombectomy
1001668|NCT02016547|Mechanical Thrombolysis
1001669|NCT02016547|Abciximab
1001670|NCT02016534|MET Amplified Gastric / Gastroesophageal Junction / Esophageal Adenocarcinoma, or other solid tumors.
1001671|NCT02016521|Exercise
1001672|NCT02016521|Clothing
1001673|NCT02016521|Core body temperature
1001674|NCT02016521|Skin Temperature
1001675|NCT02016521|Performance
1001676|NCT02016508|Adult bone marrow stem cells
1001677|NCT02016508|AMD
1001678|NCT02016482|Nail Psoriasis
1001679|NCT02016482|Plaque Psoriasis
1001680|NCT02016456|Transcranial Magnetic Stimulation
1001682|NCT02016456|Magnetic Resonance Imaging
1001683|NCT02016443|inguinal hernia
1001684|NCT02016430|TMAO
1001685|NCT02016430|Gut Flora
1001686|NCT02016430|Dietary Intervention
1001687|NCT02016430|Choline
1001688|NCT02016430|Carnitine
1001689|NCT02016417|Nasopharyngeal carcinoma
1001690|NCT02016417|Induction chemotherapy
1001691|NCT02016417|Concurrent chemoradiotherapy
1001692|NCT02016417|Gemcitabine
1001693|NCT02016417|Docetaxel
1001694|NCT02016404|blood pressure
1001695|NCT02016404|sodium
1001696|NCT02016404|salt
1001697|NCT02016404|low sodium high potassium salt
1001698|NCT02016404|potassium
1001699|NCT02016404|Vietnam
1001700|NCT02016404|randomized controlled trial
1001701|NCT02016365|Transthyretin amyloidosis
1001702|NCT02016365|Cardiomyopathy
1001703|NCT02016365|ATTR
1001704|NCT02016365|neuropathy
1001705|NCT02016352|hydrocephalus
1001706|NCT02016352|proteomic
1001707|NCT02016352|cerebrospinal fluid
1001708|NCT02016326|Colonoscopy
1001709|NCT02016326|High Definition White Light
1001710|NCT02016326|I-Scan
1001711|NCT02016326|Adenomas
1001712|NCT02016300|cartilage
1001713|NCT02016300|microfracture
1001714|NCT02016300|knee
1001715|NCT02016300|bracing
1001716|NCT02016261|Cognitive function
1001717|NCT02016248|CyberKnife
1001718|NCT02016248|Prostate Cancer
1001719|NCT02016248|Stereotactic Body Radiation
1001720|NCT02016248|SBRT
1001721|NCT02016248|Radiosurgery
1001722|NCT02016248|SABR
1001723|NCT02016248|Stereotactic Ablative Body Radiotherapy
1001724|NCT02016248|Boost
1001725|NCT02016235|Dent
1001726|NCT02016235|Dents
1001727|NCT02016235|Dent Disease
1001728|NCT02016235|Phosphorus Supplements
1001729|NCT02016235|FGF 23
1001730|NCT02016222|primary progressive multiple sclerosis
1001731|NCT02016222|diagnosis
1001732|NCT02016222|tears
1001733|NCT02016222|isoelectric focusing
1001734|NCT02016222|oligoclonal bands
1001735|NCT02016196|TIPS
1001736|NCT02016196|portal pressure
1001737|NCT02016196|rifaximin
1001738|NCT02016196|overt hepatic encephalopathy
1001739|NCT02016196|microbiota
1001740|NCT02016183|Drug Therapy
1001741|NCT02016170|platelet reactivity
1001742|NCT02016170|ticagrelor
1001743|NCT02016170|prasugrel
1001744|NCT02016157|Moxifloxacin
1001745|NCT02016157|Chlorhexidine
1001746|NCT02016157|In situ gel
1001747|NCT02016157|Chronic periodontitis
1001748|NCT02016144|Airway management; Fiber optic technology; Intubation
1001749|NCT02016131|endoleak
1001750|NCT02016131|EVAR
1001751|NCT02016131|AAA
1001752|NCT02016131|CQDSA
1001753|NCT02016118|RUTI
1001754|NCT02016105|plaque type psoriasis
1001755|NCT02016105|equivalent efficacy
1001756|NCT02016105|safety and immunogenicity
1001757|NCT02016105|GP2017
1001758|NCT02016105|Humira®
1001759|NCT02016092|Parkinson's disease
1001760|NCT02016092|biomarkers
1001761|NCT02016092|blood
1001762|NCT02016092|urine,
1001763|NCT02016092|proteomics
1001764|NCT02016092|lipidomics
1001765|NCT02016092|metabolomics
1001766|NCT02016079|randomized controlled trial
1001767|NCT02016079|omega-3
1001768|NCT02016079|nutrition
1001769|NCT02016079|behavior problems
1001770|NCT02016079|externalizing
1001771|NCT02016079|internalizing
1001772|NCT02016079|antisocial
1001773|NCT02016079|aggressive
1001774|NCT02016066|Healthy
1001775|NCT02016066|CR6261
1001776|NCT02016066|Japanese
1001777|NCT02016066|Safety
1001778|NCT02016066|Pharmacokinetics
1001779|NCT02016066|Immunogenicity
1001780|NCT02016040|Prostate cancer
1001781|NCT02016040|HIFU Hemi-ablation
1001782|NCT02016040|Prostate biopsies
1001783|NCT02016014|Physical activity
1001784|NCT02016014|Alimentation
1001785|NCT02016014|Information and communication Technology
1001786|NCT02016014|Arterial aging
1001787|NCT02016001|fluoride
1001788|NCT02016001|dental caries
1001789|NCT02016001|prevention
1001790|NCT02015988|Acute coronary syndrome
1001791|NCT02015988|Diabetes Mellitus, Type 2
1001792|NCT02015988|Hypertriglyceridemia
1001793|NCT02015988|Simvastatin
1001794|NCT02015988|Fenofibrate
1001795|NCT02015975|patellar fracture
1001796|NCT02015975|fracture of patella
1001797|NCT02015975|patella
1001798|NCT02015975|locking plate osteosynthesis
1001799|NCT02015975|osteosynthesis
1001800|NCT02015975|star-plate
1001801|NCT02015975|arrow-plate
1001802|NCT02015962|Hypokalemia
1001803|NCT02015962|Intravenous
1001804|NCT02015962|Enteral
1001805|NCT02015962|post-cardiac surgery
1001806|NCT02015936|stage III cancer
1001807|NCT02015936|stage IV cancer
1001808|NCT02015936|cancer
1001809|NCT02015936|advanced stage cancer
1001810|NCT02015936|Nintendo Wii training
1001811|NCT02015936|exercise
1001812|NCT02015936|physical training
1001813|NCT02015936|physical function
1001814|NCT02015936|physical fitness test
1001815|NCT02015923|Colonic cancer
1001816|NCT02015923|Metastasis
1001817|NCT02015884|Incivility
1001818|NCT02015884|Rudeness
1001819|NCT02015884|Aggression
1001820|NCT02015884|Violent act
1001821|NCT02015884|Healthcare workers
1001822|NCT02015884|Emergency unit
1001823|NCT02015832|SYNTAX II Score
1001824|NCT02015832|Pressure wires
1001825|NCT02015832|instantaneous wave-free ratio
1001826|NCT02015832|fractional flow reserve
1001827|NCT02015832|intravascular ultrasound
1001828|NCT02015832|Drug eluting stents
1001829|NCT02015832|Stents
1001830|NCT02015832|Angioplasty
1001831|NCT02015832|multi slice computed tomography
1001832|NCT02015806|Quality improvement
1001833|NCT02015806|Randomized controlled trial
1001834|NCT02015806|Medication adherence
1001835|NCT02015806|RxTimer Cap
1001836|NCT02015806|PillMinder
1001837|NCT02015806|Take-N-Slide
1001838|NCT02015806|Low-touch devices
1001839|NCT02015806|Medication management
1001840|NCT02015793|Crohn's Disease
1001841|NCT02015793|Pharmacokinetics
1001842|NCT02015780|Drug therapy
1001844|NCT02015728|Refractory
1001845|NCT02015728|Recurrent
1001846|NCT02015728|Brain
1001847|NCT02015728|Tumor
1001848|NCT02015728|Pediatric
1001849|NCT02015728|Biologically Targeted Therapy
1001850|NCT02015728|Sorafenib
1001851|NCT02015728|Everolimus
1001852|NCT02015728|Erlotinib
1001853|NCT02015728|Dasatinib
1001854|NCT02015728|Temozolomide
1001855|NCT02015728|Etoposide
1001856|NCT02015702|Physicians
1001857|NCT02015702|Electronic Health Record
1001858|NCT02015702|Education
1001859|NCT02015663|Cystic Fibrosis
1001860|NCT02015663|CF
1001861|NCT02015650|Locally advanced squamous cell carcinomas of head and neck
1001862|NCT02015637|Gonorrhea
1001863|NCT02015637|N. gonorrhoeae
1001864|NCT02015637|bacterial infection
1001865|NCT02015637|Anti-Infective Agents
1001866|NCT02015637|Anti-Bacterial Agents
1001867|NCT02015624|Acute coronary syndromes
1001868|NCT02015624|Intensive Care Unit
1001869|NCT02015611|Vitamin D
1001870|NCT02015611|Muscle power
1001871|NCT02015611|Muscle fiber
1001872|NCT02015611|Falls
1001873|NCT02015611|Aging
1001874|NCT02015598|Obstructive sleep apnoea
1001875|NCT02015598|Antioxidant
1001876|NCT02015598|drug treatment
1001877|NCT02015598|oxidative stress
1001878|NCT02015598|Continuous Positive Airway Pressure
1001879|NCT02015572|Low back pain
1001880|NCT02015572|Return to work
1001881|NCT02015572|Sickness absence
1001882|NCT02015572|Rehabilitation
1001883|NCT02015572|Occupational intervention
1001884|NCT02015546|Major Depressive Disorder
1001885|NCT02015546|Vilazodone
1001886|NCT02015533|Healthy
1001887|NCT02015533|CR8020
1001888|NCT02015533|Japanese
1001889|NCT02015533|Safety
1001890|NCT02015533|Pharmacokinetics
1001891|NCT02015533|Immunogenicity
1001892|NCT02015494|Safety
1001893|NCT02015494|Immunogenicity
1001894|NCT02015481|Case control, safety, tolerability, efficacy.
1001895|NCT02015468|Distal radius fracture
1001896|NCT02015468|Wrist fracture
1001897|NCT02015468|Physiotherapy
1001898|NCT02015468|Immobilization
1001899|NCT02015468|Volar locking plates
1001900|NCT02015468|Mobilization
1001901|NCT02015455|pragmatic trial
1001902|NCT02015455|stepped-wedge design
1001903|NCT02015455|cluster-randomized trial
1001904|NCT02015442|Sucrose in diet
1001905|NCT02015429|Food intake
1001906|NCT02015429|satiety
1001907|NCT02015429|glycemia
1001908|NCT02015429|appetite
1001909|NCT02015429|blood glucose
1001910|NCT02015429|yellow peas
1001911|NCT02015429|fibre
1001912|NCT02015429|protein
1001913|NCT02015429|mixed meal
1001914|NCT02015416|Melanoma
1001915|NCT02015416|Ovarian cancer
1001916|NCT02015416|Sarcoma
1001917|NCT02015416|Non-small cell lung cancer
1001918|NCT02015416|NSCLC
1001919|NCT02015416|Breast cancer
1001920|NCT02015390|bone defects
1001921|NCT02015390|iatrogenic resection
1001922|NCT02015390|titanium mesh cage
1001923|NCT02015390|biomembrane
1001924|NCT02015390|Masquelet technique
1001925|NCT02015364|Achilles tendon
1001926|NCT02015364|Rupture
1001927|NCT02015364|Rehabilitation
1001928|NCT02015364|Dynamic rehabilitation
1001929|NCT02015351|Choroidal neovascularization
1001930|NCT02015351|Vogt Koyanagi Harada Disease
1001931|NCT02015351|Inflammatory choroidal neovascularization
1001932|NCT02015351|Anti-VEGF
1001933|NCT02015338|Hemiparesis
1001934|NCT02015338|Cerebral Palsy
1001935|NCT02015338|Congenital Stroke
1001936|NCT02015338|Congenital Infarct
1001937|NCT02015325|Water
1001938|NCT02015325|Sanitation
1001939|NCT02015325|Hygiene
1001940|NCT02015325|Education
1001941|NCT02015325|Evaluation
1001942|NCT02015312|Amyloidosis
1001943|NCT02015299|Diabetes
1001944|NCT02015299|Pulse Wave Velocity
1001945|NCT02015299|Dipeptidyl peptidase (DPP)-4 inhibitors
1001946|NCT02015299|Linagliptin
1001947|NCT02015299|Arterial Stiffness
1001948|NCT02015299|Subclinical arterial inflammation
1001949|NCT02015286|Growth disorders
1001950|NCT02015286|Saizen
1001951|NCT02015286|Easypod
1001952|NCT02015286|Growth hormone
1001953|NCT02015286|Pediatric subject
1001954|NCT02015273|easypod™
1001955|NCT02015273|SAIZEN®
1001956|NCT02015260|human papilloma virus infection
1001957|NCT02015260|Anogenital warts
1001958|NCT02015260|condylomata acuminata
1001959|NCT02015234|TNX-102 SL
1001960|NCT02015234|bedtime
1001961|NCT02015234|sublingual
1001962|NCT02015234|12-month
1001963|NCT02015234|long term safety
1001964|NCT02015234|long term efficacy
1001965|NCT02015234|Fibromyalgia
1001966|NCT02015221|chronic venous insufficiency
1001967|NCT02015221|venous leg ulcers
1001968|NCT02015221|pneumatic compression
1001969|NCT02015208|CLL
1001970|NCT02015208|cytokine signaling
1001971|NCT02015208|signal transduction inhibitors
1001972|NCT02015208|elderly
1001973|NCT02015208|p53
1001974|NCT02015195|Jellyfish stings
1001975|NCT02015195|Treatment
1001976|NCT02015195|Humans
1001977|NCT02015195|Topical Treatments
1001978|NCT02015195|Pain
1001979|NCT02015195|Erythema
1001980|NCT02015182|Bupivacaine
1001981|NCT02015182|Sensorcaine
1001982|NCT02015182|Population pharmacokinetics
1001983|NCT02015182|Children
1001984|NCT02015182|Pediatrics
1001985|NCT02015182|Transversus abdominis plane (TAP) block
1001986|NCT02015182|Regional Anesthesia
1001987|NCT02015169|gastric cancer
1001988|NCT02015169|neoadjuvant chemotherapy
1001989|NCT02015169|capecitabine
1001990|NCT02015169|oxaliplatin
1001991|NCT02015169|lapatinib
1001992|NCT02015156|Trastuzumab
1001993|NCT02015156|Healthy Male Volunteers
1001994|NCT02015156|Single-Dose
1001995|NCT02015156|Phase 1
1001996|NCT02015156|Biosimilarity
1001997|NCT02015130|Type 2 diabetes
1001998|NCT02015130|hypertension
1001999|NCT02015130|individual
1002005|NCT02015091|Healthy Subjects
1002006|NCT02015091|Vaccine-Mediated Protection
1002007|NCT02015091|Immunogenicity
1002008|NCT02015091|Sporozoites
1002009|NCT02015091|Parasitemia
1002010|NCT02015078|Eating Behavior
1002011|NCT02015078|Cancer
1002012|NCT02015078|Chronic Diseases
1002013|NCT02015078|Obesity
1002014|NCT02015065|GIST
1002015|NCT02015065|Toxicity
1002016|NCT02015065|Mesenchymal Tumor
1002017|NCT02015065|Clinical Activity
1002018|NCT02015065|Survival
1002019|NCT02015039|Occupational Therapy
1002020|NCT02015039|Botulinum Toxin
1002021|NCT02015039|Writer's Cramp
1002022|NCT02015026|Biospecimen Repository
1002023|NCT02015026|Disease Progression Pattern
1002024|NCT02015026|Specimen Analysis
1002025|NCT02015026|Genetic Analysis
1002028|NCT02015000|Pterygium
1002029|NCT02015000|Recurrence
1002030|NCT02014987|Running related injury
1002031|NCT02014987|Overuse injury
1002032|NCT02014987|Running pattern
1002033|NCT02014974|Fractures
1002034|NCT02014974|burden of fractures
1002035|NCT02014974|orthopaedic fractures
1002036|NCT02014974|orthopaedic injuries
1002037|NCT02014974|orthopaedic trauma
1002038|NCT02014974|fractures India
1002039|NCT02014974|observational study
1002040|NCT02014974|outcomes of fracture care
1002041|NCT02014974|wait times India
1002042|NCT02014974|epidemiology
1002043|NCT02014948|Low Back Pain
1002044|NCT02014948|Physiotherapy
1002045|NCT02014935|Low-intensity Laser
1002046|NCT02014935|Spasticity
1002047|NCT02014935|pain,
1002048|NCT02014935|Fatigue
1002049|NCT02014909|KTN3379
1002050|NCT02014909|Advanced cancer
1002051|NCT02014909|Phase 1
1002052|NCT02014909|Monoclonal antibody
1002053|NCT02014909|Safety and pharmacokinetics
1002054|NCT02014909|CDX3379
1002055|NCT02014896|Ischemic Stroke
1002056|NCT02014896|Transient Ischemic Attack
1002057|NCT02014896|Transient Neurological Event
1002058|NCT02014896|Atrial Fibrillation
1002059|NCT02014896|Cryptogenic Stroke
1002060|NCT02014896|Gene Expression
1002061|NCT02014896|RNA
1002062|NCT02014896|Anticoagulant
1002063|NCT02014896|NOAC
1002064|NCT02014896|Antiplatelet
1002065|NCT02014896|Cardiac monitoring
1002066|NCT02014896|Point of Care
1002067|NCT02014896|tPA
1002068|NCT02014896|Atheroembolic
1002069|NCT02014870|Influenza
1002070|NCT02014870|Vaccine
1002071|NCT02014870|Virus
1002072|NCT02014870|H1N1
1002073|NCT02014870|Challenge
1002074|NCT02014870|Vismederi
1002075|NCT02014857|Smoking, gingival crevicular fluid, matrix metalloproteinases, intercellular signaling peptides and proteins, healthy volunteers
1002076|NCT02014844|glioblastoma
1002077|NCT02014844|aldoxorubicin
1002078|NCT02014844|temozolomide
1002079|NCT02014844|brain cancer
1002080|NCT02014844|brain tumor
1002081|NCT02014831|Squamous Cell Carcinoma of the penis
1002082|NCT02014831|Stage N3
1002083|NCT02014831|Metastasis
1002084|NCT02014831|TIP
1002085|NCT02014831|Cetuximab
1002086|NCT02014831|Objective Response Rate
1002087|NCT02014831|Safety profile
1002088|NCT02014831|Overall Survival
1002089|NCT02014831|Progression Free Survival
1002090|NCT02014831|Quality of Life
1002091|NCT02014805|postoperative
1002092|NCT02014805|conformal
1002093|NCT02014805|radiotherapy
1002094|NCT02014805|thymoma
1002095|NCT02014792|Haemodialysis
1002096|NCT02014792|Heart rate variability
1002097|NCT02014792|n-3 PUFA
1002098|NCT02014779|Randomized Controlled Trial
1002099|NCT02014779|Alcohol
1002100|NCT02014779|Internet
1002101|NCT02014779|Internet based therapy
1002102|NCT02014779|Cognitive behavioral therapy
1002103|NCT02014753|AMI
1002104|NCT02014753|STEMI
1002105|NCT02014753|ACS
1002106|NCT02014740|Epicardial fat
1002107|NCT02014740|Type 2 diabetes
1002108|NCT02014740|Obesity
1002109|NCT02014740|GLP-1 analogs
1002110|NCT02014727|Malaria vaccine
1002111|NCT02014727|phase 1,
1002112|NCT02014727|AMA1-DiCO
1002113|NCT02014701|echocardiogram
1002114|NCT02014701|regional wall motion abnormalities
1002115|NCT02014701|myocardial contrast
1002116|NCT02014688|Normal subjects
1002117|NCT02014675|ICD
1002118|NCT02014675|CRT-D
1002119|NCT02014675|Lead
1002120|NCT02014662|Muscle function, Muscle damage and recovery, Eccentric exercise, Muscle soreness, Protein synthesis
1002121|NCT02014649|Influenza treatment
1002122|NCT02014649|pediatric
1002123|NCT02014649|laninamivir
1002124|NCT02014636|Pazopanib (GW786034)
1002125|NCT02014636|MK 3475
1002126|NCT02014636|Renal cell carcinoma
1002127|NCT02014623|Allergic rhinitis
1002128|NCT02014623|Asthma
1002129|NCT02014623|Regulatory T cells
1002130|NCT02014623|IgE
1002131|NCT02014623|IgG4
1002132|NCT02014610|Neutrophil
1002133|NCT02014610|Lymphocyte
1002134|NCT02014610|Eosinophil
1002135|NCT02014610|Leukocyte count
1002136|NCT02014610|Cardiovascular disease
1002137|NCT02014610|Atherosclerosis
1002138|NCT02014610|Monocyte
1002139|NCT02014610|Basophil
1002140|NCT02014597|Glaucoma
1002141|NCT02014584|quality of life
1002142|NCT02014584|safety
1002143|NCT02014584|sexual function
1002144|NCT02014584|male pattern hair loss (MPHL)
1002145|NCT02014584|Androgenic alopecia (AGA)
1002146|NCT02014584|dutasteride
1002147|NCT02014584|satisfaction with hair growth
1002148|NCT02014571|NS5B
1002149|NCT02014571|chronic hepatitis C (CHC)
1002150|NCT02014571|antiviral activity
1002151|NCT02014571|pharmacokinetics (PK)
1002152|NCT02014571|Safety
1002153|NCT02014571|hepatitis C virus (HCV)
1002154|NCT02014571|GSK2878175
1002155|NCT02014558|Acute Myeloid Leukemia
1002156|NCT02014558|ASP2215
1002157|NCT02014545|brain metastases
1002158|NCT02014545|non-small cell lung cancer
1002159|NCT02014545|whole brain radiation therapy
1002160|NCT02014545|lucanthone
1002161|NCT02014532|Leukotriene receptor antagonist
1002162|NCT02014532|Chronic periodontitis
1002163|NCT02014532|Scaling and root planing
1002164|NCT02014532|C- reactive protein
1002165|NCT02014519|Adults
1002166|NCT02014519|Hungary
1002167|NCT02014519|Bordetella pertussis
1002168|NCT02014519|Seroprevalence
1002169|NCT02014519|Pertussis antibodies
1002170|NCT02014506|Children and adolescents
1002171|NCT02014506|Malignant disease
1002172|NCT02014506|Non-malignant disease
1002173|NCT02014506|TCRαβ depletion
1002174|NCT02014506|Haploidentical hematopoietic stem cell transplantation
1002175|NCT02014493|Respiration
1002176|NCT02014493|Noninvasive Ventilation
1002177|NCT02014493|Work of breathing
1002178|NCT02014493|Infant, premature
1002179|NCT02014493|Electromyography
1002180|NCT02014493|Diaphragm
1002181|NCT02014480|Long-acting beta-agonist
1002182|NCT02014480|Chronic Obstructive Pulmonary Disease
1002183|NCT02014480|Umeclidinium
1002184|NCT02014480|Long-acting muscarinic antagonist
1002185|NCT02014480|Vilanterol
1002186|NCT02014454|Retinopathy of prematurity
1002187|NCT02014454|Propranolol
1002188|NCT02014454|Eye drops
1002189|NCT02014454|Newborns
1002190|NCT02014454|Retinal angiogenesis
1002191|NCT02014454|Retinal neovascularization
1002192|NCT02014415|Alpha-1
1002193|NCT02014415|AAT Deficiency
1002194|NCT02014415|AATD
1002195|NCT02014415|Liver
1002196|NCT02014415|Fibrosis
1002197|NCT02014415|Liver Transplant
1002198|NCT02014415|Cirrhosis
1002199|NCT02014402|Vascular surgery
1002200|NCT02014402|Hepatic surgery
1002201|NCT02014402|Soft tissue surgery
1002202|NCT02014402|Spinal surgery
1002203|NCT02014389|Retinal Dystrophies
1002204|NCT02014389|Retinitis Pigmentosa
1002205|NCT02014389|Glaucoma
1002206|NCT02014389|Visual Field
1002207|NCT02014376|Epidermolysis Bullosa
1002208|NCT02014376|Simplex
1002209|NCT02014376|Recessive Dystrophic
1002210|NCT02014376|Junctional non-Herlitz
1002211|NCT02014337|Mifepristone
1002212|NCT02014337|Eribulin Mesylate
1002213|NCT02014337|Breast Cancer
1002214|NCT02014337|Ovarian Cancer
1002215|NCT02014337|Sarcoma
1002216|NCT02014337|Non-small cell lung cancer
1002217|NCT02014337|Carcinoma, transitional cell
1002218|NCT02014337|Prostate cancer
1002219|NCT02014337|Prostatic neoplasms
1002220|NCT02014311|Multidetector Computed Tomography
1002221|NCT02014311|Myocardial Perfusion Imaging
1002222|NCT02014311|Coronary Stenosis
1002223|NCT02014311|Coronary Artery Disease
1002224|NCT02014311|Angina Pectoris
1002225|NCT02014298|Burns
1002226|NCT02014298|Non-ablative fractional laser
1002227|NCT02014298|scar texture
1002228|NCT02014298|histology
1002229|NCT02014298|laser treatment
1002230|NCT02014298|erbium:glass laser
1002231|NCT02014298|meshed skin-grafts
1002232|NCT02014298|photothermolysis
1002233|NCT02014298|skin
1002234|NCT02014285|Acute Respiratory Failure
1002235|NCT02014285|Critical Illness
1002236|NCT02014285|Mechanical Ventilation
1002237|NCT02014285|Muscle Architecture
1002238|NCT02014285|Muscle Ultrasound
1002239|NCT02014272|Bioequivalence
1002240|NCT02014272|RIN 150
1002241|NCT02014272|Healthy volunteers
1002242|NCT02014246|Movement Disorders
1002243|NCT02014246|Polymorphisms
1002244|NCT02014246|DNA
1002245|NCT02014246|Lymphoblast Cell Lines
1002246|NCT02014233|Randomized clinical trial
1002247|NCT02014233|Humans
1002248|NCT02014233|Omega-3 fatty acids
1002249|NCT02014233|Essential fatty acid
1002250|NCT02014233|Neuromuscular function
1002251|NCT02014233|Wingate
1002252|NCT02014233|Maximum voluntary contraction
1002253|NCT02014233|Electromyography
1002254|NCT02014233|Seal oil
1002255|NCT02014233|Cycling time trial
1002256|NCT02014233|Placebo controlled
1002257|NCT02014194|Attentional Bias
1002504|NCT02012894|manometry
1002258|NCT02014194|Attentional Bias modification treatment
1002259|NCT02014181|cystic fibrosis
1002260|NCT02014181|isoprostanes
1002261|NCT02014181|8-oxo-dGuo
1002262|NCT02014181|oxidative stress
1002263|NCT02014181|inflammation
1002264|NCT02014181|flaxseed
1002265|NCT02014181|enterodiol
1002266|NCT02014181|enterolactone
1002267|NCT02014155|Chronic Obstructive Pulmonary Disease,
1002268|NCT02014103|bioequivalence
1002269|NCT02014103|tacrolimus
1002270|NCT02014103|transplant
1002271|NCT02014103|CYP3A5 expressors/non expressors
1002272|NCT02014090|ECP
1002273|NCT02014090|Endurance exercise
1002274|NCT02014090|myocardial perfusion
1002275|NCT02014077|VATS( Video-Assisted Thoracoscopy )
1002276|NCT02014077|Thoracostomy Tube
1002277|NCT02014077|Empyema
1002278|NCT02014077|Thoracotomy
1002279|NCT02014064|Methamphetamine, Atomoxetine, Clinical Pharmacology
1002280|NCT02014038|Ultrarunners
1002281|NCT02014038|ultramarathon runners
1002282|NCT02014038|ULTRA
1002283|NCT02014038|Physical activity
1002284|NCT02014038|Health Risks
1002285|NCT02014038|sedentary
1002286|NCT02014038|moderately active
1002287|NCT02014025|Laparoscope hepatectomy
1002288|NCT02014025|Open hepatectomy
1002289|NCT02014025|large PHC
1002290|NCT02014025|safety and sensibility
1002291|NCT02013986|salivary cortisol
1002292|NCT02013986|circadian rhythm
1002293|NCT02013986|children
1002294|NCT02013986|etomidate
1002295|NCT02013973|Anti mullerian hormone
1002296|NCT02013973|In vitro fertilization
1002297|NCT02013973|Optimal treatment
1002298|NCT02013973|Randomized controlled trial
1002299|NCT02013947|Exercise, moderate altitude, hypoxia, metabolic syndrome
1002300|NCT02013921|Physical activity
1002301|NCT02013921|Cancer
1002302|NCT02013908|acupuncture
1002303|NCT02013908|emergency department
1002304|NCT02013908|acute pain
1002305|NCT02013908|ankle sprain
1002306|NCT02013908|neck pain
1002307|NCT02013908|primary headache
1002308|NCT02013895|liver
1002309|NCT02013895|surgery
1002310|NCT02013895|liver function
1002311|NCT02013895|GSA
1002312|NCT02013895|ICG
1002313|NCT02013882|low flow anesthesia
1002314|NCT02013882|wash-in
1002315|NCT02013882|desflurane
1002316|NCT02013869|fresh gas flow
1002317|NCT02013869|quality of anaesthesia
1002318|NCT02013869|minimal alveolar concentration
1002319|NCT02013856|Blood pressure
1002320|NCT02013856|Flavanols
1002321|NCT02013856|Cardiovascular disease
1002322|NCT02013843|Pediatric obesity
1002323|NCT02013843|Community-based treatment
1002324|NCT02013843|dyslipidemia
1002325|NCT02013843|hypertension
1002326|NCT02013843|diabetes
1002327|NCT02013778|outside of transplant criteria
1002328|NCT02013752|Delivery tears
1002329|NCT02013752|Birth injuries
1002330|NCT02013752|Perineal protection device
1002331|NCT02013713|Cardiology
1002332|NCT02013713|Family Hypercholesterolemia
1002333|NCT02013700|IPF
1002334|NCT02013700|Pulmonary fibrosis
1002335|NCT02013674|Cardiovascular, Chronic Ischemic Left Ventricular Dysfunction
1002336|NCT02013661|periodontal debridement
1002337|NCT02013661|sutures
1002338|NCT02013661|tissue reaction
1002339|NCT02013648|AML
1002340|NCT02013648|Dasatinib
1002341|NCT02013648|Core Binding Factor (CBF)
1002342|NCT02013635|cerebral venous thrombosis
1002343|NCT02013635|thrombin generation
1002344|NCT02013635|d-dimers
1002345|NCT02013635|clinical evolution
1002346|NCT02013622|schizophrenia
1002347|NCT02013622|Mental Disorders
1002348|NCT02013622|Psychotic Disorders
1002349|NCT02013622|social avoidance
1002350|NCT02013622|emotional withdrawal
1002351|NCT02013622|passive/apathetic
1002352|NCT02013622|social withdrawal
1002353|NCT02013622|antipsychotic
1002354|NCT02013609|schizophrenia
1002355|NCT02013609|Major depressive disorder
1002356|NCT02013609|Anxiety Symptoms
1002357|NCT02013609|School, Work environment
1002358|NCT02013609|Mental Disorders
1002359|NCT02013609|Psychotic Disorders
1002360|NCT02013609|antipsychotic
1002361|NCT02013596|hepatic dysfunction
1002362|NCT02013596|renal dysfunction
1002363|NCT02013596|pneumoperitoneum
1002364|NCT02013596|Transcutaneous electric stimulation
1002365|NCT02013583|Glucose Transporter Type I Deficiency
1002366|NCT02013583|Glucose Transporter Type 1 Deficiency
1002367|NCT02013583|G1D
1002368|NCT02013583|Glut1 Deficiency
1002369|NCT02013570|postoperative pain; dexmedetomidine; adenotonsillectomy
1002370|NCT02013557|Gestational Diabetes
1002371|NCT02013557|Postpartum screening
1002372|NCT02013557|Text-messages
1002373|NCT02013557|75-g oral glucose tolerance test
1002374|NCT02013544|Vulvovaginal atrophy (VVA)
1002375|NCT02013544|Vaginal atrophy
1002376|NCT02013544|Atrophic vaginitis
1002377|NCT02013544|prasterone
1002378|NCT02013544|DHEA
1002379|NCT02013544|Intrarosa
1002380|NCT02013531|schizophrenia
1002381|NCT02013531|Major depressive disorder
1002382|NCT02013531|Anxiety Symptoms
1002383|NCT02013531|Mental Disorders
1002384|NCT02013531|Psychotic Disorders
1002385|NCT02013531|emotional withdrawal
1002386|NCT02013531|antipsychotic
1002387|NCT02013518|Alzheimers' disease
1002388|NCT02013518|Cognitive behavioral therapy
1002389|NCT02013518|Depression
1002390|NCT02013518|Self-efficacy
1002391|NCT02013518|Quality of Life
1002392|NCT02013505|Colonoscopy
1002393|NCT02013492|Beta-Blocker
1002394|NCT02013492|metastatic melanoma
1002395|NCT02013492|hepatocellular carcinoma
1002396|NCT02013466|Bioavailability
1002397|NCT02013466|Amino Acids
1002398|NCT02013466|Elderly
1002399|NCT02013466|Supplement
1002400|NCT02013427|chronic
1002401|NCT02013427|back
1002402|NCT02013427|pain
1002403|NCT02013427|brain
1002404|NCT02013427|MRI
1002405|NCT02013401|mother-infant dyadic regulation
1002406|NCT02013401|stress
1002407|NCT02013401|psychophysiology
1002408|NCT02013401|emotion regulation
1002409|NCT02013388|N91115
1002410|NCT02013388|GSNORi
1002411|NCT02013388|SNO
1002412|NCT02013388|Cavosonstat
1002413|NCT02013336|pediatric
1002414|NCT02013336|MM-398
1002415|NCT02013336|cyclophosphamide
1002416|NCT02013336|irinotecan
1002417|NCT02013323|Septiline, chronic periodontitis, Immunomodulator, microbiology
1002418|NCT02013297|Pediatrics
1002419|NCT02013297|SBRT
1002420|NCT02013297|Brain metastasis
1002421|NCT02013297|Pulmonary metastasis
1002422|NCT02013297|Spinal metastasis
1002423|NCT02013297|Pulmonary primary tumor
1002424|NCT02013297|Spinal primary tumor
1002425|NCT02013297|Relapsed ependymoma
1002426|NCT02013297|Relapsed irradiated tumors
1002427|NCT02013297|Local control rate
1002428|NCT02013297|Safety
1002429|NCT02013297|Overall survival
1002430|NCT02013297|Progression Free Survival
1002431|NCT02013258|Prader Willi syndrome
1002432|NCT02013258|Oxytocin
1002433|NCT02013232|Risperidone;
1002434|NCT02013232|Aripiprazole;
1002435|NCT02013232|Hyperprolactinemia;
1002436|NCT02013232|dose effects
1002437|NCT02013193|drug-coated balloon
1002438|NCT02013193|drug-eluting balloon
1002439|NCT02013193|peripheral artery disease
1002440|NCT02013193|claudication
1002441|NCT02013180|Prostate cancer, PSA, zinc, zinc/PSA
1002442|NCT02013167|Relapsed; Refractory; B-precursor; Acute Lymphoblastic Leukemia; Philadelphia Negative; ALL; Blinatumomab; Leukemia; Standard of Care; SOC
1002443|NCT02013141|Gram positive bacteria
1002444|NCT02013141|Telavancin
1002445|NCT02013141|VIBATIV
1002446|NCT02013141|Pediatric
1002447|NCT02013141|Pharmacokinetics
1002448|NCT02013115|infant
1002449|NCT02013115|respiratory distress syndrome
1002450|NCT02013089|genomic sequencing, Integrated genomic network analysis
1002451|NCT02013076|Asthma; Children; Cohort study; Corticosteroids
1002452|NCT02013063|Single Pulmonary Nodule
1002453|NCT02013063|SPN
1002454|NCT02013063|Lung cancer
1002455|NCT02013063|Diagnostic
1002456|NCT02013063|Computed Tomography
1002457|NCT02013063|CT scan
1002458|NCT02013063|FDG-PET scan
1002459|NCT02013063|Dynamic CT scan
1002460|NCT02013063|DCE-CT scan
1002461|NCT02013063|Dynamic contrast enhanced CT scan
1002462|NCT02013063|soft tissue solitary dominant
1002463|NCT02013063|≥ 8mm and ≤30mm
1002464|NCT02013037|cardiac transplantation
1002465|NCT02013037|immunosuppression
1002466|NCT02013037|acute cellular rejection
1002467|NCT02013037|antibody mediated rejection
1002468|NCT02013037|sensitization
1002469|NCT02013037|antibody production in cardiac patients
1002470|NCT02013037|panel reactive antibodies
1002471|NCT02013037|desensitization strategies in heart transplant patients
1002472|NCT02013037|complement activation
1002473|NCT02013037|complement c3d and c4d deposition
1002474|NCT02013037|terminal complement inhibition
1002475|NCT02013037|complement C5 binding
1002476|NCT02013037|Eculizumab
1002477|NCT02013037|monoclonal antibody
1002478|NCT02013037|donor specific antibodies
1002479|NCT02012985|hyperoxaluria
1002480|NCT02012985|oxalate
1002481|NCT02012985|PH
1002482|NCT02012972|Antiretroviral therapy
1002483|NCT02012972|HIV/AIDS
1002484|NCT02012972|Non-communicable diseases
1002485|NCT02012972|South Africa
1002486|NCT02012959|Hyponatremia
1002487|NCT02012959|Euvolemic
1002488|NCT02012959|Hypervolemic
1002489|NCT02012959|Serum sodium
1002490|NCT02012959|Dilutional hyponatremia
1002491|NCT02012959|Electrolyte abnormality
1002492|NCT02012959|Electrolyte imbalance
1002493|NCT02012959|Metabolic disease
1002494|NCT02012933|3,4DAP, LEMS, CM
1002495|NCT02012920|castration-resistant prostate cancer
1002496|NCT02012920|CYP17
1002497|NCT02012920|P450c17a
1002498|NCT02012920|lyase
1002499|NCT02012920|Prostate Cancer
1002500|NCT02012894|Obesity
1002501|NCT02012894|Gastroesophageal reflux
1002502|NCT02012894|sleeve gastrectomy
1002503|NCT02012894|pH-monitoring
1002505|NCT02012868|obstructive sleep apnoea
1002506|NCT02012868|weight loss
1002507|NCT02012868|bariatric surgery
1002508|NCT02012842|Metabolic Syndrome
1002509|NCT02012842|Periodontal Disease
1002510|NCT02012842|Periodontal therapy
1002511|NCT02012842|inflammatory markers
1002512|NCT02012842|C reactive protein
1002513|NCT02012842|serum fibrinogen
1002514|NCT02012842|glycated hemoglobin
1002515|NCT02012829|cancer, CRC screening, communication
1002516|NCT02012816|Uncircumcised men
1002517|NCT02012816|Voluntary Medical Male circumcision
1002518|NCT02012816|Peer-referral incentive
1002519|NCT02012803|Achilles tendon rupture
1002520|NCT02012803|treatment, elongation
1002521|NCT02012803|operative treatment of achilles tendon rupture
1002522|NCT02012803|conservative treatment of achilles tendon rupture
1002523|NCT02012790|Migraine disorders
1002524|NCT02012777|sickle cell disease
1002525|NCT02012777|propanolol
1002526|NCT02012777|red blood cell adhesion
1002527|NCT02012764|Anti-CCP antibody
1002528|NCT02012764|Inflammatory arthritis
1002529|NCT02012764|Rheumatoid arthritis
1002530|NCT02012764|Musculoskeletal symptom
1002531|NCT02012751|Computer-assisted diagnosis
1002532|NCT02012751|General practice
1002533|NCT02012751|Dermatoscopy
1002534|NCT02012751|Melanoma
1002535|NCT02012751|Nevus
1002536|NCT02012725|Healthy
1002537|NCT02012725|Myocardial fibrosis
1002538|NCT02012725|Chronic kidney disease
1002539|NCT02012712|Personal health record
1002540|NCT02012712|medication management
1002541|NCT02012712|patient safety
1002542|NCT02012699|Pancreatic Cancer
1002543|NCT02012699|Thyroid Cancer
1002544|NCT02012699|Esophageal cancer
1002545|NCT02012699|Thymus cancer
1002546|NCT02012699|Pancreatic tumor
1002547|NCT02012699|Esophageal tumor
1002548|NCT02012699|Thymus tumor
1002549|NCT02012699|Thyroid Tumor
1002550|NCT02012699|Thyroid Nodule
1002551|NCT02012699|Lung Tumor
1002552|NCT02012686|transcutaneous electric nerve stimulation
1002553|NCT02012686|thyroidectomy
1002554|NCT02012686|neck pain
1002555|NCT02012686|pain management
1002560|NCT02012647|parkinson
1002561|NCT02012647|PD
1002562|NCT02012647|parkinson disease
1002563|NCT02012647|parkinson's
1002564|NCT02012647|parkinson's disease
1002565|NCT02012647|parkinsons
1002566|NCT02012647|parkinsons disease
1002567|NCT02012647|TMS
1002568|NCT02012647|DBS
1002569|NCT02012647|transcranial magnetic stimulation
1002570|NCT02012647|deep brain stimulation
1002571|NCT02012634|Breast Cancer
1002572|NCT02012634|Capecitabine
1002573|NCT02012634|Triple Negative Breast CancerTNBC（TNBC）
1002574|NCT02012621|HIV/AIDS
1002575|NCT02012621|Adherence
1002576|NCT02012621|Tenofovir
1002577|NCT02012621|Dried Blood Spots
1002578|NCT02012608|breast
1002579|NCT02012569|skin grafting
1002580|NCT02012569|elective treatment
1002581|NCT02012543|constipation, agar
1002582|NCT02012530|Articular cartilage
1002583|NCT02012530|Hyaluronic Acid (HA)
1002584|NCT02012530|Platelet rich plasma (PRP)
1002585|NCT02012517|surgical site infection
1002586|NCT02012517|breast reconstruction
1002587|NCT02012517|drains
1002588|NCT02012517|prophylaxis
1002589|NCT02012491|Spontaneous abortion
1002590|NCT02012491|Early Pregnancy Failure
1002591|NCT02012491|Mifepristone
1002592|NCT02012491|Misoprostol
1002593|NCT02012465|Steroid induced hyperglycemia
1002594|NCT02012465|Glucocorticoid induced hyperglycemia
1002595|NCT02012452|posttraumatic stress disorder
1002596|NCT02012452|tobacco dependence
1002597|NCT02012452|cognitive behavioral therapy
1002598|NCT02012439|multiple sclerosis
1002599|NCT02012439|chronic pain
1002600|NCT02012439|treatment
1002601|NCT02012439|nonpharmacological
1002602|NCT02012439|mindfulness
1002603|NCT02012439|cognitive therapy
1002604|NCT02012413|knee
1002605|NCT02012413|chondromalacia
1002606|NCT02012413|patella
1002607|NCT02012413|pulsed signal therapy
1002608|NCT02012413|PST
1002609|NCT02012400|Asthma
1002610|NCT02012400|Exercise
1002611|NCT02012400|Asthma control
1002612|NCT02012400|Physical fitness
1002613|NCT02012400|Quality of life
1002614|NCT02012387|Cholinergic urticaria
1002615|NCT02012387|Omalizumab
1002616|NCT02012374|aphasia
1002617|NCT02012374|anomia
1002618|NCT02012374|speech therapy
1002619|NCT02012374|rehabilitation
1002620|NCT02012374|neuroplasticity
1002621|NCT02012374|fMRI
1002622|NCT02012374|quality of life
1002623|NCT02012361|Ischemic preconditioning
1002624|NCT02012361|Human limb ischemia
1002625|NCT02012361|Total knee arthroplasty
1002626|NCT02012361|Supplemental inspired helium
1002627|NCT02012348|bacteria survival, surfactants
1002628|NCT02012322|Aging
1002629|NCT02012322|Coenzyme Q10
1002630|NCT02012322|Q10
1002631|NCT02012322|Quality of Life
1002632|NCT02012322|Oxidative Stress
1002633|NCT02012322|Mitochondrial Function
1002634|NCT02012322|Cell Energetics
1002635|NCT02012322|Fatigue
1002636|NCT02012322|Ubiquinone
1002637|NCT02012309|HIV
1002638|NCT02012309|Streptococcus pneumoniae infection
1002639|NCT02012309|Streptococcus pneumoniae colonization
1002640|NCT02012309|Pneumococcal vaccines
1002641|NCT02012309|Prevnar
1002642|NCT02012309|Pneumovax
1002643|NCT02012309|Nasopharyngeal microbiome
1002644|NCT02012283|spices and vegetables
1002645|NCT02012270|Aortic Aneurysm
1002646|NCT02012270|Hernia
1002647|NCT02012270|Abdominal Wound Closure Techniques
1002648|NCT02012257|anterior middle superior alveolar nerve
1002649|NCT02012257|electric pulp tester
1002650|NCT02012257|local anesthesia
1002651|NCT02012244|analgesia; colorectal surgery; immunity; local anesthetics; opioids
1002652|NCT02012231|melanoma
1002653|NCT02012231|anaplastic thyroid cancer
1002654|NCT02012231|advanced papillary thyroid cancer
1002655|NCT02012231|colorectal cancer
1002656|NCT02012231|non-small cell lung cancer
1002657|NCT02012231|cholangiocarcinoma
1002658|NCT02012231|histiocytosis
1002659|NCT02012231|hairy cell leukemia
1002660|NCT02012218|Major Depressive Disorder, Depression
1002661|NCT02012205|wet cupping - back pain - NSLBP - Saudi
1002662|NCT02012192|High-grade serous
1002663|NCT02012192|high-grade endometrioid
1002664|NCT02012192|undifferentiated
1002665|NCT02012179|Diet
1002666|NCT02012179|Dietary sodium reduction
1002667|NCT02012179|Salt restriction
1002668|NCT02012179|Nutrition
1002669|NCT02012166|Diabetes Mellitus
1002670|NCT02012166|Diabetes Mellitus, Type 2
1002671|NCT02012166|Glucose Metabolism Disorders
1002672|NCT02012166|Metabolic Diseases
1002673|NCT02012166|Endocrine System Diseases
1002674|NCT02012166|Therapeutic Uses
1002675|NCT02012166|Pharmacologic Actions
1002676|NCT02012166|Molecular Mechanisms of Pharmacological Action
1002677|NCT02012166|Physiological Effects of Drugs
1002678|NCT02012153|Mesenchymal stromal cells
1002679|NCT02012153|Kidney transplantation
1002680|NCT02012153|Tolerance
1002681|NCT02012114|Cystinosis, compliance, cysteamine, neurological assessments
1002682|NCT02012101|COPD
1002683|NCT02012101|dyspnea
1002684|NCT02012101|exercise
1002685|NCT02012101|Noninvasive Ventilation
1002686|NCT02012088|Follicular lymphoma, large B-cell lymphoma
1002687|NCT02012062|Nasopharyngeal carcinoma
1002688|NCT02012062|Neoadjuvant chemotherapy
1002689|NCT02012062|Concurrent chemotherapy
1002690|NCT02012062|Nimotuzumab
1002691|NCT02012049|Healthy
1002692|NCT02012049|Risperdal OD
1002693|NCT02012049|Risperdal Quicklet
1002694|NCT02012049|Korea
1002695|NCT02012023|Low anterior resection
1002696|NCT02012023|Anastomotic leakage
1002697|NCT02012023|Defunctioning stoma
1002698|NCT02012023|Controllable tube ileostomy
1002699|NCT02012023|Loop ileostomy
1002700|NCT02012010|hysteroscopy, water intoxication, hyponatremia
1002701|NCT02011971|epilepsy
1002702|NCT02011971|cognition
1002703|NCT02011971|memory
1002704|NCT02011958|Visceral Leishmaniasis
1002705|NCT02011958|HIV positive patients
1002706|NCT02011958|Phase III trial
1002707|NCT02011958|Randomised
1002708|NCT02011958|Liposomal amphotericin B
1002709|NCT02011958|Ambisome
1002710|NCT02011958|Miltefosine
1002711|NCT02011958|Pentamidine
1002712|NCT02011958|Efficacy
1002713|NCT02011958|Safety
1002714|NCT02011906|antioxidant enzymes
1002715|NCT02011906|omega 3
1002716|NCT02011906|vitamin E
1002717|NCT02011906|CAD
1002718|NCT02011906|Sirtuins
1002719|NCT02011906|FOXOs
1002720|NCT02011880|breast cancer
1002721|NCT02011880|bone metastasis
1002722|NCT02011880|traditional Chinese medicine(TCM)
1002723|NCT02011867|Inner Ear Malformations
1002724|NCT02011867|Gusher
1002725|NCT02011867|Cochlear Implantation
1002726|NCT02011854|acupuncture，rehabilitation,Shoulder-hand Syndrome
1002727|NCT02011841|liver cirrhosis
1002728|NCT02011841|ascites
1002729|NCT02011841|spontaneous bacterial peritonitis
1002730|NCT02011841|recurrence
1002731|NCT02011828|Hemodialysis, paricalcitol
1002732|NCT02011815|Breast neoplasms
1002733|NCT02011815|Circadian rhythm
1002734|NCT02011815|sleep
1002735|NCT02011815|survival
1002736|NCT02011815|distress
1002737|NCT02011815|anxiety
1002738|NCT02011815|depression
1002739|NCT02011815|quality of life
1002740|NCT02011815|actigraph
1002741|NCT02011815|fatigue
1002746|NCT02011789|hypercholesterolemia
1002747|NCT02011789|inflammation
1002748|NCT02011789|citrus limonoids
1002749|NCT02011776|Corticosteroids Dry Eye Sjögren syndrome inflammation treatment
1002750|NCT02011763|Hepatitis A
1002751|NCT02011763|hepatitis A virus
1002752|NCT02011763|Avaxim® 80U Pediatric
1002753|NCT02011750|schizophrenia
1002754|NCT02011750|toxoplasmosis
1002755|NCT02011737|Medical Expulsive therapy
1002756|NCT02011698|Groin hernia
1002757|NCT02011698|lichtenstein herniorrhaphy
1002758|NCT02011672|dairy
1002759|NCT02011672|glucose
1002760|NCT02011672|inflammation
1002761|NCT02011659|Ramosetron, postoperative nausea and vomiting, laparoscopy
1002762|NCT02011646|diet
1002763|NCT02011646|body weight
1002764|NCT02011646|eating
1002765|NCT02011646|eating disorder
1002766|NCT02011646|exercise
1002767|NCT02011581|Overweight
1002768|NCT02011568|Therapeutic Hypothermia
1002769|NCT02011568|Out of hospital cardiac arrest
1002770|NCT02011568|Mild hypothermia
1002771|NCT02011568|Moderate hypothermia
1002772|NCT02011542|GWI
1002773|NCT02011542|IBS
1002774|NCT02011542|Irritable Bowel Syndrome
1002775|NCT02011542|Gulf War Illness
1002776|NCT02011516|Marijuana
1002777|NCT02011516|Addiction
1002778|NCT02011516|fMRI
1002779|NCT02011516|Baclofen
1002780|NCT02011516|Treatment
1002781|NCT02011477|Neural mobilization
1002782|NCT02011477|Physical therapy
1002783|NCT02011477|Asymptomatic subjects
1002784|NCT02011451|Multiple Sclerosis
1002785|NCT02011451|Green Tea
1002786|NCT02011451|ECGC
1002787|NCT02011451|Theaphenon
1002788|NCT02011451|Randomized placebo controlled trial
1002789|NCT02011451|NAA
1002790|NCT02011451|Spectroscopy
1002791|NCT02011451|Brain Atrophy
1002792|NCT02011451|SIENA
1002793|NCT02011438|Social Anxiety
1002794|NCT02011438|Prevention
1002795|NCT02011438|Peer Relations
1002796|NCT02011438|Depression
1002797|NCT02011438|Adolescent
1002798|NCT02011438|High School
1002799|NCT02011438|Interpersonal
1002800|NCT02011438|Peer Victimization
1002801|NCT02011425|obstructive sleep apnea
1002802|NCT02011425|oral appliance
1002803|NCT02011425|therapy
1002804|NCT02011425|masseter muscle activity
1002805|NCT02011425|randomized controlled trial
1002806|NCT02011425|mandibular advancement device
1002807|NCT02011425|mandibular advancement appliance
1002808|NCT02011425|arousals
1002809|NCT02011412|Trauma
1002810|NCT02011412|Scoring Systems
1002811|NCT02011412|Intermountain Risk Score
1002812|NCT02011399|brain
1002813|NCT02011399|computer
1002814|NCT02011399|interfaces
1002815|NCT02011399|mobility impairments
1002816|NCT02011373|prolapse, laparoscopic sacrocolpopexy, IFABONDTM glue
1002817|NCT02011360|Prader Willi syndrome
1002818|NCT02011360|childhood obesity
1002819|NCT02011360|ghrelin
1002820|NCT02011360|appetite regulation
1002821|NCT02011321|subarachnoid hemorrhage
1002822|NCT02011321|aneurysm
1002823|NCT02011321|vasospasm
1002824|NCT02011321|clevidipine
1002825|NCT02011321|transcranial dopplers
1002826|NCT02011295|OLT
1002827|NCT02011295|Surgical Intervention
1002828|NCT02011295|BMAC
1002829|NCT02011282|ICU,
1002830|NCT02011282|MYOPATHY,
1002831|NCT02011282|NEUROPATHY,
1002832|NCT02011282|PNEUMONIA
1002833|NCT02011269|TSO
1002834|NCT02011269|Ova
1002835|NCT02011269|Psoriasis
1002836|NCT02011269|plaque psoriasis
1002837|NCT02011269|plaque-type
1002838|NCT02011269|Coronado
1002839|NCT02011269|Moderate to severe plaque psoriasis
1002840|NCT02011256|Transient Ischemic Attack
1002841|NCT02011256|Atrial Fibrillation
1002842|NCT02011256|NOTICE
1002843|NCT02011256|Implantable loop-recorder
1002844|NCT02011256|Holter-monitoring
1002845|NCT02011243|deficit
1002846|NCT02011243|internal rotation
1002847|NCT02011243|gleno humeral articulation
1002848|NCT02011243|hand ball
1002849|NCT02011230|Dehydration
1002850|NCT02011230|Hoist
1002851|NCT02011230|pain control
1002852|NCT02011230|The intervention is to provide a commercially available isotonic hydration solution (Hoist®) to the patients.
1002853|NCT02011230|Patients will drink this solution post procedure as needed.
1002854|NCT02011230|Patients in the control group will use their discretion to drink any solution they feel suitable
1002855|NCT02011217|Rye
1002856|NCT02011217|Dietary Fibre
1002857|NCT02011217|Bread
1002858|NCT02011217|Crisp bread
1002859|NCT02011217|Appetite
1002860|NCT02011217|Satiety
1002861|NCT02011217|Hunger
1002862|NCT02011217|Desire to eat
1002863|NCT02011217|Metabolism
1002864|NCT02011217|Glucose
1002865|NCT02011217|Insulin
1002866|NCT02011217|Gut hormones
1002867|NCT02011217|Gastric emptying rate
1002868|NCT02011191|Biotin
1002869|NCT02011191|Restless
1002870|NCT02011191|Kidney
1002871|NCT02011191|Dialysis
1002872|NCT02011191|Renal
1002873|NCT02011165|Macular hole
1002874|NCT02011165|Vitrectomy
1002875|NCT02011165|Gas tamponade
1002876|NCT02011165|Vitreomacular traction in danger of macular hole formation
1002877|NCT02011165|Epiretinal membrane in danger of macular hole formation
1002878|NCT02011113|Pomalidomide,
1002879|NCT02011113|CC-4047,
1002880|NCT02011113|Dexamethasone,
1002881|NCT02011113|Relapsed and refractory multiple myeloma,
1002882|NCT02011113|phase 2
1002883|NCT02011061|Multidetector Computed Tomography
1002884|NCT02011061|Coronary Stenosis
1002885|NCT02011061|Coronary Artery Disease
1002886|NCT02011061|Angina Pectoris
1002887|NCT02011035|Oral health
1002888|NCT02011035|Mouth health
1002889|NCT02011035|Halitosis
1002890|NCT02011035|Oral bacteria
1002891|NCT02011035|Sore throat
1002892|NCT02011035|Colds
1002893|NCT02011022|Methotrexate,
1002894|NCT02011022|Pharmacokinetic
1002895|NCT02011022|Acute lymphoblastic leukemia
1002896|NCT02011022|Model
1002897|NCT02010970|phase I
1002898|NCT02010970|healthy volunteers
1002899|NCT02010970|AZD3293
1002900|NCT02010970|itraconazole
1002901|NCT02010970|diltiazem
1002902|NCT02010970|medazolam
1002903|NCT02010970|drug interactions
1002904|NCT02010970|Pharmacokinetics
1002905|NCT02010957|123I Iodometomidate imaging
1002906|NCT02010957|18F FDG positron emission tomography
1002907|NCT02010957|Adrenal tumour
1002908|NCT02010944|Solifenacin
1002909|NCT02010944|Mirabegron
1002910|NCT02010944|Fixed-dose combination (FDC)
1002911|NCT02010944|Single Entity Tablet (SET)
1002912|NCT02010944|Pharmacokinetics
1002913|NCT02010944|Bioavailability
1002914|NCT02010918|Knee Osteoarthritis;
1002915|NCT02010918|Glucosamine;
1002916|NCT02010918|Chondroitin.
1002917|NCT02010905|Losartan
1002918|NCT02010879|patent ductus arterioses
1002919|NCT02010879|ductal closure
1002920|NCT02010879|thrombocyte
1002921|NCT02010866|internship and residency
1002922|NCT02010866|physicians
1002923|NCT02010866|prevention
1002924|NCT02010866|counseling
1002925|NCT02010866|suicide
1002926|NCT02010866|depression
1002927|NCT02010866|burnout
1002928|NCT02010853|Transient Global amnesia
1002929|NCT02010853|fMRI
1002930|NCT02010853|resting state
1002931|NCT02010840|Depressive symptoms, marital relationship, quality of life
1002932|NCT02010827|Diabetes mellitus
1002933|NCT02010827|Glucagon
1002934|NCT02010827|Endogenous glucose production
1002935|NCT02010827|Incretin hormones
1002936|NCT02010814|PCOS
1002937|NCT02010814|Inflammation
1002938|NCT02010814|Body Composition
1002939|NCT02010801|hepatocellular carcinoma
1002940|NCT02010801|irreversible electroporation
1002941|NCT02010801|liver cancer
1002942|NCT02010762|Crohn's disease
1002943|NCT02010762|Vitamin D
1002944|NCT02010762|Postoperative
1002945|NCT02010762|Recurrence
1002946|NCT02010762|Inflammatory bowel disease
1002947|NCT02010762|Gastroenteritis
1002948|NCT02010762|Gastrointestinal Diseases
1002949|NCT02010762|Digestive System Diseases
1002950|NCT02010762|Colonic Diseases
1002951|NCT02010762|Intestinal Diseases
1002952|NCT02010762|Pathologic Processes
1002953|NCT02010736|Cerebral palsy
1002954|NCT02010736|Gait
1002955|NCT02010736|Weight Bearing
1002956|NCT02010736|Rehabilitation
1002957|NCT02010723|varicosis
1002958|NCT02010723|foam sclerotherapy
1002959|NCT02010723|surgery
1002960|NCT02010710|continuous electronic fetal monitoring
1002961|NCT02010710|labour
1002962|NCT02010710|pregnancy
1002963|NCT02010710|fetal distress
1002964|NCT02010697|smoking cessation
1002965|NCT02010697|nonsmokers
1002966|NCT02010697|proxy
1002967|NCT02010697|mail intervention
1002968|NCT02010697|self-help
1002969|NCT02010697|behavioral intervention
1002970|NCT02010684|Diabetes
1002971|NCT02010684|Depression
1002972|NCT02010684|Self care
1002973|NCT02010684|Empowerment
1002974|NCT02010684|Behavioral intervention
1002975|NCT02010684|Cognitive behavioral therapy
1002976|NCT02010684|Diabetes Mellitus, Type 2
1002977|NCT02010671|Pregnancy
1002978|NCT02010671|Cesarean Section
1002979|NCT02010671|Survey
1002980|NCT02010671|Delivery
1002981|NCT02010645|Leukemia
1002982|NCT02010645|Advanced Myelodysplastic Syndrome
1002983|NCT02010645|MDS
1002984|NCT02010645|Intermediate-2 Myelodysplastic Syndrome
1002985|NCT02010645|High-Risk Myelodysplastic Syndrome
1002986|NCT02010645|Chronic myelomonocytic leukemia
1002987|NCT02010645|CMML
1002988|NCT02010645|Eltrombopag
1002989|NCT02010645|Promacta
1002990|NCT02010645|Decitabine
1002991|NCT02010645|Dacogen
1002992|NCT02010632|Clopidogrel
1002993|NCT02010632|Platelet inhibition
1002994|NCT02010632|Platelet aggregation
1002995|NCT02010606|Newly diagnosed glioblastoma
1002996|NCT02010606|Recurrent glioblastoma
1002997|NCT02010606|Dendritic cell vaccine
1002998|NCT02010606|Immunotherapy
1002999|NCT02010606|Cancer stem cells
1003000|NCT02010606|Glioma stem cells
1003001|NCT02010606|Glioma stem-like cells
1003002|NCT02010606|Cancer stem-like cells
1003003|NCT02010606|Neurosphere
1003004|NCT02010606|Therapeutic Uses
1003005|NCT02010606|Antineoplastic Agents
1003006|NCT02010606|Neoplasms
1003007|NCT02010606|Immunologic Factors
1003008|NCT02010606|Interferon Inducers
1003009|NCT02010606|Physiological Effects of Drugs
1003010|NCT02010606|Pharmacologic Actions
1003011|NCT02010567|rectal cancer
1003012|NCT02010567|colorectal cancer
1003013|NCT02010567|locally advanced rectal cancer
1003014|NCT02010567|locally advanced rectal cancer (resectable)
1003015|NCT02010567|locally advanced rectal cancer (non-resectable)
1003016|NCT02010567|chemoradiotherapy
1003017|NCT02010567|nanopharmaceuticle
1003018|NCT02010567|CLX101
1003019|NCT02010567|camptothecin
1003020|NCT02010567|capecitabine
1003021|NCT02010554|Multiple Sclerosis
1003022|NCT02010554|Disease modifying medication
1003023|NCT02010554|Relapsing-Remitting MS
1003024|NCT02010554|Motivational Interviewing
1003025|NCT02010554|Telephone Counseling
1003026|NCT02010541|type 1 diabetes among young children, sensor, insulin pump, education, psychological support
1003027|NCT02010528|Diabetes related distress, children, T1D, family hardiness, psychological well-being
1003028|NCT02010515|sudden cardiac death
1003029|NCT02010515|risk stratification
1003030|NCT02010515|t-wave alternans
1003031|NCT02010515|Holter electrocardiography
1003032|NCT02010515|heart rate turbulence
1003033|NCT02010502|Beet root
1003034|NCT02010502|exercise performance
1003035|NCT02010502|cyclists
1003036|NCT02010489|Bariatric Surgery
1003037|NCT02010489|Exercise
1003038|NCT02010489|Physical Fitness
1003039|NCT02010476|Alzheimer's disease, CSF biomarkers, Insulin resistance
1003040|NCT02010463|reward processing
1003041|NCT02010463|impulse control
1003042|NCT02010463|obese
1003043|NCT02010463|clinically obese
1003044|NCT02010450|Sudden Infant Death Syndrome
1003045|NCT02010450|SIDS
1003046|NCT02010450|safe sleep
1003047|NCT02010450|safe sleep message
1003048|NCT02010437|Superficial Venous Insufficiency
1003049|NCT02010424|reduced fertility
1003050|NCT02010398|Resistance training/methods
1003051|NCT02010398|contralateral strength training
1003052|NCT02010398|ipsilateral strength training
1003053|NCT02010398|Isokinetic contraction
1003054|NCT02010398|Adaptation, Physiological/physiology
1003055|NCT02010398|Electromyography/methods
1003056|NCT02010398|Transcranial Magnetic Stimulation/methods
1003057|NCT02010398|Evoked Potentials, Motor
1003058|NCT02010385|RYGB
1003059|NCT02010385|Bariatric surgery
1003060|NCT02010385|Taste
1003061|NCT02010385|Reward
1003062|NCT02010385|Food behaviour
1003063|NCT02010385|Gut hormones
1003064|NCT02010372|Immunization Registry
1003065|NCT02010372|Human Papillomavirus
1003066|NCT02010346|Early orthodontic treatment
1003067|NCT02010346|Class II treatment
1003068|NCT02010346|Orthodontic treatment outcome
1003069|NCT02010320|population model
1003070|NCT02010320|pharmacokinetic
1003071|NCT02010320|tacrolimus
1003072|NCT02010320|therapeutic drug monitoring
1003073|NCT02010320|individualized dosing
1003074|NCT02010294|Invasive GAS infection
1003075|NCT02010294|emm genotypes
1003076|NCT02010294|Bacterial virulence factors
1003077|NCT02010294|Mendelian susceptibility to infections
1003078|NCT02010281|rTMS
1003079|NCT02010281|peripheral neuropathic pain
1003080|NCT02010281|randomized controlled trial
1003081|NCT02010268|Faecal calprotectin
1003082|NCT02010268|Feces
1003083|NCT02010268|Preterm neonates
1003084|NCT02010268|Enterocolitis
1003085|NCT02010268|Enteropathy
1003086|NCT02010268|Necrotizing
1003087|NCT02010242|Type 2 diabetes
1003088|NCT02010242|Proteinuria
1003089|NCT02010242|Albuminuria
1003090|NCT02010229|Placenta accreta
1003091|NCT02010229|previous caesarean
1003092|NCT02010229|placenta praevia
1003093|NCT02010229|severe obstetric haemorrhage
1003094|NCT02010229|population-based study
1003095|NCT02010203|TURBT
1003096|NCT02010203|Bladder
1003097|NCT02010203|Cancer
1003098|NCT02010203|GP96
1003099|NCT02010203|Vaccine
1003100|NCT02010203|Immunotherapy
1003101|NCT02010203|Heat Biologics
1003102|NCT02010203|BCG
1003103|NCT02010203|Bacillus Calmette-Guerin
1003104|NCT02010203|Bacillus Calmette-Guérin
1003105|NCT02010190|Pediatric malignancies
1003106|NCT02010190|Cancer survivors
1003107|NCT02010190|Coronary artery risk
1003108|NCT02010190|Vascular function
1003109|NCT02010190|Cardiovascular risk in survivors of pediatric cancer
1003110|NCT02010164|Reproductive aging
1003111|NCT02010164|Mitochondria
1003112|NCT02010151|Out of Hospital Cardiac Arrest
1003113|NCT02010151|Cardiopulmonary Resuscitation
1003114|NCT02010151|dispatch
1003115|NCT02010151|emergency medicine
1003116|NCT02010138|Internal Limiting Membrane
1003117|NCT02010138|Metamorphopsia
1003118|NCT02010125|Anterior Cruciate Ligament (ACL)
1003119|NCT02010125|Magnetic Resonance Imaging (MRI)
1003120|NCT02010125|Osteoarthritis (OA)
1003121|NCT02010125|Bio-specimens
1003122|NCT02010125|Acute ACL Injury
1003123|NCT02010125|Arthritis Foundation (AF)
1003124|NCT02010112|H.Pylori
1003125|NCT02010086|Intervention
1003126|NCT02010086|Autism
1003127|NCT02010086|Treatment sensitivity
1003128|NCT02010086|School aged
1003129|NCT02010086|Cognitive behavioral therapy
1003130|NCT02010086|Social Skills Intervention
1003131|NCT02010073|Lung
1003132|NCT02010073|ARDS
1003133|NCT02010073|acute
1003134|NCT02010073|respiratory
1003135|NCT02010073|syndrome
1003136|NCT02010073|prognosis
1003137|NCT02010073|outcome research
1003138|NCT02010073|respiratory infection
1003139|NCT02010073|sepsis
1003140|NCT02010073|organ failure
1003141|NCT02010073|hypoxaemia
1003142|NCT02010060|Exercise training
1003143|NCT02010060|Non-exercise physical activity
1003144|NCT02010060|pedometers
1003145|NCT02010047|Anaplastic lymphoma kinase gene
1003146|NCT02010047|Polymerase chain reaction
1003147|NCT02010047|Immunohistochemistry
1003148|NCT02010047|Fluorescence in situ hybridization
1003149|NCT02010034|TPN
1003150|NCT02010034|Liver Function
1003151|NCT02010034|parenteral nutritional fat emulsions
1003152|NCT02010021|breast cancer
1003153|NCT02010021|postmenopausal
1003154|NCT02010021|letrozole
1003155|NCT02010021|RAD001
1003156|NCT02010021|Everolimus
1003157|NCT02010008|breast cancer
1003158|NCT02010008|cancer disparities
1003159|NCT02010008|Latino women
1003160|NCT02010008|Hispanic women
1003161|NCT02010008|mammography
1003162|NCT02010008|multi-level intervention
1003163|NCT02009995|Diabetes Mellitus
1003164|NCT02009995|Type 2 Diabetes Mellitus
1003165|NCT02009995|Resistance Training
1003166|NCT02009995|Resistance Exercise
1003167|NCT02009995|Resistance Band
1003168|NCT02009995|Thera-band
1003169|NCT02009995|elastic band
1003170|NCT02009995|exercise band
1003171|NCT02009982|Fainting
1003172|NCT02009982|Ablation
1003173|NCT02009982|Cardiology
1003174|NCT02009982|Cardiac Electrophysiology
1003175|NCT02009969|Psychosis
1003176|NCT02009969|Adverse effects
1003177|NCT02009969|Symptom Severity
1003178|NCT02009969|Magnetic Resonance Imaging
1003179|NCT02009943|critical illness
1003180|NCT02009943|iron supplementation
1003181|NCT02009943|functional iron deficiency
1003182|NCT02009943|ICU anemia
1003183|NCT02009943|red blood cell transfusion
1003184|NCT02009930|Enlisted military members
1003185|NCT02009930|CAC
1003186|NCT02009930|Coronary Artery Calcium
1003187|NCT02009930|Cardiovascular
1003188|NCT02009917|Indicator Amino Acid Oxidation
1003189|NCT02009917|Non essential Amino acids
1003190|NCT02009917|Protein
1003191|NCT02009917|Amino acid
1003192|NCT02009904|PKU
1003193|NCT02009904|Phenylketonuria
1003194|NCT02009904|Phenylalanine
1003195|NCT02009904|Children
1003196|NCT02009904|Stable isotopes
1003197|NCT02009904|Sapropterin dihydrochloride responsiveness
1003198|NCT02009891|predictive model
1003199|NCT02009891|in vitro fertilization
1003200|NCT02009891|elective single embryo transfer
1003201|NCT02009878|SIADH
1003202|NCT02009865|Hypertriglyceridemia
1003203|NCT02009865|Dyslipidemia
1003204|NCT02009865|Eicosapentaenoic acid
1003205|NCT02009865|EPA
1003206|NCT02009865|Docosahexaenoic acid
1003207|NCT02009865|DHA
1003208|NCT02009852|microRNA-29b
1003209|NCT02009852|Oral squamous cell carcinoma
1003210|NCT02009852|migration
1003211|NCT02009852|prognosis
1003212|NCT02009839|anxiety
1003213|NCT02009839|frequency of speech
1003214|NCT02009839|selective mutism
1003215|NCT02009826|Schizophrenia
1003216|NCT02009826|Psychosis
1003217|NCT02009826|Neuroinflammation
1003218|NCT02009826|Microglial activation
1003219|NCT02009813|Insulin resistance
1003220|NCT02009813|Inflammation
1003221|NCT02009813|Hypoxia
1003222|NCT02009787|hypercholesterolemia; vitamin D; adjuvant therapy
1003223|NCT02009774|Colonoscopy
1003224|NCT02009774|Adenoma detection rate
1003225|NCT02009774|Narrow band imaging
1003226|NCT02009774|Optical biopsy
1003227|NCT02009774|Accuracy
1003228|NCT02009735|Enterovirus 71 and Influenza Virus
1003229|NCT02009722|Cesarean Delivery
1003230|NCT02009722|Intrathecal Morphine
1003231|NCT02009722|Intrathecal Hydromorphone
1003232|NCT02009722|Obstetrical Analgesia
1003233|NCT02009722|Spinal Anesthesia
1003234|NCT02009709|keratoconus
1003235|NCT02009709|collagen crosslinking
1003236|NCT02009709|crosslinking
1003237|NCT02009709|ectasia
1003238|NCT02009644|Abdominal Aortic Aneurysm
1003239|NCT02009644|AAA
1003240|NCT02009644|Aneurysm
1003241|NCT02009631|Solid Tumors
1003242|NCT02009631|Ovarian Cancer
1003243|NCT02009631|Colon Cancer
1003244|NCT02009631|Lung Cancer
1003245|NCT02009631|Breast Cancer
1003246|NCT02009631|Gastric Cancer
1003247|NCT02009618|IBS
1003248|NCT02009618|Rifaximin
1003249|NCT02009605|icotinib, SCC
1003250|NCT02009592|Hepatosteatosis
1003251|NCT02009592|Steatohepatitis
1003252|NCT02009592|Rifaximin
1003253|NCT02009592|Inflammatory cytokines
1003254|NCT02009579|Uterine Cervical Cancer
1003255|NCT02009579|Paclitaxel
1003256|NCT02009579|Carboplatin
1003257|NCT02009579|Nintedanib
1003258|NCT02009553|Anxiety
1003259|NCT02009553|Urodynamics
1003260|NCT02009514|Hemodialysis
1003261|NCT02009514|Continuous glucose monitoring
1003262|NCT02009514|Hypoglycemia
1003263|NCT02009514|Hyperglycemia
1003264|NCT02009501|Infected wounds
1003265|NCT02009501|NPWTi
1003266|NCT02009501|VAC Instill
1003267|NCT02009501|Biofilm
1003268|NCT02009488|Diabetes Mellitus, Type 2
1003269|NCT02009488|Metformin
1003270|NCT02009488|Canagliflozin
1003271|NCT02009488|INVOKANA®
1003272|NCT02009488|Insulin sensitivity
1003273|NCT02009488|DPP-4 inhibitor
1003274|NCT02009488|dipeptidyl peptidase-4
1003275|NCT02009475|Rehabilitation
1003276|NCT02009475|Exercise Training
1003277|NCT02009475|Interval training
1003278|NCT02009462|HIV
1003279|NCT02009462|Facial lipoatrophy
1003280|NCT02009449|Phase 1/Phase 1b
1003281|NCT02009449|Oncology
1003282|NCT02009449|Cancer
1003283|NCT02009449|Solid Tumors
1003284|NCT02009423|Gastro-Intestinal Stromal Tumour, GIST, localized primary tumor, complete surgery, adjuvant therapy.
1003285|NCT02009410|Exocrine Pancreatic Insufficiency
1003286|NCT02009358|mental health promotion
1003287|NCT02009358|depression
1003288|NCT02009358|migrant workers
1003289|NCT02009358|China
1003290|NCT02009345|Familial hypercholesterolemia,
1003291|NCT02009345|High LDL-cholesterol
1003292|NCT02009345|Registry
1003293|NCT02009345|Coronary artery disease
1003294|NCT02009319|endobronchial ultrasound
1003295|NCT02009319|EBUS - TBNA
1003296|NCT02009319|elastography
1003297|NCT02009319|strain ratio
1003298|NCT02009319|lung cancer staging
1003299|NCT02009306|Palliative
1003300|NCT02009306|Symptom control
1003301|NCT02009306|Hospice
1003302|NCT02009306|Opioid
1003303|NCT02009306|Benzodiazepine
1003304|NCT02009293|idiopathic pulmonary fibrosis
1003305|NCT02009293|cough
1003306|NCT02009293|quality of life
1003307|NCT02009280|Propofol
1003308|NCT02009280|Lung transplantation
1003309|NCT02009280|Extracorporeal membrane oxygenation
1003310|NCT02009280|Acute kidney injury
1003311|NCT02009241|Lymphangioleiomyomatosis
1003312|NCT02009241|Rehabilitation
1003313|NCT02009241|Exercise
1003314|NCT02009228|Single-port laparoscopy
1003315|NCT02009228|Abdominal pain
1003316|NCT02009228|Ovarian spillage
1003317|NCT02009228|Endobag rupture
1003318|NCT02009228|Ovarian reserve
1003319|NCT02009215|Uganda
1003320|NCT02009215|intermittent preventive treatment
1003321|NCT02009215|dihydroartemisinin-piperaquine
1003322|NCT02009215|schoolchildren
1003323|NCT02009215|malaria
1003324|NCT02009202|Colon preparation
1003325|NCT02009202|Child
1003326|NCT02009189|home parenteral nutrition
1003327|NCT02009189|central venous catheter
1003328|NCT02009176|Hepatocellular Carcinoma
1003329|NCT02009176|Laparoscopic
1003330|NCT02009176|Aon-anatomical hepatectomy
1003331|NCT02009176|Anatomical hepatectomy
1003332|NCT02009176|Micrometastases
1003333|NCT02009137|small breast
1003334|NCT02009137|augmentation
1003335|NCT02009137|breast volume
1003336|NCT02009137|External Soft Tissue Expansion System(ESTES)
1003337|NCT02009124|spinal cord injury
1003338|NCT02009124|stem cell therapy
1003339|NCT02009124|bone marrow
1003340|NCT02009124|mononuclear cells
1003341|NCT02009124|autologous
1003342|NCT02009111|Transition to parenthood
1003343|NCT02009111|Relationship intervention
1003344|NCT02009098|Randomized Controlled Trial
1003345|NCT02009098|Caesarean Section
1003346|NCT02009098|preoperative
1003347|NCT02009098|intraoperative
1003348|NCT02009098|prophylactic antibiotics
1003349|NCT02009098|antibiotics
1003350|NCT02009098|timing
1003351|NCT02009098|surgical site infections
1003352|NCT02009098|endometritis
1003353|NCT02009098|wound infections
1003354|NCT02009098|urinary tract infections
1003355|NCT02009098|infectious morbidity
1003356|NCT02009098|neonatal antibiotics exposure
1003357|NCT02009098|Antibiotic Prophylaxis
1003358|NCT02009072|Pterygium surgery
1003359|NCT02009072|Sutureless glue free conjunctival autograft
1003360|NCT02009072|Amniotic membrane graft.
1003361|NCT02009059|hypothermia
1003362|NCT02009059|Temperature
1003363|NCT02009059|epitympanic
1003364|NCT02009059|pre-hospital
1003365|NCT02009046|Adolescent
1003366|NCT02009046|Sex education
1003367|NCT02009046|Sexuality education
1003368|NCT02009046|Sexually transmitted diseases
1003369|NCT02009046|Pregnancy
1003370|NCT02009046|Sexual behavior
1003371|NCT02009046|Sexuality
1003372|NCT02009046|Relationship rights
1003373|NCT02009046|Gender norms
1003374|NCT02009046|Human rights
1003375|NCT02009046|Intervention studies
1003376|NCT02009046|Parent intervention
1003377|NCT02009046|Peer intervention
1003378|NCT02009007|cerebral oximeter
1003379|NCT02009007|one lung ventilation
1003380|NCT02009007|dopamine
1003381|NCT02009007|phenylephrine
1003382|NCT02008994|metastatic breast cancer
1003383|NCT02008994|breast cancer
1003384|NCT02008994|genomics
1003385|NCT02008994|personalized medicine
1003386|NCT02008994|precision oncology
1003387|NCT02008994|breast cancer treatment
1003388|NCT02008994|metastatic breast cancer treatment
1003389|NCT02008994|genetic testing and breast cancer treatment
1003390|NCT02008994|breast cancer trial
1003391|NCT02008994|metastatic breast cancer trial
1003392|NCT02008955|lysine, indicator amino acid oxidation, elderly females
1003393|NCT02008929|NKCELL
1003394|NCT02008916|AIN457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, secukinumab, self-injection
1003395|NCT02008890|palmoplantar, pustular, psoriasis
1003396|NCT02008877|Malignant Peripheral Nerve Sheath Tumors
1003397|NCT02008877|MPNST
1003398|NCT02008877|Sarcoma
1003399|NCT02008877|Ganetespib
1003400|NCT02008877|Sirolimus
1003401|NCT02008877|mTOR inhibitor
1003402|NCT02008877|Heat shock protein
1003403|NCT02008877|Hsp90
1003404|NCT02008864|End stage renal diseases
1003405|NCT02008864|Hemodialysis
1003406|NCT02008864|Uremic pruritus
1003407|NCT02008864|Iranian traditional medicine
1003408|NCT02008864|Cassia angustifolia
1003409|NCT02008851|Chronic kidney disease
1003410|NCT02008851|Type 2 Diabetes
1003411|NCT02008851|Neo-kidney augment
1003412|NCT02008851|Regenerative medicine
1003413|NCT02008825|ViSiGi
1003414|NCT02008825|Calibration tube
1003415|NCT02008825|Sleeve gastrectomy
1003416|NCT02008812|Adenovirus
1003417|NCT02008799|Stem cell, infertility, Azoospermia
1003418|NCT02008786|Coronary Artery Dissection, Spontaneous
1003419|NCT02008786|Angina
1003420|NCT02008773|schizophrenia
1003421|NCT02008773|schizoaffective
1003422|NCT02008773|schizophreniform
1003423|NCT02008773|inflammatory markers
1003424|NCT02008773|HSV1
1003425|NCT02008773|cognition
1003426|NCT02008773|early psychosis
1003427|NCT02008773|valacyclovir
1003428|NCT02008760|pain
1003429|NCT02008760|quality of life
1003430|NCT02008760|ADL
1003431|NCT02008760|DOLO test
1003432|NCT02008760|compliance
1003433|NCT02008760|D3
1003434|NCT02008747|Atrial fibrillation
1003435|NCT02008747|Neuropathic pain
1003436|NCT02008747|Posterolateral thoracotomy
1003437|NCT02008747|Lung resection
1003438|NCT02008721|Multiple System Atrophy
1003439|NCT02008721|epigallocatechin gallate
1003440|NCT02008708|Health
1003441|NCT02008708|Microfinance
1003442|NCT02008695|Health
1003443|NCT02008695|Youth
1003444|NCT02008695|Microfinance
1003445|NCT02008669|Multiple Sclerosis, Fatigue, Nutritional Status, Disability.
1003446|NCT02008656|CAPECITABINE (ORAL)
1003447|NCT02008656|FLUOROURACIL
1003448|NCT02008656|LEUCOVORIN
1003449|NCT02008656|OXALIPLATIN
1003450|NCT02008656|Total mesorectal excision
1003451|NCT02008656|Chemoradiation therapy
1003452|NCT02008656|Total neoadjuvant therapy
1003453|NCT02008656|13-213
1003454|NCT02008643|Health related quality of life, food allergy, children, chronic diseases
1003455|NCT02008617|Anterior cruciate ligament reconstruction
1003456|NCT02008604|ischemia
1003457|NCT02008604|stroke
1003458|NCT02008604|transient ischemic attack (TIA)
1003459|NCT02008604|microbiome
1003460|NCT02008604|microbiota
1003461|NCT02008604|gut
1003462|NCT02008591|Neuraxial Technique
1003463|NCT02008591|Epidural Technique
1003464|NCT02008591|Dural Puncture Epidural Technique
1003465|NCT02008591|Combined Spinal Epidural Technique
1003466|NCT02008591|Labor Analgesia
1003467|NCT02008591|Obstetric
1003468|NCT02008578|Antiviral
1003469|NCT02008578|Adjunctive Therapy
1003470|NCT02008578|Antibody
1003471|NCT02008565|Fecal incontinence
1003472|NCT02008565|Loperamide
1003473|NCT02008565|anal exercises
1003474|NCT02008565|biofeedback
1003478|NCT02008526|Text Messaging
1003479|NCT02008526|mHealth
1003480|NCT02008526|Methamphetamine
1003481|NCT02008526|HIV
1003482|NCT02008526|AIDS
1003483|NCT02008513|AFFITOPE® AD02
1003484|NCT02008513|Alzheimer Disease
1003485|NCT02008513|Dementia
1003486|NCT02008513|Brain Disease
1003487|NCT02008513|Nervous System Diseases
1003488|NCT02008513|Tauopathies
1003489|NCT02008513|Neurodegenerative Diseases
1003490|NCT02008513|Mental Disorders
1003491|NCT02008500|Dentinal Hypersensitivity
1003492|NCT02008500|Gingival Recession
1003493|NCT02008500|Visual Analogue Score
1003494|NCT02008487|wound
1003495|NCT02008487|palliative care
1003496|NCT02008487|hospice
1003497|NCT02008487|pressure ulcers
1003498|NCT02008435|Group-delivered Diabetes Prevention Program
1003499|NCT02008435|Obesity
1003500|NCT02008435|Overweight
1003501|NCT02008435|Lifestyle change
1003502|NCT02008435|Healthy eating
1003503|NCT02008435|Weight loss
1003504|NCT02008435|Exercise
1003505|NCT02008435|Cognitive-behavioral intervention
1003506|NCT02008435|Implementation intentions
1003507|NCT02008435|Mental imagery
1003508|NCT02008435|Mental practice
1003509|NCT02008435|If-then plans
1003510|NCT02008409|Minimally Invasive Surgery
1003511|NCT02008409|EndoLift Liver Retractor
1003512|NCT02008396|MDMA
1003513|NCT02008396|autism
1003514|NCT02008396|social anxiety
1003515|NCT02008383|Colorectal cancer
1003516|NCT02008383|Panitumumab
1003517|NCT02008383|Cabozantinib
1003518|NCT02008370|minimally invasive cardiac surgery
1003519|NCT02008370|Exparel
1003520|NCT02008357|Cognition
1003521|NCT02008357|Prevention
1003522|NCT02008344|influenza
1003523|NCT02008344|flu
1003524|NCT02008344|fever
1003525|NCT02008344|cough
1003526|NCT02008344|body aches
1003527|NCT02008344|headache
1003528|NCT02008344|nasal congestion
1003529|NCT02008344|body pains
1003530|NCT02008344|sore throat
1003531|NCT02008344|fatigue
1003532|NCT02008344|T-705
1003533|NCT02008344|favipiravir
1003534|NCT02008344|favor
1003535|NCT02008344|flu symptoms
1003536|NCT02008331|chronic kidney disease
1003537|NCT02008331|p-cresol
1003538|NCT02008331|synbiotic
1003539|NCT02008292|smoking
1003540|NCT02008292|schizophrenia
1003541|NCT02008292|acetylcholine
1003542|NCT02008279|Healthy
1003543|NCT02008279|CNTO 3157
1003544|NCT02008279|Pharmacokinetics
1003545|NCT02008253|INTRASTROMAL CORNEAL RING
1003546|NCT02008253|ASTIGMATISM
1003547|NCT02008240|Infertility
1003548|NCT02008240|Hydrosalpinx
1003549|NCT02008240|IVF-ET
1003550|NCT02008240|Salpingectomy
1003551|NCT02008214|Pentoxifylline
1003552|NCT02008214|Sustained virologic response
1003553|NCT02008214|Hepatic fibrosis
1003554|NCT02008201|dose-response study
1003555|NCT02008188|Type 1 Diabetes Mellitus
1003556|NCT02008188|Artificial Pancreas
1003557|NCT02008188|Closed Loop Control
1003558|NCT02008188|Diabetes Assistant (DiAs)
1003559|NCT02008188|Continuous Glucose Monitor (CGM)
1003560|NCT02008188|Insulin Pump
1003561|NCT02008188|Metabolic Diseases
1003562|NCT02008188|Endocrine System Diseases
1003563|NCT02008188|Autoimmune Diseases
1003564|NCT02008175|paediatric, keratoconus, collagen cross linking
1003565|NCT02008162|Emphysema, COPD, bronchoreversibility, ventilatory obstruction, lung volume reduction surgery, LVRS
1003566|NCT02008149|Osteoporosis
1003567|NCT02008136|myofascial pain
1003568|NCT02008136|muscle spasm
1003569|NCT02008136|botulinum toxin
1003570|NCT02008136|cervicalgia
1003571|NCT02008136|lumbago
1003572|NCT02008136|low back pain
1003573|NCT02008123|Clopidogrel
1003574|NCT02008123|Clopidogrel Resistance
1003575|NCT02008123|Primidone
1003576|NCT02008123|Secondary Stroke Prevention
1003577|NCT02008110|Heart failure
1003578|NCT02008110|Biomarker guided-therapy
1003579|NCT02008110|Carbohydrate antigen 125
1003580|NCT02008110|Clinical outcomes.
1003581|NCT02008097|Ultrasound
1003582|NCT02008097|Ultrasonography
1003583|NCT02008097|Liver transplantation
1003584|NCT02008097|Arterial Occlusive Diseases
1003585|NCT02008097|Hypertension
1003586|NCT02008097|Pregnancy, High Risk
1003587|NCT02008097|Pregnancy
1003588|NCT02008084|hypertriglyceridemia
1003589|NCT02008084|mixed hyperlipidemia
1003590|NCT02008058|Metastatic Castrate-Resistant Prostate Cancer
1003591|NCT02008058|LCCC 1231
1003592|NCT02008058|Lineberger Comprehensive Cancer Center
1003593|NCT02008058|UNC Lineberger
1003594|NCT02008058|Prostate Cancer
1003595|NCT02008058|Pain
1003596|NCT02008045|MRI
1003597|NCT02008045|Imaging
1003598|NCT02008045|Neurocognitive
1003599|NCT02008045|White matter injury
1003600|NCT02008032|Mammography
1003601|NCT02008032|Breast
1003602|NCT02008032|Implants
1003603|NCT02008019|Chondrosarcoma
1003604|NCT02008019|Neoadjuvant therapy
1003605|NCT02008019|Phase II
1003606|NCT02008019|Everolimus
1003607|NCT02008019|Success Rate
1003608|NCT02008019|Progression Free Survival
1003609|NCT02008019|Overall Survival
1003610|NCT02008019|Safety
1003611|NCT02008019|Quality of Life
1003612|NCT02008019|Molecular study (ancillary study)
1003613|NCT02008006|Follicular Lymphoma
1003614|NCT02008006|Chemosensitive relapse
1003615|NCT02008006|High Dose Chemotherapy
1003616|NCT02008006|Bendamustine
1003617|NCT02008006|BeEAM
1003618|NCT02008006|Autologous Stem Cell Transplantation
1003619|NCT02008006|Safety
1003620|NCT02008006|Event Free Survival
1003621|NCT02008006|Overall Response Rate
1003622|NCT02008006|Progression Free Survival
1003623|NCT02008006|Overall Survival
1003624|NCT02008006|Phase II
1003625|NCT02008006|World Health Organization (WHO) 1 grade
1003626|NCT02008006|WHO 2 grade
1003627|NCT02008006|WHO 3a grade
1003628|NCT02007993|Halitosis,
1003629|NCT02007993|Photodynamic Therapy,
1003630|NCT02007993|Adolescent
1003631|NCT02007980|urological problems
1003632|NCT02007980|indwelling urologic stent
1003633|NCT02007980|kidney stone disease
1003634|NCT02007980|urinary system obstruction
1003635|NCT02007980|hydronephrosis
1003636|NCT02007980|ureteral damage
1003637|NCT02007954|HCC
1003638|NCT02007915|Adolescent
1003639|NCT02007915|Avascular Necrosis
1003640|NCT02007915|Bisphosphonates
1003641|NCT02007915|Pamidronate
1003642|NCT02007902|Preterm baby
1003643|NCT02007902|Total plasma protein
1003644|NCT02007902|Albumin
1003645|NCT02007902|Hemodynamic disturbances
1003646|NCT02007902|Perfusion
1003647|NCT02007902|Near Infra Red Spectroscopy (NIRS)
1003648|NCT02007902|Ultrasound
1003649|NCT02007876|Mobility
1003650|NCT02007876|Activity
1003651|NCT02007876|Training
1003652|NCT02007876|Abdominal
1003653|NCT02007876|Surgery
1003654|NCT02007876|Adult
1003655|NCT02007863|Leukemia
1003656|NCT02007863|Myelodysplasia
1003657|NCT02007863|Acute lymphocytic leukemia
1003658|NCT02007863|ALL
1003659|NCT02007863|Acute myelogenous leukemia
1003660|NCT02007863|AML
1003661|NCT02007863|Pediatric
1003662|NCT02007850|continuous femoral nerve block
1003663|NCT02007850|knee arthroplasty
1003664|NCT02007850|quadriceps muscle strength
1003665|NCT02007837|pregnancy induced hypertension
1003666|NCT02007837|gestational hypertension
1003667|NCT02007837|pre-eclampsia
1003668|NCT02007837|preeclampsia
1003669|NCT02007837|hypertensive disorders in pregnancy
1003670|NCT02007824|pressure ulcer
1003671|NCT02007824|chronic wound
1003672|NCT02007824|tissue necrosis
1003673|NCT02007824|slough
1003674|NCT02007824|ultra sound
1003675|NCT02007798|dexmedetomidine
1003676|NCT02007798|supratentorial tumors
1003677|NCT02007785|Cognitive Orientation to daily Occupational Performance
1003678|NCT02007785|CO-OP
1003679|NCT02007772|COPD, nHF, BiPAP
1003680|NCT02007759|Dysphagia
1003681|NCT02007759|neuromuscular electrical stimulation
1003682|NCT02007759|NMES
1003683|NCT02007759|Neonates
1003684|NCT02007759|Vitalstim
1003685|NCT02007746|sickle cell disease
1003686|NCT02007746|hemochromatosis
1003687|NCT02007746|liver fibrosis
1003688|NCT02007746|liver cirrhosis
1003689|NCT02007746|FibroScan
1003690|NCT02007746|Ferriscan
1003691|NCT02007746|liver iron
1003692|NCT02007733|Diarrhea
1003693|NCT02007733|Dehydration
1003694|NCT02007733|Children
1003695|NCT02007733|Resuscitation
1003696|NCT02007733|Clinical Prediction Rule
1003697|NCT02007733|Low Income Country
1003698|NCT02007733|Bangladesh
1003699|NCT02007720|Serelaxin,
1003700|NCT02007720|WHF,
1003701|NCT02007720|Likert Scale,
1003702|NCT02007720|RELAX-AHF-ASIA,
1003703|NCT02007720|RLX030,
1003704|NCT02007720|AHF,
1003705|NCT02007720|acute heart failure
1003706|NCT02007707|Asian American
1003707|NCT02007707|Vietnamese American
1003708|NCT02007707|Smoking cessation
1003709|NCT02007707|Community Health Worker
1003710|NCT02007707|Lay Health Worker Outreach
1003711|NCT02007707|Family Intervention
1003712|NCT02007694|Phobic Disorders (Fear of Flying and acrophobia)
1003713|NCT02007694|Virtual Reality Exposure Therapy
1003714|NCT02007694|Fear extinction
1003715|NCT02007694|propranolol
1003716|NCT02007694|Yohimbine
1003717|NCT02007681|Sedentary Behavior; Breaks; Workplace; Energy Expenditure; Physical activity; doubly labeled water
1003718|NCT02007668|low back pain
1003719|NCT02007668|kinesio taping
1003720|NCT02007655|Cardiovascular
1003721|NCT02007616|Cognitive aging
1003722|NCT02007616|Video games training
1003723|NCT02007616|Attention
1003724|NCT02007616|Memory
1003725|NCT02007616|Wellbeing
1003726|NCT02007616|Speed of processing
1003727|NCT02007616|Executive functions
1003728|NCT02007603|chronic hemodialysis
1003729|NCT02007603|ampicillin
1003730|NCT02007603|sulbactam
1003731|NCT02007603|amoxicillin
1003732|NCT02007603|clavulanic acid
1003733|NCT02007603|pharmacokinetics
1003734|NCT02007577|insulin resistant
1003735|NCT02007564|Palliative care dyads
1003736|NCT02007564|Volunteers
1003737|NCT02007564|Community-based
1003738|NCT02007564|Mixed methods
1003739|NCT02007551|Social Isolation
1003740|NCT02007551|Nutrition Assessments
1003741|NCT02007551|Food Habits
1003742|NCT02007551|Meals
1003743|NCT02007551|Self Efficacy
1003744|NCT02007551|Quality of Life
1003745|NCT02007551|Peer Group
1003746|NCT02007538|Lung Cancer
1003747|NCT02007538|Bronchoscopy
1003748|NCT02007538|Fine Need Aspiration
1003749|NCT02007538|Cytochemical Assays
1003750|NCT02007512|advanced breast cancer
1003751|NCT02007512|enzalutamide
1003752|NCT02007512|MDV3100
1003753|NCT02007512|Estrogen receptor positive (ER +)
1003754|NCT02007512|Progesterone receptor positive (PgR +)
1003755|NCT02007512|HER-2 normal
1003756|NCT02007499|Prehospital emergency care
1003757|NCT02007499|Out of hospital cardiac arrest
1003758|NCT02007499|Cardiopulmonary resuscitation
1003759|NCT02007499|CPR
1003760|NCT02007499|Heart arrest
1003761|NCT02007499|Outcome
1003762|NCT02007499|Bystander
1003763|NCT02007486|Heart Failure
1003764|NCT02007486|Exercise
1003765|NCT02007486|Dyspnea
1003766|NCT02007486|Diaphragm electromyogram
1003767|NCT02007486|Respiratory mechanics
1003768|NCT02007473|Haemovigilance
1003769|NCT02007473|Plasma
1003770|NCT02007473|Pathogen reduction
1003771|NCT02007473|Methylene Blue
1003773|NCT02007421|Human Papillomavirus,
1003774|NCT02007421|Anal High Grade Squamous intraepithelial lesions,
1003775|NCT02007421|Homosexual Men
1003776|NCT02007421|High resolution anoscopy,
1003777|NCT02007421|Cancer Screening
1003778|NCT02007421|HIV
1003779|NCT02007408|abortion
1003780|NCT02007408|analgesia
1003781|NCT02007408|paracervical block
1003782|NCT02007408|lidocaine spray
1003783|NCT02007343|Enterobacteriaceae
1003784|NCT02007343|Pseudomonas
1003785|NCT02007343|Acinetobacter
1003786|NCT02007343|Stenotrophomonas
1003787|NCT02007343|Mortality
1003788|NCT02007343|Morbidity
1003789|NCT02007343|Cost of Illness
1003790|NCT02007343|Causality
1003791|NCT02007343|Multicenter Study
1003792|NCT02007343|Cohort Studies
1003793|NCT02007343|Case-Control Studies
1003794|NCT02007343|Prospective Studies
1003795|NCT02007343|Follow-up Studies
1003796|NCT02007330|systemic lidocaine
1003797|NCT02007330|postoperative pain
1003798|NCT02007330|recovery, pediatric
1003799|NCT02007330|inguinal hernia
1003800|NCT02007330|laparoscopy
1003801|NCT02007317|BCC
1003802|NCT02007291|Alzheimer, MMSE, response, colinesterase inhibitors (ChEI)
1003803|NCT02007278|diabetes
1003804|NCT02007278|hypoglycemia
1003805|NCT02007278|glycemic variability
1003806|NCT02007278|vildagliptin
1003807|NCT02007278|glimepiride
1003808|NCT02007252|Abdominal Aortic Aneurysm
1003809|NCT02007252|AAA
1003810|NCT02007252|IL-1b
1003811|NCT02007252|Abdominal ultrasound
1003812|NCT02007239|tocilizumab
1003813|NCT02007239|hemophagocytic lymphohistiocytosis (HLH)
1003814|NCT02007239|cytokine
1003815|NCT02007239|cytokine release syndrome
1003816|NCT02007226|Coronary Heart Disease
1003817|NCT02007226|spinal cord injury
1003818|NCT02007226|risk factor
1003819|NCT02007226|postprandial lipemia
1003820|NCT02007213|Neuromuscular Disease
1003821|NCT02007213|Motor Function
1003822|NCT02007213|Proxy Reported Outcome
1003823|NCT02007213|Young Children
1003824|NCT02007187|Unstable Angina Pectoris
1003825|NCT02007187|Randomized Controlled Trial
1003826|NCT02007187|Traditional Chinese Medicine
1003827|NCT02007174|recurrent pterygium
1003828|NCT02007174|bevacizumab
1003829|NCT02007174|triple dose
1003830|NCT02007148|gastric adenocarcinoma,
1003831|NCT02007148|capecitabine,
1003832|NCT02007148|second line treatment,
1003833|NCT02007148|recurrent or metastatic disease,
1003834|NCT02007148|overall survival,
1003835|NCT02007148|tumor response,
1003836|NCT02007148|quality of life
1003837|NCT02007122|HD
1003838|NCT02007122|CVVH
1003839|NCT02007122|renal replacement therapy
1003840|NCT02007122|ceftaroline
1003841|NCT02007122|pharmacokinetics
1003842|NCT02007096|Transabdominal plane block
1003843|NCT02007096|ventral hernia
1003844|NCT02007096|umbilical hernia
1003845|NCT02007096|incisional hernia
1003846|NCT02007096|hernia repair
1003847|NCT02007083|Lumbar Spinal stenosis
1003848|NCT02007083|Surgical treatment of LSS.
1003849|NCT02007070|PD1
1003850|NCT02007070|PD-1
1003851|NCT02007070|PDL1
1003852|NCT02007070|PD-L1
1003853|NCT02007057|Suprascapular nerve block
1003854|NCT02007057|Interscalene nerve block
1003855|NCT02007044|Leukemia
1003856|NCT02007044|Chronic lymphocytic leukemia
1003857|NCT02007044|CLL
1003858|NCT02007044|Relapsed
1003859|NCT02007044|Ibrutinib
1003860|NCT02007044|PCI-32765
1003861|NCT02007044|Rituximab
1003862|NCT02007044|Rituxan
1003863|NCT02007031|Hypertension
1003864|NCT02007031|Cold temperature
1003865|NCT02007031|Blood pressure
1003866|NCT02007031|Electrocardiography
1003867|NCT02007018|Surgical Site Infections
1003868|NCT02007018|Colorectal Resection
1003869|NCT02007018|Negative Pressure Wound Therapy
1003870|NCT02007005|superficial bladder cancer
1003871|NCT02007005|mistletoe extract
1003872|NCT02007005|maximum tolerated dose
1003873|NCT02007005|marker tumor
1003874|NCT02007005|remission
1003875|NCT02007005|recurrence rate
1003876|NCT02006979|cardiotoxicity
1003877|NCT02006979|Chemotherapy, Adjuvant
1003878|NCT02006979|Breast Neoplasms
1003879|NCT02006979|Exercise
1003880|NCT02006979|Cardiotoxins
1003881|NCT02006979|Echocardiography
1003882|NCT02006979|Speckle tracking
1003883|NCT02006979|Biological Markers
1003884|NCT02006979|Electrocardiography
1003885|NCT02006966|Systemic lidocaine
1003886|NCT02006966|postoperative pain
1003887|NCT02006966|Video-assisted thoracic surgery
1003888|NCT02006966|VATS
1003889|NCT02006953|gastrostomy
1003890|NCT02006953|enteral
1003891|NCT02006940|alveoflex
1003892|NCT02006940|probe-based confocal laser endomicroscopy
1003893|NCT02006940|pCLE
1003894|NCT02006940|alveoscopy
1003895|NCT02006940|morphology
1003896|NCT02006940|high resolution computed tomography
1003897|NCT02006927|Prostate Cancer
1003898|NCT02006914|Insulin resistance
1003899|NCT02006914|HIV disease
1003900|NCT02006914|chromium picolinate
1003901|NCT02006901|surgical procedures, operative
1003902|NCT02006901|lumbar vertebrae
1003903|NCT02006901|decompression, surgical
1003904|NCT02006901|microdecompression
1003905|NCT02006901|laminectomy
1003906|NCT02006901|registries
1003907|NCT02006888|Inflammation
1003908|NCT02006888|cataract surgery
1003909|NCT02006875|repetitive transcranial magnetic stimulation
1003910|NCT02006875|postural
1003911|NCT02006875|balance
1003912|NCT02006875|mobility
1003913|NCT02006875|leg
1003914|NCT02006875|stroke
1003915|NCT02006862|olanzapine
1003916|NCT02006862|olanzapine treatment efficacy
1003917|NCT02006849|AfricanAmericans
1003918|NCT02006849|Hypertension
1003919|NCT02006849|Proteinuria
1003920|NCT02006849|ApoL1 gene
1003921|NCT02006836|glycemic index
1003922|NCT02006836|glycemic response
1003923|NCT02006836|diabetes
1003924|NCT02006836|pomelo
1003925|NCT02006823|Chronic Hepatitis C
1003926|NCT02006810|Endothelium biomarkers
1003927|NCT02006810|Atherosclerotic disease
1003928|NCT02006810|Endothelial function
1003929|NCT02006810|Nutritional stimuli
1003930|NCT02006797|reconciliation
1003931|NCT02006797|discharge
1003932|NCT02006797|pharmacist
1003933|NCT02006797|drug related problems
1003934|NCT02006771|Meal
1003935|NCT02006771|Postprandial oxidative stress
1003936|NCT02006719|Adhesive Capsulitis
1003937|NCT02006719|Frozen Shoulder
1003938|NCT02006719|Shoulder Range of Motion limitation
1003939|NCT02006719|Shoulder Pain
1003940|NCT02006693|XEN
1003941|NCT02006693|Primary Open Angle Glaucoma
1003942|NCT02006693|Filtration Device
1003943|NCT02006693|Ab interno
1003944|NCT02006680|Central Precocious Puberty
1003945|NCT02006680|Suppression
1003946|NCT02006680|Alpha Subunit
1003947|NCT02006680|Leuprolide Stimulation Test
1003948|NCT02006628|GWP42003
1003949|NCT02006628|Cannabinoids
1003950|NCT02006628|Schizophrenia
1003951|NCT02006602|Candesartan cilexetil
1003952|NCT02006602|Healthy adult human subjects
1003953|NCT02006602|Bioequivalence
1003954|NCT02006589|Bioequivalence
1003955|NCT02006589|Candesartan cilexetil
1003956|NCT02006589|Healthy adult human subjects
1003957|NCT02006576|Emphysema
1003958|NCT02006576|Prostaglandin E
1003959|NCT02006576|Bronchoalveolar lavage
1003960|NCT02006563|Brain Tumor
1003961|NCT02006563|Glioblastoma multiforme
1003962|NCT02006563|GBM
1003963|NCT02006563|Metabolic Tumor Volume
1003964|NCT02006563|MTV
1003965|NCT02006563|Clinical Tumor Volume
1003966|NCT02006563|CTV
1003967|NCT02006550|Wnt
1003968|NCT02006550|Notch
1003969|NCT02006550|Hedgehog
1003970|NCT02006550|Tumor Sample
1003971|NCT02006537|soluble epoxide hydrolase inhibitor
1003972|NCT02006537|Entero-Test
1003973|NCT02006537|pharmacokinetics
1003974|NCT02006537|COPD
1003975|NCT02006537|safety
1003976|NCT02006524|Silent atrial fibrillation
1003977|NCT02006524|primary care
1003978|NCT02006524|screening
1003979|NCT02006524|influenza vaccination
1003980|NCT02006511|incisional negative pressure wound therapy
1003981|NCT02006511|groin incision
1003982|NCT02006511|incisional VAC
1003983|NCT02006511|Prevena
1003984|NCT02006511|groin wound
1003985|NCT02006498|non-alcoholic fatty liver disease
1003986|NCT02006498|sillymarin
1003987|NCT02006498|randomised trial
1003988|NCT02006498|non-alcoholic steatohepatitis
1003989|NCT02006472|Huntington's Disease
1003990|NCT02006472|Pridopidine
1003991|NCT02006472|Pride-HD
1003992|NCT02006459|Gastrointestinal-mediated glucose disposal
1003993|NCT02006459|Total pancreatectomy
1003994|NCT02006459|Incretin hormones
1003995|NCT02006459|Glucagon
1003996|NCT02006446|Male infertility
1003997|NCT02006446|sperm head vacuoles
1003998|NCT02006446|sperm morphology
1003999|NCT02006446|aneuploidy
1004000|NCT02006446|DNA fragmentation
1004001|NCT02006446|abnormal chromatin condensation
1004002|NCT02006446|telomere abnormalities
1004003|NCT02006394|Inflammation
1004004|NCT02006394|Monocytes
1004005|NCT02006381|healthy boys
1004006|NCT02006381|plasma oxytocin
1004007|NCT02006381|pediatric
1004008|NCT02006368|Volunteers
1004009|NCT02006368|Blood Platelets
1004010|NCT02006368|Platelet Transfusion
1004011|NCT02006342|Diabetes Mellitus
1004012|NCT02006342|Diabetic Ketoacidosis
1004013|NCT02006342|Insulin Glargine
1004014|NCT02006342|Anion gap
1004015|NCT02006342|Metabolic acidosis
1004016|NCT02006303|Benign Prostate Hyperplasia
1004017|NCT02006303|Green light
1004018|NCT02006303|Photoselective vaporization of the prostate
1004019|NCT02006303|Prostatic artery embolization
1004020|NCT02006303|Outcome
1004021|NCT02006277|healthy volunteers
1004022|NCT02006277|taste
1004023|NCT02006277|bioavailability
1004024|NCT02006238|Hot flash
1004025|NCT02006238|Farabloc
1004026|NCT02006238|menopausal women
1004027|NCT02006225|autologous
1004028|NCT02006225|stem cell
1004029|NCT02006225|transplantation
1004030|NCT02006199|obsessive-compulsive disorder
1004031|NCT02006199|mindfulness
1004032|NCT02006199|meditation
1004033|NCT02006186|Bicycling
1004034|NCT02006173|Hya-Dermis mixed with lidocaine on reducing pain
1004035|NCT02006134|Vasculitis
1004036|NCT02006134|Primary CNS Vasculitis
1004037|NCT02006134|Systemic vasculitis
1004038|NCT02006134|Churg-Strauss Syndrome
1004039|NCT02006134|Polyarteritis Nodosa
1004040|NCT02006134|Wegener Granulomatosis
1004041|NCT02006134|Pediatric vasculitis
1004042|NCT02006134|Childhood vasculitis
1004043|NCT02006134|Granulomatosis with polyangiitis
1004044|NCT02006134|Microscopic Polyangiitis
1004045|NCT02006134|Takayasu Arteritis
1004046|NCT02006134|Autoimmune
1004047|NCT02006134|ANCA-associated vasculitis
1004048|NCT02006121|Parkinson's disease
1004049|NCT02006121|motor fluctuations
1004050|NCT02006121|not well controlled
1004051|NCT02006121|medical treatment
1004052|NCT02006108|kidney
1004053|NCT02006108|transplant
1004054|NCT02006108|rejection
1004055|NCT02006108|Feraheme
1004056|NCT02006108|ferumoxytol
1004057|NCT02006095|carotid artery stenting
1004058|NCT02006095|carotid endarterectomy
1004059|NCT02006095|magnetic resonance imaging (MRI)
1004060|NCT02006095|neuropsychological testing
1004061|NCT02006095|microemboli
1004062|NCT02006082|Telemedicine video-consultation (TVC)
1004063|NCT02006082|Re-admission to hospital
1004064|NCT02006082|Time to re-admission
1004065|NCT02006082|Length if hospital stay
1004066|NCT02006082|Patient satisfaction
1004067|NCT02006082|Chronic obstructive pulmonary disease (COPD)
1004068|NCT02006069|CRT, non responders, MultiPoint Pacing (MPP)
1004069|NCT02006030|Unresectable Hepatocellular Carcinoma
1004070|NCT02006030|Liver Cancer
1004071|NCT02006030|ADI
1004072|NCT02006030|ADI-PEG 20
1004073|NCT02006004|AML
1004074|NCT02005991|PF-05212377
1004075|NCT02005991|phase 1
1004076|NCT02005991|open-label
1004077|NCT02005991|5-HT2a receptor occupancy
1004078|NCT02005991|positron emission tomography
1004079|NCT02005991|healthy subjects
1004080|NCT02005991|brain
1004081|NCT02005991|cortex
1004082|NCT02005991|alzheimers disease
1004083|NCT02005965|Rectal Cancer
1004084|NCT02005965|Low Rectal Cancer
1004085|NCT02005965|MERCURY
1004086|NCT02005965|Cancer
1004087|NCT02005965|CRM
1004088|NCT02005965|Circumferential Margin
1004089|NCT02005965|Quality of Life
1004090|NCT02005965|MRI
1004091|NCT02005965|Radiology
1004092|NCT02005965|Abdominoperineal Excision
1004093|NCT02005965|Anterior Resection
1004094|NCT02005965|Surgery
1004095|NCT02005965|Pathology
1004096|NCT02005939|Pomegranate
1004097|NCT02005939|Blood pressure
1004098|NCT02005939|Insulin sensitivity
1004099|NCT02005939|Cortisol
1004100|NCT02005939|Quality of life
1004101|NCT02005939|Body composition
1004102|NCT02005926|Breast cancer
1004103|NCT02005926|Sentinel lymph node biopsy
1004104|NCT02005926|Ultrasonography
1004105|NCT02005926|Fine needle aspiration
1004106|NCT02005900|DHA
1004107|NCT02005900|Omega 3
1004108|NCT02005900|Polyunsaturated Fatty Acids
1004109|NCT02005900|Dyslipidemia induced by HAART
1004110|NCT02005900|Lipid metabolic alterations
1004111|NCT02005900|HIV
1004112|NCT02005887|Premenopausal patients
1004113|NCT02005887|ER-positive
1004114|NCT02005887|PgR+ (>50%)
1004115|NCT02005887|HER2-negative or not amplified
1004116|NCT02005861|osteochondral lesion
1004117|NCT02005861|talus
1004118|NCT02005861|ankle
1004119|NCT02005861|cartilage repair
1004120|NCT02005848|Type-1 Diabetes
1004121|NCT02005848|T1D
1004122|NCT02005848|Diabetes Mellitus
1004123|NCT02005835|HIV
1004124|NCT02005835|Option B+
1004125|NCT02005835|Prevention of Mother to Child Transmission
1004126|NCT02005822|Cytomegalovirus
1004127|NCT02005822|Congenital infection
1004128|NCT02005822|Sensorineural hearing loss
1004129|NCT02005822|Valganciclovir
1004130|NCT02005809|Endoscopic submucosal dissection
1004131|NCT02005809|gastric neoplasm
1004132|NCT02005809|second look endoscopy
1004133|NCT02005783|incidence of grade 3/4 neutropenia
1004134|NCT02005783|incidence of febrile neutropenia
1004135|NCT02005783|time to neutropenia recovery
1004136|NCT02005783|safety
1004137|NCT02005757|rheumatoid arthritis
1004138|NCT02005757|RA
1004139|NCT02005757|Mizoribine
1004140|NCT02005757|DAS28
1004141|NCT02005757|European League Against Rheumatism
1004142|NCT02005744|CKD-501
1004143|NCT02005731|Low Intensity Shockwave
1004144|NCT02005731|Extracorporeal shockwave therapy
1004145|NCT02005731|Erectile dysfunction
1004146|NCT02005692|pressure ulcers
1004147|NCT02005692|bed sores
1004148|NCT02005692|patient turn protocol
1004149|NCT02005692|patient movement
1004150|NCT02005692|patient monitoring
1004151|NCT02005679|Prelingual Deafness
1004152|NCT02005679|Retention Disorders, Cognitive
1004153|NCT02005679|Sign language
1004154|NCT02005679|Mini-Mental State
1004155|NCT02005666|Acne Vulgaris
1004156|NCT02005666|DUAC
1004157|NCT02005666|CADILA
1004158|NCT02005666|CLIANTHA
1004159|NCT02005653|Lymphatic filariasis
1004160|NCT02005653|W. bancrofti
1004161|NCT02005653|DEC
1004162|NCT02005653|Albendazole
1004163|NCT02005653|Doxycycline
1004164|NCT02005627|grass pollen allergy
1004165|NCT02005627|hayfever
1004166|NCT02005627|atopy
1004167|NCT02005627|allergic rhinitis
1004168|NCT02005627|sublingual immunotherapy tablets
1004169|NCT02005614|Rational dose selection
1004170|NCT02005614|gamma knife radiosurgery
1004171|NCT02005588|amino acid chelated iron
1004172|NCT02005588|iron salt
1004173|NCT02005588|iron deficiency anemia
1004174|NCT02005536|Poliomyelitis
1004175|NCT02005536|Poliovirus
1004176|NCT02005536|Polio
1004177|NCT02005536|IMOVAX POLIO®
1004178|NCT02005536|Inactivated polio vaccine
1004179|NCT02005510|cervical cancer
1004180|NCT02005510|screening
1004181|NCT02005510|human papillomavirus
1004182|NCT02005510|cervical intraepithelial neoplasia
1004183|NCT02005497|Cancer prevention and control
1004184|NCT02005497|Health promotion
1004185|NCT02005497|Workplace
1004186|NCT02005497|Dissemination
1004187|NCT02005497|Implementation
1004188|NCT02005458|Neutropenia
1004189|NCT02005458|Febrile neutropenia
1004190|NCT02005458|PEG-rhG-CSF
1004191|NCT02005458|Myelosuppressive chemotherapy
1004192|NCT02005445|Obstructive sleep apnea
1004193|NCT02005445|Coronary heart disease
1004194|NCT02005445|Cardiac rehabilitation
1004195|NCT02005445|Cardiopulmonary exercise testing
1004196|NCT02005432|Diabetis
1004197|NCT02005432|Retinal Neovascularization
1004198|NCT02005432|laser treatment
1004199|NCT02005419|Pancreatic Cancer
1004200|NCT02005419|Pancreatic Adenocarcinoma
1004201|NCT02005419|Metformin
1004202|NCT02005419|Gemcitabine
1004203|NCT02005419|Adjuvant Therapy
1004204|NCT02005406|Wei JET
1004205|NCT02005393|FICE
1004206|NCT02005393|NBI
1004207|NCT02005380|Alzheimer's Disease Rehabilitation
1004208|NCT02005367|substance use treatment
1004209|NCT02005367|person-centered treatment
1004210|NCT02005367|residential treatment outcomes
1004211|NCT02005367|dual diagnosis
1004212|NCT02005367|recovery model
1004213|NCT02005367|psychosocial treatment
1004214|NCT02005354|Pain
1004215|NCT02005354|Bone marrow aspiration
1004216|NCT02005354|trephine biopsy
1004217|NCT02005341|Lumbar
1004218|NCT02005341|fusion
1004219|NCT02005328|Xerostomia
1004220|NCT02005328|hyposialia
1004221|NCT02005328|hyposalivation
1004222|NCT02005328|saliva substitute
1004223|NCT02005328|Salivary Gland
1004224|NCT02005328|Mouth Diseases
1004225|NCT02005328|Dry mouth
1004226|NCT02005315|Pancreatic Cancer
1004227|NCT02005315|Stage IV Pancreatic Cancer
1004228|NCT02005302|chronic kidney disease
1004229|NCT02005302|mineral and bone disease
1004230|NCT02005302|Malnutrition
1004231|NCT02005302|Vitamin D
1004232|NCT02005302|low protein diet
1004233|NCT02005289|CLL
1004234|NCT02005289|SLL
1004235|NCT02005289|PLL
1004236|NCT02005289|Chronic Lymphocytic Leukemia
1004237|NCT02005289|Small Lymphocytic Lymphoma
1004238|NCT02005289|Prolymphocytic Leukemia
1004239|NCT02005289|MOR00208
1004240|NCT02005289|MOR208
1004241|NCT02005276|Sedentary
1004242|NCT02005276|Behavioral Economic Intervention
1004243|NCT02005276|Team Studies
1004244|NCT02005276|Financial Incentives
1004245|NCT02005276|Workplace Wellness
1004246|NCT02005276|Team Incentives
1004247|NCT02005263|Hysteroscopy
1004248|NCT02005250|osteoporosis
1004249|NCT02005250|hyperthyroidism
1004250|NCT02005250|hypothyroidism
1004251|NCT02005237|Exercise
1004252|NCT02005237|Cognition
1004253|NCT02005237|Neuroimaging
1004254|NCT02005237|Rehabilitation
1004255|NCT02005237|Connectivity
1004256|NCT02005224|Insulin sensitivity
1004257|NCT02005224|Lipid profile
1004258|NCT02005224|Body composition
1004259|NCT02005224|Weight
1004260|NCT02005211|AZD3293
1004261|NCT02005211|Healthy volunteers
1004262|NCT02005211|Young volunteers
1004263|NCT02005211|Elderly volunteers
1004264|NCT02005211|Japanese volunteers
1004265|NCT02005211|Phase 1
1004266|NCT02005211|Single and multiple ascending dose study
1004267|NCT02005172|arrhythmia, palpitations, lightheadedness
1004268|NCT02005159|Enterobacteria
1004269|NCT02005159|Bacteremia
1004270|NCT02005159|Minimum inhibitory concentration
1004271|NCT02005159|Susceptible
1004272|NCT02005159|Prognosis
1004273|NCT02005146|Hepatitis B
1004274|NCT02005146|Nucleoside/nucleotide
1004275|NCT02005146|HBsAg loss
1004276|NCT02005133|Wet age-related macular degeneration
1004277|NCT02005068|Osteoarticular infections
1004278|NCT02005068|Osteomyelitis
1004279|NCT02005068|Joint infections
1004280|NCT02005068|MRSA (Methicillin- Resistant Staphylococcus Aureus)
1004281|NCT02005068|MSSA (Methicillin- Susceptible Staphylococcus Aureus)
1004282|NCT02005055|Brachytherapy
1004283|NCT02005055|Radiotherapy
1004284|NCT02005055|Scar treatment
1004285|NCT02005042|Physical activity
1004286|NCT02005042|Ecological Momentary Assessment
1004287|NCT02005042|Ecological Momentary Intervention
1004288|NCT02005042|Accelerometer
1004289|NCT02005042|Smartphone
1004290|NCT02005029|Parkinson's Disease
1004291|NCT02005029|Levodopa
1004292|NCT02005029|motor fluctuations
1004293|NCT02005029|gastroparesis
1004294|NCT02005016|Aphasia
1004295|NCT02005016|Language Therapy
1004296|NCT02005016|Acquired Language Disorders
1004297|NCT02005016|Semantics
1004298|NCT02005016|Stroke
1004299|NCT02004990|Children, Plaque
1004300|NCT02004951|Superficial femoral artery
1004301|NCT02004951|paclitaxel
1004302|NCT02004951|stent
1004303|NCT02004951|self expandable
1004304|NCT02004951|restenosis
1004305|NCT02004951|endovascular
1004306|NCT02004951|above-the-knee intermediate length
1004307|NCT02004938|measurements
1004308|NCT02004938|jugular
1004309|NCT02004938|ultrasound
1004310|NCT02004938|pediatric
1004311|NCT02004938|respiratory
1004312|NCT02004938|diameter
1004313|NCT02004925|pneumoperitoneum
1004314|NCT02004925|free peritoneal air
1004315|NCT02004925|ultrasonography
1004316|NCT02004912|maternal
1004317|NCT02004912|neonatal
1004318|NCT02004912|child
1004319|NCT02004912|health services
1004320|NCT02004912|health care
1004321|NCT02004912|Karnataka
1004322|NCT02004912|India
1004323|NCT02004899|Labor epidural analgesia
1004324|NCT02004899|Fentanyl
1004325|NCT02004899|Bupivacaine
1004326|NCT02004899|Onset
1004327|NCT02004886|Diabetes Mellitus
1004328|NCT02004886|Diabetes Mellitus, Type 2
1004329|NCT02004886|Glucose Metabolism Disorders
1004330|NCT02004886|Metabolic Diseases
1004331|NCT02004886|Endocrine System Diseases
1004332|NCT02004886|Therapeutic Uses
1004333|NCT02004886|Pharmacologic Actions
1004334|NCT02004886|Molecular Mechanisms of Pharmacological Action
1004335|NCT02004886|Physiological Effects of Drugs
1004336|NCT02004886|Metformin
1004337|NCT02004873|pacemaker
1004338|NCT02004873|leadless
1004339|NCT02004873|single chamber
1004340|NCT02004860|local immunosuppressive
1004341|NCT02004860|Maintenance therapy
1004342|NCT02004795|Boron Neutron Capture Therapy
1004343|NCT02004795|Image-guided intensity modulation radiotherapy
1004344|NCT02004769|Metastatic gastric or gastro-esophageal junction cancer
1004345|NCT02004769|Trastuzumab
1004346|NCT02004769|HER2-positive
1004347|NCT02004769|Capecitabine
1004348|NCT02004769|Docetaxel
1004349|NCT02004769|First-line therapy
1004350|NCT02004756|pediatric
1004351|NCT02004756|fontan
1004352|NCT02004756|congenital heart disease
1004353|NCT02004756|cardiac and musculoskeletal funion
1004354|NCT02004756|cardiac and/or musculoskeletal metabolism
1004355|NCT02004756|exercise training intervention
1004356|NCT02004743|Early Intervention
1004357|NCT02004743|Prevention
1004358|NCT02004743|Risk Factors
1004359|NCT02004743|Exposure Therapy
1004360|NCT02004743|Psychoeducation
1004361|NCT02004717|advanced solid tumor
1004362|NCT02004717|Phase 1
1004363|NCT02004717|Oncology
1004364|NCT02004652|Prucalopride
1004365|NCT02004652|Gastrointestinal Diseases
1004366|NCT02004652|Postoperative ileus
1004367|NCT02004652|Randomised trial
1004368|NCT02004639|IMRT or HT with chemotherapy
1004369|NCT02004626|Collagenase
1004370|NCT02004626|Phase III
1004371|NCT02004626|National
1004372|NCT02004626|Noninferiority
1004373|NCT02004626|Double-blind
1004374|NCT02004626|Multicenter
1004375|NCT02004626|Prospective.
1004376|NCT02004587|Hepatic impairment
1004377|NCT02004587|Pharmacokinetics
1004378|NCT02004587|Pharmacodynamics
1004379|NCT02004587|Gemigliptin
1004380|NCT02004561|bariatric_surgery
1004381|NCT02004561|pediatric obesity
1004382|NCT02004561|diabetes
1004383|NCT02004535|Hearing loss
1004384|NCT02004535|Asymmetric hearing loss
1004385|NCT02004535|Cochlear implantation
1004386|NCT02004522|Phase 3
1004387|NCT02004522|CLL/SLL
1004388|NCT02004522|Pi3K
1004389|NCT02004509|atrial fibrillation
1004390|NCT02004509|stroke
1004391|NCT02004509|pacemaker
1004392|NCT02004509|anticoagulant
1004393|NCT02004483|percutaneous coronary intervention
1004394|NCT02004483|ischemia
1004395|NCT02004483|strain
1004396|NCT02004483|coronary stenosis
1004397|NCT02004470|post laparoscopic shoulder pain
1004398|NCT02004470|active suction
1004399|NCT02004470|lavage and suction
1004400|NCT02004470|right shoulder pain
1004401|NCT02004470|post operative shoulder pain
1004402|NCT02004457|HIV
1004403|NCT02004457|Primary care
1004404|NCT02004457|Engagement
1004405|NCT02004457|Acceptance
1004406|NCT02004457|Disclosure
1004407|NCT02004457|Stigma
1004408|NCT02004444|JC Virus
1004409|NCT02004444|Natalizumab
1004410|NCT02004431|Chronic post surgical pain
1004411|NCT02004431|Orthopaedic
1004412|NCT02004431|Anxiety
1004413|NCT02004431|depression
1004414|NCT02004418|C-Choline PET scans
1004415|NCT02004418|external beam radiotherapy
1004416|NCT02004405|autonomic nervous system
1004417|NCT02004405|fibromyalgia
1004418|NCT02004405|autonomic dysfunction
1004419|NCT02004405|strengthening
1004420|NCT02004405|flexibility
1004421|NCT02004405|exercise
1004422|NCT02004405|heart rate variability
1004423|NCT02004392|Alzheimer's disease
1004424|NCT02004392|Cognition
1004425|NCT02004392|Alpha-7 nAChR
1004426|NCT02004379|HCV
1004427|NCT02004379|Hepatitis C
1004428|NCT02004379|telaprevir
1004429|NCT02004379|boceprevir
1004430|NCT02004379|clinical practice
1004431|NCT02004366|Diabetes
1004432|NCT02004366|Linagliptin
1004433|NCT02004366|hospital hyperglycemia
1004434|NCT02004366|inpatient diabetes
1004435|NCT02004353|Cochlear® Hearing Implants
1004436|NCT02004340|pediatric epilepsy
1004437|NCT02004340|transcutaneous vagus nerve stimulation
1004438|NCT02004314|Chloroquine
1004439|NCT02004314|T cell immune activation
1004440|NCT02004314|CD4 recovery
1004441|NCT02004314|HIV
1004442|NCT02004301|Formulation behaviour
1004443|NCT02004301|Drug absorption profile
1004444|NCT02004288|Probiotics
1004445|NCT02004288|Anorexia nervosa
1004446|NCT02004288|Constipation
1004447|NCT02004288|Body weight
1004448|NCT02004262|cancer
1004449|NCT02004262|cancer vaccine
1004450|NCT02004262|Listeria monocytogenes
1004451|NCT02004262|Listeria-based vaccine
1004452|NCT02004262|GVAX
1004453|NCT02004262|cyclophosphamide
1004454|NCT02004262|Cytoxan
1004455|NCT02004262|immunotherapy
1004456|NCT02004262|mesothelin
1004457|NCT02004236|tRNS
1004458|NCT02004236|QEEG
1004459|NCT02004236|ERP
1004460|NCT02004236|ASD
1004461|NCT02004236|Autism
1004462|NCT02004236|verbal fluency
1004463|NCT02004236|empathy
1004464|NCT02004236|noninvasive brain stimulation
1004465|NCT02004236|tDCS
1004466|NCT02004223|Prostate Cancer
1004467|NCT02004223|Dose escalation
1004468|NCT02004223|Stereotactic
1004469|NCT02004223|SBRT
1004470|NCT02004223|Hypofractionation
1004471|NCT02004210|transarterial chemoembolization
1004472|NCT02004210|transarterial radioembolization
1004473|NCT02004210|advanced hepatocellular carcinoma
1004474|NCT02004184|Pemetrexed
1004475|NCT02004184|drug therapy
1004476|NCT02004171|electronic cigarette
1004477|NCT02004171|nicotine inhaler
1004478|NCT02004171|smoking cessation
1004479|NCT02004158|Acute coronary syndrome
1004480|NCT02004158|Health behavior
1004481|NCT02004158|Mental health
1004482|NCT02004145|MDD
1004483|NCT02004145|Positive Psychology
1004484|NCT02004145|Suicidality
1004485|NCT02004080|TBI
1004486|NCT02004080|ICU
1004487|NCT02004080|Comparative Effectiveness Research
1004488|NCT02004067|Evaporative
1004489|NCT02004067|Aqueous deficient
1004490|NCT02004067|Dry eye disease
1004491|NCT02004054|multiple sclerosis
1004492|NCT02004054|diameter pupil
1004493|NCT02004041|pruritus
1004494|NCT02004041|atopic dermatitis
1004495|NCT02004041|VLY-686
1004496|NCT02004028|Mesothelioma
1004497|NCT02004028|adenoma
1004498|NCT02004028|Neoplasms, Mesothelial
1004499|NCT02004028|Focal Adhesion Kinase Inhibitor
1004500|NCT02004015|Analytical
1004501|NCT02004015|Diagnostic
1004502|NCT02004015|Anesthesia
1004503|NCT02004015|Analgesia
1004504|NCT02003976|knee osteoarthritis
1004505|NCT02003976|high tibial osteotomy
1004506|NCT02003976|gait analysis
1004507|NCT02003976|muscular strength
1004508|NCT02003976|body composition
1004509|NCT02003976|magnetic resonance imaging
1004510|NCT02003976|biological markers
1004511|NCT02003963|Physical Activity
1004512|NCT02003963|Sedentary Behavior
1004513|NCT02003963|Video Games
1004514|NCT02003963|Exergames
1004515|NCT02003911|Asthma
1004516|NCT02003911|Acute asthma exacerbation
1004517|NCT02003911|Pediatric
1004518|NCT02003911|Azithromycin
1004519|NCT02003911|Macrolide
1004520|NCT02003911|Length of Stay
1004521|NCT02003911|Hospital Medicine
1004522|NCT02003898|Diabetes
1004523|NCT02003898|Insulin pump
1004524|NCT02003898|Threshold Suspend
1004525|NCT02003885|Desflurane, mitral annular velocity, tissue Doppler imaging
1004526|NCT02003859|IBD
1004527|NCT02003859|Pediatrics
1004528|NCT02003859|pCLE
1004529|NCT02003833|Poly-L-lactic acid
1004530|NCT02003833|Sculptra Aesthetic
1004531|NCT02003833|Skin Quality
1004532|NCT02003833|Wrinkles
1004533|NCT02003833|Filler
1004534|NCT02003820|Autism
1004535|NCT02003820|Dental Caries
1004536|NCT02003820|Prevention
1004537|NCT02003820|Oral Hygiene
1004538|NCT02003794|acute ischemic stroke
1004539|NCT02003794|intravenous fluid
1004540|NCT02003794|้hydration
1004541|NCT02003781|cardiovascular disease
1004542|NCT02003781|metabolic disease
1004543|NCT02003781|high risk
1004544|NCT02003781|prospective cohort
1004545|NCT02003768|pneumoperitoneum
1004546|NCT02003768|optic nerve sheath diameter
1004547|NCT02003768|laparoscopy
1004548|NCT02003768|Patients
1004549|NCT02003768|general anesthesia
1004550|NCT02003768|diameter
1004551|NCT02003755|Cerebral palsy
1004552|NCT02003755|Continuous passive motion
1004553|NCT02003755|Hypertonia
1004554|NCT02003742|LUTS
1004555|NCT02003742|BPH
1004556|NCT02003729|obstructive sleep apnea
1004557|NCT02003729|Portable Monitor
1004558|NCT02003729|AHI
1004559|NCT02003729|ESS
1004560|NCT02003729|Cost effectiveness
1004561|NCT02003703|Vaccine
1004562|NCT02003703|Primary Prevention
1004563|NCT02003703|Immunogenicity
1004564|NCT02003690|Bipolar disorder
1004565|NCT02003690|Adolescent suicidal behavior
1004566|NCT02003690|Psychotherapy
1004567|NCT02003664|Cocaine
1004568|NCT02003664|Treatment
1004569|NCT02003664|fMRI
1004570|NCT02003664|Outcomes
1004571|NCT02003651|Common cold
1004572|NCT02003625|Non-Hodgkin's lymphoma
1004573|NCT02003625|Hodgkin's lymphoma
1004574|NCT02003625|Multiple myeloma
1004575|NCT02003625|Hematopoietic stem cells
1004576|NCT02003599|Radiodermatitis
1004577|NCT02003599|Breast neoplasms
1004578|NCT02003599|Laser Therapy, Low- Level
1004579|NCT02003586|subjects
1004580|NCT02003560|breast cancer
1004581|NCT02003560|breast conserving therapy
1004582|NCT02003560|accelerated partial breast irradiation
1004583|NCT02003560|3D conformal radiotherapy
1004584|NCT02003560|intensity modulated radiotherapy
1004585|NCT02003521|Lung Flute
1004586|NCT02003508|Prevalence
1004587|NCT02003508|HPV
1004588|NCT02003508|Human papillomavirus
1004589|NCT02003508|Vaccination
1004590|NCT02003495|Immunogenicity, Safety, Meningococcal Conjugate Vaccine
1004591|NCT02003482|Head and Neck Cancer
1004592|NCT02003482|Head and Neck Squamous Cell Carcinoma
1004593|NCT02003482|Intensity modulated radiation therapy
1004594|NCT02003482|IMRT
1004595|NCT02003482|Anatomic Changes
1004596|NCT02003482|Postoperative
1004597|NCT02003482|Unresectable
1004598|NCT02003469|hypertension
1004599|NCT02003469|kidney disease
1004600|NCT02003469|cardiovascular disease
1004601|NCT02003456|positron emission tomography
1004602|NCT02003456|rubidium
1004603|NCT02003456|myocardial perfusion imaging
1004604|NCT02003456|viability
1004605|NCT02003456|FDG
1004606|NCT02003443|Acupressure
1004607|NCT02003443|Older Adults
1004608|NCT02003443|Knee pain
1004609|NCT02003443|Pain Treatment
1004610|NCT02003430|gynecologic malignancy
1004611|NCT02003430|non-ovarian gynecological cancer
1004612|NCT02003430|cervical cancer
1004613|NCT02003430|vaginal cancer
1004614|NCT02003430|vulvar cancer
1004615|NCT02003430|endometrial cancer
1004616|NCT02003417|Prostate cancer
1004617|NCT02003417|External beam radiation treatment
1004618|NCT02003417|Androgen deprivation therapy
1004619|NCT02003417|Definitive treatment
1004620|NCT02003417|Cardiovascular risk factors
1004621|NCT02003417|Quality of life
1004622|NCT02003404|ostomy appliance
1004623|NCT02003391|Open Angle Glaucoma
1004624|NCT02003391|Ocular Hypertension
1004625|NCT02003391|Intraocular Pressure
1004626|NCT02003378|Chronotropic incompetence
1004627|NCT02003365|osteoarthritis
1004628|NCT02003365|knee
1004629|NCT02003365|steroids
1004630|NCT02003365|FX006
1004631|NCT02003365|triamcinolone acetonide
1004632|NCT02003365|synovial fluid
1004633|NCT02003352|TBI
1004634|NCT02003352|PTSD
1004635|NCT02003352|Functional Neurology
1004636|NCT02003352|Vestibular Rehabilitation
1004637|NCT02003352|Dynamic Computerized Posturography
1004638|NCT02003352|Saccadometry
1004639|NCT02003313|safety, immunogenicity, Meningococcal Polysaccharide Vaccine
1004640|NCT02003300|Oxygen uptake
1004641|NCT02003300|Anesthetic gas uptake
1004642|NCT02003287|Deglutition Disorders
1004643|NCT02003287|Intensive Care Units, Neonatal
1004644|NCT02003274|Mixed Meal Test
1004645|NCT02003274|Insulin Pump
1004646|NCT02003274|Continuous Glucose Monitoring
1004647|NCT02003274|Metabolic Control Analysis
1004648|NCT02003274|Closed Loop Control
1004649|NCT02003274|Artificial Pancreas
1004650|NCT02003248|Parkinson's disease
1004651|NCT02003248|ultrasound
1004652|NCT02003248|dyskinesia
1004653|NCT02003248|magnetic resonance
1004654|NCT02003235|Amblyopia
1004655|NCT02003196|Brain injury
1004656|NCT02003196|virus
1004657|NCT02003196|immunosuppression
1004658|NCT02003196|mechanical ventilation
1004659|NCT02003183|CTE
1004660|NCT02003183|TBI
1004661|NCT02003183|Cognitive Impairment
1004662|NCT02003183|Brain Imaging
1004663|NCT02003183|PET
1004664|NCT02003170|Autism
1004665|NCT02003170|Autism Spectrum Disorder (ASD)
1004666|NCT02003170|Pervasive Developmental Disorder (PDD)
1004667|NCT02003170|Developmental delays
1004668|NCT02003170|Genetic disorder
1004669|NCT02003170|Mitochondrial disorder
1004670|NCT02003157|hypnosis embryo transfer IVF ICSI
1004671|NCT02003144|Long-term safety study
1004672|NCT02003144|Extension trial
1004673|NCT02003144|Eculizumab
1004674|NCT02003144|Neuromyelitis Optica Spectrum Disorder
1004675|NCT02003144|Devic's disease
1004676|NCT02003144|Transverse Myelitis
1004677|NCT02003144|Optic Neuritis
1004678|NCT02003144|Relapse
1004679|NCT02003144|NMO-IgG
1004680|NCT02003144|CNS Autoimmune Disorders
1004681|NCT02003144|Demyelinating Disorders
1004682|NCT02003131|osteoarthritis
1004683|NCT02003131|umbilical cord
1004684|NCT02003131|mesenchymal
1004685|NCT02003131|stem cells
1004686|NCT02003131|trophic factors
1004687|NCT02003092|solid tumor
1004688|NCT02003092|Rexahn
1004689|NCT02003092|Phase 1
1004690|NCT02003066|Fluid Therapy
1004691|NCT02003066|Head and Neck Neoplasms
1004692|NCT02003066|Surgical Flaps
1004693|NCT02003053|Critically ill
1004694|NCT02003053|intubated
1004695|NCT02003053|safety
1004696|NCT02003053|feasibility
1004697|NCT02003053|inspiratory muscle training
1004698|NCT02003014|Drug Therapy
1004699|NCT02002975|Drug Therapy
1004700|NCT02002949|Hemodialysis
1004701|NCT02002910|iFR
1004702|NCT02002910|FFR
1004703|NCT02002910|Medical Economy
1004704|NCT02002910|physiological assessment
1004705|NCT02002910|SYNTAX score
1004706|NCT02002897|Localized scleroderma UVA1 fractional carbon dioxide laser
1004710|NCT02002858|smoking
1004711|NCT02002858|cessation
1004712|NCT02002858|anxiety
1004713|NCT02002858|anxious
1004714|NCT02002858|depression
1004715|NCT02002858|depressed
1004716|NCT02002858|smoker
1004717|NCT02002858|stress
1004718|NCT02002845|Tongue base resection, partial glossectomy
1004719|NCT02002819|Alzheimer's disease
1004720|NCT02002819|AD
1004721|NCT02002819|Early-onset AD
1004722|NCT02002819|EOAD
1004723|NCT02002819|Early-onset Alzheimer's
1004724|NCT02002819|Early-onset Alzheimer's disease
1004725|NCT02002806|Pancreatic cancer
1004726|NCT02002806|Pain
1004727|NCT02002793|pancreatitis
1004728|NCT02002793|early stage
1004729|NCT02002793|mini-invasive abdominal drainage
1004730|NCT02002780|pediatrics
1004731|NCT02002780|stress
1004732|NCT02002780|cardiac surgery
1004733|NCT02002754|eosinophilic bronchitis
1004734|NCT02002754|cough variant asthma
1004735|NCT02002754|bronchodilator
1004736|NCT02002741|patent ductus arteriosus
1004737|NCT02002741|PDA
1004738|NCT02002741|Preterm
1004739|NCT02002741|Infant
1004740|NCT02002741|Electrocardiography
1004741|NCT02002741|Paracetamol
1004742|NCT02002741|Acamol
1004743|NCT02002741|ibuprofen
1004744|NCT02002741|Placebo
1004745|NCT02002715|eosinophilic bronchitis
1004746|NCT02002715|inhaled corticosteroids
1004747|NCT02002715|therapeutic effect
1004748|NCT02002702|Acute heart failure (AHF),
1004749|NCT02002702|Japanese,
1004750|NCT02002702|Safety and tolerability, Pharmacokinetics,
1004751|NCT02002702|Renal Impairment
1004752|NCT02002689|Solid tumor malignancy,
1004753|NCT02002689|hematologic malignancy,
1004754|NCT02002689|mutation, translocations,
1004755|NCT02002689|signature,
1004756|NCT02002689|PTCH1,
1004757|NCT02002689|SMO,
1004758|NCT02002689|LDE225,
1004759|NCT02002689|endometrial cancer,
1004760|NCT02002689|colon cancer,
1004761|NCT02002689|bladder,
1004762|NCT02002689|NSCLC
1004763|NCT02002676|rest energy expenditure,critical ill, outcome
1004764|NCT02002650|Indomethacin, pancreatitis, ERCP
1004765|NCT02002611|Lobeglitazone
1004766|NCT02002611|Warfarin
1004767|NCT02002611|Type 2 Diabetes Mellitus
1004768|NCT02002611|Drug-Drug interaction
1004769|NCT02002611|Phase 1
1004770|NCT02002598|Newly diagnosed
1004771|NCT02002598|multiple myeloma
1004772|NCT02002598|myeloma
1004773|NCT02002598|bendamustine
1004774|NCT02002598|treanda
1004775|NCT02002598|carfilzomib
1004776|NCT02002598|dexamethasone
1004777|NCT02002598|phase I
1004778|NCT02002598|phase II
1004779|NCT02002598|dose escalation
1004780|NCT02002598|transplant
1004781|NCT02002598|non-transplant, plasma cells
1004782|NCT02002585|Renal protection
1004783|NCT02002585|Renal sympathetic denervation
1004784|NCT02002572|Facial Mimic Muscle
1004785|NCT02002572|MRI
1004786|NCT02002572|Segmentation
1004787|NCT02002572|Three dimensional assessment
1004788|NCT02002572|Motion capture
1004789|NCT02002572|Movement analysis
1004790|NCT02002572|Digital Image Correlation
1004791|NCT02002546|Heart Attack
1004792|NCT02002546|Myocardial Infarction
1004793|NCT02002546|Angina
1004794|NCT02002546|Chest Pain
1004795|NCT02002520|Acute pain
1004796|NCT02002520|Epigenetic
1004797|NCT02002520|Dental pain
1004798|NCT02002468|Risk Communication
1004799|NCT02002468|Follow-up
1004800|NCT02002468|Organisation of screening
1004801|NCT02002455|FACBC
1004802|NCT02002455|PET/CT
1004803|NCT02002455|PET/MRI
1004804|NCT02002455|Radical prostatectomy
1004805|NCT02002455|Radiotherapy
1004806|NCT02002442|Mouthwash
1004807|NCT02002442|Chlorhexidine
1004808|NCT02002442|cetylpyridinium chloride
1004809|NCT02002442|Saline
1004810|NCT02002442|Implants
1004811|NCT02002442|Saliva Collection
1004812|NCT02002429|Facet joint
1004813|NCT02002429|Medial branch block
1004814|NCT02002429|Radiofrequency denervation
1004815|NCT02002429|Zygapophysial joint
1004816|NCT02002429|Low back pain
1004817|NCT02002416|C-met expression, gastric cancer, overall survival
1004818|NCT02002403|Edema
1004819|NCT02002403|Macular Edema
1004820|NCT02002403|Retinal Diseases
1004821|NCT02002403|Eye Diseases
1004822|NCT02002403|Danazol
1004823|NCT02002403|Estrogen Antagonists
1004824|NCT02002403|Estrogen Receptor Modulators
1004825|NCT02002403|Hormone Antagonists
1004826|NCT02002403|Hormones, Hormone Substitutes, and Hormone Antagonists
1004827|NCT02002403|Physiological Effects of Drugs
1004828|NCT02002403|Pharmacologic Actions
1004829|NCT02002390|Stroke,Fingolimod(FTY 720), treatment
1004830|NCT02002377|Age Related Macular Degeneration, wet
1004831|NCT02002377|aflibercept
1004832|NCT02002364|tracheal intubation
1004833|NCT02002338|pterygium surgery
1004834|NCT02002338|refractive changes
1004835|NCT02002338|surgical technique
1004836|NCT02002312|Advanced Renal Cell Carcinoma
1004837|NCT02002312|Clear Cell Renal Cell Carcinoma (ccRCC)
1004838|NCT02002312|Lutetium-177
1004839|NCT02002312|Lu-177
1004840|NCT02002312|girentuximab
1004841|NCT02002312|cG250
1004842|NCT02002312|Monoclonal Antibody
1004843|NCT02002299|colorectal cancer
1004844|NCT02002299|surface
1004845|NCT02002299|invasive front
1004846|NCT02002299|tumor budding
1004847|NCT02002286|HIV-infected immunological non-responders
1004848|NCT02002286|Tripterygium Wilfordii Hook F
1004849|NCT02002286|Immune activation
1004850|NCT02002247|antioxidants
1004851|NCT02002247|selenium
1004852|NCT02002247|heart disease
1004853|NCT02002247|cardiac surgery
1004854|NCT02002247|perioperative
1004855|NCT02002234|Hemicraniectomy, stroke, decompressive surgery, HeMMI
1004856|NCT02002221|Diabetes Mellitus (DM) ,
1004857|NCT02002221|diabetes,
1004858|NCT02002221|noninsulin-dependent diabetes mellitus (NIDDM),
1004859|NCT02002221|adult-onset diabetes,
1004860|NCT02002221|high blood sugar,
1004861|NCT02002221|T2DM
1004862|NCT02002195|metastatic gastric cancer,
1004863|NCT02002195|elderly,
1004864|NCT02002195|folinic acid,
1004865|NCT02002195|fluorouracil,
1004866|NCT02002195|oxaliplatin,
1004867|NCT02002195|capecitabine,
1004868|NCT02002195|overall survival,
1004869|NCT02002195|progression free survival
1004870|NCT02002182|HPV
1004871|NCT02002182|0ropharynx
1004872|NCT02002182|squamous cell carcinoma
1004873|NCT02002182|head and neck cancer
1004874|NCT02002182|transoral robotic surgery
1004875|NCT02002169|Catheter Related Bacteremia
1004876|NCT02002143|Diabetes
1004877|NCT02002143|Older People
1004878|NCT02002143|Seniors
1004879|NCT02002143|Group Appointments
1004880|NCT02002143|Group Medical Visits
1004881|NCT02002143|Shared Appointments
1004882|NCT02002143|Quality of Life
1004883|NCT02002143|Physical Activity
1004884|NCT02002143|Health care Utilization
1004885|NCT02002143|Depression
1004886|NCT02002143|Anxiety
1004887|NCT02002130|Diabetes
1004888|NCT02002104|Expanded polytetrafluoroethylene( ePTFE)
1004889|NCT02002091|Type2 diabetes mellitus
1004890|NCT02002091|Microangiopathy
1004891|NCT02002091|Chronic Kidney disease
1004892|NCT02002091|Cardiovascular disease
1004893|NCT02002078|caustic
1004894|NCT02002078|corticosteroid therapy
1004895|NCT02002078|stricture
1004896|NCT02002078|children
1004897|NCT02002065|hepatitis A
1004898|NCT02002065|inactivated hepatitis A vaccine
1004899|NCT02002065|attenuated alive hepatitis A vaccine
1004900|NCT02002065|immune persistence
1004901|NCT02002052|non-small cell lung cancer, radiotherapy, chemotherapy, pneumonitis, functional lung avoidance
1004902|NCT02002039|Perinatal asphyxia
1004903|NCT02002039|erythropoietin
1004904|NCT02002026|placenta previa, uterine artery ligation
1004905|NCT02002013|Adult
1004906|NCT02002013|ICU patient
1004907|NCT02002013|Fluid resuscitation
1004908|NCT02002013|observational study
1004909|NCT02002000|Vitamin D deficiency
1004910|NCT02002000|Musculoskeletal pain
1004911|NCT02002000|Vitamin D supplementation
1004912|NCT02001974|HER 2 negative
1004913|NCT02001974|metastatic breast cancer
1004914|NCT02001974|Cancer Stem Cells
1004915|NCT02001961|Fibrosis
1004916|NCT02001961|collagen metabolism
1004917|NCT02001961|paediatric, dilated cardiomyopathy
1004918|NCT02001961|biomarkers
1004919|NCT02001961|T1 mapping
1004920|NCT02001961|MRI
1004921|NCT02001948|Spinal anaesthesia
1004922|NCT02001948|morphine
1004923|NCT02001948|postoperative analgesia
1004924|NCT02001948|vomiting
1004925|NCT02001935|COPD
1004926|NCT02001935|theophylline
1004927|NCT02001935|CYP1A2
1004928|NCT02001935|CYP2E1
1004929|NCT02001922|COPD
1004930|NCT02001922|Pulmonary disease, chronic obstructive
1004931|NCT02001922|Integrated care
1004932|NCT02001922|Outcome and process assessment
1004933|NCT02001922|Quality indicators, Health care
1004934|NCT02001922|Self-management,
1004935|NCT02001922|Patient empowerment
1004936|NCT02001922|Quantitative and qualitative methods
1004937|NCT02001909|Regorafenib
1004938|NCT02001909|Neomycin
1004939|NCT02001909|Cancer
1004940|NCT02001909|Pharmacokinetics
1004941|NCT02001909|Safety
1004942|NCT02001896|NSCLC
1004943|NCT02001896|EGFR-TKI
1004944|NCT02001883|Coronary artery disease, nutraceuticals, statins
1004945|NCT02001870|Infertility
1004946|NCT02001870|female age
1004947|NCT02001870|intra-uterine insemination
1004948|NCT02001870|in vitro fecundation
1004949|NCT02001870|assisted reproductive technology center
1004950|NCT02001857|patients,
1004951|NCT02001857|undergoing
1004952|NCT02001857|pelvic
1004953|NCT02001857|lymph
1004954|NCT02001857|node
1004955|NCT02001857|dissection.
1004956|NCT02001831|Sarcopenia
1004957|NCT02001831|Frailty
1004958|NCT02001831|Aging
1004959|NCT02001831|Skeletal muscle
1004960|NCT02001831|Nutrition
1004961|NCT02001792|sedation
1004962|NCT02001792|endoscopy
1004963|NCT02001792|patient positioning
1004964|NCT02001792|hypoxemia
1004965|NCT02001779|Malignant biliary obstruction
1004966|NCT02001779|Obstruction/stricture
1004967|NCT02001779|Stent
1004968|NCT02001779|Brachytherapy
1004969|NCT02001779|Bile duct
1004970|NCT02001766|High intensity exercise
1004971|NCT02001766|Glycemic control
1004972|NCT02001766|Exercise
1004973|NCT02001740|shoulder
1004974|NCT02001701|vitreomacular adhesion
1004975|NCT02001701|vitreomacular traction
1004976|NCT02001701|macular hole
1004977|NCT02001701|epiretinal membrane
1004978|NCT02001701|intravitreal gas
1004979|NCT02001701|sulfahexafluoride gas
1004980|NCT02001701|perfluoropropane gas
1004981|NCT02001701|ocriplasmin
1004982|NCT02001701|vitrectomy
1004983|NCT02001675|Neuromuscular electrical stimulation (NMES)
1004984|NCT02001662|Minor arthroscopic knee surgery including ACL-reconstruction (hamstrins graft)
1004985|NCT02001662|High pain responders
1004986|NCT02001662|Adductore Canal Block
1004987|NCT02001662|Analgesics
1004988|NCT02001662|Ultrasound guided nerve block
1004989|NCT02001649|suicide
1004990|NCT02001649|adolescent
1004991|NCT02001649|genetic
1004992|NCT02001649|SNP
1004993|NCT02001636|Bariatric surgery
1004994|NCT02001636|Protein malnutrition
1004995|NCT02001636|Protein supplementation
1004996|NCT02001636|Body composition
1004997|NCT02001636|Body fat mass
1004998|NCT02001636|Protein intake
1004999|NCT02001623|ovary cancer
1005000|NCT02001623|cervix cancer
1005001|NCT02001623|endometrium cancer
1005002|NCT02001623|bladder cancer
1005003|NCT02001623|prostate cancer (CRPC)
1005004|NCT02001623|esophagus cancer
1005005|NCT02001623|lung cancer(NSCLC)
1005006|NCT02001623|Squamous cell carcinoma of the head and neck (SCCHN)
1005007|NCT02001610|microbiota
1005008|NCT02001610|probiotics
1005009|NCT02001610|fecal markers
1005010|NCT02001597|surgery
1005011|NCT02001597|robotic
1005012|NCT02001597|ultrasound
1005013|NCT02001597|guidance
1005014|NCT02001597|endorectal
1005015|NCT02001571|Prostate Cancer
1005016|NCT02001571|Abiraterone acetate
1005017|NCT02001571|Pharmacokinetics
1005018|NCT02001558|Spinal cord injuries
1005019|NCT02001558|Pressure ulcer
1005020|NCT02001545|acute coronary syndrome, antithrombotic management patterns,quality of life, acute clinical management strategies
1005021|NCT02001532|Diabetes Mellitus, Type 2
1005022|NCT02001532|Diabetes Complications
1005023|NCT02001532|Diabetic Angiopathies
1005024|NCT02001532|Diabetic Nephropathies
1005025|NCT02001532|Myocardial Infarction
1005026|NCT02001532|Stroke
1005027|NCT02001532|Vascular Stiffness
1005028|NCT02001532|Pulse Wave Analysis
1005029|NCT02001506|breast cancer
1005030|NCT02001506|neoadjuvant
1005031|NCT02001506|different number of chemotherapy cycles
1005032|NCT02001441|Physical Activity, Aging, Memory, Cognitive Impairment, MRI, Neuroscience
1005033|NCT02001428|malaria
1005034|NCT02001428|vivax
1005035|NCT02001428|falciparum
1005036|NCT02001428|infants
1005037|NCT02001415|Progressive Myopia
1005038|NCT02001415|Contact Lenses
1005039|NCT02001415|Spectacles
1005040|NCT02001402|climacteric symptoms ; nurse ;
1005041|NCT02001402|intervention;follow-up
1005042|NCT02001389|Enzyme occupancy
1005043|NCT02001389|Positron emission tomography (PET)
1005044|NCT02001389|Phosphodiesterase 10 inhibitor
1005045|NCT02001363|Reperfusion injury
1005046|NCT02001363|Liraglutide
1005047|NCT02001337|pancreatic cancer
1005048|NCT02001337|new-onset diabetic
1005049|NCT02001337|diabetes
1005050|NCT02001324|quality of life, heavy menstrual bleeding, electronic data collection
1005051|NCT02001311|chlorhexidine gel
1005052|NCT02001311|orthodontic brackets
1005053|NCT02001311|orthodontic patients
1005054|NCT02001311|bacterial count
1005055|NCT02001311|friction
1005056|NCT02001298|remifentanil
1005057|NCT02001298|nitroprusside
1005058|NCT02001298|hypotension
1005059|NCT02001285|remifentanil
1005060|NCT02001272|Elderly
1005061|NCT02001272|Vulnerable
1005062|NCT02001272|Ovarian cancer
1005063|NCT02001272|Chemotherapy
1005064|NCT02001259|post-operative pain control
1005065|NCT02001259|total knee arthroplasty
1005066|NCT02001259|epidural steroid injection
1005067|NCT02001246|mindfulness
1005068|NCT02001246|cognitive behavior therapy
1005069|NCT02001246|awareness
1005070|NCT02001246|anger
1005071|NCT02001246|aggression
1005072|NCT02001233|EV71 vaccine
1005073|NCT02001233|EV71-associated HFMD
1005074|NCT02001233|efficacy
1005075|NCT02001233|safety
1005076|NCT02001233|immune persistence
1005077|NCT02001220|screening
1005078|NCT02001220|invasive ventilation
1005079|NCT02001220|mechanical ventilation
1005080|NCT02001220|weaning
1005081|NCT02001220|spontaneous breathing trials
1005082|NCT02001194|Sedentary
1005083|NCT02001194|Behavioral Economic Intervention
1005084|NCT02001194|Team Studies
1005085|NCT02001194|Financial Incentives
1005086|NCT02001194|Workplace Wellness
1005087|NCT02001194|Team Incentives
1005088|NCT02001181|Atopic Dermatitis
1005089|NCT02001181|Atopic Eczema
1005090|NCT02001181|Eczema
1005091|NCT02001181|topical treatment
1005092|NCT02001181|skin diseases
1005093|NCT02001181|tofacitinib
1005094|NCT02001181|CP-690
1005095|NCT02001181|550
1005096|NCT02001181|Janus Kinase inhibitor
1005097|NCT02001155|Water drinking test
1005098|NCT02001155|trabeculectomy
1005099|NCT02001155|tube shunt
1005103|NCT02001129|Eye care adherence
1005104|NCT02001129|health care utilization
1005105|NCT02001116|Quality of care
1005106|NCT02001116|Hospital
1005107|NCT02001116|Children
1005108|NCT02001116|WHO guideline
1005109|NCT02001103|adjuvant therapy
1005110|NCT02001103|cognitive deficits
1005111|NCT02001103|first episode schizophrenia
1005112|NCT02001103|glutamate hypothesis
1005113|NCT02001103|memantine
1005114|NCT02001103|negative symptoms
1005115|NCT02001090|Cardiac Surgical Procedures
1005116|NCT02001090|Heart-Lung Machine
1005117|NCT02001090|Coronary Artery Bypass
1005118|NCT02001090|Brachial Artery
1005119|NCT02001090|Vasodilation
1005120|NCT02001090|Regional Blood Flow
1005121|NCT02001090|Ultrasonography
1005122|NCT02001064|interventions
1005123|NCT02001064|technology
1005124|NCT02001064|adherence
1005125|NCT02001064|ARV
1005126|NCT02001051|Diabetes, Hypertension, Hypercholesterolemia, Obesity, and Osteoporosis.
1005127|NCT02001051|Nonoperative and Operative Management
1005128|NCT02001051|Adrenal Incidentalomas
1005129|NCT02001051|Excess of Cortisol
1005130|NCT02001025|coronary vessels
1005131|NCT02001025|coronary stenosis
1005132|NCT02001025|percutaneous transluminal angioplasty
1005133|NCT02001025|stents
1005134|NCT02001025|drug-eluting stents
1005135|NCT02001025|bioresorbable scaffolds
1005136|NCT02001025|optical coherence tomography
1005137|NCT02001012|uncomplicated
1005138|NCT02001012|plasmodium
1005139|NCT02001012|knowlesi
1005140|NCT02001012|malaria
1005141|NCT02001012|infection
1005142|NCT02000999|Bile duct stricture
1005143|NCT02000999|Cholangiocarcinoma
1005144|NCT02000999|Pancreatic cancer
1005145|NCT02000999|Chronic pancreatitis
1005146|NCT02000986|Hodgkin's Lymphoma
1005147|NCT02000986|Brain and Nervous System
1005148|NCT02000986|Non-Hodgkin's Lymphoma
1005149|NCT02000986|Leukemia, not otherwise specified
1005150|NCT02000960|Glut1 DS
1005151|NCT02000947|anti-CTLA-4
1005152|NCT02000947|anti-PD-L1
1005153|NCT02000947|immunotherapy
1005154|NCT02000947|IMTC
1005155|NCT02000934|TAK-659
1005156|NCT02000934|Solid Tumors
1005157|NCT02000934|CLL
1005158|NCT02000934|DLBCL
1005159|NCT02000921|Cigarette Smoking
1005160|NCT02000921|Very Low Nicotine Content cigarettes (VLNC)
1005161|NCT02000921|Dual Tobacco Use
1005162|NCT02000908|gynecological cancer
1005163|NCT02000908|ovarian cancer
1005164|NCT02000908|primary peritoneal cancer
1005165|NCT02000908|cervical caner
1005166|NCT02000908|peripheral neuropathy
1005167|NCT02000882|Breast Cancer
1005168|NCT02000882|Triple Negative Breast Cancer
1005169|NCT02000882|Brain Metastases
1005170|NCT02000882|Capecitabine
1005171|NCT02000882|Metastatic Breast Cancer
1005172|NCT02000843|perforation
1005173|NCT02000843|tympanoplasty
1005174|NCT02000843|conchal cavum approach
1005175|NCT02000843|perichondrium/ cartilage
1005176|NCT02000843|scar
1005177|NCT02000830|stannsoporfin
1005184|NCT02000804|Darapladib, Safety, Pharmacokinetics, Pharmacodynamics, Healthy Chinese Subjects
1005185|NCT02000791|cLMA
1005186|NCT02000791|laryngoscopy
1005187|NCT02000791|fiberoptic
1005188|NCT02000778|Occult Ovarian Carcinoma
1005189|NCT02000765|oral
1005190|NCT02000765|ADME
1005191|NCT02000765|IV
1005192|NCT02000765|antibiotic
1005193|NCT02000765|healthy volunteer
1005194|NCT02000765|[14C]-GSK2140944
1005195|NCT02000765|mass balance
1005196|NCT02000765|radiolabel
1005197|NCT02000752|Labor
1005198|NCT02000752|Acupuncture
1005199|NCT02000752|Placental expulsion time
1005200|NCT02000752|Postpartum hemorrhage
1005201|NCT02000739|Breast cancer
1005202|NCT02000739|melanoma
1005203|NCT02000739|GI cancer
1005204|NCT02000739|ovarian cancer
1005205|NCT02000739|lung cancer
1005206|NCT02000739|metastatic cancer
1005207|NCT02000739|brain cancer
1005208|NCT02000739|head and neck cancer
1005209|NCT02000700|Diabetes Mellitus, Type 2
1005210|NCT02000700|Canagliflozin
1005211|NCT02000700|JNJ-28431754
1005212|NCT02000700|Pharmacokinetics
1005213|NCT02000700|Pharmacodynamics
1005214|NCT02000700|Children
1005215|NCT02000700|Adolescents
1005216|NCT02000674|tracheal intubation
1005217|NCT02000674|pre hospital emergency
1005218|NCT02000661|Fractional Flow Reserve (FFR)
1005219|NCT02000661|FFR guided coronary interventions
1005220|NCT02000661|Percutaneous Coronary Intervention
1005221|NCT02000648|Allergic Rhinitis
1005222|NCT02000648|Non-allergic Rhinitis
1005223|NCT02000648|Chronic urticaria
1005224|NCT02000622|Breast Cancer
1005225|NCT02000622|Metastatic
1005226|NCT02000622|Olaparib
1005227|NCT02000622|BRCA
1005228|NCT02000622|PARP inhibitor
1005229|NCT02000622|HER2
1005230|NCT02000622|chemotherapy
1005231|NCT02000609|pharmacodynamics COPD
1005232|NCT02000596|HER2 overexpressed
1005233|NCT02000596|Metastatic Breast Cancer
1005234|NCT02000596|Elderly
1005235|NCT02000583|Alzheimer's Disease
1005236|NCT02000583|AD
1005237|NCT02000583|Aerobic Exercise
1005238|NCT02000583|Exercise
1005239|NCT02000570|sitting position
1005240|NCT02000570|PPV
1005241|NCT02000570|SVV
1005242|NCT02000570|PVI
1005243|NCT02000570|fluid challenge
1005244|NCT02000570|preload indicators
1005245|NCT02000557|Photographic analysis
1005246|NCT02000557|Cephalometric analysis
1005247|NCT02000557|Standardized photographs
1005248|NCT02000557|Angular measurements
1005249|NCT02000557|Linear measurements
1005250|NCT02000557|Malocclusion
1005251|NCT02000557|Facial Profile
1005252|NCT02000544|Extracorporeal Circulation
1005253|NCT02000544|Cardiopulmonary Bypass
1005254|NCT02000544|Cardiac surgery
1005255|NCT02000531|Non-small-cell lung cancer (NSCLC)
1005256|NCT02000518|emergency radiotherapy
1005257|NCT02000518|MSCC
1005258|NCT02000518|spine
1005259|NCT02000518|neurological outcome
1005260|NCT02000466|Women
1005261|NCT02000466|Pregnancy exposure
1005262|NCT02000466|FluLaval Quadrivalent
1005263|NCT02000466|Pregnancy outcome
1005264|NCT02000466|Pregnancy Registry
1005265|NCT02000453|Quality of Life
1005266|NCT02000453|Infection
1005267|NCT02000453|GSK2586184
1005268|NCT02000453|ulcerative colitis
1005269|NCT02000440|GW856553
1005270|NCT02000440|Focal segmental glomerulosclerosis (FSGS)
1005271|NCT02000440|p38 mitogen-activated protein kinase (MAPK) inhibitor
1005272|NCT02000440|losmapimod
1005273|NCT02000440|nephrotic syndrome
1005274|NCT02000427|Relapsed; Refractory; Philadelphia Positive; B-precursor; Acute Lymphoblastic Leukemia; ALL; Blinatumomab; Leukemia;
1005275|NCT02000414|intraperitoneal
1005276|NCT02000414|peritoneal dialysis
1005277|NCT02000414|daptomycin
1005278|NCT02000414|pharmacokinetics
1005279|NCT02000414|peritonitis
1005280|NCT02000375|metastatic breastcancer
1005281|NCT02000375|ER/PgR-negative/AR-positive
1005282|NCT02000375|ER and/or PgR-positive/AR-positive
1005283|NCT02000375|Androgen Receptor positve
1005284|NCT02000362|Crohn's Disease
1005285|NCT02000362|Stem cell
1005286|NCT02000362|Cell therapy
1005287|NCT02000362|Auto-immune disease
1005288|NCT02000362|furestem
1005289|NCT02000362|CD
1005290|NCT02000362|inflammatory bowel disease
1005291|NCT02000362|MSCs
1005292|NCT02000362|Mesenchymal Stem Cells
1005293|NCT02000362|hUCB-MSC
1005294|NCT02000362|UCB-MSC
1005295|NCT02000362|Umbilical cord Blood
1005296|NCT02000349|infertility
1005297|NCT02000349|next generation sequencing
1005298|NCT02000336|radiographic damage
1005299|NCT02000336|rheumatoid arthritis
1005300|NCT02000323|pancreatitis
1005301|NCT02000323|enteral nutrition
1005302|NCT02000310|Gaucher disease
1005303|NCT02000310|Fabry disease
1005304|NCT02000310|Pompe disease
1005305|NCT02000310|Niemann-Pick disease
1005306|NCT02000297|Osteoarthritis
1005307|NCT02000297|Knee
1005308|NCT02000297|High tibial osteotomy
1005309|NCT02000297|Calcium phosphate
1005310|NCT02000297|Calcium sulfate
1005311|NCT02000284|Autism Spectrum Disorder
1005312|NCT02000284|ASD
1005313|NCT02000284|Autism
1005314|NCT02000284|Pervasive developmental disorder - Not Otherwise Specified
1005315|NCT02000284|PDD-NOS
1005316|NCT02000284|Asperger's Syndrome
1005317|NCT02000284|Mitochondrial Disease
1005318|NCT02000284|Developmental Delay
1005319|NCT02000284|Typical Development
1005320|NCT02000258|Anterior cruciate ligament reconstruction
1005321|NCT02000258|Double-bundle
1005322|NCT02000258|MRI
1005323|NCT02000258|Graft location
1005324|NCT02000245|bronchoscopy
1005325|NCT02000245|anxiety
1005326|NCT02000245|touch
1005327|NCT02000245|sympathy
1005328|NCT02000232|gout
1005329|NCT02000232|colchicine
1005330|NCT02000219|hyperoxaluria
1005331|NCT02000219|oxalate
1005332|NCT02000219|PH
1005333|NCT02000219|dialysis
1005334|NCT02000206|Ketamine
1005335|NCT02000206|Alfentanil
1005336|NCT02000206|Propofol
1005337|NCT02000206|Oxygen saturation
1005338|NCT02000206|Percutaneous carbon dioxide
1005339|NCT02000206|Bronchoscopy
1005340|NCT02000167|Electron Transport Chain
1005341|NCT02000167|Mitochondrial Disease
1005342|NCT02000167|Chromosomal Deletion
1005343|NCT02000128|Peritoneal Dialysis
1005344|NCT02000128|fluid overload
1005345|NCT02000128|bioimpedance analysis
1005346|NCT02000128|Randomized Controlled Trial
1005347|NCT02000089|familial pancreas cancer
1005348|NCT02000089|(Peutz-Jeghers Syndrome) PJS
1005349|NCT02000089|Breast cancer (BRCA) 2
1005350|NCT02000089|Partner and Locator of BRCA2 (PALB2)
1005351|NCT02000089|Familial Atypical Multiple Mole- Melanoma (FAMMM)
1005352|NCT02000089|p16
1005353|NCT02000089|Breast Cancer (BRCA)1
1005354|NCT02000089|(hereditary non-polyposis colorectal cancer or Lynch syndrome) HNPCC
1005355|NCT02000089|Lynch Syndrome
1005356|NCT02000089|hereditary pancreatitis
1005357|NCT02000089|Protease Serine (PRSS)
1005358|NCT02000089|Chymotrypsin C (CTRC)
1005359|NCT02000089|Ataxia Telangiectasia Mutated(ATM)
1005360|NCT02000076|Sleep
1005361|NCT02000076|resting state
1005362|NCT02000076|functional connectivity
1005363|NCT02000076|emotional contagion
1005364|NCT02000076|empathy
1005365|NCT02000076|emotional regulation
1005366|NCT02000063|Hepatitis C
1005367|NCT02000063|acute
1005368|NCT02000063|early chronic
1005369|NCT02000050|resectable rectal cancer
1005370|NCT02000050|up-front chemotherapy
1005371|NCT02000050|neo-adjuvant short course radiotherapy
1005372|NCT02000050|short course radiotherapy
1005373|NCT02000011|patients
1005374|NCT02000011|aged 70 years old
1005375|NCT02000011|thoracic,
1005376|NCT02000011|digestive or
1005377|NCT02000011|urological
1005378|NCT02000011|resectable
1005379|NCT01999985|Epidermal Growth Factor Receptor (EGFR)
1005380|NCT01999985|Tyrosine kinase inhibitors
1005381|NCT01999985|Neoplasms
1005382|NCT01999985|Lung Diseases
1005383|NCT01999985|Respiratory Tract Diseases
1005384|NCT01999985|Pleural Diseases
1005385|NCT01999985|Pleural Neoplasms
1005386|NCT01999985|Lung Neoplasms
1005387|NCT01999985|Pleural Effusion
1005388|NCT01999985|Pleural Effusion, Malignant
1005389|NCT01999985|Respiratory Tract Neoplasms
1005390|NCT01999985|Thoracic Neoplasms
1005391|NCT01999985|Neoplasms by Site
1005392|NCT01999985|EGFR mutation
1005393|NCT01999985|Afatinib
1005394|NCT01999985|Dasatinib
1005395|NCT01999985|Carcinoma, Bronchogenic
1005396|NCT01999985|Gene Mutation
1005397|NCT01999985|T790M mutation.
1005398|NCT01999985|Non-small cell lung cancer
1005399|NCT01999972|Carcinoma
1005400|NCT01999972|Renal Cell
1005401|NCT01999959|Unexplained Infertility, Pertubation, Gonadotrophin, Ovulation Induction, Intrauterine Insemination
1005402|NCT01999946|Heroin Dependence
1005403|NCT01999946|Opioid-Related Disorders
1005404|NCT01999933|Cervical cancer
1005405|NCT01999933|postoperative risk factor
1005406|NCT01999933|treatment
1005407|NCT01999920|Adult separation anxiety disorder
1005408|NCT01999920|ASAD
1005409|NCT01999907|asthma
1005410|NCT01999907|virus diseases
1005411|NCT01999907|pediatric
1005412|NCT01999907|RCT
1005413|NCT01999907|steroid
1005414|NCT01999894|Namenda
1005415|NCT01999894|Autism
1005416|NCT01999894|Memantine
1005417|NCT01999894|Pediatric
1005418|NCT01999894|Forest Laboratories
1005419|NCT01999868|psoriasis vulgaris
1005420|NCT01999868|ustekinumab
1005421|NCT01999868|abatacept
1005422|NCT01999842|H7N9
1005423|NCT01999842|Influenza
1005424|NCT01999842|Safety
1005425|NCT01999842|Adults
1005426|NCT01999842|Adjuvant
1005427|NCT01999842|Immunogenicity
1005428|NCT01999816|pressure ulcer
1005429|NCT01999816|lifestyle redesign
1005430|NCT01999816|spinal cord injury
1005431|NCT01999790|upper lid
1005432|NCT01999790|exophthalmos
1005433|NCT01999790|grave's orbitopathy
1005434|NCT01999777|Epilepsy
1005435|NCT01999777|seizure clusters
1005436|NCT01999777|acute repetitive seizures
1005437|NCT01999777|rescue treatment
1005438|NCT01999751|Magnetic Resonance Imaging
1005439|NCT01999751|Pacemaker, Artificial
1005440|NCT01999751|Defibrillators, Implantable
1005441|NCT01999725|Normal Volunteers, Safety, Pharmacokinetics
1005442|NCT01999712|heart failure
1005443|NCT01999712|left ventricular assist device
1005444|NCT01999712|right ventricular failure
1005445|NCT01999699|Heplisav
1005446|NCT01999686|Polycystic ovarium syndrome
1005447|NCT01999686|DLBS3233
1005448|NCT01999686|metformin
1005449|NCT01999686|insulin resistance
1005450|NCT01999686|Female
1005451|NCT01999673|SUNRISE
1005452|NCT01999673|PPHM 1202
1005453|NCT01999673|Bavituximab
1005454|NCT01999673|Peregrine
1005455|NCT01999660|Prostatic Neoplasms
1005456|NCT01999660|Radiotherapy
1005457|NCT01999660|rectal toxicity
1005458|NCT01999647|Lower Extremity
1005459|NCT01999647|Sciatic Nerve
1005460|NCT01999647|Anesthetics, Local
1005461|NCT01999647|Ropivacaine
1005462|NCT01999647|Ultrasonography
1005463|NCT01999634|rectum
1005464|NCT01999634|microdialysis
1005465|NCT01999634|anastomotic leaks
1005466|NCT01999621|organ failure
1005467|NCT01999621|intensive care
1005468|NCT01999621|palliative care
1005469|NCT01999621|patient's wishes
1005470|NCT01999608|Infertility
1005471|NCT01999595|transcutaneous electrical nerve stimulation
1005472|NCT01999595|pad size
1005473|NCT01999595|pulse frequency
1005474|NCT01999595|blunt pressure pain
1005475|NCT01999595|healthy humans.
1005476|NCT01999582|Anemia
1005477|NCT01999582|End Stage Kidney Disease
1005478|NCT01999582|Chronic Kidney Disease
1005479|NCT01999582|Dialysis
1005480|NCT01999582|Erythrpoietin Stimulating Agent (ESA)
1005481|NCT01999543|Blood glucose
1005482|NCT01999530|prazosin
1005483|NCT01999530|dopamine
1005484|NCT01999530|healthy
1005485|NCT01999530|Positron Emission Tomography
1005486|NCT01999530|PHNO
1005487|NCT01999530|scan
1005488|NCT01999530|effect
1005489|NCT01999504|Glucagon-like peptide-1
1005490|NCT01999504|Glucose-dependent Insulinotropic Peptide
1005491|NCT01999504|Peptide YY
1005492|NCT01999504|Glucagon
1005493|NCT01999504|Satiety
1005494|NCT01999504|Meal
1005495|NCT01999504|palaeolithic
1005496|NCT01999491|Advanced Cancers
1005497|NCT01999491|Lymphoma
1005498|NCT01999491|Advanced Solid Tumors
1005499|NCT01999491|NC-4016
1005500|NCT01999465|Brachial plexus injury
1005501|NCT01999465|Brachial plexus palsy
1005502|NCT01999465|Neonate
1005503|NCT01999452|Paleolithic diet
1005504|NCT01999426|Physical Therapy Modalities
1005505|NCT01999426|Pediatrics
1005506|NCT01999426|Critical Care
1005507|NCT01999426|Respiration, Artificial
1005508|NCT01999413|AML
1005509|NCT01999413|high-risk cytogenetics
1005510|NCT01999413|younger patients
1005511|NCT01999413|Induction treatment
1005512|NCT01999413|OMEGAVEN
1005513|NCT01999387|food
1005514|NCT01999387|consumption
1005515|NCT01999309|Schizophrenia spectrum disorders
1005516|NCT01999283|Cervical pain
1005517|NCT01999283|yoga
1005518|NCT01999283|pilates
1005519|NCT01999283|exercise
1005520|NCT01999257|Genetic Counseling
1005521|NCT01999257|Technology
1005522|NCT01999257|Ashkenazi Jewish
1005523|NCT01999257|Carrier screening
1005524|NCT01999244|Overweight
1005525|NCT01999244|Obesity
1005526|NCT01999244|Weight Loss
1005527|NCT01999244|Self-monitoring
1005528|NCT01999244|Food Records
1005529|NCT01999244|Self-weighing
1005530|NCT01999244|Technology
1005531|NCT01999231|Safety
1005532|NCT01999231|Tolerability
1005533|NCT01999231|ESAT6
1005534|NCT01999231|CFP10
1005535|NCT01999231|skin test
1005536|NCT01999231|diagnostic test
1005537|NCT01999205|workplace
1005538|NCT01999205|intervention
1005539|NCT01999205|physical activity
1005540|NCT01999205|sedentary behavior
1005541|NCT01999205|evaluation
1005542|NCT01999192|inadequate response to MTX
1005543|NCT01999192|Methotrexate
1005544|NCT01999192|rheumatoid Arthritis
1005545|NCT01999192|Phase 2b
1005546|NCT01999179|catheter related thrombosis
1005547|NCT01999179|upper extremity deep venous thrombosis
1005548|NCT01999179|central venous catheters
1005549|NCT01999179|cancer
1005550|NCT01999179|Catheters
1005551|NCT01999153|skin graft
1005552|NCT01999153|donor site
1005553|NCT01999114|Healthy subjects
1005554|NCT01999114|Opioid
1005555|NCT01999114|Transdermal
1005556|NCT01999114|ECG
1005557|NCT01999088|Fatty Acids, Omega-3
1005558|NCT01999088|Rosemary extract
1005559|NCT01999088|Functional meat
1005560|NCT01999088|Cardiovascular disease
1005561|NCT01999075|Duchenne Muscular Dystrophy
1005562|NCT01999075|Pulmonary complications
1005563|NCT01999075|Lung volume recruitment,
1005564|NCT01999075|Breath-stacking,
1005565|NCT01999075|Cough efficacy,
1005566|NCT01999075|Maximal insufflation capacity
1005567|NCT01999062|Breast RT
1005568|NCT01999062|Breast radiation therapy
1005569|NCT01999036|cardiac arrest, CPR, resuscitation
1005570|NCT01999010|psychiatry
1005571|NCT01999010|mental health
1005572|NCT01999010|major depressive disorder
1005573|NCT01999010|self-management
1005574|NCT01999010|data visualization
1005575|NCT01999010|mood diaries
1005576|NCT01999010|electronic diaries
1005577|NCT01999010|cell phones
1005578|NCT01999010|software
1005579|NCT01999010|mental health telemetry
1005580|NCT01999010|ecological momentary assessment
1005581|NCT01998997|Delirium
1005582|NCT01998997|Hospitalized elderly
1005583|NCT01998971|Multiple myeloma
1005584|NCT01998971|Daratumumab
1005585|NCT01998971|JNJ-54767414
1005586|NCT01998971|Velcade-dexamethasone
1005587|NCT01998971|Velcade-melphalan-prednisone
1005588|NCT01998971|Velcade-thalidomide-dexamethasone
1005589|NCT01998971|Pomalidomide-dexamethasone
1005590|NCT01998971|Carfilzomib-dexamethasone
1005591|NCT01998971|Carfilzomib-lenalidomide-dexamethasone
1005592|NCT01998971|Anti-CD38 Monoclonal Antibody
1005593|NCT01998971|Immunomodulatory drug
1005594|NCT01998971|IMiD
1005595|NCT01998958|Treatment resistant depressive disorder
1005596|NCT01998958|Intranasal esketamine
1005597|NCT01998958|Efficacy
1005598|NCT01998958|SYNAPSE
1005599|NCT01998958|JNJ-54135419
1005600|NCT01998945|Exposure therapy
1005601|NCT01998945|Cognitive behavioral therapy
1005602|NCT01998945|Relaxation Training
1005603|NCT01998945|Older Adults
1005604|NCT01998945|Fall Injury
1005605|NCT01998945|Anxiety
1005606|NCT01998945|Posttraumatic Stress
1005607|NCT01998932|Venous Ulcer
1005608|NCT01998932|Leg Ulcer
1005609|NCT01998932|Metabonomics
1005610|NCT01998932|Ulcer Fluid
1005611|NCT01998854|Menorrhagia
1005612|NCT01998854|Leiomyoma
1005613|NCT01998854|Uterine Fibroids
1005614|NCT01998828|Polycythemia
1005615|NCT01998828|Polycythemia Vera
1005616|NCT01998828|Essential Thrombocythemia
1005617|NCT01998828|Thrombocytosis
1005618|NCT01998828|Myeloproliferative Disorders
1005619|NCT01998828|Bone Marrow Diseases
1005620|NCT01998828|Hematologic Diseases
1005621|NCT01998828|Blood Coagulation Disorders
1005622|NCT01998828|Blood Platelet Disorders
1005623|NCT01998828|Hemorrhagic Disorders
1005624|NCT01998789|Liver Transplantation
1005625|NCT01998789|Everolimus
1005626|NCT01998789|Immunosuppression
1005627|NCT01998776|ulcer
1005628|NCT01998763|Vitamin D3 supplementation
1005629|NCT01998763|metabolite profile
1005630|NCT01998763|SNPs
1005631|NCT01998763|bone-turnover marker
1005632|NCT01998750|obesity
1005633|NCT01998750|genetics
1005634|NCT01998750|early-onset
1005635|NCT01998750|childhood
1005636|NCT01998737|Osteoporosis, diagnostics, ultrasound
1005637|NCT01998724|Chronic bronchitis
1005638|NCT01998724|Emphysema
1005639|NCT01998724|Pulmonary
1005640|NCT01998724|COPD
1005641|NCT01998711|Alzheimer's disease
1005642|NCT01998711|Mild cognitive impairment
1005643|NCT01998711|Memory intervention
1005644|NCT01998711|Strategy use
1005645|NCT01998711|Memory group
1005646|NCT01998698|cataract
1005647|NCT01998698|phacoemulsification
1005648|NCT01998698|monovision
1005649|NCT01998698|multifocal lens
1005650|NCT01998685|Prostatectomy
1005651|NCT01998685|Coagulation Factor
1005652|NCT01998685|Balanced Anesthesia
1005653|NCT01998685|Intravenous Anesthesia,
1005654|NCT01998646|ASP4058
1005655|NCT01998646|healthy subjects
1005656|NCT01998633|Hemophagocytic lymphohistiocytosis
1005657|NCT01998633|Chronic Active EBV
1005658|NCT01998633|Chronic Granulomatous Disease
1005659|NCT01998633|Hyperimmunoglobulin M Syndrome (Hyper IGM)
1005660|NCT01998633|Leukocyte Adhesion Deficiency
1005661|NCT01998633|IPEX
1005662|NCT01998633|Hematopoietic Stem Cell Transplant (HSCT)
1005663|NCT01998633|Non-Myeloablative Transplant (NST)
1005664|NCT01998633|Reduced-Intensity Conditioning (RIC)
1005665|NCT01998620|Hepatitis B
1005666|NCT01998620|Cholestasis
1005667|NCT01998607|Solid tumours
1005668|NCT01998607|Bone Metastasis
1005669|NCT01998594|Thumb arthritis
1005670|NCT01998594|CMC arthritis
1005671|NCT01998594|Arthroplasty
1005672|NCT01998568|Intraocular pressure
1005673|NCT01998568|Corneal edema
1005674|NCT01998568|Tonometer
1005675|NCT01998568|Dynamic contour tonometer
1005676|NCT01998568|Tonopen
1005677|NCT01998568|iCare
1005678|NCT01998568|Goldmann applanation
1005679|NCT01998542|Head and neck cancers
1005680|NCT01998542|tumor vaccine
1005681|NCT01998542|immunotherapy
1005682|NCT01998542|personalized anti-cancer vaccine
1005699|NCT01998516|Emotional Intelligence
1005700|NCT01998503|AL amyloidosis
1005701|NCT01998503|bortezomib
1005702|NCT01998503|autologous stem cell transplantation
1005703|NCT01998477|Influenza
1005704|NCT01998477|Vaccine
1005705|NCT01998477|Flu
1005706|NCT01998477|Children
1005707|NCT01998477|Adolescents
1005708|NCT01998464|Retinal Vasculitis
1005709|NCT01998464|Optical coherence tomography
1005710|NCT01998464|OCT
1005711|NCT01998464|Imaging
1005712|NCT01998451|double sphincter in gallbladder
1005713|NCT01998451|recurrence rate of gallstones
1005714|NCT01998438|tranexamic acid
1005715|NCT01998438|cardiac surgery
1005716|NCT01998438|cardiopulmonary bypass
1005717|NCT01998425|circulating fibrocytes
1005718|NCT01998425|fibrocyte
1005719|NCT01998425|NSCLC
1005720|NCT01998425|treatment response
1005721|NCT01998425|survival
1005722|NCT01998425|stage
1005723|NCT01998399|CAP
1005724|NCT01998399|Pneumonia
1005725|NCT01998399|Intensive Care Unit
1005726|NCT01998399|Mechanical Ventilation
1005727|NCT01998386|Tooth Whitening
1005728|NCT01998386|Adolescent
1005729|NCT01998386|Clinical Trial
1005730|NCT01998373|Patient training
1005731|NCT01998373|Rheumatoid arthritis
1005732|NCT01998373|Quality of life
1005733|NCT01998360|Circumcision
1005734|NCT01998360|Voluntary medical male circumcision
1005735|NCT01998360|Minimally-invasive
1005736|NCT01998360|HIV prevention
1005737|NCT01998334|Systemic Inflammatory Response Syndrome
1005738|NCT01998334|Continuous Blood Purification
1005739|NCT01998321|PSI: Patient Specific Instrument
1005740|NCT01998321|TKA: Total Knee Arthroplasty
1005741|NCT01998321|Articular Deformity
1005742|NCT01998321|Varus
1005743|NCT01998295|Clearance time
1005744|NCT01998295|Recurrence time
1005745|NCT01998295|Artemether/lumefantrine
1005746|NCT01998295|P. falciparum
1005747|NCT01998295|Uncomplicated malaria
1005748|NCT01998295|Children
1005874|NCT01997840|Neoplasms
1005749|NCT01998282|Focus of study is to assess filter/stove use and efficacy in reducing exposure to waterborne and airborne pathogens.
1005750|NCT01998256|AV optimization
1005751|NCT01998256|Interatrial conduction delay
1005752|NCT01998243|morbid obesity
1005753|NCT01998243|bioenterics intragastric balloon
1005754|NCT01998243|bariatric surgery
1005755|NCT01998230|esophageal cancer
1005756|NCT01998230|esophagectomy
1005757|NCT01998230|oral feeding
1005758|NCT01998217|extracorporeal shock wave lithotripsy
1005759|NCT01998217|remifentanil
1005760|NCT01998217|flurbiprofen
1005761|NCT01998217|pancreatic stone
1005762|NCT01998204|Parkinson's disease
1005763|NCT01998204|propofol
1005764|NCT01998204|deep brain stimulator
1005765|NCT01998191|mortality
1005766|NCT01998191|adverse events
1005767|NCT01998165|Anesthesia
1005768|NCT01998165|Remifentanil
1005769|NCT01998165|Ultiva
1005770|NCT01998113|gestational diabetes mellitus
1005771|NCT01998113|glyburide
1005772|NCT01998113|metformin
1005773|NCT01998113|oral agents
1005774|NCT01998113|insulin
1005775|NCT01998113|outcomes
1005776|NCT01998100|PTSD
1005777|NCT01998100|Anxiety
1005778|NCT01998100|Behavior Therapy
1005779|NCT01998100|Prolonged Exposure
1005780|NCT01998100|Exercise
1005781|NCT01998100|Wellness
1005782|NCT01998100|Post-traumatic
1005783|NCT01998100|Stress
1005784|NCT01998087|Exclusive breastfeeding
1005785|NCT01998087|Breastfeeding
1005786|NCT01998087|Proactive breastfeeding support
1005787|NCT01998087|Telephone breastfeeding support
1005788|NCT01998087|Infant feeding attitudes
1005789|NCT01998087|Breastfeeding self-efficacy
1005790|NCT01998087|Breastfeeding difficulties
1005791|NCT01998074|Cow's Milk protein Allergy
1005792|NCT01998048|surgical treatment
1005793|NCT01998048|Bankart
1005794|NCT01998048|Latarjet
1005795|NCT01998048|redislocation
1005796|NCT01998035|Lymphoid Malignancies
1005797|NCT01998035|Lymphoma
1005798|NCT01998035|Hodgkin Lymphoma
1005799|NCT01998035|Non-hodgkin Lymphoma
1005800|NCT01998035|Follicular Lymphoma
1005801|NCT01998035|Diffuse Large B-Cell Lymphoma
1005802|NCT01998035|Anaplastic Large Cell Lymphoma
1005803|NCT01998035|Chronic Lymphocytic Leukemia
1005804|NCT01998035|Small Lymphocytic Lymphoma
1005805|NCT01998035|Mantle Cell Lymphoma
1005806|NCT01998035|Marginal Zone Lymphoma
1005807|NCT01998035|Burkitt Lymphoma
1005808|NCT01998035|Waldenstrom Macroglobulinemia
1005809|NCT01998035|Peripheral T-cell Lymphoma
1005810|NCT01998035|Cutaneous T-cell Lymphoma
1005811|NCT01998022|hypertension
1005812|NCT01998022|knowledge
1005813|NCT01998022|blood pressure control
1005814|NCT01998009|colorectal cancer
1005815|NCT01998009|mass screening
1005816|NCT01998009|fecal occult blood
1005817|NCT01997996|Pelvic Organ Prolapse
1005818|NCT01997996|PROLIFT+M
1005819|NCT01997996|Vita sexualis
1005820|NCT01997983|interstitial cystitis
1005821|NCT01997983|PBS/IC
1005822|NCT01997983|IC
1005823|NCT01997983|Botox
1005824|NCT01997983|Botulinum toxin
1005825|NCT01997983|TC-3 Gel
1005826|NCT01997983|TCGel
1005827|NCT01997983|TheraCoat
1005828|NCT01997970|NEAT
1005829|NCT01997970|Treadmill desk
1005830|NCT01997957|Hepatocellular Carcinoma
1005831|NCT01997957|Transarterial Chemoembolization
1005832|NCT01997957|Hepatic Arterial Infusion Chemotherapy
1005833|NCT01997957|Efficacy
1005834|NCT01997931|bispectral index
1005835|NCT01997931|sedation
1005836|NCT01997931|intensive care
1005837|NCT01997931|mechanical ventilation
1005838|NCT01997918|Secondary allogeneic HSCT
1005839|NCT01997918|Haploidentical HSCT
1005840|NCT01997905|Left Atrial Appendage
1005841|NCT01997905|LAA
1005842|NCT01997905|Atrial Fibrillation
1005843|NCT01997905|AFib
1005844|NCT01997905|AF
1005845|NCT01997905|IRB approved
1005846|NCT01997905|clinical
1005847|NCT01997905|Stroke
1005848|NCT01997905|TIA
1005849|NCT01997905|contraindication to oral anticoagulation therapy
1005850|NCT01997905|Arrhythmias, Cardiac
1005851|NCT01997905|OAC
1005852|NCT01997905|trial
1005853|NCT01997905|study
1005854|NCT01997905|LAA occlusion
1005855|NCT01997905|occluded
1005856|NCT01997905|prevent
1005857|NCT01997892|CKD
1005858|NCT01997892|Darbepoetin Alfa
1005859|NCT01997892|Dialysis
1005860|NCT01997892|Hemodialysis
1005861|NCT01997892|Anemia
1005862|NCT01997892|Peg epoetin beta
1005863|NCT01997866|Obstructive Sleep Apnea
1005864|NCT01997866|Sleep Apnea
1005865|NCT01997866|Congestive Heart Failure
1005866|NCT01997866|Heart Failure
1005867|NCT01997853|Omega 3 fatty acids
1005868|NCT01997853|C Reactive Protein
1005869|NCT01997853|Host Modulation
1005870|NCT01997853|Chronic Periodontitis
1005871|NCT01997840|Multiple Myeloma
1005872|NCT01997840|Neoplasms, Plasma Cell
1005873|NCT01997840|Neoplasms by Histologic Type
1005875|NCT01997840|Blood Protein Disorders
1005876|NCT01997840|Hematologic Diseases
1005877|NCT01997840|Dexamethasone
1005878|NCT01997840|Dexamethasone acetate
1005879|NCT01997840|Pomalidomide
1005880|NCT01997814|Herbal medicine,
1005881|NCT01997814|Host modulation therapy,
1005882|NCT01997814|Periodontitis,
1005883|NCT01997814|Meta-analysis,
1005884|NCT01997814|Scaling and root planing.
1005885|NCT01997801|Thyroidectomy
1005886|NCT01997801|Endoscopy
1005887|NCT01997801|Ketamine
1005888|NCT01997801|Acute Pain
1005889|NCT01997801|Chronic Pain
1005890|NCT01997801|Postoperative period
1005891|NCT01997788|Injection, Spinal
1005892|NCT01997788|Morphine
1005893|NCT01997788|Analgesia
1005894|NCT01997788|Patient-Controlled
1005895|NCT01997788|Pain
1005896|NCT01997788|Postoperative
1005897|NCT01997788|Combined Modality Therapy
1005898|NCT01997788|Nephrectomy
1005899|NCT01997775|IL-6
1005900|NCT01997775|Metformin
1005901|NCT01997775|Non-small cell lung cancer
1005902|NCT01997775|Lung adenocarcinoma
1005903|NCT01997762|resveratrol,
1005904|NCT01997762|gestational diabetes,
1005905|NCT01997762|beta cell function
1005906|NCT01997762|history
1005907|NCT01997749|stroke, ketogenic diet, ketosis, ischemia, brain, ketones, hyperglycemia, neuroprotection
1005908|NCT01997736|Paroxysmal Atrial Fibrillation
1005909|NCT01997736|Catheter Ablation
1005910|NCT01997736|Ablation Techniques
1005911|NCT01997723|OSA, portable monitoring, home diagnosis
1005912|NCT01997684|Colorectal Cancer
1005913|NCT01997684|Colonic Obstruction
1005914|NCT01997671|Primary Care
1005915|NCT01997671|Lipid-lowering therapy
1005916|NCT01997671|Prescription
1005917|NCT01997671|Adequacy
1005918|NCT01997671|Primary prevention
1005919|NCT01997671|Cardiovascular diseases
1005920|NCT01997671|Electronic Medical records
1005921|NCT01997671|Clinical Practice Guideline
1005922|NCT01997658|Glucocorticoids
1005923|NCT01997658|Total complication rate
1005924|NCT01997658|Hepatectomy.
1005925|NCT01997645|Anal fistula
1005926|NCT01997645|Rectal fistula
1005927|NCT01997645|Intersphincteric fistula
1005928|NCT01997645|Perianal fistula
1005929|NCT01997632|Poliomyelitis
1005930|NCT01997632|Vaccine
1005931|NCT01997619|biological mesh
1005932|NCT01997619|contaminated hernia
1005933|NCT01997619|abdominal wall reconstruction
1005934|NCT01997593|analgesia
1005935|NCT01997593|pediatric
1005936|NCT01997593|pain
1005937|NCT01997593|laparoscopy
1005938|NCT01997593|ropivacaine
1005939|NCT01997580|depression
1005940|NCT01997580|treatment
1005941|NCT01997580|electrophysiology
1005942|NCT01997580|biomarker
1005943|NCT01997567|Hip Arthroscopy
1005944|NCT01997567|Regional Anesthesia
1005945|NCT01997567|Peripheral Nerve block
1005946|NCT01997554|TSH Testing
1005947|NCT01997554|sub-clinical hypothyroidism
1005948|NCT01997515|QOR-40
1005949|NCT01997515|Pain
1005950|NCT01997515|Hypoxia
1005951|NCT01997515|Gastric Surgery
1005952|NCT01997515|Obesity
1005953|NCT01997515|Ketamine
1005954|NCT01997502|Hemoglobin
1005955|NCT01997502|Non-invasive
1005956|NCT01997489|Eye
1005957|NCT01997489|Fabry
1005958|NCT01997489|vessels
1005959|NCT01997476|Combined Endoscopic Ultrasound Morphologic Evaluation.
1005960|NCT01997450|Q/LAIV/FluMist® Quadrivalent Vaccine, Inactivated Influenza Vaccine (IIV), Effectiveness, Influenza
1005961|NCT01997437|Tissue-engineered tracheal transplantation
1005962|NCT01997411|Diabetes Mellitus
1005963|NCT01997411|Glucagon
1005964|NCT01997398|Deep brain stimulation surgery under general anesthesia
1005965|NCT01997398|Deep brain stimulation target accuracy
1005966|NCT01997398|Deep brain stimulation for Parkinsons's disease
1005967|NCT01997398|Deep brain stimulation functional outcomes
1005968|NCT01997398|Deep brain stimulation quality of life outcomes
1005969|NCT01997385|adapted APD
1005970|NCT01997385|dwell time
1005971|NCT01997385|fill volume
1005972|NCT01997372|ATG
1005973|NCT01997372|SAA
1005974|NCT01997372|immunosuppressive treatment
1005975|NCT01997372|cyclosporine
1005976|NCT01997359|ART initiation
1005977|NCT01997359|HIV
1005978|NCT01997359|AIDS
1005979|NCT01997359|Ethiopia
1005980|NCT01997346|ART initiation
1005981|NCT01997346|Ethiopia
1005982|NCT01997346|Clinic observation
1005983|NCT01997346|VCT observation
1006000|NCT01997320|Sarcopenia
1006001|NCT01997320|Frailty
1006002|NCT01997320|Strength
1006003|NCT01997320|Protein supplementation
1006004|NCT01997320|Ageing
1006005|NCT01997307|acute coronary syndrome, coronary arteriography, menopause
1006006|NCT01997294|sequential therapy
1006007|NCT01997294|atorvastatin
1006008|NCT01997294|acute myocardial infarction
1006009|NCT01997281|dietary fiber
1006010|NCT01997281|diabetes mellitus
1006011|NCT01997281|gut hormone
1006012|NCT01997268|Dyslipidemia
1006013|NCT01997268|Hyperlipidemia
1006014|NCT01997268|Omega-3 Fatty Acids
1006015|NCT01997268|Metabolic Diseases
1006016|NCT01997268|TG ≥500 mg/dL and ≤ 2,000 mg/dL
1006017|NCT01997255|Everolimus
1006018|NCT01997255|Epilepsy
1006019|NCT01997255|Sturge Weber Syndrome
1006020|NCT01997255|Port wine stain
1006021|NCT01997255|Glaucoma
1006022|NCT01997242|CORONARY STENT
1006023|NCT01997242|CARDIAC SURGERY
1006024|NCT01997242|NON CARDIAC SURGEY
1006025|NCT01997229|Myasthenia Gravis
1006026|NCT01997229|Eculizumab
1006027|NCT01997229|safety
1006028|NCT01997229|efficacy
1006029|NCT01997216|contact lenses
1006030|NCT01997216|multifocal
1006031|NCT01997203|hepatitis C infection
1006032|NCT01997203|vitamin D
1006033|NCT01997190|Immunotherapy
1006034|NCT01997190|Gene therapy
1006035|NCT01997190|Tumor vaccine
1006036|NCT01997177|simulation
1006037|NCT01997177|training
1006038|NCT01997177|colonoscopy
1006039|NCT01997177|standard setting
1006040|NCT01997138|pain, inflammation, surgery
1006041|NCT01997112|Blood pressure
1006042|NCT01997112|Hypertension
1006043|NCT01997112|Paracetamol
1006044|NCT01997112|Acetaminophen
1006045|NCT01997099|Drug Library
1006046|NCT01997099|Ambulatory Infusion Pump
1006047|NCT01997099|Medication Safety Software
1006048|NCT01997099|CADD®-Solis VIP
1006049|NCT01997099|Pump Programming
1006050|NCT01997099|Home Infusion Workflow
1006051|NCT01997073|Respiratory enthalpy
1006052|NCT01997073|One Lung Ventilation
1006053|NCT01997060|Lifestyle intervention
1006054|NCT01997060|Body weight
1006055|NCT01997060|Body composition
1006056|NCT01997060|Weight loss maintenance
1006057|NCT01997060|Physical activity
1006058|NCT01997047|Pneumonia
1006059|NCT01997047|bronchiolitis
1006060|NCT01997047|asthma
1006061|NCT01997047|children
1006062|NCT01997047|tachypnea
1006063|NCT01997047|developing countries
1006064|NCT01997047|diagnostic criteria
1006065|NCT01997034|Weight loss maintenance
1006066|NCT01997034|Body composition
1006067|NCT01997034|Physical activity
1006068|NCT01997034|Lifestyle intervention
1006069|NCT01997021|Sedentary behavior
1006070|NCT01997021|physical activity
1006071|NCT01997021|older adults
1006072|NCT01996982|Induced therapeutic hypothermia
1006073|NCT01996969|metastatic colorectal cancer
1006074|NCT01996969|refractory
1006075|NCT01996969|regorafenib
1006076|NCT01996969|biomarker
1006077|NCT01996969|gene sequencing
1006078|NCT01996956|stroke volume variation,
1006079|NCT01996956|cardiac output,
1006080|NCT01996956|fluid responsiveness,
1006081|NCT01996956|noninvasive cardiac output monitor
1006082|NCT01996943|Atrial Fibrillation
1006083|NCT01996943|Alcohol
1006084|NCT01996943|Electrophysiologic properties of the atria
1006085|NCT01996943|Randomized Clinical Study
1006086|NCT01996917|wound closure
1006087|NCT01996917|prineo
1006088|NCT01996917|scar
1006089|NCT01996904|subscapularis tear
1006090|NCT01996904|arthroscopic tendon repair
1006091|NCT01996904|arthroscopic tendon debridement
1006092|NCT01996904|ASES
1006093|NCT01996891|Asthma
1006094|NCT01996891|Nutrition
1006095|NCT01996891|Anti-inflammatory diet
1006096|NCT01996878|Parkinson's disease
1006097|NCT01996878|Genetic Polymorphism
1006099|NCT01996852|Erectile dysfunction
1006100|NCT01996852|ED
1006101|NCT01996852|Prostate
1006102|NCT01996852|Prostatectomy
1006103|NCT01996826|Corneal Neovascularization
1006104|NCT01996826|Cornea Blood Vessels
1006105|NCT01996826|Corneal Graft Failure
1006106|NCT01996826|High-Risk Penetrating Keratoplasty
1006107|NCT01996826|Corneal Transplant
1006108|NCT01996813|arthroscopy
1006109|NCT01996813|shoulder
1006110|NCT01996813|obesity
1006111|NCT01996813|beach chair
1006112|NCT01996813|compression hose
1006113|NCT01996787|visibility tinted silicone hydrogel contact lenses for daily wear
1006114|NCT01996735|Endothelial function
1006115|NCT01996735|Adenosine receptor stimulation
1006116|NCT01996709|Silicone hydrogel contact lenses
1006117|NCT01996709|Multi-purpose solution
1006118|NCT01996709|Lid Papillae
1006119|NCT01996709|Palpebral Roughness
1006120|NCT01996696|metformin
1006121|NCT01996696|metabolic syndrome
1006122|NCT01996696|weight gain
1006123|NCT01996683|B-thalassemia
1006124|NCT01996683|ferritin
1006125|NCT01996657|mechanical valves replacement
1006126|NCT01996657|INR
1006127|NCT01996657|D-dimer
1006128|NCT01996657|thromboembolic events
1006129|NCT01996644|Anorexia, Bulimia, Eating disorder, Anxiety, Exposure Therapy
1006130|NCT01996618|Premature Ventricular Beats
1006131|NCT01996618|Premature Heart Beats
1006132|NCT01996618|Ranolazine
1006133|NCT01996592|chronic pain
1006134|NCT01996592|cesarean section pain
1006135|NCT01996579|Critically Ill
1006136|NCT01996579|Intensive care
1006137|NCT01996579|Nasogastric tube
1006138|NCT01996579|Orogastric tube
1006139|NCT01996579|mechanically ventilated
1006140|NCT01996579|nosocomially acquired infections
1006141|NCT01996579|length of stay
1006142|NCT01996579|lactoferrin
1006143|NCT01996579|placebo controlled
1006144|NCT01996579|antibiotic free days
1006145|NCT01996566|taste
1006146|NCT01996566|non-esterified fatty acids
1006147|NCT01996566|threshold
1006148|NCT01996566|sensitivity
1006149|NCT01996566|human
1006150|NCT01996553|blood flow, regional
1006151|NCT01996553|complications
1006152|NCT01996553|disease, arterial obstructive
1006153|NCT01996553|cardiac catheterization
1006154|NCT01996553|radial artery
1006159|NCT01996514|Children
1006160|NCT01996514|Food advertisement
1006161|NCT01996514|Obesity
1006162|NCT01996514|Television viewing
1006163|NCT01996514|Food intake
1006164|NCT01996449|Hypertension
1006165|NCT01996449|blood pressure
1006166|NCT01996449|Aldosterone
1006167|NCT01996449|Eplerenone
1006168|NCT01996449|Amlodipine
1006169|NCT01996449|Primary aldosteronism
1006170|NCT01996449|Exercise pressor reflex
1006171|NCT01996449|handgrip exercise
1006172|NCT01996449|passive arm cycling
1006173|NCT01996449|active arm cycling
1006174|NCT01996436|cerebral vasospasm
1006175|NCT01996436|aneurysmal subarachnoid hemorrhage
1006176|NCT01996436|intra arterial drug treatment for cerebral vasospasm
1006177|NCT01996436|nicardipine milrinone nitroglycerin verapamil
1006178|NCT01996423|Atopic dermatitis
1006179|NCT01996423|vitamin D
1006180|NCT01996410|Breast Cancer
1006181|NCT01996410|Acupuncture
1006182|NCT01996410|Taxol
1006183|NCT01996410|Cytoxan
1006184|NCT01996410|Adriamycin
1006185|NCT01996410|Taxotere
1006186|NCT01996410|Carboplatin
1006187|NCT01996410|Perjeta
1006188|NCT01996410|Chemotherapy
1006189|NCT01996410|Chemotherapy-induced nausea, vomiting
1006190|NCT01996410|Chemotherapy-induced peripheral neuropathy
1006191|NCT01996410|Adriamycin (60 mg/m2), Cytoxan (600 mg/m2), Taxol (175 mg/m2)
1006192|NCT01996410|Adriamycin (60 mg/m2), Cytoxan (600 mg/m2), Taxol (80 g/m2)
1006193|NCT01996410|Taxotere (75mg/m2), Cytoxan (600 mg/m2)
1006194|NCT01996410|Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose)
1006195|NCT01996397|Heart failure
1006196|NCT01996397|Bundle branch block
1006197|NCT01996397|CRT response
1006198|NCT01996384|Vulvodynia
1006199|NCT01996384|Provoked, localized vulvodynia
1006200|NCT01996384|vulvar vestibulitis
1006201|NCT01996384|provoked vestibulodynia
1006202|NCT01996384|vulvovaginal pain
1006203|NCT01996384|vulvar pain
1006204|NCT01996384|vaginal pain
1006205|NCT01996384|chronic pain
1006206|NCT01996384|lidocaine
1006207|NCT01996384|numbing agent
1006208|NCT01996384|anesthetic cream
1006209|NCT01996384|acupuncture
1006210|NCT01996384|electroacupuncture
1006211|NCT01996384|electrical stimulated acupuncture
1006212|NCT01996384|manual acupuncture
1006213|NCT01996384|classical acupuncture
1006214|NCT01996384|non-classical acupuncture
1006215|NCT01996384|Traditional Chinese Medicine
1006216|NCT01996384|TCM
1006217|NCT01996384|Chinese medicine
1006218|NCT01996384|Acupuncture and Oriental Medicine
1006219|NCT01996384|AOM
1006220|NCT01996384|treatment
1006221|NCT01996384|feasibility
1006222|NCT01996384|pilot study
1006223|NCT01996384|Patient Reported Outcomes Measure Information System
1006224|NCT01996384|Tampon Test
1006225|NCT01996384|cotton swab test
1006226|NCT01996384|pain diary
1006227|NCT01996384|Research Electronic Data Capture
1006228|NCT01996384|REDCap
1006229|NCT01996358|Succinylcholine
1006230|NCT01996358|Rocuronium
1006231|NCT01996358|Rigid Bronchoscopy
1006232|NCT01996345|Placenta Previa
1006233|NCT01996345|Vaginal Pessary
1006234|NCT01996345|Premature Birth
1006235|NCT01996319|Chronic obstructive pulmonary disease
1006236|NCT01996319|COPD
1006237|NCT01996306|AXEPT
1006238|NCT01996306|Fluorouracil
1006239|NCT01996306|CPT-11
1006240|NCT01996306|XELIRI
1006241|NCT01996306|Bevacizumab
1006242|NCT01996306|FOLFIRI
1006243|NCT01996306|Capecitabine
1006244|NCT01996306|2nd-line metastatic colorectal cancer
1006245|NCT01996293|pregnant
1006246|NCT01996293|bipolar
1006247|NCT01996293|lamotrigine
1006248|NCT01996293|lamictal
1006249|NCT01996293|women
1006250|NCT01996293|female
1006251|NCT01996267|neoadjuvant
1006252|NCT01996267|breast cancer
1006253|NCT01996267|HER2 positive
1006254|NCT01996254|electrical stimulation
1006255|NCT01996254|neurostimulation
1006256|NCT01996254|neuromodulation
1006257|NCT01996254|post-amputation pain
1006258|NCT01996254|phantom limb pain
1006259|NCT01996254|residual limb pain
1006260|NCT01996254|neuropathic pain
1006261|NCT01996254|amputee pain
1006269|NCT01996228|Type 1 diabetes
1006270|NCT01996228|autoimmune
1006271|NCT01996228|cord blood stem cell
1006272|NCT01996228|stem cell educator
1006273|NCT01996228|immune modulation
1006274|NCT01996228|children
1006275|NCT01996228|Control autoimmunity
1006276|NCT01996228|stimulate the regeneration of islet beta cells
1006277|NCT01996202|Melanoma
1006278|NCT01996176|Sedentary Lifestyle
1006279|NCT01996176|Sedentary work
1006280|NCT01996176|Office workers
1006281|NCT01996176|Work
1006282|NCT01996176|Workplace intervention
1006283|NCT01996176|Sitting time
1006284|NCT01996150|atopic dermatitis
1006285|NCT01996150|eczema
1006286|NCT01996150|bleach bath
1006287|NCT01996150|itch
1006288|NCT01996150|skin barrier
1006289|NCT01996150|staphylococcus aureus
1006290|NCT01996137|Stroke
1006291|NCT01996137|Treadmill
1006292|NCT01996137|Gait Speed
1006293|NCT01996124|COPD
1006294|NCT01996124|Pulmonary Hyperinflation
1006295|NCT01996124|Ultra Long Acting Beta 2 Agonists
1006296|NCT01996124|Cor Pulmonale
1006297|NCT01996124|Cardiac performance
1006298|NCT01996111|plantar fasciitis
1006299|NCT01996085|arterial hypertension
1006300|NCT01996085|hemodynamics
1006301|NCT01996085|impedance cardiography
1006302|NCT01996085|hypotensive therapy
1006303|NCT01996072|Primary hyperparathyroidism
1006304|NCT01996072|Parathyroid
1006305|NCT01996059|nutritional status
1006306|NCT01996059|functional jejunal interposition
1006307|NCT01996059|Roux-en-Y
1006308|NCT01996059|gastrectomy
1006309|NCT01996033|uncontrolled hypertension
1006310|NCT01996033|Renal Denervation
1006311|NCT01996007|Pneumococcus
1006312|NCT01996007|Carriage
1006313|NCT01996007|Children
1006314|NCT01996007|Parents
1006315|NCT01996007|Immunogenicity
1006316|NCT01996007|PCV13
1006317|NCT01995981|Sarcoma, Soft Tissue
1006318|NCT01995981|Pazopanib
1006319|NCT01995981|Positron-Emission Tomography
1006320|NCT01995981|Pharmacokinetics
1006321|NCT01995981|Biomarker
1006322|NCT01995968|Stillbirth
1006323|NCT01995968|Fetal growth restriction
1006324|NCT01995968|Small for gestational age
1006325|NCT01995968|Antenatal detection
1006326|NCT01995968|Prenatal Care
1006327|NCT01995968|Mass Screening
1006328|NCT01995955|Coronary Microvascular Dysfunction
1006329|NCT01995955|coronary artery disease
1006330|NCT01995955|index of myocardial resistance
1006331|NCT01995942|Rectal Cancer
1006332|NCT01995942|EMVI
1006333|NCT01995942|Extramural Venous Invasion
1006334|NCT01995942|Microarray
1006335|NCT01995942|Biomarker
1006336|NCT01995942|mrEMVI
1006337|NCT01995942|Tumour Regression Grade
1006338|NCT01995942|Cancer
1006339|NCT01995942|Circumferential Resection Margin
1006340|NCT01995942|CRM
1006341|NCT01995942|MRI
1006342|NCT01995942|Radiology
1006343|NCT01995942|Surgery
1006344|NCT01995942|Pathology
1006345|NCT01995929|neurogenic dysphagia
1006346|NCT01995929|transnasal endoscopy
1006347|NCT01995929|functional endoscopy
1006348|NCT01995890|nepafenac eye drops
1006349|NCT01995890|intraocular pressure
1006350|NCT01995864|Schizophrenia and Disorders with Psychotic Features
1006351|NCT01995864|Community Psychiatry
1006352|NCT01995851|Influenza
1006353|NCT01995851|Vaccine
1006354|NCT01995838|Chronic Insomnia
1006355|NCT01995838|Adults
1006356|NCT01995838|Elderly
1006357|NCT01995825|bioequivalence
1006358|NCT01995825|lamotrigine
1006359|NCT01995825|epilepsy
1006360|NCT01995799|Myocardial Infarction (and related inflammation)
1006361|NCT01995786|Fluid Therapy
1006362|NCT01995786|Cost-Benefit Analysis
1006363|NCT01995786|Hemodynamics
1006364|NCT01995786|Cost Control
1006365|NCT01995773|Healthy women
1006366|NCT01995773|Quality of life
1006367|NCT01995773|Glucose metabolism
1006368|NCT01995773|Adrenal reactivity
1006369|NCT01995773|Physical activity
1006370|NCT01995773|Body Composition
1006371|NCT01995760|vancomycin
1006372|NCT01995760|therapeutic response monitoring
1006373|NCT01995760|AUC/MIC
1006374|NCT01995747|IgE
1006375|NCT01995747|Atopic Dermatitis
1006376|NCT01995747|antibody
1006377|NCT01995747|allergy
1006378|NCT01995734|Acromegaly, Pituitary diseases
1006379|NCT01995721|recurrent respiratory papillomatosis
1006380|NCT01995721|human papillomavirus
1006381|NCT01995721|vaccine
1006382|NCT01995721|treatment
1006383|NCT01995721|immunology
1006384|NCT01995721|relapse
1006385|NCT01995708|CT7
1006386|NCT01995708|MAGE-A3
1006387|NCT01995708|WT1 mRNA-electroporated Autologous Langerhans
1006388|NCT01995708|vaccine
1006389|NCT01995708|Autologous Stem Cell Transplantation
1006390|NCT01995708|13-009
1006391|NCT01995682|Independent living
1006392|NCT01995682|walk with or without walking aids
1006393|NCT01995669|Lymphoma
1006394|NCT01995669|Relapsed Indolent Non-Hodgkin's Lymphoma
1006395|NCT01995669|non-Hodgkin's lymphoma
1006396|NCT01995669|NHL
1006397|NCT01995669|Relapsed/refractory indolent lymphoma
1006398|NCT01995669|Small lymphocytic lymphoma
1006399|NCT01995669|SLL
1006400|NCT01995669|Follicular lymphoma
1006401|NCT01995669|Marginal zone lymphoma
1006402|NCT01995669|Lenalidomide
1006403|NCT01995669|CC-5013
1006404|NCT01995669|Revlimid
1006405|NCT01995669|Obinutuzumab
1006406|NCT01995669|GA101
1006407|NCT01995643|Grape seed extract
1006408|NCT01995643|Polyphenols
1006409|NCT01995643|Insulin
1006410|NCT01995643|Oxidative stress Marker
1006411|NCT01995643|Inflammatory marker
1006412|NCT01995643|Healthy human
1006413|NCT01995617|vaccine
1006414|NCT01995617|Streptococcus pneumoniae
1006415|NCT01995617|Strep pneumo
1006416|NCT01995591|colon cancer
1006417|NCT01995591|sentinel lymph node
1006418|NCT01995591|Indocyanine Green
1006419|NCT01995578|5'-Azacitidine
1006420|NCT01995578|Stem cell transplant
1006421|NCT01995578|13-192
1006422|NCT01995552|Post myocardial infarction patients with low EF.
1006423|NCT01995539|Type 2
1006424|NCT01995500|CAD
1006425|NCT01995500|PCI
1006426|NCT01995500|ACS
1006427|NCT01995500|non ACS
1006428|NCT01995500|BioNIR
1006429|NCT01995500|DES
1006430|NCT01995487|more comers
1006431|NCT01995487|DES
1006432|NCT01995487|BioNIR
1006433|NCT01995487|ACS
1006434|NCT01995487|non ACS
1006435|NCT01995487|complex lesions
1006436|NCT01995474|EUS
1006437|NCT01995474|pancreatic cancer
1006438|NCT01995474|cytology
1006439|NCT01995474|fine needle aspiration
1006440|NCT01995448|The acute phase of Sepsis
1006441|NCT01995448|multiparameter 8-color flow cytometry
1006442|NCT01995422|Major depressive disorder
1006443|NCT01995422|Follow-up study
1006444|NCT01995422|Ecological momentary assessment
1006445|NCT01995422|Physical activity
1006446|NCT01995422|Depression
1006447|NCT01995422|Self-esteem
1006448|NCT01995422|Anxiety
1006449|NCT01995422|Rumination
1006450|NCT01995422|Quality of life
1006451|NCT01995396|rectal cancer,
1006452|NCT01995396|fecal incontinence,
1006453|NCT01995396|severe co-morbidity,
1006454|NCT01995396|Hartmann´s procedure,
1006455|NCT01995396|abdominoperineal excision with intersphincteric dissection,
1006456|NCT01995396|postoperative complications,
1006457|NCT01995396|pelvic abscess,
1006458|NCT01995396|perineal infections
1006459|NCT01995370|Noncardioembolic cerebral infarction
1006460|NCT01995370|Dual antiplatelet therapy (DAPT)
1006461|NCT01995370|Cilostazol
1006462|NCT01995370|Aspirin
1006463|NCT01995370|Clopidogrel
1006464|NCT01995331|aplastic anemia;
1006465|NCT01995331|cyclophosphamide;
1006466|NCT01995331|immunosuppressive therapy;
1006467|NCT01995331|cyclosporine A
1006468|NCT01995318|Kinesiotaping
1006469|NCT01995305|fanconi anemia
1006470|NCT01995305|hematopoiesis maintainance
1006471|NCT01995292|awake fiberoptic intubation
1006472|NCT01995292|spray as you go technique
1006473|NCT01995292|anesthesia
1006474|NCT01995292|Enk Fiberoptic Atomizer Set
1006475|NCT01995279|low back pain
1006476|NCT01995279|French Auriculotherapy
1006477|NCT01995279|postural control
1006478|NCT01995279|balance
1006479|NCT01995279|posture
1006480|NCT01995240|pancreatic cancer
1006481|NCT01995240|MRI
1006482|NCT01995240|reproducibility
1006483|NCT01995240|optimalization
1006484|NCT01995227|liver cancer
1006485|NCT01995227|HCC
1006486|NCT01995227|tumor vaccine
1006487|NCT01995227|immunotherapy
1006488|NCT01995227|personalized anti-cancer vaccine
1006489|NCT01995214|Postoperative delirium
1006490|NCT01995214|Geriatric
1006491|NCT01995214|General anesthesia
1006492|NCT01995214|Propofol
1006493|NCT01995214|Sevoflurane
1006494|NCT01995175|Asthma
1006495|NCT01995175|Respiratory Syncytial virus
1006496|NCT01995175|Cohort study
1006497|NCT01995175|Quarterly phone contacts
1006498|NCT01995175|Wheeze
1006499|NCT01995175|New born
1006500|NCT01995175|Lower Respiratory Tract Infection
1006501|NCT01995149|Familial Hypercholesterolemia
1006502|NCT01995149|Familial Combined Hypercholesterolemia
1006503|NCT01995149|Weight loss; Lipids; Phytosterols
1006504|NCT01995149|Obesity
1006505|NCT01995149|Overweight.
1006506|NCT01995149|Lipids
1006507|NCT01995136|Glaucoma
1006508|NCT01995136|Ocular hypertension
1006509|NCT01995123|Tobacco dependence
1006510|NCT01995123|PTSD
1006511|NCT01995123|Behavioral Activation Therapy
1006517|NCT01995084|hypoxia
1006518|NCT01995084|HX4
1006519|NCT01995084|PET
1006520|NCT01995084|cancer
1006521|NCT01995071|Chronic Hepatitis C
1006522|NCT01995071|Cirrhosis
1006523|NCT01995071|Child Pugh A
1006524|NCT01995071|Hepatitis C virus
1006525|NCT01995071|Compensated Cirrhosis
1006526|NCT01995071|Hepatitis C Genotype 1
1006527|NCT01995071|Hepatitis C
1006528|NCT01995071|Interferon-Free
1006529|NCT01995071|Cirrhotic
1006530|NCT01995058|CRPC
1006531|NCT01995058|castration resistant prostate cancer
1006532|NCT01995058|prostate cancer
1006533|NCT01995045|Retina
1006534|NCT01995045|Vitreoretinal
1006535|NCT01995045|Surgery
1006536|NCT01995032|Duchenne's muscular dystrophy
1006537|NCT01995032|DMD
1006538|NCT01995019|Arthralgia
1006539|NCT01995019|Temporomandibular joint
1006540|NCT01995019|corticosteroids
1006541|NCT01995019|injection
1006542|NCT01995019|intra-articular
1006543|NCT01995006|Effect
1006544|NCT01995006|metamizole
1006545|NCT01995006|salt-depleted
1006546|NCT01995006|subjects
1006547|NCT01994993|Antibiotics
1006548|NCT01994993|ampicillin
1006549|NCT01994993|metronidazole
1006550|NCT01994993|clindamycin
1006551|NCT01994993|piperacillin-tazobactam
1006552|NCT01994993|Safety
1006553|NCT01994993|Infants
1006554|NCT01994993|Intra abdominal infections
1006555|NCT01994967|Phase III
1006556|NCT01994967|Noninferiority
1006557|NCT01994967|Controlled
1006558|NCT01994967|Double-blind
1006559|NCT01994967|Randomized
1006560|NCT01994967|Spinal
1006561|NCT01994967|Anesthetic
1006562|NCT01994967|Lower limb
1006563|NCT01994954|newborn intensive care unit
1006564|NCT01994954|NICU
1006565|NCT01994954|supplemental oxygen
1006566|NCT01994941|Acute Coronary Syndrome
1006567|NCT01994941|Platelet Reactivity
1006568|NCT01994941|P2Y12 Receptor Blocker
1006569|NCT01994941|CYP2C19 Genotyping
1006570|NCT01994915|exacerbation
1006571|NCT01994915|functionality
1006572|NCT01994915|occupational therapy
1006573|NCT01994915|chronic obstructive pulmonary disease
1006574|NCT01994889|amyloidosis
1006575|NCT01994889|amyloid
1006576|NCT01994889|transthyretin
1006577|NCT01994889|TTR
1006578|NCT01994837|AML
1006579|NCT01994837|Acute Myelogenous Leukemia
1006580|NCT01994837|Acute Myeloid Leukemia
1006581|NCT01994837|GDC-0199
1006582|NCT01994837|ABT-199
1006583|NCT01994837|Myeloid Leukemia
1006584|NCT01994811|cancer
1006585|NCT01994811|cardiovascular disease
1006586|NCT01994811|diabetes
1006587|NCT01994785|Sedation
1006588|NCT01994785|Endoscopy
1006589|NCT01994785|Capnography
1006590|NCT01994772|Therapeutic hypothermia
1006591|NCT01994772|Targeted controlled temperature
1006592|NCT01994772|Cardiac arrest
1006593|NCT01994772|Non shockable rhythm
1006594|NCT01994772|successful resuscitation
1006595|NCT01994759|Plantar fasciitis
1006596|NCT01994759|Treatment
1006597|NCT01994759|Training
1006598|NCT01994759|Glucocorticosteroid injection
1006599|NCT01994746|Diabetes Mellitus
1006600|NCT01994746|Hypoglycemia
1006601|NCT01994746|Glucagon
1006602|NCT01994733|end-stage renal disease
1006603|NCT01994733|hemodialysis
1006604|NCT01994733|mineral metabolism
1006605|NCT01994733|serum phosphate
1006606|NCT01994733|phosphate binders
1006607|NCT01994720|Acute ischaemic stroke.
1006608|NCT01994720|Transient ischaemic attack.
1006609|NCT01994707|Remote ischemic preconditioning
1006610|NCT01994707|Coronary artery bypass graft surgery
1006611|NCT01994707|Troponin T
1006612|NCT01994707|Apoptosis
1006613|NCT01994707|Experimental
1006614|NCT01994707|Cardioprotection
1006615|NCT01994668|lorazepam
1006616|NCT01994668|intravenous
1006617|NCT01994668|pharmacolinetics
1006618|NCT01994668|healthy
1006619|NCT01994668|Japanese
1006620|NCT01994655|climacteric symptoms
1006621|NCT01994655|menopause
1006622|NCT01994655|nurses
1006623|NCT01994629|meningococcal disease
1006624|NCT01994629|children
1006625|NCT01994629|vaccination
1006626|NCT01994616|Keloid, hypertrophic scar
1006627|NCT01994603|Prevention
1006628|NCT01994603|HIV
1006629|NCT01994603|AIDS
1006630|NCT01994603|Fetal Alcohol Syndrome (FAS)
1006631|NCT01994603|Alcohol Related Neurodevelopmental Disorder (ARND)
1006632|NCT01994590|Prostate Cancer
1006633|NCT01994590|Metastatic Castrate-Resistant Prostate Cancer
1006634|NCT01994590|mCRPC
1006635|NCT01994590|Dovitinib
1006636|NCT01994590|TKI258
1006637|NCT01994590|Abiraterone Acetate
1006638|NCT01994590|Zytiga
1006639|NCT01994590|Prednisone
1006640|NCT01994577|Emergency Department
1006641|NCT01994577|Cardiac troponin
1006642|NCT01994577|Myocardial infarction
1006643|NCT01994564|OAG
1006644|NCT01994538|Urinary Tract Infections
1006645|NCT01994538|Urinary antiinfective agents
1006646|NCT01994512|Spinal stenosis
1006647|NCT01994512|Decompression
1006648|NCT01994512|Fusion
1006649|NCT01994512|Olisthesis
1006650|NCT01994486|HCV Genotype 1
1006651|NCT01994486|Hepatitis C Virus Genotype 1
1006652|NCT01994486|HCV
1006653|NCT01994486|TVR
1006654|NCT01994473|Schizophrenia
1006655|NCT01994460|Tuberculosis
1006656|NCT01994447|Informed Consent
1006657|NCT01994447|Instructional Films and Video
1006658|NCT01994447|Consent Comprehension
1006659|NCT01994447|Multimedia Consent
1006660|NCT01994447|Parent
1006661|NCT01994434|Deep branch of the ulnar nerve
1006662|NCT01994434|Distal ulnar nerve compression
1006663|NCT01994421|Facilitating kinesiotape
1006664|NCT01994421|Inhibiting kinesiotape
1006665|NCT01994421|Classical tape
1006666|NCT01994421|No tape
1006667|NCT01994408|physician inertia
1006668|NCT01994408|hypertension
1006669|NCT01994408|telemedicine
1006670|NCT01994408|mobile technology
1006671|NCT01994395|Stroke
1006672|NCT01994395|Gait
1006673|NCT01994395|Stride Management Assist
1006674|NCT01994395|Mild-moderate Stroke, post 30 days or longer
1006675|NCT01994382|Leukemia
1006676|NCT01994382|Lymphocytic
1006677|NCT01994382|Chronic
1006678|NCT01994382|B Cell
1006679|NCT01994369|Breast Cancer
1006680|NCT01994356|Contraceptive counseling
1006681|NCT01994356|Physician self disclosure
1006682|NCT01994356|Satisfaction
1006683|NCT01994356|Intrauterine contraceptive use
1006684|NCT01994343|Chronic pelvic pain, women, pain, posture.
1006685|NCT01994330|acquired von Willebrand disease
1006686|NCT01994330|severe aortic stenosis
1006687|NCT01994330|Heye´s syndrome
1006688|NCT01994330|desmopressin
1006689|NCT01994330|von Willebrand multimers
1006690|NCT01994304|Safe Childbirth Checklist
1006691|NCT01994304|Intrapartum mortality, Quality of Institutional delivery care
1006692|NCT01994304|Maternal & newborn care practices
1006693|NCT01994291|Chemokine Antagonist
1006694|NCT01994291|Diabetic Macular Edema
1006695|NCT01994291|Diabetes
1006696|NCT01994291|Diabetes Mellitus
1006697|NCT01994291|Macular Edema
1006698|NCT01994291|Diabetic Retinopathy
1006699|NCT01994291|Anti-VEGF
1006700|NCT01994265|Atrial fibrillation
1006701|NCT01994265|Cognition
1006702|NCT01994265|Cognitive impairment
1006703|NCT01994265|Anticoagulation
1006704|NCT01994265|Dabigatran
1006705|NCT01994265|Warfarin
1006706|NCT01994265|Efficacy
1006707|NCT01994252|defibrillator
1006708|NCT01994252|cardiac resynchronization
1006709|NCT01994239|Prostate-Specific Antigen
1006710|NCT01994239|LHRH antagonist
1006711|NCT01994239|Radiotherapy
1006712|NCT01994213|Famitinib
1006713|NCT01994213|Gastroenteropancreatic Neuroendocrine Tumor
1006714|NCT01994213|GEPNET
1006715|NCT01994200|Thyroid cancer
1006716|NCT01994200|New diagnosis
1006717|NCT01994200|Dedicated Nurse
1006718|NCT01994200|Interdisciplinary team
1006719|NCT01994200|Randomized Controlled Trial
1006720|NCT01994200|Intervention
1006721|NCT01994200|Supportive care
1006722|NCT01994187|Carotid stenosis
1006723|NCT01994187|Angioplasty
1006724|NCT01994187|Carotid endarterectomy
1006725|NCT01994187|Stroke
1006726|NCT01994174|vascular
1006727|NCT01994174|retina
1006728|NCT01994174|Anti-VEGF
1006729|NCT01994174|Aqueous humor dynamics
1006730|NCT01994161|ischemic stroke
1006731|NCT01994161|intracranial stenting
1006732|NCT01994161|vascular risk factor management
1006733|NCT01994148|Trauma
1006734|NCT01994148|Gastrointestinal injury
1006735|NCT01994148|Laparoscopy
1006736|NCT01994109|Sialorrhea
1006737|NCT01994109|Parkinson's disease
1006738|NCT01994109|Amyotrophic lateral sclerosis (ALS)
1006739|NCT01994109|stroke
1006740|NCT01994109|neuroleptics
1006741|NCT01994057|Non-small cell lung cancer (NSCLC);
1006742|NCT01994057|EGFR-TKI;
1006743|NCT01994057|Pharmacogenetics;
1006744|NCT01994057|Precision medicine
1006745|NCT01994057|somatic mutations ,germline mutations;
1006746|NCT01994044|Whiplash, surgery, multimodal rehabilitation, independent examiners
1006747|NCT01994031|paclitaxel liposome injection
1006748|NCT01994031|paclitaxel
1006749|NCT01994018|Vitamin D
1006750|NCT01994018|Interferon Beta
1006751|NCT01994018|Glatiramer Acetate
1006752|NCT01994018|Relapse rates
1006753|NCT01993992|Anesthesia
1006754|NCT01993979|Adjuvant chemotherapy
1006755|NCT01993979|Surveillance
1006756|NCT01993979|Nephro-ureterectomy
1006757|NCT01993966|Urothelial carcinoma (UC),
1006758|NCT01993966|(-)-epigallocatechin-3-gallate(EGCG),
1006759|NCT01993966|chemotherapy,
1006760|NCT01993966|cytotoxicity,
1006761|NCT01993966|drug resistance,
1006762|NCT01993966|xenograft.
1006763|NCT01993953|Muscle strength
1006764|NCT01993953|Body composition
1006765|NCT01993953|Body weight
1006766|NCT01993953|Resistance training
1006767|NCT01993953|Personal training
1006768|NCT01993953|BodyPump
1006769|NCT01993940|Opioid-induced Constipation
1006770|NCT01993927|Drug Therapy
1006771|NCT01993901|lung SBRT, ESAS, anxiety
1006772|NCT01993888|Hepatobiliary Surgery
1006773|NCT01993849|Anxiety
1006774|NCT01993849|Impulse control
1006775|NCT01993849|Depression
1006776|NCT01993849|ADHD
1006777|NCT01993849|Fingernail Biting
1006778|NCT01993849|N-Acetylcysteine
1006779|NCT01993849|NAC
1006780|NCT01993836|isoflurane
1006781|NCT01993836|propofol
1006782|NCT01993836|total intravenous anesthesia
1006783|NCT01993836|inhaled anesthetic
1006784|NCT01993836|volatile anesthetic
1006785|NCT01993836|anesthesia
1006786|NCT01993836|delirium
1006787|NCT01993836|Post Operative Cognitive Dysfunction
1006788|NCT01993836|Alzheimer's Disease
1006789|NCT01993836|Mild Cognitive Impairment
1006790|NCT01993810|Non small cell lung cancer
1006791|NCT01993810|NSCLC
1006792|NCT01993810|proton radiotherapy
1006793|NCT01993797|Bronchiolitis
1006794|NCT01993758|tourniquet pressure
1006795|NCT01993758|total knee arthroplasty
1006796|NCT01993745|ECMO
1006797|NCT01993745|APACH II score
1006798|NCT01993732|Cancer
1006799|NCT01993732|Cryopreservation
1006800|NCT01993732|Ovarian Function
1006801|NCT01993732|In Vitro
1006805|NCT01993706|Broadly HIV-1 Neutralizing Activity
1006806|NCT01993706|Healthy Adults
1006807|NCT01993706|Placebo
1006808|NCT01993706|HIV Prevention
1006809|NCT01993706|Monoclonal Antibodies
1006810|NCT01993706|Antibodies
1006811|NCT01993693|knee
1006812|NCT01993693|pain
1006813|NCT01993693|osteoarthritis
1006814|NCT01993693|ultrasound
1006815|NCT01993654|Pigmented Lesions
1006816|NCT01993654|PAM
1006817|NCT01993654|Ocular lesion
1006818|NCT01993641|Myelodysplastic Syndrome
1006819|NCT01993641|MDS
1006820|NCT01993641|pracinostat
1006821|NCT01993641|Hypomethylating Agent
1006822|NCT01993641|HMA
1006823|NCT01993641|azacitadine
1006824|NCT01993641|Vidaza
1006825|NCT01993641|decitabine
1006826|NCT01993641|dacogen
1006827|NCT01993615|FAI
1006828|NCT01993615|femoroacetabular impingement
1006829|NCT01993615|hip pain
1006830|NCT01993615|hip arthroscopy
1006831|NCT01993615|physical therapy
1006832|NCT01993602|general surgery
1006833|NCT01993602|postoperative care
1006834|NCT01993602|breathing exercises
1006835|NCT01993602|respiratory muscle
1006836|NCT01993602|postoperative complications
1006837|NCT01993602|lung volume measurements
1006838|NCT01993602|pulmonary ventilations
1006839|NCT01993602|thoracic wall
1006840|NCT01993589|Curettage; analgesia; paracetamol; lidocaine; Dexketoprofen trometamol; pethidine; diclofenac.
1006841|NCT01993563|Stroke
1006842|NCT01993563|Rehabilitation
1006843|NCT01993563|Motor Imagery
1006844|NCT01993563|Upper Extremity
1006845|NCT01993563|Mirror Therapy
1006846|NCT01993550|lung cancer
1006847|NCT01993550|family caregiving
1006848|NCT01993550|behavioral intervention
1006849|NCT01993550|counseling
1006850|NCT01993550|symptom management
1006851|NCT01993498|cancer toxicities
1006852|NCT01993498|cohort
1006853|NCT01993498|breast cancer
1006854|NCT01993485|transaortic valve replacement (TAVI)
1006855|NCT01993485|endothelial function
1006856|NCT01993485|circulating microparticles
1006857|NCT01993459|Quality of Recovery
1006858|NCT01993394|human centrifuge, oxygen, imaging, stroke volume, lung
1006859|NCT01993381|chemotherapy-induced nausea and vomiting
1006860|NCT01993368|wisdom teeth extraction
1006861|NCT01993355|non-specific chronic low back pain,
1006862|NCT01993355|health-related quality of life,
1006863|NCT01993355|physioterapy,
1006864|NCT01993355|sophrology,
1006865|NCT01993355|cognitive-behavioral therapy,
1006866|NCT01993355|motivational interviewing
1006867|NCT01993342|adipocytokines
1006868|NCT01993342|osteoarthritis
1006869|NCT01993342|inflammation
1006870|NCT01993342|ultrasonography
1006871|NCT01993316|neurofeedback
1006872|NCT01993316|EEG
1006873|NCT01993316|transcranial magnetic stimulation
1006874|NCT01993303|Myocardial Perfusion Imaging
1006875|NCT01993303|PET
1006876|NCT01993303|Rb-82
1006877|NCT01993264|Heart disease
1006878|NCT01993264|Echocardiogram
1006879|NCT01993264|Ultrasound
1006880|NCT01993264|Heart defect
1006881|NCT01993264|Heart Dysfunction
1006882|NCT01993264|Pediatric Cardiologists
1006883|NCT01993264|Prenatal
1006884|NCT01993251|sleep,melatonin,autism,children
1006885|NCT01993225|Low Testosterone
1006886|NCT01993212|Low Testosterone
1006887|NCT01993186|Glucose Transporter Type 1 Deficiency Syndrome Glut1
1006888|NCT01993173|Diphtheria
1006889|NCT01993173|Tetanus
1006890|NCT01993173|Pertussis
1006891|NCT01993173|ADACEL®
1006892|NCT01993173|Tdap vaccine
1006893|NCT01993160|Fluorocholine (FCH)
1006894|NCT01993160|Positron emission tomography (PET)
1006895|NCT01993160|Magnetic resonance imaging (MRI)
1006896|NCT01993147|Methylphenidate
1006897|NCT01993147|Placebo
1006898|NCT01993147|functional Magnetic Resonance Imaging (fMRI)
1006899|NCT01993147|Attention Control
1006900|NCT01993134|Postoperative infection
1006901|NCT01993134|Antibiotic prophylaxis
1006902|NCT01993134|Cefazolin
1006903|NCT01993121|diabetes
1006904|NCT01993121|exercise
1006905|NCT01993121|heart
1006906|NCT01993121|cardiovascular
1006907|NCT01993108|Methylphenidate
1006908|NCT01993108|Naltrexone
1006909|NCT01993108|Placebo
1006910|NCT01993108|Neuroimaging
1006911|NCT01993108|Prefrontal Control Circuits
1006912|NCT01993108|Attention Control
1006913|NCT01993108|Motor Control
1006914|NCT01993108|Appetitive Control
1006915|NCT01993095|Multiple Sclerosis
1006916|NCT01993095|Quality of Life
1006917|NCT01993095|Functional Fitness
1006918|NCT01993082|Caregivers
1006919|NCT01993082|Telomerase
1006920|NCT01993082|Telomere Length
1006921|NCT01993082|Psychological Stress
1006922|NCT01993082|Cardiovascular Risk
1006923|NCT01993082|Exercise
1006924|NCT01993056|injury incidence, male veteran soccer, 11+, Functional Movement Screen, FMS, warm-up
1006925|NCT01993043|ROP
1006926|NCT01993043|Bevacizumab
1006927|NCT01993043|Laser
1006928|NCT01993043|Development
1006929|NCT01993017|Acute Coronary Syndrome
1006930|NCT01993017|Depressive Symptoms
1006931|NCT01992991|transcranial stimulation
1006932|NCT01992991|Intracranial hemorrhage
1006933|NCT01992991|Home training
1006934|NCT01992991|Occupational Therapy
1006935|NCT01992991|Jebsen Taylor Hand Function Test
1006936|NCT01992978|radiofrequency-assisted（RF）
1006937|NCT01992978|hepatectomy
1006938|NCT01992978|postoperative liver injury
1006939|NCT01992965|continuous glucose monitoring；
1006940|NCT01992965|critically ill;
1006941|NCT01992939|pulse
1006942|NCT01992939|heat
1006943|NCT01992939|blood circulation
1006944|NCT01992926|health literacy
1006945|NCT01992926|health numeracy
1006946|NCT01992913|Schizophrenia
1006947|NCT01992913|Cognitive Behavioral Therapy
1006948|NCT01992913|Cognition
1006949|NCT01992913|Vocational Rehabilitation
1006950|NCT01992913|Supported Employment
1006951|NCT01992913|Schizoaffective Disorder
1006952|NCT01992900|Plasmodium falciparum Malaria
1006953|NCT01992900|Eurartesim
1006954|NCT01992900|ACT
1006955|NCT01992887|HIV/AIDS
1006956|NCT01992887|Retention
1006957|NCT01992887|ART (anti-retroviral therapy) ineligible
1006958|NCT01992874|Neoplasms
1006959|NCT01992874|Pimasertib
1006960|NCT01992874|Cancer
1006961|NCT01992822|rTMS
1006962|NCT01992822|fibromyalgia
1006963|NCT01992822|experimental pain
1006964|NCT01992809|Nonalcoholic fatty liver
1006965|NCT01992809|omega 3
1006966|NCT01992796|irbesartan, angiotensin, sepsis
1006967|NCT01992783|Resistant Starch
1006968|NCT01992783|Antioxidant Status
1006969|NCT01992783|Insulin Resistance
1006970|NCT01992783|Overweight
1006971|NCT01992783|Obesity
1006972|NCT01992770|behavioural medicine
1006973|NCT01992770|pain
1006974|NCT01992770|physical therapy
1006975|NCT01992770|physical exercise
1006976|NCT01992770|primary care
1006977|NCT01992757|functional fibrinogen assay
1006978|NCT01992757|cardiac surgery
1006979|NCT01992744|pregnancy
1006980|NCT01992744|brain-derived neurotrophic factor
1006981|NCT01992744|birth outcomes
1006982|NCT01992731|Age (38-42 years)
1006983|NCT01992731|pregnancy rates
1006984|NCT01992731|3 IUI cycles
1006985|NCT01992731|1 IVF/ICSI cycle
1006986|NCT01992705|pancreatic cancer
1006987|NCT01992692|Parkinson's disease
1006988|NCT01992692|remifentanil
1006989|NCT01992692|deep brain stimulator
1006990|NCT01992692|cardiovascular response
1006991|NCT01992666|Systemic lupus erythematosus
1006992|NCT01992666|genetic
1006993|NCT01992666|immunological
1006994|NCT01992666|pediatric
1006995|NCT01992666|mutation
1006996|NCT01992666|lupus
1006997|NCT01992627|High Intensity Laser Therapy
1006998|NCT01992627|elbow epicondylosis
1006999|NCT01992614|Single Ascending Dose
1007000|NCT01992614|healthy subjects
1007001|NCT01992614|Hypercholesterolemia
1007002|NCT01992614|Hyperlipidemias
1007003|NCT01992614|Dyslipidemias
1007004|NCT01992614|Lipid Metabolism Disorders
1007005|NCT01992614|Metabolic Diseases
1007006|NCT01992601|Drug interaction
1007007|NCT01992601|Rosuvastatin
1007008|NCT01992601|Telmisartan
1007009|NCT01992601|Pharmacokinetic
1007010|NCT01992601|(Pharmacokinetics and Drug Interaction)
1007011|NCT01992575|Retinal vein occlusion
1007012|NCT01992575|OCT
1007013|NCT01992575|Optical coherence tomography
1007014|NCT01992575|Imaging
1007015|NCT01992536|Meningococcal
1007016|NCT01992536|Booster
1007017|NCT01992536|MenABCWY
1007018|NCT01992536|Menveo
1007019|NCT01992536|Vaccine Adolescents
1007020|NCT01992536|Immune Response
1007021|NCT01992536|N. Meningitidis
1007022|NCT01992523|Ticagrelor
1007023|NCT01992523|antiplatelet
1007024|NCT01992523|Acute Coronary Syndrome
1007025|NCT01992497|Cesarean section, probiotic, formula fed, gut microbiota
1007026|NCT01992484|platelets, Acute coronary Syndrome (ACS), prasugrel, ticagrelor, aspirin
1007027|NCT01992471|BRCA1 testing
1007028|NCT01992471|BRCA2 testing
1007029|NCT01992471|13-215
1007030|NCT01992458|implantable cardioverter defibrillator
1007031|NCT01992458|death
1007032|NCT01992458|shock
1007033|NCT01992458|mortality
1007034|NCT01992458|complication
1007035|NCT01992458|sudden death
1007036|NCT01992445|suicide
1007037|NCT01992445|suicidal intent
1007038|NCT01992445|thought markers
1007039|NCT01992432|Brain magnetic resonance imaging
1007040|NCT01992432|chemotherapy toxicity
1007041|NCT01992432|older woman
1007042|NCT01992432|breast cancer
1007043|NCT01992419|Out-of-hospital Cardiac arrest
1007044|NCT01992419|telephone dispatch assisted resuscitation
1007045|NCT01992419|cardiac arrest phone detection
1007046|NCT01992393|Epilepsy
1007047|NCT01992393|Schizophrenia
1007048|NCT01992393|Schizoaffective Disorder
1007049|NCT01992393|Bipolar Disorder
1007050|NCT01992393|Depression
1007051|NCT01992393|Intervention
1007052|NCT01992393|Treatment
1007053|NCT01992393|Adherence
1007054|NCT01992341|sarcomas
1007055|NCT01992341|carcinomas
1007056|NCT01992328|Immunoglobulin G Deficiency
1007057|NCT01992315|Scar
1007058|NCT01992315|Soft tissue defect
1007059|NCT01992302|Rapid cycling
1007060|NCT01992289|XLHED
1007061|NCT01992289|HED
1007062|NCT01992289|Hypohidrotic ectodermal dysplasia
1007063|NCT01992289|Christ-Siemens-Touraine Syndrome
1007064|NCT01992276|Influenza
1007065|NCT01992276|Virus
1007066|NCT01992276|Monoclonal Antibody
1007067|NCT01992276|Immunization
1007068|NCT01992276|Treatment
1007069|NCT01992263|tuberculosis
1007070|NCT01992263|vitamin D
1007071|NCT01992263|immunity
1007072|NCT01992250|Cryoablation
1007073|NCT01992237|ALI,
1007074|NCT01992237|ARDS,
1007075|NCT01992237|ECMO,
1007076|NCT01992237|energy expenditure,
1007077|NCT01992237|mechanical ventilation,
1007078|NCT01992237|Extracorporeal Membrane Oxygenation
1007079|NCT01992237|Nutrition Assessment
1007080|NCT01992237|Pulmonary Ventilation
1007081|NCT01992224|severe acute pancreatitis
1007082|NCT01992224|mechanical ventilation
1007083|NCT01992198|antibiothearpy strategy
1007084|NCT01992198|cefoperazone
1007085|NCT01992198|metronidazole
1007086|NCT01992198|meropenem
1007087|NCT01992159|Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
1007088|NCT01992146|central sensitization
1007089|NCT01992146|endogenous opioids
1007090|NCT01992146|humans
1007091|NCT01992146|latent sensitization
1007092|NCT01992146|naloxone
1007093|NCT01992146|open groin hernia repair
1007094|NCT01992146|pain
1007095|NCT01992146|randomized controlled trial
1007096|NCT01992146|secondary hyperalgesia
1007097|NCT01992146|target-controlled infusion
1007098|NCT01992133|Former gestational Diabetes
1007099|NCT01992133|Vitamin D deficiency
1007100|NCT01992133|insulin resistance
1007101|NCT01992133|beta cell function
1007102|NCT01992120|Simulation
1007103|NCT01992120|Sepsis
1007104|NCT01992120|High-fidelity
1007105|NCT01992120|Severe Sepsis
1007106|NCT01992120|Septic Shock
1007107|NCT01992120|Education
1007108|NCT01992107|Influenza
1007109|NCT01992107|Influenza vaccine
1007110|NCT01992107|Novartis
1007111|NCT01992107|children
1007112|NCT01992094|Influenza
1007113|NCT01992094|Influenza vaccine
1007114|NCT01992094|Novartis
1007115|NCT01992094|Adults
1007116|NCT01992081|COPD, Physical Activity, Telecoaching, PROactive
1007117|NCT01992068|lung cancer
1007118|NCT01992055|Executive dysfunction
1007119|NCT01992055|Neuropsychological rehabilitation
1007120|NCT01992055|Goal Management Training
1007121|NCT01992029|ALS
1007122|NCT01992029|miRNA
1007123|NCT01992029|biomarker
1007124|NCT01992029|monocentric observational study
1007125|NCT01992016|Prostate cancer
1007126|NCT01992016|F18 FDG-PET
1007127|NCT01992016|Imaging
1007128|NCT01992016|Ranolazine
1007129|NCT01992016|Bone metastases
1007130|NCT01992016|Soft tissue metastases
1007131|NCT01991964|stridor
1007132|NCT01991964|laryngomalacia
1007133|NCT01991964|ultrasound
1007134|NCT01991938|PI3K Inhibitor
1007135|NCT01991938|mTOR Inhibitor
1007136|NCT01991938|Dual PI3K/mTOR Inhibitor
1007137|NCT01991938|CSC
1007138|NCT01991938|Cancer Stem Cells
1007139|NCT01991912|irrigation endoscopic decompression
1007140|NCT01991912|minimally invasive surgery
1007141|NCT01991912|spinal stenosis
1007142|NCT01991899|Measles, mumps and rubella vaccine
1007143|NCT01991899|Tetraviral vaccine
1007144|NCT01991899|Immunogenicity, Reactogenicity and Safety
1007145|NCT01991899|Consistency of production
1007146|NCT01991886|nasal High Flow
1007147|NCT01991886|premature baby
1007148|NCT01991886|CPAP (Continuous positive airways pressure)
1007149|NCT01991873|metastatic colorectal cancer
1007150|NCT01991873|maintenance therapy
1007151|NCT01991873|Panitumumab
1007152|NCT01991873|Vectibix®
1007153|NCT01991847|colon
1007154|NCT01991847|cancer
1007155|NCT01991847|prevention
1007156|NCT01991847|exercise
1007157|NCT01991847|physical
1007158|NCT01991847|activity
1007159|NCT01991834|laparoscopy
1007160|NCT01991834|surgical wound infection
1007161|NCT01991834|antibiotic prophylaxis
1007162|NCT01991834|gynecologic surgical procedures
1007163|NCT01991795|Diabetes
1007164|NCT01991795|Coronary artery disease
1007165|NCT01991795|Outcome
1007166|NCT01991795|Prevention
1007167|NCT01991795|Antiplatelet
1007168|NCT01991782|Telemedicine
1007169|NCT01991782|Fracture
1007170|NCT01991782|Orthopaedics
1007171|NCT01991769|exercise
1007172|NCT01991769|endothelium
1007173|NCT01991769|postprandial period
1007174|NCT01991756|Abdominal Aortic Aneurysms
1007175|NCT01991756|AAA
1007176|NCT01991743|Version
1007177|NCT01991743|Pregnancy
1007178|NCT01991743|Vaginal Delivery
1007179|NCT01991743|Pain Control
1007180|NCT01991743|Combined Spinal Epidural
1007181|NCT01991717|Victus
1007182|NCT01991717|lensfragmentation
1007183|NCT01991717|femtosecond laser assisted
1007184|NCT01991717|capsulotomy,
1007185|NCT01991717|manual, continuous curvilinear capsulorhexis (CCC)
1007186|NCT01991717|effective phaco time, phaco
1007187|NCT01991704|incubation
1007188|NCT01991704|Craving
1007189|NCT01991704|alcohol dependence
1007190|NCT01991691|Antineoplastic Agents
1007191|NCT01991665|Intrapartum Ultrasound
1007192|NCT01991665|Vacuum
1007193|NCT01991665|Occiput position
1007194|NCT01991652|Wilms tumour
1007195|NCT01991652|Childhood cancer
1007196|NCT01991652|Africa
1007197|NCT01991639|frailty
1007198|NCT01991639|community-dwelling
1007199|NCT01991639|malnutrition
1007200|NCT01991639|physical activity
1007201|NCT01991639|nutritional intervention
1007202|NCT01991600|iron absorption
1007203|NCT01991600|bioavailability
1007204|NCT01991600|anaemia
1007205|NCT01991600|iron deficiency
1007206|NCT01991600|ferrous sulphate
1007207|NCT01991587|Influenza
1007208|NCT01991587|Human
1007209|NCT01991587|RNA Virus Infections
1007210|NCT01991587|Immunologic
1007211|NCT01991587|Immunogenic Factors
1007212|NCT01991587|Physiological Effects of Drugs
1007213|NCT01991587|Virus diseases
1007214|NCT01991587|Orthomyxoviridae Infections
1007215|NCT01991587|Infection
1007216|NCT01991574|urinary phosphate
1007217|NCT01991574|iron hydroxide
1007218|NCT01991574|hypophosphatemia
1007219|NCT01991574|phosphate binder
1007220|NCT01991574|ferric hydroxide adipate
1007221|NCT01991561|Influenza, Human
1007222|NCT01991561|RNA Virus Infections
1007223|NCT01991561|Respiratory Tract Diseases
1007224|NCT01991561|Respiratory Tract Infections
1007225|NCT01991561|Aluminum Hydroxide
1007226|NCT01991561|Adjuvants, Immunologic
1007227|NCT01991561|Immunogenic Factors
1007228|NCT01991561|GLA-SE
1007229|NCT01991561|Physiological Effects of Drugs
1007230|NCT01991561|Virus Diseases
1007231|NCT01991561|Orthomyxoviridae Infections
1007232|NCT01991561|Infection
1007233|NCT01991548|Insulin pump
1007234|NCT01991470|Insulin requiring diabetes
1007235|NCT01991470|Children
1007236|NCT01991470|Sensor
1007237|NCT01991470|Accuracy
1007238|NCT01991457|ALL
1007239|NCT01991418|non-small cell lung cancer
1007240|NCT01991418|thioredoxin reductase
1007241|NCT01991418|carcina embryonic antigen
1007242|NCT01991405|Mild Cognitive Impairment
1007243|NCT01991405|Working Memory Training
1007244|NCT01991405|Neuropsychological function in MCI
1007245|NCT01991392|Pancreaticoduodenectomy
1007246|NCT01991392|nasogastric tube
1007247|NCT01991379|MEK162
1007248|NCT01991379|Imatinib
1007249|NCT01991379|13-162
1007250|NCT01991366|Major adverse microvascular integrity
1007251|NCT01991366|all cause mortality
1007252|NCT01991366|Q Wave MI
1007253|NCT01991353|Knee
1007254|NCT01991353|meniscus
1007255|NCT01991353|platelet rich plasma
1007256|NCT01991301|graft-versus-host disease
1007257|NCT01991301|stem cell transplantation
1007258|NCT01991301|matched unrelated donors
1007259|NCT01991301|proteosmoe inhibitor
1007260|NCT01991301|carfilzumib
1007261|NCT01991288|Total Knee Replacement
1007262|NCT01991288|Bupivacaine
1007263|NCT01991288|Levobupivacaine
1007264|NCT01991288|Saphenous Nerve Block
1007265|NCT01991288|Local Infiltration Analgesia
1007266|NCT01991275|Prostatic Neoplasms
1007267|NCT01991275|Laparoscopy
1007268|NCT01991275|Injections, Spinal
1007269|NCT01991275|Morphine
1007270|NCT01991249|pediatric acute leukemia
1007271|NCT01991249|Targeted high throughput sequencing
1007272|NCT01991249|messenger RNA
1007273|NCT01991197|Psoriasis
1007274|NCT01991197|Type 2 Diabetes
1007275|NCT01991197|Dipeptidyl peptidase-4 inhibition
1007276|NCT01991197|Sitagliptin
1007277|NCT01991197|Gliclazide
1007278|NCT01991197|Psoriasis area and severity index
1007279|NCT01991171|kinesio taping
1007280|NCT01991171|Muscle activation
1007281|NCT01991171|Muscle inhibition
1007282|NCT01991158|GAD-M regimen
1007283|NCT01991158|first line chemotherapy
1007284|NCT01991158|NK/T-cell Lymphoma
1007285|NCT01991145|Cerebral Palsy
1007286|NCT01991145|Umbilical Cord Blood
1007287|NCT01991145|Erythropoietin
1007288|NCT01991145|Rehabilitation
1007289|NCT01991132|Dry Eyes
1007290|NCT01991132|Meibomian glands
1007291|NCT01991132|Algorithm
1007292|NCT01991132|MediView software
1007293|NCT01991119|Atrial fibrillation
1007294|NCT01991119|Propafenone
1007295|NCT01991119|Dronedarone
1007296|NCT01991106|Exercise
1007297|NCT01991106|Myocardial function
1007298|NCT01991106|Vascular function
1007299|NCT01991106|Cardiovascular disease/prevention & control
1007300|NCT01991106|Paediatric obesity
1007301|NCT01991106|Visceral adipose tissue
1007302|NCT01991093|light transmittance aggregometry (LTA),multiple electrode aggregometry, clopidogrel-resistance
1007303|NCT01991080|biofeedback
1007304|NCT01991080|relaxation
1007305|NCT01991080|Wheat germ juice
1007306|NCT01991067|Marrow transplant recipients
1007307|NCT01991054|Diabetes mellitus
1007308|NCT01991054|HgA1C
1007309|NCT01991054|25(OH) vitamin D
1007310|NCT01991054|HgA1C levels above 7.5%
1007311|NCT01991041|Lennox-Gastaut Syndrome
1007312|NCT01991002|14/21 diet
1007313|NCT01991002|BMI
1007314|NCT01991002|biochemical blood markers
1007315|NCT01991002|quality of life
1007316|NCT01990989|clopidogrel
1007317|NCT01990989|pharmacogenomics
1007318|NCT01990989|CYP2C19
1007319|NCT01990989|platelet aggregation
1007320|NCT01990989|score system
1007321|NCT01990989|ischemic cardiovascular outcomes
1007322|NCT01990989|hemorrhage complications
1007323|NCT01990976|Muscular Dystrophy
1007324|NCT01990976|Facioscapulohumeral
1007325|NCT01990976|Physical training
1007326|NCT01990976|Magnetic Resonance Imaging
1007327|NCT01990976|Muscle Biopsy
1007328|NCT01990963|Brain trauma;
1007329|NCT01990963|MALUNA;
1007330|NCT01990963|densitometric data
1007331|NCT01990963|CT
1007332|NCT01990950|Aneurysm
1007333|NCT01990950|Aortic Aneurysm
1007334|NCT01990950|Iliac Aneurysm
1007335|NCT01990950|Aortic Aneurysm, Abdominal
1007336|NCT01990950|Vascular Diseases
1007337|NCT01990950|Cardiovascular Diseases
1007338|NCT01990950|Aortic Diseases
1007339|NCT01990937|oral midazolam
1007340|NCT01990937|sedation
1007341|NCT01990937|premedication
1007342|NCT01990937|upper gastrointestinal endoscopy
1007343|NCT01990937|EGD
1007344|NCT01990924|fluoroscopy
1007345|NCT01990924|radiation
1007346|NCT01990924|transradial
1007347|NCT01990924|diagnostic
1007348|NCT01990924|angiography
1007349|NCT01990924|cardiac
1007350|NCT01990924|coronary
1007351|NCT01990924|angioplasty
1007352|NCT01990911|hypertension
1007353|NCT01990911|hypertensive heart disease
1007354|NCT01990911|atrial fibrillation
1007355|NCT01990911|autonomic imbalance
1007356|NCT01990872|Vitamin D status
1007357|NCT01990872|25-hydroxyvitamin D
1007358|NCT01990872|Vitamin D3
1007359|NCT01990872|RCT
1007360|NCT01990872|Calcium intake
1007361|NCT01990872|Dietary requirement
1007362|NCT01990846|antiviral, influenza
1007363|NCT01990820|Pediatric Chronic Rhinosinusitis
1007364|NCT01990807|high risk
1007365|NCT01990807|Philadelphia Chromosome absent
1007366|NCT01990807|Childhood acute lymphoblastic leukemia
1007367|NCT01990794|Cobalt
1007368|NCT01990794|Dietary Supplements
1007369|NCT01990794|Hematological
1007370|NCT01990794|Thyroid
1007492|NCT01990235|Medical decision making
1007371|NCT01990781|Lidocaine, Dexamethasone, Postoperative sore throat
1007372|NCT01990768|tranexamic acid
1007373|NCT01990768|traumatic brain injury
1007374|NCT01990768|intracranial hemorrhage
1007375|NCT01990768|prehospital
1007376|NCT01990768|neurologic outcome
1007377|NCT01990768|glasgow outcome scale extended
1007378|NCT01990768|disability rating scale
1007379|NCT01990716|Adult
1007380|NCT01990716|Colonoscopy
1007381|NCT01990703|Contraception
1007382|NCT01990703|Birth Control
1007383|NCT01990703|Levonorgestrel IUD
1007384|NCT01990703|Mirena IUD
1007385|NCT01990690|oligohydramnios,antioxidant,oxidative stress and pregnancy outcomes
1007386|NCT01990677|Central Serous Chorioretinopathy
1007387|NCT01990677|csr
1007388|NCT01990677|cscr
1007389|NCT01990677|eplerenone
1007390|NCT01990677|vision
1007391|NCT01990677|choroid
1007392|NCT01990677|retina
1007393|NCT01990677|acute
1007394|NCT01990677|chronic
1007395|NCT01990638|coronary artery bypass graft
1007396|NCT01990638|Diabetes mellitus, type 2
1007397|NCT01990625|Maternal Near Miss Morbidity
1007398|NCT01990625|Maternal Mortality
1007399|NCT01990625|Neonatal Mortality
1007400|NCT01990625|Gestational Age Dating
1007401|NCT01990625|Pregnancy Complications
1007402|NCT01990625|Ultrasound
1007403|NCT01990625|Stillbirth
1007404|NCT01990599|nasopharyngeal tube
1007405|NCT01990599|airway management
1007406|NCT01990599|thermal coagulation of the Gasserian ganglion
1007407|NCT01990573|spinal surgery
1007408|NCT01990573|Methadone
1007409|NCT01990560|mild hypercortisolism
1007410|NCT01990560|Subclinical Cushing's Syndrome
1007411|NCT01990560|Preclinical Cushing's Syndrome
1007412|NCT01990547|Virtual Reality Exposure Therapy
1007413|NCT01990547|functional Magnetic Resonance Imaging
1007414|NCT01990547|Traumatic Event
1007415|NCT01990547|Trauma Survivor
1007416|NCT01990547|Combat-related PTSD
1007417|NCT01990547|mTBI
1007418|NCT01990547|mild TBI
1007419|NCT01990547|PTSD
1007420|NCT01990547|Veteran
1007421|NCT01990534|Lymphoma
1007422|NCT01990534|Hodgkin
1007423|NCT01990534|Relapsed
1007424|NCT01990534|Refractory
1007425|NCT01990534|Antigens, CD30
1007426|NCT01990534|Antibody-Drug Conjugate
1007427|NCT01990534|Antibodies, Monoclonal
1007428|NCT01990534|Monomethyl auristatin E
1007429|NCT01990534|Drug Therapy
1007430|NCT01990534|Immunotherapy
1007431|NCT01990534|Hematologic Diseases
1007432|NCT01990534|Additional Relevant MeSH terms:
1007433|NCT01990534|Lymphoma, Large B-Cell, Diffuse
1007434|NCT01990534|Lymphoma, Hodgkin
1007435|NCT01990534|Neoplasms by Histologic Type
1007436|NCT01990534|Neoplasms
1007437|NCT01990534|Lymphoproliferative Disorders
1007438|NCT01990534|Lymphatic Diseases
1007439|NCT01990534|Immunoproliferative Disorders
1007440|NCT01990534|Immune System Diseases
1007441|NCT01990534|Lymphoma, B-Cell
1007442|NCT01990534|Lymphoma, T-Cell
1007443|NCT01990534|Immunologic Factors
1007444|NCT01990534|Physiological Effects of Drugs
1007445|NCT01990534|Pharmacologic Actions
1007446|NCT01990508|sugar-sweetened beverages
1007447|NCT01990508|traffic-light labels
1007448|NCT01990508|financial incentives
1007449|NCT01990508|low-income community
1007450|NCT01990508|obesity prevention
1007451|NCT01990495|Renal failure
1007452|NCT01990495|Exercise testing
1007453|NCT01990495|Exercise training
1007454|NCT01990495|Protein signaling
1007455|NCT01990495|Skeletal muscle
1007456|NCT01990469|Type 2 Diabetes Mellitus
1007457|NCT01990456|Extracorporeal Membrane Oxygenation
1007458|NCT01990456|Ventilator-Induced Lung Injury
1007459|NCT01990456|Ventilators, Mechanical
1007460|NCT01990456|Pulmonary Heart Disease
1007461|NCT01990456|Ultrasonography
1007462|NCT01990443|Reslizumab
1007463|NCT01990443|monoclonal antibody
1007464|NCT01990417|Muscle Stretching Exercises
1007465|NCT01990417|Joint range of motion
1007466|NCT01990417|Resistance Training
1007467|NCT01990417|Physical Therapy
1007468|NCT01990404|Premixed nitrous oxide and oxygen
1007469|NCT01990404|Severe acute pain
1007470|NCT01990404|Prehospital setting
1007471|NCT01990365|Vertebral fracture, low back pain, gips, mobility
1007472|NCT01990313|Parkinson's Disease
1007473|NCT01990313|DBS
1007474|NCT01990313|Deep Brain Stimulation
1007475|NCT01990313|Subthalamic Nucleus
1007476|NCT01990300|Drug Therapy
1007477|NCT01990287|Low Back Pain
1007478|NCT01990287|Failed Back surgery Syndrome
1007479|NCT01990287|Post-Laminectomy Syndrome
1007480|NCT01990287|Spinal Cord Stimulation
1007481|NCT01990287|Peripheral Nerve field Stimulation
1007482|NCT01990287|Pain
1007483|NCT01990274|Tuberculosis
1007484|NCT01990274|Diagnosis
1007485|NCT01990274|GeneXpert MTB/RIF
1007486|NCT01990274|Point-of-treatment
1007487|NCT01990274|Mobile unit
1007488|NCT01990235|Advance care planning
1007489|NCT01990235|Aging
1007490|NCT01990235|Health communication
1007491|NCT01990235|Health literacy
1007493|NCT01990235|primary care
1007494|NCT01990235|vulnerable population
1007495|NCT01990235|chronic illness
1007496|NCT01990222|ADHD
1007497|NCT01990209|triple-negative breast cancer
1007498|NCT01990209|orteronel
1007499|NCT01990209|TAK-700
1007500|NCT01990209|metastatic breast cancer
1007501|NCT01990196|prostate cancer
1007502|NCT01990196|hormone therapy
1007503|NCT01990196|radical prostatectomy
1007504|NCT01990183|preterm infants
1007505|NCT01990183|early intervention
1007506|NCT01990183|enrichment
1007507|NCT01990183|cognitive, motor, visual development
1007508|NCT01990183|tele-rehabilitation
1007509|NCT01990131|computerized intervention
1007510|NCT01990131|cognitive bias modification
1007511|NCT01990131|anxiety
1007512|NCT01990131|suicide
1007513|NCT01990118|Renal transplant
1007514|NCT01990118|Renal allograft rejection
1007515|NCT01990118|Cyclosporine
1007516|NCT01990118|Gengraf
1007517|NCT01990105|atrial fibrillation
1007518|NCT01990105|anticoagulation
1007519|NCT01990105|antiarrhythmic medication
1007520|NCT01990105|CHA2DS2VASc score
1007521|NCT01990105|HAS-BLED score
1007522|NCT01990105|CHADS2 score
1007523|NCT01990092|Metanx
1007524|NCT01990092|B vitamins
1007525|NCT01990092|neuropathy
1007526|NCT01990092|nutrition
1007527|NCT01990079|PTSD
1007528|NCT01990079|smoking
1007529|NCT01990066|Quality of Life
1007530|NCT01990066|Physical Function
1007531|NCT01990040|Short Bowel Syndrome
1007532|NCT01990040|SBS
1007533|NCT01990040|teduglutide
1007534|NCT01990040|Gattex
1007535|NCT01990027|kidney stone
1007536|NCT01990001|contraception, adherence, medication reminder
1007537|NCT01989988|Type 2 Diabetes Mellitus (T2DM)
1007538|NCT01989988|Obesity
1007539|NCT01989988|Laparoscopic gastric bypass
1007540|NCT01989988|Duodenum exclusion
1007541|NCT01989975|Sensor-Augmented Pump Therapy
1007542|NCT01989975|Connected Care
1007543|NCT01989962|Aboriginal Health
1007544|NCT01989962|Diabetes Mellitus Type 2
1007545|NCT01989962|Cultural Competency
1007546|NCT01989962|Continuing Medical Education
1007547|NCT01989923|Smoking cessation
1007548|NCT01989923|Traditional nicotine replacement therapy
1007549|NCT01989923|Electronic nicotine delivery devices
1007550|NCT01989923|electronic cigarettes
1007551|NCT01989923|cervical dysplasia
1007552|NCT01989910|Efavirenz
1007553|NCT01989910|Raltegravir
1007554|NCT01989910|Combination antiretroviral therapy
1007555|NCT01989897|diluent
1007556|NCT01989897|rhinitis
1007557|NCT01989897|allergic
1007558|NCT01989871|preterm
1007559|NCT01989871|oral feeding
1007560|NCT01989871|outcome
1007561|NCT01989858|localized gastric adenocarcinoma, operable considered.
1007562|NCT01989832|cohort
1007563|NCT01989832|pharmaco-economic
1007564|NCT01989832|kidney
1007565|NCT01989832|transplantation
1007566|NCT01989832|quality of life
1007567|NCT01989806|Spinal cord injury
1007568|NCT01989806|robotic
1007569|NCT01989806|locomotion
1007570|NCT01989793|sarcopenia
1007571|NCT01989793|frailty
1007572|NCT01989793|losartan
1007573|NCT01989767|sickness absence
1007574|NCT01989767|rehabilitation
1007575|NCT01989767|mental disorders
1007576|NCT01989767|screening
1007577|NCT01989754|Albuminuria
1007578|NCT01989754|Canagliflozin
1007579|NCT01989754|Cardiovascular outcomes
1007580|NCT01989754|Type 2 Diabetes Mellitus
1007581|NCT01989754|T2DM
1007582|NCT01989754|JNJ-28431754
1007583|NCT01989754|Antihyperglycemic Agent
1007584|NCT01989741|sleep restriction, decision making, wakefullness
1007585|NCT01989728|sickness absence, return to work, psychiatric examination, feedback, psychological distress, quality of life, attrition analysis, multiple imputation
1007586|NCT01989689|PSORIASIS
1007587|NCT01989676|Phase 3
1007588|NCT01989676|trastuzumab
1007589|NCT01989676|Breast Neoplasms
1007590|NCT01989663|Healthy Women
1007591|NCT01989624|Pancreatic adenocarcinoma
1007592|NCT01989624|diagnosis
1007593|NCT01989624|treatment
1007594|NCT01989572|locally advanced or stage IV melanoma
1007595|NCT01989572|GM-CSF
1007596|NCT01989572|peptide vaccine
1007602|NCT01989533|HIV Vaccine
1007603|NCT01989533|Adenovirus
1007604|NCT01989520|Relative bioavailability, Healthy volunteers, Neutrophils
1007605|NCT01989507|tobacco smoking
1007606|NCT01989507|smoking cessation
1007607|NCT01989507|nicotine dependence
1007608|NCT01989507|tobacco use disorder
1007609|NCT01989494|anesthesiologists
1007610|NCT01989494|physical activity
1007611|NCT01989494|pedometer
1007612|NCT01989494|wellness
1007613|NCT01989494|exercise
1007614|NCT01989468|Psoriatic arthritis
1007615|NCT01989468|AIN457
1007616|NCT01989468|PsA
1007617|NCT01989468|ACR
1007618|NCT01989468|CASPAR
1007619|NCT01989468|PASDAS
1007620|NCT01989468|secukinumab
1007621|NCT01989468|autoinjector
1007622|NCT01989455|Healthy
1007623|NCT01989455|Deferiprone
1007624|NCT01989455|DFP
1007625|NCT01989455|L1
1007626|NCT01989442|cpap failure
1007627|NCT01989442|bronchopulmonary dysplasia
1007628|NCT01989442|nasal trauma
1007629|NCT01989442|ventilation duration
1007630|NCT01989442|non-invasive ventilation
1007631|NCT01989429|psoriasis
1007632|NCT01989429|Vitamin D3
1007633|NCT01989429|topical
1007634|NCT01989429|ointments
1007635|NCT01989416|colonization
1007636|NCT01988558|Recurrent Tonsillitis
1007637|NCT01988558|Streptococcus A
1007638|NCT01988545|GLP-1
1007639|NCT01988545|blood flow
1007640|NCT01988545|cardiac out put
1007641|NCT01988545|stroke volume
1007642|NCT01988545|beat to beat
1007643|NCT01988545|effect of GLP-1 on cardiac parameters and blood flow
1007644|NCT01988506|IL2,
1007645|NCT01988506|Interleukin 2,
1007646|NCT01988506|IL-2,
1007647|NCT01988506|Proleukin®, RhIL-2
1007648|NCT01988506|Auto-immune disease
1007649|NCT01988506|Inflammatory disease
1007650|NCT01988506|Inflammation
1007651|NCT01988506|Regulatory T cells,
1007652|NCT01988506|Treg
1007653|NCT01988506|Immunoregulation
1007654|NCT01988506|Immune tolerance
1007655|NCT01988493|Carcinoma, Hepatocellular
1007656|NCT01988493|MSC2156119J
1007657|NCT01988493|Sorafenib
1007658|NCT01988493|Recommended Phase 2 dose
1007659|NCT01988480|Guided surgery
1007660|NCT01988480|Sinus graft
1007661|NCT01988467|nasal breathing, oral breathing, secondhand smoking,
1007662|NCT01988441|autophagy
1007663|NCT01988441|children
1007664|NCT01988441|polymorphism
1007665|NCT01988428|sepsis
1007666|NCT01988428|severe sepsis
1007667|NCT01988428|septic shock
1007668|NCT01988402|gout
1007669|NCT01988402|allopurinol
1007670|NCT01989338|hallux valgus
1007671|NCT01989338|pain
1007672|NCT01989338|functional status
1007673|NCT01989338|quality of life
1007674|NCT01989312|ultrasound
1007675|NCT01989312|peripheral nerves
1007676|NCT01989312|anesthetics
1007677|NCT01989312|local
1007678|NCT01989299|Heart failure with preserved ejection fraction (HFpEF)
1007679|NCT01989299|ILR
1007680|NCT01989299|ventricular tachyarrhythmias
1007681|NCT01989299|Safety
1007682|NCT01989286|Plagiocephaly
1007683|NCT01989286|Posture
1007684|NCT01989286|Spine
1007685|NCT01989260|Endometriosis
1007686|NCT01989247|Depression
1007687|NCT01989247|Anxiety
1007688|NCT01989247|Randomized Controlled Trial
1007689|NCT01989247|Self Care
1007690|NCT01989247|Intervention Studies
1007691|NCT01989247|Health Education
1007692|NCT01989208|Heart Failure
1007693|NCT01989208|Congestive Heart Failure
1007694|NCT01989208|Oxidative Stress
1007695|NCT01989208|Hydrogen Sulfide
1007696|NCT01989195|ISCHEMIC OR CORONARY HEART DISEASE
1007697|NCT01989195|MYOCARDIAL INFARCTION
1007698|NCT01989195|MAGNETIC RESONANCE IMAGING
1007699|NCT01989195|DELAYED GADOLINIUM ENHANCEMENT MRI
1007700|NCT01989195|MANGANESE-ENHANCED MRI
1007701|NCT01989195|INFARCT VOLUME/SIZE
1007702|NCT01989195|ALL CAUSE MORTALITY
1007703|NCT01989195|VENTRICULAR ARRHYTHMIAS
1007704|NCT01989182|Endobronchial Valves
1007705|NCT01989182|Intrabronchial Valves
1007706|NCT01989182|Bronchial Valve
1007707|NCT01989182|Chronic Obstructive Pulmonary Disease
1007708|NCT01989182|COPD
1007709|NCT01989182|Pulmonary Disease, Chronic Obstructive
1007710|NCT01989182|Bronchoscopic Lung Volume Reduction
1007711|NCT01989182|BLVR
1007712|NCT01989182|TLVR
1007713|NCT01989182|Emphysema
1007714|NCT01989182|Pulmonary Emphysema
1007715|NCT01989182|Pathologic Process
1007716|NCT01989182|Lung Diseases
1007717|NCT01989182|Respiratory Tract Disease
1007718|NCT01989182|China
1007719|NCT01989156|Smoking
1007720|NCT01989156|Candidate modified risk tobacco product
1007721|NCT01989156|Menthol conventional cigarettes
1007722|NCT01989156|Reduced exposure
1007723|NCT01989156|HPHCs
1007724|NCT01989156|Ambulatory
1007725|NCT01989143|Phase 1
1007726|NCT01989143|Randomized
1007727|NCT01989143|Double-blind
1007728|NCT01989143|Placebo-controlled
1007729|NCT01989143|Dose escalating
1007730|NCT01989143|Single and Multiple doses
1007731|NCT01989143|Safety
1007732|NCT01989143|Tolerability
1007733|NCT01989143|PK/PD
1007734|NCT01989143|PF-06480605
1007735|NCT01989130|antimicrobial stewardship
1007736|NCT01989130|Cepheid Xpert CT/NG
1007737|NCT01989130|chlamydia
1007738|NCT01989130|gonorrhea
1007739|NCT01989130|emergency department
1007740|NCT01989130|Diagnostic Techniques, Obstetrical and Gynecological
1007741|NCT01989130|Diagnostic Techniques, Urological
1007742|NCT01989104|Indirect calorimetry
1007743|NCT01989091|kidney dialysis
1007744|NCT01989091|hemodialysis
1007745|NCT01989091|locking solution
1007746|NCT01989091|antimicrobial
1007747|NCT01989091|thrombolytic
1007748|NCT01989078|Kidney disorder
1007749|NCT01989078|Blood disorder
1007750|NCT01989078|Pediatrics
1007751|NCT01989065|Child obesity
1007752|NCT01989065|childhood obesity
1007753|NCT01989065|obesity treatment
1007754|NCT01989065|text messaging
1007755|NCT01989065|Lifestyle
1007756|NCT01989052|Carboxyamidotriazole Orotate
1007757|NCT01989052|CTO
1007758|NCT01989052|Lomustine
1007759|NCT01989052|N-(2-chloroethyl)-N'-cyclo-hexyl-N-nitrosourea (CCNU)
1007760|NCT01989052|CeeNU
1007761|NCT01989052|Malignant Glioma
1007762|NCT01989052|Pro00047969
1007763|NCT01989052|Desjardins
1007764|NCT01989052|Duke
1007765|NCT01989052|The Preston Robert Tisch Brain Tumor Center
1007766|NCT01989026|BCG
1007767|NCT01989026|non-specific effects
1007768|NCT01989026|neonatal mortality
1007769|NCT01989026|vaccines
1007770|NCT01989013|Parkinson's disease
1007771|NCT01989013|Craniosacral therapy
1007772|NCT01989013|cranial osteopathy
1007773|NCT01989000|Pancreatic cancer
1007774|NCT01989000|Hypoxia
1007775|NCT01989000|Vasculature
1007776|NCT01989000|Stroma
1007777|NCT01988987|Gestational diabetes
1007778|NCT01988987|Postpartum glucose testing
1007779|NCT01988987|Impaired glucose metabolism
1007780|NCT01988987|Diabetes mellitus
1007781|NCT01988961|Colitis, Ulcerative
1007782|NCT01988961|Golimumab
1007783|NCT01988961|CNTO148
1007784|NCT01988961|SIMPONI
1007785|NCT01988961|Length-109 Probe Set Panel
1007786|NCT01988948|Human papilloma virus
1007787|NCT01988948|Young women
1007788|NCT01988948|I-Share
1007789|NCT01988922|ketamine polymorphisms
1007790|NCT01988909|Cutaneous leishmaniasis
1007791|NCT01988909|Paromomycin + Gentamicin Topical Cream
1007792|NCT01988909|Safety
1007793|NCT01988909|Efficacy
1007794|NCT01988883|Postural Tachycardia Syndrome
1007795|NCT01988883|Tachycardia
1007796|NCT01988883|Orthostatic Intolerance
1007797|NCT01988883|Autonomic Nervous System Diseases
1007798|NCT01988883|Primary Dysautonomias
1007799|NCT01988883|Nervous System Diseases
1007800|NCT01988883|Cardiovascular Diseases
1007801|NCT01988883|Modafinil
1007802|NCT01988883|Propranolol
1007803|NCT01988883|Neurobehavioral Manifestations
1007804|NCT01988883|Neurologic Manifestations
1007805|NCT01988883|Cognitive Symptoms
1007806|NCT01988883|Neuropsychological Tests
1007807|NCT01988857|Vietnam
1007808|NCT01988857|Children
1007809|NCT01988857|Reactogenicity
1007810|NCT01988857|BoostrixTM
1007811|NCT01988857|Safety
1007812|NCT01988857|dTpa
1007813|NCT01988857|Booster
1007814|NCT01988857|Healthy
1007815|NCT01988844|functionality
1007816|NCT01988844|Cerebral palsy
1007817|NCT01988844|Handwriting
1007818|NCT01988831|Malignant melanoma
1007819|NCT01988831|betablocker
1007820|NCT01988831|propranolol
1007821|NCT01988831|interventional
1007822|NCT01988831|prospective
1007823|NCT01988831|adjuvant
1007824|NCT01988831|recurrence
1007825|NCT01988818|wound dressing
1007826|NCT01988818|silicone
1007827|NCT01988818|standard wound dressing
1007828|NCT01988766|Thrombosis
1007829|NCT01988766|Central Venosis Catheter
1007830|NCT01988766|Renal Disease
1007831|NCT01988766|Vascular Access
1007832|NCT01988753|Serum Biomarkers
1007833|NCT01988753|Sheer-wave Elastography
1007834|NCT01988753|Ultrasound imaging
1007835|NCT01988753|Viral hepatitis
1007836|NCT01988753|Liver Fibrosis
1007837|NCT01988753|Liver disease
1007838|NCT01988753|Hepatitis B
1007839|NCT01988753|Hepatitis C
1007840|NCT01988740|Ischemia-modified albumin
1007841|NCT01988740|Recurrent pregnancy loss
1007842|NCT01988740|Abnormal placenta
1007843|NCT01988714|Targeted cognitive training (TCT) plus evidence-based SE
1007844|NCT01988714|Computer games (CG) plus evidence-based SE
1007845|NCT01988701|GVHD
1007846|NCT01988701|chronic Graft versus Host Disease
1007847|NCT01988688|deep brain stimulation
1007848|NCT01988662|nAMD, VEGF, VEGF agent, BCVA, CRT, Ranibizumab, Lucentis, Aflibercept, Eylea
1007849|NCT01988649|Pain
1007850|NCT01988649|Oxytocin
1007851|NCT01988636|Randomized
1007852|NCT01988636|Double Blinded
1007853|NCT01988636|Mali
1007854|NCT01988636|Malaria
1007855|NCT01988636|Transmission
1007856|NCT01988623|Intellectual Disabilities
1007857|NCT01988623|Speech Delay
1007858|NCT01988623|Language Disorder
1007859|NCT01988610|cognition
1007860|NCT01988610|prediabetes
1007861|NCT01988610|mood
1007862|NCT01988597|Dry Eyes
1007863|NCT01988597|Quality of life
1007864|NCT01988597|Utility assessment
1007865|NCT01988584|Cerebral Palsy
1007866|NCT01988584|Brain Injury
1007867|NCT01988584|Stem Cells
1007868|NCT01988584|Mononuclear Cells
1007869|NCT01988584|Bone Morrow
1007870|NCT01988584|Umbilical Cord Blood
1007871|NCT01988571|Stage I breast cancer
1007872|NCT01988571|Stage II breast cancer
1007873|NCT01988571|Stage III breast cancer
1007874|NCT01988363|greater occipital nerve
1007875|NCT01988363|occipital neuralgia
1007876|NCT01988363|cervicogenic headache
1007877|NCT01988350|pancreatic insufficiency
1007878|NCT01988350|pancreatic elastase
1007879|NCT01988350|fecal elastase
1007880|NCT01988350|smoking
1007881|NCT01988350|tobacco
1007882|NCT01988311|Psilocybin
1007883|NCT01988311|Hallucinogens
1007884|NCT01988311|Pharmacologic Actions
1007885|NCT01988311|Central Nervous System Agents
1007886|NCT01988311|Therapeutic Uses
1007887|NCT01988311|Psychotropic Drugs
1007888|NCT01988285|Esophagitis
1007889|NCT01988285|Eosinophilic Esophagitis
1007890|NCT01988285|Esophageal Diseases
1007891|NCT01988285|Gastrointestinal Diseases
1007892|NCT01988285|Digestive System Diseases
1007893|NCT01988272|SPECT/CT
1007894|NCT01988272|Dosimetry
1007895|NCT01988272|Radiation absorbed dose
1007896|NCT01988272|Non-Hodgkin's Lymphoma
1007897|NCT01988272|I-131 tositumomab radioimmunotherapy
1007898|NCT01988246|Diabetes
1007899|NCT01988246|Diabetic Retinopathy
1007900|NCT01988233|Physical activity
1007901|NCT01988233|Dance
1007902|NCT01988233|Latinos
1007903|NCT01988233|Aging
1007904|NCT01988233|Older adults
1007905|NCT01988233|Health disparities
1007906|NCT01988220|stroke
1007907|NCT01988220|sensory deficit
1007908|NCT01988220|sensory retraining
1007909|NCT01988220|perceptual learning
1007910|NCT01988220|lower extremity
1007911|NCT01988207|Muscle Tension Dysphonia
1007912|NCT01988207|Voice
1007913|NCT01988207|Hyperfunction
1007914|NCT01988194|acupuncture
1007915|NCT01988194|postoperative pain
1007916|NCT01988194|nausea
1007917|NCT01988194|vomiting
1007918|NCT01988194|anxiety
1007919|NCT01988194|depression
1007920|NCT01988194|hospitalization
1007921|NCT01988194|inpatient
1007922|NCT01988181|Intradialytic Hypotension
1007923|NCT01988181|Renal Dialysis
1007924|NCT01988181|Blood Volume Determination
1007925|NCT01988181|Clinical Trials, Randomized
1007926|NCT01988181|Crossover Studies
1007927|NCT01988168|Suture Techniques
1007928|NCT01988168|Sutures
1007929|NCT01988168|Surgical Staplers
1007930|NCT01988142|Spinal Cord Injury
1007931|NCT01988142|Passive motion
1007932|NCT01988142|Fatigue index
1007933|NCT01988142|Hypertonia
1007934|NCT01988129|sleep
1007935|NCT01988129|firefighter
1007936|NCT01988129|fire
1007937|NCT01988129|apnea
1007938|NCT01988129|insomnia
1007939|NCT01988129|shift
1007940|NCT01988129|narcolepsy
1007941|NCT01988129|restless leg
1007942|NCT01988129|rls
1007943|NCT01988129|fatigue
1007944|NCT01988129|actigraph
1007945|NCT01988129|actigraphy
1007946|NCT01988129|actiwatch
1007947|NCT01988129|safety
1007948|NCT01988129|sleepiness
1007949|NCT01988129|sleepy
1007950|NCT01988129|work
1007951|NCT01988129|hours
1007952|NCT01988129|Federal Emergency Management Agency
1007953|NCT01988129|drowsy
1007954|NCT01988116|Chronic kidney disease
1007955|NCT01988116|Anemia of chronic disease
1007956|NCT01988116|Iron Metabolism
1007957|NCT01988116|Iron Homeostasis
1007958|NCT01988116|Vitamin D
1007959|NCT01988116|Calcitriol
1007960|NCT01988116|hemojuvelin
1007961|NCT01988116|hepcidin
1007962|NCT01988116|anemia
1007963|NCT01988116|ferroportin
1007964|NCT01988103|Psoriasis; Psoriatic Arthritis
1007965|NCT01988090|Breast Cancer
1007966|NCT01988090|Hormone Receptor Positive
1007967|NCT01988090|Vitamin D
1007968|NCT01988064|pulse rate
1007969|NCT01988064|patient education
1007970|NCT01988064|training
1007971|NCT01988038|Polycystic Kidney Disease
1007972|NCT01988038|Autosomal Dominant Polycystic Kidney Disease
1007973|NCT01988038|Disease Progression
1007974|NCT01987986|cellulite
1007975|NCT01987986|dimple
1007976|NCT01987986|orange peel
1007977|NCT01987986|cottage cheese
1007978|NCT01987986|mattress texture
1007979|NCT01987947|MEMP1972A
1007980|NCT01987934|Squamous Cell Carcinoma of the Head and Neck
1007981|NCT01987934|Methyl Green Pyronin Staining
1007982|NCT01987934|AgNORs
1007983|NCT01987934|Morphometry
1007984|NCT01987921|Acute kidney injury
1007985|NCT01987921|Pediatrics
1007986|NCT01987921|Critical Care
1007987|NCT01987908|Pain
1007988|NCT01987908|Biomarkers
1007989|NCT01987908|6 minute walk test
1007990|NCT01987908|5-HMF
1007991|NCT01987908|Pharmacokinetics
1007992|NCT01987908|Analgesic use
1007993|NCT01987908|Sickle cell disease
1007994|NCT01987908|Aes-103
1007995|NCT01987908|SpO2
1007996|NCT01987908|Anemia
1007997|NCT01987908|Hemoglobin
1007998|NCT01987895|Post-antibiotic diarrhea
1007999|NCT01987895|Clostridium difficile infection
1008000|NCT01987882|Outcomes research, treatment effectiveness, quality of life
1008001|NCT01987869|hiperemesis gravidarum,vomiting,serotonin levels,ketonuria
1008002|NCT01987856|aCGH
1008003|NCT01987856|chromosome
1008004|NCT01987856|blastocyst
1008005|NCT01987856|trophectoderm
1008006|NCT01987856|vitrification
1008007|NCT01987856|natural cycle
1008008|NCT01987856|pregnancy
1008009|NCT01987856|live birth
1008010|NCT01987843|Psoriasis
1008011|NCT01987843|Plaque Psoriasis
1008013|NCT01987817|Characterized Peanut Allergen
1008014|NCT01987817|Peanut
1008015|NCT01987817|OIT
1008016|NCT01987817|Oral Desensitization
1008017|NCT01987817|Peanut Allergen
1008018|NCT01987817|Allergy
1008019|NCT01987817|Peanut Allergy
1008020|NCT01987817|Peanut-Allergic Children
1008021|NCT01987817|Children
1008022|NCT01987817|Peanut-Allergic Adults
1008023|NCT01987778|Hot flashes
1008024|NCT01987778|Menopause
1008025|NCT01987778|HRQoL
1008026|NCT01987778|Resistance training
1008027|NCT01987778|Physical activity
1008028|NCT01987778|Adipose tissue
1008029|NCT01987739|Almorexant
1008030|NCT01987739|Zolpidem
1008031|NCT01987726|Solid Tumor Malignancies
1008032|NCT01987700|Abdominal Hernia Repair
1008033|NCT01987700|Dermal Allograft
1008034|NCT01987700|Mesh
1008035|NCT01987700|Component Separation
1008036|NCT01987661|COPD
1008037|NCT01987661|NIV
1008038|NCT01987661|Airtrapping
1008039|NCT01987661|Ventimotion2
1008040|NCT01987648|Craniotomy
1008041|NCT01987648|Postoperative complications
1008042|NCT01987648|Perioperative care
1008043|NCT01987648|Postoperative intracerebral hemorrhage
1008044|NCT01987648|Postoperative seizure
1008045|NCT01987635|Mitral valve disease
1008046|NCT01987635|primarily regurgitation
1008047|NCT01987635|necessitating surgical repair
1008048|NCT01987622|lumbar spinal stenosis
1008049|NCT01987622|claudication
1008050|NCT01987622|low back pain
1008051|NCT01987622|radiculopathy
1008052|NCT01987622|acupuncture
1008053|NCT01987622|Korean medicine
1008054|NCT01987622|randomized controlled trial
1008055|NCT01987609|Psoriasis
1008056|NCT01987609|Dendritic cells
1008057|NCT01987609|Hyaluronidase
1008058|NCT01987609|Hylenex
1008059|NCT01987570|Xanthine oxidase
1008060|NCT01987570|Magnetic resonance
1008061|NCT01987570|Oxidative stress
1008062|NCT01987570|Inflammation
1008063|NCT01987557|treadmill
1008064|NCT01987557|parkinson's
1008065|NCT01987557|proprioception
1008066|NCT01987557|cadence
1008067|NCT01987557|step length
1008068|NCT01987557|intrinsic feedback
1008069|NCT01987544|COPD
1008070|NCT01987544|telemonitoring
1008071|NCT01987544|training
1008072|NCT01987544|ergometer
1008073|NCT01987544|telemedicine
1008074|NCT01987531|after open cardiac chamber cardiac surgery
1008075|NCT01987466|Neutrophil Gelatinase-associated Lipocalin(NGAL)
1008076|NCT01987466|Acute renal failure
1008077|NCT01987466|Cardiac arrest
1008078|NCT01987466|Hypothermia
1008079|NCT01987453|genotype 1
1008080|NCT01987427|Overweight
1008081|NCT01987427|Obese
1008082|NCT01987427|Weight Management
1008083|NCT01987414|Stroke
1008084|NCT01987414|Cardiovascular Accident
1008085|NCT01987414|Task-oriented approach
1008086|NCT01987414|Orthosis
1008087|NCT01987414|occupational therapy
1008088|NCT01987401|pulmonary
1008089|NCT01987401|lung
1008090|NCT01987401|military and environmental exposures
1008091|NCT01987401|epidemiologic
1008092|NCT01987401|observational
1008093|NCT01987401|interview or questionnaire
1008094|NCT01987401|deployment related
1008095|NCT01987401|Enduring Freedom
1008096|NCT01987401|Iraqi Freedom
1008097|NCT01987375|HNSCC
1008098|NCT01987375|Imaging
1008099|NCT01987349|Influenza vaccines
1008100|NCT01987349|healthy participants
1008101|NCT01987349|immunity to influenza
1008102|NCT01987349|identical twins
1008103|NCT01987349|fraternal twins
1008104|NCT01987349|non-twins
1008105|NCT01987336|Standard Foley Catheter
1008106|NCT01987323|glaucoma
1008107|NCT01987323|raised intraocular pressure
1008108|NCT01987310|non alcoholic fatty liver disease
1008109|NCT01987310|endothelial function
1008110|NCT01987310|liver steatosis
1008111|NCT01987310|liver fibrosis
1008112|NCT01987310|statin treatment
1008113|NCT01987297|arsenic
1008114|NCT01987297|acute promyelocytic leukemia
1008115|NCT01987297|outcome
1008116|NCT01987271|exercise tolerance
1008117|NCT01987271|exercise test
1008118|NCT01987271|noninvasive ventilation
1008119|NCT01987258|Glycemic control
1008120|NCT01987258|excess post-exercise oxygen consumption
1008121|NCT01987219|familial dysautonomia
1008122|NCT01987206|artificial pancreas
1008123|NCT01987193|Proton radiation
1008124|NCT01987193|tumor blood flow
1008125|NCT01987180|self-efficacy
1008126|NCT01987167|acute optic neuritis
1008127|NCT01987115|Trigger Finger
1008128|NCT01987115|Physiotherapy
1008129|NCT01987115|Fascial Manipulation
1008130|NCT01987102|Methotrexate
1008131|NCT01987102|rescue treatment
1008132|NCT01987089|Insomnia
1008133|NCT01987089|Sleep initiation and maintenance disorder
1008134|NCT01987089|Alcoholism
1008135|NCT01987089|Cognitive behavioral therapy for insomnia
1008136|NCT01987076|DRESS
1008137|NCT01987076|Systemic steroid
1008138|NCT01987076|Topical steroid
1008139|NCT01987076|Treatment
1008140|NCT01987063|Twin delivery
1008141|NCT01987063|Planned vaginal delivery
1008142|NCT01987063|Planned cesarean delivery
1008143|NCT01987063|Total breech extraction
1008144|NCT01987063|Internal cephalic version
1008145|NCT01987063|External cephalic version
1008146|NCT01987037|autism spectrum disorder
1008147|NCT01987037|neuropsychomotor assessment
1008148|NCT01987037|NP-MOT
1008149|NCT01987037|motor skills
1008150|NCT01987037|gross motor
1008151|NCT01987011|Avian influenza
1008152|NCT01986998|Multiple sclerosis relapse
1008153|NCT01986998|oral methylprednisolone
1008154|NCT01986998|EDSS
1008155|NCT01986998|gadolinium
1008156|NCT01986972|Toothbrushing
1008157|NCT01986972|Dental plaque
1008158|NCT01986972|Dentifrice
1008159|NCT01986972|Oral hygiene
1008160|NCT01986959|Periodontal Dressings
1008161|NCT01986959|Surgical crown lengthening
1008162|NCT01986959|Periodontal surgery
1008163|NCT01986920|SK
1008164|NCT01986907|wet AMD
1008165|NCT01986907|macular degeneration
1008166|NCT01986907|ranibizumab
1008167|NCT01986907|mono-bilateral
1008168|NCT01986907|poor visual acuity
1008169|NCT01986907|retinal disease
1008170|NCT01986907|eye disease
1008171|NCT01986907|Angiogenesis Inhibitors
1008172|NCT01986907|Angiogenesis Modulating Agents
1008173|NCT01986894|TQT
1008174|NCT01986894|Pharmacokinetic
1008175|NCT01986894|Healthy
1008176|NCT01986868|Coronary Magnetic Resonance Angiography
1008177|NCT01986868|CMRA
1008178|NCT01986868|MRI with contrast
1008179|NCT01986868|MultiHance
1008180|NCT01986868|Optimark
1008181|NCT01986868|Gadolinium-based contrast
1008182|NCT01986868|MRA
1008183|NCT01986868|MR angiography
1008184|NCT01986842|Muscle protein synthesis
1008185|NCT01986842|Digestion and absorption kinetics
1008186|NCT01986842|Leucine
1008187|NCT01986842|Whey protein
1008188|NCT01986816|Obesity
1008189|NCT01986816|Bariatric surgery
1008190|NCT01986816|Laparoscopic gastric bypass
1008191|NCT01986816|Quality of life
1008192|NCT01986816|QALY
1008193|NCT01986803|ST-elevation Myocardial Infarction (STEMI)
1008194|NCT01986803|Primary Percutaneous Coronary Intervention within 24 hrs
1008195|NCT01986803|Healing score
1008196|NCT01986803|OFDI
1008197|NCT01986790|Health insurance
1008198|NCT01986790|Health services accessibility
1008199|NCT01986790|Decision making
1008200|NCT01986790|Health literacy
1008201|NCT01986777|cognitive complains
1008202|NCT01986777|RRSO
1008203|NCT01986777|oophorectomy
1008204|NCT01986777|memory
1008205|NCT01986777|cognition
1008206|NCT01986777|early menopause
1008207|NCT01986764|oophorectomy
1008208|NCT01986764|RRSO
1008209|NCT01986764|menopause
1008210|NCT01986764|early menopause
1008211|NCT01986764|cognition
1008212|NCT01986764|memory
1008213|NCT01986764|brain-imaging
1008214|NCT01986751|nerve
1008215|NCT01986751|block
1008216|NCT01986751|motor blockade
1008217|NCT01986751|lower extremity pain
1008218|NCT01986751|nerve block
1008219|NCT01986725|vulvar neoplasia
1008220|NCT01986725|vulvar cancer
1008221|NCT01986725|vulvar intraepithelial neoplasia
1008222|NCT01986725|self management
1008223|NCT01986725|symptom management
1008224|NCT01986712|Melanoma, Stage III, adjuvant, Quality of Life
1008225|NCT01986699|polypectomy
1008226|NCT01986699|laparoscopic
1008227|NCT01986673|Pharmacokinetic Characterization
1008228|NCT01986660|Pharmacokinetic Study
1008229|NCT01986647|exercise
1008230|NCT01986647|older adults
1008231|NCT01986647|mobility disability
1008232|NCT01986634|Laser Resurfacing
1008233|NCT01986634|Rhytids
1008234|NCT01986634|Perioral
1008235|NCT01986608|Lacosamide
1008236|NCT01986608|Vimpat
1008237|NCT01986608|Bioequivalence
1008238|NCT01986608|Bioavailability
1008239|NCT01986608|Japanese
1008240|NCT01986595|Neuroblastoma
1008241|NCT01986595|anaplastic lymphoma kinase
1008242|NCT01986595|cancer genetics
1008243|NCT01986595|target therapy
1008244|NCT01986595|RNA and genomic DNA extraction
1008245|NCT01986595|complementary DNA(cDNA) preparation
1008246|NCT01986595|Array-comparative genomic hybridization
1008247|NCT01986595|Multiplex ligation-dependent probe amplification (MLPA)
1008248|NCT01986595|Sequencing of cDNA prepared from NB
1008249|NCT01986595|Pyrosequencing
1008250|NCT01986595|Quantitative real-time polymerase chain reaction(RT-PCR)
1008251|NCT01986595|Immunohistochemistry
1008252|NCT01986582|Allergic Rhinitis
1008253|NCT01986582|Congestion
1008254|NCT01986582|Mucoadhesive Treatment
1008255|NCT01986582|Nasal Decongestant
1008256|NCT01986569|Fluoroestradiol (FES)
1008257|NCT01986569|PET/CT scan
1008258|NCT01986569|Estrogen Receptor
1008259|NCT01986569|Recurrent breast cancer
1008260|NCT01986569|Stage IV breast cancer
1008261|NCT01986543|Pharmacokinetic
1008262|NCT01986530|irisin
1008263|NCT01986530|adiponectin
1008264|NCT01986530|leptin
1008265|NCT01986530|lean body mass
1008266|NCT01986530|fat mass
1008267|NCT01986517|Feedback
1008268|NCT01986517|Therapeutic competencies
1008269|NCT01986517|Training
1008270|NCT01986504|Infection
1008271|NCT01986504|Cohort
1008272|NCT01986504|Prospective
1008273|NCT01986504|Epidemiology
1008274|NCT01986504|Outcome
1008275|NCT01986491|Healthy
1008276|NCT01986491|JNJ-39393406
1008277|NCT01986491|Relative Bioavailability
1008278|NCT01986491|Solid Formulation
1008279|NCT01986465|lateral epicondylitis
1008280|NCT01986465|treatment
1008281|NCT01986465|steroid
1008282|NCT01986465|immobilization
1008283|NCT01986452|OSA
1008284|NCT01986452|Apoplexy
1008285|NCT01986452|CPAP
1008286|NCT01986452|adherence
1008287|NCT01986452|telemonitoring
1008288|NCT01986426|Transdermal accessible tumours
1008289|NCT01986413|COPD
1008290|NCT01986413|chronic hypercapnic respiratory failure
1008291|NCT01986413|NIV
1008292|NCT01986413|respiratory events
1008293|NCT01986413|IVAPS
1008294|NCT01986400|Adolescent
1008295|NCT01986400|Skype
1008296|NCT01986400|Peer Mentorship
1008297|NCT01986400|Internet Self-Management
1008298|NCT01986387|adolescent
1008299|NCT01986387|Skype
1008300|NCT01986387|peer mentorship
1008301|NCT01986387|internet self-management
1008302|NCT01986374|IVF , embryo implantation, HCG
1008303|NCT01986361|Pharyngitis
1008304|NCT01986361|Sore Throat
1008305|NCT01986361|acute upper respiratory tract infection (URTI)
1008306|NCT01986348|GBM
1008307|NCT01986348|Glioblastoma
1008308|NCT01986348|selinexor
1008309|NCT01986348|KPT-330
1008310|NCT01986348|Karyopharm
1008311|NCT01986348|brain tumor
1008312|NCT01986348|brain cancer
1008313|NCT01986348|Glioma
1008314|NCT01986348|Astrocytoma
1008315|NCT01986348|Oligodendrogliomas
1008316|NCT01986348|Oligo-astrocytomas
1008317|NCT01986335|Combined pentavalent DTP/HB/Hib vaccine
1008318|NCT01986335|Infants
1008319|NCT01986335|Primary vaccination
1008320|NCT01986322|DTP/HB/Hib vaccine
1008321|NCT01986322|Immunogenicity
1008322|NCT01986322|Infants
1008323|NCT01986322|Safety
1008324|NCT01986309|Postoperative
1008325|NCT01986309|Nausea
1008326|NCT01986309|Vomiting
1008327|NCT01986309|Pain
1008328|NCT01986309|Surgery
1008329|NCT01986283|Abuse potential
1008330|NCT01986283|PF-00345439
1008331|NCT01986283|drug abuse
1008332|NCT01986244|Osteoarthritis
1008333|NCT01986244|Arthritis
1008334|NCT01986244|Joint Diseases
1008335|NCT01986231|diabetes
1008336|NCT01986231|insulin
1008337|NCT01986231|glucagon
1008338|NCT01986231|glycogen
1008339|NCT01986231|MRS
1008340|NCT01986205|Concussion, mild
1008341|NCT01986205|Traumatic brain injury
1008342|NCT01986205|Hyperbaric oxygenation
1008343|NCT01986205|Post-concussion symptoms
1008344|NCT01986205|Headache
1008345|NCT01986192|anticoagulation
1008346|NCT01986192|pharmacomechanical thrombolysis
1008347|NCT01986192|aspiration thrombectomy
1008348|NCT01986153|Fatty acid, essential
1008349|NCT01986153|Immune system
1008350|NCT01986153|Home parenteral nutrition
1008351|NCT01986140|Breast Cancer
1008352|NCT01986140|Alopecia
1008353|NCT01986140|Scalp
1008354|NCT01986140|Cooling
1008355|NCT01986127|Crohn disease
1008356|NCT01986075|Cocaine Dependence Treatment
1008357|NCT01986075|Computer-assisted therapy
1008358|NCT01986075|Pharmacotherapy
1008359|NCT01986062|ADHD
1008360|NCT01986062|AR11
1008361|NCT01986062|classroom design
1008362|NCT01986062|amphetamine sulfate
1008363|NCT01986023|Stroke
1008364|NCT01986023|Medication Adherence
1008365|NCT01986023|SMS
1008366|NCT01986023|Randomised
1008367|NCT01985997|FluMist, Quadrivalent, Vaccine
1008368|NCT01985984|Head and neck cancer
1008369|NCT01985906|Aorta
1008370|NCT01985906|Aneurysm
1008371|NCT01985906|Stents
1008372|NCT01985906|Collateral Circulation
1008373|NCT01985893|Metastatic
1008374|NCT01985893|breast
1008375|NCT01985893|cancer
1008376|NCT01985880|Biomarkers
1008377|NCT01985854|Desflurane
1008378|NCT01985854|Propofol
1008379|NCT01985854|Total intravenous anesthesia
1008380|NCT01985854|Neurosurgery
1008381|NCT01985841|Early breast cancer
1008382|NCT01985841|Primary operable breast cancer
1008383|NCT01985841|HER2- negative
1008384|NCT01985841|bevacizumab
1008385|NCT01985828|Prostate neoplasm
1008386|NCT01985828|Prostate Cancer
1008387|NCT01985815|obsessive-compulsive disorder
1008388|NCT01985815|Deep Brain Stimulation
1008389|NCT01985815|Psychosurgery
1008390|NCT01985789|airway hyperresponsiveness
1008391|NCT01985776|Exercise
1008392|NCT01985776|Electric Stimulation
1008393|NCT01985763|Genistein
1008394|NCT01985763|soy supplements
1008395|NCT01985763|phytoestrogens
1008396|NCT01985763|colon cancer
1008397|NCT01985763|rectal cancer
1008398|NCT01985763|colorectal cancer
1008399|NCT01985763|metastatic
1008400|NCT01985763|stage IV
1008401|NCT01985763|FOLFOX
1008402|NCT01985763|FOLFOX-Avastin
1008403|NCT01985763|Chemotherapy
1008404|NCT01985750|dyspnea
1008405|NCT01985750|fmri
1008406|NCT01985750|d-cycloserine
1008407|NCT01985737|Neonatal Intensive Care Units (NICUs)
1008408|NCT01985737|NICUs
1008409|NCT01985737|Neonates
1008410|NCT01985737|CLABSI
1008411|NCT01985737|Microbiome
1008412|NCT01985737|DNA signature
1008413|NCT01985737|Catheter infections
1008414|NCT01985724|Early breast cancer
1008415|NCT01985724|Axillary node positive
1008416|NCT01985724|HER-2 negative
1008417|NCT01985724|Adjuvant chemotherapy
1008418|NCT01985724|Dose dense
1008419|NCT01985724|Docetaxel
1008420|NCT01985724|FEC
1008421|NCT01985711|Motivational Interviewing
1008422|NCT01985711|Cognitive Behavioral Therapy
1008423|NCT01985711|Transtheoretical Model of behavior change
1008424|NCT01985711|Questionnaires
1008425|NCT01985711|Telemedicine/*methods
1008426|NCT01985711|Comorbidity
1008427|NCT01985711|Diabetes
1008428|NCT01985711|Glucose/metabolism
1008429|NCT01985711|Hemoglobin A, Glycosylated
1008430|NCT01985711|Blood Pressure
1008431|NCT01985711|Cholesterol, LDL/blood
1008432|NCT01985711|Quality of life
1008433|NCT01985711|Depressive Disorder/psychology/*therapy
1008434|NCT01985711|Randomized Controlled Trials
1008435|NCT01985698|Low rectal cancer
1008436|NCT01985698|Robotic
1008437|NCT01985698|Laparoscopic
1008438|NCT01985698|Abdominoperineal resection
1008439|NCT01985685|VO2, critically ill, oxygen consumption
1008440|NCT01985672|Infertility
1008441|NCT01985659|Lymph Node Excision
1008442|NCT01985659|Thoracic Surgical Procedures
1008443|NCT01985659|Thoracic Surgery, Video-Assisted
1008444|NCT01985659|Thoracotomy
1008445|NCT01985646|Hirschsprung disease
1008446|NCT01985646|conservative treatment
1008447|NCT01985646|surgery treatment
1008448|NCT01985646|infants
1008449|NCT01985633|Osteoarthritis
1008450|NCT01985633|stem cells
1008451|NCT01985633|Platelet gel
1008452|NCT01985633|Functional outcome
1008453|NCT01985620|Vaccination
1008454|NCT01985620|RSV
1008455|NCT01985620|Influenza
1008456|NCT01985620|Prematurity
1008457|NCT01985594|preterm labor
1008458|NCT01985581|Attention Deficit Hyperactivity Disorder
1008459|NCT01985581|Intuniv extended release
1008460|NCT01985581|Executive Function
1008461|NCT01985581|Quality of Life
1008462|NCT01985568|Obesity
1008463|NCT01985568|weight-loss
1008464|NCT01985568|Physical activity
1008465|NCT01985555|Phase I
1008466|NCT01985555|Safety
1008467|NCT01985555|Pharmacokinetics
1008468|NCT01985516|Pain
1008469|NCT01985516|Urethra
1008470|NCT01985516|Catheter
1008471|NCT01985503|positron emission tomography
1008472|NCT01985503|magnetic resonance imaging
1008473|NCT01985503|brown adipose tissue
1008474|NCT01985503|obesity
1008475|NCT01985503|cardiovascular disease
1008476|NCT01985503|subclinical atherosclerosis
1008477|NCT01985490|epiretinal membrane
1008478|NCT01985490|foveal avascular zone
1008479|NCT01985490|internal limiting membrane
1008480|NCT01985477|Myeloma
1008481|NCT01985477|Multiple myeloma
1008482|NCT01985477|MM
1008483|NCT01985477|Relapsed/Refractory Multiple Myeloma
1008484|NCT01985477|RR MM
1008485|NCT01985477|Lenalidomide
1008486|NCT01985477|CC-5013
1008487|NCT01985477|Revlimid
1008488|NCT01985477|Dexamethasone
1008489|NCT01985477|Decadron
1008490|NCT01985477|All-Trans Retinoic Acid
1008491|NCT01985477|ATRA
1008492|NCT01985477|Tretinoin (Oral)
1008493|NCT01985477|Vesanoid
1008494|NCT01985464|rheumatoid arthritis
1008495|NCT01985464|umbilical cord
1008496|NCT01985464|mesenchymal
1008497|NCT01985464|stem cells
1008498|NCT01985451|Lymphoma
1008499|NCT01985438|Head and Neck Neoplasms
1008500|NCT01985438|Nutritional Support
1008501|NCT01985438|Randomized Controlled Trial
1008502|NCT01985438|Percutaneous Endoscopic Gastrostomy tube
1008503|NCT01985438|Nasogastric tube
1008504|NCT01985438|Radiation Effects
1008505|NCT01985438|Pakistan
1008506|NCT01985412|Rejection
1008507|NCT01985412|Transplant
1008508|NCT01985412|Cardiac
1008509|NCT01985412|Pulmonary
1008510|NCT01985412|Heart
1008511|NCT01985412|Lung
1008512|NCT01985412|Cell-Free DNA
1008513|NCT01985412|cfDNA
1008514|NCT01985412|Cell
1008515|NCT01985412|Free
1008516|NCT01985412|DNA
1008517|NCT01985412|Biopsy
1008518|NCT01985412|Non-Invasive
1008519|NCT01985399|HIV
1008520|NCT01985399|AIDS
1008521|NCT01985399|Aging
1008522|NCT01985386|Iron absorption
1008523|NCT01985386|Slow release iron
1008524|NCT01985386|Gastric delivery system
1008525|NCT01985386|Iron deficiency
1008526|NCT01985373|intravenous immunoglobulin
1008527|NCT01985373|pharmacokinetics
1008528|NCT01985373|10% IVIG
1008529|NCT01985334|Moderate COPD, glycopyrronium bromide, indacaterol maleate and glycopyrronium bromide FDC, NVA237, QVA149
1008530|NCT01985321|herpes labialis
1008531|NCT01985321|cold sore
1008532|NCT01985269|High risk
1008533|NCT01985269|ART naive
1008534|NCT01985243|Dietary diversity
1008535|NCT01985243|Infant and young child
1008536|NCT01985243|Adolescents
1008537|NCT01985243|Anemia
1008538|NCT01985243|Rural health
1008539|NCT01985204|iodine
1008540|NCT01985204|thyroid hormones
1008541|NCT01985204|obesity
1008542|NCT01985204|TSH
1008543|NCT01985204|dyslipidemia
1008544|NCT01985204|insulin resistance
1008545|NCT01985139|Obesity, food pleasure, behavioral tasks, endocannabinoids
1008546|NCT01985126|Multiple myeloma
1008547|NCT01985126|Daratumumab
1008548|NCT01985126|Proteasome inhibitor
1008549|NCT01985126|Immunomodulatory drug
1008550|NCT01985126|IMiD
1008551|NCT01985113|thioredoxin reductase
1008552|NCT01985113|non-small cell lung cancer
1008553|NCT01985074|case management, disease management, emergency
1008554|NCT01985074|department
1008555|NCT01985061|Myelodysplasic syndrome
1008556|NCT01985061|Acute Myeloid leukemia
1008557|NCT01985035|Obstructive sleep apnea
1008558|NCT01985035|obesity
1008559|NCT01985035|diet
1008560|NCT01985035|energy expenditure
1008561|NCT01985022|autism
1008562|NCT01985022|autism spectrum disorders
1008563|NCT01985022|pervasive developmental disorders
1008564|NCT01985022|toddlers
1008565|NCT01985022|intervention
1008566|NCT01984983|Venezuelan equine encephalitis virus
1008567|NCT01984983|DNA vaccine
1008568|NCT01984983|electroporation
1008569|NCT01984983|intradermal
1008570|NCT01984983|intramuscular
1008571|NCT01984970|McGrath Videolaryngoscope
1008572|NCT01984970|double-lumen tube intubation
1008573|NCT01984970|Thoracic surgery
1008574|NCT01984957|ALS
1008575|NCT01984957|Motor neuron diseases
1008576|NCT01984957|Transcriptome
1008577|NCT01984944|circadian rhythm
1008578|NCT01984931|post operative nausea and vomiting
1008579|NCT01984931|Trimebutine Maleate
1008580|NCT01984905|18 FDG PET-scan
1008581|NCT01984905|angioscan
1008582|NCT01984905|aortic dissection
1008583|NCT01984892|Autologous Vaccination
1008584|NCT01984892|Intratumoral Injections
1008585|NCT01984892|Intramuscular Injections
1008586|NCT01984892|Advanced Accessible Solid Tumors
1008587|NCT01984892|Poly-ICLC
1008588|NCT01984892|Phase II Clinical Trial
1008589|NCT01984892|Safety
1008590|NCT01984892|Efficacy
1008591|NCT01984892|Autovaccination
1008592|NCT01984892|In Situ
1008593|NCT01984892|Host Targeted Strategy
1008594|NCT01984892|Overall Survival
1008595|NCT01984892|Immunotherapy
1008596|NCT01984892|Adjuvant
1008597|NCT01984866|CPR: Complete Pathological Response
1008598|NCT01984853|ACS
1008599|NCT01984853|repository
1008600|NCT01984853|Observational
1008601|NCT01984827|Hyperglycaemia
1008602|NCT01984827|Moxifloxacin
1008603|NCT01984827|QTc prolongation
1008604|NCT01984827|C-peptide
1008605|NCT01984827|Dead in bed syndrome
1008606|NCT01984801|SCD1
1008607|NCT01984801|Gel
1008608|NCT01984801|Topical Administration
1008609|NCT01984801|Acne
1008610|NCT01984788|Oral Prophylaxis
1008611|NCT01984775|safety
1008612|NCT01984775|dermal
1008613|NCT01984775|GSK2894512
1008614|NCT01984775|Cumulative irritation
1008615|NCT01984736|Pharmacokinetic
1008616|NCT01984736|Safety
1008617|NCT01984723|Pharmacokinetic
1008618|NCT01984723|Safety
1008619|NCT01984710|Treatment Resistant Depression
1008620|NCT01984710|Deep Brain Stimulation
1008621|NCT01984710|Psychiatry
1008622|NCT01984710|Neuro Surgery
1008623|NCT01984684|Bacterial skin infection
1008624|NCT01984684|infection
1008625|NCT01984684|skin
1008626|NCT01984684|delafloxacin
1008627|NCT01984684|vancomycin
1008628|NCT01984684|aztreonam
1008629|NCT01984684|MRSA bacteria
1008630|NCT01984684|bacterial infection
1008631|NCT01984684|Anti-Infective Agents
1008632|NCT01984658|pancreatic cancer
1008633|NCT01984645|Emergency Visit
1008634|NCT01984645|Secure Health messaging
1008635|NCT01984645|Inpatient
1008636|NCT01984593|Yoga
1008637|NCT01984593|Hypertension
1008638|NCT01984593|Quality of Life
1008639|NCT01984593|Primary Health Care
1008640|NCT01984593|Stress
1008641|NCT01984593|Anxiety
1008642|NCT01984593|Depression
1008643|NCT01984580|Barrett's esophagus
1008644|NCT01984580|Esophagus
1008645|NCT01984580|Adenocarcinoma
1008646|NCT01984567|Oxyphytosterols
1008647|NCT01984567|Oxidative stress
1008648|NCT01984567|Vitamin E
1008649|NCT01984567|Lipoic acid
1008650|NCT01984541|Pollen
1008651|NCT01984528|Immunotherapy
1008652|NCT01984528|Skin prick test
1008653|NCT01984528|Standardization
1008654|NCT01984528|Alternaria alternata
1008655|NCT01984515|Post-traumatic Stress Disorder
1008656|NCT01984515|Evidence-Based Psychotherapy
1008657|NCT01984515|Treatment Engagement
1008658|NCT01984515|Cognitive Behavioral Therapy
1008659|NCT01984515|Implementation Science
1008660|NCT01984502|Larynx Cancer
1008661|NCT01984489|SHR117887, Metformin,combination,PhaseII
1008662|NCT01984476|spinal cord injury
1008663|NCT01984476|autonomic dysreflexia
1008664|NCT01984476|baroreceptor integrity
1008665|NCT01984476|sympathetic integrity
1008666|NCT01984476|vagal integrity
1008667|NCT01984476|autonomic integrity
1008668|NCT01984476|arterial stiffness
1008669|NCT01984476|cognitive function
1008670|NCT01984476|traumatic brain injury
1008671|NCT01984476|cerebral blood flow
1008672|NCT01984476|white matter hyperintensities
1008673|NCT01984476|cerebral vascular resistance index
1008674|NCT01984463|Postoperative pain
1008675|NCT01984463|Shoulder pain
1008676|NCT01984463|Thoracotomy
1008677|NCT01984450|Articular cartilage
1008678|NCT01984450|Autologous collagen
1008679|NCT01984450|BMAC
1008680|NCT01984437|Vascular disease
1008681|NCT01984437|Minimally invasive treatment
1008682|NCT01984437|Endovascular treatment
1008683|NCT01984437|Magellan
1008684|NCT01984437|Robotic
1008685|NCT01984424|High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
1008693|NCT01984333|trichotillomania
1008694|NCT01984333|response inhibition
1008695|NCT01984333|cognitive retraining
1008696|NCT01984320|OHSS
1008697|NCT01984320|ICSI
1008698|NCT01984320|Coasting
1008699|NCT01984320|Cabergoline
1008700|NCT01984307|Acute coronary syndrome
1008701|NCT01984307|Myocardial infarction
1008702|NCT01984307|retrospective
1008703|NCT01984307|cohort study
1008704|NCT01984307|Healthcare resources utilization
1008705|NCT01984294|HCV genotype 1
1008706|NCT01984294|HCV
1008707|NCT01984294|Sustained Virologic Response
1008708|NCT01984294|Direct-Acting Antiviral
1008709|NCT01984294|Combination Therapy
1008710|NCT01984294|GS-7977
1008711|NCT01984294|GS-5885
1008712|NCT01984294|Ribavirin
1008713|NCT01984294|Open Label
1008714|NCT01984294|Sofosbuvir
1008715|NCT01984294|Treatment-Naive
1008716|NCT01984294|Protease Inhibitors
1008717|NCT01984294|PI
1008718|NCT01984294|Treatment experienced
1008719|NCT01984294|Cirrhotic
1008720|NCT01984281|Physical Activity
1008721|NCT01984281|Pedometers
1008722|NCT01984281|Quality of Life
1008723|NCT01984268|Rheumatoid arthritis
1008724|NCT01984268|ACTHAR
1008725|NCT01984268|Methotrexate
1008726|NCT01984268|Inadequate response
1008727|NCT01984203|Shoulder
1008728|NCT01984203|Impingement
1008729|NCT01984203|Rotator Cuff Syndrome
1008730|NCT01984203|Subacromial Impingement Syndrome
1008731|NCT01984203|Exercise
1008732|NCT01984203|Physiotherapy
1008733|NCT01984190|venous thromboembolism
1008734|NCT01984190|deep vein thrombosis
1008735|NCT01984190|pulmonary emboli
1008736|NCT01984190|hip arthroplasty
1008737|NCT01984190|knee arthroplasty
1008738|NCT01984190|efficacy
1008739|NCT01984190|mobile compression device
1008740|NCT01984190|mechanical device
1008741|NCT01984190|prophylaxis.
1008742|NCT01984177|Cocaine
1008743|NCT01984177|Substance-Related Disorders
1008744|NCT01984177|Drug Addiction
1008745|NCT01984177|Substance Addiction
1008746|NCT01984177|Dopamine
1008747|NCT01984177|Receptors, Dopamine D2
1008748|NCT01984177|Receptors, Dopamine D3
1008749|NCT01984177|Stress, Psychological
1008750|NCT01984177|Corticorelin
1008751|NCT01984177|Neuroendocrine System
1008752|NCT01984177|Cortisol
1008753|NCT01984177|Adrenocorticotropic Hormone
1008754|NCT01984177|Positron-Emission Tomography
1008755|NCT01984177|11C-PHNO
1008756|NCT01984164|cerebrovascular function
1008757|NCT01984138|estrogen receptor positive breast cancer
1008758|NCT01984138|breast cancer
1008759|NCT01984125|Adolescent Immunization Rates
1008760|NCT01984125|Provider prompts
1008761|NCT01984112|Humerus
1008762|NCT01984112|fracture
1008763|NCT01984112|nail
1008764|NCT01984112|plate
1008765|NCT01984112|tuberosity
1008766|NCT01984099|Postmolar Gestational Trophoblastic Disease, Hydatidiform Mole
1008767|NCT01984086|COPD
1008768|NCT01984086|Asthma
1008769|NCT01984086|Respiratory
1008770|NCT01984073|Atherogenic dyslipidemia phenotype
1008771|NCT01984060|Aging
1008772|NCT01984060|Physical Activity
1008773|NCT01984060|Physical Function
1008774|NCT01984060|HIV
1008775|NCT01984060|Frailty
1008776|NCT01984060|Autonomous Motivation
1008777|NCT01984060|Depression
1008778|NCT01984047|safety
1008779|NCT01984047|GSK3050002
1008780|NCT01984047|CCR6 receptor
1008781|NCT01984047|single dose escalation
1008782|NCT01984047|Phase 1
1008783|NCT01984047|CCL20
1008784|NCT01984034|Educational outreach
1008785|NCT01984034|Academic detailing
1008786|NCT01984034|Guideline adherence
1008787|NCT01984034|Family Practice
1008788|NCT01984034|Drug utilization
1008789|NCT01984034|Program evaluation
1008790|NCT01984034|Cost effectiveness
1008791|NCT01984021|Physical Therapy Modalities
1008792|NCT01984021|Neck pain
1008793|NCT01984021|Acupuncture
1008794|NCT01983995|Breast Cancer
1008795|NCT01983995|Aromatase Inhibitors
1008796|NCT01983995|Actigraphy
1008797|NCT01983995|Pain
1008798|NCT01983995|Fatigue
1008799|NCT01983995|Sleep quality
1008800|NCT01983982|Breast Cancer
1008801|NCT01983982|Chemotherapy
1008802|NCT01983982|Chronic Pain
1008803|NCT01983982|Survivorship
1008845|NCT01983956|early palliative care
1008846|NCT01983956|patient empowerment
1008847|NCT01983956|cancer
1008848|NCT01983956|assessment
1008849|NCT01983956|end of life
1008850|NCT01983930|Memory impairment
1008851|NCT01983930|Meditation
1008852|NCT01983930|Yoga
1008853|NCT01983930|memory training
1008854|NCT01983930|Mild cognitive impairment
1008855|NCT01983930|MCI
1008856|NCT01983930|geriatric
1008857|NCT01983930|fMRI
1008858|NCT01983917|diabetes
1008859|NCT01983917|mobile application
1008860|NCT01983917|diabetic retinopathy
1008861|NCT01983904|Major depressive disorder (MDD)
1008862|NCT01983904|Bi-polar disorder (BP)
1008863|NCT01983891|food shelf
1008864|NCT01983891|nutrition education
1008865|NCT01983891|cooking course
1008866|NCT01983852|End of Life Care
1008867|NCT01983852|Paediatric
1008868|NCT01983852|Experiences
1008869|NCT01983852|Needs
1008870|NCT01983852|Current Practices
1008871|NCT01983839|Moxifloxacin
1008872|NCT01983839|Pneumonia
1008873|NCT01983839|Pharmacokinetics
1008874|NCT01983826|nitrates
1008875|NCT01983826|blood flow
1008876|NCT01983826|vascular function
1008877|NCT01983826|exercise
1008878|NCT01983813|Diabetes
1008879|NCT01983813|High Blood Pressure
1008880|NCT01983813|High Cholesterol
1008881|NCT01983813|Heart Irregularity
1008882|NCT01983813|Stroke
1008883|NCT01983800|Mechanical Ventilation
1008884|NCT01983800|Volatile Sedation
1008885|NCT01983800|Intravenous Sedation
1008886|NCT01983800|Delirium
1008887|NCT01983787|Cystic Fibrosis
1008888|NCT01983787|Continuous infusion
1008889|NCT01983787|Pharmacokinetics
1008890|NCT01983774|CF
1008891|NCT01983748|Uveal Melanoma, Monosomy 3
1008892|NCT01983735|TELMINUVO Tab.
1008893|NCT01983735|CKD-828
1008894|NCT01983735|Hypertension
1008895|NCT01983735|Stage 2 Hypertension
1008896|NCT01983735|S-Amlodipine
1008897|NCT01983735|Telmisartan
1008898|NCT01983696|low oxygen tension
1008899|NCT01983696|embryo quality
1008900|NCT01983683|Clostridium difficile infection
1008901|NCT01983683|Post-antibiotic diarrhea
1008902|NCT01983670|Pre-movement facilitation
1008903|NCT01983670|Fast goal directed movement
1008904|NCT01983670|Triphasic EMG pattern
1008905|NCT01983670|Temporal electrical stimulation,
1008906|NCT01983670|Spinocerebellar Ataxia
1008907|NCT01983657|Pulmonary
1008908|NCT01983657|Pulmonary Alveolar Proteinosis
1008909|NCT01983657|PAP
1008910|NCT01983644|acute ischemic stroke,endovascular recanalization
1008911|NCT01983644|mechanical thrombectomy
1008912|NCT01983631|Whole body vibration
1008913|NCT01983631|Reciprocal inhibition
1008914|NCT01983631|Spinocerebellar ataxia
1008915|NCT01983631|voluntary activation level
1008916|NCT01983618|Cerebral ischemia
1008917|NCT01983618|Beachchair position
1008918|NCT01983618|Interscalene nerve block
1008919|NCT01983592|Homeopathy
1008920|NCT01983592|Fatigue
1008921|NCT01983592|Chemotherapy
1008922|NCT01983592|Cancer
1008923|NCT01983553|Dengue Virus
1008924|NCT01983553|Dengue Fever
1008925|NCT01983553|Dengue Hemorrhagic Fever
1008926|NCT01983553|CYD Dengue Vaccine
1008927|NCT01983540|Diphtheria
1008928|NCT01983540|Tetanus
1008929|NCT01983540|Whooping Cough
1008930|NCT01983540|Hepatitis B
1008931|NCT01983540|Poliomyelitis
1008932|NCT01983540|Pediatric combined vaccine
1008933|NCT01983527|Arthrographic distention
1008934|NCT01983527|Hydrodilatation
1008935|NCT01983527|Intra-articular corticosteroid injection
1008936|NCT01983514|oxytocin
1008937|NCT01983514|fMRI
1008938|NCT01983514|social cognition
1008939|NCT01983514|heart rate variability
1008940|NCT01983514|pupillometry
1008941|NCT01983514|eye tracking
1008942|NCT01983501|ONT-380
1008943|NCT01983501|T-DM1
1008944|NCT01983501|Kadcyla
1008945|NCT01983501|HER2 positive breast cancer
1008946|NCT01983501|Breast cancer
1008947|NCT01983501|ARRY-380
1008948|NCT01983501|Tucatinib
1008949|NCT01983488|Uveitis
1008950|NCT01983488|Vision Loss
1008951|NCT01983475|Spinal Cord Injury
1008952|NCT01983475|Denosumab
1008953|NCT01983475|Osteoporosis
1008954|NCT01983475|Dual Energy X-ray Absorptiometry
1008955|NCT01983462|Prehypertension
1008956|NCT01983462|Hypertension
1008957|NCT01983462|Obese
1008958|NCT01983462|Sympathetic Nervous System
1008959|NCT01983462|renin-angiotensin system
1008960|NCT01983462|Endothelial function
1008961|NCT01983449|Adventitia
1008962|NCT01983449|Peripheral Artery Disease
1008963|NCT01983449|Restenosis
1008964|NCT01983449|Inflammation
1008965|NCT01983449|Anti-Inflammatory
1008966|NCT01983449|Dexamethasone
1008967|NCT01983436|Maxillofacial Orthognathic Surgery
1008968|NCT01983436|Manual lymphatic drainage
1008969|NCT01983423|Endometrial Biopsy
1008970|NCT01983423|Endometrial Sampling
1008971|NCT01983423|In Vitro Fertilization
1008972|NCT01983423|Pregnancy
1008973|NCT01983423|Implantation
1008974|NCT01983410|BRCA Mutation Carriers
1008975|NCT01983410|PDAC carriers
1008976|NCT01983410|BRCAmut carriers
1008977|NCT01983410|Registry
1008978|NCT01983410|13-217
1008979|NCT01983397|aged, 80 and over
1008980|NCT01983397|Exercise
1008981|NCT01983397|Cognition
1008982|NCT01983397|Balance
1008983|NCT01983397|Randomized controlled trial
1008984|NCT01983384|Delirium
1008985|NCT01983384|Cognition
1008986|NCT01983384|Surgery
1008987|NCT01983384|Anesthesia
1008988|NCT01983384|Aging
1008989|NCT01983358|PARP-1 inhibitor
1008990|NCT01983345|Myelomeningocele
1008991|NCT01983345|Arnold Chiari malformation
1008992|NCT01983345|Spina bifida
1008993|NCT01983332|MDACC
1008994|NCT01983332|MOHO
1008995|NCT01983306|Constipation
1008996|NCT01983306|Opioid
1008997|NCT01983306|GC C Agonist
1008998|NCT01983306|Pain
1008999|NCT01983293|Non-left bundle branch block
1009000|NCT01983293|QLV
1009001|NCT01983293|LV lead pacing location
1009002|NCT01983293|CRT-D
1009003|NCT01983280|polysomnography
1009004|NCT01983280|sleep
1009005|NCT01983280|healing touch
1009006|NCT01983280|pediatric burn
1009007|NCT01983254|coping
1009008|NCT01983254|acute respiratory failure
1009009|NCT01983254|critical illness
1009010|NCT01983254|depression
1009011|NCT01983254|anxiety
1009012|NCT01983254|post-traumatic stress
1009013|NCT01983254|intensive care unit
1009014|NCT01983241|Pulmonary Emphysema
1009015|NCT01983241|Alpha-1 Antitrypsin Deficiency
1009016|NCT01983241|AATD
1009017|NCT01983241|Alpha-1 PI Deficiency
1009018|NCT01983241|Alpha-1 Protienase Inhibitor
1009019|NCT01983228|Musculoskeletal Pain
1009020|NCT01983228|Walking
1009021|NCT01983228|African American
1009022|NCT01983228|Telephone Coaching
1009023|NCT01983228|Pedometer
1009024|NCT01983215|groin incisions
1009025|NCT01983202|PCOS
1009026|NCT01983202|Pregnancy
1009027|NCT01983202|Obstetric
1009028|NCT01983189|TMS
1009029|NCT01983189|transcranial magnetic stimulation
1009030|NCT01983189|rTMS
1009031|NCT01983189|recurrent transcranial magnetic stimulation
1009032|NCT01983189|fMRI
1009033|NCT01983189|functional magnetic resonance imaging.
1009034|NCT01983176|Parotid tumor
1009035|NCT01983176|Partial superficial parotidectomy
1009036|NCT01983176|Facial palsy
1009037|NCT01983150|Population Health
1009038|NCT01983150|Smoking cessation
1009039|NCT01983150|Young adults
1009040|NCT01983150|Cancer prevention
1009041|NCT01983150|Tobacco control strategies
1009042|NCT01983150|Behaviour modification
1009043|NCT01983150|Social Media
1009044|NCT01983150|Smartphone technology
1009045|NCT01983137|Chronic pain
1009046|NCT01983137|Severe pain
1009047|NCT01983137|oxycodon
1009048|NCT01983137|naloxon
1009049|NCT01983137|opioid-induced constipation
1009050|NCT01983137|opioid
1009051|NCT01983137|quality of life
1009052|NCT01983137|laxative
1009053|NCT01983137|analgesic rescue medication
1009054|NCT01983124|Advanced Melanoma
1009055|NCT01983098|Colorectal cancer
1009056|NCT01983098|Metastatic
1009057|NCT01983098|Circulating tumor DNA
1009058|NCT01983098|Biomaker
1009059|NCT01983085|Nitric Oxide Dressing
1009060|NCT01983085|Nitric oxide
1009061|NCT01983085|Superficial partial thickness wound
1009062|NCT01983085|Burns
1009063|NCT01983085|Skin graft donor sites
1009064|NCT01983085|Improved healing
1009065|NCT01983085|Vasodilation
1009066|NCT01983085|Angiogenesis
1009067|NCT01983085|Anti-microbial
1009068|NCT01983072|colonization of the gastrointestinal tract with bacteria
1009069|NCT01983007|Diabetes Mellitus.
1009070|NCT01982994|Physical Activity Education
1009071|NCT01982994|Caregivers
1009072|NCT01982981|perception
1009073|NCT01982981|wellbeing
1009074|NCT01982981|plain water
1009075|NCT01982968|Idiopathic pulmonary fibrosis
1009076|NCT01982968|IPF
1009077|NCT01982968|Gastroesophageal reflux
1009078|NCT01982968|GER
1009079|NCT01982968|GERD
1009080|NCT01982955|MSC2156119J
1009081|NCT01982955|Gefitinib
1009082|NCT01982955|Pemetrexed
1009083|NCT01982955|Cisplatin
1009084|NCT01982955|MET positive
1009085|NCT01982955|Tepotinib
1009086|NCT01982955|Carboplatin
1009087|NCT01982955|INSIGHT
1009088|NCT01982916|Allergic Rhinitis
1009089|NCT01982916|Perennial Allergic Rhinitis
1009090|NCT01982916|Non-seasonal Allergic Rhinitis
1009091|NCT01982916|PAR
1009092|NCT01982903|kidney transplantation
1009093|NCT01982903|connective tissue growth factor
1009094|NCT01982903|fibrosis
1009095|NCT01982890|Telomere length
1009096|NCT01982890|Longitudinal observation
1009097|NCT01982877|decision making
1009098|NCT01982877|values elicitation
1009099|NCT01982877|patient centered care
1009100|NCT01982877|Four Supports
1009101|NCT01982877|Family Support
1009102|NCT01982864|Aminoglycosides
1009103|NCT01982864|hemodialysis
1009104|NCT01982864|clinical pharmacokinetics
1009105|NCT01982864|pharmacokinetic modelling
1009106|NCT01982864|Bayesian estimation
1009107|NCT01982864|Necessity
1009108|NCT01982864|of the treatment
1009109|NCT01982864|gentamicin
1009110|NCT01982851|pain
1009111|NCT01982851|epidural
1009112|NCT01982851|combined spinal epidural
1009113|NCT01982838|pain
1009114|NCT01982838|epidural
1009115|NCT01982838|combined spinal epidural
1009116|NCT01982825|Tobacco use cessation
1009117|NCT01982825|Cigarette smoking
1009118|NCT01982799|Endodontic treatment, analgesics, anesthesia, post-operative pain
1009119|NCT01982773|Virtual Hope Box
1009120|NCT01982760|Rhinoplasty
1009121|NCT01982760|Ecchymosis
1009122|NCT01982760|Edema
1009123|NCT01982747|Cardiac Safety
1009124|NCT01982747|General Safety
1009125|NCT01982747|Pharmacokinetics
1009126|NCT01982734|bioavailability
1009127|NCT01982734|curcumin
1009128|NCT01982734|pharmacokinetic
1009129|NCT01982734|curcuma longa
1009130|NCT01982734|age differences
1009131|NCT01982734|sex differences
1009132|NCT01982708|Evaluation
1009133|NCT01982695|Duchenne muscular Dystrophy (DMD)
1009134|NCT01982695|Cardiomyopathy
1009135|NCT01982695|Losartan
1009136|NCT01982695|Lisinopril
1009137|NCT01982669|Salty taste
1009138|NCT01982669|Urinary sodium excretion
1009139|NCT01982669|Spicy hedonic
1009140|NCT01982669|Blood pressure
1009141|NCT01982617|Transtheoretical Model
1009142|NCT01982617|Stages of Change
1009143|NCT01982617|Nicotine Dependence
1009144|NCT01982617|Severe Mental Illness
1009145|NCT01982578|Treatment
1009146|NCT01982578|Genistein
1009147|NCT01982578|Alzheimer's disease
1009148|NCT01982578|Cerebrospinal fluid
1009149|NCT01982578|Amyloid beta
1009150|NCT01982565|Nitric oxide
1009151|NCT01982565|Nitric oxide dressing
1009152|NCT01982565|NOx
1009153|NCT01982565|NOx dressing
1009154|NCT01982565|Diabetic
1009155|NCT01982565|Foot
1009156|NCT01982565|Ulcers
1009157|NCT01982565|Chronic
1009158|NCT01982552|Plaque psoriasis
1009159|NCT01982552|calcipotriene
1009160|NCT01982552|betamethasone dipropionate
1009161|NCT01982552|topical
1009162|NCT01982539|pain
1009163|NCT01982539|NSAID
1009164|NCT01982539|moderate pain
1009165|NCT01982539|mild pain
1009166|NCT01982539|acute pain
1009167|NCT01982539|mild acute pain
1009168|NCT01982539|moderate acute pain
1009169|NCT01982539|mild or moderate acute pain
1009170|NCT01982526|Ovarian reserve
1009171|NCT01982526|Antimullerian hormone
1009172|NCT01982513|Cardiopulmonary Resuscitation
1009173|NCT01982513|Pregnancy
1009174|NCT01982513|Ultrasound
1009175|NCT01982513|Inferior Vena Cava
1009176|NCT01982500|Ovarian Cancer
1009177|NCT01982500|Chemotherapy
1009178|NCT01982500|Anti-angiogenic agent
1009179|NCT01982500|Bevacizumab
1009180|NCT01982500|Front Line
1009181|NCT01982474|allergic rhinitis
1009185|NCT01982435|Diabetes
1009186|NCT01982435|Macular Edema
1009187|NCT01982422|Attention Deficit and Hyperactivity Disorder
1009188|NCT01982422|Nutrition
1009189|NCT01982422|Diet
1009190|NCT01982422|Developmental Origins of Disease
1009191|NCT01982396|HIV
1009192|NCT01982396|paediatric
1009193|NCT01982396|Abacavir
1009194|NCT01982396|lamivudine
1009195|NCT01982383|CSC
1009196|NCT01982383|Edema
1009197|NCT01982383|Retinopathy
1009198|NCT01982344|mini-exchange-room
1009199|NCT01982344|physical activity
1009200|NCT01982344|quality of life
1009201|NCT01982344|peritoneal dialysis
1009202|NCT01982331|H2N2
1009203|NCT01982331|vaccine
1009204|NCT01982318|Venous Leg Ulcer
1009205|NCT01982318|Leg Ulcer
1009206|NCT01982318|Venous Hypertension
1009207|NCT01982318|Venous Reflux
1009208|NCT01982318|Deep Venous System
1009209|NCT01982318|Chronic leg ulceration
1009210|NCT01982318|Calf perforator
1009211|NCT01982292|Chronic Heart Failure, CHF, Heart Failure, HF, Immunogenicity, Anti-bodies, Hypersensitivity, Serelaxin, RELAX-REPEAT
1009212|NCT01982279|Caloric compensation
1009213|NCT01982279|Eating in the absence of hunger
1009214|NCT01982279|Preschool children
1009215|NCT01982279|Maternal feeding practices
1009216|NCT01982279|Maternal eating behavior
1009217|NCT01982279|one year
1009218|NCT01982279|children
1009219|NCT01982253|Drug therapy
1009220|NCT01982240|CIC
1009221|NCT01982240|Constipation
1009222|NCT01982240|Chronic Constipation
1009223|NCT01982240|Synergy
1009224|NCT01982240|Plecanatide
1009225|NCT01982227|colorectal cancer metastatic
1009226|NCT01982227|indocyanine green
1009227|NCT01982214|osteopenia
1009228|NCT01982214|whole body vibration
1009229|NCT01982214|women
1009230|NCT01982214|bone microarchitecture
1009231|NCT01982214|bone density
1009232|NCT01982188|single incision sling
1009233|NCT01982188|cough stress test
1009234|NCT01982188|MiniArc
1009235|NCT01982188|UDI-6
1009236|NCT01982188|UIQ-7
1009237|NCT01982188|Sandvick Severity Index (SSI)
1009238|NCT01982175|Alemtuzumab
1009239|NCT01982175|B-cell chronic lymphocytic leukemia
1009240|NCT01982175|CD52
1009241|NCT01982162|Sputum
1009242|NCT01982162|Clinical cohorts
1009243|NCT01982162|Smokers
1009244|NCT01982162|Asthma
1009245|NCT01982162|Biopsies
1009246|NCT01982162|Severe asthma
1009247|NCT01982162|Collaborative research
1009248|NCT01982162|Phenotyping
1009249|NCT01982162|Lipidomics
1009250|NCT01982162|Transcriptomics
1009251|NCT01982162|Proteomics
1009252|NCT01982162|Paediatric cohort
1009253|NCT01982162|Systems Biology
1009254|NCT01982149|Chronic Obstructive Pulmonary Disease
1009255|NCT01982149|COPD
1009256|NCT01982149|Smokers
1009257|NCT01982149|Nonsmokers
1009258|NCT01982110|smoking cessation
1009259|NCT01982110|mindfulness
1009260|NCT01982110|behavioral intervention
1009261|NCT01982097|Non-interventional
1009262|NCT01982097|Nexavar
1009263|NCT01982097|Sorafenib
1009264|NCT01982097|Carcinoma, renal cell
1009265|NCT01982097|Neoadjuvant
1009266|NCT01982097|Nephrectomy
1009267|NCT01982097|Russian Federation
1009268|NCT01982084|Group B streptococcus
1009269|NCT01982084|Immunisation
1009270|NCT01982084|Pregnancy
1009271|NCT01982084|Attitudes
1009272|NCT01982071|Micafungin
1009273|NCT01982071|candidiasis
1009274|NCT01982071|candidemia
1009275|NCT01982071|Open-label design
1009276|NCT01982045|Bone graft
1009277|NCT01982045|Ceramic
1009278|NCT01982045|Spinal fusion
1009279|NCT01982045|RCT
1009280|NCT01982045|Thoracolumbar region
1009281|NCT01982032|Periprosthetic aortic valve regurgitation
1009282|NCT01982032|3D transesophageal echocardiography
1009283|NCT01982032|Cardiac MRI
1009284|NCT01982019|26RFa
1009285|NCT01982019|sleeve gastrectomy
1009286|NCT01982019|diabetes
1009287|NCT01982019|obesity
1009288|NCT01982006|cataract surgery
1009289|NCT01982006|femtosecond laser cataract surgery
1009290|NCT01982006|phacoemulsification
1009291|NCT01982006|Cost-Benefit Analysis
1009292|NCT01982006|Cost Effectiveness
1009293|NCT01982006|Hospital Costs
1009294|NCT01981980|Carbon dioxide
1009295|NCT01981980|Carboxytherapy
1009296|NCT01981980|Radiofrequency
1009297|NCT01981967|Japanese encephalitis
1009298|NCT01981967|IMOJEV®
1009299|NCT01981967|Japanese encephalitis chimeric virus vaccine
1009300|NCT01981954|Solifenacin succinate suspension
1009301|NCT01981954|Efficacy
1009302|NCT01981954|Safety
1009303|NCT01981941|Gabapentin
1009304|NCT01981941|Restless legs syndrome (RLS)
1009305|NCT01981928|Phase 1
1009306|NCT01981928|Healthy Subjects
1009307|NCT01981928|Safety
1009308|NCT01981928|Tolerability
1009309|NCT01981928|Pharmacokinetics
1009310|NCT01981928|Single Ascending Oral Dose
1009311|NCT01981928|Food Effect
1009312|NCT01981915|Cough augmentation
1009313|NCT01981915|Peak cough flow
1009314|NCT01981915|hyperinsufflation
1009315|NCT01981902|Dehydration
1009316|NCT01981889|steroid, inflammatory bowel diseases
1009317|NCT01981876|Dysplasia
1009318|NCT01981876|Esophageal Squamous Cell Carcinoma
1009319|NCT01981863|cardiac surgery
1009320|NCT01981863|cardiopulmonary bypass
1009321|NCT01981863|fibrinolysis
1009322|NCT01981863|thromboelastography
1009323|NCT01981863|D-Dimers
1009324|NCT01981863|antifibrinolytic agents
1009325|NCT01981850|fibrosis
1009326|NCT01981837|RNAi therapeutic
1009327|NCT01981824|prediction IUGR FL/MTC
1009328|NCT01981811|OPC-14597 Digital
1009329|NCT01981811|Aripiprazole
1009330|NCT01981811|Medical Information Device #1 System (MIND1)
1009331|NCT01981811|Treatment Adherence
1009332|NCT01981811|Ingestible Event Marker
1009333|NCT01981798|outpatient intervention program
1009334|NCT01981798|behavioral therapy approach
1009335|NCT01981798|unspecific back pain
1009336|NCT01981798|unspecific neck pain
1009337|NCT01981798|chronic pain
1009338|NCT01981798|physiotherapy
1009339|NCT01981798|occupational therapy
1009340|NCT01981798|psychosocial aspects
1009341|NCT01981798|fear avoidance beliefs
1009342|NCT01981798|health-related quality of life
1009343|NCT01981785|Primary immune deficiencies
1009344|NCT01981785|Autoimmune diseases
1009345|NCT01981785|Inflammatory diseases
1009346|NCT01981785|Common variable immune deficiencies
1009347|NCT01981785|Primary Immunodeficiencies
1009348|NCT01981785|Immunoglobulin
1009349|NCT01981785|IgG
1009350|NCT01981785|IVIG
1009351|NCT01981785|Recurrent Infections
1009352|NCT01981759|Schizophrenia
1009353|NCT01981759|Delusions
1009354|NCT01981759|D-Cycloserine
1009355|NCT01981759|CBT
1009356|NCT01981746|adductor canal block
1009357|NCT01981746|healthy volunteers
1009358|NCT01981746|US-guided peripheral nerve block
1009359|NCT01981746|lower limb
1009360|NCT01981733|Deep Vein Thrombosis
1009361|NCT01981707|castration-resistant prostate cancer
1009362|NCT01981707|abiraterone acetate
1009363|NCT01981707|enzalutamide
1009364|NCT01981707|choline pet
1009365|NCT01981694|Phase 1
1009366|NCT01981694|Randomized
1009367|NCT01981694|Double Blind
1009368|NCT01981694|Placebo-Controlled
1009369|NCT01981694|Single-Dose Escalation
1009370|NCT01981694|Safety
1009371|NCT01981694|Tolerability
1009372|NCT01981694|PK
1009373|NCT01981694|PD
1009374|NCT01981694|PF-06649751
1009375|NCT01981681|Phase 1
1009376|NCT01981681|Randomized
1009377|NCT01981681|Placebo-Controlled
1009378|NCT01981681|Multiple Dose Escalation
1009379|NCT01981681|Tolerability
1009380|NCT01981681|Safety
1009381|NCT01981681|PK
1009382|NCT01981681|Topical
1009383|NCT01981681|Healthy
1009384|NCT01981681|PF-06263276
1009385|NCT01981655|Sodium Lactate
1009386|NCT01981655|Acute
1009387|NCT01981655|Heart
1009388|NCT01981655|Failure
1009389|NCT01981655|Perfusion
1009390|NCT01981629|Shock
1009391|NCT01981629|USCOM
1009392|NCT01981629|Cardiac Ultrasound
1009393|NCT01981629|Emergency Department
1009394|NCT01981616|Drug therapy
1009395|NCT01981603|Navigators
1009396|NCT01981603|Kidney Transplant
1009397|NCT01981603|Hemodialysis
1009651|NCT01980355|surgical oncology
1009398|NCT01981590|breathing, heart failure, sleep apnea
1009399|NCT01981577|Parkinson Disease
1009400|NCT01981577|Subthalamic Nucleus
1009401|NCT01981577|Ultrahigh field Magnetic Resonance imaging
1009402|NCT01981577|Functional connectivity
1009403|NCT01981577|Structural connectivity
1009404|NCT01981564|Pediatric
1009405|NCT01981564|Emergency department visit
1009410|NCT01981538|Web-Based Survey
1009411|NCT01981538|Cancer Caregivers
1009412|NCT01981525|TP53 Mutation
1009413|NCT01981525|Autosomal Dominant Hereditary Disorder
1009414|NCT01981525|Chemoprevention
1009415|NCT01981499|PF-05180999
1009416|NCT01981499|safety
1009417|NCT01981499|tolerability
1009418|NCT01981499|pharmacokinetics
1009419|NCT01981499|histamine
1009420|NCT01981499|wheal
1009421|NCT01981499|flare
1009422|NCT01981499|migraine
1009423|NCT01981499|PDE2
1009424|NCT01981486|PF-05180999
1009425|NCT01981486|safety
1009426|NCT01981486|tolerability
1009427|NCT01981486|pharmacokinetics
1009428|NCT01981486|migraine
1009429|NCT01981486|PDE2
1009430|NCT01981486|cAMP
1009431|NCT01981486|cGMP
1009432|NCT01981486|cantharidin
1009433|NCT01981486|blister
1009434|NCT01981486|CYP3A induction
1009435|NCT01981473|rheumatoid arthritis
1009436|NCT01981473|etanercept
1009437|NCT01981473|adalimumab
1009438|NCT01981473|infliximab
1009439|NCT01981473|anti-drug antibody
1009440|NCT01981473|immunogenicity
1009441|NCT01981473|drug concentration
1009442|NCT01981447|epilepsy
1009443|NCT01981421|Liver fibrosis
1009444|NCT01981421|Elastography
1009445|NCT01981421|MR Elastography
1009446|NCT01981421|Quantitative imaging
1009447|NCT01981395|fenobam
1009448|NCT01981395|heat
1009449|NCT01981395|capsaicin
1009450|NCT01981395|hyperalgesia
1009451|NCT01981395|allodynia
1009452|NCT01981395|mood
1009453|NCT01981395|cognitive function
1009454|NCT01981382|low back pain
1009455|NCT01981382|pain sensitivity
1009456|NCT01981382|genes
1009457|NCT01981382|gene expression,
1009458|NCT01981382|quantitative sensory testing
1009459|NCT01981369|Dexmedetomidine sedation
1009460|NCT01981369|Regional Anesthesia
1009461|NCT01981369|Infraclavicular block
1009462|NCT01981356|Psychotic Disorders
1009463|NCT01981356|Acceptance and Commitment Therapy
1009464|NCT01981356|Inpatient psychiatry
1009465|NCT01981356|Schizophrenia
1009466|NCT01981356|Acute psychiatric disorder
1009467|NCT01981343|Gallbladder motility
1009468|NCT01981343|A-F Betafood
1009469|NCT01981343|Betaine
1009470|NCT01981343|Ejection fraction
1009471|NCT01981343|Ejection rate
1009472|NCT01981343|Ultrasound
1009473|NCT01981330|vocal fold scarring
1009474|NCT01981330|mesenchymal stem cells
1009475|NCT01981317|Obsessive Compulsive Disorder
1009476|NCT01981317|Cognitive Behavioral Therapy
1009477|NCT01981317|Stepped Care CBT
1009478|NCT01981317|Exposure and Response Prevention
1009479|NCT01981317|Psychotherapy
1009480|NCT01981317|Counseling
1009481|NCT01981304|Coronary artery disease
1009482|NCT01981304|Percutaneous coronary intervention
1009483|NCT01981291|Lower Extremity
1009484|NCT01981291|Sciatic Nerve
1009485|NCT01981291|Anesthesia, Regional
1009486|NCT01981291|Anesthetics, Local
1009487|NCT01981291|Mepivacaine
1009488|NCT01981291|Ultrasonography
1009489|NCT01981278|Healthy
1009490|NCT01981278|Tapentadol
1009491|NCT01981278|Bioequivalence
1009492|NCT01981278|Fasted
1009493|NCT01981252|Ulthera® System
1009494|NCT01981252|Ultherapy™ Treatment
1009495|NCT01981252|Ulthera, Inc.
1009496|NCT01981252|Micro-focused Ultrasound with Visualization (MFU-V)
1009497|NCT01981239|voice analysis aspiration prediction
1009498|NCT01981213|Acetaminophen
1009499|NCT01981213|Suicide
1009500|NCT01981213|Attempts
1009501|NCT01981213|Early Predictors of Hepatic Injury
1009502|NCT01981213|Childhood Suicidal Behaviour
1009503|NCT01981200|COPD acute exacerbation
1009504|NCT01981200|Physiotherapy
1009505|NCT01981200|Resistance training
1009506|NCT01981200|Muscle strength
1009507|NCT01981200|Handheld dynamometer
1009508|NCT01981161|progressive multifocal leucoencephalopathy
1009509|NCT01981161|JC virus
1009510|NCT01981161|Zoster infection
1009511|NCT01981135|Controlled Human exposure study
1009512|NCT01981135|Air Pollution
1009513|NCT01981135|Temperature
1009514|NCT01981135|Lung Function
1009515|NCT01981135|Cardiovascular
1009516|NCT01981096|juvenile fibromyalgia
1009517|NCT01981096|pain in children
1009518|NCT01981096|musculoskeletal pain
1009519|NCT01981096|cognitive behavioral therapy
1009520|NCT01981096|coping skills training
1009521|NCT01981083|Protein-Energy Malnutrition
1009522|NCT01981083|Chronic Kidney Disease
1009523|NCT01981083|Malnutrition-Inflammation Score
1009524|NCT01981083|Subjective Global Assessment
1009525|NCT01981083|Hemodialysis
1009526|NCT01981083|Egg albumin
1009527|NCT01981070|parent support
1009528|NCT01981070|mindfulness
1009529|NCT01981070|intellectual disability
1009530|NCT01981070|developmental disability
1009531|NCT01981070|empowerment
1009532|NCT01981070|psychological acceptance
1009533|NCT01981070|parental stress
1009534|NCT01981070|parental depression
1009535|NCT01981057|parenteral nutrition
1009536|NCT01981057|Numeta
1009537|NCT01981057|prescription software Cato Pan
1009538|NCT01981018|Mental imagery, CBT, anxiety, mood instability
1009539|NCT01980992|Food Allergy
1009540|NCT01980992|Wheat Allergy
1009541|NCT01980992|Oral Immunotherapy
1009542|NCT01980979|congenital heart disease,pulmonary hypertension,prostacyclin
1009543|NCT01980927|Migraine
1009544|NCT01980927|National Upper Cervical Chiropractic Association atlas correction
1009545|NCT01980914|hypoglycemia
1009546|NCT01980914|type 2 diabetes
1009547|NCT01980914|insulin glargine
1009548|NCT01980914|cardiac function
1009549|NCT01980914|myocardial ischemia
1009550|NCT01980914|cardiac rhythm
1009551|NCT01980914|autonomic cardiovascular function
1009552|NCT01980901|AAA
1009553|NCT01980849|Nadroparin
1009554|NCT01980849|venous thromboembolism prophylaxis
1009555|NCT01980836|Rheumatoid arthritis
1009556|NCT01980836|Tocilizumab
1009557|NCT01980836|Seasonal influenza vaccine
1009558|NCT01980823|Breast Cancer
1009559|NCT01980823|Metformin
1009560|NCT01980823|Atorvastatin
1009561|NCT01980823|Ki-67
1009562|NCT01980797|Bicuspid aortic valve disease
1009563|NCT01980797|Thoracic aortic disease
1009564|NCT01980797|Genetics
1009565|NCT01980797|Echocardiography
1009566|NCT01980797|Cardiac CT
1009567|NCT01980797|Cardiac MRI
1009568|NCT01980784|Spinal Cord Injury
1009569|NCT01980771|HIV
1009570|NCT01980771|prevention
1009571|NCT01980771|men
1009572|NCT01980771|African American
1009573|NCT01980758|obesity, pediatric obesity, bariatric, bariatric surgery
1009574|NCT01980745|autoimmune hepatitis
1009575|NCT01980745|recurrence
1009576|NCT01980745|treatment withdrawal
1009577|NCT01980745|chloroquine
1009578|NCT01980745|maintenance of remission
1009579|NCT01980706|Baclofen
1009580|NCT01980706|Alcohol Dependence
1009581|NCT01980667|lurbinectedin
1009582|NCT01980667|PM01183
1009583|NCT01980667|tumors
1009584|NCT01980667|cancer
1009585|NCT01980667|Pharma Mar
1009586|NCT01980654|Pharmacyclics
1009587|NCT01980654|PCYC
1009588|NCT01980654|Lymphoma
1009589|NCT01980654|Follicular Lymphoma
1009590|NCT01980654|FL
1009591|NCT01980654|Rituximab
1009592|NCT01980654|Ibrutinib
1009593|NCT01980654|Rituxan
1009594|NCT01980654|Non-Hodgkin's Lymphoma
1009595|NCT01980654|NHL
1009596|NCT01980654|B-cell Lymphoma
1009597|NCT01980641|Stroke
1009598|NCT01980641|ADL
1009599|NCT01980641|mHealth
1009600|NCT01980641|App
1009601|NCT01980641|Adherence
1009602|NCT01980641|Home
1009603|NCT01980641|Environment
1009604|NCT01980641|Tool
1009605|NCT01980641|Advice
1009606|NCT01980641|Smartphone
1009607|NCT01980628|MZL
1009608|NCT01980628|NHL
1009609|NCT01980628|SMZL
1009610|NCT01980628|NMZL
1009611|NCT01980628|MALT
1009612|NCT01980602|Intermittent claudication
1009613|NCT01980602|endothelial function
1009614|NCT01980602|cardiopulmonary testing
1009615|NCT01980602|inflammation
1009616|NCT01980602|muscle architecture
1009617|NCT01980589|multiple myeloma
1009618|NCT01980576|Pain
1009619|NCT01980576|Sensitization
1009620|NCT01980576|Spondylitis
1009621|NCT01980485|smoker
1009622|NCT01980459|Hypomagnesemia, Cellular Mg, Inflammation, Diabetes Mellitus
1009623|NCT01980446|Coma
1009624|NCT01980446|Cardiac arrest
1009625|NCT01980446|Neurophysiology
1009626|NCT01980446|Auditory evoked potential
1009627|NCT01980433|Wilson disease
1009628|NCT01980433|Dystonia
1009629|NCT01980433|Movement Disorders
1009630|NCT01980433|Handwriting
1009631|NCT01980433|Repetitive Transcranial Magnetic Stimulation
1009632|NCT01980420|Sleeve gastrectomy
1009633|NCT01980420|Oesogastric junction - GEJ
1009634|NCT01980420|Dynamic MRI Imaging
1009635|NCT01980407|S-1
1009636|NCT01980407|Oxaliplatin
1009637|NCT01980407|Leucovorin
1009638|NCT01980407|Gastric Cancer
1009639|NCT01980394|esophagus
1009640|NCT01980394|gastro-esophegeal junction
1009641|NCT01980394|cancer
1009642|NCT01980394|tumor seeding
1009643|NCT01980394|free viable tumor cells
1009644|NCT01980394|surgery
1009645|NCT01980394|intraluminal tumor cells
1009646|NCT01980394|stump washout
1009647|NCT01980355|cancer
1009648|NCT01980355|surgery
1009649|NCT01980355|oncology
1009650|NCT01980355|major
1009652|NCT01980355|tranexamic acid
1009653|NCT01980342|Long acting reversible contraception
1009654|NCT01980342|HIV
1009655|NCT01980329|CYP3A5
1009656|NCT01980329|maraviroc
1009657|NCT01980329|polymorphism
1009658|NCT01980316|Argatroban
1009659|NCT01980316|Extracranial vertebral Artery Stenting
1009660|NCT01980316|restenosis
1009661|NCT01980303|Healthy
1009662|NCT01980303|Japanese
1009663|NCT01980303|Caucasian
1009664|NCT01980303|Anesthetics
1009665|NCT01980303|Intranasal
1009666|NCT01980303|Esketamine
1009667|NCT01980303|Pharmacokinetics
1009668|NCT01980290|HCV genotype 1
1009669|NCT01980290|Liver Fibrosis
1009670|NCT01980290|ex-People who INject Drugs (ex-PWIDs)
1009671|NCT01980264|BD, AK
1009672|NCT01980251|Delirium, electroencephalography, CSD
1009673|NCT01980238|LAR
1009674|NCT01980238|anastomotic leakage
1009675|NCT01980238|Cannula ileostomy
1009676|NCT01980238|loop ileostomy
1009677|NCT01980225|vitrification, blastocyst, artificial shrinkage, collapse
1009678|NCT01980212|non-small cell lung cancer
1009679|NCT01980212|thioredoxin reductase
1009680|NCT01980199|visceral leishmaniasis
1009681|NCT01980199|fexinidazole
1009682|NCT01980199|adults
1009683|NCT01980199|proof of concept
1009684|NCT01980199|efficacy
1009685|NCT01980199|safety
1009686|NCT01980199|pharmacokinetic
1009687|NCT01980199|pharmacodynamic
1009688|NCT01980186|transcranial ultrasound
1009689|NCT01980186|autism
1009690|NCT01980186|cortical dysplasia
1009691|NCT01980186|extra-axial fluid
1009692|NCT01980173|Bakri balloon
1009693|NCT01980147|Severe Mental Illness
1009694|NCT01980134|adenomatous colorectal lesions
1009695|NCT01980134|colorectal polyps
1009696|NCT01980134|polyps
1009697|NCT01980121|Respiratory Aspiration
1009698|NCT01980121|Pregnancy
1009699|NCT01980121|Ultrasound
1009700|NCT01980121|Gastric Contents
1009701|NCT01980108|Pregnancy
1009702|NCT01980108|Respiratory Aspiration
1009703|NCT01980108|Gastric Contents
1009704|NCT01980108|Ultrasound
1009705|NCT01980095|Helicobacter pylori
1009706|NCT01980095|H. pylori
1009707|NCT01980095|Dyspepsia
1009708|NCT01980082|head and neck surgery
1009709|NCT01980082|surgical wound infection
1009710|NCT01980082|antibiotic prophylaxis
1009711|NCT01980069|Sugammadex
1009712|NCT01980069|Neostigmine
1009713|NCT01980069|Surgery
1009714|NCT01980056|INT-2 or high-risk MDS
1009715|NCT01980017|Diabetes Type 2 Mellitus
1009716|NCT01980017|Ottawa Model for Smoking Cessation
1009717|NCT01980017|Diabetes Education Programs
1009718|NCT01979965|Mitral Regurgitation
1009719|NCT01979965|cardiac resynchronization therapy
1009720|NCT01979965|ranolazine
1009721|NCT01979965|maximal medical therapy
1009722|NCT01979965|ischemic cardiomyopathy
1009723|NCT01979913|Primary Open Angle Glaucoma
1009724|NCT01979913|Ocular Hypertension
1009725|NCT01979913|Tafluprost
1009726|NCT01979913|Saflutan
1009727|NCT01979913|Intraocular pressure
1009728|NCT01979913|Preservative free
1009729|NCT01979913|Single dose unit
1009730|NCT01979900|TB Infection
1009731|NCT01979900|Lesion Degree
1009732|NCT01979900|Bacteriology Indicators
1009733|NCT01979900|Cavity
1009734|NCT01979900|Humoral Immunity
1009735|NCT01979900|Cellular Immunologic Response
1009736|NCT01979861|Endometrial ablation with vapor
1009737|NCT01979848|continence outcomes
1009738|NCT01979848|sexual function
1009739|NCT01979848|Robotic Assisted Radical Prostatectomy
1009740|NCT01979848|thermal imaging
1009741|NCT01979848|localized hypothermia
1009742|NCT01979835|intrauterine device, contraception
1009743|NCT01979822|medication pump, complications, safety observation
1009744|NCT01979809|Dietary change
1009745|NCT01979809|Young adult
1009746|NCT01979809|Prevention
1009747|NCT01979809|Web-based intervention
1009748|NCT01979809|eCoaching
1009749|NCT01979796|Addiction, Schizophrenia, Electronic cigarettes
1009750|NCT01979770|Adolescent
1009751|NCT01979770|Nutritional status
1009752|NCT01979770|Body composition
1009753|NCT01979770|Biochemical status
1009754|NCT01979744|Intravenous ultrasound,
1009755|NCT01979744|third generation drug-eluting stent
1009756|NCT01979731|Occupational health
1009757|NCT01979731|Ergonomics
1009758|NCT01979731|Environments
1009759|NCT01979731|Prevention and Control
1009760|NCT01979692|CLM
1009761|NCT01979692|The study will
1009762|NCT01979692|focus on using
1009763|NCT01979692|CLM to
1009764|NCT01979692|distinguish between
1009765|NCT01979692|viable and
1009766|NCT01979692|necrotic tissue
1009767|NCT01979692|at TTNB in real time
1009768|NCT01979666|Knee AVN, Nitrates
1009769|NCT01979640|bronchial cuff
1009770|NCT01979640|double lumen tube
1009771|NCT01979640|blood tight seal
1009772|NCT01979627|transulnar approach
1009773|NCT01979627|transradial approach
1009774|NCT01979627|angiography
1009775|NCT01979627|angioplasty
1009776|NCT01979614|coronary artery disease
1009777|NCT01979601|hypercholesterolemia,
1009778|NCT01979601|LGT209,
1009779|NCT01979601|PCSK9,
1009780|NCT01979601|LDL-C
1009781|NCT01979575|Nexfin
1009782|NCT01979575|Flotrac
1009783|NCT01979575|Esophageal
1009784|NCT01979575|Cardiac output
1009785|NCT01979562|Overuse injury
1009786|NCT01979562|Femur
1009787|NCT01979562|Tibia
1009788|NCT01979562|Running
1009789|NCT01979562|Prevention
1009790|NCT01979549|Adverse events
1009791|NCT01979549|Upper gastrointestinal endoscopy
1009792|NCT01979549|Sedation
1009793|NCT01979484|bioavailability
1009794|NCT01979471|Cardiovascular risk reduction
1009795|NCT01979471|Diabetes
1009796|NCT01979471|Chronic Kidney Disease
1009797|NCT01979471|Atherosclerotic vascular disease
1009798|NCT01979471|Community Pharmacist
1009799|NCT01979471|Randomized controlled trial
1009800|NCT01979471|[eGFR <60 ml/min/1.73m2 and/or (ACR >= 30 mg/mmol or two consecutive ACR tests which are >= 3 mg/mmol)]
1009801|NCT01979458|Colonoscopy
1009802|NCT01979445|CAD
1009803|NCT01979432|Alzheimer, cognitive diseases, Ankle-to-brachial index
1009804|NCT01979419|mild cognitive impairment
1009805|NCT01979419|Alzheimer's disease
1009806|NCT01979419|subcortical Vascular Dementia
1009807|NCT01979419|amyloid
1009808|NCT01979419|plaques
1009809|NCT01979419|neuroimaging
1009810|NCT01979419|biomarkers
1009811|NCT01979419|cognition disorder
1009812|NCT01979419|early detection
1009813|NCT01979419|pre-dementia
1009814|NCT01979419|dementia
1009815|NCT01979419|vascular MCI
1009816|NCT01979406|Anthrax vaccine
1009817|NCT01979393|Locally advanced
1009818|NCT01979393|stage III
1009819|NCT01979393|stage IV
1009820|NCT01979393|residual disease after primary surgery
1009821|NCT01979393|newly diagnosed HGUS
1009822|NCT01979393|Metastatic
1009823|NCT01979380|KD101
1009824|NCT01979380|Anti-obesity Agents
1009825|NCT01979354|spinal morphine
1009826|NCT01979354|VATs lobectomy
1009827|NCT01979341|dual trigger
1009828|NCT01979341|hCG
1009829|NCT01979341|GnRH agonist
1009830|NCT01979341|ICSI
1009831|NCT01979341|pregnancy
1009832|NCT01979341|OHSS
1009833|NCT01979328|Deep Vein Thrombosis
1009834|NCT01979302|Geriatric Depression
1009835|NCT01979302|Depression Care Management
1009836|NCT01979302|home healthcare
1009837|NCT01979302|nurse training intervention
1009838|NCT01979289|Executive Dysfunction
1009839|NCT01979289|Cognitive Remediation
1009840|NCT01979289|Geriatric
1009841|NCT01979289|Depression
1009842|NCT01979250|endothelial keratoplasty
1009843|NCT01979250|Descemet's stripping automated endothelial keratoplasty
1009844|NCT01979250|lamellar keratoplasty
1009845|NCT01979224|educational intervention, Asthma control, asthma knowledge
1009846|NCT01979211|head and neck cancer
1009847|NCT01979198|burst fracture, kyphotic angle, surgical outcome
1009848|NCT01979172|LASIK
1009849|NCT01979172|Intraocular lens
1009850|NCT01979172|Biometry
1009851|NCT01979172|IOL master
1009852|NCT01979159|aphasia
1009853|NCT01979159|apraxia of speech
1009854|NCT01979159|outcomes
1009855|NCT01979146|Cancer
1009856|NCT01979120|Sleep-disordered breathing
1009857|NCT01979120|Chronic heart failure
1009858|NCT01979120|Implantable cardioverter-defibrillator
1009859|NCT01979120|Apnea-Hypopnea-Index
1009860|NCT01979120|Portable Polygraphy Monitoring
1009861|NCT01979120|Polysomnography
1009862|NCT01979107|Health behavior
1009863|NCT01979107|Chronic disease
1009864|NCT01979107|Proactive action
1009865|NCT01979107|General practitioner
1009866|NCT01979107|Preventive health check
1009867|NCT01979107|Social inequality in health
1009868|NCT01979107|Randomised controlled trial
1009869|NCT01979055|asthma
1009870|NCT01979055|older adults
1009871|NCT01979055|elderly
1009872|NCT01979055|behavior
1009873|NCT01979042|renal colic
1009874|NCT01979042|acute renal failure
1009875|NCT01979042|Neutrophil gelatinase associated lipocalin
1009876|NCT01978977|mBC
1009877|NCT01978977|HER2 negative
1009878|NCT01978977|Chemotherapy
1009879|NCT01978977|Anti-angiogenic agent
1009880|NCT01978977|Bevacizumab
1009881|NCT01978977|1st Line
1009882|NCT01978964|ONT-10
1009883|NCT01978964|MUC1
1009884|NCT01978964|Vaccine
1009885|NCT01978964|Phase 1b
1009886|NCT01978964|Solid tumors
1009887|NCT01978964|Maintenance therapy
1009888|NCT01978951|Chronic Kidney Disease
1009889|NCT01978951|Integrated Chronic Kidney Disease Care
1009890|NCT01978951|Village Health Volunteers
1009891|NCT01978925|Pharmaceutical care
1009892|NCT01978925|Medication Adherence
1009893|NCT01978925|Blood Pressure
1009894|NCT01978925|Diabetes
1009895|NCT01978925|Emergency
1009896|NCT01978886|Diabetes Mellitus
1009897|NCT01978886|frozen shoulder
1009898|NCT01978886|adhesive capsulitis
1009899|NCT01978860|CABG Coronary artery bypass grafting
1009900|NCT01978860|CTO Chronic Total Occlusion
1009901|NCT01978860|PCI Percutaneous coronary intervention
1009902|NCT01978860|MACE Major adverse cardiovascular event(s)
1009903|NCT01978860|MI Myocardial infarction
1009904|NCT01978834|Osteoporosis, diagnosis, ultrasound
1009905|NCT01978821|Cerebral Palsy
1009906|NCT01978821|autologous bone marrow mononuclear cells
1009907|NCT01978821|stem cell therapy
1009908|NCT01978795|concussion
1009909|NCT01978795|high school
1009910|NCT01978795|web-based training
1009911|NCT01978795|school-based health care
1009912|NCT01978782|raltegravir
1009913|NCT01978782|citalopram
1009914|NCT01978782|pharmacokinetics
1009915|NCT01978782|drug-drug interaction
1009916|NCT01978756|Outpatient clinic
1009917|NCT01978756|Breast cancer
1009918|NCT01978756|Late toxicity
1009919|NCT01978743|HIV
1009920|NCT01978743|HIV-associated neurocognitive disorder
1009921|NCT01978743|neurotoxicity
1009922|NCT01978730|vascular dementia
1009923|NCT01978730|cognition
1009924|NCT01978730|stroke
1009925|NCT01978717|Anesthesia
1009926|NCT01978717|T-helper
1009927|NCT01978717|MDSCs
1009928|NCT01978717|Colorectal cancer
1009929|NCT01978717|Fast track
1009930|NCT01978691|Obesity
1009931|NCT01978691|Blood glucose
1009932|NCT01978691|Waist circumference
1009933|NCT01978691|Lipid metabolism
1009934|NCT01978691|Probiotics
1009935|NCT01978691|Prebiotics
1009936|NCT01978691|Dietary supplements
1009937|NCT01978691|Endotoxemia
1009938|NCT01978665|COPD exercise inflammation prednisone
1009939|NCT01978626|Insomnia
1009940|NCT01978626|Comorbid insomnia
1009941|NCT01978626|Cognitive Behavioral Therapy
1009942|NCT01978600|Open-Angle Glaucoma
1009943|NCT01978600|Ocular Hypertension
1009944|NCT01978600|Simbrinza™
1009945|NCT01978600|Intraocular Pressure
1009946|NCT01978587|End-stage Renal Disease
1009947|NCT01978587|Hemodialysis
1009948|NCT01978587|Pharmacokinetics
1009949|NCT01978574|Cognitive reserve
1009950|NCT01978574|intellectual enrichment
1009951|NCT01978548|Alzheimer Disease
1009952|NCT01978548|Prodromal Alzheimer Disease
1009953|NCT01978548|Safety
1009954|NCT01978548|Tolerability
1009955|NCT01978548|Pharmacokinetic
1009956|NCT01978548|Proof of Mechanism
1009957|NCT01978548|JNJ-54861911
1009958|NCT01978535|POTS
1009959|NCT01978522|Randomised trial
1009960|NCT01978522|postal questionnaires
1009961|NCT01978522|return rates
1009962|NCT01978509|Colonoscopy
1009963|NCT01978483|Humans
1009964|NCT01978483|Adult
1009965|NCT01978483|skin
1009966|NCT01978483|metabolism
1009967|NCT01978483|radiation effects
1009968|NCT01978483|Ultraviolet Rays
1009969|NCT01978483|RANKL
1009970|NCT01978483|RANK Ligand
1009971|NCT01978483|denosumab
1009972|NCT01978483|diphenylcyclopropenone
1009973|NCT01978483|diphencyprone
1009974|NCT01978483|immunology
1009975|NCT01978483|immunosuppression
1009976|NCT01978483|Antibodies, Monoclonal
1009977|NCT01978483|Dermatitis, Allergic Contact
1009978|NCT01978483|Hypersensitivity, Delayed
1009979|NCT01978470|epilepsy
1009980|NCT01978470|drug resistent epilepsy
1009981|NCT01978470|partial onset seizures
1009982|NCT01978470|trigeminal nerve stimulation
1009983|NCT01978470|neuromodulation
1009984|NCT01978444|D2 lymphadenectomy
1009985|NCT01978444|Complete Mesogastrium Excision
1009986|NCT01978418|Lung fluid
1009987|NCT01978418|Postnatal adaptation
1009988|NCT01978418|Salbutamol
1009989|NCT01978418|Albuterol
1009990|NCT01978418|Epithelial Sodium Channel
1009991|NCT01978405|Type 2 diabetes
1009992|NCT01978405|Nephropathy
1009993|NCT01978405|Contrast medium
1009994|NCT01978405|Alpha lipoic acid
1009995|NCT01978392|disability
1009996|NCT01978392|self-management
1009997|NCT01978392|chronic illness
1009998|NCT01978392|chronic pain
1009999|NCT01978392|occupation
1010000|NCT01978392|> 6 months
1010001|NCT01978379|General Anesthesia
1010002|NCT01978379|Nociception Level
1010003|NCT01978366|Duchenne muscular dystrophy
1010004|NCT01978366|halofuginone hydrobromide
1010005|NCT01978366|anti-fibrotic
1010006|NCT01978366|anti-inflammatory
1010007|NCT01978366|muscle regeneration
1010008|NCT01978366|protein synthesis inhibitor
1010009|NCT01978353|Mild cognitive impairment
1010010|NCT01978353|Dementia
1010011|NCT01978353|Alzheimer's disease
1010012|NCT01978353|Memory Training
1010013|NCT01978353|Cognitive Training
1010014|NCT01978353|Cognitive Rehabilitation
1010015|NCT01978353|Neuropsychological Rehabilitation
1010016|NCT01978327|Alzheimer's disease
1010017|NCT01978327|GSK2647544
1010018|NCT01978327|drug-drug interaction
1010019|NCT01978327|healthy subjects
1010020|NCT01978327|Lp-PLA2
1010021|NCT01978327|simvastatin
1010022|NCT01978314|Chronic Kidney Disease
1010023|NCT01978314|Acute Kidney Injury
1010024|NCT01978314|AKI
1010025|NCT01978314|CKD
1010026|NCT01978314|Plasma Volume
1010027|NCT01978314|GFR
1010028|NCT01978314|Glomerular Filtration Rate
1010029|NCT01978314|Blood volume
1010030|NCT01978314|mGFR
1010031|NCT01978314|measured GFR
1010032|NCT01978314|kidney biomarker
1010033|NCT01978314|renal disease
1010034|NCT01978314|renal biomarker
1010035|NCT01978314|Renal function
1010036|NCT01978314|kidney function
1010037|NCT01978314|organ function
1010038|NCT01978314|kidney monitor
1010039|NCT01978314|kidney device
1010040|NCT01978301|triamcinolone acetonide (TAC)
1010041|NCT01978301|heavy water
1010042|NCT01978301|fibrosis
1010043|NCT01978301|deuterium
1010044|NCT01978301|collagen degradation
1010045|NCT01978301|collagen synthesis
1010046|NCT01978301|Keloid
1010047|NCT01978301|patient
1010048|NCT01978275|total knee arthroplasty
1010049|NCT01978275|lumbar plexus block
1010050|NCT01978275|stimulating catheters
1010051|NCT01978275|peripheral nerve blocks
1010052|NCT01978262|influenza vaccine
1010053|NCT01978262|cytokines
1010054|NCT01978262|hormones
1010055|NCT01978262|progesterone
1010056|NCT01978249|Colorectal cancer
1010057|NCT01978249|Primary tumor resection
1010058|NCT01978249|Chemotherapy
1010059|NCT01978249|Overall survival
1010060|NCT01978249|Quality of life
1010061|NCT01978236|BRAF V600E mutation
1010062|NCT01978236|brain metastases
1010063|NCT01978236|BRAF V600K mutation
1010064|NCT01978236|Metastatic melanoma
1010065|NCT01978236|BRAF inhibitor
1010066|NCT01978236|brain neoplasms
1010067|NCT01978236|GSK2118436
1010068|NCT01978223|Rotarix™
1010069|NCT01978223|Case-control
1010070|NCT01978223|Venezuela
1010071|NCT01978223|Vaccine effectiveness
1010072|NCT01978223|Rotavirus Severe Gastroenteritis
1010073|NCT01978223|Children
1010074|NCT01978223|Hospitalised
1010075|NCT01978210|autism
1010076|NCT01978210|enuresis
1010077|NCT01978210|toilet-training
1010078|NCT01978184|Pancreatic Cancer, resectable adenocarcinoma of the pancreas
1010079|NCT01978171|breast neoplasms
1010080|NCT01978171|everolimus
1010081|NCT01978171|interstitial lung disease
1010082|NCT01978171|pneumonitis
1010083|NCT01978158|Oxygen
1010084|NCT01978158|Hypoxia
1010085|NCT01978158|Hyperoxia
1010086|NCT01978158|Inflammation
1010087|NCT01978158|Innate immunity
1010088|NCT01978145|efficacy
1010089|NCT01978145|tolerability
1010090|NCT01978145|capsule-based inhaler
1010091|NCT01978145|quality of life
1010092|NCT01978145|safety
1010093|NCT01978145|multi-dose inhaler
1010094|NCT01978145|fluticasone propionate/salmeterol (FSC) 250/50 mcg
1010095|NCT01978145|Chronic obstructive pulmonary disease
1010096|NCT01978132|primary hyperaldosteronism
1010097|NCT01978132|primary hypertension
1010098|NCT01978132|forearm ischemia-reperfusion
1010099|NCT01978132|(reduction) in brachial artery FMD
1010100|NCT01978132|endothelial ischemia-reperfusion injury
1010101|NCT01978119|Multi-Dose Inhaler
1010102|NCT01978119|safety
1010103|NCT01978119|Asthma
1010104|NCT01978119|efficacy
1010105|NCT01978119|pharmacodynamics
1010106|NCT01978119|fluticasone propionate/salmeterol (FSC) 250/50 mcg
1010107|NCT01978119|tolerability
1010108|NCT01978119|Capsule-Based Inhaler
1010109|NCT01978106|toric calculator
1010110|NCT01978106|toric intraocular lens power
1010111|NCT01978106|Acrysof
1010112|NCT01978106|Tecnis
1010113|NCT01978106|iTrace
1010114|NCT01978093|Conjugate
1010115|NCT01978093|Immunogenicity
1010116|NCT01978093|Hib-MenCY-TT vaccine
1010117|NCT01978093|Haemophilus type b
1010118|NCT01978093|Safety
1010119|NCT01978093|Reactogenicity
1010120|NCT01978067|Uterine Scar From Previous Cesarean Delivery
1010121|NCT01978067|previous caesarean scar deficiency
1010122|NCT01978067|transvaginal resection
1010123|NCT01978067|quality of life
1010124|NCT01978067|sexual activity
1010125|NCT01978054|Information Dissemination
1010126|NCT01978054|Information Sharing
1010127|NCT01978054|Innovation Diffusion
1010128|NCT01978054|Public Health Practice
1010129|NCT01978054|Evidence-Based Public Health
1010130|NCT01978054|Chronic Disease Prevention
1010131|NCT01978054|Cancer Prevention and Control
1010132|NCT01978041|pharmacokinetics, saliva, plasma, fluoride, dental fluorosis, dental caries
1010133|NCT01978028|heart failure
1010134|NCT01978015|primary open angle glaucoma
1010135|NCT01978015|timolol
1010136|NCT01978015|prostaglandin analogues
1010137|NCT01977976|Endometrial injury
1010138|NCT01977976|Pipelle
1010139|NCT01977976|Implantation
1010140|NCT01977976|Ongoing pregnancy rate
1010141|NCT01977976|IVF
1010142|NCT01977950|Undernutrition, Nutritional risk, NRS2002, nutritional care practices, hospital, elderly patients, nursing students
1010143|NCT01977937|gabapentin
1010144|NCT01977937|Analgesic Drugs
1010145|NCT01977937|Analgesics, Nonopioid
1010146|NCT01977924|sleep apnea
1010147|NCT01977924|polyphenols
1010148|NCT01977924|endothelial function
1010149|NCT01977911|Airway reconstruction
1010150|NCT01977911|Regenerative medicine
1010151|NCT01977898|Postdural puncture headache
1010152|NCT01977898|Intrathecal morphine
1010153|NCT01977898|Intrathecal catheter
1010154|NCT01977898|Headache
1010155|NCT01977898|Labor and delivery
1010156|NCT01977898|Unintentional dural puncture
1010157|NCT01977885|epigenetics
1010158|NCT01977885|obesity
1010159|NCT01977885|overweight
1010160|NCT01977885|high protein diet
1010161|NCT01977885|exercise
1010162|NCT01977885|post menopausal women
1010163|NCT01977872|Arthritis
1010164|NCT01977872|Physical Activity
1010165|NCT01977872|Diet
1010166|NCT01977859|B-type Natriuretic Peptide
1010167|NCT01977859|Metabolism
1010168|NCT01977859|Insulin infusion
1010169|NCT01977846|genetic testing
1010170|NCT01977846|ABCA4
1010171|NCT01977846|Stargardt
1010172|NCT01977846|retina
1010173|NCT01977846|retinal degeneration
1010174|NCT01977833|BTdiet
1010175|NCT01977833|Dtdiet
1010176|NCT01977833|High Calorie Breakfast diet (BTdiet)
1010177|NCT01977833|High Calorie Dinner diet (DTdiet)
1010178|NCT01977820|Phenylketonuria
1010179|NCT01977820|Sapropterin
1010180|NCT01977820|Placebo
1010181|NCT01977820|Cognitive Abilities
1010182|NCT01977820|Kuvan®
1010183|NCT01977807|Myopia
1010184|NCT01977807|Hyperopia
1010185|NCT01977807|Presbyopia
1010186|NCT01977807|Supracor
1010187|NCT01977807|Zyoptix
1010188|NCT01977807|Proscan
1010189|NCT01977807|LASIK
1010190|NCT01977794|Bisoprolol
1010191|NCT01977794|Amlodipine
1010192|NCT01977794|Fixed dose combination (FDC)
1010193|NCT01977794|Systolic Blood Pressure (SBP)
1010194|NCT01977794|Diastolic Blood Pressure (DBP)
1010195|NCT01977781|GVHD
1010196|NCT01977781|Ocular GVHD
1010197|NCT01977781|Tacrolimus
1010198|NCT01977781|Methylprednisolone
1010199|NCT01977768|M. vaccae
1010200|NCT01977768|TB
1010201|NCT01977768|MDR-TB
1010202|NCT01977768|V7-immunitor
1010203|NCT01977729|anxiety
1010204|NCT01977716|Peritonitis
1010205|NCT01977716|loss of residual renal function
1010206|NCT01977716|technique survival
1010207|NCT01977703|Heart Failure
1010208|NCT01977703|Advanced Heart Failure
1010209|NCT01977703|LVAD
1010210|NCT01977703|Left Ventricular Assist Device
1010211|NCT01977703|Heart-Assist Devices
1010212|NCT01977664|oocyte maturation failure
1010213|NCT01977664|Maturation induction in vitro
1010214|NCT01977651|enzalutamide
1010215|NCT01977651|Xtandi
1010216|NCT01977651|seizure
1010217|NCT01977651|Central Nervous System
1010218|NCT01977651|MDV3100
1010219|NCT01977651|metastatic castration-resistant prostate cancer (mCRPC)
1010220|NCT01977638|Advanced solid tumours
1010221|NCT01977638|Lymphoma
1010222|NCT01977638|Myeloma
1010223|NCT01977625|Menopause
1010224|NCT01977625|fMRI
1010225|NCT01977625|Vyvanse
1010226|NCT01977612|Wound infection
1010227|NCT01977612|Wound separation
1010228|NCT01977612|Skin staples
1010229|NCT01977612|Subcuticular suture
1010230|NCT01977599|Text message reminders
1010231|NCT01977599|Short Message Service (SMS) Reminders
1010232|NCT01977599|Social Health Inequalities
1010233|NCT01977599|Breast Screening
1010234|NCT01977599|Screening
1010235|NCT01977599|Public Health Intervention
1010236|NCT01977599|Missed Appointments
1010237|NCT01977599|Non-attendance
1010238|NCT01977586|Clear cell renal cell carcinoma
1010239|NCT01977586|Stage IV renal cell carcinoma
1010240|NCT01977586|Anti-angiogenic therapy
1010241|NCT01977586|Response assessment
1010242|NCT01977586|Magnetic resonance imaging
1010243|NCT01977573|Prolyl hydroxylase inhibitor
1010244|NCT01977573|pharmacokinetics
1010245|NCT01977573|GSK1278863
1010246|NCT01977573|Anemia
1010247|NCT01977573|hemoglobin
1010248|NCT01977573|erythropoiesis stimulating agents
1010249|NCT01977573|Chronic kidney disease
1010250|NCT01977560|Type 2 diabetes
1010251|NCT01977560|Exercise
1010252|NCT01977560|High protein
1010253|NCT01977547|Red blood cell transfusions
1010254|NCT01977547|Red blood cell storage age
1010255|NCT01977547|Pediatrics
1010256|NCT01977547|Critical Care
1010272|NCT01977508|Vascular access grafts
1010273|NCT01977508|Haemodialysis
1010274|NCT01977495|Diabetes
1010275|NCT01977495|Enrollment methods
1010276|NCT01977495|Behavioral Economic Intervention
1010277|NCT01977495|Opt-in Enrollment
1010278|NCT01977495|Opt-out Enrollment
1010279|NCT01977495|lottery
1010280|NCT01977495|financial incentives
1010281|NCT01977482|hemoglobin
1010282|NCT01977482|recombinant human erythropoietin
1010283|NCT01977482|Chronic kidney disease
1010284|NCT01977482|hemodialysis
1010285|NCT01977482|pharmacokinetics
1010286|NCT01977482|erythropoiesis stimulating agents
1010287|NCT01977482|Anemia
1010288|NCT01977482|GSK1278863
1010289|NCT01977469|Chronic Obstructive Pulmonary Disease
1010290|NCT01977469|Activities of Daily Living
1010291|NCT01977469|Mortality
1010292|NCT01977469|Strength Training
1010293|NCT01977456|acute ischemic stroke
1010294|NCT01977456|stroke
1010295|NCT01977456|rt-PA, thrombolytic
1010296|NCT01977456|t-PA
1010297|NCT01977456|recombinant tissue plasminogen activator
1010298|NCT01977456|Activase
1010299|NCT01977456|eptifibatide
1010300|NCT01977456|Integrilin
1010301|NCT01977456|fibrinolytic agents
1010302|NCT01977456|clot dissolving
1010303|NCT01977456|blood clot
1010304|NCT01977430|Residual renal function
1010305|NCT01977430|Combined thiazide-furosemide therapy
1010306|NCT01977430|Haemodialysis
1010307|NCT01977417|Endothelial Function
1010308|NCT01977417|Arterial Stiffness
1010309|NCT01977417|Inflammation
1010310|NCT01977417|Muscle Sympathetic Nervous System
1010311|NCT01977417|Prediabetes
1010312|NCT01977417|Autonomic function
1010313|NCT01977404|Congestive heart failure
1010314|NCT01977404|Energy expenditure
1010315|NCT01977404|Body composition
1010316|NCT01977404|Caloric intake
1010317|NCT01977365|Cluster Randomized Trial,
1010318|NCT01977365|Nutrition counseling,
1010319|NCT01977365|Caretaker's knowledge
1010320|NCT01977365|Child growth,
1010321|NCT01977365|Prevention,
1010322|NCT01977365|Acute malnutrition
1010323|NCT01977352|Exparel
1010324|NCT01977352|Liposomal Bupivacaine
1010325|NCT01977352|Arthroscopic Shoulder Surgery
1010326|NCT01977339|Femoral Nerve Block
1010327|NCT01977339|Liposomal Bupivacaine
1010328|NCT01977326|task sharing
1010329|NCT01977326|task shifting
1010330|NCT01977326|prenatal depression
1010331|NCT01977326|counselling
1010332|NCT01977326|lay health workers
1010333|NCT01977287|Multiple Sclerosis
1010334|NCT01977287|Functional Electrical Stimulation
1010335|NCT01977287|Ankle Foot Orthosis
1010336|NCT01977287|Walking performance
1010337|NCT01977287|gait analysis
1010338|NCT01977287|fatigue
1010339|NCT01977287|activity monitoring
1010340|NCT01977274|ovarian, endometrium, cervix cancer
1010341|NCT01977235|Irinotecan; Cisplatin; Small-cell lung cancer; UGT1A1
1010342|NCT01977209|NSCLC; Gossypol; APE1; Chemotherapy
1010343|NCT01977196|DTB/HB/Hib vaccine
1010344|NCT01977196|Infants
1010345|NCT01977196|Phase I
1010346|NCT01977183|gastrointestinal
1010347|NCT01977183|microbiome
1010348|NCT01977183|prebiotic
1010349|NCT01977183|starch
1010350|NCT01977170|Adults
1010351|NCT01977170|Hib vaccines
1010352|NCT01977170|Immunogenicity
1010353|NCT01977170|Safety
1010354|NCT01977157|Impedance cardiography
1010355|NCT01977157|bioimpedance
1010356|NCT01977157|spectroscopy
1010357|NCT01977157|extracellular resistance
1010358|NCT01977157|body composition
1010359|NCT01977157|hemodynamics
1010360|NCT01977157|alcohol
1010361|NCT01977144|Single Embryo Transfer
1010362|NCT01977144|Double Embryo Transfer
1010363|NCT01977144|CCS (Comprehensive Chromosome Screening)
1010364|NCT01977144|Aneuploidy
1010365|NCT01977144|Low Responders
1010366|NCT01977118|Streptokinase
1010367|NCT01977118|Percutaneous catheter drainage
1010368|NCT01977118|Pancreatic necrosis
1010369|NCT01977118|peripancreatic necrosis
1010370|NCT01977105|Infants
1010371|NCT01977105|Mothers
1010372|NCT01977105|Social media
1010373|NCT01977105|Obesity prevention
1010374|NCT01977092|sober living houses
1010375|NCT01977092|HIV
1010376|NCT01977092|alcohol and drugs
1010377|NCT01977079|pregnancy
1010378|NCT01977079|premature birth
1010379|NCT01977079|procalcitonin
1010380|NCT01977066|pancreatic cancer
1010381|NCT01977066|exercise training
1010382|NCT01977066|quality of life
1010383|NCT01977066|physical functioning
1010384|NCT01977053|breast cancer
1010385|NCT01977053|colon cancer
1010386|NCT01977053|rectal cancer
1010387|NCT01977053|adjuvant chemotherapy
1010388|NCT01977053|phone calls
1010389|NCT01977053|emotional states
1010390|NCT01977053|quality of life
1010391|NCT01977040|Vasa Previa
1010392|NCT01977027|Rehabilitation
1010393|NCT01977027|Fingers
1010394|NCT01977027|Grasp
1010395|NCT01977027|Strength
1010396|NCT01977027|Hand Function
1010397|NCT01977027|Motor Function
1010398|NCT01977027|Post Stroke
1010399|NCT01977027|Brain Infraction
1010400|NCT01977027|Biomechanis
1010401|NCT01977027|Neuronal Plasticity
1010402|NCT01977027|Weight-Bearing
1010403|NCT01977001|Primary headache
1010404|NCT01977001|Headache
1010405|NCT01977001|MigraineBox
1010406|NCT01976975|Depression
1010407|NCT01976975|Major Depressive Disorder
1010408|NCT01976975|Bipolar Disorder
1010409|NCT01976975|Mania
1010410|NCT01976975|Hypomania
1010411|NCT01976975|EEG
1010412|NCT01976975|MRI
1010413|NCT01976975|Reward
1010414|NCT01976962|Prostatic neoplasms
1010415|NCT01976962|Radiotherapy
1010416|NCT01976962|Dose fractionation
1010417|NCT01976962|Magnetic resonance imaging
1010418|NCT01976949|Cancer, social-networking intervention, cancer-related distress, internet health services, intervention delivery
1010419|NCT01976936|Stroke
1010420|NCT01976936|Rhabdomyolysis
1010421|NCT01976936|Jaundice
1010422|NCT01976923|Intravitreal Bevacizumab
1010423|NCT01976923|Tractional Retinal Detachment
1010424|NCT01976923|Proliferative Diabetic Retinopathy
1010425|NCT01976923|Small gauge pars plana vitrectomy
1010426|NCT01976923|Intraoperative bleeding
1010427|NCT01976923|Post-operative vitreous hemorrhage
1010428|NCT01976923|Visual acuity
1010429|NCT01976910|Glioblastoma multiforme
1010430|NCT01976910|Advanced cancers
1010431|NCT01976910|Brain Neoplasms, Malignant, Primary
1010432|NCT01976910|Brain Tumor, Recurrent
1010433|NCT01976910|Advanced cancer
1010434|NCT01976897|heel - mattress pressure interface
1010435|NCT01976897|flexion
1010436|NCT01976897|knee angular position
1010437|NCT01976884|sepsis
1010438|NCT01976884|immunosuppression
1010439|NCT01976884|PD-L1
1010440|NCT01976871|Restless Legs Syndrome
1010441|NCT01976871|Ekbom Syndrome
1010442|NCT01976871|Willis-Ekbom Disease
1010443|NCT01976871|Rotigotine
1010444|NCT01976871|Neupro
1010445|NCT01976871|Dopamine Agonist
1010446|NCT01976858|PEX168, diabetes, phase I
1010447|NCT01976845|propofol
1010448|NCT01976845|midazolam
1010449|NCT01976845|sedative
1010450|NCT01976845|anxiolytic
1010451|NCT01976845|amnesic
1010452|NCT01976845|recall
1010453|NCT01976845|Memory
1010454|NCT01976845|Perioperative outcomes
1010455|NCT01976806|Docosahexaenoic acid
1010456|NCT01976806|DHA
1010457|NCT01976806|Periodontitis
1010458|NCT01976806|Gingivitis
1010459|NCT01976806|Omega-3 fatty acid
1010460|NCT01976806|Fish oil
1010461|NCT01976793|Recurrent depressive disorder
1010462|NCT01976793|Depression
1010463|NCT01976793|Depressive episode
1010464|NCT01976793|Atypical antipsychotics
1010465|NCT01976780|Malaria
1010466|NCT01976780|P. falciparum mono infection
1010467|NCT01976780|Early Treatment Failure
1010468|NCT01976780|Late Treatment Failure
1010469|NCT01976767|Sputum
1010470|NCT01976767|Clinical cohorts
1010471|NCT01976767|Smokers
1010472|NCT01976767|Asthma
1010473|NCT01976767|Biopsies
1010474|NCT01976767|Severe asthma
1010475|NCT01976767|Collaborative research
1010476|NCT01976767|Phenotyping
1010477|NCT01976767|Lipidomics
1010478|NCT01976767|Transcriptomics
1010479|NCT01976767|Proteomics
1010480|NCT01976767|Paediatric cohort
1010481|NCT01976767|Systems Biology
1010493|NCT01976702|HIV risk behaviors
1010494|NCT01976702|Pregnant drug abusers
1010495|NCT01976689|Glucose Regulation
1010496|NCT01976689|Left Ventricular Hypertrophy
1010497|NCT01976689|New-onset Diabetes
1010498|NCT01976689|Renal Transplantation
1010499|NCT01976598|chronic
1010500|NCT01976598|back
1010501|NCT01976598|leg
1010502|NCT01976598|pain
1010503|NCT01976598|sub-sensory
1010504|NCT01976598|stimulation
1010505|NCT01976598|Neuromodulation
1010506|NCT01976598|Yearwood
1010507|NCT01976585|Intratumoral injections
1010508|NCT01976585|rhuFlt3L
1010509|NCT01976585|Flt3L
1010510|NCT01976585|CDX-301
1010511|NCT01976585|Vaccine
1010512|NCT01976585|Poly-ICLC
1010513|NCT01976585|iNHL
1010514|NCT01976585|TLR3
1010515|NCT01976585|Low-Grade B-cell Lymphoma
1010516|NCT01976585|Follicular
1010517|NCT01976585|Marginal Zone
1010518|NCT01976585|SLL
1010519|NCT01976585|Small lymphocytic
1010520|NCT01976572|CKD Stage V
1010521|NCT01976572|dialysis
1010522|NCT01976559|ICP
1010523|NCT01976559|Intracranial pressure
1010524|NCT01976559|Hydrocephalus
1010525|NCT01976559|Idiopathic normal pressure hydrocephalus
1010526|NCT01976559|CSF
1010527|NCT01976559|Cerebrospinal fluid
1010528|NCT01976559|Noninvasive ICP
1010534|NCT01976494|Patient controlled analgesia equipment
1010535|NCT01976494|efficacy
1010536|NCT01976494|safety
1010537|NCT01976494|Accufuser Omnibus®
1010538|NCT01976494|Upper abdominal surgery
1010539|NCT01976494|laparotomy
1010540|NCT01976455|obesity
1010541|NCT01976455|carbon13
1010542|NCT01976455|over-eating
1010543|NCT01976455|metabolic chamber
1010544|NCT01976455|room calorimeter
1010545|NCT01976442|Leukemia
1010546|NCT01976442|Transfusion
1010547|NCT01976429|barotrauma
1010548|NCT01976429|barotitis
1010549|NCT01976429|middle ear
1010550|NCT01976429|flying
1010551|NCT01976429|diving
1010552|NCT01976429|Eustachian tube
1010553|NCT01976416|Hydroxyurea
1010554|NCT01976390|Kidney
1010555|NCT01976390|Kidney transplant
1010556|NCT01976390|Renal failure
1010557|NCT01976390|End Stage Renal Disease
1010558|NCT01976390|kidney transplant recipient
1010571|NCT01976351|Barrett's esophagus
1010572|NCT01976351|image-enhanced endoscopy
1010573|NCT01976338|BRVO
1010574|NCT01976338|macular edema
1010575|NCT01976338|vision impairment
1010576|NCT01976338|retinal vein occlusion
1010577|NCT01976338|ranibizumab
1010578|NCT01976338|branch retinal vein occlusion
1010579|NCT01976338|anti-VEGF therapy
1010580|NCT01976338|RFB002
1010581|NCT01976325|decision aid
1010582|NCT01976325|imported malaria
1010583|NCT01976325|malaria prevention and control
1010584|NCT01976325|malaria chemoprophylaxis
1010585|NCT01976325|mefloquine
1010586|NCT01976325|lariam
1010587|NCT01976325|atovaquone-proguanil
1010588|NCT01976325|malarone
1010589|NCT01976325|doxycycline
1010590|NCT01976325|vibramycin
1010591|NCT01976312|CRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab
1010592|NCT01976221|Comprehensive referrals
1010593|NCT01976221|Appropriate referring
1010594|NCT01976221|Priority setting
1010595|NCT01976221|Waiting time in hospital
1010596|NCT01976208|Omalizumab
1010597|NCT01976208|IgE
1010598|NCT01976208|Asthma
1010599|NCT01976195|Thalidomide
1010600|NCT01976195|Dexamethasone
1010601|NCT01976195|ITP
1010602|NCT01976182|large granular lymphocytes leukemia
1010603|NCT01976182|immunosuppressive drugs
1010604|NCT01976182|methotrexate
1010605|NCT01976182|cyclophosphamide
1010606|NCT01976182|efficiency
1010607|NCT01976182|phase II randomized controlled trial
1010608|NCT01976169|Breast Cancer
1010609|NCT01976169|Advanced Breast Cancer
1010610|NCT01976104|Thrombocytopenia
1010611|NCT01976104|Chronic Liver Disease
1010612|NCT01976091|limb girdle muscular dystrophy
1010613|NCT01976091|LGMD2D
1010614|NCT01976091|alpha-sarcoglycan
1010615|NCT01976091|gene transfer
1010616|NCT01976091|adeno-associated virus
1010617|NCT01976078|Voriconazole
1010618|NCT01976078|Pharmacokinetics
1010619|NCT01976078|Ontogeny
1010620|NCT01976078|Modeling
1010621|NCT01976078|Bayesian
1010622|NCT01976065|Necrotic tooth pulp
1010623|NCT01976065|Immature permanent teeth
1010624|NCT01976065|Regeneration
1010625|NCT01976052|Biomarkers
1010626|NCT01976052|Genomics
1010627|NCT01976039|motorcyclist
1010628|NCT01976039|nasal mucociliary clearance
1010629|NCT01976039|physical therapy
1010630|NCT01976026|Flow Diversion
1010631|NCT01976026|Aneurysm
1010632|NCT01976026|Intracranial
1010633|NCT01976026|Cerebral
1010634|NCT01976026|Vertebral
1010635|NCT01976026|blood blister-like
1010636|NCT01976026|ruptured aneurysm
1010637|NCT01976026|Pipeline Flow Diversion
1010638|NCT01976026|Pipeline Flow Diverter
1010639|NCT01976026|Best-Standard Treatment
1010640|NCT01976013|PT
1010641|NCT01976013|INR
1010642|NCT01976013|intraventricular haemorrhage
1010643|NCT01976013|pulmonary haemorrhage
1010644|NCT01976013|ELBW infants
1010645|NCT01975987|Intubation
1010646|NCT01975987|Bonfils fiberscope
1010647|NCT01975974|vascular
1010648|NCT01975974|access
1010649|NCT01975974|ultrasound
1010650|NCT01975948|Mental Health
1010651|NCT01975948|Education and Practice Support Program
1010652|NCT01975948|Depression
1010653|NCT01975948|Primary Care
1010654|NCT01975948|Skill-based training
1010655|NCT01975935|diabetes mellitus type 2
1010656|NCT01975935|non-alcoholic fatt liver disease
1010657|NCT01975935|obesity
1010658|NCT01975922|language impairment
1010659|NCT01975922|language disorder
1010660|NCT01975922|language delay
1010661|NCT01975922|late talkers
1010662|NCT01975922|late talking
1010663|NCT01975909|Spinocerebellar Ataxia
1010664|NCT01975909|SCA
1010665|NCT01975909|Ataxia
1010666|NCT01975909|Transcranial Magnetic Stimulation
1010667|NCT01975909|TMS
1010668|NCT01975883|Blood Glucose
1010669|NCT01975883|Postoperative Complications
1010670|NCT01975883|Spine
1010671|NCT01975883|Orthopedic surgery
1010672|NCT01975870|Sedentary behavior, smartphone, application
1010673|NCT01975857|mild traumatic brain injury
1010674|NCT01975857|sleep
1010675|NCT01975857|mind body intervention
1010676|NCT01975857|mind body bridging
1010677|NCT01975844|Anemia
1010678|NCT01975844|End Stage Renal Disease
1010679|NCT01975831|Non Triple Negative Breast Cancer
1010680|NCT01975818|Anemia of CKD on dialysis
1010681|NCT01975805|cesarean delivery
1010682|NCT01975805|chlorhexidine
1010683|NCT01975805|iodine
1010684|NCT01975805|skin disinfectant
1010685|NCT01975792|PPROM
1010686|NCT01975792|Pregnant
1010687|NCT01975792|Preterm
1010688|NCT01975792|Premature, labor
1010689|NCT01975766|Carcinoma, squamous cell of head and neck
1010690|NCT01975766|Head and neck cancer
1010691|NCT01975766|ketogenic diet
1010692|NCT01975766|radiotherapy
1010693|NCT01975766|cisplatin
1010694|NCT01975753|pain
1010698|NCT01975714|Glaucoma
1010699|NCT01975714|Ocular hypertension
1010700|NCT01975714|Preservative-free prostaglandins
1010701|NCT01975701|BGJ398,
1010702|NCT01975701|recurrent glioblastoma'
1010703|NCT01975701|recurrent GBM,
1010704|NCT01975701|FGFR,
1010705|NCT01975662|MRSA
1010706|NCT01975662|bacteremia
1010707|NCT01975662|vancomycin
1010708|NCT01975662|daptomycin
1010709|NCT01975649|postmenopausal
1010710|NCT01975649|hypoactive
1010711|NCT01975649|sexual disorder
1010712|NCT01975649|androgen
1010713|NCT01975636|Metabolism and Elimination
1010714|NCT01975623|Video assisted thoracoscopic surgery (VATS)
1010715|NCT01975610|Arthritis, Rheumatoid, Autoimmune, Inflammatory, Synovial, Bruton's tyrosine kinase (Btk), CC-292, Joint Disease
1010716|NCT01975571|residual hearing
1010717|NCT01975571|hybrid
1010718|NCT01975571|hearing preservation
1010719|NCT01975545|Down syndrome
1010720|NCT01975545|Caries
1010721|NCT01975545|Dental varnish
1010722|NCT01975519|TRC105
1010723|NCT01975519|CD105
1010724|NCT01975519|Endoglin
1010725|NCT01975519|Angiogenesis Inhibitor
1010726|NCT01975519|STS
1010727|NCT01975519|Soft Tissue Sarcoma
1010728|NCT01975519|TKI
1010729|NCT01975519|Tyrosine Kinase Inhibitor
1010730|NCT01975519|Pazopanib
1010731|NCT01975519|Votrient
1010732|NCT01975519|Advanced Soft Tissue Sarcoma
1010733|NCT01975519|Angiosarcoma
1010734|NCT01975506|Head Start
1010735|NCT01975506|Occupational Therapy
1010736|NCT01975493|Infectious Diseases
1010737|NCT01975493|Paediatrics
1010738|NCT01975493|Neonatology
1010739|NCT01975493|Pharmacokinetics
1010740|NCT01975493|Antimicrobials
1010741|NCT01975467|midshaft clavicle fracture
1010742|NCT01975467|intramedullary nail
1010743|NCT01975467|sling
1010744|NCT01975454|Metastatic colorectal cancer
1010745|NCT01975454|Chemotherapy
1010746|NCT01975454|Traditional Chinese Medicine (TCM)
1010747|NCT01975454|Teng-Long-Bu-Zhong-Tang
1010748|NCT01975441|Diethycarbamazine
1010749|NCT01975441|Albendazole
1010750|NCT01975441|Ivermectin
1010751|NCT01975441|Lymphatic filariasis
1010752|NCT01975415|Meditation
1010753|NCT01975415|Sensors
1010754|NCT01975415|Digital medicine
1010755|NCT01975402|Congestive Heart Failure
1010756|NCT01975389|myocardial infarction
1010757|NCT01975389|stroke
1010758|NCT01975389|hyperlipidemia
1010759|NCT01975376|myocardial infarction
1010760|NCT01975376|stroke
1010761|NCT01975376|hyperlipidemia
1010762|NCT01975363|Breast Cancer
1010763|NCT01975350|Colistimethate sodium inhalation
1010764|NCT01975324|Ampyra
1010765|NCT01975324|NAION
1010766|NCT01975324|Dalfampridine
1010767|NCT01975298|RRMS
1010768|NCT01975285|Pain management
1010769|NCT01975285|Postoperative opioid requirements
1010770|NCT01975285|Perioperative outcomes
1010771|NCT01975285|Dexamethasone
1010772|NCT01975285|Anesthetic adjuvant
1010773|NCT01975285|Analgesic adjuvant
1010774|NCT01975272|postoperative
1010775|NCT01975272|anemia
1010776|NCT01975272|gynaecologic
1010777|NCT01975272|surgery
1010778|NCT01975233|Endovascular
1010779|NCT01975233|Brain Aneurysm
1010906|NCT01974544|Intensive medicines
1010780|NCT01975181|cardiovascular disease risk factors
1010781|NCT01975181|cardiovascular disease prevention
1010782|NCT01975168|laser acupuncture
1010783|NCT01975168|obesity
1010784|NCT01975155|Celiac disease
1010785|NCT01975155|Gluten free diet nutrient content
1010786|NCT01975155|mycotoxins
1010787|NCT01975155|Gluten free diet
1010788|NCT01975142|Metastatic breast cancer
1010789|NCT01975142|Primary tumor HER2 negative
1010790|NCT01975142|CTC HER2 positive
1010791|NCT01975077|patients with mCRC who failed 2nd therapy or more
1010792|NCT01975064|Breast neoplasms
1010793|NCT01975064|Colonic neoplasms
1010794|NCT01975064|Rectal neoplasms
1010795|NCT01975051|Kala- azar
1010796|NCT01975051|PKDL
1010797|NCT01975051|Treatment
1010798|NCT01975051|Pathogenesis
1010799|NCT01975051|Bangladesh
1010800|NCT01975038|Melanin Index
1010801|NCT01975038|Fitzpatrick Skin Phototype
1010802|NCT01975038|Spectrophotometry
1010803|NCT01975038|Skin Diseases
1010804|NCT01975025|Renal Dialysis
1010805|NCT01974999|Kidney
1010806|NCT01974999|Transplant
1010807|NCT01974999|Rejection
1010808|NCT01974986|dehydration
1010809|NCT01974986|exercise
1010810|NCT01974986|rehydration
1010811|NCT01974986|sodium
1010812|NCT01974986|water
1010813|NCT01974986|carbohydrate
1010814|NCT01974973|autism spectrum disorders
1010815|NCT01974973|stem cells
1010816|NCT01974947|Metabolic syndrome
1010817|NCT01974947|Epigenetic
1010818|NCT01974947|Male infertility
1010819|NCT01974947|Sperm parameters
1010820|NCT01974947|Biomarkers
1010821|NCT01974921|Asthma
1010822|NCT01974921|Bronchial Thermoplasty
1010823|NCT01974921|Bronchial smooth muscle
1010824|NCT01974908|Ventricular Tachycardia
1010825|NCT01974895|Children
1010826|NCT01974895|Immunogenicity
1010827|NCT01974895|Fluzone®
1010828|NCT01974895|6 to 35 months of age
1010829|NCT01974895|Seasonal influenza
1010830|NCT01974895|Safety
1010831|NCT01974882|abdominal surgery
1010832|NCT01974882|cryotherapy
1010833|NCT01974882|pain score
1010834|NCT01974882|narcotic utilization
1010835|NCT01974869|Surgery,Crohn's disease,Ulcerative colitis
1010836|NCT01974830|alpha-1
1010837|NCT01974830|anti-trypsin
1010838|NCT01974830|pulmonary function
1010839|NCT01974830|augmentation therayp
1010840|NCT01974830|home care
1010841|NCT01974817|pneumococcal vaccine
1010842|NCT01974817|end stage renal disease
1010843|NCT01974817|dialysis
1010844|NCT01974804|MRI
1010845|NCT01974804|Brain metastases
1010846|NCT01974804|13-094
1010847|NCT01974765|Enzalutamide
1010848|NCT01974765|Androgen Receptor Positive (AR+)
1010849|NCT01974765|13-119
1010850|NCT01974752|uveal melanoma
1010851|NCT01974739|intensive care
1010852|NCT01974739|diuretics
1010853|NCT01974726|ear
1010854|NCT01974726|middle ear
1010855|NCT01974726|Eustachian tube
1010856|NCT01974726|Eustachian tube dysfunction
1010857|NCT01974726|Eustachian tube function
1010858|NCT01974713|CKD progression
1010859|NCT01974713|Inflammation
1010860|NCT01974713|FGF23
1010861|NCT01974713|Genetic biomarkers
1010862|NCT01974687|Hepatitis C virus
1010863|NCT01974687|HCV
1010864|NCT01974674|diabetes
1010865|NCT01974674|transplantation
1010866|NCT01974648|Laryngeal Mask Airway Supreme
1010867|NCT01974648|propofol
1010868|NCT01974648|remifentanil
1010869|NCT01974648|effective dose of intravenous propofol
1010870|NCT01974648|ED50
1010871|NCT01974635|Spinal Cord Injury
1010872|NCT01974635|Robotic therapy
1010873|NCT01974635|Rehabilitation
1010874|NCT01974635|Sensation
1010875|NCT01974635|Movement
1010876|NCT01974635|Proprioception
1010877|NCT01974635|Stroke
1010878|NCT01974635|Acquired Brain Injury
1010879|NCT01974609|pain relief
1010880|NCT01974609|narcotic pain relief
1010881|NCT01974609|non-narcotic pain relief
1010882|NCT01974609|post-operative pain relief
1010883|NCT01974609|carpal tunnel
1010884|NCT01974596|Dental implants
1010885|NCT01974596|Probiotics
1010886|NCT01974596|Lactobacillus reuteri
1010887|NCT01974596|Periimplant mucositis
1010888|NCT01974596|Cytokines
1010889|NCT01974596|Bacterial load
1010890|NCT01974583|the split-thickness skin graft （STSG） donor site
1010891|NCT01974583|regraft
1010892|NCT01974583|wound healing
1010893|NCT01974570|Prehypertension
1010894|NCT01974570|Hypertension
1010895|NCT01974570|Shrimp protein hydrolysate
1010896|NCT01974570|Marine protein hydrolysate
1010897|NCT01974570|Ambulatory blood pressure
1010898|NCT01974570|Blood pressure
1010899|NCT01974557|Cardiac physiology
1010900|NCT01974557|ageing
1010901|NCT01974557|gender differences
1010902|NCT01974557|diastole
1010903|NCT01974557|fluid challenge
1010904|NCT01974544|diabetes complications
1010905|NCT01974544|metabolic surgery
1010907|NCT01974518|Pemphigus
1010908|NCT01974518|Rituximab
1010909|NCT01974518|Rituximab and IV cyclophosphamide combination
1011041|NCT01973868|Pharmacokinetics
1010910|NCT01974518|B cell re-population characteristics following Rituximab
1010911|NCT01974492|saphenous vein graft
1010912|NCT01974492|composite graft
1010913|NCT01974492|coronary artery bypass grafting
1010914|NCT01974492|graft remodeling
1010915|NCT01974479|Redirected Natural Killer Cells
1010916|NCT01974479|Haploidentical Cell Therapy
1010917|NCT01974466|pancreatitis
1010918|NCT01974466|resuscitation goal
1010919|NCT01974453|Radiation dose, transradial approach, percutaneous coronary interventions, coronary angiography
1010920|NCT01974440|Lymphoma
1010921|NCT01974440|Follicular lymphoma
1010922|NCT01974440|Marginal zone lymphoma
1010923|NCT01974440|Indolent Non-Hodgkin lymphoma
1010924|NCT01974440|PCI-32765
1010925|NCT01974440|Ibrutinib
1010926|NCT01974440|Bendamustine
1010927|NCT01974440|Rituximab
1010928|NCT01974440|Cyclophosphamide
1010929|NCT01974440|Doxorubicin
1010930|NCT01974440|Vincristine
1010931|NCT01974440|Prednisone
1010932|NCT01974440|R-CHOP
1010938|NCT01974414|oral lichen planus
1010939|NCT01974414|cedar honey
1010940|NCT01974414|atrophic
1010941|NCT01974414|erosive
1010942|NCT01974414|pain
1010943|NCT01974414|treatment
1010944|NCT01974414|clinical trial
1010945|NCT01974401|oral irrigator
1010946|NCT01974401|leukemia
1010947|NCT01974401|blood dyscrasia
1010948|NCT01974401|Oral Health Index Simplified (OHI-S)
1010949|NCT01974401|supra gingival irrigator
1010950|NCT01974388|Bariatric surgery, sleeve gastrectomy, gastric leak
1010951|NCT01974375|Living donor
1010952|NCT01974375|Liver transplant
1010953|NCT01974375|antifungal prevention
1010954|NCT01974362|Monolithic Zirconia
1010955|NCT01974362|Zirconia-Feldspathic zirconia
1010956|NCT01974362|Dental Implants
1010957|NCT01974362|Fracture
1010958|NCT01974362|Chipping
1010959|NCT01974349|Phase I, healthy, pharmacokinetics, food effect.
1010960|NCT01974310|Macular Holes
1010961|NCT01974310|Non face down positioning
1010962|NCT01974310|Face down positioning
1010963|NCT01974297|Hyperlipidemia
1010964|NCT01974297|Atorvastatin
1010965|NCT01974297|Fenofibric acid
1010966|NCT01974297|combination
1010967|NCT01974297|monotherapy
1010968|NCT01974245|Cholecalciferol
1010969|NCT01974245|Kidney diseases
1010970|NCT01974232|Immune Thrombocytopenia (ITP), Thrombopoietin (TPO) agents, children, romiplostim and eltrombopag
1010971|NCT01974219|HIV
1010972|NCT01974219|COPD
1010973|NCT01974219|Chronic Obstructive Pulmonary Disease
1010974|NCT01974219|Smoking
1010975|NCT01974206|ASP0113
1010976|NCT01974206|Cytomegalovirus (CMV)
1010977|NCT01974206|Kidney Transplantation
1010978|NCT01974180|Smoking
1010979|NCT01974180|COPD
1010980|NCT01974180|Chronic Obstructive Pulmonary Disease
1010981|NCT01974180|Healthy Smoker
1010982|NCT01974180|Non-smoker
1010983|NCT01974167|glucocorticoid-induced osteoporosis
1010984|NCT01974154|COPD
1010985|NCT01974154|Smoking
1010986|NCT01974154|Non-smoker
1010987|NCT01974128|MI
1010988|NCT01974115|Cellulite
1010989|NCT01974115|Extracorporeal shock wave therapy
1010990|NCT01974115|ESWT
1010991|NCT01974115|Radial shock wave therapy
1010992|NCT01974115|RSWT
1010993|NCT01974089|Dysphagia
1010994|NCT01974089|Modified diet
1010995|NCT01974089|Community acquired pneumonia
1010996|NCT01974089|Mortality
1010997|NCT01974089|Rehospitalization
1010998|NCT01974063|Smoking
1010999|NCT01974063|Smoking Cessation
1011000|NCT01974063|Healthy Smoker
1011001|NCT01974063|Shisha Smoker
1011002|NCT01974063|Non-smoker
1011003|NCT01974050|Influenza vaccination
1011004|NCT01974024|Dexamethasone
1011005|NCT01974024|Hiccup
1011006|NCT01974024|Chemotherapy
1011007|NCT01974024|Methylprednisolone
1011008|NCT01973998|COPD
1011009|NCT01973998|Emphysema
1011010|NCT01973998|Roflumilast
1011011|NCT01973998|readmission
1011012|NCT01973985|Pleural Effusion
1011013|NCT01973972|Diabetes
1011014|NCT01973972|Obesity
1011015|NCT01973972|Complex Care
1011016|NCT01973972|Primary Care
1011017|NCT01973972|Chronic Disease
1011018|NCT01973946|Cancer
1011019|NCT01973933|Metformin
1011020|NCT01973933|Pyrimethamine
1011021|NCT01973933|Drug interaction
1011022|NCT01973920|Diabetes Mellitus
1011023|NCT01973920|Oral Insulin
1011024|NCT01973907|Sepsis
1011025|NCT01973907|Septic Shock
1011026|NCT01973907|Fluid Therapy
1011027|NCT01973907|Pediatrics
1011028|NCT01973907|Resuscitation
1011029|NCT01973907|Emergency Medicine
1011030|NCT01973907|Critical Care
1011031|NCT01973894|PBPK
1011032|NCT01973894|Midazolam
1011033|NCT01973894|Pharmacokinetics
1011034|NCT01973894|Critically ill patients
1011035|NCT01973868|Regorafenib
1011036|NCT01973868|Cetuximab
1011037|NCT01973868|Solid tumors
1011038|NCT01973868|Cancer
1011039|NCT01973868|Safety
1011040|NCT01973868|Tolerability
1011042|NCT01973842|GnRH agonist
1011043|NCT01973842|OHSS
1011044|NCT01973842|Triggering final oocyte maturation
1011045|NCT01973829|CERTAIN, Checklist, ICU, Outcome, Adults
1011046|NCT01973816|deep endometriosis;
1011047|NCT01973816|rectal endometriosis;
1011048|NCT01973816|rectal shaving;
1011049|NCT01973816|colorectal resection;
1011050|NCT01973816|bowel endometriosis
1011051|NCT01973803|Carpometacarpal joint
1011052|NCT01973803|Osteoarthritis of CMC-1 joint
1011056|NCT01973777|intrauterine device, contraception
1011057|NCT01973764|Intraoperative ultrasound
1011058|NCT01973764|Ventricular System
1011059|NCT01973764|Puncture
1011060|NCT01973764|Ventricular catheter
1011061|NCT01973764|Ventriculostomy
1011062|NCT01973764|Hydrocephalus
1011063|NCT01973764|Excessive accumulation of cerebrospinal fluids within the cranium. Often associated with dilatation of cerebral ventricles
1011064|NCT01973764|Intracranial Hypertension
1011065|NCT01973764|increased pressure within the cranial vault. This may result from several conditions, including hydrocephalus, brain edema.
1011066|NCT01973738|raloxifene
1011067|NCT01973738|bazedoxifene
1011068|NCT01973738|bone mineral density
1011069|NCT01973738|bone turnover markers
1011070|NCT01973738|bone quality
1011071|NCT01973699|shoulder arthroscopy, epinephrine, visualization
1011072|NCT01973673|prostate cancer
1011073|NCT01973673|ADT
1011074|NCT01973673|bone health
1011075|NCT01973660|Human Epidermal Growth Factor Receptor 2
1011076|NCT01973660|HER2
1011077|NCT01973660|HER2 positive
1011078|NCT01973660|PAM50
1011079|NCT01973660|lapatinib
1011080|NCT01973660|trastuzumab
1011081|NCT01973660|dual HER2 blockade
1011082|NCT01973660|neoadjuvant
1011083|NCT01973647|insomnia
1011084|NCT01973647|cognitive behavioral therapy
1011085|NCT01973647|COPD
1011086|NCT01973647|fatigue
1011087|NCT01973634|Radiotherapy
1011088|NCT01973608|Melanoma
1011089|NCT01973608|MSB0010445
1011090|NCT01973608|Dose limiting toxicity
1011091|NCT01973608|Stereotactic body radiation therapy
1011092|NCT01973595|almonds
1011093|NCT01973595|inflammation
1011094|NCT01973595|immunity
1011095|NCT01973595|gut microbiota
1011096|NCT01973595|stress
1011097|NCT01973595|diet quality
1011098|NCT01973582|Hepatitis B
1011099|NCT01973582|epidemiology
1011100|NCT01973582|youth
1011101|NCT01973582|vaccine
1011102|NCT01973569|Rheumatoid Arthritis
1011103|NCT01973569|Denosumab
1011104|NCT01973569|RANKL
1011105|NCT01973569|RANK
1011106|NCT01973569|AMG 162
1011107|NCT01973569|joint damage
1011108|NCT01973569|Developmental Phase III
1011121|NCT01973530|femoral nerve block
1011122|NCT01973530|adductor canal block
1011123|NCT01973530|steroid
1011124|NCT01973530|total knee replacement
1011125|NCT01973517|Multiple sclerosis
1011126|NCT01973517|MRI
1011127|NCT01973517|USPIO
1011128|NCT01973517|Ferumoxytol
1011129|NCT01973517|Feraheme
1011130|NCT01973504|Trauma
1011131|NCT01973504|Hemorrhagic shock
1011132|NCT01973504|Hemorrhage
1011133|NCT01973504|Lactic acidosis
1011134|NCT01973504|Oxygen therapeutics
1011135|NCT01973504|Oxygen carriers
1011136|NCT01973504|Ischemic rescue therapy
1011137|NCT01973504|Hemoglobin solutions
1011138|NCT01973504|PEGylated hemoglobin
1011139|NCT01973491|ATX-MS-1467 (MSC2358825A)
1011140|NCT01973491|Relapsing Multiple Sclerosis
1011141|NCT01973491|Magnetic resonance imaging (MRI)
1011142|NCT01973491|M2736
1011143|NCT01973478|Major depressive disorder
1011144|NCT01973478|Recurrent depressive disorder
1011145|NCT01973478|Bipolar disorder
1011146|NCT01973478|Deep brain stimulation
1011147|NCT01973478|Accumbens
1011148|NCT01973465|C-Diff
1011149|NCT01973465|Diarrhea
1011150|NCT01973452|Dexmedetomidine
1011151|NCT01973452|Opioid
1011152|NCT01973452|Thoracic Surgery
1011153|NCT01973439|HIV
1011154|NCT01973439|Abacavir
1011155|NCT01973439|Lamivudine
1011156|NCT01973439|Pharmacokinetics
1011157|NCT01973426|Robot
1011158|NCT01973426|Thumb
1011159|NCT01973426|Orthosis
1011160|NCT01973426|Hemiplegia
1011161|NCT01973426|Hemiplegic Stroke
1011162|NCT01973426|Hemiplegic Cerebral Palsy
1011163|NCT01973426|Stroke
1011164|NCT01973426|Cerebral Palsy
1011165|NCT01973426|Grasp assistance
1011166|NCT01973413|Artificial Pancreas Project
1011167|NCT01973413|Diabetes Mellitus, Type 1
1011168|NCT01973413|Insulin pump therapy
1011169|NCT01973413|Continuous Glucose Monitors (CGM)
1011170|NCT01973413|Juvenile-Onset Diabetes
1011171|NCT01973413|Autoimmune Diabetes
1011172|NCT01973413|Closed-to-Range
1011173|NCT01973413|Diabetes Assistant (DiAs)
1011174|NCT01973387|Chronic lymphocytic leukemia
1011175|NCT01973387|Small lymphocytic lymphoma
1011176|NCT01973387|Relapsed or refractory chronic lymphocytic leukemia
1011177|NCT01973387|Relapsed or refractory small lymphocytic lymphoma
1011178|NCT01973387|Ibrutinib
1011179|NCT01973387|PCI-32765
1011180|NCT01973387|Bruton's tyrosine kinase inhibitor
1011181|NCT01973387|Rituximab
1011182|NCT01973387|Asia Pacific region participants
1011183|NCT01973361|Wounds
1011184|NCT01973361|Lower extremity
1011185|NCT01973361|Diabetes
1011186|NCT01973361|Arterial Insufficiency
1011187|NCT01973361|Debridement
1011188|NCT01973361|Low frequency ultrasound
1011189|NCT01973361|Contact ultrasound
1011190|NCT01973361|Wound clinic
1011191|NCT01973361|Wound bed preparation
1011192|NCT01973361|Wound infection
1011193|NCT01973361|Chronic wound inflammation
1011194|NCT01973348|amblyopia
1011195|NCT01973335|acetazolamide
1011196|NCT01973335|bumetanide
1011197|NCT01973335|cardio-renal syndrome
1011198|NCT01973335|diuretics
1011199|NCT01973335|heart failure
1011200|NCT01973335|natriuresis
1011201|NCT01973335|spironolactone
1011202|NCT01973322|Malignant melanoma stage III or IV
1011203|NCT01973322|pretreated melanoma
1011204|NCT01973322|vaccination
1011205|NCT01973322|autologous dendritic cells
1011206|NCT01973322|autologous tumor lysate or homogenate
1011207|NCT01973322|immunomodulating radiotherapy
1011208|NCT01973309|Locally Recurrent
1011209|NCT01973309|Metastatic Breast Cancer
1011210|NCT01973296|Health Literacy
1011211|NCT01973296|Care Transition Intervention
1011212|NCT01973296|Emergency Department Population
1011213|NCT01973296|Access to Care
1011214|NCT01973218|Meningitis, adolescents, Meningococcal B
1011215|NCT01973205|Migraine
1011216|NCT01973205|acetaminophen
1011217|NCT01973205|aspirin
1011218|NCT01973166|Tattoo Removal
1011219|NCT01973166|Q-switched laser
1011220|NCT01973166|Nd:YAG laser
1011221|NCT01973166|Nanosecond laser
1011222|NCT01973166|Picosecond laser
1011223|NCT01973166|Laser therapy
1011224|NCT01973166|Tattoo
1011225|NCT01973166|pulsed-laser
1011226|NCT01973166|laser treatment
1011227|NCT01973166|remove tattoo
1011228|NCT01973166|tattoo clearing
1011229|NCT01973166|tattoo lightening
1011230|NCT01973166|tattoo lighten
1011231|NCT01973153|Obesity prevention
1011232|NCT01973153|Weight management
1011233|NCT01973153|Motivational Interviewing
1011234|NCT01973140|Tolvaptan
1011235|NCT01973140|Aquaretic Efficacy
1011236|NCT01973127|alcohol
1011237|NCT01973127|addiction
1011238|NCT01973127|TMS
1011239|NCT01973127|craving
1011240|NCT01973127|use
1011241|NCT01973127|rTMS
1011242|NCT01973127|EEG
1011243|NCT01973127|LPP
1011244|NCT01973127|p300
1011245|NCT01973127|ERN
1011246|NCT01973127|SST
1011247|NCT01973127|CCT
1011248|NCT01973127|AAAT
1011249|NCT01973114|Menière's disease
1011250|NCT01973114|Vertigo
1011251|NCT01973114|Hearing loss
1011252|NCT01973114|Tinnitus
1011253|NCT01973101|Advanced carcinomas of uterine cervix
1011254|NCT01973101|Chemoradiation
1011255|NCT01973101|Chemo-induction
1011256|NCT01973101|Cisplatin
1011257|NCT01973101|Gemcitabine
1011258|NCT01973075|Premature Ovarian Insufficiency (POI)
1011259|NCT01973036|foley catheter
1011260|NCT01973036|foley bulb
1011261|NCT01973036|oxytocin
1011262|NCT01973023|botulinum toxin injection
1011263|NCT01973023|stroke
1011264|NCT01973023|3D motion analysis
1011265|NCT01973023|gait pattern
1011266|NCT01973010|massage
1011267|NCT01973010|low back pain
1011268|NCT01972984|Estrogen receptor positive
1011269|NCT01972971|warfarin
1011270|NCT01972971|pharmacist
1011271|NCT01972971|anticoagulation
1011272|NCT01972945|vaginoscopy
1011273|NCT01972945|hysteroscopy
1011274|NCT01972945|office hysteroscopy
1011275|NCT01972945|outpatient hysteroscopy
1011276|NCT01972932|Bio-K+®
1011277|NCT01972932|Placebo
1011278|NCT01972932|AAD
1011279|NCT01972932|CDI
1011280|NCT01972932|hospitalized subjects
1011281|NCT01972906|moxibustion
1011282|NCT01972906|primary dysmenorrhea
1011283|NCT01972893|Selective GLP-1 agonist
1011284|NCT01972880|Open-label design
1011285|NCT01972880|Bioequivalence
1011286|NCT01972880|ASP1941
1011287|NCT01972867|Focal
1011288|NCT01972867|Prostate
1011289|NCT01972867|Cancer
1011290|NCT01972867|Irreversible
1011291|NCT01972867|Electroporation
1011292|NCT01972867|NanoKnife
1011293|NCT01972854|keratoconus
1011294|NCT01972854|cross-linking
1011295|NCT01972854|KXL
1011296|NCT01972841|Combination Therapy
1011297|NCT01972841|Mirabegron
1011298|NCT01972841|Overactive Bladder
1011299|NCT01972841|Urgency
1011300|NCT01972841|Urinary Incontinence
1011301|NCT01972841|Nocturia
1011302|NCT01972841|Solifenacin Succinate
1011303|NCT01972828|Septic shock
1011304|NCT01972828|Randomized controlled trial
1011305|NCT01972828|Preload dependence
1011306|NCT01972828|Pulmonary thermodilution
1011307|NCT01972802|HEAD AND NECK
1011308|NCT01972789|Subfoveal choroidal neovascularization (CNV); wet age-related macular degeneration(AMD); inject and extend; retinal fluid
1011309|NCT01972776|COPD, inflammation, small airways, LCI, PFTs, lung heterogeneity
1011310|NCT01972750|glioblastoma
1011311|NCT01972750|recurrence
1011312|NCT01972737|Vaccine
1011313|NCT01972737|Colon cancer
1011314|NCT01972737|safety
1011315|NCT01972737|tolerability
1011316|NCT01972737|antibody responses
1011317|NCT01972737|T cell responses
1011318|NCT01972724|Drug therapy
1011319|NCT01972711|Schizophrenia
1011320|NCT01972698|Focused Cardiac Ultrasound
1011321|NCT01972698|Lung Ultrasound
1011322|NCT01972698|Simulation
1011323|NCT01972698|Education
1011324|NCT01972698|Web-based learning
1011325|NCT01972685|ILD, transbronchial, cryoprobe, VATS
1011326|NCT01972659|sugammadex
1011327|NCT01972659|rocuronium
1011328|NCT01972659|magnesium
1011329|NCT01972659|female
1011330|NCT01972646|Cellulitis, treatment failure, skin and soft tissue infections, risk factors.
1011331|NCT01972633|endovenous treatment
1011332|NCT01972633|Laser, Vnus Closure Fast
1011333|NCT01972633|Varicosis
1011334|NCT01972633|great saphenous vein
1011335|NCT01972633|small saphenous vein
1011336|NCT01972633|Venous Insufficiency
1011337|NCT01972620|gallstones
1011338|NCT01972620|cholelithiasis
1011339|NCT01972620|cholecystectomy, laparoscopic
1011340|NCT01972620|pain
1011341|NCT01972607|Migraine, aerobic exercise, prevention
1011342|NCT01972581|neurocognitive visual reaction training
1011343|NCT01972581|baseball
1011344|NCT01972568|Atacicept 75 and 150 mg
1011345|NCT01972568|Placebo
1011346|NCT01972542|Postprandial period
1011347|NCT01972542|triglyceride
1011348|NCT01972542|Diabetes mellitus, type 2
1011349|NCT01972542|Prediabetic state
1011350|NCT01972529|Thrombocytopenia
1011351|NCT01972529|Chronic Liver Disease
1011352|NCT01972516|Platinum-Sensitive
1011353|NCT01972516|Ovarian Cancer
1011354|NCT01972516|Fallopian Tube Cancer
1011355|NCT01972516|Primary Peritoneal Cancer
1011356|NCT01972516|High-grade Serous
1011357|NCT01972503|Colorectal Neoplasms
1011358|NCT01972503|Liver
1011359|NCT01972503|Neoplasm Metastasis
1011360|NCT01972503|Tegafur
1011361|NCT01972503|oxaliplatin
1011362|NCT01972490|colorectal neoplasms
1011363|NCT01972490|liver metastasis
1011364|NCT01972490|chemotherapy
1011365|NCT01972490|avastin
1011366|NCT01972477|DLBS1449
1011367|NCT01972477|diabetes mellitus
1011368|NCT01972477|HDL-cholesterol
1011369|NCT01972464|Progesterone
1011370|NCT01972464|Placebo
1011371|NCT01972464|Postpartum
1011372|NCT01972464|Tobacco
1011373|NCT01972464|Pregnancy
1011374|NCT01972438|Graft Versus Host Disease
1011375|NCT01972438|Hematopoietic Stem Cell Transplant
1011376|NCT01972412|nursing care
1011377|NCT01972412|diabetes mellitus
1011378|NCT01972412|phone support
1011379|NCT01972412|chronic care model
1011380|NCT01972373|VEGF
1011381|NCT01972373|Fluorescence
1011382|NCT01972373|Endoscopy
1011383|NCT01972373|Rectal cancer
1011384|NCT01972360|SPECT
1011385|NCT01972360|CMR
1011386|NCT01972360|High risk for ischemic cardiovascular events
1011387|NCT01972347|Melanoma
1011388|NCT01972347|Cutaneous melanoma
1011389|NCT01972347|Malignant melanoma
1011390|NCT01972347|Stage III B / C melanoma
1011391|NCT01972347|Neoadjuvant treatment
1011392|NCT01972347|Pyrexia
1011393|NCT01972347|Biomarkers
1011394|NCT01972347|Dabrafenib
1011395|NCT01972347|Trametinib
1011396|NCT01972334|clostridium difficile
1011397|NCT01972334|children
1011398|NCT01972334|fecal transplant
1011399|NCT01972321|Community health worker
1011400|NCT01972321|Motivation
1011401|NCT01972321|Performance
1011402|NCT01972321|Quality of care
1011403|NCT01972321|Africa
1011404|NCT01972308|asthma
1011405|NCT01972308|patient advocate
1011406|NCT01972308|health disparity
1011407|NCT01972308|patient-provider communication
1011408|NCT01972282|Atrial fibrillation
1011409|NCT01972282|Stroke
1011410|NCT01972282|Thrombus
1011411|NCT01972282|Thromboembolism
1011412|NCT01972282|Left atrial appendage
1011413|NCT01972269|Epidural
1011414|NCT01972269|Labor Analgesia
1011415|NCT01972269|Bupivacaine
1011416|NCT01972269|Minimum effective volume
1011417|NCT01972243|risk of recurrent
1011421|NCT01972191|Toric marking, Corneal horizontal marking
1011422|NCT01972165|Carpal tunnel syndrome
1011423|NCT01972152|Hypoglycemia
1011424|NCT01972152|Glucagon
1011425|NCT01972139|Uncontrolled hypertension
1011426|NCT01972139|blood pressure
1011427|NCT01972139|renal denervation
1011428|NCT01972139|HTN-4
1011429|NCT01972139|SYMPLICITY
1011443|NCT01972100|Low-level laser therapy
1011444|NCT01972100|Muscle fatigue resistance
1011445|NCT01972074|Autism spectrum disorder
1011446|NCT01972074|Treatment
1011447|NCT01972074|Adolescents
1011448|NCT01972074|Memantine
1011449|NCT01972074|functional Magnetic Resonance Imaging
1011450|NCT01972074|MRS
1011451|NCT01972074|Neuroimaging
1011452|NCT01972048|breast cancer
1011453|NCT01972048|breast cancer screening
1011454|NCT01972048|mammogram
1011455|NCT01972035|EBV
1011456|NCT01972035|CMV
1011457|NCT01972035|Kidney transplant
1011458|NCT01972035|valganciclovir
1011459|NCT01972035|valacyclovir
1011460|NCT01972022|Drug Eluting Stents
1011461|NCT01972022|Bioabsorbale Polymer Coating
1011462|NCT01972022|Neoatherosclerosis
1011463|NCT01972022|Stent Coverage
1011464|NCT01972022|Stent Failure
1011465|NCT01971996|Near infrared Spectroscopy
1011466|NCT01971983|Low back pain
1011467|NCT01971983|Spinal manipulation
1011468|NCT01971983|Osteopathy
1011469|NCT01971983|Muscle energy technique
1011470|NCT01971983|Muscle thickness
1011471|NCT01971970|Inflammatory bowel disease
1011472|NCT01971970|Pediatric
1011473|NCT01971970|Adult
1011474|NCT01971970|Biomarker
1011475|NCT01971970|Anti-TNF response
1011476|NCT01971970|Infliximab
1011477|NCT01971970|Adalimumab
1011478|NCT01971957|ichthyosis
1011479|NCT01971957|spasticity
1011480|NCT01971957|spastic diplegia
1011481|NCT01971957|intellectual disability
1011482|NCT01971944|Beta Blocker
1011483|NCT01971944|Inotrope
1011484|NCT01971918|spondyloarthritis
1011485|NCT01971918|monoclonal antibodies anti-TNF
1011486|NCT01971918|secondary treatment failure
1011487|NCT01971892|Abdominal surgery;
1011488|NCT01971892|Postoperative complication;
1011489|NCT01971892|Acute respiratory failure;
1011490|NCT01971892|Hypoxemia;
1011491|NCT01971892|Intubation;
1011492|NCT01971892|Non-invasive ventilation
1011493|NCT01971879|Remote ischemic preconditioning
1011494|NCT01971879|Obliterating Arteriopathy of the Lower Limbs
1011495|NCT01971866|Proton radiation
1011496|NCT01971866|AlignRT
1011497|NCT01971853|Analgesia
1011498|NCT01971840|Physical activity
1011499|NCT01971840|Physical fitness
1011500|NCT01971840|Obesity
1011501|NCT01971840|Adiposity
1011502|NCT01971840|Adiposity rebound period
1011503|NCT01971840|Children
1011504|NCT01971840|Blood pressure
1011505|NCT01971840|Randomized controlled trials
1011506|NCT01971840|Barriers and facilitators of the environment
1011507|NCT01971827|Physical activity
1011508|NCT01971827|Obesity
1011509|NCT01971827|Adiposity rebound period
1011510|NCT01971827|Children with ADHD
1011511|NCT01971827|Children without ADHD
1011512|NCT01971827|Academic performance
1011513|NCT01971827|Motor skills
1011514|NCT01971827|Health related-quality of life
1011515|NCT01971827|Sleep
1011516|NCT01971801|urinary incontinence
1011517|NCT01971801|bowel incontinence
1011518|NCT01971801|vitamin D
1011519|NCT01971801|overactive bladder
1011520|NCT01971801|lower urinary tract symptoms
1011521|NCT01971801|quality of life
1011522|NCT01971775|Ultrasonically Activated Shear
1011523|NCT01971775|Conventional Monopolar Electrocautery
1011524|NCT01971775|Gastric Cancer
1011525|NCT01971762|multiresistant bacteremia
1011526|NCT01971762|bacteremia management
1011527|NCT01971762|blood culture
1011528|NCT01971749|Coronary stent procedure (CSP
1011529|NCT01971749|Coronary-artery bypass grafting (CABG)
1011530|NCT01971736|1064nm YAG laser
1011531|NCT01971736|laxity
1011532|NCT01971736|rhytides
1011533|NCT01971736|asian
1011534|NCT01971723|Testosterone
1011535|NCT01971723|Estrogen
1011536|NCT01971723|Insulin
1011537|NCT01971723|Blood Lipid
1011538|NCT01971723|Glucose
1011539|NCT01971723|Creatine Kinase
1011540|NCT01971723|Strength
1011541|NCT01971723|Power Athlete
1011542|NCT01971710|HIV
1011543|NCT01971710|AIDS
1011544|NCT01971710|PMTCT
1011545|NCT01971684|ITP
1011546|NCT01971684|idiopathic thrombocytopenic purpura
1011547|NCT01971684|bleeding score
1011548|NCT01971684|platelet count
1011549|NCT01971684|health-related quality of life
1011550|NCT01971684|HRQL
1011551|NCT01971684|Purpura
1011552|NCT01971684|Purpura, Thrombocytopenic
1011553|NCT01971684|Purpura, Thrombocytopenic, Idiopathic
1011554|NCT01971684|Blood Coagulation Disorders
1011555|NCT01971684|Hematologic Diseases
1011556|NCT01971684|Hemorrhage
1011557|NCT01971684|Skin Manifestations
1011558|NCT01971684|Thrombocytopenia
1011559|NCT01971684|Blood Platelet Disorders
1011560|NCT01971684|Immune System Diseases
1011561|NCT01971684|Hemorrhagic Disorders
1011562|NCT01971684|Autoimmune Diseases
1011563|NCT01971684|Therapeutic Uses
1011564|NCT01971658|Multiple myeloma
1011565|NCT01971658|Newly Diagnosed
1011566|NCT01971645|Dexamethasone
1011567|NCT01971645|Ropivacaine
1011568|NCT01971645|Knee arthroscopy
1011569|NCT01971645|Femoral nerve blocks
1011570|NCT01971645|Peripheral nerve blocks
1011571|NCT01971645|Adjuvant
1011572|NCT01971645|Pediatrics
1011573|NCT01971606|Statin, coronary artery bypass grafting, off-pump surgery, acute coronary syndrome
1011574|NCT01971567|Insomnia
1011575|NCT01971567|Electroencephalic
1011576|NCT01971567|Biofeedback
1011577|NCT01971567|Neural oscillations
1011578|NCT01971567|Auto calibration
1011579|NCT01971567|Relaxation
1011580|NCT01971541|mindfulness
1011581|NCT01971541|behavior therapies, cognitive
1011582|NCT01971541|posttraumatic stress disorder
1011583|NCT01971541|group therapy
1011584|NCT01971528|Muscle strength, fatigue, electromyography (EMG), central fatigue, strength straining
1011601|NCT01971450|Non-interventional
1011602|NCT01971450|Ventavis
1011603|NCT01971450|Iloprost
1011604|NCT01971450|Pulmonary hypertension
1011605|NCT01971450|Compliance
1011606|NCT01971450|Russian Federation
1011607|NCT01971437|Overactive Bladder
1011608|NCT01971437|OAB
1011609|NCT01971437|Cystoscopy
1011610|NCT01971437|Cystodistension
1011611|NCT01971437|UTI
1011612|NCT01971437|Cytokines
1011613|NCT01971424|magnesium
1011614|NCT01971424|SPPB
1011615|NCT01971424|strength
1011616|NCT01971424|physical performance
1011617|NCT01971424|24 hour magnesuria
1011618|NCT01971411|Hyperparathyroidism
1011619|NCT01971411|Hypoparathyroidism
1011620|NCT01971411|Calcium
1011621|NCT01971411|Vitamin D
1011622|NCT01971411|Bone mineral density
1011623|NCT01971411|African American
1011624|NCT01971411|Female
1011625|NCT01971411|Elderly
1011626|NCT01971398|Fetal Alcohol Spectrum Disorders (FASD)
1011627|NCT01971398|Prevention
1011628|NCT01971398|Alcohol-Exposed Pregnancy
1011629|NCT01971398|Knowledge
1011630|NCT01971398|Attitudes
1011631|NCT01971359|Stroke, Intracerebral Hemorrhage, ICH
1011632|NCT01971346|Psoriasis
1011633|NCT01971346|ENBREL
1011634|NCT01971346|etanercept
1011635|NCT01971346|anti-TNF
1011636|NCT01971333|pulse pressure variation
1011637|NCT01971333|stroke volume variation
1011638|NCT01971333|plethysmographic variation index
1011639|NCT01971333|fluid responsiveness
1011640|NCT01971294|Urinary symptoms
1011641|NCT01971294|Systemic sclerosis
1011642|NCT01971294|Severity index
1011643|NCT01971294|Urinary tract infection
1011644|NCT01971294|mortality
1011645|NCT01971294|Quality of life
1011646|NCT01971281|Pancreatic adenocarcinoma
1011647|NCT01971281|Pancreas tumor
1011648|NCT01971281|Treatment
1011649|NCT01971281|Minimal toxicity
1011650|NCT01971281|TTFields
1011651|NCT01971281|Tumor Treating Fields
1011652|NCT01971281|Novocure
1011653|NCT01971268|T3 dental implants
1011654|NCT01971268|Marginal bone loss
1011655|NCT01971268|Survival rate
1011656|NCT01971255|Influenza A
1011657|NCT01971255|HAI
1011658|NCT01971255|H1N1
1011659|NCT01971255|Challenge Study
1011660|NCT01971255|Correlates of Protection
1011661|NCT01971242|Parkinson's
1011662|NCT01971242|Parkinson's Disease
1011663|NCT01971242|Exenatide
1011664|NCT01971242|Bydureon
1011665|NCT01971216|Breastfeeding, relaxation, anxiety, infant growth
1011666|NCT01971203|seroquel XR
1011667|NCT01971203|quetiapine XR
1011668|NCT01971203|major depression
1011669|NCT01971203|generalized anxiety disorder
1011670|NCT01971203|CBT
1011671|NCT01971203|co-morbid MDD
1011672|NCT01971164|anemia
1011673|NCT01971164|chronic kidney disease
1011674|NCT01971164|hemodialysis
1011675|NCT01971151|Chronic
1011676|NCT01971151|Back pain
1011677|NCT01971151|Low back
1011678|NCT01971125|Diabetes Mellitus, Type 2
1011679|NCT01971125|Heart Diseases
1011680|NCT01971125|Left Ventricular Dysfunction
1011681|NCT01971112|Multi-vitamins
1011682|NCT01971112|Minerals
1011683|NCT01971112|Respiratory infections
1011684|NCT01971112|DTH
1011685|NCT01971112|CRP
1011686|NCT01971112|Cathelicidin
1011687|NCT01971099|sexual function
1011688|NCT01971099|hypoactive
1011689|NCT01971099|desire
1011690|NCT01971099|androgens
1011691|NCT01971073|schizophrenic patients
1011692|NCT01971073|tDCS
1011693|NCT01971073|Executive functions
1011694|NCT01971073|Dorsolateral prefrontal cortex
1011695|NCT01971060|uterine fibroids
1011696|NCT01971060|barbed suture
1011697|NCT01971060|infertility
1011698|NCT01971060|adhesions
1011699|NCT01971047|Diabetes
1011700|NCT01971047|Surgery
1011701|NCT01971047|anesthesiology
1011702|NCT01971047|endocrinology
1011703|NCT01970995|Candidate modified risk tobacco product
1011704|NCT01970995|Conventional cigarettes
1011705|NCT01970995|Reduced exposure
1011706|NCT01970995|HPHCs
1011707|NCT01970995|Ambulatory
1011708|NCT01970982|Candidate modified risk tobacco product
1011709|NCT01970982|Conventional cigarette
1011710|NCT01970982|Reduced exposure
1011711|NCT01970982|HPHCs
1011712|NCT01970982|Confinement
1011713|NCT01970969|Atrial Fibrillation
1011714|NCT01970969|Cardiac monitoring
1011715|NCT01970969|Genomics
1011716|NCT01970943|migraine, headache, episodic, chronic, pain
1011717|NCT01970930|Tissue banking
1011718|NCT01970917|tear film thickness
1011719|NCT01970917|optical coherence tomography
1011720|NCT01970917|topical lubricants
1011721|NCT01970917|tear film thickness in healthy subjects
1011722|NCT01970904|Chronic hepatitis C
1011723|NCT01970904|DEB025
1011724|NCT01970904|Alisporivir
1011725|NCT01970904|ribavirin therapy
1011726|NCT01970904|genotype 2/3 treatment naive patients
1011727|NCT01970891|Freezing of Gait
1011728|NCT01970891|Gait
1011729|NCT01970891|Comfort
1011730|NCT01970891|Pain tolerance
1011731|NCT01970891|Pain
1011732|NCT01970891|Sensory threshold
1011733|NCT01970891|Motor threshold
1011734|NCT01970891|Pain threshold
1011735|NCT01970865|Phase 1
1011736|NCT01970865|Phase 2
1011737|NCT01970865|safety
1011738|NCT01970865|pharmacokinetic
1011739|NCT01970865|pharmacodynamic
1011740|NCT01970865|efficacy
1011741|NCT01970852|Inpatient
1011742|NCT01970852|PHR Portal
1011743|NCT01970852|Information Technology
1011744|NCT01970839|Tourniquet
1011745|NCT01970839|Endoneural
1011746|NCT01970839|Ischemia
1011747|NCT01970826|aseptic sterilized field
1011748|NCT01970826|clean sterilized field
1011749|NCT01970826|dental implants
1011750|NCT01970826|Surgery
1011751|NCT01970813|Parkinson's disease
1011752|NCT01970813|Idiopathic Parkinson's disease
1011753|NCT01970813|acupuncture
1011754|NCT01970813|bee venom acupuncture
1011755|NCT01970800|IGF-1
1011756|NCT01970800|Short Stature
1011757|NCT01970800|GH
1011758|NCT01970748|Variceal bleeding
1011759|NCT01970748|Portal hypertension
1011760|NCT01970748|Hepatocellular carcinoma
1011761|NCT01970748|Endoscopic variceal ligation
1011762|NCT01970748|Non-selective beta-blocker
1011763|NCT01970709|Adverse Drug Reactions
1011764|NCT01970709|Emergency Department Visits
1011765|NCT01970709|Hospitalizations
1011766|NCT01970709|Pharmacogenomic
1011767|NCT01970696|ovarian
1011768|NCT01970696|testicular
1011769|NCT01970696|stromal
1011770|NCT01970696|Sertoli
1011771|NCT01970696|Leydig
1011772|NCT01970696|gynandroblastoma
1011773|NCT01970696|juvenile granulosa cell tumor
1011774|NCT01970696|DICER1
1011777|NCT01970644|Neoplasm metastasis
1011778|NCT01970644|Brain neoplasms
1011779|NCT01970644|Radiosurgery
1011780|NCT01970644|Cognition disorders
1011781|NCT01970644|Cranial irradiation
1011782|NCT01970631|Osteoarthritis
1011783|NCT01970631|Total Knee Replacement
1011784|NCT01970631|total Knee Arthroplasty
1011785|NCT01970631|Post-operative recovery TKR
1011786|NCT01970631|Physical Activity
1011787|NCT01970631|Motivational Interviewing
1011788|NCT01970631|Financial Incentives
1011789|NCT01970592|exercise
1011790|NCT01970592|rehabilitation
1011791|NCT01970592|walking
1011792|NCT01970566|Intense Exercise/Moderate Calorie Restriction
1011793|NCT01970566|Topiramate-Phentermine
1011794|NCT01970553|lurbinectedin
1011795|NCT01970553|PM01183
1011796|NCT01970553|tumors
1011797|NCT01970553|cancer
1011798|NCT01970553|Pharma Mar
1011799|NCT01970540|lurbinectedin
1011800|NCT01970540|PM01183
1011801|NCT01970540|tumors
1011802|NCT01970540|cancer
1011803|NCT01970540|Pharma Mar
1011804|NCT01970501|atrial fibrillation
1011805|NCT01970501|atrial flutter
1011806|NCT01970501|heart failure
1011807|NCT01970501|reduced left ventricle ejection fraction
1011808|NCT01970501|electrical cardioversion
1011809|NCT01970501|GENETIC-AF
1011810|NCT01970501|Medtronic
1011811|NCT01970501|bucindolol
1011812|NCT01970501|pharmacogenetic
1011813|NCT01970501|ARCA
1011814|NCT01970501|Toprol
1011815|NCT01970501|Toprol-XL
1011816|NCT01970501|Metoprolol
1011817|NCT01970501|Metoprolol succinate
1011818|NCT01970488|Plaque Psoriasis
1011819|NCT01970475|Arthritis
1011820|NCT01970475|Rheumatoid
1011821|NCT01970436|Prenatal care
1011822|NCT01970436|Pregnancy
1011823|NCT01970436|Obstetrics
1011824|NCT01970436|Telemedicine
1011825|NCT01970423|Patients with pacemaker or ICD therapy
1011826|NCT01970410|teriflunomide
1011827|NCT01970410|natalizumab
1011828|NCT01970410|relapsing multiple sclerosis
1011829|NCT01970384|transcranial direct current stimulation
1011830|NCT01970384|stroke-related dysphagia
1011831|NCT01970384|cortical plasticity
1011832|NCT01970371|Gram-negative
1011833|NCT01970371|bacterial infection
1011834|NCT01970371|antibacterial
1011835|NCT01970371|antimicrobial
1011836|NCT01970371|CRE
1011837|NCT01970371|CPE
1011838|NCT01970371|BSI
1011839|NCT01970371|pneumonia
1011840|NCT01970371|HABP
1011841|NCT01970371|VABP
1011842|NCT01970371|AP
1011843|NCT01970371|cUTI
1011844|NCT01970371|UTI
1011845|NCT01970358|melanoma
1011846|NCT01970358|melanoma vaccine
1011847|NCT01970358|adjuvant therapy
1011848|NCT01970345|Autism Spectrum Disorder
1011849|NCT01970345|IGF-1
1011850|NCT01970332|Peripheral Arterial Disease
1011851|NCT01970332|Peripheral Vascular Disease
1011852|NCT01970332|Claudication
1011853|NCT01970332|Myopathy
1011854|NCT01970332|Oxidative stress
1011855|NCT01970332|Mitochondrial dysfunction
1011856|NCT01970332|Biomechanics
1011857|NCT01970332|Inflammation
1011858|NCT01970306|Esophageal Reinforcement
1011859|NCT01970306|ACell MatriStem
1011860|NCT01970306|13-178
1011861|NCT01970293|Alcohol use
1011862|NCT01970293|STI
1011863|NCT01970293|Incarcerated women
1011864|NCT01970293|AA
1011865|NCT01970254|hepatitis B virus infection
1011866|NCT01970254|HBV
1011867|NCT01970254|Cancer Patients
1011868|NCT01970254|chemotherapy
1011869|NCT01970254|HBV screening strategy
1011870|NCT01970254|HBV care
1011871|NCT01970254|chronic HBV
1011872|NCT01970254|concomitant HBV infection
1011873|NCT01970254|viral infections
1011874|NCT01970241|corticosteroid
1011875|NCT01970241|diabetes
1011876|NCT01970241|insulin
1011877|NCT01970202|obesity
1011878|NCT01970202|overweight
1011879|NCT01970202|sleeve gastrectomy
1011880|NCT01970189|Immune Thrombocytopenia
1011881|NCT01970189|Primary Immune Thrombocytopenia
1011882|NCT01970189|Purpura, Thrombocytopenic, Idiopathic
1011883|NCT01970189|Autoimmune Thrombocytopenia
1011884|NCT01970189|Thrombocytopenia
1011885|NCT01970163|Diabetic foot ulcer
1011886|NCT01970163|Venous stasis ulcer
1011887|NCT01970163|Wound of the lower extremity
1011888|NCT01970163|Skin substitute
1011889|NCT01970163|Acellular Dermal Matrix
1011890|NCT01970150|rTMS
1011891|NCT01970150|Alzheimer Disease
1011892|NCT01970150|Memory
1011893|NCT01970150|attention
1011894|NCT01970150|EEG
1011895|NCT01970137|Spinocerebellar degeneration (SCD)
1011896|NCT01970137|Thyrotropin-Releasing Hormone (TRH)
1011897|NCT01970137|Spinocerebellar Ataxia (SCA)
1011898|NCT01970124|Spinocerebellar degeneration (SCD)
1011899|NCT01970124|Thyrotropin-Releasing Hormone (TRH)
1011900|NCT01970124|Spinocerebellar Ataxia (SCA)
1011901|NCT01969136|Alzheimer's disease
1011902|NCT01969136|Cognition
1011903|NCT01969136|Alpha-7 nAChR
1011904|NCT01969123|Alzheimer's disease
1011905|NCT01969123|Cognition
1011906|NCT01969123|Alpha-7 nAChR
1011907|NCT01969110|Immunonutrition
1011908|NCT01969097|Stroke
1011909|NCT01969097|Hemiparesis
1011910|NCT01969097|tDCS
1011911|NCT01969097|Motor cortex
1011912|NCT01969084|Type II Diabetes Mellitus
1011913|NCT01969084|Diabetes
1011914|NCT01969084|Metabolism
1011915|NCT01969084|Linagliptin
1011916|NCT01969084|Tradjenta
1011917|NCT01969084|Glucose
1011918|NCT01969071|levosimendan
1011919|NCT01969071|mitral valve surgery
1011920|NCT01969071|cardiopulmonary bypass
1011921|NCT01969071|serum creatinine
1011922|NCT01969071|estimated glomerular filtration rate
1011923|NCT01969071|ejection fraction
1011924|NCT01969045|felxible bronchoscopy
1011925|NCT01969045|anaesthetics
1011926|NCT01969045|transcutaneous pCO2
1011927|NCT01969045|capillary pCO2
1011928|NCT01969006|inguinal hernia, postoperative pain, localanesthesia, nerve blockage
1011929|NCT01968993|Degenerative Disc Disease
1011930|NCT01968980|High Risk of cardiovascular events
1011931|NCT01968980|Heterozygous familial hypercholesterolemia
1011932|NCT01968967|mixed dyslipidemia
1011933|NCT01968967|high risk of cardiovascular events
1011934|NCT01968967|multiple cardiovascular disease risk factors
1011935|NCT01968954|mixed dyslipidemia
1011936|NCT01968954|high risk of cardiovascular events
1011937|NCT01968941|stereotactic body radiotherapy
1011938|NCT01968941|conventional radiotherapy
1011939|NCT01968941|inoperable patients
1011940|NCT01968941|local control
1011941|NCT01968941|cancer recurrence
1011942|NCT01968941|toxicity
1011943|NCT01968941|survival
1011944|NCT01970111|Spinocerebellar degeneration (SCD)
1011945|NCT01970111|Thyrotropin-Releasing Hormone (TRH)
1011946|NCT01970111|Spinocerebellar Ataxia (SCA)
1011947|NCT01970111|Cortical Cerebellar Atrophy (CCA)
1011948|NCT01970098|Spinocerebellar degeneration (SCD)
1011949|NCT01970098|Thyrotropin-Releasing Hormone (TRH)
1011950|NCT01970098|Spinocerebellar Ataxia (SCA)
1011951|NCT01970098|Cortical Cerebellar Atrophy (CCA)
1011952|NCT01970072|Remimazolam Tosylate
1011953|NCT01970072|Phase Ⅰ study
1011954|NCT01970072|Health
1011955|NCT01970059|Hypertension
1011956|NCT01970046|SP2086
1011957|NCT01970046|Phase III
1011958|NCT01970046|combination therapy
1011959|NCT01970033|SP2086
1011960|NCT01970033|Phase III
1011961|NCT01970033|Monotherapy
1011962|NCT01970020|Healthy
1011963|NCT01970020|JNJ-38518168
1011964|NCT01970020|14C-JNJ-38518168
1011965|NCT01970020|Absorption
1011966|NCT01970020|Metabolism
1011967|NCT01970020|Excretion
1011968|NCT01970007|venous
1011969|NCT01970007|outflow obstruction
1011970|NCT01970007|iliofemoral vein
1011971|NCT01969994|Epicatechin
1011972|NCT01969994|Flavanols
1011973|NCT01969994|Procyanidins
1011974|NCT01969994|Polyphenols
1011975|NCT01969994|Phytonutrients
1011976|NCT01969994|AMDE
1011977|NCT01969994|Antioxidants
1011978|NCT01969981|Peripheral Inserted Central Catheter
1011979|NCT01969955|nanoparticle albumin-bound paclitaxel
1011980|NCT01969955|Squamous Cell Carcinoma of Lung
1011981|NCT01969942|Ewings sarcoma
1011982|NCT01969916|Cardiac CT imaging
1011983|NCT01969916|Myocardial ischemia
1011984|NCT01969916|Myocardial perfusion
1011985|NCT01969916|Vasodilator stress testing
1011986|NCT01969916|Regadenoson
1011987|NCT01969903|brachial plexus block
1011988|NCT01969903|lidocaine
1011989|NCT01969903|dexmedetomidine
1011990|NCT01969903|bradycardia
1011991|NCT01969903|hypotension
1011992|NCT01969877|Head and neck cancer
1011993|NCT01969877|Cetuximab
1011994|NCT01969877|Cisplatin
1011995|NCT01969877|Radiotherapy
1011996|NCT01969877|Quality of life
1011997|NCT01969877|Human papilloma virus
1011998|NCT01969877|Health economy
1011999|NCT01969877|Biomarker investigations
1012000|NCT01969864|Randomized Controlled Trial
1012001|NCT01969864|Healthcare Disparities
1012002|NCT01969851|Lacosamide
1012003|NCT01969851|Vimpat
1012004|NCT01969851|Epilepsy
1012005|NCT01969851|Children
1012006|NCT01969825|Infertility
1012007|NCT01969825|Intrauterine insemination
1012008|NCT01969825|Male factor infertility
1012009|NCT01969825|Massage
1012010|NCT01969825|Total motile sperm count
1012011|NCT01969812|Infertility
1012012|NCT01969812|Intrauterine Insemination
1012013|NCT01969812|Slow-release Insemination
1012014|NCT01969812|Evie
1012015|NCT01969799|Gram-negative pneumonia
1012016|NCT01969799|Aerosol antibiotics
1012017|NCT01969799|Mechanical ventilation
1012018|NCT01969799|Amikacin
1012019|NCT01969799|Fosfomycin
1012020|NCT01969799|Pneumonia, Bacterial
1012021|NCT01969799|Pneumonia
1012022|NCT01969799|Bacterial Infections
1012023|NCT01969799|Lung Diseases
1012024|NCT01969799|Respiratory Tract Diseases
1012025|NCT01969799|Respiratory Tract Infections
1012026|NCT01969799|Anti-Bacterial Agents
1012027|NCT01969799|Anti-Infective Agents
1012028|NCT01969799|Therapeutic Uses
1012029|NCT01969799|Pharmacologic Actions
1012030|NCT01969773|Botulinum Toxin A (BoNT-A)
1012031|NCT01969773|Interstitial Cystitis
1012032|NCT01969734|Emphysema
1012033|NCT01969734|Moderate COPD
1012034|NCT01969734|Hyperinflation
1012035|NCT01969734|Endobronchial valves
1012036|NCT01969695|non-Hodgkin's lymphoma
1012037|NCT01969695|ABT-199
1012038|NCT01969695|Safety
1012039|NCT01969695|Refractory
1012040|NCT01969695|GDC-0199
1012041|NCT01969695|Relapsed
1012042|NCT01969695|Cancer
1012043|NCT01969682|non-Hodgkin's lymphoma
1012044|NCT01969682|GDC-0199
1012045|NCT01969682|Safety
1012046|NCT01969682|Relapsed
1012047|NCT01969682|Refractory
1012048|NCT01969682|ABT-199
1012049|NCT01969682|Pharmacokinetics
1012050|NCT01969682|Cancer
1012051|NCT01969669|non-Hodgkin's lymphoma
1012052|NCT01969669|GDC-0199
1012053|NCT01969669|Safety
1012054|NCT01969669|Relapsed
1012055|NCT01969669|Refractory
1012056|NCT01969669|ABT-199
1012057|NCT01969669|Pharmacokinetics
1012058|NCT01969669|Cancer
1012066|NCT01969630|femoropopliteal lesions
1012067|NCT01969604|Rheumatoid Arthritis
1012068|NCT01969604|Sedentary Behaviour
1012069|NCT01969604|Motivational Counselling
1012070|NCT01969604|Short Text Message Service
1012071|NCT01969604|Fatigue
1012072|NCT01969604|Pain
1012073|NCT01969604|Self-efficacy
1012074|NCT01969604|ActivPAL
1012075|NCT01969591|Fast track surgery, Laparoscopic surgery, colorectal cancer
1012076|NCT01969578|salivary duct cancer
1012077|NCT01969578|adenocarcinoma, NOS
1012078|NCT01969578|androgen deprivation
1012079|NCT01969578|androgen receptor
1012080|NCT01969552|TSH, thyroid hormones, thyroid tresting, levothyroxine
1012081|NCT01969526|Frail elderly
1012082|NCT01969513|Vestibular Diseases
1012083|NCT01969513|Vertigo
1012084|NCT01969513|Primary care
1012085|NCT01969513|Epley maneuver
1012086|NCT01969500|Schizophrenia
1012087|NCT01969500|Schizoaffective Disorder
1012088|NCT01969500|Self Management of Schizophrenia
1012089|NCT01969500|SOS
1012090|NCT01969500|SMI
1012091|NCT01969500|Psychosis
1012092|NCT01969500|Social Dysfunction
1012093|NCT01969500|Medication Adherence
1012094|NCT01969500|Mobile Application
1012095|NCT01969500|EHealth
1012096|NCT01969500|E-Health
1012097|NCT01969500|Health Technology
1012098|NCT01969500|mHealth
1012099|NCT01969500|m-Health
1012100|NCT01969474|Tinnitus Cannabis
1012101|NCT01969461|HIV positive
1012102|NCT01969461|Adolescents
1012103|NCT01969461|Adolescent Trials Network
1012104|NCT01969461|Comparative Effectiveness Trial
1012105|NCT01969461|Implementation
1012106|NCT01969461|Adherence Intervention
1012107|NCT01969461|Alcohol Intervention
1012108|NCT01969448|Nipple-areola skin sparing mastectomy
1012109|NCT01969448|Immediate reconstruction
1012110|NCT01969448|Prophylactic Mastectomy
1012111|NCT01969448|Breast-Q
1012112|NCT01969448|Breast Cancer
1012113|NCT01969448|Ductal Carcinoma in Situ - Category
1012114|NCT01969409|Lung
1012115|NCT01969409|Fibrosis
1012116|NCT01969396|Biopsy
1012117|NCT01969396|Endometrial biopsy
1012118|NCT01969396|Endometrial sampling
1012119|NCT01969396|sonohysterography
1012120|NCT01969383|healthy
1012121|NCT01969370|Cancer
1012122|NCT01969370|Cardiovascular disease
1012123|NCT01969370|Neurodegenerative disease
1012124|NCT01969370|Neurodevelopmental disease
1012125|NCT01969370|Dysmorphology
1012126|NCT01969370|Hearing loss
1012127|NCT01969370|Other conditions, including ophthalmic conditions
1012128|NCT01969357|Sp2086
1012129|NCT01969357|Phase II
1012130|NCT01969357|monotherapy
1012131|NCT01969331|Gastritis
1012132|NCT01969331|Helicobacter pylori
1012133|NCT01969318|SP2086
1012134|NCT01969318|Phase II
1012135|NCT01969318|combination therapy
1012136|NCT01969305|Kazakhstan
1012137|NCT01969305|Central Asia
1012138|NCT01969305|HIV prevention
1012139|NCT01969305|Adolescents
1012140|NCT01969305|Sexual risk behaviors
1012141|NCT01969305|Drug abuse prevention
1012142|NCT01969305|Multi-media intervention
1012143|NCT01969305|Drug use
1012144|NCT01969292|colonoscopy
1012145|NCT01969292|quality assurance
1012146|NCT01969279|Osteoporosis
1012147|NCT01969279|Bisphosphonate
1012148|NCT01969279|Atypical femoral fracture
1012149|NCT01969279|Side effect
1012150|NCT01969266|Healthy volunteer
1012151|NCT01969266|PCI-32765
1012152|NCT01969266|PCI 45227
1012153|NCT01969266|JNJ-54179060
1012154|NCT01969266|Pharmacokinetic
1012155|NCT01969253|Breast Cancer, Axillary Lymph Node Dissection, Lymphedema
1012156|NCT01969240|Chest Pain
1012157|NCT01969240|Decision Aid
1012158|NCT01969240|Acute Coronary Syndrome
1012159|NCT01969240|Cardiac
1012160|NCT01969240|Emergency Department
1012161|NCT01969240|Cardiac Testing
1012162|NCT01969240|Healthcare Utilization
1012163|NCT01969240|Patient Centered Outcomes
1012164|NCT01969240|Shared Decision Making
1012165|NCT01969240|Unnecessary hospital admissions
1012166|NCT01969201|In vitro fertilization (IVF)
1012167|NCT01969201|Assisted reproduction technologies (ART)
1012168|NCT01969201|GnRH-antagonist
1012169|NCT01969201|Follicle stimulating hormone (FSH)
1012170|NCT01969188|spondyloarthritis
1012171|NCT01969188|ankylosing spondylitis
1012172|NCT01969188|psoriatic arthritis
1012173|NCT01969149|Stress Hyperglycemia
1012174|NCT01969149|Perioperative glycemic control
1012175|NCT01969149|Cardiac surgery
1012176|NCT01969149|Coronary artery bypass surgery
1012177|NCT01968928|Bladder urothelial carcinoma (UC)
1012178|NCT01968928|pyruvate kinase
1012179|NCT01968928|drug resistance
1012180|NCT01968928|shikonin
1012181|NCT01968915|LCL161, Paclitaxel, Japanese patient, Neoplasms
1012182|NCT01968902|spasticity
1012183|NCT01968902|lower limb
1012184|NCT01968902|multiple sclerosis
1012185|NCT01968902|toxin
1012186|NCT01968889|Critical illness neuromyopathy
1012187|NCT01968889|Diaphragm dysfunction
1012188|NCT01968889|Mechanical ventilation
1012189|NCT01968889|Weaning
1012190|NCT01968889|Ultrasound
1012191|NCT01968850|osteoporosis
1012192|NCT01968850|HIV
1012193|NCT01968850|bone Mineral Density
1012194|NCT01968850|alendronate
1012195|NCT01968850|vitamin D
1012196|NCT01968824|pain
1012197|NCT01968798|ACES
1012198|NCT01968798|ASPREE Cancer Endpoints Study
1012199|NCT01968798|Cancer
1012200|NCT01968798|Aspirin
1012201|NCT01968798|Tumor
1012202|NCT01968772|Fibromyalgia
1012203|NCT01968772|Fibromyalgia Syndrome
1012204|NCT01968772|Magnesium Chloride
1012205|NCT01968772|Transdermal Magnesium Chloride
1012206|NCT01968759|Chronic kidney disease
1012207|NCT01968759|Sevelamer carbonate
1012208|NCT01968759|Proteinuria
1012209|NCT01968759|Phosphate binders
1012210|NCT01968746|Sepsis
1012211|NCT01968746|Shock
1012212|NCT01968733|Pneumonia
1012213|NCT01968733|CABP
1012214|NCT01968733|CAP
1012215|NCT01968733|Macrolide
1012216|NCT01968707|surgical prep
1012217|NCT01968707|CHG
1012218|NCT01968707|IPA
1012219|NCT01968694|endometriosis
1012220|NCT01968694|chronic pain
1012221|NCT01968694|intravenous lidocaine
1012222|NCT01968668|BAY94-8862
1012223|NCT01968668|MR antagonist
1012224|NCT01968668|Diabetic nephropathy
1012225|NCT01968668|Japanese patients
1012226|NCT01968655|Factor VIII Inhibitory Auto-antibodies
1012227|NCT01968642|Transthoracic echocardiograms
1012228|NCT01968642|Appropriate Use Criteria
1012229|NCT01968642|Medical Education
1012230|NCT01968629|Hepatocellular Carcinoma
1012231|NCT01968590|Vitamin D
1012232|NCT01968590|Cholecalciferol
1012233|NCT01968590|Bone density
1012234|NCT01968577|Coronary angioplasty
1012235|NCT01968577|Myocardial infarction
1012236|NCT01968551|HIV-1
1012237|NCT01968551|HIV
1012238|NCT01968551|Treatment-Experienced
1012239|NCT01968525|anemia
1012240|NCT01968525|non-hypoxic apnoea
1012241|NCT01968525|tracheal intubation
1012242|NCT01968525|anesthesia
1012243|NCT01968512|Attention Deficit Hyperactivity Disorder (ADHD);
1012244|NCT01968512|Transcranial Direct Current Stimulation (tDCS);
1012245|NCT01968512|Control Inhibitory;
1012246|NCT01968512|Quantitative electroencephalography;
1012247|NCT01968512|Functional Brain Network;
1012248|NCT01968512|Go/No Go test.
1012249|NCT01968499|coronary stent implantation; clopidogrel low response
1012250|NCT01968473|Parkinson's disease
1012251|NCT01968473|Freezing of Gait
1012252|NCT01968473|Neuromuscular Electrical Stimulation
1012253|NCT01968473|Comfort
1012254|NCT01968473|Pain tolerance
1012255|NCT01968473|Pain
1012256|NCT01968473|Sensory threshold
1012257|NCT01968473|Motor threshold
1012258|NCT01968473|Pain threshold
1012259|NCT01968460|Parkinson's Disease, Rasagiline, Pramipexole
1012260|NCT01968434|cough
1012261|NCT01968434|common cold
1012262|NCT01968434|antitussive agents
1012263|NCT01968434|mucosal protection
1012264|NCT01968434|medical device
1012265|NCT01968421|OM-85, bronchiectasis, placebo, acute exacerbation
1012266|NCT01968408|nosocomial diarrhea
1012267|NCT01968408|Lactobacillus reuteri DSM 17938
1012268|NCT01968408|rotavirus diarrhea
1012269|NCT01968408|probiotics
1012270|NCT01968382|IMM 124-E
1012271|NCT01968382|Bovine Colostrum
1012272|NCT01968382|Alcoholic
1012273|NCT01968382|Hepatitis
1012274|NCT01968382|LPS
1012275|NCT01968382|Hyper-immune
1012276|NCT01968369|flow mediated vasodilatation
1012277|NCT01968369|tomato
1012278|NCT01968369|arterial stiffness
1012279|NCT01968369|lycopene
1012280|NCT01968356|surgical skin prep
1012281|NCT01968356|CHG
1012282|NCT01968356|IPA
1012283|NCT01968317|Endometrial Atypical Hyperplasia
1012284|NCT01968317|Endometrial Adenocarcinoma
1012285|NCT01968317|Conservative Medication
1012286|NCT01968304|Iron Status, Cancer
1012287|NCT01968291|Health Literacy
1012288|NCT01968291|Teach-back
1012289|NCT01968291|Emergency
1012290|NCT01968265|Type 2 Diabetes Mellitus
1012291|NCT01968265|T2DM
1012292|NCT01968252|Speckle-tracking echocardiography
1012293|NCT01968252|Transthoracic echocardiography
1012294|NCT01968252|Transesophageal echocardiography
1012295|NCT01968239|BRVO
1012296|NCT01968239|Macular edema
1012297|NCT01968239|Ranibizumab
1012298|NCT01968239|re-treatment
1012299|NCT01968226|carotid artery disease
1012300|NCT01968226|carotid stenosis
1012301|NCT01968226|carotid endarterectomy
1012302|NCT01968226|RDG-K5
1012303|NCT01968226|PET imaging
1012304|NCT01968213|ARIEL3
1012305|NCT01968213|ARIEL 3
1012306|NCT01968213|platinum sensitive
1012307|NCT01968213|PARP Inhibitor
1012308|NCT01968213|rucaparib
1012309|NCT01968213|homologous recombination
1012310|NCT01968213|homologous recombination deficiency
1012311|NCT01968213|CO-338
1012312|NCT01968213|PF 01367338
1012313|NCT01968213|AG 14699
1012314|NCT01968213|platinum sensitive ovarian cancer
1012315|NCT01968213|platinum sensitive fallopian tube cancer
1012316|NCT01968213|platinum sensitive primary peritoneal cancer
1012317|NCT01968213|platinum sensitive peritoneal cancer
1012318|NCT01968213|gynecological cancer
1012319|NCT01968213|Clovis
1012320|NCT01968213|Clovis Oncology
1012321|NCT01968200|cancer
1012322|NCT01968200|chemotherapy
1012323|NCT01968200|anthracyclines
1012324|NCT01968174|astigmatism
1012325|NCT01968174|lid surgery
1012326|NCT01968174|older than 40 years
1012327|NCT01968174|can sign an acceptance form
1012328|NCT01968174|uper lid surgery
1012329|NCT01968148|glucose
1012330|NCT01968148|cardiac arrest
1012331|NCT01968148|resuscitation
1012332|NCT01968148|insulin
1012333|NCT01968148|GLP-1
1012334|NCT01968122|symptomatic Intracranial artery stenosis
1012335|NCT01968122|conventional treatment
1012336|NCT01968122|stenting
1012337|NCT01968122|stroke prevention
1012338|NCT01968122|medical treatment
1012339|NCT01968122|endovascular treatment
1012340|NCT01968096|Reflex
1012341|NCT01968096|Post activation
1012342|NCT01968096|Spinal cord injury
1012343|NCT01968096|Pre-synaptic inhibition
1012344|NCT01968096|Machine driven passive strech
1012345|NCT01968044|renal impairment
1012346|NCT01968031|Parkinson's disease
1012347|NCT01968031|Moderate to Severe Parkinson's Disease
1012348|NCT01968018|Cancer
1012349|NCT01968018|Chronic Cancer Pain
1012350|NCT01968018|Tramadol HCI
1012351|NCT01968018|Acetaminophen
1012352|NCT01968018|Analgesics
1012353|NCT01968018|Pain assessment
1012354|NCT01967992|diabetes
1012355|NCT01967992|obesity
1012356|NCT01967992|mindful eating
1012357|NCT01967992|positive affect
1012358|NCT01967992|low carbohydrate
1012359|NCT01967992|ketogenic
1012360|NCT01967992|diet
1012361|NCT01967940|HIV-1
1012362|NCT01967940|HIV
1012363|NCT01967940|Treatment-Experienced
1012364|NCT01967927|carcinoma
1012365|NCT01967927|cancer
1012366|NCT01967927|head
1012367|NCT01967927|neck
1012368|NCT01967927|otolaryngology
1012369|NCT01967901|Diabetic nephropathies
1012370|NCT01967901|Nursing
1012371|NCT01967901|Multidisciplinary
1012372|NCT01967901|Self-care
1012373|NCT01967901|Quality of Life
1012374|NCT01967888|Pancreatic islet auto-transplantation
1012375|NCT01967875|Gastric Cancer
1012376|NCT01967875|ERCC1
1012377|NCT01967875|Platinum
1012378|NCT01967875|Chemotherapy
1012379|NCT01967849|obesity
1012380|NCT01967849|type 2 diabetes
1012381|NCT01967836|Invasive Line
1012382|NCT01967836|IV Dressing protection
1012383|NCT01967836|Hygiene
1012384|NCT01967836|Oncology
1012385|NCT01967836|Ambulatory Care
1012390|NCT01967810|glioma
1012391|NCT01967810|glioblastoma
1012392|NCT01967810|brain cancer
1012393|NCT01967810|brain tumor
1012394|NCT01967810|recurrent
1012395|NCT01967797|Obesity
1012396|NCT01967784|Influenza
1012397|NCT01967784|Quadrivalent Inactivated Influenza Vaccine
1012398|NCT01967771|healthy volunteers
1012399|NCT01967771|drug interaction
1012400|NCT01967771|carbamazepine
1012401|NCT01967771|Dolutegravir
1012402|NCT01967771|pharmacokinetics
1012403|NCT01967758|Astrocytic Tumors
1012404|NCT01967758|Glioblastoma Multiforme
1012405|NCT01967758|Anaplastic Astrocytoma
1012406|NCT01967758|Brain Tumor
1012407|NCT01967758|Brain Cancer
1012408|NCT01967758|Immunotherapy
1012409|NCT01967745|open appendectomy
1012410|NCT01967745|laparoscopic appendectomy
1012411|NCT01967745|appendicitis
1012412|NCT01967732|Smoking
1012413|NCT01967732|Nicotine absorption
1012414|NCT01967732|Modified risk tobacco product
1012415|NCT01967732|Conventional cigarette
1012416|NCT01967732|Nicotine replacement therapy
1012417|NCT01967732|Nicotine nasal spray
1012418|NCT01967719|Smoking
1012419|NCT01967719|Nicotine absorption
1012420|NCT01967719|Candidate modified risk tobacco product
1012421|NCT01967719|Conventional cigarette
1012422|NCT01967719|Nicotine replacement therapy: nasal spray
1012423|NCT01967706|Smoking
1012424|NCT01967706|Nicotine absorption
1012425|NCT01967706|Modified risk tobacco product
1012426|NCT01967706|Conventional cigarette
1012427|NCT01967706|Nicotine replacement therapy
1012428|NCT01967706|Nicotine gum
1012429|NCT01967693|Laryngeal contact granuloma
1012430|NCT01967693|Treatment type
1012431|NCT01967693|Outcome
1012432|NCT01967641|opioid dependence
1012433|NCT01967641|opioid abuse
1012434|NCT01967641|suboxone
1012435|NCT01967641|prescription pain medications
1012436|NCT01967628|Vitamin D
1012437|NCT01967628|Respiratory infection
1012438|NCT01967628|Innate immunity
1012439|NCT01967615|PCI,
1012440|NCT01967615|CTO,
1012441|NCT01967615|bifurcation,
1012442|NCT01967615|clopidogrel,
1012443|NCT01967615|prasugrel,
1012444|NCT01967615|ticagrelor
1012445|NCT01967602|Acute respiratory distress syndrome (ARDS)
1012446|NCT01967602|Extracorporeal membrane oxygenation (ECMO)
1012447|NCT01967602|biomarker
1012453|NCT01967563|Energy Expenditure
1012454|NCT01967563|Obesity
1012455|NCT01967563|Carbohydrate
1012456|NCT01967563|Fat
1012457|NCT01967563|Ketones
1012458|NCT01967550|Symptomatic knee OA Kellgren-Lawrence grade 1-3
1012459|NCT01967537|NET
1012460|NCT01967537|MEN1
1012461|NCT01967537|Von Hippel Lindau (VHL)
1012462|NCT01967537|Surgical Resection
1012463|NCT01967537|Somatostatin Receptor Status
1012464|NCT01967524|Myofascial pain
1012465|NCT01967524|Perineal pain
1012466|NCT01967524|Chronic pelvic pain
1012467|NCT01967524|Botulinum toxin type A
1012468|NCT01967524|Ropivacaïne
1012469|NCT01967511|Cross-sectional study
1012470|NCT01967511|Fibromuscular dysplasia
1012471|NCT01967511|Fibroblast
1012472|NCT01967511|Spontaneous Coronary Artery Dissection
1012473|NCT01967511|Cervical Artery Dissection
1012474|NCT01967498|chronic otitis media with effusion
1012475|NCT01967498|conductive hearing loss
1012476|NCT01967485|Attention Deficit Hyperactivity Disorder
1012477|NCT01967485|Medication adherence
1012478|NCT01967485|Disease management
1012479|NCT01967485|Text message
1012480|NCT01967485|ADHD
1012481|NCT01967485|Children
1012482|NCT01967485|Reminder systems
1012483|NCT01967485|Text Messaging
1012484|NCT01967485|Telemedicine
1012485|NCT01967433|Fentanyl
1012486|NCT01967433|Midazolam
1012487|NCT01967433|Sedation
1012488|NCT01967433|Patient tolerance
1012489|NCT01967433|Duration of colonoscopy
1012490|NCT01967420|Cognitive remediation
1012491|NCT01967420|Social cognition training
1012492|NCT01967420|First episode psychosis
1012493|NCT01967420|Schizophrenia
1012494|NCT01967407|kidney tumor
1012495|NCT01967407|renal cell cancer
1012496|NCT01967407|RCC
1012497|NCT01967407|irreversible electroporation
1012498|NCT01967407|IRE
1012499|NCT01967407|partial kidney resection
1012500|NCT01967407|percutaneous
1012501|NCT01967407|ablation
1012502|NCT01967407|IRENE
1012503|NCT01967394|Health Care Quality
1012504|NCT01967394|Access
1012505|NCT01967394|Evaluation
1012506|NCT01967368|Influenza vaccine
1012507|NCT01967368|intradermal
1012508|NCT01967368|intramuscular
1012509|NCT01967368|efficacy
1012510|NCT01967368|safety
1012511|NCT01967355|preeclampsia
1012512|NCT01967355|lipid apheresis
1012513|NCT01967355|apheresis
1012514|NCT01967342|chronic pain
1012515|NCT01967342|pain
1012516|NCT01967342|chronic pain syndrome
1012517|NCT01967342|widespread chronic pain
1012518|NCT01967342|back pain
1012519|NCT01967342|literacy
1012520|NCT01967342|health literacy
1012521|NCT01967342|group therapy
1012522|NCT01967342|psychosocial treatment
1012523|NCT01967342|cognitive-behavioral therapy
1012524|NCT01967342|pain education
1012525|NCT01967342|health disparities
1012526|NCT01967342|patient-centered outcomes
1012527|NCT01967303|Restless legs syndrome
1012528|NCT01967303|Stroke
1012529|NCT01967303|Transient ischemic attack
1012530|NCT01967303|Cerebrovascular risk factors
1012531|NCT01967290|stroke
1012532|NCT01967290|motor deficits
1012533|NCT01967290|motor rehabilitation
1012534|NCT01967290|neurorehabilitation
1012535|NCT01967290|medical devices
1012536|NCT01967290|wearable devices
1012537|NCT01967290|e-health systems
1012538|NCT01967264|Drug therapy
1012539|NCT01967251|Prostatic Hyperplasia
1012540|NCT01967251|Phosphodiesterase 5 inhibitors
1012541|NCT01967251|Erectile DysfunctionDrug Therapy
1012542|NCT01967238|immune response
1012543|NCT01967225|Methicillin Resistant Staphylococcus Aureus,
1012544|NCT01967225|Skin and soft tissue infection,
1012545|NCT01967225|Bacteremia,
1012546|NCT01967225|Tedizolid
1012547|NCT01967212|stroke
1012548|NCT01967212|swallowing training
1012549|NCT01967212|game-based
1012550|NCT01967212|biofeedback
1012551|NCT01967199|drug-eluting stent
1012552|NCT01967199|drug-coated Balloon
1012553|NCT01967199|recurrent In-Stent restenosis
1012554|NCT01967186|Type 1 diabetes
1012555|NCT01967186|islets
1012556|NCT01967186|transplantation
1012557|NCT01967186|nephropathy
1012558|NCT01967186|intramuscular
1012559|NCT01967173|Asthma
1012560|NCT01967173|Fluticasone
1012561|NCT01967173|Salmeterol
1012562|NCT01967147|Dry eye
1012563|NCT01967147|Lipid deficiency
1012564|NCT01967147|Tear film break-up time
1012565|NCT01967134|HIV Negative
1012566|NCT01967121|Compex, ice
1012567|NCT01967095|Erlotinib
1012568|NCT01967095|12-278
1012569|NCT01967095|CNS involvement
1012570|NCT01967082|Cancer Prevention
1012571|NCT01967082|Tobacco Control Program for Youth
1012572|NCT01967082|Smoking cessation
1012573|NCT01967082|Smoking prevention
1012574|NCT01967082|Smokers
1012575|NCT01967082|Non smokers
1012576|NCT01967082|Students
1012577|NCT01967082|University of Houston
1012578|NCT01967082|Survey
1012579|NCT01967082|Questionnaire
1012580|NCT01967082|Telephone survey
1012581|NCT01967082|Smart phone application
1012582|NCT01967056|Muscle strength
1012583|NCT01967056|respiratory failure
1012584|NCT01967056|extubation failure
1012585|NCT01967056|intensive care unit
1012586|NCT01967056|outcome prediction
1012587|NCT01967030|gestational diabetes mellitus
1012588|NCT01967030|breastfeeding
1012589|NCT01967030|obesity
1012590|NCT01967030|diabetes
1012591|NCT01967030|lactation
1012592|NCT01967017|Intrauterine device
1012593|NCT01967017|Paracervical block
1012594|NCT01966991|Down syndrome
1012595|NCT01966991|prenatal screening
1012596|NCT01966991|trisomy 21
1012597|NCT01966991|patient satisfaction
1012598|NCT01966978|Diabetes Mellitus, Type 2
1012599|NCT01966978|Insulin
1012600|NCT01966978|Insulin, Long-Acting
1012601|NCT01966978|Insulin, Short Acting
1012602|NCT01966978|Detemir
1012603|NCT01966978|Liraglutide
1012604|NCT01966978|GLP-1
1012605|NCT01966978|Glucagon Like Peptide
1012606|NCT01966978|Metformin
1012607|NCT01966978|Uncontrolled Diabetes
1012608|NCT01966978|Elevated A1c
1012609|NCT01966978|Incretins
1012610|NCT01966965|PIOLIN®, PEDICULOSIS, EFFICACY, SAFETY, PHYTOMEDICINE,
1012611|NCT01966965|ARRUDA, RUTA
1012612|NCT01966952|Hypertension
1012613|NCT01966939|craniotomy
1012614|NCT01966939|craniectomy
1012615|NCT01966939|temporalis
1012616|NCT01966939|TMJ
1012617|NCT01966939|mastication
1012618|NCT01966939|QoL
1012619|NCT01966926|self monitoring
1012620|NCT01966926|self weighing
1012621|NCT01966926|weight tracking
1012622|NCT01966926|psychosocial outcomes
1012623|NCT01966926|feasibility
1012624|NCT01966913|Germ Cell Tumors
1012625|NCT01966913|Bevacizumab
1012626|NCT01966913|salvage therapy
1012627|NCT01966900|Human immunodeficiency disease
1012628|NCT01966900|HIV
1012629|NCT01966900|Vaccine
1012630|NCT01966900|CN54gp140
1012631|NCT01966900|Glucopyranosyl lipid adjuvant
1012632|NCT01966900|GLA
1012633|NCT01966900|GLA-AF
1012634|NCT01966887|Heart failure
1012635|NCT01966887|Gene therapy
1012636|NCT01966887|Serca2a
1012637|NCT01966887|Cardiomyopathy
1012638|NCT01966874|Medical abortion
1012639|NCT01966874|Mifepristone
1012640|NCT01966874|Misoprostol
1012641|NCT01966874|Zacafemyl
1012642|NCT01966874|Mexico
1012643|NCT01966861|mechanical ventilation
1012644|NCT01966861|weaning
1012645|NCT01966861|acute respiratory failure
1012646|NCT01966861|weaning failure
1012647|NCT01966861|lung ultrasound
1012648|NCT01966848|Knee
1012649|NCT01966848|osteoarthritis
1012650|NCT01966848|arthroplasty
1012651|NCT01966848|tka
1012652|NCT01966848|rsa
1012653|NCT01966835|sleep quality
1012654|NCT01966835|sleep disturbances
1012655|NCT01966835|high intensity aerobic interval training
1012656|NCT01966835|rheumatoid arthritis
1012657|NCT01966835|fatigue
1012658|NCT01966835|pain
1012659|NCT01966835|polysomnography
1012660|NCT01966835|watt max
1012661|NCT01966822|Osteoporosis
1012662|NCT01966822|Bone mineral density
1012663|NCT01966822|Dual-energy X-ray absorptiometry
1012664|NCT01966822|HIV infection
1012665|NCT01966822|Dolutegravir
1012666|NCT01966822|Integrase inhibitor
1012667|NCT01966809|Brain Tumor
1012668|NCT01966809|Photodynamic Therapy
1012669|NCT01966809|Photochemotherapy
1012670|NCT01966809|Astrocytoma
1012671|NCT01966809|Pilocytic Astrocytoma
1012672|NCT01966809|Low grade Astrocytoma
1012673|NCT01966809|Anaplastic Astrocytoma
1012674|NCT01966809|Glioblastoma
1012675|NCT01966809|GBM
1012676|NCT01966809|Chordoma
1012677|NCT01966809|Germinoma
1012678|NCT01966809|Germ Cell Tumor
1012679|NCT01966809|Non-germinoma
1012680|NCT01966809|CNS Lymphoma
1012681|NCT01966809|Craniopharyngioma
1012682|NCT01966809|Mixed Glioma
1012683|NCT01966809|Optic Nerve Glioma
1012684|NCT01966809|Meningioma
1012685|NCT01966809|Oligodendroglioma
1012686|NCT01966809|Pituitary Tumors
1012687|NCT01966809|Desmoplastic Neuroepithelial Tumor
1012688|NCT01966809|DNET
1012689|NCT01966809|glioblastoma multiforme
1012690|NCT01966809|glioma
1012691|NCT01966809|glioblastoma survivors
1012692|NCT01966809|what is glioblastoma
1012693|NCT01966809|gbm cancer
1012694|NCT01966809|oligoastrocytoma
1012695|NCT01966809|gbm tumor
1012696|NCT01966809|anaplastic oligodendroglioma
1012697|NCT01966809|High-Grade Glioma
1012698|NCT01966809|high grade glioma
1012699|NCT01966809|glioblastomas
1012700|NCT01966809|glioblastoma cancer
1012701|NCT01966809|anaplastic oligoastrocytoma
1012702|NCT01966809|astrocytoma glioma
1012703|NCT01966809|glioblastoma clinical trials
1012704|NCT01966809|photodynamic therapy for cancer
1012705|NCT01966809|glioblastoma multiforme clinical trials
1012706|NCT01966809|astrocytoma glioblastoma
1012707|NCT01966809|gbm grade 4
1012708|NCT01966809|clinical trials for glioblastoma
1012709|NCT01966809|photodynamic therapy cancer
1012710|NCT01966809|clinical trials glioblastoma
1012711|NCT01966809|glioblastoma clinical trials 2015
1012712|NCT01966809|glioblastoma clinical trials 2014 not open in 2014
1012713|NCT01966809|glioblastoma trials
1012714|NCT01966809|gbm clinical trials
1012715|NCT01966809|glioblastoma immunotherapy
1012716|NCT01966809|malignant gliomas
1012717|NCT01966809|anaplastic astrocytomas
1012718|NCT01966809|immunotherapy for glioblastoma
1012719|NCT01966809|immunotherapy glioblastoma
1012720|NCT01966809|High Grade Glioblastoma Multiforme
1012721|NCT01966809|clinical trial glioblastoma
1012722|NCT01966809|glioblastoma clinical trial
1012723|NCT01966809|glioblastoma trial
1012724|NCT01966809|brain tumors
1012725|NCT01966809|recurrent brain tumors
1012726|NCT01966809|glioma grade 3
1012727|NCT01966809|grade 3 brain tumor
1012728|NCT01966809|grade 4 brain tumor
1012729|NCT01966796|healthcare associated pneumonia
1012730|NCT01966796|drug-resistant bacteria
1012731|NCT01966796|pneumonia severity index
1012732|NCT01966757|Neuronal Ceroid Lipofuscinosis
1012733|NCT01966757|NCL
1012734|NCT01966757|Batten's Disease
1012735|NCT01966757|Children's Sleep Habits Questionnaire
1012736|NCT01966757|Restless Leg Syndrome
1012737|NCT01966731|Africa
1012738|NCT01966718|Rheumatoid arthritis
1012739|NCT01966718|Joint pain
1012740|NCT01966718|Repository corticotropin injection
1012741|NCT01966705|severe health anxiety
1012742|NCT01966705|somatic symptom disorder
1012743|NCT01966705|illness anxiety disorder
1012744|NCT01966705|cognitive behavior therapy
1012745|NCT01966705|bibliotherapy
1012746|NCT01966705|internet
1012747|NCT01966705|exposure
1012748|NCT01966692|Bioequivalence
1012749|NCT01966692|Fluticasone Propionate
1012750|NCT01966666|Alzheimer's disease
1012751|NCT01966666|mild to moderate
1012752|NCT01966653|nitrofurantoin
1012753|NCT01966653|fosfomycin
1012754|NCT01966653|urinary tract infection
1012755|NCT01966653|clinical efficacy
1012756|NCT01966653|bacteriologic response
1012757|NCT01966640|diagnosis of allergy
1012758|NCT01966640|Basophil Activation Test
1012759|NCT01966627|non alcoholic fatty liver
1012760|NCT01966627|childhood obesity
1012761|NCT01966627|genetic variants
1012762|NCT01966614|Benign prostatic hyperplasia
1012763|NCT01966614|BPH
1012764|NCT01966614|Enlarged prostate
1012765|NCT01966614|Lower urinary tract symptoms (LUTS)
1012766|NCT01966588|Antipsychotic agents
1012767|NCT01966588|Adverse effects
1012768|NCT01966588|Genomics
1012769|NCT01966588|Transcriptome
1012770|NCT01966575|Polycystic ovary syndrome
1012771|NCT01966575|Progestin
1012772|NCT01966575|Endometrial shedding
1012773|NCT01966575|Ovulation induction cycles
1012774|NCT01966575|Clomiphene citrate
1012775|NCT01966575|Clinical pregnancy rate
1012776|NCT01966549|Pulmonary Disease, Chronic Obstructive
1012777|NCT01966549|Moderate to Severe Chronic Obstructive Pulmonary Disease
1012778|NCT01966549|CNTO 6785
1012779|NCT01966549|Placebo
1012780|NCT01966510|cord blood transplant
1012781|NCT01966510|advanced lymphoid malignancies
1012782|NCT01966497|AML
1012783|NCT01966484|Succinylcholine
1012784|NCT01966484|Mivacurium
1012785|NCT01966484|Rigid Bronchoscopy
1012786|NCT01966484|Intubating conditions
1012787|NCT01966484|Short Procedure
1012788|NCT01966445|GSK2849330
1012789|NCT01966445|Oncology
1012790|NCT01966445|First Time in Human
1012791|NCT01966445|HER3
1012792|NCT01966432|Substance abuse
1012793|NCT01966432|Alcohol use
1012794|NCT01966432|Tobacco use
1012795|NCT01966432|Brief intervention
1012796|NCT01966432|Referral to treatment
1012797|NCT01966419|hepatic encephalopathy
1012798|NCT01966419|hyperammonemia
1012799|NCT01966419|cirrhosis
1012800|NCT01966419|ornithine phenylacetate
1012801|NCT01966419|OCR-002
1012802|NCT01966406|Pancreaticoduodenectomy
1012803|NCT01966406|nasogastric tube
1012804|NCT01966393|Type 1 diabetes
1012805|NCT01966393|Hypoglycemia
1012806|NCT01966393|Insulin
1012807|NCT01966393|Glucagon
1012808|NCT01966393|Closed-loop strategy
1012809|NCT01966393|Artificial pancreas
1012810|NCT01966367|Unrelated donor transplant
1012811|NCT01966367|Haploidentical donor transplant
1012812|NCT01966367|Peripheral blood stem cell transplantation
1012813|NCT01966367|CD34+ selection
1012814|NCT01966367|Non-malignant disease
1012815|NCT01966367|Bone marrow failure syndrome
1012816|NCT01966367|Severe Aplastic Anemia
1012817|NCT01966367|Severe Congenital Neutropenia
1012818|NCT01966367|Amegakaryocytic Thrombocytopenia
1012819|NCT01966367|Diamond-Blackfan Anemia
1012820|NCT01966367|Schwachman Diamond Syndrome
1012821|NCT01966367|Primary Immunodeficiency Syndrome
1012822|NCT01966367|Acquired Immunodeficiency Syndrome
1012823|NCT01966367|Histiocytic Syndrome
1012824|NCT01966367|Familial Hemophagocytic Lymphocytosis
1012825|NCT01966367|Lymphohistiocytosis
1012826|NCT01966367|Macrophage Activation Syndrome
1012827|NCT01966367|Langerhans Cell Histiocytosis (LCH)
1012828|NCT01966367|Hemoglobinopathies
1012829|NCT01966367|Sickle Cell Disease
1012830|NCT01966367|Sickle Cell-beta-thalassemia
1012831|NCT01966354|adult
1012832|NCT01966354|catheterization, central venous
1012833|NCT01966354|ultrasonography, interventional
1012834|NCT01966354|evidence-based medicine
1012835|NCT01966354|cost-benefit analysis
1012836|NCT01966302|Pulmonary Arterial Hypertension
1012837|NCT01966302|prostacyclin
1012838|NCT01966302|oral
1012839|NCT01966289|Colorectal Neoplasms
1012840|NCT01966289|Intestinal Neoplasms
1012841|NCT01966289|Gastrointestinal Neoplasms
1012842|NCT01966289|Digestive System Neoplasms
1012843|NCT01966289|Neoplasms by Site
1012844|NCT01966289|Neoplasms
1012845|NCT01966289|Digestive System Diseases
1012846|NCT01966289|Gastrointestinal Diseases
1012847|NCT01966289|Colonic Diseases
1012848|NCT01966289|Intestinal Diseases
1012849|NCT01966289|Rectal Diseases
1012850|NCT01966276|Chronic Fatigue Syndrome (CFS)
1012851|NCT01966276|Myalgic Encephalomyelitis (ME)
1012852|NCT01966276|central nervous system (CNS)
1012853|NCT01966276|fatigue
1012854|NCT01966276|alertness
1012855|NCT01966276|brain fog
1012856|NCT01966276|mitochondria
1012857|NCT01966276|methylphenidate
1012858|NCT01966276|Ritalin
1012859|NCT01966276|stimulant
1012860|NCT01966276|multivitamin
1012861|NCT01966276|multimineral
1012862|NCT01966276|micronutrients
1012863|NCT01966276|supplements
1012864|NCT01966263|total knee arthroplasty
1012865|NCT01966263|femoral nerve block
1012866|NCT01966263|local infiltration analgesia
1012867|NCT01966263|fast track
1012868|NCT01966198|pulse plethysmography, autonomic nervous system, heart rate variability, baro-reflex
1012869|NCT01966185|virtual simulation
1012870|NCT01966185|temporal bone
1012871|NCT01966185|surgical training
1012872|NCT01966185|medical education
1012873|NCT01966185|self-directed learning
1012874|NCT01966185|final product assessment
1012875|NCT01966185|cognitive load
1012876|NCT01966185|reaction time
1012877|NCT01966185|skills training
1012878|NCT01966185|simulator metrics
1012879|NCT01966172|NSAID, gabapentin, multimodal, morphine, dexamethasone, cardiac surgery, postoperative pain, analgesia.
1012880|NCT01966133|HCC
1012881|NCT01966133|Randomised controlled trial
1012882|NCT01966133|TACE
1012883|NCT01966133|Resection
1012884|NCT01966120|Photodynamic Therapy
1012885|NCT01966120|Field-directed Treatment
1012886|NCT01966068|Asthma
1012887|NCT01966068|Pediatrics
1012888|NCT01966068|Health Technology
1012889|NCT01966068|Meaningful Use Stage-3
1012890|NCT01966068|Web Portal
1012891|NCT01966042|Refractory angina
1012892|NCT01966042|Cell Therapy
1012893|NCT01966042|Bone Marrow
1012894|NCT01966042|Mononuclear Cells
1012895|NCT01966016|LV- Left Ventricular
1012896|NCT01966016|CRT- Cardiac resynchronization therapy
1012897|NCT01966016|MSCRT- Multisite Cardiac resynchronization therapy (P-pacemaker; D-defibrillator)
1012898|NCT01966016|BBB -bundle branch block
1012899|NCT01965990|Enteral nutrition
1012900|NCT01965990|very low-calorie diet
1012901|NCT01965990|severe obesity
1012902|NCT01965990|weight loss
1012903|NCT01965990|ketosis
1012904|NCT01965964|Dysphagia, Swallowing functions, Questionnaire in German
1012905|NCT01965925|Cognition
1012906|NCT01965925|Sleep problems
1012907|NCT01965925|Bipolar Disorder
1012908|NCT01965912|Phenylketonuria
1012909|NCT01965912|Kuvan
1012910|NCT01965912|Sapropterin dihydrochloride
1012911|NCT01965886|osteoarthritis
1012912|NCT01965886|knee
1012913|NCT01965886|arthroplasty
1012914|NCT01965886|replacement
1012915|NCT01965873|Pancreatitis, Acute necrotizing
1012916|NCT01965873|Enteral nutrition
1012917|NCT01965873|Fasting
1012918|NCT01965873|Complications
1012919|NCT01965873|Mortality
1012920|NCT01965834|Multiple Myeloma
1012921|NCT01965834|Fenofibrate
1012922|NCT01965821|tracheal cuff pressure
1012923|NCT01965821|continuous control
1012924|NCT01965821|microaspiration
1012925|NCT01965795|Brain-derived neurotrophic factor
1012926|NCT01965795|Cognitive function
1012927|NCT01965795|Dietary supplement
1012928|NCT01965795|Coffee plant extract
1012929|NCT01965769|Very low birth weight infants
1012930|NCT01965769|premature
1012931|NCT01965769|nutrition
1012932|NCT01965769|gastric residual
1012933|NCT01965756|Alzheimer's Disease
1012934|NCT01965756|Vascular Dementia
1012935|NCT01965756|Dementia
1012936|NCT01965756|Memory Impairment
1012937|NCT01965743|intrauterine contraception (IUC)
1012938|NCT01965743|social networks
1012939|NCT01965743|social influence
1012940|NCT01965743|diffusion of innovation
1012941|NCT01965743|intrauterine device (IUD)
1012942|NCT01965743|LARC
1012943|NCT01965730|dilated ascending aorta
1012944|NCT01965717|endoleak
1012945|NCT01965717|MMP- 9
1012946|NCT01965717|biomarker
1012947|NCT01965704|Narcotic addiction during pregnancy
1012948|NCT01965704|Neonatal abstinence syndrome
1012949|NCT01965704|NAS
1012950|NCT01965691|Phenylketonuria
1012951|NCT01965691|PKU
1012952|NCT01965691|Phenylalanine metabolism
1012953|NCT01965691|Protein requirements
1012954|NCT01965691|Indicator Amino acid Oxidation
1012955|NCT01965691|Stable isotopes
1012956|NCT01965678|Osteopathic manipulative treatment
1012957|NCT01965678|muscle-skeletal disorder
1012958|NCT01965678|quality of life
1012959|NCT01965665|Diabetes
1012960|NCT01965665|Surgical Intervention
1012961|NCT01965665|Honey
1012962|NCT01965652|Opioid Induced Constipation
1012963|NCT01965639|Diabetes Mellitus Type 2
1012964|NCT01965639|Standard of care
1012965|NCT01965639|Quality of life
1012966|NCT01965639|Disease management
1012967|NCT01965626|Oseltamivir
1012968|NCT01965626|Dexamethasone
1012969|NCT01965626|ITP
1012970|NCT01965613|Pyoderma Gangrenosum
1012971|NCT01965600|Endotoxin challenge
1012972|NCT01965587|novasure
1012973|NCT01965587|Mirena IUS
1012974|NCT01965587|menorrhagia
1012975|NCT01965587|pelvic pain
1012976|NCT01965587|ashermanns
1012977|NCT01965574|ARDS - FLUID LOADING - PRELOAD DEPENDENCE
1012978|NCT01965548|spleen
1012979|NCT01965548|injury
1012980|NCT01965548|patient transfer
1012981|NCT01965548|splenectomy
1012982|NCT01965548|embolization, theurapeutic
1012983|NCT01965535|Hepatitis C
1012984|NCT01965535|HCV
1012985|NCT01965535|Cirrhosis
1012986|NCT01965522|Breast cancer
1012987|NCT01965522|melatonin
1012988|NCT01965522|vitamin d
1012989|NCT01965522|ki67
1012990|NCT01965509|PEX168
1012991|NCT01965509|Phase I/II
1012992|NCT01965509|add on to metformin
1012993|NCT01965496|PEX168
1012994|NCT01965496|Phase I
1012995|NCT01965496|titration
1012996|NCT01965483|radiotherapy
1012997|NCT01965483|adjuvant
1012998|NCT01965483|weekly hypofractionation
1012999|NCT01965457|obstructive sleep apnea
1013000|NCT01965457|pediatric
1013001|NCT01965457|adenoid hypertrophy
1013002|NCT01965444|Sub-epidermal moisture
1013003|NCT01965444|Pressure Ulcers
1013004|NCT01965405|HIV
1013005|NCT01965405|AIDS
1013006|NCT01965405|Nicotine Dependence
1013007|NCT01965405|Smoking
1013008|NCT01965405|Smoking cessation
1013009|NCT01965405|Contingency Management
1013010|NCT01965379|Dialysis
1013011|NCT01965379|Phosphorus
1013012|NCT01965379|Diet
1013017|NCT01965353|Relapsed Multiple Myeloma
1013018|NCT01965353|Relapse-Refractory Multiple Myeloma
1013019|NCT01965340|patients
1013020|NCT01965327|Friedreich ataxia
1013021|NCT01965327|Interferon gamma-1b
1013022|NCT01965327|FRDA
1013023|NCT01965314|ultrasound guided regional anaesthesia
1013024|NCT01965314|upper limb surgery
1013025|NCT01965314|ultrasound guided axillary brachial plexus blockade
1013026|NCT01965275|Advanced non-small cell lung cancer
1013027|NCT01965275|High-dose
1013028|NCT01965275|Pulsatile
1013029|NCT01965275|EGFR-TKIs
1013030|NCT01965249|Laparotomy
1013031|NCT01965249|short stitch
1013032|NCT01965249|long stitch
1013033|NCT01965249|MonoMax
1013034|NCT01965236|hypertension, sodium intake, left ventricular function
1013035|NCT01965223|Oligometastatic
1013036|NCT01965223|Neoplasia
1013037|NCT01965223|Radiosurgery
1013038|NCT01965223|Stereotactic Ablative Body Radiotherapy
1013039|NCT01965223|SABR
1013040|NCT01965223|Metastases to the Lung
1013041|NCT01965223|Non Haematological
1013042|NCT01965210|Rye
1013043|NCT01965210|Fermentable dietary fibre
1013044|NCT01965210|Inulin
1013045|NCT01965210|Plant protein
1013046|NCT01965210|Gluten
1013047|NCT01965210|Porridge
1013048|NCT01965210|Bread
1013049|NCT01965210|Appetite
1013050|NCT01965210|Satiety
1013051|NCT01965210|Hunger
1013052|NCT01965210|Desire to eat
1013053|NCT01965210|Metabolism
1013054|NCT01965210|Glucose
1013055|NCT01965210|Insulin
1013056|NCT01965210|Gut hormones
1013057|NCT01965210|Metabolomics
1013058|NCT01965210|Gastric emptying rate
1013059|NCT01965210|Breath hydrogen and methane excretion
1013060|NCT01965184|child
1013061|NCT01965184|cognitive behavioral therapy
1013062|NCT01965184|CBT
1013063|NCT01965184|aggression
1013064|NCT01965184|disruptive behavior
1013065|NCT01965184|treatment
1013066|NCT01965184|frustrative non-reward
1013067|NCT01965171|hematologic malignancy
1013068|NCT01965171|iron overload
1013069|NCT01965171|magnetic resonance imaging
1013070|NCT01965171|childhood cancer survivors
1013071|NCT01965158|Opioid-induced Constipation
1013072|NCT01965132|Rheumatiod Arhthritis
1013073|NCT01965132|Ankylosing spondylitis
1013074|NCT01965132|Psoriatic arthritis
1013075|NCT01965132|Biologic agents
1013076|NCT01965132|Cohort studies
1013077|NCT01965106|Glaucoma, Angle-Closure
1013078|NCT01965106|Glaucoma, Closed-Angle
1013079|NCT01965106|Primary angle closure
1013080|NCT01965106|Acute angle closure
1013081|NCT01965106|Acute angle-closure glaucoma
1013082|NCT01965093|perioperative
1013083|NCT01965093|desaturation
1013084|NCT01965093|growth development
1013085|NCT01965093|intelligence outcome
1013086|NCT01965080|Endometrial cancer
1013087|NCT01965054|Intrahepatic cholestasis of pregnancy
1013088|NCT01965054|fish oil
1013089|NCT01965054|omega-3
1013090|NCT01965054|Docosahexaenoic acid,
1013091|NCT01965054|eicosapentaenoic acid
1013092|NCT01965041|AVA Study
1013093|NCT01965028|tinnitus
1013094|NCT01965028|transcranial random noise stimulation
1013095|NCT01965028|tRNS
1013096|NCT01965028|auditory cortex
1013097|NCT01965028|non-invasive brain stimulation
1013098|NCT01965015|Heart Failure (HF)
1013099|NCT01965015|Left Atrial Pressure
1013100|NCT01964989|Influenza
1013101|NCT01964989|children
1013102|NCT01964950|drug therapy
1013103|NCT01964911|Martorell ulcer
1013104|NCT01964911|Hypertensive leg ulcer
1013105|NCT01964911|Pain
1013106|NCT01964911|Continuous nerve block
1013107|NCT01964911|Ropivacaïne
1013108|NCT01964911|Local anesthesic
1013109|NCT01964898|Smoking
1013110|NCT01964898|Mood Management
1013111|NCT01964898|Depression
1013112|NCT01964898|Behavioral Activation
1013113|NCT01964898|Acute Coronary Syndrome
1013114|NCT01964898|Myocardial Infarction
1013115|NCT01964872|Healthy volunteers
1013116|NCT01964872|JNJ-38877618
1013117|NCT01964872|Pharmacokinetic
1013118|NCT01964872|Safety
1013119|NCT01964872|Single-ascending dose
1013120|NCT01964872|Multiple-ascending dose
1013121|NCT01964859|healthy skin
1013122|NCT01964859|wounds and injuries
1013123|NCT01964859|prosthetics
1013124|NCT01964859|amputations
1013125|NCT01964859|dermal fibroblasts
1013126|NCT01964846|inflammation
1013127|NCT01964846|high fat meal
1013128|NCT01964846|resveratrol
1013129|NCT01964846|curcumin
1013130|NCT01964846|gene expression
1013131|NCT01964833|clinical trial
1013132|NCT01964833|DMT2
1013133|NCT01964833|periodontitis
1013134|NCT01964833|PDT
1013135|NCT01964807|Cardiovascular
1013136|NCT01964807|tobacco
1013137|NCT01964807|cigarettes
1013138|NCT01964807|secondhand cigarette smoke
1013139|NCT01964807|SHS
1013140|NCT01964807|smokeless tobacco
1013141|NCT01964807|chewing tobacco
1013142|NCT01964807|snus
1013143|NCT01964807|electronic cigarettes
1013144|NCT01964807|vapor
1013145|NCT01964807|particles
1013146|NCT01964807|oxidative stress
1013147|NCT01964807|flow-mediated dilation
1013148|NCT01964807|FMD
1013149|NCT01964794|Warfarin
1013150|NCT01964781|Administration, topical
1013151|NCT01964781|tranexamic acid
1013152|NCT01964781|adrenaline
1013153|NCT01964781|bupivacaine
1013154|NCT01964781|surgery
1013155|NCT01964755|EBV+
1013156|NCT01964755|NHL
1013157|NCT01964755|HL
1013158|NCT01964755|Non Hodgkin's Lymphoma
1013159|NCT01964755|Hodgkin's Lymphoma
1013160|NCT01964755|Epstein Barr Virus
1013161|NCT01964755|Epstein Barr Virus Associated Non Hodgkin's Lymphoma
1013289|NCT01964209|Conners 3rd Edition
1013162|NCT01964755|Epstein Barr Virus Associated Hodgkin's Lymphoma
1013163|NCT01964755|Post-Transplant Lymphoproliferative Disease
1013164|NCT01964729|rTMS
1013165|NCT01964729|Pain threshold
1013166|NCT01964729|Neuromodulation
1013167|NCT01964729|Myofascial
1013168|NCT01964716|Prevenar 13
1013169|NCT01964716|13vPnC
1013170|NCT01964716|Healthy Subjects
1013171|NCT01964690|Lactate
1013172|NCT01964690|Sepsis
1013173|NCT01964690|Capillary lactate
1013174|NCT01964690|Venous lactate
1013175|NCT01964690|Quick test
1013176|NCT01964677|Magnetic Resonance Imaging (MRI)
1013177|NCT01964677|High Intensity Focused Ultrasound (HIFU)
1013178|NCT01964664|Mindfulness
1013179|NCT01964664|Meditation
1013180|NCT01964664|acute lateral sclerosis
1013181|NCT01964664|Cerebral Palsy
1013182|NCT01964664|Cerebral Ataxia
1013183|NCT01964664|Locked-in Syndrome
1013184|NCT01964651|Healthy
1013185|NCT01964651|JNJ-42165279
1013186|NCT01964651|Pharmacokinetics
1013187|NCT01964651|Elderly
1013188|NCT01964651|Young
1013189|NCT01964638|Prostate Cancer
1013190|NCT01964638|Prostate Biopsy
1013191|NCT01964638|Targeted Biopsy
1013192|NCT01964625|Chronic GvHD
1013193|NCT01964599|Fiber
1013194|NCT01964599|Gastrointestinal
1013195|NCT01964586|Septoplasty, Dexmedetomidine, Surgical Conditions
1013196|NCT01964573|Parkinson's Disease
1013197|NCT01964573|Rotigotine
1013198|NCT01964573|Pharmacokinetics
1013199|NCT01964573|Healthy subjects
1013200|NCT01964560|Lacosamide
1013201|NCT01964560|Vimpat
1013202|NCT01964560|UCB
1013203|NCT01964560|Epilepsy
1013204|NCT01964560|Partial Onset Seizures
1013205|NCT01964560|Pediatric
1013206|NCT01964547|Cognition
1013207|NCT01964547|Mood
1013208|NCT01964534|Metastatic
1013209|NCT01964534|Pancreatic
1013210|NCT01964534|Cancer
1013211|NCT01964534|Pancreas
1013212|NCT01964534|GERCOR
1013213|NCT01964534|Gemcitabine
1013214|NCT01964534|LV5FU2
1013215|NCT01964534|ABI-007
1013216|NCT01964534|PACLITAXEL ALBUMIN-BOUND PARTICLES
1013217|NCT01964482|Hospitalization
1013218|NCT01964482|Older
1013219|NCT01964482|Medical patient
1013220|NCT01964482|Strength training
1013221|NCT01964456|Bodily self-consciousness
1013222|NCT01964456|intersubjective body
1013223|NCT01964456|Anorexia Nervosa
1013224|NCT01964456|Joint perception task
1013225|NCT01964456|Interoceptive awareness
1013226|NCT01964443|Plaque Psoriasis
1013227|NCT01964443|Alexithymia
1013228|NCT01964443|Quality of life
1013229|NCT01964430|Resectable pancreatic cancer
1013230|NCT01964430|resected
1013231|NCT01964430|resectable PDA
1013232|NCT01964430|adenocarcinoma
1013233|NCT01964430|surgically resected
1013234|NCT01964430|adjuvant
1013235|NCT01964430|Abraxane
1013236|NCT01964430|nab-paclitaxel
1013237|NCT01964430|ABI-007
1013238|NCT01964430|gemcitabine
1013239|NCT01964430|Gemzar
1013240|NCT01964430|Phase 3
1013241|NCT01964417|BOWEL PREPARATION
1013242|NCT01964417|PEG
1013243|NCT01964417|Low-volume PEG Plus Ascorbic Acid
1013244|NCT01964404|Dronabinol
1013245|NCT01964404|Schizophrenia
1013246|NCT01964404|Dual Diagnosis
1013247|NCT01964404|Substance Abuse
1013248|NCT01964404|Cannabis Use Disorder
1013249|NCT01964378|cancer-related pain
1013250|NCT01964378|neuropathic related cancer pain
1013251|NCT01964378|morphine
1013252|NCT01964378|cebranopadol (GRT6005)
1013253|NCT01964378|Numerical Rating Scale
1013254|NCT01964326|atorvastatin
1013255|NCT01964326|Hypercholesterolemia
1013256|NCT01964313|Acute coronary syndrome
1013257|NCT01964313|treatment strategy
1013258|NCT01964313|genetics
1013259|NCT01964274|Nursing Delirium Screening Scale,
1013260|NCT01964274|Acetylcholinesterase Activity
1013261|NCT01964261|Neural
1013262|NCT01964261|Prosthetic
1013263|NCT01964261|Brain machine interface
1013264|NCT01964261|brain computer interface
1013265|NCT01964261|brain control
1013266|NCT01964261|paralysis
1013267|NCT01964261|tetraplegia
1013268|NCT01964261|quadriplegia
1013269|NCT01964261|spinal cord injury
1013270|NCT01964261|stimulation
1013271|NCT01964261|sensory feedback
1013272|NCT01964248|Blood gas analysis
1013273|NCT01964248|Arterial puncture
1013274|NCT01964248|Local anesthesia
1013275|NCT01964248|Eutectic mixture
1013276|NCT01964248|Lidocaïne/prilocaïne cream (5%)
1013277|NCT01964248|Placebo
1013278|NCT01964248|Pain Intensity Scale
1013279|NCT01964248|Numerical Rating Scale
1013280|NCT01964235|INC280, advanced hepatocellular carcinoma, c-MET pathway dysregulation.
1013281|NCT01964222|Cancer
1013282|NCT01964222|Clinical trials
1013283|NCT01964222|Informed consent
1013284|NCT01964222|Health literacy
1013285|NCT01964209|ADHD
1013286|NCT01964209|Validation
1013287|NCT01964209|Quality Improvement
1013288|NCT01964209|Vanderbilt
1013290|NCT01964209|ADHD Measures
1013291|NCT01964209|ADHD Adolescent
1013292|NCT01964209|ADHD Questionnaire
1013293|NCT01964209|ICISS
1013294|NCT01964209|Integrated Clinical Information Sharing System
1013295|NCT01964196|Renal anemia
1013296|NCT01964196|Chronic Renal Failure
1013297|NCT01964196|ASP1517
1013298|NCT01964183|Open-label design
1013299|NCT01964183|Pharmacokinetics
1013300|NCT01964183|Drug-Drug Interaction
1013301|NCT01964183|Mirabegron
1013302|NCT01964170|ASP3550
1013303|NCT01964170|Prostate cancer
1013304|NCT01964157|non-small cell lung cancer (NSCLC)
1013305|NCT01964144|thyroid cancer, dovitinib
1013306|NCT01964131|Bioequivalence
1013307|NCT01964131|pharmacodynamics
1013308|NCT01964131|pharmacokinetics
1013309|NCT01964131|safety
1013310|NCT01964131|tolerability
1013311|NCT01964131|D961H
1013312|NCT01964131|Japanese
1013313|NCT01964118|intermittent fasting
1013314|NCT01964118|obesity
1013315|NCT01964118|calorie restriction
1013316|NCT01964105|Hypomastia
1013317|NCT01964105|Augmentation
1013318|NCT01964105|Breast
1013319|NCT01964105|3D
1013320|NCT01964105|Breast Q
1013321|NCT01964092|Disability
1013322|NCT01964092|Individual placement and support
1013323|NCT01964092|Mental health
1013324|NCT01964092|Quality of life
1013325|NCT01964092|Randomized controlled trial
1013326|NCT01964092|Rehabilitation
1013327|NCT01964092|Return to work
1013328|NCT01964092|Supported employment
1013329|NCT01964066|therapeutic ERCP
1013330|NCT01964066|prevention of post-ERCP pancreatitis
1013331|NCT01964066|thoracic epidural analgesia
1013332|NCT01964053|Self-management adherence
1013333|NCT01964053|post acute care
1013334|NCT01964053|critical access hospitals
1013335|NCT01964053|patient activation
1013336|NCT01964053|hospital readmission
1013337|NCT01964040|femoral nerve block
1013338|NCT01964040|peri-neural dexmedetomidine
1013339|NCT01964027|second line chemoregime
1013340|NCT01964027|gastric cancer
1013341|NCT01964014|once
1013342|NCT01963988|Bladder Pain Syndrome
1013343|NCT01963988|Transurethral Resection of Ulcer
1013344|NCT01963988|Transurethral Coagulation of Ulcer
1013345|NCT01963962|Emergency contraception
1013346|NCT01963962|Levonorgestrel IUD
1013347|NCT01963962|Copper IUD
1013348|NCT01963962|Oral Levonorgestrel
1013349|NCT01963936|Infant newborn
1013350|NCT01963936|Laryngeal mask airway
1013351|NCT01963936|Positive pressure ventilation
1013352|NCT01963936|Resuscitation
1013353|NCT01963923|Pulmonary Rehabilitation
1013354|NCT01963923|Lung Cancer Resection
1013355|NCT01963923|Video-assisted thoracic surgery
1013356|NCT01963923|Exercise tolerance
1013357|NCT01963923|Quality of life
1013358|NCT01963910|Mannitol
1013359|NCT01963910|TRPV1 receptor
1013360|NCT01963910|Pain
1013361|NCT01963910|Burning pain
1013362|NCT01963910|neuropathy
1013363|NCT01963910|neuropathic pain
1013364|NCT01963897|Genotype/phenotype correlations
1013365|NCT01963897|Growth
1013366|NCT01963897|Bone health
1013367|NCT01963897|Puberty
1013368|NCT01963897|Quality of life
1013369|NCT01963884|Extraction Sockets
1013370|NCT01963884|Ridge dimensions
1013371|NCT01963884|Dental Alveolar Anatomy
1013372|NCT01963884|Dental Implants
1013373|NCT01963884|Bone Physiology
1013374|NCT01963871|chronic low back pain
1013375|NCT01963871|low back pain
1013376|NCT01963871|yoga
1013377|NCT01963832|stroke
1013378|NCT01963832|Fluoxetine (FLX)
1013379|NCT01963832|eCIMT
1013380|NCT01963832|Central Nervous System
1013381|NCT01963793|Pruritus
1013382|NCT01963780|lung transplantation
1013383|NCT01963780|lung preservation
1013384|NCT01963780|breathing lung transplant
1013385|NCT01963767|memory
1013386|NCT01963767|cognition
1013387|NCT01963767|dietary supplements
1013388|NCT01963754|Articaine 1:100.000
1013389|NCT01963754|Dental Implants
1013390|NCT01963754|Posterior mandible
1013391|NCT01963754|Loco-regional Anesthesia
1013392|NCT01963754|Subperiosteal Anesthesia
1013393|NCT01963741|Leukotriene D4
1013394|NCT01963741|allergic rhinitis
1013395|NCT01963741|nasal airway resistance
1013396|NCT01963741|nasal provocation test
1013397|NCT01963741|nasal hyperreactivity
1013398|NCT01963741|airway inflammation
1013399|NCT01963741|asthma
1013400|NCT01963728|post-transplant
1013401|NCT01963728|diabetes mellitus
1013402|NCT01963728|renal transplant
1013403|NCT01963728|kidney transplant
1013404|NCT01963728|lung transplant
1013405|NCT01963728|heart transplant
1013406|NCT01963728|insulin
1013407|NCT01963715|IMGN289
1013408|NCT01963715|Antibody Drug Conjugate
1013409|NCT01963715|antibody
1013410|NCT01963715|EGFR
1013411|NCT01963715|NSCLC
1013412|NCT01963715|SCCHN
1013413|NCT01963715|Head and neck
1013414|NCT01963715|Squamous cell carcinoma
1013415|NCT01963715|Solid tumor
1013416|NCT01963715|Immunogen
1013417|NCT01963715|Lung
1013418|NCT01963715|Phase 1
1013419|NCT01963702|predictive factor
1013420|NCT01963702|response
1013421|NCT01963702|gastric neoplasm
1013422|NCT01963702|oxaliplatin
1013423|NCT01963702|docetaxol
1013424|NCT01963702|capecitabine
1013425|NCT01963689|Anxiety
1013426|NCT01963689|Self-Esteem
1013427|NCT01963676|schizophrenia
1013428|NCT01963676|auditory hallucinations
1013429|NCT01963676|transcranial stimulation
1013430|NCT01963676|tDCS
1013431|NCT01963676|tACS
1013432|NCT01963663|YKL-40
1013433|NCT01963663|Chronic low grade inflammation
1013434|NCT01963663|type 2 diabetes mellitus
1013435|NCT01963663|metformin
1013436|NCT01963663|pioglitazone
1013437|NCT01963637|obesity, sleeve gastrectomy, gastric bypass, gastric tomodensitometry, gastric pouch size, weight regain
1013438|NCT01963624|Breast
1013439|NCT01963624|Screening
1013440|NCT01963624|Ultrasound
1013441|NCT01963624|Elastography
1013442|NCT01963624|Doppler ultrasonography
1013443|NCT01963611|Multiple Sclerosis
1013444|NCT01963611|Relapsing Remitting
1013445|NCT01963611|Plovamer acetate
1013446|NCT01963611|Copaxone
1013447|NCT01963585|C reactive protein
1013448|NCT01963585|Airway hyperreactivity
1013449|NCT01963585|Body mass index
1013450|NCT01963572|Breast cancer
1013451|NCT01963572|Care model
1013452|NCT01963572|Physical Therapy
1013453|NCT01963546|diabetic
1013454|NCT01963546|laparoscopic gastric bypass surgery
1013455|NCT01963546|stress response
1013456|NCT01963546|anesthesia
1013457|NCT01963546|dexmedetomidine
1013458|NCT01963533|lung cancer
1013459|NCT01963533|telomere length
1013460|NCT01963533|comorbidity
1013461|NCT01963533|Eastern Cooperation Oncology Group (ECOG)
1013462|NCT01963533|chemotherapy
1013463|NCT01963520|Hip prosthesis infection
1013464|NCT01963520|Reinfection
1013465|NCT01963520|Excision-synovectomy
1013466|NCT01963520|One stage/two stage revision
1013467|NCT01963520|Antibiotherapy
1013468|NCT01963494|Physical activity
1013469|NCT01963494|Health-behavior-change
1013470|NCT01963494|Dyadic Planning
1013471|NCT01963494|Individual Planning
1013472|NCT01963481|hormonal therapy
1013473|NCT01963481|immunotherapy
1013474|NCT01963468|Hearing Loss
1013475|NCT01963468|Cochlear Implant
1013476|NCT01963468|Deaf
1013477|NCT01963468|Hearing Impairment
1013478|NCT01963468|Hard of Hearing
1013479|NCT01963455|transplantation autologous stress urinary incontinence
1013480|NCT01963455|muscle derived cells
1013481|NCT01963429|hepatocellular
1013482|NCT01963429|Proton
1013483|NCT01963429|RFA
1013484|NCT01963403|etonogestrel implant
1013485|NCT01963403|birth control
1013486|NCT01963403|irregular bleeding
1013487|NCT01963403|heavy bleeding
1013488|NCT01963390|Hypogonadism
1013489|NCT01963390|Testosterone Deficiency
1013490|NCT01963377|bronchoscopy
1013491|NCT01963377|O2-supplementation
1013492|NCT01963364|fructans
1013493|NCT01963364|inulin
1013494|NCT01963364|oligofructose
1013495|NCT01963364|colonic fermentation
1013496|NCT01963364|microbiota
1013497|NCT01963364|whoe gut transit
1013498|NCT01963351|NSCLC
1013499|NCT01963351|Non-squamous
1013500|NCT01963286|ICD
1013501|NCT01963286|CRT-D
1013502|NCT01963286|Sudden cardiac death
1013503|NCT01963286|Device settings
1013504|NCT01963286|Optimized programming strategy
1013505|NCT01963221|elderly
1013506|NCT01963221|aorta
1013507|NCT01963221|inflammation
1013508|NCT01963221|arterial stiffness
1013509|NCT01963221|PET/CT Imaging
1013510|NCT01963221|hypertension
1013511|NCT01963221|MRI
1013512|NCT01963208|partial onset seizures
1013513|NCT01963208|complex partial seizures
1013514|NCT01963208|simple partial seizures
1013515|NCT01963208|anticonvulsant
1013516|NCT01963208|ganaxolone
1013517|NCT01963208|neurosteroid
1013518|NCT01963208|Marinus
1013519|NCT01963208|epilepsy
1013520|NCT01963195|Adverse Reaction to Drug
1013521|NCT01963195|Self Efficacy
1013522|NCT01963169|Bone Health
1013523|NCT01963169|Online intervention
1013524|NCT01963169|Dissemination
1013525|NCT01963169|Theory-based intervention
1013526|NCT01963156|Prescription synchronization
1013527|NCT01963156|Cardiovascular disease
1013528|NCT01963156|Medication adherence
1013529|NCT01963156|Randomized controlled trial
1013530|NCT01963156|Chronic disease
1013531|NCT01963156|Pharmacy benefit design
1013532|NCT01963156|Quality improvement
1013533|NCT01963130|Vildagliptin
1013534|NCT01963130|Portal Vein Pressure
1013535|NCT01963130|Hepatosteatosis
1013536|NCT01963104|hearing test, audiology, healthcare utilization,
1013537|NCT01963104|patient education, hearing screening
1013538|NCT01963065|Children's environmental health
1013539|NCT01963065|preterm birth
1013540|NCT01963065|newborns
1013541|NCT01963065|bisphenol A
1013542|NCT01963065|BPA
1013543|NCT01963065|phthalates
1013544|NCT01963065|metals exposure
1013545|NCT01963065|very low birth weight
1013546|NCT01963065|NICU
1013547|NCT01963052|Metastatic Urothelial Cancer
1013548|NCT01963052|AGS15E
1013549|NCT01963052|AGS15E-13-1
1013550|NCT01963052|ASG-15ME
1013551|NCT01963052|Pharmacokinetics of AGS15E
1013552|NCT01963026|spinal cord injury
1013553|NCT01963026|upper extremity
1013554|NCT01963026|skill performance
1013555|NCT01963026|motor learning
1013556|NCT01963013|Non-returning catheter valve
1013557|NCT01963013|Catheter associated urinary tract infection
1013558|NCT01963013|Critically ill patients
1013559|NCT01963013|Prevention
1013560|NCT01963000|Community Acquired Pneumonia
1013561|NCT01963000|Emergency Department
1013562|NCT01963000|Standardized Care
1013563|NCT01963000|Reduced Mortality
1013564|NCT01963000|CRB-65 Risk Classes
1013565|NCT01963000|Antibiotic Therapy
1013566|NCT01962974|Arthritis, Rheumatoid
1013567|NCT01962961|HIV
1013568|NCT01962961|Endothelial function
1013569|NCT01962961|Oxidative stress
1013570|NCT01962961|Cardiovascular disease
1013571|NCT01962961|N-acetylcysteine
1013572|NCT01962935|Healthy volunteer
1013573|NCT01962935|Multiple ascending dose
1013574|NCT01962909|Pancreatic Resection
1013575|NCT01962883|Post Concussion Syndrome
1013576|NCT01962883|Vestibular disturbance
1013577|NCT01962883|Balance
1013578|NCT01962883|Dizziness
1013579|NCT01962883|Dizziness handicap inventory
1013580|NCT01962883|Balance Error Scoring System
1013581|NCT01962857|Physical activity
1013582|NCT01962857|Exercise
1013583|NCT01962857|Insulin resistance
1013584|NCT01962857|High intensity interval training
1013585|NCT01962857|Fat oxidation
1013586|NCT01962857|Fitness
1013587|NCT01962857|Lipids
1013588|NCT01962857|Blood pressure
1013589|NCT01962844|chronic coronary artery disease
1013590|NCT01962844|coconut oil extra virgin
1013591|NCT01962844|index of diet quality
1013592|NCT01962844|nutritional treatment
1013593|NCT01962831|obesity
1013594|NCT01962831|labor, induced
1013595|NCT01962831|pregnancy
1013596|NCT01962831|cervical ripening
1013597|NCT01962831|dinoprostone
1013598|NCT01962818|Respiratory Distress Syndrome In Premature Infants
1013599|NCT01962818|Bronchopulmonary Dysplasia
1013600|NCT01962818|Ventilator-Induced Lung Injury
1013601|NCT01962818|Functional Residual Capacity
1013602|NCT01962818|Electric impedance tomography
1013603|NCT01962792|PCI-32765
1013604|NCT01962792|Multiple Myeloma
1013605|NCT01962792|Relapsed Refractory Multiple Myeloma
1013606|NCT01962792|Bruton's Tyrosine Kinase
1013607|NCT01962792|Carfilzomib
1013608|NCT01962792|Dexamethasone
1013609|NCT01962792|Ibrutinib
1013610|NCT01962779|Sleep Disordered Breathing
1013611|NCT01962779|Cognitively normal elderly
1013612|NCT01962779|Alzheimer's disease
1013613|NCT01962779|Prevention
1013614|NCT01962779|Continuous positive airway pressure (CPAP)
1013615|NCT01962753|Affective symptoms as prodromal stage of Alzheimer
1013616|NCT01962727|scapular dyskinesis, kinematics, muscular activities
1013617|NCT01962714|Behavior therapies, cognitive
1013618|NCT01962714|Mindfulness
1013619|NCT01962714|Emotion
1013620|NCT01962714|Group therapy
1013621|NCT01962701|C-section
1013622|NCT01962688|Heart Failure
1013623|NCT01962688|Handheld ultrasound
1013624|NCT01962688|Inferior Vena Cava
1013625|NCT01962675|tDCS
1013626|NCT01962675|motor training
1013627|NCT01962675|SCI
1013628|NCT01962662|stroke
1013629|NCT01962662|transcranial magnetic stimulation
1013630|NCT01962662|EMG biofeedback
1013631|NCT01962662|motor function
1013632|NCT01962662|neural plasticity
1013633|NCT01962662|force
1013634|NCT01962636|Umbilical Cord Transplant
1013635|NCT01962636|Acute Myeloid Leukemia (AML)
1013636|NCT01962636|Acute Lymphocytic Leukemia (ALL)
1013637|NCT01962636|Chronic Myelogenous Leukemia
1013638|NCT01962636|Plasma Cell Leukemia
1013639|NCT01962636|Myelofibrosis
1013640|NCT01962636|Myelodysplasia
1013641|NCT01962636|Chronic Lymphocytic Leukemia
1013642|NCT01962636|Small Lymphocytic Lymphoma
1013643|NCT01962636|Marginal Zone B-Cell Lymphoma
1013644|NCT01962636|Follicular Lymphoma
1013645|NCT01962636|Lymphoplasmacytic Lymphoma
1013646|NCT01962636|Mantle-Cell Lymphoma
1013647|NCT01962636|Prolymphocytic Leukemia
1013648|NCT01962636|Large Cell Non-Hodgkin Lymphoma
1013649|NCT01962636|Lymphoblastic Lymphoma
1013650|NCT01962636|Burkitt's Lymphoma
1013651|NCT01962636|Non-Hodgkin Lymphoma
1013652|NCT01962636|Multiple Myeloma
1013653|NCT01962623|Severe Mood Dysregulation
1013654|NCT01962623|Mood Disorders
1013655|NCT01962623|Irritability
1013656|NCT01962623|Disruptive Mood Dysregulation Disorder
1013657|NCT01962623|Interpersonal Psychotherapy
1013658|NCT01962610|Pain care
1013659|NCT01962610|emergency
1013660|NCT01962610|clinical decision support
1013661|NCT01962610|abdominal pain
1013662|NCT01962597|hemodialysis
1013663|NCT01962597|aerobic exercise
1013664|NCT01962597|resistance training
1013665|NCT01962597|walking speed
1013666|NCT01962597|randomized controlled trial
1013667|NCT01962571|Optic neuritis
1013668|NCT01962571|Multiple Sclerosis
1013669|NCT01962571|Clinically isolated syndrome
1013670|NCT01962571|Erythropoietin
1013671|NCT01962558|Tinnitus
1013672|NCT01962558|Medical Device
1013673|NCT01962558|Randomized
1013674|NCT01962558|Vagus Nerve Stimulation
1013675|NCT01962545|Atrial Fibrillation
1013676|NCT01962545|Percutaneous coronary intervention
1013677|NCT01962545|Stent
1013678|NCT01962545|Anticoagulant therapy
1013679|NCT01962545|Antiplatelet therapy
1013680|NCT01962545|Warfarin
1013681|NCT01962545|NOAC
1013682|NCT01962545|Aspirin
1013683|NCT01962545|Clopidogrel
1013684|NCT01962532|Neoplasms
1013685|NCT01962532|Lymphoma
1013686|NCT01962532|Advanced or refractory solid tumors
1013687|NCT01962532|Advanced or refractory lymphoma
1013688|NCT01962532|Gastric adenocarcinoma
1013689|NCT01962532|Gastroesophageal junctions
1013690|NCT01962532|JNJ-42756493
1013691|NCT01962532|Pharmacokinetics
1013692|NCT01962532|Japanese
1013693|NCT01962532|Asian
1013694|NCT01962532|Pharmacodynamics
1013695|NCT01962519|gastrectomy
1013696|NCT01962519|gastric cancer
1013697|NCT01962519|oral feeding
1013698|NCT01962519|complications
1013699|NCT01962506|Chest pain
1013700|NCT01962506|Copeptin
1013701|NCT01962506|High-sensitivity cardiac troponin
1013702|NCT01962506|Non-ST-Elevation (NSTE) - ACS
1013703|NCT01962467|Allergic rhinitis
1013704|NCT01962467|healthy volunteers
1013705|NCT01962467|fluticasone furoate
1013706|NCT01962467|levocabastine
1013707|NCT01962467|fixed dose combination
1013708|NCT01962467|pharmacokinetics
1013709|NCT01962454|muscle mass
1013710|NCT01962454|dynamic proteomics
1013711|NCT01962454|Duke University
1013712|NCT01962454|Microbiopsy
1013713|NCT01962454|D2O
1013714|NCT01962454|testosterone
1013715|NCT01962454|skeletal muscle
1013716|NCT01962441|7977
1013717|NCT01962441|GS-7977
1013718|NCT01962441|PSI-7977
1013719|NCT01962441|Sofosbuvir (SOF)
1013720|NCT01962441|Pegylated Interferon (PEG)
1013721|NCT01962441|Ribavirin (RBV)
1013722|NCT01962428|ticagrelor
1013723|NCT01962428|loading dose
1013724|NCT01962428|non-ST-segment elevation acute coronary syndromes
1013725|NCT01962428|percutaneous coronary intervention
1013726|NCT01962428|the antiplatelet effects
1013727|NCT01962428|bleeding events
1013728|NCT01962428|major adverse cardiac events
1013729|NCT01962415|Severe Combined Immune Deficiency (SCID)
1013730|NCT01962415|Omenn Syndrome
1013731|NCT01962415|Bare Lymphocyte Syndrome (BLS)
1013732|NCT01962415|Combined Immune Deficiency (CID) syndromes
1013733|NCT01962415|Combined Variable Immune Deficiency (CVID) syndrome
1013734|NCT01962415|Wiskott-Aldrich Syndrome
1013735|NCT01962415|Leukocyte adhesion deficiency
1013736|NCT01962415|Chronic granulomatous disease (CGD)
1013737|NCT01962415|X-linked Hyper IgM (XHIM) syndrome
1013738|NCT01962415|IPEX syndrome
1013739|NCT01962415|Chediak - Higashi Syndrome
1013740|NCT01962415|Autoimmune Lymphoproliferative Syndrome (ALPS)
1013741|NCT01962415|Hemophagocytic Lymphohistiocytosis (HLH) syndromes
1013742|NCT01962415|Lymphocyte Signaling defects
1013743|NCT01962415|Dyskeratosis Congenita (DC)
1013744|NCT01962415|Congenital Amegakaryocytic Thrombocytopenia (CAMT)
1013745|NCT01962415|Osteopetrosis
1013746|NCT01962415|Mucopolysaccharidoses
1013747|NCT01962415|Hurler syndrome (MPS I)
1013748|NCT01962415|Hunter syndrome (MPS II)
1013749|NCT01962415|Sanfilippo syndrome (MPS II)
1013750|NCT01962415|Leukodystrophies
1013751|NCT01962415|Krabbe Disease
1013752|NCT01962415|Metachromatic leukodystrophy (MLD)
1013753|NCT01962415|X-linked adrenoleukodystrophy (ALD)
1013754|NCT01962415|Alpha mannosidosis
1013755|NCT01962415|Gaucher Disease
1013756|NCT01962415|Thalassemia major
1013757|NCT01962415|Sickle cell disease (SCD)
1013758|NCT01962415|Diamond Blackfan Anemia (DBA)
1013759|NCT01962415|Crohn's Disease
1013760|NCT01962415|Inflammatory Bowel Disease
1013761|NCT01962415|Hematopoietic Stem Cell Transplant (HSCT)
1013762|NCT01962415|Congenital transfusion dependent anemias
1013763|NCT01962415|Globoid cell leukodystrophy
1013764|NCT01962389|ISR, Laser, SFA, PAD
1013765|NCT01962376|Capecitabine
1013766|NCT01962376|Oxaliplatin
1013767|NCT01962376|Bevacizumab
1013768|NCT01962376|Potentially Resectable Gastric Cancer Liver Metastasis
1013769|NCT01962363|Friedreich's ataxia point mutation
1013770|NCT01962350|Deep Brain Transcranial Magnetic Stimulation;
1013771|NCT01962350|H1-Coil deep brain rTMS;
1013772|NCT01962350|H1-Coil;
1013773|NCT01962350|Bipolar Depression;
1013774|NCT01962350|Cognition.
1013775|NCT01962324|Quality of Life
1013776|NCT01962324|Radiotherapy
1013777|NCT01962324|Radiotherapy, dose-escalation
1013778|NCT01962311|ALS
1013779|NCT01962311|Spinal Cerebrospinal Fluid
1013780|NCT01962311|Urine
1013781|NCT01962311|SERUM
1013782|NCT01962311|Diagnosis
1013783|NCT01962285|neuronal inertia
1013784|NCT01962285|loss of consciousness
1013785|NCT01962285|propofol pharmacodynamics
1013786|NCT01962285|Bispectral index
1013787|NCT01962285|anesthesia, general/pharmacology
1013788|NCT01962272|cancer
1013789|NCT01962272|radiotherapy
1013790|NCT01962272|chemotherapy
1013791|NCT01962272|nutrition
1013792|NCT01962272|dietary counseling
1013793|NCT01962272|quality of life
1013794|NCT01962246|Capecitabine
1013795|NCT01962246|Oxaliplatin
1013796|NCT01962246|Preoperative Concurrent Chemoradiotherapy
1013797|NCT01962246|Gastroesophageal Junction Adenocarcinoma
1013798|NCT01962220|HIV/AIDS
1013799|NCT01962220|PMTCT
1013800|NCT01962220|Pregnant Women
1013801|NCT01962220|Kenya
1013802|NCT01962220|Maternal Health
1013803|NCT01962207|10 years Meningitec
1013804|NCT01962207|Safety
1013805|NCT01962207|booster response
1013806|NCT01962207|Adolescents
1013807|NCT01962207|Adults
1013808|NCT01962207|Immunogenicity
1013809|NCT01962207|Mencevax ACWY
1013810|NCT01962181|EEG Attention Deficit / Hyperactivity Disorder (ADHD) Ritalin machine learning
1013811|NCT01962168|Biliary Tract Neoplasms
1013812|NCT01962168|Neoplasms
1013813|NCT01962168|Gastrointestinal Diseases
1013814|NCT01962168|Digestive System Diseases
1013815|NCT01962168|Biliary Tract
1013816|NCT01962168|Stents
1013817|NCT01962155|Fibrosis
1013818|NCT01962155|Liver Cirrhosis
1013819|NCT01962155|non-invasive
1013820|NCT01962155|biopsy
1013821|NCT01962155|hepatitis B virus
1013832|NCT01962090|Neck Pain
1013833|NCT01962090|Thoracic spine thrust manipulation
1013834|NCT01962090|Osteopathic Manipulation
1013835|NCT01962090|Dentistry
1013836|NCT01962090|Range of Motion
1013837|NCT01962077|pulpotomy
1013838|NCT01962077|MTA
1013839|NCT01962077|primary teeth
1013840|NCT01962077|formocresol
1013841|NCT01962038|Mild Cognitive Impairment
1013842|NCT01962038|Aging
1013843|NCT01962025|Renal failure
1013844|NCT01962025|Hemodialysis
1013845|NCT01962025|Canulation technique
1013846|NCT01962025|Training time
1013847|NCT01962025|Cost
1013848|NCT01962025|Patient discomfort with cannulation technique
1013849|NCT01962012|Orthodontic
1013850|NCT01962012|Orthodontic Treatment
1013851|NCT01962012|Accelerated Tooth Movement
1013852|NCT01962012|Malocclusion
1013853|NCT01962012|Device
1013854|NCT01962012|AcceleDent Aura
1013855|NCT01962012|Clear Aligners
1013856|NCT01961999|Acute kidney injury
1013857|NCT01961999|Cardiac surgery
1013858|NCT01961999|Renal replacement therapy
1013859|NCT01961986|Rotator Cuff
1013860|NCT01961986|Rotator Cuff Sparing
1013861|NCT01961986|Shoulder Replacement
1013862|NCT01961986|Total Shoulder Replacement
1013863|NCT01961986|Total Shoulder Arthroplasty
1013864|NCT01961986|Arthritis
1013865|NCT01961973|Articular cartilage
1013866|NCT01961973|Chondrocytes
1013867|NCT01961973|BMAC
1013868|NCT01961960|ASP7374
1013869|NCT01961960|Prevention of seasonal influenza
1013870|NCT01961947|ASP7374
1013871|NCT01961947|Approved egg-derived vaccine
1013872|NCT01961947|Prevention of seasonal influenza
1013873|NCT01961934|glioblastoma
1013874|NCT01961934|high grade brain tumors
1013875|NCT01961934|recurrent
1013876|NCT01961934|pseudo-progression
1013877|NCT01961934|radionecrosis
1013878|NCT01961934|carbon acetate
1013879|NCT01961934|C11 aceate
1013880|NCT01961934|PET
1013881|NCT01961934|positron emission tomography
1013882|NCT01961921|RNAi therapeutic
1013883|NCT01961895|Continuous lumbar plexus (LP) block analgesia
1013884|NCT01961882|OCV-501
1013885|NCT01961882|Acute Myeloid Leukemia
1013886|NCT01961882|Antigen specific cancer immunotherapeutic
1013887|NCT01961869|black raspberry
1013888|NCT01961869|chemoprevention
1013889|NCT01961869|oral delivery
1013890|NCT01961856|platelet reactivity
1013891|NCT01961856|ticagrelor loading dose
1013892|NCT01961856|clopidogrel loading dose
1013893|NCT01961843|Castration Resistant
1013894|NCT01961817|Retromolar
1013895|NCT01961817|Difficult Intubation
1013896|NCT01961791|gastric cancer, staging system, prognosis
1013897|NCT01961765|Relapsed acute myeloid leukemia
1013898|NCT01961765|Refractory acute myeloid leukemia
1013899|NCT01961752|bupivacaine,
1013900|NCT01961752|triamcinolone acetonide,
1013901|NCT01961752|endoscopic
1013902|NCT01961752|submucosal
1013903|NCT01961752|dissection
1013904|NCT01961752|Patients
1013905|NCT01961739|Hemorrhoids
1013906|NCT01961739|Lidocaine
1013907|NCT01961713|circulating tumor cells
1013908|NCT01961713|CTC-Chip
1013909|NCT01961661|intestinal inflammation
1013910|NCT01961661|intestinal microflora
1013911|NCT01961661|children
1013912|NCT01961648|Apnea
1013913|NCT01961648|Sleep Apnea Disorder
1013914|NCT01961648|Respiratory chemical drive
1013915|NCT01961648|CO2
1013916|NCT01961635|Dental Implants
1013917|NCT01961635|Zirconia Abutments
1013918|NCT01961635|Titanium abutments
1013919|NCT01961635|Acrylic abutments
1013920|NCT01961635|Gingival Healing
1013921|NCT01961635|Inflammation
1013922|NCT01961635|Bone loss
1013923|NCT01961622|Type 1 diabetes
1013924|NCT01961622|Closed loop insulin delivery
1013925|NCT01961622|Continuous subcutaneous glucose monitoring
1013926|NCT01961622|Continuous subcutaneous insulin infusion
1013927|NCT01961609|Chronic plaque psoriasis
1013928|NCT01961596|Cooling ice spray
1013929|NCT01961596|Time to stability
1013930|NCT01961596|Jump
1013931|NCT01961570|Early stage hand osteoarthritis
1013932|NCT01961570|Carpometacarpal osteoarthritis
1013936|NCT01961544|Breast Cancer
1013937|NCT01961544|Metastatic
1013938|NCT01961531|DCIS
1013939|NCT01961531|IDC
1013940|NCT01961531|Invasive breast carcinoma
1013945|NCT01961453|Hypertension
1013946|NCT01961453|Isosorbide Mononitrate
1013947|NCT01961453|Myocardial fibrosis
1013948|NCT01961427|dietary nitrate
1013949|NCT01961427|beetroot juice
1013950|NCT01961427|exercise performance
1013951|NCT01961427|oxygen consumption
1013952|NCT01961414|Exudative
1013953|NCT01961414|AMD
1013954|NCT01961414|Macular
1013955|NCT01961414|Degeneration
1013956|NCT01961414|Aflibercept
1013957|NCT01961414|Eylea
1013958|NCT01961414|Intravitreal
1013959|NCT01961401|exercise
1013960|NCT01961401|exercise therapy
1013961|NCT01961401|insulin resistance
1013962|NCT01961388|Type 2 Diabetes
1013963|NCT01961362|Pulmonary fibrosis
1013964|NCT01961362|Interstitial lung disease
1013965|NCT01961362|Connective tissue disease
1013966|NCT01961362|Chronic hypersensitivity pneumonitis
1013967|NCT01961362|Idiopathic pulmonary fibrosis
1013968|NCT01961362|Pulmonary fibrosis of any cause
1013969|NCT01961362|Primary supporters/caregivers
1013970|NCT01961349|sedation, propofol, gastrointestinal endoscopy
1013971|NCT01961336|IVF, poor responder, testosterone
1013972|NCT01961323|Hypertension
1013973|NCT01961323|high blood pressure
1013974|NCT01961323|stress echocardiogram
1013975|NCT01961323|nebivolol
1013976|NCT01961323|left ventricular diastolic dysfunction
1013977|NCT01961310|bacterial translocation
1013978|NCT01961310|intestinal microbiota
1013979|NCT01961297|dystonia
1013980|NCT01961297|tremor
1013981|NCT01961297|treatment
1013982|NCT01961297|sodium oxybate
1013983|NCT01961297|brain activity
1013984|NCT01961271|Norspan
1013985|NCT01961271|buprenorphine
1013986|NCT01961271|transdermal
1013987|NCT01961271|patch
1013988|NCT01961271|chronic pain
1013989|NCT01961271|non-malignant
1013990|NCT01961271|osteoarthritis
1013991|NCT01961271|rheumatoid arthritis
1013992|NCT01961271|lower back pain
1013993|NCT01961271|joint pain
1013994|NCT01961271|muscle pain
1013995|NCT01961271|opioid
1013996|NCT01961271|analgesic
1013997|NCT01961271|painkiller
1013998|NCT01961271|Mundipharma
1014244|NCT01960036|Women
1013999|NCT01961258|Severe Asthma, Community, comorbidities, patient compliance,PFT, anti-IgE therapy
1014000|NCT01961232|Pulmonary Hypertension
1014001|NCT01961232|biomarker
1014002|NCT01961232|cardiac
1014003|NCT01961232|circulation
1014004|NCT01961232|heart disease
1014005|NCT01961232|lung disease
1014006|NCT01961193|critically ill patients
1014007|NCT01961193|punctal plug
1014008|NCT01961193|corneal injuries
1014009|NCT01961180|Quality of Life
1014010|NCT01961180|Adrenal hyper activity
1014011|NCT01961180|Glucose metabolism
1014012|NCT01961154|Asthma
1014013|NCT01961154|medication reduction
1014014|NCT01961154|asthma exacerbation
1014015|NCT01961141|Ultrasound Doppler
1014016|NCT01961141|Pulmonary diseases
1014017|NCT01961141|Cardiopulmonary conditions
1014018|NCT01961128|High risk
1014019|NCT01961102|postmenopausal bleeding
1014020|NCT01961102|postmenopausal hyperplasia
1014021|NCT01961102|endometrial cancer
1014022|NCT01961102|atypical hyperplasia
1014023|NCT01961102|curettage
1014024|NCT01961102|intraoperative rapid section
1014025|NCT01961050|alcohol
1014026|NCT01961050|pregnancy
1014027|NCT01961050|fetal exposure
1014028|NCT01961050|prevention
1014029|NCT01961050|FAS
1014030|NCT01961050|Alcohol-Related Neurodevelopmental Disorder (ARND)
1014031|NCT01961037|Accidental Falls
1014032|NCT01961037|Tai Chi
1014033|NCT01961037|Older Adults
1014034|NCT01961037|Balance
1014035|NCT01961037|Moving for Better Balance
1014036|NCT01961037|Church
1014037|NCT01961037|Congregational Intervention
1014038|NCT01961037|Rural
1014039|NCT01961037|West Virginia
1014040|NCT01961024|VLDL-TG kinetics
1014041|NCT01961024|Postprandial state
1014042|NCT01961024|Obesity
1014043|NCT01961011|nerve compression, carpal tunnel, clinical decision making
1014044|NCT01960998|radical prostatectomy
1014045|NCT01960998|urinary incontinence
1014046|NCT01960998|prostate cancer
1014047|NCT01960998|telehealth
1014048|NCT01960998|pelvic floor muscle training
1014049|NCT01960985|Balance, Postural
1014050|NCT01960985|Parkinson´s Disease
1014051|NCT01960985|H&Y 1-3
1014052|NCT01960985|Exrecice
1014053|NCT01960985|Postural adjustments
1014054|NCT01960985|antecipatory postural
1014055|NCT01960985|compensatory postural adjustments
1014056|NCT01960972|Blood pressure
1014057|NCT01960972|Hypertension
1014058|NCT01960972|Stepped wedge trial design
1014059|NCT01960946|Hypertension
1014060|NCT01960946|Galectin 3
1014061|NCT01960946|Fibrosis
1014062|NCT01960946|Vascular Stiffness
1014063|NCT01960946|Echocardiography
1014064|NCT01960933|STEMI
1014065|NCT01960933|MVD
1014066|NCT01960933|Full revascularization
1014067|NCT01960933|Culprit lesion revascularization only
1014068|NCT01960933|Primary PCI
1014069|NCT01960920|Air Pollution
1014070|NCT01960920|Heart Failure
1014071|NCT01960920|Endothelium
1014072|NCT01960920|Autonomic Dysfunction
1014073|NCT01960920|Cardiopulmonary Exercise Test
1014074|NCT01960907|COPD
1014075|NCT01960907|CHF
1014076|NCT01960907|SDB
1014077|NCT01960881|Prostate cancer
1014078|NCT01960855|anti-inflammatory agents
1014079|NCT01960855|Joint Diseases
1014080|NCT01960855|Arthritis
1014081|NCT01960855|Musculoskeletal Disease
1014082|NCT01960855|antirheumatic agents
1014083|NCT01960842|levodopa
1014084|NCT01960842|Advanced Parkinson's Disease
1014085|NCT01960842|carbidopa
1014086|NCT01960842|levodopa-carbidopa intestinal gel
1014087|NCT01960842|Safety and Efficacy
1014088|NCT01960829|melanoma
1014089|NCT01960829|TOR Serine-Threonine Kinases
1014090|NCT01960816|nasal obstruction
1014091|NCT01960803|Stage I Breast Carcinoma
1014092|NCT01960790|Humira®
1014093|NCT01960790|Behcet's Disease
1014094|NCT01960790|Adalimumab
1014095|NCT01960777|Hernia, Inguinal
1014096|NCT01960777|Laparoscopy
1014097|NCT01960777|Onstep
1014098|NCT01960764|Autologous microbiome transplant
1014099|NCT01960764|Bacteria transplant
1014100|NCT01960764|Treatment for atopic dermatitis
1014101|NCT01960738|Diving
1014102|NCT01960738|Water
1014103|NCT01960738|Recreation
1014104|NCT01960738|Precursor
1014105|NCT01960725|Gastroenteritis
1014106|NCT01960725|Diarrhea
1014107|NCT01960725|Rotavirus
1014108|NCT01960725|Vaccine
1014109|NCT01960725|Dehydration
1014110|NCT01960699|Prognosis
1014111|NCT01960699|Neurological outcome
1014112|NCT01960699|Resuscitation
1014113|NCT01960699|Biomarker
1014114|NCT01960673|supraglottic airway,igel-LMA, ambu-LMA, changing position, head and neck position, oropharyngeal leak pressure,degree of rotation
1014115|NCT01960660|Fish Oil
1014116|NCT01960660|EPA
1014117|NCT01960660|DHA
1014118|NCT01960660|Omega-Score
1014119|NCT01960660|Lipemic Index
1014120|NCT01960660|ethyl esters
1014121|NCT01960660|triglycerides
1014122|NCT01960660|phospholipids
1014123|NCT01960595|PCA,Nerve block,Hullax Valgus
1014124|NCT01960582|Housing adaptation
1014125|NCT01960582|Independence
1014126|NCT01960582|Costs
1014127|NCT01960569|Thrombexx
1014128|NCT01960569|Topical r-Hirudin
1014129|NCT01960569|Efficacy
1014130|NCT01960569|haematoma
1014131|NCT01960556|simulation
1014132|NCT01960543|Intrathecal anesthesia
1014133|NCT01960543|Levobupivacaine
1014134|NCT01960543|Bupivacaine
1014135|NCT01960543|Hip fracture
1014136|NCT01960517|Urinary
1014137|NCT01960517|Incontinence
1014138|NCT01960517|Catheter
1014139|NCT01960504|DREAMS
1014140|NCT01960504|Drug Eluting Absorbable Metal Scaffold
1014141|NCT01960504|Scaffold
1014142|NCT01960504|Coronary Artery Disease
1014143|NCT01960504|Myocardial Ischemia
1014144|NCT01960504|Atherosclerosis
1014145|NCT01960465|CPAP treatment
1014146|NCT01960465|hypertension
1014147|NCT01960452|Insomnia
1014148|NCT01960452|Primary insomnia
1014149|NCT01960452|High density EEG
1014150|NCT01960452|Polysomnography
1014151|NCT01960452|Healthy sleeping controls
1014152|NCT01960439|disease activity
1014153|NCT01960439|central reader
1014154|NCT01960439|endoscopic indices
1014155|NCT01960426|Harvey Bradshaw score
1014156|NCT01960426|Partial Mayo Clinical Score
1014157|NCT01960426|Infliximab
1014158|NCT01960426|Adalimumab
1014159|NCT01960400|Complex regional pain syndrome type 1 (CRPS)
1014160|NCT01960400|Transcranial direct current stimulation (tDCS)
1014161|NCT01960400|Graded motor imagery (GMI)
1014162|NCT01960400|Magnetic resonance imaging (MRI)
1014163|NCT01960400|Functional magnetic resonance imaging (fMRI)
1014164|NCT01960387|AML
1014165|NCT01960387|clofarabine
1014166|NCT01960387|cytarabine
1014167|NCT01960387|persistent AML
1014168|NCT01960387|induction therapy
1014169|NCT01960374|RAS or RAF oncogenes, Inhibition of MEK pathway, inhibition cancer cell proliferation promising anti-cancer therapeutic strategy.
1014170|NCT01960348|RNAi therapeutic
1014171|NCT01960348|FAP
1014172|NCT01960348|Familial Amyloid Polyneuropathy
1014173|NCT01960348|TTR
1014174|NCT01960348|Transthyretin
1014175|NCT01960348|Amyloidosis
1014176|NCT01960335|whey protein intake
1014177|NCT01960335|obesity
1014178|NCT01960335|visceral fat
1014179|NCT01960335|resistance exercise training
1014180|NCT01960335|sprint interval training
1014181|NCT01960335|endurance exercise training
1014182|NCT01960335|yoga training
1014183|NCT01960335|healthy eating
1014184|NCT01960335|healthy lifestyle strategies
1014185|NCT01960335|leptin
1014186|NCT01960335|hunger
1014187|NCT01960322|adherence
1014188|NCT01960322|nonadherence
1014189|NCT01960322|compliance
1014190|NCT01960322|noncompliance
1014191|NCT01960322|liver transplantation
1014192|NCT01960296|clopidogrel
1014193|NCT01960296|general surgery
1014194|NCT01960270|relapse after an initial clinical response
1014195|NCT01960257|tuberculosis
1014196|NCT01960257|tuberculosis treatment
1014197|NCT01960257|wirelessly observed therapy
1014198|NCT01960257|proteus digital health
1014199|NCT01960257|digital health feedback system
1014200|NCT01960244|familial
1014201|NCT01960244|hypercholesterolemia
1014202|NCT01960244|FH
1014203|NCT01960218|acute decompensated heart failure
1014204|NCT01960218|gas exchange
1014205|NCT01960218|cardiopulmonary
1014206|NCT01960218|dyspnea
1014207|NCT01960218|cardiopulmonary analyzer
1014208|NCT01960218|heart disease
1014209|NCT01960218|cardiovascular disease
1014210|NCT01960218|cardiopulmonary exercise
1014211|NCT01960205|Saxagliptin, prediabetes, glucose intolerance,obesity
1014212|NCT01960192|primary CNS lymphoma;chemotherapy;
1014213|NCT01960192|RR;PFS;OS
1014214|NCT01960153|Heart failure
1014215|NCT01960153|Pulmonary hypertension
1014216|NCT01960153|tadalafil
1014217|NCT01960153|Phosphodiesterase Type 5 Inhibition
1014218|NCT01960114|Acetaminophen
1014219|NCT01960114|Paracetamol Analgesics
1014220|NCT01960114|Analgesics
1014221|NCT01960114|Non-Narcotic Pain
1014222|NCT01960114|Postoperative Pain
1014223|NCT01960114|Antipyretics Dental Surgery
1014224|NCT01960114|Third molar extraction
1014225|NCT01960101|xerostomia
1014226|NCT01960101|Saliva
1014227|NCT01960101|iatrogenic oral dryness
1014228|NCT01960101|antidepressants
1014229|NCT01960101|mouth dryness
1014230|NCT01960101|milk product
1014231|NCT01960088|Adolescent vaccines
1014232|NCT01960088|HPV vaccine
1014233|NCT01960088|Pharmacies
1014234|NCT01960075|status epilepticus, refractory, benzodiazepine, fosphenytoin, levetiracetam, valproic acid
1014235|NCT01960062|diabetes
1014236|NCT01960062|web-based
1014237|NCT01960062|software
1014238|NCT01960062|device
1014239|NCT01960049|Postoperative pain
1014240|NCT01960049|Liver resection
1014241|NCT01960049|Medial Open Transversus Abdominis Plane catheter
1014242|NCT01960036|Substance Use Disorders
1014243|NCT01960036|Complementary Therapies
1014245|NCT01960036|Mind-Body Therapies
1014246|NCT01960036|Behavior and Behavior Mechanisms
1014247|NCT01960023|Colorectal cancer
1014248|NCT01960023|KRAS
1014249|NCT01960023|BRAF
1014250|NCT01960023|NRAS
1014251|NCT01960023|PIK3CA
1014252|NCT01960023|NSABP
1014253|NCT01959958|Nocturnal enuresis
1014254|NCT01959958|Barriers to treatment
1014255|NCT01959945|Prevention
1014256|NCT01959932|Smoking
1014257|NCT01959932|Candidate Modified Risk Tobacco Product
1014258|NCT01959932|Conventional cigarettes
1014259|NCT01959932|Reduced exposure
1014260|NCT01959932|Confinement
1014261|NCT01959906|Esophagectomy
1014262|NCT01959880|Breast Augmentation
1014263|NCT01959880|Breast Reconstruction
1014264|NCT01959880|Breast Revision
1014265|NCT01959880|Silicone Gel
1014266|NCT01959880|Contour Profile Gel
1014267|NCT01959880|Siltex
1014268|NCT01959880|CPG Styles
1014269|NCT01959867|mastectomy
1014270|NCT01959867|breast reconstruction
1014271|NCT01959867|bovine
1014272|NCT01959867|ADM
1014273|NCT01959867|breast cancer
1014274|NCT01959867|breast implants
1014275|NCT01959867|breast expanders
1014276|NCT01959867|radiation therapy
1014277|NCT01959828|pulmonary hypertension
1014278|NCT01959828|cardiac surgery
1014279|NCT01959828|Glenn surgery
1014280|NCT01959828|fontan surgery
1014281|NCT01959828|left ventricular assist device
1014282|NCT01959828|LVAD
1014283|NCT01959802|Macular pseudohole
1014284|NCT01959802|Cone outer segment tips line
1014285|NCT01959789|Randomized Controlled Clinical Trial
1014286|NCT01959789|Tooth Bleaching
1014287|NCT01959776|cone outer segment tips line, foveal displacement
1014288|NCT01959763|Metabolic syndrome
1014289|NCT01959763|obesity
1014290|NCT01959763|overweight
1014291|NCT01959763|weight loss intervention
1014292|NCT01959763|cognitive behavioral therapy
1014293|NCT01959763|ICT intervention
1014294|NCT01959763|cardiovascular disease
1014295|NCT01959763|persuasive systems design
1014296|NCT01959737|reactivity of HPA axis
1014297|NCT01959724|Macular detachment
1014298|NCT01959724|Macular retinoschisis
1014299|NCT01959724|Vitrectomy
1014300|NCT01959711|Lateral transperitoneal laparoscopic adrenalectomy
1014301|NCT01959711|Posterior retroperitoneoscopic adrenalectomy
1014302|NCT01959646|Immune Function
1014303|NCT01959646|Aged Garlic Extract
1014304|NCT01959646|Supplementation
1014305|NCT01959646|Inflammation
1014306|NCT01959620|PTSD
1014307|NCT01959607|Smoking
1014308|NCT01959607|Nicotine absorption
1014309|NCT01959607|Modified risk tobacco product
1014310|NCT01959607|Conventional cigarettes
1014311|NCT01959607|Nicotine Replacement Therapy gum (NRT gum)
1014312|NCT01959594|multiple doses
1014313|NCT01959594|pharmacokinetics
1014314|NCT01959594|safety
1014315|NCT01959594|tolerability
1014316|NCT01959594|healthy volunteers
1014317|NCT01959594|steady state
1014318|NCT01959594|cognitive impairment associated with schizophrenia
1014319|NCT01959581|Wilmington Robotic Exoskeleton
1014320|NCT01959581|Reaching
1014321|NCT01959581|Upper extremity function
1014322|NCT01959581|Preterm Infants
1014323|NCT01959581|Brain injury
1014324|NCT01959581|Pediatrics
1014325|NCT01959581|Early Intervention
1014326|NCT01959581|Arthrogryposis
1014327|NCT01959568|Retinal Detachment
1014328|NCT01959568|Double Tamponade
1014329|NCT01959568|Perfluorocarbon liquids
1014330|NCT01959568|Vitrectomy
1014331|NCT01959542|Prostate Cancer
1014332|NCT01959516|COPD, early morning symptoms
1014333|NCT01959503|Aorta
1014334|NCT01959503|Aortic
1014335|NCT01959503|Reconstruction
1014336|NCT01959503|CABG
1014337|NCT01959503|Bypass
1014338|NCT01959464|Assisted reproductive technology
1014339|NCT01959464|Infertility
1014340|NCT01959464|Progesterone
1014341|NCT01959464|Vaginal gel
1014342|NCT01959464|Luteal-phase support
1014345|NCT01959438|Phase I study for safety
1014346|NCT01959438|Later Phase II study for responses
1014354|NCT01959412|wheezing, short of breath, laba, inhaler
1014355|NCT01959399|ASP015K
1014356|NCT01959399|healthy subjects
1014357|NCT01959360|Arthroplasty, Total Hip Replacement, Hip
1014358|NCT01959360|Surgical Procedures, Operative
1014359|NCT01959360|Surgical Procedures, Minimally Invasive
1014360|NCT01959347|urinary incontinence
1014361|NCT01959347|midurethral sling
1014362|NCT01959347|pelvic floor therapy
1014363|NCT01959334|Diabetes Mellitus
1014364|NCT01959334|Hypoglycemia
1014365|NCT01959334|Glucagon
1014366|NCT01959334|Anti-glucagon Antibody
1014367|NCT01959334|Immunogenicity
1014368|NCT01959308|Adherence
1014369|NCT01959308|Compliance
1014370|NCT01959308|Immunosuppressive Therapy
1014371|NCT01959308|Liver Transplant
1014372|NCT01959308|Liver Recipients
1014373|NCT01959308|Adult
1014374|NCT01959308|Adolescent
1014375|NCT01959282|Colitis, Ulcerative
1014376|NCT01959282|JNJ-54781532
1014377|NCT01959282|Moderate
1014378|NCT01959282|Severe
1014379|NCT01959282|Active
1014380|NCT01959256|Stroke
1014381|NCT01959256|Visual Field Defect
1014382|NCT01959256|Visual perceptual learning
1014383|NCT01959256|Brain connectivity
1014384|NCT01959243|Ocular redness
1014385|NCT01959230|Ocular redness
1014386|NCT01959217|HIV
1014387|NCT01959217|Substance Abuse
1014388|NCT01959217|Prospective Memory
1014389|NCT01959204|pharmacokinetics
1014390|NCT01959204|safety
1014391|NCT01959191|Platelet activity, CABG, off-pump surgery
1014392|NCT01959165|Ulcerative Colitis, Japanese, subcutaneously
1014393|NCT01959152|Cochlear Implant
1014394|NCT01959152|HiRes™ 90K Advantage implant
1014395|NCT01959152|Cochlear Implantation
1014396|NCT01959152|HiFocus™ Mid-Scala electrode
1014397|NCT01959152|Listening Benefits
1014398|NCT01959152|Adults
1014399|NCT01959152|Cochlear Implant Benefit
1014400|NCT01959152|HiRes Fidelity 120™
1014401|NCT01959152|Electrical Stimulation
1014402|NCT01959126|Telomerase
1014403|NCT01959126|Telomere length
1014404|NCT01959126|Psychological Sress
1014405|NCT01959126|Mindfulness
1014406|NCT01959113|Microbiome
1014407|NCT01959113|Bacteria transplant
1014408|NCT01959113|Atopic dermatitis treatments
1014409|NCT01959100|hematopoietic stem cell transplantation
1014410|NCT01959100|pulmonary non-infectious complications
1014411|NCT01959100|bronchiolitis obliterans syndrome
1014412|NCT01959087|Single port surgery
1014413|NCT01959087|Colonic surgery
1014414|NCT01959087|Postoperative morbidity
1014415|NCT01959087|Postoperative outcomes
1014416|NCT01959061|Advanced colorectal cancer of liver metastatic
1014417|NCT01959048|Clostridium difficile associated disease
1014418|NCT01959048|fecal microbiota transplantation
1014419|NCT01959022|Posttramatic Stress Disorder
1014420|NCT01959022|Post-traumatic Stress Disorder
1014421|NCT01959022|PTSD
1014422|NCT01959022|Doxazosin
1014423|NCT01959022|Nightmares
1014424|NCT01959022|Sleep Disturbance
1014425|NCT01959009|newborn, lung disease, mechanical ventilation, lung recruitment, high frequency ventilation
1014426|NCT01958983|dementia
1014427|NCT01958983|drumming
1014428|NCT01958983|emotion
1014429|NCT01958983|cognition
1014430|NCT01958983|functional MRI
1014431|NCT01958970|End Stage Renal Disease
1014432|NCT01958970|ESRD
1014433|NCT01958970|Maintenance Hemodialysis
1014434|NCT01958970|Hemodialysis
1014435|NCT01958970|Dialysis
1014436|NCT01958970|MHD
1014437|NCT01958970|Protein Energy Wasting
1014438|NCT01958970|PEW
1014439|NCT01958957|ischemic stroke
1014440|NCT01958957|safety
1014441|NCT01958957|Ginkgolides Meglumine Injection
1014442|NCT01958944|CF
1014443|NCT01958944|Cystic Fibrosis
1014444|NCT01958944|NO
1014445|NCT01958944|nitric oxide
1014446|NCT01958944|inhalation
1014447|NCT01958918|neovascular AMD
1014448|NCT01958918|ranibizumab
1014449|NCT01958918|aflibercept
1014450|NCT01958918|BCVA
1014451|NCT01958918|SD OCT
1014452|NCT01958892|BPH
1014453|NCT01958879|internal derangement,arthrocentesis,corticosteroid
1014454|NCT01958866|Fever
1014455|NCT01958866|Body temperature
1014456|NCT01958853|Pain
1014457|NCT01958840|Behavioral
1014458|NCT01958840|Activation
1014459|NCT01958840|Treatment
1014460|NCT01958827|Dose Escalation
1014461|NCT01958827|Crohn's Disease
1014462|NCT01958801|Supraclavicular brachial plexus block
1014463|NCT01958801|Interscalene brachial plexus block
1014464|NCT01958801|Arthroscopic shoulder surgery
1014465|NCT01958788|Cognitive-behavioral treatment
1014466|NCT01958788|Generalized anxiety disorder
1014467|NCT01958788|Worry
1014468|NCT01958788|Behavioral experiments
1014469|NCT01958788|Safety behaviors
1014470|NCT01958788|Anxiety
1014471|NCT01958775|Lipoproteins, apoB, GLP-2
1014472|NCT01958762|Screening
1014473|NCT01958762|Cancer
1014474|NCT01958762|Tobacco
1014475|NCT01958762|General Practitioner
1014476|NCT01958762|Precancerous Lesion
1014477|NCT01958762|Dysplasia
1014478|NCT01958762|Tobacco vendor
1014479|NCT01958723|Problem Specific Template
1014480|NCT01958723|Physician Documentation
1014481|NCT01958723|Electronic Medical Record Documentation
1014482|NCT01958710|Catheterization, Bronchial
1014483|NCT01958710|Pneumonectomy
1014484|NCT01958710|Lobectomy
1014485|NCT01958710|Thoracoplasty
1014486|NCT01958697|Nutritional Disorders
1014487|NCT01958697|Feeding Behavior
1014488|NCT01958684|Bleeding pattern
1014489|NCT01958684|LNG-IUS
1014490|NCT01958684|Cu-IUD
1014491|NCT01958684|postabortion
1014492|NCT01958645|Phase 1, healthy male subjects, safety and tolerability, pharmacodynamic, pharmacokinetic
1014493|NCT01958619|open label
1014494|NCT01958619|healthy volunteers
1014495|NCT01958619|pharmacokinetic
1014496|NCT01958619|parallel group
1014497|NCT01958606|Stroke
1014498|NCT01958606|Rehabilitation
1014499|NCT01958606|Exercise
1014500|NCT01958606|Intensity
1014501|NCT01958606|Gait
1014502|NCT01958593|PTSD
1014503|NCT01958593|Posttraumatic stress disorder
1014504|NCT01958593|MDMA
1014505|NCT01958593|psychotherapy
1014506|NCT01958567|Scleritis
1014507|NCT01958567|Episcleritis
1014508|NCT01958567|Optical coherence Tomography
1014509|NCT01958541|Sleep
1014510|NCT01958541|Insomnia
1014511|NCT01958541|Suicidal Symptoms
1014512|NCT01958541|Suicidal Ideation
1014513|NCT01958541|Military Veteran
1014514|NCT01958541|Service Member
1014515|NCT01958541|Depression
1014516|NCT01958515|Radiation Therapy
1014517|NCT01958515|Chemotherapy
1014518|NCT01958515|Chemoradiation Therapy
1014519|NCT01958502|nonunion
1014520|NCT01958502|mesenchymal stem cell
1014521|NCT01958502|scaffold
1014522|NCT01958502|BMP2
1014523|NCT01958502|long bone
1014524|NCT01958476|Neonatal Abstinence Syndrome
1014525|NCT01958476|Opioids
1014526|NCT01958463|Clostridium Difficile Infection
1014527|NCT01958463|Fecal Microbiota Transplantation
1014528|NCT01958450|acne scar
1014529|NCT01958450|Laser therapy
1014530|NCT01958450|wound healing
1014531|NCT01958437|Aging
1014532|NCT01958437|Alzheimer's Disease/Dementia
1014533|NCT01958437|Cognitive Disorders
1014534|NCT01958437|Imaging
1014535|NCT01958437|Magnetic Resonance Imaging (MRI)
1014536|NCT01958437|Neurology
1014537|NCT01958437|Physical Medicine & Rehabilitation
1014538|NCT01958437|transcranial direct current stimulation
1014539|NCT01958424|metabolic syndrome
1014540|NCT01958424|in vitro fertilization
1014541|NCT01958424|c reactive protein
1014542|NCT01958424|over-weight women
1014543|NCT01958424|ovarian stimulation
1014544|NCT01958398|Randomized Controlled Trial
1014545|NCT01958398|Alcohol
1014546|NCT01958398|Internet
1014547|NCT01958398|Mobile phone
1014548|NCT01958398|Screening
1014549|NCT01958398|Brief intervention
1014550|NCT01958385|Total Body Weight Loss
1014551|NCT01958359|Randomized Controlled Trial
1014552|NCT01958359|Alcohol
1014553|NCT01958359|Telephone
1014554|NCT01958359|Mobile phone
1014555|NCT01958359|Screening
1014556|NCT01958359|Brief intervention
1014557|NCT01958359|IVR-based conversation menu with exercises and vignettes
1014558|NCT01958333|Health-Related Physical Fitness
1014559|NCT01958333|Aerobic Endurance
1014560|NCT01958333|Muscular Endurance
1014561|NCT01958333|Flexibility
1014562|NCT01958320|patent ductus arteriosus
1014563|NCT01958320|patent ductus arteriosus ligation
1014564|NCT01958320|necrotizing enterocolitis
1014565|NCT01958320|spontaneous intestinal perforation
1014566|NCT01958255|tobacco quit rates
1014567|NCT01958242|Cardiopulmonary bypass
1014568|NCT01958242|pediatric
1014569|NCT01958242|blood products
1014570|NCT01958242|conservation
1014571|NCT01958216|TICE-human-stable isotopes
1014572|NCT01958190|Liver transplantation long term renal function
1014573|NCT01958190|tacrolimus sirolimus
1014574|NCT01958177|stem cell
1014575|NCT01958177|cerebellar ataxia
1014576|NCT01958177|BMMNC
1014577|NCT01958151|colonoscopy
1014578|NCT01958151|deep sedation
1014579|NCT01958151|anxiety
1014580|NCT01958138|Laryngeal Mask Airway
1014581|NCT01958138|Propofol
1014582|NCT01958138|Isoflurane
1014583|NCT01958138|Pediatric patients
1014584|NCT01958138|Emergence
1014585|NCT01958125|vagus nerve stimulation
1014586|NCT01958125|vagal nerve stimulation
1014587|NCT01958125|nVNS
1014588|NCT01958125|VNS
1014589|NCT01958125|cluster headache
1014590|NCT01958125|non invasive
1014591|NCT01958125|gammacore
1014595|NCT01958099|Injury Prevention
1014596|NCT01958086|Neural
1014597|NCT01958086|Prosthetic
1014598|NCT01958086|brain machine interface
1014599|NCT01958086|brain computer interface
1014600|NCT01958086|brain control
1014601|NCT01958086|paralysis
1014602|NCT01958086|tetraplegia
1014603|NCT01958086|quadriplegia
1014604|NCT01958086|spinal cord injury
1014605|NCT01958073|Recurrent Urinary Tract Infection
1014606|NCT01958073|Postmenopausal
1014607|NCT01958073|Vaginal Estrogen
1014608|NCT01958047|Phase I
1014609|NCT01958047|ASP3652
1014610|NCT01958047|Single dose
1014611|NCT01958047|Dietary intake
1014612|NCT01958021|HR-positive
1014613|NCT01958021|HER2-negative
1014614|NCT01958021|Advanced breast cancer
1014615|NCT01958021|LEE011
1014616|NCT01958021|Letrozole
1014617|NCT01958021|CDK
1014618|NCT01958021|CDK4
1014619|NCT01958021|CDK6
1014620|NCT01958021|CDK4/6
1014621|NCT01958021|Phase III
1014622|NCT01958021|ER-positive
1014623|NCT01958021|PR-positive
1014624|NCT01958021|Postmenopausal
1014625|NCT01957943|Omega 3 lipid emulsions
1014626|NCT01957943|Liver transplantation
1014627|NCT01957943|Ischemia reperfusion injury
1014628|NCT01957943|graft function
1014629|NCT01957930|HbA1c
1014630|NCT01957930|Iontophoresis
1014631|NCT01957930|Intensified insulin treatment
1014632|NCT01957930|Ischemic foot ulcer
1014633|NCT01957930|Type 1 diabetes
1014634|NCT01957917|HIV
1014635|NCT01957917|Food Insecurity
1014636|NCT01957917|Antiretroviral Therapy
1014637|NCT01957904|ArterX, surgical sealant
1014638|NCT01957891|Hypoxia
1014639|NCT01957891|Multiple wavelengths
1014640|NCT01957865|HIV/AIDS
1014641|NCT01957865|adherence
1014642|NCT01957865|real time monitoring
1014643|NCT01957865|SMS
1014644|NCT01957865|mHealth
1014645|NCT01957865|social support
1014646|NCT01957826|mesenchymal
1014647|NCT01957826|stem cells
1014648|NCT01957826|transendocardial injection
1014649|NCT01957826|dilated idiopathic cardiomyopathy
1014650|NCT01957826|idiopathic cardiomyopathy
1014651|NCT01957813|APHIA AIDS, Population and Health Integrated Assistance
1014652|NCT01957813|DIC Drop-in center
1014653|NCT01957813|DMPA depot medroxyprogesterone acetate
1014654|NCT01957813|DRH Division of Reproductive Health
1014655|NCT01957813|FAIR Family AIDS Initiative Response
1014656|NCT01957813|FHOK Family Health Options Kenya
1014657|NCT01957813|FP Family planning
1014658|NCT01957813|FGD Focus group discussion
1014659|NCT01957813|FSW Female sex worker
1014660|NCT01957813|GSKenya Gold Star Kenya
1014661|NCT01957813|HTC HIV testing and counseling
1014662|NCT01957813|HIV Human Immunodeficiency Virus
1014663|NCT01957813|KNASP Kenya National AIDS Strategic Plan
1014664|NCT01957813|MARPS Most at-risk populations
1014665|NCT01957813|MoPHS Ministry of Public Health and Sanitation
1014666|NCT01957813|MMS Ministry of Medical Services
1014667|NCT01957813|NASCOP National AIDS and STI Control Program
1014668|NCT01957813|RH Reproductive health
1014669|NCT01957813|SRH Sexual and reproductive health
1014670|NCT01957813|STI Sexually transmitted infection
1014671|NCT01957813|USAID United States Agency for International Development
1014672|NCT01957800|weight loss
1014673|NCT01957800|healthy diet
1014674|NCT01957800|website
1014675|NCT01957800|action planning
1014676|NCT01957800|phone
1014677|NCT01957800|social
1014678|NCT01957787|Metastatic lung tumors
1014679|NCT01957787|Pulmonary metastatic disease
1014680|NCT01957748|Retention
1014681|NCT01957748|Care
1014682|NCT01957748|Engagement
1014683|NCT01957735|metastatic cancer
1014684|NCT01957735|solid tumor
1014685|NCT01957735|unresectable tumor
1014686|NCT01957735|brain cancer
1014687|NCT01957735|lymphoma
1014688|NCT01957696|Diabetes mellitus
1014689|NCT01957696|Pancreas transplantation
1014690|NCT01957696|Rejection
1014691|NCT01957696|Surgical complications
1014692|NCT01957696|Allograft biopsies
1014693|NCT01957696|Immunological analyses
1014694|NCT01957696|Pancreas graft survival
1014695|NCT01957683|intracranial aneurysm
1014696|NCT01957683|bifurcation
1014697|NCT01957683|wide-neck
1014698|NCT01957683|saccular
1014699|NCT01957683|endovascular treatment
1014700|NCT01957683|coil embolization
1014701|NCT01957683|stent
1014702|NCT01957683|bare platinum
1014703|NCT01957670|Keratoconjunctivitis Sicca
1014704|NCT01957670|Dry Eye Syndromes
1014705|NCT01957631|Plantar Fasciitis
1014706|NCT01957631|Steroid
1014707|NCT01957631|Platelet rich plasma
1014708|NCT01957631|Injection
1014709|NCT01957631|Ultrasound
1014710|NCT01957605|prone position
1014711|NCT01957605|hemodynamic variation
1014712|NCT01957605|mean systemic pressure
1014713|NCT01957579|Phase I
1014714|NCT01957579|advanced
1014715|NCT01957579|B cell malignancies
1014716|NCT01957579|dose escalation
1014717|NCT01957579|CD19
1014718|NCT01957579|Japanese
1014719|NCT01957566|propofol sedation
1014720|NCT01957566|children
1014721|NCT01957566|procedure sedation
1014722|NCT01957540|ticagrelor
1014723|NCT01957540|prasugrel
1014724|NCT01957540|endothelial function
1014725|NCT01957527|ticagrelor
1014726|NCT01957527|endothelial function
1014727|NCT01957527|peripheral arterial tonometry
1014728|NCT01957501|Major Depressive Disorder
1014729|NCT01957501|Bipolar Disorder
1014730|NCT01957501|Adolescents
1014731|NCT01957501|Biomarker
1014732|NCT01957436|prostate
1014733|NCT01957436|cancer
1014734|NCT01957436|metastatic hormone-naive
1014735|NCT01957436|radiotherapy
1014736|NCT01957436|abiraterone acetate
1014737|NCT01957423|Crohn's disease
1014738|NCT01957423|whey protein
1014739|NCT01957423|soy protein
1014740|NCT01957423|nutritional status
1014741|NCT01957423|activity of disease
1014742|NCT01957410|Major Depressive Disorder
1014743|NCT01957410|Ketamine
1014744|NCT01957410|Evoked potentials
1014745|NCT01957410|Somatosensory evoked potentials
1014746|NCT01957410|Motor evoked potentials
1014747|NCT01957410|Cortical plasticity
1014748|NCT01957371|PTSD
1014749|NCT01957371|Yoga
1014750|NCT01957371|Complementary and Alternative Medicine (CAM)
1014751|NCT01957371|Chronic Pain
1014752|NCT01957345|constitutional functional disorders of platelets
1014753|NCT01957345|platelet signalling defects
1014754|NCT01957332|molecular imaging
1014755|NCT01957332|HER2-PET
1014756|NCT01957332|89Zr-trastuzumab
1014757|NCT01957332|FES-PET
1014758|NCT01957332|metastatic breast cancer
1014759|NCT01957332|clinical utility
1014760|NCT01957306|hot flashes, night sweats
1014761|NCT01957280|HER3
1014762|NCT01957267|Glaucoma
1014763|NCT01957267|Optical Coherence Tomography
1014764|NCT01957267|Intraocular pressure
1014765|NCT01957267|Optic nervehead
1014766|NCT01957267|Nerve fiber layer
1014767|NCT01957202|levocabastine fixed dose combination, Rhinitis, Allergic, Perennial and Seasonal, Allergic Rhinitis, fluticasone furoate
1015020|NCT01955889|Telemedicine
1014768|NCT01957189|pharmacokinetics, Chinese
1014769|NCT01957189|Avodart, Duodart, dutasteride, tamsulosin, drug-drug interaction,
1014770|NCT01957176|myelodysplastic syndromes
1014771|NCT01957176|thrombocytopenia
1014772|NCT01957176|acute myeloid leukemia
1014773|NCT01957176|, idiopathic thrombocytopenic purpura
1014774|NCT01957176|Eltrombopag
1014775|NCT01957176|pediatrics
1014776|NCT01957163|dry powder inhaler
1014777|NCT01957163|fluticasone furoate/vilanterol
1014778|NCT01957163|umeclidinium bromide
1014779|NCT01957163|safety
1014780|NCT01957163|long acting beta2- receptor agonist
1014781|NCT01957163|long acting muscarininc receptor antagonist
1014782|NCT01957163|efficacy
1014783|NCT01957163|COPD
1014784|NCT01957163|inhaled corticosteroid
1014785|NCT01957137|Urinary
1014786|NCT01957137|Urge
1014787|NCT01957137|Incontinence
1014788|NCT01957098|L-arabinose
1014789|NCT01957098|D-xylose
1014790|NCT01957098|sucrose
1014791|NCT01957098|glucose
1014792|NCT01957098|insulin
1014793|NCT01957098|C-peptide
1014794|NCT01957098|GLP-1
1014795|NCT01957085|Hepatitis C
1014796|NCT01957072|Cystic fibrosis
1014797|NCT01957072|Nutrition
1014798|NCT01957072|Weight
1014799|NCT01957072|BMI
1014800|NCT01957072|Behaviour change
1014801|NCT01957059|DMD
1014802|NCT01957059|Duchenne muscular dystrophy
1014803|NCT01957059|Duchenne
1014804|NCT01957059|BMN053
1014805|NCT01957059|BioMarin
1014806|NCT01957046|Opioid induced constipation
1014807|NCT01957046|Laxatives
1014808|NCT01957033|whiplash
1014809|NCT01957033|neck pain
1014810|NCT01957033|manual therapy
1014811|NCT01957033|exercise
1014812|NCT01957033|dosage
1014813|NCT01957007|Phase 1
1014814|NCT01957007|dose escalation
1014815|NCT01957007|histologically confirmed
1014816|NCT01957007|malignancy metastatic
1014817|NCT01956994|Whey Protein
1014818|NCT01956994|Arterial Stiffness
1014819|NCT01956994|Neurovascular Coupling
1014820|NCT01956994|Cerebrovascular Reactivity
1014821|NCT01956994|Hemodynamics
1014822|NCT01956994|Blood Flow
1014823|NCT01956994|Pulsatility
1014824|NCT01956981|controlled hypotension, dexmedetomidine, magnesium sulfate.
1014825|NCT01956968|Shoulder pain, Scapular dyskinesia, Physical examination
1014826|NCT01956942|GLAUCOMA
1014827|NCT01956942|MICROPULSE
1014828|NCT01956942|LASER
1014829|NCT01956942|TRABECULOPLASTY
1014830|NCT01956942|OPEN ANGLE
1014831|NCT01956942|INTRAOCULAR PRESSURE
1014832|NCT01956929|Insulin Resistance
1014833|NCT01956929|Prediabetic State
1014834|NCT01956929|Metformin
1014835|NCT01956916|Pulmonary exacerbation
1014836|NCT01956916|Inflammation
1014837|NCT01956916|Intestinal microbiota
1014838|NCT01956903|mesenchymal stem cell transplantation
1014839|NCT01956890|Breast neoplasms
1014840|NCT01956890|PET
1014841|NCT01956890|MRI
1014842|NCT01956864|Vitamin D
1014843|NCT01956851|insulin, kisspeptin, GLP 1
1014844|NCT01956838|food intake
1014845|NCT01956838|tastants
1014846|NCT01956838|obesity
1014847|NCT01956825|non alcoholic fatty liver disease
1014848|NCT01956825|LCARNITINE amino acid
1014849|NCT01956825|magnesium
1014850|NCT01956825|fat content
1014851|NCT01956812|clivatuzumab tetraxetan
1014852|NCT01956812|90Y-clivatuzumab tetraxetan
1014853|NCT01956812|IMMU-107
1014854|NCT01956799|MDS
1014855|NCT01956799|PMF
1014856|NCT01956799|CMML
1014857|NCT01956799|AA
1014858|NCT01956786|Amlodipine
1014859|NCT01956786|Folic Acid
1014860|NCT01956786|Homocysteine
1014861|NCT01956786|Blood Pressure
1014862|NCT01956773|family health history
1014863|NCT01956773|prevention
1014864|NCT01956773|genetic risk
1014865|NCT01956773|clinical decision support
1014866|NCT01956760|Insomnia
1014867|NCT01956734|glioblastoma
1014868|NCT01956734|first recurrence
1014869|NCT01956734|temozolomide
1014870|NCT01956721|Heart Failure , Skeletal muscle,Calcium,Ryanodine Receptor, Mitochondria, Exercise training, Muscle biopsy, Healthy volunteers
1014871|NCT01956669|VEGF
1014872|NCT01956669|Pazopanib
1014873|NCT01956669|Sarcoma
1014874|NCT01956669|GW786034
1014875|NCT01956669|Refractory Solid Tumors
1014876|NCT01956656|lotus leaf, mouthwash, gingivitis
1014877|NCT01956643|sham feeding
1014878|NCT01956643|postoperative ileus
1014879|NCT01956643|liver transplantation
1014880|NCT01956591|Treatment efficacy
1014881|NCT01956591|Long-term effects
1014882|NCT01956591|Tachyphylaxis
1014883|NCT01956591|Undesirable effects
1014884|NCT01956591|Side effects
1014885|NCT01956591|Self-assessment
1014886|NCT01956591|Hyperhidrosis
1014887|NCT01956591|Quality of life
1014888|NCT01956565|Pulmonary Disease, Chronic Obstructive
1014889|NCT01956565|Rehabilitation
1014890|NCT01956565|Physiotherapy
1014891|NCT01956565|Patient Compliance
1014892|NCT01956565|Inspiratory Muscle Training
1014893|NCT01956565|Respiratory Muscle Training
1014894|NCT01956552|Metastatic breast cancer
1014895|NCT01956552|Tumor biopsy
1014896|NCT01956552|Phenotype and genotype characterization
1014897|NCT01956526|Heart Failure with Preserved Ejection Fraction (HFpEF)
1014898|NCT01956526|Diastolic Heart Failure (DHF)
1014899|NCT01956526|Diastolic Dysfunction (DD)
1014900|NCT01956513|ADC
1014901|NCT01956513|breast cancer
1014902|NCT01956513|complete pathological response
1014903|NCT01956500|glucosamine
1014904|NCT01956500|inflammation
1014905|NCT01956500|quality of life
1014906|NCT01956500|physical function
1014907|NCT01956487|Bioequivalence
1014908|NCT01956487|RYTHMOL SR®
1014909|NCT01956487|Atrial fibrillation
1014910|NCT01956487|Propafenone
1014911|NCT01956487|Pharmavokinetics
1014912|NCT01956474|keratoconus
1014913|NCT01956474|cross-linking
1014914|NCT01956474|Post-LASIK ectasia
1014915|NCT01956474|Pellucid marginal degeneration
1014916|NCT01956474|Forme fruste pellucid marginal degeneration
1014917|NCT01956474|FFKC
1014918|NCT01956474|Radial Keratotomy
1014919|NCT01956474|Terrien's Marginal Degeneration
1014920|NCT01956461|osteoporosis
1014921|NCT01956461|BMD
1014922|NCT01956461|teriparatide
1014923|NCT01956461|nursing home
1014924|NCT01956448|Percutaneous coronary intervention
1014925|NCT01956448|DES
1014926|NCT01956448|Angina pectoris
1014927|NCT01956448|Stent
1014928|NCT01956409|breast neoplasms
1014929|NCT01956409|18F-FCH PET
1014930|NCT01956409|MRI
1014931|NCT01956396|male circumcision
1014932|NCT01956396|HIV
1014933|NCT01956396|Zimbabwe
1014934|NCT01956383|male circumcision
1014935|NCT01956383|HIV
1014936|NCT01956383|Zimbabwe
1014937|NCT01956370|Male Circumcision
1014938|NCT01956370|HIV Prevention
1014939|NCT01956370|Medical Device
1014940|NCT01956357|aquatic exercises;
1014941|NCT01956357|deep water running;
1014942|NCT01956357|diabetes;
1014943|NCT01956357|blood glucose;
1014944|NCT01956357|inflammation.
1014945|NCT01956344|Hoarding Disorder
1014946|NCT01956344|Clutter
1014947|NCT01956344|CBT
1014948|NCT01956344|Cognitive behavior therapy
1014949|NCT01956344|fMRI
1014950|NCT01956344|Obsessive compulsive disorder (OCD)
1014951|NCT01956344|Healthy control
1014952|NCT01956331|NSC lung Cancer,Elderly patients,post operative,
1014953|NCT01956318|Chronic venous insufficiency
1014954|NCT01956318|Varicose vein
1014955|NCT01956318|Crenobalneotherapy
1014956|NCT01956318|Balneotherapy
1014957|NCT01956318|Spa therapy
1014958|NCT01956279|Pregnenolone
1014959|NCT01956279|Gulf War Veteran
1014960|NCT01956279|Fatigue
1014961|NCT01956279|Musculoskeletal Pain
1014962|NCT01956279|Cognitive Decline
1014963|NCT01956279|Placebo Control
1014964|NCT01956266|Prosody
1014965|NCT01956266|Communication
1014966|NCT01956266|Dysarthria
1014967|NCT01956253|Bladder Cancer
1014968|NCT01956253|Neratinib
1014969|NCT01956253|13-2526
1014970|NCT01956240|shoulder
1014971|NCT01956240|pectoralis minor
1014972|NCT01956240|stretching
1014973|NCT01956240|scapular kinematics
1014974|NCT01956214|hemodialysis
1014975|NCT01956214|exercise
1014976|NCT01956214|electrical stimulation
1014977|NCT01956175|electrical pharyngeal stimulation
1014978|NCT01956175|stroke-related dysphagia
1014979|NCT01956175|tracheostomy
1014980|NCT01956175|decannulation
1014981|NCT01956149|gastric cancer
1014982|NCT01956149|second-line treatment
1014983|NCT01956149|Cabazitaxel
1014984|NCT01956149|response
1014985|NCT01956045|Intensive Care Units
1014986|NCT01956045|Judgment
1014987|NCT01956045|Disability Evaluation
1014988|NCT01956045|Autonomy
1014989|NCT01956032|LCIG
1014990|NCT01956032|Parkinson's disease
1014991|NCT01956032|levodopa carbidopa intestinal gel
1014992|NCT01956032|Telemedicine
1014993|NCT01955993|Obesity, adolescence,pharmacokinetics,fentanyl
1014994|NCT01955980|CRS
1014995|NCT01955980|without polyposis
1014996|NCT01955967|Effect
1014997|NCT01955967|Lidocaine
1014998|NCT01955954|carbon dioxide monitoring
1014999|NCT01955954|panic disorder
1015000|NCT01955954|biofeedback
1015001|NCT01955954|breathing training
1015002|NCT01955954|Primary diagnosis
1015003|NCT01955941|Uveal melanoma
1015004|NCT01955941|brachytherapy
1015005|NCT01955941|radiation
1015006|NCT01955941|ciliary body
1015007|NCT01955941|choroid
1015008|NCT01955941|I-125 plaque brachytherapy
1015009|NCT01955915|choroid
1015010|NCT01955915|tumor
1015011|NCT01955915|OCT
1015012|NCT01955915|malignant melanoma
1015013|NCT01955902|Opioid dependence
1015014|NCT01955902|Buprenorphine
1015015|NCT01955902|Adherence
1015016|NCT01955902|Substance use
1015017|NCT01955902|Suboxone
1015018|NCT01955889|Exercise
1015019|NCT01955889|Rehabilitation
1015021|NCT01955876|Fosrenol
1015022|NCT01955876|hyperphosphatemia
1015023|NCT01955876|chronic kidney disease not on dialysis
1015024|NCT01955863|Prostatic Neoplasms
1015025|NCT01955863|Prostatectomy, Retropubic
1015026|NCT01955863|Patient Discharge
1015027|NCT01955824|bronchoscopy
1015028|NCT01955824|lignocaine
1015029|NCT01955824|cough
1015030|NCT01955811|platelet transfusion
1015031|NCT01955811|Fibrinogen
1015032|NCT01955811|blood coagulation
1015033|NCT01955811|Thrombocytopenia
1015034|NCT01955811|in-vitro experiments
1015035|NCT01955811|FGTW
1015036|NCT01955811|Fit2012
1015037|NCT01955811|factor I
1015038|NCT01955811|Fibrin
1015039|NCT01955798|Laparoscopy
1015040|NCT01955798|Gyneacological
1015041|NCT01955798|Entry techniques
1015042|NCT01955785|Traumatic brain injury
1015043|NCT01955785|Intracranial pressure
1015044|NCT01955785|Ventilation
1015045|NCT01955785|Respiratory therapy
1015046|NCT01955772|Haematopoietic stem cell transplantation
1015047|NCT01955772|Malignant hemopathy
1015048|NCT01955772|Artificial nutrition
1015049|NCT01955694|BAY94-8862
1015050|NCT01955694|MR antagonist
1015051|NCT01955694|Heart failure
1015052|NCT01955694|Japanese patients
1015053|NCT01955681|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor retrement.
1015054|NCT01955668|11q-deleted relapsed/refractory chronic lymphocytic leukaemia
1015055|NCT01955668|Prolymphocytic leukaemia
1015056|NCT01955668|B cell lymphomas
1015057|NCT01955655|Baclofen
1015058|NCT01955655|cerebral palsy
1015059|NCT01955655|colic
1015060|NCT01955655|crying infant
1015061|NCT01955655|recurrent crying spells
1015062|NCT01955655|spasticity
1015063|NCT01955655|therapy
1015064|NCT01955642|Clopidogrel
1015065|NCT01955642|Brain Ischemia
1015066|NCT01955642|Ischemic attack
1015067|NCT01955642|Biological response to clopidogrel
1015068|NCT01955616|Parkinson's disease, chronic constipation
1015069|NCT01955590|Metacognitive therapy
1015070|NCT01955590|Eye Movement Desensitization Reprocessing (EMDR)
1015071|NCT01955590|Cognitive therapy
1015072|NCT01955577|Vitamin D deficiency
1015073|NCT01955577|Ring fixator
1015074|NCT01955577|Tibial fracture
1015075|NCT01955525|Acute coronary syndrome
1015076|NCT01955525|health related quality of life
1015077|NCT01955525|mortality
1015078|NCT01955486|flight simulation
1015079|NCT01955486|middle ear
1015080|NCT01955486|Eustachian tube function
1015081|NCT01955473|Solid tumors
1015082|NCT01955473|Sym004
1015083|NCT01955473|Phase 1
1015084|NCT01955460|Melanoma
1015085|NCT01955460|Metastatic
1015086|NCT01955460|T-cells
1015087|NCT01955460|Autologous tumor infiltrating lymphocytes
1015088|NCT01955460|TIL
1015089|NCT01955460|DNRII
1015090|NCT01955460|NGFR
1015091|NCT01955460|Cyclophosphamide
1015092|NCT01955460|Cytoxan
1015093|NCT01955460|Neosar
1015094|NCT01955460|Mesna
1015095|NCT01955460|Mesnex
1015096|NCT01955460|Fludarabine
1015097|NCT01955460|Fludarabine phosphate
1015098|NCT01955460|Fludara
1015099|NCT01955460|Interleukin-2
1015100|NCT01955460|IL-2
1015101|NCT01955460|Aldesleukin
1015102|NCT01955460|Proleukin
1015103|NCT01955447|Blood glucose
1015104|NCT01955421|NSCLC
1015105|NCT01955421|stage IIIB
1015106|NCT01955421|stage IV)
1015107|NCT01955421|confirmed by histology or cytology methods
1015108|NCT01955421|Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation
1015109|NCT01955408|overactive bladder
1015110|NCT01955408|bladder cancer
1015111|NCT01955408|Synergo
1015112|NCT01955408|urodynamic study
1015113|NCT01955395|Relaxation Response Resiliency Program (3RP)
1015114|NCT01955395|monoclonal gammopathy of undetermined significance
1015115|NCT01955395|smoldering multiple myeloma
1015116|NCT01955382|Parasite Clearance Rate
1015117|NCT01955382|Parasite Half Life
1015118|NCT01955382|Actidose Aqua
1015119|NCT01955382|Severe Malaria
1015120|NCT01955369|incidence
1015121|NCT01955369|phenotype
1015122|NCT01955369|mortality
1015123|NCT01955356|Scratching
1015124|NCT01955356|Endometrial biopsy
1015125|NCT01955356|Ongoing embryo implantation
1015126|NCT01955356|Assisted reproductive techniques
1015129|NCT01955330|CABG, Hybrid, Robotic surgery
1015130|NCT01955317|Neonate
1015131|NCT01955317|Bangladesh
1015132|NCT01955317|Health behavior
1015133|NCT01955317|Handwashing
1015134|NCT01955317|Developing countries
1015135|NCT01955317|Infectious disease
1015136|NCT01955291|Virtual Reality, Motor Learning, Rehabilitation, Upper Limb
1015137|NCT01955278|Laparoscopic colorectal surgery
1015138|NCT01955278|Parastomal hernia
1015139|NCT01955278|Prophylactic
1015140|NCT01955278|Mesh
1015141|NCT01955265|Positive youth development
1015142|NCT01955265|Sports / physical activity
1015143|NCT01955252|Endemic treponematoses
1015144|NCT01955252|Azithromycin
1015145|NCT01955252|Mass drug administration
1015146|NCT01955252|Eradication
1015152|NCT01955213|constipation, methylnaltrexone, opoid
1015153|NCT01955200|Stent implantation
1015154|NCT01955200|Clopidogrel low response
1015155|NCT01955200|Ticagrelor
1015156|NCT01955200|Cilostazol
1015157|NCT01955200|Clopidogrel
1015158|NCT01955187|SEQUENTIAL THERAPY
1015159|NCT01955187|PRIMARY MEMBRANOUS NEPHROPATHY
1015160|NCT01955187|TACROLIMUS
1015161|NCT01955187|RITUXIMAB
1015162|NCT01955174|Botulinum toxin
1015163|NCT01955174|Esophageal motility disorder
1015164|NCT01955174|Distal esophageal spasm
1015165|NCT01955148|PTB
1015166|NCT01955148|sPTB
1015167|NCT01955148|cervical cerclage
1015168|NCT01955148|LEEP
1015169|NCT01955148|PROM
1015170|NCT01955148|short cervix
1015171|NCT01955135|Prematurity, Retinopathy, propofol, ketamine, sedation
1015172|NCT01955122|polyp/adenoma miss rate
1015173|NCT01955122|colonoscopy add-on device
1015174|NCT01955122|enhanced screening
1015175|NCT01955109|Food allergy
1015176|NCT01955109|Immediate hypersensitivity
1015177|NCT01955109|Whole peanut extract
1015178|NCT01955109|Allergenic product
1015179|NCT01955109|Specific Immunotherapy
1015180|NCT01955109|Epicutaneous Immunotherapy (EPIT)
1015181|NCT01955096|fast-track surgery, laparoscopic gastrectomy
1015182|NCT01955083|Obstructive sleep apnea
1015183|NCT01955083|snoring
1015184|NCT01955083|radiofrequency
1015185|NCT01955083|pillar implant
1015186|NCT01955083|snore sound analysis
1015187|NCT01955070|Informed consent
1015188|NCT01955070|Ethics
1015189|NCT01955044|neonatal prematurity
1015190|NCT01955044|infant, extremely low birth weight
1015191|NCT01955044|fatty acids, polyunsaturated
1015192|NCT01955031|Telemedicine
1015193|NCT01955031|Telemonitoring
1015194|NCT01955031|Education
1015195|NCT01955031|Nutrition
1015196|NCT01955031|Food behaviour
1015197|NCT01955031|Weight
1015198|NCT01955031|Physical activity
1015199|NCT01955031|Glycaemia
1015200|NCT01955031|Self-monitoring blood glucose
1015201|NCT01955018|computed tomography
1015202|NCT01955018|radiation
1015203|NCT01955018|screening
1015204|NCT01955018|asbestos
1015205|NCT01955018|workers
1015206|NCT01955018|cancer
1015207|NCT01955005|Health Records, Personal
1015208|NCT01955005|Delivery of healthcare
1015209|NCT01955005|Consumer Participation
1015210|NCT01955005|Internet
1015211|NCT01954992|glufosfamide
1015212|NCT01954992|5-FU
1015213|NCT01954992|metastatic pancreatic adenocarcinoma
1015214|NCT01954979|Graft versus Host Disease
1015215|NCT01954979|ABATACEPT
1015216|NCT01954966|Nicotine
1015217|NCT01954966|Smoking
1015218|NCT01954953|Retinitis Pigmentosa Syndromic
1015219|NCT01954953|Congenital Deafness
1015220|NCT01954953|Usher Syndrome Retinitis Pigmentosa and Deafness
1015221|NCT01954953|Progressive Hearing Loss
1015222|NCT01954953|Retinitis Pigmentosa
1015223|NCT01954940|Whole body vibration therapy, muscle strength testing, bone health, ambulatory, endurance.
1015224|NCT01954927|Pain control
1015225|NCT01954914|Plerixafor
1015226|NCT01954914|donor
1015227|NCT01954914|allogeneic peripheral stam cell donation
1015228|NCT01954914|PBSC
1015229|NCT01954914|poor donors
1015230|NCT01954875|neurodegenerative diseases
1015231|NCT01954875|amyotrophic lateral sclerosis
1015232|NCT01954875|multiple sclerosis
1015233|NCT01954875|Parkinson's Disease
1015234|NCT01954862|Water-aided colonoscopy
1015235|NCT01954862|Water Immersion colonoscopy
1015236|NCT01954862|Water Exchange colonoscopy
1015237|NCT01954862|Carbon-dioxide colonoscopy
1015238|NCT01954862|Painless unsedated colonoscopy
1015239|NCT01954862|Adenoma detection rate
1015240|NCT01954862|Mean Adenomas per Procedure
1015241|NCT01954849|gingivitis
1015242|NCT01954849|inflammation
1015243|NCT01954849|plaque
1015244|NCT01954849|orthodontics
1015245|NCT01954836|short-term fasting
1015246|NCT01954836|adjuvant chemotherapy
1015247|NCT01954836|toxicity
1015248|NCT01954836|side-effects
1015249|NCT01954836|ovarial carinoma
1015250|NCT01954836|breast cancer
1015251|NCT01954823|Multiple sclerosis, Patient-reported outcomes, patient diary
1015252|NCT01954810|JECV
1015253|NCT01954810|IMOJEV
1015254|NCT01954810|Booster response
1015255|NCT01954810|Children
1015256|NCT01954810|antibody response
1015257|NCT01954810|Duration
1015258|NCT01954797|Physical fitness
1015259|NCT01954797|relaxation
1015260|NCT01954797|stroke
1015261|NCT01954797|cerebral ischemia
1015262|NCT01954797|cerebral perfusion
1015263|NCT01954797|biomarkers
1015264|NCT01954797|MRI
1015265|NCT01954758|Window of implantation
1015266|NCT01954758|Personalized embryo transfer
1015267|NCT01954758|Fresh embryo transfer
1015268|NCT01954758|Delayed embryo transfer
1015269|NCT01954758|Elective deferred embryo transfer
1015270|NCT01954758|Endometrial receptivity array
1015271|NCT01954758|Endometrial receptivity analysis
1015272|NCT01954758|Endometrial receptivity test
1015273|NCT01954745|Bile Duct Cancer
1015274|NCT01954745|intrahepatic cholangiocarcinoma
1015275|NCT01954745|extrahepatic cholangiocarcinoma
1015276|NCT01954745|Cabozantinib
1015277|NCT01954719|Cervix Uteri, Cesarean Section, Infection, Dilatation
1015278|NCT01954693|Tuberous Sclerosis
1015279|NCT01954693|Everolimus
1015280|NCT01954693|Neurocognitive functioning
1015281|NCT01954680|bipolar disorder
1015282|NCT01954680|child
1015283|NCT01954680|adolescent
1015284|NCT01954667|Gastroesophageal Reflux Disease; Anthropometric Measures; Leptin
1015285|NCT01954641|breast cancer
1015286|NCT01954641|lung cancer
1015287|NCT01954641|cancer treatments
1015288|NCT01954641|racial inequity
1015289|NCT01954641|health systems change
1015290|NCT01954641|transparency
1015291|NCT01954641|accountability
1015292|NCT01954628|Exacerbation of COPD
1015293|NCT01954628|Unstable COPD
1015294|NCT01954615|ACT-281959
1015295|NCT01954615|ACT-246475
1015296|NCT01954602|Biliary cannulation
1015297|NCT01954602|Endoscopic retrograde cholangiopancreatography
1015298|NCT01954602|Touch guide-wire techniques
1015299|NCT01954602|No touch guide-wire techniques
1015300|NCT01954589|ACT-462206
1015301|NCT01954589|Selective dual orexin receptor antagonist
1015302|NCT01954563|Tuberculosis
1015303|NCT01954563|Vaccine
1015304|NCT01954563|Immunogenicity
1015305|NCT01954550|Exercise
1015306|NCT01954550|Dementia
1015307|NCT01954550|Cognition
1015308|NCT01954550|Brain Volume
1015309|NCT01954550|Aging
1015310|NCT01954537|Exertional heat illness
1015311|NCT01954537|Hydration Status
1015312|NCT01954537|Preseason football
1015313|NCT01954537|heat stroke
1015314|NCT01954511|Stomatognathic diseases;
1015315|NCT01954511|Temporomandibular Joint Dysfunction Syndrome
1015316|NCT01954498|Randomized controlled trial
1015317|NCT01954498|Spermatozoa
1015318|NCT01954498|Sperm
1015319|NCT01954498|Male Infertility
1015320|NCT01954498|Walnuts
1015321|NCT01954498|Nutrition
1015322|NCT01954498|Male Reproduction
1015323|NCT01954485|LaserLok, connective tissue, adhesion
1015324|NCT01954472|Portfolio diet
1015325|NCT01954472|dietary modification
1015326|NCT01954472|hypercholesterolemia
1015327|NCT01954472|diabetes
1015328|NCT01954472|Exercise
1015329|NCT01954472|CVD risk
1015330|NCT01954472|glycemic index
1015331|NCT01954472|inflammatory biomarkers
1015332|NCT01954472|monounsaturated fat
1015333|NCT01954472|saturated fat
1015334|NCT01954472|nuts
1015335|NCT01954472|plant sterols
1015336|NCT01954472|vegetable protein
1015337|NCT01954472|viscous fiber
1015338|NCT01954472|soy
1015339|NCT01954459|Type 1 diabetes
1015340|NCT01954459|Continuous glucose sensor
1015341|NCT01954459|Insupatch
1015342|NCT01954433|Cost-effectiveness analyses
1015343|NCT01954433|Cost-utility analyses
1015344|NCT01954433|Upper extremity
1015345|NCT01954433|Orthopedic
1015346|NCT01954433|Shoulder arthroplasty
1015347|NCT01954433|Rotator cuff tear repair
1015348|NCT01954433|Resection interposition suspension arthroplasty
1015349|NCT01954420|Pain
1015350|NCT01954420|Fatigue
1015351|NCT01954420|Sleep
1015352|NCT01954420|Cancer
1015353|NCT01954420|Relaxation
1015354|NCT01954420|Distraction
1015355|NCT01954420|Symptoms
1015356|NCT01954407|smoking-related messages
1015357|NCT01954407|anti-smoking messages
1015358|NCT01954407|smoking-related beliefs
1015359|NCT01954407|anti-smoking intentions
1015360|NCT01954355|advanced solid tumor
1015361|NCT01954355|ovarian cancer
1015362|NCT01954355|LDE225
1015363|NCT01954355|Paclitaxel
1015364|NCT01954355|Hedgehog inhibitor
1015365|NCT01954342|Pregnancy
1015366|NCT01954342|Postpartum
1015367|NCT01954329|Biomarkers
1015368|NCT01954329|TIA
1015369|NCT01954329|Diagnosis
1015370|NCT01954316|advanced cancer
1015371|NCT01954316|CFI-400945 fumarate
1015372|NCT01954316|polo-like kinase 4
1015373|NCT01954316|PLK4
1015374|NCT01954316|tablet
1015375|NCT01954316|dose escalation
1015376|NCT01954316|genetic testing
1015377|NCT01954290|Stroke
1015378|NCT01954290|Brain Edema
1015379|NCT01954290|Brain Herniation
1015380|NCT01954290|Conivaptan
1015381|NCT01954277|Chronic Tension-Type Headache
1015382|NCT01954277|Electroacupuncture
1015383|NCT01954277|Headache Impact
1015384|NCT01954277|BDNF
1015385|NCT01954277|TNF
1015386|NCT01954264|Saharan Western Africa
1015387|NCT01954264|Epidemiology
1015388|NCT01954264|Post-Approval Programme study
1015389|NCT01954264|Malaria
1015390|NCT01954264|Burden of Disease Study
1015391|NCT01954251|FLU-D-QIV
1015392|NCT01954251|Adults
1015393|NCT01954251|Safety
1015394|NCT01954251|Immunogenicity
1015395|NCT01954251|co-administration
1015396|NCT01954251|Herpes zoster
1015397|NCT01954238|Anti-coagulant
1015398|NCT01954238|Coagulation factor Xa inhibitor
1015399|NCT01954225|Fistula in ano
1015400|NCT01954225|Bhagandara
1015401|NCT01954225|Udumbara sutra
1015402|NCT01954212|Oral health
1015403|NCT01954199|Sciatica
1015404|NCT01954199|Nerve pain
1015405|NCT01954199|Low back pain
1015406|NCT01954186|Oxytocin
1015407|NCT01954186|Active Management of Third Stage of Labour
1015408|NCT01954134|Tumor Suppressor Protein p53,
1015409|NCT01954134|Iodine Radioisotopes
1015410|NCT01954121|Levetiracetam
1015411|NCT01954121|Keppra
1015412|NCT01954121|Monotherapy
1015413|NCT01954121|China
1015414|NCT01954121|Epilepsy
1015415|NCT01954121|Partial-onset Seizures
1015416|NCT01954108|tendinopathy
1015417|NCT01954108|hyaluronan
1015418|NCT01954108|tendon
1015419|NCT01954108|hyaluronic acid
1015420|NCT01954108|extracorporeal shock wave
1015421|NCT01954095|17-OHPC, Prometrium, Cerclage, Pre-term birth, Short cervix
1015425|NCT01954056|NICHD Neonatal Research Network
1015426|NCT01954056|Mechanical ventilation
1015427|NCT01954056|Intubation
1015428|NCT01954056|Neurodevelopmental impairment
1015429|NCT01954043|melanoma
1015430|NCT01954043|dabrafenib
1015431|NCT01954043|BRAF V600
1015432|NCT01954043|rabeprazole
1015433|NCT01954043|rifampin
1015434|NCT01954030|Carboxyamidotriazole Orotate
1015435|NCT01954030|CTO
1015436|NCT01954030|Bevacizumab
1015437|NCT01954030|Avastin
1015438|NCT01954030|Malignant Glioma
1015439|NCT01954030|Pro00044274
1015440|NCT01954030|Desjardins
1015441|NCT01954030|Duke
1015442|NCT01954030|The Preston Robert Tisch Brain Tumor Center
1015443|NCT01953978|Pain
1015444|NCT01953978|Analgesia
1015445|NCT01953978|Postoperative
1015446|NCT01953978|Dexamethasone
1015447|NCT01953978|Spine surgery
1015458|NCT01953900|Sarcoma
1015459|NCT01953900|T-Cells
1015460|NCT01953900|varicella zoster virus (VZV)
1015461|NCT01953900|GD2
1015462|NCT01953887|Phase I
1015463|NCT01953887|Final formulation EC905
1015464|NCT01953887|Solifenacin succinate
1015465|NCT01953887|Tamsulosin HCl
1015466|NCT01953887|Marketed drugs
1015467|NCT01953874|heart failure
1015468|NCT01953874|congestive heart failure
1015469|NCT01953874|acute decompensated heart failure
1015470|NCT01953874|chronic heart failure
1015471|NCT01953874|left-sided heart failure
1015472|NCT01953874|heart failure decompensation
1015473|NCT01953874|sleep apnea
1015474|NCT01953874|sleep disordered breathing
1015475|NCT01953874|central sleep apnea
1015476|NCT01953874|obstructive sleep apnea
1015477|NCT01953874|cheyne-stokes respiration
1015478|NCT01953861|Phase I
1015479|NCT01953861|Combination tablet EC905
1015480|NCT01953861|Omnic OCAS®
1015481|NCT01953861|Vesicare®
1015482|NCT01953861|Food effect
1015483|NCT01953861|Vesomni
1015484|NCT01953861|VesiFlow
1015485|NCT01953861|Urizia
1015486|NCT01953848|Phase I
1015487|NCT01953848|Combination tablet EC905
1015488|NCT01953848|Steady-state
1015489|NCT01953848|Vesomni
1015490|NCT01953848|VesiFlow
1015491|NCT01953848|Urizia
1015492|NCT01953835|Pharmacokinetics
1015493|NCT01953835|GSK2586184
1015494|NCT01953835|Simvastatin
1015495|NCT01953835|Rosuvastatin
1015496|NCT01953835|Poloxamer
1015497|NCT01953822|Observational
1015498|NCT01953822|Cohort
1015499|NCT01953822|Autoimmune disease
1015500|NCT01953822|Cervarix®
1015501|NCT01953822|Women aged 9 to 25 years
1015502|NCT01953822|United Kingdom
1015503|NCT01953809|oral
1015504|NCT01953809|oral contraceptive
1015505|NCT01953809|pharmacokinetics
1015506|NCT01953809|drug interaction
1015507|NCT01953809|pharmacodynamics
1015508|NCT01953809|GSK1322322
1015509|NCT01953809|antibiotic
1015510|NCT01953809|safety
1015511|NCT01953796|Polycystic Ovarian Syndrome stair step traditional protocol
1015512|NCT01953770|Acute lymphoblastic leukemia, children, adolescents, L-asparaginase, methotrexate
1015513|NCT01953757|diabetic neuropathy, diet, vegan, vegetarian
1015514|NCT01953744|Fluconazole; Meglumine antimoniate;L.Braziliensis;
1015515|NCT01953744|L.Guyanensis
1015516|NCT01953731|palbociclib
1015517|NCT01953731|PD-0332991
1015518|NCT01953731|rifampin
1015519|NCT01953731|drug-drug interaction study
1015520|NCT01953705|omega 3 fatty acids
1015521|NCT01953705|cognitive decline
1015522|NCT01953705|MRI
1015523|NCT01953705|endothelial function
1015524|NCT01953705|white matter
1015525|NCT01953705|executive function
1015526|NCT01953705|prevention
1015527|NCT01953705|DTI
1015528|NCT01953705|ASL
1015529|NCT01953692|PD1
1015530|NCT01953692|PD-1
1015531|NCT01953692|PDL1
1015532|NCT01953692|PD-L1
1015533|NCT01953666|word prediction software, text input speed, copm, occupational therapist, rehabilitation, spinal cord injury
1015534|NCT01953614|quantitative encephalography
1015535|NCT01953614|brain computer interface
1015536|NCT01953614|chiropractic
1015537|NCT01953614|sacro-occipital technique
1015538|NCT01953575|Mucosal Impedance
1015539|NCT01953575|Eosinophilic Esophagitis
1015540|NCT01953575|EoE
1015541|NCT01953562|infants
1015542|NCT01953562|NICU
1015543|NCT01953562|intubated
1015544|NCT01953562|ventilator
1015545|NCT01953549|physical activity, relaxation, activities of daily living, motor functions, cognitive functions
1015546|NCT01953523|erectile dysfunction
1015547|NCT01953523|peyronies
1015548|NCT01953523|interstitial cystitis
1015549|NCT01953523|cardiomyopathy
1015550|NCT01953523|emphysema
1015551|NCT01953523|copd
1015552|NCT01953523|arthritis
1015553|NCT01953523|multiple sclerosis
1015554|NCT01953523|parkinson's
1015555|NCT01953510|Pneumococcal vaccines
1015556|NCT01953510|10-valent pneumococcal vaccine
1015557|NCT01953510|13-valent pneumococcal vaccine
1015558|NCT01953510|Immunization Schedule
1015559|NCT01953510|Public Health
1015560|NCT01953458|Hepatitis B and C
1015561|NCT01953458|ANRS HEPATHER French Cohort
1015562|NCT01953432|Cocaine-Related Disorders
1015563|NCT01953432|Cocaine
1015564|NCT01953432|Doxazosin
1015565|NCT01953432|Cardiovascular Agents
1015566|NCT01953432|Antihypertensive Agents
1015567|NCT01953432|Adrenergic alpha-1 Receptor Antagonists
1015568|NCT01953432|Adrenergic alpha-Antagonists
1015569|NCT01953432|Adrenergic Antagonists
1015570|NCT01953432|Molecular Mechanisms of Pharmacological Action
1015571|NCT01953432|Neurotransmitter Agents
1015572|NCT01953432|Therapeutic Uses
1015573|NCT01953432|Pharmacologic Actions
1015574|NCT01953432|Substance-Related Disorders
1015575|NCT01953406|hepatocellular carcinoma
1015576|NCT01953406|lung metastasis
1015577|NCT01953406|5-fluorouracil/mitomycin
1015578|NCT01953380|Intervention Studies
1015579|NCT01953380|Eczema
1015580|NCT01953380|Randomized Controlled Trial
1015581|NCT01953380|Knowledge
1015582|NCT01953380|Quality of Life
1015583|NCT01953367|Bioequivalence
1015584|NCT01953367|AUC
1015585|NCT01953367|Cmax
1015586|NCT01953354|Ulcerative colitis (UC)
1015587|NCT01953354|Inflammatory Bowel Disease (IBD)
1015588|NCT01953354|Trichuris suis ova (TSO)
1015589|NCT01953341|Migraine
1015590|NCT01953328|Japanese, high cholesterol, LDL-C, High Cardiovascular Risk
1015591|NCT01953315|urinary incontinence, muscle progenitor cells, MPCs
1015592|NCT01953302|ventral hernia
1015593|NCT01953302|infection
1015594|NCT01953302|hematoma
1015595|NCT01953302|seroma
1015596|NCT01953302|recurrence
1015597|NCT01953302|mesh technique
1015598|NCT01953289|Appendicitis
1015599|NCT01953289|Free fluid
1015600|NCT01953276|Acute Coronary Syndrome
1015601|NCT01953276|Chest pain
1015602|NCT01953276|Electrocardiograms
1015603|NCT01953276|Risk Stratification
1015604|NCT01953276|Emergency Department
1015605|NCT01953263|urinary incontinence, muscle fibers
1015606|NCT01953250|Deep infiltrating endometriosis
1015607|NCT01953250|Laparoscopic sigmoid resection
1015608|NCT01953250|laparoscopic rectum resection
1015609|NCT01953250|Colorectal surgery
1015610|NCT01953237|Schizophrenia
1015611|NCT01953237|antipsychotic medication adherence
1015612|NCT01953237|mobile phones
1015613|NCT01953224|Physical activity
1015614|NCT01953224|Video game
1015615|NCT01953224|Mobile
1015616|NCT01953224|Technology
1015617|NCT01953224|Obesity
1015618|NCT01953198|hypoxia hypobaric
1015619|NCT01953185|elderly
1015620|NCT01953185|subjects
1015621|NCT01953146|PCOS
1015622|NCT01953107|Anemia
1015623|NCT01953107|Ovarian cancer
1015624|NCT01953107|Uterine cancer
1015625|NCT01953107|Cervical cancer
1015626|NCT01953107|Oral iron
1015627|NCT01953094|Cervical
1015628|NCT01953081|Enteral feeding
1015629|NCT01953068|POCD
1015630|NCT01953068|Executive Reaction Time Test
1015631|NCT01953068|Aortic valve surgery
1015632|NCT01953068|Cognitive functions
1015633|NCT01953068|Transcatheter Aortic Valve Implantation
1015634|NCT01953055|stereotactic ablative radiotherapy
1015635|NCT01953055|androgen deprivation therapy
1015636|NCT01953042|Obsessive-Compulsive Disorder
1015637|NCT01953042|Health Education
1015638|NCT01953016|ADA-SCID
1015639|NCT01953016|Adenosine Deaminase Deficiency
1015640|NCT01953016|Wiskott Aldrich Syndrome
1015641|NCT01953016|Severe Combined Immune Deficiency
1015642|NCT01953016|Primary Immunodeficiency
1015643|NCT01952990|Pharmacokinetic
1015644|NCT01952964|exit site infection
1015645|NCT01952964|skin allergy
1015646|NCT01952964|physical damage
1015647|NCT01952951|rectal neoplasms
1015648|NCT01952951|radiotherapy
1015649|NCT01952951|Antineoplastic Agents
1015650|NCT01952938|knee revision surgery,
1015651|NCT01952938|rotating hinge prosthesis
1015652|NCT01952899|Intensive Care Unit
1015653|NCT01952899|Delirium
1015654|NCT01952899|Implementation
1015655|NCT01952899|Guideline
1015656|NCT01952886|malignant glioma
1015657|NCT01952886|antiemetic
1015658|NCT01952886|ondansetron
1015659|NCT01952886|granisetron
1015660|NCT01952886|Preston Robert Tisch Brain Tumor Center
1015661|NCT01952886|Pro00041233
1015662|NCT01952886|Duke
1015663|NCT01952873|stents
1015664|NCT01952873|angioplasty, balloon, coronary
1015665|NCT01952873|coronary artery stenosis
1015666|NCT01952873|optical coherence tomography
1015667|NCT01952860|Lung Cancer
1015668|NCT01952860|Non-small cell lung cancer
1015669|NCT01952860|NSCLC
1015670|NCT01952860|Caregiving partner
1015671|NCT01952860|Hatha Yoga
1015672|NCT01952860|Radiation therapy
1015673|NCT01952860|XRT
1015674|NCT01952860|Questionnaires
1015675|NCT01952860|Surveys
1015676|NCT01952847|Advanced Cancers
1015677|NCT01952847|Mucositis
1015678|NCT01952847|Esophagitis
1015679|NCT01952847|mTOR Inhibitor-based Regimen
1015680|NCT01952847|Radiation to the Esophagus
1015681|NCT01952847|Thoracic malignancies
1015682|NCT01952847|Placebo
1015683|NCT01952847|Glutamine
1015684|NCT01952847|Enterex
1015685|NCT01952847|Glutapak-10
1015686|NCT01952847|NutreStore
1015687|NCT01952847|Resource
1015688|NCT01952847|GlutaSolve
1015689|NCT01952847|Sympt-X G.I.
1015690|NCT01952847|Sympt-X
1015691|NCT01952847|Questionnaires
1015692|NCT01952847|Surveys
1015693|NCT01952834|coronary artery disease
1015694|NCT01952834|probiotic
1015695|NCT01952834|endothelial function
1015696|NCT01952834|brachial artery
1015697|NCT01952834|ntric oxide
1015698|NCT01952821|Head and Neck Cancer
1015699|NCT01952821|Physical function
1015700|NCT01952821|Cancer Related Fatigue
1015701|NCT01952821|Gait Speed
1015702|NCT01952821|6MWT
1015703|NCT01952821|10-Meter Walk Test
1015704|NCT01952821|30-Second Chair Stand
1015705|NCT01952821|Linear Analog Scale of Function
1015706|NCT01952821|Modified Brief Fatigue Inventory
1015707|NCT01952769|anti PD1,diffuse pontine glioma
1015708|NCT01952756|cilostazol
1015709|NCT01952756|endothelial progenitor cells
1015710|NCT01952756|vasculogenesis
1015711|NCT01952756|angiogenesis
1015712|NCT01952756|peripheral arterial disease
1015713|NCT01952756|biomarkers
1015714|NCT01952743|Atrial Fibrillation
1015715|NCT01952743|Hypertension
1015716|NCT01952743|Renal Denervation
1015717|NCT01952730|Stage IV
1015718|NCT01952730|Hepatic Lesions
1015719|NCT01952691|hallux valgus
1015720|NCT01952691|pain
1015721|NCT01952691|conservative
1015722|NCT01952691|treatment
1015723|NCT01952678|DaTscan
1015724|NCT01952678|Parkinson's Disease
1015725|NCT01952652|Naproxen-codeine
1015726|NCT01952652|preemptive analgesia
1015727|NCT01952652|day case surgery
1015728|NCT01952626|intrathecal
1015729|NCT01952626|morphine
1015730|NCT01952626|ondansetron
1015731|NCT01952626|palonosetron
1015732|NCT01952626|pruritus
1015733|NCT01952613|Foot drop
1015734|NCT01952613|Functional Electrical Stimulation
1015735|NCT01952600|Chronic Kidney Disease
1015736|NCT01952600|Hemodialysis
1015737|NCT01952600|Peritoneal Dialysis
1015738|NCT01952574|migraine, headache, prevention, prophylaxis
1015739|NCT01952561|pharmacokinetics
1015740|NCT01952561|vaginal ring
1015741|NCT01952522|Resistance training
1015742|NCT01952522|Walking
1015743|NCT01952522|Weight bearing
1015744|NCT01952496|Cerebral Palsy
1015745|NCT01952496|Non ambulatory
1015746|NCT01952496|Neuromuscular disability
1015747|NCT01952496|Children
1015748|NCT01952483|Multiple Sclerosis (MS)
1015749|NCT01952470|Lung transplantation
1015750|NCT01952470|Respiratory Tract Infections
1015751|NCT01952470|Respiratory Therapy
1015752|NCT01952470|Isotonic Solutions
1015753|NCT01952470|Sodium Chloride
1015754|NCT01952470|Postoperative complications
1015755|NCT01952470|Postoperative care
1015756|NCT01952470|dornase alpha
1015757|NCT01952431|Total Lung Capacity
1015758|NCT01952392|Effectiveness study
1015759|NCT01952392|Acute coronary Syndrome
1015760|NCT01952392|Real-life
1015761|NCT01952392|France
1015762|NCT01952379|Melasma
1015763|NCT01952379|Lymphocytes
1015764|NCT01952379|Macrophages
1015765|NCT01952379|Mast cells
1015766|NCT01952379|Interleukin 17
1015767|NCT01952379|COX-2
1015768|NCT01952379|Inflammation
1015769|NCT01952366|Aged
1015770|NCT01952366|Depression
1015771|NCT01952366|Cognition
1015772|NCT01952366|Longitudinal study
1015773|NCT01952353|Hepatocellular Carcinoma; Transarterial Chemoembolization; Hepatic Resection; Portal Vein Tumor Thrombosis
1015774|NCT01952301|Autologous; Collagen Matrix; Keratinized Tissue
1015775|NCT01952262|ultrasound
1015776|NCT01952262|diaphragm
1015777|NCT01952262|intensive care
1015778|NCT01952262|critical care
1015779|NCT01952249|Ovarian
1015780|NCT01952249|Primary Peritoneal
1015781|NCT01952249|Fallopian Tube Cancer
1015782|NCT01952236|Smoking
1015783|NCT01952236|Quit
1015784|NCT01952236|Tobacco
1015785|NCT01952236|Abstinence
1015786|NCT01952236|Adult
1015787|NCT01952236|Text Messaging
1015788|NCT01952236|Web-based
1015789|NCT01952236|Mobile phone
1015790|NCT01952236|smartphone
1015791|NCT01952236|internet
1015792|NCT01952236|web
1015793|NCT01952223|adenocarcinome
1015794|NCT01952223|prostate
1015795|NCT01952223|relapse
1015796|NCT01952223|Radiotherapy
1015797|NCT01952223|Androgen Deprivation Therapy
1015798|NCT01952223|Cabazitaxel
1015799|NCT01952197|Passive Leg Raise
1015800|NCT01952197|Cardiac arrest
1015801|NCT01952197|Survival after CPR
1015802|NCT01952184|vitrification
1015803|NCT01952184|oocyte
1015804|NCT01952184|donor
1015805|NCT01952184|open
1015806|NCT01952184|closed
1015811|NCT01952158|Multidrug-Resistant Organisms
1015812|NCT01952158|Hospital Infection
1015813|NCT01952158|Colonization
1015814|NCT01952158|Healthcare Personnel
1015815|NCT01952132|Schizophrenia
1015816|NCT01952119|hypertension
1015817|NCT01952106|venepuncture
1015818|NCT01952106|distraction
1015819|NCT01952106|distress
1015820|NCT01952093|Early intervention
1015821|NCT01952093|Mother-child interaction
1015822|NCT01952093|Neurodevelopment
1015823|NCT01952093|Parenting
1015824|NCT01952093|Prematurity
1015825|NCT01952093|School age
1015826|NCT01952080|Short Bowel Syndrome
1015827|NCT01952080|SBS
1015828|NCT01952080|Pediatric SBS
1015829|NCT01952067|Hip Prosthesis
1015830|NCT01952067|surgery
1015831|NCT01952067|cements
1015832|NCT01952067|Radiostereometric Analysis
1015833|NCT01952054|Breast cancer
1015834|NCT01952054|Breast carcinoma
1015835|NCT01952054|Bone metastasis
1015836|NCT01952054|Cancer that has spread to the bone
1015837|NCT01952054|Denosumab
1015838|NCT01952054|AMG 162
1015839|NCT01952054|Prolia
1015840|NCT01952054|Hormonal agent
1015841|NCT01952041|Schizophrenia
1015842|NCT01952041|Schizoaffective Disorder
1015843|NCT01952041|Mobile Application
1015844|NCT01952041|Relapse Signature
1015845|NCT01952041|Relapse
1015846|NCT01952041|SMI
1015847|NCT01952041|EHealth
1015848|NCT01952041|E-Health
1015849|NCT01952041|Health Technology
1015850|NCT01952041|mHealth
1015851|NCT01952041|m-Health
1015852|NCT01952028|MDC1A
1015853|NCT01952028|Congenital Muscular Dystrophy
1015854|NCT01952028|Merosin Deficient
1015855|NCT01952028|LAMA2
1015856|NCT01952028|brain white matter abnormalities
1015857|NCT01952028|Seizure
1015858|NCT01952015|generalized pustular psoriasis
1015859|NCT01952002|Blood Pressure
1015860|NCT01952002|heart rate
1015861|NCT01952002|electrocardiogram
1015862|NCT01952002|Cardiac arrhythmias
1015863|NCT01952002|respiratory exercise
1015864|NCT01951989|Gaucher disease
1015865|NCT01951989|Imiglucerase
1015866|NCT01951989|Pharmacokinetics
1015867|NCT01951976|breast
1015868|NCT01951976|carcinoma
1015869|NCT01951976|stage 0-III breast cancer
1015870|NCT01951976|post-menopausal
1015871|NCT01951976|aromatase inhibitor (AI)
1015872|NCT01951976|joint pain
1015873|NCT01951976|AI-associated joint pain
1015874|NCT01951963|pain management
1015875|NCT01951963|ketamine
1015876|NCT01951963|morphine
1015877|NCT01951963|pediatrics
1015878|NCT01951963|emergency medicine
1015879|NCT01951937|Cognitive Test
1015880|NCT01951937|Omega-3 Fatty acids
1015881|NCT01951924|Multifocal Motor Neuropathy
1015882|NCT01951911|Pain Management
1015883|NCT01951911|Ketamine
1015884|NCT01951911|Palliative care
1015885|NCT01951898|asthma
1015886|NCT01951898|regulatory T cells
1015887|NCT01951898|leukotriene antagonist
1015888|NCT01951872|caffeine dependence
1015889|NCT01951872|caffeine withdrawal
1015890|NCT01951872|caffeine use disorder
1015891|NCT01951833|Lung clearance index (LCI)
1015892|NCT01951807|Psychosocial Effects of Cancer and Treatment
1015893|NCT01951807|Coping
1015894|NCT01951794|HIV infected
1015895|NCT01951794|HIV exposed
1015896|NCT01951794|HIV-free
1015897|NCT01951781|marker CD64
1015898|NCT01951781|blood sample
1015899|NCT01951781|nosocomial infection
1015900|NCT01951781|preterm newborn
1015901|NCT01951755|Inoperable NSCLC
1015902|NCT01951755|TKIs
1015903|NCT01951742|wrinkles
1015904|NCT01951729|Blood sugar
1015905|NCT01951729|GIP
1015906|NCT01951729|Xenin-25
1015907|NCT01951729|Cholinergic Signaling
1015908|NCT01951729|Atropine
1015909|NCT01951729|Insulin
1015910|NCT01951729|Glucagon
1015911|NCT01951729|Pancreatic polypeptide
1015912|NCT01951716|Vagotomy
1015913|NCT01951716|Vagus Nerve
1015914|NCT01951716|Xenin-25
1015915|NCT01951716|GIP
1015916|NCT01951716|Insulin Secretion
1015917|NCT01951716|Glucagon Secretion
1015918|NCT01951716|Gastric Emptying
1015919|NCT01951690|Focal Adhesion Kinase inhibitor
1015920|NCT01951690|FAK inhibitor
1015921|NCT01951690|Cancer Stem Cells
1015922|NCT01951690|CSC
1015923|NCT01951690|KRAS mutation
1015924|NCT01951677|hepatitis B virus
1015925|NCT01951677|vaccine
1015926|NCT01951677|adjuvant
1015927|NCT01951677|prophylaxis
1015928|NCT01951651|Diabetes
1015929|NCT01951638|Worsening Heart Failure
1015930|NCT01951638|Heart Failure with Preserved Ejection Fraction
1015931|NCT01951625|Worsening Heart Failure
1015932|NCT01951625|Heart Failure with Reduced Ejection Fraction
1015933|NCT01951612|cognitive impairment
1015934|NCT01951612|ischemic white matter disease
1015935|NCT01951612|small vessel disease
1015936|NCT01951612|transient ischemic attack
1015937|NCT01951612|mild stroke
1015938|NCT01951612|stroke risk
1015939|NCT01951599|Phase I, healthy, bioavailability, pharmacokinetics, safety, tolerability.
1015940|NCT01951573|contact lenses
1015941|NCT01951573|multifocal
1015942|NCT01951573|daily disposable
1015943|NCT01951573|silicone hydrogel
1015944|NCT01951573|presbyopia
1015945|NCT01951547|HbA1c
1015946|NCT01951547|hs-CRP
1015947|NCT01951547|non-surgical periodontal therapy
1015948|NCT01951547|oral health education
1015949|NCT01951547|probing pocket depth
1015950|NCT01951547|plaque index
1015951|NCT01951547|gingival bleeding index.
1015952|NCT01951534|breast reconstruction
1015953|NCT01951521|Rectal cancer
1015954|NCT01951521|Locally advanced rectal cancer
1015955|NCT01951521|Radiotherapy
1015956|NCT01951521|Boost
1015957|NCT01951521|Dose-escalation
1015958|NCT01951521|Pathological complete response
1015959|NCT01951521|Response
1015960|NCT01951508|Methylphenidate
1015961|NCT01951508|Modafinil
1015962|NCT01951508|MDMA
1015963|NCT01951508|fMRI
1015964|NCT01951508|emotion-processing
1015965|NCT01951508|social cognition
1015966|NCT01951456|Smoking cessation
1015967|NCT01951456|resistance training
1015968|NCT01951443|ginseng
1015969|NCT01951443|clinical trial
1015970|NCT01951443|vascular
1015971|NCT01951443|ginsenosides
1015972|NCT01951443|blood pressure
1015973|NCT01951430|Adult patients
1015974|NCT01951430|Infective events
1015975|NCT01951430|Antibiotic
1015976|NCT01951430|Antifungal
1015977|NCT01951430|Myelodysplastic syndrome
1015978|NCT01951404|Left Ventricular Hypertrophy
1015979|NCT01951404|Allopurinol
1015980|NCT01951404|End Stage Renal Disease
1015981|NCT01951404|Haemodialysis
1015982|NCT01951404|Renal Replacement Therapy
1015983|NCT01951404|MRI
1015984|NCT01951391|study
1015985|NCT01951391|subjects
1015986|NCT01951378|Asthma
1015987|NCT01951378|Asthma exacerbation
1015988|NCT01951365|Schwannoma
1015989|NCT01951365|Growth
1015990|NCT01951365|intradural
1015991|NCT01951365|natural history
1015992|NCT01951352|study
1015993|NCT01951352|meant
1015994|NCT01951352|individuals
1015995|NCT01951339|diabetes
1015996|NCT01951339|type 2 diabetes
1015997|NCT01951339|exercise
1015998|NCT01951339|echo
1015999|NCT01951339|heart
1016000|NCT01951339|sitagliptin
1016001|NCT01951339|glimepiride
1016002|NCT01951339|cardiovascular
1016008|NCT01951313|Meal tolerance test focusing on carotenoids absorption
1016009|NCT01951261|Telemonitoring
1016010|NCT01951261|COPD
1016011|NCT01951261|Home care
1016012|NCT01951248|chronic kidney disease
1016013|NCT01951248|obstructive sleep apnea
1016014|NCT01951248|24-h blood pressure
1016015|NCT01951248|central blood pressure
1016016|NCT01951248|peripheral blood pressure
1016017|NCT01951222|Asthma, COPD, broncodilator, airway, lung, inhalation, antimuscarinic
1016018|NCT01951209|Human
1016019|NCT01951209|Hepatitis C
1016020|NCT01951209|Cirrhosis
1016021|NCT01951209|B-cell
1016022|NCT01951209|Rifaximin
1016023|NCT01951196|Chronic kidney disease
1016024|NCT01951196|24 hour blood pressure
1016025|NCT01951196|central blood pressure
1016026|NCT01951196|peripheral blood pressure
1016027|NCT01951196|obstructive sleep apnea
1016028|NCT01951144|Phase 1
1016029|NCT01951144|Single Dose
1016030|NCT01951144|Pharmacokinetics
1016031|NCT01951144|Safety
1016032|NCT01951144|Toleration
1016033|NCT01951144|Pharmacodynamics
1016034|NCT01951118|Smell
1016035|NCT01951118|Olfaction Disorders
1016036|NCT01951118|Atropine
1016037|NCT01951118|Donepezil
1016038|NCT01951118|Cholinesterase Inhibitors
1016039|NCT01951118|Cognition Disorders
1016040|NCT01951105|Subacute
1016041|NCT01951105|Back
1016042|NCT01951105|Pain
1016043|NCT01951105|Brain
1016044|NCT01951105|MRI
1016045|NCT01951092|HIV
1016046|NCT01951092|adherence
1016047|NCT01951092|retention
1016048|NCT01951092|texting
1016049|NCT01951079|Digoxin
1016050|NCT01951079|Intra-amniotic injection
1016051|NCT01951079|feticide
1016052|NCT01951079|second trimester abortion
1016053|NCT01951053|Healthy
1016054|NCT01951053|Safety
1016055|NCT01951053|Tolerability
1016056|NCT01951053|Pharmacokinetics
1016057|NCT01951053|Pharmacodynamics
1016058|NCT01951053|JNJ-40411813
1016059|NCT01951053|Positive allosteric modulator
1016060|NCT01951040|Oxytocin, breastfeeding
1016061|NCT01951027|Safety
1016062|NCT01951027|Pharmacokinetics
1016063|NCT01951027|Pharmacodynamics
1016064|NCT01951027|DLT
1016065|NCT01951027|Immunogenecity
1016066|NCT01951014|Adolescence
1016067|NCT01951014|Pregnancy
1016068|NCT01951014|Telemedicine
1016069|NCT01951001|Acute Coronary Syndrome, Asians, platelet, prasugrel
1016070|NCT01950936|Infection
1016071|NCT01950936|Antibiotics
1016072|NCT01950936|COLD
1016073|NCT01950910|Amyotrophic lateral sclerosis
1016074|NCT01950910|motor neuron disease
1016075|NCT01950910|biological markers
1016076|NCT01950910|biomarkers
1016077|NCT01950897|muscular dystrophies
1016078|NCT01950897|muscular dystrophy
1016079|NCT01950884|•Non-alcoholic Steatohepatitis (NASH)
1016080|NCT01950871|HistoScanning
1016081|NCT01950871|TRUS
1016082|NCT01950871|Prostate cancer
1016083|NCT01950871|Biopsy guidance
1016084|NCT01950845|anesthesiology, Closed-Loop system, automated fluid management, cardiac output optimization, high risk surgical patient, major abdominal surgery
1016085|NCT01950832|Structure of Retina
1016086|NCT01950832|Macular Thickness
1016087|NCT01950832|Retinal Nerve Fiber Layer
1016088|NCT01950832|Choroidal Thickness
1016089|NCT01950832|PCOS
1016090|NCT01950832|Optical Coherence Tomography
1016091|NCT01950819|kidney failure
1016092|NCT01950819|dialysis
1016093|NCT01950819|renal failure
1016094|NCT01950819|transplantation
1016095|NCT01950793|Hyaluronic acid, trigger finger
1016096|NCT01950780|Alopecia Areata
1016097|NCT01950780|Ruxolitinib
1016098|NCT01950728|volunteers
1016099|NCT01950728|18 to 65 years
1016100|NCT01950728|Females
1016101|NCT01950715|Irritable Bowel Syndrome
1016102|NCT01950715|Sacral Nerve Stimulation
1016103|NCT01950715|Gastro-colic response
1016104|NCT01950715|Multimodal Stimulation
1016105|NCT01950663|Diagnostic Equipment
1016106|NCT01950663|Validation Studies
1016107|NCT01950624|Patient Registry
1016108|NCT01950624|Down Syndrome
1016109|NCT01950611|acute promyelocytic leukemia
1016110|NCT01950611|arsenic trioxide
1016111|NCT01950611|proteasome inhibition
1016112|NCT01950611|bortezomib
1016113|NCT01950598|Boston Keratoprosthesis type I surgery, frozen corneal graft
1016114|NCT01950585|Hydroxyurea
1016115|NCT01950585|Pulmonary Hypertension
1016116|NCT01950585|Idiopathic Pulmonary Arterial Hypertension
1016117|NCT01950585|Familial Pulmonary Arterial Hypertension
1016118|NCT01950585|CD34 + Cells
1016119|NCT01950572|Samples
1016120|NCT01950572|Biobank
1016121|NCT01950572|Pleural Mesothelioma
1016122|NCT01950572|Peritoneal Mesothelioma
1016123|NCT01950559|soy allergy
1016124|NCT01950559|food allergy
1016125|NCT01950559|pediatric
1016126|NCT01950559|adult
1016127|NCT01950546|silver nanoparticles
1016128|NCT01950546|antimicrobial activity
1016129|NCT01950546|toxicity
1016130|NCT01950546|biofilm
1016131|NCT01950546|cariostatic agents
1016132|NCT01950533|Peanut allergy
1016133|NCT01950533|Milk allergy
1016134|NCT01950533|Egg allergy
1016135|NCT01950533|Pediatric
1016136|NCT01950533|Adult
1016137|NCT01950533|Food allergy
1016138|NCT01950520|Adipose Tissue
1016139|NCT01950520|Adult
1016140|NCT01950520|Body Composition
1016141|NCT01950520|Brown Adipose Tissue
1016142|NCT01950520|Non-Shivering Thermogenesis
1016143|NCT01950507|Fluconazole
1016144|NCT01950507|Graft Versus Host Disease
1016145|NCT01950507|Voriconazole
1016146|NCT01950507|Azoles
1016147|NCT01950494|hand dermatitis
1016148|NCT01950494|health care workers
1016149|NCT01950494|hand sanitizer
1016150|NCT01950481|LDK378
1016151|NCT01950481|pharmacokinetics
1016152|NCT01950481|hepatic impairment
1016153|NCT01950468|Parkinson's Disease
1016154|NCT01950455|Parkinson's Disease
1016155|NCT01950442|malignant strictures
1016156|NCT01950442|esophageal staging
1016157|NCT01950429|Microbiome
1016158|NCT01950429|Sickle Cell Disease
1016159|NCT01950429|Bone Marrow Transplant
1016160|NCT01950416|ST elevation myocardial infarction
1016161|NCT01950416|Fibrinolysis
1016162|NCT01950416|Ticagrelor
1016163|NCT01950416|Clopidogrel
1016164|NCT01950416|Platelet reactivity
1016165|NCT01950377|Dopamine Transporter
1016166|NCT01950377|D2 Dopamine Receptor Subtype
1016167|NCT01950377|Dopamine
1016168|NCT01950377|Dopamine Genes
1016169|NCT01950377|Dopaminergic Mechanisms
1016170|NCT01950364|Lymphoma
1016171|NCT01950364|Hodgkin
1016172|NCT01950364|Anaplastic Large-cell
1016173|NCT01950364|Relapsed
1016174|NCT01950364|Refractory
1016175|NCT01950364|Antigens, CD30
1016176|NCT01950364|Antibody-Drug Conjugate
1016177|NCT01950364|Antibodies, Monoclonal
1016178|NCT01950364|Lymphoma, Non-Hodgkin
1016179|NCT01950364|Lymphoma, Large-Cell, Anaplastic
1016180|NCT01950364|Monomethyl auristatin E
1016181|NCT01950364|Drug Therapy
1016182|NCT01950364|Immunotherapy
1016183|NCT01950364|Hematologic Diseases
1016194|NCT01950325|HIV-1 Viral Load
1016195|NCT01950325|CD4 Count
1016196|NCT01950325|Antiviral
1016197|NCT01950325|HIV-1 Infection
1016198|NCT01950325|Broadly Neutralizing Antibody
1016199|NCT01950312|Autoimmune Inner Ear Disease
1016200|NCT01950312|Inner Ear Disease
1016201|NCT01950312|Meniere's Disease
1016202|NCT01950312|Sudden Sensorineural Hearing Loss
1016203|NCT01950286|T-cell Acute Lymphoblastic Leukemia
1016204|NCT01950286|chemotherapy
1016205|NCT01950286|allogeneic stem cell transplantation
1016206|NCT01950260|Graves' disease
1016207|NCT01950260|Radioactive iodine
1016208|NCT01950260|Hypothyroidism
1016209|NCT01950221|Double-blind Trial
1016210|NCT01950221|Placebo-controlled
1016211|NCT01950221|Pomegranate
1016212|NCT01950221|Memory
1016213|NCT01950221|Memory Impairment
1016214|NCT01950221|Cognition
1016215|NCT01950221|Ages 50-75
1016216|NCT01950208|Assessment
1016217|NCT01950195|Melanoma
1016218|NCT01950195|Metastases
1016219|NCT01950195|Brain
1016220|NCT01950195|Spine
1016221|NCT01950195|SRS(Stereotactic Radiosurgery))
1016222|NCT01950195|Ipilimumab
1016223|NCT01950182|Luminal B2 subtype
1016224|NCT01950182|First line treatment
1016225|NCT01950169|Hip fracture
1016226|NCT01950169|Nutritional supplement
1016227|NCT01950169|Bisphosphonates
1016228|NCT01950169|Bone mineral density
1016229|NCT01950169|Body composition
1016230|NCT01950143|prostate cancer prevention
1016231|NCT01950143|diet
1016232|NCT01950143|global gene expression
1016233|NCT01950143|metabolic changes
1016234|NCT01950130|IABP
1016235|NCT01950130|IABC
1016236|NCT01950130|coronary artery disease
1016237|NCT01950130|prophylactic
1016238|NCT01950130|cardiac assist
1016239|NCT01950117|nonpedunculated
1016240|NCT01950117|neoplastic
1016241|NCT01950117|colorectal
1016242|NCT01950117|polyps
1016243|NCT01950104|Embryo biopsy
1016244|NCT01950104|Blastocyst stage
1016245|NCT01950104|Day 3
1016246|NCT01950104|Preimplantation genetic screening
1016247|NCT01950091|low back pain
1016248|NCT01950091|internet
1016249|NCT01950091|app
1016250|NCT01950091|prevention
1016251|NCT01950091|treatment
1016252|NCT01950078|gene polymorphism
1016253|NCT01950078|pain perception
1016254|NCT01950078|postoperative pain
1016255|NCT01950052|VLCD
1016256|NCT01950052|Low calorie diet
1016257|NCT01950052|very low calorie diet
1016258|NCT01950052|pre-operative diet
1016259|NCT01950052|liver shrinking diet
1016260|NCT01950052|bariatric surgery
1016261|NCT01950052|gastric bypass
1016262|NCT01950039|Obesity
1016263|NCT01950039|Glucose Intolerance
1016264|NCT01950026|skin temperature
1016265|NCT01950026|ethnic groups
1016266|NCT01950026|cryotherapy
1016267|NCT01950013|Presbycusis
1016268|NCT01950013|Aging
1016269|NCT01950013|hearing aids
1016270|NCT01950013|hearing training
1016271|NCT01950000|Pain. Analgesia. Prevention
1016272|NCT01949974|Palliative Chemotherapy
1016273|NCT01949974|Integral Attention Program
1016274|NCT01949974|Advanced cancer
1016275|NCT01949974|Randomized Clinical Trial
1016276|NCT01949961|intervention
1016277|NCT01949961|sonothrombolysis
1016278|NCT01949961|Ultrasound treatment
1016279|NCT01949948|treatment, intervention, thrombolysis
1016280|NCT01949935|Mupirocin
1016281|NCT01949935|Surgical Site Infections
1016282|NCT01949935|Coronary Artery Bypass Grafting
1016283|NCT01949922|regenerative medicine
1016284|NCT01949922|fecal incontinence
1016285|NCT01949922|muscle fiber injection
1016286|NCT01949909|plasmodium falciparum
1016287|NCT01949909|long synthetic peptide
1016288|NCT01949909|antibody
1016289|NCT01949909|T cell
1016290|NCT01949909|cytokine
1016291|NCT01949909|vaccine
1016292|NCT01949909|safety
1016293|NCT01949909|phase 1
1016294|NCT01949896|Pro inflammatory cytokine
1016295|NCT01949896|Necrotizing enterocolitis
1016296|NCT01949896|Packed red blood cell transfusion
1016297|NCT01949883|Phase 1
1016298|NCT01949883|Oncology
1016299|NCT01949883|BET Inhibitor
1016300|NCT01949857|Hepatitis A
1016301|NCT01949857|Vaccine
1016302|NCT01949857|Safety
1016303|NCT01949857|efficacy
1016304|NCT01949844|MRI
1016305|NCT01949844|Magnetic Resonance Imaging
1016306|NCT01949844|myocardial perfusion
1016307|NCT01949844|myocardial perfusion imaging
1016308|NCT01949844|Novel MRI Techniques
1016309|NCT01949831|functional assessment
1016310|NCT01949831|acute care
1016311|NCT01949831|older medical patients
1016312|NCT01949753|Obsessive-compulsive disorder (OCD)
1016313|NCT01949753|Exposure therapy
1016314|NCT01949753|Extinction learning
1016315|NCT01949753|Pregnenolone
1016316|NCT01949727|AECOPD
1016317|NCT01949727|COPD
1016318|NCT01949727|Emphysema
1016319|NCT01949727|Chronic bronchitis
1016320|NCT01949675|Cholera
1016321|NCT01949675|Shanchol™
1016322|NCT01949675|Cholera Vaccine
1016323|NCT01949662|Advanced Cancers
1016324|NCT01949662|Locally advanced cancer
1016325|NCT01949662|Metastatic cancer
1016326|NCT01949662|Recurrent cancer
1016327|NCT01949662|Incurable cancer
1016328|NCT01949662|Delirium
1016329|NCT01949662|Agitation
1016330|NCT01949662|Lorazepam
1016331|NCT01949662|Haloperidol
1016332|NCT01949662|Placebo
1016333|NCT01949662|Questionnaires
1016334|NCT01949662|Surveys
1016335|NCT01949662|Acute palliative care unit
1016336|NCT01949649|body image
1016337|NCT01949649|body dissatisfaction
1016338|NCT01949623|RP
1016339|NCT01949610|Healthy Participants
1016340|NCT01949610|JNJ26489112
1016341|NCT01949610|14C-JNJ26489112
1016342|NCT01949610|Absorption
1016343|NCT01949610|Metabolism
1016344|NCT01949610|Excretion
1016345|NCT01949571|Mirtazapine.
1016346|NCT01949571|Addiction.
1016347|NCT01949571|Cocaine.
1016348|NCT01949571|Cocaine-craving.
1016349|NCT01949571|Cocaine-withdrawal
1016350|NCT01949558|diet
1016351|NCT01949558|lifestyle
1016352|NCT01949519|prostate cancer
1016353|NCT01949519|lycopene
1016354|NCT01949519|docetaxel
1016355|NCT01949519|metastatic
1016356|NCT01949519|castration resistant
1016357|NCT01949506|Lung metastases
1016358|NCT01949506|Radiation Therapy
1016359|NCT01949506|Stereotactic Body Radiation Therapy
1016360|NCT01949493|carpal tunnel syndrome
1016361|NCT01949493|traction
1016362|NCT01949493|mechanical traction
1016363|NCT01949493|Phystrac
1016364|NCT01949480|Peripheral nerve block
1016365|NCT01949480|Ultrasound guidance
1016366|NCT01949480|Postoperative pain management post status thoracotomy
1016367|NCT01949480|Postoperative pain management post status VATS
1016368|NCT01949467|ferroportin disease
1016369|NCT01949467|dysmetabolic hepatosiderosis
1016370|NCT01949467|genetic hemochromatosis
1016371|NCT01949467|hyperferritinemia
1016372|NCT01949467|hepcidin
1016373|NCT01949467|iron fumarate
1016374|NCT01949467|physiopathological study
1016375|NCT01949467|diagnosis
1016376|NCT01949467|HFE gene
1016377|NCT01949467|TRF2 gene
1016378|NCT01949467|iron parameters
1016379|NCT01949467|divalent cations
1016380|NCT01949454|trachoma
1016381|NCT01949454|trichiasis
1016382|NCT01949454|trachomatous trichiasis
1016383|NCT01949454|bilamellar tarsal rotation
1016384|NCT01949454|fluorometholone
1016385|NCT01949454|placebo controlled
1016386|NCT01949441|HDM Allergy
1016387|NCT01949441|Rhinoconjunctivitis
1016388|NCT01949441|Immunotherapy
1016389|NCT01949441|ToleroMune HDM
1016390|NCT01949428|HDM Allergy
1016391|NCT01949428|Rhinoconjunctivitis
1016392|NCT01949415|House Dust Mite
1016393|NCT01949415|Rhinoconjunctivitis
1016394|NCT01949415|ToleroMune
1016395|NCT01949376|breast cancer
1016396|NCT01949376|invasive ductal carcinoma
1016397|NCT01949376|cognitive impairment
1016398|NCT01949376|adjuvant therapy
1016399|NCT01949376|hormone therapy
1016400|NCT01949376|hormonal therapy
1016401|NCT01949376|chemotherapy
1016402|NCT01949376|chemo brain
1016403|NCT01949376|MRI
1016404|NCT01949363|Gonococcal Infections, Cefixime, Neisseria gonorrhoeae, Azithromycin, antibiotic, cephalosporin
1016406|NCT01949298|immediate loading of dental implant
1016407|NCT01949298|implant supported over denture
1016408|NCT01949285|Spinal cord injury
1016409|NCT01949285|Paralysis
1016410|NCT01949285|Rehabilitation
1016411|NCT01949285|Assessment
1016412|NCT01949285|Theranostics
1016413|NCT01949272|ARDS
1016414|NCT01949259|Retrospective
1016415|NCT01949259|Lung cancer
1016416|NCT01949246|Biomarkers
1016417|NCT01949220|Inherited
1016418|NCT01949220|Von Willebrand disease
1016419|NCT01949220|Von Willebrand factor
1016420|NCT01949220|Deficiency
1016421|NCT01949220|safety
1016422|NCT01949207|Incompetent perforating veins
1016423|NCT01949207|EVLA
1016424|NCT01949207|Phlebectomies
1016425|NCT01949207|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
1016426|NCT01949194|liver metastases
1016427|NCT01949181|Metals
1016428|NCT01949181|Metalloids
1016429|NCT01949181|Blood
1016430|NCT01949181|Hair
1016431|NCT01949181|Lung
1016432|NCT01949181|Lung cancer
1016433|NCT01949181|Chronic obstructive pulmonary disease
1016434|NCT01949155|otitis media
1016435|NCT01949155|otorrhea
1016436|NCT01949155|middle ear effusion
1016437|NCT01949155|tympanostomy tubes
1016438|NCT01949142|otitis media
1016439|NCT01949142|otorrhea
1016440|NCT01949142|middle ear effusion
1016441|NCT01949142|tympanostomy tubes
1016442|NCT01949129|stem cell transplantation
1016443|NCT01949129|children and adolescents
1016444|NCT01949129|high risk acute lymphoblastic leukaemia
1016445|NCT01949103|Gram-positive
1016446|NCT01949090|H7N1
1016447|NCT01949090|AS03 adjuvant
1016448|NCT01949090|Safety
1016449|NCT01949090|Immunogenicity
1016450|NCT01949090|Influenza
1016451|NCT01949090|Adults
1016452|NCT01949090|Elderly adults
1016453|NCT01949077|Hepatitis
1016454|NCT01949077|Hepatitis C
1016455|NCT01949077|Observational study
1016456|NCT01949077|Biomarkers of treatment response
1016457|NCT01949051|Allergic rhinitis
1016458|NCT01949051|levocabastine
1016459|NCT01949051|allergen challenge
1016460|NCT01949038|Pain
1016461|NCT01949038|Discomfort
1016462|NCT01949038|Anxiety
1016463|NCT01949038|Satisfaction
1016464|NCT01949038|Compliance
1016465|NCT01949012|Midazolam
1016466|NCT01949012|Endtidal carbon dioxide
1016467|NCT01949012|Desaturation
1016468|NCT01948999|electroconvulsive therapy
1016469|NCT01948999|treatment-refractory schizophrenia
1016470|NCT01948973|Irritable Bowel Syndrome
1016471|NCT01948973|Sacral Nerve Stimulation
1016472|NCT01948973|Symptoms
1016473|NCT01948973|Quality of Life
1016474|NCT01948973|Bowel habits
1016475|NCT01948960|Breast Neoplasms
1016476|NCT01948960|everolimus
1016477|NCT01948960|pharmacokinetics
1016478|NCT01948960|elderly patients
1016479|NCT01948960|obese patients
1016480|NCT01948934|Skin
1016481|NCT01948934|Injury
1016482|NCT01948934|Membrane amniotic
1016483|NCT01948934|Wound
1016484|NCT01948921|EGD
1016485|NCT01948921|tolerance
1016486|NCT01948921|discomfort
1016487|NCT01948908|Sedation
1016488|NCT01948908|Laceration repair
1016489|NCT01948908|Children
1016490|NCT01948908|Intranasal
1016491|NCT01948908|Midazolam
1016492|NCT01948895|Desvenlafaxine
1016493|NCT01948895|Open-label
1016494|NCT01948895|Flexible-dose
1016495|NCT01948895|Dysthymic disorder
1016496|NCT01948895|Anxiety disorders
1016497|NCT01948895|Generalized anxiety disorder
1016498|NCT01948895|Social anxiety disorder
1016499|NCT01948895|Post-traumatic stress disorder
1016500|NCT01948882|Birth control
1016501|NCT01948869|Phoenix
1016502|NCT01948869|Mild atopic dermatitis
1016503|NCT01948869|efficacy
1016504|NCT01948869|safety
1016505|NCT01948856|Recurrent common cold
1016506|NCT01948856|laryngitis
1016507|NCT01948856|pharyngitis/tonsillitis
1016508|NCT01948856|acute rhinitis
1016509|NCT01948856|acute rhinosinusitis
1016510|NCT01948856|acute otitis media
1016511|NCT01948843|HER2 Negative Metastatic Breast Cancer
1016512|NCT01948830|Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen
1016513|NCT01948817|Thalassemia
1016514|NCT01948791|Alzheimer's disease
1016515|NCT01948791|ENA713
1016516|NCT01948791|Chinese patients
1016517|NCT01948791|INSTINCT
1016518|NCT01948765|xenon anesthesia
1016519|NCT01948765|Off-pump coronary artery bypass graft surgery
1016520|NCT01948752|Nutrition policy
1016521|NCT01948752|food labelling
1016522|NCT01948752|diet
1016523|NCT01948752|obesity
1016524|NCT01948752|health behavior
1016525|NCT01948739|Brain machine interface
1016526|NCT01948739|Rehabilitation robotics
1016527|NCT01948739|Stroke
1016528|NCT01948739|Hemiparesis
1016529|NCT01948726|Breast cancer
1016530|NCT01948726|Hypofractionation
1016531|NCT01948726|Simultaneous integrated boost
1016532|NCT01948726|Toxicity
1016533|NCT01948700|Motivational Interviewing
1016534|NCT01948700|Problem Drinking
1016535|NCT01948700|Adolescents
1016536|NCT01948700|Minority Health
1016537|NCT01948687|real time elastography
1016538|NCT01948687|hepatitis
1016539|NCT01948648|plant sterols
1016540|NCT01948648|cholesterol
1016541|NCT01948648|colesevelam
1016542|NCT01948648|phytosterolemia
1016543|NCT01948648|fish oil
1016544|NCT01948635|tracheal cuff shape
1016545|NCT01948635|microaspiration
1016546|NCT01948635|pepsin
1016547|NCT01948635|ventilator-associated pneumonia
1016548|NCT01948622|Anxiety
1016549|NCT01948622|Third molar surgery
1016550|NCT01948622|Blood pressure
1016551|NCT01948622|Heart rate
1016552|NCT01948622|Oxygen saturation
1016553|NCT01948596|pregnant women
1016554|NCT01948596|depression
1016555|NCT01948596|depressive symptoms
1016556|NCT01948596|omega-3 fatty acids
1016557|NCT01948583|vaginal dryness
1016558|NCT01948583|hyaluronic acid
1016559|NCT01948583|menopause
1016560|NCT01948570|acne,comedones, oily skin
1016561|NCT01948557|Breastfeeding
1016562|NCT01948557|Infants
1016563|NCT01948557|Mother to child transmission of HIV
1016564|NCT01948557|Survival
1016565|NCT01948544|COPD
1016566|NCT01948544|LTOT
1016567|NCT01948544|Long-Term Oxygen Therapy
1016568|NCT01948544|Portable Oxygen Concentrator
1016569|NCT01948544|Quality of Life
1016570|NCT01948544|Six Minute Walk Distance Test
1016571|NCT01948531|Antiage
1016572|NCT01948518|Pulmonary hypertension
1016573|NCT01948518|Parenchymal Lung Disease
1016574|NCT01948518|Diffusion Capacity
1016575|NCT01948505|Craniotomy
1016576|NCT01948466|Nutrition
1016577|NCT01948466|Commercials
1016578|NCT01948466|Elementary
1016579|NCT01948466|Lunchroom
1016580|NCT01948466|Fruits
1016581|NCT01948466|Vegetables
1016582|NCT01948453|CAD
1016583|NCT01948453|CIMT
1016584|NCT01948453|FMD
1016585|NCT01948440|Substance abuse, early recovery, relapse prevention
1016586|NCT01948427|UCD
1016587|NCT01948427|BUPHENYL
1016588|NCT01948427|RAVICTI
1016589|NCT01948427|Urea
1016590|NCT01948427|Urea cycle disorder
1016591|NCT01948427|Glycerol phenylbutyrate
1016592|NCT01948427|Benzoate
1016593|NCT01948427|Sodium phenylbutyrate
1016594|NCT01948427|Ornithine transcarbamylase (OTC)
1016595|NCT01948427|Argininosuccinate synthetase (ASS)
1016596|NCT01948427|Argininosuccinate lyase (ASL)
1016597|NCT01948427|Carbamyl phosphate synthetase (CPS)
1016598|NCT01948427|Arginine
1016599|NCT01948427|Citrulline
1016600|NCT01948427|Ammonia
1016601|NCT01948414|Obesity
1016602|NCT01948414|Hyperalimentation
1016603|NCT01948414|Event-Related Potential
1016604|NCT01948414|P300
1016605|NCT01948388|Rheumatoid arthritis
1016606|NCT01948375|subject blinding
1016607|NCT01948375|placebo needle
1016608|NCT01948336|Contrast-induced nephropathy, Dexmedetomidine, Endothelin-1
1016609|NCT01948323|Pregnancy
1016610|NCT01948323|Maternal health
1016611|NCT01948323|Newborn health
1016612|NCT01948323|Information technology
1016613|NCT01948323|Health education
1016614|NCT01948323|Cellphone
1016615|NCT01948323|Touch screen technology
1016616|NCT01948323|Pregnancy outcome
1016617|NCT01948323|Low-Middle income
1016618|NCT01948323|Nurse-led
1016619|NCT01948323|Nutrition
1016620|NCT01948323|Exercise
1016621|NCT01948284|cecal intubation time
1016622|NCT01948284|water exchange
1016623|NCT01948284|pain
1016624|NCT01948271|Psoriasis
1016625|NCT01948271|Trichuris suis ova
1016626|NCT01948271|T-lymphocytes
1016627|NCT01948258|Pregnancy
1016628|NCT01948245|Catheter Related Blood Stream Infection
1016629|NCT01948245|Long-term intestinal Failure
1016630|NCT01948245|Taurolidine
1016631|NCT01948245|Catheter lock solution
1016632|NCT01948245|Antimicrobial agent
1016633|NCT01948245|Home Parenteral Nutrition
1016634|NCT01948245|Anti-infective agents
1016635|NCT01948206|Sudden Cardiac Death
1016636|NCT01948206|Implantable Cardioverter-Defibrillator
1016637|NCT01948206|Cardiomyopathy
1016638|NCT01948206|Prolonged Paced QRS Duration
1016639|NCT01948193|Diphtheria
1016640|NCT01948193|Tetanus
1016641|NCT01948193|Whooping Cough
1016642|NCT01948193|Hepatitis B
1016643|NCT01948193|Poliomyelitis
1016644|NCT01948193|DTaP IPV-Hep B-PRP~T combined vaccine (Hexaxim™)
1016645|NCT01948180|NKTCL
1016646|NCT01948180|T cell
1016647|NCT01948180|CITADEL
1016648|NCT01948180|Epstein-Barr Virus
1016649|NCT01948180|Natural Killer
1016650|NCT01948167|Depression
1016651|NCT01948167|Prevention
1016652|NCT01948167|Adolescents
1016653|NCT01948154|Cerebral Palsy
1016654|NCT01948154|Early Intervention
1016655|NCT01948154|Speech Function
1016656|NCT01948154|Quality of Life
1016657|NCT01948128|Breast
1016658|NCT01948115|Breech presentation
1016659|NCT01948115|equimolar mixture of oxygen and nitrous oxide
1016660|NCT01948115|external cephalic version
1016661|NCT01948102|Amyotrophic Lateral Sclerosis
1016662|NCT01948102|motor neuron disease
1016663|NCT01948102|biological markers
1016664|NCT01948102|biomarkers
1016665|NCT01948089|Chronic Stroke
1016666|NCT01948089|near transfer
1016667|NCT01948089|far transfer
1016668|NCT01948089|working memory
1016669|NCT01948089|fluid intelligence
1016670|NCT01948089|cognitive training
1016671|NCT01948089|dual n-back
1016672|NCT01948076|splenomegaly
1016673|NCT01948076|pleural effusion
1016674|NCT01948037|hydrotherapy
1016675|NCT01948037|randomized controlled trial
1016676|NCT01948037|lower extremity arterial disease
1016677|NCT01948037|diabetes
1016678|NCT01947998|Rivaroxaban,
1016679|NCT01947998|Pulmonary Embolism,
1016680|NCT01947998|Venous Thrombosis,
1016681|NCT01947998|Venous Thromboembolism,
1016682|NCT01947998|Acute Coronary Syndrome,
1016683|NCT01947998|Intracranial Hemorrhages,
1016684|NCT01947998|Gastrointestinal Hemorrhage,
1016685|NCT01947998|Warfarin
1016686|NCT01947985|Rivaroxaban
1016687|NCT01947985|Stroke Prevention in Atrial Fibrillation,
1016688|NCT01947985|Anticoagulants
1016689|NCT01947985|Hematologic Agents
1016690|NCT01947985|Therapeutic Uses
1016691|NCT01947985|Observational
1016692|NCT01947985|Venous Thromboembolism
1016693|NCT01947985|Secondary Prevention of Acute Coronary Syndrome
1016694|NCT01947985|Intracranial Hemorrhages
1016695|NCT01947985|Gastrointestinal Hemorrhage
1016696|NCT01947972|preterm neonate
1016697|NCT01947972|tailored fortification
1016698|NCT01947972|nutrition
1016699|NCT01947972|maternal breast milk composition
1016700|NCT01947959|Rivaroxaban
1016701|NCT01947959|Stroke Prevention in Atrial Fibrillation,
1016702|NCT01947959|Anticoagulants
1016703|NCT01947959|Hematologic Agents
1016704|NCT01947959|Therapeutic Uses
1016705|NCT01947959|Observational
1016706|NCT01947959|Venous Thromboembolism
1016707|NCT01947959|Secondary Prevention of Acute Coronary Syndrome
1016708|NCT01947959|Intracranial Hemorrhages
1016709|NCT01947959|Gastrointestinal Hemorrhage,
1016710|NCT01947946|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
1016711|NCT01947920|Healthy
1016712|NCT01947920|Pain
1016713|NCT01947920|Tramadol hydrochloride
1016714|NCT01947920|Tramadol HCl
1016715|NCT01947920|Analgesic
1016716|NCT01947920|QT prolongation
1016717|NCT01947920|RWJ-26898-002
1016718|NCT01947907|Human Growth Hormone
1016719|NCT01947907|rhGH
1016720|NCT01947907|hGH
1016721|NCT01947907|GHD
1016722|NCT01947881|Diabetic Macular Edema
1016723|NCT01947881|anti-VEGF
1016724|NCT01947881|Treatment Response
1016725|NCT01947842|Smartphone
1016726|NCT01947842|adherence
1016727|NCT01947842|contraceptives
1016728|NCT01947842|college
1016729|NCT01947842|females
1016730|NCT01947829|hemodialysis
1016731|NCT01947829|dialysis dose
1016732|NCT01947816|Ulcerative Colitis
1016733|NCT01947803|Schizophrenia
1016734|NCT01947803|Paliperidone
1016735|NCT01947803|Safety
1016736|NCT01947803|Effectiveness
1016737|NCT01947803|Chinese
1016738|NCT01947790|Type 2 diabetes
1016739|NCT01947790|left ventricular mass
1016740|NCT01947790|pioglitazone
1016741|NCT01947777|Phase 1
1016742|NCT01947777|Healthy subjects
1016743|NCT01947777|DDI
1016744|NCT01947777|CYP3A
1016745|NCT01947764|HIV
1016746|NCT01947764|Disclosure
1016747|NCT01947764|Pediatrics
1016748|NCT01947751|Catheter related infection
1016749|NCT01947751|Central venous catheter
1016750|NCT01947751|CVC infection
1016751|NCT01947738|Healthy
1016752|NCT01947738|Subjects
1016753|NCT01947738|Safety
1016754|NCT01947738|Tolerability
1016755|NCT01947738|VBY891
1016756|NCT01947738|Maximum
1016757|NCT01947738|Pharmacodynamic
1016758|NCT01947738|Pharmacokinetic
1016759|NCT01947725|Posttraumatic Stress Disorders
1016760|NCT01947725|PTSD
1016761|NCT01947725|Smoking Cessation
1016762|NCT01947725|Smoking
1016763|NCT01947725|Behavior Therapy
1016764|NCT01947712|Peripheral arterial disease
1016765|NCT01947712|Oxidative stress
1016766|NCT01947712|Cocoa
1016767|NCT01947712|polyphenols
1016768|NCT01947712|NADPH oxidase
1016769|NCT01947686|osteoarthritis, patellofemoral
1016770|NCT01947647|behavior therapy
1016771|NCT01947647|Randomized Controlled Trials
1016772|NCT01947647|Depressive Disorder
1016773|NCT01947647|Anxiety Disorders
1016774|NCT01947647|comorbidity
1016775|NCT01947621|Broken heart syndrome, stress cardiomyopathy
1016776|NCT01947595|diabetes mellitus type 2
1016777|NCT01947595|impaired glucose tolerance
1016778|NCT01947595|lifestyle intervention
1016779|NCT01947595|body fat distribution
1016780|NCT01947595|prevention
1016781|NCT01947582|multiple sclerosis
1016782|NCT01947582|gait
1016783|NCT01947582|ankle foot orthosis (AFO)
1016784|NCT01947556|diabetes
1016785|NCT01947556|insulin administration
1016786|NCT01947556|hyperglycaemia
1016787|NCT01947556|insulin aspart
1016788|NCT01947478|Drug-Eluting Angioplasty Balloon
1016789|NCT01947478|Drug Coated Angioplasty Balloon
1016790|NCT01947478|Peripheral Artery Disease
1016791|NCT01947478|Experimental
1016792|NCT01947478|Percutaneous Transluminal Angioplasty (PTA)
1016793|NCT01947452|Youth violence reduction
1016794|NCT01947452|Youth crime reduction
1016795|NCT01947452|School engagement
1016796|NCT01947452|Employment
1016797|NCT01947452|Social-emotional learning
1016798|NCT01947439|multivessel stenting
1016799|NCT01947426|DHA, term neonates, mother milk
1016800|NCT01947413|repetitive transcranial magnetic stimulation
1016801|NCT01947413|BoNTA
1016802|NCT01947413|stroke
1016803|NCT01947413|optimal treatment protocol
1016804|NCT01947413|randomized controlled trial
1016805|NCT01947413|motor control
1016806|NCT01947413|clinical predictors
1016807|NCT01947400|Physician and Patient Communication
1016808|NCT01947400|Acknowledge Introduce Duration Explanation Thank
1016809|NCT01947400|Hospital Consumer Assessment of Health Plans Survey
1016810|NCT01947374|Cartilage
1016811|NCT01947374|Articular
1016812|NCT01947335|Coronary
1016813|NCT01947335|Angioplasty
1016814|NCT01947335|Percutaneous coronary intervention
1016815|NCT01947335|Stent
1016816|NCT01947335|Contrast
1016817|NCT01947335|Acute Renal failure
1016818|NCT01947335|Intravascular ultrasound
1016819|NCT01947335|Prevention
1016820|NCT01947322|Natural killer cell
1016821|NCT01947322|Haploidentical
1016822|NCT01947322|Acute myeloid leukemia
1016823|NCT01947322|Chemotherapy
1016824|NCT01947309|Revlimid, lenalidomide, multiple myeloma, PFS, Response Rates
1016825|NCT01947296|Oral antineoplastic agent
1016826|NCT01947296|Adverse Effects
1016827|NCT01947296|Cancer Networks
1016828|NCT01947296|Continuity of care
1016829|NCT01947296|Coordination of patient's care
1016830|NCT01947283|Patient-Provider Relationship
1016831|NCT01947283|Shared Decision Making
1016832|NCT01947283|Therapeutic Alliance
1016833|NCT01947283|Mental Health
1016834|NCT01947283|Minority Health
1016835|NCT01947283|Patient Activation
1016836|NCT01947283|Communication
1016837|NCT01947270|Potentially inappropriate medications
1016838|NCT01947270|Elderly
1016839|NCT01947270|Prevention
1016840|NCT01947270|Multidisciplinary program
1016841|NCT01947270|Checklist
1016842|NCT01947270|Stepped wedge design
1016843|NCT01947270|AGED, 75 AND OVER
1016844|NCT01947244|Doulas
1016845|NCT01947244|Parenting
1016846|NCT01947244|Breast Feeding
1016847|NCT01947244|Pregnancy in Adolescence
1016848|NCT01947244|Child Development
1016849|NCT01947231|neck pain
1016850|NCT01947231|chronic
1016851|NCT01947231|Global Postural Re-education
1016852|NCT01947231|manual therapy
1016853|NCT01947231|physical therapy
1016854|NCT01947205|Curettage
1016855|NCT01947205|analgesia
1016856|NCT01947205|paracervical block
1016857|NCT01947205|paracetamol
1016858|NCT01947205|lidocaine
1016859|NCT01947205|Dexketoprofen trometamol
1016860|NCT01947192|Chlorhexidine
1016861|NCT01947192|Matrix metalloproteinases (MMP) inhibitor
1016862|NCT01947192|Adhesive system
1016863|NCT01947192|Controlled clinical trial
1016864|NCT01947192|Dental restoration
1016865|NCT01947192|Noncarious cervical lesions
1016866|NCT01947192|Dental restoration failure
1016867|NCT01947166|Whipple
1016868|NCT01947140|Lymphoid Malignancies
1016869|NCT01947140|Multiple Myeloma
1016870|NCT01947140|Lymphoma
1016871|NCT01947140|Hodgkin Lymphoma
1016872|NCT01947140|Non-hodgkin Lymphoma
1016873|NCT01947140|Follicular Lymphoma
1016874|NCT01947140|Diffuse Large B-Cell Lymphoma
1016875|NCT01947140|Anaplastic Large Cell Lymphoma
1016876|NCT01947140|Chronic Lymphocytic Leukemia
1016877|NCT01947140|Small Lymphocytic Lymphoma
1016878|NCT01947140|Mantle Cell Lymphoma
1016879|NCT01947140|Marginal Zone Lymphoma
1016880|NCT01947140|Burkitt Lymphoma
1016881|NCT01947140|Waldenstrom Macroglobulinemia
1016882|NCT01947140|Peripheral T-cell Lymphoma
1016883|NCT01947140|Cutaneous T-cell Lymphoma
1016884|NCT01947127|Lactate
1016885|NCT01947127|Sepsis
1016886|NCT01947127|Septic shock
1016887|NCT01947127|Disease progression
1016888|NCT01947127|Prognosis
1016889|NCT01947114|General anesthesia,
1016890|NCT01947114|Children,
1016891|NCT01947114|Rigid Bronchoscopy,
1016892|NCT01947114|Remifentanil,
1016893|NCT01947114|Propofol,
1016894|NCT01947114|Ketamine.
1016895|NCT01947101|Stool transplant
1016896|NCT01947101|Ulcerative Colitis
1016897|NCT01947101|Fecal transplant
1016898|NCT01947101|Inflammatory Bowel Disease
1016899|NCT01947088|Epilepsy, seizure disorder
1016900|NCT01947075|Fever
1016901|NCT01947075|Tanzania
1016902|NCT01947075|Pneumonia
1016903|NCT01947075|HIV
1016904|NCT01947075|Diabetes
1016905|NCT01947075|Indoor Air Pollution
1016906|NCT01947062|NSCLC
1016907|NCT01947062|Metronomic chemotherapy
1016908|NCT01947062|Metronomic cyclophosphamide
1016909|NCT01947049|Influenza
1016910|NCT01947049|diagnostic testing
1016911|NCT01947049|antiviral treatment
1016912|NCT01947049|rapid influenza testing
1016913|NCT01947036|autoimmune disease
1016914|NCT01947036|immune-mediated disease
1016915|NCT01947036|T and B cells immunophenotype
1016916|NCT01947036|IL23 signaling
1016917|NCT01947036|genetic risk variants
1016918|NCT01947010|antibodies
1016919|NCT01946984|diclofenac, ERCP and pancreatitis
1016920|NCT01946958|Triple P
1016921|NCT01946945|infertility
1016922|NCT01946945|recurrent pregnancy loss
1016923|NCT01946945|miscarriage
1016924|NCT01946945|Next Generation Sequencing
1016925|NCT01946932|Induced hypothermia
1016926|NCT01946932|Mild induced hypothermia
1016927|NCT01946932|Resuscitation
1016928|NCT01946932|Therapeutic hypothermia
1016929|NCT01946932|Neurological function
1016930|NCT01946932|Cardiovascular diseases
1016931|NCT01946932|Rehabilitation
1016932|NCT01946932|Quality of life
1016933|NCT01946932|Cognition
1016934|NCT01946919|Cinepazide
1016935|NCT01946919|Adverse Drug Reaction
1016936|NCT01946919|Safety
1016937|NCT01946919|Real World Study
1016938|NCT01946893|meditation
1016939|NCT01946893|education
1016940|NCT01946893|stress, psychological
1016941|NCT01946893|aged
1016942|NCT01946880|Systemic Lupus Erythematosus
1016943|NCT01946880|Mycophenolate Mofetil (MMF)
1016944|NCT01946867|Oral cavity Cancer
1016945|NCT01946867|Oropharynx Cancer
1016946|NCT01946854|Gastrointestinal
1016947|NCT01946854|Metastatic Well-differentiated Mucinous Appendiceal Adenocarcinomas with Pseudomyxoma Peritonea
1016948|NCT01946854|Appendiceal cancer
1016949|NCT01946854|Surgically unresectable
1016950|NCT01946854|Chemotherapy
1016951|NCT01946854|Observation
1016952|NCT01946854|Questionnaires
1016953|NCT01946841|Chronic kidney disease
1016954|NCT01946841|Hemodialysis
1016955|NCT01946841|Severe malnutrition
1016956|NCT01946841|Enteral nutrition
1016957|NCT01946828|Field Induced Mydriasis
1016958|NCT01946828|FIM
1016959|NCT01946828|ATI
1016960|NCT01946802|Heart arrest
1016961|NCT01946802|Cardiopulmonary resuscitation
1016962|NCT01946802|Hypothermia induced
1016963|NCT01946802|Seizures
1016964|NCT01946802|Electroencephalography
1016965|NCT01946789|cancer
1016966|NCT01946789|IL-15
1016967|NCT01946789|melanoma
1016968|NCT01946789|metastatic
1016969|NCT01946789|unresectable
1016970|NCT01946789|solid tumors
1016971|NCT01946789|renal cell
1016972|NCT01946789|non-small cell lung
1016973|NCT01946789|squamous cell head and neck
1016974|NCT01946737|Coronary
1016975|NCT01946737|Artery
1016976|NCT01946737|Disease
1016977|NCT01946737|Diagnostic
1016978|NCT01946737|Performance
1016979|NCT01946737|Angiography
1016980|NCT01946711|CRS
1016981|NCT01946711|polyposis
1016982|NCT01946672|gynaecological malignancy
1016983|NCT01946672|pelvic lymphadenectomy
1016984|NCT01946672|lymphedema
1016985|NCT01946672|sentinel node
1016986|NCT01946672|reverse mapping
1016987|NCT01946659|Tailored Telephone Intervention
1016988|NCT01946620|Chronic Obstructive Pulmonary Disease
1016989|NCT01946620|Exacerbations
1016990|NCT01946620|FEV1 ≤ 50%
1016991|NCT01946607|Neuroticism
1016992|NCT01946607|Emotion processing
1016993|NCT01946607|Eye gaze movements
1016994|NCT01946607|Heart Rate Variability
1016995|NCT01946594|fever
1016996|NCT01946594|antipyretics
1016997|NCT01946594|acetaminophen
1016998|NCT01946594|influenza vaccine
1016999|NCT01946594|influenza, human
1017000|NCT01946594|body temperature changes
1017001|NCT01946594|Orthomyxoviridae Infections
1017002|NCT01946594|RNA virus infections
1017003|NCT01946594|Virus Diseases
1017004|NCT01946594|Respiratory Tract Infections
1017005|NCT01946594|Respiratory Tract Diseases
1017006|NCT01946555|Breakthrough cancer pain
1017007|NCT01946555|Neuropathic pain
1017008|NCT01946555|Major opioid
1017009|NCT01946555|Analgesics
1017010|NCT01946542|exercise
1017011|NCT01946542|heart failure
1017012|NCT01946542|fatigue
1017013|NCT01946542|physical endurance
1017014|NCT01946542|functional food
1017015|NCT01946516|viral screening
1017016|NCT01946503|Short Gut
1017017|NCT01946503|Short Bowel Syndrome
1017018|NCT01946503|Intestinal Failure
1017019|NCT01946503|Home parenteral nutrition
1017020|NCT01946503|Feeding Behavior
1017021|NCT01946503|Enteral Nutrition
1017022|NCT01946503|Parent-Child Relations
1017023|NCT01946503|Parenteral Nutrition
1017024|NCT01946503|Digestive System Diseases
1017025|NCT01946477|Multiple Myeloma, MM, cancer, oncology, hematology, plasma, neoplasm, plasmacytoma
1017026|NCT01946464|edentulous
1017027|NCT01946464|bearded
1017028|NCT01946464|patients
1017029|NCT01946464|requiring
1017030|NCT01946464|general anesthesia
1017031|NCT01946464|Mallampati Class II or IV
1017032|NCT01946451|idiopathic epiretinal membranes
1017033|NCT01946451|secondary epiretinal membranes
1017034|NCT01946438|Influenza
1017035|NCT01946438|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),
1017036|NCT01946438|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),
1017037|NCT01946438|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
1017038|NCT01946425|Influenza
1017039|NCT01946425|Influenza virus vaccine
1017040|NCT01946425|Fluzone® Quadrivalent Influenza Vaccine (No Preservative)
1017041|NCT01946412|Cystic Fibrosis
1017042|NCT01946373|Melanoma
1017043|NCT01946373|Dendritic cell vaccination
1017044|NCT01946373|Lymphodepletion
1017045|NCT01946373|Adoptive cell transfer
1017046|NCT01946373|T cells
1017047|NCT01946373|Tumor infiltrating lymphocytes
1017048|NCT01946373|Fludarabine
1017049|NCT01946373|IL-2
1017050|NCT01946373|Interleukin-2
1017051|NCT01946373|Cyclophosphamide
1017052|NCT01946373|Phase I study
1017053|NCT01946373|Monocytes
1017054|NCT01946373|Autologous
1017055|NCT01946373|NY-ESO-1
1017056|NCT01946347|Insulin Resistance
1017057|NCT01946347|Hyperglycemia
1017058|NCT01946347|Endothelial function
1017059|NCT01946347|Oxidative stress
1017060|NCT01946308|sleep
1017061|NCT01946308|sleep efficiency
1017062|NCT01946308|active sleep
1017063|NCT01946308|quiet sleep
1017064|NCT01946308|arousals
1017065|NCT01946308|premature infant
1017066|NCT01946308|conformational positioning
1017067|NCT01946308|mattress
1017068|NCT01946308|feeding difficulty
1017069|NCT01946308|neonatal intensive care unit
1017070|NCT01946308|sleep state
1017071|NCT01946308|behavioral observation
1017072|NCT01946308|stress behavior
1017073|NCT01946308|self-regulatory behavior
1017074|NCT01946308|surgery
1017075|NCT01946308|gastrointestinal
1017082|NCT01946204|Prostate neoplasms
1017083|NCT01946204|Prostate cancer
1017084|NCT01946204|Castration-resistant prostate cancer
1017085|NCT01946204|Non-metastatic castration-resistant prostate cancer
1017086|NCT01946204|ARN-509
1017087|NCT01946204|Apalutamide
1017088|NCT01946191|Weight maintenance
1017089|NCT01946191|Electronic health record
1017090|NCT01946191|Primary care
1017091|NCT01946178|Uterine Fibroids
1017092|NCT01946178|Leiomyomas
1017093|NCT01946178|High-Intensity Focused Ultrasound Ablation
1017094|NCT01946178|Ultrasonography
1017095|NCT01946165|Prostate Cancer
1017096|NCT01946165|High risk prostate cancer
1017097|NCT01946165|Abiraterone acetate
1017098|NCT01946165|Zytiga
1017099|NCT01946165|Prednisone
1017100|NCT01946165|Enzalutamide
1017101|NCT01946165|MDV3100
1017102|NCT01946165|XTANDI
1017103|NCT01946165|Androgen ablation
1017104|NCT01946165|LHRHa
1017105|NCT01946165|Hormonal therapy
1017106|NCT01946152|Myeloma
1017107|NCT01946152|Relapsed/Refractory Multiple Myeloma
1017108|NCT01946152|MM
1017109|NCT01946152|Pomalidomide
1017110|NCT01946152|CC-4047
1017111|NCT01946152|Dexamethasone
1017112|NCT01946152|Decadron
1017113|NCT01946152|C-CSF
1017114|NCT01946152|Filgrastim
1017115|NCT01946152|Neupogen
1017116|NCT01946152|Granulocyte colony stimulating factor
1017117|NCT01946100|multifocal
1017118|NCT01946100|genetic
1017119|NCT01946100|bronchoalveolar carcinoma
1017120|NCT01946100|adenocarcinoma in situ
1017121|NCT01946100|ground glass opacity
1017122|NCT01946100|next generation sequencing
1017123|NCT01946087|Remote ischemic preconditioning
1017124|NCT01946087|cardiac surgery
1017125|NCT01946087|left ventricular hypertrophy
1017126|NCT01946087|reperfusion injury salvage kinase
1017127|NCT01946074|advanced solid tumor
1017128|NCT01946074|cancer
1017129|NCT01946074|neoplasm
1017130|NCT01946074|colorectal cancer
1017131|NCT01946061|Oxaliplatin, S-1, Gastric cancer, Adjuvant chemotherapy
1017132|NCT01946022|infertility
1017133|NCT01946022|ovulation induction
1017134|NCT01946022|luteal phase
1017135|NCT01946022|granulosa cells function
1017136|NCT01946022|GnRH agonist and antagonist
1017137|NCT01946022|HMG
1017138|NCT01946022|FSHr
1017139|NCT01945996|Hispanic Americans
1017140|NCT01945996|Cellular Phone
1017141|NCT01945996|Behavior
1017142|NCT01945983|Septic shock
1017143|NCT01945983|Severe sepsis
1017144|NCT01945983|Norepinephrine
1017145|NCT01945970|Vascular function
1017146|NCT01945970|Flow mediated dilation
1017147|NCT01945970|Tea
1017148|NCT01945957|autism
1017149|NCT01945957|brain
1017150|NCT01945957|functional magnetic resonance imaging
1017151|NCT01945957|oxytocin
1017152|NCT01945944|pediatric
1017153|NCT01945944|mucolytic
1017154|NCT01945944|respiratory failure
1017155|NCT01945944|atelectasis
1017156|NCT01945944|hypertonic saline
1017157|NCT01945931|Maternal health
1017158|NCT01945931|perinatal health
1017159|NCT01945931|mHealth
1017160|NCT01945931|smartphone
1017161|NCT01945931|mobile phone
1017162|NCT01945931|Ethiopia
1017163|NCT01945918|Diabetes Mellitus, Type 2
1017164|NCT01945918|Diabetes Mellitus
1017165|NCT01945918|Primary Health Care
1017166|NCT01945918|Self care
1017167|NCT01945905|Tuberculosis
1017168|NCT01945905|Adherence, medication
1017169|NCT01945905|Patient compliance
1017170|NCT01945892|macular edema, irvine gass syndrome, ozurdex
1017171|NCT01945879|pancreatic cancer
1017172|NCT01945879|heparin
1017173|NCT01945879|thromboembolic events
1017174|NCT01945879|bleedings
1017175|NCT01945866|Diabetic Macular Edema
1017176|NCT01945866|Anti-vascular endothelial growth factor
1017177|NCT01945866|Dexamethasone Intravitreal implant
1017178|NCT01945866|Ranibizumab intravitreal injection
1017179|NCT01945801|Sleep apnea
1017180|NCT01945801|Treatment
1017181|NCT01945801|Sodium-Restricted Diet
1017182|NCT01945801|Diuretic
1017183|NCT01945801|Lasilactone
1017184|NCT01945775|Breast cancer
1017185|NCT01945775|BRCA mutation
1017186|NCT01945775|PARP inhibitor
1017187|NCT01945775|BRCA 1
1017188|NCT01945775|BRCA 2
1017189|NCT01945762|RET Mutation
1017190|NCT01945762|DIagnostics
1017191|NCT01945762|Medullary Thyroid Cancer
1017192|NCT01945762|MTC
1017193|NCT01945736|Opiate withdrawal in children
1017194|NCT01945723|Endoscopy
1017195|NCT01945723|Gastrointestinal tract
1017196|NCT01945723|Bacterial markers
1017197|NCT01945723|volunteers
1017198|NCT01945710|Tumors
1017199|NCT01945697|DNA methylation, biomarkers, oral cancer
1017200|NCT01945645|Prevention
1017201|NCT01945645|Screening
1017202|NCT01945645|Type 2 diabetes
1017203|NCT01945645|Action Competence
1017204|NCT01945645|Family practice
1017205|NCT01945645|Health Services Research
1017206|NCT01945619|CMV
1017207|NCT01945619|Adenovirus
1017208|NCT01945619|EBV
1017209|NCT01945619|Stem cell transplant
1017210|NCT01945619|cytotoxic T-lymphocytes
1017211|NCT01945580|POP
1017212|NCT01945580|Transvaginal
1017213|NCT01945580|Native Tissue Repair
1017214|NCT01945580|Repair Augmented with Mesh
1017215|NCT01945580|Biologic Graft
1017216|NCT01945580|Pelvic Organ Prolapse
1017217|NCT01945567|Parkinson's disease
1017218|NCT01945567|Essential tremor
1017219|NCT01945567|Tremor
1017220|NCT01945567|Deep brain stimulation
1017221|NCT01945567|Posterior subthalamic area
1017222|NCT01945567|Zona incerta
1017223|NCT01945554|infiltrative therapy
1017224|NCT01945554|cervical disc herniation
1017225|NCT01945554|lumbar disc herniation
1017226|NCT01945541|Intraoperative Fluid Administration
1017227|NCT01945541|Body Composition Measurement
1017228|NCT01945528|Platelet Rich Plasma
1017229|NCT01945528|tendinopathy
1017230|NCT01945528|epicondylitis
1017231|NCT01945528|ultrasound
1017232|NCT01945528|injection therapy
1017233|NCT01945528|needle tenotomy
1017234|NCT01945515|Stroke
1017235|NCT01945515|transcranial direct current stimulation
1017236|NCT01945515|robotic rehabilitation
1017237|NCT01945515|gait
1017238|NCT01945476|midazolam
1017239|NCT01945476|premedication
1017240|NCT01945476|functional recovery
1017241|NCT01945476|breast cancer
1017245|NCT01945411|Airway Management
1017246|NCT01945411|Ventilation
1017247|NCT01945398|Pulmonary Rehabilitation
1017248|NCT01945398|Inspiratory Muscle Training
1017249|NCT01945398|Inspiratory Muscle Strength
1017250|NCT01945398|Vascular Resistance
1017251|NCT01945398|Exercise
1017252|NCT01945398|Chronic Obstructive Pulmonary Disease
1017253|NCT01945385|Abortion
1017254|NCT01945385|LARC
1017255|NCT01945385|Contraception
1017256|NCT01945385|IUD
1017257|NCT01945385|Contraceptive implant
1017258|NCT01945385|behavioral change
1017259|NCT01945385|video intervention
1017260|NCT01945359|Relapsing Multiple Sclerosis
1017261|NCT01945359|Dimethyl Fumarate
1017262|NCT01945359|Natalizumab
1017263|NCT01945346|PRX167700
1017264|NCT01945346|Osteoarthritis
1017265|NCT01945333|Cognitive remediation
1017266|NCT01945333|Schizophrenia
1017267|NCT01945333|Schizoaffective disorder
1017268|NCT01945320|hemodialysis
1017269|NCT01945320|wasting and malnutrition
1017270|NCT01945320|nutrition status
1017271|NCT01945320|bioelectrical impedance analysis
1017272|NCT01945320|body composition
1017273|NCT01945307|Complement
1017274|NCT01945307|Serum Bactericidal Assay
1017275|NCT01945268|vascular, influenza, vaccine, heart failure
1017276|NCT01945255|Calcification
1017277|NCT01945255|aortic pulse wave velocity
1017278|NCT01945255|peripheral artery occlusion disease
1017279|NCT01945255|hemodialysis
1017280|NCT01945255|metabolic syndrome
1017281|NCT01945242|Drug Therapy
1017282|NCT01945216|Drug therapy
1017283|NCT01945203|Calcification
1017284|NCT01945203|aortic pulse wave velocity
1017285|NCT01945203|peripheral artery occlusion disease
1017286|NCT01945203|peritoneal dialysis
1017287|NCT01945203|metabolic syndrome
1017288|NCT01945177|endoscopy
1017289|NCT01945177|gastric intestinal metaplasia
1017290|NCT01945177|gastric cancer
1017291|NCT01945164|XL999
1017292|NCT01945164|Advanced Malignancy
1017293|NCT01945151|spastic hemiparesis
1017294|NCT01945138|Total Pancreatectomy
1017295|NCT01945138|Islet Auto-Transplantation
1017296|NCT01945138|Closed Loop Insulin Pump
1017297|NCT01945099|diabetes, insulin,post prandial, closed loop, artificial pancreas, hyperglycemia
1017298|NCT01945086|Dermatitis, Atopic
1017299|NCT01945086|Eczema
1017300|NCT01945086|Ustekinumab
1017301|NCT01945086|CNTO1275
1017302|NCT01945086|STELARA
1017303|NCT01945073|Educational intervention
1017304|NCT01945073|Formal Counselling
1017305|NCT01945073|Knowledge
1017306|NCT01945073|Illness Perception
1017307|NCT01945060|Artificial Pancreas Project
1017308|NCT01945060|Diabetes Assistant (DiAs) Medical Platform System
1017309|NCT01945060|Artificial Pancreas Platform
1017310|NCT01945060|Insulin Pump
1017311|NCT01945060|Continuous Glucose Monitor
1017312|NCT01945060|Closed-Loop Control
1017313|NCT01945060|heart rate Control to Range System (hrCTR)
1017314|NCT01945047|depression
1017315|NCT01945047|treatment
1017316|NCT01945047|ketamine
1017317|NCT01945047|ottawa
1017318|NCT01945047|treatment-resistant
1017319|NCT01945047|infusion
1017320|NCT01945034|topical ibuprofen
1017321|NCT01945034|ankle sprain
1017322|NCT01945021|Non small cell lung cancer
1017323|NCT01945021|NSCLC
1017324|NCT01945021|ROS1
1017325|NCT01945021|ROS1 positive
1017326|NCT01945021|ROS1 proto oncogene
1017327|NCT01945021|c ros tyrosine kinases
1017328|NCT01945021|ROS1 positive NSCLC
1017329|NCT01945021|ROS1 lung cancer
1017330|NCT01945021|ALK negative
1017331|NCT01945021|Lung Carcinoma
1017332|NCT01945021|Neoplasm
1017333|NCT01945021|Crizotinib
1017334|NCT01945021|Xalkori
1017335|NCT01945021|Previously treated or untreated
1017336|NCT01945021|North East Asian
1017337|NCT01945008|HCV
1017338|NCT01945008|observational study
1017339|NCT01945008|HCV direct-acting antiviral agents
1017340|NCT01944982|Immunotherapy
1017341|NCT01944982|NKAEs
1017342|NCT01944982|Expanded haploidentical natural killer cells
1017343|NCT01944982|Activated natural killer cells
1017344|NCT01944956|Maturation
1017345|NCT01944956|preterm infants
1017346|NCT01944956|sucking and swallowing
1017347|NCT01944943|refractory/relapsed
1017348|NCT01944943|diffuse large B-cell lymphoma
1017349|NCT01944943|indolent non-hodgkin lymphoma
1017350|NCT01944943|Primary central nervous system lymphoma
1017351|NCT01944943|chronic lymphocytic leukemia
1017352|NCT01944917|Electromagnetic field
1017353|NCT01944917|VAS score
1017354|NCT01944917|Heart Rate Variability
1017355|NCT01944904|XOS
1017356|NCT01944904|pre-diabetic
1017357|NCT01944904|abnormal glucose levels
1017358|NCT01944891|Adolescent girls
1017359|NCT01944891|Mozambique
1017360|NCT01944891|Diet
1017361|NCT01944891|Anthropometrics
1017362|NCT01944891|Serum biomarkers
1017363|NCT01944878|Peptic ulcer
1017364|NCT01944878|Liver cirrhosis
1017365|NCT01944878|Portal hypertension
1017366|NCT01944865|Aerobic Interval Training
1017367|NCT01944865|Supramaximal Training
1017372|NCT01944839|Wet AMD
1017373|NCT01944839|choroidal neovascularization
1017374|NCT01944839|Fovista®
1017375|NCT01944839|E10030
1017376|NCT01944839|Lucentis®
1017377|NCT01944826|Dyspnea
1017378|NCT01944826|Angina pectoris
1017379|NCT01944813|Advance Care planning
1017380|NCT01944813|End-of-life Discussions
1017381|NCT01944813|Questionaires
1017382|NCT01944813|Palliative Care
1017383|NCT01944800|Ticagrelor
1017384|NCT01944800|Prasugrel
1017385|NCT01944800|Acute coronary syndrome
1017386|NCT01944800|Percutaneous coronary intervention
1017387|NCT01944774|Moxifloxacin
1017388|NCT01944761|pediatrics
1017389|NCT01944761|Brain Tumor
1017390|NCT01944761|Neuro-radiation
1017391|NCT01944761|Exercise
1017392|NCT01944709|melanoma
1017393|NCT01944709|dendritic cells
1017394|NCT01944709|peptide
1017395|NCT01944709|Melan-A
1017396|NCT01944696|hyperbilirubinemia
1017397|NCT01944696|prematurity
1017398|NCT01944696|extremely low birth weight (ELBW)
1017399|NCT01944696|phototherapy
1017400|NCT01944696|cycled phototherapy
1017401|NCT01944696|intermittent phototherapy
1017402|NCT01944657|Major Depressive Disorder Clinical Outcomes
1017403|NCT01944657|Transcranial Magnetic Stimulation
1017404|NCT01944657|Standard Medication Monotherapy
1017405|NCT01944657|Exploratory Field Study
1017406|NCT01944605|Endotoxin
1017407|NCT01944605|Cytokine
1017408|NCT01944605|Metabolism
1017409|NCT01944592|Gynaecology Teaching Associate
1017410|NCT01944592|Pelvic examination
1017411|NCT01944592|Students
1017412|NCT01944553|Spine
1017413|NCT01944553|Accurancy
1017414|NCT01944553|Robotic
1017415|NCT01944553|Screw placement
1017416|NCT01944553|Degenerative
1017417|NCT01944514|Action potential duration restitution
1017418|NCT01944514|Ventricular arrhythmia
1017419|NCT01944514|Sudden cardiac death
1017420|NCT01944514|Peri-infarct zone
1017421|NCT01944514|Electrocardiogram
1017422|NCT01944501|tinnitus
1017423|NCT01944501|hearing loss
1017424|NCT01944501|Transcranial magnetic stimulation
1017425|NCT01944501|Transcranial direct current stimulation
1017426|NCT01944488|Precocious puberty
1017427|NCT01944488|GnRH-test
1017428|NCT01944475|Precocious puberty
1017429|NCT01944475|Premature thelarche
1017430|NCT01944475|Tanner-stage
1017431|NCT01944475|GnRH-test
1017432|NCT01944462|pneumococcal vaccine
1017433|NCT01944462|pharmacist vaccination
1017434|NCT01944462|Pneumovax 23
1017435|NCT01944462|pneumococcal vaccine polyvalent
1017436|NCT01944449|Type 2 diabetes (T2D)
1017437|NCT01944449|Whey Protein Concentrate (WPC)
1017438|NCT01944436|Pharmacogenomics
1017439|NCT01944436|Dementia with Lewy bodies
1017440|NCT01944436|Adverse events
1017441|NCT01944436|Polymorphisms
1017442|NCT01944436|Acetylcholinesterase
1017443|NCT01944436|Parkinson's Disease Dementia
1017444|NCT01944436|Cognitive enhancers
1017445|NCT01944436|Clinical efficacy
1017446|NCT01944436|Cytochrome P450
1017447|NCT01944436|Butyrylcholinesterase
1017448|NCT01944410|PRP
1017449|NCT01944410|TBC
1017450|NCT01944410|Treatment
1017451|NCT01944397|Atrial fibrillation
1017452|NCT01944397|Heart failure
1017453|NCT01944397|Stroke
1017454|NCT01944397|Myocardial infarction
1017455|NCT01944371|Latent reservoir
1017456|NCT01944358|Syphilis; human immunodeficiency virus; penicillin
1017457|NCT01944332|gamete treatment
1017458|NCT01944332|ICSI
1017459|NCT01944332|IVF
1017460|NCT01944332|infertility
1017461|NCT01944332|oocyte activation
1017462|NCT01944319|Infection; Meropenem; Pharmacokinetics; Pharmacodynamics
1017463|NCT01944306|Pharmacokinetics
1017464|NCT01944306|Pharmacology, Clinical
1017465|NCT01944306|Drug Efficacy
1017466|NCT01944306|Drug Failure
1017467|NCT01944306|Contraceptive Agents
1017468|NCT01944293|Ketamine
1017469|NCT01944293|Midazolam
1017470|NCT01944293|Bipolar Disorder
1017471|NCT01944293|Major Depressive Episode
1017472|NCT01944293|Suicidal Ideation
1017473|NCT01944293|Suicide
1017474|NCT01944293|Depression
1017475|NCT01944293|Treatment
1017476|NCT01944293|Ketamine Treatment
1017477|NCT01944254|Cardiac surgical procedures
1017478|NCT01944254|Pulmonary Artery Catheterizations
1017479|NCT01944254|Cardiac output
1017480|NCT01944254|Swan Ganz Catheterization
1017481|NCT01944241|cervical surgery
1017482|NCT01944241|LLETZ
1017483|NCT01944241|LEEP
1017484|NCT01944241|Cone biopsy
1017485|NCT01944241|Fertility
1017486|NCT01944228|inflammation
1017487|NCT01944228|vagus nerve stimulation
1017488|NCT01944228|chronic heart failure
1017489|NCT01944228|Systemic Inflammatory Response Syndrome
1017490|NCT01944228|sepsis
1017491|NCT01944228|auto-immune diseases
1017492|NCT01944215|Normal subjects
1017493|NCT01944215|Female
1017494|NCT01944215|Molecular Breast Imaging
1017495|NCT01944215|Fasting
1017496|NCT01944215|Exercise
1017497|NCT01944215|Tracer Uptake
1017498|NCT01944215|Tc-99m Sestamibi
1017499|NCT01944215|Prandial status
1017500|NCT01944215|metabolic status
1017501|NCT01944215|negative mammogram
1017502|NCT01944215|Caffeine
1017503|NCT01944215|External Warming
1017504|NCT01944202|Echocardiography
1017505|NCT01944202|Appropriate Use Criteria
1017506|NCT01944202|Educational Intervention
1017507|NCT01944189|lumefantrine pharmacokinetics & bioavailability
1017508|NCT01944176|COPD
1017509|NCT01944176|Statins
1017510|NCT01944176|Cytokines
1017511|NCT01944163|Low back pain
1017512|NCT01944163|Impact analysis
1017513|NCT01944163|Cluster randomized trial
1017514|NCT01944163|Referral rule
1017515|NCT01944163|Axial spondyloarthritis
1017516|NCT01944150|Hypnosis
1017517|NCT01944150|chronic pain
1017518|NCT01944150|transcutaneous electrical nerve stimulation
1017519|NCT01944150|nociceptive pain
1017520|NCT01944150|neuropathic pain
1017521|NCT01944150|complementary therapies
1017522|NCT01944137|colonic neoplasms
1017523|NCT01944137|Lung neoplasms
1017524|NCT01944137|patient-centered nursing
1017525|NCT01944137|breast neoplasms
1017526|NCT01944124|Mobile health
1017527|NCT01944124|Metabolic syndrome
1017528|NCT01944124|Exercise prescription
1017529|NCT01944124|Exercise intervention
1017530|NCT01944124|Disease prevention
1017531|NCT01944124|Rural health
1017532|NCT01944111|Gastric plication
1017533|NCT01944085|children
1017534|NCT01944085|supracondylar fracture
1017535|NCT01944085|pin removal
1017536|NCT01944085|analgesia
1017537|NCT01944085|pain score
1017538|NCT01944072|Chronic Obstructive Pulmonary Disease
1017539|NCT01944072|COPD
1017540|NCT01944072|Pulmonary rehabilitation
1017541|NCT01944072|Aerobic exercise
1017542|NCT01944072|CEDOC
1017543|NCT01944072|FCM
1017544|NCT01944072|UNL
1017545|NCT01944072|NOVA MEDICAL SCHOOL
1017546|NCT01944046|autism, ASD, autistic, Asperger's, PDD-NOS, oxytocin
1017547|NCT01944033|β2-agonist
1017548|NCT01944033|Ipratropium Bromide
1017549|NCT01944033|Chronic Obstructive Pulmonary Disease Exacerbation
1017550|NCT01944033|Emergency departement
1017551|NCT01944020|Sleep Apnea, Obstructive
1017552|NCT01944020|Energy Balance
1017553|NCT01944020|Food Intake
1017554|NCT01944020|Energy Expenditure
1017555|NCT01944020|Sleep
1017556|NCT01944020|Obesity
1017557|NCT01944007|CLP
1017558|NCT01943994|Psilocybin
1017559|NCT01943994|Smoking cessation
1017560|NCT01943955|dizziness
1017561|NCT01943955|vertigo
1017562|NCT01943955|unsteadiness
1017563|NCT01943955|unbalance
1017564|NCT01943955|falls
1017565|NCT01943942|Mexico
1017566|NCT01943942|Montelukast
1017567|NCT01943942|Pharmacokinetics
1017568|NCT01943942|Bioequivalence
1017569|NCT01943929|Nasal septum
1017570|NCT01943929|Headache
1017571|NCT01943929|Mucosa contact point headache
1017572|NCT01943916|breast imaging diagnosis
1017573|NCT01943916|breast ultrasound
1017574|NCT01943916|Imagio
1017575|NCT01943916|Seno Medical Instruments, Inc.
1017576|NCT01943916|Seno
1017577|NCT01943916|opto-acoustics
1017578|NCT01943916|OA
1017579|NCT01943916|angiogenesis
1017580|NCT01943916|blood map
1017581|NCT01943890|Hypertonic saline
1017582|NCT01943890|Lung physiotherapy
1017583|NCT01943864|pharmacokinetics
1017584|NCT01943864|second line monotherapy
1017585|NCT01943864|GSK1120212 (trametinib)
1017586|NCT01943864|MEK inhibitor
1017587|NCT01943864|locally advanced or metastatic biliary tract cancers
1017588|NCT01943851|leukemia
1017589|NCT01943851|Acute myeloid leukemia
1017590|NCT01943851|BET inhibitor
1017591|NCT01943851|lymphoma
1017592|NCT01943851|Myelodysplastic syndromes
1017593|NCT01943851|Oncology
1017594|NCT01943851|multiple myeloma
1017595|NCT01943851|GSK525762
1017596|NCT01943825|Dengue
1017597|NCT01943825|Dengue fever
1017598|NCT01943825|CYD dengue vaccine
1017599|NCT01943825|IXIARO JE vaccine
1017600|NCT01943825|Flavivirus
1017601|NCT01943799|Hepatitis B (HBV)
1017602|NCT01943799|Oral antiviral (OAV)
1017603|NCT01943799|GS-4774
1017604|NCT01943786|Wild type KRAS
1017605|NCT01943773|delirium
1017606|NCT01943773|surgery
1017607|NCT01943773|operation
1017608|NCT01943773|geriatric
1017609|NCT01943773|complication
1017610|NCT01943760|Tramadol
1017611|NCT01943760|Children
1017612|NCT01943760|Hernioplasty
1017613|NCT01943760|Wound infiltration
1017614|NCT01943747|sepsis
1017615|NCT01943747|severe sepsis
1017616|NCT01943747|septic shock
1017617|NCT01943747|infection
1017618|NCT01943747|organ dysfunction
1017619|NCT01943747|quality improvement
1017620|NCT01943734|Information
1017621|NCT01943734|Lifestyle
1017622|NCT01943734|Occupational Health
1017623|NCT01943695|Breast Cancer
1017624|NCT01943695|Exercise
1017625|NCT01943695|Chemotherapy
1017626|NCT01943695|15-178
1017627|NCT01943682|Relapsed acute myeloid leukemia
1017628|NCT01943682|non-therapy related acute myeloid leukemia
1017629|NCT01943682|Refractory acute myeloid leukemia
1017630|NCT01943682|Untreated acute myeloid leukemia
1017631|NCT01943682|Lymphoma
1017632|NCT01943682|Leukemia
1017633|NCT01943669|Spinal Cord Injury
1017634|NCT01943656|Spinal Cord Injury
1017635|NCT01943643|angiography, bifurcation, stenting, CT
1017636|NCT01943630|HPV condyloma acuminata
1017637|NCT01943617|Liver Cirrhosis
1017638|NCT01943617|Hepatitis B
1017639|NCT01943617|Compensation
1017640|NCT01943617|Efficacy
1017641|NCT01943604|Neuropsychology
1017642|NCT01943604|Breakfast eating patters
1017643|NCT01943604|Glucose
1017644|NCT01943604|Child Psychology
1017645|NCT01943591|treatment trial
1017646|NCT01943591|cerebral aneurysm
1017647|NCT01943591|randomized
1017648|NCT01943591|coils
1017649|NCT01943591|endovascular
1017650|NCT01943591|Aneurysm
1017651|NCT01943591|Intracranial Aneurysm
1017652|NCT01943591|Vascular Diseases
1017653|NCT01943591|Cardiovascular Diseases
1017654|NCT01943591|Intracranial Arterial Diseases
1017655|NCT01943591|Cerebrovascular Disorders
1017656|NCT01943591|Brain Diseases
1017657|NCT01943591|Central Nervous System Diseases
1017658|NCT01943591|Nervous System Diseases
1017659|NCT01943565|Pregnancy
1017660|NCT01943565|Healthy
1017661|NCT01943565|Intrathecal
1017662|NCT01943565|Opioids
1017663|NCT01943565|Spinal
1017664|NCT01943565|Anesthesia
1017665|NCT01943565|Pain
1017666|NCT01943565|Cesarean
1017667|NCT01943565|Delivery
1017668|NCT01943565|Human
1017669|NCT01943526|Ireland
1017670|NCT01943526|Natalizumab
1017671|NCT01943513|Muscle Disuse Atrophy
1017672|NCT01943500|Breast cancer
1017673|NCT01943500|Prostate cancer
1017674|NCT01943500|Colorectal cancer
1017675|NCT01943500|Circulating tumor cell (CTC)
1017676|NCT01943487|Phase I
1017677|NCT01943487|Verapamil
1017678|NCT01943487|Tamsulosin OCAS
1017679|NCT01943487|Solifenacin
1017680|NCT01943487|Pharmacokinetics
1017681|NCT01943487|EC905
1017682|NCT01943474|IV Catheter comparison
1017683|NCT01943474|AccuCath versus Conventional IV Catheters
1017684|NCT01943474|IV Catheter Study
1017685|NCT01943474|IV Catheter User Preference Comparison
1017686|NCT01943474|First Attempt Success Rate for IV Catheters
1017687|NCT01943474|AccuCath Device Performance
1017688|NCT01943474|Complication Rates for IV Catheters
1017689|NCT01943474|Average Dwell Time for IV Catheters
1017690|NCT01943474|Patient Satisfaction with IV Catheters
1017691|NCT01943474|Clinician Satisfaction with AccuCath Device Performance
1017697|NCT01943448|Macula Lutea Hemorrhage
1017698|NCT01943448|High Myopia
1017699|NCT01943448|Optical Coherence Tomography
1017700|NCT01943435|Spinal Stenosis
1017701|NCT01943435|Spinal manipulation
1017702|NCT01943435|Exercise
1017703|NCT01943435|Epidural injection
1017704|NCT01943422|advanced
1017705|NCT01943422|melanoma
1017706|NCT01943422|Vemurafenib
1017707|NCT01943422|High-dose Interferon alfa-2b
1017708|NCT01943409|Parenteral nutrition
1017709|NCT01943409|lipid emulsion
1017710|NCT01943409|Intralipid
1017711|NCT01943409|ClinOleic
1017712|NCT01943409|Inflammation
1017713|NCT01943409|Infection
1017714|NCT01943409|Bloodstream Infection
1017715|NCT01943409|length of stay
1017716|NCT01943409|mortality
1017717|NCT01943396|age-related macular degeneration
1017718|NCT01943396|AMD
1017719|NCT01943396|rheohemapheresis
1017720|NCT01943396|plasma filtration
1017721|NCT01943396|electroretinography
1017722|NCT01943396|ERG
1017723|NCT01943396|multifocal ERG
1017724|NCT01943396|double plasma filtration
1017725|NCT01943383|Hypertension
1017726|NCT01943370|endoscopic sinus surgery
1017727|NCT01943370|post-operative irrigation
1017728|NCT01943370|pain
1017729|NCT01943370|debridement
1017730|NCT01943357|diabetes
1017731|NCT01943357|patient education
1017732|NCT01943357|self management
1017733|NCT01943357|health improvement
1017734|NCT01943344|vascular large hole closure
1017735|NCT01943344|arteriotomy closure
1017736|NCT01943344|Large hole vascular closure device
1017737|NCT01943344|vascular closure device
1017738|NCT01943344|percutaneous vascular closure device
1017739|NCT01943318|Liver Cirrhosis
1017740|NCT01943318|Hepatocellular carcinoma
1017741|NCT01943305|Yellow Fever
1017742|NCT01943305|vaccination
1017743|NCT01943305|Japanese encephalitis
1017744|NCT01943305|antibodies
1017745|NCT01943292|Focal Adhesion Kinase inhibitor
1017746|NCT01943292|FAK inhibitor
1017747|NCT01943292|Cancer Stem Cells
1017748|NCT01943292|CSC
1017749|NCT01943279|medical abortion
1017750|NCT01943279|telephone follow-up
1017751|NCT01943279|ultrasound
1017752|NCT01943279|serum hCG
1017753|NCT01943279|methotrexate
1017754|NCT01943279|misoprostol
1017755|NCT01943253|Early gastric cancer,
1017756|NCT01943253|endoscopic submucosal dissection (ESD)
1017757|NCT01943253|water-jet assisted ESD
1017758|NCT01943227|humidity
1017759|NCT01943227|enthalpy
1017760|NCT01943227|mechanical ventilation
1017761|NCT01943214|Diabetes Mellitus
1017762|NCT01943214|Body constitution
1017763|NCT01943175|schizophrenia
1017764|NCT01943175|stem cells
1017765|NCT01943175|neurons
1017766|NCT01943175|genetic hish risk for schizophrenia
1017767|NCT01943136|impetigo
1017768|NCT01943136|papaya extract ointment
1017769|NCT01943123|probiotics,
1017770|NCT01943123|streptococcus mutans,
1017771|NCT01943123|lactobacilli,
1017772|NCT01943123|plaque index,
1017773|NCT01943123|gingival index
1017774|NCT01943110|Intradermal injections
1017775|NCT01943110|Vaccine delivery devices
1017776|NCT01943071|dementia
1017777|NCT01943071|day care centre programs
1017778|NCT01943071|patients
1017779|NCT01943071|family carers
1017780|NCT01943071|cost-consequence analysis
1017781|NCT01943006|Mucopolysaccaride polysulfate (MPS)
1017782|NCT01943006|MPS
1017783|NCT01943006|Heparinoide
1017784|NCT01943006|Infusionphlebitis
1017785|NCT01943006|Prevention
1017786|NCT01943006|Superficial thrombophlebitis
1017787|NCT01943006|Treatment
1017788|NCT01942993|melanoma
1017789|NCT01942993|unresectable
1017790|NCT01942993|mutation
1017791|NCT01942993|BRAF protein
1017794|NCT01942967|Neonate
1017795|NCT01942967|Hemodynamic
1017796|NCT01942967|Tissue oxygenation
1017797|NCT01942967|Non invasive ventilation
1017798|NCT01942954|Alcohol Dependence
1017799|NCT01942954|Cognitive Therapy
1017800|NCT01942954|Executive Function
1017801|NCT01942954|Mobile Health
1017802|NCT01942954|Recovery of Function
1017803|NCT01942954|Rehabilitation
1017804|NCT01942889|COPD
1017805|NCT01942889|exercise training
1017806|NCT01942889|pulmonary rehabilitation
1017807|NCT01942889|antioxidant
1017808|NCT01942889|muscle
1017809|NCT01942876|Drugs
1017810|NCT01942876|at risk
1017811|NCT01942876|community health center patients
1017814|NCT01942811|DRUG PREVENTION
1017815|NCT01942811|BINATIONAL
1017816|NCT01942811|CASUAL USE OF ILLICIT DRUGS
1017817|NCT01942811|BRIEF INTERVENTION
1017818|NCT01942811|SBIRT
1017819|NCT01942798|Rehabilitation
1017820|NCT01942798|Lower Limb Amputation
1017821|NCT01942798|Prosthetic
1017822|NCT01942798|Walking
1017823|NCT01942798|unilateral transtibial amputation
1017824|NCT01942798|unilateral transfemoral amputation
1017825|NCT01942798|older adults
1017826|NCT01942798|cognitive computer games
1017827|NCT01942798|home-based training
1017828|NCT01942798|Nintendo Wii
1017829|NCT01942798|virtual reality
1017830|NCT01942772|powered ankle-foot orthosis
1017831|NCT01942772|mechanical structure
1017832|NCT01942772|optimization
1017833|NCT01942772|dorsiflexion
1017834|NCT01942772|plantar flexion
1017835|NCT01942772|gait
1017836|NCT01942772|servomotor
1017837|NCT01942772|ankle rehabilitation
1017838|NCT01942759|Breast Neoplasms
1017839|NCT01942759|Positron-Emission Tomography
1017840|NCT01942759|Diffusion Magnetic Resonance Imaging
1017841|NCT01942746|blueberry
1017842|NCT01942746|anthocyanin
1017843|NCT01942746|dark vision
1017844|NCT01942746|photo bleaching
1017845|NCT01942746|Visual Perception
1017846|NCT01942746|Photic Stimulation
1017847|NCT01942707|Abdominoplasty,Seroma,Bariatric surgery
1017848|NCT01942694|Prediabetes
1017849|NCT01942694|Vitamin D
1017850|NCT01942681|female
1017851|NCT01942681|mixed urinary incontinence
1017852|NCT01942668|Vasomotor symptoms
1017853|NCT01942668|Hot flashes
1017854|NCT01942668|Endometrial protection
1017855|NCT01942655|HIV
1017856|NCT01942655|Chronic inflammatory bowel disease
1017857|NCT01942655|Reservoirs
1017858|NCT01942655|IL-17
1017859|NCT01942655|IL-23
1017860|NCT01942655|Intestinal biopsies
1017861|NCT01942642|cataract surgery, meibomian gland dysfunction, meibum expressibility, meibography
1017862|NCT01942629|prognostic markers,Pancreatic ductal adenocarcinoma
1017863|NCT01942616|IPV
1017864|NCT01942603|Minimal (SN) tumor burden
1017865|NCT01942603|Stage III
1017866|NCT01942603|Patients
1017867|NCT01942603|Lymphnode Dissections
1017868|NCT01942590|Pompe disease
1017869|NCT01942577|NoSting
1017870|NCT01942577|Skin protectants
1017871|NCT01942577|Emollients
1017872|NCT01942577|Skin microbiome
1017873|NCT01942564|traumatic brain injury
1017874|NCT01942564|photophobia
1017875|NCT01942564|photosensitivity
1017876|NCT01942564|pupil
1017877|NCT01942538|rTMS
1017878|NCT01942538|fibromyalgia
1017879|NCT01942538|sham
1017880|NCT01942538|maintenance session
1017881|NCT01942538|pain
1017882|NCT01942525|IUGR
1017883|NCT01942525|aEEG
1017884|NCT01942525|preterm infants
1017885|NCT01942525|neurodevelopmental outcome
1017886|NCT01942512|Intracranial Aneurysm - Endovascular treatment -
1017887|NCT01942512|Coiling - Stenting - Flow diversion - Flow disruption -
1017888|NCT01942512|Recanalization - Risk factors
1017889|NCT01942499|COPD, exercise, community
1017890|NCT01942486|migraine
1017891|NCT01942486|photophobia
1017892|NCT01942486|light sensitivity
1017893|NCT01942486|melanopsin cells
1017894|NCT01942486|intrinsically photosensitive retinal ganglion cells
1017895|NCT01942460|Iron
1017896|NCT01942460|Anemia
1017897|NCT01942460|Chronic Kidney Disease
1017898|NCT01942460|Peritoneal Dialysis
1017899|NCT01942460|Inflammation
1017900|NCT01942460|Oxidative stress
1017901|NCT01942447|Fecal microbiota transplantation
1017902|NCT01942447|microbiota
1017903|NCT01942447|clostridium difficile
1017904|NCT01942447|clostridium difficile infection
1017905|NCT01942447|Efficacy of FMT
1017906|NCT01942434|Fatty acids
1017907|NCT01942434|Breast milk nutrients
1017908|NCT01942434|Cognitive development
1017909|NCT01942434|Electrophysiology
1017910|NCT01942434|Long-term assessment
1017911|NCT01942421|Limbal deficiency
1017912|NCT01942421|Cultivated limbal transplantation
1017913|NCT01942421|Ex vivo limbal transplantation
1017914|NCT01942421|Cultivated autologous mucosal epithelial transplantation
1017915|NCT01942408|Atrial fibrillation
1017916|NCT01942408|Pulmonary vein isolation
1017917|NCT01942408|Pulmonary vein reconnection
1017918|NCT01942395|Diet
1017919|NCT01942395|Sodium
1017920|NCT01942395|Hypertension
1017921|NCT01942395|Potassium
1017922|NCT01942395|Antioxidants
1017923|NCT01942395|Congestive Heart Failure
1017924|NCT01942395|Heart failure with normal ejection fraction
1017925|NCT01942395|Heart failure with preserved ejection fraction
1017926|NCT01942382|Schizophrenia
1017927|NCT01942382|JNS010
1017928|NCT01942382|Paliperidone Palmitate
1017929|NCT01942382|Clinical Pharmacology
1017930|NCT01942369|Endometriosis
1017931|NCT01942304|Sinus Floor Augmentation
1017932|NCT01942304|Maxillary Sinus
1017933|NCT01942304|Bone Substitutes
1017934|NCT01942304|Bone Regeneration
1017935|NCT01942291|Niacin
1017936|NCT01942291|Endothelial function
1017937|NCT01942291|Laropiprant
1017938|NCT01942291|HDL
1017939|NCT01942278|Healthcare
1017940|NCT01942278|Patients
1017941|NCT01942265|Influenza, Immunogenicity, Monovalent, A/H7N9, Vaccine, AS03, Adjuvant
1017942|NCT01942252|Secondhand smoking, pain, postoperative complications
1017943|NCT01942239|hypoglycemia
1017944|NCT01942239|very low birth weight neonate
1017945|NCT01942239|continuous glucose monitoring
1017946|NCT01942226|Dry eye syndrome
1017947|NCT01942213|Macular
1017948|NCT01942213|Degeneration
1017949|NCT01942213|Age related
1017950|NCT01942213|Neovascular
1017951|NCT01942200|carcinoma
1017952|NCT01942200|colon cancer
1017953|NCT01942200|colorectal cancer
1017954|NCT01942200|ambulant chemotherapy
1017955|NCT01942200|treatment cycles
1017956|NCT01942200|Oxaliplatin
1017957|NCT01942200|Oxaliplatin onkovis
1017958|NCT01942200|Quantity of Oxaliplatin
1017959|NCT01942200|Packaging Sizes
1017960|NCT01942174|Antipneumococcal vaccination
1017961|NCT01942174|Methotrexate treatment
1017962|NCT01942161|Schyzophrenia, pediatric patients
1017963|NCT01942148|Schizophrenia, Pediatric patients
1017964|NCT01942135|Palbociclib (PD-0332991)
1017965|NCT01942135|Fulvestrant
1017966|NCT01942135|Goserelin
1017967|NCT01942135|Hormone receptor-+
1017968|NCT01942135|HER2-negative
1017969|NCT01942135|Prior Endocrine treatment
1017970|NCT01942135|any menopausal status
1017971|NCT01942135|PALOMA-3
1017977|NCT01942109|heart failure
1017978|NCT01942109|diuretics
1017979|NCT01942109|furosemide
1017980|NCT01942109|torasemide
1017981|NCT01942070|Cardiovascular Disease
1017982|NCT01942070|Myocardial Infarction
1017983|NCT01942070|Bioresorbable vascular scaffold
1017984|NCT01942070|Durable polymer everolimus-eluting stent
1017985|NCT01942070|Primary angioplasty
1017986|NCT01942070|Stent
1017987|NCT01942044|Shear stress
1017988|NCT01942044|Optical coherence tomography
1017989|NCT01942044|Drug-eluting stents
1017990|NCT01942031|Ischemic stroke
1017991|NCT01942031|Hemorrhagic stroke
1017992|NCT01942031|TIA
1017993|NCT01942031|Atrial fibrillation
1017994|NCT01942031|prevention
1017995|NCT01942031|primary care
1017996|NCT01942018|esophagogastric junction outflow obstruction
1017997|NCT01942018|EGOO
1017998|NCT01942018|Per oral endoscopic myotomy
1017999|NCT01942018|POEM
1018000|NCT01942018|Gastroesophageal reflux disease
1018001|NCT01942018|GERD
1018002|NCT01941992|head and neck
1018003|NCT01941992|Squamous Cell Carcinoma
1018004|NCT01941992|oral mucositis
1018005|NCT01941992|Chemo-radiotherapy
1018006|NCT01941966|Anal canal cancer;capecitabine; mitomycin; radiotherapy.
1018007|NCT01941953|Metformin
1018008|NCT01941953|Metastatic Colorectal Cancer
1018009|NCT01941953|Fluorouracil
1018010|NCT01941927|Melanoma
1018011|NCT01941927|Wild-type
1018012|NCT01941927|BRAF
1018013|NCT01941914|Calcium electroporation
1018014|NCT01941914|calcium
1018015|NCT01941914|electroporation
1018016|NCT01941914|electrotransfer
1018017|NCT01941914|keloid
1018018|NCT01941901|Cutaneous metastases
1018019|NCT01941875|controlled ovarian hyperstimulation
1018020|NCT01941875|gonadotropins
1018021|NCT01941875|intrauterine insemination
1018022|NCT01941875|infertility
1018023|NCT01941875|luteal progesterone
1018024|NCT01941862|computerized intervention
1018025|NCT01941862|cognitive bias modification
1018026|NCT01941862|anxiety
1018027|NCT01941862|mood
1018028|NCT01941862|perceived burdensomeness
1018029|NCT01941862|thwarted belongingness
1018030|NCT01941862|suicide
1018031|NCT01941862|post-traumatic stress disorder
1018032|NCT01941849|Phaeochromocytoma
1018033|NCT01941849|Paraganglioma
1018034|NCT01941849|Neuroendocrine Tumour
1018035|NCT01941849|Vandetanib
1018036|NCT01941849|131I-mIBG
1018037|NCT01941849|Radionucleotide Therapy
1018038|NCT01941849|Vascular Endothelial Growth Factor (VEGF)
1018039|NCT01941849|Epidermal Growth Factor Receptor (EGFR)
1018040|NCT01941849|RET
1018041|NCT01941849|Tyrosine Kinase
1018042|NCT01941836|Statin intolerant
1018043|NCT01941836|Statin tolerant
1018044|NCT01941836|LDL
1018045|NCT01941836|Cholesterol
1018046|NCT01941823|acute renal failure
1018047|NCT01941823|CRRT
1018048|NCT01941823|continuous dialysis
1018049|NCT01941823|carnitine
1018050|NCT01941823|cardiac strain
1018051|NCT01941771|Breast cancer
1018052|NCT01941771|Metronomic chemotherapy
1018053|NCT01941771|Vinorelbine
1018054|NCT01941771|Navelbine
1018055|NCT01941771|Capecitabine
1018056|NCT01941771|Xeloda
1018057|NCT01941771|Antineoplastic Agents
1018058|NCT01941719|Diabetes Mellitus
1018059|NCT01941719|Diabetic Foot
1018060|NCT01941719|Diabetic Peripheral Neuropathy
1018061|NCT01941719|Diabetic Foot Education
1018062|NCT01941706|Epilepsy
1018063|NCT01941706|Seizure
1018064|NCT01941706|Cognitive Behavioral Therapy
1018065|NCT01941706|Mindfulness
1018066|NCT01941706|Depression
1018067|NCT01941706|Depressive symptoms
1018068|NCT01941706|prevention
1018069|NCT01941706|Coping skills
1018070|NCT01941706|Quality of life
1018071|NCT01941706|Telehealth
1018072|NCT01941706|Phone intervention
1018073|NCT01941706|Internet-based intervention
1018074|NCT01941693|alcohol
1018075|NCT01941693|anxiety
1018076|NCT01941693|depression
1018077|NCT01941693|comorbidity
1018078|NCT01941693|CBT
1018079|NCT01941667|Congenital Heart Disease
1018080|NCT01941667|Neonates and infants
1018081|NCT01941667|Telehealth
1018082|NCT01941667|Virtual Home Visits
1018083|NCT01941628|Cesarean section
1018084|NCT01941628|General anesthesia
1018085|NCT01941628|neuromuscular blockade
1018086|NCT01941628|Surgical conditions
1018087|NCT01941602|surgery
1018088|NCT01941602|enoxaparin
1018089|NCT01941602|venous thromboembolism
1018090|NCT01941602|perioperative care
1018091|NCT01941576|Heart defects, Congenital
1018092|NCT01941576|rhBNP
1018093|NCT01941576|heart failure
1018094|NCT01941550|untreated, high risk prostate cancer
1018095|NCT01941537|Atopic Dermatitis
1018096|NCT01941524|Brain oxygenation
1018097|NCT01941524|NIRS
1018098|NCT01941524|aEEG
1018099|NCT01941524|surfactant
1018100|NCT01941511|QTc
1018101|NCT01941511|African-American
1018102|NCT01941511|GMI-1070
1018103|NCT01941511|QT/QTc interval prolongation
1018104|NCT01941498|nearsighted
1018105|NCT01941498|farsighted
1018106|NCT01941498|astigmatism
1018107|NCT01941498|LASIK
1018108|NCT01941498|refractive surgery
1018109|NCT01941498|WaveLight
1018110|NCT01941485|nearsighted
1018111|NCT01941485|astigmatism
1018112|NCT01941485|LASIK
1018113|NCT01941485|refractive surgery
1018114|NCT01941485|WaveLight
1018115|NCT01941459|CK-MB
1018116|NCT01941459|troponin-T
1018117|NCT01941433|rheumatoid arthritis
1018118|NCT01941433|self-management
1018119|NCT01941433|online
1018120|NCT01941433|patient passport
1018121|NCT01941420|CK-MB
1018122|NCT01941420|troponin-T
1018123|NCT01941420|Cytokines under ischemia
1018124|NCT01941394|GVHD
1018125|NCT01941394|Relapse
1018126|NCT01941394|Overall Survival
1018127|NCT01941381|Otitis Media
1018128|NCT01941381|Tympanometry
1018129|NCT01941368|Performance
1018130|NCT01941368|Aerobic Exercise
1018131|NCT01941342|Obstructive Jaundice
1018132|NCT01941342|Preoperative Biliary Drainage
1018133|NCT01941342|Pancreatoduodenectomy
1018134|NCT01941329|Diabetes
1018135|NCT01941329|Proliferative Retinopathy
1018136|NCT01941329|Ranibizumab
1018137|NCT01941329|Panretinal Photocoagulation
1018138|NCT01941316|Carfilzomib
1018139|NCT01941316|Irinotecan
1018140|NCT01941316|Small Cell Lung Cancer
1018141|NCT01941316|Non Small Cell Lung Cancer
1018142|NCT01941316|Ovarian Cancer
1018143|NCT01941316|Gastric Cancer
1018144|NCT01941316|Esophageal Cancer
1018145|NCT01941316|Cervical Cancer
1018146|NCT01941303|Non-small cell lung cancer
1018147|NCT01941290|International
1018148|NCT01941290|Multicenter
1018149|NCT01941290|Observational registry
1018150|NCT01941290|Orsiro Drug Eluting Stents (DES)
1018151|NCT01941290|Stenting
1018152|NCT01941290|Treatment of Coronary Artery Disease
1018153|NCT01941290|Coronary Revascularization
1018154|NCT01941290|Percutaneous Coronary Intervention (PCI)
1018155|NCT01941290|Diabetes Mellitus Type 1
1018156|NCT01941290|Diabetes Mellitus Type 2
1018157|NCT01941290|STEMI
1018158|NCT01941290|NSTEMI
1018159|NCT01941290|Ischemia
1018160|NCT01941290|Angina
1018161|NCT01941290|Subgroups
1018162|NCT01941290|Acute Myocardial Infarction
1018163|NCT01941290|Small Vessels
1018164|NCT01941290|Chronic Total Occlusion
1018165|NCT01941264|malaria
1018166|NCT01941264|placenta
1018167|NCT01941264|pregnancy
1018168|NCT01941264|plasmodium falciparum
1018169|NCT01941264|screening and treatment
1018170|NCT01941264|rapid diagnostic test
1018171|NCT01941264|coartem
1018172|NCT01941264|artemether-lumefantrine
1018173|NCT01941264|community health worker
1018174|NCT01941251|Transcranial Magnetic Stimulation
1018175|NCT01941251|Repetitive Transcranial Magnetic Stimulation
1018176|NCT01941251|Schizophrenia
1018177|NCT01941251|Schizoaffective Disorder
1018178|NCT01941251|Treatment
1018179|NCT01941251|Negative Symptoms
1018180|NCT01941251|Positive Symptoms
1018181|NCT01941251|TMS
1018182|NCT01941251|rTMS
1018183|NCT01941238|Ramadan
1018184|NCT01941238|Fasting
1018185|NCT01941238|Diabetes
1018186|NCT01941238|Type1
1018187|NCT01941238|Insulin
1018188|NCT01941238|Pump
1018189|NCT01941225|Chronic obstructive pulmonary disease
1018190|NCT01941225|Pulmonary vasculature
1018191|NCT01941225|Inhaled iloprost
1018192|NCT01941225|Inhaled prostacyclin
1018193|NCT01941225|Dynamic hyperinflation
1018194|NCT01941225|Oxidative stress
1018195|NCT01941225|Cardiopulmonary exercise testing
1018196|NCT01941225|B-type natriuretic peptide
1018197|NCT01941212|Music therapy
1018198|NCT01941212|pain
1018199|NCT01941212|gynecological surgeries
1018200|NCT01941186|Children
1018201|NCT01941186|Developmental Delays
1018202|NCT01941186|Early Intervention (EI)
1018203|NCT01941186|Patient Decision Aid (PDA)
1018204|NCT01941147|Acute Stroke
1018205|NCT01941147|Brain Ischemia
1018206|NCT01941147|Extremely Low Frequency Magnetic Fields
1018207|NCT01941121|HIV Screening
1018208|NCT01941121|Linkage to PrEP
1018209|NCT01941121|Linkage to Care
1018210|NCT01941121|CCTG
1018211|NCT01941121|593
1018212|NCT01941108|AIDS
1018213|NCT01941108|peer navigation
1018214|NCT01941108|ecological momentary assessment
1018215|NCT01941108|eMOCHA
1018216|NCT01941108|Baltimore
1018217|NCT01941108|IDU
1018218|NCT01941030|Peripheral Artery Disease
1018219|NCT01941030|Critical Limb Ischemia
1018220|NCT01941030|Orbital Atherectomy
1018221|NCT01941030|Balloon Angioplasty
1018222|NCT01941030|Intravascular Ultrasound (IVUS)
1018223|NCT01941030|Fractional Flow Reserve (FFR)
1018224|NCT01941030|Quality of Life
1018225|NCT01941004|multiple sclerosis (MS)
1018226|NCT01941004|relapsing remitting multiple sclerosis (RRMS)
1018227|NCT01941004|fingolimod
1018228|NCT01940978|Methamphetamine
1018229|NCT01940978|Methylphenidate
1018230|NCT01940978|ADHD
1018231|NCT01940939|schizophrenia
1018232|NCT01940926|rheumatoid arthritis
1018233|NCT01940926|angiogenesis
1018234|NCT01940926|68Ga-PRGD2
1018235|NCT01940926|18F-FDG
1018236|NCT01940926|positron emission tomography/computed tomography
1018237|NCT01940900|Wet AMD
1018238|NCT01940900|choroidal neovascularization
1018239|NCT01940900|Fovista®
1018240|NCT01940900|E10030
1018241|NCT01940900|Lucentis®
1018242|NCT01940887|Wet AMD
1018243|NCT01940887|choroidal neovascularization
1018244|NCT01940887|Fovista®
1018245|NCT01940887|E10030
1018246|NCT01940887|Avastin®
1018247|NCT01940887|Eylea®
1018248|NCT01940874|Cerebral Oximetry.
1018249|NCT01940874|Aortic valve stenosis.
1018250|NCT01940874|Aortic valve regurgitation.
1018251|NCT01940874|Coronary artery disease.
1018252|NCT01940848|Iberogast
1018253|NCT01940848|efficacy
1018254|NCT01940848|safety
1018255|NCT01940796|Brentuximab Vedotin
1018256|NCT01940796|GVHD
1018257|NCT01940796|Refractory Chronic Graft vs Host Disease
1018258|NCT01940770|Diabetes Mellitus(DM)
1018259|NCT01940770|Bydureon
1018260|NCT01940770|Exenatide
1018261|NCT01940757|Necator americanus
1018262|NCT01940757|Hookworm Infection
1018263|NCT01940757|Experimental challenge infection
1018264|NCT01940744|Low back pain
1018265|NCT01940744|Non-specific Low back pain
1018266|NCT01940718|Priapism
1018267|NCT01940718|Sickle cell disease
1018268|NCT01940718|Testosterone
1018269|NCT01940718|Androgen deficiency
1018270|NCT01940705|hearing aids
1018271|NCT01940705|counseling
1018272|NCT01940705|outcomes assessment (health care)
1018273|NCT01940705|rehabilitation
1018274|NCT01940666|Hyperandrogenism/
1018275|NCT01940666|FAI/
1018276|NCT01940666|Metabolic syndrome/
1018277|NCT01940666|Adipocytokines/
1018278|NCT01940666|Insulin resistance.
1018279|NCT01940640|neonates, DHA
1018280|NCT01940627|Ubiquinol, exercise
1018281|NCT01940614|Copeptin
1018282|NCT01940614|differential diagnosis of polyuria polydipsia syndrome
1018283|NCT01940614|diabetes insipidus
1018284|NCT01940614|compulsive water drinking
1018285|NCT01940614|water deprivation test
1018286|NCT01940601|solid tumors
1018287|NCT01940601|balugrastim
1018288|NCT01940575|Tissue restorative biomaterial
1018289|NCT01940575|Hyaluronic acid
1018290|NCT01940575|Restylane®
1018291|NCT01940575|Wrinkle Severity Rating Scale (WSRS)
1018292|NCT01940575|Global Aesthetic Improvement Scale (GAIS)
1018293|NCT01940575|Nasolabial fold(NLF)
1018294|NCT01940562|cord blood transplantation
1018295|NCT01940562|platelets
1018296|NCT01940562|eltrombopag
1018297|NCT01940549|PTSD
1018298|NCT01940549|tDCS
1018299|NCT01940549|Trauma
1018300|NCT01940536|Hip Fracture
1018301|NCT01940536|Blood Transfusion
1018302|NCT01940536|Blood Loss
1018303|NCT01940536|Tranexamic Acid
1018304|NCT01940523|total knee arthroplasty
1018305|NCT01940523|total knee replacement
1018306|NCT01940523|tranexamic acid
1018307|NCT01940523|osteoarthritis
1018555|NCT01939535|Endometriosis
1018308|NCT01940523|degenerative joint disease
1018309|NCT01940471|Hepatitis
1018310|NCT01940471|Tenofovir
1018311|NCT01940471|Viread
1018312|NCT01940432|simple stress urinary incontinence
1018313|NCT01940419|Reduction of blood loss
1018314|NCT01940419|Surgical complication
1018315|NCT01940419|Hysterectomy
1018316|NCT01940419|Antifibrinolytic Agents
1018317|NCT01940419|Randomized Controlled Trials
1018318|NCT01940406|Essential Tremor
1018319|NCT01940406|Parkinson Disease
1018320|NCT01940406|Electrical Stimulation
1018321|NCT01940406|Tremor
1018322|NCT01940393|urticaria
1018323|NCT01940393|bilastine
1018324|NCT01940393|fexofenadine
1018325|NCT01940393|cetirizine
1018326|NCT01940393|ebastine
1018327|NCT01940393|desloratadine
1018328|NCT01940367|Overactive Bladder
1018329|NCT01940367|TENS
1018330|NCT01940367|PTNS
1018331|NCT01940367|Electrical Nerve Stimulation
1018332|NCT01940367|Urge Urinary Incontinence
1018333|NCT01940354|IV Catheter comparison
1018334|NCT01940354|AccuCath versus Conventional IV Catheters
1018335|NCT01940354|IV Catheter Study
1018336|NCT01940354|IV Catheter User Preference Comparison
1018337|NCT01940354|First Attempt Success Rate for IV Catheters
1018338|NCT01940354|AccuCath Device Performance
1018339|NCT01940354|Patient Satisfaction with IV Catheters
1018340|NCT01940354|Clinician Satisfaction with AccuCath Device Performance
1018341|NCT01940341|Hepatitis
1018342|NCT01940341|Tenofovir
1018343|NCT01940341|Viread
1018344|NCT01940328|Ultrasound Doppler
1018345|NCT01940328|Congestive heart failure
1018346|NCT01940328|Pulmonary Edema
1018347|NCT01940315|Defender Study
1018348|NCT01940315|experimental vaccine
1018349|NCT01940315|inhalational intoxication
1018350|NCT01940302|Malnutrition; Metabolic disorders
1018351|NCT01940289|algometry
1018352|NCT01940289|pain
1018353|NCT01940289|VAS
1018354|NCT01940276|Prostate cancer
1018355|NCT01940276|metastatic
1018356|NCT01940276|castrate resistant
1018357|NCT01940276|abiraterone acetate
1018358|NCT01940276|prednisone
1018359|NCT01940276|metastatic prostate cancer
1018360|NCT01940263|oxidative stress
1018361|NCT01940263|dyslipidemia
1018362|NCT01940263|inflammation
1018363|NCT01940263|apoptosis
1018364|NCT01940250|Hand, foot and mouth disease
1018365|NCT01940250|Autonomic nervous system dysregulation
1018366|NCT01940250|Magnesium sulphate
1018367|NCT01940237|Depression
1018368|NCT01940237|Psychotherapy
1018369|NCT01940237|Cancer
1018370|NCT01940237|Pancreatic Cancer
1018371|NCT01940237|Lung Cancer
1018372|NCT01940237|Colon Cancer
1018373|NCT01940237|Prostate Cancer
1018374|NCT01940224|Pregabalin
1018375|NCT01940224|Laparoscopic colorectal surgery
1018376|NCT01940224|Postoperative pain
1018377|NCT01940224|Opioid consumption
1018378|NCT01940198|Atazanavir
1018379|NCT01940198|long-term
1018380|NCT01940198|primary care setting
1018381|NCT01940198|sydney
1018382|NCT01940159|Schizophrenia
1018383|NCT01940159|Schizoaffective disorders
1018384|NCT01940120|Mitral Valve Insufficiency
1018385|NCT01940120|Mitral Valve Regurgitation
1018386|NCT01940120|Mitral Valve Incompetence
1018387|NCT01940120|Mitral Regurgitation
1018388|NCT01940120|Mitral Insufficiency
1018389|NCT01940120|Mitral Valve
1018390|NCT01940120|MR
1018391|NCT01940120|Mitral Valve Prolapse
1018392|NCT01940120|Edge to Edge (E2E)
1018393|NCT01940120|Alfieri Technique
1018394|NCT01940120|MitraClip
1018395|NCT01940120|Functional MR
1018396|NCT01940120|Degenerative MR
1018397|NCT01940120|Echocardiogram
1018398|NCT01940120|Coronary Artery Disease (CAD)
1018399|NCT01940120|Heart Failure
1018400|NCT01940120|Heart Attack
1018401|NCT01940120|EVEREST
1018402|NCT01940120|EVEREST I
1018403|NCT01940120|EVEREST II
1018404|NCT01940120|REALISM
1018405|NCT01940107|breast cancer,
1018406|NCT01940107|radiotherapy,
1018407|NCT01940107|physical therapy,
1018408|NCT01940107|upper limb
1018409|NCT01940094|Granulomatosis with polyangiitis
1018410|NCT01940094|Wegener's granulomatosis
1018411|NCT01940094|WG
1018412|NCT01940094|GPA
1018413|NCT01940094|ANCA-Associated Vasculitis
1018414|NCT01940094|AAV
1018415|NCT01940094|Vasculitis
1018416|NCT01940094|Prednisone
1018417|NCT01940094|Glucocorticoid
1018418|NCT01940094|Taper
1018419|NCT01940081|Cardiomyopathy, Dilated
1018420|NCT01940081|Tachycardia, Ventricular
1018421|NCT01940081|Ventricular Fibrillation
1018422|NCT01940081|Arrhythmias, Cardiac/etiology
1018423|NCT01940081|Arrhythmias, Cardiac/physiopathology
1018424|NCT01940081|Magnetic Resonance Imaging
1018425|NCT01940081|3-Iodobenzylguanidine/diagnostic use
1018426|NCT01940081|Sympathetic Nervous System/radionuclide imaging
1018427|NCT01940081|Electrophysiologic Techniques, Cardiac
1018428|NCT01940081|Biopsy
1018429|NCT01940081|Genetic Testing
1018430|NCT01940081|Echocardiography
1018431|NCT01940081|Electrocardiography, Ambulatory
1018432|NCT01940081|Exercise Test
1018433|NCT01940068|Hypersensitivity
1018434|NCT01940068|Milk Hypersensitivity
1018435|NCT01940068|Immune System Diseases
1018436|NCT01940068|Food Hypersensitivity
1018437|NCT01940055|Balance
1018438|NCT01940055|Gait
1018439|NCT01940055|Instrumented Treadmill
1018440|NCT01940055|Recumbent cycle
1018441|NCT01940055|Cognitive games
1018442|NCT01940029|vancomycin, neurosurgery, critical ill, pharmacokinetics
1018443|NCT01940016|Feasibility study
1018444|NCT01940016|Interactive voice response system (IVR)
1018445|NCT01940016|health coach
1018446|NCT01940016|no evidence of disease
1018447|NCT01940003|Diabetes, Gestational
1018448|NCT01940003|Pregnancy Outcome
1018449|NCT01940003|Exercise
1018450|NCT01940003|glycemic control
1018451|NCT01939990|Chronic Obstructive Pulmonary Disease
1018452|NCT01939977|Hyperparathyroidism
1018453|NCT01939977|Hyperparathyroidism Secondary
1018454|NCT01939977|Paricalcitol
1018455|NCT01939977|Calcifediol
1018456|NCT01939977|Parathyroid hormone
1018457|NCT01939977|Renal transplantation
1018458|NCT01939964|Wrinkles
1018459|NCT01939964|Activation Mist
1018460|NCT01939951|Asthma
1018461|NCT01939951|Persistent
1018462|NCT01939925|patient education
1018463|NCT01939925|Health Knowledge, Attitudes, Practice
1018464|NCT01939925|comprehension
1018465|NCT01939925|consumer health information
1018466|NCT01939899|MLN9708
1018467|NCT01939899|Lymphoma
1018468|NCT01939899|IXAZOMIB
1018469|NCT01939886|Malaria treatment efficacy
1018470|NCT01939886|Malaria transmission
1018471|NCT01939873|Kristeller maneuver; Second stage of labor;
1018472|NCT01939873|Perineal laceration; Obstetrical outcome;
1018473|NCT01939873|Neonatal outcome
1018474|NCT01939847|Metastatic breast cancer
1018475|NCT01939847|Breast cancer
1018476|NCT01939847|Molecular profiling
1018477|NCT01939847|Personalized medicine
1018478|NCT01939834|Type 1 Diabetes Mellitus
1018479|NCT01939834|Artificial Pancreas
1018480|NCT01939834|Diabetes Assistant (DiAs)
1018481|NCT01939834|Continuous Glucose Monitor
1018482|NCT01939821|Fecal incontinence
1018483|NCT01939821|attitudes
1018484|NCT01939821|knowledge
1018485|NCT01939821|quality of care
1018486|NCT01939795|cardiac resynchronization therapy (CRT)
1018487|NCT01939782|Metabolic CLock Genes (MCG)
1018488|NCT01939782|Type 2 Diabetes (T2D)
1018489|NCT01939769|fMRI
1018490|NCT01939769|Catecholamines
1018491|NCT01939769|Stress
1018492|NCT01939769|Exercise
1018493|NCT01939769|Memory
1018494|NCT01939756|High risk non-muscle invasive urothelial bladder cancer
1018495|NCT01939756|Intravesical BCG
1018496|NCT01939756|Local toxicity
1018497|NCT01939756|Natural baobab oil
1018498|NCT01939730|Lymphoma
1018499|NCT01939730|Follicular B-Cell Lymphoma
1018500|NCT01939730|Rituximab
1018501|NCT01939730|Rituxan
1018502|NCT01939730|GM-CSF
1018503|NCT01939730|Sargramostim
1018504|NCT01939730|Leukine
1018505|NCT01939717|Parkinson's disease
1018506|NCT01939717|Irish set dancing
1018507|NCT01939691|difluprednate
1018508|NCT01939691|prednisolone acetate
1018509|NCT01939691|nepafenac
1018638|NCT01939132|Psoriatic Arthritis
1018510|NCT01939665|Locally advanced pancreatic carcinoma
1018511|NCT01939665|LAPC
1018512|NCT01939665|Irreversible electroporation
1018513|NCT01939665|NanoKnife
1018514|NCT01939665|IRE
1018515|NCT01939665|Safety
1018516|NCT01939665|Efficacy
1018517|NCT01939665|Non-thermal ablation
1018518|NCT01939665|Percutaneous ablation
1018519|NCT01939665|Low Energy Direct Current
1018520|NCT01939652|minilaparotomy
1018521|NCT01939652|AAA
1018522|NCT01939652|fluid regime
1018523|NCT01939639|Oxytocin
1018524|NCT01939639|fMRI
1018525|NCT01939626|embryo
1018526|NCT01939626|culture
1018527|NCT01939613|fluid resuscitation
1018528|NCT01939613|burn
1018529|NCT01939613|colloid,
1018530|NCT01939613|multiple organ dysfunction
1018531|NCT01939613|intra-abdominal pressure
1018532|NCT01939600|Resistant starch
1018533|NCT01939600|Ileostomy
1018534|NCT01939600|In vivo
1018535|NCT01939600|Carbohydrate digestibility
1018536|NCT01939587|Adenosine A1 receptor antagonist
1018537|NCT01939587|Asthma
1018538|NCT01939587|adenosine receptor modulator
1018539|NCT01939587|COPD
1018540|NCT01939574|Glioblastoma
1018541|NCT01939574|Potential Image Biomarkers
1018542|NCT01939574|PFS
1018543|NCT01939574|Bevacizumab
1018544|NCT01939574|Conventional Therapy
1018545|NCT01939561|Myotonia
1018546|NCT01939561|Lamotrigine
1018547|NCT01939561|RCT
1018548|NCT01939561|treatment
1018549|NCT01939548|PF-02545920
1018550|NCT01939548|schizophrenia
1018551|NCT01939548|outpatient
1018552|NCT01939548|safety
1018553|NCT01939548|efficacy
1018554|NCT01939548|suboptimal response
1018556|NCT01939535|Magnetic resonance imaging
1018557|NCT01939522|diabetes
1018558|NCT01939522|pneumococcal
1018559|NCT01939496|Diabetes Mellitus, Type 2
1018560|NCT01939496|Hypertension
1018561|NCT01939496|Canagliflozin
1018562|NCT01939496|JNJ 28431754
1018563|NCT01939496|Sodium-Glucose Transporter 2
1018564|NCT01939496|Blood Glucose
1018565|NCT01939496|Type 2 Diabetes Mellitus
1018566|NCT01939483|Irinotecan hydrochloride
1018567|NCT01939483|Irinotecan
1018568|NCT01939483|CAMPTOSAR
1018569|NCT01939470|osteoporosis
1018570|NCT01939470|bone
1018571|NCT01939470|inflammation
1018572|NCT01939470|diabetes
1018573|NCT01939470|vitamin D
1018574|NCT01939444|Antidotes
1018575|NCT01939444|naloxone
1018576|NCT01939444|administration, intravenous
1018577|NCT01939444|administration, intranasal
1018578|NCT01939444|pharmacology
1018579|NCT01939431|Podoconiosis
1018580|NCT01939431|Gene Expression
1018581|NCT01939431|Genomics
1018582|NCT01939431|Pathogenesis
1018583|NCT01939418|metastatic breast cancer
1018584|NCT01939418|triple negative breast cancer
1018585|NCT01939418|gemcitabine
1018586|NCT01939418|RAD001
1018587|NCT01939405|Obesity
1018588|NCT01939405|Overweight
1018589|NCT01939405|Physical Activity
1018590|NCT01939405|Built Environment
1018591|NCT01939405|counseling
1018592|NCT01939392|Resistant hypertension
1018593|NCT01939392|Uncontrolled hypertension
1018594|NCT01939392|Renal artery ablation
1018595|NCT01939379|Total knee arthroplasty
1018596|NCT01939379|nerve block
1018597|NCT01939379|Pain control after surgery
1018598|NCT01939366|Painful Diabetic Peripheral Neuropathy
1018599|NCT01939353|Adult ADHD
1018600|NCT01939327|diffuse large B cell
1018601|NCT01939327|non-Hodgkin lymphoma
1018602|NCT01939314|Headache
1018603|NCT01939314|Migraine
1018604|NCT01939301|Pulmonary embolism clot
1018605|NCT01939262|Arthritis
1018606|NCT01939262|Pain
1018607|NCT01939262|Function
1018608|NCT01939262|Diet
1018609|NCT01939262|Vegan
1018610|NCT01939262|Vegetarian
1018611|NCT01939262|Restriction
1018612|NCT01939236|chronic heart failure
1018613|NCT01939236|traditional Chinese medicine
1018614|NCT01939236|syndrome differentiation
1018615|NCT01939223|Stage IV colorectal cancer / Liver Metastasis
1018616|NCT01939197|Cirrhotic
1018617|NCT01939197|HCV Genotype 4
1018618|NCT01939197|Hepatitis C Genotype 1
1018619|NCT01939197|HCV Genotype 1
1018620|NCT01939197|Compensated Cirrhosis
1018621|NCT01939197|Hepatitis C Genotype 4
1018622|NCT01939197|Interferon-Free
1018623|NCT01939197|HIV-1
1018624|NCT01939197|HCV / HIV coinfection
1018625|NCT01939197|Hepatitis C
1018626|NCT01939171|Thymoglobulin
1018627|NCT01939171|Cadaver donor
1018628|NCT01939171|Kidney injury brain death related
1018629|NCT01939158|Co-administration
1018630|NCT01939158|Safety
1018631|NCT01939158|Persistence
1018632|NCT01939158|Immunogenicity
1018633|NCT01939158|Prevenar 13
1018634|NCT01939158|Meningococcal vaccine
1018635|NCT01939158|Toddlers
1018636|NCT01939158|5 years
1018637|NCT01939145|hospital admission
1018639|NCT01939132|ACTH
1018640|NCT01939132|Acthar
1018641|NCT01939119|retinal vascular occlusion
1018642|NCT01939119|drinking habits
1018643|NCT01939119|body hydration
1018644|NCT01939119|body-fluid balance
1018645|NCT01939106|Stoma
1018646|NCT01939106|Ileostomy
1018647|NCT01939106|pouch
1018648|NCT01939106|Drainable Pouch for collection of stool
1018649|NCT01939093|Quetiapine
1018650|NCT01939093|Haloperidol
1018651|NCT01939093|Methamphetamine
1018652|NCT01939093|Psychosis
1018653|NCT01939080|moderate risk
1018654|NCT01939080|high risk
1018655|NCT01939067|respiratory distress
1018656|NCT01939067|Heated Humidified High Flow Nasal Cannula (HHHFNC)
1018657|NCT01939067|HHHFNC
1018658|NCT01939067|noninvasive nasal continuous positive airway pressure (NCPAP)
1018659|NCT01939067|NCPAP
1018660|NCT01939041|Subacute Stroke
1018661|NCT01939041|Unilateral Robot-Assisted Training
1018662|NCT01939041|Bilateral Robot-Assisted Training
1018663|NCT01939041|Motor control
1018664|NCT01939041|Physiological Response
1018665|NCT01939015|3D miniplate
1018666|NCT01939015|angle mandibular fracture
1018667|NCT01939015|champy technique
1018668|NCT01939015|internal rigid fixation
1018669|NCT01939002|flu-like symptoms
1018670|NCT01938989|cataract
1018671|NCT01938989|intraocular lens
1018672|NCT01938989|IOL
1018673|NCT01938989|blue light filter
1018674|NCT01938976|Asthma
1018675|NCT01938976|Tobacco
1018676|NCT01938976|Waterpipe
1018677|NCT01938976|Cigarettes
1018678|NCT01938976|Adolescents
1018679|NCT01938976|Peer education
1018680|NCT01938976|Jordan
1018681|NCT01938963|Depression
1018682|NCT01938963|Hypertension
1018683|NCT01938963|Older Adults
1018684|NCT01938911|Trier social stress test
1018685|NCT01938911|Oxytocin
1018686|NCT01938911|Hypertension
1018687|NCT01938898|Randomized trial
1018688|NCT01938898|Invitation letter
1018689|NCT01938898|Recruitment
1018690|NCT01938898|Retention
1018691|NCT01938872|critical limb ischemia
1018692|NCT01938872|drug-eluting balloon
1018693|NCT01938872|restenosis
1018694|NCT01938859|bipolar disorder
1018695|NCT01938859|lithium
1018696|NCT01938859|quetiapine
1018697|NCT01938859|Medicine, Chinese Traditional
1018698|NCT01938859|efficacy
1018699|NCT01938859|safety
1018700|NCT01938859|Recurrence
1018701|NCT01938820|Hepatitis B
1018702|NCT01938820|Liver Cirrhosis
1018703|NCT01938820|Regression
1018704|NCT01938820|Efficacy
1018705|NCT01938807|type 1 diabetes
1018706|NCT01938807|parents
1018707|NCT01938807|mobile application
1018708|NCT01938807|diabetes management
1018709|NCT01938781|Hepatitis B
1018710|NCT01938781|Liver fibrosis
1018711|NCT01938781|Regression
1018712|NCT01938781|Efficacy
1018713|NCT01938768|Multiple trauma
1018714|NCT01938768|Polytrauma
1018715|NCT01938768|Hyperfibrinolysis
1018716|NCT01938768|Tranexamic acid
1018717|NCT01938768|Thrombelastometry
1018718|NCT01938742|A/H7N9,Adjuvant,Immunogenicity,Influenza,MF59,Monovalent,Vaccine
1018719|NCT01938729|HEPATIC ARTERIAL INFUSION
1018720|NCT01938729|FLOXURIDINE
1018721|NCT01938729|DEXAMETHASONE
1018722|NCT01938729|GEMCITABINE
1018723|NCT01938729|Pump
1018724|NCT01938729|13-148
1018725|NCT01938716|Pancreatic Cancer
1018726|NCT01938716|Adenocarcinoma of the Pancreas
1018727|NCT01938716|Intratumoral gemcitabine levels
1018728|NCT01938716|Pancreatic surgery
1018729|NCT01938716|Pharmacokinetic testing
1018730|NCT01938716|PK
1018731|NCT01938716|Gemcitabine
1018732|NCT01938716|Gemcitabine Hydrochloride
1018733|NCT01938716|Gemzar
1018734|NCT01938690|stroke, transcranial magnetic stimulation, rehabilitation
1018735|NCT01938677|Vestibular schwannoma
1018736|NCT01938677|Gamma knife radiosurgery
1018737|NCT01938677|Hearing preservation
1018738|NCT01938664|cocaine
1018739|NCT01938664|dependence
1018740|NCT01938664|pharmacotherapy
1018741|NCT01938638|Advanced malignancies
1018742|NCT01938638|TNBC
1018743|NCT01938638|DLBCL
1018744|NCT01938638|Gastric cancer
1018745|NCT01938625|Hepatitis C, Chronic
1018746|NCT01938625|Recurrent Chronic Hepatitis C
1018747|NCT01938625|Pharmacokinetics
1018748|NCT01938625|Simeprevir
1018749|NCT01938625|Daclatasvir
1018750|NCT01938625|Ribavirin
1018751|NCT01938625|Orthotopic Liver Transplantation
1018752|NCT01938625|TMC435
1018753|NCT01938625|BMS-790052
1018754|NCT01938625|RBV
1018755|NCT01938612|MEDI4736
1018756|NCT01938612|Advanced solid tumors
1018757|NCT01938612|squamous cell carcinoma of the head and Neck
1018758|NCT01938612|biliary tract cancer
1018759|NCT01938612|squamous cell carcinoma of esophagus cancer
1018760|NCT01938612|B7-H1
1018761|NCT01938612|PD-L1
1018762|NCT01938599|Plaque Psoriasis
1018763|NCT01938586|Scar
1018764|NCT01938586|Appearance
1018765|NCT01938547|perioperative
1018766|NCT01938547|blood pressure
1018767|NCT01938547|pediatrics
1018768|NCT01938547|pediatric surgery
1018769|NCT01938521|Red Grape Cells powder (RGC)
1018770|NCT01938521|Placebo (PLA)
1018771|NCT01938508|dermatitis
1018772|NCT01938508|Minocycline
1018773|NCT01938508|bioavailability
1018774|NCT01938495|ALS
1018775|NCT01938495|DPS
1018776|NCT01938495|Diaphragm Pacing
1018777|NCT01938482|SCD1
1018778|NCT01938482|Topical Administration
1018779|NCT01938482|Acne
1018780|NCT01938482|Gel
1018781|NCT01938469|Bariatric
1018782|NCT01938469|Gastric Bypass
1018783|NCT01938469|Gastric Banding,
1018784|NCT01938469|Incretins
1018785|NCT01938469|glucagon-like peptide-1(GLP-1)
1018786|NCT01938469|gastric inhibitory peptide (GIP)
1018787|NCT01938456|Non-small cell lung cancer
1018788|NCT01938456|GSK1120212 (trametinib)
1018789|NCT01938456|Japanese
1018790|NCT01938456|Phase Ib
1018791|NCT01938456|combination therapy
1018792|NCT01938456|docetaxel
1018793|NCT01938456|MEK inhibitor
1018794|NCT01938443|pharmacodynamics
1018795|NCT01938443|MEK inhibitor
1018796|NCT01938443|Focal adhesion kinase inhibitor
1018797|NCT01938443|cancer
1018798|NCT01938443|pharmacokinetic
1018799|NCT01938443|mesothelioma
1018800|NCT01938443|Phase 1
1018801|NCT01938417|tobramycin
1018802|NCT01938417|bone graft substitute
1018803|NCT01938417|pharmacokinetics
1018804|NCT01938417|renal failure
1018805|NCT01938404|Plasma exchange
1018806|NCT01938404|Thrombotic Thrombocytopenic Purpura
1018807|NCT01938404|TTP
1018808|NCT01938391|Peripheral Artery Disease
1018809|NCT01938391|PAD
1018810|NCT01938391|Claudication
1018811|NCT01938391|Peripheral Vascular Disease
1018812|NCT01938391|PVD
1018813|NCT01938391|Orbital Atherectomy
1018814|NCT01938391|Balloon Angioplasty
1018815|NCT01938391|Intravascular Ultrasound (IVUS)
1018816|NCT01938378|Octaplas
1018817|NCT01938352|Influenza
1018818|NCT01938352|Virus
1018819|NCT01938352|Monoclonal Antibody
1018820|NCT01938352|Immunization
1018821|NCT01938352|Treatment
1018822|NCT01938339|prostate cancer
1018823|NCT01938339|MRI
1018824|NCT01938339|PET
1018825|NCT01938326|Stomach neoplasm
1018826|NCT01938326|TLDG
1018827|NCT01938326|SIDG
1018828|NCT01938326|single-port
1018829|NCT01938326|inflammatory response
1018830|NCT01938313|gastric cancer
1018831|NCT01938313|ERAS (early recovery after surgery)
1018832|NCT01938313|fast track
1018833|NCT01938313|laparoscopic gastrectomy
1018834|NCT01938274|Hip
1018835|NCT01938274|Knee
1018836|NCT01938274|Osteoarthritis
1018837|NCT01938274|Arthroplasty
1018838|NCT01938274|Physical Activity
1018839|NCT01938274|Expectations
1018840|NCT01938274|Leisure Activity
1018841|NCT01938248|Pacemaker, Artificial
1018842|NCT01938248|Defibrillators, Implantable
1018843|NCT01938248|Atrial Fibrillation
1018844|NCT01938248|Stroke Risk
1018845|NCT01938235|Myocardial infarction
1018846|NCT01938235|Percutaneous coronary intervention
1018847|NCT01938235|Reperfusion injury
1018848|NCT01938235|Exenatide
1018849|NCT01938235|Magnetic resonance imaging
1018850|NCT01938222|abdominal wall closure
1018851|NCT01938222|short stitch technique
1018852|NCT01938196|Chronic Constipation
1018853|NCT01938196|Constipation
1018854|NCT01938196|Functional gastrointestinal disorders
1018855|NCT01938183|chronic periodontitis
1018856|NCT01938183|metronidazole
1018857|NCT01938157|High Risk of Breast Cancer
1018858|NCT01938157|Diffusion Magnetic Resonance Imaging
1018859|NCT01938144|Common cold
1018860|NCT01938144|efficacy
1018861|NCT01938144|symptoms
1018862|NCT01938144|Wisconsin Upper Respiratory Symptom Survey - 21
1018863|NCT01938144|ibuprofen
1018864|NCT01938144|phenylephrine
1018865|NCT01938144|pseudoephedrine
1018866|NCT01938131|knee, osteoarthritis, muscle vibration
1018867|NCT01938118|Infant diet
1018868|NCT01938118|Family diet
1018869|NCT01938118|Responsive feeding
1018870|NCT01938118|Infant temperament
1018871|NCT01938118|Physical activity
1018872|NCT01938118|Television
1018873|NCT01938105|Cervical cancer
1018874|NCT01938105|Nimotuzumab
1018875|NCT01938105|Intensity-modulated radiation therapy
1018876|NCT01938105|Concurrent chemoradiotherapy
1018877|NCT01938092|High-tone pelvic floor dysfunction
1018878|NCT01938092|Spasm
1018879|NCT01938092|Pelvic pain
1018880|NCT01938092|Diazepam
1018881|NCT01938092|Female
1018882|NCT01938092|Randomized trial
1018883|NCT01938079|ECMO
1018884|NCT01938079|Ketamine
1018885|NCT01938079|Opiates
1018886|NCT01938079|Lung failure
1018887|NCT01938079|Extracorporeal membrane oxygenation
1018888|NCT01938079|Mechanical ventilation
1018889|NCT01938079|Sedation
1018890|NCT01938066|procellera
1018891|NCT01938053|STI, STD
1018892|NCT01938040|laparoscopic cholecystectomy
1018893|NCT01938027|Rectal Neoplasms
1018894|NCT01938027|Colorectal Neoplasms
1018895|NCT01938027|transanal surgery
1018896|NCT01938014|MPS I
1018897|NCT01938014|MPS II
1018898|NCT01938014|MPS III
1018899|NCT01938014|MPS VI
1018900|NCT01938014|Krabbe disease
1018901|NCT01938014|globoid cell leukodystrophy
1018902|NCT01938014|galactosylceramide lipidosis
1018903|NCT01938014|mucopolysaccharidoses
1018904|NCT01938014|mucopolysaccharidosis
1018905|NCT01938014|Rare Diseases Clinical Research Network
1018906|NCT01938014|Lysosomal Disease Network
1018907|NCT01938014|enzyme replacement therapy
1018908|NCT01938014|hematopoietic stem cell transplant
1018909|NCT01938014|telephone-based surveillance
1018910|NCT01938014|Hurler syndrome
1018911|NCT01938014|Hunter syndrome
1018912|NCT01938014|Scheie syndrome
1018913|NCT01938014|Hurler-Scheie syndrome
1018914|NCT01938014|Sanfilippo syndrome
1018915|NCT01938014|Maroteaux-Lamy syndrome
1018916|NCT01938001|Non-Hodgkins Follicular lymphoma, Non-Hodgkins Marginal zone lymphoma, treatment for follicular lymphoma, treatment for Marginal zone lymphoma
1018917|NCT01937988|Doula
1018918|NCT01937988|Abortion
1018919|NCT01937988|Pain
1018920|NCT01937988|support
1018921|NCT01937949|Aortic aneurysm
1018922|NCT01937936|caregiver stress
1018923|NCT01937936|depression
1018924|NCT01937936|quality of life
1018925|NCT01937936|cognitive behavioral therapy
1018926|NCT01937910|neuroplastic change
1018927|NCT01937910|myelin
1018928|NCT01937897|Unilateral Massage
1018929|NCT01937897|Depression
1018930|NCT01937858|HbA1c
1018931|NCT01937858|glycated hemoglobin
1018932|NCT01937858|correlation
1018933|NCT01937858|diabetes
1018934|NCT01937858|renal failure
1018935|NCT01937819|BOWEL PREPARATION
1018936|NCT01937819|SMARTPHONE APPLICATION
1018937|NCT01937806|Chronic hepatitis B
1018938|NCT01937793|radiation
1018939|NCT01937793|speech-language pathology
1018940|NCT01937754|Prehypertension
1018941|NCT01937754|Nitric Oxide
1018942|NCT01937754|Blood Pressure
1018943|NCT01937754|Functional Capacity
1018944|NCT01937754|Quality of Life
1018945|NCT01937728|Hepatitis C
1018946|NCT01937728|Genotype 1
1018947|NCT01937728|Peg interferon
1018948|NCT01937728|alfa 1a
1018949|NCT01937728|Ribavirin
1018950|NCT01937689|Breast cancer
1018951|NCT01937689|advanced
1018952|NCT01937689|Pyrotinib
1018953|NCT01937689|Phase I
1018954|NCT01937689|HER2 positive advanced breast cancer
1018955|NCT01937663|Chronic Constipation
1018956|NCT01937663|Constipation
1018957|NCT01937663|Functional gastrointestinal disorders
1018958|NCT01937650|Radiotherapy, metronidazole, cervical cancer, Mulago
1018959|NCT01937637|Cognitive Behavioral Intervention for Breathlessness
1018960|NCT01937624|Diagnostic ultrasound
1018961|NCT01937611|dexmedetomidine
1018962|NCT01937611|intramuscular premedication
1018963|NCT01937611|bradycardiac
1018964|NCT01937598|Incretin, DPP-4 inhibitor
1018965|NCT01937585|prostate cancer
1018966|NCT01937585|partner
1018967|NCT01937585|communication messages
1018968|NCT01937585|monitoring style
1018969|NCT01937585|AA men
1018970|NCT01937572|Total knee arthroplasty (TKA)
1018971|NCT01937572|Computer aided systems
1018972|NCT01937559|tranexaminic acid (TXA)
1018973|NCT01937546|Anal Canal/injuries
1018974|NCT01937546|Delivery, Obstetric/methods
1018975|NCT01937546|Labour Stage, Second
1018976|NCT01937546|Lacerations/prevention & control
1018977|NCT01937546|Obstetric Labour Complications/prevention & control
1018978|NCT01937546|perineum/injuries
1018979|NCT01937533|Magnetic Resonance Imaging
1018980|NCT01937520|acupuncture
1018981|NCT01937520|inflammation
1018982|NCT01937520|thyroid
1018983|NCT01937520|parathyroid
1018984|NCT01937494|asthma
1018985|NCT01937494|bronchial hyperresponsiveness
1018986|NCT01937494|histamine challenge test
1018987|NCT01937494|spirometry
1018988|NCT01937481|Child, Preschool
1018989|NCT01937481|Parents
1018990|NCT01937481|Family
1018991|NCT01937481|Obesity
1018992|NCT01937481|Overweight
1018993|NCT01937481|Diet
1018994|NCT01937481|Overnutrition
1018995|NCT01937481|Motor Activity
1018996|NCT01937481|Child Care
1018997|NCT01937481|Schools
1018998|NCT01937468|Chronic GVHD
1018999|NCT01937468|Chronic graft versus host disease
1019000|NCT01937468|Allogeneic stem cell transplant
1019001|NCT01937455|HIV
1019002|NCT01937455|AIDS
1019003|NCT01937455|HIV vaccine
1019004|NCT01937455|HIV prevention
1019005|NCT01937455|AAV
1019006|NCT01937455|PG9
1019007|NCT01937442|Multiple myeloma
1019008|NCT01937442|Pharmacokinetics
1019009|NCT01937442|Thalidomide
1019010|NCT01937429|Colonoscopy - Chromoendoscopy - Indigo Carmin® - Adenoma detection - Tepid water
1019011|NCT01937403|Physical Therapy
1019012|NCT01937403|Return to sport
1019013|NCT01937351|Atherectomy
1019014|NCT01937351|Optical Coherence Tomography
1019015|NCT01937351|Lumivascular
1019016|NCT01937338|Healthy volunteers, Phase 1
1019017|NCT01937325|Eligible CF patients with G551D gene mutation
1019018|NCT01937312|glaucoma
1019019|NCT01937312|prostaglandin analogue
1019020|NCT01937312|brinzolamide
1019021|NCT01937312|brimonidine
1019022|NCT01937299|glaucoma
1019023|NCT01937299|prostaglandin analogue
1019024|NCT01937299|brinzolamide
1019025|NCT01937299|brimonidine
1019026|NCT01937286|LDLT,HCC, Microvascular invasion
1019027|NCT01937273|Nutritional status, malnutrition, chemo-radiotherapy
1019028|NCT01937247|Operative Time
1019029|NCT01937247|Operating Rooms
1019030|NCT01937247|Efficiency
1019031|NCT01937221|mild cognitive impairment
1019032|NCT01937221|mild to moderate cognitive impairment
1019033|NCT01937208|Esophageal Carcinoma
1019034|NCT01937208|chemoradiation
1019035|NCT01937208|radiation dose
1019036|NCT01937195|IV Catheter comparison
1019037|NCT01937195|AccuCath versus Conventional IV Catheters
1019038|NCT01937195|IV Catheter Study
1019039|NCT01937195|IV Catheter User Preference Comparison
1019040|NCT01937195|First Attempt Success Rate for IV Catheters
1019041|NCT01937195|AccuCath Device Performance
1019042|NCT01937195|Complication Rates for IV Catheters
1019043|NCT01937195|Average Dwell Time for IV Catheters
1019044|NCT01937195|Patient Satisfaction with IV Catheters
1019045|NCT01937195|Clinician Satisfaction with AccuCath Device Performance
1019046|NCT01937182|Stroke
1019047|NCT01937182|SSRI (Selective Serotonin Reuptake Inhibitors)
1019048|NCT01937182|Serotonin
1019049|NCT01937182|5-HT (5-Hydroxytryptamine)
1019050|NCT01937182|Neuroprotection
1019051|NCT01937182|MRI (Magnetic Resonance Imaging)
1019052|NCT01937182|Platelet
1019053|NCT01937182|CT (computerized tomography)
1019054|NCT01937182|Post Stroke Depression
1019055|NCT01937143|parent education
1019056|NCT01937143|immunization
1019057|NCT01937143|vaccination
1019058|NCT01937143|infant
1019059|NCT01937143|pain management
1019060|NCT01937130|Liver Failure
1019061|NCT01937130|Cirrhosis
1019062|NCT01937130|Alcoholic Hepatitis
1019063|NCT01937117|Breast cancer
1019064|NCT01937117|Preoperative treatment
1019065|NCT01937117|Neoadjuvant treatment
1019066|NCT01937104|Intracranial pressure
1019067|NCT01937104|Laparoscopy
1019068|NCT01937104|Optic nerve sheath diameter
1019069|NCT01937104|Position
1019070|NCT01937091|HIV
1019071|NCT01937091|clinical trials
1019072|NCT01937013|Frontotemporal Dementia
1019073|NCT01937013|emotion
1019074|NCT01937013|oxytocin
1019075|NCT01937013|fMRI
1019076|NCT01936961|Cancer
1019077|NCT01936948|Large colon polyps
1019078|NCT01936948|Polyp resection
1019079|NCT01936948|Colon cancer screening
1019080|NCT01936948|Colonoscopy
1019081|NCT01936948|Endoscopic mucosal resection
1019082|NCT01936935|Insulin sensitivity
1019083|NCT01936922|Fall accidents
1019084|NCT01936922|Gait
1019085|NCT01936922|Balance
1019086|NCT01936922|Fear of falling
1019087|NCT01936922|Virtual reality
1019088|NCT01936896|Acute myocardial infarction
1019089|NCT01936896|Heart Failure
1019090|NCT01936896|Inflammation
1019091|NCT01936883|prostatic neoplasm
1019092|NCT01936883|brachytherapy
1019093|NCT01936883|quality of life
1019094|NCT01936883|high dose rate
1019095|NCT01936883|low dose rate
1019096|NCT01936870|Toviaz
1019097|NCT01936870|Fesoterodine
1019098|NCT01936870|Post marketing surveillance
1019099|NCT01936870|Japanese
1019100|NCT01936870|Overactive Bladder
1019101|NCT01936870|OAB
1019102|NCT01936870|Good post marketing practice
1019103|NCT01936870|Regulatory Post Marketing Commitment Plan
1019104|NCT01936792|Concussion
1019105|NCT01936792|Mild Traumatic Brain Injury
1019106|NCT01936792|Traumatic Brain Injury
1019107|NCT01936779|plasma triglycerides
1019108|NCT01936779|dietary fat
1019109|NCT01936779|liver fat metabolism
1019110|NCT01936779|human
1019111|NCT01936766|malaria, falciparum
1019112|NCT01936766|sepsis
1019113|NCT01936766|fluid therapy
1019114|NCT01936766|thermodilution
1019115|NCT01936766|extravascular lung water
1019116|NCT01936766|acute kidney injury
1019117|NCT01936753|PMTCT
1019118|NCT01936753|HIV
1019119|NCT01936753|Mentor Mothers
1019120|NCT01936753|Nigeria
1019121|NCT01936753|Retention
1019122|NCT01936753|Adherence
1019123|NCT01936740|Efficacy and Safety
1019124|NCT01936727|efficiency and safety
1019125|NCT01936714|Efficacy and Safety
1019126|NCT01936675|Coronary Artery Disease
1019127|NCT01936675|Myocardial Infarction
1019128|NCT01936675|Genomic Risk Communication
1019129|NCT01936675|Risk Stratification
1019130|NCT01936662|Airway management comparison
1019131|NCT01936649|Nuclear imaging
1019132|NCT01936649|Radiopharmaceutical
1019133|NCT01936649|Iobenguane
1019134|NCT01936649|I-123
1019135|NCT01936649|reproducibility
1019136|NCT01936649|Quantitative measurements
1019137|NCT01936649|myocardial uptake
1019138|NCT01936649|SPECT imaging
1019139|NCT01936649|planar imaging
1019140|NCT01936649|AdreView™
1019141|NCT01936636|Breakthrough cancer pain
1019142|NCT01936636|diary
1019143|NCT01936636|quality of life
1019144|NCT01936636|Abstral
1019145|NCT01936636|BTcP
1019146|NCT01936623|brief intervention
1019147|NCT01936623|computerized brief intervention
1019148|NCT01936610|Lecture
1019149|NCT01936610|Role-playing
1019150|NCT01936610|Knowledge
1019151|NCT01936610|Attitude
1019152|NCT01936610|Decision making
1019153|NCT01936610|Type of delivery
1019154|NCT01936597|external cardiac massage, medical hotline,
1019155|NCT01936545|Liver transplantation, reactive oxygen species, antioxidant
1019156|NCT01936532|multiple myeloma
1019157|NCT01936519|Everolimus
1019158|NCT01936519|Zortress
1019159|NCT01936519|Renal Function
1019160|NCT01936519|Tacrolimus
1019161|NCT01936519|Cyclosporine
1019162|NCT01936519|Myfortic
1019163|NCT01936519|Mycophenolic Acid
1019164|NCT01936519|Liver Transplantation
1019165|NCT01936506|Cognitive training
1019166|NCT01936506|Depression
1019167|NCT01936493|Uterine leiomyomas (fibroids or myomas)
1019168|NCT01936493|Uterine fibroids
1019169|NCT01936493|Fibroids
1019170|NCT01936493|Uterine leiomyomas
1019171|NCT01936467|Pancreatic solid lesions
1019172|NCT01936467|Pancreatic mass
1019173|NCT01936467|Pancreatic cancer
1019174|NCT01936467|Endoscopic Ultrasound
1019175|NCT01936467|EUS
1019176|NCT01936467|Fine needle aspiration
1019177|NCT01936467|FNA
1019178|NCT01936467|EUS-FNA
1019179|NCT01936441|Menopause
1019180|NCT01936441|Vasomotor
1019181|NCT01936441|Symptoms
1019182|NCT01936441|Sleep
1019183|NCT01936441|Cognitive Behavioral Therapy
1019184|NCT01936415|Knee prosthesis
1019185|NCT01936402|Cardiopulmonary Resuscitation
1019186|NCT01936376|kidney safety
1019187|NCT01936376|biomarkers
1019188|NCT01936376|serum creatinine
1019189|NCT01936376|BUN
1019190|NCT01936376|cystic fibrosis
1019191|NCT01936376|head and neck cancer
1019192|NCT01936376|renal injury
1019193|NCT01936376|drug induced acute kidney injury
1019194|NCT01936376|aminoglycoside
1019195|NCT01936376|cisplatin
1019196|NCT01936376|nephrotoxicity
1019197|NCT01936376|biomarker qualification
1019198|NCT01936363|Ovarian Cancer
1019199|NCT01936363|Pimasertib
1019200|NCT01936363|Placebo
1019201|NCT01936363|SAR245409
1019202|NCT01936350|Heart failure
1019203|NCT01936324|acne vulgaris
1019204|NCT01936311|Health Behavior
1019205|NCT01936311|Behavior change
1019206|NCT01936311|self-management goal
1019207|NCT01936311|health goal
1019208|NCT01936298|Hand Edema
1019209|NCT01936298|Exercise Therapy
1019210|NCT01936233|Hepatocellular Carcinoma
1019211|NCT01936233|Aspirin
1019212|NCT01936233|antiviral treatment
1019213|NCT01936233|recurrence free survival
1019214|NCT01936233|radical therapy
1019215|NCT01936220|Schizophrenia
1019216|NCT01936220|First-psychotic episode
1019217|NCT01936220|Initial phase
1019218|NCT01936220|Relapse prevention
1019219|NCT01936220|Specialized treatment
1019220|NCT01936220|Parent groups
1019221|NCT01936220|Social functioning
1019222|NCT01936207|acute
1019223|NCT01936207|respiratory
1019224|NCT01936207|syndrome
1019225|NCT01936207|prognosis
1019226|NCT01936207|outcome research
1019227|NCT01936207|respiratory infection
1019228|NCT01936207|sepsis
1019229|NCT01936207|organ failure
1019230|NCT01936181|Rheumatoid Arthritis
1019231|NCT01936181|Infliximab
1019232|NCT01936181|Biosimilar
1019233|NCT01936168|GSV
1019234|NCT01936168|Primary Varicose Veins
1019235|NCT01936168|Great Saphenous Vein
1019236|NCT01936168|Treatment
1019237|NCT01936155|Joint Mobility
1019238|NCT01936155|Skin Tissue Oxygenation
1019239|NCT01936155|Neuromuscular Electrical Stimulation
1019240|NCT01936155|Goniometry
1019241|NCT01936155|Transcutaneous Oxygen Measurements (tcpO2)
1019242|NCT01936155|Water Displacement
1019243|NCT01936142|Resynchroniztion therapy
1019244|NCT01936142|Kidney
1019245|NCT01936142|Contrast media
1019246|NCT01936142|Prevention
1019247|NCT01936116|Sonohysterography
1019248|NCT01936116|catheter placement
1019249|NCT01936116|pain magnitude
1019250|NCT01936116|vasovagal reaction
1019251|NCT01936103|Acute anterior myocardial infarction
1019252|NCT01936103|Percutaneous coronary stent implantation
1019253|NCT01936103|Intensive statin therapy
1019254|NCT01936103|Left ventricular function
1019255|NCT01936077|Infertility, IVF, ovarian stimulation, rec LH, GnRH antagonist
1019256|NCT01936064|Breast Cancer
1019257|NCT01936064|Jobelyn
1019258|NCT01936064|Sorghum bicolor
1019259|NCT01936038|CPAP
1019260|NCT01936038|Upper Airway Toning
1019261|NCT01936038|Obstructive Sleep Apnoea
1019262|NCT01936025|Diabetes mellitus
1019263|NCT01936012|Lisinopril
1019264|NCT01936012|Bioequivalence
1019265|NCT01936012|Bioavailability
1019266|NCT01936012|Pharmacokinetic
1019267|NCT01936012|Angiotensin-converting enzyme inhibitor
1019268|NCT01935999|Colostomy
1019269|NCT01935999|peristomal skin
1019270|NCT01935999|stoma
1019271|NCT01935999|pouch
1019272|NCT01935908|Subarachnoid Hemorrhage
1019273|NCT01935908|Seizures
1019274|NCT01935908|Prophylaxis
1019275|NCT01935908|Levetiracetam
1019276|NCT01935895|blood pressure reduction
1019277|NCT01935895|vascular reactivity
1019278|NCT01935895|combined exercise session
1019279|NCT01935856|patients
1019280|NCT01935856|receiving
1019281|NCT01935856|hemodialysis
1019282|NCT01935856|Secondary
1019283|NCT01935843|CART-HER-2
1019284|NCT01935843|HER-2 positive
1019285|NCT01935843|Advanced
1019286|NCT01935843|Refactory
1019287|NCT01935843|Solid tumors
1019288|NCT01935830|PET Imaging
1019289|NCT01935830|Efavirenz
1019290|NCT01935830|Ritonavior [11C] LAAM
1019291|NCT01935830|Healthy volunteers
1019292|NCT01935804|pioglitazone
1019293|NCT01935804|metformin
1019294|NCT01935804|hyperglycemic agents
1019295|NCT01935804|physiological effects of drugs
1019296|NCT01935804|bone health
1019297|NCT01935765|Type 1 diabetes, sleep apnea, polysomnography,
1019298|NCT01935765|autonomic neuropathy, intima media thickness
1019299|NCT01935752|fibromuscular
1019300|NCT01935752|dysplasia
1019301|NCT01935752|endothelium
1019302|NCT01935752|microparticles
1019303|NCT01935752|microRNA
1019304|NCT01935726|Pulmonary fibrosis
1019305|NCT01935726|Interstitial lung disease
1019306|NCT01935726|Connective tissue disease
1019307|NCT01935726|Chronic hypersensitivity pneumonitis
1019308|NCT01935726|Idiopathic pulmonary fibrosis
1019309|NCT01935700|hepatocellular carcinoma
1019310|NCT01935700|colchicine
1019311|NCT01935687|Instrumented Wheel
1019312|NCT01935687|Manual Wheelchair
1019313|NCT01935687|Spinal Cord Injury (SCI)
1019314|NCT01935687|Manual wheelchair Users
1019315|NCT01935687|Aged between 18-70 years
1019316|NCT01935674|Hypercholesterolaemia
1019317|NCT01935674|HIV
1019318|NCT01935674|Rosuvastatin
1019319|NCT01935674|Protease inhibitor switching
1019320|NCT01935661|Blood transfusion
1019321|NCT01935661|Hemosiderosis
1019322|NCT01935661|ERP
1019323|NCT01935648|Knee arthroplasty
1019324|NCT01935635|CHB
1019325|NCT01935635|Antiviral
1019326|NCT01935635|Dentritic cells
1019327|NCT01935635|Immune Therapy
1019328|NCT01935622|heart failure
1019329|NCT01935622|non-ischemic cardiomyopathy
1019330|NCT01935609|traumatic brain injury
1019331|NCT01935609|acquired brain injury
1019332|NCT01935596|Anesthesia
1019333|NCT01935596|Randomized study
1019334|NCT01935596|Lower limbs surgery
1019335|NCT01935583|traumatic brain injury
1019336|NCT01935570|Bioavailability of magnesium
1019337|NCT01935570|Digestive and general tolerance
1019338|NCT01935557|Continuous heparin infusion
1019339|NCT01935557|Intermittent heparin infusion
1019340|NCT01935557|during catheter ablation
1019341|NCT01935544|Botulinum Toxin
1019342|NCT01935544|Ultrasound-guidance
1019343|NCT01935544|Stroke
1019344|NCT01935544|Spasticity
1019345|NCT01935544|Ultrasonography
1019346|NCT01935544|Hemiplegia
1019347|NCT01935531|actinic keratoses
1019348|NCT01935531|tumor metabolism
1019349|NCT01935531|glycolysis
1019350|NCT01935531|diclofenac
1019351|NCT01935531|warburg effect
1019352|NCT01935505|smoking cessation
1019353|NCT01935505|intervention model
1019354|NCT01935505|Chinese
1019355|NCT01935505|quitting rate
1019356|NCT01935492|metastatic breast cancer
1019357|NCT01935492|HER2/neu negative
1019358|NCT01935492|paclitaxel
1019359|NCT01935492|bevacizumab
1019360|NCT01935492|liposomal doxorubicine
1019361|NCT01935492|capecitabine
1019362|NCT01935479|AK159, teriparatide acetate
1019363|NCT01935466|Pioglitazone
1019364|NCT01935466|Bladder cancer
1019365|NCT01935466|Type 2 Diabetes
1019366|NCT01935440|HIV, drug use
1019367|NCT01935427|Pulse Oximeter
1019368|NCT01935427|Stroke Volume
1019369|NCT01935427|Hemorrhagic shock
1019370|NCT01935427|Compensatory Reserve Index
1019371|NCT01935401|Bulimia Nervosa
1019372|NCT01935401|Bulimia
1019373|NCT01935401|Response Inhibition
1019374|NCT01935401|fNIR
1019375|NCT01935401|Neuroimaging
1019376|NCT01935388|Mechanical ventilation
1019377|NCT01935388|chronic obstructive pulmonary disease
1019378|NCT01935388|asthma
1019379|NCT01935388|common canister
1019380|NCT01935388|MDI
1019381|NCT01935388|ventilator associated pneumonia
1019382|NCT01935375|Postpartum Depression
1019383|NCT01935375|Nurse Midwife
1019384|NCT01935375|Interpersonal Psychotherapy
1019385|NCT01935362|Flavanones
1019386|NCT01935362|Bioavailability
1019387|NCT01935362|Blood vessel health
1019388|NCT01935362|Blood glucose
1019389|NCT01935349|Diabetes mellitus (DM)
1019390|NCT01935349|hypertension (HT)
1019391|NCT01935349|Hong Kong
1019392|NCT01935336|Lung Cancer
1019393|NCT01935336|Malignancy
1019394|NCT01935336|Predictive biomarkers
1019395|NCT01935323|high intensity interval training
1019396|NCT01935323|aerobic exercise
1019397|NCT01935323|insulin sensitivity
1019398|NCT01935323|obesity
1019399|NCT01935323|cardiovascular fitness
1019400|NCT01935310|Photoaging
1019401|NCT01935310|imiquimod
1019402|NCT01935310|wrinkles
1019403|NCT01935310|elastosis
1019404|NCT01935271|immunosenescence
1019405|NCT01935271|sarcopenia
1019406|NCT01935258|Medically unexplained symptoms
1019407|NCT01935258|Somatization
1019408|NCT01935258|Psychosomatic therapy
1019409|NCT01935245|Coronary artery bypass grafting
1019410|NCT01935245|Extracorporeal circulation
1019411|NCT01935245|Minimal extracorporeal circulation
1019412|NCT01935245|Coagulopathy
1019413|NCT01935245|Thrombocytopathy
1019414|NCT01935245|Platelet dysfunction
1019415|NCT01935232|Osteoporosis, diagnostics, ultrasound
1019416|NCT01935219|mild cognitive impairment
1019417|NCT01935219|seniors
1019418|NCT01935219|cognitive training
1019419|NCT01935219|driving
1019420|NCT01935219|driving simulation
1019421|NCT01935219|intervention
1019422|NCT01935219|goal management training
1019423|NCT01935219|process speed training
1019424|NCT01935206|secondary hyperalgesia
1019425|NCT01935206|allodynia
1019426|NCT01935206|mechanical pain threshold
1019427|NCT01935206|naloxone
1019428|NCT01935206|endogenous opioids
1019429|NCT01935206|pain
1019430|NCT01935193|platelets aggregation
1019431|NCT01935193|asa resistance
1019432|NCT01935180|colon polyps
1019433|NCT01935180|adenoma resection
1019434|NCT01935180|colon cancer screening
1019435|NCT01935180|colonoscopy
1019436|NCT01935180|polyp detection
1019437|NCT01935167|Microalbuminuria
1019438|NCT01935154|NSCLC
1019439|NCT01935154|Vaccine
1019440|NCT01935141|Pulmonary Embolus
1019441|NCT01935141|Radio Contrast Material
1019442|NCT01935141|Computed Tomography
1019443|NCT01935128|Renal Transplant
1019444|NCT01935128|Immunosuppression
1019445|NCT01935128|Steroid Avoidance
1019446|NCT01935128|Calcineurin Avoidance
1019447|NCT01935128|Mammalian Target of Rapamycin (mTOR)
1019448|NCT01935128|Kidney
1019449|NCT01935115|Depression
1019450|NCT01935115|MDD
1019451|NCT01935115|Treatment Resistant Depression
1019452|NCT01935115|Electroconvulsive Therapy
1019453|NCT01935115|ECT
1019454|NCT01935115|Ketamine
1019455|NCT01935115|Propofol
1019456|NCT01935115|NMDA
1019457|NCT01935102|metastatic breast cancer
1019458|NCT01935102|bevacizumab
1019459|NCT01935102|single nucleotide polymorphism
1019460|NCT01935102|VEGF-A
1019461|NCT01935102|VEGFR-2
1019462|NCT01935102|IL-8
1019463|NCT01935089|HIV-1
1019464|NCT01935089|Interferon alpha
1019465|NCT01935089|Integrated DNA
1019466|NCT01935089|Latent reservoir
1019467|NCT01935076|Maternal obesity
1019468|NCT01935076|Macrosomic
1019469|NCT01935076|miRNA
1019470|NCT01935076|Fetal overgrowth
1019481|NCT01935050|Depression
1019482|NCT01935050|Parkinson's disease
1019483|NCT01935050|Cognitive-Behavioral Treatment
1019484|NCT01935024|Alzheimer's disease
1019485|NCT01935024|dementia
1019486|NCT01935024|aerobic exercise
1019487|NCT01934998|SCA6, parkinsonism, Datscan
1019488|NCT01934985|Single-Photon Emission-Computed Tomography
1019489|NCT01934985|Myocardial Perfusion Imaging
1019490|NCT01934985|Ischemia
1019491|NCT01934985|Stress test
1019492|NCT01934985|Coronary Artery Disease (CAD)
1019493|NCT01934985|Coronary Flow Reserve (CFR)
1019494|NCT01934985|Coronary Angiography
1019495|NCT01934972|Bipolar disorder
1019496|NCT01934946|hip fracture
1019497|NCT01934933|ossification
1019498|NCT01934933|etanercept
1019499|NCT01934894|HER2-positive breast cancer
1019500|NCT01934894|intracranial metastases
1019501|NCT01934894|lapatinib
1019502|NCT01934894|cabazitaxel
1019503|NCT01934868|low back pain
1019504|NCT01934868|sciatica
1019505|NCT01934868|spinal stenosis
1019506|NCT01934868|epidural injections
1019507|NCT01934868|prolotherapy
1019508|NCT01934868|sacroiliac pain or dysfunction.
1019509|NCT01934855|cancer
1019510|NCT01934855|radiotherapy
1019511|NCT01934855|4D-MRI
1019512|NCT01934855|4D-CT
1019513|NCT01934855|MRI
1019514|NCT01934816|Incretins, KATP channels, intradermal injection
1019515|NCT01934803|Alcohol Use
1019516|NCT01934803|Microbial Translocation
1019517|NCT01934803|Inflammation
1019518|NCT01934803|Altered Coagulation
1019519|NCT01934803|Russia
1019520|NCT01934803|Zinc
1019521|NCT01934803|AMI
1019522|NCT01934803|VACS index
1019523|NCT01934803|Reynolds risk score
1019524|NCT01934777|NAFLD
1019525|NCT01934777|NASH
1019526|NCT01934777|fibrosis
1019527|NCT01934738|Multiple dose
1019528|NCT01934738|safety
1019529|NCT01934738|tolerability
1019530|NCT01934738|PK
1019531|NCT01934725|Ischemic Stroke
1019532|NCT01934725|Brain Infarction
1019533|NCT01934725|Patent Foramen Ovale
1019534|NCT01934725|Stroke in the Young
1019535|NCT01934725|Myocardial Infarction
1019536|NCT01934725|Cerebral Venous Thrombosis
1019537|NCT01934725|Pulmonary Embolism
1019538|NCT01934725|Deep Vein Thrombosis
1019539|NCT01934725|Subarachnoid Hemorrhage
1019540|NCT01934725|Prognosis
1019541|NCT01934725|Databases, Genetic
1019542|NCT01934699|Coronary stenosis
1019543|NCT01934699|Angina pectoris
1019544|NCT01934699|Left ventricular wall motion abnormalities
1019545|NCT01934699|2D-Strain
1019546|NCT01934660|Cardiovascular Disease
1019547|NCT01934660|Diabetes Mellitus
1019548|NCT01934660|Inflammation
1019549|NCT01934634|Pancreatic Cancer
1019550|NCT01934634|Stage IV Pancreatic Cancer
1019551|NCT01934634|Stage IV metastatic pancreatic ductal adenocarcinoma
1019552|NCT01934621|Stroke
1019553|NCT01934621|Rehabilitation
1019554|NCT01934621|Cognition
1019555|NCT01934621|Disability
1019556|NCT01934595|Critically ill
1019557|NCT01934595|Protein
1019558|NCT01934595|Supplement
1019559|NCT01934595|ICU
1019560|NCT01934595|Protein synthesis
1019561|NCT01934530|implant complications
1019562|NCT01934530|esthetics
1019563|NCT01934530|soft tissue grafting
1019564|NCT01934504|clinical tolerance
1019565|NCT01934504|biomarker(s) identification
1019566|NCT01934491|Cognitive training
1019567|NCT01934491|Depression
1019568|NCT01934478|Breast
1019569|NCT01934478|Cancer
1019570|NCT01934478|Human Epidermal Growth Factor 2 (Her2)
1019571|NCT01934478|irradiation
1019572|NCT01934465|NSCLC
1019573|NCT01934465|Chemotherapy
1019574|NCT01934465|Anti-angiogenic agent
1019575|NCT01934465|Bevacizumab
1019576|NCT01934465|1st Line
1019577|NCT01934452|complete remission
1019578|NCT01934439|Stroke
1019579|NCT01934439|Rehabilitation
1019580|NCT01934439|Dyssynergia
1019581|NCT01934439|Robotics
1019582|NCT01934439|AMES
1019583|NCT01934439|Cerebrovascular Accident
1019584|NCT01934426|Admission High Risk Elderly
1019585|NCT01934413|Palliative Care
1019586|NCT01934413|Technology
1019587|NCT01934413|Rural
1019588|NCT01934413|Transitional Care
1019589|NCT01934400|Osteoporosis
1019590|NCT01934400|fall prevention
1019591|NCT01934400|high risk population
1019592|NCT01934387|World Health Organization Fracture Risk Assessment Tool
1019593|NCT01934387|Osteoporosis
1019594|NCT01934387|Aged
1019595|NCT01934387|Prevention
1019596|NCT01934387|Fracture
1019597|NCT01934387|FRAX
1019598|NCT01934374|task-oriented training, long-term effects, plasticity
1019599|NCT01934361|BKM120
1019600|NCT01934361|Recurrent glioblastoma multiforme
1019601|NCT01934361|rGBM
1019602|NCT01934361|buparlisib
1019603|NCT01934335|breast cancer, TKI, tyrosine kinase inhibitor, vandetanib, Ki-67
1019604|NCT01934322|frequent users of the emergency department
1019605|NCT01934322|vulnerable populations
1019606|NCT01934322|case management
1019607|NCT01934322|cost savings intervention
1019608|NCT01934322|quality of life
1019609|NCT01934322|number of emergency department visits
1019610|NCT01934309|tuberculosis
1019611|NCT01934309|isoniazid preventative therapy
1019612|NCT01934309|clinical decision support
1019613|NCT01934309|HIV
1019614|NCT01934309|Kenya
1019615|NCT01934309|eHealth
1019616|NCT01934296|deep brain stimulation
1019617|NCT01934296|cortical recording
1019618|NCT01934296|neuroprosthesis
1019619|NCT01934231|Acute bacterial rhinosinusitis
1019620|NCT01934231|Amoxicilin
1019621|NCT01934231|Infection
1019622|NCT01934231|Potassium clavulanate
1019623|NCT01934218|Knee
1019624|NCT01934218|Osteoarthritis
1019625|NCT01934218|Intra-articular injection
1019626|NCT01934205|GSK2140944
1019627|NCT01934205|pharmacokinetics
1019628|NCT01934205|bronchoalveolar lavage
1019629|NCT01934205|pulmonary
1019630|NCT01934205|antimicrobial
1019631|NCT01934205|healthy volunteer
1019632|NCT01934192|tolerability
1019633|NCT01934192|camicinal
1019634|NCT01934192|single dose
1019635|NCT01934192|acetaminophen
1019636|NCT01934192|gastric emptying
1019637|NCT01934192|critically ill
1019638|NCT01934192|GSK962040
1019639|NCT01934192|pharmacokinetics
1019640|NCT01934192|pharmacodynamics
1019641|NCT01934192|gut motility
1019642|NCT01934153|hyperhidrosis
1019643|NCT01934153|topical
1019644|NCT01934153|[14C] radiolabel
1019645|NCT01934153|palm
1019646|NCT01934153|GSK573719
1019647|NCT01934153|axilla
1019648|NCT01934153|Umeclidinium
1019649|NCT01934140|Healthy
1019650|NCT01934140|Adults
1019651|NCT01934140|Safety
1019652|NCT01934140|Neisseria meningitidis
1019653|NCT01934140|Booster response
1019654|NCT01934140|Immunogenicity
1019655|NCT01934140|Adolescents
1019656|NCT01934140|Serogroups A, C, W-135, and Y
1019657|NCT01934140|long-term antibody persistence
1019658|NCT01934127|Immunogenicity
1019659|NCT01934127|H7N1
1019660|NCT01934127|Influenza
1019661|NCT01934127|Safety
1019662|NCT01934127|AS03 adjuvant
1019663|NCT01934127|Adults
1019664|NCT01934088|Inflammatory Bowel disease
1019665|NCT01934088|IBD
1019666|NCT01934088|Sedation
1019667|NCT01934088|NAPS
1019668|NCT01934088|Propofol
1019669|NCT01934088|Midazolam
1019670|NCT01934088|Satisfaction
1019671|NCT01934088|Feasibility
1019672|NCT01934075|Obstetric fistula
1019673|NCT01934075|Mental health
1019674|NCT01934075|Tanzania
1019675|NCT01934036|Weight loss
1019676|NCT01934036|Nutritional supplement
1019677|NCT01934036|Waist
1019678|NCT01934036|Body composition
1019679|NCT01934036|Skinfolds
1019680|NCT01934023|plasticity, schizophrenia, varenicline, non smokers,
1019681|NCT01933997|pharmacokinetics
1019682|NCT01933997|metadoxine
1019683|NCT01933984|Bronchodilator agents,
1019684|NCT01933984|chronic obstructive pulmonary disease,
1019685|NCT01933984|endotracheal intubation,
1019686|NCT01933984|mechanical ventilator
1019687|NCT01933958|Regorafenib
1019688|NCT01933958|Gastrointestinal stromal tumors
1019689|NCT01933932|Mitogen-Activated Protein Kinase Kinase inhibitor; Non Small Cell Lung Cancer; metastatic; second line treatment for Non Small Cell Lung Cancer; KRAS mutation
1019690|NCT01933919|Obsessive Compulsive Disorder
1019691|NCT01933919|Adolescent Subjects
1019692|NCT01933919|Pediatric Subjects
1019693|NCT01933906|CML
1019694|NCT01933906|Chronic myeloid leukemia
1019695|NCT01933906|Chronic myeloid leukaemia
1019696|NCT01933906|PEG-Proline-Interferon-alpha 2b
1019697|NCT01933906|Interferon
1019698|NCT01933906|P1101
1019699|NCT01933906|Imatinib
1019700|NCT01933893|Pipelle, luteal, follicular, implantation
1019701|NCT01933880|Attention Deficit Hyperactivity Disorder
1019702|NCT01933880|Methylphenidate Hydrochloride
1019703|NCT01933880|CONCERTA
1019704|NCT01933867|water
1019705|NCT01933867|colonoscopy
1019706|NCT01933867|Crohn´s disease
1019707|NCT01933867|ulcerative colitis
1019708|NCT01933854|Urinary incontinence
1019709|NCT01933854|riverside
1019710|NCT01933854|women
1019711|NCT01933854|Amapa
1019712|NCT01933841|Post operative residual curaization
1019713|NCT01933841|Neuromuscular blocking drugs
1019714|NCT01933828|Lung cancer
1019715|NCT01933828|surgery video-assisted
1019716|NCT01933828|robot
1019717|NCT01933828|surgical treatment
1019718|NCT01933815|Glioblastoma multiforme
1019719|NCT01933815|Glioblastoma
1019720|NCT01933815|Radiotherapy
1019721|NCT01933815|Temozolomide
1019722|NCT01933815|TPI 287
1019723|NCT01933815|Taxoid
1019724|NCT01933815|Avastin
1019725|NCT01933815|Bevacizumab
1019726|NCT01933802|mesenchymal stem cells
1019727|NCT01933802|neural progenitors
1019728|NCT01933802|autologous
1019729|NCT01933802|bone marrow
1019730|NCT01933802|multiple sclerosis
1019731|NCT01933789|Palliative Care
1019732|NCT01933789|End-of-Life Issues
1019733|NCT01933789|Patient/Clinician Communication
1019734|NCT01933789|Patient/Family Communication
1019735|NCT01933789|Concordance
1019736|NCT01933789|Treatment Preferences
1019737|NCT01933789|Anxiety
1019738|NCT01933789|Depressive Symptoms
1019739|NCT01933789|Talking with Your Doctor
1019740|NCT01933789|Coping with Serious Illness
1019741|NCT01933789|Outpatient Collaboration
1019742|NCT01933776|Diphtheria
1019743|NCT01933776|Tetanus
1019744|NCT01933776|Pertussis
1019745|NCT01933776|ADACEL®
1019746|NCT01933776|Tdap vaccine
1019747|NCT01933750|Presbyopia
1019748|NCT01933750|Reading Glasses
1019749|NCT01933750|Near Vision
1019750|NCT01933737|postural balance;
1019751|NCT01933737|elderly;
1019752|NCT01933737|proprioception;
1019753|NCT01933737|prevention;
1019754|NCT01933737|fall
1019755|NCT01933724|granulomatosis with polyangiitis
1019756|NCT01933724|GPA
1019757|NCT01933724|Wegeners'
1019758|NCT01933724|WG
1019759|NCT01933724|vasculitis
1019760|NCT01933724|taper
1019761|NCT01933724|prednisone
1019762|NCT01933724|glucocorticoid
1019763|NCT01933724|ANCA-associated vasculitis
1019764|NCT01933724|AAV
1019765|NCT01933724|Wegener Granulomatosis
1019766|NCT01933724|Systemic Vasculitis
1019767|NCT01933724|Lung diseases, interstitial
1019768|NCT01933724|Lung diseases
1019769|NCT01933724|Respiratory Tract Diseases
1019770|NCT01933724|Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
1019771|NCT01933724|Vascular Diseases
1019772|NCT01933724|Cardiovascular Diseases
1019773|NCT01933724|Glucocorticoids
1019774|NCT01933724|Hormones
1019775|NCT01933724|Hormones, Hormone Substitutes, and Hormone Antagonists
1019776|NCT01933724|Physiological Effects of Drugs
1019777|NCT01933724|Pharmacologic Actions
1019778|NCT01933724|Antineoplastic Agents, Hormonal
1019779|NCT01933724|Antineoplastic Agents
1019780|NCT01933724|Therapeutic Uses
1019781|NCT01933724|Anti-Inflammatory Agents
1019782|NCT01933711|CD20+ aggressive lymphoma
1019783|NCT01933711|mantle cell lymphoma
1019784|NCT01933711|rituximab
1019785|NCT01933711|maintenance
1019786|NCT01933698|Bioequivalence
1019787|NCT01933698|Amoxicillin
1019788|NCT01933698|Human
1019789|NCT01933672|Phase 1b
1019790|NCT01933672|type 2 diabetes
1019791|NCT01933672|metformin background
1019792|NCT01933672|PF-04937319
1019793|NCT01933659|Helicobacter pylori
1019794|NCT01933659|deep see water
1019795|NCT01933646|Group B streptococcus
1019796|NCT01933646|Incidence
1019797|NCT01933646|Case fatality rate
1019798|NCT01933646|Serotype distribution
1019799|NCT01933633|Pregnancy
1019800|NCT01933633|Fertility
1019801|NCT01933633|exercise
1019802|NCT01933633|Fertilization in vitro
1019806|NCT01933542|Chlorzoxazone
1019807|NCT01933542|Postoperative pain
1019808|NCT01933542|Spine surgery
1019809|NCT01933542|Opioid consumption
1019810|NCT01933529|diabetes
1019811|NCT01933529|glucose tolerance
1019812|NCT01933529|insulin secretion
1019813|NCT01933529|insulin sensitivity
1019814|NCT01933529|erythropoietin
1019815|NCT01933529|inflammation
1019816|NCT01933529|cytokines
1019817|NCT01933516|GP2013
1019818|NCT01933516|Japanese
1019819|NCT01933516|indolent B-cell non-Hodgkin's lymphoma
1019820|NCT01933516|biosimilar
1019821|NCT01933516|CD20
1019822|NCT01933516|GP13-101
1019823|NCT01933503|MAD
1019824|NCT01933503|SAD
1019825|NCT01933503|Obeticholic Acid (OCA)
1019826|NCT01933490|hyperinsulinemic hypoglycemia
1019827|NCT01933477|Maternal Health
1019828|NCT01933477|Child Health
1019829|NCT01933477|HIV infection
1019830|NCT01933477|Antenatal care
1019831|NCT01933477|Postpartum care
1019832|NCT01933477|Prevention of mother to child transmission (PMTCT)
1019833|NCT01933477|Breast feeding
1019834|NCT01933477|Antiretrovirals
1019835|NCT01933464|Rosacea
1019836|NCT01933464|Cromolyn sodium
1019837|NCT01933451|fluid therapy
1019838|NCT01933451|Intraoperative care
1019839|NCT01933451|Patient Outcome Assessment
1019840|NCT01933451|pulse pressure variation
1019841|NCT01933451|restrictive fluid therapy
1019842|NCT01933451|goal-directed fluid therapy
1019843|NCT01933451|esophagectomy
1019844|NCT01933438|birth related brachial plexus injury
1019845|NCT01933438|brachial plexus
1019846|NCT01933438|splint
1019847|NCT01933425|surgical conditions
1019848|NCT01933425|laparoscopy
1019849|NCT01933412|Dialysis
1019850|NCT01933412|Hepatitis B
1019851|NCT01933399|Low back pain
1019852|NCT01933399|Back brace
1019853|NCT01933399|Lumbar orthoses
1019854|NCT01933399|Lumbosacral orthoses
1019855|NCT01933399|Low back pain treatment
1019856|NCT01933386|Single Sided Deafness
1019857|NCT01933386|SSD
1019858|NCT01933386|Unilateral hearing loss
1019859|NCT01933373|Randomized
1019860|NCT01933373|Toupet
1019861|NCT01933373|Dor
1019862|NCT01933373|Achalasia
1019863|NCT01933360|Misoprostol
1019864|NCT01933360|First trimester pregnancy
1019865|NCT01933360|Surgical abortion
1019866|NCT01933360|Cervical priming
1019867|NCT01933334|pirfenidone
1019868|NCT01933334|SSc-ILD
1019869|NCT01933334|scleroderma
1019870|NCT01933334|systemic sclerosis
1019871|NCT01933334|interstitial lung disease
1019872|NCT01933321|ALS, stem cells
1019873|NCT01933308|Pulmonary Rehabilitation
1019874|NCT01933308|Comparison of exercise training protocol
1019875|NCT01933308|Exercise tolerance
1019876|NCT01933308|Functional and quality of life status
1019877|NCT01933308|Cognitive and psychological status
1019878|NCT01933308|Compliance to exercise recommendations
1019879|NCT01933308|Long term adherence to exercise recommendations
1019880|NCT01933295|treatment
1019881|NCT01933282|MESA, chemotherapy,NK/T cell lymphoma
1019882|NCT01933256|Type 2 Diabetes Mellitus
1019883|NCT01933256|HIP2B
1019884|NCT01933256|Placebo
1019885|NCT01933256|islet β cell
1019886|NCT01933243|Anxiety
1019887|NCT01933243|Anorexia nervosa
1019888|NCT01933243|Adolescents
1019889|NCT01933243|Fish oil
1019890|NCT01933217|TBI
1019891|NCT01933217|traumatic brain injury
1019892|NCT01933217|ADHD
1019893|NCT01933217|methylphenidate
1019894|NCT01933217|Concerta
1019895|NCT01933217|attention problems
1019896|NCT01933204|perimenopause
1019897|NCT01933204|hot flash
1019898|NCT01933204|palpitation
1019899|NCT01933191|Dental Anxiety, Physical Activity, Dental Phobia
1019900|NCT01933191|Cortisol, Amylase
1019901|NCT01933178|Dry eyes
1019902|NCT01933178|Cirrus AS-OCT
1019903|NCT01933178|Excess folds of the conjunctiva
1019904|NCT01933165|Dry Eyes
1019905|NCT01933165|LipiView
1019906|NCT01933165|Lipid thickness
1019907|NCT01933152|wAMD
1019908|NCT01933152|anti-VEGF
1019909|NCT01933139|Informed consent
1019910|NCT01933139|preoperative counseling
1019911|NCT01933139|hysterectomy
1019912|NCT01933113|Obesity
1019913|NCT01933113|Deep Brain Stimulation
1019914|NCT01933113|LHA
1019915|NCT01933100|Functional constipation
1019916|NCT01933100|Brown rice based-meal
1019917|NCT01933100|Polished rice based-meal
1019918|NCT01933100|Wheat based-meal
1019919|NCT01933087|Hand hygiene,
1019920|NCT01933087|Randonmised Controlled Trials,
1019921|NCT01933087|Hospital
1019922|NCT01933074|Urinary Urgency
1019923|NCT01933061|Skin cancer, Melanoma
1019924|NCT01933048|influenza
1019925|NCT01933035|ITP
1019926|NCT01933035|Thrombocytopenia
1019927|NCT01933035|mean platelet mass
1019928|NCT01933035|mean platelet component
1019929|NCT01933022|Exploratory
1019930|NCT01933022|Biomarkers
1019931|NCT01933022|Eligard
1019932|NCT01933022|Metastatic prostate cancer
1019933|NCT01932996|Smoking Cessation
1019934|NCT01932996|Smoking Cessation Products
1019935|NCT01932996|Tobacco Use Cessation Products
1019936|NCT01932983|Neuromuscular blockade
1019937|NCT01932983|TOF test
1019938|NCT01932983|Quantitative TOF method
1019939|NCT01932983|Visual interpretation of TOF
1019940|NCT01932970|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
1019941|NCT01932957|Laparoscopy
1019942|NCT01932957|Ruptured ectopic pregnancy
1019943|NCT01932931|Vitamin D
1019944|NCT01932931|Major depression
1019945|NCT01932931|SSRIs
1019946|NCT01932931|Osteoporosis
1019947|NCT01932918|reactive oxygen species
1019948|NCT01932918|ischemia reperfusion injury
1019949|NCT01932905|deep repetitive transcranial magnetic stimulation
1019950|NCT01932905|chronic pain
1019951|NCT01932905|assessment
1019952|NCT01932905|neuropathic pain
1019953|NCT01932905|central pain
1019954|NCT01932905|treatment
1019955|NCT01932892|transhumeral
1019956|NCT01932866|pre-diabetes
1019957|NCT01932866|diabetes risk score
1019958|NCT01932866|motivation
1019959|NCT01932866|Air Force
1019960|NCT01932866|Military
1019961|NCT01932866|Lifestyle change
1019962|NCT01932840|attitudes and understanding of plant sterol claims
1019963|NCT01932840|general Canadian population
1019964|NCT01932827|Attitudes and understanding of oat fibre claims
1019965|NCT01932827|Food labels
1019966|NCT01932827|General Canadian population
1019967|NCT01932814|Aminoglycosides
1019968|NCT01932814|Acute kidney injury
1019969|NCT01932814|Severe sepsis
1019970|NCT01932814|Critically ill patient
1019971|NCT01932801|harm reduction, naltrexone, alcohol dependence, homelessness
1019972|NCT01932788|pregnancy
1019973|NCT01932788|Vitamin D status
1019974|NCT01932736|middle ear
1019975|NCT01932736|Eustachian tube
1019976|NCT01932736|fMRI
1019977|NCT01932723|Stabilization exercises, Pain, Disability, Menstruation
1019978|NCT01932710|Leukemia
1019979|NCT01932710|Acute myelogenous leukemia
1019980|NCT01932710|AML
1019981|NCT01932710|High-risk myelodysplastic leukemia
1019982|NCT01932710|MDS
1019983|NCT01932710|Infection risk
1019984|NCT01932710|White Blood Cell transfusion
1019985|NCT01932710|Prophylactic therapy
1019986|NCT01932671|Cardiovascular diseases
1019987|NCT01932671|Atherosclerosis
1019988|NCT01932671|Multidetector Computed Tomography
1019989|NCT01932671|Diabetes Mellitus, Type 2
1019990|NCT01932658|autologous
1019991|NCT01932658|Lymphoablation
1019992|NCT01932658|hematopoietic
1019993|NCT01932658|immune system
1019994|NCT01932645|prostatitis
1019995|NCT01932645|pelvic pain
1019996|NCT01932645|urinary symptoms
1019997|NCT01932645|sexual dysfunction
1019998|NCT01932632|Polypharmacy
1019999|NCT01932632|De-prescribing
1020000|NCT01932632|Frailty
1020001|NCT01932593|multiple sclerosis
1020002|NCT01932593|bone marrow
1020003|NCT01932593|stem cell therapy
1020004|NCT01932580|gastric
1020005|NCT01932580|esophageal
1020006|NCT01932580|adenocarcinoma
1020007|NCT01932554|Sickle Cell Pain Crisis
1020008|NCT01932554|Abciximab
1020009|NCT01932554|Integrins
1020010|NCT01932554|Cell Adhesion Molecules
1020017|NCT01932528|Absorption
1020018|NCT01932528|Metabolism
1020019|NCT01932528|Excretion
1020020|NCT01932502|epilepsy
1020021|NCT01932502|Onfi
1020022|NCT01932502|clonazepam
1020023|NCT01932463|Tremor
1020024|NCT01932463|Essential Tremor
1020025|NCT01932463|Medication-refractory Essential Tremor
1020026|NCT01932450|hypertension
1020027|NCT01932450|radiofrequency ablation
1020028|NCT01932450|autosomal dominant polycystic kidney disease
1020029|NCT01932424|Children
1020030|NCT01932398|Alpha
1020031|NCT01932398|Lateralization
1020032|NCT01932398|Attention
1020033|NCT01932398|ADHD
1020034|NCT01932398|Oscillation
1020035|NCT01932385|Sorafenib
1020036|NCT01932385|Hepatocellular carcinoma
1020037|NCT01932385|Best supportive care
1020038|NCT01932385|Survival
1020044|NCT01932359|Scar outcome
1020045|NCT01932359|Mohs surgery
1020046|NCT01932359|face
1020047|NCT01932346|near infra-red spectroscopy, coronary artery bypass grafting
1020048|NCT01932333|Healthy
1020049|NCT01932333|Safety
1020050|NCT01932333|Tolerability
1020051|NCT01932333|Pharmacokinetics
1020052|NCT01932333|Pharmacodynamics
1020053|NCT01932333|JNJ-40411813
1020054|NCT01932333|Positive allosteric modulator
1020055|NCT01932320|Healthy
1020056|NCT01932320|Relative Bioavailability
1020057|NCT01932320|Food effect
1020058|NCT01932320|JNJ-40411813
1020059|NCT01932320|Positive allosteric modulator
1020060|NCT01932320|Solid Dosage Formulation of JNJ-40411813
1020061|NCT01932320|Ketoconazole
1020062|NCT01932307|Surgeon neck health
1020063|NCT01932294|Advanced Heart Failure
1020064|NCT01932294|Refractory Heart Failure
1020065|NCT01932294|Mechanical Circulatory Support Device
1020066|NCT01932294|Ventricular Assist Device
1020067|NCT01932294|Medamacs
1020068|NCT01932281|muscle power
1020069|NCT01932281|muscle fatigue
1020070|NCT01932281|SierraSil
1020071|NCT01932255|microvascular decompression surgery
1020072|NCT01932255|cerebrospinal fluid leakage
1020073|NCT01932255|postoperative complications
1020074|NCT01932229|Advanced NSCLC
1020075|NCT01932229|EGFR mutation
1020076|NCT01932229|TKIs
1020077|NCT01932229|Tyrosine Kinase Inhibitors
1020078|NCT01932216|robotic single-site cholecystectomy
1020079|NCT01932216|laparoscopic cholecystectomy
1020080|NCT01932216|cosmesis
1020081|NCT01932216|quality of life
1020082|NCT01932203|Cerebral small vessel disease
1020083|NCT01932203|Leukoaraiosis
1020084|NCT01932203|Magnetic Resonance Imaging
1020085|NCT01932203|Diffusion Tensor Imaging
1020086|NCT01932190|Acute Kidney Injury
1020087|NCT01932190|Critical Care
1020088|NCT01932190|Renal Replacement Therapy
1020089|NCT01932190|Treatment Outcome
1020090|NCT01932177|Everolimus ; Sorafenib ; Phase 1 trial ; Solid tumor
1020091|NCT01932164|Cleft lip and palate
1020092|NCT01932164|Deciduous dental pulp stem cells
1020093|NCT01932164|mesenchymal stem cells
1020094|NCT01932164|tissue engineering
1020095|NCT01932164|bone tissue engineering
1020096|NCT01932164|bioengineering
1020097|NCT01932151|type-1 HRS
1020098|NCT01932151|active bacterial infections
1020099|NCT01932151|terlipressin and albumin
1020100|NCT01932151|kidney function
1020101|NCT01932138|Community-based intervention
1020102|NCT01932138|Community health workers
1020103|NCT01932138|Antenatal care
1020104|NCT01932138|HIV
1020105|NCT01932138|PMTCT
1020106|NCT01932138|HIV vertical transmission
1020107|NCT01932138|Public-sector health systems
1020108|NCT01932112|Pulmonary Vein Isolation
1020109|NCT01932112|Adenosin effect
1020110|NCT01932112|Atrial fibrillation ablation
1020111|NCT01932099|pathological constriction; restricted outflow, stenosis
1020112|NCT01932086|male
1020113|NCT01932086|Glucose
1020114|NCT01932086|Triglyceride
1020115|NCT01932086|Glycemic index
1020116|NCT01932086|White rice
1020117|NCT01932086|Brown rice
1020118|NCT01932086|Black rice
1020119|NCT01932086|Bread
1020120|NCT01932073|Radiation
1020121|NCT01932073|dermatitis
1020122|NCT01932073|radiodermatitis
1020123|NCT01932073|radiotherapy induced
1020124|NCT01932073|skin reactions
1020125|NCT01932073|low level laser therapy
1020126|NCT01932073|breast cancer
1020127|NCT01932060|Oxytocin
1020128|NCT01932060|blood loss
1020129|NCT01932060|Cesarean delivery
1020130|NCT01932034|Vancomycin
1020131|NCT01932034|Pharmacokinetics
1020132|NCT01932034|Pharmacodynamics
1020133|NCT01932034|Decision support
1020134|NCT01932021|necrotitis angiodermatitis
1020135|NCT01932021|autologous fat transplantation
1020136|NCT01932021|mesenchymal stem cells
1020137|NCT01932008|Coronary artery bypass grafting
1020138|NCT01932008|Chronic kidney disease
1020139|NCT01932008|Body composition
1020140|NCT01932008|Physical activity
1020141|NCT01932008|Physical function
1020142|NCT01931982|diabetes, GLP-1, Victoza, CFR, microvascular dysfunction
1020143|NCT01931969|Vein catheterization; Ultrasound; Landmark; Complication
1020144|NCT01931956|Mitral Valve Insufficiency
1020145|NCT01931956|Mitral Valve Regurgitation
1020146|NCT01931956|Mitral Valve Incompetence
1020147|NCT01931956|Mitral Regurgitation
1020148|NCT01931956|Mitral Insufficiency
1020149|NCT01931956|Mitral Valve
1020150|NCT01931956|MR
1020151|NCT01931956|Mitral Valve Prolapse
1020152|NCT01931956|E2E - Edge to Edge
1020153|NCT01931956|Alfieri Technique
1020154|NCT01931956|MitraClip
1020155|NCT01931956|Functional MR
1020156|NCT01931956|Degenerative MR
1020157|NCT01931956|Echocardiogram
1020158|NCT01931956|CAD - Coronary Artery Disease
1020159|NCT01931956|Heart Failure
1020160|NCT01931956|Heart Attack
1020161|NCT01931956|EVEREST
1020162|NCT01931956|EVEREST I
1020163|NCT01931956|EVEREST II
1020164|NCT01931956|REALISM
1020165|NCT01931930|Gastrointestinal discomfort
1020166|NCT01931930|Perilla frutescens
1020167|NCT01931930|bloating
1020168|NCT01931930|abdominal discomfort
1020169|NCT01931930|human study
1020170|NCT01931930|healthy subjects
1020171|NCT01931917|Prevention
1020172|NCT01931917|Parenting
1020173|NCT01931917|Infants
1020174|NCT01931917|Family programs
1020175|NCT01931917|Early intervention
1020176|NCT01931904|IOP
1020177|NCT01931904|Glaucoma
1020178|NCT01931904|Trabeculectomy
1020179|NCT01931891|preeclampsia, ADAMTS , wharton jelly, extracellüler matrix, placenta
1020180|NCT01931878|Restless Legs Syndrome
1020181|NCT01931878|Leg pain
1020182|NCT01931878|Sleep
1020183|NCT01931878|Dysesthesias
1020184|NCT01931878|incobotulinumtoxin
1020185|NCT01931865|cancer pain, radiation therapy, surgery, incobotulinum toxin
1020186|NCT01931852|Acute Coronary Syndrome
1020187|NCT01931852|Chest pain
1020188|NCT01931852|Cardiac MRI
1020189|NCT01931852|Risk Stratification
1020190|NCT01931852|Emergency Department
1020191|NCT01931852|Elevated Troponin
1020192|NCT01931852|Troponin
1020193|NCT01931852|Non-ST Elevation Myocardial Infarction
1020194|NCT01931826|Schistosomiasis
1020195|NCT01931826|Surgical treatment
1020196|NCT01931826|Endoscopic treatment
1020197|NCT01931774|acne vulgaris cognitive functions
1020198|NCT01931761|Pharmacokinetics, mass balance, AZD6244
1020199|NCT01931735|menisci
1020200|NCT01931735|tibial
1020201|NCT01931722|branched chain amino acid requirement
1020202|NCT01931722|older men
1020203|NCT01931722|strength training
1020204|NCT01931722|sarcopenia
1020205|NCT01931696|Efficacy
1020206|NCT01931696|Acupuncture
1020207|NCT01931696|Asthma
1020208|NCT01931683|LMA removal
1020209|NCT01931683|remifentanil
1020210|NCT01931683|propofol
1020211|NCT01931670|Dysmenorrhea (DYS)
1020212|NCT01931670|Elagolix
1020213|NCT01931670|Gonadotropin-Releasing Hormone Antagonist
1020214|NCT01931670|Non-Menstrual Pelvic Pain (NMPP)
1020215|NCT01931670|Endometriosis Associated Pain
1020216|NCT01931657|LNG-IUS
1020217|NCT01931657|Mirena
1020218|NCT01931657|Contraception
1020219|NCT01931657|Bleeding
1020220|NCT01931657|Hormonal effects in the breast
1020221|NCT01931644|Graft-versus-Host Disease (GVHD)
1020222|NCT01931644|Amyotrophic Lateral Sclerosis (ALS)
1020223|NCT01931644|Cancer
1020224|NCT01931644|Diabetes
1020225|NCT01931644|Melanoma
1020226|NCT01931644|Hepatitis B
1020227|NCT01931644|Lupus
1020228|NCT01931644|Multiple Sclerosis
1020229|NCT01931644|Asthma
1020230|NCT01931644|Crohn's Disease
1020231|NCT01931644|Ulcerative Colitis
1020232|NCT01931644|Kidney Disease
1020233|NCT01931644|Alzheimer's Disease
1020234|NCT01931644|Parkinson's Disease
1020235|NCT01931644|Huntington's Disease
1020236|NCT01931644|Rheumatoid Arthritis
1020237|NCT01931644|Sjogren's Syndrome
1020238|NCT01931644|Leukemia
1020239|NCT01931644|Lymphoma
1020240|NCT01931644|Myeloma
1020241|NCT01931644|CIDP
1020242|NCT01931644|COPD
1020243|NCT01931644|Idiopathic Thrombocytopenia Purpura
1020244|NCT01931644|Cystic Fibrosis
1020245|NCT01931644|Primary Biliary Cirrhosis
1020246|NCT01931631|Diabetes Mellitus, Type 2
1020247|NCT01931631|Diet, Vegetarian
1020248|NCT01931631|Diet, Fat-Restricted
1020249|NCT01931631|Glycemic Index
1020250|NCT01931618|alcohol
1020251|NCT01931618|online intervention
1020252|NCT01931618|hazardous drinking
1020253|NCT01931618|harmful drinking
1020254|NCT01931618|early intervention
1020255|NCT01931618|behavior change intervention
1020256|NCT01931592|ESBL
1020257|NCT01931592|neutropenia
1020258|NCT01931592|eradication
1020259|NCT01931592|bloodstream infection
1020260|NCT01931592|immunosuppression
1020261|NCT01931579|confocal endo-microscopy, lung nodule, respiratory neoplasms
1020262|NCT01931566|Drug therapy
1020263|NCT01931540|Obesity
1020264|NCT01931540|Epigenesis, Genetic
1020265|NCT01931540|Exercise Therapy
1020266|NCT01931527|Obesity
1020267|NCT01931527|Metabolic syndrome
1020268|NCT01931527|Hyperuricemia
1020273|NCT01931449|Pancreatoduodenectomy
1020274|NCT01931449|Digestive Tract Reconstruction
1020275|NCT01931449|Pancreas
1020276|NCT01931436|Menopause, pharmacokinetic
1020277|NCT01931397|Dried blood spots
1020278|NCT01931397|kidney transplant
1020279|NCT01931397|Children
1020280|NCT01931384|Luteal phase support
1020281|NCT01931384|Human chorionic gonadotrophin
1020282|NCT01931384|frozen-thawed embryo transfer cycle
1020283|NCT01931371|fistula in ano
1020284|NCT01931371|anal fistula
1020285|NCT01931371|recurrence
1020286|NCT01931371|costs
1020287|NCT01931345|Rapid HIV testing
1020288|NCT01931345|MSM
1020289|NCT01931345|Motivational Interviewing
1020290|NCT01931345|HIV prevention
1020291|NCT01931345|HIV/AIDS
1020292|NCT01931345|At-risk anal intercourse
1020293|NCT01931345|Randomized trial
1020294|NCT01931332|Arthroplasty
1020295|NCT01931332|Analgesia
1020296|NCT01931319|baclofen withdrawal
1020297|NCT01931319|interruption
1020298|NCT01931319|spasticity
1020299|NCT01931319|pharmacokinetics
1020300|NCT01931319|tolerability
1020301|NCT01931319|intravenous
1020302|NCT01931293|atrophic glossitis, burning mouth syndrome, gastric parietal cell antibody, thyroglobulin antibody, thyroid microsomal antibody, HLA-DR, HLA-DQ
1020303|NCT01931280|Gestational diabetes
1020304|NCT01931241|atherosclerosis
1020305|NCT01931241|atherosclerotic heart disease
1020306|NCT01931241|hypercholesteremia
1020307|NCT01931241|atherosclerotic plaque
1020308|NCT01931241|hyperlipidemia
1020309|NCT01931228|Intensive care unit
1020310|NCT01931228|acute respiratory insufficiency
1020311|NCT01931228|Respiratory failure
1020312|NCT01931228|Mechanical Insufflation-Exsufflation
1020313|NCT01931150|Topical Dapsone 5% Gel
1020314|NCT01931150|Moisturizer
1020315|NCT01931150|rash
1020316|NCT01931150|13-012
1020317|NCT01931124|maximal oxygen uptake, activity levels, elderly
1020318|NCT01931111|physical activity
1020319|NCT01931111|maximal oxygen uptake
1020320|NCT01931098|Brain Tumors
1020321|NCT01931072|Exercise
1020322|NCT01931072|High-intensity interval training
1020323|NCT01931072|Moderate training
1020324|NCT01931072|Healthy elderly
1020325|NCT01931072|Skeletal muscle
1020326|NCT01931072|DNA-methylation
1020327|NCT01931072|Gene expression
1020328|NCT01931072|subjects
1020329|NCT01931059|Imaging
1020330|NCT01931059|Risperidone
1020331|NCT01931059|Placebo
1020332|NCT01931059|antipsychotic
1020333|NCT01931046|prostate cancer
1020334|NCT01931046|adenocarcinoma of the prostate
1020342|NCT01931020|Pain
1020343|NCT01931020|Preterm
1020344|NCT01931020|Neonates
1020345|NCT01931020|24% Sucrose
1020346|NCT01931020|25% Dextrose
1020347|NCT01931007|osteoarthritis
1020348|NCT01930994|LNG: Levonorgestrel
1020349|NCT01930994|MSI: Marie Stopes International
1020350|NCT01930994|MSK: Marie Stopes Kenya
1020351|NCT01930994|PK: Pharmacokinetic
1020352|NCT01930981|quality of life
1020353|NCT01930981|toxicities
1020354|NCT01930981|hematopoietic stem cell transplantation
1020355|NCT01930968|Uveal melanoma, ocular melanoma
1020356|NCT01930955|Non-antibiotic prescribing
1020357|NCT01930955|acute upper respiratory tract infection
1020358|NCT01930955|white cell count
1020359|NCT01930955|vomiting
1020360|NCT01930942|rectal carcinoma
1020361|NCT01930942|preoperative concurrent chemoradiotherapy
1020362|NCT01930929|Bariatric surgery
1020363|NCT01930929|Complications
1020364|NCT01930929|Drugs
1020365|NCT01930916|Prothrombin Time/instrumentation
1020366|NCT01930916|Prothrombin Time/utilization
1020367|NCT01930916|Blood Coagulation Disorders/blood
1020368|NCT01930916|Blood Coagulation Disorders/complications
1020369|NCT01930916|Blood Coagulation Disorders/diagnosis
1020370|NCT01930916|Prospective Studies
1020371|NCT01930916|Adult
1020372|NCT01930916|Reproducibility of Results
1020373|NCT01930916|Point-of-Care Systems/utilization
1020374|NCT01930916|Aged
1020375|NCT01930916|Elderly
1020376|NCT01930903|PRO-Kinetic Energy BMS + Pantera Lux DEB combination
1020377|NCT01930877|quality of recovery
1020378|NCT01930877|spine surgery
1020379|NCT01930877|intravenous lidocaine
1020383|NCT01930851|Bariatric surgery
1020384|NCT01930851|Quality of life
1020385|NCT01930851|Complications
1020386|NCT01930838|Bariatric surgery
1020387|NCT01930838|Complications
1020388|NCT01930838|Osteoporosis
1020389|NCT01930838|Neuropathy
1020390|NCT01930838|Vitamine deficiency
1020391|NCT01930812|18F-NaF PET/CT
1020392|NCT01930812|Bone imaging
1020393|NCT01930773|clopidogrel
1020394|NCT01930773|prasugrel
1020395|NCT01930773|platelet function testing
1020396|NCT01930773|genotyping
1020397|NCT01930773|peri-procedural MI
1020398|NCT01930760|pediatric
1020399|NCT01930760|Childhood Obesity
1020400|NCT01930760|motivational interviewing
1020401|NCT01930760|pediatric primary care physicians
1020402|NCT01930747|pneumoperitoneum
1020403|NCT01930747|laparoscopy
1020404|NCT01930734|Heart Failure
1020405|NCT01930734|Dobutamine
1020406|NCT01930708|BG-12
1020407|NCT01930695|DX functionality
1020408|NCT01930695|Atrial fibrillation
1020409|NCT01930695|CRT-D indication
1020410|NCT01930682|Myocardial Infarction
1020411|NCT01930682|Catheterization
1020412|NCT01930682|Fibrinolysis
1020413|NCT01930669|Heart Rate Variability
1020414|NCT01930669|Multiple Organ Dysfunction Syndrome
1020415|NCT01930669|Critically Ill
1020416|NCT01930656|osteoporisis
1020417|NCT01930656|fracture
1020418|NCT01930656|risk
1020419|NCT01930656|cost effectiveness
1020420|NCT01930656|FRAX
1020421|NCT01930656|mobile device
1020422|NCT01930643|Electric muscle stimulation
1020423|NCT01930643|mechanical ventilation
1020424|NCT01930643|chronic respiratory failure
1020425|NCT01930630|extraesophageal saline injection (ESI);
1020426|NCT01930630|esophageal squamous cell carcinoma (ESCC);
1020427|NCT01930630|esophageal cancer;
1020428|NCT01930630|endoscopic ultrasonography (EUS)
1020429|NCT01930617|surgery
1020430|NCT01930617|trephining
1020431|NCT01930617|drainage
1020432|NCT01930617|therapeutic irrigation
1020433|NCT01930617|subdural space
1020434|NCT01930617|postoperative complications
1020435|NCT01930617|mortality
1020436|NCT01930604|Palmar hyperhidrosis.
1020437|NCT01930604|Plantar hyperhidrosis.
1020438|NCT01930604|Inguinal (groins and buttocks) hyperhidrosis.
1020439|NCT01930604|Craniofacial hyperhidrosis.
1020440|NCT01930604|Truncal hyperhidrosis.
1020441|NCT01930591|fibrinolytic therapy
1020442|NCT01930591|stenting
1020443|NCT01930591|platelet activity
1020444|NCT01930578|bioimpedance analysis
1020445|NCT01930578|spectroscopy
1020446|NCT01930578|electrolyte sodium bromide
1020447|NCT01930578|extracellular water
1020448|NCT01930565|acne
1020449|NCT01930565|therapeutics
1020450|NCT01930565|clinical trial
1020451|NCT01930565|natural compound
1020452|NCT01930565|Lactobacillus fermented Chamaecypris obtuse
1020453|NCT01930565|tea tree oil
1020454|NCT01930526|COPD
1020455|NCT01930526|Exercise
1020456|NCT01930526|Cycling
1020457|NCT01930526|Single leg
1020458|NCT01930526|Pulmonary Rehabilitation
1020459|NCT01930513|Obesity
1020460|NCT01930513|Obstructive Sleep Apnea
1020461|NCT01930513|Exercise
1020462|NCT01930513|Walking tests
1020463|NCT01930513|Cardiopulmonary exercise tests
1020464|NCT01930513|Physical activity
1020465|NCT01930487|Primary open angle glaucoma
1020466|NCT01930487|intraocular pressure
1020467|NCT01930487|ocular perfusion pressure
1020468|NCT01930487|retrobulbar blood flow
1020469|NCT01930487|retinal capillary blood flow
1020470|NCT01930487|choroidal blood flow
1020471|NCT01930474|lung cancer, plasma DNA, free DNA, EGFR, ALK
1020472|NCT01930448|Bariatric
1020473|NCT01930448|Gastric Bypass
1020474|NCT01930448|Gastric Banding,
1020475|NCT01930448|Type 2 Diabetes
1020476|NCT01930448|Incretins
1020477|NCT01930448|GLP-1
1020478|NCT01930448|GIP
1020479|NCT01930448|Insulin secretion
1020480|NCT01930448|insulin sensitivity
1020481|NCT01930435|Quality of Life
1020482|NCT01930422|Direct transcranial electrical stimulation (tDCS)
1020483|NCT01930422|Sham procedure
1020484|NCT01930422|Tobacco consumption
1020485|NCT01930422|Craving
1020486|NCT01930409|Femoral Fractures
1020487|NCT01930409|Hip Fractures
1020488|NCT01930409|Frail older adults
1020489|NCT01930409|Quality of Life
1020490|NCT01930409|Feasibility Studies
1020491|NCT01930396|Hemodialysis
1020492|NCT01930396|Anticoagulation
1020493|NCT01930396|Tinzaparin
1020494|NCT01930396|Unfractionated Heparin
1020495|NCT01930396|Randomized Controlled Trial
1020496|NCT01930383|biomarkers
1020497|NCT01930370|pediatrics
1020498|NCT01930370|phosphate and postassium revmoval
1020499|NCT01930370|dialysate bicarbonate modeling
1020500|NCT01930357|Rabies
1020627|NCT01929538|Chronic pancreatitis
1020501|NCT01930357|Purified Vero Rabies Vaccine - Serum Free (VRVg)
1020502|NCT01930357|Imovax® rabies
1020503|NCT01930357|Human Diploid Cell Vaccine
1020504|NCT01930344|stereopsis
1020505|NCT01930344|3D laparoscopy
1020506|NCT01930344|OCHRA
1020507|NCT01930331|Uncomplicated Plasmodium falciparum Malaria
1020508|NCT01930305|Heating transfusion
1020509|NCT01930279|T cell markers
1020510|NCT01930227|hypotension
1020511|NCT01930227|spinal anesthesia
1020512|NCT01930227|cesarean
1020513|NCT01930175|Pemphigus vulgaris
1020514|NCT01930175|pemphigus
1020515|NCT01930175|blistering disease
1020516|NCT01930162|single umbilical cord blood transplantation, non-myeloablative conditioning
1020517|NCT01930149|Cholesterol screening
1020518|NCT01930149|High cholesterol
1020519|NCT01930149|Cardiovascular disease
1020520|NCT01930149|Statin treatment
1020521|NCT01930136|Calorie restriction
1020522|NCT01930136|Type 2 diabetes
1020523|NCT01930136|Obesity
1020524|NCT01930136|Diabetic nephropathy prevention
1020525|NCT01930123|Fructose
1020526|NCT01930123|NASH
1020527|NCT01930123|advanced fibrosis
1020528|NCT01930123|biomarker
1020529|NCT01930123|magnetic resonance
1020530|NCT01930110|Type 1 diabetes
1020531|NCT01930110|Hypoglycemia
1020532|NCT01930110|Insulin
1020533|NCT01930110|Glucagon
1020534|NCT01930110|Closed-loop system
1020535|NCT01930110|Artificial pancreas
1020536|NCT01930097|Type 1 diabetes
1020537|NCT01930097|Hypoglycemia
1020538|NCT01930097|Insulin
1020539|NCT01930097|Glucagon
1020540|NCT01930097|Closed-loop system
1020541|NCT01930097|Artificial pancreas
1020542|NCT01930097|Carbohydrate counting
1020543|NCT01930084|HIV
1020544|NCT01930084|linkage
1020545|NCT01930084|retention
1020546|NCT01930032|Clostridium difficile infection
1020547|NCT01930019|etomidate,
1020548|NCT01930019|thiopental,
1020549|NCT01930019|serum cortisol concentration,
1020550|NCT01930006|c-Met
1020551|NCT01930006|VEGFR
1020552|NCT01930006|Ron
1020553|NCT01930006|Cancer
1020554|NCT01930006|Tumor
1020555|NCT01930006|Safety
1020556|NCT01930006|Phase 1
1020557|NCT01929993|Conization
1020558|NCT01929993|Cervical Intraepithelial Neoplasia
1020559|NCT01929993|Cervix Dysplasia
1020560|NCT01929993|Therapy
1020561|NCT01929993|Electrosurgery
1020562|NCT01929980|HSCT
1020563|NCT01929980|cytopenia
1020564|NCT01929980|immune suppression
1020565|NCT01929980|proteasome inhibitor
1020566|NCT01929967|Heterotaxy syndrome
1020567|NCT01929967|Asplenia
1020568|NCT01929967|Polysplenia
1020569|NCT01929889|schizophrenia
1020570|NCT01929889|schizoaffective disorder
1020571|NCT01929889|iloperidone
1020572|NCT01929889|Fanapt
1020573|NCT01929889|social cognition
1020574|NCT01929889|cognition
1020575|NCT01929863|Metformin
1020576|NCT01929863|Diabetes
1020577|NCT01929837|Tinnitus
1020578|NCT01929837|Transcranial magnetic stimulation
1020579|NCT01929824|dysphagia, trouble swallowing, chest pain
1020580|NCT01929798|artificial pancreas
1020581|NCT01929785|post tranplant heart allograft
1020582|NCT01929759|HIV
1020583|NCT01929759|neurocognitive symptoms
1020584|NCT01929759|efavirenz
1020585|NCT01929759|elvitegravir
1020586|NCT01929759|neurometabolites
1020587|NCT01929733|Patent Ductus Arteriosus
1020588|NCT01929720|cancer
1020589|NCT01929720|cancer survivors
1020590|NCT01929720|worry
1020591|NCT01929720|insomnia
1020592|NCT01929720|symptoms
1020593|NCT01929720|fatigue
1020594|NCT01929720|depression
1020595|NCT01929720|anxiety
1020596|NCT01929681|Low Field Magnetic Stimulation
1020597|NCT01929681|bipolar
1020598|NCT01929681|depression
1020599|NCT01929681|alternative treatment
1020600|NCT01929668|ulcerative colitis
1020601|NCT01929668|bowel preparation
1020602|NCT01929655|Phase II
1020603|NCT01929655|symptomatic castration-resistant prostate cancer
1020604|NCT01929655|bone metastases
1020605|NCT01929642|Tuberous Sclerosis Complex (TSC)
1020606|NCT01929642|self-injury
1020607|NCT01929642|Autism
1020608|NCT01929629|Phase 1
1020609|NCT01929629|Healthy Volunteers
1020610|NCT01929629|First Time in Man
1020611|NCT01929629|Pharmacokinetics
1020612|NCT01929616|adenocarcinoma, colorectal,regorafenib
1020613|NCT01929603|oncology, cancer, tumour, anticancer drug, pharmacokinetics, olaparib, rifampicin, neoplasm, CYP P450 inducer
1020614|NCT01929590|Colonoscopy
1020615|NCT01929590|Preparation
1020616|NCT01929590|Polyp
1020617|NCT01929590|Polyethylene glycol
1020618|NCT01929577|ASP015K
1020619|NCT01929577|healthy subjects
1020620|NCT01929564|cardiovascular disease
1020621|NCT01929564|risk factor
1020622|NCT01929564|broccoli
1020623|NCT01929564|GST
1020624|NCT01929564|blood pressure
1020625|NCT01929564|Total cholesterol
1020626|NCT01929551|glycemic index
1020628|NCT01929538|Biliary stricture
1020629|NCT01929538|Endoscopic treatment
1020630|NCT01929538|cSEMS
1020631|NCT01929499|Colon cancer
1020632|NCT01929499|Cytokine-induced killer cells
1020633|NCT01929499|Adjuvant immunotherapy
1020634|NCT01929499|Adjuvant chemotherapy
1020635|NCT01929473|Pertussis infection
1020636|NCT01929473|Risk factors
1020637|NCT01929447|sleep disorders
1020638|NCT01929447|sleep apnea
1020639|NCT01929447|ambulatory device
1020640|NCT01929447|WatchPAT
1020641|NCT01929434|cerebral palsy
1020642|NCT01929434|cell transplantation
1020643|NCT01929434|rehabilitation
1020644|NCT01929421|colorectal cancer
1020645|NCT01929421|gemcitabine
1020646|NCT01929421|S-1
1020647|NCT01929395|Breast Cancer
1020648|NCT01929395|Breast Conserving Surgery
1020649|NCT01929395|Breast diagnostics
1020650|NCT01929395|Breast imaging
1020651|NCT01929382|dose titration
1020652|NCT01929382|FLS
1020653|NCT01929382|flu like symptoms
1020654|NCT01929382|Actimmune
1020655|NCT01929369|ESRD
1020656|NCT01929369|CKD
1020657|NCT01929369|AV GRAFTS
1020658|NCT01929369|THROMBOSED AV GRAFTS
1020659|NCT01929356|lung function tests
1020660|NCT01929356|chest physiotherapy
1020661|NCT01929343|cocaine
1020662|NCT01929343|addiction
1020663|NCT01929343|lidocaine
1020664|NCT01929343|memory
1020665|NCT01929343|drug abuse
1020666|NCT01929330|Bioequivalence
1020667|NCT01929330|Healthy Male Volunteers
1020668|NCT01929330|Androgenetic Alopecia
1020669|NCT01929330|Dutasteride
1020670|NCT01929330|Safety
1020671|NCT01929330|Tolerability
1020672|NCT01929317|Ropinirole
1020673|NCT01929317|Parkinson's disease
1020674|NCT01929291|Korea
1020675|NCT01929291|Post-marketing surveillance
1020676|NCT01929291|Boostrix
1020677|NCT01929291|Prescribing information
1020678|NCT01929291|Safety
1020679|NCT01929265|INFL
1020680|NCT01929265|Indolent non-follicular
1020681|NCT01929265|untreated INFL
1020682|NCT01929252|dexmedetomidine
1020683|NCT01929252|wound infiltration
1020684|NCT01929252|postoperative analgesia
1020685|NCT01929187|Onychomycosis, BioEqual carrier system, amorolfine.
1020686|NCT01929174|Congenital heart disease
1020687|NCT01929174|Myocardial fibrosis
1020688|NCT01929174|Diastolic dysfunction
1020689|NCT01929161|positive emotions
1020690|NCT01929161|meditation
1020691|NCT01929161|oxytocin
1020692|NCT01929148|risk-reducing salpingectomy
1020693|NCT01929148|prophylactic bilateral salpingectomy
1020694|NCT01929148|ovarian cancer prevention
1020695|NCT01929148|ovarian reserve
1020696|NCT01929135|Periodontal Disease
1020697|NCT01929135|Chronic Periodontitis
1020698|NCT01929135|Atorvastatin
1020699|NCT01929135|Statins
1020700|NCT01929135|Hydroxymethylglutaryl-coenzyme A Reductase Inhibitors
1020701|NCT01929135|Dentifrice
1020702|NCT01929122|Prevention & control
1020703|NCT01929122|Diet
1020704|NCT01929122|Functional food
1020705|NCT01929122|Nutrition Assessment
1020706|NCT01929122|Oryza sativa
1020707|NCT01929122|Rice Bran
1020708|NCT01929122|Phaseolus vulgaris L.
1020709|NCT01929122|Legumes
1020710|NCT01929122|Microbiome
1020711|NCT01929122|Metabolomics
1020712|NCT01929122|Prebiotics
1020713|NCT01929083|Torsades de pointes
1020714|NCT01929083|Progesterone
1020715|NCT01929083|Clinical trial
1020716|NCT01929083|Risk reduction
1020717|NCT01929083|Electrocardiography
1020718|NCT01929070|HCP1007
1020719|NCT01929070|Rosuvastatin
1020720|NCT01929070|Omega-3
1020721|NCT01929018|Amputation
1020722|NCT01929018|Rehabilitation
1020723|NCT01929018|Exercise
1020724|NCT01929018|Movement
1020725|NCT01929005|Comprehensive care
1020726|NCT01929005|Medicare
1020727|NCT01929005|Cost-sharing
1020728|NCT01929005|Quality of care
1020729|NCT01928992|Mammography
1020730|NCT01928992|3D
1020731|NCT01928992|Breast Cancer Detection
1020732|NCT01928979|LA/LAA Thrombus
1020733|NCT01928979|Atrial Fibrillation
1020734|NCT01928979|Observation
1020735|NCT01928966|dietary fat
1020736|NCT01928966|fat intake
1020737|NCT01928966|blood pressure
1020738|NCT01928966|women
1020739|NCT01928966|phytoestrogen
1020740|NCT01928966|pumpkin seeds
1020741|NCT01928966|cardiovascular disease
1020742|NCT01928966|heart disease
1020743|NCT01928966|secoisolariciresinol
1020744|NCT01928966|monounsaturated fat
1020745|NCT01928966|polyunsaturated fat
1020746|NCT01928966|feeding study
1020747|NCT01928953|opioid induced constipation in patients without cancer and with cancer
1020748|NCT01928940|Advanced solid tumors
1020749|NCT01928940|BRAF
1020750|NCT01928940|Melanoma
1020751|NCT01928888|Acute heartburn episodes
1020752|NCT01928849|Amputation
1020753|NCT01928849|Post-amputation Pain
1020754|NCT01928849|Neuropathic pain
1020755|NCT01928849|Valproic Acid
1020756|NCT01928849|Anesthesia, Conduction
1020757|NCT01928849|Neuralgia, stump
1020758|NCT01928836|Carcinoma, Non-Small-Cell Lung
1020759|NCT01928836|Small Cell Lung Carcinoma
1020760|NCT01928836|Biological Markers
1020761|NCT01928836|ROC Curve
1020762|NCT01928836|Delayed Diagnosis
1020763|NCT01928823|agoraphobia
1020764|NCT01928823|panic disorder
1020765|NCT01928823|D-Cycloserine
1020766|NCT01928823|DCS
1020767|NCT01928823|exposure
1020768|NCT01928823|cognitive behavioral therapy
1020769|NCT01928823|CBT
1020770|NCT01928823|augmentation
1020771|NCT01928810|Panic Disorder
1020772|NCT01928810|Agoraphobia
1020773|NCT01928810|Physical Activity
1020774|NCT01928797|cardiac output pregnancy spinal anesthesia
1020775|NCT01928784|Low back pain
1020776|NCT01928784|extracorporeal shock wave therapy
1020777|NCT01928784|Trigger Points
1020778|NCT01928771|Asthma,
1020779|NCT01928771|Bronchial Diseases,
1020780|NCT01928771|Respiratory Tract Diseases,
1020781|NCT01928771|Lung Diseases,
1020782|NCT01928771|Obstructive Lung Diseases
1020783|NCT01928758|Smoking
1020784|NCT01928758|Nicotine
1020785|NCT01928745|Stewart approach
1020786|NCT01928745|sepsis
1020787|NCT01928745|SIRS
1020788|NCT01928745|cardiothoracic surgery
1020789|NCT01928745|CABG
1020790|NCT01928719|Smoking
1020791|NCT01928719|Nicotine
1020792|NCT01928706|edentulism
1020793|NCT01928706|denture liner
1020794|NCT01928706|prosthodontics
1020795|NCT01928706|OHIP EDENT
1020796|NCT01928693|infectious corneal ulcers
1020797|NCT01928680|Triple Negative Breast Cancer, Cisplatin, Capecitabine
1020798|NCT01928654|Edema
1020799|NCT01928654|Diabetic
1020800|NCT01928654|Laser
1020801|NCT01928654|Treatment
1020802|NCT01928602|Crossover
1020803|NCT01928602|Chronic stroke
1020804|NCT01928602|Stroke
1020805|NCT01928602|Rehabilitation
1020806|NCT01928602|Language Therapy
1020807|NCT01928602|Aphasia
1020808|NCT01928602|Aphasia Therapy
1020809|NCT01928602|Computerised Therapy
1020810|NCT01928602|Computerised Rehabilitation
1020811|NCT01928602|Tablet
1020812|NCT01928602|Apps
1020813|NCT01928602|Aphasia Rehabilitation
1020814|NCT01928602|Rehabilitation on Portable Tablets
1020815|NCT01928589|Cyclophosphamide
1020816|NCT01928589|Doxorubicin
1020817|NCT01928589|Docetaxel
1020818|NCT01928589|Carboplatin
1020819|NCT01928589|Herceptin
1020820|NCT01928589|Partial Breast Irradiation
1020821|NCT01928589|Concurrent Chemotherapy
1020822|NCT01928550|Diabetes
1020823|NCT01928550|OCT
1020824|NCT01928550|PDR
1020825|NCT01928537|International Working Group
1020826|NCT01928537|azacitidine
1020827|NCT01928537|decitabine
1020828|NCT01928524|Gastric cancer
1020829|NCT01928524|Cancer of the esophagus
1020830|NCT01928524|Oxaliplatin
1020831|NCT01928524|Docetaxel
1020832|NCT01928524|S1
1020833|NCT01928511|Hepatitis B virus
1020834|NCT01928511|HBeAg positive
1020835|NCT01928511|HBeAg negative
1020836|NCT01928511|antiviral therapy
1020837|NCT01928511|nucleoside analogues
1020838|NCT01928498|arteriovenous fistulae
1020839|NCT01928498|arteriovenous graft
1020840|NCT01928498|restenosis
1020841|NCT01928498|angioplasty
1020842|NCT01928498|drug eluting balloon
1020843|NCT01928472|Influenza, H7N9, Vaccine
1020844|NCT01928459|BGJ398
1020845|NCT01928459|BYL719
1020846|NCT01928459|advanced solid tumor
1020847|NCT01928459|metastatic breast cancer
1020848|NCT01928459|PK3CA
1020849|NCT01928459|FGFR
1020850|NCT01928459|fibroblast growth factor receptor
1020851|NCT01928446|Lithium
1020852|NCT01928446|Placebos
1020853|NCT01928446|Double-blind methods
1020854|NCT01928446|Clinical Trials, Randomized
1020855|NCT01928446|Veterans
1020856|NCT01928433|Urinary Tract Infection
1020857|NCT01928433|Pyelonephritis
1020858|NCT01928420|Alzheimer Disease
1020859|NCT01928420|Alzheimer Type Senile Dementia
1020860|NCT01928420|Alzheimer's Disease
1020861|NCT01928420|clinical trial
1020862|NCT01928420|dementia
1020863|NCT01928420|diabetes
1020864|NCT01928420|dietary supplements
1020865|NCT01928420|Senile Dementia, Alzheimer
1020866|NCT01928420|Therapeutics
1020867|NCT01928420|Brain Diseases
1020868|NCT01928420|Central Nervous System Diseases
1020869|NCT01928420|Nervous System Diseases
1020870|NCT01928420|Neurodegenerative Diseases
1020871|NCT01928420|Delirium, Dementia, Amnestic, Cognitive
1020872|NCT01928420|Disorders
1020873|NCT01928420|Mental Disorders
1020874|NCT01928407|naives, CD4 < 200 cell/mm3, Atazanavir, Darunavir
1020875|NCT01928368|Mild asthma
1020876|NCT01928368|Atopic asthma
1020877|NCT01928368|Healthy volunteers
1020878|NCT01928368|First-in-human
1020879|NCT01928316|Healthy
1020880|NCT01928316|Bioequivalence
1020881|NCT01928316|Mizolastine
1020882|NCT01928316|Domestic
1020883|NCT01928316|Imported
1020884|NCT01928303|opioids
1020885|NCT01928303|chronic pain
1020886|NCT01928303|oxycodone
1020887|NCT01928303|oxymorphone
1020888|NCT01928303|patients using opioid pain medication
1020889|NCT01928277|Symptom assessment agreement
1020890|NCT01928277|Work of breathing
1020891|NCT01928264|Mental disorders
1020892|NCT01928264|Physical activity
1020893|NCT01928264|Disability pension
1020894|NCT01928264|Disability pension due to mental illness
1020895|NCT01928264|Ability to work
1020896|NCT01928264|Mental toughness
1020897|NCT01928238|NIV
1020898|NCT01928238|NAVA
1020899|NCT01928238|noninvasive neurally adjusted ventilatory
1020900|NCT01928238|noninvasive pressure support ventilation
1020901|NCT01928225|HSIL
1020902|NCT01928225|CIN
1020903|NCT01928225|HPV
1020904|NCT01928225|HPV vaccination
1020905|NCT01928225|gardasil
1020906|NCT01928225|HIV
1020907|NCT01928225|cervical dysplasia
1020908|NCT01928225|LEEP
1020909|NCT01928225|cervical cancer
1020910|NCT01928212|retinal nerve fiber layer thickness
1020911|NCT01928212|optical coherence tomography
1020912|NCT01928212|Parkinson disease
1020913|NCT01928199|diabetes
1020914|NCT01928199|transplant
1020915|NCT01928199|kidney
1020916|NCT01928173|Sleep Initiation and Maintenance Disorders
1020917|NCT01928173|Cognitive Therapy
1020918|NCT01928160|Non-small cell lung cancer, EGFR mutation, erlotinib acquired resistance
1020919|NCT01928147|NS5B polymerase inhibitor
1020920|NCT01928147|Phase 1
1020921|NCT01928147|Genotype 1
1020922|NCT01928134|Vitamin K2
1020923|NCT01928134|Vitamin D3
1020924|NCT01928134|Bioavailability of calcium
1020925|NCT01928134|volunteers
1020926|NCT01928134|Men
1020927|NCT01928134|non-pregnant women
1020928|NCT01928134|twenty years of age
1020929|NCT01928121|nurse
1020930|NCT01928121|expert program
1020931|NCT01928121|primary care
1020932|NCT01928121|implementation
1020933|NCT01928121|interdisciplinary
1020934|NCT01928121|effectiveness
1020935|NCT01928121|disease management system
1020936|NCT01928095|atherosclerosis
1020937|NCT01928095|carotid endartherectomy
1020938|NCT01928082|Hypercalciuria, Familial Idiopathic
1020939|NCT01928082|Hypercalciuria
1020940|NCT01928082|Osteopenia
1020941|NCT01928082|Osteoporosis
1020942|NCT01928082|Postmenopausal women
1020943|NCT01928004|edentulous
1020944|NCT01928004|complete denture
1020945|NCT01927991|tinnitus
1020946|NCT01927991|cognitive behavioural therapy
1020947|NCT01927991|internet treatment
1020948|NCT01927978|Esophageal cancer
1020949|NCT01927978|18F-FDG PET
1020950|NCT01927978|staging
1020951|NCT01927978|therapy planning
1020952|NCT01927978|therapy response monitoring
1020953|NCT01927978|prognosis
1020954|NCT01927965|gastrointestinal tract
1020955|NCT01927965|GI tract
1020956|NCT01927965|advanced gastrointestinal tumors
1020957|NCT01927965|gastrointestinal tumors
1020958|NCT01927965|GI tumors
1020959|NCT01927965|biliary
1020960|NCT01927965|gallbladder,
1020961|NCT01927965|colorectal,
1020962|NCT01927965|gastric,
1020963|NCT01927965|hepatocellular
1020964|NCT01927965|esophageal
1020965|NCT01927965|pancreatic
1020966|NCT01927952|hammertoe
1020967|NCT01927939|Breast cancer; bone metastases; 18F-FDG PET; 99mTc bone scintigraphy; therapy response monitoring; prognosis
1020968|NCT01927926|Energy intake
1020969|NCT01927926|appetite
1020970|NCT01927926|satiety
1020971|NCT01927926|gut hormones
1020972|NCT01927900|Human milk oligosaccharides
1020973|NCT01927900|Microbiota
1020974|NCT01927900|Prebiotics
1020975|NCT01927887|Papillary Carcinoma of Thyroid
1020976|NCT01927887|Follicular thyroid cancer lymph node metastasis
1020977|NCT01927887|Metastatic medullary thyroid cancer
1020978|NCT01927874|infiltration
1020979|NCT01927874|hemorrhoidectomy
1020980|NCT01927874|Postoperative pain
1020981|NCT01927822|termination of pregnancy, abortion
1020982|NCT01927809|Hereditary Diseases
1020983|NCT01927809|Colon
1020984|NCT01927783|Cardiovascular Disease
1020985|NCT01927783|Obesity
1020986|NCT01927770|Whole Genome Sequencing
1020987|NCT01927770|Informed Choice
1020988|NCT01927757|rheumatoid arthritis
1020989|NCT01927757|etanercept
1020990|NCT01927757|arthritis
1020991|NCT01927757|adalimumab failure to respond
1020992|NCT01927757|loss of response to adalimumab
1020993|NCT01927757|ACR20
1020994|NCT01927757|methotrexate
1020995|NCT01927757|Swollen joints
1020996|NCT01927757|tender joints
1020997|NCT01927744|Head and Neck Cancer
1020998|NCT01927744|Squamous cell carcinoma of the head and neck
1020999|NCT01927744|SCCHN
1021000|NCT01927744|Oral cavity squamous cell carcinomas
1021001|NCT01927744|Docetaxel
1021002|NCT01927744|Taxotere
1021003|NCT01927744|Erlotinib
1021004|NCT01927744|Erlotinib Hydrochloride
1021005|NCT01927744|OSI-774
1021006|NCT01927744|CP358774
1021007|NCT01927744|Tarceva
1021008|NCT01927744|Questionnaire
1021009|NCT01927744|Survey
1021010|NCT01927744|Phone call
1021018|NCT01927718|Blood And Marrow Transplantation
1021019|NCT01927718|Myeloma
1021020|NCT01927718|Multiple myeloma
1021021|NCT01927718|MM
1021022|NCT01927718|Autologous stem cell transplantation
1021023|NCT01927718|ASCT
1021024|NCT01927718|Thalidomide
1021025|NCT01927718|Thalomid
1021026|NCT01927718|Lenalidomide
1021027|NCT01927718|CC-5013
1021028|NCT01927718|Revlimid
1021029|NCT01927718|Questionnaires
1021030|NCT01927718|Surveys
1021031|NCT01927705|Atopic dermatitis
1021032|NCT01927705|Stem cell
1021033|NCT01927705|Cell therapy
1021034|NCT01927705|skin disease
1021035|NCT01927705|furestem
1021036|NCT01927705|AD
1021037|NCT01927705|hUCB-MSC
1021038|NCT01927705|UCB-MSC
1021039|NCT01927705|Umbilical cord Blood
1021040|NCT01927692|MG
1021041|NCT01927666|glucoraphanin
1021042|NCT01927666|broccoli
1021043|NCT01927666|gut microbiota
1021044|NCT01927653|Amnestic mild cognitive impairment
1021045|NCT01927653|Dysexecutive mild cognitive impairment
1021046|NCT01927653|Diffusion MRI
1021047|NCT01927640|Cocaine
1021048|NCT01927640|Dexmedetomidine
1021049|NCT01927640|Myocardial Contrast Echocardiography
1021050|NCT01927627|Prostate cancer
1021051|NCT01927627|adenocarcinoma of the prostate
1021052|NCT01927627|Enzalutamide
1021053|NCT01927614|Cardiac Allograft Vasculopathy
1021054|NCT01927614|Cardiac MRI
1021055|NCT01927614|Cardiac CT
1021056|NCT01927614|Observational study
1021057|NCT01927601|TAVR
1021058|NCT01927601|aortic disease
1021059|NCT01927588|Certican
1021060|NCT01927588|Renal Transplant
1021061|NCT01927588|Cytomegalovirus Infection
1021062|NCT01927575|TOMOSYNTHESIS
1021063|NCT01927549|cardiogenic shock
1021064|NCT01927549|infarction
1021065|NCT01927549|multivessel coronary artery disease
1021066|NCT01927549|angioplasty
1021067|NCT01927523|Youth violence
1021068|NCT01927523|Crime
1021069|NCT01927523|Educational achievement
1021070|NCT01927510|Early mobilization, rehabilitation, intensive care
1021071|NCT01927497|Rectal cancer
1021072|NCT01927497|Extralevator abdominoperineal resection
1021073|NCT01927497|Biological Mesh
1021074|NCT01927497|Primary closure
1021075|NCT01927484|methotrexate,
1021076|NCT01927484|osteoarthritis,
1021077|NCT01927484|pain,
1021078|NCT01927484|function,
1021079|NCT01927484|synovitis
1021080|NCT01927471|Menstrual cycles
1021081|NCT01927471|Ultrasound
1021082|NCT01927471|Ovary
1021083|NCT01927471|Polycystic Ovary Syndrome (PCOS)
1021084|NCT01927471|Physical activity
1021085|NCT01927471|Diet
1021086|NCT01927432|Polycystic Ovary Syndrome (PCOS)
1021087|NCT01927432|Nutrition
1021088|NCT01927432|Metabolism
1021089|NCT01927432|Antral follicle growth
1021090|NCT01927432|Menstrual Cyclicity
1021091|NCT01927406|Thyroid Eye Disease
1021092|NCT01927406|Graves' Disease
1021093|NCT01927406|Prostaglandin Analogues
1021094|NCT01927380|autonomic nervous system modulation
1021095|NCT01927380|heart rate variability
1021096|NCT01927380|prostatectomy
1021097|NCT01927380|steep trendelenburg
1021098|NCT01927380|pneumoperitoneum
1021099|NCT01927367|Clinical Decision Support System
1021100|NCT01927367|Primary Health Care
1021101|NCT01927367|Clinical Practice Guidelines
1021102|NCT01927354|Head-and-Neck squamous cell carcinoma (HNSCC)
1021103|NCT01927354|epithelial-mesenchymal transition (EMT)
1021104|NCT01927354|microRNA29
1021105|NCT01927354|Twist1
1021106|NCT01927341|MEK162,
1021107|NCT01927341|panitumumab,
1021108|NCT01927341|mutant RAS,
1021109|NCT01927341|wild-type RAS,
1021110|NCT01927341|metastatic colorectal cancer,
1021111|NCT01927341|adult mCRC patient
1021112|NCT01927328|Adenocarcinoma
1021113|NCT01927328|Anemia
1021114|NCT01927328|Palliative therapy
1021115|NCT01927328|Palliative care
1021116|NCT01927328|Palliative treatments
1021117|NCT01927328|Chemotherapy
1021118|NCT01927328|Esophageal Cancer
1021119|NCT01927328|Gastric Cancer
1021120|NCT01927315|Stem cells
1021121|NCT01927315|Regeneration
1021122|NCT01927315|Angiogenesis
1021123|NCT01927315|Prevention
1021124|NCT01927302|Aphasia
1021125|NCT01927302|Dysgraphia
1021126|NCT01927302|Anomia
1021127|NCT01927302|Agrammatism
1021128|NCT01927302|Stroke
1021129|NCT01927302|Language Recovery
1021130|NCT01927302|Treatment
1021131|NCT01927302|Biomarkers of Recovery
1021132|NCT01927289|Ultrasound
1021133|NCT01927289|supraclavicular block
1021134|NCT01927289|distal forearm block
1021135|NCT01927289|Grip Strength
1021136|NCT01927289|Satisfaction
1021137|NCT01927276|Schizophrenia
1021138|NCT01927276|Gluten
1021139|NCT01927250|cohort study
1021140|NCT01927250|diet program
1021141|NCT01927250|art therapy
1021142|NCT01927250|laying-on-of-hands
1021143|NCT01927250|quality of life
1021144|NCT01927237|pulmonary artery pressure
1021145|NCT01927237|ARDS
1021146|NCT01927237|alveolar hypoventilation
1021147|NCT01927237|hypercapnic acidosis
1021148|NCT01927237|permissive hypercapnia
1021149|NCT01927237|myocardial strain
1021150|NCT01927211|cesarean section incisions
1021151|NCT01927211|silver
1021152|NCT01927211|C-section
1021153|NCT01927211|wound infection
1021154|NCT01927211|scar appearance
1021155|NCT01927211|pain
1021156|NCT01927185|central venous access
1021157|NCT01927185|ultrasonography
1021158|NCT01927185|subclavian vein
1021159|NCT01927185|pneumothorax
1021160|NCT01927185|vessel view
1021161|NCT01927159|Tuberculosis
1021162|NCT01927159|TB
1021163|NCT01927159|Pulmonary
1021164|NCT01927159|Vaccine
1021165|NCT01927159|Adjuvant
1021166|NCT01927146|Lauren classification
1021167|NCT01927146|HER2 status
1021168|NCT01927146|Resectable gastric cancer
1021169|NCT01927133|Fibrosis, HBV, HCV, ALD, NAFLD
1021170|NCT01927120|GVHD
1021171|NCT01927120|Allogeneic
1021172|NCT01927120|Hematopoietic Cell Transplant
1021173|NCT01927107|probiotics
1021174|NCT01927107|obesity
1021175|NCT01927107|oxidative stress
1021176|NCT01927094|probiotics, diarrhea
1021177|NCT01927055|NOH
1021178|NCT01927055|OH
1021179|NCT01927055|PD
1021180|NCT01927055|MSA
1021181|NCT01927055|PAF
1021182|NCT01927055|DBH
1021183|NCT01927042|Eating Disorders
1021184|NCT01927042|Carers
1021185|NCT01927029|twin pregnancy
1021186|NCT01927029|progesterone
1021187|NCT01927029|preterm delivery
1021188|NCT01927029|>14 years
1021189|NCT01927029|Abscense of cerclage,
1021190|NCT01927029|TTTS, hemorrage,
1021191|NCT01927029|history of thrombosis.
1021192|NCT01927029|cervix >15mm
1021193|NCT01927016|Esophageal Neoplasm
1021194|NCT01927016|Esophagus
1021195|NCT01927016|Surgery
1021196|NCT01927016|Outcome assessment
1021197|NCT01927003|defect,
1021198|NCT01927003|dorsal branch of the digital artery,
1021199|NCT01927003|dorsal digital flap,
1021200|NCT01927003|dorsal metacarpal artery flap.
1021201|NCT01926964|Adjuvant treatment recommendation
1021202|NCT01926964|Early breast cancer
1021203|NCT01926964|Oncotype DX
1021204|NCT01926964|Genetic profiling
1021205|NCT01926951|hypertension
1021206|NCT01926925|Type 2 diabetes, Endothelium, children/adolescents
1021207|NCT01926912|Schizophrenia
1021208|NCT01926912|Paliperidone Palmitate
1021209|NCT01926912|Hospital setting
1021210|NCT01926912|Schizophrenic Disorders
1021211|NCT01926860|Prevenar13
1021212|NCT01926860|pneumococcal conjugate vaccine
1021213|NCT01926860|Epaxal
1021214|NCT01926860|hepatitis A vaccine
1021215|NCT01926847|Digital ischemia
1021216|NCT01926847|Raynaud's phenomenon
1021217|NCT01926834|promoting angiogenesis in multiple targets
1021218|NCT01926834|herbal medicine
1021219|NCT01926834|traditional chinese medicine
1021220|NCT01926834|random clinical trial
1021221|NCT01926795|toddler's fracture
1021222|NCT01926795|tibial fracture
1021223|NCT01926795|children
1021224|NCT01926769|Colorectal cancer
1021225|NCT01926769|Metformin
1021226|NCT01926769|FOLFOX6
1021227|NCT01926769|FOFIRI
1021228|NCT01926769|5FU
1021229|NCT01926769|irinotecan
1021230|NCT01926769|oxaliplatin
1021231|NCT01926756|bacteriuria
1021232|NCT01926756|straight catheterization
1021233|NCT01926756|urinary tract infections
1021234|NCT01926756|iatrogenic
1021235|NCT01926743|near infrared
1021236|NCT01926743|fluorescence imaging
1021237|NCT01926743|indocyanine green
1021238|NCT01926743|gastrectomy
1021239|NCT01926717|Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy
1021240|NCT01926691|dementia
1021241|NCT01926691|poststroke cognitive impairment
1021242|NCT01926691|inflammation
1021243|NCT01926691|stress
1021244|NCT01926678|swedish massage
1021245|NCT01926678|fatigue
1021246|NCT01926678|light touch
1021247|NCT01926678|inflammation
1021248|NCT01926665|Blood And Marrow Transplantation
1021249|NCT01926665|Mantle cell lymphoma
1021250|NCT01926665|MCL
1021251|NCT01926665|T-cell lymphoma
1021252|NCT01926665|TCL
1021253|NCT01926665|Diffuse large b-cell lymphoma
1021254|NCT01926665|DLBCL
1021255|NCT01926665|Autologous stem cell transplantation
1021256|NCT01926665|ASCT
1021257|NCT01926665|Carfilzomib
1021258|NCT01926665|CFZ
1021259|NCT01926665|Dexamethasone
1021260|NCT01926665|Decadron
1021261|NCT01926639|Follicular lymphoma
1021262|NCT01926639|Rituximab
1021263|NCT01926639|Autologous dendritic cells
1021264|NCT01926639|Cancer vaccine
1021265|NCT01926626|Nicotine addiction
1021266|NCT01926626|Smoking Cessation
1021267|NCT01926626|Quit Smoking
1021268|NCT01926626|moclobemide
1021269|NCT01926626|Nicotine Patch
1021270|NCT01926613|Schizophrenia
1021271|NCT01926613|Chronic Mental Disorder
1021272|NCT01926613|Employment
1021273|NCT01926613|Cognitive remediation
1021274|NCT01926613|Vocational rehabilitation
1021275|NCT01926600|gastric ulcer
1021276|NCT01926600|duodenal ulcer
1021277|NCT01926600|re-bleeding rate
1021278|NCT01926600|intragastric pH
1021279|NCT01926600|proton pump inhibitor
1021280|NCT01926587|rigosertib
1021281|NCT01926587|ON 01910.Na
1021282|NCT01926587|azacitidine
1021283|NCT01926587|Vidaza
1021284|NCT01926574|absenteeism
1021285|NCT01926574|rehabilitation
1021286|NCT01926574|return to work
1021287|NCT01926561|Hypotensive bradycardic event
1021288|NCT01926561|Interscalene brachial plexus block
1021289|NCT01926561|Sitting position
1021290|NCT01926561|Shoulder arthroscopic surgery
1021291|NCT01926548|Pharmacokinetics
1021292|NCT01926548|Safety
1021293|NCT01926535|amniotic membrane
1021294|NCT01926535|contact lens
1021295|NCT01926535|bullous keratopathy
1021296|NCT01926522|Exercise Therapy
1021297|NCT01926483|Stage IIIA-N2 NSCLC
1021298|NCT01926470|epidural injections, intravascular injection
1021299|NCT01926457|First trimester treatment of prediabetes
1021300|NCT01926457|First trimester treatment of gestational diabetes
1021301|NCT01926457|Umbilical cord C-Peptide
1021302|NCT01926457|Neonatal fat mass
1021303|NCT01926457|Gestational weight gain
1021304|NCT01926457|Infant obesity
1021305|NCT01926444|colonoscopy
1021306|NCT01926444|sedation-free
1021307|NCT01926444|colorectal cancer
1021308|NCT01926444|CRC screening
1021309|NCT01926444|prevention
1021310|NCT01926444|analgesia
1021311|NCT01926444|colonic
1021312|NCT01926444|kappa
1021313|NCT01926444|opioid agonist
1021314|NCT01926444|pain management
1021315|NCT01926444|oral
1021316|NCT01926444|hydrogen sulfide
1021317|NCT01926444|peripheral
1021318|NCT01926418|HIV
1021319|NCT01926418|Condoms
1021320|NCT01926418|Men who have sex with men
1021321|NCT01926418|implementation intentions
1021322|NCT01926418|executive function
1021323|NCT01926405|hypersomnia
1021324|NCT01926405|narcolepsy
1021325|NCT01926405|amylase
1021326|NCT01926405|salivary sampling
1021327|NCT01926379|Ethiopia
1021328|NCT01926379|TB
1021329|NCT01926379|tuberculosis
1021330|NCT01926379|HIV
1021331|NCT01926379|IPT
1021332|NCT01926379|isoniazid
1021333|NCT01926379|adherence
1021334|NCT01926379|combination intervention package
1021335|NCT01926379|retention
1021336|NCT01926353|Vesicoureteral Reflux (VUR)
1021337|NCT01926353|Complicated Urinary Tract Infection
1021338|NCT01926353|Vantris
1021339|NCT01926353|Polyacrylate Polyalcohol Copolymer
1021340|NCT01926327|PRP PRGF Osteoarthritis
1021341|NCT01926301|sepsis
1021342|NCT01926301|cerebrovascular autoregulation
1021343|NCT01926301|delirium
1021344|NCT01926275|COPD
1021345|NCT01926275|Noninvasive Positive Pressure Ventilation
1021346|NCT01926275|Respiratory Muscle Training
1021347|NCT01926262|Pain, Neck, Exercise, Pilots, Crewmembers,
1021348|NCT01926249|Alzheimer's disease
1021349|NCT01926249|Mild Cognitive Impairment
1021350|NCT01926210|Poor ovarian response
1021351|NCT01926210|in vitro fertilization
1021352|NCT01926210|mild ovarian stimulation
1021353|NCT01926210|controlled ovarian stimulation
1021354|NCT01926184|HIV/AIDS
1021355|NCT01926184|Treatment as Prevention
1021356|NCT01926184|Methamphetamine
1021357|NCT01926184|Cocaine
1021358|NCT01926184|HIV viral Load
1021359|NCT01926158|Denosumab
1021360|NCT01926158|Osteoporosis
1021361|NCT01926158|Hip replacement
1021362|NCT01926158|Osteoarthritis
1021363|NCT01926158|Radiostereometric analysis (RSA)
1021364|NCT01926158|Dual energy X-ray absorptiometry (DXA)
1021365|NCT01926132|ascorbic acid
1021366|NCT01926132|fatigue
1021367|NCT01926132|mitochondrial DNA
1021368|NCT01926132|patient for more than 6 months
1021369|NCT01926106|Nasal Intermittent Positive-Pressure Ventilation
1021370|NCT01926106|Nasal Continuous Positive Airway Pressure
1021371|NCT01926106|twin
1021372|NCT01926106|respiratory distress syndrome
1021373|NCT01926093|Acute Respiratory Distress Syndrome (ARDS)
1021374|NCT01926080|Depression
1021375|NCT01926080|Spirituality
1021376|NCT01926080|Neonatal death
1021377|NCT01926080|Bereavement
1021378|NCT01926080|Randomized controlled trial
1021379|NCT01926067|Accelerometer
1021380|NCT01926067|Cardiopulmonary by pass
1021381|NCT01926041|community
1021382|NCT01926041|preventive medicine
1021383|NCT01926041|prediabetes
1021384|NCT01926041|smoking cessation
1021385|NCT01926028|recurrent vulvovaginal candidiasis
1021386|NCT01926028|candida
1021387|NCT01926028|NDV3
1021388|NCT01926028|vaginal thrush
1021389|NCT01926028|chronic yeast infection
1021390|NCT01925976|obesity
1021391|NCT01925976|dietetic intervention
1021392|NCT01925976|eating behaviors
1021393|NCT01925976|children
1021394|NCT01925976|healthy eating
1021395|NCT01925976|energy dense foods
1021396|NCT01925963|Normal
1021397|NCT01925963|Traumatic brain injury
1021398|NCT01925963|Neuroimaging
1021399|NCT01925963|Hyperbaric oxygen
1021400|NCT01925963|Neurobehavioral symptom inventory
1021401|NCT01925950|BDP
1021402|NCT01925950|orBec
1021403|NCT01925950|GVHD
1021404|NCT01925950|beclomethasone dipropionate
1021405|NCT01925950|bone marrow transplant
1021406|NCT01925950|hematopoietic cell transplant
1021407|NCT01925950|HCT
1021408|NCT01925950|stem cell transplant
1021409|NCT01925950|marrow transplant
1021410|NCT01925950|SCT
1021411|NCT01925950|beclomethasone 17,21-dipropionate
1021412|NCT01925937|Coenzyme Q10
1021413|NCT01925937|Atorvastatin
1021414|NCT01925937|clinical trial
1021415|NCT01925937|congestive heart failure
1021416|NCT01925924|Dental cements
1021417|NCT01925924|Orthodontic adhesives
1021418|NCT01925924|Glass ionomer cement
1021419|NCT01925924|Tooth demineralization
1021420|NCT01925911|Phase 1
1021421|NCT01925911|Healthy subjects
1021422|NCT01925911|DDI
1021423|NCT01925911|CYP3A
1021424|NCT01925898|Laceration
1021425|NCT01925898|Sedation
1021426|NCT01925898|Pediatrics
1021427|NCT01925885|Atrial Arrhythmia
1021428|NCT01925872|ischemic cerebrovascular disease
1021429|NCT01925872|Percutaneous transluminal angioplasty and stenting
1021430|NCT01925872|Clopidogrel resistance
1021431|NCT01925859|Pharmacokinetic analysis
1021432|NCT01925859|EryDex
1021433|NCT01925846|Pseudomonas aeruginosa
1021434|NCT01925846|type three secretory system
1021435|NCT01925846|contact lens associated microbial keratitis
1021436|NCT01925820|Hepatitis B,Entecavir,Pegylated IFN
1021437|NCT01925807|Adolescent
1021438|NCT01925807|Suicidal Ideation
1021439|NCT01925807|Emergency Department
1021440|NCT01925807|Crisis
1021441|NCT01925807|Attachment
1021442|NCT01925807|Coping
1021443|NCT01925794|Stent, Coronary Arteries for Early healing
1021444|NCT01925781|Smoking Cessation
1021445|NCT01925781|Nicotine Addiction
1021446|NCT01925781|e-Cigarette
1021447|NCT01925781|electronic nicotine delivery device
1021448|NCT01925781|electronic cigarette
1021449|NCT01925781|nicotine replacement therapy
1021450|NCT01925768|Apremilast, Psoriatic Arthritis, PDE4 inhibitor
1021451|NCT01925755|Non-interventional
1021452|NCT01925755|Rivaroxaban
1021453|NCT01925755|Prevention in prior stroke or TIA
1021454|NCT01925755|Russian Federation
1021455|NCT01925742|Fetal aneuploidy
1021456|NCT01925729|middle ear
1021457|NCT01925729|allergy
1021458|NCT01925729|nose
1021459|NCT01925716|cholesterol,LDL
1021460|NCT01925716|vegetable oils
1021461|NCT01925716|heart diseases
1021462|NCT01925690|Multiple Sclerosis
1021463|NCT01925690|Disease modifying medication
1021464|NCT01925690|Relapsing-Remitting MS
1021465|NCT01925690|Motivational Interviewing
1021466|NCT01925690|Telephone Counseling
1021467|NCT01925677|Transplant
1021468|NCT01925677|donor
1021469|NCT01925677|nephrectomy
1021470|NCT01925677|robotic
1021471|NCT01925677|laparoscopy
1021472|NCT01925677|single-port
1021473|NCT01925664|Doulas
1021474|NCT01925664|Parenting
1021475|NCT01925664|Breastfeeding
1021476|NCT01925664|Pregnancy in Adolescence
1021477|NCT01925651|Post Mastectomy Radiotherapy
1021478|NCT01925651|Breast Cancer
1021479|NCT01925651|Bolus
1021480|NCT01925651|Radiodermatitis
1021481|NCT01925638|Healthy Volunteers
1021482|NCT01925638|Refametinib
1021483|NCT01925638|Ketoconazole
1021484|NCT01925638|Pharmacokinetics
1021485|NCT01925612|Antibodies, Monoclonal
1021486|NCT01925612|Antibody-Drug Conjugate
1021487|NCT01925612|Antigens, CD30
1021488|NCT01925612|Drug Therapy
1021489|NCT01925612|Hematologic Diseases
1021490|NCT01925612|Lymphoma, B-cell
1021491|NCT01925612|Lymphoma, Large B-cell, Diffuse
1021492|NCT01925612|Monomethyl auristatin E
1021493|NCT01925599|Nevus
1021494|NCT01925599|Choroidal Melanoma
1021495|NCT01925599|BAP1 mutation
1021496|NCT01925573|RECURRENT GLIOBLASTOMA
1021497|NCT01925573|Brain Tumor
1021498|NCT01925534|Optiflow
1021499|NCT01925534|Humidified high-flow oxygen therapy
1021500|NCT01925534|Noninvasive ventilation
1021501|NCT01925534|Acute respiratory failure
1021502|NCT01925534|Standard oxygen therapy
1021503|NCT01925521|Intestinal Infection
1021504|NCT01925495|otitis media
1021505|NCT01925495|middle ear
1021506|NCT01925495|feedback pathways
1021507|NCT01925495|middle-ear pressure
1021508|NCT01925482|middle ear
1021509|NCT01925482|otitis
1021510|NCT01925482|gas exchange
1021511|NCT01925469|Hysterosalpingogram
1021512|NCT01925469|HSG
1021513|NCT01925469|Pain relief
1021514|NCT01925469|Analgesia
1021515|NCT01925469|Benzocaine
1021516|NCT01925456|urge urinary incontinence
1021517|NCT01925443|diabetes mellitus non-insulin-dependent
1021518|NCT01925443|low level laser therapy
1021519|NCT01925430|Observational
1021520|NCT01925430|Sleep
1021521|NCT01925430|Algorithm
1021522|NCT01925417|Clostridium difficile
1021523|NCT01925417|C diff
1021524|NCT01925417|Microbiota Restoration Therapy
1021525|NCT01925417|MRT
1021526|NCT01925417|microbiota suspension
1021527|NCT01925417|CDI
1021528|NCT01925417|CDAD
1021529|NCT01925417|Fecal transplant
1021530|NCT01925417|Fecal Microbiota Transplant
1021531|NCT01925417|FMT
1021532|NCT01925417|Diarrhea
1021533|NCT01925417|Fecal bacteriotherapy
1021534|NCT01925404|Physical activity
1021535|NCT01925404|parks
1021536|NCT01925404|programming
1021537|NCT01925404|public health
1021538|NCT01925391|Pediatric glaucoma
1021539|NCT01925391|Intraocular pressure
1021540|NCT01925391|pediatric glaucoma diagnosis
1021541|NCT01925391|Volatiles and intraocular pressure
1021542|NCT01925391|nitrous oxide
1021543|NCT01925391|Tetracaine
1021544|NCT01925378|Cervical Dysplasia
1021545|NCT01925352|ischemic heart disease
1021546|NCT01925352|adenovirus
1021547|NCT01925352|hepatocyte growth factor
1021548|NCT01925313|Safety
1021549|NCT01925313|Pharmacokinetics
1021550|NCT01925300|Pharmacokinetics
1021551|NCT01925300|Pharmacodynamics
1021552|NCT01925300|Safety
1021553|NCT01925300|Tolerability
1021554|NCT01925287|bioavailability
1021555|NCT01925287|curcumin
1021556|NCT01925287|curcuma longa
1021557|NCT01925287|healthy humans
1021558|NCT01925287|safety
1021559|NCT01925287|sex differences
1021560|NCT01925274|metastatic colorectal cancer
1021561|NCT01925274|colorectal cancer
1021562|NCT01925274|KRAS
1021563|NCT01925274|colon cancer
1021564|NCT01925274|mCRC
1021565|NCT01925274|CRC
1021566|NCT01925274|PF-05212384
1021567|NCT01925274|KRAS wild type colorectal cancer
1021568|NCT01925274|irinotecan
1021569|NCT01925274|cetuximab
1021570|NCT01925274|NRAS
1021571|NCT01925261|knee osteoarthritis
1021572|NCT01925261|bilateral
1021573|NCT01925261|osteoarthritis
1021574|NCT01925248|Whey protein
1021575|NCT01925248|protein supplement
1021576|NCT01925248|Diabetes
1021577|NCT01925248|Type 2 DM
1021578|NCT01925248|Hyperglycemia
1021579|NCT01925248|Insulin secretagogue
1021580|NCT01925235|remote ischemic preconditioning
1021581|NCT01925235|acute kidney injury
1021582|NCT01925235|TAVI
1021583|NCT01925235|RenPRO trial
1021584|NCT01925235|parameters
1021585|NCT01925209|sporadic inclusion body myositis,
1021586|NCT01925209|myositis,
1021587|NCT01925209|muscle wasting,
1021588|NCT01925209|controlled clinical trial,
1021589|NCT01925209|randomized,
1021590|NCT01925209|body mass,
1021591|NCT01925209|muscle function,
1021592|NCT01925209|strength,
1021593|NCT01925209|performance,
1021594|NCT01925209|physical function
1021595|NCT01925196|Motor Neuron Disease
1021596|NCT01925196|Frontotemporal Dementia
1021597|NCT01925196|Cognitive Testing
1021598|NCT01925196|Magnetic Resonance Imaging (MRI)
1021740|NCT01924598|Capacity
1021599|NCT01925196|Transcranial Magnetic Stimulation (TMS)
1021600|NCT01925183|Boceprevir
1021601|NCT01925183|HIV/HCV-coinfection
1021602|NCT01925183|HIV/HCV coinfection
1021603|NCT01925183|HIV/HCV
1021604|NCT01925183|Response-guided therapy
1021605|NCT01925170|Dense breast tissue
1021606|NCT01925170|Breast Cancer Screening
1021607|NCT01925170|Molecular Breast Imaging
1021608|NCT01925170|Breast Cancer
1021609|NCT01925170|Breast
1021610|NCT01925105|Polypharmacy
1021611|NCT01925092|Cushing's disease
1021612|NCT01925092|Mifepristone
1021613|NCT01925092|Cushing's syndrome
1021614|NCT01925092|Pharmacokinetic-pharmacodynamic
1021615|NCT01925092|Child/pediatric population
1021616|NCT01925092|Safety-efficacy
1021617|NCT01925079|acute coronary syndrome
1021618|NCT01925079|statins
1021619|NCT01925079|LDL-C
1021620|NCT01925079|intensive education
1021621|NCT01925027|Nano+ DES
1021622|NCT01925027|OCT
1021623|NCT01925027|Neointimal hyperplasia
1021624|NCT01925027|DAPT
1021625|NCT01925027|3 month
1021626|NCT01925014|Appendectomy
1021627|NCT01925014|Appendicitis
1021628|NCT01925014|False Positive Reactions
1021629|NCT01925014|Humans
1021630|NCT01925014|Radiation Dosage
1021631|NCT01925014|Tomography, X-Ray Computed
1021632|NCT01925014|Young Adult
1021633|NCT01925001|Sickle cell anemia
1021634|NCT01925001|Sickle cell disease
1021635|NCT01925001|Sickling crisis
1021636|NCT01925001|Vaso-occlusive crisis
1021637|NCT01925001|Carboxyhemoglobin
1021638|NCT01925001|Oxygen therapeutic
1021639|NCT01925001|Ischemic rescue therapy
1021640|NCT01925001|Hemoglobin solution
1021641|NCT01925001|Pegylated hemoglobin
1021642|NCT01924988|BPH, benign prostatic hyperplasia
1021643|NCT01924962|chronic occlusion of coronary artery
1021644|NCT01924962|left ventricular function
1021645|NCT01924962|revascularisation
1021646|NCT01924949|7977
1021647|NCT01924949|5885
1021648|NCT01924949|GS-7977
1021649|NCT01924949|GS-5885
1021650|NCT01924949|SOF
1021651|NCT01924949|LDV
1021652|NCT01924949|Sofosbuvir
1021653|NCT01924949|Ledipasvir
1021654|NCT01924949|FDC
1021655|NCT01924923|uveal melanoma
1021656|NCT01924923|biopsy
1021657|NCT01924923|enucleation
1021658|NCT01924923|ocular cancer
1021659|NCT01924910|Healthy, by self report
1021660|NCT01924897|CPET test
1021661|NCT01924897|Exercise training
1021662|NCT01924897|Prehabilitation
1021663|NCT01924897|Exercise Test
1021664|NCT01924884|Vacuum-Assisted Closure
1021665|NCT01924884|Topical Negative-Pressure Therapy
1021666|NCT01924884|Negative-Pressure Dressings
1021667|NCT01924858|PET, healthy subjects
1021668|NCT01924858|Lp-PLA2
1021669|NCT01924858|positron emission tomography
1021670|NCT01924858|Alzheimer's disease
1021671|NCT01924858|brain exposure
1021672|NCT01924858|GSK2647544
1021673|NCT01924819|Gastric cancer
1021674|NCT01924819|Stomach cancer
1021675|NCT01924819|Chemoradiotherapy
1021676|NCT01924819|Surgery
1021677|NCT01924819|Chemotherapy
1021678|NCT01924819|Neoadjuvant
1021679|NCT01924806|debridement
1021680|NCT01924806|post-debridement
1021681|NCT01924806|infection
1021682|NCT01924806|prevention
1021683|NCT01924806|wound
1021684|NCT01924806|wound tissue
1021685|NCT01924806|wound management
1021686|NCT01924806|WoundWand
1021687|NCT01924806|wound size reduction
1021688|NCT01924806|wound bed debridement
1021689|NCT01924806|WoundWand Debridement Device
1021690|NCT01924806|chronic wound
1021691|NCT01924806|delayed healing
1021692|NCT01924806|cellular senescence
1021693|NCT01924806|acute wound
1021694|NCT01924806|diabetic foot ulcer
1021695|NCT01924806|venous leg ulcers
1021696|NCT01924806|radiofrequency debridement
1021697|NCT01924806|necrotic tissue
1021698|NCT01924806|wound healing
1021699|NCT01924806|skin
1021700|NCT01924780|Dose-Response Relationship, Immunologic
1021701|NCT01924754|HPV
1021702|NCT01924754|Gardasil
1021703|NCT01924754|seroconversion
1021704|NCT01924741|Liver neoplasms
1021705|NCT01924741|Liver regeneration
1021706|NCT01924715|somatoform disorder
1021707|NCT01924715|psychotherapy
1021708|NCT01924715|depression
1021709|NCT01924715|anxiety
1021710|NCT01924715|personality disorder
1021725|NCT01924676|food effect
1021726|NCT01924676|pharmacokinetics
1021727|NCT01924676|bioavailability
1021728|NCT01924676|oxycodone
1021729|NCT01924676|management of moderate to severe pain
1021730|NCT01924663|Heart Failure
1021731|NCT01924663|Acute Kidney Injury
1021732|NCT01924663|Myocardial Dysfunction
1021733|NCT01924663|Pediatric Critical Care
1021734|NCT01924663|Pediatric Intensive Care Units
1021735|NCT01924663|Respiratory Virus
1021736|NCT01924611|Dental caries
1021737|NCT01924611|Atraumatic Restorative Technique
1021738|NCT01924598|Anorexia Nervosa
1021739|NCT01924598|Treatment Development
1021741|NCT01924598|Neuroimaging
1021742|NCT01924598|Magnetoencephalography
1021743|NCT01924598|functional MRI
1021744|NCT01924598|Reward processing
1021745|NCT01924598|Habit formation
1021746|NCT01924585|Colorectal
1021747|NCT01924585|Surgery
1021748|NCT01924585|Frailty
1021749|NCT01924585|Elderly
1021750|NCT01924585|Quality of Life
1021751|NCT01924572|umbilical cord clamping
1021752|NCT01924572|Placental residual blood volume
1021753|NCT01924572|hematocrit
1021754|NCT01924572|hemoglobin
1021755|NCT01924572|bilirubin
1021756|NCT01924559|Airway
1021757|NCT01924546|cognition
1021758|NCT01924546|hydration
1021759|NCT01924546|schoolchildren
1021760|NCT01924520|Antipsychotic
1021761|NCT01924520|FK949E
1021762|NCT01924520|Quetiapine
1021763|NCT01924507|Sleep medicine
1021764|NCT01924507|Sleep apnea
1021891|NCT01923948|Postoperative Pain
1021765|NCT01924507|Acute myocardial infarction
1021766|NCT01924507|Heart failure
1021767|NCT01924507|CPAP
1021768|NCT01924494|telemedicine, tele-endoscopy
1021769|NCT01924481|Caffeine
1021770|NCT01924481|Flavonoids
1021771|NCT01924481|MRI
1021772|NCT01924481|Brain blood flow
1021773|NCT01924481|Cognition
1021774|NCT01924481|Perfusion
1021775|NCT01924481|Resting functional magnetic resonance imaging (fMRI)
1021776|NCT01924468|Cognitive Control
1021777|NCT01924468|fMRI
1021778|NCT01924468|Genetics
1021779|NCT01924468|Dopamine
1021780|NCT01924455|HIV
1021781|NCT01924455|HBV
1021782|NCT01924442|Coronary Artery Disease
1021783|NCT01924442|Off-Pump
1021784|NCT01924442|Myocardial Ischemia
1021785|NCT01924442|Heart Disease
1021786|NCT01924429|Attention Deficit Hyperactivity Disorder
1021787|NCT01924429|ADHD
1021788|NCT01924429|fMRI
1021789|NCT01924429|Imaging
1021790|NCT01924429|Vyvanse
1021791|NCT01924429|Stimulant Medication
1021792|NCT01924429|Treatment
1021793|NCT01924429|Clinical Trial
1021794|NCT01924429|Adult
1021795|NCT01924403|TKA
1021796|NCT01924403|Wound Closure
1021797|NCT01924403|Wound Perfusion
1021798|NCT01924390|Tooth extraction
1021799|NCT01924377|AF
1021800|NCT01924364|Craniomaxillofacial (CMF) Battle-injured (BI)
1021801|NCT01924364|Facial Trauma
1021802|NCT01924364|Fat Grafts
1021803|NCT01924364|Autogenous Fat Transfers (AFT)
1021804|NCT01924364|Wounded warriors
1021805|NCT01924351|Breast Cancer with Brain Metastasis
1021806|NCT01924351|HER2-positive
1021807|NCT01924351|HER-2 therapy
1021808|NCT01924338|Patient
1021809|NCT01924338|localisation
1021810|NCT01924338|in cranial
1021811|NCT01924338|radiation
1021812|NCT01924338|therapy
1021813|NCT01924338|thickness of
1021814|NCT01924325|apixaban
1021815|NCT01924325|clopidogrel
1021816|NCT01924325|aspirin
1021817|NCT01924325|new oral anticoagulant
1021818|NCT01924325|TIA
1021819|NCT01924325|acute minor ischemic stroke
1021820|NCT01924312|stroke, dementia, hypertension, diabetes, hyperlipidemia, smoking, obesity
1021821|NCT01924286|HIV
1021822|NCT01924286|Tuberculosis
1021823|NCT01924286|Immune reconstitution inflammatory syndrome
1021824|NCT01924286|Highly active antiretroviral therapy
1021825|NCT01924286|Glucocorticoids
1021826|NCT01924286|Prednisone
1021827|NCT01924286|Preventive therapy
1021828|NCT01924273|Port Wine Stain Birthmarks
1021829|NCT01924234|Remifentanil
1021830|NCT01924234|Pharyngeal dysfunction
1021831|NCT01924234|Subjective swallowing difficulties
1021832|NCT01924234|Pulmonary aspiration
1021833|NCT01924208|Timothy
1021834|NCT01924208|Influenza
1021835|NCT01924208|Interferon
1021836|NCT01924208|T cell
1021837|NCT01924208|Tonsil
1021838|NCT01924195|lung
1021839|NCT01924195|Anlotinib
1021840|NCT01924195|AL3818
1021841|NCT01924195|NSCLC
1021842|NCT01924195|Cancer
1021843|NCT01924182|chronic pain
1021844|NCT01924182|inadequate pain relief
1021845|NCT01924182|intolerable side effects
1021846|NCT01924169|Hematologic Disorder
1021847|NCT01924169|Chronic Lymphocytic Leukemia
1021848|NCT01924169|CLL
1021849|NCT01924169|Hypogammaglobulinemia
1021850|NCT01924169|Impaired Response to Vaccinations
1021851|NCT01924169|Immunoglobulins
1021852|NCT01924169|Immune system's function
1021853|NCT01924169|Lenalidomide
1021854|NCT01924169|CC-5013
1021855|NCT01924169|Revlimid
1021856|NCT01924169|Flu vaccine
1021857|NCT01924169|TIV
1021858|NCT01924169|Pneumonia vaccine
1021859|NCT01924143|ADHD
1021860|NCT01924143|Fibromyalgia
1021861|NCT01924117|cervical intraepithelial neoplasia, HPV, Cancer
1021862|NCT01924104|IVF failure, implantation rate, heparin & aspirin
1021863|NCT01924078|breast cancer
1021864|NCT01924078|metronomic chemotherapy
1021865|NCT01924078|aromatase inhibitors
1021866|NCT01924065|Atrial fibrillation, conversion, stroke
1021867|NCT01924039|Psychosis
1021868|NCT01924039|Substance Use
1021869|NCT01924039|Motivational Enhancement Therapy
1021870|NCT01924026|Phenylketonuria
1021871|NCT01924026|Mild Hyperphenylalaninemia
1021872|NCT01924026|PKU
1021873|NCT01924026|MHP
1021874|NCT01924013|Pregnancy
1021875|NCT01924013|Infant Growth
1021876|NCT01924013|Vitamin D
1021877|NCT01924013|Bangladesh
1021878|NCT01923987|Short course radiotherapy
1021879|NCT01923987|Modified FOLFOX6
1021880|NCT01923987|Delayed surgery
1021881|NCT01923987|Rectal cancer
1021882|NCT01923987|Synchronous metastasis
1021883|NCT01923987|Liver metastasis
1021884|NCT01923987|Lung metastasis
1021885|NCT01923961|Maintenance hemodialysis or hemodiafiltration
1021886|NCT01923961|>18 years
1021887|NCT01923961|Stable condition
1021888|NCT01923948|Hepatocellular carcinoma
1021889|NCT01923948|Hepatectomy
1021890|NCT01923948|randomized controlled trials(RCTs)
1021892|NCT01923935|Multiple myeloma, busulfan, melphalan,transplantation
1021893|NCT01923922|glioblastoma multiforme
1021894|NCT01923922|CT Perfusion
1021895|NCT01923922|Survival
1021896|NCT01923909|Knee
1021897|NCT01923909|Osteoarthritis
1021898|NCT01923909|Bahrain
1021899|NCT01923909|PRP
1021900|NCT01923909|Steroid
1021901|NCT01923909|WOMAC
1021902|NCT01923909|Oxford Knee Score
1021903|NCT01923909|Platelet-rich plasma
1021904|NCT01923896|food refusal
1021905|NCT01923896|behavioral intervention
1021906|NCT01923896|D-cycloserine
1021907|NCT01923844|Newborn
1021908|NCT01923844|perfusion index
1021909|NCT01923844|pulsatility index
1021910|NCT01923844|respiratory distress syndrome
1021911|NCT01923844|surfactant
1021912|NCT01923844|transcutaneous carbon monoxide
1021913|NCT01923831|Magnesium, Post operative sore throat, Prone position, Tracheal intubation
1021914|NCT01923818|rivaroxaban
1021915|NCT01923818|aspirin
1021916|NCT01923818|new oral anticoagulant
1021917|NCT01923818|TIA
1021918|NCT01923818|acute minor ischemic stroke
1021919|NCT01923792|House Dust Mite Allergy
1021920|NCT01923792|Rhinoconjunctivitis
1021921|NCT01923792|Environmental Exposure Unit
1021922|NCT01923792|Immunotherapy
1021923|NCT01923792|ToleroMune HDM
1021924|NCT01923779|Grass allergy
1021925|NCT01923779|Rhinoconjunctivitis
1021926|NCT01923779|Environmental Exposure Unit
1021927|NCT01923779|Immunotherapy
1021928|NCT01923779|ToleroMune Grass
1021929|NCT01923766|Transplantation
1021930|NCT01923753|Cystic Fibrosis
1021931|NCT01923753|Neural respiratory drive
1021932|NCT01923753|Airway clearance technique
1021933|NCT01923753|Expectoration
1021934|NCT01923753|Positive expiratory pressure device
1021935|NCT01923740|Absorb™ BVS
1021936|NCT01923740|Angioplasty
1021937|NCT01923740|Bioabsorbable
1021938|NCT01923740|BVS
1021939|NCT01923740|Bioresorbable
1021940|NCT01923740|Coronary Artery Disease
1021941|NCT01923740|Coronary Artery Endothelial Responsiveness
1021942|NCT01923740|Coronary artery restenosis
1021943|NCT01923740|Coronary artery stenosis
1021944|NCT01923740|Coronary scaffold
1021945|NCT01923740|Coronary Stent
1021946|NCT01923740|Drug eluting stents
1021947|NCT01923740|Everolimus
1021948|NCT01923740|Myocardial ischemia
1021949|NCT01923740|Stent thrombosis
1021950|NCT01923740|Stents
1021951|NCT01923727|[89Zr]Df-IAB2M
1021952|NCT01923727|Prostate
1021953|NCT01923727|PET Scan
1021954|NCT01923714|Glaucoma
1021955|NCT01923701|At Risk Mental State
1021956|NCT01923701|Attenuated Psychosis Syndrome
1021957|NCT01923701|Prodrom
1021958|NCT01923701|Paranoia
1021959|NCT01923701|Psychosis
1021960|NCT01923701|Cognitive Behavioral Therapy
1021961|NCT01923701|Group
1021962|NCT01923701|Family
1021963|NCT01923701|ARMS
1021964|NCT01923688|Prediction Prevention Severe Hypoglycemia RealTime Alert
1021965|NCT01923675|myopia
1021966|NCT01923675|nearsightedness
1021967|NCT01923675|axial elongation of the eye
1021968|NCT01923675|refractive error
1021969|NCT01923662|Paraplegia
1021970|NCT01923662|Tetraplegia
1021971|NCT01923662|Spinal Cord Injury
1021972|NCT01923662|FES
1021973|NCT01923649|postoperative dumping
1021974|NCT01923649|somatostatin analogues
1021975|NCT01923649|somatulin
1021976|NCT01923649|lanreotide
1021977|NCT01923649|dumping syndrome
1021978|NCT01923636|Cytomegalovirus, congenital, handicap
1021979|NCT01923610|Low risk HIV infection
1021980|NCT01923610|HIV Seronegativity
1021981|NCT01923610|HIV Preventive Vaccine
1021982|NCT01923597|Proteinuria
1021983|NCT01923597|Oxidative stress
1021984|NCT01923597|Epigallocatechin gallate
1021985|NCT01923545|PEG-G-CSF
1021986|NCT01923493|neck pain
1021987|NCT01923493|tuina
1021988|NCT01923467|smoking
1021989|NCT01923467|nicotine replacement
1021990|NCT01923467|internet
1021991|NCT01923454|paracentesis
1021992|NCT01923454|primary acute angle closure
1021993|NCT01923454|iridotomy
1021994|NCT01923454|filtration
1021995|NCT01923454|glaucoma
1021996|NCT01923415|Lupus Erythematosus, Subacute, Cutaneous
1021997|NCT01923415|Lupus Erythematosus, Systemic
1021998|NCT01923415|Lupus Erythematosus, Discoid
1021999|NCT01923415|Active Cutaneous Lupus Erythematosus
1022000|NCT01923415|Systemic Cutaneous Lupus Erythematosus
1022001|NCT01923415|Skin Biopsy
1022002|NCT01923415|Lesions
1022003|NCT01923402|Biomarkers
1022004|NCT01923402|Metabolic Profiling
1022005|NCT01923402|Metabolomics
1022006|NCT01923402|Tobacco
1022007|NCT01923402|Smokeless Tobacco
1022008|NCT01923402|Moist Snuff
1022009|NCT01923389|T2DM
1022010|NCT01923389|obesity
1022011|NCT01923389|safety
1022012|NCT01923389|multiple dose
1022013|NCT01923389|intravenous
1022014|NCT01923376|hepatic encephalopathy
1022015|NCT01923376|hepatic coma
1022016|NCT01923376|HE
1022017|NCT01923376|PSE
1022018|NCT01923376|lactulose
1022019|NCT01923376|golytely
1022020|NCT01923376|cirrhosis
1022021|NCT01923376|Hepatic Insufficiency
1022022|NCT01923376|Liver Cirrhosis
1022023|NCT01923376|Fibrosis
1022024|NCT01923376|Brain Damage, Chronic
1022025|NCT01923376|Delirium
1022026|NCT01923376|Encephalitis
1022027|NCT01923376|Neurotoxicity Syndromes
1022028|NCT01923376|Liver Failure
1022029|NCT01923376|Liver Diseases
1022030|NCT01923376|Digestive System Diseases
1022031|NCT01923376|Brain Diseases, Metabolic
1022032|NCT01923376|Brain Diseases
1022033|NCT01923376|Central Nervous System Diseases
1022034|NCT01923376|Nervous System Diseases
1022035|NCT01923376|Metabolic Diseases
1022036|NCT01923376|Pathologic Processes
1022037|NCT01923376|Confusion
1022038|NCT01923376|Neurobehavioral Manifestations
1022039|NCT01923376|Neurologic Manifestations
1022040|NCT01923376|Signs and Symptoms
1022041|NCT01923376|Delirium, Dementia, Amnestic, Cognitive Disorders
1022042|NCT01923376|Mental Disorders
1022043|NCT01923376|Central Nervous System Viral Diseases
1022044|NCT01923376|Virus Diseases
1022045|NCT01923376|Central Nervous System Infections
1022046|NCT01923376|Poisoning
1022047|NCT01923376|Substance-Related Disorders
1022048|NCT01923376|Citric Acid
1022049|NCT01923363|pharmacokinetics
1022050|NCT01923363|obesity
1022051|NCT01923363|piperacillin-tazobactam combination product
1022052|NCT01923363|pharmacodynamics
1022053|NCT01923363|piperacillin/tazobactam
1022054|NCT01923350|Weight reduction
1022055|NCT01923350|Behavioral intervention
1022056|NCT01923350|Gestational diabetes mellitus
1022057|NCT01923350|Type 2 diabetes
1022058|NCT01923350|Diabetes testing
1022059|NCT01923337|Colorectal cancer
1022060|NCT01923311|Pediatrics
1022061|NCT01923311|Adolescents
1022062|NCT01923311|HIV
1022063|NCT01923311|HIV-1
1022064|NCT01923311|Treatment-experienced
1022065|NCT01923246|Alcohol consumption
1022066|NCT01923246|Brief intervention
1022067|NCT01923246|Automated techniques
1022068|NCT01923233|liver cancer
1022069|NCT01923233|HCC
1022070|NCT01923233|tumor vaccine
1022071|NCT01923233|immunotherapy
1022072|NCT01923220|Breast Cancer
1022073|NCT01923220|Radiation Therapy
1022074|NCT01923220|Radiation Dermatitis
1022075|NCT01923168|Breast Cancer, Pathological Complete Response, neoadjuvant, hormone receptor-positive
1022076|NCT01923142|Vitiligo
1022077|NCT01923142|Outer-Root-Sheath
1022078|NCT01923142|Melanocytes
1022079|NCT01923142|Hair Follicles
1022080|NCT01923129|indwelling catheter
1022081|NCT01923129|foley
1022082|NCT01923129|duration
1022083|NCT01923116|Anal intraepithelial neoplasia
1022084|NCT01923116|HIV
1022085|NCT01923116|HPV
1022086|NCT01923116|Vaccination
1022087|NCT01923116|Treatment
1022088|NCT01923077|acute myocardial infarction
1022089|NCT01923077|Statin
1022090|NCT01923077|speckle tracking echocardiography
1022091|NCT01923077|Strain
1022092|NCT01923077|MSCT
1022093|NCT01923077|plaque
1022094|NCT01923077|vulnerable plaque
1022095|NCT01923051|chronic obstructive pulmonary disease
1022096|NCT01923051|COPD
1022097|NCT01923051|national database
1022098|NCT01923051|observational
1022099|NCT01923038|atelectasis
1022100|NCT01923038|laparoscopic surgery
1022101|NCT01923038|anesthesia
1022102|NCT01923038|mechanical ventilation
1022103|NCT01923038|Prevent
1022104|NCT01923038|shape of the airway
1022105|NCT01923038|pressure-time curve
1022106|NCT01922986|stroke
1022107|NCT01922986|rehabilitation
1022108|NCT01922986|hemiplegia
1022109|NCT01922986|repetitive transcranial magnetic stimulation
1022110|NCT01922973|ghrelin
1022111|NCT01922973|growth hormone
1022112|NCT01922973|aging
1022113|NCT01922973|normal volunteers
1022114|NCT01922960|trauma
1022115|NCT01922960|multiple organ dysfunction syndrome
1022116|NCT01922908|Ischemic
1022117|NCT01922908|Stroke
1022118|NCT01922908|Stem Cells
1022119|NCT01922908|MSC
1022120|NCT01922908|Allogeneic
1022121|NCT01922908|Bone Marrow
1022122|NCT01922895|Alcoholic Hepatitis
1022123|NCT01922895|MELD < 20
1022124|NCT01922895|Probiotic
1022125|NCT01922895|Nutritional Supplement
1022126|NCT01922895|Lactobacillus Rhamnosus GG
1022127|NCT01922882|HIV
1022128|NCT01922882|Maternal disclosure
1022129|NCT01922882|Health promotion
1022130|NCT01922882|Maternal mental health
1022131|NCT01922882|Child behavior
1022132|NCT01922869|Absorption
1022133|NCT01922869|Metabolism
1022134|NCT01922869|Excretion
1022135|NCT01922869|Flavonoids
1022136|NCT01922869|Polyphenols
1022137|NCT01922869|Genes
1022138|NCT01922869|Gut-microflora
1022139|NCT01922843|Hemodialysis
1022140|NCT01922830|Sleeve Gastrectomy
1022141|NCT01922830|NAFLD
1022142|NCT01922830|gut microbiot
1022143|NCT01922830|Bariatric surgery
1022144|NCT01922791|Nutrition
1022145|NCT01922791|Probiotics
1022146|NCT01922791|Fish oil
1022147|NCT01922765|Helicobacter
1022148|NCT01922765|Eradication
1022149|NCT01922752|CEP-37440
1022150|NCT01922752|Advanced solid tumors
1022151|NCT01922752|Metastatic solid tumors
1022152|NCT01922739|low back pain
1022153|NCT01922739|hydrocodone bitartrate
1022154|NCT01922739|opioids
1022155|NCT01922713|biofortification
1022156|NCT01922713|vitamin A
1022157|NCT01922713|maize
1022158|NCT01922713|beta-carotene
1022159|NCT01922713|breastmilk
1022160|NCT01922713|Zambia
1022161|NCT01922700|Pepper spray
1022162|NCT01922700|bronchospasm
1022163|NCT01922700|lacrimation
1022164|NCT01922648|RSV
1022165|NCT01922648|Immune response
1022166|NCT01922648|Paediatric
1022167|NCT01922635|Primary lymphedema quality of life, genetic research
1022168|NCT01922622|minimum effective dose of local anaesthetic
1022169|NCT01922622|spinal catheter
1022170|NCT01922622|fractured neck of femur
1022171|NCT01922622|a step up, step down methodology
1022172|NCT01922609|Carotid stenting
1022173|NCT01922609|Proximal protection system
1022174|NCT01922609|Transcranial Doppler ultrasound
1022175|NCT01922609|Cerebrovascular reserve
1022176|NCT01922596|Total Knee Arthroplasty
1022177|NCT01922596|Adductor Canal Blockade
1022178|NCT01922596|Us-guided nerve blockade
1022179|NCT01922583|NSCLC, EGFR mutation
1022180|NCT01922570|Enteral nutrition
1022181|NCT01922570|Supplemental parenteral nutrition
1022182|NCT01922570|Critical illness
1022183|NCT01922570|ICU patients
1022184|NCT01922570|diarrhea
1022185|NCT01922544|heart failure
1022186|NCT01922544|cardiac resynchronization therapy
1022187|NCT01922544|coronary sinus lead
1022188|NCT01922531|mTBI
1022189|NCT01922531|Mild Traumatic Brain Injury
1022190|NCT01922531|Axonal Injury
1022191|NCT01922518|atrioventricular block, cardiomyopathy
1022192|NCT01922492|autologous islet transplantation
1022193|NCT01922492|partial pancreatectomy
1022194|NCT01922492|pancreatogenic diabetes
1022195|NCT01922479|Heart Failure
1022196|NCT01922479|Anemia
1022197|NCT01922479|Iron Deficiency
1022198|NCT01922479|Ferric Carboxymaltose
1022199|NCT01922479|Asian
1022200|NCT01922466|chronic neck pain
1022201|NCT01922466|combined treatment between conventional and complementary alternative medical treatment
1022202|NCT01922466|bee venom acupuncture
1022203|NCT01922466|NSAIDs
1022204|NCT01922453|breech presentation
1022205|NCT01922453|vertex presentation
1022206|NCT01922440|Registry
1022207|NCT01922440|Chronic Hypoparathyroidism
1022208|NCT01922440|Observational study
1022209|NCT01922440|Natural History
1022210|NCT01922440|Chronic HPTH
1022211|NCT01921426|Squamous Cell Carcinoma of the Head and Neck
1022212|NCT01921426|Oral Cavity
1022213|NCT01921426|Oropharynx
1022214|NCT01921426|Radiation
1022215|NCT01921426|Chemotherapy
1022216|NCT01921426|Cisplatin
1022217|NCT01921426|Oral Mucositis
1022218|NCT01921426|Superoxide Dismutase
1022219|NCT01921413|Plasmodium falciparum
1022220|NCT01921413|Clinical Malaria
1022221|NCT01921413|Fever
1022222|NCT01921413|Schistosoma hematobium
1022223|NCT01921413|Rheumatoid arthritis
1022224|NCT01921400|Hepatitis C (HCV)
1022225|NCT01921400|Infection Transmission, Maternal-Fetal
1022226|NCT01921400|Placenta
1022227|NCT01921400|Trophoblast
1022228|NCT01921374|Duchenne;
1022229|NCT01921374|mothers caregivers;
1022230|NCT01921374|sleep;
1022231|NCT01921374|hormonal profile;
1022232|NCT01921374|cardiac profile;
1022233|NCT01921374|biochemical profile;
1022234|NCT01921374|inflammatory profile.
1022235|NCT01921361|Shivering
1022236|NCT01921361|Dexmedetomidine
1022237|NCT01921361|Spinal anesthesia
1022238|NCT01921348|Hay Fever
1022239|NCT01921348|Hayfever
1022240|NCT01921348|Pollen Allergy
1022241|NCT01921348|Pollinosis
1022242|NCT01921348|Seasonal Allergic Rhinitis
1022243|NCT01921335|ARRY-380
1022244|NCT01921335|Trastuzumab
1022245|NCT01921335|Advanced HER2-positive breast cancer
1022246|NCT01921309|osteoarthritis
1022247|NCT01921309|avascular necrosis
1022248|NCT01921309|rheumatoid arthritis
1022249|NCT01921309|correction of functional deformity
1022250|NCT01921309|dysplasia of the hip
1022251|NCT01921296|Breast cancer
1022252|NCT01921296|Aromatase inhibitor
1022253|NCT01921283|propofol, endoscopy, bispectral index
1022254|NCT01921270|Oromandibular Dystonia
1022255|NCT01921270|Oral Dystonia
1022256|NCT01921270|Tardive Dystonia
1022257|NCT01921270|botulinum toxin
1022258|NCT01921270|abobotulinumtoxinA
1022259|NCT01921257|Cat Allergy
1022260|NCT01921257|Rhinoconjunctivitis
1022261|NCT01922414|Staghorn stones
1022262|NCT01922414|Percutaneous nephrolithotomy
1022263|NCT01922414|Laser
1022264|NCT01922414|Randomized trial
1022265|NCT01922414|Lithotripsy
1022266|NCT01922388|Parkinson disease
1022267|NCT01922388|deep brain stimulation
1022268|NCT01922388|subthalamic nucleus
1022269|NCT01922388|motor complication
1022270|NCT01922388|quality of life
1022271|NCT01922362|STSG
1022272|NCT01922362|wound healing
1022273|NCT01922336|Pharmacokinetics
1022274|NCT01922323|Living liver donor
1022275|NCT01922297|Delinquency
1022276|NCT01922297|HIV Associated Risk Behavior
1022277|NCT01922297|Juveniles
1022278|NCT01922297|Family based treatment
1022279|NCT01922297|Multidimensional Family Therapy
1022280|NCT01922284|HIV
1022281|NCT01922284|Vaccine
1022282|NCT01922284|Immunisation
1022283|NCT01922284|DNA
1022284|NCT01922284|Adverse events
1022285|NCT01922284|MVA-C
1022286|NCT01922284|GLA-AF
1022287|NCT01922284|Antibody
1022288|NCT01922271|COPD
1022289|NCT01922258|OPC-34712
1022290|NCT01922258|brexpiprazole
1022291|NCT01922258|Dementia
1022292|NCT01922258|Alzheimer's Disease
1022293|NCT01922258|Cognitive Disorders
1022294|NCT01922258|Memory
1022295|NCT01922258|Agitation
1022296|NCT01922245|aphasia
1022297|NCT01922245|therapy
1022298|NCT01922245|stroke
1022299|NCT01922245|language
1022300|NCT01922245|naming
1022301|NCT01922245|quality of life
1022302|NCT01922245|tDCS
1022303|NCT01922245|treatment
1022304|NCT01922219|depression
1022305|NCT01922219|cognitive therapy
1022306|NCT01922219|cognitive behavioral therapy
1022307|NCT01922219|CBT
1022308|NCT01922219|psychotherapy
1022309|NCT01922219|MDD
1022310|NCT01922219|major depressive disorder
1022311|NCT01922219|MRI
1022312|NCT01922219|fMRI
1022313|NCT01922206|HIV
1022314|NCT01922206|Maternal Disclosure
1022315|NCT01922180|Chest Computed Tomography
1022316|NCT01922167|Aging
1022317|NCT01922167|Frailty
1022318|NCT01922167|Leucine
1022319|NCT01922167|Resistance Exercise
1022320|NCT01922154|Angiogenesis inhibitors
1022321|NCT01922154|Neovascular
1022322|NCT01922154|Intraocular pressure
1022323|NCT01922154|Retinal Vein Occlusion
1022324|NCT01922154|Vascular Endothelial Growth Factor
1022325|NCT01922141|High blood pressure, stage 1 and 2 hypertension
1022326|NCT01922128|Non-exudative, dry AMD
1022327|NCT01922115|COGNITIVE FUNCTION
1022328|NCT01922115|OVERACTIVE BLADDER
1022329|NCT01922115|[C23.888.942.343.780]
1022330|NCT01922102|Pathologic myopia (PM), choroidal neovascularization (CNV), ranibizumab, verteporfin PDT, Brilliance
1022331|NCT01922089|Heart failure, reduced ejection fraction, LCZ696, titration, safety, tolerability
1022332|NCT01922063|disc herniation surgery
1022333|NCT01922063|physiotherapy, exercise therapy
1022334|NCT01922063|randomized
1022335|NCT01922063|long term
1022336|NCT01922063|follow up
1022337|NCT01921972|AD, Dementia
1022338|NCT01921946|Fimasartan
1022339|NCT01921933|End-stage renal disease
1022340|NCT01921933|ESRD
1022341|NCT01921933|AVF
1022342|NCT01921933|Fistulas
1022343|NCT01921920|Omeprazole, Prilosec, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence
1022344|NCT01921907|Actinic keratosis
1022345|NCT01921907|topical
1022346|NCT01921907|dermatology
1022347|NCT01921907|treatment
1022348|NCT01921907|clinical study
1022349|NCT01921907|double blinded
1022350|NCT01921894|asthma
1022351|NCT01921894|vitamin D
1022352|NCT01921881|Glucose tolerance
1022353|NCT01921829|Cardiorenal failure
1022354|NCT01921829|Cardiorenal syndrome
1022355|NCT01921829|Diuretic resistance
1022356|NCT01921829|Volume overload
1022357|NCT01921829|Edema
1022358|NCT01921829|Health-related quality of life
1022359|NCT01921829|Outcomes
1022360|NCT01921829|Treatment protocol
1022361|NCT01921790|Avastin+ GemAOD
1022362|NCT01921790|first line chemotherapy
1022363|NCT01921790|NK/T-cell Lymphoma
1022364|NCT01921777|Muscle
1022365|NCT01921777|exercise
1022366|NCT01921777|soreness
1022367|NCT01921777|Damage
1022368|NCT01921777|Traumeel
1022369|NCT01921777|homeopathy
1022370|NCT01921751|SMAD4
1022371|NCT01921751|IMRT
1022372|NCT01921751|gemcitabine
1022373|NCT01921751|FOLFIRINOX
1022374|NCT01921751|high-dose radiotherapy
1022375|NCT01921738|Chronic Periodontitis, Azithromycin, SRP
1022376|NCT01921725|wound healing
1022377|NCT01921725|carbon
1022378|NCT01921712|COPD
1022379|NCT01921712|Chronic Obstructive Pulmonary Disease
1022380|NCT01921699|macrophages
1022381|NCT01921699|adenocarcinoma
1022382|NCT01921699|chemoresistance
1022383|NCT01921686|Eosinophil
1022384|NCT01921686|Reflux
1022385|NCT01921686|Esophagus
1022386|NCT01921686|Food allergy
1022387|NCT01921686|Trouble Swallowing
1022388|NCT01921686|Pediatrics
1022389|NCT01921686|Healthy Volunteers
1022390|NCT01921673|Gastric cancer
1022391|NCT01921673|Phase I/II
1022392|NCT01921673|Second-line chemotherapy
1022393|NCT01921673|Dovitinib
1022394|NCT01921673|Docetaxel
1022395|NCT01921673|Refractory to first-line chemotherapy
1022396|NCT01921647|safety/tolerability and pharmacokinetics/pharmacodynamics
1022397|NCT01921621|proficiency based progression
1022398|NCT01921621|surgical skill
1022399|NCT01921621|metric validation
1022400|NCT01921621|formative feedback
1022401|NCT01921621|simulator model
1022402|NCT01921608|Male Circumcision
1022403|NCT01921608|HIV Prevention
1022404|NCT01921608|HIV Infections
1022405|NCT01921595|balanced salt colloid, coagulation profiles, spinal cord tumor
1022406|NCT01921543|Deep Brain Stimulation
1022407|NCT01921543|Major Depressive Disorder
1022408|NCT01921543|Psychosurgery
1022409|NCT01921543|Electrical stimulation
1022410|NCT01921530|Posterolateral Fusion
1022411|NCT01921530|Interbody Fusion
1022412|NCT01921530|Lumbar
1022413|NCT01921530|Spinal Stenosis
1022414|NCT01921530|Degenerative Spondylolisthesis
1022415|NCT01921517|Biomechanics
1022416|NCT01921517|Osteogenesis
1022417|NCT01921504|Functional Dyspepsia
1022418|NCT01921504|Acupuncture
1022419|NCT01921504|Genotype
1022420|NCT01921504|Ghrelin
1022421|NCT01921465|outpatient care
1022422|NCT01921465|videoconferencing
1022423|NCT01921465|elective cesarean section
1022424|NCT01921452|Hypothyroidism
1022425|NCT01921452|Third generation TSH kit
1022426|NCT01921452|Quantitative POC TSH kit
1022427|NCT01921452|Qualitative POC TSH kit
1022428|NCT01921439|smoking
1022429|NCT01921439|quit smoking
1022430|NCT01921439|smoking cessation
1022431|NCT01921439|smoking study
1022432|NCT01921439|secondhand smoke
1022433|NCT01921439|smokers
1022434|NCT01921244|Autistic Disorder
1022435|NCT01921244|Decision Making
1022436|NCT01921244|Medication Therapy Management
1022437|NCT01921218|Kidney transplant
1022438|NCT01921205|Lacosamide
1022439|NCT01921205|Vimpat
1022440|NCT01921205|UCB
1022441|NCT01921205|Epilepsy
1022442|NCT01921205|Partial Onset Seizures
1022443|NCT01921205|Pediatric
1022444|NCT01921179|Post Traumatic Stress Disorder,
1022445|NCT01921179|Mild Traumatic Brain Injury
1022446|NCT01921179|Concussion
1022447|NCT01921179|Cognitive Rehabilitation
1022448|NCT01921166|infertility
1022449|NCT01921166|diminished ovarian reserve
1022450|NCT01921166|fertilization in vitro
1022451|NCT01921166|ovulation inducion
1022452|NCT01921166|vitrification
1022453|NCT01921140|Oncology, cancer, tumour, neoplasm, anticancer drug, food, area under the curve, pharmacokinetics, olaparib, neoplasm, metabolites, QT interval effects
1022454|NCT01921127|COPD, Comparative effectiveness, Symbicort
1022455|NCT01921101|nutrition
1022456|NCT01921101|enteral feeding
1022457|NCT01921101|parenteral feeding
1022458|NCT01921101|hospital malnutrition
1022459|NCT01921088|fMRI
1022460|NCT01921088|Neurofeedback
1022461|NCT01921088|Blood pressure
1022462|NCT01921088|Psychophysiology
1022463|NCT01921075|physiology, normal function
1022464|NCT01921062|Distal radius fracture
1022465|NCT01921062|Motor imagery
1022466|NCT01921062|Immobilisation
1022467|NCT01921062|Effectivity
1022468|NCT01921023|Blood Gas analysis
1022469|NCT01920997|Healthy
1022470|NCT01920997|normal menstrual cycles
1022471|NCT01920971|chronic low back pain
1022472|NCT01920971|infrared energy
1022473|NCT01920971|effects
1022474|NCT01920932|Pediatric cancer
1022475|NCT01920932|Hodgkin lymphoma
1022476|NCT01920932|Targeted therapy
1022477|NCT01920932|Frontline therapy
1022478|NCT01920932|Brentuximab vedotin
1022479|NCT01920932|Quality of Life
1022480|NCT01920932|OEPA/COPDac
1022481|NCT01920906|Psoriasis
1022482|NCT01920906|Korean
1022483|NCT01920906|Healthy Volunteers
1022484|NCT01920880|Anterior cutaneous nerve entrapment syndrome
1022485|NCT01920880|ACNES
1022486|NCT01920880|chronic abdominal wall pain
1022487|NCT01920880|CAWP
1022488|NCT01920867|Stem Cells
1022489|NCT01920867|Bone Marrow Derived Stem Cells
1022490|NCT01920867|BMSC
1022491|NCT01920867|BMC (Bone Marrow Cell)
1022492|NCT01920867|Mesenchymal Stem Cells
1022493|NCT01920867|MSC
1022494|NCT01920867|Eye Disease
1022495|NCT01920867|Eye Stem Cells
1022496|NCT01920867|Ophthalmology
1022497|NCT01920867|Ophthalmic Disease
1022498|NCT01920867|Retina
1022499|NCT01920867|Retinal Disease
1022500|NCT01920867|Macular Degeneration
1022501|NCT01920867|Age Related Macular Degeneration
1022502|NCT01920867|Myopic Macular Degeneration
1022503|NCT01920867|Geographic Atrophy
1022504|NCT01920867|Dry Macular Degeneration
1022505|NCT01920867|Wet Macular Degeneration
1022506|NCT01920867|Retinal Atrophy
1022507|NCT01920867|Retinal Dystrophy
1022508|NCT01920867|Hereditary Retinal Dystrophy
1022509|NCT01920867|Retinitis Pigmentosa
1022510|NCT01920867|Stargardt Disease
1022511|NCT01920867|Cone Dystrophy
1022512|NCT01920867|Cone Rod Dystrophy
1022513|NCT01920867|Maculopathy
1022514|NCT01920867|Optic Nerve Disease
1022515|NCT01920867|Optic Nerve Atrophy
1022516|NCT01920867|Optic Atrophy
1022517|NCT01920867|Ischemic Optic Neuropathy
1022518|NCT01920867|Optic Nerve Damage
1022519|NCT01920867|Optic Nerve Compression
1022520|NCT01920867|Compressive Optic Neuropathy
1022521|NCT01920867|Devics Syndrome
1022522|NCT01920854|Soluble Ferric Pyrophosphate, Pharmacokinetics, Iron, Hemodialysis
1022523|NCT01920841|lipolytic
1022524|NCT01920841|herbal extracts
1022525|NCT01920841|thigh girth
1022526|NCT01920841|thigh smoothness
1022527|NCT01920789|Non-small call lung cancer
1022528|NCT01920789|Medically inoperable
1022529|NCT01920789|Stage one
1022530|NCT01920789|Radiotherapy
1022531|NCT01920789|SBRT
1022532|NCT01920789|Hypofractionation
1022533|NCT01920789|Conventional fractionation
1022534|NCT01920776|critical ultrasound
1022535|NCT01920763|Intracerebral hemorrhage
1022536|NCT01920763|Surgical evacuation
1022537|NCT01920763|Minimally-invasive surgery
1022538|NCT01920750|Leprosy, skin test, MLSA-LAM, MLCwA, diagnosis, Protocol 98-202
1022539|NCT01920737|ALL
1022540|NCT01920737|Bone Marrow
1022541|NCT01920737|Ph Negative
1022542|NCT01920737|Daunorubicin
1022543|NCT01920737|Vincristine
1022544|NCT01920737|Prednisone
1022545|NCT01920737|PEG-Asparaginase
1022546|NCT01920737|Methotrexate
1022547|NCT01920737|16-MP (6-Mercaptopurine)
1022548|NCT01920737|Cyclophosphamide
1022549|NCT01920737|Cytarabine
1022550|NCT01920737|Leucovorin
1022551|NCT01920737|Dexamethasone
1022552|NCT01920737|12-266
1022553|NCT01920724|Preschool children
1022554|NCT01920724|Body composition
1022555|NCT01920711|Heart failure
1022556|NCT01920711|preserved ejection fraction
1022557|NCT01920711|diastolic heart failure
1022558|NCT01920698|Heart Valve Diseases
1022559|NCT01920698|Heart failure
1022560|NCT01920698|Heart diseases
1022561|NCT01920698|Mitral valve insufficiency
1022562|NCT01920685|Paranoia
1022563|NCT01920685|CBT
1022564|NCT01920685|Reasoning
1022565|NCT01920685|Anxiety
1022566|NCT01920659|High Intensity Training
1022567|NCT01920659|Insulin sensitivity
1022568|NCT01920659|Fitness
1022569|NCT01920620|obesity, inpatient, intervention, weight loss
1022570|NCT01920607|Fecal Incontinence.
1022571|NCT01920607|Anal Incontinence.
1022572|NCT01920607|Functional Bowel Disorders.
1022573|NCT01920607|SNS.
1022574|NCT01920607|Artificial Sphincters.
1022575|NCT01920607|Magnetic Anal Sphincter.
1022576|NCT01920594|GSK1278863
1022577|NCT01920594|Thoracic Aortic Aneurysm Repair
1022578|NCT01920581|CEIP
1022579|NCT01920581|pharmacodependance
1022580|NCT01920581|addictovigilance
1022581|NCT01920581|benzodiazepines and benzodiazepines related drugs
1022582|NCT01920581|elderly
1022583|NCT01920568|GSK2371746
1022584|NCT01920568|Denosumab
1022585|NCT01920568|China
1022586|NCT01920568|skeletal-related events
1022587|NCT01920568|bone metastases
1022588|NCT01920568|bridging study
1022589|NCT01920568|solid tumors
1022590|NCT01920555|Depression
1022591|NCT01920555|Treatment Resistant Depression
1022592|NCT01920555|Ketamine
1022593|NCT01920555|Antidepressant
1022594|NCT01920555|MDD
1022595|NCT01920555|Major Depression
1022596|NCT01920529|asthma, aerobic exercise, child, cytokines
1022597|NCT01920516|Isolated limb infusion
1022598|NCT01920516|Melphalan
1022599|NCT01920516|Limb Melanoma
1022600|NCT01920516|Tumor response
1022601|NCT01920503|cholangiocarcinoma
1022602|NCT01920503|transarterial chemoembolization
1022603|NCT01920503|doxorubicin
1022604|NCT01920503|tumor response
1022605|NCT01920477|Pemphigus
1022606|NCT01920477|(MAB)
1022607|NCT01920477|autoimmune disorder
1022608|NCT01920477|human CD20 antigen
1022609|NCT01920477|subcutaneous
1022610|NCT01920477|Pemphigus vulgaris
1022611|NCT01920477|Phase 3
1022612|NCT01920477|monoclonal antibody
1022613|NCT01920477|ofatumumab
1022614|NCT01920477|PV
1022615|NCT01920477|rare disease
1022616|NCT01920451|sleep
1022617|NCT01920451|insomnia
1022618|NCT01920451|posttraumatic stress disorder
1022619|NCT01920451|hypertension
1022620|NCT01920451|cardiovascular disease
1022621|NCT01920438|Percutaneous endoscopic gastrostomy,
1022622|NCT01920438|Radiologically inserted gastrostomy,
1022623|NCT01920438|Complications
1022624|NCT01920425|Parkinson's disease
1022625|NCT01920425|dyskinesia
1022626|NCT01920425|fluctuations
1022627|NCT01920425|tremor
1022628|NCT01920425|bradykinesia
1022629|NCT01920425|levodopa
1022630|NCT01920412|Atrial fibrillation
1022631|NCT01920412|Thrombosis
1022632|NCT01920412|Ischemic stroke
1022633|NCT01920412|Left atrial appendage occluder
1022634|NCT01920412|Intervention method
1022635|NCT01920399|CAZ-AVI China phase I PK study
1022636|NCT01920386|Acute Toothache
1022637|NCT01920386|Wontran
1022638|NCT01920386|Wontran SR Tab.
1022639|NCT01920386|Tramadol Hydrochloride/Acetaminophen
1022640|NCT01920373|degenerative joint disease
1022641|NCT01920373|temporomandibular joint
1022642|NCT01920360|KNEE OSTEOARTHRITIS
1022643|NCT01920360|BALNEOTHERAPY
1022644|NCT01920360|SULPHUROUS WATERS
1022645|NCT01920360|WOMAC
1022646|NCT01920360|LEQUESNE
1022647|NCT01920360|HEALTH ASSESSMENT QUESTIONNAIRE
1022648|NCT01920360|SHORT FORM - 36
1022649|NCT01920360|VAS
1022650|NCT01920347|hypoxic encephalopathy
1022651|NCT01920347|cardiac arrest
1022652|NCT01920347|outcome
1022653|NCT01920347|pupillary reflex
1022654|NCT01920334|coronary disease
1022655|NCT01920334|heart diseases
1022656|NCT01920334|enzymes
1022657|NCT01920334|sleep
1022658|NCT01920334|troponin
1022659|NCT01920334|zolpidem
1022660|NCT01920321|COPD
1022661|NCT01920321|Bronchoscopic LVR
1022662|NCT01920321|Emphysema
1022663|NCT01920321|Hot injury
1022664|NCT01920269|non-muscle invasive bladder cancer
1022665|NCT01920269|intravesical chemotherapy
1022666|NCT01920269|mitomycin
1022667|NCT01920269|passive diffusion
1022668|NCT01920269|electromotive drug administration
1022669|NCT01920256|Insulin therapy
1022670|NCT01920256|Type 2 diabetes
1022671|NCT01920243|Telemedicine
1022672|NCT01920243|self-management
1022673|NCT01920243|Medical psychology
1022674|NCT01920243|Health psychology
1022675|NCT01920243|Rehabilitation
1022676|NCT01920243|Education, Health
1022677|NCT01920230|Burnout
1022678|NCT01920230|Stress
1022679|NCT01920230|Mindfulness
1022680|NCT01920230|Acceptance-commitment therapy (ACT)
1022681|NCT01920230|Intervention
1022682|NCT01920230|Effectiveness
1022683|NCT01920230|Working conditions
1022684|NCT01920230|Work engagement
1022685|NCT01920230|Psychological well-being
1022686|NCT01920230|Life situation
1022687|NCT01920217|sepsis
1022688|NCT01920217|SNP
1022689|NCT01920217|mortality
1022690|NCT01920204|Mastocytosis
1022691|NCT01920204|ISM
1022692|NCT01920204|SSM
1022693|NCT01920191|Glioblastoma
1022694|NCT01920165|respiratory tract infections
1022695|NCT01920165|upper respiratory tract infections
1022696|NCT01920165|lower respiratory tract infections
1022697|NCT01920165|hospitalisation
1022698|NCT01920165|child
1022699|NCT01920165|children
1022700|NCT01920165|minors
1022701|NCT01920165|infants
1022702|NCT01920165|second-hand smoke
1022703|NCT01920165|tobacco smoke pollution
1022704|NCT01920165|smoke-free
1022705|NCT01920165|smoke-free policy
1022706|NCT01920165|smoke-free legislation
1022707|NCT01920165|public places
1022708|NCT01920152|Hip, Chondropenia, Osteoarthritis.
1022709|NCT01920126|sodium bicarbonate, renal function, infective endocarditis, open heart surgery
1022710|NCT01920113|Endoscopic submucosal dissection
1022711|NCT01920113|propofol
1022712|NCT01920113|remifentanil
1022713|NCT01920113|dexmedetomidine
1022714|NCT01920113|efficacy
1022715|NCT01920113|safeness
1022716|NCT01920100|Health Care Costs
1022717|NCT01920100|Genetic Polymorphism
1022718|NCT01920087|Atypical Facial Pain
1022719|NCT01920087|Persistent Idiopathic Facial Pain
1022720|NCT01920087|Atypical Trigeminal Neuralgia
1022721|NCT01920087|Orofacial Pain
1022722|NCT01920087|Orofacial neuropathic pain
1022723|NCT01920087|Fothergill Disease
1022724|NCT01920087|Tic Douloureux
1022725|NCT01920087|Prosopalgia
1022726|NCT01920074|Anal Fissure
1022727|NCT01920074|Nitroglycerin
1022728|NCT01920074|Pediatrics
1022729|NCT01920074|RECTIV®
1022730|NCT01920074|Pediatric Research Equity Act
1022731|NCT01920061|Advanced cancer
1022732|NCT01920061|solid tumors
1022733|NCT01920061|PI3K
1022734|NCT01920061|mTOR
1022735|NCT01920061|PI3K/mTOR
1022736|NCT01920061|metastatic
1022737|NCT01920048|Heart Failure
1022738|NCT01920048|Ventricular Dysfunction
1022739|NCT01920048|Ischemic Cardiomyopathy
1022740|NCT01920048|Ischemic Heart Disease
1022741|NCT01920048|Revascularization
1022742|NCT01920048|Percutaneous Coronary Intervention
1022743|NCT01920048|Randomized Control Trial
1022872|NCT01919632|prevention
1022744|NCT01920048|Implantable Cardioverter Defibrillator
1022745|NCT01920035|Incontinence post RARP
1022746|NCT01920035|Surgery induced incontinence
1022747|NCT01920035|Incontinence after prostatectomy
1022748|NCT01920035|Neuropathy-induced incontinence
1022749|NCT01920022|medical abortion
1022750|NCT01920022|postabortion contraception
1022751|NCT01920022|LARC
1022752|NCT01920022|Nexplanon
1022753|NCT01920022|subdermal contraceptive implant
1022754|NCT01920009|pharmacy care
1022755|NCT01920009|adherence
1022756|NCT01920009|coronary heart disease
1022757|NCT01919996|Ocular safety
1022758|NCT01919996|azithromycin
1022759|NCT01919996|pharyngitis
1022760|NCT01919996|tonsillitis
1022761|NCT01919983|cardiac
1022762|NCT01919983|innervation
1022763|NCT01919983|inflammation
1022764|NCT01919983|sudden
1022765|NCT01919983|death
1022766|NCT01919970|Autism
1022767|NCT01919970|Asperger's Syndrome
1022768|NCT01919970|Pervasive Developmental Disorder Not Otherwise Specified
1022769|NCT01919970|Treatment
1022770|NCT01919970|Cognitive-behavioral therapy
1022771|NCT01919970|Anxiety
1022772|NCT01919970|Children
1022773|NCT01919970|Therapy
1022774|NCT01919970|Generalized Anxiety Disorder
1022775|NCT01919970|Social Phobia
1022776|NCT01919970|Separation Anxiety Disorder
1022777|NCT01919970|Obsessive-compulsive Disorder
1022778|NCT01919970|Specific Phobia
1022779|NCT01919957|epilepsy
1022780|NCT01919957|surgery
1022781|NCT01919957|functional MRI
1022782|NCT01919957|memory outcome
1022783|NCT01919944|itch
1022784|NCT01919931|Candida albicans
1022785|NCT01919931|Candidiasis
1022786|NCT01919931|Biofilm
1022787|NCT01919931|Flow cytometry
1022788|NCT01919931|Mannose Binding Lectin
1022789|NCT01919905|Mozzarella cheese fortification
1022790|NCT01919905|Bioavailability of Vitamin D
1022791|NCT01919892|predictors of response
1022792|NCT01919892|bipolar disorder
1022793|NCT01919892|depression
1022794|NCT01919892|lithium treatment
1022795|NCT01919892|biomarkers
1022796|NCT01919879|Chemotherapy refractory
1022797|NCT01919879|wtKRAS metastatic colorectal cancer
1022798|NCT01919879|cross over
1022799|NCT01919853|Cancer
1022800|NCT01919853|Fatigue
1022801|NCT01919853|Mindfulness
1022802|NCT01919853|Meditation
1022803|NCT01919853|Neoplasms
1022804|NCT01919853|Signs and symptoms
1022805|NCT01919840|hemostatic disorders
1022806|NCT01919840|ardiac surgery
1022807|NCT01919840|cardiopulmonary bypass
1022808|NCT01919827|Idiopathic pulmonary fibrosis
1022809|NCT01919827|Stem cells
1022810|NCT01919827|Mesenchymal stem cells
1022811|NCT01919801|ACE-I
1022812|NCT01919801|Firazyr
1022813|NCT01919801|icatibant
1022814|NCT01919788|Diabetes Mellitus Type I
1022815|NCT01919788|Hypoglycemia
1022816|NCT01919788|Counter-regulatory mechanisms
1022817|NCT01919762|Bacteremia
1022818|NCT01919762|Sepsis
1022819|NCT01919762|Acinetobacter baumannii
1022820|NCT01919762|Staphylococcus aureus
1022821|NCT01919762|Klebsiella pneumonia
1022822|NCT01919762|Pseudomonas aeruginosa
1022823|NCT01919762|Enterococcus faecalis
1022824|NCT01919762|Magnetic Relaxation Detection
1022825|NCT01919762|Nuclear Magnetic Resonance Detection
1022826|NCT01919762|Blood culture
1022827|NCT01919749|breast cancer metastatic
1022828|NCT01919749|molecular profiling
1022829|NCT01919749|sequencing
1022830|NCT01919749|profiling
1022831|NCT01919749|breast cancer
1022832|NCT01919736|knee OA
1022833|NCT01919723|PCI
1022834|NCT01919723|Ticagrelor
1022835|NCT01919723|Eptifibatide
1022836|NCT01919710|Neutropenia
1022837|NCT01919710|chemotherapy
1022838|NCT01919710|rHSA/GCSF
1022839|NCT01919697|Plecantaide
1022840|NCT01919697|Chronic Idiopathic Constipation
1022841|NCT01919697|Chronic
1022842|NCT01919697|Idiopathic
1022843|NCT01919697|Constipation
1022844|NCT01919697|Synergy
1022845|NCT01919697|CIC
1022846|NCT01919697|CIC study
1022847|NCT01919697|CIC OLE
1022848|NCT01919697|CIC OLE study
1022849|NCT01919697|OLE
1022850|NCT01919697|OLE CIC
1022851|NCT01919697|OLE CIC3
1022852|NCT01919697|Open label
1022853|NCT01919697|Open label study
1022854|NCT01919697|Long term
1022855|NCT01919697|Long term study
1022856|NCT01919697|Extension
1022857|NCT01919697|Extension study
1022858|NCT01919684|Glucagon receptor antagonist
1022859|NCT01919671|Ischemic Stroke
1022860|NCT01919671|Tongxinluo capsule
1022861|NCT01919658|nerve blocks in Anterior cruciate ligament surgery
1022862|NCT01919645|Rheumatoid Arthritis
1022863|NCT01919645|Sleep Disorders
1022864|NCT01919645|Polysomnography
1022865|NCT01919645|Sleep Stages
1022866|NCT01919645|Physical Exercise
1022867|NCT01919632|lifestyle
1022868|NCT01919632|physical activity
1022869|NCT01919632|endothelial function
1022870|NCT01919632|cardiovascular
1022871|NCT01919632|occupational
1022873|NCT01919619|Blood And Marrow Transplantation
1022874|NCT01919619|Leukemia
1022875|NCT01919619|Lymphoma
1022876|NCT01919619|Allogeneic stem cell transplant
1022877|NCT01919619|Autologous stem cell transplant
1022878|NCT01919619|SCT
1022879|NCT01919619|Lenalidomide CC-5013
1022880|NCT01919619|Revlimid
1022881|NCT01919619|Ipilimumab
1022882|NCT01919619|Yervoy
1022883|NCT01919619|BMS-734016
1022884|NCT01919619|MDX010
1022885|NCT01919606|hysterectomy
1022886|NCT01919606|analgesia
1022887|NCT01919593|Blood culture
1022888|NCT01919593|Contamination
1022889|NCT01919593|Chlorhexidine gluconate
1022890|NCT01919593|Povidone iodine
1022891|NCT01919580|Gα12
1022892|NCT01919580|Oral cancer
1022893|NCT01919567|SOX-9
1022894|NCT01919567|Oral cancer
1022895|NCT01919567|arecoline
1022896|NCT01919554|House Dust Mite Allergic Rhinitis
1022897|NCT01919554|Phase I
1022898|NCT01919554|House Dust Mite Allergen Extract
1022899|NCT01919541|Colorectal Surgery
1022900|NCT01919528|ultrasonography
1022901|NCT01919528|catheterization
1022902|NCT01919528|central line
1022903|NCT01919528|mechanical ventilation
1022904|NCT01919528|intensive care
1022905|NCT01919528|axillary vein
1022906|NCT01919515|pediatric
1022907|NCT01919515|primary molars
1022908|NCT01919515|stainless steel crowns
1022909|NCT01919489|Incretins
1022910|NCT01919489|Liraglutide
1022911|NCT01919489|Glargine
1022912|NCT01919489|Randomized controlled trial
1022913|NCT01919489|basal insulin
1022914|NCT01919489|hospital discharge
1022915|NCT01919489|inpatient diabetes
1022916|NCT01919476|Postprandial
1022917|NCT01919476|Insulin resistance
1022918|NCT01919476|Lipids
1022919|NCT01919476|Satiety
1022920|NCT01919476|Almonds
1022921|NCT01919463|Colonoscopy
1022922|NCT01919463|Lower Gastrointestinal Tract
1022923|NCT01919463|Magnetic Endoscopic Imaging
1022924|NCT01919463|Abdominal Compression
1022925|NCT01919450|PET
1022926|NCT01919450|Lexiscan
1022927|NCT01919450|Regadenoson
1022928|NCT01919450|Rubidium
1022929|NCT01919450|Blood Flow Reserve
1022930|NCT01919450|Myocardial Perfusion
1022931|NCT01919450|Quantitated Myocardial Perfusion
1022932|NCT01919411|Chronic rhinosinusitis
1022933|NCT01919411|Sinus surgery
1022934|NCT01919411|Antibiotics
1022935|NCT01919385|Type 1 diabetes
1022936|NCT01919385|Insulin Pump
1022937|NCT01919359|ablative laser
1022938|NCT01919359|soft tissue filler
1022939|NCT01919346|Kidney Transplantation
1022940|NCT01919346|Delayed Graft Function
1022941|NCT01919320|SynCardia
1022942|NCT01919320|Total Artificial Heart
1022943|NCT01919320|TAH-t
1022944|NCT01919307|Seizures
1022945|NCT01919307|Convulsions
1022946|NCT01919307|Anticonvulsants
1022947|NCT01919307|Epilepsy
1022948|NCT01919307|Neurologic
1022949|NCT01919294|nonalcoholic fatty liver disease
1022950|NCT01919294|nonalcoholic steatohepatitis
1022951|NCT01919294|hypogonadism
1022952|NCT01919294|testosterone replacement therapy
1022953|NCT01919281|exercise
1022954|NCT01919281|resistance training
1022955|NCT01919281|insulin resistance
1022956|NCT01919281|high intensity interval training
1022957|NCT01919268|Pilates-based exercises
1022958|NCT01919268|Electrotherapy
1022959|NCT01919268|Interferencial current
1022960|NCT01919255|Colonoscopy
1022961|NCT01919255|Bowel preparation
1022962|NCT01919255|Picolight
1022963|NCT01919255|Clicolon
1022964|NCT01919255|Coolprep
1022965|NCT01919229|HR-positive
1022966|NCT01919229|HER2-negative
1022967|NCT01919229|Breast cancer
1022968|NCT01919229|LEE011
1022969|NCT01919229|Letrozole
1022970|NCT01919229|CDK
1022971|NCT01919229|CDK4
1022972|NCT01919229|CDK6
1022973|NCT01919229|CDK4/6
1022974|NCT01919229|Pharmacodynamics
1022975|NCT01919229|Pre-surgical
1022976|NCT01919229|Postmenopausal
1022977|NCT01919177|Heart Failure
1022978|NCT01919177|Arterial hemodynamics
1022979|NCT01919177|Exercise capacity
1022980|NCT01919177|Mitochondrial oxidative capacity
1022981|NCT01919164|Osteoarthritis of knee
1022982|NCT01919164|AS902330
1022983|NCT01919164|Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)
1022984|NCT01919164|Sprifermin
1022985|NCT01919164|Placebo
1022986|NCT01919151|survival
1022987|NCT01919125|Chronic hepatitis C
1022988|NCT01919125|Hepatitis C virus
1022989|NCT01919125|HCV
1022990|NCT01919112|Brain stimulation
1022991|NCT01919099|Transplantation Costs
1022992|NCT01919099|Risk Factors
1022993|NCT01919099|Transplant Infections
1022994|NCT01919086|Bortezomib
1022995|NCT01919086|Dexamethasone
1022996|NCT01919086|Lenalidomide
1022997|NCT01919086|13-064
1022998|NCT01919073|Attention Deficit, ADD, ADHD, ODD, Oppositional Behavior, Disruptive Behavior, Behavior Modification, Parent Management Training, Pre-School
1022999|NCT01919047|overactive bladder
1023000|NCT01919047|mirabegron
1023001|NCT01919047|occurrence of adverse events
1023002|NCT01919047|Overactive Bladder Symptom Score
1023003|NCT01919034|Interleukin-20, Thrombomodulin, Huntington disease, patient control analgesic
1023004|NCT01919008|FK949E
1023005|NCT01919008|Pharmacokinetics
1023006|NCT01919008|Major Depressive Disorder
1023007|NCT01918995|CVT3146
1023008|NCT01918995|Regadenoson
1023009|NCT01918982|Aortic aneurysm
1023010|NCT01918982|circulating endothelial progenitor cells
1023011|NCT01918969|Endothelial progenitor cells
1023012|NCT01918969|Healthy blood donors
1023013|NCT01918956|immunotherapy
1023014|NCT01918956|birch pollen
1023015|NCT01918956|seasonal allergy
1023016|NCT01918956|up-dosing
1023017|NCT01918943|Spine
1023018|NCT01918943|Aspen device
1023019|NCT01918943|PLIF
1023020|NCT01918943|Low back pain
1023021|NCT01918930|Melanoma
1023022|NCT01918930|Accessible tumors
1023023|NCT01918930|B7-H3 positive tumors
1023024|NCT01918917|Arthroscopic knee surgery
1023025|NCT01918917|Dexmedetomidine
1023026|NCT01918917|Analgesia
1023027|NCT01918904|calcinosis
1023028|NCT01918904|sodium thiosulfate
1023029|NCT01918904|topical treatment
1023030|NCT01918904|connective tissue disease
1023031|NCT01918891|stroke
1023032|NCT01918891|transient ischemic attack
1023033|NCT01918891|High blood pressure
1023034|NCT01918891|Hypertension
1023035|NCT01918878|age-related macular degeneration
1023036|NCT01918878|intravitreal injections
1023037|NCT01918878|Aflibercept
1023038|NCT01918878|EYLEA
1023039|NCT01918865|Type 2 Diabetes Mellitus
1023040|NCT01918865|T2DM
1023041|NCT01918852|Hand-foot syndrome
1023042|NCT01918852|Toxicity
1023043|NCT01918852|Fluoropyrimidine
1023044|NCT01918852|Capecitabine
1023045|NCT01918852|Teysuno
1023046|NCT01918852|S1
1023047|NCT01918839|Investigational Device (VINCI Plus)
1023048|NCT01918839|Correction of nasolabial fold
1023049|NCT01918839|Wrinkle improvement
1023050|NCT01918839|Wrinkle correction
1023051|NCT01918800|fatigue
1023052|NCT01918800|quality of life
1023053|NCT01918800|rehabilitation
1023054|NCT01918800|self management
1023055|NCT01918800|energy effectiveness
1023056|NCT01918774|Unemployment
1023057|NCT01918774|Cognitive Behavioral Therapy
1023058|NCT01918774|Mental Disorders
1023059|NCT01918761|NSCLC
1023060|NCT01918761|Stage IV
1023061|NCT01918761|Pemetrexed
1023062|NCT01918761|Dacomitinib
1023063|NCT01918735|Safety
1023064|NCT01918735|Tolerability
1023065|NCT01918735|Assessment of potential adverse events
1023066|NCT01918735|Assessment of potential laboratory abnormalities
1023067|NCT01918722|Activating blood stagnation and expelling blood stasis
1023068|NCT01918722|Hematoma enlargement
1023069|NCT01918722|herbal medicine
1023070|NCT01918722|traditional chinese medicine
1023071|NCT01918722|random clinical trial
1023072|NCT01918696|suicide
1023073|NCT01918696|anger
1023074|NCT01918696|interpretation modification
1023075|NCT01918696|computerized treatment
1023076|NCT01918670|atrial fibrillation; catheter ablation; relapse; stroke; death
1023077|NCT01918657|Interventional
1023078|NCT01918657|Randomized
1023079|NCT01918657|Double blind
1023080|NCT01918657|Placebo controlled
1023081|NCT01918657|Pediatric
1023082|NCT01918618|levosimendan
1023083|NCT01918618|renal effects
1023084|NCT01918618|cardiac surgery
1023085|NCT01918618|left heart insufficiency
1023086|NCT01918605|prostate cancer
1023087|NCT01918605|brachytherapy
1023088|NCT01918605|spacer
1023089|NCT01918605|side effect
1023090|NCT01918592|bladder cancer
1023091|NCT01918592|neoadjuvant chemotherapy
1023092|NCT01918592|radical cystectomy
1023093|NCT01918592|lymphadenectomy
1023094|NCT01918592|biomarker
1023095|NCT01918553|AMD
1023096|NCT01918553|epidemiology
1023097|NCT01918553|risk factors
1023098|NCT01918553|cohort study
1023099|NCT01918540|Radiostereometry
1023100|NCT01918540|Total Hip Arthroplasty
1023101|NCT01918540|Stem design
1023102|NCT01918527|Locally advanced colon cancer
1023103|NCT01918527|Neoadjuvant chemotherapy
1023104|NCT01918514|Magnesium sulfate
1023105|NCT01918514|epidural
1023106|NCT01918514|interscalene
1023107|NCT01918514|NMDA receptor
1023108|NCT01918501|multiple sclerosis
1023109|NCT01918501|Remyelination
1023110|NCT01918501|Mitochondria
1023111|NCT01918501|fatty acids
1023112|NCT01918488|Diabetic Nephropathies
1023113|NCT01918488|Hypertension
1023114|NCT01918488|Proteinuria
1023115|NCT01918488|Albuminuria
1023116|NCT01918488|Epithelial Sodium Channels
1023117|NCT01918488|Epithelial Sodium Channel Blockers
1023118|NCT01918488|Amiloride
1023119|NCT01918475|randomized controlled trial
1023120|NCT01918475|placebo controlled trial
1023121|NCT01918475|cross over trial
1023122|NCT01918462|Alcoholic hepatitis
1023123|NCT01918462|IL-22
1023124|NCT01918462|Kupffer cells
1023125|NCT01918449|OSA
1023126|NCT01918449|CPAP treatment
1023127|NCT01918449|primary care
1023128|NCT01918449|efficacy
1023129|NCT01918436|Attention Deficit Hyperactivity Disorder
1023130|NCT01918436|Neurocognitive training for preschool children with ADHD
1023131|NCT01918436|Play intervention for children with ADHD
1023132|NCT01918423|Childhood adiposity
1023133|NCT01918423|Metabolic risk factors
1023134|NCT01918423|Bone mineralization
1023135|NCT01918410|contact lens
1023136|NCT01918410|alginic
1023137|NCT01918410|dry eyes
1023138|NCT01918384|Duchenne muscular dystrophy
1023139|NCT01918384|NPC-14
1023140|NCT01918384|Arbekacin
1023141|NCT01918384|nonsense
1023142|NCT01918384|readthrough
1023143|NCT01918345|Diabetes
1023144|NCT01918345|Diabetes Mellitus
1023145|NCT01918345|Diabetes Mellitus, Type 2
1023146|NCT01918345|Diabetes, gestational
1023147|NCT01918345|Prevention & control
1023148|NCT01918345|Postpartum Period
1023149|NCT01918345|Mothers
1023150|NCT01918345|Diet
1023151|NCT01918345|Diabetic Diet
1023152|NCT01918345|Exercise
1023153|NCT01918345|Life Style
1023154|NCT01918345|Motivation
1023155|NCT01918345|Health Behavior
1023156|NCT01918345|Insulin-Secreting Cells
1023157|NCT01918345|Randomized Controlled Trial
1023158|NCT01918345|Clinical Trial
1023159|NCT01918345|Pilot Projects
1023160|NCT01918345|Feasibility Studies
1023161|NCT01918306|Triple Negative Breast Cancer
1023162|NCT01918306|Estrogen receptor negative breast cancer
1023163|NCT01918306|Metastatic breast cancer
1023164|NCT01918306|Stage IV breast cancer
1023165|NCT01918306|HER2 negative breast cancer
1023166|NCT01918293|ASTHMA
1023167|NCT01918293|SMARTPHONE APPLICATION
1023168|NCT01918280|Klinefelter Syndrome
1023169|NCT01918280|Azoospermia
1023170|NCT01918280|Seminal analyses
1023171|NCT01918280|Testicular biopsy
1023172|NCT01918241|Pegylation
1023173|NCT01918241|G-CSF
1023174|NCT01918241|Efficacy
1023175|NCT01918241|Satety
1023176|NCT01918202|Enzyme occupancy
1023177|NCT01918202|PET
1023178|NCT01918202|Phosphodiesterase 10 inhibitor
1023179|NCT01918189|back pain
1023180|NCT01918189|low back pain
1023181|NCT01918189|chronic pain
1023182|NCT01918189|cognitive behavior therapy
1023183|NCT01918189|behavior therapy
1023184|NCT01918176|Palbociclib
1023185|NCT01918176|PD-0332991
1023186|NCT01918176|Proton Pump Inhibitor
1023187|NCT01918176|DDI
1023188|NCT01918176|Healthy Volunteers
1023189|NCT01918176|Pharmacokinetics
1023190|NCT01918176|Rabeprazole
1023191|NCT01918163|pomegranate pills, male infertility, pregnancy rate, semen analysis, ROS, oxidative stress
1023192|NCT01918124|disease free survival, overall survival
1023193|NCT01918111|Renal denervation, Exercise diastolic function, Atherosclerosis, New methods
1023194|NCT01918072|Women's Health
1023195|NCT01918072|Hospitals, Veterans
1023196|NCT01918072|Education
1023197|NCT01918072|Remote consultation
1023198|NCT01918072|Videoconferencing
1023199|NCT01918059|Trauma
1023200|NCT01918059|Eyelid
1023201|NCT01918059|Laceration
1023202|NCT01918059|Tissue adhesive
1023203|NCT01918059|suture
1023204|NCT01918059|cosmetic
1023205|NCT01918059|octyl-2-cyanoacrylate
1023206|NCT01918046|biomarker
1023207|NCT01918046|MIOX
1023208|NCT01918033|Rhinitis
1023209|NCT01918033|Allergic Rhinitis
1023210|NCT01918033|Nose Diseases
1023211|NCT01918033|Respiratory Tract Diseases
1023212|NCT01918033|Immune System Diseases
1023213|NCT01918033|Cholinergic Antagonists
1023214|NCT01918033|Cholinergic Agents
1023215|NCT01918033|Neurotransmitter Agents
1023216|NCT01918033|Histamine H1 Antagonists, Non-Sedating
1023217|NCT01918033|Histamine H1 Antagonists
1023218|NCT01918033|Histamine Antagonists
1023219|NCT01918033|Histamine Agents
1023220|NCT01918020|Fruit
1023221|NCT01918020|Vegetables
1023222|NCT01918020|Motor Activity
1023223|NCT01918007|Apnea
1023224|NCT01918007|Sleep Apnea Syndromes
1023225|NCT01918007|Snoring
1023226|NCT01918007|Sleep Apnea, Obstructive
1023227|NCT01918007|Respiration Disorders
1023228|NCT01918007|Respiratory Tract Diseases
1023229|NCT01918007|Signs and Symptoms, Respiratory Signs and Symptoms
1023230|NCT01918007|Sleep Disorders, Intrinsic
1023231|NCT01918007|Dyssomnias
1023232|NCT01918007|Sleep Disorders
1023233|NCT01918007|Respiratory Sounds
1023234|NCT01917981|Intermittent cardiac monitoring
1023235|NCT01917981|Implantable device
1023236|NCT01917968|POP
1023237|NCT01917968|Transvaginal
1023238|NCT01917968|Native Tissue Repair
1023239|NCT01917968|Repair Augmented with Mesh
1023240|NCT01917968|Pelvic Organ Prolapse
1023241|NCT01917955|MRI
1023242|NCT01917942|Radiotherapy
1023243|NCT01917942|Humidification
1023244|NCT01917942|Mucositis
1023245|NCT01917929|[E04.555.110.110.110]
1023246|NCT01917903|walking
1023247|NCT01917903|Parkinson's disease
1023248|NCT01917903|traumatic brain injury
1023249|NCT01917903|multiple sclerosis
1023250|NCT01917903|physical therapy
1023251|NCT01917903|falls
1023252|NCT01917903|memory
1023253|NCT01917903|attention
1023254|NCT01917903|multitasking
1023255|NCT01917903|exercise
1023256|NCT01917890|curcumin
1023257|NCT01917890|radioprotective
1023258|NCT01917890|radiosensitizer
1023259|NCT01917877|Becacizumab
1023260|NCT01917877|pulmonary fibrosis
1023261|NCT01917877|irradiation
1023262|NCT01917877|chemotherapy
1023263|NCT01917864|Autism
1023264|NCT01917864|Autism Spectrum Disorders
1023265|NCT01917864|Prosody
1023266|NCT01917864|Speech treatment
1023267|NCT01917851|Accurate
1023268|NCT01917851|Hb
1023269|NCT01917851|noninvasive measurement
1023270|NCT01917838|Mental Health Services
1023271|NCT01917825|radicular pain
1023272|NCT01917812|physical activity
1023273|NCT01917812|exercise
1023274|NCT01917812|mHealth
1023275|NCT01917812|smartphone
1023276|NCT01917812|activity tracker
1023277|NCT01917812|pedometer
1023278|NCT01917812|text messaging
1023279|NCT01917812|SMS
1023280|NCT01917799|Aspirin
1023281|NCT01917799|Heparin
1023282|NCT01917799|pregnancy
1023283|NCT01917799|miscarriage
1023284|NCT01917760|Gamma-aminobutyric acid
1023285|NCT01917760|Pharmacokinetics
1023286|NCT01917760|Pharmacodynamics
1023287|NCT01917760|Insulin
1023288|NCT01917760|C-peptide
1023289|NCT01917760|Glucagon
1023290|NCT01917747|Infant hearing screening
1023291|NCT01917747|Patient Navigator
1023292|NCT01917734|severe acute malnutrition
1023293|NCT01917734|severe wasting
1023294|NCT01917734|facility-based care
1023295|NCT01917734|community-based care
1023296|NCT01917734|Madhya Pradesh
1023297|NCT01917734|India
1023298|NCT01917721|Kawasaki disease
1023299|NCT01917721|doxycycline
1023300|NCT01917721|coronary artery aneurysm
1023301|NCT01917708|non malignant conditions
1023302|NCT01917708|blood and marrow transplant
1023303|NCT01917695|Bulky cervical cancers
1023304|NCT01917695|Neoadjuvant Chemotherapy
1023305|NCT01917695|Neoadjuvant Chemoradiotherapy
1023306|NCT01917682|robotic-assisted PCI
1023307|NCT01917682|coronary intervention
1023308|NCT01917682|CorPath PRECISION Registry
1023309|NCT01917682|PCI
1023310|NCT01917682|angioplasty
1023311|NCT01917643|COPD, Comparative Effectiveness, Symbicort
1023312|NCT01917630|Celiac disease
1023313|NCT01917630|Gluten-free diet
1023314|NCT01917630|Coeliac disease
1023315|NCT01917630|Celiac sprue
1023316|NCT01917604|open versus closed surgical technique
1023317|NCT01917604|impacted maxillary canine
1023318|NCT01917604|orthodontic disimpaction
1023319|NCT01917591|Bandages
1023320|NCT01917591|Biological Dressings
1023321|NCT01917591|Chronic Disease
1023322|NCT01917591|Collagen
1023323|NCT01917591|Epithelium
1023324|NCT01917591|Extracellular Matrix
1023325|NCT01917591|Extra Cellular Matrix
1023326|NCT01917591|Fibroblasts
1023327|NCT01917591|Granulation Tissue
1023328|NCT01917591|Leg Ulcer
1023329|NCT01917591|Middle Aged
1023330|NCT01917591|Prospective Studies
1023331|NCT01917591|Soft Tissue Injuries
1023332|NCT01917591|Treatment Outcome
1023333|NCT01917591|Varicose Ulcer
1023334|NCT01917591|Wound Healing
1023335|NCT01917591|Wounds and Injuries
1023336|NCT01917591|biopsy
1023337|NCT01917591|autoimmunity
1023338|NCT01917578|Breast Cancer
1023339|NCT01917578|shrinkage modes
1023340|NCT01917578|three-dimensional reconstruction
1023341|NCT01917578|neoadjuvant chemotherapy
1023342|NCT01917578|Magnetic Resonance Imaging
1023343|NCT01917565|airway management
1023344|NCT01917565|laryngoscope
1023345|NCT01917565|Airtraq
1023346|NCT01917565|Macintosh laryngoscope
1023347|NCT01917565|fiberoptic bronchoscope
1023348|NCT01917565|intubation
1023349|NCT01917552|Gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, adjuvant, capecitabine, gastric cancer, stage 1b
1023350|NCT01917526|Oxygen
1023351|NCT01917526|PACU
1023352|NCT01917526|Hypoxemia
1023353|NCT01917513|Adenoma
1023354|NCT01917513|Polyps
1023355|NCT01917513|CRC
1023356|NCT01917513|Colonoscopy
1023357|NCT01917513|Detection Yield
1023358|NCT01917500|Continues non-invasive Blood pressure measurement
1023359|NCT01917500|Continues non-invasive Cardiac Output measurement
1023360|NCT01917474|low-lipid diet
1023361|NCT01917474|normal lipid intake
1023362|NCT01917474|saturated fats reduction
1023363|NCT01917474|headache attacks
1023364|NCT01917448|postoperative pain
1023365|NCT01917448|spinal morphine
1023366|NCT01917448|video-assisted thoracoscopic surgery
1023367|NCT01917435|fiberoptic bronchoscopy,
1023368|NCT01917435|Video-stylet,
1023369|NCT01917435|Nasotracheal Intubation
1023621|NCT01916343|Curriculum
1023370|NCT01917409|Conventional Laryngoscopy ,
1023371|NCT01917409|Video-stylet ,
1023372|NCT01917409|Nasotracheal Intubation
1023373|NCT01917396|caesarean, bowel, gass
1023374|NCT01917383|glaucoma
1023375|NCT01917383|primary open angle glaucoma
1023376|NCT01917383|ocular hypertension
1023377|NCT01917383|adenosine agonist
1023378|NCT01917383|eye drop
1023379|NCT01917383|trabodenoson
1023380|NCT01917383|trabecular meshwork
1023381|NCT01917370|intrahepatic cholangiocarcinoma
1023382|NCT01917370|icc
1023383|NCT01917370|vegf signal pathway
1023384|NCT01917357|Vaccination
1023385|NCT01917357|Immunisation
1023386|NCT01917357|Virus
1023387|NCT01917357|Diphtheria
1023388|NCT01917357|Pertussis
1023389|NCT01917357|Tetanus
1023390|NCT01917357|Hepatitis B
1023391|NCT01917357|Haemophilus Influenzae
1023392|NCT01917357|Immunity
1023393|NCT01917344|Phenylketonuria
1023394|NCT01917344|MRI
1023395|NCT01917344|Neuropsychological functioning
1023396|NCT01917344|Neurological functioning
1023397|NCT01917344|EEG
1023398|NCT01917331|spirometry
1023399|NCT01917331|severe COPD
1023400|NCT01917331|lung disease
1023401|NCT01917331|fixed combination
1023402|NCT01917318|Post traumatic stress disorder
1023403|NCT01917318|Treatment of post traumatic stress disorder
1023404|NCT01917318|Symptoms of arousal in post traumatic stress disorder
1023405|NCT01917318|Iloperidone in post traumatic stress disorder
1023406|NCT01917305|Bacteria
1023407|NCT01917305|bone level
1023408|NCT01917305|bone loss
1023409|NCT01917305|dental implants
1023410|NCT01917305|implant design
1023411|NCT01917305|platform-shifting
1023412|NCT01917305|platform-matching
1023413|NCT01917292|Periodontitis
1023414|NCT01917292|Prehypertension
1023415|NCT01917292|Periodontal Intervention
1023416|NCT01917279|Metastatic Breast Cancer
1023417|NCT01917279|Antineoplastic Agents
1023418|NCT01917279|Therapeutic Uses
1023419|NCT01917279|Antimetabolites
1023420|NCT01917279|Tubulin Modulators
1023421|NCT01917279|Maintenance chemotherapy
1023422|NCT01917279|Metronomic chemotherapy
1023423|NCT01917279|Capecitabine
1023424|NCT01917279|Docetaxel
1023425|NCT01917253|infiltration, phlebitis, occlusion, thrombosis
1023426|NCT01917240|Monophasic
1023427|NCT01917240|Sequential
1023428|NCT01917240|Media
1023429|NCT01917201|Coronary Artery Disease
1023430|NCT01917201|Drug Eluting Stents
1023431|NCT01917201|Intravascular Ultrasound
1023432|NCT01917201|Optical Coherence Tomography
1023433|NCT01917201|Intravascular Visualization
1023434|NCT01917175|HIV
1023435|NCT01917175|Cohort
1023436|NCT01917175|Early HIV infection
1023437|NCT01917175|Côte d'Ivoire
1023438|NCT01917175|Disease progression
1023439|NCT01917162|contact lenses
1023440|NCT01917162|daily disposable contact lenses
1023441|NCT01917162|silicone hydrogel
1023442|NCT01917162|contact lens comfort
1023443|NCT01917162|near-sighted
1023444|NCT01917149|Dilated cardiomyopathy
1023445|NCT01917149|High dose ACEI/ARB
1023451|NCT01917123|L-Citrulline malate,Coronary Heart Disease, Brachial Index
1023452|NCT01917084|Passive range of motion
1023453|NCT01917084|Single ventricle
1023454|NCT01917084|Infants
1023455|NCT01917084|Congenital heart disease
1023456|NCT01917058|Alopecia Areata
1023457|NCT01917058|Abatacept
1023458|NCT01917045|sufentanil
1023459|NCT01917045|morphine
1023460|NCT01917045|postoperative pain control
1023461|NCT01917045|body fat percentage
1023462|NCT01917045|gynecology laparoscopic surgery
1023463|NCT01917045|lipid solubility
1023464|NCT01917032|Trace Elements
1023465|NCT01917032|Preschool
1023466|NCT01917032|Malnutrition
1023467|NCT01917032|Fortified Food
1023468|NCT01917019|Japan
1023469|NCT01916980|Dermatitis
1023470|NCT01916980|Dermatitis, Atopic
1023471|NCT01916980|Skin Diseases
1023472|NCT01916980|Skin Diseases, Genetic
1023473|NCT01916980|Genetic Diseases, Inborn
1023474|NCT01916980|Skin Diseases, Eczematous
1023475|NCT01916980|Hypersensitivity, Immediate
1023476|NCT01916980|Hypersensitivity
1023477|NCT01916980|Immune System Diseases
1023478|NCT01916967|Urticaria
1023479|NCT01916967|Skin Diseases, Vascular
1023480|NCT01916967|Skin Diseases
1023481|NCT01916967|Hypersensitivity, Immediate
1023482|NCT01916967|Hypersensitivity
1023483|NCT01916967|Immune System Diseases
1023484|NCT01916967|Cholinergic Antagonists
1023485|NCT01916967|Cholinergic Agents
1023486|NCT01916967|Neurotransmitter Agents
1023487|NCT01916967|Histamine H1 Antagonists, Non-Sedating
1023488|NCT01916967|Histamine H1 Antagonists
1023489|NCT01916967|Histamine Antagonists
1023490|NCT01916967|Histamine Agents
1023491|NCT01916954|Malaria
1023492|NCT01916954|Pregnancy
1023493|NCT01916954|Plasmodium falciparum
1023494|NCT01916928|Circulating cell free fetal DNA
1023495|NCT01916928|Intrauterine fetal demise
1023496|NCT01916928|Miscarriage
1023497|NCT01916902|Optical Coherence Tomography
1023498|NCT01916902|Ticagrelor
1023499|NCT01916889|Delirium
1023500|NCT01916876|medical in-patients
1023501|NCT01916876|follow-up care
1023502|NCT01916876|developing country
1023503|NCT01916837|Breast cancer
1023504|NCT01916837|Feasibility
1023505|NCT01916837|Genomic grade index
1023506|NCT01916824|depression
1023507|NCT01916824|melancholia
1023508|NCT01916824|treatment
1023509|NCT01916811|Low Back Pain
1023510|NCT01916811|Load quantitative MRI
1023511|NCT01916798|Infertility
1023512|NCT01916798|intralipid
1023513|NCT01916798|invitro fertilization
1023514|NCT01916798|repeated implantation failure
1023515|NCT01916798|repeated miscarriage
1023516|NCT01916772|cherubism
1023517|NCT01916772|bone tumors
1023518|NCT01916759|immunization
1023519|NCT01916746|Caesarean Scar Pregnancy
1023520|NCT01916746|Transvaginal Resection
1023521|NCT01916746|treatment
1023522|NCT01916707|trauma
1023523|NCT01916707|enoxaparin
1023524|NCT01916707|weight based
1023525|NCT01916707|prophylaxis
1023526|NCT01916694|Gestational diabetes mellitus
1023527|NCT01916694|m Health
1023528|NCT01916694|Smartphone
1023529|NCT01916694|Blood glucose monitoring
1023530|NCT01916681|Induction
1023531|NCT01916681|Labor
1023532|NCT01916681|Cervical foley
1023533|NCT01916681|Misoprostol
1023534|NCT01916681|Pitocin
1023535|NCT01916681|Oxytocin
1023536|NCT01916681|Cytotec
1023537|NCT01916681|Delivery
1023538|NCT01916681|IOL
1023539|NCT01916655|Obstructive Sleep Apnea
1023540|NCT01916655|Adherence
1023541|NCT01916655|Chronic Disease
1023542|NCT01916655|Telemedicine
1023543|NCT01916655|Continuous Positive Airway Pressure
1023544|NCT01916655|Mobile Health
1023545|NCT01916642|iv lidocaine
1023546|NCT01916642|inducing dose
1023547|NCT01916642|etomidate
1023548|NCT01916642|dose response
1023549|NCT01916616|paradoxical vocal fold motion
1023550|NCT01916616|cognitive-behavioral therapy
1023551|NCT01916590|Post-operative pain
1023552|NCT01916590|Anterior Cruciate Ligament repair
1023553|NCT01916577|Stem Cell Mobilization
1023554|NCT01916577|Stem Cells
1023555|NCT01916577|Transplantation
1023556|NCT01916577|Autologous
1023557|NCT01916564|Bowel preparation
1023558|NCT01916564|Morning colonoscopy
1023559|NCT01916564|Split-dose
1023560|NCT01916564|Same-morning whole-dose
1023561|NCT01916564|Reduced-volume PEG-ELS
1023562|NCT01916538|anorexia nervosa
1023563|NCT01916538|genetics
1023564|NCT01916538|gene
1023565|NCT01916538|eating disorder
1023566|NCT01916525|Acute coronary syndrome
1023567|NCT01916525|Cost-effectiveness
1023568|NCT01916525|Cardiac rehabilitation
1023569|NCT01916525|Exercise
1023570|NCT01916525|Physical activity
1023571|NCT01916525|Home monitoring
1023572|NCT01916512|CETP, HDL, LDL, apoB-100, apoB-48, remnants
1023573|NCT01916499|Child, adolescent
1023574|NCT01916499|Coronary artery disease
1023575|NCT01916499|Magnetic resonance imaging
1023576|NCT01916473|Epidural analgesia
1023577|NCT01916473|continuous wound infusion
1023578|NCT01916473|ropivacaine
1023579|NCT01916473|total abdominal hysterectomy
1023580|NCT01916460|Gastroparesis
1023581|NCT01916460|Endoscopic ultrasound
1023582|NCT01916460|Interstitial cell of Cajal
1023583|NCT01916447|Angiogenesis Inhibitor
1023584|NCT01916447|Monoclonal Antibody
1023585|NCT01916447|Vascular Endothelial Growth Factor A (VEGF-A)
1023586|NCT01916434|Farmed fish
1023587|NCT01916434|Dietary intervention
1023588|NCT01916434|Long-term intervention
1023589|NCT01916434|Omega-3 index
1023590|NCT01916434|Cardiovascular risk markers
1023591|NCT01916434|Coagulation and endothelial activation
1023592|NCT01916434|Bleeding time
1023593|NCT01916434|Inflammation
1023594|NCT01916434|Oxidative stress
1023595|NCT01916434|Gut health
1023596|NCT01916434|Micronutrient availability
1023597|NCT01916421|Pancreatic adenocarcinoma
1023598|NCT01916421|lymphadenopathy
1023599|NCT01916421|Endoscopic ultrasound
1023600|NCT01916408|Exercise
1023601|NCT01916408|Inflammation
1023602|NCT01916408|Upper Respiratory Tract Illness
1023603|NCT01916408|Oral Proteolytic and Hydrolytic Enzymes
1023604|NCT01916408|Flavinoids
1023605|NCT01916395|Migraine
1023606|NCT01916382|Alkaptonuria, nitisinone,Ochronosis, Homogentisic acid
1023607|NCT01916369|Peripheral Arterial Disease
1023608|NCT01916369|Fontaine Stage II, III or IV
1023609|NCT01916369|Vascular disease
1023610|NCT01916369|Cardiovascular diseases
1023611|NCT01916369|Neural stem cell
1023612|NCT01916356|Infertility
1023613|NCT01916356|Education
1023614|NCT01916356|Risk Factors
1023615|NCT01916356|Fertility knowledge
1023616|NCT01916356|Fertility myths
1023617|NCT01916343|Laparoscopy
1023618|NCT01916343|Surgical skills
1023619|NCT01916343|Team training
1023620|NCT01916343|Obstetrics and Gynecology
1023622|NCT01916304|Drug Therapy
1023623|NCT01916252|Multiple Myeloma
1023624|NCT01916252|MEL200
1023625|NCT01916252|BUMEL
1023626|NCT01916239|Pomegranate
1023627|NCT01916239|Urolithins
1023628|NCT01916239|Colorectal cancer
1023629|NCT01916239|Colon cancer
1023630|NCT01916239|Metabolite
1023631|NCT01916239|Gene expression
1023632|NCT01916239|microRNA
1023633|NCT01916239|Nutraceutical
1023634|NCT01916239|Food supplement
1023635|NCT01916239|Polyphenol
1023636|NCT01916239|Gut microbiota
1023637|NCT01916226|cetirizine
1023638|NCT01916226|seasonal allergic rhinitis
1023639|NCT01916226|Quality of Life
1023640|NCT01916226|fluticasone propionate nasal spray
1023641|NCT01916161|Crohn's disease
1023642|NCT01916161|ulcerative colitis
1023643|NCT01916161|anxiety
1023644|NCT01916161|patient knowledge
1023645|NCT01916161|information sources
1023646|NCT01916148|Hypoglycemia
1023647|NCT01916148|Hyperinsulinism
1023652|NCT01916122|Fluorestradiol (FES)
1023653|NCT01916122|PET/CT scan
1023654|NCT01916122|Estrogen Receptor
1023655|NCT01916122|13-071
1023656|NCT01916109|Gemcitabine
1023657|NCT01916109|Carboplatin
1023658|NCT01916109|Panitumumab
1023659|NCT01916109|(GCaP)
1023660|NCT01916109|radical cystectomy
1023661|NCT01916109|10-103
1023662|NCT01916070|syncope
1023663|NCT01916070|near syncope
1023664|NCT01916070|prognosis
1023665|NCT01916070|emergency department
1023666|NCT01916057|Positron-Emission Tomography Scan
1023667|NCT01916057|Fluorodeoxyglucose F18
1023668|NCT01916057|Magnetic Resonance Imaging
1023669|NCT01916057|Enzyme-Linked Immunospot Assay
1023670|NCT01916057|Immune Reconstitution Inflammatory Syndrome
1023671|NCT01916057|Real-Time Polymerase Chain Reaction
1023672|NCT01916057|beta-1,3-D-glucan
1023673|NCT01916057|Candida spp.
1023674|NCT01916057|Genetic Susceptibility
1023675|NCT01916057|Genotype
1023676|NCT01916044|caesarean,
1023677|NCT01916044|trial of labor,
1023678|NCT01916044|ultrasound
1023679|NCT01916018|Congenital hypothyroidism
1023680|NCT01916018|Thyroid dysgenesis
1023681|NCT01916018|Genetics
1023682|NCT01916018|Associated malformations
1023683|NCT01916018|Psychomotor delay
1023684|NCT01916018|Mental retardation
1023685|NCT01915979|plasma rich in growth factors, tendinopathy, traumatology
1023686|NCT01915979|,rotator cuff, effectiveness, plasma rich in platelets
1023687|NCT01915953|Accurte Hb noninvasive measurement
1023688|NCT01915940|Glaucoma
1023689|NCT01915940|Primary Open-Angle Glaucoma
1023690|NCT01915940|Ocular Hypertension
1023691|NCT01915888|Clinical
1023692|NCT01915888|Children
1023693|NCT01915888|Rotavirus
1023694|NCT01915888|Cost
1023695|NCT01915888|Rotarix vaccination
1023696|NCT01915875|Cystic fibrosis-pain-sophrology
1023697|NCT01915862|Acute ischemic stroke
1023698|NCT01915862|Blood pressure variability
1023699|NCT01915862|Ambulatory arterial stiffness index
1023700|NCT01915862|Ambulatory blood pressure monitoring
1023701|NCT01915862|Outcome
1023702|NCT01915836|11-043
1023703|NCT01915836|MSKCC Tobacco Cessation Program
1023704|NCT01915810|Tobacco Use Cessation
1023705|NCT01915810|Smoking Cessation with Physical Activity
1023706|NCT01915810|SCwPA
1023707|NCT01915810|Cancer Prevention
1023708|NCT01915810|African American cigarette smoker
1023709|NCT01915810|Questionnaires
1023710|NCT01915810|Surveys
1023711|NCT01915810|Phone Counseling
1023712|NCT01915810|Breath Test
1023713|NCT01915810|Walking Program
1023714|NCT01915810|Nicotine Patch
1023715|NCT01915810|Audio Recorded Focus Group
1023716|NCT01915797|Pediatric patients, tumor, developmental abnormalities
1023717|NCT01915745|Osteoporosis
1023718|NCT01915745|Bone densitometry
1023719|NCT01915745|Fracture
1023720|NCT01915745|Anti-osteoporotic treatment
1023721|NCT01915745|Short message service
1023722|NCT01915706|Glaucoma drainage device
1023723|NCT01915706|Baerveldt 350
1023724|NCT01915706|Ripcord
1023725|NCT01915706|Complications
1023726|NCT01915693|Radiotherapy
1023727|NCT01915693|stent
1023728|NCT01915693|quality of life
1023729|NCT01915654|Cardiac surgery
1023730|NCT01915654|Transfusion
1023731|NCT01915641|walking capacity
1023732|NCT01915641|COPD
1023733|NCT01915641|OSA
1023734|NCT01915641|CPAP
1023735|NCT01915628|MACE
1023736|NCT01915628|Safety
1023737|NCT01915628|Efficacy
1023738|NCT01915628|On label
1023739|NCT01915628|Myocardial Infarction
1023740|NCT01915628|Cardiac death
1023741|NCT01915628|TVR
1023742|NCT01915628|stent thrombosis
1023743|NCT01915615|Hypertrophic cardiomyopathy
1023744|NCT01915615|Cardiac magnetic resonance imaging
1023745|NCT01915615|CMR
1023746|NCT01915615|Genetics
1023747|NCT01915615|Biomarkers
1023748|NCT01915615|Late gadolinium enhancement
1023749|NCT01915615|T1 mapping
1023750|NCT01915602|Hepatocellular Carcinoma
1023751|NCT01915602|Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor
1023752|NCT01915602|Sorafenib
1023753|NCT01915602|Objective tumor response rate (ORR)
1023754|NCT01915602|modified RECIST criteria
1023755|NCT01915589|Hepatocellular Carcinoma
1023756|NCT01915589|Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor
1023757|NCT01915589|Objective tumor response rate (ORR)
1023758|NCT01915589|modified RECIST criteria
1023759|NCT01915563|Mechanical ventilation
1023760|NCT01915563|Weaning
1023761|NCT01915563|Extubation failure
1023762|NCT01915550|Diabetes mellitus
1023763|NCT01915550|Pregnancy
1023764|NCT01915550|Insulin
1023765|NCT01915550|Metformin
1023766|NCT01915537|poor prognosis
1023767|NCT01915537|severe RA
1023768|NCT01915537|infliximab
1023769|NCT01915511|Idiopathic pulmonary fibrosis
1023770|NCT01915511|Pulmonary fibrosis
1023771|NCT01915511|IPF
1023772|NCT01915511|Registry
1023773|NCT01915511|1199.174
1023774|NCT01915498|acute myeloid leukemia
1023775|NCT01915498|AML
1023776|NCT01915498|myelodysplastic syndrome
1023777|NCT01915498|MDS
1023778|NCT01915498|hematologic malignancies
1023779|NCT01915498|IDH2
1023780|NCT01915498|Phase I
1023781|NCT01915498|Phase II
1023782|NCT01915498|AG-221
1023783|NCT01915498|relapse AML
1023784|NCT01915498|refractory AML
1023785|NCT01915472|Metastatic Colorectal Cancer
1023786|NCT01915472|Colorectal Cancer
1023787|NCT01915472|Rectal Cancer
1023788|NCT01915472|previously treated
1023789|NCT01915459|Stroke
1023790|NCT01915459|Spasticity
1023791|NCT01915446|EVAR
1023792|NCT01915446|endovascular aortic repair
1023793|NCT01915446|acute kidney failure
1023794|NCT01915446|mesenteric ischemia
1023795|NCT01915433|Secondary Progressive Multiple Sclerosis
1023796|NCT01915433|Primary Progressive Multiple Sclerosis
1023797|NCT01915433|Relapsing progressive multiple sclerosis
1023798|NCT01915433|relapsing remitting multiple sclerosis
1023799|NCT01915433|Fatigue
1023800|NCT01915433|Quality of life
1023801|NCT01915433|Paleo
1023802|NCT01915433|Nutrition
1023803|NCT01915433|Ketogenic
1023804|NCT01915420|Drug eluting stent
1023805|NCT01915420|Bioabsorbable
1023806|NCT01915420|Bioresorbable
1023807|NCT01915420|Coronary Stent
1023808|NCT01915420|Scaffold
1023809|NCT01915420|Stents
1023810|NCT01915420|Angioplasty
1023811|NCT01915420|Coronary Artery Disease
1023812|NCT01915420|Stentthrombosis
1023813|NCT01915420|Rotational atherectomy
1023814|NCT01915394|Respiratory Syncytial Virus Infections
1023815|NCT01915394|Epidemics
1023816|NCT01915394|Neonatal Intensive Care Unit
1023817|NCT01915394|Newborn infants
1023818|NCT01915381|Intellectual disability
1023819|NCT01915381|mHealth
1023820|NCT01915381|App
1023821|NCT01915381|Physical activity
1023822|NCT01915381|Adherence
1023823|NCT01915368|Exercise
1023824|NCT01915368|Rehabilitation
1023825|NCT01915368|Dose
1023826|NCT01915368|Randomized controlled trial
1023827|NCT01915368|Stroke
1023828|NCT01915355|onychomycosis
1023829|NCT01915355|nail
1023830|NCT01915355|fungus
1023831|NCT01915342|Monosynaptic reflex
1023832|NCT01915342|H-reflex
1023833|NCT01915329|CRPS
1023834|NCT01915329|repetitive sensory stimulation
1023835|NCT01915329|cortical reorganization
1023836|NCT01915329|2-point-discrimination
1023837|NCT01915303|Cushing's disease, pituitary tumors, pasireotide, cabergoline, combination treatment, UFC, hormone disorder, cortisol, adrenocorticotropic hormone
1023838|NCT01915290|physical activity
1023839|NCT01915290|maximal oxygen uptake
1023840|NCT01915277|Pediatric corrective cardiac surgery
1023841|NCT01915264|Diabetes Mellitus
1023842|NCT01915264|Type 2 Diabetes
1023843|NCT01915264|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination
1023844|NCT01915251|Vulvovaginal Candidiasis
1023845|NCT01915251|Amoxicilin
1023846|NCT01915251|Microbiome
1023847|NCT01915238|Age-Related Macular Degeneration (AMD)
1023848|NCT01915238|AMD
1023849|NCT01915225|Tissue Procurement
1023850|NCT01915225|Surgery
1023851|NCT01915225|Metastasectomy
1023852|NCT01915212|Vaccination
1023853|NCT01915212|Replication-Defective
1023854|NCT01915212|Genital Herpes
1023855|NCT01915212|Safety
1023856|NCT01915212|Immune Responses
1023857|NCT01915186|DHEA
1023858|NCT01915186|Poor ovarian reserve
1023859|NCT01915186|Normal ovarian reserve
1023860|NCT01915186|In vitro fertilization treatment
1023861|NCT01915186|Ovarian response
1023862|NCT01915186|Pregnancy outcomes
1023863|NCT01915173|Gastroesophageal reflux disease (GERD)
1023864|NCT01915173|Heartburn
1023865|NCT01915173|Dyspepsia
1023866|NCT01915147|oxycodone naloxone combination
1023867|NCT01915147|severe chronic pain
1023868|NCT01915147|non-malignant pain
1023869|NCT01915147|Non-malignant pain that requires around-the-clock opioid therapy
1023870|NCT01915134|nasopharyngeal carcinoma
1023871|NCT01915134|Recombinant Human Endostatin
1023872|NCT01915134|chemotherapy
1023873|NCT01915134|gemcitabine and cisplatin
1023874|NCT01915121|Bladder Cancer
1023875|NCT01915121|Intervention
1023876|NCT01915121|Education
1023877|NCT01915121|Randomized Controlled Trials
1023878|NCT01915095|spinal cord injury
1023879|NCT01915095|neural control
1023880|NCT01915095|motor function
1023881|NCT01915095|hand movement
1023882|NCT01915082|Lung Function
1023883|NCT01915082|Allograft Outcome
1023884|NCT01915069|contraception
1023885|NCT01915069|Cilostazol
1023886|NCT01915069|phosphodiesterase inhibitors
1023887|NCT01915069|To assess the ability of Cilostazol to act as a contraceptive agent
1023888|NCT01915056|Comprehensive Geriatric Assessment (CGA)
1023889|NCT01915056|GA-driven interventions
1023890|NCT01915056|Toxicity
1023891|NCT01915056|Outcomes
1023892|NCT01915056|providing information
1023893|NCT01915056|older cancer patients
1023894|NCT01915056|first-line chemotherapy
1023895|NCT01915056|second-line chemotherapy
1023896|NCT01915043|lymphedema, prevention, ehealth, cancer
1023897|NCT01915030|Muscle
1023898|NCT01915030|Physical performance
1023899|NCT01915030|Protein
1023900|NCT01915030|Diet
1023901|NCT01915030|Caloric restriction
1023902|NCT01915017|Cognitive Adaptation Training
1023903|NCT01915017|Cognitive Behavior Therapy for Psychosis
1023904|NCT01915017|Schizophrenia
1023905|NCT01915004|Pediatric Urology
1023906|NCT01915004|Urotherapy
1023907|NCT01915004|Nonneurogenic Lower Urinary Tract Dysfunction
1023908|NCT01915004|Dysfunctional Elimination Syndrome
1023909|NCT01915004|Randomized Controlled Trial
1023910|NCT01914991|proximal interphalangeal joint
1023911|NCT01914991|Orthoses
1023912|NCT01914965|Huntington's disease
1023913|NCT01914965|Apathy
1023914|NCT01914965|Bupropion
1023915|NCT01914952|CaHMB
1023916|NCT01914952|HMB free acid
1023917|NCT01914952|HMB
1023918|NCT01914939|autism spectrum disorder
1023919|NCT01914939|social skills deficits
1023920|NCT01914939|cognitive behavioral therapy
1023921|NCT01914939|oxytocin
1023922|NCT01914939|young adult
1023923|NCT01914926|metoprolol
1023924|NCT01914926|diltiazem
1023925|NCT01914926|heart rate
1023926|NCT01914913|retinitis pigmentosa
1023927|NCT01914913|Bone marrow
1023928|NCT01914913|stem cell
1023929|NCT01914913|BMMNC
1023930|NCT01914900|oral cavity cancer
1023931|NCT01914900|induction chemotherapy
1023932|NCT01914900|TP53
1023933|NCT01914900|beta tubulin II
1023934|NCT01914887|Ulcerative Colitis
1023935|NCT01914887|Inflammatory Bowel Disease
1023936|NCT01914887|Mesenchymal stem cells
1023937|NCT01914874|Community Sample
1023938|NCT01914835|cocaine dependence
1023939|NCT01914835|neuropsychological rehabilitation
1023940|NCT01914835|executive functions
1023941|NCT01914822|Ritalin
1023942|NCT01914822|methylphenidate hydrochloride
1023943|NCT01914822|experimental pain
1023944|NCT01914796|Phase 1
1023945|NCT01914796|Randomized
1023946|NCT01914796|Double Blind
1023947|NCT01914796|Placebo-Controlled
1023948|NCT01914796|Single-Dose Escalation
1023949|NCT01914796|Safety
1023950|NCT01914796|Tolerability
1023951|NCT01914796|PK
1023952|NCT01914796|PD
1023953|NCT01914796|PF-06412562
1023954|NCT01914783|air pollution
1023955|NCT01914783|ozone
1023956|NCT01914783|fine particle
1023957|NCT01914783|cytokine
1023958|NCT01914783|chemokine
1023959|NCT01914783|oxidative stress
1023960|NCT01914783|inflammation
1023961|NCT01914783|heart rate variability
1023962|NCT01914783|autonomic nervous system
1023963|NCT01914783|sympathetic nerve activity
1023964|NCT01914783|plasma catecholamine
1023965|NCT01914770|pooled analyses
1023966|NCT01914770|quality of life
1023967|NCT01914770|SELENA SLEDAI
1023968|NCT01914770|SLE
1023969|NCT01914770|steroid use
1023970|NCT01914770|responder rate
1023971|NCT01914770|flares
1023972|NCT01914770|belimumab
1023973|NCT01914770|BILAG
1023974|NCT01914757|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
1023975|NCT01914744|NHL
1023976|NCT01914744|HBV
1023977|NCT01914744|entecavir
1023978|NCT01914744|lamivudine
1023979|NCT01914731|Fecal Microbiota Transplant
1023980|NCT01914731|Clostridium difficile
1023981|NCT01914731|Diarrhea
1023982|NCT01914718|DLBCL
1023983|NCT01914718|DA-EPOCH-R
1023984|NCT01914705|Landmark
1023985|NCT01914705|Ultrasound
1023986|NCT01914705|central venous catheter
1023987|NCT01914679|Fibromyalgia
1023988|NCT01914679|Pain
1023989|NCT01914679|Brain
1023990|NCT01914679|Stimulation
1023991|NCT01914679|Device
1023992|NCT01914679|Treatment
1023993|NCT01914666|Chronic Low Back Pain
1023994|NCT01914666|CLBP
1023995|NCT01914640|Waist circumference, Metabolic Syndrome, Cardiovascular risk
1023996|NCT01914627|Psoriasis capitis
1023997|NCT01914627|Scaling
1023998|NCT01914627|Salicylic acid
1023999|NCT01914627|Dimethicone
1024000|NCT01914627|Plaque removal
1024001|NCT01914614|Breast Cancer
1024002|NCT01914614|Working Women
1024003|NCT01914601|Laryngoscope
1024004|NCT01914601|Macintosh
1024005|NCT01914601|King Vision
1024006|NCT01914601|tracheal intubation
1024007|NCT01914601|cervical spines
1024008|NCT01914536|POMPE
1024009|NCT01914536|Glycogenosis type II
1024010|NCT01914536|Acid maltase deficiency
1024011|NCT01914523|Laryngoscope
1024012|NCT01914523|Macintosh
1024013|NCT01914523|Glidescope
1024014|NCT01914523|King Vision
1024015|NCT01914523|AirTraq
1024016|NCT01914523|tracheal intubation
1024017|NCT01914510|ovarian
1024018|NCT01914510|cancer
1024019|NCT01914510|clear cell
1024020|NCT01914510|ENMD-2076
1024021|NCT01914510|oral
1024022|NCT01914510|capsule
1024023|NCT01914484|tyrosine kinase inhibitor resistance
1024024|NCT01914484|chronic myeloid leukemia
1024025|NCT01914484|acute lymphoblastic leukemia
1024026|NCT01914484|nilotinib
1024027|NCT01914484|ruxolitinib
1024028|NCT01914458|Lung cancer
1024029|NCT01914458|Low-dose computed tomography scan
1024030|NCT01914419|Postpartum hemorrhage
1024031|NCT01914419|Oxytocin
1024032|NCT01914419|Prevention
1024033|NCT01914419|Third stage of labor
1024034|NCT01914419|Hemoglobin
1024035|NCT01914419|Intravenous
1024036|NCT01914419|Intramuscular
1024037|NCT01914419|Bolus
1024038|NCT01914406|Heart transplant recipients
1024039|NCT01914406|Exercise capacity
1024040|NCT01914406|endothelial function
1024041|NCT01914406|Quality of life
1024042|NCT01914393|Schizophrenia
1024043|NCT01914393|Autism
1024044|NCT01914393|Lurasidone
1024045|NCT01914393|Latuda
1024046|NCT01914380|Wet age-related macular degeneration
1024047|NCT01914380|Anti-VEGF-Therapy
1024048|NCT01914380|Observational study
1024049|NCT01914354|T cells
1024050|NCT01914354|Human Alloimmune Reactivity
1024051|NCT01914354|immunosuppression
1024052|NCT01914341|Infant
1024053|NCT01914341|Newborn
1024054|NCT01914341|Music
1024055|NCT01914328|Postoperative Pulmonary Complications
1024056|NCT01914328|PORC
1024057|NCT01914328|Surgical Related Outcome
1024058|NCT01914328|Surgical Related Mortality
1024059|NCT01914328|Postoperative ICU length of stay
1024060|NCT01914315|Rehabilitation
1024061|NCT01914315|Heart failure
1024062|NCT01914315|HFPEF
1024063|NCT01914315|Exercise training
1024064|NCT01914289|Intrahepatic Cholangiocarcinoma
1024065|NCT01914289|Prognosis
1024066|NCT01914289|Resection
1024067|NCT01914289|Radiotherapy
1024068|NCT01914263|Cord blood-Derived cytokine induced killer cells,
1024069|NCT01914263|Radical resection
1024070|NCT01914250|Frenotomy
1024071|NCT01914250|Pain
1024072|NCT01914237|Single-Branched Stent Graft System
1024073|NCT01914237|Aortic Dissection
1024074|NCT01914237|Endovascular Repair
1024075|NCT01914224|Prehypertension
1024076|NCT01914224|Hypertension
1024077|NCT01914224|Sodium
1024078|NCT01914224|Potassium
1024079|NCT01914224|renin
1024080|NCT01914224|aldosterone
1024081|NCT01914198|sleep study
1024082|NCT01914198|NCH
1024083|NCT01914185|Childhood
1024084|NCT01914185|Physical activity
1024085|NCT01914185|Nutrition
1024086|NCT01914185|Health Promotion
1024087|NCT01914172|rare disease
1024088|NCT01914172|community-based participatory research
1024089|NCT01914172|health promotion
1024090|NCT01914172|quantitative research
1024091|NCT01914172|qualitative research
1024092|NCT01914172|focus group
1024098|NCT01914133|Acarbose
1024099|NCT01914133|PPH (Post Prandial Hypotension)
1024100|NCT01914133|Falls
1024101|NCT01914133|Syncope
1024102|NCT01914133|Elderly
1024103|NCT01914120|lung cancer
1024104|NCT01914120|quality of life
1024105|NCT01914120|FACT-L
1024106|NCT01914107|malignancy
1024107|NCT01914107|solid tumor
1024108|NCT01914107|cancer pain
1024109|NCT01914094|Preoperative care
1024110|NCT01914094|Exercise therapy
1024111|NCT01914094|Cardiac surgery
1024112|NCT01914081|Non-ischemic cardiomyopathy
1024113|NCT01914081|Resveratrol
1024114|NCT01914068|Neoadjuvant chemoradiotherapy (NACRT)
1024115|NCT01914068|Rectal cancer
1024116|NCT01914068|Physical fitness
1024117|NCT01914068|Exercise programme
1024118|NCT01914068|Surgery
1024119|NCT01914068|Stage III/IV
1024120|NCT01914068|Locally advanced operable
1024121|NCT01914068|patients
1024122|NCT01914042|Opioid induced hyperalgesia
1024123|NCT01914042|Neuropathic pain
1024124|NCT01914042|Opioids
1024125|NCT01914042|Sciatica
1024126|NCT01914042|Serotonin-norepinephrine reuptake inhibitor (SNRI)
1024127|NCT01913990|Nausea
1024128|NCT01913990|Vomiting
1024129|NCT01913938|Hemophagocytosis, adults, rhG-CSF
1024130|NCT01913899|phantom limb pain
1024131|NCT01913899|mirror therapy
1024132|NCT01913899|amputees
1024133|NCT01913899|phantom limb
1024134|NCT01913899|occupational therapy
1024135|NCT01913886|Cardiovascular Diseases
1024136|NCT01913886|Myocardial Ischemia
1024137|NCT01913886|Coronary Artery Disease
1024138|NCT01913886|Heart Diseases
1024139|NCT01913886|Coronary Disease
1024140|NCT01913886|Ventricular Dysfunction
1024141|NCT01913886|Arteriosclerosis
1024142|NCT01913873|High-sensitivity Cardiac Troponin
1024143|NCT01913873|Creatinin Kinase MB
1024144|NCT01913873|Cardiac Surgery
1024145|NCT01913873|Myocardial injury
1024146|NCT01913873|Myocardial infarction
1024147|NCT01913873|Concentration change
1024148|NCT01913860|UTI
1024149|NCT01913860|antibiotics
1024150|NCT01913860|prescribing
1024151|NCT01913860|primary care
1024152|NCT01913834|Parathyroid hormone 1-34
1024153|NCT01913808|Postoperative anemia
1024154|NCT01913808|Total knee arthroplasty
1024155|NCT01913808|Iron therapy
1024156|NCT01913782|Chronic low back pain, CLBC, fMRI
1024157|NCT01913769|post-RT
1024158|NCT01913769|myocardial perfusion images
1024159|NCT01913743|fMRI
1024160|NCT01913743|cognitive strategies
1024161|NCT01913743|obesity
1024162|NCT01913743|weight loss
1024163|NCT01913743|mindsets
1024164|NCT01913730|Multiple Myeloma
1024165|NCT01913730|Refractory
1024166|NCT01913730|Relapsed
1024167|NCT01913717|Prostate cancer
1024168|NCT01913717|Radiotherapy
1024169|NCT01913717|hypofractionated radiotherapy
1024170|NCT01913704|venous leg ulcer
1024171|NCT01913704|mixed aetiology leg ulcers
1024172|NCT01913691|Neuroendocrine Skin Cancer
1024173|NCT01913691|Merkel Cell Polyomavirus
1024174|NCT01913691|Immunotherapy
1024175|NCT01913652|dedifferentiated liposarcoma
1024176|NCT01913652|cabazitaxel
1024177|NCT01913652|ifosfamide
1024178|NCT01913639|BAY 73-4506 (REGORAFENIB)
1024179|NCT01913639|FLUOROURACIL
1024180|NCT01913639|LEUCOVORIN
1024181|NCT01913639|OXALIPLATIN
1024182|NCT01913626|subjective memory complains
1024183|NCT01913600|TARGET LESION REVASCULARIZATION (TLR)
1024184|NCT01913600|TARGET VESSEL REVASCULARIZATION (TVR)
1024185|NCT01913600|Coronary Artery Disease
1024186|NCT01913600|MYOCARDIAL INFARCTION (MI)
1024187|NCT01913600|PERCUTANEOUS CORONARY INTERVENTION (PCI)
1024188|NCT01913600|STENT THROMBOSIS
1024189|NCT01913600|TARGET LESION FAILURE (TLF)
1024190|NCT01913561|Electrocardiogram
1024191|NCT01913561|gel electrodes
1024192|NCT01913561|textile electrodes
1024193|NCT01913535|Depression
1024194|NCT01913535|Treatment Resistant Depression
1024195|NCT01913535|Antidepressant
1024196|NCT01913535|Major Depression
1024197|NCT01913535|MDD
1024198|NCT01913509|hemiplegic shoulder pain
1024199|NCT01913509|poststroke fatigue
1024200|NCT01913509|functional electrical stimulation
1024201|NCT01913509|stroke rehabilitation
1024202|NCT01913496|web application
1024203|NCT01913496|nutrition knowledge
1024204|NCT01913496|physical activity
1024205|NCT01913470|NAFLD
1024206|NCT01913470|Non-alcoholic Fatty Liver Disease
1024207|NCT01913470|Obesity
1024208|NCT01913470|Pediatrics
1024209|NCT01913470|Children
1024210|NCT01913470|Losartan
1024211|NCT01913470|Cozaar
1024212|NCT01913457|Ultrasound Doppler
1024213|NCT01913457|Lungs
1024214|NCT01913457|Pulmonary artery hypertension
1024215|NCT01913444|Recombinant Antithrombin
1024216|NCT01913444|ATryn
1024217|NCT01913444|Pharmacokinetics
1024218|NCT01913444|ECMO
1024219|NCT01913444|Neonates
1024220|NCT01913418|Traditional Chinese Medicine
1024221|NCT01913418|Suan-Zao-Ren Tang
1024222|NCT01913418|Methadone
1024223|NCT01913418|Opiate dependence
1024224|NCT01913418|Sleep
1024225|NCT01913379|Phase 1
1024226|NCT01913379|MDV3100
1024227|NCT01913379|Gemfibrozil
1024228|NCT01913379|Itraconazole
1024229|NCT01913379|Xtandi
1024230|NCT01913379|enzalutamide
1024231|NCT01913340|erythropoietin
1024232|NCT01913340|therapeutic hypothermia
1024233|NCT01913327|cognition
1024234|NCT01913327|executive function
1024235|NCT01913327|prefrontal cortex
1024236|NCT01913327|locus coeruleus
1024237|NCT01913288|neonatal care, preterm, maternal sounds, auditory stimulation
1024238|NCT01913275|cholecystojejunostomy
1024239|NCT01913275|whipple's pancreaticoduodenectomy
1024240|NCT01913275|endoscopic stenting
1024241|NCT01913275|hyperbilirubinemia
1024242|NCT01913262|depression
1024243|NCT01913262|phq9
1024244|NCT01913262|phq-9
1024245|NCT01913262|standard treatment
1024246|NCT01913249|Anorectal fistula
1024247|NCT01913249|LIFT
1024248|NCT01913249|Seton
1024249|NCT01913236|Tailored implementation interventions
1024250|NCT01913236|Primary care
1024251|NCT01913236|Depression in the elderly
1024379|NCT01912469|Damage
1024252|NCT01913223|Endoscopic submucosal dissection
1024253|NCT01913223|jet injector
1024254|NCT01913223|saline solution
1024255|NCT01913223|safety
1024256|NCT01913223|effectiveness
1024257|NCT01913197|Prostate Brachytherapy
1024258|NCT01913119|extranodal NKTcell lymphoma
1024259|NCT01913093|Childhood leukemia survivors
1024260|NCT01913093|Acute lymphoblastic leukemia
1024261|NCT01913093|Leukemia
1024262|NCT01913093|Late effects
1024263|NCT01913093|Folate
1024264|NCT01913093|Blood folate
1024265|NCT01913093|Neurotoxicity
1024266|NCT01913093|Methotrexate
1024267|NCT01913093|Pharmacogenetics
1024268|NCT01913093|Cognitive
1024269|NCT01913093|Cognitive late effects
1024270|NCT01913093|N-PhenoGENICS
1024271|NCT01913080|health management
1024272|NCT01913067|brain metastasis
1024273|NCT01913067|breast cancer
1024274|NCT01913067|HER2 negative
1024275|NCT01913067|NSCLC
1024276|NCT01913054|Etomidate
1024277|NCT01913054|Propofol
1024278|NCT01913054|Painless gastroscopy
1024279|NCT01913041|perioperative hypothermia
1024280|NCT01913041|Epidemiology
1024281|NCT01913041|Tympanic temperature
1024282|NCT01913028|safety, tolerability, pharmacokinetics,immunogenicity, MEDI9929, Japanese
1024283|NCT01912989|motivational interviewing
1024284|NCT01912989|obesity
1024285|NCT01912989|parent
1024286|NCT01912976|Bowen's disease
1024287|NCT01912976|Er:YAG
1024288|NCT01912976|AFL-assisted
1024289|NCT01912976|MAL-PDT
1024290|NCT01912963|HER-2 Positive Breast Cancer
1024291|NCT01912950|intense pulsed light
1024292|NCT01912950|IPL
1024293|NCT01912950|healthy volunteer
1024294|NCT01912950|light-based hair removal
1024295|NCT01912950|hair removal
1024296|NCT01912950|epilation
1024297|NCT01912950|laser hair removal
1024298|NCT01912950|permanent hair reduction
1024299|NCT01912937|Paclitaxel
1024300|NCT01912937|Percutaneous Transluminal Angioplasty
1024301|NCT01912937|Balloon Catheter
1024302|NCT01912937|Pharmacokinetic
1024303|NCT01912937|Peripheral Artery Disease
1024304|NCT01912937|PAD
1024305|NCT01912924|chronic pain from failed knee surgery
1024306|NCT01912846|End-of-life care
1024307|NCT01912846|Preference of end-of-life care
1024308|NCT01912846|RCT
1024309|NCT01912846|Terminally ill cancer patients
1024310|NCT01912833|postpartum depression
1024311|NCT01912807|Postoperative vomiting
1024312|NCT01912807|Children
1024313|NCT01912794|Cerebrovascular Accident
1024314|NCT01912794|Rehabilitation
1024315|NCT01912794|Sensory System
1024316|NCT01912781|contact lenses
1024317|NCT01912781|contact lens solution
1024318|NCT01912781|gas permeable contact lenses
1024319|NCT01912768|contact lenses
1024320|NCT01912768|contact lens solution
1024321|NCT01912768|soft contact lenses
1024322|NCT01912755|Pulpitis
1024323|NCT01912755|Hot tooth
1024324|NCT01912755|Articaine
1024325|NCT01912755|Lidocaine
1024326|NCT01912755|Local anesthetics
1024327|NCT01912742|Weight loss
1024328|NCT01912742|Speed of weight loss
1024329|NCT01912742|Metabolic compensation
1024330|NCT01912742|Diet therapy
1024331|NCT01912729|Depression prevention
1024332|NCT01912729|Technology Assisted
1024333|NCT01912729|Adolescents
1024334|NCT01912729|Peer networked
1024335|NCT01912716|pancreatitis
1024336|NCT01912716|ERCP
1024337|NCT01912677|hypertension in pregnancy
1024338|NCT01912677|preeclampsia
1024339|NCT01912677|anti-hypertension
1024340|NCT01912677|labetalol
1024341|NCT01912677|nifedipine
1024342|NCT01912677|methyldopa
1024343|NCT01912664|Depression
1024344|NCT01912664|Web-based Intervention
1024345|NCT01912651|facial skin wound
1024346|NCT01912651|facial wound
1024347|NCT01912651|skin wound
1024348|NCT01912651|facial defect
1024349|NCT01912651|reconstructive skin graft
1024350|NCT01912638|Trabeculectomy
1024351|NCT01912638|Glaucoma
1024352|NCT01912638|Steroids
1024353|NCT01912638|Ologen
1024354|NCT01912638|Viscoelastic
1024355|NCT01912612|Breast cancer
1024356|NCT01912612|Pain sensitivity
1024357|NCT01912599|Glaucoma
1024358|NCT01912599|Intraocular Pressure
1024359|NCT01912599|Blood Pressure
1024360|NCT01912586|erectile dysfunction
1024361|NCT01912586|laparoscopic surgery
1024362|NCT01912586|rectal cancer
1024363|NCT01912586|sildenafil
1024364|NCT01912586|vacuum erection device
1024365|NCT01912573|heroin
1024366|NCT01912573|prescription pain killers
1024367|NCT01912573|narcotics
1024368|NCT01912534|Sarcomere Mutations
1024369|NCT01912521|HIV
1024370|NCT01912521|Stigma
1024371|NCT01912521|Social support
1024372|NCT01912521|Social network
1024373|NCT01912521|Kenya
1024374|NCT01912508|cervical length
1024375|NCT01912508|cervical curvature
1024376|NCT01912469|Muscle
1024377|NCT01912469|exercise
1024378|NCT01912469|soreness
1024380|NCT01912469|Traumeel
1024381|NCT01912456|Hereditary Angioedema
1024382|NCT01912430|Integrated Care Coaching
1024383|NCT01912430|Chronic Care Coaching
1024384|NCT01912430|Care Coaching
1024385|NCT01912417|HEMODIALYSIS
1024386|NCT01912417|Kidney Failure, Chronic
1024387|NCT01912417|AEROBIC EXERCISE
1024388|NCT01912404|alcoholic hepatitis
1024389|NCT01912391|Depression
1024390|NCT01912391|Anxiety
1024391|NCT01912391|Headaches
1024392|NCT01912391|Migraines
1024393|NCT01912391|Irritable Bowel Syndrome IBS
1024394|NCT01912391|Neurodermatitis
1024395|NCT01912391|Fibromyalgia
1024396|NCT01912391|Premenstrual Syndrome PMS
1024397|NCT01912391|Temporomandibular Joint Dysfunction TMJ
1024398|NCT01912365|Fracture
1024399|NCT01912365|Supracondylar
1024400|NCT01912365|Pediatric
1024401|NCT01912365|Orthopedic
1024402|NCT01912352|ADHD
1024403|NCT01912352|ADRA2A
1024404|NCT01912352|Methylphenidate
1024405|NCT01912352|Response
1024406|NCT01912339|Hyperlasia
1024407|NCT01912339|Retention
1024408|NCT01912339|Prostate
1024409|NCT01912326|pacemaker
1024410|NCT01912326|atrial fibrillation
1024411|NCT01912313|IBS patients
1024412|NCT01912313|healthy subjects
1024413|NCT01912287|Generalized Anxiety Disorder
1024414|NCT01912287|GAD
1024415|NCT01912287|Yoga
1024416|NCT01912287|CBT
1024417|NCT01912274|AML
1024418|NCT01912274|open label
1024419|NCT01912274|nonrandomized
1024420|NCT01912274|single arm
1024421|NCT01912274|elderly patients
1024422|NCT01912274|HMA
1024423|NCT01912274|newly diagnosed
1024424|NCT01912261|Coronary artery bypass gafting
1024425|NCT01912261|Anemia
1024426|NCT01912261|Postoperative fatigue
1024427|NCT01912261|Functional Capacity
1024428|NCT01912261|Iron
1024429|NCT01912261|Adherence
1024430|NCT01912248|acute rise of systolic and diastolic bloodpressure
1024431|NCT01912235|Arginine synthesis
1024432|NCT01912235|15N2 arginine, 1-13C Glutamine, 2-15N Glutamine, 15N Proline
1024433|NCT01912209|employees
1024434|NCT01912209|metabolic syndrome
1024435|NCT01912209|obesity
1024436|NCT01912209|sub-clinical cardiovascular disease
1024437|NCT01912209|weight loss
1024438|NCT01912209|diet
1024439|NCT01912196|Depressive Disorder
1024440|NCT01912183|pediatric obesity
1024441|NCT01912183|e-learning
1024442|NCT01912183|personal health record
1024443|NCT01912183|personal electronic device
1024444|NCT01912183|pilot
1024445|NCT01912170|omega-3 fatty acid
1024446|NCT01912170|gestational diabetes
1024447|NCT01912170|insulin sensitivity
1024448|NCT01912131|13-120
1024449|NCT01912118|Nociception
1024450|NCT01912118|General anesthesia
1024451|NCT01912105|endotracheal tube
1024452|NCT01912105|ct scan
1024453|NCT01912105|cleaning device
1024454|NCT01912105|biofilm
1024455|NCT01912105|mechanical ventilation
1024456|NCT01912053|Intra-hepatic Cholangiocarcinoma treatment
1024457|NCT01912040|Safety profile
1024458|NCT01912040|locally produced 123 Iodine MIBG
1024459|NCT01912014|stroke
1024460|NCT01912014|psychosocial
1024461|NCT01912014|intervention
1024462|NCT01912014|quality of life
1024463|NCT01912001|end stage renal disease
1024464|NCT01912001|kidney failure
1024465|NCT01912001|home dialysis
1024466|NCT01912001|hemodialysis
1024467|NCT01912001|peritoneal dialysis
1024468|NCT01912001|gaps in care
1024469|NCT01912001|co-morbidity
1024470|NCT01912001|transitions of care settings
1024471|NCT01911988|Peripheral immune cells
1024472|NCT01911988|Colorectal Cancers
1024473|NCT01911988|Stage II/ Stage III
1024474|NCT01911988|Recurrence
1024475|NCT01911988|Metastasis
1024476|NCT01911975|Small Fiber Neuropathy
1024477|NCT01911975|Painful Neuropathy
1024478|NCT01911975|NAV1.7 Voltage-Gated Sodium Channel
1024479|NCT01911975|SCN9A
1024480|NCT01911949|femoral nerve block
1024481|NCT01911949|ultrasound guided
1024482|NCT01911949|total hip arthroplasty
1024483|NCT01911936|CLJM716,
1024484|NCT01911936|Japanese patients,
1024485|NCT01911936|Neoplasms
1024486|NCT01911910|primary prevention
1024487|NCT01911910|Cardiovascular disease
1024488|NCT01911910|Cardiovascular magnetic resonance (CMR)
1024489|NCT01911910|Electronic coaching (e-coaching)
1024490|NCT01911897|Hypertension
1024491|NCT01911884|Rokitansky syndrome
1024492|NCT01911884|surgical or vaginal dilatation of vaginal aplasia
1024493|NCT01911884|quality of global and sexual life
1024494|NCT01911871|Thalassemia
1024495|NCT01911871|sickle cell disease
1024496|NCT01911871|myelodysplasia
1024497|NCT01911871|transfusion
1024498|NCT01911871|chelation
1024499|NCT01911845|HCV Genotype 1
1024500|NCT01911845|Hepatitis Genotype 1
1024501|NCT01911845|Interferon Free
1024502|NCT01911845|methadone
1024503|NCT01911845|HCV
1024504|NCT01911845|Buprenorphine
1024505|NCT01911845|Hepatitis C
1024506|NCT01911845|Viekira Pak
1024507|NCT01911845|paritaprevir
1024508|NCT01911845|Viekira
1024509|NCT01911845|ombitasvir
1024510|NCT01911845|dasabuvir
1024511|NCT01911832|Cancer of the esophagogastric junction
1024512|NCT01911832|Reconstruction of gastric tube
1024513|NCT01911832|Quality of life
1024514|NCT01911832|Width
1024515|NCT01911832|Regurgitation
1024516|NCT01911819|Histomorphometric Analysis
1024517|NCT01911819|New bone Formation
1024518|NCT01911819|Sinus Augmentation
1024519|NCT01911819|Bone Graft Materials
1024520|NCT01911806|Back care pillow
1024521|NCT01911806|chronic non-specific low back pain
1024522|NCT01911806|randomized controlled trial
1024523|NCT01911793|stoma
1024524|NCT01911793|ileus
1024525|NCT01911793|postoperative
1024526|NCT01911793|stoma tube
1024527|NCT01911741|Phase I
1024528|NCT01911741|Enzalutamide
1024529|NCT01911741|Relative bioavailability of MDV3100
1024530|NCT01911741|Immediate release oral formulation
1024531|NCT01911741|Xtandi
1024532|NCT01911728|Phase 1
1024533|NCT01911728|Enzalutamide
1024534|NCT01911728|MDV3100
1024535|NCT01911728|Drug-Drug Interaction
1024536|NCT01911728|Xtandi
1024537|NCT01911715|Phase 1
1024538|NCT01911715|Mass Balance
1024539|NCT01911715|MDV3100
1024540|NCT01911715|Xtandi
1024541|NCT01911715|Enzalutamide
1024542|NCT01911715|Metabolism
1024543|NCT01911715|Excretion
1024544|NCT01911689|pancreatitis
1024545|NCT01911689|MRI
1024546|NCT01911689|APACHEⅡ
1024547|NCT01911689|T2*
1024548|NCT01911689|T2 star
1024549|NCT01911650|Achilles
1024550|NCT01911650|tendinopathy
1024551|NCT01911637|Healthy
1024552|NCT01911637|Subjects
1024553|NCT01911637|Safety
1024554|NCT01911637|Tolerability
1024555|NCT01911637|VBY-036
1024556|NCT01911637|Maximum
1024557|NCT01911637|Pharmacodynamic
1024558|NCT01911637|Pharmacokinetic
1024559|NCT01911585|Posttraumatic Stress Disorder
1024560|NCT01911585|PTSD
1024561|NCT01911585|Prolonged Exposure Therapy
1024562|NCT01911585|Cognitive Behavioral Therapy
1024563|NCT01911572|Streptococcus species
1024564|NCT01911572|Streptococcus pyogenes
1024565|NCT01911572|Streptococcus agalactiae
1024566|NCT01911572|Necrotising fasciitis
1024567|NCT01911572|Sepsis
1024568|NCT01911559|Standing-frame
1024569|NCT01911559|Chronic constipation
1024570|NCT01911559|Cerebral palsy
1024571|NCT01911559|Quadriplegia
1024572|NCT01911559|Severe diplegia
1024573|NCT01911494|cluster randomized controlled trial
1024574|NCT01911494|pre-eclampsia
1024575|NCT01911494|eclampsia
1024576|NCT01911494|maternal mortality
1024577|NCT01911468|PCOS
1024578|NCT01911468|obesity
1024579|NCT01911468|GLP-1 receptor agonist
1024580|NCT01911468|liraglutide
1024581|NCT01911468|metformin
1024582|NCT01911455|Fragile X Syndrome
1024583|NCT01911442|Autism, Lurasidone, Latuda
1024584|NCT01911429|schizophrenia
1024585|NCT01911429|Lurasidone
1024586|NCT01911429|Latuda
1024587|NCT01911403|Femoral Artery puncture
1024588|NCT01911390|High cholesterol.
1024589|NCT01911364|Frequent exacerbators
1024590|NCT01911351|nitrous oxide
1024591|NCT01911351|pediatric pain and anxiety
1024592|NCT01911338|Spinal Manipulation
1024593|NCT01911338|Teaching
1024594|NCT01911338|Thoracic Vertebrae
1024595|NCT01911338|Feedback
1024596|NCT01911325|Squamous non-small cell lung cancer
1024597|NCT01911325|NSCLC
1024598|NCT01911325|Docetaxel
1024599|NCT01911325|Buparlisib
1024600|NCT01911325|BKM120
1024601|NCT01911325|Metastatic
1024602|NCT01911325|Stage IIIb
1024603|NCT01911325|Stage IV
1024604|NCT01911325|PI3K inhibitor
1024605|NCT01911299|Choline
1024606|NCT01911299|Glycerophosphocholine
1024607|NCT01911299|Choline alphoscerate
1024608|NCT01911299|Fetal alcohol spectrum disorders
1024609|NCT01911299|Fetal alcohol syndrome
1024610|NCT01911299|Partial fetal alcohol syndrome
1024611|NCT01911299|Alcohol-related neurodevelopmental disorder
1024612|NCT01911299|Prenatal alcohol exposure
1024613|NCT01911299|Fetal Alcohol Effects
1024614|NCT01911299|Pregnancy Complications
1024615|NCT01911299|Alcohol-Induced Disorders
1024616|NCT01911299|Alcohol-Related Disorders
1024617|NCT01911299|Central Nervous System Agents
1024618|NCT01911299|Therapeutic Uses
1024619|NCT01911273|Hepatocellular carcinoma
1024620|NCT01911273|monoclonal antibody
1024621|NCT01911273|ALK-1
1024622|NCT01911273|best supportive care
1024623|NCT01911260|Zinc
1024624|NCT01911260|Growth
1024625|NCT01911260|Child
1024626|NCT01911260|Dietary Supplements
1024627|NCT01911260|Randomized Controlled Trial
1024628|NCT01911221|Meningococcal disease,
1024629|NCT01911221|Adults
1024630|NCT01911208|Minority
1024631|NCT01911208|Recruitment
1024632|NCT01911195|General anesthesia
1024633|NCT01911195|cognition
1024634|NCT01911195|consciousness
1024635|NCT01911182|apnea of prematurity
1024636|NCT01911182|control of breathing
1024637|NCT01911182|newborn
1024638|NCT01911182|CO2 inhalation
1024639|NCT01911169|atherosclerosis
1024640|NCT01911169|systemic lupus erythematosus
1024641|NCT01911169|flow mediated dilation
1024642|NCT01911169|interferon gene signature
1024643|NCT01911156|Chronic Hepatitis B
1024644|NCT01911130|outcomes measures
1024645|NCT01911130|strength measurement
1024646|NCT01911130|disease progression
1024647|NCT01911104|muscle
1024648|NCT01911104|mitochondrial function
1024649|NCT01911104|exercise resistance
1024650|NCT01911104|human
1024651|NCT01911104|myotubes
1024652|NCT01911104|epigenetics
1024653|NCT01911091|skeletal muscle
1024654|NCT01911091|adipose tissue
1024655|NCT01911091|metabolism
1024656|NCT01911091|oxidation
1024657|NCT01911091|mitochondrial capacity
1024658|NCT01911078|Metabolic syndrome
1024659|NCT01911078|Renal denervation
1024660|NCT01911078|Renal artery
1024661|NCT01911078|Muscle sympathetic nerve activity
1024662|NCT01911065|Herpes zoster
1024663|NCT01911065|immune response
1024664|NCT01911065|Zostavax
1024665|NCT01911065|twins
1024666|NCT01911065|non-twins
1024667|NCT01911052|Bowel preparation
1024668|NCT01911039|GVHD
1024669|NCT01911039|cGVHD
1024670|NCT01911026|Bowel preparation
1024671|NCT01911013|degenerative cervical disease
1024672|NCT01911013|anterior cervical discectomy and fusion
1024673|NCT01911013|plate and cage
1024674|NCT01911013|cage alone
1024675|NCT01910987|Multiple Myeloma
1024676|NCT01910987|bortezomib
1024677|NCT01910987|Velcade
1024678|NCT01910987|First or Second Relapse
1024679|NCT01910987|retreatment
1024680|NCT01910987|Prolonged therapy
1024681|NCT01910974|oesophagus
1024682|NCT01910974|stomach
1024683|NCT01910974|intestine
1024684|NCT01910974|rectum
1024685|NCT01910948|omega-3 gastric cancer perioperation
1024686|NCT01910935|Physical activity
1024687|NCT01910935|Hypertension
1024688|NCT01910935|Scheme reference
1024689|NCT01910935|Primary care
1024690|NCT01910922|vegetable acceptance
1024691|NCT01910922|vegetable intake
1024692|NCT01910922|vegetable liking
1024693|NCT01910922|learning mechanisms
1024694|NCT01910922|repeated exposure to flavor
1024695|NCT01910922|flavor learning
1024696|NCT01910922|replace salt with spice
1024697|NCT01910909|Hepatocellular carcinoma
1024698|NCT01910909|unresectable
1024699|NCT01910909|small size
1024700|NCT01910909|Stereotactic body radiotherapy
1024701|NCT01910883|Safety
1024702|NCT01910883|Tolerability
1024703|NCT01910883|Pharmacokinetic
1024704|NCT01910870|Early-relapse
1024705|NCT01910844|triple negative breast cancer
1024706|NCT01910844|late-relapse
1024707|NCT01910831|bruising, reduction, older age, aging
1024708|NCT01910818|radiation
1024709|NCT01910818|dermatitis
1024710|NCT01910818|laser
1024711|NCT01910818|fractional
1024712|NCT01910818|CO2
1024713|NCT01910818|chronic
1024714|NCT01910818|fibrosis
1024715|NCT01910818|scar
1024716|NCT01910805|Gestational diabetes
1024717|NCT01910805|Diabetes mellitus
1024718|NCT01910805|diabetes in pregnancy
1024719|NCT01910805|diabetes risk
1024720|NCT01910805|diabetes risk awareness
1024721|NCT01910805|African-American
1024722|NCT01910805|Women
1024723|NCT01910779|Atrial Fibrillation
1024724|NCT01910779|Cardioversion
1024725|NCT01910779|Biphasic Shock
1024726|NCT01910766|pcos
1024727|NCT01910766|coenzymeQ10
1024728|NCT01910766|clomiphene citrate
1024729|NCT01910753|Head and neck cancer,
1024730|NCT01910753|physical activity,
1024731|NCT01910753|nutrition therapeutic education
1024732|NCT01910740|Randomized Controlled Trial
1024733|NCT01910740|Exercise Movement Techniques
1024734|NCT01910740|Frail Elderly
1024735|NCT01910740|Gait
1024736|NCT01910727|American Indian
1024737|NCT01910727|Diabetes
1024738|NCT01910727|Pre-diabetes
1024739|NCT01910727|Family health Coach
1024740|NCT01910714|HIV/AIDS
1024741|NCT01910714|Prevention
1024742|NCT01910714|American Indian
1024743|NCT01910714|Substance use
1024744|NCT01910714|CBPR
1024745|NCT01910701|Home visiting interventions
1024746|NCT01910701|American Indian
1024747|NCT01910701|Community based participatory research
1024748|NCT01910688|RGB Salvage, RFA
1024749|NCT01910662|Suction Skin Blister
1024750|NCT01910662|Induration
1024751|NCT01910662|Tuberculin Purified Protein Derivative
1024752|NCT01910662|Erythema
1024753|NCT01910662|Biopsy
1024754|NCT01910662|Keyhole Limpet Hemocyanin
1024755|NCT01910662|Delayed Type Hypersensitivity
1024756|NCT01910649|drisapersen
1024757|NCT01910636|HCV genotype 2 (GT-2)
1024758|NCT01910623|Quality of life
1024759|NCT01910623|Health related quality of life outcomes
1024760|NCT01910623|Long-term
1024761|NCT01910623|Aida 0493
1024762|NCT01910623|AIDA 2000
1024763|NCT01910610|wild-type RAS metastatic colorectal cancer
1024764|NCT01910584|quality of life
1024765|NCT01910584|sexual activity
1024766|NCT01910584|Novasure endometrial ablation
1024767|NCT01910584|menorrhagia
1024768|NCT01910558|Alpha-cyclodextrin
1024769|NCT01910558|Dietary fiber
1024770|NCT01910558|Fecal fat
1024771|NCT01910558|Saturated fat
1024772|NCT01910519|influenza A (H5N1) virus
1024773|NCT01910519|H5N1 influenza
1024774|NCT01910519|influenza A/H5/N1
1024775|NCT01910519|monovalent H5N1 influenza vaccine
1024776|NCT01910519|systems biology
1024777|NCT01910519|AS03 adjuvant
1024778|NCT01910519|unadjuvanted
1024779|NCT01910493|mhealth
1024780|NCT01910493|mobile health
1024781|NCT01910493|SMS
1024782|NCT01910493|SMS reminders
1024783|NCT01910493|ART retention in care
1024784|NCT01910493|PMTCT
1024785|NCT01910493|PMTCT cascade
1024786|NCT01910493|retention in care
1024787|NCT01910454|Stroke
1024788|NCT01910454|Occupational Therapy
1024789|NCT01910454|Cognition
1024790|NCT01910441|Type 2 Diabetes Mellitus, Glycemic variability
1024791|NCT01910428|L-asparaginase encapsulated in RBCs, leukemia, lymphoma
1024792|NCT01910402|antiretroviral therapy naïve
1024793|NCT01910402|women
1024794|NCT01910402|once daily
1024795|NCT01910402|HIV infection
1024796|NCT01910402|atazanavir
1024797|NCT01910402|tenofovir/emtricitabine
1024798|NCT01910402|dolutegravir/abacavir/lamivudine fixed dose combination
1024799|NCT01910402|integrase inhibitor
1024800|NCT01910402|ritonavir
1024801|NCT01910389|Heart failure
1024802|NCT01910389|Pulmonary hypertension
1024803|NCT01910389|tadalafil
1024804|NCT01910389|Phosphodiesterase Type 5 Inhibition
1024805|NCT01910363|poststroke spasticity
1024806|NCT01910363|lower limb
1024807|NCT01910363|botulinum toxin
1024808|NCT01910363|A2
1024809|NCT01910350|Breast & cervical cancer prevention & screening
1024810|NCT01910337|ASA I patients
1024811|NCT01910324|Juvenile Offenders
1024812|NCT01910324|HIV/STD Prevention
1024813|NCT01910324|Adolescent Substance Abuse
1024814|NCT01910324|Multidimensional Family Therapy
1024815|NCT01910298|Breast reconstruction
1024816|NCT01910298|Breast implant
1024817|NCT01910298|Breast cancer
1024818|NCT01910298|Mastectomy
1024819|NCT01910285|Anesthetic induction
1024820|NCT01910285|Intubation conditions
1024821|NCT01910285|Tooth extraction
1024822|NCT01910285|Propofol
1024823|NCT01910285|Sufentanil
1024824|NCT01910285|Remifentanil
1024825|NCT01910272|Radiation attenuation
1024826|NCT01910272|Fluoroscopy
1024827|NCT01910272|Invasive cardiac procedures
1024828|NCT01910272|Cardiac Catheterization
1024829|NCT01910259|Secondary Progressive Multiple Sclerosis
1024830|NCT01910259|Neuroprotective
1024831|NCT01910259|Repurposed drugs
1024832|NCT01910259|Brain atrophy
1024833|NCT01910259|Percentage Brain Volume Change
1024834|NCT01910259|Magnetic Resonance Imaging
1024835|NCT01910259|Optical Coherence Tomography
1024836|NCT01910259|Cerebrospinal fluid
1024837|NCT01910259|Ibudilast
1024838|NCT01910259|Amiloride
1024839|NCT01910259|Riluzole
1024840|NCT01910259|Double blind
1024841|NCT01910259|Placebo
1024842|NCT01910246|Metformin
1024843|NCT01910246|Insulin Resistance
1024844|NCT01910246|Cardiac Function
1024845|NCT01910233|dyspnea
1024846|NCT01910233|registry
1024847|NCT01910233|baseline characteristics
1024848|NCT01910233|mortality
1024849|NCT01910233|risk assessment
1024850|NCT01910233|emergency department
1024851|NCT01910142|bone metabolism
1024852|NCT01910129|vagus nerve stimulation
1024853|NCT01910129|vagal nerve stimulation
1024854|NCT01910129|nVNS
1024855|NCT01910129|VNS
1024856|NCT01910129|epilepsy
1024857|NCT01910129|non invasive
1024858|NCT01910129|gammacore
1024859|NCT01910116|osteoarthritis
1024860|NCT01910116|hand
1024861|NCT01910116|Shinbaro
1024862|NCT01910116|GCSB-5
1024863|NCT01910103|Breast Neoplasms/radiography
1024864|NCT01910103|Mammography/methods
1024865|NCT01910103|Mass Screening
1024866|NCT01910103|Tomography, X-Ray Computed/methods
1024867|NCT01910103|Predictive Value of Tests
1024868|NCT01910103|False Positive Reactions
1024869|NCT01910090|fasting condition
1024870|NCT01910077|tacrolimus
1024871|NCT01910077|tacrobell capsule
1024872|NCT01910077|prograf capsule
1024873|NCT01910077|bioequivalence
1024874|NCT01910064|Acne Vulgaris
1024875|NCT01910025|Argininosuccinate Synthetase
1024876|NCT01910025|Arginine
1024877|NCT01910025|Arginine deiminase
1024878|NCT01910012|Argininosuccinate Synthetase
1024879|NCT01910012|Arginine
1024880|NCT01910012|Arginine deiminase
1024881|NCT01909999|Dental Implants
1024882|NCT01909999|Osseointegration
1024883|NCT01909999|Immediate Dental Implant Loading
1024884|NCT01909999|Bone formation
1024885|NCT01909986|ONO-4053
1024886|NCT01909986|Healthy adult male subjects
1024887|NCT01909986|pharmacokinetics
1024888|NCT01909986|metabolism
1024889|NCT01909986|excretion
1024890|NCT01909986|mass balance
1024891|NCT01909973|Depression
1024892|NCT01909973|Antidepressant Medication
1024893|NCT01909973|Adherence
1024894|NCT01909973|Mobile Smartphone Intervention
1024895|NCT01909973|Telemedicine
1024896|NCT01909973|Primary Care
1024897|NCT01909960|Normal pressure hydrocephalus
1024898|NCT01909960|Flow MRI
1024899|NCT01909960|Dementia
1024900|NCT01909960|Cerebrospinal fluid
1024901|NCT01909960|Shunt
1024902|NCT01909947|Respiratory rate variability
1024903|NCT01909947|Heart rate variability
1024904|NCT01909947|Extubation readiness
1024905|NCT01909947|Extubation failure
1024906|NCT01909947|Clinical predictors
1024907|NCT01909934|Lymphoma
1024908|NCT01909934|Anaplastic Large-cell
1024909|NCT01909934|Relapsed
1024910|NCT01909934|Refractory
1024911|NCT01909934|Antigens, CD30
1024912|NCT01909934|Antibody-Drug Conjugate
1024913|NCT01909934|Antibodies, Monoclonal
1024914|NCT01909934|Lymphoma, Non-Hodgkin
1024915|NCT01909934|Lymphoma, Large-Cell, Anaplastic
1024916|NCT01909934|monomethyl auristatin E
1024917|NCT01909934|Drug Therapy
1024918|NCT01909934|Immunotherapy
1024919|NCT01909934|Hematologic Diseases
1024920|NCT01909908|Wounds and injuries
1024921|NCT01909908|Ulcer
1024922|NCT01909908|Diabetic angiopathies
1024923|NCT01909908|Diabetic foot
1024924|NCT01909908|Venous insufficiency
1024925|NCT01909908|Extracellular matrix
1024926|NCT01909882|Family member's massage therapy
1024927|NCT01909882|Vital signs
1024928|NCT01909882|Glasgow coma scale
1024929|NCT01909882|Intensive care unit
1024930|NCT01909882|Randomized controlled Clinical Trial
1024931|NCT01909882|Iran
1024932|NCT01909869|MACE
1024933|NCT01909869|TVR
1024934|NCT01909869|MI
1024935|NCT01909869|TLF
1024936|NCT01909869|Death
1024937|NCT01909830|Colorectal Cancer Metastatic
1024938|NCT01909830|pretreated
1024939|NCT01909804|Hepatitis
1024940|NCT01909804|Genotype 1
1024941|NCT01909804|Genotype 3
1024942|NCT01909804|Treatment experienced
1024943|NCT01909791|Diabetic Macular Edema
1024944|NCT01909791|anti-vascular endothelial growth factor
1024945|NCT01909765|Circumcision
1024946|NCT01909765|postoperative pain
1024947|NCT01909752|Lung cancer
1024948|NCT01909752|DRibble Vaccine
1024949|NCT01909752|Imiquimod
1024950|NCT01909752|GM-CSF
1024951|NCT01909752|HPV vaccine (Ceravix)
1024952|NCT01909752|Cyclophosphamide
1024953|NCT01909739|AKI, atrovastatin, Valvular heart surgery
1024954|NCT01909726|Hospital Design
1024955|NCT01909726|Technology
1024956|NCT01909726|Anxiety
1024957|NCT01909713|acne, pediatric
1024958|NCT01909700|Single Incision, Mesh, Complications
1024959|NCT01909687|blood glucose monitoring systems
1024960|NCT01909687|ISO 15197
1024961|NCT01909687|system accuracy
1024962|NCT01909661|allergy
1024963|NCT01909661|Cow's milk protein
1024964|NCT01909661|Tolerance
1024965|NCT01909661|Efficacy
1024966|NCT01909661|Infants' growth
1024967|NCT01909622|Vitamin D
1024968|NCT01909622|Milk fortification
1024969|NCT01909622|Children
1024970|NCT01909622|Colombia
1024972|NCT01909583|congenital
1024973|NCT01909583|surgery
1024974|NCT01909583|peri-operative
1024975|NCT01909583|counselling
1024976|NCT01909557|Acetyl-L-carnitine
1024977|NCT01909557|Interferons
1024978|NCT01909557|Ribavirin
1024979|NCT01909557|Hepatitis C
1024980|NCT01909557|Fatigue
1024981|NCT01909544|Pulmonary Disease, Chronic Obstructive
1024982|NCT01909544|Muscle fatigue
1024983|NCT01909544|Energy metabolism
1024984|NCT01909544|Muscle oxygenation
1024985|NCT01909531|Deep Brain Stimulation
1024986|NCT01909531|Parkinsons Disease
1024987|NCT01909531|Essential Tremor
1024988|NCT01909531|Asleep DBS
1024989|NCT01909518|Esophageal Squamous Intraepithelial Neoplasia
1024990|NCT01909518|surface maturation scoring
1024991|NCT01909518|probe-based confocal laser endomicroscopy
1024992|NCT01909518|virtual chromoendoscopy
1024993|NCT01909492|Multiple Sclerosis
1024994|NCT01909492|MS
1024995|NCT01909492|Relaxin
1024996|NCT01909466|OPC-14597
1024997|NCT01909466|Aripiprazole
1024998|NCT01909466|Schizophrenia
1024999|NCT01909453|Melanoma
1025000|NCT01909453|Cutaneous melanoma
1025001|NCT01909453|Skin disease
1025002|NCT01909453|Skin cancer
1025003|NCT01909453|Skin Neoplasms
1025004|NCT01909453|Neoplasm Metastasis
1025005|NCT01909453|BRAF mutant
1025006|NCT01909453|BRAF V600E
1025007|NCT01909453|BRAF V600K
1025008|NCT01909453|Cancer
1025009|NCT01909453|LGX818
1025010|NCT01909453|MEK162
1025011|NCT01909453|vemurafenib
1025012|NCT01909453|combination
1025013|NCT01909453|BRAF inhibitor
1025014|NCT01909453|resistance
1025015|NCT01909453|The combination of a selective BRAF- and a MEK1/2-inhibitor
1025016|NCT01909453|Prior immunotherapy
1025017|NCT01909453|MEK inhibitor
1025018|NCT01909453|Phase III
1025019|NCT01909453|Combo 300, Combo 450
1025020|NCT01909427|Active rheumatoid arthritis despite methotrexate therapy
1025021|NCT01909427|CNTO 6785
1025022|NCT01909427|Methotrexate
1025023|NCT01909401|Liver Transplantation
1025024|NCT01909388|Cancer
1025025|NCT01909388|Prostate Cancer
1025026|NCT01909388|Brachytherapy
1025027|NCT01909388|Dose escalation
1025028|NCT01909388|High Dose Rate
1025029|NCT01909388|MRI-TRUS fusion
1025030|NCT01909388|Detection of DILs by MRI
1025031|NCT01909362|advanced metastatic colorectal cancer
1025032|NCT01909362|mCRC
1025033|NCT01909362|Colorectal Cancer
1025034|NCT01909362|Colorectal Carcinoma
1025035|NCT01909362|Colorectal Tumors
1025036|NCT01909362|Genetic mutation testing
1025037|NCT01909362|Tumor tissue sampling
1025038|NCT01909349|medical rehabilitation
1025039|NCT01909349|aftercare
1025040|NCT01909349|multiple health behavior change
1025041|NCT01909349|diet
1025042|NCT01909349|physical activity
1025043|NCT01909349|computer
1025044|NCT01909349|international study
1025045|NCT01909349|ETHNOPSYCHOLOGY
1025046|NCT01909349|HABIT
1025047|NCT01909349|HEALTH
1025048|NCT01909349|eHealth
1025049|NCT01909349|eLearning
1025050|NCT01909310|anesthesia, cardiac arrest, resuscitation, ventilation
1025051|NCT01909297|airway management
1025052|NCT01909271|Stroke
1025053|NCT01909271|Community Health Education
1025054|NCT01909271|Minority Health
1025055|NCT01909271|healthcare disparities
1025056|NCT01909245|Islet cells
1025057|NCT01909245|hypoglycemia
1025058|NCT01909245|hypoglycemia unawareness
1025059|NCT01909245|islet after kidney transplantation
1025060|NCT01909245|islet transplant
1025061|NCT01909245|insulin independence
1025062|NCT01909245|insulin dependence
1025063|NCT01909232|Depression
1025064|NCT01909232|Depressive Disorder
1025065|NCT01909232|Major depression
1025066|NCT01909232|Major depressive disorder
1025067|NCT01909232|MDD
1025068|NCT01909232|Treatment resistant depression
1025069|NCT01909232|Treatment intolerant depression
1025070|NCT01909232|TRMD
1025071|NCT01909232|TIMD
1025072|NCT01909232|Transcranial Magnetic Stimulation
1025073|NCT01909232|TMS
1025074|NCT01909219|preparation, cleansing, colon
1025075|NCT01909167|Pregnancy
1025076|NCT01909167|symptoms of depression
1025077|NCT01909167|anxiety
1025078|NCT01909167|online CBT therapy
1025079|NCT01909167|treatment as usual
1025080|NCT01909167|maternal bonding
1025081|NCT01909167|postnatal period
1025082|NCT01909154|neurophysiological parameters improvement
1025083|NCT01909154|spinal cord injury
1025084|NCT01909154|biology therapy
1025085|NCT01909141|letrozole
1025086|NCT01909141|clomiphene citrate
1025087|NCT01909141|pioglitazone
1025088|NCT01909141|metformin
1025089|NCT01909141|ovulation induction
1025090|NCT01909141|PCOS
1025091|NCT01909128|children, fermented milk fermented rice, gastrointestinal infections, respiratory infections
1025092|NCT01909102|Acceptance and Commitment Therapy
1025093|NCT01909102|Cardiac rehabilitation
1025094|NCT01909050|celiac disease
1025095|NCT01909050|refractory celiac disease
1025096|NCT01909050|gluten sensitivity
1025097|NCT01909037|osteoarthritis
1025098|NCT01909037|curcumin
1025099|NCT01909037|biomarker
1025100|NCT01909037|pain
1025101|NCT01909024|Randomised controlled trial
1025102|NCT01909024|Endovenous laser treatment
1025103|NCT01909024|Transjugular coil embolisation
1025104|NCT01908998|Y-Balance test
1025105|NCT01908985|glaucoma
1025106|NCT01908985|high intensity focused ultrasound
1025107|NCT01908985|aqueous humor
1025108|NCT01908985|fluorophotometry
1025109|NCT01908972|Hemangioma
1025110|NCT01908972|Propranolol
1025111|NCT01908972|prednisolone
1025112|NCT01908972|steroid
1025113|NCT01908959|Hispanic Women
1025114|NCT01908959|Postpartum
1025115|NCT01908959|Overweight Hispanic Women
1025116|NCT01908959|Low-income
1025117|NCT01908959|Physical Activity
1025118|NCT01908959|Walking
1025119|NCT01908946|Polio
1025120|NCT01908933|Advanced Emphysema
1025121|NCT01908933|Heterogeneous Lower Lobe Predominant Emphysema
1025122|NCT01908933|Heterogeneous Upper and Lower Lobe Predominant
1025123|NCT01908907|Premature Infants
1025124|NCT01908907|DHA(docosahexaenoic acid)
1025125|NCT01908907|DHA deficit
1025126|NCT01908881|Child Development
1025127|NCT01908881|Mother-Child relations
1025128|NCT01908881|Primary Health Care
1025129|NCT01908881|Public Policy
1025130|NCT01908855|somatoform symptoms
1025131|NCT01908855|somatic symptoms
1025132|NCT01908855|somatoform disorder
1025133|NCT01908855|somatic symptom disorder
1025134|NCT01908855|cognitive-behavioral therapy
1025135|NCT01908855|emotion regulation training
1025136|NCT01908842|Opioid
1025137|NCT01908842|Dependence
1025138|NCT01908842|agonist
1025139|NCT01908842|buprenorphine
1025140|NCT01908842|naloxone
1025141|NCT01908842|BUP/NAL
1025142|NCT01908829|Overactive Bladder (OAB)
1025143|NCT01908829|Urinary incontinence
1025144|NCT01908829|Urgency incontinence
1025145|NCT01908829|Frequency
1025146|NCT01908829|Urgency
1025147|NCT01908829|Micturition
1025148|NCT01908829|YM178
1025149|NCT01908829|Mirabegron
1025150|NCT01908829|Solifenacin
1025151|NCT01908829|Betmiga
1025152|NCT01908829|Myrbetriq
1025153|NCT01908829|Betanis
1025154|NCT01908829|Vesicare
1025155|NCT01908829|Vesitrim
1025156|NCT01908829|Vesikur
1025157|NCT01908829|YM905
1025158|NCT01908803|AOMT
1025159|NCT01908803|tympanostomy tubes
1025160|NCT01908803|Otorrhea
1025161|NCT01908803|anti-infective
1025162|NCT01908790|venous oximeter
1025163|NCT01908790|non-invasive monitor
1025164|NCT01908790|heart failure (HF)
1025165|NCT01908764|ear tubes
1025166|NCT01908764|tympanostomy tubes
1025167|NCT01908764|Otitis Media at the time of Tympanostomy Tube surgery
1025168|NCT01908764|OMTT
1025169|NCT01908738|Endometrial biopsy
1025170|NCT01908738|paracervical block
1025171|NCT01908738|Lidocaine spray
1025172|NCT01908738|women
1025173|NCT01908738|abnormal uterine bleeding
1025174|NCT01908686|ASD
1025175|NCT01908673|heart rate variability biofeedback
1025176|NCT01908673|automatic self transcedental meditation
1025177|NCT01908660|HIV
1025178|NCT01908660|hepatitis C virus
1025179|NCT01908660|hepatitis B virus
1025180|NCT01908660|antiretroviral drugs
1025181|NCT01908660|nucleos(t)ide reverse transcriptase inhibitors
1025182|NCT01908660|non-nucleos(t)ide reverse transcriptase inhibitors
1025183|NCT01908660|protease inhibitors
1025184|NCT01908660|integrase inhibitors
1025185|NCT01908660|entry inhibitors
1025186|NCT01908660|transaminase elevations
1025187|NCT01908660|alanine aminotransferase
1025188|NCT01908660|aspartate aminotransferase
1025189|NCT01908660|bilirubin elevations
1025190|NCT01908660|hepatic fibrosis
1025191|NCT01908647|mTBI
1025192|NCT01908647|PTSD
1025193|NCT01908634|Bioavailability
1025194|NCT01908634|Strawberry polyphenols
1025195|NCT01908634|Fruit Beverage Matrix
1025196|NCT01908621|multiple myeloma
1025197|NCT01908621|mobilization
1025198|NCT01908621|G-CSF
1025199|NCT01908621|filgrastim
1025200|NCT01908621|cytosine arabinoside
1025201|NCT01908621|autologous stem cell transplantation
1025202|NCT01908569|MACS, time-lapse, embryo, spermatozoid, sperm
1025203|NCT01908543|Iron deficiency
1025204|NCT01908543|Nosebleeds
1025205|NCT01908530|Diabetes,Continuous Glucose Monitoring,Microprobes
1025206|NCT01908517|HPV Vaccine Adherence
1025207|NCT01908517|Electronic Reminders
1025208|NCT01908491|patient controlled analgesia
1025209|NCT01908491|wound catheter infusion
1025210|NCT01908491|postoperative pain control
1025211|NCT01908491|pectus excavatum
1025212|NCT01908491|pain score
1025213|NCT01908478|locally advanced
1025214|NCT01908478|unresectable
1025215|NCT01908478|pancreatic
1025216|NCT01908478|pancreas
1025217|NCT01908478|pancreatic adenocarcinoma
1025218|NCT01908452|Schizophrenia
1025219|NCT01908452|pyridoxal kinase activity
1025220|NCT01908452|plasma pyridoxal level
1025221|NCT01908439|muscle electrical activity
1025222|NCT01908439|whole-body vibration
1025223|NCT01908439|latency
1025224|NCT01908426|cabozantinib
1025225|NCT01908426|XL184
1025226|NCT01908426|liver cancer
1025227|NCT01908426|hepatocellular carcinoma
1025228|NCT01908426|tyrosine kinase inhibitor
1025229|NCT01908426|MET
1025230|NCT01908426|vascular endothelial growth factor receptor 2 (VEGFR2)
1025231|NCT01908413|Advanced Solid Tumors
1025232|NCT01908413|Lymphoma
1025233|NCT01908413|Open-Label
1025234|NCT01908413|Dose-Escalation
1025235|NCT01908413|IAP
1025236|NCT01908400|Mental retardation , stem cell,BMMNC
1025237|NCT01908387|Oral azacitidine
1025238|NCT01908387|CC-486
1025239|NCT01908387|Hematological neoplasms
1025240|NCT01908387|Phase 1
1025241|NCT01908374|Active-placebo controlled double blind cross over
1025242|NCT01908361|comparative efficacy research
1025243|NCT01908361|combination therapy
1025244|NCT01908361|neurorehabilitation
1025245|NCT01908361|robotic rehabilitation
1025246|NCT01908361|restraint therapy
1025247|NCT01908335|interferon
1025248|NCT01908335|ribavirin
1025249|NCT01908335|virological response
1025250|NCT01908322|Hepatocellular carcinoma
1025251|NCT01908322|Intermediate stage
1025252|NCT01908322|Observational study
1025253|NCT01908309|acute kidney injury
1025254|NCT01908309|contrast media
1025255|NCT01908309|cystatin-C
1025256|NCT01908296|FK949E
1025257|NCT01908296|fluvoxamine
1025258|NCT01908296|Antipsychotic
1025259|NCT01908296|Quetiapine
1025260|NCT01908244|Preterm infants, music, Neonatal Intensive Care Unit (NICU)
1025261|NCT01908231|Pulmonary embolism, plasma lactate, right ventricular dysfunction
1025262|NCT01908218|ULBT, diffficult laryngoscopy, Predictive Value of Tests
1025263|NCT01908205|Autism
1025264|NCT01908205|Social
1025265|NCT01908205|Functioning
1025266|NCT01908205|Cognition
1025267|NCT01908205|Repetitive Behaviors
1025268|NCT01908205|Anxiety
1025269|NCT01908205|Quality of Life
1025270|NCT01908192|Sodium Benzoate
1025271|NCT01908192|Schizophrenia
1025272|NCT01908192|Adolescent
1025273|NCT01908192|Antipsychotic
1025274|NCT01908192|Anti-psychotic
1025275|NCT01908192|NMDA
1025276|NCT01908192|NaBen
1025277|NCT01908192|pediatric
1025278|NCT01908179|Sterotactic Radiosurgery
1025279|NCT01908153|Picture food type
1025280|NCT01908153|Taste type
1025281|NCT01908127|film modelling
1025282|NCT01908127|dental anxiety
1025283|NCT01908127|cooperative behaviour
1025284|NCT01908127|children
1025285|NCT01908114|Polio disease
1025286|NCT01908114|Intervention Package
1025287|NCT01908114|Polio sero prevalence and sero conversion
1025288|NCT01908114|Polio high risk areas of Pakistan
1025289|NCT01908088|Epidermolysis Bullosa mitten hand deformity autologous cultured fibroblast
1025290|NCT01908088|amniotic membrane
1025291|NCT01908075|Primary care
1025292|NCT01908075|Asthma management
1025293|NCT01908075|Real-world
1025294|NCT01908075|Observational
1025295|NCT01908075|Fostair
1025296|NCT01908075|Seretide
1025297|NCT01908062|Substance related disorders
1025298|NCT01908062|HIV
1025299|NCT01908062|naltrexone
1025300|NCT01908049|Probiotic
1025301|NCT01908049|HIV
1025302|NCT01908049|Microbial translocation
1025303|NCT01908049|inflammation
1025304|NCT01908049|microbiota composition
1025305|NCT01908036|Chronic fatigue syndrome
1025306|NCT01908036|CFS
1025307|NCT01908036|myalgic encephalomyelitis
1025308|NCT01908036|M.E.
1025309|NCT01908036|activity monitor
1025310|NCT01908023|exercise therapy
1025311|NCT01908023|oxygen consumption
1025312|NCT01908010|Alzheimer's disease
1025313|NCT01907997|Systemic lidocaine, Intravenous lidocaine infusion, postoperative pain, quality of recovery, Robot-assisted thyroidectomy, thyroid cancer
1025314|NCT01907984|premedication
1025315|NCT01907984|diclofenac
1025316|NCT01907984|postoperative headache
1025317|NCT01907984|Visual Analog Scale
1025318|NCT01907958|Microalbuminuria
1025319|NCT01907958|Hypertensive
1025320|NCT01907958|Diabetics
1025321|NCT01907958|urine albumin
1025322|NCT01907945|Household water treatment
1025323|NCT01907945|Waterborne illness
1025324|NCT01907945|ceramic filters
1025325|NCT01907945|social network
1025326|NCT01907932|splenomegaly
1025327|NCT01907932|ultrasound
1025328|NCT01907932|VScan
1025329|NCT01907919|Pulp capping, Diode laser 808 nm, Tertiary dentin, RM-GIC
1025330|NCT01907906|Pathogen reduction technology
1025331|NCT01907880|breast
1025332|NCT01907880|bone
1025333|NCT01907880|pain
1025334|NCT01907841|Investigate IPC on EIMD
1025335|NCT01907789|Ovarian Carcinoma
1025336|NCT01907789|Ovary
1025337|NCT01907789|BRCA Mutation Carriers
1025338|NCT01907789|BRCA1 or BRCA2 mutation
1025339|NCT01907789|High risk for developing ovarian cancer
1025340|NCT01907789|Ovarian cancer screening
1025341|NCT01907789|Risk-reducing salpingo-oophorectomy
1025342|NCT01907789|RRSO
1025343|NCT01907789|Prophylactic salpingectomy with delayed oophorectomy
1025344|NCT01907789|PSDO
1025345|NCT01907789|Questionnaire
1025346|NCT01907789|Quality of life
1025347|NCT01907789|QOL
1025348|NCT01907789|Survey
1025349|NCT01907789|Transvaginal ultrasound
1025350|NCT01907789|Phone call
1025351|NCT01907763|asthma
1025352|NCT01907763|SOTB07
1025353|NCT01907750|biliary fistula
1025354|NCT01907750|biliary stricture
1025355|NCT01907750|biliary drainage tube
1025356|NCT01907724|Chronic hepatitis C
1025357|NCT01907724|Hepatitis C virus
1025358|NCT01907724|HCV
1025359|NCT01907711|Acupuncture.
1025360|NCT01907711|Fatigue syndrome chronic.
1025361|NCT01907711|Sleep disturbances.
1025362|NCT01907711|Pain.
1025363|NCT01907711|Cognitive impairment.
1025364|NCT01907698|vaginal intercourse
1025365|NCT01907698|labour
1025366|NCT01907698|term pregnancy
1025367|NCT01907672|Malaria
1025368|NCT01907672|Rapid Diagnostic Tests for Malaria
1025369|NCT01907672|Chemical Shops
1025370|NCT01907672|Drug Shops
1025371|NCT01907672|Diagnostics
1025372|NCT01907672|Testing for Malaria
1025373|NCT01907659|Respiratory
1025374|NCT01907659|Viruses
1025375|NCT01907659|Bacterial
1025376|NCT01907659|Antibiotics
1025377|NCT01907659|Procalcitonin
1025378|NCT01907646|bladder training, radical hysterectomy,gynaecologic cancer
1025379|NCT01907633|Death, Sudden, Cardiac
1025380|NCT01907633|Risk of Sudden Cardiac Death
1025381|NCT01907633|Domperidone
1025382|NCT01907633|Proton Pump Inhibitors (PPI)
1025383|NCT01907633|Metoclopramide
1025384|NCT01907633|Observational Study
1025385|NCT01907607|Advanced Gastrointestinal Stromal Tumor Refractory to Imatinib and Sunitinib
1025386|NCT01907607|PD-0332991
1025387|NCT01907607|Orally
1025388|NCT01907607|Efficacy and safety
1025389|NCT01907607|Adult patients
1025390|NCT01907607|Refractory
1025391|NCT01907607|Imatinib
1025392|NCT01907607|Sunitinib
1025393|NCT01907490|Topical treatment of Head Lice Infestation
1025394|NCT01907464|Anorexia nervosa
1025395|NCT01907464|Bone mineral density
1025396|NCT01907464|Teenagers or young women
1025397|NCT01907464|Bone remodelling markers
1025398|NCT01907438|BRCA
1025399|NCT01907438|estrogen
1025400|NCT01907438|epithelial breast cells
1025401|NCT01907438|genome profile
1025402|NCT01907412|First time parents
1025403|NCT01907412|Coparenting
1025404|NCT01907412|Family Foundations
1025405|NCT01907399|obese patients
1025406|NCT01907399|obese patients with type 2 diabetes
1025407|NCT01907399|healthy volunteers
1025408|NCT01907386|Endoleaks
1025409|NCT01907386|Non-invasive vascular elastography
1025410|NCT01907373|olmesartan
1025411|NCT01907373|probenecid
1025412|NCT01907373|pharmacokinetics
1025413|NCT01907373|tolerability
1025414|NCT01907347|intensive care unit (ICU)
1025415|NCT01907347|body composition
1025416|NCT01907347|phase angle
1025417|NCT01907347|mortality
1025418|NCT01907347|nosocomial infection
1025419|NCT01907347|bioimpedance analysis
1025420|NCT01907347|nutrition
1025421|NCT01907334|oscillometry
1025422|NCT01907334|asthma
1025423|NCT01907334|methacholine
1025424|NCT01907321|stroke
1025425|NCT01907321|dysphagia
1025426|NCT01907321|dystussia
1025427|NCT01907321|cough
1025428|NCT01907321|maximum expiratory pressure
1025429|NCT01907308|Bladder cancer
1025430|NCT01907308|Urothelial cancer
1025431|NCT01907308|Urothelial carcinoma
1025432|NCT01907295|idiopathic
1025433|NCT01907295|heritable
1025434|NCT01907295|anorexigen
1025435|NCT01907282|Schizophrenia
1025436|NCT01907282|psychosis
1025437|NCT01907230|Rheumatoid arthritis
1025438|NCT01907230|Inactive HBV carrier
1025439|NCT01907230|Resolved Hepatitis B
1025440|NCT01907230|HBV reactivation
1025441|NCT01907230|Anti-tumor necrotic factor-alfa
1025442|NCT01907217|Electroconvulsive therapy
1025443|NCT01907217|ECT
1025444|NCT01907217|electrode placement
1025445|NCT01907217|effectiveness
1025446|NCT01907217|cognition
1025447|NCT01907217|autobiographical memory
1025448|NCT01907191|Hip Arthroscopy
1025449|NCT01907191|Liposomal Bupivacaine
1025450|NCT01907191|Bupivacaine
1025451|NCT01907178|total knee arthroplasty
1025452|NCT01907152|malnutrition
1025453|NCT01907152|undernourishment
1025454|NCT01907152|loss of muscle mass
1025455|NCT01907139|comparative efficacy research
1025456|NCT01907139|combination therapy
1025457|NCT01907139|neurorehabilitation
1025458|NCT01907139|robot-assisted therapy
1025459|NCT01907139|constraint-induced therapy
1025460|NCT01907126|HIV
1025461|NCT01907126|Sexually transmitted infections
1025462|NCT01907126|Sexual abuse
1025463|NCT01907126|Physical abuse
1025464|NCT01907126|Women
1025465|NCT01907126|Prison
1025466|NCT01907087|Late infantile Neuronal Ceroid Lipofuscinosis Type 2
1025467|NCT01907087|LINCL
1025468|NCT01907087|NCL2
1025469|NCT01907087|CLN2
1025470|NCT01907087|Jansky-Bielschowsky disease
1025471|NCT01907074|liver function tests
1025472|NCT01907074|end stage liver disease
1025473|NCT01907074|cirrhosis
1025474|NCT01907074|living liver donor
1025475|NCT01907061|acute renal failure
1025476|NCT01907061|post liver transplant
1025477|NCT01907048|Survey
1025478|NCT01907048|Effectiveness of risk minimization measures
1025479|NCT01907048|Rivaroxaban
1025480|NCT01907048|Anticoagulants
1025481|NCT01907022|repetitive transcranial magnetic stimulation
1025482|NCT01907022|chronic tinnitus
1025483|NCT01907022|relaxation
1025484|NCT01906944|trigger point injection
1025485|NCT01906944|transversus abdominis plane
1025486|NCT01906944|abdominal wall pain
1025487|NCT01906931|Interstitial lung disease
1025488|NCT01906931|Oxygen therapy
1025489|NCT01906931|Walk
1025490|NCT01906918|ischemia
1025491|NCT01906918|reperfusion
1025492|NCT01906918|myocardial ischemia
1025493|NCT01906918|myocardial reperfusion
1025494|NCT01906866|Sleep disturbance
1025495|NCT01906866|Circadian
1025496|NCT01906866|Prolong release melatonin
1025497|NCT01906866|Autism Spectrum Disorder
1025498|NCT01906866|Smith-Magenis Syndrome
1025499|NCT01906866|Angelman Syndrome
1025500|NCT01906866|tuberous sclerosis
1025501|NCT01906853|BCG
1025502|NCT01906853|Bacille Calmette Guérin
1025503|NCT01906853|Allergy
1025504|NCT01906853|Immunity
1025505|NCT01906853|Immune response
1025506|NCT01906853|Vaccine
1025507|NCT01906853|Infants
1025508|NCT01906853|Children
1025509|NCT01906853|Infection
1025510|NCT01906840|Chronic renal failure
1025511|NCT01906840|Hemodialysis
1025512|NCT01906840|Oxidative stress
1025513|NCT01906840|Turmeric
1025514|NCT01906827|cholestasis
1025515|NCT01906827|pregnancy
1025516|NCT01906827|p wave dispersion
1025517|NCT01906827|arrhythmia
1025518|NCT01906801|Osteoarthritis
1025519|NCT01906801|Glucosamine sulfate
1025520|NCT01906801|Diacerein
1025521|NCT01906801|Randomized controlled trial
1025522|NCT01906775|ICD
1025523|NCT01906775|ventricular tachyarrhythmia
1025524|NCT01906775|shock
1025525|NCT01906775|sub-threshold pacing
1025526|NCT01906762|Morphine, Acetaminophen, Renal colic, Emergency treatment
1025527|NCT01906749|Acute coronary syndrome
1025528|NCT01906749|Colchicine
1025529|NCT01906710|Adverse Drug Events
1025530|NCT01906710|Drug related problems
1025531|NCT01906710|Medication Reconciliation
1025532|NCT01906710|Medication review
1025533|NCT01906710|discharge counseling
1025534|NCT01906710|Hospital Pharmacy based
1025535|NCT01906710|integrated medicines management
1025536|NCT01906710|patient safety
1025537|NCT01906684|Acthar Gel
1025538|NCT01906684|MS relapse
1025539|NCT01906684|7T MRI imaging
1025540|NCT01906684|Quality of Life
1025541|NCT01906671|6-mercaptopurine
1025542|NCT01906671|Drug formulation
1025543|NCT01906658|H.P. Acthar Gel
1025544|NCT01906658|Acthar
1025545|NCT01906658|amyotrophic lateral sclerosis
1025546|NCT01906658|ALS
1025547|NCT01906645|Patient Readmission
1025548|NCT01906645|Continuity of Patient Care
1025549|NCT01906619|Febrile Seizure
1025550|NCT01906619|Respiratory physiology
1025551|NCT01906619|Respiratory drive
1025552|NCT01906619|Respiratory alkalosis
1025553|NCT01906606|child nutritional status
1025554|NCT01906606|child development
1025555|NCT01906606|maternal depression
1025556|NCT01906593|safety
1025557|NCT01906593|influenza vaccine
1025558|NCT01906593|post-marketing
1025559|NCT01906580|HBV
1025560|NCT01906580|entecavir
1025561|NCT01906580|peginterferon
1025562|NCT01906567|cadmium
1025563|NCT01906567|lead
1025564|NCT01906567|mercury
1025565|NCT01906567|preeclampsia
1025566|NCT01906567|pregnancy
1025567|NCT01906541|X-CGD
1025568|NCT01906541|chronic granulomatous disease
1025569|NCT01906541|gene-therapy
1025570|NCT01906528|Nondepolarizing neuromuscular blocking drug
1025571|NCT01906528|Mivacurium
1025572|NCT01906528|Sensitivity
1025573|NCT01906528|Sex
1025574|NCT01906515|Anemia
1025575|NCT01906515|Blood transfusion
1025576|NCT01906515|non invasive hemoglobin monitoring
1025577|NCT01906515|patient safety
1025578|NCT01906489|anemia
1025579|NCT01906489|chronic kidney disease
1025580|NCT01906489|CKD
1025581|NCT01906489|chronic renal insufficiency
1025582|NCT01906489|renal impairment
1025583|NCT01906489|erythropoietin
1025584|NCT01906489|kidney
1025585|NCT01906489|oral anemia treatment
1025586|NCT01906489|hemoglobin
1025587|NCT01906489|hypoxia-inducible factor
1025588|NCT01906489|HIF
1025589|NCT01906489|hypoxia-inducible factor prolyl-hydroxylase inhibitor
1025590|NCT01906489|HIF-PHI
1025591|NCT01906489|efficacy
1025592|NCT01906489|safety
1025593|NCT01906489|pharmacokinetics
1025594|NCT01906476|Depression
1025595|NCT01906476|Telephone Cognitive Behavior Therapy
1025596|NCT01906476|Internet Cognitive Behavioral Therapy
1025597|NCT01906437|Cardiac fibrosis and Lymphoma
1025598|NCT01906424|spinal cord injury
1025599|NCT01906424|quadriplegia
1025600|NCT01906424|tetraplegia
1025601|NCT01906424|stimulation
1025602|NCT01906398|Refractory epilepsy
1025603|NCT01906398|ketogenic diet
1025604|NCT01906398|efficacy
1025605|NCT01906385|Glioblastoma
1025606|NCT01906385|Astrocytoma
1025607|NCT01906385|Brain Tumor
1025608|NCT01906385|Radiotherapy
1025609|NCT01906372|dermatomyositis
1025610|NCT01906372|polymyositis
1025611|NCT01906359|Interesterified fat
1025612|NCT01906359|Stereospecific number 2
1025613|NCT01906359|Gut hormones
1025614|NCT01906359|GIP
1025615|NCT01906359|Insulin sensitivity
1025616|NCT01906359|Postprandial lipaemia
1025617|NCT01906359|Haemostatic markers
1025618|NCT01906333|Exercise
1025619|NCT01906333|Ectopic fat accumulation
1025620|NCT01906320|anorexia nervosa
1025621|NCT01906320|restricting type
1025622|NCT01906320|muscle strength
1025623|NCT01906320|exercise
1025624|NCT01906320|body composition
1025625|NCT01906320|physical activity
1025626|NCT01906307|hepatorenal syndrome
1025627|NCT01906294|Type 2 Diabetes Mellitus
1025628|NCT01906281|adipocytokines
1025629|NCT01906281|osteoarthritis
1025630|NCT01906281|cardiovascular risk
1025631|NCT01906268|Generalized Anxiety Disorder
1025632|NCT01906268|Social Anxiety Disorder
1025633|NCT01906268|Panic Disorder
1025634|NCT01906268|Antidepressants Resistant
1025635|NCT01906268|Attentional Bias Modification Treatment (ABMT)
1025636|NCT01906268|Attentional Retraining
1025637|NCT01906268|Adjuvant Therapy
1025645|NCT01906216|Hepatocellular carcinoma
1025646|NCT01906216|sorafenib
1025647|NCT01906216|transarterial chemoembolization
1025648|NCT01906203|Ultramarathon
1025649|NCT01906203|bioelectrical impedance
1025650|NCT01906203|Phase-Angle
1025651|NCT01906190|influenza vaccine
1025652|NCT01906190|immune response
1025653|NCT01906190|persistence
1025654|NCT01906164|RSV
1025655|NCT01906125|Bioequivalence
1025656|NCT01906125|Cmax
1025657|NCT01906125|AUC
1025658|NCT01906073|fentanyl
1025659|NCT01906073|administration, intranasal
1025660|NCT01906073|morphine
1025661|NCT01906073|patient satisfaction
1025662|NCT01906073|patient preference
1025663|NCT01906047|Non-cystic fibrosis bronchiectasis
1025664|NCT01906021|Thermomap
1025665|NCT01906021|Hepatic Lesions
1025666|NCT01906021|Radiofrequency Ablation
1025667|NCT01906021|Microwave
1025668|NCT01906021|Non-Invasive Technique
1025669|NCT01906008|Colorectal cancer
1025670|NCT01906008|CRC
1025671|NCT01906008|Acute peripheral neuropathy
1025672|NCT01906008|Numbness
1025673|NCT01906008|Pain
1025674|NCT01906008|Loss of motor function
1025675|NCT01906008|Minocycline
1025676|NCT01906008|Dynacin
1025677|NCT01906008|Minocin
1025678|NCT01906008|Minocin PAC
1025679|NCT01906008|Myrac
1025680|NCT01906008|Solodyn
1025681|NCT01906008|Placebo
1025682|NCT01906008|Questionnaires
1025683|NCT01906008|Surveys
1025684|NCT01906008|Sensory tests
1025685|NCT01905995|deep brain sitimulation
1025686|NCT01905995|local field potentials
1025687|NCT01905969|Gastric caner, adjuvant chemotherapy
1025688|NCT01905917|Stroke
1025689|NCT01905904|electroconvulsive therapy
1025690|NCT01905904|seizures
1025691|NCT01905904|sevoflurane
1025692|NCT01905891|Non melanoma skin cancer
1025693|NCT01905891|Field of cancerization
1025694|NCT01905891|Skin carcinogenesis
1025695|NCT01905865|Uncertainty
1025696|NCT01905865|Undiagnosed Disease
1025697|NCT01905865|Coping
1025698|NCT01905852|Transcatheter Aortic Valve Replacement
1025699|NCT01905852|Ejection Fraction
1025700|NCT01905852|Fractional Flow Reserve
1025701|NCT01905852|Myocardial Fibrosis
1025702|NCT01905839|Rigidity
1025703|NCT01905839|Assessment
1025704|NCT01905839|Parkinson's Disease
1025705|NCT01905839|Physiological Measures
1025711|NCT01905800|Vertigo and dizziness.
1025712|NCT01905800|semicircular canals
1025713|NCT01905774|Renal Function
1025714|NCT01905761|obesity
1025715|NCT01905748|Coagulation
1025716|NCT01905735|RA
1025717|NCT01905722|MRI
1025718|NCT01905722|metabolism
1025719|NCT01905722|healthy
1025720|NCT01905722|7 Tesla
1025721|NCT01905709|C diff
1025722|NCT01905709|CDI
1025723|NCT01905709|clostridium difficile associated diarrhea
1025724|NCT01905670|Cardiac Resynchronization Therapy
1025725|NCT01905670|cardiac pacing
1025726|NCT01905670|electrical stimulation
1025727|NCT01905670|bi-ventricular pacing
1025728|NCT01905657|PD1
1025729|NCT01905657|PD-1
1025730|NCT01905657|PDL1
1025731|NCT01905657|PD-L1
1025732|NCT01905644|Vaginal delivery
1025733|NCT01905644|Perineal lesions
1025734|NCT01905644|Anal sphincter rupture
1025735|NCT01905644|Ultrasound
1025736|NCT01904786|Hypoxic Ischemic Encephalopathy
1025737|NCT01904786|Newborn
1025738|NCT01904786|Outcomes
1025739|NCT01904786|Melatonin
1025740|NCT01904773|Combined Multiple Motor and Vocal Tic Disorder; Tourette Disorder; Gilles de la Tourette Syndrome; Tourette Disease
1025741|NCT01904760|agitation
1025742|NCT01904760|delirium
1025743|NCT01904760|dexmedetomidine
1025744|NCT01904760|head and neck surgery
1025745|NCT01904760|microvascular free tissue transfer
1025746|NCT01904760|flap
1025747|NCT01904747|Food
1025748|NCT01904747|Bioavailability
1025749|NCT01904747|Fasted
1025750|NCT01904747|Fed
1025751|NCT01904734|testosterone
1025752|NCT01904734|hypogonadism
1025753|NCT01904734|pituitary
1025754|NCT01904708|Phenylketonuria
1025755|NCT01904708|PKU
1025756|NCT01904708|Exercise
1025757|NCT01904708|Muscle Protein Synthesis
1025758|NCT01904708|Plasma Phenylalanine concentration
1025759|NCT01904695|resistant hypertension
1025760|NCT01904695|causal inference
1025761|NCT01904695|a chorot study
1025762|NCT01904695|recipe of removing both phlegm and blood stasis
1025763|NCT01904682|Erythrocyte transfusion
1025764|NCT01904682|Erythropoiesis-stimulating agent
1025765|NCT01904682|International Prognostic Scoring System
1025766|NCT01904669|Fertility
1025767|NCT01904669|Infertility
1025768|NCT01904669|Pregnancy
1025769|NCT01904669|Conception
1025770|NCT01904669|Behavioral
1025771|NCT01904669|Lifestyle
1025772|NCT01904669|Preconception Care
1025773|NCT01904669|Women's Health
1025774|NCT01904669|Abortion, Spontaneous
1025775|NCT01904669|Cohort Studies
1025776|NCT01904669|Epidemiology
1025777|NCT01904669|Internet
1025778|NCT01904656|Colorectal Cancer Screening
1025779|NCT01904656|Ohio Appalachia
1025780|NCT01904630|gene sequencing
1025781|NCT01904630|familial
1025782|NCT01904630|risk factors
1025783|NCT01905618|Medical Education
1025784|NCT01905618|Tobacco Dependence Treatment
1025785|NCT01905618|Physician Delivered Intervention
1025786|NCT01905592|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1025787|NCT01905592|BRCA1 Gene Mutation
1025788|NCT01905592|BRCA2 Gene Mutation
1025789|NCT01905592|Parp Inhibitor
1025790|NCT01905592|BRCA
1025791|NCT01905579|flaremetry
1025792|NCT01905579|aqueous proteins
1025793|NCT01905579|clinical grading
1025794|NCT01905579|Compare flaremetry readings with the protein content of the aqueous
1025795|NCT01905579|Compare flaremetry readings with clinical grading of flare
1025796|NCT01905566|Plaque, Atherosclerotic
1025797|NCT01905566|clopidogrel
1025798|NCT01905566|ticagrelor
1025799|NCT01905566|Fluorodeoxyglucose F18
1025800|NCT01905566|Positron-Emission Tomography and Computed Tomography
1025801|NCT01905527|Multiple Sclerosis
1025802|NCT01905527|Relapsing-Remitting
1025803|NCT01905527|Rebif
1025804|NCT01905527|Quintiles Geographic Area Group
1025805|NCT01905527|Standard Subgroup
1025806|NCT01905527|Custom Subgroup
1025807|NCT01905527|RxCrossroads Geographic Area Group
1025808|NCT01905501|Balanced anesthesia
1025809|NCT01905501|Inhalation anesthesia
1025810|NCT01905501|Reperfusion injury
1025811|NCT01905501|Microsurgical Free flap
1025812|NCT01905475|STEMI
1025813|NCT01905475|AMI
1025814|NCT01905475|repair
1025815|NCT01905462|Cervarix
1025816|NCT01905462|Spontaneous abortion
1025817|NCT01905462|Vaccine
1025818|NCT01905462|Human Papillomavirus
1025819|NCT01905436|Filariasis
1025820|NCT01905436|Onchocerciasis
1025821|NCT01905436|Albendazole
1025822|NCT01905436|Ivermectin
1025823|NCT01905436|STH Soil Transmitted Helminth infections
1025824|NCT01905436|MDA Mass Drug Administration
1025825|NCT01905423|Filariasis
1025826|NCT01905423|Albendazole
1025827|NCT01905423|Diethylcarbamazine
1025828|NCT01905423|STH Soil Transmitted Helminths
1025829|NCT01905423|MDA Mass Drug Administration
1025830|NCT01905384|pancreatic cancer
1025831|NCT01905384|cholangiocarcinoma
1025832|NCT01905384|metastatic malignancy
1025833|NCT01905384|jaundice
1025834|NCT01905371|amphetamine
1025835|NCT01905371|stroke recovery
1025836|NCT01905319|juvenile idiopathic arthritis
1025837|NCT01905319|incidence rate
1025838|NCT01905306|dental implants
1025839|NCT01905306|immediate loading
1025840|NCT01905306|full-arch
1025841|NCT01905306|computer guided implant surgery
1025842|NCT01905280|allograft
1025843|NCT01905280|acellular dermal matrix
1025844|NCT01905280|alveolar ridge
1025845|NCT01905267|mindfulness
1025846|NCT01905267|relapse prevention
1025847|NCT01905267|recovery
1025848|NCT01905267|depression
1025849|NCT01905267|adolescents
1025850|NCT01905254|Transient elastography
1025851|NCT01905254|mini-laparoscopy
1025852|NCT01905254|liver biopsy
1025853|NCT01905254|liver cirrhosis
1025854|NCT01905254|autoimmune hepatitis
1025855|NCT01905228|Metastatic Advance Solid Neoplasms
1025856|NCT01905228|Unresectable Advance Solid Neoplasms
1025857|NCT01905215|Immunogenicity
1025858|NCT01905215|Respiratory Syncytial Virus
1025859|NCT01905215|Reactogenicity
1025860|NCT01905215|Vaccination
1025861|NCT01905215|Safety
1025862|NCT01905202|Proton Pump Inhibitor
1025863|NCT01905202|Safety
1025864|NCT01905202|Tolerability
1025865|NCT01905202|pH control
1025866|NCT01905202|Bile Acid
1025867|NCT01905189|pulmonary arterial hypertension
1025868|NCT01905189|cardiac resynchronization therapy
1025869|NCT01905176|Heart Failure
1025870|NCT01905176|Randomized Control Trial
1025871|NCT01905176|Disease management
1025872|NCT01905176|Self-care
1025873|NCT01905176|Nursing
1025874|NCT01905176|Patient education as topic
1025875|NCT01905163|Laparoscopy, interval debulking surgery
1025876|NCT01905150|pancreatic Cancer
1025877|NCT01905150|G-FLIP, Gemcitabine 5FU Leucovorin Irinotecan Oxaliplatin
1025878|NCT01905150|G-FLIP-DM (G-FLIP + Low doses Docetaxel and Mitomycin C)
1025879|NCT01905150|Vitamin C (ascorbic acid)
1025880|NCT01905137|Myofascial pelvic pain
1025881|NCT01905124|Uveitis
1025882|NCT01905124|Intermediate uveitis
1025883|NCT01905124|Posterior uveitis
1025884|NCT01905098|Detoxification
1025885|NCT01905098|Sauna
1025886|NCT01905098|Hyperthermia
1025887|NCT01905072|Obesity
1025888|NCT01905072|Breastfeeding
1025889|NCT01905072|Educational Intervention
1025890|NCT01905059|HIV infection
1025891|NCT01905059|second line ART
1025892|NCT01905059|maintenance strategies
1025893|NCT01905059|Protease inhibitors
1025894|NCT01905059|mono or bi-therapy
1025895|NCT01905033|Sepsis
1025896|NCT01905033|Pneumonia
1025897|NCT01905033|Peritonitis
1025898|NCT01905033|Biomarkers
1025899|NCT01905033|Transcriptomics
1025900|NCT01905033|Pathogen detection
1025901|NCT01905020|Type 1 diabetes
1025902|NCT01905020|Hypoglycemia
1025903|NCT01905020|Insulin
1025904|NCT01905020|Glucagon
1025905|NCT01905020|Closed-loop system
1025906|NCT01905020|Artificial pancreas
1025907|NCT01905007|Implantable cardioverter defibrillator
1025908|NCT01905007|Defibrillation threshold testing
1025909|NCT01904994|HIV (Human Immunodeficiency Virus)
1025910|NCT01904994|ART (antiretroviral therapy)
1025911|NCT01904994|financial incentive
1025912|NCT01904994|linkage
1025913|NCT01904994|retention
1025914|NCT01904994|SMS (Short Message Service) appointment reminder
1025915|NCT01904994|accelerated ART
1025916|NCT01904994|CD4+ count
1025917|NCT01904903|Breast Cancer HER2 Positive
1025918|NCT01904903|Cardiac Safety
1025919|NCT01904890|Asian Americans
1025920|NCT01904890|colorectal cancer screening
1025921|NCT01904890|cancer prevention
1025922|NCT01904890|Filipinos Americans
1025923|NCT01904890|Hmong Americans
1025924|NCT01904890|Korean Americans
1025925|NCT01904890|Randomized Controlled Trials
1025926|NCT01904877|HIV testing
1025927|NCT01904877|linkage
1025928|NCT01904877|care
1025929|NCT01904864|randomized controlled trial
1025930|NCT01904864|iron medication
1025931|NCT01904864|Anemia
1025932|NCT01904864|Hematologic Disease
1025933|NCT01904864|Anemia, Iron deficiency
1025934|NCT01904864|anemia, nutritional
1025935|NCT01904864|ferrous sulfate
1025936|NCT01904864|NovaFerrum®
1025937|NCT01904851|Peripheral Arterial Disease
1025938|NCT01904851|Stents
1025939|NCT01904851|Registry
1025940|NCT01904851|Angioplasty
1025941|NCT01904851|Endovascular Procedures
1025942|NCT01904617|Length of labor
1025943|NCT01904617|second stage of labor
1025944|NCT01904617|intravenous hydration of labor
1025945|NCT01904617|intravenous glucose
1025946|NCT01904604|Peanut Allergy
1025947|NCT01904604|Food Allergy
1025948|NCT01904604|Viaskin peanut patch
1025949|NCT01904604|Allergen Immunotherapy
1025950|NCT01904604|Epicutaneous Immunotherapy
1025951|NCT01904604|Whole peanut extract
1025952|NCT01904604|Allergenic product
1025953|NCT01904604|Immediate hypersensitivity
1025954|NCT01904591|Spinal Cord Injury
1025955|NCT01904591|Antioxidants
1025956|NCT01904591|tractography
1025957|NCT01904591|ASIA assessment
1025958|NCT01904578|Menopause
1025959|NCT01904578|Sleep quality
1025960|NCT01904578|Acupressure
1025961|NCT01904565|Hyperthermia,
1025962|NCT01904565|Proton beam therapy
1025963|NCT01904565|Soft Tissue Sarcoma
1025964|NCT01904565|Radiotherapy
1025965|NCT01904565|Phase I/II trial
1025966|NCT01904552|Apical periodontitis
1025967|NCT01904552|Dentaport ZX
1025968|NCT01904552|electronic apex locators
1025969|NCT01904552|i-Root
1025970|NCT01904552|Raypex 5
1025971|NCT01904552|working length
1025972|NCT01904526|Guanfacine
1025973|NCT01904526|PK/PD
1025974|NCT01904526|Smokers
1025975|NCT01904513|Metals
1025976|NCT01904513|Pesticides
1025977|NCT01904513|Toxicity
1025978|NCT01904500|Cesarean delivery
1025979|NCT01904474|obesity
1025980|NCT01904474|overweight
1025981|NCT01904474|technology
1025982|NCT01904474|internet
1025983|NCT01904474|intervention
1025984|NCT01904474|adolescents
1025985|NCT01904461|tonsillectomy
1025986|NCT01904461|children
1025987|NCT01904461|vacuum
1025988|NCT01904461|medical device
1025989|NCT01904461|pain
1025990|NCT01904461|hemorrhage
1025991|NCT01904461|post-surgical complications
1025992|NCT01904448|pediatric
1025993|NCT01904448|profound hearing loss
1025994|NCT01904448|auditory brainstem implant
1025995|NCT01904448|cochlear implant
1025996|NCT01904448|developmental or acquired cochlear nerve deficiency (CND)
1025997|NCT01904448|cochlear aplasia (Michel)
1025998|NCT01904448|post-meningitis cochlear ossification
1025999|NCT01904448|cochlear malformation
1026000|NCT01904448|CND
1026001|NCT01904422|Diabetes mellitus.
1026002|NCT01904422|Periodontitis
1026003|NCT01904422|Periodontal treatment.
1026004|NCT01904357|Cefazolin, Pediatric
1026005|NCT01904344|Sleep
1026006|NCT01904344|Sleep- related breathing disorders
1026007|NCT01904344|Respiratory pathology
1026008|NCT01904331|Cardiotoxicity
1026009|NCT01904331|long-term effects
1026010|NCT01904331|chemotherapy
1026011|NCT01904331|radiotherapy
1026012|NCT01904318|male
1026013|NCT01904318|Phase I
1026014|NCT01904318|A dose block-randomized
1026015|NCT01904318|Double-blinded
1026016|NCT01904318|Placebo controlled
1026017|NCT01904318|Single Dose
1026018|NCT01904318|dose Escalation
1026019|NCT01904318|IDP-73152 mesylate
1026020|NCT01904318|Food Effect
1026021|NCT01904318|Pharmacokinetics
1026022|NCT01904318|health male volunteer
1026023|NCT01904318|PDF inhibitor
1026024|NCT01904305|Pneumonia
1026025|NCT01904253|Second line Small Cell Lung Cancer, (SCLC), Refractory or Sensitive to First line Platinum based chemotherapy
1026026|NCT01904240|Parkinson's disease
1026027|NCT01904240|GI tract
1026028|NCT01904240|Lipopolysaccharide binding protein
1026029|NCT01904227|Borderline Personality Disorder
1026030|NCT01904227|Dialectical Behavior Therapy
1026031|NCT01904214|renal impairement
1026032|NCT01904214|pharmacokinetics
1026033|NCT01904201|Immune function
1026034|NCT01904201|Interferon-gamma release assays
1026035|NCT01904201|Active HIV cell Reservoirs
1026036|NCT01904188|microbial identification
1026037|NCT01904188|antibiotic resistance
1026038|NCT01904188|GeneZ
1026039|NCT01904188|sepsis
1026040|NCT01904188|Systemic Inflammatory Response Syndrome
1026041|NCT01904175|Stem cell transplantation, non-myeloablative
1026042|NCT01904149|Moderate to severe acute pain
1026043|NCT01904149|Postoperative pain
1026044|NCT01904149|Abdominal hysterectomy
1026045|NCT01904149|Analgesics
1026046|NCT01904149|Dexketoprofen
1026047|NCT01904149|Tramadol
1026048|NCT01904136|Leukemia
1026049|NCT01904136|Myeloproliferative Diseases
1026050|NCT01904136|Blood And Marrow Transplantation
1026051|NCT01904136|High Risk Myeloid Malignancies
1026052|NCT01904136|Acute myeloid leukemia
1026053|NCT01904136|AML
1026054|NCT01904136|Myelodysplastic syndrome
1026055|NCT01904136|MDS
1026056|NCT01904136|Chronic myeloid leukemia
1026057|NCT01904136|CML
1026058|NCT01904136|Haploidentical Stem-cell Transplantation
1026059|NCT01904136|HaploSCT
1026060|NCT01904136|Expanded natural killer cells
1026061|NCT01904136|NK
1026062|NCT01904136|Melphalan
1026063|NCT01904136|Alkeran
1026064|NCT01904136|Mesna
1026065|NCT01904136|Mesnex
1026066|NCT01904136|Cyclophosphamide
1026067|NCT01904136|Cytoxan
1026068|NCT01904136|Neosar
1026069|NCT01904136|Tacrolimus
1026070|NCT01904136|Prograf
1026071|NCT01904136|Mycophenolate mofetil
1026072|NCT01904136|MMF
1026073|NCT01904136|CellCept
1026074|NCT01904136|G-CSF
1026075|NCT01904136|Filgrastim
1026076|NCT01904136|Neupogen
1026077|NCT01904136|Fludarabine
1026078|NCT01904136|Fludarabine phosphate
1026079|NCT01904136|Fludara
1026080|NCT01904123|Brain cancer
1026081|NCT01904123|Central nervous system neoplasms
1026082|NCT01904123|CNS
1026083|NCT01904123|Melanoma
1026084|NCT01904123|Glioblastoma Multiforme
1026085|NCT01904123|GBM
1026086|NCT01904123|Solid tumors
1026087|NCT01904123|Metastatic to the brain
1026088|NCT01904123|WP1066
1026089|NCT01904123|Recurrent malignant glioma
1026090|NCT01904123|Glioblastoma
1026091|NCT01904123|Anaplastic glioma
1026092|NCT01904123|Advanced Brain Tumor Imaging
1026093|NCT01904123|ABTI
1026094|NCT01904110|Risedronate,cholecalciferol,BMD,montly,weekly,compliance
1026095|NCT01904097|Fibromyalgia
1026096|NCT01904097|Transcranial Direct Current Stimulation
1026097|NCT01904097|tDCS
1026098|NCT01904097|Pregabalin
1026099|NCT01904097|Functional Neuroimaging
1026100|NCT01904097|Near Infrared Spectroscopy
1026101|NCT01904097|NIRS
1026102|NCT01904097|Chronic Pain
1026103|NCT01904097|Transcranial Magnetic Stimulation
1026104|NCT01904097|TMS
1026105|NCT01904084|Distal radius fracture
1026106|NCT01904071|Hip Fracture
1026107|NCT01904071|Ultrasound
1026108|NCT01904071|Nerve Block
1026109|NCT01904058|PBC
1026115|NCT01904019|arthroplasty
1026116|NCT01904019|trapezio-metacarpial
1026117|NCT01904006|Embryo, group,low oxygen tension, assisted reproduction
1026118|NCT01903980|Epipericardial Fat Necrosis
1026119|NCT01903980|Fat Necrosis
1026120|NCT01903980|Chest Pain
1026121|NCT01903980|Pericardial Necrosis
1026122|NCT01903980|Pleuritic pain
1026123|NCT01903967|Pituitary
1026124|NCT01903967|CGH array
1026125|NCT01903967|Tumor
1026126|NCT01903941|exercise
1026127|NCT01903928|cytomegalovirus
1026128|NCT01903928|DNA vaccine
1026129|NCT01903928|transplantation
1026130|NCT01903928|HCT
1026131|NCT01903902|Coronary artery disease
1026132|NCT01903902|Balloon angioplasty
1026133|NCT01903902|Drug-eluting balloon
1026134|NCT01903889|AE adverse event
1026135|NCT01903889|AIDS acquired immunodeficiency syndrome
1026136|NCT01903889|ALT (SGPT) alanine aminotransferase
1026137|NCT01903889|ART antiretroviral therapy
1026138|NCT01903889|AST (SGOT) aspartate aminotransferase
1026139|NCT01903889|DCF data collection forms
1026140|NCT01903889|DMC Data Monitoring Committee
1026141|NCT01903889|FDA (U.S.) Food and Drug Administration
1026142|NCT01903889|GCP Good Clinical Practice guidelines
1026143|NCT01903889|HB sAg Hepatitis B surface antigen
1026144|NCT01903889|ICH International Conference of Harmonization
1026145|NCT01903889|IND Investigational New Drug Application
1026146|NCT01903889|IRB Institutional Review Board
1026147|NCT01903889|IU International units
1026148|NCT01903889|mg milligram(s)
1026149|NCT01903889|mm3 cubic millimeter(s)
1026150|NCT01903889|PCR polymerase chain reaction
1026151|NCT01903889|SAE serious adverse event
1026152|NCT01903889|µg microgram
1026153|NCT01903889|ULN upper limit of the normal range
1026154|NCT01903889|WB Western Blot
1026155|NCT01903889|ANC Antenatal care
1026156|NCT01903889|ARV Antiretroviral
1026157|NCT01903889|C&T Care and treatment
1026158|NCT01903889|CPR Contraceptive prevalence rate
1026159|NCT01903889|DHS Demographic and Health Survey
1026160|NCT01903889|EGPAF Elizabeth Glaser Pediatric AIDS Foundation
1026161|NCT01903889|FP Family planning
1026162|NCT01903889|HIV Human immunodeficiency virus
1026163|NCT01903889|HTC HIV testing and counseling
1026164|NCT01903889|IUCD Intrauterine contraceptive device
1026165|NCT01903889|MCH Maternal/child health
1026166|NCT01903889|PDA Personal digital assistant
1026167|NCT01903889|PEPFAR President's Emergency Plan for AIDS Relief
1026168|NCT01903889|PHSC Protection of Human Subjects Committee
1026169|NCT01903889|PMTCT Prevention of maternal to child transmission
1026170|NCT01903889|STAR-SW Strengthening TB and HIV/AIDS Response in the South Western Region of Uganda
1026171|NCT01903889|STI Sexually transmitted infection
1026172|NCT01903889|TM Technical monitor
1026173|NCT01903889|USAID United States Agency for International Development
1026174|NCT01903889|WHO World Health Organization
1026175|NCT01903863|FFP
1026176|NCT01903863|fresh frozen plasma
1026177|NCT01903863|ECMO
1026178|NCT01903863|extracorporeal membrane oxygenation
1026179|NCT01903863|anticoagulation
1026180|NCT01903863|transfusion
1026181|NCT01903850|Benign central airway obstruction
1026182|NCT01903850|Malignant central airway obstruction
1026183|NCT01903850|Spray cryotherapy
1026184|NCT01903850|Endoluminal tumors
1026185|NCT01903850|Airway granulation tissue
1026186|NCT01903837|Schizophrenia
1026187|NCT01903837|Olanzapine
1026188|NCT01903837|Samidorphan
1026189|NCT01903837|Alkermes
1026190|NCT01903824|Irdabisant
1026191|NCT01903824|cognitive impairment
1026192|NCT01903811|carfilzomib
1026193|NCT01903811|relapsed
1026194|NCT01903811|refractory
1026195|NCT01903811|multiple myeloma
1026196|NCT01903785|exercise-induced bronchoconstriction (EIB)
1026197|NCT01903785|inhaled salbutamol
1026198|NCT01903785|performance enhancing
1026199|NCT01903785|cycling
1026200|NCT01903733|Subjects
1026201|NCT01903733|Chronic Myeloid Leukemia
1026202|NCT01903733|CML
1026203|NCT01903733|Bosutinib
1026204|NCT01903733|Extension
1026205|NCT01903707|Schizophrenia
1026206|NCT01903707|Psychosis
1026207|NCT01903707|Cognitive deficits
1026208|NCT01903681|Sleep problems, autism spectrum disorder, prolonged-release melatonin, Circadin, endogenous saliva melatonin
1026209|NCT01903681|Smith-Magenis syndrome, Angelman syndrome, Tuberous Sclerosis
1026210|NCT01903603|cerebral palsy
1026211|NCT01903603|multi-modal brain techniques
1026212|NCT01903603|MRI
1026213|NCT01903603|Kinematic
1026214|NCT01903603|motor control
1026215|NCT01903590|TVT,TOT,Randomized
1026216|NCT01903577|Ergonomics
1026217|NCT01903577|Robotic Surgery
1026218|NCT01903577|Laparoscopic Surgery
1026219|NCT01903564|fetus
1026220|NCT01903564|fetal arrhythmia
1026221|NCT01903564|fetal heart rate
1026222|NCT01903564|long QT syndrome
1026223|NCT01903551|post-operative pain
1026224|NCT01903551|loco-regional analgesia
1026225|NCT01903551|minimally invasive surgery
1026226|NCT01903512|TMJ arthrocentesis
1026227|NCT01903512|internal derangement
1026228|NCT01903512|conservative treatment
1026229|NCT01903486|Trouble swallowing
1026230|NCT01903486|dysphagia
1026231|NCT01903486|disorder of the esophagus
1026232|NCT01903473|Allogeneic hematopoietic cell transplantation
1026233|NCT01903473|GVHD
1026234|NCT01903473|Regulatory T cells
1026235|NCT01903473|Steroid refractory
1026236|NCT01903473|Rapamycin
1026237|NCT01903473|Immune recovery
1026238|NCT01903473|Infusion
1026239|NCT01903473|HLA-identical sibling
1026240|NCT01903473|HLA-matched unrelated donor
1026241|NCT01903447|Internalizing psychopathologies
1026242|NCT01903447|Depression
1026243|NCT01903447|Anxiety
1026244|NCT01903447|MRI
1026245|NCT01903447|medication treatment
1026246|NCT01903447|psychotherapy
1026247|NCT01903447|brain function
1026248|NCT01903421|Elderly surgical patients
1026249|NCT01903421|Alzheimer's disease
1026250|NCT01903421|Dementia
1026251|NCT01903421|Elderly
1026252|NCT01903421|Surgery
1026253|NCT01903395|Colorectal Neoplasms/*drug therapy/*secondary
1026254|NCT01903395|Health Services Accessibility
1026255|NCT01903395|Humans
1026256|NCT01903395|Supportive Care Needs
1026257|NCT01903395|Psychooncology
1026258|NCT01903395|Primary Health Care/*methods
1026259|NCT01903395|Treatment Outcome
1026260|NCT01903395|Socioeconomic Factors
1026261|NCT01903395|Quality Assurance, Health Care
1026262|NCT01903395|Adult
1026263|NCT01903395|Aged
1026264|NCT01903395|Aged, 80 and over
1026265|NCT01903369|Shear wave
1026266|NCT01903369|Elastography
1026267|NCT01903369|Repeatability and Reproducibility
1026268|NCT01903343|Shear wave
1026269|NCT01903343|Elastography
1026270|NCT01903343|Repeatability and Reproducibility
1026271|NCT01903330|ERC1671
1026272|NCT01903330|GM-CSF
1026273|NCT01903330|Cyclophosphamide
1026274|NCT01903330|Bevacizumab
1026275|NCT01903304|Olive oil
1026276|NCT01903304|DTH
1026277|NCT01903304|elderly
1026278|NCT01903278|interferon
1026279|NCT01903278|ribavirin
1026280|NCT01903278|sustained virological response
1026281|NCT01903265|pain
1026282|NCT01903265|sleep
1026283|NCT01903252|UC
1026284|NCT01903226|spinal cord injury
1026285|NCT01903226|physical capacity
1026286|NCT01903226|energy expenditure
1026287|NCT01903226|training
1026288|NCT01903213|Peritoneal dialysis
1026289|NCT01903213|Bixalomer
1026290|NCT01903213|Chronic renal failure patients with Hyperphosphatemia
1026291|NCT01903213|Kiklin®
1026292|NCT01903200|Antipsychotic
1026293|NCT01903200|FK949E
1026294|NCT01903200|Quetiapine
1026295|NCT01903200|Elderly
1026296|NCT01903187|hypertension
1026297|NCT01903187|resistant hypertension
1026298|NCT01903187|renal denervation
1026299|NCT01903174|Breast Cancer
1026300|NCT01903174|Breast Reconstruction
1026301|NCT01903174|Breast Tissue Expansion
1026302|NCT01903174|Breast Tissue Expander
1026303|NCT01903174|Two Stage Breast Reconstruction
1026304|NCT01903161|delayed remote ischemic preconditioning
1026305|NCT01903161|troponin
1026306|NCT01903161|valve replacement surgery
1026307|NCT01903148|ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
1026308|NCT01903135|Obesity Hypoventilation Syndrome
1026309|NCT01903135|Prevalence
1026310|NCT01903135|Bicarbonate
1026311|NCT01903096|Panic disorder
1026312|NCT01903096|Generalized anxiety disorder
1026313|NCT01903096|Social phobia
1026314|NCT01903096|Specific phobia
1026315|NCT01903096|Major depressive disorder
1026316|NCT01903096|Dysthymia
1026317|NCT01903096|Somatizations disorder
1026318|NCT01903096|Pain disorder
1026319|NCT01903083|Pancreas
1026320|NCT01903083|Pancreatic cancer
1026321|NCT01903083|Immunotherapy
1026322|NCT01903083|Chemotherapy
1026323|NCT01903083|Radiation
1026324|NCT01903083|Surgery
1026325|NCT01903083|Pancreaticoduodenectomy
1026326|NCT01903057|Mass Drug Administration
1026327|NCT01903057|Neglected Tropical Diseases
1026328|NCT01903057|Preventive Chemotherapy and Transmission Control
1026329|NCT01903057|Preventive Chemotherapy
1026330|NCT01903044|Lowe extremity ischemia
1026331|NCT01903044|Bone marrow
1026332|NCT01903044|Neoangiogenesis
1026333|NCT01903005|Opioid, Dependence, agonist, Buprenorphine, Naloxone
1026334|NCT01902966|Cervical Cancer
1026335|NCT01902966|Propranolol
1026336|NCT01902966|Betachron
1026337|NCT01902966|Inderal
1026338|NCT01902966|Beta blocker
1026339|NCT01902966|Questionnaires
1026340|NCT01902966|Surveys
1026341|NCT01902966|Symptom inventory
1026342|NCT01902966|Anxiety and depression survey
1026343|NCT01902966|Pain inventory
1026344|NCT01902966|Quality of life survey
1026345|NCT01902966|Relaxation audio recording
1026346|NCT01902966|MP3 player
1026347|NCT01902966|Diary
1026348|NCT01902953|Sentinel lymph nodes
1026349|NCT01902953|colon cancer
1026350|NCT01902953|rectal cancer
1026351|NCT01902953|immunohistochemistry
1026352|NCT01902927|Exercise tolerance
1026353|NCT01902927|Dyspnea
1026354|NCT01902927|Affective distraction
1026355|NCT01902914|hearing aids
1026356|NCT01902914|hearing disability
1026357|NCT01902914|community
1026358|NCT01902914|hearing aids service
1026359|NCT01902901|Whole Genome Sequencing
1026360|NCT01902901|Carrier status
1026361|NCT01902901|Genetics
1026362|NCT01902888|popliteal artery
1026363|NCT01902888|aneurysm
1026364|NCT01902888|popliteal artery aneurysm
1026365|NCT01902888|asymptomatic aneurysm
1026366|NCT01902888|mural thrombus
1026367|NCT01902888|Viabahn
1026368|NCT01902888|Gore
1026369|NCT01902888|Endoprosthesis
1026370|NCT01902862|Lymphoma, follicular
1026371|NCT01902862|Bortezomib
1026372|NCT01902862|Rituximab
1026373|NCT01902849|intravenous anesthesia
1026374|NCT01902849|inhalational anesthesia
1026375|NCT01902849|interleukins
1026376|NCT01902849|colorectal surgery
1026377|NCT01902836|Dialyzable Leukocyte Extracts
1026378|NCT01902836|Transferon
1026379|NCT01902836|atopic dermatitis
1026380|NCT01902823|Nurse Navigator
1026381|NCT01902823|Satisfaction with Care
1026382|NCT01902823|Quality of Life
1026383|NCT01902823|Symptom Distress
1026384|NCT01902797|Refugee camps
1026385|NCT01902797|Household residence
1026386|NCT01902797|Treated bednets
1026387|NCT01902797|PCR
1026388|NCT01902784|Intensive Care Unit patients and families
1026389|NCT01902784|Surrogate decision making
1026390|NCT01902784|Life Sustaining Treatments (LST)
1026391|NCT01902771|Dendritic Cell Vaccine
1026392|NCT01902771|DCV
1026393|NCT01902771|Pediatric
1026394|NCT01902771|Brain Tumor
1026395|NCT01902771|In Situ
1026396|NCT01902771|Lysate
1026397|NCT01902771|Tumor Lysate
1026398|NCT01902771|Glioblastoma Multiforme
1026399|NCT01902771|GBM
1026400|NCT01902771|Pheresis
1026401|NCT01902771|Leukapheresis
1026402|NCT01902771|High Grade Glioma
1026403|NCT01902771|HGG
1026404|NCT01902758|exercise performance
1026405|NCT01902693|HIV
1026406|NCT01902693|Chemotherapy
1026407|NCT01902693|Cohort
1026408|NCT01902693|Cancer
1026409|NCT01902693|HAART
1026410|NCT01902693|Malignancy
1026411|NCT01902680|Prostate cancer, permanent implant brachytherapy, image fusion, focal therapy, active surveillance
1026412|NCT01902667|Retroperitoneal Sarcoma
1026413|NCT01902667|Magnetic Resonance Imaging
1026414|NCT01902654|Osteoarthritis
1026415|NCT01902654|cardiovascular disease
1026416|NCT01902641|succinylcholine
1026417|NCT01902641|rocuronium
1026418|NCT01902641|sugammadex
1026419|NCT01902641|Intubating Conditions
1026420|NCT01902641|short Procedures
1026421|NCT01902563|osteopathic manipulative treatment
1026422|NCT01902563|newborns
1026423|NCT01902563|preterm infants
1026424|NCT01902563|procedures
1026425|NCT01902550|Healthy
1026426|NCT01902550|JNJ-54452840
1026427|NCT01902550|Metoprolol Tartrate Immediate-Release
1026428|NCT01902550|Placebo
1026429|NCT01902550|Male
1026430|NCT01902537|Constipation
1026431|NCT01902537|Prucalopride
1026432|NCT01902524|Chronic Pain
1026433|NCT01902524|Fentanyl-TTS
1026434|NCT01902524|Fentanyl Patch
1026435|NCT01902524|Transdermal
1026436|NCT01902524|Non-cancer Pain
1026437|NCT01902498|aspirin
1026438|NCT01902485|Contraception
1026439|NCT01902485|Medical Abortion
1026440|NCT01902485|Implant
1026441|NCT01902485|Injectable
1026442|NCT01902485|Quickstart
1026449|NCT01902459|Hemostasis
1026450|NCT01902446|Chlorhexidine
1026451|NCT01902446|Randomized Controlled Trial
1026452|NCT01902446|Emergency Medical Services
1026453|NCT01902446|Intubation, Endotracheal
1026454|NCT01902407|Pcrit
1026455|NCT01902407|Critical closing pressure
1026456|NCT01902407|Down syndrome
1026457|NCT01902407|Obstructive Sleep Apnea
1026458|NCT01902407|Sleep MRI
1026459|NCT01902394|digestive health and natural defenses
1026460|NCT01902368|Gluten free diet
1026461|NCT01902355|Central Venous Catheterization
1026462|NCT01902329|Acute Myeloid Leukemia
1026463|NCT01902329|Antibody-Drug Conjugate
1026464|NCT01902329|CD33 Antigen
1026465|NCT01902329|Immunotherapy
1026466|NCT01902329|Drug Therapy
1026467|NCT01902329|Acute Myelogenous Leukemia
1026468|NCT01902329|Acute Promyelocytic Leukemia
1026469|NCT01902329|APL
1026470|NCT01902316|Type 2 Diabetes Mellitus
1026471|NCT01902316|peptide biomarker
1026472|NCT01902316|early diagnosis
1026473|NCT01902316|label free
1026474|NCT01902303|Herpes Labialis
1026475|NCT01902303|Herpes Simplex
1026476|NCT01902303|Herpes
1026477|NCT01902303|Ultra Violet (UV) Induced
1026478|NCT01902290|Inadequately controlled asthma, brodalumab, AMG 827
1026479|NCT01902277|Delirium
1026480|NCT01902277|Intensive Care Unit
1026481|NCT01902277|Critical illness
1026482|NCT01902264|Levomefolate calcium
1026483|NCT01902264|Contraceptives, oral, combined
1026484|NCT01902264|Neural tube defects
1026485|NCT01902251|Phase 1
1026486|NCT01902251|Prostate cancer
1026487|NCT01902251|Bioavailability
1026488|NCT01902251|Food effect
1026489|NCT01902251|Pharmacokinetics
1026490|NCT01902251|Xtandi
1026491|NCT01902251|Enzalutamide
1026492|NCT01902251|MDV3100
1026493|NCT01902238|neuroendocrine tumor
1026494|NCT01902238|ethanol
1026495|NCT01902238|endoscopic ultrasonography
1026496|NCT01902225|Lymphoma
1026497|NCT01902225|T-Cell
1026498|NCT01902225|Cutaneous
1026499|NCT01902225|Doxil
1026500|NCT01902225|romidepsin
1026501|NCT01902225|skin
1026502|NCT01902186|HIV
1026503|NCT01902186|osteopenia
1026504|NCT01902186|t-score
1026505|NCT01902186|DEXA
1026506|NCT01902186|tenofovir
1026507|NCT01902186|raltegravir
1026508|NCT01902147|abdominal
1026509|NCT01902147|thoracic
1026510|NCT01902147|arthroplasty
1026511|NCT01902134|Moderate to severe acute pain
1026512|NCT01902134|Postoperative pain
1026513|NCT01902134|Hip arthroplasty
1026514|NCT01902134|Analgesics
1026515|NCT01902134|Dexketoprofen
1026516|NCT01902134|Tramadol
1026517|NCT01902108|clonidine
1026518|NCT01902108|bupivacaine
1026519|NCT01902108|post-operative pain
1026520|NCT01902108|arthrodesis
1026521|NCT01902108|discectomy
1026522|NCT01902108|local infiltration
1026523|NCT01902095|tooth pastes
1026524|NCT01902095|tooth powders
1026525|NCT01902095|Stain Index
1026526|NCT01902082|ARDS
1026527|NCT01902082|mesenchymal stem cells
1026528|NCT01902082|Safety
1026529|NCT01902082|Cytokines
1026530|NCT01902069|sweet and fat preference
1026531|NCT01902056|allograft
1026532|NCT01902056|acellular dermal matrix
1026533|NCT01902056|Alloderm
1026534|NCT01902043|diabetes mellitus
1026535|NCT01902043|cohort study
1026536|NCT01902043|quality of care
1026537|NCT01902043|quality indicators, Health care
1026538|NCT01902043|quality of Health Care
1026539|NCT01902043|outcome and process assessment
1026540|NCT01902043|health services research
1026541|NCT01902043|chronic diseases prevention and management
1026542|NCT01902017|Joint
1026543|NCT01902017|Contracture
1026544|NCT01902017|Elbow
1026545|NCT01902017|Fracture
1026546|NCT01902017|Dislocation
1026547|NCT01902004|Major Depression
1026548|NCT01902004|Geriatric Major Depression
1026549|NCT01902004|Executive Cognitive Dysfunction
1026550|NCT01902004|Mild Cognitive Impairment
1026551|NCT01902004|Older Adults
1026552|NCT01902004|Geriatric
1026553|NCT01902004|Executive Cognitive Impairment
1026554|NCT01902004|Quality of Life
1026555|NCT01902004|Disability
1026556|NCT01902004|Comorbidity
1026557|NCT01902004|Medical Burden
1026558|NCT01902004|Safety
1026559|NCT01902004|Candidate Genes
1026560|NCT01901991|Nonpalpable breast lesions
1026561|NCT01901991|Breast Cancer and carcinoma in situ
1026562|NCT01901991|Radioactive seed localization
1026563|NCT01901991|Wire-guided localization
1026564|NCT01901991|Randomized study
1026565|NCT01901978|Obesity
1026566|NCT01901978|Insulin Resistance
1026567|NCT01901978|Weight loss
1026568|NCT01901978|Women
1026569|NCT01901952|Self management diabetes intervention
1026570|NCT01901939|exercise
1026571|NCT01901939|elderly
1026572|NCT01901939|activities of daily living
1026573|NCT01901939|disability
1026574|NCT01901913|Type 1 Diabetes
1026575|NCT01901913|Artificial pancreas
1026576|NCT01901913|Closed loop
1026577|NCT01901900|moderate to severe RA
1026578|NCT01901900|anti-TNF inadequate responders
1026579|NCT01901887|Adults
1026580|NCT01901887|Suicidality
1026581|NCT01901861|GLP-1, GIP, DPP-4 inhibition, iset function
1026582|NCT01901848|Smoking Cessation
1026583|NCT01901848|Stress Disorders, Post-Traumatic
1026584|NCT01901848|Psychotherapy
1026585|NCT01901822|acellular dermal matrix
1026586|NCT01901809|Heart failure, diastolic
1026587|NCT01901809|HFpEF
1026588|NCT01901809|Diuretics
1026589|NCT01901809|Dopamine
1026590|NCT01901796|Anxiety
1026591|NCT01901796|Depression
1026592|NCT01901796|CBT
1026593|NCT01901783|allograft
1026594|NCT01901783|regeneration
1026595|NCT01901783|alveolar ridge
1026596|NCT01901770|HPV
1026597|NCT01901770|Ohio Appalachia
1026598|NCT01901770|HPV vaccine
1026599|NCT01901770|No evidence of disease
1026600|NCT01901744|Contrast Sensitivity , Pediatric Cataract Surgery,
1026601|NCT01901731|transjugular coil embolisation
1026602|NCT01901731|endovenous treatment of varicose veins
1026603|NCT01901731|pelvic venous reflux
1026604|NCT01901731|recurrent varicose veins
1026605|NCT01901718|Breakthrough Pain
1026606|NCT01901718|Subsys
1026607|NCT01901718|Fentanyl
1026608|NCT01901718|Opioid
1026609|NCT01901718|Persistent Pain
1026610|NCT01901705|Psoriasis
1026611|NCT01901705|Indigo Naturalis
1026612|NCT01901705|chinese medicine
1026613|NCT01901679|Obesity
1026614|NCT01901679|Post-menopausal
1026615|NCT01901666|growth hormone, Chronic Myelogenous Leukemia, Imatinib,serum IGF-1
1026616|NCT01901653|Small cell lung cancer
1026617|NCT01901627|Spondylitis, Ankylosing
1026618|NCT01901627|adalimumab
1026619|NCT01901627|Prospective Studies
1026620|NCT01901614|Keratoconus
1026621|NCT01901614|Corneal Opacity
1026622|NCT01901614|Keratoplasty
1026623|NCT01901601|KERATOPLASTY
1026624|NCT01901601|STROMAL OPACITIES
1026625|NCT01901588|strabismus
1026626|NCT01901588|pediatric
1026627|NCT01901588|emergence delirium
1026628|NCT01901588|precedex/dexmedetomidine
1026629|NCT01901575|idiopathic ventricular tachycardia
1026630|NCT01901562|ductoscopy
1026631|NCT01901562|nipple discharge
1026632|NCT01901562|breast
1026633|NCT01901562|papilloma
1026634|NCT01901536|First time parents
1026635|NCT01901536|Coparenting
1026636|NCT01901536|Family Foundations
1026637|NCT01901523|Discrepancy
1026638|NCT01901523|Committee on Publication Ethics
1026639|NCT01901523|Correction
1026640|NCT01901523|Erratum
1026641|NCT01901523|Retraction
1026642|NCT01901510|polyp
1026643|NCT01901497|non invasive ventilation
1026644|NCT01901497|single limb circuit ventilator
1026645|NCT01901497|bilevel
1026646|NCT01901497|nebulization
1026647|NCT01901497|nebulizer
1026648|NCT01901497|vibrating mesh nebulizer
1026649|NCT01901497|amikacin
1026650|NCT01901484|Schistosoma mansoni
1026651|NCT01901484|morbidity
1026652|NCT01901484|chemotherapy
1026653|NCT01901471|Cyclosporine, cardiogenic shock, SOFA score,
1026654|NCT01901458|apheresis
1026655|NCT01901458|peripheral blood progenitor cells
1026656|NCT01901458|peripheral blood stem cells
1026657|NCT01901445|Quality of life
1026658|NCT01901445|Constipation
1026659|NCT01901445|Focus groups
1026660|NCT01901445|Health education
1026661|NCT01901445|Problem-based learning
1026662|NCT01901432|chronic myeloproliferative neoplasms
1026663|NCT01901432|Polycythemia Vera
1026664|NCT01901432|Essential Thrombocythemia
1026665|NCT01901432|Primary Myelofibrosis
1026666|NCT01901432|Post-Polycythemia Vera Myelofibrosis
1026667|NCT01901432|Post-Essential Thrombocythemia Myelofibrosis
1026668|NCT01901432|Givinostat
1026669|NCT01901419|nitroglycerin
1026670|NCT01901419|cardiopulmonary bypass
1026671|NCT01901419|cardiac surgery
1026672|NCT01901406|epiretinal membrane, stereopsis, aniseikonia
1026673|NCT01901393|Post Operative Pain,
1026674|NCT01901393|Pail relief
1026675|NCT01901367|Adiponectin, Glucose, Insulin, Leptin
1026676|NCT01901354|Acute lung injury (ALI)
1026677|NCT01901354|Adult respiratory distress syndrome (ARDS)
1026678|NCT01901354|Low-tidal-volume strategy
1026679|NCT01901354|ARDSNet
1026680|NCT01901354|airway pressure release ventilation (APRV)
1026681|NCT01901354|biomarkers of lung injury
1026682|NCT01901341|Opioid
1026683|NCT01901341|Constipation
1026684|NCT01901341|Chronic
1026685|NCT01901341|Pain
1026686|NCT01901328|Opioid
1026687|NCT01901328|Constipation
1026688|NCT01901328|Chronic
1026689|NCT01901328|Pain
1026690|NCT01901315|telepsychiatry
1026691|NCT01901315|telemental health
1026692|NCT01901315|teleassistance
1026693|NCT01901315|health care delivery
1026694|NCT01901315|depression
1026695|NCT01901315|Telemedicine
1026696|NCT01901315|Remote Consultation
1026697|NCT01901315|Videoconferencing
1026698|NCT01901315|Community Mental Health Services
1026699|NCT01901302|Opioid
1026700|NCT01901302|Constipation
1026701|NCT01901302|Chronic
1026702|NCT01901302|Pain
1026703|NCT01901289|Peripheral Vascular Disease
1026704|NCT01901289|Femoral Artery
1026705|NCT01901289|Popliteal Artery
1026706|NCT01901289|Drug-Eluting Stent
1026707|NCT01901276|Proton Pump Inhibitors
1026708|NCT01901276|Microbiome
1026709|NCT01901276|Clostridium difficile
1026710|NCT01901263|Cognitive and behavioral units
1026711|NCT01901263|Alzheimer Disease
1026712|NCT01901263|Dementia
1026713|NCT01901250|Dental Caries
1026714|NCT01901250|Xylitol
1026715|NCT01901250|Prevention
1026716|NCT01901237|Cancer
1026717|NCT01901237|Adolescent and Young Adult
1026718|NCT01901237|Exercise
1026719|NCT01901237|Physical Activity
1026720|NCT01901237|Quality of Life
1026721|NCT01901237|End-of-Life
1026722|NCT01901237|Palliative
1026723|NCT01901237|Terminal
1026724|NCT01901237|Yoga
1026725|NCT01901237|Alternative Therapies
1026726|NCT01901237|Fitness
1026727|NCT01901237|Fatigue
1026728|NCT01901211|Cerebral palsy
1026729|NCT01901211|Interactive computer play
1026730|NCT01901211|Multi-player gaming
1026731|NCT01901211|Exercise
1026732|NCT01901146|Human Epidermal Growth Factor Receptor 2 (HER2)
1026733|NCT01901146|Positive Early Breast Cancer
1026734|NCT01901133|Phase 1
1026735|NCT01901133|MDV3100
1026736|NCT01901133|Hepatic Impairment
1026737|NCT01901133|Kidney Diseases
1026738|NCT01901133|Xtandi
1026739|NCT01901133|enzalutamide
1026740|NCT01901120|Betanis®
1026741|NCT01901120|mirabegron
1026742|NCT01901120|Overactive Bladder
1026743|NCT01901107|Hemodialysis
1026744|NCT01901107|CKD (chronic kidney disease)
1026745|NCT01901107|ASP1585
1026746|NCT01901107|Hyperphosphatemia
1026747|NCT01901081|Implantable Myoelectric Sensor
1026748|NCT01901081|IMES
1026749|NCT01901081|transradial
1026750|NCT01901081|amputation
1026751|NCT01901081|myoelectric
1026752|NCT01901081|prosthesis
1026753|NCT01901081|prosthetic control
1026754|NCT01901068|Laparotomy
1026755|NCT01901068|Surgical Procedures, Elective
1026756|NCT01901068|Sutures
1026757|NCT01901068|Abdominal Wound Closure Techniques
1026758|NCT01901055|sleep apnea
1026759|NCT01901055|diabetes
1026760|NCT01901042|Quality of life
1026761|NCT01901042|Symbiotic
1026762|NCT01901042|Proctitis/Radiotherapy
1026763|NCT01901029|Male Reproductive Health
1026764|NCT01901029|Floating Population
1026765|NCT01901029|Sexual Behavior
1026766|NCT01901029|Erectile Dysfunction
1026767|NCT01901029|Premature Ejaculation
1026768|NCT01901016|HIV
1026769|NCT01901016|depressive symptoms
1026770|NCT01901016|quality of life
1026771|NCT01901016|relaxation
1026772|NCT01901016|viral load
1026773|NCT01901016|CD4+ T cell count
1026774|NCT01900990|Noninvasive Positive Pressure Ventilation
1026775|NCT01900990|Invasive Positive Pressure Ventilation
1026776|NCT01900990|tracheotomy
1026777|NCT01900977|Universal Test and Treat (UTT)
1026778|NCT01900977|Combination Prevention
1026779|NCT01900964|Regeneration
1026780|NCT01900964|Bone regeneration
1026781|NCT01900964|Grafting, Bone
1026782|NCT01900964|Allograft
1026783|NCT01900964|Xenograft
1026784|NCT01900951|Small cell lung cancer
1026785|NCT01900951|temozolomide
1026786|NCT01900951|Maintenance chemotherapy
1026787|NCT01900938|Cholangiopancreatography
1026788|NCT01900938|Endoscopic Retrograde
1026789|NCT01900925|Low back pain, non-specific low back pain
1026790|NCT01900912|sanitation
1026791|NCT01900912|diarrhea prevalence
1026792|NCT01900912|health
1026793|NCT01900912|social networks
1026794|NCT01900912|cooperation
1026795|NCT01900899|Healthy
1026796|NCT01900899|Immunogenicity
1026797|NCT01900899|Children
1026798|NCT01900899|Neisseria meningitidis
1026799|NCT01900899|Long-term antibody persistence
1026800|NCT01900899|Safety
1026801|NCT01900899|Serogroups A, C, W-135, and Y
1026802|NCT01900886|prison, disorder, hepatitis c
1026803|NCT01900873|Inspiratory Muscle Training
1026804|NCT01900873|COPD
1026805|NCT01900873|Inspiratory Muscle Function
1026806|NCT01900873|Dyspnea
1026807|NCT01900860|Vitamin D
1026808|NCT01900860|Bone quality
1026809|NCT01900860|Bone density
1026810|NCT01900860|calcium metabolism
1026811|NCT01900860|High resolution peripheral quantitative computed tomography
1026812|NCT01900860|Dual X-ray absorptiometry
1026813|NCT01900860|Quality of life
1026814|NCT01900847|Ketamine
1026815|NCT01900847|Acute Pain
1026816|NCT01900795|Postsurgical pain
1026817|NCT01900743|Sarcoma
1026818|NCT01900743|Metastatic
1026819|NCT01900743|Regorafenib
1026820|NCT01900730|Breast cancer
1026821|NCT01900730|Metastatic
1026822|NCT01900730|Indwelling pleural catheter
1026823|NCT01900730|Valproic acid
1026824|NCT01900730|VPA
1026825|NCT01900730|Depakene
1026826|NCT01900730|Placebo
1026827|NCT01900730|Pill diary
1026828|NCT01900730|Drainage diary
1026829|NCT01900730|Questionnaires
1026830|NCT01900730|Surveys
1026831|NCT01900691|Esophageal Fistula
1026832|NCT01900691|Esophageal Neoplasms
1026833|NCT01900691|Esophageal Perforation
1026834|NCT01900691|Esophageal Stenosis
1026835|NCT01900691|Stents
1026836|NCT01900639|aspirin
1026837|NCT01900639|circadian rhythm
1026838|NCT01900639|platelet reactivity
1026839|NCT01900639|platelet activation
1026840|NCT01900639|time dependent
1026841|NCT01900613|child obesity
1026842|NCT01900613|Mexican-American
1026843|NCT01900613|Nutrition education
1026844|NCT01900613|Intervention
1026845|NCT01900587|Healthy
1026846|NCT01900587|Bio-equivalence
1026847|NCT01900587|Tapentadol extended release
1026848|NCT01900587|Tamper-resistant formulation
1026849|NCT01900574|Colitis, Ulcerative
1026850|NCT01900574|Ulcerative Colitis
1026851|NCT01900574|Moderately to Severely Active Ulcerative Colitis
1026852|NCT01900574|Golimumab
1026853|NCT01900574|Simponi
1026854|NCT01900574|Human anti-TNFα Antibody
1026855|NCT01900574|Pediatric participants
1026856|NCT01900574|Safety and Pharmacokinetics
1026857|NCT01900561|prostate cancer
1026858|NCT01900561|survivorship
1026859|NCT01900561|intervention
1026860|NCT01900561|telemedicine
1026861|NCT01900548|Osteopenia
1026862|NCT01900548|Sarcopenia
1026863|NCT01900548|Osteoporosis
1026864|NCT01900548|Physical function
1026865|NCT01900548|Body composition
1026866|NCT01900548|Muscle protein
1026867|NCT01900548|Leucine
1026868|NCT01900548|Ketogenic amino acids
1026869|NCT01900548|Resistance Training
1026870|NCT01900548|Whey protein
1026871|NCT01900548|Soy protein
1026872|NCT01900548|Bone turnover
1026873|NCT01900535|chlorhexidine
1026874|NCT01900535|gingivitis
1026875|NCT01900535|periodontitis
1026876|NCT01900522|Drug therapy
1026877|NCT01900509|Childhood leukemia
1026878|NCT01900509|Childhood lymphoma
1026879|NCT01900509|Bendamustine
1026880|NCT01900496|cHL
1026881|NCT01900496|Hodgkin lymphoma
1026882|NCT01900496|Lymphoma
1026883|NCT01900496|relapsed Lymphoma
1026884|NCT01900496|SGN-35
1026885|NCT01900496|Brentuximab Vedotin
1026886|NCT01900496|Rituxan
1026887|NCT01900496|Rituximab
1026888|NCT01900470|Multiple chronic conditions
1026889|NCT01900444|Japanese encephalitis
1026890|NCT01900444|Japanese encephalitis chimeric virus vaccine
1026891|NCT01900444|IMOJEV®
1026892|NCT01900418|breast cancer
1026893|NCT01900418|aromatase inhibitors
1026894|NCT01900418|physical activity
1026895|NCT01900418|joint pain
1026896|NCT01900405|Dexmedetomidine
1026897|NCT01900405|Administration, Intranasal
1026898|NCT01900405|Children
1026899|NCT01900405|Computerized Tomography
1026900|NCT01900379|Obstructive sleep apneas syndrome
1026901|NCT01900379|Continuous positive airway pressure treatment
1026902|NCT01900379|Heart failure
1026903|NCT01900379|Coronary reperfusion surgery
1026904|NCT01900366|Obesity
1026905|NCT01900366|Healthy Volunteers
1026906|NCT01900340|GLP-1
1026907|NCT01900340|satiation peptides
1026908|NCT01900340|food intake
1026909|NCT01900327|pancreatic cancer
1026910|NCT01900327|surgery
1026911|NCT01900327|chemoradiation
1026912|NCT01900327|neoadjuvant treatment
1026913|NCT01900327|overall survival
1026914|NCT01900314|Major Depression
1026915|NCT01900314|Major Depressive Disorder
1026916|NCT01900314|TMS
1026917|NCT01900314|rTMS
1026918|NCT01900301|exposure
1026919|NCT01900301|scopolamine
1026920|NCT01900301|extinction learning
1026921|NCT01900301|social anxiety
1026922|NCT01900288|short bowel disorder
1026923|NCT01900288|short bowel syndrome
1026924|NCT01900288|home parenteral nutrition
1026925|NCT01900288|HPN
1026926|NCT01900288|total parenteral nutrition
1026927|NCT01900288|TPN
1026928|NCT01900288|telehealth
1026929|NCT01900288|telemedicine
1026930|NCT01900275|Sepsis
1026931|NCT01900275|Trauma
1026932|NCT01900275|Shock
1026933|NCT01900275|Acute kidney injury
1026934|NCT01900275|Heparanase
1026935|NCT01900262|Biomechanics
1026936|NCT01900262|Ankle Strength
1026937|NCT01900262|Postural Control
1026938|NCT01900262|Running Mechanics
1026939|NCT01900236|Patients newly initiating outpatient HIV medical care
1026940|NCT01900210|Criminal justice
1026941|NCT01900210|substance abuse treatment
1026942|NCT01900210|HIV risk behaviors
1026943|NCT01900158|Phase I, Phase II, Dose Escalation, Safety, Tolerability,
1026944|NCT01900158|Efficacy, Amphinex induced Photochemical Internalisation, PCI, Amphinex, Gemcitabine, Cisplatin,
1026945|NCT01900158|Inoperable Cholangiocarcinomas, CCA, Cholangiocarcinoma, bile duct cancer, photodynamic therapy
1026946|NCT01900132|Electrophysiology
1026947|NCT01900132|Neuromuscular Disease
1026948|NCT01900119|Oral Microbiome
1026949|NCT01900119|Next Generation Sequencing
1026950|NCT01900106|late presenter
1026951|NCT01900106|naïve
1026952|NCT01900106|advanced HIV disease
1026953|NCT01900080|HIV
1026954|NCT01900080|AIDS
1026955|NCT01900080|Antiretroviral therapy
1026956|NCT01900080|Retention in care
1026957|NCT01900080|Adherence
1026958|NCT01900080|Cost-effectiveness
1026959|NCT01900054|TAU-284
1026960|NCT01900054|Bepotastine besilate
1026961|NCT01900054|Histamine H1 receptor antagonists
1026962|NCT01900054|children
1026963|NCT01900028|oncology,
1026964|NCT01900028|cancer,
1026965|NCT01900028|tumour,
1026966|NCT01900028|anticancer drug,
1026967|NCT01900028|pharmacokinetics,
1026968|NCT01900028|olaparib,itraconazole,
1026969|NCT01900028|neoplasm,
1026970|NCT01900028|QT interval
1026971|NCT01900002|Liver Cancer
1026972|NCT01900002|Advanced Hepatocellular Carcinoma
1026973|NCT01900002|HCC
1026974|NCT01900002|Sorafenib
1026975|NCT01900002|Nexavar
1026976|NCT01900002|BAY 43-9006
1026977|NCT01900002|Yttrium-90
1026978|NCT01900002|Microspheres
1026979|NCT01900002|Phone calls
1026980|NCT01899989|Stereotactic Body Radiation Therapy (SBRT)
1026981|NCT01899989|Chemotherapy
1026982|NCT01899989|13-113
1026983|NCT01899976|covered biliary stent
1026984|NCT01899976|X-Suit NIR Covered Biliary Stent
1026985|NCT01899976|malignant strictures in biliary tree
1026986|NCT01899963|wet Age Related Macular Degeneration
1026987|NCT01899963|Diabetic Macular Edema
1026988|NCT01899963|Telemedicine
1026989|NCT01899963|Teleophthalmology
1026990|NCT01899963|Time to Treatment
1026991|NCT01899950|Niemann-Pick disease type C
1026992|NCT01899950|Lysosomal disease
1026993|NCT01899937|Endothelial dysfunction
1026994|NCT01899937|Flow mediated dilation
1026995|NCT01899937|Brachial artery flow mediated dilation
1026996|NCT01899937|FMD
1026997|NCT01899898|Refractory epilepsy
1026998|NCT01899898|Dietary therapy
1026999|NCT01899898|Non-Pharmacological therapy
1027000|NCT01899898|Simplified Modified Atkins Diet
1027001|NCT01899885|Emergency laparotomy
1027002|NCT01899885|Emergency laparoscopy
1027003|NCT01899872|Type 1 Diabetes Mellitus
1027004|NCT01899872|Endothelial progenitor cell
1027005|NCT01899872|Endothelial function
1027006|NCT01899872|Exercise
1027007|NCT01899859|Non-Alcoholic Steatohepatitis (NASH)
1027008|NCT01899846|Makena
1027009|NCT01899846|Pharmacokinetics
1027010|NCT01899846|Prior preterm delivery
1027011|NCT01899846|Hydroxyprogesterone Caproate
1027012|NCT01899846|17P
1027013|NCT01899833|Coronary Artery Disease
1027014|NCT01899833|CAD
1027015|NCT01899781|Lacerations
1027016|NCT01899781|Tendons
1027017|NCT01899781|Antobiotic
1027018|NCT01899768|efficacy
1027019|NCT01899768|hypertussive challenge
1027020|NCT01899768|voltage gated sodium channels (VGSC)
1027021|NCT01899768|anaesthesia
1027022|NCT01899768|Safety and tolerability
1027023|NCT01899768|capsaicin challenge
1027024|NCT01899768|cough
1027025|NCT01899768|citric acid challenge
1027026|NCT01899768|pharmacokinetics
1027027|NCT01899755|monoclonal antibody
1027028|NCT01899755|healthy volunteer
1027029|NCT01899755|TNF alpha
1027030|NCT01899729|plaque psoriasis
1027031|NCT01899729|autoimmune disease
1027032|NCT01899729|Toll like receptor
1027033|NCT01899716|Severe Depression
1027034|NCT01899716|Quality of life
1027035|NCT01899716|Exercise
1027036|NCT01899716|BDNF
1027037|NCT01899716|TBARS
1027038|NCT01899703|Intestinal bile acid transport inhibitor
1027039|NCT01899703|Pruritus
1027040|NCT01899703|Primary biliary cirrhosis
1027041|NCT01899703|Ursodeoxycholic acid
1027042|NCT01899703|GSK2330672
1027043|NCT01899703|Pharmacokinetics
1027044|NCT01899690|breast reconstruction
1027045|NCT01899690|cancer
1027046|NCT01899690|expander
1027047|NCT01899690|antibiotics
1027048|NCT01899690|infection
1027049|NCT01899690|surgical site infection
1027050|NCT01899690|surgery
1027051|NCT01899690|oncology
1027052|NCT01899690|plastic surgery
1027053|NCT01899677|Symbiotic,cytokines, necrotising enterocolitis
1027054|NCT01899664|peripheral nerves
1027055|NCT01899664|quadriplegia
1027056|NCT01899664|nerve transfer
1027057|NCT01899664|surgical procedures, operative
1027058|NCT01899664|hand
1027059|NCT01899664|upper extremity
1027060|NCT01899664|quality of life
1027061|NCT01899651|EEG
1027062|NCT01899651|Brain
1027063|NCT01899651|Infants
1027064|NCT01899651|Preterm
1027065|NCT01899651|Hemorrhage
1027066|NCT01899651|Bleeding
1027067|NCT01899625|Obesity
1027068|NCT01899625|weight loss
1027069|NCT01899625|young adults
1027070|NCT01899612|menopause
1027071|NCT01899612|vaginal atrophy
1027072|NCT01899612|cytokine
1027073|NCT01899612|IL-1beta
1027074|NCT01899612|IL-6
1027075|NCT01899612|IL-8
1027076|NCT01899612|TNF-alpha
1027077|NCT01899586|Aging
1027078|NCT01899586|Functional Capacity
1027079|NCT01899586|Exercise Independence
1027080|NCT01899586|Peripheral Adaptations
1027081|NCT01899586|Vascular
1027082|NCT01899573|Heart failure
1027083|NCT01899573|mitral regurgitation
1027084|NCT01899573|mitral valve
1027085|NCT01899560|Acute respiratory distress syndrome (ARDS)
1027086|NCT01899560|positive end expiratory pressure (PEEP)
1027087|NCT01899560|Staircase recruitment maneuver (SRM)
1027088|NCT01899560|Lung elastance
1027089|NCT01899560|chest wall elastance
1027090|NCT01899534|Pregnancy
1027091|NCT01899534|Mental Health
1027092|NCT01899534|Screening
1027093|NCT01899534|Computer
1027094|NCT01899534|Feasibility
1027095|NCT01899521|alcoholism
1027096|NCT01899521|lung health
1027097|NCT01899521|pulmonary
1027098|NCT01899521|macrophage
1027099|NCT01899521|zinc
1027100|NCT01899521|SAMe
1027101|NCT01899521|S-adenosylmethionine
1027102|NCT01899521|alveolar
1027103|NCT01899495|blood pressure
1027104|NCT01899495|hypertension
1027105|NCT01899495|salt sensitivity
1027106|NCT01899482|Venous Insufficiency
1027107|NCT01899482|Physical Therapy Techniques
1027108|NCT01899482|Manual Lymphatic Drainage
1027109|NCT01899443|total hip replacement
1027110|NCT01899443|total knee replacement
1027111|NCT01899443|patient outcomes
1027112|NCT01899443|health services research
1027113|NCT01899430|PCOS
1027114|NCT01899430|obesity
1027115|NCT01899430|GLP-1 receptor agonist
1027116|NCT01899430|liraglutide
1027117|NCT01899430|metformin
1027118|NCT01899417|osteoarthritis
1027119|NCT01899417|knee replacement
1027120|NCT01899417|patient-specific
1027121|NCT01899417|economics
1027122|NCT01899404|Cervical Cancer
1027123|NCT01899404|PET Scan for cervix
1027124|NCT01899404|MRI for cervix
1027125|NCT01899391|Prostate cancer
1027126|NCT01899378|probiotics
1027127|NCT01899365|anti-pneumococcal vaccination
1027128|NCT01899365|information
1027129|NCT01899365|emergency department
1027130|NCT01899339|submassive pulmonary embolism
1027131|NCT01899339|Ultrasonic energy
1027132|NCT01899339|Ekosonic Endovascular Device
1027133|NCT01899339|RV:LV function after Pulmonary Embolism
1027134|NCT01899313|methamphetamine dependence
1027135|NCT01899313|texting
1027136|NCT01899313|short message service
1027137|NCT01899313|addiction
1027138|NCT01899313|amphetamine
1027139|NCT01899313|outpatient
1027140|NCT01899300|Refractory Benign Esophageal Strictures caused by Caustic Ingestion
1027141|NCT01899287|workers education
1027142|NCT01899287|occupational
1027143|NCT01899209|Obstructed Defecation
1027144|NCT01899209|Rectal rectocele
1027145|NCT01899209|Intussusception
1027146|NCT01899209|STARR
1027147|NCT01899209|Ventral Rectopexy
1027148|NCT01899196|Cardiac surgery
1027149|NCT01899183|Chronic cough
1027150|NCT01899183|Esophagus
1027151|NCT01899183|Gastro-esophageal reflux disease
1027152|NCT01899183|Esophageal surgery
1027153|NCT01899183|Minimally invasive surgery
1027154|NCT01899183|Extra-esophageal reflux symptoms.
1027155|NCT01899170|deep brain stimulation
1027156|NCT01899170|multi-coil transcranial magnetic stimulation
1027157|NCT01899170|PET-imaging
1027158|NCT01899170|personalized treatment
1027159|NCT01899157|Nutritional status
1027160|NCT01899157|Nutritional situation
1027161|NCT01899144|Albuterol Spiromax
1027162|NCT01899144|ProAir HFA
1027163|NCT01899144|albuterol sulfate
1027164|NCT01899131|dental implants
1027165|NCT01899131|crestal bone
1027166|NCT01899131|gingival margin
1027167|NCT01899118|locally advanced rectal cancer
1027168|NCT01899118|Neoadjuvant chemoradiotherapy
1027169|NCT01899118|Nimotuzumab
1027170|NCT01899092|Genotype 1
1027171|NCT01899092|Chronic Hepatitis C
1027172|NCT01899092|CHC
1027173|NCT01899092|HCV
1027174|NCT01899092|Hepatitis
1027175|NCT01899092|RNAi
1027176|NCT01899092|shRNA
1027177|NCT01899092|ddRNAi
1027178|NCT01899092|AAV8
1027179|NCT01899092|AAV
1027180|NCT01899092|Adeno-associated virus
1027181|NCT01899092|Adeno-associated viral vectors
1027182|NCT01899079|Breast Cancer
1027183|NCT01899079|Prosigna
1027184|NCT01899079|FFPE
1027185|NCT01899079|node negative
1027186|NCT01899079|estrogen receptor positive
1027187|NCT01899079|HER2 negative
1027188|NCT01899066|Efficacy
1027189|NCT01899053|Solid tumors
1027190|NCT01899053|MLN0128
1027191|NCT01899053|MLN1117
1027192|NCT01899040|neuromodulation
1027193|NCT01899040|migraine headache
1027194|NCT01899027|Arterial hypertension
1027195|NCT01899027|Radiofrequency ablation
1027196|NCT01899027|Renal function
1027197|NCT01899014|Atherosclerosis
1027198|NCT01899014|18F-choline
1027199|NCT01899014|PET-CT
1027200|NCT01899014|MRI
1027201|NCT01899014|Ultrasound
1027202|NCT01899001|Polycystic Ovary Syndrome
1027203|NCT01899001|PCOS
1027204|NCT01899001|Depression
1027205|NCT01899001|Anxiety
1027206|NCT01899001|Weight loss
1027207|NCT01899001|Exercise
1027208|NCT01899001|Nutrition
1027209|NCT01899001|Therapy
1027210|NCT01899001|Mood symptoms
1027211|NCT01899001|Stress
1027212|NCT01898975|Neurosurgical patients
1027213|NCT01898975|Fluid loading
1027214|NCT01898975|Fluid responsiveness
1027215|NCT01898975|NICOM
1027216|NCT01898975|Stroke volume variation
1027217|NCT01898975|Pulse pressure variation
1027218|NCT01898975|Total peripheral resistance
1027219|NCT01898975|Gray zone approach
1027220|NCT01898962|Oligometastases
1027221|NCT01898962|Metastatic cancer
1027222|NCT01898962|Stereotactic radiosurgery
1027223|NCT01898949|Diet-induced thermogenesis
1027224|NCT01898949|Cold-induced thermogenesis
1027225|NCT01898949|Brown adipose tissue
1027226|NCT01898949|Brown fat
1027227|NCT01898923|WH-1,Diabetic Foot,Ulcer
1027228|NCT01898845|Neoplasms
1027229|NCT01898832|Cholestasis, pregnant, interleukin 17
1027230|NCT01898819|DEXMEDETOMIDINE
1027231|NCT01898819|intraocular pressure
1027232|NCT01898806|Alopecia Areata
1027233|NCT01898806|Kenalog
1027234|NCT01898806|Triamcinolone
1027238|NCT01898754|Transmitted Drug Resistance
1027239|NCT01898741|Pancreatic cancer
1027240|NCT01898741|Radiotherapy
1027241|NCT01898741|SBRT
1027242|NCT01898715|Adrenocortical carcinoma
1027243|NCT01898715|Adrenal cancer
1027244|NCT01898715|ACC
1027245|NCT01898676|Extended-release divalproex sodium
1027246|NCT01898676|Depakote ER
1027247|NCT01898650|craniosynostosis
1027248|NCT01898650|sagittal synostosis
1027249|NCT01898650|metopic synostosis
1027250|NCT01898650|coronal synostosis
1027251|NCT01898650|lambdoid synostosis
1027252|NCT01898637|pulmonary embolism
1027253|NCT01898637|pulse oximetry
1027254|NCT01898637|change in oxygen saturation
1027255|NCT01898637|hypoxemia
1027256|NCT01898637|emergency department
1027257|NCT01898637|deep inspiration
1027258|NCT01898637|vital capacity
1027259|NCT01898637|clinical diagnosis
1027260|NCT01898624|mirabegron
1027261|NCT01898624|Overactive Bladder
1027262|NCT01898624|Betanis®
1027263|NCT01898624|glaucoma
1027264|NCT01898611|Frailty
1027265|NCT01898611|Sarcopenia
1027266|NCT01898611|Weight Loss
1027267|NCT01898611|Exercise
1027268|NCT01898611|Aging
1027269|NCT01898611|Ghrelin
1027270|NCT01898611|Elderly
1027271|NCT01898572|Newly Diagnosed Type II Diabetes Mellitus
1027272|NCT01898572|Carotid Intimae-media Thickness
1027273|NCT01898572|Carotid Plaque
1027274|NCT01898572|Cardiovascular Disease
1027275|NCT01898559|little cigars
1027276|NCT01898559|cigarettes
1027277|NCT01898559|smoking
1027278|NCT01898546|Ischemic postconditioning
1027279|NCT01898546|Myocardial Infarction
1027280|NCT01898546|Microvascular Obstruction
1027281|NCT01898520|Spasticity
1027285|NCT01898481|Health care decision making
1027286|NCT01898468|Neuropathic pain symptoms
1027287|NCT01898468|Intracostal Closure Technique
1027288|NCT01898468|Pericostal Suture Closure Technique
1027289|NCT01898468|Post surgical pain
1027290|NCT01898468|Post thoracotomy pain
1027291|NCT01898455|Migraine
1027292|NCT01898455|Cluster headache
1027293|NCT01898455|headache
1027294|NCT01898442|platelet function
1027295|NCT01898442|ticagrelor
1027296|NCT01898442|STEMI
1027297|NCT01898429|Treatment Resistant Depression
1027298|NCT01898429|Treatment Refractory Depression
1027299|NCT01898429|Treatment Resistant Bipolar Disorder
1027300|NCT01898429|Treatment Refractory Bipolar Disorder
1027301|NCT01898429|Deep brain stimulation
1027302|NCT01898429|DBS
1027303|NCT01898390|Parkinson's Disease
1027304|NCT01898390|Allo-Transplantation
1027305|NCT01898390|Fetal Ventral Mesencephalic Tissue
1027306|NCT01898377|Children
1027307|NCT01898377|Chronic graft-versus-host disease
1027308|NCT01898351|Alternative sources of plant proteins
1027309|NCT01898351|High protein diets
1027310|NCT01898351|Satiety
1027311|NCT01898351|Postprandial effects
1027312|NCT01898351|Bioactive phytochemicals
1027313|NCT01898351|Phytochemicals bioactivity and metabolism
1027314|NCT01898351|Macronutrients metabolism
1027315|NCT01898351|Health effects of plant proteins vs. meat proteins
1027316|NCT01898351|Partial meat proteins replacement with plant proteins
1027317|NCT01898351|Satiety of meals rich in plant proteins
1027318|NCT01898351|Postprandial effects of meals rich in plant proteins
1027319|NCT01898351|Plant phytochemicals and macronutrients bioavailability and metabolism
1027320|NCT01898338|MRSA
1027321|NCT01898338|bacteremia
1027322|NCT01898338|therapy
1027323|NCT01898325|Fibrosis
1027324|NCT01898325|Gaucher disease
1027325|NCT01898299|Schizophrenia
1027326|NCT01898286|C peptide
1027327|NCT01898286|beta cell function
1027328|NCT01898286|immune modulation of type 1 diabetes
1027329|NCT01898286|immune intervention in type 1 diabetes
1027330|NCT01898273|Glioma
1027331|NCT01898273|Glioblastoma Multiforme
1027332|NCT01898273|PET
1027333|NCT01898273|Imaging
1027334|NCT01898273|Radiopharmaceutical
1027335|NCT01898273|Diagnostic
1027336|NCT01898260|contact lenses
1027337|NCT01898260|daily disposable contact lenses
1027338|NCT01898260|silicone hydrogel
1027339|NCT01898260|contact lens comfort
1027340|NCT01898260|near-sighted
1027341|NCT01898247|Thoracentesis
1027342|NCT01898247|Simulation Based Mastery Learning
1027343|NCT01898247|Medical Education
1027344|NCT01898247|Length of Stay
1027345|NCT01898247|Cost of Care
1027346|NCT01898234|Hemodynamics
1027347|NCT01898234|intradialytic hypotension
1027348|NCT01898234|subjective tolerance
1027349|NCT01898234|dialysis membranes
1027350|NCT01898234|high flux
1027351|NCT01898234|low flux
1027352|NCT01898234|hemodialysis
1027353|NCT01898208|Bacteremia
1027354|NCT01898208|Fungemia
1027355|NCT01898208|Bloodstream infection
1027356|NCT01898208|susceptibility
1027357|NCT01898208|MRSA
1027358|NCT01898208|VRE
1027359|NCT01898143|Whole body vibration, cardiorespiratory response
1027360|NCT01898117|Triple negative
1027361|NCT01898117|Metastatic
1027362|NCT01898104|rectal
1027363|NCT01898104|low risk
1027364|NCT01898104|moderate risk
1027365|NCT01898091|Oral
1027366|NCT01898091|Mucositis
1027367|NCT01898091|Stomatitis
1027368|NCT01898091|Radiotherapy
1027369|NCT01898078|MLN8237
1027370|NCT01898078|alisertib
1027371|NCT01898078|food effects
1027372|NCT01898065|Hypoxia
1027373|NCT01898065|radiotherapy
1027374|NCT01898065|PET with 18-F-MISO
1027375|NCT01898065|MRI
1027376|NCT01898052|pain control
1027377|NCT01898052|periarticular injection
1027378|NCT01898052|Total knee arthroplasty
1027379|NCT01898052|levobupivacaine
1027380|NCT01898052|multimodal drug injection
1027381|NCT01898039|malignant melanoma
1027382|NCT01898039|vaccine
1027383|NCT01898039|cell line
1027384|NCT01898039|high risk
1027385|NCT01898039|residual disease
1027386|NCT01898026|PGX
1027387|NCT01898026|fibre
1027388|NCT01898026|postprandial glycemia
1027389|NCT01898013|pain
1027390|NCT01898013|pregnenolone
1027391|NCT01898013|Veterans
1027392|NCT01898013|clinical trial
1027393|NCT01898013|neurosteroid
1027394|NCT01898013|allopregnanolone
1027395|NCT01898013|low back
1027396|NCT01898013|placebo controlled
1027397|NCT01898013|randomized
1027398|NCT01898013|musculoskeletal
1027399|NCT01898000|Gingivitis
1027400|NCT01898000|Herbal medicine
1027401|NCT01898000|Plaque control
1027402|NCT01897987|Human Umbilical Cord Blood Derived Mesenchymal Stem Cells
1027403|NCT01897987|Bronchopulmonary dysplasia
1027404|NCT01897987|Premature infants
1027405|NCT01897935|Uveitis
1027406|NCT01897896|Chorea
1027407|NCT01897896|Huntington Disease
1027408|NCT01897870|continuity of care
1027409|NCT01897870|medicines management
1027410|NCT01897870|home visit
1027411|NCT01897870|drug-related problems
1027412|NCT01897857|diabetes mellitus(DM)
1027413|NCT01897857|radial artery cannulation
1027414|NCT01897857|artery blood flow
1027415|NCT01897857|complication
1027416|NCT01897857|End stage renal disease undergoing kidney transplantation
1027417|NCT01897844|volunteers
1027418|NCT01897831|Piperacillin Sodium and sulbactam sodium
1027419|NCT01897831|Phase IV clinical studies
1027420|NCT01897831|Respiratory and urinary tract infections
1027421|NCT01897805|Coronary artery disease
1027422|NCT01897766|Genotropin
1027423|NCT01897766|Somatropin
1027424|NCT01897766|Long Term Follow-Up
1027425|NCT01897766|Special Investigation
1027426|NCT01897766|Small for Gestational Age
1027427|NCT01897766|SGA
1027428|NCT01897753|SGA
1027429|NCT01897753|Growth hormone
1027430|NCT01897740|sildenafil
1027431|NCT01897740|pulmonary arterial hypertension
1027432|NCT01897740|PAH
1027433|NCT01897727|sleep apnea
1027434|NCT01897727|hypertension
1027435|NCT01897727|aldosterone
1027436|NCT01897727|hyperaldosteronism
1027437|NCT01897727|spironolactone
1027438|NCT01897727|blood pressure
1027439|NCT01897727|resistant
1027440|NCT01897701|H7N9
1027441|NCT01897688|Diabetes
1027442|NCT01897688|Islet
1027443|NCT01897688|Pancreas
1027444|NCT01897688|Hypoglycemia
1027445|NCT01897688|T1D
1027446|NCT01897688|Transplant
1027447|NCT01897675|Cutaneous Abscess
1027448|NCT01897675|Emergency Department
1027449|NCT01897662|overweight
1027450|NCT01897662|satiety
1027451|NCT01897662|functional food
1027452|NCT01897662|food intake
1027453|NCT01897662|digestive tolerance
1027454|NCT01897649|functional food
1027455|NCT01897649|digestive tolerance
1027456|NCT01897649|microbiota
1027457|NCT01897649|bifidogenic effect
1027458|NCT01897636|endoscopic ultrasound-guided fine-needle injection
1027459|NCT01897636|dendritic cell
1027460|NCT01897636|vaccination
1027461|NCT01897610|Immuncell-LC, advanced hepatocellular carcinoma
1027462|NCT01897584|laparoscopy, Trendelenburg Position, ventilation
1027463|NCT01897545|Arterial hypertension
1027464|NCT01897545|Atrial Fibrillation
1027465|NCT01897545|Percutaneous renal denervation
1027466|NCT01897519|High risk surgery
1027467|NCT01897519|Acute Kidney Injury
1027468|NCT01897506|Food insecurity
1027469|NCT01897506|Health literacy
1027470|NCT01897506|Quality of life
1027471|NCT01897402|Central Nervous System Infections
1027472|NCT01897402|Meningitis
1027473|NCT01897402|toxoid
1027474|NCT01897402|Meningococcal vaccine
1027475|NCT01897402|conjugate vaccines
1027476|NCT01897389|Healthy volunteers
1027477|NCT01897389|Bioavailability
1027478|NCT01897389|Abiraterone acetate
1027479|NCT01897389|ZYTIGA
1027480|NCT01897376|wound
1027481|NCT01897376|infection
1027482|NCT01897376|cesarean delivery
1027483|NCT01897376|obesity
1027484|NCT01897363|Prader Willi Syndrome
1027485|NCT01897363|Hypoglycemia
1027486|NCT01897363|Fasting study
1027487|NCT01897350|STEMI
1027488|NCT01897350|Myocardial edema
1027489|NCT01897350|Cardiovascular magnetic resonance
1027490|NCT01897324|Poor Ovarian Response
1027491|NCT01897324|Poor Responders
1027492|NCT01897324|IVF/ICSI
1027493|NCT01897324|Growth Hormone
1027494|NCT01897311|cesarean section
1027495|NCT01897311|pain
1027496|NCT01897311|transcutaneous electrical nerve stimulation
1027497|NCT01897311|postpartum period
1027498|NCT01897298|chronic obstructive pulmonary disease (COPD)
1027499|NCT01897298|urban training
1027500|NCT01897298|physical activity
1027501|NCT01897298|active aging
1027502|NCT01897285|Performance and safety of the AQUACEL® foam adhesive dressing
1027503|NCT01897272|carpal tunnel syndrome
1027504|NCT01897272|splinting
1027505|NCT01897272|nerve decompression
1027506|NCT01897259|tennis elbow
1027507|NCT01897259|lateral epicondylitis
1027508|NCT01897246|distal radius malunion
1027509|NCT01897246|extra-articular
1027510|NCT01897220|Noncardiac surgery;
1027511|NCT01897220|Perioperative ischemic complications;
1027512|NCT01897220|Perioperative bleeding complications;
1027513|NCT01897220|Antithrombotic therapy;
1027514|NCT01897220|Coronary artery disease;
1027515|NCT01897220|Stent thrombosis;
1027516|NCT01897220|Perioperative infarction.
1027517|NCT01897207|prostate cancer
1027518|NCT01897207|dendritic cells
1027519|NCT01897207|vaccination
1027520|NCT01897181|Central auditory processing
1027521|NCT01897181|Bilateral sensorineural hearing loss
1027522|NCT01897181|Hearing aids
1027523|NCT01897155|analgesia, postoperative;
1027524|NCT01897155|analgesics opioid;
1027525|NCT01897155|hyperalgesia;
1027526|NCT01897155|remifentanil;
1027527|NCT01897155|hypertension.
1027528|NCT01897103|Peripheral Artery Disease
1027529|NCT01897103|Endarterectomy (Carotid)
1027530|NCT01897103|Aortic Aneurysm, Abdominal
1027531|NCT01897103|Aortic Aneurysm, Thoracic
1027532|NCT01897103|Amputation
1027533|NCT01897103|Platelet Activity
1027534|NCT01897103|Thrombin
1027535|NCT01897103|Transcriptomics
1027536|NCT01897090|Elimination Diet
1027537|NCT01897090|Crohn's disease
1027538|NCT01897077|Food Allergy
1027539|NCT01897077|Peanut
1027540|NCT01897077|Sublingual Immunotherapy
1027541|NCT01897064|Schizophrenia
1027542|NCT01897064|Cognition
1027543|NCT01897064|Aerobic Exercise
1027544|NCT01897051|Liver cirrhosis
1027545|NCT01897051|Portal hypertension
1027546|NCT01897051|Hepatic Venous Pressure Gradient
1027547|NCT01897051|Rifaximin
1027548|NCT01897025|Stroke
1027549|NCT01897025|Noninvasive brain stimulation
1027550|NCT01897025|Brain-computer interface
1027551|NCT01897025|Motor imagery
1027552|NCT01897025|Rehabilitation
1027553|NCT01896986|Special risk patients
1027554|NCT01896986|Immunosuppressive biologic treatments
1027555|NCT01896986|PRD (Paediatric Rheumatological Disease)
1027556|NCT01896986|IBD (Inflammatory Bowel Disease)
1027557|NCT01896973|Benign Prostatic Hyperplasia
1027558|NCT01896973|BPH
1027559|NCT01896973|LUTS
1027560|NCT01896973|Vortx Rx
1027561|NCT01896973|Histotripsy
1027562|NCT01896960|Post spinal hypotension
1027563|NCT01896960|Cesarian Section
1027564|NCT01896960|ET50
1027565|NCT01896960|Bupivacaine
1027566|NCT01896960|Fentanyl
1027567|NCT01896934|Depression
1027568|NCT01896934|Antidepressants
1027569|NCT01896934|Elderly
1027570|NCT01896934|Geriatrics
1027571|NCT01896921|HIV
1027572|NCT01896908|diastolic dysfunction
1027573|NCT01896908|Sodium restriction
1027574|NCT01896908|Randomized clinical trial
1027575|NCT01896882|Diet, Sodium-Restricted
1027576|NCT01896882|Food and Nutrition Education
1027577|NCT01896882|Renal Dialyisis
1027578|NCT01896869|Pancreatic Cancer
1027579|NCT01896869|Vaccine
1027580|NCT01896869|Immunotherapy
1027581|NCT01896869|Ipilimumab
1027582|NCT01896869|CTLA-4
1027583|NCT01896869|antibody
1027584|NCT01896869|FOLFIRINOX
1027585|NCT01896856|SGI-110
1027586|NCT01896856|irinotecan
1027587|NCT01896856|regorafenib
1027588|NCT01896856|methylation
1027589|NCT01896856|colorectal
1027590|NCT01896856|metastatic
1027591|NCT01896856|TAS-102
1027592|NCT01896856|lonsurf
1027593|NCT01896843|Positron Emission Tomography (PET)
1027594|NCT01896843|Metabotropic Glutamate Receptors
1027595|NCT01896830|Clostridium difficile infection
1027596|NCT01896830|Clostridium difficile Toxoid Vaccine
1027597|NCT01896739|Healthy infants with over than 37 weeks gestation periods.
1027598|NCT01896739|over than 2.5Kg at at birth weight.
1027599|NCT01896713|Prostate Cancer
1027600|NCT01896713|MRI
1027601|NCT01896713|TRUSBx
1027602|NCT01896700|Multiple sclerosis
1027603|NCT01896700|postural balance
1027604|NCT01896700|walking
1027605|NCT01896687|nonspecific low back pain
1027606|NCT01896687|chronic low back pain
1027607|NCT01896674|Computed tomography
1027608|NCT01896661|Sleep apnea
1027609|NCT01896661|Hypertension
1027610|NCT01896661|Treatment
1027611|NCT01896661|Diuretics
1027612|NCT01896661|Chlorthalidone
1027613|NCT01896661|Amlodipine
1027614|NCT01896635|Ulcerative Colitis
1027615|NCT01896635|Inflammatory Bowel Disease
1027616|NCT01896635|Fecal Transplantation
1027617|NCT01896635|Fecal Microbiota Transplantation
1027618|NCT01896622|Dabigatran Etexilate
1027619|NCT01896622|Ritonavir
1027620|NCT01896622|Cobicistat
1027621|NCT01896622|P-Glycoprotein
1027622|NCT01896609|Chronic hepatitis c
1027623|NCT01896609|Egyptian population
1027624|NCT01896609|Reiferon Retard
1027625|NCT01896609|Ribavirin
1027626|NCT01896609|Nitazoxanide
1027627|NCT01896609|Bon one
1027628|NCT01896596|vaccines
1027629|NCT01896596|immunogenicity
1027630|NCT01896596|adverse reactions
1027631|NCT01896570|atrial fibrillation
1027632|NCT01896570|catheter ablation
1027633|NCT01896570|subsequent atrial tachycardia
1027634|NCT01896570|mechanisms
1027635|NCT01896557|clopidogrel
1027636|NCT01896557|omeprazole
1027637|NCT01896557|ranitidin
1027638|NCT01896557|interaction
1027639|NCT01896557|aggregability
1027640|NCT01896544|cholecalciferol
1027641|NCT01896544|vitamin D
1027642|NCT01896544|sepsis
1027643|NCT01896544|infection
1027644|NCT01896518|second hand smoke exposure; children
1027645|NCT01896505|bone
1027646|NCT01896505|soft-tissue
1027647|NCT01896505|sarcoma
1027648|NCT01896505|KPT-330
1027649|NCT01896505|food
1027650|NCT01896505|effects
1027651|NCT01896505|Selinexor
1027652|NCT01896492|PCOS,
1027653|NCT01896492|NAC,
1027654|NCT01896492|OVULATION INDUCTION,
1027655|NCT01896492|CLOMOPHEN CITRATE
1027656|NCT01896479|thyroid cancer
1027657|NCT01896479|medullary thyroid cancer
1027658|NCT01896466|Fall Risk
1027659|NCT01896466|Gait
1027660|NCT01896466|Dynamic Balance
1027661|NCT01896466|Static Balance
1027662|NCT01896466|Neuromodulation
1027663|NCT01896440|Pediatric
1027664|NCT01896440|Ondansetron
1027665|NCT01896440|Cardiac repolarization
1027666|NCT01896440|QTc interval
1027667|NCT01896427|Third Molar
1027668|NCT01896427|Edema
1027669|NCT01896427|pain
1027670|NCT01896427|trismus
1027671|NCT01896414|Metabolic Syndrome
1027672|NCT01896414|Omega 3 Fish Oil
1027673|NCT01896401|large bore endovascular catheterization procedures
1027674|NCT01896401|Vascular Closure Device
1027675|NCT01896388|PTSD/ifenprodil
1027676|NCT01896375|Gutkha
1027677|NCT01896375|Pan masala ban
1027678|NCT01896375|Legislation
1027679|NCT01896375|Smokeless tobacco
1027680|NCT01896349|Psychotherapy, Treatment Resistant Depression, depression
1027681|NCT01896271|kidney cancer
1027682|NCT01896271|metastatic cancer
1027683|NCT01896245|hoarseness
1027684|NCT01896245|sore throat
1027685|NCT01896245|intubating conditions
1027686|NCT01896245|vocal cord injuries
1027687|NCT01896245|sevoflurane
1027688|NCT01896232|Secondary Hyperparathyroidism, renal, kidney, kidneys, dialysis, hemodialysis, chronic kidney disease, CKD, SHPT
1027689|NCT01896219|Medical device
1027690|NCT01896219|CT
1027691|NCT01896219|Needle
1027692|NCT01896219|Navigation
1027693|NCT01896219|IMACTIS-CT®
1027694|NCT01896219|Thoraco-abdominal level
1027695|NCT01896219|anesthesia needles
1027696|NCT01896180|POAG
1027697|NCT01896180|OHT
1027698|NCT01896180|OHTN
1027699|NCT01896180|IOP
1027700|NCT01896167|Headache
1027701|NCT01896167|Migraine
1027702|NCT01896167|Aura
1027703|NCT01896167|Cerebral hemodynamics
1027704|NCT01896154|dietary fibers, influenza vaccination, HI titres
1027705|NCT01896128|stroke
1027706|NCT01896128|CVA
1027707|NCT01896128|cerebrovascular accident
1027708|NCT01896128|hemiparesis
1027709|NCT01896128|impairment
1027710|NCT01896128|motor recovery
1027711|NCT01896128|neuroplasticity
1027712|NCT01896128|nuvigil
1027713|NCT01896128|armodafinil
1027714|NCT01896115|Stimulation, implantable pulse generator, deep brain stimulation
1027719|NCT01896076|caudal space
1027720|NCT01896076|children
1027721|NCT01896076|ultrasound evaluation
1027722|NCT01896063|Electroacupuncture, Sedation
1027723|NCT01896050|Joint pain
1027724|NCT01896050|Grip strength
1027725|NCT01896050|Hormone receptor positive breast cancer
1027726|NCT01896037|Spinal cord injury
1027727|NCT01896037|Tetraplegia
1027728|NCT01896037|Quadraplegia
1027729|NCT01896037|Cholesterol
1027730|NCT01896037|HDL-c
1027731|NCT01896037|LDL-c
1027732|NCT01896037|Omega-3 fatty acids
1027733|NCT01895998|sickle cell disease
1027734|NCT01895998|pulmonary hypertension
1027735|NCT01895998|airway hyperreactivity
1027736|NCT01895998|acute chest syndrome
1027737|NCT01895959|knee osteoarthritis (OA)
1027738|NCT01895959|hyaluronic acid injection
1027739|NCT01895946|Advanced solid malignancy, AZD5363,
1027740|NCT01895946|food effect,
1027741|NCT01895946|formulation comparison
1027742|NCT01895933|Investigational device (chitosan gel)
1027743|NCT01895933|Wound healing
1027744|NCT01895933|Endoscopic sinus surgery
1027745|NCT01895933|SurgiShield
1027746|NCT01895920|HIV
1027747|NCT01895920|Biofilm
1027748|NCT01895920|Transmission
1027749|NCT01895907|Special Olympics
1027750|NCT01895907|occupational therapy
1027751|NCT01895907|SCOPE
1027752|NCT01895907|life participation improvement
1027753|NCT01895894|Mycophenolate mofetil
1027754|NCT01895894|Immunosuppressive Agents
1027755|NCT01895894|Nephrosis
1027756|NCT01895881|Intracranial Aneurysm
1027757|NCT01895881|Estradiol
1027758|NCT01895868|Ultrasound training
1027759|NCT01895868|Ultrasound simulation
1027760|NCT01895868|Ultrasound assessment
1027761|NCT01895868|Technology-enhanced learning
1027762|NCT01895868|virtual reality simulation
1027763|NCT01895842|Leukemia
1027764|NCT01895842|Myelodysplastic syndrome
1027765|NCT01895842|MDS
1027766|NCT01895842|Low or intermediate-1 risk
1027767|NCT01895842|Maximum tolerated dose
1027768|NCT01895842|MTD
1027769|NCT01895842|Ruxolitinib
1027770|NCT01895842|Jakafi
1027771|NCT01895842|INCB018424
1027772|NCT01895842|INC424
1027773|NCT01895829|Head and Neck Cancer
1027774|NCT01895829|Squamous cell carcinomas of the head and neck
1027775|NCT01895829|HNSCC
1027776|NCT01895829|Magnetic resonance imaging
1027777|NCT01895829|MRI
1027778|NCT01895829|Ferumoxytol
1027779|NCT01895829|Ultra-small superparamagnetic iron oxide nanoparticle
1027780|NCT01895829|USPIO
1027781|NCT01895829|Contrast agent
1027782|NCT01895829|Dynamic contrast imaging
1027783|NCT01895829|DCI
1027784|NCT01895816|male infertility,oligo spermia
1027785|NCT01895803|smoking woman
1027786|NCT01895790|Pancreatic Cancer
1027787|NCT01895790|Pancreatic Duct
1027788|NCT01895790|Stent
1027789|NCT01895790|Pancreatic Duct Stent
1027790|NCT01895790|Cancer
1027791|NCT01895790|Pain
1027792|NCT01895790|Obstructive Pain
1027793|NCT01895790|Palliative
1027794|NCT01895764|ankylosing spondylitis
1027795|NCT01895751|Non-ST elevation myocardial infarction (NSTEMI)
1027796|NCT01895751|Non-ST elevation acute coronary syndrome (NSTE-ACS)
1027797|NCT01895751|Unstable Angina
1027798|NCT01895751|Medical therapy
1027799|NCT01895751|Coronary angiogram
1027800|NCT01895751|Percutaneous coronary intervention
1027801|NCT01895751|Coronary artery bypass surgery
1027802|NCT01895751|Coronary revascularization
1027803|NCT01895751|Health economics
1027804|NCT01895738|Trauma
1027805|NCT01895738|Injuries
1027806|NCT01895738|Violence
1027807|NCT01895738|Adolescent
1027808|NCT01895738|WrapAround care
1027809|NCT01895712|International
1027810|NCT01895712|Multicenter
1027811|NCT01895712|Observational registry
1027812|NCT01895712|Orsiro Drug Eluting Stents (DES)
1027813|NCT01895712|Stenting
1027814|NCT01895712|Treatment of Coronary Artery Disease
1027815|NCT01895712|Coronary revascularization
1027816|NCT01895712|Percutaneous Coronary Intervention (PCI)
1027817|NCT01895712|Diabetes Mellitus Type 1
1027818|NCT01895712|Diabetes Mellitus Type 2
1027819|NCT01895712|STEMI
1027820|NCT01895712|NSTEMI
1027821|NCT01895712|Ischemia
1027822|NCT01895712|Angina
1027823|NCT01895712|Subgroups
1027824|NCT01895712|Acute Myocardial Infarction
1027825|NCT01895712|Small vessels
1027826|NCT01895712|Chronic Total Occlusion
1027827|NCT01895699|Contrast agent
1027828|NCT01895699|endothelium
1027829|NCT01895699|Free radical
1027830|NCT01895699|Alpha lipoic acid
1027831|NCT01895686|open angle glaucoma
1027832|NCT01895686|narrow angles
1027833|NCT01895686|angle closure glaucoma
1027834|NCT01895686|gonioscopy
1027835|NCT01895686|anterior segment OCT
1027836|NCT01895673|FDG-PET
1027837|NCT01895673|Radiofrequency Ablation
1027838|NCT01895673|Magnetic Resonance Imaging
1027839|NCT01895660|P-CIMT
1027840|NCT01895660|Pediatric Constraint Induced Movement Therapy
1027841|NCT01895660|Hemiparesis
1027842|NCT01895660|Cerebral Palsy
1027843|NCT01895660|Children
1027844|NCT01895647|electric muscle stimulation
1027845|NCT01895647|respiratory failure
1027846|NCT01895647|sepsis
1027847|NCT01895647|interleukin 6
1027848|NCT01895647|interleukin 15
1027849|NCT01895634|Ischemia
1027850|NCT01895634|Stroke
1027851|NCT01895634|Ischemic Stroke
1027852|NCT01895634|Thrombectomy
1027853|NCT01895634|Brain clot
1027854|NCT01895634|Cerebrovascular disease
1027855|NCT01895634|Recanalization
1027856|NCT01895634|Revascularization
1027857|NCT01895634|Clot Retriever
1027858|NCT01895634|Neurovascular Intervention
1027859|NCT01895634|Interventional Neuroradiology
1027860|NCT01895634|neurovascular clinical trial
1027861|NCT01895608|aged or aged 80 and over
1027862|NCT01895608|gait disorder
1027863|NCT01895608|attention
1027864|NCT01895595|obesity
1027865|NCT01895595|stress
1027866|NCT01895595|intuitive eating
1027867|NCT01895595|guided imagery
1027868|NCT01895595|latinos
1027869|NCT01895595|adolescents
1027870|NCT01895595|insulin resistance
1027871|NCT01895582|Ageing
1027872|NCT01895582|Tuberculosis
1027873|NCT01895582|Interferon gamma releasing tests
1027874|NCT01895556|Malawi
1027875|NCT01895556|Risk Compensation
1027876|NCT01895556|Male Circumcision
1027877|NCT01895556|Demand
1027878|NCT01895530|Probiotics
1027879|NCT01895530|colorectal cancer
1027880|NCT01895530|postoperative infection
1027881|NCT01895530|immune function
1027882|NCT01895530|bacterial translocation
1027883|NCT01895530|gastrointestinal surgery
1027884|NCT01895504|Colonoscopy
1027885|NCT01895504|Colorectal cancer
1027886|NCT01895504|Adenoma
1027887|NCT01895478|asthma
1027888|NCT01895478|pediatrics
1027889|NCT01895478|control
1027890|NCT01895478|medication adherence
1027891|NCT01895465|urine collection, contamination
1027892|NCT01895452|Schizophrenia
1027893|NCT01895439|Bone marrow derived Mesenchymal Stem Cells
1027894|NCT01895439|Multiple Sclerosis
1027895|NCT01895439|Oligodendrocytes
1027896|NCT01895439|Neuroimmunology
1027897|NCT01895439|Autoimmune disease
1027898|NCT01895413|Cartilage injury
1027899|NCT01895413|Osteoarthritis
1027900|NCT01895413|Mesenchymal stem cells
1027901|NCT01895400|Renexin for Recurrent Vestibulopathy
1027902|NCT01895374|Laser therapy
1027903|NCT01895374|Biological dressing
1027904|NCT01895374|Amniotic membrane
1027905|NCT01895374|Hydrocolloid bandages
1027906|NCT01895374|wound healing
1027907|NCT01895361|SelG1
1027908|NCT01895361|P-selectin
1027909|NCT01895361|monoclonal antibody
1027910|NCT01895361|sickle cell disease
1027911|NCT01895361|sickle cell anemia
1027912|NCT01895361|sickle cell
1027913|NCT01895361|pain crisis
1027914|NCT01895361|pain crises
1027915|NCT01895361|vasoocclusion
1027916|NCT01895361|vaso-occlusion
1027917|NCT01895361|priapism
1027918|NCT01895361|hepatic sequestration
1027919|NCT01895361|splenic sequestration
1027920|NCT01895361|chest syndrome
1027921|NCT01895322|Tolvaptan
1027922|NCT01895322|dialysis
1027923|NCT01895309|Rheumatoid Arthritis
1027924|NCT01895309|Etanercept
1027925|NCT01895309|Biosimilar
1027926|NCT01895296|dumping syndrome
1027927|NCT01895296|OGTT
1027928|NCT01895296|hypoglycemia
1027929|NCT01895283|Aerobic training
1027930|NCT01895283|VO2max
1027931|NCT01895283|Bethlem myopathy
1027932|NCT01895270|opioid dependence
1027933|NCT01895270|buprenorphine
1027934|NCT01895270|isradipine
1027935|NCT01895270|opioid withdrawal
1027936|NCT01895270|opioid detoxification
1027937|NCT01895257|TTP1
1027938|NCT01895257|TTP2
1027939|NCT01895257|PFS
1027940|NCT01895257|Safety
1027941|NCT01895257|R0 resection rate
1027942|NCT01895257|Quality of life
1027943|NCT01895257|Overall Survival
1027944|NCT01895244|scleroderma
1027945|NCT01895244|autologous stem cell transplantation
1027946|NCT01895244|thiotepa
1027947|NCT01895244|cluster of differentiation (CD) 34 selection
1027948|NCT01895192|sperm morphology
1027949|NCT01895192|vacuoles
1027950|NCT01895192|fertile
1027951|NCT01895192|Motile Sperm Organellar Morphology Examination
1027952|NCT01895192|high magnification
1027953|NCT01895192|reference values
1027954|NCT01895179|Time-restricted feeding
1027955|NCT01895179|Intermittent fasting
1027956|NCT01895179|Prediabetes
1027957|NCT01895179|Insulin resistance
1027958|NCT01895179|Glucose tolerance
1027959|NCT01895179|Insulin sensitivity
1027960|NCT01895179|Circadian rhythms
1027961|NCT01895179|Diurnal
1027962|NCT01895166|Endobronchial ultrasonography with a guide sheath
1027963|NCT01895166|Peripheral pulmonary lesions
1027964|NCT01895166|Transbronchial biopsy
1027965|NCT01895153|bladder pain syndrome
1027966|NCT01895153|pentosan polysulfate
1027967|NCT01895153|hydrodistension
1027968|NCT01895140|Treatment-resistant hypertension
1027969|NCT01895140|Renal denervation
1027970|NCT01895140|Ambulatory blood pressure
1027971|NCT01895127|Kidney Transplant
1027972|NCT01895127|Renal Transplant
1027973|NCT01895127|Rejection
1027974|NCT01895127|Antibody mediated
1027975|NCT01895127|Humoral
1027976|NCT01895127|Eculizumab
1027977|NCT01895114|Renal function
1027978|NCT01895114|cirrhotic patients
1027979|NCT01895114|transplant evaluation
1027980|NCT01895101|blood loss
1027981|NCT01895101|tranexamix acid
1027982|NCT01895101|cardiac surgery
1027983|NCT01895088|presbyopia
1027984|NCT01895075|Budesonide
1027985|NCT01895075|Inhalation
1027986|NCT01895075|Premature infants
1027987|NCT01895062|colonoscopy
1027988|NCT01895062|oxygen desaturation
1027989|NCT01895049|Tacrolimus
1027990|NCT01895049|Everolimus
1027991|NCT01895049|Cytomegalovirus
1027992|NCT01895049|Thymoglobulin
1027993|NCT01895049|Deceased donors
1027994|NCT01895049|Expanded criteria
1027995|NCT01895036|maintained on 2 mg or less of buprenorphine, in which discontinuation of agonist treatment is clinically feasible but difficult
1027996|NCT01895010|prevention and treatment
1027997|NCT01895010|improvement of the patient's appetite
1027998|NCT01895010|TACE
1027999|NCT01894997|Deep Vein Thrombosis
1028000|NCT01894997|Neuromuscular Electrical Stimulation
1028001|NCT01894997|Intermittent Pneumatic Compression
1028002|NCT01894997|Doppler Ultrasound
1028003|NCT01894984|Schizophrenia
1028004|NCT01894984|Risperidone
1028005|NCT01894984|Risperdal Consta
1028006|NCT01894984|Oral antipsychotic
1028007|NCT01894958|Fragile X disorder
1028008|NCT01894958|Autism
1028009|NCT01894932|Psychotherapy, Group
1028010|NCT01894919|Meningococcal B disease,
1028011|NCT01894919|Antibody persistence
1028012|NCT01894906|Soluble Ferric Pyrophosphate,
1028013|NCT01894906|Pharmacokinetics,
1028014|NCT01894906|Iron, Mass Transfer,
1028015|NCT01894906|Hemodialysis
1028016|NCT01894906|chronic therapy;
1028017|NCT01894867|LIVER CIRRHOSIS
1028018|NCT01894867|MAGNESIUM
1028019|NCT01894867|MINIMAL ENCEPHALOPATHY
1028020|NCT01894867|MUSCLE WEAKNESS
1028021|NCT01894854|Radiostereometry
1028022|NCT01894854|Total Hip Arthroplasty
1028023|NCT01894854|Stem design
1028024|NCT01894841|depression
1028025|NCT01894841|prevention
1028026|NCT01894841|Veterans health
1028027|NCT01894828|Nutritional support
1028028|NCT01894828|Gastrointestinal cancer
1028029|NCT01894828|Malnutrition
1028030|NCT01894815|major depressive disorder
1028031|NCT01894815|major depression
1028032|NCT01894815|depressive disorder
1028033|NCT01894815|major depressive episode
1028034|NCT01894802|Tetraplegia
1028035|NCT01894802|Quadriplegia
1028036|NCT01894802|Spinal cord injury
1028037|NCT01894802|Brainstem or spinal stroke
1028038|NCT01894802|Neuroprosthetic
1028039|NCT01894802|Brain-machine interface
1028040|NCT01894802|Brain-computer interface
1028041|NCT01894802|Neural activity
1028042|NCT01894802|Sensory stimulation
1028043|NCT01894802|Microstimulation
1028044|NCT01894789|myocardial blood flow
1028045|NCT01894789|myocardial perfusion imaging
1028046|NCT01894789|myocardial blood flow reserve
1028047|NCT01894789|positron emission tomography
1028048|NCT01894789|adenosine
1028049|NCT01894789|ticagrelor
1028050|NCT01894789|clopidogrel
1028051|NCT01894776|healthy volunteers
1028052|NCT01894763|esophagus
1028053|NCT01894763|cancer
1028054|NCT01894750|Heart Failure
1028055|NCT01894750|Self-Care
1028056|NCT01894685|Colorectal
1028057|NCT01894685|Adenoma
1028058|NCT01894685|Recurrence
1028059|NCT01894685|Mesalazine
1028060|NCT01894685|Chemoprevention
1028061|NCT01894672|LGX818
1028062|NCT01894672|BRAF Inhibitor
1028063|NCT01894672|Stage IV melanoma
1028064|NCT01894672|unresectable stage III melanoma
1028065|NCT01894672|BRAFV600 mutation
1028066|NCT01894672|13-053
1028067|NCT01894633|Prophylactic Cranial Irradiation
1028068|NCT01894633|Metastasis
1028069|NCT01894633|Cloroquine
1028070|NCT01894620|Alzheimer's
1028071|NCT01894620|rTMS
1028072|NCT01894620|sleep quality
1028073|NCT01894620|dementia
1028074|NCT01894620|memory
1028075|NCT01894607|Kidney Cancer
1028076|NCT01894607|Renal Mass
1028077|NCT01894607|Open partial nephrectomy
1028078|NCT01894607|Ultrasound-guided surgery
1028079|NCT01894607|DEFINITY
1028080|NCT01894607|Contrast agent
1028081|NCT01894607|Phone call
1028082|NCT01894594|Sickle cell disease
1028083|NCT01894594|Chronic kidney disease
1028084|NCT01894594|Bicarbonate therapy
1028085|NCT01894555|Platelet Transcriptome
1028086|NCT01894555|Coronary Artery Disease
1028087|NCT01894555|Myocardial Ischemia
1028088|NCT01894555|Coronary Disease
1028089|NCT01894555|Heart Diseases
1028090|NCT01894555|Cardiovascular Diseases
1028091|NCT01894555|Arteriosclerosis
1028092|NCT01894555|Arterial Occlusive Diseases
1028093|NCT01894555|Vascular Diseases
1028094|NCT01894555|Aspirin
1028095|NCT01894529|ischemic stroke
1028096|NCT01894529|immune biomarkers
1028097|NCT01894529|stroke-associated infection
1028098|NCT01894529|functional outcome
1028099|NCT01894529|prediction
1028100|NCT01894490|Gastrointestinal surgery, complications, length of hospital stay, mortality
1028101|NCT01894464|truancy
1028102|NCT01894464|attendance
1028103|NCT01894464|education
1028104|NCT01894464|primary school
1028105|NCT01894464|elementary school
1028106|NCT01894451|Inflammatory Breast Carcinoma
1028107|NCT01894451|89Zr-bevacizumab
1028108|NCT01894438|NAFLD
1028109|NCT01894438|NASH
1028110|NCT01894438|Mediterranean diet
1028111|NCT01894438|Mediterranean lifestyle
1028112|NCT01894425|Medically assisted procreation
1028113|NCT01894425|Assisted reproductive technology
1028114|NCT01894425|Human papilloma virus
1028115|NCT01894399|HM61713
1028116|NCT01894399|pharmacokinetics
1028117|NCT01894399|Phase I
1028118|NCT01894399|healthy
1028119|NCT01894399|olmutinib
1028120|NCT01894386|GW642444 (Vilanterol)
1028121|NCT01894386|GSK573719 (Umeclidinium)
1028122|NCT01894386|GW685698 (Fluticasone Furoate)
1028123|NCT01894386|pharmacokinetics
1028124|NCT01894386|Healthy subjects
1028125|NCT01894360|Pharmacokinetics
1028126|NCT01894360|Phase 1
1028127|NCT01894360|Healthy Subjects
1028128|NCT01894360|Comparability
1028129|NCT01894360|Belimumab
1028130|NCT01894347|Colistin, MDR, inhalative therapy
1028131|NCT01894334|Aortic dissection
1028132|NCT01894334|acute lung injury
1028133|NCT01894334|injury mechanism
1028134|NCT01894334|early intervention
1028135|NCT01894321|Acute cholecystitis
1028136|NCT01894321|Elderly
1028137|NCT01894321|Critically ill patients
1028138|NCT01894321|Surgical high risk
1028139|NCT01894321|Percutaneous cholecystostomy
1028140|NCT01894321|Cholecystectomy
1028141|NCT01894308|Male Hormone Replacement
1028142|NCT01894308|Multiple Dose
1028143|NCT01894308|Single Period
1028144|NCT01894308|Phase II
1028145|NCT01894308|Dose Ranging
1028146|NCT01894308|Adult Male Subjects
1028147|NCT01894308|Testosterone Replacement
1028148|NCT01894295|Vitamin D analogues
1028149|NCT01894295|Resting Metabolic rate
1028150|NCT01894295|obesity
1028151|NCT01894282|Chronic Lower Back Pain
1028152|NCT01894282|Manual Therapy
1028153|NCT01894282|Cognitive Behavioral Therapy
1028154|NCT01894256|oncology,
1028155|NCT01894256|cancer,
1028156|NCT01894256|neoplasm,
1028157|NCT01894256|anticancer drug,
1028158|NCT01894256|pharmacokinetics,
1028159|NCT01894256|area under curve,
1028160|NCT01894256|olaparib,
1028161|NCT01894256|solid tumour,
1028162|NCT01894256|mild renal impairment,
1028163|NCT01894256|moderate renal impairment
1028164|NCT01894243|oncology,
1028165|NCT01894243|cancer,
1028166|NCT01894243|neoplasm,
1028167|NCT01894243|anticancer drug,
1028168|NCT01894243|pharmacokinetics,
1028169|NCT01894243|area under curve,
1028170|NCT01894243|olaparib,
1028171|NCT01894243|solid tumour,
1028172|NCT01894243|mild hepatic impairment,
1028173|NCT01894243|moderate hepatic impairment
1028180|NCT01894217|high cholesterol
1028181|NCT01894217|genetic testing
1028182|NCT01894217|medication adherence
1028183|NCT01894217|statins
1028184|NCT01894217|Adverse Effects
1028185|NCT01894217|Pharmacogenetic
1028188|NCT01894191|adenoma detection rate
1028189|NCT01894191|colonoscopy
1028190|NCT01894191|water exchange
1028191|NCT01894165|molybdenum cofactor deficiency (MoCD)
1028192|NCT01894165|deficiency of activity of molybdenum-dependent enzymes
1028193|NCT01894152|XIENCE PRIME EECSS
1028194|NCT01894152|XIENCE V EECSS
1028195|NCT01894152|XIENCE PRIME
1028196|NCT01894152|SPIRIT PRIME
1028197|NCT01894152|XIENCE PRIME SV (Small Vessel)
1028198|NCT01894152|XIENCE PRIME LL (Long Lesion)
1028199|NCT01894152|Coronary Artery Disease
1028200|NCT01894152|Coronary Heart Disease
1028201|NCT01894152|Cardiovascular Disease
1028202|NCT01894152|Myocardial Infarction
1028203|NCT01894152|Stent Thrombosis
1028204|NCT01894139|Gestational weight gain
1028205|NCT01894139|Obese women
1028206|NCT01894139|Fetal programming
1028207|NCT01894139|Metabolic disorders
1028208|NCT01894139|Development of obesity
1028209|NCT01894139|Development og overweight
1028210|NCT01894139|Complications during pregnancy and birth
1028211|NCT01894113|interstitial lung disease
1028212|NCT01894113|transbronchial biopsy
1028213|NCT01894113|cryobiopsy
1028214|NCT01894074|Subfertility
1028215|NCT01894074|Anovulatory
1028216|NCT01894074|Obese
1028217|NCT01894074|Women
1028218|NCT01894061|adult giant cell glioblastoma
1028219|NCT01894061|adult glioblastoma
1028220|NCT01894061|adult gliosarcoma
1028221|NCT01894061|recurrent adult brain tumor
1028222|NCT01894061|Bevacizumab-naive
1028223|NCT01894061|NovoTTF-100A
1028224|NCT01894048|asthma control
1028225|NCT01894048|small airways
1028226|NCT01894048|extra-fine particle inhaled corticosteroids
1028227|NCT01894035|Pulmonary Hypertension
1028228|NCT01894035|Ventavis
1028229|NCT01894035|Patient compliance
1028230|NCT01894022|Inoperable chronic thromboembolic pulmonary hypertension, endothelin receptor antagonist
1028231|NCT01894009|Osteopathic manipulation
1028232|NCT01894009|Exercise therapy
1028233|NCT01894009|Pregnancy pelvic girdle pain
1028234|NCT01893996|rheumatoid
1028235|NCT01893996|arthritis
1028236|NCT01893996|cardiovascular
1028237|NCT01893996|adalimumab
1028238|NCT01893996|tnf
1028239|NCT01893996|biologic
1028244|NCT01893957|breast cancer
1028245|NCT01893957|physical therapy
1028246|NCT01893957|electrical stimulation
1028247|NCT01893957|tactile sensitivity
1028248|NCT01893957|flow blood
1028249|NCT01893944|Breast cancer
1028250|NCT01893944|vibratory therapy
1028251|NCT01893944|virtual reality
1028252|NCT01893931|Geriatrics
1028253|NCT01893931|Emergency Medicine
1028254|NCT01893931|Care Transitions
1028255|NCT01893918|Smoking
1028256|NCT01893918|Dyspnea
1028257|NCT01893892|Basal Cell Carcinoma
1028258|NCT01893892|Gorlin syndrome
1028259|NCT01893892|Erivedge
1028260|NCT01893892|Basal Cell Nevus Syndrome
1028261|NCT01893853|dehydration
1028262|NCT01893853|fluid balance
1028263|NCT01893853|exercise
1028264|NCT01893853|heat
1028265|NCT01893853|body weight
1028266|NCT01893853|performance
1028267|NCT01893827|Naltrexone
1028268|NCT01893827|Extended-release naltrexone
1028269|NCT01893827|Oral naltrexone
1028270|NCT01893827|Vivitrol
1028271|NCT01893827|XR-NTX
1028272|NCT01893827|alcohol dependence
1028273|NCT01893827|primary care
1028274|NCT01893827|Medical Management
1028275|NCT01893801|pancreatic cancer
1028276|NCT01893801|pancreatic adenocarcinoma
1028277|NCT01893801|Stage IV pancreatic cancer
1028278|NCT01893801|pancreas
1028279|NCT01893801|pancreatic
1028280|NCT01893788|hypertension
1028281|NCT01893788|left ventricular hypertrophy
1028282|NCT01893788|renin angiotensin system
1028283|NCT01893788|aldosterone
1028284|NCT01893788|aliskiren
1028285|NCT01893788|eplerenone
1028286|NCT01893788|P3NP
1028290|NCT01893762|neutrophil
1028291|NCT01893762|exercise
1028292|NCT01893762|URTI
1028293|NCT01893762|Innate
1028294|NCT01893762|Immune
1028295|NCT01893749|depression
1028296|NCT01893749|prevention
1028297|NCT01893749|teen
1028298|NCT01893749|at risk
1028299|NCT01893749|internet
1028300|NCT01893736|Breastfeeding
1028301|NCT01893736|professional support
1028302|NCT01893736|postnatal
1028303|NCT01893736|interventions
1028304|NCT01893736|exclusive breastfeeding
1028305|NCT01893736|randomized controlled trial
1028306|NCT01893723|autonomous nervous system monitoring
1028307|NCT01893723|analgesia nociception balance
1028308|NCT01893723|remifentanil
1028309|NCT01893723|analgesia nociception index
1028310|NCT01893723|hemodynamic reactivity
1028311|NCT01893710|peritoneal dialysis
1028312|NCT01893710|parietal peritoneum
1028313|NCT01893710|omentum
1028314|NCT01893710|children
1028315|NCT01893684|protein
1028316|NCT01893684|physical function
1028317|NCT01893684|muscle quality
1028318|NCT01893684|fatigue
1028319|NCT01893684|weight loss
1028320|NCT01893671|LASIK
1028321|NCT01893671|corneal power
1028322|NCT01893671|astigmatism
1028323|NCT01893671|HOA
1028324|NCT01893671|Optical Coherence Tomography
1028325|NCT01893658|Interstitial Nephritis
1028326|NCT01893658|Nephritis
1028327|NCT01893658|Tubulointerstitial
1028328|NCT01893658|Renal disease
1028329|NCT01893658|Kidney
1028330|NCT01893645|Pronto-7
1028331|NCT01893645|SpHb
1028332|NCT01893645|Obstetric patients
1028333|NCT01893632|Benzodiazepines
1028334|NCT01893632|clonazepam
1028335|NCT01893632|alprazolam
1028336|NCT01893632|Klonopin
1028337|NCT01893632|Xanax
1028338|NCT01893632|diazepam
1028339|NCT01893632|Valium
1028340|NCT01893632|lorazepam
1028341|NCT01893632|Ativan
1028342|NCT01893619|Chronic fatigue syndrome
1028343|NCT01893619|Karnofsky score
1028344|NCT01893619|supplements
1028345|NCT01893606|diarrhea
1028346|NCT01893606|abdominal pain
1028347|NCT01893593|Cardiovascular risk
1028348|NCT01893593|lifestyle change
1028349|NCT01893593|blood pressure
1028350|NCT01893593|body mass index
1028351|NCT01893593|tobacco
1028352|NCT01893580|Cancer
1028353|NCT01893580|Rehabilitation
1028354|NCT01893580|Exercise
1028355|NCT01893580|Lung cancer
1028356|NCT01893580|NSCLC
1028357|NCT01893541|CIRRHOTIC
1028358|NCT01893541|VARICEAL BLEEDING
1028359|NCT01893541|PRIMARY PROPHYLAXIS
1028360|NCT01893489|positron emission tomography
1028361|NCT01893489|macrophage
1028362|NCT01893489|neomannosyl human serum albumin
1028363|NCT01893476|chronic obstructive pulmonary disease
1028364|NCT01893476|implementation
1028365|NCT01893463|hemorrhage control
1028366|NCT01893463|wound closure
1028367|NCT01893450|Graves ophthalmopathy
1028368|NCT01893450|Exophthalmos
1028369|NCT01893450|Proptosis
1028370|NCT01893450|Quality of life
1028371|NCT01893424|Biological Availability
1028372|NCT01893424|Pharmacokinetics
1028373|NCT01893385|vitamin D
1028374|NCT01893385|supplementation
1028375|NCT01893385|immunocompetente cells, immune system
1028376|NCT01893385|influenza vaccine
1028377|NCT01893385|elderly
1028378|NCT01893372|Leukemia
1028379|NCT01893372|Myelodysplastic syndrome
1028380|NCT01893372|MDS
1028381|NCT01893372|Overall response rate
1028382|NCT01893372|ORR
1028383|NCT01893372|Eltrombopag
1028384|NCT01893372|Promacta
1028385|NCT01893372|Hypomethylating Agent
1028389|NCT01893346|Ceftazidime, Avibactam, Anti-Infectives
1028390|NCT01893333|cervical cancer
1028391|NCT01893333|nerve sparing radical hysterectomy
1028392|NCT01893320|Leukemia
1028393|NCT01893320|Acute Myeloid Leukemia
1028394|NCT01893320|AML
1028395|NCT01893320|High-risk Myelodysplastic Syndrome
1028396|NCT01893320|MDS
1028397|NCT01893320|Chronic Myelomonocytic Leukemia
1028398|NCT01893320|CMM
1028399|NCT01893320|Maximum tolerated dose
1028400|NCT01893320|MTD
1028401|NCT01893320|Vosaroxin
1028402|NCT01893320|Decitabine
1028403|NCT01893320|Dacogen
1028404|NCT01893307|Head And Neck Cancer
1028405|NCT01893307|Oropharyngeal Cancer
1028406|NCT01893307|Squamous cell carcinoma of the oropharynx
1028407|NCT01893307|Acute and late toxicity
1028408|NCT01893307|Intensity modulated photon therapy
1028409|NCT01893307|IMRT
1028410|NCT01893307|Intensity modulated proton therapy
1028411|NCT01893307|IMPT
1028412|NCT01893307|Modified barium swallow
1028413|NCT01893307|MBS
1028414|NCT01893307|Questionnaires
1028415|NCT01893307|Surveys
1028416|NCT01893229|Bipolar disorder
1028417|NCT01893229|Comparative Effectiveness Research
1028418|NCT01893229|Therapeutics
1028419|NCT01893229|Patient Dropouts
1028420|NCT01893216|anxiety
1028421|NCT01893216|depression
1028422|NCT01893216|sexual dysfunction
1028423|NCT01893216|infertility
1028424|NCT01893190|Ruptured saccular aneurysm
1028425|NCT01893190|nimodipine
1028426|NCT01893190|safety
1028427|NCT01893190|tolerability
1028428|NCT01893190|Subarachnoid hemorrhage
1028429|NCT01893177|Influenza
1028430|NCT01893177|Virus
1028431|NCT01893177|Vaccination
1028432|NCT01893177|Inflexal V
1028433|NCT01893164|cubital tunnel syndrome
1028434|NCT01893164|simple decompression
1028435|NCT01893164|anterior subcutaneous transposition of ulnar nerve
1028436|NCT01893164|anterior intramuscular transposition of ulnar nerve
1028437|NCT01893164|severity scale
1028438|NCT01893151|Iguratimod
1028439|NCT01893151|MRI
1028440|NCT01893151|Rheumatoid Arthritis
1028441|NCT01893138|Urinary Incontinence, Stress
1028442|NCT01893138|Tissue Therapy (Cell Therapy)
1028443|NCT01893138|Transplantation, Autologous
1028444|NCT01893060|Prematurity
1028445|NCT01893060|Central line care
1028446|NCT01893060|Umbilical line colonization
1028447|NCT01893060|Colonization
1028448|NCT01893060|Newborn Intensive Care Unit
1028449|NCT01893060|Neonatal Intensive Care Unit
1028450|NCT01893047|breast milk production
1028451|NCT01893034|Femoroacetabular Impingement
1028452|NCT01893034|Arthroscopy
1028453|NCT01893034|Physiotherapy
1028454|NCT01893034|Randomised Controlled Trial
1028455|NCT01893008|Esophageal cancer
1028456|NCT01893008|Surgery
1028457|NCT01892995|suicide
1028458|NCT01892995|ketamine
1028459|NCT01892995|low-dose ketamine
1028460|NCT01892995|suicidal ideations
1028461|NCT01892995|emergency department
1028462|NCT01892982|Maternal Depression
1028463|NCT01892982|Preterm Birth
1028464|NCT01892982|Preterm Outcomes
1028465|NCT01892982|Child Development
1028466|NCT01892917|International
1028467|NCT01892917|Multicenter
1028468|NCT01892917|Observational registry
1028469|NCT01892917|Orsiro Drug Eluting Stent (DES)
1028470|NCT01892917|Stenting
1028471|NCT01892917|Treatment of Coronary Artery Disease
1028472|NCT01892917|Coronary revascularization
1028473|NCT01892917|Percutaneous Coronary Intervention
1028474|NCT01892917|STEMI
1028475|NCT01892917|NSTEMI
1028476|NCT01892917|Ischemia
1028477|NCT01892917|Subgroups
1028478|NCT01892917|Acute Myocardial Infarction
1028479|NCT01892917|Diabetes
1028480|NCT01892917|Small Vessels
1028481|NCT01892917|Chronic Total Occlusion (CTO)
1028482|NCT01892904|YAZ
1028483|NCT01892904|Flexible regimen
1028484|NCT01892904|Drospirenone
1028485|NCT01892904|Ethinylestradiol Betadex
1028486|NCT01892904|Dysmenorrhea
1028487|NCT01892904|Japanese patients
1028488|NCT01892891|Healthy
1028489|NCT01892891|Subjects
1028490|NCT01892891|Safety
1028491|NCT01892891|Tolerability
1028492|NCT01892891|VBY036
1028493|NCT01892891|maximum
1028494|NCT01892891|pharmacodynamic
1028495|NCT01892891|pharmacokinetic
1028496|NCT01892865|Operating room utilization
1028497|NCT01892852|Acupuncture
1028498|NCT01892852|Traditional Korean Medicine
1028499|NCT01892826|FET
1028500|NCT01892826|Blastocyst
1028501|NCT01892826|natural cycle
1028502|NCT01892826|hCG
1028503|NCT01892826|Spontaneous LH pic
1028504|NCT01892813|Nicotine dependence
1028505|NCT01892813|Smoking cessation
1028506|NCT01892813|Telehealth
1028507|NCT01892813|Alcohol use
1028508|NCT01892813|Depression
1028509|NCT01892813|Body weight
1028510|NCT01892800|Lung Cancer
1028511|NCT01892800|Ventricular function, Right
1028512|NCT01892787|Asthma
1028513|NCT01892787|Small airways
1028514|NCT01892787|Extra fine particle long-acting beta agonists
1028515|NCT01892774|LSPAF
1028516|NCT01892774|asymptomatic
1028517|NCT01892774|exercise tolerance
1028518|NCT01892761|mycophenolate mofetil
1028519|NCT01892761|mycophenolic acid
1028520|NCT01892761|MPA
1028521|NCT01892761|MMF
1028522|NCT01892761|Pharmacokinetics
1028523|NCT01892761|renal transplantation
1028524|NCT01892748|Lupus
1028525|NCT01892748|Juvenile
1028526|NCT01892748|Cholecalciferol
1028527|NCT01892748|Disease activity
1028528|NCT01892748|Bone Mass
1028529|NCT01892748|Fatigue
1028530|NCT01892748|Safety
1028531|NCT01892722|pediatric
1028532|NCT01892722|multiple sclerosis
1028533|NCT01892709|acute
1028534|NCT01892709|pain
1028535|NCT01892709|emergency department
1028536|NCT01892709|hydromorphone
1028537|NCT01892709|in ER
1028538|NCT01892696|inspiratory flow pattern
1028539|NCT01892696|mechanical ventilation
1028540|NCT01892696|cardiac preload
1028541|NCT01892696|arterial pulse pressure variation
1028542|NCT01892696|inferior vena cava collapsibility
1028543|NCT01892683|propofol
1028544|NCT01892683|exhaled
1028545|NCT01892683|monitoring
1028546|NCT01892683|anesthesia
1028547|NCT01892670|Blood
1028548|NCT01892670|Whole blood
1028549|NCT01892670|Cold-storage
1028550|NCT01892670|Filtration
1028551|NCT01892670|Transfusion
1028552|NCT01892670|Platelet-function
1028553|NCT01892657|Cetaphil Daily Facial Moisturizer with SPF 50+
1028554|NCT01892657|Hypoallergenicity
1028555|NCT01892657|Skin Irritation
1028556|NCT01892644|Hemochromatosis
1028557|NCT01892644|Myelodysplastic syndromes
1028558|NCT01892644|Iron overload
1028559|NCT01892644|Deferasirox
1028560|NCT01892644|Chelation therapy
1028561|NCT01892644|Venesection
1028562|NCT01892644|Phlebotomy
1028563|NCT01892644|Ferritin
1028564|NCT01892644|Transfusional siderosis
1028565|NCT01892631|Text messaging
1028566|NCT01892605|Mozart K.448
1028567|NCT01892605|first unprovoked seizure
1028568|NCT01892605|epileptiform discharges
1028569|NCT01892605|music therapy
1028570|NCT01892605|children
1028571|NCT01892592|Hypertension
1028572|NCT01892592|African American
1028573|NCT01892592|Health Disparities
1028574|NCT01892592|Stroke
1028575|NCT01892592|Cardiovascular Disease
1028576|NCT01892579|Agitation
1028577|NCT01892579|Dementia
1028578|NCT01892579|Alzheimer's Disease
1028579|NCT01892579|Neuropsychiatric Behaviors
1028580|NCT01892566|HIV
1028581|NCT01892566|mobile health
1028582|NCT01892566|spirometry
1028583|NCT01892553|Dyspnea
1028584|NCT01892553|Transcranial direct current stimulation (tDCS)
1028585|NCT01892553|Perception
1028586|NCT01892527|Colorectal Cancer Metastatic
1028587|NCT01892527|wild type KRAS
1028588|NCT01892527|C-met overexpression
1028589|NCT01892527|Tivantinib
1028590|NCT01892527|Cetuximab
1028591|NCT01892514|osteonecrosis
1028592|NCT01892514|bone marrow concentrate
1028593|NCT01892514|demineralized bone matrix
1028594|NCT01892514|homologous lyophilized bone chips
1028595|NCT01892514|autologous platelet rich fibrin
1028596|NCT01892514|mesenchymal stromal cells
1028597|NCT01892501|Mediastinal lymphadenopathy
1028598|NCT01892501|PET CT to 18FDG
1028599|NCT01892501|EUS
1028600|NCT01892488|COPD
1028601|NCT01892488|AE-COPD
1028602|NCT01892488|Chronic obstructive pulmonary disease
1028603|NCT01892488|acute exacerbations of Chronic obstructive pulmonary disease
1028604|NCT01892475|Physical Activity
1028605|NCT01892475|Incentives
1028606|NCT01892475|Mental Accounting
1028607|NCT01892475|Older adults
1028608|NCT01892436|Extension study, psoriatic arthritis, pre-filled syringe
1028609|NCT01892397|intracranial supratentorial meningioma
1028610|NCT01892397|Atypical and Anaplastic Meningioma
1028611|NCT01892397|Optune (NovoTTF-100A)
1028612|NCT01892397|13-067
1028613|NCT01892371|Leukemia
1028614|NCT01892371|Acute Myeloid Leukemia
1028615|NCT01892371|AML
1028616|NCT01892371|Myelodysplastic Syndrome
1028617|NCT01892371|MDS
1028618|NCT01892371|Quizartinib
1028619|NCT01892371|AC220
1028620|NCT01892371|ASP2689
1028621|NCT01892371|Cytarabine
1028622|NCT01892371|Ara-C
1028623|NCT01892371|Cytosar
1028624|NCT01892371|DepoCyt
1028625|NCT01892371|Cytosine arabinosine hydrochloride
1028626|NCT01892371|AZA
1028627|NCT01892371|Vidaza
1028628|NCT01892371|Azacitidine
1028629|NCT01892371|5-Azacytidine
1028630|NCT01892371|5-AZA
1028631|NCT01892371|5-AZC
1028632|NCT01892371|AZA-CR
1028633|NCT01892371|Ladakamycin
1028634|NCT01892371|NSC-102816
1028635|NCT01892371|Azacytidine
1028636|NCT01892371|Maximum tolerated dose
1028637|NCT01892371|MTD
1028638|NCT01892371|Overall response
1028639|NCT01892371|Complete remission
1028640|NCT01892371|CR
1028641|NCT01892371|Complete remission with incomplete blood count recovery
1028642|NCT01892371|Cri
1028643|NCT01892371|Partial remission
1028644|NCT01892371|PR
1028645|NCT01892371|Hematologic improvement
1028646|NCT01892371|HI
1028647|NCT01892358|injection drug use
1028648|NCT01892345|Neuromyelitis Optica
1028649|NCT01892345|Neuromyelitis Optica Spectrum Disorder
1028650|NCT01892345|Devic's disease, Transverse Myelitis
1028651|NCT01892345|Optic Neuritis
1028652|NCT01892345|relapse
1028653|NCT01892345|eculizumab
1028654|NCT01892345|soliris
1028655|NCT01892345|NMO-IgG
1028656|NCT01892345|CNS Autoimmune Disorders
1028657|NCT01892345|Demyelinating Disorders
1028661|NCT01892267|PEGJ
1028662|NCT01892267|PEG-J
1028663|NCT01892267|Percutaneous Endoscopic Gastrostomy
1028664|NCT01892267|Feeding tube
1028665|NCT01892267|Gastroparesis
1028666|NCT01892267|Acute pancreatitis
1028667|NCT01892267|Stroke
1028668|NCT01892267|Respiratory failure
1028669|NCT01892267|GERD
1028670|NCT01892267|Balloon
1028671|NCT01892267|Self-propelled
1028672|NCT01892254|incretin effect
1028673|NCT01892254|PCOS
1028674|NCT01892254|insulin resistance
1028675|NCT01892254|OGTT
1028676|NCT01892254|IIGI
1028677|NCT01892241|Chronic hepatitis B,Spontaneous Decline of HBV DNA,Peginterferon a-2a, entecavir
1028678|NCT01892228|antiretroviral therapy
1028679|NCT01892228|education
1028680|NCT01892228|mortality
1028684|NCT01892189|Drug therapy
1028685|NCT01892176|coenzyme Q10, Parkinson disease, oxidative damage
1028686|NCT01892163|Diabetic macular edema, Ozurdex
1028687|NCT01892137|Actinic Keratosis
1028688|NCT01892137|Histopathology
1028689|NCT01892137|Reflectance Confocal Microscopy
1028690|NCT01892137|Local Skin Reaction
1028691|NCT01892124|Motivational Interviewing
1028692|NCT01892124|Cognitive Therapy
1028693|NCT01892124|Community-Based Participatory Research
1028694|NCT01892124|Indians, North American
1028695|NCT01892111|SET
1028696|NCT01892111|infertility
1028697|NCT01892111|IVF/ICSI
1028698|NCT01892111|pregnancy
1028699|NCT01892098|Zinc
1028700|NCT01892098|Bone
1028701|NCT01892098|Adolescents
1028702|NCT01892098|Growth
1028703|NCT01892085|Breast milk
1028704|NCT01892085|lactogenesis stage two
1028705|NCT01892085|premature infant
1028706|NCT01892085|insufficient milk supply
1028707|NCT01892085|breast milk expression
1028708|NCT01892072|hepatocellular carcinoma
1028709|NCT01892072|HCC
1028710|NCT01892072|VEGF signaling pathway
1028711|NCT01892059|renal tumour
1028712|NCT01892059|partial nephrectomy
1028713|NCT01892059|laparoscope
1028714|NCT01892059|segmental renal artery clamping
1028715|NCT01892046|Small Cell Lung Cancer
1028716|NCT01892046|Non Small Cell Lung Cancer
1028717|NCT01892046|Hsp90
1028718|NCT01892033|Posttraumatic Stress Disorder
1028719|NCT01892033|PTSD
1028720|NCT01892033|Aerobic Exercise
1028721|NCT01892033|Women
1028722|NCT01892033|Veteran
1028723|NCT01892007|Hearing loss
1028724|NCT01892007|Hearing aid
1028725|NCT01892007|Speech intelligibility
1028726|NCT01892007|Speech perception
1028727|NCT01892007|Cognitive training
1028728|NCT01892007|Working memory
1028729|NCT01892007|Working memory training
1028730|NCT01891994|Cytokine
1028731|NCT01891994|Hematopoiesis
1028732|NCT01891994|Autoimmunity
1028733|NCT01891994|Thrombocytopenia
1028734|NCT01891994|Neutropenia
1028735|NCT01891981|Leukemia
1028736|NCT01891981|Acute Lymphoblastic Leukemia
1028737|NCT01891981|ALL
1028738|NCT01891981|Relapsed and/or refractory
1028739|NCT01891981|Moxetumomab Pasudotox
1028740|NCT01891981|Maximum tolerated dose
1028741|NCT01891981|MTD
1028742|NCT01891968|Leukemia
1028743|NCT01891968|Myelodysplastic syndrome
1028744|NCT01891968|MDS
1028745|NCT01891968|Low or intermediate-1
1028746|NCT01891968|Bortezomib
1028747|NCT01891968|Velcade
1028748|NCT01891968|LDP-341
1028749|NCT01891968|MLN341
1028750|NCT01891968|PS-341
1028751|NCT01891955|Diabetes mellitus type 2
1028752|NCT01891955|Cereals
1028753|NCT01891955|Dairy
1028754|NCT01891955|Dietary carbohydrates
1028755|NCT01891955|Dietary fiber
1028756|NCT01891955|Food
1028757|NCT01891955|Metabolic syndrome
1028758|NCT01891955|Satiety
1028759|NCT01891942|Normal
1028760|NCT01891942|subjects
1028761|NCT01891929|Schizophrenia
1028762|NCT01891929|Cognitive Remediation
1028763|NCT01891929|Working abilities and social functioning
1028764|NCT01891877|Sickle Cell Trait
1028765|NCT01891877|Football
1028766|NCT01891877|Sickling
1028767|NCT01891877|Heat Illness
1028768|NCT01891877|SCT
1028769|NCT01891851|Healthy
1028770|NCT01891851|Hepatitis C
1028771|NCT01891851|TMC435350
1028772|NCT01891851|Ritonavir
1028773|NCT01891851|Pharmacokinetics
1028774|NCT01891838|surgery
1028775|NCT01891838|transsphenoidal surgery
1028776|NCT01891838|pituitary adenoma
1028777|NCT01891838|mechanical ventilation
1028778|NCT01891838|bleeding
1028779|NCT01891825|Atrial fibrillation
1028780|NCT01891825|Persistent atrial fibrillation
1028781|NCT01891825|Atrial fibrillation ablation
1028782|NCT01891812|Sickle cell disease
1028783|NCT01891812|Vaso-occlusive crisis
1028784|NCT01891812|Nitrous oxide
1028785|NCT01891812|Emergency department
1028786|NCT01891799|HIV/AIDS
1028787|NCT01891799|PMTCT
1028788|NCT01891799|Option B+
1028789|NCT01891799|Swaziland
1028790|NCT01891773|Asthma
1028791|NCT01891773|Inhaled Corticosteroids
1028792|NCT01891773|School Nurses
1028793|NCT01891747|gliomas
1028794|NCT01891734|Veterans
1028795|NCT01891734|Health Services
1028796|NCT01891734|Mental Health
1028797|NCT01891734|Technology
1028798|NCT01891734|Primary Health Care
1028799|NCT01891734|Psychotherapy
1028800|NCT01891721|cognitive training
1028801|NCT01891721|schizophrenia
1028802|NCT01891721|mismatch negativity
1028803|NCT01891721|cognition
1028804|NCT01891721|functional capacity
1028805|NCT01891721|EEG
1028806|NCT01891682|Methionine Metabolism
1028807|NCT01891682|Parenteral Nutrition
1028808|NCT01891682|Pediatric
1028809|NCT01891682|Pediatrics
1028810|NCT01891682|Sepsis
1028811|NCT01891682|Observational Study
1028812|NCT01891669|ADC 5T4
1028813|NCT01891669|PF-06263507
1028814|NCT01891669|solid tumors
1028815|NCT01891669|lung cancer
1028816|NCT01891669|breast cancer
1028817|NCT01891669|ovarian cancer
1028818|NCT01891669|cancer
1028819|NCT01891669|tumors
1028820|NCT01891669|neoplasm metastasis
1028821|NCT01891656|Motivational Interviewing
1028822|NCT01891656|Internet
1028823|NCT01891656|Treatment
1028824|NCT01891656|Substance-Related Disorders
1028825|NCT01891656|Criminal Justice
1028826|NCT01891630|African American
1028827|NCT01891630|Asthma
1028828|NCT01891617|exercise
1028829|NCT01891617|high carbohydrate and high fat diets
1028830|NCT01891617|insulin
1028831|NCT01891617|gut peptides
1028832|NCT01891617|appetite
1028833|NCT01891617|metabolism
1028834|NCT01891617|glucose
1028835|NCT01891591|Obesity
1028836|NCT01891591|Gastric bypass
1028837|NCT01891591|Energy balance
1028838|NCT01891591|Nutritional status
1028839|NCT01891591|Protein balance
1028840|NCT01891552|Colon Cancer, Liver Metastasis, DEBIRI, cetuximab, efficacy
1028841|NCT01891539|Hepatocellular carcinoma, doxorubicin, chemoembolization
1028842|NCT01891526|Metabolisation of 9-cis-retinoic acid
1028843|NCT01891526|hepatic patients
1028844|NCT01891526|investigation of urine and blood samples
1028845|NCT01891513|Physical activity
1028846|NCT01891513|Hypertension
1028847|NCT01891513|Physical function
1028848|NCT01891513|Aging
1028849|NCT01891500|Persistent Fetal Circulation Syndrome
1028850|NCT01891500|Infant, Newborn
1028851|NCT01891500|Nitric Oxide
1028852|NCT01891500|Oxidative Stress
1028853|NCT01891500|Endothelin 1
1028854|NCT01891500|Vascular Endothelial Growth Factor
1028855|NCT01891487|Eyebrow
1028856|NCT01891487|Hypotrichosis
1028857|NCT01891487|Thinning
1028858|NCT01891487|Bimatoprost
1028859|NCT01891461|total knee arthroplasty
1028860|NCT01891461|post-operative bleeding
1028861|NCT01891461|floseal
1028862|NCT01891435|antipyretics
1028863|NCT01891435|oral paracetamol
1028864|NCT01891435|intravenous paracetamol
1028865|NCT01891435|intramuscular diclofenac
1028866|NCT01891435|emergency department
1028867|NCT01891422|Glycoprotein Storage Disease
1028868|NCT01891422|Lysosomal Storage Disease
1028869|NCT01891422|mannosidase deficiency disorders
1028870|NCT01891422|Neuraminidase deficiency with beta-galactosidase deficiency
1028871|NCT01891422|mucolipidoses
1028872|NCT01891422|Oligosaccharidoses
1028873|NCT01891422|Lysosomal Disease
1028874|NCT01891422|Metabolic Disease, Inborn
1028875|NCT01891422|aspartylglucosaminuria
1028876|NCT01891422|fucosidosis
1028877|NCT01891422|galactosialidosis
1028878|NCT01891422|alpha mannosidosis
1028879|NCT01891422|beta mannosidosis
1028880|NCT01891422|mucolipidosis II
1028881|NCT01891422|mucolipidosis III
1028882|NCT01891422|Schindler disease
1028883|NCT01891422|sialidosis
1028884|NCT01891409|HIV prevention
1028885|NCT01891409|Male Circumcision
1028886|NCT01891409|Children
1028887|NCT01891409|Childhood
1028888|NCT01891409|Shang Ring
1028889|NCT01891396|Knee osteoarthritis
1028890|NCT01891396|Hyaluronic acid
1028891|NCT01891396|HA Injection
1028892|NCT01891396|Steroid Injection
1028893|NCT01891396|Knee injection
1028894|NCT01891383|Dementia
1028895|NCT01891383|Traumatic brain injury (TBI)
1028896|NCT01891383|Mild cognitive impairment (MCI)
1028897|NCT01891383|Chronic traumatic encephalopathy (CTE)
1028898|NCT01891383|Remote effects of TBI
1028899|NCT01891383|Post-traumatic stress disorder (PTSD_
1028900|NCT01891357|Unilateral primary invasive carcinoma of the breast
1028901|NCT01891344|ovarian cancer
1028902|NCT01891344|fallopian tube cancer
1028903|NCT01891344|primary peritoneal cancer
1028904|NCT01891344|peritoneal cancer
1028905|NCT01891344|platinum sensitive
1028906|NCT01891344|relapsed disease
1028907|NCT01891344|PARP Inhibitor
1028908|NCT01891344|rucaparib
1028909|NCT01891344|homologous recombination
1028910|NCT01891344|homologous recombination deficiency
1028911|NCT01891344|genomic scarring
1028912|NCT01891344|loss of heterozygosity
1028913|NCT01891344|CO-338
1028914|NCT01891344|PF 01367338
1028915|NCT01891344|AG 14699
1028916|NCT01891344|platinum sensitive ovarian cancer
1028917|NCT01891344|platinum sensitive fallopian tube cancer
1028918|NCT01891344|platinum sensitive primary peritoneal cancer
1028919|NCT01891344|platinum sensitive peritoneal cancer
1028920|NCT01891344|gynecological cancer
1028921|NCT01891344|Clovis
1028922|NCT01891344|Clovis Oncology
1028923|NCT01891344|ARIEL2
1028924|NCT01891344|ARIEL 2
1028925|NCT01891344|ARIEL3
1028926|NCT01891344|ARIEL 3
1028927|NCT01891279|short bowel syndrome
1028928|NCT01891279|Elemental formula
1028929|NCT01891279|partially hydrolyzed formula
1028930|NCT01891279|Enteral feeding
1028931|NCT01891279|TPN dependency
1028932|NCT01891279|Intestinal adaptation
1028933|NCT01891279|TPN cholestasis
1028934|NCT01891253|cardiac output
1028935|NCT01891253|mechanical ventilation
1028936|NCT01891253|inert gas rebreathing
1028937|NCT01891253|pulse contour analysis
1028938|NCT01891240|Diagnostic
1028939|NCT01891240|Pre-eclampsia
1028940|NCT01891240|Pregnancy outcome
1028941|NCT01891240|Mass screening
1028942|NCT01891240|Diagnostic Techniques and Procedures
1028943|NCT01891227|Bendamustine
1028944|NCT01891227|Capecitabine
1028945|NCT01891227|Pretreated
1028946|NCT01891227|Her2 negative
1028947|NCT01891227|Advanced breast cancer
1028948|NCT01891227|Metastatic breast cancer
1028949|NCT01891227|Anthracycline pretreatment
1028950|NCT01891227|Taxane pretreatment
1028951|NCT01891214|Inflammatory bowel diseases
1028952|NCT01891214|Inflammatory Bowel Disease Questionnaire (IBDQ)
1028953|NCT01891201|Bonding
1028954|NCT01891201|Oxytocin
1028955|NCT01891201|Breastfeeding
1028956|NCT01891201|Newborn
1028957|NCT01891201|Delivery
1028958|NCT01891188|hepatic blood,
1028959|NCT01891188|cardiac cath,
1028960|NCT01891188|hepatic oxygenation,
1028961|NCT01891188|pediatrics
1028962|NCT01891175|Caesarean
1028963|NCT01891175|hypotension
1028964|NCT01891175|Spinal Anaesthesia
1028965|NCT01891175|intermittent pneumatic compression
1028966|NCT01891175|lower extremities
1028967|NCT01891162|quality of life, incontinence urinary, socioeconomic
1028968|NCT01891136|Peanut allergy
1028969|NCT01891123|Non-small Cell Lung Cancer
1028970|NCT01891123|Breast cancer
1028971|NCT01891123|plasma drug concentration
1028972|NCT01891123|Nasopharygeal carcinoma
1028973|NCT01891110|electric stimulation
1028974|NCT01891110|tilt-table
1028975|NCT01891097|Insomnia
1028976|NCT01891097|Acupuncture
1028977|NCT01891097|Electroacupuncture
1028978|NCT01891097|Aricular acupuncture
1028979|NCT01891097|Randomized Clinical Trial
1028980|NCT01891097|Traditional Chinese Medicine
1028981|NCT01891084|Influenza
1028982|NCT01891084|Antipyretics
1028983|NCT01891084|Fever
1028984|NCT01891071|Multiple sclerosis
1028985|NCT01891071|Lung volume recruitment
1028986|NCT01891071|Pulmonary function impairment
1028987|NCT01891071|Cough impairment
1028988|NCT01891045|Psychotherapy
1028989|NCT01891045|Drug addiction
1028990|NCT01891045|Drop-out
1028991|NCT01891045|OQ-45.2
1028992|NCT01891045|Clinical trial
1028993|NCT01891045|Randomized Controlled Trail
1028994|NCT01891032|acute kidney injury, partial nephrectomy, biomarker
1028995|NCT01891006|Randomized Controlled Trial
1028996|NCT01891006|Economical Evaluation
1028997|NCT01891006|Caesarean Section
1028998|NCT01891006|Cesarean Section
1028999|NCT01891006|Postoperative Wound Treatment
1029000|NCT01891006|Surgical Site Infections
1029001|NCT01891006|Wound Infections
1029002|NCT01891006|Infectious Morbidity
1029003|NCT01891006|Negative Pressure Wound Therapy
1029004|NCT01890980|WT-1-vaccine Montanide
1029005|NCT01890980|GM-CSF
1029006|NCT01890980|Wilms Tumor-1 vaccine
1029007|NCT01890980|immunotherapy
1029008|NCT01890980|Montanide
1029009|NCT01890980|Sargramostim
1029010|NCT01890980|Granulocyte Macrophage Colony Stimulating Factor
1029011|NCT01890980|Malignant Pleural Mesothelioma
1029012|NCT01890980|MPM
1029013|NCT01890980|soluble mesothelin related protein
1029014|NCT01890980|SMRP
1029015|NCT01890967|low density lipoprotein, heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia
1029016|NCT01890954|Type 1 Diabetes Mellitus (T1DM)
1029017|NCT01890954|Closed Loop Control (CLC)
1029018|NCT01890954|Diabetes Assistant (DiAs)
1029019|NCT01890954|Continuous Glucose Monitor (CGM)
1029020|NCT01890941|Dry eye syndromes
1029021|NCT01890941|Corneal diseases
1029022|NCT01890941|Conjunctival diseases
1029023|NCT01890928|Gluconeogenesis
1029024|NCT01890928|Glycogenolysis
1029025|NCT01890928|Pyruvate cycling
1029026|NCT01890928|Glucose production rates
1029027|NCT01890928|Mitochondria
1029028|NCT01890928|Acylcarnitines
1029029|NCT01890915|Spinal cord injury
1029030|NCT01890915|Body temperature
1029031|NCT01890915|Executive function
1029032|NCT01890915|Sweat
1029033|NCT01890889|Total Cholesterol
1029034|NCT01890889|LDL
1029035|NCT01890876|glucose tolerance, hypoxia, myokines, exercise
1029036|NCT01890863|asthma
1029037|NCT01890863|fluticasone propionate/salmeterol
1029038|NCT01890863|PK equivalence
1029039|NCT01890863|COPD
1029040|NCT01890863|pharmacokinetics
1029041|NCT01890863|fluticasone propionate/salmeterol in a capsule-based inhaler
1029042|NCT01890863|fluticasone propionate/salmeterol in a multi-dose dry powder inhaler
1029043|NCT01890863|Respiratory
1029044|NCT01890850|Risk factors
1029045|NCT01890850|U.S. commercially insured population
1029046|NCT01890850|Pertussis/whooping cough infection
1029047|NCT01890850|Retrospective database study
1029048|NCT01890837|Rectal Compliance
1029049|NCT01890837|Rectal Sensation
1029050|NCT01890837|Rectal Tone
1029051|NCT01890824|Breast Cancer
1029052|NCT01890824|Fat metabolism
1029053|NCT01890824|Fat digestion
1029054|NCT01890824|physical activity
1029055|NCT01890824|muscle function
1029056|NCT01890811|CKD
1029057|NCT01890811|Hemodialysis
1029058|NCT01890811|Protein Digestion
1029059|NCT01890811|Fat Digestion
1029060|NCT01890811|Gut Function
1029061|NCT01890811|Glucose Absorption
1029062|NCT01890811|Muscle Function
1029063|NCT01890798|Duchenne Muscular Dystrophy
1029064|NCT01890798|GSK2402968
1029065|NCT01890798|drisapersen
1029066|NCT01890772|Hepatitis C Genotype 1
1029067|NCT01890772|Vitamin D
1029068|NCT01890772|treatment-naive
1029069|NCT01890759|Meningitis
1029070|NCT01890759|Meningococcal Infection
1029071|NCT01890759|Menactra®
1029072|NCT01890746|de novo AML
1029073|NCT01890746|Eltrombopag
1029074|NCT01890746|leukemia
1029075|NCT01890746|sAML/MDS
1029076|NCT01890746|acute myeloid leukemia
1029077|NCT01890746|secondary acute myeloid
1029078|NCT01890746|thrombocytopenia
1029079|NCT01890733|Massive Rotator Cuff Tear, Sub-acromial spacer, Best repair of rotator cuff,
1029080|NCT01890720|Randomized Controlled Trial
1029081|NCT01890720|Economical Evaluation
1029082|NCT01890720|Caesarean Section
1029083|NCT01890720|postoperative wound treatment
1029084|NCT01890720|surgical site infections
1029085|NCT01890720|wound infections
1029086|NCT01890720|infectious morbidity
1029087|NCT01890720|Negative Pressure Wound Therapy
1029088|NCT01890720|Incisional Negative Pressure Wound Therapy
1029089|NCT01890720|Obesity
1029090|NCT01890707|Gynecology
1029091|NCT01890707|Pain
1029092|NCT01890707|Anesthesia
1029093|NCT01890707|Quality of Recovery 40
1029094|NCT01890694|Hyponatremia
1029095|NCT01890694|Dilutional Hyponatremia
1029096|NCT01890694|Euvolemic Hyponatremia
1029097|NCT01890694|Hypervolemic Hyponatremia
1029098|NCT01890694|Fluid Restriction
1029099|NCT01890694|Tolvaptan
1029100|NCT01890681|childhood obesity
1029101|NCT01890681|child care
1029102|NCT01890681|infant
1029103|NCT01890681|toddler
1029104|NCT01890668|Breastfeeding behaviour
1029105|NCT01890668|OMT (Osteopathic Manipulative Treatment)
1029106|NCT01890668|suboptimal infant breastfeeding behaviour
1029107|NCT01890668|healthy newborns
1029108|NCT01890655|relapsing-remitting multiple sclerosis
1029109|NCT01890655|RRMS
1029110|NCT01890642|Pain
1029111|NCT01890642|Children
1029112|NCT01890642|Venipuncture
1029113|NCT01890642|J tip
1029114|NCT01890642|Lidocaine
1029115|NCT01890642|video observation
1029116|NCT01890629|diabetes mellitus
1029117|NCT01890603|Care coordination, primary care
1029118|NCT01890603|nurse care management
1029119|NCT01890603|practice facilitation
1029120|NCT01890590|Renal Cell Carcinoma
1029121|NCT01890590|Cyberknife
1029122|NCT01890577|Chronic kidney disease
1029123|NCT01890577|Dialysis
1029124|NCT01890577|Erythropoiesis stimulating agent
1029125|NCT01890577|South Africa
1029126|NCT01890551|Adoloescent, patellofemoral, instability,biomechanics, magnetic resonance imaging
1029127|NCT01890538|vertigo
1029128|NCT01890538|dimenhydrinate
1029129|NCT01890538|piracetam
1029130|NCT01890525|radiation
1029131|NCT01890499|tolerability
1029132|NCT01890499|diet after operation
1029133|NCT01890447|Cocooning
1029134|NCT01890447|Web-based questionnaire
1029135|NCT01890447|Italy
1029136|NCT01890447|Pertussis
1029137|NCT01890447|Spain
1029138|NCT01890447|Survey
1029139|NCT01890434|Myocardial Perfusion Imaging
1029141|NCT01890408|Laparotomy
1029142|NCT01890408|Hepatic resection
1029143|NCT01890408|continuous wound catheter analgesia
1029144|NCT01890408|morphine
1029145|NCT01890408|post operative recovery
1029146|NCT01890395|mitochondrial DAMPS
1029147|NCT01890382|resistance exercise
1029148|NCT01890382|protein
1029149|NCT01890382|creatine
1029150|NCT01890382|leucine
1029151|NCT01890382|aging
1029152|NCT01890369|Old Age
1029153|NCT01890369|Sarcopenia
1029154|NCT01890369|Amino Acid
1029155|NCT01890369|Muscle
1029156|NCT01890356|Depression
1029157|NCT01890356|Treatment
1029158|NCT01890356|Transcranial electrical stimulation
1029159|NCT01890356|Maintenance
1029160|NCT01890330|Canola Oil
1029161|NCT01890330|Metabolic Syndrome
1029162|NCT01890330|Serum LDL cholesterol
1029163|NCT01890317|Cardiogenic shock
1029164|NCT01890317|acute myocardial infarction
1029165|NCT01890317|mild hypothermia
1029166|NCT01890304|Traumatic Brain Injury
1029167|NCT01890304|TBI
1029168|NCT01890304|Concussion
1029169|NCT01890304|Sports related injury
1029170|NCT01890291|Immuncell-LC, Hepatocellular carcinoma
1029171|NCT01890278|Brain Cancer
1029172|NCT01890278|Metastatic Brain Cancer
1029173|NCT01890278|IMRT
1029301|NCT01889693|neomannosyl human serum albumin
1029174|NCT01890265|Idiopathic Pulmonary Fibrosis, IPF, Idiopathic Interstitial Pneumonia, Interstitial Lung Disease, Lung Fibrosis
1029179|NCT01890200|add-on treatment
1029180|NCT01890200|botanical drug
1029181|NCT01890200|HCV genotype 1
1029182|NCT01890200|TCM-700C
1029183|NCT01890161|asthma
1029184|NCT01890148|Asthma
1029185|NCT01890135|randomized
1029186|NCT01890135|double blind
1029187|NCT01890135|blood flow
1029188|NCT01890135|muscle perfusion
1029189|NCT01890135|safety
1029190|NCT01890122|Drug therapy
1029191|NCT01890109|Vasomotor symptoms; Hot Flashes
1029192|NCT01890096|HDR
1029193|NCT01890096|monotherapy
1029194|NCT01890096|low
1029195|NCT01890096|intermediate
1029196|NCT01890096|prostate cancer
1029197|NCT01890083|Hepatitis C
1029198|NCT01890083|Interferon-alpha
1029199|NCT01890083|Depression
1029200|NCT01890083|Major Depressive Disorder
1029201|NCT01890083|Exercise
1029202|NCT01890083|Physical Activity
1029203|NCT01890070|mediterranean diet, nutrigenomics, body composition, inflammation, oxidative stress
1029204|NCT01890044|VTE
1029205|NCT01890044|DVT
1029206|NCT01890044|Venous Thromboembolism
1029207|NCT01890044|Deep Vein Thrombosis
1029208|NCT01890044|Pulmonary embolus
1029209|NCT01890044|Trauma
1029210|NCT01890031|cardiovascular disease
1029211|NCT01890031|cholesterol
1029212|NCT01890018|Acute Myocardial Infarction (AMI)
1029213|NCT01890018|taking a statin medication
1029214|NCT01890018|also have a medication adherence ratio (MPR)
1029215|NCT01890005|Preeclampsia
1029216|NCT01890005|Low dose aspirin
1029217|NCT01890005|Fetal growth restriction
1029218|NCT01890005|Neonatal death
1029219|NCT01890005|Stillbirth
1029220|NCT01890005|Abruptio placenta
1029221|NCT01889992|Heart transplantation
1029222|NCT01889992|Cardiac allograft remodeling
1029223|NCT01889992|Immunosuppression
1029224|NCT01889992|Cardiac MRI
1029225|NCT01889992|M-TOR inhibitor
1029226|NCT01889979|Pain during labour
1029227|NCT01889979|Duration of labour
1029228|NCT01889979|Apgar score
1029229|NCT01889979|Umbilical cord pH
1029230|NCT01889966|vasoreactivity testing
1029231|NCT01889966|Sildenafil
1029232|NCT01889966|precapillary pulmonary hypertension
1029233|NCT01889966|connective tissue disease
1029234|NCT01889966|mean pressure in the pulmonary artery 25 mmHg or more
1029235|NCT01889966|mean pulmonary capillary wedge pressure below 16 mmHg
1029236|NCT01889953|EUS-Guided Biliary Drainage
1029237|NCT01889953|Endoscopic retrograde cholangiopancreatography
1029238|NCT01889953|Malignant Biliary Obstruction
1029239|NCT01889940|Acute Spinal Cord Injury
1029240|NCT01889940|Patient Satisfaction
1029241|NCT01889940|Psychological Distress
1029242|NCT01889940|Rehabilitation
1029243|NCT01889940|Training Professionals
1029244|NCT01889940|Burnout
1029245|NCT01889940|Job Content
1029246|NCT01889927|exercise
1029247|NCT01889927|physiotherapy
1029248|NCT01889927|lung function
1029249|NCT01889927|quality of life
1029250|NCT01889901|Physical Activity
1029251|NCT01889901|Epilepsy
1029252|NCT01889901|Seizures
1029253|NCT01889901|Quality of Life
1029254|NCT01889888|Male urethral stricture
1029255|NCT01889888|ADRC
1029256|NCT01889888|Adipose-derived regenerative cells
1029257|NCT01889888|Fat tissue
1029258|NCT01889888|Stem cells
1029259|NCT01889862|PKU
1029260|NCT01889862|PEG-PAL
1029261|NCT01889862|Prism
1029262|NCT01889862|BioMarin
1029263|NCT01889862|rAvPAL-PEG
1029264|NCT01889862|Pegvalaise
1029265|NCT01889836|meningococcal conjugate vaccine serogroup C
1029266|NCT01889836|Prevention
1029267|NCT01889823|Oxygen
1029268|NCT01889823|Hypoxia
1029269|NCT01889823|Hyperoxia
1029270|NCT01889823|Inflammation
1029271|NCT01889823|Innate immunity
1029272|NCT01889810|Vitamin D, Pre-diabetes, Insulin Resistance
1029273|NCT01889797|Untreated Non-Hodgkin's Lymphoma
1029274|NCT01889797|Low Tumor Burden Non-Hodgkin's Lymphoma
1029275|NCT01889797|NHL
1029276|NCT01889797|Indolent
1029277|NCT01889797|Rituximab
1029278|NCT01889797|Rituxan
1029279|NCT01889797|GA101
1029280|NCT01889797|Obinutuzumab
1029281|NCT01889784|diabetes mellitus, type 2
1029282|NCT01889784|phototherapy
1029283|NCT01889784|physical exercise
1029284|NCT01889784|oxygen consumption
1029285|NCT01889784|arterial blood pressure
1029286|NCT01889784|heart rate
1029287|NCT01889784|baroreflex sensitivity
1029288|NCT01889784|cardiovascular autonomic control
1029289|NCT01889758|bioequivalence
1029290|NCT01889758|tacrolimus
1029291|NCT01889758|kidney
1029292|NCT01889758|liver
1029293|NCT01889758|transplant
1029294|NCT01889719|HIV Prevention
1029295|NCT01889706|Type 1 diabetes mellitus,
1029296|NCT01889706|metformin,
1029297|NCT01889706|insulin resistance,
1029298|NCT01889706|obesity
1029299|NCT01889693|positron emission tomography
1029300|NCT01889693|macrophage
1029302|NCT01889680|colorectal cancer
1029303|NCT01889680|metastatic colorectal cancer
1029304|NCT01889680|ziv-aflibercept
1029305|NCT01889680|NSABP
1029306|NCT01889667|Oral Insulin
1029307|NCT01889667|Diabetes Mellitus Type 2
1029308|NCT01889667|Safety
1029309|NCT01889667|Pharmacodynamics
1029310|NCT01889667|Pharmacokinetics
1029311|NCT01889628|Glycaemic response
1029312|NCT01889628|Glycaemic Index
1029313|NCT01889628|Nutritional formula
1029314|NCT01889628|Asia
1029315|NCT01889628|Ethnic differences
1029316|NCT01889628|Chinese
1029317|NCT01889628|Malay
1029318|NCT01889628|Indian
1029319|NCT01889615|Ovarian cancer
1029320|NCT01889615|PET/CT
1029321|NCT01889615|glucose 6 phosphatase
1029322|NCT01889602|Healthy volunteers
1029323|NCT01889602|Topiramate
1029324|NCT01889602|Neurocognition
1029325|NCT01889602|Drug-induced cognitive deficits
1029326|NCT01889576|glucose
1029327|NCT01889563|chronic obstructive pulmonary disease
1029328|NCT01889563|heart rate variability
1029329|NCT01889563|physical training
1029330|NCT01889550|Screening
1029331|NCT01889550|Downs syndrome
1029332|NCT01889550|Informed choice
1029333|NCT01889550|eHealth
1029334|NCT01889537|Virtual Reality Ketamine
1029335|NCT01889511|Text Messaging
1029336|NCT01889511|Medication Adherence
1029337|NCT01889511|Oral Agents
1029338|NCT01889498|Acetazolamide, intracranial/cerebrospinal fluid pressure, paraplegia, thoracoabdominal aortic surgery
1029339|NCT01889485|Aortic Aneurysm, Abdominal
1029340|NCT01889485|Carotid Stenosis
1029341|NCT01889485|Peripheral Arterial Disease
1029342|NCT01889485|Health Services Accessibility
1029343|NCT01889472|CPAP compliance
1029344|NCT01889472|leaks
1029345|NCT01889472|Respiratory disturbances index
1029346|NCT01889472|quality of life
1029347|NCT01889446|Propionic acid
1029348|NCT01889446|Food preservatives
1029349|NCT01889433|Hepatitis C
1029350|NCT01889433|Cepeginterferon alfa
1029351|NCT01889433|Peginterferon
1029352|NCT01889433|Treatment
1029353|NCT01889420|myeloma
1029354|NCT01889420|relapse
1029355|NCT01889420|refractory
1029356|NCT01889420|relapsed
1029357|NCT01889420|pomalidomide
1029358|NCT01889420|pomalyst
1029359|NCT01889420|everolimus
1029360|NCT01889420|afinitor
1029361|NCT01889420|dexamethasone
1029362|NCT01889407|Acute Myeloid Leukemia
1029363|NCT01889394|pilonidal sinus
1029364|NCT01889394|excision
1029365|NCT01889394|primary wound closure
1029366|NCT01889394|limberg flap
1029373|NCT01889355|diabetes
1029374|NCT01889355|glucose
1029375|NCT01889355|glucometer
1029376|NCT01889342|MCT
1029377|NCT01889342|Metacognitive therapy
1029378|NCT01889342|Anxiety disorders
1029379|NCT01889342|Transdiagnostic
1029380|NCT01889316|Fetal monitoring
1029381|NCT01889316|ECG
1029382|NCT01889303|concurrent chemoradiotherapy
1029383|NCT01889303|FOLFOX6
1029384|NCT01889303|chemotherapy
1029385|NCT01889303|docetaxel
1029386|NCT01889303|cisplatin
1029387|NCT01889303|gastric cancer
1029388|NCT01889290|methylnaltrexone
1029389|NCT01889290|opioid-antagonist
1029390|NCT01889290|Obstipation
1029391|NCT01889290|pharmacokinetics
1029392|NCT01889277|Diabetic Nephropathy
1029393|NCT01889264|Methionine Metabolism
1029394|NCT01889264|Enteral Nutrition
1029395|NCT01889264|Pediatric
1029396|NCT01889264|Pediatrics
1029397|NCT01889264|Sepsis
1029398|NCT01889264|Observational Study
1029399|NCT01889251|Vitreomacular Adhesion
1029400|NCT01889251|Vitreomacular Traction
1029401|NCT01889251|Vitreomacular Traction Syndrome
1029402|NCT01889251|Vitrectomy
1029403|NCT01889251|Central Visual Field Defect
1029404|NCT01889251|Blind Spot
1029405|NCT01889251|Intravitreal Injection
1029406|NCT01889251|Macula
1029407|NCT01889251|Retina
1029408|NCT01889251|Decreased Visual Acuity
1029409|NCT01889251|Visual Complaint
1029410|NCT01889251|SD-OCT
1029411|NCT01889251|Macular Hole
1029412|NCT01889238|breast cancer
1029413|NCT01889238|triple negative
1029414|NCT01889238|androgen receptor positive
1029415|NCT01889199|polycystic ovary syndrome
1029416|NCT01889199|hirsutism
1029417|NCT01889199|anovulation
1029418|NCT01889199|oligomenorrhea
1029419|NCT01889199|amenorrhea
1029420|NCT01889199|hyperandrogenism
1029421|NCT01889199|antiandrogen effect
1029422|NCT01889186|Chronic Lymphocytic Leukemia
1029423|NCT01889186|17 p Deletion
1029424|NCT01889160|Healthy volunteers, Phase 1
1029425|NCT01889147|Peak plasma concentration
1029426|NCT01889147|safety and efficacy
1029427|NCT01889147|therapeutic agent
1029428|NCT01889147|LPS-mediated diseases
1029429|NCT01889147|Pharmacokinetics of administered hRESCAP
1029430|NCT01889147|Determine half-time
1029431|NCT01889134|primary hyperparathyroidism
1029432|NCT01889134|RANKL
1029433|NCT01889134|osteoprotegerin
1029434|NCT01889134|bone mineral density
1029435|NCT01889134|alendronate
1029436|NCT01889134|parathyroidectomy
1029437|NCT01889108|Premature
1029438|NCT01889108|Development
1029439|NCT01889108|Motor
1029440|NCT01889108|Cognitive
1029441|NCT01889108|Parent
1029442|NCT01889082|Obesity
1029443|NCT01889082|weight loss
1029444|NCT01889082|young adults
1029445|NCT01889056|Erythropoietin
1029446|NCT01889056|Cognition
1029447|NCT01889056|Exercise
1029448|NCT01889043|Amyotrophic Lateral Sclerosis
1029449|NCT01889043|Noninvasive Ventilation
1029450|NCT01889043|Polysomnography
1029451|NCT01889030|Cardiovascular primary prevention
1029452|NCT01889030|Cardiovascular risk strtification
1029453|NCT01889017|generic immunosuppressive
1029454|NCT01889004|Cerebral blood flow
1029455|NCT01889004|Consciousness
1029456|NCT01889004|Dexmedetomidine
1029457|NCT01889004|EEG
1029458|NCT01889004|Event related potentials
1029459|NCT01889004|Functional magnetic resonance imaging
1029460|NCT01889004|General anesthesia
1029461|NCT01889004|Positron emission tomography
1029462|NCT01889004|Propofol
1029463|NCT01888991|Glucose
1029464|NCT01888991|Exercise
1029465|NCT01888991|Metabolic flexibility
1029466|NCT01888991|Substrate Oxidation
1029467|NCT01888991|Food intake
1029468|NCT01888978|Pancreas
1029469|NCT01888978|cancer
1029470|NCT01888978|metastatic
1029471|NCT01888978|chemotherapy
1029472|NCT01888965|Maintenance therapy
1029473|NCT01888965|Adjuvant Therapy
1029474|NCT01888939|Executive Function
1029475|NCT01888939|Child
1029476|NCT01888939|Obesity
1029477|NCT01888939|Exercise
1029478|NCT01888939|Insulin Sensitivity
1029479|NCT01888926|rPAS
1029480|NCT01888926|Dystonia
1029481|NCT01888913|Body Weight
1029482|NCT01888913|Virtual Reality Technology
1029483|NCT01888900|Hepatitis C
1029484|NCT01888900|Non-Responders
1029485|NCT01888900|Direct Acting Antivirals
1029486|NCT01888900|Interferon Free
1029487|NCT01888900|Cirrhosis
1029488|NCT01888874|Methotrexate insufficient responders
1029489|NCT01888861|length of stay in ICU
1029490|NCT01888861|ventilator free days
1029491|NCT01888848|Postural Balance
1029492|NCT01888848|Walking
1029493|NCT01888848|Gait
1029494|NCT01888848|Cognition
1029495|NCT01888848|Learning
1029496|NCT01888848|Memory
1029497|NCT01888848|Blueberry
1029498|NCT01888848|Antioxidants
1029499|NCT01888848|Anti-Inflammatory Agents
1029500|NCT01888848|Brain
1029501|NCT01888835|HIV
1029502|NCT01888835|sexual behavior
1029503|NCT01888822|Laparoscopic cholecystectomy
1029504|NCT01888822|Prophylactic antibiotics
1029505|NCT01888809|teen parents
1029506|NCT01888809|early childhood development
1029507|NCT01888809|home visitation
1029508|NCT01888809|evidence-based treatment
1029509|NCT01888796|T2DM
1029510|NCT01888796|diastolic dysfunction
1029511|NCT01888783|CRPS Type I
1029512|NCT01888783|tactile acuity
1029513|NCT01888783|2-point-discrimination
1029514|NCT01888783|Grating Orientation Task
1029515|NCT01888783|sensory signs
1029516|NCT01888757|Bioequivalence
1029517|NCT01888757|Lamotrigine Extended Release
1029518|NCT01888757|crossover
1029519|NCT01888744|Intracytoplasmic sperm injection (ICSI)
1029520|NCT01888744|PGD
1029521|NCT01888744|GnrH agonist
1029522|NCT01888744|GnRH antagonist
1029523|NCT01888731|Bioequivalence
1029524|NCT01888731|Lamotrigine Extended Release
1029525|NCT01888731|crossover
1029526|NCT01888705|COPD
1029527|NCT01888705|Complexity
1029528|NCT01888705|Entropy Sampling
1029529|NCT01888705|Variability
1029530|NCT01888705|Respiratory Mechanics
1029531|NCT01888705|FOT
1029532|NCT01888692|PET/CT
1029533|NCT01888692|Radiotherapy
1029534|NCT01888692|Lung Cancer
1029535|NCT01888679|Airway
1029536|NCT01888679|Endotracheal intubation
1029537|NCT01888679|selective intubation
1029538|NCT01888653|PTSD
1029539|NCT01888653|Attention Bias to threat
1029540|NCT01888653|Attention Bias Modification Treatment
1029541|NCT01888640|TENS
1029542|NCT01888640|Fibromyalgia
1029543|NCT01888640|Accelerometer
1029544|NCT01888627|Schizophrenia
1029545|NCT01888627|Bipolar disorder
1029546|NCT01888627|Assertive community treatment
1029547|NCT01888627|Integrated care
1029548|NCT01888627|Severe and persistent mental disorder
1029549|NCT01888614|carbon mono oxide
1029550|NCT01888614|sickle cell
1029551|NCT01888614|hemolysis
1029552|NCT01888588|Uncomplicated peptic ulcer
1029553|NCT01888588|Low dose aspirin (ASA)
1029554|NCT01888588|Acid-suppressing drugs
1029555|NCT01888588|Epidemiology
1029556|NCT01888575|Discontinuation of low dose ASA,
1029557|NCT01888575|Secondary cardiovascular prevention,
1029558|NCT01888575|Acid-suppressing drugs,
1029559|NCT01888575|Gastrointestinal risk,
1029560|NCT01888575|Epidemiology
1029561|NCT01888549|Chronic cough, proton pump inhibitor, GERD, nonacid reflux,
1029562|NCT01888497|Sleeplessness
1029563|NCT01888484|PID
1029564|NCT01888471|serotype specific
1029565|NCT01888471|anti-capsular antibodies
1029566|NCT01888471|Group B Streptococcus
1029567|NCT01888471|Feasibility
1029568|NCT01888458|Adult
1029569|NCT01888458|allo-Stem Cell Transplantation
1029570|NCT01888458|Cord Blood
1029571|NCT01888445|Renal anemia
1029572|NCT01888445|Chronic Renal Failure
1029573|NCT01888445|ASP1517
1029574|NCT01888432|liver transplantation
1029575|NCT01888432|everolimus
1029576|NCT01888432|tacrolimus
1029577|NCT01888432|reduced calcineuron inhibitor
1029578|NCT01888432|renal function
1029579|NCT01888432|living donor
1029580|NCT01888432|RAD001H2307
1029581|NCT01888432|RAD001H
1029582|NCT01888419|Post Breast Therapy Pain Syndrome
1029583|NCT01888419|Lipotransplantation
1029584|NCT01888419|Breast Cancer
1029585|NCT01888419|Pain
1029586|NCT01888406|Obesity
1029587|NCT01888406|Weight gain prevention
1029588|NCT01888406|Eating disorder
1029589|NCT01888406|Binge eating
1029590|NCT01888393|pharmacokinetics, hepatic impairment
1029591|NCT01888380|Autopsy
1029592|NCT01888380|Minimally invasive
1029593|NCT01888380|Foetuses
1029594|NCT01888380|Newborns
1029595|NCT01888380|Children
1029596|NCT01888380|Adolescents
1029597|NCT01888354|MS
1029598|NCT01888354|Multiple Sclerosis
1029599|NCT01888315|Hypertension
1029600|NCT01888315|Heart Failure
1029601|NCT01888315|Sympathetic activity
1029602|NCT01888276|Words generation, compulsive gamblers
1029603|NCT01888263|Bioequivalence
1029604|NCT01888263|Lamotrigine Extended Release
1029605|NCT01888263|crossover
1029606|NCT01888250|Bioequivalence
1029607|NCT01888250|Lamotrigine Extended Release
1029608|NCT01888250|crossover
1029609|NCT01888237|Dyspepsia
1029610|NCT01888237|Helicobacter pylori
1029611|NCT01888237|Clarithromycin resistance
1029612|NCT01888237|Other Specified Disorders of Function of Stomach
1029613|NCT01888198|ablation
1029614|NCT01888198|quality of Life (QOL)
1029615|NCT01888198|kidney
1029616|NCT01888198|registry
1029617|NCT01888198|Ablation of Renal Masses Outcomes Registry (ARMOR)
1029618|NCT01888198|13-116
1029619|NCT01888185|Parkinson's
1029620|NCT01888185|PD
1029621|NCT01888185|nigrostriatal
1029622|NCT01888185|substantia nigra
1029623|NCT01888185|MRI
1029624|NCT01888185|DTI
1029625|NCT01888185|FA
1029626|NCT01888185|R2*
1029627|NCT01888185|Parkinson's Disease Biomarkers Program
1029628|NCT01888185|PDBP
1029629|NCT01888185|ferritin
1029630|NCT01888185|transferrin
1029631|NCT01888185|Fe
1029632|NCT01888185|iron protein
1029633|NCT01888185|PSP
1029634|NCT01888185|MSA
1029635|NCT01888146|Pain management
1029636|NCT01888146|Opioid use
1029637|NCT01888146|Pragmatic
1029638|NCT01888146|Collaborative care
1029639|NCT01888146|Primary care
1029640|NCT01888107|Schizophrenia
1029641|NCT01888107|Schizoaffective Disorder
1029642|NCT01888107|Antipsychotics
1029643|NCT01888107|Risperidone
1029644|NCT01888107|Long-acting injectable
1029645|NCT01888094|Central venous catheter
1029646|NCT01888094|Complications
1029647|NCT01888094|Ultrasound
1029648|NCT01888094|Subclavian vein cannulation
1029649|NCT01888094|Critical care
1029650|NCT01888094|Echocardiography
1029651|NCT01888094|Chest radiographyiography
1029652|NCT01888055|Healthy older adults Cortical Plasticity
1029653|NCT01888055|Transcranial Direct Current Stimulation
1029654|NCT01888029|mild cognitive impairment
1029655|NCT01888029|Transcranial Direct Current Stimulation
1029656|NCT01888029|Cortical Plasticity
1029657|NCT01888003|anemia
1029658|NCT01887977|Orthognathic surgery
1029659|NCT01887977|Speech production
1029660|NCT01887977|MRI
1029661|NCT01887964|Diabetes
1029662|NCT01887964|Obesity
1029663|NCT01887964|Cardiovascular disease
1029664|NCT01887964|Metabolic syndrome
1029665|NCT01887925|breast neoplasms
1029666|NCT01887925|sleep
1029667|NCT01887925|anxiety
1029668|NCT01887925|depression
1029669|NCT01887925|life quality
1029670|NCT01887912|Clostridium difficile Toxoid Vaccine
1029671|NCT01887912|Clostridium difficile infection
1029672|NCT01887912|Cdiffense
1029673|NCT01887899|cortical plasticity
1029674|NCT01887899|transcranial direct current stimulation
1029675|NCT01887873|open angle glaucoma
1029676|NCT01887873|cataract
1029677|NCT01887860|Cetaphil Daily Facial Moisturizer SPF 50
1029678|NCT01887847|nicotine
1029679|NCT01887847|pharmacokinetics
1029680|NCT01887834|bloating
1029681|NCT01887834|constipation
1029682|NCT01887834|diarrhea
1029683|NCT01887834|gas
1029684|NCT01887834|mucous
1029685|NCT01887834|cramping
1029686|NCT01887808|Determine
1029687|NCT01887808|Hypoallergenicity
1029688|NCT01887808|Cetaphil DermaControl Oil Control Moisturizer SPF 30
1029689|NCT01887795|Informed Consent;
1029690|NCT01887795|Ethical Principles;
1029691|NCT01887795|Data collection
1029692|NCT01887782|depression
1029693|NCT01887782|magnetic
1029694|NCT01887782|brain stimulation
1029695|NCT01887782|treatment-resistant
1029696|NCT01887769|Lung cancer
1029697|NCT01887769|Body composition analysis
1029698|NCT01887769|Ct-Scan
1029699|NCT01887769|Muscle mass
1029700|NCT01887769|Cachexia
1029701|NCT01887756|telerehabilitation stroke virtual reatlity
1029702|NCT01887743|GERD
1029703|NCT01887743|Obesity
1029704|NCT01887743|Pediatric
1029705|NCT01887743|Pantoprazole
1029706|NCT01887743|CYP2C19
1029707|NCT01887743|Pharmacokinetic
1029708|NCT01887730|Hand Hygiene
1029709|NCT01887730|Communicable Diseases
1029710|NCT01887730|Prevention
1029711|NCT01887717|hepatocellular carcinoma
1029712|NCT01887717|portal vein thrombosis
1029713|NCT01887691|Diabetes
1029714|NCT01887691|Prediabetic
1029715|NCT01887691|Prediabetes
1029716|NCT01887691|Glucose intolerance
1029717|NCT01887691|Sleep quality
1029718|NCT01887691|Continuous glucose monitoring
1029719|NCT01887691|Diabetes risk
1029720|NCT01887691|eszopiclone
1029721|NCT01887665|substance use disorders
1029722|NCT01887665|substance abuse
1029723|NCT01887665|substance abuse treatment
1029724|NCT01887665|contingency management
1029725|NCT01887652|In Vitro Fertilization
1029726|NCT01887652|ovulation induction
1029727|NCT01887652|anti-mullerian hormone
1029728|NCT01887639|Non-psychotic unipolar major depression
1029729|NCT01887639|Resistant depression
1029730|NCT01887626|Phase 1, pharmacokinetic, safety, Ticagrelor
1029731|NCT01887613|Gabapentin
1029732|NCT01887600|anemia
1029733|NCT01887600|chronic kidney disease (CKD)
1029734|NCT01887600|Hemoglobin (Hb)
1029735|NCT01887600|non-dialysis
1029736|NCT01887548|Crohn's disease
1029737|NCT01887548|inflammatory bowel disease
1029738|NCT01887548|quality of life
1029739|NCT01887548|personality
1029740|NCT01887548|neuroticism
1029741|NCT01887535|Healthy
1029742|NCT01887535|Elderly
1029743|NCT01887535|Safety
1029744|NCT01887535|Tolerability
1029745|NCT01887535|Pharmacokinetic
1029746|NCT01887535|Alzheimer's Disease
1029747|NCT01887535|JNJ-54861911
1029748|NCT01887522|Children
1029749|NCT01887522|Adolescents
1029750|NCT01887522|Young Adults
1029751|NCT01887509|Rectal cancer
1029752|NCT01887509|Tumor margin
1029753|NCT01887509|Confocal endomicroscopy
1029754|NCT01887509|Virtual biopsy
1029755|NCT01887509|Fluorescein
1029756|NCT01887496|Varicella
1029757|NCT01887496|Turkey
1029758|NCT01887496|hospitalization
1029759|NCT01887496|varicella vaccine
1029760|NCT01887483|IBS
1029761|NCT01887483|bowel function
1029762|NCT01887483|probiotic
1029763|NCT01887470|Bowel Evacuation
1029764|NCT01887470|Colonoscopy Preparation
1029765|NCT01887457|voriconazole
1029766|NCT01887457|VFEND
1029767|NCT01887457|individualised
1029768|NCT01887457|personalised
1029769|NCT01887444|Pediatric Gastroenterology
1029770|NCT01887444|Probiotics
1029771|NCT01887444|Lactobacillus reuteri
1029772|NCT01887431|Diabetes Mellitus, Type 1
1029773|NCT01887431|Adult
1029774|NCT01887431|Insulin Infusion Systems
1029775|NCT01887431|Telecare
1029776|NCT01887418|Hypogonadism
1029777|NCT01887418|Testosterone enanthate
1029778|NCT01887405|Adrenaline
1029779|NCT01887405|Auto-injector
1029780|NCT01887405|Jext
1029781|NCT01887405|Epipen
1029782|NCT01887392|Long-term Care
1029783|NCT01887392|Knowledge Translation
1029784|NCT01887379|Gastroretentive drug formulation
1029785|NCT01887379|Furosemide
1029786|NCT01887379|Magnetic Marker Monitoring
1029787|NCT01887379|Magnetic marker
1029788|NCT01887379|Oedema
1029789|NCT01887366|Cocaine addiction
1029790|NCT01887366|TV-1380
1029791|NCT01887366|Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)
1029792|NCT01887353|atrial fibrillation
1029793|NCT01887353|heart failure
1029794|NCT01887353|ranolazine
1029795|NCT01887353|cardioversion
1029796|NCT01887353|persistent AF
1029797|NCT01887353|paroxysmal AF
1029798|NCT01887327|G6PD deficiency
1029799|NCT01887327|ABO incompatibility
1029800|NCT01887327|Coombs positive ABO/RH incompatibility
1029801|NCT01887327|intensive phototherapy in neonates
1029802|NCT01887327|Hyperbilirubinemia
1029803|NCT01887327|Neonatal Jaundice
1029804|NCT01887314|Cancer
1029805|NCT01887314|Cisplatin
1029806|NCT01887314|Nausea
1029807|NCT01887314|Ginger
1029808|NCT01887314|Zingiber officinale
1029809|NCT01887314|5HT3
1029810|NCT01887314|Dexamethasone
1029811|NCT01887314|Neurokinin-1 (NK-1)
1029812|NCT01887314|Interleukin-6 (IL-6)
1029813|NCT01887314|Tumor necrosis factor-alpha (TNF-alpha)
1029814|NCT01887314|Insulin like growth factor-1 (IGF-1)
1029815|NCT01887314|Placebo
1029816|NCT01887314|FLIE
1029817|NCT01887314|BFI
1029818|NCT01887275|Chronic hepatitis B
1029819|NCT01887275|Medical Ozone
1029820|NCT01887275|Interferon-α
1029821|NCT01887275|Efficacy
1029822|NCT01887262|fluid
1029823|NCT01887262|edema
1029824|NCT01887223|Encapsulated blebs
1029825|NCT01887223|trabeculectomy failure
1029826|NCT01887223|glaucoma
1029827|NCT01887210|HIV
1029828|NCT01887210|youth
1029829|NCT01887210|medical adherence
1029830|NCT01887197|cystic fibrosis
1029831|NCT01887197|mucociliary clearance
1029832|NCT01887197|airway surface liquid
1029833|NCT01887197|nuclear medicine
1029834|NCT01887197|mannitol
1029835|NCT01887171|Liver transplantation
1029836|NCT01887171|Early allograft dysfunction
1029837|NCT01887171|Ischemic reperfusion injury
1029838|NCT01887171|Portal and arterial ex vivo HTK flush
1029839|NCT01887145|Carpal tunnel syndrome
1029840|NCT01887145|Surgery
1029841|NCT01887145|Outcomes
1029842|NCT01887132|Sleep Architecture
1029843|NCT01887132|Autism
1029844|NCT01887132|Language Development
1029845|NCT01887093|coronary artery disease
1029846|NCT01887093|walking
1029847|NCT01887093|lipids
1029848|NCT01887093|inflammatory markers
1029849|NCT01887093|time of day
1029850|NCT01887080|Cardiovascular rehabilitation home-based
1029851|NCT01887080|Acute myocardial infarction
1029852|NCT01887080|Obesity
1029853|NCT01887080|Microcurrent
1029854|NCT01887067|Hypertension
1029855|NCT01887067|Diabetes Mellitus
1029856|NCT01887041|Advanced, metastasising pancreatic head carcinoma
1029857|NCT01887041|Jaundice
1029858|NCT01887041|Biliodigestive anastomosis
1029859|NCT01887041|Endoscopically inserted biliary tract drainage
1029860|NCT01887041|Quality of Life
1029861|NCT01887028|Carbon deoxide pneumoperitoneum
1029862|NCT01887028|Intraperitoneal pressure
1029863|NCT01887028|Peritoneum
1029864|NCT01887028|Gene expression
1029865|NCT01887028|Post-operative recovery
1029866|NCT01887028|Laparoscopic Humidification System
1029867|NCT01887015|Postoperative pulmonary complications
1029868|NCT01887015|Oxygen therapy
1029869|NCT01887015|Nasal high flow oxygen therapy
1029870|NCT01887015|Nasal high flow cannula
1029871|NCT01887002|Irritable Bowel Syndrome
1029872|NCT01887002|IBS
1029873|NCT01887002|ONO-2952
1029874|NCT01886989|diabetes
1029875|NCT01886989|cocoa polyphenols
1029876|NCT01886989|postprandial glycemia
1029877|NCT01886989|postprandial lipemia
1029878|NCT01886976|multiple myeloma
1029879|NCT01886950|CKD stage 5
1029880|NCT01886950|Bone histomorphometry
1029881|NCT01886950|Renal transplantation
1029882|NCT01886924|Tobacco
1029883|NCT01886924|Nicotine
1029884|NCT01886924|Dependence
1029885|NCT01886924|Quitline
1029886|NCT01886911|prosocial behavior
1029887|NCT01886911|prosocial
1029888|NCT01886911|attention training
1029889|NCT01886911|attention
1029890|NCT01886911|empathy
1029891|NCT01886911|emotion recognition
1029892|NCT01886885|Mindfulness
1029893|NCT01886885|Meditation
1029894|NCT01886885|Chronic Pain
1029895|NCT01886833|Rotavirus
1029896|NCT01886833|Diarrhoea
1029897|NCT01886833|Dmmunisation
1029898|NCT01886833|Seroconversion
1029899|NCT01886833|Breastmilk
1029900|NCT01886833|HIV
1029901|NCT01886833|Zinc
1029902|NCT01886833|Vitamin A
1029903|NCT01886833|Failure
1029904|NCT01886820|Dementia
1029905|NCT01886820|Alzheimer's Disease
1029906|NCT01886820|Terminally Ill
1029907|NCT01886794|pelvic floor dysfunction
1029908|NCT01886794|pelvic organ prolapse
1029909|NCT01886794|vaginal estrogen effects
1029910|NCT01886781|only constipation and diarrhea predominant
1029911|NCT01886781|no mixed or alternating types
1029912|NCT01886768|Nasal anesthesia
1029913|NCT01886768|endoscopes
1029914|NCT01886768|transnasal endoscopy
1029915|NCT01886755|Acute gastroenteritis
1029916|NCT01886755|Probiotics
1029917|NCT01886755|Lactobacillus reuteri
1029918|NCT01886755|Zinc supplementation
1029919|NCT01886755|Infants
1029920|NCT01886755|Age 6 months to 36 months
1029923|NCT01886729|transcranial direct current stimulation
1029924|NCT01886729|time shift
1029925|NCT01886716|Alcohol Abuse
1029926|NCT01886716|Alcohol Dependence
1029927|NCT01886716|Alcohol Drinking
1029928|NCT01886716|Social Anxiety
1029929|NCT01886716|Social Phobia
1029930|NCT01886716|Anxiety Disorders
1029931|NCT01886703|Physical activity
1029932|NCT01886703|Exercise
1029933|NCT01886703|Quality of Life
1029934|NCT01886703|Radiation Therapy
1029935|NCT01886703|Breast Cancer
1029936|NCT01886703|Head and Neck Cancer
1029937|NCT01886677|prostate cancer
1029938|NCT01886677|intervention
1029939|NCT01886677|diet
1029940|NCT01886677|physical activity
1029941|NCT01886677|exercise
1029942|NCT01886677|weight loss
1029943|NCT01886677|biomarkers
1029944|NCT01886677|cancer progression
1029945|NCT01886651|acute lymphoblastic leukemia
1029946|NCT01886651|child
1029947|NCT01886651|6-mercaptopurine
1029948|NCT01886651|methotrexate
1029949|NCT01886638|Platelets
1029950|NCT01886638|HIV
1029951|NCT01886638|Cardiovascular disease
1029952|NCT01886638|Acute myocardial infarction
1029953|NCT01886638|Abacavir
1029954|NCT01886638|Antiretrovirals
1029955|NCT01886612|Deep Vein Thrombosis
1029956|NCT01886612|Neuromuscular Electrical Stimulation
1029957|NCT01886612|Intermittent Pneumatic Compression
1029958|NCT01886612|Doppler Ultrasound
1029959|NCT01886586|Mild Cognitive Impairment
1029960|NCT01886586|memory impairment
1029961|NCT01886586|problem-solving therapy
1029962|NCT01886586|depression prevention
1029963|NCT01886586|caregiver stress
1029964|NCT01886586|exercise
1029965|NCT01886534|Heart failure
1029966|NCT01886534|Heart diseases
1029967|NCT01886534|Cardiovascular diseases
1029968|NCT01886534|Health information technology
1029969|NCT01886534|Disease management
1029970|NCT01886534|Patient care management
1029971|NCT01886534|Self care
1029972|NCT01886534|Informal caregiver
1029973|NCT01886534|Care partner
1029974|NCT01886534|Peer support
1029975|NCT01886534|Transitional care
1029976|NCT01886534|Patient education
1029977|NCT01886534|Teach-back
1029978|NCT01886534|Clinical decision aid
1029979|NCT01886443|Liver
1029980|NCT01886443|Transplantation
1029981|NCT01886443|Ischemia-reperfusion
1029982|NCT01886443|Safety
1029983|NCT01886404|HIV
1029984|NCT01886404|efavirenz
1029985|NCT01886404|Sustiva
1029986|NCT01886404|pharmacokinetics
1029987|NCT01886404|Pharmacogenomics
1029988|NCT01886391|Heart Failure
1029989|NCT01886391|Dyspnea
1029990|NCT01886391|Diaphragmatic breathing retraining
1029991|NCT01886391|Fatigue
1029992|NCT01886391|Health-related Outcomes
1029993|NCT01886378|FAOD
1029994|NCT01886378|VLCAD
1029995|NCT01886378|CPT II
1029996|NCT01886378|CPT2
1029997|NCT01886378|CPT 2
1029998|NCT01886378|LCHAD
1029999|NCT01886378|UX007
1030000|NCT01886378|Triheptanoin
1030001|NCT01886378|TFP
1030002|NCT01886378|C7
1030003|NCT01886365|Computer based glycemic control, insulin, blood glucose
1030004|NCT01886352|laparoscopic
1030005|NCT01886352|pain
1030006|NCT01886326|Obesity
1030007|NCT01886326|energy balance
1030008|NCT01886326|variety
1030009|NCT01886326|nut intake
1030010|NCT01886313|Herpes Zoster
1030011|NCT01886313|Postherpetic Neuralgia
1030012|NCT01886313|Shingles
1030013|NCT01886313|Civamide
1030014|NCT01886313|Zucapsaicin
1030015|NCT01886313|Neuropeptides
1030016|NCT01886313|TRPV-1
1030017|NCT01886287|endocrine system
1030018|NCT01886287|neuroendocrine tumors
1030019|NCT01886287|neuroendocrine cancer
1030020|NCT01886287|metastatic
1030021|NCT01886287|neuroendocrine
1030022|NCT01886287|gastrointestinal (GI)
1030023|NCT01886287|high-dose octreotide
1030024|NCT01886287|flushing
1030025|NCT01886287|diarrhea
1030026|NCT01886287|quality of life in patients
1030027|NCT01886287|disease-related symptoms
1030028|NCT01886274|EEG
1030029|NCT01886274|migraine
1030030|NCT01886274|pain
1030031|NCT01886274|phosphene
1030032|NCT01886274|tDCs
1030033|NCT01886274|TMS
1030034|NCT01886261|validation
1030035|NCT01886261|physical activity
1030036|NCT01886261|place-based interventions
1030037|NCT01886261|construct validity
1030038|NCT01886261|divergent validity
1030039|NCT01886261|usability
1030040|NCT01886261|gps
1030041|NCT01886261|PALMS
1030042|NCT01886248|hepatic veno-occlusive disease after hematopoietic stem cell transplantation
1030043|NCT01886222|Traumatic brain injury
1030044|NCT01886196|elderly
1030045|NCT01886196|women
1030046|NCT01886196|exercise
1030047|NCT01886196|pQCT
1030048|NCT01886196|ibuprofen
1030049|NCT01886183|Postural Balance
1030050|NCT01886183|Virtual Reality Exposure Therapy
1030051|NCT01886183|Gait
1030052|NCT01886183|Stroke
1030053|NCT01886170|Adults with self-reported diagnosis of diabetes recruited from waiting rooms at outpatient primary care sites at the University of Pennsylvania
1030054|NCT01886157|trigger finger
1030055|NCT01886157|orthotic intervention
1030056|NCT01886144|OA
1030057|NCT01886144|arthritis
1030058|NCT01886144|knee OA
1030059|NCT01886131|REM behaviour disorder
1030060|NCT01886131|Subthalamic nucleus
1030061|NCT01886131|Local field potential
1030062|NCT01886131|Motor control
1030063|NCT01886118|In vitro fertilization
1030064|NCT01886118|Autologous Endometrial Co-Culture
1030065|NCT01886105|Osteosarcoma
1030066|NCT01886105|Osteogenic Sarcoma
1030067|NCT01886105|Sarcoma
1030068|NCT01886105|Bone Cancer
1030069|NCT01886092|tinnitus
1030070|NCT01886027|IBS
1030071|NCT01886027|Relaxation
1030072|NCT01886027|Emotional exposure
1030073|NCT01886027|Emotional Processing
1030074|NCT01886014|pain
1030075|NCT01886014|pain modulation
1030076|NCT01886014|placebo analgesia
1030077|NCT01886001|Newborn Intensive Care Unit
1030078|NCT01886001|Neonatal Intensive Care Unit
1030079|NCT01886001|Colonization
1030080|NCT01886001|Line Colonization
1030081|NCT01886001|Umbilical line
1030082|NCT01886001|Umbilical Cord Care
1030083|NCT01885988|Erectile dysfunction
1030084|NCT01885975|Apical Ballooning syndrome
1030085|NCT01885975|Personality
1030086|NCT01885962|pressure ulcer prevention
1030087|NCT01885962|spinal cord injury
1030088|NCT01885962|internet delivered pressure ulcer intervention
1030089|NCT01885949|Metastatic
1030090|NCT01885936|LOPD
1030091|NCT01885936|Pompe Disease
1030092|NCT01885923|schizophrenia; relapse prevention; information technology
1030093|NCT01885897|Acute myelogenous leukemia (AML)
1030094|NCT01885897|Acute lymphoblastic leukemia (ALL)
1030095|NCT01885897|Myelodysplastic syndromes (MDS)
1030096|NCT01885897|Lymphoma
1030097|NCT01885897|Myeloma
1030098|NCT01885897|Chronic Lymphocytic Leukemia (CLL)
1030099|NCT01885897|Chronic myelogenous leukemia (CML)
1030100|NCT01885884|Supportive Care
1030101|NCT01885884|Palliative Care
1030102|NCT01885884|Pancreatic Cancer
1030103|NCT01885884|Embedded, coordinated model of supportive care within oncology care
1030104|NCT01885884|Patient and Caregiver support
1030105|NCT01885871|Sun
1030106|NCT01885871|Age
1030107|NCT01885871|Spot
1030108|NCT01885858|health services research
1030109|NCT01885858|family planning
1030110|NCT01885858|ethnicity
1030111|NCT01885858|healthcare disparities
1030112|NCT01885845|postpartum blood loss measurement
1030113|NCT01885845|BRASSS-V drape
1030114|NCT01885832|autologous adipose stem cells
1030115|NCT01885832|stromal vascular fraction
1030116|NCT01885832|osteoarthritis
1030117|NCT01885819|Adipose stromal vascular fraction
1030118|NCT01885819|Rheumatoid arthritis
1030119|NCT01885819|adult stem cells
1030120|NCT01885806|Apathy; Alzheimer's disease; Cognition; Burden of Care
1030121|NCT01885780|Astigmatism, arcuate incisions, astigmatic keratotomy
1030122|NCT01885767|Neurofibromatosis
1030123|NCT01885767|NF
1030124|NCT01885767|Neurofibromatosis 1
1030125|NCT01885767|NF1
1030126|NCT01885767|Neurofibromatosis 2
1030127|NCT01885767|NF2
1030128|NCT01885767|Schwannomatosis
1030129|NCT01885754|Biopsy
1030130|NCT01885754|Maximal incremental cardiopulmonary test
1030131|NCT01885754|Muscle strength test
1030132|NCT01885754|magnetic stimulation
1030133|NCT01885702|Dendritic cell vaccination
1030134|NCT01885702|MSI-high colorectal cancer (CRC)
1030135|NCT01885702|Vaccines
1030136|NCT01885702|Immunotherapy
1030137|NCT01885702|CRC
1030138|NCT01885702|Germline MMR-gene mutation without disease criteria of CRC
1030139|NCT01885663|Umbilical cord blood
1030140|NCT01885663|Acquired brain injury
1030141|NCT01885650|Non invasive ventilation
1030142|NCT01885650|Chest physiotherapy
1030143|NCT01885650|Airway clearance
1030144|NCT01885637|Palliative
1030145|NCT01885637|Palliation
1030146|NCT01885637|Cancer
1030147|NCT01885637|Care
1030148|NCT01885637|SPC
1030149|NCT01885637|Caregivers
1030150|NCT01885637|Home Care Services, Hospital-Based
1030151|NCT01885637|Psychological
1030152|NCT01885637|From Oncological Treatment to Palliative Care at Home
1030153|NCT01885637|Place of death
1030154|NCT01885624|TAB08
1030155|NCT01885624|healthy volunteers
1030156|NCT01885611|Leprosy
1030157|NCT01885572|breast reconstruction
1030158|NCT01885572|mastectomy
1030159|NCT01885572|mesh
1030160|NCT01885572|breast cancer
1030161|NCT01885559|polycystic kidney disease
1030162|NCT01885559|polycystic
1030163|NCT01885559|kidney
1030164|NCT01885559|disease
1030165|NCT01885559|adpkd
1030166|NCT01885559|halt
1030167|NCT01885559|pkd
1030168|NCT01885559|blood pressure
1030169|NCT01885559|bp
1030170|NCT01885559|hypertension
1030171|NCT01885559|renal
1030172|NCT01885559|renin-angiotensin-aldosterone-system
1030173|NCT01885559|RAAS
1030174|NCT01885546|diabetes
1030175|NCT01885546|glucose
1030176|NCT01885546|glucometer
1030177|NCT01885533|Graves' disease
1030178|NCT01885533|radioiodine
1030179|NCT01885533|thyroid
1030180|NCT01885533|hypothyroidism
1030181|NCT01885533|Graves' orbitopathy
1030182|NCT01885520|low back pain
1030183|NCT01885481|dexamethasone
1030184|NCT01885481|betamethasone
1030185|NCT01885481|epidural steroid injection
1030186|NCT01885481|comparative effectiveness research
1030187|NCT01885468|Hydrocephalus shunt
1030188|NCT01885468|proGAV
1030189|NCT01885455|non-small cell lung cancer (NSCLC)
1030190|NCT01885442|mechanical ventilation
1030191|NCT01885442|cycle ergometry
1030192|NCT01885442|intensive care unit
1030193|NCT01885442|rehabilitation
1030194|NCT01885429|Protein Turnover
1030195|NCT01885429|Resistance Exercise
1030196|NCT01885429|Whey Protein
1030197|NCT01885429|Leucine
1030198|NCT01885403|Acute Cardiogenic Pulmonary Edema,
1030199|NCT01885403|Acute Decompensated Heart Failure,
1030200|NCT01885403|BiLevel Positive Airway Pressure,
1030201|NCT01885403|Continuous Positive Airway Pressure
1030202|NCT01885390|Hypertension
1030203|NCT01885390|High blood pressure
1030204|NCT01885390|Resistant blood pressure
1030205|NCT01885390|Uncontrolled blood pressure
1030206|NCT01885377|Subacromial pain
1030207|NCT01885377|Impingement
1030208|NCT01885377|Exercises
1030209|NCT01885377|Physical therapy
1030210|NCT01885377|Primary care
1030211|NCT01885364|esmolol
1030212|NCT01885364|pain
1030213|NCT01885364|propofol
1030214|NCT01885364|remifentanil
1030215|NCT01885351|Colorectal Cancer Screening
1030216|NCT01885351|Ambulatory Care
1030217|NCT01885351|Patient-Centered Care
1030218|NCT01885351|Intervention Studies
1030219|NCT01885351|Longitudinal Studies
1030220|NCT01885338|Schizophrenia
1030221|NCT01885338|Cognition
1030222|NCT01885338|Neurocognition
1030223|NCT01885338|N-Acetylcysteine
1030224|NCT01885338|NAC
1030225|NCT01885338|EEG
1030226|NCT01885325|Physical Activity
1030227|NCT01885325|Sedentary Behavior
1030228|NCT01885325|Preschool Children
1030229|NCT01885312|Drinking
1030230|NCT01885312|Heavy Drinking
1030231|NCT01885312|Technology
1030232|NCT01885312|Mobile Phone
1030233|NCT01885312|Text Message
1030234|NCT01885312|Problem Drinking
1030235|NCT01885312|Alcohol Problems
1030236|NCT01885312|Alcoholism
1030237|NCT01885312|Moderation-Oriented Treatment
1030238|NCT01885312|Controlled Drinking
1030239|NCT01885312|Reduced Drinking
1030240|NCT01885299|Radiosurgery
1030241|NCT01885299|CyberKnife
1030242|NCT01885299|Benign tumors
1030243|NCT01885299|Malignant tumors
1030244|NCT01885299|Cranial tumors
1030245|NCT01885299|Extracranial tumors
1030246|NCT01885299|Lung
1030247|NCT01885299|Liver
1030248|NCT01885299|Pancreas
1030249|NCT01885299|Prostate
1030250|NCT01885299|Stereotactic radiosurgery
1030251|NCT01885299|Stereotactic body radiotherapy
1030252|NCT01885286|circumcision
1030253|NCT01885286|HIV prevention
1030254|NCT01885273|pressurized irrigation
1030255|NCT01885273|wound cleansing method
1030256|NCT01885273|irrigation
1030257|NCT01885273|swabbing
1030258|NCT01885273|appropriate pressure for irrigation
1030259|NCT01885260|Type 2 Diabetes Mellitus
1030260|NCT01885260|T2DM
1030261|NCT01885234|Glycated hemoglobin
1030262|NCT01885234|HOMA
1030263|NCT01885234|Pregnancy
1030264|NCT01885234|aerobic exercise
1030265|NCT01885221|smokeless tobacco cessation
1030266|NCT01885221|social support
1030267|NCT01885221|partner support
1030268|NCT01885195|RAS, RAF, MEK, NF1, MEK162, signature, papillary thyroid, small intestine, bladder, esophagus, lung cancer, NSCLC, acute myelogenous leukemia, AML
1030269|NCT01885169|Cystic fibrosis
1030270|NCT01885169|Influenza
1030271|NCT01885169|Vaccine
1030272|NCT01885143|Mammography
1030273|NCT01885117|Influenza,
1030274|NCT01885117|Adults,
1030275|NCT01885117|Elderly,
1030276|NCT01885117|Immunology,
1030277|NCT01885117|Safety
1030278|NCT01885052|Smoking Cessation Clinical Trial
1030279|NCT01885052|Text Messaging Program
1030280|NCT01885052|Smoking Cessation Aid
1030281|NCT01885039|Cancer
1030282|NCT01885039|Breast Cancer
1030283|NCT01885039|Molecular Subtypes
1030284|NCT01885039|Asian Breast Cancer
1030285|NCT01885026|Randomized Controlled Trial
1030286|NCT01885026|Alcohol
1030287|NCT01885026|Drugs
1030288|NCT01885026|Internet
1030289|NCT01885026|Screening
1030290|NCT01885026|Brief intervention
1030291|NCT01885013|HER2 negative
1030292|NCT01885013|metastatic breast cancer
1030293|NCT01885013|non endocrine responsive disease
1030294|NCT01884974|Myeloproliferative disease
1030295|NCT01884974|Pulmonary Hypertension
1030296|NCT01884948|at least 1 segment
1030297|NCT01884948|multiple wedge resections (≥3)
1030298|NCT01884935|Pediatric
1030299|NCT01884922|Children
1030300|NCT01884922|adolescents
1030301|NCT01884922|young adults
1030302|NCT01884870|Asymptomatic
1030303|NCT01884870|ureteral
1030304|NCT01884870|calculi
1030305|NCT01884870|renal function
1030306|NCT01884870|treatment
1030307|NCT01884831|damage to the skin, the skin equivalent, cell therapy
1030308|NCT01884818|Thoracic spine, pain, manipulation
1030309|NCT01884805|Adaptive Optics Visual Simulator
1030310|NCT01884805|Wavefront aberrometer
1030311|NCT01884805|Optical Aberrations
1030312|NCT01884805|Hyperopia
1030313|NCT01884792|prediabetes
1030314|NCT01884792|physical inactivity
1030315|NCT01884792|sedentary
1030316|NCT01884792|standing
1030317|NCT01884779|HIV
1030318|NCT01884779|Histoplasmosis
1030319|NCT01884779|Histoplasma capsulatum var.capsulatum
1030320|NCT01884779|ELISA test
1030321|NCT01884753|lower urinary tract symptoms
1030322|NCT01884753|overactive bladder syndrome
1030323|NCT01884753|antimuscarinic drug
1030324|NCT01884753|three-dimensional power Doppler ultrasound
1030325|NCT01884753|sexual dysfunction
1030326|NCT01884740|GBM
1030327|NCT01884740|AA
1030328|NCT01884740|FA
1030329|NCT01884740|PXA
1030330|NCT01884740|AOA
1030331|NCT01884740|High grade glioma
1030332|NCT01884727|Obesity
1030333|NCT01884727|Overweight
1030334|NCT01884727|Over nutrition
1030335|NCT01884727|nutrition disorders
1030336|NCT01884727|energy expenditure
1030337|NCT01884727|metabolic rate
1030338|NCT01884714|diabetes
1030339|NCT01884714|obesity
1030340|NCT01884714|metabolism
1030341|NCT01884714|clinical study
1030342|NCT01884701|Chronic Total Occlusion CTO
1030343|NCT01884688|Asymptomatic Multiple Myeloma
1030344|NCT01884688|Auto-ENK Cell Therapy
1030345|NCT01884688|Natural Killer Cells
1030346|NCT01884675|Endothelin Receptor Antagonist
1030347|NCT01884675|Inoperable Chronic Thromboembolic Pulmonary Hypertension
1030348|NCT01884662|spinal cord injury
1030349|NCT01884662|neuropathic pain
1030350|NCT01884649|Acute phase reactant, fetuin A, Hashimoto thyroiditis
1030351|NCT01884636|Isavuconazole
1030352|NCT01884636|Pharmacokinetics
1030353|NCT01884636|Healthy Subjects
1030354|NCT01884636|BAL8557
1030355|NCT01884636|BAL4815
1030356|NCT01884636|methotrexate
1030357|NCT01884597|PEARL2
1030358|NCT01884597|PCV
1030359|NCT01884597|Polypoidal Choroidal Vasculopathy
1030360|NCT01884571|Immunosuppression
1030361|NCT01884571|ALS
1030362|NCT01884558|Isavuconazole
1030363|NCT01884558|Pharmacokinetics
1030364|NCT01884558|Healthy Subjects
1030365|NCT01884558|BAL8557
1030366|NCT01884558|BAL4815
1030367|NCT01884558|metformin
1030368|NCT01884545|heart disease
1030369|NCT01884545|type 2 diabetes
1030370|NCT01884545|genetic testing
1030371|NCT01884545|health coaching
1030372|NCT01884545|risk assessment
1030373|NCT01884532|Adverse Local Tissue Reaction
1030374|NCT01884532|Metal Ions
1030375|NCT01884532|Serum
1030376|NCT01884532|Whole Blood
1030377|NCT01884532|Metal-on-Metal
1030378|NCT01884532|Total Hip Arthroplasty
1030379|NCT01884532|ASR-XL Metal-on-Metal
1030380|NCT01884532|Revised ASR-XL Metal-on-Metal
1030381|NCT01884519|Elderly
1030382|NCT01884519|Influenza
1030383|NCT01884519|Safety
1030384|NCT01884519|Adults
1030385|NCT01884519|Immunogenicity
1030386|NCT01884493|Parkinson's Disease
1030387|NCT01884493|Freezing of Gait
1030388|NCT01884493|movement-related cortical potential
1030389|NCT01884493|repetitive transcranial magnetic stimulation
1030390|NCT01884480|Advagraf, pharmacogenetics, Cyp3A5
1030391|NCT01884467|Urinary Tract Infections
1030392|NCT01884467|Gentamicin
1030393|NCT01884454|sleep
1030394|NCT01884454|obstructive sleep apnea
1030395|NCT01884454|reproduction
1030396|NCT01884454|sperm
1030397|NCT01884454|hormones
1030398|NCT01884454|men
1030399|NCT01884441|Hodgkin
1030400|NCT01884441|Lymphoma
1030401|NCT01884441|refractory
1030402|NCT01884441|relapsed
1030403|NCT01884428|Hodgkin
1030404|NCT01884428|Lymphoma
1030405|NCT01884389|HIV
1030406|NCT01884389|Chronic disease
1030407|NCT01884389|Early palliative care
1030408|NCT01884389|Patient navigation
1030409|NCT01884376|nerve biopsy
1030410|NCT01884376|nerve regeneration
1030411|NCT01884376|neuroma pain
1030412|NCT01884376|loss of sensation
1030413|NCT01884363|Endothelial function
1030414|NCT01884363|walnuts
1030415|NCT01884363|clinical trial
1030416|NCT01884363|Nutrition
1030417|NCT01884363|cardiovascular disease
1030418|NCT01884324|Gastroschisis
1030419|NCT01884324|Cesarean delivery
1030420|NCT01884324|Neonatal outcomes
1030421|NCT01884311|Primary Immune Deficiency Disorders
1030422|NCT01884311|Common Variable Immunodeficiency
1030423|NCT01884311|X-linked agammaglobulinaemia
1030424|NCT01884311|Hyper-IgM Syndrome
1030425|NCT01884311|Subcutaneous
1030426|NCT01884311|Immunoglobulins
1030427|NCT01884298|remifentanil
1030428|NCT01884298|isolated systolic hypertension
1030429|NCT01884298|morbidity
1030430|NCT01884298|epidural combined general anesthesia
1030431|NCT01884285|Advanced Castrate-resistant Prostate Cancer(CRPC)
1030432|NCT01884285|Squamous Non-Small Cell Lung Cancer(sqNSCLC)
1030433|NCT01884285|Triple Negative Breast Cancer(TNBC)
1030434|NCT01884285|PTEN-deficient/mutated Advanced Solid Malignancies
1030435|NCT01884285|PIK3CB mutated/amplified advanced solid malignancies
1030445|NCT01884246|lifestyle change
1030446|NCT01884246|behavior change
1030447|NCT01884246|obesity
1030448|NCT01884246|hypertension
1030449|NCT01884246|hyperlipidemia
1030450|NCT01884246|physical inactivity
1030451|NCT01884246|depression
1030452|NCT01884233|HIV
1030453|NCT01884233|Opioid Abuse
1030454|NCT01884233|Mobile technology
1030455|NCT01884220|Wolman Disease
1030456|NCT01884220|Cholesteryl Ester Storage Disease
1030457|NCT01884220|Enzyme deficiency
1030458|NCT01884220|Natural History
1030459|NCT01884220|Medical Records Review
1030460|NCT01884194|retinoblastoma
1030461|NCT01884194|pineoblastoma
1030462|NCT01884181|Huntington Disease, diffusion MRI, diagnosis, fast imaging
1030463|NCT01884129|Circulating tumor cells
1030464|NCT01884129|Head and neck cancer
1030465|NCT01884129|Squamous cell carcinoma
1030466|NCT01884129|Survival
1030467|NCT01884129|Prognosis
1030468|NCT01884116|Capsaicin
1030469|NCT01884116|myofascial pain syndrome
1030470|NCT01884116|non-steroidal anti-inflammatory agents
1030471|NCT01884116|transcutaneous electric nerve stimulation
1030472|NCT01884103|TBI
1030473|NCT01884103|Trauma
1030474|NCT01884103|Traumatic Brain Injury
1030475|NCT01884090|Empowerment
1030476|NCT01884090|Youth
1030477|NCT01884090|Violence
1030478|NCT01884090|Community
1030479|NCT01884090|Prevention
1030480|NCT01884077|patient outcomes two years after shoulder replacement
1030481|NCT01884077|seventy years of age and older
1030482|NCT01884064|focal hand dystonia
1030483|NCT01884064|rehabilitation
1030484|NCT01884064|rTMS
1030485|NCT01884064|writer's cramp
1030486|NCT01884064|clinical
1030487|NCT01884051|Pulmonary arterial hypertension
1030488|NCT01884038|Liver Transplant
1030489|NCT01884038|Prostacyclin
1030490|NCT01884038|Treprostinil sodium
1030491|NCT01884038|Remodulin
1030492|NCT01884038|Reperfusion Injury
1030493|NCT01884038|Primary Nonfunction
1030494|NCT01884025|patient centered care
1030495|NCT01884025|physical activity
1030496|NCT01884025|behavioral activation
1030497|NCT01884025|self efficacy
1030498|NCT01884025|serious mental illness
1030499|NCT01883986|palliative care
1030500|NCT01883973|PD
1030501|NCT01883973|DBS
1030502|NCT01883960|cerebral palsy
1030503|NCT01883960|cerebral vascular accident
1030504|NCT01883960|multi-modal brain techniques
1030505|NCT01883960|MRI
1030506|NCT01883960|motor control
1030507|NCT01883947|Stroke
1030508|NCT01883947|Massage
1030509|NCT01883947|General Health
1030510|NCT01883947|Independence
1030511|NCT01883934|In Vitro Fertilization (IVF)
1030512|NCT01883934|Embryo donation
1030531|NCT01883908|Acupuncture therapy
1030532|NCT01883908|Mucositis
1030533|NCT01883908|oropharyngeal cancer
1030534|NCT01883895|Pain
1030535|NCT01883895|exercise-induced hypoalgesia
1030536|NCT01883882|chronic non-cancer pain
1030537|NCT01883882|opioid taper
1030538|NCT01883882|chronic pain self-management
1030539|NCT01883882|motivational interviewing
1030540|NCT01883869|Platelet inhibition
1030541|NCT01883869|Platelet-leukocyte aggregates
1030542|NCT01883869|Platelet-neutrophil aggregates
1030543|NCT01883869|CAP
1030544|NCT01883869|HAP
1030545|NCT01883869|ALI
1030546|NCT01883869|Blood Platelets
1030547|NCT01883856|Refractory Glaucoma
1030548|NCT01883856|Intractable Glaucoma
1030549|NCT01883856|Primary Open Angle Glaucoma
1030550|NCT01883856|Neovascular Glaucoma
1030551|NCT01883843|Chronic Stroke
1030552|NCT01883843|tDCS
1030553|NCT01883843|transcranial direct current stimulation
1030554|NCT01883843|task oriented circuit training
1030555|NCT01883843|TOCT
1030556|NCT01883843|gait training
1030557|NCT01883830|traumatic brain injury (TBI)
1030558|NCT01883830|balance disorders
1030559|NCT01883830|attention deficits
1030560|NCT01883830|x-box
1030561|NCT01883830|gaming
1030562|NCT01883830|virtual reality
1030563|NCT01883817|ADHD
1030564|NCT01883804|Diabetes
1030565|NCT01883804|Diabetes Mellitus
1030566|NCT01883804|Type 1 Diabetes
1030567|NCT01883791|substance abuse prevention and treatment
1030568|NCT01883791|comorbidity
1030569|NCT01883791|SBIRT
1030570|NCT01883778|Attitudes of health personnel
1030571|NCT01883778|Attitudes of patients
1030572|NCT01883778|Medical compliance
1030573|NCT01883778|Cost awareness
1030574|NCT01883778|Cost analysis
1030575|NCT01883778|Patient knowledge
1030576|NCT01883778|Physician knowledge
1030577|NCT01883778|Medical economics
1030578|NCT01883778|Policy
1030579|NCT01883778|Questionnaires
1030580|NCT01883778|Health literacy
1030581|NCT01883765|ADHD, Neurofeedback, CBT
1030582|NCT01883752|Goal-directed fluid therapy
1030583|NCT01883739|Parental anxiety
1030584|NCT01883739|Children's safety
1030585|NCT01883739|Family Centered Care
1030586|NCT01883739|Bedside Transfer Rounds
1030587|NCT01883739|Pediatric Cardiac Intensive Care
1030588|NCT01883726|Unilateral complete cleft lip, Nasoalveolar molding
1030589|NCT01883713|anemia
1030590|NCT01883713|CPB
1030591|NCT01883713|methemoglobin
1030592|NCT01883713|hypoxia
1030593|NCT01883700|Healthy
1030594|NCT01883700|Glycemic Index
1030595|NCT01883700|Glycemic Load
1030596|NCT01883700|Blood Glucose
1030597|NCT01883700|Arterial Stiffness
1030598|NCT01883674|Sarcopenia
1030599|NCT01883674|Physical capacity
1030600|NCT01883674|Muscle force
1030601|NCT01883674|Muscle quality
1030602|NCT01883674|Milk proteins
1030603|NCT01883674|Essential amino acids
1030604|NCT01883674|Proteins
1030605|NCT01883674|Resistance training
1030606|NCT01883674|Exercise
1030607|NCT01883661|stem cell
1030608|NCT01883661|Multiple Sclerosis
1030609|NCT01883661|BMMNC
1030610|NCT01883648|Mild to Moderate Alzheimer's disease
1030611|NCT01883622|diabetes
1030612|NCT01883622|pregnancy
1030613|NCT01883622|glucose variability
1030614|NCT01883622|continuous glucose monitoring (CGM)
1030615|NCT01883622|gestational diabetes mellitus (GDM)
1030616|NCT01883609|Plasmodium Falciparum
1030617|NCT01883609|Malaria
1030618|NCT01883609|Vaccine
1030619|NCT01883609|Plasmodium
1030620|NCT01883609|Falciparum
1030621|NCT01883583|Ultrasound
1030622|NCT01883583|Perfusion Imaging
1030623|NCT01883583|Elasticity Imaging Techniques
1030624|NCT01883583|Kidney Transplantation
1030625|NCT01883583|Graft Rejection
1030626|NCT01883583|Chronic allograft nephropathy
1030627|NCT01883570|visual search strategy, training, chest x-ray
1030628|NCT01883544|Safety
1030629|NCT01883544|Tolerability
1030630|NCT01883544|Pharmacokinetics
1030631|NCT01883544|Pharmacodynamics
1030632|NCT01883544|ALXN1007
1030633|NCT01883544|Healthy Male and Female Subjects
1030634|NCT01883531|improving lung function
1030635|NCT01883531|paediatric and adolescent
1030636|NCT01883531|FEV1
1030637|NCT01883518|Fibrosarcoma
1030638|NCT01883518|Neurofibrosarcoma
1030639|NCT01883518|Histiocytoma
1030640|NCT01883518|Histiocytoma, Malignant Fibrous
1030641|NCT01883518|Chondrosarcoma
1030642|NCT01883518|Synovial Sarcoma
1030643|NCT01883518|Leiomyosarcoma
1030644|NCT01883518|Liposarcoma
1030645|NCT01883518|Myosarcoma
1030646|NCT01883518|Rhabdomyosarcoma
1030647|NCT01883518|Sarcoma, Alveolar Soft Part
1030648|NCT01883518|NY-ESO-1
1030649|NCT01883518|MAGE
1030650|NCT01883518|MAGE A3
1030651|NCT01883518|Vaccine
1030652|NCT01883518|Immunotherapy
1030653|NCT01883505|Motor fluctuations
1030654|NCT01883505|levodopa pharmacokinetics
1030655|NCT01883505|levodopa and carbidopa solution
1030656|NCT01883505|continuous subcutaneous delivery
1030657|NCT01883505|Patch-pump
1030660|NCT01883466|Air Pollution
1030661|NCT01883466|Biodiesel exhaust
1030662|NCT01883466|Diesel exhaust
1030663|NCT01883466|Vascular function
1030664|NCT01883466|Fibrinolysis
1030665|NCT01883466|Acute endothelial responses
1030666|NCT01883440|Duration
1030667|NCT01883427|Days with URTI symptoms
1030668|NCT01883414|Ulthera, Ultherapy, Surgical scar, scar,
1030669|NCT01883401|Strawberries
1030670|NCT01883401|Heart health
1030671|NCT01883401|Anthocyanins
1030672|NCT01883388|Lung Cancer
1030673|NCT01883388|blood sample
1030674|NCT01883375|Palliative Care
1030675|NCT01883375|Family
1030676|NCT01883375|adaptation, psychological
1030677|NCT01883362|acute myeloid leukemia
1030678|NCT01883362|AML
1030679|NCT01883362|FLT3-ITD
1030680|NCT01883362|midostaurin
1030681|NCT01883362|PKC412
1030682|NCT01883362|allogeneic hematopoeitic stem cell tranplant
1030683|NCT01883362|SCT
1030684|NCT01883362|HSCT
1030685|NCT01883362|CR1
1030686|NCT01883336|Incidental pancreatic cysts
1030687|NCT01883323|Measurable
1030688|NCT01883323|Unresectable
1030689|NCT01883323|Stage III
1030690|NCT01883323|Stage IV
1030691|NCT01883323|Metastatic
1030692|NCT01883323|Melanoma
1030693|NCT01883323|Tumor-Infiltrating Lymphocytes
1030694|NCT01883323|Low-Dose Interleukin-2
1030695|NCT01883323|Cyclophosphamide
1030696|NCT01883323|Fludarabine
1030697|NCT01883310|Multiple Sclerosis
1030698|NCT01883310|transcranial direct current stimulation
1030699|NCT01883310|TOCT
1030700|NCT01883310|task-oriented circuit training
1030701|NCT01883310|locomotor function
1030702|NCT01883310|mobility
1030703|NCT01883310|balance
1030704|NCT01883297|Measurable
1030705|NCT01883297|Recurrent
1030706|NCT01883297|Platinum resistant
1030707|NCT01883297|Tumor-Infiltrating Lymphocytes
1030708|NCT01883297|Low-Dose Interleukin-2
1030709|NCT01883297|Autologous dendritic cells
1030710|NCT01883297|Anti-CD3 monoclonal antibody
1030711|NCT01883297|High grade serous ovarian, fallopian tube, or primary peritoneal cancer
1030712|NCT01883297|Cyclophosphamide
1030713|NCT01883284|Cystic Fibrosis
1030714|NCT01883284|nasal epithelia
1030715|NCT01883284|mucins
1030716|NCT01883245|Orofacial chronic pain
1030717|NCT01883245|tDCS
1030718|NCT01883245|Transcranial direct current stimulation
1030719|NCT01883245|Brain stimulation
1030720|NCT01883219|Philadelphia chromosome
1030721|NCT01883219|Acute lymphoblastic leukemia
1030722|NCT01883219|Allogeneic hematopoietic cell transplantation
1030723|NCT01883219|Minimal residual disease
1030724|NCT01883219|Tyrosine kinase inhibitor
1030725|NCT01883206|Cytomegalovirus
1030726|NCT01883193|preconception maternal nutrition
1030727|NCT01883193|LBW
1030728|NCT01883193|Length-for-age
1030729|NCT01883193|maternal nutrition supplement
1030730|NCT01883193|multi-micronutrient fortified lipid-based supplement
1030731|NCT01883193|infant growth
1030732|NCT01883193|low-resource settings
1030733|NCT01883180|haploidentical hematopoietic Stem Cell Transplantation
1030734|NCT01883180|Antithymocyte globulin
1030735|NCT01883180|viral infection
1030736|NCT01883128|Biochemical Failure
1030737|NCT01883128|Radiotherapy
1030738|NCT01883128|Radiorecurrent Prostate Cancer
1030739|NCT01883128|MRI Prostate
1030740|NCT01883128|Whole Body MRI
1030741|NCT01883128|Bone Scan
1030742|NCT01883128|Choline PET
1030743|NCT01883128|Focal Salvage Treatment
1030744|NCT01883128|HIFU
1030745|NCT01883128|Cryotherapy
1030746|NCT01883115|Telescopic extraperitoneal dissection
1030747|NCT01883115|Single incision laparosocpic surgery
1030748|NCT01883115|Inguinal hernia
1030749|NCT01883115|Triport system
1030750|NCT01883076|Hypoplastic Left Heart Syndrome
1030751|NCT01883076|HLHS
1030752|NCT01883076|Congenital Heart Disease
1030753|NCT01883076|Umbilical cord blood
1030754|NCT01883076|UCB
1030755|NCT01883076|Cord blood
1030756|NCT01883076|Stem cells
1030757|NCT01883076|Regenerative therapy
1030758|NCT01883076|Stage II Glenn
1030759|NCT01883076|Glenn Surgery
1030760|NCT01883050|Coronary artery disease
1030761|NCT01883050|Percutaneous Intervention
1030762|NCT01883050|Stent
1030763|NCT01883050|Balloon angioplasty
1030764|NCT01883050|Angiogram
1030765|NCT01883050|Coronary angiogram
1030766|NCT01883037|Cystic Fibrosis
1030767|NCT01883037|Cystic Fibrosis related diabetes
1030768|NCT01883037|Oral glucose tolerance test
1030769|NCT01883024|Real time continuous glucose monitoring, decision support software, smartphone application.
1030770|NCT01883011|Piracetam
1030771|NCT01883011|Stroke
1030772|NCT01883011|Aphasia
1030773|NCT01883011|Acute
1030774|NCT01883011|Cerebral
1030775|NCT01883011|Ischemic
1030776|NCT01883011|Nootropil
1030777|NCT01882998|HIV and pregnancy
1030778|NCT01882998|HIV and breastfeeding
1030779|NCT01882998|Mother-to-child transmission of HIV
1030780|NCT01882998|Africa
1030781|NCT01882998|Uganda
1030782|NCT01882985|docetaxel
1030783|NCT01882985|lycopene
1030784|NCT01882985|prostate cancer
1030785|NCT01882933|Gastric adenocarcinoma
1030786|NCT01882933|HIPEC
1030787|NCT01882933|Oxaliplatin
1030788|NCT01882933|Signet ring cell
1030789|NCT01882920|Cytoreductive surgery
1030790|NCT01882920|hyperthermic intraperitoneal chemotherapy
1030791|NCT01882920|Goal directed fluid therapy
1030792|NCT01882907|vildagliptin
1030793|NCT01882907|metformin
1030794|NCT01882894|Plantar fasciitis, orthotic, functional outcome
1030795|NCT01882842|Infertility
1030796|NCT01882842|Endometrium
1030797|NCT01882842|Live birth
1030798|NCT01882829|depression
1030799|NCT01882829|major depressive disorder
1030800|NCT01882829|treatment resistant
1030801|NCT01882829|Nuedexta
1030802|NCT01882829|dextromethorphan
1030803|NCT01882829|antidepressant
1030804|NCT01882829|glutamate
1030805|NCT01882829|NMDA receptor
1030806|NCT01882816|non-anaplastic
1030807|NCT01882816|non-medullary
1030808|NCT01882816|radiation
1030809|NCT01882816|IMRT
1030810|NCT01882816|Doxorubicin
1030811|NCT01882816|13-070
1030812|NCT01882803|PI3K Inhibitor
1030813|NCT01882790|coronary artery spasm
1030814|NCT01882790|hypertension
1030815|NCT01882790|Pathophysiology
1030816|NCT01882790|atrioventricular block
1030817|NCT01882790|blood pressure
1030818|NCT01882790|autonomic nervous function
1030819|NCT01882751|kinematics
1030820|NCT01882751|knee joint
1030821|NCT01882738|Cervical length
1030822|NCT01882738|BMI
1030823|NCT01882699|Insomnia
1030824|NCT01882686|Pain
1030825|NCT01882686|Back Pain
1030826|NCT01882686|Low Back Pain
1030827|NCT01882686|Chronic Low Back Pain
1030828|NCT01882686|Cognitive Functional Therapy
1030829|NCT01882686|Intervention
1030830|NCT01882686|Subclassification
1030831|NCT01882686|Multidimensional
1030832|NCT01882673|Tobacco
1030833|NCT01882673|nicotine
1030834|NCT01882673|dependence
1030835|NCT01882673|quitline
1030836|NCT01882647|psoriasis
1030837|NCT01882647|lotion
1030838|NCT01882647|investigator's global assessment
1030839|NCT01882621|NSCLC
1030840|NCT01882621|Monosialoganglioside(GM1)
1030841|NCT01882621|neurotoxicity
1030842|NCT01882608|psychiatry
1030843|NCT01882608|mental health
1030844|NCT01882608|mood disorders
1030845|NCT01882608|mood diaries
1030846|NCT01882608|electronic diaries
1030847|NCT01882608|cell phones
1030848|NCT01882608|software
1030849|NCT01882608|mental health telemetry
1030850|NCT01882608|ecological momentary assessment
1030851|NCT01882595|Nebulization aerosol nebulizer tracheostomy
1030852|NCT01882556|Early treatment of spasticity.
1030853|NCT01882556|Post stroke spasticity.
1030854|NCT01882543|Interstitial cystitis
1030855|NCT01882543|Bladder pain syndrome
1030856|NCT01882543|IC/BPS
1030857|NCT01882543|AQX-1125
1030858|NCT01882543|SHIP1
1030859|NCT01882530|Post operative analgesia ;
1030860|NCT01882530|Paracetamol ;
1030861|NCT01882530|Ketoprofen ;
1030862|NCT01882530|Nefopam ;
1030863|NCT01882530|Morphine
1030864|NCT01882504|Pyoderma Gangrenosum
1030865|NCT01882504|Classic Pyoderma Gangrenosum
1030866|NCT01882504|Atypical Pyoderma Gangrenosum
1030867|NCT01882504|Peristomal Pyoderma Gangrenosum
1030868|NCT01882491|Erosive Osteoarthritis
1030869|NCT01882491|Osteoarthritis
1030870|NCT01882491|Osteoarthritis of the Hand
1030871|NCT01882478|Barrett's esophagus
1030872|NCT01882478|Early esophageal adenocarcinoma
1030873|NCT01882478|Radio Frequency Ablation
1030874|NCT01882478|Cryotherapy
1030875|NCT01882452|Memory specificity training
1030876|NCT01882452|Autobiographical memory
1030877|NCT01882452|Major depressive disorder
1030878|NCT01882439|psoriatic arthritis
1030879|NCT01882439|tofacitinib
1030880|NCT01882439|ACR20
1030881|NCT01882439|HAQ-DI
1030882|NCT01882439|TNF inhibitor failure
1030883|NCT01882426|CONSTRUCT
1030884|NCT01882426|Cluster randomization controlled trial
1030885|NCT01882426|Gastroenterology practices in North America
1030886|NCT01882400|Osteoporosis
1030887|NCT01882400|Severe muscular dystrophy
1030888|NCT01882400|Cystic fibrosis
1030889|NCT01882387|Allogeneic Peripheral Blood Stem Cell Transplantation
1030890|NCT01882387|Graft-vs-Host Disease
1030891|NCT01882387|Neutrophil Engraftment
1030892|NCT01882387|Platelet Engraftment
1030893|NCT01882387|Immune Reconstitution
1030894|NCT01882387|Mucositis
1030895|NCT01882374|Double Umbilical Cord Blood Transplantation
1030896|NCT01882374|Acute Graft versus Host Disease
1030897|NCT01882374|Neutrophil Engraftment
1030898|NCT01882374|Platelet Recovery
1030899|NCT01882374|Immune Reconstitution
1030900|NCT01882374|Mucositis
1030901|NCT01882361|opioid addiction
1030902|NCT01882361|opioid treatment
1030903|NCT01882361|naloxone
1030904|NCT01882348|tobacco control, tobacco treatment, pediatrics, parents
1030905|NCT01882335|Human capital formation
1030906|NCT01882322|FK506
1030907|NCT01882322|tacrolimus
1030908|NCT01882322|immunosuppressant
1030909|NCT01882283|serum lipids
1030910|NCT01882283|cholesterol
1030911|NCT01882283|serum cholesterol
1030912|NCT01882283|black tea
1030913|NCT01882283|flavonoids
1030914|NCT01882283|crossover trial
1030915|NCT01882283|randomized control trial
1030916|NCT01882283|diet controlled
1030917|NCT01882270|pericoronitis
1030918|NCT01882270|periodontal
1030919|NCT01882257|obstructive sleep apnea
1030920|NCT01882257|sleep-disordered breathing
1030921|NCT01882257|hypercapnia
1030922|NCT01882257|spinal cord injury
1030923|NCT01882244|traumatic brain injury
1030924|NCT01882244|cognition
1030925|NCT01882244|rehabilitation
1030926|NCT01882244|attentional regulation
1030927|NCT01882244|working memory
1030928|NCT01882231|Osteosarcoma
1030929|NCT01882231|Ewing sarcoma
1030930|NCT01882231|Paget's disease
1030931|NCT01882231|bone cancer
1030932|NCT01882231|childhood cancers
1030933|NCT01882231|DCE MRI
1030934|NCT01882231|DW MRI
1030935|NCT01882231|CEST MRI
1030936|NCT01882231|MT MRI
1030937|NCT01882218|Liver cancer
1030938|NCT01882205|Ulcerative colitis
1030939|NCT01882205|DALM
1030940|NCT01882205|chromoendoscopy
1030941|NCT01882205|dysplasia
1030942|NCT01882205|virtual chromoendoscopy
1030943|NCT01882205|FICE
1030944|NCT01882205|NBI
1030945|NCT01882205|I-scan
1030946|NCT01882192|family
1030947|NCT01882192|physical activity
1030948|NCT01882192|planning
1030949|NCT01882179|Reperfusion injury
1030950|NCT01882179|myocardial infarct size
1030951|NCT01882179|MRI
1030952|NCT01882179|spironolactone
1030953|NCT01882166|Fertilization in Vitro
1030954|NCT01882166|Sperm Injections, Intracytoplasmic
1030955|NCT01882166|Follicle Stimulating Hormone
1030956|NCT01882166|Embryonic Development
1030957|NCT01882140|burns
1030958|NCT01882140|wound healing
1030959|NCT01882140|magnetic field therapy
1030960|NCT01882127|Purpura
1030961|NCT01882127|Idiopathic Thrombocytopenic Purpura
1030962|NCT01882101|Fecal incontinence
1030963|NCT01882101|posterior tibial nerve stimulation
1030964|NCT01882101|biofeedback
1030965|NCT01882101|quality of life
1030966|NCT01882075|Anesthesia
1030967|NCT01882075|Fluid administration
1030968|NCT01882075|Closed-loop
1030969|NCT01882023|EDNOS
1030970|NCT01882023|adolescents
1030971|NCT01882010|Parkinson's disease
1030972|NCT01882010|motor function
1030973|NCT01882010|immune activation
1030974|NCT01882010|T cells
1030975|NCT01882010|CD4
1030976|NCT01882010|GMCSF
1030977|NCT01882010|leukine
1030978|NCT01882010|sargramostim
1030979|NCT01882010|magnetoencephalography
1030980|NCT01881997|Procedure
1030981|NCT01881997|Abscess
1030982|NCT01881997|Emergency Department
1030983|NCT01881997|Opioid
1030984|NCT01881997|Fentanyl
1030985|NCT01881984|Medium-chain acyl-CoA dehydrogenase deficiency
1030986|NCT01881984|MCAD deficiency
1030987|NCT01881984|MCADD
1030988|NCT01881984|ACADM deficiency
1030989|NCT01881984|MCADH deficiency
1030990|NCT01881984|985A>G mutation
1030991|NCT01881984|K304E mutation
1030992|NCT01881984|Ravicti
1030993|NCT01881984|glycerol phenylbutyrate
1030994|NCT01881971|HIV
1030995|NCT01881971|lung
1030996|NCT01881971|lipids
1030997|NCT01881971|no lipid lowering medication
1030998|NCT01881971|normal liver and kidney function
1030999|NCT01881971|on stable ART regimen
1031000|NCT01881971|not pregnant
1031001|NCT01881945|Swallowing
1031002|NCT01881945|Hyperventilation
1031003|NCT01881932|acupuncture therapy
1031004|NCT01881932|sham acupuncture therapy
1031005|NCT01881932|chemotherapy-induced peripheral neuropathy (CIPN)
1031006|NCT01881919|Functional Food
1031007|NCT01881906|aerobic exercise
1031008|NCT01881906|Lung cancer
1031009|NCT01881906|psyco-social
1031010|NCT01881893|Quality of life
1031011|NCT01881893|Psychosocial Support Systems
1031012|NCT01881893|Randomized Controls as Topic
1031013|NCT01881893|Cognitive Therapy
1031014|NCT01881893|Feasibility Studies
1031015|NCT01881880|Tomosynthesis
1031016|NCT01881880|Mammography
1031017|NCT01881880|Breast cancer
1031018|NCT01881841|Alcohol abuse
1031019|NCT01881841|Substance use
1031020|NCT01881841|Tobacco use disorder
1031021|NCT01881841|Motivational Enhancement Therapy
1031022|NCT01881841|Adolescents
1031023|NCT01881815|Chronic wounds with different etiologies
1031024|NCT01881815|Diabetic foot ulcers
1031025|NCT01881815|venous leg ulcers
1031026|NCT01881815|pressure sores
1031027|NCT01881815|acute wounds
1031028|NCT01881802|Opioid drug Abuse
1031029|NCT01881802|Morphine
1031030|NCT01881802|Immune Function
1031035|NCT01881776|Single injection interscalene brachial plexus block
1031036|NCT01881776|Continuous interscalene brachial plexus block
1031037|NCT01881776|General anesthesia
1031038|NCT01881776|Postoperative pain
1031039|NCT01881776|Recovery profile
1031040|NCT01881763|Electroconvulsive Therapy
1031041|NCT01881763|Ketamine
1031042|NCT01881763|anesthesia
1031043|NCT01881763|depression
1031044|NCT01881763|unipolar
1031045|NCT01881763|bipolar
1031046|NCT01881750|Autism PRT
1031047|NCT01881737|autism
1031048|NCT01881711|hydrocephalus
1031049|NCT01881711|CSF shunt
1031050|NCT01881711|shunt malfunction
1031051|NCT01881711|shunt obstruction
1031052|NCT01881711|ShuntCheck
1031053|NCT01881711|ShuntCheck-Micro-Pumper
1031054|NCT01881698|pregnancy
1031055|NCT01881698|platelet function
1031056|NCT01881698|monitoring
1031057|NCT01881698|multiple electrode aggregometry
1031058|NCT01881672|Aspiration pneumonia
1031059|NCT01881672|Coma
1031060|NCT01881672|Mechanical ventilation
1031061|NCT01881659|cervical cancer
1031062|NCT01881659|cancer prevention
1031063|NCT01881659|cervical screening
1031064|NCT01881659|HPV testing
1031065|NCT01881659|triage techniques
1031066|NCT01881646|Neuroinflammation
1031067|NCT01881646|Postoperative cognitive dysfunction
1031068|NCT01881633|gaucher disease, imiglucerase, ISU302
1031069|NCT01881620|PET scan
1031070|NCT01881620|CT scan
1031071|NCT01881620|Diagnostic performance
1031072|NCT01881607|tobacco smoke pollution
1031073|NCT01881607|Tobacco use
1031074|NCT01881594|ileostomy closure,postoperative ileus,stimulation ileostomy
1031075|NCT01881581|Therapeutic
1031076|NCT01881581|Vaccine
1031077|NCT01881581|HIV
1031078|NCT01881581|MVA
1031079|NCT01881581|DNA
1031080|NCT01881568|Total Knee Arthroplasty, TKA, blood loss
1031081|NCT01881555|fractional flow reserve
1031082|NCT01881555|multivessel coronary artery disease
1031083|NCT01881555|angiography
1031084|NCT01881542|preeclampsia
1031085|NCT01881542|proteinuria
1031086|NCT01881542|urine collection
1031087|NCT01881529|limited scleroderma
1031088|NCT01881529|diffuse scleroderma
1031089|NCT01881529|Sclerosis
1031090|NCT01881529|Progressive
1031091|NCT01881529|Limited
1031092|NCT01881503|life-threatening anemia
1031093|NCT01881503|blood alternative
1031094|NCT01881503|HBOC
1031095|NCT01881490|Crohn's Disease
1031096|NCT01881490|MRE
1031097|NCT01881490|Pelvic MRI
1031098|NCT01881490|P-MRI
1031099|NCT01881490|colonoscopy
1031100|NCT01881490|gastroscopy
1031101|NCT01881477|immobilization
1031102|NCT01881477|physical therapy
1031103|NCT01881477|intensive care
1031104|NCT01881477|bed rest
1031105|NCT01881477|movement
1031106|NCT01881451|Tumour hypoxia
1031107|NCT01881451|Clear Cell Ovarian Cancer
1031108|NCT01881451|Recurrent
1031109|NCT01881451|Metastatic
1031110|NCT01881438|Retinal Detachment
1031111|NCT01881438|Fluoroquinolones
1031112|NCT01881438|Ciprofloxacin
1031113|NCT01881438|Levofloxacin
1031114|NCT01881438|Gatifloxacin
1031115|NCT01881438|Gemifloxacin
1031116|NCT01881438|Moxifloxacin
1031117|NCT01881438|Norfloxacin
1031118|NCT01881438|Ofloxacin
1031119|NCT01881438|Beta-Lactam
1031120|NCT01881425|POAG
1031121|NCT01881412|Asthma
1031122|NCT01881412|Children
1031123|NCT01881412|Inhaled Corticosteroids
1031124|NCT01881412|Emergency Department
1031125|NCT01881399|Cholelithiasis
1031126|NCT01881399|Gallbladder polyps
1031127|NCT01881399|Fluorescence
1031128|NCT01881399|Indocyanine green (ICG)
1031129|NCT01881399|Intraoperative cholangiography (IOC)
1031130|NCT01881399|da Vinci surgical system
1031131|NCT01881386|Magnetic Resonance Spectroscopy
1031132|NCT01881386|Lactate
1031133|NCT01881373|Obesity
1031134|NCT01881373|Child
1031135|NCT01881373|Food
1031136|NCT01881373|Physical Activity
1031137|NCT01881373|Pacific
1031138|NCT01881360|fibromyalgia
1031139|NCT01881360|celiac-type symptoms
1031140|NCT01881360|gluten-free diet
1031141|NCT01881360|hypocaloric diet
1031142|NCT01881347|endothelium
1031143|NCT01881347|mitochondria
1031144|NCT01881347|reactive oxygen species
1031145|NCT01881347|vascular biology
1031146|NCT01881347|arterial stiffness
1031147|NCT01881347|nitric oxide
1031148|NCT01881334|Haploidentical Donor
1031149|NCT01881334|T-cell depleted Stem Cells
1031150|NCT01881334|Allogeneic Transplant
1031151|NCT01881334|Umbilical Cord Blood Donor
1031152|NCT01881334|High Risk Malignancies
1031153|NCT01881334|Metabolic Disorders
1031154|NCT01881334|Immune Deficiency
1031155|NCT01881334|Acute Lymphoblastic Leukemia
1031156|NCT01881334|Acute Myelogenous Leukemia
1031157|NCT01881334|Myelodysplastic Syndrome
1031158|NCT01881334|ALL
1031159|NCT01881334|AML
1031160|NCT01881334|MDS
1031161|NCT01881334|CGD
1031162|NCT01881334|SCID
1031163|NCT01881334|Adrenoleukodystrophy
1031164|NCT01881334|Metachromaticleukodystrophy
1031165|NCT01881334|Krabbe
1031166|NCT01881334|PMD
1031167|NCT01881334|Hunter's
1031168|NCT01881334|Hurler's
1031169|NCT01881334|Severe Aplastic Anemia
1031170|NCT01881334|Lymphoma
1031171|NCT01881334|Sickle Cell Disease
1031172|NCT01881334|Thalassemia
1031173|NCT01881321|Contraception
1031174|NCT01881321|Counseling
1031175|NCT01881295|Potassium
1031176|NCT01881295|Potato
1031177|NCT01881295|French Fries
1031178|NCT01881295|Bioavailability
1031179|NCT01881295|Blood Pressure
1031180|NCT01881282|Hemorrhoids
1031181|NCT01881282|Carraghenates
1031182|NCT01881282|Mayinglong Musk
1031183|NCT01881282|Titanoreine
1031184|NCT01881256|Preterm birth
1031185|NCT01881256|Parenteral and enteral nutrition
1031186|NCT01881256|Body composition in preterm infants
1031187|NCT01881243|Cardiac Arrest, Hyperoxia, Ischemia-reperfusion Injury, Reactive Oxygen Species, Oxidative Stress, Neuropsychological Tests
1031188|NCT01881230|Breast Cancer
1031189|NCT01881230|Cancer of the Breast
1031190|NCT01881230|Metastatic Breast Cancer
1031191|NCT01881230|Metastatic Triple Negative Breast Cancer
1031192|NCT01881230|Triple Negative Breast Cancer
1031193|NCT01881230|Triple Negative Metastatic Breast Cancer
1031194|NCT01881230|Basal-like breast cancer
1031195|NCT01881230|Hormone receptor negative breast cancer
1031196|NCT01881230|Estrogen receptor negative breast cancer
1031197|NCT01881230|Progesterone negative receptor breast cancer
1031198|NCT01881230|HER2 Negative Breast Cancer
1031199|NCT01881230|Abraxane
1031200|NCT01881230|nab-Paclitaxel
1031201|NCT01881230|ABI-007
1031202|NCT01881230|gemcitabine
1031203|NCT01881230|Gemzar
1031204|NCT01881230|carboplatin
1031205|NCT01881230|Paraplatin
1031206|NCT01881230|Paraplatin AQ
1031207|NCT01881230|Phase 2
1031208|NCT01881230|Phase 3
1031209|NCT01881217|Phase I
1031210|NCT01881217|Dose escalation
1031211|NCT01881217|Advanced, refractory solid tumors
1031212|NCT01881217|FGFR2
1031213|NCT01881204|Hesperidin
1031214|NCT01881204|Osteoporosis
1031215|NCT01881204|Bone Loss
1031216|NCT01881191|multiple sclerosis
1031217|NCT01881191|relapsing remitting
1031218|NCT01881191|MRI
1031219|NCT01881191|teriflunomide
1031220|NCT01881191|aubagio
1031221|NCT01881191|gray matter atrophy
1031222|NCT01881191|gray matter pathology
1031223|NCT01881178|CRP
1031224|NCT01881178|Nopalea
1031225|NCT01881178|Fruit
1031226|NCT01881178|Juice
1031227|NCT01881152|Stroke
1031228|NCT01881152|Community education
1031229|NCT01881152|Awareness
1031230|NCT01881152|Prehospital delay
1031231|NCT01881139|Exercise
1031232|NCT01881139|Lipid
1031233|NCT01881139|Left ventricular
1031234|NCT01881139|heart function
1031235|NCT01881100|resin infiltration
1031236|NCT01881100|randomized clinical trial
1031237|NCT01881100|fluoride varnish
1031238|NCT01881100|caries lesion
1031239|NCT01881100|deciduous teeth
1031240|NCT01881087|Knee Arthroscopy
1031241|NCT01881087|Levobupivacaine
1031242|NCT01881087|Spinal Anesthesia
1031243|NCT01881087|Motor Block
1031244|NCT01881074|Type II Diabetes
1031245|NCT01881074|Periodontal Disease
1031246|NCT01881074|Periodontitis
1031247|NCT01881074|Gum Disease
1031248|NCT01881074|Gingivitis
1031249|NCT01881074|Triclosan
1031250|NCT01881074|Inflammatory Markers
1031251|NCT01881074|Immune Response
1031252|NCT01881061|Sonography
1031253|NCT01881061|ICU
1031254|NCT01881061|PEEP
1031255|NCT01881048|Breast cancer
1031256|NCT01881048|Omega-3 Fatty Acid
1031257|NCT01881048|Celecoxib
1031258|NCT01881048|Celebrex
1031259|NCT01881048|Surgery
1031260|NCT01881035|Hypertension
1031261|NCT01881035|End stage renal disease
1031262|NCT01881022|Breast Cancer
1031263|NCT01881022|Couples
1031264|NCT01881022|Sexual Dysfunction
1031265|NCT01881022|Psychosexual Intervention
1031266|NCT01881022|Sex Therapy
1031267|NCT01881022|Online Support
1031268|NCT01881022|e-health
1031269|NCT01881009|Diabetes
1031270|NCT01881009|Insulin
1031271|NCT01881009|Closed loop
1031272|NCT01881009|Nocturnal glucose control
1031273|NCT01880996|Ovarian Cancer
1031274|NCT01880996|Gynecological Malignancies
1031275|NCT01880996|Chemotherapy
1031276|NCT01880996|Tai-chi
1031277|NCT01880996|Qigong
1031278|NCT01880996|Fatigue
1031279|NCT01880996|Quality of life
1031280|NCT01880996|Sleep disturbance
1031281|NCT01880983|EPP
1031282|NCT01880983|Bloomer
1031283|NCT01880983|Porphyria
1031284|NCT01880957|bipolar disorder
1031285|NCT01880957|bipolar depression
1031286|NCT01880957|serotonin transporter
1031287|NCT01880957|serotonin receptors
1031288|NCT01880957|binding potential
1031289|NCT01880957|brain imaging
1031290|NCT01880957|unipolar depression
1031291|NCT01880944|spine
1031292|NCT01880944|trauma
1031293|NCT01880944|MRI
1031294|NCT01880944|contrast
1031295|NCT01880918|Compression Anastomosis
1031296|NCT01880905|the length of uterine ovarian ligament
1031297|NCT01880879|coronary artery disease
1031298|NCT01880879|PCI
1031299|NCT01880879|stent
1031300|NCT01880866|PAH
1031301|NCT01880853|breast cancer
1031302|NCT01880853|screening
1031303|NCT01880853|mammography
1031304|NCT01880853|ultrasound
1031305|NCT01880827|GIP
1031306|NCT01880827|GLP-1
1031307|NCT01880827|type 2 diabetes
1031308|NCT01880827|obesity
1031309|NCT01880827|splanchnic blood flow
1031310|NCT01880827|incretin hormones
1031311|NCT01880814|Depression, child, cognitive behavioral treatment, parent training, personalized treatment
1031312|NCT01880801|ITP
1031313|NCT01880788|Age Related Macular Degeneration
1031314|NCT01880788|Choroidal Neovascularization
1031315|NCT01880788|Central Serous Chorioretinopathy
1031316|NCT01880762|PET MR development and validation
1031317|NCT01880723|exhaled breath condensate
1031318|NCT01880723|diffusion capacity of the lungs for carbon monoxide and nitric oxide
1031319|NCT01880723|albuterol
1031320|NCT01880723|peripheral oxygen saturation
1031321|NCT01880723|ion regulation
1031322|NCT01880710|long term follow-up
1031323|NCT01880710|urinary incontinence
1031324|NCT01880710|pelvic organ prolapse
1031325|NCT01880710|total versus subtotal hysterectomy
1031326|NCT01880697|Influenza
1031327|NCT01880697|adults
1031328|NCT01880697|elderly
1031329|NCT01880697|immunology
1031330|NCT01880697|safety
1031331|NCT01880684|Thermodilution
1031332|NCT01880684|Blood Volume
1031333|NCT01880684|Cardiac Output
1031334|NCT01880684|Leg
1031335|NCT01880684|Capnography
1031336|NCT01880684|Blood Pressure
1031337|NCT01880658|Maintenance therapy
1031338|NCT01880658|Capecitabine
1031339|NCT01880658|Adjuvant chemotherapy
1031340|NCT01880658|Post-operation
1031341|NCT01880645|Breast Cancer
1031342|NCT01880645|Invasive breast cancer
1031343|NCT01880645|Axillary lymph node metastases
1031344|NCT01880645|Ultrasound
1031345|NCT01880645|Fine needle aspiration
1031346|NCT01880645|FNA
1031347|NCT01880645|Lymph node surgery
1031348|NCT01880645|Partial mastectomy
1031349|NCT01880645|Total mastectomy
1031350|NCT01880632|XELOX
1031351|NCT01880632|perioperative treatment
1031352|NCT01880632|locally advanced gastric adenocarcinoma
1031353|NCT01880632|D2 resection
1031354|NCT01880619|Double J
1031355|NCT01880619|Ureteral stents
1031356|NCT01880619|Symptoms
1031357|NCT01880619|Alpha blockers
1031358|NCT01880619|Anticholinergic
1031359|NCT01880593|Ketamine
1031360|NCT01880593|glutamate
1031361|NCT01880593|N-methyl-D-aspartate
1031362|NCT01880593|depression
1031363|NCT01880593|major depressive disorder
1031364|NCT01880593|treatment resistant
1031365|NCT01880593|antidepressant
1031366|NCT01880593|lithium
1031367|NCT01880567|Lymphoma
1031368|NCT01880567|Relapsed/Refractory Mantle Cell Lymphoma
1031369|NCT01880567|R/R MCL
1031370|NCT01880567|Ibrutinib
1031371|NCT01880567|PCI-32765
1031372|NCT01880567|Rituximab
1031373|NCT01880567|Rituxan
1031374|NCT01880567|Newly-Diagnosed Untreated Mantle Cell Lymphoma
1031375|NCT01880567|MCL
1031376|NCT01880554|Liver metastases
1031377|NCT01880554|Colorectal primary cancer
1031378|NCT01880554|Contrast-enhanced ultrasound
1031379|NCT01880554|Sonovue®
1031380|NCT01880541|Patients with breast cancer and breast surgery requiring
1031381|NCT01880515|Lung cancer
1031382|NCT01880515|BIBW 2992
1031383|NCT01880515|Skin Rash
1031384|NCT01880515|Tetracycline
1031385|NCT01880515|Afatinib
1031386|NCT01880502|Healthy, Volunteers
1031387|NCT01880489|transgender women
1031388|NCT01880489|sexual risk
1031389|NCT01880489|substance use
1031390|NCT01880489|HIV prevention
1031391|NCT01880489|behavioral intervention
1031392|NCT01880476|Diabetes Mellitus, Type 2
1031393|NCT01880476|Comorbidity
1031394|NCT01880476|Aged
1031395|NCT01880476|Health Services
1031396|NCT01880463|Dry eye disease
1031397|NCT01880463|incidence
1031398|NCT01880463|progression
1031399|NCT01880411|PEK fusion protein Healthbanks
1031400|NCT01880398|FIstula in ano; Bhagandar
1031401|NCT01880385|bevacizumab
1031402|NCT01880385|inflammatory breast cancer
1031403|NCT01880385|non metastatic
1031404|NCT01880385|Avastin
1031405|NCT01880372|Diabetes
1031406|NCT01880372|Diabetic Retinopathy
1031407|NCT01880372|Retinopathy
1031408|NCT01880372|Free radical
1031409|NCT01880372|Retinal diseases
1031410|NCT01880372|Antioxidants
1031411|NCT01880372|Protective agents
1031412|NCT01880372|Thioctic acid
1031413|NCT01880346|Cystic Fibrosis
1031414|NCT01880346|Vitamin D
1031415|NCT01880346|absorption
1031416|NCT01880346|vitamin Deficiency
1031417|NCT01880346|fat soluble
1031418|NCT01880333|Refractory epilepsy
1031419|NCT01880333|dietary therapy
1031420|NCT01880333|non-pharmacological therapy
1031421|NCT01880333|Modified Atkin Diet
1031422|NCT01880307|Crohn's disease
1031423|NCT01880307|pediatric
1031424|NCT01880307|infliximab
1031425|NCT01880307|top-down
1031426|NCT01880307|ITSKids
1031427|NCT01880294|Constipation
1031428|NCT01880294|Chronic constipation
1031429|NCT01880294|Asia-Pacific
1031430|NCT01880294|Gastroentrology
1031431|NCT01880294|Asian participants
1031432|NCT01880281|G protein-coupled receptor 99 (GPR99)
1031433|NCT01880281|2-oxoglutarate receptor 1 (OXGR1)
1031434|NCT01880281|alpha-ketoglutarate
1031435|NCT01880281|urine
1031436|NCT01880281|pH
1031437|NCT01880281|acidosis
1031438|NCT01880281|alkalosis
1031439|NCT01880281|Healthy volunteers
1031440|NCT01880255|Repetitive Transcranial Magnetic Stimulation
1031441|NCT01880255|Schizophrenia
1031442|NCT01880255|Cognition
1031443|NCT01880255|Working Memory
1031444|NCT01880242|International
1031445|NCT01880242|Multicenter
1031446|NCT01880242|Observational registry
1031447|NCT01880242|Orsiro Drug Eluting Stent (DES)
1031448|NCT01880242|Stenting
1031449|NCT01880242|Treatment of Coronary Artery Disease
1031450|NCT01880242|Coronary revascularization
1031451|NCT01880242|Percutaneous Coronary Intervention (PCI)
1031452|NCT01880242|STEMI
1031453|NCT01880242|NSTEMI
1031454|NCT01880242|Ischemia
1031455|NCT01880242|Angina
1031456|NCT01880242|Subgroups
1031457|NCT01880242|Acute Myocardial Infarction
1031458|NCT01880242|Diabetes
1031459|NCT01880242|Small Vessels
1031460|NCT01880242|Chronic Total Occlusion (CTO)
1031461|NCT01880216|Deep vein thrombosis
1031462|NCT01880216|DVT
1031463|NCT01880216|Treatment
1031464|NCT01880216|Low molecular weight heparin
1031465|NCT01880216|Bemiparin
1031466|NCT01880216|Enoxaparin
1031467|NCT01880203|thyroid
1031468|NCT01880203|elastography SWE
1031469|NCT01880203|indeterminate cytology
1031470|NCT01880164|Scoliosis
1031471|NCT01880164|Kyphosis
1031472|NCT01880164|Sagittal plane deformity
1031473|NCT01880151|Alzheimer's disease
1031474|NCT01880151|Dementia
1031475|NCT01880151|Prodromal
1031476|NCT01880151|EEG
1031477|NCT01880151|ERP
1031478|NCT01880151|Biomarkers
1031479|NCT01880138|Animated cartoon, Emergence agitation
1031480|NCT01880125|Tramadol
1031481|NCT01880125|Acetaminophen
1031482|NCT01880125|Pharmacokinetics
1031483|NCT01880125|Sustained release
1031484|NCT01880125|Immediate release
1031485|NCT01880112|Infection
1031486|NCT01880112|Cesarean delivery
1031487|NCT01880112|Antibiotic prophylaxis
1031488|NCT01880112|Cefazolin dosing
1031489|NCT01880099|addiction
1031490|NCT01880099|smoking
1031491|NCT01880099|tobacco
1031492|NCT01880099|cigarettes
1031493|NCT01880086|Chronic pain
1031494|NCT01880086|Low testosterone
1031495|NCT01880086|Hypogonadism
1031496|NCT01880086|Opioid analgesics
1031497|NCT01880086|Narcotics
1031498|NCT01880086|Opioid-induced androgen deficiency
1031499|NCT01880086|OPIAD
1031500|NCT01880086|Male infertility
1031501|NCT01880086|Clomiphene citrate
1031502|NCT01880086|Selective Estrogen Receptor Modulators
1031503|NCT01880086|Testosterone replacement therapy
1031504|NCT01880060|Worksite
1031505|NCT01880060|weight loss
1031506|NCT01880060|obesity
1031507|NCT01880047|Immune Thrombocytopenia
1031508|NCT01880047|ITP
1031509|NCT01880047|Eltrombopag
1031510|NCT01880047|Promacta
1031511|NCT01880008|positron emission tomography
1031512|NCT01880008|magnetic resonance imaging
1031513|NCT01880008|diffusion magnetic resonance imaging
1031514|NCT01880008|radionuclide imaging
1031515|NCT01880008|disease management
1031516|NCT01880008|radiation therapy
1031517|NCT01879982|Bipolar disorder
1031518|NCT01879982|subtypes
1031519|NCT01879969|computer-assisted orthognathic surgery; facial asymmetry
1031520|NCT01879956|Executive Functions
1031521|NCT01879956|Schizophrenia
1031522|NCT01879956|Occupational Therapy
1031523|NCT01879943|Colorectal cancer
1031524|NCT01879943|Follow up
1031525|NCT01879943|Colonoscopy
1031526|NCT01879943|Videocapsule
1031527|NCT01879930|randomized
1031528|NCT01879930|placebo-controlled
1031529|NCT01879930|double-blind study
1031530|NCT01879930|doxycycline
1031531|NCT01879917|c-peptide
1031532|NCT01879917|insulin
1031533|NCT01879917|hypoglycemia
1031534|NCT01879917|Newly onset
1031535|NCT01879917|Diabetes
1031536|NCT01879917|Type 1
1031537|NCT01879917|Beta cell
1031538|NCT01879917|Autoimmune
1031539|NCT01879917|Glucagon
1031540|NCT01879917|Meal test
1031541|NCT01879904|Colorectal Neoplasms
1031542|NCT01879891|Exercise Intensity
1031543|NCT01879891|Metabolism
1031544|NCT01879891|Insulin
1031545|NCT01879878|pancreatic adenocarcinoma
1031546|NCT01879878|broccoli sprouts
1031547|NCT01879878|sulforaphane
1031548|NCT01879878|palliative chemotherapy
1031549|NCT01879878|cancer stem cells
1031550|NCT01879865|PKPD
1031551|NCT01879865|Dexmedetomidine
1031552|NCT01879865|Auditory Stimulation
1031553|NCT01879865|Cardiac Output
1031554|NCT01879852|Quadriceps strength
1031555|NCT01879852|Knee
1031556|NCT01879852|Rehabilitation
1031557|NCT01879826|Aculaser
1031558|NCT01879826|Microlight ML830
1031559|NCT01879826|Kidney biopsy
1031560|NCT01879826|Pain
1031561|NCT01879826|Anxiety
1031562|NCT01879826|Sedation
1031563|NCT01879813|Memory
1031564|NCT01879813|Attention
1031565|NCT01879787|Stroke
1031566|NCT01879787|transcranial direct current stimulation
1031567|NCT01879787|constraint-induced movement therapy
1031568|NCT01879787|mental practice
1031569|NCT01879774|Hyponatremia
1031570|NCT01879761|Immunosuppressed
1031571|NCT01879761|Sepsis
1031572|NCT01879761|Staphylococcus Aureus
1031573|NCT01879761|Bacteremia
1031574|NCT01879761|HLA-DR
1031575|NCT01879748|Parkinson's disease
1031576|NCT01879748|Azilect
1031577|NCT01879748|rasagiline mesylate
1031578|NCT01879722|Drug therapy
1031579|NCT01879709|schizophrenia
1031580|NCT01879709|Cognition
1031581|NCT01879709|Independent living skills
1031582|NCT01879683|Hunner's lesion
1031583|NCT01879644|ADHD
1031584|NCT01879644|Neurofeedback
1031585|NCT01879644|Self-Management
1031586|NCT01879644|Parental Psychoeducation
1031587|NCT01879644|Social Support
1031588|NCT01879631|radial keratotomy; keratoconus; optical rehabilitation
1031589|NCT01879618|Fragmin
1031590|NCT01879618|dalteparin
1031591|NCT01879618|hemodialysis
1031592|NCT01879618|anticoagulation
1031593|NCT01879618|Renal Failure
1031594|NCT01879605|Spinal surgery
1031595|NCT01879605|Bowel preparation
1031596|NCT01879605|Ileus
1031597|NCT01879605|Constipation
1031598|NCT01879605|Well-being
1031599|NCT01879592|Sickle cell disease
1031600|NCT01879592|Asthma
1031601|NCT01879592|Metabolomics
1031602|NCT01879592|Gene expression
1031603|NCT01879579|Insulin
1031604|NCT01879579|Telemedicine
1031605|NCT01879553|Influenza,
1031606|NCT01879553|Adults,
1031607|NCT01879553|Elderly,
1031608|NCT01879553|Immunology,
1031609|NCT01879553|Safety
1031610|NCT01879540|Influenza,
1031611|NCT01879540|Elderly,
1031612|NCT01879540|Immunology,
1031613|NCT01879540|Safety
1031614|NCT01879514|IgA nephropathy
1031615|NCT01879514|Therapy of Chinese medicine
1031616|NCT01879501|Low vision
1031617|NCT01879501|Self management
1031618|NCT01879501|Randomized controlled trial
1031619|NCT01879501|Quality of life
1031620|NCT01879501|Self efficacy
1031621|NCT01879501|Effectiveness
1031622|NCT01879501|Chronic eye diseases management
1031623|NCT01879488|Aerosol
1031624|NCT01879488|Lung deposition
1031625|NCT01879488|Mechanical ventilation
1031626|NCT01879462|chronic hepatitis C (CHC)
1031627|NCT01879462|Hepatitis C virus (HCV)
1031628|NCT01879462|NS5B
1031629|NCT01879462|pharmacokinetics
1031630|NCT01879462|GSK2878175
1031631|NCT01879462|safety
1031632|NCT01879462|FTIH
1031633|NCT01879462|healthy subjects
1031634|NCT01879449|Spasticity
1031635|NCT01879449|Veterans
1031636|NCT01879449|Prevalence
1031637|NCT01879436|Pregnancy, Placenta, Cancer
1031638|NCT01879410|GSK573719
1031639|NCT01879410|lung function
1031640|NCT01879410|salmeterol (SAL)
1031641|NCT01879410|umeclidinium bromide (UMEC)
1031642|NCT01879410|GW642444
1031643|NCT01879410|Chronic obstructive pulmonary disease
1031644|NCT01879410|Novel Dry Powder Inhaler (NDPI)
1031645|NCT01879410|fluticasone propionate (FP)
1031646|NCT01879410|vilanterol (VI)
1031647|NCT01879397|atherosclerosis
1031648|NCT01879397|arteriosclerosis
1031649|NCT01879397|carotid stenosis
1031650|NCT01879397|carotid endarterectomy
1031651|NCT01879397|Stroke
1031652|NCT01879384|microdialysis
1031653|NCT01879384|bone free flap
1031654|NCT01879384|head and neck
1031655|NCT01879384|monitoring free flap
1031656|NCT01879384|reconstructive surgery
1031657|NCT01879358|Drug-eluting stent
1031658|NCT01879358|Safety
1031659|NCT01879358|Efficacy
1031660|NCT01879345|Anticonvulsant
1031661|NCT01879332|Anticonvulsant
1031662|NCT01879319|LDL-C, triglycerides, high cholesterol
1031663|NCT01879293|Metformin
1031664|NCT01879293|Left ventricular mass
1031665|NCT01879293|Endothelial dysfunction
1031666|NCT01879293|cardiac magnetic resonance
1031667|NCT01879293|aortic pulse wave
1031668|NCT01879280|pterional craniotomy
1031669|NCT01879280|osteoplastic craniotomy
1031670|NCT01879280|temporalis
1031671|NCT01879280|minimally-invasive
1031672|NCT01879254|obsessive compulsive disorder (OCD)
1031673|NCT01879254|deep brain stimulation (DBS)
1031674|NCT01879254|psychosurgery
1031675|NCT01879254|long-term follow-up
1031676|NCT01879241|amyotrophic lateral sclerosis
1031677|NCT01879241|survival time
1031678|NCT01879241|ALS functioning Rating Scale
1031679|NCT01879241|quality of life
1031680|NCT01879241|survival
1031681|NCT01879228|Cystic Fibrosis
1031682|NCT01879228|Diabetes
1031683|NCT01879228|Pancreatic Insufficiency
1031684|NCT01879202|multiple sclerosis
1031685|NCT01879202|fatigue
1031686|NCT01879202|fatigue severity scale
1031687|NCT01879202|fatigue impact scale
1031688|NCT01879202|quality of life
1031689|NCT01879163|Vaccine
1031690|NCT01879163|Immunogenicity
1031691|NCT01879137|Copeptin
1031692|NCT01879137|Arginin stimulation test
1031693|NCT01879111|Depressive episode
1031694|NCT01879111|Chronic ischaemic heart disease
1031695|NCT01879111|Hypertension
1031696|NCT01879098|probiotics
1031697|NCT01879098|inflammation
1031698|NCT01879098|bile
1031699|NCT01879098|hunger
1031700|NCT01879098|satiety
1031701|NCT01879085|advanced
1031702|NCT01879085|metastatic
1031703|NCT01879085|unresectable
1031704|NCT01879085|soft
1031705|NCT01879085|tissue
1031706|NCT01879085|sarcomas
1031707|NCT01879072|Biomarkers
1031708|NCT01879072|Hematopoietic stem cell transplant
1031709|NCT01879059|insulin resistance
1031710|NCT01879059|exercise
1031711|NCT01879059|continuous glucose monitoring
1031712|NCT01879059|blood flow
1031713|NCT01879059|endothelial function
1031714|NCT01879046|Mesenchymal stem cells
1031715|NCT01879046|articular cartilage
1031716|NCT01879046|tissue engineering
1031717|NCT01879046|immunomodulation
1031718|NCT01879046|osteo-arthritis
1031719|NCT01879033|Obesity
1031720|NCT01879033|endothelial function
1031721|NCT01879033|Rh-PAT
1031722|NCT01879033|adipocytokines
1031723|NCT01879020|MT-8995
1031724|NCT01879020|Dyslipidemia
1031725|NCT01879020|Cholesteryl ester transfer proteins
1031726|NCT01878994|Overweight
1031727|NCT01878994|Obesity
1031728|NCT01878994|Children
1031729|NCT01878994|Behaviour
1031730|NCT01878994|Physical Activity
1031731|NCT01878994|Nutrition
1031732|NCT01878981|Catheter Ablation versus Drug Therapy in AF in China
1031733|NCT01878955|Antimullarian hormone(AMH)
1031734|NCT01878955|Polycystic Ovary
1031735|NCT01878955|Multicystic Ovary
1031736|NCT01878942|LSD
1031737|NCT01878942|Pharmacology
1031738|NCT01878942|Pharmacokinetics
1031739|NCT01878942|Pharmacodynamics
1031740|NCT01878942|Mechanism of action
1031741|NCT01878942|Psychedelic
1031742|NCT01878942|Serotonin
1031743|NCT01878942|Prepulse inhibition
1031744|NCT01878942|LSD-induced neuroendocrine effects
1031745|NCT01878942|Long-term psychological effects
1031746|NCT01878929|pollen
1031747|NCT01878929|allergen immunotherapy
1031748|NCT01878929|subcutaneous allergen immunotherapy
1031749|NCT01878929|SCIT
1031750|NCT01878916|the incidence of thrombosis,
1031751|NCT01878916|the effect of Hcy on thrombosis formation,
1031752|NCT01878916|the relation between Hcy and plasma vitamin levels,
1031753|NCT01878916|to compare these results with the control group
1031754|NCT01878890|Solid tumors (other than pancreas)
1031755|NCT01878877|Chronic pain
1031756|NCT01878877|neuropathic pain
1031757|NCT01878864|Pain, Discomfort, Periodontitis, Scaling and Root Planning, Visual Analogue Scale, McGills Pain Questionnaire
1031758|NCT01878825|Immunogenicity
1031759|NCT01878825|Trivalent
1031760|NCT01878825|Safety
1031761|NCT01878825|Adults
1031762|NCT01878825|Elderly
1031763|NCT01878825|Influenza
1031764|NCT01878812|Immunogenicity
1031765|NCT01878812|Influenza
1031766|NCT01878812|Adults
1031767|NCT01878812|Safety
1031768|NCT01878812|Elderly
1031769|NCT01878799|Direct Acting Antiviral
1031770|NCT01878799|Treatment Naive
1031771|NCT01878799|Interferon Sparing
1031772|NCT01878799|Ribavirin Sparing
1031773|NCT01878786|kidney failure
1031774|NCT01878773|Prostate Cancer
1031775|NCT01878773|MRI scan
1031776|NCT01878773|External beam radiotherapy
1031777|NCT01878760|APRICOT
1031778|NCT01878760|Anaesthesia
1031779|NCT01878760|Children
1031780|NCT01878760|kids
1031781|NCT01878760|Paediatric Anaesthesia
1031782|NCT01878760|Observational Trial
1031783|NCT01878760|epidemiology
1031784|NCT01878760|severe critical events in
1031785|NCT01878760|European Society of Anaesthesiology
1031786|NCT01878760|Europe
1031787|NCT01878747|Pediatric
1031788|NCT01878747|Pain
1031789|NCT01878747|Postoperative
1031790|NCT01878747|General Anesthesia
1031791|NCT01878747|Anesthesia Recovery Period
1031792|NCT01878747|Infant Behavior
1031793|NCT01878747|Adolescent Behavior
1031794|NCT01878747|Patient Satisfaction
1031795|NCT01878721|PET/CT
1031796|NCT01878721|infection
1031797|NCT01878721|vasculitis
1031798|NCT01878708|T-Cell Lymphoma
1031799|NCT01878708|Relapsed T-Cell Lymphoma
1031800|NCT01878708|Refractory T-Cell Lymphoma
1031801|NCT01878708|Oncaspar®
1031802|NCT01878708|PEG-L-asparaginase and dexamethasone
1031803|NCT01878695|Integrative Medicine
1031804|NCT01878695|Breast Cancer
1031805|NCT01878695|Stage 0
1031806|NCT01878695|Stage 1
1031807|NCT01878669|n-acetyl cysteine
1031808|NCT01878669|percutaneous coronary intervention
1031809|NCT01878643|aerosolized antibiotic
1031810|NCT01878643|ventilator-associated pneumonia
1031811|NCT01878643|bacterial resistance
1031812|NCT01878643|ventilator -associated tracheobronchitis
1031813|NCT01878643|clinical pulmonary infection score
1031814|NCT01878630|Chronic Heart Failure
1031815|NCT01878630|CHF
1031816|NCT01878617|SJMB12
1031817|NCT01878617|Brain Cancer
1031818|NCT01878617|Brain Tumors in Children
1031819|NCT01878617|Cisplatin
1031820|NCT01878617|Cyclophosphamide
1031821|NCT01878617|Embryonal Tumors of CNS
1031822|NCT01878617|GDC-0449
1031823|NCT01878617|Gemcitabine
1031824|NCT01878617|Hedgehog Pathway Inhibitor
1031825|NCT01878617|Infratentorial
1031826|NCT01878617|Mass in Brain
1031827|NCT01878617|Medulloblastoma
1031828|NCT01878617|Medulloblastoma Brain Tumor
1031829|NCT01878617|Medulloblastoma Tumor
1031830|NCT01878617|Molecular
1031831|NCT01878617|Neuroectodermal Tumor, Primitive
1031832|NCT01878617|Newly Diagnosed Childhood Medulloblastoma
1031833|NCT01878617|Non-SHH Non-WNT
1031834|NCT01878617|Pediatric Brain Tumor
1031835|NCT01878617|Pemetrexed
1031836|NCT01878617|Posterior Fossa Tumor
1031837|NCT01878617|Proton Beam Therapy
1031838|NCT01878617|Radiation Therapy
1031839|NCT01878617|Rare Brain Tumor
1031840|NCT01878617|Risk
1031841|NCT01878617|SHH
1031842|NCT01878617|Sonic Hedgehog Pathway
1031843|NCT01878617|St Jude Medullo
1031844|NCT01878617|St. Jude Brain Tumor Studies
1031845|NCT01878617|St. Jude Medullo
1031846|NCT01878617|St. Jude Studies
1031847|NCT01878617|St. Jude Treatment
1031848|NCT01878617|Treatment for Brain Tumors in Children
1031849|NCT01878617|Untreated Childhood Medulloblastoma
1031850|NCT01878617|Vincristine
1031851|NCT01878617|Vismodegib
1031852|NCT01878617|WNT
1031853|NCT01878591|labour
1031854|NCT01878591|dystocia
1031855|NCT01878591|operative delivery
1031856|NCT01878591|vacuum
1031857|NCT01878591|ultrasound
1031858|NCT01878578|Anticonvulsant, BIA 2-093
1031859|NCT01878565|HBIg
1031860|NCT01878565|GM-CSF
1031861|NCT01878565|HBV vaccine
1031862|NCT01878565|immune regulatory therapy
1031863|NCT01878526|gastroesophageal reflux disease
1031864|NCT01878526|heart burn
1031865|NCT01878526|regurgitation
1031866|NCT01878526|systemic sclerosis
1031867|NCT01878526|scleroderma
1031868|NCT01878526|proton pump inhibitor
1031869|NCT01878526|alginic acid
1031870|NCT01878526|omeprazole
1031871|NCT01878526|prokinetic
1031872|NCT01878500|Bladder exstrophy epispadias complex
1031873|NCT01878500|Pelvic floor musculature
1031874|NCT01878500|Intraoperative stereotactic imaging
1031875|NCT01878487|Acute MI
1031876|NCT01878487|Primary percutaneous coronary intervention
1031877|NCT01878487|thrombus aspiration, IVUS
1031878|NCT01878474|MT-8995
1031879|NCT01878474|Dyslipidemia
1031880|NCT01878474|Cholesteryl ester transfer proteins
1031881|NCT01878435|Short Message System
1031882|NCT01878435|SMS reminder
1031883|NCT01878435|mobile phone
1031884|NCT01878435|cell phone
1031885|NCT01878435|vaccination
1031886|NCT01878435|immunization
1031887|NCT01878435|mHealth
1031888|NCT01878409|Sexuality
1031889|NCT01878409|Parkinson Disease
1031890|NCT01878409|BISF
1031891|NCT01878409|IIEF
1031892|NCT01878409|FSFI
1031893|NCT01878396|Circulating Melanoma cells in metastatic melanoma
1031894|NCT01878383|(HSV)
1031895|NCT01878357|MST
1031896|NCT01878357|Malaria
1031897|NCT01878357|Indonesia
1031898|NCT01878357|Transmission
1031899|NCT01878305|hepatic encephalopathy
1031900|NCT01878305|brain waves
1031901|NCT01878305|electroencephalogram
1031902|NCT01878305|transcranial Doppler ultrasonography
1031903|NCT01878305|physiological monitoring
1031904|NCT01878305|intensive care
1031905|NCT01878266|Diffuse Intrinsic Pontine Glioma (DIPG)
1031906|NCT01878266|Hypofractionated Radiotherapy
1031907|NCT01878266|Radiotherapy
1031908|NCT01878266|Median survival
1031909|NCT01878240|Vascular surgery
1031910|NCT01878240|Abdominal Aortic aneurysm
1031911|NCT01878240|endovascular
1031912|NCT01878214|Health communication
1031913|NCT01878214|Smoking cessation
1031914|NCT01878214|Health behavior
1031915|NCT01878214|Construction industry
1031916|NCT01878214|Audience segmentation
1031917|NCT01878201|Fimasartan
1031918|NCT01878201|24 hours ABP monitoring(ABPM)
1031919|NCT01878201|antihypertension
1031920|NCT01878175|Arthroplasty, Replacement, Hip
1031921|NCT01878175|Veterans
1031922|NCT01878175|Exercise
1031923|NCT01878162|Prevention
1031924|NCT01878162|Wellness
1031925|NCT01878162|Occupation
1031926|NCT01878162|Work
1031927|NCT01878162|Law Enforcement
1031928|NCT01878162|Exercise
1031929|NCT01878123|Arthritis
1031930|NCT01878123|Rheumatoid Arthritis
1031931|NCT01878123|Joint Diseases
1031932|NCT01878123|Musculoskeletal Diseases
1031933|NCT01878123|Rheumatic Diseases
1031934|NCT01878123|Connective Tissue Diseases
1031935|NCT01878123|Autoimmune Diseases
1031936|NCT01878123|Immune System Diseases
1031937|NCT01878123|Antirheumatic agents
1031938|NCT01878110|Trichotillomania
1031939|NCT01878110|Hair pulling
1031940|NCT01878110|Behavior therapy
1031941|NCT01878084|Tissue regeneration
1031942|NCT01878084|sol gel bioglass
1031943|NCT01878084|alveolar ridge preservation
1031944|NCT01878084|children
1031945|NCT01878084|Egyptian
1031946|NCT01878084|class II orthodontic cases
1031947|NCT01878058|Prostate cancer
1031948|NCT01878058|Brachytherapy
1031949|NCT01878058|Seed implant
1031950|NCT01878045|American Indians
1031951|NCT01878045|Diabetic Nephropathy
1031952|NCT01878045|Kidney Biopsy
1031953|NCT01878045|Type 2 Diabetes Mellitus
1031954|NCT01878045|Retinopathy
1031955|NCT01878032|Retinal Disease
1031956|NCT01878032|Inherited Retinal Degeneration
1031957|NCT01878019|Pain
1031958|NCT01878019|Placebo
1031959|NCT01878019|Opiate Antagonist
1031960|NCT01878006|Opiate Receptor
1031961|NCT01878006|Genotype
1031962|NCT01878006|PET Imaging
1031963|NCT01877993|coronary artery spasm
1031964|NCT01877993|pathophysiology
1031965|NCT01877993|atrioventricular block
1031966|NCT01877993|blood pressure
1031967|NCT01877993|autonomic nervous function
1031968|NCT01877954|hydrofluoroalkane beclomethasone
1031969|NCT01877954|fluticasone
1031970|NCT01877954|paediatrics
1031971|NCT01877954|real-life
1031972|NCT01877954|observational
1031973|NCT01877954|primary care
1031974|NCT01877941|cardiac output
1031975|NCT01877941|pulse oximetry
1031976|NCT01877941|hemodynamics
1031977|NCT01877928|Obstructive sleep apnea, CPAP, Boussignac
1031978|NCT01877915|Heart Failure
1031979|NCT01877915|Coronary Artery Disease
1031980|NCT01877915|Stroke
1031981|NCT01877915|Myocardial Infarction
1031982|NCT01877915|Anticoagulation
1031983|NCT01877889|Healthy
1031984|NCT01877889|Canagliflozin
1031985|NCT01877889|INVOKANA
1031986|NCT01877889|Dapagliflozin
1031987|NCT01877889|FORXIGA
1031988|NCT01877889|Pharmacodynamics
1031989|NCT01877863|intradialytic exercise
1031990|NCT01877863|hemodialysis
1031991|NCT01877837|Stem cell transplant
1031992|NCT01877837|Sickle cell
1031993|NCT01877837|Stem cell transplantation
1031994|NCT01877837|Related
1031995|NCT01877837|Unrelated
1031996|NCT01877824|Surgery
1031997|NCT01877824|Training
1031998|NCT01877811|Lung Cancer
1031999|NCT01877811|RET Inhibitor
1032000|NCT01877811|Solid Tumors
1032001|NCT01877811|RET mutations or rearrangements
1032002|NCT01877811|BRAF mutations or rearrangements
1032003|NCT01877811|Squamous NSCLC
1032004|NCT01877811|KRAS mutation
1032005|NCT01877811|Other Lung adenocarcinomas
1032006|NCT01877772|cuff repair
1032007|NCT01877772|arthroscopic
1032008|NCT01877772|Trephination
1032009|NCT01877772|Bone
1032010|NCT01877772|cuff tear
1032011|NCT01877759|Stem cell ,liver cirrhosis
1032012|NCT01877746|ICM
1032013|NCT01877746|myocarditis
1032014|NCT01877746|cardiomyopathy
1032015|NCT01877746|endomyocardial biopsy
1032016|NCT01877746|immunosuppression
1032017|NCT01877733|Resistance training
1032018|NCT01877720|Preterm infant less than 32 weeks of gestation age
1032019|NCT01877720|intubated more than 48 hours after birth
1032020|NCT01877720|postextubation
1032021|NCT01877694|pink eye
1032022|NCT01877668|psoriatic arthritis
1032023|NCT01877668|radiographic changes
1032024|NCT01877668|active comparator
1032025|NCT01877668|tofacitinib
1032026|NCT01877655|ASP0113
1032027|NCT01877655|Cytomegalovirus (CMV)
1032028|NCT01877655|Hematopoietic Cell Transplant (HCT)
1032029|NCT01877642|ADASUVE
1032030|NCT01877642|inhaled loxapine
1032031|NCT01877642|drug drug interaction
1032032|NCT01877642|lorazepam
1032033|NCT01877642|acute treatment of agitation
1032034|NCT01877629|ACT-129968
1032035|NCT01877629|Pharmacokinetics
1032036|NCT01877629|Safety
1032037|NCT01877629|Tolerability
1032038|NCT01877616|sleep disorders
1032039|NCT01877616|insomnia
1032040|NCT01877616|hypersomnia
1032041|NCT01877616|sleep-disordered breathing
1032042|NCT01877616|cardiovascular health
1032043|NCT01877616|stroke
1032044|NCT01877616|ischemic heart disease
1032045|NCT01877616|Atahualpa
1032046|NCT01877551|HIV
1032047|NCT01877551|Protease inhibitor
1032048|NCT01877551|insulin resistance
1032049|NCT01877551|Tauroursodeoxycholic acid
1032050|NCT01877525|colorectal polyps
1032051|NCT01877525|resect and discard
1032052|NCT01877525|endoscopic prediction
1032053|NCT01877525|histological diagnosis
1032054|NCT01877525|narrow band imaging
1032055|NCT01877499|Hemodiafiltration
1032056|NCT01877499|Convection volume
1032057|NCT01877499|Filtration fraction
1032058|NCT01877499|Blood flow
1032059|NCT01877499|Treatment time
1032060|NCT01877486|atrial fibrillation
1032061|NCT01877486|cryoballoon ablation
1032062|NCT01877486|persistent AF
1032063|NCT01877486|paroxysmal AF
1032064|NCT01877486|dofetilide
1032065|NCT01877473|atrial fibrillation
1032066|NCT01877473|persistent AF
1032067|NCT01877473|catheter ablation
1032068|NCT01877473|duration of 7 days to one year
1032069|NCT01877473|with symptoms and failure of at least one antiarrhythmic drug
1032070|NCT01877460|sodium alginate
1032071|NCT01877460|chocolate milk
1032072|NCT01877460|satiety
1032073|NCT01877460|energy intake
1032074|NCT01877460|glycemia
1032075|NCT01877460|insulinemia
1032076|NCT01877447|tDCS
1032077|NCT01877447|Brain stimulation
1032078|NCT01877447|depressive disorder
1032079|NCT01877434|Reversed shoulder arthroplasty
1032080|NCT01877434|Treatment
1032081|NCT01877434|TESS
1032082|NCT01877421|Reducing plaque
1032083|NCT01877421|Reducing gingivitis
1032084|NCT01877421|safety
1032085|NCT01877421|proof of concept
1032086|NCT01877421|antiplaque chewing gum
1032087|NCT01877408|disposable circumcision device
1032088|NCT01877408|Tissue adhesive
1032089|NCT01877408|Open surgical circumcision
1032090|NCT01877408|Minimally-invasive circumcision
1032091|NCT01877395|Rabies
1032092|NCT01877395|Purified Vero Rabies Vaccine - Serum Free
1032093|NCT01877395|Human Diploid Cell Vaccine
1032094|NCT01877395|Imovax® Rabies
1032095|NCT01877356|ambulatory surgery
1032096|NCT01877356|spinal anesthesia
1032097|NCT01877356|micturition
1032098|NCT01877356|bladder retention
1032099|NCT01877356|unilateral block
1032100|NCT01877356|prilocaine hyperbaric
1032101|NCT01877356|prilocaine plain
1032102|NCT01877356|local anaesthetic dose
1032103|NCT01877343|cardiac functional health classification
1032104|NCT01877343|Congenital heart failure
1032105|NCT01877343|chronic heart failure
1032106|NCT01877330|shoulder arthroscopy
1032107|NCT01877330|ultrasound guided nerve block
1032108|NCT01877330|interscalene nerve block
1032109|NCT01877317|Audiology
1032110|NCT01877317|hearing loss
1032111|NCT01877317|hearing healthcare
1032112|NCT01877317|mobile app
1032113|NCT01877317|hearing aid fitting
1032114|NCT01877317|audiometry
1032115|NCT01877317|audiogram
1032116|NCT01877291|smoking, nasal lavage, exhaled breath condensate, mucociliary transport
1032117|NCT01877278|Osteoarthritis
1032118|NCT01877278|Pulsed electromagnetic fields
1032119|NCT01877278|Device
1032120|NCT01877278|Pain
1032121|NCT01877278|Pressure algometry
1032122|NCT01877252|critical limb ischemia
1032123|NCT01877252|endovascular treatment
1032124|NCT01877252|open surgical repair
1032125|NCT01877252|diabetic foot
1032126|NCT01877226|Healthy
1032127|NCT01877226|Tapentadol
1032128|NCT01877213|coaching
1032129|NCT01877213|therapeutic education
1032130|NCT01877213|hospital admission
1032131|NCT01877213|quality improvement strategies
1032132|NCT01877213|management program
1032133|NCT01877213|nurse follow up
1032134|NCT01877213|discharge planning
1032135|NCT01877213|rehospitalization
1032136|NCT01877187|Primary liver cancer
1032137|NCT01877187|Metastatic liver cancer
1032138|NCT01877174|Internal Carotid Stenosis
1032139|NCT01877174|Reverse Flow
1032140|NCT01877174|Carotid stenting
1032141|NCT01877174|MICHI(TM) NPS+f
1032142|NCT01877148|Parkinson, rehabilitation, tDCS
1032143|NCT01877135|anal carcinoma
1032144|NCT01877135|AIN3
1032145|NCT01877135|cohort study
1032146|NCT01877109|Lymphoma
1032147|NCT01877109|Prognosis
1032148|NCT01877109|Biomarker
1032149|NCT01877109|Quality of life
1032150|NCT01877096|Motivational Interviewing
1032151|NCT01877096|Screening Colonoscopy
1032152|NCT01877096|Cancer Prevention
1032153|NCT01877083|KIF5B-RET-Positive Adenocarcinoma
1032154|NCT01877083|Lung Cancer
1032155|NCT01877083|NSCLC
1032156|NCT01877083|Non-Small Cell Lung Cancer
1032157|NCT01877070|assessments
1032158|NCT01877070|13-076
1032159|NCT01877057|Pea protein
1032160|NCT01877057|Satiety hormone
1032161|NCT01877057|Ussing Chamber
1032162|NCT01877044|Prebiotics
1032163|NCT01877044|Intestinal permeability
1032164|NCT01877044|Gut barrier function
1032165|NCT01877044|Immunity
1032166|NCT01877031|central line
1032167|NCT01877031|ultrasound guided central line insertion
1032168|NCT01877031|virtual reality
1032169|NCT01877031|augmented reality
1032170|NCT01877018|Comparative Effectiveness Research
1032171|NCT01877018|Reminder Systems
1032172|NCT01877018|Patient Participation
1032173|NCT01877018|Primary Health Care
1032174|NCT01877018|Early Detection of Cancer
1032175|NCT01877018|Colorectal Neoplasms
1032176|NCT01877005|Multicenter, single arm and opened label phase II study
1032177|NCT01876992|diabetes
1032178|NCT01876992|pediatrics
1032179|NCT01876992|obesity
1032180|NCT01876992|healthy volunteers
1032181|NCT01876992|metformin
1032182|NCT01876992|nutrition
1032183|NCT01876992|healthy controls
1032184|NCT01876992|bmi
1032185|NCT01876966|HIV
1032186|NCT01876966|pharmacokinetic interaction
1032187|NCT01876966|healthy HIV-negative person
1032188|NCT01876940|supraglottic airway
1032189|NCT01876940|children
1032190|NCT01876940|tracheal intubation
1032191|NCT01876940|fiberoptic bronchoscopy
1032192|NCT01876927|Locally
1032193|NCT01876927|Advanced
1032194|NCT01876927|Resectable
1032195|NCT01876927|Gastric Cancer
1032196|NCT01876914|Diabetes
1032197|NCT01876914|Edema
1032198|NCT01876914|DME
1032199|NCT01876914|OCT
1032200|NCT01876901|Rectal cancer
1032201|NCT01876901|Coloanal anastomosis
1032202|NCT01876901|Phase 2 clinical trial
1032203|NCT01876888|patient satisfaction
1032204|NCT01876888|physical therapy
1032205|NCT01876888|MedRisk instrument
1032206|NCT01876875|psoriasis
1032207|NCT01876875|obesity
1032208|NCT01876862|HIV-1
1032209|NCT01876862|chronic infection
1032210|NCT01876862|cure
1032211|NCT01876862|remission
1032212|NCT01876849|diabetes
1032213|NCT01876849|exenatide
1032214|NCT01876849|Byetta
1032215|NCT01876849|Amylin
1032216|NCT01876849|Lilly
1032217|NCT01876836|i-gel
1032218|NCT01876836|C-LMA
1032219|NCT01876836|gastroeosephageal reflux
1032220|NCT01876836|sore troat
1032221|NCT01876823|Memory Decline
1032222|NCT01876823|Depression
1032223|NCT01876823|Elderly
1032224|NCT01876823|Antidepressants
1032225|NCT01876823|Treatment
1032226|NCT01876823|memantine
1032227|NCT01876810|Gemfibrozil
1032228|NCT01876810|Nicotine Dependence
1032229|NCT01876810|Smoking
1032230|NCT01876810|Cigarettes
1032231|NCT01876784|vandetanib, AZD 6474, Differentiated Thyroid Cancer
1032232|NCT01876771|177lutetium-DOTA(O)Tyr3)octreotate
1032233|NCT01876758|ECT
1032234|NCT01876758|Memory Training
1032235|NCT01876758|Cognitive Remediation
1032236|NCT01876758|Electroconvulsive Therapy
1032237|NCT01876758|Treatment Resistant Depression
1032238|NCT01876758|Depression
1032239|NCT01876758|Geriatric Depression
1032240|NCT01876758|Memory Loss
1032241|NCT01876758|Cognitive Training
1032242|NCT01876732|hemodialysis
1032243|NCT01876732|viatmin B12 deficiency
1032244|NCT01876732|Epogen
1032245|NCT01876719|ADHD
1032246|NCT01876719|AR08
1032247|NCT01876719|adrenergic receptor agonists
1032248|NCT01876719|randomized, placebo-controlled clinical trial
1032249|NCT01876706|UroLift System
1032250|NCT01876680|chronic
1032251|NCT01876680|neck
1032252|NCT01876680|shoulder
1032253|NCT01876680|exercise
1032254|NCT01876654|Total Knee Replacement
1032255|NCT01876654|Patient specific instrumentation
1032256|NCT01876641|Metastatic melanoma
1032257|NCT01876641|melanoma
1032258|NCT01876641|BRAF-mutated Metastatic Melanoma
1032259|NCT01876641|V600EBRAF-mutated metastatic melanoma
1032260|NCT01876641|Decitabine
1032261|NCT01876641|Vemurafenib
1032262|NCT01876628|Clindamycin
1032263|NCT01876628|Cellulitis
1032264|NCT01876628|Flucloxacillin
1032265|NCT01876628|Group A streptococcus
1032266|NCT01876628|Staphylococcus aureus
1032518|NCT01875523|Pharmacokinetics
1032267|NCT01876615|safety/tolerability and pharmacokinetics/pharmacodynamics
1032268|NCT01876602|adolescents
1032269|NCT01876602|exercise
1032270|NCT01876602|fitness
1032271|NCT01876602|school-based
1032272|NCT01876589|Coronary Artery Disease (CAD)
1032273|NCT01876589|Invasive coronary angiography (ICA)
1032274|NCT01876589|Positron Emission Tomography (PET)
1032275|NCT01876576|colonoscopy
1032276|NCT01876563|thioredoxin
1032277|NCT01876563|TBP-2
1032278|NCT01876563|thioredoxin reductase
1032279|NCT01876563|vitamin D
1032280|NCT01876563|DIABETES
1032281|NCT01876550|Mupirocin Calcium Cream 2%
1032282|NCT01876550|Bactroban® Cream
1032283|NCT01876550|Secondarily infected traumatic skin lesions
1032284|NCT01876524|Substance Use Disorder
1032285|NCT01876524|Attention Deficit Disorder With Hyperactivity
1032286|NCT01876524|Schizophrenia
1032287|NCT01876524|Bipolar disorder
1032288|NCT01876524|Personality disorder
1032289|NCT01876511|MSI
1032290|NCT01876511|MSS
1032291|NCT01876511|MLH 1
1032292|NCT01876511|MSH 2
1032293|NCT01876511|MSH 6
1032294|NCT01876511|PMS2
1032295|NCT01876511|BRAF pV600E
1032296|NCT01876511|TGFBR2
1032297|NCT01876485|Diabetes Mellitus
1032298|NCT01876485|health literacy
1032299|NCT01876485|patient activation
1032300|NCT01876485|goals of care
1032301|NCT01876394|Healthy
1032302|NCT01876394|Arterial Stiffness
1032303|NCT01876394|Blood Pressure
1032304|NCT01876394|Blood Glucose
1032305|NCT01876394|Vascular Function
1032306|NCT01876368|hypertension,
1032307|NCT01876368|LCZ696,
1032308|NCT01876368|olmesartan
1032309|NCT01876355|Delirium, clonidine, ICU, sedation
1032310|NCT01876342|sports hernia
1032311|NCT01876342|sportsman's hernia
1032312|NCT01876342|chronic groin pain
1032313|NCT01876342|open minimal repair
1032314|NCT01876342|totally extraperitoneal endoscopic technique
1032315|NCT01876329|Rheumatoid Arthritis
1032316|NCT01876329|Vitamin B12 deficiency
1032317|NCT01876329|Autoimmune Thyroid Disease
1032318|NCT01876329|Autoantibodies
1032319|NCT01876316|Moxifloxacin
1032320|NCT01876316|QT interval prolongation
1032321|NCT01876316|Korean
1032322|NCT01876316|Japanese
1032323|NCT01876290|Anesthesiology
1032324|NCT01876290|Complications
1032325|NCT01876290|Closed-loop
1032326|NCT01876277|Cancer
1032327|NCT01876277|Body image
1032328|NCT01876277|Adolescent
1032329|NCT01876264|Colorectal surgery
1032330|NCT01876264|Colonoscopy
1032331|NCT01876264|Randomized controlled trial
1032332|NCT01876251|Breast cancer metastatic
1032333|NCT01876251|docetaxel
1032334|NCT01876251|PF-03084014
1032335|NCT01876238|Breast Cancer
1032336|NCT01876238|Patient-Doctor Communication
1032337|NCT01876238|Supportive Care
1032338|NCT01876225|cervical biopsy
1032339|NCT01876225|forced cough
1032340|NCT01876225|pain
1032341|NCT01876225|VAS scale
1032342|NCT01876212|melanoma
1032343|NCT01876212|metastatic
1032344|NCT01876212|vaccine
1032345|NCT01876212|BRAF
1032346|NCT01876199|HIV-1
1032347|NCT01876199|acute
1032348|NCT01876199|diagnosis
1032349|NCT01876199|pharmacies
1032350|NCT01876199|healthcare facilities
1032351|NCT01876186|antimuscarinic treatment
1032352|NCT01876186|urodynamic studies
1032353|NCT01876186|nerve growth factor
1032354|NCT01876173|Sudden cardiac death
1032355|NCT01876173|implantable cardioverter defibrillator
1032356|NCT01876173|decision aid
1032357|NCT01876147|Low vision
1032358|NCT01876147|Vision testing
1032359|NCT01876147|Retinitis Pigmentosa
1032360|NCT01876147|AMD
1032361|NCT01876147|Visual acuity
1032362|NCT01876147|Poor vision
1032363|NCT01876147|Quantification
1032364|NCT01876134|Cardiac surgery
1032365|NCT01876134|Acute kidney injury
1032366|NCT01876134|Cyr-61
1032367|NCT01876134|Pulse wave analysis
1032368|NCT01876121|NSAIDs
1032369|NCT01876121|Acute pain
1032370|NCT01876108|Steatohepatitis
1032371|NCT01876108|Helicobacter pylori
1032372|NCT01876108|Alanine aminotransferase
1032373|NCT01876108|Aspartate aminotransferase
1032374|NCT01876108|Fatty Liver
1032375|NCT01876108|Liver Diseases
1032376|NCT01876108|Digestive System Diseases
1032377|NCT01876082|Desmoids tumors
1032378|NCT01876082|Pazopanib
1032379|NCT01876082|Phase 2 clinical trial
1032380|NCT01876082|Cross over
1032381|NCT01876056|Psychosis
1032382|NCT01876056|Culture
1032383|NCT01876056|CBT
1032384|NCT01876030|Functional electrical stimulation (FES)
1032385|NCT01876030|Sub acute stroke
1032386|NCT01876030|Gait analysis
1032387|NCT01876017|CRF
1032388|NCT01876017|STEM CELL
1032389|NCT01876017|CKD
1032390|NCT01876004|ectopic pregnancy
1032391|NCT01876004|methotrexate
1032392|NCT01876004|human chorionic gonadotropin beta subunit
1032393|NCT01876004|expectant management
1032394|NCT01875978|Phytosterols
1032395|NCT01875978|Endothelial progenitor cells
1032396|NCT01875952|Latent tuberculosis infection
1032397|NCT01875952|Human immunodeficiency virus (HIV)
1032398|NCT01875952|Treatment
1032399|NCT01875952|Isoniazid
1032400|NCT01875939|healthy volunteers
1032401|NCT01875913|Curiosity
1032402|NCT01875913|Intention
1032403|NCT01875913|Follow Through
1032404|NCT01875900|neonatal resuscitation
1032405|NCT01875900|video-assisted learning
1032406|NCT01875900|self-directed training
1032407|NCT01875900|simulation
1032408|NCT01875900|simulation-based training
1032409|NCT01875900|simulation-based medical education
1032410|NCT01875900|objective structured clinical examination
1032411|NCT01875874|liver failure
1032412|NCT01875874|acute liver failure
1032413|NCT01875874|fulminant hepatic failure
1032414|NCT01875874|primary graft non-function
1032415|NCT01875874|surgically-induced liver failure
1032416|NCT01875874|ELAD
1032417|NCT01875874|ALF
1032418|NCT01875874|FHF
1032419|NCT01875874|PNF
1032420|NCT01875861|Antipsychotic Agents
1032421|NCT01875861|Metabolic Syndrome
1032422|NCT01875861|Quality Improvement
1032423|NCT01875848|pain management
1032424|NCT01875835|Acute myocardiac infarction
1032425|NCT01875835|Bare-metal stent
1032426|NCT01875835|Everolimus-eluting stent
1032427|NCT01875835|Optical coherence tomography
1032428|NCT01875822|Curcumin
1032429|NCT01875822|Epigenetics
1032430|NCT01875822|Schizophrenia
1032431|NCT01875822|Nitric Oxide synthetase
1032432|NCT01875822|cognition
1032433|NCT01875822|negative symptoms
1032434|NCT01875809|RDN
1032435|NCT01875809|renal denervation
1032436|NCT01875809|catecholamine
1032437|NCT01875809|spill-over
1032438|NCT01875809|blood pressure
1032439|NCT01875809|electrophysiology
1032440|NCT01875809|ablation
1032441|NCT01875796|cannabis
1032442|NCT01875796|marijuana
1032443|NCT01875796|anxiety
1032444|NCT01875796|transdiagnostic
1032445|NCT01875796|dual diagnosis
1032446|NCT01875796|cannabis abuse
1032447|NCT01875796|cannabis dependence
1032448|NCT01875796|cannabis use disorder
1032449|NCT01875783|diabetes
1032450|NCT01875783|diabetic macular edema
1032451|NCT01875783|diabetic retinopathy
1032452|NCT01875783|optical coherence tomography
1032453|NCT01875770|Retinal Vein Occlusion
1032454|NCT01875757|Vitamin D
1032455|NCT01875757|Acute bronchitis
1032456|NCT01875757|Upper respiratory tract infection
1032457|NCT01875757|Recurrent bronchitis
1032458|NCT01875757|Acute bronchiolitis
1032459|NCT01875757|Infants
1032460|NCT01875744|constipation
1032461|NCT01875744|children
1032462|NCT01875744|polyethylene glycol
1032463|NCT01875731|Pneumonia
1032464|NCT01875731|Acute respiratory infection
1032465|NCT01875731|Decision-support techniques
1032466|NCT01875692|Metagenomic
1032467|NCT01875692|Ventilator-Associated Pneumonia (VAP)
1032468|NCT01875679|Surgical education
1032469|NCT01875679|Deliberate practice
1032470|NCT01875679|Debriefing
1032471|NCT01875679|Behaviour modelling
1032472|NCT01875666|breast cancer
1032473|NCT01875666|Kinome
1032474|NCT01875666|HER two positive
1032475|NCT01875653|metastatic melanoma
1032476|NCT01875653|dendritic cells
1032477|NCT01875653|immunotherapy
1032478|NCT01875653|Granulocyte-Macrophage Colony Stimulating Factor
1032479|NCT01875653|overall survival
1032480|NCT01875653|autologous
1032481|NCT01875653|peripheral blood mononuclear cells
1032482|NCT01875653|treatment
1032483|NCT01875653|phase 3
1032484|NCT01875653|tumor cells
1032618|NCT01875237|AP 1903
1032485|NCT01875640|disorder of sex development
1032486|NCT01875640|intersex
1032487|NCT01875640|46,XX congenital adrenal hyperplasia
1032488|NCT01875640|hypospadias
1032489|NCT01875640|decision support tool
1032490|NCT01875601|NK Cells
1032491|NCT01875601|Cytokine
1032492|NCT01875601|Lymphodepleting Chemotherapy
1032493|NCT01875601|Immunotherapy
1032494|NCT01875601|Pediatric
1032500|NCT01875575|glucagon-like peptide-1
1032501|NCT01875575|peptide tyrosine tyrosine
1032502|NCT01875575|ghrelin
1032503|NCT01875575|stomach
1032504|NCT01875575|small intestine
1032505|NCT01875575|gastric emptying
1032506|NCT01875562|Neck pain
1032507|NCT01875562|Cervical radiculopathy
1032508|NCT01875562|Qishe Pill
1032509|NCT01875562|Traditional Chinese Medicine
1032510|NCT01875536|transcranial magnetic stimulation
1032511|NCT01875536|spasticity
1032512|NCT01875536|physiotherapy
1032513|NCT01875536|Rehabilitation
1032514|NCT01875523|Renal disease
1032515|NCT01875523|renal impairment
1032516|NCT01875523|End stage renal disease
1032517|NCT01875523|Healthy volunteer
1032519|NCT01875497|athletes, polyphenols, nutrition, oxidative stress
1032520|NCT01875484|miR-126
1032521|NCT01875484|Left Ventricular Remodeling
1032522|NCT01875484|Myocardial Infarction
1032523|NCT01875484|primary percutaneous coronary intervention
1032524|NCT01875484|left ventricular end diastolic volume
1032525|NCT01875484|left ventricular ejection fraction
1032526|NCT01875484|major adverse cardiovascular events
1032527|NCT01875458|Aclasta
1032528|NCT01875458|Actonel
1032529|NCT01875458|alendronate
1032530|NCT01875458|alendronate/cholecalciferol
1032531|NCT01875458|Aredia
1032532|NCT01875458|Atelvia
1032533|NCT01875458|Boniva
1032534|NCT01875458|Didronel
1032535|NCT01875458|etidronate
1032536|NCT01875458|Fosamax
1032537|NCT01875458|Fosamax Plus D
1032538|NCT01875458|ibandronate
1032539|NCT01875458|pamidronate
1032540|NCT01875458|Reclast
1032541|NCT01875458|risedronate
1032542|NCT01875458|Skelid
1032543|NCT01875458|tiludronate
1032544|NCT01875458|zoledronic acid
1032545|NCT01875458|Zometa
1032546|NCT01875458|Bisphosphonate
1032547|NCT01875458|Atypical Femur Fracture (AFF)
1032548|NCT01875458|Osteoporosis
1032549|NCT01875458|Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ)
1032550|NCT01875445|Inositol
1032551|NCT01875445|Trichotillomania
1032552|NCT01875445|Hair Pulling
1032553|NCT01875445|Impulse Control Disorder
1032554|NCT01875393|Prostatic Disease
1032555|NCT01875393|Genital Neoplasm,male
1032556|NCT01875393|Urogenital neoplasm
1032557|NCT01875393|Genital disease,male
1032558|NCT01875393|Male urogenital disease
1032559|NCT01875393|Neoplasms
1032560|NCT01875393|Neoplasms by site
1032561|NCT01875393|Prostatic neoplasm
1032562|NCT01875393|Carcinoma
1032563|NCT01875380|metastatic colorectal cancer
1032564|NCT01875380|frail and unfit patient
1032565|NCT01875380|regorafenib
1032566|NCT01875367|Subcutaneous trastuzumab
1032567|NCT01875367|Intravenous trastuzumab
1032568|NCT01875367|HER2 positive
1032569|NCT01875367|Advanced Breast Cancer
1032570|NCT01875341|type 2 diabetes
1032571|NCT01875341|diabetic nephropathy
1032572|NCT01875341|hypertension
1032573|NCT01875341|sleep apnea
1032574|NCT01875341|sympathetic hyperactivity
1032575|NCT01875328|stroke
1032576|NCT01875328|blood pressure
1032577|NCT01875328|telemedicine
1032578|NCT01875302|COPD PRO Instraments equivalency
1032579|NCT01875276|Rhinitis
1032580|NCT01875276|Antihistamine
1032581|NCT01875276|Nasal Steroid Therapy
1032582|NCT01875263|catheter-related bacteremia, SAMS
1032583|NCT01875263|catheter related bacteremia
1032584|NCT01875263|susceptible
1032585|NCT01875263|aureus meticillin
1032586|NCT01875250|Gene Transfer
1032587|NCT01875250|Androgen Receptor Antagonist
1032588|NCT01875250|PSA
1032589|NCT01875250|Immune Response
1032590|NCT01875250|Immunotherapy
1032591|NCT01875237|Leukemia
1032592|NCT01875237|Myeloma
1032593|NCT01875237|Myeloproliferative Diseases
1032594|NCT01875237|Myelodysplastic syndrome
1032595|NCT01875237|MDS
1032596|NCT01875237|Lymphoma
1032597|NCT01875237|Hodgkin disease
1032598|NCT01875237|Multiple myeloma
1032599|NCT01875237|MM
1032600|NCT01875237|Transplant donor
1032601|NCT01875237|T-cells
1032602|NCT01875237|G-versus-host disease
1032603|NCT01875237|GvHD
1032604|NCT01875237|G-CSF
1032605|NCT01875237|Filgrastim
1032606|NCT01875237|Neupogen
1032607|NCT01875237|Fludarabine
1032608|NCT01875237|Fludarabine phosphate
1032609|NCT01875237|Fludara
1032610|NCT01875237|Melphalan
1032611|NCT01875237|Alkeran
1032612|NCT01875237|Alemtuzumab
1032613|NCT01875237|CAMPATH-1H
1032614|NCT01875237|Campath
1032615|NCT01875237|Tacrolimus
1032616|NCT01875237|Prograf
1032617|NCT01875237|Mini-methotrexate
1032619|NCT01875237|Methylprednisolone
1032620|NCT01875237|Depo-Medrol
1032621|NCT01875237|Medrol
1032622|NCT01875237|Solu-Medrol
1032623|NCT01875237|Stem cell infusion
1032624|NCT01875237|Donor lymphocyte infusion
1032625|NCT01875237|DLI
1032626|NCT01875237|Questionnaire
1032627|NCT01875237|Survey
1032628|NCT01875224|kidney transplant
1032629|NCT01875224|diabetes after transplant
1032630|NCT01875224|belatacept
1032631|NCT01875198|Splenectomy;
1032632|NCT01875198|Spleen-preserving
1032633|NCT01875185|acute coronary syndrome
1032634|NCT01875185|clotting
1032635|NCT01875185|hormones
1032636|NCT01875185|women
1032637|NCT01875172|bupropion SR
1032638|NCT01875172|randomized controlled trial
1032639|NCT01875172|pregnancy
1032640|NCT01875159|Prematurity
1032641|NCT01875159|Apnea of prematurity
1032642|NCT01875159|Intermittent hypoxia
1032643|NCT01875133|airway disease
1032644|NCT01875133|bronchitis
1032645|NCT01875133|emphysema
1032646|NCT01875133|lung
1032647|NCT01875120|Anxiety
1032648|NCT01875120|Somatoform Disorders
1032649|NCT01875068|referrals
1032650|NCT01875068|nurse practitioners
1032651|NCT01875068|physician assistants
1032652|NCT01875068|consultative general internal medicine
1032653|NCT01875055|Cerebral
1032654|NCT01875055|desaturation
1032655|NCT01875029|Low back pain
1032656|NCT01875029|chronic pain
1032657|NCT01875029|tDCS
1032658|NCT01875029|transcranial direct current stimulation
1032659|NCT01875016|Cryo ablation
1032660|NCT01875016|Cardiomyopathy
1032661|NCT01874977|rheumatoid arthritis
1032662|NCT01874977|fatigue
1032663|NCT01874977|physical activity
1032664|NCT01874964|HIV Prevention
1032665|NCT01874964|Opioid-Related Disorders
1032666|NCT01874964|Medication Assisted Treatment
1032667|NCT01874964|Methadone
1032668|NCT01874951|Depression
1032669|NCT01874951|Recurrence
1032670|NCT01874951|Relapse
1032671|NCT01874951|Antidepressants
1032672|NCT01874951|Naltrexone
1032673|NCT01874951|Drug augmentation
1032674|NCT01874886|Magnetic resonance imaging
1032675|NCT01874886|Diffusion tensor imaging
1032676|NCT01874886|Hippocampus
1032677|NCT01874886|Cannabis
1032678|NCT01874886|Geriatrics
1032679|NCT01874886|Neuropsychology
1032680|NCT01874886|Apolipoprotein E
1032681|NCT01874847|melatonin
1032682|NCT01874847|placebo
1032683|NCT01874847|post-concussion syndrome
1032684|NCT01874847|mild traumatic brain injury
1032685|NCT01874847|concussion
1032686|NCT01874847|treatment
1032687|NCT01874847|outcome
1032688|NCT01874847|children
1032689|NCT01874847|functional magnetic resonance imaging
1032690|NCT01874847|transcranial magnetic stimulation
1032691|NCT01874847|sleep
1032692|NCT01874834|ozone
1032693|NCT01874834|diesel
1032694|NCT01874834|lung function
1032695|NCT01874834|cardiac electrophysiology
1032696|NCT01874834|mediators of inflammation and clotting
1032697|NCT01874821|Frozen Shoulder
1032698|NCT01874821|Adhesive Capsulitis
1032699|NCT01874821|ROM
1032700|NCT01874821|Dynasplint
1032701|NCT01874808|movement preparation
1032702|NCT01874808|gait
1032703|NCT01874808|gait initiation
1032704|NCT01874808|postural control
1032705|NCT01874808|neuroimaging
1032706|NCT01874795|Autonomic Nervous System
1032707|NCT01874795|Neuromodulation
1032708|NCT01874795|Exercise
1032709|NCT01874795|Pulmonary oxygen kinetics
1032710|NCT01874795|Oxygen uptake
1032711|NCT01874782|spinal cord injury
1032712|NCT01874782|cardiovascular
1032713|NCT01874782|orthostatic hypotension
1032714|NCT01874782|transcranial electrical stimulation
1032715|NCT01874782|electrotherapy
1032716|NCT01874769|RDEB
1032717|NCT01874769|COL7A1
1032718|NCT01874769|Collagen VII
1032719|NCT01874756|schizophrenia
1032720|NCT01874756|Estrogen receptor agonist
1032721|NCT01874756|cognitive impairment
1032722|NCT01874756|negative symptoms
1032723|NCT01874743|HIV,
1032724|NCT01874743|Rosuvastatine,
1032725|NCT01874743|Antiretroviral therapy
1032726|NCT01874730|colorectal surgery
1032727|NCT01874730|fluid therapy
1032728|NCT01874717|Conscious sedation
1032729|NCT01874717|Dental anxiety
1032730|NCT01874717|Oral midazolam
1032731|NCT01874717|Intravenous midazolam
1032732|NCT01874717|Behaviour
1032733|NCT01874704|Stress, occupation, biomarkers, emergency, physicians
1032734|NCT01874691|acute myocardial infarction
1032735|NCT01874691|China
1032736|NCT01874691|Registry
1032737|NCT01874665|Gastrointestinal Neoplasms
1032738|NCT01874665|Gastrointestinal stromal tumor
1032739|NCT01874665|mesenchymal tumor
1032740|NCT01874639|Hepatectomy
1032741|NCT01874639|blood loss
1032742|NCT01874639|hemostasis
1032743|NCT01874639|coagulation
1032744|NCT01874639|Liver surgery (benign or malign)
1032745|NCT01874639|Resection of 2 or more segments
1032746|NCT01874626|acute ankle sprain
1032747|NCT01874626|Grade I or Grade II
1032748|NCT01874613|Craniofacial bone reconstruction
1032749|NCT01874613|Fibre-reinforced composite
1032750|NCT01874613|Bioactive glass
1032751|NCT01874613|Craniotomy
1032752|NCT01874613|Skull bone defect
1032753|NCT01874587|Adaptative radiotherapy
1032754|NCT01874587|oropharynx carcinoma
1032755|NCT01874587|xerostomia
1032756|NCT01874574|Knee Osteoarthritis
1032757|NCT01874574|Corticosteroid
1032758|NCT01874574|Hyaluronic acid
1032759|NCT01874574|Intra-articular injection
1032760|NCT01874561|Custirsen sodium
1032761|NCT01874561|TV1011
1032762|NCT01874561|OGX-011
1032763|NCT01874561|Thorough QT study
1032764|NCT01874561|cancer
1032765|NCT01874548|Autophagy
1032766|NCT01874548|Cancer metabolism
1032767|NCT01874548|Cervical cancer
1032768|NCT01874548|Diffusion weighted imaging
1032769|NCT01874548|Human papillomavirus
1032770|NCT01874548|Magnetic resonance spectroscopy.
1032894|NCT01873807|Etoposide
1032895|NCT01873807|HSCT
1032771|NCT01874522|Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
1032772|NCT01874405|Iron overload
1032773|NCT01874405|thalassaemia
1032774|NCT01874405|deferasirox
1032775|NCT01874405|magnetic resonance
1032776|NCT01874405|endocrine function
1032777|NCT01874379|Joint Replacement
1032778|NCT01874379|Hip Replacement
1032779|NCT01874379|Knee Replacement
1032780|NCT01874379|Complementary Medicine Intervention
1032781|NCT01874353|BRCA
1032782|NCT01874353|Ovarian cancer
1032783|NCT01874353|Chemotherapy
1032784|NCT01874353|PARP Inhibitor
1032785|NCT01874353|Platinum sensitive
1032786|NCT01874340|Multiple Sclerosis
1032787|NCT01874340|Relapsing Multiple Sclerosis
1032788|NCT01874340|AIN457
1032789|NCT01874340|Secukinumab
1032790|NCT01874340|Magnetic Resonance Imaging
1032791|NCT01874340|Relapsing Remitting Multiple Sclerosis
1032792|NCT01874340|Autoimmune Diseases
1032793|NCT01874340|Nervous System Diseases
1032794|NCT01874340|Immune System Diseases
1032795|NCT01874340|Demyelinating Diseases
1032796|NCT01874314|tuberculosis, SQ109, QTc, moxifloxacin, crossover, placebo, pharmacokinetic, randomized, single-center
1032797|NCT01874288|NHL
1032798|NCT01874288|Immunocytokine
1032799|NCT01874288|Lymphoma
1032800|NCT01874288|Non-Hodgkin
1032801|NCT01874288|B-cell
1032802|NCT01874288|IL (interleukin)
1032803|NCT01874249|Hepatic fibrosis
1032804|NCT01874249|Steatosis
1032805|NCT01874249|Noninvasive markers.
1032806|NCT01874236|SI joint pain, SI joint dysfunction, degenerative sacroiliitis, sacroiliac joint disruption
1032807|NCT01874223|Interstitial Lung Disease (ILD)
1032808|NCT01874223|Idiopathic Pulmonary Fibrosis (IPF)
1032809|NCT01874197|Thoracoabdominal Aortic Aneurysm
1032810|NCT01874197|Branched vessels
1032811|NCT01874158|Trichomonas vaginalis
1032812|NCT01874145|Multiple Sclerosis
1032813|NCT01874145|Relapsing-Remitting Multiple Sclerosis
1032814|NCT01874145|Glatiramer Acetate
1032815|NCT01874145|Glatiramer
1032816|NCT01874132|Exercise
1032817|NCT01874132|Blood pressure
1032818|NCT01874132|Lipids
1032819|NCT01874132|Body composition
1032820|NCT01874132|Fitness
1032821|NCT01874132|Bone density
1032822|NCT01874132|Quality of life
1032823|NCT01874119|melanoma
1032824|NCT01874119|renal cell carcinoma
1032825|NCT01874119|interleukin-2
1032826|NCT01874106|Hemodialysis
1032827|NCT01874106|Diet
1032828|NCT01874106|Inflammation
1032829|NCT01874106|Malnutrition
1032830|NCT01874054|Antibody-Drug Conjugate
1032831|NCT01874054|Antibodies, Monoclonal
1032832|NCT01874054|Hodgkin Disease
1032833|NCT01874054|Hematologic Diseases
1032834|NCT01874054|Drug Therapy
1032835|NCT01874054|Immunotherapy
1032836|NCT01874054|Antigens, CD30
1032837|NCT01874054|Lymphoma
1032838|NCT01874054|monomethylauristatin E
1032839|NCT01874041|Physical Therapy Modalities
1032840|NCT01874041|Facial Pain
1032841|NCT01874041|Orthodontic Appliances
1032842|NCT01874028|Trientine
1032843|NCT01874028|Pharmacokinetics
1032844|NCT01874015|Crohn's disease
1032845|NCT01874015|mesenchymal stem cell
1032846|NCT01874015|fistula
1032847|NCT01874002|Stents
1032848|NCT01874002|Stent
1032849|NCT01874002|Drug eluting
1032850|NCT01874002|Drug eluting stent
1032851|NCT01874002|Drug eluting stents
1032852|NCT01874002|Endothelial progenitor cell
1032853|NCT01874002|Endothelial progenitor cell capturing
1032854|NCT01874002|Sirolimus
1032855|NCT01874002|Sirolimus eluting
1032856|NCT01874002|Percutaneous Coronary Intervention
1032857|NCT01874002|PCI
1032858|NCT01874002|Registry
1032859|NCT01874002|Registries
1032860|NCT01874002|Multi center
1032861|NCT01874002|Multi centre
1032862|NCT01873989|Chronic pain
1032863|NCT01873989|Opioid addiction
1032864|NCT01873989|Symptomatic hypogonadism
1032865|NCT01873989|Testosterone replacement
1032866|NCT01873989|Opioid agonist maintenance
1032867|NCT01873989|Methadone
1032868|NCT01873989|Buprenorphine
1032869|NCT01873937|Lasertherapy
1032870|NCT01873937|Ledtherapy
1032871|NCT01873937|TMJs
1032872|NCT01873937|pain relief
1032873|NCT01873937|oral aperture
1032874|NCT01873924|Batten disease
1032875|NCT01873924|NCL
1032876|NCT01873924|Neuronal Ceroid Lipofuscinosis
1032877|NCT01873911|MPS IIIA
1032878|NCT01873911|MPS IIIB
1032879|NCT01873911|Sanfilippo syndrome type A
1032880|NCT01873911|Sanfilippo syndrome type B
1032881|NCT01873911|Hurler syndrome
1032882|NCT01873911|cognitive decline
1032883|NCT01873911|MPS IH
1032884|NCT01873885|PB1046, VIP, Essential Hypertension, Vasomera
1032885|NCT01873859|Lactic acidosis
1032886|NCT01873859|Contrast media
1032887|NCT01873859|Angiography
1032888|NCT01873859|Diabetic
1032889|NCT01873859|Metformin
1032890|NCT01873820|Vitamin C
1032891|NCT01873820|calcium ascorbate
1032892|NCT01873820|ascorbic acid
1032893|NCT01873807|Idarubicin
1032896|NCT01873807|Acute Lymphoblastic Leukemia
1032897|NCT01873794|Fatigue
1032898|NCT01873794|Sleep
1032899|NCT01873794|Quality of life
1032900|NCT01873794|Cancer
1032901|NCT01873794|Light
1032902|NCT01873768|Tranexamic acid
1032903|NCT01873768|6-Aminocaproic Acid
1032904|NCT01873768|Arthroplasty
1032905|NCT01873768|Osteoarthritis
1032906|NCT01873768|Arthritis
1032907|NCT01873768|Joint Diseases
1032908|NCT01873768|Musculoskeletal Diseases
1032909|NCT01873768|Rheumatic Diseases
1032910|NCT01873768|Antifibrinolytic Agents
1032911|NCT01873768|Fibrin Modulating Agents
1032912|NCT01873768|Pharmacologic Actions
1032913|NCT01873768|Coagulants
1032914|NCT01873768|Therapeutic Uses
1032915|NCT01873755|asthma
1032916|NCT01873755|children
1032917|NCT01873755|physical activity
1032918|NCT01873755|school
1032919|NCT01873742|Psychotherapy feedback
1032920|NCT01873729|ADHD
1032921|NCT01873729|Naltrexone
1032922|NCT01873729|Adults
1032923|NCT01873716|Atherosclerosis
1032924|NCT01873716|Molecular Imaging
1032925|NCT01873716|Vascular Biology
1032926|NCT01873716|Inflammation
1032927|NCT01873716|Fluorescence
1032928|NCT01873703|MDS
1032929|NCT01873703|High risk myelodysplastic syndrome
1032930|NCT01873703|Intermediate-2 Myelodysplastic syndrome
1032931|NCT01873703|Untreated
1032932|NCT01873690|Antibiotics
1032933|NCT01873690|Shock Wave Lithotripsy
1032934|NCT01873690|Urinary Tract Infection
1032935|NCT01873664|fMRI
1032936|NCT01873664|Jaw tapping
1032937|NCT01873664|Memory disorder
1032938|NCT01873664|Mild cognitive impairment
1032939|NCT01873664|MCI
1032940|NCT01873664|Working memory
1032941|NCT01873638|5-year outcome after cholecystectomy
1032942|NCT01873625|mesenchymal stem cells
1032943|NCT01873625|osteoarthritis
1032944|NCT01873625|arthritis rheumatoid
1032945|NCT01873612|Dexmedetomidine
1032946|NCT01873612|Propofol
1032947|NCT01873612|Hypoxic ventilatory response
1032948|NCT01873612|Hypercapnic ventilatory response
1032949|NCT01873573|radiation-induced stricture
1032950|NCT01873573|anastomotic stricture
1032951|NCT01873573|esophagogastroduodenoscopy (EGD)
1032952|NCT01873573|dilation
1032953|NCT01873573|steroid injection
1032954|NCT01873573|triamcinolone
1032955|NCT01873573|difficulty swallowing
1032956|NCT01873560|fractional flow reserve
1032957|NCT01873560|drug eluting stent
1032958|NCT01873560|coronary atherosclerosis
1032959|NCT01873547|spinal cord injury
1032960|NCT01873547|cell transplantation
1032961|NCT01873547|rehabilitation
1032962|NCT01873534|Anemia
1032963|NCT01873521|Positive Pressure Ventilation
1032964|NCT01873521|Neurally Adjusted Ventilatory Assist
1032965|NCT01873521|Patient/ventilator Asynchrony
1032966|NCT01873521|Pediatric patient
1032967|NCT01873521|Infant
1032970|NCT01873430|Melatonin
1032971|NCT01873430|Sunburn
1032972|NCT01873430|Erythema
1032973|NCT01873430|Sunlight
1032974|NCT01873430|Ultraviolet rays
1032975|NCT01873391|Diagnostic hysteroscopy
1032976|NCT01873391|Pain
1032977|NCT01873391|VAS
1032978|NCT01873391|Multivariate analysis
1032979|NCT01873391|Normal saline
1032980|NCT01873391|Carbon dioxide
1032981|NCT01873378|Uterine myoma
1032982|NCT01873378|GnRHa
1032983|NCT01873378|Hysteroscopy
1032984|NCT01873378|Cold loop
1032985|NCT01873365|Quality of life
1032986|NCT01873365|Herpes zoster
1032987|NCT01873365|Postherpetic neuralgia
1032988|NCT01873365|Japan
1032989|NCT01873365|Physician-practice
1032990|NCT01873365|Adults
1032991|NCT01873365|Health economics
1032992|NCT01873339|Drug interaction, healthy volunteer, SB-480848, Lp-PLA2, darapladib, atherosclerosis, midazolam
1032993|NCT01873326|newly diagnosed GCT
1032994|NCT01873326|Intermediate
1032995|NCT01873326|Poor-Risk
1032996|NCT01873326|BLEOMYCIN
1032997|NCT01873326|CISPLATIN
1032998|NCT01873326|ETOPOSIDE (VP-16)
1032999|NCT01873326|IFOSFAMIDE
1033000|NCT01873326|TAXOL (PACLITAXEL)
1033001|NCT01873326|13-074
1033002|NCT01873300|Achalasia
1033003|NCT01873300|Dysphagia
1033004|NCT01873300|Endoscopic
1033005|NCT01873300|Myotomy
1033006|NCT01873300|Heller
1033007|NCT01873300|NOTES
1033008|NCT01873300|POEM
1033009|NCT01873287|Concussions
1033010|NCT01873287|Persistent post-concussion symptoms
1033011|NCT01873287|PCS
1033012|NCT01873287|Clinical Prediction Rule
1033013|NCT01873261|Neurally Adjusted Ventilatory Assist
1033014|NCT01873261|Pediatric Acute Respiratory Failure
1033015|NCT01873261|non-invasive ventilation
1033016|NCT01873248|Neuroendocrine Carcinoma
1033017|NCT01873222|Coronary Artery Disease
1033018|NCT01873222|Percutaneous Coronary Intervention
1033019|NCT01873222|Optical Frequency Domain Imaging
1033020|NCT01873222|Intravascular Ultrasound
1033021|NCT01873183|echocardiography
1033022|NCT01873183|morbid obesity
1033023|NCT01873183|bariatric surgery
1033024|NCT01873183|venous return
1033025|NCT01873183|mean arterial blood pressure
1033026|NCT01873170|immune cells
1033027|NCT01873170|contraception
1033028|NCT01873170|intrauterine device
1033029|NCT01873170|IUD
1033030|NCT01873170|copper
1033031|NCT01873170|microflora
1033032|NCT01873170|DMPA
1033033|NCT01873170|etonogestrel
1033034|NCT01873170|subdermal implant
1033035|NCT01873157|Kidney transplantation
1033036|NCT01873157|Antibody formation
1033037|NCT01873157|Graft rejection
1033038|NCT01873157|Proteasome inhibitors
1033039|NCT01873157|Randomized controlled trial
1033040|NCT01873144|Bronchiolitis
1033041|NCT01873144|Hypertonic saline solution
1033042|NCT01873144|High-flow oxygen therapy
1033043|NCT01873144|Respiratory distress
1033044|NCT01873144|Comfort
1033045|NCT01873131|hemangioma
1033046|NCT01873131|infantile hemangioma
1033047|NCT01873131|pulsed dye laser
1033048|NCT01873131|PDL
1033049|NCT01873131|topical beta blocker
1033050|NCT01873131|timolol maleate
1033051|NCT01873131|timolol
1033052|NCT01873118|hospital discharge
1033053|NCT01873118|discharge readiness
1033054|NCT01873118|readmission
1033055|NCT01873118|Emergency Department visits
1033056|NCT01873118|Nurse assessment
1033057|NCT01873092|Oximetry
1033058|NCT01873092|Physical Activity
1033059|NCT01873079|ERCP
1033060|NCT01873079|sphincterotomy
1033061|NCT01873079|proton pump inhibitor
1033062|NCT01873066|Type 1 diabetes
1033063|NCT01873066|Closed-loop glucose control
1033064|NCT01873066|Artificial Pancreas
1033065|NCT01873066|Continuous subcutaneous insulin infusion
1033066|NCT01873066|Continuous glucose monitoring
1033067|NCT01873053|Osteoarthritis, Knee
1033068|NCT01873053|WIN-34B
1033069|NCT01873040|Social Media
1033070|NCT01873040|Vaccine
1033071|NCT01873040|Immunization
1033072|NCT01873027|Coronary Artery Disease
1033073|NCT01873027|Percutaneous Coronary Intervention
1033074|NCT01873027|Optical Frequency Domain Imaging
1033075|NCT01873027|Intravascular Ultrasound
1033076|NCT01873001|Healthy volunteers
1033077|NCT01873001|Drug-drug Interaction
1033078|NCT01873001|Pharmacokinetics
1033079|NCT01873001|Abiraterone
1033080|NCT01873001|JNJ-589485
1033081|NCT01873001|Abiraterone acetate
1033082|NCT01873001|JNJ-212082
1033083|NCT01873001|Pioglitazone HCl
1033084|NCT01872988|antiviral therapy
1033085|NCT01872988|intermediate stage
1033086|NCT01872988|hepatitis B virus
1033087|NCT01872962|Nasopharyngeal carcinoma
1033088|NCT01872962|Induction chemotherapy
1033089|NCT01872962|Concurrent chemoradiotherapy
1033090|NCT01872962|Clinical trial
1033091|NCT01872949|Heart Failure
1033092|NCT01872949|NYHA Class III
1033093|NCT01872949|NYHA Class IV
1033094|NCT01872923|Amphinex
1033095|NCT01872923|PCI
1033096|NCT01872923|Bleomycin
1033097|NCT01872923|Cutaneous malignancies
1033098|NCT01872923|Sub-cutaneous malignancies
1033099|NCT01872923|Safety
1033100|NCT01872923|Phase I
1033101|NCT01872923|Photochemical Internalisation
1033102|NCT01872923|Squamous Cell Carcinoma
1033103|NCT01872923|Head and Neck cancer
1033104|NCT01872923|Breast Cancer
1033105|NCT01872923|HNSCC
1033106|NCT01872923|SCCHN
1033107|NCT01872923|Advanced or metastatic cancer
1033108|NCT01872923|Dose finding
1033109|NCT01872910|Wisdom tooth extraction
1033110|NCT01872897|Gastroesophageal Reflux Disease
1033111|NCT01872897|GERD
1033112|NCT01872897|Acid reflux
1033113|NCT01872897|Compound Sodium Alginate Double Action Chewable Tablet
1033114|NCT01872897|Gaviscon Double Action Tablets
1033115|NCT01872884|Stroke
1033116|NCT01872884|Ischemic stroke
1033117|NCT01872884|Acute stroke
1033118|NCT01872884|Embolectomy
1033119|NCT01872884|Endovascular therapy
1033120|NCT01872884|Intra-arterial therapy
1033121|NCT01872884|Sedation
1033122|NCT01872884|Anesthesia
1033123|NCT01872845|Statin
1033124|NCT01872845|CIMT
1033125|NCT01872845|BES
1033126|NCT01872793|bioelectrical impedance vector analysis
1033127|NCT01872793|nutritional assessment
1033128|NCT01872793|nutritional status
1033129|NCT01872793|mortality
1033130|NCT01872793|complications
1033131|NCT01872780|CYP2C8
1033132|NCT01872780|genetic polymorphism
1033133|NCT01872780|rosiglitazone
1033134|NCT01872780|Korean
1033135|NCT01872767|Acute on Chronic Liver Failure (ACLF),Cirrhosis,
1033136|NCT01872767|Institute of Liver & Biliary Sciences (ILBS)
1033137|NCT01872754|Bronchial fibroscopy
1033138|NCT01872754|Remifentanil
1033139|NCT01872754|Propofol
1033140|NCT01872754|Sedation
1033141|NCT01872754|Target Controlled Infusion
1033142|NCT01872741|craniotomy,
1033143|NCT01872741|intracerebral aneurysms,
1033144|NCT01872741|atrophy,
1033145|NCT01872741|temporal muscle,
1033146|NCT01872741|outcome
1033147|NCT01872728|facial block
1033148|NCT01872728|levobupivacaine
1033149|NCT01872728|regional anesthesia
1033150|NCT01872728|rhinoplasty
1033151|NCT01872728|outpatient
1033152|NCT01872715|Papulopustular Rosacea
1033153|NCT01872715|Oracea
1033154|NCT01872715|anti inflammatory doxycycline
1033155|NCT01872702|Malaria elimination
1033156|NCT01872702|Chemotherapy
1033157|NCT01872702|Epidemiology
1033158|NCT01872702|South East Asia
1033159|NCT01872702|Artemisinin resistance
1033160|NCT01872702|Dihydroartemisinin piperaquine
1033161|NCT01872702|Primaquine
1033162|NCT01872676|Thermography
1033163|NCT01872676|Skin Temperature
1033164|NCT01872676|Manipulation, Spinal
1033165|NCT01872676|Physical Therapy Modalities
1033166|NCT01872663|Morbid obesity
1033167|NCT01872663|Bariatric surgery
1033168|NCT01872663|Pulmonary atelectasis
1033169|NCT01872663|Spirometry
1033170|NCT01872663|Continuos Positive Airway Pressure
1033171|NCT01872663|Physical therapy speciality
1033172|NCT01872650|postoperative adhesions
1033173|NCT01872650|adhesion prevention
1033174|NCT01872650|colorectal surgery
1033175|NCT01872650|temporary ostomy
1033176|NCT01872611|Diabetes Type I
1033177|NCT01872611|Diabetes Type II
1033178|NCT01872611|Non-proliferative diabetic retinopathy
1033179|NCT01872611|Macular edema
1033180|NCT01872611|Cataract
1033181|NCT01872598|Alzheimer
1033182|NCT01872598|dementia
1033183|NCT01872598|cognitive disease
1033184|NCT01872598|memory loss
1033185|NCT01872598|cerebrovascular disease
1033186|NCT01872585|Parenting
1033187|NCT01872585|Mental Illness
1033188|NCT01872585|Maternal sensitivity
1033189|NCT01872585|Parent-child relationship
1033190|NCT01872533|obesity
1033191|NCT01872533|hypoxia
1033192|NCT01872533|insulin sensitivity
1033193|NCT01872533|altitude
1033194|NCT01872520|the Injection of DanShenDuoFenSuanYan
1033195|NCT01872520|Magnesium Lithospermate B
1033196|NCT01872520|Safety
1033197|NCT01872520|Real World Study
1033198|NCT01872507|cerebral palsy
1033199|NCT01872507|autonomic nerveus system
1033200|NCT01872507|heart rate variability
1033201|NCT01872494|Local analgesia system
1033202|NCT01872494|Ropivacaine
1033203|NCT01872494|Analgesic efficacy after operation
1033204|NCT01872494|Postoperative
1033205|NCT01872481|Phantom limb pain syndrome
1033206|NCT01872481|Neuropathic pain
1033207|NCT01872481|Antipersonnel landmines
1033208|NCT01872481|Transcranial Magnetic Stimulation
1033209|NCT01872468|Glomerular filtration Rate.
1033210|NCT01872468|Primary Health Care.
1033211|NCT01872468|Cluster Clinical Trial.
1033212|NCT01872429|subtotal parathyroidectomy
1033213|NCT01872429|calcium
1033214|NCT01872429|phosphorus
1033215|NCT01872429|parathyroid hormone
1033216|NCT01872429|hyperparathyroidism
1033217|NCT01872416|Refractory and relapsed small cell lung cancer
1033218|NCT01872416|Liposomal Doxorubicin
1033219|NCT01872416|ifosfamide
1033220|NCT01872403|Squamous Cell Carcinoma of the lung
1033221|NCT01872390|Lesotho
1033222|NCT01872390|TB
1033223|NCT01872390|tuberculosis
1033224|NCT01872390|HIV
1033225|NCT01872390|antiretroviral therapy
1033226|NCT01872390|ART
1033227|NCT01872390|adherence
1033228|NCT01872390|combination intervention package
1033229|NCT01872390|retention
1033230|NCT01872377|pancreas
1033231|NCT01872377|pancreatic
1033232|NCT01872377|unresectable
1033233|NCT01872377|CyberKnife
1033234|NCT01872377|SBRT
1033235|NCT01872364|Hernia repair
1033236|NCT01872364|Hydrocelectomy
1033237|NCT01872364|Global Health
1033238|NCT01872364|Global Disease Burden
1033239|NCT01872364|Surgical Mission
1033240|NCT01872364|Dominican Republic
1033241|NCT01872364|Cost-minimization
1033242|NCT01872364|Procedural cost
1033243|NCT01872364|Material cost
1033244|NCT01872364|Item utilization
1033245|NCT01872364|Excision of benign cutaneous mass
1033246|NCT01872364|Minor procedure
1033247|NCT01872351|chronic fatigue syndrome
1033248|NCT01872351|mitochondrial disorder
1033249|NCT01872351|conditioning exercise
1033250|NCT01872351|nutraceutical supplements
1033251|NCT01872351|high protein diet
1033252|NCT01872338|suicide prevention
1033253|NCT01872338|cognitive behavioral therapy
1033254|NCT01872338|mindfulness meditation
1033255|NCT01872338|Veterans
1033256|NCT01872338|safety planning
1033257|NCT01872325|cardiac arrest
1033258|NCT01872325|bystander cardiopulmonary resuscitation CPR
1033259|NCT01872325|dispatch-assisted CPR instructions
1033260|NCT01872325|agonal breathing
1033261|NCT01872312|BPF(Bronchopleural fistulae)
1033262|NCT01872286|Capsule Endoscopy
1033263|NCT01872273|Metabolic Syndrome
1033264|NCT01872273|Obese
1033265|NCT01872273|Overweight
1033266|NCT01872273|Hypertension
1033267|NCT01872273|Hyperlipidemia
1033268|NCT01872273|Glucose Intolerant
1033269|NCT01872273|High blood sugar
1033270|NCT01872273|Exercise in obesity
1033271|NCT01872273|Platelets
1033272|NCT01872260|Hormone-receptor positive
1033273|NCT01872234|Heart Failure
1033274|NCT01872234|Cardiac Resynchronization Therapy
1033275|NCT01872234|Mild systolic dysfunction
1033276|NCT01872234|Left Bundle Branch Block
1033277|NCT01872221|Glioblastoma
1033278|NCT01872221|Spectroscopy
1033279|NCT01872221|MRI
1033280|NCT01872221|Glioma stem cells
1033281|NCT01872221|Surgery
1033282|NCT01872221|Radioresistance
1033283|NCT01872208|PAD
1033284|NCT01872208|Atherosclerosis
1033285|NCT01872208|Peripheral circulation
1033286|NCT01872208|Blood Vessel Prosthesis
1033287|NCT01872208|Tissue-Engineered Vascular Graft
1033288|NCT01872208|Vascular Prosthesis Implantation
1033289|NCT01872208|Femoro-Popliteal Bypass
1033290|NCT01872195|Checklist
1033291|NCT01872195|In-Hospital Mortality
1033292|NCT01872195|In-Hospital Morbidity
1033293|NCT01872156|Smoking
1033294|NCT01872156|Primary care
1033295|NCT01872130|Moh's Surgery
1033296|NCT01872130|mosaicing algorithm
1033297|NCT01872130|intraoperative imaging
1033298|NCT01872130|12-239
1033299|NCT01872104|rectal cancer
1033300|NCT01872104|rectal adenocarcinoma
1033301|NCT01872104|photodynamic therapy
1033302|NCT01872104|chemothrapy
1033303|NCT01872078|Pharmacokinetics, Pharmacodynamics, endocrinopathies, PCOS, female, hormone, LH
1033304|NCT01872039|Nicardipine
1033305|NCT01872039|Hypertension
1033306|NCT01872039|Calcium blocker
1033307|NCT01872026|Plasma concentration
1033308|NCT01872026|Pharmacokinetics
1033309|NCT01872026|Pharmacodynamics
1033310|NCT01872026|ASP7991
1033311|NCT01872013|Plasma concentration
1033312|NCT01872013|Urinary concentration
1033313|NCT01872013|ASP7991
1033314|NCT01872000|Intraocular lens
1033315|NCT01872000|Phacoemulsification
1033316|NCT01871987|FK949E
1033317|NCT01871987|Quetiapine
1033318|NCT01871987|Antipsychotic
1033319|NCT01871974|FK949E
1033320|NCT01871974|Antipsychotic
1033321|NCT01871974|Quetiapine
1033322|NCT01871909|Physical trauma
1033323|NCT01871896|Surgical Endoscopy
1033324|NCT01871896|Morbid Obesity
1033325|NCT01871896|Weight Loss
1033326|NCT01871896|Bariatrics
1033327|NCT01871896|Surgical Revision
1033328|NCT01871883|Sensitive skin
1033329|NCT01871883|Transient potential receptor vanilloid 1
1033330|NCT01871883|TRPV1
1033331|NCT01871883|Transepidermal water loss
1033332|NCT01871883|Skin Phototype
1033333|NCT01871883|Lactic acid test
1033334|NCT01871883|Skin irritancy tests
1033335|NCT01871818|Multiple sclerosis
1033336|NCT01871818|Rehabilitation
1033337|NCT01871818|Chronic evolutive disease
1033338|NCT01871818|Physiotherapy
1033339|NCT01871818|Resistance training
1033340|NCT01871818|Endurance training
1033341|NCT01871792|Contrast-induced nephropathy
1033342|NCT01871792|Prevention
1033343|NCT01871792|Statin
1033344|NCT01871792|Pitavastatin
1033345|NCT01871766|Rhabdomyosarcoma
1033346|NCT01871766|Radiation therapy
1033347|NCT01871766|Proton beam
1033348|NCT01871740|Folic acid
1033349|NCT01871740|Renal function decline
1033350|NCT01871740|Hypertension
1033351|NCT01871740|Hyperhomocysteinemia
1033352|NCT01871740|Chronic kidney disease
1033353|NCT01871740|MTHFR C677T genotype
1033354|NCT01871740|Randomized controlled trial
1033355|NCT01871727|Persistent or Recurrent Cutaneous T-Cell Lymphoma
1033356|NCT01871727|E7777
1033357|NCT01871714|XLHED
1033358|NCT01871714|HED
1033359|NCT01871714|Hypohidrotic Ectodermal Dysplasia
1033360|NCT01871714|X Linked Hypohidrotic Ectodermal Dysplasia
1033361|NCT01871701|Corrected QT interval prolongation
1033362|NCT01871701|Psychotropic drugs
1033363|NCT01871688|pelvic floor dysfunction
1033364|NCT01871688|neuromodulation
1033365|NCT01871688|rehabilitation
1033366|NCT01871675|Lymphoma
1033367|NCT01871675|Chronic Lymphocytic Leukemia
1033368|NCT01871675|Non-Hodgkin Lymphoma
1033369|NCT01871675|T-cell Lymphoma
1033370|NCT01871675|Rituxan
1033371|NCT01871675|Bendamustine
1033372|NCT01871675|Hematologic Malignancy
1033373|NCT01871675|Relapsed
1033374|NCT01871675|Refractory
1033375|NCT01871662|HCV
1033376|NCT01871662|Hepatitis C
1033377|NCT01871649|psoriatic arthritis
1033378|NCT01871649|golimumab
1033379|NCT01871649|methotrexate
1033380|NCT01871649|minimal disease activity
1033381|NCT01871649|safety
1033382|NCT01871649|withdrawal
1033383|NCT01871636|endoscopy
1033384|NCT01871636|WESD
1033385|NCT01871636|EMR
1033386|NCT01871623|Cleft lip and palate
1033387|NCT01871623|Cone-Beam Computed Tomography
1033388|NCT01871623|Le Fort I Osteotomy
1033389|NCT01871623|Segmental Osteotomy
1033390|NCT01871623|Stability
1033391|NCT01871610|Traumatic brain injury
1033392|NCT01871610|mild TBI
1033393|NCT01871610|Alzheimer's disease
1033394|NCT01871610|[18F]AV-45 PET amyloid binding imaging
1033395|NCT01871597|Lung cancer
1033396|NCT01871597|VATS procedure
1033397|NCT01871597|Pulmonary Artery Sealing
1033398|NCT01871584|A colon hydrotherapy system
1033399|NCT01871584|Hydrocolonic preparation
1033400|NCT01871584|Preparation for colonoscopy
1033401|NCT01871558|type 2 diabetes
1033402|NCT01871558|basal insulin
1033403|NCT01871558|vildagliptin
1033404|NCT01871545|hepatocellular carcinoma
1033405|NCT01871545|HCC
1033406|NCT01871545|liver cancer
1033407|NCT01871545|liver disease
1033408|NCT01871545|magnetic resonance imaging
1033409|NCT01871545|MRI
1033410|NCT01871532|Monofollicular Development
1033411|NCT01871532|Gonal-f®
1033412|NCT01871532|Recombinant Follicle Stimulating Hormone
1033413|NCT01871532|Ovarian hyperstimulation syndrome (OHSS)
1033414|NCT01871519|vertebral body compression fracture
1033415|NCT01871480|NSCLC
1033416|NCT01871480|CIK
1033417|NCT01871480|Gefitinib
1033418|NCT01871480|Adenocarcinoma
1033419|NCT01871402|psoriasis
1033420|NCT01871402|lotion
1033421|NCT01871402|investigator's global assessment
1033422|NCT01871376|PCV
1033423|NCT01871363|Preoperative Chemoradiotherapy
1033424|NCT01871363|Bevacizumab
1033425|NCT01871363|Locally Advanced Rectal Cancer
1033426|NCT01871350|Cancer
1033427|NCT01871350|Chemotherapy
1033428|NCT01871350|Chemo related toxicity
1033429|NCT01871350|Protein digestion
1033430|NCT01871350|Fat digestion
1033431|NCT01871350|Gut function
1033432|NCT01871350|Glucose absorption
1033433|NCT01871350|Muscle function
1033434|NCT01871337|Multiple Sclerosis
1033435|NCT01871337|urinary incontinence
1033436|NCT01871311|metastatic Kras wildtype
1033437|NCT01871311|squamous cell carcinoma
1033438|NCT01871311|cetuximab
1033439|NCT01871311|nilotinib
1033440|NCT01871298|internet and mobile technology use
1033441|NCT01871298|history of drug use
1033442|NCT01871298|injection drug user (IDU) syringe customers
1033443|NCT01871285|ATC, Opioid, withdrawal, switch
1033444|NCT01871259|Sedation, sleep apnea, propofol
1033445|NCT01871233|anti-epileptic drug
1033446|NCT01871233|Extended Access Program
1033447|NCT01871233|partial onset seizures
1033448|NCT01871233|Perampanel
1033449|NCT01871220|Implant Abutments
1033450|NCT01871220|Oral Mucosa Changes
1033451|NCT01871220|Implant Esthetics
1033452|NCT01871207|Erythropoietin (EPO)
1033453|NCT01871207|Diabetes
1033454|NCT01871207|Diabetic Retinopathy
1033455|NCT01871207|Vascular Endothelial Growth Factor (VEGF)
1033456|NCT01871207|Erythropoiesis Stimulating Agents (ESA)
1033457|NCT01871142|5 Hydroxymethyl 2 Furfural
1033458|NCT01871142|AES103
1033459|NCT01871142|Exercise
1033460|NCT01871129|Dexmedetomidine
1033461|NCT01871129|Postoperative Period
1033462|NCT01871129|Airway extubation
1033463|NCT01871129|Systolic Pressure
1033464|NCT01871116|breast cancer
1033465|NCT01871116|early stage
1033466|NCT01871116|weight loss
1033467|NCT01871103|Soft tissue defect
1033468|NCT01871103|dorsal branch of the digital artery
1033469|NCT01871103|dorsal branch of the digital nerve
1033470|NCT01871103|dorsal homodigital island flap
1033471|NCT01871090|Remote Monitoring
1033472|NCT01871090|Remote Care
1033473|NCT01871090|Cardiac Resynchronization Therapy
1033474|NCT01871090|Pacemaker
1033475|NCT01871090|Implantable Cardioverter Defibrillator
1033476|NCT01871064|Laparotomy
1033477|NCT01871064|laparoscopic surgery
1033478|NCT01871064|general anesthesia
1033479|NCT01871064|Neuromuscular Block
1033480|NCT01871038|vaccine effectiveness
1033481|NCT01871038|rotavirus
1033482|NCT01871038|acute gastroenteritis
1033483|NCT01871025|Chronic obstructive pulmonary disease
1033484|NCT01871012|Nerve Block
1033485|NCT01871012|Intraoperative Care
1033486|NCT01871012|Postoperative Recovery and Complications
1033487|NCT01871012|Stress and Inflammation
1033488|NCT01870986|Healthy Volunteers
1033489|NCT01870986|Phase 1
1033490|NCT01870986|PK
1033491|NCT01870986|adalimumab
1033492|NCT01870986|Single-dose
1033493|NCT01870986|Immunology
1033494|NCT01870986|Bioequivalence
1033495|NCT01870986|Biosimilarity
1033496|NCT01870986|Similarity.
1033497|NCT01870973|postoperative pain
1033498|NCT01870973|root canal treatment
1033499|NCT01870947|Stage I endometrial adenocarcinoma
1033500|NCT01870947|Obesity
1033501|NCT01870947|Exercise and Physical Fitness
1033502|NCT01870947|Diet
1033503|NCT01870947|Cancer
1033504|NCT01870934|Telemedicine
1033505|NCT01870934|Diabetes
1033506|NCT01870934|Foot Ulcers
1033507|NCT01870895|YM060
1033508|NCT01870895|Ramosetron
1033509|NCT01870895|Diarrhea-predominant Irritable Bowel Syndrome
1033510|NCT01870882|Opioid-Related Disorders
1033511|NCT01870882|Cocaine-Related Disorders
1033512|NCT01870882|Substance-Related Disorders
1033513|NCT01870882|Mental Disorders
1033514|NCT01870882|Cocaine
1033515|NCT01870882|Methadone
1033516|NCT01870882|Therapeutic Uses
1033517|NCT01870856|Ocular discomfort
1033518|NCT01870856|Contact lenses
1033519|NCT01870856|Myopia
1033520|NCT01870843|Depressive Disorder, Major
1033521|NCT01870843|Depressive Disorder
1033522|NCT01870843|Depression
1033523|NCT01870843|Anxiety
1033524|NCT01870843|Escitalopram
1033525|NCT01870843|Quality of life
1033526|NCT01870843|Social functionality
1033527|NCT01870817|Randomized
1033528|NCT01870817|Jejunostomy
1033529|NCT01870817|Enteral
1033530|NCT01870817|Nutrition
1033531|NCT01870817|Esophagectomy
1033532|NCT01870817|Gastrectomy
1033533|NCT01870804|Statins
1033534|NCT01870804|Contrast-Induced Acute Kidney Injury
1033535|NCT01870804|Periprocedural Myocardial Damage
1033536|NCT01870791|Esophageal adenocarcinoma
1033537|NCT01870791|Gastric adenocarcinoma
1033538|NCT01870778|acute heart failure,
1033539|NCT01870778|AHF,
1033540|NCT01870778|multi-center,
1033541|NCT01870778|randomized,
1033542|NCT01870778|double-blind
1033543|NCT01870739|LCZ696,
1033544|NCT01870739|Hypertension,
1033545|NCT01870739|Aortic stiffness,
1033546|NCT01870739|Central blood pressure,
1033547|NCT01870739|Cardiovascular MRI
1033548|NCT01870713|gastric bypass surgery
1033549|NCT01870713|proteomics
1033550|NCT01870687|vitex agnus castus
1033551|NCT01870687|clinical trial
1033552|NCT01870687|cyclic mastodynia
1033553|NCT01870687|PMS
1033554|NCT01870687|prospective
1033555|NCT01870674|safety
1033556|NCT01870674|tolerability
1033557|NCT01870674|pharmacokinetics
1033558|NCT01870674|pharmacodynamics
1033559|NCT01870661|Intravenous placement
1033560|NCT01870661|Ultrasound
1033561|NCT01870648|Low-middle income country
1033562|NCT01870648|Dehydration
1033563|NCT01870648|Intravenous Rehydration
1033564|NCT01870648|Pakistan
1033565|NCT01870635|Low-middle income country
1033566|NCT01870635|Dehydration
1033567|NCT01870635|Intravenous Rehydration
1033568|NCT01870635|Pakistan
1033569|NCT01870622|Newborn,
1033570|NCT01870622|Infant,
1033571|NCT01870622|Endotracheal Intubation,
1033572|NCT01870622|Carbon dioxide detector,
1033573|NCT01870622|Flow waves
1033574|NCT01870583|Cesarean delivery
1033575|NCT01870583|Surgical site infection
1033576|NCT01870583|Pregnancy
1033577|NCT01870583|Postpartum
1033578|NCT01870570|Glycaemia
1033579|NCT01870570|Insulinemia
1033580|NCT01870557|Diabetes Mellitus
1033581|NCT01870557|Bone
1033582|NCT01870557|Bone Status
1033583|NCT01870557|Glycemic Markers
1033584|NCT01870557|Osteoporosis
1033585|NCT01870557|Osteopenia
1033586|NCT01870544|gastric bypass
1033587|NCT01870544|microbiota
1033588|NCT01870544|probiotic
1033589|NCT01870531|Transient Ischemic Attack
1033590|NCT01870518|Parkinson's disease
1033591|NCT01870518|Dementia
1033592|NCT01870505|BYL719
1033593|NCT01870505|Letrozole
1033594|NCT01870505|Exemestane
1033595|NCT01870505|13-027
1033596|NCT01870492|IV-tPA
1033597|NCT01870492|Activase
1033598|NCT01870492|endovascular therapy
1033599|NCT01870479|Malignant Lymphoma
1033600|NCT01870479|Chemotherapy
1033601|NCT01870479|Music therapy
1033602|NCT01870453|Alzheimer Disease
1033603|NCT01870453|Dementia
1033604|NCT01870453|Postoperative Care
1033605|NCT01870453|Cognitive Reserve
1033606|NCT01870440|Uveitis
1033607|NCT01870440|Macular Edema
1033608|NCT01870427|Macular Edema
1033609|NCT01870427|Central Retinal Vein Occlusion
1033610|NCT01870427|CRVO
1033611|NCT01870427|Aflibercept
1033612|NCT01870427|VEGF Trap-Eye
1033613|NCT01870427|Eylea
1033614|NCT01870427|Ranibizumab
1033615|NCT01870427|Bevacizumab
1033616|NCT01870375|Mucopolysaccharidosis
1033617|NCT01870375|Longitudinal
1033618|NCT01870375|Brain
1033619|NCT01870375|Cognition
1033620|NCT01870375|Quality-of-Life
1033621|NCT01870375|Hurler syndrome
1033622|NCT01870375|Hunter syndrome
1033623|NCT01870375|Hurler-Scheie syndrome
1033624|NCT01870375|Scheie syndrome
1033625|NCT01870375|Maroteaux-Lamy syndrome
1033626|NCT01870375|MPS I
1033627|NCT01870375|MPS II
1033628|NCT01870375|MPS VI
1033629|NCT01870375|Mucopolysaccharidosis type I
1033630|NCT01870375|Mucopolysaccharidosis type II
1033631|NCT01870375|Mucopolysaccharidosis type VI
1033632|NCT01870375|MPS IV
1033633|NCT01870375|MPS VII
1033634|NCT01870375|Mucopolysaccharidosis type IV
1033635|NCT01870375|Mucopolysaccharidosis type VII
1033636|NCT01870375|Morquio syndrome
1033637|NCT01870375|Sly syndrome
1033638|NCT01870349|cytokines
1033639|NCT01870349|dental implants
1033640|NCT01870349|peri-implantitis
1033641|NCT01870310|Heart failure
1033642|NCT01870310|Renal denervation
1033643|NCT01870271|PTSD
1033644|NCT01870271|childhood sexual abuse
1033645|NCT01870271|physical abuse
1033646|NCT01870271|developmentally adapted cognitive processing therapy
1033647|NCT01870258|Myocardial infarction
1033648|NCT01870258|artificial neural networks
1033649|NCT01870258|Electrocardiography
1033650|NCT01870232|Greater palatine nerve Block
1033651|NCT01870232|Inferior Alveolar nerve block
1033652|NCT01870232|dental anesthesia
1033653|NCT01870232|Ultrasonography
1033654|NCT01870219|sevoflurane
1033655|NCT01870219|ketamine
1033656|NCT01870219|QT interval
1033657|NCT01870206|Immunogenicity
1033658|NCT01870206|Safety
1033659|NCT01870206|Efficacy
1033660|NCT01870206|Poliomyelitis
1033661|NCT01870206|Newborn
1033662|NCT01870193|Glutathione deficiency in aging
1033663|NCT01870193|Impaired mitochondrial fatty-acid oxidation in aging
1033664|NCT01870180|Meibomian Glad Dysfunction
1033665|NCT01870180|EyeBag
1033666|NCT01870180|Hot Compress
1033667|NCT01870180|Dry Eyes
1033668|NCT01870167|PEG
1033669|NCT01870167|Percutaneous Endoscopic Gastrostomy
1033670|NCT01870167|antibiotic prophylaxis
1033671|NCT01870154|Burnout syndrome
1033672|NCT01870154|Job stressors
1033673|NCT01870154|Primary Health Care
1033674|NCT01870154|Health professional
1033675|NCT01870141|Glucose Control
1033676|NCT01870141|Depression
1033677|NCT01870141|Self-Efficacy
1033678|NCT01870128|Rheumatoid arthritis
1033679|NCT01870128|Steroid
1033680|NCT01870115|Melatonin
1033681|NCT01870115|Strontium Citrate
1033682|NCT01870115|Osteoporosis
1033683|NCT01870115|Osteopenia
1033684|NCT01870089|Non invasive ventilation
1033685|NCT01870089|Computer-driven system
1033686|NCT01870089|Acute respiratory failure
1033687|NCT01870063|5 minute bleeding test
1033688|NCT01870063|swamb
1033689|NCT01870063|fibtem
1033690|NCT01870063|extem
1033691|NCT01870050|lichen simplex chronicus
1033692|NCT01870050|prurigo
1033693|NCT01870037|OAB, gene therapy
1033694|NCT01870024|status epilepticus
1033695|NCT01870024|epilepsy
1033696|NCT01870024|seizures
1033697|NCT01870024|convulsive seizures
1033698|NCT01870024|convulsions
1033699|NCT01870024|benzodiazepines
1033700|NCT01870024|anticonvulsants
1033701|NCT01870011|Propofol, renal protection, kidney transplantation
1033702|NCT01869998|Vortex
1033703|NCT01869998|Thrombus
1033704|NCT01869998|Contrast echocardiography
1033705|NCT01869998|Prediction and prevention of apical thrombus formation in acute myocardial infarction patient by using Vortex parameters.
1033706|NCT01869985|HCP1104
1033707|NCT01869985|Eperisone Hydrochloride
1033708|NCT01869985|Aceclofenac
1033709|NCT01869972|PKU
1033710|NCT01869972|phenylketonuria
1033711|NCT01869972|hyperphenylalaninemia
1033712|NCT01869972|Kuvan
1033713|NCT01869972|sapropterin
1033714|NCT01869946|Hip arthroplasty
1033715|NCT01869933|Proliferative, Diabetic, Retinopathy
1033716|NCT01869920|breastfeeding
1033717|NCT01869920|education
1033718|NCT01869920|intervention
1033719|NCT01869894|Malignant biliary obstruction
1033720|NCT01869894|metal stent
1033721|NCT01869894|patency
1033722|NCT01869855|chronic subdural hematoma
1033723|NCT01869855|traumatic brain injury
1033724|NCT01869855|burr hole trepanation
1033725|NCT01869855|drainage after evacuation of chronic subdural hematoma
1033726|NCT01869855|intracranial bleed
1033727|NCT01869842|Resolute zotarolumus-eluting stent
1033728|NCT01869842|optical coherence tomography
1033732|NCT01869738|heart attack
1033733|NCT01869725|Neuroendocrine Tumor
1033734|NCT01869725|Ga-DOTATOC PET
1033735|NCT01869725|Imaging
1033736|NCT01869712|cupping therapy
1033737|NCT01869712|acupuncture
1033738|NCT01869712|partially randomized
1033739|NCT01869712|patient preference
1033740|NCT01869712|fibromyalgia
1033741|NCT01869712|criteria formulated by American College Rheumatology 2002
1033742|NCT01869699|Fever
1033743|NCT01869699|Acetaminophen
1033744|NCT01869699|Critical Care
1033745|NCT01869699|ICU
1033746|NCT01869699|Febrile
1033747|NCT01869673|Difficult mask ventilation
1033748|NCT01869673|extubation
1033749|NCT01869673|nasal surgery
1033750|NCT01869660|First hospitalization
1033751|NCT01869647|kidney stones
1033752|NCT01869634|HIV
1033753|NCT01869634|cardiovascular risk
1033754|NCT01869634|systemic immune activation
1033755|NCT01869608|postpartum screening
1033756|NCT01869608|type 2 diabetes
1033757|NCT01869595|2000 MSM and TG sites in Bangkok,Lampang,Ubonratchathani
1033758|NCT01869582|Fetal hypoxia
1033759|NCT01869582|Birth asphyxia
1033760|NCT01869582|Neonatal resuscitation
1033764|NCT01869556|pregnancy
1033765|NCT01869556|postpartum hemorrhage
1033766|NCT01869556|Cesarean delivery
1033767|NCT01869556|failure to progress in labor
1033768|NCT01869504|Ballooned intercostal drain
1033769|NCT01869504|Pleural effusion
1033770|NCT01869491|Gastroesophageal Reflux Disease
1033771|NCT01869491|GERD
1033772|NCT01869491|Dyspepsia
1033773|NCT01869491|Indigestion
1033774|NCT01869491|Heartburn
1033775|NCT01869491|Acid reflux
1033776|NCT01869491|Compound Sodium Alginate Double Action Chewable Tablets
1033777|NCT01869491|Gaviscon Double Action Tablets
1033778|NCT01869452|education
1033779|NCT01869452|risk factors
1033780|NCT01869452|quality of life
1033781|NCT01869452|coronary disease
1033782|NCT01869452|telephone follow up
1033783|NCT01869452|dedicated nurse
1033784|NCT01869439|Pressure Ulcers
1033785|NCT01869439|Bed Sores
1033786|NCT01869439|Measuring
1033787|NCT01869439|Visual Images
1033788|NCT01869439|Thermal Images
1033789|NCT01869439|External Wounds
1033790|NCT01869439|Area
1033791|NCT01869439|Length
1033792|NCT01869439|Width
1033793|NCT01869439|Gradiency
1033794|NCT01869426|colics
1033795|NCT01869413|urothelial cell carcinoma
1033796|NCT01869413|transition cell carcinoma
1033797|NCT01869413|bladder cancer
1033798|NCT01869413|radical cystectomy
1033799|NCT01869413|cystectomy
1033800|NCT01869413|bladder removal
1033801|NCT01869413|tranexamic acid
1033802|NCT01869413|cyklokapron
1033803|NCT01869374|Depression
1033804|NCT01869374|Brain Stimulation
1033805|NCT01869374|Seizure therapy
1033806|NCT01869374|Convulsive Therapy
1033807|NCT01869361|preterm labor
1033808|NCT01869361|tocolysis
1033809|NCT01869361|indomethacin
1033810|NCT01869348|Physical activity
1033811|NCT01869348|Activity monitor
1033812|NCT01869348|Technology
1033813|NCT01869348|Obesity
1033814|NCT01869348|Aging muscle
1033815|NCT01869335|breast cancer
1033816|NCT01869335|MRI
1033817|NCT01869335|mammography
1033818|NCT01869335|microcalcifications
1033819|NCT01869335|Local staging of breast microcalcifications
1033820|NCT01869335|Evaluation of ex vivo MRI for breast malignancies detected by MRI only
1033821|NCT01869322|Humerus
1033822|NCT01869322|Fracture
1033823|NCT01869322|Sling
1033824|NCT01869322|Splint
1033825|NCT01869322|Coaptation
1033826|NCT01869309|Coronary artery disease
1033827|NCT01869309|anti-platelet medications
1033828|NCT01869309|Platelet-aggregation Inhibitors
1033829|NCT01869296|unsedated
1033830|NCT01869296|water immersion colonoscopy
1033831|NCT01869296|endoscope water pump flow rates
1033832|NCT01869283|Physical Therapy Modalities
1033833|NCT01869283|Myofascial Pain Syndromes
1033834|NCT01869283|Skeletal Muscle
1033835|NCT01869270|hexosaminidase deficiency
1033836|NCT01869270|Tay-Sachs disease
1033837|NCT01869270|Sandhoff disease
1033838|NCT01869270|late-onset Tay-Sachs disease
1033839|NCT01869270|adult-onset Tay-Sachs disease
1033840|NCT01869270|late onset Tay Sachs disease
1033841|NCT01869270|adult onset Tay Sachs disease
1033842|NCT01869270|retrospective
1033843|NCT01869270|hexosaminidase A activity
1033844|NCT01869270|GM2-ganglioside
1033845|NCT01869270|gangliosidoses
1033846|NCT01869270|natural history
1033847|NCT01869270|hexosaminidase
1033848|NCT01869257|triclosan
1033849|NCT01869257|colorectal
1033850|NCT01869257|surgery
1033851|NCT01869257|surgical site infection
1033852|NCT01869218|Cancer
1033853|NCT01869218|Advanced
1033854|NCT01869218|Solid
1033855|NCT01869218|Hematological
1033856|NCT01869218|Malignancy
1033857|NCT01869218|Tissue
1033858|NCT01869218|Bank
1033863|NCT01869192|Malignant
1033864|NCT01869192|Neoplasm
1033865|NCT01869192|Cancer
1033866|NCT01869192|Female
1033867|NCT01869192|Breast
1033868|NCT01869192|Stage II
1033869|NCT01869192|Stage III
1033870|NCT01869179|Well being
1033871|NCT01869179|Low income
1033872|NCT01869179|Choir singing
1033873|NCT01869179|Spanish speaking
1033874|NCT01869179|Community based
1033875|NCT01869179|Seniors
1033876|NCT01869179|60+ aged adults
1033877|NCT01869166|chemotherapy and/or EGFR-antibody/kinase inhibitor therapy refractory solid tumors
1033878|NCT01869153|Growth, weight
1033879|NCT01869127|hookworm
1033880|NCT01869127|necator americanus
1033881|NCT01869127|ancyclostoma duodenale
1033882|NCT01869127|shoes
1033883|NCT01869127|anaemia
1033884|NCT01869127|children
1033885|NCT01869101|Prediabetes
1033886|NCT01869101|Diabetes prevention
1033887|NCT01869088|TACE
1033888|NCT01869088|Carcinoma,Hepatocellular
1033889|NCT01869088|Liver Neoplasms
1033890|NCT01869088|overall survival
1033891|NCT01869088|Recombinant Human Adenovirus Type 5 Injection
1033892|NCT01869075|Quality Improvement
1033893|NCT01869075|Patient Safety
1033894|NCT01869075|Knowledge Translation
1033895|NCT01869062|CRT
1033896|NCT01869049|Immune Thrombocytopenia
1033897|NCT01869049|macrophage
1033898|NCT01869049|spleen tissue
1033899|NCT01869036|Caudal
1033900|NCT01869036|anesthesia
1033901|NCT01869036|morphine
1033902|NCT01869036|children
1033903|NCT01869023|Advanced Malignant Pleural Mesothelioma
1033904|NCT01869023|Gemcitabine and cisplatin
1033905|NCT01869023|Gemcitabine continuous infusion
1033906|NCT01869010|HIV infection
1033907|NCT01869010|Antiretroviral treatment
1033908|NCT01869010|Renal disease
1033909|NCT01869010|Renal tubular damage
1033910|NCT01869010|Free-water clearance
1033911|NCT01868997|Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated
1033912|NCT01868997|Ophthalmopathy
1033913|NCT01868958|Magnetic resonance imaging (MRI)
1033914|NCT01868958|Diffusion tensor imaging
1033915|NCT01868958|Spine
1033916|NCT01868945|Vitamin D3
1033917|NCT01868945|Calcifediol 25
1033918|NCT01868945|Frail
1033919|NCT01868945|Dose-response
1033920|NCT01868932|wheeze
1033921|NCT01868932|early childhood
1033922|NCT01868932|asthma
1033923|NCT01868932|bronchiolitis
1033924|NCT01868932|infection triggered
1033925|NCT01868919|"Pilot Projects[Mesh]"
1033926|NCT01868919|"Parenting[Mesh]"
1033927|NCT01868919|"Child Behaviour[Mesh]"
1033928|NCT01868919|"Mental Health[Mesh]"
1033929|NCT01868919|"Family Practice[Mesh]"
1033930|NCT01868906|Anaplastic Astrocytoma
1033931|NCT01868906|Brain Tumors
1033932|NCT01868906|Cancer Imaging
1033933|NCT01868906|Fluoromisonidazole
1033934|NCT01868906|FMISO PET
1033935|NCT01868906|Glioblastoma
1033936|NCT01868906|High Grade Glioma
1033937|NCT01868906|Hypoxia Modification
1033938|NCT01868906|Positron Emission Tomography
1033939|NCT01868906|Radiation-Sensitizing Agents
1033940|NCT01868906|Spinal Cord Stimulation
1033941|NCT01868906|Tumor Hypoxia Measurement
1033942|NCT01868854|Tip catheter
1033943|NCT01868854|Peritoneal Dialysis
1033944|NCT01868854|Risk Factot
1033945|NCT01868854|Mecanical Function
1033946|NCT01868841|123I-mIBG
1033947|NCT01868841|AdreView
1033948|NCT01868841|SPECT
1033949|NCT01868841|Heart to Mediastinal Ratio
1033950|NCT01868828|Multiple Myeloma
1033951|NCT01868828|Combination Therapy
1033952|NCT01868802|Ketamine
1033953|NCT01868802|Depression
1033954|NCT01868802|Depressive Disorder
1033955|NCT01868789|Adult-acquired flatfoot disorder (AAFD)
1033956|NCT01868789|flexible flatfoot
1033957|NCT01868789|computed tomography (CT)
1033958|NCT01868763|telemedicine
1033959|NCT01868763|coaching
1033960|NCT01868763|lifestyle change
1033961|NCT01868763|weight loss
1033962|NCT01868737|Human Immunodeficiency Virus
1033963|NCT01868737|Necrotizing Enterocolitis
1033964|NCT01868737|Premature infant
1033965|NCT01868737|Probiotic
1033966|NCT01868737|Very Low Birth Weight
1033967|NCT01868724|Kidney Renal
1033968|NCT01868711|Major Depressive Disorder
1033969|NCT01868711|Cognitive Behavior Therapy
1033970|NCT01868711|Psychological Mindedness
1033971|NCT01868698|Physical Therapy Modalities
1033972|NCT01868698|Electric Stimulation Therapy
1033973|NCT01868698|Hyperthermia, Induced
1033974|NCT01868698|Diabetes Mellitus
1033975|NCT01868685|Muscle, anabolism, cachexia, respiratory failure, diaphragm
1033976|NCT01868672|Secondhand smoke exposure
1033977|NCT01868672|Smoke-free homes
1033978|NCT01868672|Smoke-free home bans
1033979|NCT01868646|Combined Treatment of Patients With Type II Diabetes Mellitus
1033980|NCT01868633|Cesarean delivery
1033981|NCT01868633|Analgesia
1033982|NCT01868633|Pain
1033983|NCT01868633|Dexamethasone
1033984|NCT01868633|intrathecal morphine
1033985|NCT01868633|spinal anesthesia
1033986|NCT01868620|Progressive keratoconus
1033987|NCT01868620|standard CXL
1033988|NCT01868620|iontophoretic CXL
1033989|NCT01868620|keratometry
1033990|NCT01868607|Respiratory resistance
1033991|NCT01868607|Respiratory reactance
1033992|NCT01868607|Adult lung function
1033993|NCT01868607|Forced oscillation technique
1033994|NCT01868607|subjects
1033995|NCT01868594|Combined treatment of patients with type I diabetes mellitus
1033996|NCT01868490|Cholangiocarcinoma
1033997|NCT01868490|Cytokine induced killer cells
1033998|NCT01868490|CIK
1033999|NCT01868490|Treg
1034000|NCT01868490|Th17
1034001|NCT01868477|myelodysplastic syndrome
1034002|NCT01868477|MDS
1034003|NCT01868477|myelodysplasia
1034004|NCT01868477|blood disorder
1034005|NCT01868477|cytopenias
1034006|NCT01868477|low blood counts
1034007|NCT01868477|progressive bone marrow failure
1034008|NCT01868464|challenge
1034009|NCT01868464|Mycobacterium tuberculosis
1034010|NCT01868464|parent protocol
1034011|NCT01868464|TB
1034012|NCT01868464|Tice BCG
1034013|NCT01868464|tuberculosis
1034014|NCT01868451|DACARBAZINE
1034015|NCT01868451|DOXORUBICIN/ADRIAMYCIN
1034016|NCT01868451|SGN-35 (BRENTUXIMAB VEDOTIN)
1034017|NCT01868451|VINBLASTINE
1034018|NCT01868451|Involved-site radiation therapy (ISRT)
1034019|NCT01868451|Early stage
1034020|NCT01868451|13-034
1034021|NCT01868438|Pyronaridine artesunate tablet
1034022|NCT01868438|Pyronaridine artesunate granules
1034023|NCT01868438|Pyramax tablet
1034024|NCT01868438|Pyramax granules
1034025|NCT01868438|Bioavailability
1034026|NCT01868412|Wound healing
1034027|NCT01868412|Wound infection
1034028|NCT01868412|Resin salve
1034029|NCT01868412|Medical honey
1034030|NCT01868399|dengue virus
1034031|NCT01868386|Radiotherapy, hypofractionated
1034032|NCT01868386|Salvage therapy
1034033|NCT01868386|Radiotherapy, adjuvant
1034034|NCT01868373|commensal microbiota bacteroides colitis pseudomembranous
1034035|NCT01868360|cornea
1034036|NCT01868360|transplant
1034037|NCT01868360|graft
1034038|NCT01868360|neovascularization
1034039|NCT01868347|obese patients
1034040|NCT01868347|specific elastance
1034041|NCT01868347|Trendelenburg Position
1034042|NCT01868347|Pneumoperitoneum
1034043|NCT01868347|robotic surgery
1034044|NCT01868347|Prostatectomy
1034045|NCT01868334|influenza vaccine
1034046|NCT01868334|PPSV
1034047|NCT01868334|Tdap
1034048|NCT01868334|vaccination
1034049|NCT01868334|adult
1034050|NCT01868321|Mechanical ventilation
1034051|NCT01868321|Acute respiratory failure
1034052|NCT01868321|Acute respiratory distress syndrome
1034053|NCT01868282|anterior cruciate ligament repair, Obturator nerve block, Hamstrings graft, Ropivacaine,
1034054|NCT01868282|Postoperative pain
1034055|NCT01868256|myocardial infarction
1034056|NCT01868256|primary percutaneous intervention
1034057|NCT01868256|prognosis
1034058|NCT01868256|early discharge
1034059|NCT01868243|Atrial Fibrillation
1034060|NCT01868243|Bioprosthesis
1034061|NCT01868243|Stroke
1034062|NCT01868243|Dabigatran
1034063|NCT01868243|Warfarin
1034064|NCT01868204|Obesity
1034065|NCT01868204|Binge eating disorder
1034066|NCT01868204|Pharmacogenetic
1034067|NCT01868204|Food craving
1034068|NCT01868204|Brain areas
1034069|NCT01868204|Topiramate
1034070|NCT01868191|Diabetes
1034071|NCT01868191|Neuropathy
1034072|NCT01868178|awareness
1034073|NCT01868165|Cognitive decline
1034074|NCT01868165|High blood pressure
1034075|NCT01868165|Hypertension
1034076|NCT01868165|Ageing
1034077|NCT01868165|Dementia
1034078|NCT01868165|Antihypertensives
1034079|NCT01868152|sufentanil
1034080|NCT01868152|individual variation
1034081|NCT01868152|pain threshold
1034082|NCT01868152|narcotrend index
1034083|NCT01868139|Cryotherapy
1034084|NCT01868139|Esophageal cancer
1034085|NCT01868139|Esophageal carcinoma
1034086|NCT01868139|Liquid nitrogen
1034087|NCT01868139|Esophageal adenocarcinoma
1034088|NCT01868139|Esophageal squamous cell carcinoma
1034089|NCT01868139|Endoscopy
1034090|NCT01868139|Ablation
1034091|NCT01868126|Santen
1034092|NCT01868126|Eye
1034093|NCT01868126|Glaucoma
1034094|NCT01868126|Ocular hypertension
1034095|NCT01868113|Children U-5
1034096|NCT01868113|ALRI
1034097|NCT01868113|Inhaled Corticosteroids
1034098|NCT01868100|Cancer
1034099|NCT01868100|quality of life
1034100|NCT01868100|palliative care
1034101|NCT01868100|supportive care
1034102|NCT01868100|Financial distress
1034103|NCT01868087|nutritional supplement
1034104|NCT01868087|immune system
1034105|NCT01868087|RC surgery
1034106|NCT01868074|pregnancy, arch height, collapsed arch
1034107|NCT01868048|Spasticity
1034108|NCT01868048|Multiple Sclerosis
1034109|NCT01868035|radioimmunotherapy
1034110|NCT01868035|Iodine 131 Tositumomab
1034111|NCT01868022|FGFR1
1034112|NCT01868022|FP1039
1034113|NCT01868022|GSK3052230
1034114|NCT01868022|docetaxel
1034115|NCT01868022|FGFR
1034116|NCT01868022|carboplatin
1034117|NCT01868022|HGS1036
1034118|NCT01868022|squamous non-small cell lung cancer
1034119|NCT01868022|paclitaxel
1034120|NCT01868009|fluticasone furoate
1034121|NCT01868009|COPD
1034122|NCT01868009|ELLIPTA
1034123|NCT01868009|fluticasone propionate
1034124|NCT01868009|DISKUS
1034125|NCT01868009|Novel Dry Powder Inhaler (NDPI)
1034126|NCT01868009|device preference
1034127|NCT01868009|salmeterol
1034128|NCT01868009|vilanterol
1034129|NCT01867996|Retosiban, Efavirenz, Induction
1034130|NCT01867983|Tobacco cessation
1034131|NCT01867983|Weight gain prevention
1034132|NCT01867970|remote sensing technology
1034133|NCT01867970|physical activity
1034134|NCT01867970|self-management support
1034135|NCT01867970|primary care nursing
1034136|NCT01867957|anthrax
1034137|NCT01867957|vaccine
1034138|NCT01867957|bioterrorism
1034139|NCT01867957|efficacy
1034140|NCT01867957|safety
1034141|NCT01867944|Chronic constipation
1034142|NCT01867944|Hemorrhoids
1034143|NCT01867944|Acupressure
1034144|NCT01867905|Severe sepsis
1034145|NCT01867905|Septic shock
1034146|NCT01867905|Bacteremia
1034147|NCT01867905|Antibiotics
1034148|NCT01867905|Blood culture positivity
1034149|NCT01867892|Locally Advanced Pancreatic Cancer
1034150|NCT01867879|Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
1034151|NCT01867866|Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
1034152|NCT01867801|PCI
1034153|NCT01867801|Coronary disease
1034154|NCT01867801|Ischemia
1034155|NCT01867775|Alzheimer's disease
1034156|NCT01867775|Sleep disorders
1034157|NCT01867775|Mirtazapine
1034158|NCT01867775|Treatment
1034159|NCT01867775|Intervention
1034160|NCT01867775|insomnia
1034161|NCT01867762|Chronic Obstructive Pulmonary Disease
1034162|NCT01867762|JNJ 49095397
1034163|NCT01867762|RV568
1034164|NCT01867762|Forced expiratory volume in one second
1034165|NCT01867762|FEV1
1034166|NCT01867749|Major Depressive Disorder (MDD)
1034167|NCT01867749|Miscarriage
1034168|NCT01867749|Stillbirth
1034169|NCT01867749|Neonatal death
1034170|NCT01867749|Interpersonal psychotherapy
1034171|NCT01867749|Group Therapy
1034172|NCT01867749|Coping with Depression (CWD)
1034173|NCT01867736|Stenosis
1034174|NCT01867736|Occlusions
1034175|NCT01867736|Infrapopliteal arteries
1034176|NCT01867736|Below the knee arteries
1034177|NCT01867736|PTA
1034178|NCT01867736|POBA
1034179|NCT01867736|DRB
1034180|NCT01867723|Cancer internet support program
1034181|NCT01867710|Mineralocorticoid Excess ; Chemotherapy-Naïve; Metastatic Castration-Resistant Prostate Cancer; Abiraterone Acetate; Zytiga; Prednisone; dexamethasone
1034182|NCT01867684|Stroke
1034183|NCT01867684|Acquired brain injury
1034184|NCT01867671|Allergy, Peanut
1034185|NCT01867671|Peanut allergy
1034186|NCT01867671|Hypersensitivity
1034187|NCT01867671|Immunotherapy
1034188|NCT01867671|Desensitization, Immunologic
1034189|NCT01867658|Pleural Air Leak
1034190|NCT01867658|Pulmonary resection
1034191|NCT01867658|Video Assisted
1034192|NCT01867658|Robotic Assisted
1034193|NCT01867645|Critical illness
1034194|NCT01867645|Critical illness polyneuropathy and/or myopathy
1034195|NCT01867645|Intravenous immunoglobulins
1034196|NCT01867645|Multiple organ failure
1034197|NCT01867645|SIRS
1034198|NCT01867645|Sepsis
1034199|NCT01867632|Furlow Palatoplasty
1034200|NCT01867632|Acellular Dermal Matrix
1034201|NCT01867619|Brain Neoplasms
1034202|NCT01867619|Melanoma
1034203|NCT01867619|Metastatic Melanoma
1034204|NCT01867619|Brain Metastasis
1034205|NCT01867619|Temozolomide
1034206|NCT01867619|Temodar
1034207|NCT01867619|Thalidomide
1034208|NCT01867619|Thalomid
1034209|NCT01867619|Lomustine
1034210|NCT01867619|CCNU
1034211|NCT01867619|CeeNU
1034212|NCT01867593|Newly diagnosed
1034213|NCT01867567|cesarean
1034214|NCT01867567|bandage removal
1034215|NCT01867567|infection
1034216|NCT01867567|disruption
1034217|NCT01867567|satisfaction
1034218|NCT01867567|patient satisfaction
1034219|NCT01867554|Intellectual disability
1034220|NCT01867554|Autism spectrum disorders
1034221|NCT01867554|gene
1034222|NCT01867554|Next generation sequencing
1034223|NCT01867541|cataract surgery
1034224|NCT01867541|intraocular lens power calculation
1034225|NCT01867541|effective lens position
1034226|NCT01867541|improving the refractive outcome after cataract surgery
1034227|NCT01867541|predicting the IOL position
1034228|NCT01867515|Hearing
1034229|NCT01867515|Hearing Loss, sensorineural
1034230|NCT01867515|Speech Perception
1034231|NCT01867463|Antigen
1034232|NCT01867463|Ookinetes
1034233|NCT01867463|Mosquito
1034234|NCT01867463|Membrane
1034235|NCT01867463|Assay
1034236|NCT01867450|Biomarkers
1034237|NCT01867450|Deisel Exhaust
1034238|NCT01867450|Occupational Exposure
1034239|NCT01867450|Cross-Sectional Study
1034240|NCT01867437|24 Hour Energy Expenditure
1034241|NCT01867437|Resting Energy Expenditure
1034242|NCT01867437|Obesity
1034243|NCT01867437|Healthy Volunteers
1034244|NCT01867424|Testosterone Membrane Transporter
1034245|NCT01867424|OATP1B3
1034246|NCT01867424|Castration Resistant Prostate Cancer
1034247|NCT01867424|Prostatectomy
1034248|NCT01867424|Gadolinium-Based Contrast Agent
1034249|NCT01867411|Smoking Cessation
1034250|NCT01867411|Biomarkers
1034251|NCT01867411|fMRI
1034252|NCT01867411|e-Cigarettes
1034253|NCT01867398|Conduct Disorder
1034254|NCT01867398|Antipsychotic
1034255|NCT01867398|Treatment Study
1034256|NCT01867398|Functional Magnetic Resonance Imaging (fMRI)
1034257|NCT01867398|Adolescents
1034258|NCT01867385|Fatigue
1034259|NCT01867385|Chronic Hepatitis
1034260|NCT01867385|Chronic Hepatitis B
1034261|NCT01867385|Chronic Hepatitis C
1034262|NCT01867385|Hepatitis
1034263|NCT01867372|Alzheimer's Disease
1034264|NCT01867359|Alzheimer Disease
1034265|NCT01867359|Molecular
1034266|NCT01867359|Molecular Genetics
1034267|NCT01867359|DNA
1034268|NCT01867346|Cognition
1034269|NCT01867346|Aging
1034270|NCT01867346|Cognitive Decline
1034271|NCT01867346|Dementia
1034272|NCT01867346|Alzheimer's Disease
1034273|NCT01867333|Immunotherapy
1034274|NCT01867333|Gene Transfer
1034275|NCT01867333|Androgen Receptor Antagonist
1034276|NCT01867333|PSA
1034277|NCT01867333|Immune Response
1034278|NCT01867320|HTLV-1
1034279|NCT01867320|HTLV-1 Associated Myelopathy
1034280|NCT01867281|aspirin
1034281|NCT01867281|asthma
1034282|NCT01867281|Aspirin desensitization
1034283|NCT01867281|Aspirin induced asthma
1034284|NCT01867281|Immune System Diseases
1034285|NCT01867281|Respiratory Hypersensitivity
1034286|NCT01867268|Acetazolamide administration
1034287|NCT01867268|prone positioning
1034288|NCT01867268|Cerebrospinal fluid leakage
1034289|NCT01867268|Cerebrospinal fluid collection
1034290|NCT01867268|wound dehiscence
1034291|NCT01867255|venlafaxine
1034292|NCT01867255|Effexor
1034293|NCT01867255|antidepressive agent
1034294|NCT01867242|cigarette
1034295|NCT01867242|snus
1034296|NCT01867242|smoking
1034297|NCT01867242|tobacco
1034298|NCT01867229|pre-menauposal
1034299|NCT01867229|neo-adjuvant or adjuvant chemotherapy
1034300|NCT01867229|no metastases
1034301|NCT01867190|CLI
1034302|NCT01867177|HIV
1034303|NCT01867177|health care utilization
1034304|NCT01867177|HIV testing
1034305|NCT01867177|access to care
1034306|NCT01867164|Vaginitis
1034307|NCT01867164|Infectious vaginosis
1034308|NCT01867164|Terconazole
1034309|NCT01867164|Clindamycin
1034310|NCT01867164|Fluocinolone
1034311|NCT01867164|Metronidazole
1034312|NCT01867164|Nystatin
1034313|NCT01867151|Burning Mouth Syndrome
1034314|NCT01867151|Gluten
1034315|NCT01867151|Gluten Free Diet
1034316|NCT01867138|Coagulase negative staphylococcus
1034317|NCT01867138|nosocomial neonatal sepsis
1034318|NCT01867138|cefazolin
1034319|NCT01867138|vancomycin
1034320|NCT01867138|newborn
1034321|NCT01867086|ovarian cancer
1034322|NCT01867060|Cardiac monitoring
1034323|NCT01867060|Biomarkers
1034324|NCT01867060|Transthoracic echocardiography
1034325|NCT01867034|non ST segment myocardial infarction
1034326|NCT01867021|Trivalent inactivated subunit influenza vaccines
1034327|NCT01867021|50 years and above
1034328|NCT01867021|healthy subjects
1034329|NCT01866995|Ginseng
1034330|NCT01866995|Prostatostasis
1034331|NCT01866995|Erectile Dysfunction
1034332|NCT01866982|umbilical cord milking
1034333|NCT01866982|delayed cord clamping
1034334|NCT01866943|Blood Loss
1034335|NCT01866943|Tranexamic Acid
1034336|NCT01866943|Total Hip Arthroplasty
1034337|NCT01866943|Post Op
1034338|NCT01866943|Post Operative
1034339|NCT01866943|Prevent Post Operative Blood Loss
1034340|NCT01866917|Transversis Abdominis Plane Block
1034341|NCT01866917|obese
1034342|NCT01866917|robotic surgery
1034343|NCT01866917|laparoscopic surgery
1034344|NCT01866904|Coronary artery disease, Myocardial infarction
1034345|NCT01866891|hemodialysis
1034346|NCT01866891|microcirculation
1034347|NCT01866891|physical perdialytic activity
1034348|NCT01866891|cycling
1034349|NCT01866878|transcutaneous electrical nerve stimulation, sensitivity, multiple sclerosis,Reeducation through labor tactile discrimination
1034350|NCT01866865|BRCA1
1034351|NCT01866865|BRCA2
1034352|NCT01866852|Longitudinal Study
1034353|NCT01866839|Acute Lymphoblastic Leukemia (ALL)
1034354|NCT01866839|Acute Myelogenous Leukemia (AML)
1034355|NCT01866839|Chronic Lymphocytic Leukemia (CLL)
1034356|NCT01866839|Chronic Myelogenous Leukemia (CML)
1034357|NCT01866839|Myelodyplastic Syndrome (MDS)
1034358|NCT01866826|HIV
1034359|NCT01866826|Eradication Strategies
1034360|NCT01866826|Immune Activation
1034361|NCT01866813|breast cancer
1034362|NCT01866813|cancer survivors
1034363|NCT01866800|TAVI
1034364|NCT01866800|TAVR
1034365|NCT01866800|CIN
1034366|NCT01866800|AKI
1034367|NCT01866787|Postoperative orthostatic intolerance
1034368|NCT01866787|Surgical inflammatory response
1034369|NCT01866722|nicotine dependence
1034370|NCT01866722|smoking cessation
1034371|NCT01866722|lapse
1034372|NCT01866722|relapse
1034373|NCT01866722|tobacco
1034374|NCT01866722|quit attempts
1034375|NCT01866722|abstinence
1034376|NCT01866722|motivation
1034377|NCT01866722|reduction
1034378|NCT01866696|Computer assisted implant surgery,
1034379|NCT01866696|Immediate loading,
1034380|NCT01866696|CAD/CAM
1034381|NCT01866683|Yoga
1034382|NCT01866683|Electroencephalography
1034383|NCT01866683|Heart rate variability
1034384|NCT01866683|Breathing Exercises
1034385|NCT01866683|Quality of life
1034386|NCT01866670|spiritual distress
1034387|NCT01866670|nursing
1034388|NCT01866670|breast neoplasms
1034389|NCT01866657|cerebral oximetry
1034518|NCT01866007|CNTO1959
1034390|NCT01866657|randomized controlled pilot study
1034391|NCT01866657|thoracic surgery
1034392|NCT01866657|single lung ventilation
1034393|NCT01866644|Liver transplantation, n-acetylcysteine
1034394|NCT01866618|Natural
1034395|NCT01866618|IVF Cycle
1034396|NCT01866605|anxiety
1034397|NCT01866605|midazolam
1034398|NCT01866605|forced-air warming
1034399|NCT01866592|Psoriasis
1034400|NCT01866592|Cardiovascular Disease
1034401|NCT01866592|Vascular Inflammation
1034402|NCT01866592|Lipid Biomarkers
1034403|NCT01866592|Metabolic biomarkers
1034404|NCT01866592|FDG-PET/CT
1034405|NCT01866579|Retinal Nerve Fiber Layer Thickness, Optical Coherence Tomography, Ethambutol optic neuropathy
1034406|NCT01866553|CML
1034407|NCT01866553|suboptimal molecular response
1034408|NCT01866553|nilotinib
1034409|NCT01866553|pegylated interferon α2b
1034410|NCT01866540|influenza, LAIV, immune response
1034411|NCT01866527|Developmental dysplasia of the hip,
1034412|NCT01866527|DDH,
1034413|NCT01866527|avascular necrosis,
1034414|NCT01866527|late detected cases
1034415|NCT01866514|EZ-IO
1034416|NCT01866514|IO
1034417|NCT01866514|Intraosseous Vascular Access
1034418|NCT01866501|Intraosseous Vascular Access
1034419|NCT01866501|IO Access
1034420|NCT01866501|IO Vascular Access
1034421|NCT01866501|EZ-IO
1034422|NCT01866488|Labor induction
1034423|NCT01866488|Misoprostol
1034424|NCT01866488|Cytotec
1034425|NCT01866488|Cook Obstetric Double Balloon Catheter
1034426|NCT01866475|IO access
1034427|NCT01866475|Intraosseous vascular access
1034428|NCT01866475|EZ-IO
1034429|NCT01866436|Cognitive skills
1034430|NCT01866436|Multimedia
1034431|NCT01866436|Education
1034432|NCT01866436|Colorectal surgery
1034433|NCT01866397|cidofovir
1034434|NCT01866397|cvvh
1034435|NCT01866397|renal replacement therapy
1034436|NCT01866397|HCMV
1034437|NCT01866397|Pharmacokinetics of cidofovir during CVVH
1034438|NCT01866397|continuous venovenous hemofiltration
1034442|NCT01866345|orthodontics
1034443|NCT01866345|Tooth Movement
1034444|NCT01866345|Bone Remodeling
1034445|NCT01866345|Mandible
1034446|NCT01866345|Osteotomy
1034447|NCT01866332|back pain
1034448|NCT01866332|tape
1034449|NCT01866332|chronic
1034450|NCT01866319|PD-1
1034451|NCT01866319|PD1
1034452|NCT01866319|PD-L1
1034453|NCT01866319|PDL1
1034454|NCT01866293|Cabozantinib (XL184)
1034455|NCT01866293|12-240
1034456|NCT01866280|Sleep
1034457|NCT01866280|Sleep duration
1034458|NCT01866280|Meals
1034459|NCT01866280|Food intake
1034460|NCT01866280|Obesity
1034461|NCT01866267|Human Immunodeficiency Virus
1034462|NCT01866267|AIDS
1034463|NCT01866254|Hydromorphone
1034464|NCT01866254|Morphine
1034465|NCT01866254|cesarean delivery
1034466|NCT01866254|pain management
1034467|NCT01866254|respiratory depression
1034468|NCT01866228|Consultation Recording
1034469|NCT01866228|Brain Tumor
1034470|NCT01866228|Neuroendocrine Cancer
1034471|NCT01866228|Quality of Life
1034472|NCT01866228|Patient Satisfaction
1034473|NCT01866215|gluconeogenesis
1034474|NCT01866215|de novo lipogenesis
1034475|NCT01866215|intramyocellular lipids
1034476|NCT01866215|muscle glycogen
1034477|NCT01866215|fructose
1034478|NCT01866189|ischemic stroke
1034479|NCT01866189|hypoxic tissues
1034480|NCT01866189|F-MISO uptake
1034481|NCT01866189|Magnetic Resonance Imaging
1034482|NCT01866189|F-MISO Positon Emission Tomography
1034483|NCT01866137|Copeptin
1034484|NCT01866137|psychological stress
1034485|NCT01866137|The Trier Social Stress Test (TSST)
1034486|NCT01866124|acute malnutrition
1034487|NCT01866124|multiannual and seasonal cash transfers
1034488|NCT01866124|safety nets
1034489|NCT01866124|Burkina Faso
1034490|NCT01866098|antipsychotic
1034491|NCT01866098|severe mental illness
1034492|NCT01866098|weight loss
1034493|NCT01866085|stress urinary incontinence
1034494|NCT01866085|post prostatectomy
1034495|NCT01866072|ACLF
1034496|NCT01866072|AVH
1034497|NCT01866072|Fibroscan
1034498|NCT01866072|Transient elastography
1034499|NCT01866059|root caries
1034500|NCT01866059|GIC
1034501|NCT01866059|RMGIC
1034502|NCT01866059|Biodentine
1034503|NCT01866059|Calcium silicate
1034504|NCT01866046|battered women
1034505|NCT01866046|HIV risk
1034506|NCT01866046|STI risk
1034507|NCT01866033|Healthy volunteer
1034508|NCT01866033|PCI-32765
1034509|NCT01866033|PCI 45227
1034510|NCT01866033|13C6 PCI-32765
1034511|NCT01866033|Pharmacokinetic
1034512|NCT01866033|Bioavailability
1034513|NCT01866020|aspergillosis
1034514|NCT01866020|fungal infection
1034515|NCT01866020|ICU
1034516|NCT01866007|Healthy
1034517|NCT01866007|Guselkumab
1034519|NCT01866007|Pharmacokinetics
1034520|NCT01866007|UltraSafe Passive Delivery System (PFS-U)
1034521|NCT01866007|Prefilled syringe facilitated injection device (PFS FID)
1034522|NCT01865994|Cardiac Output
1034523|NCT01865994|esCCO
1034524|NCT01865994|TEE
1034525|NCT01865994|Pediatric cardiac surgery
1034526|NCT01865981|iPS cells
1034527|NCT01865981|cardiomyocytes
1034528|NCT01865981|Brugada
1034529|NCT01865981|Ventricular Fibrillation
1034530|NCT01865981|electrophysiology
1034531|NCT01865968|inactivated HAV vaccine; live attenuated HAV vaccine; immunogenicity; safety
1034532|NCT01865955|Ultrasound
1034533|NCT01865955|Spinal anesthesia
1034534|NCT01865955|Cesarean section
1034535|NCT01865942|spinal metastases
1034536|NCT01865942|spine surgery
1034537|NCT01865942|metastatic spinal cord compression
1034538|NCT01865942|EQ-5D
1034539|NCT01865942|HRQOL
1034540|NCT01865903|NSCLC
1034541|NCT01865903|sarcopenia
1034542|NCT01865903|cachexia
1034543|NCT01865890|Plavix or clopidogrel resistance
1034544|NCT01865877|Parkinson's disease
1034545|NCT01865877|Motor
1034546|NCT01865877|Non-motor
1034547|NCT01865877|Progression
1034548|NCT01865877|Complications
1034549|NCT01865864|CPAP
1034550|NCT01865864|diurnal blood pressure
1034551|NCT01865864|obstructive sleep apnea
1034552|NCT01865864|24 hour blood pressure monitor
1034553|NCT01865851|Inspired oxygen
1034554|NCT01865851|end-tidal oxygen
1034555|NCT01865851|end-tidal carbon dioxide
1034556|NCT01865851|respiratory rate
1034557|NCT01865851|preoxygenation
1034558|NCT01865851|classic face mask
1034559|NCT01865851|NuMask
1034560|NCT01865838|Total thyroidectomy
1034561|NCT01865838|Seprafilm
1034562|NCT01865838|Swallowing difficulty post thyroidectomy
1034563|NCT01865825|Erosive Esophagitis
1034564|NCT01865825|Gastroesophageal reflux disease
1034565|NCT01865799|FTC/TDF
1034566|NCT01865799|PrEP
1034567|NCT01865799|Truvada
1034568|NCT01865799|Drug utilization
1034569|NCT01865786|FTC/TDF
1034570|NCT01865786|Truvada
1034571|NCT01865786|PrEP
1034572|NCT01865786|Antiretroviral Pregnancy Registry
1034573|NCT01865760|Glucagon like peptide 1
1034574|NCT01865760|Insulin secretion
1034575|NCT01865760|Hypoglycemia
1034576|NCT01865747|renal cell cancer
1034577|NCT01865747|kidney
1034578|NCT01865747|vascular endothelial growth factor receptor 2 (VEGFR2)
1034579|NCT01865747|tyrosine kinase inhibitor
1034580|NCT01865747|hepatocyte growth factor receptor protein (MET)
1034581|NCT01865747|von Hippel-Lindau gene
1034582|NCT01865734|Fasciitis, Plantar
1034583|NCT01865734|Heel Pain
1034584|NCT01865734|Physical Therapy
1034585|NCT01865734|Podiatry
1034586|NCT01865734|Musculoskeletal Manipulations
1034587|NCT01865734|Exercise Therapy
1034588|NCT01865721|Bowel cancer screening
1034589|NCT01865721|Analgesia
1034590|NCT01865721|Entonox
1034591|NCT01865721|Pain
1034592|NCT01865721|Side effects
1034593|NCT01865721|Colonoscopy
1034594|NCT01865708|Ethanol Lock
1034595|NCT01865708|Alcohol lock
1034596|NCT01865708|Urinary catheter
1034597|NCT01865708|Safety
1034598|NCT01865695|pancreatic exocrine insufficiency
1034599|NCT01865695|faecal elastase
1034600|NCT01865695|diarrhoea
1034601|NCT01865695|coeliac
1034602|NCT01865695|creon
1034603|NCT01865695|gastrointestinal
1034604|NCT01865682|Ankle
1034605|NCT01865682|Knee
1034606|NCT01865682|Orthosis
1034607|NCT01865682|Kinematics
1034608|NCT01865682|Kinetics
1034609|NCT01865669|Uterine contraction
1034610|NCT01865669|Dose response
1034611|NCT01865669|Oxytocin
1034612|NCT01865656|provider skill and self-efficacy
1034613|NCT01865656|Appropriate and timely referral for obstetric emergencies
1034614|NCT01865656|Intervention feasibility and acceptability
1034615|NCT01865643|Laryngoscopy
1034616|NCT01865643|Intubation
1034617|NCT01865643|Glidescope
1034618|NCT01865630|Prophylactic treatment with Etanercept in aSAH.
1034619|NCT01865630|Safety of Etanercept in the prevention of DCI in aSAH.
1034620|NCT01865591|hypertension
1034621|NCT01865591|uncontrolled hypertension
1034622|NCT01865591|resistant hypertension
1034623|NCT01865565|gastrointestinal stromal tumor
1034624|NCT01865565|GIST
1034625|NCT01865565|neoadjuvant
1034626|NCT01865565|imatinib
1034627|NCT01865552|Pharmacokinetics
1034628|NCT01865539|Chronic lower back pain
1034629|NCT01865539|Custom foot orthotics
1034630|NCT01865539|Veterans
1034631|NCT01865526|Chronic kidney disease
1034632|NCT01865526|Low protein diet
1034633|NCT01865526|CKD stage 3b-5
1034634|NCT01865513|Anaesthesia
1034635|NCT01865513|Anaesthesiology
1034636|NCT01865513|muscle Relaxants
1034637|NCT01865513|POPULAR
1034638|NCT01865513|postoperative pulmonary complications
1034639|NCT01865513|Respiratory failure
1034640|NCT01865513|Suspected pulmonary infection
1034641|NCT01865513|Pulmonary infiltrates
1034642|NCT01865513|Pleural effusion
1034643|NCT01865513|Atelectasis
1034644|NCT01865513|Pneumothorax
1034645|NCT01865513|Bronchospasm
1034646|NCT01865513|Aspiration pneumonitis
1034647|NCT01865513|Cardiopulmonary oedema
1034648|NCT01865513|European Society of Anaesthesiology
1034649|NCT01865513|neuromuscular blockade
1034650|NCT01865513|europe
1034651|NCT01865500|COPD exacerbation
1034652|NCT01865500|Nebulized budesonide
1034653|NCT01865500|Parenteral steroid
1034654|NCT01865487|BCG Vaccinated
1034655|NCT01865487|HIV Negative
1034656|NCT01865474|DLBS1033, Type 2 DM, fibrinolytic, hypercoagulation
1034657|NCT01865461|Magnetic Resonance Imaging
1034658|NCT01865448|Docosahexaenoic Acids
1034659|NCT01865448|Fatty Acids, Omega-3
1034660|NCT01865448|Obesity
1034661|NCT01865448|Inflammation
1034662|NCT01865409|Newborn
1034663|NCT01865409|Prematures
1034664|NCT01865409|Feeding difficulty
1034665|NCT01865409|Kangaroo Care
1034666|NCT01865409|Heart rate variability
1034667|NCT01865266|ventilator-associated pneumonia
1034668|NCT01865266|mechanical ventilation
1034669|NCT01865266|ulinastatin for injection
1034670|NCT01865266|bronchoalveolar lavage fluid
1034671|NCT01865266|inflammatory factors
1034672|NCT01865253|renal denervation
1034673|NCT01865253|blood pressure
1034674|NCT01865253|cardiovascular risk
1034675|NCT01865253|target organ damage
1034676|NCT01865253|sympathetic activity
1034677|NCT01865253|chronic kidney disease
1034678|NCT01865253|non-compliance
1034679|NCT01865240|renal denervation
1034680|NCT01865240|blood pressure
1034681|NCT01865240|cardiovascular risk
1034682|NCT01865240|target organ damage
1034683|NCT01865240|sympathetic activity
1034684|NCT01865227|Obesity
1034685|NCT01865227|Bariatric surgery
1034686|NCT01865227|Binge Eating Disorder
1034687|NCT01865227|Psychological Health
1034688|NCT01865227|Counselling
1034689|NCT01865201|Radiotherapy
1034690|NCT01865201|Radiation-induced brain necrosis
1034691|NCT01865201|Edaravone
1034692|NCT01865201|Effectiveness
1034693|NCT01865201|Safety
1034694|NCT01865188|LCZ696,
1034695|NCT01865188|amlodipine,
1034696|NCT01865188|hypertension,
1034697|NCT01865188|ABPM
1034698|NCT01865162|Glioblastoma multiforme, ketogenic diet, neoplasm
1034699|NCT01865149|Child
1034700|NCT01865149|Optic nerve sheath diameter
1034701|NCT01865149|Hydrocephalus
1034702|NCT01865149|Intracranial hypertension
1034703|NCT01865123|post-traumatic stress disorder
1034704|NCT01865123|transcendental meditation
1034705|NCT01865123|cognitive behavioral therapy
1034706|NCT01865123|prolonged exposure
1034707|NCT01865110|Mantle Cell Lymphoma
1034708|NCT01865110|RCHOP
1034709|NCT01865110|RHAD
1034710|NCT01865110|rituximab
1034711|NCT01865110|lenalidomide
1034712|NCT01865097|Imagery
1034713|NCT01865097|Pain
1034714|NCT01865097|Depression
1034715|NCT01865097|Non-Motor
1034716|NCT01865071|ileostomy
1034717|NCT01865071|rectal resection
1034718|NCT01865071|proctectomy
1034719|NCT01865071|stoma closure
1034720|NCT01865071|rectal cancer
1034721|NCT01864993|non celiac gluten sensitivity
1034722|NCT01864993|gluten
1034723|NCT01864993|irritable bowel syndrome
1034724|NCT01864993|functional disorders
1034725|NCT01864967|carbon dioxide infusion
1034726|NCT01864967|dilatation of peripheral blood vessels
1034727|NCT01864967|capillaries
1034728|NCT01864967|macrophags
1034729|NCT01864967|fibroblasts
1034730|NCT01864967|Improvement granulation tissue in chronic wounds
1034731|NCT01864954|Smoking
1034732|NCT01864954|Postpartum
1034733|NCT01864954|Pregnancy
1034734|NCT01864954|Quit
1034735|NCT01864954|Tobacco
1034736|NCT01864954|Abstinence
1034737|NCT01864954|Relapse
1034738|NCT01864954|Relapse prevention
1034739|NCT01864941|Multiple Sclerosis
1034740|NCT01864941|MS
1034741|NCT01864941|CCSVI
1034742|NCT01864941|Zamboni
1034743|NCT01864941|catheter venography
1034744|NCT01864941|balloon angioplasty
1034747|NCT01864915|colon capsule
1034748|NCT01864915|bowel preparation
1034749|NCT01864915|booster
1034750|NCT01864915|prucalopride
1034751|NCT01864915|picosalax
1034752|NCT01864902|CD33 positive acute myeloid leukemia (AML)
1034753|NCT01864850|HNSCC
1034754|NCT01864850|Elderly
1034755|NCT01864850|Geriatry
1034756|NCT01864837|tongue coating thickness
1034757|NCT01864837|tongue diagnosis system
1034758|NCT01864837|tongue coating percentage
1034759|NCT01864837|availability
1034760|NCT01864837|diagnostic device
1034761|NCT01864824|air pollution
1034762|NCT01864824|particulate matter 2.5 (PM2.5)
1034763|NCT01864824|methyl donor
1034764|NCT01864824|DNA methylation
1034765|NCT01864824|mRNA
1034766|NCT01864824|epigenetics
1034767|NCT01864824|controlled human exposures
1034768|NCT01864824|cardiovascular responses
1034769|NCT01864811|infants
1034770|NCT01864811|unilateral cerebral pares
1034771|NCT01864811|hand function
1034772|NCT01864811|early intervention
1034773|NCT01864811|constraint induced movement therapy
1034774|NCT01864798|Young
1034775|NCT01864798|Breast Neoplasms
1034776|NCT01864798|Denosumab
1034777|NCT01864798|RANKL
1034778|NCT01864785|Operative treatment
1034779|NCT01864785|internal fixation
1034780|NCT01864785|posterior spinal fusion
1034781|NCT01864772|HNSCC
1034782|NCT01864772|Metastatic
1034783|NCT01864772|Recurrent
1034784|NCT01864772|Elderly
1034785|NCT01864772|Geriatry
1034786|NCT01864759|melanoma
1034787|NCT01864759|oncolytic
1034788|NCT01864759|adenovirus
1034789|NCT01864759|virotherapy
1034790|NCT01864759|locally advanced
1034791|NCT01864759|metastatic
1034792|NCT01864733|Chronic heart failure
1034793|NCT01864733|Undernutrition
1034794|NCT01864733|Rehabilitation
1034795|NCT01864733|Physical exercise
1034796|NCT01864733|Nutrition
1034797|NCT01864733|n-3 fatty acids
1034798|NCT01864733|Androgen
1034799|NCT01864733|Testosterone
1034800|NCT01864720|stepped care model
1034801|NCT01864720|insomnia
1034802|NCT01864720|cancer
1034803|NCT01864720|cognitive-behavioural therapy
1034804|NCT01864720|self-help treatment
1034805|NCT01864720|Internet
1034806|NCT01864720|non-inferiority design
1034807|NCT01864720|cost-effectiveness
1034808|NCT01864707|multiple sclerosis, fatigue
1034809|NCT01864694|behavioral research
1034810|NCT01864694|diet
1034811|NCT01864694|health information systems
1034812|NCT01864681|NSCLC
1034813|NCT01864681|TKIs
1034814|NCT01864681|Metformin
1034815|NCT01864681|PFS
1034816|NCT01864681|overall survival
1034817|NCT01864681|IL-6
1034818|NCT01864668|Acute respiratory distress syndrome
1034819|NCT01864668|lung strain
1034820|NCT01864668|small tidal volume
1034821|NCT01864616|Vitamin D
1034822|NCT01864616|Crohn disease
1034823|NCT01864616|Disease activity
1034824|NCT01864616|Inflammation
1034825|NCT01864616|prevention
1034826|NCT01864603|HIV treatment and prevention
1034827|NCT01864603|Tuberculosis
1034828|NCT01864603|Community health campaign
1034829|NCT01864603|PrEP
1034830|NCT01864590|Open Abdomen
1034831|NCT01864590|Negative Pressure Wound Therapy
1034832|NCT01864590|Temporary Abdominal Closure
1034833|NCT01864590|Mesh
1034834|NCT01864590|Abdominal reconstruction
1034835|NCT01864564|Gestational diabetes
1034836|NCT01864564|Screening
1034837|NCT01864564|Obesity
1034838|NCT01864564|Anhydroglucitol
1034839|NCT01864538|TH-302
1034840|NCT01864538|Advanced Melanoma
1034841|NCT01864538|Metastatic
1034842|NCT01864538|Biomarker
1034843|NCT01864538|Mucosal Melanoma
1034844|NCT01864538|Evofosfamide
1034845|NCT01864525|voice
1034846|NCT01864525|tremor
1034847|NCT01864525|essential tremor
1034848|NCT01864525|essential voice tremor
1034849|NCT01864525|voice treatment
1034850|NCT01864525|octanoic acid
1034851|NCT01864525|octanol
1034852|NCT01864525|voice disorder
1034853|NCT01864525|dysphonia
1034854|NCT01864512|Immune Thrombocytopenia
1034855|NCT01864512|eltrombopag
1034856|NCT01864512|immune regulation
1034857|NCT01864473|Fistula , Bhagandar
1034858|NCT01864460|autonomic
1034859|NCT01864460|neuropathy
1034860|NCT01864460|balance
1034861|NCT01864460|exercise
1034862|NCT01864447|VTE
1034863|NCT01864447|Exercise
1034864|NCT01864447|Diet
1034865|NCT01864447|Weight loss
1034866|NCT01864447|DVT
1034867|NCT01864447|PE
1034868|NCT01864434|Knee Prosthesis
1034869|NCT01864434|Total Knee Arthroplasty
1034870|NCT01864434|Cruciate Retaining
1034871|NCT01864434|Posterior Cruciate Retaining
1034872|NCT01864421|Infant, Newborn
1034873|NCT01864421|Delivery, Obstetric
1034874|NCT01864421|Umbilical Cord
1034875|NCT01864408|Patient counseling
1034876|NCT01864408|Patient satisfaction
1034877|NCT01864408|Pelvic organ prolapse
1034878|NCT01864395|cardiovascular surgery
1034879|NCT01864395|cardiac surgery
1034880|NCT01864395|cardiopulmonary bypass
1034881|NCT01864395|IV fluids
1034882|NCT01864395|blood pressure
1034883|NCT01864395|heart-lung machine
1034884|NCT01864395|hemofilter
1034885|NCT01864395|online MUF
1034886|NCT01864395|offline MUF
1034887|NCT01864395|modified ultrafiltration
1034888|NCT01864395|multiple-pass hemofiltration
1034889|NCT01864395|centrifugation method
1034890|NCT01864395|blood transfusion
1034891|NCT01864395|plasma proteins
1034892|NCT01864395|post-cardiopulmonary bypass
1034893|NCT01864395|hemoglobin
1034894|NCT01864395|clotting factors
1034895|NCT01864395|systemic blood pressure
1034896|NCT01864395|cardiac index
1034897|NCT01864395|cytokines
1034898|NCT01864395|post-operative bleeding
1034899|NCT01864395|protamine administration
1034900|NCT01864395|patient size
1034901|NCT01864395|allogeneic transfusion
1034902|NCT01864395|total protein
1034903|NCT01864395|albumin
1034904|NCT01864395|vasoactive inotrope score
1034905|NCT01864395|fluid balance
1034906|NCT01864395|chest tube loss
1034907|NCT01864395|length of stay
1034908|NCT01864395|ventilation time
1034909|NCT01864395|markers of inflammation
1034910|NCT01864382|Trunk performance
1034911|NCT01864382|exercise,
1034912|NCT01864382|"core stability,"
1034913|NCT01864382|sitting balance
1034914|NCT01864369|Heart Failure
1034915|NCT01864369|e-counseling
1034916|NCT01864369|quality of life
1034917|NCT01864369|self-care
1034918|NCT01864356|IVF failure
1034919|NCT01864356|Repeated IVF failure
1034920|NCT01864356|Implantation failure
1034921|NCT01864356|Repeated implantation failure
1034922|NCT01864356|IVF
1034923|NCT01864356|NT100
1034924|NCT01864343|Myocardial Infarction
1034925|NCT01864343|Myocardial Reperfusion Injury
1034926|NCT01864343|Reperfusion Injury
1034927|NCT01864343|Anterior Wall Myocardial Infarction
1034928|NCT01864343|Inferior Wall Myocardial Infarction
1034929|NCT01864343|Myocardial Ischemia
1034930|NCT01864330|topical lubricants
1034931|NCT01864330|optical coherence tomography
1034932|NCT01864330|tear break up time
1034933|NCT01864330|Schirmer I test
1034934|NCT01864317|7-Tesla Magnetic Resonance Imaging
1034935|NCT01864317|Intraocular Pressure
1034936|NCT01864317|Retinal Nerve Fiber Thickness
1034937|NCT01864317|Visual Field Test
1034938|NCT01864304|Williams Syndrome
1034939|NCT01864291|Auditory Brainstem Implant
1034940|NCT01864291|ABI
1034941|NCT01864291|Nucleus 24
1034942|NCT01864291|Deafness
1034943|NCT01864291|Hearing loss
1034944|NCT01864291|Non-tumor
1034945|NCT01864291|Non-NF2
1034946|NCT01864291|Pediatric
1034947|NCT01864291|ABI541
1034948|NCT01864265|Rheumatoid arthritis
1034949|NCT01864265|functional MRI
1034950|NCT01864265|Prediction of Response
1034951|NCT01864265|Certolizumab Pegol
1034952|NCT01864265|RF and/or ACPA positive
1034953|NCT01864239|Adherence
1034954|NCT01864187|Pharmacokinetics
1034955|NCT01864187|Dexmedetomidine
1034956|NCT01864187|Obesity
1034957|NCT01864122|nutrient biomarkers
1034958|NCT01864122|food frequency questionnaire
1034959|NCT01864122|predictors of CVD
1034960|NCT01864122|fatty acids
1034961|NCT01864122|phylloquinone
1034962|NCT01864122|dihydrophylloquinone
1034963|NCT01864109|CYCLOPHOSPHAMIDE (CYTOXAN)
1034964|NCT01864109|DOXORUBICIN/ADRIAMYCIN
1034965|NCT01864109|ETOPOSIDE (VP-16)
1034966|NCT01864109|IFOSFAMIDE
1034967|NCT01864109|IRINOTECAN (CPT-11) CAMPTOSAR
1034968|NCT01864109|TEMOZOLOMIDE
1034969|NCT01864109|VINCRISTINE
1034970|NCT01864109|13-068
1034971|NCT01864096|localized
1034972|NCT01864096|prostate
1034973|NCT01864096|cancer
1034974|NCT01864096|metformin
1034975|NCT01864096|active surveillance
1034976|NCT01864083|FACBC PET/PEM
1034977|NCT01864083|MR
1034978|NCT01864083|11-177
1034979|NCT01864070|Liver cancer
1034980|NCT01864070|Neuroendocrine tumors
1034981|NCT01864070|NET
1034982|NCT01864070|Liver dominant disease
1034983|NCT01864070|TheraSphere
1034984|NCT01864070|Yttrium-90
1034985|NCT01864070|Y-90
1034986|NCT01864070|Everolimus
1034987|NCT01864070|Afinitor
1034988|NCT01864070|Zortress
1034989|NCT01864070|RAD001
1034990|NCT01864070|Microspheres
1034991|NCT01864057|thiamine deficiency
1034992|NCT01864031|Alcohol
1034993|NCT01864031|Drinking
1034994|NCT01864031|Abstainers
1034995|NCT01864031|Former drinkers
1034996|NCT01864031|Ex-drinkers
1034997|NCT01864031|Aetiology
1034998|NCT01864031|Initial presentation
1034999|NCT01864031|Chronic Stable Angina
1035000|NCT01864031|Unstable Angina
1035001|NCT01864031|Coronary Heart Disease Not Otherwise Specified
1035002|NCT01864031|Acute Myocardial Infarction
1035003|NCT01864031|Heart Failure
1035004|NCT01864031|ST elevation Myocardial Infarction (STEMI)
1035005|NCT01864031|non-ST elevation Myocardial Infarction (nSTEMI)
1035006|NCT01864031|Myocardial Infarction Not Otherwise Specified (MI NOS)
1035007|NCT01864031|Ventricular Arrhythmias
1035008|NCT01864031|Cardiac Arrest
1035009|NCT01864031|Abdominal Aortic Aneurysm
1035010|NCT01864031|Peripheral Arterial Disease
1035011|NCT01864031|Ischaemic Stroke
1035012|NCT01864031|Subarachnoid Haemorrhagic Stroke
1035013|NCT01864031|Intracerebral haemorrhagic Stroke
1035014|NCT01864031|Stroke Not Otherwise Specified
1035015|NCT01864031|Sudden Cardiac Death
1035016|NCT01864031|Unheralded Coronary Death
1035017|NCT01864031|Mortality
1035018|NCT01864031|Coronary Heart Disease (CHD)
1035019|NCT01864031|Cardiovascular Disease (CVD)
1035020|NCT01864031|Fatal Cardiovascular Disease (fatal CVD)
1035021|NCT01864005|Non-ST or ST Elevation Acute Coronary Syndromes, Ticagrelor, Clopidogrel, Antiplatelet Effect
1035022|NCT01863992|home ventilation
1035023|NCT01863979|Atrial Fibrillation
1035024|NCT01863979|Thromboembolism
1035025|NCT01863966|Achalasia
1035026|NCT01863966|Hot water drinking therapy
1035027|NCT01863966|Pneumatic dilation
1035028|NCT01863914|ESRD
1035029|NCT01863914|Diabetes mellitus
1035030|NCT01863914|Endothelial progenitor cells
1035031|NCT01863914|Hemodialysis
1035032|NCT01863914|rosuvastatin
1035033|NCT01863875|Cochlear Implant
1035034|NCT01863875|Hearing loss
1035035|NCT01863875|Language Development
1035036|NCT01863875|Quality of life
1035037|NCT01863862|Rectal cancer
1035038|NCT01863862|Chemoradiation
1035039|NCT01863862|Complete pathological response
1035040|NCT01863849|uncontrolled,
1035041|NCT01863849|open,
1035042|NCT01863849|multi-centre
1035043|NCT01863849|immunogenicity and tolerability
1035044|NCT01863849|two groups according to age (18-59 years and ≥60 years)
1035045|NCT01863836|Radial endobronchial ultrasound
1035046|NCT01863836|Peripheral lung lesion
1035047|NCT01863836|Fluoroscopy
1035048|NCT01863836|Lung cancer
1035049|NCT01863823|Symptomatic patients
1035050|NCT01863823|asymptomatic individuals
1035051|NCT01863823|clinical trial
1035052|NCT01863810|Diabetic Neuropathy
1035053|NCT01863810|Neuropathic Pain
1035054|NCT01863810|Pregabalin
1035055|NCT01863784|Hepatic Impairment
1035056|NCT01863784|Mild and moderate hepatic impairment
1035057|NCT01863784|Normal hepatic function
1035058|NCT01863784|Pharmacokinetics
1035059|NCT01863784|JNJ-38518168
1035060|NCT01863771|Ulcerative Colitis
1035061|NCT01863771|Japanese
1035062|NCT01863771|Subcutaneous
1035063|NCT01863771|Golimumab
1035064|NCT01863745|ggastrointestinal stromal tumors
1035065|NCT01863745|gastrointestinal,
1035066|NCT01863745|stromal,
1035067|NCT01863745|tumors,
1035068|NCT01863745|GIST,
1035069|NCT01863745|AMN107,
1035070|NCT01863745|nilotinib
1035071|NCT01863732|AIN457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, PFS, pre-filled syringe, secukinumab, self-injection
1035072|NCT01863719|Colistin
1035073|NCT01863719|Multi Drug Resistant
1035074|NCT01863719|Nosocomial Pneumonia
1035075|NCT01863719|Pneumococcal Infections
1035076|NCT01863706|Misoprostol
1035077|NCT01863706|Oxytocin
1035078|NCT01863706|Post Partum Hemorrhage (PPH)
1035079|NCT01863706|Third stage of labour
1035080|NCT01863680|Infertility
1035081|NCT01863680|COL-1620
1035082|NCT01863680|progesterone gel
1035083|NCT01863680|Fertilization in Vitro
1035084|NCT01863680|Embryo Transfer
1035085|NCT01863654|Bioequivalence
1035086|NCT01863654|Mexico
1035087|NCT01863654|Asthma
1035088|NCT01863654|Montelukast
1035089|NCT01863654|Chewable
1035090|NCT01863641|lupus nephritis
1035091|NCT01863641|proteinuria
1035092|NCT01863641|SLE
1035093|NCT01863641|calcitriol
1035094|NCT01863628|Prodromal Symptoms
1035095|NCT01863628|bipolar disorder
1035096|NCT01863628|Neuropsychological Tests
1035097|NCT01863628|Magnetic Resonance Imaging
1035098|NCT01863628|Treatment Outcome
1035099|NCT01863628|aerobic exercise
1035100|NCT01863628|psychotherapy
1035101|NCT01863615|pharmacokinetics
1035102|NCT01863615|Isotretinoin
1035103|NCT01863615|bioequivalence
1035104|NCT01863615|Mexico
1035105|NCT01863576|Chagas disease
1035106|NCT01863576|Chagas Cardiomyopathy
1035107|NCT01863576|Trypanosoma cruzi
1035108|NCT01863576|Omega-3
1035109|NCT01863576|Cytokines
1035110|NCT01863576|Lipid profile
1035111|NCT01863576|Nutritional assessment
1035112|NCT01863563|tonsillectomy
1035113|NCT01863563|adenoidectomy
1035114|NCT01863563|obstructive sleep apnea
1035115|NCT01863524|Abdominal Aortic Aneurysm (AAA),
1035116|NCT01863524|Echocardiography (TTE),
1035117|NCT01863524|Acute Coronary Syndrome (ACS)
1035118|NCT01863524|Patients over 65 years old
1035119|NCT01863511|Treatment options for acute decompensated heart failure
1035120|NCT01863511|Ultrafiltration
1035121|NCT01863511|tolvaptan
1035122|NCT01863498|pectus excavatum
1035123|NCT01863498|pain control
1035124|NCT01863485|advanced cancer
1035125|NCT01863459|ADHD
1035126|NCT01863459|ADD
1035127|NCT01863459|Anxiety
1035128|NCT01863459|Anxiety Disorders
1035129|NCT01863459|Depression
1035130|NCT01863459|Attention
1035131|NCT01863459|Attention Deficit
1035136|NCT01863420|gastric cancer
1035137|NCT01863420|rectal cancer
1035138|NCT01863420|bone marrow toxicity
1035139|NCT01863420|IMRT
1035140|NCT01863420|hematologic toxicity
1035141|NCT01863407|Ileus
1035142|NCT01863407|Intestinal Obstruction
1035143|NCT01863407|Intestinal Diseases
1035271|NCT01862822|Urinary tract infection
1035144|NCT01863407|Gastrointestinal Diseases
1035145|NCT01863407|Digestive System Diseases
1035146|NCT01863394|Screening
1035147|NCT01863394|Malnutrition
1035148|NCT01863394|Community Management of Acute Malnutrition
1035149|NCT01863381|Hydrocephalus
1035150|NCT01863381|Idiopathic intracranial hypertension
1035151|NCT01863381|Pseudotumor cerebri
1035152|NCT01863381|ICP
1035153|NCT01863381|Intracranial pressure
1035154|NCT01863381|CSF pressure
1035155|NCT01863381|VIIP
1035156|NCT01863368|Dry eye syndrome
1035157|NCT01863368|Systane Ultra
1035158|NCT01863368|Optive
1035159|NCT01863368|Ocular Surface Staining
1035160|NCT01863368|OSDI
1035161|NCT01863368|Eye drops
1035162|NCT01863355|IntravenousPCA, fentanyl, postoperative pain, laparoscopic gastrectomy
1035163|NCT01863342|central sensitization; osteoarthritis; epidural analgesia
1035164|NCT01863329|Optic nerve sheath diameter
1035165|NCT01863329|Hydrocephalus
1035166|NCT01863329|Intracranial hypertension
1035167|NCT01863316|LMA Supreme, i-gel, supraglottic airway
1035168|NCT01863303|colorectal cancer
1035169|NCT01863303|epidemiology
1035170|NCT01863303|industry
1035171|NCT01863303|genetic
1035172|NCT01863290|prison
1035173|NCT01863290|reentry
1035174|NCT01863290|health care utilization
1035175|NCT01863264|dysphagia
1035176|NCT01863264|swallowing
1035177|NCT01863264|infant
1035178|NCT01863264|premature
1035179|NCT01863264|neonate
1035180|NCT01863264|thermal
1035181|NCT01863264|cold
1035182|NCT01863264|bolus
1035183|NCT01863264|temperature
1035184|NCT01863264|deglutition
1035185|NCT01863264|NICU
1035186|NCT01863264|bottle
1035187|NCT01863264|nippling
1035188|NCT01863251|Opiates
1035189|NCT01863251|ATS
1035190|NCT01863251|HIV Risks
1035191|NCT01863238|Cystic Fibrosis
1035192|NCT01863199|Wet AMD
1035193|NCT01863199|AMD
1035194|NCT01863199|Choroidal neovascularization
1035195|NCT01863199|Neovascular membrane
1035196|NCT01863186|lofexidine
1035197|NCT01863186|opioid dependence
1035198|NCT01863186|acute withdrawal syndrome
1035199|NCT01863186|opioid withdrawal
1035200|NCT01863173|Thalassemia cardiomyopathy
1035201|NCT01863173|metoprolol succinate
1035202|NCT01863173|echocardiography
1035203|NCT01863173|six minute walk test
1035204|NCT01863160|Safety
1035205|NCT01863160|Tolerability
1035206|NCT01863160|Pharmacokinetic profile
1035207|NCT01863160|ZEP-3 Cream (0.1% and 1.0%)
1035208|NCT01863160|administered topically
1035209|NCT01863147|Type 2 diabetes
1035210|NCT01863147|left ventricular mass
1035211|NCT01863147|inhibitor of dipeptidyl peptidase-4
1035212|NCT01863121|cirrhosis
1035213|NCT01863121|CTPK
1035214|NCT01863121|CTP
1035215|NCT01863121|MELD
1035216|NCT01863121|Severity Score
1035217|NCT01863108|Melanoma
1035218|NCT01863108|Immunotherapy
1035219|NCT01863108|Dermatology
1035220|NCT01863108|cancer vaccine
1035221|NCT01863108|Plasmacytoid dendritic cell line
1035222|NCT01863108|Advanced Medicinal Therapy Product
1035223|NCT01863108|allogeneic
1035224|NCT01863082|Resistant Hypertension
1035225|NCT01863069|inhaled
1035226|NCT01863069|interferon beta-1a
1035227|NCT01863069|healthy subjects
1035228|NCT01863056|Sedentary time
1035229|NCT01863056|Non Exercise Activity
1035230|NCT01863056|Sit Stand Workstation
1035231|NCT01863043|Premature Infant
1035232|NCT01863043|Nutrition
1035233|NCT01863043|Enteral
1035234|NCT01863030|Resorbable mesh
1035235|NCT01863030|Phasix mesh
1035236|NCT01863017|Obesity
1035237|NCT01863017|Over weight
1035238|NCT01862991|Induced Abortion
1035239|NCT01862991|Mifepristone
1035240|NCT01862991|Dilation and Evacuation
1035241|NCT01862991|Cervical Preparation
1035242|NCT01862991|Osmotic Dilators
1035243|NCT01862978|Stroke
1035244|NCT01862978|Heparin
1035245|NCT01862978|Nadroparin
1035246|NCT01862965|firstline
1035247|NCT01862965|treatment
1035248|NCT01862965|prednisone
1035249|NCT01862965|everolimus
1035250|NCT01862939|type 2 diabetes mellitus
1035251|NCT01862926|connective tissue disease
1035252|NCT01862926|interstitial lung disease
1035253|NCT01862926|pulmonary fibrosis
1035254|NCT01862926|rituximab
1035255|NCT01862926|scleroderma
1035256|NCT01862926|polymyositis
1035257|NCT01862926|dermatomyositis
1035258|NCT01862913|depression
1035259|NCT01862913|adolescents
1035260|NCT01862900|Breast Cancer
1035261|NCT01862900|Metastatic
1035262|NCT01862900|Lung metastases
1035263|NCT01862900|Liver metastases
1035264|NCT01862900|Stereotactic body radiation
1035265|NCT01862900|anti-OX40 antibody
1035266|NCT01862900|MEDI6469
1035267|NCT01862900|Immunotherapy
1035268|NCT01862861|Bioidentical Hormone Replacement Therapy
1035269|NCT01862848|Topical Compounded Pain Creams and Pain Perception
1035270|NCT01862822|Paediatrics
1035272|NCT01862822|Urine collection
1035273|NCT01862809|Oral Microbiota
1035274|NCT01862809|Cigarette Smoking
1035275|NCT01862809|Tobacco- Related Cancer
1035276|NCT01862796|Food Intake
1035277|NCT01862796|Weight Loss
1035278|NCT01862796|Compliance
1035279|NCT01862783|Erythrocytes
1035280|NCT01862783|Parasites
1035281|NCT01862783|Plasmodium Falciparum
1035282|NCT01862783|Placenta
1035283|NCT01862783|Resistant
1035284|NCT01862770|Lung Cancer
1035285|NCT01862770|Smokers
1035286|NCT01862770|Genetic Risk Communication
1035287|NCT01862770|Smoking Cessation
1035288|NCT01862757|Obesity
1035289|NCT01862757|Insulin
1035290|NCT01862757|Skeletal Muscle
1035291|NCT01862757|Strength Testing
1035292|NCT01862744|Parkinson's Disease
1035293|NCT01862744|MRI
1035294|NCT01862744|Cognitive
1035295|NCT01862731|Muscle Force
1035296|NCT01862731|Knee
1035297|NCT01862731|Magnetic Resonance Imaging
1035298|NCT01862731|Quadriceps
1035299|NCT01862731|Ultrasound
1035300|NCT01862718|Fusion
1035301|NCT01862718|Tracking
1035302|NCT01862718|Ablation
1035303|NCT01862718|Hepatic Neoplasms
1035304|NCT01862666|Barrett's Esophagus
1035305|NCT01862666|Dysplasia
1035306|NCT01862666|Intramucosal Adenocarcinoma
1035307|NCT01862666|EMR
1035308|NCT01862666|Endoscopy
1035309|NCT01862653|Post Traumatic Stress Disorder
1035310|NCT01862653|Sleep Disturbance
1035311|NCT01862653|Acupuncture
1035312|NCT01862640|OPC-34712
1035313|NCT01862640|brexpiprazole
1035314|NCT01862640|Dementia
1035315|NCT01862640|Alzheimer's Disease
1035316|NCT01862640|Cognitive Disorders
1035317|NCT01862640|Memory
1035318|NCT01862640|Agitation
1035319|NCT01862627|Macular retinoschisis
1035320|NCT01862627|Macular detachment
1035321|NCT01862627|vitrectomy
1035322|NCT01862614|Degree of pulpal anesthesia obtained.
1035323|NCT01862614|Primary infiltration in the lower first molar.
1035324|NCT01862614|Buffered local anesthetic.
1035325|NCT01862588|septic shock
1035326|NCT01862588|acute kidney injury
1035327|NCT01862588|renal resistive index
1035328|NCT01862562|Laparoscopic surgery
1035329|NCT01862562|Colorectal cancer
1035330|NCT01862562|Elderly patient
1035331|NCT01862562|Randomized control study
1035332|NCT01862536|Randomized trial
1035333|NCT01862536|COPD
1035334|NCT01862536|tadalafil
1035335|NCT01862536|Phosphodiesterase inhibitor
1035336|NCT01862536|Pulmonary hypertension
1035337|NCT01862510|Celiac Disease
1035338|NCT01862510|Hypothyroidism
1035339|NCT01862510|Celiac Sprue
1035340|NCT01862510|Malabsorption
1035341|NCT01862497|Intradialytic Hypertension
1035342|NCT01862497|Hemodialysis
1035343|NCT01862497|Hypertension
1035344|NCT01862497|Extracellular Volume
1035345|NCT01862497|Endothelial Cell Dysfunction
1035346|NCT01862497|Endothelin 1
1035347|NCT01862497|Carvedilol
1035348|NCT01862484|ADHD
1035349|NCT01862484|Diet
1035350|NCT01862484|Functional Magnetic Resonance Imaging
1035351|NCT01862471|Deep Vein Thrombosis
1035352|NCT01862471|Neuromuscular Electrical Stimulation
1035353|NCT01862471|Intermittent Pneumatic Compression
1035354|NCT01862471|Doppler Ultrasound
1035355|NCT01862458|empyema
1035356|NCT01862458|tPA
1035357|NCT01862458|dornase
1035358|NCT01862445|Chronic Lymphoid Leukemia, Chlorambucil, Rituximab
1035359|NCT01862393|electrical stimulation
1035360|NCT01862393|torque
1035361|NCT01862380|Adrenocortical function
1035362|NCT01862380|Adrenal hyperplasia, Congenital
1035363|NCT01862380|21-hydroxylase
1035364|NCT01862380|deficiency
1035365|NCT01862380|cortisol
1035366|NCT01862380|replacement therapy
1035367|NCT01862380|Woman
1035368|NCT01862380|Healthy people
1035369|NCT01862354|Postoperative analgesia
1035370|NCT01862354|Abdominoplasty
1035371|NCT01862354|Continuous wound infusion
1035372|NCT01862354|Transverse abdominal plan block
1035373|NCT01862354|Local anesthetics : Ropivacaine
1035374|NCT01862354|Regional anesthesia
1035375|NCT01862341|Constipation
1035376|NCT01862341|Bowel movement
1035377|NCT01862341|Intestinal health
1035378|NCT01862328|MLN4924
1035379|NCT01862328|Solid Tumors
1035386|NCT01862302|Prevention delirium
1035387|NCT01862302|Cardiac surgery
1035388|NCT01862289|difficult asthma
1035389|NCT01862289|hyperventilation syndrome
1035390|NCT01862289|prevalence
1035391|NCT01862263|Diabetes,
1035392|NCT01862263|Type 2 diabetes,
1035393|NCT01862263|Diabetes mellitus,
1035394|NCT01862263|insulin,
1035395|NCT01862237|Type II diabetes
1035396|NCT01862237|aortic valve stenosis
1035397|NCT01862237|left ventricular remodeling
1035398|NCT01862237|aortic valve replacement surgery
1035399|NCT01862224|Active rheumatoid arthritis despite methotrexate therapy
1035400|NCT01862224|JNJ-38518168
1035401|NCT01862224|Synovial
1035402|NCT01862211|alpha antitrypsin, hepatic disease, genetic, polymorphism
1035403|NCT01862185|semiquantitative
1035404|NCT01862185|procalcitonin
1035405|NCT01862185|sepsis
1035406|NCT01862185|antibiotics
1035407|NCT01862185|mortality
1035408|NCT01862172|Cortical focal atrophy
1035409|NCT01862172|Stroke
1035410|NCT01862172|Internal capsule
1035411|NCT01862172|Corticospinal tract
1035412|NCT01862172|Wallerian degeneration
1035413|NCT01862172|Primary motor area.
1035414|NCT01862159|bariatric surgery
1035415|NCT01862159|postoperative complications
1035416|NCT01862146|TCA
1035417|NCT01862146|FMD
1035418|NCT01862146|IMT
1035419|NCT01862146|Smoking
1035420|NCT01862133|Electronic Health Record
1035421|NCT01862133|Health Information Technology
1035422|NCT01862133|Patient Privacy
1035423|NCT01862133|Personal Health Information
1035424|NCT01862120|Recently diagnosed
1035425|NCT01862120|Regulatory T Cells
1035426|NCT01862120|Tolerance Induction
1035427|NCT01862120|Paediatrics
1035428|NCT01862120|Low dose
1035429|NCT01862120|IL-2
1035430|NCT01862107|Biomarkers
1035431|NCT01862107|Immune Responses
1035432|NCT01862107|Lumbar Puncture
1035433|NCT01862107|Neurological Diseases
1035434|NCT01862107|Novel Pathogens
1035435|NCT01862068|Pronostic factors
1035436|NCT01862068|Neutrophils
1035437|NCT01862068|Granulomatosis with polyangiitis
1035438|NCT01862068|Microscopic polyangiitis
1035439|NCT01862068|ANCA associated vasculitis
1035440|NCT01862068|Proteomics
1035441|NCT01862055|Stress
1035442|NCT01862055|Anxiety
1035443|NCT01862055|Cesarean Section
1035444|NCT01862055|Spinal anesthesia
1035445|NCT01862055|Hypotension
1035446|NCT01862042|Spinal Muscular Atrophy (SMA) type 1
1035447|NCT01862042|Supportive care
1035448|NCT01862042|Palliative care
1035449|NCT01862029|Mitochondria in Diabetes
1035450|NCT01862029|Obesity
1035451|NCT01862029|Roflumilast
1035452|NCT01862029|Phosphodiesterase-4
1035453|NCT01862029|Pre-Diabetes
1035454|NCT01862016|Acute respiratory distress syndrome
1035455|NCT01862016|APRV ventilatory mode
1035456|NCT01862016|Spontaneous breathing
1035457|NCT01862016|Intensive Care Unit
1035458|NCT01862003|Colorectal cancer
1035459|NCT01862003|Metastatic Colorectal cancer
1035460|NCT01862003|Recurrent Colorectal cancer
1035461|NCT01862003|FOLFIRI
1035462|NCT01862003|AZD8931
1035463|NCT01862003|Chemotherapy
1035464|NCT01862003|EGFR
1035465|NCT01861990|Glioma
1035466|NCT01861990|Glioblastoma
1035467|NCT01861990|Pediatric
1035468|NCT01861990|Child
1035469|NCT01861990|Brain tumor
1035470|NCT01861990|Astrocytoma
1035471|NCT01861990|Medulloblastoma
1035472|NCT01861990|PNET
1035473|NCT01861977|Cognitive Therapy
1035474|NCT01861977|Health Education
1035475|NCT01861977|Secondary Prevention
1035476|NCT01861977|Cardiovascular Disease
1035477|NCT01861964|XOS
1035478|NCT01861964|Xylooligosarcharide
1035479|NCT01861964|Prebiotic
1035480|NCT01861951|soft tissue sarcoma
1035481|NCT01861951|firstline treatment
1035482|NCT01861951|eldery patients
1035483|NCT01861938|melanoma
1035484|NCT01861938|vaccine
1035485|NCT01861938|Resectable AJCC stage IV
1035486|NCT01861938|AJCC stages IIb-c, III
1035487|NCT01861938|Patients with low-burden
1035488|NCT01861938|failed
1035489|NCT01861938|respond
1035490|NCT01861938|one treatment line
1035491|NCT01861912|Carcinoma, Hepatocellular
1035492|NCT01861912|Arsenic trioxide
1035493|NCT01861899|Sacro-iliac Joint
1035494|NCT01861886|Birth control
1035495|NCT01861886|Permanent Contraception
1035496|NCT01861873|liver function
1035497|NCT01861873|galactose
1035498|NCT01861873|18-F-deoxy-galactose
1035499|NCT01861860|stenting using IVUS in long lEsion
1035500|NCT01861834|Total parenteral nutrition
1035501|NCT01861834|TPN
1035502|NCT01861834|Intestinal Failure
1035503|NCT01861834|Short Bowel Syndrome
1035504|NCT01861834|Cholestasis
1035505|NCT01861834|Intestinal failure associated liver disease
1035506|NCT01861834|Parenteral nutrition associated liver disease
1035507|NCT01861821|Epidural catheter
1035508|NCT01861821|Epidural analgesia
1035509|NCT01861821|Labor epidural analgesia
1035510|NCT01861821|Analgesic efficacy
1035511|NCT01861821|Multiport epidural catheter
1035512|NCT01861821|Uniport epidural catheter
1035513|NCT01861821|Flexible epidural catheter
1035514|NCT01861808|Spinal Cord Injuries
1035515|NCT01861808|Cerebrospinal Fluid
1035516|NCT01861795|Drug therapy
1035517|NCT01861769|Cognitive Processing Therapy
1035518|NCT01861769|Consultation
1035519|NCT01861756|Shared Decision Making
1035520|NCT01861756|Decision Aids
1035521|NCT01861743|Multi-modal Pain Management
1035522|NCT01861743|Lumbar fusion
1035523|NCT01861743|misTLIF
1035524|NCT01861730|BCG Vaccinated
1035525|NCT01861730|HIV Negative
1035526|NCT01861717|excess growth hormone
1035527|NCT01861717|excess GH
1035528|NCT01861717|gigantism
1035529|NCT01861717|pituitary tumor
1035530|NCT01861717|pituitary adenoma
1035531|NCT01861717|growth hormone tumor
1035532|NCT01861717|GH secreting adenoma
1035533|NCT01861717|Somatuline
1035534|NCT01861717|lanreotide
1035535|NCT01861704|Mild to moderate hearing loss
1035536|NCT01861691|Transverse colon cancer
1035537|NCT01861691|Descending colon cancer
1035538|NCT01861691|Laparoscopic surgery
1035539|NCT01861691|Randomized controlled trial
1035540|NCT01861678|Rectal cancer
1035541|NCT01861678|Anterior resection
1035542|NCT01861678|High tie of inferior mesenteric artery
1035543|NCT01861678|Low tie of inferior mesenteric artery
1035544|NCT01861678|Randomized controlled trial
1035545|NCT01861652|Restless legs syndrome, Ekbom syndrome, Restless legs
1035546|NCT01861600|Stool composition
1035547|NCT01861535|VIN
1035548|NCT01861535|Imiquimod
1035549|NCT01861535|Surgery
1035550|NCT01861535|HPV
1035551|NCT01861535|Patient satisfaction
1035552|NCT01861522|TAU-284
1035553|NCT01861522|Bepotastine besilate
1035554|NCT01861522|Histamine H1 receptor antagonists
1035555|NCT01861522|children
1035556|NCT01861509|BP-C1
1035557|NCT01861509|CDBPA
1035558|NCT01861509|Metronomic chemotherapy
1035559|NCT01861509|Platinum analogue
1035560|NCT01861509|Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
1035561|NCT01861509|Benzene polycarboxylic acids complex with cis-diammineplatinum(II)
1035562|NCT01861509|Breast cancer
1035563|NCT01861509|Cisplatin
1035564|NCT01861509|Metastatic Breast Cancer
1035565|NCT01861496|Cisplatin
1035566|NCT01861496|Liposomal formulation
1035567|NCT01861457|nasal sanitizer®
1035568|NCT01861457|S. aureus
1035569|NCT01861457|general bacteria
1035570|NCT01861457|nasal carriage
1035571|NCT01861457|decolonization
1035572|NCT01861431|HIV, prevention, microfinance, sex work, Mongolia
1035573|NCT01861418|chronic low back pain
1035574|NCT01861418|low back pain
1035575|NCT01861418|lumbopelvic manipulation
1035576|NCT01861418|Chicago manipulation
1035577|NCT01861418|EMG median frequency
1035578|NCT01861418|electromyography
1035579|NCT01861418|reliability
1035580|NCT01861392|postural balance sensory motor trayning physical therapy modalities diabetes mellitus
1035581|NCT01861366|Implementation
1035582|NCT01861366|Guidelines
1035583|NCT01861366|Nutrition
1035584|NCT01861366|Nursing home
1035585|NCT01861327|Carbon dioxide
1035586|NCT01861327|aortic aneurysm
1035587|NCT01861327|angioplasty
1035588|NCT01861327|Critical lower limb ischemia
1035589|NCT01861288|Inflammatory Bowel Disease
1035590|NCT01861288|Fecal Calprotectin
1035591|NCT01861288|Clinical IBD score (SCCAI, PUCAI, aPCDAI)
1035592|NCT01861288|Endoscopic deep remission
1035593|NCT01861288|Histopathologic deep remission
1035594|NCT01861288|Immunological deep remission
1035595|NCT01861288|Treatment algorithm
1035596|NCT01861275|osa
1035597|NCT01861275|cerebral palsy
1035598|NCT01861275|thrombolysis in cerebral palsy
1035599|NCT01861275|sleep registration
1035600|NCT01861262|emergency
1035601|NCT01861262|drug poisoning
1035602|NCT01861262|StO2 measurement
1035603|NCT01861262|blood pressure
1035604|NCT01861262|hemodynamic failure
1035605|NCT01861223|acquired resistance
1035606|NCT01861223|gefitinib
1035607|NCT01861223|erlotinib
1035608|NCT01861210|Homosexuality, Male
1035609|NCT01861197|Efficacy
1035610|NCT01861197|Dovitinib
1035611|NCT01861197|Squamous NSCLC
1035612|NCT01861184|Lower respiratory tract infection
1035613|NCT01861184|LRTI
1035614|NCT01861184|Pneumococcal carriage
1035615|NCT01861158|Parenting
1035616|NCT01861158|Adolescence
1035617|NCT01861158|Delinquency
1035618|NCT01861158|Online intervention
1035619|NCT01861158|Juvenile Justice
1035620|NCT01861145|Intranasal steroids
1035621|NCT01861132|Pregnancy, cesarean delivery, blood pressure, cardiac output
1035627|NCT01861093|Unrelated Hematopoietic Stem Cell Transplantation
1035628|NCT01861093|Cryopreserved Cord Blood Units
1035629|NCT01861093|National Cord Blood Program
1035630|NCT01861080|target organ damage
1035631|NCT01861080|incident hypertension
1035632|NCT01861080|cohort
1035633|NCT01861054|Cancer Stem Cells
1035634|NCT01861054|Novel targeted therapy
1035635|NCT01861054|CXCR1/2 Inhibitors
1035636|NCT01861041|low dose
1035637|NCT01861041|different baricity
1035638|NCT01861041|spinal anesthesia
1035639|NCT01861028|total knee replacement
1035640|NCT01861028|total knee arthroplasty
1035641|NCT01861028|patient-specific
1035642|NCT01861002|Relapse
1035643|NCT01861002|Lymphoblastic
1035644|NCT01861002|Leukemia
1035645|NCT01861002|Azacytidine
1035646|NCT01861002|Refractory
1035647|NCT01861002|Myelogenous
1035648|NCT01861002|Acute
1035649|NCT01861002|Childhood
1035650|NCT01861002|Pediatric
1035651|NCT01861002|ALL
1035652|NCT01861002|AML
1035653|NCT01861002|Methylation
1035654|NCT01861002|Epigenetic therapy
1035655|NCT01860989|parasitemia
1035656|NCT01860963|ASIL
1035657|NCT01860963|Anal dysplasia
1035658|NCT01860963|IBD
1035659|NCT01860963|HPV DNA
1035660|NCT01860950|Healthy Adults
1035661|NCT01860950|Pain Perception
1035662|NCT01860937|T cell Immunotherapy
1035663|NCT01860937|CD19 Targeted Therapy
1035664|NCT01860937|Chimeric Antigen Receptor (CAR) Modified T cells
1035665|NCT01860937|Conditioning Chemotherapy
1035666|NCT01860937|13-052
1035667|NCT01860924|exercise
1035668|NCT01860924|depression
1035669|NCT01860924|smoking
1035670|NCT01860898|lung
1035671|NCT01860898|cancer
1035672|NCT01860898|thoracic
1035673|NCT01860898|chest
1035674|NCT01860898|pulmonary
1035675|NCT01860885|naloxone
1035676|NCT01860885|children
1035677|NCT01860885|opioid
1035678|NCT01860885|respiratory depression
1035679|NCT01860885|safety
1035680|NCT01860872|Cystic Fibrosis
1035681|NCT01860872|Pulmonary perfusion
1035682|NCT01860872|Inflammatory markers
1035683|NCT01860872|MRI
1035684|NCT01860872|CT of chest
1035685|NCT01860872|Lung Clearance Index
1035686|NCT01860859|cesarean
1035687|NCT01860859|ultrasound
1035688|NCT01860859|hysterotomy
1035689|NCT01860859|uterus
1035690|NCT01860859|suture
1035691|NCT01860846|Crohn's Disease
1035692|NCT01860833|Knee Osteoarthritis
1035693|NCT01860820|IPC/TEDS
1035694|NCT01860820|Geko device
1035695|NCT01860807|methamphetamine
1035696|NCT01860807|ibudilast
1035697|NCT01860807|HIV
1035698|NCT01860781|Schizophrenia
1035699|NCT01860781|Injection
1035700|NCT01860781|Switch
1035701|NCT01860781|Paliperidone
1035702|NCT01860781|refractory, chronic akathisia, poor complianc
1035703|NCT01860768|Acute aortic dissection
1035704|NCT01860768|Serum biomarkers
1035705|NCT01860768|Early diagnosis
1035706|NCT01860755|Sport-related concussion
1035707|NCT01860755|Dizziness
1035708|NCT01860755|Neck pain
1035709|NCT01860755|Headaches
1035710|NCT01860755|Physiotherapy
1035711|NCT01860755|Treatment
1035712|NCT01860742|Peptide Receptor Radionuclide Therapy (PRRT)
1035713|NCT01860742|Neuroendocrine Tumors
1035714|NCT01860742|Interferon alpha
1035715|NCT01860716|Melatonin, liver transplant, oxidative stress
1035716|NCT01860703|Ferriprox®
1035717|NCT01860703|LI
1035718|NCT01860703|DFP
1035719|NCT01860703|Deferiprone
1035720|NCT01860703|Healthy Volunteers
1035721|NCT01860690|MTX
1035722|NCT01860690|Ectopic pregnancy
1035723|NCT01860690|medical treatment
1035724|NCT01860677|cranial stimulation
1035725|NCT01860677|BOLD (Blood Oxygenation Level Dependent)
1035726|NCT01860677|fMRI (Functional Magnetic Resonance Imaging)
1035727|NCT01860677|spectroscopy
1035728|NCT01860664|allergy
1035729|NCT01860664|allergic
1035730|NCT01860664|conjunctivitis
1035731|NCT01860664|corticosteroid
1035732|NCT01860664|hydrocortisone
1035733|NCT01860664|ophthalmic
1035734|NCT01860664|ointment
1035735|NCT01860651|Inflammatory Bowel Disease
1035736|NCT01860651|Ulcerative Colitis
1035737|NCT01860651|Crohn´s Disease
1035738|NCT01860651|Children
1035739|NCT01860651|Adolescence
1035740|NCT01860651|E-health web-monitoring
1035741|NCT01860651|Adherence
1035742|NCT01860651|Disease activity
1035743|NCT01860651|Fecal Calprotectin
1035744|NCT01860599|prediabetes
1035745|NCT01860599|EPC's
1035746|NCT01860599|vascular reactivity
1035747|NCT01860586|pvr
1035748|NCT01860586|rd
1035749|NCT01860586|Proliferative Vitreoretinopathy
1035750|NCT01860586|retinal detachment
1035751|NCT01860586|detachment
1035752|NCT01860573|Amino acids
1035753|NCT01860573|Protein
1035754|NCT01860560|OSA
1035755|NCT01860560|Obstructive Sleep Apnea
1035756|NCT01860560|High Flow Therapy
1035757|NCT01860560|CPAP
1035758|NCT01860560|HFT
1035759|NCT01860560|Continuous Positive Airway Pressure
1035760|NCT01860560|Mild OSA
1035761|NCT01860560|Moderate OSA
1035762|NCT01860534|pain
1035763|NCT01860534|mydriasis
1035764|NCT01860534|light
1035765|NCT01860521|Termination of pregnancy
1035766|NCT01860521|Second trimester
1035767|NCT01860521|Programmed intermittent epidural bolus
1035768|NCT01860521|Continuous epidural infusion
1035769|NCT01860521|Epidural analgesia
1035770|NCT01860521|Legally Induced Abortion
1035771|NCT01860508|Progression free Survival
1035772|NCT01860495|growth factors
1035773|NCT01860495|periodontal pockets
1035774|NCT01860482|Refractory Reflux Esophagitis
1035775|NCT01860482|GERD
1035776|NCT01860482|Phase 4
1035777|NCT01860456|Chronic myeloid leukemia
1035778|NCT01860456|Imatinib
1035779|NCT01860456|Nilotinib
1035780|NCT01860456|Polymorphism, Single Nucleotide
1035781|NCT01860456|Pharmacokinetics
1035782|NCT01860456|ATP-Binding Cassette Transporters
1035783|NCT01860456|SLC Transporters
1035784|NCT01860456|Treatment outcome
1035785|NCT01860456|Toxicity
1035786|NCT01860443|depression
1035787|NCT01860443|adolescents
1035788|NCT01860430|Locally Advanced
1035789|NCT01860430|Head and Neck Cancer
1035790|NCT01860430|Ipilimumab (YERVOY®)
1035791|NCT01860417|Degenerative Disc Disease,
1035792|NCT01860417|Intervertebral Disc Disease
1035793|NCT01860417|Low Back Pain
1035794|NCT01860417|Nucleus pulposus
1035795|NCT01860417|Stem cell
1035796|NCT01860417|Cellular therapy
1035797|NCT01860417|Regenerative therapy
1035798|NCT01860417|Mesenchymal stem cells
1035799|NCT01860417|Bone marrow
1035800|NCT01860417|Musculoskeletal Diseases
1035801|NCT01860417|Mesenchymal Stromal Cells (allogenic)
1035802|NCT01860404|Concussion
1035803|NCT01860404|Branched chain amino acids
1035804|NCT01860404|BCAA
1035805|NCT01860404|HIT HEADS
1035806|NCT01860391|Silver
1035807|NCT01860391|Fluoride
1035808|NCT01860391|Diammine Silver Fluoride
1035809|NCT01860391|Saliva
1035810|NCT01860378|Whooping Cough
1035811|NCT01860378|Pertussis
1035812|NCT01860378|Tdap vaccination
1035813|NCT01860378|Randomized placebo controlled factorial trial
1035814|NCT01860365|Quality of life
1035815|NCT01860365|Integrative medicine
1035816|NCT01860365|Supportive care
1035817|NCT01860365|Cancer
1035818|NCT01860365|Chemotherapy
1035819|NCT01860352|Fish Oil
1035820|NCT01860352|colon health
1035821|NCT01860352|fatty acid metabolism
1035822|NCT01860339|Huntington's Disease
1035823|NCT01860339|HD
1035824|NCT01860339|Huntington Disease
1035825|NCT01860339|Juvenile Huntington's Disease
1035826|NCT01860339|JHD
1035827|NCT01860326|hepatic impairment
1035828|NCT01860326|mild and moderate hepatic impairment
1035829|NCT01860326|Alisporivir
1035830|NCT01860313|effectiveness
1035831|NCT01860313|distance learning
1035832|NCT01860313|mental health
1035833|NCT01860300|Tic Disorders
1035834|NCT01860300|Tourette Syndrome
1035835|NCT01860287|opioid
1035836|NCT01860287|subjective
1035837|NCT01860287|stress
1035838|NCT01860287|buprenorphine
1035839|NCT01860274|Mesh
1035840|NCT01860274|Graft
1035841|NCT01860274|Patency
1035842|NCT01860261|HIV
1035843|NCT01860261|AIDS
1035844|NCT01860261|sedentary
1035845|NCT01860261|fitness
1035846|NCT01860261|aging
1035847|NCT01860261|V02max
1035848|NCT01860261|d-dimer
1035849|NCT01860261|IL-6
1035850|NCT01860261|CRP
1035851|NCT01860261|ChiWalking
1035852|NCT01860261|ChiRunning
1035853|NCT01860261|aerobic exercise
1035854|NCT01860261|strength training
1035855|NCT01860248|vapocoolant effectiveness
1035856|NCT01860248|arterial puncture
1035857|NCT01860235|Local anesthesia
1035858|NCT01860235|Pain measurement
1035859|NCT01860235|Pain perception
1035860|NCT01860235|Dental anesthesia
1035861|NCT01860235|Root planing
1035862|NCT01860222|Hepatocellular carcinoma
1035863|NCT01860222|CSPH
1035864|NCT01860222|Hepatectomy
1035865|NCT01860222|percutaneous local ablative
1035866|NCT01860222|therapy (PLAT)
1035867|NCT01860222|randomized controlled trials(RCTs)
1035868|NCT01860209|obstructive sleep apnea
1035869|NCT01860209|overhydration
1035870|NCT01860209|end stage renal disease
1035871|NCT01860209|intermittent ambulatory hemodialysis
1035872|NCT01860209|polysomnography
1035873|NCT01860209|bioimpedance
1035874|NCT01860209|leg fluid shift
1035875|NCT01860209|neck circumference
1035876|NCT01860183|kidney transplantation
1035877|NCT01860183|chronic allograft dysfunction
1035878|NCT01860183|mycophenolate mofetil
1035879|NCT01860183|Chronic
1035880|NCT01860170|Blood and Marrow Transplant (BMT)
1035881|NCT01860170|MRD
1035882|NCT01860170|MUD
1035883|NCT01860170|GVHD
1035884|NCT01860157|rTMS
1035885|NCT01860157|depression
1035886|NCT01860157|magnetic
1035887|NCT01860144|bevacizumab
1035888|NCT01860144|overall survival
1035889|NCT01860144|adverse events
1035890|NCT01860144|tumor resection rate
1035891|NCT01860131|bariatrics, lifestyle and behavioral modification programs
1035892|NCT01860079|Early discharge
1035893|NCT01860079|STEMI
1035894|NCT01860079|PPCI
1035895|NCT01860066|COPD
1035896|NCT01860014|Pulmonary hemorrhage
1035897|NCT01860014|Mortality
1035898|NCT01860014|Newborn
1035899|NCT01860001|cancer
1035900|NCT01860001|metabolic acidosis
1035901|NCT01859988|Eczema
1035902|NCT01859962|Liver diseases
1035903|NCT01859962|Virus diseases
1035904|NCT01859962|Ribavirin
1035905|NCT01859962|protease inhibitor
1035906|NCT01859962|NS5B polymerase inhibitor
1035907|NCT01859962|NS5A inhibitor
1035908|NCT01859949|Genotropin(somatropin)
1035909|NCT01859949|SGA
1035910|NCT01859949|Short Stature
1035911|NCT01859949|Long-term
1035912|NCT01859949|Safety
1035913|NCT01859923|Tuberculosis
1035914|NCT01859923|Tuberculosis, Multidrug-Resistant
1035915|NCT01859923|Mycobacterium Infections
1035916|NCT01859923|Actinomycetales Infections
1035917|NCT01859923|Gram-Positive Infections
1035918|NCT01859923|Bacterial Infections
1035919|NCT01859923|Pediatric
1035920|NCT01859884|Kidney transplantation
1035921|NCT01859884|Increased risk donor kidneys
1035922|NCT01859884|Kidney donation
1035923|NCT01859884|Organ donation
1035924|NCT01859884|Human Immunodeficiency Virus
1035925|NCT01859884|Hepatitis B
1035926|NCT01859884|Hepatitis C
1035927|NCT01859884|Infectious disease
1035928|NCT01859884|Disease transmission
1035929|NCT01859884|Centers for Disease Control (CDC)
1035930|NCT01859884|Web-based intervention
1035931|NCT01859871|Living kidney donation
1035932|NCT01859871|End-stage renal disease
1035933|NCT01859871|Latinos
1035934|NCT01859871|Undocumented Immigrants
1035935|NCT01859871|Bilingual
1035936|NCT01859871|Spanish
1035937|NCT01859871|Website
1035938|NCT01859871|Dialysis
1035939|NCT01859871|Hispanics
1035940|NCT01859871|Transplantation
1035941|NCT01859858|mCRC (metastatic colorectal cancer)
1035942|NCT01859858|CRC (colorectal cancer)
1035943|NCT01859858|Advanced colorectal cancer
1035944|NCT01859858|Metastatic colorectal cancer
1035945|NCT01859858|Colon cancer
1035946|NCT01859845|Melanoma
1035947|NCT01859845|Opportunistic surveillance
1035948|NCT01859845|Melanoma simulation model
1035949|NCT01859845|Smartphone devices
1035950|NCT01859832|renal transplant
1035951|NCT01859832|kidney transplantation
1035952|NCT01859832|immune status
1035953|NCT01859832|immunosuppressive medications
1035954|NCT01859819|Pediatric
1035955|NCT01859819|Lymphoma (NOT primary mediastinal B-cell lymphoma)
1035956|NCT01859819|B-Cell---Burkitt's like
1035957|NCT01859819|Rituximab
1035958|NCT01859819|Liposomal ARA-C
1035959|NCT01859806|periampullary tumour
1035960|NCT01859806|isolated Roux loop PJ
1035961|NCT01859806|PG
1035962|NCT01859793|dipeptidyl peptidase-4 inhibitor
1035963|NCT01859793|endothelium, vascular
1035964|NCT01859793|diabetes type 2
1035965|NCT01859793|nitric oxide
1035966|NCT01859793|inflammation
1035967|NCT01859780|Poison control
1035968|NCT01859780|Child resistant packaging
1035969|NCT01859780|prescription vials
1035970|NCT01859780|prescription blisters
1035971|NCT01859780|drug packaging
1035972|NCT01859767|Alzheimer's disease
1035973|NCT01859767|SPECT
1035974|NCT01859754|Primary Immune Deficiency Syndrome
1035975|NCT01859754|Primary immunodeficiency Disease (PIDD)
1035976|NCT01859754|PID
1035977|NCT01859741|Newly diagnosed Stage IV Small Cell Lung Cancer
1035978|NCT01859728|biliary cancer
1035979|NCT01859728|irinotecan
1035980|NCT01859728|cisplatin
1035981|NCT01859728|gemcitabine
1035982|NCT01859715|Drug Interactions
1035983|NCT01859715|CYP2D6
1035984|NCT01859715|opioid efficacy
1035985|NCT01859715|pain
1035986|NCT01859715|nausea
1035987|NCT01859702|Aqueous Humor
1035988|NCT01859702|Moxifloxacin
1035989|NCT01859702|Vigadexa
1035990|NCT01859663|Polycystic Ovary Syndrome (PCOS)
1035991|NCT01859663|Diet
1035992|NCT01859663|Exercise
1035993|NCT01859663|Questionnaires
1035994|NCT01859663|Health Beliefs
1035995|NCT01859637|Filgrastim, immunogenicity, severe chronic neutropenia
1035996|NCT01859624|LOPD
1035997|NCT01859624|Pompe Disease
1035998|NCT01859598|diabetes
1035999|NCT01859598|basal insulin
1036000|NCT01859598|effectiveness and safety
1036001|NCT01859598|oral antidiabetic drugs
1036002|NCT01859598|real world clinical practice
1036003|NCT01859585|preemptive analgesia
1036004|NCT01859585|lumbar fusion
1036005|NCT01859585|Parecoxib
1036006|NCT01859585|Ketorolac
1036007|NCT01859572|Stroke
1036008|NCT01859572|Cerebral Infarction
1036009|NCT01859572|Brain Disorders
1036010|NCT01859572|Central Nervous System Diseases
1036011|NCT01859572|Nervous System Diseases
1036012|NCT01859572|Vascular Diseases
1036013|NCT01859572|Cardiovascular Diseases
1036014|NCT01859572|Brain Infarction
1036015|NCT01859572|Brain Ischaemia
1036016|NCT01859559|ultrasound
1036017|NCT01859559|peripheral intravenous access
1036018|NCT01859559|operator experience
1036019|NCT01859546|SMS
1036020|NCT01859520|Spermatozoa
1036021|NCT01859520|DNA fragmentation
1036022|NCT01859520|Swim-up
1036023|NCT01859520|Density gradient
1036024|NCT01859507|Vaginismus
1036025|NCT01859507|Botox
1036026|NCT01859507|Sex
1036027|NCT01859507|Clostridium
1036028|NCT01859507|Botulinum
1036029|NCT01859507|Neurotoxin
1036030|NCT01859507|Perineal
1036031|NCT01859507|Muscles
1036032|NCT01859455|Hypercholesterolemia,
1036033|NCT01859455|LDL cholesterol lowering,
1036034|NCT01859455|proprotein convertase subtilisin/kexin type 9 (PCSK9),
1036035|NCT01859455|LGT209,
1036036|NCT01859455|drug safety,
1036037|NCT01859455|pharmacokinetics,
1036038|NCT01859455|pharmacodynamics
1036039|NCT01859429|Cancer patients
1036040|NCT01859429|Psycho-oncological Care Provision
1036041|NCT01859429|Structured Screening
1036042|NCT01859429|Stepped care
1036043|NCT01859403|veteran
1036044|NCT01859403|obesity
1036045|NCT01859403|personalized genomics
1036046|NCT01859390|Antioxidants
1036047|NCT01859390|Vitamins
1036048|NCT01859390|Inflammation
1036049|NCT01859390|Oxidative stress
1036050|NCT01859364|Tobacco
1036051|NCT01859364|Smoking
1036052|NCT01859364|Smoking Cessation
1036053|NCT01859364|Outcome
1036054|NCT01859364|Nicotine Dependence
1036055|NCT01859325|HIV-MAG pDNA Prime
1036056|NCT01859325|HIV Therapy
1036057|NCT01859325|Therapeutic Vaccine
1036058|NCT01859312|Glucocorticoids
1036059|NCT01859312|Adrenal Insufficiency
1036060|NCT01859312|Congenital Adrenal Hyperplasia (CAH)
1036061|NCT01859312|Adrenal
1036065|NCT01859273|renal failure
1036066|NCT01859273|medication adherence
1036067|NCT01859273|hypertension
1036068|NCT01859260|chronic kidney disease, acute kidney injury, obstructive sleep apnea
1036069|NCT01859247|cervical dystonia
1036070|NCT01859247|torticollis
1036071|NCT01859247|rTMS
1036072|NCT01859234|multiple myeloma
1036073|NCT01859234|PET scan
1036074|NCT01859221|Prostate cancer
1036075|NCT01859221|Oligometastatic prostate cancer
1036076|NCT01859221|Proton radiation
1036077|NCT01859195|HIV/STI
1036078|NCT01859195|Prevention
1036079|NCT01859195|Microbicides, Topical
1036080|NCT01859169|bili duct neoplasms
1036081|NCT01859169|bile duct cancer
1036082|NCT01859169|photodynamic therapy
1036083|NCT01859169|biliary drainage
1036084|NCT01859156|Carbon Monoxide
1036085|NCT01859156|Carboxyhemoglobin
1036086|NCT01859156|End-tidal carbon dioxide
1036087|NCT01859156|Capnography
1036088|NCT01859143|Trivalent
1036089|NCT01859143|Influenza
1036090|NCT01859143|FluMist Quadrivalent
1036091|NCT01859143|Vaccine
1036092|NCT01859143|Prevention
1036093|NCT01859143|Healthy
1036094|NCT01859117|Peripheral arterial disease
1036095|NCT01859117|diabetic foot
1036096|NCT01859091|Lipolysis
1036097|NCT01859091|Cryolipolysis
1036098|NCT01859091|Fat Reduction
1036099|NCT01859065|Non-urgent ED visits
1036100|NCT01859065|Neonates
1036101|NCT01859065|Newborn care
1036102|NCT01859052|migraine
1036103|NCT01859052|obesity
1036104|NCT01859052|low fat diet
1036105|NCT01859052|low carbohydrate diet
1036106|NCT01859039|Egg allergy
1036107|NCT01859039|Anaphylaxis
1036108|NCT01859039|Children
1036109|NCT01859039|Influenza vaccine
1036110|NCT01859026|Epidermal growth factor receptor (EGFR)
1036111|NCT01859026|EGFR mutation
1036112|NCT01859026|Kirsten rat sarcoma 2 viral oncogene homolog(KRAS)
1036113|NCT01859026|KRAS mutation
1036114|NCT01859026|Non-Small Cell Lung Cancer (NSCLC)
1036115|NCT01859026|Advanced-stage IV
1036116|NCT01859000|Adolescents
1036117|NCT01859000|Hurricane Katrina
1036118|NCT01859000|Family-based treatment
1036119|NCT01859000|Multidimensional Family Therapy
1036120|NCT01859000|Group CBT
1036121|NCT01858974|multiplex PCR
1036122|NCT01858974|MALDI-TOF
1036123|NCT01858974|pneumonia
1036124|NCT01858974|microbiological investigation
1036125|NCT01858974|intensive care
1036126|NCT01858948|Bipolar disorder
1036127|NCT01858948|Second-generation antipsychotics
1036128|NCT01858948|Obesity
1036129|NCT01858948|Cardiometabolic risk
1036130|NCT01858922|Hodgkin's Lymphoma
1036131|NCT01858922|ABVE-PC
1036132|NCT01858922|doxorubicin
1036133|NCT01858922|bleomycin
1036134|NCT01858922|vincristine
1036135|NCT01858922|etoposide
1036136|NCT01858922|prednisone
1036137|NCT01858922|cyclophosphamide
1036138|NCT01858922|DECA
1036139|NCT01858922|decadron
1036140|NCT01858922|cisplatin
1036141|NCT01858922|cytarabine
1036142|NCT01858922|Radiation
1036143|NCT01858909|Sepsis
1036144|NCT01858896|hypoglycemia
1036145|NCT01858896|GLP-1
1036146|NCT01858896|Type 2 diabetes
1036147|NCT01858896|endothelial function
1036148|NCT01858870|Lacosamide
1036149|NCT01858870|Partial Crisis
1036150|NCT01858857|geriatric psychiatry
1036151|NCT01858857|pharmacovigilance
1036152|NCT01858818|CAIS Computer Assisted Infusion System
1036153|NCT01858818|real life drinking behavior
1036154|NCT01858818|family history of alcoholism
1036155|NCT01858818|conditioning
1036156|NCT01858818|instrumental learning
1036157|NCT01858818|habitization
1036158|NCT01858805|esophagus carcinoma
1036159|NCT01858805|surgery
1036160|NCT01858805|circulating tumor cells
1036161|NCT01858779|stroke
1036162|NCT01858779|atrial fibrillation
1036163|NCT01858779|secondary prevention of stroke
1036164|NCT01858779|peripheral pulse measurement
1036165|NCT01858766|Hepatitis
1036166|NCT01858766|HCV Genotype 1
1036167|NCT01858766|HCV Genotype 2
1036168|NCT01858766|HCV Genotype 3
1036169|NCT01858766|HCV Genotype 4
1036170|NCT01858766|HCV Genotype 5
1036171|NCT01858766|HCV Genotype 6
1036172|NCT01858766|treatment naive
1036173|NCT01858753|burn scars
1036174|NCT01858753|restrictive
1036175|NCT01858753|contractures
1036176|NCT01858753|autologous fibroblasts
1036177|NCT01858727|forced-air
1036178|NCT01858727|hypothermia
1036179|NCT01858727|TUR-P surgery
1036180|NCT01858727|core temperatures
1036181|NCT01858727|prewarming
1036182|NCT01858727|general anaesthesia
1036183|NCT01858714|obesity
1036184|NCT01858714|overweight
1036185|NCT01858714|weight loss
1036186|NCT01858701|myopia
1036187|NCT01858701|hyperopia
1036188|NCT01858701|astigmatism
1036189|NCT01858701|contact lenses
1036190|NCT01858688|Prostate Cancer
1036191|NCT01858688|MRI
1036192|NCT01858688|Active surveillance in prostate cancer
1036193|NCT01858675|ProADM
1036194|NCT01858675|ProANP
1036195|NCT01858675|proendothelin
1036196|NCT01858675|proAVP
1036197|NCT01858675|Cr 51
1036198|NCT01858675|Volemia
1036199|NCT01858675|fluid management
1036200|NCT01858675|ICU patients
1036201|NCT01858675|poly trauma patients
1036202|NCT01858662|metastatic colorectal cancer
1036203|NCT01858662|Liver
1036204|NCT01858662|cetuximab
1036205|NCT01858662|Pathological response
1036212|NCT01858623|Healthy Normotensive Participants
1036213|NCT01858623|Fixed dose combination
1036214|NCT01858623|Pharmacokinetics
1036215|NCT01858623|Losartan
1036216|NCT01858623|Hydrochlorothiazide
1036217|NCT01858610|Fixed dose combination
1036218|NCT01858610|Pharmacokinetics
1036219|NCT01858610|Irbesartan
1036220|NCT01858610|Hydrochlorothiazide
1036221|NCT01858610|Pharmacodynamics
1036222|NCT01858610|Normotensive Participants
1036223|NCT01858597|GDM, FGF
1036224|NCT01858584|GER
1036225|NCT01858584|Alginate
1036226|NCT01858584|Regurgitation
1036227|NCT01858584|questionnaire
1036228|NCT01858571|Childhood Cancer
1036229|NCT01858532|Diabetes
1036230|NCT01858532|Nephropathy
1036231|NCT01858519|pancreatic enzyme replacement therapy
1036232|NCT01858519|antibodies
1036233|NCT01858519|porcine viruses
1036234|NCT01858519|epidemiology
1036235|NCT01858519|prospective
1036236|NCT01858506|Type 2 diabetes mellitus
1036237|NCT01858506|Lifestyle counselling
1036238|NCT01858506|Lifestyle assessment
1036239|NCT01858506|Randomized controlled trial
1036240|NCT01858506|Diabetes education
1036241|NCT01858493|Urinary incontinence
1036242|NCT01858493|Falls
1036243|NCT01858493|Quality of life
1036244|NCT01858493|Stigma
1036245|NCT01858493|Community-dwelling older women
1036246|NCT01858493|Continence promotion
1036247|NCT01858480|CHF
1036248|NCT01858467|Airway, Cesarean
1036249|NCT01858402|Pediatric spinal anesthesia, paracetamol, dipyrone
1036250|NCT01858389|Non-small cell lung cancer
1036251|NCT01858389|T790M mutation. dacomitinib
1036252|NCT01858376|LDL cholesterol
1036253|NCT01858376|anti-hyperlipidemic
1036254|NCT01858376|hyperlipidemic
1036255|NCT01858376|Capros
1036256|NCT01858376|Natural Supplement
1036257|NCT01858363|Peripheral arterial disease
1036258|NCT01858363|claudication
1036259|NCT01858363|drug-coated balloon
1036260|NCT01858363|drug-eluting balloon
1036261|NCT01858350|CAM
1036262|NCT01858350|Sedation
1036263|NCT01858350|MRI
1036264|NCT01858350|Music Therapy
1036265|NCT01858337|weaning
1036266|NCT01858337|infants
1036267|NCT01858337|vegetables
1036268|NCT01858337|repeated-exposure
1036269|NCT01858324|Preeclampsia
1036270|NCT01858324|Hypertensive disorders of pregnancy
1036271|NCT01858324|Patient education
1036272|NCT01858324|Educationnal tools
1036273|NCT01858324|Pamphlet
1036274|NCT01858324|Video
1036275|NCT01858324|Knowledge
1036276|NCT01858324|Anxiety
1036277|NCT01858324|Satisfaction
1036278|NCT01858311|Stroke survivors
1036279|NCT01858311|TIA survivors
1036280|NCT01858311|Vitamin E
1036281|NCT01858311|Carotech
1036282|NCT01858311|Tocotrienol
1036283|NCT01858298|Dental caries
1036284|NCT01858298|Quality of Life
1036285|NCT01858298|Pulpectomy
1036286|NCT01858298|Tooth extraction
1036287|NCT01858285|Epilepsy
1036288|NCT01858285|Ohtahara
1036289|NCT01858285|Dravet
1036290|NCT01858285|MMPEI
1036291|NCT01858285|EMEE
1036292|NCT01858285|EIEE
1036293|NCT01858246|Hearing Loss, Conductive
1036294|NCT01858246|Bone Conduction
1036295|NCT01858246|bone conduction thresholds better than 45 dBHL
1036296|NCT01858233|Gestational diabetes
1036297|NCT01858220|Gastroparesis
1036298|NCT01858220|Small bowel video capsule
1036299|NCT01858220|gastric retention
1036300|NCT01858207|HCC
1036301|NCT01858207|hepatocellular carcinoma
1036302|NCT01858207|liver cancer
1036303|NCT01858194|Tachycardia, Renal Sympathetic Denervation
1036304|NCT01858194|Catheter Ablation
1036305|NCT01858194|Cardioverter-Defibrillator
1036306|NCT01858142|Pediatric anesthesia
1036307|NCT01858142|Pre-operative anxiety
1036308|NCT01858142|parental presence
1036309|NCT01858142|children
1036310|NCT01858142|elective surgical procedures
1036311|NCT01858142|mask induction
1036312|NCT01858129|TTN
1036313|NCT01858103|Mucopolysaccharidosis IVA Type A
1036314|NCT01858103|MPS IVA Type A
1036315|NCT01858103|Mucopolysaccharidosis IVA
1036316|NCT01858103|MPS IVA
1036317|NCT01858103|Morquio A Syndrome
1036318|NCT01858103|Lysosomal Storage Disorder
1036319|NCT01858103|LSD
1036320|NCT01858103|N-acetylgalactosamine-6-sulfatase
1036321|NCT01858103|N-acetylgalactosamine-6-sulfate
1036322|NCT01858090|spinal anesthesia
1036323|NCT01858090|caesarean section
1036324|NCT01858090|local anesthetics
1036325|NCT01858090|levobupivacaine
1036326|NCT01858090|sufentanil
1036327|NCT01858090|fentanyl
1036328|NCT01858090|above 18 years of age
1036329|NCT01858090|pregnant women
1036330|NCT01858090|multiparous
1036331|NCT01858090|nulliparous
1036332|NCT01858064|ADHD
1036333|NCT01858064|OROS-MPH
1036334|NCT01858064|Adults
1036335|NCT01858064|Functional Magnetic Resonance Imaging
1036336|NCT01858051|Vitamin D
1036337|NCT01858051|Perioperative immune regulation
1036338|NCT01858051|LL-37
1036339|NCT01858051|Hospital-acquired infection
1036340|NCT01858051|Surgical site infections
1036341|NCT01858038|Scar
1036342|NCT01858012|insulin resistance
1036343|NCT01857999|Renin-aldosterone system
1036344|NCT01857999|Hemodynamic
1036345|NCT01857999|Low cardiac output
1036346|NCT01857999|Vasodilation
1036347|NCT01857999|Natriuretic peptide
1036348|NCT01857986|Endotracheal intubation
1036349|NCT01857986|Mechanical ventilation
1036350|NCT01857986|Critical care
1036351|NCT01857973|OCL
1036352|NCT01857973|Type 1 Diabetes
1036353|NCT01857973|Sensor
1036354|NCT01857973|Artificial calibration error
1036355|NCT01857960|Acne
1036356|NCT01857960|Treatment
1036357|NCT01857960|Cost
1036358|NCT01857960|Behavior
1036359|NCT01857947|AECOPD Mr ProADM Biomarkers ER Outcome
1036360|NCT01857934|Anti-GD2 monoclonal antibody
1036361|NCT01857934|hu14.18K322A
1036362|NCT01857934|High-risk neuroblastoma
1036363|NCT01857934|Phase II
1036364|NCT01857934|Allogeneic NK cells
1036365|NCT01857908|Adenocarcinoma
1036366|NCT01857908|Abiraterone
1036367|NCT01857908|Abiraterone Acetate
1036368|NCT01857908|Zytiga
1036369|NCT01857908|Correlative study
1036370|NCT01857908|Castrate Resistant Prostate Cancer
1036371|NCT01857908|Abiraterone Correlative study
1036372|NCT01857895|Nausea
1036373|NCT01857895|subcutaneous infusion
1036374|NCT01857895|exenatide
1036375|NCT01857882|breast cancer
1036376|NCT01857882|breast reconstruction
1036377|NCT01857882|shared decision making
1036378|NCT01857882|decision support intervention
1036379|NCT01857869|Efficacy
1036380|NCT01857869|Sporozoite challenge model
1036381|NCT01857869|Malaria
1036382|NCT01857869|Immunogenicity
1036383|NCT01857869|Malaria- naïve adults
1036384|NCT01857869|Safety
1036385|NCT01857856|Phospholamban
1036386|NCT01857856|cardiomyopathy
1036387|NCT01857856|Eplerenone
1036388|NCT01857856|presymptomatic
1036389|NCT01857830|Telomerase
1036390|NCT01857830|Telomere Length
1036391|NCT01857830|Psychological Stress
1036392|NCT01857830|Amyloid beta proteins
1036393|NCT01857830|Meditation
1036394|NCT01857804|peri-implantitis
1036395|NCT01857804|surgical therapy
1036396|NCT01857804|systemic antibiotics
1036397|NCT01857804|local antiseptics
1036398|NCT01857778|Breastfeeding
1036399|NCT01857778|Breast tissue
1036400|NCT01857778|Breast pump
1036401|NCT01857765|rehabilitation
1036402|NCT01857765|reconstructive surgery
1036403|NCT01857752|Retinoblastoma
1036404|NCT01857726|hepatocellular carcinoma
1036405|NCT01857726|portal vein invasion
1036406|NCT01857726|transarterial chemoembolization
1036407|NCT01857726|transarterial chemoinfusion
1036408|NCT01857674|Laryngeal edema
1036409|NCT01857674|Post-extubation
1036410|NCT01857674|Acute respiratory distress
1036411|NCT01857674|Ultrasonography
1036412|NCT01857674|Intensive care unit
1036413|NCT01857661|tinnitus
1036414|NCT01857661|hearing loss
1036415|NCT01857661|hearing devices
1036416|NCT01857648|Physical Activity
1036417|NCT01857648|Health Promotion
1036418|NCT01857648|Primary Health Care
1036419|NCT01857648|Intervention Studies
1036420|NCT01857648|Public health Practice
1036421|NCT01857635|Acute respiratory failure
1036422|NCT01857635|Hypercapnia
1036423|NCT01857635|Non invasive ventilation
1036424|NCT01857635|Transcutaneous CO2 measurement
1036425|NCT01857622|anticoagulant
1036426|NCT01857622|DU-176b
1036427|NCT01857622|edoxaban
1036428|NCT01857622|factor Xa
1036429|NCT01857622|oral
1036430|NCT01857622|atrial fibrillation
1036431|NCT01857622|severe renal impairment
1036432|NCT01857609|Metformin
1036433|NCT01857609|Proton pump inhibitor
1036434|NCT01857609|Drug interaction
1036435|NCT01857596|Female Sexual Dysfunction
1036436|NCT01857596|Hypoactive Sexual Desire Disorder
1036437|NCT01857596|Sexual Interest/Arousal Disorder
1036438|NCT01857596|Lorexys
1036439|NCT01857596|Premenopausal female health
1036440|NCT01857583|anticoagulant
1036441|NCT01857583|DU-176b
1036442|NCT01857583|edoxaban
1036443|NCT01857583|factor Xa
1036444|NCT01857583|oral
1036445|NCT01857583|orthopedic surgery of lower limbs
1036446|NCT01857583|severe renal impairment
1036447|NCT01857570|Radius fracture
1036448|NCT01857570|Scaphoid fracture
1036449|NCT01857570|Tomography, x-ray computed
1036450|NCT01857557|Exercise
1036451|NCT01857557|Fitness program
1036452|NCT01857544|Retinal Vein Occlusion
1036453|NCT01857544|Central Retinal Vein Occlusion
1036454|NCT01857544|Macular Edema
1036455|NCT01857531|Smoking Cessation
1036456|NCT01857531|Quit Smoking
1036457|NCT01857531|Ganaxolone
1036458|NCT01857531|Nicotine Patch
1036459|NCT01857505|Total Hip replacement
1036460|NCT01857505|Fracture table
1036461|NCT01857505|DePuySynthes
1036462|NCT01857505|Direct anterior approach hip replacement
1036463|NCT01857505|Posterior approach hip replacement
1036464|NCT01857492|abdominal pain
1036465|NCT01857492|pancreatitis
1036466|NCT01857492|chronic abdominal pain
1036467|NCT01857492|visceral pain
1036468|NCT01857492|meditation
1036469|NCT01857492|tDCS
1036470|NCT01857492|noninvasive brain stimulation
1036471|NCT01857492|EEG
1036472|NCT01857492|Kirtan Kriya
1036473|NCT01857479|ABPA
1036474|NCT01857453|Adult Patients Medulloblatoma Standard risk group Chemotherapy Radiotherapy Quality of Life
1036475|NCT01857440|Glaucoma
1036476|NCT01857440|Pupil
1036477|NCT01857440|Melanopsin
1036478|NCT01857414|ST-elevation myocardial infarction
1036479|NCT01857414|Remote Ischaemic Conditioning
1036480|NCT01857414|Myocardial Reperfusion Injury
1036481|NCT01857414|Cardiovascular mortality
1036482|NCT01857388|school-based program, mental health, implementation
1036483|NCT01857375|Diabetes - insulin administration
1036484|NCT01857362|Orfadin
1036485|NCT01857362|Nitisinone
1036486|NCT01857362|Bioequivalence
1036490|NCT01857323|asthma
1036491|NCT01857323|chronic obstructive pulmonary disease
1036492|NCT01857323|COPD
1036493|NCT01857323|Albuterol Spiromax®
1036494|NCT01857310|Folic Acid
1036495|NCT01857310|Zinc
1036496|NCT01857310|Semen
1036497|NCT01857310|In vitro fertilization
1036498|NCT01857310|Assisted reproductive technology
1036499|NCT01857310|Ovulation induction
1036500|NCT01857310|Intrauterine insemination
1036501|NCT01857310|Pregnancy
1036502|NCT01857310|Live Birth
1036503|NCT01857310|Abortion, spontaneous
1036504|NCT01857284|Tauroursodeoxycholic Acid
1036505|NCT01857284|Primary Biliary Cirrhosis
1036506|NCT01857284|Safety
1036507|NCT01857284|Efficacy
1036508|NCT01857258|green tea
1036509|NCT01857258|catechins
1036510|NCT01857258|vascular endothelial function
1036511|NCT01857258|postprandial hyperglycemia
1036512|NCT01857258|oxidative stress
1036513|NCT01857245|addiction
1036514|NCT01857245|Adherence (attribute)
1036515|NCT01857245|Adverse effects
1036516|NCT01857245|Agonist
1036517|NCT01857245|Antiviral Agents
1036518|NCT01857245|arm
1036519|NCT01857245|base
1036520|NCT01857245|care delivery
1036521|NCT01857245|Caring
1036522|NCT01857245|Chronic Hepatitis C
1036523|NCT01857245|Clinic
1036524|NCT01857245|Clinical Trials
1036525|NCT01857245|Complex
1036526|NCT01857245|Computer Simulation
1036527|NCT01857245|cost
1036528|NCT01857245|cost effective
1036529|NCT01857245|cost effectiveness
1036530|NCT01857245|Data
1036531|NCT01857245|Development
1036532|NCT01857245|Directly Observed Therapy
1036533|NCT01857245|Disease
1036534|NCT01857245|Dose
1036535|NCT01857245|Drug resistance
1036536|NCT01857245|drug resistant virus
1036537|NCT01857245|Educational aspects
1036538|NCT01857245|Epidemic
1036539|NCT01857245|experience
1036540|NCT01857245|Frequencies (time pattern)
1036541|NCT01857245|Fright
1036542|NCT01857245|Genotype
1036543|NCT01857245|Group Therapy
1036544|NCT01857245|Health Care Costs
1036545|NCT01857245|Health Personnel
1036546|NCT01857245|Healthcare Systems
1036547|NCT01857245|Hepatitis C
1036548|NCT01857245|Hepatitis C Prevalence
1036549|NCT01857245|Hepatitis C Transmission
1036550|NCT01857245|Hepatitis C virus
1036551|NCT01857245|HIV
1036552|NCT01857245|Homelessness
1036553|NCT01857245|improved
1036554|NCT01857245|Incidence
1036555|NCT01857245|Infection
1036556|NCT01857245|Injecting drug user
1036557|NCT01857245|Injection of therapeutic agent
1036558|NCT01857245|Intensive Care
1036559|NCT01857245|Interferons
1036560|NCT01857245|Intervention
1036561|NCT01857245|Knowledge
1036562|NCT01857245|Life
1036563|NCT01857245|Liver diseases
1036564|NCT01857245|Liver Failure
1036565|NCT01857245|liver transplantation
1036566|NCT01857245|Living Costs
1036567|NCT01857245|Mental disorders
1036568|NCT01857245|Methadone
1036569|NCT01857245|methadone clinic/center
1036570|NCT01857245|Modeling
1036571|NCT01857245|Mortality Vital Statistics
1036572|NCT01857245|Motivation
1036573|NCT01857245|multidisciplinary
1036574|NCT01857245|Opiates
1036575|NCT01857245|Oral
1036576|NCT01857245|Outcome
1036577|NCT01857245|Patients
1036578|NCT01857245|Persons
1036579|NCT01857245|Pharmaceutical Preparations
1036580|NCT01857245|Physicians
1036581|NCT01857245|pill (pharmacologic)
1036582|NCT01857245|Play
1036583|NCT01857245|Poverty
1036584|NCT01857245|Primary Health Care
1036585|NCT01857245|programs
1036586|NCT01857245|Psychiatric therapeutic procedure
1036587|NCT01857245|psychosocial
1036588|NCT01857245|Publishing
1036589|NCT01857245|Quality-Adjusted Life Years
1036590|NCT01857245|Randomized
1036591|NCT01857245|Randomized Controlled Trials
1036592|NCT01857245|randomized trial
1036593|NCT01857245|Recruitment Activity
1036594|NCT01857245|Regimen
1036595|NCT01857245|Resistance
1036596|NCT01857245|Resistance development
1036597|NCT01857245|response
1036598|NCT01857245|Risk
1036599|NCT01857245|risk perception
1036600|NCT01857245|Role
1036601|NCT01857245|Site
1036602|NCT01857245|skills
1036603|NCT01857245|Social support
1036604|NCT01857245|standard care
1036605|NCT01857245|substance abuse treatment
1036606|NCT01857245|success
1036607|NCT01857245|Time
1036608|NCT01857245|Treatment outcome
1036609|NCT01857245|Treatment Protocols
1036610|NCT01857245|treatment site
1036611|NCT01857245|Trust
1036612|NCT01857245|United States
1036613|NCT01857245|Viral
1036614|NCT01857245|Virus
1036615|NCT01857219|fMRI
1036616|NCT01857206|Influenza
1036617|NCT01857206|children and adolescents
1036618|NCT01857206|trivalent vaccine
1036619|NCT01857206|cell culture
1036620|NCT01857206|embryonated chicken eggs
1036621|NCT01857193|Open label; dose escalation; ER+; LEE011; CDK4/6; everolimus; advanced breast cancer; mTOR; HR positive; HER2 negative
1036622|NCT01857167|omega-3 fatty acids
1036623|NCT01857167|randomized controlled trial
1036624|NCT01857154|Bone mineral density
1036625|NCT01857154|Bone mineral content
1036626|NCT01857154|Bone density
1036627|NCT01857154|Bone health
1036628|NCT01857154|Dual-energy x-ray absorptiometry
1036629|NCT01857141|dexmedetomidine
1036630|NCT01857141|heart rate variability
1036631|NCT01857141|preemptive epidural
1036632|NCT01857141|gastrectomy
1036633|NCT01857115|Multiple myeloma
1036634|NCT01857115|Diagnosis
1036635|NCT01857115|Weekly
1036636|NCT01857115|CCyd
1036637|NCT01857089|Pressure Ulcer
1036638|NCT01857089|prevention
1036639|NCT01857076|Type 2 Diabetes mellitus
1036640|NCT01857076|Grade I obesity
1036641|NCT01857076|Inadequate glycemic control
1036642|NCT01857011|Anemia, Iron-Deficiency
1036643|NCT01857011|bariatric surgery
1036644|NCT01857011|abdominoplasty
1036645|NCT01857011|surgery, plastic
1036646|NCT01857011|iron
1036647|NCT01856998|Therapeutic Equivalence
1036648|NCT01856998|Propofol
1036649|NCT01856985|Medical abortion
1036650|NCT01856985|Misoprostol
1036651|NCT01856985|Mifepristone
1036652|NCT01856972|Limited Dorsiflexion Range of Motion
1036653|NCT01856972|Gastrocnemius tightness
1036654|NCT01856972|Soleus tightness
1036655|NCT01856959|magnesium sulfate
1036656|NCT01856959|nebulized
1036657|NCT01856959|lung function
1036658|NCT01856933|GBM
1036659|NCT01856933|Glioblastoma Multiforme
1036660|NCT01856933|Gliosarcoma
1036661|NCT01856920|Calcitonin
1036662|NCT01856920|T-cells
1036663|NCT01856920|Immune Response
1036664|NCT01856920|HLA Patients
1036665|NCT01856920|Vaccine
1036666|NCT01856907|prediabetes
1036667|NCT01856907|impaired fasting/impaired glucose tolerance
1036668|NCT01856907|post gestational diabetes
1036669|NCT01856907|diabetes prevention
1036670|NCT01856894|polycystic ovary syndrome
1036671|NCT01856894|Anti-Mullerian Hormone
1036672|NCT01856894|obesity
1036673|NCT01856881|Type 2 diabetes
1036674|NCT01856868|BMD
1036675|NCT01856868|Becker muscular dystrophy
1036676|NCT01856868|epicatechin
1036677|NCT01856868|clinical trial
1036678|NCT01856868|neuromuscular disease
1036679|NCT01856855|Prostate Cancer
1036680|NCT01856855|Prostate Adenocarcinoma
1036681|NCT01856855|Radiation
1036682|NCT01856855|SBRT
1036683|NCT01856855|Stereotactic Body Radiation Therapy
1036684|NCT01856842|Pulmonary Arteriovenous Malformations
1036685|NCT01856842|Hereditary Hemorrhagic Telangiectasia (HHT)
1036686|NCT01856842|Embolization
1036687|NCT01856842|reperfusion rates
1036688|NCT01856777|Medical Abortion
1036689|NCT01856777|Pregnancy Test
1036690|NCT01856777|continuing pregnancy
1036691|NCT01856764|Atopic dermatitis
1036692|NCT01856751|Haemophilia
1036693|NCT01856751|TGA
1036694|NCT01856751|TEM
1036695|NCT01856738|Parkinson's disease
1036696|NCT01856738|Visual hallucinations
1036697|NCT01856738|Rivastigmine
1036698|NCT01856738|Cholinesterase inhibitor
1036699|NCT01856738|Randomized controlled trial
1036700|NCT01856738|Cost-effectiveness analysis
1036701|NCT01856712|alcohol
1036702|NCT01856712|veterans
1036703|NCT01856699|supratentorial superficial siderosis
1036704|NCT01856699|intracerebral hemorrhage
1036705|NCT01856699|cerebral amyloid angiopathy
1036706|NCT01856686|ADD
1036707|NCT01856686|ADHD
1036708|NCT01856686|Proteins
1036709|NCT01856686|Dietary
1036710|NCT01856686|Nutrition
1036711|NCT01856686|QEEG
1036712|NCT01856686|ERP
1036713|NCT01856686|ICA
1036714|NCT01856673|Mental Health
1036715|NCT01856673|Displacement
1036716|NCT01856673|Torture
1036717|NCT01856673|Violence
1036718|NCT01856673|Post-Traumatic Stress Disorder
1036719|NCT01856673|Depression
1036720|NCT01856673|Anxiety
1036721|NCT01856673|Community-based intervention
1036722|NCT01856673|Prevention trial
1036723|NCT01856673|Disabled Persons
1036724|NCT01856660|Obesity
1036725|NCT01856660|Weight Loss
1036726|NCT01856660|Body Weight Change
1036727|NCT01856660|Taste
1036728|NCT01856660|Taste Phenotype
1036729|NCT01856660|Lifestyle Intervention
1036730|NCT01856647|Psoriasis
1036731|NCT01856647|Obesity
1036732|NCT01856634|Tuberculosis
1036733|NCT01856634|Tuberculosis, Multidrug-Resistant
1036734|NCT01856634|Mycobacterium Infections
1036735|NCT01856634|Actinomycetales Infections
1036736|NCT01856634|Gram-Positive Infections
1036737|NCT01856634|Bacterial Infections
1036738|NCT01856634|Pediatric
1036739|NCT01856582|Primary Immunodeficiency Disease(s)
1036740|NCT01856582|Mixed Donor Chimerism
1036741|NCT01856582|bone marrow failure syndromes
1036742|NCT01856582|allogeneic hematopoietic stem cell transplant (HSCT)
1036743|NCT01856582|children
1036744|NCT01856556|safety
1036745|NCT01856556|tolerability
1036746|NCT01856556|pharmacokinetics
1036747|NCT01856543|Breast cancer
1036748|NCT01856543|Status post mastectomy
1036749|NCT01856543|plan to receive PMRT
1036750|NCT01856543|Topical
1036751|NCT01856543|steroid cream
1036752|NCT01856543|emollient skin care
1036753|NCT01856543|Eucerin
1036754|NCT01856543|Mometasone Furoate 0.1%
1036755|NCT01856517|pressor response
1036756|NCT01856517|chronotropic response
1036757|NCT01856504|Heart Disease
1036758|NCT01856504|Coronary Artery Disease
1036759|NCT01856504|Coronary Arteriosclerosis
1036760|NCT01856491|RELIANCE 4-FRONT
1036761|NCT01856491|Implantable Cardioverter Defibrillator (ICD)
1036762|NCT01856491|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
1036763|NCT01856465|Bariatric surgery
1036764|NCT01856465|NAFLD
1036765|NCT01856465|Steatohepatitis
1036766|NCT01856465|Simple Steatosis
1036767|NCT01856465|Intestinal Microbiota
1036768|NCT01856452|Sentinel lymph node
1036769|NCT01856452|multimodal
1036770|NCT01856452|breast cancer
1036771|NCT01856439|ProSavin
1036772|NCT01856439|Gene therapy
1036773|NCT01856426|Hepatitis C infected subjects
1036774|NCT01856413|Prevention
1036775|NCT01856413|Hepatitis B virus re-infection
1036776|NCT01856413|HBV-DNA negative
1036777|NCT01856413|Liver transplantation
1036778|NCT01856400|ventricular arrythmias
1036779|NCT01856400|SERCA2a
1036780|NCT01856400|Chronic Kidney Disease
1036781|NCT01856400|microvolt T wave alternans
1036782|NCT01856387|preeclampsia
1036783|NCT01856387|eclampsia
1036784|NCT01856387|prediction
1036785|NCT01856387|neutrophil-to Lymphocyte ratio
1036786|NCT01856361|Male infertility
1036787|NCT01856361|Low sperm count
1036788|NCT01856361|Poor sperm motility
1036789|NCT01856361|Poor Sperm shape and morphology
1036790|NCT01856335|Seizures
1036791|NCT01856335|Epilepsy
1036792|NCT01856322|Colorectal Cancer
1036793|NCT01856322|Liver Metastasis
1036794|NCT01856322|Sulindac
1036795|NCT01856309|Rheumatoid Arthritis
1036796|NCT01856309|Sirukumab
1036797|NCT01856309|CNTO 136
1036798|NCT01856309|CNTO136ARA3002
1036799|NCT01856309|SIRROUND-D
1036800|NCT01856309|CNTO136ARA3003
1036801|NCT01856309|SIRROUND-T
1036802|NCT01856309|SIRROUND-LTE
1036803|NCT01856270|Traumatic brain injury
1036804|NCT01856270|Post-traumatic headache
1036805|NCT01856270|Drug therapy
1036806|NCT01856257|Kidney Transplantation
1036807|NCT01856257|Transplantation
1036808|NCT01856257|NULOJIX
1036809|NCT01856257|belatacept
1036810|NCT01856257|chronic immunosuppression
1036811|NCT01856244|Parkinson's Disease
1036812|NCT01856244|treadmill training
1036813|NCT01856244|gait
1036814|NCT01856244|balance
1036815|NCT01856244|mobility
1036816|NCT01856231|COPD
1036817|NCT01856231|Physical activity
1036818|NCT01856218|Mucopolysaccharidosis type 7, MPS 7, Sly syndrome, enzyme replacement therapy, rare disease, lysosomal storage disease, metabolic disorder
1036819|NCT01856205|Japanese Encephalitis, Randomized Controlled Trial, intravenous immunoglobulin, safety, efficacy, Nepal
1036820|NCT01856179|Conversion of ALA and SDA
1036821|NCT01856179|Metabolism of n-3 fatty acids
1036822|NCT01856166|Nulliparous
1036823|NCT01856166|Singleton
1036824|NCT01856166|delivery
1036825|NCT01856166|pregnancy
1036826|NCT01856153|Bioavailability
1036827|NCT01856153|Strawberry polyphenols
1036828|NCT01856153|Time Influence
1036829|NCT01856140|adipose derived mesenchymal stem cell
1036830|NCT01856140|allogeneic stem cell
1036831|NCT01856127|Sexual Dysfunction
1036832|NCT01856127|Antidepressant
1036833|NCT01856127|Major Depressant
1036834|NCT01856127|SSRI
1036835|NCT01856127|SNRI
1036836|NCT01856127|Vilazodone
1036837|NCT01856127|Sertraline
1036838|NCT01856114|Advanced Cancers
1036839|NCT01856114|Cancer with evidence of active disease
1036840|NCT01856114|Exercise induced breakthrough dyspnea
1036841|NCT01856114|Shortness of breath
1036842|NCT01856114|Fentanyl Buccal Tablets
1036843|NCT01856114|FBT
1036844|NCT01856114|Placebo
1036845|NCT01856114|Walk tests
1036846|NCT01856114|Questionnaires
1036847|NCT01856114|Surveys
1036848|NCT01856101|TCC
1036849|NCT01856101|Failure of platinum based chemotherapy
1036850|NCT01856088|Coronary artery
1036851|NCT01856088|Drug eluting stent
1036852|NCT01856088|thrombosis
1036853|NCT01856075|Atrial Fibrillation
1036854|NCT01856075|Dronedarone
1036855|NCT01856075|Cohort
1036856|NCT01856075|Effectiveness
1036857|NCT01856062|ovulation induction
1036858|NCT01856062|dexamethasone
1036859|NCT01856049|HLHS
1036860|NCT01856049|Hypoplastic Left Heart Syndrome
1036861|NCT01856049|UCB (umbilical cord blood)
1036862|NCT01856049|Umbilical cord blood
1036863|NCT01856049|Cord blood
1036864|NCT01856049|Cardiac regeneration
1036865|NCT01856036|Ductal Histology
1036866|NCT01856036|Unifocal
1036867|NCT01856036|Estrogen Receptor Positive
1036868|NCT01856036|her2neu negative
1036869|NCT01856023|melanoma
1036870|NCT01856023|metastatic
1036871|NCT01856023|skin cancer
1036872|NCT01856023|Stage IV
1036873|NCT01856023|interleukin-2
1036874|NCT01856010|Dementia
1036875|NCT01856010|Aggression
1036876|NCT01856010|Agitation
1036877|NCT01855984|ADHD
1036878|NCT01855984|Children
1036879|NCT01855984|Tocotrienol
1036880|NCT01855958|Osteoarthritis
1036881|NCT01855958|Electro acupuncture
1036882|NCT01855958|Deep intramuscular stimulation
1036883|NCT01855958|Transcranial Magnetic Stimulation
1036884|NCT01855958|Pain pressure threshold
1036885|NCT01855958|Conditioned pain modulation
1036886|NCT01855958|Clinical trial
1036887|NCT01855945|Influenza
1036888|NCT01855919|Chronic Low Back Pain
1036889|NCT01855919|CLBP
1036890|NCT01855906|Total knee replacement
1036891|NCT01855906|Gap balanced
1036892|NCT01855906|Measured resection
1036893|NCT01855893|Neck pain
1036894|NCT01855880|psoriasis
1036895|NCT01855880|dermatology
1036896|NCT01855880|monoclonal antibody
1036897|NCT01855867|HIV
1036898|NCT01855867|PEP
1036899|NCT01855867|nPEP
1036900|NCT01855867|Prophylaxis
1036901|NCT01855867|Post Exposure Prophylaxis
1036902|NCT01855867|exposure to HIV
1036903|NCT01855867|HIV prevention
1036904|NCT01855841|ERCP
1036905|NCT01855841|virgin papilla
1036906|NCT01855841|risk of post-ERCP acute pancreatitis
1036907|NCT01855802|Greece
1036908|NCT01855802|Ophthalmology
1036909|NCT01855802|Glaucoma
1036910|NCT01855802|Generics
1036911|NCT01855802|Perception
1036912|NCT01855776|Physical Activity/Walking
1036913|NCT01855776|Full-time employees
1036914|NCT01855776|RCT
1036915|NCT01855776|Incentives
1036916|NCT01855776|Wireless pedometer
1036917|NCT01855763|gestational diabetes
1036918|NCT01855763|type 2 diabetes
1036919|NCT01855763|pregnancy
1036920|NCT01855763|metformin
1036921|NCT01855763|insulin
1036922|NCT01855750|Lymphoma
1036923|NCT01855750|B-cell lymphoma
1036924|NCT01855750|Non-germinal center B-cell subtype
1036925|NCT01855750|Diffuse large B-cell lymphoma
1036926|NCT01855750|Bruton's tyrosine kinase inhibitor
1036927|NCT01855750|PCI-32765
1036928|NCT01855750|JNJ-54179060
1036929|NCT01855750|Ibrutinib
1036930|NCT01855750|Rituximab
1036931|NCT01855750|Cyclophosphamide
1036932|NCT01855750|Doxorubicin
1036933|NCT01855750|Vincristine
1036934|NCT01855750|Prednisone
1036935|NCT01855737|gene guided
1036936|NCT01855737|warfarin dose
1036937|NCT01855737|Chinese
1036938|NCT01855711|Alosetron hydrochloride
1036939|NCT01855711|Global Improvement Scale(GIS)
1036940|NCT01855711|Diarrhea-predominant IBS
1036941|NCT01855698|hematologic neoplasm, profhylaxis, arterial and venous thromboembolism
1036942|NCT01855685|XCGD, lentivirus, cellular therapy
1036943|NCT01855672|Migraine, occipital nerve, stimulation
1036944|NCT01855659|Lung diseases,
1036945|NCT01855659|Obstructive,
1036946|NCT01855659|Peak Inspiratory Flow
1036947|NCT01855659|[C08.381.495.389]
1036948|NCT01855620|Contraception
1036949|NCT01855620|Implant
1036950|NCT01855620|Obesity
1036951|NCT01855607|chemotherapy induced neuropathy
1036952|NCT01855542|metabolic acidosis, plasmalyte solution, 0.9% normal saline
1036953|NCT01855529|ropivacaine, pain, mastectomy
1036954|NCT01855516|Antithrombotic prophylaxis
1036955|NCT01855503|Metastatic
1036956|NCT01855503|Breast Cancer
1036957|NCT01855503|Metastatic Breast Cancer
1036958|NCT01855503|Breast
1036959|NCT01855503|Biopsy
1036960|NCT01855503|Molecular
1036961|NCT01855503|Genetic
1036962|NCT01855464|pneumothorax
1036963|NCT01855464|primary pneumothorax
1036964|NCT01855464|lung collapse
1036965|NCT01855451|Human Papilloma Virus
1036966|NCT01855451|HPV
1036967|NCT01855451|Oropharyngeal
1036968|NCT01855451|Squamous Cell
1036969|NCT01855451|Carcinoma
1036970|NCT01855438|Live donor kidney transplantation
1036971|NCT01855438|Living donation
1036972|NCT01855438|Patient education
1036973|NCT01855438|Kidney transplant candidates
1036977|NCT01855399|Peer Support
1036978|NCT01855399|Self Management
1036979|NCT01855399|Health Disparities
1036980|NCT01855373|Blood Sugar
1036981|NCT01855373|Endothelial Function
1036982|NCT01855373|Blood Vessel Health
1036983|NCT01855360|amyloid
1036984|NCT01855360|amyloidosis
1036985|NCT01855360|cardiac amyloidosis
1036986|NCT01855360|senile amyloidosis
1036987|NCT01855360|familial amyloidosis
1036988|NCT01855360|transthyretin amyloidosis
1036989|NCT01855347|Prematurity
1036990|NCT01855347|Hypoxia
1036991|NCT01855347|Necrotizing Enterocolitis
1036992|NCT01855347|Near Infrared Spectroscopy
1036993|NCT01855347|Abdominal tissue oxygenation
1036994|NCT01855347|NICU
1036995|NCT01855334|Dialysis
1036996|NCT01855334|ESRD
1036997|NCT01855334|Cardiovascular disease
1036998|NCT01855334|spironolactone
1036999|NCT01855334|L-arginine
1037000|NCT01855334|myocardial perfusion
1037001|NCT01855334|coronary flow reserve
1037002|NCT01855334|diastolic function
1037003|NCT01855321|uncontrolled diabetes
1037004|NCT01855321|vitamin D deficiency
1037005|NCT01855295|Dialysis
1037006|NCT01855295|End Stage Renal Disease
1037007|NCT01855295|Protein supplementation
1037008|NCT01855295|Inflammation
1037009|NCT01855295|Quality of Life
1037010|NCT01855282|Diabetes Type II,
1037011|NCT01855282|Overweight,
1037012|NCT01855282|Obesity,
1037013|NCT01855282|Behavioral Intervention,
1037014|NCT01855282|Latino, farm worker
1037015|NCT01855282|randomized controlled intervention
1037016|NCT01855269|probiotic
1037017|NCT01855269|infantile colic
1037018|NCT01855256|hyperhidrosis
1037019|NCT01855256|oxybutynin
1037020|NCT01855243|Type 2 D M
1037021|NCT01855243|sliding scale insulin
1037022|NCT01855243|70/30 insulin
1037023|NCT01855243|basals insulin
1037024|NCT01855243|supplemental insulin
1037025|NCT01855217|morbid
1037026|NCT01855217|obesity
1037027|NCT01855217|sugammadex
1037028|NCT01855217|pharmacodynamics
1037029|NCT01855204|Computed Tomography, Spiral
1037030|NCT01855204|Urography
1037031|NCT01855204|Radiation dosage
1037032|NCT01855204|Contrast media
1037033|NCT01855178|nocturnal
1037034|NCT01855178|epilepsy
1037035|NCT01855165|chronic heart failure
1037036|NCT01855165|drug-drug interactions
1037037|NCT01855165|pharmacist's intervention
1037038|NCT01855152|Dementia
1037039|NCT01855152|Care Homes
1037040|NCT01855152|Quality of life
1037041|NCT01855152|Antipsychotic medication
1037042|NCT01855152|Behavioural symptoms
1037043|NCT01855152|Cost effectiveness
1037044|NCT01855152|Implementation
1037045|NCT01855152|Person centred care
1037046|NCT01855152|Social interaction
1037047|NCT01855139|Non-valvular atrial fibrillation
1037048|NCT01855139|Stroke
1037049|NCT01855139|Systemic embolism
1037050|NCT01855139|Oral anticoagulation
1037051|NCT01855139|Real-life setting
1037052|NCT01855139|Preventive measure
1037053|NCT01855126|light
1037054|NCT01855126|circadian rhythms
1037055|NCT01855126|dim light melatonin onset
1037056|NCT01855126|sleep
1037057|NCT01855113|PAIN
1037058|NCT01855113|ORTHODONTIC TREATMENT
1037059|NCT01855113|INVISALIGN
1037060|NCT01855100|Treatment of acute deep vein thrombosis
1037061|NCT01855100|Prevention of recurrence
1037062|NCT01855100|Oral anticoagulation
1037063|NCT01855100|Real-life setting
1037064|NCT01855074|Schizophrenia
1037065|NCT01855074|Schizophreniform Disorder
1037066|NCT01855074|Schizoaffective Disorder
1037067|NCT01855074|Risperidone
1037068|NCT01855074|Risperdal consta
1037069|NCT01855061|Feasibility studies
1037070|NCT01855061|Sequence analysis, DNA
1037071|NCT01855061|Biological markers
1037072|NCT01855061|Solid tumors
1037073|NCT01855061|Neoplasm metastasis
1037074|NCT01855061|Irinotecan
1037075|NCT01855061|Pharmacokinetics SN-38
1037076|NCT01855061|Carboxylesterase activity within metastasis
1037077|NCT01855048|N-Rephasin® SAL200
1037078|NCT01855048|endolysin
1037079|NCT01855048|Placebo
1037080|NCT01855035|ischemic stroke
1037081|NCT01855035|ECG monitoring
1037082|NCT01855035|atrial fibrillation (/flutter)
1037083|NCT01855022|Motivational interviewing
1037084|NCT01855022|Interactive voice response
1037085|NCT01855022|Hospital readmission
1037086|NCT01855009|Quality of Life
1037087|NCT01855009|Body Weight and Measures
1037088|NCT01855009|Malnutrition
1037089|NCT01855009|Adolescent Nutrition Sciences
1037090|NCT01855009|Sleep Initiation and Maintenance Disorder
1037091|NCT01855009|Motor Activity
1037092|NCT01855009|Drinking
1037093|NCT01854983|fluorescence colposcopy
1037094|NCT01854983|cervical cancer
1037095|NCT01854957|Multiple sclerosis
1037096|NCT01854957|Mesenchymal stem cells
1037097|NCT01854931|Tai Ji Quan
1037098|NCT01854931|fall prevention
1037099|NCT01854931|community dissemination
1037100|NCT01854918|High cholesterol
1037101|NCT01854918|Raised cholesterol
1037102|NCT01854918|Cholesterol
1037103|NCT01854918|Elevated Cholesterol
1037104|NCT01854892|low back pain
1037105|NCT01854892|manipulation
1037106|NCT01854892|laser therapy
1037107|NCT01854892|osteopathic
1037108|NCT01854892|chiropractic
1037109|NCT01854892|mobilization
1037110|NCT01854892|muscle energy
1037111|NCT01854892|physical therapy
1037112|NCT01854892|muscle
1037113|NCT01854892|spine
1037114|NCT01854892|adjustment
1037115|NCT01854892|rehabilitation
1037116|NCT01854866|Pleural Effusion
1037117|NCT01854866|ascites
1037118|NCT01854866|Malignant
1037119|NCT01854853|unsafe sex
1037120|NCT01854853|safer sex
1037121|NCT01854853|HIV
1037122|NCT01854853|STI
1037123|NCT01854853|Pregnancy
1037124|NCT01854840|hyaline membrane disease
1037125|NCT01854840|placenta
1037126|NCT01854840|betamethasone
1037127|NCT01854827|Biliary atresia
1037128|NCT01854827|Hepatic portoenterostomy
1037129|NCT01854827|Intravenous immunoglobulin
1037130|NCT01854801|IEI-EMF
1037131|NCT01854801|WI-FI
1037132|NCT01854801|DECT
1037133|NCT01854801|Electro-sensitivity
1037134|NCT01854801|Radiofrequency
1037135|NCT01854801|EHS
1037136|NCT01854801|Idiopathic
1037137|NCT01854801|Environmental
1037138|NCT01854801|Intolerance fields
1037139|NCT01854801|Mobile phone
1037140|NCT01854788|Airway clearance techniques
1037141|NCT01854788|Mucus clearance
1037142|NCT01854788|Chest physiotherapy
1037143|NCT01854788|Autogenic drainage
1037144|NCT01854788|Slow expiration with glottis opened in lateral posture(ELTGOL)
1037145|NCT01854788|Temporary-positive expiratory pressure (T-PEP)
1037146|NCT01854788|Non cystic fibrosis bronchiectasis
1037147|NCT01854775|Adolescents
1037148|NCT01854775|HIV-1
1037149|NCT01854775|HIV
1037150|NCT01854775|Treatment-naive
1037151|NCT01854762|HIV
1037152|NCT01854762|Treatment
1037153|NCT01854762|Pregnancy
1037154|NCT01854749|ESCC
1037160|NCT01854723|Diabetes
1037161|NCT01854723|Insulin glargine
1037162|NCT01854723|NPH insulin
1037163|NCT01854710|ADASUVE
1037164|NCT01854710|inhaled loxapine
1037165|NCT01854710|thorough QT/QTc study
1037166|NCT01854697|Chronic Hepatitis C
1037167|NCT01854697|Interferon Free
1037168|NCT01854697|Hepatitis C Treatment Naive
1037169|NCT01854697|Hepatitis C Virus
1037170|NCT01854697|Hepatitis C Genotype 1
1037171|NCT01854671|postpartum contraception
1037172|NCT01854671|contraceptive counseling
1037173|NCT01854632|influenza vaccine
1037174|NCT01854632|trivalent live-attenuated influenza vaccine
1037175|NCT01854632|efficacy
1037176|NCT01854632|Africa
1037177|NCT01854632|Senegal
1037178|NCT01854619|chronic rhinosinusitis
1037179|NCT01854619|sinusitis
1037180|NCT01854619|photodisinfection
1037181|NCT01854619|photodynamic therapy
1037182|NCT01854619|antimicrobial photodynamic therapy
1037183|NCT01854619|aPDT
1037184|NCT01854619|PDT
1037185|NCT01854619|paranasal sinus diseases
1037186|NCT01854619|respiratory tract infections
1037187|NCT01854619|respiratory tract diseases
1037188|NCT01854606|Diffuse Large B-Cell Lymphoma, DBCL, AEB071, Everolimus
1037189|NCT01854580|Comparative effectiveness research
1037190|NCT01854580|health economic evaluation
1037191|NCT01854567|Cord Blood
1037192|NCT01854567|Stem Cells
1037193|NCT01854567|MPC
1037194|NCT01854567|Mesoblast
1037195|NCT01854567|Expanded
1037196|NCT01854567|AML
1037197|NCT01854567|ALL
1037198|NCT01854567|NHL
1037199|NCT01854567|Leukemia
1037200|NCT01854567|Lymphoma
1037201|NCT01854554|Brain cancer
1037202|NCT01854554|Glioblastoma
1037203|NCT01854554|Glioblastoma Multiforme
1037204|NCT01854554|GBM
1037205|NCT01854554|Intensity Modulated Proton Radiotherapy
1037206|NCT01854554|IMPT
1037207|NCT01854554|Intensity Modulated Radiotherapy
1037208|NCT01854554|IMRT
1037209|NCT01854554|Radiotherapy
1037210|NCT01854554|XRT
1037211|NCT01854554|Cognitive tests
1037212|NCT01854554|Thinking skills tests
1037213|NCT01854554|Questionnaires
1037214|NCT01854554|Surveys
1037215|NCT01854554|Quality of life
1037216|NCT01854554|QOL
1037217|NCT01854541|Cancer
1037218|NCT01854541|Radiotherapy
1037219|NCT01854528|Partial responder
1037220|NCT01854528|Interferon free
1037221|NCT01854528|Treatment-experienced
1037222|NCT01854528|Relapser
1037223|NCT01854528|Hepatitis C Virus
1037224|NCT01854528|Null responder
1037225|NCT01854528|Hepatitis C Genotype 1
1037226|NCT01854528|paritaprevir
1037227|NCT01854528|ombitasvir
1037228|NCT01854528|dasabuvir
1037229|NCT01854528|ribavirin
1037230|NCT01854528|Viekira PAK
1037231|NCT01854528|Chronic hepatitis C
1037232|NCT01854502|Young children
1037233|NCT01854502|counseling
1037234|NCT01854502|fluoride
1037235|NCT01854502|xylitol
1037236|NCT01854489|Buprenorphine
1037237|NCT01854489|Rifampicin
1037238|NCT01854489|Interactions
1037239|NCT01854489|Pharmakokinetics
1037240|NCT01854489|Pharmakodynamics
1037241|NCT01854476|Hemodialysis
1037242|NCT01854476|Bleeding
1037243|NCT01854476|Hemostatic dressing
1037244|NCT01854476|Tranexamic Acid
1037245|NCT01854463|DIABETES MELLITUS
1037246|NCT01854463|VITAMIN D
1037247|NCT01854463|ARTERIAL STIFFNESS
1037248|NCT01854463|FATTY LIVER
1037249|NCT01854463|BONE TURNOVER
1037250|NCT01854450|Occipitoposterior position
1037251|NCT01854450|Maternal posturing
1037252|NCT01854450|Labor
1037253|NCT01854437|mg oxide
1037254|NCT01854437|hyperphosphatemia
1037255|NCT01854437|plasma phosphor level
1037256|NCT01854424|Fibrocyte
1037257|NCT01854424|Acute Respiratory Distress Syndrome
1037258|NCT01854424|Serum Amyloid P
1037259|NCT01854424|Fibrosis
1037260|NCT01854424|Mortality
1037261|NCT01854411|Analgesics
1037262|NCT01854411|Ibuprofene
1037263|NCT01854411|Ketoprofene
1037264|NCT01854411|Breastmilk
1037265|NCT01854411|Relative Infant Dose
1037266|NCT01854411|Theoric Infant Dose
1037267|NCT01854398|Obstructive sleep apnea
1037268|NCT01854398|Continuous positive airway pressure
1037269|NCT01854398|diastolic function
1037270|NCT01854385|Post-traumatic headache
1037271|NCT01854385|Traumatic brain injury
1037272|NCT01854385|Sumatriptan
1037273|NCT01854359|Multiple Sclerosis
1037274|NCT01854359|Extension Trial
1037275|NCT01854346|Autism spectrum disorder
1037276|NCT01854346|Social skills training
1037277|NCT01854346|Group training
1037278|NCT01854346|Comorbidity
1037279|NCT01854346|Intervention
1037280|NCT01854346|Evidence-based
1037281|NCT01854333|Diagnostics
1037282|NCT01854333|ADOS
1037283|NCT01854333|ADI-R
1037284|NCT01854333|Psychometrics
1037285|NCT01854333|Autism spectrum disorders
1037286|NCT01854333|Autism
1037287|NCT01854307|Difference of
1037288|NCT01854307|measurements
1037289|NCT01854307|before and after
1037290|NCT01854294|ALS
1037291|NCT01854294|motorneuron disease
1037292|NCT01854294|Central Nervous System (CNS) disease
1037293|NCT01854294|neurodegeneration
1037294|NCT01854294|neuroprotective
1037295|NCT01854294|mechanisms of action
1037296|NCT01854294|pathways
1037297|NCT01854294|biomarkers
1037298|NCT01854294|Cerebral Spinal Fluid (CSF)
1037299|NCT01854294|blood biomarkers
1037300|NCT01854294|multi-factorial
1037301|NCT01854294|multisystem
1037302|NCT01854294|single target
1037303|NCT01854294|pathogenic mechanisms
1037304|NCT01854294|Protein Bands Selection by Function
1037305|NCT01854294|in silico analysis
1037306|NCT01854294|active site
1037307|NCT01854294|protein
1037308|NCT01854294|peptide
1037309|NCT01854294|embryonic stage
1037310|NCT01854294|endogenous
1037311|NCT01854294|master regulators
1037312|NCT01854294|fetal development
1037313|NCT01854294|embryonic development
1037314|NCT01854294|common pathways
1037315|NCT01854294|Blood Brain Barrier (BBB)
1037316|NCT01854294|anti-inflammatory
1037317|NCT01854294|anti-apoptotic
1037318|NCT01854294|anti-oxidative
1037319|NCT01854294|regenerative
1037320|NCT01854294|distress signals
1037321|NCT01854294|neurotrophin
1037322|NCT01854294|Motoneuronotrophic factor (MNTF)
1037323|NCT01854294|ALS model
1037324|NCT01854294|life span
1037325|NCT01854294|disease onset
1037326|NCT01854294|grip strength
1037327|NCT01854294|protein expression
1037328|NCT01854294|DNA microarray
1037329|NCT01854294|differential expression
1037330|NCT01854294|Phase 1 clinical trial
1037331|NCT01854294|rare disease
1037332|NCT01854294|common underlying pathogenic mechanisms
1037333|NCT01854294|neurological deficits
1037334|NCT01854294|gene mutation
1037335|NCT01854294|misfolded proteins
1037336|NCT01854294|inadvertent errors
1037337|NCT01854294|modulation of genes
1037338|NCT01854294|master regulator peptide drug
1037339|NCT01854294|ALS related genes
1037340|NCT01854294|mitochondria dysfunction
1037341|NCT01854294|excitotoxicity
1037342|NCT01854294|axonal transport
1037343|NCT01854294|oxidative stress
1037344|NCT01854294|protein aggregation
1037345|NCT01854294|pathogenesis
1037346|NCT01854294|target biomarkers
1037347|NCT01854294|efficacy biomarkers
1037348|NCT01854281|Patent foramen ovale
1037349|NCT01854281|Catheter-based closure
1037350|NCT01854281|Nitrogen bubbles
1037351|NCT01854281|Decompression sickness
1037352|NCT01854268|cough
1037353|NCT01854255|Gastric
1037354|NCT01854255|Cancer
1037355|NCT01854255|Chemotherapy
1037356|NCT01854255|Intraperitoneal
1037357|NCT01854229|Morphine
1037358|NCT01854229|Implantable Infusion Pumps
1037359|NCT01854229|Intrathecal Pump
1037360|NCT01854216|Rotigotine
1037361|NCT01854216|Neupro
1037362|NCT01854216|Japanese
1037363|NCT01854216|Caucasian
1037364|NCT01854216|Male
1037365|NCT01854216|Female
1037366|NCT01854216|Single dose
1037367|NCT01854216|Pharmacokinetics
1037368|NCT01854203|Cisplatin
1037369|NCT01854203|neoadjuvant chemotherapy
1037370|NCT01854203|intensity-modulated radiation therapy
1037371|NCT01854203|concurrent chemoradiotherapy
1037372|NCT01854190|Obstructive sleep apnea
1037373|NCT01854190|Resistent hypertension
1037374|NCT01854190|Endothelial function
1037375|NCT01854190|Blood pressure
1037376|NCT01854177|breathlessness; substance P; beta-endorphin
1037377|NCT01854164|HGE, impaired fasting glucose, clinical trial
1037378|NCT01854151|Medication errors
1037379|NCT01854151|Medication dosing
1037380|NCT01854138|primary knee arthroplasty
1037381|NCT01854138|primary hip arthroplasty
1037382|NCT01854138|negative pressure wound therapy
1037383|NCT01854125|immun function
1037384|NCT01854125|liver function
1037385|NCT01854125|ascites
1037386|NCT01854125|quality of life
1037387|NCT01854125|Child-Pugh score
1037388|NCT01854112|Helical tomotherapy
1037389|NCT01854112|total skin electron therapy
1037390|NCT01854112|TSEB
1037391|NCT01854112|irradiation 5.
1037392|NCT01854099|Brain Tumor
1037393|NCT01854086|osteoporosis
1037394|NCT01854086|postmenopausal
1037395|NCT01854086|patient compliance
1037396|NCT01854086|compliance
1037397|NCT01854086|diphosphonates
1037398|NCT01854086|bisphosphonates
1037399|NCT01854060|Irritable bowel syndrome
1037400|NCT01854060|Epidimiology
1037401|NCT01854060|Deterioration in the severity of irritable bowel syndrome
1037402|NCT01854034|Advanced disease
1037403|NCT01854034|EGFR mutation
1037404|NCT01854021|Anesthesia
1037405|NCT01854021|general
1037406|NCT01854021|Immunity
1037407|NCT01854021|Tongue neoplasms
1037408|NCT01854021|immune
1037409|NCT01854021|general anesthesia
1037410|NCT01854008|Exercise, Physical activity, Rehabilitation, COPD.
1037411|NCT01853995|Fixed Lingual Mandibular Growth Modificator (FLMGM)
1037412|NCT01853995|Class II division 1 malocclusion
1037413|NCT01853995|Sagittal Occlusal Correction
1037414|NCT01853995|Skeletal changes
1037415|NCT01853995|Dental changes
1037416|NCT01853956|Mexico
1037417|NCT01853956|Bioequivalence
1037418|NCT01853956|Alprazolam
1037419|NCT01853956|Pharmacokinetics
1037420|NCT01853943|Transradial approach
1037421|NCT01853943|radial occlusion
1037422|NCT01853943|hand grip
1037423|NCT01853943|coronary angiography
1037424|NCT01853930|reading rehabilitation
1037425|NCT01853930|macular degeneration
1037426|NCT01853930|eccentric viewing
1037427|NCT01853904|Bronchoscopy
1037428|NCT01853904|BAL
1037429|NCT01853904|Suction
1037430|NCT01853878|Non-Small Cell Lung Cancer
1037431|NCT01853878|Immunotherapy
1037432|NCT01853878|Antigen-Specific
1037433|NCT01853865|Endometrial cancer
1037434|NCT01853865|Follow-up examination
1037435|NCT01853813|colorectal cancer
1037436|NCT01853813|advanced disease
1037437|NCT01853813|LDH
1037438|NCT01853800|Relative bioavailability
1037439|NCT01853800|Rivaroxaban
1037440|NCT01853787|COPD
1037441|NCT01853787|bronchial inflammation
1037442|NCT01853787|NO concentration
1037443|NCT01853787|small airways
1037444|NCT01853787|LABA
1037445|NCT01853787|Small Airways Stretching
1037446|NCT01853787|Stretch and strain of small airways in COPD
1037447|NCT01853787|Acute LABA effect on NO production
1037448|NCT01853787|Pulmonary desufflation
1037449|NCT01853774|Tailored navigation
1037450|NCT01853774|Tailored messages
1037451|NCT01853761|abdominal fat
1037452|NCT01853761|metabolic syndrome
1037453|NCT01853761|microcurrent
1037454|NCT01853761|aerobic exercise
1037455|NCT01853722|DCN01
1037456|NCT01853722|Ocular Surgical Preparation
1037457|NCT01853722|Prophylaxis against infection
1037458|NCT01853722|Pre-operative prep
1037459|NCT01853683|General Surgery
1037460|NCT01853644|Cancer
1037461|NCT01853644|Recurrent
1037462|NCT01853644|Ovary
1037463|NCT01853644|Fallopian Tube
1037464|NCT01853644|Primary Peritioneal
1037465|NCT01853644|Phase II
1037466|NCT01853644|Platinum Resistant
1037467|NCT01853631|chronic Lymphocytic Leukemia
1037468|NCT01853631|refractory
1037469|NCT01853631|recurrent
1037470|NCT01853631|aggressive B-cell Lymphoma
1037471|NCT01853631|CD19
1037472|NCT01853631|Non-Hodgkin Lymphoma
1037473|NCT01853631|CD28
1037474|NCT01853631|CD137
1037475|NCT01853631|4-1BB
1037476|NCT01853631|acute lymphocytic leukemia
1037481|NCT01853592|Gadolinium Contrast
1037482|NCT01853592|Cardiac MRI
1037483|NCT01853592|MRA
1037484|NCT01853592|MRI
1037485|NCT01853592|MRI Safety
1037486|NCT01853579|Randomized controlled trial
1037487|NCT01853579|Subclinical hypothyroidism
1037488|NCT01853579|Levothyroxine
1037489|NCT01853579|Depression
1037490|NCT01853566|Muscle Strength
1037491|NCT01853566|Growth Hormone
1037492|NCT01853566|men
1037493|NCT01853540|Ciliary Beat Frequency (CBF)
1037494|NCT01853540|Nasal Nitric Oxide (nNO)
1037495|NCT01853540|Mucociliary Dysfunction
1037496|NCT01853527|CT coronary angiography
1037497|NCT01853527|Contrast stress echocardiography
1037498|NCT01853527|Arterial stiffness
1037499|NCT01853527|Quality of life
1037500|NCT01853527|Biochemical and genetic markers
1037501|NCT01853514|Low income
1037502|NCT01853514|Fruit and vegetables
1037503|NCT01853514|Conventional produce
1037504|NCT01853514|Organic produce
1037505|NCT01853514|Pesticide
1037506|NCT01853514|Purchasing behavior
1037507|NCT01853514|Message framing
1037508|NCT01853501|POF
1037509|NCT01853488|Osteoporosis
1037510|NCT01853488|BMD
1037511|NCT01853488|SCI
1037512|NCT01853488|DXA
1037513|NCT01853488|pQCT
1037514|NCT01853475|pharmacokinetics
1037515|NCT01853475|safety
1037516|NCT01853475|tolerability
1037517|NCT01853475|bioavailability
1037518|NCT01853449|Fentanyl Citrate
1037519|NCT01853449|Opioids
1037520|NCT01853449|Exercise
1037521|NCT01853436|Breast Cancer
1037522|NCT01853436|Reconstructive Tissue Matrix
1037523|NCT01853436|Acellular Dermal Matrices (ADM)
1037524|NCT01853423|Rapamune
1037525|NCT01853423|Topical
1037526|NCT01853423|Pediatric
1037527|NCT01853423|Safety
1037528|NCT01853423|Efficiency
1037529|NCT01853423|Angiofibroma
1037530|NCT01853423|Skin Cream
1037531|NCT01853410|coronary artery disease
1037532|NCT01853410|coronary flow reserve
1037533|NCT01853410|endothelial function
1037534|NCT01853384|Venous leg ulcer
1037535|NCT01853384|ulcer
1037536|NCT01853384|venous stasis
1037537|NCT01853384|compression
1037538|NCT01853384|venous
1037539|NCT01853384|venous stasis ulcer
1037540|NCT01853384|vlu
1037541|NCT01853384|wound
1037542|NCT01853384|varicose veins
1037543|NCT01853384|venous insufficiency
1037544|NCT01853384|dvt
1037545|NCT01853384|deep vein thrombosis
1037546|NCT01853358|hematological malignancy
1037547|NCT01853358|stem cell transplantation
1037548|NCT01853345|Refractory
1037549|NCT01853345|Recurrent
1037550|NCT01853345|High Risk
1037551|NCT01853332|Cardiovascular Disease
1037552|NCT01853332|Diabetes
1037553|NCT01853332|Adjustment
1037554|NCT01853332|Adversity
1037555|NCT01853332|Psychology
1037556|NCT01853332|Midlife
1037557|NCT01853332|Functioning
1037558|NCT01853332|Socioeconomic
1037559|NCT01853332|Psychosocial outcomes
1037560|NCT01853319|Regorafenib
1037561|NCT01853319|Metastatic colorectal cancer
1037562|NCT01853306|High grade serous ovarian cancer
1037563|NCT01853306|BRCA mutated breast cancer
1037564|NCT01853306|BRCA mutated
1037565|NCT01853306|Oncology
1037566|NCT01853293|Alcohol Abuse
1037567|NCT01853293|Alcohol Dependence
1037568|NCT01853293|Heavy drinking days
1037569|NCT01853293|Kudzu
1037570|NCT01853280|ADHD
1037571|NCT01853280|Attention Deficit Hyperactivity Disorder
1037572|NCT01853280|Deplin
1037573|NCT01853280|L-methylfolate
1037574|NCT01853280|Natural Treatments
1037575|NCT01853280|Medical Food
1037576|NCT01853267|Colorectal
1037577|NCT01853267|Surgery
1037578|NCT01853267|Perianal
1037579|NCT01853267|Abscess
1037580|NCT01853241|small intestine
1037581|NCT01853241|endoscopy, gastrointestinal
1037582|NCT01853228|Acute myeloid leukemia
1037583|NCT01853228|Relapsed or refractory acute myeloid leukemia
1037584|NCT01853228|Children
1037585|NCT01853228|Decitabine
1037586|NCT01853228|DACOGEN
1037587|NCT01853228|Cytarabine
1037588|NCT01853215|sternal intraosseous infusion study
1037589|NCT01853202|Cancer
1037590|NCT01853202|Chemotherapy
1037591|NCT01853202|Thrombosis
1037592|NCT01853202|Prevention
1037593|NCT01853202|Exercise
1037594|NCT01853189|pediatrics
1037595|NCT01853189|asthma
1037596|NCT01853189|osteopathic manipulative treatment
1037597|NCT01853176|Pain, Postoperative
1037598|NCT01853176|Analgesia
1037599|NCT01853176|Anesthesia, local
1037600|NCT01853176|Abdominoplasty
1037601|NCT01853163|Gadolinium
1037602|NCT01853163|Contrast Agent
1037603|NCT01853163|Long-term retention
1037604|NCT01853137|Class II division 1 malocclusion
1037605|NCT01853137|Dentofacial orthopedics
1037606|NCT01853137|Fixed Lingual Mandibular Growth Modificator (FLMGM)
1037608|NCT01853098|loving-kindness meditation
1037609|NCT01853098|mindfulness meditation
1037610|NCT01853098|compassion
1037611|NCT01853072|Diabetes Type I
1037612|NCT01853072|Diabetes Type II
1037613|NCT01853072|non-proliferative diabetic retinopathy
1037614|NCT01853072|macular edema
1037615|NCT01853072|Cataract
1037616|NCT01853059|Anal cancer
1037617|NCT01853059|Squamous cell cancer
1037618|NCT01853059|Radiotherapy
1037619|NCT01853059|Chemoradiotherapy
1037620|NCT01853059|Conformational radiotherapy
1037621|NCT01853059|Intensity modulated radiation therapy
1037622|NCT01853059|IMRT
1037623|NCT01853046|Regorafenib
1037624|NCT01853046|pharmacokinetics
1037625|NCT01853046|safety
1037626|NCT01853046|severe renal impairment
1037627|NCT01853046|Solid tumors
1037628|NCT01853033|Tolerability
1037629|NCT01853033|Immunogenicity
1037630|NCT01853033|Safety
1037631|NCT01853033|Rheumatoid Arthritis
1037632|NCT01853033|Pharmacokinetics
1037633|NCT01853020|Cannabinoids
1037634|NCT01853020|Eyeblink Conditioning
1037635|NCT01853020|EBC
1037636|NCT01853007|End stage renal disease
1037637|NCT01853007|Kidney transplantation
1037638|NCT01853007|Transplant options (living and deceased donor)
1037639|NCT01853007|Patient education
1037640|NCT01853007|Communication skills training
1037641|NCT01852981|Physical activity promotion
1037642|NCT01852981|Intervention
1037643|NCT01852981|Public Health
1037644|NCT01852968|hypoglycemia
1037645|NCT01852968|hypoglycemia unawareness
1037646|NCT01852968|type 1 diabetes, hippocampus
1037647|NCT01852968|glucose transport
1037648|NCT01852968|cognitive dysfunction
1037649|NCT01852955|Outpatient
1037650|NCT01852955|Surgery
1037651|NCT01852955|Breast
1037652|NCT01852955|Pain
1037653|NCT01852942|Infection
1037654|NCT01852942|HIV 1
1037655|NCT01852942|HIV
1037656|NCT01852942|Losartan
1037657|NCT01852942|Fibrosis
1037658|NCT01852942|Immune Activation
1037659|NCT01852942|Immune Reconstitution
1037660|NCT01852929|Memory
1037661|NCT01852916|RDS
1037662|NCT01852903|vitamin C
1037663|NCT01852903|calcium ascorbate
1037664|NCT01852903|ascorbic acid
1037665|NCT01852903|bioavailability
1037666|NCT01852890|Ascorbate
1037667|NCT01852890|Vitamin C
1037668|NCT01852890|Radiation
1037669|NCT01852890|Gemcitabine
1037670|NCT01852890|Ascorbic Acid
1037671|NCT01852877|HIV Diagnosis
1037672|NCT01852877|Case Management
1037673|NCT01852877|Telemedicine
1037674|NCT01852877|Patient Compliance
1037675|NCT01852877|Prisoners
1037676|NCT01852864|Prostate cancer
1037677|NCT01852864|testosterone
1037678|NCT01852864|castration
1037679|NCT01852864|degarelix
1037680|NCT01852864|proliferation
1037681|NCT01852838|lung cancer
1037682|NCT01852838|volatile organic compounds
1037683|NCT01852838|Warburg effect
1037684|NCT01852838|early detection
1037685|NCT01852799|Multiple myeloma
1037686|NCT01852799|PAD
1037687|NCT01852799|ASCT
1037688|NCT01852799|Bone metabolites
1037689|NCT01852799|Bone marker
1037690|NCT01852786|Contraception
1037691|NCT01852786|Hyperandrogenism
1037692|NCT01852786|Female sexual function
1037693|NCT01852773|blunt
1037694|NCT01852773|injury
1037695|NCT01852773|aorta
1037696|NCT01852773|endovascular
1037697|NCT01852760|endoscopic ultrasound
1037698|NCT01852760|ulcerative colitis
1037699|NCT01852760|inflammatory bowel disease
1037700|NCT01852747|Spinal Deformity
1037701|NCT01852747|Multilevel
1037702|NCT01852747|Posterior
1037703|NCT01852747|Lumbar
1037704|NCT01852747|Fusion
1037705|NCT01852747|Levoscoliosis
1037706|NCT01852747|Dextroscoliosis
1037707|NCT01852747|Graft
1037708|NCT01852721|Cardiovascular diseases
1037709|NCT01852721|Nutritional intervention program
1037710|NCT01852721|Self-Determination Theory
1037711|NCT01852721|Motivational interviewing
1037712|NCT01852721|Gender differences
1037713|NCT01852721|Women
1037714|NCT01852721|Men
1037715|NCT01852721|Motivation
1037716|NCT01852721|Dietary intakes
1037717|NCT01852721|Mediterranean diet
1037718|NCT01852721|Eating behaviors
1037719|NCT01852721|Lipid profile
1037720|NCT01852708|22q
1037721|NCT01852708|1p36
1037722|NCT01852708|Angelman
1037723|NCT01852708|Cri-du-chat
1037724|NCT01852708|Prader-Willi
1037725|NCT01852708|DiGeorge
1037726|NCT01852708|Turner syndrome
1037727|NCT01852708|Patau syndrome
1037728|NCT01852708|Edwards syndrome
1037729|NCT01852708|Down syndrome
1037730|NCT01852695|Family integrated Care
1037731|NCT01852695|Family centered care
1037732|NCT01852695|NICU family centered care
1037733|NCT01852695|NICU parent program
1037734|NCT01852682|Peritoneal Dialysis
1037735|NCT01852682|Hyperphosphatemia
1037736|NCT01852656|Influenza, Human
1037737|NCT01852656|Immunization
1037738|NCT01852643|Rhinoplasty
1037739|NCT01852643|Spreader graft technique
1037740|NCT01852643|Lateral crural overlay technique
1037741|NCT01852643|Rhinomanometry
1037742|NCT01852617|Smoking Cessation
1037743|NCT01852617|Pregnancy
1037744|NCT01852617|Implementation
1037745|NCT01852617|Knowledge translation
1037746|NCT01852604|HCV
1037747|NCT01852604|Hepatitis C
1037748|NCT01852604|chronic hepatitis C
1037749|NCT01852604|antiviral
1037750|NCT01852591|autologous transplant
1037751|NCT01852591|multiple myeloma
1037752|NCT01852578|Metastatic NSCLC
1037753|NCT01852578|2nd Line
1037754|NCT01852578|Docetaxel-based treatment
1037755|NCT01852578|Progressed
1037756|NCT01852578|Refractory
1037757|NCT01852565|CYP3A4
1037758|NCT01852565|Lp-PLA2
1037759|NCT01852565|Atherosclerosis
1037760|NCT01852565|healthy volunteer
1037761|NCT01852565|Drug interaction
1037762|NCT01852552|Aortic stenosis
1037763|NCT01852552|Transcatheter aortic valve implantation
1037764|NCT01852552|Aortic valve replacement
1037765|NCT01852552|Costs
1037766|NCT01852552|Cognitive function
1037767|NCT01852552|Quality of life
1037768|NCT01852539|LMA insertion
1037769|NCT01852539|dexmedetomidine
1037770|NCT01852539|propofol
1037771|NCT01852526|degenerative disc disease
1037772|NCT01852526|spondylolisthesis
1037773|NCT01852526|Lumbar spine
1037774|NCT01852526|fusion
1037775|NCT01852526|adjacent instability
1037776|NCT01852487|Pumpkin seed oil
1037777|NCT01852487|Hair growth
1037778|NCT01852487|Men
1037779|NCT01852474|motor learning
1037780|NCT01852474|cortical plasticity
1037781|NCT01852474|direct current stimulation
1037782|NCT01852461|natural surfactants; perfusion index
1037783|NCT01852435|diffuse large B-cell lymphoma
1037784|NCT01852435|follicular lymphoma grade 3B
1037785|NCT01852409|refractory malignant ascites
1037786|NCT01852409|Bevacizumab
1037787|NCT01852409|intraperitoneal
1037788|NCT01852409|phase I
1037789|NCT01852396|Infraclavicular block
1037790|NCT01852396|Brachial Plexus
1037791|NCT01852396|Retroclavicular Approach
1037792|NCT01852396|Complications of retroclavicular approach
1037793|NCT01852396|Success of retroclavicular approach
1037794|NCT01852383|Duloxetine
1037795|NCT01852383|Antidepressant
1037796|NCT01852383|Depression
1037797|NCT01852383|Dysthymic Disorder
1037798|NCT01852383|Side Effects
1037799|NCT01852383|Elderly
1037809|NCT01852344|Methylphenidate
1037810|NCT01852344|Effortful Control
1037811|NCT01852344|Attention Control
1037812|NCT01852344|Cognitive functions
1037813|NCT01852331|Schizophrenia
1037814|NCT01852331|Schizophrenic Disorder
1037815|NCT01852331|Hyperprolactinemia
1037816|NCT01852331|Hyperprolactinaemia
1037817|NCT01852331|Chinese herbal medicine
1037818|NCT01852331|Traditional Chinese medicine
1037819|NCT01852331|Peony-Glycyrrhiza Decoction
1037820|NCT01852331|PGD
1037821|NCT01852331|Glycyrrhiza Radix
1037822|NCT01852331|Liquorice Root
1037823|NCT01852331|Gancao
1037824|NCT01852331|Paeoniae Alba Radix
1037825|NCT01852331|White Peony Root
1037826|NCT01852331|Baishao
1037827|NCT01852318|uremic pruritus
1037828|NCT01852318|pregabalin
1037829|NCT01852318|gabapentin
1037830|NCT01852318|fexofenadine
1037831|NCT01852305|Obstructive sleep apnea
1037832|NCT01852305|Continuous positive airway pressure (CPAP)
1037833|NCT01852305|Oximetry
1037834|NCT01852305|Bariatric Surgery
1037835|NCT01852305|Anesthesia
1037836|NCT01852305|Oxygen desaturation index (ODI)
1037837|NCT01852292|platinum pre-treated recurrent or metastatic
1037838|NCT01852292|Head and neck squamous cell carcinoma,
1037839|NCT01852292|recurrent
1037840|NCT01852292|metastatic
1037841|NCT01852292|BKM120
1037842|NCT01852253|Dental implants
1037843|NCT01852253|Periodontal diseases
1037844|NCT01852253|Peri-implantitis
1037845|NCT01852253|Chlorhexidine
1037846|NCT01852253|Microbiology
1037847|NCT01852214|Diabetes mellitus
1037848|NCT01852214|Coronary artery disease
1037849|NCT01852214|prasugrel
1037850|NCT01852214|ticagrelor
1037851|NCT01852188|Intrapartum
1037852|NCT01852188|Glove
1037853|NCT01852188|Chorioamnionitis
1037854|NCT01852175|Coronary artery disease
1037855|NCT01852175|Dual antiplatelet therapy
1037856|NCT01852175|prasugrel
1037857|NCT01852175|ticagrelor
1037858|NCT01852162|Coronary artery disease
1037859|NCT01852162|antiplatelet therapy
1037860|NCT01852162|anticoagulant therapy
1037861|NCT01852149|Mitral Valve Regurgitation
1037862|NCT01852149|Coaptation
1037863|NCT01852149|Mitral Valve Repair
1037864|NCT01852149|Plication
1037865|NCT01852149|Leaflet
1037866|NCT01852149|Annulus
1037867|NCT01852149|Mitral Annuloplasty
1037868|NCT01852136|pen needle
1037869|NCT01852136|insulin
1037870|NCT01852123|High-sensitivity troponin assay
1037871|NCT01852123|Myocardial infarction
1037872|NCT01852123|Unstable angina
1037873|NCT01852123|Myocardial injury
1037874|NCT01852123|Cluster randomized trial
1037875|NCT01852097|Inflammatory Bowel Disease (IBD)
1037876|NCT01852097|Crohn's disease
1037877|NCT01852097|Ulcerative colitis
1037878|NCT01852097|Cognitive Behavioural Therapy (CBT)
1037879|NCT01852097|Medication adherence
1037880|NCT01852071|gene therapy, hematopoietic stem cell, SCID, lentivirus
1037881|NCT01852032|Breast Cancer
1037882|NCT01852019|CAD
1037883|NCT01851993|Ondansetron
1037884|NCT01851993|Exercise
1037885|NCT01851980|Furosemide
1037886|NCT01851980|Exercise
1037887|NCT01851980|Restrictive pulmonary disorder
1037888|NCT01851967|Major depressive disorder
1037889|NCT01851967|Cognitive behavioral therapy
1037890|NCT01851967|Computerized CBT
1037891|NCT01851967|Online CBT
1037892|NCT01851915|Major depression
1037893|NCT01851915|Interpersonal psychotherapy
1037894|NCT01851915|Cognitive Behavioral Therapy
1037895|NCT01851915|Alliance
1037896|NCT01851915|Return to Work
1037897|NCT01851902|Atrial Fibrillation
1037898|NCT01851902|Atrial Flutter
1037899|NCT01851902|Arrhythmia
1037900|NCT01851863|functional dyspepsia
1037901|NCT01851863|depression
1037902|NCT01851863|compliance
1037903|NCT01851850|PD
1037904|NCT01851850|Off periods
1037905|NCT01851850|quality of life
1037906|NCT01851850|dyskinesia
1037907|NCT01851850|end-off-dose motor fluctuations
1037908|NCT01851811|OSA
1037909|NCT01851798|OSA
1037910|NCT01851798|Sleep disordered breathing
1037911|NCT01851798|anesthesia
1037912|NCT01851798|ambulatory orthopedic surgery
1037913|NCT01851785|Knee Arthroplasty
1037914|NCT01851785|Knee Osteoarthritis
1037915|NCT01851785|Osteoarthritis
1037916|NCT01851785|disparity
1037917|NCT01851785|joint replacement
1037918|NCT01851772|cervical
1037919|NCT01851772|cancer
1037920|NCT01851772|brachytherapy
1037921|NCT01851772|electronic
1037922|NCT01851772|device
1037923|NCT01851772|applicator
1037924|NCT01851772|toxicity
1037925|NCT01851772|gynecologic
1037926|NCT01851772|high-dose-rate (HDR)
1037927|NCT01851772|x-ray
1037928|NCT01851772|safety
1037929|NCT01851772|external beam radiation therapy (EBRT)
1037930|NCT01851746|recurrent ovarian cancer
1037931|NCT01851746|lobaplatin
1037932|NCT01851746|docetaxel
1037933|NCT01851746|carboplatin
1037934|NCT01851694|Cystic Fibrosis
1037935|NCT01851694|Diabetes
1037936|NCT01851694|Pancreatic insufficiency
1037937|NCT01851681|dental implants
1037938|NCT01851681|wound healing
1037939|NCT01851681|amoxicillin
1037940|NCT01851681|pain
1037941|NCT01851668|vibration
1037942|NCT01851668|noise
1037943|NCT01851668|transfer
1037944|NCT01851668|intraventricular hemorrhage
1037945|NCT01851655|rehabilitation
1037946|NCT01851655|plyometric
1037947|NCT01851642|Macrophage
1037948|NCT01851642|Alpha-1 Antitrypsin Deficiency
1037949|NCT01851642|Cystic Fibrosis
1037950|NCT01851629|Locomotor training
1037951|NCT01851629|Walking recovery
1037952|NCT01851629|Neuroplasticity
1037953|NCT01851616|glucose, blood
1037954|NCT01851603|Schizophrenia
1037955|NCT01851590|Dermatophyte onychomycosis
1037956|NCT01851590|Fungal nail infection
1037957|NCT01851590|Resin Lacquer
1037958|NCT01851590|Amorolfine
1037959|NCT01851590|Terbinafine
1037960|NCT01851577|Coparenting
1037961|NCT01851577|Problem solving
1037962|NCT01851577|Child development
1037963|NCT01851577|Father involvement
1037964|NCT01851564|Gastrointestinal Haemorrhage
1037965|NCT01851564|Varices
1037966|NCT01851564|Liver Cirrhosis
1037967|NCT01851564|Stent
1037968|NCT01851551|NHL
1037969|NCT01851551|non-Hodgkin's lymphoma
1037970|NCT01851551|diffuse large b-cell lymphoma
1037971|NCT01851551|mantle cell lymphoma
1037972|NCT01851538|Heart failure
1037973|NCT01851538|Biomarkers
1037974|NCT01851538|Echocardiography
1037975|NCT01851525|Atrial fibrillation
1037976|NCT01851525|Ablation
1037977|NCT01851499|Neuropathic pain following spinal cord injury
1037978|NCT01851473|Cocaine
1037979|NCT01851473|Pharmacokinetics
1037980|NCT01851473|Pharmacodynamics
1037981|NCT01851473|Drug Interactions
1037982|NCT01851473|Acetazolamide
1037983|NCT01851460|Staphylococcus Infection
1037984|NCT01851460|RFA
1037985|NCT01851460|Hepatic
1037986|NCT01851460|CGD
1037987|NCT01851447|Muscle
1037988|NCT01851447|Inflammatory Cytokines
1037989|NCT01851447|Exercise
1037990|NCT01851447|Biomarkers
1037991|NCT01851447|Predictors of Outcome
1037992|NCT01851434|OCT
1037993|NCT01851434|Multiple Sclerosis
1037994|NCT01851434|Optic Neuritis
1037995|NCT01851434|Magnetic Resonance Imaging (MRI)
1037996|NCT01851421|Body Fat
1037997|NCT01851421|Adult
1037998|NCT01851421|Obesity
1037999|NCT01851421|Free Fatty Acids
1038000|NCT01851421|Melanocortin-3 Receptor
1038001|NCT01851408|Sorafenib
1038002|NCT01851408|Temsirolimus
1038003|NCT01851408|Stage IV
1038004|NCT01851408|recurrent
1038005|NCT01851408|unresectable
1038006|NCT01851408|non-choroidal origin
1038007|NCT01851408|CCI-779
1038008|NCT01851408|BAY43-9006
1038009|NCT01851408|metastatic melanoma
1038010|NCT01851395|Palliative
1038011|NCT01851395|Tumor Heterogeneity
1038012|NCT01851395|Genomic and Proteomic Alterations
1038013|NCT01851395|Deep Sequencing and Global Analysis
1038014|NCT01851395|Clonal Evolution
1038015|NCT01851382|ELISA
1038016|NCT01851382|Spectrometry
1038017|NCT01851382|Protein Biomarkers
1038018|NCT01851382|Proteomic Analyses
1038019|NCT01851369|Solid Tumors
1038020|NCT01851369|Lymphomas
1038021|NCT01851369|DNA Damage
1038022|NCT01851369|Pharmacodynamics
1038023|NCT01851369|Pharmacokinetics
1038024|NCT01851356|PBR28
1038025|NCT01851356|Depression
1038026|NCT01851356|PET Imaging
1038027|NCT01851356|Neuroinflammation
1038028|NCT01851343|Stem Cell Infusion
1038029|NCT01851343|Crohns
1038030|NCT01851343|Ulcerative Colitis
1038031|NCT01851343|Inflammation
1038032|NCT01851343|Diarrhea
1038033|NCT01851330|HCV genotype 1 (GT-1)
1038034|NCT01851330|HCV
1038035|NCT01851330|Sustained Virologic Response
1038036|NCT01851330|Direct Acting Antiviral
1038037|NCT01851330|Combination Therapy
1038038|NCT01851330|GS-7977
1038039|NCT01851330|GS-5885
1038040|NCT01851330|Ribavirin
1038041|NCT01851330|Open Label
1038042|NCT01851330|Sofosbuvir
1038043|NCT01851330|Additional relevant MeSH terms:
1038044|NCT01851330|Hepatitis
1038045|NCT01851330|Hepatitis, Chronic
1038046|NCT01851330|Hepatitis C
1038047|NCT01851330|Hepatitis C, Chronic
1038048|NCT01851330|Liver Diseases
1038049|NCT01851330|Digestive System Diseases
1038050|NCT01851330|Hepatitis, Viral, Human
1038051|NCT01851330|Virus Diseases
1038052|NCT01851330|Enterovirus Infections
1038053|NCT01851330|Picornaviridae Infections
1038054|NCT01851330|RNA Virus Infections
1038055|NCT01851330|Flaviviridae Infections
1038056|NCT01851330|Antiviral Agents
1038057|NCT01851330|Anti-Infective Agents
1038058|NCT01851330|Therapeutic Uses
1038059|NCT01851330|Pharmacologic Actions
1038060|NCT01851330|Antimetabolites
1038061|NCT01851330|Molecular Mechanisms of Pharmacological Action
1038062|NCT01851304|beta-Glucans
1038063|NCT01851304|Bitter
1038064|NCT01851304|Bread
1038065|NCT01851304|Coffee
1038066|NCT01851304|Gentiana lutea
1038067|NCT01851304|Melanoidins
1038068|NCT01851304|Microencapsulation
1038069|NCT01851278|injection
1038070|NCT01851278|arthritis
1038071|NCT01851278|corticosteroid
1038072|NCT01851265|oncology, cancer, tumour, neoplasm, anticancer drug, food effect, area under the curve, pharmacokinetics, olaparib, solid tumour, metabolites, drug availability
1038073|NCT01851239|Venous Thromboembolism Prophylaxis
1038074|NCT01851239|ICU
1038075|NCT01851213|genomics
1038076|NCT01851213|cancer
1038077|NCT01851213|registry
1038078|NCT01851213|neoplasm metastasis
1038079|NCT01851200|Testicular neoplasms
1038080|NCT01851200|Germ Cell cancers
1038081|NCT01851200|Embryonal Carcinoma
1038082|NCT01851200|Metastatic
1038083|NCT01851200|Brentuximab Vedotin
1038084|NCT01851187|Psychological intervention,
1038085|NCT01851187|prenatal period,
1038086|NCT01851187|cesarean section rate,
1038087|NCT01851187|stage of labor
1038088|NCT01851148|osteopathic manipulative treatment
1038089|NCT01851148|migraine
1038090|NCT01851135|Quality of life
1038091|NCT01851135|Neuropsychological disorders
1038092|NCT01851135|Neurofibromatosis type 1
1038093|NCT01851122|l-theanine
1038094|NCT01851122|alertness
1038095|NCT01851122|well-being
1038096|NCT01851109|ovarian cancer
1038097|NCT01851109|prevention
1038098|NCT01851109|prophylactic surgery
1038099|NCT01851109|risk
1038100|NCT01851109|biomarkers
1038101|NCT01851109|screening
1038102|NCT01851109|symptoms
1038103|NCT01851096|Hsp90
1038104|NCT01851096|SNX-5422
1038105|NCT01851096|Erlotinib
1038106|NCT01851096|Lung adenocarcinoma
1038107|NCT01851083|Traumatic Brain Injury
1038108|NCT01851083|TBI
1038109|NCT01851083|pediatric
1038110|NCT01851083|acute
1038111|NCT01851083|stem cells
1038112|NCT01851057|Epilepsy
1038117|NCT01851031|medial or low condylar fractures
1038118|NCT01851031|the minor parotid anterior approach
1038119|NCT01851031|the retromandibular approach
1038120|NCT01851018|Prostate cancer
1038121|NCT01851018|brachytherapy
1038122|NCT01851018|hypofractionated radiation therapy
1038123|NCT01851018|hormonal therapy
1038124|NCT01851005|Dexmedetomidine
1038125|NCT01851005|Anesthesia
1038126|NCT01851005|Recovery profile
1038127|NCT01850992|Obstructive sleep apnea.
1038128|NCT01850992|sleep
1038129|NCT01850992|male hormones
1038130|NCT01850979|CYCLOSPORINE/TACROLIMUS [VA Drug Interaction]
1038131|NCT01850966|Arthritis, Rheumatoid, Iguratimod
1038132|NCT01850953|Varenicline
1038133|NCT01850953|Schizophrenia
1038134|NCT01850953|smoking
1038135|NCT01850953|Lapse
1038136|NCT01850940|Cirrhotic Patients
1038137|NCT01850940|Hyponatremia
1038138|NCT01850940|tolvaptan
1038139|NCT01850914|Normal pressure hydrocephalus
1038140|NCT01850914|Vascular risk factors
1038141|NCT01850901|Hypertension
1038142|NCT01850901|Renal denervation
1038143|NCT01850901|Sympathetic denervation
1038144|NCT01850888|neuroblastoma
1038145|NCT01850888|pheochromocytoma
1038146|NCT01850875|Eye-Movement-Desensitization and Reprocessing
1038147|NCT01850875|EMDR
1038148|NCT01850875|Chronic back pain
1038149|NCT01850875|CBP
1038150|NCT01850875|treatment
1038151|NCT01850836|Aphasia, Stroke, repetitive transcranial magnetic stimulation.
1038152|NCT01850797|oral anticoagulants
1038153|NCT01850797|ischemic stroke
1038154|NCT01850797|blood thinner
1038155|NCT01850797|intracranial hemorrhage
1038156|NCT01850784|Congenital heart disease, Growth,Neurodevelopment
1038157|NCT01850771|Lumbar Radiculopathy
1038158|NCT01850771|Disc bulge
1038159|NCT01850771|Disc herniation
1038160|NCT01850771|Disc degeneration
1038161|NCT01850758|ACL
1038162|NCT01850758|Anterior Cruciate Ligament
1038163|NCT01850758|ACL Tear
1038164|NCT01850758|Anterior Cruciate Ligament Tear
1038165|NCT01850758|Partial ACL Tear
1038166|NCT01850745|Chronic hepatitis C virus infection (CHC)
1038167|NCT01850719|Tibial meniscus
1038168|NCT01850719|Arthroscopy
1038169|NCT01850719|Meniscectomy
1038170|NCT01850719|Conservative treatment
1038171|NCT01850719|Physical therapy
1038172|NCT01850719|Osteoarthritis knee joint
1038173|NCT01850706|uNGF
1038174|NCT01850706|urinary nerve growth factor
1038175|NCT01850706|detrusor overactivity
1038176|NCT01850706|InterStim
1038177|NCT01850706|sacral neuromodulation
1038178|NCT01850706|sacral nerve stimulation
1038179|NCT01850706|quality of life
1038180|NCT01850706|questionnaire
1038181|NCT01850706|urodynamic detrusor overactivity
1038182|NCT01850706|overactive bladder
1038183|NCT01850693|coronary artery disease
1038184|NCT01850693|stroke
1038185|NCT01850693|coronary CT angiography
1038186|NCT01850667|Hepatocellular carcinoma
1038187|NCT01850667|Stereotactic body radiotherapy
1038188|NCT01850667|Stereotactic ablative radiotherapy
1038189|NCT01850654|colorectal cancer
1038190|NCT01850654|colon cancer
1038191|NCT01850654|rectal cancer
1038192|NCT01850654|endometrial cancer
1038193|NCT01850654|Lynch syndrome
1038194|NCT01850654|Ohio colon cancer study
1038195|NCT01850654|OSU colon study
1038196|NCT01849679|Dysphagia
1038197|NCT01849679|extubation
1038198|NCT01849679|aspiration
1038199|NCT01849653|vaginal swabs
1038200|NCT01849653|diagnosis
1038201|NCT01849640|Malaria
1038202|NCT01849640|Drug resistance
1038203|NCT01849640|DHA-piperaquine
1038204|NCT01849640|Cambodia
1038205|NCT01849640|Transmission Blocking
1038206|NCT01849627|weight loss maintenance
1038207|NCT01849588|Hepatitis C positive
1038208|NCT01849575|Ultrasonography
1038209|NCT01849575|Cardiovascular diseases
1038210|NCT01849575|Prevention
1038211|NCT01849575|Risk communication
1038212|NCT01849575|Risk assessment
1038213|NCT01849575|Behavioral change
1038214|NCT01849562|Hepatitis C, Chronic
1038215|NCT01849562|Genotype 1
1038216|NCT01849562|Hepatitis C
1038217|NCT01849562|Liver Diseases
1038218|NCT01849562|Hepatitis, viral, human
1038219|NCT01849562|ribavirin
1038220|NCT01849562|antiviral agents
1038221|NCT01849562|anti-infective agents
1038222|NCT01849562|protease inhibitors
1038223|NCT01849562|NS5a inhibitors
1038224|NCT01849549|neuropsychological Study
1038225|NCT01849549|brain Imaging
1038226|NCT01849536|Open angle glaucoma
1038227|NCT01849536|Corneal biomechanics
1038228|NCT01849536|Intra ocular pressure
1038229|NCT01849536|IOP
1038230|NCT01849536|IOP fluctuation
1038231|NCT01849536|Continuous IOP monitoring
1038232|NCT01849536|SENSIMED Triggerfish®
1038233|NCT01849523|Neuroendocrine tumor
1038234|NCT01849523|Website
1038235|NCT01849523|Information
1038236|NCT01849523|Psychosocial support
1038237|NCT01849510|spinal metastases
1038238|NCT01849510|vertebral body
1038239|NCT01849510|stereotaxis
1038240|NCT01849510|image-guided radiotherapy
1038241|NCT01849510|hypofractionated
1038242|NCT01849510|dose intensified
1038243|NCT01849510|dose elevation
1038244|NCT01849497|LDL-C, triglycerides, high cholesterol
1038245|NCT01849484|meningioma
1038246|NCT01849484|skull base meningioma
1038247|NCT01849484|pituitary adenoma
1038248|NCT01849484|brain metastases
1038249|NCT01849484|small cell lung carcinoma
1038250|NCT01849471|socioeconomic aspects
1038251|NCT01849471|costs of therapy
1038252|NCT01849471|follow-up costs
1038253|NCT01849471|primary radiation
1038254|NCT01849471|percutaneous
1038255|NCT01849471|interstitial
1038256|NCT01849393|Adolescents
1038257|NCT01849393|Medication Compliance
1038258|NCT01849393|Rewards-Based Incentive Programs
1038259|NCT01850641|Hemodialysis
1038260|NCT01850641|Hyperphosphatemia
1038261|NCT01850628|National Surgical Adjuvant Breast and Bowel Project (NSABP)
1038262|NCT01850628|paclitaxel
1038263|NCT01850628|trastuzumab
1038264|NCT01850628|pertuzumab
1038265|NCT01850628|HER2 positive (human epidermal growth factor receptor 2)
1038266|NCT01850628|Proteomics
1038267|NCT01850628|Neoadjuvant Therapy
1038268|NCT01850628|Anthracycline therapy
1038269|NCT01850628|Locally advanced
1038270|NCT01850628|Operable
1038271|NCT01850628|Biomarkers
1038272|NCT01850602|Hemodialysis
1038273|NCT01850602|Hyperphosphatemia
1038274|NCT01850576|prevention
1038275|NCT01850576|testing
1038276|NCT01850576|counseling
1038277|NCT01850576|linkage
1038278|NCT01850563|Demonstrate coordination of HBO with SRS treatments is feasible.
1038279|NCT01850563|Demonstrate outcomes for patients treated with combination of HBO and SRS are non-inferior .
1038280|NCT01850550|Weight loss
1038281|NCT01850537|DDD
1038282|NCT01850537|PROW
1038283|NCT01850537|FUSION
1038284|NCT01850537|eSPIN
1038285|NCT01850537|Cage
1038286|NCT01850537|IBF
1038287|NCT01850537|Discectomy
1038288|NCT01850537|Lumbar Fusion
1038289|NCT01850537|TLIF
1038290|NCT01850537|MIS
1038291|NCT01850524|Newly Diagnosed multiple myeloma
1038292|NCT01850524|multiple myeloma
1038293|NCT01850524|MLN9708
1038294|NCT01850524|IXAZOMIB
1038295|NCT01850524|Proteasome inhibitor
1038296|NCT01850524|Tourmaline MM2
1038297|NCT01850511|Nasal obstruction
1038298|NCT01850511|Vibrissae
1038299|NCT01850511|Nasal hair
1038300|NCT01850498|Epilepsy
1038301|NCT01850498|Seizure
1038302|NCT01850498|Motor
1038303|NCT01850498|Motion
1038304|NCT01850498|Accelerometer
1038305|NCT01850485|cardiac arrest
1038306|NCT01850485|therapeutic hypothermia
1038307|NCT01850485|microcirculation
1038308|NCT01850472|Anhedonia
1038309|NCT01850472|Depression
1038310|NCT01850472|Stress
1038311|NCT01850472|Cortisol
1038312|NCT01850472|Inflammatory cytokines
1038313|NCT01850472|Learning
1038314|NCT01850472|Magnetic resonance imaging (MRI)
1038315|NCT01850433|BDD
1038316|NCT01850433|CBT
1038317|NCT01850420|fibromyalgia
1038318|NCT01850420|Myofascial
1038319|NCT01850407|Lack of Preparation for Abused Children during Medical Examination
1038320|NCT01850381|Parkinson Disease
1038321|NCT01850381|Efficacy
1038322|NCT01850381|Safety
1038323|NCT01850381|Tolerability
1038324|NCT01850381|Phase 2A
1038325|NCT01850381|Pilot trial
1038326|NCT01850381|human Motoneuronotrophic Factor
1038327|NCT01850381|neuroprotective agent
1038328|NCT01850381|neurodegenerative diseases
1038329|NCT01850381|rate of clinical progression of PD
1038330|NCT01850381|UPDRS
1038331|NCT01850381|Proof of principle
1038332|NCT01850368|Hepatocellular carcinoma
1038333|NCT01850368|Stereotactic ablative radiotherapy
1038334|NCT01850368|Stereotactic body radiotherapy
1038335|NCT01850368|Portal vein tumor thrombus
1038336|NCT01850355|Autism Spectrum Disorders
1038337|NCT01850355|Anxiety
1038338|NCT01850355|Children
1038339|NCT01850355|Adolescents
1038340|NCT01850355|Buspar
1038341|NCT01850355|Buspirone
1038342|NCT01850355|Pervasive Developmental Disorders
1038343|NCT01850342|Male stress urinary incontinence
1038344|NCT01850342|Cell-assisted lipotransfer
1038345|NCT01850342|Adipose-derived regenerative cells
1038346|NCT01850342|ADRC
1038347|NCT01850342|Micrograft
1038348|NCT01850342|Fat tissue
1038349|NCT01850342|Stem cells
1038350|NCT01850303|Elderly
1038351|NCT01850303|lung cancer
1038352|NCT01850303|switch
1038353|NCT01850303|maintenance
1038354|NCT01850303|Elderly patients (between 70 and 89 years)
1038355|NCT01850303|NSCLC
1038356|NCT01850290|TBI
1038357|NCT01850277|Atrial fibrillation
1038358|NCT01850277|Cardiac resynchronization therapy
1038359|NCT01850277|Heart failure
1038360|NCT01850277|Rhythm control strategy
1038361|NCT01850264|cardiac resynchronization therapy; heart failure, congestive
1038362|NCT01850251|Hip fractures
1038363|NCT01850251|Ageing
1038364|NCT01850251|Sarcopenia
1038365|NCT01850251|Function
1038366|NCT01850238|Alzheimer disease
1038367|NCT01850238|tau protein
1038368|NCT01850238|neurofibrillary degeneration
1038369|NCT01850238|disease-modifying
1038370|NCT01850212|Treatment Experienced
1038371|NCT01850212|Male greater than or equal to 50 years
1038372|NCT01850212|Female postmenopausal
1038373|NCT01850199|Gestational diabetes
1038374|NCT01850199|Telemedicine
1038375|NCT01850199|Artificial Intelligence
1038376|NCT01850160|Hypertension
1038377|NCT01850160|High blood pressure
1038378|NCT01850160|Drug therapy combination
1038379|NCT01850160|Valsartan
1038380|NCT01850160|Chlorthalidone
1038381|NCT01850160|Safety
1038382|NCT01850160|Efficacy
1038383|NCT01850147|sunitinib
1038384|NCT01850147|chemotherapy
1038385|NCT01850147|non-small cell lung cancer
1038386|NCT01850147|NSCLC
1038387|NCT01850121|Ankylosing Spondylitis
1038388|NCT01850121|infiximab
1038389|NCT01850121|single armed trial
1038390|NCT01850095|acne
1038391|NCT01850095|adult
1038392|NCT01850095|women
1038393|NCT01850095|TLR
1038394|NCT01850095|CD1d
1038395|NCT01850095|androgens
1038396|NCT01850082|Coronary artery disease
1038397|NCT01850082|CABG
1038398|NCT01850082|Coronary revascularization
1038399|NCT01850082|Endoscopic vein harvest
1038400|NCT01850082|Saphenous vein graft
1038401|NCT01850082|Graft failure
1038402|NCT01850069|Intracranial hypertension
1038403|NCT01850069|intracranial elastance
1038404|NCT01850056|drug eluting balloon catheter
1038405|NCT01850017|Opiate consumption
1038406|NCT01850017|Visual Analogue Scale
1038407|NCT01849991|Crying
1038408|NCT01849991|Fussiness
1038409|NCT01849991|Gas
1038410|NCT01849991|Hydrogen Breath
1038411|NCT01849991|Fecal Calprotectin
1038412|NCT01849978|breast cancer
1038413|NCT01849978|survivor
1038414|NCT01849978|exercise
1038415|NCT01849978|physical activity
1038416|NCT01849978|strenuous exercise
1038417|NCT01849978|moderate exercise
1038418|NCT01849978|enjoyable exercise
1038419|NCT01849978|enjoy exercise
1038420|NCT01849978|breast cancer survivor
1038421|NCT01849965|diabetic foot ulcers
1038422|NCT01849965|Wagner Grade 1 or 2 ulcers
1038423|NCT01849952|glioblastoma
1038424|NCT01849952|miRNA
1038425|NCT01849952|GBM
1038426|NCT01849952|astrocytoma
1038427|NCT01849939|Allogeneic transplantation of hematopoietic stem cells transplantation
1038428|NCT01849939|Chronic Lymphocytic Leukemia
1038429|NCT01849939|Donor Lymphocyte Injection
1038430|NCT01849939|Preemptive immunointervention
1038431|NCT01849913|neck pain
1038432|NCT01849913|hydrocortisone
1038433|NCT01849913|stress
1038434|NCT01849913|electromyography
1038435|NCT01849913|adolescent
1038436|NCT01849913|low-level laser therapy
1038437|NCT01849900|Menstrual cycle
1038438|NCT01849900|Ovulation time
1038439|NCT01849900|pregnancy recognition
1038440|NCT01849900|Community-based participatory research
1038441|NCT01849900|Unintended pregnancy
1038442|NCT01849861|Cardiopulmonary Capacity
1038443|NCT01849861|Ranges of TSH
1038444|NCT01849861|Elderly Population
1038445|NCT01849835|rate of positive detection
1038446|NCT01849822|neural
1038447|NCT01849822|prosthetic
1038448|NCT01849822|brain machine interface
1038449|NCT01849822|brain computer interface
1038450|NCT01849822|brain control
1038451|NCT01849822|paralysis
1038452|NCT01849822|tetraplegia
1038453|NCT01849822|quadriplegia
1038454|NCT01849822|spinal cord injury
1038455|NCT01849796|tDCS
1038456|NCT01849796|Neuropathic
1038457|NCT01849796|Facial
1038458|NCT01849796|Pain
1038459|NCT01849796|Neuralgia
1038460|NCT01849796|deafferentation
1038461|NCT01849796|Trigeminal
1038462|NCT01849770|SALS
1038463|NCT01849770|Mexiletine
1038464|NCT01849770|Safety
1038465|NCT01849757|Cardiopulmonary bypass
1038466|NCT01849757|prime
1038467|NCT01849757|crystalloid
1038468|NCT01849757|albumin
1038469|NCT01849757|HES 130/0.4
1038470|NCT01849744|Focal Adhesion Kinase inhibitor
1038471|NCT01849744|FAK inhibitor
1038472|NCT01849744|Cancer Stem Cells
1038473|NCT01849744|CSC
1038474|NCT01849731|Diabetes Mellitus type 2;
1038475|NCT01849731|Primary Care, healthcare inequalities;
1038476|NCT01849731|Diabetes self-management,
1038477|NCT01849731|Quality of diabetes care
1038478|NCT01849705|Obesity
1038479|NCT01849705|MC4R
1038480|NCT01849705|Blood pressure
1038481|NCT01849705|Blood glucose
1038482|NCT01849692|Exudative Age-Related Macular Degeneration
1038483|NCT01849692|Wet AMD
1038484|NCT01849692|Choroidal neovascularization (CNV)
1038485|NCT01849692|Vascular endothelial growth factor (VEGF)
1038486|NCT01849380|Local Advanced Breast Neoplasms
1038487|NCT01849380|Neoadjuvant Chemotherapy
1038488|NCT01849380|S-1
1038489|NCT01849341|COPD
1038490|NCT01849302|Appetite
1038491|NCT01849302|Satiety hormones
1038492|NCT01849302|Dietary Protein
1038493|NCT01849237|Mesenchymal Stromal Cells
1038494|NCT01849237|Septic Shock
1038495|NCT01849237|Neutropenia
1038496|NCT01849237|Procalcitonin
1038497|NCT01849237|Interleukin-6
1038498|NCT01849237|Interleukin-10
1038499|NCT01849237|C-reactive protein
1038500|NCT01849237|Survival
1038501|NCT01849237|Organ dysfunction
1038502|NCT01849224|Lower extremity edema
1038503|NCT01849224|Lower leg lymphedema
1038504|NCT01849224|Lower leg edema
1038505|NCT01849224|Lymphedema
1038506|NCT01849224|Pelvic lymphadenectomy
1038507|NCT01849224|Exercise
1038508|NCT01849211|ventilation
1038509|NCT01849211|face mask
1038510|NCT01849211|NMBA
1038511|NCT01849198|accelerometry
1038512|NCT01849198|neuromuscular block
1038513|NCT01849198|m. trapezius
1038514|NCT01849185|Hypercholesterolemia
1038515|NCT01849159|Mesenchymal stem cells
1038516|NCT01849159|Hypoxia
1038517|NCT01849159|Emphysema
1038518|NCT01849133|Breast cancer
1038519|NCT01849133|conservative surgery
1038520|NCT01849133|intraoperative radiation therapy
1038521|NCT01849133|mobile linear accelerator
1038522|NCT01849120|near infrared spectroscopy (NIRS)
1038523|NCT01849120|EQUANOX Advance 8004CB probes
1038524|NCT01849120|cerebral vascular circulation
1038525|NCT01849120|peripheral perfusion
1038526|NCT01849107|Radiation-induced small bowel toxicity
1038527|NCT01849107|Plasma citrulline
1038528|NCT01849081|Non-alcoholic fatty liver disease
1038529|NCT01849081|Obstructive sleep apnea
1038530|NCT01849029|Post traumatic Stress Disorders
1038531|NCT01849029|PTSD
1038532|NCT01849029|HIV risk
1038533|NCT01849029|sexual risk
1038534|NCT01849029|substance use
1038535|NCT01849029|alcohol misuse
1038536|NCT01849029|Substance Abuse
1038537|NCT01849029|Substance Addiction
1038538|NCT01849029|Substance Dependence
1038539|NCT01849029|Substance Use Disorders
1038540|NCT01849029|Alcohol-Related Disorders
1038541|NCT01849029|Binge Drinking
1038542|NCT01849029|Sexual Partners
1038543|NCT01849029|Sexual Behavior
1038544|NCT01849029|Unsafe Sex
1038545|NCT01849016|Sickle Cell Disease
1038546|NCT01849016|Sickle Cell Anemia
1038547|NCT01849016|Pain
1038548|NCT01849016|N-Acetylcysteine
1038549|NCT01849016|Acetylcysteine
1038550|NCT01849016|Oxidative stress
1038551|NCT01849003|Long QT Syndrome
1038552|NCT01849003|LQTS
1038553|NCT01849003|Long QT-3 Syndrome
1038554|NCT01849003|LQT-3
1038555|NCT01849003|prolonged QT interval
1038556|NCT01849003|GS-6615
1038557|NCT01849003|late sodium current inhibitor
1038558|NCT01848990|Type 1 Diabetes Mellitus
1038559|NCT01848990|Sub Cutaneous Insulin Infusion
1038560|NCT01848990|Rapid Acting Analog Insulin
1038561|NCT01848990|Hylenex
1038562|NCT01848990|Halozyme
1038563|NCT01848990|Phase 4
1038564|NCT01848977|Measures
1038565|NCT01848977|near-Infrared spectroscopy
1038566|NCT01848977|ischemia
1038567|NCT01848977|reperfusion
1038568|NCT01848964|amputation
1038569|NCT01848964|prosthesis
1038570|NCT01848964|stump
1038571|NCT01848964|socket
1038572|NCT01848964|pressure
1038573|NCT01848964|gait
1038574|NCT01848964|posture
1038575|NCT01848938|female
1038576|NCT01848938|stress urinary incontinence
1038577|NCT01848938|treatment
1038578|NCT01848938|pelvic floor muscle training
1038579|NCT01848938|smartphone
1038580|NCT01848938|internet
1038581|NCT01848938|life style
1038582|NCT01848938|eHealth
1038583|NCT01848925|SANGUINATE
1038584|NCT01848899|Coronary angiography
1038585|NCT01848899|Percutaneous coronary intervention
1038586|NCT01848899|Contrast media
1038587|NCT01848899|Platelet activity
1038588|NCT01848899|Thrombin generation
1038589|NCT01848899|Fibrinolysis
1038590|NCT01848886|ERAH
1038591|NCT01848886|Endoscopic Radial Artery Harvest
1038592|NCT01848886|Y-graft
1038593|NCT01848886|Radial Artery Harvest
1038594|NCT01848886|Total Arterial Revascularisation
1038595|NCT01848886|CABG
1038596|NCT01848886|Radial Artery Conduit
1038597|NCT01848873|Hyperhomocysteinemia
1038598|NCT01848873|Amlodipine-folic acid tablets
1038599|NCT01848873|Hypertension
1038600|NCT01848873|MTHFR C677T
1038601|NCT01848860|Pneumothorax
1038602|NCT01848860|thoracoscopy
1038603|NCT01848860|mesh
1038604|NCT01848860|pleurodesis
1038605|NCT01848860|treatment
1038606|NCT01848847|Hysteroscopy
1038607|NCT01848847|Bladder
1038608|NCT01848847|Pain
1038609|NCT01848847|Feasibility
1038610|NCT01848847|Duration
1038611|NCT01848821|OASIS ultra
1038612|NCT01848821|faster healing time
1038613|NCT01848821|better healing quality
1038614|NCT01848821|standard of care
1038615|NCT01848795|Type 2 Diabetes
1038616|NCT01848795|Obesity
1038617|NCT01848795|gastrointestinal hormones
1038618|NCT01848795|intestinal bypass
1038619|NCT01848795|endoscopy
1038620|NCT01848782|abstract
1038621|NCT01848782|meta-analysis
1038622|NCT01848782|systematic review
1038623|NCT01848782|interpretation
1038624|NCT01848782|results
1038625|NCT01848782|quality
1038626|NCT01848782|bias
1038627|NCT01848782|spin
1038628|NCT01848782|limits
1038629|NCT01848782|limitation
1038630|NCT01848782|risk of bias
1038631|NCT01848769|Asthma
1038632|NCT01848769|ICS+LABA
1038633|NCT01848769|Children
1038634|NCT01848769|Inhalation
1038635|NCT01848769|pMDI
1038636|NCT01848756|SNX-5422
1038637|NCT01848756|HER2 positive cancer
1038638|NCT01848743|tenofovir, lamivudine, hepatitis B, acute exacerbation
1038639|NCT01848704|spin
1038640|NCT01848704|interpretation
1038641|NCT01848704|bias
1038642|NCT01848652|cerebral lymphoma B cell refractory
1038643|NCT01848652|Myocet
1038644|NCT01848652|efficacy
1038645|NCT01848652|safety
1038646|NCT01848639|chronic kidney disease
1038647|NCT01848639|end-stage renal disease
1038648|NCT01848639|hemodialysis (ESRD)
1038649|NCT01848639|cardiovascular morbimortality
1038650|NCT01848639|aldosterone antagonist
1038651|NCT01848639|spironolactone
1038652|NCT01848600|limitation
1038653|NCT01848600|quality
1038654|NCT01848600|bias
1038655|NCT01848600|meta-analysis
1038656|NCT01848600|interpretation
1038657|NCT01848600|abstract
1038658|NCT01848587|Pregnancy
1038659|NCT01848587|Acupuncture
1038660|NCT01848587|Pelvic and low back pain
1038661|NCT01848587|Impairment
1038662|NCT01848587|Economic evaluation
1038663|NCT01848574|Understanding
1038664|NCT01848574|Patients
1038665|NCT01848574|Emergency
1038666|NCT01848574|Information
1038667|NCT01848561|Inflammatory Bowel Diseases
1038668|NCT01848561|Gastroenteritis
1038669|NCT01848561|Adalimumab
1038670|NCT01848561|Ulcerative Colitis
1038671|NCT01848561|Registry
1038672|NCT01848561|Gastrointestinal Diseases
1038673|NCT01848561|Colitis
1038674|NCT01848535|intestinal microbiota composition
1038675|NCT01848535|intestinal microbiota activity
1038676|NCT01848535|gastro-intestinal complains
1038677|NCT01848522|qualitative study
1038678|NCT01848522|rehabilitation
1038679|NCT01848522|physical therapy
1038680|NCT01848522|patient education
1038681|NCT01848522|health care
1038682|NCT01848522|administration
1038683|NCT01848522|patient satisfaction
1038684|NCT01848522|handicap
1038685|NCT01848509|CPAP
1038686|NCT01848509|adherence
1038687|NCT01848509|SAOS
1038688|NCT01848509|telemedicine
1038689|NCT01848483|Early Palliative Care
1038690|NCT01848483|Motivational Interviewing
1038691|NCT01848483|Persons Living With Human immunodeficiency virus(HIV)
1038692|NCT01848483|Acquired Immunodeficiency Syndrome (AIDS)
1038693|NCT01848457|Osteosarcoma
1038694|NCT01848457|Cancer
1038695|NCT01848457|Nephrotoxicity
1038696|NCT01848457|Ototoxicity
1038697|NCT01848457|Cisplatin
1038698|NCT01848457|High-dose methotrexate
1038699|NCT01848457|Biomarkers
1038700|NCT01848457|Patient reported outcomes
1038701|NCT01848444|Public Health
1038702|NCT01848444|Epidemiology
1038703|NCT01848444|Pharmacy Toxicology
1038704|NCT01848444|Perinatal period
1038705|NCT01848418|ICF
1038706|NCT01848418|Core sets
1038707|NCT01848418|Systemic sclerosis
1038708|NCT01848418|Function
1038709|NCT01848418|Evaluation
1038710|NCT01848392|Cystic fibrosis
1038711|NCT01848392|Adults
1038712|NCT01848392|Physical activity
1038713|NCT01848366|Frequency
1038714|NCT01848366|urgency
1038715|NCT01848366|incontinence
1038716|NCT01848340|mass balance
1038717|NCT01848340|GSK1265744
1038718|NCT01848340|supratherapeutic
1038719|NCT01848340|integrase inhibitor
1038720|NCT01848340|healthy volunteer
1038721|NCT01848327|Cognition
1038722|NCT01848327|Neuropsychology
1038723|NCT01848327|Multiple Sclerosis
1038724|NCT01848301|Optical Coherence Tomography
1038725|NCT01848301|OCT
1038726|NCT01848301|Coronary Allograft Vasculopathy
1038727|NCT01848301|Donor Specific Antibodies
1038728|NCT01848301|Acetylcholine
1038729|NCT01848301|Coronary endothelial function
1038730|NCT01848301|Brachial Artery Flow Mediated Dilation
1038731|NCT01848301|Heart transplantation
1038732|NCT01848288|Cataract
1038733|NCT01848288|Phacoemulsification
1038734|NCT01848288|Cumulative Dissipated Energy (CDE)
1038735|NCT01848262|ECALMIST
1038736|NCT01848262|InSurE
1038737|NCT01848262|CPAP
1038738|NCT01848262|Ventilation
1038739|NCT01848262|Vascular Catheter
1038748|NCT01848223|quality of life
1038749|NCT01848223|QoL
1038750|NCT01848223|late menopause
1038751|NCT01848210|Drug therapy
1038752|NCT01848184|PARIETEX Composite Ventral Patch
1038753|NCT01848184|PCO VP OR PCOVP
1038754|NCT01848184|Primary ventral hernia repair
1038755|NCT01848184|Panacea
1038756|NCT01848171|Hypothyroidism
1038757|NCT01848171|Lipid
1038758|NCT01848171|Atherosclerosis
1038759|NCT01848171|Oxidative Stress
1038760|NCT01848171|Chronic Inflammation
1038761|NCT01848171|Endothelial Function
1038762|NCT01848171|Adipocytokine
1038763|NCT01848171|L-thyroxine
1038764|NCT01848158|acupuncture
1038765|NCT01848158|pediatric
1038766|NCT01848158|critical care
1038767|NCT01848158|mechanical ventilation
1038768|NCT01848158|sedation
1038769|NCT01848158|comfort
1038770|NCT01848145|Chronic Lymphocytic Leukemia
1038771|NCT01848145|Ofatumumab
1038772|NCT01848145|Rapid Infusion
1038773|NCT01848132|Lymphoma
1038774|NCT01848132|Large B-Cell
1038775|NCT01848119|Gabapentin
1038776|NCT01848119|Cesarean section
1038777|NCT01848106|Percutaneous Coronary Intervention
1038778|NCT01848106|Coronary Artery Disease
1038779|NCT01848106|Acute Coronary Syndrome
1038780|NCT01848106|Regado
1038781|NCT01848106|Reg 1
1038782|NCT01848106|bivalirudin
1038783|NCT01848093|lung
1038784|NCT01848093|airway
1038785|NCT01848093|pulmonary exacerbation
1038786|NCT01848093|mucus
1038787|NCT01848080|Telemedicine
1038788|NCT01848080|Telerehabilitation
1038789|NCT01848080|Acute Stroke
1038790|NCT01848080|Tai Chi
1038791|NCT01848080|Tai Ji
1038792|NCT01848080|Rehabilitation
1038793|NCT01848080|Home care services
1038794|NCT01848080|Single blind method
1038795|NCT01848080|Randomized controlled trial
1038796|NCT01848054|opioid dependence, buprenorphine/naloxone, sublingual
1038797|NCT01848041|Blepharoptosis
1038798|NCT01848041|Ptosis
1038799|NCT01848028|Patient registry
1038800|NCT01848028|Germany
1038801|NCT01848028|Psoriasis
1038802|NCT01848028|psoriatic-arthritis
1038803|NCT01848028|Efalizumab
1038804|NCT01848028|Psonet
1038805|NCT01848028|Effectiveness
1038806|NCT01848028|Safety
1038807|NCT01848015|CTCs before and after gastrectomy
1038808|NCT01847976|breast
1038809|NCT01847976|bone pain
1038810|NCT01847963|Urolithiasis
1038811|NCT01847963|Kalladaippu Kudineer
1038812|NCT01847963|Siddha
1038813|NCT01847963|Sindhuvallathy
1038814|NCT01847963|Kidney stones
1038815|NCT01847911|self instructed resuscitation training
1038816|NCT01847898|Osteoporosis
1038817|NCT01847898|Vertebral Body
1038818|NCT01847898|Compression Fracture
1038819|NCT01847898|Kyphoplasty
1038820|NCT01847885|electrical stimulation
1038821|NCT01847885|neurostimulation
1038822|NCT01847885|neuromodulation
1038823|NCT01847885|post-stroke shoulder pain
1038824|NCT01847885|hemiplegic shoulder pain
1038825|NCT01847872|Inactivated Poliovirus Vaccine
1038826|NCT01847872|Randomised Control Phase IV Study
1038827|NCT01847872|Gambia
1038828|NCT01847872|IPV
1038829|NCT01847872|Safety and Immunogenicity
1038830|NCT01847872|Non-interference study
1038831|NCT01847872|IM Jet injector
1038832|NCT01847872|ID Jet Injector
1038833|NCT01847859|Cardiothoracic surgery
1038834|NCT01847859|Post-operative
1038835|NCT01847859|Nurses
1038836|NCT01847859|Cardiac
1038837|NCT01847859|Echocardiography
1038838|NCT01847859|Pocket-size
1038839|NCT01847859|Hand-held
1038840|NCT01847820|ROM
1038841|NCT01847820|PROM
1038842|NCT01847820|PPROM (preterm premature rupture of membranes)
1038843|NCT01847807|5-10 gram astragalus per day
1038844|NCT01847781|Opsonophagocytic antibodies
1038845|NCT01847781|Cellular immunity
1038846|NCT01847781|Vaccine immunity
1038847|NCT01847781|Antimicrobial peptides
1038848|NCT01847768|asthma
1038849|NCT01847768|rhinovirus
1038850|NCT01847768|remodeling mediators
1038851|NCT01847768|human rhinovirus infection
1038852|NCT01847729|Opiate dependence
1038853|NCT01847729|Opiate substitution treatment
1038854|NCT01847729|co-addictions
1038855|NCT01847729|Patients addicted to opiates
1038856|NCT01847729|methadone
1038857|NCT01847729|buprenorhine
1038858|NCT01847729|morphine
1038859|NCT01847729|OST in place
1038860|NCT01847729|pathological gambling
1038861|NCT01847729|pharmacokinetic
1038862|NCT01847729|pharmacogenetic
1038863|NCT01847729|polymorphism
1038864|NCT01847729|cytochrome P450 2D6
1038865|NCT01847729|Therapeutic Drug Monitoring
1038866|NCT01847716|Muscle weakness
1038867|NCT01847716|Pulmonary arterial hypertension
1038868|NCT01847716|Transforming growth factor beta
1038869|NCT01847716|Growth and differentiation factor 15
1038870|NCT01847690|Addison Disease
1038871|NCT01847677|ovarian cancer
1038872|NCT01847677|neoadyuvant
1038873|NCT01847677|bevacizumab
1038874|NCT01847651|hepatic encephalopathy
1038875|NCT01847651|minimal hepatic encephalopathy
1038876|NCT01847651|cirrhosis
1038877|NCT01847651|lateral vastus
1038878|NCT01847651|muscle biopsy
1038879|NCT01847651|L ornithine L aspartate
1038880|NCT01847651|functional magnetic resonance imaging
1038881|NCT01847651|magnetic resonance spectroscopy
1038882|NCT01847651|cognitive testing
1038883|NCT01847651|Paper and pencil Hepatic Encephalopathy score (PHES)
1038884|NCT01847651|Cogstate
1038885|NCT01847651|urine metabonomics
1038886|NCT01847651|plasma metabonomics
1038887|NCT01847651|muscle metabonomics
1038888|NCT01847638|Retinal edema
1038889|NCT01847638|Cataract
1038890|NCT01847638|inflammation
1038891|NCT01847612|per operative cholangiography
1038892|NCT01847612|liver resection
1038893|NCT01847612|biliary fistula
1038894|NCT01847599|educational intervention
1038895|NCT01847599|adherence
1038896|NCT01847599|capecitabine
1038897|NCT01847599|lapatinib
1038898|NCT01847586|Alzheimer's Disease
1038899|NCT01847586|Brain stimulation
1038900|NCT01847586|transcranial magnetic stimulation
1038901|NCT01847573|halofuginone hydrobromide
1038902|NCT01847573|anti-fibrotic
1038903|NCT01847573|anti-inflammatory
1038904|NCT01847573|muscle regeneration
1038905|NCT01847573|protein synthesis inhibitor
1038906|NCT01847495|Stage IV Colorectal Carcinoma
1038907|NCT01847495|Liver metastasis
1038908|NCT01847495|Cyberknife
1038909|NCT01847495|Stereotactic Body Radiotherapy
1038910|NCT01847495|SBRT
1038911|NCT01847495|Irinotecan HCl
1038912|NCT01847495|CPT-11
1038913|NCT01847482|Cardiac arrest
1038914|NCT01847482|Return of Spontaneous Circulation (ROSC)
1038915|NCT01847482|IntraVascular Temperature Management (IVTM)
1038916|NCT01847482|Therapeutic Hypothermia
1038917|NCT01847482|Japan
1038918|NCT01847469|Alcohol Dependence
1038919|NCT01847469|Post-Traumatic Stress Disorder (PTSD)
1038920|NCT01847469|Zonisamide
1038921|NCT01847469|Cognitive Processing Therapy (CPT)
1038922|NCT01847456|whole body insulin sensitivity
1038923|NCT01847456|insulin action in the brain
1038924|NCT01847443|nicotine
1038925|NCT01847443|nicotine replacement therapy
1038926|NCT01847443|nicotine gum
1038927|NCT01847430|Healthy
1038928|NCT01847430|Hepatitis B
1038929|NCT01847430|Adolescents
1038930|NCT01847430|Engerix™-B Kinder
1038931|NCT01847417|Acetylsalicylic acid
1038932|NCT01847417|Pantoprazole
1038933|NCT01847417|Fixed dose combination
1038934|NCT01847404|Fixed dose combination
1038935|NCT01847404|Acetylsalicylic acid
1038936|NCT01847404|Pantoprazole
1038937|NCT01847391|Ischemic Heart Disease
1038938|NCT01847391|Heart Disease
1038939|NCT01847378|ventricular tachycardia
1038940|NCT01847378|catheter ablation
1038941|NCT01847378|chagas disease
1038942|NCT01847378|epicardial mapping
1038943|NCT01847378|magnetic resonance imaging
1038944|NCT01847365|Retinitis Pigmentosa
1038945|NCT01847365|Transcorneal electrical stimulation
1038946|NCT01847365|Okustim
1038947|NCT01847352|Hypoxia
1038948|NCT01847352|Pulmonary hypertension
1038949|NCT01847352|Iron deficiency
1038950|NCT01847352|Hypoxic pulmonary vasoconstriction
1038951|NCT01847300|alcohol abuse
1038952|NCT01847300|tobacco dependence
1038953|NCT01847300|substance abuse
1038954|NCT01847300|SBIRT
1038955|NCT01847287|Multiple sclerosis
1038956|NCT01847287|Tysabri
1038957|NCT01847287|MRI
1038958|NCT01847287|Natalizumab
1038959|NCT01847274|ovarian cancer
1038960|NCT01847274|platinum sensitive
1038961|NCT01847274|gBRCAmut
1038962|NCT01847274|BRCA
1038963|NCT01847274|high-grade serous histology
1038964|NCT01847274|PARP inhibitor
1038965|NCT01847261|soy
1038966|NCT01847261|whey
1038967|NCT01847261|muscle
1038968|NCT01847261|older
1038969|NCT01847261|mTOR
1038970|NCT01847261|sarcopenia
1038971|NCT01847248|sepsis
1038972|NCT01847248|biomarker
1038973|NCT01847248|HSPA12B
1038974|NCT01847235|Temozolomide
1038975|NCT01847209|lung nodule
1038976|NCT01847209|lung cancer
1038977|NCT01847209|lung mass
1038978|NCT01847196|Pulmonary Embolism
1038979|NCT01847196|PE
1038980|NCT01847196|DVT
1038981|NCT01847196|Deep Vein Thrombosis
1038982|NCT01847196|VTE
1038983|NCT01847196|Venous Thromboembolism
1038984|NCT01847196|prophylaxis
1038985|NCT01847196|thromboprophylaxis
1038986|NCT01847196|contraindications to thromboprophylaxis
1038987|NCT01847196|prophylactic
1038988|NCT01847196|prevention
1038989|NCT01847196|Inferior vena cava filter
1038990|NCT01847196|IVC filter
1038991|NCT01847196|filter
1038992|NCT01847196|prevention of pulmonary embolism
1038993|NCT01847196|trauma
1038994|NCT01847196|critically-ill
1038995|NCT01847183|heavy drinking
1038996|NCT01847183|prevention
1038997|NCT01847183|high school
1038998|NCT01847183|adolescence
1038999|NCT01847157|recovery of function
1039000|NCT01847157|stroke
1039001|NCT01847157|Upper extremity
1039002|NCT01847157|Motor
1039003|NCT01847157|transcranial direct current stimulation
1039004|NCT01847131|Rhinitis
1039005|NCT01847131|Oxymetazoline
1039006|NCT01847092|albuminuria
1039007|NCT01847066|wrinkles
1039008|NCT01847066|acne scars
1039009|NCT01847066|pigmentation
1039010|NCT01847053|Cinnamon
1039011|NCT01847053|Bioavailability
1039012|NCT01847053|Glucose
1039013|NCT01847053|Proanthocyanidins
1039014|NCT01847040|Traumatic Brain Injury
1039015|NCT01847040|Epidemiology
1039016|NCT01847040|Concussion
1039017|NCT01847040|Outcomes
1039018|NCT01847040|PTSD
1039019|NCT01847040|Prospective
1039020|NCT01847040|Longitudinal
1039021|NCT01847040|Military
1039022|NCT01847040|Symptoms
1039023|NCT01847040|Validation
1039024|NCT01847040|Screening
1039025|NCT01847040|Mild Traumatic Brain Injury
1039026|NCT01847027|Healthy
1039027|NCT01847027|Stem cells
1039028|NCT01847027|Aging
1039029|NCT01847027|Increase stem cell replacement
1039030|NCT01847027|decreased stem cell proliferation
1039031|NCT01847014|Pulmonary Arterial Hypertension (PAH)
1039032|NCT01847014|psychometric instrument
1039033|NCT01847014|PAH-SYMPACT
1039034|NCT01847001|Breast Cancer
1039035|NCT01847001|Neoadjuvant
1039036|NCT01847001|Experimental
1039037|NCT01847001|Biomarker
1039038|NCT01847001|Breast imaging
1039039|NCT01846988|Obstructive Sleep Apnea
1039040|NCT01846988|Pediatric Obstructive Sleep Apnea
1039041|NCT01846988|Auto PAP
1039042|NCT01846988|Auto-adjustable Positive Airway Pressure
1039043|NCT01846988|APAP
1039044|NCT01846988|CPAP
1039045|NCT01846975|Abatacept
1039046|NCT01846975|Low disease activity
1039047|NCT01846975|Intravenous
1039048|NCT01846975|Subcutaneous
1039049|NCT01846975|Rheumatoid arthritis
1039050|NCT01846962|Eosinophilic esophagitis (EoE)
1039051|NCT01846962|budesonide
1039052|NCT01846962|fluticasione
1039053|NCT01846962|six-foods elimination diet
1039054|NCT01846936|one lung ventilation
1039055|NCT01846936|efficacy
1039056|NCT01846936|bronchial blocker
1039057|NCT01846910|Cessation
1039058|NCT01846845|Amputee
1039059|NCT01846832|Hepatitis C, Chronic
1039060|NCT01846832|Infection
1039061|NCT01846832|Triple therapy
1039062|NCT01846832|TMC435
1039063|NCT01846832|simeprevir
1039064|NCT01846832|Pegylated interferon alfa-2a (PegIFNα-2a)
1039065|NCT01846832|ribavirin (RBV)
1039066|NCT01846832|PEGASYS
1039067|NCT01846832|COPEGUS
1039068|NCT01846806|Hepatic Encephalopathy
1039069|NCT01846793|Benign prostatic hyperplasia
1039070|NCT01846793|BPH
1039071|NCT01846793|Lower urinary tract symptoms
1039072|NCT01846793|LUTS
1039073|NCT01846793|LUTS secondary to BPH
1039074|NCT01846793|LUTS/BPH
1039075|NCT01846793|Benign prostatic obstruction (BPO)
1039076|NCT01846793|BPO
1039077|NCT01846793|Bladder outlet obstruction
1039078|NCT01846793|BOO
1039079|NCT01846767|13CO2
1039080|NCT01846767|Breath test
1039081|NCT01846767|Glucose oxidation
1039082|NCT01846767|Diabetes mellitus
1039083|NCT01846754|Hemodialysis
1039084|NCT01846754|Fatigue
1039085|NCT01846754|Muscle strength
1039086|NCT01846754|Metabolomics
1039087|NCT01846741|Automatic Magnet Mode (AMM)
1039088|NCT01846741|Vagus Nerve Stimulation (VNS)
1039089|NCT01846715|Kidney disease
1039090|NCT01846715|Renal insufficiency
1039091|NCT01846715|CKD
1039092|NCT01846715|Autologous cell therapy
1039093|NCT01846676|Hearing loss, rehabilitation programs, adherence to hearing aids.
1039094|NCT01846663|Hepatic Encephalopathy
1039095|NCT01846663|Liver Failure
1039096|NCT01846663|Hepatic Insufficiency
1039097|NCT01846663|Liver Diseases
1039098|NCT01846663|Brain Diseases
1039099|NCT01846663|Rifaximin
1039100|NCT01846663|Cirrhosis
1039101|NCT01846611|Ovarian neoplasms
1039102|NCT01846611|Peritoneal neoplasms
1039103|NCT01846611|Fallopian tube neoplasms
1039233|NCT01845922|Refeeding Syndrome
1039104|NCT01846611|Advanced-relapsed epithelial ovarian cancer
1039105|NCT01846611|Advanced-relapsed primary peritoneal cancer
1039106|NCT01846611|Advanced-relapsed fallopian tube cancer
1039107|NCT01846611|Trabectedin
1039108|NCT01846611|Yondelis
1039109|NCT01846611|Doxil
1039110|NCT01846611|Caelyx
1039111|NCT01846611|Platinum sensitive
1039112|NCT01846611|Tthird-line
1039113|NCT01846611|BRCA
1039114|NCT01846611|Patient related outcome
1039115|NCT01846572|Stroke
1039116|NCT01846572|Clopidogrel
1039117|NCT01846572|Aggregometry
1039118|NCT01846572|Antiplatelet therapy
1039119|NCT01846572|Platelet function tests
1039120|NCT01846559|Immune system processes
1039121|NCT01846546|Traumatic brain injury;
1039122|NCT01846546|Endostatin/collagen XVIII;
1039123|NCT01846546|Cerebrospinal fluid;
1039124|NCT01846546|Prognosis
1039125|NCT01846507|Heavy Menstrual Bleeding
1039126|NCT01846507|HMB
1039127|NCT01846507|Lysteda
1039128|NCT01846481|Cocaine
1039129|NCT01846468|Healthy volunteers and patients,
1039130|NCT01846468|renal insufficiency,
1039131|NCT01846455|Hepatic
1039132|NCT01846455|Hepatitis C Virus
1039133|NCT01846455|Suboxone
1039134|NCT01846455|Buprenorphine
1039135|NCT01846455|Naloxone
1039136|NCT01846442|Vulvar/vaginal atrophy
1039137|NCT01846442|Atrophic Vaginitis
1039138|NCT01846442|Dehydroepiandrosterone
1039139|NCT01846442|DHEA
1039140|NCT01846442|Prasterone
1039141|NCT01846442|Vaginorm
1039142|NCT01846442|Menopause
1039143|NCT01846442|Intrarosa
1039144|NCT01846429|cancer
1039145|NCT01846429|pain fibers
1039146|NCT01846429|acid levels
1039147|NCT01846429|tumor related pain
1039148|NCT01846429|cancer related pain
1039149|NCT01846429|sodium bicarbonate
1039150|NCT01846429|pain reliever
1039151|NCT01846429|metastatic
1039152|NCT01846429|unresectable
1039153|NCT01846429|solid malignancy
1039154|NCT01846429|hematologic malignancy
1039155|NCT01846429|multiple myeloma
1039156|NCT01846429|lymphoma
1039157|NCT01846377|video game
1039158|NCT01846377|diet
1039159|NCT01846377|physical activity
1039160|NCT01846377|sedentary behavior
1039161|NCT01846377|obesity
1039162|NCT01846377|diabetes
1039163|NCT01846364|Thyroid
1039164|NCT01846364|DIM
1039165|NCT01846351|choroidal neovascularization
1039166|NCT01846351|epiretinal membrane
1039167|NCT01846351|anti-VEGF
1039168|NCT01846338|acne, EGCG, green tea
1039169|NCT01846299|Vision Impairment
1039170|NCT01846286|Neuropathic Pain
1039171|NCT01846286|Squamous cell cancer of the head and neck
1039172|NCT01846286|acute pain
1039173|NCT01846286|pain management
1039174|NCT01846286|genome-wide analyses
1039175|NCT01846286|Squamous cell carcinoma of the head and neck
1039176|NCT01846286|chronic pain
1039177|NCT01846286|neuropathic
1039178|NCT01846286|locoregional squamous cell carcinoma of the head and neck
1039179|NCT01846247|stroke
1039180|NCT01846234|Multiple Sclerosis
1039181|NCT01846234|Salt
1039182|NCT01846221|Analgesia
1039183|NCT01846221|Epidural
1039184|NCT01846221|Pregnancy
1039185|NCT01846221|Labor
1039186|NCT01846221|Clonidine
1039187|NCT01846221|Fentanyl
1039188|NCT01846221|Bupivacaine
1039189|NCT01846221|Childbirth
1039190|NCT01846208|Egg Allergy
1039191|NCT01846208|Egg Oral Immunotherapy
1039192|NCT01846208|Food Allergy
1039193|NCT01846195|blood loss
1039194|NCT01846182|Gulf War Illness
1039195|NCT01846182|Pregabalin
1039196|NCT01846182|Duloxetine
1039197|NCT01846182|Gulf War Veterans
1039198|NCT01846182|Cymbalta
1039199|NCT01846182|Lyrica
1039200|NCT01846169|food insecurity
1039201|NCT01846169|older adults
1039202|NCT01846169|nutrition
1039203|NCT01846169|food deliveries
1039204|NCT01846156|convulsion rate
1039205|NCT01846130|Bed rest,
1039206|NCT01846117|lignans
1039207|NCT01846117|oxidative stress
1039208|NCT01846117|inflammation
1039209|NCT01846117|aging
1039210|NCT01846117|muscle weakness
1039211|NCT01846117|pain
1039213|NCT01846013|Sit-Stand Workstations
1039214|NCT01846013|Increase Workplace Physical Activity
1039215|NCT01846000|temporomandibular joint
1039216|NCT01846000|temporomandibular disorder
1039217|NCT01846000|electromyography
1039218|NCT01846000|low-level laser therapy
1039219|NCT01845987|Palmoplantaris Pustulosis
1039220|NCT01845987|CNTO 1959
1039221|NCT01845987|Psoriasis
1039222|NCT01845987|Anti-IL 23 Monoclonal Antibody
1039223|NCT01845974|Radiofrequency Catheter Ablation
1039224|NCT01845974|Atrial Fibrillation
1039225|NCT01845948|parents
1039226|NCT01845948|school transition
1039227|NCT01845948|parental-child relationship
1039228|NCT01845935|Cryoablation
1039229|NCT01845935|Venous vascular malformation
1039230|NCT01845935|MRI
1039231|NCT01845935|safety
1039232|NCT01845935|pain
1039234|NCT01845922|low sodium
1039235|NCT01845922|slowly absorbed carbohydrates
1039236|NCT01845922|hypopotassemia
1039237|NCT01845922|hypophosphatemia
1039238|NCT01845909|Sudden cardiac death
1039239|NCT01845909|Young adults
1039240|NCT01845909|Cardiac Disease
1039241|NCT01845909|Arrhythmia
1039242|NCT01845909|Sports
1039243|NCT01845896|high intensity interval training
1039244|NCT01845896|combined training
1039245|NCT01845896|insulin resistance
1039246|NCT01845896|muscle contractile properties
1039247|NCT01845857|Long term health problems
1039248|NCT01845857|chronic disease
1039249|NCT01845831|Diabetes
1039250|NCT01845831|DPP4 inhibitors
1039251|NCT01845831|Sitagliptin
1039252|NCT01845831|Glargine
1039253|NCT01845831|RCT
1039254|NCT01845831|basal insulin
1039255|NCT01845831|hospital hyperglycemia
1039256|NCT01845831|inpatient diabetes
1039257|NCT01845818|work productivity
1039258|NCT01845818|multicenter study
1039259|NCT01845792|Metastatic Castrate Resistant Prostate Cancer
1039260|NCT01845766|sepsis, septic shock, rehabilitation, exercise
1039261|NCT01845740|systemic lupus erythematoses
1039262|NCT01845740|lupus
1039263|NCT01845740|SLE
1039264|NCT01845727|Cutaneous leishmaniasis
1039265|NCT01845727|Topical treatment
1039266|NCT01845727|Colombia
1039267|NCT01845714|Keratoconus
1039268|NCT01845714|Corneal cross Linking
1039269|NCT01845714|Topo guided PRK
1039270|NCT01845714|Quality of Life
1039271|NCT01845701|malaria, cure rate, efficacy, safety
1039272|NCT01845688|Idiopathic Membranous Nephropathy
1039273|NCT01845688|Traditional Chinese Medicine
1039274|NCT01845688|Randomized Control Trial
1039275|NCT01845675|temozolomide
1039276|NCT01845675|endostatin
1039277|NCT01845675|advanced
1039278|NCT01845675|well-differentiated
1039279|NCT01845675|pancreatic neuroendocrine tumor
1039280|NCT01845662|splenectomy
1039281|NCT01845662|embolization
1039282|NCT01845662|observation
1039283|NCT01845662|blood transfusion
1039284|NCT01845649|Vulvovaginal Atrophy
1039285|NCT01845649|Dyspareunia
1039286|NCT01845649|Postmenopausal
1039287|NCT01845636|Olfaction
1039288|NCT01845636|Donepezil
1039289|NCT01845636|Alzheimer's Disease
1039290|NCT01845636|Mild Cognitive Impairment
1039291|NCT01845636|Memory
1039292|NCT01845623|Asthma
1039293|NCT01845623|Indacaterol
1039294|NCT01845623|QAB149
1039295|NCT01845584|IVIG in Neuromyelitis Optica spectrum disorder
1039296|NCT01845584|Patients with Neuromyelitis Optica spectrum disorder
1039297|NCT01845558|Muscle soreness
1039298|NCT01845558|Exercise induced muscle damage
1039299|NCT01845558|Inflammation
1039300|NCT01845558|Proteolytic enzymes
1039301|NCT01845558|Muscle strength Dynamometer
1039302|NCT01845545|microfinance
1039303|NCT01845545|under five mortality
1039304|NCT01845545|underweight
1039305|NCT01845545|malnutrition
1039306|NCT01845506|wireless pressure sensor
1039307|NCT01845506|Elderly
1039308|NCT01845493|asthma
1039309|NCT01845493|Asthmatics
1039310|NCT01845493|allergic
1039311|NCT01845493|allergies
1039312|NCT01845480|health promotion
1039313|NCT01845480|obesity prevention
1039314|NCT01845480|Childhood obesity
1039315|NCT01845480|home-based
1039316|NCT01845480|Lifestyle intervention
1039317|NCT01845480|Body composition
1039318|NCT01845480|quality of life
1039319|NCT01845480|physical activity
1039320|NCT01845480|nutrition
1039321|NCT01845467|Secretin MRCP, diagnosis, Autoimmune pancreatitis
1039322|NCT01845454|Barrett's Esophagus
1039323|NCT01845454|Spray cryotherapy
1039324|NCT01845441|Dexmedetomidine
1039325|NCT01845441|Endovascular procedure
1039326|NCT01845441|Stroke
1039327|NCT01845441|Vasospasm, intracranial
1039328|NCT01845441|Conscious sedation
1039329|NCT01845428|nephrotic
1039330|NCT01845428|hyperlipidemia
1039331|NCT01845428|oxLDL
1039332|NCT01845428|kidney
1039333|NCT01845402|Kidney Failure, Chronic
1039334|NCT01845402|Adolescent
1039335|NCT01845402|Heart Defects, Congenital
1039336|NCT01845389|Anesthesia
1039337|NCT01845389|Regional
1039338|NCT01845389|Epidural
1039339|NCT01845389|Continuous spinal
1039340|NCT01845389|Wiley Catheter
1039341|NCT01845389|Geriatric
1039342|NCT01845389|TURP
1039343|NCT01845376|Inflammatory Markers after Inguinal Hernia Repair
1039344|NCT01845376|Anesthetic technique for hernia repair
1039345|NCT01845363|Obesity
1039346|NCT01845363|Bariatric surgery
1039347|NCT01845363|Cefazolin
1039348|NCT01845363|antimicrobial prophylaxis
1039349|NCT01845363|administration and dosage
1039350|NCT01845324|Pregnancy
1039351|NCT01845324|Diabetes Mellitus
1039352|NCT01845285|transcatheter valve replacement
1039353|NCT01845285|aortic valve disease
1039354|NCT01845285|aortic stenosis
1039355|NCT01845285|Aortic regurgitation,catheter
1039356|NCT01845285|Effective orifice area
1039357|NCT01845246|Colistin
1039358|NCT01845246|Polymyxins
1039359|NCT01845246|Therapeutic drug monitoring
1039360|NCT01845246|Multi Drug resistant Gram negative bacterial infections
1039361|NCT01845220|Broccoli sprouts
1039362|NCT01845220|alcohol sensitivity
1039363|NCT01845220|sulforaphane
1039364|NCT01845220|alcohol metabolism
1039365|NCT01845220|in the Asian Community
1039366|NCT01845207|Aortic stenosis
1039367|NCT01845207|Aortic valve replacement
1039368|NCT01845207|Transcatheter aortic valve implantation
1039369|NCT01845207|Outcomes
1039370|NCT01845207|Frailty
1039371|NCT01845207|Elderly
1039372|NCT01845194|pharmacokinetic
1039373|NCT01845194|heritability
1039374|NCT01845194|drug membrane transport
1039375|NCT01845194|drug biotransformation
1039376|NCT01845181|Adenosine A1 receptor antagonist
1039377|NCT01845181|Asthma
1039378|NCT01845181|adenosine receptor modulator
1039379|NCT01845181|COPD
1039380|NCT01845168|Bleeding peptic ulcer
1039381|NCT01845168|NSAID and Aspirin
1039382|NCT01845168|Computer-alert
1039383|NCT01845168|General practitioner
1039384|NCT01845155|Tinnitus
1039385|NCT01845155|music therapy
1039386|NCT01845155|directive counselling
1039387|NCT01845155|acoustic stimulation
1039388|NCT01845155|group comparison
1039389|NCT01845155|subjective evaluation
1039390|NCT01845155|pitch
1039391|NCT01845142|vitamin D
1039392|NCT01845142|vitamin D deficiency
1039393|NCT01845142|immune cells
1039394|NCT01845142|pharmacokinetic
1039395|NCT01845142|< 50 nmol/L 25(OH)D serum concentration
1039396|NCT01845116|PNALD
1039397|NCT01845116|Cholestasis
1039398|NCT01845116|Omegaven®
1039399|NCT01845116|Short Bowel Syndrome
1039400|NCT01845103|ANGINA
1039401|NCT01845103|Thoracoscopic
1039402|NCT01845064|type 2 diabetes
1039403|NCT01845064|diabetes mellitus
1039404|NCT01845064|type 2 diabetes mellitus
1039405|NCT01845064|HbA1c
1039406|NCT01845064|blood glucose
1039407|NCT01845064|glucose control
1039408|NCT01845064|DiaMedica
1039409|NCT01845064|DM-199
1039410|NCT01845064|DM199
1039411|NCT01845064|recombinant human tissue kallikrein-1
1039412|NCT01845064|tissue kallikrein-1
1039413|NCT01845051|Migraine
1039414|NCT01845051|allergic rhinitis
1039415|NCT01845051|Specific Immunoglobulin E (IgE)
1039416|NCT01845051|nasal symptoms
1039417|NCT01845051|signs of allergy.
1039418|NCT01845025|Asthma
1039419|NCT01845025|formoterol fumarate
1039420|NCT01845025|Foradil
1039421|NCT01845025|inhaled corticosteroid
1039422|NCT01845025|fluticasone propionate
1039423|NCT01845025|safety
1039424|NCT01845012|Short daily hemodialysis
1039425|NCT01845012|Low dialysate flow
1039426|NCT01845012|End stage renal disease
1039427|NCT01844999|Prostate cancer
1039428|NCT01844999|Decision
1039429|NCT01844986|BRCA
1039430|NCT01844986|Ovarian Cancer
1039431|NCT01844986|Chemotherapy
1039432|NCT01844986|PARP inhibitor
1039433|NCT01844986|First Line
1039434|NCT01844986|FIGO Stage III
1039435|NCT01844986|FIGO Stage IV
1039436|NCT01844960|Single Incision Surgery
1039437|NCT01844960|SILS
1039438|NCT01844960|Laparoscopic Gastric Band
1039439|NCT01844960|Morbid Obesity
1039440|NCT01844960|Bariatric Surgery
1039441|NCT01844934|Knee Arthroplasty
1039442|NCT01844934|Knee Replacement
1039443|NCT01844934|Prehabilitation
1039444|NCT01844882|The effects
1039445|NCT01844882|dietary
1039446|NCT01844882|fiber
1039447|NCT01844882|kidney function
1039448|NCT01844882|CKD patients
1039449|NCT01844869|omacetaxine
1039450|NCT01844869|omacetaxine mepesuccinate
1039451|NCT01844869|pharmacokinetics
1039452|NCT01844869|hematologic malignancies
1039453|NCT01844869|advanced solid tumors
1039454|NCT01844843|Drug eluting stents
1039455|NCT01844843|coronary artery disease
1039456|NCT01844843|Percutaneous Coronary Intervention
1039457|NCT01844843|Tomography, Optical Coherence
1039458|NCT01844830|operative
1039459|NCT01844830|dental procedure
1039460|NCT01844817|untreated
1039461|NCT01844817|metastatic
1039462|NCT01844817|OGX-427
1039463|NCT01844804|Bioequivalence
1039464|NCT01844804|Biosimilarity
1039465|NCT01844804|Similarity
1039466|NCT01844804|PK
1039467|NCT01844804|Phase 1
1039468|NCT01844804|Infliximab
1039469|NCT01844804|Healthy Volunteers
1039470|NCT01844804|Single-dose
1039471|NCT01844804|Immunology
1039472|NCT01844791|Non-small cell lung cancer
1039473|NCT01844791|OCZ103-OS
1039474|NCT01844791|Pentamidine bis(2-hydroxyethanesulfonate)
1039475|NCT01844791|platinum-gemcitabine based doublet first line therapy
1039476|NCT01844778|Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI,
1039477|NCT01844778|colistimethate
1039478|NCT01844778|Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI, colistimethate
1039479|NCT01844765|Tasigna
1039480|NCT01844765|nilotinib treatment
1039481|NCT01844765|chronic phase
1039482|NCT01844765|Ph+ CML
1039483|NCT01844765|accelerated phase
1039484|NCT01844765|newly diagnosed Ph+ CML
1039485|NCT01844765|pediatric
1039486|NCT01844765|24 month treatment
1039487|NCT01844752|acne
1039488|NCT01844739|Propionibacterium acnes
1039489|NCT01844739|acne
1039490|NCT01844726|healthy individuals
1039491|NCT01844726|schizophrenia
1039492|NCT01844726|schizoaffective disorder
1039493|NCT01844726|learning
1039494|NCT01844726|memory
1039495|NCT01844726|cognitive enhancement
1039496|NCT01844726|fMRI
1039497|NCT01844713|Kidney transplant
1039498|NCT01844713|Renal transplant
1039499|NCT01844713|Sun protection
1039500|NCT01844713|Skin cancer
1039501|NCT01844700|MC4R genotype
1039502|NCT01844700|antipsychotic induced weight gain
1039503|NCT01844700|pediatric population
1039504|NCT01844687|reinforcement, good drug effect, high, mood, cannabidiol
1039505|NCT01844661|Mesenchymal stem cells
1039506|NCT01844661|Oncolytic adenovirus
1039507|NCT01844648|Parkinson's disease
1039508|NCT01844648|Sialorrhea
1039509|NCT01844648|Tropicamide
1039510|NCT01844648|Non-motor symptoms
1039511|NCT01844648|Thin strip delivery
1039512|NCT01844622|Digestive System Diseases Disease
1039513|NCT01844609|Comprehension
1039514|NCT01844609|Verbal Learning
1039515|NCT01844609|Writing
1039516|NCT01844609|Testing
1039517|NCT01844596|linkage to care
1039518|NCT01844596|hypertension management
1039519|NCT01844596|behavioral science
1039520|NCT01844596|cardiovascular health
1039521|NCT01844596|global health
1039522|NCT01844596|multi-disciplinary implementation research approach
1039523|NCT01844596|linking and retaining
1039524|NCT01844596|community health workers
1039525|NCT01844596|CHWs
1039526|NCT01844596|behavioral communication strategy
1039527|NCT01844596|smartphone-based tool
1039528|NCT01844596|electronic health record
1039529|NCT01844596|retention to care
1039530|NCT01844557|Head And Neck Cancer
1039531|NCT01844557|Nasopharyngeal cancer
1039532|NCT01844557|Oropharyngeal cancer
1039533|NCT01844557|Hypopharyngeal cancer
1039534|NCT01844557|Laryngeal cancer
1039535|NCT01844557|Primary cancer with cervical metastases
1039536|NCT01844557|Swallowing exercises
1039537|NCT01844557|Videotape
1039538|NCT01844557|Videocamera
1039539|NCT01844557|M.D. Anderson Symptom Inventory
1039540|NCT01844557|Questionnaires
1039541|NCT01844557|Surveys
1039542|NCT01844544|drug related problems
1039543|NCT01844544|clinical pharmacist
1039544|NCT01844544|femoral neck fractures
1039545|NCT01844544|orthopedic patients
1039546|NCT01844492|decision making for incapacitated patients
1039547|NCT01844492|intensive care
1039548|NCT01844492|surrogate decision making
1039549|NCT01844492|patient centered care
1039550|NCT01844492|Palliative Care
1039551|NCT01844492|End of Life
1039552|NCT01844492|Quality of Communication
1039553|NCT01844479|diabetic foot ulcer
1039554|NCT01844479|diabetic foot
1039555|NCT01844466|course of motor and visual rehabilitation
1039556|NCT01844466|improvement of deficits
1039557|NCT01844466|stroke patients
1039558|NCT01844453|Subfertility
1039559|NCT01844453|Recurrent Implantation Failure
1039560|NCT01844440|GERD
1039561|NCT01844440|tLESR
1039562|NCT01844440|impedance
1039563|NCT01844440|manometry
1039564|NCT01844427|ADHD
1039565|NCT01844427|Executive function deficits
1039566|NCT01844427|Psychiatry
1039567|NCT01844427|Psychopharmacology
1039568|NCT01844427|Namenda
1039569|NCT01844414|Homeless Men
1039570|NCT01844414|Parolees
1039571|NCT01844414|Hepatitis B
1039572|NCT01844414|Hepatitis C
1039573|NCT01844414|HIV
1039574|NCT01844414|Community Drug Treatment
1039575|NCT01844414|Recidivism
1039576|NCT01844401|persistent asthma
1039577|NCT01844401|Albuterol Spiromax®
1039578|NCT01844401|ProAir® HFA
1039579|NCT01844401|Pediatric Patients
1039580|NCT01844401|Phase 1
1039581|NCT01844375|oral carbohydrate loading
1039582|NCT01844375|walking capacity
1039583|NCT01844362|uterus
1039584|NCT01844362|transplantation
1039585|NCT01844362|infertility
1039586|NCT01844349|North Africa
1039587|NCT01844349|Urban women
1039588|NCT01844349|Double burden of malnutrition
1039589|NCT01844349|Iron depletion
1039590|NCT01844349|Overweight/obesity
1039591|NCT01844349|Metabolic syndrome
1039592|NCT01844349|Abdominal obesity
1039593|NCT01844349|Excess body fat
1039594|NCT01844284|Absorb™ BVS
1039595|NCT01844284|Angioplasty
1039596|NCT01844284|Bioabsorbable
1039597|NCT01844284|Bioreabsorbable
1039598|NCT01844284|BVS
1039599|NCT01844284|Coronary Artery Disease
1039600|NCT01844284|Coronary Artery Endothelial Responsiveness
1039601|NCT01844284|Coronary artery restenosis
1039602|NCT01844284|Coronary artery stenosis
1039603|NCT01844284|Coronary scaffold
1039604|NCT01844284|Coronary Stent
1039605|NCT01844284|Drug eluting stents
1039606|NCT01844284|Everolimus
1039607|NCT01844284|Myocardial ischemia
1039608|NCT01844284|Stent thrombosis
1039609|NCT01844284|Stents
1039610|NCT01844271|LLLT
1039611|NCT01844271|muscle fatigue and recovery
1039612|NCT01844271|phototherapy parameter
1039613|NCT01844258|pediatric cataract
1039614|NCT01844258|lens regeneration
1039615|NCT01844258|endogenous lens epithelial stem cells
1039616|NCT01844258|visual axis opacification
1039617|NCT01844258|visual function
1039618|NCT01844245|Cholangiocarcinoma
1039619|NCT01844245|Ampullary carcinoma
1039620|NCT01844245|Endoscopic retrograde cholangiopancreatography
1039621|NCT01844245|Radiofrequency ablation
1039622|NCT01844232|Multiple sclerosis
1039623|NCT01844232|spasticity
1039624|NCT01844232|arbaclofen
1039625|NCT01844219|aortic surgery
1039626|NCT01844219|acute kidney injury
1039627|NCT01844219|gray zone approach
1039628|NCT01844206|Post-cesarean analgesia
1039629|NCT01844206|Second dose of epidural morphine after surgery
1039630|NCT01844206|Post-operative analgesia
1039631|NCT01844206|Self-administered epidural morphine
1039632|NCT01844206|Pain management after cesarean
1039633|NCT01844180|Irritable Bowel Syndrome
1039634|NCT01844180|IBS
1039635|NCT01844180|ONO-2952
1039636|NCT01844167|noxipoint
1039637|NCT01844167|physical therapy
1039638|NCT01844167|cervical pain
1039639|NCT01844167|trigger point
1039640|NCT01844167|neck pain
1039641|NCT01844167|TENS
1039642|NCT01844167|transcutaneous electrical nerve stimulation
1039643|NCT01844141|phenol
1039644|NCT01844141|ingrown toenail
1039645|NCT01844141|chemical matricectomy
1039646|NCT01844128|MMA, AFC, Ovarian reserve
1039647|NCT01844115|Generalized Anxiety Disorder, GAD
1039648|NCT01844102|HIV Prevention, PrePex, voluntary medical circumcision, non-surgical,
1039649|NCT01844102|medical device, wound healing, Zambia
1039650|NCT01844089|Postpartum hemorrhage
1039651|NCT01844089|Bakri Postpartum Balloon
1039652|NCT01844076|advanced stage colorectal adenocarcinoma
1039653|NCT01844050|Chinese herbal medicine
1039654|NCT01844050|diabetes symptoms
1039655|NCT01844011|fetal movement
1039656|NCT01844011|pregnancy
1039657|NCT01843998|Early stage
1039658|NCT01843998|Stage 1A
1039659|NCT01843998|Cutaneous T-cell Lymphoma
1039660|NCT01843998|CTCL
1039661|NCT01843985|Stage IV cancer
1039662|NCT01843985|Survival
1039663|NCT01843959|adenovirus-36
1039664|NCT01843959|Emirati population
1039665|NCT01843920|eye
1039666|NCT01843920|pneumatic retinopexy
1039667|NCT01843920|topical
1039668|NCT01843894|sever dry eye,keratoconjunctivitis sicca
1039669|NCT01843881|Gastric Bypass
1039670|NCT01843881|bariatric surgery
1039671|NCT01843881|carbohydrate metabolism
1039672|NCT01843868|Lymphoma
1039673|NCT01843868|Non-Hodgkin
1039674|NCT01843868|Emesis
1039675|NCT01843868|Chemotherapy
1039676|NCT01843868|Nausea
1039677|NCT01843868|Vomiting
1039678|NCT01843868|Aprepitant
1039679|NCT01843855|Gastric Bypass
1039680|NCT01843855|bariatric surgery
1039681|NCT01843855|glucose metabolism
1039682|NCT01843829|Oesophageal cancer
1039683|NCT01843816|Tragus-to-wall distance
1039684|NCT01843816|obesity
1039685|NCT01843816|body shape
1039686|NCT01843816|height
1039687|NCT01843816|weight
1039688|NCT01843803|patient centered care
1039689|NCT01843803|collaborative decision making
1039690|NCT01843803|cost impact
1039691|NCT01843777|hearing loss
1039692|NCT01843777|hearing aids
1039693|NCT01843777|motivational interviewing
1039694|NCT01843777|counseling
1039695|NCT01843777|rehabilitation
1039696|NCT01843764|RDT
1039697|NCT01843764|malaria
1039698|NCT01843764|treatment follow up
1039699|NCT01843764|diagnosis
1039700|NCT01843725|breast cancer
1039701|NCT01843725|digestive cancer
1039702|NCT01843712|Caloric compensation
1039703|NCT01843712|Eating in the absence of hunger
1039704|NCT01843712|Children
1039705|NCT01843712|Parental feeding practices
1039711|NCT01843673|Lip, Oral Cavity and Pharynx
1039712|NCT01843673|Larynx
1039713|NCT01843660|Low back pain
1039714|NCT01843660|Shoulder pain
1039715|NCT01843660|Neck pain
1039716|NCT01843660|Tramadol hydrochloride
1039717|NCT01843660|Paracetamol
1039718|NCT01843621|Dengue, Vaccine, Thailand
1039719|NCT01843608|Physical treatment
1039720|NCT01843608|Exercise prescription to breast cancer survival
1039721|NCT01843608|Side cancer effect treatment
1039722|NCT01843582|Keyword: blind spot
1039723|NCT01843569|In Vitro Maturation
1039724|NCT01843569|IVM
1039725|NCT01843569|Natural cycle IVF
1039726|NCT01843569|PCOS
1039727|NCT01843543|Functional MRI (fMRI)
1039728|NCT01843543|Resting state functional connectivity MRI (rs-fcMRI)
1039729|NCT01843543|Diffusion Tensor Imaging (DTI)
1039730|NCT01843517|Pain
1039731|NCT01843517|Facilitation
1039732|NCT01843517|Inhibition
1039733|NCT01843517|Oxytocin
1039734|NCT01843517|Postpartum
1039735|NCT01843504|platelet rich plasma
1039736|NCT01843504|PRP
1039737|NCT01843504|plasma
1039738|NCT01843504|plasma injection
1039739|NCT01843504|patellar tendinopathy
1039740|NCT01843504|patella tendon
1039741|NCT01843504|patella
1039742|NCT01843504|ultrasound
1039743|NCT01843504|shear wave ultrasound
1039744|NCT01843504|tendinosis
1039745|NCT01843504|tendinopathy
1039746|NCT01843504|tendinitis
1039747|NCT01843504|jumper's knee
1039748|NCT01843478|women
1039749|NCT01843478|human immunodeficiency virus
1039750|NCT01843478|cervical cancer screening
1039751|NCT01843478|Pap testing
1039752|NCT01843478|human papillomavirus
1039753|NCT01843465|atrial fibrillation
1039754|NCT01843465|balloon cryoablation
1039755|NCT01843465|pulmonary veins
1039756|NCT01843439|Acute exacerbation
1039757|NCT01843439|Quality of life
1039758|NCT01843439|Magnesium deficiency
1039759|NCT01843439|Multidisciplinary intervention
1039760|NCT01843426|Comorbidity
1039761|NCT01843413|unspecified adult solid tumor, protocol specific
1039762|NCT01843400|Regorafenib
1039763|NCT01843400|Colorectal Neoplasms
1039764|NCT01843387|Diabetic nephropathy
1039765|NCT01843387|Chronic kidney disease
1039766|NCT01843387|Metabolic disease
1039767|NCT01843387|Diabetes mellitus, type 2
1039768|NCT01843374|tremelimumab
1039769|NCT01843374|pleural, peritoneal
1039770|NCT01843374|malignant mesothelioma
1039771|NCT01843374|CTLA-4
1039772|NCT01843361|Stroke
1039773|NCT01843361|Clopidogrel
1039774|NCT01843361|Aggregometry
1039775|NCT01843361|Antiplatelet therapy
1039776|NCT01843361|Platelet function tests
1039777|NCT01843348|Transplant
1039778|NCT01843348|Renal transplant
1039779|NCT01843348|Rejection,allograf
1039780|NCT01843348|Rejection
1039781|NCT01843348|Xenograft rejection
1039782|NCT01843348|Host vs graft disease
1039783|NCT01843348|Kidney Transplant
1039784|NCT01843335|Cardiovascular Diagnostic Technique
1039785|NCT01843335|Ultrasound
1039786|NCT01843322|Image guided therapy
1039787|NCT01843322|Endovascular procedures
1039788|NCT01843322|Angiography
1039789|NCT01843322|Vascular surgical procedures
1039790|NCT01843296|Spinal Anesthesia
1039791|NCT01843296|Bupivacaine
1039792|NCT01843296|Fentanyl
1039793|NCT01843296|Magnesium sulfate
1039794|NCT01843296|Postoperative Pain
1039795|NCT01843283|Mild Cognitive Impairment
1039796|NCT01843283|Family Caregivers
1039797|NCT01843283|Intervention studies
1039798|NCT01843270|general anesthesia
1039799|NCT01843270|body weight
1039800|NCT01843270|laryngeal mask airway size
1039801|NCT01843257|Alcohol intake after bariatric surgery
1039802|NCT01843257|Alcohol and bariatric surgery
1039803|NCT01843244|plethysmography
1039804|NCT01843231|g-Cath EZ Suture Anchor Delivery Catheter
1039805|NCT01843231|Weight Loss Intervention
1039806|NCT01843218|Localized rectal cancer in a male patient
1039807|NCT01843179|Newly diagnosed
1039808|NCT01843179|Complete Remission
1039809|NCT01843166|Pessary
1039810|NCT01843166|Patient Satisfaction
1039811|NCT01843166|Estrogen Cream
1039812|NCT01843153|pain score
1039813|NCT01843140|cancer
1039814|NCT01843140|fertility preservation
1039815|NCT01843140|infertility
1039816|NCT01843140|pregnancy
1039817|NCT01843114|Retinal blood flow
1039818|NCT01843114|Retinal vessel diameter
1039819|NCT01843114|Fourier Domain Optical Coherence Tomography
1039820|NCT01843114|Retinal blood velocities
1039821|NCT01843101|Optical Coherence Tomography
1039822|NCT01843101|Cornea
1039823|NCT01843101|Imaging
1039824|NCT01843088|Pain
1039825|NCT01843088|exercise
1039826|NCT01843088|muscle
1039827|NCT01843062|Selumetinib, Differentiated Thyroid Cancer , AZD6244
1039828|NCT01843036|Child Abuse
1039829|NCT01843036|Child Neglect
1039830|NCT01843036|Child Emergency Medical Care Presentations
1039831|NCT01843036|Child Well-Care Compliance
1039832|NCT01843036|Mother Well-Care Compliance
1039833|NCT01843036|Mother Emergency Medical Care Presentations
1039834|NCT01843036|Mother Mental Health
1039835|NCT01843036|Family Connections to Community Resources
1039836|NCT01843036|Parent-Child Relationship Quality
1039837|NCT01843023|opioid dependence
1039838|NCT01843010|NSAIDs
1039839|NCT01843010|Hyperalgesia
1039840|NCT01843010|Postlaparoscopic shoulder pain
1039841|NCT01842997|Flu
1039842|NCT01842997|non-adjuvanted H1N1 vaccine
1039843|NCT01842997|Safety
1039844|NCT01842997|pregnant women
1039845|NCT01842984|Loneliness
1039846|NCT01842984|Social isolation
1039847|NCT01842984|Depression
1039848|NCT01842984|Older adults
1039849|NCT01842984|Social competence
1039850|NCT01842984|Social integration
1039851|NCT01842971|two stage hepatectomy
1039852|NCT01842971|liver metastasis
1039853|NCT01842971|colorectal cancer
1039854|NCT01842958|Dental Implant
1039855|NCT01842945|Procrastination
1039856|NCT01842945|internet based cognitive behavior therapy
1039857|NCT01842945|randomized controlled trial
1039858|NCT01842932|Colonoscopy
1039859|NCT01842932|Anticholinergics
1039860|NCT01842906|positive end expiratory pressure
1039861|NCT01842906|acute mountain sickness
1039862|NCT01842906|prevention
1039863|NCT01842906|high altitude
1039864|NCT01842893|fentanyl
1039865|NCT01842893|breakthrough pain
1039866|NCT01842893|opioid treated cancer patients
1039867|NCT01842880|MicroRNAs
1039868|NCT01842880|Chagas disease
1039869|NCT01842880|Biomarkers
1039870|NCT01842867|Syndecan-4
1039871|NCT01842867|Chagas disease
1039872|NCT01842867|Biomarkers
1039873|NCT01842854|Galectin-3
1039874|NCT01842854|Chagas disease
1039875|NCT01842854|Biomarkers
1039876|NCT01842789|Acessa
1039877|NCT01842789|Fibroids
1039878|NCT01842789|Halt
1039879|NCT01842789|Targeting Animation
1039880|NCT01842789|Image Overlay
1039881|NCT01842789|Radiofrequency Ablation
1039882|NCT01842789|RFA
1039883|NCT01842763|Chronic daily headache
1039884|NCT01842763|treated by occipital nerves stimulation
1039885|NCT01842763|peripheral neuromodulation
1039886|NCT01842763|occipital nerves
1039887|NCT01842763|network
1039888|NCT01842763|database
1039889|NCT01842737|Low Back Pain
1039890|NCT01842737|Chiropractic
1039891|NCT01842737|Spinal Manipulation
1039892|NCT01842737|Massage
1039893|NCT01842698|Thoracotomy surgery
1039894|NCT01842698|Anesthesia
1039895|NCT01842698|Ultrasound-guided PVB
1039896|NCT01842698|Post-operative pain
1039897|NCT01842685|Overactive Bladder
1039898|NCT01842685|Bladder Distention
1039899|NCT01842672|pediatric non-hodgkins lymphoma
1039900|NCT01842672|pediatric acute leukemia
1039901|NCT01842672|clofarabine
1039902|NCT01842672|mitoxantrone
1039903|NCT01842659|MI
1039904|NCT01842659|amniocentesis
1039905|NCT01842659|cord blood
1039906|NCT01842659|placenta
1039907|NCT01842659|Silver Russell Syndrome
1039908|NCT01842659|Beckwith Wiedemann Syndrome
1039909|NCT01842646|Leukemia
1039910|NCT01842646|Myeloid Malignancies
1039911|NCT01842620|Metformin
1039912|NCT01842620|Bioequivalence
1039913|NCT01842607|eosinophils
1039914|NCT01842607|mepolizumab
1039915|NCT01842607|SB-240563
1039916|NCT01842607|safety
1039917|NCT01842607|extension study
1039918|NCT01842607|Severe refractory asthma
1039919|NCT01842594|Sarcoma, Hydroxychloroquine, Sirolimus, PET
1039920|NCT01842581|Liver Failure
1039921|NCT01842581|Hepatic Insufficiency
1039922|NCT01842581|Liver Diseases
1039923|NCT01842581|Brain Diseases
1039924|NCT01842581|Rifaximin
1039925|NCT01842581|Cirrhosis
1039926|NCT01842568|Cardiac surgery
1039927|NCT01842568|Troponin
1039928|NCT01842568|Vascular events
1039929|NCT01842568|Myocardial injury
1039930|NCT01842568|Observational cohort study
1039931|NCT01842568|Public health
1039932|NCT01842555|PDT
1039933|NCT01842555|Photodynamic therapy
1039934|NCT01842542|Postpartum Depression, NeuroStar TMS Therapy, TMS
1039935|NCT01842503|alcohol dependence
1039936|NCT01842503|cue reactivity
1039937|NCT01842503|alcohol self administration
1039938|NCT01842490|Biomarker
1039939|NCT01842490|Carotid enhanced ultrasound
1039940|NCT01842490|Intraplaque neovascularization
1039941|NCT01842438|Sexual Dysfunctions, Psychological
1039942|NCT01842425|Liver volume
1039943|NCT01842425|Gastric bypass
1039944|NCT01842425|Magnetic resonance imaging
1039945|NCT01842412|Mitochondria, Muscle
1039946|NCT01842412|Exercise
1039947|NCT01842399|Vascular Stiffness
1039948|NCT01842399|Aging
1039949|NCT01842399|Resveratrol
1039950|NCT01842399|Aerobic Capacity
1039951|NCT01842399|Inflammation
1039952|NCT01842386|Anti-CD20
1039953|NCT01842386|Anticytokine Autoanitbody-Associated Disease
1039954|NCT01842386|Rituximab
1039955|NCT01842373|topical anesthetics
1039956|NCT01842373|laser resurfacing
1039957|NCT01842360|Vaccine
1039958|NCT01842360|Chronic obstructive pulmonary disease (COPD)
1039959|NCT01842334|Nicotine Dependence
1039960|NCT01842334|Smoking Cessation
1039961|NCT01842334|D-cycloserine
1039962|NCT01842321|locally advanced
1039963|NCT01842321|metastatic
1039964|NCT01842321|Breast Cancer
1039965|NCT01842321|Molecular Apocrine
1039966|NCT01842321|HER2-negative
1039967|NCT01842321|Abiraterone acetate
1039968|NCT01842295|Obesity
1039969|NCT01842295|Bariatric surgery
1039970|NCT01842295|Sperm quality
1039971|NCT01842295|Fertility
1039972|NCT01842282|diabetes mellitus type 2
1039973|NCT01842282|non alcoholic fatty liver disease
1039974|NCT01842282|obesity
1039975|NCT01842282|amlexanox
1039976|NCT01842269|Mycophenolate Mofetil
1039977|NCT01842269|MMF
1039978|NCT01842256|Telminouveau
1039979|NCT01842256|Atorvastatin
1039980|NCT01842256|Pharmacokinetic
1039981|NCT01842256|Healthy volunteers
1039982|NCT01842243|Ventricular dysfunction
1039983|NCT01842243|MRI
1039984|NCT01842243|Echocardiography
1039985|NCT01842243|Pacemakers
1039986|NCT01842230|Telminuvo
1039987|NCT01842230|Telmisartan
1039988|NCT01842230|S-amlodipine
1039989|NCT01842230|Atorvastatin
1039990|NCT01842230|pharmacokinetics
1039991|NCT01842230|Healthy volunteers
1039992|NCT01842217|18F-FES PET
1039993|NCT01842217|Nuclear Medicine
1039994|NCT01842217|Premenopausal
1039995|NCT01842217|Postmenopausal
1039996|NCT01842217|Estrogen receptor
1039997|NCT01842217|Anxiety
1039998|NCT01842217|Depression
1039999|NCT01842217|Cognition
1040000|NCT01842204|inguinal hernia
1040001|NCT01842191|R-R MS
1040002|NCT01842165|Peptide Receptor Radionuclide Therapy (PRRT)
1040003|NCT01842165|Neuroendocrine Tumors
1040004|NCT01842126|Sciatica
1040005|NCT01842100|Induced abortion
1040006|NCT01842100|Postaboral pelvic inflammatory disease
1040007|NCT01842100|Sexually transmitted infections
1040008|NCT01842100|Universal antibiotic prophylaxis
1040009|NCT01842100|Screen-and-treat approach
1040010|NCT01842087|Chronic Kidney Disease
1040011|NCT01842087|Fiber
1040012|NCT01842087|BUN
1040013|NCT01842087|Serum Creatinine
1040014|NCT01842087|Uremic Symptoms
1040015|NCT01842087|Quality of Life
1040016|NCT01842074|bortezomib
1040017|NCT01842074|desensitization
1040018|NCT01842074|living kidney transplantation
1040019|NCT01842061|active living
1040020|NCT01842061|retirement
1040021|NCT01842048|External-beam radiotherapy
1040022|NCT01842048|Hyperthermia
1040023|NCT01842035|Implantable cardiac defibrillator
1040024|NCT01842035|regadenoson
1040025|NCT01842035|sudden cardiac death
1040026|NCT01842035|heart rate response
1040027|NCT01842022|Glycemic load
1040028|NCT01842022|memory
1040029|NCT01842022|mood
1040030|NCT01842009|transcranial stimulation
1040031|NCT01842009|direct current
1040032|NCT01841983|Total worker health
1040033|NCT01841983|Sleep
1040034|NCT01841983|MSDs
1040035|NCT01841983|Diet
1040036|NCT01841983|Physical Activity
1040037|NCT01841957|Bilateral Cataract
1040038|NCT01841957|Simultaneous Cataract Surgery
1040039|NCT01841957|ISBCS
1040040|NCT01841944|Fatty Acids, Omega-3
1040041|NCT01841944|Aged
1040042|NCT01841944|Myocardial Infarction
1040043|NCT01841931|Opioids
1040044|NCT01841931|Dependence
1040045|NCT01841931|Buprenorphine
1040046|NCT01841931|Pain
1040047|NCT01841905|Alzheimer's Disease
1040048|NCT01841905|Family History
1040049|NCT01841905|Memory Concerns
1040050|NCT01841866|post operative sore throat
1040051|NCT01841866|laryngeal mask airway
1040052|NCT01841866|children
1040053|NCT01841853|Elderly
1040054|NCT01841853|Health promotion
1040055|NCT01841853|Randomized controlled study
1040056|NCT01841853|Immigrant
1040057|NCT01841853|Vulnerable population
1040058|NCT01841853|ADL
1040059|NCT01841853|KASAM
1040060|NCT01841853|Implementation
1040061|NCT01841840|Stroke
1040062|NCT01841840|Hemiparetic
1040063|NCT01841840|Passive Vibration
1040064|NCT01841840|Arterial Stiffness
1040065|NCT01841840|Pulse Wave Velocity
1040066|NCT01841840|Wave Reflection
1040067|NCT01841840|Body Composition
1040068|NCT01841840|Autonomic Function
1040069|NCT01841814|Lymphoma
1040070|NCT01841814|Osteoporosis
1040071|NCT01841814|Chemotherapy
1040072|NCT01841814|Patient with
1040073|NCT01841775|Hepatitis C, Chronic
1040074|NCT01841775|Genotype 2/3
1040075|NCT01841775|Interferon α 2b
1040076|NCT01841775|Ribavirin
1040077|NCT01841775|Pharmacovigilance
1040078|NCT01841762|PAH-SYMPACT
1040079|NCT01841762|Pulmonary Arterial Hypertension
1040080|NCT01841762|psychometric instrument
1040081|NCT01841749|Breast cancer
1040082|NCT01841710|Bitter Taste
1040083|NCT01841710|Pediatric Medications
1040084|NCT01841697|Diabetes Mellitus
1040085|NCT01841697|Diabetes Mellitus, Type 2
1040086|NCT01841697|Glucose Metabolism Disorders
1040087|NCT01841697|Metabolic Diseases
1040088|NCT01841697|Endocrine System Diseases
1040089|NCT01841697|Glimepiride
1040090|NCT01841697|Metformin
1040091|NCT01841697|Hypoglycemic Agents
1040092|NCT01841697|Physiological Effects of Drugs
1040093|NCT01841697|Pharmacologic Actions
1040094|NCT01841684|HoFH
1040095|NCT01841671|Polio
1040096|NCT01841671|IPV
1040097|NCT01841671|bOPV
1040098|NCT01841671|mOPV
1040099|NCT01841671|vaccination
1040100|NCT01841658|Folate Status
1040101|NCT01841658|Folate Biomarkers
1040102|NCT01841645|CLA-enriched butter
1040103|NCT01841645|CLA metabolism
1040104|NCT01841645|inflammation
1040105|NCT01841632|Liver transplantation
1040106|NCT01841632|Allogeneic liver transplantation
1040107|NCT01841632|Solid organ transplantation
1040234|NCT01840982|Mixed grains
1040108|NCT01841619|skin, lupus, intravenous immunoglobulin, ivig
1040109|NCT01841606|Spinal anesthesia
1040110|NCT01841606|Elective cesarean deliveries
1040111|NCT01841606|Ondansetron
1040112|NCT01841580|Tear proteins profiles
1040113|NCT01841580|Longitudinal
1040114|NCT01841580|Ocular surface damage
1040115|NCT01841580|Trabeculectomy
1040116|NCT01841567|hip
1040117|NCT01841567|knee
1040118|NCT01841554|Mitral Valve
1040119|NCT01841554|Annuloplasty
1040120|NCT01841541|Tuberculosis
1040121|NCT01841541|Informal providers
1040122|NCT01841541|Informal carers
1040123|NCT01841541|Barriers to health system
1040124|NCT01841528|Polycystic Ovary Syndrome
1040125|NCT01841528|Infertility
1040126|NCT01841528|In-vitro fertilization
1040127|NCT01841528|fresh embryo transfer
1040128|NCT01841528|frozen-thawed embryo transfer
1040129|NCT01841502|telaprevir
1040130|NCT01841502|paroxetine
1040131|NCT01841502|interaction
1040132|NCT01841502|pharmacokinetics
1040133|NCT01841489|Chronic Lymphocytic Leukemia
1040134|NCT01841489|CLL
1040135|NCT01841476|Peripheral blood
1040136|NCT01841476|HSC
1040137|NCT01841476|Mobilization
1040138|NCT01841476|CXCR4
1040139|NCT01841476|volunteers
1040140|NCT01841463|Malignant Melanoma
1040141|NCT01841450|Primary open-angle glaucoma (POAG)
1040142|NCT01841450|Trabecular meshwork
1040143|NCT01841450|iStent
1040144|NCT01841437|Primary open-angle glaucoma (POAG)
1040145|NCT01841437|Trabecular meshwork
1040146|NCT01841437|iStent
1040147|NCT01841424|dietary counseling
1040148|NCT01841424|food diary
1040149|NCT01841424|obesity
1040150|NCT01841424|pregnancy
1040151|NCT01841424|weight gain
1040152|NCT01841411|bacterial vaginosis, recurrence, N-Acetyl cysteine
1040153|NCT01841398|Cardiovascular
1040154|NCT01841398|Prevention
1040155|NCT01841398|Ethnicity
1040156|NCT01841398|Culture
1040157|NCT01841398|Internet
1040158|NCT01841398|Text Message
1040159|NCT01841385|Exercise
1040160|NCT01841385|spirometry
1040161|NCT01841385|muscle strength
1040162|NCT01841385|physical therapy modalities
1040163|NCT01841372|Obesity
1040164|NCT01841372|Overweight
1040165|NCT01841372|Weight Maintenance
1040166|NCT01841359|Hypoglycemia
1040167|NCT01841359|Gastric bypass surgery
1040168|NCT01841346|Outcome after PCI
1040169|NCT01841346|Middle Eastern Patients
1040170|NCT01841333|Lymphoblastic leukemia in remission
1040171|NCT01841333|Myeloid leukemia in remission
1040172|NCT01841333|Recurrent lymphoblastic leukemia
1040173|NCT01841333|Recurrent myeloid leukemia
1040174|NCT01841281|Asthma
1040175|NCT01841281|Severe Asthma
1040176|NCT01841268|premature, preterm, premie, skin
1040177|NCT01841255|Preoxygenation
1040178|NCT01841255|Device
1040179|NCT01841255|Tolerability
1040180|NCT01841255|Efficacy
1040181|NCT01841242|Infection
1040182|NCT01841242|Cardiac Resynchronization Device
1040183|NCT01841242|Heart Failure
1040184|NCT01841216|Gluteus Maximus
1040185|NCT01841216|Gluteus Medius
1040186|NCT01841216|TFL
1040187|NCT01841216|EMG
1040188|NCT01841216|Perceived Exertion
1040189|NCT01841216|Thera-Band
1040190|NCT01841203|Diagnosis
1040191|NCT01841203|Rapid tests
1040192|NCT01841203|non-treponemal serology
1040193|NCT01841203|eradication
1040194|NCT01841190|Prognosis
1040195|NCT01841190|Sepsis
1040196|NCT01841190|Septic shock
1040197|NCT01841190|Procalcitonin
1040198|NCT01841190|SOFA
1040199|NCT01841177|Congenital Heart Disease
1040200|NCT01841177|Pediatrics
1040201|NCT01841177|Milrinone
1040202|NCT01841177|Cardiopulmonary Bypass
1040203|NCT01841177|Therapeutic Drug Monitoring
1040204|NCT01841164|Leukotriene responsiveness
1040205|NCT01841164|LTE4
1040206|NCT01841164|asthma
1040207|NCT01841164|airway hyperresponsiveness
1040208|NCT01841164|bronchoprovocation
1040209|NCT01841164|anti-asthmatic agents
1040210|NCT01841164|human
1040211|NCT01841151|AD/HD in Children and Adolescents
1040212|NCT01841138|colonoscopy
1040213|NCT01841138|bowel preparation
1040214|NCT01841138|electrolytes
1040215|NCT01841138|osmolality
1040216|NCT01841138|water
1040217|NCT01841125|Alzheimer's Disease
1040218|NCT01841125|depressive disorder
1040219|NCT01841073|Prediabetes
1040220|NCT01841073|Fermentable carbohydrate
1040221|NCT01841073|Appetite
1040222|NCT01841073|Glucose homeostasis
1040223|NCT01841073|Weight management
1040224|NCT01841060|Malignant Non-small Cell Neoplasm of Lung
1040225|NCT01841047|Retroperitoneal liposarcoma operable
1040226|NCT01841034|Male
1040227|NCT01841021|Peripheral T-Cell Lymphoma (PTCL)
1040228|NCT01841021|Relapsed
1040229|NCT01841021|Refractory
1040230|NCT01841021|CD30 Receptor
1040231|NCT01841021|Large B-Cell Lymphoma
1040232|NCT01841008|[C17.800.621]
1040233|NCT01840995|stellate ganglion block
1040235|NCT01840982|Glycemic index
1040236|NCT01840982|Giant embryonic brown rice
1040237|NCT01840982|Giant embryonic rice
1040238|NCT01840982|diabetes
1040239|NCT01840969|off-pump coronary artery bypass surgery
1040240|NCT01840969|common carotid artery
1040241|NCT01840969|speckle tracking analysis
1040242|NCT01840969|peak strain
1040243|NCT01840956|End-stage Renal Disease
1040244|NCT01840956|Hemodialysis
1040245|NCT01840956|Chronic Renal Insufficiency
1040246|NCT01840956|Renal Dialysis
1040247|NCT01840956|Hemodiafiltration
1040248|NCT01840956|Blood Vessel Prosthesis
1040249|NCT01840956|Tissue-Engineered Vascular Graft
1040250|NCT01840956|Vascular Prosthesis Implantation
1040251|NCT01840956|Kidney Diseases
1040252|NCT01840956|Kidney Failure, Chronic
1040253|NCT01840956|Renal Insufficiency
1040254|NCT01840956|Urologic Diseases
1040255|NCT01840943|Epithelial ovarian cancer
1040256|NCT01840943|Recurrent epithelial ovarian carcinoma
1040257|NCT01840943|Carcinoma
1040258|NCT01840943|Malignancy
1040259|NCT01840943|Ovarian carcinoma
1040260|NCT01840943|CAELYX
1040261|NCT01840943|Topotecan hydrochloride
1040262|NCT01840943|Topotecan
1040263|NCT01840943|Platinum-based regimen chemotherapy
1040264|NCT01840943|Chinese patients
1040265|NCT01840930|Cohort
1040266|NCT01840930|Cerebral Palsy
1040267|NCT01840930|Children
1040268|NCT01840930|Pain
1040269|NCT01840930|Orthopedic complications
1040270|NCT01840930|Epidemiology
1040271|NCT01840865|young healthy subjects
1040272|NCT01840865|brain stimulation
1040273|NCT01840865|tSOS
1040274|NCT01840865|tDCS
1040275|NCT01840865|sleep
1040276|NCT01840865|daytime sleep
1040277|NCT01840865|nap
1040278|NCT01840865|memory
1040279|NCT01840865|memory consolidation
1040280|NCT01840839|aging
1040281|NCT01840839|cognitive decline
1040282|NCT01840839|brain stimulation
1040283|NCT01840839|tSOS
1040284|NCT01840839|tDCS
1040285|NCT01840839|sleep
1040286|NCT01840839|nap
1040287|NCT01840839|daytime sleep
1040288|NCT01840839|memory
1040289|NCT01840839|memory consolidation
1040290|NCT01840826|Rehospitalization
1040291|NCT01840826|Reutilization
1040292|NCT01840826|Depressive Symptoms
1040293|NCT01840826|Pharmacotherapy
1040294|NCT01840826|Cognitive Therapy
1040295|NCT01840826|Self-help
1040296|NCT01840826|Complementary Therapies
1040297|NCT01840813|Intraumbilical misoprostol
1040298|NCT01840813|Retained placenta
1040299|NCT01840813|Active management of third stage of labour
1040300|NCT01840800|Postoperative pain
1040301|NCT01840800|anterior cruciate ligament reconstruction
1040302|NCT01840800|ultrasound guided nerve blocks
1040303|NCT01840800|opioid consumption
1040304|NCT01840761|delayed vasospasm,
1040305|NCT01840761|medicine,
1040306|NCT01840761|standardization
1040307|NCT01840735|CF
1040308|NCT01840735|Cystic Fibrosis
1040309|NCT01840735|PK
1040310|NCT01840722|HIV
1040311|NCT01840722|HCV
1040312|NCT01840722|Substance abuse
1040313|NCT01840722|women
1040314|NCT01840709|Systemic lupus erythematosus
1040315|NCT01840709|Psychotherapy
1040316|NCT01840683|Age-Related Macular Degeneration (AMD)
1040317|NCT01840683|Age Related Eye Disease Study (AREDS)
1040318|NCT01840683|Best-Corrected Visual Acuity (BCVA)
1040319|NCT01840683|Early Treatment Diabetic Retinopathy Study (ETDRS)
1040320|NCT01840683|Heparin-Induced Extracorporeal LDL-Cholesterol Precipitation (HELP)
1040321|NCT01840683|Visual Function Questionnaire (VFQ)
1040322|NCT01840670|Inferior Vena Cava
1040323|NCT01840670|Central Venous Pressure
1040324|NCT01840670|Abdominal Pressure
1040325|NCT01840657|CMDIR (Congenital Muscle Disease International Registry)
1040326|NCT01840657|X-linked myotubular myopathy
1040327|NCT01840657|centronuclear myopathy
1040328|NCT01840657|myotubularin
1040329|NCT01840657|MTM1 gene
1040330|NCT01840657|mutation
1040331|NCT01840657|survival
1040332|NCT01840657|adverse event
1040333|NCT01840657|disease complication
1040334|NCT01840657|hospital admission
1040335|NCT01840657|emergency room visit
1040336|NCT01840657|motor function
1040337|NCT01840657|respiratory function
1040338|NCT01840657|natural history study
1040339|NCT01840631|Obesity
1040340|NCT01840631|Nutritional counseling
1040341|NCT01840631|Physical activity
1040342|NCT01840631|Food diary
1040343|NCT01840618|insulin function
1040344|NCT01840618|sleep apnea
1040345|NCT01840618|girls
1040346|NCT01840618|PCOS
1040347|NCT01840618|insulin action
1040348|NCT01840592|Liver
1040349|NCT01840592|Sorafenib
1040350|NCT01840592|Doxorubicin
1040351|NCT01840592|12-259
1040352|NCT01840566|Relapsed
1040353|NCT01840566|Refractory
1040354|NCT01840566|Autologous Stem Cell Transplantation
1040355|NCT01840566|HIGH DOSE CHEMOTHERAPY
1040356|NCT01840566|19-28z T cells/kg
1040357|NCT01840566|12-117
1040358|NCT01840540|renal artery stenosis
1040359|NCT01840540|renovascular hypertension
1040360|NCT01840540|ischemic nephropathy
1040361|NCT01840540|chronic kidney disease
1040362|NCT01840527|Biomarker
1040363|NCT01840527|BRAF
1040364|NCT01840527|blood-based
1040365|NCT01840514|recipient
1040366|NCT01840501|Healthy
1040367|NCT01840501|JNJ-42721458
1040368|NCT01840501|Male
1040369|NCT01840501|Safety
1040370|NCT01840501|Tolerability
1040371|NCT01840501|Pharmacokinetics
1040372|NCT01840501|Pharmacodynamics
1040373|NCT01840501|Immunogenicity
1040374|NCT01840436|MUCIPLIQ
1040375|NCT01840436|Matrix therapy
1040376|NCT01840436|RGTA
1040377|NCT01840436|Oral mucositis
1040378|NCT01840423|First in man study
1040379|NCT01840423|Volunteer study
1040380|NCT01840410|Vision Impairment
1040381|NCT01840410|Abnormal growth of blood vessels
1040382|NCT01840397|S-100B
1040383|NCT01840397|NSE
1040384|NCT01840384|Healthy infants
1040385|NCT01840384|Anemia, iron-deficiency
1040386|NCT01840371|ERCP
1040387|NCT01840371|Sedation
1040388|NCT01840371|Fentanyl
1040389|NCT01840371|Propofol
1040390|NCT01840358|Hypoglycemias
1040391|NCT01840358|Insulin pump
1040392|NCT01840358|Children
1040393|NCT01840345|uncontrolled
1040394|NCT01840345|neuropathic pain
1040395|NCT01840332|thyroid cancer
1040396|NCT01840280|carcinoma
1040397|NCT01840280|colorectal cancer
1040398|NCT01840280|ambulant chemotherapy
1040399|NCT01840280|treatment cycles
1040400|NCT01840280|Irinotecan
1040401|NCT01840280|Irinotecan onkovis
1040402|NCT01840280|Quantity of Irinotecan
1040403|NCT01840280|Packaging Sizes
1040404|NCT01840267|pneumoperitoneum
1040405|NCT01840267|pediatric laparoscopy
1040406|NCT01840267|optic nerve sheath diameter
1040407|NCT01840267|intracranial pressure
1040408|NCT01840254|PONV
1040409|NCT01840254|IV PCA
1040410|NCT01840254|dexmedetomidine
1040411|NCT01840254|Female
1040412|NCT01840254|non-smoking
1040413|NCT01840254|lumbar spine surgery
1040414|NCT01840241|sodium bicarbonate
1040415|NCT01840241|acute kidney injury
1040416|NCT01840241|OPCAB
1040417|NCT01840228|Preterm
1040418|NCT01840228|Progesterone
1040419|NCT01840189|Addison disease
1040420|NCT01840189|Type 1 diabetes
1040421|NCT01840189|treatment
1040422|NCT01840176|McCall culdoplasty
1040423|NCT01840176|Total laparoscopic hysterectomy
1040424|NCT01840176|Vaginal vault prolapse
1040425|NCT01840176|Sexual function
1040426|NCT01840124|Fibroids
1040427|NCT01840124|Radiofrequency ablation
1040428|NCT01840111|smoking environment
1040429|NCT01840111|cue-exposure
1040430|NCT01840111|cigarettes
1040431|NCT01840111|nicotine
1040432|NCT01840111|fMRI
1040433|NCT01840085|Diabetic foot ulcer
1040434|NCT01840085|plantar neuropathic ulcer
1040435|NCT01840085|plantar neuroischemic ulcer
1040436|NCT01840085|Wagner Grade 1 or Grade 2 DFU
1040437|NCT01840072|Ischemic stroke
1040438|NCT01840072|Hypertension
1040439|NCT01840072|Antihypertensive Agents
1040440|NCT01840072|Randomized Controlled Trial
1040441|NCT01840059|Cardiac Failure
1040442|NCT01840059|Autonomic Denervation
1040443|NCT01840020|bariatric surgery
1040444|NCT01840020|alcohol drinking
1040445|NCT01840020|alcoholism
1040446|NCT01840020|ethanol
1040447|NCT01840020|metabolism
1040448|NCT01839994|prostate cancer,
1040449|NCT01839994|high-dose-rate brachytherapy boost,
1040450|NCT01839994|stereotactic body radiotherapy boost,
1040451|NCT01839994|conformal radiotherapy,
1040452|NCT01839994|randomized trial
1040453|NCT01839942|Hernia, Ventral
1040454|NCT01839929|tacrolimus
1040455|NCT01839929|immunosuppressant
1040456|NCT01839929|FK506
1040457|NCT01839903|Smoking
1040458|NCT01839903|Tobacco
1040459|NCT01839903|Emergency Department
1040460|NCT01839890|Paclitaxel
1040461|NCT01839890|stent
1040462|NCT01839890|Acute infarction
1040463|NCT01839890|Systolic time elevation
1040464|NCT01839877|Metastatic colorectal Cancer
1040465|NCT01839864|Promotoras
1040466|NCT01839864|Hispanic Adults
1040467|NCT01839864|metabolic syndrome
1040468|NCT01839864|rural
1040469|NCT01839864|patient attitudes
1040470|NCT01839864|provider cultural competency
1040471|NCT01839864|patient activation measure
1040472|NCT01839851|Hair cortisol
1040473|NCT01839851|asthma
1040474|NCT01839851|allergic rhinitis
1040475|NCT01839851|inhaled corticosteroids
1040476|NCT01839851|intranasal glucocorticoids
1040477|NCT01839838|Women
1040478|NCT01839838|age 50 and above
1040479|NCT01839838|with
1040480|NCT01839838|that has been
1040481|NCT01839838|surgically excised
1040482|NCT01839825|elderly
1040483|NCT01839825|fall
1040484|NCT01839825|acute illness
1040485|NCT01839825|care giver
1040486|NCT01839812|Cardiopulmonary bypass
1040487|NCT01839812|Cortisol
1040488|NCT01839812|Dexamethasone
1040489|NCT01839799|Patients
1040490|NCT01839799|with
1040491|NCT01839799|resected
1040492|NCT01839786|Pulmonary Hypertension
1040493|NCT01839786|Doppler
1040494|NCT01839786|Valsalva
1040495|NCT01839773|Stomach Neoplasms
1040496|NCT01839773|Cancer of Stomach
1040497|NCT01839773|Gastric Cancer
1040498|NCT01839773|Gastric Neoplasms
1040499|NCT01839773|Neoplasms, Gastric
1040500|NCT01839773|Neoplasms, Stomach
1040501|NCT01839773|Stomach Cancer
1040502|NCT01839773|paclitaxel
1040503|NCT01839773|Taxol
1040504|NCT01839760|Influenza
1040505|NCT01839760|Virus
1040506|NCT01839760|Viral shedding
1040507|NCT01839760|Epidemiology
1040508|NCT01839747|Pediatric
1040509|NCT01839734|CD4+
1040510|NCT01839721|Probiotics
1040511|NCT01839721|radiation-induced enteritis
1040512|NCT01839721|radiation-induced diarrhea
1040513|NCT01839721|radiation, diarrhea, enteritis
1040514|NCT01839721|diet
1040515|NCT01839721|nutrition
1040516|NCT01839708|Intervention
1040517|NCT01839695|Thoracic Aneurysm
1040518|NCT01839695|Endovascular Aortic Repair
1040519|NCT01839695|TEVAR
1040520|NCT01839682|StabiliT
1040521|NCT01839682|Kyphoplasty
1040522|NCT01839682|Vertebral
1040523|NCT01839682|Compression
1040524|NCT01839682|Fracture
1040525|NCT01839682|Osteoporosis
1040526|NCT01839669|conservative therapy
1040527|NCT01839669|Foot-Function-Index
1040528|NCT01839669|functional movement changes
1040529|NCT01839669|non-surgical treatment
1040530|NCT01839669|pes planovalgus
1040531|NCT01839669|posterior tibial tendon dysfunction
1040532|NCT01839656|Spinal Muscular Atrophy
1040533|NCT01839656|SMA
1040534|NCT01839656|SMN
1040535|NCT01839656|SMNRx
1040536|NCT01839656|ISIS-SMNRx
1040537|NCT01839656|ISIS 396443
1040538|NCT01839656|IONIS-SMNRx
1040539|NCT01839656|Spinraza
1040540|NCT01839643|pharmacokinetic
1040541|NCT01839630|Sorafenib
1040542|NCT01839630|Hepatocellular cancer
1040543|NCT01839630|TACE combination
1040544|NCT01839630|Treatment pattern
1040545|NCT01839630|Safety
1040546|NCT01839630|Effectiveness
1040547|NCT01839617|parenteral nutrition
1040548|NCT01839617|early nutrition
1040549|NCT01839617|abdominal surgery
1040550|NCT01839617|cancer
1040551|NCT01839604|Child-Pugh A to B7,
1040552|NCT01839604|Advanced/Metastatic Hepatocellular Carcinoma,
1040553|NCT01839604|AZD9150,
1040554|NCT01839604|Antisense Oligonucleotide Inhibitor of STAT3
1040555|NCT01839578|cytokines
1040556|NCT01839578|blood purification
1040557|NCT01839578|super high flux hemodialysis
1040558|NCT01839565|Adverse events
1040559|NCT01839565|Osteosynthesis
1040560|NCT01839565|Quality of life
1040561|NCT01839552|Fentanyl Citrate Nasal Spray (FCNS)
1040562|NCT01839552|Lazanda
1040563|NCT01839552|Breakthrough pain in cancer patients
1040564|NCT01839539|colorectal cancer
1040565|NCT01839539|DC-CIK
1040566|NCT01839539|CRC
1040567|NCT01839526|Fabry disease
1040568|NCT01839513|Analgesia/nociception index
1040569|NCT01839513|Desflurane
1040570|NCT01839513|Remifentanil
1040571|NCT01839513|Orthopedic surgery
1040572|NCT01839513|Ear-nose-throat surgery
1040573|NCT01839513|Hemodynamic reactivity
1040574|NCT01839487|pancreatic ductal carcinoma(PDA)
1040575|NCT01839487|Pancreatic ductal carcinoma
1040576|NCT01839487|PEGPH20
1040577|NCT01839487|Gemcitabine
1040578|NCT01839487|Nab-paclitaxel
1040579|NCT01839474|Continuous Positive Airway Pressure
1040580|NCT01839474|Controlled trial
1040581|NCT01839474|Pneumonia
1040582|NCT01839474|Children
1040583|NCT01839461|Pharmacogenetics
1040584|NCT01839461|postoperative
1040585|NCT01839461|pediatric
1040586|NCT01839461|opioid
1040587|NCT01839461|perioperative
1040588|NCT01839461|respiratory depression
1040589|NCT01839461|chronic pain
1040590|NCT01839448|post partum diabetes
1040591|NCT01839448|impaired fasting glucose
1040592|NCT01839435|appendectomy
1040593|NCT01839435|acute appendicitis
1040594|NCT01839435|outpatient
1040595|NCT01839409|Circadian Rhythm
1040596|NCT01839409|Exercise
1040597|NCT01839409|Reflex, Vestibular Ocular
1040598|NCT01839409|Postural Balance
1040599|NCT01839396|Intrepid, Vercise, PD, DBS, Boston Scientific
1040600|NCT01839370|Pramlintide
1040601|NCT01839370|Closed Loop
1040602|NCT01839370|Continuous Glucose Monitor (CGM)
1040603|NCT01839370|Diabetes Assistant (DiAs)
1040604|NCT01839357|Rivaroxaban
1040605|NCT01839357|Oral anticoagulant
1040606|NCT01839357|Nonvalvular atrial fibrillation
1040607|NCT01839357|Left atrial thrombus
1040608|NCT01839357|Transesophageal echocardiography
1040609|NCT01839357|Thrombus resolution
1040610|NCT01839357|Stroke
1040611|NCT01839357|Thromboembolism
1040612|NCT01839344|hyperglycemia
1040613|NCT01839344|Diabetes Mellitus, Type 2
1040614|NCT01839344|endothelial dysfunction
1040615|NCT01839344|quercetin
1040616|NCT01839344|Acarbose
1040617|NCT01839344|glucose tolerance
1040618|NCT01839344|maltose
1040619|NCT01839331|osteoarthritis
1040620|NCT01839331|osteoarthrisis of the knee
1040621|NCT01839318|Soft contact lenses
1040622|NCT01839318|Daily disposable contact lenses
1040623|NCT01839318|Tear Film Break Up Time
1040624|NCT01839318|Contact lens wettability
1040625|NCT01839305|Kinematics
1040626|NCT01839305|Fibromyalgia
1040627|NCT01839305|Physical Therapy
1040628|NCT01839305|3D Kinematics
1040629|NCT01839305|Heart Rate Frequency
1040630|NCT01839305|Hydrotherapy
1040631|NCT01839292|gastric outlet obstruction
1040632|NCT01839292|palliative treatment
1040633|NCT01839292|stent
1040634|NCT01839266|acute PTE, prognostic factors
1040635|NCT01839253|antihypertensive agents
1040636|NCT01839253|hemodynamic
1040637|NCT01839253|anesthetics reduction
1040638|NCT01839253|orthognathic surgery
1040639|NCT01839227|Post-operative cognitive dysfunction
1040640|NCT01839227|regional cerebral oxygen saturation
1040641|NCT01839227|elderly
1040642|NCT01839201|anesthesia
1040643|NCT01839201|modification of dreaming
1040644|NCT01839201|suggestions
1040645|NCT01839162|Transradial approach
1040646|NCT01839162|shield drape
1040647|NCT01839162|radiation
1040648|NCT01839162|PTCA
1040649|NCT01839149|Refractory Chronic Migraine
1040650|NCT01839149|Medically Intractable Chronic Migraine
1040651|NCT01839149|Oxytocin
1040652|NCT01839149|Intranasal oxytocin
1040653|NCT01839136|Assisted Reproductive Techniques
1040654|NCT01839136|Health Services Accessibility
1040655|NCT01839136|Ovulation Induction
1040656|NCT01839136|Embryo Transfer
1040657|NCT01839123|Amputee
1040661|NCT01839097|PTCL
1040662|NCT01839097|Maximum Tolerated Dose
1040663|NCT01839097|Belinostat
1040664|NCT01839084|Xenon
1040665|NCT01839084|Isoflurane
1040666|NCT01839084|Anesthetics, Inhalation
1040667|NCT01839084|Nephroprotection
1040668|NCT01839084|Partial nephrectomy
1040669|NCT01839084|Xenon versus Isoflurane anesthesia
1040670|NCT01839058|Non Cardiac Chest Pain
1040671|NCT01839045|Woman
1040672|NCT01839045|Breast Cancer
1040673|NCT01839045|Cancer
1040674|NCT01839045|Mammogram
1040675|NCT01839045|Ultrasound
1040676|NCT01839045|Imaging
1040677|NCT01839045|Biomarkers
1040678|NCT01839045|ACR BI RAD Category 3
1040679|NCT01839045|ACR BI RAD Category 4
1040680|NCT01839019|Healthy volunteers
1040681|NCT01839006|hydronephrosis
1040682|NCT01839006|ultrasonography
1040683|NCT01839006|Kidney Function Test
1040684|NCT01839006|Patients with unilateral UPJO and patients with preop HN in USG and supranormal renal function in DTPA renography
1040685|NCT01838993|anesthetics,
1040686|NCT01838993|local,
1040687|NCT01838993|lidocaine;
1040688|NCT01838993|nebulizers and vaporizers;
1040689|NCT01838993|complications,
1040690|NCT01838993|intubation,
1040691|NCT01838993|intratracheal.
1040692|NCT01838980|Colonoscopy Cleaning
1040693|NCT01838967|cilnidipin and valsartn
1040694|NCT01838967|pharmacokinetic drug drug interaction
1040695|NCT01838967|oral administration
1040696|NCT01838967|healthy male subjects
1040697|NCT01838954|hand osteoarthritis
1040698|NCT01838954|short-wave diathermy
1040699|NCT01838941|Peroxisome Biogenesis Disorder
1040700|NCT01838941|PBD
1040701|NCT01838941|neonatal adrenoleukodystrophy
1040702|NCT01838941|infantile Refsum disease
1040703|NCT01838941|PEX1 mutation
1040704|NCT01838941|Betaine
1040705|NCT01838928|Axillary brachial plexus block
1040706|NCT01838928|Ultrasound
1040707|NCT01838928|Minimum effective concentration
1040708|NCT01838928|Bupivacaine
1040709|NCT01838928|ultrasound-guided axillary brachial plexus block
1040710|NCT01838915|HIV
1040711|NCT01838915|immunoactivation
1040712|NCT01838915|bacterial translocation
1040713|NCT01838915|prebiotics
1040714|NCT01838915|glutamine
1040715|NCT01838915|microbiota
1040716|NCT01838902|Malaria
1040717|NCT01838902|Falciparum
1040718|NCT01838902|Direct membrane feeding
1040719|NCT01838902|QT-NASBA
1040720|NCT01838902|Asexual parasite
1040721|NCT01838902|Asymptomatic carrier
1040722|NCT01838902|Gametocytocidal, Gametocyte
1040723|NCT01838902|Transmission blocking
1040724|NCT01838902|Sexual stage
1040725|NCT01838902|Primaquine
1040726|NCT01838902|Dihydroartemisinin
1040727|NCT01838902|Piperaquine
1040728|NCT01838902|Gambia
1040729|NCT01838902|Africa
1040730|NCT01838889|Culturally adapted
1040731|NCT01838889|Group psychological intervention
1040732|NCT01838889|British South Asian women
1040733|NCT01838889|CBT
1040734|NCT01838876|Major Depressive Disorder
1040735|NCT01838876|MDD
1040736|NCT01838876|Depression
1040737|NCT01838863|coagulopathy
1040738|NCT01838863|hemorrhagic shock
1040739|NCT01838863|plasma
1040863|NCT01838252|Lower eyelid retraction
1040740|NCT01838863|blood product transfusion
1040741|NCT01838824|Processing Speed
1040742|NCT01838824|Intervention
1040743|NCT01838824|Multiple Sclerosis
1040744|NCT01838824|Cognition
1040745|NCT01838811|Processing Speed
1040746|NCT01838811|Intervention
1040747|NCT01838811|Traumatic Brain Injury
1040748|NCT01838811|Cognition
1040749|NCT01838798|cognitive disorders
1040750|NCT01838798|quality of life
1040751|NCT01838798|Intensive care
1040752|NCT01838785|18F-DTBZ AV-133 imaging
1040753|NCT01838772|HCV and HIV co-infection
1040754|NCT01838759|Bioimpedance spectroscopy
1040755|NCT01838759|Hypervolemia
1040756|NCT01838759|Hypovolemia
1040757|NCT01838746|Percutaneous coronary intervention
1040758|NCT01838746|Coronary artery bypass grafting
1040759|NCT01838746|Coronary artery bypass surgery
1040760|NCT01838746|Survival
1040761|NCT01838746|Acute coronary syndrome
1040762|NCT01838746|ST segment elevation myocardial infarction
1040763|NCT01838746|Non-ST segment elevation myocardial infarction
1040764|NCT01838746|Younge patient
1040765|NCT01838720|renal cell carcinoma
1040766|NCT01838720|ischemia
1040767|NCT01838720|radio frequency ablation
1040768|NCT01838707|postoperative
1040769|NCT01838707|spine surgery
1040770|NCT01838655|Albinism
1040771|NCT01838655|Nitisinone
1040772|NCT01838655|Melanin
1040773|NCT01838655|Vision Loss
1040774|NCT01838642|Monoclonal Antibody
1040775|NCT01838642|AP24534
1040776|NCT01838642|RET Mutation Positive
1040777|NCT01838642|RET Mutation Negative
1040778|NCT01838642|RET Inhibitor
1040779|NCT01838616|Severe chronic low back pain
1040780|NCT01838616|Neuropathic pain
1040781|NCT01838616|Constipation
1040782|NCT01838590|Liver Diseases
1040783|NCT01838590|Digestive System Diseases
1040784|NCT01838590|Hepatitis, Viral, Human
1040785|NCT01838590|Virus Diseases
1040786|NCT01838590|Enterovirus Infections
1040787|NCT01838590|Picornaviridae Infections
1040788|NCT01838590|RNA Virus Infections
1040789|NCT01838590|Flaviviridae Infections
1040790|NCT01838590|Antiviral Agents
1040791|NCT01838590|Anti-Infective Agents
1040792|NCT01838590|Therapeutic Uses
1040793|NCT01838590|Pharmacologic Actions
1040794|NCT01838590|Antimetabolites
1040795|NCT01838590|Molecular Mechanisms of Pharmacological Action
1040796|NCT01838590|HCV genotype 4 (GT-4)
1040797|NCT01838590|HCV
1040798|NCT01838590|Sustained Virologic Response
1040799|NCT01838590|Direct Acting Antiviral
1040800|NCT01838590|Combination Therapy
1040801|NCT01838590|GS-7977
1040802|NCT01838590|Ribavirin
1040803|NCT01838590|Open Label
1040804|NCT01838590|Sofosbuvir
1040805|NCT01838590|Additional relevant MeSH terms:
1040806|NCT01838590|Hepatitis
1040807|NCT01838590|Hepatitis, Chronic
1040808|NCT01838590|Hepatitis C
1040809|NCT01838590|Hepatitis C, Chronic
1040810|NCT01838564|Pediatric Advanced Cancer
1040811|NCT01838564|Children
1040812|NCT01838564|Quality of Life
1040813|NCT01838564|Health Information technology
1040814|NCT01838564|Patient reported outcomes
1040815|NCT01838525|sepsis
1040816|NCT01838525|alpha-1-acid glycoprotein (AGP)
1040817|NCT01838525|diagnosis
1040818|NCT01838525|prognosis
1040819|NCT01838525|SIRS
1040820|NCT01838486|Interstitial cystitis
1040821|NCT01838486|painful bladder syndrome
1040822|NCT01838486|bladder hydrodistention
1040823|NCT01838486|hyperthermia
1040824|NCT01838473|smokeless tobacco
1040825|NCT01838473|Nicotine
1040826|NCT01838473|Cadmium
1040827|NCT01838473|lead
1040828|NCT01838473|Tobacco Specific Nitrosamines
1040829|NCT01838447|Vitamin D
1040830|NCT01838447|Congenital Heart Disease
1040831|NCT01838447|Cardiac Surgery
1040832|NCT01838447|Pediatrics
1040833|NCT01838447|Phase II Clinical Trial
1040834|NCT01838408|screening colonoscopy
1040835|NCT01838408|surveillance colonoscopy
1040836|NCT01838408|colonoscopy
1040837|NCT01838395|AML
1040838|NCT01838395|Acute Myeloid Leukemia
1040839|NCT01838395|Relapsed Acute Myeloid Leukemia
1040840|NCT01838395|Refractory Acute Myeloid Leukemia
1040841|NCT01838382|pain
1040842|NCT01838382|total laparoscopic hysterectomy
1040843|NCT01838356|Depression
1040844|NCT01838356|Vascular depression
1040845|NCT01838356|Intracranial atherosclerosis
1040846|NCT01838356|Coronary artery disease
1040847|NCT01838356|Coronary artery bypass graft
1040848|NCT01838356|Cognitive impairment
1040849|NCT01838330|Kidney Disease
1040850|NCT01838330|Fiber
1040851|NCT01838330|Dietary Intervention
1040852|NCT01838304|propofol sedation endoscopy
1040853|NCT01838291|Ferriprox
1040854|NCT01838291|Deferiprone
1040855|NCT01838291|DFP
1040856|NCT01838291|L1
1040857|NCT01838278|Vojta therapy
1040858|NCT01838278|Exercise Movement Technique
1040859|NCT01838278|Early intervention
1040860|NCT01838252|Ectropion
1040861|NCT01838252|Hyaluronic Acid
1040862|NCT01838252|Keratoconjunctivitis Sicca
1040864|NCT01838239|Fish oil
1040865|NCT01838239|Omega-3 fatty acids
1040866|NCT01838226|Chronic Disease
1040867|NCT01838226|Prevention
1040868|NCT01838226|cardiovascular disease
1040869|NCT01838213|Urinary tract infection
1040870|NCT01838213|ESBL
1040871|NCT01838213|treatment
1040872|NCT01838213|carriage
1040873|NCT01838213|risk factors
1040874|NCT01838213|water contamination
1040875|NCT01838200|BCG
1040876|NCT01838200|Bacillus Calmette-Guérin
1040877|NCT01838200|Ipilimumab
1040878|NCT01838200|YERVOY
1040879|NCT01838200|Advanced Metastatic Melanoma
1040880|NCT01838200|Metastatic Melanoma
1040881|NCT01838174|Optic Neuritis
1040882|NCT01838161|adolescents
1040883|NCT01838161|immunizations
1040884|NCT01838148|coronary artery disease
1040885|NCT01838148|angina, stable
1040886|NCT01838148|exercise test
1040887|NCT01838148|biological Markers
1040888|NCT01838148|SPECT
1040889|NCT01838135|wheelchair
1040890|NCT01838135|manual wheelchair
1040891|NCT01838135|rehabilitation
1040892|NCT01838135|self-efficacy
1040893|NCT01838135|older adults
1040894|NCT01838135|feasibility
1040895|NCT01838135|intervention
1040896|NCT01838135|training
1040897|NCT01838122|PCOS
1040898|NCT01838122|HbA1C
1040899|NCT01838122|Insulin resistance
1040900|NCT01838122|OGTT
1040901|NCT01838122|HOMA-IR
1040902|NCT01838122|HOMA-B-cell
1040903|NCT01838070|Hepatitis A
1040904|NCT01838070|Hepatitis A vaccine
1040905|NCT01838070|AVAXIM 160U
1040906|NCT01838031|antenatal thyroid screening
1040907|NCT01838031|subclinical hypothyroidism
1040908|NCT01838031|thyroid function
1040909|NCT01838031|thyroid antibody
1040910|NCT01838031|pregnancy outcome
1040911|NCT01838031|childhood cognitive function
1040912|NCT01838018|PKAN
1040913|NCT01838018|brain iron
1040914|NCT01838018|NBIA
1040915|NCT01838018|neurodegeneration with brain iron accumulation
1040916|NCT01838018|Hallervorden Spatz Syndrome
1040917|NCT01838005|Contingency management
1040918|NCT01838005|conditional cash transfer
1040919|NCT01838005|PMTCT
1040920|NCT01838005|Retention
1040921|NCT01838005|HIV
1040922|NCT01837979|prenatal testing for fetal aneuploidy
1040923|NCT01837979|dried blood spots
1040924|NCT01837979|cell-free fetal DNA
1040925|NCT01837979|detection rate
1040926|NCT01837979|cost-effectiveness
1040927|NCT01837966|re-operative anxiety
1040928|NCT01837966|breast surgery
1040929|NCT01837966|lavender oil
1040930|NCT01837966|aromatherapy
1040931|NCT01837927|Efficacy, NVA237, Tiotropium, Chronic Obstructive Pulmonary Disease, COPD
1040932|NCT01837901|transcorneal electrostimulation
1040933|NCT01837888|wheelchair
1040934|NCT01837888|manual wheelchair
1040935|NCT01837888|rehabilitation
1040936|NCT01837888|self-efficacy
1040937|NCT01837888|older adults
1040938|NCT01837888|feasibility
1040939|NCT01837888|intervention
1040940|NCT01837888|training
1040941|NCT01837888|Wheelchair mobility
1040942|NCT01837875|Intervention
1040943|NCT01837875|Quality of life
1040944|NCT01837875|African American
1040945|NCT01837875|Stress
1040946|NCT01837862|pilomyxoid astrocytoma
1040947|NCT01837862|Pilocytic Astrocytoma
1040948|NCT01837862|Glioma
1040949|NCT01837862|Optic Nerve Glioma
1040950|NCT01837862|mebendazole
1040951|NCT01837862|Pleomorphic Xanthoastrocytoma
1040952|NCT01837862|glioblastoma multiforme
1040953|NCT01837862|anaplastic astrocytoma
1040954|NCT01837862|gliosarcoma
1040955|NCT01837862|diffuse intrinsic pontine glioma
1040956|NCT01837862|DIPG
1040957|NCT01837862|low-grade glioma
1040958|NCT01837862|high-grade glioma
1040959|NCT01837862|brainstem glioma
1040960|NCT01837862|pediatric
1040961|NCT01837849|heart failure
1040962|NCT01837849|rhBNP
1040963|NCT01837849|Dobutamine
1040964|NCT01837836|Health education
1040965|NCT01837836|water handling practices
1040966|NCT01837836|Bacteriological quality of water
1040967|NCT01837823|Coronary artery disease
1040968|NCT01837823|Lipid
1040969|NCT01837823|Regression
1040970|NCT01837823|Plaque
1040971|NCT01837810|Post tonsillectomy hemorrhage
1040972|NCT01837810|post operative hemorrhage
1040973|NCT01837810|complications
1040974|NCT01837810|tonsillectomy
1040975|NCT01837758|Platelet function
1040976|NCT01837758|hemofiltration
1040977|NCT01837758|Multiplate
1040978|NCT01837732|Chronic pain
1040979|NCT01837732|elderly
1040980|NCT01837732|relational touch
1040981|NCT01837706|Empathy
1040982|NCT01837706|Communication
1040983|NCT01837706|Physician litigation
1040984|NCT01837693|cervical cancer screening
1040985|NCT01837693|CIN
1040986|NCT01837693|cervical cancer
1040987|NCT01837693|biomarkers
1040988|NCT01837693|sensitivity and specificity
1040989|NCT01837680|Insulin, Long-Acting
1040990|NCT01837654|Detrusor Overactivity
1040991|NCT01837654|Plantarflexion
1040992|NCT01837654|Urgency
1040993|NCT01837628|Urodynamic
1040994|NCT01837628|Paraffin oil
1040995|NCT01837628|Lidocaine gel
1040996|NCT01837628|Pain
1040997|NCT01837615|Ulcerative Colitis
1040998|NCT01837615|Ulcerative Proctitis
1040999|NCT01837615|Low Level Light Therapy
1041000|NCT01837615|Safety
1041001|NCT01837615|Efficacy
1041005|NCT01837589|Cystic fibrosis-DXA-QCT-Osteopenia- Osteoporosis
1041006|NCT01837576|Psoriasis Vulgaris
1041007|NCT01837576|Calcipotriol
1041008|NCT01837576|Betamethasone Dipropionate
1041009|NCT01837550|audiologic rehabilitation
1041010|NCT01837550|hearing loss
1041011|NCT01837550|patient education
1041012|NCT01837550|patient participation
1041013|NCT01837550|structured rehabilitation
1041014|NCT01837550|counseling
1041015|NCT01837550|Internet
1041016|NCT01837524|Dietary advice
1041017|NCT01837524|Nutritional knowledge
1041018|NCT01837524|Self-efficacy
1041019|NCT01837524|Nutrition
1041020|NCT01837511|Tumor antigens
1041021|NCT01837511|Asiatic patients
1041022|NCT01837511|Reverse Transciptase-Polymerase chain reaction (RT-PCR)
1041023|NCT01837511|Non-small cell lung cancer (NSCLC)
1041024|NCT01837498|residual neuromuscular blockade, sugammadex, neostigmine, thoracic surgery
1041025|NCT01837485|Irritable bowel syndrome
1041026|NCT01837485|Functional gastrointestinal disorders
1041027|NCT01837485|Gut flora
1041028|NCT01837485|Probiotics
1041029|NCT01837472|Irritable bowel syndrome
1041030|NCT01837472|Functional gastrointestinal disorders
1041031|NCT01837472|Gut flora
1041032|NCT01837472|Probiotics
1041033|NCT01837459|Obstructive Sleep Apnea
1041034|NCT01837459|Sleep Disordered Breathing
1041035|NCT01837459|Vascular function
1041036|NCT01837459|Arterial stiffness
1041037|NCT01837459|Polysomnography
1041038|NCT01837459|Cytokines
1041039|NCT01837446|mucositis
1041040|NCT01837446|topical morphine
1041041|NCT01837446|pain
1041042|NCT01837446|head and neck carcinoma
1041043|NCT01837433|Efficacy
1041044|NCT01837433|safety
1041045|NCT01837433|short
1041046|NCT01837433|term
1041047|NCT01837433|subacute thyroiditis
1041048|NCT01837407|Soft tissue loss
1041049|NCT01837407|nerve defect
1041050|NCT01837407|dorsal branch of the proper digital nerve
1041051|NCT01837407|heterodigital arterialized nerve pedicle flap
1041052|NCT01837407|Composite Flap
1041053|NCT01837407|nerve flap
1041054|NCT01837407|nerve transfer
1041055|NCT01837394|Nerve block
1041056|NCT01837394|Ultrasound
1041057|NCT01837394|postoperative pain
1041058|NCT01837394|Saphenous nerve
1041059|NCT01837394|Obturator nerve
1041060|NCT01837329|Non-Squamous
1041061|NCT01837329|NSCLC
1041062|NCT01837329|Adenocarcinoma
1041063|NCT01837329|Lung Cancer
1041064|NCT01837329|Tetrathiomolybdate
1041065|NCT01837329|Copper
1041066|NCT01837329|Carboplatin
1041067|NCT01837329|Pemetrexed Platinum
1041068|NCT01837329|Newly Diagnosed
1041069|NCT01837329|Chemo-naive
1041070|NCT01837316|pharmacodynamics
1041071|NCT01837316|FF/VI
1041072|NCT01837316|asthma
1041073|NCT01837316|duration of action
1041074|NCT01837303|Cervical dysplasia
1041075|NCT01837303|Cervical cancer
1041076|NCT01837290|Renal failure,
1041077|NCT01837290|hip fracture,
1041078|NCT01837290|spinal anesthesia,
1041079|NCT01837290|dexmedetomidine
1041080|NCT01837290|patient
1041081|NCT01837264|Magellan MAR01
1041082|NCT01837264|Autologous Platelet Rich Plasma
1041083|NCT01837264|Compartment Syndrome
1041084|NCT01837264|Battlefield Trauma
1041085|NCT01837264|Fasciotomy
1041086|NCT01837251|Ovarian Carcinoma
1041087|NCT01837251|Bevacizumab
1041088|NCT01837251|Gemcitabine
1041089|NCT01837251|PLD
1041090|NCT01837251|pegylated liposomal doxorubicin
1041091|NCT01837251|Carboplatin
1041092|NCT01837251|best therapeutic index
1041093|NCT01837251|progression-free survival
1041094|NCT01837238|hemodialysis
1041095|NCT01837238|physical function
1041096|NCT01837225|Fluorescence Imaging
1041097|NCT01837225|Breast Tumor Margins
1041098|NCT01837225|Real-time Assessment
1041099|NCT01837199|Periodontal disease
1041100|NCT01837199|Scaling and root planing
1041101|NCT01837199|Metronidazole
1041102|NCT01837199|Amoxicillin
1041103|NCT01837199|Generalized chronic periodontitis
1041104|NCT01837199|Periodontal treatment
1041105|NCT01837186|Surgery
1041106|NCT01837186|NSCLC
1041107|NCT01837173|Adenocarcinoma
1041108|NCT01837173|Squamous Cell Carcinoma
1041109|NCT01837173|Neoadjuvant treatment
1041110|NCT01837173|Esophagectomy
1041111|NCT01837160|Angiogenesis
1041112|NCT01837160|Fibrosis
1041113|NCT01837160|Aortic Stenosis
1041114|NCT01837160|Imaging
1041115|NCT01837160|CT-PET
1041116|NCT01837160|PET-CT
1041117|NCT01837160|Cardiac MRI
1041118|NCT01837147|primary prevention
1041119|NCT01837147|sedentary
1041120|NCT01837147|overweight
1041121|NCT01837147|obesity
1041122|NCT01837147|breast cancer
1041123|NCT01837147|post-menopausal
1041124|NCT01837147|women
1041125|NCT01837134|telemedicine
1041126|NCT01837134|overweight
1041127|NCT01837134|obesity
1041128|NCT01837121|not-attended rate
1041129|NCT01837121|re-visit
1041130|NCT01837121|vision
1041131|NCT01837121|knowledge
1041132|NCT01837121|satisfaction
1041133|NCT01837108|healthy
1041134|NCT01837095|Overall survival
1041135|NCT01837095|Progression free survival
1041136|NCT01837082|Heart Failure
1041137|NCT01837082|Iron Deficiency
1041138|NCT01837082|Anemia
1041139|NCT01837082|Ferric Carboxymaltose
1041140|NCT01837069|Hypertension
1041141|NCT01837069|Diabetes
1041142|NCT01837069|Coronary Artery Disease
1041143|NCT01837069|Peripheral Vascular Disease
1041144|NCT01837056|Toxoplasma gondii
1041145|NCT01837056|Toxocara canis
1041146|NCT01837043|Delayed Graft Function
1041147|NCT01837043|Renal Transplantation
1041148|NCT01837043|Kidney Transplant
1041149|NCT01837017|Falls,
1041150|NCT01837017|Balance,
1041151|NCT01837017|Gait,
1041152|NCT01837017|Older adults
1041153|NCT01837004|adherence
1041154|NCT01837004|cognition
1041155|NCT01837004|exercise
1041156|NCT01837004|aging
1041157|NCT01836991|gastric cancer
1041158|NCT01836991|surgery
1041159|NCT01836991|surgery safety
1041160|NCT01836991|effect
1041161|NCT01836965|Aspergers
1041162|NCT01836965|Social Skills
1041163|NCT01836965|Adolescents
1041164|NCT01836965|High-functioning Autism
1041165|NCT01836939|psoriasis, oral therapy
1041166|NCT01836939|ova
1041167|NCT01836939|Trichuris suis ova
1041168|NCT01836939|TSO
1041169|NCT01836939|CNDO 201 Trichuris suis ova
1041170|NCT01836926|sphincter sparing procedures
1041171|NCT01836926|intersphincteric resection
1041172|NCT01836926|rectal cancer
1041173|NCT01836926|low rectal cancer
1041174|NCT01836926|sphincter preserving procedures
1041175|NCT01836926|Abdominoperineal resection
1041176|NCT01836926|laparoscopic resection of rectal cancer
1041177|NCT01836926|laparoscopic versus open colorectal resection
1041178|NCT01836926|laparoscopic versus open rectal surgery
1041179|NCT01836926|neoadjuvant chemo-radiotherapy for rectal cancer
1041180|NCT01836913|PET/CT
1041181|NCT01836913|Esophageal cancer
1041182|NCT01836913|Radiotherapy
1041183|NCT01836900|OTSC
1041184|NCT01836900|Upper gastrointestinal bleeding
1041185|NCT01836887|Polyphenol
1041186|NCT01836887|Fruit
1041187|NCT01836887|Metabolic
1041188|NCT01836887|Healthy
1041189|NCT01836874|Migraine
1041190|NCT01836874|Indian
1041191|NCT01836874|Topiramate
1041192|NCT01836861|Phase I
1041193|NCT01836861|healthy male volunteers
1041194|NCT01836861|ADME
1041195|NCT01836861|Bioavailability
1041196|NCT01836861|PI3K inhibitor
1041197|NCT01836861|Absorption
1041198|NCT01836861|Distribution
1041199|NCT01836861|Metabolism
1041200|NCT01836861|Excretion
1041201|NCT01836861|safety
1041202|NCT01836848|subarachnoid hemorrhage
1041203|NCT01836848|near-infrared-spectroscopy
1041204|NCT01836848|indocyanine green
1041205|NCT01836848|secondary ischemia
1041206|NCT01836835|Hyperemesis gravidarum
1041207|NCT01836835|Pregnancy
1041208|NCT01836835|Nausea
1041209|NCT01836835|Nutritional status
1041210|NCT01836835|Questionnaire
1041211|NCT01836835|Case-control
1041212|NCT01836822|mediastinal lymph node enlargement
1041213|NCT01836822|sarcoidosis
1041214|NCT01836822|bronchoscopy
1041215|NCT01836822|EBUS guided transbronchial needle aspiration (EBUS-TBNA)
1041216|NCT01836822|transbronchial needle aspiration (EBUS-TBNA)
1041217|NCT01836822|EBUS guided transbronchial forceps biopsy EBUS-TBFB)
1041218|NCT01836809|Total Artificial Heart
1041219|NCT01836809|Left Ventricular Assist Device
1041220|NCT01836809|Natriuretic peptides
1041221|NCT01836809|Heart Failure
1041222|NCT01836809|Cardiorenal Syndrome
1041223|NCT01836783|Allograft
1041224|NCT01836783|Amnion Allograft
1041225|NCT01836770|Transforaminal Epidural Steroid Injections
1041226|NCT01836757|osteoarthritis
1041227|NCT01836757|CAM treatments
1041228|NCT01836757|MSM
1041229|NCT01836731|weight-for age
1041230|NCT01836731|height-for-age
1041231|NCT01836731|water sanitation facilities
1041232|NCT01836731|hygiene behavior
1041233|NCT01836718|Hepatitis C Virus
1041234|NCT01836718|Liver Transplantation
1041235|NCT01836718|Antiviral Therapy
1041236|NCT01836718|HCV
1041237|NCT01836679|Chidamide,lung cancer
1041238|NCT01836653|Bevacizumab
1041239|NCT01836653|Cetuximab
1041240|NCT01836653|KRAS wild type colorectal cancer
1041241|NCT01836653|RAS wild type colorectal cancer
1041242|NCT01836653|liver metastasis
1041243|NCT01836627|Congenital Muscular Dystrophy
1041244|NCT01836627|Collagen VI Deficiency
1041245|NCT01836627|Hyperinsufflation
1041246|NCT01836627|Cough Assist
1041247|NCT01836627|LAMA2- Muscular Dystrophy
1041248|NCT01836601|safety
1041249|NCT01836601|patient experience
1041250|NCT01836601|family-centered rounds
1041251|NCT01836575|Advanced NSCLC
1041252|NCT01836575|PS2
1041253|NCT01836575|Pemetrexed
1041254|NCT01836575|First line
1041255|NCT01836575|non squamous
1041256|NCT01836562|Autism stem cell MNCs
1041257|NCT01836536|High grade glioma
1041258|NCT01836536|Bevacizumab
1041259|NCT01836536|Chemotherapy
1041260|NCT01836536|Myeloid Cells
1041261|NCT01836536|Treg
1041262|NCT01836510|Heart Failure
1041263|NCT01836510|Remote Monitoring
1041264|NCT01836510|Lung Edema
1041265|NCT01836510|Patient Monitoring
1041266|NCT01836510|Prediction
1041267|NCT01836484|Surgically staged endometrial carcinoma
1041268|NCT01836484|Surgically staged cervical carcinoma
1041269|NCT01836458|Malaria, KAE609
1041270|NCT01836432|Pancreatic Cancer
1041271|NCT01836432|Immunotherapy
1041272|NCT01836432|Vaccine Therapy
1041273|NCT01836419|classic laryngeal mask airway
1041274|NCT01836419|elderly patients
1041275|NCT01836406|ketorolac
1041276|NCT01836406|remote ischemic preconditioning
1041277|NCT01836406|partial nephrectomy
1041278|NCT01836393|Plai
1041279|NCT01836393|Efficacy
1041280|NCT01836393|OA knee
1041281|NCT01836393|The efficacy study of Plai cream for OA knee
1041282|NCT01836367|Actinic Keratosis
1041283|NCT01836367|Face
1041284|NCT01836367|Scalp
1041285|NCT01836367|Ingenol Mebutate
1041286|NCT01836354|stroke
1041287|NCT01836354|interactive educational intervention
1041288|NCT01836354|acute ischemic stroke
1041289|NCT01836354|transient ischemic attack
1041290|NCT01836341|Afatinib
1041291|NCT01836341|Cisplatin
1041292|NCT01836341|Carboplatin
1041293|NCT01836341|Pemetrexed
1041294|NCT01836341|Radiation therapy
1041295|NCT01836341|EGFR mutation
1041296|NCT01836341|12-279
1041297|NCT01836328|Methadone
1041298|NCT01836328|Pain
1041299|NCT01836328|Neoplasms
1041300|NCT01836328|Ratio
1041301|NCT01836237|Surgical site infection rate
1041302|NCT01836237|Wound protector use
1041303|NCT01836237|Whipple
1041304|NCT01836211|Chest pain
1041305|NCT01836211|Acute coronary syndrome
1041306|NCT01836211|Cardiac biomarkers
1041307|NCT01836211|Computed coronary tomography angiography
1041308|NCT01836211|Emergency department
1041309|NCT01836172|The treatment of diabetic complication
1041310|NCT01836159|Stroke Rehabilitation
1041311|NCT01836159|iPad
1041312|NCT01836159|Fine Motor Function
1041313|NCT01836159|Ischemic Stroke
1041314|NCT01836159|Visual Neglect
1041315|NCT01836120|second-line chemotherapy
1041316|NCT01836120|Raltitrexed
1041317|NCT01836107|Clinical notes
1041318|NCT01836107|Communication between physicians
1041319|NCT01836107|Quality
1041320|NCT01836107|Cross-cultural adaptation
1041321|NCT01836094|Methylene Blue
1041322|NCT01836094|Memory
1041323|NCT01836094|Mental Fatigue
1041324|NCT01836094|Brain metabolism
1041325|NCT01836094|fMRI
1041326|NCT01836094|psychomotor vigilance task (PVT)
1041327|NCT01836094|delayed match-to-sample memory task
1041328|NCT01836094|PVT
1041329|NCT01836094|DMS
1041330|NCT01836081|fluid responsiveness
1041331|NCT01836081|carotid artery peak velocity variation
1041332|NCT01836081|coronary disease
1041333|NCT01836068|HIV positive
1041334|NCT01836068|HIV-1
1041335|NCT01836068|Bone Marrow Transplant
1041336|NCT01836068|Allogeneic BMT
1041337|NCT01836068|BMT
1041338|NCT01836055|Multiple Sclerosis
1041339|NCT01836055|White Matter Lesions
1041340|NCT01836055|Contrast Agent
1041341|NCT01836055|Magnetic Resonance Imaging
1041342|NCT01836042|Primary open-angle glaucoma (POAG)
1041343|NCT01836042|Trabecular meshwork
1041344|NCT01836042|iStent
1041345|NCT01836029|SCCHN
1041346|NCT01836029|HNSCC
1041347|NCT01836016|Pulmonary Disease, Chronic Obstructive
1041348|NCT01836016|Comparative effectiveness research
1041349|NCT01836016|Medicine, Chinese Traditional
1041350|NCT01836016|Humans
1041351|NCT01836016|Treatment Outcome
1041352|NCT01836003|Pregnancy
1041353|NCT01836003|Prevention of Mother to Child Transmission
1041354|NCT01836003|Short Message Service (SMS)
1041355|NCT01836003|HIV infection
1041356|NCT01836003|CD4 testing
1041357|NCT01836003|Antiretroviral therapy
1041358|NCT01835990|venous thromboembolism
1041359|NCT01835990|trauma
1041360|NCT01835990|mechanical methods of prophylaxis
1041361|NCT01835977|Focal therapy
1041362|NCT01835977|Irreversible electroporation
1041363|NCT01835977|Unilateral prostate cancer
1041364|NCT01835964|Glucose Variability (GV)
1041365|NCT01835964|Continuous Glucose Monitor (CGM)
1041366|NCT01835951|Simulation
1041367|NCT01835951|Debriefing
1041368|NCT01835951|Anaesthesia Crisis Management
1041369|NCT01835951|Cardiac Arrest
1041370|NCT01835951|Pregnancy
1041371|NCT01835938|Hepatitis C Virus infection
1041372|NCT01835938|entry inhibitor
1041373|NCT01835938|kinase inhibitor
1041374|NCT01835925|adenocarcinoma of rectum
1041375|NCT01835925|rectal cancer
1041376|NCT01835925|stage II
1041377|NCT01835925|stage III
1041378|NCT01835912|performance
1041379|NCT01835912|speed
1041380|NCT01835912|exertion
1041381|NCT01835860|BPH
1041382|NCT01835834|zirconia crown
1041383|NCT01835821|zirconia
1041384|NCT01835821|crown
1041385|NCT01835821|IPS e.max CAD
1041386|NCT01835808|Fractional flow reserve
1041387|NCT01835795|Myofascial Pain Syndromes
1041388|NCT01835795|Myofascial Trigger Point
1041389|NCT01835795|Low Back Pain
1041390|NCT01835795|Lumbago
1041391|NCT01835795|Shock Waves, High-Energy
1041392|NCT01835795|High-Energy Shock Waves
1041393|NCT01835795|Interdisciplinary Health Team
1041394|NCT01835795|Multidisciplinary Pain Centers
1041395|NCT01835782|ALS
1041396|NCT01835782|L-Serine
1041397|NCT01835782|BMAA
1041398|NCT01835717|Preclinical phase of Alzheimer's disease
1041399|NCT01835717|Asymptomatic phase of Alzheimer's disease
1041400|NCT01835717|Cognitive normal
1041401|NCT01835717|Exogenous factors
1041402|NCT01835717|Endogenous factors
1041403|NCT01835717|Episodic memory test
1041404|NCT01835717|Executive function test
1041405|NCT01835717|Memory binding test validation into Spanish
1041406|NCT01835717|Memory binding test validation into Catalan
1041407|NCT01835691|Chronic Kidney Disease
1041408|NCT01835691|Vitamin D
1041409|NCT01835691|Vitamin D2
1041410|NCT01835691|Vitamin D3
1041411|NCT01835652|Exercise
1041412|NCT01835652|Parkinson's Disease
1041413|NCT01835652|Positron Emission Tomography
1041414|NCT01835652|fMRI
1041415|NCT01835639|Glomerular Disease
1041416|NCT01835639|Vitamin D
1041417|NCT01835639|Steroid-resistant nephrotic syndrome
1041418|NCT01835639|Minimal change disease
1041419|NCT01835639|Focal segmental glomerulosclerosis (FSGS)
1041420|NCT01835639|Membranous Nephropathy
1041421|NCT01835639|Membranoprolfierative Glomerulonephritis
1041422|NCT01835639|immunoglobulin A (IgA) Nephropathy
1041423|NCT01835639|FSGS
1041424|NCT01835639|IgA Nephropathy
1041425|NCT01835626|Locally advanced basal cell carcinoma
1041426|NCT01835626|Skin cancer
1041427|NCT01835626|Radiation therapy
1041428|NCT01835626|Vismodegib
1041429|NCT01835626|Head and neck cancer
1041430|NCT01835626|Cutaneous malignancy
1041431|NCT01835613|Rheumatoid Arthritis
1041432|NCT01835613|Early RA
1041433|NCT01835613|RA
1041434|NCT01835613|IL-6
1041435|NCT01835613|IL-6R
1041436|NCT01835613|Inhibitor
1041437|NCT01835613|Inhibition
1041438|NCT01835613|Tocilizumab
1041439|NCT01835613|Biomarkers
1041440|NCT01835613|DMARDs
1041441|NCT01835613|Biological
1041442|NCT01835613|DAS
1041443|NCT01835613|SDAI
1041444|NCT01835613|AR/BIOM
1041445|NCT01835613|OEG
1041446|NCT01835587|Acute myeloid leukemia,
1041447|NCT01835587|myelodysplastic syndromes,
1041448|NCT01835587|CC-486, oral Azacitidine,
1041449|NCT01835587|transplantation,
1041450|NCT01835587|allogeneic,
1041451|NCT01835587|HSCT.
1041452|NCT01835574|Amphetamine-type substance use
1041453|NCT01835561|Hepatic, Liver disease; Pharmacokinetic; Healthy
1041454|NCT01835509|Childhood Cancer Survivors
1041455|NCT01835496|sickle cell disease
1041456|NCT01835496|iron overload
1041457|NCT01835496|pharmacokinetics
1041458|NCT01835496|Ferriprox
1041459|NCT01835496|deferiprone
1041460|NCT01835457|Endotoxemia
1041461|NCT01835457|Autonomic Nervous System
1041462|NCT01835457|Inflammation
1041463|NCT01835457|Meditation
1041464|NCT01835457|Concentration
1041465|NCT01835457|Iceman
1041466|NCT01835457|LPS
1041467|NCT01835457|Cortisol
1041468|NCT01835457|Catecholamines
1041469|NCT01835444|Physician Assistant
1041470|NCT01835444|Substitution
1041471|NCT01835444|Hospital ward care
1041472|NCT01835444|Secondary health care
1041473|NCT01835418|managed with bedtime administration of lisinopril versus amlodipine
1041474|NCT01835392|Remote ischemic preconditioning
1041475|NCT01835392|Heart defects, congenital
1041476|NCT01835392|cardiac surgery
1041477|NCT01835392|Neurodevelopmental outcomes
1041478|NCT01835379|Diabetes
1041479|NCT01835379|Diabetic Foot Ulcer
1041480|NCT01835379|Diabetic Foot Wound
1041481|NCT01835379|Non-healing foot wound
1041482|NCT01835379|Oasis
1041483|NCT01835379|Diabetic neuropathy
1041484|NCT01835353|prasugrel
1041485|NCT01835353|ST elevation myocardial infarction
1041486|NCT01835327|intraoperative, post-operative recovery
1041487|NCT01835327|thoracic surgery
1041488|NCT01835327|cerebral oximetry
1041489|NCT01835262|pain
1041490|NCT01835262|Ketamine
1041491|NCT01835262|Emergency Medicine
1041492|NCT01835262|morphine
1041493|NCT01835249|Hypertension
1041494|NCT01835249|Nighttime blood pressure
1041495|NCT01835236|Breast cancer
1041496|NCT01835236|HER2-positive
1041497|NCT01835236|Metastases
1041498|NCT01835197|Phase 1
1041499|NCT01835197|Randomized
1041500|NCT01835197|Double Blind
1041501|NCT01835197|Placebo-Controlled
1041502|NCT01835197|Single- & Multiple Dose Escalation
1041503|NCT01835197|Safety
1041504|NCT01835197|Tolerability
1041505|NCT01835197|PK
1041506|NCT01835197|PD
1041507|NCT01835197|Pf-04965842
1041508|NCT01835132|Scleritis
1041509|NCT01835132|IL-1
1041510|NCT01835119|gynecological malignancies
1041511|NCT01835119|postoperative
1041512|NCT01835119|bowel activity
1041513|NCT01835119|gum chewing
1041514|NCT01835106|Postoperative Care
1041515|NCT01835080|Obstructive Sleep Apnea, OSA, Pulmonary Arterial Hypertension, PAH, sleep study, polysomnogram, Respiratory Disturbance Index, RDI
1041516|NCT01835067|Macular degeneration
1041517|NCT01835067|Submacular haemorrhage
1041518|NCT01835054|Mitral regurgitation
1041519|NCT01835054|Mitral valve prolapse
1041520|NCT01835054|Echocardiography, Doppler
1041521|NCT01835054|Stress echocardiography
1041522|NCT01835054|Cardiopulmonary exercice testing
1041523|NCT01835054|Magnetic Resonance Imaging
1041524|NCT01835054|Cardiac neurohormones
1041525|NCT01835054|Visceral obesity
1041526|NCT01835054|Cardiometabolic risk
1041527|NCT01835054|Risk stratification
1041528|NCT01835028|Aortic Stenosis
1041529|NCT01835028|Low Flow
1041530|NCT01835028|Low Gradient
1041531|NCT01835028|Left Ventricle
1041532|NCT01835028|Echocardiography, Doppler
1041533|NCT01835015|First in human
1041534|NCT01835015|Safety
1041535|NCT01835015|Tolerability
1041536|NCT01835015|Serum PK
1041537|NCT01835015|Intravitreal (IVT)
1041538|NCT01835015|Age-related macular degeneration
1041539|NCT01835015|AMD
1041540|NCT01835015|Geographic Atrophy
1041541|NCT01835015|Choroidal neovascularization
1041542|NCT01835002|transcorneal electrostimulation
1041543|NCT01834976|cardiac biomarker
1041544|NCT01834976|congenital heart disease
1041545|NCT01834976|surgery
1041546|NCT01834937|ExAblate
1041547|NCT01834937|MRgFUS
1041548|NCT01834937|Bone Metastases
1041549|NCT01834937|Pain Palliation
1041550|NCT01834924|Health literacy
1041551|NCT01834924|Patient education
1041552|NCT01834911|Huntington disease
1041553|NCT01834911|HD
1041554|NCT01834911|tetrabenazine
1041555|NCT01834911|Stroop
1041556|NCT01834898|postoperative
1041557|NCT01834898|analgesia
1041558|NCT01834898|adverse effects
1041559|NCT01834898|opioid
1041560|NCT01834898|oxycodone
1041561|NCT01834885|COPD
1041562|NCT01834859|weight reduction programs
1041563|NCT01834859|diet
1041564|NCT01834859|Caloric restriction
1041565|NCT01834859|weight loss
1041566|NCT01834859|weight gain
1041567|NCT01834846|comparative study
1041568|NCT01834846|Cardiac Surgical Procedures
1041569|NCT01834833|Acute heart failure; rehospitalisation; education; follow-up
1041570|NCT01834820|Bronchiolitis
1041571|NCT01834820|Epinephrine
1041572|NCT01834820|Dexamethasone
1041573|NCT01834820|Hospitalization
1041574|NCT01834820|Hypertonic Saline
1041575|NCT01834794|Tobacco Use
1041576|NCT01834781|multiple chemical sensitivity, re5 therapy, pulsed electromagnetic fields
1041577|NCT01834742|Moviprep
1041578|NCT01834742|PEG3350
1041579|NCT01834742|Laxative
1041580|NCT01834742|Stool Output
1041581|NCT01834690|Liver transplantation/epidemiology
1041582|NCT01834690|Liver transplantation/pharmacology
1041583|NCT01834690|Health status/drug effects
1041584|NCT01834690|Agents, immunosuppressive agents
1041585|NCT01834677|Depression
1041586|NCT01834677|Neurocognition
1041587|NCT01834677|Electroconvulsive Therapy (ECT)
1041588|NCT01834677|Parkinson's Disease
1041589|NCT01834664|Ataxic Infantile Cerebral Palsy stem cell therapy
1041590|NCT01834651|liver metastasis
1041591|NCT01834651|lung metastasis
1041592|NCT01834651|metastatic castrate-resistant
1041593|NCT01834651|prostate cancer
1041594|NCT01834638|schizophrenia
1041595|NCT01834612|blood loss, hemorrhage, hemorrhagic shcok
1041596|NCT01834599|placental oxygenation
1041597|NCT01834599|obstetric anesthesia
1041598|NCT01834599|NIRS
1041599|NCT01834599|cerebral oximetry
1041600|NCT01834599|cerebral oximeter
1041601|NCT01834573|inflammatory bowel disease
1041602|NCT01834573|IBD
1041603|NCT01834573|quality of life
1041604|NCT01834573|Inflammatory Bowel Disease Questionnaire
1041605|NCT01834560|deep brain stimulation
1041606|NCT01834560|subgenual cortex (CG25)
1041607|NCT01834547|chess, cognition
1041608|NCT01834521|Breast cancer
1041609|NCT01834521|psychosocial
1041610|NCT01834521|website
1041611|NCT01834521|empowerment
1041612|NCT01834508|Experienced Treatment
1041613|NCT01834495|Peripheral artery disease
1041614|NCT01834495|atherosclerosis
1041615|NCT01834495|stent
1041616|NCT01834482|seizures
1041617|NCT01834482|epilepsy
1041618|NCT01834482|adult
1041619|NCT01834482|intractable
1041620|NCT01834482|medically refractory
1041621|NCT01834482|Atkins
1041622|NCT01834482|ketogenic
1041623|NCT01834482|diet
1041624|NCT01834469|Ovarian,metastasis
1041625|NCT01834456|Medically Complex Children
1041626|NCT01834456|Family Experience in Healthcare
1041627|NCT01834456|Patient Centered Care
1041628|NCT01834456|Family Centered Care
1041629|NCT01834456|Case Management
1041630|NCT01834456|Care Management
1041631|NCT01834456|Care Coordination
1041632|NCT01834456|Care Plan
1041633|NCT01834456|Extensivist
1041634|NCT01834456|Medical Home
1041635|NCT01834456|Children with Special Health Care Needs
1041636|NCT01834456|Coordinated Care
1041637|NCT01834456|Quality in Healthcare
1041638|NCT01834456|Satisfaction in Healthcare
1041639|NCT01834456|Cost
1041640|NCT01834456|Utilization
1041641|NCT01834456|Impact on Family
1041642|NCT01834456|Quality of Life
1041643|NCT01834456|Palliative Care
1041644|NCT01834456|Complex Chronic Conditions
1041645|NCT01834456|Life-limiting illness
1041646|NCT01834456|Integrative Care
1041647|NCT01834456|Primary Care
1041648|NCT01834456|Comprehensive Care
1041649|NCT01834456|Behavioral Care
1041650|NCT01834443|spatial neglect
1041651|NCT01834443|galvanic vestibular stimulation as therapy
1041652|NCT01834417|Pressure ulcer, spinal cord injury, on-board device
1041653|NCT01834404|Obesity
1041654|NCT01834404|BMI
1041655|NCT01834404|Incretin
1041656|NCT01834404|Satiety
1041657|NCT01834404|Phentermine
1041658|NCT01834404|Topiramate
1041659|NCT01834378|diabetes
1041660|NCT01834378|insulin resistance
1041661|NCT01834378|exercise
1041662|NCT01834365|Hypertension
1041663|NCT01834352|Walnut hypersensitivity
1041664|NCT01834352|Tree nut hypersensitivity
1041665|NCT01834339|vestibuloplasty
1041666|NCT01834326|dental implants
1041667|NCT01834326|deficient keratinized oral mucosa
1041668|NCT01834313|Willingness-to-pay
1041669|NCT01834313|Patient-centredness
1041670|NCT01834313|Health insurers
1041671|NCT01834313|Fertility care
1041672|NCT01834300|Hepatic insulin sensitivity
1041673|NCT01834300|Muscle insulin sensitivity
1041674|NCT01834300|B cell function
1041675|NCT01834300|VLDL1 TG metabolism
1041676|NCT01834300|VLDL2 TG metabolism
1041677|NCT01834287|Physical Activity
1041678|NCT01834287|Latinas
1041679|NCT01834287|Web-based
1041680|NCT01834287|Spanish-language
1041681|NCT01834274|Drug Therapy
1041682|NCT01834261|oxytocin
1041683|NCT01834261|trust
1041684|NCT01834261|kinship
1041685|NCT01834261|kin selection
1041686|NCT01834235|Pancreatic neoplasms
1041687|NCT01834235|Pancreatic cancer
1041688|NCT01834235|Pancreatic cancer, adult
1041689|NCT01834235|Adenoma of the pancreas
1041690|NCT01834235|Carcinoma of the pancreas
1041691|NCT01834209|Prostate neoplasms
1041692|NCT01834209|Prostate cancer
1041693|NCT01834209|Metastatic prostate cancer
1041694|NCT01834209|Metatatic castration resistant prostate cancer
1041695|NCT01834209|Abiraterone acetate
1041696|NCT01834209|Prednisone
1041697|NCT01834209|Prednisolone
1041698|NCT01834209|Early access program
1041699|NCT01834196|retinal vascular disease
1041700|NCT01834196|Swept-Source Ocular Coherence Tomography
1041701|NCT01834196|SSOCT
1041702|NCT01834183|Metastatic
1041703|NCT01834170|Pancreatic cancer
1041704|NCT01834170|Pancreatic adenocarcinoma
1041705|NCT01834170|Endoscopic ultrasound
1041706|NCT01834144|Type 1 Diabetes
1041707|NCT01834144|Hypoglycaemia
1041708|NCT01834144|Glycaemic variability
1041709|NCT01834144|Vigorous Intensity Physical Activity
1041710|NCT01834144|Continuous Glucose Monitoring
1041711|NCT01834131|hypertension
1041712|NCT01834131|community health worker
1041713|NCT01834131|home health education
1041714|NCT01834131|medication adherence
1041715|NCT01834131|mobile health
1041716|NCT01834131|physician education
1041717|NCT01834131|home blood pressure monitoring
1041718|NCT01834131|implementation
1041719|NCT01834105|Postmenopausal osteoporosis; Kidney Yin deficiency syndrome; Liuwei dihuang pill; CLCF1; JAK - STAT signal pathway
1041720|NCT01834092|Abdominal Aortic Aneurism
1041721|NCT01834092|Endothelia
1041722|NCT01834092|Glycocalyx
1041723|NCT01834092|Reperfusion
1041724|NCT01834092|Plasma
1041725|NCT01834079|Optic Atrophy,Stem cell therapy
1041726|NCT01834066|muscular Dystrophy stem cell
1041727|NCT01834053|Huntington Disease,stem cell therapy
1041728|NCT01834040|Duchenne Muscular Dystrophy
1041729|NCT01834040|Muscular Dystrophy
1041730|NCT01834040|Myopathy
1041731|NCT01834027|music
1041732|NCT01834027|stress
1041733|NCT01834027|anxiety
1041734|NCT01834027|post-surgical
1041735|NCT01834027|pain
1041736|NCT01834014|Liver only metastasis from KRAS Exon 2 wild type
1041737|NCT01834014|Liver only metastasis from RAS wild type
1041738|NCT01834001|MRI
1041739|NCT01834001|Prostate Cancer
1041740|NCT01834001|MRI-Guided Biopsy
1041741|NCT01834001|Radiation
1041742|NCT01834001|Biochemical Failure
1041743|NCT01833988|bionic pancreas
1041744|NCT01833988|artificial pancreas
1041745|NCT01833988|insulin
1041746|NCT01833988|glucagon
1041747|NCT01833988|continuous glucose monitoring (CGM)
1041748|NCT01833988|outpatient
1041749|NCT01833988|insulin pump
1041750|NCT01833988|pediatrics
1041751|NCT01833988|children
1041752|NCT01833988|camp
1041753|NCT01833988|summer camp
1041754|NCT01833975|Spinal Cord Injury stem cell
1041755|NCT01833962|Lumbar fusion rates
1041756|NCT01833962|Actifuse synthetic bone graft
1041757|NCT01833962|Baxter Healthcare
1041758|NCT01833962|Other synthetic bone graft
1041759|NCT01833949|polycystic ovary syndrome,laparoscopic ovarian drilling
1041760|NCT01833936|Achilles
1041761|NCT01833923|Advanced cancer
1041762|NCT01833910|Cardiopulmonary Resuscitation
1041763|NCT01833910|Education
1041764|NCT01833897|Bipolar Disorder
1041765|NCT01833884|Hodgkin Lymphoma, Adult
1041766|NCT01833884|Cytokines
1041767|NCT01833884|TARC
1041768|NCT01833884|IL-6
1041769|NCT01833884|IL1-RA
1041770|NCT01833884|sCD30
1041771|NCT01833884|TNFR1
1041772|NCT01833845|HCV
1041773|NCT01833845|Hepatitis C
1041774|NCT01833845|Hep-C
1041775|NCT01833832|Synergy for Cisplatin and Hyperthermia
1041776|NCT01833832|Rare Tumor
1041777|NCT01833832|Poor Prognosis
1041778|NCT01833819|Laparoscopic cholecystectomy,
1041779|NCT01833819|Total intravenous anesthesia,
1041780|NCT01833819|Propofol,
1041781|NCT01833819|Dexmedetomidine,
1041782|NCT01833819|Lidocaine,
1041783|NCT01833819|Remifentanil,
1041784|NCT01833819|Postoperative analgesic consumption,
1041785|NCT01833819|Postoperative nausea and vomiting
1041786|NCT01833793|Mirena
1041787|NCT01833793|Contraception
1041788|NCT01833793|Amenorrhea
1041789|NCT01833780|carriage status
1041790|NCT01833780|Culture
1041791|NCT01833780|PCR
1041792|NCT01833754|Osteoporosis, Bone, Renal, Insufficiency, Kidney, Hemodialysis, Impairment
1041793|NCT01833715|Pain, Postoperative
1041794|NCT01833715|Analgesics, Opioid
1041795|NCT01833715|Methadone
1041796|NCT01833715|Morphine
1041797|NCT01833702|Sickle cell
1041798|NCT01833702|Pain
1041799|NCT01833689|glucose response
1041800|NCT01833689|glycaemic index
1041801|NCT01833676|sevoflurane
1041802|NCT01833676|desflurane
1041803|NCT01833676|protective airway reflexes
1041804|NCT01833676|elderly
1041805|NCT01833663|Overactive Bladder
1041806|NCT01833663|Solifenacin Succinate Tablets
1041807|NCT01833663|Estrogen
1041808|NCT01833650|thyroid cancer
1041809|NCT01833650|radioiodine treatment
1041810|NCT01833650|xerostomia
1041811|NCT01833650|sialadenitis
1041812|NCT01833637|Advanced Care Planning
1041813|NCT01833637|Palliative Care
1041814|NCT01833637|Women
1041815|NCT01833598|Chronic tendinopathy
1041816|NCT01833598|platelet rich plasma
1041817|NCT01833598|tendonitis
1041818|NCT01833598|percutaneous tendon tenotomy
1041819|NCT01833598|pain
1041820|NCT01833598|shoulder
1041821|NCT01833598|knee
1041822|NCT01833598|ankle
1041823|NCT01833598|foot
1041824|NCT01833585|critical limb ischemia
1041825|NCT01833585|atherosclerosis
1041826|NCT01833585|ischemic ulcer
1041827|NCT01833585|rest pain
1041828|NCT01833585|gangrene
1041829|NCT01833572|epidermal growth factor receptor
1041830|NCT01833572|EGFR mutation
1041831|NCT01833572|Tyrosine kinase inhibitor
1041832|NCT01833572|gefitinib
1041833|NCT01833572|neo-adjuvant therapy
1041834|NCT01833546|Solid tumor
1041835|NCT01833546|Pancreatic cancer
1041836|NCT01833546|TH-302
1041837|NCT01833546|gemcitabine
1041838|NCT01833546|Evofosfamide
1041839|NCT01833533|Chronic Hepatitis C
1041840|NCT01833533|Hepatitis C Virus
1041841|NCT01833533|Hepatitis C Genotype 1a
1041842|NCT01833533|Hepatitis C
1041843|NCT01833533|Treatment-Naïve
1041844|NCT01833533|Interferon-Free
1041845|NCT01833533|Paritaprevir
1041846|NCT01833533|Ombitasvir
1041847|NCT01833533|Dasabuvir
1041848|NCT01833533|Ribavirin
1041849|NCT01833533|Viekira PAK
1041850|NCT01833520|Sarcoma
1041851|NCT01833520|Osteosarcoma
1041852|NCT01833520|recurrent or metastatic
1041853|NCT01833520|Ra-223 dichloride
1041854|NCT01833520|Radium-223 chloride
1041855|NCT01833520|Alpharadin
1041856|NCT01833507|increased activity
1041857|NCT01833507|weight loss
1041858|NCT01833507|obesity
1041859|NCT01833494|Hemodialysis
1041860|NCT01833494|Hyperphosphatemia
1041861|NCT01833481|Surgical approach
1041862|NCT01833481|Direct-anterior
1041863|NCT01833481|Anterior-lateral
1041864|NCT01833481|Posterior-lateral
1041865|NCT01833481|Hip implant
1041866|NCT01833481|Total Hip Arthroplasty
1041867|NCT01833481|Total Hip replacement
1041868|NCT01833481|Hip replacement
1041869|NCT01833481|Hip prosthesis
1041870|NCT01833468|ankylosing spondylitis
1041871|NCT01833468|Psoriatic arthritis
1041872|NCT01833468|Foot
1041873|NCT01833468|FAOS
1041874|NCT01833468|SpA-TRI
1041875|NCT01833442|OCD
1041876|NCT01833442|YBOCS
1041877|NCT01833429|Resistant hypertension
1041878|NCT01833429|White-coat phenomenon
1041879|NCT01833429|Heart rate variability
1041880|NCT01833429|autonomic activity
1041881|NCT01833416|CMV infection
1041882|NCT01833416|CMV disease
1041883|NCT01833416|Natural history
1041884|NCT01833416|Kidney transplant
1041885|NCT01833403|bariatric surgery, l
1041886|NCT01833403|liver insulin resistance,
1041887|NCT01833390|Hyperpolarized Xenon
1041888|NCT01833390|HXe
1041889|NCT01833390|MagniXene
1041890|NCT01833377|obesity
1041891|NCT01833377|overweight
1041892|NCT01833377|BMI
1041893|NCT01833364|Parkinson's Disease
1041894|NCT01833364|Deep Brain Stimulation
1041895|NCT01833364|Peripheral Nerve Graft
1041896|NCT01833351|Phase I
1041897|NCT01833351|safety and pharmacokinetics,
1041898|NCT01833351|intravenous ascorbate,
1041899|NCT01833351|IV Vitamin C,
1041900|NCT01833351|Oncology
1041901|NCT01833338|Non ST elevation myocardial infarction
1041902|NCT01833338|optical coherence tomography
1041903|NCT01833338|intravascular ultrasound
1041904|NCT01833338|multi-slice computed tomography
1041905|NCT01833325|Age-Related Macular Degeneration
1041906|NCT01833325|Macular Degeneration
1041907|NCT01833325|Proton radiation
1041908|NCT01833325|Choroidal Neovascular Membranes
1041909|NCT01833312|acute ischemic stroke
1041910|NCT01833312|hypothermia
1041911|NCT01833299|TACE
1041912|NCT01833299|Sorafenib
1041913|NCT01833299|overall survival
1041914|NCT01833299|time to progression
1041915|NCT01833286|hepatocellular carcinoma
1041916|NCT01833286|repeat hepatectomy
1041917|NCT01833286|radiofrequency ablation
1041918|NCT01833286|transcatheter arterial chemoembolization
1041919|NCT01833247|epilepsy
1041920|NCT01833247|lactic acid
1041921|NCT01833247|saliva
1041922|NCT01833247|postictal
1041923|NCT01833234|epilepsy
1041924|NCT01833234|quality of life
1041925|NCT01833234|seizure severity
1041926|NCT01833234|antiepileptic drug side effects
1041927|NCT01833234|questionnaire
1042058|NCT01832714|I-Portal
1041928|NCT01833234|patient reported outcomes
1041929|NCT01833221|facial palsy
1041930|NCT01833221|lengthening temporalis myoplasty
1041931|NCT01833221|neurotization of facial muscles
1041932|NCT01833195|molecular diagnostics
1041933|NCT01833195|heart transplantation
1041934|NCT01833195|risk factors
1041935|NCT01833195|prognosis
1041936|NCT01833182|falls in community dwelling older adults
1041937|NCT01833182|falls and ADL performance
1041938|NCT01833182|tailored home intervention
1041939|NCT01833169|Solid tumor
1041940|NCT01833169|malignancy
1041941|NCT01833169|hematologi malignancy
1041942|NCT01833169|PI3K pathway activation
1041943|NCT01833169|BKM120
1041944|NCT01833169|signature
1041945|NCT01833169|AML, acute myelogenous leukemia
1041946|NCT01833169|cervical, ovarian
1041947|NCT01833169|hepatobiliary
1041948|NCT01833169|buparlisib
1041949|NCT01833156|local edema
1041950|NCT01833156|dielectric constant values
1041951|NCT01833156|validation study
1041952|NCT01833143|KRAS-Mutant
1041953|NCT01833143|Bortezomib
1041954|NCT01833143|KRAS G12D
1041955|NCT01833143|12-222
1041956|NCT01833117|Dry eye
1041957|NCT01833117|Tear film
1041958|NCT01833117|Tear break-up time
1041959|NCT01833117|Ocular surface
1041960|NCT01833117|Eye drops
1041961|NCT01833104|Healthy subjects
1041962|NCT01833039|Mantle Cell Lymphoma
1041963|NCT01833039|Ibrutinib
1041964|NCT01833026|pulmonary disease
1041965|NCT01833026|chronic obstructive airflow
1041966|NCT01833026|spirometry
1041967|NCT01833026|primary healthcare
1041968|NCT01833026|guideline-based therapy
1041969|NCT01833013|Endometriosis
1041970|NCT01833013|Cohort study
1041971|NCT01833013|fertility
1041972|NCT01833013|pregnancy
1041973|NCT01833013|assisted reproductive technics
1041974|NCT01833013|laparoscopy
1041975|NCT01833000|rectal bleeding
1041976|NCT01833000|necrotizing enterolitis
1041977|NCT01833000|splanchnic oxygenation
1041978|NCT01833000|mesenteric doppler
1041979|NCT01832987|co-trimoxazole
1041980|NCT01832987|sulfamethoxazole
1041981|NCT01832987|tuberculosis
1041982|NCT01832987|pharmacokinetics
1041983|NCT01832974|Adrenal Gland Cancer
1041984|NCT01832974|Treatment Refractory Malignancies
1041985|NCT01832974|Metastatic Cancer
1041986|NCT01832961|COPD
1041987|NCT01832961|physiotherapy care
1041988|NCT01832961|lung function testing
1041989|NCT01832961|inflammation
1041990|NCT01832935|Glargin
1041991|NCT01832935|NPH
1041992|NCT01832935|Cost-effectiveness
1041993|NCT01832922|bendamustine
1041994|NCT01832922|rituximab
1041995|NCT01832922|Chronic Lymphocytic Leukemia
1041996|NCT01832922|comorbidities
1041997|NCT01832922|renal insufficiency
1041998|NCT01832909|metabolizable energy
1041999|NCT01832909|walnuts
1042000|NCT01832909|Atwater factors
1042001|NCT01832909|energy value
1042002|NCT01832896|Hereditary Angioedema
1042003|NCT01832896|Children
1042004|NCT01832896|Adolescents
1042005|NCT01832896|Ecallantide
1042006|NCT01832857|metastatic
1042007|NCT01832857|advanced
1042008|NCT01832857|solid tumor
1042009|NCT01832857|cancer
1042010|NCT01832857|colon cancer
1042011|NCT01832857|hepatocellular carcinoma
1042012|NCT01832857|breast cancer
1042013|NCT01832857|lung cancer
1042014|NCT01832857|gastric cancer
1042015|NCT01832857|esophageal cancer
1042016|NCT01832844|Scan control
1042017|NCT01832844|Epidural infiltration
1042018|NCT01832844|visual analogue scale (VAS)
1042019|NCT01832818|Total Disc Replacement
1042020|NCT01832805|depression
1042021|NCT01832779|Achalasia
1042022|NCT01832766|schizophrenia
1042023|NCT01832766|dronabinol
1042024|NCT01832766|P50
1042025|NCT01832766|cannabis
1042026|NCT01832766|memory
1042027|NCT01832766|symptoms
1042028|NCT01832753|Down syndrome
1042029|NCT01832753|subclinical hypothyroidism
1042030|NCT01832753|thyroid
1042031|NCT01832753|levothyroxine
1042032|NCT01832740|young healthy subjects
1042033|NCT01832740|brain stimulation
1042034|NCT01832740|tSOS
1042035|NCT01832740|tDCS
1042036|NCT01832740|sleep
1042037|NCT01832740|memory
1042038|NCT01832740|memory consolidation
1042039|NCT01832727|multiple myeloma
1042040|NCT01832727|oprozomib
1042041|NCT01832727|OPZ
1042042|NCT01832727|ONX 0912
1042043|NCT01832727|Onyx
1042044|NCT01832727|proteasome inhibitor
1042045|NCT01832727|oprozomib tablets
1042046|NCT01832714|Concussion
1042047|NCT01832714|mTBI
1042048|NCT01832714|military
1042049|NCT01832714|MACE
1042050|NCT01832714|NKI
1042051|NCT01832714|NOTC
1042052|NCT01832714|VNG
1042053|NCT01832714|VOG
1042054|NCT01832714|Neuro Kinetics
1042055|NCT01832714|oculomotor
1042056|NCT01832714|vestibular
1042057|NCT01832714|reaction time
1042059|NCT01832714|eye tracking
1042060|NCT01832714|Dizziness Handicap Inventory
1042061|NCT01832688|iron and folic acid supplements
1042062|NCT01832688|anemia
1042063|NCT01832688|gestational weight gain
1042064|NCT01832675|Endoscopy
1042065|NCT01832675|Anesthetics, Local
1042066|NCT01832675|Bupivacaine
1042067|NCT01832675|Lidocaine
1042068|NCT01832649|Exercise
1042069|NCT01832649|Cocaine dependence
1042070|NCT01832636|L-Alanyl-L-Glutamine
1042071|NCT01832636|Environmental enteric dysfunction
1042072|NCT01832636|Tropical enteropathy
1042073|NCT01832623|Vitamin D
1042074|NCT01832623|bone
1042075|NCT01832623|cardiovascular status
1042076|NCT01832623|nutritional status
1042077|NCT01832584|Red Grapes
1042078|NCT01832584|polyphenols
1042079|NCT01832584|cyclists
1042080|NCT01832584|resveratrol
1042081|NCT01832584|aerobic fitness
1042082|NCT01832584|trained
1042083|NCT01832571|HIV
1042084|NCT01832571|PrEP
1042085|NCT01832571|Female Sex Workers
1042086|NCT01832571|Kenya
1042087|NCT01832545|Aquatic exercise
1042088|NCT01832545|Knee Osteoarthritis
1042089|NCT01832545|Exercise
1042090|NCT01832545|Pain
1042091|NCT01832545|Obesity.
1042092|NCT01832532|Sleep Apnea
1042093|NCT01832532|Sleep Disordered Breathing
1042094|NCT01832532|liraglutide
1042095|NCT01832532|glucagon-like peptide-1 agonist
1042096|NCT01832532|Orexin
1042097|NCT01832532|leptin,
1042098|NCT01832519|Cystic Fibrosis
1042099|NCT01832519|CF
1042100|NCT01832519|MRI
1042101|NCT01832519|vascularization
1042102|NCT01832519|perfusion
1042103|NCT01832506|Solid Tumors
1042104|NCT01832506|MSC2156119J
1042105|NCT01832506|c-Met inhibitor
1042106|NCT01832506|Japanese
1042107|NCT01832506|Phase 1
1042108|NCT01832480|Trichomonas vaginalis
1042109|NCT01832480|metronidazole
1042110|NCT01832467|cetuximab-based chemotherapy
1042111|NCT01832467|previously treated
1042112|NCT01832454|cerebral palsy stem cells [MNCS]
1042113|NCT01832441|Diabetes Mellitus stem cells [MNCS ]
1042114|NCT01832415|First line treatment
1042115|NCT01832415|Ovarian cancer
1042116|NCT01832415|Avastin
1042117|NCT01832415|fallopian tube or primary peritoneal
1042118|NCT01832402|Advanced Cancers
1042119|NCT01832402|Exercise-Induced Breakthrough Dyspnea
1042120|NCT01832402|Shortness of breath
1042121|NCT01832402|Fentanyl pectin nasal spray
1042122|NCT01832402|Placebo nasal spray
1042123|NCT01832402|Walk test
1042124|NCT01832402|Questionnaires
1042125|NCT01832402|Surveys
1042126|NCT01832402|Mental ability tests
1042127|NCT01832389|Subarachnoid Haemorrhage (SAH)
1042128|NCT01832389|vasospasm
1042129|NCT01832389|delayed cerebral ischaemia (DCI)
1042130|NCT01832389|goal directed therapy (GDT)
1042131|NCT01832389|Pulse Contour Cardiac Output (PiCCO)
1042132|NCT01832376|Calcific tendinitis
1042133|NCT01832376|Shoulder
1042134|NCT01832376|Needle lavage
1042135|NCT01832376|Ultrasound-guided
1042136|NCT01832363|Severe asthma
1042137|NCT01832363|Bronchial thermoplasty
1042138|NCT01832363|MagniXene
1042139|NCT01832363|Hyperpolarized Xenon
1042140|NCT01832363|HXe
1042141|NCT01832363|HyXe
1042142|NCT01832324|Food Allergy
1042143|NCT01832324|Eosinophilic Esophagitis
1042144|NCT01832324|Food Protein Induced Enterocolitis
1042145|NCT01832324|iNKT Cells
1042146|NCT01832324|T cells
1042147|NCT01832311|type 2 diabetes mellitus
1042148|NCT01832311|cataract
1042149|NCT01832311|cytokines
1042150|NCT01832311|chemokines
1042151|NCT01832311|aqueous humor
1042152|NCT01832298|Tolerability
1042153|NCT01832298|Pharmacokinetics
1042154|NCT01832285|fluvoxamine
1042155|NCT01832285|cognition
1042156|NCT01832285|schizophrenia
1042157|NCT01832285|protein expression
1042158|NCT01832272|Osteoarthritis
1042159|NCT01832272|Knee
1042160|NCT01832272|Total knee arthroplasty
1042161|NCT01832272|Tourniquet
1042162|NCT01832272|Early release
1042163|NCT01832272|Reinflation
1042164|NCT01832246|endoscopy
1042165|NCT01832246|endosonography
1042166|NCT01832246|stomach cancer
1042167|NCT01832246|tumor staging
1042168|NCT01832220|Genomics
1042169|NCT01832220|Microbiome
1042170|NCT01832220|Microflora
1042171|NCT01832220|Virome
1042172|NCT01832220|Alpha-1
1042173|NCT01832194|Scrotal pain
1042174|NCT01832194|Botox
1042175|NCT01832181|Diabetes
1042176|NCT01832181|MiTy
1042177|NCT01832181|Metformin in Women
1042178|NCT01832181|Type 2 Diabetes Pregnancy
1042179|NCT01832155|Yoga
1042180|NCT01832155|Knee osteoarthritis
1042181|NCT01832155|Symptom management
1042182|NCT01832155|Older women
1042183|NCT01832155|Pain
1042184|NCT01832155|Stiffness
1042185|NCT01832155|Physical function)
1042186|NCT01832155|Physical function of the lower extremities
1042187|NCT01832155|Quality of sleep
1042188|NCT01832155|Quality of life
1042189|NCT01832116|Pancreatic cancer
1042190|NCT01832116|Ovarian cancer
1042191|NCT01832077|sensibility
1042192|NCT01832077|specificity
1042193|NCT01832077|positive predictive value
1042194|NCT01832077|negative predictive value
1042195|NCT01832077|Cost-effectiveness
1042196|NCT01832064|chronic disease
1042197|NCT01832064|patient education
1042198|NCT01832064|self management
1042199|NCT01832051|HER2-PET
1042200|NCT01832051|89Zr-trastuzumab
1042201|NCT01832051|metastatic breast cancer
1042202|NCT01832051|clinical dilemma
1042203|NCT01832038|Lacosamide
1042204|NCT01832038|Epilepsy
1042205|NCT01832038|Partial-onset Seizures
1042206|NCT01832025|intraoperative
1042207|NCT01832025|postoperative
1042208|NCT01832025|complications
1042209|NCT01832025|discomfort
1042210|NCT01832025|external
1042211|NCT01832025|internal
1042212|NCT01832025|maxillary
1042213|NCT01832025|elevation
1042214|NCT01832025|implant
1042215|NCT01832025|reconstruction
1042216|NCT01832025|bone
1042217|NCT01832025|sinus
1042218|NCT01832012|Eliciting which type of refresher provides the greatest improvement in BLS CPR skills.
1042219|NCT01831999|Web-based
1042220|NCT01831999|HIV Assessment
1042221|NCT01831999|Outreach
1042222|NCT01831999|Retention
1042223|NCT01831999|Substance Abuse Treatment
1042224|NCT01831986|Schizophrenia
1042225|NCT01831986|Schizoaffective disorder
1042226|NCT01831986|Pregnenolone
1042227|NCT01831986|L-Theanine
1042228|NCT01831986|Augmentation
1042229|NCT01831960|Intrepid
1042230|NCT01831960|cortexolone
1042231|NCT01831960|cortexolone 17α-propionate
1042232|NCT01831960|anti-androgen
1042233|NCT01831947|age-related macular degeneration
1042234|NCT01831947|Ranibizumab
1042235|NCT01831934|Mitochondrial disorder
1042236|NCT01831934|Trivalent inactivated influenza vaccine
1042237|NCT01831934|Adolescents and adults
1042238|NCT01831934|Immune response
1042239|NCT01831934|Metabolic response
1042240|NCT01831921|pre diabetes
1042241|NCT01831921|obesity
1042242|NCT01831921|weight loss
1042243|NCT01831921|lifestyle
1042244|NCT01831921|prevention
1042245|NCT01831908|cardiovascular health, stroke, ischemic heart disease
1042246|NCT01831895|Hypertension
1042247|NCT01831895|Carotid Sinus
1042248|NCT01831869|Subclinical hypothyroidism
1042249|NCT01831869|L-thyroxine
1042250|NCT01831869|Lipid
1042251|NCT01831869|endothelial function
1042252|NCT01831869|inflammatory factor
1042253|NCT01831869|adipocytokine
1042254|NCT01831856|Cardiovascular diseases
1042255|NCT01831856|Chronic Heart Failure
1042256|NCT01831843|core body temperature
1042257|NCT01831843|humidity
1042258|NCT01831843|circuit temperature
1042259|NCT01831830|traumatic brain injury
1042260|NCT01831830|occupational therapy
1042261|NCT01831830|family
1042262|NCT01831804|diabetic foot ulcer
1042263|NCT01831804|pharmacodynamics
1042264|NCT01831804|pharmacokinetics
1042265|NCT01831804|ischemic
1042266|NCT01831791|male pattern hair loss
1042267|NCT01831791|safety
1042268|NCT01831791|Dutasteride
1042269|NCT01831791|efficacy
1042270|NCT01831791|hair growth
1042271|NCT01831791|Androgenetic alopecia
1042272|NCT01831791|hair restoration
1042273|NCT01831778|mammography
1042274|NCT01831778|screening
1042275|NCT01831752|Diabetes
1042276|NCT01831752|Type 1
1042277|NCT01831752|Continuous glucose monitor
1042278|NCT01831739|Genomics
1042279|NCT01831739|Microbiome
1042280|NCT01831739|Microflora
1042281|NCT01831739|Virome
1042282|NCT01831726|Solid tumor malignancy
1042283|NCT01831726|hematologic malignancy
1042284|NCT01831726|mutation
1042285|NCT01831726|translocations
1042286|NCT01831726|FGFR
1042287|NCT01831726|PDGFR
1042288|NCT01831726|VEGF
1042289|NCT01831726|cKIT
1042290|NCT01831726|FLT3
1042291|NCT01831726|CSR1
1042292|NCT01831726|Trk
1042293|NCT01831726|RET
1042294|NCT01831726|TKI258
1042295|NCT01831726|dovitinib
1042296|NCT01831726|signature
1042297|NCT01831726|AML
1042298|NCT01831726|acute myelogenous leukemia
1042299|NCT01831726|GIST
1042300|NCT01831726|gastrointestinal stromal tumor
1042301|NCT01831726|Head and Neck cancer
1042302|NCT01831726|Melanoma
1042303|NCT01831726|NSCLC
1042304|NCT01831726|non-small cell lung carcinoma
1042305|NCT01831726|lung cancer
1042306|NCT01831726|ovarian cancer
1042307|NCT01831726|thyroid cancer
1042308|NCT01831726|amplification
1042309|NCT01831648|IGF1
1042310|NCT01831648|standards
1042311|NCT01831648|Assays
1042312|NCT01831648|Z-score
1042313|NCT01831648|Healthy volunteers
1042314|NCT01831648|Population
1042315|NCT01831622|Decision-Making
1042316|NCT01831622|functional MRI
1042317|NCT01831622|pharmacological MRI
1042318|NCT01831622|Reinforcement Learning
1042319|NCT01831622|Methylphenidate
1042320|NCT01831609|Gastrointestinal
1042321|NCT01831609|Genitourinary
1042322|NCT01831609|Rare Cancer
1042323|NCT01831583|sleep apnea
1042324|NCT01831570|Hand osteoarthritis
1042325|NCT01831570|predictive factors
1042326|NCT01831570|erosive hand OA
1042327|NCT01831544|Heart Failure
1042328|NCT01831518|Heart Failure
1042329|NCT01831518|Cardiac Resynchronization Therapy
1042330|NCT01831518|ECG Imaging
1042331|NCT01831518|Body Surface Mapping
1042332|NCT01831505|personalized medicine
1042333|NCT01831505|in vivo drug sensitivity
1042334|NCT01831505|chemotherapy
1042335|NCT01831505|lymphoma
1042336|NCT01831505|microinjection
1042337|NCT01831492|performance
1042338|NCT01831492|acidosis
1042339|NCT01831492|oxidative stress
1042340|NCT01831492|inflammation
1042341|NCT01831492|oxygen uptake
1042342|NCT01831479|Pharmacokinetics, drug-drug interaction
1042343|NCT01831466|plaque psoriasis
1042344|NCT01831466|vulgaris
1042345|NCT01831466|topical treatment
1042346|NCT01831466|skin diseases
1042347|NCT01831466|papulosquamous
1042348|NCT01831466|Tofacitinib
1042349|NCT01831466|CP-690550
1042350|NCT01831466|Xeljanz
1042351|NCT01831466|psoriasis
1042352|NCT01831466|moderate
1042353|NCT01831466|severe
1042354|NCT01831466|itch
1042355|NCT01831466|nail psoriasis
1042356|NCT01831453|omega-3
1042357|NCT01831453|recurrent aphthous stomatitis
1042358|NCT01831453|quality of life
1042359|NCT01831440|depression
1042360|NCT01831440|remission
1042361|NCT01831440|Pharmacotherapy
1042362|NCT01831440|psychotherapy
1042363|NCT01831440|neuroimaging
1042364|NCT01831440|psychology
1042365|NCT01831427|ulcerative colitis
1042366|NCT01831427|moderate
1042367|NCT01831427|severe
1042368|NCT01831414|Lung function
1042369|NCT01831414|Water immersion
1042370|NCT01831414|Balneotherapy
1042371|NCT01831401|Acetabular component inclination
1042372|NCT01831388|Dyspnea
1042373|NCT01831388|Breath Training Exercise
1042374|NCT01831388|12-261
1042375|NCT01831336|International
1042376|NCT01831336|Multicenter
1042377|NCT01831336|Observational registry
1042378|NCT01831336|Orsiro Drug Eluting Stent (DES)
1042379|NCT01831336|Stenting
1042380|NCT01831336|Treatment of Coronary Artery Disease
1042381|NCT01831336|Coronary revascularization
1042382|NCT01831336|Percutaneous Coronary Intervention
1042383|NCT01831336|STEMI
1042384|NCT01831336|NSTEMI
1042385|NCT01831336|Ischemia
1042386|NCT01831336|Angina
1042387|NCT01831336|Subgroups
1042388|NCT01831336|Acute Myocardial Infarction
1042389|NCT01831336|Diabetes
1042390|NCT01831336|Small Vessels
1042391|NCT01831336|Chronic Total Occlusion (CTO)
1042392|NCT01831310|Colorectal cancer
1042393|NCT01831310|nutrition
1042394|NCT01831310|neutrophil phagocytosis
1042395|NCT01831310|neutrophil adhesivity
1042396|NCT01831310|glutamine
1042397|NCT01831310|omega 3 fatty acids
1042398|NCT01831271|Exercise, Physical
1042399|NCT01831271|Physical Activity
1042400|NCT01831271|Outcome Measures
1042401|NCT01831219|osteoarthritis
1042402|NCT01831219|arthroplasty
1042403|NCT01831219|hip arthroplasty
1042404|NCT01831206|corneal ulcer
1042405|NCT01831206|keratitis
1042406|NCT01831180|hair
1042407|NCT01831180|scalp
1042408|NCT01831180|blood flow
1042409|NCT01831180|Caucasian
1042410|NCT01831180|Histamine stimulation
1042411|NCT01831180|Wake Forest
1042412|NCT01831167|dynamic light application
1042413|NCT01831167|sustained attention
1042414|NCT01831167|divided attention
1042415|NCT01831167|nursing
1042416|NCT01831154|Glycemic control
1042417|NCT01831141|Congenital Solitary Kidney
1042418|NCT01831141|Glomerular filtration rate
1042419|NCT01831141|Chronic kidney damage
1042420|NCT01831141|Hypertension
1042421|NCT01831141|Proteinuria
1042422|NCT01831128|Congestive Heart Failure
1042423|NCT01831128|Central Sleep Apnea
1042424|NCT01831128|Sleep-Disordered Breathing
1042425|NCT01831115|heart failure
1042426|NCT01831115|BNP
1042427|NCT01831115|acute dyspnoea
1042428|NCT01831102|insulin resistance
1042429|NCT01831102|ethnic disparities
1042430|NCT01831102|adiponectin
1042431|NCT01831076|Breast cancer
1042432|NCT01831076|estrogen receptor-positive breast cancer
1042433|NCT01831076|progesterone receptor-positive breast cancer
1042434|NCT01831076|Postmenopausal
1042435|NCT01831076|Exemestane
1042436|NCT01831076|Tamoxifen
1042437|NCT01831063|Seizure
1042438|NCT01831063|Caregivers
1042439|NCT01831063|Family Centered Care
1042440|NCT01831063|Learning modality
1042441|NCT01831050|Poliovirus
1042442|NCT01831050|Inactivated poliovirus vaccine
1042443|NCT01831050|Trivalent oral polio vaccine
1042444|NCT01831050|Bivalent oral polio vaccine
1042445|NCT01831050|Stool shedding index
1042446|NCT01831050|Polio eradication
1042447|NCT01831037|Hepatocellular carcinoma
1042448|NCT01831037|Regressed cirrhosis
1042449|NCT01831037|Hepatitis C
1042450|NCT01831037|Hepatitis B
1042451|NCT01831037|Noninvasive markers of fibrosis
1042452|NCT01831037|FibroTest
1042453|NCT01831037|FibroSure
1042454|NCT01831037|FibroScan
1042455|NCT01831037|Transient elastography
1042456|NCT01831024|Cold cap
1042457|NCT01831024|Scalp cooling
1042458|NCT01831024|Chemotherapy induced alopecia
1042459|NCT01831024|Breast cancer
1042460|NCT01831011|randomized trial
1042461|NCT01831011|acute ischemic stroke
1042462|NCT01831011|mildronate
1042463|NCT01830998|Dementia
1042464|NCT01830998|Olfactory
1042465|NCT01830959|Sarcoidosis, fibrosis, bronchiectasis
1042466|NCT01830946|Protein
1042467|NCT01830946|Metabolism
1042468|NCT01830946|Nighttime eating
1042469|NCT01830946|Exercise Training
1042470|NCT01830933|Breast cancer concern, breast cancer risk perception, breast cancer risk
1042471|NCT01830920|Acute Kidney Injury
1042472|NCT01830920|AKI
1042473|NCT01830920|Cardiac surgery
1042474|NCT01830907|Malnutrition
1042475|NCT01830907|Gastric cancer
1042476|NCT01830907|preoperative nutrition
1042477|NCT01830881|pain
1042478|NCT01830881|anxiety
1042479|NCT01830881|surgical abortion
1042480|NCT01830881|midazolam
1042481|NCT01830881|benzodiazepine
1042482|NCT01830868|ZNS
1042483|NCT01830868|AED
1042484|NCT01830868|Partial Onset Seizures
1042485|NCT01830868|Retention Rate
1042486|NCT01830868|Seizure Control
1042487|NCT01830868|Antiepileptic
1042488|NCT01830868|Secondary generalization
1042489|NCT01830868|Seizure freedom rates
1042490|NCT01830842|Nicotine
1042491|NCT01830842|Smoking
1042492|NCT01830842|Cigarettes
1042493|NCT01830842|Reinforcement Learning
1042494|NCT01830842|fMRI
1042495|NCT01830829|BPH
1042496|NCT01830829|CPPS
1042497|NCT01830816|Relapsed
1042498|NCT01830816|Refractory
1042499|NCT01830816|Multiple Myeloma
1042500|NCT01830816|Advanced solid tumors
1042501|NCT01830803|howRU
1042502|NCT01830803|howRwe
1042503|NCT01830803|reliability
1042504|NCT01830803|quality of life
1042505|NCT01830803|quality of care
1042506|NCT01830803|patient satisfaction
1042639|NCT01830101|re-irradiation
1042507|NCT01830751|self treatment technique
1042508|NCT01830751|chronic
1042509|NCT01830751|non specific
1042510|NCT01830751|LBP
1042511|NCT01830751|control trunk flexion
1042512|NCT01830751|diurnal
1042513|NCT01830738|laparoscopy
1042514|NCT01830738|hysterectomy
1042515|NCT01830738|single-port trocar
1042516|NCT01830738|surgical technique
1042517|NCT01830738|trocar
1042518|NCT01830725|Xanthine Oxidase
1042519|NCT01830725|Gout
1042520|NCT01830725|Hyperuricemia
1042521|NCT01830725|SNP
1042522|NCT01830725|Single Nucleotide Polymorphisms
1042523|NCT01830699|Rilonacept
1042524|NCT01830699|Subacromial Bursitis treatment
1042525|NCT01830699|Corticosteroid Injection
1042526|NCT01830686|Sugarcane bagasse, glucose tolerance, insulin resistance
1042527|NCT01830673|T-regulatory cells
1042528|NCT01830673|TH1, TH2 cells
1042529|NCT01830673|specific IgE
1042530|NCT01830673|specific IgG
1042531|NCT01830673|specific IgG4
1042532|NCT01830673|IL2
1042533|NCT01830673|IL5
1042534|NCT01830673|IL10
1042535|NCT01830673|IL12/23
1042536|NCT01830673|Y-IFN
1042537|NCT01830673|TNF-a
1042538|NCT01830634|Community-dwelling elderly
1042539|NCT01830634|Rehabilitation
1042540|NCT01830634|Theraband
1042541|NCT01830634|Strengthening and stretching exercise
1042545|NCT01830569|Decision Support Systems, Clinical
1042546|NCT01830569|Evidence-Based practice
1042547|NCT01830569|Family Practice
1042548|NCT01830543|Atrial Fibrillation
1042549|NCT01830543|Irregular heart beat
1042550|NCT01830543|rivaroxaban
1042551|NCT01830543|aspirin
1042552|NCT01830543|clopidogrel
1042553|NCT01830543|prasugrel
1042554|NCT01830543|ticagrelor
1042555|NCT01830543|vitamin K antagonist
1042556|NCT01830530|arterial hypertension
1042557|NCT01830530|high altitude
1042558|NCT01830530|hypobaric hypoxia
1042559|NCT01830530|combination treatment
1042560|NCT01830530|angiotensin receptor blocker
1042561|NCT01830530|calcium antagonist
1042562|NCT01830504|thyroid cancers
1042563|NCT01830504|refractory
1042564|NCT01830504|PI3K inhibitor
1042565|NCT01830465|Non Hodgkin's Follicular Lymphoma
1042566|NCT01830465|relapsed
1042567|NCT01830465|progressed
1042568|NCT01830452|Chronic pain
1042569|NCT01830452|Progrip Mesh
1042570|NCT01830452|Self gripping mesh
1042571|NCT01830452|Lichtenstein
1042572|NCT01830439|tuberculosis
1042573|NCT01830439|PK
1042574|NCT01830439|PA-824
1042575|NCT01830439|food effect
1042576|NCT01830439|pretomanid
1042577|NCT01830439|CL-009
1042578|NCT01830413|stent, systematic Intracranial artery stenosis
1042579|NCT01830400|ESL
1042580|NCT01830400|Partial onset seizures
1042581|NCT01830400|Retention Rate
1042582|NCT01830400|Seizure Control
1042583|NCT01830400|Antiepileptic
1042584|NCT01830400|Secondary Generalisation
1042585|NCT01830387|Polymetric Clips (Hem-o-Lok)
1042586|NCT01830387|Laparoscopic Appendectomy
1042587|NCT01830387|Endoscopic Staplers
1042588|NCT01830374|Bulimia nervosa
1042589|NCT01830374|Eating disorder
1042590|NCT01830374|Weight suppression
1042591|NCT01830374|Dieting
1042592|NCT01830361|AML
1042593|NCT01830361|Acute Myeloid Leukemia
1042594|NCT01830361|c-KIT
1042595|NCT01830361|FLT3-ITD
1042596|NCT01830361|t(8;21)
1042597|NCT01830361|chemotherapy
1042598|NCT01830361|midostaurin
1042599|NCT01830348|diabetic foot ulcers
1042600|NCT01830348|Wagner Grade 1 or 2 foot ulcers
1042601|NCT01830322|metastatic
1042602|NCT01830322|pancreatic
1042603|NCT01830322|adenocarcinoma
1042604|NCT01830322|cancer
1042605|NCT01830309|Food-Effect
1042606|NCT01830309|Pharmacokinetics
1042607|NCT01830309|Pharmacodynamics
1042608|NCT01830296|Postthoracotomy pain,
1042609|NCT01830296|patient controlled analgesia,
1042610|NCT01830296|remifentanil and
1042611|NCT01830296|morphine.
1042612|NCT01830270|medical oncology
1042613|NCT01830270|chemotherapy optimization
1042614|NCT01830270|dose density
1042615|NCT01830244|chemotherapy
1042616|NCT01830244|nab paclitaxel
1042617|NCT01830244|neoadjuvant therapy
1042618|NCT01830244|breast cancer
1042619|NCT01830244|pathologic complete response
1042620|NCT01830231|TCCU
1042621|NCT01830231|Vinflunine
1042622|NCT01830231|Cabazitaxel
1042623|NCT01830231|Metastatic
1042624|NCT01830231|Locally advance
1042625|NCT01830192|endometrial cancer
1042626|NCT01830192|score
1042627|NCT01830192|nomogram
1042628|NCT01830192|ultrasound
1042629|NCT01830192|HE4
1042630|NCT01830153|Soft tissue sarcomas
1042631|NCT01830153|Bone sarcomas
1042632|NCT01830153|RAD001
1042633|NCT01830153|Refractory to conventional chemotherapy
1042634|NCT01830114|alcohol abuse
1042635|NCT01830114|drug abuse
1042636|NCT01830114|hazardous alcohol use
1042637|NCT01830114|hazardous drug use
1042638|NCT01830101|recurrent glioblastoma
1042640|NCT01830101|continuous low-dose temozolomide
1042641|NCT01830036|cardiological treatment
1042642|NCT01830036|sleep Apnea
1042643|NCT01830023|cardiac ultrasound
1042644|NCT01830023|vitality
1042645|NCT01830023|data
1042646|NCT01830023|patients
1042647|NCT01830023|examined
1042648|NCT01829984|Injection Teaching
1042649|NCT01829984|13-057
1042650|NCT01829971|microRNA
1042651|NCT01829971|Advanced cancer
1042652|NCT01829958|Geriatric
1042653|NCT01829958|Toxicity
1042654|NCT01829958|rituximab
1042655|NCT01829958|prednisone
1042656|NCT01829958|Comprehensive Geriatric Assessment (CGA)
1042657|NCT01829958|13-028
1042658|NCT01829932|Diet
1042659|NCT01829919|Menopause
1042660|NCT01829919|Hot flashes
1042661|NCT01829919|Vasomotor symptoms
1042662|NCT01829919|Climacteric symptoms
1042663|NCT01829919|perimenopause
1042664|NCT01829919|Mesafem
1042665|NCT01829919|Brisdelle
1042666|NCT01829919|Low-Dose Mesylate salt of Paroxetine (LDMP)
1042667|NCT01829906|weight loss
1042668|NCT01829906|bariatric surgery
1042669|NCT01829906|gastric bypass
1042670|NCT01829906|health education
1042671|NCT01829906|nutrition therapy
1042672|NCT01829906|diet
1042673|NCT01829906|exercise
1042674|NCT01829906|cognitive therapy
1042675|NCT01829893|Benign Prostatic Hyperplasia (BPH)
1042676|NCT01829893|pharmacokinetics
1042677|NCT01829893|bioequivalence
1042678|NCT01829893|finasteirde
1042679|NCT01829893|tamsulosin
1042680|NCT01829880|Chronic heart failure
1042681|NCT01829880|Bisoprolol
1042682|NCT01829880|Ramipril
1042683|NCT01829880|Pharmacokinetic
1042684|NCT01829880|Cachexia
1042685|NCT01829880|Body composition
1042686|NCT01829880|Renal function
1042687|NCT01829880|Iohexol
1042688|NCT01829841|MRCC
1042689|NCT01829841|Metastatic Renal Cell Cancer
1042690|NCT01829841|Famitinib
1042691|NCT01829841|Sunitinib
1042692|NCT01829828|Pain
1042693|NCT01829828|Cancer pain
1042694|NCT01829828|Self-reported pain scoring tool
1042695|NCT01829828|Opioid analgesics
1042696|NCT01829815|Child
1042697|NCT01829815|Parents
1042698|NCT01829815|Parenting
1042699|NCT01829815|Child Development
1042700|NCT01829815|Parent Child Relations
1042701|NCT01829815|Malaria
1042702|NCT01829815|Primary Prevention
1042703|NCT01829815|Punishment
1042704|NCT01829815|Education
1042705|NCT01829802|HIV
1042706|NCT01829802|Raltegravir
1042707|NCT01829802|Boosted atazanavir
1042708|NCT01829789|Adolescents
1042709|NCT01829789|Teens
1042710|NCT01829789|Parents
1042711|NCT01829789|Parenting
1042712|NCT01829789|Substance Abuse
1042713|NCT01829789|Treatment Efficacy
1042714|NCT01829776|Accidental falls
1042715|NCT01829776|Multiple Sclerosis
1042716|NCT01829776|Education
1042717|NCT01829776|Exercise
1042718|NCT01829776|Postural balance
1042719|NCT01829750|Univentricular heart
1042720|NCT01829737|Asymptomatic Parasitemia
1042721|NCT01829737|RBC Polymorphism
1042722|NCT01829737|Acquired Immunity
1042723|NCT01829724|Functional Brain Imaging
1042724|NCT01829724|Cerebral Palsy
1042725|NCT01829724|Motion Analysis
1042726|NCT01829724|Macro- EMG
1042727|NCT01829711|Moxetumomab Paudotox
1042728|NCT01829711|CAT-8015
1042729|NCT01829711|anti-CD22 recombination immunotoxin
1042730|NCT01829711|Biologic Therapy
1042731|NCT01829711|Recombinant Immunotoxin
1042732|NCT01829711|Monoclonal Antibody
1042733|NCT01829711|Pseudomonas Exotoxin
1042734|NCT01829711|Targeted Therapy
1042735|NCT01829698|tudca PBC Cholestasis tauroursodeoxycholic acid taurolite
1042736|NCT01829672|Early diagnosis of pulmonary arterial hypertension
1042737|NCT01829672|dynamic dual-energy computed tomography
1042738|NCT01829646|DWI
1042739|NCT01829646|DCE MRI
1042740|NCT01829646|ADC
1042741|NCT01829646|FDG PET
1042742|NCT01829646|Hypoxia
1042743|NCT01829646|Prognostic and predictive model
1042744|NCT01829620|suicide
1042745|NCT01829620|suicide intervention
1042746|NCT01829620|suicide prevention
1042747|NCT01829620|military
1042748|NCT01829620|military suicide
1042749|NCT01829620|caring letters
1042750|NCT01829620|caring contacts
1042751|NCT01829620|text messages
1042752|NCT01829594|Case Management
1042753|NCT01829594|Frail Elderly
1042754|NCT01829594|Health Services Administration
1042755|NCT01829594|Delivery of Health Care
1042756|NCT01829594|Accidental Falls
1042757|NCT01829594|Health Status
1042758|NCT01829594|Health Care Economics
1042759|NCT01829542|flow-mediated dilation
1042760|NCT01829542|blueberry polyphenols
1042761|NCT01829542|dose-dependency
1042762|NCT01829529|Antibiotic prophylaxis
1042763|NCT01829503|Phase II
1042764|NCT01829503|decitabine
1042765|NCT01829503|cytarabine
1042766|NCT01829503|older patients
1042767|NCT01829503|newly diagnosed
1042768|NCT01829503|AML
1042769|NCT01829503|Newly Diagnosed AML
1042770|NCT01829490|Vaccine
1042771|NCT01829490|Immunogenicity
1042772|NCT01829477|Drug Therapy
1042773|NCT01829464|Drug Therapy
1042774|NCT01829438|exercise tolerance
1042775|NCT01829438|6MWT
1042776|NCT01829425|Hypnosis
1042777|NCT01829425|Mind-Body Therapy
1042778|NCT01829425|Anticholinergics
1042779|NCT01829425|fMRI
1042780|NCT01829425|Functional Neuroimaging
1042781|NCT01829425|Gyrus Cinguli
1042782|NCT01829425|Female Urogenital Diseases
1042783|NCT01829399|Tourniquet pain
1042784|NCT01829399|Subcutaneous axillary local anesthetic
1042785|NCT01829399|ability to tolerate tourniquet discomfort.
1042786|NCT01829373|lung cancer
1042787|NCT01829347|liver failure
1042788|NCT01829347|acute alcoholic hepatitis
1042789|NCT01829347|patients failing steroid therapy
1042790|NCT01829347|alcoholic hepatitis
1042791|NCT01829347|steroid failure
1042792|NCT01829347|Lille criteria
1042793|NCT01829347|ELAD
1042794|NCT01829334|dental caries
1042795|NCT01829308|implementation
1042796|NCT01829308|SBIRT
1042797|NCT01829308|alcohol screening
1042798|NCT01829308|drug screening
1042799|NCT01829308|Brief Intervention
1042800|NCT01829308|Referral to Treatment
1042801|NCT01829308|adolescents
1042802|NCT01829308|Federally Qualified Health Centers
1042803|NCT01829295|antimetabolite, noninfectious
1042804|NCT01829282|Implementation
1042805|NCT01829282|HIV
1042806|NCT01829282|serodiscordant couples
1042807|NCT01829282|African American
1042808|NCT01829282|Cultural congruency
1042809|NCT01829243|Milnacipran
1042810|NCT01829243|Fibromyalgia
1042811|NCT01829243|Neurocognition
1042812|NCT01829178|cisplatin
1042813|NCT01829178|nephrotoxicity
1042814|NCT01829178|antioxidant
1042815|NCT01829178|urine neutrophil gelatinase-associated lipocalin (NGAL)
1042816|NCT01829152|heart failure
1042817|NCT01829139|Common bile duct stone
1042818|NCT01829139|Gallbladder in situ
1042819|NCT01829139|Choleretics
1042820|NCT01829113|Recurrent Lung Cancer
1042821|NCT01829113|Stage IV Lung Cancer
1042822|NCT01829113|OGX-427
1042823|NCT01829113|Sarah Cannon Research Institute
1042824|NCT01829113|SCRI
1042825|NCT01829113|OncoGenex
1042826|NCT01829113|NSCLC
1042827|NCT01829113|Non Small Cell Lung Cancer
1042828|NCT01829100|Adolescent
1042829|NCT01829100|Transdiagnostic therapy
1042830|NCT01829100|Behavioral activation
1042831|NCT01829100|Exposure therapy
1042832|NCT01829100|Depressive Disorder
1042833|NCT01829100|Anxiety Disorders
1042834|NCT01829074|Laryngopharyngeal Reflux
1042835|NCT01829074|Hoarseness
1042836|NCT01829074|Throat Clearing
1042837|NCT01829074|Globus Sensation
1042838|NCT01829061|Type I Diabetes
1042839|NCT01829061|Type II Diabetes
1042840|NCT01829061|HbA1C
1042841|NCT01829048|PF-02545920
1042842|NCT01829048|safety
1042843|NCT01829048|schizophrenia
1042844|NCT01829035|TACE
1042845|NCT01829035|Sorafenib
1042846|NCT01829022|Myoma
1042847|NCT01829022|Uterine myomectomy
1042848|NCT01829009|Sarcopenia
1042849|NCT01829009|Elderly
1042850|NCT01829009|Women
1042851|NCT01829009|Resistance
1042852|NCT01829009|Exercise
1042853|NCT01828996|Chronic pelvic pain syndrome
1042854|NCT01828996|Chronic prostatitis
1042855|NCT01828996|Shock wave therapy
1042856|NCT01828996|Prostate
1042857|NCT01828996|Pelvic floor
1042858|NCT01828996|Pain
1042859|NCT01828983|Telephone
1042860|NCT01828983|Support groups
1042861|NCT01828983|Social support
1042862|NCT01828983|Depression
1042863|NCT01828970|Diabetes Mellitus
1042864|NCT01828970|Hemodialysis
1042865|NCT01828970|Continuous glucose monitoring
1042866|NCT01828970|Insulin analogues
1042867|NCT01828957|Human Umbilical Cord Blood Derived Mesenchymal Stem Cells
1042868|NCT01828957|Bronchopulmonary dysplasia
1042869|NCT01828957|Premature infants
1042870|NCT01828944|Vitamin D
1042871|NCT01828944|bone loss
1042872|NCT01828918|early diagnosis
1042873|NCT01828918|prediction
1042874|NCT01828918|prognosis
1042875|NCT01828905|tibia fracture
1042876|NCT01828905|bone graft
1042877|NCT01828905|iliac crest
1042878|NCT01828905|bone graft substitute
1042879|NCT01828905|Cerament
1042880|NCT01828905|void filler
1042881|NCT01828905|quality of life
1042882|NCT01828905|pain
1042883|NCT01828905|costs of care
1042884|NCT01828892|Autologous platelet rich fibrin glue
1042885|NCT01828892|Enterocutaneous fistulas
1042886|NCT01828892|Single low output GI fistulas
1042887|NCT01828879|Dermatitis, Atopic
1042888|NCT01828879|Tacrolimus
1042889|NCT01828866|EMDR
1042890|NCT01828866|Alcohol
1042891|NCT01828866|Relapse
1042892|NCT01828866|Craving
1042893|NCT01828853|Membrane sweeping
1042894|NCT01828853|Membrane stripping
1042895|NCT01828853|Maternal outcomes
1042896|NCT01828853|Neonatal outcomes
1042897|NCT01828840|morphine
1042898|NCT01828840|fentanyl
1042899|NCT01828840|methadone
1042900|NCT01828840|epidural
1042901|NCT01828840|intravenous
1042902|NCT01828840|pain
1042903|NCT01828840|analgesia
1042904|NCT01828827|tuberculosis
1042905|NCT01828827|PK
1042906|NCT01828827|PA-824
1042907|NCT01828827|food effect,
1042908|NCT01828827|bioavailability
1042909|NCT01828827|pretomanid
1042910|NCT01828827|CL-003
1042911|NCT01828814|pediatrics
1042912|NCT01828814|Ready-to-use Supplementary Food
1042913|NCT01828814|corn soy blend
1042914|NCT01828814|cash transfer
1042915|NCT01828814|prevention of malnutrition
1042916|NCT01828814|Niger
1042917|NCT01828801|Adverse Local Tissue Reaction
1042918|NCT01828801|Metal Ions
1042919|NCT01828801|Serum
1042920|NCT01828801|Whole Blood
1042921|NCT01828801|Metal-on-Metal
1042922|NCT01828801|Total Hip Arthroplasty
1042923|NCT01828788|Sternotomy
1042924|NCT01828788|Anesthesia
1042925|NCT01828788|Post-operative pain
1042926|NCT01828762|DC
1042927|NCT01828762|Immunotherapy
1042928|NCT01828762|TC
1042929|NCT01828749|blunt abdominal trauma
1042930|NCT01828749|CT
1042931|NCT01828749|radiation exposure, pediatric
1042932|NCT01828736|Urothelial carcinoma
1042933|NCT01828736|Trastuzumab
1042934|NCT01828736|Treatment
1042935|NCT01828723|Autologous Adult Stem Cell
1042936|NCT01828723|Adipose Derived Stem Cell
1042937|NCT01828723|Stromal Vascular Fraction
1042938|NCT01828723|SVF
1042939|NCT01828723|Antria
1042940|NCT01828723|Shah Rahimian
1042941|NCT01828723|Leonard Maliver
1042942|NCT01828723|David Bizousky
1042943|NCT01828723|Rahul Gore
1042944|NCT01828723|Lee Quist
1042945|NCT01828723|Dudley McNitt
1042946|NCT01828710|Myo-inositol
1042947|NCT01828710|oligoasthenoteratospermia
1042948|NCT01828710|semen parameters
1042949|NCT01828710|IVF
1042950|NCT01828697|Low-molecular-weight heparin
1042951|NCT01828697|Pregnancy
1042952|NCT01828697|Venous thrombosis
1042953|NCT01828684|Migraine with Aura
1042954|NCT01828684|Migraine without Aura
1042955|NCT01828684|Photophobia
1042956|NCT01828684|Chronic Daily Headache
1042957|NCT01828671|Soy
1042958|NCT01828671|Corn
1042959|NCT01828671|Flour
1042960|NCT01828671|Tortilla
1042961|NCT01828671|Glycemic
1042962|NCT01828671|Glucose,
1042963|NCT01828671|glycemic index
1042964|NCT01828658|hemodialysis
1042965|NCT01828658|fluid management
1042966|NCT01828658|bioimpedance
1042967|NCT01828658|mortality
1042968|NCT01828658|arterial stiffness
1042969|NCT01828645|gastric emptying
1042970|NCT01828645|whey protein
1042971|NCT01828645|carbohydrate
1042972|NCT01828645|fasting
1042973|NCT01828632|Obesity, Morbid; Hypoxemia; Postoperative complications; Bariatric surgery; Respiratory physical therapy; Preoperative care.
1042974|NCT01828619|Hematopoietic Stem Cell Transplantation
1042975|NCT01828619|Busulfan
1042976|NCT01828619|Fludarabine
1042977|NCT01828606|leg lymphedema
1042978|NCT01828606|volume measurement
1042979|NCT01828606|compression therapy
1042980|NCT01828606|interface pressure
1042981|NCT01828606|static stiffness index (SSI)
1042982|NCT01828606|volume change
1042983|NCT01828580|laparoscopic Cholecystectomy
1042984|NCT01828580|Gallbladder removal
1042985|NCT01828580|laparoscope holder
1042986|NCT01828567|veterans
1042987|NCT01828567|health risk assessment
1042988|NCT01828567|primary prevention
1042989|NCT01828567|shared decision making
1042990|NCT01828567|Healthy Living Assessment
1042991|NCT01828554|Capecitabine pharmacokinetics PK
1042992|NCT01828554|Elevated Body Mass Index (BMI)
1042993|NCT01828554|Advanced Solid Tumors
1042994|NCT01828541|Burn injuries
1042995|NCT01828528|Nonalcoholic fatty liver disease
1042996|NCT01828528|Nonalcoholic steatohepatitis
1042997|NCT01828528|Obesity
1042998|NCT01828528|Bariatric surgery
1042999|NCT01828528|Weight loss
1043000|NCT01828502|Cotinine
1043001|NCT01828502|Secondhand Smoke Exposure (SHSE)
1043002|NCT01828502|Secondhand Smoke (SHS)
1043003|NCT01828476|prostate cancer
1043004|NCT01828476|hormone-resistant prostate cancer
1043005|NCT01828476|recurrent prostate cancer
1043006|NCT01828476|stage IV prostate cancer
1043007|NCT01828424|acute pain
1043008|NCT01828411|Cardiac surgery
1043009|NCT01828411|Echocardiography
1043010|NCT01828411|Cerebral perfusion
1043011|NCT01828411|Intraoperative period
1043012|NCT01828385|Physiological Effects of Drugs
1043013|NCT01828385|Rocuronium
1043014|NCT01828385|Sugammadex sodium
1043015|NCT01828385|Magnesium
1043016|NCT01828385|Molecular Mechanisms of Pharmacological Action
1043017|NCT01828385|Neuromuscular block, antagonism
1043018|NCT01828385|Pharmacologic Actions
1043019|NCT01828372|concomitant diseases
1043149|NCT01827748|Autorefractor
1043020|NCT01828372|multiple drug consumption
1043021|NCT01828372|therapeutic drug monitoring
1043022|NCT01828372|TDM
1043023|NCT01828372|drug monitoring
1043024|NCT01828372|drug level
1043025|NCT01828372|quantification
1043026|NCT01828372|drug
1043027|NCT01828372|drug concentration
1043028|NCT01828372|concentration
1043029|NCT01828372|therapeutic range
1043030|NCT01828372|therapeutic index
1043031|NCT01828346|TL32711
1043032|NCT01828346|Birinapant
1043033|NCT01828346|5-Azacitidine
1043034|NCT01828346|Myelodysplastic syndrome
1043035|NCT01828346|MDS
1043036|NCT01828346|Relapsed
1043037|NCT01828346|Refractory
1043038|NCT01828346|Failed
1043039|NCT01828346|open-label
1043040|NCT01828346|non-Randomized
1043041|NCT01828346|dose-escalation
1043042|NCT01828346|dose-expansion
1043043|NCT01828333|Malaria
1043044|NCT01828333|Severe
1043045|NCT01828333|Artesunate
1043046|NCT01828333|Quinine
1043047|NCT01828333|Democratic Republic of Congo
1043048|NCT01828320|Risk: Emotional, Cognitive, Behavioral, Social, Physical
1043049|NCT01828294|MG
1043050|NCT01828268|HIV
1043051|NCT01828268|Metabolomics Fingerprinting
1043052|NCT01828242|HbA1C
1043053|NCT01828229|Inactivity
1043054|NCT01828229|Obesity
1043055|NCT01828229|Type 2 diabetes
1043056|NCT01828229|glucose metabolism
1043057|NCT01828229|Lipid metabolism
1043058|NCT01828229|Cognitive function
1043059|NCT01828203|minocycline
1043060|NCT01828203|randomized control trial
1043061|NCT01828203|phase 3
1043062|NCT01828203|spinal cord injury
1043063|NCT01828190|crohn's disease
1043064|NCT01828190|perianal fistulas
1043065|NCT01828190|TNF alpha blockers
1043066|NCT01828190|hyperbaric oxygen therapy
1043067|NCT01828177|PreCision
1043068|NCT01828177|PDI-320
1043069|NCT01828177|Foam
1043070|NCT01828164|Orthodontics
1043071|NCT01828164|Braces
1043072|NCT01828164|Tooth
1043073|NCT01828151|Pressure ulcer
1043074|NCT01828151|Noninvasive ventilation
1043075|NCT01828138|Proteinuria
1043076|NCT01828138|Pregnancy
1043077|NCT01828138|Hypertension
1043078|NCT01828138|Plasmin
1043079|NCT01828138|Plasminogen
1043080|NCT01828138|Aldosterone
1043081|NCT01828138|Angiotensin
1043082|NCT01828138|Renin
1043083|NCT01828138|sodium chloride
1043084|NCT01828138|epithelial sodium channel
1043085|NCT01828138|Placenta
1043086|NCT01828125|Type 1 diabetes
1043087|NCT01828125|Hypoglycemia
1043088|NCT01828125|Glucagon
1043089|NCT01828125|Hypoglycaemic hyperinsulinemic clamp
1043090|NCT01828112|Non-Small Cell Lung Cancer, ALK, LDK378
1043091|NCT01828099|Non-Small Cell Lung Cancer, ALK, LDK378
1043092|NCT01828086|Psoriasis, chronic plaque-type psoriasis, IL17, monoclonal antibody
1043093|NCT01828034|Gemcitabine
1043094|NCT01828034|Cisplatin
1043095|NCT01828034|MEK162
1043096|NCT01828034|13-004
1043097|NCT01828021|HER2 2+
1043098|NCT01828021|FISH non-amplified
1043099|NCT01828021|Relapsed
1043100|NCT01828021|Refractory
1043101|NCT01828021|Advanced
1043102|NCT01828021|Margetuximab
1043103|NCT01828021|MGAH22
1043104|NCT01828008|Mabthera
1043105|NCT01828008|cytokine induced killer cell
1043106|NCT01827995|Low sensitivity urinary hCG
1043107|NCT01827995|follow up
1043108|NCT01827995|medical abortion
1043109|NCT01827995|rural India
1043110|NCT01827995|RCT
1043111|NCT01827982|Healthy
1043112|NCT01827982|Safety
1043113|NCT01827982|Tolerability
1043114|NCT01827982|Pharmacokinetic
1043115|NCT01827982|Alzheimer's Disease
1043116|NCT01827982|JNJ-54861911
1043117|NCT01827969|Women
1043118|NCT01827969|breast tumor
1043119|NCT01827969|planned mastectomy
1043120|NCT01827956|Upper aero-digestive tract tumours
1043121|NCT01827956|FCGR3A and FCGR2A receptor polymorphism
1043122|NCT01827956|Cetuximab efficacy
1043123|NCT01827943|Relapsed bladder cancer
1043124|NCT01827930|chronic myeloid leukemia in chronic phase
1043125|NCT01827904|ExAblate Transcranial MRgFUS
1043126|NCT01827891|acute kidney injury
1043127|NCT01827891|percutaneous coronary intervention
1043128|NCT01827891|remote ischemic preconditioning
1043129|NCT01827839|Adults
1043130|NCT01827839|Safety
1043131|NCT01827839|Immunogenicity
1043132|NCT01827839|Zoster
1043133|NCT01827826|Intervention
1043134|NCT01827826|Telephone
1043135|NCT01827826|Diabetes
1043136|NCT01827826|Prevention
1043137|NCT01827813|prostate-specific antigen
1043138|NCT01827813|digital rectal examination
1043139|NCT01827813|transrectal ultrasonography
1043140|NCT01827813|needle biopsy
1043141|NCT01827813|prostate cancer
1043142|NCT01827800|weight loss
1043143|NCT01827800|primary care
1043144|NCT01827800|eHealth
1043145|NCT01827774|Pelvic organ prolapse
1043146|NCT01827774|Graft repair
1043147|NCT01827761|chemotherapy teaching
1043148|NCT01827761|questionnaire
1043150|NCT01827735|Interleukin 2
1043151|NCT01827735|Type 1 diabetes
1043152|NCT01827735|T regulatory cells
1043153|NCT01827735|Adaptive trial
1043154|NCT01827722|Macular edema
1043155|NCT01827722|Central retinal vein occlusion
1043156|NCT01827722|CRVO
1043157|NCT01827722|Retinal vein occlusion
1043158|NCT01827722|RVO
1043159|NCT01827722|Ozurdex
1043160|NCT01827722|Dexamethasone intravitreal implant
1043161|NCT01827722|Lucentis
1043162|NCT01827722|Ranibizumab
1043163|NCT01827709|DWI
1043164|NCT01827709|ADC
1043165|NCT01827709|DCE-MRI
1043166|NCT01827709|FDG-PET
1043167|NCT01827709|SUV
1043168|NCT01827709|Hypoxia
1043169|NCT01827709|Head and neck squamous cell carcinoma
1043170|NCT01827696|Muscle
1043171|NCT01827696|Soreness
1043172|NCT01827696|Muscle function
1043173|NCT01827696|Damage
1043174|NCT01827696|Ginseng
1043175|NCT01827683|hyperbaric oxygen
1043176|NCT01827683|fibromyalgia
1043177|NCT01827683|chronic pain syndrome
1043178|NCT01827657|plasma
1043179|NCT01827657|tolerability
1043180|NCT01827657|safety
1043181|NCT01827657|matched control
1043182|NCT01827657|GSK2336805
1043183|NCT01827657|hepatic impairment
1043184|NCT01827657|pharmacokinetics
1043185|NCT01827644|AKT inhibitor
1043186|NCT01827644|formulation
1043187|NCT01827644|food effect
1043188|NCT01827644|bioavailability
1043189|NCT01827644|GSK2110183
1043190|NCT01827631|healthy
1043191|NCT01827631|GSK1605786
1043192|NCT01827631|CCR9 receptor antagonist
1043193|NCT01827631|Chinese subjects
1043194|NCT01827631|pharmacokinetics
1043195|NCT01827618|bladder
1043196|NCT01827618|Cancer
1043197|NCT01827618|Cystectomy
1043198|NCT01827618|Rapamycin
1043199|NCT01827605|Relapsed follicular Lymphoma
1043200|NCT01827605|RIT
1043201|NCT01827605|Zevalin
1043202|NCT01827579|Transplant
1043203|NCT01827579|CD25/71 allodepleted donor T cells
1043204|NCT01827579|Infection
1043205|NCT01827579|Acute Myeloid Leukaemia
1043206|NCT01827579|Acute Lymphoblastic Leukaemia
1043207|NCT01827579|Adult
1043208|NCT01827579|Diffuse Large B-Cell Lymphoma
1043209|NCT01827579|Mantle Cell Lymphoma
1043210|NCT01827566|Celiac Disease
1043211|NCT01827566|Gluten Sensitivity
1043212|NCT01827566|Gluten
1043213|NCT01827566|Double-blind challenge, placebo-controlled challenge
1043214|NCT01827566|Gluten free flour
1043215|NCT01827553|pancreatic cancer
1043216|NCT01827553|chemoradiotherapy
1043217|NCT01827553|chemotherapy
1043218|NCT01827553|FOLFIRINOX
1043219|NCT01827553|gemcitabine
1043220|NCT01827540|HIV/AIDS
1043221|NCT01827540|Cenicriviroc (CVC)
1043222|NCT01827540|Dolutegravir (DTG)
1043223|NCT01827540|Midazolam
1043224|NCT01827540|Healthy Subjects
1043225|NCT01827527|Adenosine Triphosphate
1043226|NCT01827527|Validation
1043227|NCT01827527|Magnetic Resonance Spectroscopy
1043228|NCT01827527|Optical Spectroscopy
1043229|NCT01827514|cancer, erythropoetin
1043230|NCT01827501|postoperative delirium
1043231|NCT01827501|hemodynamic management
1043232|NCT01827501|goal directed therapy
1043233|NCT01827475|musculoskeletal pain
1043234|NCT01827475|acetaminophen
1043235|NCT01827475|ibuprofen
1043236|NCT01827462|Inactivated, trivalent influenza vaccine
1043237|NCT01827462|elderly
1043238|NCT01827462|immunosenescence
1043239|NCT01827462|longitudinal study
1043240|NCT01827462|Inactivated, High-Dose trivalent influenza vaccine
1043241|NCT01827462|Inactivated, quadrivalent influenza vaccine
1043242|NCT01827462|young adults
1043243|NCT01827449|rewarming
1043244|NCT01827449|core cooling
1043245|NCT01827449|afterdrop
1043246|NCT01827449|hospital treatment
1043247|NCT01827449|hypothermia
1043248|NCT01827436|pediatric stroke
1043249|NCT01827436|hemiplegia
1043250|NCT01827436|physical therapy
1043251|NCT01827436|gait training
1043252|NCT01827436|transcranial magnetic stimulation
1043253|NCT01827436|gait asymmetry
1043254|NCT01827423|squamous cell carcinoma antigen
1043255|NCT01827423|sinonasal inverted papilloma
1043256|NCT01827423|clinical marker
1043257|NCT01827423|hidden reccurence
1043258|NCT01827423|surgery
1043259|NCT01827397|Safety of this HIV vaccine
1043260|NCT01827371|Smallpox, vaccine, IMVAMUNE, Stratis, parent protocol
1043261|NCT01827358|antibacterial agent
1043262|NCT01827358|children
1043263|NCT01827358|colonisation
1043264|NCT01827358|critically ill
1043265|NCT01827358|infants
1043266|NCT01827358|mupirocin
1043267|NCT01827358|prevention
1043268|NCT01827358|Staphylococcus aureus
1043269|NCT01827345|Vitamin D
1043270|NCT01827345|Falls
1043271|NCT01827345|Balance
1043272|NCT01827345|Physical Function
1043273|NCT01827332|marijuana
1043274|NCT01827332|substance abuse
1043275|NCT01827332|drug abuse
1043276|NCT01827332|marijuana dependence
1043277|NCT01827332|drug addiction
1043278|NCT01827319|Angina
1043279|NCT01827319|Transmyocardial revascularization
1043280|NCT01827280|endothelial function
1043281|NCT01827280|microvascular function
1043282|NCT01827280|incretins
1043283|NCT01827280|diabetes mellitus
1043284|NCT01827280|postprandial lipemia
1043285|NCT01827267|Lung cancer
1043286|NCT01827267|Puma
1043287|NCT01827267|neratinib
1043288|NCT01827254|sutent rechallenge
1043289|NCT01827241|Gastroenterology
1043290|NCT01827241|Colonoscopy
1043291|NCT01827241|Screening
1043292|NCT01827241|Surveillance
1043293|NCT01827241|Symptom evaluation
1043294|NCT01827241|Chart review
1043295|NCT01827241|Data review
1043296|NCT01827241|Examination findings
1043297|NCT01827241|Resection techniques
1043298|NCT01827241|Pathology reports
1043299|NCT01827228|HIV
1043300|NCT01827228|transmission prevention
1043301|NCT01827228|social network and venue
1043302|NCT01827228|community intervention
1043303|NCT01827228|treatment as prevention
1043304|NCT01827228|recent infection
1043305|NCT01827228|phylogenetics
1043306|NCT01827228|infection chains
1043307|NCT01827215|Preconception Care
1043308|NCT01827215|Racial Disparities
1043309|NCT01827215|Health Information Technology
1043310|NCT01827202|renin-angiotensin-system
1043311|NCT01827202|RAS blockade
1043312|NCT01827189|primary care, Medicare costs, hospitalizations
1043313|NCT01827176|Characteristic
1043314|NCT01827176|Recurrent Acute Rhinosinusitis
1043315|NCT01827176|Children
1043316|NCT01827163|Paclitaxel
1043317|NCT01827163|Trastuzumab
1043318|NCT01827163|Lapatinib
1043319|NCT01827163|HER2
1043320|NCT01827163|13-002
1043321|NCT01827137|WT1 Analog Peptide Vaccine
1043322|NCT01827137|12-288
1043323|NCT01827124|CARBETOCIN AND OXYTOCIN AND SECOND TRIMESTER INTERRUPTION
1043324|NCT01827111|Melanoma
1043325|NCT01827111|Metastatic Melanoma
1043326|NCT01827111|Advanced stage IV melanoma
1043327|NCT01827111|Unresectable stage III mucosal melanoma
1043328|NCT01827111|Cutaneous melanoma
1043329|NCT01827111|Progression-free survival
1043330|NCT01827111|(PFS)
1043331|NCT01827111|ABI-007
1043332|NCT01827111|Nab-paclitaxel
1043333|NCT01827111|Paclitaxel
1043334|NCT01827111|Abraxane
1043335|NCT01827111|Ipilimumab
1043336|NCT01827111|Yervoy
1043337|NCT01827111|BMS-734016
1043338|NCT01827111|MDX010
1043344|NCT01827072|IVIG in Multifocal Motor Neuropathy
1043345|NCT01827072|Patients with Multifocal Motor Neuropathy
1043346|NCT01827046|intracerebral hemorrhage
1043347|NCT01827046|ICH
1043348|NCT01827046|brain hemorrhage
1043349|NCT01827046|minimally invasive surgery
1043350|NCT01827046|rt-PA
1043351|NCT01827007|norepinephrine infusion
1043352|NCT01827007|under 48 hours in ICU
1043353|NCT01826968|Lung recruitment, cesarean, lung compliance, atelectasis
1043354|NCT01826955|pneumoperitoneum, cognitive function
1043355|NCT01826942|Scar prevention
1043356|NCT01826942|CO2 fractional laser
1043357|NCT01826929|Health Services Research
1043358|NCT01826929|Cardiovascular Diseases
1043359|NCT01826929|Primary Care
1043360|NCT01826929|Secondary Prevention.
1043361|NCT01826903|Depression
1043362|NCT01826903|Cognitive Behavior Therapy
1043363|NCT01826903|Child Development
1043364|NCT01826890|Ventilator Weaning
1043365|NCT01826890|Mechanical Ventilation
1043366|NCT01826890|Critical Care
1043367|NCT01826890|Neurally Adjusted Ventilatory Assist
1043368|NCT01826890|Diaphragm
1043369|NCT01826851|Pain management
1043370|NCT01826851|Anesthetic, local
1043371|NCT01826851|Nerve blockade
1043372|NCT01826851|Coronary Artery Bypass Surgery
1043373|NCT01826851|Analgesics, opioid
1043374|NCT01826851|Postoperative complications
1043375|NCT01826851|Bupivacaine
1043376|NCT01826838|Prostate Cancer
1043377|NCT01826825|aging
1043378|NCT01826825|cognition
1043379|NCT01826825|surgery
1043380|NCT01826799|sleep
1043381|NCT01826799|noise
1043382|NCT01826799|ICU
1043383|NCT01826799|delirium
1043384|NCT01826799|RCSQ
1043385|NCT01826786|Healthy
1043386|NCT01826786|Anxiety Disorders
1043387|NCT01826786|Anxiety Modulation
1043388|NCT01826786|Male
1043389|NCT01826773|CardioPET
1043390|NCT01826773|Coronary Artery Disease
1043391|NCT01826773|Myocardial Perfusion Imaging
1043392|NCT01826773|Coronary Angiography
1043393|NCT01826773|Myocardial Fatty Acid Utilization
1043394|NCT01826747|intrauterine insemination
1043395|NCT01826747|luteal phase
1043396|NCT01826747|gonadotrophins
1043397|NCT01826734|dacryolith
1043398|NCT01826734|dacryocystorhinostomy
1043399|NCT01826734|composition
1043400|NCT01826734|chemical analysis
1043401|NCT01826734|infrared spectrometry
1043402|NCT01826734|scanning electron microscopy
1043403|NCT01826734|elemental analysis
1043404|NCT01826721|Solid organ transplantation
1043405|NCT01826721|Immunosuppression
1043406|NCT01826721|Education
1043407|NCT01826721|E-learning
1043408|NCT01826721|Medication knowledge
1043409|NCT01826721|Patient satisfaction
1043410|NCT01826721|Medication adherence
1043411|NCT01826708|Chromosomal translocations
1043412|NCT01826708|psychomotor delay
1043413|NCT01826695|Fibromyalgia, neurodynamic, dexterity
1043414|NCT01826682|COPD, physiotherapy, exacerbation
1043415|NCT01826656|intramembranous bone healing
1043416|NCT01826656|post-menopausal osteoporosis
1043417|NCT01826656|tooth extraction
1043418|NCT01826630|CLn Body Wash
1043419|NCT01826630|CLn BodyWash
1043420|NCT01826617|Prostate Disease Nomogram
1043421|NCT01826617|Asian Men
1043422|NCT01826604|cesarean section
1043423|NCT01826604|Pregnant
1043424|NCT01826565|success
1043425|NCT01826552|Orsiro hybrid stent
1043426|NCT01826552|Drug-eluting stent
1043427|NCT01826552|Zotarolimus-eluting stent
1043428|NCT01826552|Coronary heart disease
1043429|NCT01826552|Cobalt chromium
1043430|NCT01826539|Dorsal digital nerve
1043431|NCT01826539|dorsal branch of the digital nerve
1043432|NCT01826539|dorsal branch of the digital artery
1043433|NCT01826539|dorsal digital island flap
1043434|NCT01826539|finger pulp defect.
1043435|NCT01826513|Obstructive sleep apnea
1043436|NCT01826513|Efficacy
1043437|NCT01826513|Subjective feedback
1043438|NCT01826513|Preference
1043439|NCT01826500|embryo transfer
1043440|NCT01826500|IVF cycle
1043441|NCT01826500|endometriosis
1043442|NCT01826487|Duchenne muscular dystrophy
1043443|NCT01826487|Dystrophinopathy
1043444|NCT01826487|Nonsense mutation
1043445|NCT01826487|Premature stop codon
1043446|NCT01826487|Becker muscular dystrophy
1043447|NCT01826487|DMD/BMD
1043448|NCT01826487|PTC124
1043449|NCT01826487|Ataluren
1043450|NCT01826474|Duchenne muscular dystrophy
1043451|NCT01826474|DMD
1043452|NCT01826474|Prosensa
1043453|NCT01826474|Duchenne
1043454|NCT01826461|atopic dermatitis
1043455|NCT01826461|eczema
1043456|NCT01826461|PDI-192
1043457|NCT01826461|Precision
1043458|NCT01826422|Muscular Dystrophy
1043459|NCT01826422|Duchenne Muscular Dystrophy
1043460|NCT01826422|Becker Muscular Dystrophy
1043461|NCT01826422|Omega 3
1043462|NCT01826422|Eicosapentaenoic fatty acid
1043463|NCT01826422|Docosahexaenoic fatty acid
1043464|NCT01826383|Infant
1043465|NCT01826383|Immunization
1043466|NCT01826357|metabolic syndrome
1043467|NCT01826357|cluster analysis
1043468|NCT01826357|PCOS
1043469|NCT01826318|Stress
1043470|NCT01826318|coping
1043471|NCT01826318|simulation
1043472|NCT01826292|Post anesthesia care unit length of stay
1043473|NCT01826279|Obesity
1043474|NCT01826279|Gastric bypass surgery
1043475|NCT01826279|Resveratrol
1043476|NCT01826279|Insulin sensitivity
1043477|NCT01826279|Lipid turnover
1043478|NCT01826279|VLDL-triglyceride uptake
1043479|NCT01826279|Liver
1043480|NCT01826266|PER977
1043481|NCT01826266|Activated partial thromboplastin time
1043482|NCT01826266|Assessment
1043483|NCT01826266|D-dimer
1043484|NCT01826266|Enrollment
1043485|NCT01826266|Investigational drug
1043486|NCT01826266|Investigational treatment
1043487|NCT01826266|Period
1043488|NCT01826266|Premature subject withdrawal
1043489|NCT01826266|Prothrombin time
1043490|NCT01826266|Randomization number
1043491|NCT01826266|Study discontinuation
1043492|NCT01826266|Study drug
1043493|NCT01826266|Subject number
1043494|NCT01826266|Study treatment
1043495|NCT01826266|Thromboelastography-reaction time
1043496|NCT01826253|Hypovolemia
1043497|NCT01826253|Fluid challenge
1043498|NCT01826253|Fluid expansion
1043499|NCT01826253|Oxygene delivery
1043500|NCT01826253|Cardiac output
1043501|NCT01826227|PET (Positron Emission Tomography)
1043502|NCT01826227|18F-FDG
1043503|NCT01826227|Cytoreductive Surgery
1043504|NCT01826227|13-017
1043505|NCT01826214|acute myeloid leukemia
1043506|NCT01826214|AML
1043507|NCT01826214|acute lymphoblastic leukemia
1043508|NCT01826214|ALL
1043509|NCT01826214|leukemia
1043510|NCT01826214|acute
1043511|NCT01826214|LDE225
1043512|NCT01826214|adult patients
1043513|NCT01826214|relapsed/refractory
1043514|NCT01826201|psoriasis
1043515|NCT01826188|Crohn's disease
1043516|NCT01826188|IBD Cannabis
1043517|NCT01826188|THC
1043518|NCT01826188|CBD
1043519|NCT01826175|Optical Coherence Tomography
1043520|NCT01826175|ticagrelor
1043521|NCT01826175|clopidogrel
1043522|NCT01826123|Coagulopathy
1043523|NCT01826123|Hemorrhage
1043524|NCT01826123|Cardiac surgery
1043525|NCT01826123|Point-of-Care testing
1043526|NCT01826123|POC
1043527|NCT01826123|ROTEM
1043528|NCT01826123|multiplate
1043529|NCT01826123|Multiple electrode aggregometry (MEA)
1043530|NCT01826097|Cytology
1043531|NCT01826097|Whole body massage vibration
1043532|NCT01826071|Osgood-Schlatter syndrome (OSS)
1043533|NCT01826071|Sinding-Larsen and Johansson syndrome (SLJ)
1043534|NCT01826071|Sever's disease
1043535|NCT01826071|apophysitis
1043536|NCT01826058|Stereotactic body radiation therapy
1043537|NCT01826058|Radiosurgery
1043538|NCT01826045|Treatment of Cervical Intraepithelial Neoplasia(CIN1)
1043539|NCT01826006|Myocardial Infarction
1043540|NCT01826006|No-reflow
1043541|NCT01826006|Primary PCI
1043542|NCT01826006|Coronary no-reflow phenomenon
1043543|NCT01826006|Primary percoutaneous coronary intervention (primary PCI)
1043544|NCT01825993|Peridural catheter
1043545|NCT01825993|Morphine PCA
1043546|NCT01825993|Transabdominal Block
1043547|NCT01825993|laparoscopic sigmoidectomy
1043548|NCT01825954|Fibromyalgia
1043549|NCT01825954|Pain
1043550|NCT01825954|Brain
1043551|NCT01825954|Stimulation
1043552|NCT01825954|Device
1043553|NCT01825941|migraine
1043554|NCT01825941|headache
1043555|NCT01825941|metoclopramide
1043556|NCT01825941|diphenhydramine
1043557|NCT01825928|Methamphetamine
1043558|NCT01825928|paliperidone
1043559|NCT01825915|Laparoscopic
1043560|NCT01825915|Hysterectomy
1043561|NCT01825915|Total
1043562|NCT01825915|Subtotal
1043563|NCT01825915|Recovery
1043564|NCT01825915|Outcomes
1043565|NCT01825915|Surgery
1043566|NCT01825863|Laparoscopy
1043567|NCT01825863|Adult
1043568|NCT01825863|Nerve block
1043569|NCT01825863|Ultrasonography
1043570|NCT01825837|bipolar I disorder
1043571|NCT01825837|Eslicarbazepine acetate
1043572|NCT01825837|BIA 2-093
1043573|NCT01825824|Hepatocellular carcinoma
1043574|NCT01825824|Stereotactic ablative radiotherapy
1043575|NCT01825824|Stereotactic body radiotherapy
1043576|NCT01825811|Cell mediated gene therapy
1043577|NCT01825811|Osteoarthritis
1043578|NCT01825811|Fibrin-glue
1043579|NCT01825811|Degenerative Arthritis
1043580|NCT01825798|Metformin
1043581|NCT01825798|Overweight
1043582|NCT01825798|Atypical Antipsychotic
1043583|NCT01825798|Medication
1043584|NCT01825798|Randomized Clinical Trial
1043585|NCT01825798|Children
1043586|NCT01825772|Cross-Sectional Studies
1043587|NCT01825772|Prevalence
1043588|NCT01825772|Peri-Implantitis
1043589|NCT01825733|palonosetron, ramosetron, PONV, opioid
1043590|NCT01825720|GIK, valvular heart surgery, lactate
1043591|NCT01825694|Substance Abuse
1043592|NCT01825694|Traumatic Stress
1043593|NCT01825681|positive affect
1043594|NCT01825681|caregivers
1043595|NCT01825681|caregiving
1043596|NCT01825681|stress
1043597|NCT01825681|mood
1043598|NCT01825681|dementia
1043599|NCT01825681|Alzheimer's
1043600|NCT01825681|FTD
1043601|NCT01825681|Lewy
1043602|NCT01825681|mindfulness
1043603|NCT01825681|help
1043604|NCT01825642|Prostate cancer
1043605|NCT01825642|sexual function
1043606|NCT01825642|seminal vesicle sparing
1043607|NCT01825642|nerve-sparing
1043608|NCT01825642|radical prostatectomy
1043609|NCT01825629|Pain
1043610|NCT01825629|Temporomandibular joint
1043611|NCT01825629|Manual therapy
1043612|NCT01825629|Physical therapy
1043613|NCT01825629|Fibromyalgia Syndrome
1043614|NCT01825616|Strength
1043615|NCT01825616|Anaerobic power
1043616|NCT01825616|Muscle soreness
1043617|NCT01825616|Immune function
1043618|NCT01825590|hemodialysis
1043619|NCT01825590|dialysate and serum sodium
1043620|NCT01825577|Alzheimer Dementia
1043621|NCT01825577|Gait
1043622|NCT01825564|G-tube
1043623|NCT01825564|Feeding tube
1043624|NCT01825564|Feeding tube placement verification
1043625|NCT01825564|Enteral feeding
1043626|NCT01825551|Amyotrophic Lateral Sclerosis
1043627|NCT01825551|Granulocyte Colony Stimulating Factor
1043628|NCT01825538|Chronic obstructive pulmonary disease
1043629|NCT01825538|Pulmonary fibrosis
1043630|NCT01825538|Advanced care planning
1043631|NCT01825512|chronic iron overload
1043632|NCT01825512|hereditary haemoglobinopathy
1043633|NCT01825512|beta thalassaemia major
1043634|NCT01825512|chelating agents
1043635|NCT01825512|deferiprone
1043636|NCT01825512|deferasirox
1043637|NCT01825512|children
1043638|NCT01825512|paediatrics
1043639|NCT01825499|Birth weight
1043640|NCT01825499|Gestational age
1043641|NCT01825499|Very low birth weight
1043642|NCT01825486|Balance
1043643|NCT01825486|Gait characteristics
1043644|NCT01825473|neonate
1043645|NCT01825473|apnea
1043646|NCT01825473|preterm
1043647|NCT01825473|reflux
1043648|NCT01825473|gastroesophageal reflux
1043649|NCT01825473|impedance
1043650|NCT01825473|erythromycin
1043651|NCT01825473|desaturation
1043652|NCT01825473|bradycardia
1043653|NCT01825473|hypoxia
1043654|NCT01825460|Cervical spine
1043655|NCT01825460|Neck pain
1043656|NCT01825460|Manual therapy
1043657|NCT01825460|Controlled clinical trial
1043658|NCT01825447|abuse potential
1043659|NCT01825447|abuse liability
1043660|NCT01825447|drug liking
1043661|NCT01825447|oxycodone
1043662|NCT01825447|naltrexone
1043663|NCT01825447|intravenous
1043664|NCT01825447|pharmacodynamic
1043665|NCT01825434|chronic constipation
1043666|NCT01825434|Lactobacillus acidophilus NCFM
1043667|NCT01825434|Bifidobacterium lactis HN019
1043668|NCT01825421|Infant
1043669|NCT01825421|Infection
1043670|NCT01825421|Newborn
1043671|NCT01825421|Antibiotics
1043672|NCT01825421|Neutrophil CD64
1043673|NCT01825421|Blood Culture
1043674|NCT01825369|congenital heart disease
1043675|NCT01825369|ventricular septal defect
1043676|NCT01825369|atrioventricular septal defect
1043677|NCT01825369|increased pulmonary blood flow
1043678|NCT01825369|nitric oxide
1043679|NCT01825343|fall
1043680|NCT01825343|burn
1043681|NCT01825343|road traffic crash
1043682|NCT01825330|Alzheimer's Disease
1043683|NCT01825330|Alzheimer's
1043684|NCT01825330|TMS
1043685|NCT01825330|Cognitive Training
1043686|NCT01825330|NeuroAD
1043687|NCT01825317|Alzheimer's disease
1043688|NCT01825317|TMS
1043689|NCT01825317|NeuroAd
1043690|NCT01825317|cognitive training
1043691|NCT01825317|ADAS-Cog
1043692|NCT01825304|mechanical ventilation
1043693|NCT01825304|Intra-abdominal hypertension
1043694|NCT01825304|positive end-expiratory pressure
1043695|NCT01825291|sleep apnea
1043696|NCT01825291|co-morbidities of sleep apnea
1043697|NCT01825291|CPAP treatment
1043698|NCT01825278|respiratory rate
1043699|NCT01825278|tidal volume
1043700|NCT01825278|minute ventilation
1043701|NCT01825278|obese patients
1043702|NCT01825278|obstructive sleep apnea
1043703|NCT01825265|Neoplasm Metastasis
1043704|NCT01825265|Breast Cancer
1043705|NCT01825265|Docetaxel
1043706|NCT01825265|RAD001
1043707|NCT01825265|Taxotere
1043708|NCT01825252|HIV
1043709|NCT01825252|sexually transmitted diseases
1043710|NCT01825239|ischemic cardiomyopathy
1043711|NCT01825239|cardiomyopathy
1043712|NCT01825239|left ventricular lead
1043713|NCT01825239|cardiac electrophysiologic studies
1043714|NCT01825213|Liver disease
1043715|NCT01825213|Multi Spectral CT
1043716|NCT01825200|Influenza
1043717|NCT01825148|Diabetes
1043718|NCT01825135|muscle strength
1043719|NCT01825135|muscle function
1043720|NCT01825135|functional status
1043721|NCT01825109|Rotavirus
1043722|NCT01825109|Immunogenicity
1043723|NCT01825109|vaccine, Bangladesh
1043724|NCT01825096|cerebral metabolism
1043725|NCT01825096|functional magnetic resonance imaging
1043726|NCT01825096|near infrared spectroscopy
1043727|NCT01825083|Hypercarbia
1043728|NCT01825083|TOSCA monitor
1043729|NCT01825083|Ketamine
1043730|NCT01825083|Fentanyl
1043731|NCT01825083|Intraoperative monitoring
1043732|NCT01825070|Montmorency tart cherries
1043733|NCT01825070|Inflammation
1043734|NCT01825070|Uric acid
1043735|NCT01825057|implementation study
1043736|NCT01825057|motivational interviewing
1043737|NCT01825057|substance use
1043738|NCT01825044|Traumatic Brain Injury
1043739|NCT01825044|TBI
1043740|NCT01825044|ciclosporin
1043741|NCT01825044|pharmacokinetic
1043742|NCT01825044|safety
1043743|NCT01825044|microdialysis
1043744|NCT01825044|mitochondrial protection
1043745|NCT01825031|HIV
1043746|NCT01825018|HIV
1043747|NCT01825018|AIDS
1043748|NCT01825018|treatment adherence
1043749|NCT01825005|cervical cancer
1043750|NCT01824966|Esophagectomy
1043751|NCT01824966|Signet Ring Cells
1043752|NCT01824953|Gastric atrophy
1043753|NCT01824953|Helicobacter pylori
1043754|NCT01824953|Pepsinogen
1043755|NCT01824953|Gastric cancer
1043756|NCT01824953|Gastric adenoma
1043757|NCT01824940|Cluster randomized trial
1043758|NCT01824940|Nutrition
1043759|NCT01824940|Water Sanitation Hygiene
1043760|NCT01824940|Environmental enteropathy
1043761|NCT01824914|videolaryngoscope
1043762|NCT01824914|tracheal intubation
1043763|NCT01824914|Cormack-Lehane grade
1043764|NCT01824914|airway evaluation
1043765|NCT01824914|sedation
1043766|NCT01824914|anesthesia
1043767|NCT01824901|AZD4547
1043768|NCT01824901|recurrent non-small cell lung cancer
1043769|NCT01824888|JUC
1043770|NCT01824888|hand rub
1043771|NCT01824888|European standard
1043772|NCT01824862|clinically significant macular edema
1043773|NCT01824862|foveal thickness
1043774|NCT01824862|foveal sensitivity
1043775|NCT01824862|perimetry
1043776|NCT01824862|diabetic retinopathy
1043777|NCT01824849|Vocal cords
1043778|NCT01824849|Vocal cord paralysis
1043779|NCT01824849|Arytenoid cartilage
1043780|NCT01824823|afatinib
1043781|NCT01824823|head and neck squamous cell carcinoma
1043782|NCT01824810|Intramuscular Stimulation
1043783|NCT01824810|myoActivation
1043784|NCT01824810|Neural Prolotherapy
1043785|NCT01824810|Whiplash-Associated Disorders
1043786|NCT01824810|myofascial pain
1043787|NCT01824797|Bone mineral density
1043788|NCT01824797|sleeve gastrectomy
1043789|NCT01824797|roux-en-y
1043790|NCT01824797|postmenopausal females
1043791|NCT01824797|bone loss
1043792|NCT01824784|Normal Eyes
1043793|NCT01824771|Continuous veno-venoous haemofiltration
1043794|NCT01824771|Plasma lactate
1043795|NCT01824771|Critical illness
1043796|NCT01824771|Acute kidney injurytissue perfusion
1043797|NCT01824771|Multiple organ dysfunction syndrome
1043798|NCT01824758|esmolol, injection pain, lidocaine, rocuronium
1043799|NCT01824706|cranial prosthesis
1043800|NCT01824680|Obesity
1043801|NCT01824680|Appetite regulation
1043802|NCT01824680|Hormones
1043803|NCT01824680|Adolescents
1043804|NCT01824680|Exercise
1043805|NCT01824654|Aortic Aneurysm, Abdominal
1043806|NCT01824654|Imaging, Three-Dimensional
1043807|NCT01824654|Tomography Scanners, X-Ray Computed
1043808|NCT01824654|Angiography, Digital Subtraction
1043809|NCT01824654|Endovascular Procedures
1043810|NCT01824654|Radiography, Interventional
1043811|NCT01824641|Acute myocardial infarction
1043812|NCT01824641|Manual thrombus aspiration
1043813|NCT01824641|Coronary physiology
1043814|NCT01824615|Sunitinib
1043815|NCT01824615|recurrent ovarian cancer
1043816|NCT01824615|clear cell carcinoma
1043817|NCT01824602|BIPOLAR I DISORDER, Eslicarbazepine acetate
1043818|NCT01824589|traumatic brain injury
1043819|NCT01824589|TBI
1043820|NCT01824589|ITPR
1043821|NCT01824589|intrathoracic pressure regulator
1043822|NCT01824589|hepatic encephalopathy
1043823|NCT01824589|pseudotumorcerebri
1043824|NCT01824589|obstructive hydrocephalus
1043825|NCT01824589|intracranial hemorrhage
1043826|NCT01824576|ITPR
1043827|NCT01824576|CPP
1043828|NCT01824576|TBI
1043829|NCT01824576|traumatic brain injury
1043830|NCT01824576|cerebral perfusion pressure
1043831|NCT01824576|intrathoracic pressure regulator
1043832|NCT01824537|Human papillomavirus (HPV)
1043833|NCT01824537|Vaccination
1043834|NCT01824537|Cervical cancer prevention
1043835|NCT01824537|Herd immunity
1043836|NCT01824524|Pain
1043837|NCT01824524|Hydromorphone
1043838|NCT01824524|OROS
1043839|NCT01824511|smoking
1043840|NCT01824511|nicotine
1043841|NCT01824511|tobacco
1043842|NCT01824511|anhedonia
1043843|NCT01824511|reward
1043844|NCT01824511|withdrawal
1043845|NCT01824498|omega-3 fatty acids
1043846|NCT01824498|sex hormones
1043847|NCT01824498|urinary sex hormone metabolites
1043848|NCT01824485|Osteoarthritis
1043849|NCT01824485|Knee
1043850|NCT01824485|Viscosupplementation
1043851|NCT01824485|Clinical Trial
1043852|NCT01824459|Diffuse-type gastric cancer
1043853|NCT01824459|Advance Gastric Cancer
1043854|NCT01824459|Recurrent Gastric Cancer
1043855|NCT01824459|Gastroesophageal Junction Adenocarcinoma
1043856|NCT01824459|SOX, S-1+Oxaliplatin
1043857|NCT01824459|OS,
1043858|NCT01824459|ORR,
1043859|NCT01824459|TTP,
1043860|NCT01824459|TTF,
1043861|NCT01824459|safety
1043862|NCT01824433|venlafaxine
1043863|NCT01824433|fluoxetine
1043864|NCT01824433|postmenopause
1043865|NCT01824433|major depressive disorder
1043866|NCT01824420|Refractory overactive bladder syndrome
1043867|NCT01824420|Antimuscarinic agent
1043868|NCT01824407|foot
1043869|NCT01824407|ulcers
1043870|NCT01824407|diabetes
1043871|NCT01824407|wound
1043872|NCT01824407|healing
1043873|NCT01824394|nMARQ
1043874|NCT01824394|Atrial Fibrillation
1043875|NCT01824394|Drug Refractory
1043876|NCT01824394|Radio Frequency
1043877|NCT01824381|extensive wounds
1043878|NCT01824381|amniotic membrane
1043879|NCT01824381|healing
1043880|NCT01824381|patients
1043881|NCT01824381|phase granulation
1043882|NCT01824329|Bladder Cancer
1043883|NCT01824329|Transitional cell carcinoma of the bladder
1043884|NCT01824264|Type 2 Diabetes mellitus, SGLT inhibitors, dose-response
1043885|NCT01824251|IVIG in Chronic Inflammatory Demyelinating Polyneuropathy
1043886|NCT01824251|Patients with Chronic Inflammatory Demyelinating Polyneuropathy
1043887|NCT01824225|aflibercept
1043888|NCT01824225|intravitreal injection
1043889|NCT01824212|Ventricular fibrillation
1043890|NCT01824212|Cardiac arrest
1043891|NCT01824212|Mobile technology
1043892|NCT01824199|Esophagitis
1043893|NCT01824173|muscle
1043894|NCT01824173|mitochondria
1043895|NCT01824173|amino acids
1043896|NCT01824173|exercise
1043897|NCT01824147|ASS-Nonresponse
1043898|NCT01824147|cardiac
1043899|NCT01824147|surgery
1043900|NCT01824121|Progressive Supranuclear palsy
1043901|NCT01824121|stem cell therapy
1043902|NCT01824108|Lumbar disc herniation
1043903|NCT01824108|Wallis interspinous implants
1043904|NCT01824108|lumbar discectomy
1043905|NCT01824108|interspinous dynamic stability system
1043906|NCT01824082|phantom pain
1043907|NCT01824082|traumatic limb amputation
1043908|NCT01824082|amputees
1043909|NCT01824069|Critical Ischemia
1043910|NCT01824069|Amputation
1043911|NCT01824056|18F-FDG
1043912|NCT01824043|diabetic retinopathy
1043913|NCT01824043|vitreous hemorrhage
1043914|NCT01824043|intravitreal ranibizumab
1043915|NCT01824030|FFR, OCT, Seattle Angina Questionnaire
1043916|NCT01824017|Type 2 diabetes
1043917|NCT01824017|metabolic syndrome
1043918|NCT01824017|oxidative stress
1043919|NCT01824017|GSH
1043920|NCT01824004|Gastric cancer
1043921|NCT01824004|Adjuvant
1043922|NCT01824004|Chemoradiotherapy
1043923|NCT01824004|S-1
1043924|NCT01824004|Cisplatin
1043925|NCT01823991|polyphenolics
1043926|NCT01823991|anthocyanins
1043927|NCT01823991|n-3 fatty acids
1043928|NCT01823978|metastatic
1043929|NCT01823978|castration resistant prostate cancer
1043930|NCT01823978|Therapeutic Vaccine
1043931|NCT01823978|Dendritic cell
1043932|NCT01823978|BPX-201
1043933|NCT01823978|BPX201
1043934|NCT01823978|AP1903
1043935|NCT01823952|HAMS
1043936|NCT01823952|ORS
1043937|NCT01823952|Cholera
1043938|NCT01823952|Diarrhea
1043939|NCT01823939|Cholera
1043940|NCT01823939|V. Cholerae O1
1043941|NCT01823939|iOWH032
1043942|NCT01823939|diarrhoea
1043943|NCT01823939|pharmacokinetic
1043944|NCT01823939|Bangladesh
1043945|NCT01823926|vibrating mesh nebulizers
1043946|NCT01823926|noninvasive ventilation
1043947|NCT01823926|residual volume
1043948|NCT01823926|pulmonary scintigraphy
1043949|NCT01823926|radioaerosol
1043950|NCT01823926|nebulization.
1043951|NCT01823913|Pharmacokinetics
1043952|NCT01823900|Pharmacokinetics
1043953|NCT01823887|Heart Failure
1043954|NCT01823887|Vagus Nerve
1043955|NCT01823887|VNS
1043956|NCT01823874|Virtual reality analgesia
1043957|NCT01823874|pain control
1043958|NCT01823848|constipation
1043959|NCT01823848|enema
1043960|NCT01823822|Anorexia nervosa
1043961|NCT01823822|Protein supplements
1043962|NCT01823822|IGF-I
1043963|NCT01823809|Coronary Artery Disease
1043964|NCT01823809|Computed Tomography
1043965|NCT01823809|Cardiac Magnetic Resonance
1043966|NCT01823809|Fractional Flow Reserve
1043967|NCT01823796|Fibromyalgia
1043968|NCT01823796|balance
1043969|NCT01823796|falls
1043970|NCT01823783|Duchenne muscular distrophy
1043971|NCT01823783|Endomysial Fibrosis
1043972|NCT01823783|Muscular Inflammatory Response
1043973|NCT01823783|Calcium Homeostasis Dysfunction
1043974|NCT01823783|Muscle biopsy
1043975|NCT01823770|Restless Legs Syndrome (RLS)
1043976|NCT01823770|Rotigotine
1043977|NCT01823770|HTA
1043978|NCT01823770|Cardiovascular diseases
1043979|NCT01823770|Periodic Limb Movements in Sleep (PLMS)
1043980|NCT01823770|dopaminergic agonist
1043981|NCT01823770|Sympathetic overactivity
1043982|NCT01823770|blood pressure
1043983|NCT01823757|elderly
1043984|NCT01823757|potential inappropriate medications
1043985|NCT01823757|pharmaceutical care
1043986|NCT01823757|quality of life
1043987|NCT01823757|medical expenditure
1043988|NCT01823744|micronutrient
1043989|NCT01823744|genomic
1043990|NCT01823744|SAM/SAH ratio
1043991|NCT01823731|PCI,SOTOC, Ovarian cancer
1043992|NCT01823692|Radius Fracture
1043993|NCT01823692|Sensitivity
1043994|NCT01823692|Reduction
1043995|NCT01823692|Adequacy
1043996|NCT01823666|Dementia
1043997|NCT01823666|Alzheimer's disease
1043998|NCT01823666|mild cognitive impairment
1043999|NCT01823640|HRV
1044000|NCT01823640|Pharmacodynamics / kinetics
1044001|NCT01823640|Resistance
1044002|NCT01823627|COPD
1044003|NCT01823627|Psychiatric inpatient
1044004|NCT01823627|Smoking
1044005|NCT01823614|HIV infection
1044006|NCT01823614|tropism determination
1044007|NCT01823614|genotypic methodic
1044008|NCT01823614|R5-tropic variant
1044009|NCT01823614|X4-tropic variant
1044010|NCT01823601|Well-Being
1044011|NCT01823601|Life Management Program
1044012|NCT01823601|Breathing
1044013|NCT01823601|Meditation
1044014|NCT01823601|Cognitive-Behavioral Training
1044015|NCT01823575|malignant ureteral obstruction
1044016|NCT01823575|silicone-covered metallic ureteral stent
1044017|NCT01823575|double-J stent
1044018|NCT01823562|Lyophilized Black Raspberry
1044019|NCT01823562|Prostate Cancer
1044020|NCT01823562|Surgery
1044021|NCT01823549|CAM
1044022|NCT01823549|Alternative Medicine
1044023|NCT01823536|Meningitis
1044024|NCT01823510|Antiplatelet
1044025|NCT01823510|Ticagrelor
1044026|NCT01823510|Clopidogrel
1044027|NCT01823510|Thrombosis
1044028|NCT01823510|Diabetes
1044029|NCT01823510|Coronary Artery Disease
1044030|NCT01823497|Neonatal Intensive Care Unit
1044031|NCT01823497|neonate
1044032|NCT01823497|pain
1044033|NCT01823497|morphine
1044034|NCT01823497|Parent/Nurse Controlled Analgesia
1044035|NCT01823484|hemofilter
1044036|NCT01823484|coagulation
1044037|NCT01823484|CRRT
1044038|NCT01823484|critically ill
1044039|NCT01823471|HNPCC
1044040|NCT01823471|Hereditary non-polyposis colon carcinoma
1044041|NCT01823471|Lynch syndrome
1044042|NCT01823471|i-scan
1044043|NCT01823471|virtual chromo-endoscopy
1044044|NCT01823471|chromo-endoscopy
1044045|NCT01823471|high definition endoscopy
1044046|NCT01823471|polyp detection
1044047|NCT01823471|adenoma detection
1044048|NCT01823471|adenoma miss rate
1044049|NCT01823458|behavioral economics
1044050|NCT01823458|incentives
1044051|NCT01823458|health behavior
1044052|NCT01823458|exercise
1044053|NCT01823445|Xylitol
1044054|NCT01823445|Dental caries
1044055|NCT01823393|balloon aortic valvuloplasty indication
1044056|NCT01823393|heparin
1044057|NCT01823393|hemorrhagic
1044058|NCT01823393|ischemic
1044059|NCT01823380|Amyotrophic lateral sclerosis
1044060|NCT01823380|Vitamin D
1044061|NCT01823380|Blood Levels
1044062|NCT01823367|type 2 diabetes mellitus prevention
1044063|NCT01823367|gestational diabetes mellitus
1044064|NCT01823367|pre-diabetes
1044065|NCT01823367|lifestyle interventions
1044066|NCT01823367|pediatric primary prevention of type 2 diabetes
1044067|NCT01823354|Restless Legs Syndrome
1044068|NCT01823354|Polysomnography
1044069|NCT01823354|Executive cognition
1044070|NCT01823341|Type 1 Diabetes
1044071|NCT01823341|Hypoglycemia
1044072|NCT01823341|Continuous Glucose Monitoring
1044073|NCT01823341|Pump Suspension
1044074|NCT01823328|Intubation
1044075|NCT01823328|Airway
1044076|NCT01823328|Emergent intubation
1044077|NCT01823328|Rapid sequence intubation
1044078|NCT01823328|Rapid sequence induction
1044079|NCT01823328|RSI
1044080|NCT01823328|Ketamine
1044081|NCT01823328|Etomidate
1044082|NCT01823328|Sepsis
1044083|NCT01823328|Sedative
1044084|NCT01823328|Sedation
1044085|NCT01823302|Children with picky-eating behaviors
1044086|NCT01823302|Children aged 2.5 - 5 years
1044087|NCT01823302|reported by caregivers
1044088|NCT01823302|with weight-for-height z-scores ≤ 25th percentile at enrollment
1044089|NCT01823289|Invasive Pulmonary Fungal Infection
1044090|NCT01823289|Itraconazole
1044091|NCT01823250|Hispanic
1044092|NCT01823250|adolescent
1044093|NCT01823250|drug abuse treatment
1044094|NCT01823250|evidence-based
1044095|NCT01823250|family therapy
1044096|NCT01823250|adaptive family treatment
1044097|NCT01823250|Culturally Informed Family-Based Treatment for Adolescents
1044098|NCT01823237|Dystonia
1044099|NCT01823237|Transcranial Magnetic Stimulation
1044100|NCT01823237|Rehabilitation
1044101|NCT01823237|Plasticity
1044102|NCT01823211|ICD (Implantable cardioverter-defibrillator)
1044103|NCT01823211|Heart rate variability
1044104|NCT01823211|MTWA (Microvolt T-alternans)
1044105|NCT01823211|Magnetic resonance imaging (MRI)
1044135|NCT01823185|Clopidogrel
1044136|NCT01823185|Ticagrelor
1044137|NCT01823185|Prasugrel
1044138|NCT01823185|Platelet aggregation inhibitor
1044139|NCT01823185|Dammam University
1044140|NCT01823185|King Fahd Hospital
1044141|NCT01823185|Purinergic P2 receptor Antagonists
1044142|NCT01823172|breast cancer
1044143|NCT01823172|melanoma
1044144|NCT01823172|sentinel lymph node biopsy
1044145|NCT01823172|lymphadenectomy
1044146|NCT01823159|retigabine
1044147|NCT01823159|cortical excitability
1044148|NCT01823159|Transcranial Magnetic Stimulation
1044149|NCT01823146|oxytocin
1044150|NCT01823146|socioemotional functioning
1044151|NCT01823146|trust
1044152|NCT01823146|amygdala
1044153|NCT01823146|aging
1044154|NCT01823120|Self harm
1044155|NCT01823120|Emergency Department
1044156|NCT01823120|Repetition
1044157|NCT01823120|Supportive Text messages
1044158|NCT01823120|Interactive
1044159|NCT01823107|Meso BioMatrix
1044160|NCT01823107|Breast
1044161|NCT01823107|Breast Cancer
1044162|NCT01823107|Mastectomy
1044163|NCT01823107|Biologic Mesh
1044164|NCT01823107|Breast Reconstruction
1044165|NCT01823094|lung cancer
1044166|NCT01823094|computed tomography
1044167|NCT01823094|blood flow
1044168|NCT01823068|Lung cancer
1044169|NCT01823068|RET fusion
1044170|NCT01823068|Vandetanib
1044171|NCT01823042|Crohn's Disease
1044172|NCT01823042|maintain remission
1044173|NCT01823042|postoperative recurrence
1044174|NCT01823042|surgery
1044175|NCT01823042|living quality
1044176|NCT01823029|Crohn's Disease
1044177|NCT01823029|intravenous iron
1044178|NCT01823029|iron deficiency anaemia
1044179|NCT01823029|Oxidative Stress
1044180|NCT01823029|inflammation
1044181|NCT01823016|Uncontrolled, persistent asthma
1044182|NCT01823003|Carcinoma, Non-Small-Cell Lung
1044183|NCT01823003|Neoplasm Metastasis
1044184|NCT01823003|Radiosurgery
1044185|NCT01822990|Anti-beta2-glycoprotein antibodies
1044186|NCT01822990|Peripheral arterial disease
1044187|NCT01822990|Inflammation
1044188|NCT01822990|Nitric oxide
1044189|NCT01822990|Endothelial dysfunction
1044190|NCT01822977|gut microbiota
1044191|NCT01822977|proton pump inhibitor
1044192|NCT01822977|Clostridium difficile infection
1044193|NCT01822977|Fecal microbiome
1044194|NCT01822977|single episode of CDI
1044195|NCT01822951|DAT Study
1044196|NCT01822925|Diabetes
1044197|NCT01822925|Pain
1044198|NCT01822925|Neuropathy
1044199|NCT01822912|Skilled Nursing Facility
1044200|NCT01822912|Heart Failure
1044201|NCT01822912|Transitional Care
1044202|NCT01822899|Novel Dry Powder Inhaler (NDPI)
1044203|NCT01822899|umeclidinium bromide (UMEC)
1044204|NCT01822899|GSK573719
1044205|NCT01822899|lung function
1044206|NCT01822899|GW642444
1044207|NCT01822899|salmeterol (SAL)
1044208|NCT01822899|fluticasone propionate (FP)
1044209|NCT01822899|vilanterol (VI)
1044210|NCT01822899|Chronic obstructive pulmonary disease
1044211|NCT01822886|T-cell lymphoma
1044212|NCT01822886|Romidepsin
1044213|NCT01822860|Hypertension
1044214|NCT01822860|Endothelial dysfunction
1044215|NCT01822847|adrenal
1044216|NCT01822847|steroids
1044217|NCT01822847|cortisol
1044218|NCT01822847|stress
1044219|NCT01822821|Males or females
1044220|NCT01822821|18 years of age or older.
1044221|NCT01822821|Non-emergency
1044222|NCT01822821|cardiac surgery
1044223|NCT01822821|midline sternotomy.
1044224|NCT01822808|acute heart failure
1044225|NCT01822808|left ventricular dysfunction
1044226|NCT01822808|hydralazine
1044227|NCT01822808|isosorbide dinitrate
1044228|NCT01822795|Chronic obstructive pulmonary disease
1044229|NCT01822795|Endoscopic lung volume reduction
1044230|NCT01822782|Perineal tear
1044231|NCT01822782|Perineal lesion
1044232|NCT01822782|Vaginal flora
1044233|NCT01822782|Birth
1044234|NCT01822769|congenital heart disease
1044235|NCT01822769|adult congenital heart disease
1044236|NCT01822769|cardiac rehabilitation
1044237|NCT01822769|cardiopulmonary rehabilitation
1044238|NCT01822769|exercise
1044239|NCT01822769|cardiopulmonary exercise testing
1044240|NCT01822769|peak vO2
1044241|NCT01822769|quality of life
1044242|NCT01822743|Osteopathy
1044243|NCT01822743|Sleep Apnea Syndromes
1044244|NCT01822743|Obstructive Sleep Apnea
1044245|NCT01822743|Pcrit
1044246|NCT01822743|Polysomnography
1044247|NCT01822730|Methamphetamine-Associated Psychosis
1044248|NCT01822730|Aripiprazole
1044249|NCT01822730|Risperidone
1044250|NCT01822717|Diabetes
1044251|NCT01822717|Visual Impairment
1044252|NCT01822717|Blindness
1044253|NCT01822717|Foot Care
1044254|NCT01822717|Self-Management
1044255|NCT01822704|Stroke
1044256|NCT01822704|Exercise
1044257|NCT01822704|Rehabilitation
1044258|NCT01822704|Vibration
1044259|NCT01822691|myelodysplastic syndromes (MDS)
1044260|NCT01822691|neoplastic stem cell disorders
1044261|NCT01822691|refractory cytopenias
1044262|NCT01822691|dysplastic morphological features
1044263|NCT01822691|acute myeloid leukemia (AML)
1044264|NCT01822652|Neuroblastoma
1044265|NCT01822652|Solid tumor
1044266|NCT01822652|Neuroblastoma-specific immunotherapy targeting GD2
1044267|NCT01822652|CAR T cells
1044268|NCT01822652|Gene Therapy
1044269|NCT01822652|Relapsed
1044270|NCT01822652|Refractory
1044271|NCT01822639|Hypertension
1044272|NCT01822639|enalapril maleate
1044273|NCT01822639|healthy volunteers
1044274|NCT01822639|amlodipine
1044275|NCT01822639|pharmacokinetics
1044276|NCT01822626|overweight
1044277|NCT01822626|obesity
1044278|NCT01822626|children
1044279|NCT01822626|BMI
1044280|NCT01822626|counseling
1044281|NCT01822626|pediatrician
1044282|NCT01822613|esophageal cancer
1044283|NCT01822600|hypoalbuminemia
1044284|NCT01822600|peptic ulcer
1044285|NCT01822600|rebleeding
1044286|NCT01822600|hospitalization
1044287|NCT01822587|Drug Abuse
1044288|NCT01822587|Cocaine
1044289|NCT01822587|Addiction
1044295|NCT01822548|EPC
1044296|NCT01822548|diabetes
1044297|NCT01822548|DPP IV inhibitors
1044298|NCT01822535|Quadriplegia
1044299|NCT01822535|Spinal Cord Injuries
1044300|NCT01822535|Body Temperature Regulation
1044301|NCT01822535|Mild Cognitive Impairment
1044302|NCT01822483|Renal transplantation
1044303|NCT01822483|mycophenolic acid
1044304|NCT01822483|mycophenolate mofetil
1044305|NCT01822483|mycophenolate sodium
1044306|NCT01822483|area under the curve
1044307|NCT01822470|functional dyspepsia
1044308|NCT01822470|post prandial distress syndrome
1044309|NCT01822470|small bowel bacteria overgrowth
1044310|NCT01822470|epigastric pain syndrome
1044311|NCT01822470|diarrhea
1044312|NCT01822470|bloating
1044313|NCT01822470|post prandial fullness
1044314|NCT01822470|weight loss
1044315|NCT01822444|Colorectal Cancer
1044316|NCT01822444|Advanced Colorectal Cancer
1044317|NCT01822444|Metastatic Colorectal Cancer
1044318|NCT01822444|Locally Advanced Colorectal Cancer
1044319|NCT01822444|Colon Cancer
1044320|NCT01822444|Rectal Cancer
1044321|NCT01822418|Schizophrenia
1044322|NCT01822418|Depression
1044323|NCT01822418|Cognition
1044324|NCT01822418|Agomelatine
1044325|NCT01822418|Antidepressant
1044326|NCT01822392|Online treatment
1044327|NCT01822392|Treatment of conduct problems
1044328|NCT01822392|Parent training
1044329|NCT01822366|Children
1044330|NCT01822366|Adolescents
1044331|NCT01822366|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
1044332|NCT01822366|Low- and Middle-Income Countries (LAMIC)
1044333|NCT01822366|Randomized Controlled Trial (RCT)
1044334|NCT01822366|Evidence-Based Practice (EBP)
1044335|NCT01822366|Childhood Traumatic Grief (CTG)
1044336|NCT01822366|Post-Traumatic Stress Disorder (PTSD)
1044337|NCT01822366|Kenya
1044338|NCT01822366|Tanzania
1044339|NCT01822366|East Africa
1044340|NCT01822366|Mental Health
1044341|NCT01822353|food allergy
1044342|NCT01822353|milk allergy
1044343|NCT01822353|egg allergy
1044344|NCT01822353|nut allergy
1044345|NCT01822340|AGHD
1044346|NCT01822314|breast
1044347|NCT01822314|cancer
1044348|NCT01822314|unilateral
1044349|NCT01822314|non metastatic
1044350|NCT01822314|HER2 negative
1044351|NCT01822301|Craniomaxillofacial (CMF) Battle-injured (BI)
1044352|NCT01822301|Facial Trauma
1044353|NCT01822301|Fat Grafts
1044354|NCT01822301|Autogenous Fat Transfers (AFT)
1044355|NCT01822301|Wounded warriors
1044356|NCT01822288|Menopause
1044357|NCT01822288|Tibolone
1044358|NCT01822288|Estradiol
1044359|NCT01822288|Hormone therapy
1044360|NCT01822275|GBM
1044361|NCT01822262|Cholecystolithotomy with gallbladder reservation
1044362|NCT01822262|cholecystolithiasis
1044363|NCT01822249|Rett syndrome
1044364|NCT01822249|EPI-743
1044365|NCT01822249|Edison
1044366|NCT01822236|low back pain
1044367|NCT01822236|Manual Therapy
1044368|NCT01822236|Randomized Controlled Trial
1044369|NCT01822236|Quality of life
1044370|NCT01822223|Dental Implants
1044371|NCT01822223|Implant abutments
1044372|NCT01822210|Botulinum Toxins
1044373|NCT01822210|Injections
1044374|NCT01822210|Stomach
1044375|NCT01822210|Tomography, X-Ray Computed
1044376|NCT01822197|Phototherapy
1044377|NCT01822184|Neurodevelopmental Status
1044378|NCT01822184|Pediatric Hunter syndrome patients
1044379|NCT01822184|Central Nervous System (CNS) involvement
1044380|NCT01822184|Observational study
1044381|NCT01822184|Cognitive impairment
1044382|NCT01822171|Heart Failure
1044383|NCT01822171|Medication Therapy Management
1044384|NCT01822158|Vaginal Delivery
1044385|NCT01822158|Debrief
1044386|NCT01822158|Medical Team Communication
1044387|NCT01822158|Obstetrical Safety
1044388|NCT01822145|implantable-cardioverter-defibrillator
1044389|NCT01822145|ventricular tachycardia
1044390|NCT01822145|ventricular fibrillation
1044391|NCT01822145|sudden cardiac arrest
1044392|NCT01822080|Endometriosis
1044393|NCT01822080|Efficacy
1044394|NCT01822080|Safety
1044395|NCT01822080|Dienogest
1044396|NCT01822041|healthy volunteers
1044397|NCT01822041|mass balance study
1044398|NCT01822041|Pharmacokinetics
1044399|NCT01822028|diarrhea
1044400|NCT01822002|Vertigo
1044401|NCT01822002|Nystagmus
1044402|NCT01822002|BPPV = benign paroxysmal positional vertigo
1044403|NCT01822002|Treatment outcome
1044404|NCT01821963|Infection
1044405|NCT01821963|Hepatitis C Genotype 1 Infection
1044406|NCT01821963|Hepatitis C virus
1044407|NCT01821963|HCV
1044408|NCT01821963|Hepatocellular Carcinoma
1044409|NCT01821963|HCC
1044410|NCT01821963|Liver Transplantation
1044411|NCT01821963|Pegylated Interferon Alfa 2a
1044412|NCT01821963|PegIFN alfa-2a
1044413|NCT01821963|Ribavirin
1044414|NCT01821963|RBV
1044415|NCT01821963|Telaprevir
1044416|NCT01821963|Incivek
1044417|NCT01821963|Antiviral drugs
1044418|NCT01821950|Mental health
1044419|NCT01821950|Substance use
1044420|NCT01821950|Substance use initiation
1044421|NCT01821950|Education
1044422|NCT01821950|Mind Body Therapies
1044423|NCT01821950|Yoga
1044424|NCT01821950|Meditation
1044425|NCT01821950|Adolescent
1044426|NCT01821950|Adolescence
1044427|NCT01821950|Child
1044428|NCT01821950|Children
1044429|NCT01821950|Middle School
1044430|NCT01821898|Eosinophil
1044431|NCT01821898|Reflux
1044432|NCT01821898|Esophagus
1044433|NCT01821898|Food allergy
1044434|NCT01821898|Trouble Swallowing
1044435|NCT01821898|Pediatrics
1044436|NCT01821885|Spirometry
1044437|NCT01821885|screening
1044438|NCT01821885|smoking cessation
1044439|NCT01821885|tobacco
1044440|NCT01821885|COPD
1044441|NCT01821872|paracetamol
1044442|NCT01821872|acetaminophen
1044443|NCT01821872|AM404
1044444|NCT01821872|CSF
1044445|NCT01821872|pharmacokinetics
1044446|NCT01821833|omega-3
1044447|NCT01821833|fatty acids
1044448|NCT01821833|paclitaxel
1044449|NCT01821833|acute pain syndrome
1044450|NCT01821833|peripheral neuropathy
1044451|NCT01821833|chemotherapy induced neuropathy
1044452|NCT01821820|Inflammation
1044453|NCT01821820|Oxidative stress
1044454|NCT01821820|Immune dysfunction
1044455|NCT01821820|Metabolites
1044456|NCT01821807|spinal anesthesia
1044457|NCT01821807|spinal needle
1044458|NCT01821807|cesarean section
1044459|NCT01821807|headache
1044460|NCT01821807|backache
1044461|NCT01821781|Immune deficiency
1044462|NCT01821781|Immune disorders
1044463|NCT01821781|Immune dysregulatory
1044464|NCT01821781|Reduced Intensity
1044465|NCT01821781|Alemtuzumab
1044466|NCT01821781|Campath
1044467|NCT01821742|Shock
1044468|NCT01821742|Fluid bolus
1044469|NCT01821742|Cardiac output
1044470|NCT01821742|Children in intensive care
1044471|NCT01821729|Locally Advanced
1044472|NCT01821690|Traumatic Brain Injury
1044473|NCT01821690|Buspirone
1044474|NCT01821690|Behavior
1044475|NCT01821690|Irritability
1044476|NCT01821690|Aggression
1044477|NCT01821664|Prosthetic vascular graft infection
1044478|NCT01821664|negative pressure wound therapy
1044479|NCT01821664|microbiology
1044480|NCT01821664|antimicrobial therapy
1044481|NCT01821651|TAVI
1044482|NCT01821651|MitraClip
1044483|NCT01821651|image modality
1044484|NCT01821651|echocardiography
1044485|NCT01821651|angiography
1044486|NCT01821638|Heart failure
1044487|NCT01821638|Cognition
1044488|NCT01821638|Brain
1044489|NCT01821638|Older adults
1044490|NCT01821625|Thrombocytopenia
1044491|NCT01821625|HCV
1044492|NCT01821625|Hepatitis
1044493|NCT01821625|Platelets
1044494|NCT01821625|Eltrombopag
1044495|NCT01821625|Liver Disease
1044496|NCT01821625|Antiviral Treatment
1044497|NCT01821599|Anterior Cruciate Ligament
1044498|NCT01821599|Knee
1044499|NCT01821599|Rehabilitation
1044500|NCT01821586|Diarrhoea;
1044501|NCT01821586|Severe malnutrition;
1044502|NCT01821586|Benefiber;
1044503|NCT01821586|ReSoMal;
1044504|NCT01821586|modified ORS
1044505|NCT01821573|botulinum toxin injection,3D motion analysis, muscular lengthening,muscle strength
1044506|NCT01821560|Nicotine Addiction
1044507|NCT01821560|fMRI
1044508|NCT01821560|Baclofen
1044509|NCT01821508|Gastroplasty, Diabetes Mellitus Type II, Obesity
1044510|NCT01821495|NPC,DC-CIK
1044511|NCT01821482|Hepatocellular carcinoma, DC-CIK
1044512|NCT01821469|bipolar disorders
1044513|NCT01821469|euthymic
1044514|NCT01821469|psychotherapy
1044515|NCT01821469|Functional magnetic resonance imaging
1044516|NCT01821456|hematological malignancies
1044517|NCT01821456|cancer
1044518|NCT01821456|chemotherapy
1044519|NCT01821456|anti-infectives
1044520|NCT01821456|treatment
1044521|NCT01821456|outcome
1044522|NCT01821443|1 to 10 measurable brain metastases
1044523|NCT01821430|Chronic Pain
1044524|NCT01821430|Narcotic Abuse
1044525|NCT01821430|Opioid related disorders
1044526|NCT01821430|Opiate substitution treatment
1044527|NCT01821430|Buprenorphrine
1044528|NCT01821430|Pregabalin
1044529|NCT01821430|Methadone
1044530|NCT01821417|dental implants
1044531|NCT01821417|screw-vent dental implants
1044532|NCT01821404|Apoptosis
1044533|NCT01821404|Atorvastatin
1044534|NCT01821404|Inflammation
1044535|NCT01821404|Pre-surgical trial
1044536|NCT01821404|Proliferation
1044537|NCT01821404|Prostate cancer
1044538|NCT01821391|actinic keratoses
1044539|NCT01821391|photodynamic therapy
1044540|NCT01821391|natural daylight
1044541|NCT01821378|Schizophrenia
1044542|NCT01821378|Lurasidone
1044543|NCT01821378|Latuda
1044544|NCT01821365|COPD,PETCO2,PaCO2
1044545|NCT01821326|capsule endoscopy
1044546|NCT01821326|obscure gastrointestinal bleeding
1044547|NCT01821326|rebleeding
1044548|NCT01821326|risk factors
1044549|NCT01821313|Childhood obesity
1044550|NCT01821313|Inflammation
1044551|NCT01821313|Endothelial function
1044552|NCT01821313|Exercise
1044553|NCT01821300|Down syndrome
1044554|NCT01821300|Philadelphia
1044555|NCT01821300|The Children's Hospital of Philadelphia
1044556|NCT01821300|Body composition
1044557|NCT01821300|Obesity
1044558|NCT01821300|Cardiovascular
1044559|NCT01821222|Maternal health
1044560|NCT01821222|Neonatal health
1044561|NCT01821222|mHealth
1044562|NCT01821222|Mobile phones
1044563|NCT01821222|Access to health services
1044564|NCT01821222|Health behavior
1044565|NCT01821209|prostate cancer, robotic surgery, urethral sling,
1044566|NCT01821196|Tumor Markers, Biological
1044567|NCT01821196|PGP9.5 protein, human
1044568|NCT01821196|adenocarcinoma
1044569|NCT01821170|ADHD
1044570|NCT01821170|children
1044571|NCT01821170|cognitive remediation
1044572|NCT01821170|virtual reality
1044573|NCT01821157|crown lengthening
1044574|NCT01821157|gingivoplasty
1044575|NCT01821157|surgical procedures
1044576|NCT01821157|gingivectomy
1044577|NCT01821157|esthetic surgery
1044578|NCT01821144|dietary salt
1044579|NCT01821144|24 hour urinary sodium
1044580|NCT01821144|blood pressure
1044581|NCT01821131|flax
1044582|NCT01821131|muffin
1044583|NCT01821131|cholesterol
1044584|NCT01821131|lignan
1044585|NCT01821131|ALA
1044586|NCT01821118|Cerebral amyloid angiopathy (CAA)
1044587|NCT01821118|cerebrovascular reactivity
1044588|NCT01821118|functional MRI
1044589|NCT01821118|randomized
1044590|NCT01821118|double blind
1044591|NCT01821118|safety
1044592|NCT01821118|efficacy
1044593|NCT01821105|computed tomography
1044594|NCT01821105|CT scan
1044595|NCT01821105|positron emission tomography
1044596|NCT01821105|PET
1044597|NCT01821105|Metastatic Colorectal Cancer
1044598|NCT01821092|osseointegrated Implant, bone level
1044599|NCT01821079|Single dose
1044600|NCT01821079|Relative Bioavailability
1044601|NCT01821079|Food effect
1044602|NCT01821079|Healthy subjects
1044603|NCT01821079|Diabetes Mellitus Type 2
1044604|NCT01821066|PD-0332991
1044605|NCT01821066|palbociclib
1044606|NCT01821066|tamoxifen
1044607|NCT01821066|drug-drug interaction (DDI) study
1044608|NCT01821053|Preeclampsia
1044609|NCT01821053|Pregestational Type 1 diabetes
1044610|NCT01821053|diabetes mellitus
1044611|NCT01821053|proteinuria
1044612|NCT01821053|plasminogen
1044613|NCT01821053|plasmin
1044614|NCT01821053|renin
1044615|NCT01821053|aldosterone
1044616|NCT01821053|angiotensin
1044617|NCT01821053|epithelial sodium channel
1044618|NCT01821053|ENaC
1044619|NCT01821040|Polymyalgia rheumatica
1044620|NCT01821040|PMR
1044621|NCT01821040|Modified release prednisone
1044622|NCT01821027|Healthy
1044623|NCT01821027|Canagliflozin (JNJ-28431754)
1044624|NCT01821027|Pharmacokinetics
1044625|NCT01821027|Pharmacodynamics
1044626|NCT01821027|Simvastatin (ZOCOR)
1044627|NCT01821014|Diagnostic concordance
1044628|NCT01821014|Treatment concordance
1044629|NCT01821014|patient satisfaction
1044630|NCT01821014|physician satisfaction
1044631|NCT01821014|Medical Outreach Clinics
1044632|NCT01821014|Medical Brigades
1044633|NCT01821014|Medical Missions
1044634|NCT01821014|Telemedicine
1044635|NCT01821014|Videoconference
1044636|NCT01821014|diagnoses
1044637|NCT01821014|treatments
1044638|NCT01821014|Satellite Internet
1044639|NCT01821014|VSAT
1044640|NCT01821014|cross cultural telemedicine
1044641|NCT01821001|Adenomyosis
1044642|NCT01821001|Dysmenorrhea
1044643|NCT01821001|Abnormal Uterine bleeding
1044644|NCT01821001|Heavy Menstrual Bleeding
1044645|NCT01821001|Menorrhagia
1044646|NCT01820975|Muscle protein synthesis
1044647|NCT01820975|Dietary protein
1044648|NCT01820962|hematological patients
1044649|NCT01820962|central venous catheters
1044650|NCT01820962|catheter related thrombosis
1044651|NCT01820962|catheter related infections
1044652|NCT01820962|concentrated citrate
1044653|NCT01820949|patient blood management
1044654|NCT01820949|patients safety
1044655|NCT01820936|Healthy volunteers
1044656|NCT01820936|PCI-32765
1044657|NCT01820936|PCI-45227
1044658|NCT01820936|Pharmacokinetics
1044659|NCT01820871|T2DM
1044660|NCT01820871|smartphone application
1044661|NCT01820871|serum fasting glucose
1044662|NCT01820871|HbA1c
1044663|NCT01820845|Plethysmographic Variability Index
1044664|NCT01820845|Esophageal Doppler
1044665|NCT01820845|Scoliosis
1044666|NCT01820845|Children
1044667|NCT01820845|Age < 18 years
1044668|NCT01820845|Scheduled for Scoliosis Surgery
1044669|NCT01820832|mild proteinuria
1044670|NCT01820832|calcitriol
1044671|NCT01820832|renal function
1044672|NCT01820832|blood pressure
1044673|NCT01820819|Inpatient
1044674|NCT01820819|Liver cirrhosis
1044675|NCT01820819|Liver Cirrhosis, Alcoholic
1044676|NCT01820819|Physician's Practice Patterns
1044677|NCT01820819|Liver Transplantation
1044678|NCT01820819|Delivery of Health Care
1044679|NCT01820819|Resource Allocation
1044680|NCT01820793|antibiotic resistance
1044681|NCT01820793|E.coli
1044682|NCT01820793|cefoxitin
1044683|NCT01820793|pyelonephritis
1044684|NCT01820780|Heart failure
1044685|NCT01820780|Disease management program
1044686|NCT01820767|Chronic Kidney Disease
1044687|NCT01820767|Vd-stadium.
1044688|NCT01820767|Inflammatory patterns
1044689|NCT01820767|Paricalcitol
1044690|NCT01820767|Atorvastatin
1044691|NCT01820754|Non Small Cell Lung Cancer
1044692|NCT01820754|Lung Cancer
1044693|NCT01820754|Non Small Cell
1044694|NCT01820702|bone metabolism
1044695|NCT01820702|acid base balance
1044696|NCT01820702|bed rest
1044697|NCT01820663|stroke
1044698|NCT01820663|ketones
1044699|NCT01820663|ketogenic diet
1044700|NCT01820663|impairment
1044701|NCT01820663|disability
1044702|NCT01820650|osteoarthritis
1044703|NCT01820650|knee replacement
1044704|NCT01820650|patient-specific
1044705|NCT01820637|atherosclerosis
1044706|NCT01820637|SFA
1044707|NCT01820637|PPA
1044708|NCT01820637|lower extremities
1044709|NCT01820637|stenting
1044710|NCT01820637|paclitaxel
1044711|NCT01820585|fibromyalgia
1044712|NCT01820585|Eslicarbazepine acetate (BIA 2-093)
1044713|NCT01820585|ESL
1044714|NCT01820559|migraine; ESL; eslicarbazepine acetate
1044715|NCT01820533|Smoking
1044716|NCT01820533|Cellular phones
1044717|NCT01820533|Low income population
1044718|NCT01820507|Post-extubation respiratory failure
1044719|NCT01820507|Endotracheal intubation
1044720|NCT01820507|Mechanical ventilation
1044721|NCT01820494|growth
1044722|NCT01820494|infants
1044723|NCT01820481|Asthma
1044724|NCT01820481|Bronchial Diseases
1044725|NCT01820481|Respiratory Tract Diseases
1044726|NCT01820481|Lung Diseases, Obstructive
1044727|NCT01820481|Lung Diseases
1044728|NCT01820455|MRSA decolonization
1044729|NCT01820455|MRSA subtyping
1044730|NCT01820455|MRSA infection rates
1044731|NCT01820442|lofexidine
1044732|NCT01820442|buprenorphine
1044733|NCT01820442|interaction
1044734|NCT01820442|pharmacodynamic
1044735|NCT01820442|ECG
1044736|NCT01820442|QTc
1044737|NCT01820429|Platelet aggregation
1044738|NCT01820429|Aspirin
1044739|NCT01820416|Hearing Loss, Bilateral
1044740|NCT01820416|Hearing Loss, Sensorineural
1044741|NCT01820390|Deep Brain Stimulation (DBS)
1044742|NCT01820390|Parkinson's Disease
1044743|NCT01820390|Essential Tremor
1044744|NCT01820377|Peer-mentoring
1044745|NCT01820377|Obesity
1044746|NCT01820377|Type 2 Diabetes
1044747|NCT01820377|Physical Activity
1044748|NCT01820377|After-school program
1044749|NCT01820364|open-label study
1044750|NCT01820364|BRAF inhibitor
1044751|NCT01820364|LGX818
1044752|NCT01820364|MEK1620
1044753|NCT01820364|MAPK1/2 inhibitor
1044754|NCT01820364|Pi3K inhibitor
1044755|NCT01820364|FGFR
1044756|NCT01820364|c-Met
1044757|NCT01820364|CDK4/6
1044758|NCT01820364|metastatic melanoma
1044759|NCT01820364|BRAF
1044760|NCT01820364|V600
1044761|NCT01820338|Children, Obesity, Intervention
1044762|NCT01820325|Squamous non-small cell lung cancer
1044763|NCT01820325|NSCLC
1044764|NCT01820325|stage IV
1044765|NCT01820325|BKM120
1044766|NCT01820286|Bipolar disorder
1044767|NCT01820286|Depression
1044768|NCT01820286|Positive psychology
1044769|NCT01820273|Type 2 diabetes
1044770|NCT01820273|Bariatric surgery
1044771|NCT01820273|incretines
1044772|NCT01820273|GLP-1
1044773|NCT01820273|GIP
1044774|NCT01820273|gastric bypass
1044775|NCT01820273|foregut
1044776|NCT01820273|hindgut
1044777|NCT01820247|Crohn's Disease
1044778|NCT01820247|enteral nutrition
1044779|NCT01820247|Tripterygium Glycosides
1044780|NCT01820247|induction remission
1044781|NCT01820234|Skin cancer
1044782|NCT01820234|Teledermatology
1044783|NCT01820234|Screening
1044784|NCT01820234|Store-and-forward
1044785|NCT01820221|cesarean delivery
1044786|NCT01820221|wound complications
1044787|NCT01820221|skin closure methods
1044788|NCT01820195|Contrast Nephropathy
1044789|NCT01820195|N-Acetyl Cystein
1044790|NCT01820195|Prophylaxy
1044791|NCT01820117|long-term health outcomes
1044792|NCT01820078|Chronic
1044793|NCT01820078|Kidney
1044794|NCT01820078|Disease
1044795|NCT01820078|Proteinuria
1044796|NCT01820078|Albuminuria
1044797|NCT01820078|Paricalcitol
1044798|NCT01820052|Fibromyalgia
1044799|NCT01820039|e-health intervention
1044800|NCT01820039|infertility
1044801|NCT01820039|primary care
1044802|NCT01820039|referral rate
1044803|NCT01820026|healthcare infection cirrhosis antibiotic
1044804|NCT01820013|Pelvic Girdle pain
1044805|NCT01820013|Symphysis Pubis Dysfunction
1044806|NCT01820013|Sacroiliac Joint
1044807|NCT01820013|Sacroiliitis
1044808|NCT01820013|Physiotherapy
1044809|NCT01820013|Physical Therapy
1044810|NCT01820013|Orthotic Devices
1044811|NCT01819987|Overweight
1044812|NCT01819987|mother
1044813|NCT01819987|childhood obesity prevention
1044814|NCT01819987|Chinese American
1044815|NCT01819948|Breast cancer
1044816|NCT01819948|Stage 0-IIIA
1044817|NCT01819948|No evidence of disease
1044818|NCT01819935|MRSA. pneumonia
1044819|NCT01819935|outcomes
1044820|NCT01819922|Cardiopulmonary exercise testing
1044821|NCT01819922|metabolic parameters
1044822|NCT01819922|Diabetes Mellitus Type 2
1044823|NCT01819909|Rotator cuff repair
1044824|NCT01819909|Shoulder
1044825|NCT01819909|Surgery
1044826|NCT01819909|Rehabilitation
1044827|NCT01819909|Pulleys
1044828|NCT01819909|Jackins
1044829|NCT01819870|Carvedilol
1044830|NCT01819870|Dilatrend SR capsule
1044831|NCT01819870|Dilatrend Tablet
1044832|NCT01819870|Pharmacokinetics
1044833|NCT01819870|Healthy male subjects
1044834|NCT01819844|Closed-loop blood glucose control
1044835|NCT01819844|Continuous glucose monitoring
1044836|NCT01819844|Bionic pancreas
1044837|NCT01819844|Artificial pancreas
1044838|NCT01819831|extremity soft tissue sarcoma
1044839|NCT01819831|proton radiation
1044840|NCT01819831|preoperative radiation
1044841|NCT01819818|Schizophrenia
1044842|NCT01819818|Paliperidone palmitate
1044843|NCT01819818|Invega
1044844|NCT01819818|Sustenna
1044845|NCT01819818|Korea
1044846|NCT01819805|Chronic pain
1044847|NCT01819805|Chronic non-malignant pain
1044848|NCT01819805|Non-malignant
1044849|NCT01819805|Pain
1044850|NCT01819805|Extended release tablet
1044851|NCT01819805|Tramadol hydrochloride
1044852|NCT01819805|Tramadol HCl
1044853|NCT01819805|Acetaminophen
1044854|NCT01819805|Ultracet ER
1044855|NCT01819792|Acute Myeloid Leukemia
1044856|NCT01819766|Cancer
1044857|NCT01819766|Colorectal Cancer
1044858|NCT01819766|Neoplasm
1044859|NCT01819766|Colorectal Neoplasm
1044860|NCT01819766|Intestinal Neoplasms
1044861|NCT01819766|Gastrointestinal Neoplasms
1044862|NCT01819766|Digestive System Neoplasms
1044863|NCT01819766|Neoplasms by Site
1044864|NCT01819766|Neoplasms
1044865|NCT01819766|Digestive System Diseases
1044866|NCT01819766|Gastrointestinal Diseases
1044867|NCT01819766|Colonic Diseases
1044868|NCT01819766|Intestinal Diseases
1044869|NCT01819766|Inflammatory Bowel Disease
1044870|NCT01819766|Primary Sclerosing Cholangitis
1044871|NCT01819753|percutaneous nephrolithotomy
1044872|NCT01819753|urinary Stones
1044873|NCT01819753|99m-Technetium-Dimercaptosuccinic Acid
1044874|NCT01819727|PKU
1044875|NCT01819727|PEG-PAL
1044876|NCT01819727|BioMarin
1044877|NCT01819727|rAv-PAL PEG
1044878|NCT01819727|BMN 165
1044879|NCT01819727|open label
1044880|NCT01819727|Prism301
1044881|NCT01819727|Pegvaliase
1044882|NCT01819714|Snoezelen
1044883|NCT01819714|Multi-sensorial care session
1044884|NCT01819714|Alzheimer's-type neurodegenerative disease
1044885|NCT01819714|Dementia
1044886|NCT01819688|laparoscopic liver resection
1044887|NCT01819688|cytokine release
1044894|NCT01819662|Pacemaker, heart failure, hospitalisation
1044895|NCT01819649|selenium
1044896|NCT01819649|selenium supplementation
1044897|NCT01819649|randomised controlled trial
1044898|NCT01819649|prevention
1044899|NCT01819636|Blood triglyceride
1044900|NCT01819636|Bicarbonated mineral wate
1044901|NCT01819636|Post-prandial triglyceridemia
1044902|NCT01819636|lipid metabolism
1044903|NCT01819636|Cardiovascular risk
1044904|NCT01819623|Mild Cognitive Impairment
1044905|NCT01819623|Cognitive training
1044906|NCT01819610|Postoperative pain management
1044907|NCT01819597|Intracranial Arterial Stenosis
1044908|NCT01819597|Atherosclerosis
1044909|NCT01819597|Stroke
1044910|NCT01819597|EDAS
1044911|NCT01819597|Angiogenesis
1044912|NCT01819571|pulse pressure variation
1044913|NCT01819571|fluid responsiveness
1044914|NCT01819571|diastolic dysfunction
1044915|NCT01819558|acute myeloid leukemia
1044916|NCT01819558|chronic myeloid leukemia
1044917|NCT01819558|myelodysplastic syndrome
1044918|NCT01819558|allograft
1044919|NCT01819558|WT1 expression
1044920|NCT01819545|Alzheimer's disease
1044921|NCT01819545|diagnosis
1044922|NCT01819545|MicRNA
1044923|NCT01819545|mRNA
1044924|NCT01819532|neonate
1044925|NCT01819532|umbilical cord
1044926|NCT01819532|cord milking
1044927|NCT01819532|prematurity
1044928|NCT01819519|Intervention studies
1044929|NCT01819519|Pregnancy
1044930|NCT01819519|Cytomegalovirus Infections
1044931|NCT01819506|rehabilitation
1044932|NCT01819506|occupational therapy
1044933|NCT01819506|upper extremity
1044934|NCT01819493|Diabetes Prevention
1044935|NCT01819493|Lifestyle Intervention
1044936|NCT01819493|African American Families
1044937|NCT01819480|Surgery
1044938|NCT01819480|Robotic
1044939|NCT01819480|Carcinoma
1044940|NCT01819480|squamous cell of head and neck
1044941|NCT01819454|chronic rhinosinusitis
1044942|NCT01819454|extraesophageal reflux
1044943|NCT01819454|Restech system
1044944|NCT01819454|antireflux therapy
1044945|NCT01819441|cerebral small Vessel diseases, blood pressure,CCB, ACEI
1044946|NCT01819428|EGFR mutation
1044947|NCT01819428|Lung Adenocarcinoma
1044948|NCT01819428|Firstline therapy
1044949|NCT01819428|Second generation of tyrosine kinase
1044950|NCT01819415|wet AMD
1044951|NCT01819415|Omega-3
1044952|NCT01819415|VEGF
1044953|NCT01819415|Lipidomics
1044954|NCT01819415|DHA
1044955|NCT01819415|EPA
1045080|NCT01818869|pharmacokinetic,
1044956|NCT01819402|visceral fat metabolism; FDG-PET/CT; pioglitazone; glimepiride; adiponectin
1044957|NCT01819389|Chronic myeloid leukemia
1044958|NCT01819389|suboptimal response
1044959|NCT01819389|imatinib
1044960|NCT01819389|nilotinib
1044961|NCT01819376|Obesity
1044962|NCT01819376|Overweight
1044963|NCT01819376|Adolescents
1044964|NCT01819376|Teenagers
1044965|NCT01819376|Facebook
1044966|NCT01819376|Social Networks
1044967|NCT01819363|Pleural effusion
1044968|NCT01819363|Pleural elastance
1044969|NCT01819363|Pleurodesis
1044970|NCT01819363|Quality of life
1044971|NCT01819363|Computed Tomography
1044972|NCT01819350|Dental caries
1044973|NCT01819350|Sucrose
1044974|NCT01819350|Oral administration
1044975|NCT01819350|Ion Concentration of Hydrogen
1044976|NCT01819350|Pediatric medicines
1044977|NCT01819324|breast cancer survivors
1044978|NCT01819324|lifestyle intervention
1044979|NCT01819324|health behaviors
1044980|NCT01819285|Malignant Neoplasm of Prostate
1044981|NCT01819285|Tumor-node-metastasis (TNM) Staging Regional Lymph Nodes (N0-2)
1044982|NCT01819285|Not suitable for local treatment with curative intent
1044983|NCT01819259|Nonsmoker
1044984|NCT01819259|ADHD
1044985|NCT01819259|Nicotine
1044986|NCT01819259|Nicotine Nasal Spray
1044987|NCT01819259|Nicotine Reinforcement
1044988|NCT01818219|Electrical activity of the diaphragm
1044989|NCT01818219|Neuro regulation of breathing
1044990|NCT01818219|Abnormal respiratory mechanics
1044991|NCT01818219|Assisted mechanical ventilation
1044992|NCT01818219|Pressure support
1044993|NCT01818219|Neurally adjusted ventilatory assist
1044994|NCT01818206|Cystic Fibrosis
1044995|NCT01818206|Bacteriophages
1044996|NCT01818206|Pseudomonas aeruginosa
1044997|NCT01818206|Sputum
1044998|NCT01818193|Pulmonary transplant
1044999|NCT01818167|Hidradenitis Suppurativa
1045000|NCT01818167|HS
1045001|NCT01818167|Acne Inversa
1045002|NCT01818167|Velpeau's disease
1045003|NCT01818167|Verneuil's disease
1045004|NCT01818154|phototherapy
1045005|NCT01818154|light emitting diode
1045006|NCT01818154|minimal erythema dose
1045007|NCT01818154|narrowband UVB
1045008|NCT01819181|TAVI
1045009|NCT01819181|women
1045010|NCT01819181|aortic stenosis
1045011|NCT01819181|VARC2
1045012|NCT01819155|influenza
1045013|NCT01819155|influenza vaccine
1045014|NCT01819155|immunogenicity
1045015|NCT01819155|Africa
1045016|NCT01819155|Senegal
1045017|NCT01819142|non healing wound
1045018|NCT01819142|pressure ulcer
1045019|NCT01819116|Tissue Oxygen Saturation
1045020|NCT01819116|Management of the DNC Organ Donor
1045021|NCT01819103|Mortality
1045022|NCT01819103|Acute Myocardial Infarction
1045023|NCT01819103|Drug Adherence
1045024|NCT01819103|Drug Compliance
1045025|NCT01819103|Health-related quality of life
1045026|NCT01819090|Neuromuscular disorder
1045027|NCT01819090|Mechanical ventilation
1045028|NCT01819090|Speech
1045029|NCT01819090|Respiratory failure
1045030|NCT01819077|Cervical cancer
1045031|NCT01819077|TMMR
1045032|NCT01819077|therapeutic lymphadenectomy
1045033|NCT01819077|register study
1045034|NCT01819064|Atropine
1045035|NCT01819064|bradycardia
1045036|NCT01819064|tachycardia
1045037|NCT01819025|Depression
1045038|NCT01819025|Behavioral activation
1045039|NCT01819025|Smartphone application
1045040|NCT01819025|Face-to-face
1045041|NCT01819025|Blended therapy
1045042|NCT01819012|Isoflurane
1045043|NCT01819012|mitral valve annular velocity
1045044|NCT01819012|tissue Doppler imaging
1045045|NCT01819012|Monitoring
1045046|NCT01819012|echocardiography
1045047|NCT01818999|METASTATIC BREAST CANCER
1045048|NCT01818973|Rectal Cancer
1045049|NCT01818973|Bevacizumab
1045050|NCT01818973|capecitabine
1045051|NCT01818973|oxaliplatin
1045052|NCT01818973|preoporative IMRT
1045053|NCT01818960|Stent, Myocardial Infarction, Coronary Intervention
1045054|NCT01818947|Lung cancer
1045055|NCT01818947|epidermal growth factor receptor mutation
1045056|NCT01818947|gefitinib
1045057|NCT01818947|Iressa
1045058|NCT01818934|hip dysplasia
1045059|NCT01818934|screening
1045060|NCT01818921|Beloranib
1045061|NCT01818921|ZGN-440
1045062|NCT01818921|ZGN-440 for injectable suspension
1045063|NCT01818921|ZGN-433
1045064|NCT01818908|non-Hodgkin's lymphoma
1045065|NCT01818908|hemophagocytic lymphohistiocytosis
1045066|NCT01818908|DA-EPOCH
1045067|NCT01818908|rituximab
1045068|NCT01818895|Mechanical ventilation
1045069|NCT01818895|End of life
1045070|NCT01818895|Extubation
1045071|NCT01818895|Terminal weaning
1045072|NCT01818895|Complicated grief
1045073|NCT01818882|Vscan
1045074|NCT01818882|portable ultrasound
1045075|NCT01818882|emergency care
1045076|NCT01818882|emergency room
1045077|NCT01818869|Safety,
1045078|NCT01818869|tolerability,
1045079|NCT01818869|Phase I,
1045081|NCT01818869|pharmacodynamic,
1045082|NCT01818869|inhaled
1045083|NCT01818856|Chronic hepatitis C
1045084|NCT01818856|HIV-infection
1045085|NCT01818856|Drug interaction
1045086|NCT01818843|Carbon monoxide
1045087|NCT01818843|safety
1045088|NCT01818843|Adverse Reaction
1045089|NCT01818843|newborn
1045090|NCT01818817|Ultrasound-guided paravertebral block
1045091|NCT01818817|regional anesthesia
1045092|NCT01818817|breast surgery
1045093|NCT01818765|Cardiac resynchronisation therapy
1045094|NCT01818765|Endocardial
1045095|NCT01818765|Pacing
1045096|NCT01818739|Endometrial Cancer
1045097|NCT01818739|Robotic-Assisted Staging
1045098|NCT01818726|Aplastic anemia, deferasirox, renal function
1045099|NCT01818713|2B3-101, liposomal doxorubicin, leptomeningeal metastases
1045100|NCT01818661|apraxia of speech
1045101|NCT01818661|non-fluent aphasia
1045102|NCT01818661|aphasia
1045103|NCT01818622|Bipolar disorder
1045104|NCT01818622|Mania
1045105|NCT01818622|Blue-blockers
1045106|NCT01818622|Virtual darkness therapy
1045107|NCT01818622|Actigraphy
1045108|NCT01818622|Randomized controlled trial
1045109|NCT01818609|sarcopenia
1045110|NCT01818609|muscle
1045111|NCT01818609|reduced activity
1045112|NCT01818609|insulin sensitivity
1045113|NCT01818609|protein
1045114|NCT01818609|step reduction
1045115|NCT01818609|muscle protein synthesis
1045116|NCT01818609|whey protein
1045117|NCT01818609|leg strength
1045118|NCT01818609|whole body protein
1045119|NCT01818596|HIV
1045120|NCT01818596|HIV-1 Infected
1045121|NCT01818596|Treatment Experienced
1045122|NCT01818596|Treatment Naive
1045123|NCT01818583|Atrial fibrillation
1045124|NCT01818583|Atrial flutter
1045125|NCT01818583|Potassium
1045126|NCT01818583|Cardioversion
1045127|NCT01818570|Gastroesophageal Reflux
1045128|NCT01818557|glucose monitoring
1045129|NCT01818557|gestational diabetes
1045130|NCT01818544|Elastase Inhibition
1045131|NCT01818531|Partial knee replacement
1045132|NCT01818518|Preterm delivery
1045133|NCT01818518|Premature delivery
1045134|NCT01818518|Premature birth
1045135|NCT01818505|antiphospholipid syndrome
1045136|NCT01818505|gouty arthritis
1045137|NCT01818505|Hyperuricemia
1045138|NCT01818505|metabolic syndrome
1045139|NCT01818505|osteoarthritis
1045140|NCT01818505|cardiovascular co-morbidities
1045141|NCT01818453|Mood Disorders
1045142|NCT01818453|Depression
1045143|NCT01818453|Genetics
1045144|NCT01818453|Treatment response
1045145|NCT01818453|Treatment study
1045146|NCT01818440|Surgical Navigation
1045147|NCT01818440|Liver
1045148|NCT01818440|Cancer
1045149|NCT01818440|Image-guided Therapy
1045150|NCT01818427|hemmorhagic shock, plasma, air medical transport, randomized, multicenter
1045151|NCT01818414|Misoprostol administration & dosage
1045152|NCT01818414|Abortion techniques
1045153|NCT01818414|Abortion Induced methods
1045154|NCT01818414|Dilatation and Curettage
1045155|NCT01818401|Ancillary tailored
1045156|NCT01818401|medico-economic study,
1045157|NCT01818401|total knee replacement
1045158|NCT01818401|primary or secondary osteoarthritis
1045159|NCT01818362|Influenza
1045160|NCT01818362|T cells
1045161|NCT01818349|stroke
1045162|NCT01818349|exercise
1045163|NCT01818349|muscle strength
1045164|NCT01818349|gait
1045165|NCT01818349|rehabilitation
1045166|NCT01818336|penicillin allergy
1045167|NCT01818323|Chimeric antigen receptor
1045168|NCT01818323|Immunotherapy
1045169|NCT01818323|Head and Neck Cancer
1045170|NCT01818323|Phase I trial
1045171|NCT01818323|Maximum tolerated dose
1045172|NCT01818310|ischemia
1045173|NCT01818310|diabetes mellitus
1045174|NCT01818310|bone marrow aspirate concentrate (BMAC)
1045175|NCT01818284|Blood And Marrow Transplantation
1045176|NCT01818284|Normal allogeneic donors
1045177|NCT01818284|Stem cell mobilization
1045178|NCT01818284|peripheral blood progenitor cells
1045179|NCT01818284|PBPC
1045180|NCT01818284|Allogeneic hematopoietic stem cell transplantation
1045181|NCT01818284|HSCT
1045182|NCT01818284|Donating blood stem cells
1045183|NCT01818284|C-CSF
1045184|NCT01818284|Neupogen
1045185|NCT01818284|Filgrastim
1045186|NCT01818284|Plerixafor
1045187|NCT01818284|Mobozil
1045188|NCT01818284|Apheresis
1045189|NCT01818271|community-stroke-rehabilitation,
1045190|NCT01818271|group-exercise,
1045191|NCT01818271|balance-mobility-exercise,
1045192|NCT01818271|instrumented treadmill
1045193|NCT01818258|HIV
1045194|NCT01818258|Children
1045195|NCT01818258|HAART
1045196|NCT01818258|Malnourished
1045197|NCT01818115|POAG
1045198|NCT01818115|PXG
1045199|NCT01818115|IOL Surgery
1045200|NCT01818115|CE Surgery
1045201|NCT01818024|healthy volunteer
1045202|NCT01818024|TNFR1
1045203|NCT01818024|domain antibody
1045204|NCT01818024|Lung injury
1045205|NCT01818011|Japanese, GSK1322322, pharmacokinetics, relative bioavailability, single dose, repeat dose, healthy subjects, dose-escalation, antimicrobial, over granulation,
1045206|NCT01817985|Hepatitis C (HCV) Infection
1045207|NCT01817985|Moderate Hepatic Impairment
1045208|NCT01817985|Severe Hepatic Impairment
1045209|NCT01817972|Crohn's Disease
1045210|NCT01817972|Crohn's colitis
1045211|NCT01817972|Crohn's ileocolitis
1045212|NCT01817959|Pancreatic islet transplantation
1045213|NCT01817959|Diabetes Mellitus Type 1
1045214|NCT01817959|Islet transplantation graft survival & function
1045215|NCT01817946|Congenital Myopathy
1045216|NCT01817946|Centronuclear Myopathy
1045217|NCT01817946|Myotubular Myopathy
1045218|NCT01817946|Myotubularin
1045219|NCT01817946|MTM1 Gene
1045220|NCT01817946|Genetic testing
1045221|NCT01817946|Sequencing
1045222|NCT01817946|Deletion/Duplication Mutation
1045223|NCT01817946|CGH array
1045224|NCT01817907|Apnea- Hypopnea index
1045225|NCT01817907|Arousal Threshold
1045226|NCT01817894|Unwanted facial hair growth
1045227|NCT01817868|Hemophilia
1045228|NCT01817868|Turkey
1045229|NCT01817868|Observational
1045230|NCT01817868|Adult
1045231|NCT01817855|Phase 1,
1045232|NCT01817855|Safety,
1045233|NCT01817855|Tolerability,
1045234|NCT01817855|Healthy,
1045235|NCT01817855|COPD patients
1045236|NCT01817842|mHealth
1045237|NCT01817842|EMA
1045238|NCT01817842|Ecological Momentary Assessment
1045239|NCT01817842|Personal Informatics
1045240|NCT01817842|Tobacco Quitline
1045241|NCT01817803|Heart failure
1045242|NCT01817803|diuretics
1045243|NCT01817803|kidney
1045244|NCT01817803|glomerular filtration rate
1045245|NCT01817777|Socioeconomic category
1045246|NCT01817777|Medication compliance
1045247|NCT01817777|Metformin
1045248|NCT01817777|small pack
1045249|NCT01817764|umeclidinium bromide (UMEC)
1045250|NCT01817764|vilanterol (VI)
1045251|NCT01817764|salmeterol (SAL)
1045252|NCT01817764|fluticasone propionate (FP)
1045253|NCT01817764|Novel Dry Powder Inhaler (NDPI)
1045254|NCT01817764|Chronic obstructive pulmonary disease
1045255|NCT01817764|GW642444
1045256|NCT01817764|GSK573719
1045257|NCT01817764|lung function
1045258|NCT01817751|central nervous system
1045259|NCT01817751|Brain and Nervous System
1045260|NCT01817738|Metastatic
1045261|NCT01817738|Castrate-refractory
1045262|NCT01817725|Therapeutic vaccine
1045263|NCT01817725|HBsAg clearance
1045264|NCT01817725|Immune clearance
1045265|NCT01817725|HBsAg clearance induced by vaccination
1045266|NCT01817725|s seroconversion in carriers after vaccination
1045267|NCT01817712|Posttraumatic neuroses
1045268|NCT01817712|posttraumatic stress disorder
1045269|NCT01817712|PTSD
1045270|NCT01817712|Supported employment
1045271|NCT01817712|IPS
1045272|NCT01817712|CWT
1045273|NCT01817712|TWP
1045274|NCT01817712|Individual placement and support
1045275|NCT01817712|Compensated work therapy
1045276|NCT01817712|Transitional work program
1045277|NCT01817699|Cholecalciferol
1045278|NCT01817699|Methoxy polyethylene glycol-epoetin beta
1045279|NCT01817699|Hematinics
1045280|NCT01817699|Bone Diseases, Metabolic
1045281|NCT01817699|Neoplasms
1045282|NCT01817699|Cardiovascular Diseases
1045283|NCT01817699|Graft Rejection
1045284|NCT01817660|popliteal artery aneurysm
1045285|NCT01817660|endovascular repair
1045286|NCT01817660|open surgical repair
1045287|NCT01817660|comparative study
1045288|NCT01817647|AL
1045289|NCT01817647|Enhanced recovery after surgery (ERAS)
1045290|NCT01817647|reduce postoperative complications
1045291|NCT01817647|increased risk of delayed diagnosis and treatment of AL
1045292|NCT01817647|diagnose anastomotic leak
1045293|NCT01817634|Malnutrition.
1045294|NCT01817621|Body Image Disturbance
1045295|NCT01817621|Medication Adherence
1045296|NCT01817621|Sexual Risk Behavior
1045297|NCT01817621|HIV
1045298|NCT01817621|MSM
1045299|NCT01817608|sf-36
1045300|NCT01817608|Katz
1045301|NCT01817595|Type 2 Diabetes
1045302|NCT01817595|Internet Blood Glucose Monitoring
1045303|NCT01817595|iphone
1045304|NCT01817595|meter
1045305|NCT01817582|Dry Eye Disease
1045306|NCT01817569|Diabetes Mellitus (DM)
1045307|NCT01817569|Byetta
1045308|NCT01817569|Exenatide
1045309|NCT01817543|venous leg ulcers
1045310|NCT01817543|non healing wounds
1045311|NCT01817530|Uterine Fibroids
1045312|NCT01817530|Leiomyomata
1045313|NCT01817530|Elagolix
1045314|NCT01817530|Menorrhagia
1045315|NCT01817530|Elagolix sodium
1045316|NCT01817530|Heavy Uterine Bleeding
1045317|NCT01817530|ABT-620
1045318|NCT01817504|Renal failure,
1045319|NCT01817504|Transplantectomy
1045320|NCT01817504|Immunosuppression
1045321|NCT01817504|Sensitization
1045322|NCT01817491|Vegan Diet
1045323|NCT01817491|Hypercholesterolemia
1045324|NCT01817491|American Heart Association Diet
1045325|NCT01817491|Cardiovascular Risk
1045326|NCT01817491|Obesity
1045327|NCT01817478|conjunctival flora
1045328|NCT01817439|oral Amiodarone
1045329|NCT01817439|IV Amiodarone
1045330|NCT01817439|phlebitis
1045331|NCT01817439|thrombophlebitis
1045332|NCT01817439|adverse events
1045333|NCT01817413|Calcium hydroxide
1045334|NCT01817413|Pulp regeneration
1045335|NCT01817413|Regenerative endodontics
1045336|NCT01817413|Pulp revitalisation
1045337|NCT01817413|Triple antibiotic paste
1045338|NCT01817413|Root canal therapy
1045339|NCT01817413|Root end closure
1045340|NCT01817413|Tooth root
1045341|NCT01817413|Tooth apex
1045342|NCT01817413|Dental trauma
1045343|NCT01817413|Non-vital
1045344|NCT01817413|Immature
1045345|NCT01817413|Incisor
1045346|NCT01817413|Periapical periodontitis
1045347|NCT01817413|Dental pulp
1045348|NCT01817374|Breast Cancer
1045349|NCT01817374|Definity
1045350|NCT01817374|Ultrasound
1045351|NCT01817361|oral health
1045352|NCT01817348|Adhesive capsulitis
1045353|NCT01817348|Frozen shoulder
1045354|NCT01817348|Shoulder pain
1045355|NCT01817348|Intra-articular injection
1045356|NCT01817348|Lidocaine injection
1045357|NCT01817348|Physiotherapy
1045358|NCT01817348|Manipulation
1045359|NCT01817348|Stretch exercise
1045360|NCT01817322|kidney transplantation
1045361|NCT01817309|renal failure
1045362|NCT01817309|survival
1045363|NCT01817309|peritoneal failure
1045364|NCT01817296|Klinefelter
1045365|NCT01817296|Fertility
1045366|NCT01817283|HIV-infected immunological non-responders
1045367|NCT01817283|Triptolide
1045368|NCT01817283|immune activation
1045369|NCT01817283|inflammation
1045370|NCT01817283|CD4 T cell
1045371|NCT01817257|Cancer
1045372|NCT01817257|Thrombosis
1045373|NCT01817257|Venous thromboembolism
1045374|NCT01817257|Deep vein thrombosis
1045375|NCT01817257|Pulmonary embolus
1045376|NCT01817244|care management
1045377|NCT01817244|depression
1045378|NCT01817244|elderly
1045379|NCT01817244|Korea
1045380|NCT01817231|breast cancer
1045381|NCT01817231|vitamin D
1045382|NCT01817231|25 OH vitamin D
1045383|NCT01817218|PRP
1045384|NCT01817218|chronic vascular ulcer
1045385|NCT01817218|primary care
1045386|NCT01817192|Non-Squamous
1045387|NCT01817192|Adjuvant Chemotherapy
1045388|NCT01817179|hemiplegia, cerebral palsy, neuroprosthesis, children
1045393|NCT01817140|oral cancer
1045394|NCT01817140|mandibular invasion
1045395|NCT01817140|SWIFT MRI
1045396|NCT01817114|Remote Ischemic Conditioning
1045397|NCT01817114|PCI
1045398|NCT01817114|STEMI
1045399|NCT01817114|LAD
1045400|NCT01817088|Deep Brain Stimulation (DBS)
1045401|NCT01817088|Parkinson disease
1045402|NCT01817088|Stereotaxis Technique
1045403|NCT01817088|Subthalamic nucleus
1045404|NCT01817062|Capillary leakage
1045405|NCT01817062|Acute Abdomen
1045406|NCT01817062|Low birth weight
1045407|NCT01817049|prevention
1045408|NCT01817049|sport injury
1045409|NCT01817049|soccer
1045410|NCT01817049|youth
1045411|NCT01817049|neuromuscular training
1045412|NCT01817049|intervention
1045413|NCT01817049|behaviour
1045414|NCT01817036|vitamin D
1045415|NCT01817036|deficiency
1045416|NCT01817036|dose response
1045417|NCT01817023|Nasopharyngeal carcinoma
1045418|NCT01817023|current chemotherapy
1045419|NCT01817023|intensity-modulated radiotherapy
1045420|NCT01817023|low-risk
1045421|NCT01817010|Total Hip Arthroplasty
1045422|NCT01817010|Muscle Strength
1045423|NCT01817010|Hip Osteoarthritis
1045424|NCT01816997|Statins
1045425|NCT01816997|Glucose homeostasis
1045426|NCT01816997|Diabetes
1045427|NCT01816997|Impaired fasting glucose
1045428|NCT01816958|thalamocortical dysrhythmia
1045429|NCT01816958|transcranial magnetic stimulation (TMS)
1045430|NCT01816958|transcranial Electrical Stimulation (tES)
1045431|NCT01816958|(N-methyl-D-aspartate) NMDA-R antagonist
1045432|NCT01816958|ketamine infusion
1045433|NCT01816958|neuromodulation
1045434|NCT01816958|synergistic effect
1045435|NCT01816958|remission
1045436|NCT01816945|Depression
1045437|NCT01816945|Stress
1045438|NCT01816945|Social support
1045439|NCT01816945|Social capital
1045440|NCT01816945|Maternal
1045441|NCT01816893|Hypoglycemia
1045442|NCT01816893|Autonomic Nervous System
1045443|NCT01816867|hernia
1045444|NCT01816867|Treatment
1045445|NCT01816867|laparoscopic
1045446|NCT01816867|open technique
1045447|NCT01816854|SFA,
1045448|NCT01816854|stent,
1045449|NCT01816854|endovascular
1045450|NCT01816854|Patient outcome
1045451|NCT01816841|Direct Visual Fluorescense
1045452|NCT01816841|Oral Examination
1045453|NCT01816841|oral cancer
1045454|NCT01816828|HIV, MSM, unprotected anal intercourse, sexual health
1045455|NCT01816815|PK/PD
1045456|NCT01816815|BAY1002670
1045457|NCT01816802|In vitro fertilization
1045458|NCT01816802|Assisted reproductive therapy
1045459|NCT01816802|Time-lapse image recording
1045460|NCT01816802|Image analysis software
1045461|NCT01816789|Starting dose
1045462|NCT01816789|rFSH
1045463|NCT01816789|controlled
1045464|NCT01816789|ovarian
1045465|NCT01816789|stimulation
1045466|NCT01816789|IVF/ICSI
1045467|NCT01816789|cycles
1046090|NCT01814215|Intervention Studies
1045468|NCT01816763|Health Care Quality, Access, and Evaluation
1045469|NCT01816763|Primary Health Care
1045470|NCT01816763|Medical Informatics
1045471|NCT01816750|CT coronary angiography
1045472|NCT01816750|Coronary disease
1045473|NCT01816750|Gemstone Spectral Imaging
1045474|NCT01816750|Diagnostic value
1045475|NCT01816750|Adaptive statistical iterative reconstruction
1045476|NCT01816750|iterative reconstruction
1045477|NCT01816750|Feasibility of coronary and myocardial assessment
1045478|NCT01816750|novel Cardiac CT GSI protocol
1045479|NCT01816724|NOCTURIA
1045480|NCT01816724|SYMPTOMATIC QUESTIONNAIRE
1045481|NCT01816724|N-QOL
1045482|NCT01816711|Frail elderly
1045483|NCT01816711|Hip fracture
1045484|NCT01816711|Vitamin D
1045485|NCT01816711|Geriatrics
1045486|NCT01816698|Hypertension
1045487|NCT01816698|Taurine
1045488|NCT01816698|Metabolism
1045489|NCT01816672|Wagner 1
1045490|NCT01816672|Wagner 2
1045491|NCT01816672|Non healing diabetic foot wound
1045492|NCT01816659|Colorectal Carcinoma
1045493|NCT01816659|Endoscopically Non- Resectable Adenomas
1045494|NCT01816659|Colonic lesion
1045495|NCT01816659|Biomarker
1045496|NCT01816659|Metformin-ER
1045497|NCT01816659|Metformin
1045498|NCT01816659|Extended release
1045499|NCT01816659|Colonoscopy
1045500|NCT01816659|Colon cancer surgery
1045501|NCT01816646|Blood And Marrow Transplantation
1045502|NCT01816646|Hemorrhagic Cystitis
1045503|NCT01816646|Bleeding from bladder
1045504|NCT01816646|Foley catheter
1045505|NCT01816646|Probenecid
1045506|NCT01816646|Cidofovir
1045507|NCT01816646|Vistide
1045508|NCT01816633|non healing wound
1045509|NCT01816620|POEMS Syndrome
1045510|NCT01816620|lenalidomide
1045511|NCT01816620|newly diagnosed
1045512|NCT01816620|plasma cell disorder
1045513|NCT01816620|Dexamethasone
1045514|NCT01816607|Magnetic Resonance Imaging
1045515|NCT01816607|Magnetic Resonance Imaging, Functional
1045516|NCT01816594|HER2, breast cancer, neoadjuvant, PI3K inhibitor, first line chemotherapy, trastuzumab, GBG, SOLTI, BIG
1045517|NCT01816568|appendicitis, laparoscopy, single incision
1045518|NCT01816542|patch-testing
1045519|NCT01816542|personal-care
1045520|NCT01816542|cosmetic
1045521|NCT01816542|dermatitis
1045522|NCT01816542|allergy
1045523|NCT01816542|sensitive skin
1045524|NCT01816516|childhood obesity
1045525|NCT01816516|low-income
1045526|NCT01816516|maternal responsiveness
1045527|NCT01816516|infant feeding
1045528|NCT01816516|infant feeding practices
1045529|NCT01816516|infant feeding style
1045530|NCT01816516|primary prevention
1045531|NCT01816503|Pain
1045532|NCT01816503|Cancer pain
1045533|NCT01816503|Fentanyl
1045534|NCT01816503|Fentanyl matrix
1045535|NCT01816503|Opioid analgesic
1045536|NCT01816464|Influenza
1045537|NCT01816464|Vaccination
1045538|NCT01816451|aerobic capacity
1045539|NCT01816451|cardiorespiratory training
1045540|NCT01816451|blood lactate concentration
1045541|NCT01816451|heart rate
1045542|NCT01816438|abnormal histological colorectal lesions
1045543|NCT01816425|Dental Prosthesis
1045544|NCT01816425|Dental Prosthesis Design
1045545|NCT01816412|Arms
1045546|NCT01816412|Experimental
1045547|NCT01816412|Drug Coated Angioplasty Balloon
1045548|NCT01816412|Active Comparator
1045549|NCT01816412|Standard angioplasty balloon
1045550|NCT01816386|acupuncture
1045551|NCT01816386|anaesthetic recovery
1045552|NCT01816386|perioperative care
1045553|NCT01816386|Age 18+
1045554|NCT01816386|ASA-score ≤ 2
1045555|NCT01816386|Surgery: Uterus
1045556|NCT01816386|Surgery: Adnex
1045557|NCT01816386|Surgery: Ovaries
1045558|NCT01816373|Chest wall; Chest, funnel; pectus excavatum; congenital abnormality
1045559|NCT01816360|Womens health
1045560|NCT01816360|Menopause
1045561|NCT01816360|Complementary therapies
1045562|NCT01816360|Aromatherapy
1045563|NCT01816360|Essential oils
1045564|NCT01816360|Yogatherapy
1045565|NCT01816360|Psychoneuroendocrineimmunology
1045566|NCT01816334|sciatica
1045567|NCT01816334|Anti-Inflammatory Agents, Non-Steroidal
1045568|NCT01816334|Glucocorticoids
1045569|NCT01816308|AF
1045570|NCT01816308|MCI
1045571|NCT01816282|TKR
1045572|NCT01816282|Blood loss
1045573|NCT01816282|Fibrin Sealant
1045574|NCT01816269|Helicobacter pylori
1045575|NCT01816269|Dental scaling
1045576|NCT01816269|Eradication
1045577|NCT01816269|Reinfection
1045578|NCT01816269|Helicobacter status
1045579|NCT01816243|Chronic Pain
1045580|NCT01816243|Chronic Non-Malignant Pain
1045581|NCT01816243|TTS-fentanyl
1045582|NCT01816243|Durogesic
1045583|NCT01816217|Difficult intubation
1045584|NCT01816217|Complications
1045585|NCT01816217|Intensive care units
1045586|NCT01816217|Videolaryngoscope
1045587|NCT01816217|Laryngoscopy
1045588|NCT01816204|anxiety treatment
1045589|NCT01816204|anxiety online treatment
1045590|NCT01816204|anxiety electronic treatment
1045591|NCT01816204|anxiety therapist assisted
1045592|NCT01816178|Autism spectrum Disorders
1045593|NCT01816178|Voice Output Communication
1045594|NCT01816165|diabetes
1045595|NCT01816165|insulin
1045596|NCT01816165|blood vessel
1045597|NCT01816165|type 1
1045598|NCT01816152|light treatment
1045599|NCT01816152|circadian rhythms
1045600|NCT01816152|sleep
1045601|NCT01816152|agitation
1045602|NCT01816152|depression
1045603|NCT01816139|vaginal dryness
1045604|NCT01816139|vaginal atrophy
1045605|NCT01816139|estrogen
1045606|NCT01816113|PvDBP
1045607|NCT01816113|Malaria
1045608|NCT01816113|Plasmodium vivax
1045609|NCT01816100|multiple sclerosis
1045610|NCT01816100|exercise
1045611|NCT01816100|MEG
1045612|NCT01816100|DTI
1045613|NCT01816100|Brain changes
1045614|NCT01816074|Mothers
1045615|NCT01816074|ADHD
1045616|NCT01816074|Treatment
1045617|NCT01816074|Child
1045618|NCT01816061|Veterans Health
1045619|NCT01816061|Social Adjustment
1045620|NCT01816061|Traumatic Brain Injury (TBI)
1045621|NCT01816061|Post-Traumatic Stress Disorder (PTSD)
1045622|NCT01816061|Independent Living
1045623|NCT01816061|Goals
1045624|NCT01816061|Education
1045625|NCT01816048|prostate, prostate cancer
1045626|NCT01816022|CMPN
1045627|NCT01816022|Fracture
1045628|NCT01816022|Osteoporosis
1045629|NCT01816022|Biochemical Bone Markers
1045630|NCT01816009|infection
1045631|NCT01816009|antibiotic
1045632|NCT01816009|prosthesis
1045633|NCT01815996|Pregnancy
1045634|NCT01815996|pulmonary embolism
1045635|NCT01815996|myocardial infarction
1045636|NCT01815996|autoimmune disease
1045637|NCT01815996|healthy controls
1045638|NCT01815983|Laryngoscopy
1045639|NCT01815983|Tracheal Intubation
1045640|NCT01815983|Video Laryngoscopy
1045641|NCT01815970|dyspnea
1045642|NCT01815970|exercise
1045643|NCT01815970|neuromechanical uncoupling
1045644|NCT01815970|COPD
1045645|NCT01815970|pulmonary rehabilitation
1045646|NCT01815957|coronary microcirculation
1045647|NCT01815957|coronary artery disease
1045648|NCT01815957|myocardial disease
1045649|NCT01815957|ischemia
1045650|NCT01815944|onset time
1045651|NCT01815944|ultrasound-guided supraclavicular block
1045652|NCT01815944|ropivacaine
1045653|NCT01815944|normal saline
1045654|NCT01815944|dextrose 5%
1045655|NCT01814943|Uncomplicated peptic ulcer
1045656|NCT01814943|Acid-suppressing drugs
1045657|NCT01814943|Epidemiology
1045658|NCT01815918|Orthopedic Procedures
1045659|NCT01815918|Prostheses and Implants
1045660|NCT01815918|Joint Prosthesis
1045661|NCT01815918|Knee Prosthesis
1045662|NCT01815918|Arthroplasty, Knee
1045663|NCT01815918|Thromboembolism
1045664|NCT01815918|Inflammation
1045665|NCT01815918|B-Cell Differentiation Factor-2
1045666|NCT01815918|Differentiation Factor-2, B-Cell
1045667|NCT01815918|B-Cell Stimulatory Factor-2
1045668|NCT01815918|BSF-2
1045669|NCT01815918|IFN-beta 2
1045670|NCT01815918|MGI-2
1045671|NCT01815918|Interleukin-6 (IL-6)
1045672|NCT01815918|Steroids
1045673|NCT01815918|Pregnenediones
1045674|NCT01815918|Hydrocortisone
1045675|NCT01815918|Physiological Effects of Drugs
1045676|NCT01815918|Therapeutic Uses
1045677|NCT01815892|Hemodialysis
1045678|NCT01815892|Response to Furosemide
1045679|NCT01815879|metastatic colorectal cancer
1045680|NCT01815879|liver metastases
1045681|NCT01815879|90Y resin microsphere radioembolization
1045682|NCT01815879|retrospective data analysis
1045683|NCT01815866|Positive Nontuberculous Mycobacteria
1045684|NCT01815853|pre-operative,
1045685|NCT01815853|chemoradiotherapy,
1045686|NCT01815853|chemotherapy,
1045687|NCT01815853|treatment
1045688|NCT01815853|outcome
1045689|NCT01815814|spasticity
1045690|NCT01815814|cerebral palsy
1045691|NCT01815814|hemiplegia
1045692|NCT01815814|hemiparesis
1045693|NCT01815814|diplegia
1045694|NCT01815814|paraplegia
1045695|NCT01815814|quadriplegia
1045696|NCT01815814|quadriparesis
1045697|NCT01815775|Normal pressure hydrocephalus
1045698|NCT01815775|flow MRI
1045699|NCT01815775|dementia
1045700|NCT01815775|cerebrospinal fluid
1045701|NCT01815775|shunt
1045702|NCT01815762|bioimpedance
1045703|NCT01815762|overhydration
1045704|NCT01815762|hemodialysis
1045705|NCT01815762|arterial stiffness
1045706|NCT01815762|mortality
1045707|NCT01815736|HIV
1045708|NCT01815736|HIV 1 Infected
1045709|NCT01815736|Virologically-Suppressed
1045710|NCT01815723|Psoriasis
1045711|NCT01815723|Dimethyl fumarate
1045712|NCT01815723|Fumaderm®
1045713|NCT01815710|Clinical Pathways
1045714|NCT01815710|Knowledge translation
1045715|NCT01815710|Evaluation
1045716|NCT01815697|Lower Urinary Tract Symptoms
1045717|NCT01815697|Benign Prostatic Hyperplasia
1045718|NCT01815697|Urinary Retention
1045719|NCT01815697|Vascular Endothelium
1045720|NCT01815697|Counterpulsation, External
1045721|NCT01815684|Phase I
1045722|NCT01815684|ASP3652
1045723|NCT01815684|Dose escalation
1045724|NCT01815684|Maximum Tolerated Dose (MTD)
1045725|NCT01815671|colonoscopy
1045726|NCT01815671|technique
1045727|NCT01815671|tilt
1045728|NCT01815671|insertion
1045729|NCT01815671|safety
1045730|NCT01815671|efficacy
1045731|NCT01815645|Cocaine related disorders
1045732|NCT01815645|Contingency Management
1045733|NCT01815645|psychosocial treatment
1045734|NCT01815632|multiple sclerosis
1045735|NCT01815632|progressive MS
1045736|NCT01815632|stem cell
1045737|NCT01815632|cell therapy
1045738|NCT01815632|neurodegeneration
1045739|NCT01815632|CNS repair
1045740|NCT01815606|Pancreas
1045741|NCT01815606|cancer
1045742|NCT01815606|EUS-FNA
1045743|NCT01815606|19Gauge
1045744|NCT01815606|25Gauge
1045745|NCT01815606|35mm mass
1045746|NCT01815593|Erectile Dysfunction
1045747|NCT01815593|Vascular Endothelium
1045748|NCT01815593|Counterpulsation, External
1045749|NCT01815580|HIV
1045750|NCT01815580|Treatment as Prevention
1045751|NCT01815580|Seek, Test, Treat, Retain Strategies
1045752|NCT01815567|Hypertension
1045753|NCT01815567|Retinal Disorder
1045754|NCT01815567|Cognitive impairment
1045755|NCT01815554|Tetraplegia
1045756|NCT01815554|Spinal Cord Injury
1045757|NCT01815554|Ventilator
1045758|NCT01815554|Diaphragmatic Pacing System
1045759|NCT01815541|subcutaneous teicoplanin
1045760|NCT01815541|osteoarticular
1045761|NCT01815541|infections
1045762|NCT01815541|tolerance
1045763|NCT01815541|teicoplanin
1045764|NCT01815528|recurrent epithelial ovarian cancer
1045765|NCT01815515|Metastatic Prostate Cancer
1045766|NCT01815502|Single ventricle
1045767|NCT01815502|Fontan
1045768|NCT01815502|Sildenafil
1045769|NCT01815502|Pressure-Volume Loops
1045770|NCT01815489|Necrotizing Pancreatitis
1045771|NCT01815489|Pancreatitis
1045772|NCT01815489|Infection
1045773|NCT01815489|Bacteria
1045774|NCT01815489|Microbiology
1045775|NCT01815476|DCIS
1045776|NCT01815476|Early Stage Invasive breast cancer
1045777|NCT01815476|Prone breast radiotherapy
1045778|NCT01815463|stool
1045779|NCT01815463|monoclonal antibody
1045780|NCT01815463|Adnab-9
1045781|NCT01815463|FOBT
1045782|NCT01815463|FIT
1045783|NCT01815463|iFOBT
1045784|NCT01815463|colonoscopy
1045785|NCT01815463|barium enema
1045786|NCT01815463|flexible sigmoidoscopy
1045787|NCT01815424|Tofacitinib
1045788|NCT01815424|CP-690
1045789|NCT01815424|550
1045790|NCT01815424|Xeljanz
1045791|NCT01815424|Jak-Inhibitor
1045792|NCT01815424|Oral Treatment
1045793|NCT01815424|Psoriasis vulgaris
1045794|NCT01815424|Pruritus
1045795|NCT01815424|Itch
1045796|NCT01815424|DLQI
1045797|NCT01815424|moderate
1045798|NCT01815424|severe
1045799|NCT01815424|chronic
1045800|NCT01815424|plaque psoriasis
1045801|NCT01815411|Rheumatoid arthritis
1045802|NCT01815411|symptom score
1045803|NCT01815411|fatigue
1045804|NCT01815411|life quality
1045805|NCT01815411|cytokines
1045806|NCT01815411|mRNA expression
1045807|NCT01815411|Quality of Life
1045808|NCT01815411|Signs and Symptoms
1045809|NCT01815411|Indication for Modification of Patient Physical Status
1045810|NCT01815385|Term gestation
1045811|NCT01815385|Environmental exposure
1045812|NCT01815385|Benzo(a)pyrene
1045813|NCT01815385|Polycyclic aromatic hydrocarbons
1045814|NCT01815385|Adiposity
1045815|NCT01815385|Cytosine methylation
1045816|NCT01815372|nerve blocks
1045817|NCT01815372|ultrasound-guided
1045818|NCT01815372|leg surgery
1045819|NCT01815359|ICARuS
1045820|NCT01815359|Intraperitoneal Chemotherapy
1045821|NCT01815359|hyperthermic intraperitoneal chemotherapy
1045822|NCT01815359|Optimal Surgical Debulking
1045823|NCT01815359|Leucovorin
1045824|NCT01815359|Floxuridine (FUDR)
1045825|NCT01815359|Mitomycin
1045826|NCT01815359|12-289
1045827|NCT01815346|Breast Cancer
1045828|NCT01815346|Breast cancer survivors
1045829|NCT01815346|Chronic, taxane-based chemotherapy-induced peripheral neuropathy
1045830|NCT01815346|CIPN
1045831|NCT01815346|Acupuncture treatments
1045832|NCT01815346|Quality of life
1045833|NCT01815346|Hand function
1045834|NCT01815346|Balance
1045835|NCT01815346|Questionnaires
1045836|NCT01815346|Surveys
1045837|NCT01815333|Cancer of Lymph Node
1045838|NCT01815333|Magnetic resonance imaging
1045839|NCT01815333|MRI
1045840|NCT01815333|Ultrasuperparamagnetic nanoparticle iron oxide
1045841|NCT01815333|USPIO
1045842|NCT01815333|Feraheme
1045843|NCT01815333|Ferumoxytole
1045844|NCT01815320|Renal Transplant
1045845|NCT01815320|Contrast-enhanced ultrasound
1045846|NCT01815320|Acute allograft rejection
1045847|NCT01815294|Ovarian cancer
1045848|NCT01815294|Breast cancer
1045849|NCT01815294|Solid malignancy
1045850|NCT01815294|Advanced or refractory solid malignancy
1045851|NCT01815294|Metastatic cancer
1045852|NCT01815294|DOXIL/CAELYX
1045853|NCT01815294|Doxorubicin HCL
1045854|NCT01815294|Bioequivalence
1045855|NCT01815268|Randomized Controlled Trial
1045856|NCT01815268|Influenza
1045857|NCT01815268|Influenza vaccine
1045858|NCT01815268|Flu Vaccine
1045859|NCT01815268|Fluzone
1045860|NCT01815268|HD Fluzone
1045861|NCT01815268|Nursing Home
1045862|NCT01815268|Hospitalization
1045863|NCT01815268|Mortality
1045864|NCT01815268|Health Care worker vaccination
1045865|NCT01815268|ADL decline
1045866|NCT01815268|Effectiveness
1045867|NCT01815268|Elderly
1045868|NCT01815268|Morbidity
1045869|NCT01815268|Nursing Home resident
1045870|NCT01815268|Frail
1045871|NCT01815268|Institutionalized
1045872|NCT01815268|Epidemiology
1045873|NCT01815268|CDC
1045874|NCT01815268|US
1045875|NCT01815268|city
1045876|NCT01815255|TDF-based regimen
1045877|NCT01815255|HIV-infected children
1045878|NCT01815255|Thai
1045879|NCT01815255|generic
1045880|NCT01815255|safety and efficacy
1045881|NCT01815255|renal status
1045882|NCT01815255|To assess effect of TDF on renal problem in HIV-infected children receiving TDF-based once daily regimen
1045883|NCT01815255|To compare the effectiveness and clinical usefulness of different tools of adherence
1045884|NCT01815229|endotracheal
1045885|NCT01815229|intubation
1045886|NCT01815216|Bariatric surgery
1045887|NCT01815216|Cognition
1045888|NCT01815216|Satiety hormones
1045889|NCT01815216|Brain networks
1045890|NCT01815216|Inhibitory control
1045891|NCT01815216|Food intake
1045892|NCT01815203|Caffeine effects
1045893|NCT01815203|Inhibitory control
1045894|NCT01815190|immune complex vasculitis
1045895|NCT01815190|cutaneous vasculitis
1045896|NCT01815190|IgA vasculitis
1045897|NCT01815190|IgA nephropathy
1045898|NCT01815138|OHSS, GnRH agonist trigger, low dose hCG, PCOS, IVF
1045899|NCT01815125|Mild traumatic brain injury
1045900|NCT01815125|Brain concussion
1045901|NCT01815125|Post-concussion syndrome
1045902|NCT01815125|Emergency department
1045903|NCT01815125|Ondansetron
1045904|NCT01815112|Neurodegenerative disease
1045905|NCT01815112|Elderly
1045906|NCT01815112|Dementia
1045907|NCT01815112|FDG-PET
1045908|NCT01815112|MRI
1045909|NCT01815112|Neuroimaging
1045910|NCT01815086|Radioimmunoimaging
1045911|NCT01815086|AL Amyloidosis
1045912|NCT01815086|PET/CT
1045913|NCT01815047|Vitamin D
1045914|NCT01815047|Pregnancy
1045915|NCT01815047|Inflammation
1045916|NCT01815047|Infection
1045917|NCT01815047|Placenta
1045918|NCT01815047|Cytokine
1045919|NCT01815047|Microbiome
1045920|NCT01815008|Platelet aggregation
1045921|NCT01815008|Clopidogrel
1045922|NCT01815008|Platelet transcriptome
1045923|NCT01814995|behavioural
1045924|NCT01814995|diabetes prevention
1045925|NCT01814995|overweight
1045926|NCT01814995|physical activity
1045927|NCT01814995|gestational diabetes
1045928|NCT01814982|Traumatic brain injury
1045929|NCT01814982|JNJ-17299425
1045930|NCT01814982|Intracranial pressure
1045931|NCT01814982|Intravascular bolus injection
1045932|NCT01814969|Rectal neoplasm
1045933|NCT01814969|Preoperative hyperfractionated radiotherapy
1045934|NCT01814969|Preoperative hyperfractionated radiochemotherapy
1045935|NCT01814891|vitamin A
1045936|NCT01814891|maize
1045937|NCT01814891|total body reserves
1045938|NCT01814891|Condition is vitamin A status.
1045939|NCT01814891|Focus: change in vitamin A status with maize feeding.
1045940|NCT01814891|Focus: feeding orange maize to children for 90 days.
1045941|NCT01814891|Focus: total body reserves of vitamin A.
1045942|NCT01814878|Pain, Postoperative
1045943|NCT01814878|Tramadol Hydrochloride
1045944|NCT01814878|Acetaminophen
1045945|NCT01814878|Ultracet
1045946|NCT01814865|Post-menopausal
1045947|NCT01814865|ER+
1045948|NCT01814865|Stage I-IIIA
1045949|NCT01814865|Operable
1045950|NCT01814865|Breast Cancer
1045951|NCT01814852|Low Intensity Shockwave
1045952|NCT01814852|Extracorporeal shockwave therapy
1045953|NCT01814852|Erectile dysfunction
1045954|NCT01814839|RNAi therapeutic
1045955|NCT01814826|MLN4924
1045956|NCT01814826|Acute
1045957|NCT01814826|Myelogenous
1045958|NCT01814826|Leukemia
1045959|NCT01814800|PIDD, PID, humoral immunity, antibody deficiency
1045960|NCT01814787|Type 2 Diabetes
1045961|NCT01814787|Pediatrics
1045962|NCT01814787|Computerized Decision Support System
1045963|NCT01814748|Diabetes Mellitus
1045964|NCT01814748|Diabetes Mellitus, Type 2
1045965|NCT01814748|Glucose Metabolism Disorders
1045966|NCT01814748|Metabolic Diseases
1045967|NCT01814748|Endocrine System Diseases
1045968|NCT01814748|Metformin
1045969|NCT01814748|Hypoglycemic Agents
1045970|NCT01814748|Pharmacologic Actions
1045971|NCT01814748|Therapeutic Uses
1045972|NCT01814722|HIV Infections
1045973|NCT01814722|Anti-HIV Agents
1045974|NCT01814722|Anti-Retroviral Agents
1045975|NCT01814722|Nucleoside Reverse Transcriptase Inhibitors
1045976|NCT01814722|Non-nucleoside Reverse Transcriptase Inhibitor
1045977|NCT01814722|Protease inhibitors
1045978|NCT01814696|Heart Failure
1045979|NCT01814696|Congestive Heart Failure
1045980|NCT01814696|Medication Adherence
1045981|NCT01814696|Medication Compliance
1045982|NCT01814696|Telemedicine
1045983|NCT01814696|Telehealth
1045984|NCT01814683|Vivax malaria
1045985|NCT01814683|Primaquine
1045986|NCT01814683|Placebo
1045987|NCT01814683|Recurrence
1045988|NCT01814657|Infertility
1045989|NCT01814605|Sciatic Nerve Block
1045990|NCT01814605|Subgluteal space
1045991|NCT01814605|Infragluteal space
1045992|NCT01814592|coronally positioned flap
1045993|NCT01814592|connective tissue
1045994|NCT01814592|gingival margin
1045995|NCT01814592|gingival recession/ treatment
1045996|NCT01814592|gingival recession/ surgery
1045997|NCT01814592|subepithelial connective tissue graft
1045998|NCT01814592|randomized controlled clinical trial
1045999|NCT01814592|surgical flaps
1046000|NCT01814592|Treatment outcome
1046001|NCT01814579|vaginal
1046002|NCT01814579|cuff
1046003|NCT01814579|robotic
1046004|NCT01814579|hysterectomy
1046005|NCT01814579|vloc
1046006|NCT01814579|v-loc
1046007|NCT01814579|vicryl
1046008|NCT01814579|unidirectional
1046009|NCT01814579|barbed
1046010|NCT01814579|suture
1046011|NCT01814527|Fish oil
1046012|NCT01814527|Omega 3 Fatty acids
1046013|NCT01814527|Docosahexaenoic acid
1046014|NCT01814527|Mild Concussion
1046015|NCT01814527|Brain Concussion
1046016|NCT01814527|Cerebral Concussion
1046017|NCT01814514|hypertensive
1046018|NCT01814514|phase
1046019|NCT01814514|success rate
1046020|NCT01814514|AGV
1046021|NCT01814501|Metastatic colon cancer
1046022|NCT01814488|Active acute leukemia
1046023|NCT01814488|PIF
1046024|NCT01814488|Allogeneic transplant
1046025|NCT01814488|Acute Myeloid Leukemia
1046026|NCT01814488|Acute Lymphoblastic Leukemia
1046027|NCT01814488|Marrow Unrelated Donor
1046028|NCT01814488|Cord Blood
1046029|NCT01814488|Family Haploidentical donor
1046037|NCT01814462|Obstructive Sleep Apnea
1046038|NCT01814462|Pulse wave analysis
1046039|NCT01814449|Breast cancer
1046040|NCT01814449|Hypoxia
1046041|NCT01814449|Hypoxia related gene
1046042|NCT01814449|Endocrine therapy
1046043|NCT01814449|Treatment resistance
1046044|NCT01814423|Plasmodium falciparum
1046045|NCT01814423|malaria
1046046|NCT01814423|chloroquine
1046047|NCT01814423|pharmacokinetic
1046048|NCT01814423|children
1046049|NCT01814410|Intravenous Ethanol
1046050|NCT01814410|Intravenous Nicotine
1046051|NCT01814410|Interactive effects
1046052|NCT01814410|cognition
1046053|NCT01814410|subjective effects
1046054|NCT01814410|healthy subjects
1046055|NCT01814397|Aromatase inhibitor
1046056|NCT01814397|Pain threshold
1046057|NCT01814384|Ancillary tailored
1046058|NCT01814384|medico-economic study,
1046059|NCT01814384|total knee replacement
1046060|NCT01814384|primary or secondary osteoarthritis
1046061|NCT01814371|Abscesses
1046062|NCT01814371|Furunculosis
1046063|NCT01814371|Staphylococcus aureus colonization
1046064|NCT01814371|Staphylococcal Skin Infection
1046065|NCT01814371|MRSA
1046066|NCT01814345|Her2 testing (Human Epidermal Growth Factor Receptor 2)
1046067|NCT01814332|Stress disorders, Post-traumatic
1046068|NCT01814332|Sleep
1046069|NCT01814319|heart failure
1046070|NCT01814319|ejection fraction equal or less than 40%
1046071|NCT01814306|LMA Supreme,LMA Proseal,airway management,prone position
1046072|NCT01814293|Pediatric
1046073|NCT01814293|Upper Respiratory infection
1046074|NCT01814293|Over the Counter Drugs
1046075|NCT01814293|Drugs, Non-Prescription
1046076|NCT01814293|Vaporizer
1046077|NCT01814280|Medication errors
1046078|NCT01814280|Medication review
1046079|NCT01814280|Risk stratification
1046080|NCT01814280|Patient safety
1046081|NCT01814267|innovative care
1046082|NCT01814267|telemedicine
1046083|NCT01814267|cost effectiveness
1046084|NCT01814267|diabetes
1046085|NCT01814241|Peanut allergy
1046086|NCT01814215|Obesity
1046087|NCT01814215|Prevention and Control
1046088|NCT01814215|Diet
1046089|NCT01814215|Motor Activity
1046091|NCT01814215|Child, Preschool
1046092|NCT01814215|Child Care
1046093|NCT01814215|Food Habits
1046094|NCT01814215|Feeding Behavior
1046095|NCT01814215|Child Behavior
1046096|NCT01814163|First line treatment
1046097|NCT01814163|Non small cell lung cancer, non squamous
1046098|NCT01814150|Docetaxel
1046099|NCT01814150|Alpha 1 Acid Glycoprotein
1046100|NCT01814150|Outcome
1046101|NCT01814111|Hypertension
1046102|NCT01814111|Atrial Fibrillation
1046103|NCT01814111|Arrhythmias, Cardiac
1046104|NCT01814111|Heart Diseases
1046105|NCT01814111|Cardiovascular Diseases
1046106|NCT01814098|Depressive Disorder, Major
1046107|NCT01814098|Escitalopram
1046108|NCT01814098|Lexapro
1046109|NCT01814085|Major Depressive Disorder
1046110|NCT01814085|Escitalopram
1046111|NCT01814085|Lexapro
1046112|NCT01814059|Sirolimus
1046113|NCT01814059|Eosinophilic Esophagitis
1046114|NCT01814059|Eosinophilic Gastroenteritis
1046115|NCT01814059|T -Cells
1046116|NCT01814059|Food Allergy
1046117|NCT01814046|Metastatic
1046118|NCT01814046|Ocular Melonoma
1046119|NCT01814046|Autologous Tumor-Infiltrating Lymphocytes
1046120|NCT01814046|Uveal Melanoma
1046121|NCT01814046|Adoptive Cell Therapy
1046122|NCT01814033|LRU
1046123|NCT01814033|Total Knee Arthroplasty
1046124|NCT01814033|Total Knee Replacement
1046125|NCT01814033|Acute Rehabilitation Total Knee
1046126|NCT01814033|Total Knee Range of Motion
1046127|NCT01814033|Total Knee Acute care Outcomes
1046128|NCT01814020|DSO
1046132|NCT01813994|Statin; Gastric inflammation; Gastric cancer
1046133|NCT01813968|Ischemic postconditioning
1046134|NCT01813968|Adult cardiac surgery
1046135|NCT01813968|Aortic valve surgery
1046136|NCT01813968|Swan-Ganz
1046137|NCT01813968|Cardiac index
1046138|NCT01813955|phosphodiesterase inhibitor
1046139|NCT01813955|Psychophysiology
1046140|NCT01813955|Cognition
1046141|NCT01813955|Schizophrenia
1046142|NCT01813955|Papaverine
1046143|NCT01813942|clinical narrative report
1046144|NCT01813942|time series data
1046145|NCT01813942|missing value
1046146|NCT01813929|Diabetes
1046147|NCT01813929|Insulin
1046148|NCT01813929|Metformin
1046149|NCT01813929|Vascular
1046150|NCT01813929|Vessels
1046151|NCT01813929|Type 1
1046152|NCT01813916|Osteoarthritis
1046153|NCT01813916|synovial fluid
1046154|NCT01813916|hyaluronic acid
1046155|NCT01813890|Bunionectomy
1046156|NCT01813890|Acute pain
1046157|NCT01813890|Post-operative pain
1046158|NCT01813890|Tapentadol IR
1046159|NCT01813890|Analgesia
1046160|NCT01813890|Hallux valgus
1046161|NCT01813864|treatment planning
1046162|NCT01813864|resource guide
1046163|NCT01813864|service matching
1046164|NCT01813864|Service matching for substance abuse clients
1046165|NCT01813864|CASPAR resource guide
1046166|NCT01813864|Improved treatment planning
1046167|NCT01813851|Dialysis, Exercise, Protein Energy Wasting, Nutrition and Physical Fitness
1046168|NCT01813825|Mammosite
1046169|NCT01813799|Diabetic Neuropathies
1046170|NCT01813734|RET gene mutation
1046171|NCT01813721|NHL
1046172|NCT01813721|Breast Cancer
1046173|NCT01813721|Lung Cancer
1046174|NCT01813708|Type 2 Diabetes
1046175|NCT01813708|Intensive Life-Style
1046176|NCT01813708|Collaborative Education
1046177|NCT01813708|Clinical Trial
1046178|NCT01813708|Metabolic Control
1046179|NCT01813695|Preemptive genetic testing
1046180|NCT01813695|Pain
1046181|NCT01813695|Pediatrics
1046182|NCT01813695|Orthopedics
1046183|NCT01813695|Pectus excavatum
1046184|NCT01813695|Scoliosis
1046185|NCT01813682|preterm infant
1046186|NCT01813682|anemia
1046187|NCT01813682|iron fortified TPN
1046188|NCT01813669|Childhood anxiety
1046189|NCT01813669|Pediatric Pain
1046190|NCT01813669|Yoga
1046191|NCT01813669|Cognitive behavioral therapy
1046192|NCT01813656|Methamphetamine-Associated Psychosis
1046193|NCT01813656|Aripiprazole
1046194|NCT01813643|Methamphetamine-Associated Psychosis
1046195|NCT01813643|Aripiprazole
1046196|NCT01813643|Risperidone
1046197|NCT01813630|Turner's Syndrome
1046198|NCT01813630|Short Stature
1046199|NCT01813630|Dwarfism
1046200|NCT01813617|Polymyositis
1046201|NCT01813617|Dermatomyositis
1046202|NCT01813617|Muscle endurance
1046203|NCT01813617|Muscle stength
1046204|NCT01813617|Outcome
1046205|NCT01813604|Polio
1046206|NCT01813604|Inactivated polio vaccine
1046207|NCT01813604|oral polio vaccine
1046208|NCT01813604|vaccine trial
1046209|NCT01813591|Chronic Migraine
1046210|NCT01813591|Headache
1046211|NCT01813591|Refractory Chronic Migraine
1046212|NCT01813578|Systemic sclerosis
1046213|NCT01813578|Exercise
1046214|NCT01813578|Physical capacity
1046215|NCT01813578|Aerobic capacity
1046216|NCT01813578|Muscle function
1046217|NCT01813578|Fatigue
1046218|NCT01813552|HCV
1046219|NCT01813552|Hepatitis C
1046220|NCT01813552|antiviral drugs
1046221|NCT01813552|liver
1046222|NCT01813539|malignancy
1046223|NCT01813513|HCV
1046224|NCT01813513|Hepatitis C Virus
1046225|NCT01813513|Hepatitis C
1046226|NCT01813513|antiviral drugs
1046227|NCT01813513|liver
1046228|NCT01813474|Cancer
1046229|NCT01813474|Tumour
1046230|NCT01813474|Solid Malignancies
1046231|NCT01813461|BAL8557
1046232|NCT01813461|14C-labeled isavuconazole
1046233|NCT01813461|14C-labeled prodrug isavuconazonium sulfate (BAL8557)/([cyano-14C]ASP9766 sulfate)
1046234|NCT01813448|Fidaxomicin
1046235|NCT01813448|OPT-80
1046236|NCT01813448|Healthy Subjects
1046237|NCT01813435|CAD
1046238|NCT01813435|ACS
1046239|NCT01813435|All comers
1046240|NCT01813435|DAPT
1046241|NCT01813435|PCI
1046246|NCT01813396|shoulder
1046247|NCT01813396|muscle stiffness
1046248|NCT01813396|shoulder physical activity
1046249|NCT01813396|range of motion
1046250|NCT01813396|joint mobility
1046251|NCT01813383|Celiac disease
1046252|NCT01813383|HLA-DQ2.2
1046253|NCT01813383|HLA-DQ2.5
1046254|NCT01813383|HLA-DR7-DQ2
1046255|NCT01813383|HLA-DR3-DQ2
1046256|NCT01813370|TAX 3503
1046257|NCT01813370|MSKCC IRB#07-101
1046258|NCT01813370|12-225
1046259|NCT01813357|HIV
1046260|NCT01813357|Cardiovascular disease
1046261|NCT01813357|Inflammation
1046262|NCT01813357|Statin
1046263|NCT01813344|Adult lymphoblastic lymphoma
1046264|NCT01813344|Hyper-CVAD
1046265|NCT01813344|first-line treatment
1046266|NCT01813305|Diabetic Foot Ulcer
1046267|NCT01813305|Diabetes Mellitus
1046268|NCT01813305|Debridement
1046269|NCT01813305|Standard of Care
1046270|NCT01813305|wounds
1046271|NCT01813292|male patients
1046272|NCT01813292|treated by TRUVADA® or VIREAD® for more than 60 months
1046273|NCT01813253|epidermal growth factor receptor
1046274|NCT01813253|second line
1046275|NCT01813214|melanoma
1046276|NCT01813214|vemurafenib
1046277|NCT01813214|cobitmetinib
1046278|NCT01813201|Testosterone
1046279|NCT01813201|Anabolic deterioration
1046280|NCT01813188|Fractures
1046281|NCT01813188|Bone
1046282|NCT01813188|Stem Cells
1046283|NCT01813149|Complex Regional Pain Syndrome (CRPS)
1046284|NCT01813136|radioiodine refractory Differentiated Thyroid Carcinoma
1046285|NCT01813136|pazopanib
1046286|NCT01813136|intermittent administration
1046287|NCT01813136|time to treatment failure
1046288|NCT01813136|TUTHYREF
1046289|NCT01813123|gender-specific
1046290|NCT01813123|web-based
1046291|NCT01813123|drug abuse
1046292|NCT01813123|prevention
1046293|NCT01813110|inflammation
1046294|NCT01813110|omega-3
1046295|NCT01813110|fish oil
1046296|NCT01813097|To detective the effect of the treatment of combination iodine 125 seed implants and LHRH agonists for the patients with locally advanced prostate cancer.
1046297|NCT01813071|Enterobacteriaceae Infections
1046298|NCT01813071|Gram-Negative Bacterial Infections
1046299|NCT01813071|Bacterial Infections
1046300|NCT01813071|Gastroenteritis
1046301|NCT01813071|Gastrointestinal Diseases
1046302|NCT01813071|Digestive System Diseases
1046303|NCT01813071|Intestinal Diseases
1046304|NCT01813071|Shigellosis
1046305|NCT01813058|Tranexamic acid, Blood loss
1046306|NCT01813045|Angiogenesis
1046307|NCT01813045|Fibrosis
1046308|NCT01813045|Myocardial Infarction
1046309|NCT01813045|Imaging
1046310|NCT01813045|CT-PET
1046311|NCT01813045|PET-CT
1046312|NCT01813045|Cardiac MRI
1046313|NCT01813032|firefighters
1046314|NCT01813032|police officers
1046315|NCT01813032|emergency service professionals
1046316|NCT01813032|myocardial infarction
1046317|NCT01813032|endothelial function
1046318|NCT01813032|thrombosis
1046319|NCT01813019|Obsessive compulsive disorder (OCD), obsessive fears, obsessions,
1046320|NCT01813019|compulsions, OCD SSRI resistant
1046321|NCT01812993|Ischemic stroke, sleep apnea, non-invasive ventilatory treatment
1046322|NCT01812980|Influenza
1046323|NCT01812980|Human Immunodeficiency Virus
1046324|NCT01812954|moderate-to-severe psoriasis
1046325|NCT01812954|cost utility analysis
1046326|NCT01812954|cost effectiveness analysis
1046327|NCT01812954|systemic treatment
1046328|NCT01812941|burns
1046329|NCT01812941|trauma
1046330|NCT01812928|Flexible Cystoscopy
1046331|NCT01812928|Pain control
1046332|NCT01812928|Diclofenac
1046333|NCT01812928|Non steroidal anti inflammatory drug
1046334|NCT01812915|Cuff pressure
1046335|NCT01812915|Cylindrical cuff
1046336|NCT01812915|Endotracheal tube
1046337|NCT01812915|Nitrous oxide
1046338|NCT01812915|Tapered cuff
1046339|NCT01812902|Prostate cancer
1046340|NCT01812902|Prostate specific antigen
1046341|NCT01812902|lymphadenectomy
1046342|NCT01812902|Limited lymphadenectomy
1046343|NCT01812902|Extended lymphadenectomy
1046344|NCT01812902|Immunohistochemistry
1046345|NCT01812889|bacterial vaginosis, vulvovaginal candidiasis, TOL-463, intravaginal therapy, vaginitis, women, cross-over
1046346|NCT01812863|Pain Management
1046347|NCT01812863|Child
1046348|NCT01812863|Surgery
1046349|NCT01812850|Temporomandibular joint
1046350|NCT01812850|Orofacial muscular complex
1046351|NCT01812850|Bruxism
1046352|NCT01812850|Clenching
1046353|NCT01812850|Orthodontic treatment
1046354|NCT01812850|Invisalign®
1046355|NCT01812837|actinic keratosis
1046356|NCT01812837|microneedles
1046357|NCT01812837|photodynamic therapy
1046358|NCT01812837|levulan
1046359|NCT01812837|Aminolevulinic acid
1046360|NCT01812824|Preconception Health
1046361|NCT01812824|Health Information Technology
1046362|NCT01812824|Reproductive Life Plan
1046363|NCT01812824|Healthcare Disparities
1046364|NCT01812824|Low birth-weight
1046365|NCT01812824|Preterm Delivery
1046366|NCT01812811|pulse wave analysis
1046367|NCT01812811|pulse wave velocity
1046368|NCT01812811|Arteriograph24
1046369|NCT01812811|Ambulatory
1046370|NCT01812811|diabetes
1046371|NCT01812811|reproducibility
1046372|NCT01812811|diurnal variation
1046373|NCT01812798|Peanut allergy
1046374|NCT01812798|Threshold
1046375|NCT01812798|Modelling
1046376|NCT01812798|Risk assessment
1046377|NCT01812785|Fever
1046378|NCT01812785|Children
1046379|NCT01812785|Non-malaria fevers
1046380|NCT01812785|Diagnosis
1046381|NCT01812772|urinary stents
1046382|NCT01812772|ureteroscopy
1046383|NCT01812759|Pain
1046384|NCT01812759|Breakthrough cancer pain
1046385|NCT01812759|Emergency Department
1046386|NCT01812759|ED
1046387|NCT01812759|Fentanyl nasal spray
1046388|NCT01812759|Lazanda
1046389|NCT01812759|Placebo nasal spray
1046390|NCT01812759|Hydromorphone PCA
1046391|NCT01812759|Dilaudid
1046392|NCT01812694|Pregnancy
1046393|NCT01812694|Weight Control
1046394|NCT01812694|Weight Gain
1046395|NCT01812681|vitamin D, Respiratory distress syndrome, sepsis, preterm
1046396|NCT01812655|pain
1046397|NCT01812655|anxiety
1046398|NCT01812655|children
1046399|NCT01812655|adolescents
1046400|NCT01812655|burn
1046401|NCT01812655|virtual reality
1046402|NCT01812655|distraction
1046403|NCT01812642|Schizophrenia
1046404|NCT01812642|JNJ-37822681
1046405|NCT01812642|Placebo
1046406|NCT01812616|Cancer
1046407|NCT01812616|Safety
1046408|NCT01812603|Cancer
1046409|NCT01812603|Safety
1046410|NCT01812564|Platelet rich plasma
1046411|NCT01812564|Interventional
1046412|NCT01812564|Randomized
1046413|NCT01812564|Double-blind
1046414|NCT01812551|cystic fibrosis
1046415|NCT01812551|children
1046416|NCT01812551|adolescents
1046417|NCT01812551|low bone mass
1046418|NCT01812551|osteoporosis
1046419|NCT01812551|alendronate
1046420|NCT01812551|fractures
1046421|NCT01812525|Bronchiolitis
1046422|NCT01812525|Moderate to Severe
1046423|NCT01812525|Hypertonic saline
1046424|NCT01812525|NaCl 3% inhalations
1046425|NCT01812525|Standard therapy
1046426|NCT01812525|Wang score
1046427|NCT01812525|in-patients
1046428|NCT01812512|Heart Failure
1046429|NCT01812512|Communication
1046430|NCT01812512|Telemedicine
1046431|NCT01812512|Veterans
1046432|NCT01812512|Nurse-patient relations
1046433|NCT01812499|blood transfusion
1046434|NCT01812499|adverse event
1046435|NCT01812499|incident reporting
1046436|NCT01812473|protein binding
1046437|NCT01812473|voriconazole
1046438|NCT01812473|pediatrics
1046439|NCT01812473|hematology
1046440|NCT01812473|intensive care
1046441|NCT01812473|albumin
1046442|NCT01812473|alpha-1-acid-glycoprotein
1046443|NCT01812460|COPD
1046444|NCT01812460|muscle strength
1046445|NCT01812460|resistance training
1046446|NCT01812460|Physiotherapi
1046447|NCT01812460|m. quadriceps
1046448|NCT01812460|Acute exacerbation
1046449|NCT01812447|Endobronchial Valves
1046450|NCT01812447|Intrabronchial Valves
1046451|NCT01812447|Bronchial Valve
1046452|NCT01812447|Chronic Obstructive Pulmonary Disease
1046453|NCT01812447|COPD
1046454|NCT01812447|Pulmonary Disease, Chronic Obstructive
1046455|NCT01812447|Bronchoscopic Lung Volume Reduction
1046456|NCT01812447|BLVR
1046457|NCT01812447|TLVR
1046458|NCT01812447|Emphysema
1046459|NCT01812447|Pulmonary Emphysema
1046460|NCT01812447|Pathologic Process
1046461|NCT01812447|Lung Diseases
1046462|NCT01812447|Respiratory Tract Disease
1046463|NCT01812395|thyroidectomy
1046464|NCT01812395|ultrasonic dissector
1046465|NCT01812395|harmonic focus device
1046466|NCT01812395|superior laryngeal nerve
1046467|NCT01812382|Penetration
1046468|NCT01812382|Antibiotic
1046469|NCT01812382|Microdialysis
1046470|NCT01812382|Formulation Pharmacokinetics
1046471|NCT01812382|Feasibility
1046472|NCT01812356|Atrial fibrillation
1046473|NCT01812356|maze operation
1046474|NCT01812356|cryoablation
1046475|NCT01812343|Ankle Brachial Index
1046476|NCT01812343|Maximal Exercise Test
1046477|NCT01812330|ACS
1046478|NCT01812330|CR
1046479|NCT01812330|PCI
1046480|NCT01812330|Platelet funtion
1046481|NCT01812330|Ticagrelor
1046482|NCT01812317|firefighters
1046483|NCT01812317|fire-simulation training
1046484|NCT01812317|myocardial infarction
1046485|NCT01812317|endothelial function
1046486|NCT01812317|thrombosis
1046487|NCT01812291|Major Depression
1046488|NCT01812291|Minor Depression
1046489|NCT01812291|Sub-Threshold Depression
1046490|NCT01812291|Affective Condition
1046491|NCT01812291|Mood Disorder
1046492|NCT01812291|Light Affective Disorder
1046493|NCT01812291|Subclinical Depressive Symptoms
1046494|NCT01812291|Diabetes Mellitus
1046495|NCT01812291|Diabetes-Related Distress
1046496|NCT01812291|Self-Care Behaviour
1046497|NCT01812291|Glycaemic Control
1046498|NCT01812291|Inflammatory Markers
1046499|NCT01812252|myelodysplastic syndrome
1046500|NCT01812252|chronic myelomonocytic leukemia
1046501|NCT01812252|bone marrow transplant
1046502|NCT01812252|hypomethylating agent
1046503|NCT01812252|induction chemotherapy
1046504|NCT01812239|premature birth
1046505|NCT01812239|twins
1046506|NCT01812239|short cervix
1046507|NCT01812213|Mild Cognitive Impairment
1046508|NCT01812187|Alcohol
1046509|NCT01812187|Alcohol Abuse
1046510|NCT01812187|Alcohol Dependence
1046511|NCT01812187|Veterans
1046512|NCT01812174|heart valve
1046513|NCT01812161|Electro-acupuncture
1046514|NCT01812161|HCG stimulation test
1046515|NCT01812161|Menstrual frequency
1046516|NCT01812161|polycystic ovary syndrome
1046517|NCT01812161|Randomized
1046518|NCT01812161|controlled
1046519|NCT01812161|trial
1046520|NCT01812148|Peritoneal Mesotheliomas
1046521|NCT01812148|hyperthermic intra-peritoneal chemotherapy (HIPEC)
1046522|NCT01812148|Oxaliplatin
1046523|NCT01812148|Cytoreductive surgery
1046524|NCT01812148|Oxaliplatin HIPEC
1046525|NCT01812109|Acute Scrotum
1046526|NCT01812109|Testicular Torsion
1046527|NCT01812096|multiple myeloma
1046528|NCT01812096|bortezomib
1046529|NCT01812096|Subcutaneous
1046530|NCT01812083|Periodontitis; adverse pregnancy outcomes; IL-1 polymorphism
1046531|NCT01812070|smoking cessation
1046532|NCT01812070|quit smoking
1046533|NCT01812057|Anesthesia
1046534|NCT01812057|Cesarean Section
1046535|NCT01812057|Pain, Postoperative
1046536|NCT01812057|Postoperative Nausea and Vomiting
1046537|NCT01812057|Dexamethasone
1046538|NCT01812057|Injections, Spinal
1046539|NCT01812057|morphine
1046540|NCT01812031|PET/CT
1046541|NCT01812031|18F-fluoro-2-deoxyglucose
1046542|NCT01812031|lung neoplasms
1046543|NCT01812031|respiratory motion
1046544|NCT01812018|Soft Tissue Sarcoma
1046545|NCT01812018|Pulmonary metastases
1046546|NCT01812005|MLN8237
1046547|NCT01812005|B-cell Non Hodgkin Lymphoma
1046548|NCT01812005|Rituximab
1046549|NCT01811979|eye examination, oral sucrose, premature infant pain scale
1046550|NCT01811966|preoperative volume substitution
1046551|NCT01811966|hypovolemia
1046552|NCT01811966|preoperative fasting
1046553|NCT01811940|cocaine dependence
1046554|NCT01811940|adderall
1046555|NCT01811940|topiramate
1046556|NCT01811914|focused TTE
1046557|NCT01811914|intraoperative TTE
1046558|NCT01811914|transthoracic echocardiography
1046559|NCT01811914|high risk non-cardiac surgery
1046560|NCT01811914|hemodynamic instabilities
1046561|NCT01811901|inhospital delays, door-to-needle time, thrombolysis, acute ischemic stroke, SITS, SITS-WATCH, stroke registry
1046562|NCT01811875|Haemophilia A
1046563|NCT01811862|Acupuncture
1046564|NCT01811862|Hematopoietic stem cell transplantation (HSCT)
1046565|NCT01811862|13-038
1046566|NCT01811849|diabetes
1046567|NCT01811823|Tuberculosis
1046568|NCT01811823|HIV infection
1046569|NCT01811823|Immune responses to Influenza vaccination
1046570|NCT01811810|Men under the age of 75 with histologically confirmed high risk
1046571|NCT01811797|Erectile Dysfunction
1046572|NCT01811797|Extracorporeal shockwave
1046573|NCT01811797|Low intensity shockwaves
1046574|NCT01811784|Nipah virus infection
1046575|NCT01811784|date palm sap
1046576|NCT01811784|community intervention
1046577|NCT01811784|capacity building
1046578|NCT01811784|disease prevention
1046579|NCT01811784|Bangladesh
1046580|NCT01811784|Healthy Community people
1046581|NCT01811784|Sap harvesters
1046582|NCT01811784|Date palm three owners
1046583|NCT01811784|Date palm sap consumers
1046584|NCT01811758|Culturally Specific Cognitive Behavioral Therapy
1046585|NCT01811758|Standard Cognitive Behavioral Therapy
1046586|NCT01811745|Aged
1046587|NCT01811745|Cognition
1046588|NCT01811745|Exercise
1046589|NCT01811745|Falls
1046590|NCT01811745|Gait
1046591|NCT01811745|Physical function
1046592|NCT01811745|Dual-task
1046593|NCT01811745|Music
1046594|NCT01811745|Postural Balance
1046595|NCT01811745|Randomized controlled trial
1046596|NCT01811732|Bacterial skin infection
1046597|NCT01811732|skin infection
1046598|NCT01811732|infection
1046599|NCT01811732|skin
1046600|NCT01811732|delafloxacin
1046601|NCT01811732|vancomycin
1046602|NCT01811732|aztreonam
1046603|NCT01811732|MRSA bacteria
1046604|NCT01811732|bacterial infection
1046605|NCT01811732|Anti-Infective Agents
1046606|NCT01811732|Anti-Bacterial Agents
1046607|NCT01811719|Intimate Partner Physical Violence
1046608|NCT01811719|Intimate Partner Emotional Abuse
1046609|NCT01811719|Intimate Partner Controlling Behaivor
1046610|NCT01811719|Pregnancy Outcomes
1046611|NCT01811719|Quality of Parental Care Giving
1046612|NCT01811719|Maternal Life Course
1046613|NCT01811693|Stroke
1046614|NCT01811693|Intracerebral Hemorrhage
1046615|NCT01811693|Prehospital
1046616|NCT01811693|Antihypertensive
1046617|NCT01811680|Stroke
1046618|NCT01811680|Hemiplegia
1046619|NCT01811680|Variable automated treadmill treadmill
1046620|NCT01811667|Vascular Abnormalities
1046621|NCT01811654|Patellofemoral
1046622|NCT01811654|Hyaluronan
1046623|NCT01811654|Intra-articular
1046624|NCT01811654|Hyaluronic acid
1046625|NCT01811641|season of conception
1046626|NCT01811641|maternal nutritional status
1046627|NCT01811641|infant DNA methylation
1046628|NCT01811628|Cancer Prevention
1046629|NCT01811628|Tobacco Use Cessation
1046630|NCT01811628|Smokers
1046631|NCT01811628|Recent quitters
1046632|NCT01811628|Latino
1046633|NCT01811628|Hispanic
1046634|NCT01811628|Information
1046635|NCT01811628|Interview
1046636|NCT01811628|Questionnaire
1046637|NCT01811628|Survey
1046638|NCT01811628|Audio-recorded
1046639|NCT01811602|Training
1046640|NCT01811602|Physiotherapy
1046641|NCT01811602|Pelvic floor muscles
1046642|NCT01811589|ventricular catheter, hydrocephalus, shunt, brain disease
1046643|NCT01811576|Growth hormone deficiency
1046644|NCT01811576|Insulin-like growth factor I (IGF-I)
1046645|NCT01811576|TV-1106
1046646|NCT01811563|Total Knee Replacement
1046647|NCT01811563|Lower Quarter Y-Balance Test
1046648|NCT01811563|Functional Outcomes
1046649|NCT01811563|Patient Reported Outcomes
1046650|NCT01811537|Artificial Chordae
1046651|NCT01811537|Mitral Valve Repair
1046652|NCT01811524|Brain tumor
1046653|NCT01811524|Glioma
1046654|NCT01811524|Meningioma
1046655|NCT01811524|Diagnosis
1046656|NCT01811524|Prognosis
1046657|NCT01811524|Heredity
1046658|NCT01811472|Multi-center,
1046659|NCT01811472|randomized,
1046660|NCT01811472|double-blind,
1046661|NCT01811472|NAFLD,
1046662|NCT01811472|elevated triglycerides
1046663|NCT01811459|Delirium
1046664|NCT01811459|ICU
1046665|NCT01811459|Burn patients
1046666|NCT01811459|Antipsychotics
1046667|NCT01811459|Haloperidol
1046668|NCT01811459|Quetiapine
1046669|NCT01811433|Postoperative Period
1046670|NCT01811433|Anesthesia Recovery Period
1046671|NCT01811433|Postoperative Complications
1046672|NCT01811433|Pulse Oximetry
1046673|NCT01811420|dental caries
1046674|NCT01811420|caries removal
1046675|NCT01811420|chemomechanical caries removal
1046676|NCT01811394|sacral chordoma
1046677|NCT01811394|chordoma
1046678|NCT01811394|carbon ion therapy
1046679|NCT01811394|proton therapy
1046680|NCT01811394|hypofractionation
1046681|NCT01811381|Alzheimer
1046682|NCT01811381|Prevention
1046683|NCT01811381|mild cognitive impairment
1046684|NCT01811381|physical exercise
1046685|NCT01811381|synergism
1046686|NCT01811381|curcumin
1046687|NCT01811381|dietary supplement
1046688|NCT01811381|anti-inflammatory
1046689|NCT01811381|anti-tau
1046690|NCT01811381|subjective memory complaints without MCI
1046691|NCT01811355|Muscle cramps
1046692|NCT01811355|Cramp
1046693|NCT01811355|ALS
1046694|NCT01811355|Amyotrophic Lateral Sclerosis
1046695|NCT01811355|Lou Gehrig's disease
1046696|NCT01811355|Motor Neuron Disease
1046697|NCT01811355|MND
1046698|NCT01811342|Hemoglobin
1046699|NCT01811342|Patient Monitoring
1046700|NCT01811277|palliative chemotherapy
1046701|NCT01811277|ORR
1046702|NCT01811277|PFS
1046703|NCT01811277|OS
1046704|NCT01811277|safety
1046705|NCT01811277|advanced Biliary Tract Carcinoma
1046706|NCT01811264|Metastatic
1046707|NCT01811264|Quality of life
1046708|NCT01811264|Decision making
1046709|NCT01811251|Co-analgesia
1046710|NCT01811251|Dexamethasone
1046711|NCT01811251|Pregabalin
1046712|NCT01811251|Lumbar slipped disc surgery
1046713|NCT01811251|Post-operative pain
1046714|NCT01811238|spinal disorders
1046718|NCT01811199|Thyroid cancer
1046719|NCT01811199|Breast cancer
1046720|NCT01811199|Dexamethasone
1046721|NCT01811199|Emesis
1046722|NCT01811186|moderate to severe non-malignant chronic pain
1046723|NCT01811173|multimorbidity
1046724|NCT01811173|primary care
1046725|NCT01811173|physician - nurse team
1046726|NCT01811173|proactive monitoring
1046727|NCT01811173|support for self-care
1046728|NCT01811173|primary caregiver
1046729|NCT01811160|Melatonin
1046730|NCT01811160|Second generation antipsychotic
1046731|NCT01811160|bipolar disorder
1046732|NCT01811160|schizophrenia
1046733|NCT01811160|Metabolic
1046734|NCT01811147|Bipolar
1046735|NCT01811147|Depression
1046736|NCT01811147|Mania
1046737|NCT01811147|Hypomania
1046738|NCT01811147|fMRI
1046739|NCT01811147|antidepressant
1046740|NCT01811134|endovascular procedure; flow diverter stent
1046741|NCT01811121|Glioblastoma
1046742|NCT01811121|5ALA
1046743|NCT01811121|fluorescence
1046744|NCT01811121|resection
1046745|NCT01811108|mCRC
1046746|NCT01811108|KRAS mutation
1046747|NCT01811108|Chemotherapy
1046748|NCT01811108|Anti-angiogenic agent
1046749|NCT01811108|Bevacizumab
1046750|NCT01811108|1st Line
1046751|NCT01811095|Robotics
1046752|NCT01811095|Computer-assisted surgery
1046753|NCT01811095|Computer simulation
1046754|NCT01811095|Gynecology
1046755|NCT01811095|General surgery
1046756|NCT01811069|Obese patients
1046757|NCT01811069|Upper airway patency
1046758|NCT01811056|medical abortion
1046759|NCT01811056|mifepristone
1046760|NCT01811043|breast biopsy
1046761|NCT01811043|anxiety
1046762|NCT01810978|congenital heart disease, probiotic, prebiotic
1046763|NCT01810965|Hemochromatosis type 1
1046764|NCT01810952|glucocorticoids
1046765|NCT01810952|hyperglycemia
1046766|NCT01810952|diabetes mellitus
1046767|NCT01810939|Chronic Kidney Disease
1046768|NCT01810939|Treatment of Hyperkalemia
1046769|NCT01810939|Hyperkalemia
1046770|NCT01810926|indication for HSCT
1046771|NCT01810926|matched related donor
1046772|NCT01810926|MRD
1046773|NCT01810926|Matched Unrelated Donor
1046774|NCT01810926|MUD
1046775|NCT01810900|anti-adhesive effect and safety, laparoscopic myomectomy
1046776|NCT01810887|Healthy
1046777|NCT01810887|Darunavir
1046778|NCT01810887|JNS011
1046779|NCT01810887|Ritonavir
1046780|NCT01810874|extraperitoneal
1046781|NCT01810874|transperitoneal
1046782|NCT01810874|laparoscopic aortic lymphadenectomy
1046783|NCT01810874|endometrial ovarian cancer
1046784|NCT01810874|ovarian cancer
1046785|NCT01810874|surgical staging
1046789|NCT01810848|Knee Osteoarthritis
1046790|NCT01810848|Osteoarthritis
1046791|NCT01810848|Synvisc
1046792|NCT01810848|Hylan G-F 20
1046793|NCT01810848|Exercise
1046794|NCT01810848|Cardiovascular risk
1046795|NCT01810848|Knee pain
1046796|NCT01810848|Pain
1046797|NCT01810835|HBV mother-to-child transmission
1046798|NCT01810835|women with HBV DNA > 105 I.U./mL
1046799|NCT01810835|France
1046800|NCT01810822|oxidative stress
1046801|NCT01810822|genetic susceptibility
1046802|NCT01810822|GPX4
1046803|NCT01810822|NOX2
1046804|NCT01810809|Osteoarthritis
1046805|NCT01810809|Hip
1046806|NCT01810809|Viscosupplementation
1046807|NCT01810809|Clinical Trial
1046808|NCT01810770|Radium-223 Dichloride
1046809|NCT01810770|Prostatic Neoplasms
1046810|NCT01810770|Bone Metastasis
1046811|NCT01810731|influenza vaccine immunogenicity
1046812|NCT01810731|HIV
1046813|NCT01810731|pregnancy
1046814|NCT01810731|influenza vaccine safety
1046815|NCT01810718|cGVHD
1046816|NCT01810718|steroid therapy
1046817|NCT01810718|Nilotinib
1046818|NCT01810718|cGVHD steroid refractory
1046819|NCT01810718|intolerant to steroid therapy
1046820|NCT01810718|Tasigna
1046821|NCT01810718|MTD
1046822|NCT01810705|myeloid
1046823|NCT01810705|leukemia
1046824|NCT01810679|aortic valve replacement
1046825|NCT01810679|aortic stenosis
1046826|NCT01810679|aortic steno-insufficiency
1046827|NCT01810679|Perceval
1046828|NCT01810679|Sutureless aortic heart valve
1046829|NCT01810653|Macrogol
1046830|NCT01810640|Liver biopsy
1046831|NCT01810640|organ donation
1046832|NCT01810640|donor management
1046833|NCT01810627|Prostate
1046834|NCT01810627|Cancer
1046835|NCT01810614|ADPKD
1046836|NCT01810614|PKD
1046837|NCT01810614|Kidney Disease
1046838|NCT01810614|ADPKD diet
1046839|NCT01810601|Embryo transfer, transabdominal ultrasound, IVF, ICSI
1046840|NCT01810588|Allogeneic transplant
1046841|NCT01810588|Hematologic Malignancies
1046842|NCT01810588|Acute Leukemia
1046843|NCT01810588|Myeloproliferative disorders
1046844|NCT01810588|Lymphoma
1046845|NCT01810588|Myeloma
1046846|NCT01810562|Stroke
1046847|NCT01810562|Tactile
1046848|NCT01810562|Sensibility
1046849|NCT01810562|Stimulation
1046850|NCT01810562|Extremities
1046851|NCT01810562|Arm
1046852|NCT01810562|Leg
1046853|NCT01810549|Fatigue
1046854|NCT01810536|Cystic fibrosis
1046855|NCT01810536|oxygen
1046856|NCT01810536|respiratory failure
1046857|NCT01810523|Acute
1046858|NCT01810523|lower
1046859|NCT01810523|extremity
1046860|NCT01810523|not requiring
1046861|NCT01810523|diagnostic
1046862|NCT01810523|imaging
1046863|NCT01810510|respiration, artificial
1046864|NCT01810497|External ear
1046865|NCT01810497|Ear abnormalities
1046866|NCT01810497|External ear cartilages
1046867|NCT01810484|Ulthera® System
1046868|NCT01810484|Ultherapy® Treatment
1046869|NCT01810484|Ulthera, Inc.
1046870|NCT01810484|Ultrasound treatment for skin
1046871|NCT01810458|Liver
1046872|NCT01810458|Fibrosis
1046873|NCT01810458|Alpha-1
1046874|NCT01810458|AAT
1046875|NCT01810458|AATD
1046876|NCT01810445|Bladder Cancer
1046877|NCT01810445|Laser
1046878|NCT01810445|Optical
1046879|NCT01810419|splenomegaly
1046880|NCT01810419|ultrasound
1046881|NCT01810419|Vscan
1046882|NCT01810367|PFS
1046883|NCT01810354|Cefazolin
1046884|NCT01810354|Tissue concentration
1046885|NCT01810354|infection
1046886|NCT01810354|cesarean section
1046887|NCT01810354|obese
1046888|NCT01810341|Autism
1046889|NCT01810341|Autism Spectrum Disorders
1046890|NCT01810341|RNA
1046891|NCT01810341|Gene expression
1046892|NCT01810341|Developmental Delay
1046893|NCT01810341|Metabolites
1046894|NCT01810341|DNA
1046895|NCT01810302|Vasospasm
1046896|NCT01810302|Subarachnoid hemorrhage
1046897|NCT01810302|Aneurysmal subarachnoid hemorrhage
1046898|NCT01810302|Nicardipine
1046899|NCT01810302|Intrathecal
1046900|NCT01810302|SAH
1046901|NCT01810302|aSAH
1046902|NCT01810289|HIV, ART, CD4
1046903|NCT01810276|traumatic head injury
1046904|NCT01810276|intracranial hemorrhage
1046905|NCT01810276|platelets
1046906|NCT01810276|anti-platelet therapy
1046907|NCT01810276|plavix
1046908|NCT01810276|asprin
1046909|NCT01810263|stroke
1046910|NCT01810263|malnutrition
1046911|NCT01810263|high protein
1046912|NCT01810211|Shoulder
1046913|NCT01810211|Surgery
1046914|NCT01810211|Posterior Shoulder Tightness
1046915|NCT01810211|Flexibility
1046916|NCT01810211|Range of Motion
1046917|NCT01810198|Coronary Artery Disease
1046918|NCT01810198|Cardiac CT
1046919|NCT01810198|Catheterization
1046920|NCT01810185|Inflammatory Bowel Disease
1046921|NCT01810185|Crohn's disease
1046922|NCT01810185|Ulcerative colitis
1046923|NCT01810185|Naltrexone
1046924|NCT01810185|Low Dose Naltrexone
1046925|NCT01810185|Inflammatory Bowel Disease Questionnaire
1046926|NCT01810172|lobectomy
1046927|NCT01810172|segmentectomy
1046928|NCT01810172|pneumothorax
1046929|NCT01810172|pleural
1046930|NCT01810172|digital
1046931|NCT01810172|air leak
1046932|NCT01810159|substance use disorders
1046933|NCT01810159|implementation science
1046934|NCT01810159|collaborative care
1046935|NCT01810159|opiate disorders
1046936|NCT01810159|alcohol disorders
1046937|NCT01810146|Patients eligible for bariatric surgery (BMI>40kg/m2)
1046938|NCT01810133|Comorbidity
1046939|NCT01810120|Hematologic
1046940|NCT01810120|Malignant
1046941|NCT01810120|Non-Malignant
1046942|NCT01810120|Allogeneic
1046943|NCT01810120|Transplant
1046944|NCT01810120|Non-Hodgkin Lymphoma
1046945|NCT01810120|Pediatric
1046946|NCT01810120|Acute lymphoblastic leukemia
1046947|NCT01810120|Acute Myeloid leukemia
1046948|NCT01810120|Myelodysplastic Syndromes
1046949|NCT01810120|T cells receptor alfa beta
1046950|NCT01810094|thoracolumbar fracture
1046951|NCT01810094|fixation
1046952|NCT01810094|fixateur interne
1046953|NCT01810094|minimal invasive
1046954|NCT01810094|percutaneous
1046955|NCT01810081|Cholelithiasis
1046956|NCT01810081|Gastric H.Pylori infection
1046957|NCT01810081|H.Pylori infection
1046958|NCT01810081|Gastric mucosa
1046959|NCT01810068|BPH- Erectile function- Transurethral- Laser
1046960|NCT01810042|age-related macular degeneration
1046961|NCT01810042|choroidal neovascularization
1046962|NCT01810042|ranibizumab
1046963|NCT01810042|indocyanine angiography
1046964|NCT01810029|transcendental meditation
1046965|NCT01810029|cardiac rehabilitation
1046966|NCT01810016|NY-ESO-1
1046967|NCT01810016|Metastatic Melanoma
1046968|NCT01810016|Ipilimumab
1046969|NCT01810016|Phase I
1046970|NCT01810016|Adjuvant
1046971|NCT01810016|Immunologic
1046972|NCT01810016|Vaccination
1046973|NCT01810016|Immunotherapy
1046974|NCT01810016|Neoplasm
1046975|NCT01810003|Cardiovascular disease
1046976|NCT01810003|Inflammation
1046977|NCT01810003|EPA/DHA supplementation
1046978|NCT01809990|cognitive behavior therapy
1046979|NCT01809990|pediatric obsessive-compulsive disorder
1046980|NCT01809990|internet-delivered cognitive behavior therapy
1046981|NCT01809977|Keratoconus
1046982|NCT01809977|remove
1046983|NCT01809977|cornea
1046984|NCT01809977|visual acuity
1046985|NCT01809938|Gastrointestinal tract emptying
1046986|NCT01809938|Pre-operative fasting
1046987|NCT01809938|Ultrasound
1046988|NCT01809938|Paracetamol Absorption
1046989|NCT01809912|solid tumor
1046990|NCT01809899|Trauma
1046991|NCT01809899|Abuse
1046992|NCT01809899|Domestic Violence
1046993|NCT01809899|Rape
1046994|NCT01809899|Assault
1046995|NCT01809899|MRI
1046996|NCT01809886|Neuromuscular relaxants
1046997|NCT01809886|short-term pediatric surgery
1046998|NCT01809886|reverses neuromuscular blockade
1046999|NCT01809873|Malaria
1047000|NCT01809873|Diagnostics
1047001|NCT01809873|Health Services
1047002|NCT01809860|isavuconazole
1047003|NCT01809860|sirolimus
1047004|NCT01809860|BAL8557
1047005|NCT01809860|Healthy Volunteers
1047006|NCT01809847|CLL
1047007|NCT01809847|Chronic Lymphatic Leukemia
1047008|NCT01809847|Leukemia
1047009|NCT01809847|HLA
1047010|NCT01809847|Histocompatibility
1047011|NCT01809847|HCT
1047012|NCT01809847|hematopoietic stem cell transplantation
1047013|NCT01809847|Ofatumumab
1047014|NCT01809847|CD20
1047015|NCT01809821|Hypertension
1047016|NCT01809821|Sleep Disorders
1047017|NCT01809821|Insomnia
1047018|NCT01809821|Cardiovascular Diseases
1047019|NCT01809821|Internet treatment
1047020|NCT01809808|Acromegaly
1047021|NCT01809808|Pituitary tumor
1047022|NCT01809795|Obesity
1047023|NCT01809795|Exercise
1047024|NCT01809795|Blueberry Plant
1047025|NCT01809743|Coronary artery disease
1047026|NCT01809743|Regadenoson
1047027|NCT01809743|Adenosine
1047028|NCT01809743|Maximal hyperemia
1047029|NCT01809743|Fractional flow reserve
1047030|NCT01809743|FFR
1047031|NCT01809691|Prostate cancer
1047032|NCT01809691|TAK-700
1047033|NCT01809691|Bicalutamide
1047034|NCT01809691|S1216
1047035|NCT01809691|androgen therapy
1047036|NCT01809691|Phase III
1047037|NCT01809678|Smoking
1047038|NCT01809678|Tobacco
1047039|NCT01809678|Yoga
1047040|NCT01809665|ICD therapy
1047041|NCT01809665|CRT-P therapy
1047042|NCT01809665|MRI
1047043|NCT01809652|Pacemaker
1047044|NCT01809652|Defibrillator
1047045|NCT01809652|Remote Consultation
1047046|NCT01809639|Concussion
1047047|NCT01809613|Parkinson disease
1047048|NCT01809613|Deep Brain Stimulation
1047049|NCT01809613|Functional Magnetic Resonance Imaging
1047050|NCT01809574|Interstitial lung disease
1047051|NCT01809574|Idiopathic pulmonary fibrosis
1047052|NCT01809574|Connective tissue disease
1047053|NCT01809561|endometriosis
1047054|NCT01809561|telomere
1047055|NCT01809561|telomerase
1047056|NCT01809548|complementary feeding
1047057|NCT01809548|premature infant
1047058|NCT01809548|body composition
1047059|NCT01809548|atopy
1047060|NCT01809548|neurodevelopmental outcome
1047061|NCT01809548|obesity
1047062|NCT01809535|endoscopic variceal ligation
1047063|NCT01809535|post-EVL ulcer
1047064|NCT01809535|variceal bleeding
1047065|NCT01809522|Robotic-assisted radical prostatectomy
1047066|NCT01809522|Urinary continence
1047067|NCT01809522|Posterior reconstruction of the rhabdosphincter
1047068|NCT01809522|Posterior musculofascial plate reconstruction
1047069|NCT01809509|CYTOKINES , IL11 IL6 IMLANTATION RATE IVF.
1047070|NCT01809496|hearing loss
1047071|NCT01809496|hearing aids
1047072|NCT01809496|spouses
1047073|NCT01809496|rehabilitation
1047074|NCT01809483|mechanical corneal erosion
1047075|NCT01809483|bandage contact lens
1047076|NCT01809483|pressure patching
1047077|NCT01809483|erosion area
1047078|NCT01809483|pain scale
1047079|NCT01809470|Blood pressure
1047080|NCT01809470|Appetite
1047081|NCT01809470|Heart rate
1047082|NCT01809470|Salivary cortisol
1047083|NCT01809457|educational poster, knowledge, dental trauma,
1047084|NCT01809431|gestational diabetes
1047085|NCT01809431|women
1047086|NCT01809431|infants
1047087|NCT01809431|blood glucose
1047088|NCT01809431|weight
1047089|NCT01809431|adiposity
1047090|NCT01809431|health behaviors
1047091|NCT01809431|self-efficacy
1047092|NCT01809392|Decitabine
1047093|NCT01809392|hematopoietic stem cell transplant
1047094|NCT01809392|Wilms' tumor 1
1047095|NCT01809392|cytolytic T lymphocyte
1047096|NCT01809392|Regulatory T cell
1047097|NCT01809379|ovarian cancer, recurrent, chemotherapy, intraperitoneal
1047098|NCT01809366|seminal plasma/uterine receptivity
1047099|NCT01809353|Healthy
1047100|NCT01809353|Japanese
1047101|NCT01809353|Caucasian
1047102|NCT01809353|Male
1047103|NCT01809353|Pharmacokinetic
1047104|NCT01809353|JNJ-54452840
1047105|NCT01809340|Depressive Disorder
1047106|NCT01809340|Major Depressive Disorder
1047107|NCT01809340|Depression
1047108|NCT01809340|Bipolar Disorder Type II
1047109|NCT01809340|Anti-depressant
1047110|NCT01809340|Ketamine
1047111|NCT01809340|Minocycline
1047112|NCT01809327|Diabetes Mellitus, Type 2
1047113|NCT01809327|Diabetes Mellitus
1047114|NCT01809327|Canagliflozin (JNJ-28431754)
1047115|NCT01809327|Metformin
1047116|NCT01809301|Bioavailability
1047117|NCT01809288|Women
1047118|NCT01809288|Diet
1047119|NCT01809288|Obesity
1047120|NCT01809288|African
1047121|NCT01809288|African Americans
1047122|NCT01809275|Crohn's Disease
1047123|NCT01809275|Inflammatory Bowel Disease
1047124|NCT01809275|CDAI
1047125|NCT01809249|Living donor liver transplantation
1047126|NCT01809249|Donar safety
1047127|NCT01809210|MEK1/2 inhibitor,
1047128|NCT01809210|Non Small Cell Lung Cancer,
1047129|NCT01809210|metastatic,
1047130|NCT01809210|first line treatment for Non Small Cell Lung Cancer
1047131|NCT01809197|Refractive error
1047132|NCT01809197|Myopia
1047133|NCT01809197|Hyperopia
1047134|NCT01809197|Astigmatism
1047135|NCT01809197|Presbyopia
1047136|NCT01809197|Contact lenses
1047137|NCT01809197|Contact lens solution
1047138|NCT01809197|Comfort
1047139|NCT01809145|sarcoidosis
1047140|NCT01809145|occupational exposure
1047141|NCT01809145|MELISA
1047142|NCT01809132|Hepatitis, alcoholic
1047143|NCT01809132|pentoxifylline
1047144|NCT01809132|zinc
1047145|NCT01809132|anakinra
1047146|NCT01809132|glucocorticoids
1047147|NCT01809132|MELD score
1047148|NCT01809132|Intestinal mucosa
1047149|NCT01809119|Kidney Neoplasms, Minimally invasive surgery, Renal cell carcinoma
1047150|NCT01809106|cancer pain
1047151|NCT01809106|major opioid
1047152|NCT01809106|analgesics
1047153|NCT01809093|PEDF
1047154|NCT01809093|TSP1
1047155|NCT01809093|Thrombospondin
1047156|NCT01809093|pigment epithelium derived factor
1047157|NCT01809093|Wills Eye Institute
1047158|NCT01809093|Pars plana vitrectomy
1047159|NCT01809093|Vitreous levels
1047160|NCT01809093|Mid Atlantic Retina
1047161|NCT01809093|Blood draw
1047162|NCT01809093|Blood test
1047163|NCT01809067|stress
1047164|NCT01809067|anxiety
1047165|NCT01809067|MRI
1047166|NCT01809067|aromatherapy
1047167|NCT01809054|Hip, Knee, Arthroplasty, venous thromboembolic events, blood loss
1047168|NCT01809028|cell block, number of passes
1047169|NCT01809015|Oral Anticoagulation
1047170|NCT01809015|Regular Medical Care
1047171|NCT01809015|Coagulation Service
1047172|NCT01809015|Vitamin-K Antagonists
1047173|NCT01809015|Quality of therapy
1047174|NCT01809015|Atrial fibrillation
1047175|NCT01809015|Venous thromboembolism
1047176|NCT01809015|Bypass surgery
1047177|NCT01809015|Prosthetic heart valve
1047178|NCT01808989|peripheral artery disease
1047179|NCT01808989|tcpo2
1047180|NCT01808989|treadmill walking test
1047181|NCT01808989|intermittent claudication
1047182|NCT01808963|Enthalpy
1047183|NCT01808963|Physiologic Monitors
1047184|NCT01808963|Critical Care Medicine
1047185|NCT01808924|aging
1047186|NCT01808924|insulin resistance
1047187|NCT01808924|diabetes
1047188|NCT01808924|sarcopenia in aging
1047189|NCT01808924|muscle mitochondria
1047190|NCT01808924|intramyocellular lipids
1047191|NCT01808911|Acquired haemophilia
1047192|NCT01808911|Comparative and randomized study
1047193|NCT01808911|Cyclophosphamide
1047194|NCT01808911|Rituximab
1047195|NCT01808898|Ablation
1047196|NCT01808898|Outpatient
1047197|NCT01808885|safety
1047198|NCT01808885|multiple sclerosis
1047199|NCT01808885|olesoxime
1047200|NCT01808885|double-blind
1047201|NCT01808885|randomized
1047202|NCT01808859|Total Knee Arthroplasty
1047203|NCT01808859|Thigh Tourniquet
1047204|NCT01808846|Obesity
1047205|NCT01808846|Insulin Resistance
1047206|NCT01808846|functional magnetic resonance imaging
1047207|NCT01808846|glucose
1047208|NCT01808846|fructose
1047209|NCT01808846|hypothalamus
1047210|NCT01808846|neuronal circuits
1047211|NCT01808846|feeding behavior
1047212|NCT01808833|Frailty
1047213|NCT01808833|Geriatric oncology
1047214|NCT01808820|Malignant Glioma
1047215|NCT01808820|Glioblastoma Multiforme
1047216|NCT01808820|Anaplastic Astrocytoma
1047217|NCT01808820|High Grade Glioma
1047218|NCT01808820|HGG
1047219|NCT01808820|Dendritic Cell Vaccine
1047220|NCT01808820|DC Vaccine
1047221|NCT01808820|Leukapheresis
1047222|NCT01808807|cesarean section rate
1047223|NCT01808807|the cesarean section rate audit
1047224|NCT01808794|membranes
1047225|NCT01808794|Mucograft
1047226|NCT01808794|Dynamatrixw
1047227|NCT01808794|ridge
1047228|NCT01808794|preservation
1047229|NCT01808794|bone
1047230|NCT01808794|allograft
1047231|NCT01808794|extraction
1047232|NCT01808794|site
1047233|NCT01808794|healing
1047234|NCT01808781|Power
1047235|NCT01808781|muscle strength
1047236|NCT01808781|total knee replacement
1047237|NCT01808781|physical activity behavior
1047238|NCT01808755|recurrent urinary tract infections
1047239|NCT01808755|D Mannose
1047240|NCT01808755|cystitis
1047241|NCT01808755|antibiotic treatment
1047242|NCT01808729|fibromuscular dysplasia
1047243|NCT01808729|coronary artery disease
1047244|NCT01808716|low-level laser therapy
1047245|NCT01808716|muscle damage
1047246|NCT01808703|Periodontitis
1047247|NCT01808703|Periodontal pocket
1047248|NCT01808703|Periodontal diseases
1047249|NCT01808690|Adolescent
1047250|NCT01808690|Youth
1047251|NCT01808690|Diabetes
1047252|NCT01808690|Insulin Resistance
1047253|NCT01808690|Cardiovascular
1047254|NCT01808690|Metformin
1047255|NCT01808677|Non-Small Cell Lung Cancer
1047256|NCT01808677|NSCLC
1047257|NCT01808677|Thoracic reirradiation
1047258|NCT01808677|Proton beam therapy
1047259|NCT01808677|PBT
1047260|NCT01808677|Intensity modulated radiation therapy
1047261|NCT01808677|IMRT
1047262|NCT01808677|Registry
1047263|NCT01808677|Data
1047264|NCT01808638|Adenocarcinoma
1047265|NCT01808638|Pancreas
1047266|NCT01808638|Gemcitabine
1047267|NCT01808638|Atu027
1047268|NCT01808625|BRAIN MALIGNANCIES , RADIATION THERAPY
1047269|NCT01808586|Neck
1047270|NCT01808586|chronic pain
1047271|NCT01808586|facet injection
1047272|NCT01808521|Purpura, Thrombotic Thrombocytopenic
1047273|NCT01808521|TTP
1047274|NCT01808508|Down syndrome
1047275|NCT01808508|Obstructive sleep apnea syndrome
1047276|NCT01808508|Continuous positive airway pressure
1047277|NCT01808508|sham or placebo CPAP
1047278|NCT01808495|Human corneal fibroblasts
1047279|NCT01808495|Fibulin-1
1047280|NCT01808495|Nuclear accumulation
1047281|NCT01808482|monoclonal antibody
1047282|NCT01808482|Multiple Sclerosis
1047283|NCT01808482|Interleukin-7 Receptor
1047284|NCT01808456|kidney transplant
1047285|NCT01808456|heart transplant
1047286|NCT01808456|lung transplant
1047287|NCT01808456|influenza vaccine
1047288|NCT01808443|cryotherapy
1047289|NCT01808443|laser
1047290|NCT01808443|cutaneous warts
1047291|NCT01808430|NSCLC
1047292|NCT01808404|Acceptance and Commitment Therapy
1047293|NCT01808404|Mindfulness
1047294|NCT01808404|Guided Self-Help
1047295|NCT01808404|College
1047296|NCT01808391|Coronary artery disease
1047297|NCT01808391|Heart disease
1047298|NCT01808391|Myocardial ischemia
1047299|NCT01808391|Cardiovascular disease
1047300|NCT01808391|Arteriosclerosis
1047301|NCT01808391|Vascular disease
1047302|NCT01808378|Bilateral limbic associated keratopathy
1047303|NCT01808378|Expanded Adipose Derived Stem Cells
1047304|NCT01808365|Philippines
1047305|NCT01808365|carriage
1047306|NCT01808365|Neisseria meningitidis
1047307|NCT01808365|meningococcus
1047308|NCT01808352|AE adverse event
1047309|NCT01808352|AIDS acquired immunodeficiency syndrome
1047310|NCT01808352|ALT (SGPT) alanine aminotransferase
1047311|NCT01808352|ART antiretroviral therapy
1047312|NCT01808352|AST (SGOT) aspartate aminotransferase
1047313|NCT01808352|DCF data collection forms
1047314|NCT01808352|DMC Data Monitoring Committee
1047315|NCT01808352|FDA (U.S.) Food and Drug Administration
1047316|NCT01808352|GCP Good Clinical Practice guidelines
1047317|NCT01808352|HB sAg Hepatitis B surface antigen
1047318|NCT01808352|ICH International Conference of Harmonisation
1047319|NCT01808352|IND Investigational New Drug Application
1047320|NCT01808352|IRB Institutional Review Board
1047321|NCT01808352|IU International units
1047322|NCT01808352|mg milligram(s)
1047323|NCT01808352|mm3 cubic millimeter(s)
1047324|NCT01808352|PCR polymerase chain reaction
1047325|NCT01808352|SAE serious adverse event
1047326|NCT01808352|µg microgram
1047327|NCT01808352|ULN upper limit of the normal range
1047328|NCT01808352|WB Western Blot
1047329|NCT01808339|Fluticasone Furoate, FF Inhalation Powder, morning dosing, evening dosing, efficacy, FEV1
1047330|NCT01808287|Transcatheter Aortic Valve Replacement
1047331|NCT01808287|Aortic Stenosis
1047332|NCT01808274|Transcatheter Aortic Valve Replacement
1047333|NCT01808274|Aortic Stenosis
1047334|NCT01808261|Ischemic Stroke
1047335|NCT01808248|HCV genotype 2 (GT-2)
1047336|NCT01808248|HCV genotype 3 (GT-3)
1047337|NCT01808248|HCV
1047338|NCT01808248|Sustained Virologic Response
1047339|NCT01808248|Direct Acting Antiviral
1047340|NCT01808248|Combination Therapy
1047341|NCT01808248|Treatment-Naïve
1047342|NCT01808248|GS-7977
1047343|NCT01808248|Ribavirin
1047344|NCT01808248|RBV
1047345|NCT01808248|Peginterferon Alfa 2a
1047346|NCT01808248|PEG
1047347|NCT01808248|Additional relevant MeSH terms:
1047348|NCT01808248|Hepatitis
1047349|NCT01808248|Hepatitis A
1047350|NCT01808248|Hepatitis, Chronic
1047351|NCT01808248|Hepatitis C
1047352|NCT01808248|Hepatitis C, Chronic
1047353|NCT01808248|Liver Diseases
1047354|NCT01808248|Digestive System Diseases
1047355|NCT01808248|Hepatitis, Viral, Human
1047356|NCT01808248|Virus Diseases
1047357|NCT01808248|Enterovirus Infections
1047358|NCT01808248|Picornaviridae Infections
1047359|NCT01808248|RNA Virus Infections
1047360|NCT01808248|Flaviviridae Infections
1047361|NCT01808248|Peginterferon alfa-2a
1047362|NCT01808248|Interferon-alpha
1047363|NCT01808248|Antiviral Agents
1047364|NCT01808248|Anti-Infective Agents
1047365|NCT01808248|Therapeutic Uses
1047366|NCT01808248|Pharmacologic Actions
1047367|NCT01808248|Antimetabolites
1047368|NCT01808248|Molecular Mechanisms of Pharmacological Action
1047369|NCT01808248|Immunologic Factors
1047370|NCT01808248|Physiological Effects of Drugs
1047371|NCT01808196|Eosinophilic Esophagitis
1047372|NCT01808196|Connective Tissue Disorders
1047373|NCT01808196|Drug trial
1047374|NCT01808183|supracondylar
1047375|NCT01808183|pediatric
1047376|NCT01808183|humerus
1047377|NCT01808183|NIRS
1047378|NCT01808183|near Infrared spectroscopy
1047379|NCT01808183|compartment perfusion
1047380|NCT01808170|Laparoscopy
1047381|NCT01808170|AMH
1047382|NCT01808170|AFC
1047383|NCT01808170|Endometrioma
1047384|NCT01808170|ovarian reserve
1047385|NCT01808170|Ovarian cystectomy
1047386|NCT01808170|ovarian cyst deroofing
1047387|NCT01808157|atopic dermatitis
1047388|NCT01808157|pruritus
1047389|NCT01808144|Gout
1047390|NCT01808131|Gout
1047391|NCT01808118|Musculoskeletal Diseases
1047392|NCT01808118|Joint Diseases
1047393|NCT01808118|Adalimumab
1047394|NCT01808118|Spondylarthropathy
1047395|NCT01808118|Arthritis
1047396|NCT01808118|Anti-Inflammatory Agents
1047397|NCT01808118|Spondyloarthritis
1047398|NCT01808118|Spinal Diseases
1047399|NCT01808118|Antirheumatic Agents
1047400|NCT01808118|Ankylosing Spondyloarthritis
1047401|NCT01808118|Spondylitis
1047402|NCT01808092|Ceftazidime,
1047403|NCT01808092|Meropenem,
1047404|NCT01808092|Anti-Bacterial Agents,
1047405|NCT01808092|Anti-Infective Agents,
1047406|NCT01808092|Therapeutic Uses,
1047407|NCT01808092|Pharmacologic Actions,
1047408|NCT01808092|Physiological Effects of Drugs
1047409|NCT01808040|breast cancer
1047410|NCT01808040|ER positive
1047411|NCT01808040|PR positive
1047412|NCT01808040|post menopausal
1047413|NCT01808027|quality of life drug adherence drug compliance mortality
1047414|NCT01808014|nefopam, spinal surgery, postoperative pain control
1047415|NCT01807988|Relapse, Recurrence, Depression, Internet, Sick-leave
1047416|NCT01807962|Injections, Subcutaneous
1047417|NCT01807962|Cortisone
1047418|NCT01807962|Anesthetics, Local
1047419|NCT01807936|Esophageal Neoplasms
1047420|NCT01807936|lymphadenectomy
1047421|NCT01807910|Obesity
1047422|NCT01807910|NAFLD
1047423|NCT01807910|NASH
1047424|NCT01807910|Steatosis
1047425|NCT01807897|Heart Failure
1047426|NCT01807897|Sleep Apnea
1047427|NCT01807897|Ventricular Ejection Fraction
1047428|NCT01807897|Exercise Test
1047429|NCT01807884|Microaspiration
1047430|NCT01807884|Ventilator acquired Pneumonia
1047431|NCT01807884|Amylase
1047432|NCT01807884|Mechanical ventilation
1047433|NCT01807884|Suction
1047434|NCT01807871|nicotine dependence
1047435|NCT01807871|smoking cessation
1047436|NCT01807871|lapse
1047437|NCT01807871|relapse
1047438|NCT01807871|tobacco
1047439|NCT01807871|nicotine patch
1047440|NCT01807871|nicotine replacement therapy
1047441|NCT01807871|NRT
1047442|NCT01807858|Necrotizing enterocolitis
1047443|NCT01807858|Sepsis
1047444|NCT01807858|Length of hospital stay
1047445|NCT01807858|Mortality
1047446|NCT01807845|Casein micelles
1047447|NCT01807845|vitamin D3 (cholecalciferol)
1047448|NCT01807845|Bioavailability
1047449|NCT01807845|Nanoencapsulation
1047450|NCT01807845|Nutrition
1047451|NCT01807832|chronic cough
1047452|NCT01807832|cough reflex hypersensitivity
1047453|NCT01807832|capsaicin
1047454|NCT01807819|Heart Failure
1047455|NCT01807819|Myocardial Strain
1047456|NCT01807819|Functional Capacity
1047457|NCT01807806|veterans, military, families
1047458|NCT01807793|Stroke
1047459|NCT01807793|TIA
1047460|NCT01807793|African American
1047461|NCT01807754|automated ultrasound imaging (AUS)
1047462|NCT01807754|digital breast tomosynthesis (DBT)
1047463|NCT01807754|photoacoustic imaging (PAT)
1047464|NCT01807741|Bipolar Disorder
1047465|NCT01807741|Depression
1047466|NCT01807728|Quality of life
1047467|NCT01807728|Participation
1047468|NCT01807728|Training
1047469|NCT01807715|first trimester
1047470|NCT01807715|surgical abortion
1047471|NCT01807715|contraception
1047472|NCT01807702|dichloroacetate
1047473|NCT01807702|pyruvate
1047474|NCT01807702|lactate
1047475|NCT01807702|pyruvate dehydrogenase
1047476|NCT01807689|Dry mouth
1047477|NCT01807689|Dry eyes
1047478|NCT01807689|Saliva
1047479|NCT01807689|Salivary gland biopsy
1047480|NCT01807663|neuromuscular disease
1047481|NCT01807650|Split-Thickness Skin Graft Donor Site
1047482|NCT01807650|Split-thickness skin graft
1047483|NCT01807650|STSG
1047484|NCT01807650|Wound healing
1047485|NCT01807650|Skin grafting
1047486|NCT01807650|Superficial wound
1047487|NCT01807650|Partial-thickness wound
1047488|NCT01807650|Time to wound closure
1047489|NCT01807624|Pharmacokinetic
1047490|NCT01807611|Haploidentical donor transplantation
1047491|NCT01807611|NK cell
1047492|NCT01807585|GSV
1047493|NCT01807559|Single Sided Deafness
1047494|NCT01807559|Conductive Hearing Loss
1047495|NCT01807559|Unilateral Hearing Loss
1047496|NCT01807559|SSD
1047497|NCT01807546|Head and neck cancer
1047498|NCT01807546|Platinum-resistant
1047499|NCT01807546|Squamous cell carcinoma
1047500|NCT01807533|Environment
1047501|NCT01807533|Gene
1047502|NCT01807533|Intervention
1047503|NCT01807533|Neurodevelopment
1047504|NCT01807533|Pathways
1047505|NCT01807533|Preterm infants
1047506|NCT01807520|Moderate nail psoriasis
1047507|NCT01807520|Severe nail psoriasis
1047508|NCT01807520|psoriasis
1047509|NCT01807520|Secukinumab
1047510|NCT01807507|Veins
1047511|NCT01807507|Vascular Access
1047512|NCT01807481|Mircera
1047513|NCT01807481|PD
1047514|NCT01807481|Maitenance
1047515|NCT01807468|haploidentical stem cell transplantation
1047516|NCT01807468|natural killer cell therapy
1047517|NCT01807468|pediatric solid tumor
1047518|NCT01807442|Acute Coronary Syndrome
1047519|NCT01807442|Positive Psychology
1047520|NCT01807442|Adherence to Health Behaviors
1047521|NCT01807429|Ketamine,
1047522|NCT01807429|Midazolam,
1047523|NCT01807429|Morphine,
1047524|NCT01807429|visual analogue score
1047525|NCT01807416|Osseointegrated Implant, Bone level
1047526|NCT01807403|Obsessive-Compulsive Disorder
1047527|NCT01807403|Deep brain stimulation
1047528|NCT01807403|Subthalamic nucleus
1047529|NCT01807403|Caudate nucleus
1047530|NCT01807403|Nucleus accumbens
1047531|NCT01807390|Minimally invasive surgery
1047532|NCT01807390|Patient perspectives
1047533|NCT01807390|Lung cancer
1047534|NCT01807390|Esophageal cancer
1047535|NCT01807390|Pain
1047536|NCT01807364|Congenital adrenal hyperplasia (CAH)
1047537|NCT01807364|Cardiovascular risk
1047538|NCT01807364|Microvascular dysfunction
1047539|NCT01807351|Diabetes Mellitus
1047540|NCT01807351|Hypertension
1047541|NCT01807351|Impaired Fasting Glucose
1047542|NCT01807351|Primary Health Care
1047543|NCT01807351|Chinese
1047544|NCT01807312|colonoscopy
1047545|NCT01807299|Physical Training
1047546|NCT01807299|ADHD-Attention deficit hyperactivity disorder
1047547|NCT01807299|Omega 3
1047548|NCT01807286|Myeloma
1047549|NCT01807286|Untreated Systemic AL Amyloidosis
1047550|NCT01807286|Amyloid light-chain (AL) amyloidosis
1047551|NCT01807286|Pomalidomide
1047552|NCT01807286|Melphalan
1047553|NCT01807286|Alkeran
1047554|NCT01807286|Dexamethasone
1047555|NCT01807286|Decadron
1047556|NCT01807286|Questionnaires
1047557|NCT01807286|Surveys
1047558|NCT01807273|hemiplegic
1047559|NCT01807273|time up and go test
1047560|NCT01807273|motion analysis
1047561|NCT01807273|center of mass
1047562|NCT01807247|Strengthening muscle
1047563|NCT01807247|Central nervous system diseases
1047564|NCT01807247|Gait
1047565|NCT01807221|Heart Decompensation
1047566|NCT01807208|Acute myocardial infarction
1047567|NCT01807208|patient education
1047568|NCT01807208|prevention
1047569|NCT01807195|contrast
1047570|NCT01807195|Intensive care unit
1047571|NCT01807195|Acute kidney injury
1047572|NCT01807169|colon
1047573|NCT01807169|endoscopy
1047574|NCT01807169|resection
1047575|NCT01807169|clopidogrel
1047576|NCT01807156|Tivozanib
1047577|NCT01807156|Advanced hepatocellular cancer
1047578|NCT01807156|Angiogenesis
1047579|NCT01807130|Heart Failure
1047580|NCT01807130|Medical Therapy
1047581|NCT01807130|ICD
1047582|NCT01807130|CRT
1047583|NCT01807104|Anterior Approach
1047584|NCT01807104|Posterior Approach
1047585|NCT01807078|Coronary artery disease
1047586|NCT01807039|hip fracture
1047587|NCT01807039|proximal femur
1047588|NCT01807039|pertrochanteric fracture
1047589|NCT01807039|subtrochanteric fracture
1047590|NCT01807039|subcapital fracture
1047591|NCT01807039|safety issue
1047592|NCT01807039|anesthesia
1047593|NCT01807013|cirrhosis
1047594|NCT01807013|liver
1047595|NCT01807013|elastometry
1047596|NCT01807013|ultrasound
1047597|NCT01807013|laparoscopy
1047598|NCT01807013|diagnosis
1047599|NCT01806987|school readiness
1047600|NCT01806987|literacy
1047601|NCT01806987|social emotional skills
1047602|NCT01806987|self regulation
1047603|NCT01806987|caregiver involvement
1047604|NCT01806987|socioeconomic disadvantage
1047605|NCT01806974|Periodontitis
1047606|NCT01806974|rheumatoid arthritis
1047607|NCT01806974|anti-interleukin 6
1047608|NCT01806974|immunotherapy
1047609|NCT01806974|inflammation
1047610|NCT01806974|bacteria
1047611|NCT01806974|periodontal sulci
1047612|NCT01806974|periodontal pockets
1047613|NCT01806935|associated
1047614|NCT01806935|aged population
1047615|NCT01806922|Yoga
1047616|NCT01806922|Stroke
1047617|NCT01806922|Standing balance
1047618|NCT01806922|Depression
1047621|NCT01806883|Hemiparesis,
1047622|NCT01806883|Rehabilitation,
1047623|NCT01806883|WII,
1047624|NCT01806883|Upper limb,
1047625|NCT01806883|Movement strategies.
1047626|NCT01806870|HIV
1047627|NCT01806870|ART
1047628|NCT01806857|Amyotrophic lateral sclerosis
1047629|NCT01806857|ALS
1047630|NCT01806857|Nuedexta
1047631|NCT01806857|Bulbar function
1047632|NCT01806857|motor neurons
1047633|NCT01806844|Cardiac arrest
1047634|NCT01806844|Cerebral oxygenation
1047635|NCT01806844|Pre-hospital
1047636|NCT01806805|Movement disorder
1047637|NCT01806805|Myoclonus dystonia
1047638|NCT01806805|DYT 11
1047639|NCT01806805|Antiepileptic drugs
1047640|NCT01806805|Zonisamide
1047641|NCT01806805|Clinical Trial
1047642|NCT01806805|Double-mind method
1047643|NCT01806792|Osteoporosis
1047644|NCT01806779|Nicotine addiction
1047645|NCT01806779|Cigarette smoking
1047646|NCT01806779|Smoking cessation
1047647|NCT01806779|Zyban
1047648|NCT01806779|Chantix
1047649|NCT01806779|Nicotine patches
1047650|NCT01806779|varenicline
1047651|NCT01806779|bupropion
1047652|NCT01806766|cementless total hip arthroplasty
1047653|NCT01806766|ceramic on ceramic bearing
1047654|NCT01806766|ceramic on highly cross linked polyethylene
1047655|NCT01806766|young patient
1047656|NCT01806753|Endoscopic submucosal dissection
1047657|NCT01806753|Sedation
1047658|NCT01806753|Propofol
1047659|NCT01806753|Midazolam
1047660|NCT01806740|DCE-MRI
1047661|NCT01806740|Sorafenib response
1047662|NCT01806727|Diabetes
1047663|NCT01806727|Diabetes Self Management
1047664|NCT01806727|LIFT Diabetes
1047665|NCT01806727|Weight Loss
1047666|NCT01806727|Diet
1047667|NCT01806727|Physical Activity
1047668|NCT01806727|Overweight
1047669|NCT01806727|Obese
1047670|NCT01806714|HPV vaccination
1047671|NCT01806714|Adolescent well care
1047672|NCT01806714|Adolescent HPV immunization
1047673|NCT01806714|HPV
1047674|NCT01806701|fMRI
1047675|NCT01806701|neuroimaging
1047676|NCT01806701|PTSD
1047677|NCT01806701|adolescent
1047678|NCT01806701|trauma
1047679|NCT01806701|brain
1047680|NCT01806688|satiety
1047681|NCT01806688|appetite
1047682|NCT01806688|snack
1047683|NCT01806662|Atopic Dermatitis
1047684|NCT01806662|Eczema
1047685|NCT01806649|esophageal cancer
1047686|NCT01806649|second line therapy
1047687|NCT01806649|BKM120
1047688|NCT01806636|Coil
1047689|NCT01806636|RePneu
1047690|NCT01806636|PneumRx
1047691|NCT01806636|LVRC
1047692|NCT01806610|Randomized
1047693|NCT01806610|Placebo-controlled trial
1047694|NCT01806610|BPS804
1047695|NCT01806610|Safety, tolerability, and PK
1047696|NCT01806610|Patients with late-stage chronic kidney disease.
1047697|NCT01806597|Moderate palmoplantar psoriasis
1047698|NCT01806597|Severe palmoplantar psoriasis
1047699|NCT01806597|psoriasis
1047700|NCT01806597|Secukinumab
1047701|NCT01806584|Vascular Injury
1047702|NCT01806584|Arteriovenous Graft Surgery
1047703|NCT01806584|Hemodialysis Access
1047704|NCT01806558|Breast cancer
1047705|NCT01806558|molecular breast imaging
1047706|NCT01806558|breast
1047707|NCT01806558|breast lesion
1047708|NCT01806545|Arteriovenous Fistula Surgery
1047709|NCT01806545|Vascular Injury
1047710|NCT01806545|Hemodialysis Access
1047711|NCT01806532|computed tomography and positron emission tomography
1047712|NCT01806532|respiration, artificial
1047713|NCT01806532|respiratory distress syndrome, adult
1047714|NCT01806519|neck pain
1047715|NCT01806519|motor control
1047716|NCT01806519|intervention
1047717|NCT01806519|forward head posture
1047718|NCT01806506|Bariatric surgery
1047719|NCT01806506|Gastric bypass
1047720|NCT01806506|Sleeve gastrectomy
1047721|NCT01806506|Weight loss
1047722|NCT01806506|Lipoproteins
1047723|NCT01806506|Insulin resistance
1047724|NCT01806506|Incretins
1047725|NCT01806506|Quality of life
1047726|NCT01806493|body composition
1047727|NCT01806493|obesity
1047728|NCT01806480|Breastfeeding, Preterm Infant, Neonatal Care, Support, Mothers.
1047729|NCT01806415|Fenobam,
1047730|NCT01806415|Pharmacokinetics
1047731|NCT01806415|side effects
1047732|NCT01806389|Breast milk
1047733|NCT01806389|Breastfeeding
1047734|NCT01806389|Lactation
1047735|NCT01806389|Buprenorphine
1047736|NCT01806389|Opioid
1047737|NCT01806363|Pharmacokinetics
1047738|NCT01806363|Safety
1047739|NCT01806363|Male
1047740|NCT01806350|Pelvic floor muscle training; incontinence; quality of life
1047741|NCT01806337|peripheral T cell lymphoma
1047742|NCT01806337|alemtuzumab
1047743|NCT01806337|consolidation
1047744|NCT01806311|Pharmacokinetics
1047745|NCT01806311|Safety
1047746|NCT01806311|Male
1047747|NCT01806298|Adult Growth hormone deficiency
1047748|NCT01806298|Saizen®
1047749|NCT01806298|Recombinant human growth hormone (r-hGH)
1047750|NCT01806298|Somatropin
1047751|NCT01806285|Respiratory Virus
1047752|NCT01806272|rhGM-CSF
1047753|NCT01806272|Oral Mucositis
1047754|NCT01806272|Primary Nasopharyngeal Cancers
1047755|NCT01806272|Chemoradiotherapy
1047756|NCT01806246|rehabilitation
1047757|NCT01806246|adolescent
1047758|NCT01806246|heart rate variability biofeedback
1047759|NCT01806246|psychoeducation
1047760|NCT01806220|Gastroesophageal Reflux Disease (GERD)
1047761|NCT01806220|Chronic Laryngitis
1047762|NCT01806220|Epidermal Growth factor receptor
1047763|NCT01806168|Post-traumatic stress disorder
1047764|NCT01806168|Repetitive transcranial magnetic stimulation
1047765|NCT01806168|Civilians
1047766|NCT01806168|Neurostimulation
1047767|NCT01806168|Dorsolateral prefrontal cortex
1047768|NCT01806155|craniotomy
1047769|NCT01806155|headache
1047770|NCT01806155|postoperative
1047771|NCT01806116|myelodysplastic syndrome
1047772|NCT01806116|higher-risk
1047773|NCT01806116|acute myeloid leukemia
1047774|NCT01806116|relapsed /refractory
1047775|NCT01806116|decitabine
1047776|NCT01806116|hematopoietic cell transplantation
1047777|NCT01806116|bridge therapy
1047778|NCT01806103|antimicrobial stewardship program
1047779|NCT01806103|inappropriate prescribing of antibiotics
1047780|NCT01806103|physician prescribing
1047781|NCT01806103|antibiotic prescribing for respiratory tract infections
1047782|NCT01806103|respiratory tract infections
1047783|NCT01806077|Cardiovascular Diseases
1047784|NCT01806077|Vascular Diseases
1047785|NCT01806077|Coronary Artery Disease
1047786|NCT01806077|Coronary Disease
1047787|NCT01806077|Arteriosclerosis
1047788|NCT01806077|Platelet Aggregation Inhibitors
1047789|NCT01806064|TRC105
1047790|NCT01806064|CD105
1047791|NCT01806064|RCC
1047792|NCT01806064|Renal Cell Carcinoma
1047793|NCT01806064|Axitinib
1047794|NCT01806064|INLYTA
1047795|NCT01806064|Advanced Renal Cell Carcinoma
1047796|NCT01806038|Adverse events
1047797|NCT01806038|Drug interactions
1047798|NCT01806038|Healthcare utilization
1047799|NCT01806038|Discharge medication counseling
1047800|NCT01806025|Cystic Fibrosis
1047801|NCT01806025|Haptoglobin
1047802|NCT01806012|Supracervical Hysterectomy
1047803|NCT01806012|Leiomyomas
1047804|NCT01806012|Adenomyosis
1047805|NCT01805999|Ispaghula
1047806|NCT01805999|Gastrointestinal physiology
1047807|NCT01805999|Gastrointestinal response to sugars
1047808|NCT01805999|MRI
1047809|NCT01805999|gastrointestinal
1047810|NCT01805999|stomach
1047811|NCT01805999|small bowel
1047812|NCT01805999|colon
1047813|NCT01805986|Multiple Sclerosis, other neurological conditions
1047814|NCT01805934|Helicobacter pylori, rescue, quadruple therapy，dual therapy
1047815|NCT01805921|Respiratory Syncytial Virus
1047816|NCT01805921|RSV
1047817|NCT01805921|Vaccine
1047818|NCT01805908|metastatic
1047819|NCT01805908|breast cancer
1047820|NCT01805908|herceptin
1047821|NCT01805908|imaging
1047822|NCT01805908|tumour response
1047823|NCT01805908|adenocarcinoma
1047824|NCT01805908|SPECT-CT
1047825|NCT01805908|pertuzumab
1047826|NCT01805908|trastuzumab
1047827|NCT01805908|locally advanced
1047828|NCT01805895|Stroke
1047829|NCT01805895|Acute Intracerebral Hemorrhage
1047830|NCT01805895|Intracerebral Hemorrhage
1047831|NCT01805895|Hemorrhagic stroke
1047832|NCT01805895|Hemorrhage
1047833|NCT01805895|Minocycline
1047834|NCT01805882|Interferon Sparing
1047835|NCT01805882|Directly Acting Antiviral
1047836|NCT01805882|Ribavarin Sparing
1047837|NCT01805869|Third Molar
1047838|NCT01805869|Specimen Acquisition
1047839|NCT01805856|antimicrobial prophylaxis
1047840|NCT01805856|AMP
1047841|NCT01805856|surgical site infection
1047842|NCT01805856|SSI
1047843|NCT01805856|thyroid
1047844|NCT01805856|thyroidectomy
1047845|NCT01805856|parathyroid
1047846|NCT01805856|surgery
1047847|NCT01805843|Pulmonary hypertension
1047848|NCT01805843|chronic myeloid leukemia
1047849|NCT01805843|dasatinib
1047850|NCT01805843|nilotinib
1047851|NCT01805830|Type2DM / DPP-IV inhibitors
1047852|NCT01805817|lipid profile
1047853|NCT01805817|bleeding scores
1047854|NCT01805817|menstrual pattern
1047855|NCT01805817|beneficial
1047856|NCT01805817|side effects
1047857|NCT01805817|changes in a year period
1047858|NCT01805804|dual chamber pacing, left ventricle remodeling, valsartan
1047859|NCT01805791|Ulcerative Colitis,
1047860|NCT01805791|UC
1047861|NCT01805791|Patients
1047862|NCT01805791|active
1047863|NCT01805791|mild
1047864|NCT01805791|moderate
1047865|NCT01805765|menopausal syndrome
1047866|NCT01805765|climacteric syndrome
1047867|NCT01805765|Hot flashes
1047868|NCT01805765|Sweat
1047869|NCT01805752|Prevention of mother to child HIV transmission
1047870|NCT01805752|HIV/AIDS
1047871|NCT01805739|transcatheter aortic valve implantation
1047872|NCT01805739|CT
1047873|NCT01805739|MRI
1047874|NCT01805739|angiography
1047875|NCT01805739|echocardiography
1047876|NCT01805739|rotational C-arm CT
1047877|NCT01805726|bronchoscopy
1047878|NCT01805726|sedation
1047879|NCT01805726|pulmonary function
1047880|NCT01805726|tolerance
1047881|NCT01805726|xylocain
1047882|NCT01805726|dexmedetomidine
1047883|NCT01805726|alfentanil
1047884|NCT01805713|Biomarkers
1047885|NCT01805700|type 1
1047886|NCT01805700|diabetes
1047887|NCT01805700|caffeine-enhanced energy drink
1047888|NCT01805700|cardiac output
1047889|NCT01805700|glucose
1047890|NCT01805700|cognitive performance
1047891|NCT01805674|menopause
1047892|NCT01805674|quality of life
1047893|NCT01805674|soy isoflavones
1047894|NCT01805674|magnolia extract
1047895|NCT01805661|early ambulation
1047896|NCT01805661|knee arthroplasty
1047897|NCT01805648|ITP
1047898|NCT01805648|rhTPO
1047899|NCT01805635|Children
1047900|NCT01805635|Asthma
1047901|NCT01805635|Allergic rhinitis
1047902|NCT01805635|Atopic dermatitis
1047903|NCT01805635|Urticaria
1047904|NCT01805635|Healthy
1047905|NCT01805622|community-based participatory research
1047906|NCT01805622|colorectal cancer screening
1047907|NCT01805609|practice nurse
1047908|NCT01805609|clinical Nurse
1047909|NCT01805609|inpatient staff
1047910|NCT01805609|inpatient social worker
1047911|NCT01805609|didactic training sessions
1047912|NCT01805609|13-030
1047913|NCT01805596|coronary artery disease
1047914|NCT01805596|endothelial function
1047915|NCT01805596|antiplatelet agent
1047916|NCT01805570|platelet inhibitor
1047917|NCT01805570|ST-segment Elevation
1047918|NCT01805570|Myocardial Infarction
1047919|NCT01805570|stent
1047920|NCT01805570|prasugrel
1047921|NCT01805570|ticagrelor
1047922|NCT01805557|Diffuse Large B-cell Lymphoma (DLBCL)
1047923|NCT01805557|Bortezomib
1047924|NCT01805544|SF36 questionnaire
1047925|NCT01805544|Anti Clot Treatment Scale
1047926|NCT01805544|Satisfaction
1047927|NCT01805544|Quality of Life
1047928|NCT01805544|Rivaroxaban
1047929|NCT01805544|Prevention & control
1047930|NCT01805544|Pulmonary embolism
1047931|NCT01805531|SF36 questionnaire
1047932|NCT01805531|Anti Clot Treatment Scale
1047933|NCT01805531|Satisfaction
1047934|NCT01805531|Quality of Life
1047935|NCT01805531|Rivaroxaban
1047936|NCT01805531|Stroke prevention
1047937|NCT01805518|CNSVS
1047938|NCT01805518|Tower of London
1047939|NCT01805518|Letter-Number Test
1047940|NCT01805518|Trail Making Test
1047941|NCT01805518|Vital signs
1047942|NCT01805518|Mood
1047943|NCT01805518|Suicidal ideation
1047944|NCT01805518|ECG
1047945|NCT01805518|Physical exam
1047946|NCT01805518|Blood
1047947|NCT01805518|Urine (Including pregnancy and drug screen)
1047948|NCT01805518|Cytokines
1047949|NCT01805518|Side effects
1047950|NCT01805518|Brief Psychiatric Rating Scale
1047951|NCT01805518|Positive and Negative Symptom Scale
1047952|NCT01805505|Female infertility
1047953|NCT01805505|Oocyte donation
1047954|NCT01805505|Embryo transfer
1047955|NCT01805505|Transvaginal ultrasonography
1047956|NCT01805505|Transabdominal ultrasonography
1047957|NCT01805492|Heart diseases
1047958|NCT01805492|Cardiovascular diseases
1047959|NCT01805492|Lifestyle modification
1047960|NCT01805492|Diet
1047961|NCT01805492|Exercise
1047962|NCT01805479|exercise
1047963|NCT01805479|depression
1047964|NCT01805479|traumatic brain injury
1047965|NCT01805466|Extracorporeal Vacuum Assisted Device Optimised (EVADO)
1047966|NCT01805453|Glioblastoma
1047967|NCT01805453|Angiotensin-II inhibitors
1047968|NCT01805453|Losartan
1047969|NCT01805453|steroids
1047970|NCT01805453|Radiotherapy
1047971|NCT01805453|Edema
1047972|NCT01805453|Randomized trial
1047973|NCT01805440|Adolescent
1047974|NCT01805440|Bipolar Disorder
1047975|NCT01805440|Bipolar Depression
1047976|NCT01805440|Manic Depression
1047977|NCT01805440|Neuroimaging
1047978|NCT01805440|Magnetic Resonance Spectroscopy
1047979|NCT01805440|Uridine
1047980|NCT01805440|Pyrimidines
1047981|NCT01805427|trough concentration
1047982|NCT01805427|weight
1047983|NCT01805427|HIV
1047984|NCT01805427|virological failure
1047985|NCT01805414|inpatient diabetes
1047986|NCT01805414|inpatient diabetes nutrition
1047987|NCT01805401|Decision-making
1047988|NCT01805401|Impulse control
1047989|NCT01805401|Transcranial direct current stimulation
1047990|NCT01805401|Brain stimulation
1047991|NCT01805401|Neuromodulation
1047992|NCT01805401|tDCS
1047993|NCT01805401|Iowa Gambling Task
1047994|NCT01805401|Stroop Word-Color Task
1047995|NCT01805388|Dental Pulp Regeneration
1047996|NCT01805375|Phase I, Cancer, CD19 positive, B-Cell lymphoma, chronic lymphocytic leukaemia
1047997|NCT01805375|Waldenström Macroglobulinaemia
1047998|NCT01805336|Relapsing-Remitting MS
1047999|NCT01805336|cognitive impairment
1048000|NCT01805336|virtual reality
1048001|NCT01805310|Pelvic organ prolapse
1048002|NCT01805310|Prolapse
1048003|NCT01805310|Cathartics
1048004|NCT01805310|Mechanical bowel preparation
1048005|NCT01805297|Proliferative Diabetic Retinopathy
1048006|NCT01805284|pneumonia
1048007|NCT01805271|ER-positive HER2-negative
1048008|NCT01805258|India
1048009|NCT01805258|Nevirapine
1048010|NCT01805258|Rifampicin
1048011|NCT01805258|Efavirenz
1048012|NCT01805258|HIV
1048013|NCT01805258|TB
1048014|NCT01805232|severe
1048015|NCT01805232|Falciaparum
1048016|NCT01805232|Malaria
1048017|NCT01805206|Prematurity
1048018|NCT01805206|Necrotizing Enterocolitis
1048019|NCT01805206|Biomarkers
1048020|NCT01805206|Intestinal Fatty Acid Binding Protein
1048021|NCT01805206|Feeding
1048022|NCT01805193|Coronary heart disease
1048023|NCT01805193|computed tomography myocardial perfusion
1048024|NCT01805193|positron emission tomography
1048025|NCT01805193|oxygen 15 labelled water
1048026|NCT01805193|myocardial perfusion
1048027|NCT01805193|myocardial blood flow
1048028|NCT01805167|Subject with cochlear implant
1048029|NCT01805141|Cervix Uteri
1048030|NCT01805128|Schizophrenia
1048031|NCT01805128|Autistic Disorder
1048032|NCT01805128|social cognition
1048033|NCT01805115|hysteroscopy
1048034|NCT01805115|misoprostol
1048035|NCT01805102|In vitro fertilization
1048036|NCT01805102|implantation
1048037|NCT01805102|miscarriage
1048038|NCT01805102|live birth
1048039|NCT01805063|firefighters
1048040|NCT01805063|myocardial infarction
1048041|NCT01805063|endothelial function
1048042|NCT01805063|thrombosis
1048043|NCT01805063|fire suppression
1048044|NCT01805063|non-fire emergency duty
1048045|NCT01805063|sedentary shift
1048046|NCT01805050|HAGL
1048047|NCT01805050|Shoulder instability
1048048|NCT01804998|laparoscopic sentinel lymph node biopsy
1048049|NCT01804998|phase 3
1048050|NCT01804998|early gastric cancer
1048051|NCT01804972|Patient information
1048052|NCT01804972|Vascular disease
1048053|NCT01804972|Abdominal aortic aneurysm
1048054|NCT01804972|Varicose veins
1048055|NCT01804972|Web based information
1048056|NCT01804933|profound muscle relaxation
1048057|NCT01804933|muscle trauma
1048058|NCT01804933|postoperative analgesic demand
1048059|NCT01804933|postoperative pulmonary function
1048060|NCT01804907|HAART adherence
1048061|NCT01804907|HIV
1048062|NCT01804907|Fatigue
1048063|NCT01804907|treatment
1048064|NCT01804868|case vignette
1048065|NCT01804868|nurse
1048066|NCT01804868|critical assessment
1048067|NCT01804868|randomized controlled trial
1048068|NCT01804855|Obesity; mobile health; telemedicine; family-based treatment
1048069|NCT01804829|HCV Liver Transplant Immunoglobulin PCR SVR
1048070|NCT01804816|Chronic Heart Failure
1048071|NCT01804816|Heart Failure
1048072|NCT01804803|glycated hemoglobin
1048073|NCT01804803|hyperglycemia
1048074|NCT01804803|hypoglycemia
1048075|NCT01804803|insulin
1048076|NCT01804803|self-monitoring of blood glucose
1048077|NCT01804803|telemedicine
1048078|NCT01804790|rectum
1048079|NCT01804790|cancer
1048080|NCT01804790|locally advanced
1048081|NCT01804777|ENaC
1048082|NCT01804777|Amiloride
1048083|NCT01804777|Hydrochlorothiazide(HCTZ)
1048084|NCT01804777|Hypertension
1048085|NCT01804777|Type II Diabetes
1048086|NCT01804777|Natriuresis
1048087|NCT01804777|Proteinuria
1048088|NCT01804764|Severe Sepsis
1048089|NCT01804764|Septic Shock
1048090|NCT01804764|Sepsis Six bundle
1048091|NCT01804738|Ethnic differences
1048092|NCT01804738|Inter-individual variability
1048093|NCT01804738|Glycemic response
1048094|NCT01804738|Insulin response
1048095|NCT01804738|Mastication
1048096|NCT01804738|Salivary alpha-amylase
1048097|NCT01804738|Gastric emptying
1048098|NCT01804738|Metagenome
1048099|NCT01804725|bike seats
1048100|NCT01804725|Erectile dysfunction
1048101|NCT01804725|Perineum
1048102|NCT01804725|Impotence
1048103|NCT01804712|Prostate
1048104|NCT01804712|Cancer
1048105|NCT01804712|Castration-resistant
1048106|NCT01804712|Rituximab
1048107|NCT01804712|neoadjuvant
1048108|NCT01804712|Rituxan
1048109|NCT01804699|ARVC, Cardiomyopathy
1048110|NCT01804686|Chronic lymphocytic leukemia
1048111|NCT01804686|Small lymphocytic lymphoma
1048112|NCT01804686|Mantle cell lymphoma
1048113|NCT01804686|Follicular lymphoma
1048114|NCT01804686|Diffuse large B-cell lymphoma
1048115|NCT01804686|PCI-32765
1048116|NCT01804686|Ibrutinib
1048117|NCT01804686|Bruton's tyrosine kinase inhibitor
1048118|NCT01804686|IMBRUVICA
1048119|NCT01804686|JNJ-54179060
1048120|NCT01804673|Postoperative Pain
1048121|NCT01804673|Fentanyl Hydrochloride
1048122|NCT01804673|IONSYS
1048123|NCT01804660|Multiple Sclerosis (MS)
1048124|NCT01804660|Multiple Sclerosis associated RetroVirus (MSRV)
1048125|NCT01804660|MSRV envelop protein (MSRV-Env)
1048126|NCT01804647|Multiple sclerosis (MS)
1048127|NCT01804647|Relapsing-Remitting MS
1048128|NCT01804647|Primary progressive MS
1048129|NCT01804647|Secondary progressive MS
1048130|NCT01804647|Clinically Isolated Syndrome (CIS)
1048131|NCT01804647|Multiple Sclerosis associated RetroVirus (MSRV)
1048132|NCT01804647|MSRV envelop protein (MSRV-Env)
1048133|NCT01804634|Solid Tumors
1048134|NCT01804634|Neuroblastoma
1048135|NCT01804634|Osteosarcoma
1048136|NCT01804634|Ewing Sarcoma
1048137|NCT01804634|Rhabdomyosarcoma
1048138|NCT01804634|Hepatoblastoma
1048139|NCT01804634|Melanoma
1048140|NCT01804634|Desmoplastic Round Cell Tumor
1048141|NCT01804634|brain tumors
1048142|NCT01804621|Exercise
1048143|NCT01804621|Nutrition
1048144|NCT01804621|Mammography
1048145|NCT01804621|Colorectal screening
1048146|NCT01804595|Worksite intervention
1048147|NCT01804595|Sun protection intervention
1048148|NCT01804595|Operating Engineers
1048149|NCT01804582|Family navigator
1048150|NCT01804582|Patient Centered Outcomes
1048151|NCT01804582|Pediatric Antipsychotic treatment
1048152|NCT01804556|muscle cramps, trigger points, sleep disturbance
1048153|NCT01804530|solid tumors
1048154|NCT01804530|activating NTRK point or fusion mutations
1048155|NCT01804530|Tenosynovial giant cell tumor
1048156|NCT01804530|TGCT
1048157|NCT01804517|migraine
1048158|NCT01804504|Metabolic syndrome
1048159|NCT01804504|Eating out of home
1048160|NCT01804504|Nutrition education
1048161|NCT01804465|castration resistant
1048162|NCT01804465|prostate
1048163|NCT01804465|cancer
1048164|NCT01804465|ipilimumab
1048165|NCT01804465|provenge
1048166|NCT01804465|SipT
1048167|NCT01804452|Progressive Supranuclear Palsy
1048168|NCT01804452|Corticobasal Degeneration
1048169|NCT01804452|Biomarker
1048170|NCT01804452|Neuroimaging
1048171|NCT01804452|MRI
1048172|NCT01804452|Tau
1048173|NCT01804452|Oculomotor
1048174|NCT01804439|Heart diseases
1048175|NCT01804439|Cardiovascular diseases
1048176|NCT01804439|Coronary heart disease not otherwise specified
1048177|NCT01804439|Cerebrovascular disorders
1048178|NCT01804439|Brain diseases
1048179|NCT01804439|Central nervous system diseases
1048180|NCT01804439|Nervous system diseases
1048181|NCT01804439|Atherosclerosis
1048182|NCT01804439|Arteriosclerosis
1048183|NCT01804439|Pathologic processes
1048184|NCT01804439|Acute myocardial infarction
1048185|NCT01804439|Myocardial infarction
1048186|NCT01804439|Myocardial ischemia
1048187|NCT01804439|Infarction
1048188|NCT01804439|Necrosis
1048189|NCT01804439|Unstable angina
1048190|NCT01804439|Chronic stable angina
1048191|NCT01804439|Stable angina
1048192|NCT01804439|Angina pectoris
1048193|NCT01804439|Chest pain
1048194|NCT01804439|Pain
1048195|NCT01804439|Signs and symptoms
1048196|NCT01804439|Ischemia
1048197|NCT01804439|Ischemic stroke
1048198|NCT01804439|Hemorrhagic stroke
1048199|NCT01804439|Stroke
1048200|NCT01804439|Subarachnoid hemorrhage
1048201|NCT01804439|Transient ischemic attack
1048202|NCT01804439|Abdominal aortic aneurysm
1048203|NCT01804439|Aneurysm
1048204|NCT01804439|Aortic aneurysm
1048205|NCT01804439|Aortic aneurysm, abdominal
1048206|NCT01804439|Aortic diseases
1048207|NCT01804439|Peripheral arterial diseases
1048208|NCT01804439|Peripheral vascular diseases
1048209|NCT01804439|Vascular diseases
1048210|NCT01804439|Peripheral occlusive diseases
1048211|NCT01804439|Sudden coronary death
1048212|NCT01804439|Ventricular arrhythmia
1048213|NCT01804439|Sudden cardiac death
1048214|NCT01804439|Cardiac arrest
1048215|NCT01804439|Heart failure
1048216|NCT01804426|PTSD
1048217|NCT01804426|Post Traumatic Stress Disorder
1048218|NCT01804426|Cortisol
1048219|NCT01804426|Alpha-Amylase
1048220|NCT01804426|bio-Markers
1048221|NCT01804413|Pegvisomant
1048222|NCT01804413|Growth hormone
1048223|NCT01804413|Cortisol
1048224|NCT01804413|Glucagon
1048225|NCT01804413|Insulin
1048226|NCT01804387|Chronic Hepatitis B
1048227|NCT01804387|Telbivudine
1048228|NCT01804387|Adefovir
1048229|NCT01804387|Lamivudine resistance
1048230|NCT01804374|osteosarcoma
1048231|NCT01804374|sorafenib
1048232|NCT01804374|everolimus
1048233|NCT01804374|sarcoma
1048234|NCT01804361|Dry Eye Syndromes
1048235|NCT01804348|PROM
1048236|NCT01804335|Lymphoma
1048237|NCT01804335|Early Stage Cutaneous T-Cell Lymphoma
1048238|NCT01804335|CTCL
1048239|NCT01804335|CD5789 0.01% cream
1048240|NCT01804322|epilepsy
1048241|NCT01804322|chronic comorbidities
1048242|NCT01804322|educational strategies
1048243|NCT01804322|drug interactions
1048244|NCT01804322|drug adverse effects
1048245|NCT01804309|axyllary lymph node
1048246|NCT01804309|sentinel lymph node
1048247|NCT01804309|lymphatic drainage
1048248|NCT01804309|early breast cancer
1048249|NCT01804309|axillary lymph node dissection
1048250|NCT01804296|Teen
1048251|NCT01804296|Adolescent
1048252|NCT01804296|Depression
1048253|NCT01804296|Transcranial Magnetic Stimulation
1048254|NCT01804296|TMS
1048255|NCT01804270|Teen
1048256|NCT01804270|Adolescent
1048257|NCT01804270|Depression
1048258|NCT01804270|Transcranial Magnetic Stimulation
1048259|NCT01804270|TMS
1048260|NCT01804257|Adherence
1048261|NCT01804257|Bipolar disorder
1048262|NCT01804257|Cellular phone
1048263|NCT01804257|Cloud computing
1048264|NCT01804257|Computers
1048265|NCT01804257|Computers, handheld
1048266|NCT01804257|Digital health
1048267|NCT01804257|Digital health feedback system
1048268|NCT01804257|Ingestion Sensor
1048269|NCT01804257|Medication adherence
1048270|NCT01804257|Medication non-adherence
1048271|NCT01804257|Medication nonadherence
1048272|NCT01804257|Mobile phone
1048273|NCT01804257|Mobile health
1048274|NCT01804257|Patient adherence
1048275|NCT01804257|Patient non-adherence
1048276|NCT01804257|Patient nonadherence
1048277|NCT01804257|Schizophrenia
1048278|NCT01804257|Telehealth
1048279|NCT01804257|Telemedicine
1048280|NCT01804257|Telenursing
1048281|NCT01804257|Wearable sensor
1048282|NCT01804244|Healthy
1048283|NCT01804244|Pharmacokinetics
1048284|NCT01804244|Japanese
1048285|NCT01804231|Prostate Cancer
1048286|NCT01804231|PET
1048287|NCT01804231|MRI
1048288|NCT01804231|Hybrid
1048289|NCT01804231|Recurrence
1048290|NCT01804231|Fluorocholine
1048291|NCT01804205|magnesium sulfate
1048292|NCT01804205|rocuronium
1048293|NCT01804205|neuromuscular block
1048294|NCT01804205|onset time
1048295|NCT01804205|elderly
1048296|NCT01804192|Acu-TENS
1048297|NCT01804192|MAP
1048298|NCT01804192|HR
1048299|NCT01804192|HRV
1048300|NCT01804179|colon
1048301|NCT01804179|rectum
1048302|NCT01804179|cancer
1048303|NCT01804179|screening
1048304|NCT01804179|questionnaire
1048305|NCT01804179|testing
1048306|NCT01804179|educational materials
1048307|NCT01804166|Lymphoma, T-Cell, Peripheral, Infliximab, Golimumab, Remicade, Simponi, Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease
1048308|NCT01804153|Feminine stress urinary incontinence
1048309|NCT01804153|Autologous expanded stem cells
1048310|NCT01804127|DLBCL
1048311|NCT01804127|R-CHOP
1048312|NCT01804127|PET/CT
1048313|NCT01804088|Peripheral artery disease
1048314|NCT01804088|Iliac arteries
1048315|NCT01804088|Balloon-expandable stent
1048316|NCT01804075|NAS
1048317|NCT01804075|NICU
1048318|NCT01804075|EMMC
1048319|NCT01804049|metformin
1048320|NCT01804049|muscle
1048321|NCT01804049|insulin resistance
1048322|NCT01804049|sarcopenia
1048323|NCT01804049|older adults
1048324|NCT01804049|impaired fasting glucose
1048325|NCT01803997|Child
1048326|NCT01803997|Nutrition
1048327|NCT01803997|resonance Raman spectroscopy
1048328|NCT01803997|Fruit & Vegetable
1048329|NCT01803997|Children Cooking
1048330|NCT01803984|Migraine
1048331|NCT01803984|Brain structure
1048332|NCT01803984|MRI
1048333|NCT01803971|cardiac arrest
1048334|NCT01803971|peripheral venous access
1048335|NCT01803971|intraosseous access
1048336|NCT01803945|Parkinson's disease
1048337|NCT01803945|cognitive impairment
1048338|NCT01803945|movement disorder
1048339|NCT01803932|intimate partner violence
1048340|NCT01803932|gender
1048341|NCT01803932|primary prevention intervention
1048342|NCT01803932|conflict
1048343|NCT01803932|Cote d'Ivoire
1048344|NCT01803932|Ivory Coast
1048345|NCT01803919|Spinal cord injuries
1048346|NCT01803919|Urinary tract infection
1048347|NCT01803919|Urinary catheters
1048348|NCT01803919|Protocol
1048349|NCT01803919|Randomized clinical trial
1048350|NCT01803906|mitochondrial disorder
1048351|NCT01803906|mitochondria
1048352|NCT01803906|oxidative phosphorylation
1048353|NCT01803906|oxidative phosphorylation disorders
1048354|NCT01803906|respiratory chain disorders
1048355|NCT01803906|mitochondrial disease
1048356|NCT01803906|melas
1048357|NCT01803906|kearns sayer
1048358|NCT01803906|NARP
1048359|NCT01803906|MNGIE
1048360|NCT01803906|LHON
1048361|NCT01803906|Mitochondrial depletion syndrome
1048362|NCT01803906|Leigh's disease
1048363|NCT01803893|In vitro fertilization
1048364|NCT01803893|implantation
1048365|NCT01803893|miscarriage
1048366|NCT01803893|live birth
1048367|NCT01803880|Articular cartilage
1048368|NCT01803880|Cartilage lesion
1048369|NCT01803880|Cartilage defect
1048370|NCT01803880|Radiofrequency
1048371|NCT01803880|Debridement
1048372|NCT01803880|Cartilage
1048373|NCT01803880|Coblation
1048374|NCT01803880|Knee
1048375|NCT01803880|Meniscus
1048376|NCT01803880|Meniscectomy
1048377|NCT01803880|MR imaging
1048378|NCT01803880|Mechanical debridement
1048379|NCT01803880|Mechanical shaver
1048380|NCT01803880|Torn meniscus
1048381|NCT01803880|Arthroscopic knee surgery
1048382|NCT01803880|Damaged cartilage
1048383|NCT01803867|MS
1048384|NCT01803867|Multiple Sclerosis
1048385|NCT01803841|Coronary artery disease
1048386|NCT01803828|Diabetic Cardiomyopathy
1048387|NCT01803828|Genders
1048388|NCT01803828|Phosphodiesterase 5A inhibitors
1048389|NCT01803828|miRNAs
1048390|NCT01803828|Chemokines
1048391|NCT01803815|obstructive sleep apnea
1048392|NCT01803815|hypertension
1048393|NCT01803815|antihypertensive drugs
1048394|NCT01803802|childhood sexual abuse
1048395|NCT01803802|depression
1048396|NCT01803802|PTSD
1048397|NCT01803802|sexual function
1048398|NCT01803802|women
1048399|NCT01803789|Metacarpal V Fractures
1048400|NCT01803789|Single Kirschner Wires
1048401|NCT01803789|Double Kirschner Wires
1048402|NCT01803776|child
1048403|NCT01803776|physical activity
1048404|NCT01803776|sedentary activity
1048405|NCT01803776|nutrition
1048406|NCT01803776|diet
1048407|NCT01803776|body composition
1048408|NCT01803776|overweight
1048409|NCT01803776|obesity
1048410|NCT01803776|glucose metabolism disorders
1048411|NCT01803776|lipid metabolism disorders
1048412|NCT01803776|physical fitness
1048413|NCT01803776|cardiovascular system
1048414|NCT01803776|musculoskeletal system
1048415|NCT01803776|bone mineral density
1048416|NCT01803776|oral health
1048417|NCT01803776|quality of life
1048418|NCT01803776|wellbeing
1048419|NCT01803776|gene-lifestyle interaction
1048420|NCT01803776|health economics
1048421|NCT01803763|Omalizumab
1048422|NCT01803763|Xolair
1048423|NCT01803763|Urticaria
1048424|NCT01803763|basophils
1048425|NCT01803763|chronic Urticaria
1048426|NCT01803763|Fc Receptor
1048427|NCT01803750|Primary Care Providers
1048428|NCT01803750|Latino Populations
1048429|NCT01803750|Disseminate Cancer Prevention
1048430|NCT01803750|semi-structured interviews
1048431|NCT01803750|13-031
1048432|NCT01803737|Weight Loss
1048433|NCT01803737|Physical Activity
1048434|NCT01803737|Dietary Intake
1048435|NCT01803737|Weight Loss Self-Efficacy
1048436|NCT01803737|Motivation
1048437|NCT01803724|Irritable Bowel Syndrome
1048438|NCT01803724|Small Intestinal Bacterial Overgrowth
1048439|NCT01803724|Lactulose breath test
1048440|NCT01803724|Glucose breath test
1048441|NCT01803724|Rifaximin
1048442|NCT01803711|Omega 3 fatty acid
1048443|NCT01803711|Fish oil
1048444|NCT01803711|Depression
1048445|NCT01803711|cancer
1048446|NCT01803711|diabetes
1048447|NCT01803711|high blood pressure
1048448|NCT01803711|cardiovascular
1048449|NCT01803698|Pregnancy
1048450|NCT01803698|Gestational weight gain
1048451|NCT01803698|Primary care
1048452|NCT01803698|Guidelines
1048453|NCT01803685|Intracranial Arteriovenous Malformations
1048454|NCT01803685|Surgical removal
1048455|NCT01803685|Endovascular embolism
1048456|NCT01803685|Stereotaxic radiosurgery
1048457|NCT01803685|Outcomes
1048458|NCT01803672|Adventure-Based training
1048459|NCT01803672|Health education
1048460|NCT01803672|childhood cancer
1048461|NCT01803672|physical activity
1048462|NCT01803659|b-carotene
1048463|NCT01803659|breastmilk
1048464|NCT01803659|vitamin A
1048465|NCT01803568|Myokine
1048466|NCT01803568|Insulin sensitivity
1048467|NCT01803568|Exercise
1048468|NCT01803568|Skeletal muscle
1048469|NCT01803555|Budesonide/Formoterol SPIROMAX®
1048470|NCT01803555|SYMBICORT® TURBOHALER®
1048471|NCT01803555|Asthma
1048472|NCT01803542|Non-small Cell Lung Cancer
1048473|NCT01803542|Stereotactic radiation for Lung Cancer
1048474|NCT01803542|Cone beam CT for Lung Cancer
1048475|NCT01803542|PET/CT for Lung Cancer
1048476|NCT01803529|thorax
1048477|NCT01803529|Intercostal Muscles
1048478|NCT01803529|massage
1048479|NCT01803529|heat-pack
1048480|NCT01803529|hot temperature
1048481|NCT01803516|Quality of Life
1048482|NCT01803516|Assessments
1048483|NCT01803516|Radiation
1048484|NCT01803516|Telangiectasias
1048485|NCT01803516|13-013
1048486|NCT01803464|Botox
1048487|NCT01803464|Muscle strength
1048488|NCT01803451|gastric bypass
1048489|NCT01803451|glucose metabolism
1048490|NCT01803451|hypoglycemia
1048491|NCT01803438|paroxysmal Atrial Fibrillation
1048492|NCT01803438|Cryoablation
1048493|NCT01803438|Pulmonary Vein Isolation
1048494|NCT01803425|Post-marketing surveillance
1048495|NCT01803425|Prescribing Information (PI)
1048496|NCT01803425|Healthy infants and children
1048497|NCT01803425|Streptococcus pneumoniae
1048498|NCT01803425|Synflorix™
1048499|NCT01803425|Sri Lanka
1048500|NCT01803412|GSK2402968
1048501|NCT01803412|open-label extension
1048502|NCT01803412|safety
1048503|NCT01803412|drisapersen
1048504|NCT01803412|Duchenne Muscular Dystrophy
1048505|NCT01803412|tolerability
1048506|NCT01803412|Quality of Life
1048507|NCT01803399|cardiac repolarization
1048508|NCT01803399|oral
1048509|NCT01803399|QTc
1048510|NCT01803399|GSK1322322
1048511|NCT01803399|antibiotic
1048512|NCT01803399|12-lead ECG
1048513|NCT01803399|placebo
1048514|NCT01803399|IV
1048515|NCT01803399|moxifloxacin
1048516|NCT01803386|ALS
1048517|NCT01803386|EIM
1048518|NCT01803373|Healthy
1048519|NCT01803373|Biological Availability
1048520|NCT01803373|Bioavailability
1048521|NCT01803373|TMC207
1048522|NCT01803373|Bedaquiline
1048523|NCT01803373|R207910
1048524|NCT01803347|phase III
1048525|NCT01803347|Adipose derived stem cells
1048526|NCT01803347|Anal fistula
1048527|NCT01803347|Cell therapy
1048528|NCT01803347|Stem cell therapy
1048529|NCT01803334|surgical incision
1048530|NCT01803334|laparoscopy
1048531|NCT01803334|pain
1048532|NCT01803321|SJIA
1048533|NCT01803308|Hepatitis C Infection
1048534|NCT01803308|Treatment Naïve, Chronic
1048535|NCT01803308|First In Human
1048536|NCT01803308|Single Ascending Dose
1048537|NCT01803308|Multiple Ascending Dose
1048538|NCT01803295|Non Muscle Invasive Bladder Cancer
1048539|NCT01803295|Intravesical instillation
1048540|NCT01803295|Mitomycin C
1048541|NCT01803295|Hydrogel Reverse thermal gelation
1048542|NCT01803295|Drug retention
1048543|NCT01803295|Urinary Bladder Neoplasms
1048544|NCT01803295|Urologic Neoplasms
1048545|NCT01803295|Urinary Bladder Diseases
1048546|NCT01803295|Urologic Diseases
1048547|NCT01803295|Mitomycin
1048548|NCT01803282|Solid Tumor
1048549|NCT01803282|NSCLC
1048550|NCT01803282|Pancreatic
1048551|NCT01803282|Esophagogastric
1048552|NCT01803282|Colorectal
1048553|NCT01803282|Breast
1048554|NCT01803230|children
1048555|NCT01803204|Anxiety
1048556|NCT01803204|Orthognathic surgery
1048557|NCT01803204|Patient educational as topic
1048558|NCT01803204|Patient educational handout
1048559|NCT01803204|Pamphlets
1048560|NCT01803191|Transrectal ultrasound-guided prostate biopsy
1048561|NCT01803191|Bacteriuria
1048562|NCT01803191|Antibiotic prophylaxis
1048563|NCT01803191|Prostate-Specific antigen
1048564|NCT01803178|vascular function
1048565|NCT01803178|plant sterols
1048566|NCT01803178|blood lipids
1048567|NCT01803165|emesis,post operative.
1048568|NCT01803165|cognitive dysfunction, post operative.
1048569|NCT01803165|wound infection, post operative.
1048570|NCT01803165|pain, post operative.
1048571|NCT01803165|Anesthesia, Conduction/methods
1048572|NCT01803165|Anesthesiology/methods
1048573|NCT01803165|Arteriovenous Shunt, Surgical/adverse effects
1048574|NCT01803165|Regional Blood Flow/drug effects
1048575|NCT01803165|Risk Factors
1048576|NCT01803165|Thrombosis
1048577|NCT01803165|Treatment Outcome
1048578|NCT01803165|Vascular Surgical Procedures/methods
1048579|NCT01803165|Vasodilation/drug effects
1048580|NCT01803152|Metastatic Sarcoma
1048581|NCT01803152|Relapsed Sarcoma
1048582|NCT01803152|Dendritic Cell
1048583|NCT01803152|Myeloid Derived Suppressor Cells
1048584|NCT01803152|MDSC
1048585|NCT01803152|MDSC Inhibition
1048586|NCT01803139|Breast cancer radiotherapy IMRT
1048587|NCT01803126|atherosclerosis
1048588|NCT01803113|Pregnancy
1048589|NCT01803113|hCG
1048590|NCT01803100|Bacterial Colonization
1048591|NCT01803087|adolescents
1048592|NCT01803087|adults
1048593|NCT01803061|Head and neck cancer
1048594|NCT01803061|Quality of life
1048595|NCT01803061|Symptom-burden
1048596|NCT01803061|Late effects
1048597|NCT01803048|Traumatic Brain Injury
1048598|NCT01803048|Diffusion Weighted Imaging
1048599|NCT01803048|Resting State Functional Connectivity
1048600|NCT01803048|Cognition
1048601|NCT01803035|Impetigo
1048602|NCT01803035|LTX-109
1048603|NCT01803035|Topical
1048604|NCT01803035|Antibiotic
1048605|NCT01803035|Placebo
1048606|NCT01803035|Lytic
1048607|NCT01803035|Peptide
1048608|NCT01803035|Gram Positive
1048609|NCT01803022|Venous Thromboembolism
1048610|NCT01803022|Cancer
1048611|NCT01803022|Low Molecular Weight Heparin
1048612|NCT01802983|Aged
1048613|NCT01802983|Multiple organ failure
1048614|NCT01802983|Extubation
1048615|NCT01802983|Prognosis
1048616|NCT01802983|MODS
1048617|NCT01802983|invasive mechanical ventilation
1048618|NCT01802970|Anakinra
1048619|NCT01802970|Nab Paclitaxel
1048620|NCT01802970|Capecitabine
1048621|NCT01802970|Eribulin
1048622|NCT01802970|Vinorelbin
1048623|NCT01802931|GSK239512
1048624|NCT01802931|H3 receptor antagonist
1048625|NCT01802931|drug-drug interaction
1048626|NCT01802931|pharmacokinetics
1048627|NCT01802931|ketoconazole
1048628|NCT01802918|single dose
1048629|NCT01802918|HIV
1048630|NCT01802918|maturation inhibitor
1048631|NCT01802918|GSK2838232
1048632|NCT01802918|FTIH
1048633|NCT01802918|healthy subjects
1048634|NCT01802905|neoplasm
1048635|NCT01802905|metastatic cancer
1048636|NCT01802905|cancer genome
1048637|NCT01802905|genomic analysis
1048638|NCT01802905|adults
1048639|NCT01802892|ronacaleret
1048640|NCT01802892|parathyroid hormone (PTH)
1048641|NCT01802892|CD34+cells
1048642|NCT01802892|calcium sensing receptor antagonist
1048643|NCT01802892|hematopoietic stem cells
1048644|NCT01802892|stem cell mobilization
1048645|NCT01802892|plerixafor
1048646|NCT01802892|healthy human volunteer, phase Ib
1048647|NCT01802879|Hematologic Neoplasms, LBH589,
1048648|NCT01802879|Panobinostat,
1048649|NCT01802866|Geographic atrophy
1048650|NCT01802866|GA
1048651|NCT01802866|Dry AMD
1048652|NCT01802827|airway colonization
1048653|NCT01802827|tracheobronchitis
1048654|NCT01802827|pneumonia
1048655|NCT01802814|ALL
1048656|NCT01802788|Aortic Stenosis
1048657|NCT01802788|Heart Valve Prosthesis
1048658|NCT01802788|Trans Catheter Aortic Valve Replacement
1048659|NCT01802788|TAVR
1048660|NCT01802788|Trans Catheter Aortic Valve Implant
1048661|NCT01802788|TAVI
1048662|NCT01802749|second line
1048663|NCT01802749|platinum sensitive
1048664|NCT01802749|first line bevacizumab
1048665|NCT01802749|biologic factors
1048666|NCT01802749|clinical factors
1048667|NCT01802736|Alcohol HIV intervention counselling
1048668|NCT01802736|Alcohol Use in HIV infected Persons
1048669|NCT01802697|volunteers
1048670|NCT01802684|unresectable
1048671|NCT01802684|metastatic
1048672|NCT01802684|colorectal
1048673|NCT01802684|cancer
1048674|NCT01802684|OPTIMOX
1048675|NCT01802684|aflibercept
1048676|NCT01802671|Low back pain
1048677|NCT01802671|Cognitive behavioural treatment
1048678|NCT01802671|internet
1048679|NCT01802671|disability
1048680|NCT01802658|Bone marrow demineralization lesions,: efficacy and tolerability, zoledronic acid
1048681|NCT01802645|neoadjuvant
1048682|NCT01802645|cetuximab
1048683|NCT01802645|irinotecan
1048684|NCT01802645|bevacizumab
1048685|NCT01802645|oxaliplatin
1048686|NCT01802645|5-FU
1048687|NCT01802645|Resection
1048688|NCT01802645|colorectal liver metastases
1048689|NCT01802645|liver resection
1048690|NCT01802645|Chemotherapy
1048691|NCT01802645|k-ras
1048692|NCT01802645|non-resectable
1048693|NCT01802632|Oncology,
1048694|NCT01802632|Non Small Cell Lung Cancer,
1048695|NCT01802632|Metastatic,
1048696|NCT01802632|EGFR sensitivity mutation,
1048697|NCT01802632|T790M resistance mutation
1048698|NCT01802606|surgery
1048699|NCT01802606|administration
1048700|NCT01802606|infection
1048701|NCT01802593|Pediatric
1048702|NCT01802593|Crohn's disease
1048703|NCT01802593|Infliximab
1048704|NCT01802593|Thiopurine
1048705|NCT01802554|Behavioral Activation
1048706|NCT01802554|Caregiver
1048707|NCT01802554|Dementia
1048708|NCT01802554|Cardiovascular Disease
1048709|NCT01802554|Alzheimer's Disease
1048710|NCT01802554|Coagulation
1048711|NCT01802541|diacylglycerol oil
1048712|NCT01802541|insulin sensitivity
1048713|NCT01802541|type 2 diabetes
1048714|NCT01802541|cardiovascular disease
1048715|NCT01802541|risk factors
1048716|NCT01802528|obturator externus
1048717|NCT01802515|addiction
1048718|NCT01802515|cocaine
1048719|NCT01802515|methadone
1048720|NCT01802515|opiates
1048721|NCT01802515|atomoxetine
1048722|NCT01802502|tuberculous meningitis
1048723|NCT01802502|rifampicin
1048724|NCT01802502|bioequivalence
1048725|NCT01802502|oral administration
1048726|NCT01802502|intravenous administration
1048727|NCT01802489|Optic neuritis
1048728|NCT01802489|Multiple sclerosis
1048729|NCT01802489|Retinal nerve fibre layer
1048730|NCT01802489|Axonal loss
1048731|NCT01802489|Neuroprotection
1048732|NCT01802489|MRI
1048733|NCT01802489|Optical coherence tomography
1048734|NCT01802489|Amiloride
1048735|NCT01802489|Acid Sensing Ion Channels
1048736|NCT01802476|PD-0332991
1048737|NCT01802476|Absolute Bioavailability Study
1048738|NCT01802424|Open trial
1048739|NCT01802424|Indicative prevention
1048740|NCT01802424|Youth anxiety
1048741|NCT01802424|Cognitive behavioral therapy
1048742|NCT01802411|liposome bupivacaine
1048743|NCT01802411|posterolateral thoracotomy
1048744|NCT01802411|intercostal nerve block
1048745|NCT01802411|postoperative pain
1048746|NCT01802398|Risk Stratification
1048747|NCT01802398|Syncope
1048748|NCT01802398|Geriatric
1048749|NCT01802385|cryptococcal meningitis
1048750|NCT01802385|cryptococcus
1048751|NCT01802385|meningitis
1048752|NCT01802385|yeast
1048753|NCT01802385|fungus
1048754|NCT01802372|Hypertension
1048755|NCT01802372|High Blood Pressure
1048756|NCT01802372|Cardiovascular Diseases
1048757|NCT01802372|Health Insurance Coverage
1048758|NCT01802372|Low income countries
1048759|NCT01802372|Ghana
1048760|NCT01802372|Low resource settings
1048761|NCT01802372|Comparative Effectiveness
1048762|NCT01802372|Global Health
1048766|NCT01802307|Focal therapy
1048767|NCT01802307|Brachytherapy
1048768|NCT01802307|Active surveillance
1048769|NCT01802307|low risk cancer
1048770|NCT01802294|Randomized Controlled Trials as Topic
1048771|NCT01802294|Child
1048772|NCT01802294|Parents
1048773|NCT01802268|sirolimus
1048774|NCT01802268|tacrolimus
1048775|NCT01802268|early conversion
1048776|NCT01802255|Inhalatory sedation
1048777|NCT01802255|Sevoflurane
1048778|NCT01802255|AnaConDa
1048779|NCT01802255|Nephrotoxicity
1048780|NCT01802255|Hepatotoxicity
1048781|NCT01802255|Midazolam
1048782|NCT01802255|Propofol
1048783|NCT01802242|Prostate Cancer
1048784|NCT01802242|Prostate tumour
1048785|NCT01802242|Prostate radiotherapy
1048786|NCT01802242|prostate cancer treatment
1048787|NCT01802216|chronic kidney disease progression
1048788|NCT01802216|periodontal disease
1048789|NCT01802216|intensive periodontal disease treatment
1048790|NCT01802203|Barrett esophagus
1048791|NCT01802203|Esophageal dysplasia
1048792|NCT01802203|Upper gastrointestinal squamous dysplasia
1048793|NCT01802203|Esophageal cancer
1048794|NCT01802203|Endobronchial cancer
1048795|NCT01802203|Central airway cancer
1048796|NCT01802203|Central airway precancerous disease
1048797|NCT01802203|Central airway granulation tissue
1048798|NCT01802203|Central airway papillomatosis
1048799|NCT01802203|Central airway sarcoidosis
1048800|NCT01802203|Central airway tuberculosis
1048801|NCT01802203|Tracheal stenosis
1048802|NCT01802203|Bronchial stenosis
1048803|NCT01802190|Genetic deafness
1048804|NCT01802190|SLC17A8 et POU4F3 genes
1048805|NCT01802177|Alopecia areata
1048806|NCT01802177|Excimer
1048807|NCT01802177|UVB
1048808|NCT01802151|probiotics
1048809|NCT01802151|microbiota
1048810|NCT01802151|survival
1048811|NCT01802151|gastrointestinal
1048812|NCT01802151|wellness
1048813|NCT01802138|refractory/relapsed neuroblastoma patients
1048814|NCT01802112|Colonic transit
1048815|NCT01802112|Dietary Fiber
1048816|NCT01802112|Radiopaque marker
1048817|NCT01802099|mechanical ventilation
1048818|NCT01802099|early enteral nutrition
1048819|NCT01802099|intensive care unit
1048820|NCT01802099|early parenteral nutrition
1048821|NCT01802099|critical care medicine
1048822|NCT01802099|nosocomial infection
1048823|NCT01802099|mortality
1048824|NCT01802099|shock
1048825|NCT01802099|vasoactive drug
1048826|NCT01802086|Children
1048827|NCT01802086|Pain
1048828|NCT01802086|Vaccination
1048829|NCT01802086|Emla
1048830|NCT01802086|Pneumococcal
1048831|NCT01802086|Painscale
1048832|NCT01802073|Inflammation of the bile ducts
1048833|NCT01802073|biliary scarring
1048834|NCT01802073|obstruction
1048835|NCT01802060|Persona
1048836|NCT01802060|E3G
1048837|NCT01802060|LH
1048838|NCT01802060|ovulation
1048839|NCT01802047|Mothers of Preterms
1048840|NCT01802047|Breastfeeding Mothers of Preterm infants
1048841|NCT01802047|mother milk feeding
1048842|NCT01802021|chinese medicine
1048843|NCT01802021|non-small cell lung cancer
1048844|NCT01802021|immunosuppression
1048845|NCT01802008|Polyp/adenoma detection rate
1048846|NCT01802008|Polyp/adenoma miss rate
1048847|NCT01802008|Colonoscopy withdrawal time
1048848|NCT01801982|PPHN; development progress after PPHN; developmental progress after sildenafil.
1048849|NCT01801969|Brain injuries
1048850|NCT01801969|Rehabilitation services
1048851|NCT01801969|Return to Work
1048852|NCT01801969|Quality of life
1048853|NCT01801956|Maximum oxygen uptake
1048854|NCT01801956|Physical activity
1048855|NCT01801956|Physical inactivity
1048856|NCT01801956|Motivational interview
1048857|NCT01801956|Cardiorespiratory fitness
1048858|NCT01801956|Primary care
1048859|NCT01801956|Community care
1048860|NCT01801930|OCV-C02
1048861|NCT01801930|Colorectal Cancer
1048862|NCT01801930|Antigen specific cancer immunotherapeutic
1048863|NCT01801917|Polymyositis, Myositis, PM
1048864|NCT01801904|cetuximab-refractory
1048865|NCT01801891|Venous ulceration
1048866|NCT01801891|Leg ulcers
1048867|NCT01801891|Venous haemodynamics
1048868|NCT01801891|Surface neuromuscular electrical stimulation
1048869|NCT01801891|SNMES
1048870|NCT01801878|breast cancer
1048871|NCT01801878|loss of elasticity in irradiated breast skin
1048872|NCT01801878|Other Reconstructive Surgery
1048873|NCT01801865|NICU
1048874|NCT01801865|MRI
1048875|NCT01801865|Neonatal
1048876|NCT01801865|Cincinnati
1048877|NCT01801813|Neuro-surgery
1048878|NCT01801813|Post-operative complications
1048879|NCT01801813|Neuro-ICU resources
1048880|NCT01801800|Aneurysmal subarachnoid haemorrhage
1048881|NCT01801774|post-operative inflammation
1048882|NCT01801774|steroid
1048883|NCT01801774|intraocular pressure
1048884|NCT01801748|wheat allergy
1048885|NCT01801748|wheat outgrowing
1048886|NCT01801748|wheat hypersensitivity
1048887|NCT01801748|omega-5-gliadin
1048888|NCT01801748|natural history of wheat hypersensitivity
1048889|NCT01801709|Brain Gene Therapy
1048890|NCT01801709|Adeno Associated vector
1048891|NCT01801709|Lysosomal sotage diseases
1048892|NCT01801709|Leukodystrophies
1048893|NCT01801696|Massage
1048894|NCT01801696|effectiveness
1048895|NCT01801696|autism
1048896|NCT01801696|parent stress
1048897|NCT01801683|EBM
1048898|NCT01801683|general practice
1048899|NCT01801670|itch
1048900|NCT01801670|pruritus
1048901|NCT01801670|skin
1048902|NCT01801670|vorinostat
1048903|NCT01801670|cutaneous T-cell lymphoma
1048904|NCT01801670|mycosis fungoides
1048905|NCT01801657|bronchiectasis
1048906|NCT01801657|exacerbation
1048907|NCT01801657|virus
1048908|NCT01801644|bladder cancer
1048909|NCT01801644|neoadjuvant chemotherapy
1048910|NCT01801644|gem/cis
1048911|NCT01801631|Type 2 diabetes
1048912|NCT01801631|Acute Coronary Event (ACE)
1048913|NCT01801631|Distress
1048914|NCT01801631|Self-efficacy
1048915|NCT01801631|Quality of Life
1048916|NCT01801631|Depression
1048917|NCT01801631|Primary care
1048918|NCT01801631|Illness representations
1048919|NCT01801618|HIV
1048920|NCT01801618|PI based 2nd line ARV treatment
1048921|NCT01801618|Virological failure
1048922|NCT01801618|Drug resistance
1048923|NCT01801618|Cambodia
1048924|NCT01801618|Adherence
1048925|NCT01801605|IBS - rectal hypersensitivity - rectal barostat - rTMS.
1048926|NCT01801592|OBSTRUCTIVE SLEEP APNOEA
1048927|NCT01801592|INTERMITTENT CLAUDICATION
1048928|NCT01801592|Respiratory disease
1048929|NCT01801592|Peripheral artery disease
1048930|NCT01801579|Ankle Brachial Index
1048931|NCT01801579|Maximal exercise
1048932|NCT01801566|Mandibular Prosthesis Implantation
1048933|NCT01801566|Prostheses and Implants
1048934|NCT01801566|Denture, Complete, Lower
1048935|NCT01801553|spinal manipulation
1048936|NCT01801553|low back pain
1048937|NCT01801553|manual therapy
1048938|NCT01801553|clinical predictive rule
1048939|NCT01801527|Telehealth
1048940|NCT01801527|Fatigue
1048941|NCT01801527|Breast cancer
1048942|NCT01801527|Exercise
1048943|NCT01801527|Quality of life
1048944|NCT01801527|Telerehabilitation
1048945|NCT01801475|Pharmacokinetics of ondansetron in women
1048946|NCT01801475|Pharmacokinetics of ondansetron in neonates
1048947|NCT01801475|Term pregnancy
1048948|NCT01801475|Cesarean section
1048949|NCT01801462|Medical education
1048950|NCT01801462|Simulation
1048951|NCT01801462|Ultrasound training
1048952|NCT01801462|Patient safety
1048953|NCT01801449|DIRA
1048954|NCT01801449|Clinical Trial
1048955|NCT01801449|IL-1
1048956|NCT01801449|Autoinflammatory Syndrome
1048957|NCT01801449|Rilonacept
1048958|NCT01801436|Multiple Myeloma
1048959|NCT01801436|Bortezomib
1048960|NCT01801436|Velcade
1048961|NCT01801423|transcranial Doppler
1048962|NCT01801423|stroke
1048963|NCT01801423|sickle cell anemia
1048964|NCT01801423|Nigeria
1048965|NCT01801423|hydroxyurea
1048966|NCT01801423|low income country
1048967|NCT01801410|pre-eclampsia
1048968|NCT01801410|labor induction
1048969|NCT01801410|misoprostol
1048970|NCT01801410|Foley catheter
1048971|NCT01801384|pregnancy
1048972|NCT01801384|cigarette smoking
1048973|NCT01801384|incentives
1048974|NCT01801384|smoking cessation
1048975|NCT01801384|birth outcomes
1048976|NCT01801371|Glioma
1048977|NCT01801371|Diagnostic imaging
1048978|NCT01801371|Integrin receptor
1048979|NCT01801371|68Ga-BNOTA-PRGD2
1048980|NCT01801371|PET/CT
1048981|NCT01801358|Melanoma,
1048982|NCT01801358|melanoma of the eye,
1048983|NCT01801358|uveal,
1048984|NCT01801358|MEK162,
1048985|NCT01801358|AEB071
1048986|NCT01801345|Human Performance
1048987|NCT01801345|Clinical Performance
1048988|NCT01801319|major depressive disorder (MDD)
1048989|NCT01801319|deep brain stimulation (DBS)
1048990|NCT01801319|subcallosal cingulate gyrus
1049121|NCT01800552|IV Infiltration
1048991|NCT01801319|Therapy-Resistant Depression
1048992|NCT01801319|Electrical Stimulation of the Brain
1048993|NCT01801319|Brain Stimulation, Deep
1048994|NCT01801293|RSV infection
1048995|NCT01801280|immunosuppressive medication
1048996|NCT01801280|mycophenolic acid
1048997|NCT01801280|interaction
1048998|NCT01801280|proton pump inhibitor
1048999|NCT01801280|pantoprazole
1049000|NCT01801280|renal transplant patients
1049001|NCT01801280|pharmacokinetics
1049002|NCT01801280|pharmacodynamics
1049003|NCT01801280|bioavailability
1049004|NCT01801267|Hydrocephalus
1049005|NCT01801267|Pediatric
1049006|NCT01801267|Ventricular shunt
1049007|NCT01801267|Ventriculoperitoneal shunt
1049008|NCT01801267|Third ventriculostomy
1049009|NCT01801267|Randomized controlled trial
1049010|NCT01801254|Obesity
1049011|NCT01801254|Type II diabetes
1049012|NCT01801254|Cardiovascular disease
1049013|NCT01801254|Health behavior promotion
1049014|NCT01801254|Neuroeconomics
1049015|NCT01801254|EEG biofeedback
1049016|NCT01801254|Low-resolution electromagnetic tomography (LORETA)
1049017|NCT01801254|EEG
1049018|NCT01801176|proved by biopsy
1049019|NCT01801150|Diabetes
1049020|NCT01801150|Apnea- hypopnea Syndrome
1049021|NCT01801150|Glycemic control
1049022|NCT01801150|Prevalence
1049023|NCT01801150|SAHS
1049024|NCT01801150|life quality
1049025|NCT01801124|analgesia
1049026|NCT01801124|hernia repair
1049027|NCT01801098|TAVI
1049028|NCT01801098|complete AV-block
1049029|NCT01801098|HV-interval
1049030|NCT01801098|permanent pacemaker
1049031|NCT01801085|Time-and-Motion
1049032|NCT01801085|Neoplasm
1049033|NCT01801085|Colorectal Cancer
1049034|NCT01801059|colon cancer
1049035|NCT01801059|Colorectal Cancer Screening
1049036|NCT01801033|Trioodothyronine (T3)
1049037|NCT01801033|Thyroid Hormone Action
1049038|NCT01801033|Deiodinases
1049039|NCT01801033|Hypothyroid
1049040|NCT01801033|Propylthiouracil (PTU)
1049041|NCT01801020|temperature
1049042|NCT01800994|convenience
1049043|NCT01800981|Functionality
1049044|NCT01800981|extremities
1049045|NCT01800981|ROM
1049046|NCT01800981|Upper and lower Extremity for burned patients
1049047|NCT01800955|physical therapy
1049048|NCT01800955|diathermy
1049049|NCT01800955|knee
1049050|NCT01800955|osteoarthritis
1049051|NCT01800955|pain
1049052|NCT01800955|physical function
1049053|NCT01800942|prevention
1049054|NCT01800942|bacterial infection
1049055|NCT01800942|neonates
1049056|NCT01800942|women in labour
1049057|NCT01800942|Azithromycin
1049058|NCT01800916|ileostomy
1049059|NCT01800916|Subjects
1049060|NCT01800890|stoma ileostomy
1049061|NCT01800877|hypotension
1049062|NCT01800877|vasopressors
1049063|NCT01800877|titration
1049064|NCT01800877|tissue perfusion
1049065|NCT01800877|organ failure
1049066|NCT01800851|Kidney transplantation
1049067|NCT01800851|Energy expenditure
1049068|NCT01800851|Weight gain
1049069|NCT01800851|Insulin resistance
1049070|NCT01800825|Pregnancy
1049071|NCT01800825|Prematurity
1049072|NCT01800825|Preterm birth
1049073|NCT01800825|bacterial vaginosis
1049074|NCT01800799|Urinary tract infection
1049075|NCT01800799|Urothelium
1049076|NCT01800799|Inflammation
1049077|NCT01800799|Apoptosis
1049078|NCT01800773|PTSD
1049079|NCT01800773|exposure treatment
1049080|NCT01800773|clinical trial
1049081|NCT01800773|trauma
1049085|NCT01800747|Delayed antibiotic treatment
1049086|NCT01800747|Acute respiratory infections
1049087|NCT01800747|Pediatrics
1049088|NCT01800747|Satisfaction
1049089|NCT01800734|Mixed meal test
1049090|NCT01800734|Insulin pump
1049091|NCT01800734|Continuous glucose monitoring
1049092|NCT01800734|Metabolic control analysis
1049093|NCT01800734|Closed loop control
1049094|NCT01800734|Artificial pancreas
1049095|NCT01800721|HIV
1049096|NCT01800721|testing
1049097|NCT01800721|Social Network
1049098|NCT01800721|African American
1049099|NCT01800721|MSM
1049100|NCT01800721|Men who have sex with men
1049101|NCT01800695|GBM
1049102|NCT01800682|Healthy
1049103|NCT01800682|Tramodol
1049104|NCT01800682|Ultram
1049105|NCT01800669|Computer based clinical decision support
1049106|NCT01800669|medical legal partnership
1049107|NCT01800669|child
1049108|NCT01800669|pediatrics
1049109|NCT01800643|Busulfan
1049110|NCT01800643|plasmatic dosage
1049111|NCT01800643|Stem Cell Transplantation
1049112|NCT01800578|Cerebral State Index Monitor
1049113|NCT01800565|precocious puberty
1049114|NCT01800565|urinary LH
1049115|NCT01800565|GnRH stimulation test
1049116|NCT01800565|gonadotropins
1049117|NCT01800552|Infiltration
1049118|NCT01800552|Extravasation
1049119|NCT01800552|Leaking
1049120|NCT01800552|PIV Infiltration
1049122|NCT01800552|Ultrasound Detection of Infiltration
1049123|NCT01800552|Ultrasound Imaging
1049124|NCT01800539|Autism
1049125|NCT01800539|Early Intervention
1049126|NCT01800539|Minority
1049127|NCT01800526|Sickle Cell Disease
1049128|NCT01800526|Sickle Cell Anemia
1049129|NCT01800513|Implantation Failure
1049130|NCT01800513|In-vitro Fertilization
1049131|NCT01800513|Infertility
1049132|NCT01800513|Endometrial Biopsy
1049133|NCT01800487|Drug-induced liver injury
1049134|NCT01800487|Tuberculosis
1049135|NCT01800487|Silymarin
1049136|NCT01800461|Participation
1049137|NCT01800461|Occupational Therapy
1049138|NCT01800461|Valued Activities
1049139|NCT01800448|Respiratory monitoring
1049140|NCT01800448|cardiac monitoring
1049141|NCT01800448|skin conductance monitoring
1049142|NCT01800448|variability
1049143|NCT01800409|Tetraplegia
1049144|NCT01800396|Bacterial infection
1049145|NCT01800396|Dairy
1049146|NCT01800396|Diarrhea
1049147|NCT01800396|Diet
1049148|NCT01800396|E.Coli
1049149|NCT01800396|Gastroenteritis
1049150|NCT01800396|Milk
1049151|NCT01800396|Stool consistency
1049152|NCT01800383|posttraumatic stress disorder
1049153|NCT01800383|fear conditioning
1049154|NCT01800383|proton magnetic resonance spectroscopy
1049155|NCT01800383|GABA
1049156|NCT01800370|Healthy
1049157|NCT01800370|Male
1049158|NCT01800357|randomized trial
1049159|NCT01800357|acute ischemic stroke
1049160|NCT01800357|mildronate
1049161|NCT01800344|Airway Cuff
1049162|NCT01800344|LMA
1049163|NCT01800344|Ultra
1049164|NCT01800344|Cuff Pressure
1049165|NCT01800344|Ventilation
1049166|NCT01800344|Anesthesia
1049167|NCT01800344|Intubation
1049168|NCT01800318|NESAP
1049169|NCT01800318|sucrose
1049170|NCT01800318|pain
1049171|NCT01800318|infants
1049172|NCT01800305|PK & PD study
1049173|NCT01800305|rhEPO
1049174|NCT01800305|Pegylated rhEPO
1049175|NCT01800305|male healthy subject
1049176|NCT01800292|Pulmonary Artery Hypertension
1049177|NCT01800292|pulmonary capillary wedge pressure
1049178|NCT01800292|sildenafil
1049179|NCT01800292|echocardiography
1049180|NCT01800292|left ventricular longitudinal wall strain
1049181|NCT01800292|strain rate pre and post medical therapy
1049182|NCT01800292|speckle tracking
1049183|NCT01800279|Fibromyalgia Syndrome, Temporomandibular Joint, Pain.
1049184|NCT01800266|Supervision
1049185|NCT01800266|Implementation
1049186|NCT01800266|Community Based Mental Health Services
1049187|NCT01800266|Trauma Focused Cognitive Behavioral Therapy
1049188|NCT01800266|Skill Building and Behavioral Rehearsal
1049189|NCT01800266|Symptom and Fidelity Monitoring
1049190|NCT01800266|Children
1049191|NCT01800266|Adolescents
1049192|NCT01800214|neurodengeneration
1049193|NCT01800214|neuroimaging
1049194|NCT01800201|Initial occurrence Acute Myocardial Infarction (AMI)
1049195|NCT01800188|Dialysis
1049196|NCT01800188|Incretin hormones
1049197|NCT01800149|Tooth extraction
1049198|NCT01800149|Ridge Preservation
1049199|NCT01800149|Ridge Augmentation
1049200|NCT01800149|Guided Bone Regeneration
1049201|NCT01800136|pain
1049202|NCT01800136|neuropathic
1049203|NCT01800136|cortical stimulation
1049204|NCT01800136|motor cortex
1049205|NCT01800136|plasticity
1049206|NCT01800136|rTMS
1049207|NCT01800136|tDCS
1049208|NCT01800123|Intoxication, overdose, poisoning, EtCO2, emergency medicine
1049209|NCT01800097|stroke
1049210|NCT01800097|fatigue
1049211|NCT01800097|modafinil
1049212|NCT01800084|ASIR
1049213|NCT01800084|image acquisition
1049214|NCT01800084|FBP
1049215|NCT01800071|Nasopharyngeal cancer
1049216|NCT01800071|Epstein Barr Virus Infections
1049217|NCT01800071|Vaccination
1049218|NCT01800045|Narcolepsy
1049219|NCT01800045|Cataplexy
1049220|NCT01800045|Sleep disorder
1049221|NCT01800045|Excessive daytime sleepiness
1049226|NCT01799993|Gram-negative pneumonia
1049227|NCT01799993|Intubation
1049228|NCT01799993|Mechanical ventilation
1049229|NCT01799993|Amikacin
1049230|NCT01799980|Lung cancer
1049231|NCT01799980|Cervical mediastinoscopy
1049232|NCT01799980|Endobronchial ultrasound
1049233|NCT01799980|Staging
1049234|NCT01799967|gastro-esophageal junction
1049235|NCT01799967|minimally invasive
1049236|NCT01799967|Achalasia
1049237|NCT01799967|Paraesophageal hernia
1049238|NCT01799967|GERD
1049239|NCT01799967|Epiphrenic diverticula
1049240|NCT01799967|Zenker's diverticulum
1049241|NCT01799967|All minimally invasive surgeries of the gastro-esophageal junction
1049242|NCT01799902|Observational
1049243|NCT01799902|Non-Interventional Prospective
1049244|NCT01799902|Phase IV Treatment
1049245|NCT01799902|Overactive Bladder Syndrome
1049246|NCT01799902|Solifenacin
1049247|NCT01799889|GS-US-339-0102
1049248|NCT01799889|SYK inhibitor
1049249|NCT01799889|GS-9973
1049250|NCT01799889|entospletinib
1049251|NCT01799889|CLL
1049252|NCT01799889|leukemia
1049253|NCT01799889|lymphoma
1049254|NCT01799889|MCL
1049255|NCT01799889|DLBCL
1049256|NCT01799889|iNHL
1049257|NCT01799889|FL
1049258|NCT01799889|MZL
1049259|NCT01799889|LPL
1049260|NCT01799889|SLL
1049261|NCT01799889|WM
1049262|NCT01799889|Waldenström's macroglobulinemia
1049263|NCT01799876|knee
1049264|NCT01799876|cartilage
1049265|NCT01799876|microfracture
1049266|NCT01799876|cell therapy
1049267|NCT01799863|Conjunctivitis, Viral
1049268|NCT01799863|Ketorolac
1049269|NCT01799863|Artificial tears
1049270|NCT01799850|muscle
1049271|NCT01799850|glucose transporters
1049272|NCT01799850|GLUT4
1049273|NCT01799850|GLUT5
1049274|NCT01799850|Actos
1049275|NCT01799837|PTSD
1049276|NCT01799811|allograft
1049277|NCT01799811|limb salvage
1049278|NCT01799811|patency
1049279|NCT01799811|Cryopreserved
1049280|NCT01799811|open bypass
1049281|NCT01799798|Osteogenesis imperfecta
1049282|NCT01799798|COL1A1/A2
1049283|NCT01799798|Denosumab
1049284|NCT01799798|Bisphosphonates
1049285|NCT01799798|Children
1049286|NCT01799798|Areal bone mineral density
1049287|NCT01799759|Body Mass Percentile
1049288|NCT01799759|Authoritative parenting
1049289|NCT01799759|Online interventions
1049290|NCT01799759|Prevention
1049291|NCT01799733|Premenstrual Dysphoric Disorder
1049292|NCT01799733|Women
1049293|NCT01799733|Depression
1049294|NCT01799733|Light therapy
1049295|NCT01799733|Wake therapy
1049296|NCT01799733|Phase
1049297|NCT01799733|Chronobiology
1049298|NCT01799720|blood cholesterol
1049299|NCT01799720|blood lipid profile
1049300|NCT01799720|triglycerides
1049301|NCT01799720|commercial pills
1049302|NCT01799720|fish oil
1049303|NCT01799720|lipid peroxidation
1049304|NCT01799720|Circulating lipidic profile
1049305|NCT01799707|vision
1049306|NCT01799707|restoration
1049307|NCT01799707|visual field
1049308|NCT01799694|Urinary incontinence
1049309|NCT01799694|Autologous expanded stem cells
1049310|NCT01799694|Radical prostate cancer surgery
1049311|NCT01799681|randomised controlled trial, postural balance, rehabilitation, exercise therapy, accidental falls
1049312|NCT01799668|Psychotherapy
1049313|NCT01799668|Preferences
1049314|NCT01799642|dyspnea
1049315|NCT01799642|exercise
1049316|NCT01799642|cystic fibrosis
1049317|NCT01799642|neuromechanical dissociation
1049318|NCT01799629|Glycerin suppositories
1049319|NCT01799629|Feeding intolerance
1049320|NCT01799629|preterm infants
1049321|NCT01799629|prophylactic use
1049322|NCT01799629|elimination of meconium
1049323|NCT01799616|MODIC changes
1049324|NCT01799616|Chronic low back pain
1049325|NCT01799616|Pamidronate
1049326|NCT01799616|Magnetic resonance imaging
1049327|NCT01799616|Vertebrae
1049328|NCT01799616|Intervertebral disc
1049329|NCT01799603|Healthy
1049330|NCT01799603|TMC435
1049331|NCT01799603|G008
1049332|NCT01799590|Migraine
1049333|NCT01799590|Topiramate
1049334|NCT01799577|laparoscopy, accuracy, duration
1049335|NCT01799564|Geographic atrophy
1049336|NCT01799564|Age-related macular degeneration
1049337|NCT01799564|Fundus autofluorescence
1049338|NCT01799551|Depression
1049339|NCT01799551|Culture
1049340|NCT01799551|CBT
1049341|NCT01799551|Adaptation
1049342|NCT01799538|Albuterol
1049343|NCT01799538|Bronchodilator
1049344|NCT01799538|Nebulizer
1049345|NCT01799538|Metered Dose Inhaler
1049346|NCT01799525|Aneurysm
1049347|NCT01799525|subarachnoid hemorrhage
1049348|NCT01799525|vasospasm
1049349|NCT01799525|cerebral ischemia
1049350|NCT01799525|stroke
1049351|NCT01799512|medical ICU patients
1049352|NCT01799512|APACHE-II score ≥20
1049353|NCT01799499|Non Muscle Invasive Bladder Cancer
1049354|NCT01799499|Intravesical instillation
1049355|NCT01799499|Mitomycin C
1049356|NCT01799499|Hydrogel
1049357|NCT01799499|Reverse thermal gelation
1049358|NCT01799499|Drug retention
1049359|NCT01799499|Urinary Bladder Neoplasms
1049360|NCT01799499|Carcinoma
1049361|NCT01799499|Urologic Neoplasms
1049362|NCT01799499|Urogenital Neoplasms
1049363|NCT01799499|Neoplasms by Site
1049364|NCT01799499|Neoplasms
1049365|NCT01799499|Urinary Bladder Diseases
1049366|NCT01799499|Urologic Diseases
1049367|NCT01799499|Neoplasms, Glandular and Epithelial
1049368|NCT01799499|Neoplasms by Histologic Type Mitomycins
1049369|NCT01799499|Mitomycin
1049370|NCT01799499|Antibiotics, Antineoplastic
1049371|NCT01799499|Antineoplastic Agents
1049372|NCT01799499|Therapeutic Uses
1049373|NCT01799499|Pharmacologic Actions
1049374|NCT01799499|Nucleic Acid Synthesis Inhibitors
1049375|NCT01799499|Enzyme Inhibitors
1049376|NCT01799499|Molecular Mechanisms of Pharmacological Action
1049377|NCT01799499|Alkylating Agents
1049378|NCT01799486|Telbivudine
1049379|NCT01799486|renoprotective efficacy
1049380|NCT01799486|liver cirrhosis
1049381|NCT01799473|Tyvaso
1049382|NCT01799473|PAH
1049383|NCT01799460|single-nucleotide-polymorphism
1049384|NCT01799460|Traditional Chinese Medicine
1049385|NCT01799460|the Comprehensive Treatment Regimen
1049386|NCT01799447|Early intervention
1049387|NCT01799447|Intervention study
1049388|NCT01799447|Infant mother relations
1049389|NCT01799447|First time mothers
1049390|NCT01799447|Parental program
1049391|NCT01799447|Marte Meo method
1049392|NCT01799447|Video guidances
1049393|NCT01799369|Surgical Apgar Score
1049394|NCT01799356|Treatment, moksifloksasin
1049395|NCT01799343|Prenatal care
1049396|NCT01799343|Blood flow velocity
1049397|NCT01799343|Hydrotherapy
1049398|NCT01799343|Fetalplacental circulation
1049399|NCT01799343|Uteroplacental circulation
1049400|NCT01799330|COPD
1049401|NCT01799330|Rehabilitation
1049402|NCT01799330|Exercise
1049403|NCT01799330|TCEMS
1049404|NCT01799304|Locomotion
1049405|NCT01799304|cerebral palsy
1049406|NCT01799304|Postural; Defect
1049407|NCT01799291|Decision Making
1049408|NCT01799291|Pediatric Bipolar Disorder
1049409|NCT01799291|Assessment
1049410|NCT01799291|Intervention
1049411|NCT01799278|Metastatic prostate carcinoma
1049412|NCT01799265|obstructive sleep apnea
1049413|NCT01799265|OSA
1049414|NCT01799265|AutoPAP
1049415|NCT01799265|PAP
1049416|NCT01799265|sleep disordered breathing
1049417|NCT01799265|CPAP
1049418|NCT01799265|Apnea hypopnea index
1049419|NCT01799265|AHI
1049420|NCT01799252|medical abortion
1049421|NCT01799252|doxycycline
1049422|NCT01799252|antibiotics
1049423|NCT01799252|adherence
1049424|NCT01799252|nausea
1049425|NCT01799239|stoma ileostomy
1049426|NCT01799213|Knee Osteoarthritis
1049427|NCT01799213|NSAID
1049428|NCT01799213|Cognitive Behavioral Therapy
1049429|NCT01799200|Collegiate Athletes
1049430|NCT01799200|Hip Pathomorphology
1049431|NCT01799200|Age-Matched Controls
1049432|NCT01799200|Femoroacetabular Impingement
1049433|NCT01799200|Dysplasia
1049434|NCT01799187|Immature Permanent Teeth
1049435|NCT01799161|NSCLC
1049436|NCT01799161|Lung Cancer
1049437|NCT01799161|gp96
1049438|NCT01799161|gp96 Vaccine
1049439|NCT01799161|AD100-gp96Ig-HLA A1
1049440|NCT01799148|Acute coronary syndrome
1049441|NCT01799148|Air pollution.
1049442|NCT01799148|Inflammation.
1049443|NCT01799148|Oxidative Stress.
1049444|NCT01799148|Prognosis
1049445|NCT01799109|magnesium sulfate
1049446|NCT01799109|nebulization
1049447|NCT01799109|lung function
1049448|NCT01799083|Advanced solid tumors
1049449|NCT01799083|B cell lymphoma
1049450|NCT01799070|Prediction
1049451|NCT01799070|Transcranial Doppler
1049452|NCT01799057|Peripheral Arterial Disease
1049453|NCT01799057|Intermittent Claudication
1049454|NCT01799057|Peripheral Vascular Diseases
1049455|NCT01799057|Vascular Diseases
1049456|NCT01799057|Cardiovascular Diseases
1049457|NCT01799057|Arterial Occlusive Diseases
1049458|NCT01799057|Atherosclerosis
1049459|NCT01799057|Insulin Resistance
1049460|NCT01799057|Glucose Metabolism
1049461|NCT01799057|Blood Glucose
1049462|NCT01799057|Metformin
1049463|NCT01799057|Biguanides
1049464|NCT01799057|Hypoglycemic Agents
1049465|NCT01799057|Endothelium, Vascular
1049466|NCT01799057|Hemorheology
1049467|NCT01799057|Blood Circulation
1049468|NCT01799057|Regional Blood Flow
1049469|NCT01799057|Microcirculation
1049470|NCT01799057|Exercise
1049471|NCT01799057|Physical Fitness
1049472|NCT01799057|Exercise Test
1049473|NCT01799057|Sedentary Lifestyle
1049474|NCT01799057|Quality of Life
1049475|NCT01799057|Plethysmography
1049476|NCT01799044|Irreversible electroporation
1049477|NCT01799044|IRE
1049478|NCT01799044|Electroporation
1049479|NCT01799044|Colorectal liver metastases
1049480|NCT01799044|CRLM
1049481|NCT01799044|Safety
1049482|NCT01799044|Feasibility
1049483|NCT01799044|Efficacy
1049484|NCT01799044|Single-center
1049485|NCT01799044|Low Energy Direct Current
1049486|NCT01799044|Ablate-and-resect
1049487|NCT01799044|Nonthermal ablation
1049488|NCT01799044|Ablation
1049489|NCT01799018|Xanthine Oxidase
1049490|NCT01799018|Cerebrospinal fluid
1049491|NCT01799005|flavanols
1049492|NCT01799005|diet
1049493|NCT01799005|endothelial function
1049494|NCT01799005|blood pressure
1049495|NCT01799005|FLAVIOLA
1049496|NCT01798992|ejection fraction
1049497|NCT01798992|beta-blocker
1049498|NCT01798992|carvedilol
1049499|NCT01798992|metoprolol
1049500|NCT01798992|myocardial gene expression
1049501|NCT01798992|human heart
1049502|NCT01798992|ventricular remodeling
1049503|NCT01798992|wall stress
1049504|NCT01798992|adrenergic signaling
1049505|NCT01798992|myosin heavy chain
1049506|NCT01798953|Ulcerative Colitis
1049507|NCT01798953|Primary Sclerosing Cholangitis
1049508|NCT01798953|Ileal pouch-anal anastomosis
1049509|NCT01798953|Ileorectal anastomosis
1049510|NCT01798953|Surgical outcome
1049511|NCT01798953|Functional outcome
1049512|NCT01798953|Failure
1049513|NCT01798927|Parkinson's disease
1049514|NCT01798927|ankle foot orthosis (AFO)
1049515|NCT01798927|gait
1049516|NCT01798901|Acute Myeloid Leukemia
1049517|NCT01798901|AML
1049518|NCT01798901|AR-42
1049519|NCT01798901|Decitabine
1049520|NCT01798888|Deep Brain Stimulation
1049521|NCT01798888|Alcohol Dependence
1049522|NCT01798875|pcos
1049523|NCT01798875|metformin
1049524|NCT01798875|oral contraception
1049525|NCT01798875|cyproterone acetate
1049526|NCT01798862|Failed IVF cycles
1049527|NCT01798862|IVF outcome parameters
1049528|NCT01798862|endometrial injury
1049529|NCT01798862|hysteroscopy
1049530|NCT01798862|pipelle sampling
1049531|NCT01798862|Repeated implantation failures
1049532|NCT01798836|IVF/ICSI cycles, poor responders, ultrashort flare protocol, antagonist protocol
1049533|NCT01798823|children
1049534|NCT01798823|asthma
1049535|NCT01798810|Surgical Site Infection Risk Prediction
1049536|NCT01798810|Bacterial species type and antibacterial sensitivities
1049537|NCT01798810|Resource Utilization and Cost
1049538|NCT01798797|Heart Failure
1049539|NCT01798797|HFRS
1049540|NCT01798797|OptiVol
1049541|NCT01798797|ICD
1049542|NCT01798797|CRT-D
1049543|NCT01798771|primary brain tumor
1049544|NCT01798771|malignant glioma
1049545|NCT01798771|intraoperative MRI
1049546|NCT01798771|5-ALA
1049547|NCT01798745|Heart failure
1049548|NCT01798745|JNJ-54452840
1049549|NCT01798745|Anti-beta-1 adrenergic receptor auto antibodies
1049550|NCT01798745|Beta-1 adrenergic receptor
1049551|NCT01798745|Antibodies
1049552|NCT01798745|Auto antibodies
1049553|NCT01798745|Systolic function
1049554|NCT01798719|NAFLD
1049555|NCT01798719|Clinical Trial
1049556|NCT01798719|Mediterranean Diet
1049557|NCT01798719|Low Glycemic Index
1049558|NCT01798693|Shoulder
1049559|NCT01798693|Supplement
1049560|NCT01798693|Amino Acids
1049561|NCT01798693|Collagen
1049562|NCT01798693|Standard of Care
1049563|NCT01798641|Hydrocephalus
1049564|NCT01798641|Cross-over
1049565|NCT01798628|Healthy volunteers
1049566|NCT01798628|Abiraterone acetate
1049567|NCT01798628|Pharmacokinetics
1049568|NCT01798602|H1N1
1049569|NCT01798602|Rosuvastatin
1049570|NCT01798589|ethylenediamine dihydrochloride
1049571|NCT01798563|Parkinson
1049572|NCT01798563|Parkinson Disease
1049573|NCT01798550|Enoxaparin dosing
1049574|NCT01798550|Obesity
1049575|NCT01798524|Transplant
1049576|NCT01798524|Kidney
1049577|NCT01798524|England
1049578|NCT01798511|enteral nutrition
1049579|NCT01798511|acute pancreatitis
1049580|NCT01798511|oral food intolerance
1049581|NCT01798472|displaced femoral neck fractures
1049582|NCT01798472|treatment
1049583|NCT01798472|uncemented arthroplasty
1049584|NCT01798472|cemented arthroplasty
1049585|NCT01798459|Attention Deficit Hyperactivity Disorder
1049586|NCT01798459|Methylphenidate
1049587|NCT01798459|Placebo
1049588|NCT01798459|State anxiety
1049589|NCT01798446|Renal cell carcinoma
1049590|NCT01798446|Nonclear cell
1049591|NCT01798446|Temsirolimus resistance
1049592|NCT01798433|Angioplasty
1049593|NCT01798433|Transluminal
1049594|NCT01798433|Percutaneous Coronary
1049595|NCT01798420|COPD
1049596|NCT01798420|Diabetes
1049597|NCT01798420|steroids
1049598|NCT01798420|Hemoglobin A1C DIFFERENCE
1049599|NCT01798407|Deep Brain Stimulation
1049600|NCT01798407|Major Depressive Disorder
1049601|NCT01798407|Depression
1049602|NCT01798407|Lateral Habenula
1049603|NCT01798394|pregnant
1049604|NCT01798394|smoker
1049605|NCT01798394|cigarette
1049606|NCT01798394|tobacco
1049607|NCT01798355|Dental Fear
1049608|NCT01798355|Dental Phobia
1049609|NCT01798355|Cognitive Behavior Therapy
1049610|NCT01798355|Specific Phobia
1049611|NCT01798355|Children and Adolescents anxiety
1049612|NCT01798355|Self Efficacy
1049613|NCT01798342|preoperative care
1049614|NCT01798342|maltodextrine
1049615|NCT01798342|glutamine
1049616|NCT01798342|gastric residual volume
1049617|NCT01798342|MRI
1049618|NCT01798329|Minimal Hepatic Encephalopathy
1049619|NCT01798329|Pre-hepatic Portal Hypertension
1049620|NCT01798329|portal vein thrombosis
1049621|NCT01798316|IV Acetaminophen
1049622|NCT01798316|Laparoscopic cholecystectomy
1049623|NCT01798316|Postoperative nausea
1049624|NCT01798316|Postoperative vomiting
1049625|NCT01798277|Keywords provided by Newmarket Electrophysiology Research Group Inc:
1049626|NCT01798277|Ventricular tachycardia
1049627|NCT01798277|Ventricular tachyarrhythmia
1049628|NCT01798277|Ablation
1049629|NCT01798277|Coronary artery disease
1049630|NCT01798277|Ischemic heart disease
1049631|NCT01798277|Amiodarone
1049632|NCT01798277|Sotalol
1049633|NCT01798277|Anti-Arrhythmia Agents
1049634|NCT01798277|Therapeutic Uses
1049635|NCT01798277|Pharmacologic Actions
1049636|NCT01798277|Additional relevant MeSH terms:
1049637|NCT01798277|Atrial Fibrillation
1049638|NCT01798277|Arrhythmias, Cardiac
1049639|NCT01798277|Heart Diseases
1049640|NCT01798277|Cardiovascular Diseases
1049641|NCT01798277|Pathologic Processes
1049642|NCT01798277|Catheter Ablation, Radiofrequency
1049643|NCT01798251|Elderly Gastric Cancer
1049644|NCT01798251|Capecitabine Maintenance
1049645|NCT01798238|Type 2 Diabetes Mellitus / Dipeptidyl peptidase-IV inhibitors
1049646|NCT01798225|Periodontal Disease
1049647|NCT01798225|Type 2 Diabetes Mellitus
1049648|NCT01798225|Gullah African Americans
1049649|NCT01798212|GERD
1049650|NCT01798199|Alzheimer
1049651|NCT01798199|virtual reality system
1049652|NCT01798199|Alzheimer's disease related conditions
1049653|NCT01798173|Hepatocellular carcinoma
1049654|NCT01798173|Cirrhosis
1049655|NCT01798173|Environmental risk factors
1049656|NCT01798173|Nutrition
1049657|NCT01798173|Metabolic syndrome
1049658|NCT01798147|Cholangiocellular Carcinoma
1049659|NCT01798147|TACE
1049660|NCT01798147|SIRT
1049661|NCT01798134|To show safety
1049662|NCT01798134|and efficacy
1049663|NCT01798134|investigational product
1049664|NCT01798121|PPD
1049665|NCT01798121|Tuberculosis
1049666|NCT01798108|Advanced skeletal metastases
1049667|NCT01798108|Radium-223
1049668|NCT01798108|Radium-223 dichloride
1049669|NCT01798108|Alpharadin
1049670|NCT01798095|TB, Aplisol
1049671|NCT01798056|≥18 years of age
1049672|NCT01798056|Chemotherapy
1049673|NCT01798056|Solid tumours
1049674|NCT01798056|Immunogenicity
1049675|NCT01798056|Herpes Zoster
1049676|NCT01798056|Safety
1049677|NCT01798056|Shingles
1049678|NCT01798030|Vitamin D
1049679|NCT01798030|Diabetes
1049680|NCT01798030|Osteoporosis
1049681|NCT01798030|Cardiovascular Risk
1049682|NCT01798017|menstrual regulation
1049683|NCT01798017|mifepristone
1049684|NCT01798017|misoprostol
1049685|NCT01797991|Hypersensitivity, drug
1049686|NCT01797978|Sepsis
1049687|NCT01797978|Septic shock
1049688|NCT01797978|Methylene blue
1049689|NCT01797952|lactobacillus CD 2
1049690|NCT01797952|oral mucositis
1049691|NCT01797952|hematopoietic stem cell transplantation
1049692|NCT01797939|Erosive reflux disease (ERD)
1049693|NCT01797939|Non-erosive reflux disease (NERD)
1049694|NCT01797939|Functional heartburn (FH)
1049695|NCT01797926|pharmacokinetics
1049696|NCT01797926|Hypertension
1049697|NCT01797926|losartan
1049698|NCT01797926|healthy volunteers
1049699|NCT01797926|amlodipine
1049700|NCT01797900|adjuvants
1049701|NCT01797900|inductive
1049702|NCT01797900|concurrent
1049703|NCT01797900|chemoradiotherapy
1049704|NCT01797900|high-risk
1049705|NCT01797900|locally advanced
1049706|NCT01797900|NPC
1049707|NCT01797887|Burnout-Syndrome
1049708|NCT01797887|Ayurveda
1049709|NCT01797887|Ayurvedic
1049710|NCT01797887|Traditional Indian Medicine
1049711|NCT01797887|CAM
1049712|NCT01797887|Whole Medical System
1049713|NCT01797887|Diet and Lifestyle Counseling
1049714|NCT01797874|pazopanib maintenance
1049715|NCT01797874|efficacy
1049716|NCT01797874|SCLC
1049717|NCT01797861|chronic central serous chorioretinopathy
1049718|NCT01797861|photodynamic therapy
1049719|NCT01797861|micropulse laser
1049720|NCT01797835|adolescents
1049721|NCT01797835|intervention
1049722|NCT01797835|motivational interviewing
1049723|NCT01797835|alcohol and drug use
1049724|NCT01797783|Myopia
1049725|NCT01797783|Presbyopia
1049726|NCT01797783|Refractive error
1049727|NCT01797783|Contact lenses
1049728|NCT01797783|Multifocal
1049729|NCT01797770|mechanical bowel preparation
1049730|NCT01797770|Colon Cancer
1049731|NCT01797757|EPA
1049732|NCT01797757|LC-PUFA
1049733|NCT01797757|Orlistat
1049734|NCT01797757|Obesity
1049735|NCT01797744|Stroke
1049736|NCT01797744|Dizziness
1049737|NCT01797744|Vestibular rehabiliation
1049738|NCT01797744|Balance
1049739|NCT01797731|Orthalign
1049740|NCT01797731|KneeAlign
1049741|NCT01797731|Total Knee Replacement
1049742|NCT01797731|Total Knee Arthroplasty
1049743|NCT01797731|Degenerative joint disease
1049744|NCT01797731|Osteoarthritis
1049745|NCT01797731|Unilateral
1049746|NCT01797718|Puberty
1049747|NCT01797718|Constitutional
1049748|NCT01797718|Delay
1049749|NCT01797718|Letrozole
1049750|NCT01797718|Testosterone
1049751|NCT01797692|prostate cancer cured
1049752|NCT01797692|aged patients
1049888|NCT01797055|transferrin
1049753|NCT01797679|Osteoarthritis,Articular Cartilage, Relaxometry, Morphometry, MRI, T2 mapping, T1 rho
1049754|NCT01797640|Tibia Fractures
1049755|NCT01797640|Medial Fractures
1049756|NCT01797640|Posterior Malleolar Fractures
1049757|NCT01797627|Pediatric Hydrocephalus
1049758|NCT01797627|Ventricular Size
1049759|NCT01797627|Neuropsychological Outcomes
1049760|NCT01797627|Quality of Life
1049761|NCT01797614|intra-abdominal pressure
1049762|NCT01797614|spontaneous breathing trail
1049763|NCT01797614|weaning
1049764|NCT01797588|Total Knee Arthroplasty
1049765|NCT01797588|Pain
1049766|NCT01797588|Periarticular infiltration
1049767|NCT01797588|Adductor canal block
1049768|NCT01797588|Postoperative
1049769|NCT01797575|Bipolar Disorder
1049770|NCT01797575|Mood Disorder
1049771|NCT01797575|Bipolar Depression
1049772|NCT01797575|Mood Swings
1049773|NCT01797562|Contact dermatitis
1049774|NCT01797562|Eczema
1049775|NCT01797549|Traumatic brain injury
1049776|NCT01797549|functional near infrared spectroscopy
1049786|NCT01797497|Parents
1049787|NCT01797497|Primary Care Providers
1049788|NCT01797497|Specialists
1049789|NCT01797497|Children with Special Healthcare Needs
1049790|NCT01797497|Referral
1049791|NCT01797497|Health Outcomes
1049792|NCT01797497|Self-Efficacy
1049793|NCT01797497|Communication
1049794|NCT01797484|ischemia
1049795|NCT01797484|myocardium
1049796|NCT01797484|Ranolazine
1049797|NCT01797484|dyskinesia
1049798|NCT01797484|speckle tracking echocardiography
1049799|NCT01797471|Non-Small Cell Lung Cancer
1049800|NCT01797471|NSCLC
1049801|NCT01797471|Lung Cancer
1049802|NCT01797458|class II carious primary molar
1049803|NCT01797458|Opening-up cavities
1049804|NCT01797458|Hall Technique
1049805|NCT01797458|Conventional restorations
1049806|NCT01797445|HIV
1049807|NCT01797445|Treatment Naive
1049808|NCT01797445|HIV 1 Infected
1049809|NCT01797445|Women
1049810|NCT01797445|Female
1049811|NCT01797419|Respiratory
1049812|NCT01797419|Syncytial
1049813|NCT01797419|Virus
1049814|NCT01797419|RSV
1049815|NCT01797380|Depression
1049816|NCT01797380|HIV
1049817|NCT01797367|HIV
1049818|NCT01797367|COPD
1049819|NCT01797367|FEV1
1049820|NCT01797367|respiratory function
1049821|NCT01797354|patients at the end of treatment
1049822|NCT01797341|Renal Transplantation
1049823|NCT01797341|Kidney transplantation
1049824|NCT01797341|Pancreas Transplantation
1049825|NCT01797341|Tacrolimus
1049826|NCT01797341|Advagraf
1049827|NCT01797341|Prograf
1049828|NCT01797341|Drug Adherence
1049829|NCT01797328|brown adipose tissue, human
1049830|NCT01797302|Obesity
1049831|NCT01797302|Vitamin D Deficiency
1049832|NCT01797302|Vascular Function
1049833|NCT01797302|Insulin resistance
1049834|NCT01797302|metabolic syndrome
1049835|NCT01797289|syncope
1049836|NCT01797289|pulmonary embolism
1049837|NCT01797276|Dichloroacetate (DCA)
1049838|NCT01797276|Congenital Lactic Acidosis (CLA)
1049839|NCT01797276|acidosis
1049840|NCT01797276|orphan disease
1049841|NCT01797263|fibromyalgia
1049842|NCT01797263|yoga
1049843|NCT01797263|exercise
1049844|NCT01797263|pain
1049845|NCT01797237|surgery
1049846|NCT01797237|fixation
1049847|NCT01797237|intramedullary nail
1049848|NCT01797224|Autoimmune disease
1049849|NCT01797224|certolizumab pegol
1049850|NCT01797224|Cimzia
1049851|NCT01797224|pregnancy
1049852|NCT01797224|birth defect
1049853|NCT01797224|birth outcome
1049854|NCT01797224|TNF
1049855|NCT01797224|Tumor necrosis factor
1049856|NCT01797211|Mediterranean diet; FMD; obesity; cardiovascular risk.
1049857|NCT01797198|Phase I
1049858|NCT01797198|ASP3652
1049859|NCT01797198|Gemfibrozil
1049860|NCT01797198|Repaglinide
1049861|NCT01797198|Pharmacokinetics
1049862|NCT01797185|baclofen, spasticity
1049863|NCT01797172|nucleoplasty
1049864|NCT01797172|pulsed radio frequency
1049865|NCT01797172|herniated disc
1049866|NCT01797172|cervical
1049867|NCT01797172|percutaneous disc decompression
1049868|NCT01797172|cervical radiculopathy
1049869|NCT01797159|Prophylactic Cranial Irradiation
1049870|NCT01797159|PCI
1049871|NCT01797159|Hippocampal-sparing irradiation
1049872|NCT01797120|Post-Menopausal Patients
1049873|NCT01797120|Hormone-Receptor Positive
1049874|NCT01797120|Resistant to Aromatase Inhibitor Therapy
1049875|NCT01797120|Fulvestrant
1049876|NCT01797120|Faslodex
1049877|NCT01797120|mTOR Inhibitor
1049878|NCT01797120|Everolimus
1049879|NCT01797120|RAD001
1049880|NCT01797120|Afinitor
1049881|NCT01797107|Meibomian gland dysfunction
1049882|NCT01797068|HEALTHCARE UTILIZATION
1049883|NCT01797068|ED UTILIZATION
1049884|NCT01797068|PRIMARY CARE UTILIZATION
1049885|NCT01797068|PATIENT NAVIGATION
1049886|NCT01797068|UNDERSERVED POPULATIONS
1049887|NCT01797068|HEALTH DISPARITIES
1049889|NCT01797055|anemia
1049890|NCT01797055|iron overload
1049891|NCT01797042|Fructose
1049892|NCT01797042|High fructose corn syrup
1049893|NCT01797042|Energy regulation
1049894|NCT01797042|Ectopic fat
1049895|NCT01797042|Understanding
1049896|NCT01797042|potential
1049897|NCT01797016|Myocardial Infarction
1049898|NCT01797016|flow cytometry
1049899|NCT01797016|Blood Cell Count
1049900|NCT01797016|Platelet Activation
1049901|NCT01797003|osteoarthritis
1049902|NCT01797003|osteotomy
1049903|NCT01797003|closing
1049904|NCT01797003|opening
1049905|NCT01797003|wedge
1049906|NCT01797003|kne
1049907|NCT01797003|tibia
1049908|NCT01796990|physical activity
1049909|NCT01796990|psychological well-being
1049910|NCT01796990|acceptance and commitment therapy
1049911|NCT01796990|adults
1049912|NCT01796977|Nipple-sparing Mastectomy
1049913|NCT01796977|NSM
1049914|NCT01796977|Nipple Sparing Mastectomy
1049915|NCT01796964|Age-Related Macular Degeneration
1049916|NCT01796964|Wet
1049917|NCT01796964|Exudative
1049918|NCT01796964|AMD
1049919|NCT01796964|Intravitreal injection
1049920|NCT01796964|Retina
1049921|NCT01796938|Lacosamide
1049922|NCT01796938|Vimpat
1049923|NCT01796938|Single Dose
1049924|NCT01796938|Pharmacokinetics
1049925|NCT01796938|Renal Impairment
1049926|NCT01796925|Apnea
1049927|NCT01796925|Respiration Disorders
1049928|NCT01796925|Signs and Symptoms
1049929|NCT01796925|Signs and Symptoms, Respiratory
1049930|NCT01796925|Sleep Apnea Syndromes
1049931|NCT01796925|Sleep Apnea, Obstructive
1049932|NCT01796925|Respiratory Tract Diseases
1049933|NCT01796925|Sleep Disorders, Intrinsic
1049934|NCT01796925|Sleep Disorders
1049935|NCT01796925|Nervous System Diseases
1049936|NCT01796899|Healthy Volunteers
1049937|NCT01796899|Brivaracetam
1049938|NCT01796873|Female
1049939|NCT01796873|Hispanic
1049940|NCT01796873|Percutaneous Coronary Intervention
1049941|NCT01796860|Gait
1049942|NCT01796860|AFO
1049943|NCT01796860|MS
1049944|NCT01796847|ICU
1049945|NCT01796847|Hyperglycemia
1049946|NCT01796847|Length of stay
1049947|NCT01796834|Mindfulness-Based Stress Reduction
1049948|NCT01796834|Diabetes Management
1049949|NCT01796834|Stress Reduction
1049950|NCT01796834|Diabetes Testing
1049951|NCT01796821|Condyloma acuminata
1049952|NCT01796821|Genital warts
1049953|NCT01796821|Condylomata acuminata
1049954|NCT01796821|Venereal warts
1049955|NCT01796808|pedal
1049956|NCT01796808|atrophy
1049957|NCT01796808|fat grafting
1049958|NCT01796808|adipose tissue
1049959|NCT01796795|common wart
1049960|NCT01796795|verruca vulgaris
1049961|NCT01796769|Obstructive Sleep Apnea Syndrome
1049962|NCT01796769|Telemedicine
1049963|NCT01796769|Patient Compliance
1049964|NCT01796756|Handover
1049965|NCT01796756|Handoff
1049966|NCT01796756|Signout
1049967|NCT01796756|Quality Improvement
1049968|NCT01796756|General Internal Medicine
1049969|NCT01796743|MRI
1049970|NCT01796743|Double Inversion radial fast Spin Echo T2 mapping
1049971|NCT01796743|Heart failure risk stratification
1049972|NCT01796743|30 day post hospitalization outcome
1049973|NCT01796730|efficacy
1049974|NCT01796730|safety
1049975|NCT01796730|Bambuterol tablets
1049976|NCT01796730|COPD
1049977|NCT01796717|Piperacillin/tazobactam
1049978|NCT01796717|MIC
1049979|NCT01796704|functional capacity
1049980|NCT01796704|NYHA class
1049981|NCT01796691|Clopidogrel
1049982|NCT01796691|aspirin
1049983|NCT01796691|low response
1049984|NCT01796691|platelet aggregation
1049985|NCT01796691|Acute Coronary Syndrome
1049986|NCT01796691|Coronary Stent Implantation
1049987|NCT01796678|sickle cell disease
1049988|NCT01796678|vaso-occlusive pain episodes
1049989|NCT01796678|arginine
1049990|NCT01796678|nitric oxide
1049991|NCT01796652|Acute interstitial pancreatitis
1049992|NCT01796652|Home therapy
1049993|NCT01796600|distal limbs fracture, acute trauma, imaging, cone beam computed tomography,
1049994|NCT01796574|status epilepticus
1049995|NCT01796574|seizure
1049996|NCT01796574|epilepsy
1049997|NCT01796574|ketogenic diet
1049998|NCT01796574|modified Atkins diet
1049999|NCT01796548|Detrusor function, overactive
1050000|NCT01796548|Urinary incontinence
1050001|NCT01796548|Oxybutynin
1050002|NCT01796548|Lyrinel
1050003|NCT01796509|Quality of life,
1050004|NCT01796509|Sequela disorders,
1050005|NCT01796509|Socio-professional impact,
1050006|NCT01796509|Anxiety, depression,
1050007|NCT01796509|Post traumatic stress disorder,
1050008|NCT01796509|ICU acquired paresis.
1050009|NCT01796496|Low back pain.
1050010|NCT01796496|Manipulative therapy techniques.
1050011|NCT01796496|Randomized controlled trial.
1050012|NCT01796496|Chronic pain.
1050013|NCT01796483|Parkinson disease
1050014|NCT01796483|STN-DBS
1050015|NCT01796483|Impulsivity
1050016|NCT01796483|Akinesia
1050017|NCT01796483|Noradrenergic
1050018|NCT01796483|system
1050019|NCT01796470|GS-US-339-0103
1050020|NCT01796470|SYK inhibitor
1050021|NCT01796470|PI3K inhibitor
1050022|NCT01796470|GS-9973
1050023|NCT01796470|GS 9973
1050024|NCT01796470|GS-1101
1050025|NCT01796470|GS 1101
1050026|NCT01796470|Cal-101
1050027|NCT01796470|Cal 101
1050028|NCT01796470|idelalisib
1050029|NCT01796470|leukemia
1050030|NCT01796470|lymphoma
1050031|NCT01796470|CLL
1050032|NCT01796470|MCL
1050033|NCT01796470|DLBCL
1050034|NCT01796470|iNHL
1050035|NCT01796470|FL
1050036|NCT01796470|MZL
1050037|NCT01796470|LPL
1050038|NCT01796470|SLL
1050039|NCT01796470|WM
1050040|NCT01796470|Waldenström's macroglobulinemia
1050041|NCT01796457|Hepatitis B
1050042|NCT01796457|Immunology
1050043|NCT01796457|HBV
1050044|NCT01796457|Immune tolerant
1050045|NCT01796457|Immune active
1050046|NCT01796444|Breast Cancer
1050047|NCT01796444|Sentinel Lymph Node Biopsy
1050048|NCT01796444|Axillary Lymph Node Dissection
1050049|NCT01796392|emphysema
1050050|NCT01796392|endobronchial valve
1050051|NCT01796392|treatments
1050052|NCT01796392|pulmonary rehabilitation
1050053|NCT01796392|lung volume reduction
1050054|NCT01796353|heart disease
1050055|NCT01796353|sexual dysfunction
1050056|NCT01796353|exercise test
1050057|NCT01796353|comprehensive rehabilitation
1050058|NCT01796353|complex intervention
1050059|NCT01796340|cue exposure
1050060|NCT01796340|childhood
1050061|NCT01796340|overeating
1050062|NCT01796340|overweight
1050063|NCT01796340|obese
1050064|NCT01796340|treatment
1050065|NCT01796327|dacomitinib
1050066|NCT01796327|PF-00299804
1050067|NCT01796327|pharmacokinetics
1050068|NCT01796327|bioavailability
1050069|NCT01796314|Therapeutic educational programme for Alzheimer's disease patients and their caregiver
1050070|NCT01796314|Alzheimer's disease, mild to moderately severe stages
1050071|NCT01796314|Community dwelling patients with family caregiver
1050072|NCT01796314|Alzheimer's disease patient's quality of life
1050073|NCT01796301|Postmenopausal Osteoporosis
1050074|NCT01796288|NSCLC
1050075|NCT01796288|oligometastatic
1050076|NCT01796288|second-line
1050077|NCT01796288|Radiotherapy
1050078|NCT01796288|Erlotinib
1050079|NCT01796262|ADHD
1050080|NCT01796262|DHA
1050081|NCT01796262|neuropsychological task
1050082|NCT01796262|fNIRS
1050083|NCT01796262|Docosahexaenoic Acid
1050084|NCT01796262|n-3 polyunsaturated fatty acid
1050085|NCT01796262|cognition
1050086|NCT01796262|behavior
1050087|NCT01796249|Analgesia Nociception Index
1050088|NCT01796249|ANI
1050089|NCT01796236|Bone anchored hearing aid
1050090|NCT01796236|Bone anchored implant
1050091|NCT01796236|Abbreviated Profile of Hearing Aid Benefit (APHAB)
1050092|NCT01796236|Health Utility Index (HUI)
1050093|NCT01796236|Holgers Index
1050094|NCT01796236|Implant stability
1050095|NCT01796223|Community mental health services
1050096|NCT01796223|Psychotherapy
1050097|NCT01796223|Physician-Patient Relations
1050098|NCT01796223|Norway
1050099|NCT01796210|Analgesia/nociception index
1050100|NCT01796210|Bispectral index
1050101|NCT01796210|Propofol
1050102|NCT01796210|Remifentanil
1050103|NCT01796210|Suspension laryngoscopy
1050104|NCT01796210|Endoscopy
1050105|NCT01796210|Ear-nose-throat
1050106|NCT01796184|Inflammation
1050107|NCT01796184|Glycation
1050108|NCT01796184|Continuous glucose monitoring
1050109|NCT01796184|Adult population
1050110|NCT01796171|Radioimmunotherapy
1050111|NCT01796171|Lu-177
1050112|NCT01796171|Phase I study
1050113|NCT01796171|Phase II study
1050114|NCT01796171|Betalutin
1050115|NCT01796158|adolescents
1050116|NCT01796158|alcohol abuse
1050117|NCT01796158|drug abuse
1050118|NCT01796158|substance use
1050119|NCT01796132|Depression
1050120|NCT01796132|Lactation
1050121|NCT01796132|Breastfeeding
1050122|NCT01796132|Pharmacokinetics
1050123|NCT01796132|Antidepressant
1050124|NCT01796119|Dental implants, Ridge splitting, Ridge expansion
1050125|NCT01796106|caries infiltration
1050126|NCT01796106|caries progression
1050127|NCT01796106|Icon
1050128|NCT01796093|Digoxin
1050129|NCT01796093|Ivabradine
1050130|NCT01796093|Cardiac failure
1050131|NCT01796093|Economics
1050132|NCT01796067|Motivational intervention
1050133|NCT01796067|Positive Parenting Intervention
1050134|NCT01796067|Obesity
1050135|NCT01796067|Physical Activity
1050136|NCT01796067|Diet
1050137|NCT01796067|African American
1050138|NCT01796067|Adolescent
1050139|NCT01796054|Perceived stress
1050140|NCT01796054|Burnout
1050141|NCT01796054|Mindfulness
1050142|NCT01796054|Intent to leave nursing
1050143|NCT01796028|Prostate Cancer
1050144|NCT01796015|paediatrics
1050145|NCT01796015|optic nerve sheath diameter
1050146|NCT01796015|ultrasound
1050147|NCT01796002|PTCL
1050148|NCT01795989|Coil
1050149|NCT01795989|MRI
1050150|NCT01795989|safety
1050151|NCT01795989|efficacy
1050152|NCT01795989|musculoskeletal imaging
1050153|NCT01795989|Cincinnati
1050154|NCT01795989|Safety and efficacy of a new elbow coil on pediatric patients and healthy participants
1050155|NCT01795976|Oesophageal cancer
1050156|NCT01795963|intimate partner violence
1050157|NCT01795950|cell therapy
1050158|NCT01795950|Pulmonary arterial hypertension
1050159|NCT01795898|Osteoarthritis
1050160|NCT01795898|Low back pain
1050161|NCT01795898|Fentanyl transdermal patch
1050162|NCT01795898|Durogesic-D-Trans
1050163|NCT01795885|Pregnancy in Adolescence
1050164|NCT01795885|Contraception
1050165|NCT01795859|Huntington disease
1050166|NCT01795859|Chorea
1050167|NCT01795859|Tetrabenazine
1050168|NCT01795846|allergen specific immunotherapy, house dust mite (Der p), monosensitization, polysensitization, allergic rhinitis, asthma,
1050169|NCT01795833|Prediabetes
1050170|NCT01795833|Prediabetic State
1050171|NCT01795820|ticagrelor
1050172|NCT01795820|clopidogrel
1050173|NCT01795820|platelet aggregation
1050174|NCT01795781|Anticoagulant measurement
1050175|NCT01795781|Anticoagulant reversal
1050176|NCT01795781|Dabigatran
1050177|NCT01795781|Rivaroxaban
1050178|NCT01795768|Non randomised
1050179|NCT01795768|Open label
1050180|NCT01795768|Multicentre
1050181|NCT01795768|Phase II biomarker study
1050182|NCT01795755|Horse Assisted Therapy (HAT)
1050183|NCT01795755|Equine Assisted Psychotherapy (EAP)
1050184|NCT01795755|clinical trial
1050185|NCT01795755|Randomised Controlled Trial (RCT)
1050186|NCT01795755|psychotherapy
1050187|NCT01795742|Asthma
1050188|NCT01795742|Nebulizers
1050189|NCT01795742|Salbutamol
1050190|NCT01795742|Developing Countries
1050191|NCT01795729|Heart transplant
1050192|NCT01795729|Coronary artery disease
1050193|NCT01795729|Allograft vascular disease
1050194|NCT01795729|Coronary stent
1050195|NCT01795729|Optimal medical therapy
1050196|NCT01795729|Prognosis
1050197|NCT01795703|Prostate Cancer
1050198|NCT01795703|Abiraterone Acetate
1050199|NCT01795703|JNJ-212082
1050200|NCT01795690|Anemia
1050201|NCT01795690|Cancer
1050202|NCT01795690|Hemoglobin
1050203|NCT01795690|Quality of Life
1050204|NCT01795690|FACT-An
1050205|NCT01795690|FACT-GP
1050206|NCT01795690|Erythropoiesis-Stimulating Agents (ESA)
1050207|NCT01795690|Epoetin
1050208|NCT01795690|Ferric Carboxymaltose
1050209|NCT01795690|Blood Transfusions
1050210|NCT01795677|JAK2 inhibitor RUXOLITINIB
1050211|NCT01795677|Primary or secondary myelofibrosis
1050212|NCT01795664|Asthma
1050213|NCT01795664|Salmeterol xinafoate and Fluticasone propionate
1050214|NCT01795664|Seretide Evohaler
1050215|NCT01795664|Functional Respiratory Imaging
1050216|NCT01795664|Computational Fluid Dynamic
1050217|NCT01795651|teaching
1050218|NCT01795651|knowledge translation
1050219|NCT01795651|ICU
1050220|NCT01795651|postgraduate
1050221|NCT01795651|lecture
1050222|NCT01795638|anthropometrics
1050223|NCT01795638|weight
1050224|NCT01795638|nutrition
1050225|NCT01795586|breast - female
1050226|NCT01795586|advanced breast cancer
1050227|NCT01795586|histologically confirmed
1050228|NCT01795586|cytologically confirmed
1050229|NCT01795586|metastatic
1050230|NCT01795586|locally advanced
1050231|NCT01795586|unresectable
1050232|NCT01795573|GVHD
1050233|NCT01795573|AML
1050234|NCT01795573|ALL
1050235|NCT01795573|MDS
1050236|NCT01795573|CLL
1050237|NCT01795573|NHL
1050238|NCT01795573|HL
1050239|NCT01795573|MM
1050240|NCT01795560|Periappendicular abscess
1050241|NCT01795560|Ultrasound
1050242|NCT01795521|NSCLC, SBRT, PET, Medically Inoperable
1050243|NCT01795508|Parent training
1050244|NCT01795508|Child behavior
1050245|NCT01795508|Randomized Controlled Trials
1050246|NCT01795495|Spinal Fusion
1050247|NCT01795495|Scoliosis
1050248|NCT01795495|Methadone
1050249|NCT01795495|Magnesium
1050250|NCT01795495|Adolescents
1050251|NCT01795495|Back Surgery
1050252|NCT01795482|perioperative hypothermia
1050253|NCT01795482|prewarming
1050254|NCT01795482|preoperative warming
1050255|NCT01795482|general anaesthesia
1050256|NCT01795482|epidural anaesthesia
1050257|NCT01795482|temperature measurement
1050258|NCT01795469|POTS
1050259|NCT01795469|Orthostatic
1050260|NCT01795469|Adolescent
1050261|NCT01795456|Takayasu's arteritis
1050262|NCT01795456|Giant Cell arteritis
1050263|NCT01795456|Arteritis
1050264|NCT01795456|Vasculitis
1050265|NCT01795456|Aortitis
1050266|NCT01795456|Disease Activity
1050267|NCT01795456|Carotidynia
1050268|NCT01795456|Neovascularization
1050269|NCT01795456|Carotid Intima Media Thickness
1050270|NCT01795443|vibration
1050271|NCT01795443|proprioception
1050272|NCT01795417|wrinkles
1050273|NCT01795417|rhytids
1050274|NCT01795417|periorbital
1050275|NCT01795404|IBSR
1050276|NCT01795404|Cancer Survivors
1050277|NCT01795404|Katie Byron
1050278|NCT01795404|Quality of Life
1050279|NCT01795404|Stress
1050280|NCT01795404|Stress reduction
1050281|NCT01795391|Prevention
1050282|NCT01795391|Dressings
1050283|NCT01795391|Catheters
1050284|NCT01795378|acute myelogenous leukemia
1050285|NCT01795378|acute lymphoblastic leukemia
1050286|NCT01795378|donor natural killer cells
1050287|NCT01795378|HLA-haploidentical hematopoietic cell transplantation
1050288|NCT01795352|EGFR,
1050289|NCT01795352|lung cancer,
1050290|NCT01795352|mutated
1050291|NCT01795339|AZD3293
1050292|NCT01795339|Healthy volunteers
1050293|NCT01795339|Elderly volunteers
1050294|NCT01795339|Alzheimer's Disease patients
1050295|NCT01795339|AD patients
1050296|NCT01795339|Phase 1
1050297|NCT01795339|Multiple Ascending Dose Study
1050298|NCT01795326|Effectiveness of risk minimization
1050299|NCT01795326|Metabolic monitoring
1050300|NCT01795326|Seroquel®
1050301|NCT01795326|Seroquel® XR/quetiapine fumarate
1050302|NCT01795287|tibial fracture
1050303|NCT01795287|intramedullary nailing
1050304|NCT01795287|spinal anesthesia
1050305|NCT01795287|patient safety
1050306|NCT01795261|HIV
1050307|NCT01795248|gestational diabetes mellitus
1050308|NCT01795248|incretin
1050309|NCT01795248|glucose homeostasis
1050310|NCT01795248|GLP-1
1050311|NCT01795248|type 2 diabetes mellitus
1050312|NCT01795248|liraglutide
1050313|NCT01795248|Victoza
1050314|NCT01795235|men
1050315|NCT01795222|conscious sedation
1050316|NCT01795222|stress psychological
1050317|NCT01795222|dental care for children
1050318|NCT01795222|child behavior
1050319|NCT01795222|saliva
1050320|NCT01795209|Branch retinal vein occlusion
1050321|NCT01795209|Macular edema
1050322|NCT01795209|Ranibizumab
1050323|NCT01795196|pediatric extubation failure
1050324|NCT01795196|weaning
1050325|NCT01795196|integrated pulmonary index
1050326|NCT01795196|mechanical ventilation
1050327|NCT01795196|extubation readiness
1050328|NCT01795196|respiratory monitoring tool
1050329|NCT01795196|Endotracheal Extubation
1050330|NCT01795196|Pediatric Intensive Care Unit
1050331|NCT01795196|Rapid Shallow Breathing Index
1050332|NCT01795196|Physiologic Deadspace
1050333|NCT01795170|Pyridoxine Dependant Epilepsy
1050334|NCT01795170|Antiquitin Deficiency
1050335|NCT01795170|Lysine Restricted Diet
1050336|NCT01795157|decision support systems, clinical
1050337|NCT01795157|decision making, computer assisted
1050338|NCT01795157|evidence based practice
1050339|NCT01795157|practice guidelines as topic
1050340|NCT01795131|Nutritional anemia
1050341|NCT01795131|Vitamin B12
1050342|NCT01795131|flu vaccine
1050343|NCT01795131|immunity
1050344|NCT01795092|Cellulitis
1050345|NCT01795092|Outpatient Medicine
1050346|NCT01795079|transcranial stimulation
1050347|NCT01795079|direct current
1050348|NCT01795053|ADHD preschoolers
1050349|NCT01795053|playtraining
1050350|NCT01795053|child-focused intervention
1050351|NCT01795040|omega-3/omega-6 fatty acids
1050352|NCT01795040|Pre-school children with ADHD symptoms
1050353|NCT01795040|randomized controlled trial
1050354|NCT01795027|gastric cancer
1050355|NCT01795027|chemotherapy
1050356|NCT01795027|D2 resection
1050357|NCT01795027|S-1
1050358|NCT01795001|pathophysiology
1050359|NCT01794988|Acute Pain
1050360|NCT01794988|Low Back Pain
1050361|NCT01794988|Back Pain
1050362|NCT01794988|Functional Magnetic Resonance Imaging (fMRI)
1050363|NCT01794988|Cognitive Behavioral Therapy
1050364|NCT01794988|Pain Education
1050365|NCT01794975|PET
1050366|NCT01794975|striatum
1050367|NCT01794975|receptor occupancy
1050368|NCT01794975|noradrenaline
1050369|NCT01794975|alpha2c
1050370|NCT01794962|Classification
1050371|NCT01794962|LBP
1050372|NCT01794962|Cognitive functional therapy
1050373|NCT01794962|Manual Therapy
1050374|NCT01794949|Angioplasty
1050375|NCT01794949|Atherosclerosis
1050376|NCT01794949|Wound Healing
1050377|NCT01794936|Prostate cancer
1050378|NCT01794936|Nerve Sparing Prostatectomy
1050379|NCT01794936|VTI Probe
1050380|NCT01794923|Delayed onset muscle soreness
1050381|NCT01794923|ibuprofen
1050382|NCT01794923|topical
1050383|NCT01794910|Pregnancy
1050384|NCT01794910|Pelvic Floor
1050385|NCT01794910|Muscle strength
1050386|NCT01794910|Exercise therapy
1050387|NCT01794910|natural childbirth
1050388|NCT01794910|cesarean section
1050389|NCT01794910|physiotherapy
1050390|NCT01794884|Glutamine
1050391|NCT01794884|Cardiosurgery
1050392|NCT01794884|Cardiopulmonary bypass
1050393|NCT01794884|Cardiac function
1050394|NCT01794884|Recovery
1050395|NCT01794845|SCCHN
1050396|NCT01794845|Head and Neck Cancer
1050397|NCT01794845|Squamous Cell Carcinoma
1050398|NCT01794845|Recurrent
1050399|NCT01794832|HRQoL
1050400|NCT01794832|Aortic stenosis
1050401|NCT01794832|Aortic valve surgery
1050402|NCT01794819|antibiotics
1050403|NCT01794819|primary care
1050404|NCT01794819|radiology/radiography
1050405|NCT01794819|respiratory tract infections
1050406|NCT01794793|SOM230,
1050407|NCT01794793|roll-over study
1050408|NCT01794793|pasireotide LAR
1050409|NCT01794793|Cushing's disease
1050410|NCT01794793|Acromegaly
1050411|NCT01794793|neuroendocrine tumorsNETs
1050412|NCT01794793|pituitary tumors
1050413|NCT01794793|Ectopic ACTH secreting
1050414|NCT01794793|EAS
1050415|NCT01794793|Dumping Syndrome
1050416|NCT01794793|metastatic prostate cancer, metastatic melanoma
1050417|NCT01794793|bRAF
1050418|NCT01794793|nRAS
1050419|NCT01794767|peripheral venous catheter, children.
1050420|NCT01794754|Hand osteoarthritis
1050421|NCT01794754|CMC1-joint
1050422|NCT01794754|surgery
1050423|NCT01794754|occupational therapy
1050424|NCT01794754|hand exercises
1050425|NCT01794754|assistive devices
1050426|NCT01794754|orthoses
1050427|NCT01794728|Pain Management
1050428|NCT01794715|Heart failure
1050429|NCT01794715|Nurse led
1050430|NCT01794715|Outpatient clinic
1050431|NCT01794715|Echocardiography
1050432|NCT01794715|Pocket-size
1050433|NCT01794715|Ultrasound
1050434|NCT01794702|Leukemia
1050435|NCT01794702|Acute Leukemia
1050436|NCT01794702|Acute myelogenous leukemia
1050437|NCT01794702|AML
1050438|NCT01794702|Acute lymphoblastic leukemia
1050439|NCT01794702|ALL
1050440|NCT01794702|Maximum Tolerated Dose
1050441|NCT01794702|MTD
1050442|NCT01794702|Response Rate
1050443|NCT01794702|Decitabine
1050444|NCT01794702|Dacogen
1050445|NCT01794702|Idarubicin
1050446|NCT01794702|Idamycin
1050447|NCT01794702|Cytarabine
1050448|NCT01794702|Ara-C
1050449|NCT01794702|Cytosar
1050450|NCT01794702|DepoCyt
1050451|NCT01794702|Cytosine Arabinosine Hydrochloride
1050452|NCT01794676|Pancreatic cancer
1050453|NCT01794676|Thymic cancer
1050454|NCT01794676|Parathyroid disease
1050455|NCT01794676|MEN1 syndrome
1050456|NCT01794676|Genomic DNA
1050457|NCT01794676|MEN1 gene sequence
1050458|NCT01794663|Early kidney graft dysfunction
1050459|NCT01794663|renal transplantation
1050460|NCT01794650|T1DM, Exercise, Hypoglycaemia
1050461|NCT01794637|End stage liver disease
1050462|NCT01794637|Peripheral microcirculatory dysfunction
1050463|NCT01794637|Liver transplantation
1050464|NCT01794637|Near infrared spectroscopy
1050465|NCT01794624|TMD
1050466|NCT01794624|TMJD
1050467|NCT01794624|Temporomandibular Joint Disorders
1050468|NCT01794624|Sleep Continuity Disturbance
1050469|NCT01794624|Pain Catastrophizing
1050470|NCT01794624|Cognitive Therapy
1050471|NCT01794624|Behavioral Therapy
1050472|NCT01794598|Heart failure
1050473|NCT01794598|depression
1050474|NCT01794598|depression care education
1050475|NCT01794585|traumatic brain injury
1050476|NCT01794585|balance deficits
1050477|NCT01794585|virtual reality
1050478|NCT01794585|home-based therapy
1050479|NCT01794572|Multiple Myeloma
1050480|NCT01794572|Relapse
1050481|NCT01794572|Complete Remission
1050482|NCT01794572|Very Good Partial Remission
1050483|NCT01794546|pediatric obesity
1050484|NCT01794546|telehealth
1050485|NCT01794533|Irreversible Pulpitis
1050486|NCT01794533|Infiltration injection
1050487|NCT01794533|Fentanyl
1050488|NCT01794533|Lidocaine
1050489|NCT01794520|relapsed/refractory multiple myeloma
1050490|NCT01794520|multiple myeloma
1050491|NCT01794520|refractory multiple myeloma
1050492|NCT01794520|relapsed multiple myeloma
1050493|NCT01794507|refractory multiple myeloma
1050494|NCT01794507|relapsed/refractory multiple myeloma
1050495|NCT01794507|relapsed multiple myeloma
1050496|NCT01794507|multiple myeloma
1050497|NCT01794494|Peripheal arterial disease
1050498|NCT01794494|Critical limb ischemia
1050499|NCT01794494|Bypass surgery
1050500|NCT01794494|Subintimal angioplasty
1050501|NCT01794494|Health related cost
1050502|NCT01794468|Dermal blood flow
1050503|NCT01794468|critically ill
1050504|NCT01794455|Depression
1050505|NCT01794455|Depressive Disorder
1050506|NCT01794455|Geriatrics
1050507|NCT01794455|Hypertension
1050508|NCT01794429|Obesity
1050509|NCT01794429|The Metabolic Syndrome/disturbances
1050510|NCT01794429|Drug-induced adipositas
1050511|NCT01794429|Schizophrenia
1050512|NCT01794429|GLP-1 analogue
1050513|NCT01794429|cerebral effects
1050514|NCT01794403|Prostate Cancer
1050515|NCT01794403|Prostate
1050516|NCT01794403|Radiation Therapy
1050517|NCT01794403|Hypofractionation Radiotherapy
1050518|NCT01794403|Extended Hypofractionation Radiotherapy
1050519|NCT01794403|Accelerated Hypofractionation Radiotherapy
1050520|NCT01794403|AHRT
1050521|NCT01794403|EHRT
1050522|NCT01794390|COPD (Chronic Obstructive Pulmonary Disease)
1050523|NCT01794390|Asthma
1050524|NCT01794390|Pulmojet
1050525|NCT01794390|Inhalers
1050526|NCT01794390|Respiratory
1050527|NCT01794390|Inhaler Technique
1050528|NCT01794390|Critical Errors
1050529|NCT01794377|Obesity
1050530|NCT01794364|T2DM
1050531|NCT01794364|Diabetes Mellitus Type 2
1050532|NCT01794325|Occupational radiation exposure
1050533|NCT01794325|Transradial approach
1050534|NCT01794325|Transfemoral approach
1050535|NCT01794299|Haploidentical stem cell transplantation
1050536|NCT01794299|Graft-versus-host disease
1050537|NCT01794299|Immune reconstitution
1050538|NCT01794299|Alloreactive T-cells
1050539|NCT01794299|Photodepletion
1050540|NCT01794299|Photodynamic treatment
1050541|NCT01794299|TH9402
1050542|NCT01794299|Transplant-related mortality
1050543|NCT01794299|Hematologic malignancy
1050544|NCT01794273|Ephedrine
1050545|NCT01794273|Phenylephrine
1050546|NCT01794273|Vasopressor
1050547|NCT01794273|Carotid surgery
1050548|NCT01794273|Hypotension
1050549|NCT01794273|Haemodynamics
1050550|NCT01794273|Brain ischemia
1050551|NCT01794273|Tissue perfusion
1050552|NCT01794273|Stroke
1050553|NCT01794273|anaesthesia;
1050554|NCT01794260|Osteoarthritis
1050555|NCT01794260|Moderate ot severe pain
1050556|NCT01794260|ZINGIBER CASSUMUNAR ROXB
1050557|NCT01794221|circumcision
1050558|NCT01794221|2 octyl cyanoacrylate
1050559|NCT01794221|phimosis
1050560|NCT01794208|in-vitro fertilization
1050561|NCT01794208|reproductive disorder
1050562|NCT01794195|Parkinson's disease
1050563|NCT01794195|Apathy
1050564|NCT01794195|diffusion tensor imaging
1050565|NCT01794195|tractography
1050566|NCT01794156|Inference-based therapy
1050567|NCT01794156|Cognitive behavior therapy
1050568|NCT01794156|Obsessive compulsive disorder
1050569|NCT01794156|Randomized clinical trial
1050570|NCT01794143|Treatment of Type 2 diabetes
1050571|NCT01794143|Comparative effectiveness research
1050572|NCT01794143|Clinical trial
1050573|NCT01794143|Patient-centered outcomes
1050574|NCT01794117|Efficacy
1050575|NCT01794117|Optimal Dosing
1050576|NCT01794117|Safety
1050577|NCT01794117|Pustular Skin Lesion
1050578|NCT01794117|Neutrophilic Pustulosis
1050584|NCT01794091|Cardiac Magnetic Resonance Imaging
1050585|NCT01794091|Diabetes
1050586|NCT01794078|Acute Mountain Sickness
1050587|NCT01794078|High altitude induced fatigue
1050588|NCT01794026|diffusion weighted
1050589|NCT01794026|magnetic resonance imaging
1050590|NCT01794026|surgery
1050591|NCT01794026|histopathology
1050592|NCT01794013|Parent training
1050593|NCT01794013|DIR/ Floortime Approach
1050594|NCT01794013|Children with developmental disabilities
1050595|NCT01793987|blood loss between two groups
1050596|NCT01793974|LADA
1050597|NCT01793974|Latent Autoimmune Diabetes in Adults
1050598|NCT01793974|Latent Autoimmune Diabetes
1050599|NCT01793974|Latent Diabetes in Adults
1050600|NCT01793935|Schizophrenia
1050601|NCT01793935|Sensoril
1050602|NCT01793935|Withania Somnifera extract
1050603|NCT01793935|Total/ Positive / Negative Symptoms
1050604|NCT01793935|Stress
1050605|NCT01793935|Inflammation
1050606|NCT01793935|Immunomodulation
1050607|NCT01793909|Type 2 Diabetes
1050608|NCT01793909|Exercise Impairment
1050609|NCT01793909|Blood Flow
1050610|NCT01793909|Muscle Oxygen Uptake
1050611|NCT01793909|Exercise Training
1050612|NCT01793896|Metabolic syndrome
1050613|NCT01793896|Ageing
1050614|NCT01793896|Mitochondrial density
1050615|NCT01793896|Oxidative damage
1050616|NCT01793896|Inflammatory mediators
1050617|NCT01793896|AMPK
1050618|NCT01793896|Adipogenesis
1050619|NCT01793883|Influenza Laninamivir Octanoate
1050620|NCT01793870|pharmacokinetic
1050621|NCT01793870|carvedilol
1050622|NCT01793870|Stable isotope technique
1050623|NCT01793857|Primary caregiver
1050624|NCT01793857|Survey
1050625|NCT01793857|Acute Otitis Media
1050626|NCT01793857|Ear infection
1050627|NCT01793857|Panama
1050628|NCT01793857|Healthcare seeking behaviour
1050629|NCT01793844|diffuse large B cell lymphoma
1050630|NCT01793844|DFS
1050631|NCT01793844|OS
1050632|NCT01793831|Crohn's diseases
1050633|NCT01793831|Inflammatory bowel disease
1050634|NCT01793831|Fecal transplantation
1050635|NCT01793831|Fecal bacteriotherapy
1050636|NCT01793831|Fecal microbiota transplantation
1050637|NCT01793818|Vaccine
1050638|NCT01793818|HIV-1
1050639|NCT01793818|Tat
1050640|NCT01793792|intracranial, saccular, aneurysms, stenting, coiling
1050641|NCT01793740|sickle cell disease
1050642|NCT01793740|pediatric
1050643|NCT01793740|learning disability
1050644|NCT01793740|cognitive impairment
1050645|NCT01793740|memory
1050646|NCT01793740|attention
1050647|NCT01793740|Children with sickle cell disease
1050648|NCT01793727|infants
1050649|NCT01793727|general anesthesia
1050650|NCT01793727|tracheal intubation
1050651|NCT01793714|Magnetic Resonance Imaging
1050652|NCT01793701|Cervical Cancer, Intensity-modulated radiotherapy
1050653|NCT01793688|UNASYN-S
1050654|NCT01793688|High Dose
1050655|NCT01793662|Aortobifemoral bypass
1050656|NCT01793662|Laparoscopic aortic surgery
1050657|NCT01793662|Aortoiliac occlusive disease
1050658|NCT01793662|TASC Type D Lesions
1050659|NCT01793662|Open aortic surgery
1050660|NCT01793649|Respiratory health
1050661|NCT01793649|Cystic Fibrosis
1050662|NCT01793649|Chronic Obstructive Pulmonary Disease
1050663|NCT01793623|atrial fibrillation
1050664|NCT01793623|genetics
1050665|NCT01793623|cardiac arrhythmias
1050666|NCT01793623|heart disease
1050667|NCT01793610|MDMA
1050668|NCT01793610|Posttraumatic stress disorder
1050669|NCT01793610|sleep
1050670|NCT01793610|Depression
1050671|NCT01793610|Safety
1050672|NCT01793597|ticagrelor
1050673|NCT01793597|Coronary artery bypass surgery
1050674|NCT01793597|platelet function
1050675|NCT01793597|receptor binding
1050676|NCT01793597|platelet reactivity
1050677|NCT01793597|reversible binding
1050678|NCT01793584|Comparative effectiveness
1050679|NCT01793584|Surgical success
1050680|NCT01793571|Abdominal Muscles/Ultrasonography
1050681|NCT01793571|Adult
1050682|NCT01793571|Ambulatory Surgical Procedures
1050683|NCT01793571|Anesthetics, Local/Administration & Dosage
1050684|NCT01793571|Levobupivacaine/Administration & Dosage
1050685|NCT01793571|Levobupivacaine/Analogs & Derivatives
1050686|NCT01793571|Hernia, Inguinal/Surgery
1050687|NCT01793571|Humans
1050688|NCT01793571|Nerve Block/Methods
1050689|NCT01793571|Pain Measurement/Methods
1050690|NCT01793571|Pain, Postoperative/Prevention & Control
1050691|NCT01793571|Ultrasonography, Interventional
1050692|NCT01793558|Thermoregulation Impairment
1050693|NCT01793558|hypothermia
1050694|NCT01793558|Postoperative shivering
1050695|NCT01793558|cesarean section
1050696|NCT01793558|newborn
1050697|NCT01793545|Endometrial Cancer
1050698|NCT01793545|Gynecological Cancers
1050699|NCT01793545|Screening
1050700|NCT01793532|PET Imaging
1050701|NCT01793532|Epilepsy
1050702|NCT01793532|Inflammation
1050703|NCT01793532|Brain Imaging
1050704|NCT01793519|Rheumatoid Arthritis
1050705|NCT01793519|Autoimmune Diseases
1050706|NCT01793519|Anti-TNF
1050707|NCT01793506|immunodeficiency
1050708|NCT01793493|Mild Cognitive Impairment
1050709|NCT01793493|Cognitive Stimulation
1050710|NCT01793493|Aging
1050711|NCT01793493|Elderly
1050712|NCT01793493|Randomized Controlled Trial
1050713|NCT01793480|Methadone in cancer pain
1050714|NCT01793428|adults admitted in vital emergency unit
1050715|NCT01793389|gingival recession
1050716|NCT01793389|fibrin
1050717|NCT01793389|connective tissue
1050718|NCT01793389|root coverage
1050719|NCT01793389|microsurgery
1050720|NCT01793389|case-control studies
1050721|NCT01793363|Tracheotomy
1050722|NCT01793363|Weaning from mechanical ventilation
1050723|NCT01793363|Lung ultrasound score
1050724|NCT01793350|Diabetes
1050725|NCT01793350|Mellitus
1050726|NCT01793350|Painful
1050727|NCT01793350|Neuropathy
1050728|NCT01793350|Peripheral
1050729|NCT01793324|Effectiveness of risk minimization
1050730|NCT01793324|Metabolic monitoring
1050731|NCT01793324|Seroquel® or Seroquel® XR/quetiapine fumarate
1050732|NCT01793311|intraocular pressure
1050733|NCT01793311|caffeine
1050734|NCT01793311|dosage
1050735|NCT01793246|lung cancer
1050736|NCT01793246|lung neoplasms
1050737|NCT01793246|lung transplant
1050738|NCT01793194|venous insufficiency
1050739|NCT01793194|varicose veins
1050740|NCT01793194|pregnancy
1050741|NCT01793194|DVT
1050742|NCT01793194|superficial thrombophlebitis
1050743|NCT01793181|Vitamin d deficiency
1050744|NCT01793181|Central retinal vein occlusion
1050745|NCT01793168|Rare Diseases
1050746|NCT01793168|Neglected Diseases
1050747|NCT01793168|Orphan Diseases
1050748|NCT01793168|Rare Disease Research
1050749|NCT01793168|Registries
1050750|NCT01793168|WAGR Syndrome
1050751|NCT01793168|Ataxia
1050752|NCT01793168|Cornelia de Lange Syndrome
1050753|NCT01793168|Stickler Syndrome
1050754|NCT01793168|Ataxia Telangiectasia
1050755|NCT01793168|Kawasaki Disease
1050756|NCT01793168|Batten Disease
1050757|NCT01793168|Mucolipidosis IV
1050758|NCT01793168|Klippel-Feil
1050759|NCT01793155|Lung cancer surgery
1050760|NCT01793155|Inspiratory muscle training
1050761|NCT01793155|Postoperative pulmonary complications
1050762|NCT01793155|Functional outcomes
1050763|NCT01793155|Health related quality of life
1050764|NCT01793142|Osteoporosis
1050765|NCT01793142|postmenopausal
1050766|NCT01793142|SERM
1050902|NCT01792635|Safety & Tolerability
1050772|NCT01793116|NICHD Neonatal Research Network
1050773|NCT01793116|Moderately Preterm
1050774|NCT01793090|Cobalamin C defect
1050775|NCT01793090|methylmalonic aciduria with homocystinuria
1050776|NCT01793090|Visual function
1050777|NCT01793090|VEP
1050778|NCT01793090|ERG
1050779|NCT01793090|antioxidant drugs
1050780|NCT01793077|Prostate Cancer
1050781|NCT01793077|Phase 4
1050782|NCT01793077|Data collection
1050783|NCT01793077|Observational
1050784|NCT01793077|Depo-Eligard
1050785|NCT01793077|Prospective
1050786|NCT01793077|Non-interventional
1050787|NCT01793077|Treatment
1050788|NCT01793064|Pedometer,
1050789|NCT01793064|adaptive,
1050790|NCT01793064|exercise,
1050791|NCT01793064|reinforcement,
1050792|NCT01793064|goal setting,
1050793|NCT01793064|technology,
1050794|NCT01793064|email,
1050795|NCT01793064|weight loss
1050796|NCT01793064|mHealth
1050797|NCT01793064|eHealth
1050798|NCT01793051|Myeloma
1050799|NCT01793051|Multiple Myeloma
1050800|NCT01793051|MM
1050801|NCT01793051|Symptom Burden
1050802|NCT01793051|Symptom reduction
1050803|NCT01793051|Maintenance therapy with lenalidomide
1050804|NCT01793051|Minocycline
1050805|NCT01793051|Dynacin
1050806|NCT01793051|Minocin
1050807|NCT01793051|Minocin PAC
1050808|NCT01793051|Myrac
1050809|NCT01793051|Solodyn
1050810|NCT01793051|Placebo
1050811|NCT01793051|Sugar pill
1050812|NCT01793051|MD Anderson Symptom Inventory
1050813|NCT01793051|MDASI
1050814|NCT01793051|Questionnaires
1050815|NCT01793051|Surveys
1050816|NCT01793038|PCOS
1050817|NCT01793038|clomiphene citrate resistant PCOS
1050818|NCT01793038|Aromatase inhibitors
1050819|NCT01793025|leukemia
1050820|NCT01793025|myeloid
1050821|NCT01793025|acute
1050822|NCT01793025|acute myeloid leukemia
1050823|NCT01793025|allogeneic
1050824|NCT01793025|transient chimerism
1050825|NCT01793025|cell therapy
1050826|NCT01793025|immunotherapy
1050827|NCT01793012|therapeutic drug monitoring
1050828|NCT01793012|antibiotics
1050829|NCT01793012|inflammation parameters
1050830|NCT01793012|critically ill patients
1050831|NCT01793012|septicaemia
1050832|NCT01793012|intensive care unit
1050833|NCT01792986|Diabetes
1050834|NCT01792986|Fasting
1050835|NCT01792986|Pre-diabetes
1050836|NCT01792986|Hemoglobin A1C
1050837|NCT01792973|HIV
1050838|NCT01792973|HPV
1050839|NCT01792973|Women
1050840|NCT01792973|Thailand
1050841|NCT01792973|Antiretrovirals
1050842|NCT01792973|Cervical cancer
1050843|NCT01792921|Age 7-10 years old
1050844|NCT01792921|regular education system
1050845|NCT01792921|no moderate or severe neurological and/or psychiatric disorders
1050846|NCT01792908|ankle lateral ligament
1050847|NCT01792908|athletic tape
1050848|NCT01792908|position sense
1050849|NCT01792908|Proprioception
1050850|NCT01792895|Posterior Neck Pain
1050851|NCT01792895|Cervical spine pain
1050852|NCT01792895|Manual therapy
1050853|NCT01792856|coaching
1050854|NCT01792856|early psychosis
1050855|NCT01792856|schizophrenia
1050856|NCT01792830|Coronary Artery Bypass Graft surgery
1050857|NCT01792817|Cluster Headache
1050858|NCT01792817|GammaCore
1050859|NCT01792817|vagal nerve stimulation
1050860|NCT01792817|nVNS
1050861|NCT01792817|VNS
1050862|NCT01792817|non invasive
1050863|NCT01792817|vagus nerve stimulation
1050864|NCT01792804|Staphylococcus aureus
1050865|NCT01792804|Bloodstream infection
1050866|NCT01792804|Oral switch
1050867|NCT01792778|IV Catheters
1050868|NCT01792778|Blood control
1050869|NCT01792765|urolithiasis
1050870|NCT01792765|radiation free
1050871|NCT01792765|ultrasound guidance
1050872|NCT01792765|ureteroscopy
1050873|NCT01792752|HIV/AIDS
1050874|NCT01792752|Drug Users
1050875|NCT01792752|Puerto Rico
1050876|NCT01792739|Probiotics
1050877|NCT01792739|Diarrhea
1050878|NCT01792739|Intentive care units
1050879|NCT01792726|breast cancer
1050880|NCT01792726|radiotherapy
1050881|NCT01792726|TARGIT
1050882|NCT01792726|Intrabeam
1050883|NCT01792713|Skin alterations
1050884|NCT01792713|Atopic Dermatitis
1050885|NCT01792687|Metastatic castrate resistant prostate cancer (CRPC)
1050886|NCT01792674|Education
1050887|NCT01792674|Patient simulation
1050888|NCT01792674|In situ simulation
1050889|NCT01792674|Stress
1050890|NCT01792661|Chronic Kidney Disease
1050891|NCT01792661|Electronic Health Record
1050892|NCT01792661|Personal Health Record
1050893|NCT01792661|Chronic Kidney Disease registry
1050894|NCT01792661|Glomerular Filtration Rate
1050895|NCT01792661|Patient Navigator
1050896|NCT01792648|Almond
1050897|NCT01792648|Carbohydrate
1050898|NCT01792648|Diet
1050899|NCT01792648|Cholesterol
1050900|NCT01792635|Type 2 Diabetes Mellitus
1050901|NCT01792635|Pharmacodynamics
1050903|NCT01792622|Instrument Development
1050904|NCT01792622|Patient Reported Outcomes
1050905|NCT01792622|Pulmonary Arterial Hypertension.
1050906|NCT01792609|Scoliosis
1050907|NCT01792609|Cobb Angle
1050908|NCT01792609|Screw Density
1050909|NCT01792609|Outcomes Measures
1050910|NCT01792583|pregnancy
1050911|NCT01792570|HIV-1
1050912|NCT01792570|darunavir
1050913|NCT01792570|rilpivirine
1050914|NCT01792570|strategic study
1050915|NCT01792557|Pilonidal sinus
1050916|NCT01792557|Crystallized phenol
1050917|NCT01792557|Limberg Flap
1050918|NCT01792557|Modified Limberg Flap
1050919|NCT01792557|Karydakis
1050920|NCT01792557|Recurrence
1050921|NCT01792557|Complications
1050922|NCT01792557|Recovery duration
1050923|NCT01792557|Time to return to work
1050924|NCT01792531|children
1050925|NCT01792531|obesity
1050926|NCT01792531|treatment
1050927|NCT01792531|family
1050928|NCT01792492|Thyroid Neoplasms
1050929|NCT01792492|Optical Devices
1050930|NCT01792492|Spectrum Analysis
1050931|NCT01792492|Thyroid diseases
1050932|NCT01792479|NSCLC
1050933|NCT01792479|lung cancer
1050934|NCT01792466|difficult biliary cannulation
1050935|NCT01792453|Gastrointestinal physiology
1050936|NCT01792453|MRI
1050937|NCT01792453|Small bowel water volumes
1050938|NCT01792453|Gastric volumes
1050939|NCT01792401|Critical illness
1050940|NCT01792401|Dietary supplements
1050941|NCT01792401|Gastrointestinal tract/physio-pathology
1050942|NCT01792388|Crohn's Disease
1050943|NCT01792388|Vitamin D
1050944|NCT01792388|Intestinal Permeability
1050945|NCT01792388|Tara Raftery
1050946|NCT01792375|Cervical ripening
1050947|NCT01792375|Dinoprostone
1050948|NCT01792375|Labor induction
1050949|NCT01792375|Membrane sweeping
1050950|NCT01792375|Nulliparous women
1050951|NCT01792375|Trial
1050952|NCT01792362|Anti-mullerian hormone (AMH) level, poly cystic ovarian syndrome obese infertility weight loss diet
1050958|NCT01792323|insulin pump therapy
1050959|NCT01792323|insulin bolus
1050960|NCT01792323|rapid acting insulin
1050961|NCT01792323|insulin lispro
1050962|NCT01792323|pharmacodynamics
1050963|NCT01792323|pharmacokinetics
1050964|NCT01792323|glucose clamp
1050965|NCT01792310|Glioma
1050966|NCT01792310|Solid Tumours
1050967|NCT01792310|Minerval
1050968|NCT01792297|Sarcopenia
1050969|NCT01792297|Osteoporosis
1050970|NCT01792297|Cognition
1050971|NCT01792297|Inflammation
1050975|NCT01792258|Percutaneous tracheostomy
1050976|NCT01792258|Intensive Care Unit
1050977|NCT01792258|Ineffective Airway Clearance
1050978|NCT01792258|Weaning failure
1050979|NCT01792245|narrow band UVB; PUVA; psoriasis; eczema; hand
1050980|NCT01792232|Diesel exhaust
1050981|NCT01792232|Air pollution
1050982|NCT01792232|Airway responsiveness
1050983|NCT01792232|Allergies
1050984|NCT01792219|interprofessional learning
1050985|NCT01792219|interprofessional collaboration
1050986|NCT01792219|residents
1050987|NCT01792219|nursing homes
1050988|NCT01792206|Stage 3 chronic kidney disease (CKD)
1050989|NCT01792206|Stage 4 chronic kidney disease (CKD)
1050990|NCT01792206|CKD
1050991|NCT01792180|Gait speed
1050992|NCT01792180|Mobility
1050993|NCT01792180|Falls
1050994|NCT01792180|Fall risk
1050995|NCT01792180|Self-management
1050996|NCT01792180|Mental wellbeing
1050997|NCT01792180|Elderly
1050998|NCT01792115|Fatty Liver
1050999|NCT01792115|Alpha-Tocopherol
1051000|NCT01792115|Vitamin E
1051001|NCT01792115|Non-Alcoholic Steatohepatitis
1051002|NCT01792102|Multiple Myeloma
1051003|NCT01792102|Carfilzomib
1051004|NCT01792102|Krypolis
1051005|NCT01792102|60 minute infusion
1051006|NCT01792089|de novo lipogenesis
1051007|NCT01792089|fructose
1051008|NCT01792089|roux-en-Y gastric bypass
1051009|NCT01792089|post-prandial triglycerides
1051010|NCT01792050|IDO
1051011|NCT01792050|IDO Inhibitor
1051012|NCT01792050|Metastatic Breast Cancer
1051013|NCT01792011|Elective living donor liver transplantation
1051014|NCT01791985|Breast Cancer
1051015|NCT01791985|AZD4547
1051016|NCT01791985|Safety Run-In
1051017|NCT01791985|FGFR1
1051018|NCT01791985|ER positive breast cancer
1051019|NCT01791985|Single arm phase IIa study
1051020|NCT01791972|Exercise-Induced Bronchoconstriction (EIB)
1051021|NCT01791972|Spiromax®
1051022|NCT01791972|Albuterol sulfate
1051023|NCT01791946|lazy eye
1051024|NCT01791946|cross eye
1051025|NCT01791946|cross eyed
1051026|NCT01791933|LBP
1051027|NCT01791933|Neck pain
1051028|NCT01791933|Integrative package
1051029|NCT01791933|CAM
1051030|NCT01791868|Generalized convulsive status epilepticus
1051031|NCT01791868|Sodium valproate
1051032|NCT01791868|Refractory status epilepticus
1051033|NCT01791868|Mortality
1051034|NCT01791868|Epilepsy
1051035|NCT01791868|Intensive Care Unit
1051036|NCT01791868|Neurological sequela
1051037|NCT01791868|Quality of life
1051038|NCT01791868|Adult
1051039|NCT01791855|Subjects with Renal Impairment
1051040|NCT01791855|healthy
1051041|NCT01791842|fibrous dysplasia of bone
1051042|NCT01791842|tocilizumab
1051043|NCT01791842|McCune-Albright syndrome
1051046|NCT01791816|Vasovagal Syncope
1051047|NCT01791816|Postural Tachycardia Syndrome
1051048|NCT01791816|Orthostatic Intolerance
1051049|NCT01791816|Nitric Oxide (NO)
1051050|NCT01791816|Orthostatic Stress
1051051|NCT01791816|L-Ng-monomethyl Arginine (L-NMMA)
1051052|NCT01791816|Phenylephrine
1051053|NCT01791816|Sodium Nitroprusside
1051054|NCT01791803|Smoking cessation
1051055|NCT01791803|Tobacco abstinence
1051056|NCT01791803|hypnotherapy
1051057|NCT01791803|Nicotine replacement therapy
1051058|NCT01791790|old Subjects
1051059|NCT01791790|Controls
1051060|NCT01791790|brain stimulation
1051061|NCT01791790|tSOS
1051062|NCT01791790|tDCS
1051063|NCT01791790|sleep
1051064|NCT01791790|memory
1051065|NCT01791790|memory consolidation
1051066|NCT01791777|fidelity
1051067|NCT01791777|implementation science
1051068|NCT01791777|competence
1051069|NCT01791777|training
1051070|NCT01791777|coaching
1051071|NCT01791738|Total Hip Arthroplasty (THA)
1051072|NCT01791738|Patient-Specific Instruments
1051073|NCT01791738|Acetabular Cup Placement
1051074|NCT01791738|Accuracy
1051075|NCT01791699|atrial fibrillation
1051076|NCT01791699|paroxysmal
1051077|NCT01791699|persistent
1051078|NCT01791699|ablation
1051079|NCT01791699|pulmonary vein isolation
1051080|NCT01791699|recurrence
1051081|NCT01791686|Dense Deposit Disease
1051082|NCT01791686|DDD
1051083|NCT01791673|Glaucoma
1051084|NCT01791673|Cyclocoagulation
1051085|NCT01791673|HIFU - High Intensity Focused Ultrasound
1051086|NCT01791673|Ciliary Body
1051087|NCT01791647|Polycystic ovary syndrome
1051088|NCT01791647|myoinositol
1051089|NCT01791647|metformin
1051090|NCT01791647|glucose-insulinemic metabolism
1051091|NCT01791647|menstrual pattern
1051092|NCT01791647|insulin-lowering therapies
1051093|NCT01791621|Irritable Bowel Syndrome
1051094|NCT01791621|Elimination diet
1051095|NCT01791621|Food allergies
1051096|NCT01791608|Child, Preschool
1051097|NCT01791608|Dietary Zinc
1051098|NCT01791608|Zinc sulfate
1051099|NCT01791608|zinc-glycine chelate
1051100|NCT01791595|Phase I
1051101|NCT01791595|Cancer
1051102|NCT01791595|Solid Tumours
1051103|NCT01791595|Prostate Cancer
1051104|NCT01791595|Gastric Cancer
1051105|NCT01791595|Diffuse Large B Cell Lymphoma
1051106|NCT01791595|Monocarboxylate Transporter 1 Inhibitor
1051107|NCT01791595|lactate
1051108|NCT01791556|HIV
1051109|NCT01791556|AIDS
1051110|NCT01791556|Kenya
1051111|NCT01791556|viral load
1051112|NCT01791556|Antiretroviral therapy
1051113|NCT01791556|randomized clinical trial
1051114|NCT01791556|ART monitoring
1051115|NCT01791556|treatment failure
1051116|NCT01791556|HIV resistance
1051117|NCT01791543|ventricular tachycardia
1051118|NCT01791543|ablation
1051119|NCT01791543|ventricular arrhythmia
1051120|NCT01791530|VAT
1051121|NCT01791530|VAP
1051122|NCT01791530|Transition from VAT to VAP
1051123|NCT01791504|Abdominoplasty
1051124|NCT01791478|-Metastatic breast cancer, PI3K inhibitor, Endocrine therapy
1051125|NCT01791465|HIV
1051126|NCT01791465|Diabetes
1051127|NCT01791400|Metoclopramide
1051128|NCT01791400|Sumatriptan
1051129|NCT01791400|migraine
1051130|NCT01791400|headache
1051131|NCT01791387|Renal cell
1051132|NCT01791387|Kidney
1051133|NCT01791387|Cancer
1051134|NCT01791387|Metastatic carcinoma
1051135|NCT01791374|Advanced Solid Tumors
1051136|NCT01791374|Advanced or Metastatic Gastric Cancer
1051137|NCT01791374|Advanced or Metastatic GEJ
1051138|NCT01791374|Gastric Cancer
1051139|NCT01791361|Metastatic colorectal cancer
1051140|NCT01791335|Glottis
1051141|NCT01791335|Respiratory Muscles
1051142|NCT01791335|Upper airway
1051143|NCT01791335|Noninvasive ventilation
1051144|NCT01791309|Vemurafenib
1051145|NCT01791309|Panitumumab
1051146|NCT01791309|V600E BRAF mutation
1051147|NCT01791309|colon
1051148|NCT01791309|12-221
1051149|NCT01791296|sedation
1051150|NCT01791296|sleep
1051151|NCT01791296|delirium
1051152|NCT01791296|critical illness
1051153|NCT01791296|sub-syndromal delirium
1051154|NCT01791296|intensive care
1051155|NCT01791283|Left ventricular stroke volume
1051156|NCT01791283|Arterial waveform analysis
1051157|NCT01791283|Esofageal doppler
1051158|NCT01791283|Ultrasound
1051159|NCT01791283|Cardiac magnetic Imaging
1051160|NCT01791283|Limits of agreement
1051161|NCT01791270|Obstructive Sleep Apnea
1051162|NCT01791270|Hypertension
1051163|NCT01791270|β1 Subunit of Maxi-k+Channel
1051164|NCT01791270|Cardiovascular Risk
1051165|NCT01791257|delayed
1051166|NCT01791257|cerebral
1051167|NCT01791257|ischemia
1051168|NCT01791257|microrna
1051169|NCT01791257|cerebrospinal fluid
1051170|NCT01791257|subarachnoid
1051171|NCT01791257|hemorrhage
1051172|NCT01791244|Multiple Sclerosis
1051173|NCT01791244|Relapsing-Remitting
1051174|NCT01791244|Rebif
1051175|NCT01791244|RebiSmart
1051176|NCT01791244|Patient support program
1051177|NCT01791231|Healthy
1051178|NCT01791231|Male
1051179|NCT01791231|Canagliflozin (JNJ-28431754)
1051180|NCT01791231|Radiolabeled 14C-canagliflozin
1051181|NCT01791231|Absorption
1051182|NCT01791231|Metabolism
1051183|NCT01791231|Excretion
1051184|NCT01791231|Radioactivity
1051185|NCT01791218|Pulmonary vein isolation
1051186|NCT01791218|Paroxysmal atrial fibrillation
1051187|NCT01791218|Quality of life
1051188|NCT01791192|Uveitis, Fingolimod, Phase II, Visual Acuity, Vitreous Haze, OCT
1051189|NCT01791114|Insulin sensitivity
1051190|NCT01791114|Diabetes Prevention
1051191|NCT01791114|Obesity
1051192|NCT01791114|Brown adipose tissue
1051193|NCT01791101|Thrombocytopenia
1051194|NCT01791101|Eltrombopag
1051195|NCT01791075|DSAEK
1051196|NCT01791075|Tan Endoglide
1051197|NCT01791075|Endosaver/Endoserter
1051198|NCT01791062|cartilage tissue engineering
1051199|NCT01791062|hyaluronan
1051200|NCT01791062|hyaluronic acid
1051201|NCT01791049|Gram-positive
1051202|NCT01791049|Infections
1051203|NCT01791049|Bacterial infections
1051204|NCT01791036|Adductor canal block
1051205|NCT01791036|Femoral Nerve Block
1051206|NCT01791023|Depression
1051207|NCT01791023|Physical exercise
1051208|NCT01791023|Stress
1051209|NCT01791010|Breathing exercises
1051210|NCT01791010|Aged
1051211|NCT01790997|DLBS1033
1051212|NCT01790997|Lumbrokinase
1051213|NCT01790997|Acute ischemic stroke
1051214|NCT01790997|Bleeding profile
1051215|NCT01790997|Clinical outcome
1051216|NCT01790997|Aspirin
1051217|NCT01790997|Clopidogrel
1051218|NCT01790984|Dietary extrinsic sugars, atherogenic lipoprotein phenotype, lipoprotein kinetics, fatty liver
1051219|NCT01790971|Obstructive sleep apnea
1051220|NCT01790971|Spinal morphine
1051221|NCT01790932|Metastatic
1051222|NCT01790932|Triple Negative
1051223|NCT01790919|Depression, Adults
1051224|NCT01790906|Chronic Heart Failure
1051225|NCT01790906|Renal Sympathetic Denervation
1051226|NCT01790893|Histoplasmosis
1051227|NCT01790880|Aphasia
1051228|NCT01790880|Stroke
1051229|NCT01790880|Speech Rehabilitation
1051230|NCT01790854|prasugrel
1051231|NCT01790854|antiplatelet
1051232|NCT01790854|Acute Coronary Syndrome
1051233|NCT01790815|Acute Malnutrition
1051234|NCT01790815|Mid Upper Arm Circumference
1051235|NCT01790815|Screening
1051362|NCT01790061|Bacteriotherapy
1051236|NCT01790802|laser treatment, high risk, early AMD
1051237|NCT01790776|urethrography
1051238|NCT01790763|Burn
1051239|NCT01790763|Second-degree
1051240|NCT01790750|PDA
1051241|NCT01790750|Echo
1051242|NCT01790750|PES
1051243|NCT01790750|Handheld echo system
1051244|NCT01790737|myeloma, stem cell mobilization, autologous stem cell transplantation
1051245|NCT01790737|induction treatment, maintenance treatment
1051246|NCT01790711|Gut bacteria
1051247|NCT01790711|Bacteria
1051248|NCT01790711|Fecal transplant
1051249|NCT01790711|Bacteriotherapy
1051250|NCT01790698|Necrotizing fasciitis
1051251|NCT01790698|Streptococcus pyogenes
1051252|NCT01790698|Staphylococcus aureus
1051253|NCT01790698|Immunopathogenesis
1051254|NCT01790672|Antioxidants
1051255|NCT01790672|Central Nervous System Agents
1051256|NCT01790672|Wine
1051257|NCT01790659|leishmaniasis
1051258|NCT01790659|cutaneous leishmaniasis
1051259|NCT01790659|Leishmania panamensis
1051260|NCT01790659|L panamensis
1051261|NCT01790659|Paromomycin
1051262|NCT01790659|Paromomycin/Gentamicin
1051263|NCT01790633|rapid test
1051264|NCT01790633|screening
1051265|NCT01790633|ELISA
1051266|NCT01790633|hepatitis B virus
1051267|NCT01790633|hepatitis C virus
1051268|NCT01790633|human immunodeficiency virus
1051269|NCT01790633|access to care
1051270|NCT01790620|Severe sepsis
1051271|NCT01790620|Septic shock
1051272|NCT01790620|Acute renal failure
1051273|NCT01790620|Acute kidney injury
1051274|NCT01790620|Continuous renal replacement therapies CRRT
1051275|NCT01790607|Adult healthy subjects will be matched with individual subjects by age (± 5 years, gender, and BMI (± 15%)
1051276|NCT01790594|transplantation
1051277|NCT01790594|kidney
1051278|NCT01790594|pancreas
1051279|NCT01790594|immunosuppression
1051280|NCT01790594|calcineurin inhibitor (CNI)
1051281|NCT01790581|Chronic Ankle Instability
1051282|NCT01790555|Postsurgical
1051283|NCT01790555|Pain
1051284|NCT01790555|THC
1051285|NCT01790555|Sensitization
1051286|NCT01790542|Iron
1051287|NCT01790542|Intestinal inflammation
1051288|NCT01790542|ROS
1051289|NCT01790516|Head and neck cancer
1051290|NCT01790516|genetic testing
1051291|NCT01790516|cisplatin
1051292|NCT01790516|erbitux
1051293|NCT01790516|radiation therapy
1051294|NCT01790503|glioblastoma
1051295|NCT01790503|GBM
1051296|NCT01790477|Tonsillectomy
1051297|NCT01790477|Acupuncture
1051298|NCT01790464|Glossopharyngeal nerve block
1051299|NCT01790464|Airway anesthesia
1051300|NCT01790464|Awake intubation
1051301|NCT01790451|focal therapy
1051302|NCT01790451|irreversible electroporation
1051303|NCT01790451|prostate cancer
1051304|NCT01790412|pregnancy, exercise, gestational diabetes
1051305|NCT01790399|SENTINEL NODE
1051306|NCT01790386|hemostasis
1051307|NCT01790386|thromboelastography
1051308|NCT01790386|coagulation
1051309|NCT01790386|TEG
1051310|NCT01790373|Suubi
1051311|NCT01790373|Adolescents
1051312|NCT01790373|Poverty
1051313|NCT01790373|Economic empowerment interventions
1051314|NCT01790373|Adherence to HIV antiretroviral therapy
1051315|NCT01790373|Wisepill
1051316|NCT01790373|HIV/AIDS infected Children
1051317|NCT01790373|Medical event monitoring system
1051318|NCT01790373|Uganda
1051319|NCT01790360|MSM
1051320|NCT01790360|HIV
1051321|NCT01790360|Substance Abuse
1051322|NCT01790360|Sexual Behavior
1051323|NCT01790347|Exercise
1051324|NCT01790347|Aerobic
1051325|NCT01790347|Resistance training
1051326|NCT01790347|Pregnancy
1051327|NCT01790347|Maternal weight gain
1051328|NCT01790347|IOM recommendations
1051329|NCT01790295|Myelofibrosis
1051330|NCT01790295|Stem cell transplant
1051331|NCT01790295|Ruxolitinib
1051332|NCT01790282|luteal support
1051333|NCT01790282|high responder
1051334|NCT01790282|ICSI
1051335|NCT01790282|ivf
1051336|NCT01790282|cycle outcome
1051337|NCT01790269|Relapsing-Remitting Multiple Sclerosis
1051338|NCT01790269|NK cells
1051339|NCT01790269|Fingolimod
1051340|NCT01790204|mutant p53
1051341|NCT01790204|watercress
1051342|NCT01790204|Phenethyl isothyocyanate
1051343|NCT01790204|oral cells of smokers
1051344|NCT01790191|Children
1051345|NCT01790191|Eating behaviour
1051346|NCT01790191|Intake
1051347|NCT01790191|Liking
1051348|NCT01790191|Conditioned liking
1051349|NCT01790191|Flavour
1051350|NCT01790191|Nutrient
1051351|NCT01790191|Vegetable
1051352|NCT01790165|Onychomycosis
1051353|NCT01790165|Open Label
1051354|NCT01790165|PK
1051355|NCT01790126|Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
1051356|NCT01790074|cervicogenic headache
1051357|NCT01790074|trigger point
1051358|NCT01790074|sternocleidomastoid
1051359|NCT01790074|manual therapy
1051360|NCT01790061|Gut bacteria
1051361|NCT01790061|Gut flora
1051363|NCT01790061|Fecal Microbiota Transplantation
1051364|NCT01790061|Inflammatory bowel disease
1051365|NCT01790061|Ulcerative colitis
1051366|NCT01790048|MAM
1051367|NCT01790009|ADME
1051368|NCT01790009|Flavanols
1051369|NCT01790009|Age
1051370|NCT01790009|Pharmacokinetics
1051371|NCT01789996|6 minute walk test
1051372|NCT01789996|idiopathic pulmonary fibrosis
1051373|NCT01789996|pulmonary arterial hypertension
1051374|NCT01789996|interstitial lung disease
1051375|NCT01789983|Physical Activity
1051376|NCT01789983|Chemotherapy
1051377|NCT01789983|Elderly
1051378|NCT01789983|Geriatric
1051379|NCT01789983|Walking
1051380|NCT01789983|Geriatric Assessment
1051381|NCT01789983|Geriatric Oncology
1051382|NCT01789970|chronic low back pain
1051383|NCT01789970|hydrocodone bitartrate
1051384|NCT01789970|opioids
1051385|NCT01789944|Childhood Obesity
1051386|NCT01789918|Hypertension
1051387|NCT01789918|Blood pressure
1051388|NCT01789918|Renal denervation
1051389|NCT01789905|Tygacil
1051390|NCT01789905|Tigecycline
1051391|NCT01789905|Post marketing surveillance
1051392|NCT01789905|Japanese
1051393|NCT01789905|Infection
1051394|NCT01789879|Levonorgestrel
1051395|NCT01789879|Efavirenz
1051396|NCT01789879|Nevirapine
1051397|NCT01789879|Pharmacokinetics
1051398|NCT01789866|DHA
1051399|NCT01789866|lutein
1051400|NCT01789866|cognitive development
1051401|NCT01789866|fMRI
1051402|NCT01789853|stroke, rehabilitation, gait training
1051403|NCT01789840|BPH
1051404|NCT01789840|Prostate
1051405|NCT01789840|Prostatic Hyperplasia
1051406|NCT01789840|enlarged prostate
1051407|NCT01789840|LUTS
1051408|NCT01789840|urinary retention
1051409|NCT01789814|Percutaneous Coronary Intervention
1051410|NCT01789814|Platelet Aggregation Inhibitors
1051411|NCT01789814|bivalirudin
1051412|NCT01789762|Platelet transfusions
1051413|NCT01789762|Pathogen reduction
1051414|NCT01789762|Haemorrhagic episodes
1051415|NCT01789736|Glaucoma
1051416|NCT01789736|Ocular hypertension
1051417|NCT01789736|AR-12286
1051418|NCT01789736|Travoprost
1051419|NCT01789710|smoking
1051420|NCT01789710|homelessness
1051421|NCT01789710|contingency management
1051422|NCT01789684|cluster
1051423|NCT01789684|genetic counseling
1051424|NCT01789684|breast cancer
1051425|NCT01789684|HBOC
1051426|NCT01789684|provider intervention
1051427|NCT01789671|Childhood Obesity
1051428|NCT01789658|Oral Mucositis
1051429|NCT01789658|Children
1051430|NCT01789658|Cryotherapy
1051431|NCT01789658|Hematopoietic Stem Cell Transplantation
1051432|NCT01789645|Carpal tunnel
1051433|NCT01789645|Physical therapy
1051434|NCT01789645|Surgery
1051435|NCT01789645|Efficacy
1051436|NCT01789606|Self-selection and actual use/compliance trial.
1051437|NCT01789580|Experimental study, moderators, online gambling,
1051438|NCT01789580|problem gambling prevention
1051439|NCT01789554|Out of hospital cardiac arrest
1051440|NCT01789554|Cardiopulmonary resuscitation
1051441|NCT01789554|Bystander CPR
1051442|NCT01789554|Mobile phone positioning system
1051443|NCT01789528|Phase I,
1051444|NCT01789528|open label,
1051445|NCT01789528|CAZ-AVI,
1051446|NCT01789528|CXL,
1051447|NCT01789528|healthy volunteers,
1051448|NCT01789528|intestinal flora.
1051449|NCT01789502|self-expandable metal stent; plastic stent
1051450|NCT01789476|pain
1051451|NCT01789476|acute pain
1051452|NCT01789476|kappa agonis
1051453|NCT01789476|opioid analgesia
1051454|NCT01789476|bunionectomy
1051455|NCT01789476|peripheral nervous system agents
1051456|NCT01789476|physiological effects of drugs
1051457|NCT01789476|surgery
1051458|NCT01789476|post-operative
1051459|NCT01789476|post-operative complications
1051460|NCT01789450|sensitivity
1051461|NCT01789450|section of periareolar dermis
1051462|NCT01789450|breast reduction
1051463|NCT01789437|retinal vein occlusion
1051464|NCT01789437|systemic hypertension
1051465|NCT01789437|arteriolar diameter
1051466|NCT01789385|Deep brain stimulation
1051467|NCT01789385|Parkinson
1051468|NCT01789372|paroxysmal atrial fibrillation
1051469|NCT01789372|yoga
1051470|NCT01789372|quality of life
1051471|NCT01789372|blood pressure
1051472|NCT01789372|heart rate
1051473|NCT01789372|heart rate variability
1051474|NCT01789359|anthocyanin
1051475|NCT01789359|bioavailability
1051476|NCT01789359|urine
1051477|NCT01789359|long-term
1051478|NCT01789346|Scar
1051479|NCT01789346|Scars
1051480|NCT01789346|Surgical Scar
1051481|NCT01789346|Surgical Scars
1051482|NCT01789346|Cicatrix
1051483|NCT01789346|Hypertrophic Cicatrix
1051484|NCT01789346|Keloid
1051485|NCT01789346|Hypertrophic Scar
1051486|NCT01789346|Surgical Incision
1051487|NCT01789346|Scarring
1051488|NCT01789346|Abdominoplasty
1051489|NCT01789346|Tummy Tuck
1051490|NCT01789346|Augmentation Mammoplasty
1051491|NCT01789346|Breast Augmentation
1051492|NCT01789346|Thyroidectomy
1051493|NCT01789333|Keratoconus
1051494|NCT01789333|Ectasia
1051495|NCT01789333|UVA light
1051496|NCT01789333|riboflavin
1051497|NCT01789333|post-LASIK
1051498|NCT01789333|irregular astigmatism
1051499|NCT01789320|uveitis
1051500|NCT01789320|intermediate uveitis
1051501|NCT01789320|posterior uveitis
1051502|NCT01789320|panuveitis
1051503|NCT01789320|noninfectious uveitis
1051504|NCT01789320|microneedle
1051505|NCT01789320|suprachoroidal space
1051506|NCT01789320|SCS
1051507|NCT01789320|inflammation
1051508|NCT01789320|ocular inflammatory conditions
1051509|NCT01789320|triamcinolone acetonide
1051510|NCT01789320|TA
1051511|NCT01789320|Triesence
1051512|NCT01789320|injection
1051513|NCT01789320|IVT
1051514|NCT01789320|intravitreal
1051515|NCT01789320|corticosteroid
1051516|NCT01789320|sympathetic ophthalmia
1051517|NCT01789320|temporal arteritis
1051518|NCT01789320|vitreous haze
1051519|NCT01789294|lymphoid nodular hyperplasia
1051520|NCT01789294|food allergy
1051521|NCT01789281|Neoplasms, Carcinoid tumor, Neuroendocrine tumor
1051522|NCT01789268|acute
1051523|NCT01789268|adaptive cellular immune phenotypes
1051524|NCT01789268|infants
1051525|NCT01789268|Lymphocyte
1051526|NCT01789268|premature
1051527|NCT01789268|respiratory viral infections
1051528|NCT01789229|Breast cancer
1051529|NCT01789229|Ovarian cancer
1051530|NCT01789229|Endometrium carcinoma
1051531|NCT01789229|Cervix carcinoma,
1051532|NCT01789229|Mamma carcinoma,
1051533|NCT01789229|Prostata carcinoma
1051534|NCT01789229|Colon carcinoma
1051535|NCT01789229|Rectal carcinoma
1051536|NCT01789229|Bronchus carcinoma
1051537|NCT01789229|NSCLC (non small cell lung cancer) & SCLC (small cell lung cancer)
1051538|NCT01789229|Prostate carcinoma
1051539|NCT01789216|Pilon fractures
1051540|NCT01789216|Calcaneus fractures
1051541|NCT01789216|Acute pain
1051542|NCT01789216|Chronic pain
1051543|NCT01789216|Isolated
1051544|NCT01789216|unilateral
1051545|NCT01789216|Grade I
1051546|NCT01789216|Grade II
1051547|NCT01789216|open
1051548|NCT01789216|closed
1051549|NCT01789203|BK infection
1051550|NCT01789203|BK viremia
1051551|NCT01789203|BK nephropathy
1051552|NCT01789203|polyomavirus
1051553|NCT01789203|fluoroquinolone
1051554|NCT01789203|ciprofloxacin
1051555|NCT01789190|Honeymoon
1051556|NCT01789190|Type 1 diabetes
1051557|NCT01789177|Spirometry
1051558|NCT01789177|Postoperative Care
1051559|NCT01789164|TBI
1051560|NCT01789164|fNIRS
1051561|NCT01789164|hypercapnea
1051562|NCT01789164|Cerebrovascular reactivity
1051563|NCT01789151|arthritis
1051564|NCT01789151|nuclear imaging
1051565|NCT01789151|rheumatoid
1051566|NCT01789151|ankylosing spondylitis
1051567|NCT01789151|glucosamine
1051568|NCT01789138|Antiretroviral Therapy
1051569|NCT01789138|Adherence
1051570|NCT01789138|Intervention
1051571|NCT01789125|anxiety
1051572|NCT01789125|stress
1051573|NCT01789125|smoking
1051574|NCT01789125|cessation
1051575|NCT01789099|Lung cancer
1051576|NCT01789099|Peptide vaccine
1051577|NCT01789073|Postoperative
1051578|NCT01789073|Complications
1051579|NCT01789073|Elective
1051580|NCT01789073|Surgery
1051581|NCT01789073|GI surgery
1051582|NCT01789073|Immunonutrition
1051583|NCT01789073|Immune-enhancing
1051584|NCT01789073|Immune-modulating
1051585|NCT01789073|Nutrition
1051586|NCT01789073|Pancreatic cancer
1051587|NCT01789073|Postoperative complications and length of hospital stay after major gastrointestinal (GI) elective surgery.
1051588|NCT01789047|Parkinson's disease
1051589|NCT01789047|dyskinesia
1051590|NCT01789047|Indonesia
1051591|NCT01789047|amantadine
1051592|NCT01789021|blood glucose monitoring systems
1051593|NCT01789021|ISO 15197
1051594|NCT01789021|system accuracy
1051595|NCT01789008|Transient elastography
1051596|NCT01789008|Alcoholic liver disease
1051597|NCT01789008|liver fibrosis
1051598|NCT01788982|Thyroid Cancer
1051599|NCT01788982|Medullary thyroid cancer (MTC)
1051600|NCT01788982|Differentiated thyroid cancer (DTC)
1051601|NCT01788969|Gait training
1051602|NCT01788969|Lexapro
1051603|NCT01788969|Tizanidine
1051604|NCT01788956|venous oximeter
1051605|NCT01788956|CO-Oximeter
1051606|NCT01788956|ICU Patients
1051607|NCT01788956|Sepsis
1051608|NCT01788956|non-invasive device
1051609|NCT01788943|positron emission tomography
1051610|NCT01788943|nicotine receptor
1051611|NCT01788917|n-3 LC-PUFA, vegetarians, fatty acids, blood lipids
1051612|NCT01788904|Acute mesenteric ischemia
1051613|NCT01788904|Percutaneous endovascular revascularization
1051614|NCT01788904|Intestinal plasma fatty acid binding protein (i-FABP)
1051615|NCT01788904|Bowel necrosis
1051616|NCT01788891|longitudinal observational cohort study
1051617|NCT01788891|multicenter
1051618|NCT01788891|pediatrics
1051619|NCT01788891|Asian
1051620|NCT01788891|treatment failure
1051621|NCT01788891|renal status
1051622|NCT01788891|toxicities
1051623|NCT01788891|therapeutic drug monitoring (TDM)
1051624|NCT01788891|drug levels in blood and hair
1051625|NCT01788878|socio-professional future
1051626|NCT01788865|covered Metal stent
1051627|NCT01788865|ureteral obstruction
1051628|NCT01788852|HPV
1051629|NCT01788852|HIV
1051630|NCT01788852|cervical/anal dysplasia
1051631|NCT01788852|intraepithelial neoplasia
1051632|NCT01788852|E6/E7 biomarker
1051633|NCT01788852|perinatally HIV-infected adolescents
1051634|NCT01788852|behaviorally HIV-infected adolescents
1051635|NCT01788852|anal and pap smear
1051636|NCT01788839|Sexual and Reproductive Health
1051637|NCT01788839|premenopausal
1051638|NCT01788839|postmenopausal
1051639|NCT01788839|12-249
1051640|NCT01788839|Fertility
1051641|NCT01788826|Ventral hernia
1051642|NCT01788826|surgical meshes
1051643|NCT01788826|polypropylenes
1051644|NCT01788813|Repeat Dose Safety
1051645|NCT01788813|Allergic Asthma
1051646|NCT01788813|Effect on Allergen Reactivity
1051647|NCT01788813|Allergic Rhinitis
1051648|NCT01788813|TLR7 Agonist
1051649|NCT01788813|Pharmacodynamics
1051650|NCT01788800|Panic disorder
1051651|NCT01788800|Physical activity
1051652|NCT01788787|Cancer Prevention
1051653|NCT01788787|Tobacco Use Cessation
1051654|NCT01788787|Ask Advise Connect
1051655|NCT01788787|AAC
1051656|NCT01788787|Smoking Cessation Treatment
1051657|NCT01788787|Texas Quitline
1051658|NCT01788787|Saliva sample
1051659|NCT01788787|Telephone Counseling
1051660|NCT01788787|Nicotine replacement
1051661|NCT01788787|Interviews
1051662|NCT01788774|Pharmacokinetics
1051663|NCT01788774|Safety
1051664|NCT01788774|Risperidone ISM®
1051665|NCT01788774|Intramuscular
1051666|NCT01788774|Schizophrenia
1051667|NCT01788761|Probiotics
1051668|NCT01788761|Feeding Tolerance
1051669|NCT01788761|Extremely Low Birthweight Infants
1051670|NCT01788748|fractional
1051671|NCT01788748|bipolar
1051672|NCT01788748|radiofrequency
1051673|NCT01788748|striae
1051674|NCT01788748|infrared
1051675|NCT01788748|combined
1051676|NCT01788735|unexplained infertility
1051677|NCT01788735|asthma
1051678|NCT01788735|allergy
1051679|NCT01788709|colonoscopy
1051680|NCT01788709|preparation
1051681|NCT01788696|Parkinsonism
1051682|NCT01788696|Idiopathic Parkinson Disease
1051683|NCT01788683|Rotator Cuff
1051684|NCT01788683|Rotator Cuff Tear
1051685|NCT01788683|Supraspinatus Tear
1051686|NCT01788670|Antioxidants, Central Nervous System Agents
1051687|NCT01788657|Depression
1051688|NCT01788657|Internet
1051689|NCT01788657|Cognitive Behavior Therapy
1051690|NCT01788644|Child adiposity
1051691|NCT01788644|Infancy
1051692|NCT01788644|Motor activity
1051693|NCT01788644|Feeding behavior
1051694|NCT01788644|Sleep
1051695|NCT01788644|Stress, Physiological
1051696|NCT01788618|Cognitive functions
1051697|NCT01788618|Quality of life
1051698|NCT01788618|Cancer
1051699|NCT01788605|hematologic malignancies
1051700|NCT01788605|hematopoietic stem cell transplantation
1051701|NCT01788605|ramosetron
1051702|NCT01788605|emesis
1051703|NCT01788592|coronary artery disease
1051704|NCT01788592|drug eluting stent
1051705|NCT01788579|Intimate Partner Violence (IPV)
1051706|NCT01788579|Drug Abuse
1051707|NCT01788579|Criminal Justice
1051708|NCT01788553|remission
1051709|NCT01788553|generalized anxiety disorder
1051710|NCT01788540|Recurrent miscarriage
1051711|NCT01788540|Implantation failure
1051712|NCT01788540|Intralipid
1051713|NCT01788540|ICSI / IVF failure
1051714|NCT01788527|Diabetes
1051715|NCT01788527|Type 1
1051716|NCT01788527|CGM
1051717|NCT01788527|Continuous Glucose Monitor
1051718|NCT01788527|HGM
1051719|NCT01788527|HbA1c
1051720|NCT01788488|procalcitonin
1051721|NCT01788488|antimicrobial stewardship
1051722|NCT01788488|pneumonia
1051723|NCT01788475|Diabetic Macular Edema
1051724|NCT01788475|DME
1051725|NCT01788475|Pars Plana Vitrectomy
1051726|NCT01788462|Tesamorelin
1051727|NCT01788462|Egrifta
1051728|NCT01788462|HIV
1051729|NCT01788462|Lipodystrophy
1051730|NCT01788462|Sleep Apnea
1051731|NCT01788449|Antibiotic Bacterial Resistance
1051732|NCT01788436|Schizophrenia
1051733|NCT01788436|Young healthy volunteers
1051734|NCT01788436|Elderly healthy volunteers
1051735|NCT01788436|Learning performance
1051736|NCT01788423|presbycusis
1051737|NCT01788423|hearing aids
1051738|NCT01788410|Cryoablation
1051739|NCT01788410|Nerves
1051740|NCT01788410|Facet joint
1051741|NCT01788410|Pain
1051742|NCT01788410|Neuralgia
1051743|NCT01788410|Neuropathy
1051744|NCT01788410|Image-guided
1051745|NCT01788397|physical disabilities
1051746|NCT01788397|rehabilitation
1051747|NCT01788384|acne
1051748|NCT01788384|Clindamycin Phosphate/Benzoyl Peroxide
1051749|NCT01788384|Acanya
1051750|NCT01788384|Mild to severe acne vulgaris
1051751|NCT01788358|Drug combination
1051752|NCT01788358|Nifedipine GITS
1051753|NCT01788358|Candesartan Cilexetil
1051754|NCT01788358|Hypertension
1051755|NCT01788358|Combination therapy
1051756|NCT01788345|non-invasion ventilation
1051757|NCT01788345|Boussignac
1051758|NCT01788332|NSCLC
1051759|NCT01788332|non-small cell
1051760|NCT01788332|lung cancer
1051761|NCT01788319|laser trabeculoplasty
1051762|NCT01788319|glaucoma
1051763|NCT01788306|Elevated risk
1051764|NCT01788306|opioid overdose
1051765|NCT01788293|Fluid management
1051766|NCT01788293|Pleth Variability Index (PVI)
1051767|NCT01788293|monitoring
1051768|NCT01788293|high-risk surgery
1051769|NCT01788267|Cystic Fibrosis
1051770|NCT01788267|High-Resolution peripheral Quantitative Computed Tomography
1051771|NCT01788267|Bone Mass Density
1051772|NCT01788254|pharmacokinetic/genetic
1051773|NCT01788254|Cyp450 polymorphisms
1051774|NCT01788254|Noninvasive functional characterization of liver heart and kidneys using MRI
1051775|NCT01788241|coronary artery disease
1051776|NCT01788241|Atherosclerosis
1051777|NCT01788241|Coronary Stenosis
1051778|NCT01788241|Cardiovascular Diseases
1051779|NCT01788241|Non-significant coronary artery disease
1051780|NCT01788241|Mild Stenosis
1051781|NCT01788241|Vascular Irregularities
1051782|NCT01788241|Psychosocial factors
1051783|NCT01788241|Personality
1051784|NCT01788241|Type D personality
1051785|NCT01788241|Hostility
1051786|NCT01788241|Depression
1051787|NCT01788241|Anxiety
1051788|NCT01788241|Fatigue
1051789|NCT01788241|Social Support
1051790|NCT01788241|Socioeconomic Status
1051791|NCT01788241|Patient Reported Outcomes
1051792|NCT01788241|Patient Perceived Symptoms
1051793|NCT01788241|Health Status
1051794|NCT01788241|Quality of Life
1051795|NCT01788241|Chest pain
1051796|NCT01788241|Cardiac risk factors
1051797|NCT01788241|Metabolic Syndrome
1051798|NCT01788241|BMI
1051799|NCT01788241|Obesity
1051800|NCT01788241|Waist Circumference
1051801|NCT01788241|Lifestyle
1051802|NCT01788241|Smoking
1051803|NCT01788241|Alcohol use
1051804|NCT01788241|Activity
1051805|NCT01788241|Hypertension
1051806|NCT01788241|Diabetes
1051807|NCT01788241|Familial Cardiovascular Disease
1051808|NCT01788241|Coronary angiography
1051809|NCT01788241|Computed Tomography
1051810|NCT01788228|Vaccine
1051811|NCT01788228|Occupational exposure
1051812|NCT01788228|Influenza
1051813|NCT01788228|H5N1
1051814|NCT01788215|Polycystic Ovarian Syndrome
1051815|NCT01788215|Irregular Menstrual Cycles
1051816|NCT01788215|Androgen Excess in Women
1051817|NCT01788202|cocaine and general anesthesia
1051818|NCT01788189|Lymphoma
1051819|NCT01788189|CD20
1051820|NCT01788189|Relapse
1051821|NCT01788189|Lenalidomide
1051822|NCT01788176|Complex Regional Pain Syndromes
1051823|NCT01788176|drug therapy
1051824|NCT01788176|zoledronic acid
1051825|NCT01788163|EGFR
1051826|NCT01788163|aNSCLC
1051827|NCT01788163|mutation status
1051828|NCT01788163|diagnostic study
1051829|NCT01788163|Russia
1051830|NCT01788163|China
1051831|NCT01788163|Asia
1051832|NCT01788137|T-cell lymphoma,DFS,OS
1051833|NCT01788124|Speculum
1051834|NCT01788124|Metal
1051835|NCT01788124|Plastic
1051836|NCT01788124|Visual Analoge Scale
1051837|NCT01788124|Discomfort
1051838|NCT01788085|GERD
1051839|NCT01788072|Autism Spectrum Disorders
1051840|NCT01788072|Oxytocin
1051841|NCT01788072|Adults
1051842|NCT01788059|nonunion
1051843|NCT01788059|mesenchymal stem cell
1051844|NCT01788059|long bone
1051845|NCT01788046|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
1051846|NCT01788007|Actinic Keratosis
1051847|NCT01788007|Imiquimod Topical Cream 3.75%
1051848|NCT01788007|Zyclara® (imiquimod) Topical Cream 3.75%
1051849|NCT01787968|Congenital transmission
1051850|NCT01787968|Trypanosoma cruzi
1051851|NCT01787968|Chagas disease
1051852|NCT01787955|Pylorus preserving pancreaticoduodenectomy(PPPD), Delayed gastric emptying syndrome(DGE), Braun anastomosis
1051853|NCT01787942|Lipid thickness
1051854|NCT01787942|Blepharoplasty
1051855|NCT01787942|Tear break up time
1051856|NCT01787942|Corneal staining
1051857|NCT01787916|type 1 diabetes
1051858|NCT01787916|overweight
1051859|NCT01787916|insulin
1051860|NCT01787916|liraglutide
1051861|NCT01787903|Type 1 diabetes mellitus
1051862|NCT01787903|Hypoglycemia unawareness
1051863|NCT01787903|Real-time continuous glucose monitoring
1051864|NCT01787903|Glucose control
1051865|NCT01787877|Cerebrovascular Accident, Inflammatory biomarkers
1051866|NCT01787864|Barrett's Esophagus
1051867|NCT01787864|Intestinal metaplasia
1051868|NCT01787864|Intramucosal Adenocarcinoma
1051869|NCT01787864|Gastric Cardia
1051870|NCT01787864|High Cardia Dysplasia
1051871|NCT01787864|Radiofrequency ablation (RFA)
1051872|NCT01787851|Heart failure
1051873|NCT01787851|Anaplerosis
1051874|NCT01787851|Medium-chain fatty acid
1051875|NCT01787838|Pneumococcal vaccination rates, ambulatory settings
1051876|NCT01787825|intestinal disease
1051877|NCT01787825|inflammatory bowel disease
1051878|NCT01787825|crohn disease
1051879|NCT01787825|ulcer
1051880|NCT01787825|celiac disease
1051881|NCT01787825|angioectasia
1051882|NCT01787825|polyp
1051883|NCT01787799|Drug-eluting stents
1051884|NCT01787786|Crohn's Disease
1051885|NCT01787786|Ulcerative Colitis
1051886|NCT01787786|Optimal Use of infliximab
1051887|NCT01787773|Inferior Vena Cava Filter
1051888|NCT01787773|Vena Cava Filters
1051889|NCT01787747|Pharmacokinetics
1051890|NCT01787747|Healthy Volunteers
1051891|NCT01787747|dextromethorphan with quinidine
1051892|NCT01787747|deuterated dextromethorphan
1051893|NCT01787721|Gait
1051894|NCT01787721|Ankle joint
1051895|NCT01787721|Manipulation, Chiropractic
1051896|NCT01787708|Vitiligo
1051897|NCT01787708|red
1051898|NCT01787708|laser
1051899|NCT01787708|light
1051900|NCT01787695|Vitiligo
1051901|NCT01787695|UVA1
1051902|NCT01787695|Phototherapy
1051903|NCT01787682|CHF
1051904|NCT01787682|Protein digestion
1051905|NCT01787682|Fat digestion
1051906|NCT01787682|Gut function
1051907|NCT01787682|Glucose absorption
1051908|NCT01787682|Muscle function
1051909|NCT01787669|diabetic macular oedema
1051910|NCT01787669|diabetic macular edema
1051911|NCT01787669|diabetic retinopathy
1051912|NCT01787669|dexamethasone
1051913|NCT01787669|Ozurdex
1051914|NCT01787669|Avastin
1051915|NCT01787669|bevacizumab
1051916|NCT01787669|DME
1051917|NCT01787669|DMO
1051918|NCT01787643|height-adjustable desk
1051919|NCT01787643|office workers
1051920|NCT01787643|sitting occupations
1051921|NCT01787643|energy expenditure
1051922|NCT01787643|BMI
1051923|NCT01787643|Weight
1051924|NCT01787643|Lower fat diet
1051925|NCT01787630|Prostatic cancer
1051926|NCT01787630|Radiotherapy
1051927|NCT01787630|Hyaluronic acid
1051928|NCT01787617|Exercise Training
1051929|NCT01787617|Strength Training
1051930|NCT01787617|African American Men
1051931|NCT01787617|Insulin Resistance
1051932|NCT01787604|Valve-sparing
1051933|NCT01787604|Valve repair
1051934|NCT01787591|Vitamin E
1051935|NCT01787591|Metabolic syndrome
1051936|NCT01787591|Liver disease
1051937|NCT01787591|Non-alcoholic liver steatohepatitis
1051938|NCT01787591|Fatty liver
1051939|NCT01787591|Dairy consumption
1051940|NCT01787578|X-linked adrenoleukodystrophy
1051941|NCT01787578|adrenomyeloneuropathy
1051942|NCT01787578|sobetirome
1051943|NCT01787578|thyroid
1051944|NCT01787578|thyromimetic
1051945|NCT01787565|non-interventional
1051946|NCT01787565|clinical
1051947|NCT01787565|investigation
1051948|NCT01787565|low
1051949|NCT01787565|back
1051950|NCT01787565|pain
1051951|NCT01787565|painPREMIER
1051952|NCT01787552|Dose escalation
1051953|NCT01787552|Maximum Tolerated Dose
1051954|NCT01787552|MTD
1051955|NCT01787552|Safety Expansion
1051956|NCT01787552|Safety
1051957|NCT01787552|Efficacy
1051958|NCT01787552|Myelofibrosis
1051959|NCT01787552|Post-polycythemia vera myelofbrosis (Post PV-PMF)
1051960|NCT01787552|Post essential thrombocythemia myelofibrosis (Post ET-MF)
1051961|NCT01787552|Primary myelofibrosis (PMF)
1051962|NCT01787552|Intermediate risk myelofibrosis
1051963|NCT01787552|High risk myelofibrosis
1051964|NCT01787552|Combination Treatment
1051965|NCT01787552|Hedgehog Signaling Pathway
1051966|NCT01787552|Smoothened inhibitor
1051967|NCT01787552|JAK inhibitor
1051968|NCT01787539|gastric cancer
1051969|NCT01787539|perioperative chemotherapy
1051970|NCT01787539|combined modality therapy
1051971|NCT01787539|gastrectomy
1051972|NCT01787526|iron depletion
1051973|NCT01787526|donor safety
1051974|NCT01787526|blood donation
1051975|NCT01787526|transfusion medicine
1051976|NCT01787526|iron deficiency
1051977|NCT01787526|intravenous iron
1051978|NCT01787526|fatigue
1051979|NCT01787526|restless legs syndrome
1051980|NCT01787526|anemia
1051998|NCT01787487|Leukemia
1051999|NCT01787487|Myelofibrosis
1052000|NCT01787487|Myelodysplastic syndrome
1052001|NCT01787487|Myeloproliferative neoplasm
1052002|NCT01787487|Ruxolitinib
1052003|NCT01787487|RUX
1052004|NCT01787487|Jakafi
1052005|NCT01787487|INCB018424
1052006|NCT01787487|INC424
1052007|NCT01787487|Azacitidine
1052008|NCT01787487|AZA
1052009|NCT01787487|5-Azacitidine
1052010|NCT01787487|5-aza
1052011|NCT01787487|Vidaza
1052012|NCT01787487|5-AZC
1052013|NCT01787487|AZA-CR
1052014|NCT01787487|Ladakamycin
1052015|NCT01787487|NSC-102816
1052016|NCT01787474|Leukemia
1052017|NCT01787474|Acute Myeloid Leukemia
1052018|NCT01787474|Blood And Marrow Transplantation
1052019|NCT01787474|Natural killer cells
1052020|NCT01787474|NK
1052021|NCT01787474|mbIL21-expanded haploidentical NK cells
1052022|NCT01787474|G-CSF
1052023|NCT01787474|Filgrastim
1052024|NCT01787474|Neupogen
1052025|NCT01787474|Fludarabine monophosphate
1052026|NCT01787474|Fludarabine Phosphate
1052027|NCT01787474|Fludara
1052028|NCT01787474|Cytarabine
1052029|NCT01787474|Ara-C
1052030|NCT01787474|Cytosar
1052031|NCT01787474|DepoCyt
1052032|NCT01787474|Cytosine arabinosine hydrochloride
1052033|NCT01787461|Trial assessing effects of an oral dietary supplement on overall facial appearance among healthy women with photodamaged skin.
1052034|NCT01787448|repeat insult patch test
1052035|NCT01787435|Asthma,
1052036|NCT01787435|acid-suppressing drugs,
1052037|NCT01787435|pregnancy,
1052038|NCT01787435|epidemiology
1052039|NCT01787422|Telemedicine
1052040|NCT01787383|Actinic Keratosis
1052041|NCT01787383|Ingenol mebutate gel
1052042|NCT01787370|coronary artery disease, endothelial dysfunction
1052043|NCT01787357|Healthy
1052044|NCT01787357|Canagliflozin (JNJ-28431754)
1052045|NCT01787357|Pharmacokinetics
1052046|NCT01787357|Moxifloxacin
1052047|NCT01787357|Electrocardiogram Parameters
1052048|NCT01787357|QT/QTc Interval
1052049|NCT01787357|Therapeutic dose
1052050|NCT01787357|Supra-Therapeutic dose
1052051|NCT01787344|Other Infantile Cerebral Palsy
1052052|NCT01787331|biochemically relapsed
1052053|NCT01787331|hormone sensitive
1052054|NCT01787331|non-metastatic
1052055|NCT01787331|prostate cancer
1052056|NCT01787331|after prior definitive local therapy
1052057|NCT01787331|PSA
1052058|NCT01787331|Hedgehog-signaling pathway
1052063|NCT01787292|Exercise
1052064|NCT01787292|Magnetic Resonance Imaging
1052065|NCT01787292|Transcranial Magnetic Stimulation
1052066|NCT01787292|Aging
1052067|NCT01787214|glucose variability
1052068|NCT01787214|glycemia
1052069|NCT01787214|type-2 diabetes
1052070|NCT01787175|Medication Therapy Management
1052071|NCT01787175|Clinical Decision Support Systems
1052072|NCT01787175|Medical Informatics
1052073|NCT01787175|Patient Care Management
1052074|NCT01787175|United States Department of Veterans Affairs
1052075|NCT01787162|Myeloproliferative disorders
1052076|NCT01787162|pulmonary hypertension
1052077|NCT01787162|pulmonary vascular diseases
1052078|NCT01787149|ENIA11
1052079|NCT01787149|DMARDs
1052080|NCT01787149|RA
1052081|NCT01787149|TNF
1052082|NCT01787110|Acute coronary syndrome
1052083|NCT01787110|Acute myocardial infarction
1052084|NCT01787110|Non ST-segment Myocardial Infarction
1052085|NCT01787110|ST-segment Myocardial Infarction
1052086|NCT01787110|STEMI
1052087|NCT01787110|NSTEMI
1052088|NCT01787110|Oxygen
1052089|NCT01787110|Unstable angina
1052090|NCT01787110|Randomised trial
1052091|NCT01787110|CMR
1052092|NCT01787110|Mortality
1052093|NCT01787110|RCRT
1052094|NCT01787110|RRCT
1052095|NCT01787084|Aortic Stenosis
1052096|NCT01787084|TAVR
1052097|NCT01787071|fluids
1052098|NCT01787071|crtically ill patients
1052099|NCT01787071|functional hemodynamics
1052100|NCT01787071|cvp
1052101|NCT01787058|WASH
1052102|NCT01787058|schoolchildren
1052103|NCT01787058|absenteeism
1052104|NCT01787045|SEPSIS
1052105|NCT01787006|non resectable
1052106|NCT01787006|locally advanced
1052107|NCT01787006|Cetuximab
1052108|NCT01787006|radiation
1052112|NCT01786954|vitreoretinal surgery
1052113|NCT01786954|intraocular pressure
1052114|NCT01786954|applanation
1052115|NCT01786954|rebound
1052116|NCT01786954|tonometry
1052117|NCT01786941|Branched-chain Amino Acids
1052118|NCT01786941|Insulin Sensitivity
1052119|NCT01786941|Exercise
1052120|NCT01786941|Leucine
1052121|NCT01786928|chronic obstructive pulmonary disease
1052122|NCT01786928|exacerbation
1052123|NCT01786928|resistance training
1052124|NCT01786928|muscle force
1052125|NCT01786902|growth hormone
1052126|NCT01786876|AME
1052127|NCT01786876|Radiolabelled
1052128|NCT01786850|Locally advanced Pancreatic Cancer
1052129|NCT01786850|Noninvasive treatment
1052130|NCT01786850|High Intensity focused ultrasound
1052131|NCT01786850|Magnetic Resonance
1052132|NCT01786837|constipation
1052133|NCT01786837|gastric emptying
1052134|NCT01786824|contrast induced nephropathy
1052135|NCT01786824|hydration strategy
1052136|NCT01786824|L-carnitine
1052137|NCT01786798|Transvaginal sonography
1052138|NCT01786798|Endometrial thickness
1052139|NCT01786798|Endometrial pattern
1052140|NCT01786798|Abnormal uterine bleeding
1052141|NCT01786798|Endometrial hyperplasia
1052142|NCT01786798|Endometrial cancer
1052143|NCT01786772|arthroscopic partial meniscectomy
1052144|NCT01786772|meniscus
1052145|NCT01786772|quadriceps strength
1052146|NCT01786772|quadriceps voluntary activation
1052147|NCT01786772|cryotherapy
1052148|NCT01786772|compression
1052149|NCT01786772|vasopneumatic compression
1052150|NCT01786772|intermittent pneumatic compression
1052151|NCT01786759|lipids
1052152|NCT01786759|preterm infants
1052153|NCT01786759|parenteral nutrition
1052154|NCT01786759|liver function
1052155|NCT01786746|depression
1052156|NCT01786746|cognitive behavioral therapy
1052157|NCT01786746|culture
1052158|NCT01786746|Chinese Americans
1052159|NCT01786746|psychotherapy
1052160|NCT01786733|Acute Inpatient Psychiatry
1052161|NCT01786733|Continuity of Care
1052162|NCT01786733|Behavioral Activation
1052163|NCT01786733|Depression
1052164|NCT01786720|COPD
1052165|NCT01786720|Triple Therapy
1052166|NCT01786720|ICS
1052167|NCT01786720|LABA
1052168|NCT01786720|LAMA
1052169|NCT01786707|Type 2 Diabetes Mellitus
1052170|NCT01786707|Hyperbaric oxygen therapy (HOT)
1052171|NCT01786707|Autologous Bone Marrow-Derived Buffy Coat
1052172|NCT01786707|Stem cells (SC)
1052173|NCT01786694|rectum
1052174|NCT01786694|microdialysis
1052175|NCT01786694|quality of life
1052176|NCT01786681|Morbid obesity
1052177|NCT01786681|Bariatric Surgery
1052178|NCT01786681|Pulmonary Atelectasis
1052179|NCT01786681|Spirometry
1052180|NCT01786681|Continuous Positive Airway Pressure
1052181|NCT01786681|Physical Therapy Specialty
1052182|NCT01786668|Ankylosing Spondylitis
1052183|NCT01786668|Spondylitis
1052184|NCT01786668|Ankylosing
1052185|NCT01786668|Spondyloarthritis
1052186|NCT01786668|Spondyloarthropathy
1052187|NCT01786668|Oral preparation
1052188|NCT01786655|local anesthetic
1052189|NCT01786655|neosaxitoxin
1052190|NCT01786655|neoSTX
1052191|NCT01786655|bupivacaine
1052192|NCT01786655|safety
1052193|NCT01786655|phase 1
1052194|NCT01786655|pharmacokinetic
1052195|NCT01786577|Neuroimaging Biomarkers
1052196|NCT01786577|Cognitive Decline in Elderly
1052197|NCT01786577|Memory, Thinking problems for Older Adults
1052198|NCT01786577|Executive Decline
1052199|NCT01786577|Post-operative cognitive change
1052200|NCT01786564|diabetes
1052201|NCT01786564|sleep
1052202|NCT01786525|Live Donor Kidney Transplantation
1052203|NCT01786525|LDKT
1052204|NCT01786525|African American
1052205|NCT01786525|Disparity
1052206|NCT01786525|Education
1052207|NCT01786525|Patient Support
1052208|NCT01786512|Pharmacokinetics
1052209|NCT01786512|Omecamtiv mecarbil
1052210|NCT01786512|AMG 423
1052211|NCT01786512|Double-blind
1052212|NCT01786512|Randomized
1052213|NCT01786512|Placebo-controlled
1052214|NCT01786512|Oral forumlation
1052215|NCT01786512|CK-1827452
1052216|NCT01786512|Cardiac myosin activator
1052217|NCT01786499|Burnout
1052218|NCT01786499|Stress
1052219|NCT01786499|Provider
1052220|NCT01786499|Relaxation Response
1052221|NCT01786434|colonoscopy
1052222|NCT01786434|pain
1052223|NCT01786421|Ethanol
1052224|NCT01786421|Lipemia
1052225|NCT01786421|Postprandial
1052226|NCT01786421|Triglyceride
1052227|NCT01786395|UF-021
1052228|NCT01786395|unoprostone
1052229|NCT01786395|rp
1052230|NCT01786369|Schizophrenia
1052231|NCT01786369|Psychotic Disorders
1052232|NCT01786369|Bipolar Disorder
1052233|NCT01786369|Antipsychotic Agents
1052234|NCT01786369|Drug Monitoring
1052235|NCT01786356|posterior capsule opacification
1052236|NCT01786356|PCO
1052237|NCT01786356|after cataract
1052238|NCT01786356|intraocular lens
1052239|NCT01786343|Leukemia
1052240|NCT01786343|Acute myeloid leukemia
1052241|NCT01786343|AML
1052242|NCT01786343|Response rates
1052243|NCT01786343|Decitabine
1052244|NCT01786343|Dacogen
1052245|NCT01786317|Fecal incontinence, ano-rectal manometry
1052246|NCT01786304|Fecal incontinence, sacral nerve stimulation
1052247|NCT01786291|obstructive sleep apnea
1052248|NCT01786291|continuous positive airway pressure
1052249|NCT01786291|cardiopulmonary exercise test
1052250|NCT01786291|VE/VCO2
1052251|NCT01786278|adenocarcinoma
1052252|NCT01786278|esophago-gastric junction
1052253|NCT01786278|dysphagia
1052254|NCT01786278|brachytherapy
1052255|NCT01786278|endoscopic stenting
1052256|NCT01786265|Prostate Cancer
1052257|NCT01786265|PSA Progression After Prostatectomy and/or Radiotherapy
1052258|NCT01786265|Prostate specific antigen
1052259|NCT01786265|PSA
1052260|NCT01786265|Luteinizing-hormone-releasing hormone
1052261|NCT01786265|LHRH
1052262|NCT01786265|Finite maximal androgen ablation
1052263|NCT01786265|Lupron
1052264|NCT01786265|Leuprolide Acetate
1052265|NCT01786265|Lupron Depot
1052266|NCT01786265|Zoladex
1052267|NCT01786265|Goserelin
1052268|NCT01786265|Degarelix
1052269|NCT01786265|Abiraterone Acetate
1052270|NCT01786265|Zytiga
1052271|NCT01786265|Prednisone
1052272|NCT01786252|embryo
1052273|NCT01786252|implantation
1052274|NCT01786252|blastocyst
1052275|NCT01786252|in vitro fertilization
1052276|NCT01786252|human chorionic gonadotropin
1052277|NCT01786239|Adolescence
1052278|NCT01786239|Adult
1052279|NCT01786239|Antipsychotic Agents
1052280|NCT01786239|Female
1052281|NCT01786239|Human
1052282|NCT01786239|Male
1052283|NCT01786239|Risperidone
1052284|NCT01786239|Omega-3
1052285|NCT01786239|Schizophrenia
1052286|NCT01786239|Schizophreniform
1052287|NCT01786239|Schizoaffective
1052288|NCT01786239|Schizophrenia -- *drug therapy
1052289|NCT01786226|leiomyoma, fibroid, mifepristone, antiprogestins
1052290|NCT01786213|adenoma detection rate, colonoscopy, trainee, learning curve
1052291|NCT01786200|colon
1052292|NCT01786200|cancer
1052293|NCT01786200|NSAID
1052294|NCT01786200|inflammation
1052295|NCT01786187|Lung Cancer
1052296|NCT01786187|Symptoms
1052297|NCT01786174|ALS
1052298|NCT01786174|Gilenya
1052299|NCT01786174|Fingolimod
1052300|NCT01786148|HIV/AIDS
1052301|NCT01786148|Adherence
1052302|NCT01786148|Self-management
1052303|NCT01786148|Antiretroviral therapy
1052304|NCT01786135|Antibodies, Monoclonal
1052305|NCT01786135|Antibody-Drug Conjugate
1052306|NCT01786135|Antigens, CD19
1052307|NCT01786135|B-Lineage Lymphoblastic Lymphoma
1052308|NCT01786135|Burkitt Lymphoma
1052309|NCT01786135|Diffuse Large B-Cell Lymphoma
1052310|NCT01786135|Mantle Cell Lymphoma
1052311|NCT01786135|B-Cell Lymphoma
1052312|NCT01786135|Drug Therapy
1052313|NCT01786135|Monomethylauristatin F
1052314|NCT01786135|Follicular Lymphoma Grade 3
1052315|NCT01786122|physical exercise
1052316|NCT01786122|Health Related Quality of Life
1052317|NCT01786122|Non-Small-Cell Lung Carcinoma
1052318|NCT01786122|digestive system neoplasms
1052319|NCT01786122|breast neoplasms
1052320|NCT01786109|anandamide
1052321|NCT01786109|cannabinoid
1052322|NCT01786109|fatty acid amide hydrolase
1052323|NCT01786109|gastric
1052324|NCT01786109|motility
1052325|NCT01786109|small bowel
1052326|NCT01786109|sensory
1052327|NCT01786109|motor
1052328|NCT01786096|Burkitt Lymphoma
1052329|NCT01786096|Antibodies, Monoclonal
1052330|NCT01786096|Antibody-Drug Conjugate
1052331|NCT01786096|B-Lineage Acute Lymphoblastic Leukemia
1052332|NCT01786096|B-Lineage Lymphoblastic Lymphoma
1052333|NCT01786096|Burkitt Leukemia
1052334|NCT01786096|Monomethylauristatin F
1052335|NCT01786096|Antigens, CD19
1052336|NCT01786096|Drug Therapy
1052337|NCT01786083|family caregivers
1052338|NCT01786083|dependency
1052339|NCT01786083|Problem Solving Technique
1052340|NCT01786083|home based nursing
1052341|NCT01786044|patient education
1052342|NCT01786044|primary health care
1052343|NCT01786018|Non Hodgkin lymphomas
1052344|NCT01786018|Allogeneic Transplantation
1052345|NCT01786018|Thiotepa
1052346|NCT01786018|Busulfan
1052347|NCT01786018|Fludarabin
1052348|NCT01785992|Oestrogen receptor
1052349|NCT01785992|Locally advanced
1052350|NCT01785992|Metastatic
1052351|NCT01785992|Breast cancer
1052352|NCT01785992|Sulfatase inhibitor
1052353|NCT01785966|Critical care
1052354|NCT01785966|quality improvement
1052355|NCT01785966|checklist
1052356|NCT01785940|Interscalene Block
1052357|NCT01785940|Perineural catheter
1052358|NCT01785940|Ropivacaine
1052359|NCT01785940|Postoperative pain
1052360|NCT01785940|Home regional
1052361|NCT01785927|Antituberculosis
1052362|NCT01785927|Dry powder aerosols
1052363|NCT01785927|Inhalation
1052364|NCT01785901|asthma
1052365|NCT01785901|control rate
1052366|NCT01785901|budesonide/formoterol
1052367|NCT01785901|Non-Interventional study
1052368|NCT01785888|EGFR,
1052369|NCT01785888|aNSCLC,
1052370|NCT01785888|mutation status,
1052371|NCT01785888|diagnostic study,
1052372|NCT01785888|Europe,
1052373|NCT01785888|Japan
1052374|NCT01785875|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
1052375|NCT01785862|sore throat pain
1052376|NCT01785862|tonsillopharyngitis
1052377|NCT01785862|upper respiratory tract infection
1052378|NCT01785849|Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism
1052379|NCT01785823|analgesia
1052380|NCT01785823|fentanyl
1052381|NCT01785823|total intravenous anesthesia
1052382|NCT01785758|complications, renal;
1052383|NCT01785758|kidney, failure;
1052384|NCT01785758|neuromuscular block, antagonism;
1052385|NCT01785758|neuromuscular block, rocuronium;
1052386|NCT01785758|safety, drug
1052387|NCT01785758|sugammadex
1052388|NCT01785745|conservative treatment
1052389|NCT01785745|shoulder
1052390|NCT01785745|neurocognitive therapeutic exercise
1052391|NCT01785745|traditional therapeutic exercise
1052392|NCT01785745|pain
1052393|NCT01785719|Weight Loss
1052394|NCT01785719|Polycystic Ovary Syndrome (PCOS)
1052395|NCT01785719|Ovarian Follicle Development
1052396|NCT01785719|Metabolism
1052397|NCT01785693|Nerve block
1052398|NCT01785693|Femoropopliteal bypass
1052399|NCT01785693|Postoperative analgesia
1052400|NCT01785693|Peripheral circulation
1052401|NCT01785693|Levobupivacaine
1052402|NCT01785693|Clonidine
1052403|NCT01785693|Pain
1052404|NCT01785680|MAM
1052405|NCT01785680|SAM
1052406|NCT01785654|Reventilation collapse
1052407|NCT01785654|Rate of reventilation collapse
1052408|NCT01785654|Risk factor of reventilation collapse
1052409|NCT01785654|Hemodynamic profile of reventilation collapse
1052410|NCT01785654|Biologic approach of reventilation collapse
1052411|NCT01785641|peritoneal dialysis
1052412|NCT01785641|peritonitis
1052413|NCT01785628|Parkinson's disease
1052414|NCT01785628|dementia
1052415|NCT01785628|NMDA
1052416|NCT01785628|event related potential
1052417|NCT01785628|Bereitschaftspotential
1052418|NCT01785615|metabolic syndrome
1052419|NCT01785615|atorvastatin
1052420|NCT01785615|women
1052421|NCT01785602|Atopic eczema
1052422|NCT01785602|Skin Diseases
1052423|NCT01785589|coronary artery disease
1052424|NCT01785589|cardiac nuclear medicine
1052425|NCT01785589|myocardial perfusion imaging
1052426|NCT01785589|invasive coronary angiography
1052427|NCT01785576|couples
1052428|NCT01785576|head and neck cancer
1052429|NCT01785576|oncology
1052430|NCT01785576|spousal support
1052431|NCT01785563|NAVA
1052432|NCT01785563|NIV-NAVA
1052433|NCT01785563|VLBW
1052434|NCT01785563|electrical activity of the diaphragm
1052435|NCT01785563|neural trigger, mechanical ventilation
1052436|NCT01785563|respiratory distress syndrome
1052437|NCT01785537|e-cigarette smoking
1052438|NCT01785537|cigarette smoking
1052439|NCT01785537|cardiovascular disease
1052440|NCT01785537|hospitalization
1052441|NCT01785537|chronic obstructive pulmonary diseases
1052442|NCT01785537|observational study
1052443|NCT01785537|efficacy
1052444|NCT01785537|safety
1052445|NCT01785524|Cardiovascular Diseases
1052446|NCT01785524|Vascular Diseases
1052447|NCT01785524|Arterial Occlusive Diseases
1052448|NCT01785524|Diabetes
1052449|NCT01785524|Exercise
1052450|NCT01785524|Functional Capacity
1052451|NCT01785511|hypertension
1052452|NCT01785511|UV radiation
1052453|NCT01785511|coronary flow reserve
1052454|NCT01785511|nitric oxide
1052455|NCT01785498|children
1052456|NCT01785498|quality of life
1052457|NCT01785498|physical activity
1052458|NCT01785498|healthy lifestyle
1052459|NCT01785485|Integrative medicine
1052460|NCT01785485|primary care
1052461|NCT01785485|cost-effectiveness
1052462|NCT01785472|Essential hypertension
1052463|NCT01785472|LCZ696
1052464|NCT01785459|headache
1052465|NCT01785459|migraine
1052466|NCT01785459|bupivacaine
1052467|NCT01785446|Dexmedetomidine
1052468|NCT01785446|Cisatracurion infusion
1052469|NCT01785446|Sufentanil
1052470|NCT01785446|Recovery Index
1052471|NCT01785446|Closed loop computer control system
1052472|NCT01785433|COPD, pharmacokinetics, tiotropium
1052473|NCT01785420|Pre-operative Trastuzumab Protocol
1052474|NCT01785407|Iron bio availability
1052475|NCT01785407|Hepcidin
1052476|NCT01785407|Iron absorption
1052477|NCT01785394|pollinosis
1052478|NCT01785394|sublingual immunotherapy
1052479|NCT01785394|exhaled breath temperature
1052480|NCT01785381|Osteoporosis, hip fracture, fractures, Bone density
1052481|NCT01785368|guidelines
1052482|NCT01785368|referral guidelines
1052483|NCT01785368|exam delays
1052484|NCT01785368|exam relevance
1052485|NCT01785355|periodontal disease
1052486|NCT01785355|CKD
1052487|NCT01785355|nutrition
1052488|NCT01785355|inflammation
1052489|NCT01785355|anemia response to ESA
1052490|NCT01785355|quality of life
1052491|NCT01785355|hemodialysis
1052492|NCT01785316|Perfusion Cancer Chemotherapy, Regional
1052493|NCT01785303|CBT
1052494|NCT01785303|CPAP
1052495|NCT01785303|Multidisciplinary Treatment
1052496|NCT01785303|Combination treatment
1052497|NCT01785290|Delirium
1052498|NCT01785290|Survival
1052499|NCT01785290|Side-effects
1052500|NCT01785290|QoL
1052501|NCT01785277|Spinal Cord Independence Measure
1052502|NCT01785277|SCIM
1052503|NCT01785277|Spinal cord injury
1052504|NCT01785277|Traumatic spine injury
1052505|NCT01785264|Achilles
1052506|NCT01785264|Tendon
1052507|NCT01785264|Rupture
1052508|NCT01785264|Acute
1052509|NCT01785264|Treatment
1052510|NCT01785264|Outcome measure
1052511|NCT01785251|Neuromuscular electrical stimulation
1052512|NCT01785251|NMES
1052513|NCT01785251|Deep vein thrombosis
1052514|NCT01785251|DVT
1052515|NCT01785251|total hip arthroplasty
1052516|NCT01785251|lower limb hemodynamics
1052517|NCT01785238|preterm infants
1052518|NCT01785238|acute renal failure
1052519|NCT01785238|nephronic reduction
1052520|NCT01785199|apnea-hypopnea index
1052521|NCT01785199|obstructive sleep apnea
1052522|NCT01785199|body posture
1052523|NCT01785199|ultra-wideband
1052524|NCT01785186|TB
1052525|NCT01785186|Tuberculosis
1052526|NCT01785186|MAMS - Multiple-arm, multiple-stage
1052527|NCT01785186|Pulmonary
1052528|NCT01785186|SQ109
1052529|NCT01785186|High dose rifampicin
1052530|NCT01785186|moxifloxacin
1052531|NCT01785173|Endoscopes
1052532|NCT01785173|Esophago-gastro-duodenoscopy
1052533|NCT01785173|Transnasal endoscopy
1052534|NCT01785173|Nasal anesthesia
1052535|NCT01785147|Tobacco addition
1052536|NCT01785134|Obesity
1052537|NCT01785134|Bariatric Surgery
1052538|NCT01785134|Insulin Sensitivity
1052539|NCT01785108|Diamyd
1052540|NCT01785108|Diabetes
1052541|NCT01785108|Juvenile Diabetes
1052542|NCT01785108|Diabetes type 1
1052543|NCT01785108|Autoimmune Diabetes
1052544|NCT01785108|Insulin dependent Diabetes
1052545|NCT01785108|Type 1 diabetes
1052546|NCT01785108|Type 1 diabetes mellitus
1052547|NCT01785108|rhGAD65
1052548|NCT01785108|GAD
1052549|NCT01785108|GAD65
1052550|NCT01785108|GAD-alum
1052551|NCT01785108|Diabetes Mellitus
1052552|NCT01785108|Diabetes Mellitus, Type 1
1052553|NCT01785108|Glucose Metabolism Disorders
1052554|NCT01785108|Metabolic Diseases
1052555|NCT01785108|Vitamin D
1052556|NCT01785108|Ibuprofen
1052557|NCT01785082|13-C-Methacetin
1052558|NCT01785082|partial liver resection
1052559|NCT01785082|liver function tests
1052560|NCT01785056|Systemic Sclerosis
1052561|NCT01785056|Diffuse Scleroderma
1052562|NCT01785056|SSc
1052563|NCT01785043|DIABETES Mellitus Type 2
1052564|NCT01785043|Difficult control
1052565|NCT01785017|critical
1052566|NCT01785017|asthma
1052567|NCT01785017|children
1052568|NCT01785004|Adiposity
1052569|NCT01785004|Body composition
1052570|NCT01785004|Vitamin D
1052571|NCT01785004|Adipokines
1052572|NCT01785004|Omega-3 fatty acid
1052573|NCT01784991|Pain
1052574|NCT01784991|Opioids
1052575|NCT01784991|Hydromorphone
1052576|NCT01784991|regimen
1052577|NCT01784978|cancer
1052578|NCT01784978|renal
1052579|NCT01784978|metastatic
1052580|NCT01784978|clear
1052581|NCT01784978|cell
1052582|NCT01784978|Sunitinib
1052583|NCT01784978|Everolimus
1052584|NCT01784978|Alternating
1052585|NCT01784939|hereditary hemochromatosis C282Y homozygous
1052586|NCT01784939|Iron Reabsorption Index (IRI)
1052587|NCT01784939|Hepcidin / ferritin (H / F) ratio
1052588|NCT01784926|cataract surgery
1052589|NCT01784926|scleral suturing
1052590|NCT01784926|Verisyse
1052591|NCT01784926|Late in-the-bag IOL dislocation
1052592|NCT01784913|Prostate
1052593|NCT01784913|cancer
1052594|NCT01784913|vaccine
1052595|NCT01784874|Rabies
1052596|NCT01784874|Human Diploid Cell Vaccine
1052597|NCT01784874|Imovax® Rabies
1052598|NCT01784848|high blood pressure
1052599|NCT01784848|hypertension
1052600|NCT01784848|bariatric surgery
1052601|NCT01784848|Laparoscopic Roux-en-Y gastric bypass (LRYGB)
1052602|NCT01784848|obesity
1052603|NCT01784835|Osteopathic manipulative treatment
1052604|NCT01784835|neonatology
1052605|NCT01784835|neonatal care
1052606|NCT01784835|prematurity
1052607|NCT01784835|complementary and alternative medicine
1052608|NCT01784835|length of stay
1052609|NCT01784822|Ventral hernia
1052610|NCT01784822|Graft repair
1052611|NCT01784809|HIV
1052612|NCT01784809|STIs
1052613|NCT01784809|Condom Use
1052614|NCT01784809|Criminal Justice
1052615|NCT01784809|Drug Use
1052616|NCT01784796|cardiovascular disease
1052617|NCT01784796|women's health
1052618|NCT01784796|psychological stress
1052619|NCT01784796|Veterans
1052620|NCT01784796|stroke
1052621|NCT01784783|HIV transmission
1052622|NCT01784783|PMTCT
1052623|NCT01784783|Discordancy
1052624|NCT01784783|Home-based testing
1052625|NCT01784783|Couple counseling
1052626|NCT01784783|Couple testing
1052627|NCT01784783|Facility delivery
1052628|NCT01784783|Exclusive breastfeeding
1052629|NCT01784783|Family planning
1052630|NCT01784783|Postpartum contraceptives
1052631|NCT01784783|Linkage to care
1052632|NCT01784783|ART initiation
1052633|NCT01784770|Legionnaires' disease
1052634|NCT01784770|Legionella pneumophila
1052635|NCT01784770|Zithromax
1052636|NCT01784770|Zithromac
1052637|NCT01784770|Japanese
1052638|NCT01784770|Regulatory Post Marketing Commitment Plan
1052639|NCT01784744|Autism
1052640|NCT01784744|ASD
1052641|NCT01784744|Aspergers
1052642|NCT01784744|Autism Spectrum Disorder
1052643|NCT01784692|Immulina
1052644|NCT01784692|Elderly
1052645|NCT01784692|Immune
1052646|NCT01784679|Hereditary Inclusion Body Myopathy
1052647|NCT01784679|GNE Myopathy
1052648|NCT01784679|Nonaka Disease
1052649|NCT01784679|Quadriceps Sparing Myopathy
1052650|NCT01784679|distal myopathy with rimmed vacuoles
1052651|NCT01784679|ultragenyx
1052652|NCT01784679|rare disease
1052653|NCT01784666|Bipolar Disorder
1052654|NCT01784666|Depression
1052655|NCT01784666|Lithium
1052656|NCT01784666|Valproate
1052657|NCT01784666|Isradipine
1052658|NCT01784653|Substance abuse
1052659|NCT01784653|Drug abuse
1052660|NCT01784653|Alcohol abuse
1052661|NCT01784653|Tobacco
1052662|NCT01784653|Adolescent
1052663|NCT01784627|substance use
1052664|NCT01784627|alcohol abuse
1052665|NCT01784627|cannabis abuse
1052666|NCT01784627|nicotine dependence
1052667|NCT01784627|adolescents
1052668|NCT01784601|Interscalene block
1052669|NCT01784601|Hemidiaphragm palsy
1052670|NCT01784575|Quality of care
1052671|NCT01784575|Pediatric
1052672|NCT01784575|Pregnancy
1052673|NCT01784575|Low-income
1052674|NCT01784575|Low literacy
1052675|NCT01784562|Chronic thromboembolic pulmonary hypertension
1052676|NCT01784549|NSCL
1052677|NCT01784549|biomarkers
1052678|NCT01784549|Customized Neoadjuvant Therapy
1052679|NCT01784523|antiphospholipid autoantibodies
1052680|NCT01784523|antiphospholipid positive
1052681|NCT01784497|Health Related Quality of Life (HRQL)
1052682|NCT01784497|Living Donor Liver Transplantation(LDLT)
1052683|NCT01784471|Foot Symptoms
1052684|NCT01784471|Diabetes
1052685|NCT01784471|Peripheral Vascular Disease
1052686|NCT01784471|Magic Foot shoe
1052687|NCT01784458|severe sepsis
1052688|NCT01784458|intra-abdominal hypertension
1052689|NCT01784458|intra-abdominal pressure
1052690|NCT01784445|Endoscopic Retrograde Cholangiopancreatography,
1052691|NCT01784432|low-level laser therapy
1052692|NCT01784432|muscle performance
1052693|NCT01784432|strength training
1052694|NCT01784432|gene expression
1052695|NCT01784432|microarrays
1052696|NCT01784419|Cystic fibrosis
1052697|NCT01784419|Ivacaftor
1052698|NCT01784419|Genotype
1052699|NCT01784419|Phenotype
1052700|NCT01784419|Sweat chloride
1052701|NCT01784419|Pancreatic sufficient
1052702|NCT01784406|Self-management intervention
1052703|NCT01784406|Psychosocial care
1052704|NCT01784406|Autonomy-supportive
1052705|NCT01784406|Gynaecological cancer survivors
1052706|NCT01784406|Guided self-Determination
1052707|NCT01784367|Hypercapnia
1052708|NCT01784367|noninvasive ventilation
1052709|NCT01784367|acute respiratory failure
1052710|NCT01784367|endotracheal intubation
1052711|NCT01784367|invasive mechanical ventilation
1052712|NCT01784341|Bipolar, Circadian, Melatonin
1052713|NCT01784328|Peristeen Bowel Irrigation System
1052714|NCT01784328|Cauda Equina Syndrome
1052715|NCT01784328|Lower Motor Neuron Neurogenic Bowel
1052716|NCT01784315|The presence of parasites in the blood
1052717|NCT01784289|Interleukin 7
1052718|NCT01784289|adipose tissue
1052719|NCT01784276|Children
1052720|NCT01784276|Autism Spectrum Disorders
1052721|NCT01784276|Electronic Screen Media
1052722|NCT01784276|Dental fear
1052723|NCT01784263|Intervention
1052724|NCT01784263|Autism
1052725|NCT01784263|Treatment sensitivity
1052726|NCT01784263|School aged
1052727|NCT01784263|Cognitive behavioral therapy
1052728|NCT01784250|Clonidine
1052729|NCT01784250|Propranolol
1052730|NCT01784250|Third molar
1052731|NCT01784250|Anxiety
1052732|NCT01784237|Endoscopes
1052733|NCT01784237|Esophago-gastro-duodenoscopy
1052734|NCT01784237|Transnasal endoscopy
1052735|NCT01784237|Anterior meatoscopy
1052736|NCT01784198|pregnancy
1052737|NCT01784198|protein requirements
1052738|NCT01784198|Indicator Amino acid oxidation
1052739|NCT01784198|Stable isotopes
1052866|NCT01783457|BDNF
1052740|NCT01784185|EBUS guided transbronchial needle aspiration (EBUS-TBNA)
1052741|NCT01784185|virtual bronchoscopy (VB)
1052742|NCT01784185|VB guided transbronchial needle aspiration VB-TBNA)
1052743|NCT01784185|mediastinal sampling
1052744|NCT01784185|transbronchial needle aspiration (TBNA)
1052745|NCT01784172|efficacy
1052746|NCT01784172|safety
1052747|NCT01784172|electroacupuncture
1052748|NCT01784172|simple female stress urinary incontinence
1052749|NCT01784133|rosacea
1052750|NCT01784120|breast cancer
1052751|NCT01784120|doxorubicin
1052752|NCT01784120|genexol-PM
1052753|NCT01784120|paclitaxel
1052754|NCT01784107|SCLC
1052755|NCT01784107|belotecan
1052756|NCT01784107|Ifosfamide
1052757|NCT01784081|palliative care
1052758|NCT01784081|decision aid
1052766|NCT01784055|NeoChord
1052767|NCT01784055|DS1000
1052768|NCT01784055|Mitral Valve
1052769|NCT01784055|Mitral Valve Regurgitation
1052770|NCT01784055|MR
1052771|NCT01784055|Mitral Valve Repair
1052772|NCT01784055|Mitral Valve Prolapse
1052773|NCT01784055|Artificial Chordae
1052774|NCT01784042|breast cancer
1052775|NCT01784042|omega-3 fatty acids
1052776|NCT01784029|adolescents
1052777|NCT01784029|minority
1052778|NCT01783964|Elacytarabine
1052779|NCT01783964|pharmacokinetic
1052780|NCT01783964|Microdose
1052781|NCT01783964|Mass Balance Recovery
1052782|NCT01783951|Gastric cancer
1052783|NCT01783951|S-1
1052784|NCT01783951|DC-CIK
1052785|NCT01783912|Smoking
1052786|NCT01783912|Nicotine Dependence
1052787|NCT01783912|Mental Disorders
1052788|NCT01783886|Diabetic Macular Edema
1052789|NCT01783886|DME
1052790|NCT01783886|VEGF Trap-Eye
1052791|NCT01783886|best-corrected visual acuity (BCVA)
1052792|NCT01783860|Azithromycin
1052793|NCT01783860|Doxycycline
1052794|NCT01783860|Posterior Blepharitis
1052795|NCT01783847|Erythropoietin
1052796|NCT01783847|Traumatic Optic Neuropathy
1052797|NCT01783847|Visual function
1052798|NCT01783834|Pemetrexed
1052799|NCT01783834|Gefitinib
1052800|NCT01783834|iressa
1052801|NCT01783834|alimta
1052802|NCT01783821|Acute respiratory distress syndrome (ARDS)
1052803|NCT01783808|COPD
1052804|NCT01783808|Physical capacity
1052805|NCT01783808|Physical activity
1052806|NCT01783808|Inflammatory markers
1052807|NCT01783808|Health related quality of life
1052816|NCT01783782|Capsule Endoscopy
1052817|NCT01783782|colon cleansing
1052818|NCT01783782|children
1052819|NCT01783782|age 2 -18 years
1052820|NCT01783769|neurosurgery
1052821|NCT01783769|operating room personnel
1052822|NCT01783769|sterile procedures
1052823|NCT01783769|infection
1052824|NCT01783769|Conditions requiring surgery
1052825|NCT01783743|Trichiasis
1052826|NCT01783743|Trachoma
1052827|NCT01783743|Mass treatment
1052828|NCT01783730|Rheumatoid arthritis
1052829|NCT01783704|hip fracture
1052830|NCT01783704|randomized controlled trial
1052831|NCT01783704|exercise
1052832|NCT01783691|Sickle cell disease
1052833|NCT01783652|Adolescent depression
1052834|NCT01783652|internet intervention
1052835|NCT01783639|Carotid
1052836|NCT01783639|Carotid artery stenting
1052837|NCT01783639|Stent
1052838|NCT01783639|Embolic protection
1052839|NCT01783639|Atherosclerotic Disease
1052840|NCT01783600|Peripheral Arterial Disease
1052841|NCT01783600|Infrapopliteal lesions
1052842|NCT01783600|balloon catheter
1052843|NCT01783574|Depression
1052844|NCT01783574|Major Depressive Disorder (MDD)
1052845|NCT01783561|caffeine
1052846|NCT01783561|intubation
1052847|NCT01783561|hemodynamic
1052848|NCT01783548|allergic rhinitis
1052849|NCT01783548|pediatric subjects
1052850|NCT01783548|BDP nasal aerosol
1052851|NCT01783535|intraocular retinoblastoma
1052852|NCT01783509|GENETICALLY CONFIRMED limb girdle muscular dystrophy
1052853|NCT01783483|CABG
1052854|NCT01783483|Valve replacement
1052855|NCT01783483|sternal closure
1052856|NCT01783483|midline sternotomy
1052857|NCT01783483|sternal plates
1052858|NCT01783470|adipose tissue, brown
1052859|NCT01783470|obesity
1052860|NCT01783470|Adrenergic beta-3 Receptor Agonists
1052861|NCT01783470|thermogenesis
1052862|NCT01783470|metabolism
1052863|NCT01783457|First psychotic episode
1052864|NCT01783457|Individual psychoeducation
1052865|NCT01783457|Telemedicine
1052867|NCT01783457|Oxidative stress
1052868|NCT01783444|Estrogen receptor positive, locally advanced, metastatic breast cancer
1052869|NCT01783418|mindfulness-based meditation
1052870|NCT01783418|pediatric cancer
1052871|NCT01783418|adolescence
1052872|NCT01783418|quality of life
1052873|NCT01783418|sleep
1052874|NCT01783418|affect
1052875|NCT01783418|health psychology
1052876|NCT01783405|LDLR mutation
1052877|NCT01783405|Statin
1052878|NCT01783405|Cardiovascular disease
1052879|NCT01783392|overactive bladder
1052880|NCT01783392|transcutaneous posterior tibial nerve stimulation
1052881|NCT01783392|placebo PTNS
1052882|NCT01783379|invasive fungal infection
1052883|NCT01783379|micafungin
1052884|NCT01783379|intensive care
1052885|NCT01783379|pharmacokinetics
1052886|NCT01783366|nasogastric tube, tube exchange catheter
1052887|NCT01783353|Recalcitrant cutaneous warts
1052888|NCT01783353|verruca
1052889|NCT01783340|Malaria
1052890|NCT01783340|P falciparum
1052891|NCT01783340|Chloroquine
1052892|NCT01783340|Azithromycin
1052893|NCT01783340|Immunization
1052894|NCT01783327|Diabetes Mellitus, Type 1
1052895|NCT01783327|Self care
1052896|NCT01783327|Coping skills
1052897|NCT01783327|Adolescent
1052898|NCT01783327|Internet
1052899|NCT01783327|Intervention Studies
1052900|NCT01783327|Chronic Disease
1052901|NCT01783314|hepatic fibrosis
1052902|NCT01783314|Eovist
1052903|NCT01783314|gadoxetate disodium
1052904|NCT01783314|biomarker
1052905|NCT01783314|liver biopsy
1052906|NCT01783314|liver function
1052907|NCT01783314|MRI
1052908|NCT01783314|Hepatitis C
1052909|NCT01783301|follicle stimulating hormone
1052910|NCT01783301|ovarian stimulation
1052911|NCT01783301|antimullerian hormone
1052912|NCT01783301|antral follicle count
1052913|NCT01783301|assisted reproductive technologies
1052914|NCT01783288|Postural tachycardia syndrome
1052915|NCT01783288|orthostatic intolerance
1052916|NCT01783288|orthostatic tachycardia
1052917|NCT01783288|POTS
1052918|NCT01783275|Obesity
1052919|NCT01783275|Type 2 diabetes
1052920|NCT01783275|Liver
1052921|NCT01783236|VATS
1052922|NCT01783236|thoracic surgery
1052923|NCT01783236|acetaminophen
1052924|NCT01783236|ofirmev
1052925|NCT01783236|lung surgery
1052926|NCT01783236|thoracoscopic
1052927|NCT01783236|intravenous acetaminophen
1052928|NCT01783158|head and neck carcinoma
1052929|NCT01783158|chromoendoscopy
1052930|NCT01783158|Lugol's solution
1052931|NCT01783158|esophageal carcinoma
1052932|NCT01783158|synchronous tumors
1052933|NCT01783158|deglutition
1052934|NCT01783158|deglutition disorders
1052935|NCT01783158|Newly diagnosed HNSCC
1052936|NCT01783145|survivorship care
1052937|NCT01783145|testicular cancer
1052938|NCT01783145|shared care model
1052939|NCT01783119|Ulcerative Colitis
1052940|NCT01783119|Aloe Vera
1052941|NCT01783106|Crohn's
1052942|NCT01783106|antibiotics
1052943|NCT01783106|hydroxychloroquine
1052944|NCT01783106|ciprofloxacin
1052945|NCT01783106|doxycycline
1052946|NCT01783080|Chronic depression
1052947|NCT01783080|Dysthymic disorder
1052948|NCT01783080|Double Depression
1052949|NCT01783080|Behavioral Activation therapy
1052950|NCT01783080|Work impairment
1052951|NCT01783080|Unemployment
1052952|NCT01783067|Biofortification
1052953|NCT01783067|Pearl millet
1052954|NCT01783067|Iron absorption
1052955|NCT01783067|Zinc absorption
1053082|NCT01782586|kidney transplant
1052956|NCT01783054|NEOADJUVANT GEMCITABINE AND ABRAXANE CHEMOTHERAPY
1052957|NCT01783054|SURGERY
1052958|NCT01783054|RESECTABLE ADENOCARCINOMA OF THE PANCREAS
1052959|NCT01783041|Prematurity
1052960|NCT01783041|Carnitine supplementation
1052961|NCT01783041|Neonatal Intensive Care
1052962|NCT01783041|MRI
1052963|NCT01783041|Amplitude-integrated EEG
1052964|NCT01783041|NICU Network Neurobehavioral Scale
1052965|NCT01783041|Bayley Scale of Infant Development III
1052966|NCT01783028|asthma
1052967|NCT01783015|Rheumatoid arthritis
1052968|NCT01783015|etanercept
1052969|NCT01783015|methotrexate
1052970|NCT01783015|infliximab
1052971|NCT01783015|adalimumab
1052972|NCT01783015|anti-drug antibody
1052973|NCT01782989|geographic atrophy
1052974|NCT01782989|non-exudative age-related macular degeneration
1052975|NCT01782989|macular degeneration
1052976|NCT01782989|dry macular degeneration
1052977|NCT01782989|dry AMD
1052978|NCT01782976|Glioblastoma
1052979|NCT01782976|GBM
1052980|NCT01782976|Intracranial glioblastoma
1052981|NCT01782976|Recurrent
1052982|NCT01782976|MD Anderson Symptom Inventory for Brain Tumors
1052983|NCT01782976|MDASI-BT
1052984|NCT01782976|Questionnaire
1052985|NCT01782976|Survey
1052986|NCT01782963|Newly diagnosed
1052987|NCT01782950|HIV
1052988|NCT01782950|Tuberculosis
1052989|NCT01782950|Antituberculosis drugs
1052990|NCT01782911|Androgen
1052991|NCT01782911|IVF
1052992|NCT01782911|Resveratrol
1052993|NCT01782911|PCOS.
1052994|NCT01782898|Anesthesia
1052995|NCT01782898|MEDOC neuro sensory analyzer
1052996|NCT01782898|Pain
1052997|NCT01782898|Quality of recovery
1052998|NCT01782885|Osteoarthritis
1052999|NCT01782885|Platelet-Rich Plasma
1053000|NCT01782885|Intra-articular
1053001|NCT01782885|Injection
1053002|NCT01782807|Ovarian function
1053003|NCT01782807|Hysterectomy
1053004|NCT01782807|Salpingectomy
1053005|NCT01782807|Anti mullerian hormone
1053006|NCT01782794|Vaccination
1053007|NCT01782794|Acceptability
1053008|NCT01782794|General population
1053009|NCT01782794|Hepatitis B
1053010|NCT01782794|Vaccine coverage
1053011|NCT01782781|Analgesia
1053012|NCT01782781|Local infiltration analgesia
1053013|NCT01782781|Pain, relief
1053014|NCT01782781|Pain, Postoperative
1053015|NCT01782781|Ropivacaine
1053016|NCT01782781|Ketorolac
1053017|NCT01782781|Epinephrine
1053018|NCT01782781|Adrenergic Agonists
1053019|NCT01782781|Sympathomimetics
1053020|NCT01782781|Therapeutic Uses
1053021|NCT01782781|Anti-Inflammatory Agents, Non-Steroidal
1053022|NCT01782781|Analgesics, Non-Narcotic
1053023|NCT01782781|Analgesics
1053024|NCT01782781|Opioids
1053025|NCT01782781|Morphine
1053026|NCT01782781|Pain
1053027|NCT01782781|Postoperative Complications
1053028|NCT01782781|Physiological Effects of Drugs
1053029|NCT01782781|Anesthetics, Local
1053030|NCT01782781|Anesthetics
1053031|NCT01782768|Neural respiratory drive in different level of NPPV
1053032|NCT01782755|Probiotics
1053033|NCT01782755|Ventilator Associated Pneumonia (VAP)
1053034|NCT01782755|Infection
1053035|NCT01782755|Antibiotic-Associated Diarrhea
1053036|NCT01782755|C-Difficile
1053037|NCT01782742|Mild to Moderate Alzheimer's Disease
1053038|NCT01782729|Dermatitis, Atopic
1053039|NCT01782729|Tacrolimus
1053040|NCT01782716|Mortality
1053041|NCT01782716|Length
1053042|NCT01782716|hospitalization
1053043|NCT01782716|cardiac surgery
1053044|NCT01782716|patients
1053045|NCT01782703|Atopic Dermatitis
1053046|NCT01782703|Filaggrin
1053047|NCT01782703|Biomarkers
1053048|NCT01782703|Eczema
1053049|NCT01782664|PASI
1053050|NCT01782664|DLQI
1053051|NCT01782664|GSK2586184
1053052|NCT01782664|plaque-type psoriasis
1053053|NCT01782664|PGA
1053054|NCT01782664|inflammatory gene transcription
1053055|NCT01782664|JAK-1 inhibitor
1053056|NCT01782664|serum neopterin
1053057|NCT01782664|skin biopsy
1053058|NCT01782664|ACR response criteria
1053059|NCT01782664|VAS itch score
1053060|NCT01782651|HER2 positive
1053061|NCT01782651|Breast Cancer
1053062|NCT01782651|treatment patterns
1053063|NCT01782638|Parkinson's disease
1053064|NCT01782638|Deep brain stimulation
1053065|NCT01782638|Gait
1053066|NCT01782638|Freezing
1053067|NCT01782638|Electrode placements
1053068|NCT01782625|diving
1053069|NCT01782625|cognitive impairment
1053070|NCT01782625|nitrogen narcosis
1053071|NCT01782625|narcosis
1053072|NCT01782625|end tidal carbon dioxide
1053073|NCT01782625|arterial carbon dioxide
1053074|NCT01782625|immersion
1053075|NCT01782612|Balanced Anesthesia
1053076|NCT01782612|Nerve Block
1053077|NCT01782612|Postoperative Recovery
1053078|NCT01782612|Delirium
1053079|NCT01782612|Postoperative Complications
1053080|NCT01782612|Stress
1053081|NCT01782612|Inflammation
1053083|NCT01782586|gene expression markers
1053084|NCT01782586|renal allograft function
1053085|NCT01782573|pre - disinfection scrubbing solution
1053086|NCT01782573|surgical site culture
1053087|NCT01782573|surgical site infection
1053088|NCT01782573|liver tumors
1053089|NCT01782573|hepatectomy
1053090|NCT01782573|chlorhexidine gluconate
1053091|NCT01782560|Laryngomalacia
1053092|NCT01782560|Acid-reflux
1053093|NCT01782547|diabetes mellitus
1053094|NCT01782547|adolescents
1053095|NCT01782521|Bracket failure rate
1053096|NCT01782521|Orthodontic bonding
1053097|NCT01782521|Primer
1053098|NCT01782508|melanoma,adjuvant therapy,kit mutated melanoma
1053099|NCT01782495|Hepatitis C Genotype 4
1053100|NCT01782495|Chronic Hepatitis
1053101|NCT01782495|Interferon-Free
1053102|NCT01782495|Hepatitis C Virus
1053103|NCT01782495|Renal Transplant
1053104|NCT01782495|Liver Transplant
1053105|NCT01782495|Hepatitis C Genotype 1
1053106|NCT01782482|Color contact lenses
1053107|NCT01782482|Refractive error
1053108|NCT01782482|Myopia
1053109|NCT01782469|Synovitis
1053110|NCT01782469|Rheumatoid Arthritis
1053111|NCT01782443|Progressive
1053112|NCT01782443|Metastatic
1053113|NCT01782430|Preoxygenation
1053114|NCT01782430|Intubation
1053115|NCT01782417|osteoarthritis
1053116|NCT01782417|Hispanic
1053117|NCT01782417|behavior
1053118|NCT01782417|intervention
1053119|NCT01782417|Spanish
1053120|NCT01782391|mild cognitive impairment
1053121|NCT01782391|dementia
1053122|NCT01782391|MCI
1053123|NCT01782391|brain stimulation
1053124|NCT01782391|tSOS
1053125|NCT01782391|tDCS
1053126|NCT01782391|sleep
1053127|NCT01782391|memory
1053128|NCT01782391|memory consolidation
1053129|NCT01782378|Persian Gulf Syndrome
1053130|NCT01782378|Veterans Health
1053131|NCT01782378|Executive Function
1053132|NCT01782378|Memory
1053133|NCT01782378|Attention
1053134|NCT01782378|Cognition
1053135|NCT01782378|Laser Therapy, Low-Level
1053136|NCT01782378|Phototherapy
1053137|NCT01782378|Light Therapy
1053138|NCT01782378|Depression
1053139|NCT01782365|mild cognitive impairment
1053140|NCT01782365|dementia
1053141|NCT01782365|MCI
1053142|NCT01782365|brain stimulation
1053143|NCT01782365|tSOS
1053144|NCT01782365|tDCS
1053145|NCT01782365|sleep
1053146|NCT01782365|nap
1053147|NCT01782365|daytime sleep
1053148|NCT01782365|memory
1053149|NCT01782365|memory consolidation
1053150|NCT01782352|age-related macular degeneration
1053151|NCT01782352|incidence
1053152|NCT01782352|progression
1053153|NCT01782326|COPD, QVA149, FLAME( EFfect of Indacaterol Glycopyronium Vs Fluticasone salmeterol on COPD Exacerbations)
1053154|NCT01782287|Neoplasm Metastasis
1053155|NCT01782287|Brain metastasis
1053156|NCT01782287|Lung cancer
1053157|NCT01782274|Neoplasm Metastasis
1053158|NCT01782274|Brain metastasis
1053159|NCT01782274|Breast cancer
1053160|NCT01782261|autoimmune disease
1053161|NCT01782261|diabetes type 1
1053162|NCT01782261|incretin effect
1053163|NCT01782222|Parkinson's Disease
1053164|NCT01782222|Rotigotine
1053165|NCT01782222|Apathy
1053166|NCT01782222|Nonmotor
1053167|NCT01782222|Motor
1053168|NCT01782222|Neupro
1053169|NCT01782209|BK virus viremia
1053170|NCT01782209|renal transplant
1053171|NCT01782209|other viral pathogens
1053172|NCT01782183|sore throat
1053173|NCT01782183|thermal camera photo
1053174|NCT01782183|normal tonsils and pharynx
1053175|NCT01782183|redness of tonsils and/or pharynx
1053176|NCT01782183|exudates on tonsils
1053177|NCT01782183|petechiae of the palate
1053178|NCT01782170|Gingivitis
1053179|NCT01782170|Biomarkers
1053180|NCT01782170|Biological Markers of Inflammation
1053181|NCT01782157|dementia
1053182|NCT01782144|Obesity
1053183|NCT01782144|Foot pain
1053184|NCT01782105|weight gain
1053185|NCT01782105|healthy lifestyle
1053186|NCT01782105|gestational diabetes
1053187|NCT01782105|adipokins
1053188|NCT01782105|glycemic regulation
1053189|NCT01782092|diabetes
1053190|NCT01782079|Lactobacillus brevis
1053191|NCT01782079|Oral health
1053192|NCT01782079|Bacterial adhesion
1053193|NCT01782040|Premenstrual syndrome
1053194|NCT01782040|Physical distress
1053195|NCT01782040|Behavioral changes
1053196|NCT01782027|healthy controls
1053197|NCT01782027|Tangier Disease
1053198|NCT01782027|Adenosine triphosphate-binding cassette transporter 1 (ABCA1)
1053199|NCT01782027|apoA-I
1053200|NCT01782027|LCAT deficiency
1053201|NCT01782027|Scavenger receptor BI (SRBI) deficiency
1053202|NCT01782027|CETP deficiency
1053203|NCT01782014|Screening colonoscopy
1053204|NCT01782014|Water method
1053205|NCT01782014|Carbon dioxide method
1053206|NCT01782014|Air method
1053207|NCT01782014|Water versus carbon dioxide versus air insufflation colonoscopy
1053208|NCT01782014|Adenoma Detection Rate
1053209|NCT01782014|Pain Scores in colonoscopy
1053210|NCT01782001|Vitamin A
1053211|NCT01782001|Zinc
1053212|NCT01782001|Malaria
1053213|NCT01782001|Morbidity
1053214|NCT01782001|MRDR
1053215|NCT01781988|lung cancer
1053216|NCT01781988|gemcitabine
1053217|NCT01781988|carboplatin
1053218|NCT01781988|pemetrexed
1053219|NCT01781949|HIV infection
1053220|NCT01781949|Targeted screening
1053221|NCT01781949|Nontargeted screening
1053222|NCT01781949|Emergency department
1053223|NCT01781949|Urgent care
1053224|NCT01781949|Effectiveness
1053225|NCT01781923|Cognitive remediation
1053226|NCT01781923|Social Cognition
1053227|NCT01781910|branched chain amino acids, exercise, delayed onset muscle soreness
1053228|NCT01781897|acupuncture
1053229|NCT01781897|electro-acupuncture
1053230|NCT01781871|Pneumococcal vaccination
1053231|NCT01781871|immunogenicity
1053232|NCT01781871|solid organ transplant
1053233|NCT01781858|Pulmonary embolism
1053234|NCT01781858|Chronic thromboembolic pulmonary hypertension
1053235|NCT01781858|Venous thromboembolism
1053236|NCT01781793|dyspnea, exercise endurance, lung disease
1053237|NCT01781780|Obesity
1053238|NCT01781780|Weight Loss
1053239|NCT01781780|Breakfast
1053240|NCT01781767|UCP2
1053241|NCT01781767|Thyroid function
1053242|NCT01781767|Thyroid carcinoma
1053243|NCT01781754|Glycemic control
1053244|NCT01781754|Metabolic control
1053245|NCT01781754|Oxidative stress
1053246|NCT01781754|Diabetes
1053247|NCT01781728|recurrent
1053248|NCT01781728|unresectable
1053249|NCT01781728|residual
1053250|NCT01781728|stereotactic body radiation therapy (SBRT)
1053251|NCT01781728|palliative management
1053252|NCT01781715|STEMI, Multivessel Coronary Artery Disease, Primary PCI, multivessel stenting, zotarolimus-eluting stent
1053253|NCT01781689|cortical activation
1053254|NCT01781689|motor function
1053255|NCT01781689|activity of daily living
1053256|NCT01781650|Warm Water Infusion colonoscopy
1053257|NCT01781650|Water Immersion colonoscopy
1053258|NCT01781650|Water Exchange colonoscopy
1053259|NCT01781650|Painless unsedated colonoscopy
1053260|NCT01781650|Adenoma detection rate
1053261|NCT01781650|Adenoma resection rate
1053262|NCT01781637|Xolair
1053263|NCT01781637|omalizumab
1053264|NCT01781637|peanut
1053265|NCT01781637|oral desensitization
1053266|NCT01781611|lupus
1053267|NCT01781611|dipyridamole
1053268|NCT01781598|Total knee arthroplasty
1053269|NCT01781598|Patient specific instruments
1053270|NCT01781598|Patient matched cutting blocks
1053271|NCT01781598|Alignment
1053272|NCT01781598|Learning curve
1053273|NCT01781598|VISIONAIRE
1053274|NCT01781585|Sustained low-efficiency dialysis;
1053275|NCT01781585|Continuous venovenous hemofiltration;
1053276|NCT01781585|hemodynamic stability,
1053277|NCT01781585|Intracranial pressure
1053278|NCT01781546|drug eluting balloon
1053279|NCT01781546|bare metal stent
1053280|NCT01781546|coronary artery disease
1053281|NCT01781546|acute coronary syndrome
1053282|NCT01781546|percutaneous coronary intervention
1053283|NCT01781546|DEB
1053284|NCT01781546|BMS
1053285|NCT01781520|Pancreatic Cancer
1053286|NCT01781520|S1
1053287|NCT01781520|DC-CIK
1053288|NCT01781507|Asthma
1053289|NCT01781507|Allergic rhinitis
1053290|NCT01781507|Cetirizine
1053291|NCT01781507|Impulse oscillometry
1053292|NCT01781481|Psychosocial Stress and Adjustment
1053293|NCT01781481|Pediatric Chronic Illness
1053294|NCT01781481|Decision-support tool
1053295|NCT01781481|Integrated Health Care
1053296|NCT01781481|Case Complexity
1053297|NCT01781442|Metastatic Renal Cell Carcinoma
1053298|NCT01781416|cardiovascular risk
1053299|NCT01781416|SCORE
1053300|NCT01781416|cardiovascular primary prevention
1053301|NCT01781416|risk factors
1053302|NCT01781403|Temozolomide
1053303|NCT01781403|capecitabine
1053304|NCT01781403|rectal cancer
1053305|NCT01781390|Acute Myocardial Infarction
1053306|NCT01781390|STEMI
1053307|NCT01781390|Heart Attack
1053308|NCT01781390|AMI
1053309|NCT01781390|Stem Cells
1053310|NCT01781377|NAUSEA
1053311|NCT01781377|VOMITING
1053312|NCT01781377|CESAREAN SECTION
1053313|NCT01781377|PREVENTION
1053314|NCT01781377|PROPOFOL
1053315|NCT01781364|Brain Oscillations
1053316|NCT01781364|Cognitive Performance
1053317|NCT01781325|musculoskeletal, physical therapy
1053318|NCT01781299|Breast Cancer
1053319|NCT01781299|Mastectomy
1053320|NCT01781299|Immediate reconstruction
1053321|NCT01781286|Obesity
1053322|NCT01781286|Snacking
1053323|NCT01781286|Appetite
1053324|NCT01781286|Protein
1053325|NCT01781286|Soy
1053326|NCT01781286|Reward driven eating
1053327|NCT01781286|Satiety
1053328|NCT01781273|impaired driving
1053329|NCT01781260|Prone position
1053330|NCT01781260|Cardiac output
1053331|NCT01781260|Liver Circulation
1053332|NCT01781247|Stress Disorders, Post-Traumatic
1053333|NCT01781247|Myocardial Infarction
1053334|NCT01781247|Psychotherapy
1053335|NCT01781247|Preventive Therapy
1053336|NCT01781247|Randomized Controlled Trial
1053337|NCT01781247|Cardiovascular Diseases
1053338|NCT01781247|Psychological Stress
1053339|NCT01781247|Biomarkers
1053340|NCT01781195|Advagraf
1053341|NCT01781195|MELD-score
1053342|NCT01781195|Na-MELD-score
1053343|NCT01781195|liver function
1053344|NCT01781195|LiMAx-test
1053345|NCT01781195|infection rate
1053346|NCT01781195|HLA-DR status
1053347|NCT01781195|immunostatus
1053348|NCT01781169|Vitamin D,
1053349|NCT01781169|Oral supplementation,
1053350|NCT01781169|Obese males
1053351|NCT01781156|phosphorus
1053352|NCT01781156|hemodialysis
1053353|NCT01781156|cardiac biomarkers
1053354|NCT01781117|Benign prostatic obstruction (BPO)
1053355|NCT01781117|Detrusor overactivity (DO)
1053356|NCT01781117|Urinary nerve growth factor (NGF)
1053357|NCT01781104|constipation gastric emptying gastrointestinal motility ghrelin
1053358|NCT01781078|Single chamber pacing
1053359|NCT01781078|Dual chamber pacing
1053360|NCT01781078|MRI
1053361|NCT01781078|MR scans
1053362|NCT01781052|Iloprost Compliance
1053363|NCT01781039|"hair cell"
1053364|NCT01781039|"spiral ganglion"
1053365|NCT01781039|"hearing aid"
1053366|NCT01781039|"hearing loss"
1053367|NCT01781026|B-raf V600E
1053368|NCT01781026|V600K mutation
1053369|NCT01781026|metastatic melanoma
1053370|NCT01781013|Depression screening
1053371|NCT01781013|Depression monitoring
1053372|NCT01781013|Chronic illness
1053373|NCT01781013|Behavioral health
1053374|NCT01781013|Care management
1053375|NCT01781013|Automatic telephone assessment
1053376|NCT01781013|Clinical decision support
1053377|NCT01781013|Suicide alert
1053378|NCT01781000|Cognitive Training
1053379|NCT01781000|Neuroplasticity
1053380|NCT01781000|MEG
1053381|NCT01781000|MATRICS
1053382|NCT01780987|DVT
1053383|NCT01780987|PE
1053384|NCT01780987|VTE
1053385|NCT01780974|Hypertension
1053386|NCT01780974|Vascular Risk
1053387|NCT01780974|Alzheimer's Risk
1053388|NCT01780974|fish oil
1053389|NCT01780974|Lipoic acid
1053390|NCT01780961|Esophageal Cancer
1053391|NCT01780961|ESBX
1053392|NCT01780948|Drug Interaction
1053393|NCT01780948|Pharmacokinetics
1053394|NCT01780948|Everolimus
1053395|NCT01780948|Atorvastatin
1053396|NCT01780922|Inflammation
1053397|NCT01780922|Oxidative Stress
1053398|NCT01780922|Vaccinium macrocarpon
1053399|NCT01780896|Topographical Memory
1053400|NCT01780896|Non-Topographical Memory
1053401|NCT01780896|Vestibular Function
1053402|NCT01780896|Alzheimer's Disease
1053403|NCT01780883|melatonin
1053404|NCT01780883|childhood autism
1053405|NCT01780883|6-Sulphatoxymelatonin
1053406|NCT01780883|autistic disorder
1053407|NCT01780883|dose-effect relation
1053408|NCT01780870|Overweight
1053409|NCT01780870|Obesity
1053410|NCT01780870|Obese
1053411|NCT01780870|Weight loss
1053412|NCT01780857|palmoplantar pustulosis
1053413|NCT01780857|psoriasis
1053414|NCT01780844|Kidney Transplantation
1053415|NCT01780844|de novo Kidney Transplantation
1053416|NCT01780844|ASKP1240
1053417|NCT01780818|Warm Water Infusion colonoscopy
1053418|NCT01780818|Water Immersion colonoscopy
1053419|NCT01780818|Water Exchange colonoscopy
1053420|NCT01780818|Painless unsedated colonoscopy
1053421|NCT01780818|Adenoma detection rate
1053422|NCT01780818|Adenoma resection rate
1053423|NCT01780792|multiple sclerosis
1053424|NCT01780792|mobility
1053425|NCT01780792|cognition
1053426|NCT01780792|neuroplasticity
1053427|NCT01780792|videogame play
1053428|NCT01780779|Diffusion weighted MRI
1053429|NCT01780779|Patient outcome assessment
1053430|NCT01780779|Treatment response
1053431|NCT01780779|Histopathology
1053432|NCT01780766|Whole body MRI
1053433|NCT01780766|Multiple myeloma
1053434|NCT01780766|Diffusion Weighted MRI
1053435|NCT01780766|Whole body scan
1053436|NCT01780753|Primaquine
1053437|NCT01780753|Vivax malaria
1053438|NCT01780753|G6PD
1053439|NCT01780740|Bypass Surgery, Coronary Artery
1053440|NCT01780740|Atrial fibrillation
1053441|NCT01780740|Ischaemia-reperfusion injury
1053442|NCT01780740|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1053443|NCT01780740|Statins, HMG-CoA
1053444|NCT01780727|echocardiography
1053445|NCT01780727|hemodynamic management
1053446|NCT01780714|smoking
1053447|NCT01780714|cigarette
1053448|NCT01780714|exposure
1053449|NCT01780714|biomarker
1053450|NCT01780714|human smoking topography (HST)
1053451|NCT01780714|modified risk tobacco product (MRTP)
1053452|NCT01780714|THS 2.1
1053453|NCT01780701|prostate cancer aggressiveness
1053454|NCT01780701|magnetic resonance imaging
1053455|NCT01780701|fatty acid synthase
1053456|NCT01780688|Modified risk tobacco product (MRTP)
1053457|NCT01780688|Smoking
1053458|NCT01780688|Nicotine profile
1053459|NCT01780675|Prophylactic Cranial Irradiation
1053460|NCT01780675|Hippocampal Avoidance Prophylactic Cranial Irradiation
1053461|NCT01780649|IMSI
1053462|NCT01780649|ICSI
1053463|NCT01780649|ART Assisted reproductive technology
1053464|NCT01780649|Spermatozoa
1053465|NCT01780649|male infertility
1053466|NCT01780649|vacuoles
1053467|NCT01780636|Non relaxing puborectalis syndrome
1053468|NCT01780636|Botulinum toxin A
1053469|NCT01780636|Botox
1053470|NCT01780636|Constipation
1053471|NCT01780623|fatigue
1053472|NCT01780623|sleep
1053473|NCT01780623|quality of life
1053474|NCT01780623|light
1053475|NCT01780623|cancer
1053476|NCT01780610|endometrium preparation protocols
1053477|NCT01780610|frozen-thawed embryo transfer
1053478|NCT01780610|irregular cycle
1053479|NCT01780610|randomized controlled trial
1053480|NCT01780597|Heart transplantation
1053481|NCT01780597|Ev Vivo Perfusion
1053482|NCT01780597|Cardiac function
1053483|NCT01780584|congenital heart surgery, thyroid hormones
1053484|NCT01780571|Obesity
1053485|NCT01780571|general anaesthesia
1053486|NCT01780571|preoxygenation
1053487|NCT01780571|atelectasis
1053488|NCT01780558|endometrium preparation protocols
1053489|NCT01780558|frozen-thawed embryo transfer
1053490|NCT01780558|natural cycles
1053491|NCT01780558|hormone replacement therapy cycles
1053492|NCT01780558|randomized controlled trial
1053493|NCT01780545|OGX-427
1053494|NCT01780545|Docetaxel
1053495|NCT01780519|Alzheimer's disease (AD)
1053496|NCT01780506|HIV
1053497|NCT01780506|Treatment Naive
1053498|NCT01780506|HIV 1 Infected
1053499|NCT01780506|Female
1053500|NCT01780506|Women
1053501|NCT01780493|Nipple
1053502|NCT01780493|Technique
1053503|NCT01780493|Ureter
1053504|NCT01780493|Vesicoureteral Reflux
1053505|NCT01780480|Ischemic Stroke
1053506|NCT01780480|Convalescence
1053507|NCT01780480|Randomized Controlled Trial
1053508|NCT01780480|Pilot Study
1053509|NCT01780480|Traditional Chinese Medicine
1053510|NCT01780467|Loss aversion
1053511|NCT01780467|Dopamine
1053512|NCT01780467|Parkinson's disease
1053513|NCT01780454|End Stage Renal Disease
1053514|NCT01780454|Renal Transplant
1053515|NCT01780454|Bone Marrow Transplant
1053516|NCT01780454|Tolerance
1053517|NCT01780454|Chimerism
1053518|NCT01780454|ESRD
1053519|NCT01780441|Tuberous Sclerosis Complex
1053520|NCT01780441|TSC
1053521|NCT01780441|Autism
1053522|NCT01780441|ASD
1053523|NCT01780441|Biomarkers
1053524|NCT01780441|Infants
1053525|NCT01780428|Pain
1053526|NCT01780428|Nausea
1053527|NCT01780428|Vomiting
1053528|NCT01780415|Blastocoele fluid
1053529|NCT01780415|Human DNA
1053530|NCT01780415|molecular diagnosis
1053531|NCT01780402|feeding difficulty
1053532|NCT01780402|eating difficulty
1053533|NCT01780402|dementia
1053534|NCT01780402|nursing home
1053535|NCT01780402|careful hand feeding
1053536|NCT01780389|Knee
1053537|NCT01780389|Pain
1053538|NCT01780389|Osteoarthritis
1053539|NCT01780376|whole-body vibration
1053540|NCT01780376|latency
1053541|NCT01780376|reflex response
1053542|NCT01780376|muscle
1053543|NCT01780337|Oxytocin
1053544|NCT01780337|Arrhythmia
1053545|NCT01780298|COPD
1053546|NCT01780298|Biomarkers
1053547|NCT01780298|Cigarette Smoke
1053548|NCT01780298|Lung Inflammation
1053549|NCT01780298|FEV
1053550|NCT01780298|Sputum
1053551|NCT01780285|Hiatal hernia
1053552|NCT01780285|Gastro-oesophageal reflux disease
1053553|NCT01780285|Laparoscopic hiatal repair
1053554|NCT01780285|Laparoscopic anti-reflux surgery
1053555|NCT01780285|Partially absorbable lightweight mesh
1053556|NCT01780285|Polytetrafluoroethylene
1053557|NCT01780285|PTFE
1053558|NCT01780285|Nitinol
1053559|NCT01780285|Nitinol-framed lightweight PTFE mesh
1053560|NCT01780259|Healthy
1053561|NCT01780259|Esketamine
1053562|NCT01780259|Pharmacokinetics
1053563|NCT01780259|Intranasal
1053564|NCT01780246|Spinal Muscular Atrophy
1053565|NCT01780246|SMA
1053566|NCT01780246|SMN
1053567|NCT01780246|SMNRx
1053568|NCT01780246|ISIS-SMNRx
1053569|NCT01780246|ISIS 396443
1053570|NCT01780220|abiraterone
1053571|NCT01780220|biochemically-relapsing
1053572|NCT01780220|prostate adenocarcinoma
1053573|NCT01780181|lung cancer
1053574|NCT01780181|traditional Chinese medicine
1053575|NCT01780168|Inborn Error of Metabolism
1053576|NCT01780168|Metabolism
1053577|NCT01780168|UCD
1053578|NCT01780168|Immunity
1053579|NCT01780168|Nutrition
1053580|NCT01780168|Mitochondrial Disease
1053581|NCT01780155|Oxidative Stress
1053582|NCT01780155|Hyperoxia
1053583|NCT01780155|Brochopulmonary Dysplasia
1053584|NCT01780155|Retinopathy of Prematurity
1053585|NCT01780155|Very Low Birth Rate
1053586|NCT01780142|Airflow Obstruction
1053587|NCT01780142|Airflow Inflammation
1053588|NCT01780142|Corticosteroid Resistance
1053589|NCT01780142|Exacerbations
1053590|NCT01780142|Quality of Life
1053591|NCT01780116|schizophrenia
1053592|NCT01780116|adherence therapy
1053593|NCT01780116|medication
1053594|NCT01780116|randomized controlled trial
1053595|NCT01780116|cost-effectiveness
1053596|NCT01780090|autism
1053597|NCT01780090|prosody
1053598|NCT01780090|speech
1053599|NCT01780090|autism spectrum disorder
1053600|NCT01780077|Scar
1053601|NCT01780077|Scar prevention
1053602|NCT01780077|Fibrosis
1053603|NCT01780051|Diabetes Mellitus, Type 2
1053604|NCT01780051|Pharmacokinetics
1053605|NCT01780038|Cigarette Smoking
1053606|NCT01780038|Nicotine Dependence
1053607|NCT01780038|Smoking Abstinence
1053608|NCT01780038|Health Literacy
1053609|NCT01780038|Genetic Predisposition Testing
1053610|NCT01780038|Heredity
1053611|NCT01780025|Hearing
1053612|NCT01780025|Thresholds
1053613|NCT01780025|Coupling to the inner ear
1053614|NCT01780012|osteoporosis
1053615|NCT01780012|fragility fracture
1053616|NCT01780012|secondary prevention
1053617|NCT01779999|central venous catheters
1053618|NCT01779999|thrombosis
1053619|NCT01779999|secondary prevention
1053620|NCT01779973|Skype
1053621|NCT01779973|compliance
1053622|NCT01779973|remote dosing
1053623|NCT01779973|suboxone
1053624|NCT01779973|opiate
1053625|NCT01779973|opiates
1053626|NCT01779973|heroin
1053627|NCT01779973|oxycontin
1053628|NCT01779973|Philadelphia
1053629|NCT01779960|Pulmonary Disease, Chronic Obstructive
1053630|NCT01779960|Motor activity
1053631|NCT01779960|Climatologic station
1053632|NCT01779908|Vitamin D supplementation
1053633|NCT01779908|Insulin resistance
1053634|NCT01779895|Dust mite
1053635|NCT01779895|Perennial allergic rhinitis
1053636|NCT01779869|PET MR myocardial perfusion imaging
1053637|NCT01779856|End Stage Renal Disease, Hemodialysis, Arrhythmia, Reveal ICM
1053638|NCT01779843|Newly diagnosed
1053639|NCT01779804|foot , ankle, injury
1053640|NCT01779791|Lymphoma
1053641|NCT01779791|Refractory follicular lymphoma
1053642|NCT01779791|Chemoimmunotherapy-resistant follicular lymphoma
1053643|NCT01779791|PCI-32765
1053644|NCT01779791|Ibrutinib
1053645|NCT01779791|IMBRUVICA
1053646|NCT01779765|IBS
1053647|NCT01779765|Diarrhea
1053648|NCT01779765|Constipation
1053649|NCT01779765|Fibers
1053650|NCT01779739|vaginal prolapse
1053651|NCT01779739|sexual function
1053652|NCT01779739|sexual dysfunction
1053653|NCT01779739|prolapse surgery
1053654|NCT01779726|Organization
1053655|NCT01779726|of fast track
1053656|NCT01779713|Aneurysmal subarachnoid hemorrhage
1053657|NCT01779713|Vasospasm
1053658|NCT01779713|Transcriptomic
1053659|NCT01779713|Case-Control Study
1053660|NCT01779700|psychosis
1053661|NCT01779700|schizophrenia
1053662|NCT01779700|cognition
1053663|NCT01779700|fingolimod
1053664|NCT01779687|pharmacokinetic
1053665|NCT01779687|interaction
1053666|NCT01779687|cholesterol
1053667|NCT01779687|raltegravir
1053668|NCT01779687|atorvastatin
1053669|NCT01779661|Neurodevelopment, Infant-Aquatics, Prematurity
1053670|NCT01779648|deep vein thrombosis
1053671|NCT01779648|intermittent pneumatic compression
1053672|NCT01779648|venous hemodynamics
1053673|NCT01779635|Heparin-grafted membrane
1053674|NCT01779635|Circuit lifespan
1053675|NCT01779635|Continuous renal replacement therapy
1053676|NCT01779635|Anticoagulation free
1053677|NCT01779635|Bleeding risk
1053678|NCT01779635|Acute kidney injury
1053679|NCT01779635|Critical illness
1053680|NCT01779622|mixed meal¨
1053681|NCT01779622|insulin
1053682|NCT01779622|glucagon
1053683|NCT01779622|GIP
1053684|NCT01779622|GLP-1
1053685|NCT01779596|diabetes
1053686|NCT01779596|endothelial function
1053687|NCT01779596|exercise
1053688|NCT01779596|blood flow
1053689|NCT01779596|bosentan
1053690|NCT01779583|Advanced gastric cancer
1053691|NCT01779570|Influenza
1053692|NCT01779570|Macrolide
1053693|NCT01779570|Anti-inflammatory
1053694|NCT01779557|CAPD
1053695|NCT01779557|efficacy
1053696|NCT01779557|safety
1053697|NCT01779557|survival rate
1053698|NCT01779544|rehabilitation,surgery,brief intervention, exercises
1053699|NCT01779531|HER2-negative Luminal B breast cancer
1053700|NCT01779518|HCV
1053701|NCT01779518|Sustained Virologic Response
1053702|NCT01779518|Direct Acting Antiviral
1053703|NCT01779518|GS-7977
1053704|NCT01779518|Pegylated interferon
1053705|NCT01779518|Ribavirin
1053706|NCT01779518|Open Label
1053707|NCT01779518|Sofosbuvir
1053708|NCT01779518|Liver transplant
1053709|NCT01779518|Hepatitis
1053710|NCT01779518|Hepatitis, Chronic
1053711|NCT01779518|Hepatitis C
1053712|NCT01779518|Hepatitis C, Chronic
1053713|NCT01779518|Liver Diseases
1053714|NCT01779518|Digestive System Diseases
1053715|NCT01779518|Hepatitis, Viral, Human
1053716|NCT01779518|Virus Diseases
1053717|NCT01779518|Enterovirus Infections
1053718|NCT01779518|Picornaviridae Infections
1053719|NCT01779518|RNA Virus Infections
1053720|NCT01779518|Flaviviridae Infections
1053721|NCT01779518|Antiviral Agents
1053722|NCT01779518|Anti-Infective Agents
1053723|NCT01779518|Therapeutic Uses
1053724|NCT01779518|Pharmacologic Actions
1053725|NCT01779518|Antimetabolites
1053726|NCT01779518|Molecular Mechanisms of Pharmacological Action
1053727|NCT01779492|Oxycodone, controlled release formulation
1053728|NCT01779479|German Breast Group
1053729|NCT01779479|GBG Forschungs GmbH
1053730|NCT01779479|GBG
1053731|NCT01779479|GBG 74
1053732|NCT01779479|Genevieve
1053733|NCT01779479|Breast Cancer
1053734|NCT01779479|Primary Breast Cancer
1053735|NCT01779479|Cabazitaxel
1053736|NCT01779479|Paclitaxel
1053737|NCT01779479|neo-adjuvant
1053738|NCT01779479|triple negative
1053739|NCT01779479|luminal B
1053740|NCT01779453|Atorvastatin
1053741|NCT01779453|Drug-drug interaction
1053742|NCT01779453|Combination therapy
1053743|NCT01779440|Mental Illness
1053744|NCT01779440|Tobacco Smoking
1053745|NCT01779440|Young Adults
1053746|NCT01779440|Treatment Engagement
1053747|NCT01779440|Motivational Intervention
1053748|NCT01779427|traumatic brain injury (TBI)
1053749|NCT01779427|intracranial edema
1053750|NCT01779427|brain edema
1053751|NCT01779427|craniocerebral trauma
1053752|NCT01779427|head injury
1053753|NCT01779427|brain hemorrhage, traumatic
1053754|NCT01779427|subdural hematoma
1053755|NCT01779427|brain concussion
1053756|NCT01779427|head injuries, closed
1053757|NCT01779427|epidural hematoma
1053758|NCT01779427|extra-axial hemorrhage
1053759|NCT01779427|cortical contusion
1053760|NCT01779427|wounds and injuries
1053761|NCT01779427|disorders of environmental origin
1053762|NCT01779427|trauma, nervous system
1053763|NCT01779427|brain injuries
1053764|NCT01779427|attention deficit hyperactivity disorder (ADHD)
1053765|NCT01779427|attention
1053766|NCT01779414|Suicide Ideation
1053767|NCT01779401|PCI
1053768|NCT01779401|platelet function monitoring
1053769|NCT01779401|Thrombelastography
1053770|NCT01779401|clopidogrel
1053771|NCT01779401|cilostazol
1053772|NCT01779401|in-stent thrombosis
1053773|NCT01779388|Lung nodule
1053774|NCT01779388|PET scanner
1053775|NCT01779388|Bronchoscopy
1053776|NCT01779388|Electromagnetic navigation
1053777|NCT01779375|Children
1053778|NCT01779375|Pediatric
1053779|NCT01779349|benign prostatic hyperplasia (BPH)
1053780|NCT01779349|acoustic vibration
1053781|NCT01779336|Advanced Refractory Solid Tumors
1053782|NCT01779323|SUI
1053783|NCT01779323|stress urinary incontinence
1053784|NCT01779323|male
1053785|NCT01779323|transobturator sling
1053786|NCT01779297|new integrative weaning indexes
1053787|NCT01779297|mechanical ventilation
1053788|NCT01779297|ICU
1053789|NCT01779284|glaucoma
1053790|NCT01779284|fixed combinations
1053791|NCT01779284|24-hour monitoring
1053792|NCT01779271|Pelubi
1053793|NCT01779271|Pelubiprofen
1053794|NCT01779271|Loxoprofen
1053795|NCT01779271|Anti-pyretic
1053796|NCT01779271|Fever
1053797|NCT01779258|xerosis
1053798|NCT01779258|dry skin
1053799|NCT01779258|dermatitis
1053800|NCT01779258|eczema
1053801|NCT01779258|emollient
1053802|NCT01779258|corticosteroid
1053803|NCT01779258|flare
1053804|NCT01779232|endometriosis
1053805|NCT01779232|ivf
1053806|NCT01779232|ovarian reserve
1053807|NCT01779232|danazol
1053808|NCT01779219|intraoperative magnetic resonance
1053809|NCT01779219|stereotactic biopsy
1053810|NCT01779219|brain tumor
1053811|NCT01779219|frameless stereotaxy
1053812|NCT01779219|image-guided neurosurgery
1053813|NCT01779193|group B streptococcus
1053814|NCT01779193|pregnancy
1053815|NCT01779193|probiotics
1053816|NCT01779180|Vitamin A supplementation
1053817|NCT01779180|BCG vaccination
1053818|NCT01779180|diphtheria-tetanus-pertussis vaccination
1053819|NCT01779180|measles vaccination
1053820|NCT01779180|atopy
1053821|NCT01779167|WM
1053822|NCT01779154|eosinophilic esophagitis
1053823|NCT01779154|eosinophilic gastritis
1053824|NCT01779154|eosinophilic enteritis
1053825|NCT01779154|eosinophilic colitis
1053826|NCT01779141|Type 1 Diabetes Mellitus - T1DM
1053827|NCT01779141|Pregnancy
1053828|NCT01779141|Insulin Pump
1053829|NCT01779141|Glucose Sensor
1053830|NCT01779141|Continuous Subcutaneous Insulin Infusion - CSII
1053831|NCT01779141|Sensor Augmented Pump - SAP
1053832|NCT01779141|Continuous Glucose Monitoring - CGM
1053833|NCT01779115|Registry,Diabetes,Health Maintenance Organization
1053834|NCT01779089|diabetic nephropathy
1053835|NCT01779089|diabetic kidney disease
1053836|NCT01779089|minocycline
1053837|NCT01779089|proteinuria
1053838|NCT01779089|albuminuria
1053839|NCT01779063|lymphedema
1053840|NCT01779063|self-care
1053841|NCT01779063|breast cancer
1053842|NCT01779024|Addiction
1053843|NCT01779024|Alcohol
1053844|NCT01779024|Alcohol Clamp
1053845|NCT01778998|incision
1053846|NCT01778998|pre-cut
1053847|NCT01778998|wound architecture
1053848|NCT01778998|OCT
1053849|NCT01778985|Pelvic organ prolapse
1053850|NCT01778985|Menopause
1053851|NCT01778985|Estrogen
1053852|NCT01778985|Premarin
1053853|NCT01778972|Fall prevention
1053854|NCT01778972|Home exercise
1053855|NCT01778972|Strength training
1053856|NCT01778972|Balance training
1053857|NCT01778946|Nicotine
1053858|NCT01778946|Down Syndrome
1053859|NCT01778946|Mild Cognitive Impairment
1053860|NCT01778946|Event Related Potential
1053861|NCT01778946|Memory
1053862|NCT01778946|Attention
1053863|NCT01778946|Trisomy 21
1053864|NCT01778946|Neuroprotection
1053865|NCT01778946|Cognitive Enhancement
1053866|NCT01778946|Alzheimer's Disease
1053867|NCT01778946|Dementia
1053868|NCT01778946|APOE
1053869|NCT01778933|Renal cell carcinoma
1053870|NCT01778933|Renal nodules
1053871|NCT01778907|Pharmacogenetics
1053872|NCT01778907|Depression
1053873|NCT01778907|Depressive Disorder
1053874|NCT01778907|Cytochrome P-450 CYP2D6
1053875|NCT01778907|Antidepressive Agents, Tricyclic
1053876|NCT01778907|Antidepressive Agents, Second-Generation
1053877|NCT01778907|Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
1053878|NCT01778907|Intermediate Metabolizer Due to Cytochrome P450 CYP2D6 Variant
1053879|NCT01778907|Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant
1053880|NCT01778907|Multicenter studies
1053881|NCT01778894|Diastolic Dysfunction, Diastolic Heart Failure, Diastolic
1053882|NCT01778894|Echocardiography
1053883|NCT01778881|Bruxism
1053884|NCT01778881|Physical therapy modalities
1053885|NCT01778881|Massage
1053886|NCT01778881|Muscle stretching exercises
1053887|NCT01778881|Relaxation therapy
1053888|NCT01778881|Imagination
1053889|NCT01778855|stroke
1053890|NCT01778855|hypothermia
1053891|NCT01778855|thrombolysis
1053892|NCT01778855|imaging
1053893|NCT01778855|collateral circulation
1053894|NCT01778855|recanalization
1053895|NCT01778855|reperfusion
1053896|NCT01778842|antiplatelet effect
1053897|NCT01778842|prasugrel
1053898|NCT01778842|clopidogrel
1053899|NCT01778842|acute coronary syndrome
1053900|NCT01778816|Achilles tendon, muscle volume, Achilles tendon length, force, ATRS, Hannover, AOFAS
1053901|NCT01778777|rotator cuff tear arthropathy
1053902|NCT01778777|inverse prosthesis
1053903|NCT01778777|safety
1053904|NCT01778777|universe reverse
1053905|NCT01778751|Self-Management Support
1053906|NCT01778751|Depression
1053907|NCT01778751|Home Telehealth
1053908|NCT01778725|Chorioamnionitis, S100B, Brain, Neuro-development
1053909|NCT01778712|Multi-level intervention
1053910|NCT01778712|Menopause
1053911|NCT01778712|Body composition
1053912|NCT01778712|Abdominal adipose tissue
1053913|NCT01778712|Visceral adipose tissue
1053914|NCT01778712|Perceived stress
1053915|NCT01778712|Computed tomography
1053916|NCT01778712|Dual energy X-ray absorptiometry
1053917|NCT01778699|Lactobacillus brevis CD2
1053918|NCT01778699|caries incidence
1053919|NCT01778699|plaque-pH
1053920|NCT01778686|Positron Emission Tomography
1053921|NCT01778686|Serotonin
1053922|NCT01778686|5-HT2A
1053923|NCT01778686|Radioligand
1053924|NCT01778660|Fecal Incontinence
1053925|NCT01778660|Treatment options
1053926|NCT01778660|Patient Satisfaction
1053927|NCT01778647|ADHD
1053928|NCT01778647|Omega- 3 Fatty acids
1053929|NCT01778647|CGI
1053930|NCT01778647|Conners rating scale
1053931|NCT01778647|Stimulants
1053932|NCT01778634|Ureaplasma parvum
1053933|NCT01778634|Ureaplasma urealyticum
1053934|NCT01778634|prematurity
1053935|NCT01778634|bronchopulmonary dysplasia
1053936|NCT01778634|azithromycin
1053937|NCT01778621|Acupuncture
1053938|NCT01778621|AMH
1053939|NCT01778621|Infertility
1053940|NCT01778621|PCOS
1053941|NCT01778621|Pregnancy rate
1053942|NCT01778608|Sedation
1053943|NCT01778595|Microbiome
1053944|NCT01778595|Feces
1053945|NCT01778595|Cancer Screening
1053946|NCT01778582|Emotion
1053947|NCT01778582|Informed Consent
1053948|NCT01778569|Psoriasis
1053949|NCT01778569|Cardiovascular Risk Factors
1053950|NCT01778569|Inflammation
1053951|NCT01778569|Lipoproteins
1053952|NCT01778569|Metabolic Dysfunction
1053953|NCT01778556|Lipodystrophy
1053954|NCT01778556|Leptin
1053955|NCT01778556|Energy Expenditure
1053956|NCT01778556|Diabetes
1053957|NCT01778556|Hypertriglyceridemia
1053959|NCT01778530|Glioblastoma
1053960|NCT01778530|Anti-Angiogenesis
1053961|NCT01778530|Radiotherapy
1053962|NCT01778530|Malignant Glioma
1053963|NCT01778530|Progression
1053964|NCT01778517|Psychogenic Movement Disorders
1053965|NCT01778504|Children and Adolescents
1053966|NCT01778504|Natural History Study
1053967|NCT01778504|Neurodevelopmental Disorders
1053968|NCT01778504|Autism
1053969|NCT01778504|Obsessive Compulsive Disorder
1053970|NCT01778491|Phenotype-Genotype correlation
1053971|NCT01778491|Phenotype
1053972|NCT01778491|Phenotypes
1053973|NCT01778491|Age Related Macular Degeneration
1053974|NCT01778478|Anxiety
1053975|NCT01778478|Depression
1053976|NCT01778478|Adolescents and Adults
1053977|NCT01778478|Cancer Diagnosis
1053978|NCT01778465|Chronic Rhinosinusitis
1053979|NCT01778465|Aspirin exacerbated respiratory disease
1053980|NCT01778465|Asthma
1053981|NCT01778465|Aspirin sensitivity
1053982|NCT01778465|Salicylate
1053983|NCT01778452|Endometrial priming, genomic expression. Natural cycle. Antagonist GnRH.
1053984|NCT01778439|Phase 1
1053985|NCT01778439|Dose escalation
1053986|NCT01778439|relapsed or refractory
1053987|NCT01778439|solid tumor
1053988|NCT01778426|Chronic neuropathic pain syndrome
1053989|NCT01778426|Spinal Cord Stimulation
1053990|NCT01778426|Painstim devices
1053991|NCT01778426|Efficacy
1053992|NCT01778426|Safety
1053993|NCT01778400|Ultrasound
1053994|NCT01778400|Radiofrequency
1053995|NCT01778400|Ethanol
1053996|NCT01778400|Predominantly cystic thyroid nodule
1053997|NCT01778400|Thyroid nodule
1053998|NCT01778400|Thyroid
1053999|NCT01778374|Emergency Medicine
1054000|NCT01778374|Screening
1054001|NCT01778374|Point of care testing
1054002|NCT01778374|Video assisted counseling
1054003|NCT01778361|Human immunodeficiency virus
1054004|NCT01778361|low bone mineral density
1054005|NCT01778361|osteopenia
1054006|NCT01778361|osteoporosis
1054007|NCT01778361|fracture
1054008|NCT01778348|Type 1 diabetes
1054009|NCT01778348|Closed-loop glucose control
1054010|NCT01778348|Artificial Pancreas
1054011|NCT01778348|Continuous subcutaneous insulin infusion
1054012|NCT01778348|Continuous glucose monitoring
1054013|NCT01778335|recanalization
1054014|NCT01778335|endovascular
1054015|NCT01778335|thrombectomy
1054016|NCT01778309|aseptic inflammation
1054017|NCT01778309|skeletal muscle function
1054018|NCT01778309|exercise
1054019|NCT01778296|Dorsal branch of the digital nerve;
1054020|NCT01778296|dorsal digital artery;
1054021|NCT01778296|dorsal digital island flap;
1054022|NCT01778296|neurocutaneous island flap.
1054023|NCT01778270|pleural effusion
1054024|NCT01778270|pleural drainage
1054025|NCT01778270|thorax impedance
1054026|NCT01778270|respiration parameters
1054027|NCT01778270|heart sounds analysis
1054028|NCT01778257|Mate extracts
1054029|NCT01778257|Obesity
1054030|NCT01778257|abdominal fat
1054031|NCT01778244|schizophrenia; dyslipidemia
1054032|NCT01778231|Focus
1054033|NCT01778231|uptake
1054034|NCT01778231|Lutein
1054035|NCT01778231|Zeaxanthin
1054036|NCT01778231|individuals
1054037|NCT01778218|Coronary Artery Disease
1054038|NCT01778218|CAD
1054039|NCT01778192|Bowel preparation
1054040|NCT01778192|Polyethylene glycol
1054041|NCT01778192|Sodium picosulphate
1054042|NCT01778179|Lentigines
1054043|NCT01778179|Cryotherapy
1054044|NCT01778179|hyperpigmentation
1054045|NCT01778166|Early enteral nutrition
1054046|NCT01778166|Laparoscopic gastrointestinal surgery
1054047|NCT01778166|Immuno-enhanced nutrition
1054048|NCT01778153|Fitness training
1054049|NCT01778153|Personal training
1054050|NCT01778140|Clinical Decision Support Systems
1054051|NCT01778140|Contrast-induced nephropathy
1054052|NCT01778127|Cancer Survivor
1054053|NCT01778127|Physical Activity
1054054|NCT01778127|Health Outcomes
1054055|NCT01778127|Rewards-Based Intervention
1054056|NCT01778127|Cardiovascular Health
1054057|NCT01778127|Musculoskeletal Health
1054058|NCT01778127|Exercise
1054059|NCT01778114|Vitamin D2
1054060|NCT01778114|Vitamin D3
1054061|NCT01778114|Vitamin D
1054062|NCT01778114|Orange Juice
1054063|NCT01778101|preterm infants
1054064|NCT01778101|reflux
1054065|NCT01778101|impedance
1054066|NCT01778101|pH
1054067|NCT01778101|monitoring
1054068|NCT01778101|lansoprazole
1054069|NCT01778075|Healthy
1054070|NCT01778075|Ultracet extended release (ER)
1054071|NCT01778075|Tramadol hydrochloride
1054072|NCT01778075|Acetaminophen
1054073|NCT01778075|Bioequivalence
1054074|NCT01778036|Neck movement
1054075|NCT01778036|motor control
1054076|NCT01778036|disability
1054077|NCT01778036|psychological variables
1054078|NCT01778036|Head Movements
1054079|NCT01778036|Physical therapy
1054080|NCT01778036|Fear avoidance
1054081|NCT01778036|Self Efficacy
1054082|NCT01778036|Catastrophizing
1054083|NCT01778036|Fly test
1054084|NCT01778036|Postural sway
1054085|NCT01778010|cocaine
1054086|NCT01778010|modafinil
1054087|NCT01778010|self-administration
1054088|NCT01778010|DRD4
1054089|NCT01777906|nasal polyps
1054090|NCT01777906|nasal steriod sprays
1054091|NCT01777893|Type-2 diabetes mellitus
1054092|NCT01777893|Obesity
1054093|NCT01777893|High protein diet
1054094|NCT01777893|Low GI
1054095|NCT01777893|Physical activity
1054096|NCT01777815|NeoChord
1054097|NCT01777815|DS1000
1054098|NCT01777815|Mitral Valve
1054099|NCT01777815|Mitral Valve Regurgitation
1054100|NCT01777815|MR
1054101|NCT01777815|Mitral Valve Repair
1054102|NCT01777815|Mitral Valve Prolapse
1054103|NCT01777815|Artificial Chordae
1054104|NCT01777789|fMRI
1054105|NCT01777789|Dementia
1054106|NCT01777789|Alzheimer's disease
1054107|NCT01777789|functional neuroimaging
1054108|NCT01777789|Memory
1054109|NCT01777776|Open-label dose escalation
1054110|NCT01777776|BRAF inhibitor
1054111|NCT01777776|LEE011
1054112|NCT01777776|CDK4/6
1054113|NCT01777776|LGX818
1054114|NCT01777776|RAF kinase inhibitor
1054115|NCT01777776|Metastatic melanoma
1054116|NCT01777776|BRAF
1054117|NCT01777776|V600
1054118|NCT01777750|Myocardial Infarction
1054119|NCT01777750|Myocardial Reperfusion Injury
1054120|NCT01777750|Reperfusion Injury
1054121|NCT01777750|Anterior Wall Myocardial Infarction
1054122|NCT01777750|Inferior Wall Myocardial Infarction
1054123|NCT01777750|Pathologic Processes
1054124|NCT01777750|Myocardial Ischemia
1054125|NCT01777737|Idiopathic Pulmonary Fibrosis
1054126|NCT01777737|Trimethoprim-sulfamethoxazole
1054127|NCT01777737|Pneumocystis jiroveci
1054128|NCT01777711|mental contrasting
1054129|NCT01777711|weight loss
1054130|NCT01777711|obese couples
1054131|NCT01777711|obesity
1054132|NCT01777711|overweight
1054133|NCT01777711|planning
1054134|NCT01777711|health
1054135|NCT01777711|diet
1054136|NCT01777711|exercise
1054137|NCT01777711|physical activity
1054138|NCT01777711|goal
1054139|NCT01777711|goal-setting
1054140|NCT01777698|body composition
1054141|NCT01777698|hepatocellular carcinoma
1054142|NCT01777698|chemoembolization
1054143|NCT01777685|Sulpiride
1054144|NCT01777685|Therapeutic drug monitoring
1054145|NCT01777685|Pharmacokinetics
1054146|NCT01777659|exercise
1054147|NCT01777659|neuromodulation
1054148|NCT01777659|blood flow
1054149|NCT01777659|exercise capacity
1054150|NCT01777646|Mesenchymal Strmal Cells (MSC)
1054151|NCT01777646|Amyotrophic Lateral Sclerosis (ALS)
1054152|NCT01777646|Neuroprotection
1054153|NCT01777646|Neurodegeneration
1054154|NCT01777646|Stem cells
1054155|NCT01777594|hepatocellular carcinoma
1054156|NCT01777594|HCC
1054157|NCT01777594|liver
1054158|NCT01777594|liver cancer
1054159|NCT01777594|sorafenib
1054160|NCT01777581|sciatica radiculopathy lumbar disc lumbosacral disc
1054161|NCT01777555|Parkinson's Disease
1054162|NCT01777555|Motor fluctuations
1054163|NCT01777555|levodopa
1054164|NCT01777555|inhaled drugs
1054165|NCT01777555|Off episodes
1054166|NCT01777542|Rett syndrome
1054167|NCT01777542|RTT
1054168|NCT01777542|IGF-1
1054169|NCT01777542|autism spectrum disorder
1054170|NCT01777529|Measles
1054171|NCT01777529|Mumps
1054172|NCT01777529|Rubella
1054173|NCT01777516|Platelet Aggregation
1054174|NCT01777516|Cardiovascular Diseases
1054175|NCT01777516|Salicylic Acid
1054176|NCT01777503|acute coronary syndrome
1054177|NCT01777503|elderly
1054178|NCT01777503|percutaneous revascularization
1054179|NCT01777503|antiaggregant drugs
1054180|NCT01777490|Caregivers - Not professionals
1054181|NCT01777490|Frail Elderly
1054182|NCT01777490|Long-term Care
1054183|NCT01777490|Quality of Life
1054184|NCT01777451|Whole Body Imaging
1054185|NCT01777451|Magnetic Resonance Imaging
1054186|NCT01777451|Neurofibromatosis 1
1054187|NCT01777451|Diffusion Magnetic Resonance Imaging
1054188|NCT01777451|Peripheral Nerve Sheath Tumors, Malignant
1054189|NCT01777412|NMO
1054190|NCT01777412|NMOSD
1054191|NCT01777412|NMO-IgG
1054192|NCT01777412|Aquaporin-4
1054193|NCT01777412|AQP4
1054194|NCT01777412|anti-AQP4
1054195|NCT01777386|scar
1054196|NCT01777386|contracture
1054197|NCT01777386|perforator flap
1054198|NCT01777386|preexpanded perforator flap
1054199|NCT01777386|perforator vessel
1054200|NCT01777386|artery diameter
1054201|NCT01777373|conducting airway, bronchiolization
1054202|NCT01777360|severe
1054203|NCT01777360|uncontrolled
1054204|NCT01777347|Keywords provided by ASSISTANCE PUBLIQUE HOPITAUX DE PARIS:
1054205|NCT01777347|Acute Viral bronchiolitis
1054206|NCT01777347|Hypertonic saline
1054207|NCT01777347|Hospitalization
1054208|NCT01777347|Infants
1054209|NCT01777347|Hospital admissions
1054210|NCT01777347|Additional relevant MeSH terms:
1054211|NCT01777347|Bronchiolitis
1054212|NCT01777347|Bronchiolitis, Viral
1054213|NCT01777347|Bronchial Diseases
1054214|NCT01777347|Respiratory Tract Diseases
1054215|NCT01777347|Lung Diseases, Obstructive
1054216|NCT01777347|Respiratory Tract Infections
1054217|NCT01777347|Virus Diseases
1054218|NCT01777321|Herpes Zoster
1054219|NCT01777321|Intramuscular
1054220|NCT01777321|Subcutaneous
1054221|NCT01777321|Safety
1054222|NCT01777321|≥50 years of age
1054223|NCT01777321|Adults
1054224|NCT01777321|Immunogenicity
1054225|NCT01777321|Elderly
1054226|NCT01777308|Immunogenicity
1054227|NCT01777308|Booster
1054228|NCT01777308|Healthy
1054229|NCT01777308|Vaccine response
1054230|NCT01777308|Safety
1054231|NCT01777308|Neisseria meningiditis
1054232|NCT01777308|Antibody persistence
1054233|NCT01777308|Meningococcal conjugate vaccine
1054234|NCT01777295|Adults
1054235|NCT01777295|Reactogenicity
1054236|NCT01777295|Naive
1054237|NCT01777295|Immune responses
1054238|NCT01777295|Read-outs
1054239|NCT01777295|Hepatitis B
1054240|NCT01777295|Healthy
1054241|NCT01777282|albiglutide
1054242|NCT01777282|Japanese
1054243|NCT01777282|glucagon-like peptide-1
1054244|NCT01777282|GSK716155
1054245|NCT01777256|systemic lupus erythematosus
1054246|NCT01777256|adaptive design
1054247|NCT01777256|clinical safety and efficacy
1054248|NCT01777256|pharmacodynamics
1054249|NCT01777243|pharmacokinetic
1054250|NCT01777243|systemic amyloidosis
1054251|NCT01777243|safety
1054252|NCT01777243|dose escalation
1054253|NCT01777243|Carboxy Pyrrolidine Hexanoyl Pyrrolidine Carboxylate (CPHPC)
1054254|NCT01777243|biomarker
1054255|NCT01777243|GSK2315698
1054256|NCT01777243|GSK2398852
1054257|NCT01777243|SAP
1054258|NCT01777243|pharmacodynamic
1054259|NCT01777243|co-administration
1054260|NCT01777243|intravenous
1054261|NCT01777217|Urination Disorder
1054262|NCT01777217|Overactive Bladder
1054263|NCT01777217|Prostate Cancer Radiation
1054264|NCT01777217|Vesicare
1054265|NCT01777204|Renal transplant, Gastrointestinal motility, Biomagnetism
1054266|NCT01777178|bicarbonate
1054267|NCT01777178|dialysis
1054268|NCT01777165|GFR
1054269|NCT01777165|Acute Kidney Injury
1054270|NCT01777165|High Risk cardiac surgery
1054271|NCT01777152|Antibodies, Monoclonal
1054272|NCT01777152|Antibody-Drug Conjugate
1054273|NCT01777152|Antigens, CD30
1054274|NCT01777152|Drug Therapy
1054275|NCT01777152|Hematologic Diseases
1054276|NCT01777152|Lymphoma
1054277|NCT01777152|Monomethyl auristatin E
1054278|NCT01777152|Lymphoma, T-Cell
1054279|NCT01777152|Lymphoma, Non-Hodgkin
1054280|NCT01777152|Lymphoma, Large-Cell, Anaplastic
1054281|NCT01777139|Retigabine
1054282|NCT01777139|Drug-Resistant
1054283|NCT01777139|Epilepsy
1054284|NCT01777139|Partial-Onset Seizures
1054285|NCT01777139|Safety and Tolerability
1054286|NCT01777139|Immediate Release
1054287|NCT01777139|Long-Term
1054288|NCT01777139|Adjunctive Therapy
1054289|NCT01777139|Asian Subjects
1054290|NCT01777139|Efficacy
1054291|NCT01777139|GW582892
1054292|NCT01777126|cystectomy
1054293|NCT01777126|parenteral nutrition
1054294|NCT01777126|discharge
1054295|NCT01777126|outcome
1054296|NCT01777113|Chronic Stroke
1054297|NCT01777113|Gait
1054298|NCT01777113|Exercise
1054299|NCT01777113|High intensity aerobic training
1054300|NCT01777113|Strength training
1054301|NCT01777113|Randomized controlled trial
1054302|NCT01777100|Postoperative pain
1054303|NCT01777100|Patient controlled analgesia
1054304|NCT01777100|Hyperalgesia
1054305|NCT01777100|Remifentanil
1054306|NCT01777100|Sufentanil
1054307|NCT01777100|Morphine
1054308|NCT01777100|Abdominal surgery
1054309|NCT01777100|Safety
1054310|NCT01777087|Pain
1054311|NCT01777087|Functional Magnetic Resonance Imaging
1054312|NCT01777074|Vaccination
1054313|NCT01777074|Acceptability
1054314|NCT01777074|Hepatitis B
1054315|NCT01777061|Prostate Cancer
1054316|NCT01777061|Recurrent Prostate Cancer
1054317|NCT01777061|PET Scan
1054318|NCT01777061|FDG-PET
1054319|NCT01777061|[11C]Acetate
1054320|NCT01777061|C11-Acetate
1054321|NCT01777035|mechanical ventilation
1054322|NCT01777035|physical therapy
1054323|NCT01777035|occupational therapy
1054324|NCT01777035|ICU acquired weakness
1054325|NCT01777035|critical illness myopathy
1054326|NCT01777022|Education, Stillbirth, Prevention, Management
1054327|NCT01777009|Total Knee Replacement
1054328|NCT01777009|Patellar Eversion
1054329|NCT01777009|Surgical Exposure
1054330|NCT01777009|Outcomes
1054331|NCT01777009|Quadriceps Strength
1054332|NCT01777009|Straight Leg Raise
1054333|NCT01777009|SF-36
1054334|NCT01776996|Expanded access, HIV, maraviroc
1054335|NCT01776970|Motor Neuron Disease
1054336|NCT01776970|Amyotrophic lateral sclerosis
1054337|NCT01776970|Cannabinoids
1054338|NCT01776970|Sativex
1054339|NCT01776970|Spasticity
1054340|NCT01776957|Abortion rate
1054341|NCT01776957|Intrauterine device
1054342|NCT01776944|Resting energy expenditure
1054343|NCT01776944|Handheld calorimeter
1054344|NCT01776944|Obese and overweight
1054345|NCT01776944|Pediatrics
1054346|NCT01776931|Indicator Amino acid technique
1054347|NCT01776931|Lysine requirements
1054348|NCT01776931|Pregnancy
1054349|NCT01776931|Dietary protein
1054350|NCT01776918|POLG1 Mutation
1054351|NCT01776918|Phenylketonuria
1054352|NCT01776905|Melanoma
1054353|NCT01776905|Cancer
1054354|NCT01776892|Collagenase
1054355|NCT01776892|Needle aponeurotomy
1054356|NCT01776866|Coronary Angiography
1054357|NCT01776866|Rotational Coronary Angiography
1054358|NCT01776866|Contrast Media
1054359|NCT01776866|Radiation
1054360|NCT01776866|Quantitative Coronary Angiography
1054361|NCT01776853|Irritable Bowel Syndrome
1054362|NCT01776853|Fructose
1054363|NCT01776853|Fructans
1054364|NCT01776853|MRI
1054365|NCT01776853|Fermentation
1054366|NCT01776853|Breath Tests
1054367|NCT01776853|Flatulence
1054368|NCT01776853|Abdominal Pain
1054369|NCT01776853|Diarrhoea
1054370|NCT01776840|Mantle cell lymphoma
1054371|NCT01776840|Ibrutinib
1054372|NCT01776840|Bruton's tyrosine kinase inhibitor
1054373|NCT01776840|Bendamustine hydrochloride
1054374|NCT01776840|Rituximab
1054375|NCT01776827|GERD
1054376|NCT01776827|Hiatal Hernia
1054377|NCT01776827|Paraesophageal Hernia
1054378|NCT01776827|Biologic Mesh
1054379|NCT01776814|Entecair
1054380|NCT01776814|Tenofovir
1054381|NCT01776801|intracranial baroreflex
1054382|NCT01776762|Nutrition
1054383|NCT01776762|Rehabilitation
1054384|NCT01776762|Weightloss
1054385|NCT01776749|low back pain
1054386|NCT01776749|failed back surgery syndrome
1054387|NCT01776749|spinal cord stimulation
1054388|NCT01776749|subcutaneous stimulation
1054389|NCT01776749|peripheral nerve field stimulation
1054390|NCT01776736|Scoliosis
1054391|NCT01776736|Posture correction
1054392|NCT01776723|Chronic Myelomonocytic Leukemia
1054393|NCT01776723|CMML
1054394|NCT01776723|Leukemia
1054395|NCT01776710|Intermittent claudication
1054396|NCT01776710|Behavior therapy
1054397|NCT01776710|Walking
1054398|NCT01776710|Exercise
1054399|NCT01776710|Patient education
1054400|NCT01776710|Randomized controlled trial
1054401|NCT01776658|Ocular pain
1054402|NCT01776658|Dry Eye Syndrome
1054403|NCT01776658|siRNA
1054404|NCT01776658|RNAi
1054405|NCT01776658|TRPV1
1054406|NCT01776619|Safety
1054407|NCT01776619|tolerability
1054408|NCT01776619|PK
1054409|NCT01776593|bladder capacity; bladder diary; bladder oversensitivity; lower urinary tract symptoms
1054410|NCT01776580|Pelvic organ prolapse
1054411|NCT01776580|lower urinary tract symptoms
1054412|NCT01776580|sexual dysfunction
1054413|NCT01776567|coronary artery disease
1054414|NCT01776567|stents
1054415|NCT01776567|optical imaging
1054416|NCT01776554|Influenza, Pandemic, H5N1, Children
1054417|NCT01776541|Influenza, Pandemic, H5N1, Adults
1054418|NCT01776515|Low back pain
1054419|NCT01776515|Wontran
1054420|NCT01776515|Wontran SR Tab.
1054421|NCT01776515|Tramadol Hydrochloride/Acetaminophen
1054422|NCT01776489|Food allergy
1054423|NCT01776489|Sphingosine-1-phosphate
1054424|NCT01776489|Biomarker
1054425|NCT01776489|Double-blind placebo-controlled food challenge
1054426|NCT01776489|Anaphylaxis
1054427|NCT01776476|glutamine dipeptide
1054428|NCT01776476|randomized controlled trial
1054429|NCT01776476|insulin resistance
1054430|NCT01776476|critical illness
1054431|NCT01776476|trauma
1054432|NCT01776463|Z-360
1054433|NCT01776463|Japanese
1054434|NCT01776463|pK
1054435|NCT01776450|Abdominal Aortic Aneurysm
1054436|NCT01776424|Cardiovascular events
1054437|NCT01776424|Rivaroxaban
1054438|NCT01776424|Xarelto
1054439|NCT01776424|anticoagulant
1054440|NCT01776424|blood thinner
1054441|NCT01776424|aspirin
1054442|NCT01776424|ASA
1054443|NCT01776424|CAD
1054444|NCT01776424|coronary disease
1054445|NCT01776424|artery disease
1054446|NCT01776424|coronary artery bypass graft
1054447|NCT01776424|stroke
1054448|NCT01776424|heart attack
1054449|NCT01776424|angina
1054450|NCT01776424|arterial vascular disease
1054451|NCT01776424|transient ischemic attack
1054452|NCT01776424|TIA
1054453|NCT01776424|heart disease
1054454|NCT01776398|COPD
1054455|NCT01776398|Chronic Obstructive Pulmonary Disease
1054456|NCT01776398|Lung disease
1054457|NCT01776398|Emphysema
1054458|NCT01776398|Smoking
1054459|NCT01776398|Healthy Smoker
1054460|NCT01776398|Smoker
1054461|NCT01776398|Non-smoker
1054462|NCT01776385|[C08.785.640]
1054463|NCT01776385|(C08.528.778)
1054464|NCT01776385|[C19.642.713]
1054465|NCT01776385|mesothelium
1054466|NCT01776372|Drainage
1054467|NCT01776372|Chest tubes
1054468|NCT01776372|Randomized Controlled Trial
1054469|NCT01776359|Muscle
1054470|NCT01776359|Protein
1054471|NCT01776359|Diet
1054472|NCT01776359|Exercise
1054473|NCT01776333|ICU
1054474|NCT01776320|Erectile Dysfunction
1054475|NCT01776320|Topical Alprostadil
1054476|NCT01776307|BBI608
1054477|NCT01776294|Prehypertension
1054478|NCT01776294|Prevalence
1054479|NCT01776294|Cardiovascular Risk Factors
1054480|NCT01776281|effects
1054481|NCT01776281|KMC
1054482|NCT01776281|LBW
1054483|NCT01776281|preterm
1054484|NCT01776281|temperature
1054485|NCT01776281|breastfeeding
1054486|NCT01776281|secondary hospitals
1054487|NCT01776268|antimicrobial proteins
1054488|NCT01776255|Obesity
1054489|NCT01776255|Overweight
1054490|NCT01776255|Lifestyle
1054491|NCT01776255|American Indian
1054492|NCT01776242|low back pain
1054493|NCT01776242|elderly
1054494|NCT01776242|back pain
1054495|NCT01776242|lumbar pain
1054496|NCT01776242|over 65
1054497|NCT01776229|nightmare
1054498|NCT01776229|PTSD
1054499|NCT01776229|trauma
1054500|NCT01776229|children
1054501|NCT01776229|cognitive behavior therapy
1054502|NCT01776229|stress
1054503|NCT01776229|sleep
1054504|NCT01776216|Endothelial function
1054505|NCT01776216|Dairy
1054506|NCT01776177|Allergic asthma
1054507|NCT01776177|Omalizumab therapy
1054508|NCT01776177|IgE profile
1054509|NCT01776164|Friedreich
1054510|NCT01776164|ataxia
1054511|NCT01776164|FRDA
1054512|NCT01776164|FA
1054513|NCT01776164|recessive
1054514|NCT01776164|neurodegenerative
1054515|NCT01776164|cerebellum
1054516|NCT01776151|HIV
1054517|NCT01776151|cardiovascular diseases
1054518|NCT01776151|vascular stiffness
1054519|NCT01776138|Elderly
1054520|NCT01776138|Chemotherapy
1054521|NCT01776138|Cystectomy
1054522|NCT01776138|Radical Cystectomy
1054523|NCT01776138|University of North Carolina
1054524|NCT01776138|Cancer
1054525|NCT01776138|Bladder Cancer
1054526|NCT01776138|Bladder
1054527|NCT01776125|Neurofibromatosis Type One
1054528|NCT01776125|Scoliosis
1054529|NCT01776112|schizophrenia
1054530|NCT01776112|negative symptoms
1054531|NCT01776112|cognitive deficits
1054532|NCT01776112|synaptic plasticity
1054533|NCT01776099|type 2 diabetes
1054534|NCT01776099|nutrition
1054535|NCT01776099|fibers
1054536|NCT01776073|Transplantation
1054537|NCT01776073|Healthcare Disparities
1054538|NCT01776073|Quality Assurance
1054539|NCT01776060|Primary Progressive Multiple Sclerosis
1054540|NCT01776060|Multiple Sclerosis
1054541|NCT01776060|biomarker
1054542|NCT01776060|'omic
1054543|NCT01776060|progression
1054544|NCT01776034|Self Care
1054545|NCT01776034|Exercise
1054546|NCT01776034|Weight management
1054547|NCT01776021|Urinary tract infection
1054548|NCT01776021|Recurrent urinary tract infection
1054549|NCT01776021|Cranberry
1054550|NCT01776021|Prevention
1054551|NCT01776021|E-coli
1054552|NCT01775995|Chronic Pain
1054553|NCT01775995|Low Back Pain
1054554|NCT01775982|French language validation
1054555|NCT01775982|The Confusion Assessment Method (CAM)
1054556|NCT01775943|Epidermal growth factor receptor
1054557|NCT01775943|Mutation
1054558|NCT01775943|Lung cancer
1054559|NCT01775943|Drug sensitivity
1054560|NCT01775930|Kidney Cancer
1054561|NCT01775930|Refractory Renal Cell Carcinoma
1054562|NCT01775930|RCC
1054563|NCT01775930|Clear cell kidney cancer with metastatic disease
1054564|NCT01775930|Carfilzomib
1054565|NCT01775891|pilsicainide
1054566|NCT01775891|class IC antiarrhythmic drug
1054567|NCT01775891|paroxysmal atrial fibrillation
1054568|NCT01775891|catheter ablation
1054569|NCT01775878|Diabetes
1054570|NCT01775878|HbA1c
1054571|NCT01775878|Fructosamine
1054572|NCT01775878|Blood Pressure
1054573|NCT01775878|Telemonitoring
1054574|NCT01775865|aortic stiffness
1054575|NCT01775865|endothelium-dependent dilation
1054576|NCT01775865|vascular aging
1054577|NCT01775865|oxidative stress
1054578|NCT01775865|inflammation
1054579|NCT01775865|nitric oxide
1054580|NCT01775865|nuclear factor kappa B
1054581|NCT01775852|Acceptance and Commitment Therapy (ACT)
1054582|NCT01775852|Depression
1054583|NCT01775852|Illness Management
1054584|NCT01775852|Behavioral treatment
1054585|NCT01775852|Impairment
1054586|NCT01775826|physical activity
1054587|NCT01775826|sedentary behavior
1054588|NCT01775826|accelerometer
1054589|NCT01775826|GPS
1054590|NCT01775826|GIS
1054591|NCT01775826|machine learning
1054592|NCT01775813|Insulin resistance
1054593|NCT01775813|Puberty
1054594|NCT01775813|Obesity
1054595|NCT01775813|Hypogonadism
1054596|NCT01775813|Gonadal dysfunction
1054597|NCT01775813|Metformin
1054598|NCT01775787|smoking
1054599|NCT01775774|Acute Respiratory Distress Syndrome
1054600|NCT01775774|Acute Lung Injury
1054601|NCT01775774|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
1054602|NCT01775761|Thorough QTc evaluation of tafamidis compared to the effects of moxifloxacin and placebo in healthy volunteers.
1054603|NCT01775735|headache
1054604|NCT01775735|pain
1054605|NCT01775735|chronic
1054606|NCT01775709|middler ear infection
1054607|NCT01775696|Alzheimer's disease
1054608|NCT01775696|Pittsburgh binding Compound (PiB)
1054609|NCT01775696|Positron Emission Tomography (PET)
1054610|NCT01775696|Inflammation
1054611|NCT01775696|Anti Abeta immune responses
1054612|NCT01775696|Blood markers
1054613|NCT01775696|MRI
1054614|NCT01775683|homelessness
1054615|NCT01775670|Arthrosis
1054616|NCT01775657|pulmonary air leak
1054617|NCT01775657|Thopaz
1054618|NCT01775657|digital
1054619|NCT01775657|analog
1054620|NCT01775657|randomized
1054621|NCT01775618|Hemophilia A
1054622|NCT01775618|Factor VIII
1054623|NCT01775618|Prophylaxis
1054624|NCT01775618|Pediatric
1054625|NCT01775605|Subject
1054626|NCT01775592|P.f resistance
1054627|NCT01775553|Relapsed Multiple Myeloma
1054628|NCT01775553|Refractory Multiple Myeloma
1054629|NCT01775553|High-Dose Carfilzomib
1054630|NCT01775553|Standard Dose Carfilzomib
1054631|NCT01775553|Carfilzomib
1054632|NCT01775540|Dry eye
1054633|NCT01775540|Artificial tears
1054634|NCT01775540|Ocular surface inflammation
1054635|NCT01775501|sorafenib
1054636|NCT01775501|FOLFOX
1054637|NCT01775488|Benign Prostatic Hyperplasia
1054638|NCT01775488|BPH
1054639|NCT01775488|LUTS
1054640|NCT01775488|Vortx Rx
1054641|NCT01775488|Histotripsy
1054642|NCT01775462|Hypohidrotic Ectodermal Dysplasia
1054643|NCT01775462|XLHED
1054644|NCT01775449|Anticancer drug;
1054645|NCT01775449|Oxaliplatin;
1054646|NCT01775449|Digestive cancer system
1054647|NCT01775449|Acute oxaliplatin-induced hypersensitivity
1054648|NCT01775449|Hyperalgesia;
1054649|NCT01775449|Allodynia;
1054650|NCT01775449|Dysesthesia
1054651|NCT01775449|Polyamines depleted diet
1054652|NCT01775436|palliative care
1054653|NCT01775436|HIV/AIDS
1054654|NCT01775436|quality of life
1054655|NCT01775436|adherence
1054656|NCT01775436|spiritual
1054657|NCT01775436|threat appraisal
1054658|NCT01775436|treatment congruence
1054659|NCT01775436|treatment preferences
1054660|NCT01775436|dialysis
1054661|NCT01775436|hospitalization
1054662|NCT01775436|communication
1054663|NCT01775436|family intervention
1054664|NCT01775436|Family Centered Advance Care Planning
1054665|NCT01775436|decision making
1054666|NCT01775436|advance care planning
1054667|NCT01775436|end of life
1054668|NCT01775397|Clostridium
1054669|NCT01775397|Difficile
1054670|NCT01775397|Infections
1054671|NCT01775397|Immunosuppression
1054672|NCT01775397|Fidaxomicin
1054673|NCT01775397|Vancomycin
1054674|NCT01775397|Efficacy
1054675|NCT01775397|Stem Cells
1054676|NCT01775397|Transplantation
1054677|NCT01775397|Adult
1054678|NCT01775397|Dificid
1054679|NCT01775384|Inflammation
1054680|NCT01775384|Oxidative stress
1054681|NCT01775384|Immune dysfunction
1054682|NCT01775384|Metabolomics.
1054683|NCT01775371|Pain
1054684|NCT01775371|Emergency
1054685|NCT01775371|Analgesia
1054686|NCT01775371|ED patients
1054687|NCT01775371|acute pain
1054688|NCT01775371|IV opioid
1054689|NCT01775345|Partial meniscectomy
1054690|NCT01775345|Physiotherapy
1054691|NCT01775345|Isokinetics
1054692|NCT01775345|Cost-effectiveness
1054693|NCT01775319|Zinc
1054694|NCT01775293|Non-absorbable polypropylene mesh
1054695|NCT01775293|WSRS
1054696|NCT01775293|Rhytidectomy
1054697|NCT01775254|Colon Cancer
1054698|NCT01775254|FOLFOX
1054699|NCT01775254|Laparoscopic Colectomy
1054700|NCT01775254|Open Colectomy
1054701|NCT01775254|Robotic Colectomy
1054702|NCT01775254|Quality of Life
1054703|NCT01775254|Sexual Function
1054704|NCT01775254|Peripheral Neuropathy
1054705|NCT01775254|Demands of Illness
1054706|NCT01775254|Cancer Survivor
1054707|NCT01775228|Depression, peer support, recovery, health services
1054708|NCT01775215|Left Ventricular Function
1054709|NCT01775215|Aortic Valve Replacement
1054710|NCT01775215|Late Gadolinium Enhancement
1054711|NCT01775215|Cardiac I123 MIBG
1054712|NCT01775215|Longitudinal Strain
1054713|NCT01775215|Brain Natriuretic Peptide
1054714|NCT01775215|High Sensitivity Troponin I
1054715|NCT01775189|Relative abuse potential study
1054716|NCT01775189|Chronic pain
1054717|NCT01775189|oxycodone
1054718|NCT01775189|naltrexone
1054719|NCT01775189|opioid-related disorders
1054720|NCT01775189|drug abusers
1054721|NCT01775176|PCOS, Weight, Insulin Sensitivity, Reproductive Function
1054722|NCT01775163|Energy
1054723|NCT01775163|Metabolism
1054724|NCT01775163|Weight Loss
1054725|NCT01775163|Exercise
1054726|NCT01775150|mobile phone text messaging
1054727|NCT01775150|maternality
1054728|NCT01775150|infant
1054729|NCT01775150|death rate
1054730|NCT01775137|CF, Open-label, TIP, phase IV, extension study
1054731|NCT01775111|strength training
1054732|NCT01775111|protein supplementation
1054733|NCT01775111|sarcopenia
1054734|NCT01775098|Gout
1054735|NCT01775098|uric acid
1054736|NCT01775098|allopurinol
1054737|NCT01775085|Interventions
1054738|NCT01775085|Meaning-Centered Group (MCG)
1054739|NCT01775085|Discussion Group (DG)
1054740|NCT01775085|Modules
1054741|NCT01775085|Sessions
1054742|NCT01775085|12-291
1054743|NCT01775072|tissue
1054744|NCT01775072|blood
1054745|NCT01775072|salvia
1054746|NCT01775072|buccal swab
1054747|NCT01775072|Genomic Profiling
1054748|NCT01775072|Solid Tumors
1054749|NCT01775072|hematologic cancer
1054750|NCT01775072|Clinical Assay
1054751|NCT01775072|Research Assay
1054752|NCT01775072|12-245
1054753|NCT01775046|Valiant
1054754|NCT01775046|Captivia
1054755|NCT01775046|Stent Graft
1054756|NCT01775046|Thoracic
1054757|NCT01775046|Aortic
1054758|NCT01775033|Pediatrics
1054759|NCT01775033|Emergency medical services
1054760|NCT01775033|Emergency Treatment
1054761|NCT01775033|Telemedicine
1054762|NCT01775007|Lens
1054763|NCT01775007|Cornea
1054764|NCT01775007|Stiffness
1054765|NCT01775007|Brillouin Shift
1054766|NCT01775007|Young Modulus
1054767|NCT01774994|volunteers
1054768|NCT01774942|Diabetes Mellitus
1054769|NCT01774942|C-Reactive Protein
1054770|NCT01774942|Dental Implants, Single-Tooth
1054771|NCT01774942|Dental Prosthesis, Implant-Supported
1054772|NCT01774929|Osteoarthritis
1054773|NCT01774929|Transdermal Therapeutic System (TTS)-fentanyl
1054774|NCT01774929|Durogesic
1054775|NCT01774903|Low Back Pain
1054776|NCT01774903|TTS-fentanyl
1054777|NCT01774903|Durogesic
1054778|NCT01774877|xinfeng capsule;
1054779|NCT01774877|rheumatoid arthritis (RA);
1054780|NCT01774877|randomized;
1054781|NCT01774877|double-blind;
1054782|NCT01774851|HER-2 Gene Amplification
1054783|NCT01774851|Esophagus Cancer
1054784|NCT01774851|Gastroesophageal Junction Cancer
1054785|NCT01774851|Stomach Cancer
1054786|NCT01774851|Her2 Positive
1054787|NCT01774851|Her2+
1054788|NCT01774851|Esophageal Cancer
1054789|NCT01774851|Metastatic
1054790|NCT01774825|Irritable bowel syndrome
1054791|NCT01774825|IBS
1054792|NCT01774812|vitamin D
1054793|NCT01774812|hemodialysis
1054794|NCT01774812|sudden cardiac death
1054795|NCT01774812|heart rate variability
1054796|NCT01774812|cardiac autonomic tone
1054797|NCT01774799|advanced dementia
1054798|NCT01774799|advance care planning
1054799|NCT01774799|nursing home
1054800|NCT01774760|18F-EF5
1054801|NCT01774760|PET/CT
1054802|NCT01774760|Reproducibility
1054803|NCT01774747|Pharmacokinetics
1054804|NCT01774734|Chronic neck pain
1054805|NCT01774734|Neck strength exerciser
1054806|NCT01774734|Biofeedback
1054807|NCT01774734|Physiotherapy
1054808|NCT01774734|Strengthening exercise
1054809|NCT01774734|Randomized trials
1054810|NCT01774721|first-line
1054811|NCT01774721|locally advanced or metastatic
1054812|NCT01774721|non-small cell lung cancer
1054813|NCT01774721|epidermal growth factor receptor
1054814|NCT01774721|EGFR
1054815|NCT01774721|Archer
1054816|NCT01774721|mutation
1054817|NCT01774721|dacomitinib
1054818|NCT01774721|SFJ
1054819|NCT01774721|PF-00299804
1054820|NCT01774695|IBS
1054821|NCT01774695|physical activity
1054822|NCT01774695|exercise
1054823|NCT01774682|obesity
1054824|NCT01774682|surgery
1054825|NCT01774669|ischemic stroke
1054826|NCT01774669|hemorrhagic stroke
1054827|NCT01774669|upper limb
1054828|NCT01774669|virtual reality
1054829|NCT01774669|physiotherapy
1054830|NCT01774669|occupational therapy
1054831|NCT01774656|heart-assist device
1054832|NCT01774643|Pancreatic cancer
1054833|NCT01774643|Liver metastases
1054834|NCT01774643|Tumor tissue biopsy
1054835|NCT01774643|Blood samples
1054836|NCT01774643|Xenografts
1054837|NCT01774643|Murine
1054838|NCT01774643|Genomic profiling
1054839|NCT01774643|Circulating biomarkers
1054840|NCT01774630|Treatment, relapse, complete molecular response
1054841|NCT01774617|portal hypertension
1054842|NCT01774617|elastography
1054843|NCT01774617|Hepatic venous pressure gradient measurement
1054844|NCT01774604|Post ERCP acute pancreatitis
1054845|NCT01774604|Post Fine Needle Aspiration (FNA) acute pancreatitis
1054846|NCT01774604|Indomethacin
1054847|NCT01774604|Rectal Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
1054848|NCT01774591|Post Menopause
1054849|NCT01774591|Female
1054850|NCT01774591|Obese
1054851|NCT01774578|Non-small Cell Lung Cancer
1054852|NCT01774578|Vaccine Therapy
1054853|NCT01774578|Immunotherapy
1054854|NCT01774578|Second line therapy
1054855|NCT01774578|Progressive
1054856|NCT01774578|Relapsed
1054857|NCT01774565|Diabetes
1054858|NCT01774565|Insulin
1054859|NCT01774565|Closed-Loop
1054860|NCT01774565|Real-time CGM
1054861|NCT01774565|Subcutaneous insulin pump
1054862|NCT01774565|Hospital
1054863|NCT01774539|Fracture
1054864|NCT01774539|Physeal injury
1054865|NCT01774539|Diffusion MRI
1054866|NCT01774500|biomarkers
1054867|NCT01774500|Emergency Department
1054868|NCT01774500|Seizures
1054869|NCT01774500|epilepsy
1054870|NCT01774500|S100b
1054871|NCT01774500|copeptin
1054872|NCT01774487|Biliary Atresia
1054873|NCT01774487|Pentoxifylline
1054874|NCT01774487|Trental
1054875|NCT01774487|Serum bilirubin
1054876|NCT01774487|Conjugated bilirubin
1054877|NCT01774487|Liver transplantation
1054878|NCT01774487|Fibrosis
1054879|NCT01774474|Prevention
1054880|NCT01774448|Dementia
1054881|NCT01774448|Spouse Caregiver
1054882|NCT01774448|Depression
1054883|NCT01774448|Mind Body Therapy
1054884|NCT01774448|Cognitive Therapy
1054885|NCT01774448|Quality of Life
1054886|NCT01774448|Attention
1054887|NCT01774448|Memory
1054888|NCT01774435|Schizophrenia
1054889|NCT01774435|Schizophrenic
1054890|NCT01774435|Stable Schizophrenic
1054891|NCT01774422|Hypercapnia
1054892|NCT01774422|Respiratory Distress Syndrome
1054893|NCT01774422|Extracorporeal CO2 remover
1054894|NCT01774422|Noninvasive ventilation
1054895|NCT01774409|all advanced malignant tumor
1054896|NCT01774396|Hands Rejuvenation, fillers
1054897|NCT01774383|Parkinson's disease
1054898|NCT01774383|sub-thalamic nucleus
1054899|NCT01774383|oscillation
1054900|NCT01774383|local field potential
1054901|NCT01774344|Regorafenib
1054902|NCT01774344|BAY73-4506
1054903|NCT01774318|sleep-wake-cycles
1054904|NCT01774318|preterm infants
1054905|NCT01774318|aEEG
1054906|NCT01774318|conventional EEG
1054907|NCT01774318|polysomnography
1054908|NCT01774292|Impact of alkalized lidocaine on coughing at extubation
1054909|NCT01774266|Gastric Cancer
1054910|NCT01774266|DNA methylation
1054911|NCT01774266|Reprimo
1054912|NCT01774266|cell-free DNA
1054913|NCT01774266|non-invasive
1054914|NCT01774253|DIPG
1054915|NCT01774240|Delirium
1054916|NCT01774240|Cardiac surgery
1054917|NCT01774240|DOS scale
1054918|NCT01774227|Refractory glaucoma
1054919|NCT01774227|Transcleral cyclophotocoagulation (TSCPC)
1054920|NCT01774227|Dark iris
1054921|NCT01774227|Pops-titration
1054922|NCT01774227|Slow-coagulation
1054923|NCT01774214|Resuscitation
1054924|NCT01774214|Shock
1054925|NCT01774214|Fluid Therapy
1054926|NCT01774214|Pediatrics
1054927|NCT01774201|Multiple sclerosis
1054928|NCT01774201|Self-assessment
1054929|NCT01774201|Physical endurance
1054930|NCT01774201|Respiratory function
1054931|NCT01774201|Fatigue
1054932|NCT01774188|Enhanced Extracorporeal Counterpulsation
1054933|NCT01774188|intraocular pressure
1054934|NCT01774188|Pen type tonometer
1054935|NCT01774175|Bowel preparation
1054936|NCT01774175|PEG with ascorbic acid
1054937|NCT01774175|Picosulfate
1054938|NCT01774162|Endoscopic Ultrasound
1054939|NCT01774162|Fine needle aspiration
1054940|NCT01774162|Fine needle biopsy
1054941|NCT01774162|ProCore
1054942|NCT01774136|community health workers
1054943|NCT01774136|HIV
1054944|NCT01774136|PMTCT
1054945|NCT01774136|antenatal
1054946|NCT01774136|postnatal
1054947|NCT01774136|breastfeeding
1054948|NCT01774136|South Africa
1054949|NCT01774110|stroke
1054950|NCT01774110|gait
1054951|NCT01774110|acute
1054952|NCT01774097|Peripheral Artery Disease
1054953|NCT01774097|Intermittent Claudication
1054954|NCT01774097|Autologous Stem Cells
1054955|NCT01774097|ALDH cells
1054956|NCT01774097|Claudicants
1054957|NCT01774097|PAD
1054958|NCT01774097|Peak Walking Time
1054959|NCT01774097|MRI
1054960|NCT01774097|Vascular Flow
1054961|NCT01774097|Anatomy
1054962|NCT01774097|Perfusion
1054963|NCT01774084|Insulin sensitivity
1054964|NCT01774084|Beta cell function
1054965|NCT01774084|Carbohydrate preload
1054966|NCT01774084|Elective hip replacement
1054967|NCT01774084|Double-blind randomized control study
1054968|NCT01774071|89Zr-DFO-MSTP2109A
1054969|NCT01774071|tracer
1054970|NCT01774071|pet scan
1054971|NCT01774071|12-178
1054972|NCT01774058|blood flow volume
1054973|NCT01774058|ilomedin
1054974|NCT01774058|measurement
1054975|NCT01774058|intraarterial
1054976|NCT01774058|neuropathy
1054977|NCT01774045|Major depressive disorder
1054978|NCT01774045|Depression
1054979|NCT01774019|Pancreatic
1054980|NCT01774019|Periampullary Cancer
1054981|NCT01774019|Preoperative Biliary Drainage
1054982|NCT01774019|Resectable
1054983|NCT01774006|In vitro fertilization
1054984|NCT01774006|Embryo transfer
1054985|NCT01774006|Embryo culture
1054986|NCT01774006|individual culture
1054987|NCT01774006|Group culture
1054988|NCT01774006|embryo quality
1054989|NCT01774006|Pregnancy rate
1054990|NCT01774006|Implantation
1054997|NCT01773967|Lactobacillus rhamnosus GG
1054998|NCT01773967|LGG
1054999|NCT01773967|Probiotic
1055000|NCT01773967|Gastroenteritis
1055001|NCT01773967|acute gastroenteritis
1055002|NCT01773967|child
1055003|NCT01773967|pediatric
1055004|NCT01773967|RCT
1055005|NCT01773954|amd
1055006|NCT01773954|age related macular degeneration
1055007|NCT01773954|macular degeneration
1055008|NCT01773954|neovascular
1055009|NCT01773109|Male and female subjects 18 years of age and older
1055010|NCT01773109|metastatic or recurrent NSCLC
1055011|NCT01773109|who have failed 2nd line therapy (with up to two prior cytotoxic regimens and one prior exposure to an oral TKI).
1055012|NCT01773096|opioid-induced
1055013|NCT01773083|Inhalation trauma
1055014|NCT01773083|pulmonary coagulopathy
1055015|NCT01773083|heparin nebulization
1055016|NCT01773083|mechanical ventilation
1055017|NCT01773928|Active immunization against influenza disease
1055018|NCT01773889|Epithelial Ovarian Cancer
1055019|NCT01773889|FIGO (International Federation of Gynecology and Obstetrics )Stage III or Stage IV
1055020|NCT01773889|Extraovarian Peritoneal Cancer
1055021|NCT01773889|Fallopian Tube Carcinoma Failing
1055022|NCT01773876|survival without proven invasive candidiasis
1055023|NCT01773876|effectiveness
1055024|NCT01773876|micafungin versus placebo
1055025|NCT01773876|pharmacokinetic
1055026|NCT01773876|pharmacodynamic
1055027|NCT01773876|tolerance
1055028|NCT01773863|Community-acquired pneumonia
1055029|NCT01773863|Acute myocardial infarction
1055030|NCT01773863|Platelet activation
1055031|NCT01773863|Coagulation abnormalities,
1055032|NCT01773863|Thrombosis
1055033|NCT01773863|Isoprosantes
1055034|NCT01773863|NADPH oxidase
1055035|NCT01773863|Major adverse cardiac and cerebrovascular events
1055036|NCT01773850|breast cancer
1055037|NCT01773837|asthenia
1055038|NCT01773837|advanced cancer
1055039|NCT01773837|randomized controlled trial
1055040|NCT01773824|antibiotic
1055041|NCT01773824|prescription rate
1055042|NCT01773811|Posttraumatic Stress Disorder (PTSD)
1055043|NCT01773811|Narrative Writing
1055044|NCT01773759|Immunizations
1055045|NCT01773759|Child care
1055046|NCT01773759|School health promotion
1055047|NCT01773746|neonatal
1055048|NCT01773746|resuscitation
1055049|NCT01773746|room air
1055050|NCT01773720|cardiac index
1055051|NCT01773720|coronary artery bypass
1055052|NCT01773720|uncalibrated pulse contour analysis
1055053|NCT01773720|hemodynamic monitoring
1055054|NCT01773707|prevention of type 1 diabetes
1055055|NCT01773707|prevention of abnormal glucose tolerance
1055056|NCT01773694|Post-operative management
1055057|NCT01773694|Post-operative complications
1055058|NCT01773694|Post-operative treatment
1055059|NCT01773694|water
1055060|NCT01773694|skin
1055061|NCT01773694|Dermatologic Surgical Procedures
1055062|NCT01773655|somatic
1055063|NCT01773655|germline
1055064|NCT01773655|mutations
1055065|NCT01773655|BAP1 (BRCA associated protein-1)
1055066|NCT01773655|12-235
1055067|NCT01773642|pediatric HIV diagnosis disclosure
1055068|NCT01773642|cognitive behavioral intervention
1055069|NCT01773642|Uganda
1055070|NCT01773629|Depression
1055071|NCT01773629|Pregnancy
1055072|NCT01773629|Postpartum
1055073|NCT01773629|Perinatal
1055074|NCT01773616|Systemic lupus erythematosus
1055075|NCT01773616|Lupus
1055076|NCT01773616|Nephritis
1055077|NCT01773603|Time-lapse
1055078|NCT01773603|morphokinetics
1055079|NCT01773603|blastocyst transfer
1055080|NCT01773603|eSET
1055081|NCT01773577|EHR
1055082|NCT01773577|VHR
1055083|NCT01773577|Electronic Health Record
1055084|NCT01773564|Dressings, Prevention,
1055085|NCT01773538|quality of life
1055086|NCT01773512|Intravascular ultrasound
1055087|NCT01773512|Virtual histology
1055088|NCT01773512|Optical coherence tomography
1055089|NCT01773512|Coronary atherosclerosis
1055090|NCT01773512|Statins
1055091|NCT01773512|Retinal imaging
1055092|NCT01773499|cellulitis
1055093|NCT01773499|ultrasound
1055094|NCT01773486|Obesity
1055095|NCT01773486|Insulin Resistance
1055096|NCT01773486|Endothelial dysfunction
1055097|NCT01773486|Blood pressure
1055098|NCT01773460|everolimus progress exemestane
1055099|NCT01773460|treated with exemestane and everolimus
1055100|NCT01773460|progress under this treatment
1055101|NCT01773395|Advanced
1055102|NCT01773369|cerebral palsy
1055103|NCT01773369|physical therapy
1055104|NCT01773369|rehabilitation
1055105|NCT01773356|Obesity
1055106|NCT01773356|Body Weight
1055107|NCT01773356|Body Composition
1055108|NCT01773356|Metabolism
1055109|NCT01773356|Resting Energy Expenditure
1055110|NCT01773343|skin texture, efficacy, adverse effects
1055111|NCT01773330|high resolution manometry
1055112|NCT01773330|provocative swallow
1055113|NCT01773330|impedence
1055114|NCT01773304|Obesity
1055115|NCT01773304|Adults
1055116|NCT01773304|Bone metabolism
1055117|NCT01773304|Metabolic profile
1055118|NCT01773304|Dairy protein
1055119|NCT01773304|Meat protein
1055120|NCT01773291|Acupuncture; laser acupuncture; traumatic brain injury
1055121|NCT01773278|Antioxidant treatment
1055122|NCT01773278|Oxysterols
1055123|NCT01773278|Cholesterol deficiency
1055124|NCT01773278|Accumulation of 7-dehydrocholesterol
1055125|NCT01773278|electroretinogram (ERG)
1055126|NCT01773278|Auditory Brainstem Response (ABR)
1055127|NCT01773252|RLS
1055128|NCT01773252|RTLS
1055129|NCT01773252|PFO
1055130|NCT01773252|ASD
1055131|NCT01773252|shunt
1055132|NCT01773252|cardiac
1055133|NCT01773252|paradoxical thromboembolism
1055134|NCT01773252|interventional cardiology
1055135|NCT01773252|stroke
1055136|NCT01773252|migraine
1055137|NCT01773252|aura
1055138|NCT01773252|obstructive sleep apnea
1055139|NCT01773252|decompression illness
1055140|NCT01773252|neurology
1055141|NCT01773252|transesophageal echocardiography
1055142|NCT01773252|TEE
1055143|NCT01773252|transthoracic echocardiography
1055144|NCT01773252|TTE
1055145|NCT01773252|transcranial Doppler
1055146|NCT01773252|ultrasound
1055147|NCT01773252|TCD
1055148|NCT01773252|power m Mode
1055149|NCT01773252|indocyanine green dye
1055150|NCT01773252|ICG
1055151|NCT01773252|Valsalva
1055152|NCT01773239|social cognition
1055153|NCT01773239|cognitive deficits
1055154|NCT01773239|prodromal schizophrenia
1055155|NCT01773239|recent-onset schizophrenia
1055156|NCT01773239|remediation
1055157|NCT01773239|computer training
1055158|NCT01773239|cognitive training exercises
1055159|NCT01773226|Autologous Protein Solution
1055160|NCT01773226|APS
1055161|NCT01773226|Osteoarthritis
1055162|NCT01773226|Injection
1055163|NCT01773213|Lower urinary tract
1055164|NCT01773213|Bladder
1055165|NCT01773213|Neuropathic bladder
1055166|NCT01773213|Overactive bladder
1055167|NCT01773200|endothelial progenitor cells
1055168|NCT01773200|aneurysmal subarachnoid hemorrhage
1055169|NCT01773200|vasospasm
1055170|NCT01773200|BNP
1055171|NCT01773187|Myelofibrosis
1055172|NCT01773187|Post-Polycythemia Vera Myelofibrosis
1055173|NCT01773187|Post-Essential Thrombocythemia Myelofibrosis
1055174|NCT01773187|Primary Myelofibrosis
1055175|NCT01773187|Polycythemia
1055176|NCT01773187|Polycythemia Vera
1055177|NCT01773187|Thrombocythemia, Essential
1055178|NCT01773187|Thrombocythemia
1055179|NCT01773187|Myeloproliferative Disorders
1055180|NCT01773187|Bone Marrow Disease
1055181|NCT01773187|Hematologic Diseases
1055182|NCT01773187|Blood Platelet Disorders
1055183|NCT01773187|Hemorrhagic Disorders
1055184|NCT01773187|Splenomegaly
1055185|NCT01773187|Pacritinib
1055186|NCT01773187|MPN-SAF
1055187|NCT01773187|MPN-SAF TSS
1055188|NCT01773187|Anemia
1055189|NCT01773187|Myeloproliferative
1055190|NCT01773187|Myeloproliferative Neoplasm
1055191|NCT01773187|Spleen
1055192|NCT01773187|Spleen volume
1055193|NCT01773187|Thrombocytopenia
1055194|NCT01773187|SB1518
1055195|NCT01773161|Cerebral Palsy
1055196|NCT01773161|Hip surgery
1055197|NCT01773161|Quality of Life
1055198|NCT01773135|threatened preterm labor
1055199|NCT01773135|ACTH
1055200|NCT01773135|PTL
1055201|NCT01773070|Chronic Hepatitis C
1055202|NCT01773070|Hepatitis C virus
1055203|NCT01773070|Direct Acting Antiviral
1055204|NCT01773070|Sustained Virologic Response
1055205|NCT01773070|Hepatitis C
1055206|NCT01773057|Computerized Decision Support System
1055207|NCT01773057|Heart failure
1055208|NCT01773057|Effects on quality of care
1055209|NCT01773057|Process of care
1055210|NCT01773057|Patient outcomes
1055211|NCT01773031|Autoimmune pancreatitis
1055212|NCT01773031|MR pancreatography
1055213|NCT01773005|Anesthetics, Intravenous
1055214|NCT01772992|HIV couples adherence linkage to care viral suppression
1055215|NCT01772979|Trabectedin
1055216|NCT01772979|BRCA1 and BRCA2
1055217|NCT01772979|BRCAness
1055218|NCT01772979|Ovarian cancer
1055219|NCT01772966|neck
1055220|NCT01772966|pain
1055221|NCT01772966|chronic
1055222|NCT01772966|manipulation
1055223|NCT01772966|control
1055224|NCT01772966|randomized trial
1055225|NCT01772953|AML
1055226|NCT01772953|MDS
1055227|NCT01772953|Treosulfan
1055228|NCT01772940|First-line therapy
1055229|NCT01772940|Protease inhibitor
1055230|NCT01772940|Non-Nucleoside Reverse transcriptase Inhibitor
1055231|NCT01772940|Resource-limited setting
1055232|NCT01772927|parenteral nutrition
1055233|NCT01772927|Very low birth weight infants
1055234|NCT01772927|preterm infants
1055235|NCT01772927|biochemical tolerance
1055236|NCT01772927|nutritional intake
1055237|NCT01772914|Copeptin
1055238|NCT01772914|eating
1055239|NCT01772914|glucose tolerance test
1055240|NCT01772914|mixed meal test
1055241|NCT01772914|physiological
1055242|NCT01772901|influenza
1055243|NCT01772901|influenza vaccines
1055244|NCT01772901|infectious disease
1055245|NCT01772901|pregnancy
1055246|NCT01772875|urinary catheter
1055247|NCT01772875|UTI
1055248|NCT01772875|bladder lavage
1055249|NCT01772862|childhood
1055250|NCT01772862|cancer
1055251|NCT01772862|physical activity
1055252|NCT01772862|quality of life
1055253|NCT01772849|childhood
1055254|NCT01772849|cancer
1055255|NCT01772849|education
1055256|NCT01772849|physical activity
1055257|NCT01772849|quality of life
1055258|NCT01772823|HIV, PrEP, FTC/TDF, Truvada
1055259|NCT01772810|Paralysis due to chronic spinal cord injury (SCI)
1055260|NCT01772797|anaplastic lymphoma kinase, ALK-rearranged lung cancer, non-small cell lung cancer
1055261|NCT01772784|subjects
1055262|NCT01772771|Cancer
1055263|NCT01772771|Molecular testing
1055264|NCT01772771|Personalized Cancer Therapy Program
1055265|NCT01772771|Bladder
1055266|NCT01772771|Bone
1055267|NCT01772771|Breast
1055268|NCT01772771|Cytology
1055269|NCT01772771|Endocrine
1055270|NCT01772771|Gynecology
1055271|NCT01772771|Endocrine - Neoplasia
1055272|NCT01772771|genitourinary
1055273|NCT01772771|Research Biorepository
1055274|NCT01772771|Head and Neck
1055275|NCT01772771|Aerodigestive Tract
1055276|NCT01772771|Hematopathology
1055277|NCT01772771|Human Cancer Genetics
1055278|NCT01772771|Kidney
1055279|NCT01772771|Leukemia
1055280|NCT01772771|Lower Gastrointestinal
1055281|NCT01772771|Lymphoma
1055282|NCT01772771|Melanoma
1055283|NCT01772771|Neurology
1055284|NCT01772771|Brain
1055285|NCT01772771|Non-Melanoma Skin
1055286|NCT01772771|Pancreas
1055287|NCT01772771|Pediatrics
1055288|NCT01772771|Prostate
1055289|NCT01772771|Breast Cancer Patients, Serum
1055290|NCT01772771|Plasma
1055291|NCT01772771|Soft Tissue Sarcoma
1055292|NCT01772771|Thoracic
1055293|NCT01772771|Lung
1055294|NCT01772771|S.P.O.R.E.
1055295|NCT01772771|Upper Gastrointestinal
1055296|NCT01772745|single incision
1055297|NCT01772745|cholecystectomy
1055298|NCT01772745|laparoscopy
1055299|NCT01772732|Simotinib
1055300|NCT01772732|Non-small Cell Lung Cancer
1055301|NCT01772719|refractory multiple myeloma
1055302|NCT01772706|Head and neck cancer
1055303|NCT01772706|Low level laser therapy
1055304|NCT01772706|Mucositis induced by radiochemotherpy
1055305|NCT01772693|ExAblate Transcranial MRgFUS
1055306|NCT01772680|Thalassemia
1055307|NCT01772680|Diabetes
1055308|NCT01772680|Zinc
1055309|NCT01772680|Iron-Overload
1055310|NCT01772667|pulmonary fibrosis
1055311|NCT01772667|interstitial lung disease
1055312|NCT01772667|pulmonary rehabilitation
1055313|NCT01772667|exercise capacity
1055314|NCT01772667|physical activity
1055315|NCT01772667|quality of life
1055316|NCT01772654|Epilepsy
1055317|NCT01772654|Arterial Spin Labeled MRI
1055318|NCT01772654|Brain lesions
1055319|NCT01772654|Cerebral blood flow
1055320|NCT01772641|cigarette
1055321|NCT01772641|smoking
1055322|NCT01772641|cessation
1055323|NCT01772641|varenicline
1055324|NCT01772641|scheduled reduction
1055325|NCT01772641|craving
1055326|NCT01772628|Communication
1055327|NCT01772628|Healthy sexual behaviour
1055328|NCT01772628|Sexual and reproductive health
1055329|NCT01772628|Adolescents
1055330|NCT01772615|EcN, Nissle, Mutaflor, Ulcerative Colitis, antibiotics, Inflammatory Bowel Diseases
1055331|NCT01772602|Amyotrophic Lateral Sclerosis
1055332|NCT01772602|Lou Gehrig's Disease
1055333|NCT01772602|Motor Neuron Disease
1055334|NCT01772576|Reliance
1055335|NCT01772576|Implantable Cardioverter Defibrillator (ICD)
1055336|NCT01772576|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
1055337|NCT01772550|CECT, catheter, contrast
1055338|NCT01772537|thoracoabdominal
1055339|NCT01772537|aneurysm
1055340|NCT01772537|open
1055341|NCT01772537|stent
1055342|NCT01772537|cardiopulmonary
1055343|NCT01772537|abdominal
1055344|NCT01772537|bypass
1055345|NCT01772524|Migraine Disorders
1055346|NCT01772524|Phase 1
1055347|NCT01772524|ALD403
1055348|NCT01772511|questionnaire
1055349|NCT01772511|prior therapy
1055350|NCT01772511|prior study volunteer
1055351|NCT01772511|prior study patient
1055352|NCT01772511|cancer
1055353|NCT01772511|oncology
1055354|NCT01772498|depression
1055355|NCT01772498|anxiety
1055356|NCT01772498|sleep
1055357|NCT01772498|pain
1055358|NCT01772498|biofeedback
1055359|NCT01772498|breathing
1055360|NCT01772498|resonant
1055361|NCT01772459|Scoliosis
1055362|NCT01772459|Adolescents
1055363|NCT01772459|Questionnaire
1055364|NCT01772459|Reliability
1055365|NCT01772446|diabetes
1055366|NCT01772446|management
1055367|NCT01772446|glycated hemoglobin
1055368|NCT01772446|preventive activities
1055369|NCT01772433|Low Back Pain
1055370|NCT01772433|Topical Olive Oil
1055371|NCT01772433|Phonophoresis
1055372|NCT01772407|Colon Cancer Surgery
1055373|NCT01772407|Laparoscopy
1055374|NCT01772407|Open surgery
1055375|NCT01772407|Costs
1055376|NCT01772407|Mortality
1055377|NCT01772407|Morbidity
1055378|NCT01772407|Quality of life
1055379|NCT01772394|Anorexia Nervosa
1055380|NCT01772394|Cognitive remediation therapy
1055381|NCT01772394|Randomized clinical trial
1055382|NCT01772381|Dexamethasone, term, elective cesarean section
1055383|NCT01772368|Asthma
1055384|NCT01772368|dry powder inhaler
1055385|NCT01772368|long-acting beta2-agonist
1055386|NCT01772368|bronchodilation
1055387|NCT01772368|bronchodilator
1055388|NCT01772368|metered dose inhaler
1055389|NCT01772368|inhaled corticosteroid
1055390|NCT01772355|orbit; tumor; core biopsy
1055391|NCT01772342|Sleep Fragmentation
1055392|NCT01772342|Quality of Life
1055393|NCT01772342|Air Filters
1055394|NCT01772303|Pressure Ulcers, diabetic Ulcers, post operational wounds
1055395|NCT01772277|Endoscopic dacryocystorhinostomy
1055396|NCT01772277|Mitomycin C
1055397|NCT01772251|Diabetes Mellitus
1055398|NCT01772251|Oral Insulin
1055399|NCT01772238|Mexico
1055400|NCT01772238|Respiratory infections
1055401|NCT01772238|Amoxicillin-Clavulanic Acid
1055402|NCT01772238|Bioequivalence
1055403|NCT01772225|Observational Retrospective
1055404|NCT01772225|Health-related quality of life (HRQoL)
1055405|NCT01772225|Patients
1055406|NCT01772225|Stage IB-IIIA
1055407|NCT01772225|Burden of Illness
1055408|NCT01772225|Non-small Cell Lung Cancer (NSCLC)
1055413|NCT01772199|GSK239512
1055414|NCT01772199|remyelination
1055415|NCT01772199|magnetic resonance imaging
1055416|NCT01772199|Relapsing Remitting Multiple Sclerosis
1055417|NCT01772199|Histamine 3 Receptor Antagonist
1055418|NCT01772199|magnetization transfer ratio
1055419|NCT01772186|Freezing of gait
1055420|NCT01772186|Parkinson's disease
1055421|NCT01772186|Somatosensory stimulation
1055422|NCT01772186|Fall prevention
1055423|NCT01772173|diabetes
1055424|NCT01772173|computer
1055425|NCT01772173|retina
1055426|NCT01772173|vessel
1055427|NCT01772173|analysis
1055437|NCT01772121|HBV, HCV, chronic, India, observational study, prevalence,
1055438|NCT01772121|genotypes, SNPs, viral hepatitis
1055439|NCT01772108|Heart Valve Diseases
1055440|NCT01772095|Donepezil (Dementis)
1055441|NCT01772095|Elderly
1055442|NCT01772069|systemic lupus erythematosus, disease activity, sleep, quality of life
1055443|NCT01772056|Dermatitis, Atopic
1055444|NCT01772056|Randomized Controlled Trial
1055445|NCT01772056|Child
1055446|NCT01772056|Fluticasone
1055447|NCT01772056|Preventive therapy
1055448|NCT01772043|muscular dystrophy
1055449|NCT01772043|tissue bank
1055450|NCT01772030|Atrial Fibrillation
1055451|NCT01772030|Cryoballoon Ablation
1055452|NCT01772017|Obstructive Sleep Apnea
1055453|NCT01772017|OSA
1055454|NCT01772017|Snoring
1055455|NCT01772017|Tongue Advancement Retainer Device
1055473|NCT01771991|fibrosis
1055474|NCT01771991|radiation
1055475|NCT01771991|neck
1055476|NCT01771991|cancer
1055477|NCT01771991|Sodermix
1055478|NCT01771978|ischaemia-reperfusion injury
1055479|NCT01771978|cardiac surgery
1055480|NCT01771978|oxidative stress markers
1055481|NCT01771978|troponin
1055482|NCT01771978|diltiazem
1055483|NCT01771978|acetylcystein
1055484|NCT01771952|Patellofemoral Chondromalacia
1055485|NCT01771952|Anterior Knee Pain
1055486|NCT01771952|Patellofemoral Pain Syndrome
1055487|NCT01771952|Synvisc-One
1055488|NCT01771952|Hyaluronic Acid
1055489|NCT01771939|Idiopathic epiretinal membranes
1055490|NCT01771939|25-G surgery in idiopathic epiretinal membranes
1055491|NCT01771926|resistant starch
1055492|NCT01771926|lifestyle intervention
1055493|NCT01771913|adipocytes
1055494|NCT01771913|cell transplantations
1055495|NCT01771913|mesenchymal stem cell
1055496|NCT01771913|immunophenotyping
1055497|NCT01771913|adipose tissue
1055498|NCT01771913|breast reconstruction
1055499|NCT01771913|mammaplasty
1055500|NCT01771913|magnetic resonance imaging
1055501|NCT01771913|fat necrosis
1055502|NCT01771900|heart failure
1055503|NCT01771900|exercise
1055504|NCT01771900|adherence to exercise
1055505|NCT01771887|Diabetic Type2
1055506|NCT01771887|education
1055507|NCT01771887|self-management behaviors
1055508|NCT01771887|self-efficacy
1055509|NCT01771887|HbA1c
1055510|NCT01771874|MDMA
1055511|NCT01771874|pharmacokinetics
1055512|NCT01771874|pharmacodynamics
1055513|NCT01771874|emotions
1055514|NCT01771874|Mechanism of action of MDMA
1055515|NCT01771874|Interaction study
1055516|NCT01771874|Effect of MDMA and bupropion on emotions
1055517|NCT01771848|Malaria
1055518|NCT01771848|Plasmodium falciparum
1055519|NCT01771835|diabetes mellitus
1055520|NCT01771835|retinal venous pressure
1055521|NCT01771835|endothelin-1
1055522|NCT01771822|cumulative irritancy patch test (CIPT)
1055523|NCT01771809|Anti-TNF Refractory
1055524|NCT01771809|Immunosuppressant Refractory
1055525|NCT01771809|Active Ulcerative Colitis
1055526|NCT01771796|Exercise; lung cancer; aerobic training, resistance training; respiratory muscle training
1055527|NCT01771783|RAS-Peptide Profile
1055528|NCT01771783|Renin-Angiotensin-System
1055529|NCT01771783|Angiotensin-Converting-Enzyme-Inhibitor
1055530|NCT01771783|Angiotensin-Receptor-Antagonist
1055531|NCT01771783|Renin-inhibitor
1055532|NCT01771770|retinal venous pressure (RVP)
1055533|NCT01771770|chronically reduced ambient pressure
1055534|NCT01771770|oxygen partial pressure
1055535|NCT01771770|mountain sickness
1055536|NCT01771757|retinal venous pressure
1055537|NCT01771757|reduced ambient pressure
1055538|NCT01771757|oxygen partial pressure
1055539|NCT01771757|short-term hypoxic changes
1055540|NCT01771705|Transplantation
1055541|NCT01771705|Kidney
1055542|NCT01771705|calcineurin inhibitor
1055543|NCT01771705|NFAT
1055544|NCT01771705|tacrolimus
1055545|NCT01771692|Orthodontics
1055546|NCT01771679|Mesenchymal Stem Cells
1055547|NCT01771679|Bone Marrow Cells
1055548|NCT01771679|Allogeneic Transplantation
1055549|NCT01771679|Skin Wrinkling
1055550|NCT01771679|Solar Aging of Skin
1055551|NCT01771679|Intravenous Administration
1055552|NCT01771653|Hepatitis C infection
1055553|NCT01771653|Hepatitis C Virus
1055554|NCT01771653|HCV
1055555|NCT01771640|ALS intrathecal injection bone marrow mesenchymal stem cell
1055556|NCT01771614|Glucotoxicity
1055557|NCT01771614|Exercise
1055558|NCT01771614|Beta-cell function
1055559|NCT01771601|Near-infrared spectroscopy, cerebral oxygenation, term newborn, reproducibility,
1055560|NCT01771562|HIV-1
1055561|NCT01771562|Child
1055562|NCT01771562|Adolescent
1055563|NCT01771562|Growth
1055564|NCT01771562|Lipodystrophy
1055565|NCT01771562|ARV treatment
1055566|NCT01771562|Senegal
1055567|NCT01771549|Adriamycin
1055568|NCT01771549|Trastuzumab
1055569|NCT01771549|Brain Natriuretic Peptide (BNP)
1055570|NCT01771549|Troponin
1055571|NCT01771523|thyroidectomy
1055572|NCT01771523|drain use
1055573|NCT01771497|Breast CT
1055574|NCT01771484|tachycardia
1055575|NCT01771484|pots
1055576|NCT01771484|orthostatic intolerance
1055577|NCT01771471|back pain
1055578|NCT01771471|intervertebral disc
1055579|NCT01771471|lumbar spine
1055580|NCT01771458|Metastatic/Reccurent
1055581|NCT01771458|Solid Tumor
1055582|NCT01771458|Refractory
1055583|NCT01771458|Molecular profile
1055584|NCT01771458|Targeted treatment
1055585|NCT01771445|IL-1
1055586|NCT01771445|IL-6
1055587|NCT01771445|Inflammation
1055588|NCT01771419|loop-tip
1055589|NCT01771419|ERCP
1055590|NCT01771419|cannulation of CBD
1055591|NCT01771393|arthroscanner
1055592|NCT01771393|cone-beam computed tomodensitometry
1055593|NCT01771354|Volunteers
1055594|NCT01771354|Identify
1055595|NCT01771354|Biomarkers
1055596|NCT01771354|Vaccine Safety
1055597|NCT01771341|NAVA
1055598|NCT01771341|post operative
1055599|NCT01771328|Adrenal Hyperplasia, Congenital
1055600|NCT01771315|total knee arthroplasty
1055601|NCT01771315|telephone follow-up
1055602|NCT01771315|physical function
1055603|NCT01771315|health related quality of life
1055604|NCT01771315|self-efficacy
1055605|NCT01771302|PRGF-Endoret
1055606|NCT01771302|Bone graft
1055607|NCT01771302|Maxillary sinus
1055608|NCT01771302|Vertical bone augmentation
1055609|NCT01771289|Lung Cancer
1055610|NCT01771276|POSE
1055611|NCT01771263|Anesthesia
1055612|NCT01771263|Propofol
1055613|NCT01771263|Remifentanil
1055614|NCT01771263|NeuroSENSE
1055615|NCT01771237|HIV infection
1055616|NCT01771224|Palmitoleic acid ulcerative colitis
1055617|NCT01771211|MCI
1055618|NCT01771211|Word-retrieval
1055619|NCT01771211|tDCS
1055620|NCT01771211|fMRI
1055621|NCT01771198|Chronic rhinosinusitis
1055622|NCT01771198|Refractory to treatment
1055623|NCT01771198|SIMVASTATIN
1055624|NCT01771185|Diabetes
1055625|NCT01771185|metabolic surgery
1055626|NCT01771185|insulin resistance
1055627|NCT01771159|Spinal cord injury
1055628|NCT01771159|Urinary dysfunction
1055629|NCT01771159|Bladder drainage
1055630|NCT01771146|Non-metastatic Pancreas Cancer
1055631|NCT01771146|Pancreatic Cancer
1055632|NCT01771146|Cancer of Pancreas
1055633|NCT01771146|Adenocarcinoma of Pancreas
1055634|NCT01771146|Neoadjuvant
1055635|NCT01771133|Obesity
1055636|NCT01771133|Maternal Welfare
1055637|NCT01771133|Child Welfare
1055638|NCT01771133|Nutritional Sciences
1055639|NCT01771133|Clinical Trial
1055640|NCT01771133|Pregnancy
1055641|NCT01771133|Physical activity
1055642|NCT01771133|Fetal Development
1055643|NCT01771133|Metabolic Diseases
1055644|NCT01771133|Life style
1055645|NCT01771133|Behavior and Behavior Mechanisms
1055646|NCT01771133|LIFE-Moms
1055647|NCT01771120|Asthma
1055648|NCT01771120|Rhinitis
1055649|NCT01771120|Control
1055650|NCT01771120|Burden
1055651|NCT01771081|Longitudinal Studies,
1055652|NCT01771081|Observation
1055653|NCT01771081|Epidemiology
1055654|NCT01771055|Trauma
1055655|NCT01771055|Hypovolemia
1055656|NCT01771042|weight loss
1055657|NCT01771042|metabolic syndrome
1055658|NCT01771042|sympathetic nervous system
1055659|NCT01771042|insulin resistance
1055660|NCT01771042|glucose tolerance
1055661|NCT01771029|Procalcitonin
1055662|NCT01771029|Infection
1055663|NCT01771029|Point-of-Care
1055664|NCT01771016|Emergency contraception
1055665|NCT01771016|Emergency hormonal contraception
1055666|NCT01771016|Community pharmacies
1055667|NCT01771016|Pharmaceutical care
1055668|NCT01771016|Time to access
1055669|NCT01771016|Written assessments
1055670|NCT01771016|Switzerland
1055671|NCT01771003|Partial nephrectomy
1055672|NCT01771003|renal cell carcinoma
1055673|NCT01771003|Renal Function
1055674|NCT01771003|Remote ischemia preconditioning
1055675|NCT01770990|depression
1055676|NCT01770990|telephone-based psychotherapy
1055677|NCT01770990|cognitive-behavioral psychotherapy
1055678|NCT01770990|manualized psychotherapy
1055679|NCT01770990|telephone counseling
1055680|NCT01770990|telephone psychological treatment
1055681|NCT01770990|telephone-administered therapy
1055682|NCT01770990|low-intensity treatment
1055683|NCT01770990|motivational mail
1055684|NCT01770990|reminder
1055685|NCT01770990|letter
1055686|NCT01770977|Light-emitting diode therapy
1055687|NCT01770977|Muscle performance
1055688|NCT01770977|Aerobic performance
1055689|NCT01770977|Lactate
1055690|NCT01770977|Creatine kinase
1055691|NCT01770938|Light-emitting diode therapy
1055692|NCT01770938|Muscle performance
1055693|NCT01770938|Gene expression
1055694|NCT01770938|Functional performance
1055695|NCT01770912|facial pain
1055696|NCT01770912|temporomandibular joint
1055697|NCT01770912|arthrocentesis
1055698|NCT01770912|steroid
1055699|NCT01770899|Montelukast
1055700|NCT01770899|Singulair
1055701|NCT01770899|status asthmaticus
1055702|NCT01770886|Drug Safety
1055703|NCT01770873|Youth
1055704|NCT01770873|Violence
1055705|NCT01770873|Assault-injured
1055706|NCT01770873|Mentoring
1055707|NCT01770873|Emergency Room
1055708|NCT01770873|Urban
1055709|NCT01770860|Adhesive Bandages
1055710|NCT01770860|Dermabrasion Wounds
1055711|NCT01770821|sip drink
1055712|NCT01770821|protein
1055713|NCT01770821|muscle strength
1055714|NCT01770821|6 minutes walking test
1055715|NCT01770808|Bloating
1055716|NCT01770808|Flatulence
1055717|NCT01770808|Stomach discomfort
1055718|NCT01770795|non-small cell lung cancer
1055719|NCT01770795|gemcitabine
1055720|NCT01770795|genexol-PM
1055721|NCT01770795|paclitaxel
1055722|NCT01770782|Palatal Expansion Technique
1055723|NCT01770782|Orthognathic Surgery
1055724|NCT01770782|Three Dimensional images
1055725|NCT01770769|Femoral Neck Fracture
1055726|NCT01770769|undisplaced
1055727|NCT01770769|minimally displaced
1055728|NCT01770769|internal fixation
1055729|NCT01770769|hemiarthroplasty
1055730|NCT01770769|harris hip score
1055731|NCT01770769|hospital cost
1055732|NCT01770769|society cost
1055733|NCT01770769|quality of life
1055734|NCT01770769|Timed Up and go test
1055735|NCT01770756|Hypertension
1055736|NCT01770756|High blood pressure
1055737|NCT01770756|Willpower
1055738|NCT01770756|Self care
1055739|NCT01770743|post-exposure prophylaxis
1055740|NCT01770743|toxin neutralization assay
1055741|NCT01770730|urine LAM strip test
1055742|NCT01770730|diagnostics
1055743|NCT01770730|tuberculosis
1055744|NCT01770704|Bipolar disorder
1055745|NCT01770704|Clinical management
1055746|NCT01770704|Clinical outcomes
1055747|NCT01770678|Children
1055748|NCT01770678|Cerebral Palsy
1055749|NCT01770678|Randomised
1055750|NCT01770678|Constraint Induced Movement Therapy
1055751|NCT01770652|Renal Impairment
1055752|NCT01770652|Kidney Impairment
1055753|NCT01770652|Kidney Disease
1055754|NCT01770652|Ferriprox
1055755|NCT01770652|Deferiprone
1055756|NCT01770652|DFP (deferiprone)
1055757|NCT01770652|L1
1055758|NCT01770639|charcot foot
1055759|NCT01770639|charcot neuroarthropathy
1055760|NCT01770639|midfoot arthrodesis
1055761|NCT01770639|midfoot fusion
1055762|NCT01770613|Adult
1055763|NCT01770613|Allogeneic
1055764|NCT01770613|Stem
1055765|NCT01770613|Cells
1055766|NCT01770613|Myocardial
1055767|NCT01770613|Infarction
1055768|NCT01770600|Age 19 to 64
1055769|NCT01770600|Medically stable
1055770|NCT01770600|No current or history of psychosis
1055771|NCT01770600|No alcohol or benzodiazepine withdrawal
1055772|NCT01770587|Insomnia
1055773|NCT01770587|Sleep
1055774|NCT01770587|Behavioral Medicine
1055775|NCT01770587|Suicide
1055776|NCT01770587|Suicidal Ideation
1055777|NCT01770574|calcaneal lengthening
1055778|NCT01770574|calcium ceramics
1055779|NCT01770574|noninferiority
1055780|NCT01770574|radiostereometric analysis
1055781|NCT01770535|Ovarian cancer, paclitaxel
1055782|NCT01770522|Bodyweight
1055783|NCT01770522|Physical Acivitiy
1055784|NCT01770522|Diet
1055785|NCT01770522|Bodymass index
1055786|NCT01770522|Pregnancy
1055787|NCT01770522|Postnatal
1055788|NCT01770509|Chronic venous leg ulcers
1055789|NCT01770509|Venous ulcer
1055790|NCT01770509|Stasis ulcer
1055791|NCT01770509|Varicose ulcer
1055792|NCT01770496|immunization
1055793|NCT01770496|vaccination
1055794|NCT01770496|immunization information system
1055795|NCT01770496|immunization registry
1055796|NCT01770496|reminder / recall
1055797|NCT01770483|Nitazoxanide,
1055798|NCT01770483|Sustained viral response
1055799|NCT01770483|Type 2 DIABETICS
1055800|NCT01770470|serum phosphate
1055801|NCT01770470|chitosan
1055802|NCT01770470|kidney disease
1055803|NCT01770470|salivary phosphate
1055804|NCT01770457|ICU population
1055805|NCT01770444|Acute coronary syndrome
1055806|NCT01770444|Cardiac computed tomographic angiography
1055807|NCT01770444|Radiation dose reduction
1055808|NCT01770444|Medical radiation exposure
1055809|NCT01770431|Huaier Granule;
1055810|NCT01770431|After radical hepatectomy;
1055811|NCT01770431|Prevention of Recurrence and Metastasis;
1055812|NCT01770431|Safety.
1055818|NCT01770405|endomicroscopy
1055819|NCT01770405|needle-based
1055820|NCT01770405|pancreatic
1055821|NCT01770405|cyst
1055822|NCT01770405|mass
1055823|NCT01770405|EUSFNA
1055824|NCT01770379|Rheumatoid Arthritis, RA, IL-17 blocker, subcutaneous, self-injection, AIN457, AIN457F, secukinumab, anti-TNFα, pre-filled syringe
1055825|NCT01770366|obesity
1055826|NCT01770366|weight loss surgery
1055827|NCT01770366|virtual support
1055828|NCT01770366|wireless devices
1055829|NCT01770366|Internet
1055830|NCT01770353|solid tumors
1055831|NCT01770353|Triple Negative Breast Cancer
1055832|NCT01770353|Colorectal Cancer
1055833|NCT01770353|MM-398
1055834|NCT01770353|nanoliposomal irinotecan
1055835|NCT01770353|Ferumoxytol
1055836|NCT01770353|ER/PR positive Breast Cancer
1055837|NCT01770353|Pancreatic Cancer
1055838|NCT01770353|Ovarian Cancer
1055839|NCT01770353|Gastric Cancer
1055840|NCT01770353|Gastro-Esophageal Junction Adenocarcinoma
1055841|NCT01770353|Head and Neck Cancer
1055842|NCT01770353|TNBC
1055843|NCT01770340|radical prostatectomy
1055844|NCT01770340|erectile function
1055845|NCT01770340|nerve grafting
1055846|NCT01770340|allogenic
1055847|NCT01770340|prostate cancer
1055848|NCT01770340|Allogenic nerve graft
1055849|NCT01770340|Time required for nerve grafting
1055850|NCT01770314|Opioid Pain Medication
1055851|NCT01770314|Medication Safety
1055852|NCT01770314|Correct storage
1055853|NCT01770314|Correct disposal
1055854|NCT01770314|Correct Use
1055855|NCT01770288|Anerobic exercise
1055856|NCT01770288|Pain
1055857|NCT01770288|Analgesia
1055858|NCT01770288|Diffuse Noxious Inhibitory Control (DNIC)
1055859|NCT01770288|psychological stress
1055860|NCT01770275|esophagus
1055861|NCT01770249|dysphagia
1055862|NCT01770210|hypercholesterolemia
1055863|NCT01770210|atorvastatin
1055864|NCT01770210|cardiovascular events
1055865|NCT01770197|China
1055866|NCT01770197|Stroke
1055867|NCT01770197|Thrombolytic therapy
1055868|NCT01770184|Self-management
1055869|NCT01770184|Rehabilitation
1055870|NCT01770184|Occupational Therapy
1055871|NCT01770171|endometrial cancer
1055872|NCT01770171|recurrent endometrial cancer
1055873|NCT01770171|bevacizumab
1055874|NCT01770158|Acute myeloid leukemia (AML)
1055875|NCT01770158|Histamine Dihydrochloride
1055876|NCT01770158|Interleukin-2
1055877|NCT01770145|Motor symptoms
1055878|NCT01770145|Parkinson's Disease
1055879|NCT01770145|Delayed Onset
1055880|NCT01770145|Akinesia
1055881|NCT01770145|Hypomobility
1055882|NCT01770145|Unified Parkinson Disease Rating Scale (UPDRS) motor scores
1055883|NCT01770145|Dopamine agonist
1055884|NCT01770145|Apomorphine
1055885|NCT01770145|Apokyn
1055886|NCT01770145|Levodopa
1055887|NCT01770119|Measles
1055888|NCT01770119|Mumps
1055889|NCT01770119|Rubella
1055890|NCT01770119|Pediatric
1055891|NCT01770119|Solid-organ transplant
1055892|NCT01770119|serology
1055893|NCT01770119|vaccine
1055894|NCT01770106|Rheumatoid arthritis
1055895|NCT01770106|Bone density
1055896|NCT01770106|Bone microarchitecture
1055897|NCT01770106|HR-pQCT
1055898|NCT01770067|Cardiac Resynchronization Therapy Devices
1055899|NCT01770054|metabolic syndrome
1055900|NCT01770054|diabetes mellitus
1055901|NCT01770028|Obesity
1055902|NCT01770028|Pregnancy
1055903|NCT01770028|Spouse
1055904|NCT01770028|Weight loss
1055905|NCT01770028|Behavioral
1055906|NCT01770015|patient ventilated for at least five days
1055907|NCT01769963|Advanced glycation end-products
1055908|NCT01769963|chronic kidney disease
1055909|NCT01769963|nutrition
1055910|NCT01769963|inflammation
1055911|NCT01769963|insulin resistance
1055912|NCT01769963|endothelial function
1055913|NCT01769950|Choline PET
1055914|NCT01769950|Choline PET-CT
1055915|NCT01769950|Positron emission tomography
1055916|NCT01769950|Prostate cancer
1055917|NCT01769937|Lupus
1055918|NCT01769937|SLE
1055919|NCT01769937|ACTH
1055920|NCT01769937|Acthar
1055921|NCT01769924|kidney donors
1055922|NCT01769924|arterial stiffness
1055923|NCT01769924|blood pressure
1055924|NCT01769898|Bronchiectasis
1055925|NCT01769898|Theophylline
1055926|NCT01769898|Therapeutic Uses
1055927|NCT01769898|HDAC
1055928|NCT01769898|HAT
1055929|NCT01769898|Random placebo study
1055930|NCT01769898|ICS(inhaled corticosteroid)
1055931|NCT01769898|corticosteroid
1055932|NCT01769898|Inhaled corticosteroid
1055933|NCT01769859|Bipolar Disorder
1055934|NCT01769859|Major Depressive Disorder
1055935|NCT01769859|Genetics
1055936|NCT01769833|HBsAg
1055937|NCT01769833|Chronic hepatitis B
1055938|NCT01769833|PEGinterferon Alfa-2A
1055939|NCT01769820|Heavy menstrual bleeding (HMB)
1055940|NCT01769820|Dexamethasone
1055941|NCT01769820|glucocorticoid
1055942|NCT01769807|Sleep apnea
1055943|NCT01769807|CPAP treatment
1055944|NCT01769807|Plasma nitrate
1055945|NCT01769807|Urinary norepinephrine
1055946|NCT01769807|Blood pressure
1055947|NCT01769794|Hand, Foot and Mouth Disease
1055948|NCT01769794|Medicine, Chinese Traditional
1055949|NCT01769794|Enterovirus
1055950|NCT01769794|Fever
1055951|NCT01769781|endometriosis recurrence
1055952|NCT01769781|pelvic pain
1055953|NCT01769781|aromatase inhibitor
1055954|NCT01769768|Adults, Hh (Hedgehog) pathway inhibitor, LDE225, Warfarin, Bupropion, advanced solid tumor, drug-drug interaction, pharmacokinetic
1055955|NCT01769755|Crohn's disease
1055956|NCT01769755|Fistula
1055957|NCT01769755|Diarrhea
1055958|NCT01769755|Colon
1055959|NCT01769755|Stem cells
1055960|NCT01769742|Pneumonia
1055961|NCT01769742|promotion of activity
1055962|NCT01769729|integrated primary care
1055963|NCT01769729|depression
1055964|NCT01769729|chronic low back pain
1055965|NCT01769716|Global developmental delay
1055966|NCT01769716|Umbilical cord blood
1055967|NCT01769716|Rehabilitation
1055968|NCT01769690|PD
1055969|NCT01769690|Parkinson's Disease
1055970|NCT01769690|DBS
1055971|NCT01769690|deep brain stimulation
1055972|NCT01769677|Bioequivalence
1055973|NCT01769677|Hydrocodone bitartrate extended-release tablets
1055974|NCT01769664|Acne vulgaris
1055975|NCT01769664|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
1055976|NCT01769664|Duac® Topical Gel
1055977|NCT01769651|drug user patients
1055978|NCT01769651|addiction nurses
1055979|NCT01769651|overdose risk
1055980|NCT01769638|Orally disintegrating Film
1055981|NCT01769638|Film Coated Tablet
1055982|NCT01769638|Sildenafil
1055983|NCT01769638|Pharmacokinetics
1055984|NCT01769625|breast
1055985|NCT01769625|high risk women
1055986|NCT01769625|biomarkers
1055987|NCT01769625|vitamin D
1055988|NCT01769586|Sedation
1055989|NCT01769586|Endoscopy
1055990|NCT01769586|Diphenhydramine
1055991|NCT01769586|Midazolam
1055992|NCT01769573|normal
1055993|NCT01769560|tailored intervention
1055994|NCT01769560|college aged students
1055995|NCT01769560|HPV
1055996|NCT01769521|Glaucoma
1055997|NCT01769521|IOP
1055998|NCT01769521|Blood pressure
1055999|NCT01769521|ECG
1056000|NCT01769508|Esophagogastric Adenocarcinoma
1056001|NCT01769508|5-Fluorouracil
1056002|NCT01769508|Oxaliplatin
1056003|NCT01769508|Lapatinib
1056004|NCT01769508|Radiation Therapy
1056005|NCT01769508|Surgery
1056006|NCT01769495|Emergency department, Geriatrics, mortality, readmission rates.
1056007|NCT01769495|Patients 75 years of age and older.
1056008|NCT01769482|microvascular angina
1056009|NCT01769482|PDE-5 inhibitors
1056010|NCT01769482|Heart disease
1056011|NCT01769482|Ischemia
1056012|NCT01769482|Cardiac MRI
1056013|NCT01769469|Tenofovir
1056014|NCT01769469|Emtricitabine
1056015|NCT01769469|Truvada
1056016|NCT01769469|Renal, endocrine, bone changes
1056017|NCT01769469|HIV prevention
1056018|NCT01769469|PrEP
1056019|NCT01769456|HIV, PrEP, FTC/TDF, Truvada
1056020|NCT01769443|desensitization therapy
1056021|NCT01769443|bortezomib (VELCADE®)
1056022|NCT01769443|plasmapheresis
1056023|NCT01769430|influenza virus
1056024|NCT01769430|aerosol transmission
1056025|NCT01769430|contact transmission
1056026|NCT01769430|large droplet transmission
1056027|NCT01769430|airborne infection
1056028|NCT01769391|NSCLC
1056029|NCT01769365|Helicobacter pylori infection
1056030|NCT01769352|cystoid macular edema
1056031|NCT01769339|Vulvar Candidiasis
1056032|NCT01769339|Miconazole
1056033|NCT01769339|Hydrocortisone
1056034|NCT01769339|Daktacort Feminine Care Cream
1056035|NCT01769326|Stroke
1056036|NCT01769313|Cataract
1056037|NCT01769313|Laser-assisted
1056038|NCT01769313|Femtosecond
1056039|NCT01769300|Clinical decision support
1056040|NCT01769300|Electronic health records
1056041|NCT01769300|Electronic medical records
1056042|NCT01769300|Attention deficit-hyperactivity disorder
1056043|NCT01769300|Primary care Pediatric research network
1056044|NCT01769287|Atrial fibrillation
1056045|NCT01769287|Electrophysiological Assessment
1056046|NCT01769287|12 months post-operatively
1056047|NCT01769287|High Intensity Ultrasound
1056048|NCT01769261|quality of health care
1056049|NCT01769261|continuity of patient care
1056050|NCT01769261|adverse effects
1056051|NCT01769261|outcome and process assessment (health care)
1056052|NCT01769248|EUS
1056053|NCT01769248|FNA
1056054|NCT01769248|FNB
1056055|NCT01769235|Acne Vulgaris
1056056|NCT01769235|Clindamycin Phosphate and Benzoyl Peroxide Gel
1056057|NCT01769235|Acanya® Gel
1056058|NCT01769196|Idiopathic
1056059|NCT01769196|Pulmonary
1056060|NCT01769196|Fibrosis
1056061|NCT01769196|IPF
1056062|NCT01769183|Proliferative Diabetic Retinopathy
1056063|NCT01769170|CMV
1056064|NCT01769170|Hematopoietic Stem Cell Transplant Recipients
1056065|NCT01769170|CMV seropositive
1056066|NCT01769144|wound healing
1056067|NCT01769144|wound infection
1056068|NCT01769144|pain
1056069|NCT01769144|pruritus
1056070|NCT01769144|cicatrix
1056071|NCT01769144|dressings
1056072|NCT01769144|acticoat absorbent
1056073|NCT01769144|BCT
1056074|NCT01769144|KoCarbonAg
1056075|NCT01769131|cervix
1056076|NCT01769131|Allis
1056077|NCT01769131|Tenaculum
1056078|NCT01769131|gynecology
1056079|NCT01769118|Autonomic nervous system
1056080|NCT01769105|Meibomian Gland Dysfunction
1056081|NCT01769105|Lipiflow
1056082|NCT01769092|Epilepsy
1056083|NCT01769092|Seizure
1056084|NCT01769092|Fish Oil
1056085|NCT01769053|Acute Lung Injury
1056086|NCT01769053|Adult Respiratory Distress Syndrome
1056087|NCT01769053|Interactive Ventilatory Support
1056088|NCT01769053|Positive-Pressure Respiration
1056089|NCT01769053|Ventilator-Induced Lung Injury
1056090|NCT01769040|Decompensated liver cirrhosis
1056091|NCT01769040|Ascites
1056092|NCT01769040|Haemodynamics
1056093|NCT01769040|Small intestinal bacterial overgrowth
1056094|NCT01769040|Pathophysiology
1056095|NCT01769014|adherence
1056096|NCT01769001|Fabry disease
1056097|NCT01769001|Alpha galactosidase deficiency
1056098|NCT01769001|Metabolic storage disease
1056099|NCT01768975|Knee
1056100|NCT01768975|Osteoarthritis
1056101|NCT01768975|OA
1056102|NCT01768975|Knee pain
1056103|NCT01768975|Moderate pain
1056104|NCT01768975|Severe pain
1056105|NCT01768975|Inflammation
1056106|NCT01768975|Safety
1056107|NCT01768975|Efficacy
1056108|NCT01768975|Randomized
1056109|NCT01768975|Topical
1056110|NCT01768975|Gel
1056111|NCT01768975|Olatec
1056112|NCT01768975|OLT1177
1056113|NCT01768975|Joint Diseases
1056114|NCT01768975|Musculoskeletal Diseases
1056115|NCT01768975|Rheumatic Diseases
1056116|NCT01768975|Arthritis
1056117|NCT01768975|Therapeutic
1056118|NCT01768975|Analgesic
1056119|NCT01768962|Microbicides
1056120|NCT01768962|Tenofovir
1056121|NCT01768962|Reduced-glycerin
1056122|NCT01768962|Vaginal use
1056123|NCT01768962|Rectal use
1056124|NCT01768962|Pharmacokinetics
1056125|NCT01768949|Acute respiratory distress syndrome
1056126|NCT01768949|Echocardiography
1056127|NCT01768949|Recruitment maneuver
1056128|NCT01768936|on-demand relaparotomy
1056129|NCT01768936|PCT
1056130|NCT01768936|procalcitonin
1056131|NCT01768936|peritonitis
1056132|NCT01768936|sepsis
1056133|NCT01768936|focus index
1056134|NCT01768923|Early Rheumatoid Arthritis
1056135|NCT01768923|Arterial stiffness
1056136|NCT01768923|SDAI remission group
1056137|NCT01768923|Minimal disease activity remission group
1056138|NCT01768910|lower urinary tract
1056139|NCT01768910|bladder
1056140|NCT01768910|supraspinal control
1056141|NCT01768910|neuroimaging
1056142|NCT01768910|functional magnetic resonance imaging
1056143|NCT01768910|diffusion tensor imaging
1056144|NCT01768910|functional connectivity
1056145|NCT01768910|neurogenic lower urinary tract dysfunction
1056146|NCT01768910|overactive bladder
1056147|NCT01768910|multiple sclerosis
1056148|NCT01768910|spinal cord injury
1056149|NCT01768884|Infants
1056150|NCT01768884|Bronchiolitis
1056151|NCT01768884|NO
1056152|NCT01768884|inhalation
1056153|NCT01768858|Arthritis
1056154|NCT01768858|Morbus Crohn
1056155|NCT01768858|Adherence
1056156|NCT01768858|Spondylitis
1056157|NCT01768858|Ulcerative colitis
1056158|NCT01768858|Monoclonals
1056159|NCT01768858|Rheumatoid
1056160|NCT01768858|Antibodies
1056161|NCT01768858|Ankylosing
1056162|NCT01768858|Plaque psoriasis
1056163|NCT01768858|Psoriatic
1056164|NCT01768858|Crohn´s disease
1056165|NCT01768858|Antirheumatic Agents
1056166|NCT01768845|Chronic myelogenous leukemia (CML)
1056167|NCT01768845|Acute myelogenous leukemia (AML)
1056168|NCT01768845|Myelodysplastic syndrome
1056169|NCT01768845|Multiple myeloma
1056170|NCT01768845|Hodgkin lymphoma
1056171|NCT01768845|Non Hodgkin lymphoma
1056172|NCT01768845|Chronic lymphocytic leukemia (CLL)
1056173|NCT01768845|Acute lymphocytic leukemia (ALL)
1056174|NCT01768845|Severe Aplastic Anemia
1056175|NCT01768845|Cord Blood
1056176|NCT01768845|Umbilical cord blood transplantation
1056177|NCT01768845|UBC transplantation
1056178|NCT01768832|Parkinson disease
1056179|NCT01768832|walking
1056180|NCT01768832|fMRI
1056181|NCT01768832|exercise
1056182|NCT01768832|dance
1056183|NCT01768832|treadmill
1056184|NCT01768819|aging
1056185|NCT01768819|exercise
1056186|NCT01768819|muscle strength
1056187|NCT01768819|physical activity
1056188|NCT01768806|Autism
1056189|NCT01768806|Autism Spectrum Disorder
1056190|NCT01768806|PLAY and Language for Autistic Youngsters
1056191|NCT01768806|Intensive Early Intervention
1056192|NCT01768806|Parent Training
1056193|NCT01768793|Obesity
1056194|NCT01768793|Pregnancy
1056195|NCT01768793|Body Weight Changes
1056196|NCT01768793|Diet Therapy
1056197|NCT01768780|spinal anesthesia
1056198|NCT01768780|peripheral nerve stimulator
1056199|NCT01768780|sensory block level
1056200|NCT01768754|Exercise testing
1056201|NCT01768754|Functional status
1056202|NCT01768754|Pulmonary rehabilitation
1056203|NCT01768741|hepatocellular carcinoma
1056204|NCT01768715|Alcoholic hepatitis
1056205|NCT01768715|Liver transplantation
1056206|NCT01768715|Survival
1056207|NCT01768715|Alcoholism
1056208|NCT01768702|Chronic Heart Failure of Ischemic Origin
1056209|NCT01768689|adherence
1056210|NCT01768689|chronic myeloid leukemia
1056211|NCT01768689|tyrosine kinase inhibitors
1056212|NCT01768676|healthy male
1056213|NCT01768650|traumatic brain injury
1056214|NCT01768650|chronic pain
1056215|NCT01768650|headache
1056216|NCT01768650|Veteran
1056217|NCT01768637|Chronic kidney disease
1056218|NCT01768637|Platelet function
1056219|NCT01768637|aspirin
1056220|NCT01768637|antiplatelet agent
1056221|NCT01768624|chronic kidney disease
1056222|NCT01768624|dialysis
1056223|NCT01768624|pre dialysis education
1056224|NCT01768624|transplantation
1056225|NCT01768624|conservative care
1056226|NCT01768598|Wrist Fracture
1056227|NCT01768598|Adolescents
1056228|NCT01768598|Risk Taking Behaviour
1056229|NCT01768598|Bone Microstructure
1056230|NCT01768546|Diabetes Prevention Program
1056231|NCT01768546|obesity
1056232|NCT01768546|activity
1056233|NCT01768546|diabetes
1056234|NCT01768533|pediatric
1056235|NCT01768533|obesity
1056236|NCT01768533|prevention
1056237|NCT01768533|health behaviors
1056238|NCT01768533|guidelines
1056239|NCT01768481|Obesity
1056240|NCT01768481|Dyslipidemia
1056241|NCT01768481|Cholesterol
1056242|NCT01768481|Intima media thickness
1056243|NCT01768468|LAYLA
1056244|NCT01768468|Non-inferiority
1056245|NCT01768468|100mm pain VAS
1056246|NCT01768442|Head and neck cancer
1056247|NCT01768403|Hypercholesterolemia
1056248|NCT01768403|Cardiovascular disease
1056249|NCT01768403|Hypertension
1056250|NCT01768403|Coronary Heart disease
1056251|NCT01768403|Peripheral Arterial disease
1056252|NCT01768390|caries
1056253|NCT01768390|prevention
1056254|NCT01768390|orthodontics
1056255|NCT01768390|fixed appliances
1056256|NCT01768390|adolescents
1056257|NCT01768377|Awake intubation
1056258|NCT01768377|Nerve block
1056259|NCT01768377|Sedation
1056260|NCT01768377|Physician satisfaction
1056261|NCT01768351|anemia
1056262|NCT01768351|chronic kidney disease
1056263|NCT01768351|vitamin D
1056264|NCT01768351|paricalcitol
1056265|NCT01768351|hyperparathyroidism
1056266|NCT01768325|ProCore Needle
1056267|NCT01768299|abortion
1056268|NCT01768299|medical abortion
1056269|NCT01768299|mifepristone
1056270|NCT01768299|misoprostol
1056271|NCT01768286|HCV genotype 1 (GT-1)
1056272|NCT01768286|HCV
1056273|NCT01768286|Sustained Virologic Response
1056274|NCT01768286|Direct Acting Antiviral
1056275|NCT01768286|Combination Therapy
1056276|NCT01768286|GS-7977
1056277|NCT01768286|GS-5885
1056278|NCT01768286|Ribavirin
1056279|NCT01768286|Open Label
1056280|NCT01768286|Sofosbuvir
1056281|NCT01768286|Additional relevant MeSH terms:
1056282|NCT01768286|Hepatitis
1056283|NCT01768286|Hepatitis, Chronic
1056284|NCT01768286|Hepatitis C
1056285|NCT01768286|Hepatitis C, Chronic
1056286|NCT01768286|Liver Diseases
1056287|NCT01768286|Digestive System Diseases
1056288|NCT01768286|Hepatitis, Viral, Human
1056289|NCT01768286|Virus Diseases
1056290|NCT01768286|Enterovirus Infections
1056291|NCT01768286|Picornaviridae Infections
1056292|NCT01768286|RNA Virus Infections
1056293|NCT01768286|Flaviviridae Infections
1056294|NCT01768286|Antiviral Agents
1056295|NCT01768286|Anti-Infective Agents
1056296|NCT01768286|Therapeutic Uses
1056297|NCT01768286|Pharmacologic Actions
1056298|NCT01768286|Antimetabolites
1056299|NCT01768286|Molecular Mechanisms of Pharmacological Action
1056300|NCT01768273|PA-824,
1056301|NCT01768273|midazolam
1056302|NCT01768273|drug-drug interaction
1056303|NCT01768273|pharmacokinetics
1056304|NCT01768273|pretomanid
1056305|NCT01768273|CL-006
1056306|NCT01768260|visual acuity
1056307|NCT01768260|artery flow velocity
1056308|NCT01768260|Enhanced External Counterpulsation
1056309|NCT01768260|Ischemic
1056310|NCT01768260|Optic Neuropathy
1056311|NCT01768247|endometrium
1056312|NCT01768247|thickness
1056313|NCT01768247|pregnancy
1056314|NCT01768247|HCG
1056315|NCT01768247|frozen cycles
1056316|NCT01768234|cognition
1056317|NCT01768234|hydration
1056318|NCT01768234|schoolchildren
1056319|NCT01768221|Palliative Care
1056320|NCT01768221|Caregiver Outlook
1056321|NCT01768195|Lymphoma
1056322|NCT01768195|Hepatitis B Virus
1056323|NCT01768195|Therapeutic Uses
1056324|NCT01768195|Antiviral Agents
1056325|NCT01768195|rituximab
1056326|NCT01768182|folic acid; folates; Vascular Reactivity; HIV
1056327|NCT01768169|metabolic syndrome,
1056328|NCT01768169|waist, blood pressure,
1056329|NCT01768169|fasting plasma glucose,
1056330|NCT01768169|HDL cholesterol,
1056331|NCT01768169|triglycerides
1056332|NCT01768156|ovarian cancer
1056333|NCT01768156|biomarker
1056334|NCT01768156|metastatic
1056335|NCT01768143|Propofol
1056336|NCT01768143|Sedation
1056337|NCT01768143|Endoscopy
1056338|NCT01768143|nonanesthesiologist
1056339|NCT01768104|upper gastrointestinal submucosal tumors
1056340|NCT01768104|SMTs
1056341|NCT01768104|Gastrointestinal stromal tumors
1056342|NCT01768104|GISTs
1056343|NCT01768104|Leiomyoma
1056344|NCT01768104|Endoscopic submucosal tunnel dissection
1056345|NCT01768104|ESTD
1056346|NCT01768104|Submucosal tunneling endoscopic resection
1056347|NCT01768104|STER
1056348|NCT01768104|Submucosal endoscopic tumor resection
1056349|NCT01768104|SET
1056350|NCT01768091|Esophageal achalasia
1056351|NCT01768091|Peroral endoscopic myotomy
1056352|NCT01768091|POEM
1056353|NCT01768091|Pneumatic dilation
1056354|NCT01768065|NEPAP
1056355|NCT01768065|CPAP
1056356|NCT01768065|alternative
1056357|NCT01768065|OSAS
1056358|NCT01768052|MDD, major depression, treatment-resistant
1056359|NCT01768039|Multiple sclerosis
1056360|NCT01768039|Vitamin D
1056361|NCT01768039|EDSS
1056362|NCT01768039|ARR
1056363|NCT01768026|Dystrophic Epidermolysis Bullosa
1056364|NCT01768026|Type VII Collagen
1056365|NCT01768026|QOL Evaluation in Epidermolysis Bullosa
1056366|NCT01768026|Instrument for Scoring Clinical Outcomes for Research of Epidermolysis Bullosa
1056367|NCT01768026|Birmingham Epidermolysis Bullosa Severity Score
1056368|NCT01768000|Psychosis
1056369|NCT01768000|Psychosis NOS
1056370|NCT01768000|Schizophrenia
1056371|NCT01768000|Schizoaffective Disorder
1056372|NCT01768000|Bipolar Disorder
1056373|NCT01767987|Acute Coronary Syndrome
1056374|NCT01767987|ACS
1056375|NCT01767987|Percutaneous Coronary Intervention
1056376|NCT01767987|PCI
1056377|NCT01767987|Ranolazine
1056378|NCT01767987|Coronary Angiogram
1056379|NCT01767987|Cardioprotectant
1056380|NCT01767974|Non-Small Cell lung cancer
1056381|NCT01767948|Hepatic Impairment
1056382|NCT01767948|PCI 32765
1056383|NCT01767948|Metabolite PCI-45227
1056384|NCT01767948|Pharmacokinetics
1056385|NCT01767922|Super-Oxyd-Dismutase
1056386|NCT01767922|SOD
1056387|NCT01767922|melon juce
1056388|NCT01767922|perceived stress
1056389|NCT01767909|Intranasal insulin
1056390|NCT01767909|Alzheimer's disease
1056391|NCT01767909|Amnestic mild cognitive impairment
1056392|NCT01767909|Dementia
1056393|NCT01767909|Brain diseases
1056394|NCT01767909|Memory problems
1056395|NCT01767909|Mental disorders
1056396|NCT01767909|Cognitive disorders
1056397|NCT01767896|Influenza vaccine
1056398|NCT01767883|Chronic Kidney Disease
1056399|NCT01767883|CKD
1056400|NCT01767883|TRANSLATE
1056401|NCT01767883|Practice Facilitation
1056402|NCT01767883|Practice-based research
1056403|NCT01767883|CKD Guidelines
1056404|NCT01767870|advanced colorectal adenoma
1056405|NCT01767870|colonoscopy
1056406|NCT01767870|sigmoidoscopy
1056407|NCT01767870|fecal immunochemical test
1056412|NCT01767844|Rheumatoid Arthritis
1056413|NCT01767844|Arthritis
1056414|NCT01767844|Rheumatology
1056415|NCT01767844|Creatine
1056416|NCT01767831|Type 1 Diabetes Mellitus (T1DM)
1056417|NCT01767831|Continuous Glucose Monitor (CGM)
1056418|NCT01767831|Simulation-based Education
1056419|NCT01767818|Parkinson's Disease
1056420|NCT01767792|Neurofibromatosis Type 2
1056421|NCT01767792|Progressive Vestibular Schwannomas
1056422|NCT01767779|Epilepsy
1056423|NCT01767779|TSC
1056424|NCT01767779|Tuberous Sclerosis Complex
1056425|NCT01767779|Infants
1056426|NCT01767779|Seizures
1056427|NCT01767779|Biomarkers
1056428|NCT01767779|EEG
1056429|NCT01767753|Glaucoma
1056430|NCT01767753|SLT
1056431|NCT01767740|Rotator Cuff Tear
1056432|NCT01767740|Supraspinatus Tear
1056433|NCT01767727|surgical flap;
1056434|NCT01767727|dorsal branch of the digital artery
1056435|NCT01767714|hematopoietic stem cell transplantation
1056436|NCT01767701|raltegravir
1056437|NCT01767701|MS
1056438|NCT01767701|RRMS
1056439|NCT01767701|Charcot Project
1056440|NCT01767688|Diabetes Mellitus
1056441|NCT01767688|Diabetes Mellitus, Type 2
1056442|NCT01767688|Glucose Metabolism Disorders
1056443|NCT01767688|Metabolic Diseases
1056444|NCT01767688|Endocrine System Diseases
1056445|NCT01767675|Secondary Cytoreductive Surgery
1056446|NCT01767675|Carboplatin
1056447|NCT01767675|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
1056448|NCT01767675|12-275
1056449|NCT01767662|TCV
1056450|NCT01767649|Pregnancy
1056451|NCT01767649|Remodelling
1056452|NCT01767649|Extracellular matrix
1056453|NCT01767649|Biomarkers
1056454|NCT01767597|rapid test
1056455|NCT01767597|screening
1056456|NCT01767597|ELISA
1056457|NCT01767597|hepatitis B virus
1056458|NCT01767597|access to care
1056459|NCT01767584|Pharmacokinetics
1056460|NCT01767584|Bioequivalence
1056461|NCT01767584|Mexico
1056462|NCT01767584|Cephalexin
1056463|NCT01767571|Mexico
1056464|NCT01767571|Respiratory infections
1056465|NCT01767571|Bioequivalence
1056466|NCT01767571|Cepphalexin
1056471|NCT01767506|Trachoma
1056472|NCT01767506|Azithromycin
1056473|NCT01767506|Mass treatment
1056474|NCT01767493|Multiple sclerosis
1056475|NCT01767480|Intensive Robot Assisted Therapy
1056476|NCT01767480|Subacute Stroke
1056477|NCT01767480|Brain Reorganization
1056478|NCT01767480|Sensory Motor
1056479|NCT01767480|Physiological Marker
1056480|NCT01767467|Immunogenicity
1056481|NCT01767467|Safety
1056482|NCT01767467|Herpes zoster
1056483|NCT01767467|Vaccination
1056484|NCT01767467|Haematologic malignancies
1056485|NCT01767454|BRAF V600E
1056486|NCT01767454|Melanoma
1056487|NCT01767454|V600K
1056488|NCT01767454|Trametinib
1056489|NCT01767454|Dabrafenib
1056490|NCT01767454|Ipilimumab
1056491|NCT01767441|bariatric surgery
1056492|NCT01767441|gastric bypass
1056493|NCT01767441|gastric banding
1056494|NCT01767441|sleeve gastrectomy
1056495|NCT01767441|weight loss
1056496|NCT01767441|Type 2 Diabetes mellitus
1056497|NCT01767441|GLP1
1056498|NCT01767441|obesity
1056499|NCT01767441|mixed meal test
1056500|NCT01767415|brain tumor
1056501|NCT01767415|resection
1056502|NCT01767415|indigo carmine dye
1056503|NCT01767402|Safety
1056504|NCT01767402|Pneumococcal Infections
1056505|NCT01767402|Immunogenicity
1056506|NCT01767402|PhtD vaccine
1056507|NCT01767402|Healthy adults
1056508|NCT01767402|Reactogenicity
1056509|NCT01767389|utilization
1056510|NCT01767389|acute pancreatitis
1056511|NCT01767389|Exenatide
1056512|NCT01767389|DPP-4 inhibitors
1056513|NCT01767389|liraglutide
1056514|NCT01767389|GLP-1 receptor agonist
1056515|NCT01767389|adherence
1056516|NCT01767376|Young adults
1056517|NCT01767376|Adolescents
1056518|NCT01767376|Reactogenicity
1056519|NCT01767376|Diphtheria
1056520|NCT01767376|pertussis
1056521|NCT01767376|Immunogenicity
1056522|NCT01767376|Tetanus
1056523|NCT01767376|Meningococcal vaccines
1056524|NCT01767376|Safety
1056525|NCT01767376|Neisseria meningitidis
1056526|NCT01767376|Healthy
1056527|NCT01767363|5-alpha reductase inhibitor
1056528|NCT01767363|benign prostatic hyperplasia treatment
1056529|NCT01767363|Prostate cancer mortality
1056530|NCT01767350|Pediatric transplantation
1056531|NCT01767350|Pharmacogenetics
1056532|NCT01767350|Pharmacokinetics
1056533|NCT01767350|Calcineurin inhibitors
1056534|NCT01767350|CYP3A
1056535|NCT01767350|Pgp
1056536|NCT01767337|microneedle-based delivery
1056537|NCT01767337|hollow microneedle
1056538|NCT01767337|intracutaneous
1056539|NCT01767337|drug delivery
1056540|NCT01767324|microneedle-based array
1056541|NCT01767324|hollow microneedle
1056542|NCT01767324|intracutaneous
1056543|NCT01767324|drug delivery
1056544|NCT01767324|vaccine delivery
1056545|NCT01767311|Alzheimer's Disease
1056546|NCT01767311|BAN2401
1056547|NCT01767298|Fixed dose combination
1056548|NCT01767298|Pharmacokinetics
1056549|NCT01767298|Valsartan
1056550|NCT01767298|Hydrochlorothiazide
1056551|NCT01767285|Etonogestrel Implant
1056552|NCT01767285|Implanon
1056553|NCT01767285|Nexplanon
1056554|NCT01767285|Long Acting Reversible Contraception
1056555|NCT01767272|Fexofenadine
1056556|NCT01767272|Pharmacokinetics
1056557|NCT01767272|Bioavailability
1056558|NCT01767272|Linearity
1056559|NCT01767272|HPLC
1056560|NCT01767272|Dose proportionality of fexofenadine in Egyptian volunteers
1056561|NCT01767259|Fixed dose combination
1056562|NCT01767259|Pharmacokinetics
1056563|NCT01767259|Valsartan
1056564|NCT01767259|Hydrochlorothiazide
1056565|NCT01767233|Acute necrotizing pancreatitis
1056566|NCT01767233|ERCP
1056567|NCT01767233|Pancreatic stenting
1056568|NCT01767220|ventricular tachycardia
1056569|NCT01767220|endocardial ablation
1056570|NCT01767220|epicardial ablation
1056571|NCT01767181|Light therapy
1056572|NCT01767181|physical exercise
1056573|NCT01767181|night shift workers
1056574|NCT01767181|genetic markers
1056575|NCT01767181|PBMCs
1056579|NCT01767129|levodopa
1056580|NCT01767129|dyskinesia
1056581|NCT01767129|parkinson's disease
1056582|NCT01767129|AVP-923
1056583|NCT01767129|dextromethorphan
1056584|NCT01767129|quinidine
1056585|NCT01767116|Interferon-Free
1056586|NCT01767116|Hepatitis C Genotype 1b
1056587|NCT01767116|Chronic Hepatitis C
1056588|NCT01767116|Hepatitis C Virus
1056589|NCT01767116|Hepatitis C
1056590|NCT01767116|Treatment-Naive
1056591|NCT01767116|Paritaprevir
1056592|NCT01767116|Ombitasvir
1056593|NCT01767116|Dasabuvir
1056594|NCT01767116|Viekira PAK
1056595|NCT01767116|Ribavirin
1056596|NCT01767103|Hepatic Impairment
1056597|NCT01767103|Liver Impairment
1056598|NCT01767103|Liver Disease
1056599|NCT01767103|Ferriprox®
1056600|NCT01767103|LI
1056601|NCT01767103|DFP
1056602|NCT01767103|Deferiprone
1056603|NCT01767090|Endometriosis
1056604|NCT01767090|ASP1707
1056605|NCT01767090|Pelvic pain
1056606|NCT01767090|Double-blind
1056607|NCT01767090|Placebo-controlled
1056608|NCT01767090|Phase 2
1056609|NCT01767077|Saturated fat
1056610|NCT01767077|Dairy products
1056611|NCT01767077|Milk fat globule membrane
1056612|NCT01767077|Cholesterol
1056613|NCT01767077|Butter
1056614|NCT01767077|Cream
1056615|NCT01767064|ARIs, antibiotics, public commitment, quality improvement
1056616|NCT01767051|PCOS
1056617|NCT01767051|Children
1056618|NCT01767051|Cardiovascular
1056619|NCT01767051|Follow-up
1056620|NCT01767025|Influence
1056621|NCT01767025|oxytocin
1056622|NCT01767025|automatic imitation
1056623|NCT01767025|behaviour
1056624|NCT01767025|volunteers
1056625|NCT01766999|pulse oximetry
1056626|NCT01766999|tumescent anesthesia
1056627|NCT01766960|Bile acids
1056628|NCT01766960|Pharmacokinetics
1056629|NCT01766947|Glaucoma
1056630|NCT01766947|Deep sclerectomy
1056631|NCT01766934|Peripheral blood progenitor cell mobilization
1056632|NCT01766934|allogenic hematopoetic stem cell transplantation
1056633|NCT01766934|recombinant human granulocyte colony stimulating factor
1056634|NCT01766934|filgrastim
1056635|NCT01766921|Influenza, Pandemic, H5N1, Elderly adults
1056636|NCT01766908|Timing of Umbilical Cord clamping
1056637|NCT01766908|Cord Clamp 20 seconds
1056638|NCT01766908|Cord Clamp 40 seconds
1056639|NCT01766908|Cord Clamp 60 seconds
1056640|NCT01766895|uremia
1056641|NCT01766895|HBV
1056642|NCT01766895|HCV
1056643|NCT01766895|seroclearance
1056644|NCT01766882|Hemodialysis
1056645|NCT01766882|Blood Pressure
1056646|NCT01766882|Hydration Status
1056647|NCT01766882|Low-sodium diet
1056648|NCT01766869|Prostate Cancer
1056649|NCT01766869|MRI/MRS
1056650|NCT01766856|perforation
1056651|NCT01766856|tympanoplasty
1056652|NCT01766856|myringoplasty
1056653|NCT01766856|Eustachian tube function
1056654|NCT01766856|tympanostomy tube
1056655|NCT01766817|IPF
1056656|NCT01766804|Acute Lymphoblastic Leukemia
1056657|NCT01766804|Bovine Colostrum
1056658|NCT01766804|Inflammation
1056659|NCT01766804|Infection
1056660|NCT01766804|Toxicity
1056661|NCT01766791|resistance exercise
1056662|NCT01766791|muscle mass
1056663|NCT01766791|abdominal fat
1056664|NCT01766791|strength
1056665|NCT01766791|Coronary Heart Disease (CHD)-risk
1056666|NCT01766791|myocardial mass
1056667|NCT01766778|type-2 diabetes mellitus, inadequately controlled Metformin
1056668|NCT01766739|GL-ONC1
1056669|NCT01766739|pleural effusion
1056670|NCT01766739|12-169
1056671|NCT01766726|HIV
1056672|NCT01766726|Atherosclerosis
1056673|NCT01766700|Obesity, weight loss, weight maintenance
1056674|NCT01766687|Chronic Kidney Disease
1056675|NCT01766687|estimated glomerular filtration rate
1056676|NCT01766687|water intake
1056677|NCT01766687|fluid intake
1056678|NCT01766687|renal decline
1056679|NCT01766674|Kyphosis
1056680|NCT01766648|Distal
1056681|NCT01766648|Femur
1056682|NCT01766648|Locking
1056683|NCT01766648|Screw
1056684|NCT01766648|Fracture
1056685|NCT01766648|Healing
1056686|NCT01766622|Apoptosis
1056687|NCT01766622|Pro-Apoptotic Effects
1056688|NCT01766622|PET Imaging
1056689|NCT01766622|TL32711
1056690|NCT01766622|Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer
1056691|NCT01766609|Vitiligo; Intralesional; Triamcinolone acetonide
1056692|NCT01766596|Ophthalmology
1056693|NCT01766596|Age-related ocular pathologies
1056694|NCT01766583|Open label, 3 + 3 dose escalation study followed by an expansion phase.
1056695|NCT01766570|insulin sensitivity,
1056696|NCT01766570|glucose tolerance,
1056697|NCT01766570|inflammatory markers,
1056698|NCT01766570|lipid profile,
1056699|NCT01766570|oxidative stress,
1056700|NCT01766570|pancreatic β-cell function
1056701|NCT01766557|Polycystic ovarian syndrome, sex hormones, ovarian function, women, fish protein, insulin sensitivity, glucose tolerance, β-cell function, inflammation
1056702|NCT01766544|asthma
1056703|NCT01766544|COPD
1056704|NCT01766544|guidelines
1056705|NCT01766544|knowledge transfer
1056706|NCT01766544|medical education
1056707|NCT01766544|care gaps
1056708|NCT01766531|Bioelectrical impedance
1056709|NCT01766531|Nutrition
1056710|NCT01766531|Phase angle
1056711|NCT01766531|ICU patients
1056712|NCT01766518|liver transplantation
1056713|NCT01766518|LT
1056714|NCT01766518|Mycophenolate mofetil
1056715|NCT01766518|MMF
1056716|NCT01766505|hypertension, heart failure, candesartan, losartan
1056717|NCT01766492|prostate cancer
1056718|NCT01766492|CyberKnife
1056719|NCT01766479|Colorectal cancer
1056720|NCT01766479|colorectal neoplasia
1056721|NCT01766479|CT colonography
1056722|NCT01766479|advanced neoplasia
1056723|NCT01766479|colonoscopy
1056724|NCT01766479|family history
1056725|NCT01766453|South Asian
1056726|NCT01766453|Cardiovascular
1056727|NCT01766453|Exercise
1056728|NCT01766453|Obesity
1056729|NCT01766453|Visceral Adipose Tissue
1056730|NCT01766401|Generalized Anxiety Disorder
1056731|NCT01766401|GAD
1056732|NCT01766375|idarubicin
1056733|NCT01766375|busulfan
1056734|NCT01766375|cyclophosphamide
1056735|NCT01766375|pretreatment
1056736|NCT01766375|high-risk acute myeloid leukemia patient
1056737|NCT01766349|Esophageal cancer
1056738|NCT01766349|Respiratory muscle strength
1056739|NCT01766349|Pulmonary function testing
1056740|NCT01766349|Functional exercise capacity
1056741|NCT01766336|Agitation
1056742|NCT01766336|Aggression
1056743|NCT01766336|AD patients
1056744|NCT01766323|Morphine
1056745|NCT01766323|Palliation
1056746|NCT01766323|Cancer
1056747|NCT01766323|Hospice
1056748|NCT01766323|Sleepiness
1056749|NCT01766323|Modafinil
1056750|NCT01766310|Folic acid
1056751|NCT01766310|Folate
1056752|NCT01766310|Homocysteine
1056753|NCT01766310|Obese
1056754|NCT01766310|Children
1056758|NCT01766284|Human Papillomavirus
1056759|NCT01766284|Optical Coherence Tomography
1056760|NCT01766284|Imaging Systems
1056761|NCT01766284|Cervical intraepithelial neoplasia
1056762|NCT01766284|Cervical Cancer
1056763|NCT01766284|Cervical Dysplasia
1056764|NCT01766271|Coronary heart disease
1056765|NCT01766271|cardiovascular disease
1056766|NCT01766271|risk
1056767|NCT01766258|Parkinson's Disease
1056768|NCT01766258|Motor-fluctuation
1056769|NCT01766258|Wearing-off
1056770|NCT01766245|mm
1056771|NCT01766206|conjugate vaccine
1056772|NCT01766206|phase IV clinical trial
1056773|NCT01766206|Neisseria meningitidis
1056774|NCT01766193|Delivery, obstetric
1056775|NCT01766193|Obstetric Surgical Procedures
1056776|NCT01766193|Vacuum Extraction, Obstetrical
1056777|NCT01766193|Cesarean Section
1056778|NCT01766193|Obstetrical Forceps
1056779|NCT01766193|Epidemiology
1056780|NCT01766193|Norway
1056781|NCT01766180|Memory
1056782|NCT01766180|Fruitflow
1056783|NCT01766180|Resveratrol (resVida)
1056784|NCT01766180|Cerebral blood flow
1056785|NCT01766180|Cardiopulmonary exercise test
1056786|NCT01766180|Maximal VO2
1056787|NCT01766167|Genotype 2
1056788|NCT01766154|tirofiban
1056789|NCT01766154|pharmacokinetic
1056790|NCT01766154|renal insufficiency
1056791|NCT01766154|Phase 1
1056792|NCT01766154|pharmacodynamic
1056793|NCT01766141|Spinal manipulation
1056794|NCT01766141|Tumor necrosis factor
1056795|NCT01766141|Interleukin 1
1056796|NCT01766141|Interleukin 10
1056797|NCT01766141|Inflammatory cytokines
1056798|NCT01766128|Parkinson disease
1056799|NCT01766128|Early stage
1056800|NCT01766128|Zonisamide
1056801|NCT01766128|UPDRS
1056802|NCT01766115|HCV
1056803|NCT01766115|needlestick
1056804|NCT01766115|occupational
1056805|NCT01766115|transmission
1056806|NCT01766115|health care worker
1056807|NCT01766115|telaprevir
1056808|NCT01766102|Mammography
1056809|NCT01766089|Caesarean delivery
1056810|NCT01766089|severe pre-eclampsia
1056811|NCT01766089|remifentanil
1056812|NCT01766089|dexmedetomidine
1056813|NCT01766089|cardiovascular response
1056814|NCT01766076|immune activation
1056815|NCT01766076|antiretroviral therapy
1056816|NCT01766076|atorvastatin
1056817|NCT01766076|immune exhaustion
1056818|NCT01766076|adults
1056819|NCT01766076|Africa
1056820|NCT01766063|Multiple Sclerosis
1056821|NCT01766063|Sleep
1056822|NCT01766063|Quality of life
1056823|NCT01766063|Observational study
1056824|NCT01766037|obesity
1056825|NCT01766037|obese
1056826|NCT01766037|weight loss
1056827|NCT01766024|interferon beta-1a
1056828|NCT01766024|pharmacokinetics
1056829|NCT01766024|pharmacodynamics
1056830|NCT01766024|volunteers
1056831|NCT01765998|Crohn's disease, endothelial progenitor cells, probiotic
1056832|NCT01765985|palmoplantar
1056833|NCT01765959|Insomnia
1056834|NCT01765959|Auricular acupuncture
1056835|NCT01765959|CBT
1056836|NCT01765946|Insulin resistance
1056837|NCT01765946|Prediabetes
1056838|NCT01765946|Longevity genes
1056839|NCT01765946|Inflammation
1056840|NCT01765946|Metformin
1056841|NCT01765933|1,3-dimethylamylamine
1056842|NCT01765894|glucose homeostasis
1056843|NCT01765894|endogenous glucose production
1056844|NCT01765894|moderate exercise
1056845|NCT01765894|type 2 diabetes
1056846|NCT01765894|metformin
1056847|NCT01765881|Induction of labor
1056848|NCT01765881|cervical ripening
1056849|NCT01765881|misoprostol,
1056850|NCT01765881|prostaglandin
1056851|NCT01765881|cost-effectiveness
1056852|NCT01765868|Betrixaban
1056853|NCT01765868|Healthy
1056854|NCT01765868|Bioavailability
1056855|NCT01765855|Betrixaban
1056856|NCT01765855|Healthy
1056857|NCT01765855|Mass Balance
1056858|NCT01765842|Lupus Nephritis
1056859|NCT01765842|remission
1056860|NCT01765842|immunosuppressive treatment
1056861|NCT01765829|Non Affective Psychosis
1056862|NCT01765829|First episode
1056863|NCT01765829|Discontinuation scheme
1056864|NCT01765816|Exercise
1056865|NCT01765816|Elderly
1056866|NCT01765816|Blood volume
1056867|NCT01765816|Hemoglobin
1056868|NCT01765803|Mellaril
1056869|NCT01765803|Thioridazine
1056870|NCT01765803|CD34+
1056871|NCT01765803|Stem cells
1056872|NCT01765803|Progenitor cells
1056873|NCT01765803|Peripheral blood
1056874|NCT01765803|mobilization
1056875|NCT01765803|circulation
1056876|NCT01765777|Low back pain
1056877|NCT01765777|Lower back pain
1056878|NCT01765777|Chronic back pain
1056879|NCT01765751|Cervical pain
1056880|NCT01765751|Neck pain
1056881|NCT01765751|Arm pain
1056882|NCT01765738|PICC
1056883|NCT01765725|Chronic Fatigue Syndrome
1056884|NCT01765725|Coping
1056885|NCT01765725|Patient education
1056886|NCT01765712|PRP
1056887|NCT01765712|BPTB
1056888|NCT01765712|VAS
1056889|NCT01765712|Anterior Knee Pain
1056890|NCT01765673|Swallowing
1056891|NCT01765673|Dysphagia
1056892|NCT01765673|Stroke
1056893|NCT01765673|Sensory stimulation
1056894|NCT01765673|Home based therapy
1056895|NCT01765660|Hematopoietic Stem Cell Transplantation
1056896|NCT01765660|Mesenchymal Stem Cells
1056897|NCT01765660|Chronic Graft-versus-host disease
1056898|NCT01765647|Celiac disease
1056899|NCT01765647|AGY
1057154|NCT01764373|Diabetes
1056900|NCT01765634|Hematopoietic Stem Cell Transplantation
1056901|NCT01765634|Mesenchymal Stem Cells
1056902|NCT01765634|Acute Graft-versus-host disease
1056903|NCT01765621|health care expenditure
1056904|NCT01765621|drug drug interactions
1056905|NCT01765621|electronic decision support systems
1056906|NCT01765621|pharmacogenetics
1056907|NCT01765621|Potential Reduction
1056908|NCT01765608|Zonisamide
1056909|NCT01765608|Zonegran
1056910|NCT01765608|Obstructive Sleep apnea
1056911|NCT01765608|Apnea
1056912|NCT01765608|Respiration Disorders
1056913|NCT01765608|Sleep Disorders
1056914|NCT01765608|Obesity
1056915|NCT01765608|Anti-Obesity Agents
1056916|NCT01765608|Carbonic Anhydrase
1056917|NCT01765608|Carbonic Anhydrase Inhibitors
1056918|NCT01765608|Enzyme Inhibitors
1056919|NCT01765608|Sulfonamides
1056920|NCT01765608|Therapeutic Uses
1056921|NCT01765608|Pharmacologic Actions
1056922|NCT01765595|health care expenditure
1056923|NCT01765595|drug drug interactions
1056924|NCT01765595|electronic decision support systems
1056925|NCT01765595|Potential reduction
1056926|NCT01765530|Medical Devices
1056927|NCT01765530|Ventilator-Associated Pneumonia (VAP)
1056928|NCT01765530|Ventilator-Associated Events (VAE)
1056929|NCT01765530|Endotracheal Tube
1056930|NCT01765530|Microbial Diversity
1056931|NCT01765530|Anti-Resistance
1056932|NCT01765530|Computed Tomography (CT)
1056933|NCT01765517|Diabetes Mellitus
1056934|NCT01765504|Cardiac surgery; near infrared spectroscopy
1056935|NCT01765491|colonoscopy
1056936|NCT01765491|bowel preparation
1056937|NCT01765491|polyethylene glycol
1056938|NCT01765478|Rheumatoid Arthritis
1056939|NCT01765465|postcholecystectomy syndrome
1056940|NCT01765465|laparoscopic cholecystectomy
1056941|NCT01765465|Rowachol
1056942|NCT01765439|bile acids
1056943|NCT01765439|metabolism
1056944|NCT01765439|probiotics
1056945|NCT01765426|Prophylactic vaccination
1056946|NCT01765413|To identify
1056947|NCT01765413|biomarkers
1056948|NCT01765413|of vaccine safety
1056949|NCT01765413|Volunteers
1056950|NCT01765400|Heart failure
1056951|NCT01765400|Antiplatelet therapy
1056952|NCT01765400|Platelet aggregation
1056953|NCT01765400|Clopidogrel
1056954|NCT01765400|Prasugrel
1056955|NCT01765387|Spatherpy
1056956|NCT01765387|Aerobic exercise
1056957|NCT01765374|rituximab
1056958|NCT01765374|sonography
1056959|NCT01765374|clinical response
1056960|NCT01765348|language impairment
1056961|NCT01765348|language disorders
1056962|NCT01765348|syntax treatment
1056963|NCT01765348|narrative-based treatment
1056964|NCT01765335|heart failure, BNP, NICaS system, readmition
1056965|NCT01765309|Tissue expanders
1056966|NCT01765309|Botulinum toxin
1056967|NCT01765309|Botox
1056968|NCT01765283|CN,
1056969|NCT01765283|UCD
1056970|NCT01765270|Diabetes
1056971|NCT01765270|Diabetes Mellitus
1056972|NCT01765270|Type 2 Diabetes
1056973|NCT01765270|Cardiovascular Disease
1056974|NCT01765270|Coronary Artery Bypass Surgery
1056975|NCT01765257|Drug-naïve patients with Parkinson's disease
1056976|NCT01765257|Apathy
1056977|NCT01765257|Rasagiline
1056978|NCT01765244|Corneal trophic ulcers
1056979|NCT01765231|Lymphoma
1056980|NCT01765231|Hepatitis B virus
1056981|NCT01765231|Therapeutic Uses
1056982|NCT01765231|Antiviral Agents
1056988|NCT01765205|congenital cardiovascular malformation
1056989|NCT01765205|newborn
1056990|NCT01765192|Drug therapy
1056991|NCT01765179|testosterone
1056992|NCT01765179|male hypogonadism
1056993|NCT01765179|low testosterone
1056994|NCT01765166|Social Skill Training
1056995|NCT01765166|Social Interaction
1056996|NCT01765166|Peer relations
1056997|NCT01765153|physical therapy
1056998|NCT01765153|rehabilitation
1056999|NCT01765153|neuroplasticity
1057000|NCT01765140|3,4 diaminopyridine (DAP)
1057001|NCT01765101|knee osteoarthritis
1057002|NCT01765101|therapeutic effect
1057003|NCT01765101|insole
1057004|NCT01765088|High-grade glioma
1057005|NCT01765088|chemotherapy
1057006|NCT01765088|Temozolomide
1057007|NCT01765088|Interferon-alpha
1057008|NCT01765075|Electrophysiological mapping
1057009|NCT01765075|Multi-electrode catheter
1057010|NCT01765062|Rapid maxillary expansion
1057011|NCT01765062|Cross bite
1057012|NCT01765062|Haas appliance
1057013|NCT01765062|Lateral cephalograms
1057014|NCT01765049|breast density change
1057015|NCT01765049|endocrine therapy response
1057016|NCT01765049|aromatase inhibitor
1057017|NCT01765036|contrast-enhanced endoscopic ultrasound
1057018|NCT01765036|pancreatic adenocarcinoma
1057019|NCT01765010|Vitamin D
1057020|NCT01765010|Serum sclerostin
1057021|NCT01765010|Serum dickkopf1
1057022|NCT01764984|total knee arthroplasty
1057023|NCT01764984|trabecular metal
1057024|NCT01764984|bone mineral density
1057025|NCT01764971|Chronic ITP, Cerebral dysfunction
1057026|NCT01764958|mother-infant interaction
1057027|NCT01764958|general movements
1057028|NCT01764958|preterm infants
1057029|NCT01764893|Overactive Bladder
1057030|NCT01764880|Heparanase inhibitor
1057031|NCT01764880|Multiple myeloma
1057032|NCT01764867|major depressive disorder
1057033|NCT01764867|algorithm guided treatment
1057034|NCT01764867|treatment as usual
1057035|NCT01764867|escitalopram
1057036|NCT01764867|mirtazapine
1057037|NCT01764867|transcranial magnetic stimulation (rTMS)
1057038|NCT01764867|modified electroconvulsive therapy (mECT)
1057039|NCT01764867|remission
1057040|NCT01764867|relapse
1057041|NCT01764867|quality of life
1057042|NCT01764854|Hemodialysis
1057043|NCT01764841|Ciprofloxacin
1057044|NCT01764841|Dry Powder for Inhalation
1057045|NCT01764841|Exacerbation
1057046|NCT01764841|Bronchiectasis
1057047|NCT01764828|Phase I
1057048|NCT01764828|Pharmacokinetics
1057049|NCT01764828|Safety measurements
1057050|NCT01764802|Psychosexual Intervention
1057051|NCT01764802|Cancer
1057052|NCT01764802|Gynecologic Cancer
1057053|NCT01764802|Breast Cancer
1057054|NCT01764789|psychological intervention
1057055|NCT01764789|breast cancer
1057056|NCT01764789|gynecologic cancer
1057057|NCT01764776|LDE225
1057058|NCT01764776|Pharmacokinetics
1057059|NCT01764776|PK
1057060|NCT01764776|Postmenopausal women
1057061|NCT01764776|normal hepatic function
1057062|NCT01764776|mild hepatic impairment
1057063|NCT01764776|moderate hepatic impairment
1057064|NCT01764776|severe hepatic impairment
1057065|NCT01764750|Intrasite
1057066|NCT01764750|Antibiotic
1057067|NCT01764750|Vancomycin
1057068|NCT01764750|Infection
1057069|NCT01764750|Pharmacokinetics
1057070|NCT01764737|VX15/2503
1057071|NCT01764737|Semaphorin 4D
1057072|NCT01764737|SEMA4D
1057073|NCT01764737|CD100
1057074|NCT01764737|safety
1057075|NCT01764737|tolerability
1057076|NCT01764737|pharmacokinetics
1057077|NCT01764737|immunogenicity
1057078|NCT01764737|multiple sclerosis
1057079|NCT01764737|monoclonal antibody
1057080|NCT01764724|Attitudes and understanding of sodium claims
1057081|NCT01764724|General canadian population
1057082|NCT01764711|POTS
1057083|NCT01764698|anxiety disorders
1057084|NCT01764698|substance use disorders
1057085|NCT01764698|treatment effectiveness
1057086|NCT01764698|cognitive behavioral therapy
1057087|NCT01764672|Attention Deficit Hyperactivity Disorder
1057088|NCT01764672|Healthy Adults
1057089|NCT01764672|Methylphenidate
1057090|NCT01764672|Functional connectivity
1057091|NCT01764672|Functional Magnetic Resonance Imaging
1057092|NCT01764659|4D-CT
1057093|NCT01764659|Contrast Enhanced CT
1057094|NCT01764659|Radiotherapy Simulation
1057095|NCT01764646|Prostate cancer
1057096|NCT01764646|Radiation therapy
1057102|NCT01764620|shoulder
1057103|NCT01764620|muscle fatigue
1057104|NCT01764620|kinematics
1057105|NCT01764620|athletes
1057106|NCT01764607|Squamous
1057107|NCT01764607|Renal
1057108|NCT01764607|Transplant
1057109|NCT01764594|Lupus
1057110|NCT01764594|SLE
1057111|NCT01764581|immune monitoring
1057112|NCT01764581|immune cell function ImmuKnow
1057113|NCT01764581|randomized controlled trial
1057114|NCT01764581|immunosuppression management
1057115|NCT01764581|infection
1057116|NCT01764581|rejection
1057117|NCT01764581|liver transplantation
1057118|NCT01764581|Cylex
1057119|NCT01764568|Metacognitive training
1057120|NCT01764568|Cognitive behavioral therapy
1057121|NCT01764568|Clinical trial
1057122|NCT01764568|Group intervention
1057123|NCT01764568|Group therapy
1057124|NCT01764568|Schizophrenia
1057125|NCT01764568|Psychosis
1057126|NCT01764568|Cognitive remediation
1057127|NCT01764542|Ulcerative colitis
1057128|NCT01764542|dysplasia
1057129|NCT01764542|risk factor
1057130|NCT01764542|surgery
1057131|NCT01764516|zinc
1057132|NCT01764516|selenium
1057133|NCT01764516|serum
1057134|NCT01764516|epilepsy
1057135|NCT01764516|antioxidants
1057136|NCT01764503|ampullary tumors
1057137|NCT01764503|endoscopic treatment
1057138|NCT01764490|Bloodstream infections caused by multidrug-resistant Enterobacteriaceae, extended-spectrum β-lactamase-producers, carbapenemase-producing organisms
1057139|NCT01764464|post laminectomy pain syndrome, failed back surgery syndrome
1057140|NCT01764451|Hispanic
1057141|NCT01764425|P7435
1057142|NCT01764425|Healthy,overweight and or obese subjects
1057143|NCT01764425|Single ascending dose
1057144|NCT01764425|Multiple ascending dose
1057145|NCT01764425|Pharmacokinetics
1057146|NCT01764412|Healthy women
1057147|NCT01764412|Menstrual cycle
1057148|NCT01764412|Hepcidin
1057149|NCT01764412|Seric iron
1057150|NCT01764399|cardiovascular risk factors
1057151|NCT01764386|obesity, overweight
1057152|NCT01764373|Pain
1057153|NCT01764373|Fitness
1057155|NCT01764373|Aerobic Exercise
1057156|NCT01764334|NonST elevation myocardial infarction (NSTEMI)
1057157|NCT01764334|Fractional flow reserve (FFR)
1057158|NCT01764334|Coronary angiogram
1057159|NCT01764334|Diagnosis
1057160|NCT01764334|Coronary revascularization
1057161|NCT01764334|Prognosis
1057162|NCT01764334|Health economics
1057163|NCT01764321|Certolizumab Pegol
1057164|NCT01764321|Cimzia®
1057165|NCT01764321|TNF inhibitor
1057166|NCT01764321|DMARD
1057167|NCT01764321|Rheumatoid Arthritis
1057168|NCT01764308|acne; omega-3; isotretinoin; placebo
1057169|NCT01764282|HIV
1057170|NCT01764282|serodiscordant couples HIV sero-conversion
1057171|NCT01764282|anti-retroviral therapy
1057172|NCT01764282|intervention
1057173|NCT01764256|rotavirus
1057174|NCT01764256|vaccine
1057175|NCT01764243|Alzheimer's Disease
1057176|NCT01764243|Nicotinic Acetylcholine Receptor Agonist
1057177|NCT01764243|Cognitive function
1057178|NCT01764243|Dementia
1057179|NCT01764243|Central Nervous System Agents
1057180|NCT01764230|Hodgkin lymphoma
1057181|NCT01764230|Hodgkin disease
1057182|NCT01764217|Cervix Cancer
1057183|NCT01764217|SUV
1057184|NCT01764217|Radiotherapy
1057185|NCT01764217|Outcome Prediction
1057186|NCT01764217|Imaging
1057187|NCT01764217|PET
1057188|NCT01764178|Pitavastatin
1057189|NCT01764178|Valsartan
1057190|NCT01764165|COPD
1057191|NCT01764165|Sleep
1057192|NCT01764165|Supplemental oxygen
1057193|NCT01764165|Breathing mechanics
1057194|NCT01764165|nasal insufflation
1057195|NCT01764152|Prevention,
1057196|NCT01764152|influenza,
1057197|NCT01764152|adults hospitalized,
1057198|NCT01764152|vaccines,
1057199|NCT01764152|Effectiveness
1057200|NCT01764139|Minimal knee changes
1057201|NCT01764126|Safety
1057202|NCT01764126|immunogenicity
1057203|NCT01764126|pneumococcal
1057204|NCT01764126|protein
1057205|NCT01764126|vaccine
1057206|NCT01764113|Obesity
1057207|NCT01764113|Adolescence
1057208|NCT01764113|Mindful Eating
1057209|NCT01764087|Stomach Neoplasms
1057210|NCT01764087|Breast Neoplasms
1057211|NCT01764087|Carcinoma
1057212|NCT01764087|Neoplasms
1057213|NCT01764087|Paclitaxel
1057214|NCT01764087|Tubulin Modulators
1057215|NCT01764087|Antimitotic Agents
1057216|NCT01764087|Protein Kinase Inhibitors
1057217|NCT01764087|Enzyme Inhibitors
1057218|NCT01764087|Pharmacologic Actions
1057219|NCT01764074|Bipolar Disorder
1057220|NCT01764074|Sleep Intervention
1057221|NCT01764074|Suicide
1057222|NCT01764074|Cognitive Behavioral Therapy
1057223|NCT01764074|Sleep Quality
1057224|NCT01764061|Red Cells
1057225|NCT01764061|Blood donors
1057226|NCT01764048|pain management
1057227|NCT01764048|cesarean section
1057228|NCT01764035|Psychotherapy
1057229|NCT01764035|Bipolar Disorder
1057230|NCT01764035|Sleep Problems
1057231|NCT01764035|Insomnia
1057232|NCT01764035|Hypersomnia
1057233|NCT01764035|Mindfulness
1057234|NCT01764035|Meditation
1057235|NCT01764035|Sleep Disturbance
1057236|NCT01764022|breast cancer
1057237|NCT01764022|trastuzumab
1057238|NCT01764009|Advanced Melanoma
1057239|NCT01764009|Metastatic Melanoma
1057240|NCT01764009|Melanoma Stage III and IV
1057241|NCT01763996|Drug therapy
1057242|NCT01763983|Multiple Sclerosis
1057243|NCT01763983|Stress, Psychological
1057244|NCT01763983|Psychological Stress
1057245|NCT01763983|Emotional Stress
1057246|NCT01763983|Cognitive Deficits
1057247|NCT01763983|Cognitive Dysfunction
1057248|NCT01763970|Stereotactic
1057249|NCT01763970|Radiotherapy
1057250|NCT01763970|Hypofractionated
1057251|NCT01763944|diet
1057252|NCT01763944|prostate cancer
1057253|NCT01763944|carbohydrate
1057254|NCT01763944|lifestyle
1057255|NCT01763931|Digoxin
1057256|NCT01763918|High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
1057257|NCT01763905|High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
1057258|NCT01763892|Pediatric
1057259|NCT01763892|Traumatic Brain Injury
1057260|NCT01763892|TBI
1057261|NCT01763892|Apolipoprotein E
1057262|NCT01763892|apo-E
1057263|NCT01763892|Vasospasm
1057264|NCT01763892|Genetics
1057265|NCT01763892|Physiologic Mechanisms
1057266|NCT01763892|Neurocognitive Outcomes
1057267|NCT01763892|Endothelin 1
1057268|NCT01763879|Thoracic surgery
1057269|NCT01763879|one lung ventilation
1057270|NCT01763879|pressure-controlled ventilation
1057271|NCT01763879|volume-controlled ventilation
1057272|NCT01763879|right ventricular function
1057273|NCT01763866|High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
1057274|NCT01763853|Acute respiratory distress syndrome (ARDS)
1057275|NCT01763853|Pulmonary edema
1057276|NCT01763853|Alveolar fluid clearance
1057277|NCT01763853|Alveolar epithelial dysfunction
1057278|NCT01763853|Receptor for advanced glycation end-products (RAGE)
1057279|NCT01763853|Fluid resuscitation therapy
1057280|NCT01763853|Hypovolemia
1057281|NCT01763853|Crystalloid
1057282|NCT01763853|Hydroxyethyl Starch
1057283|NCT01763853|Intensive care unit
1057284|NCT01763840|Pediatric Abdominal Trauma Ultrasound Contrast
1057285|NCT01763827|High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
1057286|NCT01763801|chemo port
1057287|NCT01763801|intravenous electrocardiographic guidance
1057288|NCT01763801|P maximal wave
1057289|NCT01763801|P submaximal wave
1057290|NCT01763801|catheter tip
1057291|NCT01763775|weight
1057292|NCT01763775|total body water
1057293|NCT01763775|body fat
1057294|NCT01763775|muscle mass
1057295|NCT01763775|bone mass
1057296|NCT01763762|Electrical pudendal nerve stimulation
1057297|NCT01763762|Pelvic floor muscle training
1057298|NCT01763762|Transvaginal electrical stimulation
1057299|NCT01763762|Stress urinary incontinence
1057300|NCT01763762|Comparative study
1057301|NCT01763723|Intense pulsed light,
1057302|NCT01763723|UV-exposure,
1057303|NCT01763723|skin type,
1057304|NCT01763723|safety,
1057305|NCT01763723|pigment,
1057306|NCT01763723|home-use
1057307|NCT01763723|subjects
1057308|NCT01763710|Breast cancer
1057309|NCT01763710|Neurotoxicity
1057310|NCT01763697|Taste acuity
1057311|NCT01763697|Feeding behavior
1057312|NCT01763697|opioid
1057313|NCT01763697|Quantitative assessment
1057314|NCT01763684|Osteoarthritis
1057315|NCT01763684|Osteoarthritis, Knee
1057316|NCT01763684|Osteonecrosis
1057317|NCT01763684|Arthritis
1057318|NCT01763684|Knee Arthritis
1057319|NCT01763684|Knee Replacement
1057320|NCT01763671|Lung cancer
1057321|NCT01763671|Paclitaxel bevacizumab
1057322|NCT01763658|ITP, antioxidant therapy, oxidant status
1057323|NCT01763645|NSCLC
1057324|NCT01763645|bevacizumab
1057325|NCT01763645|pharmacokinetics
1057326|NCT01763632|Hyperbilirubinemia
1057327|NCT01763632|Neonatal
1057328|NCT01763632|Transcutaneous Bilirubin
1057329|NCT01763619|Cervical DDD
1057330|NCT01763619|DDD
1057331|NCT01763619|degenerative disc disease
1057332|NCT01763619|C3-C7
1057333|NCT01763606|Enoxaparin
1057334|NCT01763606|Aspirin
1057335|NCT01763606|stroke
1057336|NCT01763606|12-264
1057337|NCT01763593|Patients having cataract
1057338|NCT01763580|Glomerulonephritis
1057339|NCT01763580|Tacrolimus
1057340|NCT01763580|Nephrotic syndrome
1057341|NCT01763567|Medtronic
1057342|NCT01763567|Diabetes
1057343|NCT01763567|Hospital
1057344|NCT01763567|Continuous Glucose Monitor
1057345|NCT01763567|Intensive Care Unit
1057346|NCT01763554|Lu-177
1057347|NCT01763554|Lutetium-177
1057348|NCT01763554|DOTA-TATE
1057349|NCT01763554|Neuroendocrine tumors
1057350|NCT01763554|radiopharmaceutical
1057351|NCT01763541|Natriuretic Peptides
1057352|NCT01763528|body weight
1057353|NCT01763528|Low-density-lipoprotein-type
1057354|NCT01763515|Joint Diseases
1057355|NCT01763515|Arthritis
1057356|NCT01763515|Osteoarthritis
1057357|NCT01763502|Cognitive development
1057358|NCT01763502|Anemia
1057359|NCT01763502|Preschool
1057360|NCT01763502|Food transfers
1057361|NCT01763502|Cash transfers
1057362|NCT01763502|Early childhood
1057363|NCT01763502|Nutrition
1057364|NCT01763489|randomized controlled trial
1057365|NCT01763489|applicability
1057366|NCT01763489|ASSIST tool
1057367|NCT01763489|surgery
1057368|NCT01763489|digestive cancer
1057369|NCT01763476|long infrapopliteal artery lesions
1057370|NCT01763476|drug-coated balloon angioplasty
1057371|NCT01763476|atherectomy
1057372|NCT01763463|pneumonia requiring hospitalization
1057373|NCT01763463|COPD
1057374|NCT01763463|long-acting bronchodilators (LABD)
1057375|NCT01763463|Inhaled Corticosteroids (ICS)
1057376|NCT01763450|Bevacizumab
1057377|NCT01763450|conversion therapy
1057378|NCT01763450|liver metastases
1057379|NCT01763450|colorectal cancer
1057380|NCT01763450|objective response rate
1057381|NCT01763437|Chalazia
1057382|NCT01763437|Chalazion
1057383|NCT01763437|Meibomian gland dysfunction
1057384|NCT01763437|Rosacea
1057385|NCT01763437|Ocular rosacea
1057386|NCT01763411|Cataract
1057387|NCT01763411|Vision
1057388|NCT01763411|Intraocular lens
1057389|NCT01763411|Multifocal
1057390|NCT01763411|Monofocal
1057391|NCT01763385|Erlotinib
1057392|NCT01763385|brain radiotherapy
1057393|NCT01763385|NSCLC
1057394|NCT01763385|brain metastases
1057395|NCT01763372|Arthroscopic
1057396|NCT01763372|Iliopsoas
1057397|NCT01763372|MRI
1057398|NCT01763359|acetabular fracture
1057399|NCT01763359|pelvic fracture
1057400|NCT01763359|hip adductor strength
1057401|NCT01763359|obturator nerve palsy
1057402|NCT01763359|modified Stoppa approach
1057403|NCT01763346|type 2 diabetes
1057404|NCT01763346|prediabetes
1057405|NCT01763346|obesity
1057406|NCT01763346|gastric banding
1057407|NCT01763346|metformin
1057408|NCT01763320|ischemic stroke
1057409|NCT01763320|intracranial stenting
1057410|NCT01763320|vascular risk factor management
1057411|NCT01763307|EGFRI
1057412|NCT01763307|COLON CANCER
1057413|NCT01763307|SKIN TOXICITY
1057414|NCT01763307|RECONVAL K1 cream
1057415|NCT01763294|multifocal refractory epilepsy
1057416|NCT01763294|tDCS
1057417|NCT01763294|neurostimulation
1057418|NCT01763294|seizures
1057419|NCT01763268|Immunogenicity
1057420|NCT01763268|Reactogenicity
1057421|NCT01763268|Trivivac
1057422|NCT01763268|Measles
1057423|NCT01763268|Mump
1057424|NCT01763268|Rubella
1057425|NCT01763255|cerebral palsy CD133 cells intrathecal injection
1057426|NCT01763242|CKD, Anaemia, Synchronization, Monthly dosing, Home Delivery
1057427|NCT01763216|depressive symptoms
1057428|NCT01763216|clinical depression
1057429|NCT01763216|visual processing speed
1057430|NCT01763216|anxiety
1057431|NCT01763216|pain
1057432|NCT01763216|health-related quality of life
1057433|NCT01763203|Self-management
1057434|NCT01763203|Chronic Care Model
1057435|NCT01763203|Community health worker
1057436|NCT01763177|nebulizer
1057437|NCT01763177|oxygen
1057438|NCT01763177|post-operative sore throat
1057439|NCT01763164|Melanoma
1057440|NCT01763164|Cutaneous melanoma
1057441|NCT01763164|Skin disease
1057442|NCT01763164|Skin cancer
1057443|NCT01763164|Skin Neoplasms
1057444|NCT01763164|Neoplasm Metastasis
1057445|NCT01763151|cataract surgery, astigmatism, opposite clear corneal incision, toric IOL, IOL rotational stability
1057446|NCT01763125|Breast cancer
1057447|NCT01763125|Ovarian cancer
1057448|NCT01763125|Endometrium carcinoma
1057449|NCT01763125|Cervix carcinoma,
1057450|NCT01763125|Mamma carcinoma,
1057451|NCT01763125|Prostata carcinoma
1057452|NCT01763125|Colon carcinoma
1057453|NCT01763125|Rectal carcinoma
1057454|NCT01763125|Bronchus carcinoma
1057455|NCT01763125|NSCLC & SCLC (Non Small Cell Lung Cancer & Small Cell Lung Cancer))
1057456|NCT01763125|Prostate carcinoma
1057457|NCT01763112|Influence of training with whole body vibration device
1057458|NCT01763099|Autologous Hematopoietic Stem Cell Transplantation
1057459|NCT01763099|Mesenchymal Stem Cells
1057460|NCT01763099|Cord Blood
1057461|NCT01763099|Graft failure
1057462|NCT01763086|Poor Graft Function
1057463|NCT01763086|Mesenchymal Stem Cells
1057464|NCT01763086|Allogeneic hematopoietic stem cell transplantation
1057465|NCT01763086|Third-party Donors
1057466|NCT01763060|ards
1057467|NCT01763060|ecmo
1057468|NCT01763060|h1n1
1057469|NCT01763060|pandemics
1057470|NCT01763021|Healthy participants
1057471|NCT01763021|PCI-32765
1057472|NCT01763021|Rifampin
1057473|NCT01763021|PCI-45227
1057474|NCT01763021|CYP3A4
1057475|NCT01763008|Pneumonia, Bacterial
1057476|NCT01763008|Nosocomial Infection
1057477|NCT01763008|Intraabdominal Infections
1057478|NCT01763008|Urinary Tract Infection
1057479|NCT01763008|Ventilator-associated pneumonia
1057480|NCT01763008|Doripenem
1057481|NCT01763008|Doribax
1057482|NCT01763008|Filipino
1057483|NCT01762995|Dolutegravir, pharmacokinetics, calcium, iron, drug interaction, healthy volunteers
1057484|NCT01762956|Pelvic floor
1057485|NCT01762956|Physical Therapy
1057486|NCT01762956|Prostate cancer
1057487|NCT01762956|Radiotherapy
1057488|NCT01762956|Nuclear magnetic resonance
1057489|NCT01762904|Antiseptics
1057490|NCT01762904|Administration cutaneously
1057491|NCT01762904|Anti-infecting agents, local
1057492|NCT01762891|Coumadin
1057493|NCT01762891|celecoxib
1057494|NCT01762891|rofecoxib
1057495|NCT01762891|acetaminophen
1057496|NCT01762891|antiphospholipid syndrome and INR
1057497|NCT01762878|pharmacodynamics
1057498|NCT01762878|pharmacokinetics
1057499|NCT01762878|healthy volunteers
1057500|NCT01762878|Pi3K-delta
1057501|NCT01762878|GSK2269557
1057502|NCT01762878|safety
1057503|NCT01762878|dry powder inhaler
1057504|NCT01762865|acute bronchitis, bacteria, virus, clinical symoptoms
1057505|NCT01762852|Benlysta
1057506|NCT01762852|efficacy
1057507|NCT01762852|proteinuria
1057508|NCT01762852|Idiopathic membranous nephropathy
1057509|NCT01762852|GSK1550188
1057510|NCT01762852|anti-phospholipase A2 receptor antibodies
1057511|NCT01762852|safety
1057512|NCT01762852|placebo
1057513|NCT01762852|BLyS
1057514|NCT01762852|belimumab
1057515|NCT01762852|Lymphostat-B
1057516|NCT01762852|membrane attack complex
1057517|NCT01762826|Inositol
1057518|NCT01762826|GDM
1057519|NCT01762813|Colon cancer
1057520|NCT01762813|rectal cancer
1057521|NCT01762813|liver metastasis
1057522|NCT01762813|survival
1057523|NCT01762813|biomarker
1057524|NCT01762813|molecular profile
1057525|NCT01762774|COPD
1057526|NCT01762774|forearm blood flow
1057527|NCT01762774|soluble Epoxide Hydrolase inhibitor
1057531|NCT01762748|Probiotic
1057532|NCT01762748|liver
1057533|NCT01762748|transplant
1057534|NCT01762748|permeability
1057535|NCT01762722|Spectroscopy, near infrared
1057536|NCT01762722|Oximetry
1057537|NCT01762722|Hypoxemia
1057538|NCT01762722|Tissue oxygenation
1057539|NCT01762709|Video-assisted thoracoscopic surgery
1057540|NCT01762709|one lung ventilation
1057541|NCT01762709|low tidal volume
1057542|NCT01762709|acute lung injury
1057543|NCT01762709|lung water content
1057544|NCT01762696|marijuana
1057545|NCT01762696|intervention
1057546|NCT01762696|adolescent, young adult
1057547|NCT01762696|primary care
1057548|NCT01762696|mobile
1057549|NCT01762683|pregnancy
1057550|NCT01762683|obesity
1057551|NCT01762683|differentiation
1057552|NCT01762670|Bacterial Vaginosis
1057553|NCT01762670|BV
1057554|NCT01762657|Type 1 Diabetes
1057555|NCT01762657|Insulin Independence
1057556|NCT01762657|Beta Regeneration
1057557|NCT01762657|Immune Tolerance Agent
1057558|NCT01762657|Lanzoprazole
1057559|NCT01762657|Cyclosporine
1057560|NCT01762644|Type 1 Diabetes
1057561|NCT01762644|Insulin Independence
1057562|NCT01762644|Beta Regeneration
1057563|NCT01762644|Immune Tolerance Agent
1057564|NCT01762644|Omeprazole
1057565|NCT01762644|Cyclosporine
1057566|NCT01762618|Group Cognitive Behavior Therapy, Alzheimer's disease, Caregivers¡
1057567|NCT01762579|Not-celiac wheat sensitivity
1057568|NCT01762579|Gluten
1057569|NCT01762579|esophagogastroduodenoscopy
1057570|NCT01762579|Rectoscopy
1057571|NCT01762566|Not-celiac gluten (wheat) sensitivity
1057572|NCT01762566|Bioelectrical impedance analysis
1057573|NCT01762566|Bloating
1057574|NCT01762566|Swelling
1057575|NCT01762540|Protein breakdown
1057576|NCT01762540|Insulin resistance
1057577|NCT01762540|Glucose intolerance
1057578|NCT01762540|Lipolysis
1057579|NCT01762527|Adaptive radiotherapy
1057580|NCT01762527|Bladder cancer
1057581|NCT01762514|Nasopharyngeal carcinoma
1057582|NCT01762514|Amifostine
1057583|NCT01762514|Myelosuppression
1057584|NCT01762514|Xerostomia
1057585|NCT01762514|Mucositis
1057586|NCT01762501|Hypertension
1057587|NCT01762488|Treatment Resistant Hypertension
1057588|NCT01762488|Renal Denervation
1057589|NCT01762475|Magnetic resonance imaging
1057590|NCT01762475|Blood oxygen level dependent signal
1057591|NCT01762475|Hypercapnia
1057592|NCT01762475|Endothelial progenitor cells
1057593|NCT01762449|Scleroderma
1057594|NCT01762449|interstitial lung disease
1057595|NCT01762410|Advanced refractory solid tumors
1057596|NCT01762371|ACL
1057597|NCT01762371|Knee
1057598|NCT01762371|Ligament
1057599|NCT01762371|Cruciate
1057600|NCT01762371|Anterior
1057601|NCT01762358|ACL
1057602|NCT01762358|Ligament
1057603|NCT01762358|Knee
1057604|NCT01762345|Stress urinary incontinence
1057605|NCT01762345|SUI
1057606|NCT01762332|nociception
1057607|NCT01762332|analgesia
1057608|NCT01762332|intraoperative monitoring
1057609|NCT01762293|CRC
1057610|NCT01762293|Famitinib
1057611|NCT01762293|Phase II
1057612|NCT01762293|Colorectal Cancer
1057613|NCT01762280|Famitinib
1057614|NCT01762280|Advanced Solid tumor
1057615|NCT01762280|Phase I
1057616|NCT01762254|pain score
1057617|NCT01762254|complication
1057618|NCT01762241|Prostate cancer
1057619|NCT01762241|Androgen deprivation therapy
1057620|NCT01762241|Exercise
1057621|NCT01762241|Xbox
1057622|NCT01762228|Oropharyngeal dysphagia
1057623|NCT01762228|Elderly
1057624|NCT01762228|Transcutaneous electrical stimulation
1057625|NCT01762228|TRPV1 agonist
1057626|NCT01762215|Epilepsy
1057627|NCT01762215|Seizure
1057628|NCT01762215|Veteran
1057629|NCT01762202|CLL
1057630|NCT01762202|Fludarabine
1057631|NCT01762202|Cyclophosphamide
1057632|NCT01762202|Ofatumumab
1057633|NCT01762189|Hyperbilirubinemia
1057634|NCT01762189|Neonatal
1057635|NCT01762189|Incidence
1057636|NCT01762189|Risk factors
1057637|NCT01762176|Early Rheumatoid Arthritis
1057638|NCT01762176|Usual care
1057639|NCT01762176|Intensive Care
1057640|NCT01762176|Boolean criteria
1057641|NCT01762163|Ischemic Stroke,adaptive design, randomized, double-blind
1057642|NCT01762150|collected duct carcinoma
1057643|NCT01762150|sorafenib
1057644|NCT01762137|Aneurysm
1057645|NCT01762137|Coiling
1057646|NCT01762137|Flow Diversion
1057647|NCT01762124|Pulmonary valve
1057648|NCT01762124|Congenital heart disease
1057649|NCT01762124|Transcatheter pulmonary valve
1057650|NCT01762124|Percutaneous pulmonary valve
1057651|NCT01762111|Anti-Mullerian Hormone
1057652|NCT01762111|In-Vitro fertilization
1057653|NCT01762098|In vitro fertilization
1057654|NCT01762098|Hysteroscopy
1057655|NCT01762098|Endometrial biopsy
1057656|NCT01762085|neuropathic diabetic foot ulcer
1057657|NCT01762085|nerve decompression surgery
1057658|NCT01762072|homocysteine-vitamin B12-fish oil-ferritin
1057659|NCT01762059|bionic pancreas
1057660|NCT01762059|artificial pancreas
1057661|NCT01762059|insulin
1057662|NCT01762059|glucagon
1057663|NCT01762059|continuous glucose monitoring
1057664|NCT01762059|CGM
1057665|NCT01762059|outpatient
1057666|NCT01762059|insulin pump
1057667|NCT01762046|Diabetes Mellitus, Type 2
1057668|NCT01762046|Pharmacogenetics
1057669|NCT01762046|Genetics
1057670|NCT01762046|Obesity
1057671|NCT01762033|Renal cell carcinoma
1057672|NCT01762033|Renal cell cancer
1057673|NCT01762033|ASONEP
1057674|NCT01762033|Sonepcizumab
1057675|NCT01762020|Women with Breast Cancer
1057676|NCT01762020|Receiving Adjuvant Radiation Therapy
1057677|NCT01762007|hypospadias, bladder outlet obstruction, ultrasonography
1057678|NCT01761994|nafamostat mesilate
1057679|NCT01761994|heparin
1057680|NCT01761994|continuous renal replacement therapy
1057681|NCT01761981|Haemorrhagic Hereditary Telangiectasia
1057682|NCT01761981|Rendu Osler Weber Syndrome
1057683|NCT01761981|Osler Weber Rendu Syndrome
1057684|NCT01761981|HHT
1057685|NCT01761968|chronic myeloproliferative neoplasms
1057686|NCT01761968|Polycythemia Vera
1057687|NCT01761968|Essential Thrombocythemia
1057688|NCT01761968|Primary Myelofibrosis
1057689|NCT01761968|Post-Polycythemia Vera Myelofibrosis
1057690|NCT01761968|Post-Essential Thrombocythemia Myelofibrosis
1057691|NCT01761968|Givinostat
1057692|NCT01761955|body weight
1057693|NCT01761955|lipids
1057694|NCT01761955|glucose
1057695|NCT01761955|insulin
1057696|NCT01761942|omega-3 fatty acids
1057697|NCT01761942|anorexia nervosa
1057698|NCT01761942|efficacy
1057699|NCT01761942|safety
1057700|NCT01761929|oligometastatic
1057701|NCT01761929|oligometastases
1057702|NCT01761929|stereotactic body radiotherapy
1057703|NCT01761929|radiation therapy
1057704|NCT01761929|Oligometastasis
1057705|NCT01761929|Stereotactic ablative body
1057706|NCT01761929|radiotherapy
1057707|NCT01761916|captopril, clonidine, pregnancy-induced hypertension,
1057708|NCT01761890|Chronic Myeloid Leukemia
1057709|NCT01761890|Early phase
1057710|NCT01761890|CML
1057711|NCT01761890|Dasatinib
1057712|NCT01761877|breast cancer, nonsteroidal antiinflammatory drug , breast density, chemoprevention, aromatase inhibitors
1057713|NCT01761851|Resting metabolic rate
1057714|NCT01761851|nutrition status
1057715|NCT01761851|dietary intake
1057716|NCT01761838|spinal manipulative therapy
1057717|NCT01761838|low back pain
1057718|NCT01761838|experimental pain
1057719|NCT01761838|spinal stiffness
1057720|NCT01761838|lumbar multifidus
1057721|NCT01761838|degeneration
1057722|NCT01761812|Prostate cancer
1057723|NCT01761812|MRI
1057724|NCT01761812|Elastography
1057725|NCT01761812|Gadofosveset
1057726|NCT01761799|Influenza
1057727|NCT01761799|Pertussis
1057728|NCT01761799|Vaccination
1057729|NCT01761786|Myocardial Infarction
1057730|NCT01761786|Thrombosis
1057731|NCT01761786|Acute Coronary Syndrome
1057732|NCT01761786|Myocardial Ischemia
1057733|NCT01761786|Heart Diseases
1057734|NCT01761786|Cardiovascular Diseases
1057735|NCT01761786|Vascular Diseases
1057736|NCT01761786|Embolism and Thrombosis
1057737|NCT01761786|Genetic Testing
1057738|NCT01761786|Clopidogrel
1057739|NCT01761786|Prasugrel
1057740|NCT01761786|Ticagrelor
1057741|NCT01761786|Platelet Aggregation Inhibitors
1057742|NCT01761786|Purinergic P2Y Receptor Antagonists
1057743|NCT01761747|Squamous Cell Carcinoma
1057744|NCT01761734|Influenza vaccination
1057745|NCT01761721|Endometrial cancer (MeSH)
1057746|NCT01761721|Robotics (MeSH)
1057747|NCT01761708|primary ventral hernia repair with mesh
1057748|NCT01761708|umbilical hernia repair
1057749|NCT01761708|epigastric hernia repair
1057750|NCT01761708|C-Qur V-patch
1057751|NCT01761708|Size tailored repair
1057752|NCT01761708|preperitoneal repair
1057753|NCT01761708|abdominal hernia
1057754|NCT01761708|dual sided mesh
1057755|NCT01761708|trocar-site hernia
1057756|NCT01761656|stable angina
1057757|NCT01761656|unstable angina
1057758|NCT01761656|acute non-ST-segment elevation myocardial infarction
1057759|NCT01761656|PCI
1057760|NCT01761656|perioperative myocardial infarction
1057761|NCT01761656|major adverse cardiac events
1057762|NCT01761643|PrEP
1057763|NCT01761643|Pre exposure Prophylaxis
1057764|NCT01761643|Text Messaging
1057765|NCT01761643|Truvada
1057766|NCT01761643|iTab
1057767|NCT01761643|CCTG
1057768|NCT01761643|595
1057769|NCT01761630|Asthma
1057770|NCT01761630|Severe Asthma
1057771|NCT01761630|SARP
1057772|NCT01761617|Yoga
1057773|NCT01761617|Chronic Low Back Pain
1057774|NCT01761617|CAM
1057775|NCT01761617|Complementary and Alternative Medicine
1057776|NCT01761617|Minorities
1057777|NCT01761591|CAD
1057778|NCT01761591|PCI
1057779|NCT01761591|BMS
1057780|NCT01761591|Svelte
1057781|NCT01761591|Acrobat
1057782|NCT01761591|direct stenting
1057783|NCT01761591|RCT
1057784|NCT01761578|Bioresorbable
1057785|NCT01761578|Coronary
1057786|NCT01761578|Stent
1057787|NCT01761578|Vascular Remodeling
1057788|NCT01761578|Angioplasty
1057789|NCT01761578|Coronary Artery Disease
1057790|NCT01761552|in ASA 4 AND ASA 4E patients
1057791|NCT01761539|pancreatitis
1057792|NCT01761539|pancreatitis, alcoholic
1057793|NCT01761526|Rotigotine
1057794|NCT01761526|Neupro
1057795|NCT01761526|Japanese
1057796|NCT01761526|Caucasian
1057797|NCT01761526|Male
1057798|NCT01761526|Female
1057799|NCT01761526|Single dose
1057800|NCT01761526|Pharmacokinetics
1057801|NCT01761500|Non-Hodgkin's lymphoma;
1057802|NCT01761500|Childhood and adolescence;
1057803|NCT01761500|Survival Rate
1057804|NCT01761474|Carbon dioxide insufflation
1057805|NCT01761474|Air insufflatioin
1057806|NCT01761474|ERCP
1057807|NCT01761474|Sedation
1057808|NCT01761448|Coronary Artery Disease
1057809|NCT01761448|Cardiac rehabilitation program
1057810|NCT01761448|telemedical homely rehabilitation
1057811|NCT01761448|guided exercise
1057812|NCT01761448|ECG- vest
1057813|NCT01761435|Influenza
1057814|NCT01761435|Solid Organ Transplant Recipients
1057815|NCT01761396|Anxiety
1057816|NCT01761396|Fear
1057817|NCT01761396|Worry
1057818|NCT01761396|Therapy
1057819|NCT01761396|Cognitive behavioral therapy
1057820|NCT01761383|Chronic Schizophrenia
1057821|NCT01761383|Nintendo Wii
1057822|NCT01761383|Quality of Life
1057823|NCT01761370|Non alcoholic Steatohepatitis
1057824|NCT01761370|Intra-gastric balloon
1057825|NCT01761357|Aortic valve stenosis
1057826|NCT01761357|Quality of life
1057827|NCT01761357|Burden co morbidities
1057828|NCT01761357|Transcatheter aortic valve implantation
1057829|NCT01761357|Geriatric assessment
1057830|NCT01761331|infant, colic, crying, acupuncture, stooling, sleep
1057831|NCT01761318|Diabetes mellitus type 2
1057832|NCT01761318|Glucagon-Like Peptide 1
1057833|NCT01761318|Magnetic Resonance Imaging
1057834|NCT01761318|Magnetic Resonance Spectroscopy
1057835|NCT01761318|Steatosis
1057836|NCT01761305|Idiopathic scoliosis
1057837|NCT01761305|Brace
1057838|NCT01761305|Scoliosis specific exercise
1057839|NCT01761305|Physical activity
1057840|NCT01761279|Colonic polyps
1057841|NCT01761266|Hepatocellular Carcinoma
1057842|NCT01761266|Neoplasms
1057843|NCT01761266|Cancer
1057844|NCT01761253|comorbidity, multiple chronic conditions, Medicaid, prediction of cost
1057845|NCT01761253|Predictive models, cost containment, managed care
1057846|NCT01761227|Vascular dementia
1057847|NCT01761227|Fufangdanshen Tablets
1057848|NCT01761227|Randomized Controlled trial
1057849|NCT01761227|Chinese Medicine
1057850|NCT01761214|bacteriology, inflammation, bronchiectasis, exacerbation
1057851|NCT01761201|Prophylaxis
1057852|NCT01761201|Tuberculosis
1057853|NCT01761201|Transplant recipients
1057854|NCT01761201|Transplant waiting list
1057855|NCT01761188|Persistent Atrial fibrillation;LA substrate;ablation;voltage mapping
1057856|NCT01761149|remifentanil,
1057857|NCT01761149|opioid,
1057858|NCT01761149|hyperalgesia,
1057859|NCT01761149|visual analogue score
1057860|NCT01761149|thyroidectomy,
1057861|NCT01761123|Prevention of Influenza
1057862|NCT01761110|Opioid dependence
1057863|NCT01761110|Injection drug use
1057864|NCT01761110|Buprenorphine
1057865|NCT01761110|Opioid agonist treatment
1057866|NCT01761110|Access to care
1057867|NCT01761110|HIV risk behaviors
1057868|NCT01761110|Opioids
1057869|NCT01761097|Adenoma, polyp, colonoscopy.
1057870|NCT01761084|Osteoporosis
1057871|NCT01761084|Spine fracture
1057872|NCT01761084|Vertebral fracture
1057873|NCT01761084|Exercise Interventions
1057874|NCT01761084|Exercise
1057875|NCT01761058|Asthma
1057876|NCT01761058|Bronchial Diseases
1057877|NCT01761058|Respiratory Tract Diseases
1057878|NCT01761058|Lung Diseases, Obstructive
1057879|NCT01761058|Lung Diseases
1057880|NCT01761058|Respiratory Hypersensitivity
1057881|NCT01761058|Hypersensitivity, Immediate
1057882|NCT01761058|Hypersensitivity
1057883|NCT01761058|Immune System Disease
1057884|NCT01761045|Monosodium L-Glutamate (MSG)
1057885|NCT01761045|Nucleic Acid (IMP)
1057886|NCT01761045|Satiety
1057887|NCT01761045|Gastrointestinal Sensation
1057888|NCT01761045|Consommé Soups
1057889|NCT01761045|Snack Intake
1057890|NCT01761032|Tanning
1057891|NCT01761032|neuroimaging
1057892|NCT01761032|dopamine
1057893|NCT01761032|MRI
1057894|NCT01761032|SPECT
1057895|NCT01761019|psoriasis
1057896|NCT01761019|Taclonex
1057897|NCT01761019|Acitretin
1057898|NCT01761019|Methotrexate
1057899|NCT01761006|COPD
1057900|NCT01761006|Chronic Obstructive Pulmonary Disease
1057901|NCT01761006|Exhaled Nitric Oxide
1057902|NCT01761006|NIOX MINO
1057903|NCT01761006|Acute COPD exacerbation
1057904|NCT01760993|Not Required
1057905|NCT01760980|Rate and extend of absorption of Exemestane
1057906|NCT01760967|Dexmedetomidine
1057907|NCT01760967|sepsis
1057908|NCT01760967|mortality
1057909|NCT01760967|duration of mechanical ventilation
1057910|NCT01760967|organ failure
1057911|NCT01760954|Gonadotropin-Releasing Hormone Antagonist
1057912|NCT01760954|Non-Menstrual Pelvic Pain (NMPP)
1057913|NCT01760954|Dysmenorrhea (DYS)
1057914|NCT01760954|Endometriosis associated pain
1057915|NCT01760954|Elagolix
1057916|NCT01760941|Urology
1057917|NCT01760941|Prostate
1057918|NCT01760941|Breast
1057919|NCT01760941|Lung
1057920|NCT01760941|Chest
1057923|NCT01760902|Inflammation
1057924|NCT01760876|Optical Coherence Tomography
1057925|NCT01760876|Biofreedom Stent
1057926|NCT01760863|Revision
1057927|NCT01760863|Knee
1057928|NCT01760863|Hip
1057929|NCT01760863|Arthroplasty
1057930|NCT01760863|Oral
1057931|NCT01760863|Antibiotics
1057932|NCT01760863|Infection
1057933|NCT01760837|cow's milk allergy
1057934|NCT01760837|baked milk
1057935|NCT01760837|tolerance
1057936|NCT01760837|infants and children
1057937|NCT01760824|Sequential
1057938|NCT01760824|Quadruple
1057939|NCT01760824|First
1057940|NCT01760824|Line
1057941|NCT01760824|Helicobacter
1057942|NCT01760824|pylori
1057943|NCT01760824|infection
1057944|NCT01760811|tongue
1057945|NCT01760811|Squamous cell carcinoma
1057946|NCT01760811|locally advanced
1057947|NCT01760811|cetuximab
1057948|NCT01760798|osteoporosis
1057949|NCT01760798|Teriparatide
1057950|NCT01760785|Veterans
1057951|NCT01760785|Traumatic Brain Injury(TBI)
1057952|NCT01760785|Alcoholism
1057953|NCT01760772|heart disease
1057954|NCT01760772|GLP-1
1057955|NCT01760772|Exendin-9
1057956|NCT01760772|postprandial lipids
1057957|NCT01760759|HIV
1057958|NCT01760759|Antiretroviral therapy adherence
1057959|NCT01760746|Proliferative Diabetic Retinopathy
1057960|NCT01760746|Vitrectomy
1057961|NCT01760746|Inflammatory Cytokines
1057962|NCT01760707|Diabetes mellitus
1057963|NCT01760707|Peripheral neuropathy
1057964|NCT01760707|Exercise
1057965|NCT01760707|Balance performance
1057966|NCT01760694|Pancreatic
1057967|NCT01760694|Pancreas
1057968|NCT01760694|Intraoperative Radiation Therapy
1057969|NCT01760694|Chemotherapy
1057970|NCT01760668|Sex chromosome
1057971|NCT01760668|Turner Syndrome
1057972|NCT01760668|Marfan syndrome
1057973|NCT01760668|Bicuspid aortic valve
1057974|NCT01760668|Aortic Aneurysm
1057975|NCT01760668|Epigenetics
1057976|NCT01760668|Transcriptome
1057977|NCT01760668|non-coding RNA
1057978|NCT01760668|Electron microscopy
1057979|NCT01760668|Proteomics
1057980|NCT01760642|metabolite profiles
1057981|NCT01760642|pharmacokinetics
1057982|NCT01760642|CYP3A
1057983|NCT01760642|metabolomics
1057984|NCT01760629|Encephalopathy, Newborn, Low and Middle-income countries, Hypothermia
1057985|NCT01760616|Huaier Granule;
1057986|NCT01760616|After non-radical hepatectomy;
1057987|NCT01760616|Prevention of Disease Progression of Hepatocarcinoma;
1057988|NCT01760616|Safety.
1057989|NCT01760603|pelvic organ prolapse
1057990|NCT01760590|neck pain
1057991|NCT01760590|cervical pain
1057992|NCT01760590|pain pressure thresholds
1057993|NCT01760590|pain catastrophizing
1057994|NCT01760577|osteoarthritis, botulinum toxin, hyaluronate
1057995|NCT01760564|Niemann-Pick disease type C
1057996|NCT01760564|miglustat
1057997|NCT01760551|Fracture
1057998|NCT01760551|Trauma
1057999|NCT01760551|impairment
1058000|NCT01760538|Cardiac transplant recipients
1058001|NCT01760538|Heart rate variability
1058002|NCT01760538|Exercise training
1058003|NCT01760525|p53, solid tumor
1058004|NCT01760512|Gastric bypass
1058005|NCT01760512|Robot-assisted surgery
1058006|NCT01760512|Conventional laparoscopy
1058007|NCT01760512|Pain assessment
1058008|NCT01760512|Health economics outcomes
1058009|NCT01760499|skin
1058010|NCT01760499|metastatic
1058011|NCT01760473|opioid dependence
1058012|NCT01760434|scoliosis
1058013|NCT01760434|long-term outcomes
1058014|NCT01760434|sagittal plane
1058015|NCT01760434|quality of life
1058016|NCT01760434|curve progression
1058017|NCT01760434|pulmonary function
1058018|NCT01760382|Acute myocardial infarction
1058019|NCT01760382|ST elevation myocardial infarction
1058020|NCT01760382|primary PCI
1058021|NCT01760382|reperfusion therapy
1058022|NCT01760382|angioplasty
1058023|NCT01760382|stent
1058024|NCT01760356|Liver transplantation
1058025|NCT01760356|Calcineurin inhibitors
1058026|NCT01760356|Pharmacodynamic biomarkers
1058027|NCT01760356|Calcineurin pathway
1058028|NCT01760356|Tacrolimus
1058029|NCT01760356|interindividual variability
1058030|NCT01760304|COPD
1058031|NCT01760278|Time-lapse monitoring of embryos.
1058032|NCT01760278|Embryoscope
1058033|NCT01760278|IVF-ET/ICSI
1058034|NCT01760278|Cetrorelix
1058035|NCT01760278|Gonal-F
1058036|NCT01760265|dysbetalipoproteinemia
1058037|NCT01760265|artery calcium score
1058038|NCT01760265|carotid intima media
1058039|NCT01760265|ankle brachial index
1058040|NCT01760265|dysbetalipoproteinemic patients
1058041|NCT01760252|Pancreatic Cancer
1058042|NCT01760239|Adolescent Hypertension
1058043|NCT01760239|Adolescent Pre Hypertension
1058044|NCT01760239|Adolescent Pre Hypertension and Obesity
1058045|NCT01760226|DLBCL
1058046|NCT01760226|Diffuse large B cell lymphoma
1058047|NCT01760226|dose adjusted
1058048|NCT01760226|EPOCH
1058049|NCT01760226|Etoposide
1058050|NCT01760226|Doxorubicin
1058051|NCT01760226|Vincristine
1058052|NCT01760226|Cyclophosphamide
1058053|NCT01760226|Prednisone
1058054|NCT01760226|Rituximab
1058055|NCT01760200|Coronary angioplasty
1058056|NCT01760200|Coronary stent
1058057|NCT01760200|paclitaxel drug-eluting stent
1058058|NCT01760200|drug eluting balloon
1058059|NCT01760174|Transversus abdominis plane catheter
1058060|NCT01760161|postoperative pain
1058061|NCT01760161|opioid consumption
1058062|NCT01760161|termanalgesia
1058063|NCT01760161|plasmaropivacain level
1058064|NCT01760148|Hepatitis C Virus
1058065|NCT01760148|HCV
1058066|NCT01760148|Interferon
1058067|NCT01760148|Prediction
1058068|NCT01760148|SVR
1058069|NCT01760148|Sustained Virus Response
1058070|NCT01760135|trauma
1058071|NCT01760135|nutrition
1058072|NCT01760135|hyperglycemia
1058073|NCT01760122|peginterferon
1058074|NCT01760122|HBeAg Positive
1058075|NCT01760122|Chronic hepatitis B
1058076|NCT01760109|Respiratory and urinary tract infections
1058077|NCT01760109|Piperacillin Sodium and Sulbactam Sodium for Injection (2:1)
1058078|NCT01760109|Phase IV
1058079|NCT01760096|Paroxysmal Nocturnal Hemoglobinuria
1058080|NCT01760096|Anemia
1058081|NCT01760096|Hematologic Diseases
1058082|NCT01760096|bone marrow failure
1058083|NCT01760096|Immunologic Factors
1058084|NCT01760096|Physiological Effects of Drugs
1058085|NCT01760096|Levamisole
1058086|NCT01760096|cyclosporine A
1058087|NCT01760070|cancer
1058088|NCT01760070|endoscopy
1058089|NCT01760070|endoscopic submucosal dissection
1058090|NCT01760044|tissue oxygenation
1058091|NCT01760044|perfusion status
1058092|NCT01760031|preconditioning
1058093|NCT01760031|contrast-induced acute kidney injury
1058094|NCT01760031|renal faliure
1058095|NCT01760018|desflurane, total intravenous anesthesia, QoR-40
1058096|NCT01760005|Alzheimer's
1058097|NCT01760005|Alzheimer's Disease
1058098|NCT01760005|Dementia
1058099|NCT01760005|Mutation
1058100|NCT01760005|Genetic Mutation
1058101|NCT01760005|Dominantly Inherited Alzheimer's Disease
1058102|NCT01760005|Dominantly Inherited Alzheimer's Network
1058103|NCT01760005|Autosomal Dominant Alzheimer's Disease
1058104|NCT01760005|Early Onset Alzheimer's Disease
1058105|NCT01760005|DIAN
1058106|NCT01760005|DIAN-TU
1058107|NCT01760005|DIAN TU
1058108|NCT01759992|Frail elderly
1058109|NCT01759992|Muscle weakness
1058110|NCT01759992|Institutionalization
1058111|NCT01759992|Respiratory muscle training
1058112|NCT01759979|Cholelithiasis, Common Bile Duct
1058113|NCT01759979|Choledocholithiasis
1058114|NCT01759966|Heart transplantation
1058237|NCT01759290|Angioplasty
1058115|NCT01759966|Autonomic cardiovascular control
1058116|NCT01759966|Acute rejection
1058117|NCT01759966|Cardiac allograft vasculopathy
1058118|NCT01759953|Diabetes Mellitus
1058119|NCT01759953|Insulin
1058120|NCT01759953|Video Games
1058121|NCT01759953|Medical Education
1058122|NCT01759953|Educational Technology
1058123|NCT01759953|Continuing Medical Education
1058124|NCT01759940|carotid
1058125|NCT01759940|endarterectomy
1058126|NCT01759940|cervical block
1058127|NCT01759927|Physical activity counselor
1058128|NCT01759927|Workplace intervention
1058129|NCT01759927|Active and healthy lifestyle
1058130|NCT01759901|hepatectomy
1058131|NCT01759901|vascular inflow occlusion
1058132|NCT01759862|kidney transplant
1058133|NCT01759862|Aminophylline
1058134|NCT01759862|pediatric
1058135|NCT01759849|Asthma
1058136|NCT01759849|β-chain signaling
1058137|NCT01759849|allergen inhalation challenges
1058138|NCT01759849|sputum
1058139|NCT01759849|bone marrow aspirate
1058140|NCT01759849|blood collection
1058141|NCT01759849|-methacholine challenge
1058142|NCT01759836|Prostatectomy
1058143|NCT01759836|Statins
1058144|NCT01759810|Glioblastoma, recurrent glioblastoma
1058145|NCT01759797|ALS bone marrow mesenchymal stem cell intravenous injection
1058146|NCT01759784|mesenchymal stem cell intraventricular injection ALS
1058147|NCT01759771|Prostate Cancer
1058148|NCT01759771|Vitamin D3
1058149|NCT01759771|Active surveillance
1058150|NCT01759758|boxer's fracture
1058151|NCT01759758|metacarpal neck fracture
1058152|NCT01759758|metacarpal fracture
1058153|NCT01759732|Aplastic anemia
1058154|NCT01759732|T cell dose
1058155|NCT01759732|CD3 depletion
1058156|NCT01759732|Haploidentical hematopoietic stem cell transplantation
1058157|NCT01759719|platinum-chromium stents
1058158|NCT01759719|concertina effect
1058159|NCT01759719|stent deformation
1058160|NCT01759719|everolimus eluting stents
1058161|NCT01759719|stent lenght
1058162|NCT01759693|Platelet activation
1058163|NCT01759680|Risk of falls
1058164|NCT01759680|Whole Body Vibration
1058165|NCT01759680|Nursing Home
1058166|NCT01759667|Diet-induced Thermogenesis;
1058167|NCT01759667|Respiratory Quotient;
1058168|NCT01759667|Roux-en-Y Gastric Bypass;
1058169|NCT01759667|Energy Expenditure.
1058170|NCT01759641|Dialysis
1058171|NCT01759641|Monitoring
1058172|NCT01759641|Cardiovascular stability
1058173|NCT01759641|biosignals
1058174|NCT01759628|Steatohepatitis,
1058175|NCT01759628|Helicobacter pylori,
1058176|NCT01759628|Insulin resistance,
1058177|NCT01759628|Alanine aminotransferase,
1058178|NCT01759628|Aspartate aminotransferase,
1058179|NCT01759615|Preterm
1058180|NCT01759615|SGA
1058181|NCT01759615|AREDF
1058182|NCT01759615|Early feeding
1058183|NCT01759615|Late feeding
1058184|NCT01759615|Feed intolerence
1058185|NCT01759615|Necrotizing enterocolitis
1058186|NCT01759602|Neuromyelitis optica
1058187|NCT01759602|Devic's disease
1058188|NCT01759602|NMO
1058189|NCT01759602|Devic
1058190|NCT01759589|electroconvulsive therapy,sevoflurane,propofol,remifentanil
1058191|NCT01759576|Renal Insufficiency
1058192|NCT01759576|Healthy
1058193|NCT01759576|Canagliflozin (JNJ-28431754)
1058194|NCT01759576|Pharmacokinetics
1058195|NCT01759576|Pharmacodynamics
1058196|NCT01759576|Dialysis
1058197|NCT01759550|Gastric Procedures
1058198|NCT01759550|Force Triad
1058199|NCT01759550|LigaSure Advance Pistol Grip
1058200|NCT01759550|LigaSure Blunt Tip
1058201|NCT01759524|local anaesthesia
1058202|NCT01759524|analgesia
1058203|NCT01759524|bupivacaine
1058204|NCT01759524|lidocaine
1058205|NCT01759524|clonidine
1058206|NCT01759524|sciatic nerve
1058207|NCT01759524|saphenous nerve
1058208|NCT01759511|Idiopathic
1058209|NCT01759511|Pulmonary
1058210|NCT01759511|Fibrosis
1058211|NCT01759511|IPF
1058212|NCT01759498|Inflammation
1058213|NCT01759498|Pain intensity
1058214|NCT01759498|Flexibility
1058215|NCT01759498|RICE protocol
1058216|NCT01759498|Swelling
1058217|NCT01759485|Clozapine
1058218|NCT01759485|Schizophrenia
1058219|NCT01759485|Vitamin-D
1058220|NCT01759485|Treatment-resistant
1058221|NCT01759472|leukotriene
1058222|NCT01759472|leukotriene receptor antagonist
1058223|NCT01759420|Ondansetron
1058224|NCT01759420|QT interval
1058225|NCT01759420|QTc
1058226|NCT01759420|QT prolongation
1058227|NCT01759420|Drug induced QT prolongation
1058228|NCT01759381|Spinal Deformity
1058229|NCT01759381|Complex Spinal Surgery
1058230|NCT01759381|Negative Pressure Wound Therapy
1058231|NCT01759381|Post-Operative Infection
1058232|NCT01759368|self-care, heart failure, telemonitoring, health care utilization
1058233|NCT01759342|Cystic fibrosis; pulmonary exacerbation, exercise
1058234|NCT01759329|overweight
1058235|NCT01759329|body weight
1058236|NCT01759329|coffee
1058238|NCT01759290|Bioabsorbable
1058239|NCT01759290|Bioresorbable
1058240|NCT01759290|BVS
1058241|NCT01759290|Coronary Artery Endothelial Responsiveness
1058242|NCT01759290|Coronary Scaffold
1058243|NCT01759290|Coronary Stent
1058244|NCT01759264|Fecal Calprotectin
1058245|NCT01759264|Crohn's Disease
1058246|NCT01759264|Adalimumab
1058247|NCT01759251|Meniere Disease
1058248|NCT01759251|Betahistine Dihydrochloride
1058249|NCT01759251|Vertigo
1058250|NCT01759238|colorectal cancer
1058251|NCT01759238|metastases
1058252|NCT01759238|non resectable
1058253|NCT01759238|chemoradiation
1058254|NCT01759225|Registry, Cardiovascular, CVD, Health Maintenance Organization
1058255|NCT01759212|stem cell implantation
1058256|NCT01759212|coronary artery disease
1058257|NCT01759212|left ventricular assist device
1058258|NCT01759199|COPD
1058259|NCT01759199|ST6: The six minute Stepper Test
1058260|NCT01759199|Conventional respiratory rehabilitation
1058261|NCT01759199|Pulmonary rehabilitation
1058262|NCT01759186|Asthma
1058263|NCT01759186|Biomakers
1058264|NCT01759186|Phenotype
1058265|NCT01759173|Minor traumatic brain injury (TBI)
1058266|NCT01759173|Concussion
1058267|NCT01759160|Target control infusion
1058268|NCT01759160|propofol
1058269|NCT01759160|cardiac depression
1058270|NCT01759160|induction of anesthesia
1058271|NCT01759160|hemodynamics
1058272|NCT01759134|Premature neonate
1058273|NCT01759134|Post-discharge
1058274|NCT01759134|Formula
1058275|NCT01759121|severe non-proliferative diabetic retinopathy
1058276|NCT01759121|subthreshold
1058277|NCT01759121|panretinal photocoagulation
1058278|NCT01759121|PASCAL
1058279|NCT01759121|endpoint management
1058280|NCT01759108|xerostomia
1058281|NCT01759108|rebamipide
1058282|NCT01759108|efficacy
1058283|NCT01759108|safety
1058284|NCT01759095|adherence
1058285|NCT01759095|electronic monitoring
1058286|NCT01759095|primary care
1058287|NCT01759095|community pharmacy
1058288|NCT01759095|multidrug blister pack
1058289|NCT01759095|pill box
1058290|NCT01759056|Ulcerative colitis
1058291|NCT01759043|coronary artery disease
1058292|NCT01759043|Myocardial Infarction
1058293|NCT01759043|Radial Artery
1058294|NCT01759043|Catheters
1058295|NCT01759030|rheumatoid arthritis, DMARDs
1058296|NCT01759030|rituximab
1058297|NCT01759030|biosimilar
1058298|NCT01759030|interchangeability
1058299|NCT01759017|Crohn's disease
1058300|NCT01759017|Inflammatory bowel disease
1058301|NCT01759017|IBD
1058302|NCT01759017|Infliximab
1058303|NCT01759017|PET
1058304|NCT01759017|PET/CT
1058305|NCT01759004|lipoedema
1058306|NCT01759004|obesity
1058307|NCT01758978|bioequivalence, hydrocodone bitartrate extended-release tablets
1058308|NCT01758952|Peri-operative stroke
1058309|NCT01758952|incidence
1058310|NCT01758952|risk factors
1058311|NCT01758952|prospective
1058312|NCT01758939|Peg Interferon,
1058313|NCT01758939|Ribavirin,
1058314|NCT01758939|HCV,
1058315|NCT01758939|Genotype IV.
1058316|NCT01758926|Inflammatory Bowel Disease
1058317|NCT01758926|Confocal Laser Endomicroscopy
1058318|NCT01758913|Bronchopulmonary dysplasia
1058319|NCT01758913|patent ductus arteriosus
1058320|NCT01758913|prostaglandin
1058321|NCT01758913|Respiratory distress syndrome
1058322|NCT01758900|Single-Balloon Enteroscopy
1058323|NCT01758874|Critical limb ischemia
1058324|NCT01758874|Phlebotomy
1058325|NCT01758874|Amputation
1058326|NCT01758874|Rutherford classification Grade 3, Category 5 or 6
1058327|NCT01758874|Fontaine stage IV
1058328|NCT01758861|Erythropoietin
1058329|NCT01758861|acute kidney injury
1058330|NCT01758861|valvular heart surgery
1058331|NCT01758848|overactive bladder
1058332|NCT01758848|pelvic floor muscles
1058333|NCT01758848|deep abdominal muscles
1058334|NCT01758835|ER-stress-test negative
1058335|NCT01758835|unimalleolar
1058336|NCT01758835|fibula
1058337|NCT01758835|Weber-B fractures
1058338|NCT01758822|meconium stained amniotic fluid
1058339|NCT01758822|endotracheal suction
1058340|NCT01758822|non vigorous neonates
1058341|NCT01758809|Video Assisted Thoracic Surgery
1058342|NCT01758809|Postoperative Pain
1058343|NCT01758809|Intravenous Patient Controlled Analgesia
1058344|NCT01758809|Bupivacaine
1058345|NCT01758809|Major Pulmonary Resection
1058346|NCT01758809|Post Pulmonary Resection
1058347|NCT01758796|ER-stress positive
1058348|NCT01758796|Unimalleolar fibula fracture
1058349|NCT01758796|Operative vs non-operative treatment
1058350|NCT01758770|osteoporosis
1058351|NCT01758770|osteoarthritis
1058352|NCT01758770|bone mineral density
1058353|NCT01758770|computed xray tomography
1058354|NCT01758770|liver steatosis
1058355|NCT01758770|obesity
1058356|NCT01758757|Proliferative diabetic retinopathy
1058357|NCT01758757|Vitrectomy
1058358|NCT01758744|COPD PH
1058359|NCT01758744|COPD associated Pulmonary Hypertension
1058360|NCT01758744|COPD and Pulmonary Hypertension
1058361|NCT01758744|Disease
1058362|NCT01758731|Stage IVA-B Squamous Cell Carcinomas
1058363|NCT01758731|Head and Neck Cancer
1058364|NCT01758731|Heavy drinking
1058365|NCT01758731|Smoking
1058366|NCT01758718|Down's syndrome
1058367|NCT01758718|entropion
1058368|NCT01758718|lid plasty
1058369|NCT01758705|Psoriasis
1058370|NCT01758705|Related to Health Quality of Life
1058371|NCT01758705|Patient Reported Outcomes
1058372|NCT01758705|Venezuelan Patients
1058373|NCT01758692|spinal cord injury
1058374|NCT01758692|autonomic integrity
1058375|NCT01758692|autonomic dysreflexia
1058376|NCT01758692|baroreceptor integrity
1058377|NCT01758692|sympathetic integrity
1058378|NCT01758692|vagal integrity
1058379|NCT01758679|Iodine[131I] Metuximab Injection
1058380|NCT01758653|CO poisoning
1058381|NCT01758640|mechanical heart valve
1058382|NCT01758640|pregnancy
1058383|NCT01758640|warfarin
1058384|NCT01758640|phenindione
1058385|NCT01758627|Peritoneal dialysis,
1058386|NCT01758627|chronic kidney disease,
1058387|NCT01758627|refractory heart failure
1058388|NCT01758614|carotid artery occlusion
1058389|NCT01758614|middle cerebral artery occlusion
1058390|NCT01758614|EC-IC bypass surgery
1058391|NCT01758614|stroke
1058392|NCT01758601|white fish
1058393|NCT01758601|Metabolic syndrome
1058394|NCT01758601|Cardiovascular risk
1058395|NCT01758588|Primary myelofibrosis
1058396|NCT01758588|PMF
1058397|NCT01758575|Patients
1058398|NCT01758549|pancreatitis
1058399|NCT01758549|cholangiopancreatography, endoscopic retrograde
1058400|NCT01758549|hyperamylasemia
1058401|NCT01758536|ischemic stroke
1058402|NCT01758536|neural function
1058403|NCT01758536|life quality
1058405|NCT01758510|Amyotrophic Lateral Sclerosis
1058406|NCT01758510|ALS
1058407|NCT01758510|Neurodegenerative disease
1058408|NCT01758510|Motor Neuron Disease
1058409|NCT01758510|Central Nervous System Disease
1058410|NCT01758510|Neuromuscular Disease
1058411|NCT01758510|Bone marrow derived stem cell
1058412|NCT01758510|stem cell therapy
1058413|NCT01758510|intrathecal injection
1058414|NCT01758497|Fascia Iliaca compartment block, Pain, Sensorial blockade
1058415|NCT01758484|Hematopoietic cell transplantation
1058416|NCT01758484|Supportive/palliative care
1058417|NCT01758471|Type 2 Diabetes
1058418|NCT01758471|gut microbiome
1058419|NCT01758471|incretin
1058420|NCT01758471|Sulfonylurea
1058421|NCT01758471|α-glucosidase inhibitor
1058426|NCT01758432|Healthy volunteers
1058427|NCT01758419|post-RT
1058428|NCT01758419|myocardial perfusion images
1058429|NCT01758406|Cardiac stem ce heart failure cardiac function intracoronary transplantation
1058430|NCT01758393|IgG4-related disease
1058431|NCT01758393|IgG4-RD
1058432|NCT01758380|Type 2 Diabetes Mellitus
1058433|NCT01758380|Ramadan
1058434|NCT01758380|Vildagliptin
1058435|NCT01758380|Hypoglycemia
1058436|NCT01758367|demethylating agent
1058437|NCT01758367|immunogenicity
1058438|NCT01758367|decitabine(DAC)
1058439|NCT01758367|donor lymphocyte infusion(DLI)
1058440|NCT01758367|AML
1058441|NCT01758354|Pompe disease
1058442|NCT01758354|alpha glucosidase deficiency
1058443|NCT01758341|Malignant biliary obstruction
1058444|NCT01758341|Endoscopic radiofrequency ablation
1058445|NCT01758341|Therapeutic endoscopy
1058446|NCT01758328|BUSULFAN
1058447|NCT01758328|FLUDARABINE
1058448|NCT01758328|G-CSF
1058449|NCT01758328|MELPHALAN
1058450|NCT01758328|RABBIT ATG WT1
1058451|NCT01758328|PEPTIDE SPECIFIC T CELLS
1058452|NCT01758328|12-175
1058453|NCT01758315|Ambulatory
1058454|NCT01758315|Outpatient
1058455|NCT01758315|Malpractice
1058456|NCT01758315|Quality Improvement
1058457|NCT01758315|Patient Safety
1058458|NCT01758302|taste test
1058459|NCT01758302|food consumption
1058460|NCT01758302|hunger
1058461|NCT01758289|Venezuelan Patients
1058462|NCT01758289|Depressive Symptoms
1058463|NCT01758289|Health Related Quality of Life
1058464|NCT01758276|smoking, pregnancy
1058465|NCT01758263|Hypertension
1058466|NCT01758263|Health Care Cost
1058467|NCT01758263|Monthly health care cost
1058468|NCT01758250|Autoimmune diseases with cutaneous involvement
1058469|NCT01758250|Systemic sclerosis
1058470|NCT01758250|Scleroderma
1058471|NCT01758250|Morphea
1058472|NCT01758250|Dermatomyositis
1058473|NCT01758250|Cutaneous lupus
1058474|NCT01758250|Vasculitis
1058475|NCT01758250|Sickle Cell Disease
1058476|NCT01758250|Graft versus Host Disease
1058477|NCT01758237|Laser Peripheral Iridotomy
1058478|NCT01758237|Visual Dysphotopsia
1058479|NCT01758237|Visual Disturbances
1058480|NCT01758237|Angle Closure Glaucoma
1058481|NCT01758224|Multiple Sclerosis
1058482|NCT01758224|Functional Magnetic Stimulation
1058483|NCT01758224|Pulmonary Function
1058484|NCT01758211|Intracranial Arteriovenous Malformations
1058485|NCT01758211|Functional Magnetic Resonance Imaging
1058486|NCT01758211|Neuronavigation
1058487|NCT01758185|Inactivated split influenza vaccine
1058488|NCT01758185|Immunogenicity
1058489|NCT01758185|Safety
1058490|NCT01758185|Consistence
1058491|NCT01758172|pancreaticoduodenectomy
1058492|NCT01758172|postoperative patient
1058493|NCT01758172|colloid
1058494|NCT01758172|albumin
1058495|NCT01758172|hetastarch
1058496|NCT01758146|Breast cancer
1058497|NCT01758146|obesity
1058498|NCT01758146|aromatase inhibitors
1058499|NCT01758146|postmenopausal
1058500|NCT01758120|IgA nephropathy
1058501|NCT01758120|Cyclophosphamide
1058502|NCT01758120|prednisone
1058503|NCT01758094|hypogonadism
1058504|NCT01758094|Retinol binding globulin 4
1058505|NCT01758094|Testosterone treatment
1058506|NCT01758068|Preterms
1058507|NCT01758068|Coconut Oil application
1058508|NCT01758068|Trans epidermal water loss
1058509|NCT01758068|Weight gain
1058510|NCT01758055|Mesenchymal stem cell, emphysema, lung function
1058511|NCT01758042|Kidney
1058512|NCT01758042|Chronic Kidney Disease
1058513|NCT01758042|CKD
1058514|NCT01758042|Bone Marrow
1058515|NCT01758042|Bone Marrow Transplant
1058516|NCT01758042|BMT
1058517|NCT01758042|Leukemia
1058518|NCT01758042|AML
1058519|NCT01758042|ALL
1058520|NCT01758042|CML
1058521|NCT01758042|CLL
1058522|NCT01758042|MM
1058523|NCT01758042|NHL
1058524|NCT01758042|MDS
1058525|NCT01758029|quality of life
1058526|NCT01758029|Testosterone Undecanoate
1058527|NCT01758029|partner
1058528|NCT01758029|questionnaire
1058529|NCT01758003|Physical Activity
1058530|NCT01758003|Sedentary Behaviour
1058531|NCT01758003|Healthy Volunteer
1058532|NCT01758003|Quality of Life
1058533|NCT01758003|Exercise Capacity
1058534|NCT01758003|Transtheoretical Model
1058535|NCT01757990|dental caries
1058536|NCT01757990|Stevioside
1058537|NCT01757990|Rebaudioside
1058538|NCT01757990|plaque pH
1058539|NCT01757990|Streptococcus mutans
1058540|NCT01757977|Vivasight DL
1058541|NCT01757977|double lumen endotracheal tube
1058542|NCT01757977|fiberoptic confirmation of tube position
1058543|NCT01757964|Crohns Disease
1058544|NCT01757964|Ulcerative Colitis
1058545|NCT01757964|Inflammatory Bowel Disease
1058546|NCT01757964|IBD
1058547|NCT01757951|Ankle
1058548|NCT01757951|Fracture
1058549|NCT01757951|medial malleolus
1058550|NCT01757951|Osteosynthesis
1058551|NCT01757938|HIV
1058552|NCT01757938|Prevention
1058553|NCT01757938|Adult Male Circumcision
1058554|NCT01757938|Uganda
1058555|NCT01757938|Shang Ring
1058556|NCT01757925|activity
1058557|NCT01757925|gaming
1058558|NCT01757925|obesity
1058559|NCT01757925|Active Gaming
1058560|NCT01757925|Control
1058561|NCT01757912|mechanical ventilation
1058562|NCT01757899|ALI
1058563|NCT01757899|Acute Lung Injury
1058564|NCT01757899|ARDS
1058565|NCT01757899|Acute Respiratory Distress Syndrome
1058566|NCT01757899|Pediatric Critical Care Medicine
1058567|NCT01757899|Inflammatory Response
1058568|NCT01757886|Myocardial infarction, Inflammation, Thrombus, Coronary angioplasty.
1058569|NCT01757847|Binge-Eating Disorder
1058570|NCT01757847|Obesity
1058571|NCT01757847|emotional eating
1058572|NCT01757834|Thyroid Nodule
1058573|NCT01757834|Thyroid Neoplasm
1058574|NCT01757834|Differential Diagnosis
1058575|NCT01757834|Elastography
1058576|NCT01757834|Elasticity Imaging Technique
1058577|NCT01757834|Sonoelastography
1058578|NCT01757821|Stroke
1058579|NCT01757821|rTMS
1058580|NCT01757821|TMS
1058581|NCT01757808|PAH
1058582|NCT01757808|Ranolazine
1058583|NCT01757808|right ventricle
1058584|NCT01757808|Safety
1058585|NCT01757808|cardiopulmonary exercise testing
1058586|NCT01757795|acute ischemic stroke
1058587|NCT01757795|ischemic stroke
1058588|NCT01757795|stroke
1058589|NCT01757769|Lower urinary tract symptoms
1058590|NCT01757769|benign prostatic hyperplasia
1058591|NCT01757743|Heart Septal Defects, Atrial
1058592|NCT01757743|Oedema formation
1058593|NCT01757717|radiation therapy
1058594|NCT01757717|HDR brachytherapy
1058595|NCT01757717|Ir-192 high dose rate
1058596|NCT01757717|12-260
1058597|NCT01757704|Cardiac de-airing
1058598|NCT01757704|Air emboli
1058599|NCT01757704|Trans-cranial Echo-Doppler
1058600|NCT01757704|Intraoperative Trans-esophageal Echocardiography
1058601|NCT01757691|Acute demyelinating optic neuritis
1058602|NCT01757691|Optic neuritis
1058603|NCT01757665|Aortic valve replacement
1058604|NCT01757665|Mitral valve replacement
1058605|NCT01757626|Bone Marrow
1058606|NCT01757626|Hu3F8
1058607|NCT01757626|GM-CSF
1058608|NCT01757626|12-230
1058609|NCT01757587|Type 2 Diabetes
1058610|NCT01757587|Galvus
1058611|NCT01757587|basal insulin
1058612|NCT01757587|HbA1c
1058613|NCT01757574|CIDP- chronic inflammatory demyelinating neuropathy
1058614|NCT01757574|demyelinating neuropathy
1058615|NCT01757574|alemtuzumab
1058616|NCT01757561|jugular bulb oxygen saturation
1058617|NCT01757561|postoperative cognitive dysfunction
1058618|NCT01757561|propofol
1058619|NCT01757561|sevoflurane
1058620|NCT01757548|varicocele; male infertile;varicocelectomy
1058627|NCT01757509|Parkinson's disease
1058628|NCT01757509|Set dancing
1058629|NCT01757496|Bronchiolitis
1058630|NCT01757496|Respiratory Syncytial Virus
1058631|NCT01757496|Cough Assist
1058632|NCT01757496|Physiotherapy
1058633|NCT01757470|effectiveness of risk mitigation,
1058634|NCT01757470|knowledge and understanding survey,
1058635|NCT01757470|drug utilisation study,
1058636|NCT01757470|post marketing commitments
1058637|NCT01757457|inflammation
1058638|NCT01757457|thrombosis
1058639|NCT01757457|platelets
1058640|NCT01757457|adhesion molecules
1058641|NCT01757457|endothelium
1058642|NCT01757418|Sickle Cell Disease
1058643|NCT01757418|Pain
1058644|NCT01757418|Immune Globulin
1058645|NCT01757405|with Factor VIII (FVIII) or Factor IX (FIX) inhibitors
1058646|NCT01757392|Treatment
1058647|NCT01757392|common wart lesions
1058648|NCT01757392|(verruca vulgaris)
1058649|NCT01757379|Short chain fatty acids
1058650|NCT01757379|Acetate
1058651|NCT01757379|Propionate
1058652|NCT01757379|Butyrate
1058653|NCT01757379|Bioavailability
1058654|NCT01757314|arterial lines
1058655|NCT01757301|Pain
1058656|NCT01757301|Depression
1058657|NCT01757301|Anxiety
1058658|NCT01757301|Musculoskeletal
1058659|NCT01757301|Fibromyalgia
1058660|NCT01757288|STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
1058661|NCT01757275|peptic ulcer bleeding
1058662|NCT01757275|prevention of rebleeding
1058663|NCT01757275|successful endoscopic haemostatic therapy
1058664|NCT01757262|Coronary Heart Disease
1058665|NCT01757236|Antibiotic
1058666|NCT01757236|linezolid
1058667|NCT01757236|linezolid/rifampin
1058668|NCT01757223|Diffuse Coronary Artery Disease (CAD)
1058669|NCT01757210|Aprepitant
1058670|NCT01757210|Pediatrics
1058671|NCT01757210|Chemotherapy-induced nausea/vomiting
1058672|NCT01757210|Survey
1058673|NCT01757184|Enzyme Replacement Therapy (ERT)
1058674|NCT01757184|Lysosomal Storage Disease
1058675|NCT01757184|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
1058676|NCT01757184|Acid cholesteryl ester hydrolase deficiency, type 2
1058677|NCT01757184|Acid lipase disease
1058678|NCT01757184|Cholesterol ester hydrolase deficiency
1058679|NCT01757184|LAL Deficiency
1058680|NCT01757184|LIPA Deficiency
1058681|NCT01757184|Wolman disease
1058682|NCT01757171|Gastric Cancer
1058683|NCT01757158|lung cancer
1058684|NCT01757158|lobectomy
1058685|NCT01757158|local recurrence
1058686|NCT01757145|Cord blood transplantation
1058687|NCT01757145|Eltrombopag
1058688|NCT01757145|Platelet engraftment
1058689|NCT01757106|xenon anesthesia
1058690|NCT01757106|sevoflurane anesthesia
1058691|NCT01757106|off-pump coronary artery bypass graft surgery
1058692|NCT01757093|INDIRECT CALORIMETRY
1058693|NCT01757093|MECHANICAL VENTILATION
1058694|NCT01757093|WEANING VENTILATOR
1058695|NCT01757093|AUTOMATIC TUBE COMPENSATION
1058699|NCT01757054|probiotic
1058700|NCT01757054|LGG
1058701|NCT01757054|BB-12
1058702|NCT01757054|fecal recovery
1058703|NCT01757054|healthy subjects
1058704|NCT01757041|Streptococcus agalactiae
1058705|NCT01757041|Maternal
1058706|NCT01757041|Newborn
1058707|NCT01757041|Africa
1058708|NCT01757028|Maternal and newborn health
1058709|NCT01757028|Africa
1058710|NCT01757015|COPD
1058711|NCT01757015|Chronic Obstructive Pulmonary Disease
1058712|NCT01757015|Moderate to severe airflow limitation
1058713|NCT01757015|GOLD spirometric classification 2 and 3
1058714|NCT01757015|GOLD group B and D
1058715|NCT01757015|NVA237
1058716|NCT01757015|Salmeterol fluticasone propionate
1058717|NCT01757002|Urban adolescents
1058718|NCT01757002|Acute asthma
1058719|NCT01757002|Asthma
1058720|NCT01757002|Computer tailoring
1058721|NCT01757002|Web-based intervention
1058722|NCT01757002|Puff City
1058723|NCT01756950|Influenza
1058724|NCT01756950|Virus
1058725|NCT01756950|Monoclonal
1058726|NCT01756950|Antibody
1058727|NCT01756950|Immunization
1058728|NCT01756950|Treatment
1058729|NCT01756937|osteoarthritis of the knee
1058730|NCT01756924|prosthetic joint infection
1058731|NCT01756924|hip arthroplasty
1058732|NCT01756924|MRSA
1058733|NCT01756924|knee arthroplasty
1058734|NCT01756911|MFM
1058735|NCT01756911|Multilayer Flow Modulator
1058736|NCT01756911|Multilayer stent
1058737|NCT01756911|Thoracoabdominal Aortic Aneurysm
1058738|NCT01756898|Atopic Dermatitis
1058739|NCT01756898|eczema
1058740|NCT01756885|Smoking cessation
1058741|NCT01756885|Nicotine dependence
1058742|NCT01756885|Varenicline
1058743|NCT01756885|Chantix
1058744|NCT01756885|Cancer
1058745|NCT01756872|infertility
1058746|NCT01756872|Assisted reproductive technology
1058747|NCT01756872|ovarian reserve
1058748|NCT01756859|Portal hypertension
1058749|NCT01756859|HVPG
1058750|NCT01756859|MRI
1058751|NCT01756846|HEART score
1058752|NCT01756846|risk score
1058753|NCT01756846|impact
1058754|NCT01756846|chest pain
1058755|NCT01756833|abdominal
1058756|NCT01756833|aortic
1058757|NCT01756833|aneurysm
1058758|NCT01756820|Carpal Tunnel Syndrome
1058759|NCT01756820|transverse ligament
1058760|NCT01756820|carpal tunnel release
1058761|NCT01756820|endoscopic
1058762|NCT01756820|minimal invasive
1058763|NCT01756820|mini-open
1058764|NCT01756820|median nerve
1058765|NCT01756807|Optical Coherence Tomography
1058766|NCT01756807|Geneous Stent
1058767|NCT01756807|Combo Stent
1058768|NCT01756794|Alcoholic hepatitis
1058769|NCT01756794|Liver transplantation
1058770|NCT01756794|Alcohol relapse
1058771|NCT01756794|Alcoholic cirrhosis
1058772|NCT01756781|PD-0332991
1058773|NCT01756781|Midazolam
1058774|NCT01756781|Drug-Drug Interaction Study
1058775|NCT01756781|Healthy Adult Volunteer
1058776|NCT01756768|Phase 1
1058777|NCT01756768|Mass Balance study
1058778|NCT01756768|Radio-labeled dose
1058779|NCT01756768|PD-0332991
1058780|NCT01756755|Sepsis
1058781|NCT01756742|Pleural Effusion
1058782|NCT01756742|Respiratory physiotherapy
1058783|NCT01756742|Length of stay
1058784|NCT01756729|Brain tumor
1058785|NCT01756729|Treatment
1058786|NCT01756729|Minimal toxicity
1058787|NCT01756729|GBM
1058788|NCT01756729|Glioblastoma
1058789|NCT01756729|Recurrent
1058790|NCT01756729|TTFields
1058791|NCT01756716|Diabetic Nephropathy
1058792|NCT01756703|Diabetic Nephropathy
1058793|NCT01756690|respiratory distress syndrome, adult
1058794|NCT01756690|blood component transfusion
1058795|NCT01756690|gastrointestinal hemorrhage
1058796|NCT01756690|blood coagulation
1058797|NCT01756651|Intranasal fentanyl
1058798|NCT01756651|Cystoscopy
1058799|NCT01756638|Prostate cancer
1058800|NCT01756638|Abiraterone acetate
1058801|NCT01756638|JNJ-212082
1058802|NCT01756625|cetuximab
1058803|NCT01756625|nicotine
1058804|NCT01756625|magnesium
1058805|NCT01756586|popliteal block
1058806|NCT01756586|analgesia duration
1058807|NCT01756573|block duration
1058808|NCT01756573|analgesia
1058809|NCT01756560|anterior cruciate ligament
1058810|NCT01756560|block duration
1058811|NCT01756547|Nephrocalcinosis
1058812|NCT01756547|Extreme premature
1058813|NCT01756521|QT,
1058814|NCT01756521|QTc,
1058815|NCT01756521|electrocardiogram,
1058816|NCT01756521|moxifloxacin
1058817|NCT01756508|eculizumab
1058818|NCT01756508|kidney transplantation
1058819|NCT01756508|reperfusion
1058820|NCT01756508|rejection
1058821|NCT01756508|infection
1058822|NCT01756495|QTc,
1058823|NCT01756495|GW856553 .
1058824|NCT01756495|P38,
1058825|NCT01756482|Respiratory
1058826|NCT01756482|Syncytial
1058827|NCT01756482|Virus
1058828|NCT01756482|Infections
1058829|NCT01756482|RSV
1058830|NCT01756456|Keratitis
1058831|NCT01756456|Corneal Ulcer
1058832|NCT01756443|sciatic nerve block
1058833|NCT01756443|ORIF lateral malleolus
1058834|NCT01756443|sequential injection
1058835|NCT01756443|premixed injection
1058836|NCT01756443|local anaesthetics
1058837|NCT01756430|Carvedilol SR
1058838|NCT01756430|Carvedilol IR
1058839|NCT01756430|Hypertension
1058840|NCT01756430|Essential Hypertension
1058841|NCT01756417|Healthy
1058842|NCT01756417|Canagliflozin (JNJ-28431754)
1058843|NCT01756417|Metformin
1058844|NCT01756417|Pharmacokinetics
1058845|NCT01756417|Pharmacodynamics
1058846|NCT01756404|Healthy
1058847|NCT01756404|Canagliflozin (JNJ-28431754)
1058848|NCT01756404|Pharmacokinetics
1058849|NCT01756404|Pharmacodynamics
1058850|NCT01756404|Obesity
1058851|NCT01756391|pediatric
1058852|NCT01756391|childhood
1058853|NCT01756391|allergy
1058854|NCT01756378|Mobilization with movement,knee osteoarthritis,
1058855|NCT01756352|FET
1058856|NCT01756352|Fluoroethyl tyrosine
1058857|NCT01756352|GBM
1058858|NCT01756352|Response to treatment
1058859|NCT01756352|Avastin
1058860|NCT01756352|Brain Tumor
1058861|NCT01756339|Pneumonia
1058862|NCT01756339|CABP
1058863|NCT01756339|CAP
1058864|NCT01756339|Macrolide
1058865|NCT01756326|Non-Union Fractures
1058866|NCT01756326|Impaired Healing
1058867|NCT01756326|Fractures
1058868|NCT01756326|Orthopedics
1058869|NCT01756326|Bone
1058870|NCT01756326|Musculoskeletal Disorders
1058871|NCT01756300|Essential Hypertension
1058872|NCT01756300|Renal Denervation
1058873|NCT01756300|Vascular Disease
1058874|NCT01756300|Renal Catheter Ablation
1058875|NCT01756300|Primary Hypertension
1058876|NCT01756261|EYLEA
1058877|NCT01756261|Age-Related Macular Degeneration
1058878|NCT01756261|QOL
1058879|NCT01756248|EYLEA
1058880|NCT01756248|Age-Related Macular Degeneration
1058881|NCT01756235|Post-marketing observational study (PMOS) Protocol
1058882|NCT01756235|Rheumatoid Arthritis
1058883|NCT01756235|Physical Activity
1058884|NCT01756235|Adalimumab
1058885|NCT01756235|Humira®
1058886|NCT01756222|Bicuspid Aortic Valve Disease
1058887|NCT01756222|Bicuspid Aortic Valve
1058888|NCT01756222|BAV
1058889|NCT01756196|Spinal injection; Steroid; Systemic reaction; Complication; Side effect; Diabetes mellitus; Hypertension; Risk factor
1058890|NCT01756170|cervical cancer
1058891|NCT01756170|radiotherapy
1058892|NCT01756170|postoperative therapy
1058893|NCT01756170|chemotherapy
1058894|NCT01756157|Crossover
1058895|NCT01756157|Prevention
1058896|NCT01756157|Hereditary Angioedema
1058897|NCT01756157|C1 esterase inhibitor
1058898|NCT01756157|C1 inhibitor
1058899|NCT01756157|Subcutaneous
1058900|NCT01756157|Recombinant human hyaluronidase
1058901|NCT01756092|Breast Cancer
1058902|NCT01756092|Lumpectomy
1058903|NCT01756092|Mastectomy, Segmental
1058904|NCT01756066|Obesity
1058905|NCT01756066|Weight loss program
1058906|NCT01756066|incentives
1058907|NCT01756053|Smoking
1058908|NCT01756053|Tobacco
1058909|NCT01756040|intestinal permeability
1058910|NCT01756040|preterm infants
1058911|NCT01756040|dual sugar test
1058912|NCT01756027|Rosacea
1058913|NCT01756027|Ulthera System
1058914|NCT01756027|Ultherapy™ Treatment
1058915|NCT01756027|Ulthera, Inc.
1058916|NCT01756027|Ultrasound treatment for the skin
1058917|NCT01755988|Telemedicine
1058918|NCT01755988|Heart Failure
1058919|NCT01755988|Self care
1058920|NCT01755988|Quality of life
1058921|NCT01755988|Mortality
1058922|NCT01755988|Hospitalization
1058923|NCT01755975|LENALIDOMIDE (CC-5013)
1058924|NCT01755975|Romidepsin (Istodax)
1058925|NCT01755975|12-170
1058926|NCT01755962|diet
1058927|NCT01755962|obese
1058928|NCT01755962|overweight
1058929|NCT01755962|exercise
1058930|NCT01755962|resistance training
1058931|NCT01755962|nutrition
1058932|NCT01755962|glycemic load
1058933|NCT01755962|body composition
1058934|NCT01755962|weight training
1058935|NCT01755962|lifestyle
1058936|NCT01755949|atrial fibrillation
1058937|NCT01755949|catheter ablation
1058938|NCT01755949|colchicine
1058939|NCT01755949|c reactive protein
1058940|NCT01755949|CRP
1058941|NCT01755936|Aortic Stenosis
1058942|NCT01755936|Cardiac magnetic resonance imaging
1058943|NCT01755936|Late Gadolinium enhancement
1058944|NCT01755936|T1 mapping techniques
1058945|NCT01755936|Replacement fibrosis
1058946|NCT01755936|Diffuse interstitial fibrosis
1058947|NCT01755923|non-small cell lung cancer
1058948|NCT01755923|wild-type EGFR
1058949|NCT01755923|gefitinib
1058950|NCT01755923|docetaxel
1058951|NCT01755923|second-line therapy
1058952|NCT01755910|Breast Surgery
1058953|NCT01755910|Thoracic Paravertebral Block
1058954|NCT01755910|HRV
1058955|NCT01755910|Autonomic Nervous System
1058956|NCT01755884|Wheat allergy
1058957|NCT01755884|Immunotherapy
1058958|NCT01755884|Desensitization
1058959|NCT01755884|Food allergy
1058960|NCT01755884|T cells
1058961|NCT01755858|elamipretide
1058962|NCT01755845|cervical cancer
1058963|NCT01755845|radiotherapy
1058964|NCT01755845|postoperative therapy
1058965|NCT01755845|chemotherapy
1058966|NCT01755832|inflammatory rheumatic joint disease
1058967|NCT01755832|text message
1058968|NCT01755832|> 18 years
1058969|NCT01755832|Norwegian speaking
1058970|NCT01755806|Aortic annulus
1058971|NCT01755806|Aortic calcification
1058972|NCT01755806|Multislice computed tomography
1058973|NCT01755806|Cardiac cycle
1058974|NCT01755767|MET diagnostic-high
1058975|NCT01755767|Unresectable
1058976|NCT01755767|Hepatocellular
1058977|NCT01755767|Carcinoma
1058978|NCT01755767|c-Met inhibitor
1058979|NCT01755728|Paracetamol
1058980|NCT01755728|Acetaminophen
1058981|NCT01755728|PDA
1058982|NCT01755728|Preterm infants
1058983|NCT01755715|Abortion
1058984|NCT01755715|Contraception
1058985|NCT01755715|Intrauterine Devices
1058986|NCT01755715|Intrauterine Device Expulsion
1058987|NCT01755702|caffeine
1058988|NCT01755702|paracetamol
1058989|NCT01755702|tension headache
1058990|NCT01755689|pertussis
1058991|NCT01755689|Meningococcal meningitis
1058992|NCT01755689|Meningococcal infections
1058993|NCT01755689|HPV
1058994|NCT01755689|Neisseria meningitidis
1058995|NCT01755689|Vaccines, conjugate
1058996|NCT01755689|tetanus
1058997|NCT01755689|diphtheria
1058998|NCT01755689|Meningococcal vaccines
1058999|NCT01755689|Immunogenicity
1059000|NCT01755663|CT coronary
1059001|NCT01755663|Coronary arterial disease
1059002|NCT01755663|ivabradine
1059003|NCT01755663|metoprolol
1059004|NCT01755650|18F FPM
1059005|NCT01755650|PET/CT
1059006|NCT01755650|microdosing
1059007|NCT01755624|Non-Small Cell Lung Cancer
1059008|NCT01755624|NSCLC
1059009|NCT01755624|Brain metastases
1059010|NCT01755624|Treatment
1059011|NCT01755624|Minimal toxicity
1059012|NCT01755624|TTFields
1059013|NCT01755624|TTF
1059014|NCT01755624|Tumor Treating Fields
1059015|NCT01755624|NovoCure
1059020|NCT01755598|Positive Interferon-γ release assay
1059021|NCT01755598|Efficacy
1059022|NCT01755598|Adults
1059023|NCT01755598|Tuberculosis vaccine
1059024|NCT01755598|Endemic region
1059025|NCT01755585|Radiation therapy
1059026|NCT01755585|5-fluorouracil
1059027|NCT01755585|Cisplatin
1059028|NCT01755585|Pharmacokinetics
1059029|NCT01755585|Matrix Metalloproteinase
1059030|NCT01755572|Type 2 Diabetes
1059031|NCT01755572|Hypertension
1059032|NCT01755572|Liraglutide
1059033|NCT01755572|GLP-1
1059034|NCT01755559|malaria
1059035|NCT01755559|artemisinin
1059036|NCT01755559|artemisinin-based combination therapies
1059037|NCT01755559|Plasmodium falciparum
1059038|NCT01755559|efficacy
1059039|NCT01755546|Chronic Pain
1059040|NCT01755546|CLBP
1059041|NCT01755546|Chronic Low Back Pain
1059042|NCT01755546|Back Pain
1059043|NCT01755546|Osteoarthritis
1059044|NCT01755546|OA
1059045|NCT01755546|Neuropathic Pain
1059046|NCT01755546|Nerve pain
1059047|NCT01755546|Painful neuropathy
1059048|NCT01755533|adolescent substance use
1059049|NCT01755533|rural substance use
1059050|NCT01755533|middle school prevention
1059051|NCT01755533|implementation processes
1059052|NCT01755533|implementation quality
1059053|NCT01755533|adaptation of prevention curricula
1059054|NCT01755533|dissemination
1059055|NCT01755520|CABG
1059056|NCT01755520|CAD
1059057|NCT01755520|antiplatelet drug
1059058|NCT01755520|Ticagrelor
1059059|NCT01755520|Aspirin
1059060|NCT01755507|PSC
1059061|NCT01755494|Type 2 diabetes, Saxagliptin, Metformin,Fixed dose combination tablet, Bioequivalence, pharmacokinetic, safety, tolerability
1059062|NCT01755468|beta-cell function, type 2 diabetes, intermittent insulin
1059063|NCT01755455|Cystic fibrosis
1059064|NCT01755455|Iron
1059065|NCT01755455|Hepcidin
1059066|NCT01755455|Anemia
1059067|NCT01755455|Erythropoiesis
1059068|NCT01755442|Ambulatory blood pressure
1059069|NCT01755442|Type 2 diabetes
1059070|NCT01755416|Type 1 diabetes
1059071|NCT01755416|closed loop
1059072|NCT01755416|artificial pancreas
1059073|NCT01755416|insulin
1059074|NCT01755416|victoza
1059075|NCT01755416|liraglutide
1059076|NCT01755338|cerebrospinal fluid
1059077|NCT01755338|inflammatory markers
1059078|NCT01755338|heart surgery
1059079|NCT01755338|neuronal damage
1059080|NCT01755338|blood brain barrier
1059081|NCT01755299|Energy drinks
1059082|NCT01755299|Wakefulness
1059083|NCT01755299|Caffeine
1059084|NCT01755273|Pancreaticoduodenectomy
1059085|NCT01755273|Diabetes
1059086|NCT01755260|POPF
1059087|NCT01755260|pancreaticoduodenectomy
1059088|NCT01755260|enteral nutrition
1059089|NCT01755260|parenteral nutrition
1059090|NCT01755247|acne
1059091|NCT01755234|Outpatient
1059092|NCT01755234|Surgery
1059093|NCT01755234|Anesthesia
1059094|NCT01755221|Laryngopharyngeal reflux (LPR)
1059095|NCT01755221|Extraesophageal reflux
1059096|NCT01755221|Reflux laryngitis
1059097|NCT01755221|Posterior laryngitis
1059098|NCT01755221|Proton pump inhibitor (PPI) medication
1059099|NCT01755221|Restech pH probe
1059105|NCT01755182|locoregional treatment
1059106|NCT01755182|liver metastases
1059107|NCT01755182|transarterial embolization
1059108|NCT01755182|upfront treatment
1059109|NCT01755182|inoperable
1059110|NCT01755182|octreotide
1059111|NCT01755182|gastroenteropancreatic (GEP)primary
1059112|NCT01755182|pulmonary primary
1059113|NCT01755182|primary unknown origin
1059114|NCT01755182|systemic therapy
1059115|NCT01755169|Chronic pain
1059116|NCT01755169|Child
1059117|NCT01755169|Pediatric
1059118|NCT01755169|Ketamine
1059119|NCT01755130|Breast Cancer
1059120|NCT01755130|LOUIS-3D
1059121|NCT01755130|Breast Study
1059122|NCT01755130|x-ray
1059123|NCT01755130|Multimode Laser Optoacoustic Ultrasonic Tomography System
1059124|NCT01755130|Mass palpable or nonpalpable
1059125|NCT01755130|Breast lesions
1059126|NCT01755130|Ductal carcinomas
1059127|NCT01755130|Lobular carcinomas
1059128|NCT01755130|Fibroadenomas
1059129|NCT01755078|Phosphate binder
1059130|NCT01755065|laparoscopic surgery
1059131|NCT01755065|teenager
1059132|NCT01755052|Acute Myocardial Infarction
1059133|NCT01755052|Geriatrics
1059134|NCT01755052|Cardiology
1059135|NCT01755052|Aging
1059136|NCT01755052|Heart Attack
1059137|NCT01755052|Risk Factors
1059138|NCT01755052|Quality of Care
1059139|NCT01755052|Risk Models
1059140|NCT01755026|Cesarean Delivery
1059141|NCT01755026|Wound infection
1059142|NCT01755026|Obesity
1059143|NCT01755026|Prophylactic antibiotics
1059144|NCT01755013|Cholangiocarcinoma
1059145|NCT01755013|Biliary Stricture
1059146|NCT01755013|Biliary obstruction
1059147|NCT01755013|Bile Duct Cancer
1059148|NCT01755013|PDT
1059149|NCT01755013|Photodynamic Therapy
1059150|NCT01755013|Plastic optic Diffuser
1059151|NCT01755013|Laser
1059152|NCT01754987|Vitamins
1059153|NCT01754987|Malignant Tumor, Tumour
1059154|NCT01754987|Integrative Medicine
1059155|NCT01754987|Complementary Medicine
1059156|NCT01754987|Alternative Medicine Antioxidants
1059157|NCT01754987|Molecular Mechanisms of Pharmacological Action
1059158|NCT01754987|Pharmacologic Actions
1059159|NCT01754987|Protective Agents
1059160|NCT01754987|Physiological Effects of Drugs
1059161|NCT01754987|Micronutrients
1059162|NCT01754987|Growth Substances
1059163|NCT01754987|Antineoplastic Agents, Phytogenic
1059164|NCT01754987|Antineoplastic Agents
1059165|NCT01754987|Therapeutic Uses
1059166|NCT01754987|Radiation-Sensitizing Agents
1059167|NCT01754987|Liver Cancer
1059168|NCT01754948|asthma
1059169|NCT01754948|reactive airway disease
1059170|NCT01754948|cough
1059171|NCT01754948|air pollution
1059172|NCT01754948|nano particles
1059173|NCT01754922|exercise tolerance
1059174|NCT01754922|Veterans
1059175|NCT01754922|operation enduring freedom
1059176|NCT01754922|operation Iraqi freedom
1059177|NCT01754909|lung cancer
1059178|NCT01754909|radiation pneumonitis
1059179|NCT01754909|mitigation
1059180|NCT01754909|enalapril
1059181|NCT01754909|placebo
1059182|NCT01754896|colorectal cancer
1059183|NCT01754896|fecal immunochemical test
1059184|NCT01754896|fecal occult blood test
1059185|NCT01754896|screening
1059186|NCT01754883|Posttraumatic Stess Disorder
1059187|NCT01754883|Lithium
1059188|NCT01754870|CLL
1059189|NCT01754870|SLL
1059190|NCT01754857|Lymphoid Leukemia
1059191|NCT01754857|Bendamustine
1059192|NCT01754857|Rituximab
1059193|NCT01754857|Small Lymphocytic Lymphoma
1059194|NCT01754844|Phase 1
1059195|NCT01754844|Healthy Volunteers
1059196|NCT01754844|Single Ascending Dose (SAD)
1059197|NCT01754844|First Time in Man
1059198|NCT01754844|Pharmacokinetics
1059199|NCT01754844|Pharmacodynamics
1059200|NCT01754831|children
1059201|NCT01754831|fluoride varnish
1059202|NCT01754818|Pharmacokinetics
1059203|NCT01754818|volunteers
1059204|NCT01754805|ASP015K
1059205|NCT01754805|Rheumatoid Arthritis
1059206|NCT01754779|calcium phosphate
1059207|NCT01754779|urolithiasis
1059208|NCT01754779|kidney stones
1059209|NCT01754779|hypercalciuria
1059210|NCT01754753|Mental well-being
1059211|NCT01754753|Befriending
1059212|NCT01754740|Xerostomia, Salivary flow, Burning Mouth Syndrome.
1059213|NCT01754727|Ankylosing Spondylitis
1059214|NCT01754727|Effectiveness
1059215|NCT01754727|Post-marketing observational study (PMOS)
1059216|NCT01754727|Adalimumab
1059217|NCT01754727|Humira®
1059218|NCT01754714|Steatohepatitis
1059219|NCT01754662|Type 2 diabetes
1059220|NCT01754662|Cardiovascular risk
1059221|NCT01754662|Endothelial function
1059222|NCT01754662|Insulin resistance
1059223|NCT01754662|Soy
1059224|NCT01754662|Isoflavones
1059225|NCT01754662|Cocoa
1059226|NCT01754662|Diet
1059227|NCT01754649|intrauterine device
1059228|NCT01754649|insertion failure
1059229|NCT01754636|Colorectal neoplasms
1059230|NCT01754636|Elderly
1059231|NCT01754636|Randomized clinical trials
1059232|NCT01754636|Inclusion.
1059233|NCT01754623|Pancreas
1059234|NCT01754623|Pancreatic
1059235|NCT01754623|Neoplasms
1059236|NCT01754623|Stereotactic
1059237|NCT01754623|Radiosurgery
1059238|NCT01754623|Borderline
1059239|NCT01754623|Resectable
1059240|NCT01754623|Gastrointestinal
1059241|NCT01754623|Gemcitabine
1059242|NCT01754623|Capecitabine
1059243|NCT01754623|Fluorouracil
1059244|NCT01754623|Docetaxel
1059245|NCT01754623|SBRT
1059246|NCT01754623|GTX Chemotherapy
1059247|NCT01754610|family trauma
1059248|NCT01754610|multi-family therapy
1059249|NCT01754610|Posttraumatic Stress Disorder
1059250|NCT01754610|poverty
1059251|NCT01754597|Patients with breast cancer requiring surgical management with general anesthesia
1059252|NCT01754584|hyaluronan including concentrations
1059253|NCT01754584|molecular weight
1059254|NCT01754584|mucociliary differentiation
1059255|NCT01754584|human respiratory epithelial cells
1059256|NCT01754571|medication overuse headache
1059257|NCT01754545|Infusions, Intravenous
1059258|NCT01754545|Plasma
1059259|NCT01754545|ADAMTS-13 protein, human
1059260|NCT01754532|Schizophrenia
1059261|NCT01754532|Schizo-Affective Disorder
1059262|NCT01754532|Stress
1059263|NCT01754532|Cortisol
1059264|NCT01754532|PANSS
1059265|NCT01754506|leg ulcers
1059266|NCT01754506|wounds
1059267|NCT01754506|fish oil
1059268|NCT01754506|lipid mediators
1059269|NCT01754506|chronic venous stasis ulcers
1059270|NCT01754493|Major Depression
1059271|NCT01754493|Irritable Bowel Syndrome
1059272|NCT01754493|Somatization
1059273|NCT01754493|Cymbalta
1059274|NCT01754493|Duloxetine
1059275|NCT01754480|Fibrin Sealant
1059276|NCT01754480|Parenchymous tissue open surgery
1059277|NCT01754480|Hepatic Resection
1059278|NCT01754480|Oxidized cellulose pads
1059279|NCT01754441|Spinal Muscular Atrophy
1059280|NCT01754441|SMA
1059281|NCT01754441|Motor Neuron Abnormalities
1059282|NCT01754428|Respiratory
1059283|NCT01754428|Syncytial
1059284|NCT01754428|Virus
1059285|NCT01754428|RSV
1059286|NCT01754415|Aging
1059287|NCT01754415|Chronic illness
1059288|NCT01754415|Resistance circuit training
1059289|NCT01754402|Multiple Myeloma
1059290|NCT01754376|Metastatic
1059291|NCT01754376|Unresectable
1059292|NCT01754376|V600E mutation
1059293|NCT01754363|Osteoarthritis
1059294|NCT01754350|ketogenic diet
1059295|NCT01754350|glioma
1059296|NCT01754350|fasting
1059297|NCT01754350|reirradiation
1059298|NCT01754350|nutrition
1059299|NCT01754337|Type 1 diabetes
1059300|NCT01754337|Hypoglycemia
1059301|NCT01754337|Insulin
1059302|NCT01754337|Glucagon
1059303|NCT01754337|Closed-loop system
1059304|NCT01754337|Artificial pancreas
1059305|NCT01754324|Neonatal Abstinence Syndrome
1059306|NCT01754324|Pharmacokinetics
1059307|NCT01754324|Methadone
1059308|NCT01754324|Neonate
1059309|NCT01754324|Newborn
1059310|NCT01754311|HTLV-I
1059311|NCT01754298|osteochondritis dissecans (OCD)
1059312|NCT01754298|juvenile osteochondritis dissecans (JOCD)
1059313|NCT01754298|knee osteochondritis dissecans
1059314|NCT01754298|retro-articular drilling
1059315|NCT01754298|trans-articular drilling
1059316|NCT01754298|stable osteochondritis dissecans lesion
1059317|NCT01754272|metastatic colorectal cancer
1059318|NCT01754272|mCRC
1059319|NCT01754272|Aflibercept
1059320|NCT01754272|FOLFIRI
1059321|NCT01754272|translational research
1059322|NCT01754272|retrospective
1059323|NCT01754272|noninterventional
1059324|NCT01754272|biomarkers
1059325|NCT01754272|angiogenesis
1059326|NCT01754259|type 1 diabetes
1059327|NCT01754259|type 2 diabetes
1059328|NCT01754259|exertion angina
1059329|NCT01754259|suspected CAD
1059330|NCT01754259|known CAD
1059331|NCT01754194|Gastric Sleeve
1059332|NCT01754194|Gastric Bypass
1059333|NCT01754194|Roux en Y
1059334|NCT01754194|Morbid Obesity
1059335|NCT01754194|Laparoscopy
1059336|NCT01754181|Glycemic control algorithm
1059337|NCT01754181|closed loop
1059338|NCT01754181|artificial pancreas
1059339|NCT01754168|Parkinson disease
1059340|NCT01754168|Cognition
1059341|NCT01754155|Vitamin E
1059342|NCT01754155|Zimmer
1059343|NCT01754155|RSA
1059344|NCT01754155|Radiostereometric Analysis
1059345|NCT01754129|Caregiver
1059346|NCT01754129|Quality of Life
1059347|NCT01754129|Parkinson's Disease
1059348|NCT01754116|healthy subjects
1059349|NCT01754116|GSK1265744 LAP
1059350|NCT01754116|integrase inhibitor
1059351|NCT01754116|HIV-1 infection
1059352|NCT01754116|long acting retroviral
1059353|NCT01754116|relative bioavailability
1059354|NCT01754103|blind
1059355|NCT01754103|tactile stimulation
1059356|NCT01754103|cross-modality
1059357|NCT01754103|visual qualia
1059358|NCT01754103|resting state MRI
1059359|NCT01754103|functional connectivity
1059360|NCT01754103|neuroplasticity
1059361|NCT01754090|alcohol
1059362|NCT01754090|online intervention
1059363|NCT01754090|hazardous drinking
1059364|NCT01754090|harmful drinking
1059365|NCT01754090|early intervention
1059366|NCT01754090|behavior change intervention
1059367|NCT01754077|Language
1059368|NCT01754077|Behavior change
1059369|NCT01754077|Intervention
1059370|NCT01754077|Home visiting
1059371|NCT01754077|Child language development
1059372|NCT01754064|Bradycardia
1059373|NCT01754064|Tachycardia
1059374|NCT01754064|Arrhythimas
1059375|NCT01754064|ICD
1059376|NCT01754064|pacemaker
1059377|NCT01754064|pacing lead
1059378|NCT01754038|Patient Reported Outcomes
1059379|NCT01754038|PRO
1059380|NCT01754038|Registry
1059381|NCT01754025|Gene Mutation
1059382|NCT01754012|Nutrition
1059383|NCT01754012|Dietary intervention
1059384|NCT01754012|Aging
1059385|NCT01754012|Inflammation
1059386|NCT01754012|Elderly
1059387|NCT01754012|Europe
1059388|NCT01753999|World Trade Center (WTC)
1059389|NCT01753999|nasal symptoms
1059390|NCT01753999|nasal inflammation
1059391|NCT01753999|CPAP
1059392|NCT01753973|Metabolic syndrome
1059393|NCT01753973|Renal transplantation
1059394|NCT01753895|Healthy Volunteers
1059395|NCT01753882|Gait training
1059396|NCT01753882|Lexapro
1059397|NCT01753882|Tizanidine
1059398|NCT01753843|Preterm Birth
1059399|NCT01753830|Double-blind
1059400|NCT01753830|Randomized
1059401|NCT01753830|Intraarticular injection
1059402|NCT01753830|Hyaluronic acid
1059403|NCT01753830|Placebo
1059404|NCT01753830|Knee osteoarthritis
1059405|NCT01753817|Coronary catheterization
1059406|NCT01753817|Transradial patency
1059407|NCT01753804|DMD
1059408|NCT01753804|Myopathy
1059409|NCT01753804|Natural History
1059410|NCT01753804|Muscular dystrophy
1059411|NCT01753804|Biomarkers
1059412|NCT01753804|Muscle testing
1059413|NCT01753778|Nerve Entrapment, Morton's neuroma, entrapment neuropathy
1059414|NCT01753765|occipital neuralgia
1059415|NCT01753726|stretching, diaphragm, spinal movement, thoracic movement
1059416|NCT01753700|crossover
1059417|NCT01753700|UHT milk
1059418|NCT01753700|Pasteurised milk
1059419|NCT01753700|supplement
1059420|NCT01753687|break up time
1059421|NCT01753687|tear film thickness
1059422|NCT01753687|tear film osmolarity
1059423|NCT01753687|objective scattering index
1059424|NCT01753687|impression cytology
1059425|NCT01753687|tear cytokines/chemokines
1059426|NCT01753687|visual acuity
1059427|NCT01753687|fluorescein staining
1059428|NCT01753674|metabolic syndrome, insulin resistance, HDL cholesterol,
1059429|NCT01753661|Hearing loss
1059430|NCT01753661|Language
1059431|NCT01753661|Behavior change
1059432|NCT01753661|Early Intervention
1059433|NCT01753661|Home visiting
1059434|NCT01753648|retinal blood flow
1059435|NCT01753648|retinal blood velocity
1059436|NCT01753648|retinal oxygen saturation
1059437|NCT01753648|retinal vessel diameter
1059438|NCT01753648|ocular perfusion pressure
1059439|NCT01753635|Baska mask
1059440|NCT01753635|LMA
1059441|NCT01753635|single use LMA device
1059442|NCT01753635|laryngeal mask airway
1059443|NCT01753635|supraglottic airway device
1059444|NCT01753622|Overweight, obese, pregnant, depression, outcomes
1059445|NCT01753609|Over weight
1059446|NCT01753609|Obesity
1059447|NCT01753596|topical lubricants
1059448|NCT01753596|tear film thickness
1059449|NCT01753596|break up time
1059450|NCT01753596|ocular surface disease index
1059451|NCT01753596|Schirmer I test
1059452|NCT01753583|optical coherence tomography
1059453|NCT01753583|corneal abrasion
1059454|NCT01753583|corneal infiltrate
1059455|NCT01753570|Feron
1059456|NCT01753557|Pegasys
1059457|NCT01753531|Ultra Influenza A and B
1059458|NCT01753531|Influenza Type A
1059459|NCT01753531|Influenza Type B
1059460|NCT01753531|Flu
1059461|NCT01753531|Sekisui Diagnostics
1059462|NCT01753518|Subcuticular suture
1059463|NCT01753518|Subcuticular staple
1059464|NCT01753518|Skin closure
1059465|NCT01753518|Incision closure
1059466|NCT01753518|Wound
1059467|NCT01753505|multidetector coronary CT angiography, renal transplantation
1059468|NCT01753492|Intraocular pressure
1059469|NCT01753492|glaucoma
1059470|NCT01753492|trabeculectomy
1059471|NCT01753492|Ologen
1059472|NCT01753479|Pancreatic adenocarcinoma
1059473|NCT01753453|Hematopoietic stem cell transplantation
1059474|NCT01753453|Tumour cell mobilization
1059475|NCT01753440|coronary artery disease
1059476|NCT01753440|heart failure
1059477|NCT01753440|stem cells implantation
1059478|NCT01753427|COPD,
1059479|NCT01753427|symptoms,
1059480|NCT01753427|Non-Interventional study,
1059481|NCT01753414|Lung Cancer
1059482|NCT01753401|SLE
1059483|NCT01753401|Lupus
1059484|NCT01753375|Multiple Sclerosis
1059485|NCT01753375|Relapsing rate
1059486|NCT01753375|Expanded disability status scale
1059487|NCT01753375|Vitamin D3
1059488|NCT01753323|acute malaria, KAF156
1059489|NCT01753245|Anti-TNF drugs efficacy
1059490|NCT01753245|Moderate-to-severe psoriasis vulgaris
1059491|NCT01753245|Gene polymorphism
1059492|NCT01753232|DALI adsorber
1059493|NCT01753232|MONET lipoprotein filter
1059494|NCT01753193|Systemic Lupus Erythematosus
1059495|NCT01753180|CTO
1059496|NCT01753180|PCI
1059497|NCT01753180|Angioplasty
1059498|NCT01753154|Peritoneal Dialysis
1059499|NCT01753154|Biocompatible dialysis solution
1059500|NCT01753154|Hydration status
1059501|NCT01753154|Residual renal function
1059502|NCT01753154|Body composition monitor
1059503|NCT01753154|Bioimpedance spectroscopy
1059504|NCT01753154|Cancer antigen 125
1059505|NCT01753141|Cognitive Behavioral Therapy
1059506|NCT01753141|Smoking Cessation
1059507|NCT01753115|post-exposure prophylaxis
1059508|NCT01753115|toxin neutralization assay
1059509|NCT01753102|Estradiol
1059510|NCT01753102|Vulvar atrophy
1059511|NCT01753102|vaginal atrophy
1059512|NCT01753089|Metastatic
1059513|NCT01753076|Amyotrophic lateral sclerosis
1059514|NCT01753076|efficacy
1059515|NCT01753076|ozanezumab
1059516|NCT01753076|safety
1059517|NCT01753063|Obesity
1059518|NCT01753063|Children
1059519|NCT01753063|Adolescents
1059520|NCT01753063|Attrition
1059521|NCT01753037|Hyperandrogenism
1059522|NCT01753037|Inflammation
1059523|NCT01753037|Insulin sensitivity
1059524|NCT01753037|Body composition
1059525|NCT01753024|exocrine pancreatic insufficiency
1059526|NCT01753024|fecal elastase-1
1059527|NCT01753024|amylase
1059528|NCT01753024|lipase
1059529|NCT01753024|critical illness
1059530|NCT01753024|enteral nutrition
1059531|NCT01753024|malnutrition
1059532|NCT01753024|sepsis
1059533|NCT01753024|diabetes
1059534|NCT01753024|hyperlactacidemia
1059535|NCT01753024|hemodialysis
1059536|NCT01753024|mechanical ventilation
1059537|NCT01753011|Stress urinary Incontinence
1059538|NCT01753011|Transobturator sling
1059539|NCT01753011|TOT
1059540|NCT01752998|pain
1059541|NCT01752998|depression
1059542|NCT01752998|substance use
1059543|NCT01752972|Arsenic
1059544|NCT01752972|Keratosis
1059545|NCT01752972|Linoleic acid
1059546|NCT01752972|Palm
1059547|NCT01752972|Spirulina
1059548|NCT01752972|Vitamin E
1059549|NCT01752972|Zinc
1059550|NCT01752920|FGFR
1059551|NCT01752920|ARQ 087
1059552|NCT01752920|Targeted therapy
1059553|NCT01752920|Molecular therapy
1059554|NCT01752920|Tyrosine kinase inhibitor
1059555|NCT01752920|TKI
1059556|NCT01752920|Receptor tyrosine kinase
1059557|NCT01752920|RTK
1059558|NCT01752920|Biomarker
1059559|NCT01752920|Phase 1
1059560|NCT01752920|Phase I
1059561|NCT01752920|Solid tumor
1059562|NCT01752920|Liver Cancer
1059563|NCT01752920|Hepatobiliary carcinoma
1059564|NCT01752920|Biliary tract cancer
1059565|NCT01752920|Cholangiocarcinoma
1059566|NCT01752920|Intrahepatic cholangiocarcinoma
1059567|NCT01752920|FGFR inhibitor
1059568|NCT01752920|Targeted FGFR kinase inhibitor
1059569|NCT01752920|Pan-FGFR inhibitor
1059570|NCT01752920|Selective FGFR inhibitor
1059571|NCT01752920|FGFR pathway
1059572|NCT01752920|FGFR signaling
1059573|NCT01752920|Fibroblast growth factor
1059574|NCT01752920|FGFR1
1059575|NCT01752920|FGFR2
1059576|NCT01752920|FGFR3
1059577|NCT01752920|FGFR4
1059578|NCT01752920|FGF
1059579|NCT01752920|FGF19
1059580|NCT01752920|FGF21
1059581|NCT01752920|FGF23
1059582|NCT01752920|FGFR mutation
1059583|NCT01752920|FGFR gene fusion
1059584|NCT01752920|FGFR gene translocation
1059585|NCT01752920|FGFR genetic aberration
1059586|NCT01752920|FGFR2 fusion
1059587|NCT01752920|FGFR2 translocation
1059588|NCT01752920|Phase 1 Clinical Trial
1059589|NCT01752920|Phase I Clinical Trial
1059590|NCT01752920|Clinical oncology
1059591|NCT01752920|Tumor
1059592|NCT01752920|Tumour
1059593|NCT01752907|Breast cancer
1059594|NCT01752907|Chemotherapy
1059595|NCT01752907|Pegfilgrastim
1059596|NCT01752907|Neulasta
1059597|NCT01752907|Bone Pain
1059598|NCT01752907|Education
1059599|NCT01752881|Influenza
1059600|NCT01752881|Vaccine
1059601|NCT01752881|Immunogenicity
1059602|NCT01752855|Rheumatoid Arthritis
1059603|NCT01752842|Diabetes
1059604|NCT01752842|Diabetic Cardiomyopathy
1059605|NCT01752842|Triglycerides
1059606|NCT01752829|Obesity
1059607|NCT01752829|gastric
1059608|NCT01752829|banding
1059609|NCT01752829|Weight
1059610|NCT01752829|co-morbidities
1059611|NCT01752829|dilatation
1059612|NCT01752829|Excess weight loss
1059613|NCT01752829|adjustable gastric banding
1059614|NCT01752816|endurance training,
1059615|NCT01752816|strength training,
1059616|NCT01752816|aerobic capacity,
1059617|NCT01752816|muscle strenght
1059618|NCT01752816|physical capacity
1059619|NCT01752790|Pediatric Crohn's disease
1059620|NCT01752790|Biologics
1059621|NCT01752790|Immunomodulators
1059622|NCT01752790|Top-down
1059623|NCT01752790|step-up
1059624|NCT01752777|HIV/AIDS, HIV infectiousness, Medication adherence, Sexual risks reduction
1059625|NCT01752751|Neck cancer
1059626|NCT01752751|Head cancer
1059627|NCT01752751|Lung cancer
1059628|NCT01752725|supracervical hysterectomy
1059629|NCT01752725|vessel sealing
1059630|NCT01752725|bipolar electrocoagulation
1059631|NCT01752712|Oxytocin
1059632|NCT01752712|Social function
1059633|NCT01752712|CBSST
1059634|NCT01752699|neuropathic pain,
1059635|NCT01752699|post-herpetic neuralgia,
1059636|NCT01752699|methadone,
1059637|NCT01752686|Triple negative breast cancer
1059638|NCT01752686|adjuvant chemotherapy
1059639|NCT01752673|randomized controlled study
1059640|NCT01752660|Exercise therapy
1059641|NCT01752660|Aerobic training
1059642|NCT01752660|Endurance training
1059643|NCT01752647|lung cancer
1059644|NCT01752647|screening
1059645|NCT01752647|low dose
1059646|NCT01752647|computed tomography
1059647|NCT01752634|Psoriatic arthritis, PsA, ACR, CASPAR, PASDAS
1059648|NCT01752621|Acromegaly
1059649|NCT01752621|mortality
1059650|NCT01752621|morbidity
1059651|NCT01752621|incidence
1059652|NCT01752621|prevalence
1059653|NCT01752608|Depression
1059654|NCT01752608|Real-time
1059655|NCT01752608|iPhone
1059656|NCT01752608|CBT
1059657|NCT01752608|Cognitive behavioral therapy
1059658|NCT01752582|BuMA
1059659|NCT01752582|EXCEL
1059660|NCT01752582|OCT
1059661|NCT01752582|stent
1059662|NCT01752582|neointima formation
1059663|NCT01752569|HIV
1059664|NCT01752569|Kaposi's sarcoma
1059665|NCT01752569|Anti-retroviral therapy
1059666|NCT01752569|HAART
1059667|NCT01752569|AIDS
1059668|NCT01752556|Sleep apnea, Portable monitor,autoCPAP
1059669|NCT01752543|Vasopressin
1059670|NCT01752543|Exercise capacity
1059671|NCT01752543|Conivaptan
1059672|NCT01752530|ADHD
1059673|NCT01752517|small cell lung cancer
1059674|NCT01752517|chemotherapy
1059675|NCT01752517|vinorelbine
1059676|NCT01752517|ifosfamide
1059677|NCT01752517|third-line treatment
1059678|NCT01752504|HIV prevention
1059679|NCT01752504|HIV positive communities
1059680|NCT01752491|Ascorbate
1059681|NCT01752491|Ascorbic acid
1059682|NCT01752491|Vitamin C
1059683|NCT01752491|Radiation
1059684|NCT01752491|Temozolomide
1059685|NCT01752478|ptosis
1059686|NCT01752478|retina surgery
1059687|NCT01752478|droopy eye lid
1059688|NCT01752465|Health behaviour
1059689|NCT01752465|Antipsychotic agents
1059690|NCT01752465|Adverse effects
1059691|NCT01752465|Goals
1059692|NCT01752465|Life style
1059693|NCT01752439|Chronic Migraine
1059694|NCT01752439|Medication Overuse Headache
1059695|NCT01752439|Refractory
1059696|NCT01752439|transcranial direct current stimulation
1059697|NCT01752426|Leukemia
1059698|NCT01752426|Chronic Lymphocytic Leukemia
1059699|NCT01752426|CLL
1059700|NCT01752426|Small Lymphocytic Lymphoma
1059701|NCT01752426|SLL
1059702|NCT01752426|PCI-32765
1059703|NCT01752426|Ibrutinib
1059704|NCT01752426|Btk inhibitor
1059705|NCT01752426|Heavy water
1059706|NCT01752426|2H2O
1059707|NCT01752413|Iron depletion
1059708|NCT01752413|blood donors
1059709|NCT01752413|iron replacement
1059710|NCT01752400|Advanced
1059711|NCT01752361|Gastrointestinal Motility
1059712|NCT01752361|Inflammatory Bowel Disease
1059713|NCT01752361|Transit time
1059714|NCT01752348|sepsis
1059715|NCT01752348|cytokine release
1059716|NCT01752348|fever
1059717|NCT01752335|Rheumatoid Arthritis, tocilizumab, cardiovascular risk factors
1059718|NCT01752309|Early Rheumatoid arthritis
1059719|NCT01752309|Rheumatoid arthritis
1059720|NCT01752309|Ultrasound
1059721|NCT01752309|Predictive
1059722|NCT01752309|Prognosis
1059723|NCT01752296|Morquio
1059724|NCT01752296|Mucopolysaccharidosis IV
1059725|NCT01752296|Psychological health
1059726|NCT01752283|Videoassited
1059727|NCT01752283|Thyroidectomy
1059728|NCT01752283|Minimal invasive surgery
1059729|NCT01752283|General anesthesia
1059730|NCT01752283|Hypnosis
1059731|NCT01752257|Melanoma
1059732|NCT01752244|Obesity, vitamin D analogue, VDR, PPARg, PGC1a
1059733|NCT01752218|Femto-second Laser
1059734|NCT01752218|arcuate incision
1059735|NCT01752218|corneal astigmatism
1059736|NCT01752218|astigmatic keratotomy
1059737|NCT01752218|Cataract
1059738|NCT01752205|Esophageal Squamous Carcinoma
1059739|NCT01752205|Erlotinib
1059740|NCT01752205|Chemoradiotherapy
1059741|NCT01752192|Rehabilitation
1059742|NCT01752192|Telemedicine
1059743|NCT01752192|Heart patients
1059744|NCT01752192|Social media
1059745|NCT01752192|Organisational aspects
1059746|NCT01752179|Kinesio taping
1059747|NCT01752179|Piriformis syndrome
1059748|NCT01752179|Trigger point
1059749|NCT01752166|Candida
1059750|NCT01752166|Candidemia
1059751|NCT01752166|Blood culture
1059752|NCT01752166|Diagnostics
1059753|NCT01752153|Focus
1059754|NCT01752153|immunomodulatory effect
1059755|NCT01752153|of silymarin
1059756|NCT01752153|on cell mediated immunity
1059757|NCT01752153|Beta-Thalassemia
1059758|NCT01752153|major patients.
1059759|NCT01752140|Prostate cancer
1059760|NCT01752140|Prostate biopsy
1059761|NCT01752140|Vienna nomogram
1059762|NCT01752127|Drug-eluting stent
1059763|NCT01752127|diabetes
1059764|NCT01752127|small vessel disease
1059765|NCT01752114|Precancerous conditions
1059766|NCT01752114|Carcinoma
1059767|NCT01752101|Precancerous Conditions
1059768|NCT01752101|Carcinoma
1059769|NCT01752088|apularis, MRI clinical, results
1059770|NCT01752075|Multiple myeloma
1059771|NCT01752062|Chronic Myeloid Leukemia
1059772|NCT01752062|CML
1059773|NCT01752062|Pregnancy
1059774|NCT01752049|Hereditary Hemorrhagic Telangiectasia
1059775|NCT01752049|Anti-angiogenic Therapy
1059776|NCT01752049|vascular malformations
1059777|NCT01752049|HHT
1059778|NCT01752036|stereotactic radiotherapy
1059779|NCT01752036|SRS
1059780|NCT01751984|lipid-lowering drugs
1059781|NCT01751984|statin intolerance
1059782|NCT01751945|EmONC
1059783|NCT01751945|Neonatal mortality
1059784|NCT01751945|Perinatal mortality
1059785|NCT01751919|CML
1059786|NCT01751919|GIST
1059787|NCT01751906|Absorb™ BVS
1059788|NCT01751906|Angioplasty
1059789|NCT01751906|Bioabsorbable
1059790|NCT01751906|BVS
1059791|NCT01751906|Bioresorbable
1059792|NCT01751906|Coronary Artery Disease
1059793|NCT01751906|Coronary Artery Endothelial Responsiveness
1059794|NCT01751906|Coronary artery restenosis
1059795|NCT01751906|Coronary artery stenosis
1059796|NCT01751906|Coronary scaffold
1059797|NCT01751906|Coronary Stent
1059798|NCT01751906|Drug eluting stents
1059799|NCT01751906|Everolimus
1059800|NCT01751906|Myocardial ischemia
1059801|NCT01751906|Stent thrombosis
1059802|NCT01751906|Stents
1059803|NCT01751893|Hand-foot syndrome
1059804|NCT01751893|palmar-plantar erythrodysesthesia
1059805|NCT01751893|capecitabine
1059806|NCT01751893|pegylated liposomal doxorubicin
1059807|NCT01751893|henna
1059808|NCT01751880|Gastric cancer, minimally invasive gastrectomy, Physical activity intervention
1059809|NCT01751867|Myelodysplastic Syndrome
1059810|NCT01751867|Dacogen
1059811|NCT01751867|Oncology
1059812|NCT01751867|Decitabine
1059813|NCT01751867|Bone marrow disorders
1059814|NCT01751854|pharmacology
1059815|NCT01751854|rehabilitation
1059816|NCT01751854|locomotion
1059817|NCT01751828|Depression
1059818|NCT01751828|Major Depressive Disorder
1059819|NCT01751802|Lesch Nyhan Disease
1059820|NCT01751802|Self-Injury
1059821|NCT01751789|illicit opioid drug use
1059822|NCT01751789|health service utilization
1059823|NCT01751737|prostate
1059824|NCT01751737|cancer
1059825|NCT01751737|biopsy
1059826|NCT01751737|18F-choline
1059827|NCT01751737|PET
1059828|NCT01751737|MRI
1059829|NCT01751724|Premature infants
1059830|NCT01751724|Caffeine
1059831|NCT01751724|Methylxanthines
1059832|NCT01751724|Mechanical ventilation
1059833|NCT01751724|Oxygen
1059834|NCT01751724|Weaning
1059835|NCT01751724|Bronchopulmonary dysplasia
1059836|NCT01751698|Autism
1059837|NCT01751698|Minimally Verbal
1059838|NCT01751698|School Age
1059839|NCT01751685|kyphosis
1059840|NCT01751672|SBIRT
1059841|NCT01751672|Substance Use
1059842|NCT01751672|Screening
1059843|NCT01751672|Brief Intervention
1059844|NCT01751672|Primary Care
1059845|NCT01751633|Burst fractures
1059846|NCT01751633|Thoracic or Lumbar Vertebrae/injuries [MeSH]
1059847|NCT01751633|Thoracic or Lumbar Vertebrae/surgery [MeSH]
1059848|NCT01751633|Spinal Fusion/methods [MeSH]
1059849|NCT01751633|Thoracolumbar fracture management
1059850|NCT01751633|Quality of life
1059851|NCT01751633|Functional outcome
1059852|NCT01751607|AF, catheter ablation, non-PV triggers, SNP
1059853|NCT01751581|Obesity
1059854|NCT01751581|Resting Metabolic Rate
1059855|NCT01751581|Sleep
1059856|NCT01751581|Eating
1059857|NCT01751555|HBV co-infection ART TDF
1059858|NCT01751529|renal malignancy
1059859|NCT01751529|Pilot Study
1059860|NCT01751529|LCCC 1219
1059861|NCT01751529|UNC Lineberger
1059862|NCT01751529|kidney cancer
1059863|NCT01751529|contrast-enhanced ultrasound
1059864|NCT01751529|ultrasound
1059865|NCT01751503|Foot drop deformity
1059866|NCT01751503|gold standard treatment
1059867|NCT01751503|Tibialis posterior tendon transfer
1059868|NCT01751503|Interosseous route
1059869|NCT01751503|Extramembranous or circumtibial route
1059870|NCT01751490|shoulder
1059871|NCT01751490|instability
1059872|NCT01751490|atraumatic
1059873|NCT01751477|Very Low Birth Weight Infants
1059874|NCT01751477|Probiotics
1059875|NCT01751477|Necrotizing Enterocolitis
1059876|NCT01751464|youth
1059877|NCT01751464|violence
1059878|NCT01751464|injury
1059879|NCT01751464|emergency department
1059880|NCT01751464|intervention
1059881|NCT01751451|ABIRATERONE ACETATE (CB 7630)
1059882|NCT01751451|DEGARELIX
1059883|NCT01751451|PREDNISONE
1059884|NCT01751451|12-187
1059885|NCT01751438|Prostate cancer
1059886|NCT01751438|Prostate carcinoma
1059887|NCT01751438|Metastatic
1059888|NCT01751438|M1
1059889|NCT01751438|Best Systemic Therapy
1059890|NCT01751438|BST
1059891|NCT01751438|Androgen deprivation therapy
1059892|NCT01751438|Bilateral orchiectomy
1059893|NCT01751438|Radiation
1059894|NCT01751438|Radiation Therapy
1059895|NCT01751438|External beam radiation therapy
1059896|NCT01751438|External-beam radiotherapy
1059897|NCT01751438|Xray therapy
1059898|NCT01751438|XRT
1059899|NCT01751438|Surgery
1059900|NCT01751425|Leukemia
1059901|NCT01751425|Chronic Myeloid Leukemia
1059902|NCT01751425|CML
1059903|NCT01751425|Minimal Residual Disease
1059904|NCT01751425|Philadelphia chromosome
1059905|NCT01751425|(Ph)-positive
1059906|NCT01751425|BCR/ABL-positive
1059907|NCT01751425|Ruxolitinib
1059908|NCT01751425|Jakafi
1059909|NCT01751425|INCB018424
1059910|NCT01751425|INC424
1059911|NCT01751425|TKI
1059912|NCT01751425|Tyrosine kinase inhibitor
1059913|NCT01751412|Hodgkin
1059914|NCT01751412|Non-Hodgkin Lymphoma
1059915|NCT01751412|Mediastinal
1059916|NCT01751412|Adult Lymphoma
1059917|NCT01751412|Pediatric Lymphoma
1059918|NCT01751386|Addiction
1059919|NCT01751386|Cue-Induced Craving
1059920|NCT01751386|Craving
1059921|NCT01751386|Anxiety
1059922|NCT01751386|Alcohol Consumption
1059923|NCT01751373|Botulinum Toxin
1059924|NCT01751373|Rehabilitation
1059925|NCT01751373|Electromyography
1059926|NCT01751373|Electroencephalography
1059927|NCT01751373|Transcranial Magnetic Stimulation
1059928|NCT01751347|Local anesthetics
1059929|NCT01751347|Elective hand surgeries
1059930|NCT01751334|Arthroplasty
1059931|NCT01751334|Replacement
1059932|NCT01751334|Knee
1059933|NCT01751334|Rotational Alignment
1059934|NCT01751282|Stem Cells
1059935|NCT01751282|chronic wounds
1059936|NCT01751282|fibrin
1059937|NCT01751282|Bone marrow-derived mesenchymal stem cells
1059938|NCT01751256|Postcesarean Section
1059939|NCT01751256|Postoperative Pain
1059940|NCT01751256|Care, Postoperative
1059941|NCT01751256|Anesthesia, Local
1059942|NCT01751256|Breast Feeding
1059943|NCT01751256|Morphine
1059944|NCT01751256|Pain Measurement
1059945|NCT01751256|levobupivacaine
1059946|NCT01751230|pregnancy
1059947|NCT01751230|weight loss
1059948|NCT01751217|Substance Abuse
1059949|NCT01751217|Adolescents
1059950|NCT01751217|Families
1059951|NCT01751217|Functional Family Therapy
1059952|NCT01751217|Video
1059953|NCT01751217|Teleconferencing
1059954|NCT01751217|Telemedicine
1059955|NCT01751165|≥ 50 years of age
1059956|NCT01751165|Herpes zoster
1059957|NCT01751165|Safety
1059958|NCT01751165|Immunogenicity
1059959|NCT01751165|Adults
1059960|NCT01751139|Endemic regions
1059961|NCT01751139|Brazil
1059962|NCT01751139|Incidence
1059963|NCT01751139|Surveillance
1059964|NCT01751139|Dengue
1059965|NCT01751126|vernal keratoconjunctivitis
1059966|NCT01751126|ciclosporin
1059967|NCT01751126|cyclosporine
1059968|NCT01751087|abortion, induced
1059969|NCT01751074|Drug interaction, rosuvastatin, healthy volunteer, Lp-PLA2, atherosclerosis, darapladib, pharmacokinetics.
1059970|NCT01751061|prolonged mechanical ventilation
1059971|NCT01751061|chronic critical illness
1059972|NCT01751061|decision making
1059973|NCT01751061|decision aid
1059974|NCT01751061|decisional support
1059975|NCT01751061|critical illness
1059976|NCT01751061|intensive care unit
1059977|NCT01751048|GLA-SE,LEISH-F3,leishmaniasis,MPL-SE,parent protocol,vaccine
1059978|NCT01751022|heart failure
1059979|NCT01751022|cardiac pacing
1059980|NCT01751022|cardiac resynchronization therapy
1059981|NCT01751022|left ventricular lead
1059982|NCT01751009|vitamin A, complementary foods, malnutrition, children
1059983|NCT01750983|Advanced Cancers
1059984|NCT01750983|Advanced Malignancies
1059985|NCT01750983|Metastatic cancers
1059986|NCT01750983|Ipilimumab
1059987|NCT01750983|Yervoy
1059988|NCT01750983|BMS-734016
1059989|NCT01750983|MDX010
1059990|NCT01750983|Lenalidomide
1059991|NCT01750983|CC-5013
1059992|NCT01750983|Revlimid
1059993|NCT01750944|Blood pressure site
1059994|NCT01750944|Good health
1059995|NCT01750944|Brachial blood pressure
1059996|NCT01750944|Ankle
1059997|NCT01750944|Toe
1059998|NCT01750944|Walking test
1059999|NCT01750944|Exercise
1060000|NCT01750931|BE study of Meloxicam GSK 15mg
1060001|NCT01750918|MEK inhibitor
1060002|NCT01750918|anti-EGFR antibody
1060003|NCT01750918|colorectal cancer
1060004|NCT01750918|BRAF inhibitor
1060005|NCT01750879|peanut
1060006|NCT01750879|allergy
1060007|NCT01750879|food
1060008|NCT01750879|immunotherapy
1060009|NCT01750879|tolerance
1060010|NCT01750879|desensitization
1060011|NCT01750866|Prostrate Cancer
1060012|NCT01750866|Castrate-resistant metastatic prostate cancer
1060013|NCT01750866|Cabazitaxel
1060014|NCT01750827|platelet function
1060015|NCT01750827|atherosclerosis,
1060016|NCT01750827|SB-659032
1060017|NCT01750801|clinical trial
1060018|NCT01750801|mouthwash
1060019|NCT01750801|propolis
1060020|NCT01750801|plaque
1060021|NCT01750801|gingivitis
1060022|NCT01750801|compliance
1060023|NCT01750788|Stroke
1060024|NCT01750788|Embolism
1060025|NCT01750788|Atrial Fibrillation
1060026|NCT01750775|sinus bradycardia
1060027|NCT01750775|ventricular premature contraction
1060028|NCT01750749|Venous ulcer
1060029|NCT01750749|Cell therapy
1060030|NCT01750736|Augmented Exercise
1060031|NCT01750736|Cervicalgia
1060032|NCT01750736|Manual Therapy
1060033|NCT01750736|Manipulation
1060034|NCT01750736|Quantitative Sensory
1060035|NCT01750723|Acetazolamide
1060036|NCT01750723|Headache
1060037|NCT01750723|Migraine
1060038|NCT01750710|Charcot-Marie-Tooth disease type 1A neuropathy
1060039|NCT01750710|Isokinetic
1060040|NCT01750710|Electromyography
1060041|NCT01750710|Walking
1060042|NCT01750684|Acute
1060043|NCT01750684|Traumatic
1060044|NCT01750684|SCI
1060045|NCT01750684|Spinal Cord Injury
1060046|NCT01750671|ICU
1060047|NCT01750671|Body composition
1060048|NCT01750671|Nutrition
1060049|NCT01750671|Survival
1060050|NCT01750671|Morbidity
1060051|NCT01750658|Biomarkers
1060052|NCT01750658|Exacerbations
1060053|NCT01750658|COPD
1060054|NCT01750593|radiofrequency
1060055|NCT01750593|thyroid
1060056|NCT01750593|nodule
1060057|NCT01750567|Relapsed Chronic Lymphocytic Leukemia
1060058|NCT01750567|untreated CLL patients
1060059|NCT01750567|genomic deletion 11q
1060060|NCT01750554|SpHb; hemoglobin monitoring;bupivacaine digital nerve block
1060061|NCT01750515|Acupuncture
1060062|NCT01750515|Hepatitis C (HCV)
1060063|NCT01750489|COPD
1060064|NCT01750476|oral contraception
1060065|NCT01750476|Depo-Provera
1060066|NCT01750476|Mirena
1060067|NCT01750463|Pediatric critically ill
1060068|NCT01750463|Masimo
1060069|NCT01750463|hemoglobin
1060070|NCT01750463|monitoring
1060071|NCT01750463|UNC
1060072|NCT01750463|PICU
1060073|NCT01750450|Pressure Volume Area
1060074|NCT01750450|Pressure Flow Area
1060075|NCT01750450|Myocardial Work
1060076|NCT01750437|NERD
1060077|NCT01750424|Scar
1060078|NCT01750424|Fat Grafting
1060079|NCT01750424|Adipose Grafting
1060080|NCT01750424|3-D imaging
1060081|NCT01750424|Manchester Scar Scale
1060082|NCT01750411|Severe Asthma
1060083|NCT01750411|SARP
1060084|NCT01750398|Testosterone, Leuprolide, Goserelin
1060085|NCT01750385|Esophageal Achalasia
1060086|NCT01750385|antibiotic prophylaxis
1060087|NCT01750385|blood culture
1060088|NCT01750385|procalcitonin levels
1060089|NCT01750372|Artificial limbs
1060090|NCT01750372|Questionnaires
1060091|NCT01750372|Mobility limitation
1060092|NCT01750359|antioxidants
1060093|NCT01750359|curcumin
1060094|NCT01750359|depression
1060095|NCT01750346|Blepharospasm
1060096|NCT01750346|Treatment
1060097|NCT01750346|Dystonia
1060098|NCT01750346|Acetyl-Hexapeptide
1060099|NCT01750307|Attention Deficit Hyperactivity Disorder (ADHD)
1060100|NCT01750307|Essential fatty acids (EFAs)
1060101|NCT01750307|Electroencephalography (EEG)
1060102|NCT01750307|Event-related potential (ERP)
1060103|NCT01750307|Omega 3
1060104|NCT01750307|Randomised Control Trial
1060105|NCT01750307|Fish oil
1060106|NCT01750307|Supplementation
1060107|NCT01750307|Reading
1060108|NCT01750307|Spelling
1060109|NCT01750307|Behaviour
1060110|NCT01750307|Emotional lability
1060111|NCT01750294|hypertension
1060112|NCT01750294|kidney disease
1060113|NCT01750281|Mitogen-Activated Protein Kinase Kinase inhibitor
1060114|NCT01750281|Non Small Cell Lung Cancer
1060115|NCT01750281|Metastatic
1060116|NCT01750281|Second line treatment for Non Small Cell Lung Cancer
1060117|NCT01750268|TBI
1060118|NCT01750268|hazardous and harmful alcohol use
1060119|NCT01750268|veterans
1060120|NCT01750268|co-occurring disorders
1060121|NCT01750268|pharmacotherapy
1060122|NCT01750255|Pharmaceutical care
1060123|NCT01750255|Pharmacotherapy follow-up
1060124|NCT01750255|Bipolar disorder
1060125|NCT01750255|Pharmacy services
1060126|NCT01750203|Diabetic foot ulcers, venous leg ulcers, pressure sores, acute wounds
1060127|NCT01750190|anemia
1060128|NCT01750190|chronic kidney disease (CKD)
1060129|NCT01750190|non-dialysis
1060130|NCT01750190|Hemoglobin (Hb)
1060131|NCT01750190|End-Stage Renal Disease
1060132|NCT01750190|erythropoeitin
1060133|NCT01750190|ASP1517
1060134|NCT01750190|erythropoeisis stimulating-agent
1060135|NCT01750190|AZD9941
1060136|NCT01750164|Breast Cancer
1060137|NCT01750125|Doppler
1060138|NCT01750112|Pectus excavatum
1060139|NCT01750112|funnel chest
1060140|NCT01750112|sunken chest
1060141|NCT01750099|Labor
1060142|NCT01750099|analgesia
1060143|NCT01750099|epidural
1060144|NCT01750099|spinal
1060145|NCT01750086|osteoporosis
1060146|NCT01750086|postmenopausal
1060147|NCT01750086|denosumab
1060148|NCT01750086|teriparatide
1060149|NCT01750086|alendronate
1060150|NCT01750086|Forteo®
1060151|NCT01750086|Prolia®
1060152|NCT01750047|pain perception
1060153|NCT01750047|postoperative pain
1060154|NCT01750047|demography
1060155|NCT01750047|smoking
1060156|NCT01750047|alcohol
1060157|NCT01750034|Burns
1060158|NCT01750034|Wounds and injuries
1060159|NCT01750034|Bandages
1060160|NCT01750008|Symptomatic Uterine Fibroids
1060161|NCT01750008|Menorrhagia
1060162|NCT01750008|Heavy Bleeding
1060163|NCT01750008|Myomas
1060164|NCT01750008|Radiofrequency Ablation
1060165|NCT01750008|RFA
1060166|NCT01750008|Leiomyoma
1060167|NCT01750008|Fibroids
1060168|NCT01749995|Elderly cancer patients
1060169|NCT01749995|Screening tool
1060170|NCT01749995|Cognitive impairment
1060171|NCT01749995|Freund Clock Drawing Test
1060172|NCT01749982|arsenic
1060173|NCT01749982|Bangladesh
1060174|NCT01749982|choline
1060175|NCT01749982|betaine
1060176|NCT01749982|methylation
1060177|NCT01749956|Rectal Cancer
1060178|NCT01749956|Chemoradiation
1060179|NCT01749956|Aflibercept
1060180|NCT01749956|Surgery
1060181|NCT01749930|Intraocular pressure
1060182|NCT01749917|Parkinson.
1060183|NCT01749917|Dexterity.
1060184|NCT01749917|Balance.
1060185|NCT01749917|Exercises.
1060186|NCT01749904|Intraocular pressure
1060187|NCT01749891|Age Related Wet Macular Degeneration
1060188|NCT01748864|Volunteers
1060189|NCT01748825|MK-1775
1060190|NCT01748825|Refractory
1060191|NCT01748825|Solid Tumors
1060192|NCT01748825|Wee1 Inhibitor
1060193|NCT01748825|Tyrosine Kinase
1060194|NCT01748812|Tumor Induced Osteomalacia
1060195|NCT01748812|Hypophosphatemic Rickets
1060196|NCT01748799|Cannabis dependence
1060197|NCT01748799|Sativex
1060198|NCT01748786|Fibromyalgia
1060199|NCT01748786|Mindfulness
1060200|NCT01748786|On-line intervention
1060201|NCT01748786|Chronic pain
1060202|NCT01748760|Suicide Attempts
1060203|NCT01748760|Suicidal Ideation
1060204|NCT01748734|Depression
1060205|NCT01748708|Magnetic seizure therapy
1060206|NCT01748708|Electroconvulsive therapy
1060207|NCT01748708|Treatment resistant depression
1060208|NCT01748708|Treatment resistance
1060209|NCT01748708|Randomized controlled trial
1060210|NCT01748695|Neuropathic pain
1060211|NCT01748695|Spinal cord injury
1060212|NCT01748682|Very low calorie diet
1060213|NCT01748682|liquid diet
1060214|NCT01748682|visceral fat
1060215|NCT01748682|liver fat.
1060216|NCT01748669|Arsenic
1060217|NCT01748669|Arsenicosis
1060218|NCT01748669|Garlic oil
1060219|NCT01748669|Keratosis
1060220|NCT01748656|Noninvasive ventilation
1060221|NCT01748656|Obesity Hypoventilation Syndrome
1060222|NCT01748630|scoliosis, sedation, children, fentanyl consumption, pain
1060223|NCT01748604|Lymphedema
1060224|NCT01748604|Physical Therapies
1060225|NCT01748604|Randomized controlled study
1060226|NCT01748604|Decongestive lymphatic therapy
1060227|NCT01748604|Manual lymph drainage
1060228|NCT01748604|Intermittent pneumatic compression
1060229|NCT01748604|Multilayer bandages
1060230|NCT01749813|Carbohydrate Specific Diet
1060231|NCT01749813|Crohn's Disease
1060232|NCT01749813|Immunomodulators
1060233|NCT01749800|TBI
1060234|NCT01749800|Attention deficits
1060235|NCT01749800|Upper extremity weakness
1060236|NCT01749787|arthritis
1060237|NCT01749787|rheumatoid
1060238|NCT01749787|methotrexate
1060239|NCT01749787|leflunomide
1060240|NCT01749774|Physical activity
1060241|NCT01749774|Testicular cancer
1060242|NCT01749774|Chemotherapy
1060243|NCT01749774|Feasibility
1060244|NCT01749761|IDH, intradialytic hypotension,
1060245|NCT01749761|hypotension on hemodialysis,
1060246|NCT01749761|hemodialysis,
1060247|NCT01749761|Blood pressure guided biofeedback
1060248|NCT01749748|Breast diseases
1060249|NCT01749748|magnetic resonance spectroscopy
1060250|NCT01749722|Colorectal Cancer
1060251|NCT01749722|Polyp
1060252|NCT01749722|Adenoma
1060253|NCT01749722|Detection Rate
1060254|NCT01749722|Colonoscopy
1060255|NCT01749722|NaviAid™ G-Eye procedure
1060256|NCT01749722|NaviAid™ G-Eye system
1060257|NCT01749722|G-Eye procedure
1060258|NCT01749722|G-Eye system
1060259|NCT01749709|Stroke
1060260|NCT01749709|Recovery
1060261|NCT01749709|Music
1060262|NCT01749696|Pelvic organ prolapse
1060263|NCT01749696|Connective tissue
1060264|NCT01749696|Elastin
1060265|NCT01749696|Collagen
1060266|NCT01749670|Autism Spectrum Disorder
1060267|NCT01749670|Exosomal miRNA expression
1060268|NCT01749657|biomechanics
1060269|NCT01749657|outcomes
1060270|NCT01749657|foot
1060271|NCT01749657|orthotic device
1060272|NCT01749644|Cystic Fibrosis, Chronic Pseudomonas Infection, Inhaled Tobramycin
1060273|NCT01749631|Patients suspected to have difficult intubation
1060274|NCT01749631|Intratracheal intubation
1060275|NCT01749631|Difficult to intubate
1060276|NCT01749618|Seronegative Inflammatory Arthritis
1060277|NCT01749618|SpA
1060278|NCT01749618|PsA
1060279|NCT01749618|Randomized
1060280|NCT01749618|Behavioural Change
1060281|NCT01749592|hearing loss
1060282|NCT01749592|cochlear implant
1060283|NCT01749592|PET
1060284|NCT01749592|EEG
1060285|NCT01749592|MEG
1060286|NCT01749579|propofol
1060287|NCT01749579|midazolam
1060288|NCT01749579|duration of recovery
1060289|NCT01749579|emergency procedure
1060290|NCT01749566|HIV/AIDS, preexposure prophylaxis, women's health
1060291|NCT01749527|24-hour pad test
1060292|NCT01749527|Activity
1060293|NCT01749527|Stress urinary incontinence
1060294|NCT01749514|Myelodysplastic Syndrome
1060295|NCT01749488|Dietitian
1060296|NCT01749488|Nutritional recommendations
1060297|NCT01749488|ICU nutrition
1060298|NCT01749462|chronic obstructive pulmonary disease,
1060299|NCT01749462|COPD,
1060300|NCT01749462|Oxis,
1060301|NCT01749449|high protein
1060302|NCT01749449|high carbohydrate
1060303|NCT01749449|meal frequency
1060304|NCT01749449|abdominal body fat
1060305|NCT01749449|postprandial thermogenesis
1060306|NCT01749436|Atelectasis
1060307|NCT01749436|Pneumoperitoneum
1060308|NCT01749436|Hypoxemia
1060309|NCT01749371|Alpha-Tocopherol
1060310|NCT01749371|Gamma-Tocopherol
1060311|NCT01749371|Inflammation
1060312|NCT01749371|Oxidative Stress
1060313|NCT01749371|Malondialdehyde
1060314|NCT01749371|Isoprostanes
1060315|NCT01749371|Lung Dysfunction
1060316|NCT01749371|Wound Healing
1060317|NCT01749358|stroke
1060318|NCT01749358|hemiparesis
1060319|NCT01749358|physical therapy
1060320|NCT01749358|occupational therapy
1060321|NCT01749358|neurorehabilitation
1060322|NCT01749358|patient focused
1060323|NCT01749358|motor learning
1060324|NCT01749358|motor control
1060325|NCT01749358|skill acquisition
1060326|NCT01749358|skill training
1060327|NCT01749358|motor recovery
1060328|NCT01749358|task oriented training
1060329|NCT01749358|task specific training
1060330|NCT01749358|arm function
1060331|NCT01749358|hand function
1060332|NCT01749358|upper extremity
1060333|NCT01749358|arm therapy
1060334|NCT01749358|physical rehabilitation
1060335|NCT01749358|arm rehabilitation
1060336|NCT01749358|motor function
1060337|NCT01749332|blood draw
1060338|NCT01749332|Perihepatic Phlebotomy
1060339|NCT01749332|12-236
1060340|NCT01749319|baclofen, withdrawal, interuption, spasticity, pharmacokinetics, tolerability, intravenous, oral
1060341|NCT01749306|epidermolysis bullosa, chronic wound, wound healing, dermal repair, fibroblasts, Dermagraft
1060342|NCT01749280|Abdominal Aortic Aneurysm
1060343|NCT01749280|MRI
1060344|NCT01749280|USPIO
1060345|NCT01749267|dentin remineralization
1060346|NCT01749267|caries regression
1060347|NCT01749254|Culprit plaques
1060348|NCT01749254|Vulnerable Plaques
1060349|NCT01749254|PET
1060350|NCT01749254|calcification
1060351|NCT01749254|inflammation
1060352|NCT01749228|Fed
1060353|NCT01749215|pharmacotherapy
1060354|NCT01749215|alcohol dependence
1060355|NCT01749215|Veterans
1060356|NCT01749202|Omega 3 fatty acids
1060357|NCT01749202|Omega 3 Index
1060358|NCT01749202|Stearidonic acid (SDA)
1060359|NCT01749202|Red Blood Cells
1060360|NCT01749202|Lipids
1060361|NCT01749189|soy
1060362|NCT01749189|whey
1060363|NCT01749189|casein
1060364|NCT01749189|muscle
1060365|NCT01749189|strength
1060366|NCT01749189|protein
1060367|NCT01749176|High risk Latino patients with diabetes
1060368|NCT01749137|Overweight
1060369|NCT01749124|mental illness
1060370|NCT01749124|depression
1060371|NCT01749124|schizophrenia
1060372|NCT01749124|bipolar disorder
1060373|NCT01749124|IVR
1060374|NCT01749124|automated
1060375|NCT01749124|telephone
1060376|NCT01749111|bone marrow transplantation
1060377|NCT01749111|graft versus host disease
1060378|NCT01749111|Acute myelogenous leukemia
1060379|NCT01749111|Acute lymphoid leukemia
1060380|NCT01749111|Myeloproliferative disease
1060381|NCT01749111|Myelodysplastic syndrome
1060382|NCT01749111|Chronic myeloid leukemia
1060383|NCT01749111|chronic myelomonocytic leukemia
1060384|NCT01749098|PF-04958242
1060385|NCT01749098|ketamine
1060386|NCT01749098|cognition
1060387|NCT01749098|healthy volunteers
1060388|NCT01749085|PF-04449913
1060389|NCT01749085|Food Effect
1060390|NCT01749085|Drug-drug interaction
1060391|NCT01749085|CYP3A4 inhibitor
1060392|NCT01749085|Pharmacokinetics
1060393|NCT01749072|non small cell lung cancer
1060394|NCT01749072|chemotherapy
1060395|NCT01749072|gefitinib
1060396|NCT01749072|vinorelbine
1060397|NCT01749072|ifosfamide
1060398|NCT01749046|Epileptic seizures, Partial seizures
1060399|NCT01749033|Intubation
1060400|NCT01749033|Airway
1060401|NCT01749033|Laryngeal Mask Airway
1060402|NCT01749020|Diabetes type II, Insulin sensitivity
1060403|NCT01749007|Veterans
1060404|NCT01749007|HIV
1060405|NCT01749007|AIDS
1060406|NCT01749007|Cognitive Functioning
1060407|NCT01749007|Suicide
1060408|NCT01748994|Obesity
1060409|NCT01748994|Fat distribution
1060410|NCT01748994|Adipogenesis
1060411|NCT01748994|Adipocyte
1060412|NCT01748994|Preadipocyte
1060413|NCT01748994|Ectopic fat
1060414|NCT01748981|Pulmonary function
1060415|NCT01748981|Maximal oxygen uptake
1060416|NCT01748981|Cardiorespiratory fitness
1060417|NCT01748981|High-intensity training
1060418|NCT01748981|Surgery
1060419|NCT01748968|Veterans
1060420|NCT01748968|Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)
1060421|NCT01748968|Self-Directed Violence
1060422|NCT01748955|Major Depressive Disorder
1060423|NCT01748955|MDD
1060424|NCT01748955|Reward
1060425|NCT01748955|BOLD signal
1060426|NCT01748955|Suicide
1060427|NCT01748916|Papaya
1060428|NCT01748916|Carrot
1060429|NCT01748916|Tomato
1060430|NCT01748916|Carotenoids
1060431|NCT01748916|Lycopene
1060432|NCT01748916|Beta-carotene
1060433|NCT01748916|Beta-cryptoxanthin
1060434|NCT01748903|intracranial aneurysm
1060435|NCT01748903|cerebral aneurysm
1060436|NCT01748903|packing density
1060437|NCT01748903|Target Coils
1060438|NCT01748903|aneurysm embolization
1060439|NCT01748877|shingles,
1060440|NCT01748877|neuropathic pain
1060441|NCT01748877|post herpetic neuralgia
1060442|NCT01748877|sleep
1060443|NCT01748578|Healthy
1060444|NCT01748578|Interleukin 1 Receptor Inhibitor
1060445|NCT01748578|Dry Eye
1060446|NCT01748565|biomarkers
1060447|NCT01748565|oxidative stress
1060448|NCT01748565|BPD
1060449|NCT01748565|prematurity
1060450|NCT01748526|Healthy
1060451|NCT01748526|Canagliflozin (JNJ-28431754)
1060452|NCT01748526|Pharmacokinetics
1060453|NCT01748526|Pharmacodynamics
1060454|NCT01748526|Indian
1060455|NCT01748513|morbidly obese patients,
1060456|NCT01748513|preoperative volume-challenge,
1060457|NCT01748513|transthoracic echocardiography,
1060458|NCT01748513|TTE,
1060459|NCT01748513|rapid weight loss,
1060460|NCT01748513|venous return,
1060461|NCT01748513|bariatric surgery,
1060462|NCT01748513|left ventricular outflow tract,
1060463|NCT01748513|stroke volume,
1060464|NCT01748513|diastolic function,
1060465|NCT01748513|hypervolemia,
1060466|NCT01748513|hypovolemia
1060467|NCT01748500|metastatic
1060468|NCT01748461|intervention study in elderly (65+)
1060469|NCT01748461|cycle ergometer
1060470|NCT01748461|physical activity
1060471|NCT01748461|physical fitness
1060472|NCT01748461|assisted living facility
1060473|NCT01748448|Cutaneous malignant melanoma
1060474|NCT01748448|Vitamin D
1060475|NCT01748448|Cholecalciferol
1060476|NCT01748435|Neuropathic pain
1060477|NCT01748435|Lower limb amputation
1060478|NCT01748435|Pre-emptive analgesia
1060479|NCT01748422|Neuropathic pain
1060480|NCT01748422|Arteriovenous fistulae
1060481|NCT01748422|End stage renal disease
1060482|NCT01748409|Autonomic failure, Parkinson's disease, electrophysiological assessment, neuropathological assessment
1060483|NCT01748396|FGF-23
1060484|NCT01748396|Calcitriol
1060485|NCT01748396|Calcium carbonate
1060486|NCT01748396|CKD Stage 3
1060487|NCT01748383|Bone marrow cells
1060488|NCT01748383|Acute myocardial infarction
1060489|NCT01748383|Transplantation of autologous mononuclear
1060490|NCT01748383|Transplantation of autologous CD133 + cells
1060491|NCT01748370|vitamin D
1060492|NCT01748370|hypogonadism
1060493|NCT01748370|testosterone
1060494|NCT01748370|intervention
1060495|NCT01748357|Tuberculosis
1060496|NCT01748357|Volatile organic compounds
1060497|NCT01748357|exhaled breath
1060498|NCT01748357|Siemens
1060499|NCT01748331|Heart Failure
1060500|NCT01748331|Hyponatremia
1060501|NCT01748331|Fluid restriction
1060502|NCT01748318|Community acquired MRSA
1060503|NCT01748318|New Mexico Honey
1060504|NCT01748305|GDM
1060505|NCT01748305|A1GDM
1060506|NCT01748305|A2GDM
1060507|NCT01748292|Age related
1060508|NCT01748292|Macular
1060509|NCT01748292|sub retinal fluid
1060510|NCT01748292|Age related Macular degeneration
1060511|NCT01748279|COPD
1060512|NCT01748279|Atorvastatin
1060513|NCT01748279|statins
1060514|NCT01748279|COPD treatment
1060515|NCT01748279|microarrays
1060516|NCT01748266|StO2
1060517|NCT01748266|microcirculation
1060518|NCT01748266|NIRS
1060519|NCT01748227|self-management
1060520|NCT01748227|peer support
1060521|NCT01748227|social support
1060522|NCT01748214|continuous positive airway pressure
1060523|NCT01748214|high flow nasal cannula
1060524|NCT01748214|hearing outcomes
1060525|NCT01748214|noise exposure
1060526|NCT01748214|preterm infants
1060527|NCT01748201|Osteoarthritis
1060528|NCT01748201|Hemarthrosis
1060529|NCT01748201|Hemophilia A
1060530|NCT01748201|Hemophilia B
1060531|NCT01748201|Viscosupplementation
1060532|NCT01748188|Subacromial syndrome
1060533|NCT01748188|Dexketoprofen
1060534|NCT01748188|Phonophoresis
1060535|NCT01748188|Iontophoresis
1060536|NCT01748188|Ultrasounds
1060537|NCT01748188|VAS
1060538|NCT01748188|DASH score
1060539|NCT01748188|Constant score
1060540|NCT01748175|Severe asthma
1060541|NCT01748175|longitudinal study
1060542|NCT01748175|phenotypes
1060543|NCT01748162|croup
1060544|NCT01748162|recurrent croup
1060545|NCT01748162|barky cough
1060546|NCT01748149|recurrent/refractory BRAFV600E-mutant gliomas
1060547|NCT01748149|pediatrics
1060548|NCT01748149|children
1060549|NCT01748149|neo-adjuvant vemurafenib
1060552|NCT01748110|quality of life
1060553|NCT01748110|erectile function
1060554|NCT01748097|infiltration
1060555|NCT01748097|extravasation
1060556|NCT01748097|sodium bicarbonate
1060557|NCT01748097|capnography
1060558|NCT01748097|end tidal carbon dioxide
1060559|NCT01748097|chemotherapy
1060560|NCT01748084|Systemic sclerosis
1060561|NCT01748084|Arthritis
1060562|NCT01748084|B-cell therapy, Anti-CD20 therapy
1060563|NCT01748084|Quality of life
1060564|NCT01748084|Scleroderma
1060565|NCT01748084|Lung fibrosis
1060566|NCT01748084|Randomised controled trial
1060567|NCT01748071|fentanyl
1060568|NCT01748071|sufentanil
1060569|NCT01748071|individual variation
1060570|NCT01748071|pain threshold
1060571|NCT01748071|nacro-trend index
1060572|NCT01748045|Inhaled Nitric Oxide
1060573|NCT01748045|Bronchopulmonary Dysplasia
1060574|NCT01748045|Late Prematurity
1060575|NCT01748045|Chronic Respiratory Morbidity
1060576|NCT01748032|depression
1060577|NCT01748032|intervention studies
1060578|NCT01748019|ST1968
1060579|NCT01748019|Camptothecin
1060580|NCT01748019|Solid tumors
1060581|NCT01748019|Topoisomerase I
1060582|NCT01747993|Urinary retention; urinary catheterization; alpha blocking agents; women; elder
1060583|NCT01747980|Gaucher disease
1060584|NCT01747980|human glucocerebrosidase
1060585|NCT01747980|plant recombinant human glucocerebrosidase
1060586|NCT01747967|Antibodies
1060587|NCT01747967|Beta cells
1060588|NCT01747967|C-peptide
1060589|NCT01747967|GAD
1060590|NCT01747967|Glucose
1060591|NCT01747967|Glycemia
1060592|NCT01747967|Insulin
1060593|NCT01747967|Meal test
1060594|NCT01747967|Pancreas
1060595|NCT01747967|Proinsulin,
1060596|NCT01747967|T lymphocytes
1060597|NCT01747954|Respiratory Insufficiency
1060598|NCT01747954|Physiotherapy Techniques
1060599|NCT01747954|Respiratory Mechanics
1060600|NCT01747928|usability study
1060601|NCT01747915|Primary Generalized Tonic Clonic Seizures
1060602|NCT01747915|Epilepsy
1060603|NCT01747915|Safety
1060604|NCT01747915|Efficacy
1060605|NCT01747915|Tolerability
1060606|NCT01747915|Pregabalin
1060607|NCT01747915|Lyrica
1060608|NCT01747915|Adjunctive treatment
1060609|NCT01747915|Placebo Controlled
1060610|NCT01747915|Blinded
1060611|NCT01747889|chest tube
1060612|NCT01747889|lung resection
1060613|NCT01747889|patient satisfaction
1060614|NCT01747889|mobility
1060615|NCT01747876|Phase 1
1060616|NCT01747876|pediatric
1060617|NCT01747876|CDK4/6 inhibitor
1060618|NCT01747876|dose escalation
1060619|NCT01747876|malignant rhabdoid tumors
1060620|NCT01747876|MRT
1060621|NCT01747876|neuroblastoma
1060622|NCT01747863|Hypoxic Ischemic encephalopathy
1060623|NCT01747837|Renal sympathetic denervation
1060624|NCT01747837|Renal catheter ablation
1060625|NCT01747837|Ventricular tachycardia
1060626|NCT01747824|agitation
1060627|NCT01747824|excited delirium
1060628|NCT01747824|pain
1060629|NCT01747824|unexplained-in-custody-death
1060630|NCT01747824|UICD
1060631|NCT01747824|visual analog scale
1060632|NCT01747824|VAS
1060633|NCT01747824|altered mental status
1060634|NCT01747824|AMS
1060635|NCT01747811|Mild traumatic brain injury
1060636|NCT01747811|Concussion
1060637|NCT01747811|Sleep problems
1060638|NCT01747811|brain imaging
1060639|NCT01747811|functional magnetic resonance imaging (FMRI)
1060640|NCT01747785|Heart failure
1060641|NCT01747785|HFpEF
1060642|NCT01747785|Dyspnea
1060643|NCT01747785|Fatigue
1060644|NCT01747785|Shortness of Breath
1060645|NCT01747785|exercise
1060646|NCT01747785|strain
1060647|NCT01747785|myocardial deformation
1060648|NCT01747785|cardiac rehabilitation
1060649|NCT01747785|cardiac hemodynamics
1060650|NCT01747772|Non-focal Liver Disease
1060651|NCT01747772|Fibrosis
1060652|NCT01747772|Shear Wave Sonoelastography
1060653|NCT01747772|Metavir Liver Fibrosis Grading
1060654|NCT01747759|• Knee osteoarthritis
1060655|NCT01747759|Total knee arthroplasty
1060656|NCT01747759|Selfcare
1060657|NCT01747759|Booklet
1060658|NCT01747759|Rehabilitation
1060659|NCT01747746|Rivaroxaban
1060660|NCT01747746|Warfarin
1060661|NCT01747746|Anticoagulation
1060662|NCT01747746|Stroke
1060663|NCT01747746|Thrombo-embolism
1060664|NCT01747746|Bleeding
1060665|NCT01747746|Atrial Fibrillation
1060666|NCT01747746|Cardioversion
1060667|NCT01747733|Endoscopy
1060668|NCT01747733|ERCP
1060669|NCT01747733|PCS
1060670|NCT01747733|Sedation
1060671|NCT01747733|Bispectral index
1060672|NCT01747720|breast cancer
1060673|NCT01747720|mammographic breast density
1060674|NCT01747720|vitamin D
1060675|NCT01747720|prevention
1060676|NCT01747720|randomized controlled trial
1060677|NCT01747707|gastric cancer
1060678|NCT01747707|gastroesophageal junction cancer
1060679|NCT01747707|chemotherapy
1060680|NCT01747707|docetaxel
1060681|NCT01747707|cisplatin
1060682|NCT01747707|S-1
1060683|NCT01747694|COPD,Respiratory muscle training,Exercise tolerance
1060684|NCT01747681|chondral defect
1060685|NCT01747681|microfracture
1060686|NCT01747681|arthroscopy
1060687|NCT01747681|cartilage repair
1060688|NCT01747681|outcome study
1060689|NCT01747681|Lysholm score
1060690|NCT01747668|Mother and Infant Pairs
1060691|NCT01747655|Early Observational Advanced
1060692|NCT01747655|Parkinson's Disease
1060693|NCT01747642|Hepatocellular carcinoma
1060694|NCT01747642|Oncoxin
1060695|NCT01747642|Surafenib
1060696|NCT01747629|Asthma
1060697|NCT01747629|dry powder inhaler
1060698|NCT01747629|short-acting beta2-agonist
1060699|NCT01747629|SABA
1060700|NCT01747629|bronchoconstriction
1060701|NCT01747629|bronchodilation
1060702|NCT01747629|bronchodilator
1060703|NCT01747629|metered dose inhaler
1060704|NCT01747629|Albuterol Spiromax®
1060705|NCT01747616|Chitosan-N-Acetylcysteine
1060706|NCT01747616|contact lenses
1060707|NCT01747616|safety and tolerability
1060708|NCT01747603|Late preterm infant
1060709|NCT01747603|Complications
1060710|NCT01747603|Hospital readmissions
1060711|NCT01747603|Follow-up
1060712|NCT01747603|Pilot study
1060713|NCT01747577|Muscarine antagonist
1060714|NCT01747577|Prostatectomy
1060715|NCT01747577|Uroflowmetry
1060716|NCT01747564|Pharmacokinetics
1060717|NCT01747564|Mirabegron
1060718|NCT01747564|Phase 1
1060719|NCT01747564|YM178
1060720|NCT01747551|Advanced
1060721|NCT01747538|Uveitis
1060722|NCT01747538|Non-infectious Uveitis
1060723|NCT01747538|Intermediate Uveitis
1060724|NCT01747538|Posterior Uveitis
1060725|NCT01747538|Panuveitis
1060726|NCT01747512|99mTc Pertechnetate
1060727|NCT01747512|thyroidectomy
1060728|NCT01747512|thyroid neoplasms
1060729|NCT01747473|Subjects
1060730|NCT01747460|Subjects
1060731|NCT01746693|retinal vessel diameter
1060732|NCT01746693|retinal oxygen saturation
1060733|NCT01746693|high resolution functional and anatomical imaging
1060734|NCT01746693|inner retinal function
1060735|NCT01746693|flicker response
1060736|NCT01746680|rheumatoid arthritis
1060737|NCT01746680|RA
1060738|NCT01746680|tacrolimus
1060739|NCT01746680|Disease Activity Score 28
1060740|NCT01746680|EULAR
1060741|NCT01746667|Social Anxiety Disorder
1060742|NCT01746667|Social Phobia
1060743|NCT01746667|Virtual Reality
1060744|NCT01746667|Exposure
1060745|NCT01746654|S.aureus
1060746|NCT01746654|Methicillin Resistant S.aureus (MRSA)
1060747|NCT01746654|Nasal carrier status
1060748|NCT01746654|Prophylaxis
1060749|NCT01746641|Remifentanil
1060750|NCT01746641|Propofol
1060751|NCT01746641|Sedation
1060752|NCT01746641|Endoscopy
1060753|NCT01746641|Gastroenterology
1060754|NCT01746641|Target controlled infusion effect site
1060755|NCT01746628|type 0 myomata
1060756|NCT01746628|type 1 myomata
1060757|NCT01746628|type 2 myomata
1060758|NCT01746628|bleeding
1060759|NCT01746628|hemorrhage
1060760|NCT01746628|hysteroscopy
1060761|NCT01746628|FloSeal
1060762|NCT01746615|branch retinal vein occlusion
1060763|NCT01746615|dynamic vessel analyzer
1060764|NCT01746615|fourier-domain OCT
1060765|NCT01746615|retinal oxygen saturation
1060766|NCT01746602|topical lubricants
1060767|NCT01746602|tear film thickness
1060768|NCT01746602|anti-glaucoma drugs
1060769|NCT01746602|break up time
1060770|NCT01746602|anti-glaucoma treatment
1060771|NCT01747408|subarachnoid hemorrhage
1060772|NCT01747395|Heart Failure
1060773|NCT01747395|Exercise and Physical Fitness
1060774|NCT01747382|Treatment-resistant Hypertension
1060775|NCT01747382|Chronic Kidney Disease
1060776|NCT01747382|Symplicity catheters
1060777|NCT01747382|Renal denervation
1060778|NCT01747369|surveillance study
1060779|NCT01747369|prospective
1060780|NCT01747369|observational
1060781|NCT01747369|health center-based
1060782|NCT01747369|pneumonia, bacterial
1060783|NCT01747369|pneumonia, viral
1060784|NCT01747369|meningitis, bacterial
1060785|NCT01747369|Africa south of the Sahara
1060786|NCT01747343|Incontinence
1060787|NCT01747343|Enuresis
1060788|NCT01747330|cystic fibrosis
1060789|NCT01747317|FFR
1060790|NCT01747317|fractional flow reserve
1060791|NCT01747317|CT
1060792|NCT01747317|Computed Tomography
1060793|NCT01747304|Atypical Femur Fracture
1060794|NCT01747304|DXA
1060795|NCT01747278|Pneumocystis carinii pneumonia
1060796|NCT01747278|prophylaxis
1060797|NCT01747278|trimethoprim/sulfamethoxazole
1060798|NCT01747239|Ovarian cancer
1060799|NCT01747239|Platinum refractory
1060800|NCT01747226|Oral malodor
1060801|NCT01747226|Halitosis
1060802|NCT01747226|Bad Breath
1060803|NCT01747226|Mouth rinses
1060804|NCT01747226|Mouthwashes
1060805|NCT01747226|Amine fluoride/Stannous fluoride
1060806|NCT01747226|Zinc ions
1060807|NCT01747226|Chlorhexidine
1060808|NCT01747213|Neurodegenerative
1060809|NCT01747213|Cholinergic
1060810|NCT01747213|Single Dose
1060811|NCT01747213|Inhibitor
1060812|NCT01747213|Tolerability
1060813|NCT01747200|Repetitive TMS (rTMS)
1060814|NCT01747187|Septic shock
1060815|NCT01747187|Critical care
1060816|NCT01747187|cardiac failure
1060817|NCT01747174|STEMI
1060818|NCT01747174|Microvascular Obstruction
1060819|NCT01747174|No-reflow
1060820|NCT01747174|Adenosine
1060821|NCT01747174|Sodium Nitroprusside
1060827|NCT01747135|2-Hydroxypropyl-B-Cyclodextrin
1060828|NCT01747135|Niemann-Pick Disease, Type C1
1060829|NCT01747135|Neurodegeneration
1060830|NCT01747122|epidurals
1060831|NCT01747122|wound catheters
1060832|NCT01747122|liver resection
1060833|NCT01747122|liver surgery
1060834|NCT01747109|Acute hypoxemic respiratory failure
1060835|NCT01747109|Preoxygenation
1060836|NCT01747109|Crash induction
1060837|NCT01747096|Gastroenteropancreatic Neuroendocrine Tumors
1060838|NCT01747096|immuno PET (iPET)
1060839|NCT01747096|Gallium (68-Ga)
1060840|NCT01747096|DOTANOC
1060841|NCT01747070|Electro Acupuncture
1060842|NCT01747070|Knee Osteoarthritis
1060843|NCT01747070|Chronic pain
1060844|NCT01747070|Cortical Excitability
1060845|NCT01747044|Fibromyalgia
1060846|NCT01747044|Diffuse Noxious Inhibitory Controls
1060847|NCT01747044|Milnacipran
1060848|NCT01747031|iFR
1060849|NCT01747031|FFR
1060850|NCT01747031|instantaneous wave-free ratio
1060851|NCT01747031|fractional flow reserve
1060852|NCT01747018|Platelet-Rich Plasma
1060853|NCT01747018|Knee pain
1060854|NCT01747018|osteoarthritis
1060855|NCT01747018|degenerative chondropathy
1060856|NCT01747018|Intraarticular injection
1060857|NCT01747005|abdominal hysterectomy
1060858|NCT01747005|enhanced recovery after surgery
1060859|NCT01747005|inflammatory response
1060860|NCT01747005|ERAS
1060861|NCT01747005|combined spinal-epidural anesthesia
1060862|NCT01746979|TH-302
1060863|NCT01746979|Evofosfamide
1060864|NCT01746979|Pancreatic Cancer
1060865|NCT01746979|EMR200592-001
1060866|NCT01746966|gleno-humeral joint synovitis
1060867|NCT01746966|anterior shoulder US
1060868|NCT01746966|rotator interval
1060869|NCT01746940|Surgery
1060870|NCT01746940|Surgeries
1060871|NCT01746940|Nasal
1060872|NCT01746940|Cavities
1060873|NCT01746940|Diagnosis
1060874|NCT01746940|Diagnostic
1060875|NCT01746940|Nose
1060876|NCT01746940|Rhinoplasty
1060877|NCT01746940|Endoscopy
1060878|NCT01746940|Bronchoscopy
1060879|NCT01746927|cricoid pressure, glidescope
1060880|NCT01746901|Relative abuse potential study; oxycodone; nalteone; Opioid-related disorders; drug abusers
1060881|NCT01746901|Chronic pain
1060882|NCT01746875|Angiogenesis inhibitors
1060883|NCT01746875|Photochemotherapy
1060884|NCT01746875|Vascular Endothelium Growth Factors
1060885|NCT01746875|Aflibercept
1060886|NCT01746862|Saizen®
1060887|NCT01746862|Recombinant human growth hormone (r-hGH)
1060888|NCT01746862|Idiopathic short stature
1060889|NCT01746862|Height velocity
1060890|NCT01746862|Bone age
1060891|NCT01746849|LUPRON DEPOT
1060892|NCT01746849|PALIFERMIN
1060893|NCT01746849|12-077
1060903|NCT01746823|Keratoconus
1060904|NCT01746823|Proteomics
1060905|NCT01746810|Metastatic
1060906|NCT01746810|Lung Cancer
1060907|NCT01746810|NSCLC
1060908|NCT01746797|infertility
1060909|NCT01746797|depression
1060910|NCT01746797|IVF
1060911|NCT01746797|IUI
1060912|NCT01746797|fertility treatment
1060913|NCT01746784|Cystic Fibrosis
1060914|NCT01746784|F508del-CFTR
1060915|NCT01746784|N6022
1060916|NCT01746784|S-Nitrosoglutathione
1060917|NCT01746771|HM781-36B, Paclitaxel, Trastuzumab
1060918|NCT01746758|Reproductive health, mHealth, Cluster randomised trial
1060919|NCT01746589|LASIK
1060920|NCT01746576|volunteers
1060921|NCT01746563|Proliferative Diabetic Retinopathy
1060922|NCT01746563|Ranibizumab
1060923|NCT01746563|Panretinal Photocoagulation
1060924|NCT01746524|Arthroplasty
1060925|NCT01746524|Replacement
1060926|NCT01746524|Knee
1060927|NCT01746511|glycerin suppositories
1060928|NCT01746511|glycerin shaves
1060929|NCT01746511|neonatal hyperbilirubinemia
1060930|NCT01746511|idiopathic hyperbilirubinemia
1060931|NCT01746511|jaundice
1060932|NCT01746511|neonatal jaundice
1060933|NCT01746511|prematurity
1060934|NCT01746498|Alzheimer disease
1060935|NCT01746498|Direct current stimulation
1060936|NCT01746498|cognitive function
1060937|NCT01746498|memory
1060938|NCT01746485|Volunteers
1060939|NCT01746459|Sustainability of Innovations
1060940|NCT01746459|Knowledge Translation
1060941|NCT01746459|Gerontology
1060942|NCT01746459|Mobility
1060943|NCT01746420|elbow
1060944|NCT01746407|Emergency Department
1060945|NCT01746407|Infection
1060946|NCT01746407|Sepsis
1060947|NCT01746394|obesity
1060948|NCT01746394|pregnant women
1060949|NCT01746394|nutrition assessment
1060950|NCT01746394|health behavior
1060951|NCT01746381|amyotrophic lateral sclerosis
1060952|NCT01746381|non-invasive ventilation
1060953|NCT01746381|home ventilation
1060954|NCT01746381|IVAPS
1060955|NCT01746381|neuromuscular diseases
1060956|NCT01746368|advance directives
1060957|NCT01746355|atypical facial pain
1060958|NCT01746355|atypical odontalgia
1060959|NCT01746355|repetitive transcranial magnetic stimulation
1060960|NCT01746355|neuropathic pain
1060961|NCT01746355|chronic pain
1060962|NCT01746355|assessment
1060963|NCT01746329|Obesity, insulin resistance, muscle perfusion
1060964|NCT01746303|Working memory
1060965|NCT01746303|Long-term memory
1060966|NCT01746303|Neurocognition
1060967|NCT01746303|Dietary supplementation
1060968|NCT01746303|dementia
1060969|NCT01746290|Cardiac Arrest, cardiopulmonary resuscitation, automated external defibrillators, smartphones
1060970|NCT01746277|non small cell lung cancer
1060971|NCT01746277|chemotherapy
1060972|NCT01746277|epidermal growth factor receptor tyrosine kinase inhibitor
1060973|NCT01746277|retreatment
1060974|NCT01746264|Obesity
1060975|NCT01746264|Endothelial dysfunction
1060976|NCT01746264|Vitamin D deficiency
1060977|NCT01746251|EGFR mutation
1060978|NCT01746251|Resected
1060979|NCT01746238|soft tissue
1060980|NCT01746238|high grade
1060981|NCT01746225|Metastatic
1060982|NCT01746225|Breast
1060983|NCT01746225|Cancer
1060984|NCT01746225|HER2-negative Stage IV
1060985|NCT01746225|No previous chemotherapy
1060986|NCT01746212|Degenerative Disc Disease
1060987|NCT01746212|InQu Bone Graft Extender and Substitute
1060988|NCT01746212|Anterior Lumbar Interbody Fusion
1060989|NCT01746212|Oswestry Disability Index
1060990|NCT01746212|Visual Analog Scale
1060991|NCT01746212|Stand-alone ALIF
1060992|NCT01746212|Bone Marrow Aspirate Concentrate
1060993|NCT01746212|Fusion rate
1060994|NCT01746212|Disc Height
1060995|NCT01746212|Mean Optical Density
1060996|NCT01746212|Integrated Optical Density
1060997|NCT01746173|T Cell lymphoma
1060998|NCT01746160|dental implant
1060999|NCT01746160|healing
1061000|NCT01746160|implant stability
1061001|NCT01746147|MDS
1061002|NCT01746147|AML
1061003|NCT01746147|allogeneic SCT
1061004|NCT01746108|Pneumococcal infection
1061005|NCT01746108|Synflorix
1061006|NCT01746108|Children
1061007|NCT01746108|Immunogenicity
1061008|NCT01746108|Safety
1061009|NCT01746095|Cystic Fibrosis
1061010|NCT01746095|MRSA
1061011|NCT01746095|Methicillin-resistant Staphylococcus aureus
1061012|NCT01746095|Lung infection
1061013|NCT01746095|AeroVanc
1061014|NCT01746095|Vancomycin
1061015|NCT01746082|influenza, H3N2, H3N2v, vaccine, unadjuvanted, Parent Protocol
1061016|NCT01746069|smoking
1061017|NCT01746069|smoke cessation
1061018|NCT01746069|sms
1061019|NCT01746069|quit smoke
1061020|NCT01746056|Warts
1061021|NCT01746056|Verruca
1061022|NCT01746056|Heat patch
1061023|NCT01746043|Esophageal cancer
1061024|NCT01746043|Chemotherapy
1061025|NCT01746043|Radiation therapy
1061026|NCT01746043|XRT
1061027|NCT01746043|Chemoradiation
1061028|NCT01746043|CXRT
1061029|NCT01746043|Symptom Burden
1061030|NCT01746043|Armodafinil
1061031|NCT01746043|Nuvigil
1061032|NCT01746043|Minocycline
1061033|NCT01746043|Dynacin
1061034|NCT01746043|Minocin
1061035|NCT01746043|Minocin PAC
1061036|NCT01746043|Myrac
1061037|NCT01746043|Solodyn
1061038|NCT01746043|Placebo
1061039|NCT01746043|Sugar pill
1061040|NCT01746043|Questionnaires
1061041|NCT01746043|Surveys
1061042|NCT01745952|Epilepsies, Partial
1061043|NCT01745952|Transcranial Magnetic Stimulation
1061044|NCT01745939|Back pain
1061045|NCT01745913|Leukemia
1061046|NCT01745913|Lymphoma
1061047|NCT01745900|Diabetes
1061048|NCT01745900|Gestational Diabetes
1061049|NCT01745900|Female
1061050|NCT01745887|Dry Eye Syndrome
1061051|NCT01745887|Interleukin 1 Receptor Inhibitor
1061052|NCT01745874|Rectal cancer
1061053|NCT01745874|Whole-body MRI
1061054|NCT01745874|FDG-PET-CT
1061055|NCT01745874|preoperative staging
1061056|NCT01745848|Roflumilast
1061057|NCT01745848|COPD
1061058|NCT01745822|Hepatitis B
1061059|NCT01745822|Hepatitis B sAg
1061060|NCT01745822|Hepatitis B eAg
1061061|NCT01745822|pregnancy
1061062|NCT01745796|Pseudomonas Aeruginosa
1061063|NCT01745796|Ventilated Acquired Pneumonia
1061064|NCT01745796|Transmission modes
1061065|NCT01745718|prostate cancer
1061066|NCT01745718|targeted biopsies
1061067|NCT01745718|cytological imprints
1061068|NCT01745718|histology
1061069|NCT01745705|Manipulation
1061070|NCT01745705|Balance
1061071|NCT01745705|Proprioception
1061072|NCT01745679|Ceftriaxone
1061073|NCT01745679|Adverse drug effects
1061074|NCT01745679|Therapeutic monitoring
1061075|NCT01745679|Meningitis
1061076|NCT01745666|Long QT syndrome, stress tests
1061077|NCT01745640|Multiple myeloma
1061078|NCT01745640|dexamethasone
1061079|NCT01745640|pomalidomide
1061080|NCT01745640|response
1061081|NCT01745640|safety
1061082|NCT01745640|del 17p
1061083|NCT01745640|t 4-14
1061084|NCT01745614|Bioequivalence
1061085|NCT01745614|Nimesulide
1061086|NCT01745614|Pharmacokinetics
1061087|NCT01745614|Mexico
1061088|NCT01745588|CC-4047(Pomalidomide)Pomalyst
1061089|NCT01745588|Clarithromycin
1061090|NCT01745588|Biaxin
1061091|NCT01745588|DEXAMETHASONE
1061092|NCT01745588|(ClaPD)
1061093|NCT01745588|Stem cell
1061094|NCT01745588|12-138
1061099|NCT01745562|Alprazolam
1061100|NCT01745562|Anxiety disorders
1061101|NCT01745562|Bioequivalence
1061102|NCT01745562|Mexico
1061103|NCT01745549|diabetes
1061104|NCT01745549|insulin therapy
1061105|NCT01745549|needle
1061106|NCT01745536|Oocyte vitrification
1061107|NCT01745536|survival rate
1061108|NCT01745536|egg banking
1061109|NCT01745536|ovum donation
1061110|NCT01745523|Oocyte vitrification
1061111|NCT01745523|survival rate
1061112|NCT01745523|egg banking
1061113|NCT01745523|ovum donation
1061114|NCT01745510|docosahexaenoic acid
1061115|NCT01745510|n-3 fatty acids
1061116|NCT01745510|necrotizing enterocolitis
1061117|NCT01745510|preterm infants
1061118|NCT01745497|Autism Spectrum Disorder
1061119|NCT01745497|Insomnia
1061120|NCT01745484|SPECT
1061121|NCT01745484|Toxicity
1061122|NCT01745484|Non-small-cell lung cancer
1061123|NCT01745484|Definitive Radiotherapy
1061124|NCT01745484|Radiation pneumonitis
1061125|NCT01745484|Randomized study
1061126|NCT01745471|Abdominal Adipose
1061127|NCT01745471|Gluteal Adipose
1061128|NCT01745471|Polycystic Ovary Syndrome
1061129|NCT01745471|Obesity
1061130|NCT01745471|Women
1061131|NCT01745445|limited-stage small cell lung cancer
1061132|NCT01745445|concurrent chemo-radiotherapy
1061133|NCT01745432|ADBLOCK
1061134|NCT01745432|Adhesion Barrier System
1061135|NCT01745432|laparoscopic surgery
1061136|NCT01745432|myomectomy
1061137|NCT01745419|COPD
1061138|NCT01745419|Exacerbation
1061139|NCT01745419|Haptoglobin
1061140|NCT01745393|Smoking Cessation
1061141|NCT01745393|Secondhand Smoke
1061142|NCT01745393|Passive Smoking
1061143|NCT01745393|Cotinine
1061144|NCT01745393|Nicotine Replacement Products
1061145|NCT01745380|operative
1061146|NCT01745380|dental procedure
1061147|NCT01745367|Tivozanib hydrochloride
1061148|NCT01745367|triple negative breast cancer
1061149|NCT01745367|paclitaxel
1061150|NCT01745367|pharmacokinetics
1061151|NCT01745367|biomarkers
1061152|NCT01745367|metastatic breast cancer
1061153|NCT01745367|mBC
1061154|NCT01745367|TNBC
1061155|NCT01745328|recurrent urinary tract infection
1061156|NCT01745328|antibiotics
1061157|NCT01745328|traditional chinese medicine
1061158|NCT01745315|total laparoscopic hysterectomy
1061159|NCT01745315|LigaSure
1061160|NCT01745315|EnSeal
1061161|NCT01745315|Halo PKS Cutting forceps
1061162|NCT01745315|electrothermal bipolar vessel sealer
1061163|NCT01745315|advanced bipolar device
1061164|NCT01745302|lung cancer
1061165|NCT01745302|traditional Chinese medicine
1061166|NCT01745302|EGFR-TKI
1061167|NCT01745289|Breast Cancer
1061168|NCT01745289|Survival
1061169|NCT01745289|Recurrence
1061170|NCT01745276|Pin fixation
1061171|NCT01745276|Osteotomy
1061172|NCT01745276|hemicallotasis
1061173|NCT01745250|lip
1061174|NCT01745250|fillers
1061175|NCT01745250|Hyaluronic acid
1061176|NCT01745237|Sarcoidosis
1061177|NCT01745237|Cardiac Magnetic Resonance
1061178|NCT01745198|homocysteinemia
1061179|NCT01745198|dementia
1061180|NCT01745198|depression
1061181|NCT01745198|vitamin B12
1061182|NCT01745198|folate
1061183|NCT01745198|mild cognitive impairment
1061184|NCT01745198|alzheimer's
1061185|NCT01745198|homocysteine
1061186|NCT01745185|Fabry Disease
1061187|NCT01745185|immunity
1061188|NCT01745185|antibody
1061189|NCT01745159|tacrolimus
1061190|NCT01745159|Protopic
1061191|NCT01745159|pediatric
1061192|NCT01745159|atopic dermatitis
1061193|NCT01745159|China
1061194|NCT01745146|traumatic brain injury
1061195|NCT01745146|TBI
1061196|NCT01745146|head injury
1061197|NCT01745146|brain injury
1061198|NCT01745146|Psych-educational treatment
1061199|NCT01745146|Anger
1061200|NCT01745146|irritability
1061201|NCT01745146|anger management
1061202|NCT01745133|Olux E foam
1061203|NCT01745133|Sorilux foam
1061204|NCT01745120|gene therapy
1061205|NCT01745120|beta thalassemia
1061206|NCT01745120|hemoglobin
1061207|NCT01745120|anemia
1061208|NCT01745120|CD34
1061209|NCT01745107|T2-3N0M0 disease of esophageal neoplasm
1061210|NCT01745107|postoperative radiotherapy
1061211|NCT01745107|intensity modulated radiation therapy
1061212|NCT01745107|survival
1061213|NCT01745094|mirabegron
1061214|NCT01745094|solifenacin
1061215|NCT01745068|fragility fracture
1061216|NCT01745068|osteoporosis
1061217|NCT01745068|fall prevention
1061218|NCT01745068|integrated program
1061219|NCT01745068|interorganizational collaboration
1061220|NCT01745068|Canada
1061221|NCT01745068|controlled clinical trial
1061222|NCT01745068|evaluation
1061223|NCT01745055|Pharmacokinetics
1061224|NCT01745055|oral JAK inhibitor
1061225|NCT01745055|methotrexate (MTX)
1061226|NCT01745055|rheumatoid arthritis (RA)
1061227|NCT01745042|Postmenopausal Women
1061228|NCT01745042|Body Composition
1061229|NCT01745042|Metabolic Syndrome
1061230|NCT01745042|Menopause Symptoms
1061231|NCT01745029|Gastrointestinal Motility
1061232|NCT01745029|Inflammatory Bowel Disease
1061233|NCT01745029|Transit time
1061234|NCT01745016|dietary supplement
1061235|NCT01745016|carnosine
1061236|NCT01745003|Fibromyalgia
1061237|NCT01744990|Nuts
1061238|NCT01744990|allergy
1061239|NCT01744990|Oral food challenge
1061240|NCT01744990|skin testing
1061241|NCT01744990|basophil activation tests
1061242|NCT01744990|specific IgE's
1061243|NCT01744964|apomorphine
1061244|NCT01744964|dopamine transporter gene
1061245|NCT01744964|SLC6A3
1061246|NCT01744964|cold pressor test
1061247|NCT01744964|tolerance
1061248|NCT01744964|experimental pain
1061249|NCT01744964|dopamine agonist
1061250|NCT01744951|Adoption
1061251|NCT01744951|Foster care
1061252|NCT01744951|Substance abuse
1061253|NCT01744951|Older children
1061254|NCT01744951|Mental health
1061255|NCT01744938|Postoperative Complications,
1061256|NCT01744938|mortality,
1061257|NCT01744938|length of Stay,
1061258|NCT01744938|economics
1061259|NCT01744912|Lymphoma
1061260|NCT01744912|monoclonal antibody
1061261|NCT01744912|immunomodulatory agent
1061262|NCT01744912|ublituximab
1061263|NCT01744912|lenalidomide
1061264|NCT01744899|Lumbosacral spine
1061265|NCT01744899|Nerve roots
1061266|NCT01744899|Sitting
1061267|NCT01744899|H-reflex
1061268|NCT01744886|One-Lung Ventilation
1061269|NCT01744886|Thoracic Surgical Procedures
1061270|NCT01744886|Cardiac Surgical Procedures
1061271|NCT01744834|Reward-based learning
1061272|NCT01744834|Pavlovian-to-instrumental transfer
1061273|NCT01744834|Functional imaging
1061274|NCT01744834|alcohol use disorder risk
1061275|NCT01744821|High Risk
1061276|NCT01744808|Healthy
1061277|NCT01744808|Normal
1061278|NCT01744795|cardiac output
1061279|NCT01744795|thermodilution
1061280|NCT01744795|esophageal doppler
1061281|NCT01744795|trending ability
1061282|NCT01744782|Nephropathic Cystinosis
1061283|NCT01744782|Cysteamine
1061284|NCT01744782|Delayed-release Cysteamine
1061285|NCT01744782|CTNS Protein, Human
1061286|NCT01744782|Orphan Disease
1061287|NCT01744769|thyroid cancer
1061288|NCT01744769|hypothyroidism
1061289|NCT01744769|metabolic parameters
1061290|NCT01744769|Hypothyroidism after levothyroxine withdrawal
1061291|NCT01744756|Subconjunctival Bevacizumab
1061292|NCT01744756|Recurrent pterygium
1061293|NCT01744743|preconception
1061294|NCT01744743|hypothyroidism
1061295|NCT01744743|neurocognitive development
1061296|NCT01744730|Bacterial infections
1061297|NCT01744730|Obesity
1061298|NCT01744730|pharmacokinetics
1061299|NCT01744730|clindamycin
1061300|NCT01744717|Pain
1061301|NCT01744717|mechanical ventilation
1061302|NCT01744717|uncommunicative
1061303|NCT01744717|Adult ICU patients pain
1061304|NCT01744704|Nerve Growth Factor
1061305|NCT01744704|Ophthalmic Solutions
1061306|NCT01744704|Eye Drops
1061307|NCT01744704|rh-NGF
1061308|NCT01744691|CLL
1061309|NCT01744691|SLL
1061310|NCT01744665|CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl
1061311|NCT01744652|Advanced Cancers
1061312|NCT01744652|Advanced Malignancies
1061313|NCT01744652|Unresectable
1061314|NCT01744652|Metastatic
1061315|NCT01744652|Crizotinib
1061316|NCT01744652|PF-02341066
1061317|NCT01744652|Xalkori
1061318|NCT01744652|Dasatinib
1061319|NCT01744652|BMS-354825
1061320|NCT01744652|Sprycel
1061321|NCT01744639|Hepatocellular carcinoma
1061322|NCT01744639|Radioablation
1061323|NCT01744626|Chronic Lymphocytic Leukemia
1061324|NCT01744626|Small Lymphocytic Lymphoma
1061325|NCT01744613|Clopidogrel
1061326|NCT01744613|platelet inhibition
1061327|NCT01744613|antiplatelet therapy
1061328|NCT01744613|peripheral arterial disease
1061329|NCT01744613|endovascular treatment
1061330|NCT01744613|angioplasty
1061331|NCT01744613|stenting
1061332|NCT01744600|Dementia
1061333|NCT01744600|Music Therapy
1061334|NCT01744587|EBV
1061335|NCT01744587|EGCG
1061336|NCT01744561|Exercise
1061337|NCT01744561|Motivation
1061338|NCT01744561|Feedback
1061339|NCT01744561|web-based diary
1061340|NCT01744561|pedometer
1061341|NCT01744535|smartphone
1061342|NCT01744535|smartphone app
1061343|NCT01744535|smartphone application
1061344|NCT01744535|obesity
1061345|NCT01744535|overweight
1061346|NCT01744535|self monitoring
1061347|NCT01744496|Parkinson's Disease
1061348|NCT01744496|Rotigotine
1061349|NCT01744496|Chronic Pain
1061350|NCT01744496|Nonmotor symptoms
1061351|NCT01744483|pneumonia
1061352|NCT01744483|endotracheal intubation
1061353|NCT01744470|Renal
1061354|NCT01744470|Transplantation
1061355|NCT01744470|Tacrolimus
1061356|NCT01744457|tear film osmolarity
1061357|NCT01744457|objective scattering index
1061358|NCT01744457|tear break up time
1061359|NCT01744457|Schirmer I test
1061360|NCT01744418|ESRD
1061361|NCT01744418|HEMODIALYSIS
1061362|NCT01744418|CHRONIC RENAL INSUFFICIENCY
1061363|NCT01744418|Renal Dialysis
1061364|NCT01744418|Hemodiafiltration
1061365|NCT01744418|Blood Vessel Prosthesis
1061366|NCT01744418|Tissue-Engineered Vascular Graft
1061367|NCT01744418|Vascular Prosthesis Implantation
1061368|NCT01744405|Chagas disease
1061369|NCT01744405|lactation
1061370|NCT01744405|breastmilk
1061371|NCT01744405|postpartum period
1061372|NCT01744405|infants
1061373|NCT01744405|pediatric clinical pharmacology
1061374|NCT01744405|developmental clinical pharmacology
1061375|NCT01744405|parasitology
1061376|NCT01744405|trypanosoma cruzi
1061377|NCT01744405|nifurtimox
1061378|NCT01744353|newly diagnosed
1061379|NCT01744353|advanced pancreatic cancer
1061380|NCT01744353|pancreatic cancer
1061381|NCT01744353|metastatic pancreatic cancer
1061382|NCT01744353|pancreas
1061383|NCT01744340|Head and Neck
1061384|NCT01744340|Colon
1061385|NCT01744314|Elbow trauma,Heterotopic Ossification,Indomethacin, Prophylaxis
1061386|NCT01744301|Seizure
1061387|NCT01744301|Acid-suppressing drugs
1061388|NCT01744301|Epidemiology
1061389|NCT01744288|Phase 1 Safety ,
1061390|NCT01744288|pharmacodynamic,
1061391|NCT01744288|Ticagrelor,
1061392|NCT01744288|Clopidogrel,
1061393|NCT01744288|Platelets
1061394|NCT01744275|Epilepsy
1061395|NCT01744275|Omega 3 fatty acids
1061396|NCT01744262|intraocular pressure, total intravenous anesthesia, laparoscopic prostatectomy
1061397|NCT01744249|carcinoid tumor
1061398|NCT01744249|axitinib
1061399|NCT01744236|GLP-1 Receptor Agonists, DPP-4 inhibitors
1061400|NCT01744223|iCaspase9
1061401|NCT01744223|iCasp9
1061402|NCT01744223|Inducible Caspase
1061403|NCT01744223|AP1903
1061404|NCT01744223|Dimerizer drug
1061405|NCT01744223|T depleted
1061406|NCT01744223|Suicide gene
1061407|NCT01744223|CD-34 selection
1061408|NCT01744223|haplotransplantation
1061409|NCT01744223|Graft versus host disease
1061410|NCT01744223|Allogenic transplantation
1061411|NCT01744197|Pain control
1061412|NCT01744197|Needle stick pain
1061413|NCT01744197|Venipuncture pain
1061414|NCT01744184|gastroscopy
1061415|NCT01744184|diagnostic
1061416|NCT01744184|entonox
1061417|NCT01744158|cerebral palsy
1061418|NCT01744158|spasticity
1061419|NCT01744158|dystonia
1061420|NCT01744158|hypertonia
1061421|NCT01744158|register
1061422|NCT01744158|motor function
1061423|NCT01744132|eye care utilization
1061424|NCT01744132|ophthalmology
1061425|NCT01744132|educational intervention
1061426|NCT01744132|public health screening
1061427|NCT01744093|HIV
1061428|NCT01744093|COPD
1061429|NCT01744093|Chronic Obstructive Pulmonary Disease
1061430|NCT01744093|Emphysema
1061431|NCT01744080|Rotator cuff
1061432|NCT01744067|Renal transplantation
1061433|NCT01744067|Interventional study
1061434|NCT01744067|Glomerular filtration rate
1061435|NCT01744067|Renal function
1061436|NCT01744067|Proteinuria
1061437|NCT01744067|Cardiovascular risk markers
1061438|NCT01744067|Blood pressure
1061439|NCT01744067|Flow mediated vasodilation
1061440|NCT01744067|Heart rate variability
1061441|NCT01744067|Pulse wave velocity
1061442|NCT01744067|Lipids
1061443|NCT01744067|Blood glucose
1061444|NCT01744067|Bone mineral density
1061445|NCT01744067|Body composition
1061446|NCT01744067|Fat distribution
1061447|NCT01744067|Body mass index
1061448|NCT01744067|Fatty acid composition
1061449|NCT01744067|Tacrolimus pharmacokinetics
1061450|NCT01744067|Omega-3 fatty acids
1061451|NCT01744067|Marine n-3 fatty acids
1061452|NCT01744067|Fatty acids
1061453|NCT01744067|Gas chromatography
1061454|NCT01744067|Interstitial fibrosis
1061455|NCT01744067|Inflammation
1061456|NCT01744041|depression
1061457|NCT01744041|pregnancy
1061458|NCT01744041|postpartum
1061459|NCT01744041|psychotherapy
1061460|NCT01744028|COPD, remote patient monitoring, Hub, exacerbations, EXACT
1061461|NCT01744015|Low back pain
1061462|NCT01744002|Shoulder, Impingement syndrome, Neck
1061463|NCT01743976|neuropathic pain
1061464|NCT01743976|diabetic neuropathy
1061465|NCT01743976|neuropathic pain after back surgery
1061466|NCT01743963|efficacy
1061467|NCT01743963|glucocorticoid
1061468|NCT01743950|Glioblastoma
1061469|NCT01743950|anaplastic glioma
1061470|NCT01743937|Ischemic preconditioning
1061471|NCT01743937|Ticagrelor
1061472|NCT01743937|Antiplatelet therapy
1061473|NCT01743937|Acute coronary syndrome
1061474|NCT01743924|Broccoli; Isothiocyanates; Pharmacokinetics; Sulforaphane; Myrosinase
1061475|NCT01743911|Tadalafil
1061476|NCT01743911|Resistant Hypertension
1061477|NCT01743911|Left Ventricle Diastolic Dysfunction
1061478|NCT01743911|Brain natriuretic peptide
1061479|NCT01743885|Hemangioma
1061480|NCT01743885|Beta-blocker
1061481|NCT01743885|Acebutolol
1061482|NCT01743885|Propranolol
1061483|NCT01743885|Randomized controlled trial
1061484|NCT01743885|Infants
1061485|NCT01743872|Optical Coherence Tomography
1061486|NCT01743872|Contrast
1061487|NCT01743872|Dextran
1061488|NCT01743872|Carbon Dioxide
1061489|NCT01743872|Imaging
1061490|NCT01743872|Catheter
1061491|NCT01743872|Lower Extremity Artery
1061492|NCT01743859|Myeloid
1061493|NCT01743859|Leukemia
1061494|NCT01743807|Relapsed
1061495|NCT01743807|Minimal Residual Disease
1061496|NCT01743807|MRD
1061497|NCT01743807|Acute Lymphoblastic Leukemia
1061498|NCT01743807|Acute Myelogenous Leukemia
1061499|NCT01743807|ALL
1061500|NCT01743807|AML
1061501|NCT01743807|GNKG168
1061502|NCT01743807|Pediatric
1061503|NCT01743807|Childhood
1061504|NCT01743781|comprehensive eye examination
1061505|NCT01743781|acceptance
1061506|NCT01743781|glaucoma
1061507|NCT01743781|diabetic retinopathy
1061508|NCT01743768|Antisense oligonucleotide
1061509|NCT01743768|Asthma
1061510|NCT01743768|Healthy subjects
1061511|NCT01743768|Phase 1
1061512|NCT01743768|Transcription factor GATA-3
1061513|NCT01743768|Oral inhalation
1061514|NCT01743755|Community-acquired pneumonia
1061515|NCT01743755|Dexamethasone
1061516|NCT01743755|Corticosteroid
1061517|NCT01743742|Oral vitamin E and vitamin C
1061518|NCT01743729|SAR 1118
1061519|NCT01743716|Major Depressive Disorder
1061520|NCT01743716|MDD
1061521|NCT01743716|depression
1061522|NCT01743716|adolescent
1061523|NCT01743703|traumatic injuries
1061524|NCT01743703|Whole-body MRI
1061525|NCT01743703|Skeletal survey
1061526|NCT01743703|Children
1061527|NCT01743703|Diagnostic
1061528|NCT01743690|Probiotic
1061529|NCT01743690|Candida
1061530|NCT01743690|Oral Lichen Planus
1061531|NCT01743677|TQT study
1061532|NCT01743677|CP-690,550
1061533|NCT01743664|Posttraumatic Stress Disorders
1061534|NCT01743664|Multiple Sclerosis
1061535|NCT01743664|Eye Movement Desensitization Reprocessing
1061536|NCT01743664|Psychotherapy
1061537|NCT01743664|Anxiety
1061538|NCT01743664|Depression
1061539|NCT01743664|Quality of Life
1061540|NCT01743651|spasticity
1061541|NCT01743651|multiple sclerosis
1061542|NCT01743651|arbaclofen
1061543|NCT01743612|healthy subject
1061544|NCT01743612|hand blood flow
1061545|NCT01743612|laser speckle contrast imaging
1061546|NCT01743586|Lung cancer
1061547|NCT01743586|Chest physiotherapy
1061548|NCT01743586|Respiratory muscle strength
1061549|NCT01743586|Dyspnea, Functional capacity
1061550|NCT01743586|Quality of life
1061551|NCT01743560|Breast Neoplasms
1061552|NCT01743560|Neoplasms
1061553|NCT01743560|Breast diseases
1061554|NCT01743560|Skin diseases
1061555|NCT01743560|Exemestane
1061556|NCT01743560|Antibiotics, Antineoplastic
1061557|NCT01743560|Everolimus
1061558|NCT01743560|Antineoplastic Agents
1061559|NCT01743560|Therapeutic Uses
1061560|NCT01743560|Pharmacologic Actions
1061561|NCT01743560|Immunosuppressive Agents
1061562|NCT01743560|Physiological Effects of Drugs
1061563|NCT01743560|Aromatase Inhibitors
1061564|NCT01743560|Enzyme Inhibitors
1061565|NCT01743560|Molecular Mechanisms of Pharmacological Action
1061566|NCT01743547|Women
1061567|NCT01743547|Yoga
1061568|NCT01743547|Ovarian Cancer
1061569|NCT01743547|Lifestyle
1061570|NCT01743521|Hepatitis C
1061571|NCT01743521|Individualised therapy
1061572|NCT01743521|Response-guided therapy
1061573|NCT01743521|Telaprevir
1061574|NCT01743521|PEG-IFN
1061575|NCT01743521|Ribavirin
1061576|NCT01743521|Hepatitis
1061577|NCT01743508|incomplete abortion
1061578|NCT01743508|misoprostol treatment
1061579|NCT01743508|midwife
1061580|NCT01743508|uganda
1061581|NCT01743495|Medical Costs
1061582|NCT01743495|improved IADLs
1061583|NCT01743495|and/or ADL's
1061584|NCT01743495|decreased nursing home admissions
1061585|NCT01743482|Testicular Cancer
1061586|NCT01743482|Germ Cell Tumors
1061587|NCT01743482|Salvage Therapy
1061588|NCT01743482|Pazopanib
1061589|NCT01743456|Postoperative cognitive dysfunction
1061590|NCT01743456|Coronary artery bypass graft surgery
1061591|NCT01743456|Postoperative cognitive improvement
1061592|NCT01743456|Postoperative delirium
1061593|NCT01743443|Corneal sensitivity
1061594|NCT01743443|Cross-linking
1061595|NCT01743443|Keratoconus
1061596|NCT01743430|telerehabilitation
1061597|NCT01743430|stroke
1061598|NCT01743430|Berg balance scale
1061599|NCT01743430|stroke impact scale
1061600|NCT01743430|mobility
1061601|NCT01743417|Cognitive rehabilitation
1061602|NCT01743417|malaria
1061603|NCT01743417|neuropsychology
1061604|NCT01743417|attention
1061605|NCT01743417|working memory
1061606|NCT01743404|atherosclerosis
1061607|NCT01743404|inflammation
1061608|NCT01743404|intima-media thickness
1061609|NCT01743391|IVF treatment
1061610|NCT01743391|Office-hysteroscopy
1061611|NCT01743391|Endometrial biopsy
1061612|NCT01743352|Large arteries
1061613|NCT01743352|stiffness
1061614|NCT01743352|intima media thickness
1061615|NCT01743352|ultrasound imaging
1061616|NCT01743339|Randomized Controlled Trial
1061617|NCT01743339|Cognitive Therapy
1061618|NCT01743339|Stress Disorders, Post-Traumatic
1061619|NCT01743339|Depression
1061620|NCT01743339|Sleep
1061621|NCT01743326|Zygapophyseal Joint
1061622|NCT01743313|glucose metabolism disorders
1061623|NCT01743313|metabolic syndrome
1061624|NCT01743313|joint replacement
1061625|NCT01743313|osteoarthritis
1061626|NCT01743300|sunitinib
1061627|NCT01743300|pharmacokinetics
1061628|NCT01743300|phenotyping
1061629|NCT01743300|interaction
1061630|NCT01743287|osteoarthritis of the knee
1061631|NCT01743274|acute coronary syndromes
1061632|NCT01743274|non-ST elevation myocardial infarction
1061633|NCT01743274|angioplasty
1061634|NCT01743274|fractional flow reserve
1061635|NCT01743274|optical coherence tomography
1061636|NCT01743261|severe brain injury
1061637|NCT01743261|graded intensive rehabilitation
1061638|NCT01743248|vestibular schwannoma
1061639|NCT01743248|balance
1061640|NCT01743248|psychological factors
1061641|NCT01743235|HSDD
1061642|NCT01743209|androgen antagonists
1061643|NCT01743196|Folic acid
1061644|NCT01743196|Folate
1061645|NCT01743196|Pharmacokinetics
1061646|NCT01743196|Women of Child Bearing Age
1061647|NCT01743183|hypertension
1061648|NCT01743170|Blood pressure control
1061649|NCT01743170|Hypertension
1061650|NCT01743170|Office blood pressure
1061651|NCT01743170|Self-measured blood pressure
1061652|NCT01743170|Telemonitoring
1061653|NCT01743144|emergence agitation in children
1061654|NCT01743144|sevoflurane
1061655|NCT01743144|general anesthesia
1061656|NCT01743144|magnesium sulphate
1061657|NCT01743105|diaphragm movement
1061658|NCT01743105|ultrasound
1061659|NCT01743105|emergency room
1061660|NCT01743092|Pathological gambling
1061661|NCT01743092|treatment
1061662|NCT01743092|online counselling
1061663|NCT01743092|webinar
1061664|NCT01743092|workbook
1061665|NCT01743079|Telbivudine
1061666|NCT01743079|Lamivudine
1061667|NCT01743079|safety
1061668|NCT01743079|efficacy
1061669|NCT01743079|pregnancy
1061670|NCT01743066|Arsenic
1061671|NCT01743066|Arsenicosis
1061672|NCT01743066|Buccal cells
1061673|NCT01743066|Serum
1061674|NCT01743066|Vitamin E
1061675|NCT01743066|Cholesterol
1061676|NCT01743040|Coronary Artery Disease
1061677|NCT01743040|Nuclear Stress Test
1061678|NCT01743040|CT Angiography
1061679|NCT01743040|Angiography
1061680|NCT01743027|Allergic conjunctivitis
1061681|NCT01743027|Olopatadine HCl solution
1061682|NCT01743027|Conjunctival Allergen Challenge
1061683|NCT01743027|Itching eyes
1061684|NCT01743027|Ocular allergies
1061685|NCT01743027|PATADAY
1061686|NCT01743027|PATANOL
1061687|NCT01743014|diabetes
1061688|NCT01743014|diabetic nephropathy
1061689|NCT01743014|vascular inflammation
1061690|NCT01743014|oxidative stress
1061691|NCT01743014|endothelial dysfunction
1061692|NCT01743014|Asymmetric dimethylarginine
1061693|NCT01743014|High sensitivity CRP
1061694|NCT01743014|albumine to creatinine ratio
1061695|NCT01743014|isoprostane
1061696|NCT01743014|clopidogrel
1061697|NCT01743014|ramipril
1061698|NCT01743014|carotid intima media thickness
1061699|NCT01743001|exercise capacity
1061700|NCT01743001|Eisenmenger Syndrome
1061701|NCT01742988|PI3K
1061702|NCT01742988|HDAC
1061703|NCT01742988|Open-Label
1061704|NCT01742988|Dose-Escalation
1061705|NCT01742962|Prostatectomy
1061706|NCT01742962|Prostate cancer
1061707|NCT01742962|Orgasm
1061708|NCT01742962|Urinary incontinence
1061709|NCT01742962|Climacturia(orgasm related urinary incontinence)
1061710|NCT01742962|Penis
1061711|NCT01742962|Dysorgasmia (pain in relation to orgasm)
1061712|NCT01742962|Pain
1061713|NCT01742962|Anorgasmia
1061714|NCT01742962|Penile shortening
1061715|NCT01742962|Erectile dysfunction
1061716|NCT01742923|hypertension
1061717|NCT01742923|medication adherence
1061718|NCT01742923|motivational interviewing
1061719|NCT01742897|Osteoarthritis, Knee
1061720|NCT01742897|Transdermal therapeutic system (TTS) fentanyl
1061721|NCT01742897|Durogesic
1061722|NCT01742884|Dry Eye Syndrome
1061723|NCT01742871|Antivitamin K
1061724|NCT01742871|Bleeding
1061725|NCT01742871|Haemorrhage
1061726|NCT01742871|Nutritional status
1061727|NCT01742871|impedancemetry
1061728|NCT01742845|Ultrasound-guided
1061729|NCT01742845|regional anaesthesia
1061730|NCT01742845|Cervical block
1061731|NCT01742832|Vilazodone
1061732|NCT01742832|Citalopram
1061733|NCT01742832|Major Depressive Disorder
1061734|NCT01742819|Glaucoma, Optical Coherence Tomography, Progression
1061735|NCT01742806|Gastric cancer
1061736|NCT01742806|Minimally invasive surgery
1061737|NCT01742806|Distal gastrectomy
1061738|NCT01742806|Bio-absorbable Felt
1061739|NCT01742793|relapsed /refractory Hodgkin lymphoma
1061740|NCT01742793|mature T-cell lymphoma
1061741|NCT01742793|multiple myeloma
1061742|NCT01742780|Intraosseous Vascular Access
1061743|NCT01742780|IO Access
1061744|NCT01742780|IO Vascular Access
1061745|NCT01742780|EZ-IO
1061746|NCT01742767|NSCLC; split dose Cisplatinum; Pemetrexed
1061747|NCT01742741|Diabetes Mellitus, Type 1 (T1DM)
1061748|NCT01742741|Continuous Glucose Monitor (CGM)
1061749|NCT01742741|Artificial Pancreas (AP)
1061750|NCT01742741|Insulin Pump
1061751|NCT01742741|Closed Loop Control (CLC)
1061752|NCT01742741|Open Loop treatment
1061753|NCT01742741|Diabetes Assistant
1061754|NCT01742741|DiAs
1061755|NCT01742728|oxidative stress, antioxidant, periodontitis, serum immunoglobulin G
1061756|NCT01742728|antibody titer
1061757|NCT01742715|ARDS
1061758|NCT01742715|Lung compliance
1061759|NCT01742702|Blood pressure
1061760|NCT01742702|Hypertension
1061761|NCT01742702|Arterial stiffness
1061762|NCT01742702|Cardiac output
1061763|NCT01742702|Vascular resistance
1061764|NCT01742702|Pulse wave reflection
1061765|NCT01742702|Head-up tilt
1061766|NCT01742689|Renal colic
1061767|NCT01742689|Pain
1061768|NCT01742689|Desmopressin
1061769|NCT01742689|Urinary obstruction
1061770|NCT01742689|Indomethacin
1061771|NCT01742676|tacrolimus
1061772|NCT01742676|kidney
1061773|NCT01742663|Diclofenac Sodium Gel 3%
1061774|NCT01742663|Solaraze® (diclofenac sodium) Gel 3%
1061775|NCT01742663|Actinic Keratosis
1061776|NCT01742650|ankle; fracture; syndesmosis;
1061777|NCT01742637|Acne Vulgaris
1061778|NCT01742637|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%
1061779|NCT01742637|Epiduo®
1061780|NCT01742624|immunosuppressant
1061781|NCT01742624|new-onset diabetes after kidney transplantation
1061782|NCT01742624|NODAT
1061783|NCT01742611|CKD
1061784|NCT01742611|Not on dialysis
1061785|NCT01742611|ASP1585
1061786|NCT01742611|Bixalomer
1061787|NCT01742598|TAVI
1061788|NCT01742598|TAVR
1061789|NCT01742598|aortic stenosis
1061790|NCT01742598|Transcatheter
1061791|NCT01742598|valvular heart disease
1061792|NCT01742598|aortic valve stenosis
1061793|NCT01742598|aortic valve replacement
1061794|NCT01742598|transcatheter aortic valve implantation
1061795|NCT01742585|CKD
1061796|NCT01742585|Not on dialysis
1061797|NCT01742585|ASP1585
1061798|NCT01742585|Bixalomer
1061799|NCT01742572|weight loss
1061800|NCT01742572|obesity
1061801|NCT01742572|overweight
1061802|NCT01742572|diet
1061803|NCT01742559|Treatment
1061804|NCT01742546|myofascial pain syndrome
1061805|NCT01742546|therapeutic ultrasound
1061806|NCT01742546|combine therapy
1061807|NCT01742533|Hormone Replacement Therapy，
1061808|NCT01742533|Premature Ovarian Failure，
1061809|NCT01742533|Stem Cell Therapy
1061810|NCT01742520|Preterm infant
1061811|NCT01742520|pain
1061812|NCT01742520|neurodevelopment
1061813|NCT01742507|Stent, OCT
1061814|NCT01742494|Esophageal Achalasia,
1061815|NCT01742494|Peroral endoscopic myotomy,
1061816|NCT01742494|Water-jet assisted
1061817|NCT01742481|childhood cancer survivors
1061818|NCT01742481|long-term follow-up care
1061819|NCT01742481|health communication
1061820|NCT01742481|ethnic/racial minorities
1061821|NCT01742481|longterm survivors
1061822|NCT01742468|n-3 LC-PUFA, DHA, rheumatoid arthritis
1061823|NCT01742455|Peripheral artery disease
1061824|NCT01742455|Arterial Occlusive Diseases
1061825|NCT01742455|Vascular Diseases
1061826|NCT01742455|Cardiovascular Diseases
1061827|NCT01742455|Coronary Artery Disease
1061828|NCT01742455|Myocardial Ischemia
1061829|NCT01742455|Arteriosclerosis
1061830|NCT01742455|Pathologic Processes
1061831|NCT01742442|Cancer
1061832|NCT01742442|elderly OR older
1061833|NCT01742442|chemotherapy
1061834|NCT01742442|geriatric assessment
1061835|NCT01742429|Helicobacter pylori
1061836|NCT01742429|second line treatment
1061837|NCT01742416|Arterial Cannulation
1061838|NCT01742416|Ultrasound
1061839|NCT01742416|Palpation Method
1061840|NCT01742416|Pediatrics
1061841|NCT01742416|Cardiac Surgery
1061842|NCT01742416|Craniotomies
1061843|NCT01742416|Cranial Vault Surgery
1061844|NCT01742416|Abdominal Procedures
1061845|NCT01742403|Prostate
1061846|NCT01742403|IGRT
1061847|NCT01742403|VMAT
1061848|NCT01742390|schizophrenia
1061849|NCT01742390|risperidone
1061850|NCT01742390|paliperidone
1061851|NCT01742390|aripiprazole
1061852|NCT01742377|GERD
1061853|NCT01742377|Dyspepsia
1061854|NCT01742377|Ambulatory 24-hour Esophageal pH Monitoring
1061855|NCT01742377|Minimal change erosions
1061856|NCT01742364|disposable syringe jet injector (DSJI)
1061857|NCT01742364|DSJI
1061858|NCT01742364|BCG
1061859|NCT01742364|tuberculosis
1061860|NCT01742364|intradermal delivery
1061861|NCT01742364|South Africa
1061862|NCT01742338|Chronic Obstructive Pulmonary Disease
1061863|NCT01742338|COPD
1061864|NCT01742338|Chronic bronchitis
1061865|NCT01742338|emphysema
1061866|NCT01742338|Corticosteroids
1061867|NCT01742325|fatigue
1061868|NCT01742325|walking
1061869|NCT01742325|childhood cancer
1061870|NCT01742325|sleep disturbance
1061871|NCT01742312|neoadjuvant chemotherapy
1061872|NCT01742312|oesophageal cancer
1061873|NCT01742312|cardiorespiratory performance
1061874|NCT01742299|Glivec/Gleevec
1061875|NCT01742299|CML
1061876|NCT01742299|GIST
1061877|NCT01742299|Imatinib mesylate
1061878|NCT01742286|pediatric
1061879|NCT01742286|anaplastic lymphoma kinase
1061880|NCT01742286|ALK
1061881|NCT01742286|ALK-activated tumors
1061882|NCT01742286|neuroblastoma
1061883|NCT01742286|rhabdomyosarcoma
1061884|NCT01742286|anaplastic large-cell lymphoma
1061885|NCT01742286|inflammatory myofibroblastic tumor
1061886|NCT01742260|Cranioplasty
1062137|NCT01741051|Air pollution
1061887|NCT01742260|Mesenchymal stromal cells
1061888|NCT01742260|Bioceramic polymer
1061889|NCT01742247|Moisturizer, laser
1061890|NCT01742221|Safety and Tolerability, Cytokines, Acute Radiation Syndrome, Hematopoietic Syndrome, Radiation Countermeasure
1061891|NCT01742195|Endobronchial ultrasound
1061892|NCT01742195|Bronchoscopy
1061893|NCT01742195|Patient satisfaction
1061894|NCT01742182|Parkinson's Disease
1061895|NCT01742182|Excessive Daytime Sleepiness
1061896|NCT01742182|Circadian Rhythms
1061897|NCT01742182|Light Therapy
1061898|NCT01742169|Colorectal Cancer Screening
1061899|NCT01742169|Fecal Occult Blood Testing
1061900|NCT01742156|CAD
1061901|NCT01742156|microangiopathy
1061902|NCT01742156|patients
1061903|NCT01742156|more likely
1061904|NCT01742156|to have tortuosity
1061905|NCT01742156|of conjunctival vessels
1061906|NCT01742143|Quality of life
1061907|NCT01742143|cancer
1061908|NCT01742143|12-223
1061909|NCT01742130|Contrast-induced nephropathy
1061910|NCT01742130|Contrast media
1061911|NCT01742130|Angiography
1061912|NCT01742130|Coronary percutaneous intervention
1061913|NCT01742117|percutaneous coronary intervention
1061914|NCT01742117|angioplasty
1061915|NCT01742104|glaucoma
1061916|NCT01742104|primary open-angle glaucoma
1061917|NCT01742104|observational study
1061918|NCT01742104|quality of life
1061919|NCT01742091|Postmenopausal females
1061920|NCT01742091|Volunteers
1061921|NCT01742078|Postmenopausal females
1061922|NCT01742078|Volunteers
1061923|NCT01742065|Colorectal Cancer Screening
1061924|NCT01742065|Cancer Screening
1061925|NCT01742065|Pragmatic Trial
1061926|NCT01742052|relapsing-remitting multiple sclerosis
1061927|NCT01742052|RRMS
1061928|NCT01742026|High risk aspergillosis infection patients
1061929|NCT01742013|Chronic Fatigue
1061930|NCT01742013|CFS
1061931|NCT01742013|ICF
1061932|NCT01742013|human placenta
1061933|NCT01742000|postmenopause
1061934|NCT01742000|phytoestrogen
1061935|NCT01742000|atherosclerosis
1061936|NCT01742000|intima-media thickness
1061937|NCT01741974|perimenopause
1061938|NCT01741974|phytoestrogen
1061939|NCT01741974|atherosclerosis
1061940|NCT01741974|intima-media thickness
1061941|NCT01741961|uncontrolled glaucoma
1061942|NCT01741961|glaucoma drainage device
1061943|NCT01741948|Provoked vestibulodynia
1061944|NCT01741948|Hormonal contraceptives
1061945|NCT01741922|Low dose
1061946|NCT01741922|aspirin
1061947|NCT01741922|ASA
1061948|NCT01741922|Hypertension
1061949|NCT01741922|blood pressure
1061950|NCT01741909|azythromycin
1061951|NCT01741909|community acquired pneumonia
1061952|NCT01741909|intravenous
1061953|NCT01741909|oral
1061954|NCT01741883|Randomized Controlled Trial
1061955|NCT01741883|Patients´ Expectations
1061956|NCT01741883|Breast Cancer
1061957|NCT01741883|Adjuvant Endocrine Treatment
1061958|NCT01741883|Nocebo
1061959|NCT01741870|Nutritional supplement
1061960|NCT01741870|Nutritional status
1061961|NCT01741870|Physical functional activity
1061962|NCT01741870|Nursing home elderly
1061963|NCT01741844|Acquired Immune Deficiency Syndrome
1061964|NCT01741844|TMC125
1061965|NCT01741844|Etravirine
1061966|NCT01741844|Intelence
1061967|NCT01741844|AIDS
1061968|NCT01741831|Acquired Immune Deficiency Syndrome
1061969|NCT01741831|AIDS
1061970|NCT01741831|TMC114
1061971|NCT01741831|Darunavir
1061972|NCT01741831|Prezista
1061973|NCT01741818|IVC
1061974|NCT01741818|ultrasonography
1061975|NCT01741818|IVC collapsibility index
1061976|NCT01741818|IVC diameter
1061977|NCT01741792|Relapsed DLBCL
1061978|NCT01741792|Refractory DLBCL
1061979|NCT01741792|adult DLBCL
1061980|NCT01741792|Lymphoma
1061981|NCT01741792|Non-Hodgkin Lymphoma
1061982|NCT01741792|Lymphatic diseases
1061983|NCT01741792|Lymphoproliferative disorders
1061984|NCT01741792|bispecific antibody
1061985|NCT01741792|anti-CD19
1061986|NCT01741792|Immunotherapeutic treatment
1061987|NCT01741792|Immunoproliferative disorders
1061988|NCT01741779|whole body vibration training
1061989|NCT01741779|hypocaloric diet
1061990|NCT01741779|prehypertension
1061991|NCT01741779|hypertension
1061992|NCT01741779|obesity
1061993|NCT01741779|arterial function
1061994|NCT01741779|arterial stiffness
1061995|NCT01741779|pulse wave velocity
1061996|NCT01741779|autonomic function
1061997|NCT01741779|endothelial function
1061998|NCT01741779|adipocytokines
1061999|NCT01741766|prehypertension
1062000|NCT01741766|hypertension
1062001|NCT01741766|obesity
1062002|NCT01741766|stretching
1062003|NCT01741766|arterial function
1062004|NCT01741766|arterial stiffness
1062005|NCT01741766|pulse wave velocity
1062006|NCT01741766|autonomic function
1062007|NCT01741766|endothelial function
1062008|NCT01741753|Docetaxel Pretreated
1062009|NCT01741753|Castrate Resistant
1062010|NCT01741753|Metastatic
1062011|NCT01741740|pain, hernia, chronic, discomfort, retrospective
1062012|NCT01741675|Questionnaires
1062013|NCT01741675|Quality of Life
1062014|NCT01741675|Response rate
1062015|NCT01741649|Surgical wound infection
1062016|NCT01741649|Clorhexidine
1062017|NCT01741649|Povidone
1062018|NCT01741610|Anaesthesia Spinal
1062019|NCT01741610|Ephedrine
1062020|NCT01741610|Fluid Therapy
1062021|NCT01741610|Hypotension
1062022|NCT01741558|Myocardial Ischemia
1062023|NCT01741558|Myocardial Infarction
1062024|NCT01741558|Methotrexate
1062025|NCT01741558|Inflammation
1062026|NCT01741558|Anti-Inflammatory Agents
1062027|NCT01741558|Inflammation Mediators
1062028|NCT01741532|Pantothenate Kinase-associated Neurodegeneration
1062029|NCT01741532|PKAN
1062030|NCT01741532|NBIA
1062031|NCT01741532|Deferiprone
1062032|NCT01741532|Ferriprox
1062033|NCT01741519|PK
1062034|NCT01741519|PD
1062035|NCT01741519|landiolol
1062036|NCT01741519|esmolol
1062037|NCT01741519|healthy volunteers phase I study
1062038|NCT01741506|Lung cancer
1062039|NCT01741506|Surgery
1062040|NCT01741506|Thromboembolism
1062041|NCT01741506|Bleeding
1062042|NCT01741493|Rheumatoid Arthritis
1062043|NCT01741493|Methotrexate
1062044|NCT01741493|Tolerability
1062045|NCT01741493|Pharmacokinetics
1062046|NCT01741493|Safety
1062047|NCT01741493|Tofacitinib
1062048|NCT01741480|Outcomes
1062049|NCT01741480|Early warning systems
1062050|NCT01741480|ICU transfer
1062054|NCT01741441|Duodenogastroesophageal reflux
1062055|NCT01741441|Weakly acidic reflux
1062056|NCT01741441|Gastric emptying
1062057|NCT01741441|Laparoscopic fundoplication
1062058|NCT01741428|CVD Risk score
1062059|NCT01741428|Physical activity
1062060|NCT01741428|Overweight
1062061|NCT01741428|Cholesterol
1062062|NCT01741428|LDL-Cholesterol
1062063|NCT01741428|HDL-Cholesterol
1062064|NCT01741428|Triglycerides
1062065|NCT01741428|HbA1C
1062066|NCT01741428|Quality of life
1062067|NCT01741402|Control posture
1062068|NCT01741402|Gait
1062069|NCT01741402|Virtual Reality
1062070|NCT01741402|Elderly
1062071|NCT01741389|Circadian variation, hemostasis, melatonin, tetraplegia
1062072|NCT01741363|iFOBT
1062073|NCT01741363|one-day sample
1062074|NCT01741363|two-day sample
1062075|NCT01741363|Helicobacter pylori stool antigen
1062076|NCT01741350|Methadone-maintenance
1062077|NCT01741350|HIV
1062078|NCT01741350|Risk behavior
1062079|NCT01741350|Injection drug use
1062080|NCT01741350|Condom use
1062081|NCT01741350|Health care participation
1062082|NCT01741350|Opioid replacement therapy
1062083|NCT01741337|central sleep apneas syndrome
1062084|NCT01741337|heart failure
1062085|NCT01741337|all coronary reperfusions
1062086|NCT01741337|adaptive servo-ventilation treatment
1062087|NCT01741311|viral load
1062088|NCT01741311|HIV
1062089|NCT01741311|CD4
1062090|NCT01741311|methadone maintenance
1062091|NCT01741311|substance use
1062092|NCT01741311|Antiretroviral therapy (ART)
1062093|NCT01741298|Metabolic syndrome
1062094|NCT01741285|Asthma
1062095|NCT01741285|Adenosine
1062096|NCT01741285|Small airways
1062097|NCT01741285|Smokers
1062098|NCT01741285|Ex-smokers
1062099|NCT01741272|rotator cuff tear
1062100|NCT01741272|arthroscopically assisted
1062101|NCT01741272|health related quality of life(HRQL)
1062102|NCT01741272|functional outcome
1062103|NCT01741259|analgesia
1062104|NCT01741259|meperidine
1062105|NCT01741259|epidural
1062106|NCT01741246|Episodic migraine
1062107|NCT01741246|Chronic migraine
1062108|NCT01741246|Magnetic resonance imaging
1062109|NCT01741246|Positron emission tomography
1062110|NCT01741233|SNPs
1062111|NCT01741233|vitamin D
1062112|NCT01741233|Vitamin D status
1062113|NCT01741233|UVB irradiation
1062114|NCT01741233|genetics
1062115|NCT01741181|25(OH)Vitamin D
1062116|NCT01741181|Diabetes mellitus
1062117|NCT01741181|Endothelial Function
1062118|NCT01741142|Major Depressive Disorder
1062119|NCT01741129|Nasal CPAP
1062120|NCT01741129|Nasal IMV
1062121|NCT01741129|Surfactant
1062122|NCT01741129|Preterm infants
1062123|NCT01741116|castration-resistant prostate cancer
1062124|NCT01741116|TKI258
1062125|NCT01741116|FGF23
1062126|NCT01741090|Autologous Mesenchymal stem cell
1062127|NCT01741090|alcoholic liver cirrhosis
1062128|NCT01741077|pregnancy
1062129|NCT01741077|folic acid supplementation
1062130|NCT01741077|reproduction
1062131|NCT01741077|folate
1062132|NCT01741064|Secondary Hyperparathyroidism
1062133|NCT01741064|Renal Transplantation
1062134|NCT01741064|Myocardial Infarction
1062135|NCT01741064|Fracture
1062136|NCT01741064|Graft Failure
1062138|NCT01741051|Particulate matter
1062139|NCT01741051|Mongolia
1062140|NCT01741051|Pregnancy
1062141|NCT01741051|Intrauterine growth restriction (IUGR)
1062142|NCT01741051|Fetal growth
1062143|NCT01741051|Birth weight
1062144|NCT01741051|Gestational age
1062145|NCT01741038|Cancer Vaccine
1062146|NCT01741038|AlloStim®
1062147|NCT01741038|Immunovative
1062148|NCT01741038|Immunotherapy
1062149|NCT01741038|Allogeneic Cell Therapy
1062150|NCT01741038|Cryoablation
1062151|NCT01741012|Lupus
1062152|NCT01740986|Asthma
1062153|NCT01740973|SILC
1062154|NCT01740973|lap. cholecystectomy
1062155|NCT01740973|trocar-site hernia
1062156|NCT01740960|delta-9-tetrahydrocannabinol
1062157|NCT01740960|THC
1062158|NCT01740960|Cannabis
1062159|NCT01740947|Selective decontamination of the digestive tract
1062160|NCT01740947|anastomotic leakage
1062161|NCT01740947|colorectal cancer
1062162|NCT01740934|rosacea
1062163|NCT01740934|anatabine
1062164|NCT01740934|Anatabloc
1062165|NCT01740934|dermatology
1062166|NCT01740921|GLP-1 analogues
1062167|NCT01740921|microvascular
1062168|NCT01740921|inflammation
1062169|NCT01740921|fat tissue
1062170|NCT01740921|clot structure
1062171|NCT01740908|hyperbaric oxygen
1062172|NCT01740908|stem cell
1062173|NCT01740882|incisional hernia
1062174|NCT01740882|mesh fixation
1062175|NCT01740882|absorbable tacks
1062176|NCT01740869|autism
1062177|NCT01740869|autism spectrum
1062178|NCT01740869|stem cells
1062179|NCT01740869|children
1062180|NCT01740856|cardiac catheterization
1062181|NCT01740856|safety
1062182|NCT01740856|nursing care
1062183|NCT01740856|rest
1062184|NCT01740856|Patients
1062185|NCT01740817|diabetes
1062186|NCT01740817|obesity
1062187|NCT01740817|inflammation
1062188|NCT01740804|Circulating tumor cell
1062189|NCT01740804|Non-small cell lung cancer
1062190|NCT01740804|chemotherapy
1062191|NCT01740791|Hepatitis C
1062192|NCT01740791|HCV
1062193|NCT01740791|Genotype 1
1062194|NCT01740791|Genotype 2
1062195|NCT01740791|Genotype 3
1062196|NCT01740791|Genotype 4
1062197|NCT01740791|Genotype 5
1062198|NCT01740791|Genotype 6
1062199|NCT01740791|Liver Disease
1062200|NCT01740778|Diabetes
1062201|NCT01740778|Medical Device
1062202|NCT01740778|Lancing
1062203|NCT01740752|anorexia nervosa
1062204|NCT01740752|eating disorder
1062205|NCT01740752|couples
1062206|NCT01740752|relationships
1062207|NCT01740752|couple therapy
1062208|NCT01740739|Health Risk Appraisal
1062209|NCT01740739|HCardiac Risk Factors
1062210|NCT01740726|Depression
1062211|NCT01740726|Behavioral Activation
1062212|NCT01740726|Fluoxetine
1062213|NCT01740726|Prozac
1062214|NCT01740726|Treatment
1062215|NCT01740726|Therapy
1062216|NCT01740726|Psychotherapy
1062217|NCT01740726|Antidepressant
1062218|NCT01740726|Intervention
1062219|NCT01740713|chronic iron overload
1062220|NCT01740713|hereditary haemoglobinopathy
1062221|NCT01740713|beta thalassaemia major
1062222|NCT01740700|Abdominal aortic aneurysm
1062223|NCT01740700|Endovascular
1062224|NCT01740700|Fenestration
1062225|NCT01740700|Juxtarenal
1062226|NCT01740700|Off-the-shelf
1062227|NCT01740700|Pararenal
1062228|NCT01740687|Endometrial Ablation
1062229|NCT01740687|Permanent Sterilization
1062230|NCT01740687|Essure
1062231|NCT01740687|NovaSure
1062232|NCT01740687|Prevention of Pregnancy
1062233|NCT01740674|internet data collection
1062234|NCT01740674|longitudinal research
1062235|NCT01740674|cohort retention
1062236|NCT01740648|MEK Inhibitor
1062237|NCT01740648|Trametinib
1062238|NCT01740648|Rectal Cancers
1062239|NCT01740648|KRAS
1062240|NCT01740648|BRAF
1062241|NCT01740648|NRAS Mutant
1062242|NCT01740648|Fluorouracil
1062243|NCT01740635|rehabilitation
1062244|NCT01740635|wheelchair
1062245|NCT01740635|manual wheelchair
1062246|NCT01740635|wheelchair users
1062247|NCT01740635|older adults
1062248|NCT01740635|cognitive computer games
1062249|NCT01740635|home-based training
1062250|NCT01740635|community mobility
1062251|NCT01740622|Injury
1062252|NCT01740622|Injury Prevention
1062253|NCT01740622|Cincinnati Home Injury Prevention
1062254|NCT01740622|Injury Hazards
1062255|NCT01740622|Modifiable Injury Hazards
1062256|NCT01740609|Phase 1
1062257|NCT01740609|RN168
1062258|NCT01740609|Healthy Volunteers
1062259|NCT01740596|NYHA III
1062260|NCT01740596|NYHA IV
1062261|NCT01740596|ACC Stage C
1062262|NCT01740596|Heart Failure
1062263|NCT01740596|Congestive Heart Failure
1062264|NCT01740596|C-Pulse
1062265|NCT01740596|Counterpulsation
1062266|NCT01740596|Heart Assist
1062267|NCT01740596|Sunshine Heart
1062268|NCT01740596|Left Heart Failure
1062269|NCT01740583|mitral valve, regurgitation, annuloplasty
1062270|NCT01740570|Brain cancer
1062271|NCT01740570|Malignant glioma
1062272|NCT01740570|Glioblastoma multiforme
1062273|NCT01740570|Gliosarcoma
1062274|NCT01740570|Anaplastic astrocytoma
1062275|NCT01740570|Anaplastic oligodendroglioma
1062276|NCT01740570|Anaplastic oligoastrocytoma
1062277|NCT01740570|Cabazitaxel
1062278|NCT01740570|Jevtana
1062279|NCT01740557|Melanoma
1062280|NCT01740557|Metastatic Melanoma
1062281|NCT01740557|Stage III in-transit, subcutaneous, or regional nodal disease
1062282|NCT01740557|Cytoxan
1062283|NCT01740557|Cyclophosphamide
1062284|NCT01740557|Neosar
1062285|NCT01740557|Mesna
1062286|NCT01740557|Mesnex
1062287|NCT01740557|Fludarabine
1062288|NCT01740557|Fludarabine Phosphate
1062289|NCT01740557|Fludara
1062290|NCT01740557|IL-2
1062291|NCT01740557|Interleukin-2
1062292|NCT01740557|Aldesleukin
1062293|NCT01740557|Proleukin
1062294|NCT01740557|T-cells
1062295|NCT01740557|Autologous tumor infiltrating lymphocytes
1062296|NCT01740557|TIL
1062297|NCT01740557|CXCR2
1062298|NCT01740531|S303 treated RBCs
1062299|NCT01740505|energy cost of walking
1062300|NCT01740505|energy metabolism
1062301|NCT01740505|aged
1062302|NCT01740505|older adult
1062303|NCT01740505|exercise
1062304|NCT01740505|gait
1062305|NCT01740505|walking
1062306|NCT01740505|aerobic
1062307|NCT01740505|motor skill
1062308|NCT01740492|Ketamine
1062309|NCT01740492|Acute pain
1062310|NCT01740492|Pain control
1062311|NCT01740492|Pain
1062312|NCT01740479|STEMI
1062313|NCT01740479|ticagrelor
1062314|NCT01740479|multi-vessel disease
1062315|NCT01740479|culprit lesion
1062316|NCT01740466|Prevalence
1062317|NCT01740466|Vision disorders
1062318|NCT01740466|Eye diseases
1062319|NCT01740466|Visual acuity
1062320|NCT01740466|Primary health care
1062321|NCT01740440|Healthy females
1062322|NCT01740427|breast cancer
1062323|NCT01740427|postmenopausal women
1062324|NCT01740427|estrogen-receptor positive
1062325|NCT01740427|HER2 negative
1062326|NCT01740427|locoregionally recurrent
1062327|NCT01740427|metastatic
1062328|NCT01740427|Palbociclib (PD-0332991)
1062329|NCT01740427|PALOMA-2
1062330|NCT01740414|prescription opioid abuse
1062331|NCT01740414|pain
1062332|NCT01740414|opioid withdrawal
1062333|NCT01740414|oxycodone
1062334|NCT01740414|ibudilast
1062335|NCT01740401|Melanoma
1062336|NCT01740401|Advanced Malignant Melanoma
1062337|NCT01740401|Anti CTLA4 Blockade
1062338|NCT01740401|Progression Free Survival
1062339|NCT01740401|Interventional Therapy
1062340|NCT01740401|Phase II Clinical Trial
1062341|NCT01740401|Immunotherapy
1062342|NCT01740401|T Cell Activation
1062343|NCT01740362|CP-690
1062344|NCT01740362|550
1062345|NCT01740362|pharmacokinetics
1062346|NCT01740362|renal impairment
1062347|NCT01740323|Breast Cancer
1062348|NCT01740323|Chemotherapy
1062349|NCT01740323|Radiotherapy
1062350|NCT01740323|NF-kB
1062351|NCT01740323|DNA Binding
1062352|NCT01740323|Curcumin
1062353|NCT01740310|pregnancy,
1062354|NCT01740310|vaccine acceptance,
1062355|NCT01740310|vaccination,
1062356|NCT01740310|influenza,
1062357|NCT01740310|pertussis,
1062358|NCT01740310|Tdap,
1062359|NCT01740310|minority,
1062360|NCT01740310|African-American
1062361|NCT01740297|melanoma, talimogene laherparepvec, ipilimumab, metastatic melanoma, melanoma, immunotherapy, unresectable melanoma, oncolytic immunotherapy,
1062362|NCT01740271|breast cancer
1062363|NCT01740271|non-metastatic carcinoma of the breast chemotherapy
1062364|NCT01740271|adjuvant therapy
1062365|NCT01740271|neoadjuvant
1062366|NCT01740258|malignant glioma
1062367|NCT01740258|Grade 4 malignant glioma
1062368|NCT01740258|glioblastoma
1062369|NCT01740258|gliosarcoma
1062370|NCT01740258|adult brain tumor
1062371|NCT01740245|Laser therapy
1062372|NCT01740245|Cervical lesions
1062373|NCT01740245|Polyhexamethylene biguanide
1062374|NCT01740245|Chlorhexidine
1062375|NCT01740219|Health promotion
1062376|NCT01740219|Religion and medicine
1062377|NCT01740219|Hispanic Americans
1062378|NCT01740219|Randomized controlled trial
1062379|NCT01740219|Program evaluation
1062380|NCT01740219|Neoplasms/prevention & control
1062381|NCT01740219|Mass screening
1062382|NCT01740219|Female
1062383|NCT01740219|Male
1062384|NCT01740219|Preventive Health Services/methods
1062385|NCT01740219|Adult
1062386|NCT01740219|Organizations
1062387|NCT01740193|Pain
1062388|NCT01740193|Regional Anesthesia
1062389|NCT01740193|ultrasound
1062390|NCT01740193|transversus abdominis plane
1062391|NCT01740193|herniorrhaphy
1062392|NCT01740193|pediatrics
1062393|NCT01740167|prodrome
1062394|NCT01740167|mental illness
1062395|NCT01740167|health promotion
1062396|NCT01740167|lifestyle behavior
1062397|NCT01740141|Pain
1062398|NCT01740128|spinal cord injuries
1062399|NCT01740128|paraplegia
1062400|NCT01740128|postural balance
1062401|NCT01740128|locomotor activity
1062402|NCT01740128|exercise therapy
1062403|NCT01740128|electromyography
1062404|NCT01740128|transcranial magnetic stimulation, single pulse
1062405|NCT01740115|HIV
1062406|NCT01740115|Alcohol Use
1062407|NCT01740115|Bone Disease
1062408|NCT01740115|Bone Mineral Density
1062409|NCT01740115|Bone Microarchitecture
1062410|NCT01740115|Substance Dependence
1062411|NCT01740102|Ischemic preconditioning
1062412|NCT01740102|Coronary artery bypass
1062413|NCT01740102|Preoperative care
1062414|NCT01740102|Postoperative period
1062415|NCT01740089|Hepatitis C
1062416|NCT01740089|Cepeginterferon alfa
1062417|NCT01740089|Peginterferon
1062418|NCT01740089|Treatment
1062419|NCT01740076|isoflavones, hypertension, soy, diet, nutrition, women, inflammation, hot flashes
1062420|NCT01740037|Chronic care program
1062421|NCT01740037|Nurse specialist
1062422|NCT01740037|Atrial Fibrillation guideline
1062423|NCT01740024|Immunotherapy
1062424|NCT01740024|Subcutaneous immunotherapy
1062425|NCT01740024|Skin Prick Test
1062426|NCT01740024|Dose Response Prick Test
1062427|NCT01739985|Postoperative
1062428|NCT01739985|Vomiting
1062429|NCT01739985|Children
1062430|NCT01739985|Prophylaxis
1062431|NCT01739985|Droperidol
1062432|NCT01739985|Ondansetron
1062433|NCT01739985|Dexamethasone
1062434|NCT01739972|Desiccated thyroid extract and levothyroxine
1062435|NCT01739959|Necrotizing fasciitis
1062436|NCT01739959|Fournier's gangrene
1062437|NCT01739959|Cellulitis
1062438|NCT01739959|Serum Lactate
1062439|NCT01739933|Delirium
1062440|NCT01739933|Delirium/coma-free days
1062441|NCT01739933|Long term cognitive impairment
1062442|NCT01739933|Sedation
1062443|NCT01739933|Intensive care
1062444|NCT01739933|Mechanical Ventilation
1062445|NCT01739933|Dexmedetomidine
1062446|NCT01739933|Propofol
1062447|NCT01739933|Coma-free days
1062448|NCT01739933|Sepsis
1062449|NCT01739933|Organ dysfunction
1062450|NCT01739933|Acute Respiratory Distress
1062451|NCT01739933|Markers of inflammation
1062452|NCT01739920|Povidone-Iodine
1062453|NCT01739920|Ophthalmic Solutions
1062454|NCT01739920|Endophthalmitis
1062455|NCT01739920|Preoperative procedures
1062456|NCT01739907|Iron deficiency
1062457|NCT01739907|Menstruating women
1062458|NCT01739907|Vitamin D
1062459|NCT01739907|Functional food
1062460|NCT01739894|Advanced gastric cancer
1062461|NCT01739894|unresectable gastric cancer
1062462|NCT01739894|recurrent gastric cancer
1062463|NCT01739894|with peritoneal metastasis
1062464|NCT01739894|cancer cells on peritoneal cytology
1062465|NCT01739881|Exhaled breath condensate (EBC) method
1062466|NCT01739881|Volatile Organic Compounds (VOCs)
1062467|NCT01739881|Endobronchial Ultrasound (EBUS)
1062468|NCT01739881|Confocal Endoscopy
1062469|NCT01739881|Exhaled alveolar gas
1062470|NCT01739868|Pre-diabetes
1062471|NCT01739868|Type 2 diabetes
1062472|NCT01739868|Biomarkers
1062473|NCT01739868|Diabetes risk score
1062474|NCT01739842|Alcohol consumption
1062475|NCT01739842|Kudzu extract
1062476|NCT01739842|Cerebral blood flow
1062477|NCT01739829|xenotransplantation
1062478|NCT01739829|type 1 diabetes
1062479|NCT01739829|porcine islets
1062480|NCT01739816|Compliance
1062481|NCT01739816|Adherence
1062482|NCT01739816|Polypharmacy
1062483|NCT01739816|Medicines use
1062484|NCT01739816|Medication review
1062485|NCT01739816|Pharmaceutical care
1062486|NCT01739816|Primary care
1062487|NCT01739816|Drug related problem
1062488|NCT01739816|Patient safety
1062489|NCT01739803|Immunosuppressant therapy adherence
1062490|NCT01739803|Quality of life
1062491|NCT01739803|Economic outcomes
1062492|NCT01739790|COPD
1062493|NCT01739790|Chronic Bronchitis
1062494|NCT01739790|N-acetylcysteine
1062495|NCT01739777|Heart Failure
1062496|NCT01739777|Coronary Heart Disease
1062497|NCT01739777|Adult Stem Cells
1062498|NCT01739777|Umbilical Progenitor Cells
1062499|NCT01739777|Umbilical Cord Stem Cells Allogenic
1062500|NCT01739777|Left Ventricular Function
1062501|NCT01739777|Intravenous Injection
1062502|NCT01739751|COPD
1062503|NCT01739751|Physical activity
1062504|NCT01739751|Pedometers
1062505|NCT01739751|steps
1062506|NCT01739751|non pharmacological treatment
1062507|NCT01739751|rehabilitation
1062508|NCT01739751|exercise
1062509|NCT01739738|peristalsis, kidney stones, hydronephrosis, ureteral stent
1062510|NCT01739725|kidney stones, ureteral stent, pain,
1062511|NCT01739712|Diabetes
1062512|NCT01739712|Sleep problems
1062513|NCT01739712|School
1062514|NCT01739712|Neurobehavioral
1062515|NCT01739699|craniotomy
1062516|NCT01739699|brain surgery
1062517|NCT01739699|acetaminophen
1062518|NCT01739699|Tylenol
1062519|NCT01739686|Quality of Life
1062520|NCT01739686|Symptoms
1062521|NCT01739686|Palliative care
1062522|NCT01739686|Symptom management
1062523|NCT01739686|Disease management
1062524|NCT01739686|Health delivery
1062525|NCT01739673|Infectious Keratitis
1062526|NCT01739660|Chronic Kidney Disease Stage 5
1062527|NCT01739660|Hemodialysis
1062528|NCT01739660|pegloticase
1062529|NCT01739647|AZD3293
1062530|NCT01739647|Healthy volunteers
1062531|NCT01739647|Elderly volunteers
1062532|NCT01739647|Phase 1
1062533|NCT01739647|Single Ascending Dose Study
1062534|NCT01739634|Diarrhea
1062535|NCT01739634|Medullary thyroid cancer
1062536|NCT01739608|CRC
1062537|NCT01739569|Diet treatment
1062538|NCT01739569|Mental Health
1062539|NCT01739569|Reaction time
1062540|NCT01739569|State of moods
1062541|NCT01739569|Working hours
1062542|NCT01739569|Medical Hospital Staff
1062543|NCT01739556|antiplatelet therapy
1062544|NCT01739556|primary PCI
1062545|NCT01739556|modification
1062546|NCT01739517|Short bowel syndrome
1062547|NCT01739517|Cholestasis
1062548|NCT01739517|Omegaven
1062549|NCT01739517|Parenteral nutrition-associated Liver Disease
1062550|NCT01739504|Arthritis
1062551|NCT01739504|Joint pain
1062552|NCT01739504|Articular cartilage
1062553|NCT01739504|Mesenchymal stem cells
1062554|NCT01739504|Autologous
1062555|NCT01739504|Adipose tissue
1062556|NCT01739491|Chronic lymphocytic leukemia
1062557|NCT01739491|Bendamustine hydrochloride
1062558|NCT01739491|Leukemia
1062559|NCT01739491|Filipino
1062560|NCT01739465|Cholangiocarcinoma
1062561|NCT01739465|Pathologic
1062562|NCT01739465|Digestive System
1062563|NCT01739465|Neoplasms
1062564|NCT01739465|Neoplasms by Site
1062565|NCT01739465|Digestive System Diseases
1062566|NCT01739465|Bile Duct Diseases
1062567|NCT01739465|Biliary Tract Diseases
1062568|NCT01739465|Pathological Conditions
1062569|NCT01739465|Constriction
1062570|NCT01739465|Adenocarcinoma
1062571|NCT01739465|Carcinoma
1062572|NCT01739452|Low-risk MDS
1062573|NCT01739452|myelodysplastic syndrome
1062574|NCT01739452|retrospective
1062575|NCT01739426|LigaSure V (TM)
1062576|NCT01739400|Eisenmenger Syndrome
1062577|NCT01739400|exercise capacity
1062578|NCT01739387|Flutiform®
1062579|NCT01739387|Asthma
1062580|NCT01739387|COPD
1062581|NCT01739374|pelvic floor reconstruction
1062582|NCT01739374|mesh implants
1062583|NCT01739335|Stress Disorders, Post-Traumatic
1062584|NCT01739335|Mifepristone
1062585|NCT01739335|Veterans
1062586|NCT01739335|Clinical Trial
1062587|NCT01739309|Non- Hodgkins Lymphoma
1062588|NCT01739296|osteoarthritis
1062589|NCT01739296|osteoarthritis, knee
1062590|NCT01739296|foot orthoses
1062591|NCT01739296|orthotic insoles
1062592|NCT01739270|analgesia
1062593|NCT01739270|regional anesthesia
1062594|NCT01739270|surgery
1062595|NCT01739270|duration of analgesia
1062596|NCT01739270|dexamethasone added to levobupivacaine compared to levobupivacaine alone
1062597|NCT01739244|Glaucoma
1062598|NCT01739244|Open Angle Glaucoma
1062599|NCT01739244|Ocular Hypertension
1062600|NCT01739244|IOP
1062601|NCT01739244|RNAi
1062602|NCT01739244|siRNA
1062603|NCT01739244|beta inhibitor
1062604|NCT01739205|Type 2 diabetes and depression
1062605|NCT01739179|Ventricular peritoneal Shunt
1062606|NCT01739179|Shunt Complications
1062607|NCT01739179|Shunt Failure
1062608|NCT01739179|Hydrocephalus
1062609|NCT01739166|Health Services Research
1062610|NCT01739166|Quality Assurance
1062611|NCT01739153|Dairy
1062612|NCT01739153|Cheese
1062613|NCT01739153|Blood lipid concentrations
1062614|NCT01739153|Blood lipid sizes
1062615|NCT01739153|Fecal fat
1062616|NCT01739153|Fat digestibility
1062617|NCT01739153|bile acids
1062618|NCT01739127|Antipsychotic agents
1062619|NCT01739127|Adverse effects
1062620|NCT01739127|Magnetic Resonance Imaging
1062621|NCT01739114|Lung aeration
1062622|NCT01739114|Bronchopulmonary dysplasia
1062623|NCT01739114|Positive Pressure Respiration
1062624|NCT01739114|Sustained Inflation
1062625|NCT01739114|Continuous Positive Airway Pressure
1062626|NCT01739088|Congenital heart disease
1062627|NCT01739088|pediatrics
1062628|NCT01739088|ischemia-reperfusion injury
1062629|NCT01739088|long term outcomes
1062630|NCT01739062|PSA test
1062631|NCT01739062|Prostate cancer
1062632|NCT01739062|Genetic screening
1062633|NCT01739036|Malaria
1062634|NCT01739036|Vaccine
1062635|NCT01739036|Plasmodium
1062636|NCT01739036|Falciparum
1062637|NCT01739023|paraplegia
1062638|NCT01739023|cell therapy
1062639|NCT01739023|Schwann cells
1062640|NCT01739023|spinal cord injury
1062641|NCT01738997|Benign
1062642|NCT01738997|Esophageal strictures
1062643|NCT01738997|Esophagus
1062644|NCT01738997|Balloon Dilation
1062645|NCT01738984|exercise
1062646|NCT01738984|video
1062647|NCT01738984|DVD
1062648|NCT01738984|mother
1062649|NCT01738984|infant
1062650|NCT01738971|emergency contraception
1062651|NCT01738971|community pharmacy
1062652|NCT01738958|Probiotic bacteria
1062653|NCT01738958|Caries dentalis
1062654|NCT01738958|QLF
1062655|NCT01738932|endometriosis
1062656|NCT01738932|mannan-binding lectin
1062657|NCT01738932|immunology
1062662|NCT01738867|Pharmacogenetics
1062663|NCT01738867|OPRM1
1062664|NCT01738867|Pharmacodynamics
1062665|NCT01738867|Addiction
1062666|NCT01738867|mu opioid receptors
1062667|NCT01738854|laryngeal mask airway supreme
1062668|NCT01738854|airway sealing
1062669|NCT01738854|intracuff pressure
1062670|NCT01738841|Combined measles-mumps-rubella-varicella vaccine
1062671|NCT01738841|Priorix-Tetra™
1062672|NCT01738841|MMRV
1062673|NCT01738841|children
1062674|NCT01738841|Post-marketing surveillance
1062675|NCT01738841|Philippines
1062676|NCT01738815|bladder cancer
1062677|NCT01738815|hematuria
1062678|NCT01738815|sodium valproate
1062679|NCT01738815|valproic acid
1062680|NCT01738802|Type 2 Diabetes
1062681|NCT01738802|carotid intima medial thickness
1062682|NCT01738802|micronutrient
1062683|NCT01738802|anti-oxidant
1062684|NCT01738789|Adnexal masses
1062685|NCT01738789|Magnetic resonance imaging
1062686|NCT01738789|Ovarian tumor
1062687|NCT01738776|hip fracture
1062688|NCT01738776|risk factors
1062689|NCT01738776|vitamin K1
1062690|NCT01738776|vitamin D
1062691|NCT01738776|bone turnover markers
1062692|NCT01738776|osteocalcin
1062693|NCT01738776|undercarboxylated osteocalcin
1062694|NCT01738776|bone specific alkaline phosphatase (BALP)
1062695|NCT01738776|insulin like growth factor 1 (IGF1)
1062696|NCT01738776|parathyroid hormone (PTH)
1062697|NCT01738763|Glucose
1062698|NCT01738763|Insulin
1062699|NCT01738763|3-O-methyl-D-chiro-inositol
1062700|NCT01738750|surgical choice
1062701|NCT01738750|cost of care
1062702|NCT01738750|decision making
1062703|NCT01738750|health care
1062704|NCT01738750|health care cost
1062705|NCT01738750|pediatric
1062706|NCT01738750|children
1062707|NCT01738750|appendicitis
1062708|NCT01738750|patient satisfaction
1062709|NCT01738711|Idiopathic pulmonary fibrosis
1062710|NCT01738711|Cognitive behavioural therapy
1062711|NCT01738711|Anxiety
1062712|NCT01738711|Quality of life
1062713|NCT01738685|Breast Cancer.
1062714|NCT01738685|Adjuvant Endocrine therapy.
1062715|NCT01738672|Nitrous oxide
1062716|NCT01738672|labor and delivery
1062717|NCT01738672|analgesia
1062718|NCT01738659|sodium ,diuretics, PCWP
1062719|NCT01738646|vorinostat
1062720|NCT01738646|SAHA
1062721|NCT01738646|bevacizumab
1062722|NCT01738646|AVASTIN
1062723|NCT01738646|malignant glioma
1062724|NCT01738646|GBM
1062725|NCT01738646|glioblastoma multiforme
1062726|NCT01738646|brain tumor
1062727|NCT01738633|Esophageal Cancer
1062728|NCT01738633|Quality of Life
1062729|NCT01738620|esophageal cancer
1062730|NCT01738620|sleep disturbance
1062731|NCT01738620|quality of life
1062732|NCT01738607|fecal incontinence, dietary fiber
1062733|NCT01738581|focal hand dystonia (FHD)
1062734|NCT01738581|repetitive transcranial magnetic stimulation (rTMS)
1062735|NCT01738581|sensorimotor retraining
1062736|NCT01738568|High intensity aerobic training
1062737|NCT01738555|amdoxovir
1062738|NCT01738555|zidovudine
1062739|NCT01738555|HIV
1062740|NCT01738555|HAART
1062741|NCT01738555|antiretroviral
1062742|NCT01738542|Bosentan
1062743|NCT01738542|Peripheral Arterial Disease
1062744|NCT01738529|confocal laser endomicroscopy
1062745|NCT01738529|Crohn´disease
1062746|NCT01738503|Opioid Dependence, Buprenorphine, Depot, SUBUTEX, RBP-6000
1062747|NCT01738490|Bone anchored hearing aid
1062748|NCT01738490|Bone anchored implant
1062749|NCT01738490|Implant stability
1062750|NCT01738490|Wide diameter implant
1062751|NCT01738490|Linear incision
1062752|NCT01738490|Ponto
1062753|NCT01738477|Booster
1062754|NCT01738477|Tdap
1062755|NCT01738477|Immunogenicity
1062756|NCT01738477|Repeat dose
1062757|NCT01738477|Safety
1062758|NCT01738477|BoostrixTM
1062759|NCT01738477|Persistence
1062760|NCT01738464|Pelvic Pain
1062761|NCT01738464|Interstitial Cystitis
1062762|NCT01738464|Microbiome
1062763|NCT01738464|Prostatitis
1062764|NCT01738464|Chronic
1062765|NCT01738464|Depression
1062766|NCT01738451|Holter monitor
1062767|NCT01738451|cancer
1062768|NCT01738451|BRAF inhibitor
1062769|NCT01738451|BRAF-mutation positive tumor
1062770|NCT01738451|pharmacokinetics
1062771|NCT01738451|QTc
1062772|NCT01738451|ECG intervals and morphology
1062773|NCT01738451|GSK2118436
1062774|NCT01738451|safety
1062775|NCT01738438|Metastatic
1062776|NCT01738438|Triple Negative
1062777|NCT01738438|Stage IV
1062778|NCT01738425|GIC-1001
1062779|NCT01738425|opioid agonist
1062780|NCT01738425|sulfide
1062781|NCT01738425|colonoscopy
1062782|NCT01738425|gicare
1062783|NCT01738425|Phase I
1062784|NCT01738425|safety
1062785|NCT01738425|tolerability
1062786|NCT01738425|pharmacokinetics
1062787|NCT01738425|healthy subjects
1062788|NCT01738425|single ascending dose
1062789|NCT01738425|multiple ascending dose
1062790|NCT01738425|SAD
1062791|NCT01738425|MAD
1062792|NCT01738425|food effect
1062793|NCT01738412|Stroke
1062794|NCT01738399|Insulin resistance
1062795|NCT01738399|Coffee
1062796|NCT01738399|Glucose metabolism
1062797|NCT01738386|Adaptation
1062798|NCT01738386|Coping
1062799|NCT01738386|Presenile Dementia
1062800|NCT01738386|Caregiver Burden
1062801|NCT01738373|autologous stem cell transplantation
1062802|NCT01738373|lymphoma
1062803|NCT01738373|multiple myeloma
1062804|NCT01738360|Arsenic trioxide
1062805|NCT01738360|Systemic Lupus
1062806|NCT01738360|clinically
1062807|NCT01738360|biologically active
1062808|NCT01738334|Meditation
1062809|NCT01738334|Cognition
1062810|NCT01738334|Attention Deficit Disorder with Hyperactivity
1062811|NCT01738308|Healing Touch
1062812|NCT01738308|Pediatrics
1062813|NCT01738308|surgery
1062814|NCT01738308|stress
1062815|NCT01738308|pain
1062816|NCT01738308|Pediatric Stress
1062817|NCT01738308|maladaptive behaviors
1062818|NCT01738308|energy medicine
1062819|NCT01738308|emergence delirium
1062820|NCT01738308|emergence agitation
1062821|NCT01738308|length of stay
1062822|NCT01738308|ease of wake up
1062823|NCT01738308|distress parents
1062824|NCT01738308|distress pediatric patients
1062825|NCT01738308|Pediatric Post-Traumatic Stress Disorder
1062826|NCT01738295|acetylcholine
1062827|NCT01738295|cholinergic system
1062828|NCT01738295|visual perception
1062829|NCT01738295|visual attention
1062830|NCT01738295|multiple objects tracking
1062831|NCT01738295|perceptual learning
1062832|NCT01738295|vision training
1062833|NCT01738282|baclofene
1062834|NCT01738282|Alcohol dependence
1062835|NCT01738282|Maintenance of abstinence
1062836|NCT01738269|Ovarian cancer, HE4, normal range
1062837|NCT01738256|Cognitive Behavior Therapy
1062838|NCT01738256|Acceptance Commitment Therapy
1062839|NCT01738256|Psychological Stress
1062840|NCT01738256|Metabolic Syndrome
1062841|NCT01738256|Overweight
1062842|NCT01738256|Life Style
1062843|NCT01738243|Thyroid
1062844|NCT01738243|Thyroid Eye Disease
1062845|NCT01738243|Thyroid Orbitopathy
1062846|NCT01738243|Eyelid Retraction
1062847|NCT01738243|Upper Eyelid Retraction
1062848|NCT01738217|Intra-operative imaging
1062849|NCT01738217|NIR Fluorescence
1062850|NCT01738217|Liver surgery
1062851|NCT01738217|Tumoral margins
1062864|NCT01738191|Parkinson's disease
1062865|NCT01738165|Prospective
1062866|NCT01738165|Multi-Center
1062867|NCT01738165|Pilot Study
1062868|NCT01738165|Single Arm
1062869|NCT01738165|Safety
1062870|NCT01738165|Efficacy
1062871|NCT01738152|HYALOGYN VAGINAL GEL
1062872|NCT01738152|vaginal dryness
1062873|NCT01738152|12-232
1062874|NCT01738139|Advanced Cancers
1062875|NCT01738139|Advanced Malignancies
1062876|NCT01738139|Metastatic
1062877|NCT01738139|Unresectable
1062878|NCT01738139|Ipilimumab
1062879|NCT01738139|Yervoy
1062880|NCT01738139|BMS-734016
1062881|NCT01738139|MDX010
1062882|NCT01738139|Imatinib Mesylate
1062883|NCT01738139|Imatinib
1062884|NCT01738139|Gleevec
1062885|NCT01738139|STI 571
1062886|NCT01738139|NSC-716051
1062887|NCT01738126|cerebellum
1062888|NCT01738126|fMRI
1062889|NCT01738126|DTI
1062890|NCT01738126|pain
1062891|NCT01738126|heat
1062892|NCT01738126|noxious
1062893|NCT01738126|aversion
1062894|NCT01738126|unpleasantness
1062895|NCT01738126|anger
1062896|NCT01738126|aversive stimulus
1062897|NCT01738126|motor
1062898|NCT01738126|human
1062899|NCT01738126|image analysis
1062900|NCT01738126|perception
1062901|NCT01738126|central nervous system
1062902|NCT01738126|sensory
1062903|NCT01738126|somatosensory cortex
1062904|NCT01738126|trigeminal system
1062905|NCT01738126|white matter
1062906|NCT01738113|Ilizarov
1062907|NCT01738113|distraction osteogenesis
1062908|NCT01738113|Muscle architecture
1062909|NCT01738113|muscle mechanics
1062910|NCT01738113|Rehabilitation
1062911|NCT01738087|patients
1062912|NCT01738087|Adult
1062913|NCT01738074|rotavirus
1062914|NCT01738074|trivalent genetic reassortment vaccine
1062915|NCT01738074|Phase three clinical trials
1062916|NCT01738061|Older workers
1062917|NCT01738061|Multidimensional intervention
1062918|NCT01738061|Worksite health promotion
1062919|NCT01738061|Taiwan
1062920|NCT01738048|Pain
1062921|NCT01738048|Neuropathic pain
1062922|NCT01738048|Chronic pain
1062923|NCT01738035|IgA nephropathy
1062924|NCT01738022|Sleep apnea
1062925|NCT01738022|Pathophysiology
1062926|NCT01738009|Sleep Apnea
1062927|NCT01738009|Pathophysiology
1062928|NCT01737983|cystic fibrosis
1062929|NCT01737983|probiotics
1062930|NCT01737983|Lactobacillus reuteri
1062931|NCT01737957|Proliferative Diabetic retinopathy
1062932|NCT01737957|Pan-retinal photocoagulation
1062933|NCT01737944|methotrexate injection, subcutaneous, autoinjector
1062934|NCT01737931|SPM 962
1062935|NCT01737931|rotigotine
1062936|NCT01737931|application site reaction
1062937|NCT01737918|urge urinary incontinence, cesa, vasa, TOT, solifenacin
1062938|NCT01737905|Asthma
1062939|NCT01737905|Safety
1062940|NCT01737905|Efficacy
1062941|NCT01737905|Epinephrine
1062942|NCT01737905|Bronchodilator
1062943|NCT01737905|Metered dose inhaler
1062944|NCT01737892|Asthma
1062945|NCT01737892|Pharmacokinetics
1062946|NCT01737892|Epinephrine
1062947|NCT01737892|Bronchodilator
1062948|NCT01737892|Metered dose inhaler
1062949|NCT01737879|Anemia, Chronic Kidney Disease, End Stage Renal Disease, erythropoiesis-stimulating agents, Hemodialysis, Hemoglobin
1062950|NCT01737866|Heart, Failure, Renal, Insufficiency, Cardiac, Kidney, Hemodialysis, Impairment, omecamtiv mecarbil, cardiac myosin activator, CK-1827452
1062951|NCT01737853|Primary Open-Angle Glaucoma
1062952|NCT01737853|Ocular Hypertension
1062953|NCT01737853|Ganfort
1062954|NCT01737840|dyspepsia
1062955|NCT01737840|pantoprazole
1062956|NCT01737840|ranitidine
1062957|NCT01737840|emergency department
1062958|NCT01737827|INC280, advanced hepatocellular carcinoma, c-MET pathway dysregulation
1062959|NCT01737814|sickle cell disease
1062960|NCT01737814|vaso-occlusive crisis
1062961|NCT01737801|Lung function
1062962|NCT01737801|Physiotherapy
1062963|NCT01737788|Cervical cerclage
1062964|NCT01737788|Uterine Cervical Incompetence
1062965|NCT01737775|diaphragmatic dysfunction
1062966|NCT01737775|ultrasonography
1062967|NCT01737775|respiratory distress
1062968|NCT01737775|abdominal surgery
1062969|NCT01737775|Age
1062970|NCT01737775|gender
1062971|NCT01737775|biometric
1062972|NCT01737775|body mass index
1062973|NCT01737775|ASA score
1062974|NCT01737775|smoking status
1062975|NCT01737775|history of respiratory disease
1062976|NCT01737762|Venous leg ulcer
1062977|NCT01737762|ulcer
1062978|NCT01737762|Venous stasis
1062979|NCT01737762|compression
1062980|NCT01737762|venous
1062981|NCT01737762|venous stasis ulcer
1062982|NCT01737762|vlu
1062983|NCT01737762|wound
1062984|NCT01737762|varicose veins
1062985|NCT01737762|venous insufficiency
1062986|NCT01737762|dvt
1062987|NCT01737762|deep vein thrombosis
1062988|NCT01737749|Stroke
1062989|NCT01737736|Stroke
1062990|NCT01737723|Stroke
1062991|NCT01737710|Influenza Vaccines
1062992|NCT01737710|Dermatitis
1062993|NCT01737710|Injections, Intradermal
1062994|NCT01737710|Injections, Intramuscular
1062995|NCT01737710|Skin Diseases
1062996|NCT01737710|Skin Diseases, Eczematous
1062997|NCT01737710|Hypersensitivity, Immediate
1062998|NCT01737710|Hypersensitivity
1062999|NCT01737710|Immune System Diseases
1063000|NCT01737710|Genetic Diseases, Inborn
1063001|NCT01737710|Skin Diseases, Genetic
1063002|NCT01737671|Brain tumor
1063003|NCT01737671|Malignant Fourth Ventricular Brain Tumors
1063004|NCT01737671|Ependymoma involving brain
1063005|NCT01737671|Ependymoma involving spine
1063006|NCT01737671|Recurrent ependymoma involving brain and/or spine
1063007|NCT01737671|Recurrent atypical teratoid/rhabdoid tumor involving brain
1063008|NCT01737671|Recurrent atypical teratoid/rhabdoid tumor involving spine
1063009|NCT01737671|AT/RT
1063010|NCT01737671|Ommaya reservoir catheter
1063011|NCT01737671|Methotrexate
1063012|NCT01737671|Medulloblastoma
1063013|NCT01737671|ATRT
1063014|NCT01737671|Atypical teratoid rhabdoid tumor
1063015|NCT01737671|Ependymoma
1063016|NCT01737671|Pediatric brain tumor
1063017|NCT01737671|Intraventricular chemotherapy
1063018|NCT01737632|Adolescents
1063019|NCT01737632|Residential Treatment
1063020|NCT01737632|Outpatient Treatment
1063021|NCT01737632|Substance Abuse
1063022|NCT01737632|Delinquency
1063023|NCT01737632|Family Therapy
1063024|NCT01737632|Multidimensional Family therapy
1063025|NCT01737619|Gynecologic cancer
1063026|NCT01737619|Endometrial Cancer
1063027|NCT01737619|Lymph Nodes Metastasis
1063028|NCT01737619|Surgical Staging
1063029|NCT01737619|False negative rate
1063030|NCT01737619|Detection of positive lymph nodes
1063031|NCT01737619|Histologically confirmed high grade endometrial cancer
1063032|NCT01737619|Sentinel lymph node mapping
1063033|NCT01737606|Cerebral pulsatility
1063034|NCT01737606|Fast Cerebral Pulsatility Imaging or FCPI
1063035|NCT01737606|MRI
1063036|NCT01737606|Arteriel Spin Labelling
1063037|NCT01737606|Cognitive tasks
1063038|NCT01737606|Aging
1063039|NCT01737593|acetaminophen
1063040|NCT01737593|emergence agitation
1063041|NCT01737593|children
1063042|NCT01737593|sevoflurane
1063043|NCT01737580|influenza, human
1063044|NCT01737580|influenza vaccines
1063045|NCT01737580|older adults
1063046|NCT01737580|immune response
1063047|NCT01737554|Central venous access device
1063048|NCT01737554|Catheter resistance monitoring
1063049|NCT01737541|Cerebrovascular Disorders
1063050|NCT01737541|Cardiovascular Diseases
1063051|NCT01737541|Intracerebral Hemorrhage
1063052|NCT01737541|Serotonin Uptake Inhibitors
1063053|NCT01737541|Therapeutic Uses
1063054|NCT01737528|severe symptomatic native aortic valve stenosis
1063055|NCT01737528|inoperable or high risk for open aortic valve replacement
1063056|NCT01737476|age 18-65
1063057|NCT01737463|Ampulla of Vater adenoma
1063058|NCT01737450|Metastatic head and neck cancer
1063059|NCT01737450|PI3K inhibitor
1063060|NCT01737450|Recurrent head and meck cancer
1063061|NCT01737450|Progressive head and neck cancer
1063062|NCT01737450|BKM120
1063063|NCT01737411|surgery, solifenacin, urge urinary incontinence
1063064|NCT01737398|FAP
1063065|NCT01737398|Familial Amyloid Polyneuropathy
1063066|NCT01737398|TTR
1063067|NCT01737398|Transthyretin
1063068|NCT01737398|Amyloidosis
1063069|NCT01737385|microcirculation
1063070|NCT01737385|proximal humeral fractures
1063071|NCT01737385|O2C
1063072|NCT01737372|Multiple Sclerosis
1063073|NCT01737372|Secondary Progressive Multiple Sclerosis
1063074|NCT01737372|Clinically Isolated Syndrome
1063075|NCT01737359|amdoxovir
1063076|NCT01737359|zidovudine
1063077|NCT01737359|tenofovir DF
1063078|NCT01737359|HIV
1063079|NCT01737359|HAART
1063080|NCT01737359|antiretroviral
1063081|NCT01737346|glioblastoma, recurrent, refractory, CCNU, procarbazine
1063082|NCT01737320|gram negative bacteremia
1063083|NCT01737320|Duration of antibiotic treatment
1063084|NCT01737320|safety
1063085|NCT01737320|efficacy
1063086|NCT01737320|short-course
1063087|NCT01737307|Fluoride Varnish
1063088|NCT01737307|CPP-ACP paste
1063089|NCT01737307|Dry mouth
1063090|NCT01737307|Burning sensation
1063091|NCT01737307|Chemotherapy
1063092|NCT01737294|Phase IV
1063093|NCT01737294|Peripheral Neuropathic Pain
1063094|NCT01737294|QUTENZA
1063095|NCT01737281|Smoking
1063096|NCT01737281|Tobacco control
1063097|NCT01737281|Counseling
1063098|NCT01737281|mental health
1063099|NCT01737268|patients
1063100|NCT01737268|Major depressive episode
1063101|NCT01737268|FK949E
1063102|NCT01737255|Li-Fraumeni Syndrome
1063103|NCT01737255|Whole Body Magnetic Resonance Imaging
1063104|NCT01737255|TP53
1063105|NCT01737255|Psychological Impact
1063106|NCT01737242|Prostate cancer
1063107|NCT01737242|PSA
1063108|NCT01737216|Aged
1063109|NCT01737216|patients
1063110|NCT01737203|Viagra
1063111|NCT01737203|ODT
1063112|NCT01737203|bioquivalence
1063113|NCT01737190|esophageal pressure
1063114|NCT01737190|ARDSnet protocol
1063115|NCT01737177|MCL
1063116|NCT01737177|Mantle Cell Lymphoma
1063117|NCT01737177|RELAPSED-REFRACTORY
1063118|NCT01737164|Glucose
1063119|NCT01737164|Lipid
1063120|NCT01737164|Metabolism
1063121|NCT01737164|Non Diabetic
1063122|NCT01737164|Healthy
1063123|NCT01737138|Resistant hypertension
1063124|NCT01737138|All-cause mortality
1063125|NCT01737138|Renal function
1063126|NCT01737112|Lung Cancer
1063127|NCT01737112|integrin αvβ3 receptor
1063128|NCT01737112|99mTc-3PRGD2
1063129|NCT01737112|SPECT/CT
1063130|NCT01737112|efficacy and safety
1063131|NCT01737099|omega-3
1063132|NCT01737099|DHA
1063133|NCT01737099|triglycerides
1063134|NCT01737099|lipids
1063135|NCT01737099|cardiovascular
1063136|NCT01737099|hypertriglyceridemia
1063137|NCT01737073|chronic pain
1063138|NCT01737073|opioid
1063139|NCT01737073|cognitive behavior therapy
1063140|NCT01737060|Reversed prosthesis, Philos, Severe displaced
1063141|NCT01737047|HIV
1063142|NCT01737047|Ageing
1063143|NCT01737034|partitioning of weight gain
1063144|NCT01737034|refeeding
1063145|NCT01737034|catch-up fat phenomenon
1063146|NCT01737034|glycemic index
1063147|NCT01737021|PICU
1063148|NCT01737021|Critical illness
1063149|NCT01737021|Outcomes
1063150|NCT01737021|Mental health
1063151|NCT01737021|Education
1063152|NCT01737021|Randomized Controlled Trial (RCT)
1063153|NCT01737021|Pilot
1063154|NCT01737021|Feasibility
1063155|NCT01737008|Head and neck
1063156|NCT01737008|Squamous cell carcinoma
1063157|NCT01737008|Phase 1
1063158|NCT01737008|Dacomitinib
1063159|NCT01737008|Radiation
1063160|NCT01737008|Radiotherapy
1063161|NCT01737008|Chemotherapy
1063162|NCT01737008|Chemoradiation
1063163|NCT01737008|Chemoradiotherapy
1063164|NCT01737008|Cisplatin
1063165|NCT01737008|Pharmacokinetics
1063166|NCT01737008|Maximum tolerated dose
1063167|NCT01737008|Safety
1063168|NCT01737008|Human epidermal growth factor receptor
1063169|NCT01737008|Previously Untreated
1063170|NCT01737008|Local or Locally Advanced
1063171|NCT01736995|Substance Abuse
1063172|NCT01736995|Adolescents
1063173|NCT01736995|Families
1063174|NCT01736995|Functional Family Therapy
1063175|NCT01736995|Cognitive Behavioral Therapy
1063176|NCT01736995|Motivational Therapy
1063177|NCT01736995|Contingency Management
1063178|NCT01736982|Cigarette Smoking
1063179|NCT01736982|Homeless
1063180|NCT01736982|Contingency Management
1063181|NCT01736982|Smoking Cessation
1063182|NCT01736956|aortic stenosis
1063183|NCT01736956|hypoplastic left heart syndrome
1063184|NCT01736956|fetal aortic valvuloplasty
1063185|NCT01736943|Bortezomib
1063186|NCT01736943|Doxil
1063187|NCT01736930|Type 1 Diabetes
1063188|NCT01736930|Hypoglycemia
1063189|NCT01736930|Continuous Glucose Monitoring
1063190|NCT01736930|Pump Suspension
1063191|NCT01736917|Fosaprepitant
1063192|NCT01736917|5HT3 Receptor Antagonists
1063193|NCT01736917|Dexamethasone
1063194|NCT01736917|Germ Cell Tumors
1063195|NCT01736917|Testis Cancer
1063196|NCT01736917|Rescue Medications
1063197|NCT01736904|advanced colorectal cancer
1063198|NCT01736904|FOLFIRI
1063199|NCT01736904|XELIRI
1063200|NCT01736891|Motor fluctuations
1063201|NCT01736891|Parkinson´s Disease
1063202|NCT01736891|Rasagiline
1063203|NCT01736878|Medullary Thyroid Carcinoma
1063204|NCT01736878|Sorafenib
1063205|NCT01736878|Efficacy
1063206|NCT01736852|Premature Rupture of Membrane (Pregnancy)
1063207|NCT01736852|PROM
1063208|NCT01736852|Cervical Ripening
1063209|NCT01736852|Induced Labor
1063210|NCT01736826|plasma nucleosome concentration
1063211|NCT01736826|plasma free DNA concentration
1063212|NCT01736813|colorectal cancer
1063213|NCT01736813|liver metastases
1063214|NCT01736813|chemotherapy
1063215|NCT01736813|chemokine
1063216|NCT01736813|CCR5 inhibition
1063217|NCT01736800|Temozolomide
1063218|NCT01736800|Topotecan
1063219|NCT01736800|Central Nervous System Metastases
1063220|NCT01736800|Chemotherapy
1063221|NCT01736800|Brain Metastases
1063222|NCT01736800|Solid Tumors
1063223|NCT01736787|Cauliflower Mushroom extract
1063224|NCT01736787|immunity
1063225|NCT01736774|Manual therapy
1063226|NCT01736774|Exercise
1063227|NCT01736748|obesity
1063228|NCT01736748|physical activity
1063229|NCT01736748|metabolism
1063230|NCT01736748|environment
1063231|NCT01736748|obese children, as defined by a body mass index > 95th percentile
1063232|NCT01736748|for age and sex
1063233|NCT01736722|Laser Induced Thermal Therapy
1063234|NCT01736722|Metastatic cancer
1063235|NCT01736722|Brain Tumor
1063236|NCT01736722|Visualase
1063237|NCT01736722|Treatment resistant
1063238|NCT01736722|Magnetic Resonance Thermal Imaging
1063239|NCT01736722|Magnetic Imaging
1063240|NCT01736709|2012-2013 trivalent seasonal influenza vaccine
1063241|NCT01736709|immunogenicity,
1063242|NCT01736709|safety
1063243|NCT01736696|Psoriasis
1063244|NCT01736696|PASI
1063245|NCT01736696|plaques
1063246|NCT01736696|skin biopsy
1063247|NCT01736696|immunomodulation
1063248|NCT01736683|ACE-011
1063249|NCT01736683|anemia
1063250|NCT01736683|dose-ranging
1063251|NCT01736683|intermediate-1 risk myelodysplastic syndromes
1063252|NCT01736683|low risk myelodysplastic syndromes (MDS)
1063253|NCT01736683|multicenter
1063254|NCT01736683|open-label
1063255|NCT01736683|parallel
1063256|NCT01736683|phase 2
1063257|NCT01736683|randomized
1063258|NCT01736683|Sotatercept
1063259|NCT01736683|Non-proliferative chronic myelomonocytic leukemia (CMML)
1063260|NCT01736683|hemoglobin
1063261|NCT01736683|transfusions
1063262|NCT01736644|blood loss
1063263|NCT01736644|bipolar sealer
1063264|NCT01736644|aquamantys
1063265|NCT01736644|total knee replacement
1063266|NCT01736644|primary total knee arthroplasty
1063270|NCT01736618|subcutaneous implantable defibrillator, post approval study, sudden cardiac arrest, Cameron Health defibrillator
1063271|NCT01736605|Massage
1063272|NCT01736605|Meditation
1063273|NCT01736605|Breast Cancer
1063274|NCT01736605|Breast Surgery
1063275|NCT01736605|Breast Reconstruction
1063276|NCT01736566|Primary Care
1063277|NCT01736566|Cardiology
1063278|NCT01736566|Hypertrophic Cardiomyopathy
1063279|NCT01736566|Dilated Cardiomyopathy
1063280|NCT01736566|Whole Genome Sequencing
1063281|NCT01736553|Spinal Muscular Atrophy (SMA) Biomarkers
1063282|NCT01736553|Healthy controls
1063283|NCT01736553|Infants
1063284|NCT01736540|iron overload, liver iron concentration (LIC), cardiac siderosis, transfusional siderosis, magnetic resonance imaging (MRI)
1063285|NCT01736514|xanthine oxidase inhibitor
1063286|NCT01736514|Uric acid lowering drug
1063287|NCT01736488|Hypertension
1063288|NCT01736488|Antihypertensive efficacy
1063289|NCT01736488|Neurohormonal markers
1063290|NCT01736488|Blood Pressure Response
1063291|NCT01736488|Exercise
1063292|NCT01736462|Cornea
1063293|NCT01736462|Endothelial cell density
1063294|NCT01736449|pterygium
1063295|NCT01736449|bevacizumab
1063296|NCT01736449|recurrence of pterygium
1063297|NCT01736436|MDS
1063298|NCT01736436|Myelodysplastic syndrome
1063299|NCT01736436|Low and intermediate risk
1063300|NCT01736436|Transfusion-dependent patients
1063301|NCT01736436|Transfusion
1063302|NCT01736436|Anemia
1063303|NCT01736423|YM060
1063304|NCT01736423|Ramosetron
1063305|NCT01736423|long term study
1063306|NCT01736423|Diarrhea-predominant Irritable Bowel Syndrome
1063307|NCT01736423|Female
1063308|NCT01736397|CKD
1063309|NCT01736397|Chronic Kidney Disease
1063310|NCT01736397|Phosphorus
1063311|NCT01736397|Iron Deficiency
1063312|NCT01736397|Iron Deficiency Anemia
1063313|NCT01736397|Elevated Phosphorus
1063314|NCT01736371|Sevoflurane
1063315|NCT01736371|Cisatracurium infusion consumption
1063316|NCT01736371|Closed loop computer control system
1063317|NCT01736371|Recovery Index
1063318|NCT01736358|Sprix
1063319|NCT01736358|Intranasal ketoralac
1063320|NCT01736358|Ketoralac
1063321|NCT01736358|Urolithiasis
1063322|NCT01736358|Kidney stone
1063323|NCT01736358|Uretal stone
1063324|NCT01736358|Ureteroscopic removal of stones
1063325|NCT01736358|URS
1063326|NCT01736358|Pain management
1063327|NCT01736358|Pain
1063328|NCT01736332|Methamphetamine
1063329|NCT01736332|Amphetamines
1063330|NCT01736332|Opiates
1063331|NCT01736332|Oral Opiates (poppy seeds)
1063332|NCT01736332|Intranasal amphetamines
1063333|NCT01736319|Artemisinin-based Combination Therapies
1063334|NCT01736319|Recrudescence
1063335|NCT01736319|DHA-PPQ
1063336|NCT01736319|Parasite Clearance Rate
1063337|NCT01736306|Breast Cancer
1063338|NCT01736306|Breast Milk
1063339|NCT01736306|Epigenetics
1063341|NCT01736280|Symptoms
1063342|NCT01736280|Immunogenetics
1063343|NCT01736280|Digestive Disorders
1063344|NCT01736280|Gastrointestinal
1063345|NCT01736267|Auditory Brainstem Implant
1063346|NCT01736267|ABI
1063347|NCT01736267|Nucleus 24
1063348|NCT01736267|Deafness
1063349|NCT01736267|Hearing loss
1063350|NCT01736267|Non-tumor
1063351|NCT01736267|Non-NF2
1063352|NCT01736267|ABI541
1063353|NCT01736228|xenotransplantation
1063354|NCT01736228|type 1 diabetes
1063355|NCT01736228|porcine islets
1063356|NCT01736215|Anemia - cancer related
1063357|NCT01736215|Eprex (Erythropoietin alfa)
1063358|NCT01736202|oral fat
1063359|NCT01736202|insulin sensitivity
1063360|NCT01736189|Rheumatoid arthritis
1063361|NCT01736176|Safety and efficacy
1063362|NCT01736176|Advanced Parkinson's disease
1063363|NCT01736176|levodopa-carbidopa intestinal gel,
1063364|NCT01736176|carbidopa
1063365|NCT01736176|levodopa
1063366|NCT01736176|Non-Motor Symptom Scale
1063367|NCT01736150|Hemodialysis
1063368|NCT01736137|Heart failure
1063369|NCT01736137|Autonomic Nervous System
1063370|NCT01736137|Heart rate
1063371|NCT01736137|Quality of life
1063372|NCT01736124|computerize cognitive training
1063373|NCT01736124|dementia
1063374|NCT01736124|cognitive decline
1063375|NCT01736124|Diabetes Mellitus, Type 2
1063376|NCT01736111|obesity
1063377|NCT01736111|weight loss
1063378|NCT01736111|text message
1063379|NCT01736085|tobacco cessation
1063380|NCT01736085|smoking cessation
1063381|NCT01736085|nicotine
1063382|NCT01736085|telephone counseling
1063383|NCT01736085|self-help
1063384|NCT01736085|smoking abstinence
1063385|NCT01736085|tobacco use disorder
1063386|NCT01736085|nicotine replacement therapy
1063387|NCT01736085|voucher
1063388|NCT01736072|Rectal Cancer
1063389|NCT01736072|Colorectal Cancer
1063390|NCT01736072|Laparoscopic Surgery
1063391|NCT01736072|Robotic Surgery
1063392|NCT01736072|Robotic Assisted Laparoscopic Surgery
1063393|NCT01736059|Stem cells
1063394|NCT01736059|intravitreal
1063395|NCT01736059|bone marrow CD34+ cells
1063396|NCT01736059|retinal disease
1063397|NCT01736059|clinical trial
1063398|NCT01736059|autologous
1063399|NCT01736046|CT Enterography
1063400|NCT01736046|Crohn's Disease
1063401|NCT01736046|Inflammatory Bowel Disease
1063402|NCT01736033|Lower Urinary Tracts Symptoms
1063403|NCT01736033|5 alpha reductase inhibitor
1063404|NCT01736033|Proscar
1063405|NCT01736033|Finasteride
1063406|NCT01736033|alpha blocker
1063407|NCT01736033|Tamsulosin
1063408|NCT01736033|Harnal D
1063409|NCT01736007|alopecia areata child
1063410|NCT01736007|scalp
1063411|NCT01735994|Eating disorders
1063412|NCT01735994|body image
1063413|NCT01735994|female athletes
1063414|NCT01735994|female athlete triad
1063415|NCT01735994|eating disorder prevention
1063416|NCT01735994|cluster randomization
1063417|NCT01735994|risk factors
1063418|NCT01735994|prevention
1063419|NCT01735981|Huntington's Disease
1063420|NCT01735981|gait
1063421|NCT01735981|exercise
1063422|NCT01735981|balance
1063423|NCT01735981|video game
1063424|NCT01735968|Imatinib mesylate
1063425|NCT01735968|BYL719
1063426|NCT01735968|GIST
1063427|NCT01735955|Tasigna
1063428|NCT01735955|CML
1063429|NCT01735955|GIST
1063430|NCT01735955|nilotinib
1063431|NCT01735890|Safety
1063432|NCT01735890|Pharmacokinetics
1063433|NCT01735877|Hemispatial neglect, Stroke
1063434|NCT01735864|Indigo naturalis extract in oil
1063435|NCT01735851|Thoracic epidural analgesia
1063436|NCT01735851|Paravertebral block
1063437|NCT01735851|pain
1063438|NCT01735851|postoperative
1063439|NCT01735825|coronary artery disease
1063440|NCT01735825|stent
1063441|NCT01735825|restenosis
1063442|NCT01735812|cryoablation
1063443|NCT01735812|uterine fibroid
1063444|NCT01735812|uterine myoma
1063445|NCT01735812|who completed her family planning
1063446|NCT01735812|but wishes to preserve her uterus
1063447|NCT01735786|Endoscopic Hemostasis
1063448|NCT01735786|EndoClot Absorbable Polysaccharide Hemostat
1063449|NCT01735786|Colonic Polyps
1063450|NCT01735773|hemodialysis
1063451|NCT01735773|inflammation
1063452|NCT01735773|iron
1063453|NCT01735773|peritoneal dialysis
1063454|NCT01735773|prohepcidin
1063455|NCT01735773|uremia
1063456|NCT01735760|airway management
1063457|NCT01735760|cricothyroid membrane
1063458|NCT01735747|Lymphoma
1063459|NCT01735734|Skin disease
1063460|NCT01735734|Capillary Malformation
1063461|NCT01735734|Laser therapy
1063462|NCT01735721|Sinus Floor Augmentation
1063463|NCT01735721|Bone Transplantation
1063464|NCT01735721|Bone Substitute
1063465|NCT01735708|pain
1063466|NCT01735708|depression
1063467|NCT01735708|HIV
1063468|NCT01735708|adherence
1063469|NCT01735695|Meconium
1063470|NCT01735695|concentration
1063471|NCT01735695|level
1063472|NCT01735682|older adults
1063473|NCT01735682|exercise
1063474|NCT01735682|balance
1063475|NCT01735682|gait
1063476|NCT01735682|fall
1063477|NCT01735682|rehabilitation
1063478|NCT01735682|vibration
1063479|NCT01735682|muscle
1063480|NCT01735669|Remifentanil
1063481|NCT01735669|Breech presentation
1063482|NCT01735669|Nitrous oxide
1063483|NCT01735669|Pregnancy complications
1063484|NCT01735669|Caesarean section
1063485|NCT01735669|Fetal version
1063486|NCT01735656|Coronary heart disease;
1063487|NCT01735656|Percutaneous coronary intervention;
1063488|NCT01735656|Bifurcation lesion;
1063489|NCT01735656|Double kissing culotte technique;
1063490|NCT01735656|clinical trial
1063491|NCT01735643|type 2 diabetes mellitus
1063492|NCT01735643|physical activity
1063493|NCT01735643|lifestyle change
1063494|NCT01735643|motivation
1063495|NCT01735643|patient empowerment
1063496|NCT01735630|Agitation
1063497|NCT01735630|Aggression
1063498|NCT01735630|patients
1063499|NCT01735617|congenital adrenal hyperplasia
1063500|NCT01735617|glucocorticoids
1063501|NCT01735617|cortisol
1063502|NCT01735617|adrenal
1063503|NCT01735591|Liver cirrhosis
1063504|NCT01735591|Liver transplantation
1063505|NCT01735591|Probiotics
1063506|NCT01735591|Mortality
1063507|NCT01735591|Liver function
1063508|NCT01735591|Infections
1063509|NCT01735578|splanchnic oxygen saturations
1063510|NCT01735565|NET formation
1063511|NCT01735565|neutraphil extracellular traps
1063512|NCT01735565|post-engraftment immune system
1063513|NCT01735552|gut reperfusion injury
1063514|NCT01735552|blood transfusions
1063515|NCT01735552|premature infants
1063516|NCT01735552|anemia
1063517|NCT01735552|regional oxygen saturations
1063518|NCT01735552|necrotizing enterocolitis
1063519|NCT01735552|mesenteric oxygenation
1063520|NCT01735539|old age
1063521|NCT01735539|sarcopenia
1063522|NCT01735539|essential amino acid
1063523|NCT01735539|arginine
1063524|NCT01735539|contrast enhanced ultrasound
1063525|NCT01735539|muscle microcirculation
1063526|NCT01735539|muscle protein synthesis
1063527|NCT01735526|Allogeneic and autologous
1063528|NCT01735526|hematopoietic stem-cell transplantation
1063529|NCT01735526|Lung diffusing capacity
1063530|NCT01735526|for nitric oxide
1063531|NCT01735526|carbon monoxide
1063532|NCT01735526|Lung tissue density
1063533|NCT01735526|microvascular damage
1063534|NCT01735513|transaortic TAVI or TAVR
1063535|NCT01735513|embolic protection device
1063536|NCT01735513|EmbolX
1063537|NCT01735513|efficacy
1063538|NCT01735513|during transaortic TAVI
1063539|NCT01735513|reduce the incidence of new foci of restricted diffusion on diffusion-weighted MRI
1063540|NCT01735500|Prei-procedural
1063541|NCT01735500|Elevation
1063542|NCT01735500|cardia Troponin T
1063543|NCT01735500|in stable
1063544|NCT01735500|unknown
1063545|NCT01735474|manual therapy
1063546|NCT01735474|respiratory disease
1063547|NCT01735474|thoracic movement
1063548|NCT01735448|smoking cessation
1063549|NCT01735448|tobacco
1063550|NCT01735448|addiction
1063551|NCT01735448|Aboriginal
1063552|NCT01735448|youth
1063553|NCT01735448|Indigenous
1063554|NCT01735448|pharmacological
1063555|NCT01735448|focus group
1063556|NCT01735448|interview
1063557|NCT01735435|geriatric patients
1063558|NCT01735435|nutritional support
1063559|NCT01735422|Infertility
1063560|NCT01735422|Ovulation induction
1063561|NCT01735422|Recombinant human Luteinizing Hormone (r-hLH)
1063562|NCT01735422|Urinary human Chorionic Gonadotrophin (u-hCG)
1063563|NCT01735422|Recombinant human Follicle Stimulating Hormone (Gonal-f®)
1063564|NCT01735409|Advanced Nasopharyngeal Carcinoma
1063565|NCT01735409|Abraxane
1063566|NCT01735409|Cisplatin
1063567|NCT01735409|Dose
1063568|NCT01735396|African American men
1063569|NCT01735396|metastatic prostate cancer
1063570|NCT01735396|castration resistant
1063571|NCT01735357|Eicosapentaenoic acid
1063572|NCT01735357|Docosahexaenoic acid
1063573|NCT01735357|Cardiovascular risk
1063574|NCT01735357|Platelet function
1063575|NCT01735357|Endothelial function
1063576|NCT01735357|Vascular function
1063577|NCT01735357|young males
1063578|NCT01735331|Vascular endothelial growth factor, Recurrent Pregnancy Loss
1063579|NCT01735305|Coronary Artery Disease
1063580|NCT01735305|antiplatelet therapy
1063581|NCT01735292|Ventilation, timer
1063582|NCT01735279|tobacco dependence
1063583|NCT01735279|tobacco treatment
1063584|NCT01735279|omega 3 series
1063585|NCT01735279|polyunsaturated fatty acids
1063586|NCT01735266|Colonoscopy
1063587|NCT01735253|metabolic surgery
1063588|NCT01735253|gastric bypass
1063589|NCT01735253|duodenojejunal bypass
1063590|NCT01735253|type 2 DM
1063591|NCT01735240|Phase I,
1063592|NCT01735240|healthy volunteers,
1063593|NCT01735240|fixed-sequence,
1063594|NCT01735240|open-label,
1063595|NCT01735240|ketoconazole,
1063596|NCT01735240|combination,
1063597|NCT01735240|safety
1063598|NCT01735227|pantoprazole
1063599|NCT01735227|omeprazole
1063600|NCT01735227|anti - platelet effect
1063601|NCT01735188|Natural history study
1063602|NCT01735175|biosimilars
1063603|NCT01735175|Pegfilgrastim,
1063604|NCT01735175|G-CSF,
1063605|NCT01735175|neutropenia,
1063606|NCT01735175|breast cancer,
1063607|NCT01735175|myelosuppressive chemotherapy,
1063608|NCT01735175|supportive care
1063609|NCT01735175|granulocyte-colony-stimulating factor
1063610|NCT01735162|Renal angina
1063611|NCT01735162|AKI
1063612|NCT01735162|Pediatric Intensive Care
1063613|NCT01735123|infant formula
1063614|NCT01735123|diet
1063615|NCT01735123|diabetes mellitus, type 1
1063616|NCT01735123|autoimmunity
1063617|NCT01735097|Arsenic
1063618|NCT01735097|Keratosis
1063619|NCT01735097|Nigella sativa
1063620|NCT01735097|Palm
1063621|NCT01735097|Vitamin E
1063622|NCT01735084|randomized controlled trial
1063623|NCT01735084|pneumococcal conjugate vaccines
1063624|NCT01735084|booster dose
1063625|NCT01735084|immunogenicity
1063626|NCT01735084|nasopharyngeal carriage
1063627|NCT01735084|Australian Indigenous
1063628|NCT01735084|pediatric
1063629|NCT01735071|ovarian cancer
1063630|NCT01735071|bevacizumab
1063631|NCT01735071|trabectedin
1063632|NCT01735071|carboplatin
1063633|NCT01735071|randomized trial
1063634|NCT01735071|phase II
1063635|NCT01735032|focal epilepsy
1063636|NCT01735032|pre-surgical evaluation
1063637|NCT01735032|multimodal imaging
1063638|NCT01735032|SEEG
1063639|NCT01735019|EC95, effective concentration in 95% of subjects
1063640|NCT01735006|Human Papillomavirus 16
1063641|NCT01735006|Human Papillomavirus 18
1063642|NCT01735006|vaccine
1063643|NCT01735006|Cervical Intraepithelial Neoplasia
1063644|NCT01735006|cervical Cancer
1063645|NCT01735006|Vaginal intraepithelial neoplasia
1063646|NCT01735006|Vulvar intraepithelial neoplasia
1063647|NCT01734980|Endobronchial Ultrasound
1063648|NCT01734980|transbronchial needle aspiration
1063649|NCT01734967|confocal laser endomicroscopy
1063650|NCT01734967|Pancreatic Neoplasms
1063651|NCT01734967|CHRONIC PANCREATITIS
1063652|NCT01734967|Endoscopic ultrasound
1063653|NCT01734954|Nerve block
1063654|NCT01734954|Sciatic nerve
1063655|NCT01734954|Ultrasonography
1063656|NCT01734954|Orthopedics
1063657|NCT01734954|Hallux Valgus
1063658|NCT01734954|Amputation
1063659|NCT01734954|Arthrodesis
1063660|NCT01734954|Arthroscopy
1063661|NCT01734954|Fracture fixation
1063662|NCT01734954|Osteotomy
1063663|NCT01734954|Tendon transfer
1063664|NCT01734954|Tenodesis
1063665|NCT01734954|Tenotomy
1063666|NCT01734954|Orthopedic procedure
1063667|NCT01734941|Autism
1063668|NCT01734941|Trichuris Suis Ova
1063669|NCT01734941|Behavior
1063670|NCT01734941|Irritability
1063671|NCT01734928|Multiple Myeloma
1063672|NCT01734928|Pomalidomide
1063673|NCT01734915|Advanced
1063674|NCT01734915|EGFR mutation
1063675|NCT01734889|nitisinone
1063676|NCT01734889|Orfadin
1063677|NCT01734889|suspension
1063678|NCT01734889|taste
1063679|NCT01734889|acceptability
1063680|NCT01734876|Parkinson´s disease
1063681|NCT01734876|Pain
1063682|NCT01734876|Sleep
1063683|NCT01734876|HPA axis function
1063684|NCT01734876|Health Related Quality of Life
1063685|NCT01734850|HIV-1
1063686|NCT01734837|Laparoscopic appendectomy
1063687|NCT01734837|appendical stump closure
1063688|NCT01734824|bone marrow edema, denosumab, PTH 1-84
1063689|NCT01734811|Vaccine
1063690|NCT01734811|Bronchospasm
1063691|NCT01734798|locally advanced bladder cancer
1063692|NCT01734798|Postoperative radiotherapy
1063693|NCT01734798|Adjuvant chemotherapy
1063694|NCT01734798|Radical Cystectomy
1063695|NCT01734759|medication palatability
1063696|NCT01734759|medication taste
1063697|NCT01734746|ovarian cancer
1063698|NCT01734746|sentinel node
1063699|NCT01734733|Parkinson's Disease
1063700|NCT01734733|Xenotransplantation
1063701|NCT01734733|choroid plexus
1063702|NCT01734707|atherosclerosis
1063703|NCT01734707|regression
1063704|NCT01734707|Allicor
1063705|NCT01734707|garlic
1063706|NCT01734707|intima-media thickness
1063707|NCT01734642|Medication errors, patients hospitalized, ADRs, adverse events
1063708|NCT01734629|Coronary Disease
1063709|NCT01734629|COPD
1063710|NCT01734629|Spirometry
1063711|NCT01734629|Coronary tomography
1063712|NCT01734616|Microvascular
1063713|NCT01734616|Muscle
1063714|NCT01734616|Nutrition
1063715|NCT01734616|Exercise
1063716|NCT01734616|Ageing
1063717|NCT01734603|Assessment
1063718|NCT01734603|Rehabilitation
1063719|NCT01734603|Walking Constant Test
1063720|NCT01734603|Walking Graded test
1063721|NCT01734603|Six minute Walking test
1063722|NCT01734603|Walking Distance
1063723|NCT01734590|Flour,
1063724|NCT01734590|carbohydrate,
1063725|NCT01734590|digestibility
1063726|NCT01734590|subjects
1063727|NCT01734577|Back pain
1063728|NCT01734551|Prenatal opiate exposure
1063729|NCT01734551|neonatal withdrawal
1063730|NCT01734551|Pharmacologic treatment
1063731|NCT01734525|candidemia
1063732|NCT01734525|intensive care unit
1063733|NCT01734525|1,3 beta-D-glucan
1063734|NCT01734512|pediatric recurrent progressive low-grade gliomas
1063735|NCT01734512|pediatric progressive low-grade gliomas
1063736|NCT01734512|everolimus
1063737|NCT01734512|mTOR inhibition
1063738|NCT01734499|Breast cancer
1063739|NCT01734499|Survivorship
1063740|NCT01734499|Coping
1063741|NCT01734499|Quality of Life
1063742|NCT01734473|COPD
1063743|NCT01734473|Protein synthesis
1063744|NCT01734473|Protein breakdown
1063745|NCT01734473|Muscle wasting
1063746|NCT01734473|Leucine
1063747|NCT01734473|Hydrolyzed
1063748|NCT01734473|Casein protein
1063749|NCT01734473|Carbohydrates
1063750|NCT01734460|pregnancy, snoring, fetal growth
1063751|NCT01734434|Health care access, Pregnant women
1063752|NCT01734421|Smoking cessation
1063753|NCT01734421|Primary health care
1063754|NCT01734421|Young people
1063755|NCT01734421|Cellular phone
1063756|NCT01734408|immunogenicity
1063757|NCT01734408|safety
1063758|NCT01734408|inactivated EV71 vaccine
1063759|NCT01734395|Alzheimer's disease
1063760|NCT01734395|Caregiver's Burden in Alzheimer's disease
1063761|NCT01734395|Galantamine
1063762|NCT01734395|Razadyne
1063763|NCT01734395|Reminyl
1063764|NCT01734369|Dermatomyositis
1063765|NCT01734369|Inclusion Body Myositis
1063766|NCT01734369|Myositis
1063767|NCT01734369|Polymyositis
1063768|NCT01734369|Military
1063769|NCT01734356|iPS
1063770|NCT01734356|fibroblast
1063771|NCT01734356|arrhythmias
1063772|NCT01734356|valvulopathies
1063773|NCT01734356|electrophysiology
1063774|NCT01734356|genetics
1063775|NCT01734343|posterior capsule opacification
1063776|NCT01734343|PCO
1063777|NCT01734343|after cataract
1063778|NCT01734343|intraocular lens
1063779|NCT01734330|behavior cognitive therapy
1063780|NCT01734330|Smokers
1063781|NCT01734330|randomized clinical trial
1063782|NCT01734304|vaccination
1063783|NCT01734304|postremission therapy
1063784|NCT01734304|acute myeloid leukemia
1063785|NCT01734304|dendritic cells
1063786|NCT01734291|Family psychoeducation
1063787|NCT01734291|Major depressive disorder
1063788|NCT01734291|Family burden
1063789|NCT01734174|transesophageal and transthoracic echocardiogram
1063790|NCT01734174|thermodilution
1063791|NCT01734174|left ventricular volume
1063792|NCT01734174|ejection volume
1063793|NCT01734161|cesarean section
1063794|NCT01734161|nausea
1063795|NCT01734161|vomiting
1063796|NCT01734161|dexamethasone
1063797|NCT01734161|postoperative nausea and vomiting
1063798|NCT01734161|antiemetics
1063799|NCT01734148|pediatric
1063800|NCT01734148|sleep difficulties in children
1063801|NCT01734148|Sleep Education
1063802|NCT01734135|B type natriuretic peptide
1063803|NCT01734135|heart failure
1063804|NCT01734135|cardiac imaging
1063805|NCT01734135|quality of care
1063806|NCT01734122|Stereotactic Radiosurgery
1063807|NCT01734122|Essential Tremor
1063808|NCT01734122|Parkinsonian Tremor
1063809|NCT01734122|Quality of Life
1063810|NCT01734122|Severity of Tremor
1063811|NCT01734109|Negative Pressure Wound Therapy
1063812|NCT01734109|Irrigation Therapy
1063813|NCT01734109|Pressure Ulcers
1063814|NCT01734109|Sacral Ulcers
1063815|NCT01734096|hypertension
1063816|NCT01734096|obesity
1063817|NCT01734096|white coat hypertension
1063818|NCT01734096|resistant hypertension
1063819|NCT01734083|rehabilitation
1063820|NCT01734083|exercise
1063821|NCT01734083|fall
1063822|NCT01734083|muscle
1063823|NCT01734083|vibration
1063824|NCT01734083|mobility
1063825|NCT01734083|cognition
1063826|NCT01734070|anthocyanins
1063827|NCT01734070|catechins
1063828|NCT01734070|chlorogenic acid
1063829|NCT01734070|flavanol glycosides
1063830|NCT01734057|Recombinant Human Thrombopoietin
1063831|NCT01734057|rhTPO
1063832|NCT01734057|Rituximab
1063833|NCT01734057|Dexamethasone
1063834|NCT01734044|Recombinant Human Thrombopoietin
1063835|NCT01734044|rhTPO
1063836|NCT01734044|Dexamethasone
1063837|NCT01733953|Cardiovascular Disease
1063838|NCT01733953|Childhood ALL
1063839|NCT01733953|Childhood NHL
1063840|NCT01733927|HIV screening
1063841|NCT01733927|Rapid test for HIV
1063842|NCT01733914|shoulder pain
1063843|NCT01733914|acupuncture
1063844|NCT01733901|Coronary heart disease
1063845|NCT01733901|PCI
1063846|NCT01733901|Renal sympathetic denervation
1063847|NCT01733901|Hypertension
1063848|NCT01733901|Diabetes
1063849|NCT01733888|caries
1063850|NCT01733888|caries infiltration
1063851|NCT01733888|fluorosis treatment
1063852|NCT01733875|Safety
1063853|NCT01733875|Pharmacokinetics
1063854|NCT01733875|Food effect
1063855|NCT01733875|Healthy subjects
1063856|NCT01733862|Impact
1063857|NCT01733862|Vaccination
1063858|NCT01733862|Hospitalizations
1063859|NCT01733862|Rotavirus gastroenteritis
1063860|NCT01733862|Japan
1063861|NCT01733849|Bulgaria
1063862|NCT01733849|Primary care settings
1063863|NCT01733849|Children
1063864|NCT01733849|Latvia
1063865|NCT01733849|Acute gastroenteritis
1063866|NCT01733810|Esophagitis
1063867|NCT01733810|Reflux esophagitis
1063868|NCT01733810|Gastroesophageal reflux disease
1063869|NCT01733810|Acid
1063870|NCT01733810|Inflammation
1063871|NCT01733810|Esophagus
1063872|NCT01733810|Cytokines
1063873|NCT01733810|Esophageal squamous cell
1063874|NCT01733810|Reflux
1063875|NCT01733810|Squamous epithelium
1063876|NCT01733797|Trismus
1063877|NCT01733797|Therabite
1063878|NCT01733797|Wooden spatula
1063879|NCT01733797|Head and Neck cancer
1063880|NCT01733784|Sleep Apnea
1063881|NCT01733784|Pathophysiology
1063882|NCT01733771|complementary medicine
1063883|NCT01733771|hospitalized
1063884|NCT01733758|albiglutide
1063885|NCT01733758|Japanese
1063886|NCT01733758|GSK716155
1063887|NCT01733758|Type 2 diabetes mellitus
1063888|NCT01733758|glucagon-like peptide 1
1063889|NCT01733745|dry eye
1063890|NCT01733745|lipid deficiency
1063891|NCT01733745|meibomian gland
1063892|NCT01733732|Dry eye
1063893|NCT01733732|Lipid deficiency
1063894|NCT01733732|Inflammatory markers
1063895|NCT01733706|No Nicotine Electronic Cigarette
1063896|NCT01733706|Antismoke intervention
1063897|NCT01733693|Buprenorphine
1063898|NCT01733693|Methadone
1063899|NCT01733693|Cognition
1063900|NCT01733680|ADHD
1063901|NCT01733680|executive function
1063902|NCT01733680|emotional self-regulation
1063903|NCT01733667|synechia
1063904|NCT01733667|Fess
1063905|NCT01733667|sinus surgery
1063906|NCT01733654|depression
1063907|NCT01733654|major depressive disorder
1063908|NCT01733628|Hypertension
1063909|NCT01733628|Bevacizumab Response Predictors
1063910|NCT01733628|Metastatic Breast Cancer
1063911|NCT01733628|Metastatic Colon Cancer
1063912|NCT01733615|Mucopolysaccharidosis Type IVA
1063913|NCT01733615|Mucopolysaccharidosis Type IV
1063914|NCT01733615|MPS Type IVA
1063915|NCT01733615|MPS Type IV
1063916|NCT01733615|Morquio Syndrome
1063917|NCT01733615|Morquio Syndrome Type A
1063918|NCT01733615|Urine biomarkers
1063919|NCT01733589|Recombinant human endostatin
1063920|NCT01733589|Non-small-Cell Lung Cancer
1063921|NCT01733589|chemoradiotherapy
1063922|NCT01733563|sugar sweetened beverages
1063923|NCT01733563|fructose
1063924|NCT01733563|lipogenesis
1063925|NCT01733563|beta-oxidation
1063926|NCT01733550|Intraocular Pressure
1063927|NCT01733550|Tonometry, Ocular
1063928|NCT01733550|iCare
1063929|NCT01733537|traffic accidents, motorcycle, injury, conspicuity
1063930|NCT01733524|adolescence
1063931|NCT01733524|self care
1063932|NCT01733485|Asthma
1063933|NCT01733485|Electrophilic Fatty Acids
1063934|NCT01733485|Inflammation
1063935|NCT01733472|anaesthetic techniques
1063936|NCT01733472|subarachnoid
1063937|NCT01733472|analgesia
1063938|NCT01733459|PCOS, DLBS3233, metformin,oral anti-hyperglycemic agent
1063939|NCT01733446|High frequency jet ventilation
1063940|NCT01733407|inherited neuropathies
1063941|NCT01733394|Epilepsy
1063942|NCT01733394|Generic
1063943|NCT01733381|Barefoot running, minimally shod running, non-invasive measures of autonomic nervous system (ANS) functioning and mood state.
1063944|NCT01733368|CRT
1063945|NCT01733368|Optimization
1063946|NCT01733368|Responders
1063947|NCT01733329|Buccal Misoprostol
1063948|NCT01733329|Uterine Atony
1063949|NCT01733329|Postpartum Hemorrhage
1063950|NCT01733316|Nephropathic Cystinosis
1063951|NCT01733316|Cysteamine
1063952|NCT01733316|Delayed-Release Cysteamine
1063953|NCT01733316|Orphan Disease
1063954|NCT01733316|CTNS Protein, Human
1063955|NCT01733290|Botulinum Toxin A (BoNT-A)
1063956|NCT01733290|Dysfunctional voiding
1063957|NCT01733277|Neuropathic pain
1063958|NCT01733277|Knee osteoarthritis
1063959|NCT01733277|MRI
1063960|NCT01732185|Congenital lung malformation
1063961|NCT01732185|Congenital Cystic Adenomatoid Malformation
1063962|NCT01732185|Cystic lung disease
1063963|NCT01732172|Urethritis
1063964|NCT01732172|Prevalence of a chronic inflammatory male genital tract
1063965|NCT01732159|Ambulatory surgery
1063966|NCT01732159|Checklist
1063967|NCT01732159|Cancellation
1063968|NCT01732146|Hypoxic Ischemic Encephalopathy
1063969|NCT01732146|Term neonate
1063970|NCT01732146|Neuroprotection
1063971|NCT01732146|erythropoietin
1063972|NCT01732133|Hypotension
1063973|NCT01732133|Cesarean delivery
1063974|NCT01732120|off-clamp
1063975|NCT01732120|partial nephrectomy
1063976|NCT01732120|renal cancer treatment
1063977|NCT01732120|renal ischemia
1063978|NCT01732107|Dovitinib
1063979|NCT01732107|FGFR3 Mutations
1063980|NCT01732107|BCG-Refractory Urothelial Carcinoma
1063981|NCT01732094|Poor ovarian response
1063982|NCT01732094|Poor ovarian responders
1063983|NCT01732094|Bologna criteria for poor ovarian response
1063984|NCT01732081|Hepatitis B
1063985|NCT01733238|PNT2258
1063986|NCT01733238|Lymphoma
1063987|NCT01733238|Non-Hodgkin's Lymphoma
1063988|NCT01733238|NHL
1063989|NCT01733212|Nausea
1063990|NCT01733212|Vomiting
1063991|NCT01733212|Cesaraen
1063992|NCT01733212|Ginger
1063993|NCT01733212|cesarean section
1063994|NCT01733199|Parkinson's disease
1063995|NCT01733199|Behavioural addictions
1063996|NCT01733199|Pathological gambling
1063997|NCT01733199|Dopamine agonist
1063998|NCT01733199|Dopamine dysregulation syndrome
1063999|NCT01733199|Pharmacokinetic
1064000|NCT01733199|Pramipexole
1064001|NCT01733186|human umbilical cord blood-derived mesenchymal stem cells
1064002|NCT01733186|MSC
1064003|NCT01733186|cartilage lesion
1064004|NCT01733186|cartilage defect
1064005|NCT01733186|degenerative arthritis
1064006|NCT01733186|stem cell implantation
1064007|NCT01733173|mass in posterior fossa
1064008|NCT01733173|benign
1064009|NCT01733173|malignant
1064010|NCT01733173|surgical resection
1064011|NCT01733173|MRI
1064012|NCT01733173|fMRI
1064013|NCT01733173|DTI
1064014|NCT01733173|12-121
1064015|NCT01733160|Atrial Fibrillation
1064016|NCT01733160|Stroke
1064017|NCT01733160|Anticoagulants
1064018|NCT01733147|Barrett's esophagus
1064019|NCT01733147|Obesity
1064020|NCT01733147|Omega-3 fatty acid
1064021|NCT01733134|acute heart failure
1064022|NCT01733134|emergency department
1064023|NCT01733134|copeptin
1064024|NCT01733134|adh antagonists
1064025|NCT01733108|Healthy
1064026|NCT01733108|Canagliflozin (JNJ-28431754)
1064027|NCT01733108|Pharmacokinetics
1064028|NCT01733108|Pharmacodynamics
1064029|NCT01733108|Glyburide (MICRONASE)
1064030|NCT01733056|Dermatology
1064031|NCT01733056|Influenza Vaccine
1064032|NCT01733030|PTSD
1064033|NCT01733017|heart failure
1064034|NCT01733017|nutrition therapy
1064035|NCT01733017|symptoms
1064036|NCT01733017|quality of life
1064037|NCT01733017|lycopene
1064038|NCT01733017|omega-3 fatty acids
1064039|NCT01733004|Cancer
1064040|NCT01733004|Hepatocellular Carcinoma
1064041|NCT01733004|Oncology
1064042|NCT01733004|Phase I
1064043|NCT01733004|ErbB3
1064044|NCT01733004|IGF-1R
1064045|NCT01733004|Everolimus
1064046|NCT01733004|Gemcitabine
1064047|NCT01733004|Abraxane
1064048|NCT01732991|Prostatic Hypertrophy, Benign
1064049|NCT01732991|Greenlight laser
1064050|NCT01732991|Prostatic photovaporization
1064051|NCT01732991|Prostatic MRI
1064052|NCT01732991|Prostatic contrast-enhanced ultrasound
1064053|NCT01732991|Urinary irritative signs
1064054|NCT01732991|Postoperative necrotic area
1064055|NCT01732978|Crying record
1064056|NCT01732978|Newborn
1064057|NCT01732965|Vitiligo
1064058|NCT01732965|Phototherapy
1064059|NCT01732965|Photochemotherapy
1064060|NCT01732952|the prevalence,lipid abnormalities,CV risks
1064061|NCT01732926|iNHL
1064062|NCT01732926|indolent NHL
1064063|NCT01732926|follicular lymphoma
1064064|NCT01732926|CAL-101
1064065|NCT01732926|rituximab
1064066|NCT01732926|bendamustine
1064067|NCT01732926|small lymphocytic lymphoma
1064068|NCT01732926|lymphoplasmacytoid lymphoma
1064069|NCT01732926|Waldenstrom macroglobulinemia
1064070|NCT01732926|LPL
1064071|NCT01732926|WM
1064072|NCT01732926|Marginal zone lymphoma
1064073|NCT01732926|MZL
1064074|NCT01732926|SLL
1064075|NCT01732926|FL
1064076|NCT01732926|GS-1101
1064077|NCT01732926|PI3K inhibitor
1064078|NCT01732926|idelalisib
1064079|NCT01732913|iNHL
1064080|NCT01732913|indolent NHL
1064081|NCT01732913|follicular lymphoma
1064082|NCT01732913|CAL-101
1064083|NCT01732913|Rituximab
1064084|NCT01732913|Small lymphocytic lymphoma
1064085|NCT01732913|lymphoplasmacytoid lymphoma
1064086|NCT01732913|Waldenstrom macroglobulinemia
1064087|NCT01732913|LPL
1064088|NCT01732913|WM
1064089|NCT01732913|Marginal zone lymphoma
1064090|NCT01732913|MZL
1064091|NCT01732913|SLL
1064092|NCT01732913|FL
1064093|NCT01732913|GS-1101
1064094|NCT01732913|idelalisib
1064095|NCT01732900|In vitro fertilization
1064096|NCT01732900|Assisted reproduction
1064097|NCT01732900|pregnancy outcome
1064098|NCT01732900|cumulus cells
1064099|NCT01732887|cochlear implants
1064100|NCT01732887|speech comprehension
1064101|NCT01732887|cognitive training
1064102|NCT01732887|cognitive fitness
1064103|NCT01732887|intervention
1064104|NCT01732887|memory
1064105|NCT01732887|attention
1064106|NCT01732887|rehabilitation
1064107|NCT01732874|DHA
1064108|NCT01732874|Preterm infant
1064109|NCT01732874|Inflammation
1064110|NCT01732874|Growth
1064111|NCT01732874|Developement
1064112|NCT01732861|Chronic Lymphocytic Leukemia
1064113|NCT01732861|Small Lymphocytic Leukemia
1064114|NCT01732848|Volunteers
1064115|NCT01732835|Aortic Insufficiency (AI) Aortic Regurgitation (AR)
1064116|NCT01732822|Peripheral artery disease Atherothrombotic events Atherosclerosis
1064117|NCT01732809|wrinkles
1064118|NCT01732809|botulinum toxin
1064119|NCT01732783|Wild-type RAS
1064120|NCT01732783|Metastatic Colorectal Cancer
1064121|NCT01732783|Vectibix
1064122|NCT01732744|biofilm, castor bean, sodium hypochlorite, alkaline peroxide
1064123|NCT01732731|Cerebral palsy
1064124|NCT01732731|treadmill training
1064125|NCT01732718|sickle cell disease
1064126|NCT01732718|endothelial function
1064127|NCT01732718|albuminuria
1064128|NCT01732718|atorvastatin
1064129|NCT01732718|soluble fms-like tyrosine kinase-1
1064130|NCT01732705|Type 2 diabetes
1064131|NCT01732705|Insulin sensitivity
1064132|NCT01732705|High intensity interval training
1064133|NCT01732692|Bowel preparation, MOVIPREP®
1064134|NCT01732679|stroke, rehabilitation, multidisciplinary, description
1064135|NCT01732666|Opioid-induced hyperalgesia (OIH)
1064136|NCT01732653|virtual reality,
1064137|NCT01732653|falls,
1064138|NCT01732653|elderly,
1064139|NCT01732653|Parkinson's disease,
1064140|NCT01732653|MCI
1064141|NCT01732640|Squamous cell carcinoma of the head and neck
1064142|NCT01732627|Meningitis
1064143|NCT01732627|Meningococcal Meningitis
1064144|NCT01732627|Menactra®
1064145|NCT01732627|Menomune® A/C/Y/W-135
1064146|NCT01732614|Diabetic Macular Edema
1064147|NCT01732614|DME
1064148|NCT01732614|Laser
1064149|NCT01732614|Topcon
1064150|NCT01732614|EndPoint Management
1064151|NCT01732601|Suicide Attempt
1064152|NCT01732601|Suicidal Ideation
1064153|NCT01732601|NSSI
1064154|NCT01732601|Substance Use
1064155|NCT01732588|Bioavailability
1064156|NCT01732575|everyday activities
1064157|NCT01732575|rehabilitation
1064158|NCT01732575|mental illness
1064159|NCT01732575|occupational therapy
1064160|NCT01732562|Primary Total Knee Arthroplasty
1064161|NCT01732562|Patient Expectations
1064162|NCT01732562|Patient Satisfaction
1064163|NCT01732562|Patient Education
1064164|NCT01732562|e-Learning
1064165|NCT01732523|Carotid stenosis
1064166|NCT01732523|Vasa Vasorum
1064167|NCT01732523|Ultrasonography
1064168|NCT01732497|Underarm Hair
1064169|NCT01732497|Underarm Hair Reduction
1064170|NCT01732497|Axillary Hair
1064171|NCT01732497|Axillary Hair Reduction
1064172|NCT01732497|Underarm Odor
1064173|NCT01732497|Axillary Odor
1064174|NCT01732471|EMR 700733_510, Genetic disorder, Phenylketonuria, phenylalanine, Kuvan, sapropterin dihydrochloride
1064175|NCT01732419|Rehabilitation, exercise therapy, coronary artery disease
1064176|NCT01732393|Quercetin
1064177|NCT01732393|Chemotherapy
1064178|NCT01732393|Mucositis
1064179|NCT01732393|Hematologic Malignancies
1064180|NCT01732367|Tenofovir
1064181|NCT01732367|Lamivudine
1064182|NCT01732367|Adefovir
1064183|NCT01732367|Chronic Hepatitis B
1064184|NCT01732354|Hepatitis B virus, Tenofovir
1064185|NCT01732341|STEMI
1064186|NCT01732341|BMS
1064187|NCT01732341|Self-expanding stent
1064188|NCT01732315|Adolescent vaccination
1064189|NCT01732315|Immunization rates
1064190|NCT01732315|Barriers to vaccination
1064191|NCT01732315|Attitudes
1064192|NCT01732315|Intentions
1064193|NCT01732302|Drug Utilization Review
1064194|NCT01732302|Aged
1064195|NCT01732302|Aged, 80 and over
1064196|NCT01732302|Primary Health Care
1064197|NCT01732289|Age-related hearing loss
1064198|NCT01732289|Gene
1064199|NCT01732289|Single nucleotide polymorphism
1064200|NCT01732289|environmental factors
1064201|NCT01732276|Triple-negative breast cancer
1064202|NCT01732276|Epidermal growth factor receptor
1064203|NCT01732276|Gefitinib
1064204|NCT01732250|Gram-Negative Bacterial Infections
1064205|NCT01732250|Resistant Bacteria
1064206|NCT01732250|Drug Resistance, Bacterial
1064207|NCT01732250|Colistin
1064208|NCT01732237|Healthy
1064209|NCT01732237|JNJ-42396302
1064210|NCT01732237|JNJ-42692507
1064211|NCT01732237|JNJ-53773187
1064212|NCT01732237|Pharmacokinetics
1064213|NCT01732211|Phase 2
1064214|NCT01732211|Randomized
1064215|NCT01732211|Double Blind
1064216|NCT01732211|Placebo Controlled
1064217|NCT01732211|Parallel
1064218|NCT01732211|20 Week Safety
1064219|NCT01732211|Tolerability
1064220|NCT01732211|and Efficacy Study
1064221|NCT01732068|Poor ovarian response
1064222|NCT01732068|Poor ovarian responders
1064223|NCT01732068|Bologna criteria for poor ovarian response
1064224|NCT01732055|Pregnancy
1064225|NCT01732055|Antenatal
1064226|NCT01732055|Major Depressive Disorder
1064227|NCT01732055|Psychotherapy
1064228|NCT01732055|Antidepressant Medication
1064229|NCT01732055|Partners
1064230|NCT01732055|Spouses
1064231|NCT01732055|Interpersonal Psychotherapy
1064232|NCT01732042|retinal venous pressure
1064233|NCT01732029|pulse oximeter
1064234|NCT01732029|oxygen saturation
1064235|NCT01732029|heart rate
1064236|NCT01732029|calibration
1064237|NCT01732029|accuracy
1064238|NCT01732016|pulse oximeter
1064239|NCT01732016|oxygen saturation
1064240|NCT01732016|heart rate
1064241|NCT01732016|calibration
1064242|NCT01732016|accuracy
1064243|NCT01732003|Omega-3
1064244|NCT01732003|Skeletal Muscle
1064245|NCT01732003|Eicosapentaenoic acid
1064246|NCT01732003|Docosahexaenoic acid
1064247|NCT01732003|Exercise
1064248|NCT01732003|Membrane Composition
1064249|NCT01732003|Lipid Metabolism
1064250|NCT01731990|Peripheral artery disease
1064251|NCT01731990|Intermittent claudication
1064252|NCT01731990|magnetic resonance imaging
1064253|NCT01731977|Psychotherapy, Psychotic disorders, Caregiver
1064254|NCT01731964|Macular Degeneration
1064255|NCT01731964|Visual Impairment
1064256|NCT01731964|Implantable Telescope
1064257|NCT01731951|Myelofibrosis
1064258|NCT01731951|Myelodysplastic Syndromes
1064259|NCT01731951|Myeloproliferative Neoplasm
1064260|NCT01731951|Imetelstat
1064261|NCT01731951|GRN163L
1064262|NCT01731938|Fibrin Sealant
1064263|NCT01731938|Soft tissue open surgery
1064264|NCT01731938|Oxidized cellulose pads
1064265|NCT01731925|midgut carcinoid tumors
1064266|NCT01731925|progressive
1064267|NCT01731925|advanced
1064268|NCT01731925|metastatic
1064269|NCT01731899|major depression
1064270|NCT01731899|fibromyalgia
1064271|NCT01731899|agomelatine
1064272|NCT01731899|Becks' Depression Inventory (BDI)
1064273|NCT01731899|Pittsburgh's Sleep Quality Index (PSQI)
1064274|NCT01731886|Stem cell transplant
1064275|NCT01731886|plasma cell myeloma
1064276|NCT01731886|multiple myeloma
1064277|NCT01731873|postoperative
1064278|NCT01731873|pediatric
1064279|NCT01731873|pharmacogenetic
1064280|NCT01731873|opioid
1064281|NCT01731873|perioperative
1064282|NCT01731873|respiratory depression
1064283|NCT01731860|PET/CT
1064284|NCT01731860|Philips
1064285|NCT01731847|dysphagia,endoscopy, electrical stimulation,stroke
1064286|NCT01731834|Pain
1064287|NCT01731834|Stress
1064288|NCT01731834|Physiotherapy
1064289|NCT01731834|Children
1064290|NCT01731821|Pancreaticoduodenectomy
1064291|NCT01731821|Pancreaticojejunostomy
1064292|NCT01731808|Nursing counseling
1064293|NCT01731808|diabetic foot
1064294|NCT01731795|acute respiratory distress syndrome, mechanical ventilation
1064295|NCT01731782|colorectal surgery
1064296|NCT01731769|Seroma Formation
1064297|NCT01731769|Axillary Lymph Node Dissection
1064298|NCT01731769|Breast cancer
1064299|NCT01731769|Early Vacuum Assisted Closure
1064300|NCT01731756|Palm
1064301|NCT01731756|Arsenic
1064302|NCT01731756|Keratosis
1064303|NCT01731756|Salicylic acid
1064304|NCT01731756|Azadirachta indica
1064305|NCT01731756|Neem
1064306|NCT01731730|Postsurgical pain
1064307|NCT01731730|Total knee arthroplasty
1064308|NCT01731730|Total knee replacement
1064309|NCT01731717|depression
1064310|NCT01731717|stepped care
1064311|NCT01731717|evidence-based medicine
1064312|NCT01731717|health services research
1064313|NCT01731717|psychotherapy
1064314|NCT01731717|complex intervention
1064315|NCT01731717|guideline
1064316|NCT01731704|5 or more brain metastases
1064317|NCT01731704|proven diagnosis of a non-hematopoietic malignancy
1064318|NCT01731704|non-small cell lung cancer or germ cell malignancy
1064319|NCT01731665|Crohn's disease
1064320|NCT01731665|ulcerative colitis
1064321|NCT01731665|epidemiology
1064322|NCT01731665|Korea
1064323|NCT01731652|bladder cancer
1064324|NCT01731652|carcinoma in situ
1064325|NCT01731652|non muscle invasive bladder cancer
1064326|NCT01731587|Non-small cell lung cancer (NSCLC)
1064327|NCT01731587|exploratory study
1064328|NCT01731587|L-BLP25
1064329|NCT01731561|Granulomatosis with Polyangiitis
1064330|NCT01731561|Microscopic polyangiitis
1064331|NCT01731561|Renal limited forms
1064332|NCT01731561|ANCA-associated vasculitis
1064333|NCT01731561|Rituximab
1064334|NCT01731535|osteoporosis, low trauma fracture, non-union fracture, delayed healing fracture, bisphosphonate
1064335|NCT01731509|congenital diaphragmatic hernia
1064336|NCT01731509|fetoscopy
1064337|NCT01731509|fetal endoscopic tracheal occlusion
1064338|NCT01731509|pulmonary hypoplasia
1064339|NCT01731509|fetal surgery
1064340|NCT01731509|fetal lung
1064341|NCT01731496|Human Papillomavirus
1064342|NCT01731483|virulence factors
1064343|NCT01731457|ischemia, reperfusion, kidney, transplantation
1064344|NCT01731444|blood loss
1064345|NCT01731444|burn
1064346|NCT01731444|hemostasis
1064347|NCT01731431|Gestational Diabetes,
1064348|NCT01731431|Insulin,
1064349|NCT01731431|Glyburide,
1064350|NCT01731431|Glycemia
1064351|NCT01731418|Post Traumatic Stress Disorder
1064352|NCT01731418|Depression
1064353|NCT01731418|Intimate Partner violence
1064354|NCT01731418|Narrative Exposure Therapy
1064355|NCT01731405|Medication Guides
1064356|NCT01731405|FDA
1064357|NCT01731405|Prototype
1064358|NCT01731405|Format
1064359|NCT01731392|Diarrhea
1064360|NCT01731392|Children
1064361|NCT01731392|Lactobacilli
1064362|NCT01731379|spectroscopy
1064363|NCT01731379|nerve
1064364|NCT01731379|muscle
1064365|NCT01731379|fat
1064366|NCT01731353|invasive fungal infection
1064367|NCT01731353|Web-based registry
1064368|NCT01731340|Calcium Supplements
1064369|NCT01731340|Dairy Foods
1064370|NCT01731340|Cardiovascular Diseases
1064371|NCT01731340|Osteoporosis
1064372|NCT01731340|Postmenopause
1064373|NCT01731340|Vitamin D
1064374|NCT01731340|Micronutrients
1064375|NCT01731340|Primary Prevention
1064376|NCT01731340|Bone Health
1064377|NCT01731327|Phase 1
1064378|NCT01731327|relative bioavailability
1064379|NCT01731327|modified release
1064380|NCT01731327|tofacitinib
1064381|NCT01731327|CP-690
1064382|NCT01731327|550
1064383|NCT01731327|pharmacokinetic
1064384|NCT01731301|Chronic hepatitis C
1064385|NCT01731301|HCV
1064386|NCT01731301|End stage renal disease
1064387|NCT01731301|ESRD
1064388|NCT01731301|Boceprevir
1064389|NCT01731301|Ribavirin
1064390|NCT01731301|Peg-interferon
1064391|NCT01731301|Triple therapy
1064392|NCT01731288|pregnancy
1064393|NCT01731288|childbirth
1064394|NCT01731288|pain
1064395|NCT01731288|vulvodynia
1064396|NCT01731288|provoked vestibulodynia
1064397|NCT01731275|Healthy volunteers
1064398|NCT01731275|immunogenicity
1064399|NCT01731275|anti-E6011 antibody
1064400|NCT01731262|Arthritis, Rheumatoid
1064401|NCT01731262|Sonic hedgehog protein, human
1064402|NCT01731262|Neovascularization, Pathologic
1064403|NCT01731262|Synovitis
1064404|NCT01731249|Sublingual immunotherapy
1064405|NCT01731249|Birch pollen extract solution
1064406|NCT01731249|Allergic rhinoconjunctivitis
1064407|NCT01731236|Carnitine metabolism
1064408|NCT01731236|gut flora
1064409|NCT01731223|Insomnia
1064410|NCT01731223|Primary health care
1064411|NCT01731197|obesity, isolated soy protein, satiety, food intake
1064412|NCT01731184|acute traumatic pain, pre-hospital setting, Midazolam
1064413|NCT01731171|mania
1064414|NCT01731171|manic episode
1064415|NCT01731171|mixed episode
1064416|NCT01731171|bipolar disorder
1064417|NCT01731171|schizoaffective disorder
1064418|NCT01731171|probiotics
1064419|NCT01731171|probiotic supplement
1064420|NCT01731171|relapse prevention
1064421|NCT01731171|new mood episode
1064422|NCT01731171|re-hospitalization
1064423|NCT01731145|Tremor
1064424|NCT01731145|SNUMAP
1064425|NCT01731145|accelerometry
1064426|NCT01731145|gyroscope
1064427|NCT01731145|clinical rating scale
1064428|NCT01731132|HRQoL
1064429|NCT01731132|IUD
1064430|NCT01731132|Contraception
1064431|NCT01731132|SEC-QoL
1064432|NCT01731119|Latuda,lurasidone,antipsychotics,autism, mood, psychosis
1064433|NCT01731093|aged
1064434|NCT01731093|health
1064435|NCT01731093|brain
1064436|NCT01731054|lupus nephritis
1064437|NCT01731054|normal healthy volunteer
1064438|NCT01731054|MRI
1064439|NCT01731041|coronary disease, platelet function, platelet inhibitors
1064440|NCT01731002|Glaucoma
1064441|NCT01730989|menopause
1064442|NCT01730989|Kupperman
1064443|NCT01730989|hot flushes
1064444|NCT01730989|isoflavones
1064445|NCT01730989|magnolia
1064446|NCT01730989|chaste tree
1064447|NCT01730976|asthma, elderly, vitamin D
1064448|NCT01730924|Atrial fibrillation
1064449|NCT01730924|Contact force
1064450|NCT01730924|Ablation
1064451|NCT01730911|Bleeding
1064452|NCT01730911|Cramping
1064453|NCT01730911|Pregnancy with intrauterine device in place
1064454|NCT01730911|Intrauterine device expulsion
1064455|NCT01730911|Intrauterine device removal
1064456|NCT01730859|Balance exercise
1064457|NCT01730859|Ankle
1064458|NCT01730859|Postural stability
1064459|NCT01730859|Taping
1064460|NCT01730859|Biodex
1064461|NCT01730846|smoking lapse behavior
1064462|NCT01730846|smoking cessation
1064463|NCT01730846|doxazosin
1064464|NCT01730846|medication effect on smoking lapse behavior
1064465|NCT01730846|medication effect on smoking cessation
1064466|NCT01730846|stress
1064467|NCT01730807|Atrial Flutter
1064468|NCT01730807|Ablation
1064469|NCT01730807|Type I Atrial Flutter
1064470|NCT01730807|Atrial Arrhythmia
1064471|NCT01730794|Acute Respiratory Failure
1064472|NCT01730794|Mechanical Ventilation
1064473|NCT01730794|NAVA
1064474|NCT01730794|Lung protective ventilation
1064475|NCT01730794|invasive ventilation
1064476|NCT01730794|noninvasive ventilation
1064480|NCT01730768|schizophrenia, chronic stable schizophrenia, cognition, memory, visual learning, CogState
1064481|NCT01730755|Polycythemia
1064482|NCT01730716|Human spinal cord derived neural stem cell transplantation
1064483|NCT01730716|ALS
1064484|NCT01730703|walking
1064485|NCT01730703|incentives
1064486|NCT01730703|elderly
1064487|NCT01730690|Bacterial meningitis in adults
1064488|NCT01730690|determinants of in-hospital mortality
1064489|NCT01730677|Lapatinib
1064490|NCT01730677|Vinorelbine
1064491|NCT01730664|ertapenem
1064492|NCT01730664|tuberculosis
1064493|NCT01730664|pharmacokinetics
1064494|NCT01730651|cervical cancer with metastatic lymphadenopathies
1064495|NCT01730638|thyroid,
1064496|NCT01730638|endocrine tumour
1064497|NCT01730638|Nuclear medicine,
1064498|NCT01730638|molecular imaging
1064499|NCT01730638|ImmunoTEP
1064500|NCT01730625|Attention bias modification treatment (ABMT)
1064501|NCT01730625|Attention biases
1064502|NCT01730625|Anxious children
1064503|NCT01730625|Cognitive Behavioral Therapy (CBT)
1064504|NCT01730612|ImmunoTEP
1064505|NCT01730612|HER2 negative
1064506|NCT01730612|Breast Cancer
1064507|NCT01730586|Colorectal Cancer
1064508|NCT01730586|Cancer of Gastrointestinal Tract
1064509|NCT01730586|CIMP-high Colorectal Adenocarcinoma
1064510|NCT01730586|Small Bowel Adenocarcinomas
1064511|NCT01730586|Colorectal
1064512|NCT01730586|Small bowel cancer
1064513|NCT01730586|Abraxane
1064514|NCT01730586|Nab-Paclitaxel
1064515|NCT01730586|Paclitaxel (Protein-Bound)
1064516|NCT01730586|ABI-007
1064517|NCT01730573|interscalene
1064518|NCT01730573|suprascapular
1064519|NCT01730573|axillary
1064520|NCT01730547|Mesenchymal stem cells
1064521|NCT01730547|Multiple Sclerosis
1064522|NCT01730547|Autoimmune diseases
1064526|NCT01730495|Chronic fatigue syndrome
1064527|NCT01730495|CFS
1064528|NCT01730495|Myalgic Encephalomyelitis (ME)
1064529|NCT01730495|CFS/ME
1064530|NCT01730495|Tumor necrosis factor-alpha
1064531|NCT01730495|TNF-alpha
1064532|NCT01730495|Etanercept
1064533|NCT01730482|excretion
1064534|NCT01730482|healthy volunteer
1064535|NCT01730482|migalastat hydrochloride
1064536|NCT01730482|AT1001
1064537|NCT01730482|pharmacokinetics
1064538|NCT01730482|Fabry disease
1064539|NCT01730469|Pharmacokinetics
1064540|NCT01730469|GR181413
1064541|NCT01730469|Safety
1064542|NCT01730469|AT1001
1064543|NCT01730469|Migalastat hydrochloride
1064544|NCT01730443|traumatic brain injury
1064545|NCT01730430|non-AD dementias
1064546|NCT01730430|healthy elderly controls
1064547|NCT01730417|Phase 1
1064548|NCT01730417|no carrier added metaiodobenzylguanidine
1064549|NCT01730417|radiation dosimetry
1064550|NCT01730378|Influenza vaccine
1064551|NCT01730365|spectroscopy
1064552|NCT01730365|tumour
1064553|NCT01730365|biopsy
1064554|NCT01730365|malignancy
1064555|NCT01730352|immune thrombocytopenic purpura
1064556|NCT01730352|chronic immune thrombocytopenic purpura
1064557|NCT01730352|secondary immune thrombocytopenic purpura
1064558|NCT01730352|Helicobacter pylori infection
1064559|NCT01730352|Helicobacter pylori gastritis
1064560|NCT01730352|children
1064561|NCT01730352|adolescents
1064562|NCT01730339|Skin scarring
1064563|NCT01730339|cicatrix
1064564|NCT01730339|breast scar
1064565|NCT01730339|hypertrophic scar
1064566|NCT01730326|Headache
1064567|NCT01730326|paracetamol
1064568|NCT01730326|dexketoprofen
1064569|NCT01730326|emergency department
1064570|NCT01730313|Nodding syndrome
1064571|NCT01730287|Stepwise Excavation
1064572|NCT01730287|Pulpal vitality
1064573|NCT01730287|Deep caries lesions
1064574|NCT01730287|Clinical symptoms
1064575|NCT01730287|Radiographic evaluation
1064576|NCT01730261|Traumatic Brain Injury
1064577|NCT01730261|TBI
1064578|NCT01730261|Executive Dysfunction
1064579|NCT01730261|Emotional Regulation
1064580|NCT01730261|Problem Solving
1064581|NCT01730261|Self-regulation
1064582|NCT01730261|Cognitive Rehabilitation
1064583|NCT01730261|Metacognitive Strategies
1064584|NCT01730261|Cognitive-behavioral therapy
1064585|NCT01730261|Online Therapy
1064586|NCT01730261|Group therapy
1064587|NCT01730261|Group videoconference
1064588|NCT01730261|Telehealth
1064589|NCT01730261|Telerehabilitation
1064590|NCT01730248|Myelofibrosis,
1064591|NCT01730248|PMF,
1064592|NCT01730248|PPV-MF,
1064593|NCT01730248|PET-MF,
1064594|NCT01730248|Primary Myelofibrosis,
1064595|NCT01730248|Post-polycythemia vera myelofibrosis,
1064596|NCT01730248|Post-essential thrombocythemia myelofibrosis
1064597|NCT01730222|pancreatic adenocarcinoma
1064598|NCT01730222|stage III disease
1064599|NCT01730222|stage IV disease
1064600|NCT01730222|chemotherapy
1064601|NCT01730209|Tuberous Sclerosis Complex
1064602|NCT01730209|TSC
1064603|NCT01730209|Autism
1064604|NCT01730209|Learning problems
1064605|NCT01730209|Everolimus
1064606|NCT01730209|RAD001
1064607|NCT01730209|Treatment
1064608|NCT01730209|Cognition
1064609|NCT01730209|Intellectual disability
1064610|NCT01730170|Epilepsy
1064611|NCT01730170|Pregnancy
1064612|NCT01730144|Nasal Spray Vaccine
1064613|NCT01730144|Nasal Cells
1064622|NCT01730105|Adaptive Thermogenesis
1064623|NCT01730105|Adipose Tissue
1064624|NCT01730105|Body Composition
1064625|NCT01730105|Body Weight Regulation
1064626|NCT01730105|Brown Adipose Tissue
1064627|NCT01730092|Vascular Inflammation
1064628|NCT01730092|Microarray
1064629|NCT01730092|Right Ventricular Function
1064630|NCT01730092|Endothelial Dysfunction
1064631|NCT01730092|Magnetic Resonance Imaging
1064632|NCT01730079|Attention Deficit Hyperactivity Disorder
1064633|NCT01730079|Autism
1064634|NCT01730079|Near Infrared Spectroscopy
1064635|NCT01730079|Brain Activity
1064636|NCT01730066|Probiotics
1064637|NCT01730066|Pathogenic enteric bacteria
1064638|NCT01730066|Oropharyngeal flora
1064639|NCT01730066|CRP
1064640|NCT01730066|WBC
1064641|NCT01729949|Nutrition
1064642|NCT01729949|Polyphenols
1064643|NCT01729949|Berries
1064644|NCT01729949|Overweight
1064645|NCT01729949|Lipid Panels
1064646|NCT01729936|Sitting time
1064647|NCT01729936|Overweight
1064648|NCT01729936|Obese
1064649|NCT01729936|Primary Health Care
1064650|NCT01729910|overweight
1064651|NCT01729910|obesity
1064652|NCT01729910|rural
1064653|NCT01729910|primary care
1064654|NCT01729897|gastroscopy
1064655|NCT01729897|sedation
1064656|NCT01729897|etomidate
1064657|NCT01729871|Atrial Fibrillation
1064658|NCT01729871|Irregular heart beat
1064659|NCT01729871|Catheter Ablation
1064660|NCT01729871|Rivaroxaban
1064661|NCT01729793|TNFalpha
1064662|NCT01729793|IL6
1064663|NCT01729793|postprandial
1064664|NCT01729793|digestive
1064665|NCT01729793|inflammation
1064666|NCT01729793|IL1beta
1064667|NCT01729793|CRP
1064668|NCT01729793|CBC
1064669|NCT01729793|ESR
1064670|NCT01729780|EEG-NF
1064671|NCT01729780|Neurofeedback
1064672|NCT01729780|Prevention
1064673|NCT01729780|ACS
1064674|NCT01729741|Drain or no drain
1064675|NCT01729741|Thyroid surgery
1064676|NCT01729741|Randomized Trial
1064677|NCT01729728|Tonsillectomy
1064678|NCT01729728|Dental surgery
1064679|NCT01729728|Ear surgery
1064680|NCT01729728|Nose surgery
1064681|NCT01729728|Throat surgery
1064682|NCT01729715|Pediatric
1064683|NCT01729715|Insomnia
1064684|NCT01729702|1- Hypertrophic cardiomyopathy
1064685|NCT01729702|2- BNP
1064686|NCT01729702|3- NT-proBNP
1064687|NCT01729702|4- Neurohormons
1064688|NCT01729663|melanoma
1064689|NCT01729663|irradiated-allogeneic cells
1064690|NCT01729663|therapeutic vaccine
1064691|NCT01729663|Interferon alpha 2-b
1064692|NCT01729650|Psychotic Disorders,
1064693|NCT01729650|Heart Diseases
1064694|NCT01729637|Lung Transplantation
1064695|NCT01729637|Respiratory Mechanics
1064696|NCT01729637|Isolated lung perfusion
1064697|NCT01729637|Ex-vivo lung perfusion
1064698|NCT01729637|Lung mechanics
1064699|NCT01729624|Wegener Granulomatosis
1064700|NCT01729624|Microscopic Polyangiitis
1064701|NCT01729624|Churg-Strauss Syndrome
1064702|NCT01729624|Antibodies, Antineutrophil Cytoplasmic
1064703|NCT01729611|Scleroderma
1064704|NCT01729611|Cirrhosis
1064705|NCT01729598|cognitively normal elderly population
1064706|NCT01729598|safety and tolerability
1064707|NCT01729585|cystic fibrosis
1064708|NCT01729585|quality of life
1064709|NCT01729572|schizophrenia
1064710|NCT01729572|Schizoaffective Disorder
1064711|NCT01729572|disease management
1064712|NCT01729572|treatment
1064713|NCT01729572|rehabilitation
1064714|NCT01729572|pharmacotherapy
1064715|NCT01729559|venous thromboembolic disease
1064716|NCT01729559|deep vein thrombosis
1064717|NCT01729559|pulmonary embolism
1064718|NCT01729559|trauma
1064719|NCT01729559|antithrombotic prophylaxis
1064720|NCT01729546|SMBG (self-monitoring of blood glucose)
1064721|NCT01729546|POCT
1064722|NCT01729546|System Accuracy
1064723|NCT01729533|ICSI
1064724|NCT01729533|IMSI
1064725|NCT01729533|Pregnancy
1064726|NCT01729533|Sperm morphology
1064727|NCT01729533|Unexplained infertility
1064728|NCT01729520|Total knee arthroplasty
1064729|NCT01729520|Total knee replacement
1064730|NCT01729520|Strength training
1064731|NCT01729520|Resistance training
1064732|NCT01729520|Physical therapy modalities
1064733|NCT01729520|Fatigue
1064734|NCT01729507|Smoking cessation
1064735|NCT01729507|Add on and smoking cessation
1064736|NCT01729507|Therapy for tobacco dependence
1064737|NCT01729507|Transcranial direct current stimulation
1064738|NCT01729494|belatacept
1064739|NCT01729494|rabbit antithymocyte globulin
1064740|NCT01729494|alemtuzumab
1064741|NCT01729494|corticosteroid withdrawal
1064742|NCT01729468|Low Dose Acetylsalicylic Acid
1064743|NCT01729468|Prevention
1064744|NCT01729468|Pre-eclampsia
1064745|NCT01729468|Intra-uterine Growth Restriction
1064746|NCT01729468|Primiparous Women
1064747|NCT01729468|Bilateral Uterine Artery Notches
1064748|NCT01729468|First Quarter
1064749|NCT01729455|Belimumab
1064750|NCT01729455|Connective Tissue Diseases
1064751|NCT01729455|Lupus
1064752|NCT01729455|Additional relevant MeSH terms:
1064906|NCT01728948|elderly
1064753|NCT01729455|Lupus Erythematosus, Systemic
1064754|NCT01729455|Autoimmune Diseases
1064755|NCT01729455|SLE
1064756|NCT01729455|Systemic Lupus Erythematosus
1064757|NCT01729455|Autoimmune Disease
1064758|NCT01729455|Antibodies
1064759|NCT01729455|Immune System Diseases
1064760|NCT01729429|Papillomavirus Vaccines
1064761|NCT01729429|Intervention Studies
1064762|NCT01729429|Health Services Research
1064763|NCT01729429|Cancer of Cervix
1064764|NCT01729416|colon
1064765|NCT01729416|cancer
1064766|NCT01729416|screening
1064767|NCT01729416|water exchange
1064768|NCT01729416|air
1064769|NCT01729416|method
1064770|NCT01729416|polyp
1064771|NCT01729416|adenoma
1064772|NCT01729416|detection
1064773|NCT01729416|rate
1064774|NCT01729416|sedation
1064775|NCT01729416|time
1064776|NCT01729416|procedure
1064777|NCT01729390|Feeding behavior
1064778|NCT01729364|elective CABG
1064779|NCT01729364|renal impairment
1064780|NCT01729364|GFR
1064781|NCT01729364|renal blood flow
1064782|NCT01729364|colloid
1064783|NCT01729364|crystalloid
1064784|NCT01729364|thermodilution technique
1064785|NCT01729364|oxygen supply demand
1064786|NCT01729351|Primary Care
1064787|NCT01729351|Particle size
1064788|NCT01729351|beclomethasone dipropionate
1064789|NCT01729351|Asthma Management
1064790|NCT01729351|Maintenance Therapy
1064791|NCT01729351|Metered-Dose Inhaler
1064792|NCT01729351|Smoking
1064793|NCT01729325|Post-traumatic Stress disorder (PTSD)
1064794|NCT01729325|Aggressive Behavior
1064795|NCT01729325|Appetitive Aggression
1064796|NCT01729325|Resilience
1064797|NCT01729325|Preventive Narrative Exposure Therapy
1064798|NCT01729299|ghrelin
1064799|NCT01729299|glucose control
1064800|NCT01729299|GLP-1
1064801|NCT01729299|Exendin (9-39)
1064802|NCT01729299|insulin
1064803|NCT01729260|Glioblastoma
1064804|NCT01729260|mebendazole
1064805|NCT01729260|temozolomide
1064806|NCT01729247|Asthma
1064807|NCT01729234|age related Endothelial Dysfunction
1064808|NCT01729221|Hepatocellular carcinoma
1064809|NCT01729221|Hepatitis C virus
1064810|NCT01729208|myopia progression
1064811|NCT01729208|myopia control
1064812|NCT01729195|bioabsorbable implant
1064813|NCT01729195|bone screw
1064814|NCT01729195|local antibiotic prophylaxis
1064815|NCT01729195|syndesmosis injury
1064816|NCT01729195|ankle fracture
1064817|NCT01729195|ciprofloxacin
1064821|NCT01729169|Sarcoidosis
1064822|NCT01729169|Cardiac sarcoidosis
1064823|NCT01729169|18-FDG PET
1064824|NCT01729169|68Ga-DOTANOC PET
1064825|NCT01729156|Type 2 diabetes
1064826|NCT01729156|Hepatic fatty acid oxidation
1064827|NCT01729156|Dyslipidemia
1064828|NCT01729156|Metformin
1064829|NCT01729143|black pepper
1064830|NCT01729143|metabolic chamber
1064831|NCT01729143|respiratory chamber
1064832|NCT01729117|Type 2 diabetes
1064833|NCT01729117|Obesity
1064834|NCT01729117|Insulin
1064835|NCT01729117|Hispanic
1064836|NCT01729117|Low-income
1064837|NCT01729117|Meal replacement
1064838|NCT01729104|Lymphoma
1064839|NCT01729104|Mantle cell lymphoma
1064840|NCT01729104|MCL
1064841|NCT01729104|Relapsed
1064842|NCT01729104|Refractory
1064843|NCT01729104|Carfilzomib
1064844|NCT01729104|Rituximab
1064845|NCT01729104|Rituxan
1064846|NCT01729104|Lenalidomide
1064847|NCT01729104|CC-5013
1064848|NCT01729104|Revlimid
1064871|NCT01729065|Spinal Accessory Nerve Palsy, Cranial Nerve XI, shoulder weakness, neck stiffness, head and neck cancer, neck dissection
1064872|NCT01729052|Acupuncture
1064873|NCT01729052|Children
1064874|NCT01729052|Postoperative nausea and vomiting
1064875|NCT01729052|Postoperative pain
1064876|NCT01729052|Parental attitudes
1064877|NCT01729052|Parental expectations
1064878|NCT01729039|rehabilitation
1064879|NCT01729039|aged
1064880|NCT01729039|aged, 80 and over
1064881|NCT01729039|vestibular diseases
1064882|NCT01729026|Veterans
1064883|NCT01729026|Posttraumatic Stress Disorder
1064884|NCT01729026|dog adoption
1064885|NCT01729026|companion animal
1064886|NCT01729013|vitamin D
1064887|NCT01729013|fat
1064888|NCT01729013|biopsy
1064889|NCT01729000|prematurity
1064890|NCT01729000|infection control
1064891|NCT01729000|necrotizing entercolitis
1064892|NCT01728974|Obstructive Sleep Apnea
1064893|NCT01728974|Pathophysiology
1064894|NCT01728961|HIV 1
1064895|NCT01728961|NVP
1064896|NCT01728961|malaria
1064897|NCT01728961|Children
1064898|NCT01728961|Youth
1064899|NCT01728961|nevirapine
1064900|NCT01728961|Coartem Dispersible
1064901|NCT01728961|Artemether
1064902|NCT01728961|Lumefantrine
1064903|NCT01728961|Pharmacokinetics
1064904|NCT01728948|Sorafenib
1064905|NCT01728948|renal cell carcinoma(RCC)
1064907|NCT01728948|effectiveness
1064908|NCT01728948|safety
1064909|NCT01728935|HBV
1064910|NCT01728935|Tenofovir
1064911|NCT01728935|HBV DNA
1064912|NCT01728935|HBsAg
1064913|NCT01728935|Resistance
1064914|NCT01728922|Clinically isolated syndrome
1064915|NCT01728922|Multiple sclerosis
1064916|NCT01728922|Vitamin D
1064917|NCT01728922|Immune response
1064918|NCT01728922|CD4 T cell subsets
1064919|NCT01728922|Cytokine
1064920|NCT01728909|Oxytocin
1064921|NCT01728909|Syntocinon
1064922|NCT01728909|Social Cognition
1064923|NCT01728909|Social Approach Behaviors
1064924|NCT01728896|Acute pancreatitis, nutrition
1064925|NCT01728883|Diabetic Retinopathy
1064926|NCT01728883|Diabetic Macular Edema
1064927|NCT01728883|Macular Edema
1064928|NCT01728883|Maculopathy
1064929|NCT01728883|home monitoring
1064930|NCT01728883|shape discrimination hyperacuity
1064931|NCT01728883|Psychophysical Testing
1064932|NCT01728870|Pediatric
1064933|NCT01728870|Crohn's disease
1064934|NCT01728870|Mild to moderate Crohn's Disease
1064935|NCT01728870|Diet
1064936|NCT01728870|Enteral Nutrition
1064940|NCT01728831|Red Cell Transfusion
1064941|NCT01728831|Cerebral tissue oxygenation
1064942|NCT01728831|Traumatic brain injury
1064943|NCT01728805|Cutaneous T-Cell Lymphoma (CTCL)
1064944|NCT01728805|myocis fungoides (MF)
1064945|NCT01728805|Sezary Syndrome (SS)
1064946|NCT01728792|Prophylactic vaccination
1064947|NCT01728766|Breast milk zinc transfer
1064948|NCT01728766|Bangladeshi infants
1064949|NCT01728766|appropriate-for-gestational-age
1064950|NCT01728766|small-for-gestational-age
1064951|NCT01728766|plasma zinc
1064952|NCT01728740|Bioequivalence
1064953|NCT01728740|Acarbose
1064954|NCT01728740|Metformin
1064955|NCT01728740|FDC
1064956|NCT01728727|liver cirrhosis
1064957|NCT01728727|end stage liver disease
1064958|NCT01728727|umbilical cord
1064959|NCT01728727|mesenchymal stem cells
1064960|NCT01728727|HBV
1064961|NCT01728714|Diabetes; compliance
1064962|NCT01728701|Malaria
1064963|NCT01728701|Plasmodium falciparum
1064964|NCT01728701|PfSPZ Challenge
1064965|NCT01728701|Chemoprophylaxis
1064966|NCT01728701|PfSPZ-CVac
1064967|NCT01728688|liver cirrhosis
1064968|NCT01728688|stem cell
1064969|NCT01728688|peripheral blood
1064970|NCT01728688|autologous
1064971|NCT01728688|HBV
1064972|NCT01728688|end stage liver disease
1064973|NCT01728675|Aging
1064974|NCT01728675|Skeletal muscle
1064975|NCT01728675|Biomarkers
1064976|NCT01728675|Adaptation
1064977|NCT01728662|emphysema
1064978|NCT01728662|lung volume reduction therapy
1064979|NCT01728649|Acute Ischemic Stroke
1064980|NCT01728649|Mild Hypothermia
1064981|NCT01728649|Stroke
1064982|NCT01728649|Hypothermia
1064983|NCT01728623|Thyroid cancer
1064984|NCT01728610|irritable bowel syndrome
1064985|NCT01728610|probiotic
1064986|NCT01728610|pain
1064987|NCT01728610|bloating
1064988|NCT01728610|diarrhoea
1064989|NCT01728610|constipation
1064990|NCT01728597|no history of cardiovascular diseases
1064991|NCT01728571|COPD
1064992|NCT01728571|asthma
1064993|NCT01728571|pulmonary function
1064994|NCT01728571|pneumonia
1064995|NCT01728558|Sedation
1064996|NCT01728558|Delirium
1064997|NCT01728558|Goal Directed
1064998|NCT01728558|Dexmedetomidine
1064999|NCT01728558|Mortality
1065000|NCT01728558|Mechanical ventilation
1065001|NCT01728558|Intensive care
1065002|NCT01728558|Critically Ill
1065003|NCT01728545|Cord blood registry
1065004|NCT01728545|Umbilical Cord Blood
1065005|NCT01728545|fetal blood
1065006|NCT01728545|placenta
1065007|NCT01728545|Placental Blood Stem Cell Transplantation
1065008|NCT01728545|hematopoietic progenitor cells
1065009|NCT01728545|Hematopoietic Stem Cell Transplantation
1065010|NCT01728545|cord blood unit total nucleated cell
1065011|NCT01728545|TNC
1065012|NCT01728545|CD34-positive(+) cell
1065013|NCT01728545|human leukocyte antigen
1065014|NCT01728545|HLA
1065015|NCT01728545|allogeneic transplantation
1065016|NCT01728519|Allergy
1065017|NCT01728519|Birch Pollen
1065018|NCT01728519|Immunotherapy
1065019|NCT01728506|breast cancer survivor
1065020|NCT01728506|Weight loss
1065021|NCT01728506|Exercise
1065022|NCT01728493|Prevalence
1065023|NCT01728493|Primary aldosteronism
1065024|NCT01728493|Organ damage
1065151|NCT01727960|Education
1065025|NCT01728493|Mineralocorticoid receptor antagonists
1065026|NCT01728441|PAD
1065027|NCT01728441|stenting
1065028|NCT01728441|angioplasty
1065029|NCT01728428|hemifacial spasm
1065030|NCT01728428|observational study
1065031|NCT01728428|clinical manifestation
1065032|NCT01728428|treatment
1065033|NCT01728428|Chinese
1065034|NCT01728415|Exercise
1065035|NCT01728415|Hemodialysis
1065036|NCT01728415|Physical therapy
1065037|NCT01728415|high-intensity
1065038|NCT01728389|allogenic stem cell transplantation
1065039|NCT01728389|peripheral blood stem cells
1065040|NCT01728389|intrabone
1065041|NCT01728389|intra-bone
1065042|NCT01728389|leukemia
1065043|NCT01728389|lymphoma
1065044|NCT01728363|Staphylococcal
1065045|NCT01728350|traumatic brain injury
1065046|NCT01728350|volunteering
1065047|NCT01728350|well being
1065048|NCT01728350|cortisol
1065049|NCT01728337|botulinum toxin,
1065050|NCT01728337|wrinkles
1065051|NCT01728298|House Dust Mite
1065052|NCT01728298|allergy
1065053|NCT01728298|rhinitis
1065054|NCT01728298|asthma
1065055|NCT01728285|specific allergen immunotherapy
1065056|NCT01728285|sublingual immunotherapy
1065057|NCT01728285|allergen tablets
1065058|NCT01728285|compliance
1065059|NCT01728285|electronic compliance device
1065060|NCT01728272|metoprolol, atrial fibrillation
1065061|NCT01728246|Osteoarthritis
1065062|NCT01728246|Celecoxib
1065063|NCT01728246|Tramadol
1065064|NCT01728246|Paracetamol
1065065|NCT01728233|Molecular Targeted Therapy
1065066|NCT01728233|Neoadjuvant therapy
1065067|NCT01728233|Dacomitinib
1065068|NCT01728220|Inhaled nitric oxide (iNO)
1065069|NCT01728220|Pulmonary hypertension (PH)
1065070|NCT01728220|Chronic obstructive pulmonary disease (COPD)
1065071|NCT01728220|Long term oxygen therapy (LTOT)
1065072|NCT01728207|NHL
1065073|NCT01728207|CLL
1065074|NCT01728207|follicular lymphoma
1065075|NCT01728207|mantle cell lymphoma
1065076|NCT01728207|marginal zone lymphoma
1065077|NCT01728207|chronic lymphocytic leukemia
1065078|NCT01728207|small lymphocytic lymphoma
1065079|NCT01728194|Depression
1065080|NCT01728194|Depressive Disorder
1065081|NCT01728194|Behavioral Symptoms
1065082|NCT01728194|Mood Disorders
1065083|NCT01728194|Mental Disorders
1065084|NCT01728194|Escitalopram
1065085|NCT01728194|Central Nervous System Agents
1065086|NCT01728194|Therapeutic Uses
1065087|NCT01728194|Pharmacologic Actions
1065088|NCT01728194|Physiological Effects of Drugs
1065089|NCT01728194|Muscarinic Antagonists
1065090|NCT01728194|Antidepressive Agents
1065091|NCT01728194|Psychotropic Drugs
1065092|NCT01728194|Serotonin Uptake Inhibitors
1065093|NCT01728194|Neurotransmitter Uptake Inhibitors
1065094|NCT01728194|Serotonin Agents
1065095|NCT01728194|Magnetic Resonance Imaging, Functional
1065096|NCT01728194|fMRI
1065097|NCT01728194|Magnetic Resonance Imaging
1065098|NCT01728168|lupin
1065099|NCT01728168|peanut
1065100|NCT01728168|soy
1065101|NCT01728168|pea
1065102|NCT01728168|legumes
1065103|NCT01728168|cross-reactivity
1065104|NCT01728168|sensitization
1065105|NCT01728168|atopy
1065106|NCT01728155|NEUROBLASTOMA, LOW RISK, INTERMEDIATE RISK
1065107|NCT01728142|DANA
1065108|NCT01728142|ANAM
1065109|NCT01728142|Concussion
1065110|NCT01728142|mild traumatic brain injury
1065111|NCT01728129|Concussion
1065112|NCT01728129|Mild traumatic brain injury
1065113|NCT01728129|DANA
1065114|NCT01728129|MACE
1065115|NCT01728116|glycemic control, type 2 diabetes, device, obese
1065116|NCT01728090|handwashing
1065117|NCT01728090|hand sanitizer
1065118|NCT01728090|absenteeism
1065119|NCT01728090|school age children
1065120|NCT01728090|preschool children
1065121|NCT01728077|Brivaracetam
1065122|NCT01728077|Long-term Follow-up
1065123|NCT01728077|Epilepsy
1065124|NCT01728077|Partial Onset Seizures
1065125|NCT01728077|Adjunctive treatment
1065126|NCT01728064|Friedreich's
1065127|NCT01728064|Ataxia
1065128|NCT01728064|FRDA
1065129|NCT01728064|FA
1065130|NCT01728064|EPI-743
1065131|NCT01728064|Edison
1065132|NCT01728038|Bronchiolitis
1065133|NCT01728038|Cough
1065134|NCT01728038|Ear Infection
1065135|NCT01728038|Respiratory Infection
1065136|NCT01728038|Wheezing
1065137|NCT01728025|Long QT syndrome
1065138|NCT01728025|Ranolazine
1065139|NCT01728012|Successful transplantation
1065140|NCT01728012|Long-term observation
1065141|NCT01727999|TPO response
1065142|NCT01727999|ITP
1065143|NCT01727999|immune thrombocytopenia
1065144|NCT01727973|Graves' orbitopathy
1065145|NCT01727973|Graves´ ophthalmopathy
1065146|NCT01727973|Thyroid eye disease
1065147|NCT01727973|Thyroid-associated ophthalmopathy
1065148|NCT01727973|Doxycycline
1065149|NCT01727973|EUGOGO
1065150|NCT01727973|CAS
1065152|NCT01727960|Neck pain
1065153|NCT01727960|Shoulder pain
1065154|NCT01727960|Prevalence
1065155|NCT01727960|Associated factors
1065156|NCT01727960|Students
1065157|NCT01727934|Antisense
1065158|NCT01727934|miR-122 antagonist
1065159|NCT01727934|host factor
1065160|NCT01727934|Chronic hepatitis C
1065161|NCT01727934|Hepatitis C
1065162|NCT01727921|ProCore FNA biopsy
1065163|NCT01727908|Familial Gastric Cancer Screening
1065164|NCT01727895|Betaglucan, immune modulation, immunoparalysis, immune suppression
1065165|NCT01727882|Paroled offenders
1065166|NCT01727882|Interactive Voice Response
1065167|NCT01727882|Stress
1065168|NCT01727882|Mental symptoms
1065169|NCT01727882|Alcohol consumption
1065170|NCT01727882|Substance use
1065171|NCT01727856|rehabilitation
1065172|NCT01727856|physical therapy
1065173|NCT01727856|telemedicine
1065174|NCT01727843|fracture
1065175|NCT01727843|hip
1065176|NCT01727843|tranexamic acid
1065177|NCT01727843|topical
1065178|NCT01727817|Diabetes Mellitus, Type 1
1065179|NCT01727817|Continuous Glucose Monitor
1065180|NCT01727817|Artificial Pancreas
1065181|NCT01727817|Insulin Pump
1065182|NCT01727817|Closed Loop
1065183|NCT01727817|Open Loop
1065184|NCT01727817|Diabetes Assistant
1065185|NCT01727817|DiAs
1065186|NCT01727817|Cell Phone
1065187|NCT01727791|pharmacokinetic
1065188|NCT01727791|pregabalin
1065189|NCT01727791|lactation
1065190|NCT01727765|Asthma, inspiratory muscle training
1065191|NCT01727739|Tibial tunnel widening
1065192|NCT01727739|Interference screws
1065193|NCT01727726|OPC-34712
1065194|NCT01727726|brexpiprazole
1065195|NCT01727726|Major Depressive Disorder
1065196|NCT01727726|Adjunctive Treatment
1065197|NCT01727713|Tourette Syndrome
1065198|NCT01727713|Basal Ganglia Diseases
1065199|NCT01727713|Brain Diseases
1065200|NCT01727713|Central Nervous System Diseases
1065201|NCT01727713|Tic Disorders
1065202|NCT01727713|Tics
1065203|NCT01727713|Movement Disorders
1065204|NCT01727713|Mental Disorders
1065205|NCT01727713|Aripiprazole
1065206|NCT01727700|Tourette Syndrome
1065207|NCT01727700|Basal Ganglia Diseases
1065208|NCT01727700|Brain Diseases
1065209|NCT01727700|Central Nervous System Diseases
1065210|NCT01727700|Tic Disorders
1065211|NCT01727700|Tics
1065212|NCT01727700|Movement Disorders
1065213|NCT01727700|Mental Disorders
1065214|NCT01727700|Aripiprazole
1065215|NCT01727687|To asses the training effects on traffic safety between normal and patients with Parkinson's disease
1065216|NCT01727674|Depression
1065217|NCT01727674|experiences of communication
1065218|NCT01727661|diabetes mellitus
1065219|NCT01727661|cardiopulmonary fitness
1065220|NCT01727661|lung function
1065221|NCT01727661|muscular oxygenation
1065222|NCT01727648|Stroke rehabilitation
1065223|NCT01727648|Comparative efficacy research
1065224|NCT01727648|Combined therapy
1065225|NCT01727648|Robot-Assisted Therapy
1065226|NCT01727648|Constraint-Induced Therapy
1065227|NCT01727648|Kinematic analysis
1065228|NCT01727635|Breast cancer, survivors, partners, group therapy
1065229|NCT01727609|Preterm
1065230|NCT01727609|Very low birth weight
1065231|NCT01727609|Feeding
1065232|NCT01727609|Enteral
1065233|NCT01727609|Milk
1065234|NCT01727609|Sepsis
1065235|NCT01727609|Necrotizing enterocolitis (NEC)
1065236|NCT01727583|Healthy
1065237|NCT01727570|Cancer
1065238|NCT01727570|Colon
1065239|NCT01727570|Rectum
1065240|NCT01727570|Surgery
1065241|NCT01727557|Hemodialysis and AV fistula
1065242|NCT01727544|superior semicircular canal
1065243|NCT01727544|non-vestibular dizziness
1065244|NCT01727544|vestibular dizziness
1065245|NCT01727531|chloroquine
1065246|NCT01727531|WBRT
1065247|NCT01727531|survival
1065248|NCT01727531|brain metastasis
1065249|NCT01727531|radiotherapy
1065250|NCT01727531|SNPs
1065251|NCT01727531|gene coding
1065252|NCT01727531|immunoregulatory enzyme IDO2
1065253|NCT01727518|natural history
1065254|NCT01727518|lung function
1065255|NCT01727518|general population
1065256|NCT01727518|COPD
1065257|NCT01727505|hypoxemia
1065258|NCT01727505|desaturation
1065259|NCT01727505|mechanical ventilation
1065260|NCT01727505|preterm infants
1065261|NCT01727505|volume guarantee ventilation
1065262|NCT01727492|prevention
1065263|NCT01727492|noise-induced tinnitus
1065264|NCT01727492|noise-induced hearing loss
1065265|NCT01727492|young population
1065266|NCT01727479|Peak VO2 consumption
1065267|NCT01727479|3km time trial
1065268|NCT01727479|fatigue perception
1065269|NCT01727479|lactate
1065270|NCT01727479|time to complete
1065271|NCT01727440|severe acne
1065272|NCT01727440|severe acne vulgaris
1065273|NCT01727440|acne
1065274|NCT01727440|acne vulgaris
1065275|NCT01727440|isotretinoin
1065276|NCT01727440|Accutane
1065277|NCT01727440|Sortret
1065278|NCT01727440|Amnesteem
1065279|NCT01727440|Claravis
1065280|NCT01727440|Clarus
1065281|NCT01727440|Decutan
1065282|NCT01727440|Isotane
1065283|NCT01727440|Izotek
1065284|NCT01727440|Oratane
1065285|NCT01727440|Isotret
1065286|NCT01727440|Roaccutane
1065287|NCT01727427|Unsuspected
1065288|NCT01727427|pulmonary embolism
1065289|NCT01727427|cancer
1065290|NCT01727414|ADHD
1065291|NCT01727414|Inattention
1065292|NCT01727414|Methylphenidate
1065293|NCT01727414|Pharmacogenetics
1065294|NCT01727401|Fondaparinux
1065295|NCT01727401|medical patient
1065296|NCT01727401|vein thromboembolism
1065297|NCT01727401|prophylaxis
1065298|NCT01727401|thrombocytopenia
1065299|NCT01727388|rectal examination
1065300|NCT01727388|colorectal cancer
1065301|NCT01727375|delirium, light, ICU, sleep
1065302|NCT01727362|Breast Cancer
1065303|NCT01727362|Acupuncture
1065304|NCT01727362|Quality of Life
1065305|NCT01727258|Tooth Sensitivity
1065306|NCT01727232|ITP
1065307|NCT01727232|Rituximab
1065308|NCT01727232|Efficacy
1065309|NCT01727232|Anti-CD20
1065310|NCT01727232|Regimen
1065311|NCT01727206|Erdheim-Chester disease
1065312|NCT01727206|Tocilizumab
1065313|NCT01727206|Treatment
1065314|NCT01727206|Phase II
1065315|NCT01727193|myasthenia gravis
1065316|NCT01727193|leflunomide
1065317|NCT01727167|cardiac disease
1065318|NCT01727167|mitochondrial biogenesis
1065319|NCT01727167|carbon monoxide
1065320|NCT01727141|COPD, QVA149
1065321|NCT01727128|Hepatic impairment
1065322|NCT01727128|Clinical pharmacology study
1065323|NCT01727128|Volunteer study
1065324|NCT01727063|Chronic ischemic heart disease
1065325|NCT01727063|Coronary artery disease
1065326|NCT01727063|Angina pectoris
1065327|NCT01727063|Myocardial ischemia
1065328|NCT01727063|Cardiac surgery
1065329|NCT01727037|Emphysema
1065330|NCT01727037|Chronic obstructive pulmonary disease
1065331|NCT01727037|COPD
1065332|NCT01727037|Bulla
1065333|NCT01727037|Interventional bronchoscopy
1065334|NCT01727037|Lung volume reduction
1065335|NCT01727024|Breezhaler
1065336|NCT01727024|Respimat
1065337|NCT01727024|Indacaterol
1065338|NCT01727024|Tiotropium
1065339|NCT01727011|Single fraction
1065340|NCT01727011|Elderly
1065341|NCT01727011|Breast Irradiation
1065342|NCT01726959|methotrexate
1065343|NCT01726946|Chronic Hepatitis C
1065344|NCT01726946|HCV
1065345|NCT01726946|CHC
1065346|NCT01726933|psoriasis, systemic treatment
1065347|NCT01726920|Migraine
1065348|NCT01726920|Naratriptan
1065349|NCT01726920|Naproxen
1065350|NCT01726907|submandibular gland
1065351|NCT01726907|robotic
1065352|NCT01726907|endoscopic
1065353|NCT01726907|face lift
1065354|NCT01726907|hairline
1065355|NCT01726894|Focal Therapy
1065356|NCT01726881|chronic
1065357|NCT01726881|Spinal Cord Injury patients
1065358|NCT01726855|tendon repair
1065359|NCT01726829|Type 1 Diabetes
1065360|NCT01726829|Artificial Pancreas
1065361|NCT01726829|Closed Loop
1065362|NCT01726816|Diabetic nephropathy
1065363|NCT01726816|Albumin creatinine ratio
1065364|NCT01726816|Probucol
1065365|NCT01726803|Low Back Pain
1065366|NCT01726803|Primary Care
1065367|NCT01726803|Physical Therapy
1065368|NCT01726790|corneal endothelium
1065369|NCT01726790|Bevacizumab
1065370|NCT01726790|Intravitreal injection
1065371|NCT01726790|Confoscan
1065372|NCT01726777|Randomized controlled clinical trial
1065373|NCT01726777|Diabetes
1065374|NCT01726777|Vitamin D
1065375|NCT01726777|Oral glucose tolerance
1065376|NCT01726777|Blood glucose
1065377|NCT01726777|Insulin resistance
1065378|NCT01726751|Spinal cord stimulation
1065379|NCT01726751|Irritable bowel syndrome
1065380|NCT01726751|Abdominal pain
1065381|NCT01726751|Diarrhea
1065382|NCT01726738|Melanoma
1065383|NCT01726738|Stage III
1065384|NCT01726738|Stage IV
1065385|NCT01726738|Unresectable
1065386|NCT01726738|BRAF Mutant
1065387|NCT01726738|Dabrafenib
1065388|NCT01726738|Trametinib
1065389|NCT01726738|Kinome
1065390|NCT01726738|Resistance
1065391|NCT01726738|Sequencing
1065392|NCT01726738|Mutations
1065393|NCT01726738|Kinases
1065394|NCT01726738|Mechanism
1065395|NCT01726725|hemifacial spasm
1065396|NCT01726725|microvascular decompression surgery
1065397|NCT01726725|desflurane
1065398|NCT01726712|Patient Care Management
1065399|NCT01726712|Primary Health Care
1065400|NCT01726712|HIV
1065401|NCT01726712|Patient Acceptance of Health Care
1065402|NCT01726686|Total Knee Arthroplasty
1065411|NCT01726660|Stroke
1065412|NCT01726660|Cerebrovascular Accident
1065413|NCT01726660|Cerebral stroke
1065414|NCT01726660|CVA
1065415|NCT01726660|robotic therapy
1065416|NCT01726660|upper extremity recovery
1065417|NCT01726660|kinematic training
1065418|NCT01726647|obese women
1065419|NCT01726647|fat mass distribution
1065420|NCT01726647|Metabolomic profiles
1065421|NCT01726634|upper limb
1065422|NCT01726634|functional test
1065423|NCT01726634|elastic tape
1065424|NCT01726595|critical care
1065425|NCT01726595|severe sepsis
1065426|NCT01726595|microvascular function
1065427|NCT01726595|ultrasound
1065428|NCT01726582|pancreas
1065429|NCT01726582|adenocarcinoma
1065430|NCT01726582|molecular profile
1065431|NCT01726582|molecular profiling
1065432|NCT01726582|pancreatic cancer
1065433|NCT01726582|pancreas cancer
1065434|NCT01726582|cancer
1065435|NCT01726582|molecular target
1065436|NCT01726582|pancreas head
1065437|NCT01726582|pancreas neck
1065438|NCT01726582|pancreas uncinate
1065439|NCT01726582|pancreas body
1065440|NCT01726582|pancreas tail
1065441|NCT01726569|glaucoma
1065442|NCT01726569|educational intervention
1065443|NCT01726569|post-operative satisfaction
1065444|NCT01726569|knowledges
1065445|NCT01726556|Pleural effusion
1065446|NCT01726556|Semirigid thoracoscopy
1065447|NCT01726556|Rigid thoracoscopy
1065448|NCT01726543|canaloplasty
1065449|NCT01726543|non-penetrating deep sclerectomy
1065450|NCT01726543|glaucoma
1065451|NCT01726543|cataract
1065452|NCT01726543|ophthalmology
1065453|NCT01726543|glaucoma surgery
1065454|NCT01726530|transdermal fentanyl patch, postoperative pain,
1065455|NCT01726517|HCV genotype 1 (GT-1)
1065456|NCT01726517|HCV
1065457|NCT01726517|Sustained Virologic Response
1065458|NCT01726517|Direct Acting Antiviral
1065459|NCT01726517|Combination Therapy
1065460|NCT01726517|GS-7977
1065461|NCT01726517|GS-5885
1065462|NCT01726517|Ribavirin
1065463|NCT01726517|Open Label
1065464|NCT01726517|Sofosbuvir
1065465|NCT01726517|Treatment-Naïve
1065466|NCT01726517|Protease Inhibitors
1065467|NCT01726517|PI
1065468|NCT01726504|chronic functional constipation
1065469|NCT01726504|electro-acupuncture
1065470|NCT01726504|multi-center randomized controlled trial
1065471|NCT01726504|efficacy
1065472|NCT01726504|safety
1065473|NCT01726491|Insulin resistance
1065474|NCT01726491|Exercise
1065475|NCT01726491|Type 2 diabetes mellitus
1065476|NCT01726491|Obesity
1065477|NCT01726491|Epigenetic studies
1065478|NCT01726478|Oxytocin
1065479|NCT01726478|Uterine tone
1065480|NCT01726478|Mulago Hospital
1065481|NCT01726478|Dose
1065482|NCT01726478|Side effects
1065483|NCT01726465|N-Acetylcysteine
1065484|NCT01726465|Methylprednisolone
1065485|NCT01726465|Liver ischemia reperfusion injury
1065486|NCT01726465|Pringle manoeuvre
1065487|NCT01726465|Hepatic resection
1065488|NCT01726426|Chronic arsenic poisoning
1065489|NCT01726426|Palmer arsenical keratosis
1065490|NCT01726413|Diabetic neuropathy
1065491|NCT01726400|Hepatitis C
1065492|NCT01726400|Interferon
1065493|NCT01726400|Ribavirin
1065494|NCT01726400|Hepcidin
1065495|NCT01726400|Iron metabolism
1065496|NCT01726361|Multidimension Treatment Foster Care
1065497|NCT01726361|Adolescents
1065498|NCT01726361|Disadvantaged families
1065499|NCT01726361|Out-of-home placement
1065500|NCT01726361|Conduct Disorder
1065501|NCT01726361|Family program
1065502|NCT01726361|Denmark
1065503|NCT01726361|Youth
1065504|NCT01726348|Human Immunodeficiency Virus-Type 1
1065505|NCT01726348|HIV-1
1065506|NCT01726348|TMC114
1065507|NCT01726348|Darunavir
1065508|NCT01726348|Ritonavir
1065509|NCT01726348|Filipino
1065510|NCT01726335|Schizophrenia
1065511|NCT01726335|Risperidone
1065512|NCT01726335|Risperdal consta
1065513|NCT01726283|fruste keratoconus
1065514|NCT01726283|ectasia
1065515|NCT01726257|Infrarenal
1065516|NCT01726257|Abdominal
1065517|NCT01726257|Aortic
1065518|NCT01726257|Aneurysm
1065519|NCT01726257|AAA
1065520|NCT01726257|Endologix
1065521|NCT01726257|EVAS
1065522|NCT01726257|EndoVascular
1065523|NCT01726257|Sealing
1065524|NCT01726257|System
1065525|NCT01726231|Laparoscopic access
1065526|NCT01726231|Abdominal wall lifting
1065527|NCT01726231|Direct trocar insertion
1065528|NCT01726231|Safety endoscopy
1065529|NCT01726218|Stroke
1065530|NCT01726218|Physical Medicine & Rehabilitation
1065531|NCT01726218|Neurology
1065532|NCT01726218|Neurophysiology
1065533|NCT01726218|Neuroscience
1065534|NCT01726218|Transcranial Magnetic Stimulation (TMS)
1065535|NCT01726179|caries infiltration
1065536|NCT01726179|caries arrest
1065537|NCT01726179|dental anxiety
1065538|NCT01726179|dental stress
1065539|NCT01726166|Infant
1065540|NCT01726166|contamination rates
1065541|NCT01726166|urinary catheterization
1065542|NCT01726166|suprapubic aspiration
1065543|NCT01726153|Condom Use
1065544|NCT01726153|HIV+ gay males
1065545|NCT01726153|Intervention
1065546|NCT01726153|Tailored
1065547|NCT01726153|On-line
1065548|NCT01726153|Internet
1065549|NCT01726153|Web-based
1065550|NCT01726140|intubation
1065551|NCT01726140|respiratory failure
1065552|NCT01726140|cardiac surgery
1065553|NCT01726114|Diabetes
1065554|NCT01726114|Diabetes Mellitus
1065555|NCT01726114|continuous Glucose Monitor
1065556|NCT01726088|Modafinil
1065557|NCT01726088|p50
1065558|NCT01726088|Attentional Bias
1065559|NCT01726075|diabetic retinopathy
1065560|NCT01726062|Motivational Incentives
1065561|NCT01726062|Motivational Interviewing
1065562|NCT01726062|Secondhand Smoke
1065563|NCT01726062|Neonatal Intensive Care Unit
1065564|NCT01726062|NICU
1065565|NCT01726062|High respiratory risk infants
1065566|NCT01726062|Low birth weight infants
1065567|NCT01726062|Environmental Tobacco Smoke
1065568|NCT01726062|Smoking
1065569|NCT01726062|Contingency management
1065570|NCT01726062|Infants
1065571|NCT01726062|Children
1065572|NCT01726049|HFpEF
1065573|NCT01726049|PH
1065574|NCT01726036|neonatal circumcision
1065575|NCT01726036|neonatal surgical pain
1065576|NCT01726036|Mogen
1065577|NCT01726036|Gomco
1065578|NCT01726023|Ceftazidime-avibactam,
1065579|NCT01726023|Metronidazole,
1065580|NCT01726023|Meropenem,
1065581|NCT01726023|Anti-Bacterial Agents,
1065582|NCT01726023|Anti-Infective Agents,
1065583|NCT01726023|Therapeutic Uses,
1065584|NCT01726023|Pharmacologic Actions,
1065585|NCT01726023|Physiological Effects of Drugs
1065586|NCT01725997|acromioclavicular joint dislocation
1065587|NCT01725997|ac joint dislocation
1065588|NCT01725997|acromioclavicular joint separation
1065589|NCT01725997|hook plate
1065590|NCT01725997|Rockwood
1065591|NCT01725984|Male Incontinence
1065592|NCT01725984|AdVance Male Sling
1065593|NCT01725984|AdVance XP Male Sling
1065594|NCT01725984|Male Sling
1065595|NCT01725971|Silicosis
1065596|NCT01725971|forced oscillations
1065597|NCT01725971|respiratory mechanics
1065598|NCT01725945|DASH
1065599|NCT01725945|diet
1065600|NCT01725945|asthma
1065601|NCT01725945|adults
1065602|NCT01725945|asthma control
1065603|NCT01725932|culture, depression, cognitive therapy, behaviour therapy,
1065604|NCT01725919|motor
1065605|NCT01725919|stroke
1065606|NCT01725919|hemiparesis
1065607|NCT01725919|rehabilitation
1065608|NCT01725919|constraint induced movement therapy
1065609|NCT01725919|CI therapy
1065610|NCT01725906|genotypic resistance guided therapy
1065611|NCT01725893|Claw Toe
1065612|NCT01725880|Spinal Cord Injury
1065613|NCT01725880|HuCNS-SC cells
1065614|NCT01725880|Human Neural Stem Cells
1065615|NCT01725880|Neural Stem Cells
1065616|NCT01725880|Stem Cells
1065617|NCT01725867|temporomandibular joint disorder
1065618|NCT01725867|myofascial pain
1065619|NCT01725867|manual myofascial release
1065620|NCT01725867|physical therapy
1065621|NCT01725867|oral appliance
1065622|NCT01725841|To determine the prevalence of ESBL-producing among Enterobacteriaceae isolates in Taiwan
1065623|NCT01725841|To determine the susceptibility of ertapenem and other antimicrobial agents against Enterobacteriaceae isolates with and without expression of ESBLs
1065624|NCT01725841|To determine the molecular typing of the Enterobacteriaceae isolates with expression of ESBLs
1065625|NCT01725841|To analyze the association between geographic area, hospital types against the antimicrobial susceptibility
1065626|NCT01725828|cricothyroid membrane
1065627|NCT01725828|Ultrasound
1065628|NCT01725828|Difficult Airway Management
1065629|NCT01725789|Acute isovolemic anemia after gastrectomy for gastric cancer
1065630|NCT01725776|Pulmonary hypertension
1065631|NCT01725776|Cardiac surgery
1065632|NCT01725776|Cardiopulmonary Bypass (CPB)
1065633|NCT01725750|Traumatic Brain Injury
1065634|NCT01725750|TBI
1065635|NCT01725750|Fatigue
1065636|NCT01725750|Post-TBI Fatigue
1065637|NCT01725750|PTBIF
1065638|NCT01725750|Depressed Mood
1065639|NCT01725750|Excessive Daytime Sleepiness
1065640|NCT01725750|Circadian Rhythm
1065641|NCT01725750|Anxiety
1065642|NCT01725750|Cognitive Dysfunction
1065643|NCT01725750|Intervention
1065644|NCT01725750|Treatment
1065645|NCT01725737|ADHD
1065646|NCT01725737|GlyTI-M
1065647|NCT01725724|Autologous blood transfusion
1065648|NCT01725724|Allogeneic blood transfusion
1065649|NCT01725724|Infection rate
1065650|NCT01725685|healthy volunteers
1065651|NCT01725685|Umeclidinium
1065652|NCT01725685|tolerability
1065653|NCT01725685|Safety
1065654|NCT01725685|Fluticasone Furoate
1065655|NCT01725685|Pharmacokinetics
1065656|NCT01725672|healthy volunteers
1065657|NCT01725672|Diabetes mellitus
1065658|NCT01725672|glimepiride
1065659|NCT01725672|pharmacokinetics
1065660|NCT01725672|metformin
1065661|NCT01725659|Stroke
1065662|NCT01725659|electric stimulation
1065663|NCT01725659|robotics
1065664|NCT01725659|motor learning
1065665|NCT01725646|Hypertriglyceridemia, omega-3-acid ethyl ester
1065666|NCT01725633|Stretching
1065667|NCT01725633|Nonlinear Aerobic Training
1065668|NCT01725633|14-170
1065669|NCT01725607|dexmedetomidine, thoracic epidural anesthesia
1065670|NCT01725581|OSAT
1065671|NCT01725581|Pelvic Examination
1065672|NCT01725581|Validation
1065673|NCT01725581|Reliability
1065674|NCT01725542|HCV-HIV Co-Infection
1065675|NCT01725542|Quadruple therapy
1065676|NCT01725542|null responder to a standard Pegylated interferon/Ribavirin regimen
1065677|NCT01725529|Hepatitis C, Chronic
1065678|NCT01725529|TMC435
1065679|NCT01725529|Ribavirin
1065680|NCT01725529|peginterferon-alpha (PegIFNα-2a)
1065681|NCT01725503|creatine synthesis
1065682|NCT01725490|chemoprevention, metformin, familial adenomatous polyposis
1065683|NCT01725464|thoracotomy
1065684|NCT01725464|oxygen saturation
1065685|NCT01725464|postoperative
1065686|NCT01725438|Circulating Trophoblastic Cells
1065687|NCT01725438|Non-Invasive Prenatal Diagnosis
1065688|NCT01725438|Genetic analysis
1065689|NCT01725438|Trisomy 21
1065690|NCT01725438|Down's Syndrome
1065691|NCT01725425|snack food (chips)
1065692|NCT01725425|fruit (red grapes) consumed in each condition
1065693|NCT01725425|mood
1065694|NCT01725399|post-operative vomiting
1065695|NCT01725373|left main, stent,angioplasty
1065696|NCT01725360|asthma
1065697|NCT01725360|airway hyperresponsiveness
1065698|NCT01725347|nutrition assessment
1065699|NCT01725347|children
1065700|NCT01725347|preschool
1065701|NCT01725347|eating behavior
1065702|NCT01725347|Head Start
1065703|NCT01725347|digital technology
1065704|NCT01725334|Schizophrenia
1065705|NCT01725334|Negative Symptoms
1065706|NCT01725334|Treatment Resistance
1065707|NCT01725334|Deep Brain Stimulation
1065708|NCT01725334|Electrical Stimulation
1065709|NCT01725334|Mental Disorders
1065710|NCT01725334|Brain Diseases
1065711|NCT01725334|Neurologic Manifestations
1065712|NCT01725334|Signs and Symptoms
1065713|NCT01725321|Colonoscopy
1065714|NCT01725321|colonic adenoma
1065715|NCT01725321|serrated polyps
1065716|NCT01725308|FK949E
1065717|NCT01725308|Major depressive episode
1065718|NCT01725308|patients
1065719|NCT01725295|fibromyalgia treatment
1065720|NCT01725295|physical therapy
1065721|NCT01725295|hydrotherapy
1065722|NCT01725282|patients
1065723|NCT01725282|FK949E
1065724|NCT01725269|AIR001
1065725|NCT01725269|sodium nitrite
1065726|NCT01725269|PAH
1065727|NCT01725269|Pulmonary Arterial Hypertension
1065728|NCT01725269|inhaled sodium nitrite
1065729|NCT01725256|AIR001
1065730|NCT01725256|sodium nitrite
1065731|NCT01725256|PAH
1065732|NCT01725256|Pulmonary Arterial Hypertension
1065733|NCT01725256|inhaled sodium nitrite
1065734|NCT01725243|pregnancy
1065735|NCT01725243|postpartum hemorrhage
1065736|NCT01725243|Cesarean delivery
1065737|NCT01725243|carbetocin
1065738|NCT01725243|failure to progress in labor
1065739|NCT01725230|Fostamatinib,
1065740|NCT01725230|simvastatin,
1065741|NCT01725230|rosuvastatin,
1065742|NCT01725230|Phase I,
1065743|NCT01725230|Healthy Subjects,
1065744|NCT01725230|Pharmacokinetics
1065745|NCT01725217|Meningitis
1065746|NCT01725217|children
1065747|NCT01725217|adolescents
1065748|NCT01725217|adults
1065749|NCT01725217|MenACWY
1065750|NCT01725204|dasatinib
1065751|NCT01725204|Protein Kinase Inhibitors
1065752|NCT01725204|pegylated IFN-alpha 2B
1065753|NCT01725204|Interferon-alpha
1065754|NCT01725178|Mild Cognitive Impairment
1065755|NCT01725178|Dementia
1065756|NCT01725178|Memory disorders
1065757|NCT01725178|Physical fitness
1065758|NCT01725165|Lung cancer
1065759|NCT01725165|Non-Small Cell Lung Cancer
1065760|NCT01725165|NSCLC
1065761|NCT01725165|Oligometastatic Disease
1065762|NCT01725165|Chemotherapy
1065763|NCT01725165|Surgical control
1065764|NCT01725165|primary and metastatic sites of disease
1065765|NCT01725165|Radiation therapy
1065766|NCT01725165|external beam radiation
1065767|NCT01725165|2D/conventional techniques
1065768|NCT01725165|three-dimensional conformal therapy
1065769|NCT01725165|intensity modulated radiation therapy
1065770|NCT01725165|IMRT
1065771|NCT01725165|stereotactic radiosurgery
1065772|NCT01725165|SRS
1065773|NCT01725165|proton beam therapy
1065774|NCT01725165|PBT
1065775|NCT01725152|fragile x syndrome
1065776|NCT01725152|ganaxolone
1065777|NCT01725152|anxiety
1065778|NCT01725152|attention
1065779|NCT01725152|pediatric
1065780|NCT01725126|metformin
1065781|NCT01725126|diabetes
1065782|NCT01725126|obesity
1065783|NCT01725126|liraglutide
1065784|NCT01725100|MEK inhibitor
1065785|NCT01725100|GSK1120212
1065786|NCT01725100|trametinib
1065787|NCT01725100|solid tumors
1065788|NCT01725100|dissolution
1065789|NCT01725100|DMSO content
1065790|NCT01725100|relative bioavailability
1065791|NCT01725100|pharmacokinetics
1065792|NCT01725074|Coronary Heart Disease, multimorbidity, primary care, case management, loneliness, depression, social support
1065793|NCT01725048|Major depressive disorder
1065794|NCT01725048|Neoplasms
1065795|NCT01725035|De Novo Lipogenesis
1065796|NCT01725035|Fatty Liver
1065797|NCT01725035|Hepatic Steatosis
1065798|NCT01725035|Gene variants
1065799|NCT01725022|stem cell transplant
1065800|NCT01725022|bowel microbiota
1065801|NCT01725022|home care
1065802|NCT01725009|Healthy volunteers
1065803|NCT01725009|Japanese
1065804|NCT01725009|Caucasian
1065805|NCT01724983|pain
1065806|NCT01724983|mood
1065807|NCT01724983|depression
1065808|NCT01724983|respiration
1065809|NCT01724970|anesthesia
1065810|NCT01724970|postanesthetic recovery
1065811|NCT01724970|ventilation
1065812|NCT01724970|bariatric surgery
1065813|NCT01724957|Fractional flow reserve,
1065814|NCT01724957|coronary bifurcation stenosis,
1065815|NCT01724957|intracoronary ECG,
1065816|NCT01724957|coronary stent
1065817|NCT01724957|Coronary bifurcation lesions
1065818|NCT01724957|icECG
1065819|NCT01724944|Interval debulking surgery
1065820|NCT01724944|IDS
1065821|NCT01724944|NACT
1065822|NCT01724944|Neoadjuvant chemotherapy
1065823|NCT01724944|Lymphadenectomy
1065824|NCT01724944|Ovarian cancer
1065825|NCT01724931|antifolate
1065826|NCT01724931|antiinflammatory
1065827|NCT01724931|autoimmune disease
1065828|NCT01724931|hematological treatment
1065829|NCT01724931|rheumatic disease
1065830|NCT01724931|folic acid antagonist
1065831|NCT01724931|enzyme inhibitor
1065832|NCT01724918|IV lacosamide
1065833|NCT01724918|focal epilepsy
1065834|NCT01724918|EEG
1065835|NCT01724918|EKG
1065836|NCT01724905|Diet
1065837|NCT01724905|Obesity
1065838|NCT01724905|Chronic disease
1065839|NCT01724879|philadelphia chromosome
1065840|NCT01724879|BCR-ABL
1065841|NCT01724879|ALL
1065842|NCT01724879|acute lymphoblastic leukemia
1065843|NCT01724879|dasatinib
1065844|NCT01724879|Sprycel
1065845|NCT01724853|Carpometacarpal
1065846|NCT01724853|osteoarthritis
1065847|NCT01724853|outcome measures
1065848|NCT01724827|Dental caries
1065849|NCT01724827|inlays
1065850|NCT01724827|composite resins
1065851|NCT01724827|IPS-Empress ceramic
1065852|NCT01724827|bicuspid
1065853|NCT01724827|FDI dental restorations evaluation criteria
1065854|NCT01724801|EGFR mutant
1065855|NCT01724775|complete mesocolic excision
1065856|NCT01724775|colon cancer
1065857|NCT01724775|efficacy
1065858|NCT01724775|safety
1065859|NCT01724762|Baths
1065860|NCT01724762|Anxiety
1065861|NCT01724762|Acute Coronary Syndrome
1065862|NCT01724762|Education, Nursing
1065863|NCT01724749|Atherosclerosis
1065864|NCT01724749|Sodium-Fluoride
1065865|NCT01724749|18F-Sodium Fluoride
1065866|NCT01724749|18F-NaF
1065867|NCT01724749|fluorodeoxyglucose
1065868|NCT01724749|18F-FDG
1065869|NCT01724749|FDG
1065870|NCT01724749|Positron emission tomography
1065871|NCT01724749|PET
1065872|NCT01724736|microbiome
1065873|NCT01724736|prebiotic
1065874|NCT01724736|cobiotic
1065875|NCT01724736|NM504
1065876|NCT01724736|GI microbiome
1065877|NCT01724723|hepatitis during anti-tuberculous treatment
1065878|NCT01724723|tuberculosis
1065879|NCT01724723|hepatitis B virus
1065880|NCT01724723|viral load
1065881|NCT01724723|entecavir
1065882|NCT01724697|liver cirrhosis
1065883|NCT01724697|end stage liver disease
1065884|NCT01724697|HBV
1065885|NCT01724697|autologous
1065886|NCT01724697|stem cell
1065887|NCT01724697|bone morrow
1065888|NCT01724671|MRSA
1065889|NCT01724671|Bacteremia
1065890|NCT01724671|ABSSSI
1065891|NCT01724671|Pneumonia
1065892|NCT01724671|Vancomycin
1065893|NCT01724671|Ceftaroline
1065894|NCT01724658|female sexual function
1065895|NCT01724658|postmenopause
1065896|NCT01724658|testosterone
1065897|NCT01724645|Korean Traditional diets
1065898|NCT01724645|hypertension
1065899|NCT01724645|diabetes
1065900|NCT01724632|Overweight
1065901|NCT01724632|Obesity
1065902|NCT01724632|Weight Loss
1065903|NCT01724606|Whole Brain Radiotherapy (WBRT)
1065904|NCT01724606|Sorafenib (BAY 43-9006)
1065905|NCT01724606|12-046
1065906|NCT01724593|functional recovery, critical illness, pediatrics
1065907|NCT01724567|Interval Training
1065908|NCT01724567|Weight Loss
1065909|NCT01724567|Secondary Prevention
1065910|NCT01724567|Rehabilitation
1065911|NCT01724567|Cardiovascular Risk Factors
1065912|NCT01724528|Febuxostat, Tumor lysis syndrome, leukemia, lymphoma
1065913|NCT01724515|insulin resistance
1065914|NCT01724502|insulin resistance
1065915|NCT01724463|Systemic Inflammatory Response Syndrome (SIRS)
1065916|NCT01724463|Sepsis
1065917|NCT01724463|Severe Sepsis
1065918|NCT01724463|Septic Shock
1065919|NCT01724463|Electronic Health Record
1065920|NCT01724463|Health Screening
1065921|NCT01724463|Goal Directed Therapy
1065922|NCT01724463|Infant
1065923|NCT01724463|Child
1065924|NCT01724463|Pediatric
1065925|NCT01724463|Adolescent
1065926|NCT01724463|Critical Illness
1065927|NCT01724463|Outcomes Research
1065928|NCT01724463|Resource Utilization
1065929|NCT01724450|Breast Cancer
1065930|NCT01724450|Heart Failure
1065931|NCT01724450|Cardiotoxicity
1065932|NCT01724450|Biomarkers
1065933|NCT01724411|Overweight and Obesity
1065934|NCT01724411|Appetite
1065935|NCT01724411|Gut hormones and obesity
1065936|NCT01724411|Resistant Starch
1065937|NCT01724411|Gut microbiota and obesity
1065938|NCT01724411|SmartPill
1065939|NCT01724398|mesenchymal stem cells
1065940|NCT01724398|plasma exchange
1065941|NCT01724398|liver failure
1065942|NCT01724398|hepatitis B virus
1065943|NCT01724385|bevacizumab,
1065944|NCT01724385|proliferative diabetic retinopathy,
1065945|NCT01724385|vitreous hemorrhage,
1065946|NCT01724359|Schizophrenia
1065947|NCT01724359|Paliperidone extended-release (ER)
1065948|NCT01724359|Antipsychotic agents
1065949|NCT01724346|CLL, SLL
1065950|NCT01724333|EORTC QLQ-C30
1065951|NCT01724333|Oral health
1065952|NCT01724333|Quality of life
1065953|NCT01724333|Questionnaires
1065954|NCT01724333|Patient reported
1065955|NCT01724333|outcomes
1065956|NCT01724320|solid tumors
1065957|NCT01724320|first-in-man
1065958|NCT01724320|phase I
1065959|NCT01724320|cancer
1065960|NCT01724320|galectin
1065961|NCT01724281|lateral ventricles
1065962|NCT01724281|Asymetry
1065963|NCT01724255|Caesarian section
1065964|NCT01724255|Surgical Wound
1065965|NCT01724242|Vaginal dryness
1065966|NCT01724242|Breast Cancer
1065967|NCT01724242|Urinary Incontinence
1065968|NCT01724242|Quality of Life
1065969|NCT01724242|Sexual Satisfaction
1065970|NCT01724229|Incontinence-associated dermatitis
1065971|NCT01724229|Skin care regimen for moisture-associated conditions
1065972|NCT01724229|Perineal skin care
1065973|NCT01724229|Fungal infection in perineal area
1065974|NCT01724203|Probiotics for infants
1065975|NCT01724203|Bacterial and viral infections in infants
1065976|NCT01724190|Type 1 Diabetes
1065977|NCT01724190|Vitamin D
1065978|NCT01724190|Clinical Remission
1065979|NCT01724177|Lenalidomide
1065980|NCT01724177|ATL
1065981|NCT01724177|ATLL
1065982|NCT01724138|deferasirox
1065983|NCT01724125|serious mental illness
1065984|NCT01724099|Obesity
1065985|NCT01724099|Herbal product
1065986|NCT01724099|Korean Medicine
1065987|NCT01724086|Chronic hepatitis C
1065988|NCT01724086|Chronic hepatitis C-infected patients
1065989|NCT01724086|TMC647055
1065990|NCT01724086|TMC435
1065991|NCT01724086|Ritonavir
1065992|NCT01724086|Ribavirin
1065993|NCT01724086|Genotype 1a
1065994|NCT01724086|Genotype 1b
1065995|NCT01724086|GSK2336805
1065996|NCT01724073|food to food fortification strategy
1065997|NCT01724073|leafy vegetable
1065998|NCT01724073|iron
1065999|NCT01724073|zinc
1066000|NCT01724073|vitamin A
1066001|NCT01724073|growth
1066002|NCT01724047|Autism
1066003|NCT01724047|School Based Intervention
1066004|NCT01724034|Weaning
1066005|NCT01724034|Mechanical Ventilation
1066006|NCT01724034|Lung Ultrasound
1066007|NCT01723995|nipple/injure
1066008|NCT01723995|breastfeeding
1066009|NCT01723995|pain
1066010|NCT01723995|laser
1066011|NCT01723956|Cervical Dysplasia
1066012|NCT01723956|Cin 2
1066013|NCT01723956|Cin 3
1066014|NCT01723956|HIV positive women
1066015|NCT01723956|South Africa
1066016|NCT01723904|Rotigotine
1066017|NCT01723904|Neupro
1066018|NCT01723865|Heart failure
1066019|NCT01723865|Remote Monitoring
1066020|NCT01723865|ICD
1066021|NCT01723865|Follow-up
1066022|NCT01723852|Vitamin D
1066023|NCT01723852|Infectious diseases
1066024|NCT01723852|cognitive development
1066025|NCT01723852|Bone mineral density
1066026|NCT01723852|Immunoregulation
1066027|NCT01723852|Allergy
1066028|NCT01723852|Growth
1066029|NCT01723839|CLL
1066030|NCT01723839|FCR
1066031|NCT01723839|Rituximab
1066032|NCT01723839|Lenalidomide
1066033|NCT01723839|Cyclophosphamide
1066034|NCT01723813|Immunotherapy
1066035|NCT01723813|Tumor-specific peptides
1066036|NCT01723813|GM-CT-01
1066037|NCT01723761|air pollution
1066038|NCT01723761|pacemaker
1066039|NCT01723761|ICD
1066040|NCT01723761|remote monitoring
1066041|NCT01723761|supraventricular arrhythmias
1066042|NCT01723761|ventricular arrhythmias
1066043|NCT01723748|Acromegaly
1066044|NCT01723748|Somatostatin treatment
1066045|NCT01723748|metabolic effect
1066046|NCT01723722|Neonatal Abstinence Syndrome
1066047|NCT01723722|Methadone
1066048|NCT01723722|Diluted Deodorized Tincture of Opium
1066049|NCT01723722|dDTO
1066050|NCT01723722|Phenobarbital
1066051|NCT01723709|multiple sclerosis
1066052|NCT01723709|immune response
1066053|NCT01723709|genetic
1066054|NCT01723709|progression
1066055|NCT01723709|relapse
1066056|NCT01723709|biomarkers
1066057|NCT01723709|disease
1066058|NCT01723709|proteomics
1066059|NCT01723709|genome
1066060|NCT01723709|gene
1066061|NCT01723696|In-utero smoke;
1066062|NCT01723696|Pulmonary function testing;
1066063|NCT01723696|Wheeze;
1066064|NCT01723696|Vitamin C;
1066065|NCT01723696|Forced expiratory flows
1066066|NCT01723683|Preterm infants
1066067|NCT01723683|RDS
1066068|NCT01723683|Surfactant
1066069|NCT01723683|MISTCPAP
1066070|NCT01723683|CPAP
1066071|NCT01723657|Leukemia
1066072|NCT01723657|Myeloid
1066073|NCT01723657|Acute
1066074|NCT01723657|Young
1066075|NCT01723657|CETLAM
1066076|NCT01723644|antibiotherapy, community acquired pneumonia, procalcitonin guided guidelines, clinical reassessment
1066077|NCT01723631|Multiple sclerosis
1066078|NCT01723631|TRAP
1066079|NCT01723631|TRAP-Myéline
1066080|NCT01723605|insitu repair
1066081|NCT01723605|intestinal motility
1066082|NCT01723592|chemotherapy
1066083|NCT01723592|vaginal flora
1066084|NCT01723553|aphasia
1066085|NCT01723553|logopenic
1066086|NCT01723553|PCA
1066087|NCT01723553|LPA
1066088|NCT01723540|Cholecystectomy,minilaparotomy,laparascopy,ultrasonic dissection
1066089|NCT01723527|Cocaine
1066090|NCT01723527|Heroin
1066091|NCT01723527|HIV
1066092|NCT01723527|Contingency Management
1066093|NCT01723527|Incentives
1066094|NCT01723527|Criminal Justice
1066095|NCT01723527|Methadone
1066096|NCT01723527|Buprenorphine
1066097|NCT01723527|Employment
1066098|NCT01723527|Job Training
1066099|NCT01723527|Wage Subsidies
1066100|NCT01723514|Migraine
1066101|NCT01723501|chlorhexidine
1066102|NCT01723501|sepsis
1066103|NCT01723501|neonatal
1066104|NCT01723501|whole-body skin cleansing
1066105|NCT01723488|AD
1066106|NCT01723475|Phase I
1066107|NCT01723475|Dose Escalation
1066108|NCT01723475|Prostate cancer
1066109|NCT01723475|Antibodies
1066110|NCT01723475|Bispecific T-cell Engager (BiTE)
1066111|NCT01723436|Decision fatigue
1066112|NCT01723423|breast cancer
1066113|NCT01723423|evidence based medicine
1066114|NCT01723423|reconstruction
1066115|NCT01723423|mastectomy
1066116|NCT01723423|outcomes
1066117|NCT01723423|quality of life
1066118|NCT01723384|methamphetamine
1066119|NCT01723384|alcohol
1066120|NCT01723384|HIV
1066121|NCT01723384|sexual behavior
1066122|NCT01723371|Pulmonary Arterial Hypertension (PAH
1066123|NCT01723371|Pediatrics
1066124|NCT01723371|Right Heart Failure (RHF)
1066125|NCT01723371|Carvedilol
1066126|NCT01723371|Beta-blockers
1066127|NCT01723358|pediatrics
1066128|NCT01723358|dysphagia
1066129|NCT01723345|elective percutaneous coronary intervention
1066130|NCT01723345|omega 3 polyunsaturated fatty acids (PUFAs)
1066131|NCT01723345|short-term MACE
1066132|NCT01723345|long-term MACE
1066133|NCT01723332|Transition from pediatric to adult clinical care
1066134|NCT01723319|ADHD
1066135|NCT01723319|TMS
1066136|NCT01723319|brain stimulation
1066137|NCT01723319|clinical improvement
1066138|NCT01723306|T cells
1066139|NCT01723306|gene transfer
1066140|NCT01723306|immunotherapy
1066141|NCT01723306|metastatic cancers
1066142|NCT01723306|lung cancer
1066143|NCT01723306|gastric cancer
1066144|NCT01723306|colorectal cancer
1066145|NCT01723306|solid tumors
1066146|NCT01723293|Fetal heart rate, pregnancy, fetus, cardiovascular system
1066147|NCT01723267|IVF
1066148|NCT01723267|3D ultrasound
1066149|NCT01723267|SonoAVC
1066150|NCT01723267|patients in IVF treatment
1066151|NCT01723254|Vaccines
1066152|NCT01723254|Phase 1
1066153|NCT01723254|Allergic Rhinitis
1066154|NCT01723241|volunteers
1066155|NCT01723228|Parkinson's Disease
1066156|NCT01723228|Cognition
1066157|NCT01723228|Rasagiline
1066158|NCT01723215|Attention bias modification
1066159|NCT01723215|resilience
1066160|NCT01723215|combat
1066161|NCT01723215|PTSD
1066162|NCT01723215|Depression
1066163|NCT01723215|Anxiety
1066164|NCT01723202|BRAF
1066165|NCT01723202|BRAFi
1066166|NCT01723202|thyroid cancer
1066167|NCT01723202|thyroid carcinoma
1066168|NCT01723189|central apnoeas
1066169|NCT01723189|stroke
1066170|NCT01723176|goal-directed echocardiography
1066171|NCT01723176|cardiopulmonary failure
1066172|NCT01723176|critical care ultrasound
1066173|NCT01723163|veteran
1066174|NCT01723163|smoking cessation
1066175|NCT01723150|Klebsiella pneumoniae
1066176|NCT01723137|Pain
1066177|NCT01723137|Pain measurement
1066178|NCT01723137|Visual analog scale
1066179|NCT01723137|Anxiety
1066180|NCT01723137|Stress
1066181|NCT01723137|Opioid
1066182|NCT01723137|Emergency department
1066183|NCT01723137|Demographics
1066184|NCT01723124|Dense breast tissue
1066185|NCT01723124|breast cancer screening
1066186|NCT01723124|molecular breast imaging
1066187|NCT01723124|breast cancer
1066188|NCT01723124|breast
1066189|NCT01723111|hepcidin
1066190|NCT01723111|ESA
1066191|NCT01723111|hemodialysis
1066192|NCT01723111|peritoneal dialysis
1066193|NCT01723111|iron metabolism
1066194|NCT01723111|dialysis modality
1066195|NCT01723098|Pregnancy, cardiovascular system, physical exercise
1066196|NCT01723085|Anti-Mullerian hormone
1066197|NCT01723085|Myomectomy
1066198|NCT01723085|Laparotomy
1066199|NCT01723072|Chronic spontanous urticaria, refractory CSU, Angioedema
1066200|NCT01723046|Upper extremity
1066201|NCT01723046|Rehabilitation
1066202|NCT01723046|Robot assisted therapy
1066203|NCT01723046|Robotics
1066204|NCT01723046|Devices
1066205|NCT01723046|Orthosis
1066206|NCT01723046|clinical outcome
1066207|NCT01723033|PTSD
1066208|NCT01723033|OCD
1066209|NCT01723020|Solid Tumors
1066210|NCT01723020|Multiple Myeloma
1066211|NCT01723007|Weight loss
1066212|NCT01723007|cholesterol
1066213|NCT01722968|Metastatic breast cancer
1066214|NCT01722955|Prewarmed fluid
1066215|NCT01722955|monitored anesthesia care
1066216|NCT01722955|core body temperature
1066217|NCT01722955|anesthetic satisfaction
1066218|NCT01722942|Chagas cardiomyopathy
1066219|NCT01722942|sudden cardiac death
1066220|NCT01722942|primary prevention of death
1066221|NCT01722942|amiodarone
1066222|NCT01722942|implantable cardioverter defibrillator
1066223|NCT01722903|colorectal cancer
1066224|NCT01722903|liver metastases
1066225|NCT01722903|lung metastases
1066226|NCT01722890|HER2-positive breast cancer
1066227|NCT01722890|durable complete response
1066228|NCT01722890|cytogenetic characteristics
1066229|NCT01722890|molecular characteristics
1066230|NCT01722890|trastuzumab
1066231|NCT01722877|Restenosis
1066232|NCT01722877|aspiration
1066233|NCT01722877|in-stent restenosis
1066234|NCT01722877|atherectomy
1066235|NCT01722877|superficial femoral artery
1066236|NCT01722877|popliteal artery
1066237|NCT01722851|Breast Cancer
1066238|NCT01722851|miRNAs
1066239|NCT01722851|Newly diagnosed
1066240|NCT01722851|Recurrent
1066241|NCT01722838|Black MSM
1066242|NCT01722838|HIV Prevention
1066243|NCT01722799|angioplasty
1066244|NCT01722799|Percutaneous Transluminal Coronary Angioplasty
1066245|NCT01722799|Drug elluting Balloon
1066246|NCT01722799|Coronary Balloon
1066247|NCT01722799|Dilatation
1066248|NCT01722786|severe bleeding
1066249|NCT01722786|dabigatran
1066250|NCT01722786|rivaroxaban
1066251|NCT01722786|apixaban
1066252|NCT01722786|edoxaban
1066253|NCT01722786|PCC
1066254|NCT01722786|aPCC
1066255|NCT01722786|rVIIa
1066256|NCT01722786|hemodialysis
1066257|NCT01722786|antidots
1066258|NCT01722786|idarucizumab
1066259|NCT01722773|COPD
1066260|NCT01722760|Neonatal
1066261|NCT01722760|Preterm
1066262|NCT01722760|Bronchopulmonary Dysplasia
1066263|NCT01722760|Nasal Continuous Positive airway Pressure (CPAP)
1066264|NCT01722760|Oxygen
1066265|NCT01722760|Vitamin A
1066266|NCT01722760|Vitamin D
1066267|NCT01722760|Nitrogen oxide (NO)
1066268|NCT01722760|Reference material
1066269|NCT01722734|Malaria
1066270|NCT01722734|ACTs
1066271|NCT01722708|Abnormal vaginal flora
1066272|NCT01722708|clindamycin Vs metronidazole
1066273|NCT01722708|High risk pregnancies for preterm labor
1066274|NCT01722708|Preterm labor
1066275|NCT01722708|Late abortion
1066276|NCT01722708|bacterial vaginosis
1066277|NCT01722682|Diabetes
1066278|NCT01722669|quercetin
1066279|NCT01722669|isoquercetin
1066280|NCT01722669|pharmacokinetic
1066281|NCT01722669|pharmacodynamic
1066282|NCT01722656|PED
1066283|NCT01722656|AMD
1066284|NCT01722656|CNV
1066285|NCT01722630|dopamine
1066286|NCT01722630|laparoscopy
1066287|NCT01722630|fluid management
1066288|NCT01722578|Cirrhosis
1066289|NCT01722578|Encephalopathy
1066290|NCT01722578|L-ornithine L-aspartate
1066291|NCT01722565|Parastomal hernias
1066292|NCT01722565|Tolerance of lightweight meshes
1066293|NCT01722565|laparoscopic abdominoperineal resection
1066294|NCT01722552|HIV
1066295|NCT01722552|AIDS
1066296|NCT01722552|antiretroviral therapy
1066297|NCT01722552|adherence
1066298|NCT01722552|China
1066299|NCT01722539|intermittent
1066300|NCT01722539|preventive
1066301|NCT01722539|treatment
1066302|NCT01722539|malaria
1066303|NCT01722539|soil transmitted helminths
1066304|NCT01722539|schistosomiasis
1066305|NCT01722539|schoolchildren
1066306|NCT01722526|Human acid sphingomyelinase deficiency
1066307|NCT01722513|Contrast Induced Nephropathy
1066308|NCT01722500|International
1066309|NCT01722500|Childhood
1066310|NCT01722500|Obesity
1066311|NCT01722500|ISCOLE
1066312|NCT01722500|Pennington Biomedical Research Center
1066313|NCT01722500|PBRC
1066314|NCT01722500|longitudinal
1066315|NCT01722500|multinational
1066316|NCT01722487|CLL, SLL
1066317|NCT01722474|Pulse Wave Analysis
1066318|NCT01722474|Arterial Stiffness
1066319|NCT01722461|Excessive underarm sweating
1066320|NCT01722448|muscle
1066321|NCT01722448|muscle dysfunction
1066322|NCT01722448|choline
1066323|NCT01722448|exercise
1066324|NCT01722448|exertional rhabdomyolysis
1066325|NCT01722448|rhabdomyolysis
1066326|NCT01722435|opioid dependence
1066327|NCT01722435|opiate substitution treatment
1066328|NCT01722435|methadone
1066329|NCT01722435|completion
1066330|NCT01722435|termination
1066331|NCT01722422|sepsis
1066332|NCT01722422|shock
1066333|NCT01722422|hyperoxia
1066334|NCT01722422|hypertonic saline
1066335|NCT01722409|dexmedetomidine, endovascular coil embolization
1066336|NCT01722357|bariatric surgery
1066337|NCT01722357|physical activity
1066338|NCT01722357|morbid obesity
1066339|NCT01722344|Severe mental illness
1066340|NCT01722344|Vocational rehabilitation
1066341|NCT01722344|Supported employment
1066342|NCT01722344|Individual placement and support
1066343|NCT01722344|Cognitive remediation
1066344|NCT01722344|Social skill training
1066345|NCT01722279|bariatric surgery
1066346|NCT01722279|long-term outcomes
1066347|NCT01722279|obesity
1066348|NCT01722266|Liraglutide
1066349|NCT01722266|Glucagon
1066350|NCT01722266|Systolic blood pressure
1066351|NCT01722266|Weight
1066352|NCT01722266|Carbohydrate intake
1066353|NCT01722266|Insulin dose
1066354|NCT01722266|HbA1c
1066355|NCT01722266|Post-prandial glucagon
1066356|NCT01722253|electroacupuncture
1066357|NCT01722253|acupuncture
1066358|NCT01722253|pain management
1066359|NCT01722214|Psoriasis
1066360|NCT01722214|Vascular Inflammation
1066361|NCT01722214|Coronary Atherosclerosis
1066362|NCT01722214|Ascending aorta
1066363|NCT01722214|Pet scan
1066364|NCT01722214|MRI
1066365|NCT01722188|Optim
1066366|NCT01722188|Insulation
1066367|NCT01722149|malignant pleural mesothelioma
1066368|NCT01722149|re-directed T cells
1066369|NCT01722149|FAP
1066370|NCT01722149|fibroblast activation protein
1066371|NCT01722149|CD8 positive T cells
1066372|NCT01722149|pleural effusion
1066373|NCT01722123|Decision fatigue
1066374|NCT01722071|Oxytocin
1066375|NCT01722071|Functional Magnetic Resonance Imaging
1066376|NCT01722071|Social
1066377|NCT01722071|Motivation
1066378|NCT01722058|peptide
1066379|NCT01722058|colon
1066380|NCT01722058|flat lesions
1066381|NCT01722045|AMD
1066382|NCT01722032|childhood obesity, early childhood, nutrition
1066383|NCT01722019|venous insufficiency
1066384|NCT01722006|methamphetamine
1066385|NCT01722006|subjective
1066386|NCT01722006|conditioning
1066387|NCT01722006|preference
1066388|NCT01721993|oral zoledronic acid
1066389|NCT01721967|chest pain
1066390|NCT01721967|dyspnea
1066391|NCT01721954|colon
1066392|NCT01721954|rectum
1066393|NCT01721954|metastatic colorectal cancer
1066394|NCT01721954|liver metastases
1066395|NCT01721941|hepatocellular carcinoma
1066396|NCT01721941|HCC
1066397|NCT01721941|liver cancer
1066398|NCT01721941|hepatoma
1066399|NCT01721941|TACE
1066400|NCT01721941|transarterial chemoembolization
1066401|NCT01721941|TH302
1066402|NCT01721928|Acute kidney injury
1066403|NCT01721928|Deep venous thrombosis
1066404|NCT01721928|Dialysis
1066405|NCT01721928|Prophylaxis
1066406|NCT01721915|Polycystic Ovary Syndrome (PCOS)
1066407|NCT01721915|glucose metabolism
1066408|NCT01721915|Vitamin D deficiency
1066409|NCT01721915|vitamin D supplementation
1066410|NCT01721915|pharmakogenetics
1066411|NCT01721915|women
1066412|NCT01721863|Atrial Fibrillation
1066413|NCT01721863|Exercise Training
1066414|NCT01721863|Endothelial Function
1066415|NCT01721863|Autonomic Nerve Modulation
1066416|NCT01721863|Exercise Capacity
1066417|NCT01721863|Quality of Life
1066418|NCT01721850|infant nutrition, infantile colic
1066419|NCT01721824|Supported employment
1066420|NCT01721824|Individual Placement and Support
1066421|NCT01721824|Workability
1066422|NCT01721824|Return to work
1066423|NCT01721798|AE adverse event
1066424|NCT01721798|AIDS acquired immunodeficiency syndrome
1066425|NCT01721798|ALT (SGPT) alanine aminotransferase
1066426|NCT01721798|ART antiretroviral therapy
1066427|NCT01721798|AST (SGOT) aspartate aminotransferase
1066428|NCT01721798|DCF data collection forms
1066429|NCT01721798|DMC Data Monitoring Committee
1066430|NCT01721798|FDA (U.S.) Food and Drug Administration
1066431|NCT01721798|GCP Good Clinical Practice guidelines
1066432|NCT01721798|HB sAg Hepatitis B surface antigen
1066433|NCT01721798|ICH International Conference of Harmonization
1066434|NCT01721798|IND Investigational New Drug Application
1066435|NCT01721798|IRB Institutional Review Board
1066436|NCT01721798|IU International units
1066437|NCT01721798|mg milligram(s)
1066438|NCT01721798|mm3 cubic millimeter(s)
1066439|NCT01721798|PCR polymerase chain reaction
1066440|NCT01721798|SAE serious adverse event
1066441|NCT01721798|µg microgram
1066442|NCT01721798|ULN upper limit of the normal range
1066443|NCT01721798|WB Western Blot
1066444|NCT01721785|Nodal imaging
1066445|NCT01721785|Restaging
1066446|NCT01721733|EPI743
1066447|NCT01721733|Leigh syndrome
1066448|NCT01721733|respiratory chain disease
1066449|NCT01721733|mitochondrial disorders
1066450|NCT01721720|Attention Deficit Hyperactivity Disorder
1066451|NCT01721720|Behavioral Phenotype
1066452|NCT01721720|Brain Development
1066453|NCT01721720|Complex Disease
1066454|NCT01721720|Social Networks
1066455|NCT01721707|glaucoma
1066456|NCT01721707|ocular hypertension
1066457|NCT01721707|latanoprost
1066458|NCT01721707|brinzolamide
1066459|NCT01721694|bacterial ocular inflammation
1066460|NCT01721694|blepharitis
1066461|NCT01721694|keratitis
1066462|NCT01721694|conjunctivitis
1066463|NCT01721655|Spironolactone
1066464|NCT01721655|Preterm Infants
1066465|NCT01721655|Chronic Lung Disease
1066466|NCT01721655|Bronchopulmonary Dysplasia
1066467|NCT01721655|Electrolyte Supplementation
1066468|NCT01721642|access
1066469|NCT01721642|closure
1066470|NCT01721642|trans-apical
1066471|NCT01721642|trans-catheter aortic valve implantation
1066472|NCT01721642|TAVI
1066473|NCT01721642|trans-catheter aortic valve repair
1066474|NCT01721642|TAVR
1066475|NCT01721629|Nasal cpap weaning
1066476|NCT01721629|Premature infants
1066477|NCT01721629|Respiratory distress syndrome
1066478|NCT01721629|Randomized controlled trial
1066479|NCT01721603|BRAFV600E melanoma patients
1066480|NCT01721603|melanoma
1066481|NCT01721603|stereotactic radiosurgery
1066482|NCT01721603|BRAFV600E melanoma brain metastases
1066483|NCT01721603|dabrafenib
1066484|NCT01721603|SRS
1066485|NCT01721590|high on-treatment platelet reactivity
1066486|NCT01721590|Coronary Heart Disease
1066487|NCT01721590|Tongxinluo
1066488|NCT01721577|glioblastoma
1066489|NCT01721577|gliosarcoma
1066490|NCT01721577|anaplastic astrocytoma
1066491|NCT01721577|anaplastic oligodendroglioma
1066492|NCT01721577|anaplastic oligoastrocytoma
1066493|NCT01721577|AXL1717
1066494|NCT01721577|IGF-1 receptor inhibitor
1066495|NCT01721577|picropodophyllin
1066496|NCT01721551|Dialysis fatigue,
1066497|NCT01721551|exercise intolerance,
1066498|NCT01721551|muscle atrophy,
1066499|NCT01721551|cachexia,
1066500|NCT01721551|disability,
1066501|NCT01721551|Sleep disorders
1066502|NCT01721551|Depression
1066503|NCT01721551|Mental Fatigue,
1066504|NCT01721551|Cognitive function
1066505|NCT01721551|Physical Fatigue
1066506|NCT01721538|stroke
1066507|NCT01721538|prevention
1066508|NCT01721538|obesity
1066509|NCT01721538|weight reduction
1066510|NCT01721525|BIBW2992 (AFATINIB)
1066511|NCT01721525|CARBOPLATIN
1066512|NCT01721525|RIBAVIRIN-ICN (VIRAZOLE)
1066513|NCT01721525|TAXOL (PACLITAXEL)
1066514|NCT01721525|OROPHARYNX
1066515|NCT01721525|HPV associated
1066516|NCT01721525|12-150
1066517|NCT01721512|Prospective observational study
1066518|NCT01721512|Breast feeding
1066519|NCT01721512|Infant formula
1066520|NCT01721512|Infant
1066521|NCT01721512|Indonesia
1066522|NCT01721499|Stress
1066523|NCT01721499|obesity
1066524|NCT01721499|overeating
1066525|NCT01721486|tonsillitis
1066526|NCT01721486|recurrent tonsillitis
1066527|NCT01721486|obstructed air passages
1066528|NCT01721486|swallowing difficulties
1066529|NCT01721473|Tobacco
1066530|NCT01721473|Positron Emission Tomography
1066531|NCT01721473|Marijuana
1066532|NCT01721473|Caffeine
1066533|NCT01721473|Menthol
1066534|NCT01721460|SubThalamic Nucleus
1066535|NCT01721460|Microelectrode recording
1066536|NCT01721460|Deep Brain Stimulation Electrode implantation
1066537|NCT01721447|Atrial fibrillation
1066538|NCT01721447|stroke
1066539|NCT01721447|TEE
1066540|NCT01721447|Left atrial thrombus
1066541|NCT01721434|levosimendan
1066542|NCT01721434|diaphragm function
1066543|NCT01721434|mechanically ventilated patients
1066544|NCT01721434|neuro-mechanical efficiency
1066545|NCT01721421|haemodialysis
1066546|NCT01721421|Crossover
1066547|NCT01721421|Treatment time
1066548|NCT01721421|nutritional status
1066549|NCT01721395|Cough
1066550|NCT01721395|Nocturnal Cough
1066551|NCT01721395|Agave
1066552|NCT01721395|Sleep Quality
1066553|NCT01721395|Childhood cough
1066554|NCT01721382|cystic fibrosis
1066555|NCT01721382|CF
1066556|NCT01721382|CFRD
1066557|NCT01721382|sitagliptin
1066558|NCT01721382|incretins
1066559|NCT01721382|GLP1
1066560|NCT01721382|GIP
1066561|NCT01721382|beta cell function
1066562|NCT01721382|adolescents
1066563|NCT01721330|ADHD
1066564|NCT01721330|Attention Deficit Hyperactivity Disorder
1066565|NCT01721330|Psychopharmacology
1066566|NCT01721330|Psychiatry
1066567|NCT01721330|Non-stimulant treatment
1066568|NCT01721317|Ezogabine/Retigabine
1066569|NCT01721317|Adjunctive Treatment
1066570|NCT01721317|Safety
1066571|NCT01721317|Efficacy
1066572|NCT01721317|Epilepsy
1066573|NCT01721317|Tolerability
1066574|NCT01721317|Immediate Release
1066575|NCT01721317|GW582892
1066576|NCT01721317|Dose-Optimization
1066577|NCT01721317|Partial-Onset Seizures
1066578|NCT01721304|decision making
1066579|NCT01721304|abnormal uterine bleeding
1066580|NCT01721304|adaptive conjoint analysis
1066581|NCT01721304|satisfaction
1066582|NCT01721304|regret
1066583|NCT01721291|CHRONIC OBSTRUCTIVE PULMONARY DISEASE
1066584|NCT01721291|ASTHMA
1066585|NCT01721291|SALBUTAMOL
1066586|NCT01721291|ALBUTEROL
1066587|NCT01721291|VENTOLIN
1066588|NCT01721291|LUNG PHYSIOLOGY
1066589|NCT01721291|LUNG DEPOSITION
1066590|NCT01721291|INHALERS
1066591|NCT01721291|DRUG THERAPY
1066592|NCT01721265|HCV
1066593|NCT01721265|Hepatitis C
1066594|NCT01721265|IDX184
1066595|NCT01721265|IDX719
1066596|NCT01721252|non-small cell lung cancer
1066597|NCT01721252|Erlotinib
1066598|NCT01721252|TarcevaTM
1066599|NCT01721252|proteomic signature
1066600|NCT01721239|ICU
1066601|NCT01721239|Follow-up consultations
1066602|NCT01721239|Quality of life
1066603|NCT01721239|Sense Of Coherence
1066604|NCT01721239|RCT multicenter study
1066605|NCT01721226|Linkage to HIV care following release from prison
1066606|NCT01721226|Anti-retroviral therapy adherence after release from prison
1066607|NCT01721226|HIV loads after release from prison
1066608|NCT01721226|information technology and ART adherence
1066609|NCT01721226|information technology and linkage to HIV care
1066610|NCT01721213|Epilepsy
1066611|NCT01721213|survey
1066612|NCT01721213|retigabine
1066613|NCT01721213|patient information leaflet
1066614|NCT01721213|physician's guide
1066615|NCT01721213|Trobalt™
1066616|NCT01721200|Rheumatoid Arthritis
1066617|NCT01721200|web based interactive learning tool
1066618|NCT01721187|fMRI
1066619|NCT01721187|Satiety
1066620|NCT01721187|Willingness to Pay
1066621|NCT01721187|Incentive Delay
1066622|NCT01721187|Dietary Disinhibition
1066623|NCT01721174|Pancreatic cancer
1066624|NCT01721174|Cholangiocarcinoma
1066625|NCT01721174|Endoscopic radiofrequency ablation
1066626|NCT01721161|Optic Neuritis
1066627|NCT01721135|moxifloxacin
1066628|NCT01721135|GSK2190915
1066629|NCT01721135|pharmacokinetics
1066630|NCT01721135|QTc
1066631|NCT01721109|Adolescents
1066632|NCT01721109|HIV-1
1066633|NCT01721109|HIV
1066634|NCT01721109|Treatment Naive
1066635|NCT01721096|Angioplasty
1066636|NCT01721096|Drug eluting stents
1066637|NCT01721096|Stents
1066638|NCT01721096|Real world
1066639|NCT01721083|intramuscular injection
1066640|NCT01721083|bunch
1066641|NCT01721083|z-track
1066642|NCT01721070|Area under curve, time to maximum concentration
1066643|NCT01721031|Catheter Related Bladder Discomfort
1066644|NCT01721031|Dorsal Penile Nerve Block
1066645|NCT01721018|Oncolytic virus
1066646|NCT01721018|HSV1716
1066647|NCT01721018|Mesothelioma
1066648|NCT01721018|MPM
1066649|NCT01721018|Woll
1066650|NCT01721018|Sheffield
1066651|NCT01721018|Weston Park
1066652|NCT01721018|Virttu
1066653|NCT01721018|Crusade
1066654|NCT01721005|atrial fibrillation
1066655|NCT01721005|thromboembolism
1066656|NCT01721005|patient education
1066657|NCT01720979|TBI
1066658|NCT01720979|Traumatic Brain Injury
1066659|NCT01720979|Children
1066660|NCT01720979|Prognosis
1066661|NCT01720979|Neurocognition
1066662|NCT01720966|Adhesions
1066663|NCT01720966|laparoscopy
1066664|NCT01720966|laparotomy
1066665|NCT01720966|liver resection
1066666|NCT01720966|colorectal malignancy
1066667|NCT01720953|Borderline Personality Disorder
1066668|NCT01720953|Mentalization Based Therapy
1066669|NCT01720953|DNA methylation
1066670|NCT01720953|BDNF
1066671|NCT01720953|Cortisol
1066672|NCT01720953|Neuropsychology
1066673|NCT01720927|Acute Pharyngitis, GABHS
1066674|NCT01720888|Autologous
1066675|NCT01720888|Bone Marrow
1066676|NCT01720888|Mesenchymal Stem Cells
1066677|NCT01720888|Ischemic Dilated Cardiomyopathy
1066678|NCT01720862|migraine
1066679|NCT01720862|episodic migraine
1066680|NCT01720862|chronic migraine
1066681|NCT01720862|obesity
1066682|NCT01720862|non-obese
1066683|NCT01720823|Obstructive Sleep Apnea syndrome
1066684|NCT01720823|polysomnography
1066685|NCT01720823|Home monitoring
1066686|NCT01720797|Malocclusion
1066687|NCT01720797|Accelerated tooth movement
1066688|NCT01720797|Braces
1066689|NCT01720797|Orthodontic treatment
1066690|NCT01720797|Propel
1066691|NCT01720771|bacteriotherapy
1066692|NCT01720771|caries
1066693|NCT01720771|preschool children
1066694|NCT01720771|probiotics
1066695|NCT01720745|EUS
1066696|NCT01720745|FNA
1066697|NCT01720745|Wet suction
1066698|NCT01720745|Dry suction
1066699|NCT01720745|Solid lesions
1066700|NCT01720719|Non-alcoholic Fatty Liver Disease
1066701|NCT01720719|Dyslipidemias
1066702|NCT01720719|Diabetes Mellitus
1066703|NCT01720719|atorvastatin
1066704|NCT01720719|Vitamin E
1066705|NCT01720706|Liver tumour
1066706|NCT01720706|Kidney tumour
1066707|NCT01720706|Hepatectomy
1066708|NCT01720706|Nephrectomy
1066709|NCT01720706|Metastatic Colon Cancer
1066710|NCT01720706|Renal Cell Carcinoma
1066711|NCT01720693|partial nephrectomy
1066712|NCT01720693|hypoperfusion
1066713|NCT01720693|renal function
1066714|NCT01720680|COPD
1066715|NCT01720680|Functional Imaging
1066716|NCT01720680|Patient Reported Outcome (PRO)
1066717|NCT01720680|Lung Function
1066718|NCT01720680|AlphaCore
1066719|NCT01720680|Computational Fluid Dynamics
1066720|NCT01720667|Seizures
1066721|NCT01720667|Neonates
1066722|NCT01720667|Anticonvulsants
1066723|NCT01720667|Treatment
1066724|NCT01720667|Levetiracetam
1066725|NCT01720667|Phenobarbital
1066726|NCT01720654|Expedited Partner Therapy
1066727|NCT01720654|MSM
1066728|NCT01720654|Peru
1066729|NCT01720654|Gonorrhea
1066730|NCT01720654|Chlamydia
1066731|NCT01720641|MSM
1066732|NCT01720641|Transgender Women
1066733|NCT01720641|Partner Notification
1066734|NCT01720641|Syphilis
1066735|NCT01720641|Peru
1066736|NCT01720628|Angiogenin, Behçet's disease, bFGF, VEGF
1066737|NCT01720615|EEG
1066738|NCT01720615|AEP
1066739|NCT01720615|Propofol
1066740|NCT01720615|Sevoflurane
1066741|NCT01720615|Remifentanil
1066742|NCT01720615|General anesthesia
1066743|NCT01720589|Obesity
1066744|NCT01720589|Dietary fat
1066745|NCT01720589|Energy expenditure
1066746|NCT01720589|Food intake
1066747|NCT01720563|Cancer-related fatigue
1066748|NCT01720563|astragalus polysaccharides
1066749|NCT01720563|concurrent chemoradiotherapy
1066750|NCT01720563|squamous cell carcinoma of head and neck
1066751|NCT01720550|Cancer-related fatigue
1066752|NCT01720550|Palliative Treatment
1066753|NCT01720550|Astragalus polysaccharides
1066754|NCT01720537|High Cholesterol
1066755|NCT01720537|Dyslipidemia
1066761|NCT01720472|Aging
1066762|NCT01720472|Healthy Aging
1066763|NCT01720472|Physical Performance
1066764|NCT01720472|Physical Functioning
1066765|NCT01720472|Cognitive Functioning
1066766|NCT01720472|Fitness
1066767|NCT01720472|Physical Activity
1066768|NCT01720433|laparoscopic pain prospective blinded trial
1066769|NCT01720420|edentulous
1066770|NCT01720420|maxilla
1066771|NCT01720420|mandible
1066772|NCT01720420|dental implant
1066773|NCT01720420|bar
1066774|NCT01720420|overdenture
1066775|NCT01720420|Oral Health Impact Profile (OHIP)
1066776|NCT01720420|survival rate
1066777|NCT01720420|technical complications
1066778|NCT01720420|marginal bone level
1066779|NCT01720420|soft tissue
1066780|NCT01720407|Dermatology/ Skin cancers/Lentigo maligna melanoma
1066781|NCT01720381|monitoring
1066782|NCT01720381|blood glucose
1066783|NCT01720381|intensive care unit
1066784|NCT01720368|IBD
1066785|NCT01720368|Crohn's
1066786|NCT01720342|Medtronic Enable® aortic bioprosthesis
1066787|NCT01720342|Aortic valve stenosis
1066788|NCT01720342|Aortic valve insufficiency
1066789|NCT01720342|"Real world patients"
1066790|NCT01720316|Glycine
1066791|NCT01720316|Glycine decarboxylase
1066792|NCT01720316|Psychosis
1066793|NCT01720316|Mutation
1066794|NCT01720277|Randomized Controlled Trial
1066795|NCT01720277|Influenza
1066796|NCT01720277|Influenza vaccine
1066797|NCT01720277|Flu Vaccine
1066798|NCT01720277|Fluzone
1066799|NCT01720277|HD Fluzone
1066800|NCT01720277|Nursing Homes
1066801|NCT01720277|Hospitalization
1066802|NCT01720277|Mortality
1066803|NCT01720277|Health Care worker vaccination
1066804|NCT01720277|ADL decline
1066805|NCT01720277|Pilot
1066806|NCT01720277|Effectiveness
1066807|NCT01720251|allergic rhinitis
1066808|NCT01720251|birch pollen
1066809|NCT01720251|immunotherapy
1066810|NCT01720238|Compensated Liver Cirrhosis
1066811|NCT01720238|Early Antiviral Therapy
1066812|NCT01720238|Cost Effectiveness
1066813|NCT01720225|Leukemia
1066814|NCT01720225|Myelodysplastic syndromes
1066815|NCT01720225|MDS
1066816|NCT01720225|Low and Intermediate-1 Risk Disease
1066817|NCT01720225|Decitabine
1066818|NCT01720225|DAC
1066819|NCT01720225|Dacogen
1066820|NCT01720225|Azacitidine
1066821|NCT01720225|AZA
1066822|NCT01720225|5-azacytidine
1066823|NCT01720225|5-aza
1066824|NCT01720225|Vidaza
1066825|NCT01720225|5-AZC
1066826|NCT01720225|AZA-CR
1066827|NCT01720225|Ladakamycin
1066828|NCT01720225|NSC-102816
1066829|NCT01720212|YM178
1066830|NCT01720212|Mirabegron
1066831|NCT01720212|OCAS
1066832|NCT01720212|Chinese Healthy Volunteers
1066833|NCT01720212|PK
1066834|NCT01720212|Safety
1066835|NCT01720199|universal prevention
1066836|NCT01720199|primary prevention
1066837|NCT01720199|health promotion
1066838|NCT01720199|wellbeing
1066839|NCT01720199|smoking
1066840|NCT01720199|alcohol
1066841|NCT01720199|diet
1066842|NCT01720199|physical activity
1066843|NCT01720199|emotional and social skills
1066844|NCT01720186|Lung Cancer
1066845|NCT01720186|PET/CT
1066846|NCT01720186|FDG
1066847|NCT01720186|Respiratory synchronization
1066848|NCT01720147|Fanconi Anemia
1066849|NCT01720147|FA
1066850|NCT01720147|Quercetin
1066851|NCT01720043|multiple myeloma
1066852|NCT01720030|Renal
1066853|NCT01720030|Acute Kidney Injury
1066854|NCT01720030|AKI
1066855|NCT01720030|Levosimendan
1066856|NCT01720030|Simdax
1066857|NCT01720030|Renal perfusion
1066858|NCT01720030|Mortality
1066859|NCT01720030|Renal flow
1066860|NCT01720017|Airtraq
1066861|NCT01720017|laryngoscope
1066862|NCT01720017|airway
1066863|NCT01720017|difficult
1066864|NCT01720017|training
1066865|NCT01720017|manikin
1066866|NCT01720004|human labour
1066867|NCT01720004|hands-and-knees positioning
1066868|NCT01720004|pilot trial
1066869|NCT01719991|Primary care
1066870|NCT01719991|Self-management
1066871|NCT01719991|Self-support
1066872|NCT01719991|Nurse case management
1066873|NCT01719978|Local Anaesthetics
1066874|NCT01719978|Mepivacaine
1066875|NCT01719978|hyaluronoglucosaminidase
1066876|NCT01719978|Hemodynamic
1066877|NCT01719978|Electrocardiography and Dentistry.
1066878|NCT01719965|Community Advisory Board
1066879|NCT01719965|Focus Group Discussion
1066880|NCT01719965|Interview
1066881|NCT01719965|Community Engagement
1066882|NCT01719965|Thailand
1066883|NCT01719952|pregnancy
1066884|NCT01719952|anaesthesia
1066885|NCT01719952|caesarean section
1066886|NCT01719926|Colorectal
1066887|NCT01719926|Esophageal
1066888|NCT01719926|Indomethacin
1066889|NCT01719926|PIFA
1066890|NCT01719900|Dietary intervention
1066891|NCT01719900|Dietary fibre
1066892|NCT01719900|Obesity
1066893|NCT01719900|Metabolic syndrome
1066894|NCT01719900|Weight loss
1066895|NCT01719900|Glucose regulation
1066896|NCT01719900|Pulse fibre
1066897|NCT01719887|humerus
1066898|NCT01719887|humeral
1066899|NCT01719887|shaft
1066900|NCT01719887|diaphysis
1066901|NCT01719887|fracture
1066902|NCT01719887|RCT
1066903|NCT01719874|Influenza
1066904|NCT01719874|monoclonal antibody
1066905|NCT01719848|Physical examinations, Percentage of glottic opening(POGO)
1066906|NCT01719835|T cell lymphoma
1066907|NCT01719835|untreated
1066908|NCT01719822|Treatment Outcome [E01.789.800]
1066909|NCT01719822|Rehabilitation [N02.421.784]
1066910|NCT01719822|Physical Fitness [I03.621]
1066911|NCT01719822|Lung Diseases, Obstructive [C08.381.495]
1066912|NCT01719822|Pulmonary Disease, Chronic Obstructive [C08.381.495.389]
1066913|NCT01719822|Bronchitis, Chronic [C08.381.495.389.500]
1066914|NCT01719809|Glaucoma
1066915|NCT01719809|Eye Drop
1066916|NCT01719809|Eye Drop Technique
1066917|NCT01719809|Training
1066918|NCT01719809|Instilling Eye Drops
1066919|NCT01719783|influenza
1066920|NCT01719783|vaccine
1066921|NCT01719783|pandemic
1066922|NCT01719770|cardiac arrest
1066923|NCT01719770|therapeutic hypothermia
1066924|NCT01719770|skeletal muscle paralysis
1066925|NCT01719770|shivering
1066926|NCT01719770|serum drug levels
1066927|NCT01719770|basal metabolism
1066928|NCT01719757|Targin, Cancer Pain
1066929|NCT01719744|ENMD-2076
1066930|NCT01719744|advanced
1066931|NCT01719744|metastatic
1066932|NCT01719744|soft tissue sarcoma
1066933|NCT01719731|BPD
1066934|NCT01719718|ventral hernia
1066935|NCT01719705|caesarean delivery
1066936|NCT01719705|spinal anesthesia
1066937|NCT01719705|pregabalin
1066938|NCT01719705|postoperative pain
1066939|NCT01719705|morphine
1066940|NCT01719679|school located vaccine program
1066941|NCT01719666|MPFL
1066942|NCT01719666|patella
1066943|NCT01719666|dislocation
1066944|NCT01719666|release
1066945|NCT01719653|Colonoscopy
1066946|NCT01719653|Bowel Preparation
1066947|NCT01719653|MiraLAX
1066948|NCT01719653|Gatorade
1066949|NCT01719653|PEG-3350
1066950|NCT01719653|MoviPrep
1066951|NCT01719653|SUPREP
1066952|NCT01719653|Chicago Bowel Preparation Scale
1066953|NCT01719653|Boston Bowel Preparation Scale
1066954|NCT01719640|mesenchymal stem cell
1066955|NCT01719640|central nervous system
1066956|NCT01719627|HIV, Maraviroc, PrEP, Ex vivo infection, rectal mucosa.
1066957|NCT01719614|Healthy participants
1066958|NCT01719614|Rilpivirine
1066959|NCT01719614|Metformin
1066960|NCT01719614|Pharmacokinetics
1066961|NCT01719601|Moderate to severe acute non-cancer pain
1066962|NCT01719601|Immediate release tapentadol hydrochloride
1066963|NCT01719601|Tapentadol IR
1066964|NCT01719601|Nucynta IR
1066965|NCT01719588|Moderate to severe chronic non-cancer pain
1066966|NCT01719588|Prolonged release tapentadol hydrochloride
1066967|NCT01719588|Tapentadol PR
1066968|NCT01719588|Extended release tapentadol hydrochloride
1066969|NCT01719588|Nucynta PR
1066970|NCT01719549|Gastric Cancer
1066971|NCT01719549|Dovitinib
1066972|NCT01719523|Tourette syndrome
1066973|NCT01719523|Tics
1066974|NCT01719523|Tic Disorders
1066975|NCT01719510|Group B Streptococcus,
1066976|NCT01719510|Vaginal screening
1066977|NCT01719510|Per partum antibiotic prophylaxis
1066978|NCT01719510|Meningitis
1066979|NCT01719510|Neonatal infection
1066980|NCT01719510|PCR
1066981|NCT01719510|Streptococcus agalactiae.
1066982|NCT01719445|Energy Intake
1066983|NCT01719432|Filgrastim
1066984|NCT01719432|Obese
1066985|NCT01719432|Non-obese
1066986|NCT01719432|Pharmacokinetics
1066987|NCT01719406|Gestational diabetes
1066988|NCT01719406|Exercise
1066989|NCT01719406|Diet
1066990|NCT01719406|Fruits
1066991|NCT01719406|Vegetables
1066992|NCT01719406|Whole grains
1066993|NCT01719406|pregnancy weight
1066994|NCT01719393|Asthma
1066995|NCT01719393|Pulse spectrum analysis
1066996|NCT01719393|lung function
1066997|NCT01719393|exhaled nitric oxide
1066998|NCT01719393|metabolites
1066999|NCT01719393|exhaled breath condensate
1067000|NCT01719380|Open-label dose escalation; BRAF inhibitor; LGX818; PI3K inhibitor; BYL719; EGFR; cetuximab; metastatic colorectal cancer; KRAS; BRAF; V600
1067001|NCT01719367|Baseline (pre-atenolol)
1067002|NCT01719367|Post-atenolol
1067003|NCT01719354|Community Mental Health Centers
1067004|NCT01719354|Norway
1067005|NCT01719354|Aftercare
1067006|NCT01719328|yoga,
1067007|NCT01719328|exercise
1067008|NCT01719328|affect
1067009|NCT01719328|mind/body therapies
1067010|NCT01719328|stress, psychological
1067011|NCT01719302|Soft tissue sarcoma
1067012|NCT01719302|gemcitabine
1067013|NCT01719302|docetaxel
1067014|NCT01719302|pazopanib
1067015|NCT01719289|depression
1067016|NCT01719289|problem solving
1067017|NCT01719263|emphysema
1067018|NCT01719263|InterVapor
1067019|NCT01719263|treatments
1067020|NCT01719263|pulmonary rehabilitation
1067021|NCT01719263|lung volume reduction
1067022|NCT01719263|endoscopic lung volume reduction
1067023|NCT01719237|Onset
1067024|NCT01719237|Duration
1067025|NCT01719237|Upper Limb Block
1067026|NCT01719237|Ultrasound guided supraclavicular block
1067027|NCT01719237|Ropivacaine
1067028|NCT01719237|Chloroprocaine
1067029|NCT01719211|MVP, mitral valve
1067030|NCT01719198|adenoma
1067031|NCT01719198|calprotectin
1067032|NCT01719159|Progressive multiple sclerosis
1067033|NCT01719159|Monoclonal antibodies
1067034|NCT01719159|Mabthera
1067035|NCT01719159|Intrathecal treatment
1067036|NCT01719146|Anemia
1067037|NCT01719146|Chronic Kidney Disease
1067038|NCT01719146|Erythropoiesis Stimulating Agents
1067039|NCT01719146|Erythropoietin
1067040|NCT01719146|Iron
1067041|NCT01719146|Iron Deficiency
1067042|NCT01719133|allergy
1067043|NCT01719133|birch
1067044|NCT01719120|Insomnia
1067045|NCT01719120|Cognitive-Behavioral Therapy
1067046|NCT01719120|Internet-Based
1067047|NCT01719120|Self-Help
1067048|NCT01719120|Randomized Controlled Trial
1067049|NCT01719107|Functional abdominal pain
1067050|NCT01719107|Probiotics
1067051|NCT01719107|Lactobacilus reuteri
1067052|NCT01719081|Sacroiliac Joint
1067053|NCT01719081|Ultrasound
1067054|NCT01719081|Fluoroscopy
1067055|NCT01719081|Chronic Pain
1067056|NCT01719068|Mesothelioma
1067057|NCT01719068|Lung Cancer
1067058|NCT01719068|Early Detection
1067059|NCT01719055|stimulation
1067060|NCT01719055|implantable
1067061|NCT01719055|pulse generator
1067062|NCT01719055|back pain
1067063|NCT01719055|chronic pain
1067064|NCT01719055|leg pain
1067065|NCT01719029|continuous glucose monitoring
1067066|NCT01719029|gestational diabetes
1067067|NCT01719029|diet therapy
1067068|NCT01719016|Reversible ischemia
1067069|NCT01719016|microvascular dysfunction
1067070|NCT01718977|Intervention
1067071|NCT01718977|Body Weight Supported Treadmill Training
1067072|NCT01718977|Arm Cycle Ergometry Training
1067073|NCT01718977|Aortic Pulse Wave Velocity
1067074|NCT01718951|spondyloarthropathy
1067075|NCT01718951|ankylosing spondylitis
1067076|NCT01718938|Gastroparesis
1067077|NCT01718938|Diabetic
1067078|NCT01718938|Idiopathic
1067079|NCT01718938|Delayed gastric emptying
1067080|NCT01718912|periodontal disease
1067081|NCT01718912|bleeding on probing
1067082|NCT01718912|periodontal pockets
1067083|NCT01718912|disabled
1067084|NCT01718886|Obesity
1067085|NCT01718886|Weight loss
1067086|NCT01718886|Weight control
1067087|NCT01718886|Intragastric balloon
1067088|NCT01718886|gastric balloon
1067089|NCT01718873|metastatic
1067090|NCT01718873|stage IV
1067091|NCT01718860|Cost Analysis
1067092|NCT01718860|Postoperative Complications
1067093|NCT01718860|Length of Stay
1067094|NCT01718860|Intensive Care Units
1067095|NCT01718847|EGFR Tyrosine Kinase Inhibitor
1067096|NCT01718847|Aquired resistance to EGFR TKI
1067097|NCT01718847|Pan-Her inhibitor
1067098|NCT01718834|prophylactic vaccine
1067099|NCT01718834|chronic HCV patients
1067100|NCT01718834|healthy risk volunteers
1067101|NCT01718808|Metastatic Colorectal Cancer
1067102|NCT01718808|KRAS
1067103|NCT01718808|BRAF
1067104|NCT01718808|Wild-type Metastatic
1067105|NCT01718808|Cetuximab
1067106|NCT01718808|Capecitabine
1067107|NCT01718808|Phase II Trial
1067108|NCT01718808|Elderly Patients
1067109|NCT01718795|Airway
1067110|NCT01718795|Cardiac Arrest
1067111|NCT01718795|CPR
1067112|NCT01718795|Ventilation
1067113|NCT01718782|laryngeal mask, leakage pressure, ventilation
1067114|NCT01718769|Nutritional assessment
1067115|NCT01718769|children
1067116|NCT01718769|malnutrition
1067117|NCT01718756|Orthopaedic
1067118|NCT01718756|General anaesthesia
1067119|NCT01718756|lornoxicam
1067120|NCT01718756|patient controlled analgesia
1067121|NCT01718756|morphine consumption
1067122|NCT01718743|Myeloma
1067123|NCT01718743|Multiple Myeloma
1067124|NCT01718743|MM
1067125|NCT01718743|Post Autologous Stem Cell Transplant
1067126|NCT01718743|Lenalidomide
1067127|NCT01718743|CC-5013
1067128|NCT01718743|Revlimid
1067129|NCT01718743|MLN9708
1067130|NCT01718743|Questionnaire
1067131|NCT01718743|Survey
1067132|NCT01718730|TMS
1067133|NCT01718730|Adolescent
1067134|NCT01718730|Child
1067135|NCT01718730|MDD
1067136|NCT01718730|Major depressive disorder
1067137|NCT01718730|Mild MDD
1067138|NCT01718730|Mild depression
1067139|NCT01718730|SSRI
1067140|NCT01718730|Motor cortex
1067141|NCT01718730|Cortical excitability
1067142|NCT01718730|Cortical inhibition
1067143|NCT01718730|Cortical silent period
1067144|NCT01718730|Motor threshold
1067145|NCT01718730|Intracortical facilitation
1067146|NCT01718730|Intracortical inhibition
1067147|NCT01718730|gamma-aminobutyric acid (GABA)
1067148|NCT01718730|Glutamate
1067149|NCT01718730|N-methyl-D-aspartate (NMDA)
1067150|NCT01718730|Magnetic resonance spectroscopy
1067151|NCT01718730|MRS
1067152|NCT01718717|Thoracotomy
1067153|NCT01718717|Thoracic epidural analgesia
1067154|NCT01718717|Arrythmiogenesis
1067155|NCT01718717|Atrial fibrillation
1067156|NCT01718717|Sympathetic outflow
1067157|NCT01718704|rehabilitation
1067158|NCT01718704|erectile dysfunction
1067159|NCT01718704|incontinence
1067160|NCT01718678|Multiple sclerosis
1067161|NCT01718678|Melatonin
1067162|NCT01718678|Fatigue
1067163|NCT01718678|Quality of life
1067164|NCT01718652|Healthy
1067165|NCT01718652|Canagliflozin (JNJ-28431754)
1067166|NCT01718652|Pharmacokinetics
1067167|NCT01718652|Cyclosporine
1067168|NCT01718600|carotid artery stenting
1067169|NCT01718600|neuropsychological testing
1067170|NCT01718600|microembolization
1067171|NCT01718600|MRI
1067172|NCT01718587|umbilical cord mesenchyma stem cell
1067173|NCT01718587|liver cirrhosis
1067174|NCT01718587|antiviral therapy
1067175|NCT01718574|self-help book
1067176|NCT01718574|support service
1067177|NCT01718561|Airway assessment
1067178|NCT01718561|Intubation
1067179|NCT01718561|Mask ventilation
1067180|NCT01718535|Cyp2C19
1067181|NCT01718535|Genotyping
1067182|NCT01718535|Spartan
1067183|NCT01718535|Comparison
1067184|NCT01718535|Sequencing
1067185|NCT01718496|dyspnea
1067186|NCT01718496|COPD
1067187|NCT01718496|exercise tolerance
1067188|NCT01718496|opioids
1067189|NCT01718496|morphine
1067190|NCT01718496|single dose oral Morphine
1067191|NCT01718470|Systolic blood pressure
1067192|NCT01718470|Heart rate
1067193|NCT01718470|Laryngeal mask
1067194|NCT01718470|Endotracheal tube
1067195|NCT01718470|craniotomy
1067196|NCT01718457|Endobarrier
1067197|NCT01718457|Diabetes
1067198|NCT01718457|Obesity
1067199|NCT01718457|Weight
1067200|NCT01718457|BMI
1067201|NCT01718457|Lipid profile
1067202|NCT01718457|fatty liver
1067203|NCT01718457|gut peptides
1067204|NCT01718457|HbA1c
1067205|NCT01718444|PCOS
1067206|NCT01718444|Polycystic ovary syndrome
1067207|NCT01718444|Infertility
1067208|NCT01718444|Anovulation
1067209|NCT01718444|Clomiphene citrate
1067210|NCT01718444|Clomid
1067211|NCT01718444|Progestin
1067212|NCT01718444|Provera
1067213|NCT01718444|Progesterone
1067214|NCT01718444|Endometrial shedding
1067215|NCT01718392|combined training
1067216|NCT01718392|insulin resistance
1067217|NCT01718379|Myelodysplasia
1067218|NCT01718340|PCOS
1067219|NCT01718340|Hyper insulinaemia
1067220|NCT01718340|metformin
1067221|NCT01718340|recurrent abortion
1067222|NCT01718327|Cholangiocarcinoma
1067223|NCT01718314|Hysteroscopy
1067224|NCT01718314|Misoprostol
1067225|NCT01718314|Lidocaine
1067226|NCT01718314|Visual analogue score
1067227|NCT01718301|HCV
1067228|NCT01718301|HIV
1067229|NCT01718301|Coinfection
1067230|NCT01718288|PAD; iloprost; walking distance; cardiovascular events
1067231|NCT01718275|Appendicitis
1067232|NCT01718275|Pediatrics
1067233|NCT01718275|Children
1067234|NCT01718275|Non-operative
1067235|NCT01718262|Ropivacaine Level
1067236|NCT01718262|continuous peripheral nerve blocks.
1067237|NCT01718249|Deep Brain Stimulation (DBS)
1067238|NCT01718249|Post-coma
1067239|NCT01718249|Consciousness
1067240|NCT01718249|Vegetative state
1067241|NCT01718249|Minimally conscious state
1067242|NCT01718236|caesarean section
1067243|NCT01718236|rocuronium
1067244|NCT01718236|sugammadex
1067245|NCT01718210|GM-CSF
1067246|NCT01718210|recurrent implantation failure
1067247|NCT01718210|pregnancy rate
1067248|NCT01718210|IVF
1067249|NCT01718197|Severe Asthma
1067250|NCT01718197|Bronchoscopy
1067251|NCT01718184|sulcoflex
1067252|NCT01718184|toric
1067253|NCT01718184|corneal implantation
1067254|NCT01718171|Appendicitis
1067255|NCT01718171|SIRS
1067256|NCT01718171|C-reactive protein
1067257|NCT01718132|Quality of the anaesthetic care in a PACU
1067258|NCT01718132|reduction of postoperative pain
1067259|NCT01718132|reduction of postoperative nausea and vomiting
1067260|NCT01718132|quality markers
1067261|NCT01718106|coronary artery disease
1067262|NCT01718106|drug eluting stent
1067263|NCT01718106|bioabsorbable polymer
1067264|NCT01718106|percutaneous coronary intervention
1067265|NCT01718106|restenosis
1067266|NCT01718106|late thrombosis
1067267|NCT01718093|Adolescents
1067268|NCT01718080|Obese, Lean, Pubertal, Prepubertal, Glucose, Adolescents, Type 2 Diabetes
1067269|NCT01718067|Chest physiotherapy
1067270|NCT01718067|Rehabilitation
1067271|NCT01718067|Chronic respiratory diseases
1067272|NCT01718054|Vascular function
1067273|NCT01718054|Ready to use supplementary foods
1067274|NCT01718054|Chloroquine
1067275|NCT01718054|Children
1067276|NCT01718054|Growth
1067277|NCT01718054|Nitric Oxide
1067278|NCT01718041|Growth hormone
1067279|NCT01718041|Growth hormone deficiency
1067280|NCT01718041|Growth
1067281|NCT01718041|Pediatric growth hormone deficiency
1067282|NCT01718041|Long acting growth hormone
1067283|NCT01718041|GHD
1067284|NCT01718041|PGHD
1067285|NCT01718041|VRS 317
1067286|NCT01718041|Exten
1067287|NCT01718041|Versartis
1067288|NCT01718028|Systane BALANCE
1067289|NCT01718028|Dry eye
1067290|NCT01718028|lipid deficiency
1067291|NCT01718028|NITFBUT
1067292|NCT01718015|Vascular Endothelial Growth Factor
1067293|NCT01718015|Brain-Derived Neurothropic Factor
1067294|NCT01718015|Diabetes Mellitus
1067295|NCT01718015|CD-163
1067296|NCT01718015|Cerebrospinal fluid
1067297|NCT01718015|Peripheral Nervous System Diseases
1067298|NCT01718015|Mass spectrometry
1067299|NCT01718002|Nursing
1067300|NCT01718002|Simulation
1067301|NCT01718002|Education
1067302|NCT01717989|Dialysis
1067303|NCT01717989|Prospective Payment System
1067427|NCT01717625|montelukast
1067304|NCT01717989|Center for Medicare and Medicaide Services
1067305|NCT01717989|End Stage Renal Disease
1067306|NCT01717989|Concomitant Medications Dosage /Treatment patterns
1067307|NCT01717976|emergency department use
1067308|NCT01717976|Veterans
1067309|NCT01717950|Human Hookworm
1067310|NCT01717950|Necator americanus
1067311|NCT01717950|Hookworm
1067312|NCT01717950|Hookworm Disease
1067313|NCT01717950|Iron-deficiency anemia
1067314|NCT01717950|Soil-transmitted helminth infection
1067315|NCT01717950|Neglected Tropical Disease
1067316|NCT01717950|Na-APR-1
1067317|NCT01717937|retinovascular disease
1067318|NCT01717937|imaging
1067319|NCT01717937|fluorescein angiography
1067320|NCT01717937|FA
1067321|NCT01717937|angiography
1067322|NCT01717937|optical coherence tomography
1067323|NCT01717937|OCT
1067324|NCT01717937|phase variance
1067325|NCT01717937|comparison
1067326|NCT01717937|age-related macular degeneration
1067327|NCT01717937|diabetic retinopathy
1067328|NCT01717937|hypertensive retinopathy
1067329|NCT01717937|retinal vein occlusion
1067330|NCT01717937|retinal artery occlusion
1067331|NCT01717924|Signet ring cell
1067332|NCT01717924|gastric adenocarcinoma
1067333|NCT01717924|peri-operative chemotherapy
1067334|NCT01717924|surgery
1067335|NCT01717911|Newly diagnosed type 2 diabetes
1067336|NCT01717911|Insulin, metformin, sitagliptin
1067337|NCT01717911|beta-cell function, glycemic control
1067338|NCT01717898|Castrate-resistant prostate cancer
1067339|NCT01717885|Pharmacokinetics
1067340|NCT01717885|Antimalarial
1067341|NCT01717885|HIV
1067342|NCT01717885|Antiretrovirals
1067343|NCT01717885|Childhood development
1067344|NCT01717885|Pregnancy
1067345|NCT01717872|glottis, laryngoscopy, laryngoscope blade
1067346|NCT01717859|Rheumatoid Arthritis
1067347|NCT01717846|Apoptosos
1067348|NCT01717846|Rheumatoid Arthritis
1067349|NCT01717846|T cells, B cells
1067350|NCT01717846|DAS28
1067351|NCT01717846|Clinical Disease activity Index
1067352|NCT01717846|CDAI
1067353|NCT01717833|ICU acquired weakness
1067354|NCT01717833|Critical illness polyneuromyopathy
1067355|NCT01717833|post ICU rehabilitation
1067356|NCT01717833|neuromuscular electrical rehabilitation
1067357|NCT01717833|handgrip
1067358|NCT01717820|Obesity
1067359|NCT01717820|Postmenopausal women
1067360|NCT01717820|Body composition
1067361|NCT01717820|Resveratrol
1067362|NCT01717820|Inflammatory biomarkers
1067363|NCT01717820|Bone formation
1067364|NCT01717820|Adipose metabolism
1067365|NCT01717807|epithelial growth factor receptors
1067366|NCT01717807|lung cancer
1067367|NCT01717807|advanced tumor of pancrease
1067368|NCT01717807|erlotinib
1067369|NCT01717807|C11-Erlotinib PET/CT
1067370|NCT01717794|operative time
1067371|NCT01717794|laparoscopy
1067372|NCT01717794|total hysterectomy
1067373|NCT01717794|pelvic lymphadenectomy
1067374|NCT01717794|endometrial cancer
1067375|NCT01717794|Thunderbeat
1067376|NCT01717781|operative time
1067377|NCT01717781|laparoscopy
1067378|NCT01717781|radical hysterectomy
1067379|NCT01717781|pelvic lymphadenectomy
1067380|NCT01717781|cervical cancer
1067381|NCT01717781|thunderbeat
1067382|NCT01717768|hypogonadism
1067383|NCT01717768|Gonadal Disorders
1067384|NCT01717768|Endocrine System Diseases
1067385|NCT01717768|Testosterone
1067386|NCT01717768|Testosterone enanthate
1067387|NCT01717768|Testosterone undecanoate
1067388|NCT01717768|Testosterone 17 beta-cypionate
1067389|NCT01717768|Methyltestosterone
1067390|NCT01717768|Androgens
1067391|NCT01717768|Hormones
1067392|NCT01717768|Hormones, Hormone Substitutes, and Hormone Antagonists
1067393|NCT01717768|Physiological Effects of Drugs
1067394|NCT01717768|Pharmacologic Actions
1067395|NCT01717768|Therapeutic Uses
1067396|NCT01717768|Anabolic Agents
1067397|NCT01717755|basilar
1067398|NCT01717755|stroke
1067399|NCT01717755|mechanical
1067400|NCT01717755|thrombolysis
1067401|NCT01717755|intra-arterial
1067402|NCT01717742|Randomized controlled trial
1067403|NCT01717742|Pleural Empyema
1067404|NCT01717742|tPA
1067405|NCT01717742|DNase
1067406|NCT01717729|HCC, RFA, Iodine-125, Recurrence
1067407|NCT01717716|boys
1067408|NCT01717716|obesity
1067409|NCT01717716|glucose
1067410|NCT01717716|sucrose
1067411|NCT01717716|high-fructose corn syrup-55
1067412|NCT01717703|prevention
1067413|NCT01717690|MRSA
1067414|NCT01717690|chlorhexidine
1067415|NCT01717664|Relapsing Remitting Multiple Sclerosis
1067416|NCT01717664|MAP
1067417|NCT01717664|antibiotic
1067418|NCT01717664|Interferon beta 1-a
1067419|NCT01717664|MS
1067420|NCT01717664|MRI
1067421|NCT01717664|EDSS
1067422|NCT01717664|relapse rate
1067423|NCT01717651|Atrophy
1067424|NCT01717651|Muscle wasting
1067425|NCT01717651|Sepsis
1067426|NCT01717638|Meningococcal disease, vaccines, children, persistence
1067428|NCT01717625|BPD
1067429|NCT01717625|singulair
1067430|NCT01717625|prematurity
1067431|NCT01717612|gastric varices, thrombin, histoacryl
1067432|NCT01717599|Post ERCP pancreatitis
1067433|NCT01717599|Diclofenac
1067434|NCT01717599|NSAID
1067435|NCT01717586|preeclampsia
1067436|NCT01717586|pravastatin
1067437|NCT01717586|Pravachol®
1067438|NCT01717586|statin
1067439|NCT01717586|high-risk pregnancy
1067440|NCT01717586|safety
1067441|NCT01717586|fetal morbidity and mortality
1067442|NCT01717586|maternal morbidity and mortality
1067443|NCT01717586|neonatal mortality
1067444|NCT01717586|premature delivery
1067445|NCT01717586|preemie
1067446|NCT01717573|STEMI
1067447|NCT01717573|No-reflow
1067448|NCT01717573|Primary percutaneous intervention
1067449|NCT01717573|Deferred stenting
1067450|NCT01717560|chronic hepatitis C
1067451|NCT01717560|illicit drug use
1067452|NCT01717560|Substance-Related Disorders
1067453|NCT01717560|multidisciplinary care
1067454|NCT01717560|integrated care
1067455|NCT01717560|mental health care
1067456|NCT01717560|intensive case management
1067457|NCT01717547|Veterans
1067458|NCT01717547|Yoga
1067459|NCT01717547|Stress
1067460|NCT01717534|Diarrhea
1067461|NCT01717534|Children
1067462|NCT01717534|Heat-treated lactobacilli
1067463|NCT01717521|hysterectomy
1067464|NCT01717521|gynecological abdominal surgery
1067465|NCT01717508|MDD
1067466|NCT01717508|depression
1067467|NCT01717508|major depressive disorder
1067468|NCT01717508|adolescent
1067469|NCT01717495|Pacemaker
1067470|NCT01717495|Implantable-cardioverter defibrillator
1067471|NCT01717495|Cardiac Pacing, Artificial/adverse effects
1067472|NCT01717495|Venous thrombosis
1067473|NCT01717495|Pulmonary embolism
1067474|NCT01717495|Phlebography
1067475|NCT01717495|Biological markers
1067476|NCT01717495|Computed tomography angiography
1067477|NCT01717482|Bronchoscopy
1067478|NCT01717482|Metformin
1067479|NCT01717469|Pacemaker
1067480|NCT01717469|Pacemaker implantation
1067481|NCT01717469|Coronary sinus
1067482|NCT01717469|Ventricular dysfunction
1067483|NCT01717469|Right ventricular pacing
1067484|NCT01717469|Left ventricular pacing
1067485|NCT01717456|Fecal incontinence
1067486|NCT01717456|Frail elders
1067487|NCT01717456|Home health care
1067488|NCT01717456|Nurse
1067489|NCT01717456|Patient education
1067490|NCT01717443|Human Papillomavirus
1067491|NCT01717443|Renal transplantation
1067492|NCT01717430|Injections, epidural
1067493|NCT01717430|Injections, intra-articular
1067494|NCT01717430|Chronic pain
1067495|NCT01717430|Neck pain
1067496|NCT01717430|Back pain
1067497|NCT01717430|Low back pain
1067498|NCT01717430|Sciatica
1067499|NCT01717430|Sacroiliac joint
1067500|NCT01717430|Corticosteroids
1067501|NCT01717430|Dexamethasone
1067502|NCT01717430|Adrenocorticotropic hormone
1067503|NCT01717430|Adrenal insufficiency
1067504|NCT01717430|Hemoglobin A, glycosylated
1067505|NCT01717417|impacted canine
1067506|NCT01717417|miniscrew
1067507|NCT01717417|cone beam
1067508|NCT01717404|IBS
1067509|NCT01717391|radiotherapy
1067510|NCT01717391|Positron-Emission Tomography and Computed Tomography
1067511|NCT01717391|chemotherapy
1067512|NCT01717391|bone marrow
1067513|NCT01717378|Patient Recruitment
1067514|NCT01717378|Research Subject Recruitment
1067515|NCT01717378|Research Subject Selection
1067516|NCT01717378|Selection of Subjects
1067517|NCT01717378|Health Surveys
1067518|NCT01717378|Health Questionnaires
1067519|NCT01717378|Health Interviews
1067520|NCT01717365|SCOPE
1067521|NCT01717352|Weight loss
1067522|NCT01717274|Functional Endoscopic Sinus Surgery
1067523|NCT01717274|Hot water irrigation
1067524|NCT01717261|breast cancer
1067525|NCT01717261|early breast cancer
1067526|NCT01717261|partial breast irradiation
1067527|NCT01717261|preoperative radiation
1067528|NCT01717222|Lignocaine
1067529|NCT01717222|Laparoscopic cholecystectomy
1067530|NCT01717222|Pain relief
1067531|NCT01717209|heart failure
1067532|NCT01717209|hypertension, pulmonary
1067533|NCT01717209|heart failure, right-sided
1067534|NCT01717209|heart-assist devices
1067535|NCT01717209|Heart Transplantation
1067536|NCT01717196|sample adequacy
1067537|NCT01717196|diagnostic accuracy
1067538|NCT01717196|complications
1067539|NCT01717183|Patient
1067540|NCT01717170|Non-infectious Uveitis, Tocilizumab
1067541|NCT01717157|Healthy
1067542|NCT01717157|Fentanyl
1067543|NCT01717157|Transdermal patch
1067544|NCT01717157|DUROGESIC
1067545|NCT01717144|therapeutic education
1067546|NCT01717144|Parkinson's disease
1067547|NCT01717144|quality of life
1067548|NCT01717131|Invasive breast cancer
1067549|NCT01717118|Evaluation
1067550|NCT01717118|Immunogenicity
1067551|NCT01717118|Levels
1067552|NCT01717118|Women
1067553|NCT01717118|HPV
1067554|NCT01717118|Vaccine
1067555|NCT01717118|Mexico
1067556|NCT01717105|Non-small cell lung cancer (NSCLC)
1067557|NCT01717105|Epidermal growth factor receptor (EGFR) positive mutation
1067558|NCT01717066|Hepatocellular Carcinoma
1067559|NCT01717066|ginsenoside Rg3
1067560|NCT01717040|Bipolar Disorder
1067561|NCT01717040|Insulin Resistance
1067562|NCT01717027|pharmacokinetics
1067563|NCT01717027|bioavailability
1067564|NCT01717027|oxycodone
1067565|NCT01717027|management of moderate to severe pain
1067566|NCT01717014|rectal cancer
1067567|NCT01717014|stapler
1067568|NCT01717001|kinematics
1067569|NCT01717001|knee joint
1067570|NCT01716988|Micafungin
1067571|NCT01716988|pharmacokinetics
1067572|NCT01716988|invasive candidiasis
1067573|NCT01716988|intensive care
1067574|NCT01716975|Schizophrenia
1067575|NCT01716975|Cognition
1067576|NCT01716975|Cognition Impairment
1067577|NCT01716975|Alpha-7 nAChR
1067578|NCT01716962|Acute respiratory distress syndrome, Fluid responsiveness, Pulse pressure variation
1067579|NCT01716962|Pleth variability index, Passive leg raising test
1067580|NCT01716949|rectal cancer
1067581|NCT01716949|recurrent rectal cancer
1067582|NCT01716949|hyperthermia
1067583|NCT01716949|radiation
1067584|NCT01716949|chemoradiation
1067585|NCT01716949|5-FU
1067586|NCT01716949|capecitabine
1067587|NCT01716949|oxaliplatin
1067588|NCT01716936|Thoracic Insufficiency Syndrome
1067589|NCT01716936|Early Onset Spinal Deformity
1067590|NCT01716884|STEMI
1067591|NCT01716884|reperfution
1067592|NCT01716884|primary PCI
1067593|NCT01716858|Schizophrenia
1067594|NCT01716858|Sulforaphane
1067595|NCT01716858|Psychosis
1067596|NCT01716858|Cognition
1067597|NCT01716858|Oxidative stress
1067598|NCT01716858|Antioxidant
1067599|NCT01716858|Anti-inflammatory
1067600|NCT01716845|autism
1067601|NCT01716845|autism spectrum disorders
1067602|NCT01716845|RNA
1067603|NCT01716845|gene expression
1067604|NCT01716845|developmental delay
1067605|NCT01716819|Heart failure, abdominal obesity, RAAS
1067614|NCT01716793|Primary AML
1067615|NCT01716793|Risk-adapted treatment
1067616|NCT01716793|Hematopoietic transplantation
1067617|NCT01716793|CD34+ cell selection
1067618|NCT01716767|Carpal tunnel syndrome
1067619|NCT01716767|hand pain
1067620|NCT01716767|wrist pain
1067621|NCT01716767|arm pain
1067622|NCT01716767|topical menthol
1067623|NCT01716754|asthma
1067624|NCT01716754|asthma control
1067625|NCT01716754|allergy
1067626|NCT01716754|atopic
1067627|NCT01716754|IgE
1067628|NCT01716754|double-blind
1067629|NCT01716754|placebo
1067630|NCT01716754|omalizumab
1067631|NCT01716741|Gaucher disease
1067632|NCT01716741|lysosomal storage disorder
1067633|NCT01716741|metabolic disease
1067634|NCT01716741|medical records review
1067635|NCT01716728|Lysosomal Acid Lipase Deficiency
1067636|NCT01716728|Cholesterol Ester Storage Disease
1067637|NCT01716728|Wolman Disease
1067638|NCT01716728|Lysosomal Storage Disorder
1067639|NCT01716728|Metabolic Disease
1067640|NCT01716728|Recessive Inheritance
1067641|NCT01716702|Prostate Cancer
1067642|NCT01716702|Psychosocial Intervention
1067643|NCT01716702|Sexual Rehabilitation
1067644|NCT01716702|Online Intervention
1067645|NCT01716663|Symptomatic paroxysmal
1067646|NCT01716663|Atrial fibrillation
1067647|NCT01716663|Observational
1067648|NCT01716663|Acute procedural outcomes
1067649|NCT01716663|Ablation
1067650|NCT01716650|ankle
1067651|NCT01716650|saphenous nerve block
1067652|NCT01716637|Alzheimer's Disease
1067653|NCT01716637|Dementia
1067654|NCT01716637|Cognitive decline
1067655|NCT01716637|Cognitive disorder
1067656|NCT01716637|Degenerative brain disease
1067657|NCT01716637|Cognitive impairment
1067658|NCT01716637|Memory loss
1067659|NCT01716637|TNF-alpha
1067660|NCT01716624|Pediatric
1067661|NCT01716611|liver cirrhosis
1067662|NCT01716611|hyponatemia
1067663|NCT01716611|ascites
1067664|NCT01716611|vaptans
1067665|NCT01716611|antidiuretic hormon
1067666|NCT01716611|arginine vasopressin
1067667|NCT01716598|COPD
1067668|NCT01716598|TLD Therapy
1067669|NCT01716598|Targeted Lung Denervation Therapy
1067670|NCT01716598|IPS
1067671|NCT01716598|Innovative Pulmonary Solutions, Inc.
1067672|NCT01716598|Holaira, Inc.
1067673|NCT01716585|Hepatitis C Virus
1067674|NCT01716585|Hepatitis C Genotype 1
1067675|NCT01716585|Hepatitis C
1067676|NCT01716585|Treatment-Naïve
1067677|NCT01716585|Interferon-Free
1067678|NCT01716585|Chronic Hepatitis C
1067679|NCT01716585|Viekira Pak
1067680|NCT01716585|ombitasvir
1067681|NCT01716585|paritaprevir
1067682|NCT01716585|dasabuvir
1067683|NCT01716572|Upper gastrointestinal bleeding
1067684|NCT01716572|Endoscopy
1067685|NCT01716572|Erythromycin
1067686|NCT01716572|Gastric lavage
1067687|NCT01716546|Advanced cancer of the stomach
1067688|NCT01716546|Chemotherapy - naive patients
1067689|NCT01716546|DCF
1067690|NCT01716533|Serological
1067691|NCT01716533|Adults
1067692|NCT01716533|Clostridium difficile
1067693|NCT01716533|Adult CDI patients
1067694|NCT01716520|long-acting muscarinic antagonist
1067695|NCT01716520|long-acting beta-agonist
1067696|NCT01716520|Chronic Obstructive Pulmonary Disease
1067697|NCT01716520|vilanterol
1067698|NCT01716520|umeclidinium
1067699|NCT01716507|RRD
1067700|NCT01716507|Rhegmatogenous
1067701|NCT01716507|Retinal
1067702|NCT01716507|Detachment
1067703|NCT01716507|PPV
1067704|NCT01716507|Pars Plana Vitrectomy
1067705|NCT01716507|Gauge
1067706|NCT01716494|asthma
1067707|NCT01716481|Stroke
1067708|NCT01716481|Mesenchymal stem cells
1067709|NCT01716481|Stem cells
1067710|NCT01716481|Neurogenesis
1067711|NCT01716468|Ketogenic Diet, Advanced Cancer, Neoplasm
1067712|NCT01716468|Low carbohydrate
1067713|NCT01716442|rituximab
1067714|NCT01716442|nephrotic
1067715|NCT01716442|refractory
1067716|NCT01716429|vegetarian
1067717|NCT01716429|vegan
1067718|NCT01716429|low calorie
1067719|NCT01716429|weight Loss
1067720|NCT01716429|infertility
1067721|NCT01716429|PCOS
1067722|NCT01716403|C hepatitis, telaprevir concentration, ribavirin oncentration, anemia
1067723|NCT01716377|Neck Pain
1067724|NCT01716377|Musculoskeletal pain
1067725|NCT01716377|Venlafaxine
1067726|NCT01716351|Randomized Clinical Control Trial
1067727|NCT01716351|Complementary and Alternative Medicine
1067728|NCT01716351|Yoga
1067729|NCT01716351|Electrophysiology
1067730|NCT01716351|Implantable Cardioverter Defibrillator
1067731|NCT01716351|Psychosocial
1067732|NCT01716351|Anxiety
1067733|NCT01716351|Self-Compassion
1067734|NCT01716351|Anti-Tachycardia Pacing Events
1067735|NCT01716338|glyburide
1067736|NCT01716338|glybenclamide
1067737|NCT01716338|hypoglycemia
1067738|NCT01716312|Safety Of Omalizumab In Patients With SLE
1067739|NCT01716312|Systemic Lupus Erythematosus
1067740|NCT01716299|HIV
1067741|NCT01716299|Diagnostics
1067742|NCT01716247|Mammography (CESM)
1067743|NCT01716247|MRI
1067744|NCT01716247|Breast screening
1067745|NCT01716247|12-214
1067746|NCT01716208|Fresh Frozen Plasma
1067747|NCT01716208|Complement
1067748|NCT01716208|Monoclonal Antibody
1067749|NCT01716195|Human Papillomavirus
1067750|NCT01716195|HPV
1067751|NCT01716143|atrial fibrillation
1067752|NCT01716143|catheter ablation
1067753|NCT01716143|Mapping
1067754|NCT01716130|Fluzone Intradermal vaccine
1067755|NCT01716117|Large aneurysm
1067756|NCT01716117|Giant aneurysm
1067757|NCT01716117|Wide neck aneurysm
1067758|NCT01716091|focus of study is postoperative enfectious morbidity and postoperative GİS functionally recovery
1067759|NCT01716078|Brachial Plexus
1067760|NCT01716078|Nerve Block
1067761|NCT01716078|Nerve Conduction
1067762|NCT01716065|Anesthesia, Circulating tumor cells
1067763|NCT01716052|Mammogram
1067764|NCT01716052|Ibuprofen
1067765|NCT01716052|Pain management
1067766|NCT01716039|Moderately to severely active Ulcerative Colitis
1067767|NCT01716026|high myopia
1067768|NCT01716026|choroidal neovascularization
1067769|NCT01716000|vaginal gel
1067770|NCT01716000|vaginal coating
1067771|NCT01716000|sensory perceptions
1067772|NCT01715987|Hepatitis B
1067773|NCT01715987|Antiviral
1067774|NCT01715987|Tubular dysfunction
1067775|NCT01715987|Entecavir
1067776|NCT01715987|Tenofovir
1067777|NCT01715974|G-CSF, IVF failure,pregnancy
1067778|NCT01715961|70 years old
1067779|NCT01715961|DLBCL
1067780|NCT01715961|Rituximab-CHOP
1067781|NCT01715961|Sarcopenia
1067782|NCT01715948|CROS hearing aid
1067783|NCT01715948|Bone-anchored hearing device
1067784|NCT01715935|Clear cells renal carcinoma
1067785|NCT01715935|everolimus
1067786|NCT01715935|neo-adjuvant treatment
1067787|NCT01715922|Cryptococcal meningitis
1067788|NCT01715922|HIV Infections
1067789|NCT01715922|Oral treatment
1067790|NCT01715922|High dose of fluconazole
1067791|NCT01715922|Flucytosine
1067792|NCT01715922|Burundi
1067793|NCT01715922|Ivory Coast
1067794|NCT01715896|Rheumatoid Arthritis
1067795|NCT01715896|Golimumab
1067796|NCT01715896|Mavrilimumab
1067797|NCT01715883|Lung transplant
1067798|NCT01715883|Pulmonary Graft Dysfunction
1067799|NCT01715883|Sodium Nitrite
1067800|NCT01715870|Age related macular degeneration
1067801|NCT01715870|Food habits
1067802|NCT01715870|Life style
1067803|NCT01715870|Risk factors
1067804|NCT01715870|questionnaire
1067805|NCT01715857|Economics, Pharmaceutical
1067806|NCT01715857|Physician's Practice Patterns
1067807|NCT01715857|Chinese
1067808|NCT01715857|Sevoflurane
1067809|NCT01715844|L-citrulline
1067810|NCT01715844|ADMA
1067811|NCT01715844|Asthma
1067812|NCT01715844|Obesity
1067813|NCT01715805|MDD
1067814|NCT01715805|Major Depressive Disorder
1067815|NCT01715792|Solid organ transplant rejection
1067816|NCT01715792|United Kingdom
1067817|NCT01715792|Influenza
1067818|NCT01715792|H1N1
1067819|NCT01715792|Pandemrix™
1067820|NCT01715779|Liver transplantation
1067821|NCT01715779|ENABLE
1067822|NCT01715779|observational
1067823|NCT01715779|mortality
1067824|NCT01715779|Thromboembolic Events
1067825|NCT01715779|Hepatic decompensation
1067826|NCT01715779|Long-Term follow-up
1067827|NCT01715779|TEE
1067828|NCT01715766|Proteomics study
1067829|NCT01715766|biomarker study of pain
1067832|NCT01715740|Chinese herbal medicine
1067833|NCT01715740|Urticaria
1067834|NCT01715740|Antipruritics
1067835|NCT01715740|Phase III clinical trial
1067836|NCT01715727|diffusion kurtosis imaging
1067837|NCT01715727|parkinson disease
1067838|NCT01715727|parkinsonism
1067839|NCT01715727|diagnosis
1067840|NCT01715727|differential diagnosis
1067841|NCT01715714|Coronary Artery Disease
1067842|NCT01715714|Statins
1067843|NCT01715714|Coronary Artery Bypass Grafting
1067844|NCT01715714|Cardiac Surgery
1067845|NCT01715675|asthma
1067846|NCT01715675|allergy
1067847|NCT01715675|sitostanol
1067848|NCT01715675|cytokines
1067849|NCT01715675|Th1
1067850|NCT01715675|Treg
1067851|NCT01715675|antibodies
1067852|NCT01715675|IgE
1067853|NCT01715675|vaccination
1067854|NCT01715662|rehabilitation
1067855|NCT01715662|lower limb amputation
1067856|NCT01715662|unilateral transtibial amputation
1067857|NCT01715662|unilateral transfemoral amputation
1067858|NCT01715662|older adults
1067859|NCT01715662|cognitive computer games
1067860|NCT01715662|home-based training
1067861|NCT01715662|Nintendo Wii
1067862|NCT01715662|virtual reality
1067863|NCT01715649|Type 2 diabetes
1067864|NCT01715649|self-management
1067865|NCT01715649|remote patient monitoring
1067866|NCT01715623|polymorphism
1067867|NCT01715623|serum Ig
1067868|NCT01715597|uterine leiomyoma
1067869|NCT01715597|laparoscopic myomectomy
1067870|NCT01715597|intraoperative blood loss
1067871|NCT01715597|ascorbic acid
1067872|NCT01715584|Hypertension
1067873|NCT01715584|Sevoflurane
1067874|NCT01715584|Inhaled Anesthetic
1067875|NCT01715584|Angiotensin Converting Enzyme Inhibitor
1067876|NCT01715584|Angiotensin II Receptor Blocking Agent
1067877|NCT01715571|erectile dysfunction
1067878|NCT01715571|vibratory stimulation
1067879|NCT01715571|viberect
1067880|NCT01715545|day-3 poor quality embryo
1067881|NCT01715545|vitrification
1067882|NCT01715545|clinical outcome
1067883|NCT01715532|Huachansu
1067884|NCT01715532|Na+/K+-ATPase α3
1067885|NCT01715532|transcatheter arterial chemoembolization
1067886|NCT01715532|randomized controlled trial
1067887|NCT01715519|Vilazodone
1067888|NCT01715519|PTSD
1067889|NCT01715519|Depression
1067890|NCT01715506|Dementia
1067891|NCT01715506|Resident
1067892|NCT01715506|Nursinghome
1067893|NCT01715506|Use of restraint
1067894|NCT01715506|Agitation
1067895|NCT01715493|COPD
1067896|NCT01715493|Asthma
1067897|NCT01715493|Lysozyme Hydrochloride
1067898|NCT01715480|broccoli sprout
1067899|NCT01715480|sickle cell
1067900|NCT01715480|NRF2
1067901|NCT01715467|Dupuytren
1067902|NCT01715467|Contracture
1067903|NCT01715467|Auxilium
1067904|NCT01715467|XIAFLEX
1067905|NCT01714388|remifentanil
1067906|NCT01714388|heart rate
1067907|NCT01714388|autonomic nervous system
1067908|NCT01714388|heart rate variability
1067909|NCT01714388|autonomic nervous activity
1067910|NCT01714388|vagotonic effect
1067911|NCT01714388|single dose
1067912|NCT01714362|oculocardiac effect
1067913|NCT01714362|bradycardia
1067914|NCT01714362|HRV
1067915|NCT01714349|Spinal cord injury
1067916|NCT01714349|nerve transfer
1067917|NCT01714349|tetraplegia
1067918|NCT01714349|quadriplegia
1067919|NCT01714336|Arbeitsgemeinschaft für Osteosynthesefragen (AO) fracture
1067920|NCT01714336|Orthopaedic Trauma Association (OTA) fracture
1067921|NCT01714323|Cigarette smoking
1067922|NCT01714323|Tobacco smoking
1067923|NCT01714323|Tobacco use disorder
1067924|NCT01714310|severe mood dysregulation
1067925|NCT01714310|irritability
1067926|NCT01714310|lisdexamfetamine
1067927|NCT01714310|fluoxetine
1067928|NCT01714310|newly recognized syndrome
1068055|NCT01715064|Cortical Silent Period
1067929|NCT01714297|cemented total hip arthroplasty
1067930|NCT01714297|blood loss
1067931|NCT01714297|wound discharge
1067932|NCT01714297|thromboprophylaxis
1067933|NCT01714297|biomarkers
1067934|NCT01714284|psoriasis
1067935|NCT01714258|cardiac output
1067936|NCT01714258|fick method
1067937|NCT01714258|thermodilution
1067938|NCT01714245|Eczema
1067939|NCT01714245|Atopic Dermatitis
1067940|NCT01714245|Compromised Skin
1067941|NCT01714245|Inflamed Skin
1067942|NCT01715441|Metastatic colorectal cancer patients
1067943|NCT01715441|KRAS mutation
1067944|NCT01715441|Sorafenib
1067945|NCT01715428|diabetes, cardiovascular risk
1067946|NCT01715415|Hepatitis C
1067947|NCT01715415|Treatment-Experienced
1067948|NCT01715415|Null responder
1067949|NCT01715415|Partial Responder
1067950|NCT01715415|Chronic Hepatitis
1067951|NCT01715415|Hepatitis C Genotype 1
1067952|NCT01715415|Interferon-Free
1067953|NCT01715415|Hepatitis C Virus
1067954|NCT01715415|Relapser
1067955|NCT01715415|Non responder
1067956|NCT01715415|Viekira Pak
1067957|NCT01715415|ombitasvir
1067958|NCT01715415|ribavirin
1067959|NCT01715415|ritonavir
1067960|NCT01715415|paritaprevir
1067961|NCT01715415|dasabuvir
1067962|NCT01715402|liver tumor
1067963|NCT01715402|carcinoma
1067964|NCT01715402|cholangiocarcinoma
1067965|NCT01715402|metastasis
1067966|NCT01715389|Asthma
1067967|NCT01715389|Goals
1067968|NCT01715389|Shared Decision Making
1067969|NCT01715389|Patient Portal
1067970|NCT01715389|Electronic Medical Record
1067971|NCT01715376|traditional chinese medicine
1067972|NCT01715376|complementary therapies
1067973|NCT01715376|traditional chinese medicine syndrome scale
1067974|NCT01715350|Alzheimer's Disease
1067975|NCT01715337|muscle fibre
1067976|NCT01715337|capillary
1067977|NCT01715337|rehabilitation
1067978|NCT01715337|exercise training
1067979|NCT01715324|In vitro fertilization
1067980|NCT01715324|Antagonist protocol
1067981|NCT01715324|Growth Hormone
1067982|NCT01715311|COPD
1067983|NCT01715311|Chronic obstructive pulmonary disease
1067984|NCT01715311|indacaterol
1067985|NCT01715311|tiotropium
1067986|NCT01715298|Anticholinergic
1067987|NCT01715298|Antimuscarinic
1067988|NCT01715298|Chronic Obstructive Airway Disease
1067989|NCT01715298|Chronic Obstructive Lung Disease
1067990|NCT01715298|Chronic Obstructive Pulmonary Disease
1067991|NCT01715298|COPD
1067992|NCT01715298|LAMA
1067993|NCT01715298|Lung Disease
1067994|NCT01715298|Lung Diseases, Obstructive
1067995|NCT01715298|Lung Function
1067996|NCT01715298|Muscarinic receptor antagonist
1067997|NCT01715298|Pulmonary Disease, Chronic Obstructive
1067998|NCT01715298|Respiratory Tract Diseases
1067999|NCT01715285|Prostate neoplasms
1068000|NCT01715285|Prostate cancer
1068001|NCT01715285|Metastatic prostate cancer
1068002|NCT01715285|Abiraterone acetate
1068003|NCT01715285|ZYTIGA
1068004|NCT01715285|Prednisone
1068005|NCT01715285|Androgen deprivation therapy
1068006|NCT01715259|Renal insufficiency
1068007|NCT01715259|Renal impairment
1068008|NCT01715259|End-stage renal disease
1068009|NCT01715259|Abiraterone acetate
1068010|NCT01715259|Pharmacokinetics
1068011|NCT01715246|healthy babbies
1068012|NCT01715246|infant formula
1068013|NCT01715246|growth
1068014|NCT01715246|HMO
1068015|NCT01715220|Nitroglycerin
1068016|NCT01715220|Biliary Colic
1068017|NCT01715220|Cholelithiasis
1068018|NCT01715220|Abdominal Pain.
1068019|NCT01715194|OSAS
1068020|NCT01715194|CPAP
1068021|NCT01715194|Adherence
1068022|NCT01715194|Telemedicine
1068023|NCT01715168|Doxil generic
1068024|NCT01715168|Caelyx generic
1068025|NCT01715168|generic treatment
1068026|NCT01715168|ovarian cancer
1068027|NCT01715168|ovary
1068028|NCT01715168|progressed
1068029|NCT01715168|recurred cancer
1068030|NCT01715168|platinum based therapy
1068031|NCT01715155|Metastatic Breast Cancer,
1068032|NCT01715155|retrospective study,
1068033|NCT01715155|disease progression,
1068034|NCT01715155|clinical management
1068035|NCT01715142|Pancreatic cancer
1068036|NCT01715142|Nab-paclitaxel
1068037|NCT01715142|Gemcitabine
1068038|NCT01715142|Neoadjuvant chemotherapy
1068039|NCT01715116|Cardiac arrhythmias
1068040|NCT01715116|Implantable Cardioverter-Defibrillator
1068041|NCT01715116|Patient Safety
1068042|NCT01715116|Quality of life
1068043|NCT01715103|HIV infection
1068044|NCT01715103|mucosa
1068045|NCT01715103|immunological parameters
1068046|NCT01715103|genital sampling
1068047|NCT01715103|healthy women volunteers
1068048|NCT01715077|melanoma
1068049|NCT01715077|stage IV
1068050|NCT01715077|stage III
1068051|NCT01715077|unresectable
1068052|NCT01715064|Prostate Cancer
1068053|NCT01715064|Exercise
1068054|NCT01715064|Cortical Inhibition
1068056|NCT01715064|Transcranial Magnetic Stimulation
1068057|NCT01715051|cocaine
1068058|NCT01715051|D-serine
1068059|NCT01715051|Drug dependence
1068060|NCT01715038|malnutrition
1068061|NCT01715038|stunting
1068062|NCT01715038|LNS
1068063|NCT01715038|micronutrient powder
1068064|NCT01715038|hemoglobin
1068065|NCT01715025|measured
1068066|NCT01715025|heavy menstrual bleeding
1068067|NCT01715025|combined oral contraceptive
1068068|NCT01715025|alkaline haematin method
1068069|NCT01715012|Burn
1068070|NCT01715012|Diabetes
1068071|NCT01715012|Skin graft
1068072|NCT01715012|Donor site
1068073|NCT01714999|olecranon
1068074|NCT01714999|prepatellar
1068075|NCT01714999|bursa
1068076|NCT01714999|trauma
1068077|NCT01714999|laceration
1068078|NCT01714999|bursectomy
1068079|NCT01714999|bursa reconstruction
1068080|NCT01714986|Diabetes mellitus
1068081|NCT01714986|Depression
1068082|NCT01714986|Anxiety
1068083|NCT01714986|Alexithymia
1068084|NCT01714986|Self Image
1068085|NCT01714986|HbA1c
1068086|NCT01714986|Psychoeducation
1068087|NCT01714934|IDIOPATHIC PULMONARY FIBROSIS
1068088|NCT01714934|MICROASPIRATION
1068089|NCT01714908|NSCLC
1068090|NCT01714908|EGFR mutation
1068091|NCT01714908|unresectable
1068092|NCT01714908|erlotinib
1068093|NCT01714908|concurrent radiotherapy
1068094|NCT01714895|Interstitial glucose dynamics
1068095|NCT01714895|Accuracy of continuous glucose monitoring under hypoglycemia
1068096|NCT01714895|Glucose clamp
1068097|NCT01714882|Infertility
1068098|NCT01714882|In Vitro Fertilization (IVF)
1068099|NCT01714882|Stress Management
1068100|NCT01714882|Stress Reduction
1068101|NCT01714869|Swedish massage
1068102|NCT01714869|massage
1068103|NCT01714869|osteoarthritis
1068104|NCT01714869|knee
1068105|NCT01714843|ASP0456
1068106|NCT01714843|constipation
1068107|NCT01714843|irritable bowel syndrome (IBS)
1068108|NCT01714843|linaclotide
1068109|NCT01714791|Coronary Artery Bypass Graft
1068110|NCT01714791|Osteopathic Medicine
1068111|NCT01714791|Vital Capacity
1068112|NCT01714791|Quality of Life
1068113|NCT01714791|Cardiac rehabilitation
1068114|NCT01714765|Metastatic Clear Cell Renal Cancer Dovitinib Everolimus Cohort Maximum administered dose maximum tolerated dose
1068115|NCT01714752|Diagnosis
1068116|NCT01714752|Left ventricular end diastolic pressure (LVEDP)
1068117|NCT01714752|Exercise echocardiography
1068118|NCT01714752|Left atrial remodeling
1068119|NCT01714726|MEDI2070
1068120|NCT01714726|inflammatory bowel disease
1068121|NCT01714726|moderate to severe Crohn's disease
1068122|NCT01714713|Schizophrenia
1068123|NCT01714713|Cognition
1068124|NCT01714713|Cognition Impairment
1068125|NCT01714713|Alpha-7 nAChR
1068126|NCT01714700|protein
1068127|NCT01714700|resistance exercise ghrelin
1068128|NCT01714700|overweight
1068129|NCT01714674|cardiac troponin T
1068130|NCT01714674|cTnT
1068131|NCT01714674|exercise
1068132|NCT01714674|dietary nitrate
1068133|NCT01714661|Schizophrenia
1068134|NCT01714661|Cognition
1068135|NCT01714661|Cognition Impairment
1068136|NCT01714661|Alpha-7 nAChR
1068137|NCT01714648|OVULATION INDUCTION
1068138|NCT01714635|cataract
1068139|NCT01714635|IOL
1068140|NCT01714635|intraocular lens
1068141|NCT01714622|metabolic syndrome
1068142|NCT01714622|insulin resistance
1068143|NCT01714622|gastric cancer
1068144|NCT01714609|portal hypertension
1068145|NCT01714609|sorafenib
1068146|NCT01714596|Oral Antibiotic
1068147|NCT01714596|Intravenous Antibiotic
1068148|NCT01714596|Wound infection
1068149|NCT01714596|Randomized Controlled Trial
1068150|NCT01714583|Mechanical ventilation
1068151|NCT01714583|ARDS
1068152|NCT01714583|acute lung injury
1068153|NCT01714583|cardiac function
1068154|NCT01714583|cardiac index
1068155|NCT01714583|heart-lung interaction
1068156|NCT01714531|Mild TBI
1068157|NCT01714518|Interstitial Lung Disease
1068158|NCT01714518|Diagnosis
1068159|NCT01714518|Cryobiopsy
1068160|NCT01714518|Video-assisted thoracic surgery
1068161|NCT01714518|Lung biopsy
1068162|NCT01714505|Diabetes Mellitus, Type 1
1068163|NCT01714505|Continuous Glucose Monitor
1068164|NCT01714505|Artificial Pancreas
1068165|NCT01714505|Insulin Pump
1068166|NCT01714505|Closed Loop control
1068167|NCT01714505|Open Loop treatment
1068168|NCT01714492|Total Knee Arthroplasty (TKA)
1068169|NCT01714492|in vivo mechanics
1068170|NCT01714492|kinematics
1068171|NCT01714492|fluoroscopy
1068172|NCT01714440|genomics of kidney transplantation
1068173|NCT01714440|genetic variation
1068174|NCT01714440|recipient genotypes
1068175|NCT01714440|donor genotypes
1068176|NCT01714414|HIV
1068177|NCT01714414|Fozivudine
1068178|NCT01714414|Zidovudine
1068179|NCT01714414|FATI
1068180|NCT01714219|prostatic neoplasms
1068181|NCT01714219|prostatectomy
1068182|NCT01714219|robotics
1068183|NCT01714219|urinary incontinence
1068184|NCT01714206|Healthy
1068185|NCT01714206|Canagliflozin (JNJ-28431754)
1068186|NCT01714206|Pharmacokinetics
1068187|NCT01714206|Digoxin (LANOXIN)
1068188|NCT01714193|Healthy
1068189|NCT01714193|Canagliflozin (JNJ-28431754)
1068190|NCT01714193|Pharmacokinetics
1068191|NCT01714193|Contraceptives, Oral
1068192|NCT01714193|Ethinyl Estradiol
1068193|NCT01714193|Levonorgestrel
1068194|NCT01714193|LEVORA
1068195|NCT01714180|Acyclovir
1068196|NCT01714180|Pharmacokinetics
1068197|NCT01714180|Obese
1068198|NCT01714180|Non-obese
1068199|NCT01714180|Weight
1068200|NCT01714180|Distribution
1068201|NCT01714180|Clearance
1068202|NCT01714167|Chronic
1068203|NCT01714167|Ischemic Stroke
1068204|NCT01714167|Intracerebral Hemorrhage
1068205|NCT01714167|Bone Marrow Mesenchymal Stem Cell
1068206|NCT01714141|Technology based intervention
1068207|NCT01714141|Emerging adults
1068208|NCT01714141|African Americans
1068209|NCT01714141|Asthma
1068210|NCT01714141|Controller medications
1068211|NCT01714141|Motivational intervention
1068212|NCT01714128|NCI protocol #8762
1068213|NCT01714128|Estrogen receptor positive breast cancer
1068214|NCT01714128|recurrent breast cancer
1068215|NCT01714128|stage IV breast cancer
1068216|NCT01714102|Obesity
1068217|NCT01714102|Insulin resistance
1068218|NCT01714102|Metabolic syndrome
1068219|NCT01714102|Pre-diabetes
1068220|NCT01714089|Relapsing remitting multiple sclerosis
1068221|NCT01714089|RR-MS
1068222|NCT01714063|pediatric
1068223|NCT01714063|asthma
1068224|NCT01714063|metered dose inhaler
1068225|NCT01714063|valved holding chamber
1068226|NCT01714063|pMDI
1068227|NCT01714063|VHC
1068228|NCT01714050|seasonal affective disorder
1068229|NCT01714050|winter depression
1068230|NCT01714050|cognitive-behavioral therapy
1068231|NCT01714050|light therapy
1068232|NCT01714037|Safety
1068233|NCT01714037|Efficacy
1068234|NCT01714037|HSP90
1068235|NCT01714037|Debio 0932
1068236|NCT01714037|Standard of care treatment, NSCLC
1068237|NCT01714024|Dental
1068238|NCT01714024|Implant
1068239|NCT01714024|UNC Dental School
1068240|NCT01714024|Trabecular Metal
1068241|NCT01714024|Titanium
1068242|NCT01714024|Healthy Volunteers
1068243|NCT01714024|Diabetic
1068244|NCT01714024|Osteopenic
1068245|NCT01714024|Bone Inductive Properties
1068246|NCT01714024|Osseous Healing
1068247|NCT01714024|GO Health
1068248|NCT01714024|Offenbacher
1068249|NCT01714024|Zimmer Dental, Inc.
1068250|NCT01714011|Randomized
1068251|NCT01714011|Controlled
1068252|NCT01714011|Trial
1068253|NCT01714011|Safety
1068254|NCT01714011|Efficacy
1068255|NCT01714011|Aripiprazole
1068256|NCT01714011|Ziprasidone
1068257|NCT01714011|Metabolic Syndrome
1068258|NCT01713998|Ulthera® System
1068259|NCT01713998|Ultherapy™ Treatment
1068260|NCT01713998|Ulthera, Inc.
1068261|NCT01713998|Ultrasound treatment for skin tightening
1068262|NCT01713985|Ulthera® System
1068263|NCT01713985|Ultherapy™ Treatment
1068264|NCT01713985|Ulthera, Inc.
1068265|NCT01713985|Ultrasound treatment for skin tightening
1068266|NCT01713972|BRAFi
1068267|NCT01713972|BRAF-mutated
1068268|NCT01713959|Underarm sweating
1068269|NCT01713946|TSC seizures,
1068270|NCT01713946|TSC epilepsy,
1068271|NCT01713946|mTOR inhibitor,
1068272|NCT01713946|RAD001,
1068273|NCT01713946|Everolimus
1068274|NCT01713933|Ulthera® System
1068275|NCT01713933|Ultherapy™ treatment
1068276|NCT01713933|Ulthera, Inc.
1068277|NCT01713907|Ultherapy™ treatment
1068278|NCT01713907|Ulthera® System
1068279|NCT01713907|Ulthera, Inc.
1068280|NCT01713907|Ultrasound treatment for skin tightening
1068281|NCT01713894|Counseling
1068282|NCT01713894|Limits of viability
1068283|NCT01713881|Polyp
1068284|NCT01713881|colonoscopy
1068285|NCT01713881|surveillance
1068286|NCT01713868|Breastfeeding
1068287|NCT01713868|Safe Sleep
1068288|NCT01713868|Messaging
1068289|NCT01713868|Social Media
1068290|NCT01713855|ITP
1068291|NCT01713855|Rituximab
1068292|NCT01713855|Vaccine
1068293|NCT01713855|Immune Reconstitution
1068294|NCT01713842|Tocilizumab
1068295|NCT01713842|Polymyalgia Rheumatica
1068296|NCT01713842|Glucocorticotherapy
1068297|NCT01713842|PMR-AS
1068298|NCT01713829|cranberry
1068299|NCT01713829|gamma delta T cell
1068300|NCT01713829|improvement in immune cell function in healthy humans
1068301|NCT01713829|proliferation
1068302|NCT01713816|Glutathione
1068303|NCT01713816|Ascorbate
1068304|NCT01713816|Alzheimer's disease
1068305|NCT01713816|Aging
1068306|NCT01713816|Magnetic Resonance Spectroscopy
1068307|NCT01713790|physical functional performance
1068308|NCT01713790|postural balance
1068309|NCT01713790|reaction time
1068310|NCT01713790|mobility
1068311|NCT01713790|muscle strength
1068312|NCT01713790|cognition
1068313|NCT01713777|Seizures
1068314|NCT01713764|diabetes
1068315|NCT01713764|obesity
1068316|NCT01713764|mindful eating
1068317|NCT01713764|positive affect
1068318|NCT01713764|low carbohydrate
1068319|NCT01713764|diet
1068320|NCT01713751|Surgical site infection
1068321|NCT01713751|Cesarean section
1068322|NCT01713738|ITP
1068323|NCT01713738|rituximab
1068324|NCT01713738|bleeding score
1068325|NCT01713738|platelet count
1068326|NCT01713738|health-related quality of life
1068327|NCT01713738|HRQL
1068328|NCT01713725|Chronic urticaria
1068329|NCT01713725|Chronic spontaneous urticaria
1068330|NCT01713725|Autoimmune and non autoimmune urticaria
1068331|NCT01713725|UAS7
1068332|NCT01713712|Pregnancy
1068333|NCT01713712|Obesity
1068334|NCT01713712|Nutrition therapy
1068335|NCT01713699|CTC, cytology, meningeal carcinomatosis, leptomeningeal metastases
1068336|NCT01713686|Ulthera® System
1068337|NCT01713686|Ultherapy™ Treatment
1068338|NCT01713686|Ulthera, Inc.
1068339|NCT01713686|Micro-focused Ultrasound with Visualization (MFU-V)
1068340|NCT01713673|Hyperhidrosis
1068341|NCT01713673|Axillary sweating
1068342|NCT01713673|Ulthera® System
1068343|NCT01713673|Ultherapy™ Treatment
1068344|NCT01713673|Ulthera, Inc.
1068345|NCT01713660|Cataract surgery
1068346|NCT01713660|Femtosecond laser
1068347|NCT01713660|Corneal incisions
1068348|NCT01713647|Bio-equivalence, crossover
1068349|NCT01713634|Bone resorption
1068350|NCT01713634|Diet
1068351|NCT01713621|P. falciparum
1068352|NCT01713621|malaria
1068353|NCT01713608|malaria
1068354|NCT01713608|dose escalation
1068355|NCT01713608|safety
1068356|NCT01713608|tolerability
1068357|NCT01713608|maximum tolerated dose
1068358|NCT01713595|Acute Lung Injury
1068359|NCT01713595|Mechanical Ventilation
1068360|NCT01713569|Ulthera® System
1068361|NCT01713569|Ultherapy™ Treatment
1068362|NCT01713569|Ulthera, Inc.
1068363|NCT01713569|Ultrasound treatment for skin tightening
1068364|NCT01713556|PTSD, Propranolol
1068365|NCT01713543|falls
1068366|NCT01713517|Mosquito Control
1068367|NCT01713517|Insecticide Resistance
1068368|NCT01713491|brain ischemia
1068369|NCT01713491|thrombolytic therapy
1068370|NCT01713491|Impaired cognition
1068371|NCT01713491|dementia
1068372|NCT01713478|hepatic cirrhosis
1068373|NCT01713478|subclinical myocardial dysfunction
1068374|NCT01713478|echocardiography
1068375|NCT01713478|specific biomarkers
1068376|NCT01713478|vascular assessment
1068377|NCT01713465|Diabetes
1068378|NCT01713465|Hypertension
1068379|NCT01713465|Hypercholesterolemia
1068380|NCT01713465|Obesity
1068381|NCT01713452|Surgical Stomas
1068382|NCT01713452|ileostomy
1068383|NCT01713452|surgical site infection
1068384|NCT01713439|Relapsed/Refractory Neuroblastoma
1068385|NCT01713439|Retroviral vector injections
1068386|NCT01713439|Allogeneic neuroblastoma cells
1068387|NCT01713439|Lymphotactin
1068388|NCT01713439|Interleukin-2 (IL-2)
1068389|NCT01713426|Post herpetic neuralgia
1068390|NCT01713426|Peripheral Neuropathic Pain
1068391|NCT01713426|Qutenza
1068392|NCT01713426|Pregabalin
1068393|NCT01713426|NGX-4010
1068394|NCT01713413|Oxymizer
1068395|NCT01713413|endurance time
1068396|NCT01713413|exercise test
1068397|NCT01713413|nasal cannula
1068398|NCT01713413|COPD
1068399|NCT01713413|ILD
1068400|NCT01713413|oxygenation
1068401|NCT01713400|Acute Graft vs. Host Disease (aGVHD)
1068402|NCT01713400|Graft vs. Host Disease (GVHD)
1068403|NCT01713387|adjuvant chemotherapy
1068404|NCT01713374|endothelial function
1068405|NCT01713374|sympathetic nervous system
1068406|NCT01713361|total knee arthroplasty
1068407|NCT01713361|Prophylaxis
1068408|NCT01713348|CGM
1068409|NCT01713348|MDI
1068410|NCT01713322|parent education
1068411|NCT01713322|pain management
1068412|NCT01713322|immunization
1068413|NCT01713322|infant
1068414|NCT01713309|Filgrastim
1068415|NCT01713309|G-CSF
1068416|NCT01713309|Heparin-binding protein
1068417|NCT01713309|critically ill
1068418|NCT01713309|acute respiratory failure
1068419|NCT01713296|SCLC
1068420|NCT01713296|2nd Line
1068421|NCT01713296|Relapsed or Refractory
1068422|NCT01713270|Hypertension
1068423|NCT01713270|Atrial Fibrillation
1068424|NCT01713270|Arrhythmias, Cardiac
1068425|NCT01713270|Heart Diseases
1068426|NCT01713257|Critically ill patients
1068427|NCT01713244|Hepatocellular Carcinoma
1068428|NCT01713244|Radiofrequency Ablation
1068429|NCT01713244|Hepatectomy
1068430|NCT01713244|Recurrence
1068431|NCT01713231|osteogenesis imperfecta
1068432|NCT01713231|high-dose vitamin D
1068433|NCT01713231|bone density
1068434|NCT01713231|muscle function
1068435|NCT01713218|Pancreas
1068436|NCT01713218|Cancer
1068437|NCT01713218|Hedgehog inhibitor
1068438|NCT01713218|Neoadjuvant chemotherapy
1068439|NCT01713218|Dynamic imaging
1068440|NCT01713205|trauma ; sepsis; Multiple Organ Dysfunction Syndrome; Prediction; risk
1068441|NCT01713153|postpartum hemorrhage
1068442|NCT01713153|prevention
1068443|NCT01713153|misoprostol
1068444|NCT01713153|Uniject
1068445|NCT01713153|oxytocin
1068446|NCT01713140|strength training
1068447|NCT01713140|resistance training
1068448|NCT01713140|fatigue
1068449|NCT01713140|knee extension
1068450|NCT01713140|total knee arthroplasty
1068451|NCT01713140|total knee replacement
1068452|NCT01713140|electromyography
1068453|NCT01713140|physical therapy modalities
1068454|NCT01713101|Gastrointestinal Hemorrhage
1068455|NCT01713101|Peptic Ulcer Hemorrhage
1068456|NCT01713101|Hematemesis
1068457|NCT01713101|Melena
1068458|NCT01713101|Tranexamic acid
1068459|NCT01713088|multisystemic therapy, RCT, young offenders, U.K.
1068460|NCT01713075|chronic obstructive pulmonary disease
1068461|NCT01713075|Symbicort
1068462|NCT01713075|long-term use
1068463|NCT01713049|FLT PET
1068464|NCT01713049|breast neoplasms
1068465|NCT01713049|mammography
1068466|NCT01713049|breast ultrasound
1068467|NCT01713036|Mass balance, bioavailability, cancer, 14C
1068468|NCT01713023|type 1 diabetes
1068469|NCT01713023|fructose
1068470|NCT01713023|glucose
1068471|NCT01713023|TAS1R2
1068472|NCT01713023|oxidative stress
1068473|NCT01713010|Keywords provided by Atlantic Health System:
1068474|NCT01713010|Rapid Shallow Breathing Index
1068475|NCT01713010|Mechanical Ventilation
1068476|NCT01713010|Additional relevant MeSH terms:
1068477|NCT01713010|Respiration Disorders
1068478|NCT01713010|Traumatic Brain Injury
1068479|NCT01713010|Weaning Failure
1068480|NCT01713010|Mechanical ventilation complication
1068481|NCT01712997|Treatment of
1068482|NCT01712984|Influenza
1068483|NCT01712984|Fluzone® Intradermal vaccine
1068484|NCT01712984|Influenza Virus Vaccine USP Quadrivalent
1068485|NCT01712984|Influenza Virus Vaccine USP Trivalent Types A and B
1068486|NCT01712971|surgery
1068487|NCT01712971|pancreas
1068488|NCT01712971|tumour
1068489|NCT01712971|blood loss
1068490|NCT01712958|CRC miRNA
1068491|NCT01712945|Alemtuzumab
1068492|NCT01712945|Palifermin
1068493|NCT01712945|Reconstitution
1068494|NCT01712945|Thymus
1068495|NCT01712919|Locoregionally advanced nasopharyngeal carcinoma
1068496|NCT01712919|cetuximab
1068497|NCT01712919|chemoradiation
1068498|NCT01712893|breast cancer
1068499|NCT01712893|adjuvant therapy
1068500|NCT01712893|Ovarian suppression
1068501|NCT01712854|COPD
1068502|NCT01712854|Chronic Obstructive Lung Disease
1068503|NCT01712854|Long acting beta agonist
1068504|NCT01712841|Dry AMD
1068505|NCT01712841|Age-related macular degeneration
1068506|NCT01712841|Optical coherenece tomography
1068507|NCT01712841|Imaging
1068508|NCT01712841|Blood flow
1068509|NCT01712828|Lenalidomide,
1068510|NCT01712828|Revlimid,
1068511|NCT01712828|pharmacokinetics,
1068512|NCT01712828|healthy male subjects
1068513|NCT01712789|Multiple Myeloma
1068514|NCT01712789|Relapsed Multiple Myeloma
1068515|NCT01712789|Relapsed and refractory Multiple Myeloma
1068516|NCT01712789|Pomalidomide
1068517|NCT01712789|Dexamethasone
1068518|NCT01712776|Vapocoolant
1068519|NCT01712763|Endometriosis
1068520|NCT01712763|long acting GnRH antagonist
1068521|NCT01712763|Degarelix
1068522|NCT01712763|Recurrence
1068523|NCT01712763|Pelvic Pain
1068524|NCT01712750|Regional tissue oximetry
1068525|NCT01712750|Cardiopulmonary bypass
1068526|NCT01712750|Cardiac surgical procedures
1068527|NCT01712737|raisins, grapes, snacks, appetite, food intake
1068528|NCT01712724|exercise therapy
1068529|NCT01712724|rehabilitation
1068530|NCT01712711|Steatohepatitis,
1068531|NCT01712711|Helicobacter pylori,
1068532|NCT01712711|Insulin resistance,
1068533|NCT01712711|Alanine aminotransferase,
1068534|NCT01712711|Aspartate aminotransferase,
1068535|NCT01712698|trauma
1068536|NCT01712698|spinal cord injury
1068537|NCT01712698|cervical spine
1068538|NCT01712685|Kidney Neoplasm
1068539|NCT01712685|RCC
1068540|NCT01712685|Biodistribution of 18F-VM4-037
1068541|NCT01712685|CAIX Staining
1068542|NCT01712685|Tumor Angiogenesis
1068543|NCT01712672|Dental Plaque
1068544|NCT01712672|Biofilm
1068545|NCT01712672|Bacterial Interactions
1068546|NCT01712672|Receptor Polysaccharide
1068547|NCT01712672|Oral Streptococci
1068552|NCT01712646|Oxytocin
1068553|NCT01712646|Childhood Onset Schizophrenia
1068554|NCT01712646|Double Blind
1068555|NCT01712633|fMRI
1068556|NCT01712633|Brain Perfusion
1068557|NCT01712620|Microarray
1068558|NCT01712620|Magnetic Resonance Imaging
1068559|NCT01712620|Mineralocorticoid Receptor Antagonist
1068560|NCT01712620|Neurohormonal Axis
1068561|NCT01712620|Vascular Inflammation
1068562|NCT01712620|Pulmonary Hypertension
1068563|NCT01712620|Cardiovascular Disease
1068564|NCT01712620|Vascular Disease
1068565|NCT01712607|laparoscopy
1068566|NCT01712607|surgery
1068567|NCT01712607|warm-up
1068568|NCT01712607|preoperative
1068569|NCT01712607|surgical skills
1068570|NCT01712594|United Kingdom Overnight closed loop
1068571|NCT01712581|normal myocardial T1, T2 and T2* values
1068572|NCT01712555|Anophthalmic orbits
1068573|NCT01712555|autologous fat
1068574|NCT01712555|platelet rich plasma
1068575|NCT01712555|orbital atrophy
1068576|NCT01712555|anophthalmos
1068577|NCT01712555|cannula
1068578|NCT01712529|Systemic lupus erythematosus
1068579|NCT01712529|endothelium
1068580|NCT01712529|exercise
1068581|NCT01712516|COPD, QVA149
1068582|NCT01712503|Cataract
1068583|NCT01712503|Astigmatism
1068584|NCT01712503|Toric
1068585|NCT01712503|Phacoemulsification
1068586|NCT01712503|Intraocular lens
1068587|NCT01712490|Hodgkin Lymphoma
1068588|NCT01712490|Hodgkins Lymphoma
1068589|NCT01712490|Antibody, Monoclonal
1068590|NCT01712490|Antibody-Drug Conjugate
1068591|NCT01712490|Antigens, CD-30
1068592|NCT01712490|Immunotherapy
1068593|NCT01712490|Lymphoma
1068594|NCT01712490|Lymphoma, Classical
1068595|NCT01712490|ECHELON-1
1068596|NCT01712451|adiposity
1068597|NCT01712438|Previously untreated patients
1068598|NCT01712425|vaccine
1068599|NCT01712425|recently HIV-1 infected individuals
1068600|NCT01712373|Multiple sclerosis
1068601|NCT01712373|Ginseng
1068602|NCT01712373|Fatigue
1068603|NCT01712373|Quality of life
1068604|NCT01712360|Tinea Pedis
1068605|NCT01712360|Tinea Cruris
1068606|NCT01712360|Athlete foot
1068607|NCT01712360|Jock itch
1068608|NCT01712321|Social Anxiety Disorder
1068609|NCT01712321|Social Anxiety
1068610|NCT01712321|Social Phobia
1068611|NCT01712321|SAD
1068612|NCT01712308|Leukemia
1068613|NCT01712308|Myeloproliferative Neoplasm
1068614|NCT01712308|MPN
1068615|NCT01712308|Associated Myelofibrosis
1068616|NCT01712308|Anemia
1068617|NCT01712308|Sotatercept
1068618|NCT01712308|ACE-011
1068619|NCT01712295|Warts
1068620|NCT01712295|salicylic acid
1068621|NCT01712295|ethyl pyruvate
1068622|NCT01712282|Physical Activity
1068623|NCT01712282|Accelerometer
1068624|NCT01712256|CD4
1068625|NCT01712256|Clinical trial
1068626|NCT01712256|Human immunodeficiency virus-1 (HIV-1)
1068627|NCT01712256|HIV
1068628|NCT01712256|Immunomodulary
1068629|NCT01712256|Infection
1068630|NCT01712256|Phase II
1068631|NCT01712256|Re-boost
1068632|NCT01712256|Vaccine
1068633|NCT01712256|Vacc-4x
1068634|NCT01712230|hormone therapy
1068635|NCT01712230|obesity
1068636|NCT01712230|menopause
1068637|NCT01712230|disease /disorder proneness /risk
1068638|NCT01712230|insulin sensitivity /resistance
1068639|NCT01712230|metabolic syndrome
1068640|NCT01712230|women's health
1068641|NCT01712217|Non-small cell lung cancer
1068642|NCT01712204|Prophylaxis of Acute Gout Flares
1068643|NCT01712204|Urate-Lowering Therapy
1068644|NCT01712204|Hyperuricemia
1068645|NCT01712204|Gouty arthritis
1068646|NCT01712191|NUsurface
1068647|NCT01712191|Meniscus
1068648|NCT01712191|Knee
1068649|NCT01712191|KOOS
1068650|NCT01712178|Pharmacodynamic,Pharmacokinetic
1068651|NCT01712165|Folic acid supplement
1068652|NCT01712165|Neural tube defect-affected pregnancy
1068653|NCT01712165|Homocysteine concentration
1068654|NCT01712165|Plasma Folate concentration
1068655|NCT01712165|Plasma vitamin B12 concentration
1068656|NCT01712152|Duchenne muscular dystrophy
1068657|NCT01712152|carrier
1068658|NCT01712152|cardiac MRI
1068659|NCT01712152|myocardial fibrosis
1068660|NCT01712152|female
1068661|NCT01712087|spasticity
1068662|NCT01712087|muscle spasticity
1068663|NCT01712087|muscle rigidity
1068664|NCT01712087|motor neuron disease
1068665|NCT01712087|hyperreflexia
1068666|NCT01712074|Randomized
1068667|NCT01712074|Double Blind
1068668|NCT01712074|Safety and Efficacy
1068669|NCT01712061|Diabetic nephropathy
1068670|NCT01712061|type 2 diabetes
1068671|NCT01712061|albuminuria
1068672|NCT01712061|chemokine antagonist
1068673|NCT01712035|Wet AMD
1068674|NCT01712035|Age-related macular degeneration
1068675|NCT01712035|Optical coherenece tomography
1068676|NCT01712035|Imaging
1068677|NCT01712035|Blood flow
1068678|NCT01712009|Breast cancer
1068679|NCT01712009|Chemotherapy
1068680|NCT01712009|Neulasta
1068681|NCT01712009|Pegfilgrastim
1068682|NCT01712009|Naproxen
1068683|NCT01712009|Loratadine
1068684|NCT01712009|Non-steroidal antiinflammatory drug (NSAID)
1068685|NCT01712009|Anti-histamine
1068686|NCT01712009|Bone Pain
1068687|NCT01711996|hydronephrosis
1068688|NCT01711996|biopsy
1068689|NCT01711996|biomarker
1068690|NCT01711957|Complications
1068691|NCT01711957|Mortality
1068692|NCT01711957|Liver transplantation
1068693|NCT01711957|Platelet count
1068694|NCT01711957|Survival
1068695|NCT01711944|childhood cancer
1068696|NCT01711944|Internet communication
1068697|NCT01711944|parents
1068698|NCT01711944|caregivers
1068699|NCT01711944|problem solving
1068700|NCT01711931|percutaneous coronary intervention
1068701|NCT01711931|bioresorbable vascular scaffold stents
1068702|NCT01711931|everolimus
1068703|NCT01711931|biolimus
1068704|NCT01711918|gastroparesis
1068705|NCT01711918|domperidone
1068706|NCT01711918|nausea
1068707|NCT01711918|vomiting
1068708|NCT01711892|Prostatic Neoplasms
1068709|NCT01711892|Prostate Cancer
1068710|NCT01711892|Exercise
1068711|NCT01711892|Soccer
1068712|NCT01711892|Androgen Deprivation Therapy
1068713|NCT01711892|Body Composition
1068714|NCT01711892|Cardiovascular fitness
1068715|NCT01711892|Bone Health
1068716|NCT01711892|Health Related Quality of Life
1068717|NCT01711866|Rotigotine
1068718|NCT01711866|Neupro
1068719|NCT01711866|Switch
1068720|NCT01711866|Dopamine agonists
1068721|NCT01711840|Bronchial asthma
1068722|NCT01711840|Symbicort Turbuhaler
1068723|NCT01711827|isavuconazole
1068724|NCT01711827|prednisone
1068725|NCT01711827|prednisolone
1068726|NCT01711827|BAL8557
1068727|NCT01711827|healthy volunteers
1068728|NCT01711814|Rheumatoid Arthritis
1068729|NCT01711814|ASP015K
1068730|NCT01711788|Hematopoietic stem cells
1068731|NCT01711788|Umbilical cord blood transplantation
1068732|NCT01711788|Intrabone infusion
1068733|NCT01711788|Platelet recovery
1068734|NCT01711788|Neutrophil recovery
1068735|NCT01711788|Pediatric patients
1068736|NCT01711736|Immunogenicity
1068737|NCT01711736|Children
1068738|NCT01711736|Safety
1068739|NCT01711736|Seasonal influenza
1068740|NCT01711736|Fluarix
1068741|NCT01711723|darapladib
1068742|NCT01711723|Lp-PLA2- inhibitor
1068743|NCT01711723|healthy volunteer
1068744|NCT01711723|renal impairment
1068745|NCT01711723|pharmacokinetics
1068746|NCT01711710|Breast cancer
1068747|NCT01711710|reconstruction
1068748|NCT01711710|augmentation
1068749|NCT01711710|cohesive silicone gel
1068750|NCT01711710|breast implant
1068751|NCT01711710|rupture
1068752|NCT01711710|capsular contracture
1068753|NCT01711684|Neoplasm Metastasis
1068754|NCT01711684|Melanoma
1068755|NCT01711645|Acellular
1068756|NCT01711645|Adacel®
1068757|NCT01711645|Diptheria toxoids
1068758|NCT01711645|Pertussis
1068759|NCT01711645|postpartum
1068760|NCT01711645|Tdap
1068761|NCT01711645|Tetanus
1068762|NCT01711645|women
1068763|NCT01711632|VEMURAFENIB
1068764|NCT01711632|BRAF Inhibitor
1068765|NCT01711632|12-200
1068766|NCT01711632|Zelboraf™
1068767|NCT01711606|Fragile-X Syndrome
1068768|NCT01711606|registry
1068769|NCT01711606|non-interventional trial
1068770|NCT01711606|patient-related outcome study
1068771|NCT01711606|drug utilization
1068772|NCT01711606|effectiveness
1068773|NCT01711606|treatment patterns
1068774|NCT01711606|patient characteristics under real life conditions
1068775|NCT01711606|quality of life
1068776|NCT01711606|economics
1068777|NCT01711593|Asthma
1068778|NCT01711593|Allergic
1068779|NCT01711593|Inflammation
1068780|NCT01711593|Airway
1068781|NCT01711593|Challenge
1068782|NCT01711593|Chemokines
1068783|NCT01711593|Tolerization
1068784|NCT01711580|Recurrent glioma
1068785|NCT01711580|Quality of life
1068786|NCT01711580|Glioblastoma multiforme
1068787|NCT01711580|Anaplastic glioma
1068788|NCT01711580|Cognition
1068789|NCT01711580|Re-irradiation
1068790|NCT01711567|Chronic Hepatitis B
1068791|NCT01711567|TENOFOVIR
1068792|NCT01711567|ENTECAVIR
1068793|NCT01711567|PARTIAL RESPONDER
1068794|NCT01711502|metastatic breast cancer,
1068795|NCT01711502|epidemiology,
1068796|NCT01711502|retrospective cohort
1068797|NCT01711489|isavuconazole
1068798|NCT01711489|mycophenolate mofetil (MMF)
1068799|NCT01711489|BAL8557
1068800|NCT01711489|BAL4815
1068801|NCT01711489|healthy volunteers
1068802|NCT01711489|Mycophenolic acid (MPA)
1068803|NCT01711489|Phenolic glucuronide of MPA (MPAG)
1068804|NCT01711489|CellCept
1068805|NCT01711476|PCOS
1068806|NCT01711476|Bdiet
1068807|NCT01711476|Ddiet
1068808|NCT01711476|OGTT
1068809|NCT01711463|Pharmacodynamics
1068810|NCT01711463|Fluticasone furoate (FF)
1068811|NCT01711463|novel dry powder device
1068812|NCT01711463|Safety and tolerability
1068813|NCT01711463|vilanterol(VI)
1068814|NCT01711463|Healthy Chinese subjects
1068815|NCT01711463|Pharmacokinetics
1068816|NCT01711437|colonoscopy
1068817|NCT01711437|colon cleansing
1068818|NCT01711437|children
1068819|NCT01711437|age 2 -18 years
1068820|NCT01711411|HIV prevention
1068821|NCT01711411|PrePex
1068822|NCT01711411|voluntary medical male circumcision
1068823|NCT01711411|non-surgical
1068824|NCT01711411|medical device
1068825|NCT01711411|wound healing
1068826|NCT01711411|Kenya
1068827|NCT01711398|solid tumor
1068828|NCT01711398|peptide
1068829|NCT01711385|Oral Health
1068830|NCT01711385|Prediabetes
1068831|NCT01711385|Diabetes
1068832|NCT01711385|Periodontitis
1068833|NCT01711385|Early Identification
1068834|NCT01711385|Prevention
1068835|NCT01711372|ADHD
1068836|NCT01711320|Omeprazole
1068837|NCT01711320|Metformin
1068838|NCT01711307|Achilles
1068839|NCT01711307|Rupture
1068840|NCT01711294|Pancreatic Cystic Lesions
1068841|NCT01711294|PCL
1068842|NCT01711294|EUS-FNA
1068843|NCT01711281|Heart Failure
1068844|NCT01711281|Implantable Cardioverter-Defibrillator
1068845|NCT01711281|Intracardiac Impedance Measurement
1068846|NCT01711281|Cardiac Resynchronization Therapy
1068847|NCT01711281|Home Monitoring
1068848|NCT01711281|Reverse Remodeling
1068849|NCT01711268|Sunitinib
1068850|NCT01711268|Renal Cell Carcinoma
1068851|NCT01711268|Therapeutic Drug Monitoring
1068852|NCT01711268|Pharmacokinetic
1068853|NCT01711268|Treatment toxicity
1068854|NCT01711255|Multiple sclerosis
1068855|NCT01711255|Coagulation
1068856|NCT01711255|Alternative Medicine
1068857|NCT01711255|Clotting
1068858|NCT01711255|Complementary Medicine
1068859|NCT01711255|Inflammation
1068860|NCT01711242|gastric cancer
1068861|NCT01711242|radiotherapy
1068862|NCT01711242|postoperative therapy
1068863|NCT01711242|chemotherapy
1068864|NCT01711229|oral acetaminophen
1068865|NCT01711229|IV acetaminophen
1068866|NCT01711229|Ofirmev
1068867|NCT01711229|equianalgesic
1068868|NCT01711229|arthroscopic rotator cuff repair
1068869|NCT01711216|Dydrogesterone
1068870|NCT01711216|Irregular Menstrual Cycle
1068871|NCT01711216|Progestins
1068872|NCT01711203|Spondylolysis
1068873|NCT01711203|Spondylolisthesis
1068874|NCT01711203|Rehabilitation
1068875|NCT01711203|Physical Therapy
1068876|NCT01711203|Children
1068877|NCT01711190|glaucoma
1068878|NCT01711190|trabeculectomy
1068879|NCT01711190|astigmatism
1068880|NCT01711190|intraocular pressure
1068881|NCT01711177|primary open angle glaucoma
1068882|NCT01711177|retinal oximetry
1068883|NCT01711164|HCV
1068884|NCT01711164|T regulatory cells (Tregs)
1068885|NCT01711164|FGL2
1068886|NCT01711151|ILD
1068887|NCT01711138|Physical Activity
1068888|NCT01711138|Physical Fitness
1068889|NCT01711138|Transportation
1068890|NCT01711138|Environment Design
1068891|NCT01711138|Child
1068892|NCT01711138|Adolescent
1068893|NCT01711086|asthma
1068894|NCT01711086|dry powder inhaler
1068895|NCT01711047|catheter ablation
1068896|NCT01711047|atrial fibrillation
1068897|NCT01711047|pulmonary vein isolation
1068898|NCT01711047|linear ablation
1068899|NCT01711047|CFAE ablation
1068900|NCT01711034|Solid tumors
1068901|NCT01711021|ADHD
1068902|NCT01711008|Breakfast size
1068903|NCT01711008|Exercise
1068904|NCT01711008|Cognitive performance
1068905|NCT01711008|Mood
1068906|NCT01711008|Appetite
1068907|NCT01711008|Active women
1068908|NCT01710956|concurrent chemoradiation in patients with limited disease small cell lung cancer
1068909|NCT01710943|Web-based CBT
1068910|NCT01710943|PTSD
1068911|NCT01710943|Alcohol Misuse
1068912|NCT01710943|Substance Misuse
1068913|NCT01710943|Integrated Primary Care
1068914|NCT01710943|OEF/OIF Veterans
1068915|NCT01710930|Allergic Broncho-Pulmonary Aspergillosis
1068916|NCT01710917|Chronic pain
1068917|NCT01710917|Severe pain
1068918|NCT01710917|Oxycodon
1068919|NCT01710917|Naloxon
1068920|NCT01710917|Opioid-induced constipation
1068921|NCT01710917|Opioid
1068922|NCT01710917|Quality of life
1068923|NCT01710917|Laxative
1068924|NCT01710917|Analgesic rescue medication
1068925|NCT01710904|Chronic pain
1068926|NCT01710904|Severe pain
1068927|NCT01710904|Oxycodone
1068928|NCT01710904|Naloxone
1068929|NCT01710904|Opioid-induced constipation
1068930|NCT01710904|Opioid
1068931|NCT01710904|Quality of life
1068932|NCT01710904|Laxative
1068933|NCT01710904|Analgesic rescue medication
1068934|NCT01710891|endotracheal intubation
1068935|NCT01710891|direct laryngoscopy
1068936|NCT01710891|video laryngoscopy
1068937|NCT01710865|Caries prevention
1068938|NCT01710865|pit and fissure sealants
1068939|NCT01710852|Atrial Fibrillation
1068940|NCT01710852|Paroxysmal Atrial Fibrillation
1068941|NCT01710852|AF
1068942|NCT01710839|CRVO
1068943|NCT01710839|BRVO
1068944|NCT01710839|HRVO
1068945|NCT01710839|Macular edema
1068946|NCT01710839|vein occlusion
1068947|NCT01710813|pompe disease
1068948|NCT01710813|alglucosidase alfa
1068949|NCT01710813|anaphylaxis
1068950|NCT01710813|severe cutaneous
1068951|NCT01710813|systemic immune complex-mediated reactions
1068952|NCT01710800|impedance
1068953|NCT01710800|reflux
1068954|NCT01710800|GERD
1068955|NCT01710787|operative
1068956|NCT01710787|dental procedure
1068957|NCT01710774|Diabetic Foot
1068958|NCT01710774|Diabetes Mellitus
1068959|NCT01710774|Foot Ulcer
1068960|NCT01710774|Wound Healing
1068961|NCT01710774|Delivery of Health Care
1068962|NCT01710774|Depression
1068963|NCT01710774|sequela
1068964|NCT01710774|Sick Leave
1068965|NCT01710774|Quality of Life
1068966|NCT01710774|Amputation
1068967|NCT01710761|nitric oxide
1068968|NCT01710761|cycling performance
1068969|NCT01710761|lactate
1068970|NCT01710761|VO2
1068971|NCT01710748|Percutaneous coronary intervention
1068972|NCT01710748|Drug eluting stent
1068973|NCT01710748|Neointimal hyperplasia
1068974|NCT01710748|Diabetes Mellitus
1068975|NCT01710735|TP
1068976|NCT01710735|Myofascial pain
1068977|NCT01710709|Aripiprazole, Intramuscular (IM) Depot, Bipolar
1068978|NCT01710683|Discectomy
1068979|NCT01710683|1st postoperative day
1068980|NCT01710683|Intensive exercise training
1068981|NCT01710683|Randomized controlled trial
1068982|NCT01710670|Brivaracetam
1068983|NCT01710670|Ethanol
1068984|NCT01710670|Pharmacodynamics
1068985|NCT01710670|Pharmacokinetic
1068986|NCT01710670|Interaction
1068987|NCT01710657|Lacosamide
1068988|NCT01710657|Epilepsy
1068989|NCT01710657|Partial Onset Seizures
1068990|NCT01710631|Sleep
1068991|NCT01710618|Protein Expression of Sciatic Nerve
1068992|NCT01710618|traumatized sciatic nerve
1068993|NCT01710605|Circulating tumor cells
1068994|NCT01710605|Breast Cancer
1068995|NCT01710605|Hormone-receptors positive
1068996|NCT01710579|Primary esophageal achalasia
1068997|NCT01710579|endoscopic myotomy
1068998|NCT01710579|high resolution manometry
1068999|NCT01710566|Postpartum hemorrhage
1069000|NCT01710566|prevention
1069001|NCT01710566|oxytocin
1069002|NCT01710566|misoprostol
1069003|NCT01710566|Uniject
1069004|NCT01710566|community
1069005|NCT01710527|Healthy Volunteers
1069006|NCT01710488|COPD exacerbation
1069007|NCT01710488|fluoroquinolones,
1069008|NCT01710449|Lung Transplant
1069009|NCT01710423|Obesity
1069010|NCT01710423|Nutrition
1069011|NCT01710423|Home Food Preparation
1069012|NCT01710423|Peer Mentoring
1069013|NCT01710423|Early Head Start
1069014|NCT01710423|Cooking
1069015|NCT01710423|Diet
1069016|NCT01710410|transcranial direct current stimulation
1069017|NCT01710410|nicotine dependence
1069018|NCT01710410|dorsolateral prefrontal cortex
1069019|NCT01710410|nicotine replacement therapy
1069020|NCT01710410|nicotine patch
1069021|NCT01710410|addiction
1069022|NCT01710410|smoking cessation
1069023|NCT01710410|neuroplasticity
1069026|NCT01710384|late preterm, betamethasone,
1069027|NCT01710332|Persistent
1069028|NCT01710332|Central
1069029|NCT01710332|Serous
1069030|NCT01710332|Chorioretinopathy
1069031|NCT01710332|Regeneron
1069032|NCT01710332|CSR
1069033|NCT01710332|CSCR
1069034|NCT01710319|Immunoregulation
1069035|NCT01710319|Natural Killer Cells
1069036|NCT01710306|Women
1069037|NCT01710306|Veterans
1069038|NCT01710306|PTSD
1069039|NCT01710293|Electronic Health Records
1069040|NCT01710293|Diagnostic Delay
1069041|NCT01710293|Triggers
1069042|NCT01710280|Lipemia
1069043|NCT01710280|Vascular function
1069044|NCT01710280|Blood pressure
1069045|NCT01710254|MRI
1069046|NCT01710254|Atrial Fibrillation
1069047|NCT01710228|MS
1069048|NCT01710228|Natalizumab
1069049|NCT01710228|copaxone
1069050|NCT01710215|Colorectal Neoplasms
1069051|NCT01710215|Colorectal Cancer
1069052|NCT01710215|Colon Cancer
1069053|NCT01710215|Mass Screening
1069054|NCT01710215|Health Services Research
1069055|NCT01710215|Comparative Effectiveness Research
1069056|NCT01710202|Hydrocortisone
1069057|NCT01710202|Cortisol
1069058|NCT01710202|Testosterone
1069059|NCT01710202|Stress
1069060|NCT01710202|Serotonin
1069061|NCT01710202|5-HTTLPR
1069062|NCT01710202|Amygdala
1069063|NCT01710202|Depression
1069064|NCT01710189|Tick-Borne Encephalitis Virus
1069065|NCT01710163|Lithium Carbonate
1069066|NCT01710163|Lithium
1069067|NCT01710163|Central Nervous System Agents
1069068|NCT01710163|Therapeutic Uses
1069069|NCT01710163|Pharmacologic Actions
1069070|NCT01710163|Enzyme Inhibitors
1069071|NCT01710163|Molecular Mechanisms of Pharmacological Action
1069072|NCT01710163|Neurotransmitter Agents
1069073|NCT01710163|Physiological Effects of Drugs
1069074|NCT01710163|Antimanic Agents
1069075|NCT01710163|Tranquilizing Agents
1069076|NCT01710163|Central Nervous System Depressants
1069077|NCT01710163|Psychotropic Drugs
1069078|NCT01710163|Sensory System Agents
1069079|NCT01710163|Antipsychotic Agents
1069080|NCT01710163|Antidepressive Agents
1069081|NCT01710150|typical aflutter (AFLT)
1069082|NCT01710150|CTI ablation
1069083|NCT01710150|Atrial Fibrillation (AF)
1069084|NCT01710150|PVI
1069085|NCT01710137|Smoking cessation
1069086|NCT01710137|Nicotine dependence
1069087|NCT01710137|Varenicline
1069088|NCT01710137|Chantix
1069089|NCT01710137|HIV
1069090|NCT01710137|AIDS
1069091|NCT01710124|grocery purchases
1069092|NCT01710124|financial incentives
1069093|NCT01710124|obesogenic home food environment
1069094|NCT01710111|Human challenge model
1069095|NCT01710111|Quarantine study
1069096|NCT01710111|Influenza virus
1069097|NCT01710111|Modes of transmission
1069098|NCT01710111|Droplet spray
1069099|NCT01710111|Droplet nuclei
1069100|NCT01710111|Secondary attack rate
1069101|NCT01710111|Face shield
1069102|NCT01710111|Hand hygiene
1069103|NCT01710111|Fomites
1069104|NCT01710111|Environmental deposition
1069105|NCT01710111|Environmental dispersion
1069106|NCT01710098|testosterone
1069107|NCT01710098|S3-Adherence
1069108|NCT01710098|Quality of Life
1069109|NCT01710085|Diffusion weighted MRI
1069110|NCT01710085|Curative surgery
1069111|NCT01710085|Recurrence
1069112|NCT01710072|aneurysm, inflammation, MRI
1069113|NCT01710059|Health Status Disparities
1069114|NCT01710059|Minority Health
1069115|NCT01710059|Pediatrics
1069116|NCT01710059|Behavioral Intervention
1069117|NCT01710059|Cellular Phone
1069118|NCT01710059|Peer Group
1069119|NCT01710046|plaque psoriasis
1069120|NCT01710046|tofacitinib
1069121|NCT01710046|biopsy
1069122|NCT01710046|Janus Kinase
1069123|NCT01710046|randomized placebo controlled clinical trial
1069124|NCT01710046|psoriasis vulgaris
1069125|NCT01710033|CP-690,550
1069126|NCT01710033|kidney transplant
1069127|NCT01710020|CP-690
1069128|NCT01710020|550
1069129|NCT01710020|pharmacokinetics
1069130|NCT01710020|end-stage renal disease
1069131|NCT01710007|HMG-CoA reductase inhibitors
1069132|NCT01709994|cardiovascular events
1069133|NCT01709994|chronic kidney disease
1069134|NCT01709994|bleedings
1069135|NCT01709994|progression
1069136|NCT01709994|antiinflammatory effects
1069137|NCT01709968|Nocturnal Leg Cramps
1069138|NCT01709968|Quality of life
1069139|NCT01709968|Quality of sleep
1069140|NCT01709955|Obesity
1069141|NCT01709955|Overweight
1069142|NCT01709955|Glucomannan
1069143|NCT01709942|GnRH antagonist
1069144|NCT01709942|PCOS
1069145|NCT01709942|OHSS
1069146|NCT01709942|COH
1069147|NCT01709942|IVF
1069148|NCT01709916|Glaucoma
1069149|NCT01709916|intra ocular pressure
1069150|NCT01709916|diurnal fluctuations
1069151|NCT01709903|chronic obstructive pulmonary disease
1069152|NCT01709877|Multiport laparoscopy
1069153|NCT01709877|Single Port Laparoscopy
1069154|NCT01709877|Symptomatic Gallstones
1069155|NCT01709864|Anticholinergic
1069156|NCT01709864|Antimuscarinic
1069157|NCT01709864|Chronic Obstructive Airway Disease
1069158|NCT01709864|Chronic Obstructive Lung Disease
1069159|NCT01709864|Chronic Obstructive Pulmonary Disease
1069160|NCT01709864|COPD
1069161|NCT01709864|LAMA
1069162|NCT01709864|Lung Disease
1069163|NCT01709864|Lung Diseases, Obstructive
1069164|NCT01709864|Lung Function
1069165|NCT01709864|Muscarinic receptor antagonist
1069166|NCT01709864|Pulmonary Disease, Chronic Obstructive
1069167|NCT01709864|Respiratory Tract Diseases
1069168|NCT01709851|Type 1 diabetes
1069169|NCT01709851|Intravascular continuous glucose monitoring
1069170|NCT01709851|Subcutaneous continuous glucose monitoring
1069171|NCT01709838|Non-transfusion dependent thalassemia, NTDT
1069172|NCT01709825|probiotics
1069173|NCT01709825|cold
1069174|NCT01709825|flu
1069175|NCT01709825|immune function
1069176|NCT01709825|microbiota
1069177|NCT01709799|Cognitive Training
1069178|NCT01709799|Aging
1069179|NCT01709799|Seniors
1069180|NCT01709786|Hemorrhage
1069181|NCT01709786|Hemoglobin
1069182|NCT01709786|Non-invasive monitoring
1069183|NCT01709786|Medical device accuracy
1069184|NCT01709760|ENIA11
1069185|NCT01709760|MTX
1069186|NCT01709760|RA
1069187|NCT01709760|TNF
1069188|NCT01709747|Hydromorphone Hydrochloride
1069189|NCT01709747|Hydromorphone
1069190|NCT01709747|Pain
1069191|NCT01709747|Chronic Pain
1069192|NCT01709747|Implantable Pump
1069193|NCT01709747|Pump
1069194|NCT01709747|Intrathecal
1069195|NCT01709734|prostate cancer CRPC
1069196|NCT01709721|Hydromorphone
1069197|NCT01709721|Hydromorphone Hydrochloride
1069198|NCT01709721|Pain Management
1069199|NCT01709721|Non-narcotic analgesics
1069200|NCT01709708|Migraine
1069201|NCT01709708|Headache
1069202|NCT01709708|Chronic Migraine
1069203|NCT01709708|Marcaine
1069204|NCT01709708|Tx360
1069205|NCT01709695|Intuniv
1069206|NCT01709695|Attention Deficit Hyperactivity Disorder
1069207|NCT01709695|fMRI
1069208|NCT01709682|atrial fibrillation
1069209|NCT01709682|arrhythmias
1069210|NCT01709682|anti-arrhythmic agents
1069211|NCT01709669|acute coronary syndrome
1069212|NCT01709669|gratitude
1069213|NCT01709669|health behavior
1069214|NCT01709669|myocardial infarction
1069215|NCT01709669|unstable angina
1069216|NCT01709617|carbohydrate, glycogen, glucose
1069217|NCT01709604|acute paraquat poisoning
1069218|NCT01709604|hemoperfusion
1069219|NCT01709604|continuous blood purification
1069220|NCT01709591|intrapartum pain management, epidural
1069221|NCT01709565|Sepsis
1069222|NCT01709565|Lactic acid
1069223|NCT01709565|Shock
1069224|NCT01709565|Resuscitation
1069225|NCT01709539|Cancer diagnosis center
1069226|NCT01709539|Time to diagnosis
1069227|NCT01709539|Survival
1069228|NCT01709539|Health economics
1069229|NCT01709539|Biomarkers
1069230|NCT01709526|Psychosocial functioning
1069231|NCT01709526|Cognitive performance of inpatients
1069232|NCT01709526|Psychiatric diseases
1069233|NCT01709487|HIPEC
1069234|NCT01709487|ovarian carcinoma
1069235|NCT01709487|Bordet
1069236|NCT01709474|SLE
1069237|NCT01709474|Vitamin D3
1069238|NCT01709474|Vitamin D deficiency
1069239|NCT01709474|IFN alpha expression
1069240|NCT01709448|Neoplasms, Squamous Cell
1069241|NCT01709448|Papillomavirus Infections
1069242|NCT01709448|HIV
1069243|NCT01709422|Propofol
1069244|NCT01709422|Midazolam
1069245|NCT01709422|Meperidine
1069246|NCT01709409|Prematurity
1069247|NCT01709383|Aphasia
1069248|NCT01709383|Stroke
1069249|NCT01709383|Transcranial Direct Current Stimulation
1069250|NCT01709383|Neuroplasticity
1069251|NCT01709357|manual therapy
1069252|NCT01709357|trigger point
1069253|NCT01709357|range of motion
1069254|NCT01709357|pain threshold
1069255|NCT01709357|pain perception
1069267|NCT01709279|Ischemic heart failure
1069268|NCT01709279|Myocardial regeneration
1069269|NCT01709279|ADRC
1069270|NCT01709253|hpofractionation study using proton beam therapy
1069271|NCT01709240|Chitosan
1069272|NCT01709240|Plasma
1069273|NCT01709240|Incision Closure
1069274|NCT01709227|Acute kidney injury
1069275|NCT01709227|AKI
1069276|NCT01709227|cardiopulmonary bypass
1069277|NCT01709214|Osteoarthritis
1069278|NCT01709214|Knee
1069279|NCT01709214|Pain
1069280|NCT01709214|Chronic
1069281|NCT01709214|OA
1069282|NCT01709214|Arthritis
1069289|NCT01709188|Musical Dual Task Training
1069290|NCT01709188|dementia
1069291|NCT01709188|attention control
1069292|NCT01709188|dual task cost
1069293|NCT01709188|gait stability
1069294|NCT01709175|Cancer
1069295|NCT01709175|Breast Cancer
1069296|NCT01709175|Gynecologic Cancer
1069297|NCT01709175|Strength Training
1069298|NCT01709175|Exercise
1069299|NCT01709175|Physical Activity
1069300|NCT01709175|Fatigue
1069301|NCT01709175|Quality of Life
1069302|NCT01709175|Strength
1069303|NCT01709175|Fitness
1069304|NCT01709175|Cancer Survivor
1069305|NCT01709175|Survivor
1069306|NCT01709123|Diabetes Mellitus, Juvenile Onset
1069307|NCT01709123|Cardiovascular Diseases
1069308|NCT01709123|Hyperglycemia
1069309|NCT01709123|Hyperketonemia
1069310|NCT01709110|Bone Loss
1069311|NCT01709110|Vertebral fractures
1069312|NCT01709097|Adherence
1069313|NCT01709097|Compliance
1069314|NCT01709097|Kidney Transplant Recipient
1069315|NCT01709097|An electronic drug dispenser
1069316|NCT01709097|The Portal
1069317|NCT01709084|Human immunodeficiency virus-type 1 infection
1069318|NCT01709084|HIV-1
1069319|NCT01709084|Infectious diseases
1069320|NCT01709084|Ribonucleic acid
1069321|NCT01709084|RNA
1069322|NCT01709084|Tenofovir disoproxil fumarate
1069323|NCT01709084|Emtricitabine
1069324|NCT01709084|Rilpivirine
1069325|NCT01709084|Efavirenz
1069326|NCT01709084|Edurant
1069327|NCT01709084|TMC278
1069328|NCT01709084|R278474
1069329|NCT01709084|Fixed dose combination
1069330|NCT01709071|Vaccination
1069331|NCT01709071|Inactivated poliomyelitis vaccine
1069332|NCT01709071|poliomyelitis
1069333|NCT01709071|Sabin strains
1069334|NCT01709058|Back Pain
1069335|NCT01709058|Therapeutics
1069336|NCT01709058|Aged
1069337|NCT01709058|Injections, Intramuscular
1069338|NCT01709058|Oxygen
1069339|NCT01709058|Ozone
1069340|NCT01709058|Geriatric Assessment
1069341|NCT01709058|Trace Elements
1069342|NCT01709058|Oxidative stress
1069343|NCT01709045|Endarterectomy, Carotid
1069344|NCT01709045|Carotid Arteries
1069345|NCT01709032|Thalassemia
1069346|NCT01709032|Chelation
1069347|NCT01709032|Transfusion
1069348|NCT01709032|Safety
1069349|NCT01709006|Head and neck cancer
1069350|NCT01708980|Arthroplasty, Replacement, Knee
1069351|NCT01708980|Electromyography
1069352|NCT01708980|Resistance training
1069353|NCT01708980|Physical Therapy Modalities
1069354|NCT01708967|transnasal endoscopy
1069355|NCT01708967|pretreatment method
1069356|NCT01708954|erlotinib
1069357|NCT01708954|cabozantinib
1069358|NCT01708954|non-small cell lung cancer
1069359|NCT01708928|Ulthera® System
1069360|NCT01708928|Ultherapy™ Treatment
1069361|NCT01708928|Ulthera, Inc.
1069362|NCT01708928|Ultrasound treatment for skin tightening
1069363|NCT01708876|uncomplicated
1069364|NCT01708876|plasmodium
1069365|NCT01708876|knowlesi
1069366|NCT01708876|malaria
1069367|NCT01708876|infection
1069368|NCT01708863|Hypoplastic Left Heart Syndrome
1069369|NCT01708863|Stage II palliative surgery
1069370|NCT01708863|Glenn procedure
1069371|NCT01708863|Congenital heart defect
1069372|NCT01708863|Congenital heart disease
1069373|NCT01708863|Underdeveloped left ventricle
1069374|NCT01708837|Postoperative Cognitive Dysfunction
1069375|NCT01708837|Bispectral index
1069376|NCT01708824|colorectal cancer
1069377|NCT01708824|cancer survivor
1069378|NCT01708824|western pattern diet
1069379|NCT01708824|physical activity
1069380|NCT01708824|behavioral intervention
1069381|NCT01708824|acceptability
1069382|NCT01708824|feasibility
1069383|NCT01708824|randomized controlled trial
1069384|NCT01708824|compliance
1069385|NCT01708811|Contractility
1069386|NCT01708811|human
1069387|NCT01708811|myometrium
1069388|NCT01708811|hyponatraemia
1069389|NCT01708798|Diastolic heart failure
1069390|NCT01708785|obesity
1069391|NCT01708785|overweight
1069392|NCT01708785|overweight children
1069393|NCT01708785|overweight parents
1069394|NCT01708785|overeating
1069395|NCT01708785|eating in the absence of hunger
1069396|NCT01708785|families with overweight child
1069397|NCT01708785|body mass index
1069398|NCT01708785|BMI
1069399|NCT01708785|weight
1069400|NCT01708785|childhood obesity
1069401|NCT01708785|treatment
1069402|NCT01708785|cue exposure treatment
1069403|NCT01708785|cravings
1069404|NCT01708785|habituation to food cues
1069405|NCT01708785|psychophysiological response to food cues
1069406|NCT01708785|intervention
1069407|NCT01708785|experiments
1069408|NCT01708785|family based treatment
1069409|NCT01708785|behavioral treatment
1069410|NCT01708772|TNF alpha
1069411|NCT01708772|SOFA score
1069412|NCT01708759|Serum Il-8
1069413|NCT01708759|IL8 polymorphism
1069414|NCT01708759|critically ill patients
1069415|NCT01708733|HCV carrier
1069416|NCT01708733|Chinese herbal medicine
1069417|NCT01708733|Liver function
1069418|NCT01708733|HCV RNA titer
1069419|NCT01708720|Vaccination
1069420|NCT01708720|Inactivated Poliomyelitis Vaccine
1069421|NCT01708720|Polio
1069422|NCT01708720|Sabin
1069423|NCT01708681|Seafood
1069424|NCT01708681|Meat
1069425|NCT01708681|Egg
1069426|NCT01708681|Milk
1069427|NCT01708681|Postprandial lipid metabolism
1069428|NCT01708681|Postprandial glucose metabolism
1069429|NCT01708681|Triglycerides
1069430|NCT01708681|Cholesterol
1069431|NCT01708681|Postprandial incretins
1069432|NCT01708681|Postprandial hormones
1069433|NCT01708668|Fever
1069434|NCT01708668|Patient controlled epidural analgesia
1069435|NCT01708668|Labor analgesia
1069436|NCT01708668|Epidural analgesia
1069437|NCT01708668|Combined spinal-epidural analgesia
1069438|NCT01708655|Cystic Fibrosis
1069439|NCT01708655|Sweat Evaporimeter
1069440|NCT01708629|psoriasis, brodalumab, AMG 827
1069441|NCT01708603|psoriasis, brodalumab, AMG 827
1069442|NCT01708590|psoriasis, brodalumab (AMG 827)
1069443|NCT01708577|heart rate
1069444|NCT01708577|sweating
1069445|NCT01708577|respiration
1069446|NCT01708577|acceleration of body movement
1069447|NCT01708577|heart activity.
1069448|NCT01708551|Hyperhidrosis
1069449|NCT01708551|Axillary sweating
1069450|NCT01708551|Ulthera® System
1069451|NCT01708551|Ultherapy™ Treatment
1069452|NCT01708551|Ulthera, Inc.
1069453|NCT01708538|keratoconus, corneal collagen crosslinking, riboflavin, corneal ectasia
1069454|NCT01708525|Ulthera® System
1069455|NCT01708525|Ultherapy® Treatment
1069456|NCT01708525|Ulthera, Inc.
1069457|NCT01708525|Ultrasound treatment for skin tightening
1069458|NCT01708512|Ulthera® System
1069459|NCT01708512|Ultherapy™ Treatment
1069460|NCT01708512|Ulthera, Inc.
1069461|NCT01708512|Ultrasound treatment for skin tightening
1069462|NCT01708499|Ulthera® System
1069463|NCT01708499|Ultherapy™ Treatment
1069464|NCT01708499|Ulthera, Inc.
1069465|NCT01708499|Ultrasound treatment for skin tightening
1069466|NCT01708486|asthma
1069467|NCT01708486|Dry Powder Inhalers
1069468|NCT01708486|FSI-10 questionnaire
1069469|NCT01708460|Ulthera® System
1069470|NCT01708460|Ultherapy™ Treatment
1069471|NCT01708460|Ulthera, Inc.
1069472|NCT01708460|Ultrasound treatment for skin tightening
1069473|NCT01708434|Skin laxity
1069474|NCT01708434|Knees
1069475|NCT01708408|biorepository
1069476|NCT01708408|biobank
1069477|NCT01708408|registry
1069478|NCT01708408|community
1069479|NCT01708408|biospecimens
1069480|NCT01708408|volunteers
1069481|NCT01708408|chronic disease
1069482|NCT01708408|longitudinal
1069483|NCT01708408|blood
1069484|NCT01708408|electronic health records
1069485|NCT01708408|follow-up
1069486|NCT01708395|Ulcerative colitis
1069487|NCT01708382|Ulthera® System
1069488|NCT01708382|Ultherapy™ Treatment
1069489|NCT01708382|Ulthera, Inc.
1069490|NCT01708382|Ultrasound treatment for skin tightening
1069491|NCT01708369|human carboxylesterase-1
1069492|NCT01708369|human carboxylesterase-2
1069493|NCT01708369|alcohol
1069494|NCT01708369|pharmacokinetics
1069495|NCT01708356|Air Pollution
1069496|NCT01708356|Particulate Matter
1069497|NCT01708356|Exercise
1069498|NCT01708356|Respiratory Rate
1069499|NCT01708356|Inflammation
1069500|NCT01708356|Oxidative Stress
1069501|NCT01708356|Plethysmography
1069502|NCT01708343|Myofascial Pain Syndrome,
1069503|NCT01708343|intramuscular stimulation,
1069504|NCT01708343|acupuncture,
1069505|NCT01708343|sleep quality,
1069506|NCT01708343|pain threshold.
1069507|NCT01708330|manual vacuum aspiration
1069508|NCT01708330|missed abortion
1069509|NCT01708330|incomplete abortion
1069510|NCT01708330|nonviable pregnancy
1069511|NCT01708330|topical lidocaine
1069512|NCT01708317|ACASI
1069513|NCT01708317|Gonorrhea
1069514|NCT01708317|Chlamydia
1069515|NCT01708317|Emergency Department
1069516|NCT01708317|Youth
1069517|NCT01708317|Adolescents
1069518|NCT01708317|Computer
1069519|NCT01708317|Questionnaire
1069520|NCT01708304|Dementia
1069521|NCT01708304|Alzheimer's Disease
1069522|NCT01708304|Exercise
1069523|NCT01708304|Caregiver
1069524|NCT01708304|Behavior modification
1069525|NCT01708291|youth
1069526|NCT01708291|Stress
1069527|NCT01708291|mindfulness
1069528|NCT01708291|foster care
1069529|NCT01708291|stress reduction
1069530|NCT01708291|high risk teens
1069531|NCT01708278|COPD
1069532|NCT01708278|Emphysema
1069533|NCT01708278|chronic bronchitis
1069534|NCT01708278|Quercetin
1069535|NCT01708278|flavonoids
1069536|NCT01708265|Mitral Valve Insufficiency
1069537|NCT01708265|Mitral Valve Regurgitation
1069538|NCT01708265|Asymptomatic Mitral Valve Regurgitation
1069539|NCT01708265|Asymptomatic Mitral Valve Insufficiency
1069540|NCT01708265|Mitral Valve Repair
1069541|NCT01708265|Watchful Waiting
1069542|NCT01708252|Ulthera® System
1069543|NCT01708252|Ultherapy™ Treatment
1069544|NCT01708252|Ulthera, Inc.
1069545|NCT01708252|Ultrasound treatment for skin tightening
1069546|NCT01708239|Pregnancy
1069547|NCT01708239|Deep vein thrombosis
1069548|NCT01708239|Clinical probability
1069549|NCT01708239|D-Dimer
1069550|NCT01708239|Compression ultrasonography
1069551|NCT01708226|OCD
1069552|NCT01708226|obsessive compulsive disorder
1069553|NCT01708226|children
1069554|NCT01708213|soft tissue
1069555|NCT01708213|augmentation
1069556|NCT01708213|correction
1069557|NCT01708213|wrinkles
1069558|NCT01708200|Memory
1069559|NCT01708200|Intervention
1069560|NCT01708200|Computerized
1069561|NCT01708200|Psychoeducational
1069562|NCT01708200|Mental Illness
1069563|NCT01708187|Peroneal tendon
1069564|NCT01708174|medulloblastoma,
1069565|NCT01708174|relapsed,
1069566|NCT01708174|pediatric,
1069567|NCT01708174|children,
1069568|NCT01708174|adults,
1069569|NCT01708174|Hh pathway inhibitor,
1069570|NCT01708174|LDE225
1069571|NCT01708161|PIK3CA mutation
1069572|NCT01708161|advanced solid tumor
1069573|NCT01708161|breast cancer
1069574|NCT01708161|ovarian cancer
1069575|NCT01708122|Intranasal fentanyl
1069576|NCT01708122|Cystoscopy
1069577|NCT01708070|asthma
1069578|NCT01708070|depression
1069579|NCT01708070|anxiety
1069580|NCT01708057|COPD
1069581|NCT01708057|Chronic obstructive pulmonary disease
1069582|NCT01708044|Pramlintide,
1069583|NCT01708044|insulin,
1069584|NCT01708044|type 1 diabetes,
1069585|NCT01708044|reduction in postprandial glucose,
1069586|NCT01708044|pramlintide:insulin dose-ratio
1069587|NCT01708018|Pregnancy
1069588|NCT01708018|Stress, Psychological
1069589|NCT01708018|Low Back Pain
1069590|NCT01708018|Breech Presentation
1069591|NCT01708018|Relaxation
1069592|NCT01708018|Hydrotherapy
1069593|NCT01708018|Acupressure
1069594|NCT01708018|WATSU
1069595|NCT01708005|Mild Cognitive Impairment
1069596|NCT01708005|Vitamin D
1069597|NCT01708005|Cholecalciferol
1069598|NCT01708005|Lecitone®Se-Vitamin D3
1069599|NCT01707979|Near infrared light
1069600|NCT01707979|Diabetic neuropathy
1069601|NCT01707979|Sensory neuropathy
1069602|NCT01707979|Autonomic neuropathy
1069603|NCT01707979|Vagus
1069604|NCT01707979|Sudomotor function
1069605|NCT01707979|Monofilament
1069606|NCT01707979|Impedance
1069607|NCT01707966|adenocarcinoma of the prostate
1069608|NCT01707966|metastatic castration-resistant prostate cancer
1069609|NCT01707966|maintenance therapy
1069610|NCT01707966|orteronel
1069611|NCT01707966|TAK-700
1069612|NCT01707927|EOA
1069613|NCT01707914|oxidative stress
1069614|NCT01707914|dyslipidemia
1069615|NCT01707914|inflammation
1069616|NCT01707901|GERD
1069617|NCT01707862|Intravenous leiomyomatosis
1069618|NCT01707862|Surgery
1069619|NCT01707862|Smooth muscle tumor
1069620|NCT01707849|Hepatitis C
1069621|NCT01707849|Liver Fibrosis
1069622|NCT01707849|m-TOR inhibitors
1069623|NCT01707810|Liver transplatation
1069624|NCT01707797|dental caries
1069625|NCT01707797|high risk
1069626|NCT01707797|dental cavities
1069627|NCT01707797|children dental care
1069628|NCT01707784|Pregnancy
1069629|NCT01707784|Stress
1069630|NCT01707784|Anxiety
1069631|NCT01707784|Cortisol
1069632|NCT01707784|Copeptin
1069633|NCT01707784|Gestational diabetes
1069634|NCT01707758|pancreatic cancer
1069635|NCT01707758|nanoparticle
1069636|NCT01707758|proteases
1069637|NCT01707758|cell survival
1069638|NCT01707758|tumor progression
1069639|NCT01707758|angiogenesis
1069640|NCT01707758|tissue remodeling/invasion
1069641|NCT01707732|Obesity
1069642|NCT01707732|thromboprophylaxis
1069643|NCT01707732|Enoxaparin
1069644|NCT01707719|Alzheimer's disease
1069645|NCT01707719|Oxidative stress
1069646|NCT01707719|HPA axis
1069647|NCT01707706|Insomnia
1069648|NCT01707706|Depression
1069649|NCT01707706|Electroacupuncture
1069650|NCT01707706|Acupuncture
1069651|NCT01707706|Randomized Clinical Trial
1069652|NCT01707706|Traditional Chinese Medicine
1069653|NCT01707693|physical activity
1069654|NCT01707693|prevention
1069655|NCT01707693|coronary heart disease
1069656|NCT01707693|women
1069657|NCT01707680|weaning
1069658|NCT01707680|mechanical ventilation
1069659|NCT01707680|dexmedetomidine
1069660|NCT01707680|propofol
1069661|NCT01707680|midazolam
1069662|NCT01707654|defect;
1069663|NCT01707654|dorsal branch of the proper digital nerve;
1069664|NCT01707654|proper digital nerve;
1069665|NCT01707654|finger sensory reconstruction.
1069666|NCT01707628|NHL
1069667|NCT01707628|influenza vaccination
1069668|NCT01707628|rituximab
1069669|NCT01707615|proanthocyanidin,atherosclerosis, carotid plaque
1069670|NCT01707602|Intradermal
1069671|NCT01707602|transcutaneous
1069672|NCT01707602|influenza
1069673|NCT01707602|routes of vaccination
1069674|NCT01707602|T cell responses
1069675|NCT01707602|humoral responses
1069676|NCT01707602|skin
1069677|NCT01707602|clinical trial
1069678|NCT01707602|Novel application of influenza vaccine
1069679|NCT01707602|Transcutaneous vaccination(hair follicular targeting)
1069680|NCT01707602|Intradermal vaccination(micro-needle)
1069681|NCT01707589|monitoring
1069682|NCT01707589|heart rate
1069683|NCT01707589|respiration rate
1069684|NCT01707589|temperature
1069685|NCT01707589|motion
1069686|NCT01707589|noninvasive
1069687|NCT01707589|physiologic parameters
1069688|NCT01707589|NICU
1069689|NCT01707576|Follow-Up Studies
1069690|NCT01707576|Adolescent
1069691|NCT01707576|Depressive Disorder, Major/diagnosis
1069692|NCT01707576|Attempted/prevention & control
1069693|NCT01707576|Self-report questionnaire
1069694|NCT01707576|emmergency department
1069695|NCT01707576|parental perception
1069696|NCT01707576|Emergency
1069697|NCT01707563|Marfan syndrome
1069698|NCT01707563|Variability
1069699|NCT01707563|Fibrillin 1
1069700|NCT01707563|clinical expression
1069701|NCT01707537|OCV
1069702|NCT01707537|cholera
1069703|NCT01707511|Arterial carbondioxide pressure
1069704|NCT01707511|Colon surgery
1069705|NCT01707511|End-tidal carbondioxide
1069706|NCT01707511|Laparoscopic Trendelenburg
1069707|NCT01707498|BCI
1069708|NCT01707498|TETRAPLEGIA
1069709|NCT01707498|COMMUNICATION
1069710|NCT01707498|P300
1069711|NCT01707498|ASSISTIVE TECHNOLOGIE
1069712|NCT01707485|Antibiotics
1069713|NCT01707472|Liver Fibrosis
1069714|NCT01707472|Fibrosis
1069715|NCT01707472|HIV
1069716|NCT01707472|HCV
1069717|NCT01707472|GS-6624
1069718|NCT01707472|Hepatitis
1069719|NCT01707472|Hepatitis C
1069720|NCT01707459|platelet function
1069721|NCT01707459|perioperative complications
1069722|NCT01707459|major adverse cardiac events (MACE)
1069723|NCT01707459|thromboelastography
1069724|NCT01707459|polymorphism analysis
1069725|NCT01707459|coronary stents
1069726|NCT01707459|non-cardiac surgery
1069727|NCT01707446|Cardiac surgery
1069728|NCT01707446|Delirium
1069729|NCT01707446|Cerebral Oximetry
1069730|NCT01707433|spondyloepiphyseal dysplasia
1069731|NCT01707433|multiple epiphyseal dysplasia
1069732|NCT01707433|bilateral Legg Calve Perthes
1069733|NCT01707433|bilateral proximal femoral epiphyseal dysplasia
1069734|NCT01707433|GALNS
1069735|NCT01707420|pediatric pain
1069736|NCT01707420|post operative pain
1069737|NCT01707420|opioids
1069738|NCT01707420|emergence agitation
1069739|NCT01707420|preoperative anxiety
1069740|NCT01707420|pharmacogenomics
1069741|NCT01707407|CC-4047
1069742|NCT01707407|Pomalidomide
1069743|NCT01707407|Ketoconazole
1069744|NCT01707407|Fluvoxamine
1069745|NCT01707407|Carbamazepine
1069746|NCT01707407|DDI
1069747|NCT01707407|safety
1069748|NCT01707407|tolerability
1069749|NCT01707407|pharmacokinetic
1069750|NCT01707368|Psoriasis
1069751|NCT01707368|Psoriasis vulgaris
1069752|NCT01707368|Plaque Psoriasis
1069753|NCT01707368|Daivobet® Gel
1069754|NCT01707368|Germany
1069755|NCT01707355|education, knowledge, poster, dental trauma
1069756|NCT01707342|Healthy male participants
1069757|NCT01707342|Absolute bioavailability
1069758|NCT01707342|Bioavailability
1069759|NCT01707342|Pharmacokinetics
1069760|NCT01707342|Simeprevir
1069761|NCT01707342|TMC435
1069762|NCT01707342|[3H]-TMC435
1069763|NCT01707342|Hepatitis C virus
1069764|NCT01707342|HCV
1069765|NCT01707316|Healthy
1069766|NCT01707316|JNJ-28431754
1069767|NCT01707316|Canagliflozin
1069768|NCT01707316|Pharmacokinetics
1069769|NCT01707316|Pharmacodynamics
1069770|NCT01707303|ICU
1069771|NCT01707303|Critical Care
1069772|NCT01707303|Intensive Care
1069773|NCT01707303|Critical Illness
1069774|NCT01707303|Acute Respiratory Failure
1069775|NCT01707303|Mechanical Ventilation
1069776|NCT01707303|Physical Therapy
1069777|NCT01707303|Strength
1069778|NCT01707303|Functional Status
1069779|NCT01707303|Short Physical Performance Battery
1069780|NCT01707277|Heart failure with preserved ejection fraction
1069781|NCT01707277|Inspiratory muscle training
1069782|NCT01707277|Exercise capacity
1069783|NCT01707264|AL amyloidosis
1069784|NCT01707264|Primary amyloidosis
1069785|NCT01707251|Obesity, Morbid
1069786|NCT01707251|Bariatric Surgery
1069787|NCT01707251|Laparoscopy
1069788|NCT01707251|Intravenous Ibuprofen
1069789|NCT01707251|Analgesia
1069790|NCT01707251|Morphine
1069791|NCT01707225|GI Bleeding
1069792|NCT01707225|Gastrointestinal bleeding
1069793|NCT01707225|LVAD
1069794|NCT01707212|parent education
1069795|NCT01707212|pain management
1069796|NCT01707212|immunization
1069797|NCT01707212|infant
1069798|NCT01707199|P. falciparum
1069799|NCT01707199|Sulphadoxine-pyrimethamine
1069800|NCT01707199|Artesunate
1069801|NCT01707199|Artemisinin Combination Therapy (ACT)
1069802|NCT01707173|SIDS
1069803|NCT01707121|morbidity
1069804|NCT01707121|sick-leave
1069805|NCT01707121|hospital stay
1069806|NCT01707108|dental implants
1069807|NCT01707108|bone loss
1069808|NCT01707095|Electrosurgery
1069809|NCT01707095|Radiofrequency energy
1069810|NCT01707095|Monopolar instruments
1069811|NCT01707095|Capacitive coupling
1069812|NCT01707095|Thermal injury
1069813|NCT01707095|Surgical complications
1069814|NCT01707056|levothyroxine
1069815|NCT01707056|synthroid
1069816|NCT01707056|coffee
1069817|NCT01707056|absorption
1069818|NCT01707056|tea
1069819|NCT01707056|thyroid carcinoma
1069820|NCT01707043|plaque psoriasis
1069821|NCT01707043|taclonex
1069822|NCT01707043|crossover
1069823|NCT01707030|clinical trial
1069824|NCT01707030|veteran
1069825|NCT01707030|substance use disorder
1069826|NCT01706978|rotator cuff tear
1069827|NCT01706952|Endoscopic sinus surgery
1069828|NCT01706952|Bleeding
1069829|NCT01706952|Topical Vasocontriction
1069830|NCT01706952|Cocaine
1069831|NCT01706952|Adrenaline
1069832|NCT01706939|Reduced radiotherapy
1069833|NCT01706939|Randomization, Phase III
1069834|NCT01706939|Reduced radiation therapy
1069835|NCT01706939|head and neck
1069836|NCT01706939|oropharynx
1069837|NCT01706939|unknown primary (cervical lymph nodes)
1069838|NCT01706939|nasopharynx primary
1069839|NCT01706939|HPV
1069840|NCT01706939|p16
1069841|NCT01706926|Rheumatoid Arthritis
1069842|NCT01706926|Mavrilimumab
1069843|NCT01706926|CAM-3001
1069844|NCT01706887|Nedd4-2
1069845|NCT01706887|blood pressure
1069846|NCT01706887|polymorphism
1069847|NCT01706887|salt intake
1069848|NCT01706887|between 18 and 35 years old
1069849|NCT01706887|BMI between 18 and 28 Kg per m2
1069850|NCT01706887|no active disease
1069851|NCT01706887|no alcool or drug abuse or smoke
1069852|NCT01706874|Rheumatoid arthritis
1069853|NCT01706874|P.gingivalis
1069854|NCT01706874|Periodontal disease
1069855|NCT01706874|Plaque control
1069856|NCT01706874|Prophylaxis
1069857|NCT01706874|Oral hygiene instruction
1069858|NCT01706835|solid tumor
1069859|NCT01706835|aldoxorubicin
1069860|NCT01706835|phase 1
1069861|NCT01706835|pharmacokinetic
1069862|NCT01706835|INNO-206
1069863|NCT01706796|Pain
1069864|NCT01706744|Hospital Readmissions
1069865|NCT01706744|Community Health Services
1069866|NCT01706744|Preventive Health Services
1069867|NCT01706744|Norway
1069868|NCT01706731|Buddhist monks
1069869|NCT01706731|CBT
1069870|NCT01706731|elderly
1069871|NCT01706731|depression
1069872|NCT01706718|Beetroot
1069873|NCT01706718|Blood pressure
1069874|NCT01706718|Vascular function
1069875|NCT01706705|Cervical Cancer
1069876|NCT01706705|Radiation therapy
1069877|NCT01706705|XRT
1069878|NCT01706705|External beam therapy
1069879|NCT01706705|Brachytherapy
1069880|NCT01706705|Intracavitary brachytherapy
1069881|NCT01706705|ICBT
1069882|NCT01706705|MRI compatible intracavitary applicators
1069883|NCT01706705|Computed tomography
1069884|NCT01706705|CT
1069885|NCT01706705|Magnetic resonance imaging
1069886|NCT01706705|MRI
1069887|NCT01706705|MRI compatible applicators
1069888|NCT01706705|3D image guided treatment planning
1069889|NCT01706705|2D treatment planning
1069890|NCT01706692|Methotrexate
1069891|NCT01706692|Acitretin
1069892|NCT01706692|Cyclosporine A
1069893|NCT01706692|Systemic PUVA
1069894|NCT01706692|Infliximab
1069895|NCT01706692|Adalimumab
1069896|NCT01706692|Etanercept
1069897|NCT01706692|Ustekinumab
1069898|NCT01706692|Fumaric acids
1069899|NCT01706692|Psoriasis
1069900|NCT01706692|Psoriatic arthritis
1069901|NCT01706692|Skin disease
1069902|NCT01706679|Healthy volunteers
1069903|NCT01706666|Maintenance
1069904|NCT01706666|Consolidation
1069905|NCT01706653|Polyphenol
1069906|NCT01706653|Fruit
1069907|NCT01706653|Metabolic
1069908|NCT01706653|Healthy
1069909|NCT01706627|cancer
1069910|NCT01706627|melatonin
1069911|NCT01706627|adjuvant therapy
1069912|NCT01706627|quality of life
1069913|NCT01706627|survival
1069914|NCT01706627|adverse events
1069915|NCT01706627|oxidative stress
1069916|NCT01706588|diclofenac, postsurgical pain, oral surgery
1069917|NCT01706562|Neutropenia
1069918|NCT01706562|Hematologic malignancy
1069919|NCT01706562|Itraconazole
1069920|NCT01706562|Fungal infection
1069921|NCT01706562|Antifungal agent
1069922|NCT01706562|Neutropenic fever
1069923|NCT01706549|Chronic pain
1069924|NCT01706549|Hysterectomy
1069925|NCT01706549|Quality of life
1069926|NCT01706523|Autism Spectrum Disorders
1069927|NCT01706523|Autism
1069928|NCT01706523|Asperger
1069929|NCT01706523|Pervasive Developmental Disorder - Not otherwise specified
1069930|NCT01706510|Clopidogrel
1069931|NCT01706510|Ticagrelor
1069932|NCT01706510|Coronary Artery Disease
1069933|NCT01706510|Myocardial Ischemia
1069934|NCT01706510|Coronary Disease
1069935|NCT01706510|Heart Diseases
1069936|NCT01706510|Cardiovascular Diseases
1069937|NCT01706510|Arteriosclerosis
1069938|NCT01706510|Arterial Occlusive Diseases
1069939|NCT01706510|Vascular Diseases
1069940|NCT01706510|Platelet Aggregation Inhibitors
1069941|NCT01706510|Hematologic Agents
1069942|NCT01706510|Therapeutic Uses
1069943|NCT01706510|Pharmacologic Actions
1069944|NCT01706510|Purinergic P2Y Receptor Antagonists
1069945|NCT01706510|Purinergic P2 Receptor Antagonists
1069946|NCT01706510|Purinergic Antagonists
1069947|NCT01706510|Purinergic Agents
1069948|NCT01706510|Physiological Effects of Drugs
1069949|NCT01706497|cerebral tissue oxygen saturation
1069950|NCT01706497|congenital cardiac surgery
1069951|NCT01706497|pediatric intensive care unit
1069952|NCT01706497|Near Infra-Red Spectroscopy
1069953|NCT01706497|early warning monitor
1069954|NCT01706497|outcome prediction
1069955|NCT01706484|randomized clinical trial
1069956|NCT01706484|chronic rhinosinusitis
1069957|NCT01706484|herbal extract BNO 1016
1069958|NCT01706484|exacerbation
1069959|NCT01706484|pharmacoeconomic
1069960|NCT01706484|quality of life
1069961|NCT01706471|verLowCNI
1069962|NCT01706458|Vaccine
1069963|NCT01706458|pTVG-HP
1069964|NCT01706458|Prostate Cancer
1069965|NCT01706458|Castrate Resistant
1069966|NCT01706445|cystic fibrosis
1069967|NCT01706445|exercise
1069968|NCT01706445|children
1069969|NCT01706445|cardiorespiratory fitness
1069970|NCT01706445|muscle strength
1069971|NCT01706445|pulmonary function
1069972|NCT01706445|quality of life
1069973|NCT01706419|vitamin A
1069974|NCT01706419|iron
1069975|NCT01706419|zinc
1069976|NCT01706419|school children
1069977|NCT01706419|fortified rice
1069978|NCT01706419|morbidity
1069979|NCT01706419|growth
1069980|NCT01706406|female sexual arousal
1069981|NCT01706406|female sexual desire
1069982|NCT01706406|psychoeducational intervention
1069983|NCT01706393|probiotics
1069984|NCT01706393|intestinal microbiome
1069985|NCT01706393|radiotherapy
1069986|NCT01706380|Substance use disorders
1069987|NCT01706380|Adolescents
1069988|NCT01706380|Retention
1069989|NCT01706380|Mobile telephone
1069990|NCT01706380|Follow-up
1069991|NCT01706380|Interactive voice response
1069992|NCT01706367|Clostridium difficile
1069993|NCT01706367|vaccine
1069994|NCT01706354|end stage renal disease
1069995|NCT01706354|vascular access
1069996|NCT01706354|regional anaesthesia
1069997|NCT01706341|cesarean section
1069998|NCT01706341|intravenous fluid
1069999|NCT01706341|a glucose-containing solution
1070000|NCT01706341|fetal hypoglycemia
1070001|NCT01706341|neonatal hypoglycemia
1070002|NCT01706328|Vilanterol (VI)
1070003|NCT01706328|Novel Dry Powder Inhaler (NDPI)
1070004|NCT01706328|FEV1
1070005|NCT01706328|Fluticasone Furoate (FF)
1070006|NCT01706328|COPD
1070007|NCT01706302|General Practice Research Database
1070008|NCT01706302|Burden of Disease
1070009|NCT01706302|Clinical Practice Research Datalink
1070010|NCT01706302|Hospital Episode Statistics
1070011|NCT01706302|Office of National Statistics
1070012|NCT01706302|RSV
1070013|NCT01706289|diabetes
1070014|NCT01706289|cardiovascular autonomic neuropathy
1070015|NCT01706289|VAP 1
1070016|NCT01706237|Myopia
1070017|NCT01706237|LASIK
1070018|NCT01706224|Pertussis antibodies
1070019|NCT01706224|Bordetella pertussis
1070020|NCT01706224|sero-prevalence
1070021|NCT01706224|Healthcare professionals (HCP)
1070022|NCT01706224|Spain
1070023|NCT01706211|non insulin dependent diabetes mellitus, rosiglitazone
1070024|NCT01706198|respiratory
1070025|NCT01706198|adult
1070026|NCT01706198|asthma
1070027|NCT01706185|Patients
1070028|NCT01706185|Tumor antigens
1070029|NCT01706185|Bladder cancer
1070030|NCT01706172|TMD
1070031|NCT01706172|temporomandibular
1070032|NCT01706172|dextrose
1070033|NCT01706172|prolotherapy
1070034|NCT01706146|atrial fibrillation
1070035|NCT01706146|reveal xt
1070036|NCT01706146|oral anticoagulation
1070037|NCT01706146|dabigatran
1070038|NCT01706146|rivaroxaban
1070039|NCT01706146|apixaban
1070040|NCT01706133|Frailty, emergency services, elderly
1070041|NCT01706120|prognostic factors
1070042|NCT01706120|biologic factors
1070043|NCT01706120|clinical factors
1070044|NCT01706120|routine clinical practice
1070045|NCT01706107|Quality of life
1070046|NCT01706094|stroke
1070047|NCT01706094|head position
1070048|NCT01706081|acupuncture
1070049|NCT01706068|acute ECG changes
1070050|NCT01706068|acute illness of gallbladder
1070051|NCT01706068|acute illness of biliary tract
1070052|NCT01706055|Multiple Sclerosis (MS)
1070053|NCT01706055|Interferon
1070054|NCT01706003|Migraine
1070055|NCT01706003|Headaches
1070056|NCT01706003|Telemedicine
1070057|NCT01705990|HIV
1070058|NCT01705990|AIDS
1070059|NCT01705990|HIV vaccine
1070060|NCT01705990|HIV prevention
1070061|NCT01705977|Antibodies
1070062|NCT01705977|Lupus
1070063|NCT01705977|SLE
1070064|NCT01705977|Systemic Lupus Erythematosus
1070065|NCT01705977|Autoimmune Disease
1070066|NCT01705977|Belimumab
1070067|NCT01705964|Status asthmaticus
1070068|NCT01705964|Asthma exacerbation
1070069|NCT01705964|Epinephrine
1070070|NCT01705964|Adjunctive therapy
1070071|NCT01705951|Smoking
1070072|NCT01705951|Insulin resistance
1070073|NCT01705951|Metabolic Syndrome
1070074|NCT01705951|Endothelial Function
1070075|NCT01705951|Smoking Cessation
1070076|NCT01705951|Resistance Training
1070077|NCT01705951|Nicotine Replacement
1070078|NCT01705951|Exercise
1070079|NCT01705951|Cardiovascular Disease
1070080|NCT01705951|Arterial Stiffness
1070081|NCT01705951|Body Composition
1070082|NCT01705912|fall
1070083|NCT01705912|prevention
1070084|NCT01705899|Type 1 Diabetes
1070085|NCT01705899|Islet transplant
1070086|NCT01705899|Kidney transplant
1070087|NCT01705886|Osteoarthritis
1070088|NCT01705886|Joint Disease
1070089|NCT01705886|Arthritis
1070090|NCT01705886|Musculoskeletal Disease
1070091|NCT01705873|HIV
1070092|NCT01705873|cardiovascular
1070093|NCT01705873|risk
1070094|NCT01705873|mortality
1070095|NCT01705860|Collagen, collagenase, scar
1070096|NCT01705847|chronic lymphocytic leukemia (CLL)
1070097|NCT01705847|non-Hodgkin lymphoma (NHL)
1070098|NCT01705847|Hodgkin lymphoma (HL)
1070099|NCT01705847|indolent non-Hodgkin lymphoma (iNHL)
1070100|NCT01705847|diffuse large B-cell lymphoma-activated B-cell (DLBCL-ABC)
1070101|NCT01705847|DLBCL-germinal center B-cell (GCB)
1070102|NCT01705847|mantle cell lymphoma (MCL)
1070103|NCT01705847|GS-9820
1070104|NCT01705847|phosphatidylinositol 3-kinase (PI3K)
1070105|NCT01705834|Arthritis
1070106|NCT01705834|Stiffness
1070107|NCT01705834|Range of movement
1070108|NCT01705834|Goniometry
1070109|NCT01705834|Digital
1070110|NCT01705834|Dataglove
1070111|NCT01705834|Outcome
1070112|NCT01705821|Skull base
1070113|NCT01705821|Pituitary
1070114|NCT01705821|Robotics
1070115|NCT01705821|Endonasal surgery
1070116|NCT01705821|Sinus surgery
1070117|NCT01705769|treatment
1070118|NCT01705769|severe acute malnutrition
1070119|NCT01705756|Colchicine
1070120|NCT01705756|Anakinra
1070121|NCT01705756|FMF
1070122|NCT01705756|Colchicine resistance
1070123|NCT01705743|anaesthesia
1070124|NCT01705743|middle aged
1070125|NCT01705743|minimal alveolar concentration
1070126|NCT01705743|sevoflurane
1070127|NCT01705743|nitrous oxide
1070128|NCT01705743|isoelectric EEG
1070129|NCT01705678|Males
1070130|NCT01705678|Metabolic syndrome
1070131|NCT01705678|Otherwise healthy
1070132|NCT01705652|nexrutine
1070133|NCT01705652|prostate cancer
1070134|NCT01705639|diabetes
1070135|NCT01705639|melatonin
1070136|NCT01705639|glucose tolerance
1070137|NCT01705639|sleep
1070138|NCT01705626|Peripheral Nervous System Diseases
1070139|NCT01705626|Neuromuscular Diseases
1070140|NCT01705626|Nervous System Diseases
1070141|NCT01705626|Metabolism, Inborn Errors
1070142|NCT01705626|Genetic Diseases, Inborn
1070143|NCT01705613|Attention Deficit/Hyperactivity Disorder
1070144|NCT01705613|ADHD
1070145|NCT01705613|Methylphenidate Immediate-release
1070146|NCT01705613|Cost-effectiveness
1070147|NCT01705613|Cost-utility
1070148|NCT01705613|QALYs
1070149|NCT01705600|Central Sensitization
1070150|NCT01705600|Low Back Pain
1070151|NCT01705600|Pain
1070152|NCT01705600|Pain Catastrophizing
1070153|NCT01705600|Brence
1070154|NCT01705587|osteoporosis
1070155|NCT01705587|atypical femoral fractures
1070156|NCT01705587|prior bisphosphonate treatment
1070157|NCT01705587|postmenopausal women
1070158|NCT01705587|bone loss
1070159|NCT01705574|HIV-1
1070160|NCT01705574|HIV
1070161|NCT01705574|Treatment-Naive
1070162|NCT01705574|Women
1070163|NCT01705574|WAVES
1070164|NCT01705561|fertility
1070165|NCT01705561|chemotherapy
1070166|NCT01705561|breast cancer
1070167|NCT01705561|latin american women
1070168|NCT01705561|pre menopausal
1070169|NCT01705548|Brain metastasis
1070170|NCT01705535|Fecal incontinence
1070171|NCT01705535|Pelvic floor muscle exercises
1070172|NCT01705535|Physiotherapy
1070173|NCT01705522|IBD
1070174|NCT01705522|ulcerative colitis
1070175|NCT01705522|Crohn's disease
1070176|NCT01705522|NAFLD
1070177|NCT01705522|biomarkers
1070178|NCT01705522|vitamin D
1070179|NCT01705509|The Effects of Ranolazine on CPET Parameters in Ischemic
1070180|NCT01705509|Cardiomyopathy Patients
1070181|NCT01705496|Phase II
1070182|NCT01705496|FIAU
1070183|NCT01705496|Fialuridine
1070184|NCT01705496|Prosthetic
1070185|NCT01705496|Joint
1070186|NCT01705496|Infection
1070187|NCT01705496|PET-CT
1070188|NCT01705483|ASP9853
1070189|NCT01705483|Docetaxel
1070190|NCT01705483|Paclitaxel
1070191|NCT01705470|Furosemide
1070192|NCT01705470|Anemia
1070193|NCT01705470|LV dysfunction
1070194|NCT01705470|blood transfusion
1070195|NCT01705457|multiple sclerosis
1070196|NCT01705457|Vitamin A
1070197|NCT01705457|retinoic acid receptor
1070198|NCT01705457|retinoic x receptor
1070199|NCT01705444|Urinary retention
1070200|NCT01705444|Foley catheter
1070201|NCT01705444|The Spanner
1070202|NCT01705444|Quality of life
1070203|NCT01705431|Emotional Disturbance
1070204|NCT01705431|Behavioral Disturbance
1070205|NCT01705431|EBD
1070206|NCT01705431|Middle School
1070207|NCT01705431|Special Education
1070208|NCT01705431|School Psychology
1070209|NCT01705418|Parkinson disease
1070210|NCT01705418|Deep brain stimulation
1070211|NCT01705418|behavior and psychiatric symptoms improvement
1070212|NCT01705405|cancer
1070213|NCT01705405|prostate
1070214|NCT01705379|Neisseria meningitidis, conjugate vaccine, phase IV clinical trial
1070215|NCT01705366|Osteoarthritis
1070216|NCT01705366|Joint Disease
1070217|NCT01705366|Arthritis
1070218|NCT01705366|Musculoskeletal Disease
1070219|NCT01705353|Stroke
1070220|NCT01705353|Cerebrovascular Accident
1070221|NCT01705353|HMGB-1
1070222|NCT01705353|cytokines
1070223|NCT01705353|functional recovery
1070224|NCT01705353|inflammation
1070225|NCT01705353|immune response
1070226|NCT01705327|Parkinson's
1070227|NCT01705327|Biomarkers
1070228|NCT01705327|Neurodegenerative disorder
1070229|NCT01705314|human influenza children
1070230|NCT01705288|laparotomy
1070231|NCT01705288|hysterectomy
1070232|NCT01705262|compliance
1070233|NCT01705262|Bowel preparations
1070234|NCT01705262|Moviprep
1070235|NCT01705262|Phosphoral
1070236|NCT01705223|prophylactic
1070237|NCT01705223|vaccine
1070238|NCT01705184|Stop and go
1070239|NCT01705184|Non-small cell lung cancer
1070240|NCT01705184|Non-squamous
1070241|NCT01705184|Bevacizumab
1070242|NCT01705171|IBS
1070243|NCT01705171|fructose intolerance
1070244|NCT01705171|GLUT 5
1070245|NCT01705171|GLUT 2
1070246|NCT01705158|ovarian cancer in relapse
1070247|NCT01705158|sensitive in platin
1070248|NCT01705145|Cystic Fibrosis
1070249|NCT01705119|Mechanically Ventilated
1070250|NCT01705119|Critical Care
1070251|NCT01705093|strawberry, cardiovascular, obesity, adolescent
1070252|NCT01705080|Renal Denervation
1070253|NCT01705080|Renal artery
1070254|NCT01705067|Osteoarthritis, Degenerative Knee Disease, TKA
1070259|NCT01705015|exercise
1070260|NCT01705002|phase 1
1070261|NCT01705002|dose escalating
1070262|NCT01705002|prodrug
1070263|NCT01705002|mitomycin C
1070264|NCT01705002|Capecitabine
1070265|NCT01704989|Glaucoma, SLT
1070266|NCT01704963|Recurrent mature B-cell neoplasms
1070267|NCT01704963|B-cell malignancies
1070268|NCT01704963|Bruton's Tyrosine Kinase (Btk) Inhibitor
1070269|NCT01704963|PCI-32765
1070270|NCT01704963|Tumor
1070271|NCT01704963|Pharmacokinetics
1070272|NCT01704963|Japanese
1070273|NCT01704937|Fecal Microbiota Transplant
1070274|NCT01704937|Clostridium difficile
1070275|NCT01704937|Diarrhea
1070276|NCT01704924|Prevena
1070277|NCT01704924|negative pressure wound therapy
1070278|NCT01704924|Incisional wound vac
1070279|NCT01704911|Transradial
1070280|NCT01704911|Transfemoral
1070281|NCT01704911|Coronary Intervention
1070282|NCT01704898|efavirenz
1070283|NCT01704898|bioequivalence
1070284|NCT01704898|fasting
1070285|NCT01704898|healthy volunteers
1070286|NCT01704885|Childhood Cancer
1070287|NCT01704885|Sibling Play intervention
1070288|NCT01704885|Sibling Behavioral Intervention
1070289|NCT01704885|Siblings of Cancer Patients
1070290|NCT01704872|Neuroblastoma
1070291|NCT01704872|Refractory neuroblastoma
1070292|NCT01704872|ch14.18/CHO
1070293|NCT01704859|fracture
1070294|NCT01704833|Psychosis
1070295|NCT01704833|Paranoia
1070296|NCT01704833|Cognitive Behavioral Therapy
1070297|NCT01704833|Delusions
1070298|NCT01704833|Group Therapy
1070299|NCT01704820|Colon Polyps
1070300|NCT01704820|Colon Cancer screening
1070301|NCT01704820|Colonoscopy
1070302|NCT01704807|Low Back Pain
1070303|NCT01704807|Chronic
1070304|NCT01704807|Orthotic Device
1070305|NCT01704807|Applied Kinesiology
1070306|NCT01704807|Manual Muscle Testing
1070307|NCT01704807|Chiropractic
1070308|NCT01704794|Sickle Cell Anemia
1070309|NCT01704794|Quality of Life
1070310|NCT01704794|Antioxidant
1070311|NCT01704794|Anti inflammatory
1070312|NCT01704794|Sorghum bicolor
1070313|NCT01704781|CD4
1070314|NCT01704781|Clinical trial
1070315|NCT01704781|Dose escalation assessment lenalidomide
1070316|NCT01704781|Human immunodeficiency virus-1 (HIV-1)
1070317|NCT01704781|HIV
1070318|NCT01704781|Immunomodulatory
1070319|NCT01704781|Infection
1070320|NCT01704781|Lenalidomide
1070321|NCT01704781|Phase I/II
1070322|NCT01704781|Vaccine
1070323|NCT01704781|Vacc-4x
1070324|NCT01704768|Randomized Controlled Trial
1070325|NCT01704768|School-Based Intervention
1070326|NCT01704755|Cirrhosis
1070327|NCT01704755|Hepatitis C
1070328|NCT01704755|Child Pugh A
1070329|NCT01704755|Compensated Cirrhosis
1070330|NCT01704755|Hepatitis C Genotype 1
1070331|NCT01704755|Cirrhotic
1070332|NCT01704755|Chronic Hepatitis C
1070333|NCT01704755|Hepatitis C Virus
1070334|NCT01704755|ombitasvir
1070335|NCT01704755|paritaprevir
1070336|NCT01704755|dasabuvir
1070337|NCT01704755|Interferon-Free
1070338|NCT01704755|Viekira Pak
1070339|NCT01704742|Non-Hodgkin's Lymphoma
1070340|NCT01704742|Hodgkin's Lymphoma
1070341|NCT01704742|Kenya
1070342|NCT01704742|Epstein Barr Virus (EBV)
1070343|NCT01704742|Human Immunodeficiency Virus (HIV)
1070344|NCT01704742|Kaposi's Sarcoma Herpes Virus (KSHV)
1070345|NCT01704729|Myopia
1070346|NCT01704729|Focus groups
1070347|NCT01704729|refraction
1070348|NCT01704729|Glasses
1070349|NCT01704729|spectacles
1070350|NCT01704716|neuroblastoma
1070351|NCT01704716|immunotherapy
1070352|NCT01704716|MAT
1070353|NCT01704716|antibody treatment
1070354|NCT01704703|colorectal cancer
1070355|NCT01704703|FOLFIRI
1070356|NCT01704703|Panitumumab
1070357|NCT01704703|KRAS, PIK3Ca,BRAF and NRAS genes
1070358|NCT01704703|highly sensitive techniques
1070359|NCT01704690|Esophageal cancer
1070360|NCT01704690|Chemotherapy
1070361|NCT01704690|Efficacy
1070362|NCT01704690|Toxicity
1070363|NCT01704677|Chronic low back pain
1070364|NCT01704677|Degenerated disc
1070365|NCT01704677|Total disc replacement
1070366|NCT01704677|Multidisciplinary rehabilitation
1070367|NCT01704677|Long term results
1070368|NCT01704664|malnutrition,
1070369|NCT01704664|perioperative artificial nutrition,
1070370|NCT01704664|immunonutrition,
1070371|NCT01704664|gastrectomy,
1070372|NCT01704664|lymphocytes,
1070373|NCT01704664|interleukin,
1070374|NCT01704664|blood platelets,
1070375|NCT01704664|phagocytic and bactericidal activity of blood platelets
1070376|NCT01704651|Ovary
1070377|NCT01704651|Ovarian
1070378|NCT01704651|Fallopian
1070379|NCT01704651|Peritoneal
1070380|NCT01704651|Cancer
1070381|NCT01704651|Gynecological
1070382|NCT01704651|Female
1070383|NCT01704625|pain
1070384|NCT01704625|headache
1070385|NCT01704612|local anesthetic
1070386|NCT01704612|sciatic
1070387|NCT01704612|diabetes
1070388|NCT01704612|block
1070389|NCT01704612|duration
1070390|NCT01704599|Psoriasis
1070391|NCT01704599|Adalimumab
1070392|NCT01704599|B vitamins
1070393|NCT01704599|Homocysteine
1070394|NCT01704599|Folic acid
1070395|NCT01704599|Cyanocobalamin
1070396|NCT01704599|Pyridoxine
1070397|NCT01704599|Vitamin B6
1070398|NCT01704599|Vitamin B9
1070399|NCT01704599|Vitamin B12
1070400|NCT01704586|Differentiated thyroid carcinoma
1070401|NCT01704586|PET/CT
1070402|NCT01704586|Radioiodine Remnant Ablation
1070403|NCT01704586|I-124
1070404|NCT01704586|Quality of life
1070405|NCT01704573|PET Scan
1070409|NCT01704534|Hidradenitis suppurativa
1070410|NCT01704534|Acne ectopica
1070411|NCT01704534|Inverse acne
1070412|NCT01704534|Ustekinumab
1070413|NCT01704534|Stelara
1070414|NCT01704521|Hepatitis C
1070415|NCT01704521|HCV
1070416|NCT01704521|Hemophilia
1070417|NCT01704508|Falciparum malaria
1070418|NCT01704508|children
1070419|NCT01704508|treatment
1070420|NCT01704495|Uncontrolled Asthma,
1070421|NCT01704495|Exacerbation,
1070422|NCT01704495|Safety
1070423|NCT01704469|Opioid induced hyperalgesia
1070424|NCT01704456|provoked vestibulodynia
1070425|NCT01704456|dyspareunia
1070426|NCT01704456|vulvodynia
1070427|NCT01704456|mindfulness
1070428|NCT01704456|cognitive behavioural therapy
1070429|NCT01704443|provoked vestibulodynia
1070430|NCT01704443|dyspareunia
1070431|NCT01704443|vulvodynia
1070432|NCT01704443|mindfulness
1070433|NCT01704443|cognitive behavioural therapy
1070434|NCT01704430|Cardiac surgery
1070435|NCT01704430|Cardiac bypass
1070436|NCT01704430|Intensive Care
1070437|NCT01704430|Nosocomial infection
1070438|NCT01704430|Glutamine
1070439|NCT01704430|Randomized trial
1070440|NCT01704404|Long acting muscarinic antagonist
1070441|NCT01704404|Chronic Bronchitis
1070442|NCT01704404|Emphysema
1070443|NCT01704404|Chronic Obstructive Pulmonary Disease
1070444|NCT01704404|COPD
1070445|NCT01704352|Cognitive Behavioral Therapy
1070446|NCT01704352|CBT-I
1070447|NCT01704339|End stage renal failure
1070448|NCT01704339|Neuropathic pain
1070449|NCT01704339|Critical digital ischaemia
1070450|NCT01704326|Deuce
1070451|NCT01704326|Journey Deuce
1070452|NCT01704326|Knee pain
1070453|NCT01704326|Osteoarthritis
1070454|NCT01704326|Bicompartmental
1070455|NCT01704326|Femoral
1070456|NCT01704326|Medial
1070457|NCT01704313|Vascular access
1070458|NCT01704313|Haemodialysis
1070459|NCT01704313|Suturing technique
1070460|NCT01704300|Abdominal aortic aneurysm
1070461|NCT01704300|Acute Myocardial Infarction
1070462|NCT01704300|Coronary heart disease not otherwise specified
1070463|NCT01704300|Haemorrhagic stroke
1070464|NCT01704300|Heart failure
1070465|NCT01704300|Ischaemic stroke
1070466|NCT01704300|Peripheral arterial disease
1070467|NCT01704300|Stable angina
1070468|NCT01704300|Unheralded coronary death
1070469|NCT01704300|Unstable angina
1070470|NCT01704300|Ventricular arrhythmias, cardiac arrest and sudden cardiac death
1070471|NCT01704300|Transient Ischemic Attack
1070472|NCT01704287|PD-1
1070473|NCT01704287|PD1
1070474|NCT01704287|PD-L1
1070475|NCT01704287|PDL1
1070476|NCT01704274|biochemical
1070477|NCT01704274|recurrence
1070478|NCT01704274|prostate
1070479|NCT01704274|cancer
1070480|NCT01704274|active
1070481|NCT01704274|surveillence
1070482|NCT01704248|eye drops self-instillation
1070483|NCT01704235|screening
1070484|NCT01704222|Children
1070485|NCT01704222|nursery
1070486|NCT01704222|CMV
1070487|NCT01704222|Infection
1070488|NCT01704183|relapse-remitting multiple sclerosis
1070489|NCT01704183|heart rate variability
1070490|NCT01704183|fingolimod
1070491|NCT01704183|cardiac autonomic regulation
1070492|NCT01704157|Osteoarthritis
1070493|NCT01704157|knee
1070494|NCT01704157|chronic pain
1070495|NCT01704144|Efavirenz
1070496|NCT01704144|rifampin
1070497|NCT01704144|Pharmacokinetics
1070498|NCT01704144|Drug-drug interactions
1070499|NCT01704144|Drug-gene interactions
1070500|NCT01704144|Children
1070501|NCT01704131|Levosimendan
1070502|NCT01704131|Children
1070503|NCT01704131|Pharmacokinetics
1070504|NCT01704118|I-gel
1070505|NCT01704118|ProSeal laryngeal mask
1070506|NCT01704118|small infants
1070507|NCT01704118|neonates
1070508|NCT01704105|Chlorine water treatment
1070509|NCT01704105|Point-of-use water treatment
1070510|NCT01704105|Household water treatment with safe storage
1070511|NCT01704105|Handwashing with soap
1070512|NCT01704105|Hand hygiene
1070513|NCT01704105|Latrines
1070514|NCT01704105|Water
1070515|NCT01704105|Sanitation
1070516|NCT01704105|Handwashing
1070517|NCT01704105|Breast Feeding
1070518|NCT01704105|Complementary Feeding
1070519|NCT01704105|Micronutrients
1070520|NCT01704105|Malnutrition
1070521|NCT01704105|Nutrition Disorders
1070522|NCT01704105|Diarrhea
1070523|NCT01704105|Child Development
1070524|NCT01704105|Child potties
1070525|NCT01704105|Point-of-use fortification
1070526|NCT01704105|Lipid-based nutrient supplement
1070527|NCT01704105|Exclusive breastfeeding
1070528|NCT01704105|Environmental enteropathy
1070529|NCT01704105|Tropical enteropathy
1070530|NCT01704105|Gut function
1070531|NCT01704105|Intestinal parasitic infection
1070532|NCT01704105|Soil transmitted helminths
1070533|NCT01704105|Intestinal protozoans
1070534|NCT01704105|Antibody response
1070535|NCT01704079|Parathyroid Diseases
1070536|NCT01704079|Renal Insufficiency
1070537|NCT01704079|Kidney Failure, Chronic
1070538|NCT01704079|Hyperparathyroidism, Secondary
1070539|NCT01704079|Vitamin D
1070540|NCT01704079|Hyperparathyroidism
1070541|NCT01704079|Kidney Diseases
1070542|NCT01704079|Kidney Failure
1070543|NCT01704079|Renal Insufficiency, Chronic
1070544|NCT01704066|ARDS
1070545|NCT01704066|Chest radiograph
1070546|NCT01704066|Berlin Definition
1070547|NCT01704066|Inter-observer agreement
1070548|NCT01704053|New Oral Anticoagulants
1070549|NCT01704053|Dabigatran
1070550|NCT01704053|Rivaroxaban
1070551|NCT01704053|Thrombelastometry/-graphy (ROTEM, TEG)
1070552|NCT01704053|Multiple Platelet Function Analyzer (Multiplate)
1070553|NCT01704040|Healthy volunteers and asthma
1070554|NCT01704040|CNTO 3157
1070555|NCT01704040|Rhinovirus
1070556|NCT01704027|Localized
1070557|NCT01704027|High risk
1070558|NCT01704014|occurrence of
1070559|NCT01704001|ART-123
1070560|NCT01704001|Disseminated Intravascular Coagulation
1070561|NCT01704001|Pharmacokinetics
1070562|NCT01703988|Spinal Muscular Atrophy
1070563|NCT01703988|SMA
1070564|NCT01703988|SMN
1070565|NCT01703988|SMNRx
1070566|NCT01703988|ISIS-SMNRx
1070567|NCT01703988|ISIS 396443
1070568|NCT01703975|Simulation efficiency
1070569|NCT01703975|Collaborative learning
1070570|NCT01703962|Glioma
1070571|NCT01703962|IDH1
1070572|NCT01703962|Spectroscopy
1070573|NCT01703962|Plasma
1070574|NCT01703936|economic intervention
1070575|NCT01703936|ex-combatant
1070576|NCT01703936|agriculture
1070577|NCT01703936|life skills
1070578|NCT01703910|Genomic expression profile in tumor samples
1070579|NCT01703910|Adult patients
1070580|NCT01703910|metastatic disease status and progression after two lines of systemic therapy
1070581|NCT01703897|gastric by-pass surgery
1070582|NCT01703884|Malria diagnosis
1070583|NCT01703884|Malaria prevention in pregnancy
1070584|NCT01703884|ANC services improvement
1070585|NCT01703832|acute stress reaction
1070586|NCT01703832|stress
1070587|NCT01703832|stress perception
1070588|NCT01703832|physiological stress response
1070589|NCT01703832|Neurexan
1070590|NCT01703819|acute stress reaction
1070591|NCT01703819|stress
1070592|NCT01703819|stress perception
1070593|NCT01703819|physiological stress response
1070594|NCT01703819|Neurexan
1070595|NCT01703806|Mitral regurgitation
1070596|NCT01703806|Mitral valve repair
1070597|NCT01703806|Watchful waiting
1070598|NCT01703767|patient satisfaction
1070599|NCT01703767|Gulf War 1 Veteran
1070600|NCT01703767|Desert Storm Veteran
1070601|NCT01703754|Genetically Modified Organism
1070602|NCT01703754|Metastatic Breast Cancer
1070603|NCT01703754|Recurrent Breast Cancer
1070604|NCT01703754|Breast Cancer
1070605|NCT01703754|Palifosfamide
1070606|NCT01703754|INXN1001
1070607|NCT01703754|INXN2001
1070608|NCT01703754|Adenoviral vector
1070609|NCT01703715|Hydration
1070610|NCT01703715|Elderly patients
1070611|NCT01703715|Age 65 years and over
1070612|NCT01703715|Admitted acutely to medical admissions ward
1070613|NCT01703689|Quality indicators
1070614|NCT01703689|quality of care
1070615|NCT01703689|nursing home
1070616|NCT01703689|long-term care unit
1070617|NCT01703689|nursing home organisation
1070618|NCT01703689|nursing home structure
1070619|NCT01703689|disability
1070620|NCT01703689|dependence
1070621|NCT01703689|functional decline
1070622|NCT01703689|functional impairment
1070623|NCT01703689|older adults
1070624|NCT01703689|elderly
1070625|NCT01703689|audit and feedback
1070626|NCT01703689|cooperative work
1070627|NCT01703689|geriatrician
1070628|NCT01703689|medication
1070629|NCT01703689|hospitalisation
1070630|NCT01703689|comorbidity
1070631|NCT01703676|Hypogonadism, Klinefelter Syndrome, Cardiovascular Risk, Epigenetics, Methylation of Genes
1070632|NCT01703676|Cardiovascular risk factors
1070633|NCT01703676|Gonadal status
1070634|NCT01703676|Gene expression
1070635|NCT01703676|Methylation
1070636|NCT01703663|Stroke
1070637|NCT01703663|Sleep Apnea
1070638|NCT01703650|CT
1070639|NCT01703650|pancreas adenocarcinoma
1070640|NCT01703650|RECIST
1070641|NCT01703650|perfusion
1070642|NCT01703637|Sitagliptin
1070643|NCT01703637|Vildagliptin
1070644|NCT01703637|Saxagliptin
1070645|NCT01703637|Diabetes Mellitus, Type 2
1070646|NCT01703624|glycopyrronium bromide
1070647|NCT01703624|glycopyrrolate
1070648|NCT01703624|oral inhalation
1070649|NCT01703624|COPD
1070650|NCT01703624|chronic obstructive pulmonary disease
1070651|NCT01703624|lung function
1070652|NCT01703624|pharmacokinetics
1070653|NCT01703624|tolerability
1070654|NCT01703624|safety
1070655|NCT01703624|cross-over
1070656|NCT01703624|single-dose
1070657|NCT01703624|dose-ranging
1070658|NCT01703611|Nutrition
1070659|NCT01703611|Medical Nutrition Therapy
1070660|NCT01703611|Diabetes Mellitus
1070661|NCT01703611|Nutrition outcomes
1070662|NCT01703611|Evidence Based Guidelines
1070663|NCT01703598|Parkinson's disease
1070664|NCT01703598|Deep Brain Stimulation
1070665|NCT01703585|genomic analysis
1070666|NCT01703585|genome
1070667|NCT01703585|tumor
1070668|NCT01703585|tissue
1070669|NCT01703585|archival
1070670|NCT01703585|biopsy
1070671|NCT01703585|core needle
1070672|NCT01703585|fine needle
1070673|NCT01703585|DNA
1070674|NCT01703585|gene
1070675|NCT01703585|expression
1070676|NCT01703585|sequencing
1070677|NCT01703572|Phase 1
1070678|NCT01703572|Dose escalation
1070679|NCT01703572|relapsed or refractory
1070680|NCT01703572|lymphoid malignancies
1070681|NCT01703559|Glare
1070682|NCT01703559|Starburst
1070683|NCT01703559|Halos
1070684|NCT01703559|Reduced contrast sensitivity
1070685|NCT01703546|Morbid Obesity
1070686|NCT01703546|Weight Loss Surgery
1070687|NCT01703546|Laparoscopic Adjustable Gastric Band
1070688|NCT01703546|Laparoscopic Gastric Plication
1070689|NCT01703546|Imbrication
1070690|NCT01703533|Autism
1070691|NCT01703533|Rett's Syndrome
1070692|NCT01703533|Rett Disorder
1070693|NCT01703533|Rett's Disorder
1070694|NCT01703533|Ataxia
1070699|NCT01703494|C. difficile
1070700|NCT01703494|fecal transplant
1070701|NCT01703494|stool transplant
1070702|NCT01703494|fecal flora reconstitution
1070703|NCT01703494|fecal microbiota transplant
1070704|NCT01703494|FMT
1070830|NCT01702857|Dengue fever
1070710|NCT01703455|Salivary gland cancer metastatic disease recurrent disease clinical trial
1070711|NCT01703429|Multiple Sclerosis
1070712|NCT01703429|MS
1070713|NCT01703429|Complementary and Alternative
1070714|NCT01703429|CAM
1070715|NCT01703416|COPD
1070716|NCT01703416|GOLD group C and D
1070717|NCT01703416|CDLM questionnaire
1070718|NCT01703416|visual scale - physician evaluation
1070719|NCT01703403|physical therapy
1070720|NCT01703403|treated at NTUH and received rehabilitation at the PTC in recent ten years.
1070721|NCT01703390|metastatic colorectal cancer
1070722|NCT01703390|mCRC
1070723|NCT01703390|ERCC-1
1070724|NCT01703390|ERCC1
1070725|NCT01703390|AGMT
1070726|NCT01703364|CLL
1070727|NCT01703364|Lenalidomide
1070728|NCT01703364|Revlimid
1070729|NCT01703364|AGMT
1070730|NCT01703364|T cell
1070731|NCT01703351|pain control, VATS
1070732|NCT01703338|assessment model
1070733|NCT01703338|biomechanical changes
1070734|NCT01703338|functional activities
1070735|NCT01703338|magnetic resonance imaging (MRI)
1070736|NCT01703338|causal relationship
1070737|NCT01703338|core muscles activation pattern
1070738|NCT01703338|pathological changes
1070739|NCT01703338|early rehabilitation
1070740|NCT01703338|core stability exercise
1070741|NCT01703338|minimally invasive lumbar spinal fusion surgery
1070742|NCT01703325|Psoriatic nails
1070743|NCT01703325|Triamcinolone injection
1070744|NCT01703325|clobetasol propionate
1070745|NCT01703312|Allergies, asthma, IgE
1070746|NCT01703299|imipenem
1070747|NCT01703299|ertapenem
1070748|NCT01703299|resistance
1070749|NCT01703299|commensal flora
1070750|NCT01703273|Extreme Obesity Keywords: obesity, adiposity, psychosocial, healthcare, co-morbidities, low key intervention, quality of life
1070751|NCT01703260|Drug therapy
1070752|NCT01703247|Arrhythmias
1070753|NCT01703247|Ablation
1070754|NCT01703234|FGF-23 , ramipril, endothelial dysfunction
1070755|NCT01703195|Vaginal Cancer
1070756|NCT01703195|Malignancies involving the vagina
1070757|NCT01703195|Middle third and the distal third of the vagina
1070758|NCT01703195|Pre and post radiation therapy
1070759|NCT01703195|Diffusion weighted magnetic resonance imaging
1070760|NCT01703195|DWMR
1070761|NCT01703195|Magnetic resonance imaging
1070762|NCT01703195|MRI
1070763|NCT01703195|Tumor involvement
1070764|NCT01703195|Response to radiation therapy
1070765|NCT01703195|XRT
1070766|NCT01703182|transcutaneous oximetry
1070767|NCT01703182|transcutaneous carbon dioxide
1070768|NCT01703182|leg amputation
1070769|NCT01703182|wound healing failure
1070770|NCT01703182|amputation revision
1070771|NCT01703169|severe aplastic anemia
1070772|NCT01703169|very severe aplastic anemia
1070773|NCT01703169|moderate aplastic anemia
1070774|NCT01703169|bleeding
1070775|NCT01703156|Low Risk ACS, Acute Coronary Syndrome, Stress Testing, Non-Stress Testing
1070776|NCT01703130|ISPB
1070777|NCT01703130|Brachial Plexus Block
1070778|NCT01703130|Anesthesia
1070779|NCT01703130|Pain Management
1070780|NCT01703130|Surgery
1070781|NCT01703117|Alzheimer's Disease
1070782|NCT01703117|Dementia
1070783|NCT01703104|Sorghum bicolor
1070784|NCT01703104|sickle cell anaemia
1070785|NCT01703104|haematological parameters
1070786|NCT01703065|Prostate cancer
1070787|NCT01703065|Bone metastases
1070788|NCT01703039|Major Depression
1070789|NCT01703039|Major Depressive Disorder
1070790|NCT01703039|Depression
1070791|NCT01703039|Riluzole
1070792|NCT01703039|Glutamate
1070793|NCT01703039|Sertraline
1070794|NCT01703013|Demonstrate that DEFA4 is a reliable biomarker for the prediction of adrenal insufficiency
1070795|NCT01703000|drug eluting coronary stent
1070796|NCT01702987|ubiquinol (coenzyme Q10)
1070797|NCT01702974|HIV
1070798|NCT01702974|cholecalciferol
1070799|NCT01702974|sodium phenylbutyrate
1070800|NCT01702974|antimicrobial peptides
1070801|NCT01702974|immune response
1070802|NCT01702974|inflammation
1070803|NCT01702961|Lymphoma
1070804|NCT01702961|Hodgkin's Disease
1070805|NCT01702948|Functional Magnetic Resonance Imaging (fMRI)
1070806|NCT01702948|Nicotine
1070807|NCT01702948|Repetitive TMS (rTMS)
1070808|NCT01702948|fMRI
1070809|NCT01702935|Ovarian Failure
1070810|NCT01702935|Premature Ovarian Failure
1070811|NCT01702935|Infertility
1070812|NCT01702935|Primary Ovarian Insufficiency
1070813|NCT01702935|Stem Cells
1070814|NCT01702922|Stress
1070815|NCT01702922|Marriage
1070816|NCT01702922|Dyadic Coping
1070817|NCT01702922|Mother
1070818|NCT01702922|Father
1070819|NCT01702909|Metastatic Renal Cell
1070820|NCT01702909|Metastatic Kidney Cancer
1070821|NCT01702896|Metastatic Melanoma
1070822|NCT01702883|prescriptions
1070823|NCT01702883|hypertension
1070824|NCT01702883|high cholesterol
1070825|NCT01702883|diabetes
1070826|NCT01702883|depression
1070827|NCT01702883|adherence
1070828|NCT01702870|Magnetic resonance imaging
1070829|NCT01702857|Dengue
1070831|NCT01702857|Dengue Hemorrhagic Fever
1070832|NCT01702857|Flavivirus
1070833|NCT01702844|Nab paclitaxel
1070834|NCT01702844|Abraxane
1070835|NCT01702844|First Line
1070836|NCT01702844|Non small cell lung cancer
1070837|NCT01702844|NSCLC
1070838|NCT01702844|Phase II
1070839|NCT01702844|Non-Randomized
1070840|NCT01702844|Elderly
1070841|NCT01702844|Lineberger
1070842|NCT01702844|UNC
1070843|NCT01702844|LCCC 1210
1070844|NCT01702831|Newly Diagnosed multiple myeloma
1070845|NCT01702818|Hypoactive Sexual Desire Disorder
1070846|NCT01702818|HSDD
1070847|NCT01702818|Cortisol
1070848|NCT01702818|DHEA
1070849|NCT01702818|Stress Hormones
1070850|NCT01702818|Sexual Desire
1070851|NCT01702818|Mood
1070852|NCT01702818|Sexual Function
1070853|NCT01702818|Childhood Maltreatment
1070854|NCT01702818|Childhood Abuse
1070859|NCT01702792|Immunotherapy, cancer vaccine, glioblastoma, hybridoma
1070860|NCT01702779|Weaning from mechanical ventilation
1070861|NCT01702779|Lung ultrasound
1070862|NCT01702779|Oxygen inhalation therapy
1070863|NCT01702740|Cutaneous lupus erythematosus
1070864|NCT01702740|Systemic lupus erythematosus
1070865|NCT01702740|Lupus erythematosus
1070866|NCT01702740|Human anti-IL 6 monoclonal antibody
1070867|NCT01702740|Sirukumab
1070868|NCT01702727|Amblyopia
1070869|NCT01702727|I-BiT TM
1070870|NCT01702727|Interactive games
1070871|NCT01702727|Binocular
1070872|NCT01702675|Safety
1070873|NCT01702675|Pharmacokinetics
1070874|NCT01702675|Tolerability
1070875|NCT01702675|Healthy men
1070897|NCT01702584|stent
1070898|NCT01702584|intracranial aneurysm
1070899|NCT01702584|embolization
1070900|NCT01702584|adverse event
1070901|NCT01702532|provoked craving
1070902|NCT01702506|Dacomitinib
1070903|NCT01702506|PF-00299804
1070904|NCT01702506|fed
1070905|NCT01702506|fasted
1070906|NCT01702506|antacid
1070907|NCT01702506|relative Bioavailability
1070908|NCT01702493|SRT2104
1070909|NCT01702493|Modified Release
1070910|NCT01702493|Bioavailability
1070911|NCT01702493|Crossover
1070912|NCT01702480|Consumer Healthcare
1070913|NCT01702480|Ketones
1070914|NCT01702480|Medium Chain Triglycerides
1070915|NCT01702480|Age related cognitive decline
1070916|NCT01702480|GSK Nutrition
1070917|NCT01702467|Lp-PLA2
1070918|NCT01702467|Alzheimer's disease
1070919|NCT01702454|GSK Biologicals quadrivalent influenza vaccine
1070920|NCT01702454|Influenza
1070921|NCT01702454|Children
1070922|NCT01702454|Safety
1070923|NCT01702454|Immunogenicity
1070924|NCT01702428|Safety
1070925|NCT01702428|Consistency study
1070926|NCT01702428|Measles, mumps and rubella diseases
1070927|NCT01702428|Healthy children
1070928|NCT01702428|Immunogenicity
1070929|NCT01702415|Cystic fibrosis
1070930|NCT01702415|Bone density
1070931|NCT01702402|intervention
1070932|NCT01702389|opioid induced hyperalgesia
1070933|NCT01702389|Pain
1070934|NCT01702389|Postoperative pain
1070935|NCT01702389|Hyperalgesia
1070936|NCT01702363|Chronic Obstructive Pulmonary Disease (COPD), GSK573719, Pharmacogenetics
1070941|NCT01702337|Gardasil
1070942|NCT01702337|Prevalence-model
1070943|NCT01702337|Cervarix
1070944|NCT01702337|economic
1070945|NCT01702337|health
1070946|NCT01702324|Psoriasis Vulgaris
1070947|NCT01702324|Plaque
1070948|NCT01702324|Topical
1070949|NCT01702324|Treatment
1070950|NCT01702311|Diabetes
1070951|NCT01702311|Point of care testing
1070952|NCT01702311|Hypoglycemia
1070953|NCT01702311|Basal bolus insulin
1070954|NCT01702285|Advanced Solid Tumors
1070955|NCT01702285|EGFR
1070956|NCT01702285|HDAC
1070957|NCT01702285|Her2
1070958|NCT01702285|Open-Label
1070959|NCT01702285|Dose-Escalation
1070960|NCT01702246|sickle cell disease
1070961|NCT01702246|statins
1070962|NCT01702246|vaso-occlusive pain
1070963|NCT01702246|inflammation
1070964|NCT01702246|biomarkers
1070965|NCT01702220|Generalized Anxiety Disorder
1070966|NCT01702220|Geriatric
1070967|NCT01702207|Prograf®
1070968|NCT01702207|Advagraf®
1070969|NCT01702207|tacrolimus
1070970|NCT01702207|kidney transplant
1070971|NCT01702207|renal transplant
1070972|NCT01702207|cardiovascular risk
1070973|NCT01702207|Framingham Risk
1070974|NCT01702207|Reynolds Risk
1070975|NCT01702207|immunosuppression
1070976|NCT01702194|OIC
1070977|NCT01702194|Opioid Induced Constipation
1070978|NCT01702194|Constipation
1070979|NCT01702181|Atopic Dermatitis, Eczema
1070980|NCT01702168|PTSD
1070981|NCT01702168|EBT
1070982|NCT01702168|EST
1070983|NCT01702168|Community
1070984|NCT01702168|Latino
1070985|NCT01702142|Addiction Treatment
1070986|NCT01702129|EGFR
1070987|NCT01702129|liposomes
1070988|NCT01702129|immunoliposomes
1070989|NCT01702116|rectal adenocarcinoma
1070990|NCT01702116|Standard APR
1070991|NCT01702116|Extralevator APR
1070992|NCT01702090|HIV-1
1070993|NCT01702090|TMC114
1070994|NCT01702090|Darunavir
1070995|NCT01702090|PREZISTA
1070996|NCT01702090|Ritonavir
1070997|NCT01702090|Antiretrovirals
1070998|NCT01702090|Early access
1070999|NCT01702090|Early treatment
1071000|NCT01702090|Treatment naive
1071001|NCT01702077|neurofeedback
1071002|NCT01702077|biofeedback
1071003|NCT01702077|real-time fMRI
1071004|NCT01702077|rt-fMRI
1071005|NCT01702077|functional connectivity
1071006|NCT01702077|fMRI
1071007|NCT01702064|CML
1071008|NCT01702064|CP-CML
1071009|NCT01702064|Chronic Phase-CML (CP-CML)
1071010|NCT01702064|chronic myeloid leukemia
1071011|NCT01702051|Pancreatogenic diabetes
1071012|NCT01702051|Autologou Islet Transplantation
1071013|NCT01702051|Pancreas
1071014|NCT01702051|Pancreatectomy
1071015|NCT01702025|Hypoxia
1071016|NCT01702025|Altitude
1071017|NCT01702025|Exercise
1071018|NCT01702012|Diabetes-Obesity
1071019|NCT01701999|Botulism Vaccine
1071020|NCT01701986|Lymphoma
1071021|NCT01701986|Aggressive lymphomas
1071022|NCT01701986|Allogeneic stem-cell transplant
1071023|NCT01701986|alloSCT
1071024|NCT01701986|Refractory B-cell
1071025|NCT01701986|T-cell
1071026|NCT01701986|Non-Hodgkin's lymphoma
1071027|NCT01701986|Hodgkin's lymphoma
1071028|NCT01701986|Gemcitabine
1071029|NCT01701986|Gemcitabine Hydrochloride
1071030|NCT01701986|Gemzar
1071031|NCT01701986|Clofarabine
1071032|NCT01701986|Clofarex
1071033|NCT01701986|Clolar
1071034|NCT01701986|Busulfan
1071035|NCT01701986|Busulfex
1071036|NCT01701986|Myleran
1071037|NCT01701986|Anti-Thymocyte Globulin
1071038|NCT01701986|ATG
1071039|NCT01701986|Thymoglobulin
1071040|NCT01701986|Rituximab
1071041|NCT01701986|Rituxan
1071042|NCT01701986|Filgrastim
1071043|NCT01701986|G-CSF
1071044|NCT01701986|Neupogen
1071045|NCT01701986|Tacrolimus
1071046|NCT01701986|Prograf
1071047|NCT01701986|Mycophenolate Mofetil
1071048|NCT01701986|MMF
1071049|NCT01701986|CellCept
1071050|NCT01701973|obesity
1071051|NCT01701973|growth hormone
1071052|NCT01701947|Factor XI deficiency
1071053|NCT01701947|EAP
1071054|NCT01701947|postpartum hemorrhage
1071055|NCT01701947|surgery
1071056|NCT01701947|delivery
1071057|NCT01701947|Child birth
1071058|NCT01701934|COPD
1071059|NCT01701934|Intrabdominal adiposity
1071060|NCT01701934|Body composition
1071061|NCT01701934|Triglycerides
1071062|NCT01701934|Cholesterol
1071063|NCT01701921|cardiac surgery
1071064|NCT01701921|pregabalin
1071065|NCT01701921|postoperative pain
1071066|NCT01701908|PPCs
1071067|NCT01701908|abdominal surgery
1071068|NCT01701908|postoperative infections
1071069|NCT01701908|postoperative residual curarization
1071070|NCT01701908|tracheal re-intubation
1071071|NCT01701908|mortality
1071072|NCT01701908|ICU stay
1071073|NCT01701895|Complera
1071074|NCT01701895|short-term
1071075|NCT01701895|long-term
1071076|NCT01701895|compliance
1071077|NCT01701895|caloric
1071078|NCT01701895|intake
1071079|NCT01701895|HIV
1071080|NCT01701895|positive
1071081|NCT01701895|women
1071082|NCT01701856|relapsing-remitting multiple sclerosis
1071083|NCT01701856|natalizumab
1071084|NCT01701856|de-escalation
1071085|NCT01701856|interferon beta-1b
1071086|NCT01701830|omentin-1
1071087|NCT01701830|carotid atherosclerosis
1071088|NCT01701830|kidney disease
1071089|NCT01701817|Atrial Fibrillation
1071090|NCT01701817|Irregular heart beat
1071091|NCT01701804|Failed Back Surgery Syndrome
1071092|NCT01701791|Depression
1071093|NCT01701791|Primary care
1071094|NCT01701791|Computerized decision support system
1071095|NCT01701791|General practitioner
1071096|NCT01701778|Dexmedetomidine
1071097|NCT01701778|Postoperative pain reaction
1071098|NCT01701778|anesthesia
1071099|NCT01701778|children
1071100|NCT01701765|Severe mental disorders
1071101|NCT01701765|Discharge
1071102|NCT01701765|Outcome evaluation
1071103|NCT01701752|Influenza A
1071104|NCT01701726|Essential Hypertension
1071105|NCT01701726|Acupuncture
1071106|NCT01701726|Specificity
1071107|NCT01701726|Acupoints effect
1071108|NCT01701726|randomized controlled trials
1071109|NCT01701713|TDCS
1071110|NCT01701713|STROKE
1071111|NCT01701713|APHASIA
1071112|NCT01701713|NAMING
1071113|NCT01701700|portable electronic magnifiers
1071114|NCT01701687|Cirrhosis
1071115|NCT01701687|Alcoholic liver disease
1071116|NCT01701687|Decompensated liver cirrhosis
1071117|NCT01701687|Hazardous alcohol
1071118|NCT01701674|skin cancer
1071119|NCT01701661|venous surgery
1071120|NCT01701661|compression therapy
1071121|NCT01701648|Vitiligo, amniotic membrane, malanocytes, C02 laser.
1071122|NCT01701635|Disclosure
1071123|NCT01701635|HIV-infected children
1071124|NCT01701635|Resource-limited settings
1071125|NCT01701622|Blood Pressure
1071126|NCT01701622|Gout
1071127|NCT01701622|allopurinol
1071128|NCT01701622|febuxostat
1071129|NCT01701622|uric acid
1071130|NCT01701609|early-onset schizophrenia
1071131|NCT01701609|adolescents
1071132|NCT01701609|cognition
1071133|NCT01701609|cognitive remediation therapy
1071134|NCT01701596|Rotational atherectomy
1071135|NCT01701596|Coronary dissection
1071136|NCT01701596|Percutaneous coronary intervention
1071137|NCT01701596|Calcification
1071138|NCT01701583|Chronic Idiopathic Urticaria
1071139|NCT01701583|CIU
1071140|NCT01701583|Urticaria
1071141|NCT01701583|Chronic Hives
1071142|NCT01701583|Xolair
1071143|NCT01701570|Type 2 Diabetes
1071144|NCT01701570|Exercise
1071145|NCT01701570|Rate of Perceived Exertion
1071146|NCT01701557|Ketoacidosis Fluids
1071147|NCT01701518|Ozurdex
1071148|NCT01701518|Dexamethasone
1071149|NCT01701518|Epiretinal membrane
1071150|NCT01701518|Macular edema
1071151|NCT01701505|operative
1071152|NCT01701505|dental procedure
1071153|NCT01701492|pediatric
1071154|NCT01701492|hematopoietic stem cell transplantation
1071155|NCT01701492|allogeneic bone marrow transplantation
1071156|NCT01701479|Neuroblastoma
1071157|NCT01701479|Refractory neuroblastoma
1071158|NCT01701479|Relapsed neuroblastoma
1071159|NCT01701479|ch14.18/CHO
1071160|NCT01701479|Aldesleukin (IL-2)
1071161|NCT01701466|Patients
1071162|NCT01701466|with
1071163|NCT01701453|duration of DAPT
1071164|NCT01701427|Hyperalgesia
1071165|NCT01701427|Persistent pain
1071166|NCT01701427|deep pain
1071167|NCT01701427|electrical stimulation
1071168|NCT01701427|groin hernia
1071169|NCT01701414|Femur
1071170|NCT01701414|Hip
1071171|NCT01701414|Fracture
1071172|NCT01701414|Femoral neck
1071173|NCT01701414|Femoral head
1071174|NCT01701401|HCV genotype 1 (GT-1)
1071175|NCT01701401|HCV
1071176|NCT01701401|Sustained Virologic Response
1071177|NCT01701401|Direct Acting Antiviral
1071178|NCT01701401|Combination Therapy
1071179|NCT01701401|GS-7977
1071180|NCT01701401|GS-5885
1071181|NCT01701401|Ribavirin
1071182|NCT01701401|Open Label
1071183|NCT01701401|Sofosbuvir
1071184|NCT01701401|Additional relevant MeSH terms:
1071185|NCT01701401|Hepatitis
1071186|NCT01701401|Hepatitis, Chronic
1071187|NCT01701401|Hepatitis C
1071188|NCT01701401|Hepatitis C, Chronic
1071189|NCT01701401|Liver Diseases
1071190|NCT01701401|Digestive System Diseases
1071191|NCT01701401|Hepatitis, Viral, Human
1071192|NCT01701401|Virus Diseases
1071193|NCT01701401|Enterovirus Infections
1071194|NCT01701401|Picornaviridae Infections
1071195|NCT01701401|RNA Virus Infections
1071196|NCT01701401|Flaviviridae Infections
1071197|NCT01701401|Antiviral Agents
1071198|NCT01701401|Anti-Infective Agents
1071199|NCT01701401|Therapeutic Uses
1071200|NCT01701401|Pharmacologic Actions
1071201|NCT01701401|Antimetabolites
1071202|NCT01701401|Molecular Mechanisms of Pharmacological Action
1071203|NCT01701388|Ekso
1071204|NCT01701388|Exoskeleton
1071205|NCT01701388|Spinal Cord Injury
1071206|NCT01701388|Motor Complete Incomplete
1071207|NCT01701362|post-traumatic peripheral neuropathic pain
1071208|NCT01701349|ATC
1071209|NCT01701349|Anaplastic Thyroid Cancer
1071210|NCT01701349|Stage IVC Anaplastic Thyroid Cancer
1071211|NCT01701349|Thyroid Cancer
1071212|NCT01701349|Head and Neck Tumors
1071213|NCT01701336|Hepatitis
1071214|NCT01701336|Hepatitis C
1071215|NCT01701336|HCV
1071216|NCT01701336|vaccine
1071217|NCT01701336|adenovirus
1071218|NCT01701336|MVA
1071219|NCT01701336|T cells
1071220|NCT01701336|ELISpot
1071221|NCT01701310|Adenocarcinoma
1071222|NCT01701310|Anemia
1071223|NCT01701310|Blood Transfusion
1071224|NCT01701310|Colorectal surgery
1071225|NCT01701310|Preoperative care
1071226|NCT01701310|Perioperative care
1071227|NCT01701310|Postoperative care
1071228|NCT01701310|Iron
1071229|NCT01701310|Hematinics
1071230|NCT01701310|Hepcidin
1071231|NCT01701310|Quality of life
1071232|NCT01701310|Postoperative complications
1071233|NCT01701297|Cirrhosis, ascites, infection
1071234|NCT01701284|repetitive Transcranial Magnetic Stimulation
1071235|NCT01701284|Cancer Survivors
1071236|NCT01701284|Depression
1071237|NCT01701284|Anxiety
1071238|NCT01701271|Baldness
1071239|NCT01701271|Androgenetic Alopecia
1071240|NCT01701271|Alopecia
1071241|NCT01701258|Depression
1071242|NCT01701258|Childhood Sexual Abuse
1071243|NCT01701258|Dopamine
1071244|NCT01701258|MRI
1071245|NCT01701258|PET
1071246|NCT01701258|ERP
1071247|NCT01701258|Stress
1071248|NCT01701258|Reward
1071249|NCT01701258|Childhood trauma
1071250|NCT01701245|vagus nerve stimulation
1071251|NCT01701245|vagal nerve stimulation
1071252|NCT01701245|nVNS
1071253|NCT01701245|VNS
1071254|NCT01701245|cluster headache
1071255|NCT01701245|chronic
1071256|NCT01701245|non invasive
1071257|NCT01701245|gammacore
1071258|NCT01701232|lymphoma, non-Hodgkin's
1071259|NCT01701219|Staphylococcus aureus bacteremia
1071260|NCT01701219|Methicillin-resistant Staphylococcus aureus bacteremia
1071261|NCT01701219|MRSA bacteremia
1071262|NCT01701219|Blood
1071263|NCT01701219|Adult
1071264|NCT01701219|Infections
1071265|NCT01701219|Blood Culture
1071266|NCT01701206|HIV
1071267|NCT01701206|social networking
1071268|NCT01701206|at-risk populations
1071269|NCT01701206|sexual risk behaviors
1071270|NCT01701180|Male Volunteers
1071271|NCT01701154|Pompe respiratory
1071272|NCT01701141|Positron Emission Tomography (PET)
1071273|NCT01701141|Magnetic resonance imaging (MRI)
1071274|NCT01701141|reward
1071275|NCT01701141|stress
1071276|NCT01701141|learning
1071277|NCT01701141|Major Depressive Disorder
1071278|NCT01701141|Anhedonia
1071279|NCT01701128|Physical activity, treadmill training, rehabilitation
1071280|NCT01701115|Interscalene Block
1071281|NCT01701076|Relapsed / refractory multiple myeloma
1071282|NCT01701076|2nd line treatment
1071283|NCT01701050|circulating tumor cells
1071284|NCT01701050|CTC
1071285|NCT01701050|metastatic breast cancer
1071286|NCT01701050|endocrine therapy
1071287|NCT01701050|hormone therapy
1071288|NCT01701037|Melanoma, B-RAF, biomarkers, targeted therapy, resistance
1071289|NCT01701024|Acne
1071290|NCT01701011|coping
1071291|NCT01701011|intervention
1071292|NCT01701011|waiting-period
1071293|NCT01700985|psoriasis
1071294|NCT01700985|plaque psoriasis
1071295|NCT01700985|122-0551
1071296|NCT01700985|steroid
1071297|NCT01700959|Melatonin
1071298|NCT01700959|Neurocognitive impairment
1071299|NCT01700959|Sleep disturbance
1071300|NCT01700959|Childhood cancer survivors
1071301|NCT01700946|leukemia
1071302|NCT01700946|lymphoma
1071303|NCT01700946|Non-Hodgkins
1071304|NCT01700920|Osteonecrosis of the femoral head
1071305|NCT01700920|Stem Cell
1071306|NCT01700920|Mesenchymal Stem Cells
1071307|NCT01700920|Femoral Head
1071308|NCT01700907|Postoperative cognitive dysfunction
1071309|NCT01700907|elderly patients
1071310|NCT01700907|long surgery
1071311|NCT01700894|Physical Activity
1071312|NCT01700894|African American
1071313|NCT01700894|Adherence
1071314|NCT01700881|Rheumatoid Arthritis, Diet, Fat-Restricted, Diet, Vegetarian
1071315|NCT01700868|Diabetes Mellitus, Type 2
1071316|NCT01700868|Diet, Vegetarian
1071317|NCT01700868|Diet, Fat-Restricted
1071318|NCT01700868|Glycemic Index
1071319|NCT01700855|Electroacupuncture
1071320|NCT01700855|Analgesia
1071321|NCT01700855|Anesthesia
1071322|NCT01700855|Nasal septoplasty
1071323|NCT01700855|Mammaplasty
1071324|NCT01700842|ceftaroline, infection, CAPB, CAP, ABSSSI, cSSTI
1071325|NCT01700829|Ketamine
1071326|NCT01700829|Midazolam
1071327|NCT01700829|Major Depressive Disorder
1071328|NCT01700829|Suicidal ideation
1071329|NCT01700829|Suicide
1071330|NCT01700829|Depression
1071331|NCT01700829|Treatment
1071332|NCT01700829|Ketamine Treatment
1071333|NCT01700816|Delirium
1071334|NCT01700816|Hematopoietic stem cell transplantation
1071335|NCT01700816|Bone marrow transplantation
1071336|NCT01700816|Bright Light Therapy
1071337|NCT01700803|Betadine
1071338|NCT01700803|Povidine Iodine
1071339|NCT01700803|Hand scrubbing
1071340|NCT01700803|Cesarean section wound infections
1071341|NCT01700803|post cesarean section
1071342|NCT01700790|HIV
1071343|NCT01700790|AIDS
1071344|NCT01700790|Tuberculosis
1071345|NCT01700790|Rifampin
1071346|NCT01700790|Lopinavir
1071347|NCT01700790|Pharmacokinetic
1071348|NCT01700777|bimanual training
1071349|NCT01700777|lower limb
1071350|NCT01700777|intensive rehabilitation
1071351|NCT01700777|regular rehabilitation
1071352|NCT01700777|hemiplegia
1071353|NCT01699724|JZoloft
1071354|NCT01699724|Sertraline hydrochloride
1071355|NCT01699724|ODT
1071356|NCT01699724|bioequivalence
1071357|NCT01699711|APP function (amyloid precursor protein, cognitive stimulation, alzheimer disease. program
1071358|NCT01699698|Pancreatic adenocarcinoma
1071359|NCT01699685|Moderate to severe COPD patients are included
1071360|NCT01699685|NVA
1071361|NCT01699685|QAB
1071362|NCT01699672|Patient education
1071363|NCT01699672|information
1071364|NCT01699672|communication
1071365|NCT01699659|Allergic Rhinitis
1071366|NCT01699659|Allergen Immunotherapy
1071367|NCT01699646|Intrapartum fetal surveillance
1071368|NCT01699646|CTG
1071369|NCT01699646|cardiotocography
1071370|NCT01699646|STAN
1071371|NCT01699646|ST-Analysis
1071372|NCT01699646|metabolic acidosis in umbilical artery
1071373|NCT01699646|operative delivery
1071374|NCT01699633|Drug-drug interactions
1071375|NCT01699633|Drug-gene interactions
1071376|NCT01699633|Nevirapine
1071377|NCT01699633|Rifampicin
1071378|NCT01699633|children
1071379|NCT01699620|Bone anchored hearing aid
1071380|NCT01699620|Soft tissue healing
1071381|NCT01699620|Implant stability
1071382|NCT01699620|Linear incision
1071383|NCT01699620|Dermatome technique
1071384|NCT01699620|Hearing Aids
1071385|NCT01699620|Implants, Artificial
1071386|NCT01699620|Surgical Procedures, Operative
1071387|NCT01699607|Cigarette Smokers
1071388|NCT01699607|Healthy Non Smokers
1071389|NCT01699607|Amphetamine
1071390|NCT01699607|PET
1071391|NCT01699607|Controls
1071392|NCT01699594|asthma
1071393|NCT01699594|allergies
1071394|NCT01699594|mannitol
1071395|NCT01699594|methacholine
1071396|NCT01699581|Hodgkin's Lymphoma
1071397|NCT01699581|Multiple Myeloma
1071398|NCT01699581|Non-Hodgkin's Lymphoma
1071399|NCT01699568|dental implant stability
1071400|NCT01699568|dental implant surface treatment
1071401|NCT01699568|resonance frequence analysis
1071402|NCT01699555|Multiple sclerosis
1071403|NCT01699555|GNbAC1
1071404|NCT01699555|Monoclonal antibody
1071405|NCT01699555|Multiple Sclerosis Associated Retrovirus (MSRV)
1071407|NCT01700725|Gulf War Illness
1071408|NCT01700725|xylitol
1071409|NCT01700725|nasal irrigation
1071410|NCT01700725|Desert Storm
1071411|NCT01700725|Persian Gulf Conflicts
1071412|NCT01700725|neti pot
1071413|NCT01700725|cytokines
1071414|NCT01700725|nasal mucus
1071415|NCT01700725|inflammatory mediator
1071416|NCT01700725|lactoferrin
1071417|NCT01700725|lysozyme
1071418|NCT01700712|Caries, probiotic bacteria
1071419|NCT01700699|thyroid cancer
1071420|NCT01700699|tyrosine kinase inhibitors
1071421|NCT01700699|BRAF
1071422|NCT01700699|Sorafenib
1071423|NCT01700699|Pazopanib
1071424|NCT01700699|Sunitinib
1071425|NCT01700699|Cabozantinib
1071426|NCT01700673|maintenance treatment
1071427|NCT01700673|stem cell transplant
1071428|NCT01700673|cytarabine-based chemotherapy
1071429|NCT01700647|Larynx cancer
1071430|NCT01700647|Volatile organic compounds
1071431|NCT01700647|Diagnosis
1071432|NCT01700647|Bronchoscopy
1071433|NCT01700647|Cancer staging
1071434|NCT01700634|fMRI, BOLD, pressure stimuli
1071435|NCT01700621|rotavirus
1071436|NCT01700582|lung cancer
1071437|NCT01700582|biomarkers
1071438|NCT01700582|EGFR
1071439|NCT01700582|KRAS
1071440|NCT01700582|ALK
1071441|NCT01700582|HER2
1071442|NCT01700582|PI3K
1071443|NCT01700582|BRAF
1071444|NCT01700569|high-grade
1071445|NCT01700569|glioma
1071446|NCT01700569|epigenetic
1071447|NCT01700556|Alzheimer Disease
1071448|NCT01700556|Family Caregiver
1071449|NCT01700556|Caregiver Burden
1071450|NCT01700556|Home Care Services
1071451|NCT01700556|Assistive Technologies
1071452|NCT01700543|Stemless shoulder implant
1071453|NCT01700543|Osteoarthritis
1071454|NCT01700543|Rheumatoid Arthritis
1071455|NCT01700543|Hemi Shoulder Arthroplasty
1071456|NCT01700543|Total Shoulder Arthroplasty
1071457|NCT01700543|Prospective
1071458|NCT01700543|Multi-center
1071459|NCT01700543|Europe
1071460|NCT01700543|Non-Controlled
1071461|NCT01700543|Good Bone Stock
1071462|NCT01700530|mitochondria
1071463|NCT01700530|fitness
1071464|NCT01700530|statins
1071465|NCT01700530|cholesterol
1071466|NCT01700530|metabolic syndrome
1071467|NCT01700517|total knee arthroplasty, analgesia, ultrasonography
1071468|NCT01700504|Axillary drainage volume
1071469|NCT01700504|Lavage with gentamicin solution
1071470|NCT01700491|Paravertebral Catheter
1071471|NCT01700491|Epidural Catheter
1071472|NCT01700491|Analgesia
1071473|NCT01700491|Hypotension
1071474|NCT01700491|Analgesia,Epidural
1071475|NCT01700491|Analgesia,Paravertebral
1071476|NCT01700478|Myomectomy
1071477|NCT01700465|Hemodialysis
1071478|NCT01700465|Hemodynamics
1071479|NCT01700452|Lung cancer
1071480|NCT01700452|Pulmonary nodules
1071481|NCT01700452|FISH Test
1071482|NCT01700439|Aortic valve
1071483|NCT01700439|Heart valve
1071484|NCT01700439|Tissue valve
1071485|NCT01700439|Bioprosthesis
1071486|NCT01700439|Valve disorder
1071487|NCT01700439|Valve disease
1071488|NCT01700439|Cardiac surgery
1071489|NCT01700439|Less invasive cardiac surgery
1071490|NCT01700439|Aortic valve stenosis
1071491|NCT01700439|Aortic valve regurgitation
1071492|NCT01700439|Bovine pericardium
1071493|NCT01700426|Iron Deficiency
1071494|NCT01700426|Iron Deficiency Anemia
1071495|NCT01700413|acute
1071496|NCT01700413|myeloid
1071497|NCT01700413|leukemia
1071498|NCT01700413|CETLAM
1071499|NCT01700413|Idarubicin
1071500|NCT01700400|Lung Cancer
1071501|NCT01700400|Non Small Cell Lung Cancer
1071502|NCT01700400|Advanced Lung Cancer
1071503|NCT01700387|Migraine
1071504|NCT01700387|Chronic Migraine
1071505|NCT01700387|Cognitive Efficiency
1071506|NCT01700387|Pilot Study
1071507|NCT01700387|Long Term Effect
1071508|NCT01700374|pregnancy
1071509|NCT01700374|stress, psychological
1071510|NCT01700374|stress, physiological
1071511|NCT01700374|maternal-fetal relations
1071512|NCT01700361|sexual arousal
1071513|NCT01700361|pelvic floor sEMG
1071514|NCT01700348|moderate gingivitis
1071515|NCT01700322|Coronary artery disease
1071516|NCT01700322|coronary stenting
1071517|NCT01700322|platelet aggregation
1071518|NCT01700309|Obesity prevention; Adolescent; Physical activity; Health counselling
1071519|NCT01700283|Colorectal Cancer、Fatigue、Muscle strength、Metabolomics
1071520|NCT01700257|Lung cancer screening
1071521|NCT01700257|Smokers or former smokers
1071522|NCT01700257|Family history of lung cancer
1071523|NCT01700231|hepatorenal syndrome, liver regeneration, liver dysfunction
1071524|NCT01700218|telemonitoring
1071525|NCT01700205|Formula Feeding
1071526|NCT01700205|Mother
1071527|NCT01700205|Moms
1071528|NCT01700205|Infants
1071529|NCT01700205|Babies
1071530|NCT01700205|Baby
1071531|NCT01700205|growth
1071532|NCT01700205|energy balance
1071533|NCT01700166|Autologous
1071534|NCT01700166|Cord Blood
1071535|NCT01700166|Stem Cells
1071536|NCT01700166|Pediatric stroke
1071537|NCT01700166|Children with ischemic stroke
1071538|NCT01700166|Cerebral Palsy
1071539|NCT01700166|Perinatal AIS
1071540|NCT01700153|Robotic-assisted therapy
1071541|NCT01700153|cerebral palsy
1071542|NCT01700153|ICF
1071543|NCT01700127|immune response
1071544|NCT01700127|infants
1071545|NCT01700127|rotavirus vaccine
1071546|NCT01700114|Pigmented Skin Lesions
1071547|NCT01700114|Dermatology
1071548|NCT01700114|Skin Cancer
1071549|NCT01700114|Melanoma
1071550|NCT01700114|MelaFind
1071551|NCT01700088|hypoxemia
1071552|NCT01700088|Post Pulmonary Resection
1071553|NCT01700075|atherosclerosis, development of concept, weight loss therapy
1071554|NCT01700062|medium-calorie
1071555|NCT01700062|standard calorie
1071556|NCT01700062|parenteral nutrition
1071557|NCT01700049|advanced BCC
1071558|NCT01700049|high risk
1071559|NCT01700049|locally advanced
1071560|NCT01700023|acute heart failure
1071561|NCT01700010|Urothelial
1071562|NCT01700010|Bladder
1071563|NCT01700010|Cancer
1071564|NCT01699997|Schizophrenia
1071565|NCT01699997|Oxytocin
1071566|NCT01699997|RCT
1071567|NCT01699984|Cognitive impairment.
1071568|NCT01699984|Geriatrics.
1071569|NCT01699984|Hospital admission.
1071570|NCT01699984|Hospital discharge.
1071571|NCT01699958|Problem solving therapy
1071572|NCT01699958|Behavior change
1071573|NCT01699945|Verbal autopsies
1071574|NCT01699945|Maternal deaths
1071575|NCT01699945|Still births
1071576|NCT01699919|perioperative lignocaine infusion
1071577|NCT01699919|elective open abdominal surgeries
1071578|NCT01699919|postoperative pain
1071579|NCT01699906|Obesity
1071580|NCT01699880|tracheal intubation
1071581|NCT01699880|preoxygenation
1071582|NCT01699880|desaturation
1071583|NCT01699880|hypoxemia
1071584|NCT01699880|oxygen therapy
1071585|NCT01699880|high flow nasal cannula oxygen therapy
1071586|NCT01699867|lumpectomy
1071587|NCT01699867|breast cancer
1071588|NCT01699867|optical coherence tomography
1071589|NCT01699867|tumor margin
1071590|NCT01699867|imaging
1071591|NCT01699828|buspirone
1071592|NCT01699828|smoking cessation
1071593|NCT01699828|dopamine
1071594|NCT01699828|PET imaging
1071595|NCT01699828|[11C]-(+)-PHNO
1071596|NCT01699815|acetaminophen
1071597|NCT01699815|timing
1071598|NCT01699815|arthroplasty
1071599|NCT01699789|Community Partnered Participatory Research
1071600|NCT01699789|Community Engagement
1071601|NCT01699789|Implementation
1071602|NCT01699789|Community Based Participatory Research
1071603|NCT01699789|Quality Improvement
1071604|NCT01699789|Evidence Based Practice
1071605|NCT01699789|Patient Centered Outcomes Research
1071606|NCT01699776|Digoxin
1071607|NCT01699776|Ivabradine
1071608|NCT01699776|with atrial fibrillation.
1071609|NCT01699750|contact lenses
1071610|NCT01699750|contact lens solution
1071611|NCT01699750|myopia
1071612|NCT01699750|astigmatism
1071613|NCT01699737|Diabetes
1071614|NCT01699516|allogeneic transplantation; intestinal graft-vs.-host disease; contrast enhanced ultrasound sonography
1071615|NCT01699503|Dementia
1071616|NCT01699503|Alzheimer's Disease
1071617|NCT01699503|Mild Cognitive Impairment
1071618|NCT01699503|Screening
1071619|NCT01699490|Major Depressive Disorder
1071620|NCT01699490|Antidepressants
1071621|NCT01699490|Insulin
1071622|NCT01699490|Fluoxetine
1071623|NCT01699477|FUS
1071624|NCT01699477|focused ultrasound
1071625|NCT01699477|functional brain disorders
1071626|NCT01699477|neuropathic pain
1071627|NCT01699477|movement disorders
1071628|NCT01699464|Glaucoma
1071629|NCT01699438|Irritable Bowel Syndrome
1071630|NCT01699438|Inflammation
1071631|NCT01699438|Mesalazine
1071632|NCT01699425|Stress urinary incontinence.
1071633|NCT01699425|Suburethral sling.
1071634|NCT01699425|Single-incision suburethral sling.
1071635|NCT01699425|Ajust.
1071636|NCT01699425|Transobturator tape.
1071637|NCT01699412|Bone Marrow Transplantation
1071638|NCT01699412|Graft vs Host Disease
1071639|NCT01699412|Oral Manifestations
1071640|NCT01699399|colonoscopy
1071641|NCT01699399|pain
1071642|NCT01699399|sedation
1071643|NCT01699399|water
1071644|NCT01699360|Kidney Transplantation
1071645|NCT01699360|Immunosuppressive Agents
1071646|NCT01699360|Hydrocortisone
1071647|NCT01699360|Cortisone
1071648|NCT01699347|OK432, CYSTIC MALFORMATION
1071649|NCT01699334|Whiplash injuries
1071650|NCT01699334|patient education
1071651|NCT01699334|illness perceptions
1071652|NCT01699334|RCT
1071653|NCT01699334|motor vehicle accidents
1071654|NCT01699321|physical activity
1071655|NCT01699321|barbershop
1071656|NCT01699321|cancer prevention
1071657|NCT01699321|exercise
1071658|NCT01699321|men's health
1071659|NCT01699321|African American men
1071660|NCT01699308|Traumatic Brain Injury
1071661|NCT01699308|Growth Hormone
1071662|NCT01699308|Neuroimaging
1071663|NCT01699295|academic achievement
1071664|NCT01699295|elementary school
1071665|NCT01699295|physical activity
1071666|NCT01699295|exercise
1071667|NCT01699282|oral anticoagulant
1071668|NCT01699282|in the long term (> 12 months)
1071669|NCT01699269|High grade brain tumor
1071670|NCT01699269|Glioma
1071671|NCT01699269|Glioblastoma Multiform
1071672|NCT01699269|Brain Cancer
1071673|NCT01699269|Diffusion-Weighted Magnetic Resonance Imaging
1071674|NCT01699269|High order diffusion tensor
1071675|NCT01699269|Imaging guided biopsy
1071676|NCT01699269|Histopathologic evaluation
1071677|NCT01699269|Infiltration percentage
1071678|NCT01699256|General Practice
1071679|NCT01699256|Low Back Pain
1071680|NCT01699256|Guideline
1071681|NCT01699256|Health Plan Implementation
1071682|NCT01699256|Referral and Consultation
1071683|NCT01699243|pregnancy
1071684|NCT01699243|labor
1071685|NCT01699243|epidural
1071686|NCT01699243|fetal intervention
1071687|NCT01699230|Elective cardiac surgery
1071688|NCT01699230|with sternotomy and
1071689|NCT01699230|cardiopulmonary bypass
1071690|NCT01699230|for coronary artery
1071691|NCT01699230|bypass graft.
1071692|NCT01699217|Chronic Myeloid Leukaemia
1071693|NCT01699217|Philadelphia positive
1071694|NCT01699217|BCR-ABL positive
1071695|NCT01699204|Air pollution
1071696|NCT01699204|Diesel exhaust
1071697|NCT01699204|Airway responsiveness
1071698|NCT01699204|Asthma
1071699|NCT01699204|Anti-oxidant
1071700|NCT01699191|Irritable Bowel Syndrome
1071701|NCT01699191|Celiac Desease
1071702|NCT01699191|Probiotic
1071703|NCT01699191|Lactobacillus plantarum
1071704|NCT01699191|Bifidobacterium breve
1071705|NCT01699191|Lactobacillus casei
1071706|NCT01699191|Bifidobacterium animalis
1071707|NCT01699165|rhinitis
1071708|NCT01699165|allergic
1071709|NCT01699165|seasonal
1071710|NCT01699165|double blind
1071711|NCT01699165|doubleblind
1071712|NCT01699165|randomized
1071713|NCT01699165|randomised
1071714|NCT01699165|placebo
1071715|NCT01699165|crossover
1071716|NCT01699165|clinical
1071717|NCT01699165|nasal
1071718|NCT01699165|filter
1071719|NCT01699165|controlled
1071720|NCT01699165|trial
1071721|NCT01699165|hayfever
1071722|NCT01699165|hay
1071723|NCT01699165|fever
1071724|NCT01699165|efficacy
1071725|NCT01699165|safety
1071726|NCT01699165|prevention
1071727|NCT01699165|adult
1071728|NCT01699165|grass
1071729|NCT01699165|pollen
1071730|NCT01699165|symptom
1071731|NCT01699165|Total nasal symptom score
1071732|NCT01699165|acoustic rhinometry
1071733|NCT01699152|Chronic Lymphocytic Leukemia
1071734|NCT01699152|Small Lymphocytic Lymphoma
1071735|NCT01699139|supine position
1071736|NCT01699126|Obstructive Sleep Apnea
1071737|NCT01699126|CPAP
1071738|NCT01699126|Endothelium dysfunction
1071739|NCT01699126|Hypertension
1071740|NCT01699113|YF476
1071741|NCT01699113|gastrin receptor antagonist
1071742|NCT01699113|gastric pH
1071743|NCT01699113|gastrin
1071744|NCT01699113|rabeprazole
1071745|NCT01699113|proton-pump inhibitor
1071746|NCT01699113|gastric function
1071747|NCT01699113|healthy subjects
1071748|NCT01699100|offloading
1071749|NCT01699100|plantar pressure
1071750|NCT01699100|insole
1071751|NCT01699100|foot ulcer
1071752|NCT01699087|PRK
1071753|NCT01699087|myopia
1071754|NCT01699087|astigmatism
1071755|NCT01699074|Korean White Ginseng
1071756|NCT01699074|Type 2 diabetes
1071757|NCT01699074|Metabolic syndrome
1071758|NCT01699048|multivessel PCI,MIDCAB,CABG
1071759|NCT01699048|Hybrid coronary revascularization
1071760|NCT01699035|stroke
1071761|NCT01699035|work
1071762|NCT01699035|vocational rehabilitation
1071763|NCT01699022|Contraceptive
1071764|NCT01699022|Injectable
1071765|NCT01699009|Migraines, diet, vegan, vegetarian, plant-based
1071766|NCT01698996|abscess
1071767|NCT01698996|packing
1071768|NCT01698996|emergency medicine
1071769|NCT01698996|wound care
1071770|NCT01698996|incision and drainage
1071771|NCT01698970|Probiotic
1071772|NCT01698970|capsules
1071773|NCT01698970|Crohn's disease
1071774|NCT01698970|recurrent endoscopic ileo-colonic lesions
1071775|NCT01698957|Pregnant women
1071776|NCT01698957|Uterine Artery Doppler Velocimetry
1071777|NCT01698918|metastatic breast cancer, locally advanced breast cancer, HER2-, ER+, everolimus, Afinitor
1071778|NCT01698905|Phase II, single arm, open label, nilotinib, treatment-free remission, MR4.5, confirmed loss of MR4, loss of MMR, Ph+ CML-CP
1071779|NCT01698892|I.V. sedation, midazolam, bronchoscopy
1071780|NCT01698866|Low grade lymphoma
1071781|NCT01698866|follicular lymphoma
1071782|NCT01698866|indolent lymphoproliferative disorders
1071783|NCT01698866|Vaccin GenHevac B Pasteur
1071784|NCT01698840|Vitamin D
1071785|NCT01698840|Transitional Formula
1071786|NCT01698827|gastrostomy
1071787|NCT01698827|tube
1071788|NCT01698827|endoscopic
1071789|NCT01698827|replacement
1071790|NCT01698827|tube rupture
1071791|NCT01698827|durability
1071792|NCT01698827|tube loss
1071793|NCT01698827|balloon rupture
1071794|NCT01698814|ocular safety
1071795|NCT01698814|allergic conjunctivitis
1071796|NCT01698801|Lenalidomide
1071797|NCT01698801|dexamethasone
1071798|NCT01698801|newly diagnosed multiple myeloma
1071799|NCT01698788|diabetic macular edema
1071800|NCT01698788|taut posterior hyaloid membrane
1071801|NCT01698788|ozurdex
1071802|NCT01698762|Musculoskeletal Diseases
1071803|NCT01698762|Osteoarthritis
1071804|NCT01698762|OA
1071805|NCT01698762|Rheumatoid Arthritis
1071806|NCT01698762|RA
1071807|NCT01698762|Osteoporosis
1071808|NCT01698762|OP
1071809|NCT01698762|Multimedia Patient Decision Aids
1071810|NCT01698762|MM-PtDAs
1071811|NCT01698762|DVD
1071812|NCT01698762|Comparative Effectiveness Research Summary Guide
1071813|NCT01698762|CERSG
1071814|NCT01698762|Booklet
1071815|NCT01698762|Questionnaires
1071816|NCT01698762|Surveys
1071817|NCT01698749|Ozurdex
1071818|NCT01698749|Diabetic macular edema
1071819|NCT01698749|Central macular thickness
1071820|NCT01698736|ABO isoagglutinins
1071821|NCT01698736|ABO incompatible transplantation
1071822|NCT01698736|immunoadsorption
1071823|NCT01698736|membrane filtration
1071824|NCT01698736|plasmapheresis
1071825|NCT01698723|ACLF
1071826|NCT01698723|HEV
1071827|NCT01698723|Ribavirin
1071828|NCT01698710|Premalignant
1071829|NCT01698710|Malignant
1071830|NCT01698684|ED
1071831|NCT01698645|quality of life
1071832|NCT01698645|PecFent
1071833|NCT01698645|Lazanda
1071834|NCT01698645|fentanyl
1071835|NCT01698645|intranasal
1071836|NCT01698645|breakthrough cancer pain
1071837|NCT01698632|Adnexal masses
1071838|NCT01698632|Ovarian cysts
1071839|NCT01698632|Ovarian tumors
1071840|NCT01698606|childhood obesity
1071841|NCT01698606|multidisciplinary
1071842|NCT01698606|preschool children
1071843|NCT01698606|community-based
1071844|NCT01698606|lifestyle intervention
1071845|NCT01698606|family-centered
1071846|NCT01698593|Bupivacaine
1071847|NCT01698593|digital nerve block
1071848|NCT01698593|epinephrine
1071849|NCT01698593|duration of action
1071850|NCT01698593|pain
1071851|NCT01698593|touch
1071852|NCT01698593|pressure
1071853|NCT01698593|temperature
1071854|NCT01698580|accidental falls
1071855|NCT01698580|aged
1071856|NCT01698580|aged, 80 and over
1071857|NCT01698580|prevention and control
1071858|NCT01698567|Infants
1071859|NCT01698567|Cardiopulmonary bypass
1071860|NCT01698567|anticoaglution
1071861|NCT01698541|Renal
1071862|NCT01698541|Transplantation
1071863|NCT01698541|Elderly
1071864|NCT01698528|Diabetes
1071865|NCT01698528|diabetes technologies
1071866|NCT01698528|telemedicine
1071867|NCT01698502|Incretin
1071868|NCT01698502|Training
1071869|NCT01698502|Glucagon like peptide
1071870|NCT01698502|glucose dependent insulinotropic peptide
1071871|NCT01698502|Gut
1071872|NCT01698502|Exercise
1071873|NCT01698502|Insulin
1071874|NCT01698502|Focus:
1071875|NCT01698502|Gut hormone
1071876|NCT01698502|adaptations
1071877|NCT01698476|pulmonary TB
1071878|NCT01698476|cholecalciferol
1071879|NCT01698476|sodium phenylbutyrate
1071880|NCT01698476|antimicrobial peptides
1071881|NCT01698476|immune response
1071882|NCT01698463|Falls, Fractures, Osteoporosis, Frailty, Older Adults.
1071883|NCT01698450|FUS
1071884|NCT01698450|focused ultrasound
1071885|NCT01698450|functional brain disorder
1071886|NCT01698450|neuropathic pain
1071887|NCT01698450|movement disorders
1071888|NCT01698450|malignant brain tumors
1071889|NCT01698437|FUS
1071890|NCT01698437|focused ultrasound
1071891|NCT01698437|functional brain disorders
1071892|NCT01698437|neuropathic pain
1071893|NCT01698437|movement disorders
1071894|NCT01698437|malignant of brain tumors
1071895|NCT01698411|hypertension
1071896|NCT01698411|sleep
1071897|NCT01698411|insomnia
1071898|NCT01698372|Cardiac surgery.
1071899|NCT01698372|Wound healing.
1071900|NCT01698372|Leg wound infection.
1071901|NCT01698372|Wound care.
1071902|NCT01698346|Pertussis
1071903|NCT01698346|Infants
1071904|NCT01698346|Vaccination
1071905|NCT01698346|Pregnancy
1071906|NCT01698333|122-0551
1071907|NCT01698333|steroid
1071908|NCT01698333|HPA
1071909|NCT01698307|Crohn's Disease
1071910|NCT01698307|Deep Remission
1071911|NCT01698307|Complications
1071912|NCT01698294|gut microbiome
1071913|NCT01698294|hormones
1071914|NCT01698294|women
1071915|NCT01698294|race
1071916|NCT01698294|phytoestrogens
1071917|NCT01698255|Depression
1071918|NCT01698255|Geriatrics
1071919|NCT01698242|Heart failure
1071920|NCT01698242|Self-Management
1071921|NCT01698242|Behavioral Clinical Trial
1071922|NCT01698229|Cerebrospinal fluid
1071923|NCT01698229|Lumbar puncture
1071924|NCT01698229|Spinal tap
1071925|NCT01698229|Late infantile neuronal ceroid lipofuscinosis
1071926|NCT01698229|Batten disease
1071927|NCT01698216|Paliperidone
1071928|NCT01698216|Palmitate
1071929|NCT01698216|switching
1071930|NCT01698216|schizophrenia
1071931|NCT01698216|subjective well-being
1071932|NCT01698177|Influenza
1071933|NCT01698177|Cancer
1071934|NCT01698177|Vaccination
1071935|NCT01698177|Immune response to influenza vaccination
1071936|NCT01698164|lipid profiles
1071937|NCT01698164|coronary heart disease
1071938|NCT01698164|menopausal syndrome
1071939|NCT01698164|MMSE
1071940|NCT01698164|MENQOL
1071941|NCT01698164|HAD
1071942|NCT01698151|Chronic obstructive Pulmonary Disease
1071943|NCT01698151|COPD
1071944|NCT01698138|Spinal cord injury
1071945|NCT01698138|Neurogenic overactive bladder
1071946|NCT01698138|Onabotulinum toxin A
1071947|NCT01698138|Prevention
1071948|NCT01698138|Botulinum Toxins, Type A
1071949|NCT01698125|Delirium
1071950|NCT01698125|Autonomic cardiovascular control
1071951|NCT01698125|Abdominal surgery
1071952|NCT01698125|Tilt-test
1071953|NCT01698086|Multiple Sclerosis
1071954|NCT01698086|Balance
1071955|NCT01698086|Fatigue
1071956|NCT01698086|Eye movement
1071957|NCT01698073|Teen pregnancy prevention
1071958|NCT01698073|American Indian
1071959|NCT01698073|Group-randomized trial
1071960|NCT01698060|Prevention of Avian Influenza
1071961|NCT01698047|Depressive symptoms
1071962|NCT01698047|sub-threshold depression
1071963|NCT01698047|resiliency
1071964|NCT01698047|Health Promotion
1071965|NCT01698047|minority health
1071966|NCT01698034|volunteering
1071967|NCT01698034|cardiovascular health
1071968|NCT01698021|Creatine Kinase, MB form
1071969|NCT01698021|Troponin
1071970|NCT01698021|Acute coronary syndrome
1071971|NCT01698021|myocardial infarction
1071972|NCT01698021|Unstable angina
1071973|NCT01697995|right ventricle
1071974|NCT01697995|radiotracer uptake
1071975|NCT01697995|Myocardial Perfusion Imaging
1071976|NCT01697995|balanced ischemia
1071977|NCT01697982|pilot study
1071978|NCT01697982|psychosocial intervention
1071979|NCT01697982|advanced cancer
1071980|NCT01697969|allergic conjunctivitis
1071981|NCT01697969|Pataday
1071982|NCT01697969|Olopatadine
1071983|NCT01697956|Pediatric Subjects
1071984|NCT01697943|Gastric Malignant Tumor
1071985|NCT01697943|Total Gastrectomy
1071986|NCT01697943|Reconstruction
1071987|NCT01697930|PET Imaging
1071988|NCT01697930|18F] 4-L-Fluoroglutam (2S,4R)
1071989|NCT01697930|12-168
1071990|NCT01697917|Adenocarcinoma of Esophagogastric Junction
1071991|NCT01697917|Total Gastrectomy
1071992|NCT01697917|Proximal Gastrectomy
1071993|NCT01697891|Radiation Treatment
1071994|NCT01697891|Head and Neck Cancer
1071995|NCT01697891|Dysphagia
1071996|NCT01697878|obstructive sleep apnea
1071997|NCT01697878|obesity
1071998|NCT01697878|respiratory function
1071999|NCT01697878|weight loss surgery
1072000|NCT01697865|Reverse total shoulder
1072001|NCT01697852|vector control
1072002|NCT01697852|LLIN
1072003|NCT01697852|IRS
1072004|NCT01697826|Clindamycin
1072005|NCT01697826|Clotrimazole
1072006|NCT01697826|Vaginal formulation
1072007|NCT01697826|Bacterial vaginosis
1072008|NCT01697826|Candidiasis
1072009|NCT01697826|Trichomoniasis
1072010|NCT01697826|Mixed vaginitis
1072011|NCT01697826|Infective vaginitis
1072012|NCT01697787|Treatment, diagnosis
1072013|NCT01697761|Crohn's disease,acupuncture,moxibustion,inflammation factors
1072014|NCT01697722|Primary care
1072015|NCT01697722|Asthma management
1072016|NCT01697722|Inhaled corticosteroids
1072017|NCT01697722|Extra-fine hydrofluoroalkane
1072018|NCT01697722|Long-acting beta-agonist
1072019|NCT01697722|Fixed-dose combination therapy
1072020|NCT01697709|cannabis
1072021|NCT01697709|marijuana
1072022|NCT01697709|pharmacotherapy
1072023|NCT01697696|COPD, NVA237, QAB149, glycopyrronium bromide
1072024|NCT01697605|Phase I, open-label, dose escalation, BGJ398, Japanese, Asian, FGF-R
1072025|NCT01697566|Gynecology
1072026|NCT01697566|Endometrial Cancer Chemoprevention
1072027|NCT01697566|Obese
1072028|NCT01697566|Body Mass Index (BMI) >/= 35 kg.m2
1072029|NCT01697566|Post-menopausal
1072030|NCT01697566|Hyperinsulinemia
1072031|NCT01697566|Metformin
1072032|NCT01697566|Placebo
1072033|NCT01697566|Sugar pill
1072034|NCT01697566|Lifestyle intervention
1072035|NCT01697566|Diet
1072036|NCT01697566|Exercise
1072037|NCT01697514|recurrent medulloblastoma
1072038|NCT01697397|Irritable bowel syndrome
1072039|NCT01697397|IBS
1072040|NCT01697397|Gastrointestinal pain
1072041|NCT01697397|Gastrointestinal functional disorder
1072042|NCT01697384|prostate cancer, PSA
1072043|NCT01697358|FBSS
1072044|NCT01697358|post laminectomy syndrome
1072045|NCT01697358|SCS
1072046|NCT01697358|RCT
1072047|NCT01697358|back pain
1072048|NCT01697345|Vaginal Testosterone
1072049|NCT01697345|Vaginal atrophy
1072050|NCT01697345|Female Sexual Dysfunction
1072051|NCT01697345|Aromatase Inhibitors
1072052|NCT01697332|COPD
1072053|NCT01697319|Mucopolysaccharidosis IVA Type A
1072054|NCT01697319|MPS IVA Type A
1072055|NCT01697319|Mucopolysaccharidosis IVA
1072056|NCT01697319|MPS IVA
1072057|NCT01697319|Morquio A Syndrome
1072058|NCT01697319|Lysosomal Storage Disorder
1072059|NCT01697319|LSD
1072060|NCT01697319|N-acetylgalactosamine-6-sulfatase
1072061|NCT01697319|N-acetylgalactosamine-6-sulfate
1072062|NCT01697319|sulfatase
1072063|NCT01697319|galactose-6-sulfatase
1072064|NCT01697319|GALNS
1072065|NCT01697319|enzyme replacement therapy
1072066|NCT01697319|ERT
1072067|NCT01697319|MOR-006
1072068|NCT01697319|CPET
1072069|NCT01697319|Limited ambulation
1072070|NCT01697319|Grip/ Pinch
1072071|NCT01697306|non muscle invasive bladder cancer
1072072|NCT01697280|Polio supplementary immunization activities
1072073|NCT01697280|Routine EPI vaccine
1072328|NCT01696084|AML in elderly
1072074|NCT01697280|Integration of polio NID and routine EPI
1072075|NCT01697267|vasculitis
1072076|NCT01697267|ANCA vasculitis
1072077|NCT01697267|microscopic polyangiitis
1072078|NCT01697267|granulomatosis
1072079|NCT01697267|Wegener's
1072080|NCT01697267|AAV
1072081|NCT01697267|vasculitides
1072082|NCT01697241|Exercise Therapy
1072083|NCT01697241|Education
1072084|NCT01697241|Osteoarthritis
1072085|NCT01697241|Hip
1072086|NCT01697241|Hip replacement
1072087|NCT01697228|Diabetes
1072088|NCT01697228|Vitamin D
1072089|NCT01697228|Proinflammatory markers
1072090|NCT01697189|professional drivers
1072091|NCT01697189|sleepiness
1072092|NCT01697189|stress
1072093|NCT01697189|safe driving
1072094|NCT01697189|training
1072095|NCT01697163|De Novo Resistance
1072096|NCT01697163|Iressa
1072097|NCT01697163|EGFR mutation
1072098|NCT01697163|lung cancer
1072099|NCT01697150|Type 1 diabetes mellitus
1072100|NCT01697150|closed loop artificial pancreas
1072101|NCT01697124|Physical activity
1072102|NCT01697124|children
1072103|NCT01697124|Head Start
1072104|NCT01697124|SPARK-EC
1072105|NCT01697111|YAZ
1072106|NCT01697111|Flexible regimen
1072107|NCT01697111|Drospirenone
1072108|NCT01697111|Ethinylestradiol Betadex
1072109|NCT01697111|Endometriosis
1072110|NCT01697111|Dienogest
1072111|NCT01697111|Japanese Patients
1072112|NCT01697098|Dexamethasone
1072113|NCT01697098|preterm labour
1072114|NCT01697098|respiratory distress
1072115|NCT01697085|sea buckthorn
1072116|NCT01697085|mucous membrane
1072117|NCT01697085|dryness
1072118|NCT01697085|metabolic syndrome
1072119|NCT01697085|vaginal atrophy
1072120|NCT01697072|Gastric Cancer
1072121|NCT01697072|First Line Treatment Gastroesophageal Junction (GEJ)
1072122|NCT01697072|Gastroesophageal Junction Cancer (GEJ)
1072123|NCT01697072|GEJ Cancer
1072124|NCT01697059|appendicitis
1072125|NCT01697046|peri-exposure
1072126|NCT01697046|chemoprophylaxis
1072127|NCT01696942|Crohn's disease
1072128|NCT01696942|certolizumab
1072129|NCT01696942|mesalamine
1072130|NCT01696942|recurrence
1072131|NCT01696929|tocilizumab
1072132|NCT01696929|safety
1072133|NCT01696929|tolerability
1072134|NCT01696929|efficacy
1072135|NCT01696929|schizophrenia
1072136|NCT01696929|improvement
1072137|NCT01696929|cognition
1072138|NCT01696929|psychotic symptoms
1072139|NCT01696929|baseline IL-6 levels
1072140|NCT01696916|COPD
1072141|NCT01696916|carbon dioxide
1072142|NCT01696916|6-minute walking test
1072143|NCT01696903|Postoperative pancreatic fistula
1072144|NCT01696903|Pancreatic texture
1072145|NCT01696903|Pancreatic duct diameter
1072146|NCT01696903|Pancreatic consistency
1072147|NCT01696903|Pancreaticoduodenectomy
1072148|NCT01696890|chronic heart failure
1072149|NCT01696890|telemonitoring
1072150|NCT01696890|first line practitioners
1072151|NCT01696890|integrated approach
1072152|NCT01696890|efficacy
1072153|NCT01696838|Crohn's disease
1072154|NCT01696838|acupuncture
1072155|NCT01696838|moxibustion
1072156|NCT01696838|fMRI
1072157|NCT01696838|Gut
1072158|NCT01696812|electrodeposition
1072159|NCT01696812|Subthalamic Nucleus
1072160|NCT01696812|Deep Brain Stimulation
1072161|NCT01696812|Parkinson Disease
1072162|NCT01696773|tomato
1072163|NCT01696773|tangerine tomato
1072164|NCT01696773|carotenoids
1072165|NCT01696773|lycopene
1072166|NCT01696773|flavonoids
1072167|NCT01696747|gastroparesis
1072168|NCT01696747|idiopathic gastroparesis
1072169|NCT01696747|diabetic gastroparesis
1072170|NCT01696747|post-Nissen gastroparesis
1072171|NCT01696734|Gastrointestinal diseases
1072172|NCT01696734|GI
1072173|NCT01696734|Compassionate use
1072174|NCT01696734|GI motility disorders
1072175|NCT01696734|GI disorders
1072176|NCT01696734|Gastroparesis
1072177|NCT01696734|Gastroesophageal reflux disease
1072178|NCT01696734|GERD
1072179|NCT01696734|Chronic nausea and vomiting
1072180|NCT01696734|Questionnaires
1072181|NCT01696734|Surveys
1072182|NCT01696734|Phone calls
1072183|NCT01696734|Domperidone
1072184|NCT01696721|Proton Therapy
1072185|NCT01696721|Pediatrics
1072186|NCT01696721|Radiation Oncology
1072187|NCT01696682|minimally invasive esophagectomy
1072188|NCT01696682|anastomotic leakage
1072189|NCT01696682|gastric conduit
1072190|NCT01696669|Ewing's Sarcoma
1072191|NCT01696669|P6 protocol MSKCC
1072192|NCT01696669|Gemcitabine
1072193|NCT01696669|Docetaxel
1072194|NCT01696656|Gastrointestinal drugs
1072195|NCT01696656|Antibiotics
1072196|NCT01696656|Vitamins
1072197|NCT01696656|Minerals
1072198|NCT01696656|Intestinal insufficiency
1072199|NCT01696656|Short Bowel syndrome
1072200|NCT01696656|Adjuvant therapy
1072201|NCT01696656|Antacids
1072202|NCT01696656|Gastrointestinal motility modifiers
1072203|NCT01696656|Micronutrients
1072204|NCT01696643|Opioid
1072205|NCT01696643|Constipation
1072206|NCT01696643|Chronic
1072207|NCT01696643|Pain
1072208|NCT01696630|anesthesia, epidural anagesia, colorectal surgery, xenon, hemodynamic change
1072209|NCT01696604|safety
1072210|NCT01696604|pharmacokinetics
1072211|NCT01696604|FTIH
1072212|NCT01696604|SARM
1072213|NCT01696591|Alzheimer, Mesenchymal Stem Cells, Umbilical Cord Blood
1072214|NCT01696578|PTSD
1072215|NCT01696578|Depression
1072216|NCT01696578|Anxiety
1072217|NCT01696578|Chronic pain
1072218|NCT01696578|Anger
1072219|NCT01696578|Heart rate variability
1072220|NCT01696578|Disability
1072221|NCT01696565|myelosuppression
1072222|NCT01696565|chemotherapy
1072223|NCT01696565|Astragalus membranaceus
1072224|NCT01696565|hematopoietic response
1072225|NCT01696552|Gonarthritis
1072226|NCT01696552|TKR
1072227|NCT01696552|Conventional
1072228|NCT01696552|Positioning Guides
1072229|NCT01696552|PSPG
1072230|NCT01696552|CT Perth
1072231|NCT01696539|Prostate Cancer
1072232|NCT01696526|vitamin D
1072233|NCT01696526|bioeffiency
1072234|NCT01696526|vitamin d fortified fish
1072235|NCT01696500|IVIG in Stevens-Johnson syndrome
1072236|NCT01696500|Toxic Epidermal Necrolysis
1072237|NCT01696500|Patients with Stevens-Johnson syndrome
1072238|NCT01696500|Toxic Epidermal Necrolysis unresponsive to corticosteroids
1072239|NCT01696487|non-alcoholic fatty liver disease
1072240|NCT01696487|non-alcoholic steatohepatitis
1072241|NCT01696487|NAFLD
1072242|NCT01696487|NASH
1072243|NCT01696474|Refractory cold agglutinin disease
1072244|NCT01696474|Bortezomib
1072245|NCT01696474|blood-transfusion
1072246|NCT01696448|Appetite Suppression
1072247|NCT01696448|CAR-191
1072248|NCT01696435|Depression
1072249|NCT01696435|Depressive Symptoms
1072250|NCT01696435|Mood
1072251|NCT01696435|Geriatric
1072252|NCT01696435|Prevention
1072253|NCT01696422|Dengue
1072254|NCT01696422|tetravalent attenuated Vaccine
1072255|NCT01696422|Healthy adults
1072256|NCT01696396|IBD, Crohn's Disease
1072257|NCT01696383|Intraocular Pressure (IOP)
1072258|NCT01696383|Glaucoma
1072259|NCT01696383|Ocular hypertension
1072260|NCT01696383|DuoTrav
1072261|NCT01696383|Prostaglandin analogue
1072262|NCT01696383|Beta-blocker
1072263|NCT01696370|Trimetazidine
1072264|NCT01696357|Asthma
1072265|NCT01696357|Adolescents
1072266|NCT01696357|Self-monitoring
1072267|NCT01696357|Quality of life
1072268|NCT01696357|Biomedical device
1072269|NCT01696357|Symptom monitoring
1072270|NCT01696357|Self-management
1072271|NCT01696344|LSPAF
1072272|NCT01696344|AF termination
1072273|NCT01696344|PVAI
1072274|NCT01696344|nonPV triggers
1072275|NCT01696344|Long-standing persistent
1072276|NCT01696305|Thyroid disease
1072277|NCT01696305|Hyalobarrier
1072278|NCT01696305|Thyroidectomy
1072279|NCT01696305|anti-adhesive effect
1072280|NCT01696240|Pulmonary Hypertension
1072281|NCT01696240|Exercise Capacity
1072282|NCT01696240|Cardiopulmonary Exercise Test
1072283|NCT01696240|Udenafil (Zydena)
1072284|NCT01696240|Phosphodiesterase Type 5 Inhibitors
1072285|NCT01696227|Nissle 1917
1072286|NCT01696227|Probiotic
1072287|NCT01696227|Uropathogen
1072288|NCT01696214|asthma,smokers
1072289|NCT01696201|Pregnancy, outcomes, depression, mood, physical exercise
1072290|NCT01696188|Interscalene
1072291|NCT01696188|nerve block
1072292|NCT01696188|nerve catheter
1072293|NCT01696188|in-plane
1072294|NCT01696188|out-of-plane
1072295|NCT01696188|anterolateral approach
1072296|NCT01696188|posterior approach
1072297|NCT01696188|shoulder surgery
1072298|NCT01696175|ScvO2
1072299|NCT01696175|venous
1072300|NCT01696175|oxymetry
1072301|NCT01696175|lactate
1072302|NCT01696175|children
1072303|NCT01696175|PICU
1072304|NCT01696175|Admission parameters of shock
1072305|NCT01696162|Knee pain
1072306|NCT01696162|Anterior knee pain
1072307|NCT01696162|Patellofemoral
1072308|NCT01696162|Patellofemoral syndrome
1072309|NCT01696162|Runners knee
1072310|NCT01696149|TENS, sympathetic skin response, skin temperature
1072311|NCT01696136|Ablation
1072312|NCT01696136|Multi-electrode catheter
1072313|NCT01696136|Single-tip catheter
1072314|NCT01696136|Holter
1072315|NCT01696123|Alzheimer disease
1072316|NCT01696123|Cholinesterase inhibitors
1072317|NCT01696123|MLC601
1072318|NCT01696123|NeuroAiD
1072319|NCT01696123|neuroprotection
1072320|NCT01696123|neuroregeneration
1072321|NCT01696110|Bivalirudin
1072322|NCT01696110|Acute myocardial infarction
1072323|NCT01696110|percutaneous transluminal coronary angioplasty
1072324|NCT01696084|AML
1072325|NCT01696084|Acute Myeloid Leukemia
1072326|NCT01696084|high risk AML
1072327|NCT01696084|secondary AML
1072329|NCT01696032|Ovarian Cancer
1072330|NCT01696019|magnetic resonance imaging
1072331|NCT01696019|cognition
1072332|NCT01696019|Tai Chi
1072333|NCT01696019|physical exercise
1072334|NCT01696019|mental exercise
1072335|NCT01696019|intervention trial
1072336|NCT01696019|prevention
1072337|NCT01696019|dementia
1072338|NCT01696019|Alzheimer disease
1072339|NCT01696019|mild cognitive impairment
1072340|NCT01696006|perfusion computed tomography
1072341|NCT01696006|coronary artery disease
1072346|NCT01695980|adenotonsillectomy
1072347|NCT01695967|nasal obstruction
1072348|NCT01695954|HIV
1072349|NCT01695954|Hyperlipidemia
1072350|NCT01695954|Pharmacokinetics
1072351|NCT01695954|Statins
1072352|NCT01695954|Darunavir
1072353|NCT01695954|Efavirenz
1072354|NCT01695954|Pitavastatin
1072355|NCT01695928|Velocity
1072356|NCT01695928|Location
1072357|NCT01695928|Periodontal status
1072358|NCT01695915|constipation
1072359|NCT01695915|children
1072360|NCT01695915|healthy
1072361|NCT01695915|rectal diameter
1072362|NCT01695863|Miralax with gatorade and dulcolax
1072363|NCT01695863|Movi pre
1072364|NCT01695863|Patient satisfaction and efficacy
1072365|NCT01695850|Randomized controlled trial
1072366|NCT01695850|Drugs,Chinese Herbal
1072367|NCT01695850|Constipation/drug therapy
1072368|NCT01695837|Diet counseling
1072369|NCT01695837|primary care
1072370|NCT01695824|catheter ablation
1072371|NCT01695811|Keratoconus, PKP, femtosecond laser assisted keratoplasty
1072372|NCT01695798|poliomyelitis
1072373|NCT01695798|oral polio vaccine
1072374|NCT01695798|OPV
1072375|NCT01695798|seroconversion
1072376|NCT01695798|mucosal immunity
1072377|NCT01695798|malnutrition
1072378|NCT01695798|IPV
1072379|NCT01695798|Inactivated polio vaccine
1072380|NCT01695798|Pakistan
1072381|NCT01695759|Anemia Secondary
1072382|NCT01695759|Chronic Kidney Disease
1072383|NCT01695720|Knee Injuries
1072384|NCT01695720|Meniscus Injuries
1072385|NCT01695720|Articular Cartilage Injuries
1072386|NCT01695720|Orthopaedic Diagnostic
1072387|NCT01695720|Magnetic Resonance Imaging
1072388|NCT01695707|atopic dermatitis
1072389|NCT01695707|eczema
1072390|NCT01695681|Quality of life
1072391|NCT01695681|Celiac Disease/diet therapy
1072392|NCT01695681|Celiac Disease/diagnosis
1072393|NCT01695681|Prospective Studies
1072394|NCT01695668|Graft versus Host Disease (GVHD)
1072395|NCT01695668|dry eyes
1072396|NCT01695668|Bone marrow transplant (BMT)
1072397|NCT01695668|Restasis
1072398|NCT01695668|Lotemax
1072399|NCT01695642|lasik, intralase, microkeratome
1072400|NCT01695603|Brain injury
1072401|NCT01695603|Controlled ventilation
1072402|NCT01695603|Intellivent
1072403|NCT01695603|Capnia control
1072404|NCT01695590|Myeloma
1072405|NCT01695590|PRLX93936
1072406|NCT01695577|Traumatic brain injury
1072407|NCT01695577|Dizziness
1072408|NCT01695577|Vestibular rehabilitation
1072409|NCT01695577|Balance rehabilitation
1072410|NCT01695564|atrial enlargement
1072411|NCT01695564|left atrial appendage
1072412|NCT01695551|Radiofrequency ablation
1072413|NCT01695551|fast heart rhythm
1072414|NCT01695551|ventricle
1072415|NCT01695551|catheter ablation
1072416|NCT01695551|ablation
1072417|NCT01695538|Yoga
1072418|NCT01695538|atrial tachycardia
1072419|NCT01695525|Neurocardiogenic Syncope
1072420|NCT01695525|Yoga
1072421|NCT01695486|BIS
1072422|NCT01695486|Comfort
1072423|NCT01695486|open muscle biopsy
1072424|NCT01695473|Prostate cancer
1072425|NCT01695473|High-risk prostate cancer
1072426|NCT01695473|Radical prostatectomy
1072427|NCT01695473|BKM120
1072428|NCT01695460|Migraine
1072429|NCT01695460|Vitamin D
1072430|NCT01695434|multiple sclerosis
1072431|NCT01695434|MRI
1072432|NCT01695434|Copaxone
1072433|NCT01695434|healthy controls
1072434|NCT01695434|glatiramer acetate
1072435|NCT01695421|Transcutaneous Electric Nerve Stimulation
1072436|NCT01695421|Oxygen Consumption
1072437|NCT01695421|Heart Failure
1072438|NCT01695408|Drug Treatment
1072439|NCT01695408|Treatment pathways
1072440|NCT01695408|Clinical routine
1072441|NCT01695408|Registry
1072442|NCT01695408|Outcomes
1072443|NCT01695408|Survival
1072444|NCT01695408|Patient-related outcomes
1072445|NCT01695408|Quality of life
1072446|NCT01695408|Steroids
1072447|NCT01695408|Azathioprine
1072448|NCT01695408|N-Acetylcysteine
1072449|NCT01695408|Pirfenidone
1072450|NCT01695408|Tyrosine kinase inhibitors
1072451|NCT01695408|Nintedanib
1072452|NCT01695408|multicenter
1072453|NCT01695408|Germany
1072454|NCT01695408|Safety
1072455|NCT01695408|Adverse event
1072456|NCT01695395|intellectual disability
1072457|NCT01695395|mental disorder
1072458|NCT01695395|dual diagnosis
1072459|NCT01695395|provision
1072460|NCT01695395|needs assessment
1072461|NCT01695395|quality of life
1072462|NCT01695382|Cancer
1072463|NCT01695382|Palliative Care
1072464|NCT01695382|Patient Navigation
1072465|NCT01695356|Melasma
1072466|NCT01695356|sunscreens
1072467|NCT01695356|visible light
1072468|NCT01695356|ultraviolet light
1072469|NCT01695343|Cystic Fibrosis
1072470|NCT01695343|Pseudomonas aeruginosa (Pa)
1072471|NCT01695343|CF
1072472|NCT01695330|Multiple Myeloma
1072473|NCT01695330|Relapsed
1072474|NCT01695330|Refractory
1072475|NCT01695330|Bortezomib
1072476|NCT01695330|Subcutaneous
1072477|NCT01695330|Oncotherapeutics
1072478|NCT01695317|Migraine
1072479|NCT01695317|Preventive medication
1072480|NCT01695304|Cryptosporidiosis
1072481|NCT01695304|Waterborne disease
1072482|NCT01695304|Diarrheal disease
1072483|NCT01695304|Ceramic water filters
1072484|NCT01695304|infants
1072485|NCT01695304|young children
1072486|NCT01695304|drinking water
1072487|NCT01695304|Kenya
1072488|NCT01695291|Obsessive compulsive disorder
1072489|NCT01695278|motivational interviewing
1072490|NCT01695278|telephone counseling
1072491|NCT01695278|medical education
1072492|NCT01695278|diabetes self management
1072493|NCT01695265|Airflow Obstruction
1072494|NCT01695226|Celecoxib
1072495|NCT01695226|Clinical trial, Phase II
1072496|NCT01695226|Oligonucleotide Array Sequence Analysis
1072497|NCT01695213|uncemented hip
1072498|NCT01695213|bone remodeling
1072499|NCT01695213|DEXA
1072500|NCT01695213|clinical evaluation
1072501|NCT01695187|Herpes, Herpes Labialis, nanoemulsion, NanoBio, NB-001
1072502|NCT01695174|Primary Sclerosing Cholangitis
1072503|NCT01695174|Xifaxan
1072504|NCT01695161|Mucopolysaccharidosis
1072505|NCT01695161|Fabry disease
1072506|NCT01695148|beta-carotene biofortified maize
1072507|NCT01695148|micronutrients
1072508|NCT01695148|vitamin A
1072509|NCT01695148|serum retinol
1072510|NCT01695148|dark adaptation
1072511|NCT01695135|Prostate neoplasms
1072512|NCT01695135|Prostate cancer
1072513|NCT01695135|Metastatic castration resistant prostate cancer
1072514|NCT01695135|Abiraterone acetate
1072515|NCT01695135|JNJ-212082
1072516|NCT01695122|Head and Neck Cancer
1072517|NCT01695122|Oropharyngeal cancer
1072518|NCT01695122|Oral cavity cancer
1072519|NCT01695122|Chemoradiation
1072520|NCT01695122|valproic acid
1072521|NCT01695122|histone deacetylase
1072522|NCT01695109|GLP1
1072523|NCT01695109|obesity
1072524|NCT01695109|fMRI
1072525|NCT01695109|ghrelin
1072526|NCT01695083|Non alcoholic steatohepatitis
1072527|NCT01695083|Liver fibrosis,Steatosis
1072528|NCT01695083|Liver inflammation
1072529|NCT01695083|Morbid obesity
1072530|NCT01695083|Non invasive tests
1072531|NCT01695031|Urban adolescents
1072532|NCT01695031|Acute asthma
1072533|NCT01695031|Emergency department
1072534|NCT01695031|Computer tailoring
1072535|NCT01695031|Web-based intervention
1072536|NCT01695018|oral epithelial dysplasia
1072537|NCT01695018|p16 methylation
1072538|NCT01695018|diagnostic reagents
1072539|NCT01695018|early diagnosis
1072540|NCT01694992|Stroke
1072541|NCT01694992|Early Ambulation
1072542|NCT01694992|Rehabilitation
1072543|NCT01694992|Physical Therapy
1072544|NCT01694992|Randomized controlled trial
1072545|NCT01694979|Pelvic floor
1072546|NCT01694979|Rehabilitation
1072547|NCT01694979|Respiration
1072548|NCT01694979|Urinary incontinence
1072549|NCT01694953|MNGIE
1072550|NCT01694953|Mitochondrial
1072551|NCT01694953|Mitochondrial Neurogastrointestinal encephalopathy
1072552|NCT01694940|mitochondrial disorders
1072553|NCT01694940|Mito Disease
1072554|NCT01694940|Mitochondria
1072555|NCT01694940|Mitochondrial disease
1072556|NCT01694940|MELAS
1072557|NCT01694940|MERRF
1072558|NCT01694940|LHON
1072559|NCT01694940|Leigh Syndrome
1072560|NCT01694940|NARP
1072561|NCT01694940|Kearns Sayre syndrome
1072562|NCT01694940|CPEO
1072563|NCT01694940|Alpers Huttenlocher
1072564|NCT01694940|Pearson
1072565|NCT01694940|MNGIE
1072566|NCT01694940|Barth Syndrome
1072567|NCT01694940|CoQ Deficiency
1072568|NCT01694940|DAD
1072569|NCT01694940|Diabetes and Deafness
1072570|NCT01694940|Encephalopathy
1072571|NCT01694940|Encephalomyopathy
1072572|NCT01694940|FBSN
1072573|NCT01694940|Hepatocerebral Disease
1072574|NCT01694940|Leukoencephalopathy
1072575|NCT01694940|MILS
1072576|NCT01694940|Complex I Deficiency
1072577|NCT01694940|Complex II Deficiency
1072578|NCT01694940|Complex III Deficiency
1072579|NCT01694940|Complex IV Deficiency
1072580|NCT01694940|Complex V Deficiency
1072581|NCT01694940|mitochondrial DNA depletion syndrome
1072582|NCT01694940|mtDNA depletion syndrome
1072583|NCT01694927|Mesenchymal stem cell
1072584|NCT01694927|Spinal cord injury
1072585|NCT01694914|Corneal Transplantation
1072586|NCT01694914|corneal organ culture medium
1072587|NCT01694914|free animal compound medium
1072588|NCT01694888|Students practice, Lecture; Nursing records; Nursing education; Midwifery
1072589|NCT01694875|cervix cancer
1072590|NCT01694875|HPV
1072591|NCT01694875|APTIMA
1072592|NCT01694862|quasi experimental
1072593|NCT01694862|evaluation
1072594|NCT01694862|intervention
1072595|NCT01694862|service integration
1072596|NCT01694862|cost analysis
1072597|NCT01694862|HIV
1072598|NCT01694862|FP
1072599|NCT01694862|PNC
1072600|NCT01694862|Sub-Saharan Africa
1072601|NCT01694849|PPARs
1072602|NCT01694849|NASH
1072603|NCT01694849|Non-Alcoholic Steatohepatitis
1072604|NCT01694849|Liver Diseases
1072605|NCT01694849|Fibrosis
1072606|NCT01694836|Allergic rhinitis
1072607|NCT01694836|Allergic rhinoconjunctivitis
1072608|NCT01694836|Allergy induced asthma
1072609|NCT01694836|Birch (Betula alba)
1072610|NCT01694836|Hayfever
1072611|NCT01694836|Immunotherapy
1072612|NCT01694823|Cartilage repair
1072613|NCT01694823|Cartilage defects
1072614|NCT01694823|cell sheet
1072615|NCT01694823|Autologous chondrocyte implantation
1072616|NCT01694810|acne vulgaris
1072617|NCT01694758|Benchmarking could improve quality of patient care
1072618|NCT01694758|ESC and ATP III Guidelines
1072619|NCT01694745|Newborns
1072620|NCT01694745|Premature
1072621|NCT01694745|Pain
1072622|NCT01694745|Pain assessment
1072623|NCT01694745|Endotracheal Intubation
1072624|NCT01694745|Analgesia
1072625|NCT01694745|Sedation
1072626|NCT01694745|Longterm effects of pain
1072627|NCT01694745|Epidemiology
1072628|NCT01694732|Chronic obstructive pulmonary disease
1072629|NCT01694732|Varenicline
1072630|NCT01694732|Smoking cessation
1072631|NCT01694719|Depression
1072632|NCT01694719|Major Depressive Disorder
1072633|NCT01694719|Behavioral Activation
1072634|NCT01694719|Cognitive Training
1072635|NCT01694680|AMD
1072636|NCT01694680|Lutein
1072637|NCT01694680|Visual function
1072638|NCT01694680|Early signs of AMD
1072639|NCT01694680|AREDS-category 2
1072640|NCT01694641|time lapse monitoring
1072641|NCT01694641|blastocyst
1072642|NCT01694641|single embryo transfer
1072643|NCT01694641|clinical pregnancy
1072644|NCT01694641|implantation rate
1072645|NCT01694615|Lung Transplantation
1072646|NCT01694615|Acute Rejection
1072647|NCT01694602|Cachexia
1072648|NCT01694602|Sarcopenia
1072649|NCT01694602|De Novo
1072650|NCT01694602|Deuterated
1072651|NCT01694589|pancreatic cancer
1072652|NCT01694589|resectable pancreatic cancer
1072653|NCT01694576|Nasopharyngeal carcinoma staged N2-3M0
1072654|NCT01694576|Adjuvant chemotherapy
1072655|NCT01694563|Atrial Fibrillation
1072656|NCT01694550|pacemaker
1072657|NCT01694550|ICD / CRTD
1072658|NCT01694550|corrected QT-interval
1072659|NCT01694537|lumbrokinase
1072660|NCT01694537|fibrinolytic
1072661|NCT01694537|plasmin-antiplasmin complex
1072662|NCT01694537|euglobulin clot lysis time
1072663|NCT01694537|platelet aggregation
1072664|NCT01694511|Endoscopy, Gastrointestinal
1072666|NCT01694459|angioplasty
1072667|NCT01694459|heparin
1072668|NCT01694459|trial
1072669|NCT01694446|Intestinal lipoprotein
1072670|NCT01694446|Apo B48 and apoB100
1072671|NCT01694446|Pancreatic clamp
1072672|NCT01694407|Prevention
1072673|NCT01694394|atrial fibrillation
1072674|NCT01694394|implantable cardiac monitor
1072675|NCT01694394|left atrial enlargement
1072676|NCT01694394|CHA2DS2 VASc Score
1072677|NCT01694394|cardiovascular risk
1072678|NCT01694381|Acute Ischemic Stroke
1072679|NCT01694381|TS01
1072680|NCT01694381|Mutant pro-urokinase
1072681|NCT01694381|M5
1072682|NCT01694381|C1 inhibitor
1072683|NCT01694381|Safety
1072684|NCT01694381|Stroke
1072685|NCT01694381|Tolerability
1072686|NCT01694381|Ischemia
1072687|NCT01694381|Cerebral Infarction
1072688|NCT01694381|Cerebrovascular Disorders
1072689|NCT01694381|Vascular Diseases
1072690|NCT01694381|Cardiovascular Diseases
1072691|NCT01694381|Brain Infarction
1072692|NCT01694381|Brain Ischemia
1072693|NCT01694381|Fibrinolytic Agents
1072694|NCT01694381|Thrombolytic Agents
1072695|NCT01694381|Molecular Mechanisms of Pharmacological Action
1072696|NCT01694381|Pharmacologic Actions
1072697|NCT01694381|Cardiovascular Agents
1072698|NCT01694381|Therapeutic Uses
1072699|NCT01694381|Hematologic Agents
1072700|NCT01694368|Near infrared spectroscopy; lipid core; vulnerable plaque
1072701|NCT01694329|Streptococcus pneumoniae
1072702|NCT01694329|Pneumococcal Conjugate Vaccines
1072703|NCT01694329|Immunization
1072704|NCT01694329|Otitis media
1072705|NCT01694316|Computerized neurobehavioral intervention
1072706|NCT01694277|Gastrointestinal Stromal Tumour
1072707|NCT01694277|GIST
1072708|NCT01694277|non-resectable
1072709|NCT01694277|metastatic
1072710|NCT01694277|second line treatment
1072711|NCT01694277|resistance to imatinib
1072712|NCT01694264|HBV surface antigen
1072713|NCT01694264|Anti-HBc positive
1072714|NCT01694264|Anti-TNFα Treatment
1072715|NCT01694264|Reactivation
1072716|NCT01694251|mitral valve area
1072717|NCT01694251|pressure half time
1072718|NCT01694251|3 dimensional transesophageal echocardiography
1072719|NCT01694251|computed tomography
1072720|NCT01694238|Colostomy
1072721|NCT01694238|Surgical technique
1072722|NCT01694225|Breast cancer
1072723|NCT01694225|Anti-estrogen therapy
1072724|NCT01694212|Macular edema
1072725|NCT01694212|Cataract
1072726|NCT01694212|Diabetic retinopathy
1072727|NCT01694212|Anti-inflammatory agents,Non-steroidal
1072728|NCT01694199|Pulsed Radiofrequency Energy (PRFE)
1072729|NCT01694199|Pain
1072730|NCT01694199|Postsurgical
1072731|NCT01694199|Opioids
1072732|NCT01694199|Pain relief
1072733|NCT01694199|Medical device
1072734|NCT01694199|Endorphins
1072735|NCT01694173|Type 2 diabetes mellitus, F18-FDG labelled stem cells
1072736|NCT01694160|kidney transplant patients
1072737|NCT01694160|Albuminuria
1072738|NCT01694147|relationship
1072739|NCT01694147|endothelial injury
1072740|NCT01694147|vascular permeability
1072741|NCT01694147|severe sepsis related ALI/ARDS
1072742|NCT01694134|Discopathy
1072743|NCT01694134|Modic I
1072744|NCT01694134|Corticoids
1072745|NCT01694134|Local Anaesthetic
1072746|NCT01694134|Intradiscal injection
1072747|NCT01694121|HIV prevention
1072748|NCT01694121|African American men
1072749|NCT01694121|evaluation study
1072750|NCT01694095|Geographic atrophy, prognosis, risk factors, natural history
1072751|NCT01694082|brief intervention
1072752|NCT01694082|web-based interventions
1072753|NCT01694082|computer-based interventions
1072754|NCT01694082|harm reduction
1072755|NCT01694082|young adult
1072756|NCT01694082|college student
1072757|NCT01694069|piperacillin
1072758|NCT01694069|tazobactam
1072759|NCT01694069|pseudomonas aeruginosa
1072760|NCT01694069|cystic fibrosis
1072761|NCT01694069|pulmonary exacerbation
1072762|NCT01694069|continuous infusion
1072763|NCT01694069|beta lactam
1072764|NCT01694030|Attachment security priming
1072765|NCT01694030|depressed mood
1072766|NCT01694017|HIV,treatment,cost effectiveness,drug toxicity,QOL,costs
1072767|NCT01694004|Nutrient absorption
1072768|NCT01694004|Duodenal feeding tube
1072769|NCT01694004|Gut-brain-gut axis
1072770|NCT01693978|PTSD
1072771|NCT01693978|Prolonged Exposure
1072772|NCT01693978|Comorbidity
1072773|NCT01693978|Treatment
1072774|NCT01693978|Methadone Maintenance
1072775|NCT01693978|Substance Use Disorder
1072776|NCT01693939|Lasik
1072777|NCT01693939|Myopia
1072778|NCT01693939|Femtosecond Laser
1072779|NCT01693926|Obesity
1072780|NCT01693926|Children
1072781|NCT01693926|Physical activity
1072782|NCT01693926|Stress
1072783|NCT01693926|Snacking
1072784|NCT01693900|joint replacement
1072785|NCT01693900|total hip replacement
1072786|NCT01693900|regional pain block
1072787|NCT01693900|ultrasound guidance
1072788|NCT01693900|fascia iliaca compartment block
1072789|NCT01693887|IFI
1072790|NCT01693887|empirical therapy
1072791|NCT01693887|preemptive therapy
1072792|NCT01693887|Itraconazole
1072793|NCT01693874|anxiety
1072794|NCT01693874|depression
1072795|NCT01693874|cognition
1072796|NCT01693874|MBSR
1072797|NCT01693874|mindfulness
1072798|NCT01693874|stress
1072799|NCT01693874|elderly
1072800|NCT01693861|Colorectal
1072801|NCT01693861|Cancer
1072802|NCT01693861|Metastatic
1072803|NCT01693861|Chronotherapy
1072804|NCT01693861|Urine
1072805|NCT01693861|Nucleosides
1072806|NCT01693861|Chemotherapy
1072807|NCT01693861|Treated with chemotherapy
1072808|NCT01693848|Colorectal
1072809|NCT01693848|Cancer
1072810|NCT01693848|Metastatic
1072811|NCT01693848|Control
1072812|NCT01693848|Urine
1072813|NCT01693848|Nucleosides
1072814|NCT01693848|Surgery
1072815|NCT01693848|General anesthesia
1072816|NCT01693848|Scheduled for surgery
1072817|NCT01693835|Colorectal
1072818|NCT01693835|Cancer
1072819|NCT01693835|Metastatic
1072820|NCT01693835|Healthy
1072821|NCT01693835|Control
1072822|NCT01693835|Circadian
1072823|NCT01693835|Urine
1072824|NCT01693835|Nucleosides
1072825|NCT01693822|metastatic renal cell carcinoma
1072826|NCT01693822|predominant clear cell histology
1072827|NCT01693822|Unsuitable for nephrectomy
1072828|NCT01693822|unsuitable for 'watch and wait' policy
1072829|NCT01693809|Caffeine
1072830|NCT01693809|Vestibular Evoked Myogenic Potentials
1072831|NCT01693809|dizziness
1072832|NCT01693809|vertigo
1072833|NCT01693809|tinnitus
1072834|NCT01693770|Bone Metastasis
1072835|NCT01693770|Pain Palliation
1072836|NCT01693770|High Intensity Focused Ultrasound
1072837|NCT01693757|Anterior Cruciate Ligament
1072838|NCT01693757|Hamstrings versus patellar tendon
1072839|NCT01693757|Hop test
1072840|NCT01693757|Return to sports
1072841|NCT01693744|Pseudoexfoliation, chronic kidney disease
1072842|NCT01693731|Breast cancer
1072843|NCT01693731|Periodontal Diseases
1072844|NCT01693731|Aromatase Inhibitors
1072845|NCT01693731|Oral Health Related Quality of Life
1072846|NCT01693718|cancer
1072847|NCT01693718|advanced
1072848|NCT01693718|oral cavity
1072849|NCT01693718|larynx
1072850|NCT01693705|Tracheostomy
1072851|NCT01693692|Fibromyalgia
1072852|NCT01693679|Tebivudine eGFR non-Tebivudine
1072853|NCT01693666|Pregnancy
1072854|NCT01693666|Obesity
1072855|NCT01693666|Weight gain
1072856|NCT01693666|Obstetric complications
1072857|NCT01693666|Lifestyle intervention
1072858|NCT01693653|Behcet's syndrome
1072859|NCT01693653|oral ulcers
1072860|NCT01693640|Behcet's
1072861|NCT01693614|Diffuse large B-cell lymphoma, Mantle cell lymphoma, Follicular lymphoma, PI3K inhibitor, Non-Hodgkin lymphoma, NHL
1072862|NCT01693601|Myelofibrosis
1072863|NCT01693601|Panobinostat
1072864|NCT01693601|Ruxolitinib
1072865|NCT01693588|Pain
1072866|NCT01693588|Postoperative Pain
1072867|NCT01693588|Surgical Pain
1072868|NCT01693588|Neurosurgical Pain
1072869|NCT01693575|Small pupil cataract surgery
1072870|NCT01693575|Intraoperative floppy iris syndrome (IFIS)
1072871|NCT01693562|Advanced solid tumors
1072872|NCT01693549|HER-2 negative
1072873|NCT01693549|Metastatic breast adenocarcinoma
1072874|NCT01693536|Elderly
1072875|NCT01693536|Sodium reduction
1072876|NCT01693536|Fitness increase
1072877|NCT01693536|Primary Care
1072878|NCT01693523|Pancreatic Cancer
1072879|NCT01693523|Pancreatic adenocarcinoma
1072880|NCT01693523|Locally advanced
1072881|NCT01693523|Metastatic disease
1072882|NCT01693523|Symptom reduction
1072883|NCT01693523|Minocycline
1072884|NCT01693523|Dynacin
1072885|NCT01693523|Minocin
1072886|NCT01693523|Minocin PAC
1072887|NCT01693523|Myrac
1072888|NCT01693523|Solodyn
1072889|NCT01693523|Placebo
1072890|NCT01693523|Sugar Pill
1072891|NCT01693523|Questionnaires
1072892|NCT01693523|Surveys
1072893|NCT01693510|Excess gestational weight gain (GWG)
1072894|NCT01693510|Obesity
1072895|NCT01693510|Type 2 diabetes
1072896|NCT01693510|Elevated fats in the blood
1072897|NCT01693510|High blood pressure
1072898|NCT01693497|Posttraumatic Stress Disorder
1072899|NCT01693497|PTSD
1072900|NCT01693497|psychotherapy
1072901|NCT01693497|randomized trial
1072902|NCT01693497|gestalt
1072903|NCT01693484|Calcaneus
1072904|NCT01693484|Fracture
1072905|NCT01693484|Indocyanine Green
1072906|NCT01693484|Angiography
1072907|NCT01693484|Open Reduction and Internal Fixation
1072908|NCT01693471|asthma
1072909|NCT01693471|SF-36
1072910|NCT01693471|HRQOL
1072911|NCT01693458|HIV
1072912|NCT01693458|prevention
1072913|NCT01693458|HIV-positive
1072914|NCT01693458|education
1072915|NCT01693445|Gastrointestinal neoplasms
1072916|NCT01693445|Oxaliplatin
1072917|NCT01693445|Irinotecan
1072918|NCT01693445|S-1
1072919|NCT01693432|Esophageal neoplasms
1072920|NCT01693432|Docetaxel
1072921|NCT01693432|S-1
1072922|NCT01693419|pancreas neoplasm
1072923|NCT01693419|gemcitabine
1072924|NCT01693419|erlotinib
1072925|NCT01693419|S-1
1072926|NCT01693406|human milk
1072927|NCT01693406|infant growth
1072928|NCT01693406|obesity
1072929|NCT01693406|diabetes
1072930|NCT01693406|breastfeeding
1072931|NCT01693393|primary Sjogren´s Syndrome
1072932|NCT01693393|Cyclosporine
1072933|NCT01693380|Influenza
1072934|NCT01693380|Vaccination
1072935|NCT01693380|Vaccines
1072936|NCT01693380|Schoolchildren
1072937|NCT01693380|Effectiveness
1072938|NCT01693380|Intervention studies
1072939|NCT01693380|Adolescents
1072940|NCT01693380|Laboratory Confirmed Influenza
1072941|NCT01693367|Femoral fracture
1072942|NCT01693367|Periprosthetic fracture
1072943|NCT01693367|Fracture fixation, internal
1072944|NCT01693367|Distal femur fractures
1072945|NCT01693367|Dynamic Locking Screw
1072946|NCT01693367|WOMAC
1072947|NCT01693354|dialysis
1072948|NCT01693354|mortality
1072949|NCT01693354|cardiovascular stability
1072950|NCT01693354|inflammation
1072951|NCT01693354|quality of life
1072952|NCT01693341|Chronic stroke patients
1072953|NCT01693341|Stroke rehabilitation
1072954|NCT01693341|Caregiver
1072955|NCT01693341|Caregiver-mediated intervention
1072956|NCT01693328|quality of life
1072957|NCT01693328|PecFent
1072958|NCT01693328|Lazanda
1072959|NCT01693328|fentanyl
1072960|NCT01693328|intranasal
1072961|NCT01693328|breakthrough cancer pain
1072962|NCT01693302|Blood Glucose
1072963|NCT01693302|Meal insulin
1072964|NCT01693289|Metformin
1072965|NCT01693289|letrozole
1072966|NCT01693289|ovarian drilling
1072967|NCT01693289|clomiphene resistance
1072968|NCT01693289|polycystic ovary.
1072969|NCT01693276|pancreatic cancer
1072970|NCT01693263|end stage renal disease (ESRD)
1072971|NCT01693263|brachiocephalic fistula (BCF)
1072972|NCT01693263|cephalic arch stenosis (CAS)
1072973|NCT01693263|dialysis
1072974|NCT01693250|technology
1072975|NCT01693250|healthy weight management
1072976|NCT01693250|primary care setting
1072977|NCT01693224|Tests, Diagnostic
1072978|NCT01693224|Mycobacterium tuberculosis
1072979|NCT01693224|Mycobacterium tuberculosis antigens
1072980|NCT01693224|TB
1072981|NCT01693224|Tuberculosis
1072982|NCT01693224|Tuberculosis, Pulmonary
1072983|NCT01693224|Tuberculosis, Miliary
1072984|NCT01693224|Lipoarabinomannan
1072985|NCT01693211|femtosecond laser
1072986|NCT01693211|cataract
1072987|NCT01693211|control study
1072988|NCT01693211|prospective
1072989|NCT01693198|allergy
1072990|NCT01693198|cyanobacteria
1072991|NCT01693198|sweet water swimming
1072992|NCT01693185|colonoscopy
1072993|NCT01693185|remifentanil
1072994|NCT01693185|midazolam
1072995|NCT01693185|meperidine
1072996|NCT01693172|exercise
1072997|NCT01693172|neoplasm
1072998|NCT01693159|Painful cetuximab-induced rhagades
1072999|NCT01693159|Radioimmunotherapy
1073000|NCT01693159|Head and neck cancer
1073001|NCT01693146|Oxygen
1073002|NCT01693146|High Flow
1073003|NCT01693146|COPD
1073004|NCT01693146|Hypercapnia
1073005|NCT01693120|ablation
1073006|NCT01693120|atrial fibrillation
1073007|NCT01693120|Radio frequency
1073008|NCT01693107|Atrial Fibrillation
1073009|NCT01693107|Catheter Ablation
1073010|NCT01693107|Electrophysiology
1073011|NCT01693107|Cardiac Arrhythmias
1073012|NCT01693081|Parkinson's disease
1073013|NCT01693081|inhaled apomorphine
1073014|NCT01693081|"convert off to on"
1073015|NCT01693068|Cutaneous Melanoma
1073016|NCT01693068|Dacarbazine
1073017|NCT01693068|Pimasertib
1073018|NCT01693068|N-Ras
1073019|NCT01693055|orbital Computed Tomography
1073020|NCT01693055|baggy eyelids
1073021|NCT01693055|orbital fat prolapse
1073022|NCT01693055|UltheraTM
1073023|NCT01693055|high intensity focused ultrasound
1073024|NCT01693042|heart failure
1073025|NCT01693042|old myocardial infarction
1073026|NCT01693042|bone marrow-derived mononuclear cells
1073027|NCT01693042|chronic
1073028|NCT01693042|ischemic
1073029|NCT01693029|erythropoietin alfa
1073030|NCT01693029|CKD 5d
1073031|NCT01693016|non-invasive Hb measurement in children
1073032|NCT01693003|COPD
1073033|NCT01692990|Appetite
1073034|NCT01692990|Fish oil
1073035|NCT01692990|Long-chain n-3 fatty acids
1073036|NCT01692912|Psoriatic Arthritis
1073037|NCT01692912|Randomized
1073038|NCT01692912|Single blind
1073039|NCT01692912|Treat to target
1073040|NCT01692899|Retention Rates
1073041|NCT01692899|of Adalimumab
1073042|NCT01692899|Etanercept and Infliximab
1073043|NCT01692899|as First and Second-Line Biotherapy
1073044|NCT01692899|in Patients with Rheumatoid Arthritis
1073045|NCT01692899|in Daily Practice.
1073046|NCT01692899|TNF inhibitors
1073047|NCT01692899|biotherapy
1073048|NCT01692899|retrospective study
1073049|NCT01692886|13vPnC
1073050|NCT01692886|7vPnC
1073051|NCT01692886|Healthy subjects
1073052|NCT01692886|China
1073054|NCT01692860|the impact of a higher dairy-based protein diet in
1073055|NCT01692860|combination with energy restriction on muscle health,
1073056|NCT01692860|metabolic health (including blood pressure) in overweight
1073057|NCT01692860|and obese, middle aged adults
1073058|NCT01692847|patient deterioration
1073059|NCT01692847|rapid response teams
1073060|NCT01692847|acute care teams
1073061|NCT01692847|early warning scoring
1073062|NCT01692834|bioequivalence
1073063|NCT01692834|pharmacokinetics
1073064|NCT01692834|tolerability
1073065|NCT01692834|safety
1073066|NCT01692834|ciclosporin
1073067|NCT01692834|cyclosporine
1073068|NCT01692834|cyclosporine A
1073069|NCT01692834|Sandimmune
1073070|NCT01692834|Sandimmun
1073071|NCT01692834|CicloMulsion
1073072|NCT01692834|NeuroSTAT
1073073|NCT01692821|retinal oxygen saturation
1073074|NCT01692821|retinal blood flow
1073075|NCT01692821|hyperoxia
1073076|NCT01692821|hypoxia
1073077|NCT01692808|Crohn
1073078|NCT01692808|vitamin D
1073079|NCT01692808|remission
1073080|NCT01692808|inflammation
1073081|NCT01692808|tolerance
1073082|NCT01692795|Myocardial infarction
1073083|NCT01692795|Antiplatelets
1073084|NCT01692795|Lipid lowering agents
1073085|NCT01692795|ACE inhibitors
1073086|NCT01692795|Angiotensin Receptor Blockers
1073087|NCT01692795|Beta blockers
1073088|NCT01692795|Blood pressure lowering drugs
1073089|NCT01692782|ADHD
1073090|NCT01692782|Attention deficit hyperactivity disorder
1073091|NCT01692769|Trauma
1073092|NCT01692769|Pediatric
1073093|NCT01692769|Intravenous Fluid
1073094|NCT01692769|Normal Saline
1073095|NCT01692769|Ringer's Lactate
1073096|NCT01692743|Telemedicine
1073097|NCT01692743|Inflammatory bowel disease
1073098|NCT01692743|Crohn's disease
1073099|NCT01692743|Ulcerative colitis
1073100|NCT01692743|Quality of life
1073101|NCT01692743|Health care utilization
1073102|NCT01692730|Smoking Cessation
1073103|NCT01692730|Web Assisted Tobacco Intervention
1073104|NCT01692691|Melanoma Metastatic
1073105|NCT01692678|Advanced or Metastatic liposarcoma or leiomyosarcoma
1073106|NCT01692678|Sarcoma
1073107|NCT01692678|L-sarcoma
1073108|NCT01692678|Liposarcoma
1073109|NCT01692678|Leiomyosarcoma
1073110|NCT01692678|Trabectedin
1073111|NCT01692678|Dacarbazine
1073112|NCT01692678|Yondelis
1073113|NCT01692678|Chinese patients
1073114|NCT01692678|Overall survival
1073115|NCT01692678|Pharmacokinetics
1073116|NCT01692665|meibomian gland dysfunction
1073117|NCT01692665|keratometric value
1073118|NCT01692665|ocular aberration
1073119|NCT01692626|Cetuximab rash
1073120|NCT01692626|Erbitux rash
1073121|NCT01692626|Rash
1073122|NCT01692626|Pimecrolimus
1073123|NCT01692626|1% Topical pimecrolimus cream
1073124|NCT01692600|Late oral radiation toxicity
1073125|NCT01692600|head and neck cancer patients
1073126|NCT01692600|optical coherence tomography
1073127|NCT01692600|subsurface imaging
1073128|NCT01692600|mirometer-resolution imaging
1073129|NCT01692600|vascular imaging
1073130|NCT01692600|Doppler optical coherence tomography
1073131|NCT01692600|speckle variance optical coherence tomography
1073132|NCT01692587|PSA
1073133|NCT01692587|protein
1073134|NCT01692587|prostate
1073135|NCT01692574|depression and obesity treatment
1073136|NCT01692561|Dysautonomia
1073137|NCT01692561|Postural orthostatic tachycardic hypotension
1073138|NCT01692561|Neurocardiogenic vasovagal syncope
1073139|NCT01692509|Non invasive ventilation
1073140|NCT01692509|Respiratory failure
1073141|NCT01692509|Respiratory comfort
1073142|NCT01692496|Advanced
1073143|NCT01692496|Metastatic
1073144|NCT01692496|Liposarcoma
1073145|NCT01692496|Pazopanib
1073146|NCT01692483|Prostate neoplasms
1073147|NCT01692483|Prostate cancer
1073148|NCT01692483|Castration resistant prostate cancer
1073149|NCT01692483|Hormone refractory prostate cancer
1073150|NCT01692483|Abiraterone acetate
1073151|NCT01692483|Taxane
1073152|NCT01692470|Human immunodeficiency virus type 1 (HIV-1) infection
1073153|NCT01692470|HIV-1
1073154|NCT01692470|Anti-retroviral naive
1073155|NCT01692470|ARV
1073156|NCT01692470|Filipino patients
1073157|NCT01692470|Rilpivirine hydrochloride
1073158|NCT01692470|Edurant
1073159|NCT01692457|Rheumatoid Arthritis
1073160|NCT01692457|Psoriatic Arthritis
1073161|NCT01692457|Ankylosing Spondylitis
1073162|NCT01692457|Arthritis
1073163|NCT01692457|Spondylitis
1073164|NCT01692457|Joint pain
1073165|NCT01692457|CNTO148
1073166|NCT01692457|Golimumab
1073167|NCT01692457|Simponi
1073168|NCT01692457|Filipino
1073169|NCT01692457|Post-Marketing
1073170|NCT01692457|Surveillance
1073171|NCT01692444|Chronic Obstructive Pulmonary Disease
1073172|NCT01692444|Fibrosis
1073173|NCT01692444|Fibroblast
1073174|NCT01692444|Lung attenuation
1073175|NCT01692444|Pletysmography
1073176|NCT01692418|Anaemia
1073177|NCT01692418|Blood transfusion
1073178|NCT01692418|Surgery
1073179|NCT01692418|Iron
1073180|NCT01692418|Ferric carboxymaltose
1073181|NCT01692392|Pectus carinatum
1073182|NCT01692392|Quality of life
1073183|NCT01692392|Pain, postoperative
1073184|NCT01692392|Somatosensory disorders
1073185|NCT01692379|Acute ischemic stroke
1073186|NCT01692379|endovascular treatment
1073187|NCT01692379|clinical trial
1073188|NCT01692353|Flow mediated dilation
1073189|NCT01692353|Carotid intima-media thickness
1073190|NCT01692353|Ankle-brachial index
1073191|NCT01692353|Smokeless tobacco
1073192|NCT01692353|Biological markers
1073193|NCT01692353|Nicotine
1073194|NCT01692353|Tobacco-specific nitrosamines
1073195|NCT01692353|Polycyclic aromatic hydrocarbons
1073196|NCT01692353|Aromatic amines
1073197|NCT01692353|Mercapturic acid metabolites
1073198|NCT01692353|Cholesterol
1073199|NCT01692353|Blood lipids
1073200|NCT01692353|Oxidative stress
1073201|NCT01692353|Inflammation
1073202|NCT01692353|Cytokines
1073203|NCT01692340|tomato
1073204|NCT01692340|prostate cancer
1073205|NCT01692340|metabolism
1073206|NCT01692327|glucose intolerance (20)
1073207|NCT01692327|Control (20)
1073208|NCT01692314|Endothelial function
1073209|NCT01692314|Microvascular reactivity
1073210|NCT01692314|Obesity
1073211|NCT01692314|Adolescents
1073212|NCT01692301|hypertension, elderly, central aortic pulse pressure, central pulse pressure, pulse wave velocity
1073213|NCT01692262|Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
1073214|NCT01692262|adenocarcinoma of the prostate,
1073215|NCT01692262|prostate cancer,
1073216|NCT01692262|progressive disease,
1073217|NCT01692262|advanced disease.
1073218|NCT01692249|chronic shoulder pain
1073219|NCT01692249|rotator cuff tendinopathy
1073220|NCT01692249|sap therapy
1073221|NCT01692249|balneotherapy
1073222|NCT01692236|MRI
1073223|NCT01692236|HIV
1073224|NCT01692236|Neurocognitive Disorders
1073225|NCT01692236|Major Depression
1073226|NCT01692236|Vasculopathy
1073227|NCT01692223|Personal genomics
1073228|NCT01692223|Genome Sequencing Results
1073229|NCT01692223|12-167
1073230|NCT01692210|Breast Cancer
1073231|NCT01692210|Dexmedetomidine
1073232|NCT01692210|Unilateral mastectomy
1073233|NCT01692210|Blood sample collections
1073234|NCT01692210|Immune system
1073235|NCT01692210|White blood cell levels
1073236|NCT01692197|Leukemia
1073237|NCT01692197|Acute Myeloid Leukemia
1073238|NCT01692197|Acute Myelogenous Leukemia
1073239|NCT01692197|AML
1073240|NCT01692197|Relapsed or Refractory
1073241|NCT01692197|High-Risk Myelodysplastic Syndromes
1073242|NCT01692197|HRMDS
1073243|NCT01692197|E7070
1073244|NCT01692197|Idarubicin
1073245|NCT01692197|Idamycin
1073246|NCT01692197|Cytarabine
1073247|NCT01692197|ARA-C
1073248|NCT01692197|Cytosar
1073249|NCT01692197|DepoCyt
1073250|NCT01692197|Cytosine Arabinosine Hydrochloride
1073251|NCT01692197|Dexamethasone
1073252|NCT01692197|Decadron
1073253|NCT01692184|AVL-292
1073254|NCT01692184|Safety
1073255|NCT01692184|Pharmacokinetics
1073256|NCT01692184|Pharmacodynamics
1073257|NCT01692184|Pharmacology, Clinical
1073258|NCT01692171|Subjects
1073259|NCT01692158|subjects
1073260|NCT01692145|Dry eye syndromes
1073261|NCT01692145|Corneal diseases
1073262|NCT01692145|Conjunctival diseases
1073263|NCT01692132|Chronic Constipation
1073264|NCT01692132|Prucalopride
1073265|NCT01692132|Post Marketing Surveillance
1073266|NCT01692119|chronic heart failure
1073267|NCT01692119|medication adherence
1073268|NCT01692119|pharmacy
1073269|NCT01692119|interdisciplinary care
1073270|NCT01692119|randomized controlled trial
1073271|NCT01692119|mortality
1073272|NCT01692119|hospitalization
1073273|NCT01692106|Heller myotomy
1073274|NCT01692093|SCORAD
1073275|NCT01692093|Atopic dermatits
1073276|NCT01692093|Skin health
1073277|NCT01692067|Rape
1073278|NCT01692067|Women
1073279|NCT01692067|Military
1073280|NCT01692067|Veterans
1073281|NCT01692067|Post-traumatic Stress Disorder
1073282|NCT01692067|Traumatic Brain Injury
1073283|NCT01692041|asthma
1073284|NCT01692041|children
1073285|NCT01692028|vitamin D
1073286|NCT01692028|Associational study
1073287|NCT01691976|Mild cognitive impairment
1073288|NCT01691976|Androgen deprivation therapy
1073289|NCT01691963|Epiglottis
1073290|NCT01691963|Intubation
1073291|NCT01691963|Laryngoscopy
1073292|NCT01691950|Trauma
1073293|NCT01691950|Limb reconstruction
1073294|NCT01691950|Amputation
1073295|NCT01691950|Functional outcome
1073296|NCT01691950|Sensing
1073297|NCT01691937|Thoracic paravertebral block
1073298|NCT01691937|Postoperative pain
1073299|NCT01691937|Right lobe hepatectomy
1073300|NCT01691937|Patient controlled analgesia
1073301|NCT01691924|Adenosine A2a receptor antagonist
1073302|NCT01691924|adenosine receptor modulator
1073303|NCT01691924|Cancer
1073304|NCT01691911|Vascular disease
1073305|NCT01691911|Open aortic aneurysm repair
1073306|NCT01691911|Endovascular aneurysm repair
1073307|NCT01691911|Carotid endartrectomy
1073308|NCT01691911|Lower limb surgical revascularisation
1073309|NCT01691911|Major lower limb amputation
1073316|NCT01691833|Vitamin D
1073317|NCT01691833|nonunion
1073318|NCT01691833|long bone fracture
1073319|NCT01691833|hypovitaminosis D
1073320|NCT01691820|Adolescent females
1073321|NCT01691820|Cytomegalovirus (CMV)
1073322|NCT01691807|Non-Hodgkin's Lymphoma
1073323|NCT01691807|drug-drug interaction
1073324|NCT01691807|ofatumumab
1073325|NCT01691807|bendamustine
1073326|NCT01691781|Hyperparathyroidism
1073327|NCT01691781|Renin-angiotensin-aldosterone system
1073328|NCT01691781|ACE inhibitors
1073329|NCT01691768|microbicides
1073330|NCT01691768|women
1073331|NCT01691768|HIV prevention
1073332|NCT01691768|PrEP
1073333|NCT01691768|Tenofovir gel
1073334|NCT01691742|Postoperative constipation
1073335|NCT01691742|Urogynecologic Surgery
1073336|NCT01691742|MiraLax
1073337|NCT01691742|Docusate Sodium
1073338|NCT01691716|Achilles tendinopathy
1073339|NCT01691716|Tendoactive
1073340|NCT01691716|Eccentric training
1073341|NCT01691703|Fiber Optic Technology/methods
1073342|NCT01691703|Intubation, Intratracheal/methods
1073343|NCT01691703|Laryngoscopy/methods
1073344|NCT01691664|Esophageal Cancer
1073345|NCT01691664|DC-CIK
1073346|NCT01691664|immunotherapy
1073347|NCT01691664|cellular therapy
1073348|NCT01691664|radiation therapy
1073349|NCT01691651|Keratoconus
1073350|NCT01691651|Tetanus toxin
1073351|NCT01691625|Locally advanced esophageal carcinoma
1073352|NCT01691625|DC-CIK
1073353|NCT01691625|Immunotherapy
1073354|NCT01691612|Role of Pin-1 enzyme in Asthma
1073355|NCT01691599|Infection
1073356|NCT01691599|Open tibia fractures
1073357|NCT01691599|Closed tibia fractures
1073358|NCT01691599|Wound infection
1073359|NCT01691586|implantable defibrillators
1073360|NCT01691586|remote patient monitoring
1073361|NCT01691586|patient-reported outcomes
1073362|NCT01691586|cost-effectiveness
1073363|NCT01691573|ablation
1073364|NCT01691573|procedure
1073365|NCT01691573|pediatric
1073366|NCT01691573|european
1073367|NCT01691573|cardiac
1073368|NCT01691573|arrhythmias
1073369|NCT01691573|registry
1073370|NCT01691573|observational
1073371|NCT01691573|prospective
1073372|NCT01691573|catheter
1073373|NCT01691573|cryoablation
1073374|NCT01691573|atrioventricular
1073375|NCT01691547|GW642444 (Vilanterol)
1073376|NCT01691547|pharmacokinetics
1073377|NCT01691547|pharmacodynamics
1073378|NCT01691547|GSK573719 (Umeclidinium)
1073379|NCT01691547|healthy subjects
1073380|NCT01691547|GW685698 (Fluticasone Furoate)
1073381|NCT01691534|Tuberculosis
1073382|NCT01691534|EBA
1073383|NCT01691534|PA824
1073384|NCT01691534|pretomanid
1073385|NCT01691534|TMC207
1073386|NCT01691521|safety
1073387|NCT01691521|SB-240563
1073388|NCT01691521|efficacy
1073389|NCT01691521|placebo
1073390|NCT01691521|eosinophils
1073391|NCT01691521|mepolizumab
1073392|NCT01691521|Severe refractory asthma
1073393|NCT01691508|Safety
1073394|NCT01691508|Steroid Reduction
1073395|NCT01691508|Efficacy
1073396|NCT01691508|SB-240563
1073397|NCT01691508|Eosinophils
1073398|NCT01691508|Quality of Life
1073399|NCT01691508|Mepolizumab
1073400|NCT01691508|Severe Refractory Asthma
1073401|NCT01691495|Physician Adherence
1073402|NCT01691495|superficial vein thrombosis
1073403|NCT01691495|Fondaparinux
1073404|NCT01691469|Bioequivalence
1073405|NCT01691469|Montelukast Sodium
1073406|NCT01691469|crossover
1073407|NCT01691456|Bioequivalence
1073408|NCT01691456|Montelukast Sodium
1073409|NCT01691456|crossover
1073410|NCT01691404|Flavonoids
1073411|NCT01691404|Quercetin
1073412|NCT01691404|Epicatechin
1073413|NCT01691404|Vascular function
1073414|NCT01691404|Blood pressure
1073415|NCT01691404|Endothelial function
1073416|NCT01691391|Advanced CRC
1073417|NCT01691378|Veterans
1073418|NCT01691378|Window to Hope
1073419|NCT01691378|Cognitive Behavioral Therapy
1073420|NCT01691378|Traumatic Brain Injury
1073421|NCT01691378|Hopelessness
1073422|NCT01691378|Suicide
1073423|NCT01691365|Antioxidant
1073424|NCT01691365|vitamins
1073425|NCT01691365|Diet
1073426|NCT01691352|Wound infection
1073427|NCT01691352|Ostomy reversal
1073428|NCT01691339|Influenza
1073429|NCT01691339|Influenza virus vaccine
1073430|NCT01691339|Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation
1073431|NCT01691339|Fluzone® High-Dose (Influenza Virus Vaccine) 2012-2013 Formulation
1073432|NCT01691339|Trivalent Inactivated Influenza Vaccine
1073433|NCT01691339|Fluzone® Intradermal (Influenza Virus Vaccine) 2012-2013 Formulation
1073434|NCT01691326|Influenza
1073435|NCT01691326|Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation
1073436|NCT01691326|Influenza virus vaccine
1073437|NCT01691326|Trivalent Inactivated Influenza Vaccine
1073438|NCT01691313|vanoxerine
1073439|NCT01691313|atrial fibrillation
1073440|NCT01691313|atrial flutter
1073441|NCT01691313|a-fib
1073442|NCT01691300|C11-acetate PET/CT
1073443|NCT01691300|Multiple myeloma
1073444|NCT01691300|Pretreatment staging
1073445|NCT01691300|Response assessment
1073446|NCT01691287|Type 1 Diabetes
1073447|NCT01691287|Metabolic Control
1073448|NCT01691287|Quality of Life
1073449|NCT01691274|Epilepsy
1073450|NCT01691274|Phase 1
1073451|NCT01691274|Multiple Dose
1073452|NCT01691274|Safety
1073453|NCT01691274|Pharmacokinetics
1073454|NCT01691274|Toleration
1073455|NCT01691248|Clostridium difficile
1073456|NCT01691248|Clostridium difficile-Associated Diarrhea
1073457|NCT01691248|Prophylaxis
1073458|NCT01691248|Hematopoietic Stem Cell Transplantation
1073459|NCT01691235|SIMpill
1073460|NCT01691235|HCV
1073461|NCT01691235|Chronic Hepatitis C Virus
1073462|NCT01691222|Bedside percutaneous tracheostomy
1073463|NCT01691222|Intensive Care Unit
1073464|NCT01691222|Dedicated Double-lumen tube
1073465|NCT01691222|Ineffective Airway Clearance
1073466|NCT01691222|weaning failure
1073467|NCT01691209|Phoenix
1073468|NCT01691209|Hydrocortison
1073469|NCT01691209|mild atopic dermatitis
1073470|NCT01691209|efficacy
1073471|NCT01691209|safety
1073472|NCT01691196|Obesity
1073473|NCT01691196|Peritoneal dialysis
1073474|NCT01691196|Inflammation
1073475|NCT01691196|Macrophages
1073476|NCT01691196|Innate immunity
1073477|NCT01691183|Hertel
1073478|NCT01691183|exophthalmometer
1073479|NCT01691183|proptosis
1073480|NCT01691183|eye disease
1073481|NCT01691170|Pattelofemoral pain syndrome
1073482|NCT01691170|Stretching
1073483|NCT01691170|Strengthening
1073484|NCT01691157|Subacromial impingement syndrome
1073485|NCT01691157|Rotator cuff
1073486|NCT01691157|Exercise
1073487|NCT01691157|Physiotherapy
1073488|NCT01691144|cancer
1073489|NCT01691144|gynecological
1073490|NCT01691144|expectations
1073491|NCT01691144|satisfaction
1073492|NCT01691144|cooperation
1073493|NCT01691131|Physical activity in daily life
1073494|NCT01691131|Balance
1073495|NCT01691131|COPD
1073496|NCT01691131|Exercise training
1073497|NCT01691118|Hypertension
1073498|NCT01691118|Angiotensin Receptor Blocker
1073499|NCT01691118|Diastolic Dysfunction
1073500|NCT01691105|Tobacco Use Cessation
1073501|NCT01691105|Smoking Cessation
1073502|NCT01691105|Nicotine Replacement Therapy
1073503|NCT01691105|Hospitalized Smokers
1073504|NCT01691092|Depression
1073505|NCT01691092|Ketamine
1073506|NCT01691092|PET
1073507|NCT01691092|PTSD
1073508|NCT01691053|End stage renal disease
1073509|NCT01691053|Hemodialysis
1073510|NCT01691053|Spironolactone
1073511|NCT01691053|Left ventricular hypertrophy
1073512|NCT01691040|Hepcidin
1073513|NCT01691040|Iron
1073514|NCT01691040|Anemia of Chronic Disease
1073515|NCT01691040|Anemia
1073516|NCT01691040|Cancer
1073517|NCT01691040|Interleukin-6
1073518|NCT01691040|Iron restriction
1073519|NCT01691040|Lymphoma
1073520|NCT01691040|CLL
1073521|NCT01691040|Multiple Myeloma
1073522|NCT01691040|Hodgkin
1073523|NCT01691040|anti-hepcidin
1073524|NCT01691027|scotoma, central
1073525|NCT01691027|visual motor coordination
1073526|NCT01690988|Delirium
1073527|NCT01690988|ketamine
1073528|NCT01690988|surgery
1073529|NCT01690988|neurological complications
1073530|NCT01690962|diabetic neuropathy, diet, vegan, vegetarian
1073531|NCT01690949|inflammation
1073532|NCT01690949|COPD
1073533|NCT01690949|respiratory disease
1073534|NCT01690949|healthy volunteers
1073535|NCT01690936|Almonds
1073536|NCT01690936|Body weight
1073537|NCT01690936|Snacking
1073538|NCT01690910|Ventilator
1073539|NCT01690910|Mobility Limitations
1073540|NCT01690910|Critical Care
1073541|NCT01690910|Rifton Gait Trainer
1073542|NCT01690897|Female sexual desire
1073543|NCT01690897|Psychoeducational intervention
1073544|NCT01690897|Mindfulness
1073545|NCT01690884|Adenosine
1073546|NCT01690884|Ticagrelor
1073547|NCT01690884|Microdialysis
1073548|NCT01690871|Malignant PEComa
1073549|NCT01690871|Angiomyolipoma
1073550|NCT01690871|Tuberous Sclerosis Complex
1073551|NCT01690871|Pi3kinase /m-tor inhibitors
1073552|NCT01690858|Foetal loss
1073553|NCT01690858|complement
1073554|NCT01690858|antiangiogenic factors
1073555|NCT01690858|Repeated fetal losses
1073556|NCT01690832|Contrast induced acute kidney injury
1073557|NCT01690819|Acute Respiratory Distress Syndrome
1073558|NCT01690819|Acute Brain Injury
1073559|NCT01690793|ASTHMA
1073560|NCT01690793|ACUTE EXACERBATION OF ASTHMA
1073561|NCT01690780|fracture
1073562|NCT01690780|pediatric
1073563|NCT01690780|oral morphine
1073564|NCT01690780|ibuprofen
1073565|NCT01690767|Urethral catheterization
1073566|NCT01690767|Lidocaine
1073567|NCT01690754|SMS
1073568|NCT01690754|tuberculosis
1073569|NCT01690754|impact evaluation
1073570|NCT01690741|Cancer
1073571|NCT01690741|Malignancy
1073572|NCT01690741|Solid tumors
1073573|NCT01690728|Obesity
1073574|NCT01690728|Gastric bypass
1073575|NCT01690715|Hepatocellular Carcinoma
1073576|NCT01690715|Thrombosis
1073577|NCT01690715|Portal Vein Invasion
1073578|NCT01690702|breast cancer
1073579|NCT01690702|tailored
1073580|NCT01690702|high-risk
1073581|NCT01690676|FMD
1073582|NCT01690676|epicatechin
1073583|NCT01690676|apple polyphenol
1073584|NCT01690676|borderline hypertension
1073585|NCT01690650|Preterm
1073586|NCT01690650|Newborn
1073587|NCT01690650|Neonate
1073588|NCT01690650|Cerebral oxygenation
1073589|NCT01690650|Oxygen
1073590|NCT01690637|Oseltamivir
1073591|NCT01690637|Tamiflu
1073592|NCT01690611|Balance Training
1073593|NCT01690611|Walking
1073594|NCT01690611|Falls
1073595|NCT01690598|Epithelial ovarian cancer
1073596|NCT01690598|BRCA mutation
1073597|NCT01690598|Platinum resistant
1073598|NCT01690598|Platinum sensitive
1073599|NCT01690598|Relapsed ovarian cancer
1073600|NCT01690572|drug eluting balloon
1073601|NCT01690572|constrictive remodeling
1073602|NCT01690559|Ciprofloxacin
1073603|NCT01690559|sepsis
1073604|NCT01690559|infection
1073605|NCT01690559|pneumonia
1073606|NCT01690559|peritonitis
1073607|NCT01690559|cholecystitis
1073608|NCT01690559|cholangitis
1073609|NCT01690559|anthrax
1073610|NCT01690546|Opioid Addiction
1073611|NCT01690546|Addiction
1073612|NCT01690546|Drug Dependence
1073613|NCT01690533|Avelox
1073614|NCT01690533|Laryngopharyngitis
1073615|NCT01690533|Tonsillitis
1073616|NCT01690533|Bronchitis acute
1073617|NCT01690533|Pneumonia
1073618|NCT01690533|Secondary infection in chronic respiratory diseases Sinusitis
1073619|NCT01690507|demethylating agent
1073620|NCT01690507|immunogenicity
1073621|NCT01690494|STI
1073622|NCT01690494|sexually transmitted infection
1073623|NCT01690494|HIV
1073624|NCT01690494|criminal justice
1073625|NCT01690494|probation
1073626|NCT01690494|couples
1073627|NCT01690494|drug use
1073628|NCT01690442|HIV
1073629|NCT01690442|AIDS
1073630|NCT01690442|Prevention
1073631|NCT01690429|Arousal detection
1073632|NCT01690429|Pulse Wave Amplitude
1073633|NCT01690429|Obstructive Sleep Apnea
1073634|NCT01690429|Daytime sleepiness
1073635|NCT01690429|Cardiorespiratory risk
1073636|NCT01690377|Dendritic Cells
1073637|NCT01690364|Motor evoked potential monitoring
1073638|NCT01690364|General Anesthesia
1073639|NCT01690364|Neurosurgery
1073640|NCT01690364|Cisatracurium
1073641|NCT01690364|Vecuronium
1073642|NCT01690338|TOFr (train of four ratio)
1073643|NCT01690338|airway extubation
1073644|NCT01690338|PACU (postanesthesia care unit)
1073645|NCT01690338|PORC (postoperative residual curarization)
1073646|NCT01690325|Neoadjuvant chemotherapy
1073647|NCT01690325|Neoadjuvant cytotoxic-antiangiogenic therapy
1073648|NCT01690325|Bevacizumab
1073649|NCT01690325|PET
1073650|NCT01690312|Humans
1073651|NCT01690312|Cardiovascular Disease
1073652|NCT01690312|Statins
1073653|NCT01690312|Fish Oil
1073654|NCT01690312|DHA
1073655|NCT01690312|EPA
1073656|NCT01690312|High-DHA
1073657|NCT01690312|Triglycerides
1073658|NCT01690312|Total cholesterol [TC]
1073659|NCT01690312|Lipoproteins
1073660|NCT01690312|High-density lipoprotein [HDL2, HDL3]
1073661|NCT01690312|Low-density lipoprotein [LDL1+2+3+4]
1073662|NCT01690312|Lipoprotein A [Lp(a)]
1073663|NCT01690312|Intermediate-density lipoprotein (IDL)
1073664|NCT01690312|Very low-density lipoprotein (VLDL1+2, VLDL3)
1073665|NCT01690312|Remnant Lipoproteins
1073666|NCT01690312|High-sensitivity C-Reactive Protein [hs-CRP]
1073667|NCT01690312|Homocysteine
1073668|NCT01690312|Essential Fatty Acid Profile
1073669|NCT01690312|Apolipoprotein B
1073670|NCT01690312|Apolipoprotein A-1
1073671|NCT01690312|Glucose
1073672|NCT01690312|Insulin
1073673|NCT01690312|Fasted
1073674|NCT01690312|Post-Prandial
1073675|NCT01690299|Psoriasis
1073676|NCT01690299|arthritis
1073677|NCT01690299|psoriatic
1073678|NCT01690299|palmoplantar
1073679|NCT01690299|scalp
1073680|NCT01690299|psoriasis pill
1073681|NCT01690299|psoriasis tablet
1073682|NCT01690299|plaque psoriasis
1073683|NCT01690299|plaque type psoriasis
1073684|NCT01690299|moderate to severe plaque type psoriasis
1073685|NCT01690299|psoriatic arthritis
1073686|NCT01690286|Healthy
1073687|NCT01690286|Ketoconazole
1073688|NCT01690286|JNJ-38518168
1073689|NCT01690286|Pharmacokinetics
1073690|NCT01690273|exercise
1073691|NCT01690273|mobility
1073692|NCT01690273|strengthening
1073693|NCT01690273|physiotherapy
1073694|NCT01690260|Bone
1073695|NCT01690260|Morphogenetic
1073696|NCT01690260|Protein
1073697|NCT01690260|Ilizarow
1073698|NCT01690260|Autologous
1073699|NCT01690260|Osteoarthritis
1073700|NCT01690247|mesenchymal stem cells
1073701|NCT01690247|liver transplantation
1073702|NCT01690247|clinical trial
1073703|NCT01690247|rejection
1073704|NCT01690234|Low back pain
1073705|NCT01690234|Return to work
1073706|NCT01690234|Sickness absence
1073707|NCT01690234|Rehabilitation
1073708|NCT01690234|Multidisciplinary intervention
1073709|NCT01690221|Anal
1073710|NCT01690221|Fissure
1073711|NCT01690221|Pain
1073712|NCT01690208|Diabetes
1073713|NCT01690208|Structure Care
1073714|NCT01690182|Gastrointestinal physiology
1073715|NCT01690182|MRI
1073716|NCT01690182|gastric volumes
1073717|NCT01690182|satiety
1073718|NCT01690156|In-plane
1073719|NCT01690156|Ultrasound-guided regional anesthesia performance
1073720|NCT01690156|Probe position
1073721|NCT01690156|Needle visualization
1073722|NCT01690130|nicotine
1073723|NCT01690130|craving
1073724|NCT01690130|smoking
1073725|NCT01690130|TMS
1073726|NCT01690130|prefrontal cortex
1073727|NCT01690117|family caregiver
1073728|NCT01690117|dementia
1073729|NCT01690117|intervention
1073730|NCT01690117|implementation
1073731|NCT01690104|rifampicin
1073732|NCT01690104|pregnane X receptor
1073733|NCT01690104|blood pressure
1073734|NCT01690091|chronic heart failure
1073735|NCT01690091|type 2 diabetes
1073736|NCT01690091|metformin
1073737|NCT01690091|insulin resistance
1073738|NCT01690078|Airway modeling
1073739|NCT01690078|Pierre Robin Sequence or PRS
1073740|NCT01690078|Micrognathia
1073741|NCT01690078|Subglottic Stenosis or SGS
1073742|NCT01690065|chronic myeloid leukemia
1073743|NCT01690065|myeloid blastic phase
1073744|NCT01690065|bcr-abl(+) acute myeloid leukemia
1073745|NCT01690065|nilotinib
1073746|NCT01690052|dry mouth
1073747|NCT01690039|renal tubular acidosis
1073748|NCT01690039|V-ATPase
1073749|NCT01690039|kidney stones
1073750|NCT01689974|Metastatic Melanoma
1073751|NCT01689974|Radiation Therapy
1073752|NCT01689974|Immunology
1073753|NCT01689974|Abscopal
1073754|NCT01689961|Nutrition
1073755|NCT01689961|Physical activity
1073756|NCT01689961|Gestational weight gain
1073757|NCT01689961|Pregnancy outcomes
1073758|NCT01689961|Birth
1073759|NCT01689948|Home care, rehabilitation therapy, Alzheimer's disease
1073760|NCT01689935|Acne vulgaris
1073761|NCT01689935|Photodynamic Therapy
1073762|NCT01689935|Side-effects
1073763|NCT01689935|Pain
1073764|NCT01689909|Insomnia
1073765|NCT01689909|Depression
1073766|NCT01689909|Suicidal ideation
1073767|NCT01689909|Zolpidem CR
1073768|NCT01689909|Placebo
1073769|NCT01689896|Hypogonadism
1073770|NCT01689896|Low testosterone
1073771|NCT01689896|Pain
1073772|NCT01689883|stroke
1073773|NCT01689883|electrical stimulation
1073774|NCT01689870|OX40
1073775|NCT01689870|Anti-OX40
1073776|NCT01689870|Ipilimumab
1073777|NCT01689870|Melanoma
1073778|NCT01689857|hypertropic scar, Vancouver scar scale, silicon gel sheet
1073779|NCT01689844|controlled high blood pressure
1073780|NCT01689818|insomnia, elderly, exercise training
1073781|NCT01689805|Atopic dermatitis
1073782|NCT01689805|Filaggrin
1073783|NCT01689779|vitamin D
1073784|NCT01689779|surgery
1073785|NCT01689779|acute stress
1073786|NCT01689766|Renal Cell
1073787|NCT01689753|Renal dialyse
1073788|NCT01689753|Catheter, indwelling
1073789|NCT01689753|Catheter-related infection
1073790|NCT01689740|MDMA
1073791|NCT01689740|Posttraumatic stress disorder
1073792|NCT01689740|PTSD
1073793|NCT01689740|Israel
1073794|NCT01689740|psychotherapy
1073795|NCT01689727|Pituitary Tumors
1073796|NCT01689714|Ovarian Carcinoma
1073797|NCT01689714|Recurrent Endometrial Carcinoma
1073798|NCT01689701|Erosive Gastritis
1073799|NCT01689701|Hizikia Fusiformis
1073800|NCT01689675|musculoskeletal
1073801|NCT01689675|pain
1073802|NCT01689675|pain management
1073803|NCT01689675|computer based intervention
1073804|NCT01689662|Metastatic Renal Cell Carcinoma
1073805|NCT01689649|Epilepsy
1073806|NCT01689649|Seizures
1073807|NCT01689649|Topiramate
1073808|NCT01689649|Anti-epileptic drug
1073809|NCT01689649|Nervous disorder
1073810|NCT01689636|Ovarian Cancer
1073811|NCT01689623|Healthy participants
1073812|NCT01689623|TMC435
1073813|NCT01689623|HMG-CoA reductase inhibitors
1073814|NCT01689623|Atorvastatin
1073815|NCT01689623|Simvastatin
1073816|NCT01689623|Pharmacokinetic interaction
1073817|NCT01689610|Nab-Paclitaxel
1073818|NCT01689610|Abraxane
1073819|NCT01689610|Nabucco
1073820|NCT01689610|safety
1073821|NCT01689610|breast cancer
1073822|NCT01689610|daily routine
1073823|NCT01689610|peripheral neuropathy
1073824|NCT01689610|iOMEDICO
1073825|NCT01689584|BRCA1
1073826|NCT01689584|BRCA2
1073827|NCT01689584|VUS
1073828|NCT01689584|co-segregation
1073829|NCT01689584|genetic counseling
1073830|NCT01689571|PDE4 inhibitor
1073831|NCT01689571|Allergen Challenge
1073832|NCT01689571|Asthma
1073833|NCT01689558|nasopharynx cancer,Image department of nose pharynx ministry
1073834|NCT01689545|HIV
1073835|NCT01689545|drug abuse
1073836|NCT01689545|social stigma
1073837|NCT01689545|Vietnam
1073838|NCT01689532|Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
1073839|NCT01689532|Sirukumab
1073840|NCT01689532|Human Anti-IL-6 Monoclonal Antibody
1073841|NCT01689519|Zelboraf
1073842|NCT01689519|vemurafenib
1073843|NCT01689519|RG7204
1073844|NCT01689519|PLX4032
1073845|NCT01689519|Genentech MEK inhibitor
1073846|NCT01689519|Genentech BRAF inhibitor
1073847|NCT01689519|Roche MEK inhibitor
1073848|NCT01689519|Roche BRAF inhibitor
1073849|NCT01689519|RO5185426
1073850|NCT01689519|metastatic melanoma
1073851|NCT01689519|BRAF positive melanoma
1073852|NCT01689519|BRAF mutant melanoma
1073853|NCT01689519|advanced melanoma
1073854|NCT01689519|Genentech RAF inhibitor
1073855|NCT01689519|Roche RAF inhibitor
1073856|NCT01689519|BRAF V600E kinase inhibitor
1073857|NCT01689519|Oncogenic BRAF inhibitor
1073858|NCT01689519|BRAF kinase inhibitor
1073859|NCT01689519|GDC-0973
1073860|NCT01689519|XL518
1073861|NCT01689519|melanoma
1073862|NCT01689480|Muscular Dystrophy
1073863|NCT01689480|Facioscapulohumeral
1073864|NCT01689480|Physical training
1073865|NCT01689480|Exercise
1073866|NCT01689454|IVF
1073867|NCT01689454|embryo culture
1073868|NCT01689454|Ongoing pregnancy rate
1073869|NCT01689454|Ongoing implantation rate
1073870|NCT01689454|Miscarriage
1073871|NCT01689428|IVF
1073872|NCT01689428|Embryo culture
1073873|NCT01689428|Ongoing Pregnancy rate
1073874|NCT01689428|Ongoing Implantation rate
1073875|NCT01689428|Miscarriage
1073876|NCT01689415|Renal nerve denervation
1073877|NCT01689389|Schizophrenia
1073878|NCT01689389|Bipolar episodes
1073879|NCT01689389|France
1073880|NCT01689389|Xeroquel
1073881|NCT01689389|Real-life
1073882|NCT01689363|hyaluronidase
1073883|NCT01689363|enzymes with tissue spreading activity
1073884|NCT01689363|allergic reaction
1073885|NCT01689363|intradermal skin testing
1073886|NCT01689350|Cyclophosphamide
1073887|NCT01689350|genotype-based therapy
1073888|NCT01689350|prospective study
1073889|NCT01689337|Microfracture surgery
1073890|NCT01689337|Cartilage repair
1073891|NCT01689337|Knee surgery
1073892|NCT01689324|Pertussis
1073893|NCT01689324|Tetanus
1073894|NCT01689324|Diphtheria
1073895|NCT01689324|Acellular pertussis
1073896|NCT01689324|ADACEL®
1073897|NCT01689324|Tdap vaccine
1073898|NCT01689311|Uterine contraction
1073899|NCT01689311|Dose response
1073900|NCT01689311|Non-laboring
1073901|NCT01689311|Laboring
1073902|NCT01689311|Laboring with oxytocin augmentation
1073903|NCT01689311|Oxytocin
1073904|NCT01689311|Ergonovine
1073905|NCT01689311|Prostaglandin F2alpha
1073906|NCT01689311|Misoprostol
1073907|NCT01689298|Uterine contraction
1073908|NCT01689298|Dose response
1073909|NCT01689298|Oxytocin pretreatment
1073910|NCT01689298|Oxytocin
1073911|NCT01689298|Carbetocin
1073912|NCT01689285|bioequivalence
1073913|NCT01689285|pharmacokinetics
1073914|NCT01689285|valacyclovir
1073915|NCT01689285|paediatric formulation
1073916|NCT01689272|Kidney transplantation,functional status,survival.
1073917|NCT01689246|Alzheimer's Disease
1073918|NCT01689246|Alzheimer Disease
1073919|NCT01689246|TRx0237
1073920|NCT01689246|AD
1073921|NCT01689246|Neurodegenerative Diseases
1073922|NCT01689246|Dementia
1073923|NCT01689246|Brain Diseases
1073924|NCT01689233|Alzheimer's Disease
1073925|NCT01689233|Alzheimer Disease
1073926|NCT01689233|TRx0237
1073927|NCT01689233|AD
1073928|NCT01689233|Neurodegenerative Diseases
1073929|NCT01689233|Dementia
1073930|NCT01689233|Brain Diseases
1073931|NCT01689207|Phase I, Safety, tolerability, healthy.
1073932|NCT01689155|Meningitis
1073933|NCT01689155|Meningococcal Infection
1073934|NCT01689155|Menactra®
1073935|NCT01689103|Alcohol use disorders
1073936|NCT01689103|Treatment
1073937|NCT01689103|Outpatient
1073938|NCT01689103|Therapeutic alliance
1073939|NCT01689051|Type 2 diabetes
1073940|NCT01689051|Blod pressure
1073941|NCT01689051|Glucagon-like peptide-1
1073942|NCT01689051|Human physiology
1073943|NCT01689051|Blood flow
1073944|NCT01688999|Kidney Cancer
1073945|NCT01688999|Tyrosine Kinase Inhibitor
1073946|NCT01688999|Bladder Cancer
1073947|NCT01688986|Complex Disease
1073948|NCT01688986|DNA Biorepository
1073949|NCT01688986|Genotype-Phenotype Correlation
1073950|NCT01688986|Genetics
1073951|NCT01688986|Environmental Factors
1073952|NCT01688947|Pain
1073953|NCT01688947|Neuralgia, Postherpetic
1073954|NCT01688934|Pain
1073955|NCT01688934|Osteoarthritis
1073956|NCT01688934|Knee
1073957|NCT01688921|Injections, Jet
1073958|NCT01688921|Influenza Vaccines
1073959|NCT01688908|Esophageal Squamous Cell carcinomas
1073960|NCT01688908|Endoscopy Screening
1073961|NCT01688908|High risk region
1073962|NCT01688908|China
1073963|NCT01688895|erythropoietic
1073964|NCT01688895|protoporphyria
1073965|NCT01688895|cutaneous
1073966|NCT01688895|porphyria
1073967|NCT01688882|bullous pemphigoid
1073968|NCT01688882|QGE031
1073969|NCT01688869|brain concussion
1073970|NCT01688856|hand
1073971|NCT01688856|arm
1073972|NCT01688856|stroke
1073973|NCT01688856|hemiplegia
1073974|NCT01688856|electrical stimulation
1073975|NCT01688856|recovery
1073976|NCT01688856|rehabilitation
1073977|NCT01688843|bradycardia
1073978|NCT01688843|sinus node dysfunction
1073979|NCT01688817|Colorectal Neoplasms
1073980|NCT01688817|Colonoscopy
1073981|NCT01688817|Early Detection of Cancer
1073982|NCT01688817|Patient Selection
1073983|NCT01688817|Patient Participation
1073984|NCT01688817|Physicians, Primary Care
1073985|NCT01688817|Conscious Sedation
1073986|NCT01688804|Sedentary behavior
1073987|NCT01688804|Physical activity
1073988|NCT01688804|Obesity
1073989|NCT01688804|Mobile health
1073990|NCT01688804|Smartphone
1073991|NCT01688778|Type 2 diabetes
1073992|NCT01688778|Quality of life
1073993|NCT01688778|Lifestyle intervention
1073994|NCT01688778|Telemedicine
1073995|NCT01688778|Videoconference
1073996|NCT01688765|Schizophrenia
1073997|NCT01688765|Schizoaffective disorder
1073998|NCT01688765|Bipolar disorder
1073999|NCT01688739|Migraine
1074000|NCT01688726|Dry eye
1074001|NCT01688726|Ocular surface
1074002|NCT01688726|Vision complaint
1074003|NCT01688726|Tear film stability
1074004|NCT01688726|Time controlled functional visual acuity
1074005|NCT01688726|Tear film kinetics
1074006|NCT01688700|Esophageal Squamous Cell Carcinoma
1074007|NCT01688700|neoadjuvant therapy
1074008|NCT01688700|Nimotuzumab
1074009|NCT01687699|cardiovascular event
1074010|NCT01687699|hemodialysis
1074011|NCT01687699|spironolactone
1074016|NCT01687660|acupuncture
1074017|NCT01687660|migraine prophylaxis
1074018|NCT01687647|Lung cancer screening
1074019|NCT01687647|Asbestos exposed workers
1074020|NCT01687647|Sputum analysis
1074021|NCT01687647|Automated cytometry
1074022|NCT01687647|Predictive biomarkers
1074023|NCT01687634|pregnancy
1074024|NCT01687634|home healthcare visits
1074025|NCT01687634|breast feeding
1074026|NCT01687634|nutrition
1074027|NCT01687634|community health workers
1074028|NCT01687621|Omphalitis
1074029|NCT01687621|Neonate
1074030|NCT01687621|Zambia
1074031|NCT01687621|Neonatal mortality
1074032|NCT01687621|Umbilical cord infection
1074033|NCT01687608|Hemophilia B
1074034|NCT01687608|factor IX deficiency
1074035|NCT01687608|gene therapy
1074036|NCT01687595|herpes simplex virus type 2,
1074037|NCT01687595|genital herpes
1074038|NCT01687582|type 2 diabetes
1074039|NCT01687582|psoriasis
1074040|NCT01687582|exenatide
1074041|NCT01687582|liraglutide
1074042|NCT01687569|Glycaemic Response
1074043|NCT01687556|EGCG
1074044|NCT01687556|green tea
1074045|NCT01687543|Clostridium difficile
1074046|NCT01687543|WBC
1074047|NCT01687543|CRP
1074048|NCT01687543|Lactate
1074049|NCT01687543|Urea
1074050|NCT01687543|Creatinine
1074051|NCT01687517|sarcoidosis
1074052|NCT01687517|healthy volunteers
1074053|NCT01687504|pharmacokinetics
1074054|NCT01687504|children
1074055|NCT01687504|HIV
1074056|NCT01687504|Tuberculosis
1074057|NCT01687504|Pharmacogenetics
1074058|NCT01687491|Enoxaparin
1074059|NCT01687491|Acute Coronary Syndrome
1074060|NCT01687491|Factor X
1074061|NCT01687465|glaucoma
1074062|NCT01687465|laser
1074063|NCT01687465|SLT
1074064|NCT01687465|ALT
1074065|NCT01688648|Coronary artery bypass graft
1074066|NCT01688648|dexmedetomidine
1074067|NCT01688648|lidocaine
1074068|NCT01688648|myocardial injury
1074069|NCT01688648|arrhythmia
1074070|NCT01688648|blood electrolyte balance
1074071|NCT01688635|Volunteers
1074072|NCT01688596|Local
1074073|NCT01688596|Anesthesia
1074074|NCT01688596|Pain
1074075|NCT01688596|Laparoscopic hysterectomy
1074076|NCT01688596|Trocar site
1074077|NCT01688596|Port site
1074078|NCT01688583|Chronic pain
1074079|NCT01688583|Chronic non-cancer pain
1074080|NCT01688583|Fentanyl matrix
1074081|NCT01688583|Transdermal system
1074082|NCT01688570|neuromuscular fatigue
1074083|NCT01688570|motor impairment
1074084|NCT01688557|narrow band imaging
1074085|NCT01688557|dual focus
1074086|NCT01688557|responsive insertion technique
1074087|NCT01688557|scope guide
1074088|NCT01688557|colonoscopy
1074089|NCT01688557|colorectal cancer screening
1074090|NCT01688544|Ilaprazole
1074091|NCT01688544|Intragastric pH
1074092|NCT01688544|Serum Gastrin
1074093|NCT01688544|Pharmacokinetics
1074094|NCT01688518|Evaluation
1074095|NCT01688518|Depth and Duration
1074096|NCT01688518|Anesthesia
1074097|NCT01688505|cerebral small vessel diseases
1074098|NCT01688505|cognitive impairment
1074099|NCT01688505|Blood pressure variability
1074100|NCT01688492|MDX-010 (Ipilimumab)
1074101|NCT01688492|ABIRATERONE ACETATE (CB 7630)
1074102|NCT01688492|PREDNISONE
1074103|NCT01688492|Immunotherapy-naïve
1074104|NCT01688492|castration resistant prostate cancer (CRPC)
1074105|NCT01688492|12-120
1074106|NCT01688479|Postoperative radiotherapy
1074107|NCT01688479|breast cancer
1074108|NCT01688466|Immune Modulatory
1074109|NCT01688466|Systemic Absorption
1074110|NCT01688466|Oral Agent
1074111|NCT01688453|overweight/obesity
1074112|NCT01688453|adolescence
1074113|NCT01688453|care management
1074114|NCT01688440|Endotracheal Cares
1074115|NCT01688440|Neonate
1074116|NCT01688440|TAC's
1074117|NCT01688440|Endotracheal Suctioning
1074118|NCT01688440|Tracheal Aspirate Culture
1074119|NCT01688440|Oral Cares
1074120|NCT01688440|Neonate oxygen Therapy
1074121|NCT01688401|diffuse intrinsic pontine glioma (DIPG)
1074122|NCT01688401|intra-arterial chemotherapy
1074123|NCT01688401|angiography
1074124|NCT01688388|Breast Cancer
1074125|NCT01688388|Carcinoma
1074126|NCT01688388|Radiotherapy
1074127|NCT01688388|Intraoperative Radiotherapy
1074128|NCT01688388|IORT
1074129|NCT01688375|obstructive jaundice
1074130|NCT01688375|ursodeoxycholic acid
1074131|NCT01688362|Prospective Randomized Controlled Double Blinded Trial
1074132|NCT01688362|Rotator Cuff Tear
1074133|NCT01688362|Platelet Rich Plasma
1074134|NCT01688362|Corticosteroid
1074135|NCT01688362|Ultrasound
1074136|NCT01688349|Glucocorticoids
1074137|NCT01688349|adipose tissue
1074138|NCT01688349|Cushing
1074139|NCT01688349|lipodystrophy
1074140|NCT01688349|11 beta-HSD1
1074141|NCT01688336|Pancreatic
1074142|NCT01688336|Phase II
1074143|NCT01688336|FOLFIRINOX
1074144|NCT01688336|Unresectable
1074145|NCT01688336|Regimen
1074146|NCT01688336|First-line
1074147|NCT01688336|Resectable
1074148|NCT01688336|Borderline
1074149|NCT01688336|Oxaliplatin
1074150|NCT01688336|Leucovorin
1074151|NCT01688336|Irinotecan
1074152|NCT01688336|5FU
1074153|NCT01688336|Lineberger
1074154|NCT01688336|University of North Carolina
1074155|NCT01688323|Geriatrics
1074156|NCT01688323|Oncology
1074157|NCT01688323|Biological Markers
1074158|NCT01688323|Survey Instruments
1074159|NCT01688323|p16
1074160|NCT01688323|Geriatric Oncology
1074161|NCT01688323|Biological Markers of Aging
1074162|NCT01688323|Symptom Assessment
1074163|NCT01688323|Cancer
1074164|NCT01688323|Older Persons
1074165|NCT01688323|Head and Neck Cancer
1074166|NCT01688310|Gomco clamp instrument
1074167|NCT01688310|Tissue adhesive
1074168|NCT01688310|Open surgical circumcision
1074169|NCT01688310|Minimally-invasive circumcision
1074170|NCT01688297|Influenza
1074171|NCT01688297|H1N1
1074172|NCT01688297|flu
1074173|NCT01688297|seasonal
1074174|NCT01688284|uterine natural killer cells
1074175|NCT01688284|recurrent miscarriages
1074176|NCT01688284|alloimmunity
1074177|NCT01688271|simulation
1074178|NCT01688271|ultrasound
1074179|NCT01688271|perineural infusion
1074180|NCT01688271|continuous peripheral nerve block
1074181|NCT01688245|young adults
1074182|NCT01688245|alcohol consumption
1074183|NCT01688245|mobile health
1074184|NCT01688245|text message
1074185|NCT01688232|colorectal cancer
1074186|NCT01688232|tumor resection
1074187|NCT01688232|immunoscore
1074188|NCT01688232|lymphocytic density
1074189|NCT01688232|CD3
1074190|NCT01688232|CD8
1074191|NCT01688232|CD45RO
1074192|NCT01688232|biopsy
1074193|NCT01688232|genetic feature of the tumor
1074194|NCT01688232|relapse
1074195|NCT01688232|immunohistochemistry
1074196|NCT01688232|image analysis software
1074197|NCT01688219|SAPHO syndrome
1074198|NCT01688219|Innate immunity
1074199|NCT01688219|TNF alpha
1074200|NCT01688219|Polymorphonuclear neutrophils
1074201|NCT01688219|Propionibacterium acnes
1074202|NCT01688219|Interleukin-8
1074203|NCT01688180|bronchiectasis
1074204|NCT01688180|depression
1074205|NCT01688180|anxiety
1074206|NCT01688167|HIV
1074207|NCT01688167|Male circumcision
1074208|NCT01688167|Sexual risk reduction
1074209|NCT01688167|Stages of change
1074210|NCT01688141|CKD
1074211|NCT01688128|Mild cognitive impairment
1074212|NCT01688128|Cognitive rehabilitation
1074213|NCT01688128|Cognitive therapy
1074214|NCT01688128|Spaced retrieval Training
1074215|NCT01688128|Alzheimer's disease
1074216|NCT01688128|Memory enhancement
1074217|NCT01688128|U-healthcare
1074218|NCT01688089|volunteer
1074219|NCT01688089|study
1074220|NCT01688063|Skin Elasticity
1074221|NCT01688063|Scar Elasticity
1074222|NCT01688063|Cutometer
1074223|NCT01688063|Dermal Torque Meter
1074224|NCT01688050|Blunt thoracic aortic injury
1074225|NCT01688050|Transection
1074226|NCT01688050|Endovascular graft
1074227|NCT01688024|mitomycin C
1074228|NCT01688011|Myelodysplastic Syndromes
1074229|NCT01688011|MDS
1074230|NCT01688011|Acute Myeloid Leukemia
1074231|NCT01688011|AML
1074232|NCT01688011|Registry
1074233|NCT01688011|Connect®
1074234|NCT01687972|cesarean section
1074235|NCT01687972|insorb staples
1074236|NCT01687972|absorbable staples
1074237|NCT01687972|transverse skin incision
1074238|NCT01687959|cholelithiasis
1074239|NCT01687959|laparoscopic cholecystectomy
1074240|NCT01687959|endoscopic sphincterotomy
1074241|NCT01687959|choledocholithiasis
1074242|NCT01687946|Biology of Fibrosis
1074243|NCT01687933|Labor pain
1074244|NCT01687933|Virtual reality
1074245|NCT01687933|the first stage of labor
1074246|NCT01687933|Pain relief
1074247|NCT01687933|Simulator
1074248|NCT01687920|Cardiac disorders
1074249|NCT01687907|fear of childbirth
1074250|NCT01687907|outcome of delivery
1074251|NCT01687907|music
1074252|NCT01687907|mother-baby relationship
1074253|NCT01687894|cerebral oxygen saturation
1074254|NCT01687894|beach chair position
1074255|NCT01687894|hemodynamic
1074256|NCT01687894|jugular venous oximetry
1074257|NCT01687881|Chiropractic
1074258|NCT01687881|Manipulative therapy
1074259|NCT01687881|Cervicogenic headache
1074260|NCT01687855|Obstructive Sleep
1074261|NCT01687855|Apnoea
1074262|NCT01687855|tongue
1074263|NCT01687855|alteration
1074264|NCT01687829|Macular Holes
1074265|NCT01687829|Internal limiting membrane
1074266|NCT01687829|peeling
1074267|NCT01687829|Surgery
1074268|NCT01687816|Influenza-Like-Illness
1074269|NCT01687816|nasal swabs
1074270|NCT01687816|Detection of influenza
1074271|NCT01687816|sensitivity of detection assays
1074272|NCT01687803|Obesity
1074273|NCT01687803|Sedentary lifestyle
1074274|NCT01687803|Body weight
1074275|NCT01687803|Physical fitness
1074276|NCT01687790|molecular breast imaging
1074277|NCT01687790|breast disease
1074278|NCT01687790|breast biopsy
1074279|NCT01687777|Supraspinatus tendon
1074280|NCT01687777|Mesenchymal stem cells
1074281|NCT01687777|OrthADAPT
1074282|NCT01687777|Rotator cuff
1074283|NCT01687764|Generalized Anxiety Disorder (GAD)
1074284|NCT01687764|Separation Anxiety Disorder (SeAD)
1074285|NCT01687764|Social Anxiety Disorder (SoAD)
1074286|NCT01687751|feasibility studies
1074287|NCT01687751|conscious sedation/
1074288|NCT01687751|dexmedetomidine/
1074289|NCT01687751|midazolam/
1074290|NCT01687751|infusions, subcutaneous/
1074291|NCT01687751|palliative care/
1074292|NCT01687751|terminal care/
1074293|NCT01687751|terminally ill/
1074294|NCT01687751|neoplasms/
1074295|NCT01687751|treatment outcome
1074296|NCT01687751|Precedex
1074297|NCT01687751|"end of life"
1074298|NCT01687751|Dying
1074299|NCT01687751|Advanced cancer
1074300|NCT01687751|mood/delirium/delirious
1074301|NCT01687738|non small cell lung cancer
1074302|NCT01687738|health disparities
1074303|NCT01687712|IVF
1074304|NCT01687712|In vitro fertilization
1074305|NCT01687712|Controlled ovarian stimulation
1074306|NCT01687712|Follitropin
1074307|NCT01687712|AFOLIA
1074308|NCT01687712|Finox
1074309|NCT01687374|proximal humeral fracture
1074310|NCT01687335|chemotherapy
1074311|NCT01687322|quality of life
1074312|NCT01687322|functioning
1074313|NCT01687296|PEF
1074314|NCT01687296|inhaled
1074315|NCT01687296|Fluticasone Propionate
1074316|NCT01687296|safety
1074317|NCT01687296|prednisone
1074318|NCT01687296|acute exacerbation
1074319|NCT01687296|asthma
1074320|NCT01687296|efficacy
1074321|NCT01687283|fluticasone propionate inhalation solution
1074322|NCT01687283|budesonide suspension for inhalation
1074323|NCT01687283|efficacy
1074324|NCT01687283|severe persistent asthma
1074325|NCT01687283|pharmacokinetics
1074326|NCT01687283|safety
1074327|NCT01687244|BCG Refractory or Relapsed Superficial Bladder Cancer
1074328|NCT01687244|rAd-IFN
1074329|NCT01687244|Syn3
1074330|NCT01687244|Intravesical
1074331|NCT01687244|transitional cell carcinoma of the bladder
1074332|NCT01687244|superficial non-muscle invasive tumor
1074333|NCT01687244|Interferon alpha2b
1074334|NCT01687244|INSTILADRIN
1074335|NCT01687231|Neutropenic Diet, Non-Neutropenic Diet, Allogeneic SCT
1074336|NCT01687192|Seroconversion
1074337|NCT01687192|Immunosuppressed treatment
1074338|NCT01687192|HPV vaccination
1074339|NCT01687192|Immunogenicity
1074340|NCT01687179|LAM
1074341|NCT01687179|TSC
1074342|NCT01687179|lymphangioleiomyomatosis
1074343|NCT01687166|Paroxysmal Atrial Fibrillation
1074344|NCT01687166|Cardiac Arrhythmias
1074345|NCT01687166|Heart Disease
1074346|NCT01687166|Cardiovascular Disease
1074347|NCT01687166|Radiofrequency Ablation
1074348|NCT01687153|traumatic brain injury (TBI)
1074349|NCT01687153|post traumatic stress disorder (PTSD)
1074350|NCT01687153|Alzheimer's disease (AD)
1074351|NCT01687153|mild cognitive impairment (MCI)
1074352|NCT01687153|dementia
1074353|NCT01687153|biomarkers
1074354|NCT01687153|amyloid
1074355|NCT01687153|neuroimaging
1074356|NCT01687153|cognition disorder
1074357|NCT01687153|tau
1074358|NCT01687127|folic acid
1074359|NCT01687127|folate
1074360|NCT01687127|5-methyltetrahydrofolate
1074361|NCT01687127|supplements
1074362|NCT01687127|women
1074363|NCT01687127|one-carbon metabolism
1074364|NCT01687127|methionine
1074365|NCT01687127|DNA methylation
1074366|NCT01687127|in vivo kinetics
1074367|NCT01687114|compliance, proanthocyanidin, phenoic acids, cranberry
1074368|NCT01687101|acute migraine
1074369|NCT01687101|acute migraine treatment
1074370|NCT01687101|topical treatment
1074371|NCT01687075|coronary angioplasty
1074372|NCT01687075|de novo lesion
1074373|NCT01687062|NaFeEDTA
1074374|NCT01687062|phytate
1074375|NCT01687062|injera
1074376|NCT01687062|iron absorption
1074377|NCT01687049|nonmetastatic
1074378|NCT01687049|localized
1074379|NCT01687049|prostate
1074380|NCT01687049|active surveillance
1074381|NCT01687036|Atrial fibrillation
1074382|NCT01687036|Cryoablation
1074383|NCT01687023|Tai Chi
1074384|NCT01687023|Wearable sensors
1074385|NCT01687023|Movement
1074386|NCT01687010|CRP, PCT, IL-6, Diagnosis, Prediction
1074387|NCT01686997|Bariatric surgery
1074388|NCT01686997|Roux-en-Y Gastric Bypass
1074389|NCT01686958|Prostate Cancer
1074390|NCT01686958|High intensity transurethral ultrasound ablation
1074391|NCT01686958|MRI-guided
1074392|NCT01686958|Minimally invasive
1074393|NCT01686958|Real-time temperature feedback control
1074394|NCT01686932|vildagliptin
1074395|NCT01686932|sitagliptin
1074396|NCT01686932|continuous glucose monitoring (CGM)
1074397|NCT01686932|glycemic fluctuations
1074398|NCT01686932|MAGE
1074399|NCT01686932|impact of hypoglycemia on heart function (cardiac dysfuction measured via ECG)
1074400|NCT01686932|difference in glycemic profile of vildagliptin compared to sitagliptin
1074401|NCT01686919|Gastric bypass
1074402|NCT01686919|Questionnaires
1074403|NCT01686919|Diet
1074404|NCT01686919|Milk
1074405|NCT01686906|Keratoconus
1074406|NCT01686906|Bowman layer
1074407|NCT01686893|Oxygen, Insufflation, COPD, High Flow Treatment
1074408|NCT01686880|Hepatocellular Carcinoma
1074409|NCT01686880|Liver Cirrhosis
1074410|NCT01686880|radioembolization
1074411|NCT01686880|SIRT
1074412|NCT01686880|TARE
1074413|NCT01686880|Sirspheres
1074414|NCT01686880|neoadjuvant
1074415|NCT01686880|liver cancer
1074416|NCT01686867|improved cookstove
1074417|NCT01686867|ventilated cookstove
1074418|NCT01686867|behavior change
1074419|NCT01686867|adoption
1074420|NCT01686867|indoor air pollution
1074421|NCT01686867|DLCO
1074422|NCT01686867|spirometry
1074423|NCT01686867|biomass fuel
1074424|NCT01686854|cognitive-behavioral approach
1074425|NCT01686854|obesity treatment
1074429|NCT01686828|insulin
1074430|NCT01686828|androgens
1074431|NCT01686828|insulin resistance
1074432|NCT01686828|testosterone
1074433|NCT01686828|estradiol
1074434|NCT01686828|obesity
1074435|NCT01686815|metabolic side effects
1074436|NCT01686815|atypical antipsychotics
1074437|NCT01686815|FSIVGTT
1074438|NCT01686802|oral morphine
1074439|NCT01686802|ibuprofen
1074440|NCT01686802|post-operative pain
1074441|NCT01686776|Plasma albumine
1074442|NCT01686776|Plasma volume
1074443|NCT01686776|Transcapillary escape rate
1074444|NCT01686776|Inflammation
1074445|NCT01686776|Circulation
1074446|NCT01686750|HIV
1074447|NCT01686750|injection drug use
1074448|NCT01686750|men who have sex with men
1074449|NCT01686750|voluntary counselling and testing
1074450|NCT01686750|risk reduction
1074451|NCT01686750|sexually transmitted infections
1074452|NCT01686750|community viral load
1074453|NCT01686750|antiretroviral therapy
1074454|NCT01686724|Attention Deficit Hyperactivity Disorder
1074455|NCT01686724|Psychosocial Intervention
1074456|NCT01686724|Behavioral Intervention
1074457|NCT01686724|School-home collaborative intervention
1074458|NCT01686698|cirrhosis, VSL#3, cognitive function, falls, quality of life
1074459|NCT01686685|ASD
1074460|NCT01686685|autism
1074461|NCT01686685|prematurity
1074462|NCT01686685|oxygen-dependant gene activation
1074463|NCT01686685|CXCR4
1074464|NCT01686685|Language delay
1074465|NCT01686685|Cognitive delay
1074466|NCT01686672|Cystic Fibrosis
1074467|NCT01686672|Behavioral Intervention
1074468|NCT01686672|Children
1074469|NCT01686659|Transfusion
1074470|NCT01686659|Continuous Hemoglobin Monitoring
1074471|NCT01686659|SpHb
1074472|NCT01686646|alertness
1074473|NCT01686633|asthma
1074474|NCT01686633|pharmacogenetics
1074475|NCT01686633|adult
1074476|NCT01686633|vilanterol
1074477|NCT01686633|adolescents
1074478|NCT01686633|fluticasone furoate
1074479|NCT01686620|Mealtime insulin
1074480|NCT01686620|Ultra-rapid acting insulin
1074481|NCT01686620|Prandial insulin
1074482|NCT01686607|Hepatic toxicity
1074483|NCT01686607|Renal toxicity
1074484|NCT01686607|Micafungin
1074485|NCT01686607|Hepatocellular carcinoma
1074614|NCT01685983|JNJ-212082
1074486|NCT01686607|Antifungals (parenteral)
1074487|NCT01686594|Mycosis fungoides
1074488|NCT01686594|Psoralen and UVA (PUVA)
1074489|NCT01686594|Photochemotherapy
1074490|NCT01686594|Maintenance treatment
1074491|NCT01686594|Immune function
1074492|NCT01686542|atrial fibrillation
1074493|NCT01686529|Pterygium
1074494|NCT01686529|bevacizumab
1074495|NCT01686529|autoconjunctival graft
1074496|NCT01686516|age
1074497|NCT01686516|microstructure
1074498|NCT01686516|diffusion MRI
1074499|NCT01686490|AICD
1074500|NCT01686490|focus groups
1074501|NCT01686490|cognitive-behavioral video/workbook training
1074502|NCT01686490|pre-implant concern/distress about upcoming AICD
1074503|NCT01686464|magnetic
1074504|NCT01686464|oxygen
1074505|NCT01686464|Bell's Palsy
1074506|NCT01686464|acupuncture
1074507|NCT01686438|cost effectiveness
1074508|NCT01686438|patient satisfaction
1074509|NCT01686425|Cholestasis
1074510|NCT01686425|Malignancy
1074511|NCT01686425|ERCP
1074512|NCT01686425|PTC
1074513|NCT01686425|EUS-BD
1074514|NCT01686412|Breast Cancer
1074515|NCT01686412|Hepatocellular carcinoma
1074516|NCT01686399|Sustainable diet
1074517|NCT01686399|Health promotion
1074518|NCT01686399|Obesity
1074519|NCT01686386|Relapsed
1074520|NCT01686386|Multiple Myeloma
1074521|NCT01686386|Lenalidomide
1074522|NCT01686386|Bendamustine
1074523|NCT01686373|Aphasia
1074524|NCT01686373|Brain
1074525|NCT01686373|Stimulation
1074526|NCT01686373|Communication
1074527|NCT01686373|Stoke
1074528|NCT01686373|Post
1074529|NCT01686373|Phase II Clinical Trial
1074530|NCT01686373|Treatment
1074531|NCT01686373|tDCS
1074532|NCT01686373|Fridriksson
1074533|NCT01686347|epidural analgesia
1074534|NCT01686347|fetal cardiac rythm
1074535|NCT01686347|ropivacaine
1074536|NCT01686347|sufentanil
1074537|NCT01686334|in complete remission
1074538|NCT01686334|Adult (>18 years) at very high risk of relapse
1074539|NCT01686321|elderly patients
1074540|NCT01686321|bendamustine
1074541|NCT01686308|cataract
1074542|NCT01686308|circadian rhythm
1074543|NCT01686308|pupillometry
1074544|NCT01686308|blue light transmission
1074545|NCT01686308|questionnaire
1074546|NCT01686308|sleep
1074547|NCT01686295|androgenetic alopecia
1074548|NCT01686295|Baldness
1074549|NCT01686282|Blood pressure
1074550|NCT01686282|Arterial Stiffness
1074551|NCT01686282|Blueberry Supplementation
1074552|NCT01686282|Aortic Blood Pressure
1074553|NCT01686282|Hypertension
1074554|NCT01686282|Postmenopausal
1074555|NCT01686282|Pulse Wave Velocity
1074556|NCT01686269|Endothelial progenitor cell
1074557|NCT01686269|coronary artery bypass
1074558|NCT01686256|Ovarian Cancer
1074559|NCT01686256|Endometrial Cancer
1074560|NCT01686243|epidural
1074561|NCT01686230|acupuncture
1074562|NCT01686230|Angina
1074563|NCT01686230|Stable Angina Pectoris
1074564|NCT01686217|ASP015K Extended Release
1074565|NCT01686217|ASP015K Immediate Release
1074566|NCT01686217|Food Effect
1074567|NCT01686217|Healthy Volunteers
1074568|NCT01686204|Yogurt
1074569|NCT01686204|Intestine
1074570|NCT01686204|Inflammation
1074571|NCT01686204|Obese
1074572|NCT01686191|heart transplantation
1074573|NCT01686191|chronic renal insufficiency
1074574|NCT01686191|pharmacogenomics
1074575|NCT01686191|cyclosporine
1074576|NCT01686191|tacrolimus
1074577|NCT01686178|Smoking
1074578|NCT01686178|Smoking Cessation
1074579|NCT01686178|Tobacco Use Cessation
1074580|NCT01686178|Social Networks
1074581|NCT01686178|Social Control, Informal
1074582|NCT01686139|Diabetic mellitus
1074583|NCT01686139|Diabetic foot ulcers
1074584|NCT01686139|Ischemic Limb
1074585|NCT01686126|endometrial hyperplasia
1074586|NCT01686126|endometrial adenocarcinoma
1074587|NCT01686126|Gynecological Cancer
1074588|NCT01686113|Taste
1074589|NCT01686113|Fat Taste
1074590|NCT01686113|Threshold Testing
1074591|NCT01686100|Coronary artery bypass grafting
1074592|NCT01686100|Saphenous vein grafts
1074593|NCT01686074|Motor control
1074594|NCT01686074|walking
1074595|NCT01686074|physical activity
1074596|NCT01686074|Muscle activity
1074597|NCT01686022|Grass
1074598|NCT01686022|Major allergen
1074599|NCT01686022|cross-reactivity
1074600|NCT01686009|pain
1074601|NCT01686009|analgesia
1074602|NCT01686009|ketamine
1074603|NCT01686009|intranasal
1074604|NCT01686009|emergency
1074605|NCT01685996|tobacco
1074606|NCT01685996|smoking cessation
1074607|NCT01685996|nicotine
1074608|NCT01685996|cigarettes
1074609|NCT01685996|nicotine withdrawal
1074610|NCT01685983|Prostate Cancer
1074611|NCT01685983|Metastatic-castration resistant prostate cancer
1074612|NCT01685983|Prostate specific antigen
1074613|NCT01685983|Abiraterone acetate
1074615|NCT01685983|Abiraterone
1074616|NCT01685983|Prednisolone
1074617|NCT01685983|Androgen Deprivation
1074618|NCT01685983|Docetaxel-based chemotherapy
1074619|NCT01685970|Bowel preparation
1074620|NCT01685970|colonoscopy
1074621|NCT01685970|polyethylene glycol
1074622|NCT01685970|picosulfate
1074623|NCT01685957|Weight loss
1074624|NCT01685957|Dietary intervention
1074625|NCT01685957|Self-help book
1074626|NCT01685957|Cooking
1074627|NCT01685957|Dietitian
1074628|NCT01685957|Dietary therapy
1074629|NCT01685931|Schizophrenia
1074630|NCT01685931|Paliperidone Palmitate
1074631|NCT01685931|Oral Antipsychotics
1074632|NCT01685931|Invega Sustenna
1074633|NCT01685918|Rheumatoid arthritis
1074634|NCT01685918|aged
1074635|NCT01685905|rheumatic disease, latent tuberculosis
1074636|NCT01685879|postprandial glycemic response
1074637|NCT01685879|postprandial insulin response
1074638|NCT01685879|rice
1074639|NCT01685879|appetite
1074640|NCT01685879|hunger
1074641|NCT01685866|anesthesia
1074642|NCT01685866|venous access
1074643|NCT01685840|Heart Failure
1074644|NCT01685814|multiple myeloma
1074645|NCT01685814|autologous stem cell transplant
1074646|NCT01685814|allogeneic stem cell transplant
1074647|NCT01685814|lenalidomide
1074648|NCT01685814|bortezomib
1074649|NCT01685775|Gallbladder
1074650|NCT01685775|cholecystectomy
1074651|NCT01685775|NOTES
1074652|NCT01685775|natural orifice transluminal endoscopic surgery
1074653|NCT01685775|gallstone
1074654|NCT01685762|Endometrial hyperplasia
1074655|NCT01685762|Uterus
1074656|NCT01685762|Pilot
1074657|NCT01685762|Metformin
1074658|NCT01685723|Cancer patients
1074659|NCT01685723|Smoking cessation
1074660|NCT01685723|Risk communication
1074661|NCT01685710|Arteriovenous fistula
1074662|NCT01685710|Patency
1074663|NCT01685710|GTN patch
1074664|NCT01685684|Low back pain
1074665|NCT01685684|Chronic back pain
1074666|NCT01685684|Back pain
1074667|NCT01685684|Opioid
1074668|NCT01685684|Oxycodone
1074669|NCT01685684|DETERx
1074670|NCT01685684|Chronic pain
1074671|NCT01685684|Chronic low back pain
1074672|NCT01685684|CLBP
1074673|NCT01685684|Xtampza
1074674|NCT01685671|CKD-11101
1074675|NCT01685671|NESP
1074676|NCT01685671|Darbepoetin alfa
1074677|NCT01685671|Anemia
1074678|NCT01685671|subcutaneous
1074679|NCT01685671|Pharmacokinetics
1074680|NCT01685671|Phase 1
1074681|NCT01685632|intra peritonal chemo hyperthermia
1074682|NCT01685632|peritoneal carcinomatosis
1074683|NCT01685632|colorectal cancer
1074684|NCT01685632|ovarian cancer
1074685|NCT01685619|AML
1074686|NCT01685619|Acute Myeloid Leukemia
1074687|NCT01685619|MDS
1074688|NCT01685619|Myelodysplastic Syndrome
1074689|NCT01685619|Prognostic
1074690|NCT01685619|Economic
1074691|NCT01685606|Leukemia
1074692|NCT01685606|Lymphoma
1074693|NCT01685606|Mantle cell
1074694|NCT01685606|DLBCL
1074695|NCT01685606|DLBC
1074696|NCT01685606|Diffuse large B cell
1074697|NCT01685606|T cell
1074698|NCT01685606|AML
1074699|NCT01685606|ALL
1074700|NCT01685593|abdominal binder
1074701|NCT01685580|primary lung cancer
1074702|NCT01685580|lobectomy
1074703|NCT01685580|pneumonectomy
1074704|NCT01685580|non-invasive ventilation
1074705|NCT01685567|carotid artery disease
1074706|NCT01685567|reverse flow
1074707|NCT01685554|perfusion
1074708|NCT01685554|cardiopulmonary bypass
1074709|NCT01685554|hypothermia
1074710|NCT01685554|cerebral oxygenation
1074711|NCT01685528|Anxiety
1074712|NCT01685528|Depression
1074713|NCT01685528|Geriatric
1074714|NCT01685528|Veteran
1074715|NCT01685502|Glucobay OD
1074716|NCT01685502|Diabetes Mellitus
1074717|NCT01685489|Prostate
1074718|NCT01685489|Neoplasm
1074719|NCT01685489|Adenocarcinoma
1074720|NCT01685489|Cancer
1074721|NCT01685489|Metastatic
1074722|NCT01685489|Castrate resistant
1074723|NCT01685489|Docetaxel
1074724|NCT01685489|PSK
1074725|NCT01685489|Krestin
1074726|NCT01685489|Trametes versicolor
1074727|NCT01685489|Safety
1074728|NCT01685489|Maximum tolerated dose
1074729|NCT01685489|Mushroom
1074730|NCT01685489|Natural
1074731|NCT01685489|Immunotherapy
1074732|NCT01685476|Cochlear microphonic potential
1074733|NCT01685476|non invasive method
1074734|NCT01685476|indirect monitoring
1074735|NCT01685476|intracranial pressure
1074736|NCT01685463|methamphetamine, craving, TMS, cortical excitability, prefrontal cortex
1074737|NCT01685450|Cochlear microphonic potential
1074738|NCT01685450|non invasive method
1074739|NCT01685450|indirect measurement
1074740|NCT01685450|intracranial pressure
1074741|NCT01685450|adults
1074742|NCT01685437|Peyronie's disease, penile plaque, penile curvature
1074743|NCT01685424|Etoricoxib
1074744|NCT01685424|ARCOXIA
1074745|NCT01685424|Osteoarthritis
1074746|NCT01685424|Rheumatoid Arthritis
1074747|NCT01685424|Ankylosing Spondylitis
1074748|NCT01685424|Gout
1074749|NCT01685424|Arthritis
1074750|NCT01685385|Dyspnoea
1074751|NCT01685385|BNP
1074752|NCT01685385|Chronic heart failure
1074753|NCT01685385|congestive heart failure
1074754|NCT01685346|advanced (stage IV) non-small cell lung cancer (NSCLC)
1074755|NCT01685346|biofeedback-mediated stress management (BFSM)
1074756|NCT01685333|subject
1074757|NCT01685320|Force
1074758|NCT01685320|Pressure
1074759|NCT01685320|Intubation
1074760|NCT01685320|laryngoscopy
1074761|NCT01685307|ileal digestibility
1074762|NCT01685307|metabolism
1074763|NCT01685307|stable isotopes
1074764|NCT01685294|Major Depressive Disorder (MDD)
1074765|NCT01685294|Suicidality
1074766|NCT01685294|Incarcerated Populations
1074767|NCT01685294|Prisons
1074768|NCT01685294|Interpersonal Psychotherapy (IPT)
1074769|NCT01685281|ADHD , Inattention
1074770|NCT01685268|Prostate Cancer
1074771|NCT01685255|FIGO Stage III or IV EOC
1074772|NCT01685255|PPC FTC
1074773|NCT01685255|increasing CA 125
1074774|NCT01685216|VPRIV
1074775|NCT01685216|velaglucerase alfa
1074776|NCT01685203|Hepatitis C Virus
1074777|NCT01685203|Ribavirin-Free
1074778|NCT01685203|Hepatitis C Genotype 1
1074779|NCT01685203|Hepatitis C
1074780|NCT01685203|Interferon-Free
1074781|NCT01685203|Chronic Hepatitis C
1074782|NCT01685203|Compensated cirrhosis
1074783|NCT01685203|Hepatitis C Genotype 4
1074784|NCT01685203|Paritaprevir
1074785|NCT01685203|Ombitasvir
1074786|NCT01685203|Ritonavir
1074787|NCT01685203|Ribavirin
1074788|NCT01685177|Morbid obesity
1074789|NCT01685177|Sleeve gastrectomy
1074790|NCT01685177|Duodenal Switch
1074791|NCT01685177|SADI-S
1074792|NCT01685164|nulliparous
1074793|NCT01685164|IUD
1074794|NCT01685164|IUS
1074795|NCT01685164|insertion
1074796|NCT01685164|expulsion
1074797|NCT01685151|Drug therapy
1074798|NCT01685138|Non-Small Cell Lung Cancer, ALK, LDK378
1074799|NCT01685112|adults
1074800|NCT01685112|ECMO
1074801|NCT01685099|diagnosis, inflammation-associated markers, pleural effusion, tuberculosis, tuberculous pleurisy
1074802|NCT01685086|latent tuberculosis infection, tuberculosis, chronic kidney disease, peritoneal dialysis, hemodialysis
1074803|NCT01685073|marijuana
1074804|NCT01685073|cannabis
1074805|NCT01685073|treatment
1074806|NCT01685073|insomnia
1074807|NCT01685073|relapse
1074808|NCT01685060|Non-Small Cell Lung Cancer
1074809|NCT01685060|NSCLC
1074810|NCT01685060|ALK
1074811|NCT01685060|LDK378
1074812|NCT01685060|Ceritinib
1074813|NCT01685047|Coronary Artery Disease
1074814|NCT01685047|Ventricular Arrhythmias
1074815|NCT01685047|ST Segment Changes
1074816|NCT01685034|Eosinophilic esophagitis
1074817|NCT01685034|Environmental allergens
1074818|NCT01685034|Allergy immunotherapy
1074819|NCT01685034|Tolerance
1074820|NCT01685034|Allergic rhinitis
1074821|NCT01685034|Asthma
1074822|NCT01685034|Seasonal variation
1074823|NCT01685021|B-ALL
1074824|NCT01685021|CD19
1074825|NCT01685021|MOR208
1074826|NCT01685021|MOR00208
1074827|NCT01685021|Xmab5574
1074828|NCT01685021|B-cell acute lymphoblastic leukemia
1074829|NCT01685021|Fc-optimized Anti-CD19 Antibody
1074830|NCT01685008|NHL
1074831|NCT01685008|CD19
1074832|NCT01685008|MOR208
1074833|NCT01685008|MOR00208
1074834|NCT01685008|Xmab5574
1074835|NCT01685008|B-Cell Non-Hodgkin´s Lymphoma
1074836|NCT01685008|Fc-optimized Anti-CD19 Antibody
1074837|NCT01684982|Primary PCI
1074838|NCT01684982|Drug Eluting Stent
1074839|NCT01684969|Nausea
1074840|NCT01684969|vomiting
1074841|NCT01684969|gastrointestinal symptoms
1074842|NCT01684969|palliative care
1074843|NCT01684956|intradermal
1074844|NCT01684956|pharmacokinetics
1074845|NCT01684956|microneedle
1074846|NCT01684956|insulin
1074847|NCT01684956|glucagon
1074848|NCT01684943|Pharmacokinetics
1074849|NCT01684930|Cardiovascular Diseases
1074850|NCT01684930|Vascular Diseases
1074851|NCT01684930|Arterial Occlusive Diseases
1074852|NCT01684930|Exercise
1074853|NCT01684930|Functional Capacity
1074854|NCT01684852|dry eye, sicca, HA, Hyaluronic Acid, ectoin, ectoine, bitop
1074855|NCT01684839|Painful digital neuroma
1074856|NCT01684839|nerve defect
1074857|NCT01684839|dorsal branch of the digital nerve
1074858|NCT01684839|digital nerve
1074859|NCT01684839|pedicled nerve flap
1074860|NCT01684839|Pain Disorder Associated with Psychological and Physical Factors
1074861|NCT01684826|X-rays
1074862|NCT01684826|Image processing
1074863|NCT01684826|Cardiovascular procedure
1074864|NCT01684813|Diabetes mellitus.
1074865|NCT01684813|Acute coronary syndrome.
1074866|NCT01684813|Percutaneous coronary intervention.
1074867|NCT01684787|chronic hepatitis C
1074868|NCT01684787|normal ALT
1074869|NCT01684787|HIV/HCV patients
1074870|NCT01684761|Multicenter Study
1074871|NCT01684761|Randomized Controlled Trial
1074872|NCT01684761|Individualized Medicine
1074873|NCT01684761|Immunotherapy
1074874|NCT01684761|Myelin Proteins
1074875|NCT01684761|Biological Agents
1074876|NCT01684748|angiotensin II
1074877|NCT01684748|obesity
1074878|NCT01684748|diabetes
1074879|NCT01684735|diffusion-weighted magnetic resonance imaging
1074880|NCT01684722|vitamin D3
1074881|NCT01684722|omega-3 fatty acids
1074882|NCT01684722|fish oil
1074883|NCT01684722|diabetes
1074884|NCT01684722|kidney disease
1074885|NCT01684722|albuminuria
1074886|NCT01684722|urine albumin excretion
1074887|NCT01684722|glomerular filtration rate
1074888|NCT01684722|diabetic kidney disease
1074889|NCT01684709|Type 2 Diabetes
1074890|NCT01684709|Informal Caregivers
1074891|NCT01684709|Self Care
1074892|NCT01684709|Quality of Life
1074893|NCT01684709|Health Information Technology
1074894|NCT01684696|Lung cancer
1074895|NCT01684696|stigma
1074896|NCT01684696|virtual intervention
1074897|NCT01684696|mHealth
1074898|NCT01684683|Bronchiectasis
1074899|NCT01684683|Theophylline
1074900|NCT01684683|Therapeutic Uses
1074901|NCT01684683|HDAC
1074902|NCT01684683|HAT
1074903|NCT01684683|Random placebo study
1074904|NCT01684657|Stuttering
1074905|NCT01684644|ADHD
1074906|NCT01684644|Parent Training
1074907|NCT01684644|RCT
1074908|NCT01684644|Preschool
1074909|NCT01684618|Preterm
1074910|NCT01684618|Neonate
1074911|NCT01684618|Newborn
1074912|NCT01684618|Cerebral oxygenation
1074913|NCT01684618|CPAP
1074914|NCT01684605|CKD-11101
1074915|NCT01684605|NESP
1074916|NCT01684605|Darbepoetin alfa
1074917|NCT01684605|Anemia
1074918|NCT01684605|intravenous
1074919|NCT01684605|Pharmacokinetics
1074920|NCT01684605|Phase 1
1074921|NCT01684592|smoking cessation
1074922|NCT01684592|relapse prevention
1074923|NCT01684592|pregnancy
1074924|NCT01684592|postpartum
1074925|NCT01684579|Breast Cancer
1074926|NCT01684579|African-American Women
1074927|NCT01684579|Aerobic Exercise
1074928|NCT01684553|Eating speed
1074929|NCT01684553|energy intake
1074930|NCT01684540|sinusitis, rhinosinusitis, ectoin, ectoine, bitop, SNS, SNS01
1074931|NCT01684514|confocal laser endomicroscopy
1074932|NCT01684514|inflammatory bowel disease
1074933|NCT01684514|colitis, ulcerative
1074934|NCT01684501|prosthesis
1074935|NCT01684501|amputees
1074936|NCT01684501|gait
1074937|NCT01684488|Depression/therapy;
1074938|NCT01684488|Developing Countries;
1074939|NCT01684488|Interpersonal Relations;
1074940|NCT01684488|Life Change Events;
1074941|NCT01684488|Psychotherapy, Group;
1074942|NCT01684488|Resilience, Psychological;
1074943|NCT01684488|Sierra Leone;
1074944|NCT01684488|Survivors/psychology;
1074945|NCT01684488|Social Adjustment;
1074946|NCT01684488|Social Behavior;
1074947|NCT01684488|War
1074948|NCT01684475|Novel Treatment Parkinson's disease
1074949|NCT01684462|Acute Ischemic Stroke
1074950|NCT01684462|Albumin
1074951|NCT01684449|Soft tissue sarcoma
1074952|NCT01684449|Gemcitabine
1074953|NCT01684449|Rapamycin
1074954|NCT01684449|Sirolimus
1074955|NCT01684449|mTOR inhibitor
1074956|NCT01684449|Molecular biomarkers
1074957|NCT01684410|Cystic Fibrosis
1074958|NCT01684410|Alpha1-proteinase inhibitor
1074959|NCT01684410|Alpha1-antitrypsin
1074960|NCT01684384|Pulmonary Disease, Chronic Obstructive
1074961|NCT01684384|COPD
1074962|NCT01684384|Exacerbation
1074963|NCT01684384|Functional Respiratory Imaging
1074964|NCT01684384|High Resolution Computed Tomography
1074965|NCT01684384|HRCT scan
1074966|NCT01684384|Patient Reported Outcome
1074967|NCT01684384|PRO
1074968|NCT01684384|Computational Fluid Dynamic
1074969|NCT01684384|CFD
1074970|NCT01684384|Lung function parameters
1074971|NCT01684371|Osteoarthritis
1074972|NCT01684371|Osteoarthritic pain
1074973|NCT01684371|Arthritic pain
1074974|NCT01684371|Arthritis
1074975|NCT01684371|joint inflammation
1074976|NCT01684371|Arthralgia
1074977|NCT01684358|Prostate-specific antigen
1074978|NCT01684358|Contraceptive implant
1074979|NCT01684358|Biological marker
1074980|NCT01684358|Condoms
1074981|NCT01684358|Women
1074982|NCT01684345|Uveitis
1074983|NCT01684345|Non-infectious Uveitis
1074984|NCT01684345|Intermediate Uveitis
1074985|NCT01684345|Posterior Uveitis
1074986|NCT01684345|Panuveitis
1074987|NCT01684332|Antioxidant
1074988|NCT01684332|glucose metabolism
1074989|NCT01684332|jam
1074990|NCT01684332|polyphenols
1074991|NCT01684332|postprandial
1074992|NCT01684332|strawberry
1074993|NCT01684319|Constipation
1074994|NCT01684319|Gastroeosphageal reflux
1074995|NCT01684319|Colics
1075121|NCT01682824|UE
1074996|NCT01684306|RsfMRI, brain plasticity, cognitive enhancer
1074997|NCT01684293|Cocaine
1074998|NCT01684293|Cognitive Impairment
1074999|NCT01684293|Cognitive Rehabilitation
1075000|NCT01684280|abdominal adipose tissue; microRNA
1075001|NCT01684267|Stroke
1075002|NCT01684267|Gait
1075003|NCT01684267|Rehabilitation
1075004|NCT01684254|Cerebral Palsy
1075005|NCT01684254|Home monitoring
1075006|NCT01684254|Gait
1075007|NCT01684254|Sensorized Shoe
1075008|NCT01684241|Biontech
1075009|NCT01684241|Biontech RNA Pharmaceuticals GmbH
1075010|NCT01684241|Biontech RNA
1075011|NCT01684241|MERIT
1075012|NCT01684241|RNA
1075013|NCT01684241|Immuno Therapy
1075014|NCT01684241|RB_0001-01
1075015|NCT01684241|Ribological
1075016|NCT01684241|Melanoma
1075017|NCT01684241|RBL001
1075018|NCT01684241|RBL002
1075019|NCT01684241|cancer vaccine
1075020|NCT01684228|End stage renal disease
1075021|NCT01684228|hemodialysis
1075022|NCT01684228|breath test
1075023|NCT01684228|volatile organic compound
1075024|NCT01684228|dialysis adequacy
1075025|NCT01684215|Phase 1/2
1075026|NCT01684215|PD-0332991
1075027|NCT01684215|palbociclib
1075028|NCT01684215|Cyclin Dependent Kinase 4/6 inhibitor
1075029|NCT01684215|Japanese
1075030|NCT01684215|solid tumors
1075031|NCT01684215|breast cancer
1075032|NCT01684215|A5481010
1075033|NCT01684176|Stroke
1075034|NCT01684176|Ischemic Attack, Transient
1075035|NCT01684176|Medication adherence
1075036|NCT01684176|Motivational interviewing
1075037|NCT01684176|Stroke prevention
1075038|NCT01684163|depression
1075039|NCT01684163|MDD
1075040|NCT01684163|GLYX-13
1075041|NCT01684163|HDRS-17
1075042|NCT01684163|HAMD-17
1075043|NCT01684150|Leukemia
1075044|NCT01684150|Advanced hematologic malignancies
1075045|NCT01684150|Epizyme
1075046|NCT01684150|Phase 1
1075047|NCT01684150|Mixed Lineage Leukemia (MLL)
1075048|NCT01684137|Food supplements
1075049|NCT01684137|Asthma bronchiale
1075050|NCT01684124|oxygen
1075051|NCT01684124|critical illness
1075052|NCT01684124|mechanical ventilation
1075053|NCT01684111|Non Small Cell Lung Cancer - Stage IV
1075054|NCT01684111|NSCLC Stage IV
1075055|NCT01684098|recurrent or metastatic cancer
1075056|NCT01684098|head and neck cancer
1075057|NCT01684098|pancreas cancer
1075058|NCT01684098|bladder cancer
1075059|NCT01684098|testicular cancer
1075060|NCT01684085|sleep deprivation, PTSD,prevention
1075061|NCT01684072|varicella vaccine
1075062|NCT01684072|gelatin
1075063|NCT01684046|multi-purpose solution
1075064|NCT01684046|silicone hydrogel
1075065|NCT01684046|contact lenses
1075066|NCT01684046|comfort
1075067|NCT01684046|Opti-Free
1075068|NCT01684046|RevitaLens
1075069|NCT01684033|multi-purpose solution
1075070|NCT01684033|silicone hydrogel
1075071|NCT01684033|contact lenses
1075072|NCT01684033|comfort
1075073|NCT01684033|Opti-Free
1075074|NCT01684033|Biotrue
1075075|NCT01684020|rhinoplasty
1075076|NCT01684020|external rhinoplasty
1075077|NCT01684020|open rhinoplasty
1075078|NCT01684020|nose job
1075079|NCT01684007|Intraocular lens
1075080|NCT01684007|Multifocal intraocular lens (MIOL)
1075081|NCT01683994|Angiogenesis Inhibitors
1075082|NCT01683994|Small Molecules
1075083|NCT01683994|Tyrosine Kinase Inhibitor
1075084|NCT01683981|Idiopathic Pulmonary Arterial Hypertension
1075085|NCT01683981|Eisenmenger Syndrome
1075086|NCT01683981|Exercise Capacity
1075087|NCT01683981|Quality of Life
1075088|NCT01683955|Tranexamic Acid
1075089|NCT01683955|Blood transfusion
1075090|NCT01683955|Total hip arthroplasty
1075091|NCT01682954|lifestyle risk reduction
1075092|NCT01682941|soy, isoflavones, functional food, prostate cancer
1075093|NCT01682928|Oligohydramnios
1075094|NCT01682928|Hydrotherapy
1075095|NCT01682928|Pregnancy
1075096|NCT01682915|ADHD
1075097|NCT01682915|endophenotype
1075098|NCT01682915|executive function
1075099|NCT01682915|diffusion spectrum imaging
1075100|NCT01682915|resting-state fMRI
1075101|NCT01682915|frontostriatal and frontoparietal circuitries
1075102|NCT01682915|DAT1
1075103|NCT01682876|Prevention of meningococcal disease, children, vaccine
1075104|NCT01682863|COPD, QAB149, QVA149, indacaterol maleate, gylcopyrronium bromide
1075105|NCT01682850|COPD
1075106|NCT01682850|Chronic Obstructive Lung Disease
1075107|NCT01682850|lung cancer
1075108|NCT01682850|emphysema
1075109|NCT01682850|Pulmonary Rehabilitation
1075110|NCT01682824|Central Nervous System
1075111|NCT01682824|CNS
1075112|NCT01682824|CNS tumor
1075113|NCT01682824|Adolescent or Young Adult
1075114|NCT01682824|AYA
1075115|NCT01682824|Survivors
1075116|NCT01682824|Eating Questionnaire-Ecological Momentary Assessment
1075117|NCT01682824|EQ-EMA
1075118|NCT01682824|Cognitive restraint
1075119|NCT01682824|CR
1075120|NCT01682824|Uncontrollable eating
1075122|NCT01682824|Three Factor Eating Questionnaire-R18v2
1075123|NCT01682824|TFEQ-R18v2
1075124|NCT01682824|Web-based questionnaire
1075125|NCT01682824|Multifactor Screener
1075126|NCT01682109|prophylaxis
1075127|NCT01682109|herpes zoster
1075128|NCT01682109|herpes simplex
1075129|NCT01682109|valacyclovir
1075130|NCT01682109|palatability
1075131|NCT01682109|paediatric
1075132|NCT01682096|Chest pain
1075133|NCT01682096|Emergency room
1075134|NCT01682096|Acute coronary syndrome
1075135|NCT01682096|Computed tomography coronary angiography
1075136|NCT01682096|Stress echocardiography
1075137|NCT01682083|MEK inhibitor
1075138|NCT01682083|trametinib
1075139|NCT01682083|Oncology
1075140|NCT01682083|adjuvant melanoma
1075141|NCT01682083|dabrafenib
1075142|NCT01682083|dabrafenib and trametinib combination therapy
1075143|NCT01682083|BRAF mutation-positive melanoma
1075144|NCT01682083|BRAF inhibitor
1075145|NCT01682070|Sublingual immunotherapy
1075146|NCT01682070|Dose range finding
1075147|NCT01682070|Dose tolerability
1075148|NCT01682070|grass pollen
1075149|NCT01682070|Allergic rhinitis/rhinoconjunctivitis
1075150|NCT01682070|Safety
1075151|NCT01682070|Immunogenicity
1075152|NCT01682057|High Blood Pressure
1075153|NCT01682057|Hypertension
1075154|NCT01682057|Resistant Hypertension
1075155|NCT01682018|emphysema
1075156|NCT01682018|lung transplantation
1075157|NCT01682005|Cost
1075158|NCT01682005|Children
1075159|NCT01682005|Rotavirus
1075160|NCT01682005|Rotavirus vaccination
1075161|NCT01682005|Clinical
1075162|NCT01683942|cup disc ratio measurement
1075163|NCT01683942|digital stereo optic disc images
1075164|NCT01683929|Obesity
1075165|NCT01683929|Overweight
1075166|NCT01683929|Sugar consumption
1075167|NCT01683929|Metabolic syndrome
1075168|NCT01683929|Artificially sweetened foods and beverages
1075169|NCT01683916|spinal cord injury
1075170|NCT01683916|stress hormone
1075171|NCT01683916|surgery
1075172|NCT01683916|bispectral index value
1075173|NCT01683916|volatile anesthetic
1075174|NCT01683903|heart failure
1075175|NCT01683903|cardiac rehabilitation
1075176|NCT01683903|myocardial infarction
1075177|NCT01683890|Bladder symptoms
1075178|NCT01683890|Sexual function
1075179|NCT01683890|Quality of life
1075180|NCT01683890|Simple hysterectomy
1075181|NCT01683851|pediatric
1075182|NCT01683851|conscious sedation
1075183|NCT01683851|mouthpiece
1075184|NCT01683851|airway
1075185|NCT01683851|isolite system
1075186|NCT01683838|spinal cord injury
1075187|NCT01683838|muscle spasticity
1075188|NCT01683825|Amyloidosis
1075189|NCT01683825|Cardiac
1075190|NCT01683825|Heart
1075191|NCT01683825|Imaging
1075192|NCT01683825|Diagnosis
1075193|NCT01683799|Osteoarthritis
1075194|NCT01683799|Insomnia
1075195|NCT01683799|Chronic pain
1075196|NCT01683799|Cognitive Behavioral Therapy for Insomnia
1075197|NCT01683799|Inflammation
1075198|NCT01683799|Inflammatory cytokines
1075199|NCT01683773|Tuberculosis
1075200|NCT01683773|Phase I
1075201|NCT01683773|MVA85A
1075202|NCT01683773|AERAS-402
1075203|NCT01683760|Fluconazole
1075204|NCT01683747|sepsis
1075205|NCT01683747|shock
1075206|NCT01683747|placebo controlled
1075207|NCT01683747|double blinded
1075208|NCT01683747|interventional
1075209|NCT01683708|sepsis
1075210|NCT01683708|jaundice
1075211|NCT01683708|symbiotic
1075212|NCT01683708|translocation
1075213|NCT01683708|abdominal collection
1075214|NCT01683708|morbidity
1075215|NCT01683695|Lupus Arthritis, Systemic Lupus Erythematosus, AMG 557, Lupus
1075216|NCT01683682|Non-Small Lung Cancer
1075217|NCT01683682|NSCLC Stage IV
1075218|NCT01683669|ALI
1075219|NCT01683669|ARDS
1075220|NCT01683669|Noisy pressure support ventilation
1075221|NCT01683656|HIV
1075222|NCT01683656|Atherosclerosis
1075223|NCT01683656|Niacin/laropiprant
1075224|NCT01683656|HDL
1075225|NCT01683630|Influenza
1075226|NCT01683630|Influenza type A
1075227|NCT01683630|Influenza type B
1075228|NCT01683630|hospitalization
1075229|NCT01683630|Manitoba
1075230|NCT01683630|Canada
1075231|NCT01683617|Psychological stress
1075232|NCT01683591|Acute stroke
1075233|NCT01683591|Dysphagia
1075234|NCT01683591|High-resolution manometry
1075235|NCT01683578|mechanical ventilation
1075236|NCT01683578|lung function
1075237|NCT01683578|abdominal surgery, open
1075238|NCT01683578|systemic inflammation
1075239|NCT01683552|ITCH
1075240|NCT01683539|Schizophrenia
1075241|NCT01683539|Chronic Mental Disorder
1075242|NCT01683539|Employment
1075243|NCT01683539|Cognitive remediation
1075244|NCT01683539|Vocational rehabilitation
1075245|NCT01683526|Urgent endotrachel intubation
1075246|NCT01683526|Direct laryngoscopy
1075247|NCT01683526|Video laryngoscopy
1075248|NCT01683526|Glidescope
1075249|NCT01683526|Critical Care
1075250|NCT01683513|OHSS
1075251|NCT01683513|mataphase II oocytes (MII)
1075252|NCT01683513|good quality embryo's
1075253|NCT01683513|pregnancy
1075254|NCT01683474|aortic valve stenosis
1075255|NCT01683474|Calcification
1075256|NCT01683474|TAVI
1075257|NCT01683474|aortic valve Prosthesis
1075258|NCT01683461|HIV
1075259|NCT01683461|AIDS
1075260|NCT01683448|Perioperative medications
1075261|NCT01683448|cardiac surgery
1075262|NCT01683448|outcomes
1075263|NCT01683396|Erosive Osteoarthritis
1075264|NCT01683396|Osteoarthritis
1075265|NCT01683396|Osteoarthritis of the Hand
1075266|NCT01683383|Hypoxic ischemic encephalopathy
1075267|NCT01683383|Therapeutic hypothermia
1075268|NCT01683383|Whole body cooling
1075269|NCT01683383|Transport cooling
1075270|NCT01683357|Liver Metastases
1075271|NCT01683357|Surgery
1075272|NCT01683357|Intraoperative Ultrasound
1075273|NCT01683331|Kidney transplant
1075274|NCT01683331|New onset diabetes
1075275|NCT01683331|Prevention
1075276|NCT01683331|Insulin
1075277|NCT01683305|biomarker,
1075278|NCT01683305|NAF
1075279|NCT01683305|Subjects
1075280|NCT01683292|apomorphine
1075281|NCT01683292|inhaled
1075282|NCT01683292|motor fluctuations
1075283|NCT01683279|pediatric
1075284|NCT01683279|acute lymphoblastic leukemia
1075285|NCT01683279|CD19
1075286|NCT01683279|Chimeric Antigen Receptor
1075287|NCT01683240|cholangiography
1075288|NCT01683240|cholangioscopy
1075289|NCT01683240|mother-baby
1075290|NCT01683240|cholangioscope
1075291|NCT01683240|Frimberger cholangioscope
1075292|NCT01683240|short access cholangioscopy
1075293|NCT01683240|ERCP
1075294|NCT01683240|gallstone therapy
1075295|NCT01683227|drug use; emergency department; brief intervention
1075296|NCT01683201|Total hip replacement
1075297|NCT01683201|Functional exercise class
1075298|NCT01683201|Randomised controlled trial
1075299|NCT01683188|melanoma
1075300|NCT01683188|skin cancer
1075301|NCT01683188|Stage IV
1075302|NCT01683175|Erlotinib
1075303|NCT01683175|adjuvant therapy
1075304|NCT01683175|radical operation
1075305|NCT01683175|IIIA NSCLC
1075306|NCT01683175|EGFR mutation
1075307|NCT01683162|parenteral nutrition
1075308|NCT01683162|lipid emulsion
1075309|NCT01683162|olive oil
1075310|NCT01683162|liver function
1075311|NCT01683162|fatty acid
1075312|NCT01683162|clinical outcomes
1075313|NCT01683149|Refractory
1075314|NCT01683149|Relapsed
1075315|NCT01683149|Recurrent
1075316|NCT01683149|Pediatric
1075317|NCT01683149|Malignancy
1075318|NCT01683123|Allogeneic HSCT
1075319|NCT01683123|Busulfan
1075320|NCT01683123|Fludarabina
1075321|NCT01683084|Abdominal Aortic Aneurysm
1075322|NCT01683084|AAA
1075323|NCT01683084|telmisartan
1075324|NCT01683071|Total knee arthroplasty
1075325|NCT01683071|Analgesia
1075326|NCT01683071|Pain management
1075327|NCT01683058|Schizophrenia
1075328|NCT01683045|non-paroxysmal atrial fibrillation
1075329|NCT01683045|persistent atrial fibrillation
1075330|NCT01683045|atrial fibrillation
1075331|NCT01683045|heart palpitations
1075332|NCT01683045|irregular heart beat
1075333|NCT01683045|temperature-controlled radiofrequency ablation
1075334|NCT01683045|radiofrequency energy
1075335|NCT01683045|TCRF energy
1075336|NCT01683045|RF energy
1075337|NCT01683045|epicardial and endocardial lesions
1075338|NCT01683045|concomitant heart surgery
1075339|NCT01683045|surgical ablation
1075340|NCT01683019|Depression
1075341|NCT01683019|magnetic field
1075342|NCT01683019|alpha frequency
1075343|NCT01683019|EEG
1075344|NCT01683019|NeoSync EEG Synchronization Therapy
1075345|NCT01682993|corneal cross linking
1075346|NCT01682993|topography guided excimer laser
1075347|NCT01682993|Keratoconus
1075348|NCT01682993|Pellucid marginal degeneration
1075349|NCT01682993|Post Excimer ectasia
1075350|NCT01682980|Osteoarthritis
1075351|NCT01682980|Pain
1075352|NCT01682980|Exercise
1075353|NCT01682980|Function
1075354|NCT01682980|Cartilage quality
1075355|NCT01682967|Parturients
1075356|NCT01682967|Analgesia, epidural
1075357|NCT01682967|Headache, post-dural puncture
1075358|NCT01682785|Major depressive disorder
1075359|NCT01682785|Metabolic syndrome
1075360|NCT01682785|Thyroid dysfunction
1075361|NCT01682785|incidence
1075362|NCT01682772|Olaparib
1075363|NCT01682772|Adenocarcinoma
1075364|NCT01682772|Prostate
1075365|NCT01682759|diabetes
1075366|NCT01682746|Brain Tumor
1075367|NCT01682746|Photodynamic Therapy
1075368|NCT01682746|Photochemotherapy
1075369|NCT01682746|Astrocytoma
1075370|NCT01682746|Pilocytic Astrocytoma
1075371|NCT01682746|Low grade Astrocytoma
1075372|NCT01682746|Anaplastic Astrocytoma
1075373|NCT01682746|Glioblastoma
1075374|NCT01682746|GBM
1075375|NCT01682746|Chordoma
1075376|NCT01682746|Germinoma
1075377|NCT01682746|Germ Cell Tumor
1075378|NCT01682746|Non-germinaoma
1075379|NCT01682746|CNS Lymphoma
1075380|NCT01682746|Craniopharyngioma
1075381|NCT01682746|Brain Stem Glioma
1075382|NCT01682746|Ependymoma
1075383|NCT01682746|Mixed Glioma
1075384|NCT01682746|Optic Nerve Glioma
1075385|NCT01682746|Subependymoma
1075386|NCT01682746|Medulloblastoma
1075387|NCT01682746|Meningioma
1075388|NCT01682746|Metastatic Brain Tumors
1075389|NCT01682746|Oligodendroglioma
1075390|NCT01682746|Pituitary Tumors
1075391|NCT01682746|Primitive Neuroectodermal
1075392|NCT01682746|PNET
1075393|NCT01682746|Desmoplastic Neuroepithelial Tumor
1075394|NCT01682746|DNET
1075395|NCT01682733|Obesity
1075396|NCT01682733|Weight loss
1075397|NCT01682733|Gastric reduction (volume)
1075398|NCT01682733|BMI 30-40
1075399|NCT01682720|HCV
1075400|NCT01682720|Genotype 2
1075401|NCT01682720|Genotype 3
1075402|NCT01682707|intubation
1075403|NCT01682707|coronary disease
1075404|NCT01682707|hemodynamic response
1075405|NCT01682707|anesthesia with tracheal intubation
1075406|NCT01682707|assessment of hemodynamic response
1075407|NCT01682681|Epilepsy
1075408|NCT01682681|Topiramate
1075409|NCT01682681|Topmax
1075410|NCT01682668|parkinson's disease
1075411|NCT01682668|subthalamic nucleus
1075412|NCT01682668|akinesia
1075413|NCT01682668|gait initiation
1075414|NCT01682668|neuronal activity
1075415|NCT01682668|before STN stimulation
1075416|NCT01682668|with STN stimulation
1075417|NCT01682668|functional MRI
1075418|NCT01682642|endometriosis
1075419|NCT01682642|pregnancy
1075420|NCT01682642|In Vitro Fertilization (IVF)/Intra Cytoplastic Sperm Injection (ICSI)
1075421|NCT01682642|peritoneal implants
1075422|NCT01682642|embryo quality
1075423|NCT01682629|Pediatric
1075424|NCT01682629|Cardiac
1075425|NCT01682629|Arrest
1075426|NCT01682629|Simulation
1075427|NCT01682629|Debriefing
1075428|NCT01682629|Realism
1075429|NCT01682616|Venetoclax
1075430|NCT01682616|ABT-199
1075431|NCT01682616|Rituximab
1075432|NCT01682616|Maximum Tolerated Dose
1075433|NCT01682616|Efficacy
1075434|NCT01682616|Preliminary
1075435|NCT01682616|Pharmacokinetics
1075436|NCT01682616|Tolerability
1075437|NCT01682616|Chronic Lymphocytic Leukemia
1075438|NCT01682616|Small Lymphocytic Lymphoma
1075439|NCT01682616|Safety
1075440|NCT01682616|Cancer
1075441|NCT01682603|Nerve growth factor
1075442|NCT01682603|P2X3 receptor
1075443|NCT01682603|Transient Receptor Potential Vanilloid 1 (TRPV-1) receptor
1075444|NCT01682603|Bladder function
1075445|NCT01682603|Glomerular filtration rate
1075446|NCT01682603|Detrusor overactivity
1075447|NCT01682603|Spinal cord injury
1075448|NCT01682590|septic shock; acute renal failure; renal remplacement therapy; mortality; intensive care; critical care; acute kidney injury
1075449|NCT01682577|Perindopril
1075450|NCT01682577|Perindoprilat
1075451|NCT01682577|Bioequivalence
1075452|NCT01682577|Pharmacokinetic
1075453|NCT01682577|Angiotensin-converting enzyme inhibitor
1075454|NCT01682564|Candemore
1075455|NCT01682564|Atacand
1075456|NCT01682564|Candesartan cilexetil
1075457|NCT01682564|Primary Hypertension
1075458|NCT01682564|Congestive Hypertension
1075459|NCT01682551|High altitude illness
1075460|NCT01682551|Chinese medicine body constitution
1075461|NCT01682551|Chinese Medicine
1075462|NCT01682551|High altitude medicine
1075463|NCT01682551|Mountain trekking
1075464|NCT01682538|Orfadin
1075465|NCT01682538|Nitisinone
1075466|NCT01682538|Bioequivalence
1075467|NCT01682538|Bioavailability
1075468|NCT01682525|Fertility preservation
1075469|NCT01682525|Ovarian Tissue
1075470|NCT01682525|Cryopreservation
1075471|NCT01682525|Assisted Reproductive Technology
1075472|NCT01682499|neuropathy
1075473|NCT01682499|taxane
1075474|NCT01682499|paclitaxel
1075475|NCT01682499|calcium
1075476|NCT01682499|magnesium
1075477|NCT01682499|prevention
1075478|NCT01682486|Medical device
1075479|NCT01682486|Endotracheal Tube(s), ETT
1075480|NCT01682486|Bactiguard Coated ETT
1075481|NCT01682486|Tolerability
1075482|NCT01682486|Safety
1075483|NCT01682486|Performance
1075484|NCT01682486|Bacterial colonization on ETT surface
1075485|NCT01682486|Hospital Acquired Infections, HAI
1075486|NCT01682486|Ventilator Associated Pneumonia, VAP
1075489|NCT01682447|COPD
1075490|NCT01682447|Cognitive Dysfunction
1075491|NCT01682447|Pulmonary Rehabilitation
1075492|NCT01682447|Quality of life
1075493|NCT01682447|Cognitive rehabilitation
1075494|NCT01682408|R406,
1075495|NCT01682408|Fostamatinib,
1075496|NCT01682408|Phase I,
1075497|NCT01682408|Healthy Subjects,
1075498|NCT01682408|Pharmacokinetics,
1075499|NCT01682408|Fed/Fasted
1075500|NCT01682395|Intestinal volvulus
1075501|NCT01682395|Colon, sigmoid
1075502|NCT01682395|Anastomosis, surgical
1075503|NCT01682395|Anastomotic leak
1075504|NCT01682395|Malawi
1075505|NCT01682395|Developing Country
1075506|NCT01682382|age-related macular degeneration
1075507|NCT01682382|choroidal neovascular age-related macular degeneration
1075508|NCT01682382|genetics
1075509|NCT01682382|macular pigment optical density (MPOD)
1075510|NCT01682356|heart failure
1075511|NCT01682356|hypertension, pulmonary
1075512|NCT01682356|oxygen consumption
1075513|NCT01682356|exercise tolerance
1075514|NCT01682317|eating frequency
1075515|NCT01682304|preeclampsia
1075516|NCT01682304|hypertension
1075517|NCT01682304|blood pressure
1075518|NCT01682304|pregnancy induced hypertension
1075519|NCT01682304|chronic hypertension
1075520|NCT01682291|Prehypertension
1075521|NCT01682291|Life-style modifications
1075522|NCT01682291|Dietary supplementation
1075523|NCT01682278|Health complaints
1075524|NCT01682278|Amalgam
1075525|NCT01682278|Mercury
1075526|NCT01682278|Plasma
1075527|NCT01682278|Cytokine
1075536|NCT01682213|Dabrafenib
1075537|NCT01682213|(GSK2118436)
1075538|NCT01682213|BRAFV600E/K
1075539|NCT01682213|Resected AJCC Stage IIIC
1075540|NCT01682213|12-124
1075541|NCT01682200|moderate
1075542|NCT01682200|facial acne
1075543|NCT01682200|acne vulgaris
1075544|NCT01682161|Schizophrenia
1075545|NCT01682161|Paliperidone Palmitate
1075546|NCT01682161|Invega Sustenna
1075547|NCT01682161|Antipsychotics
1075548|NCT01682161|Atypical antipsychotics
1075549|NCT01682161|Medication Satisfaction and Adherence
1075550|NCT01682122|Blood Pressure
1075551|NCT01682122|Pediatrics
1075552|NCT01682122|Infant, Newborn
1075553|NCT01682122|Cardiology
1075554|NCT01681992|Safety
1075555|NCT01681992|Measles, mumps and rubella diseases
1075556|NCT01681992|Immunogenicity
1075557|NCT01681979|fluticasone propionate
1075558|NCT01681979|asthma
1075559|NCT01681979|pregnancy
1075560|NCT01681979|major congenital malformations
1075561|NCT01681927|idiopathic edema nocturia
1075562|NCT01681914|adult HIV positive patients
1075563|NCT01681875|Biomarkers of exposure
1075564|NCT01681875|Compensatory smoking
1075565|NCT01681875|Nicotine dependence
1075566|NCT01681875|Reduced nicotine cigarettes
1075567|NCT01681875|Tobacco withdrawal
1075568|NCT01681862|Hypertension
1075569|NCT01681862|African American
1075570|NCT01681862|Personal Health Record
1075571|NCT01681862|Faith-based Organizations
1075574|NCT01681823|Prostate Cancer
1075575|NCT01681823|Prostatic Neoplasms
1075576|NCT01681823|Prostate Specific Antigen
1075577|NCT01681823|Modified Citrus Pectin
1075578|NCT01681823|PectaSol-C
1075579|NCT01681823|Biochemical Relapse
1075580|NCT01681797|fluorescent angiography
1075581|NCT01681797|reconstructive surgery
1075582|NCT01681797|perforator flap
1075583|NCT01681784|lower urinary tract symptoms
1075584|NCT01681784|biomarkers
1075585|NCT01681784|urodynamic studies
1075586|NCT01681758|cardiac surgery
1075587|NCT01681758|Pulse pressure variation
1075588|NCT01681758|intravenous fluids
1075589|NCT01681732|Asthma
1075590|NCT01681732|child
1075591|NCT01681732|pediatric
1075592|NCT01681719|VO2
1075593|NCT01681719|VCO2
1075594|NCT01681719|VE/VO2
1075595|NCT01681719|heart rate
1075596|NCT01681706|HIV
1075597|NCT01681706|Indicator disease
1075598|NCT01681654|Head/Neck Cancer
1075599|NCT01681654|Exercise
1075600|NCT01681654|Progressive Strength Training
1075601|NCT01681654|Quality of Life
1075602|NCT01681654|Cancer
1075603|NCT01681654|Randomized Controlled Trial
1075604|NCT01681654|Nutrition
1075605|NCT01681654|Lifestyle Intervention
1075606|NCT01681641|Patients
1075607|NCT01681641|Nursing
1075608|NCT01681641|Parkinsons disease
1075609|NCT01681641|Deep Brain Stimulation
1075610|NCT01681641|Spouses
1075611|NCT01681628|Thought Field Therapy.
1075612|NCT01681628|Post-traumatic stress disorder.
1075613|NCT01681628|Post-traumatic stress disorder check list for Civilians.
1075614|NCT01681628|Uganda
1075615|NCT01681628|Ugandan therapists.
1075616|NCT01681628|Community treatment.
1075617|NCT01681615|Challenge test for Aspirin Hypersensitivity
1075618|NCT01681615|Challenge test for Acetylsalicylic Hypersensitivity
1075619|NCT01681602|Alzheimer Disease
1075620|NCT01681602|Exercise
1075621|NCT01681602|Cognition
1075622|NCT01681602|Quality of life
1075623|NCT01681602|Cardiovascular fitness
1075624|NCT01681602|Behavioural or psychological symptoms
1075625|NCT01681602|Physical fitness
1075626|NCT01681589|TBI
1075627|NCT01681589|Traumatic Brain Injury
1075628|NCT01681589|Rehabilitation
1075629|NCT01681589|Therapy
1075630|NCT01681576|hypertension, salt sensitivity, valsartan, LCZ696
1075631|NCT01681537|Relapsed
1075632|NCT01681537|Refractory
1075633|NCT01681524|Flurpiridaz F18 Injection
1075634|NCT01681524|Positron Emission Tomography Myocardial Perfusion Imaging
1075635|NCT01681524|Single Positron Emission Computed Tomography
1075636|NCT01681524|Coronary Artery Disease
1075637|NCT01681524|Myocardia Ischemia
1075638|NCT01681524|Coronary Disease
1075639|NCT01681524|Heart Diseases
1075640|NCT01681524|Cardiovascular Diseases
1075641|NCT01681524|Arteriosclerosis
1075642|NCT01681524|Arterial Occlusive Diseases
1075643|NCT01681524|Vascular Diseases
1075644|NCT01681511|Catheter Associated Urinary Tract Infections
1075645|NCT01681511|CAUTI
1075646|NCT01681498|pregnant
1075647|NCT01681498|fetal ecg
1075648|NCT01681498|ecg
1075649|NCT01681485|Traditional Chinese medicine
1075650|NCT01681485|Non small cell lung cancer
1075651|NCT01681485|Surgery
1075652|NCT01681485|Chemotherapy
1075653|NCT01681485|Radiation therapy
1075654|NCT01681472|Colon cancer
1075655|NCT01681472|5,10-methylenetetrahydrofolate
1075656|NCT01681472|Rectal Neoplasms
1075657|NCT01681472|Colorectal Neoplasms
1075658|NCT01681472|Intestinal Neoplasms
1075659|NCT01681472|Gastrointestinal Neoplasms
1075660|NCT01681472|Digestive System Neoplasms
1075661|NCT01681472|Gastrointestinal Diseases
1075662|NCT01681472|Therapeutic Uses
1075663|NCT01681472|Pharmacokinetics
1075664|NCT01681472|Pharmacodynamics
1075665|NCT01681459|Free fatty acid
1075666|NCT01681459|Triglyceride
1075667|NCT01681459|Gastric emptying
1075668|NCT01681459|Satiety hormones
1075669|NCT01681459|Appetite
1075670|NCT01681459|Severe obesity
1075671|NCT01681446|hepatocellular carcinoma
1075672|NCT01681446|interferon-alpha
1075673|NCT01681446|miR-26
1075674|NCT01681433|OGX-427
1075675|NCT01681433|Abiraterone Acetate
1075676|NCT01681420|HIV counseling
1075677|NCT01681420|Blood donor HIV testing
1075678|NCT01681420|Brazil
1075679|NCT01681420|Blood banks
1075680|NCT01681420|Blood donors
1075681|NCT01681407|Depression
1075682|NCT01681407|Selective Serotonin Reuptake Inhibitors
1075683|NCT01681407|MicroRNAs
1075684|NCT01681407|Proteome
1075685|NCT01681368|NF-Kappa B Pathway
1075686|NCT01681368|Response Biomarkers
1075687|NCT01681368|Progression-Free Survival
1075688|NCT01681368|Pharmacokinetics
1075689|NCT01681368|Pharmacodynamics
1075690|NCT01681355|Healthy, term, Asian infants
1075691|NCT01681355|Infant formula
1075692|NCT01681342|stade Ib to IV cervix cancer
1075693|NCT01681342|ambulatory high dose rate brachytherapy
1075694|NCT01681329|Cognitive-behavioral therapy
1075695|NCT01681329|Interpretation modification training
1075696|NCT01681329|Randomized clinical trial
1075697|NCT01681329|Adults
1075698|NCT01681316|Chronic Stable Angina
1075699|NCT01681316|Randomized Controlled Trial
1075700|NCT01681316|Traditional Chinese Medicine
1075701|NCT01681264|Pain
1075702|NCT01681264|Pain Management
1075703|NCT01681264|Back pain
1075704|NCT01681264|Neck pain
1075705|NCT01681238|perioperative fluid optimization
1075706|NCT01681238|goal-directed therapy
1075707|NCT01681238|elderly
1075708|NCT01681238|high-risk surgery
1075709|NCT01681225|ARDS
1075710|NCT01681225|mechanical ventilation
1075711|NCT01681225|ALI
1075712|NCT01681225|esophageal pressure
1075713|NCT01681199|statin
1075714|NCT01681199|atherosclerosis
1075715|NCT01681199|Coronary heart disease
1075716|NCT01681199|OPN
1075717|NCT01681199|OPG
1075718|NCT01681173|Nutritional support
1075719|NCT01681173|Diet therapy
1075720|NCT01681173|Diabetes prevention
1075721|NCT01681173|Insoluble fiber
1075722|NCT01681173|Healthy life style
1075723|NCT01681173|Weight loss
1075724|NCT01681160|MAGGOT THERAPY
1075725|NCT01681160|DIABETIC FOOT
1075726|NCT01681160|NURSING CARE
1075727|NCT01681160|DRESSING
1075728|NCT01681147|Gestational Diabetes
1075729|NCT01681147|postpartum
1075730|NCT01681147|nutrition
1075731|NCT01681147|exercise
1075732|NCT01681134|tacrolimus
1075733|NCT01681134|Advagraf®
1075734|NCT01681134|Prograf®
1075735|NCT01681134|Glomerular Filtration Rate
1075736|NCT01681134|Effective Renal Plasma Flow
1075737|NCT01681134|Pharmacokinetics
1075738|NCT01681134|Pharmacodynamics
1075739|NCT01681095|Physiological Effects of Drugs
1075740|NCT01681095|Cardiovascular Agents
1075741|NCT01681095|Therapeutic Uses
1075742|NCT01681095|Pharmacologic Actions
1075743|NCT01681095|Mannitol
1075744|NCT01681095|Cardiac Surgery
1075745|NCT01681095|Cardioplegic Solutions
1075746|NCT01681095|HTK solution
1075747|NCT01681095|Myocardial protection
1075748|NCT01681095|Coronary Artery Disease
1075749|NCT01681095|Myocardial Ischemia
1075750|NCT01681095|Coronary Disease
1075751|NCT01681095|Heart Diseases
1075752|NCT01681056|autosuggestion
1075753|NCT01681056|quality of life
1075754|NCT01681056|geriatric
1075755|NCT01681056|serum cortisol
1075756|NCT01681056|Interferon gamma
1075757|NCT01681056|interleukin-2
1075758|NCT01681056|interleukin-6
1075759|NCT01681056|neuroplasticity
1075760|NCT01681043|Sleep
1075761|NCT01681017|Perinatal Mortality
1075762|NCT01681017|Asphyxia
1075763|NCT01681017|Stillbirth
1075764|NCT01681017|Neonatal Death
1075765|NCT01681017|Resuscitation
1075766|NCT01681017|Helping Babies Breathe
1075767|NCT01681017|among births greater than one thousand five hundred grams
1075768|NCT01681004|si joint
1075769|NCT01681004|si joint pain
1075770|NCT01681004|si joint injury
1075771|NCT01681004|si joint treatment
1075772|NCT01681004|si joint injections
1075773|NCT01681004|si joint inflammation
1075774|NCT01681004|si joint problems
1075775|NCT01681004|si joint symptoms
1075776|NCT01681004|hypermobile si joint
1075777|NCT01681004|si joint arthritis
1075778|NCT01681004|si joint pain treatment
1075779|NCT01681004|inflamed si joint
1075780|NCT01681004|si joint sclerosis
1075781|NCT01681004|locked si joint
1075782|NCT01681004|si joint injuries
1075783|NCT01681004|si joint disease
1075784|NCT01681004|si joint infection
1075785|NCT01681004|sacroiliac joint pelvic pain
1075786|NCT01681004|sacroiliac joint arthritis treatment
1075787|NCT01680965|Graft vs. Host Disease
1075788|NCT01680965|GVHD
1075789|NCT01680965|chronic graft versus host disease (cGVHD)
1075790|NCT01680965|Allogeneic Transplant
1075791|NCT01680965|Ofatumumab
1075792|NCT01680952|RECORD study
1075793|NCT01680939|Pediatrics
1075794|NCT01680939|Obstructive Sleep Apnea
1075795|NCT01680939|Adenotonsillectomy
1075796|NCT01680939|Analgesia
1075797|NCT01680926|type 2 diabetes mellitus
1075798|NCT01680926|insulin
1075799|NCT01680926|hbA1c
1075800|NCT01680926|body weight
1075801|NCT01680900|menopause
1075802|NCT01680900|hot flashes
1075803|NCT01680900|vilazodone
1075804|NCT01680887|Cocaine dependence
1075805|NCT01680874|Clostridium difficile
1075806|NCT01680874|Diarrhea
1075807|NCT01680874|Infection
1075808|NCT01680874|Lactobacilli
1075809|NCT01680874|Bifidobacteria
1075810|NCT01680874|Lactobacillus acidophilus
1075811|NCT01680874|Lactobacillus paracasei
1075812|NCT01680874|Bifidobacterium lactis
1075813|NCT01680874|Yogurt
1075814|NCT01680874|Probiotics
1075815|NCT01680861|Kidney transplant patients
1075816|NCT01680848|Dental caries,
1075817|NCT01680848|Caries diagnosis,
1075818|NCT01680848|Caries treatment,
1075819|NCT01680848|Caries risk,
1075820|NCT01680848|Practice pattern,
1075821|NCT01680848|Clinical epidemiology,
1075822|NCT01680848|Dental Practice-Based Research Network
1075823|NCT01680822|Nontuberculous, Atypical, Mycobacterial
1075824|NCT01680809|Venous insufficiency
1075825|NCT01680809|Venous stasis ulcerations
1075826|NCT01680809|Compression stockings
1075827|NCT01680809|Compression stocking compliance
1075828|NCT01680796|Multiple Myeloma
1075829|NCT01680796|Relapsed Multiple Myeloma
1075830|NCT01680796|Refractory Multiple Myeloma
1075831|NCT01680783|noninvasive ventilation
1075832|NCT01680783|acute hypoxemic respiratory failure
1075833|NCT01680783|Acute respiratory distress syndrome
1075834|NCT01680783|shock
1075835|NCT01680770|shock
1075836|NCT01680770|transthoracic echocardiography
1075837|NCT01680770|critical care
1075838|NCT01680757|Left Atrial Appendage
1075839|NCT01680757|LARIAT
1075840|NCT01680757|atrial fibrillation
1075841|NCT01680757|contraindication to oral anticoagulation therapy
1075842|NCT01680744|Transplantation
1075843|NCT01680744|Terminal creatinine
1075844|NCT01680744|Renal function
1075845|NCT01680744|GFR
1075846|NCT01680731|Pelvic floor injury
1075847|NCT01680731|Levator ani muscle
1075848|NCT01680718|oxytocin
1075849|NCT01680718|vasopressin
1075850|NCT01680718|intranasal administration
1075851|NCT01680718|healthy sample
1075852|NCT01680705|Chronic Rhinosinusitis
1075853|NCT01680705|Endoscopic Sinus Surgery
1075854|NCT01680705|Sinonasal saline irrigation
1075855|NCT01680705|Frequency
1075856|NCT01680705|Postoperative
1075857|NCT01680705|High Volume
1075858|NCT01680705|Randomized Control Trial
1075859|NCT01680705|Single Blinded
1075860|NCT01680705|Prospective Study
1075861|NCT01680705|Quality of Life
1075862|NCT01680705|Endoscopic Sinus Score
1075863|NCT01680692|Analgesia TKA
1075864|NCT01680692|Total knee arthroplasty
1075865|NCT01680692|Continuous femoral catheter
1075866|NCT01680692|Continuous tibial catheter
1075867|NCT01680692|Single shot sciatic
1075868|NCT01680679|Influenza
1075869|NCT01680679|India
1075870|NCT01680679|Children
1075871|NCT01680679|Trivalent Influenza Vaccine (TIV)
1075872|NCT01680679|Inactivated poliovirus vaccine (IPV)
1075873|NCT01680679|Direct influenza vaccine effectiveness
1075874|NCT01680679|Total influenza vaccine effectiveness
1075875|NCT01680679|Indirect influenza vaccine effectiveness
1075876|NCT01680640|non alcoholic fatty liver disease
1075877|NCT01680640|NAFLD
1075878|NCT01680640|synbiotic
1075879|NCT01680640|gut microbiota
1075880|NCT01680640|intervention
1075881|NCT01680640|RCT
1075882|NCT01680640|biomarkers
1075883|NCT01680588|Alzheimer
1075884|NCT01680575|Neutropenia
1075885|NCT01680575|Paclitaxel
1075886|NCT01680575|Carboplatin
1075887|NCT01680575|Epithelial ovarian cancer
1075888|NCT01680562|in-vivo skin imaging
1075889|NCT01680562|non-invasive non-melanoma skin cancer diagnostics
1075890|NCT01680523|cervical cancer
1075891|NCT01680523|bulky early-stage
1075892|NCT01680523|locally advanced
1075893|NCT01680523|radical hysterectomy
1075894|NCT01680523|concurrent chemoradiation therapy
1075895|NCT01680484|non-stress test
1075896|NCT01680471|emergence agitation
1075897|NCT01680471|midazolam
1075898|NCT01680471|sevoflurane
1075899|NCT01680471|strabismus
1075900|NCT01680458|antifungal treatment
1075901|NCT01680458|prophylaxis
1075902|NCT01680458|administration
1075903|NCT01680458|Japanese
1075904|NCT01680458|infants
1075905|NCT01680458|fluconazole
1075906|NCT01680458|Diflucan
1075907|NCT01680458|Regulatory Post Marketing Commitment Plan.
1075908|NCT01680445|osteoarthritis, arthritis
1075909|NCT01680432|constipation
1075910|NCT01680432|probiotics
1075911|NCT01680432|bifidobacterium
1075912|NCT01680432|cheese
1075913|NCT01680419|Veterans
1075914|NCT01680419|Reintegration
1075915|NCT01680419|Resilience
1075916|NCT01680419|Marital
1075917|NCT01680419|Spouse
1075918|NCT01680419|Behavioral intervention
1075919|NCT01680419|PTSD
1075920|NCT01680419|Integrative therapies
1075921|NCT01680419|Complementary therapies
1075922|NCT01680419|Massage
1075923|NCT01680419|Meditation
1075924|NCT01680419|Mindfulness
1075925|NCT01680419|Compassion
1075926|NCT01680419|Mental health
1075927|NCT01680406|Plasmodium vivax
1075928|NCT01680406|malaria
1075929|NCT01680406|Ethiopia
1075930|NCT01680406|Sub-Saharan Africa
1075931|NCT01680406|primaquine
1075932|NCT01680406|artemether lumefantrine
1075933|NCT01680406|chloroquine
1075934|NCT01680380|sleep apnea
1075935|NCT01680380|snoring
1075936|NCT01680315|Satiety,
1075937|NCT01680315|satiation,
1075938|NCT01680315|anticipation,
1075939|NCT01680315|food intake
1075940|NCT01680302|Atrial fibrillation
1075941|NCT01680302|Prevention
1075942|NCT01680302|Exercise
1075943|NCT01680289|Dentin bonding agents
1075944|NCT01680289|Composite restorations
1075945|NCT01680289|Dental restoration failure
1075946|NCT01680276|intellectual disability
1075947|NCT01680276|developmental disability
1075948|NCT01680276|challenging behaviour
1075949|NCT01680276|behavioural intervention
1075950|NCT01680276|training
1075951|NCT01680263|Kinesiotaping
1075952|NCT01680263|pes anserinus tendino-bursitis
1075953|NCT01680263|nonsteroidal anti-inflammatory drugs
1075954|NCT01680263|physical therapy
1075955|NCT01680250|Total liver volume
1075956|NCT01680250|Liver cyst
1075957|NCT01680237|cognitive behavior therapy
1075958|NCT01680237|exposure in-vivo
1075959|NCT01680237|panic disorder with agoraphobia
1075960|NCT01680224|Obesity
1075961|NCT01680224|Weight Gain
1075962|NCT01680224|Dissonance
1075963|NCT01680224|College,University Students
1075964|NCT01680224|Eating Disorders
1075965|NCT01680224|Obesity Prevention
1075966|NCT01680224|Selective Prevention
1075967|NCT01680224|Effectiveness
1075968|NCT01680211|Blood Sugar,
1075969|NCT01680211|Lipoproteins,
1075970|NCT01680211|Salacia,
1075971|NCT01680211|Sesame,
1075972|NCT01680211|Prediabetes,
1075973|NCT01680211|Hyperlipidemia,
1075974|NCT01680211|Herbal supplement
1075975|NCT01680198|Vitamin D
1075976|NCT01680198|Paracalcitol
1075977|NCT01680198|Chronic kidney disease
1075978|NCT01680198|Endothelial dysfunction
1075979|NCT01680198|Flow mediated vasodilation
1075980|NCT01680185|Hyperglycemia
1075981|NCT01680185|NODAT
1075982|NCT01680185|Insulin pump
1075983|NCT01680185|Semiclosed loop
1075984|NCT01680172|cancer
1075985|NCT01680172|depression
1075986|NCT01680172|anxiety
1075987|NCT01680172|palliative care
1075988|NCT01680159|Infliximab
1075989|NCT01680159|REMICADE
1075990|NCT01680159|TA-650
1075991|NCT01680159|psoriasis
1075992|NCT01680107|d-cycloserine, cognitive-behaviour therapy, panic disorder
1075993|NCT01680094|HIV Infection
1075994|NCT01680094|Panobinostat
1075995|NCT01680094|Lentivirus Infections
1075996|NCT01680094|Retroviridae Infections
1075997|NCT01680094|RNA Virus Infections
1075998|NCT01680094|Virus Diseases
1075999|NCT01680094|Sexually Transmitted Diseases, Viral
1076000|NCT01680094|Sexually Transmitted Diseases
1076001|NCT01680094|Immunologic Deficiency Syndromes
1076002|NCT01680094|Immune System Diseases
1076003|NCT01680094|Histone Deacetylase Inhibitors
1076004|NCT01680094|Therapeutic Uses
1076005|NCT01680068|Macular hole
1076006|NCT01680068|Vitreoretinal surgery
1076007|NCT01680068|Macular surgery
1076008|NCT01680068|Air tamponade
1076009|NCT01680042|inflammatory halo
1076010|NCT01680042|VAS
1076011|NCT01680016|Rabies virus, postexposure, vaccine schedule, children, older adults
1076012|NCT01679964|HIV infection
1076013|NCT01679964|Raltegravir
1076014|NCT01679964|Adverse event
1076015|NCT01679964|Life quality
1076016|NCT01679951|Rheumatoid arthritis
1076017|NCT01679951|Swollen and tender joints
1076018|NCT01679951|Methotrexate
1076019|NCT01679951|Immunology
1076020|NCT01679951|Dose range finding study
1076021|NCT01679938|obesity prevention
1076022|NCT01679938|cluster-randomized controlled trial
1076023|NCT01679938|preschool-aged children
1076024|NCT01679925|Early puberty
1076025|NCT01679925|Psychosocial impact
1076026|NCT01679925|Qualitative assessment
1076027|NCT01679912|Hereditary angioedema
1076028|NCT01679912|Emergency Medical Service
1076029|NCT01679912|Health care coast
1076030|NCT01679912|Telephone
1076031|NCT01679899|diabetes
1076032|NCT01679899|type 2 diabetes mellitus
1076033|NCT01679899|osteopenia
1076034|NCT01679899|osteoporosis
1076035|NCT01679899|glycemic variability
1076036|NCT01679899|bone markers
1076037|NCT01679899|osteocalcin
1076038|NCT01679899|NTX
1076039|NCT01679899|CTX
1076040|NCT01679899|BALP
1076041|NCT01679886|Position emission tomography;
1076042|NCT01679886|Rubidium;
1076043|NCT01679886|Women;
1076044|NCT01679886|Overweighted patients
1076045|NCT01679873|confidence
1076046|NCT01679873|funding sources
1076047|NCT01679873|conflicts of interests
1076048|NCT01679873|general practitioner
1076049|NCT01679847|Elemene
1076050|NCT01679847|pharmacokinetics
1076051|NCT01679847|Blood-brain barrier
1076052|NCT01679821|Temporomandibular disorders.
1076053|NCT01679821|Dental prosthesis.
1076054|NCT01679821|Dental students
1076055|NCT01679808|copd
1076056|NCT01679808|airway obstruction
1076057|NCT01679808|Tracheobronchomalacia
1076058|NCT01679795|hormone replacement therapy; Dopplervelocimetry; Flow-mediated dilation; menopause; tibolone
1076059|NCT01679782|COPD, nervous system, peripheral muscle dysfunction
1076060|NCT01679756|Colorectal cancer
1076061|NCT01679756|Laparoscopic right hemicolectomy
1076062|NCT01679756|Intracorporeal anastomosis
1076063|NCT01679743|Metastatic Breast Cancer
1076064|NCT01679743|Metastatic Lung Cancer
1076065|NCT01679743|Monoclonal Antibody
1076066|NCT01679743|18FLT
1076067|NCT01679743|Surgery
1076068|NCT01679717|Osteoarthritis
1076069|NCT01679717|CMC1-joint
1076070|NCT01679717|Postoperative therapy
1076071|NCT01679717|Interposition arthroplasty of the thumb
1076072|NCT01679717|Occupational therapy
1076073|NCT01679652|Essential hypertension
1076074|NCT01679652|Nitric oxide
1076075|NCT01679652|Nebivolol
1076076|NCT01679652|Fractional excretion of sodium
1076077|NCT01679626|cricoid pressure (CP)
1076078|NCT01679626|backward upward rightward pressure (BURP)
1076079|NCT01679626|AP-rima distances
1076080|NCT01679626|Glottic area
1076081|NCT01679626|Extralaryngeal manoeuvres
1076082|NCT01679600|Rehabilitation
1076083|NCT01679600|Robotics-assisted Treadmill Exercise
1076084|NCT01679600|Aerobic Capacity
1076085|NCT01679600|Exercise Testing
1076086|NCT01679574|PCO
1076087|NCT01679561|implantation failure
1076088|NCT01679561|recurrent abortion
1076089|NCT01679561|intralipid
1076090|NCT01679535|Infant nutrition disorder
1076091|NCT01679535|Child nutrition disorders
1076092|NCT01679535|Malnutrition
1076093|NCT01679535|Protein-energy malnutrition
1076094|NCT01679522|endometrial cancer
1076095|NCT01679522|laparoscopic surgical staging
1076096|NCT01679522|single-port
1076097|NCT01679522|four-port
1076098|NCT01679496|LDL-cholesterol
1076099|NCT01679470|cancer
1076100|NCT01679470|lung
1076101|NCT01679470|laser
1076102|NCT01679470|ablation
1076103|NCT01679470|airway obstruction
1076104|NCT01679444|MRS
1076105|NCT01679444|Heavy dose drinkers
1076106|NCT01679444|Alcohol
1076107|NCT01679444|NIAAA
1076108|NCT01679431|Aortic Stenosis
1076109|NCT01679431|Obesity, Abdominal
1076110|NCT01679431|Metabolic Syndrome X
1076111|NCT01679431|Insulin Resistance
1076112|NCT01679431|Echocardiography, Doppler
1076113|NCT01679431|Multidetector Computed Tomography
1076114|NCT01679431|Magnetic Resonance Imaging
1076115|NCT01679418|PONV
1076116|NCT01679418|thyroid
1076117|NCT01679418|surgery
1076118|NCT01679418|nausea and vomiting
1076119|NCT01679418|postoperative
1076120|NCT01679405|metastatic biliary tract cancer
1076121|NCT01679392|Transversus abdominis plane block
1076122|NCT01679392|Ultrasound guided nerve block
1076123|NCT01679379|Cesarean Section
1076124|NCT01679379|Obese Women
1076125|NCT01679379|Surgical Site Infection
1076126|NCT01679353|inguinal hernia, caudal analgesia, magnesium
1076127|NCT01679340|Gastric cancer
1076128|NCT01679340|D2 surgery
1076129|NCT01679340|S-1
1076130|NCT01679340|Oxaliplatin
1076131|NCT01679340|cisplatin
1076132|NCT01679314|COPD
1076133|NCT01679314|vagus nerve stimulation
1076134|NCT01679314|vagal nerve stimulation
1076135|NCT01679314|nVNS
1076136|NCT01679314|VNS
1076137|NCT01679314|non invasive
1076138|NCT01679314|gammacore
1076139|NCT01679301|oxygen
1076140|NCT01679288|Hand-Held ultrasonography
1076141|NCT01679288|Abdominal Aortic Aneurysm
1076142|NCT01679288|Abdominal Aortic Atherosclerosis
1076143|NCT01679288|Cardiovascular risk
1076144|NCT01679288|Primary Health Care
1076145|NCT01679275|Heart Defects, congenital
1076146|NCT01679275|Patient Monitoring
1076147|NCT01679275|Infant, Newborn
1076148|NCT01679275|Physiology
1076149|NCT01679249|extracellular fluid volume
1076150|NCT01679249|hypotension
1076151|NCT01679249|hemodialysis
1076152|NCT01679236|Smoking
1076153|NCT01679236|Smoking cessation
1076154|NCT01679236|Nicotine
1076155|NCT01679236|Tobacco
1076156|NCT01679236|Mindfulness
1076157|NCT01679236|Meditation
1076158|NCT01679236|MBSR
1076159|NCT01679236|Mindfulness Training
1076160|NCT01679236|Behavioral Intervention
1076161|NCT01679236|Alcohol
1076162|NCT01679236|Young Adults
1076163|NCT01679223|Breast reconstruction
1076164|NCT01679223|Hydroxyproline concentration
1076165|NCT01679223|neoangiogenesis
1076166|NCT01679223|collagen deposition
1076167|NCT01679197|Nonalcoholic fatty liver disease
1076168|NCT01679197|NAFLD
1076169|NCT01679197|Nonalcoholic steatohepatitis
1076170|NCT01679197|NASH
1076171|NCT01679197|Lipodystrophy
1076172|NCT01679197|Leptin
1076173|NCT01679197|Metreleptin
1076174|NCT01679197|Hypertriglyceridemia
1076175|NCT01679197|Diabetes mellitus
1076176|NCT01679171|Elderly
1076177|NCT01679171|Intensive care unit
1076178|NCT01679171|Outcome
1076179|NCT01679171|Comprehensive geriatric assessment
1076180|NCT01679158|Using POSE as a treatment for Obesity
1076181|NCT01679145|Reward- based learning
1076182|NCT01679145|Pavlovian-to-instrumental transfer
1076183|NCT01679145|Functional imaging
1076184|NCT01679145|Relapse risk
1076185|NCT01679132|Hypertension
1076186|NCT01679132|High Blood Pressure
1076187|NCT01679132|Blood Pressure
1076188|NCT01679132|Cardiovascular Disease
1076189|NCT01679132|Resistant Hypertension
1076190|NCT01679119|Diffuse large b cell lymphoma
1076191|NCT01679119|Inotuzumab Ozogamicin
1076192|NCT01679119|Gemcitabine
1076193|NCT01679119|Rituximab
1076194|NCT01679119|Cyclophosphamide
1076195|NCT01679119|Vincristine
1076196|NCT01679119|Prednisolone
1076197|NCT01679106|renal transplant
1076198|NCT01679106|flank incision
1076199|NCT01679093|postoperative analgesia
1076200|NCT01679093|paracetamol
1076201|NCT01679093|5-HT3 antagonist
1076202|NCT01679093|ondansetron
1076203|NCT01679093|PainMatcher
1076204|NCT01679080|Drug therapy
1076205|NCT01679080|Adult
1076206|NCT01679067|HIV
1076207|NCT01679067|GALT
1076208|NCT01679054|Neoplasm
1076209|NCT01679054|Gastric Cancer
1076210|NCT01679054|Cost
1076211|NCT01679028|T89 Safety in Healthy Japanese population
1076212|NCT01679015|Burning
1076213|NCT01679015|Dryness
1076214|NCT01679015|Itching
1076215|NCT01679015|Blurry Vision
1076216|NCT01679002|Epilepsy
1076217|NCT01679002|Oxcarbazepine
1076218|NCT01679002|Eslicarbazepine Acetate
1076219|NCT01679002|BIA 2-093
1076220|NCT01678989|Bipolar disorder
1076221|NCT01678989|Children
1076222|NCT01678989|Cranial MRI
1076223|NCT01678976|Eslicarbazepine acetate
1076224|NCT01678976|Epilepsy
1076225|NCT01678976|Oxcarbazepine
1076226|NCT01678963|Neovascular AMD
1076227|NCT01678963|Wet AMD
1076228|NCT01678963|AMD
1076229|NCT01678963|Age related macular degeneration
1076230|NCT01678950|Cardiac output monitoring
1076231|NCT01678950|Echocardiography
1076232|NCT01678950|Pulse contour system
1076233|NCT01678937|Immunosuppression
1076234|NCT01678911|Pelvic Pain
1076235|NCT01678911|Chronic Pelvic Pain
1076236|NCT01678911|Irritable Bowel Syndrome
1076237|NCT01678911|IBS
1076238|NCT01678911|Ulcerative Colitis
1076239|NCT01678911|UC
1076240|NCT01678911|Interstitial Cystitis
1076241|NCT01678911|IC
1076242|NCT01678911|Prostatitis
1076243|NCT01678911|Pain
1076244|NCT01678898|Fabry disease
1076245|NCT01678898|Alpha galactosidase deficiency
1076246|NCT01678898|Metabolic storage disease
1076247|NCT01678859|infertility
1076248|NCT01678859|cervical
1076249|NCT01678859|mucus
1076250|NCT01678859|sperm
1076251|NCT01678859|interaction
1076252|NCT01678846|corporal punishment
1076253|NCT01678846|violence
1076254|NCT01678846|education
1076255|NCT01678846|depression
1076256|NCT01678846|anxiety
1076257|NCT01678846|conduct disorder
1076258|NCT01678833|Drug Abuse/Dependence
1076259|NCT01678794|Chronic heart failure (CHF)
1076260|NCT01678794|cardiac and renal dysfunction
1076261|NCT01678781|Abdominal pain
1076262|NCT01678781|Diarrhea
1076263|NCT01678781|Mebeverine hydrochloride
1076264|NCT01678781|Constipation
1076265|NCT01678781|Pinaverium bromide
1076266|NCT01678781|Irritable bowel syndrome
1076267|NCT01678781|Bloating
1076268|NCT01678781|Quality of life
1076269|NCT01678755|schizophrenia
1076270|NCT01678742|Diet
1076271|NCT01678742|Incretins
1076272|NCT01678742|Gastrointestinal Hormones
1076273|NCT01678742|Fish Proteins
1076274|NCT01678729|refractive surgery
1076275|NCT01678729|pupil
1076276|NCT01678729|Pupil size
1076277|NCT01678716|Anemia
1076278|NCT01678716|Breastfeeding
1076279|NCT01678716|Complementary feeding
1076280|NCT01678716|Stunting
1076281|NCT01678716|Wasting
1076282|NCT01678716|Underweight
1076283|NCT01678716|Micronutrient powder
1076284|NCT01678716|Behavior change counseling
1076285|NCT01678716|Frontline health worker
1076286|NCT01678703|late abortion
1076287|NCT01678703|laminaria
1076288|NCT01678703|Misoprostol
1076289|NCT01678703|Cervical preparation
1076290|NCT01678677|non-typeable Haemophilus influenzae
1076291|NCT01678677|immunogenicity
1076292|NCT01678677|reactogenicity
1076293|NCT01678677|safety
1076294|NCT01678664|cancer
1076295|NCT01678664|neuroendocrine tumors
1076296|NCT01678664|gastrointestinal tract
1076297|NCT01678664|metastases
1076298|NCT01678664|liver
1076299|NCT01678664|hepatic
1076300|NCT01678651|time-lapse, FSH, kinetics
1076301|NCT01678638|inguinal hernia
1076302|NCT01678638|premature infants
1076303|NCT01678638|anesthesia safety
1076304|NCT01678638|neurodevelopmental outcome
1076305|NCT01678638|preterm infants
1076306|NCT01678638|neonatal prematurity
1076307|NCT01678625|Residual neuromuscular blockade
1076308|NCT01678625|Train-of-four
1076309|NCT01678625|Acceleromyography
1076310|NCT01678625|Electromyography
1076311|NCT01678612|Copper
1076312|NCT01678612|Health-Acquired Infections
1076313|NCT01678612|Bacterial Load
1076314|NCT01678612|Intensive Care Units, Pediatric
1076315|NCT01678599|Chagas Disease
1076316|NCT01678599|PCR
1076317|NCT01678599|diagnosis
1076318|NCT01678586|Pain
1076319|NCT01678586|Pain management
1076320|NCT01678573|Healthy
1076321|NCT01678573|Pharmacokinetics
1076322|NCT01678573|Abiraterone acetate
1076323|NCT01678573|Abiraterone
1076324|NCT01678573|JNJ-212082
1076325|NCT01678573|Zytiga
1076326|NCT01678573|Chinese
1076327|NCT01678573|Fasted
1076328|NCT01678560|Obstructive sleep apnea PAP adherence efficacy economics
1076329|NCT01678547|Stroke
1076330|NCT01678547|Robot
1076331|NCT01678547|Treatment
1076332|NCT01678547|Rehabilitation
1076333|NCT01678534|Cerebral infarction
1076334|NCT01678534|Cellular therapy
1076335|NCT01678521|Hypercholesterolemia
1076336|NCT01678521|LDL-apheresis
1076337|NCT01678521|Coronary artery disease
1076338|NCT01678521|PTX3
1076339|NCT01678521|CRP
1076340|NCT01678521|IL6
1076341|NCT01678521|IL10
1076342|NCT01678482|Acne, LED, blue light
1076343|NCT01678456|Atrial Fibrillation
1076344|NCT01678456|Critical Event Committee
1076345|NCT01678456|Serious adverse events
1076346|NCT01678456|Thromboembolic complications
1076347|NCT01678456|Cardiac and noncardiac complications
1076348|NCT01678456|Bleeding complications
1076349|NCT01678456|Acute heart failure
1076350|NCT01678456|Syncope
1076351|NCT01678456|Resuscitation
1076352|NCT01678430|Chronic Lymphocytic Leukaemia
1076353|NCT01678430|Less fit
1076354|NCT01678430|CD20 antibody
1076355|NCT01678430|Ofatumumab
1076356|NCT01678430|Chlorambucil
1076357|NCT01678430|Bendamustine
1076358|NCT01678378|Adolescent
1076359|NCT01678378|Intervention
1076360|NCT01678378|Female
1076361|NCT01678378|Male
1076362|NCT01678378|Interpersonal Relations
1076363|NCT01678378|School Health Services
1076364|NCT01678378|Community-Based Participatory Research
1076365|NCT01678378|Randomized Controlled Trial
1076366|NCT01678378|Health Care Provider
1076367|NCT01678378|Training Program
1076368|NCT01678378|Harm Reduction
1076369|NCT01678378|Prevention
1076370|NCT01678378|Reproductive Coercion
1076371|NCT01678378|Tech-Based Abuse
1076372|NCT01678378|Social Environment
1076373|NCT01678378|Sexual Partners
1076374|NCT01678365|complicated appendicitis
1076375|NCT01678365|Children
1076376|NCT01678365|conservative therapy
1076377|NCT01678365|Study population: Children 1 month - 14 years with Complicated appendicitis
1076378|NCT01678365|Type of the study: prospective, open randomized
1076379|NCT01678352|Glioma
1076380|NCT01678352|Vaccine
1076381|NCT01678352|Immunotherapy
1076382|NCT01678352|WHO Grade II
1076383|NCT01678339|ACS
1076384|NCT01678339|AMI
1076385|NCT01678326|Diseases Classified Elsewhere
1076386|NCT01678313|Benign prostatic hyperplasia (BPH)
1076387|NCT01678313|Lower urinary tract symptoms (LUTS)
1076388|NCT01678313|Prostatic specific antigen (PSA)
1076389|NCT01678313|Cyclooxygenase-2 (COX-2)
1076390|NCT01678300|Ulcerative Colitis
1076391|NCT01678287|ASP1941
1076392|NCT01678274|Turner Syndrome
1076393|NCT01678274|Aortic Aneurysm
1076394|NCT01678274|Ischemic heart disease
1076395|NCT01678274|Hypertension
1076396|NCT01678274|Congenital Heart Defect
1076397|NCT01678274|Pulse Wave Velocity
1076398|NCT01678274|Augmentation Index
1076399|NCT01678274|Central Blood Pressure
1076400|NCT01678274|Agatston Score
1076401|NCT01678274|Segment involvement score
1076402|NCT01678261|Sex chromosome
1076403|NCT01678261|Turner Syndrome
1076404|NCT01678261|Klinefelter Syndrome
1076405|NCT01678261|Triple X Syndrome
1076406|NCT01678261|47 XYY syndrome
1076407|NCT01678261|Aortic Aneurysm
1076408|NCT01678261|Epigenetics
1076409|NCT01678261|Transcriptome
1076410|NCT01678261|non-coding RNA
1076411|NCT01678235|diabetes
1076412|NCT01678235|insulin pump
1076413|NCT01678235|glulisine
1076414|NCT01678235|aspart
1076415|NCT01678235|glycemic index
1076416|NCT01678222|Lymphocyte
1076417|NCT01678222|Cyclooxygenase 2
1076418|NCT01678222|Eicosanoid
1076419|NCT01678222|Prostaglandin
1076420|NCT01678209|Attention Deficit Hyperactivity Disorder
1076421|NCT01678209|Stimulant
1076422|NCT01678209|Non-stimulant
1076423|NCT01678209|Drug
1076424|NCT01678209|Methylphenidate
1076425|NCT01678209|Atomoxetine
1076426|NCT01678209|Strattera
1076427|NCT01678209|Concerta
1076428|NCT01678209|MACRO
1076429|NCT01678209|Medication
1076430|NCT01678209|Treatment
1076431|NCT01678209|Youth
1076432|NCT01678209|Adolescent
1076433|NCT01678209|Functional Magnetic Resonance Imaging
1076434|NCT01678209|Brain scan
1076435|NCT01678209|Imaging
1076436|NCT01678209|Response inhibition
1076437|NCT01678209|Inattentive
1076438|NCT01678209|Hyperactive
1076439|NCT01678209|Combined
1076440|NCT01678209|Medication Treatment
1076441|NCT01678209|Brain Imaging
1076442|NCT01678196|Family Members
1076443|NCT01678196|Community Outreach
1076444|NCT01678196|Internet
1076445|NCT01678170|blood-oxygen functional imaging technology
1076446|NCT01678170|diagnosis
1076447|NCT01678157|Esophageal Hernia
1076448|NCT01678157|Hernia, Esophageal
1076449|NCT01678157|Hernia, Paraesophageal
1076450|NCT01678157|Hiatal Hernia
1076451|NCT01678157|Paraesophageal Hiatal Hernia
1076452|NCT01678157|Sliding Esophageal Hernia
1076453|NCT01678157|Sliding Hiatal Hernia
1076454|NCT01678144|mitral valve
1076455|NCT01678144|mitral surgery
1076456|NCT01678144|mitral repair
1076457|NCT01678144|mitral annuloplasty
1076458|NCT01678118|Patient Navigation
1076459|NCT01678118|Tobacco dependent
1076460|NCT01678118|smoking
1076461|NCT01678118|Cessation
1076462|NCT01678118|11-028
1076463|NCT01678105|Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
1076464|NCT01678105|Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
1076465|NCT01678105|Salivary Gland Cancers
1076466|NCT01678105|ACC
1076467|NCT01678105|Dovitinib
1076468|NCT01678105|TKI258
1076469|NCT01678105|RTK Inhibitor
1076470|NCT01678079|Pregnancy
1076471|NCT01678079|Micronutrient Powder
1076472|NCT01678079|Calcium
1076473|NCT01678079|Iron
1076474|NCT01678079|Bangladesh
1076475|NCT01678066|Noninvasive cardiac output.
1076476|NCT01678066|Pediatrics.
1076477|NCT01678053|Botulinum Toxins, Type A
1076478|NCT01678040|Ventricular Volume
1076479|NCT01678040|Cardiac Magnetic Resonance
1076480|NCT01678040|Echocardiogram
1076481|NCT01678027|Family history
1076482|NCT01678014|Anorexia
1076483|NCT01678014|DBS
1076484|NCT01678014|Capsulotomy
1076485|NCT01678014|Signs and Symptoms
1076486|NCT01678001|plantar fascia
1076487|NCT01678001|plantar fascitis
1076488|NCT01678001|botulinum toxin
1076489|NCT01678001|Xeomin
1076490|NCT01677988|NEOADJUVANT FOLFIRINOX CHEMOTHERAPY
1076491|NCT01677988|LOCALIZED PANCREATIC HEAD ADENOCARCINOMA
1076492|NCT01677988|RADIATION THERAPY
1076493|NCT01677962|locally advanced, unresectable pancreatic adenocarcinoma
1076494|NCT01677962|Poly ICLC
1076495|NCT01677962|dendritic cells
1076496|NCT01677936|diabetes
1076497|NCT01677936|blood pressure
1076498|NCT01677936|lipid
1076499|NCT01677936|waist circumference
1076500|NCT01677936|BMI
1076501|NCT01677923|weight
1076502|NCT01677923|body mass index
1076503|NCT01677923|lipid profile
1076504|NCT01677923|glucose profile
1076505|NCT01677845|Localized Prostate Cancer
1076506|NCT01677845|Radiation
1076507|NCT01677806|Percutaneous vertebroplasty
1076508|NCT01677741|Children and Adolescents
1076509|NCT01677741|BRAF
1076510|NCT01677741|dabrafenib
1076511|NCT01677741|dose escalation
1076512|NCT01677741|BRF116013
1076513|NCT01677741|V600-mutation positive
1076514|NCT01677741|BRF
1076515|NCT01677728|colorectal liver metastases
1076516|NCT01677728|chemotherapy
1076517|NCT01677728|cetuximab
1076518|NCT01677728|bevacizumab
1076519|NCT01677689|oral temperature
1076520|NCT01677689|respiratory symptom
1076521|NCT01677689|cough
1076522|NCT01677689|nasal obstruction
1076523|NCT01677689|sore throat
1076524|NCT01677689|fever
1076525|NCT01677676|Influenza A
1076526|NCT01677663|autism
1076527|NCT01677663|clinical phenotypes
1076528|NCT01677663|neuropsychology
1076529|NCT01677663|imaging endophenotypes
1076530|NCT01677663|family-based cohort
1076531|NCT01677663|knoutout mice
1076532|NCT01677650|Spinal Fusion
1076533|NCT01677650|Opioid Analgesia
1076534|NCT01677637|osteopenia, postmenopausal
1076535|NCT01677624|Hypervascular tumor
1076536|NCT01677624|arteriovenous malformation
1076537|NCT01677624|arterial embolization
1076538|NCT01677611|Resveratrol
1076539|NCT01677611|SIRT1
1076540|NCT01677611|AMPK
1076541|NCT01677598|Plaque Psoriasis
1076542|NCT01677598|Ustekinumab
1076543|NCT01677598|CNTO 1275
1076544|NCT01677598|Asia-Pacific
1076545|NCT01677546|diabetes
1076546|NCT01677546|insulin pump
1076547|NCT01677546|bolus calculator
1076548|NCT01677546|Contour Link
1076549|NCT01677533|Panel management
1076550|NCT01677533|Clinical microsystems
1076551|NCT01677533|Hypertension management
1076552|NCT01677533|Smoking cessation
1076553|NCT01677533|Continuing medical education
1076554|NCT01677533|Quality improvement,
1076555|NCT01677533|Population health
1076556|NCT01677520|adipose-derived stem cells
1076557|NCT01677520|viable ADSCs
1076558|NCT01677520|apoptosis
1076559|NCT01677520|necrosis
1076560|NCT01677520|cryopreservation
1076561|NCT01677507|glaucoma
1076562|NCT01677507|aqueous humor dynamics
1076563|NCT01677507|intraocular pressure
1076564|NCT01677468|Hepatocellular carcinoma
1076565|NCT01677468|Transarterial chemoembolization
1076566|NCT01677455|Hsp90 inhibitor
1076567|NCT01677455|ganetespib
1076568|NCT01677455|STA 9090
1076569|NCT01677442|nonintubated
1076570|NCT01677442|anaesthesia
1076571|NCT01677442|VATS
1076572|NCT01677429|panic disorder
1076573|NCT01677429|balance impairment
1076574|NCT01677429|virtual reality
1076575|NCT01677416|Rheumatoid arthritis
1076576|NCT01677416|Ultrasonography
1076577|NCT01677416|Synovitis
1076578|NCT01677416|Foot joints
1076579|NCT01677403|Bronchiectasis
1076580|NCT01677403|Tobramycin
1076581|NCT01677403|nebulised
1076582|NCT01677390|Antibody-Drug Conjugate
1076583|NCT01677390|monomethylauristatin F
1076584|NCT01677390|Carcinoma, Renal Cell
1076585|NCT01677390|Antigens, CD70
1076586|NCT01677390|Drug Therapy
1076587|NCT01677377|Schizophrenia
1076588|NCT01677377|Schizophrenic
1076589|NCT01677377|Schizophrenias
1076590|NCT01677364|induction of labour
1076591|NCT01677364|heart disease patients
1076592|NCT01677351|clonidine
1076593|NCT01677351|cataract surgery
1076594|NCT01677351|arrythmia
1076595|NCT01677351|anesthesic medication
1076596|NCT01677286|AL Amyloidosis
1076597|NCT01677286|Primary Amyloidosis
1076598|NCT01677286|Hereditary Amyloidosis
1076599|NCT01677286|Familial Amyloidosis
1076600|NCT01677286|SSA Amyloidosis
1076601|NCT01677286|Senile Systemic Amyloidosis
1076602|NCT01677286|AA Amyloidosis
1076603|NCT01677286|Secondary Amyloidosis
1076604|NCT01677286|Localized Amyloidosis
1076605|NCT01677286|Systemic Amyloidosis
1076606|NCT01677273|Respiratory chambers
1076607|NCT01677273|Energy expenditure
1076608|NCT01677273|Appetite
1076609|NCT01677273|Dairy proteins
1076610|NCT01677273|Diet induced thermogenesis
1076611|NCT01677273|Obesity
1076612|NCT01677260|Biguanide
1076613|NCT01677260|anti-hyperglycaemic
1076614|NCT01677260|bioavailability
1076615|NCT01677260|bioequivalence
1076616|NCT01677260|metformin
1076617|NCT01677260|pharmacokinetics
1076618|NCT01677247|sulphonylurea
1076619|NCT01677247|anti-hyperglycaemic
1076620|NCT01677247|bioavailability
1076621|NCT01677247|bioequivalence
1076622|NCT01677247|glimepiride
1076623|NCT01677247|pharmacokinetics
1076624|NCT01677234|Blood pressure
1076625|NCT01677221|acne
1076626|NCT01677221|inflammatory acne
1076627|NCT01677221|intense pulsed light
1076628|NCT01677208|Acute Ischemic Stroke
1076629|NCT01677208|Randomized Controlled Trial
1076630|NCT01677208|Traditional Chinese Medicine
1076631|NCT01677195|Mycotoxins
1076632|NCT01677195|Aflatoxin
1076633|NCT01677195|Fumonisin
1076634|NCT01677195|Aflatoxicosis
1076635|NCT01677195|Dietary
1076636|NCT01677195|Cancer
1076637|NCT01677182|Drug therapy
1076638|NCT01677143|Local anesthetic
1076639|NCT01677143|Preemptive analgesia
1076640|NCT01677143|Postoperative pain
1076641|NCT01677143|Laparoscopy
1076642|NCT01677143|Gynecological surgery
1076643|NCT01677143|Day-case surgery
1076644|NCT01677130|Clinical efficacy
1076645|NCT01677130|safety
1076646|NCT01677130|of HFOV treatment
1076647|NCT01677130|of patients
1076648|NCT01677104|GLP-1
1076649|NCT01677104|DPP-IV inhibitor
1076650|NCT01677104|microcirculation
1076651|NCT01677104|Exenatide
1076652|NCT01677104|Liraglutide
1076653|NCT01677104|Linagliptin
1076654|NCT01677091|Balance,Hemiplegia,Cervical vibration,Prism adaptation,Rehabilitation
1076655|NCT01677078|Major depressive disorder
1076656|NCT01677078|rTMS
1076657|NCT01677078|Neuronavigation
1076658|NCT01677065|Bioavailability
1076659|NCT01677065|Oxycodone
1076660|NCT01677065|Healthy Volunteers
1076661|NCT01677039|Bioavailability
1076662|NCT01677039|oxycodone
1076663|NCT01677039|ethanol interaction
1076664|NCT01677039|healthy volunteers
1076665|NCT01677013|Type 2; diabetes mellitus; stem cell; safety; efficacy
1076666|NCT01677000|bone infection
1076667|NCT01677000|staphylococcus aureus
1076668|NCT01677000|registry
1076669|NCT01676987|Asthma
1076670|NCT01676987|Budesonide
1076671|NCT01676987|Adrenergic beta-2 receptor agonists.
1076672|NCT01676974|Drug Resistance, Microbial
1076673|NCT01676974|Enterobacteriaceae
1076674|NCT01676974|ESBL
1076675|NCT01676974|Carbapenemase
1076676|NCT01676974|Travel
1076677|NCT01676948|SJIA
1076678|NCT01676948|Systemic Juvenile Idiopathic Arthritis
1076679|NCT01676948|children
1076680|NCT01676948|systemic autoinflammatory disease, ACZ885, canakinumab
1076681|NCT01676948|human monoclonal anti-interleukin-1β (IL-1 β) antibody
1076682|NCT01676948|hildhood immunizations vaccinations
1076683|NCT01676909|self-management
1076684|NCT01676896|children
1076685|NCT01676896|asthma
1076686|NCT01676896|quality of life
1076687|NCT01676896|self-management
1076688|NCT01676883|Body constitution
1076689|NCT01676883|Anthropometry
1076690|NCT01676883|Electric impedance
1076691|NCT01676870|exercise training
1076692|NCT01676870|exercise therapy
1076693|NCT01676870|physical fitness
1076694|NCT01676870|risk factors
1076695|NCT01676857|chronic pain, prostatitis, pelvic pain
1076696|NCT01676844|Phosphorus
1076697|NCT01676844|Phosphate
1076698|NCT01676844|Hypophosphataemia
1076699|NCT01676844|Osteopenia
1076700|NCT01676844|Prematurity
1076701|NCT01676805|Developing Novel Treatment Approaches
1076702|NCT01676805|Developing Therapeutic Agents
1076703|NCT01676805|Analysis of Genetic and Genomic Biology
1076704|NCT01676805|New Prognostic and Diagnostic Models
1076705|NCT01676805|Analysis of Cellular and Molecular Biology
1076706|NCT01676792|condyloma acuminate
1076707|NCT01676792|ano-genital warts
1076708|NCT01676792|genital warts
1076709|NCT01676792|cutaneous condyloma
1076710|NCT01676792|Vulva pre-cancerous lesions
1076711|NCT01676792|Vulvar Intraepitheral Neoplasia
1076712|NCT01676792|VIN
1076713|NCT01676792|EGW
1076714|NCT01676779|melanoma
1076715|NCT01676779|no evidence of disease
1076716|NCT01676779|resection
1076717|NCT01676779|macro-metastases
1076718|NCT01676766|Stargardt Disease
1076719|NCT01676766|Macular degeneration
1076720|NCT01676766|Retinal dystrophy
1076721|NCT01676740|hematinic therapy
1076722|NCT01676740|blood transfusion
1076723|NCT01676740|joint replacement
1076724|NCT01676727|Transcatheter Aortic valve Implantation
1076725|NCT01676727|Heart Valve Diseases
1076726|NCT01676727|Cardiovascular Diseases
1076727|NCT01676714|Dovitinib
1076728|NCT01676714|Fibroblast Growth Factor Receptor Biomarkers
1076729|NCT01676714|Anti-Vascular Endothelial Growth Factor Therapy
1076730|NCT01676688|alpha-1 antitrypsin
1076731|NCT01676688|deficiency
1076732|NCT01676688|Alfalastin
1076733|NCT01676688|safety
1076734|NCT01676675|whole virus
1076735|NCT01676675|inactivated
1076736|NCT01676675|influenza
1076737|NCT01676675|H5N1 vaccine
1076738|NCT01676675|safety
1076739|NCT01676675|immunogenicity
1076746|NCT01676636|Pregnancy
1076747|NCT01676636|Calcium
1076748|NCT01676636|Supplements
1076749|NCT01676623|Child nutrition
1076750|NCT01676623|Stunting
1076751|NCT01676623|Exclusive breastfeeding
1076752|NCT01676623|Complementary feeding
1076753|NCT01676623|Social franchise
1076754|NCT01676623|Mass media
1076755|NCT01676623|Counseling
1076756|NCT01676623|Facility-based
1076757|NCT01676610|Pulse Oximetry
1076758|NCT01676610|Pediatrics
1076759|NCT01676610|Pakistan
1076760|NCT01676610|Hypoxemia
1076761|NCT01676610|Neonatal Sepsis
1076762|NCT01676610|Pneumonia
1076763|NCT01676558|diffuse large B cell lymphoma
1076764|NCT01676558|radioimmunotherapy
1076765|NCT01676558|131I-rituximab
1076766|NCT01676532|School Board Health Center
1076767|NCT01676532|Pediatrics
1076768|NCT01676506|Wet AMD
1076769|NCT01676506|genetic polymorphisms
1076770|NCT01676506|Ranibizumab
1076771|NCT01676480|Prostate cancer
1076772|NCT01676480|ADT
1076773|NCT01676480|Endurance training
1076774|NCT01676454|Vasopressin
1076775|NCT01676454|Trauma
1076776|NCT01676454|Injury
1076777|NCT01676441|spinal cord injury
1076778|NCT01676441|mesenchymal stem cell
1076779|NCT01676428|Kidney
1076780|NCT01676428|Renal
1076781|NCT01676428|Radiotherapy
1076782|NCT01676428|Stereotactic
1076783|NCT01676428|Cancer
1076784|NCT01676415|Sinus disease
1076785|NCT01676415|Sinonasal complaints
1076786|NCT01676415|Chronic sinusitis
1076787|NCT01676415|Nasal polyps
1076788|NCT01676415|Chronic rhinosinusitis without nasal polyps
1076789|NCT01676415|Glucocorticoids
1076790|NCT01676415|Prednisone
1076791|NCT01676415|Topical mometasone
1076792|NCT01676415|Anti-inflammatory agents
1076793|NCT01676402|Influenza A (H1)
1076794|NCT01676402|Influenza A (H3)
1076795|NCT01676402|Influenza B
1076796|NCT01676402|DNA Vaccine
1076797|NCT01676402|Trivalent Inactivated Vaccine (TIV)
1076798|NCT01676402|Healthy Adults
1076799|NCT01676402|Intradermal (ID)
1076800|NCT01676389|Autism Spectrum Disorders
1076801|NCT01676376|CABG
1076802|NCT01676376|SVG
1076803|NCT01676376|nitinol mesh
1076804|NCT01676376|external saphenous vein graft support
1076805|NCT01676363|diflunisal
1076806|NCT01676363|anti-inflammatory agents, non-steroidal
1076807|NCT01676363|antiviral agents
1076808|NCT01676350|Intraosseous (IO) vascular access
1076809|NCT01676337|Text messaging
1076810|NCT01676337|Clinic appointment attendance
1076811|NCT01676337|Emergency department
1076812|NCT01676337|Primary care
1076813|NCT01676324|Fecal Calprotectin
1076814|NCT01676311|cognition
1076815|NCT01676311|seizures
1076816|NCT01676311|electroencephalography
1076817|NCT01676311|transcranial magnetic stimulation
1076818|NCT01676311|huperzine
1076819|NCT01676311|chinese club moss
1076820|NCT01676298|Cyp2C19
1076821|NCT01676298|Genotyping
1076822|NCT01676298|Spartan
1076823|NCT01676298|Reproducibility
1076824|NCT01676285|Cirrhosis
1076825|NCT01676285|cirrhotic cardiomyopathy
1076826|NCT01676285|cardiac remodeling
1076827|NCT01676285|cardiomyopathy
1076828|NCT01676285|metoprolol succinate
1076829|NCT01676285|betablockers
1076830|NCT01676259|siRNA
1076831|NCT01676259|RNA interference (RNAi)
1076832|NCT01676259|Cancer
1076833|NCT01676259|Pancreatic ductal adenocarcinoma
1076834|NCT01676259|Locally Advanced Pancreatic cancer
1076835|NCT01676259|Solid tumor
1076836|NCT01676259|Non operable pancreatic ductal adenocarcinoma
1076837|NCT01676207|coronary collateral circulation
1076838|NCT01676207|extracardiac coronary collaterals
1076839|NCT01676207|coronary artery disease
1076840|NCT01676207|coronary circulation
1076841|NCT01676207|internal mammary artery
1076842|NCT01676194|Transarterial Chemoembolization
1076843|NCT01676194|Liver transplantation
1076844|NCT01676194|Hepatocellular carcinoma
1076845|NCT01676181|Obstructive sleep apnea syndrome
1076846|NCT01676181|Children
1076847|NCT01676181|Polysomnography
1076848|NCT01676181|Surgery
1076849|NCT01676181|Coblation
1076850|NCT01676181|Tonsils
1076851|NCT01676181|Tonsillectomy
1076852|NCT01676155|Tuberculosis, latent tuberculosis infection, apoptosis, predictor
1076853|NCT01676129|temporomandibular joint disorders
1076854|NCT01676129|nocipoint
1076855|NCT01676129|physical therapy
1076856|NCT01676103|Parkinson's Disease (PD)
1076857|NCT01676103|Orthostatic hypotension (OH)
1076858|NCT01676077|LGMD2B
1076859|NCT01676077|Miyoshi Myopathy
1076860|NCT01676077|Dysferlin
1076861|NCT01676077|Dysferlinopathy
1076862|NCT01676077|Limb Girdle muscular dystrophy type 2b
1076863|NCT01676077|Muscular Dystrophy
1076864|NCT01676064|intraocular pressure
1076865|NCT01676064|perioperative fluid
1076866|NCT01676064|trendelenburg position
1076867|NCT01676064|laparoscopic gynecologic surgery
1076868|NCT01676038|Total Knee Replacement, Computer-Assisted Surgery
1076869|NCT01676025|pheochromocytoma
1076870|NCT01676025|aldosteronism
1076871|NCT01676025|cushing's syndrome
1076872|NCT01676025|adrenal incidentaloma
1076873|NCT01676025|Conn's syndrome
1076874|NCT01675999|Neoadjuvant chemotherapy
1076875|NCT01675999|Locally advanced malignant neoplasm
1076876|NCT01675999|colon cancer
1076877|NCT01675973|Ranolazine
1076878|NCT01675973|renal impairment
1076879|NCT01675960|chronic irritability
1076880|NCT01675960|chronic pain
1076881|NCT01675960|Neurologically impaired
1076882|NCT01675960|gabapentin
1076883|NCT01675921|Asthma
1076884|NCT01675921|Facebook
1076885|NCT01675921|teenagers
1076886|NCT01675921|ACT
1077138|NCT01674803|biodegradable polymer
1076887|NCT01675895|Hyperbaric Levobupivacaine
1076888|NCT01675895|İntrathecal
1076889|NCT01675895|Lidocaine
1076890|NCT01675895|TUR-P
1076891|NCT01675882|Food allergy
1076892|NCT01675882|Immediate hypersensitivity
1076893|NCT01675882|Whole peanut extract
1076894|NCT01675882|Allergenic product
1076895|NCT01675882|Specific Immunotherapy
1076896|NCT01675882|Epicutaneous Immunotherapy (EPIT)
1076897|NCT01675869|Attention-Deficit/Hyperactivity Disorder
1076898|NCT01675869|Executive function
1076899|NCT01675869|Preschooler
1076900|NCT01675869|Metacognition
1076901|NCT01675856|Glasgow-Blatchford score
1076902|NCT01675856|Gastrointestinal bleeding
1076903|NCT01675843|Infertility
1076904|NCT01675843|PCOS
1076905|NCT01675843|IUI
1076906|NCT01675817|heparin rebound
1076907|NCT01675817|protamine
1076908|NCT01675817|cardiopulmonary bypass
1076909|NCT01675817|cardiac surgery
1076910|NCT01675817|anti-Xa
1076911|NCT01675817|anti-IIa
1076912|NCT01675804|ADHD
1076913|NCT01675778|hydromorphone
1076914|NCT01675778|acute pain
1076915|NCT01675778|emergency department
1076916|NCT01675765|Cancer
1076917|NCT01675765|Cancer vaccine
1076918|NCT01675765|Listeria monocytogenes
1076919|NCT01675765|Listeria-based vaccines
1076920|NCT01675765|Pemetrexed
1076921|NCT01675765|Cisplatin
1076922|NCT01675765|T regulatory cells
1076923|NCT01675765|Mesothelin
1076924|NCT01675765|Malignant Pleural Mesothelioma
1076925|NCT01675765|Chemotherapy
1076926|NCT01675765|Standard of care
1076927|NCT01675765|Naive
1076928|NCT01675765|Front-line
1076929|NCT01675765|Immunotherapy
1076930|NCT01675765|MPM
1076931|NCT01675752|colonoscopy, narrow-band imaging
1076932|NCT01675739|colonoscopy
1076933|NCT01675739|bowel preparation
1076934|NCT01675739|short message service
1076935|NCT01675713|Lifestyle
1076936|NCT01675713|Physical activity
1076937|NCT01675700|Myofascial pain
1076938|NCT01675700|Trigger point
1076939|NCT01675700|Nitroglycerin
1076940|NCT01675687|dietary habits and obesity
1076941|NCT01675687|exercise habits and obesity
1076942|NCT01675687|cognition and obesity
1076943|NCT01675674|Mucopolysaccharidoses
1076944|NCT01675674|Prevalence
1076945|NCT01675674|Pediatric
1076946|NCT01675674|Rheumatology
1076947|NCT01675674|Mucopolysaccharidosis I
1076948|NCT01675674|Mucopolysaccharidosis II
1076949|NCT01675674|Mucopolysaccharidosis IV
1076950|NCT01675674|Mucopolysaccharidosis VI
1076951|NCT01675648|Opiate dependent
1076952|NCT01675648|inpatient detoxification
1076953|NCT01675622|Cancer Pain
1076954|NCT01675596|Aortic Stenosis
1076955|NCT01675596|Transfemoral
1076956|NCT01675596|Transcatheter Heart Valve
1076957|NCT01675583|Diabetic Wounds
1076958|NCT01675583|Hyperbaric Oxygen
1076959|NCT01675583|Laser Speckle Imaging
1076960|NCT01675583|Hyperbaric Oxygenation
1076961|NCT01675570|RX-10045
1076962|NCT01675570|Dry Eye Disease
1076963|NCT01675557|chronic kidney disease
1076964|NCT01675544|Heart failure
1076965|NCT01675531|Targin
1076966|NCT01675531|Chemotherapy Induced Peripheral Neuropathy (CIPN)
1076967|NCT01675518|Plasma concentration
1076968|NCT01675518|ASP7991
1076969|NCT01675518|food effect
1076970|NCT01675518|PTH (parathyroid hormone)
1076971|NCT01675492|Astigmatism
1076972|NCT01675492|refractive
1076973|NCT01675492|error
1076974|NCT01675492|LASIK
1076975|NCT01675479|refractive
1076976|NCT01675479|errors
1076977|NCT01675466|non-specific abdominal pain
1076978|NCT01675466|undifferentiated abdominal pain
1076979|NCT01675466|appendicitis
1076980|NCT01675466|appendicectomy
1076981|NCT01675466|appendectomy
1076982|NCT01675466|surgery
1076983|NCT01675466|laparoscopy
1076984|NCT01675466|antibiotics
1076985|NCT01675466|randomised controlled trial
1076986|NCT01675466|randomized controlled trial
1076987|NCT01675466|controlled clinical trial
1076988|NCT01675466|randomised
1076989|NCT01675466|placebo
1076990|NCT01675453|Organ dysfunction
1076991|NCT01675453|Hypertonic solution
1076992|NCT01675453|Extravascular water
1076993|NCT01675453|Cardiopulmonary Bypass
1076994|NCT01675414|ASD
1076995|NCT01675414|autism
1076996|NCT01675414|gastrointestinal
1076997|NCT01675414|gastrointestinal conditions in children with ASD
1076998|NCT01675401|Body Weight
1076999|NCT01675401|Obesity
1077000|NCT01675401|Weight Loss
1077001|NCT01675401|Vascular Function Markers
1077002|NCT01675388|Neonatal hypoxemic respiratory failure
1077003|NCT01675388|Extra Corporeal Membrane Oxygenation
1077004|NCT01675388|Neurodevelopmental outcomes
1077005|NCT01675388|Neuroimaging
1077006|NCT01675362|Extracorporeal shockwave lithotripsy (ESWL)
1077007|NCT01675362|Kidney calculi
1077008|NCT01675362|Renal protection
1077009|NCT01675362|Antioxidants
1077010|NCT01675362|Calcium channel blockers
1077139|NCT01674777|ASP1941
1077011|NCT01675362|Angiotensin receptor blockers
1077012|NCT01675349|Standardization
1077013|NCT01675349|Immunotherapy
1077014|NCT01675349|Skin prick test
1077015|NCT01675323|Restless Legs Syndrome
1077016|NCT01675323|RLS
1077017|NCT01675310|obesity, polycystic ovary syndrome, gestational diabetes
1077018|NCT01675297|Risedronate, cholecalciferol, BMD
1077019|NCT01675284|Avian Influenza
1077020|NCT01675284|Influenza A Virus Subtype H5N1
1077021|NCT01675284|Inactivated H5N1 Influenza Virion Vaccine
1077022|NCT01675284|Phase I
1077023|NCT01675284|Preventive H5N1 vaccination
1077024|NCT01675271|gestational diabetes
1077025|NCT01675271|inflammation
1077026|NCT01675271|autonomic nervous system
1077027|NCT01675245|Multiple Myeloma
1077028|NCT01675245|Cancer
1077029|NCT01675245|Velcade
1077030|NCT01675245|Bortezomib
1077031|NCT01675245|Chinese patients
1077032|NCT01675232|Atopic dermatitis
1077033|NCT01675232|Topical corticosteroid
1077034|NCT01675232|Pediatric
1077035|NCT01675232|Eczema
1077036|NCT01675219|bladder cancer
1077037|NCT01675219|recurrence
1077038|NCT01675219|photodynamic diagnosis
1077039|NCT01675219|PDD
1077040|NCT01675219|cost analysis
1077041|NCT01675206|Vascular calcification
1077042|NCT01675206|Hemodialysis
1077043|NCT01675206|Matrix Gla Protein
1077044|NCT01675206|Vitamin K2
1077045|NCT01675193|Amblyopia
1077046|NCT01675193|Vision-Screening
1077047|NCT01675180|pregnancy, oral health, attitude, awareness, streptococcus mutans, lactobacilli
1077048|NCT01675167|CLBP
1077049|NCT01675167|Chronic Low Back Pain
1077050|NCT01675167|Chronic Pain
1077051|NCT01675167|Back Pain
1077052|NCT01675154|hypertriglyceridemia
1077053|NCT01675141|NK Cell Function
1077054|NCT01675141|Immunomodulatory Drugs
1077055|NCT01675141|T Cell Activity
1077056|NCT01675141|Immune Stimulatory Effects
1077057|NCT01675141|Extended Dosing
1077058|NCT01675128|Human Eukaryotic Translation Initiation Factor 4E (eIF4E) protein
1077059|NCT01675128|Refractory
1077060|NCT01675128|Oncogene
1077061|NCT01675128|Maximum Tolerated Dose
1077062|NCT01675128|Safety
1077063|NCT01675115|Ischemic stroke
1077064|NCT01675115|Traditional Chinese Medication
1077065|NCT01675115|Aspirin
1077066|NCT01675102|del 17p
1077067|NCT01675102|chronic lymphocytic leukemia
1077068|NCT01675102|cll
1077069|NCT01675102|mutation
1077070|NCT01675102|p53
1077071|NCT01675089|bone disease
1077072|NCT01675089|kidney transplantation
1077073|NCT01675089|bisphosphonates
1077074|NCT01675076|Hematoma
1077075|NCT01675076|novel oral anti-coagulant (NOAC)
1077076|NCT01675076|Device surgery
1077077|NCT01675037|hypothalamic
1077078|NCT01675037|pituitary,
1077079|NCT01675037|endoscopic third ventriculostomy
1077080|NCT01675037|hydrocephalus
1077081|NCT01675024|Neupro, Pharmacokinetics, healthy Chinese subjects
1077082|NCT01674998|REM Sleep Behavior Disorder
1077083|NCT01674998|RBD
1077084|NCT01674998|Dream
1077085|NCT01674998|Dreams
1077086|NCT01674985|Decitabine
1077087|NCT01674985|microtransplantation
1077088|NCT01674985|myelodysplastic syndromes
1077089|NCT01674985|chemotherapy
1077090|NCT01674972|NAFLD
1077091|NCT01674972|NASH
1077092|NCT01674972|GLP-1
1077093|NCT01674959|gastric cancer
1077094|NCT01674959|radiation
1077095|NCT01674959|chemotherapy
1077096|NCT01674946|GI-physiology
1077097|NCT01674946|CDCA
1077098|NCT01674946|bile acids
1077099|NCT01674946|TGR5
1077100|NCT01674946|satiation peptides
1077101|NCT01674933|dental
1077102|NCT01674933|prevention
1077103|NCT01674933|caries
1077104|NCT01674933|oral
1077105|NCT01674933|children
1077106|NCT01674920|Pediatric obesity
1077107|NCT01674920|resiliency
1077108|NCT01674920|physical activity
1077109|NCT01674920|dietary patterns
1077110|NCT01674920|children
1077111|NCT01674881|Mindfulness
1077112|NCT01674881|breast cancer
1077113|NCT01674881|chronic pain
1077114|NCT01674881|mediators
1077115|NCT01674881|distress
1077116|NCT01674881|Breast cancer survivors
1077117|NCT01674881|Effectiveness of MBCT on chronic pain
1077118|NCT01674881|Potential mediators and moderators
1077119|NCT01674881|Effectiveness of MBCT on psychological symptoms
1077120|NCT01674868|stroke
1077121|NCT01674868|recovery
1077122|NCT01674868|fluoxetine
1077123|NCT01674868|aphasia
1077124|NCT01674868|neglect
1077125|NCT01674868|motor
1077126|NCT01674855|PEG-G-CSF
1077127|NCT01674842|Triple negative
1077128|NCT01674842|Stage II
1077129|NCT01674842|Stage III
1077130|NCT01674803|drug-eluting stent
1077131|NCT01674803|zotarolimus
1077132|NCT01674803|everolimus
1077133|NCT01674803|sirolimus
1077134|NCT01674803|all comers population
1077135|NCT01674803|target vessel failure
1077136|NCT01674803|coronary artery disease
1077137|NCT01674803|durable polymer
1077140|NCT01674777|Food effect
1077141|NCT01674777|Pharmacokinetics
1077142|NCT01674751|pre-ordering
1077143|NCT01674751|healthy eating
1077144|NCT01674751|mindfulness
1077145|NCT01674751|incentives
1077146|NCT01674751|employees
1077147|NCT01674738|Non Small Cell Lung Cancer
1077148|NCT01674738|NSCLC Stage IV
1077149|NCT01674738|Non-Squamous Advanced Non-Small-Cell Lung-Cancer (Stage IV)
1077150|NCT01674725|Hepatitis C virus
1077151|NCT01674725|Hepatitis C Genotype 1
1077152|NCT01674725|Hepatitis C
1077153|NCT01674725|Interferon-Free
1077154|NCT01674725|Chronic Hepatitis C
1077155|NCT01674725|Ombitasvir
1077156|NCT01674725|Ribavirin
1077157|NCT01674725|Viekira PAK
1077158|NCT01674725|Dasabuvir
1077159|NCT01674725|Paritaprevir
1077160|NCT01674712|Fibrates
1077161|NCT01674712|Dyslipidemia
1077162|NCT01674686|Vasospasm
1077163|NCT01674686|Sarpogrelate
1077164|NCT01674686|Statin
1077165|NCT01674673|panic disorder
1077166|NCT01674673|SSRIs pharmacotherapy
1077167|NCT01674673|Cognitive Behavioral therapy
1077168|NCT01674660|hemodialysis
1077169|NCT01674660|blood pressure variability
1077170|NCT01674660|volume status
1077171|NCT01674647|rivaroxaban
1077172|NCT01674647|oral anticoagulant
1077173|NCT01674647|nonvalvular atrial fibrillation
1077174|NCT01674647|cardioversion
1077175|NCT01674647|stroke
1077176|NCT01674647|transient ischemic attack
1077177|NCT01674647|thromboembolism
1077178|NCT01674647|cardiovascular event
1077179|NCT01674634|XIAFLEX
1077180|NCT01674634|XIAPEX
1077181|NCT01674634|Dupuytren's disease
1077182|NCT01674634|contracture
1077183|NCT01674621|BA058
1077184|NCT01674621|Abaloparatide-SC
1077185|NCT01674621|abaloparatide
1077186|NCT01674621|Abaloparatide-TD
1077187|NCT01674621|Osteo
1077188|NCT01674621|Osteoporosis
1077189|NCT01674621|Transdermal
1077190|NCT01674621|Patch
1077191|NCT01674608|intensive care
1077192|NCT01674608|mobilization
1077193|NCT01674608|rehabilitation
1077194|NCT01674608|critical care
1077195|NCT01674595|Olea sensitization
1077196|NCT01674582|Glioma
1077197|NCT01674582|Brain tumors
1077198|NCT01674582|Brain metastases
1077199|NCT01674582|MRI
1077200|NCT01674582|Cognitive measurement
1077201|NCT01674582|Neuropsychological evaluation
1077202|NCT01674582|DW-MRI
1077203|NCT01674582|P-MRI
1077204|NCT01674582|MRS
1077205|NCT01674569|VEGF
1077206|NCT01674569|PDGF
1077207|NCT01674569|AMD
1077208|NCT01674556|pancreatic
1077209|NCT01674556|cancer
1077210|NCT01674556|adenocarcinoma
1077211|NCT01674556|Ultrasound
1077212|NCT01674556|CEUS
1077213|NCT01674543|Physical exercise
1077214|NCT01674543|Schizophrenia
1077215|NCT01674543|symptoms
1077216|NCT01674543|IGF-1
1077217|NCT01674517|Bioequivalence
1077218|NCT01674517|Montelukast Sodium
1077219|NCT01674517|crossover
1077220|NCT01674504|Bioequivalence
1077221|NCT01674504|Montelukast Sodium
1077222|NCT01674504|crossover
1077223|NCT01674478|NEC, SBS, enterostomy, fish oil, Microlipid, Intralipid,
1077224|NCT01674478|enteral fat
1077225|NCT01674465|Kidney fibrosis
1077226|NCT01674465|Kidney hypoxia
1077227|NCT01674465|Calcineurin inhibitors
1077228|NCT01674452|Stroke
1077229|NCT01674452|Exercise and Physical Fitness
1077230|NCT01674439|Adipose-derived regenerative cells
1077231|NCT01674439|Cell therapy
1077232|NCT01674439|Autologous fat transfer
1077233|NCT01674439|Tissue engineering
1077234|NCT01674439|Craniofacial microsomia
1077235|NCT01674426|functional hypothalamic amenorrhea
1077236|NCT01674426|stress induced anovulation
1077237|NCT01674413|Crohn's Disease
1077238|NCT01674413|Crohn's
1077239|NCT01674413|Crohns
1077240|NCT01674413|Inflammatory Bowel Disease
1077241|NCT01674413|IBD
1077242|NCT01674413|Humira
1077243|NCT01674413|Adalimumab
1077244|NCT01674413|Adalimumab injection
1077245|NCT01674413|Higgins
1077246|NCT01674413|Calprotectin
1077247|NCT01674413|biomarkers
1077248|NCT01674413|Gastroenterology
1077249|NCT01674413|University of Michigan
1077250|NCT01674413|U of M
1077251|NCT01674387|electroacupuncture therapy
1077252|NCT01674387|neck pain
1077505|NCT01673139|Atrial fibrillation
1077253|NCT01674387|McGill Pain Questionnaire
1077254|NCT01674387|Acupuncture Therapy
1077255|NCT01674387|Electroacupuncture
1077256|NCT01674387|Meridians
1077257|NCT01674348|Diabetes Mellitus
1077258|NCT01674335|Fibromyalgia
1077259|NCT01674335|Chronic pain
1077260|NCT01674335|Chronic fatigue
1077261|NCT01674335|Activity pacing
1077262|NCT01674335|Operant learning
1077263|NCT01674335|Energy conservation
1077264|NCT01674335|Treatment
1077265|NCT01674335|Intervention
1077266|NCT01674335|Biopsychosocial factors
1077267|NCT01674335|Coping
1077268|NCT01674335|Mood
1077269|NCT01674335|Quality of life
1077270|NCT01674322|Healthy participants
1077271|NCT01674322|Ibrutinib
1077272|NCT01674322|PCI-32765
1077273|NCT01674322|B-cell malignancies
1077274|NCT01674322|CYP3A4
1077275|NCT01674296|Body Weight/physiology*
1077276|NCT01674296|Diet*/statistics & numerical data
1077277|NCT01674296|Diet*/trends
1077278|NCT01674296|Exercise/physiology*
1077279|NCT01674296|Female
1077280|NCT01674296|Humans
1077281|NCT01674296|Longitudinal Studies
1077282|NCT01674296|Middle Aged
1077283|NCT01674296|Obesity/epidemiology*
1077284|NCT01674296|Seasons*
1077285|NCT01674296|Time Factors
1077286|NCT01674257|Atherosclerosis
1077287|NCT01674257|Stroke
1077288|NCT01674257|Positron-emission tomography
1077289|NCT01674257|Ferumoxytol
1077290|NCT01674257|Magnetic resonance imaging
1077291|NCT01674257|Genetics
1077292|NCT01674257|Calcification
1077293|NCT01674257|Inflammation
1077294|NCT01674257|Flurodeoxyglucose F18
1077295|NCT01674257|Radiopharmaceuticals
1077296|NCT01674218|tuberculosis, safety, PA-824, QTc interval, moxifloxacin, healthy volunteers, crossover
1077297|NCT01674179|Fibromyalgia
1077298|NCT01674179|qEEG
1077299|NCT01674179|Sleep
1077300|NCT01674179|Pain
1077301|NCT01674153|Intra-dialytic exercise
1077302|NCT01674153|Toxin removal
1077303|NCT01674153|Hemodiafiltration
1077304|NCT01674153|Inter-compartmental resistance
1077305|NCT01674153|Cardiac output
1077306|NCT01674140|estrogen receptor-positive breast cancer
1077307|NCT01674140|HER2-negative breast cancer
1077308|NCT01674140|stage IA breast cancer
1077309|NCT01674140|stage IB breast cancer
1077310|NCT01674140|stage II breast cancer
1077311|NCT01674140|stage IIIA breast cancer
1077312|NCT01674140|stage IIIB breast cancer
1077313|NCT01674140|stage IIIC breast cancer
1077314|NCT01674140|progesterone receptor-positive breast cancer
1077315|NCT01674140|male breast cancer
1077316|NCT01674114|Cesarean Section
1077317|NCT01674114|Anesthetics, Local
1077318|NCT01674101|Lower extremity malignancy
1077319|NCT01674088|Irritable Bowel Syndrome
1077320|NCT01674088|breath testing
1077321|NCT01674088|carbon-13
1077322|NCT01674075|safety
1077323|NCT01674075|J-Tip Delivery System
1077324|NCT01674075|pharmacokinetic profile
1077325|NCT01674049|nutrition
1077326|NCT01674049|nutrient
1077327|NCT01674049|timing
1077328|NCT01674049|diabetes
1077329|NCT01674049|family history
1077330|NCT01674049|dairy
1077331|NCT01673971|hemangioma
1077332|NCT01673958|Eccentric exercise
1077333|NCT01673958|Aging
1077334|NCT01673958|Heart failure
1077335|NCT01673958|Muscle strength loss
1077336|NCT01673958|Sarcopenia
1077337|NCT01673945|EUS-FNA, Forward viewing EUS scope, accuracy, Curvilinear EUS scope
1077338|NCT01673932|stroke
1077339|NCT01673932|chronic stroke
1077340|NCT01673932|ischemic stroke
1077341|NCT01673932|umbilical cord blood
1077342|NCT01673932|mononuclear cell
1077343|NCT01673932|transplant
1077344|NCT01673906|positron-emission tomography
1077345|NCT01673906|neuroendocrine tumors
1077346|NCT01673906|endosonography
1077347|NCT01673906|tomography, X-ray computed
1077348|NCT01673906|biopsy, fine needle
1077349|NCT01673906|sensitivity and sensibility
1077350|NCT01673893|ClearWay
1077351|NCT01673893|Glycoprotein
1077352|NCT01673893|Primary Coronary Intervention
1077353|NCT01673893|Abciximab
1077354|NCT01673893|ST Elevation Myocardial Infarction
1077355|NCT01673893|Non-ST Elevation Myocardial Infarction
1077356|NCT01673893|STEMI
1077357|NCT01673893|NSTEMI
1077358|NCT01673893|Medicare
1077359|NCT01673893|Medicaid
1077360|NCT01673893|Registry
1077361|NCT01673893|catheterization
1077362|NCT01673893|readmission
1077363|NCT01673893|Acute Coronary Syndrome
1077364|NCT01673893|ClearwayRx Catheter
1077365|NCT01673841|bypass grafting
1077366|NCT01673828|Brain Injuries
1077367|NCT01673828|Pregnanolone
1077368|NCT01673828|Epilepsy
1077369|NCT01673815|optic disk
1077370|NCT01673815|fundoscopy
1077371|NCT01673815|pediatric
1077372|NCT01673815|clinical examination
1077373|NCT01673802|Cholangiocarcinoma
1077374|NCT01673789|Stem Cell Educator
1077375|NCT01673789|Cord blood stem cells
1077376|NCT01673789|Immune modulation
1077377|NCT01673789|Alopecia Areata
1077378|NCT01673776|Proximal femoral fracture
1077379|NCT01673776|multimodal intervention
1077380|NCT01673776|goal directed therapy (GDT)
1077381|NCT01673776|hemodynamic intervention
1077382|NCT01673776|outcome
1077383|NCT01673763|ERCP
1077384|NCT01673763|endoscopy
1077385|NCT01673763|pancreatitis
1077386|NCT01673750|Adolescents
1077387|NCT01673750|Body Image
1077388|NCT01673698|obesity
1077389|NCT01673698|weight loss
1077390|NCT01673685|COPD
1077391|NCT01673685|Oxygen cylinder
1077392|NCT01673685|Portable oxygen cylinder
1077393|NCT01673685|Battery powered delivery device
1077394|NCT01673685|mobility
1077395|NCT01673685|dyspnoea
1077396|NCT01673685|Quality of Life
1077397|NCT01673685|Cost effectiveness
1077398|NCT01673646|SOM230, Pasireotide, acromegaly, Phase II
1077399|NCT01673594|ADHD
1077400|NCT01673594|Naltrexone
1077401|NCT01673594|SODAS MPH
1077402|NCT01673594|Stimulant-Induced Euphoria
1077403|NCT01673594|Substance Abuse
1077404|NCT01673594|Adults
1077405|NCT01673581|Low Risk
1077406|NCT01673555|GSK1278863
1077407|NCT01673555|Pulmonary artery pressure
1077408|NCT01673529|Pruritus
1077409|NCT01673529|TRPV1
1077410|NCT01673529|Cowhage
1077411|NCT01673529|Atopic Dermatitis
1077412|NCT01673529|Capsaicin
1077413|NCT01673529|Itch
1077414|NCT01673529|Histamine
1077415|NCT01673529|healthy volunteers
1077416|NCT01673529|SB705498
1077417|NCT01673529|Clinical
1077418|NCT01673516|Renal sympathetic denervation
1077419|NCT01673516|Impedance cardiography
1077420|NCT01673503|Myopia
1077421|NCT01673503|refractive surgery
1077422|NCT01673503|all femtosecond laser
1077423|NCT01673503|ReLEx flex
1077424|NCT01673503|ReLEx smile
1077425|NCT01673490|Benign Prostatic Hyperplasia
1077426|NCT01673490|dutasteride and tamsulosin
1077427|NCT01673464|mild Traumatic Brain Injury
1077428|NCT01673464|mTBI
1077429|NCT01673464|Concussion
1077430|NCT01673451|insomnia
1077431|NCT01673438|solid tumor
1077432|NCT01673438|aldoxorubicin
1077433|NCT01673438|phase 1
1077434|NCT01673438|INNO-206
1077435|NCT01673438|doxorubicin
1077436|NCT01673425|Influenza
1077437|NCT01673425|Influenza Vaccines
1077438|NCT01673425|Vaccines, Attenuated
1077439|NCT01673425|Immunity, Mucosal
1077440|NCT01673412|venous leg ulcer healing prognostic factors
1077441|NCT01673399|repeated implantation failure (RIF)
1077442|NCT01673399|atosiban
1077443|NCT01673399|pregnancy
1077444|NCT01673386|Tivozanib hydrochloride
1077445|NCT01673386|renal cell carcinoma
1077446|NCT01673386|subject preference
1077447|NCT01673386|quality of life
1077448|NCT01673373|Renal Artery Stenosis
1077449|NCT01673373|Renal Artery Obstruction
1077450|NCT01673373|Renovascular Hypertension
1077451|NCT01673373|Resistant Hypertension
1077452|NCT01673373|Renal Revascularization
1077453|NCT01673373|Atherosclerotic Renal Artery Stenosis
1077454|NCT01673373|ARAS (Atherosclerotic Renal Artery Stenosis)
1077455|NCT01673373|RAS (Renal Artery Stenosis)
1077456|NCT01673373|Uncontrolled hypertension
1077457|NCT01673373|Hypertension
1077458|NCT01673373|systolic blood pressure
1077459|NCT01673373|blood pressure
1077460|NCT01673360|vaginal repair
1077461|NCT01673360|urinary slings
1077462|NCT01673360|POP
1077463|NCT01673360|SUI
1077464|NCT01673360|prolapse
1077465|NCT01673360|incontinence
1077466|NCT01673347|allograft
1077467|NCT01673347|great toe
1077468|NCT01673334|Pancreas Tumor EUS FNA Core Biopsy Procore FNB
1077469|NCT01673321|Yogurt
1077470|NCT01673321|Milk
1077471|NCT01673321|Protein
1077472|NCT01673321|Food intake
1077473|NCT01673321|Appetite
1077474|NCT01673321|Glucose
1077475|NCT01673321|Insulin
1077476|NCT01673295|Lupus Nephritis
1077477|NCT01673295|Rituximab
1077478|NCT01673282|Lacosamide
1077479|NCT01673282|Vimpat
1077480|NCT01673282|Focal Epilepsy
1077481|NCT01673282|Drug Load
1077482|NCT01673282|AED
1077483|NCT01673282|SP1065
1077484|NCT01673269|ERCP
1077485|NCT01673269|Direct cholangioscopic examination of the common bile duct
1077486|NCT01673269|Choledocholithiasis
1077487|NCT01673269|Cholangiocarcinoma
1077488|NCT01673269|Benign stricture of common bile duct
1077489|NCT01673243|Smoking cessation
1077490|NCT01673243|Household smoking bans
1077491|NCT01673243|Cancer
1077492|NCT01673243|Sickle cell disease
1077493|NCT01673204|surrogate marker,
1077494|NCT01673204|circulating soluble TNF receptor,
1077495|NCT01673204|diabetic nephropathy
1077496|NCT01673178|Type 2 diabetes
1077497|NCT01673178|safety
1077498|NCT01673178|multiple dose
1077499|NCT01673178|intravenous
1077500|NCT01673152|Obesity
1077501|NCT01673152|Overweight
1077502|NCT01673152|Satiety
1077503|NCT01673152|Oligofructose
1077504|NCT01673152|Prebiotic
1077506|NCT01673139|Exercise
1077507|NCT01673126|vegetative state
1077508|NCT01673126|minimally conscious state
1077509|NCT01673126|disorders of consciousness
1077510|NCT01673126|transcranial direct current stimulation
1077511|NCT01673113|cryolipolysis, sensory nerve function, Zeltiq
1077512|NCT01673100|physical activity
1077513|NCT01673100|percutaneous coronary intervention
1077514|NCT01673100|heart disease
1077515|NCT01673087|stress biology
1077516|NCT01673087|cortisol
1077517|NCT01673087|adrenocorticotropin
1077518|NCT01673087|salivary biomarkers
1077519|NCT01673061|Abscess
1077520|NCT01673061|Boils
1077521|NCT01673061|Anesthetics, Local
1077522|NCT01673061|Lidocaine
1077523|NCT01673061|Vapocoolant
1077524|NCT01673061|1,1,1,3,3-Pentafluoropropane
1077525|NCT01673061|1,1,1,2-Tetrafluoroethane
1077526|NCT01673048|Elastic stable intramedullary nailing
1077527|NCT01673048|biomechanical testing
1077528|NCT01673048|fracture
1077529|NCT01673048|femur
1077530|NCT01673048|treatment
1077531|NCT01673048|children
1077532|NCT01673048|adolescents
1077533|NCT01673009|Gleevec
1077534|NCT01672996|Use in Abdominal
1077535|NCT01672996|Contrast Enhanced
1077536|NCT01672996|Computed Tomography
1077537|NCT01672996|Optimize concentration
1077538|NCT01672996|dosage of Ioforminol Injection
1077539|NCT01672983|Japanese
1077540|NCT01672983|Hepatitis C
1077541|NCT01672983|Genotype 2
1077542|NCT01672983|Genotype 1b
1077543|NCT01672983|paritaprevir
1077544|NCT01672983|ombitasvir
1077545|NCT01672983|ritonavir
1077546|NCT01672983|VIEKIRAX Combination Tablets
1077547|NCT01672944|Biological specimen banks
1077548|NCT01672944|Health education
1077549|NCT01672944|Tissue banks
1077550|NCT01672944|Health care survey
1077551|NCT01672944|Tissue
1077552|NCT01672918|PET/CT
1077553|NCT01672918|Lymphoma
1077554|NCT01672918|Lymphadenopathy
1077555|NCT01672918|ALPS
1077556|NCT01672905|recurrent prostate cancer
1077557|NCT01672905|stage I prostate cancer
1077558|NCT01672905|stage IIA prostate cancer
1077559|NCT01672905|stage IIB prostate cancer
1077560|NCT01672905|stage III prostate cancer
1077561|NCT01672892|gastrointestinal complications
1077562|NCT01672892|perioperative/postoperative complications
1077563|NCT01672892|radiation toxicity
1077564|NCT01672892|urinary complications
1077565|NCT01672892|urinary tract toxicity
1077566|NCT01672892|endometrial clear cell carcinoma
1077567|NCT01672892|endometrial papillary serous carcinoma
1077568|NCT01672892|stage IA endometrial carcinoma
1077569|NCT01672892|stage IB endometrial carcinoma
1077570|NCT01672892|stage II endometrial carcinoma
1077571|NCT01672892|stage IIIA endometrial carcinoma
1077572|NCT01672892|stage IIIB endometrial carcinoma
1077573|NCT01672892|stage IIIC endometrial carcinoma
1077574|NCT01672892|endometrial adenocarcinoma
1077575|NCT01672892|cervical adenocarcinoma
1077576|NCT01672892|stage IB cervical cancer
1077577|NCT01672892|stage IIA cervical cancer
1077578|NCT01672892|stage IIB cervical cancer
1077579|NCT01672879|NASH
1077580|NCT01672879|cirrhosis
1077581|NCT01672879|Compensated Liver disease
1077582|NCT01672879|Monoclonal antibody
1077583|NCT01672879|LOXL2
1077584|NCT01672879|Simtuzumab
1077585|NCT01672879|Nonalcoholic Steatohepatitis
1077586|NCT01672879|Hepatic venous pressure gradient
1077587|NCT01672879|HVPG
1077588|NCT01672879|NAFLD
1077589|NCT01672879|MRE
1077590|NCT01672879|Liver biopsy
1077591|NCT01672866|NASH
1077592|NCT01672866|non cirrhotic
1077593|NCT01672866|Monoclonal antibody
1077594|NCT01672866|LOXL2
1077595|NCT01672866|Simtuzumab
1077596|NCT01672866|Nonalcoholic Steatohepatitis
1077597|NCT01672866|NAFLD
1077598|NCT01672866|Liver biopsy
1077599|NCT01672866|MRE
1077600|NCT01672853|PSC
1077601|NCT01672853|Sclerosis
1077602|NCT01672853|Monoclonal antibody
1077603|NCT01672853|LOXL2
1077604|NCT01672853|Simtuzumab
1077605|NCT01672853|Primary sclerosing cholangitis
1077606|NCT01672853|Liver fibrosis
1077607|NCT01672853|Liver disease
1077608|NCT01672853|MRCP
1077609|NCT01672853|MRE
1077610|NCT01672853|Liver biopsy
1077611|NCT01672840|Stage 1 Hypertension
1077612|NCT01672840|cocoa consumption
1077613|NCT01672840|Blood pressure
1077614|NCT01672840|Endothelial function
1077615|NCT01672840|arterial stiffness
1077616|NCT01672827|Alzheimer's Disease
1077617|NCT01672827|Mild Cognitive Impairment
1077618|NCT01672827|Positron Emission Tomography (PET)
1077619|NCT01672827|PET Images
1077620|NCT01672814|Keratoconus
1077621|NCT01672814|Collagen Crosslinking
1077622|NCT01672814|Riboflavin
1077623|NCT01672814|Microwave
1077624|NCT01672814|Keraflex
1077625|NCT01672775|Renal Cell Carcinoma
1077626|NCT01672775|AGS-16C3F
1077627|NCT01672775|Pharmacokinetics of AGS-16C3F
1077628|NCT01672762|diabetes mellitus
1077629|NCT01672762|serum Insulin
1077630|NCT01672762|blood glucose
1077631|NCT01672762|glucose excretion
1077632|NCT01672762|hypoglycemic agents
1077633|NCT01672762|ipragliflozin
1077634|NCT01672749|Scoliosis [MESH]
1077635|NCT01672749|Pediatrics [MESH]
1077636|NCT01672749|Early onset
1077637|NCT01672749|Growth guidance
1077638|NCT01672749|Growing rod
1077639|NCT01672749|Trolley
1077640|NCT01672749|Dual growing rod technique
1077641|NCT01672736|Relapsed or relapse/refractory Multiple Myeloma
1077642|NCT01672723|opioids
1077643|NCT01672723|social connection
1077644|NCT01672710|Hubbard detoxification
1077645|NCT01672710|Exercise
1077646|NCT01672710|Sauna therapy
1077647|NCT01672710|Niacin
1077648|NCT01672697|anal incontinence
1077649|NCT01672697|genital trauma
1077650|NCT01672697|physical therapy
1077651|NCT01672697|anal manometry
1077652|NCT01672684|quality of life
1077653|NCT01672658|TBI,
1077654|NCT01672658|vestibular
1077655|NCT01672645|Smoking cessation
1077656|NCT01672645|vaccine
1077657|NCT01672645|Phase 1
1077658|NCT01672619|craniosynostoses
1077659|NCT01672619|Osteogenesis Distraction
1077660|NCT01672619|craniotomy
1077661|NCT01672593|Autologous platelet rich fibrin glue;
1077662|NCT01672593|Enterocutaneous fistulas;
1077663|NCT01672593|Single low output GI fistulas;
1077664|NCT01672580|social networks
1077665|NCT01672580|nutrition
1077666|NCT01672580|vitamins
1077667|NCT01672580|chlorine
1077668|NCT01672567|Coronary Artery Disease
1077669|NCT01672567|Egg Consumption
1077670|NCT01672567|Endothelial Function
1077671|NCT01672554|Schizophrenia
1077672|NCT01672554|Anxiety disorder
1077673|NCT01672541|dating violence
1077674|NCT01672541|healthy relationship behaviors
1077675|NCT01672528|Patient Reported Outcome Measures
1077676|NCT01672528|PROMs
1077677|NCT01672528|Cardiac arrhythmia
1077678|NCT01672528|Cardiac ablation
1077679|NCT01672502|sleep
1077680|NCT01672502|firefighter
1077681|NCT01672502|fire
1077682|NCT01672502|apnea
1077683|NCT01672502|insomnia
1077684|NCT01672502|shift
1077685|NCT01672502|narcolepsy
1077686|NCT01672502|restless leg
1077687|NCT01672502|rls
1077688|NCT01672502|fatigue
1077689|NCT01672502|Optalert
1077690|NCT01672502|actigraph
1077691|NCT01672502|actigraphy
1077692|NCT01672502|actiwatch
1077693|NCT01672502|safety
1077694|NCT01672502|sleepiness
1077695|NCT01672502|sleepy
1077696|NCT01672502|work
1077697|NCT01672502|hours
1077698|NCT01672502|FEMA
1077699|NCT01672502|drowsy
1077700|NCT01672489|Drowsy
1077701|NCT01672489|Drive
1077702|NCT01672489|Driving
1077703|NCT01672489|Shift Work Disorder
1077704|NCT01672489|SWD
1077705|NCT01672489|EEG
1077706|NCT01672489|ECG
1077707|NCT01672489|Actiwatch
1077708|NCT01672489|Diary
1077709|NCT01672489|Bioharness
1077710|NCT01672489|Q-Sensor
1077711|NCT01672489|Q Sensor
1077712|NCT01672489|Liberty Mutual
1077713|NCT01672489|sleep
1077714|NCT01672489|impaired
1077715|NCT01672489|Optalert
1077716|NCT01672489|tracker
1077717|NCT01672489|vehicle
1077718|NCT01672489|questionnaire
1077719|NCT01672489|survey
1077720|NCT01672476|Fimasartan
1077721|NCT01672450|Histologically or cytologically proven melanoma; Stages III-IV; accessible cutaneous, subcutaneous, and/or nodal lesions; ECOG performance status 0 to 2
1077722|NCT01672437|Birth and parent preparation
1077723|NCT01672437|Parenting stress
1077724|NCT01672437|Depression
1077725|NCT01672437|self-efficacy
1077726|NCT01672437|social network and support
1077727|NCT01672424|NPO
1077728|NCT01672424|Gastric Emptying
1077729|NCT01672424|Ice Chips
1077730|NCT01672424|Protein Drink
1077731|NCT01672424|Ultrasound
1077732|NCT01672411|prostate cancer, PSA, markers, diagnosis, prognosis, pro-PSA
1077733|NCT01672398|CarePartner
1077734|NCT01672398|informal caregiver
1077735|NCT01672398|interactive voice response
1077736|NCT01672398|transition
1077737|NCT01672398|post-discharge
1077738|NCT01672398|chronic illness
1077739|NCT01672398|readmission
1077740|NCT01672398|self-care
1077741|NCT01672385|CarePartner
1077742|NCT01672385|informal caregiver
1077743|NCT01672385|interactive voice response
1077744|NCT01672385|transition
1077745|NCT01672385|post-discharge
1077746|NCT01672385|chronic illness
1077747|NCT01672385|readmission
1077748|NCT01672385|self-care
1077749|NCT01672359|cognitive functioning
1077750|NCT01672359|immune function
1077751|NCT01672359|cytokines
1077752|NCT01672359|growth factors
1077753|NCT01672359|quality of life
1077754|NCT01672359|dietary supplementation
1077755|NCT01672359|Ginkgo biloba
1077756|NCT01672359|Improvement of cognitive function
1077757|NCT01672346|PAF
1077758|NCT01672320|Robotic
1077759|NCT01672320|Arthroplasty
1077760|NCT01672320|Total Hip Arthroplasty
1077761|NCT01672320|Cup Positioning
1077762|NCT01672320|Outcomes
1077763|NCT01672307|hypotrichosis of eyebrows
1077764|NCT01672307|thinning eyebrows
1077765|NCT01672307|minoxidil
1077766|NCT01672307|placebo
1077767|NCT01672307|randomized
1077768|NCT01672294|caregiver
1077769|NCT01672294|end of life
1077770|NCT01672294|self-disclosure
1077771|NCT01672268|cardiac computed tomography
1077772|NCT01672268|Transcatheter Aortic Valve Implantation
1077773|NCT01672268|safety and efficacy
1077774|NCT01672255|exercise
1077775|NCT01672255|diabetes
1077776|NCT01672255|SSRIs
1077777|NCT01672216|Exercise Therapy
1077778|NCT01672216|Biofeedback (Psychology)
1077779|NCT01672216|Adult
1077780|NCT01672216|Chronic Obstipation/*therapy
1077781|NCT01672216|EMG - Biofeedback
1077782|NCT01672216|EMG - Triggered Stimulation
1077783|NCT01672216|Augmented biofeedback
1077784|NCT01672177|Geriatrics
1077785|NCT01672177|Aged
1077786|NCT01672177|Aging
1077787|NCT01672177|Chronic disease
1077788|NCT01672177|Self management
1077789|NCT01672164|proteogenomic biomarker panels
1077790|NCT01672151|Refractory Immune Thrombocytopenic Purpura
1077791|NCT01672151|rapamycin
1077792|NCT01672151|regulatory T cells
1077793|NCT01672138|PVAI
1077794|NCT01672138|CFAE
1077795|NCT01672138|NPAF
1077796|NCT01672112|analgesic efficacy
1077797|NCT01672112|oral codeine
1077798|NCT01672112|oral oxycodone
1077799|NCT01672112|postcraniotomy
1077800|NCT01672099|vitamin K2
1077801|NCT01672099|menaquinone-7
1077802|NCT01672099|vascular health
1077803|NCT01672073|pressure
1077804|NCT01672073|waveform
1077805|NCT01672073|arterial
1077806|NCT01672047|The 25(OH) vitamin D level
1077807|NCT01672047|The 1.25(OH) vitamin D level
1077808|NCT01672047|The intact PTH level
1077809|NCT01672047|The calcification score of coronary artery
1077810|NCT01672047|The microalbuminuria level
1077811|NCT01672021|Breast Cancer
1077812|NCT01672021|MRI PET-CT
1077813|NCT01672008|NOX-100
1077814|NCT01671995|Heart failure
1077815|NCT01671995|Quality of life
1077816|NCT01671969|determine effects of diet on renal and other parameters
1077817|NCT01671956|IBD
1077818|NCT01671956|UC
1077819|NCT01671956|Colitis
1077820|NCT01671956|Ulcerative Colitis
1077821|NCT01671943|small malignant invasive breast tumors
1077822|NCT01671917|Total knee arthroplasty
1077823|NCT01671917|Total knee replacement
1077824|NCT01671917|Knee osteoarthritis
1077825|NCT01671917|Education
1077826|NCT01671917|Exercise
1077827|NCT01671917|Handicap
1077828|NCT01671917|Function
1077829|NCT01671917|Cost-effectiveness
1077830|NCT01671917|Cost-utility
1077831|NCT01671917|Quality of life
1077832|NCT01671891|rectal cancer
1077833|NCT01671891|circulating tumor cells
1077834|NCT01671891|predict responses
1077835|NCT01671865|FSHD
1077836|NCT01671865|magnetic resonance imaging
1077837|NCT01671865|magnetic resonance spectroscopy
1077838|NCT01671826|Multiple Myeloma
1077839|NCT01671826|Autologous Stem Cell Transplantation
1077840|NCT01671826|Elderly Patients
1077841|NCT01671813|positive
1077842|NCT01671813|diffuse
1077843|NCT01671813|B-Cell
1077844|NCT01671813|elderly
1077845|NCT01671813|EBV
1077846|NCT01671813|DLBCL
1077847|NCT01671813|malignant
1077848|NCT01671813|pilot
1077849|NCT01671800|Hyperhidrosis
1077850|NCT01671800|Botulinum Toxin
1077851|NCT01671800|Amputation
1077852|NCT01671800|Phantom limb pain
1077853|NCT01671787|Hepatitis B
1077854|NCT01671787|HBV
1077855|NCT01671787|GS-7340
1077856|NCT01671787|TDF
1077857|NCT01671787|Tenofovir disoproxil fumarate
1077858|NCT01671787|Gilead
1077859|NCT01671787|Viread
1077860|NCT01671761|Healthy
1077861|NCT01671761|Control
1077862|NCT01671748|Venous Leg Ulcer
1077863|NCT01671748|Varicose Ulcer
1077864|NCT01671748|Chronic ulcer
1077865|NCT01671748|Chronic wound
1077866|NCT01671748|Ultrasound therapy
1077867|NCT01671748|MIST device
1077868|NCT01671748|Wound healing
1077869|NCT01671748|Low frequency non contact ultrasound
1077870|NCT01671735|prevention
1077871|NCT01671735|diabetes
1077872|NCT01671722|Bioequivalence
1077873|NCT01671722|Montelukast Sodium
1077874|NCT01671722|crossover
1077875|NCT01671709|Bioequivalence
1077876|NCT01671709|Montelukast Sodium
1077877|NCT01671709|crossover
1077878|NCT01671683|rectal cancer
1077879|NCT01671683|neoadjuvant chemoradiotherapy
1077880|NCT01671683|Capecitabine
1077881|NCT01671670|Functional dyspepsia
1077882|NCT01671670|postprandial distress syndrome
1077883|NCT01671657|In vitro fertilization
1077884|NCT01671657|Assisted reproductive therapy
1077885|NCT01671657|Time-lapse image recording
1077886|NCT01671657|Image analysis software
1077887|NCT01671644|In vitro fertilization
1077888|NCT01671644|Assisted reproductive therapy
1077889|NCT01671644|Time-lapse image recording
1077890|NCT01671644|Image analysis software
1077891|NCT01671618|Aortic dissection
1077892|NCT01671618|Aortic dilation
1077893|NCT01671618|Aortic Aneurysm
1077894|NCT01671618|ultrasound
1077895|NCT01671618|point-of-care
1077896|NCT01671618|echocardiography
1077897|NCT01671592|Cancer
1077898|NCT01671592|colorectal
1077899|NCT01671592|tumor
1077900|NCT01671592|neoplasms
1077901|NCT01671592|carcinoma
1077902|NCT01671592|vaccine
1077903|NCT01671566|Congenital Heart defect
1077904|NCT01671566|Exercise and Physical fitness
1077905|NCT01671566|Rehabilitation
1077906|NCT01671566|Quality of life
1077907|NCT01671566|Behaviour
1077908|NCT01671540|COPD
1077909|NCT01671540|IPV
1077910|NCT01671527|Deep Brain Stimulation
1077911|NCT01671527|DBS
1077912|NCT01671527|Transcranial Magnetic Stimulation
1077913|NCT01671527|TMS
1077914|NCT01671527|Cervical Dystonia
1077915|NCT01671527|Dystonia
1077916|NCT01671527|Control
1077917|NCT01671527|Healthy
1077918|NCT01671514|mitochondrial biogenesis
1077919|NCT01671514|skeletal muscle
1077920|NCT01671514|epicatechin
1077921|NCT01671501|HIV
1077922|NCT01671501|Acquired Immunodeficiency Syndrome
1077923|NCT01671501|Alcoholism
1077924|NCT01671501|Alcoholic Intoxication
1077925|NCT01671501|Substance-Related Disorders
1077926|NCT01671501|Intervention Studies
1077927|NCT01671501|Primary Health Care
1077928|NCT01671501|therapy
1077929|NCT01671501|prevention & control
1077930|NCT01671488|Anal Cancer
1077931|NCT01671488|Mitomycin
1077932|NCT01671488|5-Fluorouracil
1077933|NCT01671488|5-FU
1077934|NCT01671488|IMRT
1077935|NCT01671488|ADXS11-001
1077936|NCT01671475|Altered Mental Status
1077937|NCT01671475|Non-convulsive seizure
1077938|NCT01671475|Electroencephalography
1077939|NCT01671462|HPV
1077940|NCT01671462|Cervical Cancer
1077941|NCT01671462|Cervical Neoplasms
1077942|NCT01671449|Gastric cancer
1077943|NCT01671449|S-1
1077944|NCT01671449|Cisplatin
1077945|NCT01671449|Oxaliplatin
1077946|NCT01671436|Depression
1077947|NCT01671436|Guided Imagery
1077948|NCT01671436|Psychotherapy
1077949|NCT01671436|Meditation
1077950|NCT01671423|Cellulitis
1077951|NCT01671423|Skin infection
1077952|NCT01671423|Prednisone
1077953|NCT01671423|Steroid
1077954|NCT01671423|Anti-inflammatory
1077955|NCT01671410|Neonatal Abstinence Syndrome
1077956|NCT01671410|buprenorphine
1077957|NCT01671410|morphine
1077958|NCT01671410|benzodiazepine
1077959|NCT01671397|Obesity
1077960|NCT01671397|weight loss
1077961|NCT01671397|sleep hygiene
1077962|NCT01671397|diet
1077963|NCT01671397|exercise
1077964|NCT01671384|Valproate
1077965|NCT01671384|levocarnitine
1077966|NCT01671384|SMA
1077967|NCT01671384|physiotherapy
1077968|NCT01671384|placebo
1077969|NCT01671371|syncope
1077970|NCT01671371|point of care
1077971|NCT01671371|ultrasound
1077972|NCT01671371|echocardiography
1077973|NCT01671358|MRSA
1077974|NCT01671358|Contamination
1077975|NCT01671358|Isolation
1077976|NCT01671332|Carcinoma, non small cell lung
1077977|NCT01671332|Second line
1077978|NCT01671332|Third line
1077979|NCT01671319|breast cancer
1077980|NCT01671319|female
1077981|NCT01671319|women
1077982|NCT01671319|adjuvant
1077983|NCT01671306|Coronary collaterals
1077984|NCT01671306|diabetes mellitus
1077985|NCT01671306|monocyte subsets
1077986|NCT01671280|pneumonia
1077987|NCT01671280|pelvic inflammatory disease
1077988|NCT01671280|Zithromax
1077989|NCT01671280|Zithromac
1077990|NCT01671280|Japanese
1077991|NCT01671280|Regulatory Post Marketing Commitment Plan
1077992|NCT01671228|dialysis
1077993|NCT01671228|chronic kidney failure
1077994|NCT01671228|informed choice
1077995|NCT01671228|patient decision making
1077996|NCT01671228|decision aid
1077997|NCT01671215|endometrium
1077998|NCT01671215|myometrium
1077999|NCT01671215|fibroids
1078000|NCT01671215|uterine malformations
1078001|NCT01671176|Wide diameter implant
1078002|NCT01671176|ISQ
1078003|NCT01671176|Ponto
1078004|NCT01671176|Bone anchored implant
1078005|NCT01671163|Cancer
1078006|NCT01671163|Radiation therapy
1078007|NCT01671163|Fiducial markers
1078008|NCT01671150|inflammation
1078009|NCT01671150|depression
1078010|NCT01671150|social cognition
1078011|NCT01671150|neural activity
1078012|NCT01671137|Lactobacillus GG
1078013|NCT01671137|Functional Abdominal Pain
1078014|NCT01671137|Children
1078015|NCT01671137|Acute
1078016|NCT01671137|Gastroenteritis
1078017|NCT01671124|TG
1078018|NCT01671124|TC
1078019|NCT01671124|HDL
1078020|NCT01671124|LDL
1078021|NCT01671124|Albumin
1078022|NCT01671124|Hemoglobin
1078023|NCT01671124|Hematocrit
1078024|NCT01671124|Uric acid
1078025|NCT01671124|Sodium
1078026|NCT01671124|Potassium
1078027|NCT01671124|Calcium
1078028|NCT01671098|nitric oxide
1078029|NCT01671098|sinuplasty
1078030|NCT01671072|Chondrocyte cells
1078031|NCT01671072|Osteoarthritis
1078032|NCT01671072|Gene therapy
1078033|NCT01671033|Panic disorder
1078034|NCT01671033|cognitive behavior therapy
1078035|NCT01671033|Internet
1078036|NCT01671020|fimasartan
1078037|NCT01671020|absolute bioavailability
1078038|NCT01670994|cancer
1078039|NCT01670994|immunotherapy
1078040|NCT01670994|immunochemotherapy
1078041|NCT01670994|targeted
1078042|NCT01670994|metastatic
1078043|NCT01670994|interleukin-2
1078044|NCT01670994|antitumor
1078045|NCT01670994|TCR
1078046|NCT01670994|T-cell receptor
1078047|NCT01670994|p53
1078048|NCT01670994|p53 gene
1078049|NCT01670994|p53 tumor supressor protein
1078050|NCT01670994|HLA-A2 positive
1078051|NCT01670994|HLA-A*0201/p53 aa264-272
1078052|NCT01670994|HLA complex
1078053|NCT01670994|multiple myeloma
1078054|NCT01670994|IFN-γ and TNF-α
1078055|NCT01670994|refractory
1078056|NCT01670994|relapsed
1078057|NCT01670981|Ischemic dilated cardiomyopathy
1078058|NCT01670981|Heart failure
1078059|NCT01670981|ixCELL
1078060|NCT01670981|ixCELL DCM
1078061|NCT01670981|IDCM
1078062|NCT01670981|DCM
1078063|NCT01670981|stem cells
1078064|NCT01670981|MSC
1078065|NCT01670981|cell therapy
1078066|NCT01670955|Anemia
1078067|NCT01670955|preoperative
1078068|NCT01670955|gynecological patients
1078069|NCT01670955|Sorghum bicolor
1078070|NCT01670955|Packed Cells Volume
1078071|NCT01670942|pneumothorax
1078072|NCT01670942|trauma
1078073|NCT01670942|commercial air travel
1078074|NCT01670929|recurrent miscarriages
1078075|NCT01670929|progesterone
1078076|NCT01670916|Necrotizing enterocolitis
1078077|NCT01670916|Probiotics
1078078|NCT01670916|Preterm
1078079|NCT01670916|Infant
1078080|NCT01670890|temozolomide(TMZ)
1078081|NCT01670890|cisplatin(CDDP)
1078082|NCT01670890|recurrent malignant gliomas
1078083|NCT01670851|eLAPE,
1078084|NCT01670851|perineum,
1078085|NCT01670851|pelvic floor reconstruction
1078086|NCT01670838|subarachnoid haemorrhage
1078087|NCT01670838|cardiopulmonary complications
1078088|NCT01670825|Occipital neuralgia
1078089|NCT01670825|corticosteroid injection
1078090|NCT01670825|pulsed radiofrequency
1078091|NCT01670812|chronic lymphocytic leukemia
1078092|NCT01670812|ultra-high risk
1078093|NCT01670812|fresh frozen plasma
1078094|NCT01670812|methylprednisolone
1078095|NCT01670812|rituximab
1078096|NCT01670799|Ketorolac
1078097|NCT01670799|Bioavailability
1078098|NCT01670799|Pain
1078099|NCT01670760|Deep Tissue Temperature
1078100|NCT01670760|Zero Heat Flux Thermometry
1078101|NCT01670760|Thermometry
1078102|NCT01670760|Core Temperature
1078103|NCT01670708|Substance Use
1078104|NCT01670708|Illicit Drug Use
1078105|NCT01670708|Criminal Behavior
1078106|NCT01670695|IgG4-related disease
1078107|NCT01670695|IgG4-RD
1078108|NCT01670682|Stage III
1078109|NCT01670643|AMD
1078110|NCT01670643|vision rehabilitation
1078111|NCT01670643|video camera magnifier
1078112|NCT01670643|IVI
1078113|NCT01670643|DASS
1078114|NCT01670630|speculum
1078115|NCT01670630|vagina
1078116|NCT01670630|cervix
1078117|NCT01670630|examination
1078118|NCT01670578|P.R.P.
1078119|NCT01670578|viscosupplementation
1078120|NCT01670578|double-blind randomized
1078121|NCT01670578|intra-articular injections
1078122|NCT01670578|knee degenerative pathology
1078123|NCT01670578|early osteoarthritis
1078124|NCT01670565|Diffuse cutaneous systemic sclerosis
1078125|NCT01670565|Early Diffuse cutaneous systemic sclerosis
1078126|NCT01670539|Lung Cancer
1078127|NCT01670539|Telemonitoring
1078128|NCT01670539|Rural
1078129|NCT01670539|Nursing
1078130|NCT01670526|Traumatic Brain Injury
1078131|NCT01670526|Cognitive Impairment
1078132|NCT01670526|Rivastigmine
1078133|NCT01670526|Pharmacologic Actions
1078134|NCT01670526|TBI
1078135|NCT01670526|Memory
1078136|NCT01670526|Cholinesterase Inhibitors
1078137|NCT01670526|Cognition
1078138|NCT01670526|Head Trauma
1078139|NCT01670513|Psoriasis
1078140|NCT01670500|germline mutation
1078141|NCT01670500|BRCA1 mutation
1078142|NCT01670500|BRCA2 mutation
1078143|NCT01670487|Vapocoolant
1078144|NCT01670474|Temporary hemodialysis catheters
1078145|NCT01670474|Non-cuffed hemodialysis catheters
1078146|NCT01670474|Thrombolysis
1078147|NCT01670474|rt-PA
1078148|NCT01670474|Thrombosis
1078149|NCT01670474|Lifespan
1078150|NCT01670474|Blood flow rate
1078151|NCT01670474|Catheter related bacteriemia
1078152|NCT01670461|advance care planning, palliative care, pediatric
1078153|NCT01670448|Postoperative pain
1078154|NCT01670448|Chronic pain prevention
1078155|NCT01670448|Regional anesthesia
1078156|NCT01670448|Mastectomy
1078157|NCT01670435|Ciprofloxacin
1078158|NCT01670435|sepsis
1078159|NCT01670435|infection
1078160|NCT01670435|pneumonia
1078161|NCT01670435|peritonitis
1078162|NCT01670435|cholecystitis
1078163|NCT01670435|cholangitis
1078164|NCT01670435|anthrax
1078165|NCT01670422|CSOJ
1078166|NCT01670422|recurrence
1078167|NCT01670422|life-threatening complications
1078168|NCT01670422|risk factors
1078169|NCT01670409|Esophageal squamous cell carcinoma
1078170|NCT01670409|SMART
1078171|NCT01670409|IMRT
1078172|NCT01670409|Chemotherapy
1078173|NCT01670396|coronary stent implant
1078174|NCT01670396|polymorphism
1078175|NCT01670396|G protein
1078176|NCT01670396|drug-eluting stent
1078177|NCT01670396|restenosis
1078178|NCT01670383|Cardiac Arrest
1078179|NCT01670383|Sepsis
1078180|NCT01670383|Biological Markers
1078181|NCT01670383|Anti-Inflammation Agents
1078182|NCT01670383|Antioxidants
1078183|NCT01670370|Rituximab
1078184|NCT01670370|Gemcitabine
1078185|NCT01670370|Oxaliplatin
1078186|NCT01670370|aggressive B cell lymphoma
1078187|NCT01670357|Dry Eye Syndrome
1078188|NCT01670318|Chronic total occlusion
1078189|NCT01670318|Bifurcation lesion
1078190|NCT01670318|Left main trunk lesion
1078191|NCT01670318|Small vessel disease
1078192|NCT01670318|Multi vessel disease
1078193|NCT01670292|Low Back Pain
1078194|NCT01670279|Major Depressive Disorder (MDD)
1078195|NCT01670266|ONO-9054
1078196|NCT01670266|ocular hypertension
1078197|NCT01670266|OHT
1078198|NCT01670266|Open angle-glaucoma
1078199|NCT01670266|OAG
1078200|NCT01670266|Glaucoma
1078201|NCT01670266|Eye diseases
1078202|NCT01670240|IPAA
1078203|NCT01670240|Pouchitis
1078204|NCT01670240|Ulcerative colitis
1078205|NCT01670240|Pouch
1078206|NCT01670240|Adalimumab
1078207|NCT01670240|Humira
1078208|NCT01670227|EARLY CHILDHOOD
1078209|NCT01670227|UNIVERSAL PREVENTION
1078210|NCT01670214|RM
1078211|NCT01670214|R-CM
1078212|NCT01670214|based on ICHD-2 criteria
1078213|NCT01670188|Pneumatic sequential compression device (SCD)
1078214|NCT01670188|Peripherally Inserted Central Catheters (PICC)
1078217|NCT01670162|Pigment Epithelium of Eye
1078218|NCT01670162|Wet macular degeneration
1078219|NCT01670162|Macular degeneration
1078220|NCT01670149|Clostridium difficile
1078221|NCT01670149|Diarrhoea
1078222|NCT01670149|Rifaximin
1078223|NCT01670136|sildenafil
1078224|NCT01670136|preterm infants
1078225|NCT01670136|persistent pulmonary hypertension of the newborn
1078226|NCT01670123|Mobile phone
1078227|NCT01670123|electronic intervention
1078228|NCT01670123|behavioral intervention
1078229|NCT01670123|telehealth
1078230|NCT01670123|bipolar disorder
1078231|NCT01670110|Polycystic Liver Disease
1078232|NCT01670110|Autosomal dominant polycystic kidney disease
1078233|NCT01670110|Autosomal dominant polycystic liver disease
1078234|NCT01670110|Somatostatin analogs
1078235|NCT01670110|Pasireotide LAR
1078236|NCT01670110|SOM230
1078251|NCT01670071|Schizophrenia
1078252|NCT01670071|Paliperidone
1078253|NCT01670071|Risperidone
1078254|NCT01670071|Paliperidone extended-release (ER)
1078255|NCT01670071|Risperidone immediate-release (IR)
1078256|NCT01670019|Depression
1078257|NCT01670019|Antidepressant
1078258|NCT01670019|Antipsychotic
1078259|NCT01668953|Lateral Epicondylitis
1078260|NCT01668953|Tennis Elbow
1078261|NCT01668953|Platelet Rich Plasma
1078262|NCT01668953|Whole Blood
1078263|NCT01668953|Tendon Fenestration
1078264|NCT01668940|Morning Sickness
1078265|NCT01668940|Lillipops Iced Soothies
1078266|NCT01668940|Pregnancy
1078267|NCT01668940|Obstetrics
1078268|NCT01668914|Breast Cancer
1078269|NCT01668914|Clinically Axillary Node -Positive
1078270|NCT01668914|Sentinel Lymph Node Biopsy
1078271|NCT01668914|Internal Mammary
1078272|NCT01668901|warfarin
1078273|NCT01668901|aspirin
1078274|NCT01668875|head down postural drainage
1078275|NCT01668849|Plant exosomes
1078276|NCT01668849|Grape exosomes
1078277|NCT01668849|Grape extract
1078278|NCT01668849|Oral mucositis
1078279|NCT01668849|Head and Neck Cancer
1078280|NCT01668849|Immune response
1078281|NCT01668836|sirtuin
1078282|NCT01668836|atherosclerosis
1078283|NCT01668836|longevity
1078284|NCT01668836|calorie restriction
1078285|NCT01668836|resveratrol
1078286|NCT01668836|vascular reactivity
1078287|NCT01668810|prescription
1078288|NCT01668810|schizophrenia
1078289|NCT01668810|depression
1078290|NCT01668810|bipolar disorder
1078291|NCT01669993|Outcomes
1078292|NCT01669993|Quality improvement
1078293|NCT01669993|Patient Safety
1078294|NCT01669993|PACU
1078295|NCT01669993|Complications
1078296|NCT01669993|Adverse events
1078297|NCT01669993|Respiratory arrest
1078298|NCT01669993|Pain
1078299|NCT01669993|PONV
1078300|NCT01669993|Age
1078301|NCT01669993|Neonate
1078302|NCT01669993|Infant
1078303|NCT01669993|Child
1078304|NCT01669993|Ambulatory
1078305|NCT01669993|Inpatient
1078306|NCT01669993|General Anesthesia
1078307|NCT01669993|Otolaryngology
1078308|NCT01669993|Tonsillectomy
1078309|NCT01669993|Obstructive sleep apnea
1078310|NCT01669980|Infections
1078311|NCT01669980|Pediatrics
1078312|NCT01669980|Teflaro
1078313|NCT01669980|Ceftriaxone
1078314|NCT01669980|cephalosporin
1078315|NCT01669980|Vancomycin
1078316|NCT01669980|Clindamycin
1078317|NCT01669980|Amoxicillin Clavulanate
1078318|NCT01669980|Linezolid
1078319|NCT01669980|MRSA
1078320|NCT01669980|pneumonia
1078321|NCT01669954|HIV
1078322|NCT01669954|Bone mineral density
1078323|NCT01669954|Osteoporosis
1078324|NCT01669954|Vitamin D
1078325|NCT01669954|Fractures
1078326|NCT01669941|Pregnancy
1078327|NCT01669941|Plasmodium
1078328|NCT01669941|Malaria
1078329|NCT01669941|Prevention
1078330|NCT01669941|Kenya
1078331|NCT01669941|Piperaquine
1078332|NCT01669941|Dihydroartemisinin-Piperaquine
1078333|NCT01669941|Sulfadoxine Pyrimethamine
1078334|NCT01669876|Randomized
1078335|NCT01669876|Double-Blind
1078336|NCT01669876|Dietary Supplements
1078337|NCT01669863|ARDS
1078338|NCT01669850|Chronic kidney disease
1078339|NCT01669850|Arteriovenous fistula
1078340|NCT01669850|Surgical anastomosis
1078341|NCT01669850|Complications
1078342|NCT01669850|Patency
1078343|NCT01669850|Dialysis access
1078344|NCT01669837|Inguinal hernia
1078345|NCT01669837|Laparoscopy
1078346|NCT01669837|Surgical tissue glue
1078347|NCT01669811|Refractory Reflux Esophagitis,
1078348|NCT01669811|Japanese,
1078349|NCT01669811|Nexium,
1078350|NCT01669811|twice daily,
1078351|NCT01669811|oral administration
1078352|NCT01669798|Recurrent epithelial ovarian carcinoma
1078353|NCT01669798|Persistent epithelial ovarian carcinoma
1078354|NCT01669798|Bevacizumab resistant epithelial ovarian carcinoma
1078355|NCT01669746|Androgenetic Alopecia
1078356|NCT01669746|Male Pattern Baldness
1078357|NCT01669746|Female Pattern Baldness
1078358|NCT01669746|Hair Loss
1078359|NCT01669746|Baldness
1078360|NCT01669733|Breast Surgery
1078361|NCT01669733|Breast Biopsy
1078362|NCT01669733|Music Therapy
1078363|NCT01669720|Metastatic
1078364|NCT01669720|Colorectal
1078365|NCT01669720|Colorectal Cancer
1078366|NCT01669720|Resected or Ablated Metastatic Colorectal Cancer
1078367|NCT01669707|Endostar
1078368|NCT01669707|advanced Non-small cell lung cancer
1078369|NCT01669707|Continued Pumping into vein
1078370|NCT01669707|Gemcitabine
1078371|NCT01669707|Carboplatin
1078372|NCT01669694|Pelvic Pain
1078373|NCT01669694|Pelvic Floor Physical Therapy
1078374|NCT01669694|Biomarkers
1078375|NCT01669681|Severe asthma
1078376|NCT01669681|Medical economic
1078377|NCT01669681|care
1078378|NCT01669681|Cost efficiency
1078379|NCT01669681|CPAM
1078380|NCT01669681|EQ5D
1078381|NCT01669642|ketamine sedation
1078382|NCT01669642|pediatric
1078383|NCT01669642|abscess drainage
1078384|NCT01669642|fracture reduction
1078385|NCT01669616|Type 2 Diabetes
1078386|NCT01669616|Adults 18 years and older
1078387|NCT01669603|Common cold
1078388|NCT01669577|predictors
1078389|NCT01669577|trauma
1078390|NCT01669577|mortality
1078391|NCT01669564|Quality of Life
1078392|NCT01669564|Tobacco Use Cessation
1078393|NCT01669564|Physical Activity
1078394|NCT01669538|Galantamine
1078395|NCT01669538|Nicotine Bitartrate
1078396|NCT01669538|Nicotine Tartrate
1078397|NCT01669538|Nicotine dependence
1078398|NCT01669538|Tobacco Dependence
1078399|NCT01669512|Malaria vaccine
1078400|NCT01669512|Matrix M
1078401|NCT01669499|Bone metastases, radiotherapy, dexamethasone, pain flare
1078402|NCT01669486|Pain
1078403|NCT01669486|ICU
1078404|NCT01669486|Mechanical ventilation
1078405|NCT01669486|CPOT
1078406|NCT01669486|BPS
1078407|NCT01669473|Diabetes
1078408|NCT01669447|dmri, mnvc, lucentis
1078409|NCT01669434|Perioperative Period
1078410|NCT01669421|Alpha 1
1078411|NCT01669408|ischemic stroke
1078412|NCT01669408|hemorrhagic stroke
1078413|NCT01669408|prehospital cooling
1078414|NCT01669408|induction of cooling
1078415|NCT01669408|ambulance
1078416|NCT01669408|emergency room
1078417|NCT01669408|cold infusions
1078418|NCT01669408|hypothermia
1078419|NCT01669408|normothermia
1078420|NCT01669395|Severe heart failure
1078421|NCT01669395|Homebased rehabilitation
1078422|NCT01669395|Physical exercise
1078423|NCT01669395|Activities of daily living
1078424|NCT01669395|Intersectoral Cooperation
1078425|NCT01669382|AngioSeal, ExoSeal, PCI, puncture site
1078426|NCT01669369|Lithium Carbonate
1078427|NCT01669369|Chemotherapy
1078428|NCT01669369|prognosis
1078429|NCT01669356|malnutrition
1078430|NCT01669356|parenteral supplement
1078431|NCT01669356|rest metabolic rate
1078432|NCT01669356|postoperative complications
1078433|NCT01669343|Aromatase Inhibitors
1078434|NCT01669330|Gastroesophageal Reflux
1078435|NCT01669330|Fundoplication
1078436|NCT01669330|Surgical Procedures
1078437|NCT01669317|Cherry Juice Pilot
1078438|NCT01669304|migraine variant
1078439|NCT01669304|chronic dizziness
1078440|NCT01669304|pharmacologic dissection
1078441|NCT01669278|sheath
1078442|NCT01669278|flexible
1078443|NCT01669278|endoscopy
1078444|NCT01669278|otolaryngology
1078445|NCT01669278|office
1078446|NCT01669265|Breast cancer
1078447|NCT01669265|OSNA
1078448|NCT01669265|sentinel lymph node
1078449|NCT01669252|Breast cancer
1078450|NCT01669252|Eribulin
1078451|NCT01669252|Neoadjuvant
1078452|NCT01669252|PAM50
1078453|NCT01669252|Triple-negative
1078454|NCT01669252|Luminal A
1078455|NCT01669252|Luminal B
1078456|NCT01669239|Breast Cancer
1078457|NCT01669239|HER2 positive
1078458|NCT01669239|Neoadjuvant
1078459|NCT01669239|Liposomal doxorubicin
1078460|NCT01669239|Paclitaxel
1078461|NCT01669239|Trastuzumab
1078462|NCT01669239|Pertuzumab
1078463|NCT01669239|Safety
1078464|NCT01669226|Ovarian Cancer
1078465|NCT01669226|intraperitoneal chemotherapy
1078466|NCT01669213|5-HT3 receptor antagonist
1078467|NCT01669213|hypotension
1078468|NCT01669213|spinal anesthesia
1078469|NCT01669174|Chronic Obstructive Pulmonary Disease
1078470|NCT01669174|COPD; cachexia; muscle wasting
1078471|NCT01669161|Upper
1078472|NCT01669161|Limb
1078473|NCT01669161|Deficits
1078474|NCT01669161|Rehabilitation
1078475|NCT01669161|VNS
1078476|NCT01669148|breast cancer
1078477|NCT01669148|imaging
1078478|NCT01669135|cerebral oximetry
1078479|NCT01669135|cesarean delivery
1078480|NCT01669109|Yoga
1078481|NCT01669109|Colorectal Neoplasms
1078482|NCT01669109|Quality of Life
1078483|NCT01669109|Randomized Controlled Trial
1078484|NCT01669096|adults
1078485|NCT01669096|healthy
1078486|NCT01669096|Tuberculosis vaccine
1078487|NCT01669096|mRNA expression
1078488|NCT01669096|HIV negative
1078489|NCT01669083|Oxytocin Antagonist
1078490|NCT01669083|Embryo/Blastocyst Implantation
1078491|NCT01669070|bioavailability
1078492|NCT01669070|Fluticasone Furoate
1078493|NCT01669070|pharmacokinetics
1078494|NCT01669070|dose proportionality
1078495|NCT01669057|Congenital heart disease
1078496|NCT01669057|DNA variation
1078497|NCT01669057|methylation
1078498|NCT01669057|risk factors
1078499|NCT01669057|supplements
1078500|NCT01669031|automated perimetry
1078501|NCT01669031|visual fields
1078502|NCT01669031|reliability
1078503|NCT01669031|vision tests/standards
1078504|NCT01669031|randomized controlled trial
1078505|NCT01669031|false positive reactions
1078506|NCT01669031|false negative reactions
1078507|NCT01669031|fixation, ocular
1078508|NCT01669031|mean deviation
1078509|NCT01669031|variability
1078510|NCT01669031|program
1078511|NCT01669031|software
1078512|NCT01669031|glaucoma/diagnosis
1078513|NCT01669031|visual field tests/methods
1078514|NCT01669031|aged
1078515|NCT01669031|humans
1078516|NCT01669031|female
1078517|NCT01669031|male
1078518|NCT01669031|prospective studies
1078519|NCT01669031|reproducibility of results
1078520|NCT01669005|neutropenia
1078521|NCT01669005|multiplex PCR
1078522|NCT01669005|infection
1078523|NCT01668992|Parenting
1078524|NCT01668992|Discipline
1078525|NCT01668992|Family interventions
1078526|NCT01668992|Thailand
1078527|NCT01668992|Migration
1078528|NCT01668771|Self-Affirmation
1078529|NCT01668771|Affect
1078530|NCT01668771|Alcohol
1078531|NCT01668758|Near Infrared Spectroscopy
1078532|NCT01668758|Traumatic Brain Injury
1078533|NCT01668745|Child mortality
1078534|NCT01668745|Measles vaccine
1078535|NCT01668745|Non-specific effects
1078536|NCT01668693|Endometrial receptivity
1078537|NCT01668693|recurrent implantation failure
1078538|NCT01668693|predictor tool
1078539|NCT01668693|ERA
1078540|NCT01668693|customized microarray
1078541|NCT01668693|personalized embryo transfer
1078542|NCT01668680|Metronomic Chemotherapy
1078543|NCT01668680|Anti-Angiogenic
1078544|NCT01668680|Maintenance Treatment
1078545|NCT01668680|Colorectal Cancer Metastatic
1078546|NCT01668667|gabapentin enacarbil
1078547|NCT01668667|Horizant
1078548|NCT01668654|Epilepsy
1078549|NCT01668654|Partial Onset epilepsy
1078550|NCT01668654|Lennox-Gastaut Syndrome
1078551|NCT01668654|Open-label extension study
1078552|NCT01668641|Methotrexate insufficient responders
1078553|NCT01668628|quality of life
1078554|NCT01668628|depression
1078555|NCT01668628|BCM (body composition minitor)
1078556|NCT01668628|hydrational status
1078557|NCT01668615|idiopathicthrombocytopenic purpura
1078558|NCT01668615|all-trans retinoic acid
1078559|NCT01668615|regulory T cells
1078560|NCT01668576|mesenchymal stem cells
1078561|NCT01668576|Lung transplantation
1078562|NCT01668563|Aneurysm
1078563|NCT01668563|Intracranial Aneurysm
1078564|NCT01668563|Vascular Diseases
1078565|NCT01668563|Cardiovascular Diseases
1078566|NCT01668563|Intracranial Arterial Diseases
1078567|NCT01668563|Cerebrovascular Disorders
1078568|NCT01668563|Brain Diseases
1078569|NCT01668563|Central Nervous System Diseases
1078570|NCT01668563|Nervous System Diseases
1078571|NCT01668550|Phase I
1078572|NCT01668550|Src/Abl inhibitor
1078573|NCT01668550|Solid Tumours
1078574|NCT01668550|Cancer
1078575|NCT01668511|Immunogenicity
1078576|NCT01668511|Safety
1078577|NCT01668511|Tolerability
1078578|NCT01668511|Osteoarthritis
1078579|NCT01668511|Pharmacokinetics
1078580|NCT01668498|Can preemptive treatment of panitumumab mediated skin
1078581|NCT01668498|toxicity with oral doxycycline be replaced by local treatment with erythromycin?
1078582|NCT01668498|Panitumumab
1078583|NCT01668485|Type 1 diabetes mellitus
1078584|NCT01668485|hypoglycemia counterregulation,
1078585|NCT01668485|pancreatic islet transplantation
1078586|NCT01668472|Pregnant
1078587|NCT01668472|leaking fluid
1078588|NCT01668459|Transitional cell carcinoma
1078589|NCT01668459|Bladder cancer
1078590|NCT01668459|Cancer
1078591|NCT01668459|Oncology
1078592|NCT01668459|Cabazitaxel
1078593|NCT01668446|Sildenafil
1078594|NCT01668446|Endometrial thickness
1078595|NCT01668446|Frozen embryo transfer
1078596|NCT01668446|ultrasonographic endometrial thickness
1078597|NCT01668446|endometrial pattern
1078598|NCT01668446|Implantation rate
1078599|NCT01668446|chemical pregnancy rate
1078600|NCT01668433|G6PD
1078601|NCT01668433|Primaquine
1078602|NCT01668433|Methylene blue
1078603|NCT01668420|thermal stimulation
1078604|NCT01668420|lower extremity
1078605|NCT01668420|temperature
1078606|NCT01668420|efficacy
1078607|NCT01668407|Parkinson's disease
1078608|NCT01668407|PSP
1078609|NCT01668407|Robot
1078610|NCT01668407|Gait rehabilitation
1078611|NCT01668381|hepatocellular carcinoma
1078612|NCT01668381|Catheter Ablation
1078613|NCT01668381|T-Lymphocytes, Regulatory
1078614|NCT01668381|IL-10
1078615|NCT01668381|TGF-β
1078616|NCT01668381|IFN-γ
1078617|NCT01668368|ARDS
1078618|NCT01668368|Esophageal pressure
1078619|NCT01668368|pleural pressure
1078620|NCT01668368|pulmonary compliance
1078621|NCT01668355|Delivery of Healthcare
1078622|NCT01668355|Health Services Research
1078623|NCT01668355|Integrated Healthcare Systems
1078624|NCT01668355|Healthcare Quality, Access, and Evaluation
1078625|NCT01668329|Septic shock
1078626|NCT01668329|Inflammatory process
1078627|NCT01668329|Cytokines
1078628|NCT01668329|Hormonal response
1078629|NCT01668329|Oxydative stress
1078630|NCT01668316|Overweight
1078631|NCT01668316|Obese
1078632|NCT01668316|Postpartum
1078633|NCT01668316|Weight loss
1078634|NCT01668316|Inflammation
1078635|NCT01668316|Obesity
1078636|NCT01668316|Cardiovascular
1078637|NCT01668303|juvenile drug court
1078638|NCT01668303|adolescents
1078639|NCT01668303|substance abuse
1078640|NCT01668303|delinquency
1078641|NCT01668303|family therapy
1078642|NCT01668303|multidimensional family therapy
1078643|NCT01668290|Coronary Artery Disease
1078644|NCT01668290|Stress Echocardiography
1078645|NCT01668290|Single Photon Emission Computed Tomography
1078646|NCT01668290|Cardiac Computed Tomographic Angiography
1078647|NCT01668290|outcomes
1078648|NCT01668277|Pulmonary Hypertensive Crisis
1078649|NCT01668277|Pediatrics
1078650|NCT01668277|Hypertonic Saline
1078651|NCT01668264|Pediatrics
1078652|NCT01668264|Congenital Heart Disease
1078653|NCT01668264|Diastolic Function
1078654|NCT01668264|Echocardiograph
1078655|NCT01668264|MRI
1078656|NCT01668251|Turner syndrome
1078657|NCT01668251|Diagnosis, prenatal
1078658|NCT01668238|Thyroid tumor
1078659|NCT01668238|Breast tumor
1078660|NCT01668238|Fourier Transform Infrared Spectrometry
1078661|NCT01668238|Tumor Diagnosis
1078662|NCT01668186|Peroxisome biogenesis disorders
1078663|NCT01668186|PBD
1078664|NCT01668186|Zellweger spectrum
1078665|NCT01668186|Rhizomelic chondrodysplasia punctata
1078666|NCT01668186|RCDP
1078667|NCT01668173|HSP90 Inhibitor
1078668|NCT01668173|AUY922
1078669|NCT01668173|12-076
1078670|NCT01668160|clinical outcomes
1078671|NCT01668160|radiographic outcomes
1078672|NCT01668160|total hip arthroplasty
1078673|NCT01668160|survivorship
1078674|NCT01668147|PET Imaging
1078675|NCT01668147|Efavirenz
1078676|NCT01668147|Ritonavior
1078677|NCT01668147|[11C] desmethyl-loperamide
1078678|NCT01668147|Healthy volunteers
1078679|NCT01668108|carcinoma
1078680|NCT01668108|breast cancer
1078681|NCT01668108|non-small cell lung cancer
1078682|NCT01668108|ovarial cancer
1078683|NCT01668108|ambulant chemotherapy
1078684|NCT01668108|treatment cycles
1078685|NCT01668108|Paclitaxel
1078686|NCT01668108|Paclitaxel onkovis
1078687|NCT01668108|Quantity of Paclitaxel
1078688|NCT01668108|Packaging Sizes
1078689|NCT01668082|Patients with newly identified brain mass
1078690|NCT01668069|nausea
1078691|NCT01668069|vomiting
1078692|NCT01668069|pregnancy
1078693|NCT01668069|ondansetron
1078694|NCT01668069|doxylamine
1078695|NCT01668069|vitamin B6
1078696|NCT01668069|pyridoxine
1078697|NCT01668056|in vitro fertilization
1078698|NCT01668056|ovarian stimulation
1078699|NCT01668056|follicular waves
1078700|NCT01668056|luteal phase
1078701|NCT01668043|HIV-1
1078702|NCT01668043|CD4
1078703|NCT01668043|antibody
1078704|NCT01668043|immunotherapy
1078705|NCT01668030|Facial
1078706|NCT01668030|Partial thickness
1078707|NCT01668017|Advanced solid tumors
1078708|NCT01668017|Hepatocellular carcinoma
1078709|NCT01668017|cancer, liver
1078710|NCT01667991|Colonization
1078711|NCT01667991|infection
1078712|NCT01667991|multidrug-resistant bacteria
1078713|NCT01667991|guideline
1078714|NCT01667978|contraception
1078715|NCT01667978|mini pill
1078716|NCT01667978|norethindrone
1078717|NCT01667978|atazanavir
1078718|NCT01667978|ritonavir
1078719|NCT01667978|norvir
1078720|NCT01667978|reyataz
1078721|NCT01667978|pregnancy prevent
1078722|NCT01667978|birth control
1078723|NCT01667978|HIV
1078724|NCT01667978|AIDS
1078725|NCT01667978|antiviral
1078726|NCT01667978|antiretroviral
1078727|NCT01667965|palliative radiation
1078728|NCT01667965|12-172
1078729|NCT01667952|Family History Questionnaire (FHQ)
1078730|NCT01667952|Blood sample
1078731|NCT01667952|Salvia sample
1078732|NCT01667952|12-145
1078733|NCT01667939|adequacy
1078734|NCT01667939|diet
1078735|NCT01667939|pregnancy
1078736|NCT01667913|Hip Fracture
1078737|NCT01667913|6-minutes walking test
1078738|NCT01667913|Reliability
1078739|NCT01667887|Far Cortical Locking
1078740|NCT01667887|Distal Femur Fracture
1078741|NCT01667887|Locking Plate
1078742|NCT01667887|MotionLoc
1078743|NCT01667887|Fracture Fixation
1078744|NCT01667874|Randomized controlled trial
1078745|NCT01667874|early joint infection
1078746|NCT01667874|gentamicin impregnated sponges
1078747|NCT01667861|Glaucoma
1078748|NCT01667861|Wind instruments
1078749|NCT01667848|pain
1078750|NCT01667835|yoga
1078751|NCT01667835|postmenopausal, sedentary South Asian women
1078752|NCT01667796|Multiple sclerosis
1078753|NCT01667796|Healthy controls
1078754|NCT01667796|Pharmacokinetics
1078755|NCT01667796|Vitamin D
1078756|NCT01667783|Obesity
1078757|NCT01667783|Diabetes
1078758|NCT01667757|coronary atherosclerosis
1078759|NCT01667757|drug eluting stent
1078760|NCT01667757|intravascular ultrasound
1078761|NCT01667757|fractional flow reserve
1078762|NCT01667744|Angina
1078763|NCT01667744|Acute Coronary Syndrome
1078764|NCT01667744|Emotional Distress
1078765|NCT01667744|Citalopram
1078766|NCT01667744|Health Care Utilization
1078767|NCT01667731|Hepatitis C
1078768|NCT01667731|Chronic
1078769|NCT01667731|HCV
1078770|NCT01667731|HIV
1078771|NCT01667731|Human Immunodeficiency Virus
1078772|NCT01667731|Co-Infected
1078773|NCT01667718|eradication
1078774|NCT01667718|helicobacter pylori
1078775|NCT01667718|bismuth
1078776|NCT01667705|Stress
1078777|NCT01667705|Anxiety
1078778|NCT01667705|Skyceiling
1078779|NCT01667705|Nature
1078780|NCT01667692|H-pylori
1078781|NCT01667692|eradication
1078782|NCT01667692|azithromycin
1078783|NCT01667692|clarithromycin
1078784|NCT01667679|Migraine
1078785|NCT01667679|Headaches
1078786|NCT01667679|Sumatriptan
1078787|NCT01667666|trauma
1078788|NCT01667666|acute lung injury
1078789|NCT01667666|adult respiratory distress syndrome
1078790|NCT01667640|Brain metastases
1078791|NCT01667640|radiation
1078792|NCT01667640|sector
1078793|NCT01667640|singular
1078794|NCT01667640|solitary
1078795|NCT01667640|neurocognition
1078796|NCT01667627|IBS
1078797|NCT01667627|Probiotic
1078798|NCT01667627|hs-CRP
1078799|NCT01667627|Cholinergic status
1078800|NCT01667627|Micro-inflammation
1078801|NCT01667601|mindfulness-based program
1078802|NCT01667601|Psychoeducation
1078803|NCT01667601|schizophrenia
1078804|NCT01667601|Chinese
1078805|NCT01667601|outpatients
1078806|NCT01667588|Chronic Kidney Disease (CKD)
1078807|NCT01667588|Pediatrics
1078808|NCT01667588|Sleep Disorders
1078809|NCT01667549|Breastfeeding
1078810|NCT01667549|Flavor learning
1078811|NCT01667549|Mother
1078812|NCT01667549|Moms
1078813|NCT01667549|Infants
1078814|NCT01667549|Babies
1078815|NCT01667549|Baby
1078816|NCT01667549|Food Habits
1078817|NCT01667549|Fruits
1078818|NCT01667549|Vegetables
1078819|NCT01667536|PROSTATE CANCER
1078820|NCT01667536|HIGH-RISK
1078821|NCT01667536|PROSTATECTOMY SURGERY
1078822|NCT01667536|NEWLY DIAGNOSED
1078823|NCT01667523|capsaicin
1078824|NCT01667523|cinnamaldehyde
1078825|NCT01667510|Prehypertension
1078826|NCT01667510|anti oxidation
1078827|NCT01667510|lycopene
1078828|NCT01667497|Cognitive fatigue
1078829|NCT01667497|multiple sclerosis
1078830|NCT01667484|Cognitive Impairment
1078831|NCT01667484|Multiple Sclerosis
1078832|NCT01667484|Processing Speed
1078833|NCT01667484|Treatment
1078834|NCT01667445|total knee arthroplasty
1078835|NCT01667445|epimorph
1078836|NCT01667445|analgesia
1078837|NCT01667406|kisspeptin
1078838|NCT01667406|infertility
1078839|NCT01667406|in vitro fertilisation
1078840|NCT01667354|Parental Childhood Vaccine Hesitancy
1078841|NCT01667341|HSV
1078842|NCT01667341|Herpes
1078843|NCT01667341|genital infection
1078844|NCT01667341|vaccine
1078845|NCT01667328|Anxiety
1078846|NCT01667328|Presurgical anxiety
1078847|NCT01667328|Breast Cancer
1078848|NCT01667302|NK/T-cell lymphoma
1078849|NCT01667302|Radiotherapy
1078850|NCT01667302|Adjuvant chemotherapy
1078851|NCT01667289|NK/T-cell lymphoma
1078852|NCT01667289|Methotrexate
1078853|NCT01667289|Radiotherapy
1078854|NCT01667289|Concurrent chemoradiation
1078855|NCT01667276|AE adverse event
1078856|NCT01667276|AIDS acquired immunodeficiency syndrome
1078857|NCT01667276|ALT (SGPT) alanine aminotransferase
1078858|NCT01667276|ART antiretroviral therapy
1078859|NCT01667276|AST (SGOT) aspartate aminotransferase
1078860|NCT01667276|DCF data collection forms
1078861|NCT01667276|DMC Data Monitoring Committee
1078862|NCT01667276|FDA (U.S.) Food and Drug Administration
1078863|NCT01667276|GCP Good Clinical Practice guidelines
1078864|NCT01667276|HB sAg Hepatitis B surface antigen
1078865|NCT01667276|ICH International Conference of Harmonisation
1078866|NCT01667276|IND Investigational New Drug Application
1078867|NCT01667276|IRB Institutional Review Board
1078868|NCT01667276|IU international units
1078869|NCT01667276|mg milligram(s)
1078870|NCT01667276|mm3 cubic millimeter(s)
1078871|NCT01667276|PCR polymerase chain reaction
1078872|NCT01667276|SAE serious adverse event
1078873|NCT01667276|µg microgram
1078874|NCT01667276|ULN upper limit of the normal range
1078875|NCT01667276|WB Western Blot
1078876|NCT01667263|All-trans retinoic acid
1078877|NCT01667263|primary immune thrombocytopenia
1078878|NCT01667263|corticosteroid-resistant
1078879|NCT01667263|refractory
1078880|NCT01667263|danazol
1078881|NCT01667250|vagus nerve stimulation
1078882|NCT01667250|vagal nerve stimulation
1078883|NCT01667250|nVNS
1078884|NCT01667250|VNS
1078885|NCT01667250|chronic migraine
1078886|NCT01667250|migraine
1078887|NCT01667250|non invasive
1078888|NCT01667250|gammacore
1078889|NCT01667237|Pulmonary rehabilitation program
1078890|NCT01667237|Lung cancer
1078891|NCT01667237|Lung resection surgery
1078892|NCT01667237|Home-based
1078893|NCT01667224|Actiponin
1078894|NCT01667224|Obesity
1078895|NCT01667224|Abdominal fat
1078896|NCT01667211|Advanced uterine cervical cancer
1078897|NCT01667185|pediatric
1078898|NCT01667185|diabetes mellitus
1078899|NCT01667159|Depression
1078900|NCT01667159|Alcohol Use
1078901|NCT01667159|Outpatient Therapy
1078902|NCT01667133|Leukemia
1078903|NCT01667133|Leukemia, Myeloid
1078904|NCT01667133|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1078905|NCT01667133|Neoplasms by Histologic Type
1078906|NCT01667133|Neoplasms
1078907|NCT01667133|Lymphoproliferative Disorders
1078908|NCT01667133|Lymphatic Diseases
1078909|NCT01667133|Immunoproliferative Disorders
1078910|NCT01667133|Immune System Diseases
1078911|NCT01667133|Myeloproliferative Disorders
1078912|NCT01667133|Bone Marrow Diseases
1078913|NCT01667133|Hematologic Diseases
1078914|NCT01667120|Ketorolac
1078915|NCT01667120|postoperative pain
1078916|NCT01667120|bleeding events
1078917|NCT01667094|Pulmonary exacerbation
1078918|NCT01667094|Continuous infusion
1078919|NCT01667094|Antipseudomonal beta-lactams
1078920|NCT01667068|Cardiac Diseases
1078921|NCT01667068|HIV-Infection
1078922|NCT01667068|AIDS
1078923|NCT01667068|Antiretroviral Therapy
1078924|NCT01667068|Cardiovascular Medication
1078925|NCT01667068|Risk Factors
1078926|NCT01667068|coronary heart disease
1078927|NCT01667068|heart failure
1078928|NCT01667068|metabolic syndrome
1078929|NCT01667055|drug allergy
1078930|NCT01667055|drug hypersensitivity
1078931|NCT01667055|beta-lactam allergy
1078932|NCT01667055|penicillin allergy
1078933|NCT01667055|adverse drug reaction
1078934|NCT01667042|Scleroderma Lung
1078935|NCT01667042|Gastroesophageal Reflux
1078936|NCT01667042|Microaspiration
1078937|NCT01667042|Cough
1078938|NCT01667016|International
1078939|NCT01667016|Multicenter
1078940|NCT01667016|Observational registry
1078941|NCT01667016|Orsiro Drug Eluting Stent (DES)
1078942|NCT01667016|Stenting
1078943|NCT01667016|Treatment of Coronary Artery Disease
1078944|NCT01667016|Coronary revascularization
1078945|NCT01667016|Percutaneous Coronary Intervention
1078946|NCT01667016|STEMI
1078947|NCT01667016|NSTEMI
1078948|NCT01667016|Ischemia
1078949|NCT01667016|Angina
1078950|NCT01667016|Subgroups
1078951|NCT01667016|Acute Myocardial Infarction
1078952|NCT01667016|Diabetes
1078953|NCT01667016|Small Vessels
1078954|NCT01667016|Chronic Total Occlusion (CTO)
1078955|NCT01667003|International
1078956|NCT01667003|Multicenter
1078957|NCT01667003|Observational registry
1078958|NCT01667003|Orsiro Drug Eluting Stent (DES)
1078959|NCT01667003|Stenting
1078960|NCT01667003|Treatment of Coronary Artery Disease
1078961|NCT01667003|Coronary revascularization
1078962|NCT01667003|Percutaneous Coronary Intervention
1078963|NCT01667003|STEMI
1078964|NCT01667003|NSTEMI
1078965|NCT01667003|Ischemia
1078966|NCT01667003|Angina
1078967|NCT01667003|Subgroups
1078968|NCT01667003|Acute Myocardial Infarction
1078969|NCT01667003|Diabetes
1078970|NCT01667003|Small Vessels
1078971|NCT01666990|Tripterygium wilfordii Hook F (TwHF)
1078972|NCT01666990|HIV
1078973|NCT01666990|CD4
1078974|NCT01666990|immune over-activation
1078975|NCT01666964|Traumatic brain injury
1078976|NCT01666964|hypopituitarism
1078977|NCT01666938|Diabetes Mellitus
1078978|NCT01666938|Telephone
1078979|NCT01666938|Physical activity
1078980|NCT01666912|adolescence
1078981|NCT01666912|contraception
1078982|NCT01666912|postpartum
1078983|NCT01666912|rapid repeat pregnancy
1078984|NCT01666873|osteoarthritis
1078985|NCT01666860|anterior lumbar interbody fusion
1078986|NCT01666847|Umbilical Cord Milking
1078987|NCT01666847|Extremely Low Birth Weight Infant (ELBW)
1078988|NCT01666834|mechanical ventilation, ARDS, Ventilator strategy, outcome
1078989|NCT01666821|macular degeneration; choroidal neovascularization
1078990|NCT01666782|Influenza vaccine
1078991|NCT01666782|Oncology
1078992|NCT01666782|Chemotherapy
1078993|NCT01666769|Extracorporeal membrane oxygenation
1078994|NCT01666769|ECMO
1078995|NCT01666769|Extracorporeal life support
1078996|NCT01666769|Micafungin
1078997|NCT01666769|Mycamine
1078998|NCT01666769|Pharmacokinetics
1078999|NCT01666743|Community-Acquired Pneumonia
1079000|NCT01666743|Lung
1079001|NCT01666743|Adult
1079002|NCT01666743|Infections
1079003|NCT01666691|Obese
1079004|NCT01666691|Obesity
1079005|NCT01666691|Overweight
1079006|NCT01666691|Weight loss
1079007|NCT01666691|Weight reduction
1079008|NCT01666691|Beloranib
1079009|NCT01666678|Bioequivalence
1079010|NCT01666665|Burn
1079011|NCT01666652|Dengue
1079012|NCT01666652|Dengue fever
1079013|NCT01666652|Dengue Hemorrhagic Fever
1079014|NCT01666652|Flavivirus
1079015|NCT01666626|crohn's disease
1079016|NCT01666626|ultrasound
1079017|NCT01666626|intestinal fibrosis
1079018|NCT01666626|shear wave imaging
1079019|NCT01666626|acoustic radiation force impulse
1079020|NCT01666613|Phase I, Healthy volunteers, pharmacokinetics
1079021|NCT01666613|Bioavailability
1079022|NCT01666613|AUC
1079023|NCT01666548|haemolytic uraemic syndrome
1079024|NCT01666548|complications of HUS
1079025|NCT01666548|renal replacement treatment
1079026|NCT01666548|renal function outcome
1079027|NCT01666548|neuropsychological sequelae
1079028|NCT01666548|psychological adjustment
1079029|NCT01666548|quality of life
1079030|NCT01666535|Influenza vaccine
1079031|NCT01666535|Immune response
1079032|NCT01666535|Remicade (infliximab)
1079033|NCT01666535|Inflammatory bowel disease
1079034|NCT01666522|sarcopenia
1079035|NCT01666522|osteopenia/osteoporosis
1079036|NCT01666522|older adults
1079037|NCT01666522|vitamin D supplementation
1079038|NCT01666522|physical activity
1079043|NCT01666483|hysterectomy
1079044|NCT01666483|single-port
1079045|NCT01666483|micro-laparoscopy
1079046|NCT01666470|Quality of life
1079047|NCT01666457|Supporting Oral Feeding in Fragile Infants (SOFFI)
1079048|NCT01666457|Infant Oral Feeding
1079049|NCT01666457|Infant Growth
1079050|NCT01666457|Preterm infant oral feeding
1079051|NCT01666457|Preterm infant growth
1079052|NCT01666457|Neonatal Intensive Care Unit (NICU)
1079053|NCT01666444|recurrent epithelial ovarian cancer
1079054|NCT01666444|recurrent fallopian tube cancer
1079055|NCT01666444|recurrent primary peritoneal cavity cancer
1079056|NCT01666444|ovarian serous cystadenocarcinoma
1079057|NCT01666444|ovarian endometrioid adenocarcinoma
1079058|NCT01666444|ovarian mucinous cystadenocarcinoma
1079059|NCT01666444|ovarian undifferentiated adenocarcinoma
1079060|NCT01666444|ovarian clear cell cystadenocarcinoma
1079061|NCT01666444|ovarian mixed epithelial carcinoma
1079062|NCT01666444|Brenner tumor
1079063|NCT01666405|Fecal Incontinence
1079064|NCT01666405|Bowel Incontinence
1079065|NCT01666392|Omega-3 fatty acid
1079066|NCT01666392|Fish oil
1079067|NCT01666392|Muscle mass
1079068|NCT01666392|Muscle strength
1079069|NCT01666392|Older adults
1079070|NCT01666392|Circulating inflammatory cytokines
1079071|NCT01666392|Skeletal muscle mass
1079072|NCT01666392|Upper body strength
1079073|NCT01666392|Lower body strength
1079074|NCT01666379|Hallux valgus
1079075|NCT01666379|Forefoot
1079076|NCT01666379|transdermal fentanyl
1079077|NCT01666340|Exercise
1079078|NCT01666340|Elderly
1079079|NCT01666340|Mortality
1079080|NCT01666340|Morbidity
1079081|NCT01666340|Prognosis
1079082|NCT01666340|Longevity
1079083|NCT01666327|Crohn's Disease
1079084|NCT01666327|Ulcerative Colitis
1079085|NCT01666314|castrate resistant prostate cancer,
1079086|NCT01666314|CRPC,
1079087|NCT01666314|orteronel,
1079088|NCT01666314|TAK-700
1079089|NCT01666301|Erythropoietin stimulating agents
1079090|NCT01666301|Hemoglobin
1079091|NCT01666301|Reticulocytes
1079092|NCT01666301|Variability
1079093|NCT01666262|FLU
1079094|NCT01666262|H1N1
1079095|NCT01666262|GPO
1079096|NCT01666262|PLAIV
1079097|NCT01666249|FMH; anti-Rh; efficacy
1079098|NCT01666236|Age-Related Macular Degeneration
1079099|NCT01666236|Pigment Epithelial Detachment
1079100|NCT01666236|Polypoidal Choroidal Vasculopathy
1079101|NCT01666223|Type 2 diabetes
1079102|NCT01666223|GLP-1
1079103|NCT01666223|Bile acid
1079104|NCT01666223|TGR-5
1079105|NCT01666197|Acute Joint Pain
1079106|NCT01666184|Biomarkers study
1079107|NCT01666171|estrogen receptor-negative breast cancer
1079108|NCT01666171|progesterone receptor-negative breast cancer
1079109|NCT01666171|stage IB breast cancer
1079110|NCT01666171|stage II breast cancer
1079111|NCT01666171|stage IIIA breast cancer
1079112|NCT01666171|stage IIIC breast cancer
1079113|NCT01666145|Hepatocellular Cancer
1079114|NCT01666145|Hepatocellular Carcinoma
1079115|NCT01666145|Hepatoma
1079116|NCT01666145|Liver Cancer, Adult
1079117|NCT01666145|Liver Cell Carcinoma, Adult
1079118|NCT01666132|LVEF < 40%
1079119|NCT01666119|Opioid dependence
1079120|NCT01666119|Suboxone
1079121|NCT01666119|addiction
1079122|NCT01666119|BEMA Buprenorphine NX
1079123|NCT01666119|oral transmucosal
1079124|NCT01666093|peripheral artery disease
1079125|NCT01666093|endovascular procedure
1079126|NCT01666093|non-healing ulcer
1079127|NCT01666080|second stem cell transplant
1079128|NCT01666080|donor hematopoietic engraftment
1079129|NCT01666080|hematopoietic stem cell transplantation
1079130|NCT01666080|inherited metabolic disorder
1079131|NCT01666067|insulin resistance
1079132|NCT01666054|Weaning
1079133|NCT01666054|mechanical ventilation
1079134|NCT01666054|Proportional Assist Ventilation
1079135|NCT01666041|insulin resistance
1079136|NCT01666028|Type 1 Diabetes
1079137|NCT01666028|Closed Loop glucose control
1079138|NCT01666028|Artificial Pancreas
1079139|NCT01666028|CSII
1079140|NCT01666028|CGM
1079141|NCT01666015|pediatric
1079142|NCT01666015|exercise
1079143|NCT01666015|hematopoietic stem cell transplantation
1079144|NCT01666015|cancer
1079145|NCT01666015|quality of life
1079146|NCT01666015|immune system
1079147|NCT01666015|physical activity levels
1079148|NCT01665937|liver cancer
1079149|NCT01665937|advanced liver cancer
1079150|NCT01665937|advanced hepatocellular cancer
1079151|NCT01665911|Caries
1079152|NCT01665898|cold biopsy forceps
1079153|NCT01665898|cold snare biopsy
1079154|NCT01665885|hypothermia
1079155|NCT01665885|induction of hypothermia
1079156|NCT01665885|non invasive cooling
1079157|NCT01665885|external cooling
1079158|NCT01665885|surface cooling
1079159|NCT01665885|endovascular cooling
1079160|NCT01665885|cooling catheter
1079161|NCT01665885|stroke
1079162|NCT01665885|shivering
1079163|NCT01665885|neuro monitoring
1079164|NCT01665885|coagulation
1079165|NCT01665872|Mothers
1079166|NCT01665872|Depression
1079167|NCT01665872|Stress
1079168|NCT01665872|Trauma
1079169|NCT01665872|Public Housing
1079170|NCT01665859|readmission
1079171|NCT01665859|recurrence
1079172|NCT01665859|umbilical
1079173|NCT01665859|epigastric
1079174|NCT01665859|hernia
1079175|NCT01665859|outcome
1079176|NCT01665859|morbidity
1079177|NCT01665846|HIV associated neurocognitive disorders
1079178|NCT01665846|MRI
1079179|NCT01665846|Ferumoxytol
1079180|NCT01665833|Angina
1079181|NCT01665833|SYNTAX
1079182|NCT01665833|Coronary
1079183|NCT01665833|PCI
1079184|NCT01665833|CABG
1079185|NCT01665820|chest
1079186|NCT01665820|pathology
1079187|NCT01665807|influenza
1079188|NCT01665807|vaccine
1079189|NCT01665807|administration
1079190|NCT01665781|Hemoglobin
1079191|NCT01665781|Erythropoietin
1079192|NCT01665781|Acute Mountain sickness
1079193|NCT01665742|Obesity
1079194|NCT01665742|Chronic inflammation
1079195|NCT01665742|Anti-inflammatory dietary intervention
1079196|NCT01665742|Genetic susceptibility
1079197|NCT01665729|etiology
1079198|NCT01665729|pathogenesis
1079199|NCT01665729|minor ischaemic stroke
1079200|NCT01665729|types
1079201|NCT01665729|intervention
1079202|NCT01665703|[18F]
1079203|NCT01665703|Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging
1079204|NCT01665703|FDG-PET-MRI
1079205|NCT01665703|Renal Cell Carcinoma
1079206|NCT01665703|Pilot Study
1079207|NCT01665703|LCCC 1213
1079208|NCT01665703|UNC Lineberger
1079209|NCT01665690|patient delivered partner therapy
1079210|NCT01665690|expedited partner therapy
1079211|NCT01665690|partner notification
1079212|NCT01665690|gonorrhea
1079213|NCT01665690|chlamydia
1079214|NCT01665677|Graft vs Host Disease
1079215|NCT01665677|GVHD
1079216|NCT01665677|Allogeneic hematopoietic stem cell transplantation
1079217|NCT01665677|HSCT
1079218|NCT01665677|Atorvastatin
1079219|NCT01665664|Indirect calorimetry
1079220|NCT01665664|hypocaloric feeding
1079221|NCT01665638|Healthy
1079222|NCT01665638|Clearance
1079223|NCT01665638|Canagliflozin
1079224|NCT01665638|JNJ-28431754
1079225|NCT01665638|Placebo
1079226|NCT01665638|Somatostatin
1079227|NCT01665638|C-peptide
1079228|NCT01665625|Pancreatic cancer
1079229|NCT01665625|Intra-arterial infusion
1079230|NCT01665625|Gemcitabine
1079231|NCT01665612|Contact lens
1079232|NCT01665612|Care solution
1079233|NCT01665612|MPDS
1079234|NCT01665612|comfort
1079235|NCT01665586|dexmedetomidine
1079236|NCT01665586|sedation in elderly patient
1079237|NCT01665586|spinal anesthesia
1079238|NCT01665573|Fear Conditioning
1079239|NCT01665573|Cannabinoids
1079240|NCT01665573|Fear Response
1079241|NCT01665560|smoking
1079242|NCT01665560|fMRI
1079243|NCT01665560|odors
1079244|NCT01665560|taste
1079245|NCT01665547|clomiphene resistant
1079246|NCT01665547|pcos
1079247|NCT01665547|induction of ovulation
1079248|NCT01665547|l-carnitine
1079249|NCT01665534|hypertension
1079250|NCT01665534|inflammation
1079251|NCT01665534|salt intake
1079252|NCT01665521|Acute Coronary Syndrome
1079253|NCT01665521|Chest pain
1079254|NCT01665521|Risk Stratification
1079255|NCT01665521|HEART Pathway
1079256|NCT01665521|Emergency Department
1079257|NCT01665508|angina
1079258|NCT01665508|cardiopulmonary testing
1079259|NCT01665508|metabolomics
1079260|NCT01665508|nebivolol
1079261|NCT01665495|pericardial effusion
1079262|NCT01665495|cardiac tamponade
1079263|NCT01665495|pericardiocentesis
1079264|NCT01665495|pericardial drainage
1079265|NCT01665495|prevention
1079266|NCT01665482|Inflammation
1079267|NCT01665482|Insulin sensitivity
1079268|NCT01665482|Interleukin-6 (IL-6)
1079269|NCT01665482|C-peptide
1079270|NCT01665482|Saturated fatty acid (SFA)
1079271|NCT01665482|Monounsaturated fatty acid (MUFA)
1079272|NCT01665482|Carbohydrate (CARB)
1079273|NCT01665469|anti oxidation
1079274|NCT01665469|lycopene
1079275|NCT01665469|Ox-LDL
1079276|NCT01665456|complications
1079277|NCT01665417|Icotinib
1079278|NCT01665417|EGFR positive mutation
1079279|NCT01665417|First-line treatment
1079280|NCT01665417|Maintenance treatment
1079281|NCT01665378|prepregnancy
1079282|NCT01665378|micronutrient
1079283|NCT01665378|supplementation
1079284|NCT01665378|maternal
1079285|NCT01665378|child
1079286|NCT01665378|health
1079287|NCT01665365|Myocardial infarction
1079288|NCT01665365|Remote ischemic conditioning
1079289|NCT01665365|Clinical outcome
1079290|NCT01665339|preload
1079291|NCT01665339|anthropometric measures
1079292|NCT01665339|cardiovascular risk factors
1079293|NCT01665326|Pompe disease
1079294|NCT01665326|Glycogen Storage Disease Type II
1079295|NCT01665326|Acid Maltase Deficiency
1079296|NCT01665326|CRIM Status
1079297|NCT01665326|Acid Alpha-Glucosidase Deficiency
1079298|NCT01665326|Alglucosidase alfa
1079299|NCT01665326|Myozyme
1079300|NCT01665326|Enzyme replacement therapy
1079301|NCT01665326|Immune Tolerance Induction
1079302|NCT01665313|attention
1079303|NCT01665300|myocardial deformation imaging
1079304|NCT01665300|Trastuzumab
1079305|NCT01665287|Cerebral Oximetry
1079306|NCT01665287|Near infrared spectroscopy
1079307|NCT01665287|Fullterm
1079308|NCT01665287|Infant
1079309|NCT01665274|xelox
1079310|NCT01665274|advanced gastric cancer
1079311|NCT01665261|Congenital heart disease
1079312|NCT01665261|Newborn
1079313|NCT01665261|Pulse oximetry
1079314|NCT01665261|Screening
1079315|NCT01665248|18-F Sodium Fluoride
1079316|NCT01665248|Acute coronary syndrome
1079317|NCT01665248|Stable Angina
1079318|NCT01665196|IgG4-related disease
1079319|NCT01665196|IgG4-RD
1079320|NCT01665196|18F-FDG
1079321|NCT01665196|PET/CT
1079322|NCT01665183|argininosuccinate synthetase
1079323|NCT01665183|arginine
1079324|NCT01665183|arginine deiminase
1079325|NCT01665170|Pascoflair
1079326|NCT01665170|tsst
1079327|NCT01665170|passiflora incarnata
1079328|NCT01665170|non smoking male
1079329|NCT01665170|and female volunteers
1079330|NCT01665157|Diet Control before Colonoscopy
1079331|NCT01665144|Secondary Progressive Multiple Sclerosis
1079332|NCT01665118|Radio frequency
1079333|NCT01665118|thigh
1079334|NCT01665118|circumference
1079335|NCT01665118|reduction
1079336|NCT01665105|Pulse Rate Variability
1079337|NCT01665105|Skin Blood Flow
1079338|NCT01665105|Skin Temperature
1079339|NCT01665105|Electroacupuncture
1079340|NCT01665105|Zusanli
1079341|NCT01665105|Yanglingquan
1079342|NCT01665079|anaesthetics iv
1079343|NCT01665079|propofol
1079344|NCT01665079|pharmacokinetics
1079345|NCT01665079|pharmacodynamic
1079346|NCT01665053|Drug-Eluting Stents
1079347|NCT01665040|neurostimulation
1079348|NCT01665040|spinal cord stimulation
1079349|NCT01665040|peripheral nerve stimulation
1079350|NCT01665027|caesarean section,
1079351|NCT01665027|vacuum,
1079352|NCT01665027|fetal head extraction,
1079353|NCT01665027|maternal complication,
1079354|NCT01665027|fetal complication
1079355|NCT01665014|autologous hematopoietic stem cell transplantation
1079356|NCT01665014|total marrow irradiation
1079357|NCT01665014|melphalan
1079358|NCT01665014|multiple myeloma
1079359|NCT01665001|Acute lymphoblastic leukemia
1079360|NCT01665001|Induction
1079361|NCT01665001|Consolidation
1079362|NCT01665001|Minimal residual disease
1079363|NCT01665001|Hematopoietic stem cell transplantation
1079364|NCT01664975|Peripheral T-cell lymphoma;chemotherapy;
1079365|NCT01664975|RR;PFS;OS
1079366|NCT01664936|18F-FDG PET/CT scan
1079367|NCT01664936|131I therapy
1079368|NCT01664936|Cerenkov Luminescence Imaging
1079369|NCT01664936|12-050
1079370|NCT01664936|Lymphoma
1079371|NCT01664936|Leukemia
1079372|NCT01664936|Metastatic Lymph Nodes
1079373|NCT01664923|prostate cancer
1079374|NCT01664923|enzalutamide
1079375|NCT01664923|MDV3100
1079376|NCT01664910|Lymphoma
1079377|NCT01664910|CD22 Positive-Lymphoid Malignancies
1079378|NCT01664910|Leukemia
1079379|NCT01664910|Allogeneic stem cell transplant
1079380|NCT01664910|CMC-544
1079381|NCT01664910|Inotuzumab Ozogamicin
1079382|NCT01664910|Fludarabine
1079383|NCT01664910|Fludarabine Phosphate
1079384|NCT01664910|Fludara
1079385|NCT01664910|Bendamustine
1079386|NCT01664910|Bendamustine Hydrochloride
1079387|NCT01664910|Bendamustine HCL
1079388|NCT01664910|CEP-18083
1079389|NCT01664910|SDX105
1079390|NCT01664910|Treanda
1079391|NCT01664910|G-CSF
1079392|NCT01664910|Filgrastim
1079393|NCT01664910|Neupogen
1079394|NCT01664910|Methotrexate
1079395|NCT01664910|Rituximab
1079396|NCT01664910|Rituxan
1079397|NCT01664910|Thymoglobulin
1079398|NCT01664910|ATG
1079399|NCT01664910|Antithymocyte Globulin
1079400|NCT01664910|Tacrolimus
1079401|NCT01664910|Prograf
1079402|NCT01664897|Leukemia
1079403|NCT01664897|Acute myeloid leukemia
1079404|NCT01664897|AML
1079405|NCT01664897|refractory
1079406|NCT01664897|relapsed
1079407|NCT01664897|Erlotinib
1079408|NCT01664897|Erlotinib Hydrochloride
1079409|NCT01664897|OSI-774
1079410|NCT01664897|CP358774
1079411|NCT01664897|Tarceva
1079412|NCT01664884|INTERNALIZED STIGMA
1079413|NCT01664884|INSIGHT
1079414|NCT01664884|SOCIAL ADEQUACY
1079415|NCT01664884|BIPOLAR DISORDER
1079416|NCT01664884|SCHIZOPHRENIA
1079417|NCT01664858|Coronary Heart Disease
1079418|NCT01664858|Ischaemic Heart Disease
1079419|NCT01664858|Angina
1079420|NCT01664858|Cardiac Magnetic Resonance Imaging
1079421|NCT01664845|hepatitis c
1079422|NCT01664845|metformin
1079423|NCT01664845|pegylated interferon
1079424|NCT01664832|Premature Infants
1079425|NCT01664832|snychronized ventilation
1079426|NCT01664832|non-invasive ventilation
1079427|NCT01664832|RDS
1079428|NCT01664806|Electrosurgery
1079429|NCT01664806|Radiofrequency energy
1079430|NCT01664806|Monopolar instruments
1079431|NCT01664806|Capacitive coupling
1079432|NCT01664806|Thermal injury
1079433|NCT01664806|Surgical complications
1079434|NCT01664793|influenza
1079435|NCT01664793|vaccination
1079436|NCT01664793|strategies
1079437|NCT01664793|children/adolescents
1079438|NCT01664780|standard
1079439|NCT01664780|values
1079440|NCT01664780|share
1079441|NCT01664780|wave velocity
1079442|NCT01664780|in ARFI imaging
1079443|NCT01664767|COPD
1079444|NCT01664767|Thermal water
1079445|NCT01664767|Oxidative stress
1079446|NCT01664767|Inflammation
1079447|NCT01664741|Nicotine dependence
1079448|NCT01664741|cigarette
1079449|NCT01664741|smoking
1079450|NCT01664741|nicotine replacement therapy
1079451|NCT01664741|positron emission tomography
1079452|NCT01664728|Prostate neoplasms
1079453|NCT01664728|Hormone refractory prostate cancer
1079454|NCT01664728|Castration resistant prostate cancer
1079455|NCT01664728|Castration refractory prostate cancer
1079456|NCT01664728|Abiraterone acetate
1079457|NCT01664728|CB7630
1079458|NCT01664715|Overweight
1079459|NCT01664715|Obesity
1079460|NCT01664715|Exercise
1079461|NCT01664715|Weight Loss
1079462|NCT01664702|Dairy
1079463|NCT01664702|obesity
1079464|NCT01664676|liraglutide
1079465|NCT01664676|victoza
1079466|NCT01664676|GLP-1
1079467|NCT01664676|kidney
1079468|NCT01664676|diabetes
1079469|NCT01664676|renal
1079470|NCT01664676|diabetic nephropathy
1079471|NCT01664663|Radiotherapy
1079472|NCT01664663|Dose escalation
1079473|NCT01664663|Normal tissue constraints
1079474|NCT01664663|Locally advanced disease
1079475|NCT01664663|Good performance status
1079476|NCT01664650|menopause
1079477|NCT01664650|pre-diabetes
1079478|NCT01664637|diabetic gastroparesis
1079479|NCT01664637|delayed gastric emptying
1079480|NCT01664637|gastroparesis
1079481|NCT01664637|diabetes mellitus, Type 1
1079482|NCT01664637|diabetes mellitus, Type 2
1079483|NCT01664624|Drug Therapy
1079484|NCT01664611|Remote Ischaemic Conditioning
1079485|NCT01664611|Remodeling
1079486|NCT01664611|Heart Failure
1079487|NCT01664611|Myocardial Infarction
1079488|NCT01664611|Ischaemia/Reperfusion Injury
1079489|NCT01664611|successful primary percutaneous coronary intervention following a first STEMI
1079490|NCT01664585|headache
1079491|NCT01664585|women
1079492|NCT01664585|exercise
1079493|NCT01664585|fear avoidance
1079494|NCT01664585|physical activity
1079495|NCT01664572|laser Doppler flowmetry, skin blood flow
1079496|NCT01664559|intrauterine device
1079497|NCT01664559|ketorolac
1079498|NCT01664559|toradol
1079499|NCT01664559|mirena
1079500|NCT01664559|paragard
1079501|NCT01664559|pain control
1079502|NCT01664520|Subarachnoid hemorrhage
1079503|NCT01664520|Dexmedetomidine
1079504|NCT01664520|Autoregulation
1079505|NCT01664520|Intracranial pressure
1079506|NCT01664520|Cerebral oxygenation
1079507|NCT01664507|croup, dose, epinephrine
1079508|NCT01664273|electroporation
1079509|NCT01664273|gen electrotransfer
1079510|NCT01664273|muscle
1079511|NCT01664273|plasmid AMEP
1079512|NCT01664260|Posttraumatic Stress Disorder
1079513|NCT01664260|N-acetylcysteine
1079514|NCT01664260|Magnetic Resonance Imaging
1079515|NCT01664234|infants with cleft palate
1079516|NCT01664234|Pierre Robin
1079517|NCT01664234|Treacher Collins
1079518|NCT01664234|trisomy 21
1079519|NCT01664221|subject
1079520|NCT01664195|subjects
1079521|NCT01664169|adenocarcinoma of the pancreas
1079522|NCT01664169|recurrent pancreatic cancer
1079523|NCT01664169|stage III pancreatic cancer
1079524|NCT01664169|stage IV pancreatic cancer
1079525|NCT01664169|stage IIB pancreatic cancer
1079526|NCT01664156|Cold hypersensitivity
1079527|NCT01664156|Korean red ginseng
1079528|NCT01664156|Infrared thermography
1079529|NCT01664156|Cold stress test
1079530|NCT01664156|Distal-dorsal difference
1079531|NCT01664091|tissue expander
1079532|NCT01664091|acellular dermal matrix
1079533|NCT01664078|Abdominal Aortic Aneurysm
1079534|NCT01664065|Patient Safety
1079535|NCT01664065|Tolerability
1079536|NCT01664065|Pharmacokinetics
1079537|NCT01664039|Glaucoma
1079538|NCT01664039|Ocular hypertension
1079539|NCT01664000|Tumors
1079540|NCT01664000|carcinoma
1079541|NCT01664000|apoptosis
1079542|NCT01664000|p53
1079543|NCT01664000|p21
1079544|NCT01664000|Caspase3
1079545|NCT01664000|PARP
1079546|NCT01664000|MDM2
1079547|NCT01664000|PUMA
1079548|NCT01663974|Bipolar Disorders
1079549|NCT01663974|Sub-syndromal symptoms
1079550|NCT01663974|Acute depressive episode
1079551|NCT01663974|Symptomatic remission
1079552|NCT01663974|Functioning remission
1079553|NCT01663961|Phase I
1079554|NCT01663961|Pharmacokinetics
1079555|NCT01663961|YM178 Oral Controlled Absorption System (OCAS)
1079556|NCT01663961|Digoxin (Lanoxin)
1079557|NCT01663961|DDI (Drug-drug interaction)
1079558|NCT01663961|Open-label
1079559|NCT01663961|Steady-state
1079560|NCT01663961|subjects
1079561|NCT01663948|Plastic bronchitis
1079562|NCT01663948|PB
1079563|NCT01663935|levodopa
1079564|NCT01663935|Albinism
1079565|NCT01663935|dopamine
1079566|NCT01663935|oculocutaneous albinism
1079567|NCT01663935|vision
1079568|NCT01663935|retina function
1079569|NCT01663909|Pain
1079570|NCT01663909|Scoliosis
1079571|NCT01663909|Rehabilitation
1079694|NCT01663389|mass balance
1079572|NCT01663909|Cognitive-behavioral interventions
1079573|NCT01663909|Adolescents
1079574|NCT01663883|Blood flow autoregulation
1079575|NCT01663883|optic nerve head blood flow
1079576|NCT01663883|isometric exercise
1079577|NCT01663883|Autoregulation
1079578|NCT01663883|ocular physiology
1079579|NCT01663870|Cancer Prevention
1079580|NCT01663870|Breast cancer survivors
1079581|NCT01663870|Cancer survivorship clinic
1079582|NCT01663870|eHealth technology
1079583|NCT01663870|Internet
1079584|NCT01663870|HealthATM website
1079585|NCT01663870|Questionnaire
1079586|NCT01663870|Clinic stakeholders
1079587|NCT01663870|Clinic nurses
1079588|NCT01663870|Physicians
1079589|NCT01663870|Case managers
1079590|NCT01663870|Oncology patient navigators
1079591|NCT01663870|Audio recorded interviews
1079592|NCT01663844|Cognitive behavior therapy
1079593|NCT01663844|Internet treatment
1079594|NCT01663844|Self-help treatment
1079595|NCT01663844|Insomnia
1079596|NCT01663844|Depression
1079597|NCT01663844|ICBT
1079598|NCT01663844|CBT-i
1079599|NCT01663844|CBT-d
1079600|NCT01663831|Outdoor Malaria Transmission
1079601|NCT01663831|Anopheles
1079602|NCT01663831|Topical repellent
1079603|NCT01663831|Early biting vector
1079604|NCT01663831|Long Lasting Insecticidal Net (LLIN)
1079605|NCT01663831|Cambodia
1079606|NCT01663805|Extended Criteria Donor
1079607|NCT01663805|Delayed Graft Function
1079608|NCT01663805|DGF
1079609|NCT01663805|Deceased donors aged ≥ 60 years
1079610|NCT01663805|aged between 50 and 59 years
1079611|NCT01663805|history of systemic hypertension
1079612|NCT01663805|terminal creatinine levels > 1.5 mg/dL
1079613|NCT01663805|death by a cerebrovascular accident
1079614|NCT01663792|urokinase receptor
1079615|NCT01663792|protein expression
1079616|NCT01663792|seaweed (Undaria pinnatifida)
1079617|NCT01663766|GVHD (acute or chronic)
1079618|NCT01663766|acute myeloid or lymphoblastic leukemia (AML or ALL)
1079619|NCT01663766|myelodysplastic syndrome
1079620|NCT01663766|Chronic myelogenous leukemia (CML)
1079621|NCT01663766|Multiple Myeloma (MM)
1079622|NCT01663766|Non-Hodgekin lymphoma (NHL-both follicular & diffuse large cell)
1079623|NCT01663766|Chronic lymphocytic leukemia or small lymphocytic leukemia (CLL or SLL)
1079624|NCT01663753|2-fluoro-2-deoxy-d-glucose-positron emission tomography
1079625|NCT01663753|Positron emission tomography
1079626|NCT01663753|Magnetic resonance imaging
1079627|NCT01663753|Diffusion weighted MRI
1079628|NCT01663753|Squamous-cell cervical carcinoma
1079629|NCT01663753|Sensitivity
1079630|NCT01663714|Non-Hodgkin's Lymphoma
1079631|NCT01663714|tositumomab and iodine I 131 tositumomab
1079632|NCT01663714|Bexxar
1079633|NCT01663714|cycolophosphamide, vacristine, and pednisone
1079634|NCT01663701|Sepsis
1079635|NCT01663701|Severe sepsis
1079636|NCT01663701|Tuberculosis
1079637|NCT01663701|Bundle
1079638|NCT01663701|Zambia
1079639|NCT01663675|Down syndrome
1079640|NCT01663649|Depression
1079641|NCT01663649|Online-Therapy
1079642|NCT01663649|Deprexis
1079643|NCT01663649|Self-help
1079644|NCT01663636|vaccines
1079645|NCT01663636|SMS
1079646|NCT01663636|mobile phones
1079647|NCT01663623|Wegener's Granulomatosis
1079648|NCT01663623|anti-MPO
1079649|NCT01663623|WG
1079650|NCT01663623|Belimumab
1079651|NCT01663623|GPA
1079652|NCT01663623|anti-proteinase 3
1079653|NCT01663623|anti-neutrophil cytoplasmic antibody
1079654|NCT01663623|anti-myeloperoxidase
1079655|NCT01663623|Granulomatosis with polyangiitis
1079656|NCT01663623|Vasculitis
1079657|NCT01663623|Autoimmune Diseases
1079658|NCT01663623|Microscopic Polyangiitis
1079659|NCT01663623|anti-PR3
1079660|NCT01663623|ANCA
1079661|NCT01663623|MPA
1079662|NCT01663623|Systemic Vasculitis
1079663|NCT01663584|Spinal Muscular Atrophy (SMA)
1079664|NCT01663584|Carrier Screening
1079665|NCT01663584|Genetic Testing
1079666|NCT01663558|anal dysplasia
1079667|NCT01663558|HPV
1079668|NCT01663558|HIV
1079669|NCT01663558|MSM
1079670|NCT01663545|Epilepsy
1079671|NCT01663545|Epileptic Focus
1079672|NCT01663545|Inflammation
1079673|NCT01663545|P-Glycoprotein
1079674|NCT01663545|PET Imaging
1079675|NCT01663532|Schizophrenia
1079676|NCT01663519|Diabetic foot
1079677|NCT01663519|Offloading
1079678|NCT01663519|Prevention
1079679|NCT01663519|Orthotics
1079680|NCT01663467|tinnitus
1079681|NCT01663467|smartphone
1079682|NCT01663467|Web
1079683|NCT01663441|Chemotherapy
1079684|NCT01663441|Thrombocytopenia
1079685|NCT01663441|Interleukin-11
1079686|NCT01663441|Platelet
1079687|NCT01663428|birth related brachial plexus injury
1079688|NCT01663428|brachial plexus
1079689|NCT01663428|splint
1079690|NCT01663415|MDV3100
1079691|NCT01663415|prostate
1079692|NCT01663415|cancer
1079693|NCT01663415|enzalutamide
1079695|NCT01663389|radiolabel
1079696|NCT01663389|oral
1079697|NCT01663389|IV
1079698|NCT01663389|GSK1322322
1079699|NCT01663389|healthy volunteer
1079700|NCT01663389|antibiotic
1079701|NCT01663363|refractive
1079702|NCT01663363|LASIK
1079703|NCT01663337|Posttraumatic Stress Disorder
1079704|NCT01663337|PTSD
1079705|NCT01663337|Alcohol Abuse
1079706|NCT01663337|Alcohol Dependance
1079707|NCT01663337|Alcoholism
1079708|NCT01663337|Comorbid
1079709|NCT01663337|Relapse Prevention (RP)
1079710|NCT01663337|Cognitive Processing Therapy (CPT)
1079711|NCT01663324|Tinnitus
1079712|NCT01663324|chronic subjective Tinnitus
1079713|NCT01663324|transcranial magnetic stimulation
1079714|NCT01663324|rTMS
1079715|NCT01663324|hearing disorders
1079716|NCT01663311|rTMS
1079717|NCT01663311|repetitive transcranial magnetic stimulation
1079718|NCT01663311|chronic tinnitus
1079719|NCT01663311|subjective tinnitus
1079720|NCT01663311|double cone coil
1079721|NCT01663298|DNA methylation
1079722|NCT01663298|FGF2
1079723|NCT01663298|Wound healing
1079724|NCT01663298|Smoking
1079725|NCT01663298|Diabetes
1079726|NCT01663298|Implant
1079727|NCT01663285|Urothelial
1079728|NCT01663285|Bladder
1079729|NCT01663285|Cancer
1079730|NCT01663272|oncology
1079731|NCT01663272|pancrease
1079732|NCT01663233|Essential hypertension
1079733|NCT01663233|High blood pressure
1079734|NCT01663220|type 2 diabetes
1079735|NCT01663220|beta cell function
1079736|NCT01663220|meal tolerance test
1079737|NCT01663220|maximum stimulation test
1079738|NCT01663220|method standardization
1079739|NCT01663220|insulin secretion
1079740|NCT01663220|prediabetes
1079741|NCT01663220|insulin sensitivity
1079742|NCT01663207|type 2 diabetes
1079743|NCT01663207|beta cell function
1079744|NCT01663207|meal tolerance test
1079745|NCT01663207|maximum stimulation test
1079746|NCT01663207|method standardization
1079747|NCT01663207|insulin secretion
1079748|NCT01663207|prediabetes
1079749|NCT01663207|insulin sensitivity
1079750|NCT01663194|N/L ratio, STEMI, primary PCI, Long-term mortality
1079751|NCT01663168|HIV
1079752|NCT01663168|Tuberculosis
1079753|NCT01663168|Rifabutin
1079754|NCT01663168|HIV Protease Inhibitors
1079755|NCT01663168|EARNEST trial
1079756|NCT01663168|Randomized Controlled Trial
1079757|NCT01663168|Pilot Projects
1079758|NCT01663168|Second-line ART
1079759|NCT01663168|Drug Toxicity
1079760|NCT01663168|Pharmacokinetics
1079761|NCT01663168|Drug Interactions
1079762|NCT01663155|lung cancer
1079763|NCT01663155|chest x-ray
1079764|NCT01663155|CT scan
1079765|NCT01663155|computer aided detection (CAD)
1079766|NCT01663155|screening
1079767|NCT01663155|smokers
1079768|NCT01663142|Crohn's disease
1079769|NCT01663142|gastrointestinal tract
1079770|NCT01663129|Children
1079771|NCT01663129|Osteoporosis
1079772|NCT01663129|Vertebral Compression Fractures
1079773|NCT01663129|Chronic Illness
1079774|NCT01663129|Glucocorticoids
1079775|NCT01663129|Bone Fragility
1079776|NCT01663116|Rheumatoid arthritis
1079777|NCT01663116|Expanded adipose derived allogeneic adult stem cells (eASCs)
1079778|NCT01663103|Interleukin-1
1079779|NCT01663103|Endothelium, Vascular
1079780|NCT01663103|Vascular Stiffness
1079781|NCT01663103|Oxidative Stress
1079782|NCT01663103|Inflammation
1079783|NCT01663103|Endothelial cells
1079784|NCT01663090|Newly diagnosed
1079785|NCT01663077|Clozapine
1079786|NCT01663077|Schizophrenia
1079787|NCT01663077|Remissia
1079788|NCT01663077|polymorphism
1079789|NCT01663064|Abdominal aortic aneurysm
1079790|NCT01663064|Endovascular
1079791|NCT01663064|Fenestration
1079792|NCT01663064|Juxtarenal
1079793|NCT01663064|Off-the-shelf
1079794|NCT01663064|Pararenal
1079795|NCT01663038|Clopidogrel
1079796|NCT01663038|Aspirin
1079797|NCT01663038|Combination
1079798|NCT01663038|Pharmacokinetics
1079799|NCT01663038|Phase 1
1079800|NCT01663025|Randomised controlled trial
1079801|NCT01663025|Pain
1079802|NCT01663025|Anxiety
1079803|NCT01663025|Ambulatory surgery
1079804|NCT01663025|Hand massage
1079805|NCT01663025|Local anaesthetic
1079806|NCT01662973|Primary Biliary Cirrhosis
1079807|NCT01662973|Mesenchymal Stem Cells
1079808|NCT01662973|Serum alkaline phosphatase
1079809|NCT01662973|Serum Bilirubin
1079810|NCT01662960|stroke
1079811|NCT01662960|hemiparesis
1079812|NCT01662960|arm movement
1079813|NCT01662960|sensory functioning
1079814|NCT01662947|blood pressure
1079815|NCT01662934|dysmenorrhea
1079816|NCT01662934|transcutaneous electrical nerve stimulation
1079817|NCT01662934|heat therapy
1079818|NCT01662921|bolus treatment
1079819|NCT01662895|Brain hemorrhage
1079820|NCT01662895|Cerebral Hemorrhage
1079821|NCT01662895|Deferoxamine
1079822|NCT01662895|Hi-DEF Trial
1079823|NCT01662856|Vascular Surgery
1079824|NCT01662856|Fibrin Sealant
1079825|NCT01662856|Polytetrafluoroethylene (PTFE) grafts
1079826|NCT01662843|Dyspnea
1079827|NCT01662843|Ultrasonography
1079828|NCT01662843|Emergencies
1079829|NCT01662843|Critical Care
1079830|NCT01662830|Obesity
1079831|NCT01662830|Meal replacements
1079832|NCT01662804|INTERLEUKIN 2
1079833|NCT01662804|MAB 3F8
1079834|NCT01662804|GD2-positive tumor
1079835|NCT01662804|12-116
1079836|NCT01662791|Parkinson's Disease
1079837|NCT01662791|Small Bowel Bacterial Overgrowth
1079838|NCT01662791|Weight Loss
1079839|NCT01662791|Gastrointestinal
1079840|NCT01662791|Rifaximin
1079841|NCT01662778|Monodisperse aerosols
1079842|NCT01662778|Asthmatics
1079843|NCT01662778|Pharmacokinetics
1079844|NCT01662778|AMP Challenge
1079845|NCT01662778|Multiple Breath Nitrogen Washout
1079846|NCT01662765|Umbilical pilonidal sinus
1079847|NCT01662765|Treatment
1079848|NCT01662765|Surgery
1079849|NCT01662765|Conservative
1079850|NCT01662765|Investigational treatment
1079851|NCT01662765|After care
1079852|NCT01662752|Early colonic cancer
1079853|NCT01662752|Sentinel lymph node mapping
1079854|NCT01662752|Sentinel lymph node biopsy
1079855|NCT01662752|Near infrared imaging
1079856|NCT01662752|Indocyanine green
1079857|NCT01662752|Laparoscopic
1079858|NCT01662739|Population-Based Cancer Registry
1079859|NCT01662739|Stomach
1079860|NCT01662739|Epidemiology
1079861|NCT01662739|Risk Factor
1079862|NCT01662739|Biomolecular Features
1079863|NCT01662713|skin cancer
1079864|NCT01662713|optical imaging
1079865|NCT01662713|optical coherence tomography
1079866|NCT01662713|optical frequency domain imaging
1079867|NCT01662700|P. vivax infection
1079868|NCT01662700|Artesunate
1079869|NCT01662700|Chloroquine
1079870|NCT01662700|Primaquine
1079871|NCT01662661|Healthy participants
1079872|NCT01662661|Hepatitis C
1079873|NCT01662661|Relative bioavailability
1079874|NCT01662661|Bioavailability
1079875|NCT01662661|Pharmacokinetics
1079876|NCT01662661|JNJ-47910382
1079877|NCT01662648|Schizophrenia
1079878|NCT01662648|Paliperidone
1079879|NCT01662648|Paliperidone extended-release (ER)
1079880|NCT01662635|Non-small cell lung cancer.
1079881|NCT01662635|Diagnosis,
1079882|NCT01662635|Adenocarcinoma,
1079883|NCT01662635|ALK,
1079884|NCT01662635|FISH,
1079885|NCT01662635|IHC
1079886|NCT01662635|RT-qPCR
1079887|NCT01662622|anaesthesia
1079888|NCT01662622|middle aged
1079889|NCT01662622|minimal alveolar concentration
1079890|NCT01662622|sevoflurane
1079891|NCT01662622|isoelectric EEG
1079892|NCT01662609|pancreas
1079893|NCT01662609|high-risk
1079894|NCT01662596|Risk factors,
1079895|NCT01662596|prenatal diagnosis,
1079896|NCT01662596|fetal malformations
1079897|NCT01662583|Influenza
1079898|NCT01662583|text message
1079899|NCT01662583|vaccination
1079900|NCT01662570|Pediatric Obesity
1079901|NCT01662570|Child Overweight
1079902|NCT01662557|Pediatric Obesity
1079903|NCT01662544|Infants
1079904|NCT01662544|Bronchiolitis
1079905|NCT01662544|Hypoxia
1079906|NCT01662544|Emergency Department
1079907|NCT01662544|Length of Stay
1079908|NCT01662544|Pediatrics
1079909|NCT01662466|testosterone
1079910|NCT01662466|DHEA
1079911|NCT01662466|IVF
1079912|NCT01662466|egg quality
1079913|NCT01662466|pregnancy rates
1079914|NCT01662453|epilepsy
1079915|NCT01662453|seizures
1079916|NCT01662453|mortality
1079917|NCT01662453|sudep
1079918|NCT01662453|risk factors
1079919|NCT01662440|Rabies
1079920|NCT01662440|JE
1079921|NCT01662440|accelerated schedule
1079922|NCT01662427|Quality of life
1079923|NCT01662427|Noctural Parkinson's Disease Symptoms
1079924|NCT01662401|children
1079925|NCT01662401|laparoscopic appendectomy
1079926|NCT01662401|iliohypogastric nerve block
1079927|NCT01662401|rectus sheath nerve block
1079928|NCT01662401|ilioinguinal nerve block
1079929|NCT01662388|proximal caries, composite restoration, proximal contact
1079930|NCT01662362|Chagas Disease
1079931|NCT01662362|Trypanosoma cruzi
1079932|NCT01662362|American trypanosomiasis
1079933|NCT01662362|South American trypanosomiasis
1079934|NCT01662362|kissing bugs
1079935|NCT01662362|reduviid bugs
1079936|NCT01662336|Human Immunodeficiency Virus infection
1079937|NCT01662323|Heart failure, general practitioner, medical therapy, quality of live
1079938|NCT01662310|Schizophrenia
1079939|NCT01662310|Paliperidone
1079940|NCT01662310|Paliperidone Extended-Release
1079941|NCT01662297|Quetiapine
1079942|NCT01662297|Trazodone
1079943|NCT01662297|Insomnia
1079944|NCT01662297|Dual Diagnosis
1079945|NCT01662271|obesity
1079946|NCT01662271|adiposity
1079947|NCT01662271|psychosocial
1079948|NCT01662271|healthcare
1079949|NCT01662271|co-morbidities
1079950|NCT01662271|youth with extreme obesity
1079951|NCT01662271|weight loss
1079952|NCT01662258|Community-acquired pneumonia
1079953|NCT01662258|Targeted strategy
1079954|NCT01662258|Empiric therapy
1079955|NCT01662232|Green tea
1079956|NCT01662232|EGCG
1079957|NCT01662232|Cardiovascular diseases
1079958|NCT01662232|Endothelial function
1079959|NCT01662232|Flow-mediated dilation
1079960|NCT01662219|superficial cervical plexus block
1079961|NCT01662219|quality of recovery
1079962|NCT01662206|adults
1079963|NCT01662206|probiotics
1079964|NCT01662206|immune function
1079965|NCT01662206|microbiota
1079966|NCT01662206|digestive health
1079967|NCT01662193|Cholecalciferol
1079968|NCT01662193|Calciol
1079969|NCT01662193|vitamin D3
1079970|NCT01662193|Diabetes Mellitus
1079971|NCT01662193|Diabetes Mellitus Type 2
1079972|NCT01662193|glucose metabolism disorders
1079973|NCT01662193|ergocalciferol
1079974|NCT01662193|calcium
1079975|NCT01662193|adipicytokines
1079976|NCT01662193|inflammatory biomarkers
1079977|NCT01662180|subfertility, IUI, rec FSH, FSH, E2, AMH
1079978|NCT01662141|Cardiac output
1079979|NCT01662141|Perivascular Probe
1079980|NCT01662128|Breast Cancer
1079981|NCT01662115|ILEUS
1079982|NCT01662089|Female pattern hair loss
1079983|NCT01662076|Cancer
1079984|NCT01662076|Fatigue
1079985|NCT01662076|Chemotherapy
1079986|NCT01662076|Pediatrics
1079987|NCT01662076|Homeopathy
1079988|NCT01662050|MCL
1079989|NCT01662050|Mantle Cell Lymphoma
1079990|NCT01662050|Older
1079991|NCT01662037|Pulmonary vascular resistance
1079992|NCT01662037|Heart defects, Congenital
1079993|NCT01662037|Receptors, endothelin
1079994|NCT01662037|Bosentan
1079995|NCT01662024|Obesity
1079996|NCT01662024|BMI
1079997|NCT01662024|Weight loss
1079998|NCT01662024|Gastric restriction
1079999|NCT01662024|Bariatrics
1080000|NCT01662011|patient-ventilator interaction
1080001|NCT01662011|neurally adjusted ventilatory assist
1080002|NCT01662011|diaphragm electrical activity
1080003|NCT01662011|pressure support ventilation
1080004|NCT01661998|Adolescent Idiopathic Scoliosis
1080005|NCT01661998|Spinal Deformity
1080006|NCT01661998|Treatment Outcomes
1080007|NCT01661985|Mycoplasma genitalium
1080008|NCT01661985|Chlamydia trachomatis
1080009|NCT01661985|Treatment
1080010|NCT01661985|Antibiotic resistance
1080011|NCT01661972|colorectal cancer
1080012|NCT01661972|all solid tumors
1080013|NCT01661972|metastatic
1080014|NCT01661972|refractory
1080015|NCT01661972|advanced solid tumors
1080016|NCT01661959|Scoliosis
1080017|NCT01661959|Multi-center Database Registry
1080018|NCT01661959|Spinal Deformity
1080019|NCT01661959|Adolescent Idiopathic Scoliosis
1080020|NCT01661946|vascular endothelial growth factor
1080021|NCT01661946|macular edema
1080022|NCT01661946|diabetic retinopathy
1080023|NCT01661933|celiac disease
1080024|NCT01661933|hookworm
1080025|NCT01661933|probiotic
1080026|NCT01661920|Community Acquired Pneumonia.
1080027|NCT01661920|Treatment duration
1080028|NCT01661907|Elderly
1080029|NCT01661907|Anesthesia and postoperative analgesia
1080030|NCT01661907|Postoperative period
1080031|NCT01661907|Delirium
1080032|NCT01661907|Postoperative complications
1080033|NCT01661881|Newly diagnosed
1080034|NCT01661868|BRCA1 mutation
1080035|NCT01661868|BRCA2 mutation
1080036|NCT01661855|Autism Spectrum Disorders
1080037|NCT01661842|Autoimmune Hepatitis
1080038|NCT01661842|Mesenchymal stem cells
1080039|NCT01661842|serum albumin
1080040|NCT01661842|serum Tbil
1080041|NCT01661842|serum immunoglobulin G(IgG)
1080042|NCT01661816|breast cancer
1080043|NCT01661816|everyday issues
1080044|NCT01661816|couple
1080045|NCT01661803|bupivacaine
1080046|NCT01661803|clonidine
1080047|NCT01661803|pediatric spinal
1080048|NCT01661803|efficacy
1080049|NCT01661803|duration
1080050|NCT01661803|quality
1080051|NCT01661803|side effects
1080052|NCT01661803|intrathecal bupivacaine alone
1080053|NCT01661803|bupivacaine plus clonidine
1080054|NCT01661790|Bevacizumab;
1080055|NCT01661790|non-small cell lung cancer;
1080056|NCT01661790|malignant pleural effusion;
1080057|NCT01661790|intrapleural administration
1080058|NCT01661777|Eustachian tube dysfunction
1080059|NCT01661777|Endolymphatic hydrops
1080060|NCT01661777|Diuretic
1080061|NCT01661777|Low salt diet
1080062|NCT01661777|Myringotomy
1080063|NCT01661777|Pressure equalization tube
1080064|NCT01661777|Ear tube
1080065|NCT01661777|Ear fullness
1080066|NCT01661777|Ear pressure
1080067|NCT01661777|Allergy
1080068|NCT01661777|Nasal steroid
1080069|NCT01661777|Antihistamine
1080070|NCT01661764|Colorectal Neoplasm
1080071|NCT01661751|Group ACYW135 Meninigococcal Polysaccharide Vaccine
1080072|NCT01661738|Group ACYW135 Meninigococcal Polysaccharide Vaccine
1080073|NCT01661725|Group ACYW135 Meningococcal Polysaccharide Vaccine
1080074|NCT01661712|obstructive sleep apnoea,
1080075|NCT01661712|continuous transcutaneous electrical stimulation
1080076|NCT01661699|Obstructive Sleep Apnea
1080077|NCT01661686|esophageal cancer
1080078|NCT01661686|esophageal stenosis
1080079|NCT01661686|stent
1080080|NCT01661686|endoscopy
1080081|NCT01661634|Acute decompensated heart failure
1080082|NCT01661621|Lower urinary tract symptoms (LUTS)
1080083|NCT01661621|International Prostate Symptom Score (IPSS)
1080084|NCT01661621|Antimuscarinics
1080085|NCT01661621|α-blockers
1080086|NCT01661608|Gastric Restriction
1080087|NCT01661595|Fatigue
1080088|NCT01661595|Fatigability
1080089|NCT01661595|Surface Electromyography (sEMG)
1080090|NCT01661595|cyclic guanosine monophosphate (cGMP)
1080091|NCT01661595|Nitric Oxide (NO)
1080092|NCT01661595|NO-cGMP
1080093|NCT01661595|Phosphodiesterase (PDE)
1080094|NCT01661595|Sildenafil
1080095|NCT01661595|Tadalafil
1080096|NCT01661595|Isotope
1080097|NCT01661595|Infusion
1080098|NCT01661595|Anabolism
1080099|NCT01661595|Upregulation
1080100|NCT01661595|Accelerometer
1080101|NCT01661595|Placebo
1080102|NCT01661595|Nitrosylation
1080103|NCT01661582|Air Pollution
1080104|NCT01661582|Myocardial Ischaemia
1080105|NCT01661582|Coronary Blood Flow
1080106|NCT01661582|Diesel Exhaust
1080107|NCT01661582|Troponin
1080108|NCT01661582|Electrocardiography
1080109|NCT01661569|Mindfulness
1080110|NCT01661569|meditation
1080111|NCT01661569|stress
1080112|NCT01661569|well-being
1080113|NCT01661569|work stress
1080114|NCT01661569|blood pressure
1080115|NCT01661569|cortisol
1080116|NCT01661556|Melasma, miconazole, hydroquinone
1080117|NCT01661530|asthma
1080118|NCT01661530|pregnancy
1080119|NCT01661530|diet
1080120|NCT01661530|vitamin E
1080121|NCT01661517|substance use treatment
1080122|NCT01661439|Recurrent miscarriages
1080123|NCT01661439|recurrent pregnancy loss
1080124|NCT01661439|aps
1080125|NCT01661439|anti coagulants in pregnancy
1080126|NCT01661426|Adults
1080127|NCT01661426|Weight loss
1080128|NCT01661426|Diet
1080129|NCT01661426|Insulin Resistance
1080130|NCT01661426|Fatty acid composition
1080131|NCT01661413|Acute Leukemia
1080132|NCT01661413|Pediatrics
1080133|NCT01661413|Intrathecal methotrexate
1080134|NCT01661413|Chemotherapy
1080135|NCT01661413|Nausea
1080136|NCT01661413|Vomiting
1080137|NCT01661400|Glioma includes ependymoma and medulloblastoma
1080138|NCT01661387|Adrenal insufficiency
1080139|NCT01661387|DuoCort
1080140|NCT01661387|Congenital adrenal hyperplasia (CAH)
1080141|NCT01661387|Modified release
1080142|NCT01661387|Hydrocortisone
1080143|NCT01661361|vancomycin
1080144|NCT01661361|levels
1080145|NCT01661361|central venous port device
1080146|NCT01661361|peripherally obtained levels
1080147|NCT01661361|dose adjustments
1080148|NCT01661361|TDM
1080149|NCT01661348|Cesarian section
1080150|NCT01661348|Pregnancy
1080151|NCT01661348|Incision management
1080152|NCT01661335|Nausea
1080153|NCT01661335|Vomiting
1080154|NCT01661335|Children
1080155|NCT01661335|Aprepitant
1080156|NCT01661335|Emend®
1080157|NCT01661322|Acute ischaemic stroke
1080158|NCT01661322|TIA
1080159|NCT01661309|Hyperhomocysteinemia
1080160|NCT01661309|Methylcobalamin
1080161|NCT01661309|Cardiovascular disease
1080162|NCT01661309|Plasma total homocysteine
1080163|NCT01661309|Vegetarians
1080164|NCT01661296|cutaneous leishmaniasis, heat therapy, antimony
1080165|NCT01661283|MPNST
1080166|NCT01661283|malignant peripheral nerve sheath tumors
1080167|NCT01661283|RAD001
1080168|NCT01661283|Everolimus
1080169|NCT01661283|Bevacizumab
1080170|NCT01661283|Sarcoma
1080171|NCT01661283|Avastin
1080172|NCT01661283|mTOR inhibitor
1080173|NCT01661257|Crohn's disease
1080174|NCT01661257|Infliximab
1080175|NCT01661257|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3)
1080176|NCT01661231|Vascular intervention
1080177|NCT01661231|Endovascular
1080178|NCT01661231|Peripheral stent
1080179|NCT01661218|catheters
1080180|NCT01661218|Central Venous
1080181|NCT01661218|complications
1080182|NCT01661218|cancer
1080183|NCT01661205|Persistent AF
1080184|NCT01661205|Longstanding Persistent AF
1080185|NCT01661205|Ablation
1080186|NCT01661205|catheter ablation
1080187|NCT01661192|Type 1 Diabetes
1080188|NCT01661192|newly diagnosed
1080189|NCT01661192|Beta cell preservation
1080190|NCT01661179|Medullary Thyroid Carcinoma
1080191|NCT01661179|Medullary Thyroid Cancer
1080192|NCT01661179|Vandetanib
1080193|NCT01661166|Male adult subjects
1080194|NCT01661166|aged 30-90 years
1080195|NCT01661166|RARP
1080196|NCT01661166|AUA symptom score greater than 7 will be included
1080197|NCT01661114|Gemcitabine, Infusional 5-Fluorouracil,Cisplatin
1080198|NCT01661114|Advanced Pancreatic and Biliary Cancers
1080199|NCT01661114|untreated & previously treated pancreatic & biliary cancer.
1080200|NCT01661101|Perioperative myocardial infarction
1080201|NCT01661101|Myocardial injury
1080202|NCT01661101|noncardiac surgery
1080203|NCT01661088|Neoadjuvant FOLFIRINOX
1080204|NCT01661088|FDR-Gemcitabine
1080205|NCT01661088|Concurrent
1080206|NCT01661088|IMRT
1080207|NCT01661088|Borderline Resectable Pancreatic Cancer
1080208|NCT01661075|mTBI
1080209|NCT01661075|concussion
1080210|NCT01661075|mild traumatic brain injury
1080211|NCT01661075|athlete
1080212|NCT01661075|college
1080213|NCT01661075|football
1080214|NCT01661075|soccer
1080215|NCT01661036|Cognitive Testing
1080216|NCT01661036|Survey
1080217|NCT01661036|Interview
1080218|NCT01661023|Breast Cancer
1080219|NCT01661023|Epidemiology
1080220|NCT01661010|Infertility
1080221|NCT01661010|Male Factor Infertility
1080222|NCT01661010|Female Factor Infertility
1080223|NCT01661010|Unexplained Infertility
1080224|NCT01661010|Sex Chromosome
1080225|NCT01661010|Klinefelter Syndrome
1080226|NCT01661010|Turner's Syndrome
1080227|NCT01661010|XXY
1080228|NCT01661010|Y Chromosome Deletion
1080229|NCT01661010|Aneuploidy
1080230|NCT01660997|Proteasome Inhibitor
1080231|NCT01660997|Induction Combination Therapy
1080232|NCT01660997|Maintenance Strategy
1080233|NCT01660997|Potent Anti-Myeloma Effect
1080234|NCT01660997|Precursor Disease
1080235|NCT01660984|Thyroid Tumor
1080236|NCT01660984|Multiple Endocrine Neoplasia 2
1080237|NCT01660984|Pheochromocytoma
1080238|NCT01660984|RET Mutations
1080239|NCT01660958|Micronutrient Deficiencies
1080240|NCT01660958|Early Child Development
1080241|NCT01660958|Infant Growth
1080242|NCT01660958|Iron Deficiency
1080243|NCT01660945|statins, insulin resistance
1080244|NCT01660932|insulin resistance
1080245|NCT01660919|insulin resistance
1080246|NCT01660893|operative
1080247|NCT01660893|dental procedure
1080248|NCT01660867|hospital admission within 7 days of 3% NaCl nebulizer vs dexamethasone
1080249|NCT01660854|Plasmodium
1080250|NCT01660854|falciparum
1080251|NCT01660854|malaria
1080252|NCT01660854|heterologous
1080253|NCT01660854|immunity
1080254|NCT01660841|Magnetic resonance imaging
1080255|NCT01660841|central nervous system
1080256|NCT01660841|contrast media
1080257|NCT01660841|gadobutrol
1080258|NCT01660828|Exercise induced (high sensitive) troponin release
1080259|NCT01660828|Ischemia reperfusion injury
1080260|NCT01660828|Remote ischemic preconditioning
1080261|NCT01660789|Obesity
1080262|NCT01660789|Diabetes
1080263|NCT01660789|Physical activity
1080264|NCT01660776|diffuse large B-cell lymphoma (DLBCL)
1080265|NCT01660776|Hodgkin lymphoma
1080266|NCT01660776|metastatic breast cancer.
1080267|NCT01660776|non-small cell lung cancer
1080268|NCT01660750|newly diagnosed multiple myeloma
1080269|NCT01660750|transplant eligible multiple myeloma
1080270|NCT01660737|Hay fever
1080271|NCT01660737|Pascallerg
1080272|NCT01660711|neoadjuvant
1080273|NCT01660711|chemotherapy
1080274|NCT01660711|resectable
1080275|NCT01660711|adjuvant
1080276|NCT01660711|pancreas
1080277|NCT01660711|cancer
1080278|NCT01660711|adenocarcinoma
1080279|NCT01660711|surgery
1080280|NCT01660685|Weight loss
1080281|NCT01660685|Web-based
1080282|NCT01660685|Journaling
1080283|NCT01660685|Body Mass Index between 27 and 45
1080284|NCT01660659|Indoor air pollution
1080285|NCT01660659|pneumococcal carriage
1080286|NCT01660646|Tuberculosis case finding
1080287|NCT01660633|Multiple Myeloma
1080288|NCT01660633|High-Dose Melphalan
1080289|NCT01660633|Propylene Glycol-Free
1080290|NCT01660633|Autologous Stem Cell Transplantation
1080291|NCT01660633|Captisol
1080292|NCT01660620|betaxolol/ retinopathy of prematurity
1080293|NCT01660594|coronary disease
1080294|NCT01660594|tomography, x-ray computed
1080295|NCT01660594|calcium
1080296|NCT01660594|exercise test
1080297|NCT01660581|CD133+
1080298|NCT01660581|stem cells
1080299|NCT01660581|Coronary Artery Disease
1080300|NCT01660581|Stable Angina Pectoris
1080301|NCT01660555|Microbiota
1080302|NCT01660555|HITChip
1080303|NCT01660555|biopsies
1080304|NCT01660555|colon
1080305|NCT01660555|protected biopsies
1080306|NCT01660529|Subjects with metastatic breast cancer who have failed at least one standard
1080307|NCT01660529|of care regimen
1080308|NCT01660516|Camellia sinensis
1080309|NCT01660516|flavonoids
1080310|NCT01660516|cardiovascular risk
1080311|NCT01660516|flow mediated dilation
1080312|NCT01660503|Calcium absorption
1080313|NCT01660503|Osteoporosis
1080314|NCT01660503|Bone Health
1080315|NCT01660503|Adolescent
1080316|NCT01660490|Radiographic Image Enhancement,
1080317|NCT01660490|Intraoperative Care
1080318|NCT01660490|Femoral Fractures
1080319|NCT01660490|Femoral Neck Fractures
1080320|NCT01660490|Hip Fractures, Internal Fixators
1080321|NCT01660490|Fracture Fixation Internal
1080322|NCT01660490|Fracture Fixation Intramedullary
1080323|NCT01660490|Fractures Bone
1080324|NCT01660477|Isavuconazole
1080325|NCT01660477|Lopinavir/ritonavir
1080326|NCT01660477|Healthy Volunteers
1080327|NCT01660477|BAL8557
1080328|NCT01660477|Kaletra ®
1080329|NCT01660464|Program evaluation
1080330|NCT01660464|ADHD
1080331|NCT01660451|Clinical trial, phase II
1080332|NCT01660451|Phosphatidylinositol 3-Kinase
1080333|NCT01660451|Class I, Non-Hodgkin's lymphoma
1080334|NCT01660438|Stress urinary incontinence
1080335|NCT01660438|Suburethral sling
1080336|NCT01660425|Attention deficit-/hyperactivity disorder
1080337|NCT01660425|parenting enhancement training
1080338|NCT01660425|guided self-help
1080339|NCT01660425|methylphenidate
1080340|NCT01660412|Pain
1080341|NCT01660412|Alkalinization
1080342|NCT01660412|Technetium 99m Sulfur Colloid
1080343|NCT01660412|sentinel lymphoscintigraphy?
1080344|NCT01660399|salvage chemotherapy
1080345|NCT01660399|advanced squamous cell lung cancer
1080346|NCT01660399|Boanmycin
1080347|NCT01660386|Type 2 Diabetes
1080348|NCT01660386|Dpp-4 inhibitor
1080349|NCT01660386|Sulfonylurea
1080350|NCT01660386|beta cell function
1080351|NCT01660373|ticagrelor
1080352|NCT01660373|tirofiban
1080353|NCT01660373|glycoprotein IIa/IIIa inhibitors
1080354|NCT01660373|P2Y12 blockers
1080355|NCT01660373|acute coronary syndrome
1080356|NCT01660360|Tanibirumab Phase I trial
1080357|NCT01660334|Systemic Mycosis
1080358|NCT01660334|Scedosporium infection
1080359|NCT01660334|Scedosporisis
1080360|NCT01660334|Japanese
1080361|NCT01660334|voriconazole
1080362|NCT01660334|VFEND
1080363|NCT01660334|Regulatory Post Marketing Commitment Plan.
1080364|NCT01660321|Pediculosis capitis
1080365|NCT01660321|Head Lice
1080366|NCT01660295|Severe renal insufficiency certoparin
1080367|NCT01660295|Severe renal insufficiency
1080368|NCT01660243|Pruritus
1080369|NCT01660243|Renal dialysis
1080370|NCT01660243|Receptors, Opioid, kappa
1080371|NCT01660243|Sleep Disorders
1080372|NCT01660243|Quality of Life
1080373|NCT01660230|APC, 3K3A, 3K3A-APC, volunteer, healthy
1080374|NCT01660217|atopic dermatitis
1080375|NCT01660217|eczema action plan
1080376|NCT01660217|patient education
1080377|NCT01660217|written handout
1080378|NCT01660217|investigator's global assessment
1080379|NCT01660217|randomized controlled trial
1080380|NCT01660204|pneumonia, anti-bacterial agents, (cost)efficacy
1080381|NCT01660191|LDL, HDL
1080382|NCT01660178|newborns
1080383|NCT01660178|intensive care unit
1080384|NCT01660178|early stimulation
1080385|NCT01660165|Nutritional status
1080386|NCT01660165|Mental Health
1080387|NCT01660165|Omega-3
1080388|NCT01660165|Pregnancy
1080389|NCT01660165|Postpartum depression
1080390|NCT01660152|male erectile disorder
1080391|NCT01660152|prostate cancer
1080392|NCT01660152|Laparoscopic prostatectomy
1080393|NCT01660126|Aged
1080394|NCT01660126|Cardiovascular disease
1080395|NCT01660126|Levothyroxine
1080396|NCT01660126|Randomised controlled trial
1080397|NCT01660126|Quality of life
1080398|NCT01660126|Subclinical hypothyroidism
1080399|NCT01660100|Atrial fibrillation ablation
1080400|NCT01660087|Exhaled breath condensate (EBC) method
1080401|NCT01660087|Volatile Organic Compounds (VOCs)
1080402|NCT01660087|Endobronchial Ultrasound (EBUS)
1080403|NCT01660087|Confocal Endoscopy
1080404|NCT01660087|Exhaled alveolar gas
1080405|NCT01660074|glycemic index, resistant starch, glycemic response
1080406|NCT01660061|Antiphospholipid syndrome
1080407|NCT01660061|Antiphospholipid antibodies
1080408|NCT01660061|Vitamin-K antagonists
1080409|NCT01660061|International normalized ratio
1080410|NCT01660061|Chromogenic factor X
1080411|NCT01660048|Laparoscopic total extraperitoneal Inguinal hernia repair
1080412|NCT01660022|Healthy
1080413|NCT01660022|Volunteers
1080414|NCT01660009|Endothelial Function
1080415|NCT01660009|Hypoglycemia
1080416|NCT01660009|Mitochondria
1080417|NCT01659996|Meningitis
1080418|NCT01659996|Meningococcal Infection
1080419|NCT01659996|Diphtheria
1080420|NCT01659996|Pertussis
1080421|NCT01659996|Menactra®
1080422|NCT01659996|Pentacel®
1080423|NCT01659983|complicated appendicitis
1080424|NCT01659983|wound closure
1080425|NCT01659983|infection
1080426|NCT01659957|Alcoholism
1080427|NCT01659957|Couples
1080428|NCT01659944|Drug-drug interaction
1080429|NCT01659879|Parents
1080430|NCT01659879|Caregivers
1080431|NCT01659879|Anxiety
1080432|NCT01659879|Consumer satisfaction
1080433|NCT01659866|Infection
1080434|NCT01659866|Antibiotic resistance
1080435|NCT01659866|Prostate biopsy
1080436|NCT01659840|laser,
1080437|NCT01659840|quality of life,
1080438|NCT01659840|orofacial pain
1080439|NCT01659814|Major Depressive Disorder
1080440|NCT01659814|Anhedonia
1080441|NCT01659814|Dopamine
1080442|NCT01659814|Electroencephalography (EEG)
1080443|NCT01659814|Positron Emission Tomography (PET)
1080444|NCT01659814|Reward
1080445|NCT01659801|cataract
1080446|NCT01659801|cataract surgery
1080447|NCT01659801|intaocular lens
1080448|NCT01659801|toric lens
1080449|NCT01659788|Advanced Reproductive Age
1080450|NCT01659788|poor ovarian response
1080451|NCT01659788|Mitochondrial dysfunction
1080452|NCT01659788|Mitochondrial nutrients
1080453|NCT01659788|Coenzyme Q10
1080454|NCT01659788|Electron transfer chain
1080455|NCT01659762|inflammatory bowel disease
1080456|NCT01659762|Crohn's disease
1080457|NCT01659749|Genetics
1080458|NCT01659749|Metabolic
1080459|NCT01659749|Nutrition
1080460|NCT01659749|Maternal PKU
1080461|NCT01659749|Phenylketonuria (PKU)
1080462|NCT01659723|Radio therapy
1080463|NCT01659723|STRI
1080464|NCT01659723|Urinary bladder
1080465|NCT01659723|Hyperbaric Oxygen
1080466|NCT01659697|lifestyle
1080467|NCT01659697|diabetes prevention
1080468|NCT01659697|BMI
1080469|NCT01659697|physical activity
1080470|NCT01659684|congenital CMV infection
1080471|NCT01659684|standard immunoglobulins
1080472|NCT01659684|immunoglobulin therapy
1080473|NCT01659684|IgG CMV avidity index
1080474|NCT01659684|Cytomegalovirus
1080475|NCT01659658|MLN9708
1080476|NCT01659658|Amyloidosis
1080477|NCT01659658|Light Chain
1080478|NCT01659658|IXAZOMIB
1080479|NCT01659658|Tourmaline AL1
1080480|NCT01659658|Drug Therapy
1080481|NCT01659606|dyskeratosis congenita
1080482|NCT01659606|bone marrow failure
1080483|NCT01659606|aplastic anemia
1080484|NCT01659606|bone marrow transplantation
1080485|NCT01659606|reduced intensity conditioning
1080486|NCT01659606|campath
1080487|NCT01659606|fludarabine
1080488|NCT01659606|telomere
1080489|NCT01659593|cognitive disorders
1080490|NCT01659593|multiple sclerosis
1080491|NCT01659593|neuropsychology
1080492|NCT01659580|Angina Pectoris Treatment Prevention
1080493|NCT01659554|Primary peritoneal
1080494|NCT01659541|spinal cord injury
1080495|NCT01659541|paralysis
1080496|NCT01659541|cough
1080497|NCT01659541|cervical spinal cord injury
1080498|NCT01659541|thoracic spinal cord injury
1080499|NCT01659528|Penis
1080500|NCT01659528|Micropenis
1080501|NCT01659528|Nomograms
1080502|NCT01659528|Ultrasound
1080503|NCT01659528|Fetus
1080504|NCT01659502|Patients
1080505|NCT01659489|adnexal torsion
1080506|NCT01659489|laparoscopy
1080507|NCT01659476|methacholine
1080508|NCT01659476|deep inspiration
1080509|NCT01659476|bronchoprotective effect
1080510|NCT01659476|bronchodilating effect
1080511|NCT01659463|CARIES INFILTRATION
1080512|NCT01659463|CARIES LESION
1080513|NCT01659463|INFILTRANT
1080514|NCT01659450|overweight
1080515|NCT01659450|obesity
1080516|NCT01659450|low energy dense
1080517|NCT01659437|M. ulcerans
1080518|NCT01659437|Buruli ulcer
1080519|NCT01659437|drug trial
1080520|NCT01659437|clarithromycin
1080521|NCT01659424|Rectal cancer
1080522|NCT01659411|Congenital Heart Disease
1080523|NCT01659411|Pulmonary Arterial Hypertension
1080524|NCT01659398|Alzheimer's Disease
1080525|NCT01659398|cerebral blood flow
1080526|NCT01659398|ophthalmic blood flow
1080527|NCT01659398|blood viscosity
1080528|NCT01659372|temporomandibular disorder
1080529|NCT01659372|myofascial pain syndrome
1080530|NCT01659333|Peritoneal, Dialysis
1080531|NCT01659307|Acute Lung Injury
1080532|NCT01659307|Acute Respiratory Distress Syndrome
1080533|NCT01659307|Aspirin
1080534|NCT01659294|Type 2 diabetes
1080535|NCT01659294|outcomes
1080536|NCT01659294|case management
1080537|NCT01659281|Artesunate
1080538|NCT01659281|Mefloquine
1080539|NCT01659281|Plasmodium Falciparum
1080540|NCT01659281|Thailand
1080541|NCT01659281|Uncomplicated Plasmodium Falciparum malaria
1080542|NCT01659268|teaching
1080543|NCT01659268|patient simulation
1080544|NCT01659268|laryngeal masks
1080545|NCT01659268|baccalaureate nursing education
1080546|NCT01659268|teaching strategies
1080547|NCT01659268|simulation
1080548|NCT01659242|Rheumatoid arthritis
1080549|NCT01659242|Ultrasound
1080550|NCT01659242|Magnetic Resonance Imaging
1080551|NCT01659229|knee osteoarthritis
1080552|NCT01659216|Electrical Pudendal Nerve Stimulation
1080553|NCT01659216|Urgency-Frequency Syndrome
1080554|NCT01659216|long-term efficacy
1080555|NCT01659203|extraskeletal chondrosarcoma
1080556|NCT01659164|Cognitive Behavioral Therapy
1080557|NCT01659164|Dialectical Behavioral Therapy
1080558|NCT01659164|Group Treatment
1080559|NCT01659164|ADHD
1080560|NCT01659151|metastatic
1080561|NCT01659151|melanoma
1080562|NCT01659151|cell transfer
1080563|NCT01659151|ACT
1080564|NCT01659151|T-cell
1080565|NCT01659151|immunotherapy
1080566|NCT01659151|antibodies
1080567|NCT01659151|lymphocytes
1080568|NCT01659112|core stabilization, upper extremity, kinetic chain, movement
1080569|NCT01659099|DLBCL
1080570|NCT01659099|aa-IPI > or equal to 1
1080571|NCT01659099|Diagnosis
1080572|NCT01659099|18 to 60 years
1080573|NCT01659099|Lymphoma
1080574|NCT01659086|Influenza
1080575|NCT01659086|Immunogenicity
1080576|NCT01659086|H9N2
1080577|NCT01659086|Safety
1080578|NCT01659073|Caloric Vestibular Stimulation
1080579|NCT01659073|Functional Imaging
1080580|NCT01659060|Cacao
1080581|NCT01659060|Chocolate
1080582|NCT01659060|Theobromine
1080583|NCT01659060|Flavonoids
1080584|NCT01659060|Pregnant women
1080585|NCT01659060|Hypertension pregnancy-induced
1080586|NCT01659060|Pre-eclampsia
1080587|NCT01659060|Epicatechin
1080588|NCT01659047|Chronic Lymphocytic Leukemia
1080589|NCT01659047|CLL
1080590|NCT01659047|CAL-101
1080591|NCT01659047|Ofatumumab
1080592|NCT01659034|Anti-platelet therapy
1080593|NCT01659021|CLL
1080594|NCT01659021|Chronic Lymphocytic Leukemia
1080595|NCT01659021|GS-1101
1080596|NCT01659021|CAL-101
1080597|NCT01659021|Ofatumumab
1080598|NCT01659008|acute cyclical heavy menstrual bleeding
1080599|NCT01658995|Implanon
1080600|NCT01658995|Etonogestrel subdermal implant
1080601|NCT01658995|Nexplanon
1080602|NCT01658995|Contraception
1080603|NCT01658995|Irregular Bleeding
1080604|NCT01658995|Menometrorrhagia
1080605|NCT01658956|GCSF
1080606|NCT01658956|Chemotherapy
1080607|NCT01658956|Breast cancer
1080608|NCT01658956|Prophylaxis
1080609|NCT01658917|Tissue Acquisition
1080610|NCT01658904|Autologous Transplant
1080611|NCT01658904|Proteasome Inhibitor
1080612|NCT01658904|Melphalan
1080613|NCT01658904|Filgrastim
1080614|NCT01658839|pediatric glaucoma
1080615|NCT01658839|pediatric ocular hypertension
1080616|NCT01658839|travoprost
1080617|NCT01658826|AIC316
1080618|NCT01658826|Viral shedding
1080619|NCT01658813|Metastatic Gastrointestinal
1080620|NCT01658813|Metastatic Kidney
1080621|NCT01658813|Metastatic Lung
1080622|NCT01658800|H5N1 Influenza
1080623|NCT01658800|H5N1 Influenza vaccine
1080624|NCT01658787|Aorta
1080625|NCT01658761|Myopic traction maculopathy
1080626|NCT01658761|vitrectomy
1080627|NCT01658761|internal limiting membrane
1080628|NCT01658761|Retrospective, case control study
1080629|NCT01658748|Pilot Study
1080630|NCT01658748|Longitudinal Study
1080631|NCT01658748|Amygdaloid Body
1080632|NCT01658748|Insula of Reil
1080633|NCT01658748|Cortex, prefrontal
1080634|NCT01658748|Stimulation, Deep Brain
1080635|NCT01658748|Chronic Post Traumatic Stress Disorder
1080636|NCT01658748|Combat Stress Disorder
1080637|NCT01658748|Social Adjustments
1080638|NCT01658748|Positron-Emission Tomography, Computed Tomography
1080639|NCT01658735|Chronic low back pain
1080640|NCT01658735|Electrotherapy
1080641|NCT01658735|H-Wave
1080642|NCT01658735|H wave
1080643|NCT01658735|TENS
1080644|NCT01658735|Trial
1080645|NCT01658683|Coronary Artery Disease
1080646|NCT01658683|Cardiac Rehabilitation
1080647|NCT01658683|Exercise Maintenance
1080648|NCT01658683|Facilitator
1080649|NCT01658683|Managed Home Exercise
1080650|NCT01658683|Community Based Exercise
1080651|NCT01658670|Heart failure
1080652|NCT01658670|exercise
1080653|NCT01658670|adherence
1080654|NCT01658670|quality of life
1080655|NCT01658644|Patient satisfaction
1080656|NCT01658644|Memory recall
1080657|NCT01658644|Patient-clinician communication
1080658|NCT01658644|health communication
1080659|NCT01658644|clinical care team recall
1080660|NCT01658644|hospital quality of care
1080661|NCT01658618|Venous leg ulcer
1080662|NCT01658618|ulcer
1080663|NCT01658618|venous stasis
1080664|NCT01658618|compression
1080665|NCT01658618|venous
1080666|NCT01658618|venous stasis ulcer
1080667|NCT01658618|vlu
1080668|NCT01658618|hp802-247-09-029
1080669|NCT01658605|GSK1605786
1080670|NCT01658605|ulcerative colitis
1080671|NCT01658605|CCR9 antagonist
1080672|NCT01658605|proof of concept
1080673|NCT01658592|Alcohol Addiction;
1080674|NCT01658592|Deep Brain Stimulation;
1080675|NCT01658592|Nucleus Accumbens;
1080676|NCT01658592|Ventral Anterior Internal capsule;
1080677|NCT01658553|solid tumors
1080678|NCT01658540|Drug Eluting Balloon (DEB) technology
1080679|NCT01658540|long SFA lesions disease
1080680|NCT01658527|metastatic
1080681|NCT01658527|prostate cancer
1080682|NCT01658488|Iron deficiency anemia
1080683|NCT01658488|rice
1080684|NCT01658475|IgG titer
1080685|NCT01658475|periodontopathic bacteria
1080686|NCT01658462|locally recurrent or metastatic breast cancer
1080687|NCT01658462|Docetaxel
1080688|NCT01658462|Nintedanib
1080689|NCT01658436|advanced pancreatic neuroendocrine tumor
1080690|NCT01658436|BEZ235
1080691|NCT01658436|pNET
1080692|NCT01658423|pubic hair
1080693|NCT01658423|sprint velocity
1080694|NCT01658423|vertical jump height
1080695|NCT01658423|body composition
1080696|NCT01658423|maximal voluntary torque
1080697|NCT01658410|Coronary artery disease
1080698|NCT01658410|bypass grafting
1080699|NCT01658397|Healthy subjects
1080700|NCT01658397|Fasting
1080701|NCT01658397|Weight loss
1080702|NCT01658371|HIV
1080703|NCT01658358|ErbB receptor
1080704|NCT01658358|tyrosine kinase inhibitor
1080705|NCT01658358|Anthracycline
1080706|NCT01658345|aortic stenosis
1080707|NCT01658345|asymptomatic
1080708|NCT01658345|microvascular dysfunction
1080709|NCT01658345|Cardiac MRI
1080710|NCT01658332|lung cancer
1080711|NCT01658332|circulating tumor cells
1080712|NCT01658332|prospective
1080713|NCT01658332|monocentrique trial
1080714|NCT01658306|remote ischemic preconditioning
1080715|NCT01658306|random-controlled
1080716|NCT01658306|double blind
1080717|NCT01658306|RIPC
1080718|NCT01658293|stroke
1080719|NCT01658293|follow up
1080720|NCT01658293|upper limb
1080721|NCT01658293|rehabilitation
1080722|NCT01658280|transbronchial needle aspiration
1080723|NCT01658280|ultrasound guided transbronchial needle aspiration
1080724|NCT01658280|sensitivity
1080725|NCT01658280|hilar/mediastinal adenopathy
1080726|NCT01658254|Clinical trials
1080727|NCT01658254|Basic results
1080728|NCT01658254|Registry
1080729|NCT01658228|Depression
1080730|NCT01658228|Dysthymia
1080731|NCT01658228|Cognitive Impairment
1080732|NCT01658228|Cognitive Decline
1080733|NCT01658228|Memory
1080734|NCT01658215|Smoking cessation
1080735|NCT01658215|Nicotine
1080736|NCT01658215|Tobacco Use Disorder
1080737|NCT01658215|Central Nervous System Agents
1080738|NCT01658202|Smoking cessation
1080739|NCT01658202|Nicotine
1080740|NCT01658202|Tobacco Use Disorder
1080741|NCT01658202|Central Nervous System Agents
1080742|NCT01657136|Inappropriate sinus tachycardia
1080743|NCT01657136|ivabradine
1080744|NCT01657136|beta blockers
1080745|NCT01657123|exercise capacity
1080746|NCT01657123|Addison's disease
1080747|NCT01657110|acne
1080748|NCT01657110|inflamed lesions
1080749|NCT01657110|non-inflamed lesions
1080750|NCT01657110|complementary medicine
1080751|NCT01657110|essential oil
1080752|NCT01658176|Estrogen receptor positive
1080753|NCT01658176|Her-2 negative
1080754|NCT01658176|advanced breast cancer
1080755|NCT01658176|Breast Cancer
1080756|NCT01658163|abdominoplasty,
1080757|NCT01658163|skin closure, dressings
1080758|NCT01658150|Cognition
1080759|NCT01658150|Schizophrenia
1080760|NCT01658150|Schizoaffective disorder
1080761|NCT01658137|diet
1080762|NCT01658137|dietary pattern
1080763|NCT01658137|gene
1080764|NCT01658137|gene expression
1080765|NCT01658137|epigenomics
1080766|NCT01658137|diet-gene interaction
1080767|NCT01658137|inflammation
1080768|NCT01658137|9p21
1080769|NCT01658137|fruits
1080770|NCT01658137|vegetables
1080771|NCT01658124|haemorrhage,antifibrinolytic, clinical trial,
1080772|NCT01658111|Stroke
1080773|NCT01658111|Robots
1080774|NCT01658111|EEG
1080775|NCT01658111|EMG
1080776|NCT01658098|postpartum
1080777|NCT01658098|depression
1080778|NCT01658098|edinburgh postpartum depression scale
1080779|NCT01658098|mexican population
1080780|NCT01658085|Thyroidectomy
1080781|NCT01658085|Multinodular goiter
1080782|NCT01658085|Harmonic Focus
1080783|NCT01658085|budget impact
1080784|NCT01658085|Harmonic scalpel
1080785|NCT01658072|Total Hip Arthroplasty
1080786|NCT01658072|Total Hip Replacement
1080787|NCT01658046|COPD
1080788|NCT01658046|exercise
1080789|NCT01658046|neuromuscular electrical stimulation
1080790|NCT01658033|Metastatic Breast Cancer, Her-2 negative Breast Cancer
1080791|NCT01658033|Avastin, FOLFOX regimen
1080792|NCT01658020|Acute exacerbation of Chronic obstructive pulmonary disease
1080793|NCT01658020|Acute Exacerbation
1080794|NCT01658020|Chronic obstructive pulmonary disease(COPD)
1080795|NCT01658020|Zabofloxacin
1080796|NCT01658020|Moxifloxacin
1080797|NCT01657994|cerebral palsy
1080798|NCT01657994|gait training
1080799|NCT01657994|robotic
1080800|NCT01657994|functional electrical stimulation
1080801|NCT01657981|Pharmacokinetics
1080802|NCT01657981|Phase 1
1080803|NCT01657981|14C-labeled
1080804|NCT01657968|Acute tonsillitis
1080805|NCT01657968|Procalcitonin
1080806|NCT01657968|Streptococcal antigen test
1080807|NCT01657968|Centor Criteria
1080808|NCT01657968|Infection marker
1080809|NCT01657942|MRgFUS
1080810|NCT01657942|Prostate
1080811|NCT01657942|Low and Intermediate Risk Prostate Lesions
1080812|NCT01657942|Focal Prostate treatment
1080813|NCT01657942|InSightec
1080814|NCT01657942|ExAblate
1080815|NCT01657942|Non-invasive
1080816|NCT01657942|Gleason 6 or Gleason 7
1080817|NCT01657942|Prostate cancer
1080818|NCT01657929|Influenza
1080819|NCT01657929|Avian
1080820|NCT01657929|H5N1
1080821|NCT01657929|H5-VLP
1080822|NCT01657929|GLA
1080823|NCT01657929|GLA-AF
1080824|NCT01657916|mid-urethral sling
1080825|NCT01657916|Align urethral support system
1080826|NCT01657916|tension free vaginal tape
1080827|NCT01657916|cough stress test
1080828|NCT01657916|pelvic exam
1080829|NCT01657916|PFDI-20
1080830|NCT01657916|PFIQ
1080831|NCT01657916|SSQ
1080832|NCT01657916|Urinary retention
1080833|NCT01657916|mesh erosion
1080834|NCT01657916|urodynamics
1080835|NCT01657890|isavuconazole
1080836|NCT01657890|BAL8557
1080837|NCT01657864|Aseptic Meningitis
1080838|NCT01657864|Epidemiology
1080839|NCT01657864|Bipolar Disorder
1080840|NCT01657864|Lamotrigine
1080841|NCT01657864|Epilepsy
1080842|NCT01657838|Isavuconazole
1080843|NCT01657838|Ketoconazole
1080844|NCT01657838|Healthy Volunteers
1080845|NCT01657838|BAL8557
1080846|NCT01657838|BAL4815
1080847|NCT01657825|isavuconazole
1080848|NCT01657825|warfarin
1080849|NCT01657825|Healthy Volunteers
1080850|NCT01657825|BAL8557
1080851|NCT01657825|Coumadin
1080852|NCT01657812|dexmedetomidine
1080853|NCT01657812|Epidural Anesthesia
1080854|NCT01657812|stress response
1080855|NCT01657812|anesthesia recovery
1080856|NCT01657786|ondanstron
1080857|NCT01657786|gene polymorphism
1080858|NCT01657786|postoperative nausea and vomiting
1080859|NCT01657786|laparoscopic surgery under general anesthesia
1080860|NCT01657760|craving
1080861|NCT01657760|dopamine
1080862|NCT01657760|citalopram
1080863|NCT01657760|ssri
1080864|NCT01657747|Ovarian carcinoma
1080865|NCT01657747|Staging
1080866|NCT01657747|Early treatment follow-up
1080867|NCT01657747|Identifying tumor recurrence
1080868|NCT01657747|Whole body diffusion-weighted MRI
1080869|NCT01657734|therapy-induced inflammatory response with
1080870|NCT01657734|magnetic resonance imaging
1080871|NCT01657695|HCC
1080872|NCT01657695|Computed tomography
1080873|NCT01657695|Gene expression
1080874|NCT01657695|Fractional growth
1080875|NCT01657682|FLT3
1080876|NCT01657682|Crenolanib
1080877|NCT01657682|Acute
1080878|NCT01657682|Myeloid
1080879|NCT01657682|AML
1080880|NCT01657669|Choroidal neovascularization due to AMD
1080881|NCT01657643|Health related quality of life
1080882|NCT01657643|Functional Status
1080883|NCT01657630|Insulin Pump Therapy
1080884|NCT01657630|Type 1 Diabetes
1080885|NCT01657630|Treatment Satisfaction
1080886|NCT01657604|CML
1080887|NCT01657604|Tasigna
1080888|NCT01657604|Nilotinib
1080889|NCT01657604|Interferon
1080890|NCT01657591|skin cancer
1080891|NCT01657591|unresectable
1080892|NCT01657591|BRAF
1080893|NCT01657578|neonates
1080894|NCT01657578|reflux disease
1080895|NCT01657578|population pharmacokinetics, omeprazole
1080896|NCT01657565|LOS
1080897|NCT01657565|Ileus
1080898|NCT01657565|Fever
1080899|NCT01657565|reoperation
1080900|NCT01657552|Drug interaction
1080901|NCT01657552|INCIVEK (telaprevir),
1080902|NCT01657552|SB-497115 (eltrombopag)
1080903|NCT01657552|Pharmacokinetics
1080904|NCT01657552|Thrombocytopenia
1080905|NCT01657552|VICTRELIS (boceprevir)
1080906|NCT01657526|Healthy adults
1080907|NCT01657526|Safety
1080908|NCT01657526|Reactogenicity
1080909|NCT01657526|Immunogenicity
1080910|NCT01657526|Non-typeable H. Influenzae (NTHi)
1080911|NCT01657513|psoriasis
1080912|NCT01657513|treatment failure
1080913|NCT01657513|tnf-alfa
1080914|NCT01657500|endothelial keratoplasty
1080915|NCT01657487|COPD
1080916|NCT01657487|Fluticasone/Salmeterol
1080917|NCT01657487|high dose
1080918|NCT01657448|Symptom of Dysuria
1080923|NCT01657422|Nutrition
1080924|NCT01657422|Physical Activity
1080925|NCT01657422|Adolescents
1080926|NCT01657409|botulinum toxin
1080927|NCT01657409|detrusor overactivity
1080928|NCT01657396|Oral Care
1080929|NCT01657396|Oral Hygiene
1080930|NCT01657396|Intensive Care
1080931|NCT01657396|Mechanical Ventilation
1080932|NCT01657396|Chlorhexidine
1080933|NCT01657331|Hodgkin Lymphoma
1080934|NCT01657331|Hodgkin Disease
1080935|NCT01657331|Hodgkin's Disease
1080936|NCT01657331|Anaplastic Large Cell Lymphoma
1080937|NCT01657331|ALCL
1080938|NCT01657331|SGN+Benda
1080939|NCT01657331|Bendamustine
1080940|NCT01657331|Brentuximab Vedotin
1080941|NCT01657318|diabetic foot
1080942|NCT01657318|leg ulcer
1080943|NCT01657305|Split-Thickness Skin Graft Donor Site
1080944|NCT01657305|Split-thickness skin graft
1080945|NCT01657305|STSG
1080946|NCT01657305|Wound healing
1080947|NCT01657305|Skin grafting
1080948|NCT01657305|Superficial wound
1080949|NCT01657305|Partial-thickness wound
1080950|NCT01657305|Time to wound closure
1080951|NCT01657292|Wound healing
1080952|NCT01657292|Burn wound
1080953|NCT01657292|Superficial partial-thickness burn wound
1080954|NCT01657292|Grade 2a burn wounds
1080955|NCT01657292|Time to wound closure
1080956|NCT01657279|stroke
1080957|NCT01657279|risk score
1080958|NCT01657279|iScore
1080959|NCT01657279|outcomes
1080960|NCT01657279|mortality
1080961|NCT01657279|disability
1080962|NCT01657279|institutionalization
1080963|NCT01657227|diabetes
1080964|NCT01657227|self-management
1080965|NCT01657227|lifestyle
1080966|NCT01657227|diet
1080967|NCT01657227|physical exercise
1080968|NCT01657227|computer-assisted decision support systems
1080969|NCT01657188|Heart failure, congestive
1080970|NCT01657188|Sleep apnea syndromes
1080971|NCT01657188|Adaptive servoventilation
1080972|NCT01657188|Prognosis
1080973|NCT01657188|Cheyne-Stokes respiration
1080974|NCT01657175|Cancer
1080975|NCT01657175|long-term follow-up
1080976|NCT01657175|quality of life
1080977|NCT01657175|Surgery
1080978|NCT01657175|Nursing
1080979|NCT01657162|BA058
1080980|NCT01657162|Abaloparatide-SC
1080981|NCT01657162|abaloparatide
1080982|NCT01657162|ACTIVExtend
1080983|NCT01657162|osteoporosis
1080984|NCT01657162|fracture
1080985|NCT01657162|bone loss
1080986|NCT01657058|soluble fiber
1080987|NCT01657058|second meal effect
1080988|NCT01657058|glycemia
1080989|NCT01657058|satiety
1080990|NCT01657058|Individuals
1080991|NCT01657045|Cicatrix
1080992|NCT01657045|Wound healing
1080993|NCT01657032|diarrhea
1080994|NCT01657032|probiotics
1080995|NCT01657032|diosmectite
1080996|NCT01657006|Heart rate variability
1080997|NCT01657006|ischemic heart disease
1080998|NCT01657006|myocardial ischemia
1080999|NCT01656993|Aspirin
1081000|NCT01656993|ASA
1081001|NCT01656993|aortopulmonary shunt
1081002|NCT01656993|cavopulmonary shunt
1081003|NCT01656993|shunt
1081004|NCT01656993|TEG
1081005|NCT01656993|Antiplatelet
1081006|NCT01656967|Laryngeal Mask Airway
1081007|NCT01656967|LMA
1081008|NCT01656967|Intubation
1081009|NCT01656967|AMBU
1081010|NCT01656967|AScope
1081011|NCT01656967|Aura-I
1081012|NCT01656967|Fastrach
1081013|NCT01656967|Fiberoptic
1081014|NCT01656967|Disposable Fiberoptic
1081015|NCT01656967|Blind Intubation
1081016|NCT01656967|Fiberoptic Intubation
1081017|NCT01656954|stroke volume
1081018|NCT01656954|cardiac output
1081019|NCT01656954|pulse pressure variance
1081020|NCT01656954|stroke volume variance
1081021|NCT01656954|passive leg raise
1081022|NCT01656954|fluid challenge
1081023|NCT01656954|central venous pressure
1081030|NCT01656915|inflammation
1081031|NCT01656915|response
1081032|NCT01656915|resilience
1081033|NCT01656915|cytokines
1081034|NCT01656915|pre-diabetes
1081035|NCT01656902|Autologous Chondrocyte Transplantation
1081036|NCT01656902|NOVOCART 3D plus
1081037|NCT01656902|knee joint pain
1081038|NCT01656902|safety
1081039|NCT01656902|efficacy
1081040|NCT01656902|treatment
1081041|NCT01656902|TETEC
1081042|NCT01656902|cartilage
1081043|NCT01656902|ACT
1081044|NCT01656902|cartilage repair
1081045|NCT01656902|tissue
1081046|NCT01656902|MOCART
1081047|NCT01656889|Venous leg ulcer
1081048|NCT01656889|ulcer
1081049|NCT01656889|venous stasis
1081050|NCT01656889|compression
1081051|NCT01656889|venous
1081052|NCT01656889|venous stasis ulcer
1081053|NCT01656889|vlu
1081054|NCT01656876|Comparative effectiveness research
1081055|NCT01656876|Mirror therapy
1081056|NCT01656876|Stroke rehabilitation
1081057|NCT01656876|Clinical evaluation
1081058|NCT01656876|Kinematic analysis
1081059|NCT01656876|Mesh glove
1081060|NCT01656876|Combined therapy
1081061|NCT01656863|Dehydration
1081062|NCT01656850|hyperglycemia
1081063|NCT01656850|hyperinsulinemia
1081064|NCT01656837|Substance Abuse
1081065|NCT01656837|Child Maltreatment
1081066|NCT01656837|Multisystemic Therapy
1081067|NCT01656837|Child Trauma
1081068|NCT01656824|Bv8/PK-2
1081069|NCT01656824|MDSC Myeloid Derived Suppressor Cells
1081070|NCT01656824|BMDC Bone Marrow Derived Cells
1081071|NCT01656824|Angiogenesis
1081072|NCT01656824|Pancreatic Cancer
1081073|NCT01656785|stroke
1081074|NCT01656785|cerebrovascular disease
1081075|NCT01656785|angiogenesis imaging
1081076|NCT01656785|68Ga-BNOTA-PRGD2
1081077|NCT01656785|PET/CT
1081078|NCT01656772|magnetic navigation
1081079|NCT01656772|robotic control
1081080|NCT01656772|RMT ThermoCool catheter
1081081|NCT01656759|Blood Loss
1081082|NCT01656759|Hemoglobin
1081083|NCT01656759|Hematocrit
1081084|NCT01656759|Blood Transfusions
1081085|NCT01656746|Colorectal Disease
1081086|NCT01656746|SILS
1081087|NCT01656746|colorectal surgery
1081088|NCT01656733|Smoking Cessation
1081089|NCT01656733|Pregnancy
1081090|NCT01656733|Nicotrol Inhaler
1081091|NCT01656733|Placebo Inhaler
1081092|NCT01656733|Nicotine Inhaler
1081093|NCT01656720|Faecal Incontinence
1081094|NCT01656720|Suppository
1081095|NCT01656720|Wexner score
1081096|NCT01656707|Adolescents
1081097|NCT01656707|Substance Use Disorders
1081098|NCT01656694|Osteoarthritis
1081099|NCT01656694|Knee
1081100|NCT01656694|Replacement
1081101|NCT01656694|Unicompartmental
1081102|NCT01656694|DePuy
1081103|NCT01656694|Sigma HP
1081104|NCT01656668|Chronic
1081105|NCT01656668|Acute
1081106|NCT01656668|Persistent
1081107|NCT01656668|Longterm
1081108|NCT01656668|Cough
1081109|NCT01656655|ptsd, parenting
1081110|NCT01656642|PD-L1
1081111|NCT01656642|PD-1
1081112|NCT01656642|PDL1
1081113|NCT01656642|antiPD-L1
1081114|NCT01656642|MPDL3280A
1081115|NCT01656642|Melanoma
1081116|NCT01656642|BRAF
1081117|NCT01656642|MPDL320A
1081118|NCT01656616|Pharmacoeconomics
1081119|NCT01656616|Cost effectiveness
1081120|NCT01656616|Cyanide
1081121|NCT01656616|Fire
1081122|NCT01656616|Emergency Medical Services
1081123|NCT01656616|Smoke Inhalation
1081124|NCT01656603|cord blood
1081125|NCT01656603|transplantation
1081126|NCT01656603|stem cells
1081127|NCT01656603|adverse event
1081128|NCT01656590|Pompe disease
1081129|NCT01656590|Acid Maltase Deficiency
1081130|NCT01656577|CRF1 antagonist
1081131|NCT01656577|Stress
1081132|NCT01656577|Eating Behavior
1081133|NCT01656577|Food Craving
1081134|NCT01656564|HIV
1081135|NCT01656564|Pediatric
1081136|NCT01656564|ART
1081137|NCT01656564|Longitudinal
1081138|NCT01656564|Outcomes
1081139|NCT01656551|elderly
1081140|NCT01656551|chemotherapy
1081141|NCT01656512|ALL
1081142|NCT01656512|zoledronic acid
1081143|NCT01656512|Osteoporosis
1081144|NCT01656486|Pancreas
1081145|NCT01656486|Pancreatic fistula
1081146|NCT01656486|Stereotactic radiation
1081147|NCT01656473|Concurrent Disorders
1081148|NCT01656473|Adolescents
1081149|NCT01656473|Motivational Interviewing
1081150|NCT01656473|Dialectical Behaviour Therapy
1081151|NCT01656473|Caregiver Burden
1081152|NCT01656460|Lung Cancer
1081153|NCT01656447|Scleroderma
1081154|NCT01656447|Scleroderma Registry
1081155|NCT01656447|Hospital for Special Surgery Scleroderma
1081156|NCT01656434|Combined Oral Contraceptives
1081157|NCT01656382|ABLC
1081158|NCT01656382|cryptococcosis
1081159|NCT01656369|Delorme operation,incontinence
1081160|NCT01656356|Avian Flu
1081161|NCT01656356|H5N2
1081162|NCT01656330|Healthy
1081163|NCT01656330|Rivaroxaban
1081164|NCT01656330|JNJ-39039039
1081165|NCT01656330|BAY59-7939
1081166|NCT01656330|Prothrombin Complex Concentrate (PCC)
1081167|NCT01656317|SAH
1081168|NCT01656317|Early rehabilitation
1081169|NCT01656317|Mobilisation
1081190|NCT01656239|VA106483, fedovapagon, Nocturia, males, nocturnal voids, anti-diuretic
1081191|NCT01656226|Actinic Keratosis
1081192|NCT01656226|AK
1081193|NCT01656213|Stroke
1081194|NCT01656213|End Stage Renal Disease
1081195|NCT01656213|Recovery
1081196|NCT01656213|Haemodialysis
1081197|NCT01656200|Japanese encephalitis
1081198|NCT01656200|Japanese encephalitis vaccine
1081199|NCT01656200|T lymphocyte
1081200|NCT01656200|Immune response
1081201|NCT01656187|memantine
1081202|NCT01656187|cognition
1081203|NCT01656187|corticosteroid
1081204|NCT01656187|prednisone
1081205|NCT01656187|memory
1081206|NCT01656187|hippocampus
1081207|NCT01656148|Multiple sclerosis
1081208|NCT01656148|Walking disablility
1081209|NCT01656148|Mobility
1081210|NCT01656148|Six Spot Step Test
1081211|NCT01656148|Outcome measures
1081212|NCT01656148|Fampridine-SR
1081213|NCT01656148|Fampyra
1081214|NCT01656135|gold standard treatment
1081215|NCT01656135|immune monitoring
1081216|NCT01656135|acute rejection
1081217|NCT01656135|graft rejection
1081218|NCT01656135|living-donor
1081219|NCT01656135|renal transplantation
1081220|NCT01656135|kidney transplantation
1081221|NCT01656122|pharmacokinetic paramters
1081222|NCT01656122|abacavir
1081223|NCT01656122|lamuvidine
1081224|NCT01656122|HIV-infected children
1081225|NCT01656109|pharmacokinetics
1081226|NCT01656109|atazanavir/ritonavir
1081227|NCT01656109|HIV-infected children
1081228|NCT01656083|Mobile phone text messaging (SM)
1081229|NCT01656083|Varenicline
1081230|NCT01656083|The compliance
1081231|NCT01656083|The abstinence rate
1081232|NCT01656070|HIV
1081233|NCT01656070|children
1081234|NCT01656070|adolescents
1081235|NCT01656070|Vitamin D
1081236|NCT01656070|immunity
1081237|NCT01656070|T cell phenotype
1081238|NCT01656057|Bile acids
1081239|NCT01656057|Gall bladder emptying
1081240|NCT01656057|Human
1081241|NCT01656057|Glucagon like peptide 1
1081242|NCT01656057|GLP-1
1081243|NCT01656031|recurrent adult acute lymphoblastic leukemia
1081244|NCT01656031|recurrent adult acute myeloid leukemia
1081245|NCT01656031|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1081246|NCT01656031|adult acute myeloid leukemia with inv(16)(p13;q22)
1081247|NCT01656031|adult acute myeloid leukemia with t(16;16)(p13;q22)
1081248|NCT01656031|adult acute myeloid leukemia with t(8;21)(q22;q22)
1081249|NCT01656031|adult acute basophilic leukemia
1081250|NCT01656031|adult acute eosinophilic leukemia
1081251|NCT01656031|adult erythroleukemia (M6a)
1081252|NCT01656031|adult pure erythroid leukemia (M6b)
1081253|NCT01656031|adult acute megakaryoblastic leukemia (M7)
1081254|NCT01656031|adult acute minimally differentiated myeloid leukemia (M0)
1081255|NCT01656031|adult acute monoblastic leukemia (M5a)
1081256|NCT01656031|adult acute monocytic leukemia (M5b)
1081257|NCT01656031|adult acute myeloblastic leukemia with maturation (M2)
1081258|NCT01656031|adult acute myeloblastic leukemia without maturation (M1)
1081259|NCT01656031|adult acute myelomonocytic leukemia (M4)
1081260|NCT01656018|Healthy
1081261|NCT01656018|TMC278
1081262|NCT01656018|Human Immunodeficiency Virus Type 1
1081263|NCT01656018|HIV-1
1081264|NCT01656018|Pharmacokinetics
1081265|NCT01656018|Ex-vivo pharmacodynamics
1081266|NCT01656005|COPD
1081267|NCT01656005|Beta blockers
1081268|NCT01656005|Cardioselective
1081269|NCT01656005|Non-cardioselective
1081270|NCT01656005|Impulse oscillometry
1081271|NCT01655992|capecitabine
1081272|NCT01655992|Tegafur，Gimeracil and Oteracil Potassium Capsules
1081273|NCT01655966|chronic hepatitis c
1081274|NCT01655966|hcv
1081275|NCT01655966|vitamin d
1081276|NCT01655927|Neoplasms
1081277|NCT01655927|Tranexamic Acid
1081278|NCT01655927|Brain Tumors
1081279|NCT01655901|Active video games
1081280|NCT01655901|Food intake
1081281|NCT01655901|Energy balance
1081282|NCT01655901|Adolescents
1081283|NCT01655888|Tremelimumab
1081284|NCT01655888|anti-CTLA-4 monoclonal antibody
1081285|NCT01655888|malignant mesothelioma
1081286|NCT01655875|Allogeneic Blood and Marrow Transplantation
1081287|NCT01655823|Pain
1081288|NCT01655823|Puffer fish
1081289|NCT01655823|Tetrodotoxin
1081290|NCT01655823|TTX
1081291|NCT01655823|Neuropathy
1081292|NCT01655823|Chemotherapy
1081293|NCT01655823|WEX Pharmaceuticals
1081294|NCT01655797|insomnia
1081295|NCT01655797|cognitive behavior therapy
1081296|NCT01655797|primary care
1081297|NCT01655784|aneurysm
1081298|NCT01655784|intracranial aneurysm
1081299|NCT01655784|cerebral aneurysm
1081300|NCT01655784|intracranial embolization
1081301|NCT01655784|aneurysm embolization
1081302|NCT01655784|intracranial coil
1081303|NCT01655784|eighteen coils
1081304|NCT01655784|bare platinum coils
1081305|NCT01655784|GDC Coil
1081306|NCT01655784|Target Coil
1081307|NCT01655771|Opioid induced constipation
1081308|NCT01655771|Constipation
1081309|NCT01655758|glaucoma
1081310|NCT01655758|24-hour IOP
1081311|NCT01655758|outflow drugs
1081312|NCT01655758|inflow drugs
1081313|NCT01655745|[18F]
1081314|NCT01655745|FDG Positron Emission Tomography-Magnetic Resonance Imaging
1081315|NCT01655745|FDG-PET-MRI
1081316|NCT01655745|Muscle-Invasive Bladder Cancer
1081317|NCT01655745|Pilot Study
1081318|NCT01655745|LCCC 1209
1081319|NCT01655745|UNC Lineberger
1081320|NCT01655745|MDCT
1081321|NCT01655732|Pregnancy
1081322|NCT01655706|major depression
1081323|NCT01655706|major depressive disorder
1081324|NCT01655706|biomarkers
1081325|NCT01655706|escitalopram
1081326|NCT01655706|aripiprazole
1081327|NCT01655706|MDD
1081328|NCT01655706|neuroimaging
1081329|NCT01655706|proteomic
1081330|NCT01655706|genomics
1081331|NCT01655693|Intermediate/advanced hepatocellular carcinoma
1081332|NCT01655693|After failure or intolerance to Sorafenib.
1081333|NCT01655680|Schizophrenia
1081334|NCT01655667|Diagnosis
1081335|NCT01655667|Primary Care
1081336|NCT01655667|Comorbidities
1081337|NCT01655667|Healthcare utilisation
1081338|NCT01655654|Hypertension
1081339|NCT01655654|Acute hospital staff
1081340|NCT01655654|Exercise
1081341|NCT01655654|Diet
1081342|NCT01655641|Blood transfusion
1081343|NCT01655641|Bleeding
1081344|NCT01655641|Major Gastro-intestinal surgery
1081345|NCT01655641|Tranexamic Acid
1081346|NCT01655628|nasopharyngeal carcinoma
1081347|NCT01655628|metastasis
1081348|NCT01655628|gemcitabine
1081349|NCT01655628|CIK cells
1081350|NCT01655615|Adolescent cognitive development
1081351|NCT01655615|mental disorders
1081352|NCT01655615|Mood disorders
1081353|NCT01655615|Alcohol-Related disorders
1081354|NCT01655615|Mental disorders diagnosed in childhood
1081355|NCT01655615|Substance related disorders
1081356|NCT01655602|Trichophytic closure
1081357|NCT01655602|hair transplantation
1081358|NCT01655602|donor site
1081359|NCT01655602|Androgenetic alopecia
1081360|NCT01655576|drainage
1081361|NCT01655576|pregnancy
1081362|NCT01655576|active management
1081363|NCT01655576|postpartum hemorrhage
1081364|NCT01655563|Transplant
1081365|NCT01655563|Pediatrics
1081366|NCT01655563|Tacrolimus
1081367|NCT01655563|Prograf
1081368|NCT01655537|fibromyalgia
1081369|NCT01655537|cognitive dysfunction
1081370|NCT01655524|Regadenoson
1081371|NCT01655524|Aminophylline
1081372|NCT01655524|ASSUAGE
1081373|NCT01655524|Myocardial Perfusion Imaging (MPI)
1081374|NCT01655511|Pharmacokinetic
1081375|NCT01655511|pharmacodynamic
1081376|NCT01655498|fecal incontinence
1081377|NCT01655498|bowel control
1081378|NCT01655485|child anxiety
1081379|NCT01655485|challenging behaviors
1081380|NCT01655485|time
1081381|NCT01655485|Parent anxiety
1081382|NCT01655472|schizophrenia
1081383|NCT01655472|imaging
1081384|NCT01655459|ultrasound, LMA, fiberoptic bronchoscopy
1081385|NCT01655446|Comparative effectiveness research
1081386|NCT01655446|Robotic rehabilitation
1081387|NCT01655446|Mirror therapy
1081388|NCT01655446|Functional electrical therapy
1081389|NCT01655446|Combined therapy
1081390|NCT01655446|Stroke rehabilitation
1081391|NCT01655446|Translational science
1081392|NCT01655433|ST-elevation MI
1081393|NCT01655433|Hypothermia
1081394|NCT01655420|Myopia
1081395|NCT01655420|Hyperopia
1081396|NCT01655420|Astigmatism
1081397|NCT01655420|Patient-reported outcomes
1081398|NCT01655420|Patient satisfaction
1081399|NCT01655420|Refractive Error
1081400|NCT01655420|Emmetropia
1081401|NCT01655420|Dry eyes
1081402|NCT01655420|Glare
1081403|NCT01655420|Halos
1081404|NCT01655420|Patient expectations
1081405|NCT01655407|Split-thickness Autograft
1081406|NCT01655407|Engraftment
1081407|NCT01655407|Wound Closure
1081408|NCT01655407|Engineered Skin Substitute
1081409|NCT01655407|ESS-W
1081410|NCT01655407|Cultured Skin Substitutes
1081411|NCT01655407|Burn
1081412|NCT01655342|pulpotomy
1081413|NCT01655342|primary teeth
1081414|NCT01655342|Biodentine®
1081415|NCT01655342|formocresol
1081416|NCT01655329|Image Processing
1081417|NCT01655329|tubes
1081418|NCT01655329|lines
1081419|NCT01655329|catheters
1081420|NCT01655329|wires
1081421|NCT01655329|Bedside
1081422|NCT01655329|chest
1081423|NCT01655329|radiographs
1081424|NCT01655264|Stroke
1081425|NCT01655264|Tele-health
1081426|NCT01655264|Rehabilitation
1081427|NCT01655264|Intervention
1081428|NCT01655264|Gesture recognition system
1081429|NCT01655251|children
1081430|NCT01655251|fever
1081431|NCT01655251|emergency department
1081436|NCT01655212|Cytomegalovirus
1081437|NCT01655212|Congenital infection
1081438|NCT01655212|Sensorineural hearing loss
1081439|NCT01655212|Randomized controlled trial
1081440|NCT01655212|Valganciclovir
1081441|NCT01655199|Chronic Obstructive Pulmonary Disease
1081442|NCT01655199|Lung function
1081443|NCT01655199|Exertional dyspnea
1081444|NCT01655199|Exercise capacity
1081445|NCT01655199|Pulmonary function
1081446|NCT01655199|Pleural pressures
1081447|NCT01655186|Chronic Kidney Disease
1081448|NCT01655186|Type 2 Diabetes Mellitus
1081449|NCT01655173|Asperger syndrome
1081450|NCT01655173|Autistic disorder
1081451|NCT01655173|Adult
1081452|NCT01655173|Psychotherapy
1081453|NCT01655160|Stroke rehabilitation
1081454|NCT01655160|Mirror therapy
1081455|NCT01655160|Functional performance
1081456|NCT01655160|Kinematic analysis
1081457|NCT01655160|Functional magnetic resonance image
1081458|NCT01655160|Motor recovery
1081459|NCT01655147|Healthy
1081460|NCT01655147|Pharmacokinetics
1081461|NCT01655147|Abiraterone acetate
1081462|NCT01655147|Abiraterone
1081463|NCT01655147|JNJ-589485
1081464|NCT01655147|JNJ-212082
1081465|NCT01655147|Zytiga
1081466|NCT01655147|Rifampicin
1081467|NCT01655147|Rifadin
1081468|NCT01655147|CYP3A4 inducer
1081469|NCT01655134|Heart Failure
1081470|NCT01655134|Telemonitoring systems for congestive HF
1081471|NCT01655134|Biomarkers
1081472|NCT01655108|Androgenetic Alopecia
1081473|NCT01655108|Mesotherapy
1081474|NCT01655108|Minoxidil
1081475|NCT01655108|Trichogram
1081476|NCT01655095|Colon capsule
1081477|NCT01655095|Picosalax
1081478|NCT01655095|PEG
1081479|NCT01655095|Prucalopride
1081480|NCT01655082|Smoking cessation
1081481|NCT01655082|Nicotine
1081482|NCT01655082|Tobacco Use Disorder
1081483|NCT01655082|Central Nervous System Agents
1081484|NCT01655069|Overactive bladder (OAB)
1081485|NCT01655069|Pediatric
1081486|NCT01655069|Solifenacin succinate suspension
1081487|NCT01655069|Phase 3
1081488|NCT01655056|Pharmacokinetics
1081489|NCT01655056|Pharmacodynamics
1081490|NCT01655056|Phase 1
1081491|NCT01655056|YM150
1081492|NCT01655056|Dose-escalating
1081493|NCT01655056|Ethnicity
1081494|NCT01655056|Caucasian
1081495|NCT01655056|Japanese
1081496|NCT01655043|Magnetic Resonance Imaging
1081497|NCT01655043|regadenoson
1081498|NCT01655017|Obesity
1081499|NCT01655017|adipose tissue fibrosis
1081500|NCT01655017|Adipose tissue inflammation
1081501|NCT01655017|Low grade systemic inflammation
1081502|NCT01655017|non invasive device
1081503|NCT01655017|Bariatric surgery
1081504|NCT01655004|hormone receptor positive
1081505|NCT01655004|breast cancer
1081506|NCT01654939|HIV
1081507|NCT01654939|hepatitis C
1081508|NCT01654926|Feasibility of using the FlexFlowTM ultrafiltration pump in a non hospital environment
1081509|NCT01654913|hemoglobin determination
1081510|NCT01654913|oxygen
1081511|NCT01654887|Comparative Effectiveness
1081512|NCT01654887|Lung Ultrasound versus Chest X-ray
1081513|NCT01654887|Pneumonia
1081514|NCT01654887|Emergency Department
1081515|NCT01654848|liver transplantation
1081516|NCT01654848|thrombocytes
1081517|NCT01654848|heparin-induced thrombocytopenia
1081518|NCT01654848|multivariate analysis of associated factors of HIT 2 after OLT
1081519|NCT01654848|laboratory investigations of HIT-antibodies
1081520|NCT01654822|HPV
1081521|NCT01654822|cervix
1081522|NCT01654796|Depression
1081523|NCT01654796|Treatment Resistant Depression
1081524|NCT01654783|5-ASA, ulcerative colitis, active, remission, adherence
1081525|NCT01654770|VCE, DBE,OGIB
1081526|NCT01654770|consecutive
1081527|NCT01654770|patients
1081528|NCT01654731|PBC
1081529|NCT01654731|Bezafibrate
1081530|NCT01654692|metastatic melanoma
1081531|NCT01654692|Ipilimumab
1081532|NCT01654679|wound infection
1081533|NCT01654679|surgery
1081534|NCT01654679|surgical wound infection rate
1081535|NCT01654679|wound healing
1081536|NCT01654666|Remote ischemic preconditioning
1081537|NCT01654666|Stroke secondary prevention
1081538|NCT01654666|Carotid artery stenting
1081539|NCT01654666|Carotid stenosis
1081540|NCT01654666|Inflammation
1081541|NCT01654653|Heart disease
1081542|NCT01654653|cardiac surgery
1081543|NCT01654653|CABG
1081544|NCT01654653|Totilac
1081545|NCT01654653|Voluven
1081546|NCT01654653|6% HES
1081547|NCT01654640|schizophrenia
1081548|NCT01654640|obesity
1081549|NCT01654640|clozapine
1081550|NCT01654640|metformin
1081551|NCT01654627|Guided Tissue Regeneration
1081552|NCT01654627|Dental Implants
1081553|NCT01654627|Membrane, Synthetic
1081554|NCT01654614|Keratoconus match index
1081555|NCT01654614|keratoconus probability index
1081556|NCT01654614|ocular response analyzer
1081557|NCT01654614|Pentacam
1081558|NCT01654614|forme fruste keratoconus
1081559|NCT01654601|Schizophrenia
1081560|NCT01654588|BRONCHIAL CHALLANGE TEST, ASTHMA, METACHLINE, ADENOSINE
1081561|NCT01654575|Methotrexate
1081562|NCT01654575|Knee Osteoarthritis
1081563|NCT01654575|Synovitis
1081564|NCT01654575|Pain reduction
1081565|NCT01654575|Function scores
1081566|NCT01654549|Steatohepatitis,
1081567|NCT01654549|Helicobacter pylori,
1081568|NCT01654549|Insulin resistance,
1081569|NCT01654549|Alanine aminotransferase,
1081570|NCT01654549|Aspartate aminotransferase,
1081571|NCT01654536|PAR
1081572|NCT01654523|Trichotillomania
1081573|NCT01654497|Brain
1081574|NCT01654497|Glioma
1081575|NCT01654497|glioblastoma
1081576|NCT01654497|metastases
1081577|NCT01654497|cancer
1081578|NCT01654497|ETS2101
1081579|NCT01654497|leptomeningeal
1081580|NCT01654497|astrocytoma
1081581|NCT01654497|oligodendroglioma
1081582|NCT01654497|meningioma
1081583|NCT01654471|Walking Impairment Questionnaire
1081584|NCT01654471|Peripheral arterial occlusive disease
1081585|NCT01654471|Korean version
1081586|NCT01654458|Sexual Dysfunctions, Psychological
1081587|NCT01654458|Psychotherapy, Group
1081588|NCT01654458|Genital Neoplasms, Female
1081589|NCT01654458|Endometrial Neoplasms
1081590|NCT01654458|Fallopian Tube Neoplasms
1081591|NCT01654458|Ovarian Neoplasms
1081592|NCT01654458|Urogenital Neoplasms
1081593|NCT01654458|Uterine Cervical Neoplasms
1081594|NCT01654458|Uterine Neoplasms
1081595|NCT01654458|Vaginal Neoplasms
1081596|NCT01654458|Vulvar Neoplasms
1081597|NCT01654445|Minor stroke
1081598|NCT01654419|sliding jig
1081599|NCT01654419|Class II malocclusion
1081600|NCT01654419|Distalization mechanics
1081601|NCT01654419|Intermaxillary elastics
1081602|NCT01654406|Cesarian scar
1081603|NCT01654406|Fractional CO2 laser
1081604|NCT01654393|Triage nurse
1081605|NCT01654393|Ottawa ankle rules
1081734|NCT01653782|advice to stay active
1081735|NCT01653782|exercise training
1081606|NCT01654354|Qualitative Evaluation of abdominal CT image using 4 point scale: Excellent(4)/ Good(3) / Fair(2) / Unacceptable(1)
1081607|NCT01654328|contrast media
1081608|NCT01654328|kidney injury
1081609|NCT01654328|hydration
1081610|NCT01654315|RTP Only Group
1081611|NCT01654315|Myomo Only Group
1081612|NCT01654315|Myom0 + RTP Group
1081613|NCT01654289|respiratory tract infections
1081614|NCT01654289|common cold
1081615|NCT01654289|exercise
1081616|NCT01654289|influenza
1081617|NCT01654289|meditation
1081618|NCT01654263|13-valent
1081619|NCT01654263|23-valent
1081620|NCT01654263|elderly
1081621|NCT01654263|parent protocol
1081622|NCT01654263|Pneumococcal infections
1081623|NCT01654263|vaccine
1081624|NCT01654250|ADHD
1081625|NCT01654250|methylphenidate extended-release
1081626|NCT01654237|work
1081627|NCT01654237|WMSD
1081628|NCT01654237|prevalence
1081629|NCT01654237|occupational risks
1081630|NCT01654237|industry
1081631|NCT01654237|questionnaires
1081632|NCT01654237|musculoskeletal pain
1081633|NCT01654237|lifestyle
1081634|NCT01654224|Influenza in Long Term Care Setting
1081635|NCT01654224|High dose Inactivated influenza vaccine
1081636|NCT01654224|Standard dose inactivated influenza vaccine
1081637|NCT01654172|Diabetes
1081638|NCT01654172|peripheral neuropathy
1081639|NCT01654172|Cocoa flavanols
1081640|NCT01654159|intraocular lenses
1081641|NCT01654159|evaluation
1081642|NCT01654159|cataract
1081643|NCT01654146|Ovarian cancer
1081644|NCT01654146|Epithelial ovarian carcinoma
1081645|NCT01654146|Fallopian tube carcinoma
1081646|NCT01654146|Primary serous peritoneal carcinoma
1081647|NCT01654146|Gynaecological carcinoma
1081648|NCT01654146|Randomised controlled trial
1081649|NCT01654133|Aortic Aneurysm, abdominal
1081650|NCT01654120|insulin
1081651|NCT01654120|Type II Diabetes
1081652|NCT01654120|liraglutide
1081653|NCT01654120|Glucagon-Like Peptide 1
1081654|NCT01654107|tobacco
1081655|NCT01654107|smoking cessation
1081656|NCT01654107|nicotine dependence
1081657|NCT01654081|Lung Cancer
1081658|NCT01654081|POSITIVE NON SMALL CELL CARCINOMA
1081659|NCT01654081|ISG15
1081660|NCT01654081|IRINOTECAN
1081661|NCT01654068|Female Breast Cancer
1081662|NCT01654068|Kidney Cancer
1081663|NCT01654068|Lung Cancer
1081664|NCT01654068|Prostate Cancer
1081665|NCT01654068|Vertebral metastasis
1081666|NCT01654055|Morphine
1081667|NCT01654055|Adverse events
1081668|NCT01654055|Predictive factors
1081669|NCT01654042|anticoagulation
1081670|NCT01654042|warfarin
1081671|NCT01654042|monitoring
1081672|NCT01654042|bleeding
1081673|NCT01654042|thromboembolism
1081674|NCT01654029|Stroke
1081675|NCT01654029|Communication impairments
1081676|NCT01654029|Nurse-patient communication
1081677|NCT01654029|Patient-centred care
1081678|NCT01654016|varicose veins
1081679|NCT01654016|inflammation
1081680|NCT01654003|Goal-directed therapy
1081681|NCT01654003|severe sepsis
1081682|NCT01654003|emergency surgery
1081683|NCT01654003|vasopressor
1081684|NCT01654003|dynamic flow-related parameters
1081685|NCT01653977|Hypovolemic shock
1081686|NCT01653977|trauma
1081687|NCT01653977|emergency
1081688|NCT01653977|surgery
1081689|NCT01653977|GDT
1081690|NCT01653977|Picco
1081691|NCT01653964|suspicious
1081692|NCT01653964|lesion
1081693|NCT01653964|breast
1081694|NCT01653964|cancer
1081695|NCT01653964|screening
1081696|NCT01653964|mammogram
1081697|NCT01653964|negative
1081698|NCT01653938|CHF
1081699|NCT01653925|Prostatic Neoplasms
1081700|NCT01653925|Low grade prostate cancer
1081701|NCT01653912|cancer
1081702|NCT01653912|ovarian
1081703|NCT01653912|platinum-resistant
1081704|NCT01653899|Type I Diabetes
1081705|NCT01653886|Palatability
1081706|NCT01653886|Taste
1081707|NCT01653873|fracture
1081708|NCT01653873|vertebral column
1081709|NCT01653873|osteoporosis
1081710|NCT01653873|predictor
1081711|NCT01653873|vertebroplasty
1081712|NCT01653860|Behavior therapy
1081713|NCT01653860|Group therapy
1081714|NCT01653847|transplant
1081715|NCT01653847|kidney
1081716|NCT01653847|renal disease
1081717|NCT01653834|lymphopenia
1081718|NCT01653821|carotid body
1081719|NCT01653821|heart failure
1081720|NCT01653821|chemoreceptor
1081721|NCT01653821|hypersensitivity
1081722|NCT01653808|CKD dialysis
1081723|NCT01653808|hemodialysis
1081724|NCT01653808|hemodiafiltration
1081725|NCT01653808|Elisio dialyzer
1081726|NCT01653808|efficacy
1081727|NCT01653808|biocompatibility
1081728|NCT01653782|LPB
1081729|NCT01653782|RCT
1081730|NCT01653782|Intervention study
1081731|NCT01653782|Cost effectiveness
1081732|NCT01653782|Yoga
1081733|NCT01653782|evidence based
1081736|NCT01653769|CoSeal
1081737|NCT01653769|Surgical bleeding
1081738|NCT01653769|hemostasis
1081739|NCT01653769|Aortic anastamoses
1081740|NCT01653769|bleeding
1081741|NCT01653769|Cardiac surgery
1081742|NCT01653769|Aneurysms
1081743|NCT01653769|Aortic Dissection
1081744|NCT01653756|Asthma
1081745|NCT01653756|Allergen Challenge
1081746|NCT01653743|Japanese
1081747|NCT01653730|portable oxygen concentrator
1081748|NCT01653730|6-minute walk test
1081749|NCT01653730|chronic obstructive lung disease
1081750|NCT01653730|pulmonary fibrosis
1081751|NCT01653730|long term oxygen therapy
1081752|NCT01653717|Advanced Cancers
1081753|NCT01653717|Leukemia
1081754|NCT01653717|B-cell Chronic Lymphocytic Leukemia
1081755|NCT01653717|B-CLL
1081756|NCT01653717|CD19 positivity
1081757|NCT01653717|CD19-specific T cells
1081758|NCT01653717|T-Cell Infusion
1081759|NCT01653717|Gene Transfer
1081760|NCT01653717|Leukapheresis
1081761|NCT01653717|Fludarabine
1081762|NCT01653717|Fludarabine Phosphate
1081763|NCT01653717|Fludara
1081764|NCT01653717|Cyclophosphamide
1081765|NCT01653717|Cytoxan
1081766|NCT01653717|Neosar
1081767|NCT01653691|Pediatric
1081768|NCT01653691|Burns
1081769|NCT01653691|Scars
1081770|NCT01653691|Pulse Dye laser
1081771|NCT01653678|vitamin D-3
1081772|NCT01653678|omega-3 fatty acids
1081773|NCT01653678|fish oil
1081774|NCT01653678|hypertension
1081775|NCT01653678|blood pressure
1081776|NCT01653652|grass pollen
1081777|NCT01653652|allergic rhinitis
1081778|NCT01653652|TNSS
1081779|NCT01653652|miniRQLQ
1081780|NCT01653639|BAY14-2222
1081781|NCT01653639|Pharmacokinetics
1081782|NCT01653613|B-cell adult acute lymphoblastic leukemia
1081783|NCT01653613|B-cell childhood acute lymphoblastic leukemia
1081784|NCT01653613|untreated adult acute lymphoblastic leukemia
1081785|NCT01653613|untreated childhood acute lymphoblastic leukemia
1081786|NCT01653600|peripheral arterial disease
1081787|NCT01653600|atherosclerosis
1081788|NCT01653600|nitinol
1081789|NCT01653600|stents
1081790|NCT01653587|Transradial Approach
1081791|NCT01653587|Transfemoral Approach
1081792|NCT01653587|Vascular Closure Device
1081793|NCT01653574|Famitinib Malate
1081794|NCT01653574|Metastatic Breast Cancer
1081795|NCT01653574|HER-2 negative
1081796|NCT01653561|Metastatic breast cancer
1081797|NCT01653561|Apatinib
1081798|NCT01653561|non-triple-negative
1081799|NCT01653548|emotion dysregulation
1081800|NCT01653548|borderline personality disorder
1081801|NCT01653548|anxiety
1081802|NCT01653548|depression
1081803|NCT01653548|negative emotions
1081804|NCT01653548|outpatient interventions for negative emotions
1081805|NCT01653548|psychological distress
1081806|NCT01653548|emotion regulation problems
1081807|NCT01653535|Prevention
1081808|NCT01653535|Health Service Use
1081809|NCT01653535|Behavioral Intervention
1081810|NCT01653535|Conduct Problems
1081811|NCT01653535|Anti-Social Behavior
1081812|NCT01653509|cold sore
1081813|NCT01653496|Gastric cancer
1081814|NCT01653496|Perioperative care
1081815|NCT01653496|Enhanced recovery after surgery
1081816|NCT01653496|Multimodal rehabilitation
1081817|NCT01653496|Fast track surgery
1081818|NCT01653496|Gastrectomy
1081819|NCT01653483|Asthma
1081820|NCT01653483|Umeclidinium
1081821|NCT01653483|Adolescent
1081822|NCT01653483|Pharmacokinetics
1081823|NCT01653457|Fibromyalgia
1081824|NCT01653457|Magnetic Resonance Spectroscopy
1081825|NCT01653457|Memantine
1081826|NCT01653457|electroencephalic cordance
1081827|NCT01653405|anticoagulants
1081828|NCT01653405|pharmacists
1081829|NCT01653405|quality improvement
1081830|NCT01653405|quality of health care
1081831|NCT01653392|Maternal Mortality
1081832|NCT01653392|Obstetric Labor, Premature
1081833|NCT01653392|Eclampsia
1081834|NCT01653392|Pre-Eclampsia
1081835|NCT01653392|Abortion, Spontaneous
1081836|NCT01653392|Diabetes, Gestational
1081837|NCT01653392|Pregnancy, Ectopic
1081838|NCT01653392|Hydatidiform Mole
1081839|NCT01653392|Fetal death
1081840|NCT01653392|Live birth
1081841|NCT01653392|Still birth
1081842|NCT01653392|Premature Birth
1081843|NCT01653392|Sex ratio
1081844|NCT01653392|Birth weight
1081845|NCT01653366|Breast Cancer
1081846|NCT01653353|nursing home
1081847|NCT01653353|vitamin D supplements
1081848|NCT01653353|calcium supplements
1081849|NCT01653353|guideline adherence
1081850|NCT01653340|Refractory Chronic Migraine
1081851|NCT01653340|Medically Intractable Chronic Migraine
1081852|NCT01653340|High Frequency Spinal Cord Stimulator
1081853|NCT01653327|mucositis
1081854|NCT01653327|head and neck
1081855|NCT01653327|cancer
1081856|NCT01653327|radiation therapy
1081857|NCT01653327|chemoradiation
1081858|NCT01653327|oral
1081859|NCT01653327|pain
1081860|NCT01653275|Mediterranean Diet
1081861|NCT01653275|Bone turnover
1081862|NCT01653275|postmenopausal women
1081863|NCT01653262|Brivaracetam
1081864|NCT01653262|Levetiracetam
1081865|NCT01653262|Epilepsy
1081866|NCT01653262|Nonpsychotic behavior
1081867|NCT01653249|human papillomavirus (HPV)
1081868|NCT01653249|vaccine
1081869|NCT01653249|treatment
1081870|NCT01653210|Insulin Pump
1081871|NCT01653210|Continuous Glucose Monitor
1081872|NCT01653210|Premenopausal women
1081873|NCT01653184|AMD
1081874|NCT01653184|Vision loss
1081875|NCT01653184|omega-3
1081876|NCT01653184|supplement
1081877|NCT01653184|age related macular degeneration
1081878|NCT01653171|Acetylcysteine, Simethicone, Stomach Neoplasms
1081879|NCT01653158|non-hematologic cancer
1081880|NCT01653158|advanced solid tumors
1081881|NCT01653158|prostrate cancer
1081882|NCT01653145|Appetite
1081883|NCT01653145|Satiety
1081884|NCT01653132|PD
1081885|NCT01653119|Acute coronary syndrome
1081886|NCT01653119|Diabetes mellitus
1081887|NCT01653119|Statins
1081888|NCT01653119|High loading dose
1081889|NCT01653119|Recurrent events
1081890|NCT01653106|cryotherapy
1081891|NCT01653106|Melphalan
1081892|NCT01653106|Mucositis
1081893|NCT01653080|Solid Tumor
1081894|NCT01653080|Eye
1081895|NCT01653080|Orbit
1081896|NCT01653067|Non Hodgkin´s Lymphoma
1081897|NCT01653067|Diffuse Large B-Cell Lymphoma
1081898|NCT01653067|Aggressive Lymphoma
1081899|NCT01653067|Aggressive Non Hodgkin´s Lymphoma
1081900|NCT01653067|NHL
1081901|NCT01653067|aNHL
1081902|NCT01653067|Temsirolimus
1081903|NCT01653067|Torisel
1081904|NCT01653067|Relapsed Non Hodgkin´s Lymphoma
1081905|NCT01653067|Relapsed Diffuse Large B-Cell Lymphoma
1081906|NCT01653067|aggressive NHL
1081907|NCT01653067|B-NHL
1081908|NCT01653067|aggressive B-NHL
1081909|NCT01653041|immunosuppression, identical HLA, kidney transplantation, everolimus
1081910|NCT01653002|Lung cancer
1081911|NCT01653002|EBUS-TBNA
1081912|NCT01653002|Epigenetics
1081913|NCT01653002|shox2 protein, human
1081914|NCT01652989|weight loss
1081915|NCT01652989|weight loss maintenance
1081916|NCT01652989|community based participatory research
1081917|NCT01652989|overweight
1081921|NCT01652950|Physical activity
1081922|NCT01652950|health-insured
1081923|NCT01652950|Financial Incentives
1081924|NCT01652950|Benefits design
1081925|NCT01652937|Rheumatoid Arthritis
1081926|NCT01652937|DMARD-IR
1081927|NCT01652924|mechanical ventilation
1081928|NCT01652924|manual ventilation
1081929|NCT01652911|Islet Transplantation
1081930|NCT01652911|Cell Pouch
1081931|NCT01652898|PK
1081932|NCT01652885|atopic dermatitis
1081933|NCT01652872|anemia
1081934|NCT01652872|chronic kidney disease
1081935|NCT01652872|kidney disease
1081936|NCT01652872|renal failure
1081937|NCT01652833|Metastatic Colorectal Cancer
1081938|NCT01652820|LUNG
1081939|NCT01652820|DOCETAXEL
1081940|NCT01652820|GEMCITABINE
1081941|NCT01652820|CARBOPLATIN
1081942|NCT01652820|RADIOTHERAPY
1081943|NCT01652781|myelodysplastic syndrome
1081944|NCT01652781|azacitidine
1081945|NCT01652781|dosing schedule
1081946|NCT01652768|Malignant Brain Tumors
1081947|NCT01652768|Malignant Glioma
1081948|NCT01652768|High-grade Gliomas
1081949|NCT01652768|Oncology
1081950|NCT01652768|Cancer
1081951|NCT01652768|Patient Caregiver
1081952|NCT01652768|Caregiver Stress, Anxiety, Depression
1081953|NCT01652768|Palliative Care Intervention
1081954|NCT01652755|cystatin C,acute kidney injury,
1081955|NCT01652729|Diabetes, Type 2, exenatide, Sitagliptin
1081956|NCT01652703|Japanese, hypercholesterolemia, high risk for cardiovascular events
1081957|NCT01652677|navigation transcranial magnetic stimulation
1081958|NCT01652677|stroke rehabilitation
1081959|NCT01652651|Learning Disorders
1081960|NCT01652638|subjects
1081961|NCT01652625|Yunnan Baiyao
1081962|NCT01652625|recurrent aphthous stomatitis
1081963|NCT01652625|clinical trial
1081964|NCT01652612|positive end expiratory pressure
1081965|NCT01652599|Eltrombopag
1081966|NCT01652599|Dexamethasone
1081967|NCT01652599|High-dose
1081968|NCT01652599|ITP
1081969|NCT01652586|cardiac ablation
1081970|NCT01652573|X linked hypophosphatemia
1081971|NCT01652573|calcitonin
1081972|NCT01652573|FGF twenty three
1081973|NCT01652560|bevacizumab
1081974|NCT01652560|neoadjuvant chemotherapy
1081975|NCT01652560|HER2-negative breast cancer
1081976|NCT01652547|Melanoma
1081977|NCT01652547|Merkel cell carcinoma
1081978|NCT01652547|Metastatic skin cancer
1081979|NCT01652534|Freezing of gait
1081980|NCT01652534|gait dysfunction
1081981|NCT01652521|lung compliance
1081982|NCT01652521|pleural effusion
1081983|NCT01652521|esophageal pressure
1081984|NCT01652508|smoking cessation
1081985|NCT01652508|Acceptance and Commitment Therapy
1081986|NCT01652508|primary care setting
1081987|NCT01652508|randomised controlled trial
1081988|NCT01652495|rotatory cuff calcific tendonitis
1081989|NCT01652495|corticosteroids
1081990|NCT01652495|US guided percutaneous treatment
1081991|NCT01652495|methylprednisolone
1081992|NCT01652495|triamcinolone
1081993|NCT01652495|hypothalamus pituitary adrenal axis
1081994|NCT01652469|squamous cell
1081995|NCT01652469|NSCLC
1081996|NCT01652469|TKI
1081997|NCT01652469|Erlotinib
1081998|NCT01652469|Docetaxel
1081999|NCT01652469|VeriStrat
1082000|NCT01652469|protein signature
1082001|NCT01652456|addiction support
1082002|NCT01652456|addiction specialist
1082003|NCT01652456|lung cancer
1082004|NCT01652456|head and neck cancer
1082005|NCT01652443|OEF/OIF Veterans
1082006|NCT01652443|Relationships
1082007|NCT01652430|PTSD
1082008|NCT01652430|Suicidal ideation
1082009|NCT01652430|Cognitive processes
1082010|NCT01652417|Methylprednisolone
1082011|NCT01652417|prednisone
1082012|NCT01652417|renal sarcoidosis treatment
1082013|NCT01652404|ICU
1082014|NCT01652404|sepsis
1082015|NCT01652404|antibiotic therapy
1082016|NCT01652404|procalcitonin
1082017|NCT01652378|cocaine addiction
1082018|NCT01652378|neuroimaging
1082019|NCT01652378|functional magnetic resonance imaging (fMRI)
1082020|NCT01652365|Malaria Diagnosis
1082021|NCT01652365|Rapid Diagnostic Tests
1082022|NCT01652365|RDTs
1082023|NCT01652365|Private Sector
1082024|NCT01652365|Retail Sector
1082025|NCT01652365|Drug Shops
1082026|NCT01652352|Disabled
1082027|NCT01652352|Disability
1082028|NCT01652352|Power wheelchair
1082029|NCT01652352|Wheelchair
1082030|NCT01652352|Wheelchair mounted robotic arm
1082031|NCT01652352|WMRA
1082032|NCT01652352|Assistive
1082033|NCT01652352|Assistive robot
1082034|NCT01652352|Assistive robotics
1082035|NCT01652352|Rehabilitation robot
1082036|NCT01652352|Rehabilitation engineering
1082037|NCT01652352|Rehabilitation robotics
1082038|NCT01652300|Oral health
1082039|NCT01652300|education
1082040|NCT01652300|knowledge
1082041|NCT01652300|attitude
1082042|NCT01652300|performance
1082043|NCT01652274|Child Passenger Safety
1082044|NCT01652274|Parental perception of vulnerability
1082045|NCT01652274|Neonatology
1082046|NCT01652274|Newborn
1082047|NCT01652261|advanced stage
1082048|NCT01652248|Heart failure
1082049|NCT01652248|Pacemaker
1082050|NCT01652248|cardiac resynchronization therapy
1082051|NCT01652235|Abdominal aortic aneurysm
1082052|NCT01652235|Endovascular
1082053|NCT01652235|Fenestration
1082054|NCT01652235|Juxtarenal
1082055|NCT01652235|Off-the-shelf
1082056|NCT01652235|Pararenal
1082057|NCT01652222|Alzheimer
1082058|NCT01652222|caregiver
1082059|NCT01652222|dementia
1082060|NCT01652222|social support
1082061|NCT01652222|Montessori
1082062|NCT01652222|Therapeutic game
1082063|NCT01652196|colorectal cancer
1082064|NCT01652196|rectal cancer
1082065|NCT01652196|FOLFOX
1082066|NCT01652196|Aflibercept
1082067|NCT01652183|Intravenous paracetamol
1082068|NCT01652183|catheter related bladder discomfort
1082069|NCT01652183|urologic surgery
1082070|NCT01652157|prospective
1082071|NCT01652157|pancreatic insufficiency
1082072|NCT01652157|fibrosing colonopathy
1082073|NCT01652157|observational
1082074|NCT01652157|pancreatic enzyme replacement therapy
1082075|NCT01652131|general anesthesia
1082076|NCT01652131|volume kinetics
1082077|NCT01652118|bronchopulmonary dysplasia
1082078|NCT01652118|clarithromycin
1082079|NCT01652118|preterm babies
1082080|NCT01652105|Gastric bypass
1082081|NCT01652105|Preoperative diet
1082082|NCT01652105|Prodimed
1082083|NCT01652092|immunodeficiency disorder
1082084|NCT01652092|histiocytic disorder
1082085|NCT01652079|Epithelial
1082086|NCT01652079|Primary
1082087|NCT01652053|InterCushion
1082088|NCT01652040|Spinal Cord Injury
1082089|NCT01652040|Rehabilitation
1082090|NCT01652040|Electrical Stimulation
1082091|NCT01652040|Testosterone
1082092|NCT01652040|Body Composition
1082093|NCT01652040|Lipid and Glucose profile
1082094|NCT01652040|Ectopic Adiposity
1082095|NCT01652027|FVIII inhibitors
1082096|NCT01652014|Transplantation
1082097|NCT01652014|Hematopoietic Stem Cell Transplantation
1082098|NCT01652001|Xerostomia
1082099|NCT01652001|Antidepressant agents
1082100|NCT01652001|Antihypertensive agents
1082101|NCT01651988|ketamine
1082102|NCT01651988|propofol anesthesia
1082103|NCT01651975|Dysphagia
1082104|NCT01651975|Thickening liquid
1082105|NCT01651975|Thickening agent
1082106|NCT01651975|Fluoroscopic swallow study
1082107|NCT01651975|Aspiration
1082108|NCT01651975|History of dysphagia
1082109|NCT01651975|DSS
1082110|NCT01651975|Age > 18
1082111|NCT01651975|comprehensive DSS
1082112|NCT01651975|informed consent
1082113|NCT01651962|Labor Pain
1082114|NCT01651962|Analgesia, Epidural
1082115|NCT01651923|subjects
1082116|NCT01651910|Cancer Pain
1082117|NCT01651910|Breakthrough Pain
1082118|NCT01651910|Unmet Needs
1082119|NCT01651910|Supportive care needs
1082120|NCT01651897|delirium
1082121|NCT01651897|emergency department
1082122|NCT01651897|natural course
1082123|NCT01651897|outcomes
1082124|NCT01651897|elderly
1082125|NCT01651884|Stroke
1082126|NCT01651884|Anomia
1082127|NCT01651871|Agents, anti allergic
1082128|NCT01651871|Nasal congestion
1082129|NCT01651871|Sneezing
1082130|NCT01651871|Nasal discharge
1082131|NCT01651871|D prostanoid (DP) receptor antagonist
1082132|NCT01651832|Colorectal Neoplasms/*drug therapy/*secondary
1082133|NCT01651832|Health Services Accessibility
1082134|NCT01651832|Humans
1082135|NCT01651832|Supportive Care Needs
1082136|NCT01651832|Psychooncology
1082137|NCT01651832|Rural Population
1082138|NCT01651832|Primary Health Care/*methods
1082139|NCT01651832|Treatment Outcome
1082140|NCT01651832|Socioeconomic Factors
1082141|NCT01651832|Quality Assurance, Health Care
1082142|NCT01651832|Quality of Life
1082143|NCT01651832|Adult
1082144|NCT01651832|Aged
1082145|NCT01651832|Aged, 80 and over
1082146|NCT01651819|HTLV-1
1082147|NCT01651819|neurogenic bladder
1082148|NCT01651819|physical therapy
1082149|NCT01651819|Tropical Spastic Paraparesis
1082150|NCT01651806|Blood loss
1082151|NCT01651806|transfusion rates
1082152|NCT01651806|complications
1082153|NCT01651793|cacao
1082154|NCT01651793|theobromine
1082155|NCT01651793|flavanols
1082156|NCT01651793|caffeine
1082157|NCT01651793|sustained attention
1082158|NCT01651793|vigilance
1082159|NCT01651793|vigor
1082160|NCT01651793|vitality
1082161|NCT01651793|energy
1082162|NCT01651793|fatigue
1082163|NCT01651780|Transcatheter aortic valve replacement
1082164|NCT01651780|Aortic valve replacement
1082165|NCT01651780|Severe aortic stenosis
1082166|NCT01651767|Chronic hepatitis C virus infection
1082167|NCT01651767|JNJ-47910382
1082168|NCT01651767|Pharmacokinetics
1082169|NCT01651767|Caucasian genotype-1
1082170|NCT01651767|Non-structural protein 5A (NS5A) inhibitor
1082171|NCT01651741|Intestinal Microbiota
1082172|NCT01651741|Probiotics
1082173|NCT01651741|Seaweed
1082174|NCT01651741|Healthy Subject
1082175|NCT01651728|Simvastatin
1082176|NCT01651728|Pneumonia
1082177|NCT01651728|Elderly
1082178|NCT01651728|TNF-α
1082179|NCT01651728|IFN-ϒ
1082180|NCT01651728|PAI-1
1082181|NCT01651728|CRP
1082182|NCT01651702|Arrhythmia
1082183|NCT01651702|Electroanatomical mapping
1082184|NCT01651689|Scalp biopsy
1082185|NCT01651689|Hair count
1082186|NCT01651689|Vertical section
1082187|NCT01651689|Horizontal section
1082188|NCT01651689|Thais
1082189|NCT01651676|VQ11 questionnaire
1082190|NCT01651676|COPD
1082191|NCT01651676|LBD
1082192|NCT01651663|Influenza
1082193|NCT01651650|Asthma
1082194|NCT01651650|PIF
1082195|NCT01651637|Respiratory Distress syndrome
1082196|NCT01651637|Complications of prematurity
1082197|NCT01651624|Colorectal Cancer
1082198|NCT01651624|Screening
1082199|NCT01651624|Fecal Occult Blood Test
1082200|NCT01651624|CT Colonography
1082201|NCT01651624|Virtual Colonoscopy
1082202|NCT01651624|Colonoscopy
1082203|NCT01651611|Tobacco Cessation
1082204|NCT01651611|Public Housing
1082205|NCT01651611|Community Health Workers
1082206|NCT01651611|Motivational Interviewing
1082207|NCT01651611|Patient centered
1082208|NCT01651611|Low-income
1082209|NCT01651611|Tobacco Treatment Advocates
1082210|NCT01651611|Social Epidemiology
1082211|NCT01651611|Smoking cessation predictors
1082212|NCT01651611|Behavioral Intervention
1082213|NCT01651611|Non-pharmacologic
1082214|NCT01651585|viral disease
1082215|NCT01651585|cytomegalovirus infection
1082216|NCT01651585|is the first cause
1082217|NCT01651585|of congenital
1082218|NCT01651585|neurological handicap
1082219|NCT01651585|of infectious origin.
1082220|NCT01651572|Postoperative residual curarization
1082221|NCT01651572|Residual neuromuscular block
1082222|NCT01651572|Complications
1082223|NCT01651572|Postoperative
1082224|NCT01651572|Neuromuscular function
1082225|NCT01651572|Neuromuscular block
1082226|NCT01651559|modified PASI
1082227|NCT01651559|narrow band UVB phototherapy
1082228|NCT01651559|Dead Sea Minerals
1082229|NCT01651559|Skin auto-Fluorescence
1082230|NCT01651559|Skin wash samples
1082231|NCT01651546|Clean Intermittent Self Catheterization
1082232|NCT01651546|acceptance
1082233|NCT01651546|test
1082234|NCT01651533|Mental practice group
1082235|NCT01651533|Active control group
1082236|NCT01651520|Neurodegeneration
1082237|NCT01651520|Disability
1082238|NCT01651520|Cognition
1082239|NCT01651520|Prognosis
1082240|NCT01651507|Pulmonary Langerhans cell histiocytosis
1082241|NCT01651494|DAS181
1082242|NCT01651494|Influenza
1082243|NCT01651494|inhalation
1082244|NCT01651494|inpatient clinic
1082245|NCT01651494|Multi-Dose
1082246|NCT01651494|recombinant neuraminidase
1082247|NCT01651481|Rhinitis
1082248|NCT01651468|mild bleeding disorder
1082249|NCT01651455|Cystic Fibrosis
1082250|NCT01651455|Pseudomonas Aeruginosa
1082251|NCT01651429|Sleep Deprivation
1082252|NCT01651416|Home management of malaria
1082253|NCT01651416|Seasonal malaria chemoprevention
1082254|NCT01651403|Hepatitis
1082255|NCT01651403|Hepatitis B
1082256|NCT01651403|HBV
1082257|NCT01651390|Restenosis
1082258|NCT01651390|Drug coated balloon
1082259|NCT01651390|Drug eluting stent
1082260|NCT01651390|Paclitaxel
1082261|NCT01651390|Sirolimus
1082262|NCT01651377|Pramipexole
1082263|NCT01651377|Mirapex
1082264|NCT01651377|Cocaine
1082265|NCT01651364|Cocaine
1082266|NCT01651364|Cabergoline
1082267|NCT01651351|Condition:
1082268|NCT01651351|for this study
1082269|NCT01651351|Focus
1082270|NCT01651351|volunteers
1082271|NCT01651338|Acupuncture
1082272|NCT01651338|quality of life
1082273|NCT01651325|Isavuconazole
1082274|NCT01651325|dextromethorphan
1082275|NCT01651325|dextrorphan
1082276|NCT01651325|DXM
1082277|NCT01651325|Healthy Volunteers
1082278|NCT01651325|BAL4815
1082279|NCT01651312|Radioactivity
1082280|NCT01651312|Excretion rate
1082281|NCT01651312|Human subjects
1082282|NCT01651312|Pharmacokinetics
1082283|NCT01651312|YM178
1082284|NCT01651312|Radio-labeled
1082285|NCT01651312|Phase 1
1082286|NCT01651299|copperhead snake envenomation
1082287|NCT01651286|General anesthesia
1082288|NCT01651286|Positive-pressure ventilation
1082289|NCT01651286|Masks
1082290|NCT01651247|Toddlers
1082291|NCT01651247|Retrospective
1082292|NCT01651247|Porcine circovirus type 1 (PCV-1)
1082293|NCT01651247|Infants
1082294|NCT01651247|Laboratory evaluations
1082295|NCT01651247|IPV
1082296|NCT01651221|gustatory response
1082297|NCT01651221|olfactory response
1082298|NCT01651208|Coronary stents
1082299|NCT01651208|Medication adherence
1082300|NCT01651208|Antiplatelet medications
1082301|NCT01651208|Motivational Interviewing
1082302|NCT01651182|Blood transfusion
1082303|NCT01651182|Blood loss
1082304|NCT01651182|Postoperative complications
1082305|NCT01651182|Outcome
1082306|NCT01651169|Paired Transcranial Magnetic Stimulation
1082307|NCT01651169|Methamphetamine abuse, ADHD, Methylphenidate
1082308|NCT01651169|We study the effect of Methamphetamine abuse on Intracortical Inhibition, in ADHD patients, treated with Methylphenidate.
1082309|NCT01651130|pregnancy
1082310|NCT01651130|postpartum hemorrhage
1082311|NCT01651130|Cesarean delivery
1082312|NCT01651130|carbetocin
1082313|NCT01651117|Diabetes Mellitus
1082314|NCT01651117|Mentors
1082315|NCT01651117|Glucose control
1082316|NCT01651117|Hemoglobin A, Glycosylated
1082317|NCT01651117|Randomized Controlled Trial
1082318|NCT01651117|Veterans
1082319|NCT01651104|Influenza, Trivalent, Adjuvanted, Adjuvant, MF59, MF-59, Fluad, Seasonal
1082320|NCT01651078|Metastatic Brain Tumors
1082321|NCT01651078|Progression
1082322|NCT01651078|Radiation Necrosis
1082323|NCT01651078|Quality of Life
1082324|NCT01651052|Aortic valve replacement/regurgitation
1082325|NCT01651039|Panobinostat
1082326|NCT01651039|Lenalidomide
1082327|NCT01651039|Dexamethasone
1082328|NCT01651000|Parathyroid Diseases
1082329|NCT01651000|Renal Insufficiency
1082330|NCT01651000|Kidney Failure, Chronic
1082331|NCT01651000|Hyperparathyroidism, Secondary
1082332|NCT01651000|Vitamin D
1082333|NCT01651000|Hyperparathyroidism
1082334|NCT01651000|Kidney Diseases
1082335|NCT01651000|Kidney Failure
1082336|NCT01651000|Renal Insufficiency, Chronic
1082337|NCT01650987|carcinoma
1082338|NCT01650987|uterus
1082339|NCT01650987|Not metastatic
1082340|NCT01650974|high flow nasal oxygen therapy
1082341|NCT01650974|diagnostic bronchoscopy
1082342|NCT01650948|age-related macular degeneration
1082343|NCT01650948|AMD
1082344|NCT01650935|Nephrolithiasis
1082345|NCT01650935|Recurrent stone former
1082346|NCT01650935|DASH
1082347|NCT01650935|Urine oxalate
1082348|NCT01650935|Urine calcium oxalate supersaturation
1082349|NCT01650896|Delirium
1082350|NCT01650896|Dementia
1082351|NCT01650896|Instrumental activities of daily living
1082352|NCT01650883|Vitamin D3
1082353|NCT01650883|Vitamin D 25 OH
1082354|NCT01650870|Cathartics
1082355|NCT01650870|Laxatives
1082356|NCT01650870|Lactulose
1082357|NCT01650870|Gastrointestinal Agents
1082358|NCT01650870|Therapeutic Uses
1082359|NCT01650870|Pharmacologic Actions
1082360|NCT01650857|Pulmonary hypertension
1082361|NCT01650857|Rehabilitation
1082362|NCT01650857|Exercise capacity
1082363|NCT01650857|Body composition
1082364|NCT01650857|Health related Quality of Life
1082365|NCT01650831|Helicobacter Pylori
1082366|NCT01650831|13C Urea Breath Test
1082367|NCT01650831|BreathID
1082368|NCT01650818|Amyotrophic lateral sclerosis
1082369|NCT01650818|Aerobic training
1082370|NCT01650818|Peak oxygen consumption
1082371|NCT01650818|Quality of life
1082372|NCT01650805|Leukemia
1082373|NCT01650805|Leukemia, Myeloid
1082374|NCT01650805|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1082375|NCT01650805|Neoplasms by Histologic Type
1082376|NCT01650805|Neoplasms
1082377|NCT01650805|Lymphoproliferative Disorders
1082378|NCT01650805|Lymphatic Diseases
1082379|NCT01650805|Immunoproliferative Disorders
1082380|NCT01650805|Immune System Diseases
1082381|NCT01650805|Myeloproliferative Disorders
1082382|NCT01650805|Bone Marrow Diseases
1082383|NCT01650805|Hematologic Diseases
1082384|NCT01650792|Chagas disease
1082385|NCT01650792|Heart failure
1082386|NCT01650792|Stroke
1082387|NCT01650792|Dementia
1082388|NCT01650779|alpha-galactosidase A
1082389|NCT01650779|a-GAL
1082390|NCT01650779|Fabry
1082391|NCT01650779|GL-3
1082392|NCT01650779|Fabrazyme
1082393|NCT01650701|follicular lymphoma
1082394|NCT01650701|non-hodgkins follicular lymphoma
1082395|NCT01650701|treatment for follicular lymphoma
1082396|NCT01650701|rituximab treatment
1082397|NCT01650701|rituximab and lenalidomide treatment
1082398|NCT01650688|Epiblepharon, general anesthesia, positional change
1082399|NCT01650675|pregnancy
1082400|NCT01650675|screening
1082401|NCT01650675|motivation
1082402|NCT01650662|Acute Myocardial Infarction
1082403|NCT01650662|Cyclosporine A
1082404|NCT01650662|Reperfusion
1082405|NCT01650662|Clinical Trial
1082406|NCT01650649|lofexidine
1082407|NCT01650649|methadone
1082408|NCT01650649|interaction
1082409|NCT01650649|pharmacodynamic
1082410|NCT01650649|ECG
1082411|NCT01650649|QTc
1082412|NCT01650636|Videophone-delivered stress management intervention
1082413|NCT01650636|Chronic fatigue syndrome
1082414|NCT01650636|Symptoms
1082415|NCT01650636|Neuroimmune processes
1082416|NCT01650636|Psychosocial
1082417|NCT01650623|Parkinson´s Disease
1082418|NCT01650623|Rehabilitation
1082419|NCT01650623|Cognition
1082420|NCT01650610|Parkinson´s Disease
1082421|NCT01650610|Rehabilitation
1082422|NCT01650610|Cognition
1082423|NCT01650597|Healthy volunteers
1082424|NCT01650597|Pharmacokinetics
1082425|NCT01650597|Free fatty amides
1082426|NCT01650558|Malaria
1082427|NCT01650558|HIV
1082428|NCT01650558|Prophylaxis
1082429|NCT01650558|Antiretroviral therapy
1082430|NCT01650545|case-control study
1082431|NCT01650545|aerosolized liposomal cyclosporine A
1082432|NCT01650545|bronchiolitis obliterans syndrome
1082433|NCT01650545|Lung Transplantation
1082434|NCT01650545|Lung function
1082435|NCT01650519|knee surgery, arthroscopy; orthopaedic, orthopedic surgery
1082436|NCT01650506|Triple Negative
1082437|NCT01650506|Basal-like
1082438|NCT01650493|remineralization
1082439|NCT01650493|demineralzation
1082440|NCT01650493|in situ
1082441|NCT01650493|dentrifice
1082442|NCT01650480|COPD
1082443|NCT01650480|holistic
1082444|NCT01650480|pilot
1082445|NCT01650480|intervention
1082446|NCT01650467|abl polymorphisms
1082447|NCT01650454|Alzheimer
1082448|NCT01650454|Sleep
1082449|NCT01650454|Somnolence
1082450|NCT01650441|Asthma
1082451|NCT01650441|NEXThaler®
1082452|NCT01650441|Formoterol
1082453|NCT01650441|Beclomethasone Dipropionate
1082454|NCT01650441|Computational Fluid Dynamics
1082455|NCT01650441|Functional Imaging
1082456|NCT01650441|Central and Peripheral Airways
1082457|NCT01650441|Asthma Control Test (ACT™)
1082458|NCT01650441|Asthma Control Questionnaire (ACQ)
1082459|NCT01650428|Rectal Cancer
1082460|NCT01650428|Bevacizumab
1082461|NCT01650428|Neoadjuvant
1082462|NCT01650428|Chemotherapy
1082463|NCT01650428|Randomised
1082464|NCT01650415|Cerebral Palsy
1082465|NCT01650415|Erythropoietin
1082466|NCT01650415|Rehabilitation
1082467|NCT01650402|Hypertension, systolic
1082468|NCT01650402|Elderly (> or equal to 75 years)
1082469|NCT01650402|Cerebrovascular disease
1082470|NCT01650389|Tuberculosis
1082471|NCT01650389|HIV
1082472|NCT01650389|BCG
1082473|NCT01650389|Infant
1082474|NCT01650376|Ovarian Neoplasms
1082475|NCT01650376|Cancer of the Ovary
1082476|NCT01650376|Ovarian Cancer
1082477|NCT01650376|Uterine Neoplasms
1082478|NCT01650376|Cancer of the Uterus
1082479|NCT01650376|Uterine Cancer
1082480|NCT01650376|Olaparib
1082481|NCT01650376|AZD2281
1082482|NCT01650376|Carboplatin
1082483|NCT01650376|Paclitaxel
1082484|NCT01650376|Relapsed
1082485|NCT01650363|Complementary and alternative medicine
1082486|NCT01650363|Post operative recovery
1082487|NCT01650363|Cardio- thoracic surgery
1082488|NCT01650350|Melanoma
1082489|NCT01650350|Prostate Cancer
1082490|NCT01650350|Renal Cancer
1082491|NCT01650324|DBPR108
1082492|NCT01650324|DPP4
1082493|NCT01650324|Diabetes
1082494|NCT01650324|GLP-1
1082495|NCT01650324|Incretins
1082496|NCT01650311|IBD, CD, UC, Serotonin, 5-HT
1082497|NCT01650285|Prostate Cancer
1082498|NCT01650285|Radical prostatectomy
1082499|NCT01650207|electroacupuncture
1082500|NCT01650207|TENS
1082501|NCT01650207|shoulder disorder
1082502|NCT01650207|hemiplegia
1082503|NCT01650194|abiraterone acetate
1082504|NCT01650194|prednisone
1082505|NCT01650194|enzalutamide
1082506|NCT01650194|cancer
1082507|NCT01650194|prostate
1082508|NCT01650194|MDV3100
1082509|NCT01650181|nafld, nash, fatty liver
1082510|NCT01650168|NOMAC-E2
1082511|NCT01650168|Nomegestrol acetate
1082512|NCT01650168|Estradiol
1082513|NCT01650168|Levonorgestrel
1082514|NCT01650168|Safety
1082515|NCT01650142|Neurofibromatosis 1
1082516|NCT01650142|Phenotype
1082517|NCT01650142|Modifiers
1082518|NCT01650116|hypovolemia
1082519|NCT01650116|renal hypoperfusion
1082520|NCT01650116|liver transplantation
1082521|NCT01650116|sodium
1082522|NCT01650116|chloride
1082523|NCT01650116|PuCO2
1082524|NCT01650116|ScvO2
1082525|NCT01650116|PiCCO
1082526|NCT01650116|O2-delivery
1082527|NCT01650116|hemodynamic indexes
1082528|NCT01650103|hypovolemia
1082529|NCT01650103|renal hypoperfusion
1082530|NCT01650103|major surgery
1082531|NCT01650103|sodium
1082532|NCT01650103|potassium
1082533|NCT01650103|chloride
1082534|NCT01650103|ScvO2
1082535|NCT01650103|hemodynamic indexes
1082536|NCT01650090|Pulmonary relapse
1082537|NCT01650090|Osteosarcoma
1082538|NCT01650090|Lung metastases
1082539|NCT01650090|Pediatric osteosarcoma
1082540|NCT01650090|Inhaled chemotherapy
1082541|NCT01650090|Inhaled Lipid Cisplatin
1082542|NCT01650077|Soft tissue sarcoma
1082543|NCT01650077|Yondelis
1082544|NCT01650077|Intolerance to doxorubicin/ifosfamide
1082545|NCT01650077|CHOI criteria
1082546|NCT01650064|Hip fracture
1082547|NCT01650064|Mortality
1082548|NCT01650038|faecal transplantation
1082549|NCT01650038|ulcerative colitis
1082550|NCT01650038|inflammatory bowel disease
1082551|NCT01650025|probiotic, obesity, BMI, metabolic profile, metabolomics
1082552|NCT01649999|Rheumatoid Arthritis
1082553|NCT01649999|ASP015K
1082554|NCT01649986|Hyperlipidemia
1082555|NCT01649986|Non-pharmacologic prevention
1082556|NCT01649960|Aging
1082557|NCT01649960|Biomarkers
1082558|NCT01649960|CAD
1082559|NCT01649947|Lung cancer
1082560|NCT01649947|Non-small cell lung cancer
1082561|NCT01649947|Advanced non-small cell lung cancer
1082562|NCT01649947|Recurrent non-small cell lung cancer
1082563|NCT01649934|Appointments and Schedules
1082564|NCT01649921|Sepsis
1082565|NCT01649921|SIRS
1082566|NCT01649921|Septic shock
1082567|NCT01649921|Immunoparalysis
1082568|NCT01649921|Interferon-gamma
1082569|NCT01649895|Obsessive-compulsive disorder
1082570|NCT01649895|internet
1082571|NCT01649895|cognitive-behaviour therapy
1082572|NCT01649895|D-Cycloserine
1082573|NCT01649882|endotracheal tube position
1082574|NCT01649882|intubation
1082575|NCT01649843|Peroral endoscopic myotomy
1082576|NCT01649843|Esophageal Achalasia
1082577|NCT01649830|low-grade glioma
1082578|NCT01649830|radiotherapy
1082579|NCT01649830|chemotherapy
1082580|NCT01649765|SLE Flare Index
1082581|NCT01649765|SRI
1082582|NCT01649765|belimumab
1082583|NCT01649765|efficacy
1082584|NCT01649765|safety
1082585|NCT01649765|B lymphocyte
1082586|NCT01649765|BLyS
1082587|NCT01649765|SELENA SLEDAI
1082588|NCT01649765|BILAG
1082589|NCT01649765|Lupus
1082590|NCT01649765|Systemic Lupus Erythematosus (SLE)
1082591|NCT01649765|PGA
1082592|NCT01649765|Pharmacokinetics
1082593|NCT01649765|placebo
1082594|NCT01649765|PRINTO
1082595|NCT01649752|Stem cells
1082596|NCT01649752|Uterine cavity
1082597|NCT01649752|Implantation
1082598|NCT01649752|ICSI
1082599|NCT01649739|PAH
1082600|NCT01649713|Fluval AB
1082601|NCT01649713|influenza
1082602|NCT01649713|vaccine
1082603|NCT01649713|immunization
1082604|NCT01649713|infections
1082605|NCT01649661|MRI
1082606|NCT01649661|12-125
1082607|NCT01649661|premenopausal women
1082608|NCT01649661|postmenopausal women
1082609|NCT01649661|questionnaire
1082610|NCT01649648|Hypoxic ischemic encephalopathy
1082611|NCT01649648|Autologous cord blood
1082612|NCT01649622|Leukemia
1082613|NCT01649622|Lymphoma
1082614|NCT01649622|Acute Lymphoblastic Leukemia/Lymphoma
1082615|NCT01649622|ALL
1082616|NCT01649622|Relapsed or primary refractory B-cell/T-cell
1082617|NCT01649622|Bendamustine
1082618|NCT01649622|Bendamustine Hydrochloride
1082619|NCT01649622|Bendamustine HCL
1082620|NCT01649622|CEP-18083
1082621|NCT01649622|SDX-105
1082622|NCT01649622|Treanda
1082623|NCT01649609|BK Viremia
1082624|NCT01649609|BK Nephropathy
1082625|NCT01649609|mTOR inhibitor
1082626|NCT01649609|renal transplant
1082627|NCT01649557|Schizophrenia
1082628|NCT01649544|Mitral valvulopathy
1082629|NCT01649544|Atrial Fibrillation
1082630|NCT01649544|Amiodarone
1082631|NCT01649544|Paroxysmal Atrial Fibrillation
1082632|NCT01649544|Chronic Atrial Fibrillation
1082633|NCT01649544|Ultrasound Technique
1082634|NCT01649492|diclofenac
1082635|NCT01649492|CYP2C9
1082636|NCT01649492|bromelain
1082637|NCT01649492|pineapple juice
1082638|NCT01649479|Obstetrical antiphospholipid syndrome
1082639|NCT01649479|Thrombophilia
1082640|NCT01649466|Type 2 diabetes mellitus, diabetes
1082641|NCT01649453|Neoplasms
1082642|NCT01649453|Neoplasm Metastasis
1082643|NCT01649453|Neoplastic Processes
1082644|NCT01649453|Pathologic Processes
1082645|NCT01649440|Metabolomics
1082646|NCT01649440|serum
1082647|NCT01649440|sepsis
1082648|NCT01649440|biomarkers
1082649|NCT01649427|Pharmacokinetics Study
1082650|NCT01649427|Tacroliums
1082651|NCT01649427|GFR
1082652|NCT01649427|kdney
1082653|NCT01649401|nebulizer
1082654|NCT01649401|PARI LC Spring SP
1082655|NCT01649388|Kidney transplant
1082656|NCT01649388|Delayed tolerance
1082657|NCT01649388|Marrow/enriched hematopoetic stem cell transplant
1082658|NCT01649375|Ankylosing spondylitis
1082659|NCT01649375|AS
1082660|NCT01649375|Chronic inflammatory disease
1082661|NCT01649375|Inflammatory back pain
1082662|NCT01649375|Secukinumab
1082663|NCT01649375|Prefilled syringe (PFS)
1082664|NCT01649375|Subcutaneous injection
1082665|NCT01649375|AIN457
1082666|NCT01649375|AIN457F
1082667|NCT01649375|AIN457F2310
1082668|NCT01649362|preterm infant
1082669|NCT01649362|feeding difficulties
1082670|NCT01649362|prefeeding oral stimulation
1082671|NCT01649310|Chronic obstructive pulmonary disease (COPD)
1082672|NCT01649310|Muscle strenght
1082673|NCT01649310|Aged
1082674|NCT01649245|Chronic hepatitis C
1082675|NCT01649245|Egyptian patients
1082676|NCT01649245|pegylated interferon
1082677|NCT01649245|Ribavirin
1082678|NCT01649245|Reiferon retard
1082679|NCT01649232|tdcs
1082680|NCT01649232|tms
1082681|NCT01649232|qeeg
1082682|NCT01649232|neuroplasticity
1082683|NCT01649232|brain networks
1082684|NCT01649232|add
1082685|NCT01649232|adhs
1082686|NCT01649219|Prediabetes, objectively measured exercise, glucose and lipid metabolism, dose response, muscle metabolism.
1082687|NCT01649206|Thyroid Nodule
1082688|NCT01649206|Radiofrequency Thermal Ablation
1082689|NCT01649206|Pressure symptoms
1082690|NCT01649206|Hyperthyroidism
1082691|NCT01649193|Rehabilitation [E02.831]
1082692|NCT01649193|Exercise [G11.427.394.380]
1082693|NCT01649193|Health Education [I02.233.332]
1082694|NCT01649193|[C08]
1082695|NCT01649193|[C08.381]
1082696|NCT01649180|RCC
1082697|NCT01649180|Clear Cell Renal Cell Carcinoma
1082698|NCT01649180|ccRCC
1082699|NCT01649180|Metastatic RCC
1082700|NCT01649180|Recurrent RCC
1082701|NCT01649180|Kidney Cancer
1082702|NCT01649180|Kidney Neoplasms
1082703|NCT01649180|Axitinib
1082704|NCT01649180|AG-013736
1082705|NCT01649180|Tyrosine Kinase Inhibition
1082706|NCT01649180|TKI
1082707|NCT01649167|body mass index
1082708|NCT01649167|gestational diabetes
1082709|NCT01649167|leptin
1082710|NCT01649167|obesity
1082711|NCT01649167|pregnancy.
1082712|NCT01649141|posttraumatic stress disorder
1082713|NCT01649141|trauma-focused cognitive behavioral therapy
1082714|NCT01649141|trauma
1082715|NCT01649141|child abuse
1082716|NCT01649128|preeclampsia
1082717|NCT01649115|obesity
1082718|NCT01649115|overweight
1082719|NCT01649115|childhood obesity
1082720|NCT01649115|prevention
1082721|NCT01649115|Z score
1082722|NCT01649115|weight for length
1082723|NCT01649115|WFL
1082724|NCT01649115|body mass index
1082725|NCT01649115|BMI
1082726|NCT01649115|prenatal
1082727|NCT01649115|maternal
1082728|NCT01649115|nutrition education
1082729|NCT01649115|health education
1082730|NCT01649115|health literacy
1082731|NCT01649115|health numeracy
1082732|NCT01649115|passport
1082733|NCT01649115|healthy lifestyles
1082734|NCT01649115|growth
1082735|NCT01649115|growth chart
1082736|NCT01649102|Chronic hemodialysis
1082737|NCT01649102|Tunneled cuffed catheter
1082738|NCT01649102|Catheter-related bloodstream infection
1082739|NCT01649102|Mechanical catheter dysfunction
1082740|NCT01649102|impact of catheter design on outcome
1082741|NCT01649063|Uterine contraction;
1082742|NCT01649063|Shape; Frequency;
1082743|NCT01649063|First stage labor;
1082744|NCT01649063|Fall
1082745|NCT01649063|Rise ratio.
1082746|NCT01649050|Spasticity
1082747|NCT01649050|Multiple Sclerosis
1082748|NCT01649024|Tremelimumab
1082749|NCT01649024|Malignant Mesothelioma
1082750|NCT01649024|anti-CTLA-4 mAb
1082751|NCT01649011|Oswestry Disability Index
1082752|NCT01649011|ODI
1082753|NCT01649011|Roland Morris Disability Questionnaire
1082754|NCT01649011|RMDQ
1082755|NCT01648998|Mineralocorticoid receptor
1082756|NCT01648998|Fludrocortisone
1082757|NCT01648998|Information Processing
1082758|NCT01648998|Cognition
1082759|NCT01648998|Depression
1082760|NCT01648946|Strategies of transfusion
1082761|NCT01648946|Red blood cells
1082762|NCT01648946|Liberal
1082763|NCT01648946|Restrictive
1082764|NCT01648946|Oncologic critically ill patients
1082765|NCT01648933|sarcoidosis
1082766|NCT01648933|heart
1082767|NCT01648933|Rubidium
1082768|NCT01648933|PET
1082769|NCT01648920|Asthma
1082770|NCT01648920|Suspected but undiagnosed asthma
1082771|NCT01648907|DESIR
1082772|NCT01648907|SPONDYLARTHRITIS
1082773|NCT01648907|EARLY INFLAMMATORY RACHIIALGIA
1082774|NCT01648907|BACK PAIN
1082775|NCT01648894|Rectal cancer
1082776|NCT01648894|radiochemotherapy
1082777|NCT01648894|complete pathological response
1082778|NCT01648868|TMSAutism
1082779|NCT01648868|Eye-tracking
1082780|NCT01648868|Social perception
1082781|NCT01648868|Social cognition
1082782|NCT01648855|Circulating antiangiogenic factors
1082783|NCT01648855|Preeclampsia
1082784|NCT01648855|Developing lung
1082785|NCT01648855|Bronchopulmonary dysplasia
1082786|NCT01648842|Preeclampsia
1082787|NCT01648842|Vitamin D deficiency
1082788|NCT01648842|Pregnancy
1082789|NCT01648842|First trimester
1082790|NCT01648777|Pneumonia
1082791|NCT01648777|Postoperative infection
1082792|NCT01648777|Cardiac surgery
1082793|NCT01648777|Multiperforated catheter
1082794|NCT01648777|Analgesia
1082795|NCT01648751|Pelvic organ prolapse
1082796|NCT01648751|Pelvic floor physical therapy
1082797|NCT01648751|Vaginal estrogen
1082798|NCT01648751|Placebo
1082799|NCT01648738|Subacute low back pain
1082800|NCT01648738|Chronic low back pain
1082801|NCT01648738|Low back pain
1082802|NCT01648738|Disability
1082803|NCT01648738|Education
1082804|NCT01648738|Exercise
1082805|NCT01648738|Spa therapy
1082806|NCT01648738|Physiotherapy
1082807|NCT01648738|Multidisciplinary
1082808|NCT01648738|Cost-effectiveness
1082809|NCT01648738|Sick leave
1082810|NCT01648725|Hypnosis
1082811|NCT01648725|Anesthesia
1082812|NCT01648725|Propofol
1082813|NCT01648725|Closed-loop
1082814|NCT01648712|extracorporeal circuit, platelet function
1082815|NCT01648699|Pain
1082816|NCT01648699|Cancer
1082817|NCT01648699|Osmotic Release Oral System
1082818|NCT01648699|OROS Hydromorphone
1082819|NCT01648699|Jurnista
1082820|NCT01648686|Alendronate
1082821|NCT01648686|Dental extraction
1082822|NCT01648686|Bone healing
1082823|NCT01648686|postmenopausal women
1082824|NCT01648686|dental radiography
1082825|NCT01648673|Coronary Artery Disease
1082826|NCT01648673|Cardiac Rehabilitation
1082827|NCT01647555|Cetuximab
1082828|NCT01647555|radiotherapy
1082829|NCT01647555|epidermoid head and neck cancer
1082830|NCT01647542|Drug therapy
1082831|NCT01647529|Cytomegalovirus
1082832|NCT01647529|uveitis
1082833|NCT01647529|endotheliitis
1082834|NCT01647529|ganciclovir
1082835|NCT01647503|parathyroid gland
1082836|NCT01647503|primary hyperparathyroidism
1082837|NCT01647503|proteins
1082838|NCT01647477|non treated cancer
1082839|NCT01647477|oral cavity
1082840|NCT01647477|oropharynx
1082841|NCT01647477|hypopharynx
1082842|NCT01647477|larynx
1082843|NCT01647477|first consultation
1082844|NCT01647438|South Asians
1082845|NCT01647438|Diabetes
1082846|NCT01647438|Physical Activity
1082847|NCT01647438|Coronary Heart Disease
1082848|NCT01647438|Lifestyle
1082849|NCT01647425|head and neck cancer
1082850|NCT01647425|lung cancer
1082851|NCT01647425|tobacco use disorder
1082852|NCT01647425|alcoholism
1082853|NCT01647412|Crohn's disease
1082854|NCT01647412|Inflammatory Bowel Disease
1082855|NCT01647412|Growth Hormone
1082856|NCT01647412|Nutraceuticals
1082857|NCT01647399|Obesity
1082858|NCT01647399|Asthma
1082859|NCT01647399|Vitamin D
1082860|NCT01647399|Allergy
1082861|NCT01647399|Genetic
1082862|NCT01647399|Childhood
1082863|NCT01647399|Pediatric
1082864|NCT01647399|cohort
1082865|NCT01647399|observational
1082866|NCT01647399|prospective
1082867|NCT01647399|molecular
1082868|NCT01647373|retinal detachment
1082869|NCT01647373|scleral buckle
1082870|NCT01647373|silicone sponge
1082871|NCT01647373|axial length
1082872|NCT01647373|surgery included silicone sponge scleral buckling
1082873|NCT01647373|retina currently attached
1082874|NCT01647373|at least 6 months after surgery
1082875|NCT01647360|Metrorrhagia
1082876|NCT01647360|Menorrhagia
1082877|NCT01647347|bacteria
1082878|NCT01647347|bacteremia
1082879|NCT01647347|PVP-iodine
1082880|NCT01647347|periodontitis
1082881|NCT01647321|SPMS
1082882|NCT01648634|Nebivolol
1082883|NCT01648634|beta-blockade treatment
1082884|NCT01648621|COPD
1082885|NCT01648621|case management
1082886|NCT01648595|Fentanyl
1082887|NCT01648595|analgesia
1082888|NCT01648595|duration of the active phase
1082889|NCT01648595|pain severity
1082890|NCT01648556|Purpura thrombopenic
1082891|NCT01648556|Medullary cytogenetics
1082892|NCT01648556|Myelodysplasic syndrome
1082893|NCT01648556|bone marrow biopsy
1082894|NCT01648517|on-small cell lung carcinoma
1082895|NCT01648517|chemotherapy naive patient
1082896|NCT01648504|Colonoscopy
1082897|NCT01648504|Screening colonoscopy
1082898|NCT01648504|Electronic education
1082899|NCT01648504|Ipad
1082900|NCT01648504|Patient education
1082901|NCT01648478|IRAP
1082902|NCT01648478|insulin sensitivity marker
1082903|NCT01648465|metastatic
1082904|NCT01648465|unresectable
1082905|NCT01648465|well or moderately differentiated
1082906|NCT01648465|advanced
1082907|NCT01648452|Achromatopsia
1082908|NCT01648452|Ciliary Neurotrophic Factor
1082909|NCT01648452|CNTF
1082910|NCT01648322|Breast Cancer
1082911|NCT01648322|Taxotere Chemotherapy
1082912|NCT01648322|Neulasta
1082913|NCT01648322|efficacy and safety
1082914|NCT01648322|single cycle doses of F-627
1082915|NCT01648322|pegfilgrastim
1082916|NCT01648309|aortic stenosis
1082917|NCT01648309|TAVI
1082918|NCT01648309|neuropsychological
1082919|NCT01648309|cognitive
1082920|NCT01648309|candidates for TAVI
1082921|NCT01648296|Heart Failure
1082922|NCT01648296|Obesity
1082923|NCT01648296|Type 2 Diabetes Mellitus
1082924|NCT01648296|Health Normal Volunteer Subjects
1082925|NCT01648283|methadone polymorphisms
1082926|NCT01648270|buprenorphine concentration-effect (miosis) relationship
1082927|NCT01648257|healthy subjects
1082928|NCT01648257|relative bioavailability
1082929|NCT01648257|HIV
1082930|NCT01648257|GSK1265744
1082931|NCT01648244|DM, T2DM, Diabetes
1082932|NCT01648231|Healthy Volunteer
1082933|NCT01648218|glucocorticoid
1082934|NCT01648218|diabetes mellitus
1082935|NCT01648218|post-transplant
1082936|NCT01648218|insulin
1082937|NCT01648205|ranolazine
1082938|NCT01648205|clinical trial
1082939|NCT01648179|GSK1322322, relative bioavailability, healthy subjects, open label, food effect, weight effect
1082940|NCT01648166|trace
1082941|NCT01648166|element
1082942|NCT01648166|lung
1082943|NCT01648166|cancer
1082944|NCT01648166|Appalachia
1082945|NCT01648153|Efficacy
1082946|NCT01648153|Obese
1082947|NCT01648153|T2DM
1082948|NCT01648153|IL-18
1082949|NCT01648153|Monoclonal antibody (mAb)
1082950|NCT01648140|Genotype 4
1082951|NCT01648140|GSK2336805
1082952|NCT01648140|pegylated interferon
1082953|NCT01648140|telaprevir
1082954|NCT01648140|Genotype 1
1082955|NCT01648140|chronic hepatitis C
1082956|NCT01648140|ribavirin
1082957|NCT01648140|NS5A inhibitor
1082958|NCT01648140|hepatitis C virus (HCV) infection
1082959|NCT01648127|Ceftaroline
1082960|NCT01648127|Pharmacokinetics
1082961|NCT01648127|Obesity
1082962|NCT01648114|breastfeeding
1082963|NCT01648114|pregnancy
1082964|NCT01648114|antenatal
1082965|NCT01648114|exclusive breastfeeding
1082966|NCT01648114|education
1082967|NCT01648101|Retigabine IR
1082968|NCT01648101|Asian Subjects
1082969|NCT01648101|Adjunctive Therapy
1082970|NCT01648101|Efficacy
1082971|NCT01648101|Drug-Resistant
1082972|NCT01648101|Safety & tolerability
1082973|NCT01648101|Partial-Onset Seizures
1082974|NCT01648101|Epilepsy
1082975|NCT01648088|staphylococcus aureus
1082976|NCT01648088|prosthetic joint implantation
1082977|NCT01648075|caries
1082978|NCT01648075|probiotics
1082979|NCT01648075|lactobacilli
1082980|NCT01648062|Sleep
1082981|NCT01648062|self-regulation
1082982|NCT01648062|Implementation intentions
1082983|NCT01648062|intervention
1082984|NCT01648062|mental simulation
1082985|NCT01648023|LC Bead
1082986|NCT01648023|Irinotecan
1082987|NCT01648023|ONCOZENE BEAD
1082988|NCT01648010|Non Muscle Invasive Bladder Cancer
1082989|NCT01648010|Carcinoma of urinary bladder, invasive
1082990|NCT01648010|Intravesical instillation
1082991|NCT01648010|Mitomycin C
1082992|NCT01648010|Hydrogel
1082993|NCT01648010|Reverse thermal gelation
1082994|NCT01648010|Drug retention
1082995|NCT01648010|radical cystectomy
1082996|NCT01647997|bacterial lipopolysaccharides
1082997|NCT01647997|hyperlactatemia
1082998|NCT01647997|muscle lactate
1082999|NCT01647984|Arrhythmias
1083000|NCT01647984|Life quality
1083001|NCT01647971|Lymphoma
1083002|NCT01647971|Rituxan
1083003|NCT01647971|Relapsed
1083004|NCT01647971|Refractory
1083005|NCT01647958|TEMPO
1083006|NCT01647958|TIF
1083007|NCT01647958|Transoral Incisionless Fundoplication
1083008|NCT01647958|EsophyX System
1083009|NCT01647958|refractory symptoms
1083010|NCT01647958|proton pump inhibitors
1083011|NCT01647958|EndoGastric Solutions
1083012|NCT01647958|EGS
1083013|NCT01647958|Acid Reflux
1083014|NCT01647958|Heartburn
1083015|NCT01647958|Regurgitation
1083016|NCT01647945|PAH WHO group 1
1083017|NCT01647932|Heart Failure
1083018|NCT01647932|Diuretics
1083019|NCT01647932|Diuretic resistance
1083020|NCT01647919|Cognition
1083021|NCT01647919|Attention
1083022|NCT01647919|Memory
1083023|NCT01647919|Mood
1083024|NCT01647867|Met fragments expression
1083025|NCT01647854|emergency medical service
1083026|NCT01647854|telemedicine
1083027|NCT01647854|teleconsultation
1083028|NCT01647854|safety
1083029|NCT01647828|Newly diagnosed Stage IV Pancreatic Cancer
1083030|NCT01647815|Axillary vein ultrasound
1083031|NCT01647815|Subclavian vein ultrasound
1083032|NCT01647802|standing devices
1083033|NCT01647802|transfer devices
1083034|NCT01647789|prostate cancer, castration resistant,
1083035|NCT01647776|Colon Neoplasia
1083036|NCT01647776|Colorectal carcinoma
1083037|NCT01647776|colon cancer
1083038|NCT01647776|colon polyp
1083039|NCT01647776|colonoscopy
1083040|NCT01647776|sDNA test
1083041|NCT01647776|FIT tests (fecal immunochemical test)
1083042|NCT01647776|relating colon neoplasia to obesity, type 2 diabetes
1083043|NCT01647776|colonoscopy and pathology confirmed advanced adenomas
1083044|NCT01647763|Hemorrhoids
1083045|NCT01647737|Xerostomia
1083046|NCT01647737|Sjogren syndrome
1083047|NCT01647737|dry mouth
1083048|NCT01647724|cervical cancer
1083049|NCT01647724|prevention
1083050|NCT01647724|screening
1083051|NCT01647698|Parkinson Disease
1083052|NCT01647698|near transfer
1083053|NCT01647698|far transfer
1083054|NCT01647698|working memory
1083055|NCT01647698|fluid intelligence
1083056|NCT01647698|cognitive training
1083057|NCT01647698|dual n-back
1083058|NCT01647685|Vesselwall inflammation
1083059|NCT01647685|liposomal prednisolone
1083060|NCT01647659|MEK inhibitor GSK1120212
1083061|NCT01647659|pharmacokinetics
1083062|NCT01647659|powder for oral solution
1083063|NCT01647659|Solid Tumors
1083064|NCT01647659|pediatric formulation
1083065|NCT01647646|asthma
1083066|NCT01647646|SMART
1083067|NCT01647646|fixed dose
1083068|NCT01647633|rhinitis
1083069|NCT01647633|stuffy nose
1083070|NCT01647633|congestion
1083071|NCT01647633|Sneezing
1083072|NCT01647607|Breast Cancer
1083073|NCT01647607|Young Women
1083074|NCT01647607|Fertility
1083075|NCT01647607|Physical Activity
1083076|NCT01647607|Survivorship
1083077|NCT01647594|Breast cancer
1083078|NCT01647594|Young women
1083079|NCT01647594|Fertility
1083080|NCT01647594|Physical activity
1083081|NCT01647594|Survivorship
1083082|NCT01647581|hemoclip
1083083|NCT01647581|colonoscopy
1083084|NCT01647581|post-polypectomy bleed
1083085|NCT01647295|visual exploration
1083086|NCT01647295|pupil size
1083087|NCT01647295|social interactions
1083088|NCT01647295|faces
1083089|NCT01647295|human motion
1083090|NCT01647256|Bioavailability
1083091|NCT01647256|Fed
1083092|NCT01647256|Fasting
1083093|NCT01647243|Knee osteoarthritis
1083094|NCT01647243|Total knee arthroplasty
1083095|NCT01647243|Preoperative training
1083096|NCT01647243|Strength training
1083097|NCT01647230|Anaesthesia, spinal
1083098|NCT01647230|Cerebral oximetry
1083099|NCT01647230|Blood pressure
1083100|NCT01647230|Heart rate
1083101|NCT01647230|Cognitive Symptom
1083102|NCT01647217|Blepharitis
1083103|NCT01647217|Demodex
1083104|NCT01647217|Mites
1083105|NCT01647217|Tea Tree oil
1083106|NCT01647217|Terpinen
1083107|NCT01647204|Nutrition
1083108|NCT01647204|older
1083109|NCT01647204|hospital
1083110|NCT01647204|volunteer
1083111|NCT01647191|HCV，
1083112|NCT01647191|drug users，
1083113|NCT01647191|intervention
1083114|NCT01647165|Maintenance Strategy
1083115|NCT01647165|Plasma Cell Neoplasm
1083116|NCT01647165|Proteasome Inhibitor
1083117|NCT01647165|Immunomodulatory Drugs
1083118|NCT01647165|Novel Therapy
1083119|NCT01647152|Uveitis
1083120|NCT01647152|Ustekinumab
1083121|NCT01647152|IL 12/23
1083122|NCT01647152|Stelara
1083123|NCT01646866|autism
1083124|NCT01646866|siblings
1083125|NCT01646866|genetic test
1083126|NCT01646866|screening
1083127|NCT01646840|PF-04958242
1083128|NCT01646840|bioequivalence
1083129|NCT01646840|pharmacokinetics
1083130|NCT01646840|Schizophrenia
1083131|NCT01646827|Schizophrenia, extended release antipsychotic
1083132|NCT01646814|Healthy volunteer
1083133|NCT01646814|comparison of incidence of
1083134|NCT01646814|treatment groups.
1083135|NCT01646775|opioid
1083136|NCT01646775|malignancy
1083137|NCT01646775|epidural
1083138|NCT01646749|Energy intake
1083139|NCT01646749|Beef protein
1083140|NCT01646749|Satiety
1083141|NCT01646749|Protein leverage hypothesis
1083142|NCT01646736|Lupus Nephritis
1083143|NCT01646736|Cyclophosphamide
1083144|NCT01646736|Tripterygium
1083145|NCT01646710|Tool
1083146|NCT01646710|FBR
1083147|NCT01646710|Advocacy
1083148|NCT01646710|Development of a tool
1083149|NCT01646710|advocacy materials
1083150|NCT01646697|pancreatic cancer
1083151|NCT01646697|adenocarcinoma
1083152|NCT01646697|pancreatic resection
1083153|NCT01646684|Prostate cancer, pasireotide LAR, castration resistant prostatate cancer, CRPC, SOM230 LAR
1083154|NCT01646671|Hypertension, Severe, LCZ696
1083155|NCT01646645|CMVpp65 specific T-cells
1083156|NCT01646645|Stem Cell Transplantation
1083157|NCT01646645|12-086
1083158|NCT01646632|institutionalized ADL fitness care-dependency
1083159|NCT01646619|Hypoxic Ischemic Encephalopathy
1083160|NCT01646619|Therapeutic Hypothermia
1083161|NCT01646619|Therapeutic Hypothermia plus Adjuvant Therapy
1083162|NCT01646619|Cooling
1083163|NCT01646606|Bronchiolitis
1083164|NCT01646606|Length of stay
1083165|NCT01646606|Pilot Projects
1083166|NCT01646606|Oxygen saturation monitoring
1083167|NCT01646580|dermatomycoses, tinea, candidiasis, children
1083168|NCT01646567|psoriasis
1083169|NCT01646554|Liver metastases
1083170|NCT01646554|Colorectal Cancer
1083171|NCT01646554|KRAS mutated
1083172|NCT01646554|FOLFOX
1083173|NCT01646554|Aflibercept
1083174|NCT01646554|Randomized
1083175|NCT01646554|Phase II-III
1083176|NCT01646554|Perioperative treatment
1083177|NCT01646554|Adjuvant
1083178|NCT01646554|Neo-adjuvant
1083179|NCT01646554|Surgery
1083180|NCT01646554|Progression Free Survival
1083181|NCT01646528|Gastric Intestinal Metaplasia
1083182|NCT01646528|Confocal Laser Endomicroscopy
1083183|NCT01646515|systolic heart failure
1083184|NCT01646515|udenafil
1083185|NCT01646515|exercise capacity
1083186|NCT01646502|chronic wound
1083187|NCT01646502|treatment
1083188|NCT01646502|biofilms
1083189|NCT01646502|venous insufficiency
1083190|NCT01646502|Esp
1083191|NCT01646489|Antisense
1083192|NCT01646489|miR-122 antagonist
1083193|NCT01646489|Safety in healthy volunteers
1083194|NCT01646489|Hepatitis C
1083195|NCT01646463|mindfulness
1083196|NCT01646463|stress
1083197|NCT01646463|coping
1083198|NCT01646463|emotion
1083199|NCT01646463|depression
1083200|NCT01646463|group medical visits
1083201|NCT01646463|prenatal healthcare
1083202|NCT01646463|preterm birth
1083203|NCT01646463|birth weight
1083204|NCT01646463|postpartum depression
1083205|NCT01646463|cortisol
1083206|NCT01646463|neuroendocrine function
1083207|NCT01646463|blood pressure
1083208|NCT01646463|health disparities
1083209|NCT01646450|NSCLC
1083210|NCT01646450|EGFR Mutation
1083211|NCT01646450|Elder patients
1083212|NCT01646424|COPD,
1083213|NCT01646424|Patient satisfaction,
1083214|NCT01646424|fix combination,
1083215|NCT01646424|NIS Turkey,
1083216|NCT01646424|turbuhaler,
1083217|NCT01646424|FSI-10
1083218|NCT01646411|cytomegalovirus (CMV) IgM &IgG
1083219|NCT01646411|Lyme
1083220|NCT01646411|Toxoplasma
1083221|NCT01646411|Rubella
1083222|NCT01646411|Rubeola IgM
1083223|NCT01646411|Rocky mountain Spotted Fever IgM
1083224|NCT01646411|Ebv IgM
1083225|NCT01646411|Herpes
1083226|NCT01646411|Babesia
1083227|NCT01646411|Measles
1083228|NCT01646411|Tetanus
1083229|NCT01646411|Mumps
1083230|NCT01646411|Mycoplasma
1083231|NCT01646411|Legionella
1083232|NCT01646411|Giardia
1083233|NCT01646411|Syphilis
1083234|NCT01646411|Bordetella Pertussis
1083235|NCT01646411|H Pylori
1083236|NCT01646411|Antibody Titre
1083237|NCT01646411|Elevated IgG
1083238|NCT01646411|Abnormal IgM
1083239|NCT01646411|SLE
1083240|NCT01646398|13VPNC
1083241|NCT01646398|23VPS
1083242|NCT01646385|observational
1083243|NCT01646385|non-interventional
1083244|NCT01646385|cohort
1083245|NCT01646385|retrospective
1083246|NCT01646385|register
1083247|NCT01646385|rheumatoid arthritis
1083248|NCT01646372|Medical Education
1083249|NCT01646372|Cognitive Aid
1083250|NCT01646372|Crisis Resource Management
1083251|NCT01646372|Advanced Cardiac Life Support
1083252|NCT01646372|Skills Retention
1083253|NCT01646346|Breast Cancer
1083254|NCT01646346|Radiation for Breast Cancer
1083255|NCT01646333|Parkinson Disease
1083256|NCT01646333|Mild Cognitive Impairment
1083257|NCT01646333|Cognition
1083258|NCT01646333|Executive Function
1083259|NCT01646333|Learning
1083260|NCT01646333|Memory
1083261|NCT01646333|Problem Solving
1083262|NCT01646294|Pharmacokinetics
1083263|NCT01646294|Phase I
1083264|NCT01646294|YM178
1083265|NCT01646294|Modified release (Oral Controlled Absorption System (OCAS))
1083266|NCT01646294|Immediate release (IR)
1083267|NCT01646294|Fasted conditions
1083268|NCT01646294|Fed conditions
1083269|NCT01646281|Atrial fibrillation
1083270|NCT01646281|Vernakalant
1083271|NCT01646281|Flecainide
1083272|NCT01646281|Echocardiography
1083273|NCT01646268|Rotigotine
1083274|NCT01646268|Neupro phase 3
1083275|NCT01646268|Early phase
1083276|NCT01646268|Idiopathic Parkinson's Disease
1083277|NCT01646255|Rotigotine
1083278|NCT01646255|Neupro phase 3
1083279|NCT01646255|Advanced-stage
1083280|NCT01646255|Idiopathic Parkinson's Disease
1083281|NCT01646229|Hemoperfusion
1083282|NCT01646229|Polymyxin-B
1083283|NCT01646229|Emergency abdominal surgery
1083284|NCT01646229|Sepsis
1083285|NCT01646229|Endotoxin
1083286|NCT01646216|stroke
1083287|NCT01646216|treadmill
1083288|NCT01646216|walking
1083289|NCT01646216|hemiparesis
1083290|NCT01646216|training
1083291|NCT01646203|Advanced Solid Tumors
1083292|NCT01646190|Fast-track
1083293|NCT01646190|multimodal perioperative care
1083294|NCT01646190|enhanced recovery
1083295|NCT01646190|colorectal surgery
1083296|NCT01646190|elderly patients
1083297|NCT01646190|seniors
1083298|NCT01646164|Dill seed
1083299|NCT01646164|Pattern of uterus contractions
1083300|NCT01646164|Active phase of labor
1083301|NCT01646138|H1N1
1083302|NCT01646138|Influenza
1083303|NCT01646138|Human
1083304|NCT01646138|Challenge Study
1083305|NCT01646138|Healthy Volunteer
1083306|NCT01646125|Non-small cell lung carcinoma (NSCLC)
1083307|NCT01646125|treatment of lung cancer after first metastasis
1083308|NCT01646125|lung cancer
1083309|NCT01646125|lung adenocarcinoma
1083310|NCT01646125|Squamous cell lung carcinoma
1083311|NCT01646125|Large-cell lung carcinoma
1083312|NCT01646125|Non small cell lung carcinoma
1083313|NCT01646125|Non small cell lung cancer
1083314|NCT01646125|Non-small cell lung cancer
1083315|NCT01646125|NSCLC
1083316|NCT01646125|Large cell lung carcinoma
1083317|NCT01646125|Large cell lung cancer
1083318|NCT01646125|HSP90
1083319|NCT01646125|AUY922
1083320|NCT01646125|Pemetrexed
1083321|NCT01646125|Docetaxel
1083322|NCT01646125|EGFR TKI
1083323|NCT01646125|EGFR mutations
1083324|NCT01646112|Uncertainty
1083325|NCT01646112|HNPCC
1083326|NCT01646112|Lynch Syndrome
1083327|NCT01646112|Genetic Tests
1083328|NCT01646099|Kidney transplant
1083329|NCT01646099|Renal transplant
1083330|NCT01646099|Sun protection
1083331|NCT01646099|Skin cancer
1083332|NCT01646086|Weight Loss
1083333|NCT01646086|Self-Weighing
1083334|NCT01646086|Weight Tracking
1083335|NCT01646073|Plaque Psoriasis
1083336|NCT01646073|Psoriasis
1083337|NCT01646073|Placebo Controlled
1083338|NCT01646073|Skin Disease
1083339|NCT01646073|Double Blind
1083340|NCT01646060|blood
1083341|NCT01646060|loss
1083342|NCT01646060|healthy
1083343|NCT01646060|volume
1083344|NCT01646060|To evaluate the ability of the Zynex BVM to non-invasively detect blood loss in healthy subjects during a blood draw.
1083345|NCT01646047|diabetes
1083346|NCT01646047|diabetic retinopathy
1083347|NCT01646047|nutritional supplements
1083348|NCT01646047|visual function
1083349|NCT01646047|macular pigment
1083350|NCT01646047|macular threshold sensitivity
1083351|NCT01646047|contrast sensitivity
1083352|NCT01646047|color vision
1083353|NCT01646047|optical coherence tomography
1083354|NCT01646034|oligo metastatic
1083355|NCT01646034|HRD deficiency
1083356|NCT01646021|Mantle cell lymphoma
1083357|NCT01646021|Relapsed mantle cell lymphoma
1083358|NCT01646021|Refractory mantle cell lymphoma
1083359|NCT01646021|Ibrutinib
1083360|NCT01646021|Bruton's tyrosine kinase inhibitor
1083361|NCT01646021|Temsirolimus
1083362|NCT01645956|obesity
1083363|NCT01645956|exercise
1083364|NCT01645956|energy intake
1083365|NCT01645956|physical activity
1083366|NCT01645943|Non-ST-elevation acute myocardial infarction
1083367|NCT01645943|Comorbidities
1083368|NCT01645930|Relapsed multiple myeloma,
1083369|NCT01645930|Refractory multiple myeloma,
1083370|NCT01645930|MLN9708,
1083371|NCT01645930|Proteasome inhibitor
1083372|NCT01645917|paroxysmal atrial fibrillation
1083373|NCT01645904|Hereditary Diseases
1083374|NCT01645904|Genetic
1083375|NCT01645904|Lynch syndrome
1083376|NCT01645904|Positive or indeterminate test results for Lynch syndrome
1083377|NCT01645904|Social media
1083378|NCT01645904|Internet-based program
1083379|NCT01645904|Questionnaire
1083380|NCT01645904|Survey
1083381|NCT01645904|My Family Garden website
1083382|NCT01645904|Interview
1083383|NCT01645904|Focus group
1083384|NCT01645904|Website Analysis and MeasureMent Inventory
1083385|NCT01645904|WAMMI
1083386|NCT01645891|Diabetic Foot Ulcer
1083387|NCT01645878|Primiparous Mothers
1083388|NCT01645878|self-efficacy,
1083389|NCT01645878|hands off,
1083390|NCT01645878|hands on ,
1083391|NCT01645878|social cognitive theory
1083392|NCT01645865|HIV
1083393|NCT01645865|AIDS
1083394|NCT01645865|PMTCT
1083395|NCT01645865|Mobile Phone
1083396|NCT01645865|SMS
1083397|NCT01645839|Leptomeningeal metastasis
1083398|NCT01645839|Intrathecal chemotherapy
1083399|NCT01645839|Depocyte
1083400|NCT01645800|Lysozyme hydrochloride
1083401|NCT01645800|COPD
1083402|NCT01645787|Spinal Muscular Atrophy
1083403|NCT01645787|4-aminopyridine
1083404|NCT01645787|dalfampridine
1083405|NCT01645787|Ampyra
1083406|NCT01645774|subcutaneous injection heparin
1083407|NCT01645774|injection duration
1083408|NCT01645774|bruising pain
1083409|NCT01645774|decrease pain
1083410|NCT01645774|decrease bruising
1083411|NCT01645761|Helicobacter pylori eradication
1083412|NCT01645761|Peptic ulcer
1083413|NCT01645748|head and neck cancer
1083414|NCT01645748|docetaxel
1083415|NCT01645748|cisplatin
1083416|NCT01645748|S-1
1083417|NCT01645735|Infections
1083418|NCT01645735|Teflaro
1083419|NCT01645735|cephalosporin
1083420|NCT01645735|Ceftaroline
1083421|NCT01645735|antibiotics
1083422|NCT01645735|pneumonia
1083423|NCT01645722|Fat Grafts
1083424|NCT01645722|Autogenous Fat Transfers (AFT)
1083425|NCT01645722|Wounded warriors
1083426|NCT01645722|Amputation pain
1083427|NCT01645696|Diabetes
1083428|NCT01645696|Type 1 Diabetes
1083429|NCT01645696|Continuous glucose monitoring
1083430|NCT01645696|Blood glucose
1083431|NCT01645696|Blood glucose sensor
1083432|NCT01645696|Glucose Binding Protein (GBP)
1083433|NCT01645566|cardiopulmonary resuscitation
1083434|NCT01645566|stress
1083435|NCT01645566|intervention
1083436|NCT01645475|enuresis
1083437|NCT01645449|Bioequivalence
1083438|NCT01645449|Atorvastatin calcium
1083439|NCT01645449|crossover
1083440|NCT01645436|randomized controlled trial
1083441|NCT01645436|in-hospital exercise
1083442|NCT01645436|children
1083443|NCT01645436|cancer
1083444|NCT01645423|Bioequivalence
1083445|NCT01645423|Atorvastatin calcium
1083446|NCT01645423|crossover
1083447|NCT01645410|Bioequivalence
1083448|NCT01645410|Atorvastatin calcium
1083449|NCT01645410|crossover
1083450|NCT01645397|Asthma
1083451|NCT01645397|Deep inhalation
1083452|NCT01645397|Exhaled nitric oxide
1083453|NCT01645384|Bioequivalence
1083454|NCT01645384|Atorvastatin calcium
1083455|NCT01645384|crossover
1083456|NCT01645371|opioid-induced constipation
1083457|NCT01645358|COPD
1083458|NCT01645358|NIV
1083459|NCT01645358|Acute Hypercapnic Respiratory Failure
1083460|NCT01645358|COPD patients with hypercapnic respiratory failure
1083461|NCT01645345|wrinkles
1083462|NCT01645345|acne scars
1083463|NCT01645332|DLBS3233
1083464|NCT01645332|new onset
1083465|NCT01645332|type-2-diabetes mellitus
1083466|NCT01645332|oral anti-hyperglycemic agent
1083467|NCT01645280|Active rheumatoid arthritis
1083468|NCT01645280|Ustekinumab
1083469|NCT01645280|STELARA
1083470|NCT01645280|CNTO 1959
1083471|NCT01645254|healthy volunteers
1083472|NCT01645254|pharmacokinetics
1083473|NCT01645254|malaria
1083474|NCT01645254|Argemone mexicana
1083475|NCT01645241|Ovarian stimulation
1083476|NCT01645241|Luteal phase
1083477|NCT01645241|Egg donors
1083478|NCT01645241|Fertility preservation
1083483|NCT01645189|Hunter syndrome
1083484|NCT01645189|idursulfase-beta
1083485|NCT01645189|Hunterase
1083486|NCT01645189|GC1111
1083487|NCT01645176|OA
1083488|NCT01645176|Knee
1083489|NCT01645163|mHealth
1083490|NCT01645163|Complementary feeding
1083491|NCT01645163|ICDS
1083492|NCT01645150|physical activity
1083493|NCT01645150|exercise
1083494|NCT01645150|training
1083495|NCT01645150|fatigue
1083496|NCT01645150|cancer
1083497|NCT01645150|TKI
1083498|NCT01645150|tyrosine kinase inhibitor
1083499|NCT01645137|prematurity
1083500|NCT01645137|OMT
1083501|NCT01645137|complementary and alternative medicine
1083502|NCT01645137|neonates
1083503|NCT01645137|length of stay
1083504|NCT01645124|Polycythemia
1083505|NCT01645124|Hematocrit
1083506|NCT01645124|Thrombosis
1083507|NCT01645085|R406
1083508|NCT01645085|Fostamatinib
1083509|NCT01645085|Phase I
1083510|NCT01645085|Healthy Subjects
1083511|NCT01645085|Pharmacokinetics
1083512|NCT01645085|Bioequivalence
1083513|NCT01645072|Drug refractory epilepsy
1083514|NCT01645072|Dietary therapy
1083515|NCT01645072|ketogenic diet
1083516|NCT01645072|childhood epilepsy
1083517|NCT01645033|Cognitive Behavioral Therapy
1083518|NCT01645033|computer
1083519|NCT01645020|absorbable mesh
1083520|NCT01645020|Partially absorbed Mesh
1083521|NCT01645020|Prolift
1083522|NCT01645020|Prolift + M
1083523|NCT01645020|mesh related complications
1083524|NCT01645007|Hepatitis B
1083525|NCT01645007|Prevalence
1083526|NCT01645007|HBsAg
1083527|NCT01645007|Vaccination
1083528|NCT01645007|Galilee
1083529|NCT01644968|metastatic carcinoma
1083530|NCT01644968|lymphoma
1083531|NCT01644968|sarcoma
1083532|NCT01644968|anti-OX40
1083533|NCT01644955|Gliomas
1083534|NCT01644955|Carboplatin
1083535|NCT01644942|Obese
1083536|NCT01644942|insulin sensitive
1083537|NCT01644942|insulin resistant
1083538|NCT01644942|myotubes
1083539|NCT01644942|lipid accumulation
1083540|NCT01644929|hemiparesis
1083541|NCT01644929|bihemispheric transcranial direct current stimulation
1083542|NCT01644929|ischemic stroke
1083543|NCT01644929|subacute
1083544|NCT01644929|rehabilitation
1083545|NCT01644929|physiotherapy
1083546|NCT01644929|ergotherapy
1083547|NCT01644916|COPD
1083548|NCT01644916|Integrated care
1083549|NCT01644916|IPCL
1083550|NCT01644890|NK105, Paclitaxel, Breast cancer, Micelle
1083551|NCT01644851|veterans
1083552|NCT01644851|neuropsychology
1083553|NCT01644851|neuroimaging
1083554|NCT01644851|attention
1083555|NCT01644851|working memory
1083556|NCT01644851|inhibition
1083557|NCT01644851|magnetic resonance imaging, functional
1083558|NCT01644851|trauma
1083559|NCT01644851|stress
1083560|NCT01644851|anxiety
1083561|NCT01644851|emotion
1083562|NCT01644851|prefrontal cortex
1083563|NCT01644838|Hyoscine,
1083564|NCT01644838|Promethazine,
1083565|NCT01644838|The first stage of labor,
1083566|NCT01644838|Labor pain
1083567|NCT01644825|platinum resistant
1083568|NCT01644825|platinum refractory
1083569|NCT01644799|recurrent grade 1 follicular lymphoma
1083570|NCT01644799|recurrent grade 2 follicular lymphoma
1083571|NCT01644799|recurrent grade 3 follicular lymphoma
1083572|NCT01644786|head and neck
1083573|NCT01644786|HNSCC
1083574|NCT01644786|orophaynx
1083575|NCT01644786|hypopharynx
1083576|NCT01644786|larynx
1083577|NCT01644786|nasopharynx
1083578|NCT01644786|oral cavity
1083579|NCT01644786|prospective study
1083580|NCT01644786|predictive models for HNSCC
1083581|NCT01644786|genomic analyses
1083582|NCT01644786|outcome prediction
1083583|NCT01644760|Diaphragmatic excursion
1083584|NCT01644760|normality
1083585|NCT01644747|Resistant Depression
1083586|NCT01644747|Moods disorders
1083587|NCT01644747|Unipolar depression
1083588|NCT01644747|Bipolar disorder
1083589|NCT01644747|tDCS
1083590|NCT01644721|Child mortality
1083591|NCT01644721|Measles vaccine
1083592|NCT01644721|Non-specific effects
1083593|NCT01644708|Obesity
1083594|NCT01644708|Overweight
1083595|NCT01644708|Individual empowerment
1083596|NCT01644708|Physical parameters
1083597|NCT01644708|Self esteem
1083598|NCT01644695|BARS
1083599|NCT01644695|Bony Anchoring Reinforcement System
1083600|NCT01644695|Hernia
1083601|NCT01644695|Incisional
1083602|NCT01644695|Recurrent
1083603|NCT01644695|abdominal wall reconstruction
1083604|NCT01644695|abdominal wall defect
1083605|NCT01644695|mesh
1083606|NCT01644695|component separation
1083607|NCT01644682|Visceral leishmaniasis
1083608|NCT01644682|insecticide
1083609|NCT01644682|wall lining
1083610|NCT01644682|KO TAB123
1083611|NCT01644682|Household
1083612|NCT01644682|Kala-azar endemic area
1083613|NCT01644656|portal hypertension
1083614|NCT01644656|cirrhosis
1083615|NCT01644656|ARFI
1083616|NCT01644656|diagnostic study
1083617|NCT01644643|Ceftazidime,
1083618|NCT01644643|avibactam,
1083619|NCT01644643|metronidazone,
1083620|NCT01644643|Anti-Infectives
1083621|NCT01644604|Hypertension
1083622|NCT01644604|Vascular Diseases
1083623|NCT01644604|Cardiovascular Diseases
1083624|NCT01644604|Renal denervation
1083625|NCT01644591|Melanoma
1083626|NCT01644591|Malignant melanoma
1083627|NCT01644591|Brain Metastases
1083628|NCT01644591|Stereotactic Radiosurgery
1083629|NCT01644591|SRS
1083630|NCT01644591|XRT
1083631|NCT01644591|Questionnaires
1083632|NCT01644591|Surveys
1083633|NCT01644578|MRI
1083634|NCT01644578|real-time imaging
1083635|NCT01644578|workflow
1083636|NCT01643564|Transplant
1083637|NCT01643564|Cytokines
1083638|NCT01643564|Graft Dysfunction
1083639|NCT01643551|Heart Failure
1083640|NCT01643551|Left Ventricular Assist Device
1083641|NCT01643551|Reperfusion Injury
1083642|NCT01643551|Neuron Specific Enolase
1083643|NCT01643538|physical activity
1083644|NCT01643538|adults age 65 and older
1083645|NCT01643538|financial incentives
1083646|NCT01643525|Ischemic Stroke
1083647|NCT01643486|peritoneal dialysis
1083648|NCT01643486|phosphate
1083649|NCT01643486|iTouch
1083650|NCT01643473|Hypertension
1083651|NCT01643473|Latinos
1083652|NCT01643473|Medication Adherence
1083653|NCT01643473|Blood Pressure Control
1083654|NCT01643473|Patient-centered
1083655|NCT01643473|Black
1083656|NCT01643460|Intraductal papillary mucinous neoplasms (IPMNs)
1083657|NCT01643460|Mucinous cystadenomas [MCN])
1083658|NCT01643460|Invasive IPMNs or mucinous cystadenocarcinomas) tumors
1083659|NCT01643447|Hepatocellular Carcinoma
1083660|NCT01643447|Ulinastatin
1083661|NCT01643447|Hepatic Failure
1083662|NCT01643434|Resistant Hypertension
1083663|NCT01643408|Acute Lymphoblastic Leukemia
1083664|NCT01643408|Lymphoblastic Lymphoma
1083665|NCT01643408|Erwinaze
1083666|NCT01643408|asparaginase
1083667|NCT01643408|Eusa Pharma
1083668|NCT01643408|Pharmacokinetic study
1083669|NCT01643408|NSAA
1083670|NCT01643395|Trauma
1083671|NCT01643395|vertebral
1083672|NCT01643395|compression fracture
1083673|NCT01643395|spinal
1083674|NCT01643395|acute
1083675|NCT01643395|vertebroplasty
1083676|NCT01643395|conservative treatment
1083677|NCT01643382|diabetes
1083678|NCT01643382|kidney transplant
1083679|NCT01643382|end stage renal disease
1083680|NCT01643382|delayed draft function
1083681|NCT01643369|meditation
1083682|NCT01643369|compassion
1083683|NCT01643369|inflammation
1083684|NCT01643369|immune system
1083685|NCT01643356|weight
1083686|NCT01643356|pregnancy
1083687|NCT01643356|behavioral intervention
1083688|NCT01643356|obesity
1083689|NCT01643343|autism spectrum disorders
1083690|NCT01643343|autism
1083691|NCT01643343|joint attention
1083692|NCT01643343|imitation
1083693|NCT01643343|fluency
1083694|NCT01643330|Cardiomegaly
1083695|NCT01643330|Heart Diseases
1083696|NCT01643330|Cardiovascular Diseases
1083697|NCT01643304|Menorrhagia
1083698|NCT01643304|Heavy menstrual bleeding
1083699|NCT01643304|Uterine Hemorrhage
1083700|NCT01643304|Menstruation Disturbancies
1083701|NCT01644552|aniridia
1083702|NCT01644552|positive angle kappa
1083703|NCT01644539|Satiation
1083704|NCT01644539|Brain activation
1083705|NCT01644539|Gut peptides
1083706|NCT01644526|dialysis
1083707|NCT01644526|vascular access
1083708|NCT01644526|arteriovenous grafts
1083709|NCT01644526|valve system
1083710|NCT01644513|Age Related Macular Degeneration
1083711|NCT01644513|Choroidal Neovascular
1083712|NCT01644513|anti-VEGF Therapy
1083713|NCT01644409|OAB
1083714|NCT01644409|Overactive bladder
1083715|NCT01644409|Urgency
1083716|NCT01644409|Incontinence
1083717|NCT01644396|Moderate to Severe Plaque Psoriasis
1083718|NCT01644383|meaning of life
1083719|NCT01644383|logotherapy
1083720|NCT01644383|HIV-infected teenagers
1083721|NCT01644383|adherence
1083722|NCT01644370|HIV-infected children
1083723|NCT01644370|T cell response
1083724|NCT01644370|asthma
1083725|NCT01644292|Mobility Impairment
1083726|NCT01644292|Manual Wheelchair
1083727|NCT01644292|Older Adults
1083728|NCT01644279|aging
1083729|NCT01644279|sarcopenia
1083730|NCT01644279|mitochondria
1083731|NCT01644279|skeletal muscle
1083732|NCT01644279|apoptosis
1083733|NCT01644253|chronic lymphocytic leukemia
1083734|NCT01644253|CLL
1083735|NCT01644253|previously untreated chronic lymphocytic leukemia
1083736|NCT01644227|Hip surgery
1083737|NCT01644227|dual mobility cup
1083738|NCT01644227|dislocation
1083739|NCT01644227|total hip arthroplasty
1083740|NCT01644214|Pelvic organ prolapse
1083741|NCT01644214|Pessary
1083742|NCT01644162|Non-Invasive Positive-Pressure Ventilation
1083743|NCT01644162|Disease Exacerbation
1083744|NCT01644162|Respiratory Failure
1083745|NCT01644149|Jet Injector
1083746|NCT01644149|Stratis®
1083747|NCT01644149|PharmaJet
1083748|NCT01644149|Jet Injection
1083749|NCT01644123|Spasticity
1083750|NCT01644123|Diagnostic Algorithm
1083751|NCT01644097|Quality of Life
1083752|NCT01644084|albumin
1083753|NCT01644084|hydroxyethyl starch 130/0.4
1083754|NCT01644084|cardiopulmonary bypass
1083755|NCT01644071|violent video games
1083756|NCT01644071|serotonergic system
1083757|NCT01644058|immediate-loading
1083758|NCT01644058|patient-based outcomes
1083759|NCT01644045|Asthma
1083760|NCT01644045|COPD
1083761|NCT01644045|emergency medical service
1083762|NCT01644045|teleconsultation
1083763|NCT01644045|telemedicine
1083764|NCT01644032|telemedicine
1083765|NCT01644032|teleconsultation
1083766|NCT01644032|analgesia
1083767|NCT01644032|emergency
1083768|NCT01644032|prehospital
1083769|NCT01644019|stroke
1083770|NCT01644019|teleconsultation
1083771|NCT01644019|telemedicine
1083772|NCT01644019|emergency medical service
1083773|NCT01644006|acute coronary syndrome
1083774|NCT01644006|telemedicine
1083775|NCT01644006|teleconsultation
1083776|NCT01644006|emergency medical service
1083777|NCT01643993|IVF
1083778|NCT01643993|embryo
1083779|NCT01643967|Ozone
1083780|NCT01643967|Sunflower oil
1083781|NCT01643967|diabetes Mellitus
1083782|NCT01643954|prostatectomy
1083783|NCT01643954|surgery
1083784|NCT01643954|prostate cancer
1083785|NCT01643941|Staphylococcus aureus
1083786|NCT01643941|vaccine
1083787|NCT01643941|Staphylococcal infection
1083788|NCT01643928|extension trial
1083789|NCT01643928|rheumatoid arthritis
1083790|NCT01643928|rituximab
1083791|NCT01643915|Audiovisual distraction
1083792|NCT01643915|Pediatric dentistry
1083793|NCT01643902|Stroke
1083794|NCT01643902|Wake up
1083795|NCT01643902|IV tPA
1083796|NCT01643902|Thrombolytic
1083797|NCT01643889|Healthy
1083798|NCT01643889|Domperidone
1083799|NCT01643889|Cardiac Repolarization
1083800|NCT01643876|Denture stomatitis
1083801|NCT01643876|Denture Plaque
1083802|NCT01643876|Oral Candidiasis
1083803|NCT01643876|Oral Hygiene
1083804|NCT01643850|Pigmented Villonodular Synovitis
1083805|NCT01643850|PVNS
1083806|NCT01643850|Giant cell tumor of the tendon sheath
1083807|NCT01643850|GCCTS
1083808|NCT01643850|Tenosynovial giant cell tumor (localized or diffused type)
1083809|NCT01643850|GCTS
1083810|NCT01643850|MCS110
1083811|NCT01643837|Mastalgia
1083812|NCT01643837|Breast Pain
1083813|NCT01643837|Osteopathic Manipulative Medicine
1083814|NCT01643837|Osteopathic Manipulative Treatment
1083815|NCT01643811|early gastric cancer, diabetes, hypertension
1083816|NCT01643785|therapeutic efficacy endonase addictive effect
1083817|NCT01643759|osteoarthritis disorders
1083818|NCT01643733|Angioplasty
1083819|NCT01643707|Sick Sinus Syndrome
1083820|NCT01643707|Bradycardia
1083821|NCT01643616|Sciatic Nerve
1083822|NCT01643616|Ultrasound
1083823|NCT01643616|Anesthesia, Regional
1083824|NCT01643616|Orthopedic Surgery
1083825|NCT01643603|accelerated phase chronic myelogenous leukemia
1083826|NCT01643603|adult acute lymphoblastic leukemia in remission
1083827|NCT01643603|adult acute myeloid leukemia in remission
1083828|NCT01643603|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1083829|NCT01643603|adult acute myeloid leukemia with del(5q)
1083830|NCT01643603|adult acute myeloid leukemia with inv(16)(p13;q22)
1083831|NCT01643603|adult acute myeloid leukemia with t(15;17)(q22;q12)
1083832|NCT01643603|adult acute myeloid leukemia with t(16;16)(p13;q22)
1083833|NCT01643603|adult acute myeloid leukemia with t(8;21)(q22;q22)
1083834|NCT01643603|adult grade III lymphomatoid granulomatosis
1083835|NCT01643603|adult nasal type extranodal NK/T-cell lymphoma
1083836|NCT01643603|anaplastic large cell lymphoma
1083837|NCT01643603|angioimmunoblastic T-cell lymphoma
1083838|NCT01643603|blastic phase chronic myelogenous leukemia
1083839|NCT01643603|chronic phase chronic myelogenous leukemia
1083840|NCT01643603|contiguous stage II adult Burkitt lymphoma
1083841|NCT01643603|contiguous stage II adult diffuse large cell lymphoma
1083842|NCT01643603|contiguous stage II adult diffuse mixed cell lymphoma
1083843|NCT01643603|contiguous stage II adult diffuse small cleaved cell lymphoma
1083844|NCT01643603|contiguous stage II adult immunoblastic large cell lymphoma
1083845|NCT01643603|contiguous stage II adult lymphoblastic lymphoma
1083846|NCT01643603|contiguous stage II grade 1 follicular lymphoma
1083847|NCT01643603|contiguous stage II grade 2 follicular lymphoma
1083848|NCT01643603|contiguous stage II grade 3 follicular lymphoma
1083849|NCT01643603|contiguous stage II mantle cell lymphoma
1083850|NCT01643603|contiguous stage II marginal zone lymphoma
1083851|NCT01643603|contiguous stage II small lymphocytic lymphoma
1083852|NCT01643603|cutaneous B-cell non-Hodgkin lymphoma
1083853|NCT01643603|de novo myelodysplastic syndromes
1083854|NCT01643603|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1083855|NCT01643603|hepatosplenic T-cell lymphoma
1083856|NCT01643603|intraocular lymphoma
1083857|NCT01643603|nodal marginal zone B-cell lymphoma
1083858|NCT01643603|noncontiguous stage II adult Burkitt lymphoma
1083859|NCT01643603|noncontiguous stage II adult diffuse large cell lymphoma
1083860|NCT01643603|noncontiguous stage II adult diffuse mixed cell lymphoma
1083861|NCT01643603|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1083862|NCT01643603|noncontiguous stage II adult immunoblastic large cell lymphoma
1083863|NCT01643603|noncontiguous stage II adult lymphoblastic lymphoma
1083864|NCT01643603|noncontiguous stage II grade 1 follicular lymphoma
1083865|NCT01643603|noncontiguous stage II grade 2 follicular lymphoma
1083866|NCT01643603|noncontiguous stage II grade 3 follicular lymphoma
1083867|NCT01643603|noncontiguous stage II mantle cell lymphoma
1083868|NCT01643603|noncontiguous stage II marginal zone lymphoma
1083869|NCT01643603|noncontiguous stage II small lymphocytic lymphoma
1083870|NCT01643603|noncutaneous extranodal lymphoma
1083871|NCT01643603|peripheral T-cell lymphoma
1083971|NCT01643239|Kinematic analysis
1083872|NCT01643603|previously treated myelodysplastic syndromes
1083873|NCT01643603|recurrent adult acute lymphoblastic leukemia
1083874|NCT01643603|recurrent adult acute myeloid leukemia
1083875|NCT01643603|recurrent adult Burkitt lymphoma
1083876|NCT01643603|recurrent adult diffuse large cell lymphoma
1083877|NCT01643603|recurrent adult diffuse mixed cell lymphoma
1083878|NCT01643603|recurrent adult diffuse small cleaved cell lymphoma
1083879|NCT01643603|recurrent adult grade III lymphomatoid granulomatosis
1083880|NCT01643603|recurrent adult Hodgkin lymphoma
1083881|NCT01643603|recurrent adult immunoblastic large cell lymphoma
1083882|NCT01643603|recurrent adult lymphoblastic lymphoma
1083883|NCT01643603|recurrent adult T-cell leukemia/lymphoma
1083884|NCT01643603|recurrent cutaneous T-cell non-Hodgkin lymphoma
1083885|NCT01643603|recurrent grade 1 follicular lymphoma
1083886|NCT01643603|recurrent grade 2 follicular lymphoma
1083887|NCT01643603|recurrent grade 3 follicular lymphoma
1083888|NCT01643603|recurrent mantle cell lymphoma
1083889|NCT01643603|recurrent marginal zone lymphoma
1083890|NCT01643603|recurrent mycosis fungoides/Sezary syndrome
1083891|NCT01643603|recurrent small lymphocytic lymphoma
1083892|NCT01643603|refractory chronic lymphocytic leukemia
1083893|NCT01643603|refractory hairy cell leukemia
1083894|NCT01643603|relapsing chronic myelogenous leukemia
1083895|NCT01643603|small intestine lymphoma
1083896|NCT01643603|splenic marginal zone lymphoma
1083897|NCT01643603|stage I adult Burkitt lymphoma
1083898|NCT01643603|stage I adult diffuse large cell lymphoma
1083899|NCT01643603|stage I adult diffuse mixed cell lymphoma
1083900|NCT01643603|stage I adult diffuse small cleaved cell lymphoma
1083901|NCT01643603|stage I adult Hodgkin lymphoma
1083902|NCT01643603|stage I adult immunoblastic large cell lymphoma
1083903|NCT01643603|stage I adult lymphoblastic lymphoma
1083904|NCT01643603|stage I adult T-cell leukemia/lymphoma
1083905|NCT01643603|stage I chronic lymphocytic leukemia
1083906|NCT01643603|stage I cutaneous T-cell non-Hodgkin lymphoma
1083907|NCT01643603|stage I grade 1 follicular lymphoma
1083908|NCT01643603|stage I grade 2 follicular lymphoma
1083909|NCT01643603|stage I grade 3 follicular lymphoma
1083910|NCT01643603|stage I mantle cell lymphoma
1083911|NCT01643603|stage I marginal zone lymphoma
1083912|NCT01643603|stage I small lymphocytic lymphoma
1083913|NCT01643603|stage IA mycosis fungoides/Sezary syndrome
1083914|NCT01643603|stage IB mycosis fungoides/Sezary syndrome
1083915|NCT01643603|stage II adult Hodgkin lymphoma
1083916|NCT01643603|stage II chronic lymphocytic leukemia
1083917|NCT01643603|stage II cutaneous T-cell non-Hodgkin lymphoma
1083918|NCT01643603|stage IIA mycosis fungoides/Sezary syndrome
1083919|NCT01643603|stage IIB mycosis fungoides/Sezary syndrome
1083920|NCT01643603|stage III adult Burkitt lymphoma
1083921|NCT01643603|stage III adult diffuse large cell lymphoma
1083922|NCT01643603|stage III adult diffuse mixed cell lymphoma
1083923|NCT01643603|stage III adult diffuse small cleaved cell lymphoma
1083924|NCT01643603|stage III adult Hodgkin lymphoma
1083925|NCT01643603|stage III adult immunoblastic large cell lymphoma
1083926|NCT01643603|stage III adult lymphoblastic lymphoma
1083927|NCT01643603|stage III adult T-cell leukemia/lymphoma
1083928|NCT01643603|stage III chronic lymphocytic leukemia
1083929|NCT01643603|stage III cutaneous T-cell non-Hodgkin lymphoma
1083930|NCT01643603|stage III grade 1 follicular lymphoma
1083931|NCT01643603|stage III grade 2 follicular lymphoma
1083932|NCT01643603|stage III grade 3 follicular lymphoma
1083933|NCT01643603|stage III mantle cell lymphoma
1083934|NCT01643603|stage III marginal zone lymphoma
1083935|NCT01643603|stage III small lymphocytic lymphoma
1083936|NCT01643603|stage IIIA mycosis fungoides/Sezary syndrome
1083937|NCT01643603|stage IIIB mycosis fungoides/Sezary syndrome
1083938|NCT01643603|stage IV adult Burkitt lymphoma
1083939|NCT01643603|stage IV adult diffuse large cell lymphoma
1083940|NCT01643603|stage IV adult diffuse mixed cell lymphoma
1083941|NCT01643603|stage IV adult diffuse small cleaved cell lymphoma
1083942|NCT01643603|stage IV adult Hodgkin lymphoma
1083943|NCT01643603|stage IV adult immunoblastic large cell lymphoma
1083944|NCT01643603|stage IV adult lymphoblastic lymphoma
1083945|NCT01643603|stage IV adult T-cell leukemia/lymphoma
1083946|NCT01643603|stage IV chronic lymphocytic leukemia
1083947|NCT01643603|stage IV cutaneous T-cell non-Hodgkin lymphoma
1083948|NCT01643603|stage IV grade 1 follicular lymphoma
1083949|NCT01643603|stage IV grade 2 follicular lymphoma
1083950|NCT01643603|stage IV grade 3 follicular lymphoma
1083951|NCT01643603|stage IV mantle cell lymphoma
1083952|NCT01643603|stage IV marginal zone lymphoma
1083953|NCT01643603|stage IV small lymphocytic lymphoma
1083954|NCT01643603|stage IVA mycosis fungoides/Sezary syndrome
1083955|NCT01643603|stage IVB mycosis fungoides/Sezary syndrome
1083956|NCT01643603|T-cell large granular lymphocyte leukemia
1083957|NCT01643603|testicular lymphoma
1083958|NCT01643603|Waldenström macroglobulinemia
1083959|NCT01643577|Idiopathic
1083960|NCT01643577|gastroparesis
1083961|NCT01643577|delayed gastric emptying
1083962|NCT01643577|nausea
1083963|NCT01643577|vomiting
1083964|NCT01643577|abdominal pain
1083965|NCT01643577|bloating
1083969|NCT01643239|Modified constraint-induced therapy
1083970|NCT01643239|Children with cerebral palsy
1083972|NCT01643239|Group therapy
1083973|NCT01643200|Erectile Dysfunction
1083974|NCT01643200|Male
1083975|NCT01643200|Zotarolimus
1083976|NCT01643200|Stent
1083977|NCT01643200|Stenosis
1083978|NCT01643200|Erection
1083979|NCT01643200|PDE5 Inhibitors
1083980|NCT01643148|biomarker
1083981|NCT01643148|BMI
1083982|NCT01643148|breast cancer
1083983|NCT01643148|CA-15-3
1083984|NCT01643148|leptin
1083985|NCT01643135|tranexamic acid
1083986|NCT01643135|bleeding
1083987|NCT01643135|blood transfusion
1083988|NCT01643135|spine surgery
1083989|NCT01643122|Endometriosis, Validation study
1083990|NCT01643109|Cerebral Palsy
1083991|NCT01643109|Hemiplegia
1083992|NCT01643109|Constraint Induced Movement Therapy
1083993|NCT01643096|Zataria multiflora Boiss Sumac TEF temperament
1083994|NCT01643083|Post-prandial distress syndrome
1083995|NCT01643070|Rectal cancer
1083996|NCT01643070|Liver metastases
1083997|NCT01643070|Capecitabine
1083998|NCT01643070|Oxaliplatin
1083999|NCT01643057|Apnea
1084000|NCT01643057|Prematurity
1084001|NCT01643057|Biomarkers
1084002|NCT01643057|Stochastic Resonance
1084003|NCT01643057|Neonatal
1084004|NCT01643044|pregnancy
1084005|NCT01643044|screening
1084006|NCT01643044|motivation
1084007|NCT01643031|Diabetes
1084008|NCT01643031|Platelets aggregation inhibitors
1084009|NCT01643031|Platelet function tests
1084010|NCT01643018|cystic echinococcosis
1084011|NCT01643018|liver cyst hydatique
1084012|NCT01643018|treatment
1084013|NCT01643018|surgery
1084014|NCT01643018|laparoscopy
1084015|NCT01643005|HIV
1084016|NCT01642992|Coronary bifurcation lesion
1084017|NCT01642992|Drug-eluting stent
1084018|NCT01642979|Paroxysmal Nocturnal Hemoglobinuria
1084019|NCT01642979|Anemia
1084020|NCT01642979|Hematologic Diseases
1084021|NCT01642979|bone marrow failure
1084022|NCT01642979|Immunologic Factors
1084023|NCT01642979|Physiological Effects of Drugs
1084024|NCT01642979|Levamisole
1084025|NCT01642979|cyclosporine A
1084026|NCT01642966|ticagrelor
1084027|NCT01642966|doppler echocardiography
1084028|NCT01642953|Gastric cancer surgery
1084029|NCT01642953|Early oral feeding
1084030|NCT01642953|Fast track surgery
1084031|NCT01642927|LVAD
1084032|NCT01642927|IABP
1084033|NCT01642927|Heart Failure
1084034|NCT01642927|Thrombosis
1084035|NCT01642927|Hemorrhage
1084036|NCT01642914|Chronic Constipation
1084037|NCT01642914|Abdominal Bloating
1084038|NCT01642914|Linaclotide
1084039|NCT01642901|spinal cord injury
1084040|NCT01642901|bone mineral density
1084041|NCT01642875|Periampullary tumor
1084042|NCT01642875|Chronic pancreatitis
1084043|NCT01642875|Pancreatoduodenectomy
1084044|NCT01642875|Oral Nutrition
1084045|NCT01642875|Enteral Nutrition
1084046|NCT01642849|high protein diet
1084047|NCT01642849|high carbohydrate diet
1084048|NCT01642849|weight loss
1084049|NCT01642849|oxidative stress
1084050|NCT01642849|inflammation
1084051|NCT01642849|cardiovascular risk factors
1084052|NCT01642823|retinoblastoma
1084053|NCT01642810|Online treatment for Fibromyalgia Syndrome
1084054|NCT01642810|Acceptance-based behavioural treatment
1084055|NCT01642797|confocal laser endomicroscopy
1084056|NCT01642797|gastric intestinal metaplasia
1084057|NCT01642797|gastric intraepithelial neoplasia
1084058|NCT01642797|gastric carcinoma
1084059|NCT01642784|STEMI
1084060|NCT01642784|NSTEMI
1084061|NCT01642784|revascularization
1084062|NCT01642784|stents
1084063|NCT01642771|Triple-negative Breast Cancer
1084064|NCT01642771|Post-operative adjuvant Chemotherapy
1084065|NCT01642771|Docetaxel
1084066|NCT01642771|Capecitabine
1084067|NCT01642771|Epirubicin
1084068|NCT01642771|Cyclophosphamide
1084069|NCT01642771|Fluorouracil
1084070|NCT01642758|Thalassemia intermedia
1084071|NCT01642758|Fetal hemoglobin
1084072|NCT01642758|Hemoglobin
1084073|NCT01642732|Prostate
1084074|NCT01642732|Cancer
1084075|NCT01642732|Everolimus
1084076|NCT01642732|Radiation
1084077|NCT01642719|Sleep disturbance
1084078|NCT01642719|Aging
1084079|NCT01642719|Sleep restriction
1084080|NCT01642719|Health status
1084081|NCT01642719|Glucose tolerance
1084082|NCT01642719|Inflammation
1084083|NCT01642706|Regulatory B cells
1084084|NCT01642706|Rheumatoid arthritis
1084085|NCT01642706|Biomarker
1084086|NCT01642693|root resorption
1084087|NCT01642693|low-power laser
1084088|NCT01642693|orthodontic tooth movement
1084089|NCT01642693|pulp changes
1084090|NCT01642680|Physical activity program
1084091|NCT01642680|Chemotherapy
1084092|NCT01642680|Metabolic syndrome
1084093|NCT01642680|Reducing cardiovascular risk factors
1084094|NCT01642680|low physical activity level
1084095|NCT01642628|Mirror
1084096|NCT01642628|Body Image
1084097|NCT01642628|Mastectomy
1084098|NCT01642615|Drug therapy
1084099|NCT01642602|Drug Therapy
1084100|NCT01642589|Meningitis
1084101|NCT01642589|Meningococcal disease
1084102|NCT01642589|Menactra®
1084103|NCT01642589|Adacel®
1084104|NCT01642576|obesity
1084105|NCT01642576|men
1084106|NCT01642576|sexual function
1084107|NCT01642576|urinary tract symptoms
1084108|NCT01642576|endothelial function
1084109|NCT01642576|inflammation
1084110|NCT01642576|quality of life
1084111|NCT01642563|Platelet transfusion
1084112|NCT01642563|Leukemia
1084113|NCT01642563|Transfusion transmissible infections
1084114|NCT01642563|Chemotherapy
1084115|NCT01642563|Allogeneic hemopoietic stem cell transplant
1084116|NCT01642550|Anorexia nervosa
1084117|NCT01642550|Anorexia
1084118|NCT01642550|Eating disorders
1084119|NCT01642524|resuscitation
1084120|NCT01642511|Breast Cancer
1084121|NCT01642511|Sentinel Lymph Node Biopsy
1084122|NCT01642511|Internal Mammary
1084123|NCT01642511|Lymphoscintigraphy
1084124|NCT01642498|High Blood Pressure
1084125|NCT01642498|Hypertension
1084126|NCT01642498|Resistant Hypertension
1084127|NCT01642485|Insulin clamp
1084128|NCT01642485|Glucose clamp
1084129|NCT01642485|Moxifloxacin
1084130|NCT01642485|Fed
1084131|NCT01642485|Fasted
1084132|NCT01642485|QT/QTC interval
1084133|NCT01642485|TQT
1084134|NCT01642485|ECG
1084135|NCT01642485|Meal effects
1084136|NCT01642485|C Peptide
1084137|NCT01642485|Japanese Caucasian bridging
1084138|NCT01642485|TQT bridging
1084139|NCT01642485|FDA standard breakfast
1084140|NCT01642485|Adaptive study design
1084141|NCT01642459|arteriovenous fistula
1084142|NCT01642459|hemodialysis
1084143|NCT01642459|aneurysm
1084144|NCT01642459|vascular stenosis
1084145|NCT01642459|cannulation
1084146|NCT01642446|precise hepatectomy
1084147|NCT01642446|hepatocellular carcinoma
1084148|NCT01642446|cirrhotic
1084149|NCT01642446|portal hypertension
1084150|NCT01642446|safety
1084151|NCT01642446|combined interventional treatment
1084152|NCT01642394|Diabetes Mellitus
1084153|NCT01642394|Chronic Disease
1084154|NCT01642394|Education
1084155|NCT01642394|Primary Care
1084156|NCT01642394|Self care
1084157|NCT01642394|Self Management
1084158|NCT01642381|Drinking
1084159|NCT01642381|Alcohol Problems
1084160|NCT01642381|Alcoholism
1084161|NCT01642381|Moderation-Oriented Treatment
1084162|NCT01642381|Controlled Drinking
1084163|NCT01642381|Reduced Drinking
1084164|NCT01642381|Heavy Drinking
1084165|NCT01642381|Problematic Drinking
1084166|NCT01642381|Non-Abstinence-based Drinking
1084167|NCT01642368|Omega-3 fatty acids
1084168|NCT01642368|Omega-3 to omega-6 ratio
1084169|NCT01642368|Cognitive response
1084170|NCT01642368|Physical performance
1084171|NCT01642329|Myocardial Infarction
1084172|NCT01642329|Angina, Unstable
1084173|NCT01642316|washback, reading comprehension
1084174|NCT01642303|vodcasting,listening,language education
1084175|NCT01642277|Overactive Bladder
1084176|NCT01642277|OAB
1084177|NCT01642277|Urinary Tract Infection
1084178|NCT01642277|UTI
1084179|NCT01642277|Microbiome
1084180|NCT01642277|Bacteria
1084181|NCT01642277|Solifenacin
1084182|NCT01642277|16S rRNA sequence
1084183|NCT01642264|Tobacco Cessation
1084184|NCT01642264|Continuing Education
1084185|NCT01642264|Pediatric
1084186|NCT01642264|Respiratory Therapist
1084187|NCT01642264|Nurse
1084188|NCT01642238|Antiplatelet
1084189|NCT01642238|ticagrelor
1084190|NCT01642238|clopidogrel
1084191|NCT01642238|bivalirudin
1084192|NCT01642238|thrombosis
1084193|NCT01642212|EoE
1084194|NCT01642199|obesity
1084195|NCT01642199|weight loss
1084196|NCT01642199|lay health coach
1084197|NCT01642199|peer coach
1084198|NCT01642199|mentor coach
1084199|NCT01642199|reduced intensity weight loss program
1084200|NCT01642186|LETROZOLE
1084201|NCT01642186|LUPRON DEPOT
1084202|NCT01642186|RAD001 (EVEROLIMUS)
1084203|NCT01642186|11-211
1084204|NCT01642147|Cerebral blood flow
1084205|NCT01642147|Transcranial Doppler
1084206|NCT01642147|Emergence from general anesthesia
1084207|NCT01642134|Antiplatelet
1084208|NCT01642134|Anticoagulation
1084214|NCT01642043|greater trochanteric pain syndrome
1084215|NCT01642043|trochanteric bursitis
1084216|NCT01642043|lateral hip pain
1084217|NCT01642030|Quantitative sensory testing
1084218|NCT01642030|Cold pressor test
1084219|NCT01642030|Opioid dependence
1084220|NCT01642030|Methadone maintenance
1084221|NCT01642030|Buprenorphine maintenance
1084222|NCT01642030|Abuse liability
1084223|NCT01642030|DNIC
1084224|NCT01642030|Temporal Summation
1084225|NCT01642017|Phase I, Pazopanib, Frail elderly patients, Pharmacokinetics
1084226|NCT01641991|Bacillus anthracis, anthrax, vaccine, BioThrax®, dose-sparing
1084227|NCT01641913|Eosinophilic Esophagitis
1084228|NCT01641900|sleep
1084229|NCT01641900|memory
1084230|NCT01641900|schizophrenia
1084231|NCT01641900|eszopiclone
1084232|NCT01641887|GERD
1084233|NCT01641887|Heartburn
1084234|NCT01641887|Decision Aid
1084235|NCT01641874|Knee
1084236|NCT01641874|Osteoarthritis
1084237|NCT01641874|McKenzie system
1084238|NCT01641874|Exercise
1084239|NCT01641874|Mechanical Diagnosis and Therapy
1084240|NCT01641874|Directional preference
1084241|NCT01641861|Chemo-mechanical caries removal
1084242|NCT01641861|Papacarie®
1084243|NCT01641848|Total Ankle Arthroplasty
1084244|NCT01641809|HIV -1
1084245|NCT01641809|GSK1265744
1084246|NCT01641809|maintenance phase
1084247|NCT01641809|dose selection
1084248|NCT01641796|Cutaneous Leishmaniasis
1084249|NCT01641796|CL
1084250|NCT01641796|Lesion
1084251|NCT01641796|Topical
1084252|NCT01641796|Treatment
1084253|NCT01641796|Cream
1084254|NCT01641796|Expanded Access
1084255|NCT01641783|advanced
1084256|NCT01641783|paclitaxel
1084257|NCT01641783|capecitabine
1084258|NCT01641783|first line therapy
1084259|NCT01641757|hemodialysis
1084260|NCT01641757|periodontitis
1084261|NCT01641744|Parent Child Relationship
1084262|NCT01641744|Maltreatment
1084263|NCT01641744|Risk Behaviors
1084264|NCT01641744|Social and Emotional Development
1084265|NCT01641744|Violence and Abuse
1084266|NCT01641744|Policy
1084267|NCT01641731|cow's milk protein allergy
1084268|NCT01641731|oral tolerance induction
1084269|NCT01641718|Hernia, Inguinal
1084270|NCT01641705|rheumatoid arthritis
1084271|NCT01641705|respiratory mechanics
1084272|NCT01641705|time of disease
1084273|NCT01641692|Asthma
1084274|NCT01641692|Pharmacokinetics
1084275|NCT01641692|GSK573719
1084276|NCT01641692|Adults
1084277|NCT01641692|Pharmacogenetics
1084278|NCT01641679|Recurrent differentiated thyroid cancer
1084279|NCT01641679|I124-PET/CT
1084280|NCT01641679|FDG-PET/CT
1084281|NCT01641653|Nondiabetics undergoing hernia repair.
1084282|NCT01641640|HCV genotype 1 (GT-1)
1084283|NCT01641640|HCV genotype 4 (GT-4)
1084284|NCT01641640|HCV genotype 5 (GT-5)
1084285|NCT01641640|HCV genotype 6 (GT-6)
1084286|NCT01641640|HCV
1084287|NCT01641640|Sustained Virologic Response
1084288|NCT01641640|Direct Acting Antiviral
1084289|NCT01641640|Combination Therapy
1084290|NCT01641640|Treatment-Naïve
1084291|NCT01641640|GS-7977
1084292|NCT01641640|Ribavirin
1084293|NCT01641640|RBV
1084294|NCT01641640|Peginterferon Alfa 2a
1084295|NCT01641640|PEG
1084296|NCT01641627|knee arthritis
1084297|NCT01641627|muscle atrophy
1084298|NCT01641627|proprioceptive stimulation
1084299|NCT01641627|vibrations
1084300|NCT01641614|Mitral valve
1084301|NCT01641614|valve replacement
1084302|NCT01641614|arrested heart
1084303|NCT01641614|beating heart
1084304|NCT01641601|Induction of labor
1084305|NCT01641601|Outpatient cervical ripening
1084306|NCT01641588|cognitive executive function
1084307|NCT01641588|posture
1084308|NCT01641588|cognitive performance
1084309|NCT01641588|heart rate
1084310|NCT01641588|eeg
1084311|NCT01641575|CO-1.01
1084312|NCT01641575|CO-101
1084313|NCT01641575|gemcitabine elaidate
1084314|NCT01641575|hENT1
1084315|NCT01641575|nucleoside equilibrative transporter
1084316|NCT01641575|solid tumor
1084317|NCT01641575|non-small-cell lung cancer
1084318|NCT01641575|NSCLC
1084319|NCT01641575|lung cancer
1084320|NCT01641562|BREAST CANCER,
1084321|NCT01641562|TAXANES,
1084322|NCT01641562|SUBCLINICAL CARDIAC DYSFUNCTION ,
1084323|NCT01641562|DIAGNOSTIC TOOLS,
1084324|NCT01641562|PREDICTIVE MODELS
1084325|NCT01641549|Prosthetic valve thrombosis
1084326|NCT01641549|Fibrinolytic therapy
1084327|NCT01641549|Emergency surgery
1084328|NCT01641536|Hepatitis, Chronic
1084329|NCT01641536|Virus Diseases
1084330|NCT01641536|DNA Virus Infections
1084331|NCT01641536|Hepatitis B
1084332|NCT01641536|Liver
1084333|NCT01641536|Chronic Disease
1084334|NCT01641536|HBV
1084335|NCT01641523|Cranioplasty prosthesis
1084336|NCT01641523|Hydroxyapatite
1084337|NCT01641523|PolyMethylMethacrylate
1084338|NCT01641523|Autologous Bone
1084339|NCT01641510|reduced-function CYP2C19 allele
1084340|NCT01641510|high platelet reactivity
1084341|NCT01641510|clopidogrel
1084342|NCT01641510|prasugrel
1084343|NCT01641497|endometrial cancer
1084344|NCT01641497|IMRT
1084345|NCT01641497|age over 70
1084346|NCT01641471|Total Knee Arthroplasty (TKA)
1084347|NCT01641471|Transcutaneous Electrical Nerve Stimulation (TENS)
1084348|NCT01641471|Pain
1084349|NCT01641471|Function
1084350|NCT01641471|Knee Osteoarthritis
1084351|NCT01641458|Genotyping
1084352|NCT01641458|Area-under-the concentration-time curve
1084353|NCT01641458|Toxicity
1084354|NCT01641458|5-fluorouracil
1084355|NCT01641458|Capecitabine
1084356|NCT01641419|Pain
1084357|NCT01641419|Ropivacaine
1084358|NCT01641419|sciatic block
1084359|NCT01641419|dexamethasone
1084360|NCT01641406|NAC Protocol
1084361|NCT01641406|NAC and Oncotype Guided Hormonal therapy for breast cancer
1084362|NCT01641406|Neoadjuvant and Oncotype
1084363|NCT01641406|NAC CCAM 1101
1084364|NCT01641393|Exocrine Pancreatic Insufficiency
1084365|NCT01641393|Cystic Fibrosis
1084366|NCT01641393|Pancreatic Insufficiency
1084367|NCT01641380|Depoprovera
1084368|NCT01641380|Contraception
1084369|NCT01641380|Appointment adherence/attendance
1084370|NCT01641380|Pregnancy Prevention
1084371|NCT01641354|Hemiepiphysiodesis
1084372|NCT01641341|Irritable Bowel Syndrome
1084373|NCT01641341|Genova Diagnostics kit
1084374|NCT01641341|Stool test
1084375|NCT01641341|Rome III
1084376|NCT01641341|Practice-based research
1084377|NCT01641341|treatable parasite
1084378|NCT01641341|Pancreatic insufficiency
1084379|NCT01641341|Bowel dysbiosis
1084380|NCT01641341|High levels of inflammation, C. difficile, or H. pylori
1084381|NCT01641328|Mild Cognitive Impairment
1084382|NCT01641328|MCI
1084383|NCT01641328|Meditation
1084384|NCT01641328|Mindfulness
1084385|NCT01641328|Cognitive Activation
1084386|NCT01641328|Cognitive Training
1084387|NCT01641328|Tai Chi
1084388|NCT01641315|rabies
1084389|NCT01641315|rabies immunoglobulin
1084390|NCT01641289|Falciparum malaria
1084391|NCT01641289|Paracetamol
1084392|NCT01641289|Renal function
1084393|NCT01641289|Oxidative stress
1084394|NCT01641276|biofeedback response
1084395|NCT01641263|Depression Prevention
1084396|NCT01641263|Sleep Disturbances
1084397|NCT01641263|Inflammatory Markers
1084398|NCT01641263|Treatments for Sleep Problems
1084399|NCT01641224|Irritable bowel syndrome,
1084400|NCT01641224|Pinaverium
1084401|NCT01641224|Herbal medication for IBS,
1084402|NCT01641224|Tong Xie Yao Fang (Formula for pain and diarrhea)
1084403|NCT01641198|Dental implants, bone healing, fixed dental prostheses, implant surface
1084404|NCT01641185|prostate
1084405|NCT01641185|IPI
1084406|NCT01641185|hypofractionation
1084407|NCT01641185|carbon ions
1084408|NCT01641185|proton
1084409|NCT01641172|taste
1084410|NCT01641172|smell
1084411|NCT01641172|cancer
1084412|NCT01641172|nutrition
1084413|NCT01641159|Cocaine
1084414|NCT01641159|Crack
1084415|NCT01641159|Buspirone
1084416|NCT01641159|Relapse Prevention
1084417|NCT01641146|HIV risk reduction
1084418|NCT01641146|Stress reduction
1084419|NCT01641146|Trauma reduction
1084420|NCT01641146|PTSD
1084421|NCT01641133|pneumococcal conjugate vaccine
1084422|NCT01641133|Synflorix™
1084423|NCT01641133|Prevenar 13™
1084424|NCT01641133|Pneumococcal diseases
1084425|NCT01641120|Multiple Sclerosis
1084426|NCT01641120|Intramuscular Injections
1084427|NCT01641120|Relapsing Remitting
1084428|NCT01641107|Ph+
1084429|NCT01641107|BCR-ABL+
1084430|NCT01641107|ALL
1084431|NCT01641107|Ponatinib
1084432|NCT01641107|stem cell transplantation
1084433|NCT01641094|Hepatitis C
1084434|NCT01641094|Liver
1084435|NCT01641094|Immunology
1084436|NCT01641094|Genotype 1
1084437|NCT01641094|Treatment
1084438|NCT01641094|Chronic
1084439|NCT01641094|RNA Virus Infections
1084440|NCT01641094|Ribavirin
1084441|NCT01641094|Peginterferon alfa-2a
1084442|NCT01641094|Protease Inhibitors
1084443|NCT01641094|Telaprevir
1084444|NCT01641068|Memory
1084445|NCT01641068|Attention
1084446|NCT01641068|Chemo-brain
1084447|NCT01641068|Survivor
1084448|NCT01641068|Treatment
1084449|NCT01641042|Meningococcal vaccines
1084450|NCT01641042|Vaccines, conjugate
1084451|NCT01641042|Neisseria meningitidis
1084452|NCT01641042|Immunocompromised patient
1084453|NCT01641016|short cycle therapy
1084454|NCT01641016|young people
1084455|NCT01641016|HIV
1084456|NCT01641003|cancer stem cells
1084457|NCT01640990|Healthy male volunteers, intravenous infusion, GW328267X, dose escalation,
1084458|NCT01640977|Open PLIF
1084459|NCT01640977|MAS PLIF
1084460|NCT01640977|Lumbar spine
1084461|NCT01640964|Portal hypertension, cirrhosis, TIPSS, MRI, MRA, portal pressure, portal pressure gradient
1084462|NCT01640925|nosocomial infection
1084463|NCT01640925|hospital acquired infection
1084464|NCT01640925|chlorhexidine
1084465|NCT01640925|pneumonia, ventilator-associated
1084466|NCT01640925|catheter-related infections
1084467|NCT01640925|urinary tract infections, catheter-related
1084468|NCT01640925|surgical site infection
1084469|NCT01640912|Scar
1084470|NCT01640912|Scar prevention
1084471|NCT01640912|Fibrosis
1084472|NCT01640899|Orthotic Devices
1084473|NCT01640899|Activities of Daily Living
1084474|NCT01640899|Pain Measurement
1084475|NCT01640899|Lower Extremity
1084476|NCT01640899|Foot
1084477|NCT01640899|Personal Satisfaction
1084478|NCT01640886|Staphylococcus aureus
1084479|NCT01640886|methicillin resistant
1084480|NCT01640886|MRSA
1084481|NCT01640886|MSSA
1084482|NCT01640886|Blood Culture
1084483|NCT01640886|Diagnostic
1084484|NCT01640873|Type 2 Diabetes
1084485|NCT01640860|docetaxel
1084486|NCT01640860|cisplatin
1084487|NCT01640860|combined modality therapy
1084488|NCT01640847|Painful bone metastases
1084489|NCT01640847|Bone Cancer
1084490|NCT01640847|Bone Cancer Pain
1084491|NCT01640847|Patients with
1084492|NCT01640821|Health-At-Every-Size intervention
1084493|NCT01639729|pharmacokinetics
1084494|NCT01639729|area under curve
1084495|NCT01639729|time to maximum concentration
1084496|NCT01639716|Survey, interleukin status
1084497|NCT01639703|CT perfusion
1084498|NCT01639703|Hepatocellular Carcinoma
1084499|NCT01639703|Xenetix
1084500|NCT01639703|Contrast agent
1084501|NCT01639690|BUSULFAN
1084502|NCT01639690|G-CSF
1084503|NCT01639690|CliniMACS-CD34 Reagent System
1084504|NCT01639690|Blood transfusion
1084505|NCT01639690|10-164
1084506|NCT01639690|Autologous CD34+ cells transduced with TNS9.3.55, a lentiviral vector encoding the human β-globin gene
1084507|NCT01640782|adenocarcinoma of the stomach
1084508|NCT01640782|adenocarcinoma of the gastroesophageal junction
1084509|NCT01640769|Cardiomyopathy
1084510|NCT01640769|Cardiac Resynchronization Therapy
1084511|NCT01640756|Glaucoma Implant
1084512|NCT01640756|Trabeculectomy
1084513|NCT01640756|POAG
1084514|NCT01640743|Kidney transplantation
1084515|NCT01640743|Regulatory T cells
1084516|NCT01640743|Tolerance
1084517|NCT01640743|Tacrolimus
1084518|NCT01640743|Rejection
1084519|NCT01640691|pandemic influenza
1084520|NCT01640691|pandemic influenza vaccine
1084521|NCT01640691|Influenza
1084522|NCT01640691|Orthomyxoviruses
1084523|NCT01640691|A/H5N1
1084524|NCT01640665|histologically
1084525|NCT01640665|unresectable
1084526|NCT01640665|metastatic
1084527|NCT01640665|Phase 1
1084528|NCT01640665|Breast Cancer
1084529|NCT01640665|GI Tumors
1084530|NCT01640665|Sorafenib
1084531|NCT01640665|Capecitabine
1084532|NCT01640639|left ventricular function
1084533|NCT01640626|Health Education
1084534|NCT01640626|Soil-transmitted helminthiasis
1084535|NCT01640626|Ascaris
1084536|NCT01640626|Trichuris
1084537|NCT01640626|Hookworm
1084538|NCT01640626|Prevention and control
1084539|NCT01640613|carotid endarterectomy
1084540|NCT01640613|regional anaesthesia
1084541|NCT01640613|ultrasound guided block
1084542|NCT01640600|To determine whether 4-8 year-old children exposed to nicotine or antidepressants in utero have more behavioral problems.
1084543|NCT01640600|To determine whether 4-8 year-old children exposed to nicotine or antidepressants in utero have more cognitive problems.
1084544|NCT01640600|To determine whether 4-8 year-old children exposed to nicotine or antidepressants in utero have poorer motor development.
1084545|NCT01640587|Uncomplicated falciparum infection
1084546|NCT01640587|Mefloquine-artesunate
1084547|NCT01640587|Dihydroartemisinin-piperaquine
1084548|NCT01640574|Vivax
1084549|NCT01640574|Chloroquine
1084550|NCT01640574|Primaquine
1084551|NCT01640574|Dihydroartemisinin-Piperaquine
1084552|NCT01640561|HIV affected
1084553|NCT01640561|Child Neurodevelopment
1084554|NCT01640561|Low and Middle Income Country
1084555|NCT01640535|PAR
1084556|NCT01640522|Hepatocellular carcinoma
1084557|NCT01640522|Cholangio carcinoma
1084558|NCT01640522|Primary Liver Cancer
1084559|NCT01640522|Bile Duct CancerPancreatic Cancer
1084560|NCT01640522|Gallbladder Cancer
1084561|NCT01640522|Colorectal Carcinoma
1084562|NCT01640522|Other Primary Cancers with Liver Metastases
1084563|NCT01640509|Radiotherapy, Targeted
1084564|NCT01640496|Ulcerative Colitis
1084565|NCT01640496|Inflammatory Bowel disease
1084566|NCT01640496|IBD
1084567|NCT01640496|Vitamin D
1084568|NCT01640470|assistive technology
1084569|NCT01640470|environmental modification
1084570|NCT01640470|caregiver
1084571|NCT01640470|client-centred
1084572|NCT01640457|degenerative disc
1084573|NCT01640457|herniated disc
1084574|NCT01640457|sequestrectomy
1084575|NCT01640457|Autologous Disc Chondrocyte Transplantation
1084576|NCT01640457|nucleotomy
1084577|NCT01640457|safety
1084578|NCT01640457|efficacy
1084579|NCT01640457|treatment
1084580|NCT01640457|lumbar spine
1084581|NCT01640457|low back pain
1084582|NCT01640457|adjacent degenerative disc
1084583|NCT01640457|black disc
1084584|NCT01640457|NOVOCART
1084585|NCT01640444|colorectal carcinoma
1084586|NCT01640444|BRAF and PIK3K
1084587|NCT01640444|FOLFIRI -Bevacizumab -Cetuximab
1084588|NCT01640444|circulating tumor cells
1084589|NCT01640431|lumbar disc herniation
1084590|NCT01640431|clinical trial
1084591|NCT01640431|exercise therapy
1084592|NCT01640431|TENS
1084593|NCT01640418|pressure ulcer
1084594|NCT01640418|dressing
1084595|NCT01640418|prevention
1084596|NCT01640418|higher risk patients
1084597|NCT01640405|colorectal cancer
1084598|NCT01640405|FOLFOX
1084599|NCT01640405|Bevacizumab
1084600|NCT01640405|FOLFOXIRI
1084601|NCT01640405|circulating tumor cell
1084602|NCT01640392|Gay men
1084603|NCT01640392|African American males
1084604|NCT01640392|Unprotected anal sex
1084605|NCT01640392|HIV risk
1084606|NCT01640392|behavioral intervention
1084607|NCT01640392|group-level intervention
1084608|NCT01640379|Pelvic Inflammatory Disease (PID)
1084609|NCT01640379|Community Health Nursing
1084610|NCT01640379|Text Messaging
1084611|NCT01640379|mHealth
1084612|NCT01640379|Adolescents
1084613|NCT01640366|surgical incision
1084614|NCT01640366|reduction mammoplasty
1084615|NCT01640366|healing complications
1084616|NCT01640366|negative pressure wound therapy
1084617|NCT01640353|si joint
1084618|NCT01640353|si joint pain
1084619|NCT01640353|si joint injury
1084620|NCT01640353|si joint treatment
1084621|NCT01640353|si joint injections
1084622|NCT01640353|si joint inflammation
1084623|NCT01640353|si joint problems
1084624|NCT01640353|si joint symptoms
1084625|NCT01640353|hypermobile si joint
1084626|NCT01640353|si joint arthritis
1084627|NCT01640353|si joint pain treatment
1084628|NCT01640353|inflamed si joint
1084629|NCT01640353|si joint sclerosis
1084630|NCT01640353|locked si joint
1084631|NCT01640353|si joint injuries
1084632|NCT01640353|si joint disease
1084633|NCT01640353|si joint infection
1084634|NCT01640353|sacroiliac joint pelvic pain
1084635|NCT01640353|sacroiliac joint arthritis treatment
1084636|NCT01640340|ondansetron
1084637|NCT01640340|palonosetron
1084638|NCT01640340|emetogenic chemotherapy
1084639|NCT01640340|HEC
1084640|NCT01640327|Interpandemic influenza
1084641|NCT01640327|Adult
1084642|NCT01640327|Elderly
1084643|NCT01640327|Safety
1084644|NCT01640327|Tolerability
1084645|NCT01640327|Immunology
1084646|NCT01640314|Influenza
1084647|NCT01640314|Adults
1084648|NCT01640314|Elderly
1084649|NCT01640314|Immunology
1084650|NCT01640314|Safety
1084651|NCT01640288|COPD
1084652|NCT01640288|Pulmonary Function Testing
1084653|NCT01640288|MRI
1084654|NCT01640288|Normal Lung Function
1084655|NCT01640288|Current Smoker
1084656|NCT01640288|Non Smoker
1084657|NCT01640288|Ex Smoker
1084658|NCT01640275|General Anesthesia
1084659|NCT01640275|Alzheimers Disease
1084660|NCT01640275|Cognitive decline
1084661|NCT01640262|prostate biopsy
1084662|NCT01640262|prostate cancer
1084663|NCT01640262|Magnetic Resonance Imaging
1084664|NCT01640262|Neoplasm Staging
1084665|NCT01640236|Ocular flare
1084666|NCT01640197|Cognitive performance
1084667|NCT01640197|Cerebral blood flow
1084668|NCT01640197|Subjective sleep
1084669|NCT01640197|Subjective mood
1084670|NCT01640197|Subjective health
1084671|NCT01640184|hyperparathyroidism
1084672|NCT01640184|vitamin D
1084673|NCT01640184|ultrasonic ablation
1084674|NCT01640184|surgery
1084675|NCT01640171|anesthesia
1084676|NCT01640171|pain
1084677|NCT01640171|intravitreal
1084678|NCT01640171|anti-vegf
1084679|NCT01640158|mild Traumatic Brain Injury
1084680|NCT01640158|Cognitive remediation
1084681|NCT01640158|computer
1084682|NCT01640119|metabolic acidosis
1084683|NCT01640119|renal death
1084684|NCT01640106|Language
1084685|NCT01640106|Fatty acids
1084686|NCT01640106|Nutrition
1084687|NCT01640106|Developmental delay
1084688|NCT01640093|Healthy participants
1084689|NCT01640093|Bioavailability
1084690|NCT01640093|Pharmacokinetics
1084691|NCT01640093|Abiraterone acetate
1084692|NCT01640093|Abiraterone
1084693|NCT01640080|Major depressive disorder
1084694|NCT01640080|Treatment resistant depression
1084695|NCT01640080|Depression
1084696|NCT01640080|Esketamine
1084697|NCT01640067|amyotrophic lateral sclerosis
1084698|NCT01640067|motor neuron disease
1084699|NCT01640067|stem cells
1084700|NCT01640067|safety
1084701|NCT01640067|ALS-FRS-Functional scale R and FVC (%) variation
1084702|NCT01640067|Survival analysis
1084703|NCT01640067|Changes in quality of life scales
1084704|NCT01640054|Rheumatoid Arthritis
1084705|NCT01640015|Blood pressure
1084706|NCT01640015|eating episode
1084707|NCT01640015|eating frequency
1084708|NCT01640015|insulin sensitivity
1084709|NCT01640002|overactive bladder
1084710|NCT01640002|HTLV-1
1084711|NCT01640002|Propantheline
1084712|NCT01640002|anticholinergic
1084713|NCT01639989|Doppler, Pregnancy
1084714|NCT01639976|Missed abortion, early pregnancy loss.
1084715|NCT01639950|Self-Report
1084716|NCT01639950|Survey Scale
1084717|NCT01639950|Validate
1084718|NCT01639950|Pain Severity
1084719|NCT01639950|Reliability
1084720|NCT01639937|Cardiac MRI
1084721|NCT01639937|Congestive Heart Failure
1084722|NCT01639937|Cardiac Fibrosis
1084723|NCT01639937|Late Gadolinium Enhancement
1084724|NCT01639924|Small Bowel Disease
1084725|NCT01639924|Digestive Disease
1084726|NCT01639924|Gastrointestinal Disease
1084727|NCT01639924|Lower GI Disease
1084728|NCT01639911|malignant solid tumor
1084729|NCT01639911|advanced non-hematologic
1084730|NCT01639898|POEMS
1084731|NCT01639898|VEGF
1084732|NCT01639898|Free light
1084733|NCT01639898|lenalidomide
1084734|NCT01639898|dexamethasone
1084735|NCT01639885|p53 overexpression
1084736|NCT01639885|platinum-resistant
1084737|NCT01639872|Schizophrenia
1084738|NCT01639872|Cannabis Abuse
1084739|NCT01639872|Cannabis Dependence
1084740|NCT01639872|Dual Diagnosis
1084741|NCT01639872|Clozapine
1084742|NCT01639872|Risperidone
1084743|NCT01639859|prostate cancer
1084744|NCT01639859|elastography
1084745|NCT01639859|elasticity
1084746|NCT01639820|Cervical cancer
1084747|NCT01639820|early stage carcinoma
1084748|NCT01639820|FIGO IA1 IA2 IB1 IIA
1084749|NCT01639820|sentinel lymph node biopsy
1084750|NCT01639820|pelvic lymphadenectomy
1084751|NCT01639820|Surgery of uterine cervical carcinoma
1084752|NCT01639820|medico economic impact
1084753|NCT01639820|quality of life
1084754|NCT01639807|Open Angle Glaucoma or Ocular hypertension
1084755|NCT01639794|LUTS (Lower Urinary Tract Symptoms)
1084756|NCT01639794|Overactive Bladder (OAB)Vesitirim
1084757|NCT01639794|Solifenacin
1084758|NCT01639794|Anti-muscarinic treatment
1084759|NCT01639794|Cholinergic receptor antagonist
1084760|NCT01639794|Storage Symptom improvement
1084761|NCT01639781|flavanols
1084762|NCT01639781|age related cardiovascular effects
1084763|NCT01639768|Sublingual immunotherapy
1084764|NCT01639768|Dose range finding
1084765|NCT01639768|Dose tolerability
1084766|NCT01639768|Birch pollen
1084767|NCT01639768|Allergic rhinitis/rhinoconjunctivitis
1084768|NCT01639768|Safety
1084769|NCT01639768|Immunogenicity
1084770|NCT01639677|Obesity
1084771|NCT01639677|weight loss
1084772|NCT01639677|surgery
1084773|NCT01639677|gastric bypass
1084774|NCT01639677|VBG
1084775|NCT01639651|Physical Therapy
1084776|NCT01639651|Glenohumeral Internal Rotation Deficits
1084777|NCT01639651|Joint Mobilization
1084778|NCT01639651|Posterior capsule
1084779|NCT01639651|Capsular contracture
1084780|NCT01639638|Recurrent and non-recurrent genital condyloma
1084781|NCT01639612|Stem Cell
1084782|NCT01639612|Grade IV Malignant Glioma
1084783|NCT01639599|non-smoker
1084784|NCT01639599|female
1084785|NCT01639599|IV PCA
1084786|NCT01639599|patient-controlled analgesia
1084787|NCT01639573|Patients with Scleroderma
1084788|NCT01639560|smoking
1084789|NCT01639560|tobacco dependence
1084790|NCT01639560|nicotine dependence
1084791|NCT01639547|PEGASYS® PLUS RIBAVIRIN
1084792|NCT01639534|Biomarkers of ischemia
1084793|NCT01639534|Carotid Stenting procedure
1084794|NCT01639534|Levels Xanthine Hypoxanthine and Inosine
1084795|NCT01639534|peripheral blood
1084796|NCT01639508|Lung
1084797|NCT01639508|XL184 (CABOZANTINIB)
1084798|NCT01639508|KIF5B/RET Positive
1084799|NCT01639508|RET Fusion Positive
1084800|NCT01639508|12-097
1084801|NCT01639508|Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
1084802|NCT01639495|Drug refractory
1084803|NCT01639495|Atrial fibrillation
1084804|NCT01639495|Antiarrhythmic drug failure
1084805|NCT01639495|Atrial tachyarrhythmias
1084809|NCT01639456|acute myelogenous leukemia
1084810|NCT01639443|quality improvement
1084811|NCT01639443|Organization and Administration
1084812|NCT01639443|Costs and cost analysis
1084813|NCT01639443|Patient satisfaction
1084814|NCT01639443|Health plan implementation
1084815|NCT01639404|Cerebral Palsy
1084816|NCT01639404|Umbilical Cord Blood
1084817|NCT01639404|Rehabilitation
1084818|NCT01639365|Ventricular tachycardia
1084819|NCT01639365|Catheter ablation
1084820|NCT01639365|Tissue contact
1084821|NCT01639352|Hepatocellular Carcinoma
1084822|NCT01639352|HCC
1084823|NCT01639352|SOMO230
1084824|NCT01639352|Pasireotide LAR
1084825|NCT01639339|Antibodies
1084826|NCT01639339|Systemic Lupus Erythematosus
1084827|NCT01639339|Autoimmune Disease
1084828|NCT01639339|Glomerulonephritis
1084829|NCT01639339|Belimumab
1084830|NCT01639339|Lupus
1084831|NCT01639339|Nephritis
1084832|NCT01639339|Kidney Diseases
1084833|NCT01639339|SLE
1084834|NCT01639300|Relapsing Forms of Multiple Sclerosis
1084835|NCT01639300|Progressive Forms of Multiple Sclerosis
1084836|NCT01639300|GNbAC1
1084837|NCT01639300|Monoclonal antibody
1084838|NCT01639300|Multiple Sclerosis Associated Retrovirus (MSRV)
1084839|NCT01639261|steroid-refractory
1084840|NCT01639261|bronchiolitis obliterans
1084841|NCT01639261|allogeneic stem cell transplantation
1084842|NCT01639261|interferon gamma
1084843|NCT01639248|Breast Cancer
1084844|NCT01639235|Secondhand Smoke
1084845|NCT01639235|Flight Attendants
1084846|NCT01639235|Lung function
1084847|NCT01639235|Cardiac function
1084848|NCT01639235|Reproductive health
1084849|NCT01639222|Drug therapy
1084850|NCT01639222|Increase in calcium urinary excretion and PTH decrease in serum
1084851|NCT01639209|Retinal detachment
1084852|NCT01639209|Pneumatic retinopexy
1084853|NCT01639209|Vitrectomy
1084854|NCT01639196|Chronic pain
1084855|NCT01639196|Psychological adjustment
1084856|NCT01639196|Writing
1084857|NCT01639196|Brief intervention
1084858|NCT01639196|Online
1084859|NCT01639196|Internet interventions
1084860|NCT01639183|oral inflammation
1084861|NCT01639183|systemic inflammation
1084862|NCT01639183|compliance
1084863|NCT01639183|power toothbrushing
1084864|NCT01639183|nursing home residents
1084865|NCT01639170|Pneumoperitoneum
1084866|NCT01639170|Free air
1084867|NCT01639170|Surgery
1084868|NCT01639170|Perforation
1084869|NCT01639170|Radiograph
1084870|NCT01639144|Infection
1084871|NCT01639144|delayed wound healing
1084872|NCT01639144|platelet-rich plasma
1084873|NCT01639131|Gemcitabine
1084874|NCT01639131|Docetaxel
1084875|NCT01639131|Filgrastim
1084876|NCT01639131|Pegfilgrastim
1084877|NCT01639118|primary ventral hernia repair with mesh
1084878|NCT01639118|umbilical hernia repair
1084879|NCT01639118|epigastric hernia repair
1084880|NCT01639118|C-Qur V-patch
1084881|NCT01639118|Size tailored repair
1084882|NCT01639118|preperitoneal repair
1084883|NCT01639118|abdominal hernia
1084884|NCT01639118|dual sided mesh
1084885|NCT01639092|Resistance of Entecavir
1084886|NCT01639079|cigarette smoking behavior
1084887|NCT01639079|smoking cessation
1084888|NCT01639079|Latino smoking cessation
1084889|NCT01639066|Resistance of Adefovir
1084890|NCT01639053|Breast Augmentation
1084891|NCT01639053|Breast Reconstruction
1084892|NCT01639053|Breast Revision
1084893|NCT01639053|Silicone breast implants
1084894|NCT01639001|Crizotinib
1084895|NCT01639001|ALK positive
1084896|NCT01639001|ALK
1084897|NCT01639001|Anaplastic Lymphoma Kinase
1084898|NCT01639001|NSCLC
1084899|NCT01639001|Non-Small Cell Lung Cancer
1084900|NCT01639001|Frontline
1084901|NCT01639001|1L
1084902|NCT01639001|Previously Untreated
1084903|NCT01639001|East Asian
1084904|NCT01639001|Non-Squamous
1084905|NCT01638962|Exercise Therapy
1084906|NCT01638962|Gait
1084907|NCT01638962|Joint load
1084908|NCT01638962|Knee Joint
1084909|NCT01638962|Middle Aged
1084910|NCT01638962|Osteoarthritis, Knee/therapy
1084911|NCT01638962|Pain Management
1084912|NCT01638949|Alzheimer's disease
1084913|NCT01638949|MCI
1084914|NCT01638949|genetic
1084915|NCT01638949|AV45-PET
1084916|NCT01638936|Combination
1084917|NCT01638936|Multiple Myeloma
1084918|NCT01638923|Heavy Menstrual Bleeding
1084919|NCT01638923|Efficacy
1084920|NCT01638923|Safety
1084921|NCT01638923|Oral contraceptive
1084922|NCT01638923|Estradiol valerate
1084923|NCT01638923|Dienogest
1084924|NCT01638910|Efficacy
1084925|NCT01638910|Safety
1084926|NCT01638910|oral contraception
1084927|NCT01638910|estradiol valerate
1084928|NCT01638910|dienogest
1084929|NCT01638897|ICD
1084930|NCT01638897|CRTD
1084931|NCT01638897|DF4
1084932|NCT01638884|Prospective Memory
1084933|NCT01638884|Healthy Aging
1084934|NCT01638884|Alzheimer Disease
1084935|NCT01638884|Brain Imaging
1084936|NCT01638832|NASH; coronary artery disease
1084937|NCT01638806|Acute Coronary Syndrome
1084938|NCT01638806|Myocardial infarction
1084939|NCT01638806|Angioplasty
1084940|NCT01638806|Prehospital emergency care
1084941|NCT01638806|Biological markers
1084942|NCT01638806|Troponin
1084943|NCT01638806|Point-of-Care systems
1084944|NCT01638767|In Vitro Fertilization long protocol
1084945|NCT01638767|NuvaRing
1084946|NCT01638767|Marvelon
1084947|NCT01638767|In vitro fertilization
1084948|NCT01638715|Rheumatoid Arthritis
1084949|NCT01638715|Biologic therapies
1084950|NCT01638715|Biomarker
1084951|NCT01638715|Mode of Action
1084952|NCT01638702|Catheterisation, Central Venous
1084953|NCT01638702|Catheters, Indwelling
1084954|NCT01638689|Mechanism of Action of escitalopram
1084955|NCT01638676|Unresectable melanoma
1084956|NCT01638676|Stage IIIC and Stage IV BRAFV600E+ Melanoma
1084957|NCT01638663|Tolvaptan
1084958|NCT01638663|L-NMMA
1084959|NCT01638663|Healthy subjects
1084960|NCT01638663|Nephrology
1084961|NCT01638663|Cardiology
1084962|NCT01638624|Propofol
1084963|NCT01638624|antioxidant capacity
1084964|NCT01638624|total knee arthroplasty
1084965|NCT01638624|Propofol,antioxidant
1084966|NCT01638611|Healthy male volunteers
1084967|NCT01638572|Neuroblastoma
1084968|NCT01638572|B4GALNT3
1084969|NCT01638572|Prognosis
1084970|NCT01638559|liver transplant
1084971|NCT01638559|allograft function
1084972|NCT01638559|anti-rejection
1084973|NCT01638559|immunosuppression withdrawal
1084974|NCT01638520|Immune Therapy
1084975|NCT01638520|Interleukin 4
1084976|NCT01638520|monoclonal antibody
1084977|NCT01638507|TARGET LESION REVASCULARIZATION (TLR)
1084978|NCT01638507|TARGET VESSEL REVASCULARIZATION (TVR)
1084979|NCT01638507|Coronary Artery Disease
1084980|NCT01638507|MYOCARDIAL INFARCTION (MI)
1084981|NCT01638507|PERCUTANEOUS CORONARY INTERVENTION (PCI)
1084982|NCT01638507|STENT THROMBOSIS
1084983|NCT01638507|TARGET LESION FAILURE (TLF)
1084984|NCT01638494|25-Hydroxyvitamin D
1084985|NCT01638494|dietary counseling
1084986|NCT01638494|pediatrics
1084987|NCT01638494|allergy
1084988|NCT01638494|bone metabolism
1084989|NCT01638468|Pulmonary Embolism
1084990|NCT01638468|Acute Pulmonary Embolism
1084991|NCT01638468|Sub-massive Pulmonary Embolism
1084992|NCT01638468|Massive Pulmonary Embolism
1084993|NCT01638468|Pulmonary Thromboembolism
1084994|NCT01638442|Male subjects, healthy
1084995|NCT01638403|narcolepsy
1084996|NCT01638403|excessive daytime sleepiness
1084997|NCT01638403|cataplexy
1084998|NCT01638377|Back on Track
1084999|NCT01638377|convicted drinking drivers
1085000|NCT01638377|naltrexone
1085001|NCT01638377|alcohol dependence
1085002|NCT01638351|Diabetes mellitus
1085003|NCT01638351|Resistance exercise
1085004|NCT01638351|Elderly
1085005|NCT01638351|Skeletal muscle dysfunction
1085006|NCT01638351|Metabolomics
1085007|NCT01638338|Alcohol
1085008|NCT01638338|Risky drinking
1085009|NCT01638338|Web site
1085010|NCT01638338|Primary Care
1085011|NCT01638338|General Practice
1085012|NCT01638338|Local Community
1085013|NCT01638338|Mayors
1085014|NCT01638312|HIV, fructose
1085015|NCT01638299|Type 1 Diabetes Mellitus
1085016|NCT01638299|Artificial Pancreas
1085017|NCT01638273|Pregabalin, GLARS
1085018|NCT01638260|NEAT
1085019|NCT01638260|liraglutide
1085020|NCT01638260|glycemic control
1085021|NCT01638247|Male breast cancer
1085022|NCT01638247|neoadjuvant, adjuvant or metastatic situation
1085023|NCT01638247|anti-hormonal therapy
1085024|NCT01638234|atopic dermatitis
1085025|NCT01638234|eczema
1085026|NCT01638182|phylloquinone,
1085027|NCT01638182|menaquinone-7
1085028|NCT01638182|vitamin K-status
1085029|NCT01638182|efficacy
1085030|NCT01638156|Aortic stenosis
1085031|NCT01638143|vitamin K2
1085032|NCT01638143|menaquinone-7
1085033|NCT01638143|bioavailability
1085034|NCT01638091|Narrow band imaging
1085035|NCT01638091|Screening colonoscopy
1085036|NCT01638091|Histology
1085037|NCT01638078|coronary restenosis
1085038|NCT01638065|vein identification
1085039|NCT01638065|vascular access
1085040|NCT01638052|Tympanomastoid Surgery
1085041|NCT01638052|Cochlear Implant
1085042|NCT01638052|Mastoidectomy
1085043|NCT01638052|Cholesteatoma
1085044|NCT01638052|Pediatrics
1085045|NCT01638052|Clonidine
1085046|NCT01638052|Bupivacaine
1085047|NCT01638052|Greater Auricular Nerve Block
1085048|NCT01638052|Regional Anesthesia
1085049|NCT01638026|Gnrh agonist
1085050|NCT01638013|Rheumatoid Arthritis
1085051|NCT01638013|ASP015K
1085052|NCT01638000|Vesitrim
1085053|NCT01638000|Frequency
1085054|NCT01638000|Urgency
1085055|NCT01638000|Urgency incontinence
1085056|NCT01638000|Urinary incontinence
1085057|NCT01638000|Overactive Bladder (OAB)
1085058|NCT01638000|Micturition
1085059|NCT01638000|Mirabegron
1085060|NCT01638000|YM178
1085061|NCT01638000|Vesicare
1085062|NCT01638000|Solifenacin
1085063|NCT01637987|Peripheral intravenous catheter
1085064|NCT01637987|Vein visualization
1085065|NCT01637987|Transillumination
1085066|NCT01637987|Near infrared light
1085067|NCT01637948|Chinese medicine
1085068|NCT01637948|gingivitis
1085069|NCT01637948|cytokine
1085070|NCT01637948|microbial
1085071|NCT01637935|Drug therapy
1085072|NCT01637909|Prehypertension, Hypertension
1085073|NCT01637883|benzydamine HCl
1085074|NCT01637883|endotracheal tube
1085075|NCT01637883|postoperative sore throat
1085076|NCT01637870|Cesarean delivery
1085077|NCT01637870|Postpartum infection
1085078|NCT01637870|Wound complications
1085079|NCT01637870|Wound seroma
1085080|NCT01637870|Wound separation
1085081|NCT01637870|Wound infection
1085082|NCT01637870|Negative pressure
1085083|NCT01637857|foof hypersensitivity
1085084|NCT01637857|anal fissures
1085085|NCT01637857|ano-rectal manometry
1085086|NCT01637844|Pregnant women
1085087|NCT01637844|HBsAg positive
1085088|NCT01637844|HBeAg positive
1085089|NCT01637844|Telbivudine
1085090|NCT01637831|Obstructive Sleep Apnea
1085091|NCT01637831|Idiopathic Pulmonary Fibrosis
1085092|NCT01637818|Inguinal hernia repair
1085093|NCT01637818|long-term follow-up
1085094|NCT01637818|Surgical technique
1085095|NCT01637792|peritoneal dialysis
1085096|NCT01637792|dose
1085097|NCT01637792|residual kidney function
1085098|NCT01637792|technique survival
1085099|NCT01637792|patient survival
1085100|NCT01637792|peritonitis
1085101|NCT01637779|randomized controlled trial
1085102|NCT01637779|parent education
1085103|NCT01637779|pain management
1085104|NCT01637779|infant
1085105|NCT01637779|immunization
1085106|NCT01637766|Spinal Metastases
1085107|NCT01637766|Spinal Metastatic Disease
1085108|NCT01637766|Cord Compression
1085109|NCT01637766|Intra-arterial Chemotherapy
1085110|NCT01637766|Spinal Tumors
1085111|NCT01637740|myopia
1085112|NCT01637740|pseudoexfoliation syndrome
1085113|NCT01637740|optical low coherence reflectometry
1085114|NCT01637740|ocular optical components
1085115|NCT01637740|cataract
1085116|NCT01637727|Long term effects of gestational diabetes mellitus in a population of parous women
1085117|NCT01637727|Gestational diabetes mellitus- GDM is defined as glucose intolerance diagnosed during pregnancy and not present shortly after birth
1085118|NCT01637701|benign prostatic hypertrophy
1085119|NCT01637701|bipolar transurethral resection of the prostate
1085120|NCT01637701|plasmakinetic enucleation of the prostate
1085121|NCT01637688|cow milk allergy
1085122|NCT01637688|amino acid formula
1085123|NCT01637675|sodium tanshinone IIA sulfonate
1085124|NCT01637675|pulmonary hypertension
1085125|NCT01637649|dysphagia,diaphragm, ultrasonography, inspiration, expiration,
1085126|NCT01637636|rifampin,
1085127|NCT01637636|ketoconazole,
1085128|NCT01637636|CYP3A4,
1085129|NCT01637636|tasimelteon,
1085130|NCT01637636|VEC-162
1085131|NCT01637636|Pharmacokinetics
1085132|NCT01637623|Hypertension
1085133|NCT01637623|High Blood Pressure
1085134|NCT01637623|Sleep Apnea
1085135|NCT01637623|Obstructive Sleep Apnea
1085136|NCT01637623|OSA
1085137|NCT01637610|placental alpha microglobulin-1
1085138|NCT01637610|AmniSure
1085139|NCT01637610|preterm
1085140|NCT01637610|rupture of fetal membranes
1085141|NCT01637597|Non-small cell lung cancer(NSCLC)
1085142|NCT01637571|GERD
1085143|NCT01637571|NCCP
1085144|NCT01637571|chest pain
1085145|NCT01637571|reflux
1085146|NCT01637571|GERD related non-cardiac chest pain
1085147|NCT01637545|facial bones
1085148|NCT01637545|Post operative nasea vomiting
1085149|NCT01637545|fractures
1085150|NCT01637545|reduction
1085151|NCT01637519|kidney stones
1085152|NCT01637519|ureteral stones
1085153|NCT01637519|stent
1085154|NCT01637506|urine
1085155|NCT01637506|stool
1085156|NCT01637506|kidney stones
1085157|NCT01637493|Pegylation
1085158|NCT01637493|G-CSF
1085159|NCT01637493|Pharmacokinetics
1085160|NCT01637493|Pharmacodynamics
1085161|NCT01637467|critical illness
1085162|NCT01637467|myopathy
1085163|NCT01637467|electrical muscle stimulation
1085164|NCT01637454|noradrenaline terlipressin type 2 HRS
1085165|NCT01637441|bladder prolapse (cystocele)
1085166|NCT01637441|Pelvic organ prolapse repair
1085167|NCT01637441|coelioscopic
1085168|NCT01637441|prosthetic surgery
1085169|NCT01637441|vaginal approach
1085170|NCT01637441|Randomized study
1085171|NCT01637441|laparoscopic sacropexy
1085172|NCT01637441|vaginal mesh surgery
1085173|NCT01637441|Stage II
1085174|NCT01637441|Clavien Dindo
1085175|NCT01637415|alcohol withdrawal syndrome
1085176|NCT01637415|prediction
1085177|NCT01637415|severity
1085178|NCT01637415|alcohol use disorder
1085179|NCT01637415|complicated alcohol withdrawal
1085180|NCT01637415|alcohol withdrawal seizures
1085181|NCT01637415|delirium tremens
1085182|NCT01637415|PAWSS
1085183|NCT01637402|CRPC
1085184|NCT01637402|prostate
1085185|NCT01637402|cancer
1085186|NCT01637376|Lung neoplasms
1085187|NCT01637376|Non Small cell lung carcinoma
1085188|NCT01637376|Non small cell lung cancer
1085189|NCT01637376|Large cell carcinoma
1085190|NCT01637376|squamous cell carcinoma
1085191|NCT01637376|adenocarcinoma
1085192|NCT01637363|Psychoeducation
1085193|NCT01637363|Stress
1085194|NCT01637363|Sickness absence
1085195|NCT01637363|Psychiatric symptoms
1085196|NCT01637363|Locus of control
1085197|NCT01637363|Self reported health
1085198|NCT01637324|To assess VCT and linkage into care
1085199|NCT01637324|nPEP
1085200|NCT01637324|STIs
1085201|NCT01637324|anal dysplasia/cancer
1085202|NCT01637324|hyperlipidemia
1085203|NCT01637324|diabetes
1085204|NCT01637324|Proportion of first-time MSM clients attending multidisciplinary services who undergo HIV testing
1085205|NCT01637324|Proportion of MSM clients who have repeated HIV testing during the first six months after the first negative HIV test
1085206|NCT01637324|Proportion of HIV-positive MSM who receive HIV care within three months after HIV diagnosis or enrolment
1085207|NCT01637324|Proportion of HIV-positive MSM who still remain in HIV care at six months after enrollment
1085208|NCT01637311|Peroral endoscopic myotomy
1085209|NCT01637311|Heller myotomy
1085210|NCT01637311|persistent/recurrent achalasia.
1085211|NCT01637298|Histological HGAIN
1085212|NCT01637298|detected biomarkers
1085213|NCT01637298|MSM population
1085214|NCT01637298|HPV subtypes
1085215|NCT01637298|AIN study
1085216|NCT01637298|HIV-positive and HIV-negative MSM
1085217|NCT01637298|anal cytology and biomarkers
1085218|NCT01637298|likelihood of AIN development at month 12 and yearly thereafter
1085219|NCT01637272|Dumping syndrome
1085220|NCT01637272|SOM230
1085221|NCT01637272|pasireotide LAR
1085222|NCT01637259|proteinuria
1085223|NCT01637259|HIV
1085224|NCT01637233|HIV-1 infection
1085225|NCT01637233|neurocognitive function
1085226|NCT01637233|switch study
1085227|NCT01637220|Anaphylaxis
1085228|NCT01637220|Neutrophils
1085229|NCT01637220|Platelet activating factor
1085230|NCT01637220|Neutrophil Extracellular Traps (NETs)
1085231|NCT01637168|Disorders of cognitive function
1085232|NCT01637155|Cholecalciferol
1085233|NCT01637129|Childhood stroke
1085234|NCT01637129|Perinatal stroke
1085235|NCT01637129|Pediatric stroke
1085236|NCT01637129|Presumed perinatal stroke
1085237|NCT01637129|Children who have hemiparesis
1085238|NCT01637103|Cancer
1085239|NCT01637103|Depression
1085240|NCT01637103|Anxiety
1085241|NCT01637103|Fatigue
1085242|NCT01637103|Sleep
1085243|NCT01637103|Quality of life
1085244|NCT01637103|Cognitive therapy
1085245|NCT01637103|Bright light therapy
1085246|NCT01637064|Myositis
1085247|NCT01637064|Acthar treatment
1085248|NCT01637038|ischemia/reperfusion injury
1085249|NCT01637038|remote ischemic postconditioning
1085250|NCT01637012|ALEX
1085251|NCT01637012|coronary stent
1085252|NCT01637012|cobalt-chromium
1085253|NCT01637012|sirolimus
1085254|NCT01637012|OCT
1085255|NCT01636999|Sedara
1085256|NCT01636999|Nitrous Oxide
1085257|NCT01636999|Butorphanol
1085258|NCT01636999|Visual Analog Scale
1085259|NCT01636986|myopia
1085260|NCT01636986|contact lenses
1085261|NCT01636986|dry eyes
1085262|NCT01636986|comfort
1085263|NCT01636986|replacement
1085264|NCT01636973|Lung cancer
1085265|NCT01636947|chemotherapy
1085266|NCT01636947|nausea
1085267|NCT01636947|vomiting
1085268|NCT01636947|emetogenic
1085269|NCT01636947|cancer
1085270|NCT01636947|antiemetics
1085271|NCT01636947|tumor
1085272|NCT01636934|Lung Cancer
1085273|NCT01636934|Non Small Cell Lung Cancer
1085274|NCT01636934|NSCLC
1085275|NCT01636934|Symptom Burden
1085276|NCT01636934|Chemoradiation
1085277|NCT01636934|CXRT
1085278|NCT01636934|Minocycline
1085279|NCT01636934|Dynacin
1085280|NCT01636934|Minocin
1085281|NCT01636934|Minocin PAC
1085282|NCT01636934|Myrac
1085283|NCT01636934|Solodyn
1085284|NCT01636934|Placebo
1085285|NCT01636934|Sugar Pill
1085286|NCT01636934|Questionnaires
1085287|NCT01636934|Surveys
1085288|NCT01636921|Non-Small Cell Lung Cancer
1085289|NCT01636921|Lung Cancer
1085290|NCT01636921|NSCLC
1085291|NCT01636921|Radiation Therapy
1085292|NCT01636921|Sorafenib
1085293|NCT01636921|BAY 43-9006
1085294|NCT01636921|Thoracic Radiation
1085295|NCT01636895|malaria
1085296|NCT01636895|pregnancy
1085297|NCT01636895|prevention
1085298|NCT01636895|treatment
1085299|NCT01636895|molecular markers
1085300|NCT01636882|Melanoma
1085301|NCT01636882|CALM
1085302|NCT01636869|bupivacaine level
1085303|NCT01636869|periarticular block
1085304|NCT01636869|total knee arthroplasty
1085305|NCT01636856|oropharyngeal exercises, obstructive sleep apnea, speech therapy, magnetic resonance, PCRIT, negative expiratory pressure, snore
1085306|NCT01636830|Toothbrushing
1085307|NCT01636830|gingival recession
1085308|NCT01636804|Quicksite
1085309|NCT01636804|Quickflex
1085310|NCT01636804|St. Jude Medical
1085311|NCT01636778|Thrombocytopenia
1085312|NCT01636778|Hepatitis C, chronic
1085313|NCT01636739|Intussusceptions
1085314|NCT01636739|Special Drug Use Investigation
1085315|NCT01636739|Rotavirus
1085316|NCT01636726|COPD
1085317|NCT01636726|AMI
1085318|NCT01636726|Asthma
1085319|NCT01636726|LABAs
1085320|NCT01636700|Tramadol infiltration
1085321|NCT01636700|Analgesic effect
1085322|NCT01636700|Serum IL-6
1085323|NCT01636687|Psoriasis
1085324|NCT01636687|Moderate to Severe Plaque-type Psoriasis
1085325|NCT01636674|positron emission tomography
1085326|NCT01636674|computed tomography
1085327|NCT01636674|fluordeoxyglucose
1085328|NCT01636674|colon cancer
1085329|NCT01636674|cancer
1085330|NCT01636674|staging
1085331|NCT01636674|imaging
1085332|NCT01636648|Aortic Valve Replacement
1085333|NCT01636648|Aortic Valve Bioprosthesis
1085334|NCT01636622|Advanced Cancers
1085335|NCT01636622|Advanced Malignancy
1085336|NCT01636622|BRAF Mutation
1085337|NCT01636622|Advanced solid tumor
1085338|NCT01636622|Lymphoma
1085339|NCT01636622|Vemurafenib
1085340|NCT01636622|PLX4032
1085341|NCT01636622|RO5185426
1085342|NCT01636622|Carboplatin
1085343|NCT01636622|Paraplatin
1085344|NCT01636622|Paclitaxel
1085345|NCT01636622|Taxol
1085346|NCT01636609|Leukemia
1085347|NCT01636609|Acute Myeloid Leukemia
1085348|NCT01636609|AML
1085349|NCT01636609|Myelodysplastic Syndromes
1085350|NCT01636609|MDS
1085351|NCT01636609|Relapsed
1085352|NCT01636609|Refractory
1085353|NCT01636609|Cytarabine
1085354|NCT01636609|ARA-C
1085355|NCT01636609|Cytosar
1085356|NCT01636609|DepoCyt
1085357|NCT01636609|Cytosine Arabinosine
1085358|NCT01636609|5-Azacytidine
1085359|NCT01636609|Azacitidine
1085360|NCT01636609|5-aza
1085361|NCT01636609|Vidaza
1085362|NCT01636609|5-AZC
1085363|NCT01636609|AZA-CR
1085364|NCT01636609|Ladakamycin
1085365|NCT01636609|NSC-102816
1085366|NCT01636609|Tosedostat
1085367|NCT01636596|Alzheimer's Disease
1085368|NCT01636596|Mild Cognitive Impairment
1085369|NCT01636596|Insulin
1085370|NCT01636596|Pulsatile
1085371|NCT01636583|zinc
1085372|NCT01636583|absorption
1085373|NCT01636583|bio-availability
1085374|NCT01636583|aqueous zinc
1085375|NCT01636583|zinc deficiency
1085376|NCT01636583|zinc fortification
1085377|NCT01636570|Vitamin D
1085378|NCT01636570|Cholecalciferol
1085379|NCT01636570|Heart Failure
1085380|NCT01636570|Congestive heart failure
1085381|NCT01636570|Cardiomyopathy
1085382|NCT01636570|Strength
1085383|NCT01636570|Parathyroid Hormone
1085384|NCT01636570|Calcium
1085385|NCT01636570|Quality of Life
1085386|NCT01636570|C reactive protein
1085387|NCT01636570|Cardiopulmonary exercise testing
1085388|NCT01636570|Prognosis
1085389|NCT01636557|Rheumatoid arthritis
1085390|NCT01636557|sirukumab
1085391|NCT01636557|CNTO 136
1085392|NCT01636557|CYP450 enzyme
1085393|NCT01636557|anti-interleukin-6 monoclonal antibody
1085394|NCT01636466|Chronic allograft failure
1085395|NCT01636466|Kidney Transplantation
1085396|NCT01636453|wide-neck
1085397|NCT01636453|saccular
1085398|NCT01636453|intracranial aneurysms
1085399|NCT01636453|ICA
1085400|NCT01636453|Stent assisted coiling
1085401|NCT01636453|Liberty Stent
1085402|NCT01636440|Conditioned Pain Modulation
1085403|NCT01636427|myocardial infarction
1085404|NCT01636427|coronary angiography
1085405|NCT01636427|STEMI
1085406|NCT01636427|NSTEMI
1085407|NCT01636414|Total joint arthroplasty, blood loss
1085408|NCT01636388|Relapsed Hodgkins Lymphoma
1085409|NCT01636388|Refractory Hodgkins Lymphoma
1085410|NCT01636388|Allogeneic Stem Cell Transplantation
1085411|NCT01636388|Adoptive Immunotherapy
1085412|NCT01636388|Cellular Therapy
1085413|NCT01636388|Cytotoxic T cell lymphocytes
1085414|NCT01636362|Partial-thickness second degree burns
1085415|NCT01636362|Mepitel Ag
1085416|NCT01636362|Silver dressing
1085417|NCT01636349|Type 2 diabetes
1085418|NCT01636349|hypertension
1085419|NCT01636349|obesity
1085420|NCT01636349|metabolic syndrome
1085421|NCT01636297|Parkinson's disease
1085422|NCT01636297|Exercise
1085423|NCT01636284|Liver Cancer
1085424|NCT01636284|HCC
1085425|NCT01636284|first line HCC
1085426|NCT01636284|Pexa-Vec
1085427|NCT01636284|JX-594
1085428|NCT01636271|CV Risk
1085429|NCT01636271|Cardiovascular Disease
1085430|NCT01636271|Atherosclerosis
1085431|NCT01636271|Acute coronary syndrome
1085432|NCT01636258|Prediabetes
1085433|NCT01636258|Overweight
1085434|NCT01636258|African American
1085435|NCT01636258|Women
1085436|NCT01636258|Cooking
1085437|NCT01636258|Nutrition
1085438|NCT01636258|Exercise
1085439|NCT01636258|Stress Management
1085440|NCT01636245|71 vaccine
1085441|NCT01636245|HFMD
1085442|NCT01636245|consistency of three consecutive lots
1085443|NCT01636245|immunogenicity
1085444|NCT01636232|Vitamin D
1085445|NCT01636232|infection
1085446|NCT01636232|disease severity
1085447|NCT01636232|mortality
1085448|NCT01636232|critically ill
1085449|NCT01636232|sepsis
1085450|NCT01636219|Spirometry,
1085451|NCT01636219|Cough
1085452|NCT01636193|Rotavirus
1085453|NCT01636193|Rotarix
1085454|NCT01636193|Drug Use Investigation
1085455|NCT01636193|Safety
1085456|NCT01636180|STEMI
1085457|NCT01636180|NSTEMI
1085458|NCT01636180|clopidogrel
1085459|NCT01636180|Areplex
1085460|NCT01636180|REL-0609
1085461|NCT01636154|fire-heat syndrome
1085462|NCT01636154|blood stasis syndrome
1085463|NCT01636154|method of clearing heat
1085464|NCT01636154|method of promoting blood circulation
1085465|NCT01636154|medicinal fractions-based herbal combinations
1085466|NCT01636141|Safety
1085467|NCT01636141|Tolerability
1085468|NCT01636141|Pharmacokinetics
1085469|NCT01636141|Dose escalation
1085470|NCT01636141|Randomized
1085471|NCT01636141|Healthy volunteers
1085472|NCT01636141|Topical
1085473|NCT01636141|OLT1177
1085474|NCT01636141|Olatec
1085475|NCT01636141|Pain
1085476|NCT01636141|Inflammation
1085477|NCT01636128|Urinary
1085478|NCT01636128|biomarkers
1085479|NCT01636128|DFMO
1085480|NCT01636128|sulindac
1085481|NCT01636102|Influenza
1085482|NCT01636102|Adults
1085483|NCT01636102|Elderly
1085484|NCT01636102|Immunology
1085485|NCT01636102|Safety
1085486|NCT01636089|intensive care unit
1085487|NCT01636076|COPD
1085488|NCT01636063|Induced Abortion
1085489|NCT01636063|Abortion Techniques
1085490|NCT01636063|Mifepristone
1085491|NCT01636063|Misoprostol
1085492|NCT01636063|Initial Cervical Dilation
1085493|NCT01636050|squat exercise
1085494|NCT01636037|schizophrenia
1085495|NCT01636037|negative symptoms
1085496|NCT01636037|deficit syndrome
1085497|NCT01636037|SANS
1085498|NCT01636037|Sinemet
1085499|NCT01636037|L-dopa
1085500|NCT01636037|levodopa
1085501|NCT01636037|carbidopa
1085502|NCT01636037|augmentation
1085503|NCT01636037|antipsychotics
1085504|NCT01636024|Phase 1,
1085505|NCT01636024|healthy volunteers,
1085506|NCT01636024|safety,
1085507|NCT01636024|tolerability,
1085508|NCT01636024|pharmacokinetics,
1085509|NCT01636024|pharmacodynamics,
1085510|NCT01636024|single ascending dose study,
1085511|NCT01636024|multiple
1085512|NCT01636011|Parkinson's Disease
1085513|NCT01636011|Osteopathic Manipulative Medicine
1085514|NCT01636011|Speech
1085515|NCT01636011|Pulmonary Function
1085516|NCT01635998|renal sympathetic denervation
1085517|NCT01635998|renal catheter ablation
1085518|NCT01635998|hypertension
1085519|NCT01635985|Phase I, Healthy male volunteers, pharmacokinetics
1085520|NCT01635972|Isavuconazole
1085521|NCT01635972|Bupropion
1085522|NCT01635972|Bupropion hydrochloride
1085523|NCT01635972|Healthy Volunteers
1085524|NCT01635972|BAL8557
1085525|NCT01635972|BAL4815
1085526|NCT01635972|BAL8728
1085527|NCT01635959|upper gastro-intestinal symptoms, GERD
1085528|NCT01635946|Isavuconazole
1085529|NCT01635946|Atorvastatin
1085530|NCT01635946|Healthy Volunteers
1085531|NCT01635946|BAL8557
1085532|NCT01635946|BAL4815
1085533|NCT01635946|BAL8728
1085534|NCT01635933|contact lenses
1085535|NCT01635933|color contact lenses
1085536|NCT01635933|myopia
1085537|NCT01635920|contact lenses
1085538|NCT01635920|color contact lenses
1085539|NCT01635920|myopia
1085540|NCT01635894|female pelvic floor condition
1085541|NCT01635894|pelvic floor training
1085542|NCT01635894|supervised pelvic floor training
1085543|NCT01635894|practice nurse
1085544|NCT01635894|nurse specialist
1085545|NCT01635842|Patient
1085546|NCT01635842|information leaflet
1085547|NCT01635842|informed consent
1085548|NCT01635842|awareness
1085549|NCT01635829|Healthy participants
1085550|NCT01635829|Hepatitis C virus
1085551|NCT01635829|Telaprevir
1085552|NCT01635829|Phenytoin
1085553|NCT01635829|Carbamazepine
1085554|NCT01635829|HCV
1085555|NCT01635829|Interaction
1085556|NCT01635816|Immunogenicity
1085557|NCT01635816|SA 14-14-2 JE vaccine
1085558|NCT01635816|Bangladesh
1085559|NCT01635803|bevacizumab
1085560|NCT01635803|ranibizumab
1085561|NCT01635803|retinal vein occlusions
1085562|NCT01635803|randomized clinical trial
1085563|NCT01635803|Macular edema
1085564|NCT01635790|bevacizumab
1085565|NCT01635790|ranibizumab
1085566|NCT01635790|diabetic macular edema
1085567|NCT01635790|randomized clinical trial
1085568|NCT01635777|PKDL
1085569|NCT01635777|miltefosine
1085570|NCT01635764|hidradenitis suppurativa
1085571|NCT01635764|adalimumab
1085572|NCT01635764|open-label
1085573|NCT01635764|HS
1085574|NCT01635764|acne inversa
1085575|NCT01635764|PIONEER (OPEN-LABEL EXTENSION)
1085576|NCT01635764|acne
1085577|NCT01635764|tumor necrosis factor
1085578|NCT01635764|boil
1085579|NCT01635751|Pregabalin
1085580|NCT01635751|GLARS
1085581|NCT01635738|Probiotics
1085582|NCT01635738|Lactobacillus paracasei GMNL-133
1085583|NCT01635738|Lactobacillus fermentum GM-090
1085584|NCT01635738|Atopic dermatitis
1085585|NCT01635738|Asthma
1085586|NCT01635738|Lactobacillus paracasei
1085587|NCT01635738|Lactobacillus fermentum
1085588|NCT01635738|efficacy and safety
1085589|NCT01635725|colonoscopy
1085590|NCT01635725|bowel cleanliness
1085591|NCT01635725|bowel rating scale
1085592|NCT01635712|Hematological Malignancy
1085593|NCT01635712|Hsp90
1085594|NCT01635699|DNA oxidation
1085595|NCT01635699|obstructive sleep apnea
1085596|NCT01635699|lipid peroxidation
1085597|NCT01635699|oxidative stresses
1085598|NCT01635673|Exercise
1085599|NCT01635673|Latino
1085600|NCT01635673|Hispanic
1085601|NCT01635673|Boys
1085602|NCT01635660|Out-of-hospital
1085603|NCT01635660|airway management
1085604|NCT01635660|intubation
1085605|NCT01635660|video laryngoscope
1085606|NCT01635634|Fibromyalgia
1085607|NCT01635634|Cupping
1085608|NCT01635621|Olokizumab
1085609|NCT01635621|OKZ
1085610|NCT01635621|CDP6038
1085611|NCT01635621|Crohn's Disease
1085612|NCT01635621|CDAI
1085613|NCT01635621|IBDQ
1085614|NCT01635608|Pharmacokinetics
1085615|NCT01635608|Talinolol
1085616|NCT01635608|Amoxicillin
1085617|NCT01635608|Acetaminophen
1085618|NCT01635608|Magnetic Resonance Imaging
1085619|NCT01635582|Hand exercises
1085620|NCT01635582|Hand function
1085621|NCT01635582|Computer based exercises
1085622|NCT01635582|Therapeutic gaming
1085623|NCT01635569|Obsessive-compulsive disorder
1085624|NCT01635569|Pediatric
1085625|NCT01635569|Group-based
1085626|NCT01635569|Cognitive-behavioural therapy
1085627|NCT01635556|borderline personality disorder
1085628|NCT01635556|dialectical behavior therapy
1085629|NCT01635556|psychological treatment
1085630|NCT01635517|Diuretics
1085631|NCT01635517|Vasopressins
1085632|NCT01635517|Sodium
1085633|NCT01635504|HIV lipoatrophy
1085634|NCT01635504|masseter hypertrophy
1085635|NCT01635504|parotid enlargement
1085636|NCT01635504|botulinum toxin
1085637|NCT01635491|Gastrointestinal Motility
1085638|NCT01635491|Transit time
1085639|NCT01635426|Aspirin
1085640|NCT01635426|Clopidogrel
1085641|NCT01635426|Unexplained recurrent pregnancy loss
1085642|NCT01635426|Uterine artery pulsatility index
1085643|NCT01635400|Irinotecan
1085644|NCT01635400|UGT1A1 Gene Polymorphisms
1085645|NCT01635400|Small Cell Carcinoma of Lung
1085646|NCT01635348|gait speed
1085647|NCT01635348|cognitive processing speed
1085648|NCT01635335|HIV prevention
1085649|NCT01635335|adolescents
1085650|NCT01635335|Latinos
1085651|NCT01635335|Hispanics
1085652|NCT01635335|family
1085653|NCT01635335|health promotion
1085654|NCT01635335|disease prevention
1085655|NCT01635335|family communication
1085656|NCT01635335|parental supervision
1085657|NCT01635322|deformity
1085658|NCT01635322|adult
1085659|NCT01635322|lumbar
1085660|NCT01635322|thoraco-lumbar
1085661|NCT01635322|Sagittal vertebral Alignement (SVA)
1085662|NCT01635322|Oswestry Disability Index (ODI)
1085663|NCT01635257|pulmonary embolism diagnosis
1085664|NCT01635257|ultrasound
1085665|NCT01635244|Aortic valve prosthesis
1085666|NCT01635244|Aortic valve hemodynamics
1085667|NCT01635244|Prosthesis-patient mismatch
1085668|NCT01635244|Left ventricular diastolic function
1085669|NCT01635244|Left ventricular remodeling
1085670|NCT01635231|Nephrology
1085671|NCT01635231|sodium-channels
1085672|NCT01635231|water-channels
1085673|NCT01635231|BCM
1085674|NCT01635231|central blood pressure
1085675|NCT01635218|Depression
1085676|NCT01635218|Perimenopause
1085677|NCT01635218|Postmenopause
1085678|NCT01635218|Homeopathy
1085679|NCT01635205|Paraspinous block
1085680|NCT01635205|Non-responsive chronic pelvic pain
1085681|NCT01635192|renin
1085682|NCT01635192|angiotensin
1085683|NCT01635192|probiotic
1085684|NCT01635192|glucose absorption
1085685|NCT01635192|intestinal
1085686|NCT01635179|Videolaryngoscopy
1085687|NCT01635179|Bronchial Aspiration
1085688|NCT01635179|Hypoxia
1085689|NCT01635166|Arthroplasty
1085690|NCT01635166|Replacement
1085691|NCT01635166|Hip
1085692|NCT01635166|Cementless
1085693|NCT01635166|Ceramic on Ceramic
1085694|NCT01635153|HIV
1085695|NCT01635153|Tuberculosis
1085696|NCT01635153|Nutrition
1085697|NCT01635140|DIPG
1085698|NCT01635140|Hypofractionated Radiotherapy
1085699|NCT01635140|Radiotherapy
1085700|NCT01635140|Median survival
1085701|NCT01635101|Moderate to severe acute pain following surgery or trauma
1085702|NCT01635088|Asthma
1085703|NCT01635088|FEV1 and IOS change after mometasone for asthma
1085704|NCT01635075|psychiatric
1085705|NCT01635075|comorbidity
1085706|NCT01635075|craving
1085707|NCT01635075|tobacco
1085708|NCT01635049|in vitro fertilization
1085709|NCT01635049|assisted reproduction techniques
1085710|NCT01635049|noninvasive imaging of embryos
1085711|NCT01635049|time lapse imaging of embryos
1085712|NCT01635049|traditional morphological grading of embryos
1085713|NCT01635049|prediction of blastocysts
1085714|NCT01635049|infertility
1085715|NCT01635049|preimplantation genetic diagnosis
1085716|NCT01635049|comprehensive chromosome screening
1085717|NCT01635036|in vitro fertilization
1085718|NCT01635036|assisted reproduction techniques
1085719|NCT01635036|noninvasive imaging of embryos
1085720|NCT01635036|time lapse imaging of embryos
1085721|NCT01635036|traditional morphological grading of embryos
1085722|NCT01635036|prediction of blastocyst formation
1085723|NCT01635036|infertility
1085724|NCT01635036|male factor female factor
1085725|NCT01635036|embryo viability
1085726|NCT01635023|Phase I
1085727|NCT01635023|healthy volunteers
1085728|NCT01635023|AZD6244
1085729|NCT01635023|pharmacokinetics
1085730|NCT01635023|AUC
1085731|NCT01635023|Cmax
1085732|NCT01635023|tmax
1085733|NCT01635023|AUC(0-t)
1085734|NCT01635010|obstructive sleep apnea
1085735|NCT01635010|inflammation
1085736|NCT01635010|oxidative stress
1085737|NCT01635010|arterial stiffness
1085738|NCT01634997|Screening for Type 2 Diabetes
1085739|NCT01634984|expression of CDK5RAP2
1085740|NCT01634971|Postoperative pancreatic fistula(POPF);
1085741|NCT01634971|Postpancreatectomy hemorrhage(PPH);
1085742|NCT01634971|Delayed gastric emptying (DGE);
1085743|NCT01634971|Bile leakage after pancreatic surgery;
1085744|NCT01634971|Anastomotic leakage
1085745|NCT01634958|Allergic Rhinitis
1085746|NCT01634958|Hayfever
1085747|NCT01634958|Immunotherapy
1085748|NCT01634958|Dose-Finding-Study
1085749|NCT01634945|anemia
1085750|NCT01634945|malaria
1085751|NCT01634945|malnutrition
1085752|NCT01634945|iron fortification
1085753|NCT01634945|intermittent preventive treatment
1085754|NCT01634945|subsaharan africa
1085755|NCT01634945|ivory coast
1085756|NCT01634945|young children
1085757|NCT01634932|Iron deficiency
1085758|NCT01634932|Biofortification
1085759|NCT01634932|Pearl Millet
1085760|NCT01634932|Benin
1085761|NCT01634919|Chronic hepatitis C
1085762|NCT01634919|Liver fibrosis
1085763|NCT01634919|ARFI(Acoustic radiation force impulse)
1085764|NCT01634906|Apolipoprotein B, erythrocytes, statins
1085765|NCT01634893|Refractory or Relapsed Solid Tumors
1085766|NCT01634880|Salivary Gland Malignancies
1085767|NCT01634880|Panitumumab
1085768|NCT01634880|Postoperative
1085769|NCT01634880|Radiotherapy
1085770|NCT01634841|walnuts
1085771|NCT01634841|age related cognitive decline
1085772|NCT01634841|age related macular degeneration
1085773|NCT01634841|healthy elderly subjects
1085774|NCT01634802|Clinical Decision Support Systems
1085775|NCT01634802|Electronic Medical Record
1085776|NCT01634802|Resource constrained countries
1085777|NCT01634802|HIV
1085778|NCT01634789|bioavailability
1085779|NCT01634763|Phase I, open-label, dose escalation, oral LDK378, Japanese patients with tumors characterized by ALK genetic alterations
1085780|NCT01634750|N-Acetyl-D-mannosamine (ManNAc)
1085781|NCT01634750|HIBM
1085782|NCT01634750|GNE Myopathy
1085783|NCT01634737|shellfish
1085784|NCT01634737|tropomyosin
1085785|NCT01634737|mites
1085786|NCT01634737|food allergy
1085787|NCT01634724|GnRH agonist withdrawal
1085788|NCT01634724|OHSS
1085789|NCT01634724|E2
1085790|NCT01634724|VEGF
1085791|NCT01634711|ACL
1085792|NCT01634711|Anterior Cruciate Ligament
1085793|NCT01634711|Ligament
1085794|NCT01634711|Resorbable polymer
1085795|NCT01634711|Knee ligament
1085796|NCT01634698|chronic liver disease
1085797|NCT01634698|cirrhosis
1085798|NCT01634698|vitamin A
1085799|NCT01634698|RDR test
1085800|NCT01634698|retinol-binding protein
1085801|NCT01634685|Rectal cancer
1085802|NCT01634685|Bavituximab
1085803|NCT01634685|Capecitabine
1085804|NCT01634685|Radiation Therapy
1085805|NCT01634672|Gastroesophageal Reflux Disease
1085806|NCT01634672|peritoneal dialysis
1085807|NCT01634672|hemodialysis
1085808|NCT01634659|contact lenses
1085809|NCT01634659|myopia
1085810|NCT01634646|Observational study
1085811|NCT01634633|Endometrial nerve fibres
1085812|NCT01634620|Chronic Obstructive Pulmonary Disease (COPD)
1085813|NCT01634620|Chronic Obstructive Airways Disease
1085814|NCT01634620|Chronic Bronchitis
1085815|NCT01634620|Chronic Emphysema
1085816|NCT01634620|Asthma
1085817|NCT01634607|osteopenia
1085818|NCT01634607|vitamin D deficiency
1085819|NCT01634607|HIV-infected patients
1085820|NCT01634607|bone health
1085821|NCT01634607|Bone mineral density (BMD)
1085822|NCT01634607|HIV-uninfected patients
1085823|NCT01634607|effects of TDF on the patients' bone
1085824|NCT01634594|Deliberate hypotension, QTc, Tp-e, heart rate variability
1085825|NCT01634555|Advanced Malignant Solid Tumors
1085826|NCT01634516|Diet
1085827|NCT01634516|Pregnant
1085828|NCT01634503|3+3 design
1085829|NCT01634503|Phase 1
1085830|NCT01634503|Cervical Intraepithelial Neoplasia
1085831|NCT01634503|Adult
1085832|NCT01634503|Safety
1085833|NCT01634503|Dose Finding
1085834|NCT01634490|cow's milk allergy
1085835|NCT01634490|formulas
1085836|NCT01634490|probiotics
1085837|NCT01634477|morbidity
1085838|NCT01634477|mortality
1085839|NCT01634477|HIV-infected patients
1085840|NCT01634477|prospective cohort study
1085841|NCT01634477|highly active antiretroviral therapy (HAART)
1085842|NCT01634477|opportunistic infections
1085843|NCT01634477|Non HIV-related illness
1085844|NCT01634477|cardiovascular disease (CVD)
1085845|NCT01634477|HIV negative patients
1085846|NCT01634477|Thai HIV-infected patients
1085847|NCT01634451|Sedation
1085848|NCT01634451|Quality
1085849|NCT01634438|coronary angiography
1085850|NCT01634425|NSTEMI
1085851|NCT01634425|Point of Care Biomarkers
1085852|NCT01634334|Secondhand smoke
1085853|NCT01634295|CKD-828
1085854|NCT01634295|Hypertension
1085855|NCT01634295|Stage 2 Hypertension
1085856|NCT01634295|S-Amlodipine
1085857|NCT01634295|Telmisartan
1085858|NCT01634269|Valvular Heart Disease
1085859|NCT01634269|Severe Aortic Stenosis
1085860|NCT01634269|Aortic Valve Replacement
1085861|NCT01634243|SPM 962
1085862|NCT01634243|rotigotine
1085863|NCT01634243|Parkinson's disease
1085864|NCT01634204|weight reduction
1085865|NCT01634204|web-based intervention
1085866|NCT01634204|cost-effective
1085867|NCT01634204|overweight
1085868|NCT01634204|obesity
1085869|NCT01634204|cardiovascular risk
1085870|NCT01634191|Apremilast
1085871|NCT01634191|pharmacokinetic
1085872|NCT01634191|safety
1085873|NCT01634191|Pharmacokinetics and safety in healthy volunteer subjects
1085874|NCT01634178|Apremilast,
1085875|NCT01634178|pharmacokinetic
1085876|NCT01634178|safety
1085877|NCT01634178|Safety and pharmacokinetics in healthy volunteer subjects
1085878|NCT01634126|Colon
1085879|NCT01634126|Rectal
1085880|NCT01634126|Cancer
1085881|NCT01634126|Screening
1085882|NCT01634126|FIT
1085883|NCT01634126|Fecal
1086004|NCT01633437|MAOI
1086005|NCT01633437|cheese effect
1085884|NCT01634061|Castration-resistant prostate cancer, abiraterone acetate, BEZ235, BKM120, dose escalation, abiraterone acetate failure
1085885|NCT01634048|high protein diet
1085886|NCT01634048|meal replacements
1085887|NCT01634048|low calorie diet
1085888|NCT01634048|intra hepatocellular lipid
1085889|NCT01634035|glycated hemoglobin
1085890|NCT01634035|mean plasma glucose
1085891|NCT01634022|Acupuncture
1085892|NCT01634022|Antidepressant
1085893|NCT01634022|Monotherapy
1085894|NCT01634022|Depression
1085895|NCT01634022|Alternative treatments
1085896|NCT01634009|Severe acute malnutrition
1085897|NCT01634009|Ready to use therapeutic food
1085898|NCT01634009|Soy protein
1085899|NCT01634009|Community based management
1085900|NCT01634009|Efficacy
1085901|NCT01634009|Management of Children with SAM in Bangladesh
1085902|NCT01633996|Acupuncture
1085903|NCT01633996|Antidepressant
1085904|NCT01633996|Augmentation
1085905|NCT01633996|Depression
1085906|NCT01633983|Central Serous Chorioretinopathy
1085907|NCT01633983|Methotrexate
1085908|NCT01633957|anticoagulation
1085909|NCT01633957|bleeding
1085910|NCT01633957|CYP2C9
1085911|NCT01633957|CYP4F2
1085912|NCT01633957|VKORC1
1085913|NCT01633957|warfarin dosing
1085914|NCT01633957|Heart Valve Diseases
1085915|NCT01633957|pharmacogenomics
1085916|NCT01633944|CLBP
1085917|NCT01633944|Chronic Low Back Pain
1085918|NCT01633944|Chronic Pain
1085919|NCT01633944|Back Pain
1085920|NCT01633918|intervention
1085921|NCT01633918|health education
1085922|NCT01633918|physical activity
1085923|NCT01633918|sedentary behavior
1085924|NCT01633918|health promotion
1085925|NCT01633918|evaluation
1085926|NCT01633918|RE-AIM
1085927|NCT01633905|alcohol-dependence
1085928|NCT01633905|event-related potentials
1085929|NCT01633905|emotion
1085930|NCT01633905|crossmodal
1085931|NCT01633905|peripheral processing
1085932|NCT01633892|Craniomaxillofacial (CMF)
1085933|NCT01633892|Battle-injured (BI)
1085934|NCT01633892|Facial Trauma
1085935|NCT01633892|Fat Grafts
1085936|NCT01633892|Autogenous Fat Transfers (AFT)
1085937|NCT01633892|Wounded warriors
1085938|NCT01633892|Adipose Tissue
1085939|NCT01633879|parenting, prevention, HIV/AIDS, adolescents, Latino
1085940|NCT01633866|Magnetic Resonance Imaging
1085941|NCT01633853|chronic kidney disease mineral and bone disorder
1085942|NCT01633853|vitamin D2
1085943|NCT01633853|parathyroid hormone
1085944|NCT01633840|double-blind placebo-controlled food challenges
1085945|NCT01633840|food allergy
1085946|NCT01633840|food hypersensitivity
1085947|NCT01633840|triangle test
1085948|NCT01633840|validated recipes
1085949|NCT01633814|Physiological Processes
1085950|NCT01633814|Exercise
1085951|NCT01633814|Hormone replacement therapy
1085952|NCT01633775|Refractory primary open angle glaucoma
1085953|NCT01633775|trabeculectomy
1085954|NCT01633775|ahmed valve implant
1085955|NCT01633749|Influenza
1085956|NCT01633749|Vaccine
1085957|NCT01633749|CHMP criteria
1085958|NCT01633736|single blinded
1085959|NCT01633736|randomised
1085960|NCT01633736|controlled
1085961|NCT01633736|physiotherapy
1085962|NCT01633736|children
1085963|NCT01633736|cerebral palsy
1085964|NCT01633710|Ankle brachial pressure index
1085965|NCT01633710|Colour duplex ultrasound
1085966|NCT01633710|Diabetes
1085967|NCT01633710|Photoplethysmography
1085968|NCT01633697|emphysema
1085969|NCT01633697|chronic bronchitis
1085970|NCT01633684|diabetes mellitus
1085971|NCT01633684|bone
1085972|NCT01633671|Misadventures to Patients During Surgical and Medical Care
1085973|NCT01633671|Pulmonary Embolism Without Acute Cor Pulmonale
1085974|NCT01633671|Pulmonary Embolism Without Mention of Acute Cor Pulmonale
1085975|NCT01633658|vitamin D
1085976|NCT01633632|Smoking cessation
1085977|NCT01633632|Yoga
1085978|NCT01633632|Cognitive behavioral therapy
1085979|NCT01633619|Prosthetic Joint Infection
1085980|NCT01633606|severity of illness
1085981|NCT01633606|scoring
1085982|NCT01633606|medium care
1085983|NCT01633606|intensive care
1085984|NCT01633606|staffing
1085985|NCT01633580|ICSI
1085986|NCT01633580|GnRH antagonist
1085987|NCT01633580|corifollitropin alfa
1085988|NCT01633567|Smoking Cessation
1085989|NCT01633567|Cigarette Smoking
1085990|NCT01633567|Tobacco
1085991|NCT01633567|LGBT
1085992|NCT01633567|LGBTQ
1085993|NCT01633554|ST-2, IL-33, prediction, fibrosis, hepatitis B
1085994|NCT01633528|low dose aspirin endometrial thickness pregnancy rate ICSI IVF embryo transfer
1085995|NCT01633515|Basal cell carcinoma (BCC)
1085996|NCT01633515|Cryotherapy
1085997|NCT01633515|Cryosurgery
1085998|NCT01633476|CMV
1085999|NCT01633476|ANCA associated vasculitis
1086000|NCT01633476|CD4+CD28- T-cells
1086001|NCT01633476|Valaciclovir
1086002|NCT01633463|EMERGENCY CANCER PAIN, ASSESSMENT, TREATMENT ADEQUACY.
1086003|NCT01633437|tyramine
1086006|NCT01633437|depression
1086007|NCT01633398|Heart Failure
1086008|NCT01633398|HF
1086009|NCT01633385|bronchial inflammation
1086010|NCT01633385|Bronchiolitis obliterans
1086011|NCT01633385|Sputum
1086012|NCT01633385|Blood
1086013|NCT01633385|Inflammation
1086014|NCT01633385|adaptive immune system
1086015|NCT01633385|innate immune system
1086016|NCT01633372|Primary Myelofibrosis
1086017|NCT01633372|PMF
1086018|NCT01633372|Post Polycythemia Vera Fibrosis
1086019|NCT01633372|PPV-MF
1086020|NCT01633372|Post Essential Thrombocythemia Myelofibrosis
1086021|NCT01633372|PET-MF
1086022|NCT01633333|Colonoscopy
1086023|NCT01633333|Colorectal cancer
1086024|NCT01633333|Colorectal adenomas
1086025|NCT01633333|Pain
1086026|NCT01633320|Analgesia/Nociception index
1086027|NCT01633307|education
1086028|NCT01633307|intravenous infusion
1086029|NCT01633294|premature rupture of membranes
1086030|NCT01633294|term pregnancy
1086031|NCT01633294|chorioamnionitis
1086032|NCT01633294|endometritis
1086033|NCT01633294|neonatal sepsis
1086034|NCT01633294|antibiotic prophylaxis
1086035|NCT01633281|peripheral neuropathy
1086036|NCT01633281|acupuncture
1086037|NCT01633281|Bortezomib
1086038|NCT01633281|Thalidomide
1086039|NCT01633268|MRI (Magnetic Resonance Imaging)
1086040|NCT01633268|Traumatic Brain Injury
1086041|NCT01633255|Anti-Angiogenic
1086042|NCT01633255|Dynamic Contrast Enhanced Magnetic Resonance Imaging
1086043|NCT01633255|PET/CT Imaging Studies
1086044|NCT01633242|MRI
1086045|NCT01633242|Muscular Dystrophy
1086046|NCT01633242|Cardiac
1086047|NCT01633242|Myocardium
1086048|NCT01633242|Intramyocardial fat
1086049|NCT01633229|Immune Suppression
1086050|NCT01633229|BMSC
1086051|NCT01633229|GVHD
1086052|NCT01633229|Marrow Failure
1086053|NCT01633229|Regimen Related Toxicity
1086054|NCT01633229|Graft-Versus-Host Disease
1086055|NCT01633216|poliovirus,
1086056|NCT01633216|trivalent oral polio vaccine,
1086057|NCT01633216|bivalent oral polio vaccine,
1086058|NCT01633216|monovalent oral polio vaccine
1086059|NCT01633203|gastric cancer
1086060|NCT01633203|combination chemotherapy
1086061|NCT01633203|HER-2 gene
1086062|NCT01633203|quality of life
1086063|NCT01633190|Surveillance
1086064|NCT01633190|Rotavirus
1086065|NCT01633190|Gastroenteritis
1086066|NCT01633177|vitamin D
1086067|NCT01633177|omega-3 fatty acids
1086068|NCT01633177|Type 2 diabetes
1086069|NCT01633177|Oral glucose tolerance test (OGTT)
1086070|NCT01633177|Insulin sensitivity
1086071|NCT01633177|Beta-cell function
1086072|NCT01633164|Spinal Cord Injury
1086073|NCT01633164|Self-Efficacy
1086074|NCT01633164|Life Satisfaction
1086075|NCT01633164|Community Participation
1086076|NCT01633138|cognitive remediation therapy
1086077|NCT01633138|substance abuse treatment
1086078|NCT01633125|Group music therapy
1086079|NCT01633125|prisoners
1086080|NCT01633125|Anxiety
1086081|NCT01633125|Depression
1086082|NCT01633125|Self-esteem
1086083|NCT01633099|decitabine
1086084|NCT01633099|acute myeloid leukemia
1086085|NCT01633099|elderly patient
1086086|NCT01633060|BKM120
1086087|NCT01633060|fulvestrant
1086088|NCT01633060|breast cancer
1086089|NCT01633060|metastatic
1086090|NCT01633060|locally advanced
1086091|NCT01633060|AI treated
1086092|NCT01633060|mTOR inhibitor
1086093|NCT01633060|PI3K
1086094|NCT01633060|PIK3CA
1086095|NCT01633060|PTEN
1086096|NCT01633060|HER2-
1086097|NCT01633060|HR+
1086098|NCT01633047|Anterior Cruciate Ligament
1086099|NCT01633047|Electric Stimulation Therapy
1086100|NCT01633034|intervertebral disc degeneration
1086101|NCT01633034|back pain
1086102|NCT01633034|spine surgery
1086103|NCT01633021|Family Study
1086104|NCT01633021|Social Networks
1086105|NCT01633021|Diabetes
1086106|NCT01633008|Modified Brief Pain Inventory
1086107|NCT01633008|Quality of Life
1086108|NCT01633008|Pain-Related Coping
1086109|NCT01633008|Pain-Related Anxiety
1086110|NCT01633008|Depression
1086111|NCT01632982|opioid abuse
1086112|NCT01632982|substance abuse
1086113|NCT01632982|methadone maintenance treatment
1086114|NCT01632982|mobile technology
1086115|NCT01632982|technology-based intervention
1086116|NCT01632982|behavioral intervention
1086117|NCT01632982|psychosocial treatment
1086118|NCT01632969|12-136
1086119|NCT01632956|Support Groups
1086120|NCT01632956|Breast cancer
1086121|NCT01632956|Mandarin speaking
1086122|NCT01632956|12-105
1086123|NCT01632943|Uncontrolled Hypertension
1086124|NCT01632930|diagnosis
1086125|NCT01632930|prostate cancer
1086126|NCT01632930|urine
1086127|NCT01632930|medical economics
1086128|NCT01632917|Healthy volunteers
1086129|NCT01632904|Polycythemia Vera
1086130|NCT01632904|PV
1086131|NCT01632878|Secondary prevention post MI
1086132|NCT01632865|occlusion
1086133|NCT01632865|recanalization
1086134|NCT01632865|stenting
1086135|NCT01632839|PISQ-R
1086136|NCT01632839|new sexuality questionnaire
1086137|NCT01632826|Relapsed
1086138|NCT01632826|refractory multiple myeloma
1086139|NCT01632826|pomalidomide
1086140|NCT01632813|neurocognitive testing
1086141|NCT01632813|critical illness
1086142|NCT01632813|executive function
1086143|NCT01632813|intelligence
1086144|NCT01632800|Magnetic fields discomfort
1086145|NCT01632787|Anxiety
1086146|NCT01632787|Binocular
1086147|NCT01632787|Chronic Headache
1086148|NCT01632787|Dizziness
1086149|NCT01632787|Vertical Heterophoria
1086150|NCT01632787|Vision Dysfunction
1086151|NCT01632761|anemia
1086152|NCT01632761|vitamin D3
1086153|NCT01632761|omega-3 fatty acids
1086154|NCT01632761|fish oil
1086155|NCT01632761|primary prevention
1086156|NCT01632735|Continuing Care
1086157|NCT01632735|Youth Substance Abuse
1086158|NCT01632735|Recovery Support
1086159|NCT01632735|Mobile Texting
1086160|NCT01632722|colorectal cancer, liver metastasis, bevacizumab, perioperative/postoperative chemotherapy
1086161|NCT01632696|Antibodies, Monoclonal
1086162|NCT01632696|Biologics
1086163|NCT01632696|F(ab')2
1086164|NCT01632696|Positron-emission tomography (PET)
1086165|NCT01632696|Phosphatidylserine (PS)
1086166|NCT01632696|Solid Tumors
1086167|NCT01632696|Tumor Imaging
1086168|NCT01632683|difficult airway
1086169|NCT01632683|video laryngoscopy
1086170|NCT01632670|music
1086171|NCT01632670|cardiac catheterization
1086172|NCT01632670|endothelial function
1086173|NCT01632631|suitable for endovascular exclusion
1086174|NCT01632605|ADPKD
1086175|NCT01632605|Autosomal dominant polycystic kidney disease
1086176|NCT01632605|Sirolimus
1086177|NCT01632605|Rapamune
1086178|NCT01632605|Polycystic liver disease
1086179|NCT01632605|Rapamycin
1086180|NCT01632605|Mammalian target of rapamycin
1086181|NCT01632605|m-TOR
1086182|NCT01632605|m-TOR inhibition
1086183|NCT01632553|Observation
1086184|NCT01632553|Domestic Violence
1086185|NCT01632553|Partner Abuse
1086186|NCT01632553|Spousal Abuse
1086187|NCT01632553|Battered Women
1086188|NCT01632553|Abused Women
1086189|NCT01632553|Cortisol
1086190|NCT01632553|Mental Health
1086191|NCT01632553|Depression
1086192|NCT01632553|Anxiety
1086193|NCT01632553|Posttraumatic Stress Disorders
1086194|NCT01632527|Age-Related Macular Degeneration
1086195|NCT01632527|Dry AMD with GA
1086196|NCT01632527|Geographic Atrophy of Age-Related Macular Degeneration
1086197|NCT01632527|Stem Cell Transplantation
1086198|NCT01632527|Stem Cell transplant
1086199|NCT01632527|Stem cells for AMD
1086200|NCT01632527|Human neural stem cells
1086201|NCT01632527|multipotent stem cells
1086202|NCT01632527|Macular Degeneration
1086203|NCT01632527|Dry AMD
1086204|NCT01632527|Human central nervous system stemcells
1086205|NCT01632527|dry age-related macular degeneration
1086206|NCT01632514|hypocalcemia
1086207|NCT01632514|vitamin D deficiency
1086208|NCT01632514|cholecalciferol
1086209|NCT01632514|thyroidectomy
1086210|NCT01632488|Irritable Bowel Syndrome
1086211|NCT01632488|Inflammatory Bowel Disease
1086212|NCT01632488|Confocal Laser Endomicroscopy
1086213|NCT01632475|Human umbilical cord blood-derived mesenchymal stem cells
1086214|NCT01632475|Premature infants
1086215|NCT01632475|Bronchopulmonary dysplasia
1086216|NCT01632475|Lung injury
1086217|NCT01632475|Lung diseases
1086218|NCT01632475|Hyperplasia
1086219|NCT01632475|Ventilator-induced lung injury
1086220|NCT01632475|Respiratory lung diseases
1086221|NCT01632475|Pathologic Processes
1086222|NCT01632475|Infant, Premature, Diseases
1086223|NCT01632475|Infant, Newborn, Diseases
1086224|NCT01632462|Crohn's disease
1086225|NCT01632462|VSL#3
1086226|NCT01632462|probiotics
1086227|NCT01632462|metabolic profile
1086228|NCT01632449|bioequivalence
1086229|NCT01632436|Hepatic impairment
1086230|NCT01632436|Metastatic Cancer
1086231|NCT01632410|autonomic nerve system
1086232|NCT01632410|post stroke
1086233|NCT01632410|focus of study: to describe the autonomic nerve system function post stroke
1086234|NCT01632410|autonomic nervous system
1086235|NCT01632397|PrEP
1086236|NCT01632397|HIV
1086237|NCT01632397|Adherence
1086238|NCT01632397|MSM
1086239|NCT01632397|Men having sex with men
1086240|NCT01632384|Smoker
1086241|NCT01632384|Non-Smoker
1086242|NCT01632384|Healthy
1086243|NCT01632384|Drug free
1086244|NCT01632384|MRI
1086245|NCT01632371|In-stent Restenosis
1086246|NCT01632371|Drug Eluting Stent
1086247|NCT01632371|Paclitaxel Coated Balloon
1086248|NCT01632371|Scoring Balloon
1086249|NCT01632371|Cutting Balloon
1086250|NCT01632371|Angiographic follow-up
1086251|NCT01632371|Optical coherence tomography (OCT)
1086252|NCT01632358|safety
1086253|NCT01632358|tolerability
1086254|NCT01632358|pharmacokinetics
1086255|NCT01632280|Obesity
1086256|NCT01632280|Gastric Banding
1086257|NCT01632280|Transcranial Direct Current Stimulation
1086268|NCT01632215|gabapentine
1086269|NCT01632215|postoperative pain
1086270|NCT01632202|submucosal myomas
1086271|NCT01632202|intrauterine adhesions
1086272|NCT01632202|hysteroscopic myomectomy
1086273|NCT01632202|seprafilm
1086274|NCT01632189|Varenicline
1086275|NCT01632189|PET imaging
1086276|NCT01632189|[11C]-(+)-PHNO PET
1086277|NCT01632189|neuroimaging in smokers
1086278|NCT01632176|dating abuse
1086279|NCT01632176|dating violence
1086280|NCT01632176|domestic violence
1086281|NCT01632176|sexual violence
1086282|NCT01632176|sexual assault
1086283|NCT01632176|youth violence
1086284|NCT01632176|underage alcohol use
1086285|NCT01632176|alcohol use
1086286|NCT01632098|psychosocial
1086287|NCT01632098|healthcare
1086288|NCT01632098|co-morbidities
1086289|NCT01632098|extremely obese adolescents
1086290|NCT01632059|ADMA
1086291|NCT01632059|DDAH II
1086292|NCT01632059|SAPS
1086293|NCT01632059|SOFA
1086294|NCT01632059|Sepsis
1086295|NCT01632059|Procalcitonin
1086296|NCT01632059|ICU
1086297|NCT01632059|mortality
1086298|NCT01632059|length of stay
1086299|NCT01632046|peritoneal dialysis
1086300|NCT01632046|bicarbonate/lactate buffer
1086301|NCT01632046|peritoneal transport capacity
1086302|NCT01632046|ultrafiltration
1086303|NCT01632046|children
1086304|NCT01632033|Peripheral artery disease
1086305|NCT01632033|claudication
1086306|NCT01632033|walking
1086307|NCT01632033|questionnaire
1086308|NCT01632020|colorectal tumor
1086309|NCT01632020|colorectal cancer
1086310|NCT01632020|colorectal carcinoma
1086311|NCT01632020|neoplasms, colorectal
1086312|NCT01632020|Metformin
1086313|NCT01631994|metoclopramide video capsule endoscopy gastric transit time
1086314|NCT01631955|Acute cystitis
1086315|NCT01631955|Antibiotics
1086316|NCT01631955|Quality of life
1086317|NCT01631929|Diabetes
1086318|NCT01631929|Ketoacidosis
1086319|NCT01631929|Children
1086320|NCT01631916|community-acquired pneumonia
1086321|NCT01631916|children
1086322|NCT01631916|respiratory infections
1086323|NCT01631864|Hypertension, obesity, insulin sensitivity, lipolysis, LCZ696
1086324|NCT01631851|Autism
1086325|NCT01631851|Irritability
1086326|NCT01631851|Disruptive Behavior
1086327|NCT01631851|Aggression
1086328|NCT01631851|Behavior Therapy
1086329|NCT01631851|Cognitive Behavioral Therapy
1086330|NCT01631838|Tocotrienols
1086331|NCT01631838|Platelet aggregation
1086332|NCT01631838|Metabolic syndrome
1086333|NCT01631838|Platelet activation
1086334|NCT01631838|Thrombosis
1086335|NCT01631825|SPM 962
1086336|NCT01631825|rotigotine
1086337|NCT01631825|Parkinson's disease
1086338|NCT01631825|concomitant use of L-dopa
1086339|NCT01631812|SPM 962
1086340|NCT01631812|rotigotine
1086341|NCT01631812|Parkinson's disease
1086342|NCT01631812|concomitant use of L-dopa
1086343|NCT01631799|epidural anesthesia
1086344|NCT01631799|femoral block
1086345|NCT01631799|patient control analgesia
1086346|NCT01631786|Ovaries
1086347|NCT01631786|Imaging
1086348|NCT01631786|Ultrasonography
1086349|NCT01631786|Synchrotron
1086350|NCT01631786|Histology
1086351|NCT01631773|Aspirin-exacerbated respiratory disease
1086352|NCT01631773|Nasal polyp
1086353|NCT01631760|Asthma
1086354|NCT01631760|Asthma Exacerbations
1086355|NCT01631747|Pregnancy
1086356|NCT01631747|Weight gain
1086357|NCT01631747|Obesity
1086358|NCT01631747|Pregnancy and weight gain
1086359|NCT01631721|adolescent couple decision-making
1086360|NCT01631721|parenting practices
1086361|NCT01631721|sexual risk behavior
1086362|NCT01631708|Hereditary haemochromatosis
1086363|NCT01631708|Moderate iron overload
1086364|NCT01631708|Serum ferritin
1086365|NCT01631708|Treatment
1086366|NCT01631682|Posttraumatic Stress Disorder
1086367|NCT01631682|PTSD
1086368|NCT01631682|Anxiety
1086369|NCT01631682|Fear of spiders
1086370|NCT01631682|Reconsolidation
1086371|NCT01631682|Reconsolidation blockade
1086372|NCT01631669|Ossification
1086373|NCT01631669|Heterotopic Ossification
1086374|NCT01631656|Rosacea, Mild, Moderate, Combination Therapy, Laser, Finacea Gel, Azelaic Acid,
1086375|NCT01631643|Blood glucose monitor
1086376|NCT01631643|Pattern management
1086377|NCT01631643|Pattern guide
1086378|NCT01631643|Education
1086379|NCT01631630|Alcohol
1086380|NCT01631630|Alcohol Dependence
1086381|NCT01631630|Alcohol Use
1086382|NCT01631630|Nicotine Dependence
1086383|NCT01631630|Nicotine
1086384|NCT01631617|Investigator-Blinded
1086385|NCT01631617|Skin Biopsy
1086386|NCT01631617|Randomized
1086387|NCT01631617|Antibiotics
1086388|NCT01631617|Topical
1086389|NCT01631604|risk of falling
1086390|NCT01631604|gait patterns
1086391|NCT01631604|muscle activity
1086392|NCT01631604|fall prevention
1086393|NCT01631604|motor impairment
1086394|NCT01631578|mitochondrial injection
1086395|NCT01631565|Palliative Care
1086396|NCT01631565|Survival
1086397|NCT01631565|Quality of life
1086398|NCT01631552|Colorectal (CRC)
1086399|NCT01631552|Gastric adenocarcinoma (GC)
1086400|NCT01631552|Esophageal cancer (EC)
1086401|NCT01631552|Hepatocellular carcinoma (HCC)
1086402|NCT01631552|Non-small cell lung cancer (NSCLC)
1086403|NCT01631552|Small cell lung cancer (SCLC)
1086404|NCT01631552|Ovarian epithelial cancer (OEC)
1086405|NCT01631552|Triple-negative breast cancer (TNBC)
1086406|NCT01631552|Hormone-refractory prostate cancer (HRPC)
1086407|NCT01631552|Pancreatic ductal adenocarcinoma (PDC)
1086408|NCT01631552|Head and neck cancers- squamous cell (SCCHN)
1086409|NCT01631552|Renal cell cancer -clear cell (RCC)
1086410|NCT01631552|Bladder cancer
1086411|NCT01631552|Endometrial Cancer
1086412|NCT01631552|Cervical Cancer
1086413|NCT01631552|Breast cancer
1086414|NCT01631552|Metastatic non-triple negative breast cancer
1086415|NCT01631552|Glioblastoma multiforme
1086416|NCT01631552|Follicular thyroid cancer
1086417|NCT01631539|chemoembolization
1086418|NCT01631539|DC Bead™
1086419|NCT01631539|Irinotecan
1086420|NCT01631539|Cetuximab
1086421|NCT01631539|5FU/LV
1086422|NCT01631539|KRAS
1086423|NCT01631539|metastatic colorectal cancer
1086424|NCT01631526|Lung cancer
1086425|NCT01631526|vitamin D
1086426|NCT01631526|pharmacokinetics
1086427|NCT01631513|Chronic Low Back Pain
1086428|NCT01631513|Osteoarthritis Pain In The Hip or Knee
1086429|NCT01631513|Oxycodone
1086430|NCT01631513|Morphine, Hydrocodone
1086431|NCT01631513|Tapentadol
1086432|NCT01631513|NUCYNTA ER
1086433|NCT01631500|Integrative medicine
1086434|NCT01631500|Acupuncture
1086435|NCT01631500|Minor mental health problems
1086436|NCT01631500|Medically unexplained symptoms
1086437|NCT01631500|Minor mental health problems (e.g. minor depression and anxiety) and Medically unexplained symptoms (e.g. IBS, fibromyalgia, etc)
1086438|NCT01631487|Healthy
1086439|NCT01631487|JNJ-39439335
1086440|NCT01631487|Japanese
1086441|NCT01631487|Caucasian
1086442|NCT01631487|Male
1086443|NCT01631474|Intrepid
1086444|NCT01631474|acne
1086445|NCT01631474|antiandrogen
1086446|NCT01631461|pain
1086447|NCT01631461|breast feeding
1086448|NCT01631461|yeast
1086449|NCT01631461|candida albicance
1086450|NCT01631461|staphylococcus aureus
1086451|NCT01631461|Signs and symptoms
1086452|NCT01631448|Fibrin sealant
1086453|NCT01631448|renal transplantation
1086454|NCT01631448|surgical complication
1086455|NCT01631435|All subjects will have evidence of active symptoms associated with Crohn's disease
1086456|NCT01631409|clinical research
1086457|NCT01631409|coronary heart disease
1086458|NCT01631409|cardiac shock wave therapy
1086459|NCT01631409|ischemic heart disease
1086460|NCT01631409|myocardial revascularization
1086461|NCT01631409|observational research
1086462|NCT01631409|prospective research
1086463|NCT01631396|Morbid obesity
1086464|NCT01631396|Bariatric Surgery
1086465|NCT01631396|Neuromuscular block reversal
1086466|NCT01631383|Cocaine Use
1086467|NCT01631305|Euthyroid Sick Syndromes
1086468|NCT01631305|Thyroxine
1086469|NCT01631305|Intensive care
1086470|NCT01631279|NSCLC
1086471|NCT01631279|non-small cell lung cancer
1086472|NCT01631279|non-squamous, non-small cell lung cancer
1086473|NCT01631279|solid tumors
1086474|NCT01631279|lung cancer
1086475|NCT01631240|Sodium
1086476|NCT01631240|Potassium
1086477|NCT01631240|Iodine
1086478|NCT01631240|Creatinine
1086479|NCT01631214|Osteoporosis, Osteoporosis-postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
1086480|NCT01631201|Chlamydia
1086481|NCT01631188|Minimally Invasive Surgery
1086482|NCT01631188|Port Access Surgery
1086483|NCT01631188|Heart
1086484|NCT01631188|Pacing
1086485|NCT01631188|Wire
1086486|NCT01631188|MICS
1086487|NCT01631188|Cardiac Bypass
1086488|NCT01631188|Epicardial pacing
1086489|NCT01631188|pacing catheter
1086490|NCT01631188|pacing wire
1086491|NCT01631188|pacing swan
1086492|NCT01631188|pacing pulmonary catheter
1086493|NCT01631188|Pulmonary Endovent
1086494|NCT01631188|Catheter
1086495|NCT01631188|Aortic Valve Surgery
1086496|NCT01631188|Edwards Lifesciences
1086497|NCT01631175|sarcoma
1086498|NCT01631175|distress
1086499|NCT01631175|tumor
1086500|NCT01631175|quality of life
1086501|NCT01631175|cancer
1086502|NCT01631162|Asthma
1086503|NCT01631162|COPD
1086504|NCT01631149|urology
1086505|NCT01631149|muscle relaxation
1086506|NCT01631149|laparoscopy
1086507|NCT01631149|anesthesia
1086508|NCT01631149|rocuronium
1086509|NCT01631136|Non Small Cell Lung Cancer
1086510|NCT01631136|IFCT
1086511|NCT01631136|Maintenance
1086512|NCT01631136|Switch
1086513|NCT01631123|Twins
1086514|NCT01631123|High carbohydrat diet
1086515|NCT01631123|High fat diet
1086516|NCT01631123|Isocaloric
1086517|NCT01631123|Nutrigenomics
1086518|NCT01631110|Influenza
1086519|NCT01631110|Virus
1086520|NCT01631110|Vaccination
1086521|NCT01631110|Inflexal V
1086522|NCT01631084|Diabetes
1086523|NCT01631084|Structured care
1086524|NCT01631071|Influenza
1086525|NCT01631071|Virus
1086526|NCT01631071|Vaccination
1086527|NCT01631071|Virosomal influenza vaccine
1086528|NCT01631058|kidney transplantation
1086529|NCT01631058|chronic renal failure
1086530|NCT01631058|immunosuppressive therapy
1086531|NCT01631058|elderly
1086532|NCT01631058|pharmacokinetic
1086533|NCT01631058|tacrolimus
1086534|NCT01631058|everolimus
1086535|NCT01631058|mycophenolate sodium
1086536|NCT01631058|serious adverse events
1086537|NCT01631058|biopsy
1086538|NCT01631058|Cystatin C
1086539|NCT01631058|metabolic effects
1086540|NCT01631058|Left Ventricular Mass (LVM)
1086541|NCT01631058|Left Ventricle Ejection Fraction
1086542|NCT01631045|Obesity
1086543|NCT01631032|Allergic rhinitis
1086544|NCT01631032|Chinese herbal products
1086545|NCT01631032|Qi deficiency
1086546|NCT01631019|Chronic Obstructive Pulmonary Disease
1086547|NCT01631019|Pulmonary Rehabilitation
1086548|NCT01631019|Mobile phone
1086549|NCT01631019|Biomarker
1086550|NCT01631006|CPAP
1086551|NCT01631006|Hypertrophic cardiomyopathy
1086552|NCT01631006|Blood Pressure
1086553|NCT01631006|The focus of the present study is to evaluate the acute hemodynamic effects of CPAP in patients with non-obstructive and obstructive hypertrophic cardiomyopathy
1086554|NCT01630993|umbilical cord milking
1086555|NCT01630993|umbilical cord stripping
1086556|NCT01630993|umbilical cord clamping
1086557|NCT01630993|placental transfusion
1086558|NCT01630993|placental residual blood volume
1086559|NCT01630980|Systematic review and meta-analysis
1086560|NCT01630980|Evidence-based medicine (EBM)
1086561|NCT01630980|Evidence-based nutrition (EBN)
1086562|NCT01630980|Clinical practice guidelines
1086563|NCT01630980|Clinical trials
1086564|NCT01630980|Tree nuts
1086565|NCT01630980|Cardiometabolic risk factors
1086566|NCT01630980|Triglycerides
1086567|NCT01630980|Cholesterol
1086568|NCT01630980|Glycemic control
1086569|NCT01630980|Insulin resistance
1086570|NCT01630980|Body weight
1086571|NCT01630980|Blood pressure
1086572|NCT01630967|castrate resistance
1086573|NCT01630967|PSA progression
1086574|NCT01630967|LHRH antagonism
1086575|NCT01630954|Hydatidiform mole
1086576|NCT01630954|Molar pregnancy
1086577|NCT01630954|H Mole
1086578|NCT01630954|GTN
1086579|NCT01630954|GTD
1086580|NCT01630941|Osteoarthritis of the hip
1086581|NCT01630941|Uncemented Total Hip Arthroplasty
1086582|NCT01630941|DXA
1086583|NCT01630941|BMD
1086584|NCT01630941|PET
1086585|NCT01630941|CT
1086586|NCT01630941|Biochemical bone markers
1086587|NCT01630928|Renal denervation
1086588|NCT01630928|Resistant Hypertension
1086589|NCT01630928|Cardiovascular disease
1086590|NCT01630928|Diabetes
1086591|NCT01630928|Quality of LIfe
1086592|NCT01630889|Kidney
1086593|NCT01630889|ESRD
1086594|NCT01630889|End Stage Renal Disease
1086595|NCT01630889|Anemia
1086596|NCT01630889|Oral anemia treatment
1086597|NCT01630889|Hemoglobin levels
1086598|NCT01630889|Hemodialysis
1086599|NCT01630889|CKD
1086600|NCT01630889|Chronic Kidney Disease
1086601|NCT01630889|Peritoneal
1086602|NCT01630889|HD
1086603|NCT01630889|PD
1086604|NCT01630889|Hb
1086605|NCT01630889|Erythropoietin
1086606|NCT01630889|Blood count
1086607|NCT01630876|Epiretinal membrane
1086608|NCT01630876|triamcinolone acetonide
1086609|NCT01630863|Central serous chorioretinopathy
1086610|NCT01630863|photodynamic therapy
1086611|NCT01630863|safe and effective dose
1086612|NCT01630824|education program
1086613|NCT01630824|kidney transplantation
1086614|NCT01630824|renal transplantation
1086615|NCT01630824|evaluation
1086616|NCT01630811|Adults
1086617|NCT01630798|barrett's esophgus
1086618|NCT01630798|High grade dysplasia
1086619|NCT01630798|Esophageal adenocarcinoma
1086620|NCT01630772|women with preeclampsia
1086621|NCT01630772|physical therapy
1086622|NCT01630772|maternal-fetal hemodynamics
1086623|NCT01630772|perinatal outcomes
1086624|NCT01630759|Gestational diabetes
1086625|NCT01630759|telemonitoring
1086626|NCT01630759|telehealth
1086627|NCT01630759|feasibility study
1086628|NCT01630733|Metastatic
1086629|NCT01630733|Stage IV
1086630|NCT01630733|Advanced
1086631|NCT01630733|lung cancer
1086632|NCT01630720|ascorbic acid
1086633|NCT01630720|cholecalciferol
1086634|NCT01630720|vitamin C
1086635|NCT01630720|vitamin D
1086636|NCT01630720|hypovitaminosis
1086637|NCT01630720|mood
1086638|NCT01630720|distress
1086639|NCT01630694|Difficult airway management
1086640|NCT01630694|anesthesia
1086641|NCT01630694|difficult intubation
1086642|NCT01630629|Lactation
1086643|NCT01630629|Weaning
1086644|NCT01630629|Bone Density
1086645|NCT01630629|Endocrine
1086646|NCT01630629|Physiological Properties
1086647|NCT01630629|Bone Metabolism
1086648|NCT01630590|Prostate Cancer
1086649|NCT01630590|Metastatic Prostate Cancer
1086650|NCT01630590|Prostate adenocarcinoma
1086651|NCT01630590|Androgen-Dependent Prostate Cancer
1086652|NCT01630590|Cabozantinib
1086653|NCT01630590|XL 184
1086654|NCT01630590|Androgen Ablation
1086655|NCT01630577|acute circulatory failure
1086656|NCT01630577|hemodynamic stability
1086657|NCT01630577|hypovolemia
1086658|NCT01630564|Blood And Marrow Transplantation
1086659|NCT01630564|Leukemia
1086660|NCT01630564|Lymphoma
1086661|NCT01630564|Myeloproliferative Diseases
1086662|NCT01630564|Relapsed hematological malignancies
1086663|NCT01630564|Post-Transplant Relapsed Patients
1086664|NCT01630564|Cord Blood Lymphocyte Infusion
1086665|NCT01630564|Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion
1086666|NCT01630551|tears
1086667|NCT01630551|dry eyes
1086668|NCT01630551|ocular surface disease
1086669|NCT01630538|Transplantation
1086670|NCT01630525|Alzheimer's disease
1086671|NCT01630525|neurodegenerative signs
1086672|NCT01630499|Cancer
1086673|NCT01630499|Breast cancer
1086674|NCT01630499|Breast cancer prevention
1086675|NCT01630499|Breast cancer recurrence
1086676|NCT01630499|Weight loss
1086677|NCT01630499|Weight management
1086678|NCT01630499|Overweight
1086679|NCT01630499|Obesity
1086680|NCT01630486|renal progression
1086681|NCT01630486|mortality
1086682|NCT01630486|complications
1086683|NCT01630486|risk factors
1086684|NCT01630486|role of biochemical parameters
1086685|NCT01630486|genetic influence
1086686|NCT01630473|Tooth crowding
1086687|NCT01630473|Teeth malpositions
1086688|NCT01630473|corticotomy
1086689|NCT01630473|orthodontics
1086690|NCT01630473|tooth movement
1086691|NCT01630473|periodontal parameters
1086692|NCT01630460|Craniometaphyseal dysplasia
1086693|NCT01630460|bone
1086694|NCT01630460|hyperostosis
1086695|NCT01630460|osteoblast
1086696|NCT01630460|osteoclast
1086697|NCT01630447|cherubism
1086698|NCT01630447|bone
1086699|NCT01630447|autoinflammatory disorder
1086700|NCT01630447|osteoblast
1086701|NCT01630447|osteoclast
1086702|NCT01630447|mandible
1086703|NCT01630447|maxilla
1086704|NCT01630421|Aplasia cutis congenita
1086705|NCT01630421|bone
1086706|NCT01630421|osteoblast
1086707|NCT01630421|osteoclast
1086708|NCT01630421|skin
1086709|NCT01630408|Preserved ejection fraction
1086710|NCT01630408|Left ventricular hypertrophy
1086711|NCT01630408|Activated vitamin D
1086712|NCT01630408|Cardiac lusitropic effect
1086713|NCT01630408|Hospitalizations
1086714|NCT01630356|Secondhand Smoke
1086715|NCT01630356|Nicotine
1086716|NCT01630356|Indoor Air Pollution
1086717|NCT01630343|Geriatric hip fracture
1086718|NCT01630343|pain management
1086719|NCT01630304|telecommunications
1086720|NCT01630304|Africa
1086721|NCT01630304|randomized controlled trial
1086722|NCT01630278|Prematurity
1086723|NCT01630278|patent ductus arteriosus
1086724|NCT01630278|ibuprofen
1086725|NCT01630265|Discharge Instructions
1086726|NCT01630265|Video Discharge Instructions
1086727|NCT01630265|Video
1086728|NCT01630265|Emergency Department Discharge Instructions
1086729|NCT01630265|ED Discharge
1086730|NCT01630226|BRCA1
1086731|NCT01630226|pathological complete response
1086732|NCT01630226|neoadjuvant chemotherapy
1086733|NCT01630213|Vitamin D3
1086734|NCT01630213|Left ventricular mass
1086735|NCT01630213|Echocardiography
1086736|NCT01630213|Left ventricular systolic and diastolic function
1086737|NCT01630200|COPD
1086738|NCT01630200|comorbidity
1086739|NCT01630200|arterial stiffness
1086740|NCT01630200|roflumilast
1086741|NCT01630187|Carbetocin
1086742|NCT01630187|Uterotonic drug
1086743|NCT01630187|elective cesarean section
1086744|NCT01630174|IMRT,Pemetrexed,Cisplatin , Esophageal Cancer
1086745|NCT01630161|relapse
1086746|NCT01630161|prevention
1086747|NCT01630161|smoking
1086748|NCT01630161|habit
1086749|NCT01630161|Forever Free
1086750|NCT01630148|Thromboprophylaxis
1086751|NCT01630148|Bemiparin
1086752|NCT01630148|Low Molecular Weight Heparin
1086753|NCT01630148|Major Gynaecological Surgeries
1086754|NCT01630148|Benign Gynaecological Surgeries
1086755|NCT01630122|Trans-thoracic Needle Biopsy (TNB)
1086756|NCT01630122|Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)
1086757|NCT01630122|Trans-esophageal Ultrasound Scanning with FNA (EUS-FNA)
1086758|NCT01630070|Critical limb ischemia
1086759|NCT01630070|Rest pain
1086760|NCT01630070|Minor tissue loss
1086761|NCT01630070|Below the knee
1086762|NCT01630031|atrial fibrillation
1086763|NCT01630031|paroxysmal
1086764|NCT01630031|contact force
1086765|NCT01630031|radiofrequency
1086766|NCT01630031|catheter ablation
1086767|NCT01630031|pulmonary vein isolation
1086768|NCT01630031|recurrence
1086769|NCT01630031|follow-up
1086770|NCT01630018|Epithelial Ovarian Cancer
1086771|NCT01630018|Belotecan
1086772|NCT01630018|Topotecan
1086773|NCT01629992|Vomiting
1086774|NCT01629992|Nausea
1086775|NCT01629992|Postoperative pain
1086776|NCT01629992|Feeling
1086777|NCT01629966|Generalized Anxiety Disorder
1086778|NCT01629966|GAD
1086779|NCT01629940|X-linked Hypohidrotic Ectodermal Dysplasia
1086780|NCT01629940|Hypohidrotic Ectodermal Dysplasia
1086781|NCT01629940|XLHED
1086782|NCT01629940|HED
1086783|NCT01629927|X-linked hypohidrotic ectodermal dysplasia
1086784|NCT01629927|Hypohidrotic ectodermal dysplasia
1086785|NCT01629927|HED
1086786|NCT01629927|XLHED
1086787|NCT01629914|Attention-deficit/hyperactivity disorder
1086788|NCT01629914|executive functioning
1086789|NCT01629914|mindfulness meditation
1086790|NCT01629914|magnetic resonance imaging
1086791|NCT01629914|healthy
1086792|NCT01629901|Healthy volunteer
1086793|NCT01629888|Plant sterol
1086794|NCT01629888|Hypercholesterolemia
1086795|NCT01629888|dairy
1086796|NCT01629810|Motion platform at appropriate settings.
1086797|NCT01629810|Relief of pain.
1086798|NCT01629810|Improvement in quality of life, cognition, and mood.
1086799|NCT01629810|Effects of WBPA on cognition, mood, behavior, and functioning.
1086800|NCT01629810|Dose response effect .
1086801|NCT01629810|Gather data for long-term (2 year) study
1086802|NCT01629745|B-cell childhood acute lymphoblastic leukemia
1086803|NCT01629745|untreated childhood acute lymphoblastic leukemia
1086804|NCT01629693|contact lenses
1086805|NCT01629693|myopia
1086806|NCT01629693|astigmatism
1086807|NCT01629680|moxaverine
1086808|NCT01629680|ocular blood flow
1086809|NCT01629654|Poststroke fatigue
1086810|NCT01629654|Health promotion
1086811|NCT01629654|Patient education
1086812|NCT01629641|goniometry
1086813|NCT01629641|outcome measures
1086814|NCT01629641|shoulder assessment
1086815|NCT01629628|Crohn Disease
1086816|NCT01629628|Colitis Granulomatous
1086817|NCT01629628|Crohn's Disease
1086818|NCT01629628|Enteritis Regional
1086819|NCT01629628|Ileitis Regional
1086820|NCT01629628|Ileitis Terminal
1086821|NCT01629628|Ileocolitis
1086822|NCT01629615|breast cancer
1086823|NCT01629615|metastatic
1086824|NCT01629615|triple negative breast cancer
1086825|NCT01629615|BKM120
1086826|NCT01629615|SOLTI
1086827|NCT01629615|PI3K inhibitor
1086828|NCT01629602|defect;
1086829|NCT01629602|dorsal branch of the proper digital nerve;
1086830|NCT01629602|proper digital nerve;
1086831|NCT01629602|vascularized nerve graft
1086832|NCT01629589|Adacel® vaccine
1086833|NCT01629589|Tetanus
1086834|NCT01629589|Diphtheria
1086835|NCT01629589|whooping cough
1086836|NCT01629589|Pertussis
1086837|NCT01629589|BOOSTRIX® vaccine
1086838|NCT01629537|Post Traumatic Stress Disorder
1086839|NCT01629511|Leukemia
1086840|NCT01629511|Chronic lymphocytic leukemia
1086841|NCT01629511|CLL
1086842|NCT01629511|Allogeneic hematopoietic cell transplantation
1086843|NCT01629511|HCT
1086844|NCT01629511|Methotrexate
1086845|NCT01629511|Filgrastim
1086846|NCT01629511|G-CSF
1086847|NCT01629511|Neupogen
1086848|NCT01629511|Tacrolimus
1086849|NCT01629511|Prograf
1086850|NCT01629511|Busulfan
1086851|NCT01629511|Busulfex
1086852|NCT01629511|Myleran
1086853|NCT01629511|Clofarabine
1086854|NCT01629511|Clofarex
1086855|NCT01629511|Clolar
1086856|NCT01629511|Gemcitabine
1086857|NCT01629511|Gemcitabine Hydrochloride
1086858|NCT01629511|Gemzar
1086859|NCT01629511|Thymoglobulin
1086860|NCT01629511|ATG
1086861|NCT01629511|Antithymocyte Globulin
1086862|NCT01629498|Lung cancer
1086863|NCT01629498|Non-small cell lung cancer
1086864|NCT01629498|NSCLC
1086865|NCT01629498|Image-guided intensity-modulated scanning beam proton therapy
1086866|NCT01629498|IMPT
1086867|NCT01629498|Simultaneous integrated boost
1086868|NCT01629498|SIB
1086869|NCT01629498|Gross tumor volume
1086870|NCT01629498|GTV
1086871|NCT01629498|Chemotherapy
1086872|NCT01629498|Questionnaire
1086873|NCT01629498|Survey
1086874|NCT01629485|Mastery Learning
1086875|NCT01629485|Surgical Education
1086876|NCT01629485|Laparoscopic Hernia Repair
1086877|NCT01629485|Part vs Whole Task
1086878|NCT01629485|Contextual Interference
1086879|NCT01629485|laparoscopy
1086880|NCT01629485|training
1086881|NCT01629485|curriculum
1086882|NCT01629472|Gender norms
1086883|NCT01629472|Financial Autonomy
1086884|NCT01629472|Economic Well-being
1086885|NCT01629459|exercise
1086886|NCT01629459|strength
1086887|NCT01629459|training
1086888|NCT01629459|barth syndrome
1086889|NCT01629459|mitochondria
1086890|NCT01629459|amino acid
1086891|NCT01629459|protein
1086892|NCT01629446|Phase 1
1086893|NCT01629446|Normal healthy volunteers
1086894|NCT01629446|Mass Balance
1086895|NCT01629433|idiopathic detrusor overactivity
1086896|NCT01629433|neurogenic dysfunction
1086897|NCT01629433|onabotulinumtoxinA
1086898|NCT01628458|Pancreatic cancer
1086899|NCT01628458|locally advanced
1086900|NCT01628458|irresectable
1086901|NCT01628458|Radiofrequency
1086902|NCT01628458|RFA
1086903|NCT01628445|Diabetes
1086904|NCT01628445|Insulin
1086905|NCT01628419|Health promotion
1086906|NCT01628419|Intervention
1086907|NCT01628419|Workplace
1086908|NCT01628419|Exercise program
1086909|NCT01627444|Acupuncture
1086910|NCT01627444|Anxiety
1086911|NCT01627444|Human Milk
1086912|NCT01627444|Very low birth weight infants
1086913|NCT01627444|Mother of very low birth weight infants
1086914|NCT01627431|PAD
1086915|NCT01627431|Peripheral revascularization
1086916|NCT01627431|Antiplatelet therapy
1086917|NCT01627431|Residual platelet activity
1086918|NCT01627418|COPD
1086919|NCT01627418|CORD
1086920|NCT01627418|COAD
1086921|NCT01626365|double-lumen tube
1086922|NCT01626365|intubation
1086923|NCT01626365|thermosoftening
1086924|NCT01626352|Diffuse Large B-Cell Lymphoma
1086925|NCT01626352|Ofatumumab
1086926|NCT01626352|Bendamustine
1086927|NCT01629420|Gonadotropin-Releasing Hormone (GnRH) antagonist
1086928|NCT01629381|knee arthroscopy
1086929|NCT01629381|venous thromboembolism
1086930|NCT01629381|prevention
1086931|NCT01629355|Auditory Brainstem Response
1086932|NCT01629355|ABR
1086933|NCT01629355|SD-BERA
1086934|NCT01629329|Headache
1086935|NCT01629329|prochlorperazine
1086936|NCT01629329|excedrin migraine
1086937|NCT01629329|treatment efficacy
1086938|NCT01629329|pain scores
1086939|NCT01629316|HIV
1086940|NCT01629316|prisoners
1086941|NCT01629316|test
1086942|NCT01629316|treat
1086943|NCT01629316|link coordination
1086944|NCT01629316|retain
1086945|NCT01629316|behavioral
1086946|NCT01629316|intervention
1086947|NCT01629316|text reminders
1086948|NCT01629316|motivational interviewing
1086949|NCT01629316|medication adherence
1086950|NCT01629303|constipation
1086951|NCT01629303|sacral nerve modulation
1086952|NCT01629277|Closed-loop insulin delivery
1086953|NCT01629277|Non-compliant behaviours during adolescence
1086954|NCT01629264|Cornea
1086955|NCT01629264|biomechanics
1086956|NCT01629264|pregnancy
1086957|NCT01629264|keratoconus
1086958|NCT01629264|refractive surgery
1086959|NCT01629251|Closed-loop insulin delivery
1086960|NCT01629251|Post-prandial hypoglycaemia
1086961|NCT01629251|Meal insulin dosing
1086962|NCT01629238|cardiovascular risk
1086963|NCT01629238|dairy enriched product with plant sterols
1086964|NCT01629238|general practitioners
1086965|NCT01629238|adults followed by general practitioners
1086966|NCT01629225|men and women
1086967|NCT01629225|in southwestern Han Chinese
1086968|NCT01629186|CPR
1086969|NCT01629186|flexible bronchoscope
1086970|NCT01629186|resuscitation
1086971|NCT01629186|ventilation
1086972|NCT01629173|plantar pressure
1086973|NCT01629173|metatarsalgia
1086974|NCT01629173|insole
1086975|NCT01629147|Constipation
1086976|NCT01629108|Normative Data
1086977|NCT01629108|Vestibular
1086978|NCT01629108|Auditory
1086979|NCT01629108|Healthy Volunteers
1086980|NCT01629108|Hearing
1086981|NCT01629095|Fatty Liver
1086982|NCT01629095|Liver Transplant
1086983|NCT01629095|Non-Alcoholic Steato-Hepatitis
1086984|NCT01629095|Steatosis
1086985|NCT01629095|Cirrhosis
1086986|NCT01629095|Cryptogenic Cirrhosis
1086987|NCT01629095|Liver Failure
1086988|NCT01629095|Non-Alcoholic Fatty Liver Disease
1086989|NCT01629082|Myelodysplastic Syndromes
1086990|NCT01629082|Acute Myeloid Leukemia (AML)
1086991|NCT01629082|Chronic Myelomonocytic Leukemia (CMML)
1086992|NCT01629069|stress
1086993|NCT01629069|mindfulness
1086994|NCT01629069|coping
1086995|NCT01629056|atrial fibrillation
1086996|NCT01629056|ablation
1086997|NCT01629056|contact
1086998|NCT01629043|Parkinson's
1086999|NCT01629043|Quality of Care
1087000|NCT01629043|Improvement
1087001|NCT01629043|Mobility
1087002|NCT01629043|Cognition
1087003|NCT01629043|Caregiver burden
1087004|NCT01629043|Center difference
1087005|NCT01629030|sternal wound infection
1087006|NCT01629030|coronary artery bypass graft
1087007|NCT01629030|risk factor
1087008|NCT01629004|colorectal cancer
1087009|NCT01629004|screening
1087010|NCT01629004|fecal occult blood testing
1087011|NCT01629004|mailed invitation
1087012|NCT01628991|Behavioral Intervention Program
1087013|NCT01628991|Vaginal Cones
1087014|NCT01628991|Stress Urinary Incontinence
1087015|NCT01628991|treatment
1087016|NCT01628991|Women
1087017|NCT01628978|depth of endotracheal tube placement
1087018|NCT01628978|endotracheal intubation
1087019|NCT01628978|endobronchial intubation
1087020|NCT01628965|SPM 962
1087021|NCT01628965|rotigotine
1087022|NCT01628965|Parkinson's disease
1087023|NCT01628965|monotherapy
1087024|NCT01628939|low back pain
1087025|NCT01628939|facet joint pain
1087026|NCT01628913|Pancreatic
1087027|NCT01628913|Neuroendocrine tumors
1087028|NCT01628913|PNET
1087029|NCT01628913|BEZ235
1087030|NCT01628913|Everolimus
1087031|NCT01628900|pyelonephritis
1087032|NCT01628900|Infection
1087033|NCT01628900|Antibiotic treatment
1087034|NCT01628887|Breast Cancer
1087035|NCT01628874|Lumbar Puncture
1087036|NCT01628874|J-Tip
1087037|NCT01628874|Jet injection
1087038|NCT01628874|Local Analgesia
1087039|NCT01628861|occupation
1087040|NCT01628861|work
1087041|NCT01628861|sitting
1087042|NCT01628861|sedentary behaviour
1087043|NCT01628861|office worker
1087044|NCT01628861|adult
1087045|NCT01628861|education
1087046|NCT01628861|point-of-choice prompt
1087047|NCT01628848|SPM 962
1087048|NCT01628848|rotigotine
1087049|NCT01628848|Parkinson's disease
1087050|NCT01628848|concomitant use of L-dopa
1087051|NCT01628835|overweight
1087052|NCT01628835|pregnancy
1087053|NCT01628835|diet counselling
1087054|NCT01628835|glycemic
1087055|NCT01628822|Fibromyalgia
1087056|NCT01628822|Relaxation
1087057|NCT01628822|Improving the quality of life
1087058|NCT01628809|MBSR
1087059|NCT01628809|mindfulness
1087060|NCT01628809|stress
1087061|NCT01628783|Depression
1087062|NCT01628783|emotional processing
1087063|NCT01628783|fMRI
1087064|NCT01628783|autobiographic memory
1087065|NCT01628783|moderator of treatment response
1087066|NCT01628783|mediator of treatment response
1087067|NCT01628770|iron
1087068|NCT01628770|monofer
1087069|NCT01628770|Pakistan
1087070|NCT01628731|loop diuretics
1087071|NCT01628731|fluid balance
1087072|NCT01628731|urine output
1087073|NCT01628731|acute renal dysfunction
1087074|NCT01628718|OEF/OIF
1087075|NCT01628718|Veterans
1087076|NCT01628718|Psychotherapy
1087077|NCT01628718|PTSD
1087078|NCT01628705|Green tea
1087079|NCT01628705|oxLDL
1087080|NCT01628705|fat mass
1087081|NCT01628679|provoked
1087082|NCT01628679|vulvar
1087083|NCT01628679|vestibulodynia
1087084|NCT01628679|vestibulitis
1087085|NCT01628666|Arrhythmia
1087086|NCT01628666|Device Procedure
1087087|NCT01628666|Antibiotics
1087088|NCT01628666|Infection
1087089|NCT01628666|Cluster
1087090|NCT01628653|Mild cognitive impairment
1087091|NCT01628653|Cognitive rehabilitation
1087092|NCT01628653|Cognitive therapy
1087093|NCT01628653|Spaced retrieval Training
1087094|NCT01628653|Alzheimer's disease
1087095|NCT01628653|Memory enhancement
1087096|NCT01628653|U-healthcare
1087097|NCT01628627|Diabetic Neuropathy, Painful
1087098|NCT01628575|periodontally accelerated orthodontics PAO
1087099|NCT01628562|Remifentanil
1087100|NCT01628562|Esmolol
1087101|NCT01628562|Intracranial surgery
1087102|NCT01628562|Heart rate
1087103|NCT01628562|Blood pressure
1087104|NCT01628549|acne
1087105|NCT01628536|Black Cohosh
1087106|NCT01628536|Ductal Carcinoma in situ
1087107|NCT01628536|Breast Cancer
1087108|NCT01628523|Respiratory failure
1087109|NCT01628523|Mechanical ventilation
1087110|NCT01628523|Acute lung injury
1087111|NCT01628510|preterm
1087112|NCT01628471|Phase I b : advanced solid malignancy
1087113|NCT01628471|Phase II a: stage III b or IV, Non Small Cell Lung Cancer
1087114|NCT01628380|HIPEC
1087115|NCT01628380|Ovarian Cancer
1087116|NCT01628380|Cytoreductive Surgery
1087117|NCT01628354|Choroidal neovascularization
1087118|NCT01628354|Lucentis
1087119|NCT01628328|colonic stenting
1087120|NCT01628328|colorectal cancer obstruction
1087121|NCT01628328|circulating tumor cell
1087122|NCT01628315|Multiple Sclerosis
1087123|NCT01628315|ASA
1087124|NCT01628315|MRI
1087125|NCT01628315|Lesion activity
1087126|NCT01628302|Hypertension,plasma renin activity,salt consumption
1087127|NCT01628289|diabetic retinopathy
1087128|NCT01628289|screening
1087129|NCT01628289|co-payment
1087130|NCT01628289|health service
1087131|NCT01628276|Multiple Sclerosis
1087132|NCT01628276|MRI Scans
1087133|NCT01628263|PICU
1087134|NCT01628263|Follow up
1087135|NCT01628263|PTSD
1087136|NCT01628224|Task saturation
1087137|NCT01628211|hyperthermic chemotherapy
1087138|NCT01628211|intraperitoneal chemotherapy
1087139|NCT01628211|second-look laparoscopy
1087140|NCT01628211|peritoneal carcinosis
1087141|NCT01628211|mucinous colorectal cancer
1087142|NCT01628198|Hypertension
1087143|NCT01628198|renal denervation
1087144|NCT01628198|renal ablation
1087145|NCT01628198|uncontrolled high blood pressure
1087146|NCT01628172|renal sympathetic denervation
1087147|NCT01628172|renal catheter ablation
1087148|NCT01628172|hypertension
1087149|NCT01628146|Presbyopia
1087150|NCT01628146|hyperopia
1087151|NCT01628146|Supracor
1087152|NCT01628146|contrast sensitivity
1087153|NCT01628133|Transfusion
1087154|NCT01628133|Neonate
1087155|NCT01628133|Infant, Very Low Birth Weight
1087156|NCT01628133|Patent Ductus Arteriosus
1087157|NCT01628133|Packed Red Blood Cell
1087158|NCT01628120|Chronic renal failure
1087159|NCT01628120|Hemodialysis
1087160|NCT01628107|Chronic renal failure
1087161|NCT01628107|hemodialysis
1087162|NCT01628081|psoriasis
1087163|NCT01628081|Alga Dunaliella Bardawil
1087164|NCT01628068|Left atrial appendage occlusion
1087165|NCT01628068|gastrointestinal bleeding
1087166|NCT01628055|IVIg
1087167|NCT01628055|Acute Ischemic Stroke
1087168|NCT01628055|Stroke
1087169|NCT01628055|CVA
1087170|NCT01628055|Cerebrovascular Accident
1087186|NCT01628016|depression
1087187|NCT01628016|attention
1087188|NCT01628016|training
1087189|NCT01628016|modification
1087190|NCT01628003|Traumatic Brain Injury
1087191|NCT01628003|long-term outcome
1087192|NCT01628003|Brain Reserves
1087193|NCT01628003|Cognitive Reserves
1087194|NCT01628003|Emotional Reserves
1087195|NCT01628003|Patients 1 year or more after Moderate or Severe Traumatic Brain Injury
1087196|NCT01627990|cytotoxic chemotherapy
1087197|NCT01627990|G-CSF
1087198|NCT01627990|Solid tumour
1087199|NCT01627990|Malignant haematological tumour
1087200|NCT01627977|chromovitrectomy
1087201|NCT01627977|epiretinal membrane
1087202|NCT01627964|Heart Wall Motion Function
1087203|NCT01627951|Plasmodium falciparum
1087204|NCT01627951|malaria
1087205|NCT01627938|Multiple Sclerosis
1087206|NCT01627938|MS
1087207|NCT01627938|Mitoxantrone
1087208|NCT01627938|Dexrazoxane
1087209|NCT01627938|Cardioxane
1087210|NCT01627938|cardiotoxicity
1087211|NCT01627938|cardiac toxicity
1087212|NCT01627938|cardiotoxic side effects
1087213|NCT01627938|cardiac MRI
1087214|NCT01627938|cranial MRI
1087215|NCT01627938|LVEF
1087216|NCT01627938|neurological outcome
1087217|NCT01627925|nasal positive airway pressure
1087218|NCT01627925|upper airway obstruction
1087219|NCT01627925|mask ventilation
1087220|NCT01627912|wine
1087221|NCT01627912|inflammation
1087222|NCT01627912|oxidative stress
1087223|NCT01627912|randomized control trial
1087224|NCT01627912|postprandial intervention
1087225|NCT01627912|platelet aggregation
1087226|NCT01627912|haemostasis
1087227|NCT01627912|robola
1087228|NCT01627912|cabernet sauvignon
1087229|NCT01627912|alcohol
1087230|NCT01627912|PAF metabolism
1087231|NCT01627899|Blood glucose monitor
1087232|NCT01627899|Pattern management
1087233|NCT01627899|Pattern guide
1087234|NCT01627899|Education
1087235|NCT01627886|Bioequivalence
1087236|NCT01627886|Ibandronate Sodium
1087237|NCT01627886|crossover
1087238|NCT01627873|Major abdominal surgery
1087239|NCT01627873|analgesic method
1087240|NCT01627873|Fentanyl
1087241|NCT01627873|Remifentanyl
1087242|NCT01627873|Postoperative cognitive disorder
1087243|NCT01627873|Pro and anti inflammatory cytokines
1087244|NCT01627860|Epilepsy
1087245|NCT01627860|Topiramate
1087246|NCT01627860|Neuro-surgical patients
1087247|NCT01627860|Nervous disorder
1087248|NCT01627860|Seizures
1087249|NCT01627847|Bioequivalence
1087250|NCT01627847|Ropinirole Hydrochloride
1087251|NCT01627847|crossover
1087252|NCT01627834|Bioequivalence
1087253|NCT01627834|Ropinirole Hydrochloride
1087254|NCT01627834|crossover
1087255|NCT01627821|Heart Failure
1087256|NCT01627808|intraoperative monitoring
1087257|NCT01627808|fluid management
1087258|NCT01627795|Malignant Mesothelioma
1087259|NCT01627795|Cancer
1087260|NCT01627795|Anti cancer agents
1087261|NCT01627782|Major depressive disorder
1087262|NCT01627782|Treatment-resistant depression
1087263|NCT01627782|Ketamine
1087264|NCT01627769|scars
1087265|NCT01627769|blisters
1087266|NCT01627769|second degree burns
1087267|NCT01627769|cryosurgery
1087268|NCT01627769|keloid scars
1087269|NCT01627769|hypertrophic scars
1087270|NCT01627756|Thoracic Surgery
1087271|NCT01627756|Endotoxins
1087272|NCT01627756|Respiration, Artificial
1087273|NCT01627756|Immune System
1087274|NCT01627743|CDLM
1087275|NCT01627743|visual scale - physician evaluation
1087276|NCT01627743|COPD
1087277|NCT01627743|GOLD group C and D
1087278|NCT01627717|maraviroc
1087279|NCT01627717|boceprevir
1087280|NCT01627717|HIV
1087281|NCT01627717|HCV
1087282|NCT01627717|drug interaction
1087283|NCT01627717|pharmacokinetics
1087284|NCT01627704|PET/CT,fluoroestradiol (18F)
1087285|NCT01627704|breast cancer
1087286|NCT01627704|metastatic
1087287|NCT01627704|prediction of response
1087288|NCT01627704|hormone therapy
1087289|NCT01627678|HIV-1, Vacc-C5
1087290|NCT01627665|dabigatran
1087291|NCT01627665|rivaroxaban
1087292|NCT01627665|PKC
1087293|NCT01627665|PKD
1087294|NCT01627665|p-glycoprotein
1087295|NCT01627665|polymorphism
1087296|NCT01627652|hypoxia
1087297|NCT01627626|xerostomia
1087298|NCT01627626|pilocarpine mouthwash
1087299|NCT01627626|minor salivary gland secretion
1087300|NCT01627600|stroke
1087301|NCT01627600|myocardial infarction
1087302|NCT01627600|cardiovascular health
1087303|NCT01627600|population study
1087304|NCT01627587|preterm labor
1087305|NCT01627574|Pregnancy
1087306|NCT01627574|STI prevention
1087307|NCT01627574|adolescents
1087308|NCT01627574|probation
1087309|NCT01627561|Immune response
1087310|NCT01627561|Human papillomavirus
1087311|NCT01627561|HPV vaccine
1087312|NCT01627561|Safety
1087313|NCT01627548|PTSD
1087314|NCT01627548|Couples
1087315|NCT01627548|Combat Veteran
1087316|NCT01627548|Warfighter
1087317|NCT01627548|OEF
1087318|NCT01627548|OIF
1087319|NCT01627548|OND
1087320|NCT01627548|Structured Approach Therapy
1087321|NCT01627548|Trauma
1087322|NCT01627535|Brain Tumor
1087323|NCT01627509|continuous glucose monitoring system
1087324|NCT01627509|hypoglycemia
1087325|NCT01627509|insulin regimen
1087326|NCT01627509|basal bolus therapy
1087327|NCT01627509|modern premixed insulin
1087328|NCT01627509|diabetes control
1087329|NCT01627496|malnutrition
1087330|NCT01627496|elderly care
1087331|NCT01627496|quality of life
1087332|NCT01627496|hospital
1087333|NCT01627483|elderly
1087334|NCT01627483|hip fracture
1087335|NCT01627483|osteoporosis
1087336|NCT01627483|fall risk
1087337|NCT01627483|medication review
1087338|NCT01627470|non-invasive arterial pressure
1087339|NCT01627470|emergency
1087340|NCT01627470|intensive care
1087341|NCT01627457|Coronary Artery Disease
1087342|NCT01627457|Guided Exercise System including ECG Vest with vital signs sensors and PDA
1087343|NCT01627457|Validation Telemedical Device in regard to accuracy and safety of data
1087344|NCT01627457|Homely Rehabilitation
1087345|NCT01627457|Practicability and technical problems at home
1087346|NCT01627379|nonresectable
1087347|NCT01627379|advanced
1087348|NCT01627379|metastatic esophageal squamous cell cancer
1087349|NCT01627379|Panitumumab
1087350|NCT01627353|Hysterectomy
1087351|NCT01627353|Pain Prevention
1087352|NCT01627353|Wound Infiltration
1087353|NCT01627340|hepatitis B
1087354|NCT01627340|adults
1087355|NCT01627340|Type 2 diabetes mellitus
1087356|NCT01627340|Engerix™-B
1087357|NCT01627327|Cardiovascular event
1087358|NCT01627327|Cardiovascular disease
1087359|NCT01627275|Naive T Cell Depletion
1087360|NCT01627275|Donor Lymphocyte Infusion
1087361|NCT01627275|Allogeneic Hematopoietic Stem Cell Transplant
1087362|NCT01627262|diverticular disease
1087363|NCT01627262|colonic diverticulosis
1087364|NCT01627262|mesalamine
1087365|NCT01627262|placebo
1087366|NCT01627262|randomized
1087367|NCT01627249|Diabetic Macular Edema
1087368|NCT01627249|anti-vascular endothelial growth factor
1087369|NCT01627223|Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B
1087370|NCT01627223|Lamivudine (Zeffix®)
1087371|NCT01627223|Entecavir (Baraclude®)
1087372|NCT01627210|Diabetes Mellitus
1087373|NCT01627197|Effects of Chemotherapy
1087374|NCT01627145|overactive bladder syndrome
1087375|NCT01627145|derusor overactivity
1087376|NCT01627145|urodynamic studies
1087377|NCT01627145|bladder oversensitivity
1087378|NCT01627119|CTGF
1087379|NCT01627119|Peritoneal metastasis
1087380|NCT01627093|Head and Neck Cancer
1087381|NCT01627093|Head and Neck Malignancies
1087382|NCT01627093|Chart Review
1087383|NCT01627093|Proton Radiation Therapy
1087384|NCT01627080|Esophagus
1087385|NCT01627080|Esophageal Cancer
1087386|NCT01627080|Radiation therapy
1087387|NCT01627080|RT
1087388|NCT01627080|Chemotherapy
1087389|NCT01627080|Mid thoracic tumor
1087390|NCT01627080|Distal esophageal tumor
1087391|NCT01627080|Gastroesophageal junction tumor
1087392|NCT01627080|Cardiac biomarkers
1087393|NCT01627067|Breast Cancer
1087394|NCT01627067|Hormone Receptor Positive Metastatic Breast Cancer
1087395|NCT01627067|Hormone-sensitive
1087396|NCT01627067|Postmenopausal
1087397|NCT01627067|Body Mass Index
1087398|NCT01627067|BMI
1087399|NCT01627067|Everolimus
1087400|NCT01627067|Afinitor
1087401|NCT01627067|RAD001
1087402|NCT01627067|Exemestane
1087403|NCT01627067|Aromasin
1087404|NCT01627067|Metformin
1087405|NCT01627028|Thai traditional massage
1087406|NCT01627028|Bone formation
1087407|NCT01627028|Bone resorption
1087408|NCT01627015|Fully formula fed
1087409|NCT01627002|Phase 1
1087410|NCT01627002|First in Human
1087411|NCT01627002|Healthy Volunteers
1087412|NCT01627002|Lipopolysaccharide Challenge
1087413|NCT01626976|safety
1087414|NCT01626976|tolerability
1087415|NCT01626976|pharmacokinetics
1087416|NCT01626976|oral
1087417|NCT01626976|single ascending dose
1087418|NCT01626976|placebo-controlled
1087419|NCT01626976|healthy subjects
1087420|NCT01626963|single-port access
1087421|NCT01626963|laparoscopic surgery
1087422|NCT01626963|surgical trauma
1087423|NCT01626950|Breast cancer
1087424|NCT01626950|living conditions
1087425|NCT01626950|social fragility
1087426|NCT01626937|Acute respiratory failure
1087427|NCT01626937|Chronic obstructive pulmonary disease
1087428|NCT01626937|Non invasive ventilation
1087429|NCT01626937|Out of hospital
1087430|NCT01626924|Perinatal Asphyxia
1087431|NCT01626924|Neonatal encephalopathy
1087432|NCT01626924|Oxygen shortage at birth
1087433|NCT01626924|Antenatal asphyxia
1087434|NCT01626924|hypoxia-ischaemia
1087435|NCT01626924|birth asphyxia
1087436|NCT01626924|asphyxia neonatorum
1087437|NCT01626911|severe acute pancreatitis;
1087438|NCT01626911|continuous regional arterial infusion;
1087439|NCT01626911|low molecular weight heparin
1087440|NCT01626885|Schizophrenia
1087441|NCT01626885|Antipsychotic Agents
1087442|NCT01626885|Mental Disorder
1087443|NCT01626885|Psychotropic Drugs
1087444|NCT01626885|Dopamine Agents
1087445|NCT01626885|Central Nervous System Agents
1087446|NCT01626872|Schizophrenia
1087447|NCT01626872|Antipsychotic Agents
1087448|NCT01626872|Mental Disorder
1087449|NCT01626872|Psychotropic Drugs
1087450|NCT01626872|Dopamine Agents
1087451|NCT01626872|Risperidone
1087452|NCT01626872|Central Nervous System Agents
1087453|NCT01626859|Schizophrenia
1087454|NCT01626859|Antipsychotic Agents
1087455|NCT01626859|Mental Disorder
1087456|NCT01626859|Psychotropic Drugs
1087457|NCT01626859|Dopamine Agents
1087458|NCT01626859|Central Nervous System Agents
1087459|NCT01626846|Neurofibromatosis
1087460|NCT01626833|anorexia nervosa
1087461|NCT01626833|GH
1087462|NCT01626833|Growth velocity
1087463|NCT01626820|Immunogenicity
1087464|NCT01626820|Influenza
1087465|NCT01626820|Safety
1087466|NCT01626820|Adults
1087467|NCT01626820|Fluviral
1087468|NCT01626807|Safe Routes to School
1087469|NCT01626807|Walking School Bus
1087470|NCT01626807|Cluster Randomized Controlled Trial
1087471|NCT01626807|Physical Activity
1087472|NCT01626807|Obesity
1087473|NCT01626807|Overweight
1087474|NCT01626755|Phantom limb pain
1087475|NCT01626755|Chronic pain
1087476|NCT01626755|Amputation
1087477|NCT01626755|Peripheral vascular disease
1087478|NCT01626729|Food Labeling
1087479|NCT01626677|Umbilical Cord Blood
1087480|NCT01626677|Mesenchymal Stem Cells
1087481|NCT01626677|Cartilage injury
1087482|NCT01626677|Osteoarthritis
1087483|NCT01626664|Adult T cell Leukemia-Lymphoma (ATL)
1087484|NCT01626651|Healthy
1087485|NCT01626651|Ketoconazole
1087486|NCT01626651|Ibrutinib
1087487|NCT01626638|Patients with malignant and pre-malignant pharyngo laryngeal tumors
1087488|NCT01626625|nonunion
1087489|NCT01626625|stem cells
1087490|NCT01626625|autograft
1087491|NCT01626625|hydroxyapatite
1087492|NCT01626599|ECG
1087493|NCT01626599|Accelerometer
1087494|NCT01626599|Device
1087495|NCT01626586|Youth
1087496|NCT01626586|Family
1087497|NCT01626586|Group Therapy
1087498|NCT01626586|Type 1 Diabetes Mellitus
1087499|NCT01626586|Self-Management
1087500|NCT01626573|Rheumatoid Arthritis
1087501|NCT01626573|RA
1087502|NCT01626573|Active
1087503|NCT01626547|symptomatic anameia
1087504|NCT01626508|breast milk
1087505|NCT01626508|breast-milk bank
1087506|NCT01626508|plasma profile
1087507|NCT01626508|essential fatty acids
1087509|NCT01626443|PCOS
1087510|NCT01626443|Metabolic disorders
1087511|NCT01626443|Ovarian functionality
1087512|NCT01626443|Myo-inositol
1087513|NCT01626443|D-chiro-inositol
1087514|NCT01626430|Gamma delta TRF
1087515|NCT01626430|Insulin sensitivity
1087516|NCT01626430|Postprandial lipaemia
1087517|NCT01626430|Inflammatory markers
1087518|NCT01626430|NF-κB
1087519|NCT01626417|Stroke
1087520|NCT01626417|Tibion
1087521|NCT01626417|Bionics
1087522|NCT01626417|Rehab
1087523|NCT01626417|Therapy
1087524|NCT01626417|Robotics
1087525|NCT01626417|Intention
1087526|NCT01626404|Thoratec Corporation
1087527|NCT01626391|Alzheimer's Disease
1087528|NCT01626391|TRx0237
1087529|NCT01626391|Safety Study
1087530|NCT01626391|AD
1087531|NCT01626378|Behavioral Variant Frontotemporal Dementia
1087532|NCT01626378|bvFTD
1087533|NCT01626378|Frontotemporal Dementia
1087534|NCT01626339|Anti vascular endothelial growth factor
1087535|NCT01626339|retinal vessels
1087536|NCT01626326|smoking
1087537|NCT01626326|smoking cessation
1087538|NCT01626326|mobile app
1087539|NCT01626313|Veteran families
1087540|NCT01626313|OEF
1087541|NCT01626313|OIF
1087542|NCT01626313|OND
1087543|NCT01626313|Resiliency
1087544|NCT01626313|Psycho educational training
1087545|NCT01626313|Stress
1087546|NCT01626313|Military
1087547|NCT01626287|perineal
1087548|NCT01626287|postpartum
1087549|NCT01626287|pain
1087550|NCT01626287|treatment
1087551|NCT01626287|ice and black tea
1087552|NCT01626287|maternal satisfaction
1087553|NCT01626274|Polysomnography
1087554|NCT01626274|Long term vital signs monitoring
1087555|NCT01626274|In-ear sensor system
1087556|NCT01626274|Photoplethysmographic micro-optic device
1087557|NCT01626274|High wearing comfort
1087558|NCT01626248|Immunological
1087559|NCT01626248|biomarkers
1087560|NCT01626248|observational
1087561|NCT01626248|RRMS
1087562|NCT01626248|Relapsing
1087563|NCT01626248|Remitting Multiple Sclerosis
1087564|NCT01626235|pain control
1087565|NCT01626235|fractures
1087566|NCT01626235|sprains
1087567|NCT01626235|strains
1087568|NCT01626235|dysmenorrhea
1087569|NCT01626235|kidney stones
1087570|NCT01626235|gouty arthritis
1087571|NCT01626235|opioids
1087572|NCT01626235|NSDAIDs
1087573|NCT01626235|Emergency Department
1087574|NCT01626235|patient reported outcomes
1087575|NCT01626222|Postmenopausal
1087576|NCT01626222|Estrogen Receptor Positive
1087577|NCT01626222|HER2 negative
1087578|NCT01626222|Locally Advanced
1087579|NCT01626222|Metastatic Breast Cancer
1087580|NCT01626222|Everolimus (RAD001)
1087581|NCT01626222|Exemestane
1087582|NCT01626209|Breast cancer, NSCLC, SCCHN, esophageal cancer
1087583|NCT01626183|T-cell childhood acute lymphoblastic leukemia
1087584|NCT01626183|recurrent childhood acute lymphoblastic leukemia
1087585|NCT01626144|Exemestane
1087586|NCT01626144|Metabolism
1087587|NCT01626144|Metabolizing enzyme genotype
1087588|NCT01626144|Breast cancer
1087589|NCT01626131|combat disorders
1087590|NCT01626131|exercise therapy
1087591|NCT01626105|Hemophilia A
1087592|NCT01626105|Factor VIII
1087593|NCT01626105|Inhibitors
1087594|NCT01626105|Immunogenicity
1087595|NCT01626105|Pharmacogenetics
1087596|NCT01626105|Mutation
1087597|NCT01626105|Nonsynonymous Single Nucleotide Polymorphisms
1087598|NCT01626105|Class II Human Leukocyte Antigens
1087599|NCT01626092|bone marrow transplantation
1087600|NCT01626092|reduced intensity conditioning
1087601|NCT01626092|Adrenoleukodystrophy
1087602|NCT01626092|Metachromatic Leukodystrophy
1087603|NCT01626092|Globoid Cell Leukodystrophy
1087604|NCT01626092|Wolman's disease
1087605|NCT01626092|GM1 gangliosidosis
1087606|NCT01626092|Tay Sachs disease
1087607|NCT01626092|Sanfilippo syndrome
1087608|NCT01626092|Sandhoff disease
1087609|NCT01626092|inherited metabolic
1087610|NCT01626092|I-cell disease
1087611|NCT01626092|mucolipidosis II
1087612|NCT01626079|Functional Mitral Regurgitation
1087613|NCT01626079|Mitral Valve Regurgitation
1087614|NCT01626079|Symptomatic Heart Failure
1087615|NCT01626079|Functional MR
1087616|NCT01626079|MitraClip
1087617|NCT01626079|Mitral Valve Insufficiency
1087618|NCT01626079|Cardiopulmonary exercise testing
1087619|NCT01626053|psychological
1087620|NCT01626053|intervention
1087621|NCT01626053|stages of change
1087622|NCT01626053|motivational interviewing
1087623|NCT01626053|coping skills
1087624|NCT01626053|HbA1C
1087625|NCT01626053|psychological testing
1087626|NCT01626053|integrated care
1087627|NCT01626053|behavioral health
1087628|NCT01626027|Coronary Heart Disease
1087629|NCT01626027|Depression
1087630|NCT01626027|Health Care Services
1087631|NCT01626014|Stage III ovarian cancer
1087632|NCT01626014|Stage IV ovarian cancer
1087633|NCT01626014|recurrent ovarian cancer
1087634|NCT01626014|primary peritoneal cancer
1087635|NCT01626014|fallopian tube cancer
1087636|NCT01626001|Esophagus Cancer
1087637|NCT01626001|Lung Cancer
1087638|NCT01626001|4-dimensional computed tomography
1087639|NCT01626001|4D CT
1087640|NCT01625975|Growth modulation
1087641|NCT01625975|Eight plate
1087642|NCT01625975|Leg length discrepancy
1087643|NCT01625975|Varus/valgus deformities
1087644|NCT01625975|Pediatric
1087645|NCT01625962|PTSD
1087646|NCT01625962|mTBI
1087647|NCT01625962|mild TBI
1087648|NCT01625962|extracranial injury
1087649|NCT01625962|ECI
1087650|NCT01625962|Brain Indices
1087651|NCT01625949|myocardial infarction
1087652|NCT01625936|metastatic
1087653|NCT01625936|locally advanced
1087654|NCT01625936|unresectable
1087655|NCT01625923|Gastroparesis
1087656|NCT01625923|Idiopathic
1087657|NCT01625923|Olanzapine
1087658|NCT01625910|Childhood obesity treatment
1087659|NCT01625910|Motivational interviewing
1087660|NCT01625897|Schizophrenia
1087661|NCT01625897|Antipsychotic Agents
1087662|NCT01625897|Mental Disorder
1087663|NCT01625897|Psychotropic Drugs
1087664|NCT01625897|Dopamine Agents
1087665|NCT01625897|Risperidone
1087666|NCT01625897|Central Nervous System Agents
1087667|NCT01625884|Statin
1087668|NCT01625884|Hypercholesterolemia
1087669|NCT01625871|malaria
1087670|NCT01625871|vivax
1087671|NCT01625871|artemether/lumefantrine
1087672|NCT01625871|Sudan
1087673|NCT01625858|LMA Supreme
1087674|NCT01625845|Major Depressive Disorder
1087675|NCT01625845|Depression
1087676|NCT01625845|Depressive Symptoms
1087677|NCT01625845|Cardiovascular Disease (CVD)
1087678|NCT01625845|Coronary Artery Disease (CAD)
1087679|NCT01625845|Heart Disease
1087680|NCT01625845|Endothelial Function
1087681|NCT01625845|Inflammation
1087682|NCT01625832|intermittent coronary sinus occlusion
1087683|NCT01625832|collateral flow index
1087684|NCT01625832|collateral circulation
1087685|NCT01625832|coronary artery occlusion
1087686|NCT01625819|Tai Chi
1087687|NCT01625793|Hepatitis C
1087688|NCT01625793|interferon
1087689|NCT01625793|stress
1087690|NCT01625793|social behavior
1087691|NCT01625767|Nicotine
1087692|NCT01625767|Smoking
1087693|NCT01625767|Adolescent
1087694|NCT01625767|Tobacco
1087695|NCT01625754|Ceramides
1087696|NCT01625754|Lipids
1087697|NCT01625728|Voice
1087698|NCT01625728|aerodynamics
1087699|NCT01625728|acoustics
1087700|NCT01625715|peanut allergy
1087701|NCT01625702|no-prior chemotherapy
1087702|NCT01625689|Influenza vaccines
1087703|NCT01625689|Influenza, Human
1087704|NCT01625689|Live Attenuated Influenza Vaccine
1087705|NCT01625676|Aphasia
1087706|NCT01625676|Rehabilitation of Speech and Language Disorders
1087707|NCT01625663|barth syndrome
1087708|NCT01625663|heart failure
1087709|NCT01625663|mitochondria
1087710|NCT01625663|metabolism
1087711|NCT01625663|amino acid
1087712|NCT01625650|Rheumatoid Arthritis
1087713|NCT01625650|Registry
1087714|NCT01625650|RA
1087715|NCT01625650|Biologic
1087716|NCT01625650|Medications
1087717|NCT01625650|Rheumatology
1087718|NCT01625637|Nicotine
1087719|NCT01625637|Smoking
1087720|NCT01625637|Adolescent
1087721|NCT01625637|Tobacco
1087722|NCT01625611|Alcohol
1087723|NCT01625611|Drinking
1087724|NCT01625611|Drinkers
1087725|NCT01625611|Alcohol Drinking
1087726|NCT01625611|Naltrexone
1087727|NCT01625611|Alcohol Dependence
1087728|NCT01625611|Alcohol Abuse
1087729|NCT01625611|Alcohol-Related Disorders
1087730|NCT01625611|Ethanol
1087731|NCT01625611|Alcoholism
1087732|NCT01625598|Nonproliferative diabetic retinopathy
1087733|NCT01625598|diabetic macular edema
1087734|NCT01625598|proliferative diabetic retinopathy
1087735|NCT01625598|ophthalmologists
1087736|NCT01625598|dilated eye exam
1087737|NCT01625585|Push-and-Pull Enteroscopy
1087738|NCT01625585|Single-Balloon-Enteroscopy
1087739|NCT01625572|general anaesthesia
1087740|NCT01625572|epidural catheter
1087741|NCT01625572|intravenous pain therapy
1087742|NCT01625546|Major Depressive Disorder
1087743|NCT01625546|Whole Body Hyperthermia
1087744|NCT01625533|Coronary Angiography
1087745|NCT01625533|Rotational Coronary Angiography
1087746|NCT01625533|Contrast media
1087747|NCT01625533|Radiation
1087748|NCT01625520|Progressive metastatic
1087749|NCT01625520|postoperative persistent
1087750|NCT01625468|Secondhand smoke exposure
1087751|NCT01625468|Smoke-free homes
1087752|NCT01625468|Smoke-free home bans
1087753|NCT01625455|Sezary Syndrome
1087754|NCT01625455|Pruritus
1087755|NCT01625455|Aprepitant
1087756|NCT01625455|Neurokinin-1
1087757|NCT01625442|Metabolic syndrome
1087758|NCT01625442|hypercholesterolemia
1087759|NCT01625442|hypertriglyceridemia
1087760|NCT01625442|hyperglycemia
1087761|NCT01625416|Posttraumatic Stress Disorder
1087762|NCT01625416|Depression
1087763|NCT01625416|Suicide
1087764|NCT01625416|Traumatic Brain Injury
1087765|NCT01625416|Alcohol Use
1087766|NCT01625416|Drug Use
1087767|NCT01625416|Information Technology
1087768|NCT01625403|Recombinant BNP
1087769|NCT01625403|Diuretics
1087770|NCT01625403|Acute decompensated heart failure
1087771|NCT01625403|Acute renal injury
1087772|NCT01625403|Heart function
1087773|NCT01625403|Renal function
1087774|NCT01625390|hemophilia, haemophilia, inhibitor, FVIIa, Factor VII activated, bypassing
1087775|NCT01625377|Everolimus,
1087776|NCT01625377|liver transplantation,
1087777|NCT01625377|early introduction,
1087778|NCT01625377|renal function
1087779|NCT01625364|Health Education
1087780|NCT01625364|Health Counseling
1087781|NCT01625364|Patient Education
1087782|NCT01625338|HCV genotype 2 (GT-2)
1087783|NCT01625338|HCV genotype 3 (GT-3)
1087784|NCT01625338|HCV
1087785|NCT01625338|Sustained Virologic Response
1087786|NCT01625338|Direct Acting Antiviral
1087787|NCT01625338|Combination Therapy
1087788|NCT01625338|GS-7977
1087789|NCT01625338|Ribavirin
1087790|NCT01625338|Open Label
1087791|NCT01625325|obesity, adiposity, psychosocial, healthcare, co-morbidities, low key intervention, quality of life
1087792|NCT01625299|intestinal permeability
1087793|NCT01625299|diet
1087794|NCT01625299|gluten
1087795|NCT01625299|dairy
1087796|NCT01625286|advanced breast cancer,
1087797|NCT01625286|metastatic breast cancer,
1087798|NCT01625286|ER+ve breast cancer,
1087799|NCT01625286|Estrogen receptor positive breast cancer,
1087800|NCT01625286|PIK3CA mutated advanced or metastatic breast cancer
1087801|NCT01625286|AKT inhibitor
1087802|NCT01625273|F19
1087803|NCT01625273|Lactobacillus paracasei paracasei
1087804|NCT01625260|cancer
1087805|NCT01625260|immunotherapy
1087806|NCT01625260|targeted
1087807|NCT01625260|non-muscle invasive
1087808|NCT01625260|interleukin-2
1087809|NCT01625260|antitumor
1087810|NCT01625260|TCR
1087811|NCT01625260|T-cell receptor
1087812|NCT01625260|p53
1087813|NCT01625260|p53 gene
1087814|NCT01625260|p53 tumor supressor protein
1087815|NCT01625260|urothelial cancer
1087816|NCT01625260|bladder cancer
1087817|NCT01625260|HLA-A2 positive
1087818|NCT01625260|HLA-A*0201/p53 aa264-272
1087819|NCT01625260|HLA complex
1087820|NCT01625260|refractory
1087821|NCT01625260|relapsed
1087822|NCT01625260|BCG
1087823|NCT01625260|multi-focal
1087824|NCT01625260|carcinoma in situ
1087825|NCT01625260|transitional cell carcinoma
1087826|NCT01625260|gemcitabine
1087827|NCT01625234|Cancer
1087828|NCT01625234|Tumors
1087829|NCT01625234|ALK
1087830|NCT01625234|NSCLC
1087831|NCT01625234|Advanced Malignancies
1087832|NCT01625234|Carcinoma, Non-Small-Cell Lung
1087833|NCT01625234|Inflammatory Myofibroblastic Tumors
1087834|NCT01625221|FENIX
1087835|NCT01625182|chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, FTY720, fingolimod.
1087836|NCT01625169|Pharmacokinetics
1087837|NCT01625169|HIV
1087838|NCT01625169|Breast milk
1087839|NCT01625130|sulforaphane
1087840|NCT01625130|ozone
1087841|NCT01625130|airway inflammation
1087842|NCT01625130|broccoli sprouts
1087843|NCT01625130|NRF2
1087844|NCT01625130|controls
1087845|NCT01625117|Treatment of ex-combatants
1087846|NCT01625117|Narrative Exposure Therapy for ex-combatants
1087847|NCT01625117|Appetitive Aggression
1087848|NCT01625117|Posttraumatic Stress Disorder
1087849|NCT01625104|Myocardial Infarction
1087850|NCT01625104|Time to Treatment
1087851|NCT01625104|Door to Balloon Time
1087852|NCT01625091|HIV
1087853|NCT01625091|women
1087854|NCT01625091|drinking
1087855|NCT01625091|Naltrexone
1087856|NCT01625078|Baska Mask
1087857|NCT01625078|Supraglottic airway device
1087858|NCT01625078|Children
1087859|NCT01625078|Pediatric
1087860|NCT01625065|medication compliance
1087861|NCT01625065|adherence
1087862|NCT01625065|toxicological analyzes
1087863|NCT01625065|GC-MS
1087864|NCT01625065|HPLC
1087865|NCT01625065|pain patients
1087866|NCT01625065|opioid misuse
1087867|NCT01625065|patients with current pain
1087868|NCT01625052|mask size
1087869|NCT01625052|Baska mask
1087870|NCT01625052|supraglottic airway
1087871|NCT01625052|airway management
1087872|NCT01625039|Occupational health
1087873|NCT01625039|cognitive behavioural therapy
1087874|NCT01625039|physiotherapy
1087875|NCT01625039|physical activity
1087876|NCT01625026|Morbidly obesity
1087877|NCT01625026|Gastric bypass
1087878|NCT01625026|Cholecystolithiasis
1087879|NCT01625013|osteoarthritis
1087880|NCT01625013|viscosupplementation
1087881|NCT01625013|Active
1087882|NCT01625013|Knee
1087883|NCT01625013|Synvisc-One
1087884|NCT01625000|Schizophrenia
1087885|NCT01625000|Antipsychotic Agents
1087886|NCT01625000|Acute Schizophrenia
1087887|NCT01625000|Mental Disorder
1087888|NCT01625000|Psychotropic Drugs
1087889|NCT01625000|Dopamine Agents
1087890|NCT01625000|Risperidone
1087891|NCT01625000|Central Nervous System Agents
1087892|NCT01624987|Treatment of ex-combatants
1087893|NCT01624987|FORNET for ex-combatants
1087894|NCT01624987|Appetitive Aggression
1087895|NCT01624987|Post-traumatic Stress Disorder
1087896|NCT01624961|Controlled human malaria infection (CHMI)
1087897|NCT01624961|Malaria challenge
1087898|NCT01624961|Plasmodium falciparum
1087899|NCT01624961|PfSPZ Challenge
1087900|NCT01624948|BK virus
1087901|NCT01624948|Kidney Transplantation
1087902|NCT01624948|Immunologic Monitoring
1087903|NCT01624935|PTSD
1087904|NCT01624935|earthquake
1087905|NCT01624935|disaster
1087906|NCT01624935|global mental health
1087907|NCT01624935|disaster mental health
1087908|NCT01624935|depression
1087909|NCT01624870|Aortic Valve Stenonis
1087910|NCT01624870|Valvular Heart Disease
1087911|NCT01624870|Transcatheter Aortic Valve Implantation
1087912|NCT01624844|ultrasound
1087913|NCT01624831|Psychosis
1087914|NCT01624831|schizophrenia
1087915|NCT01624831|schizoaffective disorder
1087916|NCT01624831|Bipolar disorder with psychotic features
1087917|NCT01624831|Major depression with psychotic features
1087918|NCT01624831|Psychosis NOS
1087919|NCT01624831|Social Cognition
1087920|NCT01624818|coping
1087921|NCT01624818|physical activity
1087922|NCT01624818|psychosocial
1087923|NCT01624818|children
1087924|NCT01624818|heart disease
1087925|NCT01624818|habilitation
1087926|NCT01624805|Leukemia
1087927|NCT01624805|Aplastic Anemia
1087928|NCT01624805|AA
1087929|NCT01624805|Low/Int-1 Risk Myelodysplastic Syndrome
1087930|NCT01624805|MDS
1087931|NCT01624805|hATG
1087932|NCT01624805|Horse Antithymocyte Globulin
1087933|NCT01624805|ATG
1087934|NCT01624805|Antithymocyte Globulin
1087935|NCT01624805|Thymoglobulin
1087936|NCT01624805|Cyclosporine
1087937|NCT01624805|Sandimmune
1087938|NCT01624805|CYA
1087939|NCT01624805|Cyclosporin A
1087940|NCT01624805|Methylprednisone
1087941|NCT01624805|Methylprednisolone
1087942|NCT01624805|Depo-Medrol
1087943|NCT01624805|Medrol
1087944|NCT01624805|Solu-Medrol
1087945|NCT01624805|pegfilgrastim
1087946|NCT01624805|Neulasta
1087947|NCT01624805|PEG-G-CSF
1087948|NCT01624805|Filgrastim
1087949|NCT01624805|C-CSF
1087950|NCT01624805|Neupogen
1087951|NCT01624792|Protein metabolism
1087952|NCT01624792|casein protein
1087953|NCT01624792|EPA
1087954|NCT01624792|Fish oil
1087955|NCT01624779|autologous adipose tissue
1087956|NCT01624766|Advanced Cancers
1087957|NCT01624766|Advanced Malignancies
1087958|NCT01624766|Metastatic Cancers
1087959|NCT01624766|Everolimus
1087960|NCT01624766|Afinitor
1087961|NCT01624766|RAD001
1087962|NCT01624766|Anakinra
1087963|NCT01624766|Kineret
1087964|NCT01624766|Denosumab
1087965|NCT01624766|AMG 162
1087966|NCT01624753|interstitial lung disease
1087967|NCT01624753|interstitial pneumonia
1087968|NCT01624753|idiopathic pulmonary fibrosis
1087969|NCT01624727|Coronary heart disease
1087970|NCT01624727|metabolic syndrome
1087971|NCT01624727|CT angiography
1087972|NCT01624714|Treatment Refractory
1087973|NCT01624701|Cord blood
1087974|NCT01624701|unrelated donor
1087975|NCT01624701|allogeneic
1087976|NCT01624701|cell dose
1087977|NCT01624688|Tattoo
1087978|NCT01624688|Tattoo Removal
1087979|NCT01624675|Autistic disorder in children and adolescents
1087980|NCT01624675|Risperidone (R064766)
1087981|NCT01624675|Children
1087982|NCT01624675|Adolescents
1087983|NCT01624675|Irritability
1087984|NCT01624675|Autistic disorder
1087985|NCT01624649|Attention-deficit hyperactivity disorder
1087986|NCT01624649|Developmental disorder
1087987|NCT01624649|Atomoxetine
1087988|NCT01624649|Methylphenidate
1087989|NCT01624649|Psychiatric disorder
1087990|NCT01624636|AMD
1087991|NCT01624636|Age-related Macular Degeneration
1087992|NCT01624636|Wet AMD
1087993|NCT01624636|Neovascular AMD
1087994|NCT01624623|radiation
1087995|NCT01624623|Calypso
1087996|NCT01624623|prostatectomy
1087997|NCT01624610|Irritable bowel syndrome
1087998|NCT01624610|Diarrhea
1087999|NCT01624610|abdominal pain
1088000|NCT01624610|diet
1088001|NCT01624610|nutrition
1088002|NCT01624597|Road traffic safety
1088003|NCT01624584|child
1088004|NCT01624584|anxiety
1088005|NCT01624584|CBT
1088006|NCT01624558|malignant hyperthermia
1088007|NCT01624545|chronic subdural hematoma
1088008|NCT01624545|burr hole trepanation
1088009|NCT01624545|radiologic follow-up
1088010|NCT01624545|outcome
1088011|NCT01624545|recurrence
1088012|NCT01624532|Anthrax vaccine
1088013|NCT01624519|Arterial Lactate
1088014|NCT01624519|Central Venous Lactate
1088015|NCT01624519|Peripheral Venous Lactate
1088016|NCT01624506|GERD
1088017|NCT01624506|Fundoplication
1088018|NCT01624506|Magnetic Sphincter Augmentation
1088019|NCT01624493|Vascular Disrupting Agents
1088020|NCT01624493|BNC105P
1088021|NCT01624493|Partially platinum sensitive
1088022|NCT01624480|Pediatric Narcolepsy
1088023|NCT01624467|Advanced Solid Tumors
1088024|NCT01624454|colonoscopy
1088025|NCT01624454|bowel cleansing
1088026|NCT01624428|Tobacco
1088027|NCT01624428|Adolescent
1088028|NCT01624428|Nicotine
1088029|NCT01624428|Magnetic Resonance Imaging
1088030|NCT01624428|Varenicline
1088031|NCT01624389|[18F]AV-45 PET amyloid binding imaging
1088032|NCT01624389|Alzheimer's disease
1088033|NCT01624376|non-invasive management
1088034|NCT01624376|Fistula
1088035|NCT01624376|Crohn's Disease
1088036|NCT01624376|local administration
1088037|NCT01624376|non-invasive
1088038|NCT01624363|Pancreatic cysts incidentally found during EUS
1088039|NCT01624350|Anorectal Fistulas
1088040|NCT01624337|Plasmodium falciparum
1088041|NCT01624337|Plasmodium vivax
1088042|NCT01624324|aminoglycoside
1088043|NCT01624324|KIM-1
1088044|NCT01624324|DPOAE
1088045|NCT01624324|nephrotoxicity
1088046|NCT01624324|ototoxicity
1088047|NCT01624311|High ammonia level
1088048|NCT01624311|Hyperammonemia
1088049|NCT01624311|Poor suck
1088050|NCT01624311|Lethargy
1088051|NCT01624311|Coma
1088052|NCT01624311|Encephalopathy
1088053|NCT01624311|Seizures
1088054|NCT01624311|Brain edema
1088055|NCT01624311|Urea Cycle Disorder
1088056|NCT01624311|Ornithine Transcarbamylase Deficiency
1088057|NCT01624311|Carbamoyl Phosphate Synthetase Deficiency
1088058|NCT01624311|Citrullinemia
1088059|NCT01624311|Argininosuccinic Aciduria
1088060|NCT01624311|Organic Acidemia
1088061|NCT01624311|Propionic Aciduria
1088062|NCT01624311|Methylmalonic Aciduria
1088063|NCT01624311|Isovaleric Aciduria
1088064|NCT01624298|Randomized controlled trial
1088065|NCT01624298|Traumatized youth
1088066|NCT01624298|HIV risk
1088067|NCT01624272|Physical Therapy
1088068|NCT01624272|Respiratory Muscle Training
1088069|NCT01624272|Elderly
1088070|NCT01624220|Spinal tumor
1088071|NCT01624220|Tumor of the mid or lower spine
1088072|NCT01624220|Non-small cell lung cancer
1088073|NCT01624220|Breast cancer
1088074|NCT01624220|Prostate cancer
1088075|NCT01624220|Renal cell cancer
1088076|NCT01624220|Melanoma
1088077|NCT01624220|Gastrointestinal cancer
1088078|NCT01624220|Sarcoma
1088079|NCT01624220|Thyroid cancer
1088080|NCT01624220|Head and neck primary cancer
1088081|NCT01624220|Carcinoma of unknown primary
1088082|NCT01624220|Fiducial markers
1088083|NCT01624220|Gold seed markers
1088084|NCT01624220|Spinal stereotactic body radiation therapy
1088085|NCT01624220|Spinal SBRT
1088086|NCT01624220|Stereotactic Radiotherapy
1088087|NCT01624207|Atorva
1088088|NCT01624207|generic
1088089|NCT01624207|atorvastatin
1088090|NCT01624207|hypercholesterolemia
1088091|NCT01624181|ion mobility spectrometry
1088092|NCT01624181|hospital-acquired pneumonia
1088093|NCT01624181|microbiological investigation
1088094|NCT01624181|intensive care
1088095|NCT01624168|anxiety
1088096|NCT01624168|sleep quality
1088097|NCT01624168|tai chi chuan
1088098|NCT01624168|young adults
1088099|NCT01624155|teratogens
1088100|NCT01624155|contraception
1088101|NCT01624155|electronic medical record
1088102|NCT01624142|Hypercholesterolemia
1088103|NCT01624142|Elevated Cholesterol
1088104|NCT01624142|High Cholesterol
1088105|NCT01624142|Homozygous Familial Hypercholesterolemia
1088106|NCT01624142|PCSK9 mutations
1088107|NCT01624142|Severe Familial Hypercholesterolemia
1088108|NCT01624103|Arm Injuries
1088109|NCT01624103|Wounds and Injuries
1088110|NCT01624103|Lidocaine
1088111|NCT01624103|Levobupivacaine
1088112|NCT01624103|Bupivacaine
1088113|NCT01624103|Anesthetics
1088114|NCT01624103|Central Nervous System Depressants
1088115|NCT01624103|Physiological Effects of Drugs
1088116|NCT01624090|Cancer Stem Cell
1088117|NCT01624090|Thoracic Malignancies
1088118|NCT01624090|Mythramycin Treatment
1088119|NCT01624090|Lung Tumors
1088120|NCT01624090|Metastatic Lung Tumors
1088121|NCT01624077|Regulatory T cells
1088122|NCT01624077|Liver Transplantation
1088123|NCT01624077|Rejection
1088124|NCT01624077|Tolerance
1088125|NCT01624077|Cell tolerance
1088126|NCT01624077|Survival
1088127|NCT01624064|Renal Insufficiency, Chronic
1088128|NCT01624064|Uncertain aetiology
1088129|NCT01624064|ACEI
1088130|NCT01624051|cisplatin based chemotherapy
1088261|NCT01623336|PEGINTERFERON
1088131|NCT01624051|non-small cell lung cancer
1088132|NCT01624051|lean body mass
1088133|NCT01624051|sarcopenia
1088134|NCT01624038|Hydroxyurea
1088135|NCT01624038|Erythropoitin therapy
1088136|NCT01624038|Thalassemia intermedia
1088137|NCT01624025|AGC, second-line, docetaxel, epirubicin
1088138|NCT01624012|NIV NAVA
1088139|NCT01624012|non-invasive ventilation
1088140|NCT01623973|hemiparetic
1088141|NCT01623973|cognitive
1088142|NCT01623973|balance
1088143|NCT01623960|severe haemophilia
1088144|NCT01623960|quality of life
1088145|NCT01623947|glutamine
1088146|NCT01623947|cycling performance
1088147|NCT01623947|mental function
1088148|NCT01623934|Gestational diabetes
1088149|NCT01623934|Adiponectin
1088150|NCT01623934|Leptin
1088151|NCT01623934|Single Nucleotides Polymorphisms
1088152|NCT01623934|Insulin resistance
1088153|NCT01623921|Lung
1088154|NCT01623921|Contusion
1088155|NCT01623921|Injury
1088156|NCT01623921|Cyclooxygenase
1088157|NCT01623921|Statin
1088158|NCT01623908|Breast neoplasms
1088159|NCT01623908|Zoledronate
1088160|NCT01623908|Bone loss
1088161|NCT01623882|Diabetes Mellitus
1088162|NCT01623882|Wounds
1088163|NCT01623882|Ulcers
1088164|NCT01623843|FAI
1088165|NCT01623843|randomized
1088166|NCT01623843|hip arthroscopy
1088167|NCT01623843|lavage
1088168|NCT01623843|osteochondroplasty
1088169|NCT01623830|reconsolidation
1088170|NCT01623830|fear of flying
1088171|NCT01623830|virtual reality
1088172|NCT01623830|virtual reality exposure therapy
1088173|NCT01623804|Ultrasound therapy
1088174|NCT01623804|Tibiofemoral joint, medial
1088175|NCT01623804|Nonsurgical
1088176|NCT01623791|Pre-eclampsia
1088177|NCT01623791|Proteinuria
1088178|NCT01623791|Protein - creatinine ratio
1088179|NCT01623791|Dipstick proteinuria
1088180|NCT01623791|Severity of disease
1088181|NCT01623778|HBeAg seroconversion
1088182|NCT01623778|Peginterferon alfa-2a
1088183|NCT01623778|chronic hepatitis B(CHB
1088184|NCT01623778|Optimal therapy
1088185|NCT01623778|Response guild treatment(RGT);
1088186|NCT01623765|Endobronchial ultrasound, lung cancer
1088187|NCT01623739|Dental implants
1088188|NCT01623739|Esthetic score
1088189|NCT01623739|Immediate implants
1088190|NCT01623739|Early placement
1088191|NCT01623726|Transcranial Direct Current Stimulation
1088192|NCT01623726|Schizophrenia
1088193|NCT01623713|schizophrenia
1088194|NCT01623713|iloperidone
1088195|NCT01623713|Risperidone
1088196|NCT01623713|Efficacy
1088197|NCT01623713|Safety
1088198|NCT01623700|clopidogrel
1088199|NCT01623700|aspirin
1088200|NCT01623700|percutaneous coronary intervention
1088201|NCT01623700|coronary stenting
1088202|NCT01623700|antiplatelet
1088203|NCT01623687|total hip arthroplasty
1088204|NCT01623687|bone metabolism
1088205|NCT01623687|mineralisation
1088206|NCT01623674|Sleep deprivation in surgeons during night shifts and the effect on performance.
1088207|NCT01623661|Nephrology
1088208|NCT01623661|chronic kidney disease
1088209|NCT01623661|sodium-channels
1088210|NCT01623661|water-channels
1088211|NCT01623661|BCM
1088212|NCT01623648|whey protein
1088213|NCT01623648|hunger
1088214|NCT01623609|Phase 1
1088215|NCT01623609|Healthy volunteers
1088216|NCT01623609|Naloxegol
1088217|NCT01623609|Bioequivalence
1088218|NCT01623583|lidocaine
1088219|NCT01623583|tetracaine
1088220|NCT01623583|Renal dialysis
1088221|NCT01623570|Luteinizing Hormone
1088222|NCT01623570|Hypogonadotropic Hypogonadism
1088223|NCT01623570|Ovulation Induction
1088224|NCT01623570|Chorionic Gonadotropin
1088225|NCT01623557|Malaria
1088226|NCT01623557|Vaccine
1088227|NCT01623557|Plasmodium
1088228|NCT01623557|falciparum
1088229|NCT01623544|Asthma
1088230|NCT01623544|Comparative Effectiveness
1088231|NCT01623544|Symbicort
1088232|NCT01623531|Fibrinogen
1088233|NCT01623531|cardiac surgery
1088234|NCT01623531|high risk
1088235|NCT01623531|cardiopulmonary bypass
1088236|NCT01623531|bleeding
1088237|NCT01623531|blood transfusion
1088238|NCT01623505|Smoking Cessation
1088239|NCT01623505|Psychiatric Illness
1088240|NCT01623505|Pharmacotherapy
1088241|NCT01623492|Eisenmenger
1088242|NCT01623466|PK and Safety
1088243|NCT01623453|crohn's disease
1088244|NCT01623453|fistula
1088245|NCT01623453|complex
1088246|NCT01623427|pediatric
1088247|NCT01623427|laparoscopy
1088248|NCT01623427|vacuum
1088249|NCT01623427|dressing
1088250|NCT01623362|Dentifrices
1088251|NCT01623362|Dental Caries
1088252|NCT01623362|Fluorides
1088253|NCT01623362|Nails
1088254|NCT01623362|pH
1088255|NCT01623349|Recurrent
1088256|NCT01623349|High Grade
1088257|NCT01623349|Serous
1088258|NCT01623349|Triple Negative
1088259|NCT01623336|HEPATITIS
1088260|NCT01623336|HEPATITIS C
1088262|NCT01623336|BIOEQUIVALENCE
1088263|NCT01623336|TREATMENT
1088264|NCT01623297|Laparoscopy
1088265|NCT01623297|Surgery
1088266|NCT01623297|Acute Phase Reaction
1088267|NCT01623297|Aged
1088268|NCT01623297|Aged 80 and over
1088269|NCT01623297|Confusion
1088270|NCT01623297|Inflammation
1088271|NCT01623297|Delirium
1088272|NCT01623284|aphasia
1088273|NCT01623284|apraxia of speech
1088274|NCT01623284|language
1088275|NCT01623271|CRPS I
1088276|NCT01623232|vaccine
1088277|NCT01623232|influenzavirus A
1088278|NCT01623232|influenzavirus B
1088279|NCT01623232|adjuvant
1088280|NCT01623219|PTSD
1088281|NCT01623219|trauma
1088282|NCT01623219|combat trauma
1088283|NCT01623219|veterans
1088284|NCT01623219|telemedicine
1088285|NCT01623219|prolonged exposure
1088286|NCT01623193|Cardioplegia
1088287|NCT01623193|Blood transfusion
1088288|NCT01623193|Cardiac function
1088289|NCT01623193|Myocardial edema
1088290|NCT01623193|Coronary artery disease
1088291|NCT01623193|Valve disease
1088292|NCT01623180|DES
1088293|NCT01623180|coronary stent
1088294|NCT01623180|bare metal stent
1088295|NCT01623180|high bleeding
1088296|NCT01623180|MI
1088297|NCT01623180|angina
1088298|NCT01623167|T-cells
1088299|NCT01623167|Immunosuppression
1088300|NCT01623167|Hematopoesis
1088301|NCT01623167|Autoimmunity
1088302|NCT01623167|Thrombocytopenia
1088303|NCT01623154|Helicobacter pylori
1088304|NCT01623141|CRPS
1088305|NCT01623141|TPBS
1088306|NCT01623141|Pressure pain thresholds
1088307|NCT01623141|limb pain of other origin
1088308|NCT01623128|Breastfeeding initiation
1088309|NCT01623128|Breastfeeding duration
1088310|NCT01623128|WIC
1088311|NCT01623128|Video education
1088312|NCT01623128|Breastfeeding rates
1088313|NCT01623115|PCSK9
1088314|NCT01623102|Bevacizumab
1088315|NCT01623102|gemcitabine
1088316|NCT01623102|cisplatin
1088317|NCT01623102|EGFR wild-type
1088318|NCT01623089|severe asthma, phenotype, data
1088324|NCT01623063|endometrium
1088325|NCT01623063|infertility
1088326|NCT01623063|uterus
1088327|NCT01623063|histeroscopy
1088331|NCT01623011|Shoulder
1088332|NCT01623011|Sub-acromial
1088333|NCT01623011|Rotator Cuff
1088334|NCT01623011|Impingement
1088335|NCT01622998|Pharmacotherapy
1088336|NCT01622998|Titration
1088337|NCT01622998|Smoking Cessation
1088338|NCT01622959|emergency departement
1088339|NCT01622959|acute pain
1088340|NCT01622959|acupuncture
1088341|NCT01622959|morphine
1088342|NCT01622946|total hip arthroplasty
1088343|NCT01622946|tranexamic acid
1088344|NCT01622946|postoperative blood loss
1088345|NCT01622933|melanoma
1088346|NCT01622933|recurrent
1088347|NCT01622933|metastatic
1088348|NCT01622920|enamel erosion
1088349|NCT01622920|ultrasound
1088350|NCT01622920|reproducibility
1088351|NCT01622920|human central incisor
1088352|NCT01622920|reliability
1088353|NCT01622907|Catheter ablation, radiofrequency
1088354|NCT01622907|Epicardially applied radiofrequency ablation
1088355|NCT01622907|Minimally invasive surgical approach
1088356|NCT01622894|Alzheimer genetics
1088357|NCT01622855|Rape
1088358|NCT01622855|Secondary prevention
1088359|NCT01622855|Intervention
1088360|NCT01622842|Impedance
1088361|NCT01622842|Electrical
1088362|NCT01622842|Tissue
1088363|NCT01622842|Excitation frequency
1088364|NCT01622842|arterial distension
1088365|NCT01622842|distension wave form
1088366|NCT01622777|Rosuvastatin
1088367|NCT01622777|Diabetic polyneuropathy
1088368|NCT01622777|Nerve conduction
1088369|NCT01622777|Oxidative stress
1088370|NCT01622777|Nerve growth factor
1088371|NCT01622764|RO5323441
1088372|NCT01622764|bevacizumab
1088373|NCT01622764|PET imaging
1088374|NCT01622764|recurrent glioblastoma
1088375|NCT01622751|REM sleep
1088376|NCT01622751|Adiponectin
1088377|NCT01622751|Prader-Willi syndrome
1088378|NCT01622725|ventral hernia
1088379|NCT01622712|inguinal hernia
1088380|NCT01622699|Jaundice
1088381|NCT01622699|Neonatal Jaundice
1088382|NCT01622699|Hyperbilirubinemia
1088383|NCT01622699|Transcutaneous bilirubin measurement
1088384|NCT01622699|Transcutaneous bilirubinometry
1088385|NCT01622699|jaundice meter
1088386|NCT01622699|Visual assessment of bilirubin
1088387|NCT01622699|Newborn
1088388|NCT01622686|Prescription Labels
1088389|NCT01622686|Low Health Literacy
1088390|NCT01622686|Limited English Proficiency
1088391|NCT01622686|Spanish
1088392|NCT01622660|URETER
1088393|NCT01622660|URINARY BLADDER
1088394|NCT01622660|renal pelvis
1088395|NCT01622660|GEMCITABINE
1088396|NCT01622660|GW786034 (PAZOPANIB)
1088397|NCT01622660|11-191
1088398|NCT01622647|NCPAP
1088399|NCT01622634|cardiovascular disease
1088400|NCT01622634|diabetes mellitus
1088401|NCT01622621|Lung
1088402|NCT01622621|Cancer
1088403|NCT01622608|Adolescent vaccination
1088404|NCT01622608|Immunization rates
1088405|NCT01622608|Informational kiosk
1088406|NCT01622608|Tailored health messaging
1088407|NCT01622608|Barriers to vaccination
1088408|NCT01622608|Attitudes
1088409|NCT01622608|Intentions
1088410|NCT01622595|Aspergillosis
1088411|NCT01622595|Candidemia
1088412|NCT01622595|Candidiasis
1088413|NCT01622595|C. Difficile
1088414|NCT01622595|cytomegalovirus
1088415|NCT01622595|respiratory syncytial virus (RSV)
1088416|NCT01622595|Influenza
1088417|NCT01622595|CONS
1088418|NCT01622582|Multiple Myeloma, Engraftment syndrome
1088419|NCT01622556|Chronic Myeloid Leukemia
1088420|NCT01622556|Acute Myeloid Leukemia
1088421|NCT01622556|Acute Lymphoblastic Leukemia
1088422|NCT01622556|Non-Hodgkins Lymphoma
1088423|NCT01622556|Hodgkin's Disease
1088424|NCT01622556|Myelodysplastic Syndromes
1088425|NCT01622556|Myeloproliferative Disorder
1088426|NCT01622504|Intranasal
1088427|NCT01622504|nasal spray
1088428|NCT01622504|opioid
1088429|NCT01622504|overdose
1088430|NCT01622491|H1N1
1088431|NCT01622491|pandemic
1088432|NCT01622491|influenza
1088433|NCT01622491|pneumonia
1088434|NCT01622491|vaccine
1088435|NCT01622491|effectiveness
1088436|NCT01622491|Manitoba
1088437|NCT01622491|Canada
1088438|NCT01622478|sentinel lymph node biopsy
1088439|NCT01622478|neoadjuvant chemotherapy
1088440|NCT01622478|breast cancer
1088441|NCT01622478|locally advanced breast cancer
1088442|NCT01622478|positive axillary lymph node
1088443|NCT01622478|negative conversion
1088444|NCT01622465|Hip arthroplasty
1088445|NCT01622465|Aged
1088446|NCT01622465|Rehabilitation
1088447|NCT01622465|Exercise therapy
1088448|NCT01622452|Postoperative cognitive dysfunction
1088449|NCT01622452|Cognitive decline
1088450|NCT01622452|Valve surgery
1088451|NCT01622452|Cardiac surgery
1088452|NCT01622452|Diffusion Tensor Imaging
1088453|NCT01622452|Brain Morphometry
1088454|NCT01622452|1H-Magnetic Resonance Spectroscopy
1088455|NCT01622439|Lymphoma
1088456|NCT01622439|Diffuse large B-cell lymphoma
1088457|NCT01622439|Valproate
1088458|NCT01622439|R-CHOP
1088459|NCT01622439|CD 20
1088460|NCT01622413|lumbar spine
1088461|NCT01622413|herniated disc
1088462|NCT01622413|slipped disc
1088463|NCT01622413|disc herniation
1088464|NCT01622413|discectomy
1088465|NCT01622413|nucleotomy
1088466|NCT01622413|disc surgery
1088467|NCT01622413|endoscopy
1088468|NCT01622413|spine
1088469|NCT01622400|Cardiovascular risk, Therapeutic education, General practice
1088470|NCT01622387|Coronary artery bypass surgery
1088471|NCT01622387|Arteries
1088472|NCT01622387|Veins
1088473|NCT01622387|Conduits
1088474|NCT01622374|Music
1088475|NCT01622374|dental anxiety
1088476|NCT01622374|"music for the mind"
1088477|NCT01622374|mozart
1088478|NCT01622374|iranian traditional music
1088479|NCT01622361|Neoadjuvant
1088480|NCT01622361|endocrine therapy
1088481|NCT01622361|premenopausal
1088482|NCT01622361|hormone responsive
1088483|NCT01622361|HER2 negative
1088484|NCT01622361|lymph node positive
1088485|NCT01622348|Psoriasis
1088486|NCT01622348|Plaque Psoriasis
1088487|NCT01622309|Oxidative Stress
1088488|NCT01622309|Obesity
1088489|NCT01622309|Solanum melongena
1088490|NCT01622218|Medical clown
1088491|NCT01622192|Probing
1088492|NCT01622192|manual probe
1088493|NCT01622192|automated probe
1088494|NCT01622192|Periodontal disease
1088495|NCT01622179|surgery
1088496|NCT01622179|suture method
1088497|NCT01622179|blood supply
1088498|NCT01622140|T-SPOT.TB
1088499|NCT01622140|QuantiFERON-TB Gold In-Tube
1088500|NCT01622140|Latent tuberculosis infection
1088501|NCT01622140|Tuberculin skin test
1088502|NCT01622140|Discordance
1088503|NCT01622140|Predictive value
1088504|NCT01622140|Tuberculosis disease development
1088505|NCT01622114|Obesity
1088506|NCT01622114|Weight reduction
1088507|NCT01622114|premenopausal Women
1088508|NCT01622114|Menstrual cycle
1088509|NCT01622114|quality of life
1088510|NCT01622114|food cravings
1088511|NCT01622101|Energy expenditure
1088512|NCT01622101|Appetite
1088513|NCT01622101|Bioactive herbal compounds
1088514|NCT01622101|blood pressure
1088515|NCT01622088|ALS, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
1088519|NCT01622036|Malnutrition
1088520|NCT01622036|pre-cachexia
1088521|NCT01622036|cancer
1088522|NCT01622036|cachexia
1088523|NCT01622036|MNA
1088524|NCT01622036|weight loss
1088525|NCT01622023|insemination
1088526|NCT01622023|donor sperm
1088527|NCT01622023|natural cycle
1088528|NCT01622010|Heart Failure
1088529|NCT01622010|Patient Education as Topic
1088530|NCT01622010|Physical Therapy Specialty
1088531|NCT01621997|peritoneal dialysis
1088532|NCT01621997|retraining
1088533|NCT01621997|peritonitis
1088534|NCT01621984|Cerebral palsy
1088535|NCT01621984|brain injury
1088536|NCT01621984|spinal cord injuries
1088537|NCT01621984|muscular disease
1088538|NCT01621971|inhaled milrinone
1088539|NCT01621971|pulmonary hypertension
1088540|NCT01621971|mitral regurgitation
1088541|NCT01621971|mitral valve surgery
1088542|NCT01621958|balance loss
1088543|NCT01621958|dynamic stability
1088544|NCT01621958|motor learning
1088545|NCT01621958|plasticity
1088546|NCT01621945|Neisseria meningitidis B:14, P1-7, 16
1088547|NCT01621945|Serum bactericidal activity
1088548|NCT01621945|OMV vaccine
1088549|NCT01621932|Anterior approach
1088550|NCT01621906|Breast
1088551|NCT01621906|brain metastases
1088552|NCT01621906|18F-FLT-PET Imaging
1088553|NCT01621906|FLT(3'DEOXY-3'FLUOROTHYMIDINE)
1088554|NCT01621906|MR Imaging
1088555|NCT01621906|12-039
1088556|NCT01621893|bone marrow edema
1088557|NCT01621893|bone marrow defects
1088558|NCT01621880|radiation-induced brain necrosis
1088559|NCT01621880|nasopharyngeal carcinoma
1088560|NCT01621880|Bevacizumab
1088561|NCT01621880|Methylprednisolone
1088562|NCT01621867|Cystic fibrosis
1088563|NCT01621867|Gene therapy
1088564|NCT01621867|CFTR gene
1088565|NCT01621867|Gene expression
1088566|NCT01621867|Non-viral
1088567|NCT01621867|Multi dose
1088568|NCT01621854|cancer
1088569|NCT01621854|nucleoside analogue
1088570|NCT01621854|advanced solid tumours
1088571|NCT01621828|pre-operative anxiety
1088572|NCT01621828|multimedia information
1088573|NCT01621828|operating theatre
1088574|NCT01621815|ADHD
1088575|NCT01621815|Attention Deficit/Hyperactivity Disorder
1088576|NCT01621815|Conduct
1088577|NCT01621815|Depression
1088578|NCT01621815|Anxiety
1088579|NCT01621815|PDD
1088580|NCT01621815|Pervasive Developmental Disorders
1088581|NCT01621802|Safety
1088582|NCT01621802|Measles, mumps and rubella diseases
1088583|NCT01621802|Immunogenicity
1088584|NCT01621789|lutein
1088585|NCT01621789|zeaxanthin
1088586|NCT01621789|trypan blue
1088587|NCT01621789|dye
1088588|NCT01621776|post-prandial hyperglycemia
1088589|NCT01621737|oxytocin
1088590|NCT01621724|Gene therapy
1088591|NCT01621724|WT1 TCR
1088592|NCT01621724|AML
1088593|NCT01621724|CML
1088594|NCT01621711|substance abuse
1088595|NCT01621711|Substance Dependence
1088596|NCT01621711|Substance, addiction
1088597|NCT01621711|Alcohol Abuse
1088598|NCT01621711|prevention and control
1088599|NCT01621711|preventative health services
1088600|NCT01621711|patient centered care
1088601|NCT01621698|VATS
1088602|NCT01621698|Paravertebral blocks.
1088603|NCT01621698|Thoracoscopic surgery.
1088604|NCT01621698|Analgesia.
1088605|NCT01621685|Capsaicin
1088606|NCT01621685|Cough
1088607|NCT01621685|Cough reflex
1088608|NCT01621685|Inhalation agents
1088609|NCT01621685|Inhalation challenge
1088610|NCT01621685|TRPV1 receptor
1088611|NCT01621672|Revlimid
1088612|NCT01621672|progression free
1088613|NCT01621672|Lenalidomide
1088614|NCT01621659|multidisciplinary team
1088615|NCT01621659|exercise
1088616|NCT01621659|nutrition
1088617|NCT01621659|cardiology
1088618|NCT01621659|physiotherapy
1088619|NCT01621659|imaging
1088620|NCT01621646|lutein
1088621|NCT01621646|eggs
1088622|NCT01621646|mild cognitive impairment
1088623|NCT01621646|elderly
1088624|NCT01621633|hepatic impairment
1088625|NCT01621607|fMRI
1088626|NCT01621607|Monoamines
1088627|NCT01621607|Environment
1088628|NCT01621607|Genes
1088629|NCT01621607|Reward Learning
1088630|NCT01621594|Cardiac
1088631|NCT01621594|Computed Tomography
1088632|NCT01621594|Radiation Reduction
1088633|NCT01621594|Iterative Reconstruction
1088634|NCT01621581|Gene Therapy
1088635|NCT01621581|Parkinson's Disease
1088636|NCT01621581|Convection-Ehanced Delivery
1088637|NCT01621581|Viral Vector
1088638|NCT01621568|VEGF
1088639|NCT01621568|Anti-Angiogenesis
1088640|NCT01621568|Targeted Agent
1088641|NCT01621555|shoulder surgery
1088642|NCT01621555|Pain sensitivity
1088643|NCT01621555|Rowe score
1088644|NCT01621555|Constant Score
1088645|NCT01621555|Surgical Outcome
1088646|NCT01621555|Postoperative pain
1088647|NCT01621542|Cancer
1088648|NCT01621542|Vaccine
1088649|NCT01621542|Oncology
1088650|NCT01621542|Malignancies
1088651|NCT01621542|Wilms' Tumor
1088652|NCT01621542|WT1
1088653|NCT01621542|Ovarian
1088654|NCT01621542|Glioblastoma [GBM]
1088655|NCT01621542|Acute myeloid leukemia [AML]
1088656|NCT01621529|Positron-Emission Tomography
1088657|NCT01621529|PET Scan
1088658|NCT01621529|FDG
1088659|NCT01621529|SUV
1088660|NCT01621529|Invasive Breast cancer
1088661|NCT01621529|Surgery compare
1088662|NCT01621529|Tumor measurement
1088663|NCT01621516|Beta-cell function
1088664|NCT01621516|Liver/small bowel transplant
1088665|NCT01621516|Donor pancreas
1088666|NCT01621516|Diabetes
1088667|NCT01621516|Long-term immunesuppression
1088668|NCT01621477|Hematologic malignancy
1088669|NCT01621477|Hematopoietic cell transplant
1088670|NCT01621464|Neuromediated syncope
1088671|NCT01621464|Tilt test
1088672|NCT01621464|Pacemaker
1088673|NCT01621464|CLS sensor
1088674|NCT01621438|coronary artery
1088675|NCT01621438|atherosclerosis
1088676|NCT01621438|angina pectoris
1088677|NCT01621425|breast cancer
1088678|NCT01621425|prostate carcinoma
1088679|NCT01621425|docetaxel
1088680|NCT01621425|lean body mass
1088681|NCT01621425|Body Surface Area
1088682|NCT01621425|body weight
1088683|NCT01621425|dexascan
1088684|NCT01621412|Medication Adherence
1088685|NCT01621412|HIV infection
1088686|NCT01621412|Disclosure
1088687|NCT01621373|neonatology
1088688|NCT01621373|intratracheal intubation
1088689|NCT01621373|propofol
1088690|NCT01621360|Randomized controlled trial
1088691|NCT01621360|Intention to treat
1088692|NCT01621347|HIV
1088693|NCT01621347|Pregnancy
1088694|NCT01621347|Postpartum
1088695|NCT01621347|Women
1088696|NCT01621347|Medication Adherence
1088697|NCT01621308|Diabetes Mellitus type 1
1088698|NCT01621308|Intraperitoneal insulin administration
1088699|NCT01621308|Subcutaneous insulin administration
1088700|NCT01621308|Continuous intraperitoneal insulin infusion
1088701|NCT01621282|journal club
1088702|NCT01621269|Multiple Sclerosis
1088703|NCT01621269|MS
1088704|NCT01621269|Fingolimod
1088705|NCT01621269|Gilenya
1088706|NCT01621269|Neutralizing Antibodies
1088707|NCT01621269|NAb
1088708|NCT01621243|necuparanib
1088709|NCT01621243|gemcitabine
1088710|NCT01621243|heparin
1088711|NCT01621243|low molecular weight heparin
1088712|NCT01621243|nab-Paclitaxel
1088713|NCT01621230|Bupivacaine
1088714|NCT01621230|Fentanyl
1088715|NCT01621230|Epidural
1088716|NCT01621230|Second Stage of Labor
1088717|NCT01621230|Randomized Controlled Trial
1088718|NCT01621217|Anal cancer
1088719|NCT01621217|Locally advanced anal cancer
1088720|NCT01621217|Cetuximab
1088721|NCT01621217|5-fluoruracil
1088722|NCT01621217|Mitomycin C
1088723|NCT01621217|Radiotherapy
1088724|NCT01621204|Thrombocytopenia
1088725|NCT01621204|ITP
1088726|NCT01621204|Platelets
1088727|NCT01621204|Bleeding
1088728|NCT01621204|Immune
1088729|NCT01621204|Eltrombopag
1088730|NCT01621204|IVIG
1088731|NCT01621165|treatment of bipolar, mania
1088732|NCT01621165|double-blind, placebo-controlled study
1088733|NCT01621165|drug intervention
1088734|NCT01621165|add-on study
1088735|NCT01621165|prazosin
1088736|NCT01621165|alpha-1 adrenergic antagonist
1088737|NCT01621152|Acute renal failure
1088738|NCT01621152|acute kidney injury
1088739|NCT01621152|electronic surveillance
1088740|NCT01621152|AKI
1088741|NCT01621152|sniffer
1088742|NCT01621152|AKIN
1088743|NCT01621152|improvement in the process of care and outcomes
1088744|NCT01621126|Shoulder instability
1088745|NCT01621126|Latarjet procedure
1088746|NCT01621126|Nerve injury
1088747|NCT01621113|Spinal Cord Injuries
1088748|NCT01621113|4-Aminopyridine
1088749|NCT01621113|Physical Therapy Modalities
1088750|NCT01621113|Randomized Controlled Trial
1088751|NCT01621113|Rehabilitation
1088752|NCT01621113|Walking
1088753|NCT01621100|Cancer pain
1088754|NCT01621100|OROS
1088755|NCT01621100|Osmotic release oral system
1088756|NCT01621100|Hydromorphone
1088757|NCT01621100|Painkiller
1088758|NCT01621100|Opioid analgesic
1088759|NCT01621100|Korean patients
1088760|NCT01621061|high altitude illness
1088761|NCT01621061|pulmonary hypertension
1088762|NCT01621061|sleep apnea
1088763|NCT01621061|hypoxia
1088764|NCT01621048|Head and Neck Neoplasmsr
1088765|NCT01621048|Radiotherapy
1088766|NCT01621048|Xerostomia
1088767|NCT01621048|Deglutition Disorders
1088768|NCT01621022|smoking cessation
1088769|NCT01621022|tobacco dependence
1088770|NCT01621009|smoking cessation medications
1088771|NCT01621009|smoking cessation counseling
1088772|NCT01620996|preintervention and postintervention cohort longitudinal prospective study
1088773|NCT01620983|arthroplasty
1088774|NCT01620983|pain
1088775|NCT01620970|Transitional Cell Carcinoma
1088776|NCT01620970|Metastatic disease
1088777|NCT01620970|Bladder tumors, Recurrent
1088778|NCT01620970|Angiogenesis
1088779|NCT01620970|PF03446962
1088780|NCT01620970|Transforming growth factor beta
1088781|NCT01620970|Activin receptor like kinase 1
1088782|NCT01620970|Monoclonal Antibody
1088783|NCT01620970|Locally advanced or metastatic disease
1088784|NCT01620970|Failure of one platinum-based chemotherapy
1088785|NCT01620970|Measurable disease
1088786|NCT01620957|Default-mode network
1088787|NCT01620957|Difussion tensor imaging
1088788|NCT01620957|Cortical thickness
1088789|NCT01620957|Coma
1088790|NCT01620957|Vegetative state
1088791|NCT01620957|Minimally conscious state
1088792|NCT01620957|Neural correlate of consciousness
1088793|NCT01620892|unicondylar knee arthroplasty
1088794|NCT01620892|partial knee replacement
1088795|NCT01620866|EMDR
1088796|NCT01620866|bipolar disorder
1088797|NCT01620866|trauma
1088798|NCT01620866|subsyndromal symptoms
1088799|NCT01620866|PTSD
1088800|NCT01620853|Non-small cell lung cancer (NSCLC)
1088801|NCT01620853|ALK probe
1088802|NCT01620853|FISH
1088803|NCT01620853|Chromosomal aberrations
1088804|NCT01620840|oral administration of Lacosamide is not possible or adequate
1088805|NCT01620827|follow up
1088806|NCT01620827|cell phone
1088807|NCT01620827|hospital landline
1088808|NCT01620814|misoprostol
1088809|NCT01620814|dinoprostone
1088810|NCT01620814|cervical ripening
1088811|NCT01620814|diagnostic hysteroscopy
1088812|NCT01620801|AAV
1088813|NCT01620801|AAV8
1088814|NCT01620801|Adeno-associated virus
1088815|NCT01620801|Adeno-associated viral vectors
1088816|NCT01620801|Hemophilia
1088817|NCT01620801|Hemophilia B
1088818|NCT01620801|Severe hemophilia B
1088819|NCT01620801|Factor IX deficiency
1088820|NCT01620801|Factor IX
1088821|NCT01620801|FIX
1088822|NCT01620762|Cat allergy
1088823|NCT01620762|Rhinoconjunctivitis
1088824|NCT01620749|melanoma metastatic diagnosis
1088825|NCT01620736|Raltegravir
1088826|NCT01620736|HTLV
1088827|NCT01620736|Integrase
1088828|NCT01620723|Breastfeeding
1088829|NCT01620723|Breastfeeding self efficacy
1088830|NCT01620710|prostatectomy
1088831|NCT01620658|Occupational Exposure to Radiation
1088832|NCT01620632|laparoscopy assisted ERCP
1088833|NCT01620632|altered gastric anatomy
1088834|NCT01620619|Shoulder
1088835|NCT01620619|Bankart
1088836|NCT01620619|Anterior Instability
1088837|NCT01620619|Rotator Cuff
1088838|NCT01620606|FAP
1088839|NCT01620606|RAP
1088840|NCT01620606|Abdominal Pain
1088841|NCT01620606|IBS
1088842|NCT01620593|Prostate Cancer
1088843|NCT01620593|Metformin
1088844|NCT01620593|Castration therapy
1088845|NCT01620580|sleep disturbance
1088846|NCT01620580|tiredness
1088847|NCT01620580|itching & numbness
1088848|NCT01620567|lutein
1088849|NCT01620567|avocados
1088850|NCT01620567|chickpeas
1088851|NCT01620567|potatoes
1088852|NCT01620567|elderly
1088853|NCT01620554|Sleep disorder
1088854|NCT01620554|Obstructive Sleep Apnoea
1088855|NCT01620554|Excessive Daytime Sleepiness
1088856|NCT01620528|Gonadotropin-Releasing Hormone Antagonist
1088857|NCT01620528|Endometriosis associated pain
1088858|NCT01620528|Dysmenorrhea (DYS)
1088859|NCT01620528|Non-Menstrual Pelvic Pain (NMPP)
1088860|NCT01620528|Elagolix
1088861|NCT01620515|Prostate
1088862|NCT01620515|Prostate Cancer
1088863|NCT01620515|Localized Prostate Cancer
1088864|NCT01620515|T1c Prostate Cancer
1088865|NCT01620515|Focal Therapy
1088866|NCT01620515|NX-1207
1088867|NCT01620411|Active Duty
1088868|NCT01620411|Comprehensive Medical Management
1088869|NCT01620411|Spinal Cord Stimulator
1088870|NCT01620411|Veteran
1088871|NCT01620411|sustained
1088872|NCT01620411|military
1088873|NCT01620398|cardiovascular diseases
1088874|NCT01620398|secondary prevention
1088875|NCT01620398|diet
1088876|NCT01620385|Cochlear implants
1088877|NCT01620359|Breast cancer
1088878|NCT01620359|Breast tumor
1088879|NCT01620359|stage 1 disease
1088880|NCT01620359|T1 M0 N0
1088881|NCT01620346|advanced maternal age
1088882|NCT01620346|infertility
1088883|NCT01620346|IMSI
1088884|NCT01620346|ICSI
1088885|NCT01620346|implantation
1088886|NCT01620320|Left main coronary artery
1088887|NCT01620320|Coronary artery disease
1088888|NCT01620320|Stress echography
1088889|NCT01620320|Intrastent stenosis
1088890|NCT01620307|H1N1 patients with severe hypoxemia requiring ventilator support
1088891|NCT01620294|surgical site infection
1088892|NCT01620294|elective colorectal surgery
1089019|NCT01619774|Advanced melanoma
1088893|NCT01620294|level of surgical site infection
1088894|NCT01620294|complication of surgical site infection
1088895|NCT01620294|type of changed bandage
1088896|NCT01620294|frequency of bandage changing
1088897|NCT01620281|Back Pain
1088898|NCT01620268|leflunomide
1088899|NCT01620268|orotic acid
1088900|NCT01620268|Polyoma BK Viruria
1088901|NCT01620268|Polyoma BK Viremia
1088902|NCT01620268|Polyoma BK Nephropathy
1088903|NCT01620268|Renal Allograft Rejection
1088904|NCT01620242|recurrent or metastatic head and neck cancer
1088905|NCT01620242|cabazitaxel
1088906|NCT01620203|Premature infants
1088907|NCT01620203|Intracranial hemorrhage
1088908|NCT01620203|Intraventricular hemorrhage
1088909|NCT01620203|Cerebral oxygenation
1088910|NCT01620203|Brain function
1088911|NCT01620203|Cerebral perfusion
1088912|NCT01620177|Cannabis
1088913|NCT01620177|Marijuana
1088914|NCT01620177|Marihuana
1088915|NCT01620177|Alcohol
1088916|NCT01620177|Driving
1088917|NCT01620164|three-dimensional vision
1088918|NCT01620164|Parkinson
1088919|NCT01620151|Post-operative pain
1088920|NCT01620151|Wound bleeding requiring exploration
1088921|NCT01620151|PTH
1088922|NCT01620151|RLN complication
1088923|NCT01620151|Hypocalcaemia complication
1088924|NCT01620138|Non-functioning pituitary adenomas
1088925|NCT01620138|Prolactinomas
1088926|NCT01620138|Cabergoline
1088927|NCT01620138|Pasireotide
1088928|NCT01620138|somatostatin receptors
1088929|NCT01620138|Dopamine receptors
1088930|NCT01620125|Lactobacillus
1088931|NCT01620125|Gut microbiota
1088932|NCT01620125|Diabetes mellitus
1088933|NCT01620112|brachial plexus
1088934|NCT01620112|lidocaine
1088935|NCT01620112|alfa 2 adrenergic receptor clonidine
1088936|NCT01620112|orthopedic procedure
1088937|NCT01620099|Asthma
1088938|NCT01620099|Cigarette smoke
1088939|NCT01620099|Small airways
1088940|NCT01620099|Lung function
1088941|NCT01620099|Asthma control
1088942|NCT01620086|Schizophrenia
1088943|NCT01620086|Auditory hallucinations (AH)
1088944|NCT01620086|Phantom sound perception
1088945|NCT01620086|repetitive transcranial magnetic stimulation (rTMS)
1088946|NCT01620086|Percent habituation in the P50 amplitude with 250 ms ISI
1088947|NCT01620073|Male partner
1088948|NCT01620073|HIV counseling and testing
1088949|NCT01620073|Home based
1088950|NCT01620073|Pregnancy
1088951|NCT01620060|Schizophrenia
1088952|NCT01620060|autism
1088953|NCT01620060|bipolar
1088954|NCT01620060|Lurasidone
1088955|NCT01620060|Latuda
1088956|NCT01620047|Regional Anesthesia
1088957|NCT01620047|Post-operative pain management
1088958|NCT01620047|Femoral Nerve Block
1088959|NCT01620047|Total Knee Replacement
1088960|NCT01620021|wearable sensors
1088961|NCT01620021|kinematics
1088962|NCT01620021|gait
1088963|NCT01620008|cord clamping (delayed or immediate)
1088964|NCT01620008|Myelin content
1088965|NCT01620008|Ferritin
1088966|NCT01619995|urge incontinence
1088967|NCT01619956|dental implants
1088968|NCT01619956|osteotome sinus floor elevation
1088969|NCT01619956|survival rate
1088970|NCT01619956|sinus grafting
1088971|NCT01619956|bone remodeling
1088972|NCT01619956|RCT
1088973|NCT01619956|radiographic analysis
1088974|NCT01619943|Minor head injury
1088975|NCT01619943|CT scan
1088976|NCT01619943|Canadian CT Head Rules
1088977|NCT01619943|The New Orleans Criteria
1088978|NCT01619930|Depression
1088979|NCT01619930|Behavioral activation
1088980|NCT01619917|burn
1088981|NCT01619917|scar
1088982|NCT01619917|laser
1088983|NCT01619917|fractional
1088984|NCT01619917|vascular
1088985|NCT01619904|Pancreas Transplantation
1088986|NCT01619904|Goal-directed therapy
1088987|NCT01619904|Outcomes
1088988|NCT01619904|Immunometric
1088989|NCT01619878|plasmodium
1088990|NCT01619878|P. falciparum
1088991|NCT01619878|malaria
1088992|NCT01619878|infant
1088993|NCT01619878|neonate
1088994|NCT01619865|GA-68
1088995|NCT01619865|Gallium 68
1088996|NCT01619865|GA-68 PET
1088997|NCT01619852|Surgery
1088998|NCT01619852|Breast
1088999|NCT01619852|Pain
1089000|NCT01619852|Chronic Pain
1089001|NCT01619852|Lidocaine
1089002|NCT01619852|Anesthesia
1089003|NCT01619852|Gynecologic
1089004|NCT01619852|Urologic
1089005|NCT01619839|Nektar
1089006|NCT01619839|NKTR-181
1089007|NCT01619826|physical activity
1089008|NCT01619826|fitness
1089009|NCT01619826|brain health
1089010|NCT01619826|cognition
1089011|NCT01619826|scholastic achievement
1089012|NCT01619826|preadolescent children
1089013|NCT01619800|Chronotropic Incompetence
1089014|NCT01619800|Pacemaker
1089015|NCT01619800|Mount Sinai School of Medicine
1089016|NCT01619774|Melanoma
1089017|NCT01619774|Metastatic melanoma
1089018|NCT01619774|Refractory or Resistant to BRAF Inhibitor
1089020|NCT01619774|GSK2118436
1089021|NCT01619774|GSK1120212
1089022|NCT01619761|Leukemia
1089023|NCT01619761|Chronic Lymphocytic Leukemia
1089024|NCT01619761|CLL
1089025|NCT01619761|Cord blood
1089026|NCT01619761|CB
1089027|NCT01619761|Umbilical cord blood
1089028|NCT01619761|UCB
1089029|NCT01619761|Natural killer cells
1089030|NCT01619761|NK
1089031|NCT01619761|Graft versus host disease
1089032|NCT01619761|GVHD
1089033|NCT01619761|Lenalidomide
1089034|NCT01619761|CC-5013
1089035|NCT01619761|Revlimid
1089036|NCT01619761|Fludarabine
1089037|NCT01619761|Fludarabine Phosphate
1089038|NCT01619761|Fludara
1089039|NCT01619761|Melphalan
1089040|NCT01619761|Alkeran
1089041|NCT01619761|Rituximab
1089042|NCT01619761|Rituxan
1089043|NCT01619735|Kidney Calculi
1089044|NCT01619735|Kidney Stones
1089045|NCT01619735|Nephrolithiasis
1089046|NCT01619735|Renal Stones
1089047|NCT01619722|PKU
1089048|NCT01619722|Osteoporosis
1089049|NCT01619722|HMP
1089050|NCT01619722|Life quality
1089051|NCT01619722|Neuropsychological
1089052|NCT01619722|Nutritial evaluation
1089053|NCT01619722|Phenylketonuria
1089054|NCT01619722|Hyperphenylalaninemia
1089055|NCT01619709|Intracerebral Hemorrhage
1089056|NCT01619709|Cerebral Amyloid angiopathy
1089057|NCT01619709|Amyloid imaging
1089058|NCT01619709|18F-AV-45
1089059|NCT01619696|chemotherapy
1089060|NCT01619696|rectal adenocarcinoma
1089061|NCT01619696|proctectomy
1089062|NCT01619696|Fmiso TEP
1089063|NCT01619696|MRI
1089064|NCT01619657|Cystic Fibrosis
1089065|NCT01619657|Hypertonic Saline
1089066|NCT01619657|Infant
1089067|NCT01619657|Newborn
1089068|NCT01619657|Prevention
1089069|NCT01619644|RTS
1089070|NCT01619644|Rubinstein Taybi
1089071|NCT01619644|explorative phase 2
1089072|NCT01619644|clinical approach
1089073|NCT01619644|biological approach
1089074|NCT01619644|motor skills
1089075|NCT01619631|Depression
1089076|NCT01619631|Tai Chi
1089077|NCT01619631|Alternative medicine
1089078|NCT01619631|Mind body medicine
1089079|NCT01619618|recurrent squamous cell carcinoma of the hypopharynx
1089080|NCT01619618|stage IV squamous cell carcinoma of the hypopharynx
1089081|NCT01619618|recurrent squamous cell carcinoma of the larynx
1089082|NCT01619618|stage IVA squamous cell carcinoma of the larynx
1089083|NCT01619618|stage IVB squamous cell carcinoma of the larynx
1089084|NCT01619618|stage IVC squamous cell carcinoma of the larynx
1089085|NCT01619618|recurrent squamous cell carcinoma of the lip and oral cavity
1089086|NCT01619618|stage IVA squamous cell carcinoma of the lip and oral cavity
1089087|NCT01619618|stage IVB squamous cell carcinoma of the lip and oral cavity
1089088|NCT01619618|stage IVC squamous cell carcinoma of the lip and oral cavity
1089089|NCT01619618|recurrent metastatic squamous neck cancer with occult primary
1089090|NCT01619618|recurrent squamous cell carcinoma of the nasopharynx
1089091|NCT01619618|stage IV squamous cell carcinoma of the nasopharynx
1089092|NCT01619618|recurrent squamous cell carcinoma of the oropharynx
1089093|NCT01619618|stage IVA squamous cell carcinoma of the oropharynx
1089094|NCT01619618|stage IVB squamous cell carcinoma of the oropharynx
1089095|NCT01619618|stage IVC squamous cell carcinoma of the oropharynx
1089096|NCT01619618|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1089097|NCT01619618|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
1089098|NCT01619618|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
1089099|NCT01619618|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
1089100|NCT01619618|recurrent salivary gland cancer
1089101|NCT01619618|stage IVA salivary gland cancer
1089102|NCT01619618|stage IVB salivary gland cancer
1089103|NCT01619618|stage IVC salivary gland cancer
1089104|NCT01619605|tryptases
1089105|NCT01619605|anaphylaxis
1089106|NCT01619605|shrimp allergy
1089107|NCT01619592|patients
1089108|NCT01619592|adaptable
1089109|NCT01619592|insulin
1089110|NCT01619592|schemes
1089111|NCT01619579|Fibromyalgia
1089112|NCT01619579|Pain
1089113|NCT01619579|Non-Invasive
1089114|NCT01619579|Arthritis
1089115|NCT01619579|Rheumatoid Disease
1089116|NCT01619566|Fibromyalgia
1089117|NCT01619566|Duloxetine
1089118|NCT01619566|Cymbalta
1089119|NCT01619566|Pain
1089120|NCT01619566|Peripheral Nerve
1089121|NCT01619566|Biopsy
1089122|NCT01619566|Predictive
1089123|NCT01619553|keloid
1089124|NCT01619553|fibrosis
1089125|NCT01619553|wound healing
1089126|NCT01619553|scar
1089127|NCT01619540|COPD
1089128|NCT01619540|Left Ventricular Failure
1089129|NCT01619540|Valsalva Manoeuver
1089130|NCT01619527|Healthy participants
1089131|NCT01619527|Darunavir
1089132|NCT01619527|Cobicistat
1089133|NCT01619527|Bioequivalence
1089134|NCT01619527|Fixed dose combination
1089135|NCT01619527|Pharmacokinetics
1089136|NCT01619527|Human immunodeficiency virus
1089137|NCT01619527|Protease inhibitor
1089138|NCT01619488|Lap-Band
1089139|NCT01619488|morbid obesity
1089140|NCT01619488|adolescents
1089141|NCT01619475|Living Donor
1089142|NCT01619475|Liver Transplantation
1089143|NCT01619475|Quality of Life
1089144|NCT01619475|Biosamples
1089145|NCT01619475|Liver Recipient
1089146|NCT01619462|pneumococcal
1089147|NCT01619462|vaccine
1089148|NCT01619462|papua new guinea
1089149|NCT01619449|Acute Kidney Injury
1089150|NCT01619449|Continuous Renal Replacement Therapy
1089151|NCT01619449|Liver Transplant
1089152|NCT01619423|Metastatic colorectal cancer
1089153|NCT01619423|stage IV
1089154|NCT01619423|FOLFOX6
1089155|NCT01619423|Chemotherapy
1089156|NCT01619423|PledOx
1089157|NCT01619423|Mangafodipir
1089158|NCT01619423|Febrile neutropenia
1089159|NCT01619423|Oxidative stress
1089160|NCT01619423|Antioxidant
1089161|NCT01619423|neutropenia
1089162|NCT01619423|neuropathy
1089163|NCT01619397|Condom
1089164|NCT01619397|Medical Device
1089165|NCT01619384|posttraumatic stress
1089166|NCT01619384|irritable bowel
1089167|NCT01619371|breast pump
1089168|NCT01619371|engorgement
1089169|NCT01619371|lactation
1089170|NCT01619332|Healthy volunteers,
1089171|NCT01619332|Diabetes
1089172|NCT01619332|Glucose
1089173|NCT01619332|Pharmacokinetics
1089174|NCT01619319|schizophrenia prodrome
1089175|NCT01619319|clinical high risk of psychosis
1089176|NCT01619293|CCT
1089177|NCT01619293|brain
1089178|NCT01619293|trauma
1089179|NCT01619293|injury
1089180|NCT01619280|Acute Lung Injury
1089181|NCT01619280|Acute Respiratory Distress Syndrome
1089182|NCT01619280|Sodium Nitroprusside
1089183|NCT01619280|adult
1089184|NCT01619280|Safety
1089185|NCT01619280|Dose Finding
1089186|NCT01619280|Phase 1
1089187|NCT01619280|3 + 3 design
1089188|NCT01619280|Nebulizers and Vaporizers
1089189|NCT01619280|High-Frequency Ventilation
1089190|NCT01619280|nitric oxide
1089191|NCT01619280|lung injury
1089192|NCT01619280|Pulmonary Gas Exchange
1089193|NCT01619280|Pulmonary Alveoli
1089194|NCT01619267|pacemaker defibrillator infection
1089195|NCT01619254|Intestinal parasitic infections
1089196|NCT01619254|Anaemia
1089197|NCT01619254|School-aged children
1089198|NCT01619254|Hand washing and nail clipping
1089199|NCT01619241|lung cancer
1089200|NCT01619241|F-18 FLT PET/CT
1089201|NCT01619228|premature infant
1089202|NCT01619228|neonate
1089203|NCT01619228|skin maturation
1089204|NCT01619228|stratum corneum maturation
1089205|NCT01619228|ontogeny of neonatal skin maturation
1089206|NCT01619228|sunflower oil
1089207|NCT01619228|effect of Vitamin B3 on premature skin maturation
1089208|NCT01619228|skin acidity
1089209|NCT01619228|stratum corneum barrier integrity
1089210|NCT01619228|stratum corneum lipid composition
1089211|NCT01619228|stratum corneum biomarkers
1089212|NCT01619228|stratum corneum cytokines
1089213|NCT01619228|stratum corneum structural proteins
1089214|NCT01619202|accident prevention
1089215|NCT01619202|Adolescent
1089216|NCT01619202|examination, automobile driver
1089217|NCT01619202|Driving simulator
1089218|NCT01619202|Young drivers
1089219|NCT01619202|Driving education
1089220|NCT01619189|Cell therapy
1089221|NCT01619189|Limbal deficiency
1089222|NCT01619189|Limbal stem cell
1089223|NCT01619189|Transplantation
1089224|NCT01619176|Rheumatoid Arthritis
1089225|NCT01619176|blood
1089226|NCT01619176|gut intestinal microbiome
1089227|NCT01619163|Prednisolone,
1089228|NCT01619163|pain,
1089229|NCT01619163|inflammation,
1089230|NCT01619163|mobility
1089231|NCT01619163|Function
1089232|NCT01619150|knee
1089233|NCT01619150|osteoarthritis
1089234|NCT01619150|central sensitization
1089235|NCT01619150|mechanical detection
1089236|NCT01619150|pain threshold
1089237|NCT01619150|quantitative sensory testing
1089238|NCT01619150|pain biomarkers
1089239|NCT01619150|COX-2 inhibitors
1089240|NCT01619150|etoricoxib.
1089241|NCT01619137|ununion wound
1089242|NCT01619137|soap
1089243|NCT01619137|irrigation
1089244|NCT01619137|Povidone-iodine
1089245|NCT01619137|normal salin
1089246|NCT01619124|osteonecrosis
1089247|NCT01619124|children
1089248|NCT01619124|pediatric
1089249|NCT01619124|acute lymphoblastic leukaemia
1089250|NCT01619124|lymphoblastic lymphoma
1089251|NCT01619111|metastatic breast cancer
1089252|NCT01619111|circulating tumor cells
1089253|NCT01619111|lapatinib
1089254|NCT01619098|Hospital readmission
1089255|NCT01619098|Care transition
1089256|NCT01619098|Discharge-transfer intervention
1089257|NCT01619098|Community health worker
1089258|NCT01619098|Patient Navigatgor
1089259|NCT01619072|postpartum hemorrhage
1089260|NCT01619072|treatment
1089261|NCT01619072|misoprostol
1089262|NCT01619072|home births
1089263|NCT01619046|GreenGene™F, Previously Treated Patients
1089264|NCT01619033|Renal impairment
1089265|NCT01619020|Healthy
1089266|NCT01619020|Colon
1089267|NCT01619007|Treatment of Venous Thromboembolism
1089268|NCT01619007|Thromboembolism
1089269|NCT01619007|Venous Thromboembolism
1089270|NCT01619007|Embolism and Thrombosis
1089271|NCT01619007|Vascular Diseases
1089272|NCT01619007|Cardiovascular Diseases
1089273|NCT01619007|Thrombosis
1089274|NCT01618994|Robotic Simulator
1089275|NCT01618994|EBL
1089276|NCT01618994|Robotic Surgeons
1089277|NCT01618994|Intuitive Surgical
1089278|NCT01618994|simulation modules
1089279|NCT01618994|benchmarks
1089280|NCT01618994|Morristown Protocol
1089281|NCT01618994|Study Surgeons
1089282|NCT01618994|Control Surgeons
1089283|NCT01618994|Expert Surgeons
1089284|NCT01618994|dual-console daVinci system
1089285|NCT01618994|blinded skill assessment
1089286|NCT01618981|Heart failure with preserved ejection fraction
1089287|NCT01618981|atrial dyssynchrony syndrome
1089288|NCT01618981|left atrio-ventricular asynchrony
1089289|NCT01618981|pacemaker
1089290|NCT01618981|left atrial pacing therapy
1089291|NCT01618929|Food allergy
1089292|NCT01618929|Asthma
1089293|NCT01618929|Children
1089294|NCT01618929|Montelukast
1089295|NCT01618929|Inflammation
1089296|NCT01618903|Keppra Levetiracetam intravenous
1089297|NCT01618903|Oral tablets
1089298|NCT01618903|Bioequivalence
1089299|NCT01618903|Pharmacokinetics
1089300|NCT01618903|Safety
1089301|NCT01618903|Chinese healthy volunteers
1089306|NCT01618877|Keppra Levetiracetam intravenous
1089307|NCT01618877|Multiple dose
1089308|NCT01618877|Safety
1089309|NCT01618877|Pharmacokinetics
1089310|NCT01618877|Chinese healthy volunteers
1089311|NCT01618851|prostate cancer
1089312|NCT01618838|prostate cancer
1089313|NCT01618812|Artificial bone graft
1089314|NCT01618812|Hydroxyapatite
1089315|NCT01618812|Children
1089316|NCT01618812|Osteotomy
1089317|NCT01618812|Pes plano valgus
1089318|NCT01618812|Flatfeet
1089319|NCT01618786|Falls
1089320|NCT01618786|Fall injuries
1089321|NCT01618786|Bone fracture
1089322|NCT01618786|Hip fracture
1089323|NCT01618786|Skull fracture
1089324|NCT01618786|Wounds
1089325|NCT01618786|Closed head injury
1089326|NCT01618786|Traumatic brain injury
1089327|NCT01618786|Concussion
1089328|NCT01618786|Spinal cord injury
1089329|NCT01618786|Trauma
1089330|NCT01618786|Older adults
1089331|NCT01618786|Long-term care
1089332|NCT01618786|Compliant flooring
1089333|NCT01618786|Safety floors
1089334|NCT01618786|Balance
1089335|NCT01618786|Injury biomechanics
1089336|NCT01618786|Biomedical engineering
1089337|NCT01618786|Environmental hazards
1089338|NCT01618786|Environmental interventions
1089339|NCT01618786|Fall prevention
1089340|NCT01618786|Gerontology
1089341|NCT01618773|acne
1089342|NCT01618773|Epiduo
1089343|NCT01618773|adapalene/ benzoyl peroxide
1089344|NCT01618734|Immune Thrombocytopenia
1089345|NCT01618734|Thrombopoietin receptor agonist
1089346|NCT01618721|Chronic obstructive lung disease;
1089347|NCT01618721|Interstitial lung disease;
1089348|NCT01618721|Ultrasound Doppler;
1089349|NCT01618721|Lung disease diagnosis;
1089350|NCT01618695|Partial-onset Seizures
1089351|NCT01618695|partial seizures
1089352|NCT01618695|seizure
1089353|NCT01618695|epilepsy
1089354|NCT01618682|hand transplant
1089355|NCT01618682|hand replant
1089356|NCT01618669|Coronary Artery Disease (CAD)
1089357|NCT01618669|regadenoson
1089358|NCT01618669|pharmacologic stress
1089359|NCT01618643|Barrett's
1089360|NCT01618643|High grade dysplasia
1089361|NCT01618643|HGD
1089362|NCT01618643|IMC
1089363|NCT01618643|Intramucosal cancer
1089364|NCT01618643|Acetic acid
1089365|NCT01618643|Chromoendoscopy
1089366|NCT01618630|burn injury
1089367|NCT01618630|children
1089368|NCT01618630|nutrition
1089369|NCT01618630|lipid metabolism
1089370|NCT01618630|insulin sensitivity
1089371|NCT01618630|amino acids
1089372|NCT01618630|stable isotopes
1089373|NCT01618617|Constipation
1089374|NCT01618617|Probiotic
1089375|NCT01618617|Randomized Controlled Trial
1089376|NCT01618604|Conditioned Pain Modulation
1089377|NCT01618604|Quantitative Sensory Testing
1089378|NCT01618604|duration
1089379|NCT01618604|correlation
1089380|NCT01618591|diarrhea
1089381|NCT01618591|travelers' diarrhea
1089382|NCT01618591|watery diarrhea
1089383|NCT01618591|enteric illness
1089384|NCT01618591|dysentery
1089385|NCT01618591|gastrointestinal
1089386|NCT01618578|rubber hand illusion
1089387|NCT01618578|CRPS
1089388|NCT01618578|body image
1089389|NCT01618578|body ownership
1089390|NCT01618565|shoulder dystocia
1089391|NCT01618565|training
1089518|NCT01618123|Chest pain
1089392|NCT01618565|To assess the effectiveness of hands-on training versus expert demonstration
1089393|NCT01618552|Chronic disease
1089394|NCT01618552|Cluster randomization
1089395|NCT01618552|Comorbidity
1089396|NCT01618552|Depression
1089397|NCT01618552|Diabetes
1089398|NCT01618552|Medical history taking
1089399|NCT01618552|Office visits
1089400|NCT01618552|Patient acceptance of health care
1089401|NCT01618552|Patient compliance
1089402|NCT01618552|Patient simulation
1089403|NCT01618552|Physician patient relations
1089404|NCT01618552|Primary health care
1089405|NCT01618552|Randomized controlled trials
1089406|NCT01618552|Self care
1089407|NCT01618552|Self efficacy
1089408|NCT01618539|Total intravenous anesthesia, Bispectral Index Score
1089409|NCT01618526|Dietary fibers
1089410|NCT01618526|Butyrate
1089411|NCT01618526|Short Chain Fatty Acids
1089412|NCT01618526|Colon
1089413|NCT01618526|Metabolic Syndrome
1089414|NCT01618513|Acromegaly
1089415|NCT01618513|Somatostatin analogs
1089416|NCT01618513|Treatment
1089417|NCT01618500|Normal Pressure Hydrocephalus
1089418|NCT01618500|Neuropsychological Test
1089419|NCT01618500|Assessment of cognitive disorders/dementia
1089420|NCT01618500|Neuropsychological assessment
1089421|NCT01618487|tennis elbow
1089422|NCT01618487|lateral epicondylitis
1089423|NCT01618474|gastric cancer
1089424|NCT01618474|adjuvant chemotherapy
1089425|NCT01618461|Prescription drug information
1089426|NCT01618461|Medication management
1089427|NCT01618435|Fusion surgery
1089428|NCT01618435|Degenerative olisthesis
1089429|NCT01618435|i-FACTOR
1089430|NCT01618435|ODI
1089431|NCT01618435|Spinal stenosis
1089432|NCT01618422|DOTS plus
1089433|NCT01618422|DOTS
1089434|NCT01618422|multidrug resistant tuberculosis (MDR TB)
1089435|NCT01618409|PictureRx
1089436|NCT01618409|Health Literacy
1089437|NCT01618409|Limited English Proficiency
1089438|NCT01618409|Latinos
1089439|NCT01618409|Spanish
1089440|NCT01618396|Microcirculation
1089441|NCT01618396|Hypnotics and Sedatives,
1089442|NCT01618396|Propofol,
1089443|NCT01618396|Midazolam
1089444|NCT01618383|Parkinson's disease
1089445|NCT01618383|gut
1089446|NCT01618383|colon
1089447|NCT01618383|biopsies
1089448|NCT01618383|LRRK2
1089449|NCT01618370|Radium 223
1089450|NCT01618370|Alpharadin
1089451|NCT01618370|Prostate Cancer
1089452|NCT01618370|Bone metastases
1089453|NCT01618370|Castrate resistant prostate cancer
1089454|NCT01618370|Hormone refractory prostate cancer
1089455|NCT01618357|Veliparib
1089456|NCT01618357|ABT-888
1089457|NCT01618357|Radiation
1089458|NCT01618357|POPI
1089459|NCT01618344|neoplasms
1089460|NCT01618344|adolescent
1089461|NCT01618344|young adult
1089462|NCT01618344|medication adherence
1089463|NCT01618331|FSHD
1089464|NCT01618331|Endurance exercise
1089465|NCT01618331|Protein supplementation
1089466|NCT01618331|Placebo RCT
1089467|NCT01618318|Asthma
1089468|NCT01618318|Allergy
1089469|NCT01618318|Diagnosis
1089470|NCT01618318|Correlation study
1089471|NCT01618292|pelvic organ prolapse
1089472|NCT01618292|constipation
1089473|NCT01618292|bowel dysfunction
1089474|NCT01618292|irritable bowel syndrome (IBS)
1089475|NCT01618292|CRADI-8
1089476|NCT01618292|CRAIQ-7
1089477|NCT01618292|splinting with defecation
1089478|NCT01618292|excessive straining
1089479|NCT01618292|bowel movements
1089480|NCT01618292|fecal incontinence
1089481|NCT01618292|bowel symptoms
1089482|NCT01618279|tryptase
1089483|NCT01618279|coronary
1089484|NCT01618279|stemi
1089485|NCT01618279|nstemi
1089486|NCT01618253|Transarterial Chemoembolization
1089487|NCT01618253|TACE
1089488|NCT01618253|Sorafenib Tosylate
1089489|NCT01618253|Sorafenib
1089490|NCT01618253|Nexavar
1089491|NCT01618253|External Beam Radiation Therapy
1089492|NCT01618253|Radiation Therapy
1089493|NCT01618253|Radiotherapy
1089494|NCT01618253|Radiation
1089495|NCT01618240|FEES
1089496|NCT01618240|PAS
1089497|NCT01618240|VPSR
1089498|NCT01618240|MRC
1089499|NCT01618201|Inflammation
1089500|NCT01618201|Migraine
1089501|NCT01618201|Headache
1089502|NCT01618175|Bronchiolitis, Viral
1089503|NCT01618175|Home oxygen therapy
1089504|NCT01618175|Home Nursing
1089505|NCT01618175|Outcome and Process Assessment (Health Care)
1089506|NCT01618175|bronchiolitis severity score
1089507|NCT01618149|osteoarthritis
1089508|NCT01618149|periprosthetic bone loss
1089509|NCT01618149|dual energy x-ray absorptiometry
1089510|NCT01618136|PARP inhibitors
1089511|NCT01618136|Malignant Solid Tumour
1089512|NCT01618136|ovarian cancer
1089513|NCT01618136|triple negative breast cancer
1089514|NCT01618136|advanced melanoma
1089515|NCT01618123|Endothelial function
1089516|NCT01618123|Coronary disease
1089517|NCT01618123|Atherosclerosis
1089519|NCT01618110|ADHD
1089520|NCT01618110|Attention Deficit/Hyperactivity Disorder
1089521|NCT01618110|TMS
1089522|NCT01618110|Transcranial Magnetic Stimulation
1089523|NCT01618097|Osteoarthritis
1089524|NCT01618097|Decision Aids
1089525|NCT01618097|Health Literacy
1089526|NCT01618084|hipreplacement
1089527|NCT01618084|uncemented
1089528|NCT01618084|migration
1089529|NCT01618084|boneremodeling
1089530|NCT01618071|n-3 PUFA
1089531|NCT01618071|Endothelial cells
1089532|NCT01618071|Nitric oxide
1089533|NCT01618071|Oxidative stress
1089534|NCT01618071|Blood pressure
1089535|NCT01618071|Vasodilation
1089536|NCT01618071|Lipemia
1089537|NCT01618071|Unsaturated dietary fats
1089538|NCT01618058|HIV Infections
1089539|NCT01618058|Anti-HIV Agents
1089540|NCT01618058|HIV-1
1089541|NCT01618045|Diabetes
1089542|NCT01618045|FPP
1089543|NCT01618045|fermented papaya preparation
1089544|NCT01618019|n-3 PUFA
1089545|NCT01618019|rheumatoid arthritis
1089546|NCT01618019|inflammation
1089547|NCT01618019|eicosanoids
1089548|NCT01618019|bone turnover markers
1089549|NCT01617993|in vitro fertilization
1089550|NCT01617993|assisted reproduction
1089551|NCT01617993|noninvasive imaging of embryos
1089552|NCT01617993|time lapse imaging of embryos
1089553|NCT01617993|traditional morphological grading of embryos
1089554|NCT01617993|prediction of blastocysts
1089555|NCT01617993|infertility
1089556|NCT01617993|Genital Diseases, Male
1089557|NCT01617993|Genital Diseases, Female
1089558|NCT01617980|Hypoxia imaging
1089559|NCT01617980|FMISO-PET
1089560|NCT01617980|functional MRI
1089561|NCT01617980|Intensity modulated radiation therapy
1089562|NCT01617967|RNAi therapeutic
1089563|NCT01617941|non-chronic migraine, migraine prevention
1089564|NCT01617902|Hyperbilirubinemia
1089565|NCT01617902|cardiac
1089566|NCT01617902|surgery
1089567|NCT01617902|aorta
1089568|NCT01617902|prognosis
1089569|NCT01617876|Stomach Neoplasms
1089570|NCT01617876|early gastric cancer
1089571|NCT01617876|magnifying endoscopy
1089572|NCT01617876|narrow band imaging
1089573|NCT01617876|acetic acid
1089574|NCT01617876|indigocarmine
1089575|NCT01617837|Postoperative nausea and vomiting
1089576|NCT01617837|P6 acupressure
1089577|NCT01617837|Craniotomy.
1089578|NCT01617824|Diabetes
1089579|NCT01617824|Kidney
1089580|NCT01617824|Inflammation
1089581|NCT01617824|Metabolism
1089582|NCT01617772|Non-alcoholic steatohepatitis, Atorvastatin, L-Carnitine
1089583|NCT01617746|Asthma
1089584|NCT01617746|Endothelin
1089585|NCT01617746|Airway hyperreactivity
1089586|NCT01617720|mitral
1089587|NCT01617720|valve
1089588|NCT01617720|annuloplasty
1089589|NCT01617720|mitral regurgitation
1089590|NCT01617707|sedation
1089591|NCT01617707|endoscopy
1089592|NCT01617707|midazolam
1089593|NCT01617707|propofol
1089594|NCT01617707|chronic alcoholics
1089595|NCT01617694|dexmedetomidine
1089596|NCT01617694|remifentanil
1089597|NCT01617694|target-controlled infusion
1089598|NCT01617681|Hypertension; CKD; Pediatric
1089599|NCT01617668|Breast cancer,
1089600|NCT01617668|LCL161,
1089601|NCT01617668|paclitaxel,
1089602|NCT01617668|neoadjuvant,
1089603|NCT01617668|triple negative breast cancer
1089604|NCT01617642|Porphyria
1089605|NCT01617642|Inflammation
1089606|NCT01617642|Diet
1089607|NCT01617642|Iron status
1089608|NCT01617629|Cvac
1089609|NCT01617603|diabetes type 2
1089610|NCT01617603|insulin resistance
1089611|NCT01617603|glycaemic control
1089612|NCT01617603|Endothelial function
1089613|NCT01617603|Cocoa Polyphenols
1089614|NCT01617590|RA
1089615|NCT01617590|Leflunomide
1089616|NCT01617590|Methotrexate
1089617|NCT01617577|G-CSF
1089618|NCT01617577|granulocyte colony stimulating factor
1089619|NCT01617577|Filgrastim
1089620|NCT01617564|medical abortion
1089621|NCT01617564|second trimester
1089622|NCT01617564|para cervical blockage
1089623|NCT01617564|pain management
1089624|NCT01617551|Essential hypertension
1089625|NCT01617551|Nitric oxide
1089626|NCT01617551|Renal denervation
1089627|NCT01617551|Sodium
1089628|NCT01617551|GFR
1089629|NCT01617538|atherosclerosis
1089630|NCT01617538|stenosis
1089631|NCT01617538|statin therapy
1089632|NCT01617538|Signs and Symptoms
1089633|NCT01617538|Circulatory; Change
1089634|NCT01617499|physical activity
1089635|NCT01617499|pedometer
1089636|NCT01617499|worksite
1089637|NCT01617499|wellness
1089638|NCT01617499|cardiovascular
1089639|NCT01617499|lifestyle program
1089640|NCT01617460|Autistic Disorder, children and adolescents
1089641|NCT01617460|aripiprazole
1089642|NCT01617460|Long-term safety study
1089643|NCT01617460|children and adolescents
1089644|NCT01617447|Autistic Disorder, children and adolescents
1089645|NCT01617447|Aripiprazole
1089646|NCT01617447|Double-blind
1089647|NCT01617447|Randomized
1089648|NCT01617447|children and adolescents
1089649|NCT01617421|Yoga
1089650|NCT01617421|Arthritis
1089651|NCT01617408|Theta Burst Stimulation
1089652|NCT01617408|Transcranial Magnetic Stimulation (TMS)
1089653|NCT01617408|Visual Cortex
1089654|NCT01617408|Visual Processing
1089655|NCT01617395|Multiple Sclerosis
1089656|NCT01617395|Magnetic Resonance Imaging (MRI)
1089657|NCT01617382|HIPEC
1089658|NCT01617382|Hyperthermic (heated) chemotherapy after debulking
1089659|NCT01617356|TMD
1089660|NCT01617356|temporomandibular
1089661|NCT01617356|dextrose
1089662|NCT01617356|prolotherapy
1089663|NCT01617330|Particulate matter
1089664|NCT01617330|Air pollution
1089665|NCT01617330|Diesel exhaust
1089666|NCT01617330|Allergic rhinitis
1089667|NCT01617317|H1N1 2009
1089668|NCT01617317|hyperimmune IVIG
1089669|NCT01617317|mortality
1089670|NCT01617317|length of stay
1089671|NCT01617317|viral load
1089672|NCT01617317|cytokine
1089673|NCT01617304|advanced glycation end products
1089674|NCT01617304|insulin sensitivity
1089675|NCT01617304|obesity
1089676|NCT01617304|inflammation
1089677|NCT01617304|metabolomics
1089678|NCT01617304|appetite
1089679|NCT01617304|CVD
1089680|NCT01617291|Pre-hospital hypothermia
1089681|NCT01617291|Induced therapeutic hypothermia
1089682|NCT01617291|Cardiac arrest
1089683|NCT01617278|Colonoscopy
1089684|NCT01617278|I Scan
1089685|NCT01617278|High definition white light
1089686|NCT01617278|Adenomas
1089687|NCT01617265|intensive care
1089688|NCT01617265|mechanical ventilation
1089689|NCT01617265|sedatives
1089690|NCT01617265|morphinics
1089691|NCT01617265|oversedation
1089692|NCT01617265|mortality
1089693|NCT01617265|midazolam
1089694|NCT01617265|propofol
1089695|NCT01617265|pain
1089696|NCT01617265|agitation
1089697|NCT01617252|Cardiac surgery
1089698|NCT01617252|Acute respiratory failure
1089699|NCT01617252|High flow oxygen therapy
1089700|NCT01617239|Influenza
1089701|NCT01617239|Vaccination
1089702|NCT01617239|Virosomal influenza vaccine
1089703|NCT01617213|Multiple Myeloma
1089704|NCT01617174|prostate
1089705|NCT01617174|pain assessment
1089706|NCT01617174|12-110
1089707|NCT01617161|Low Risk
1089708|NCT01617161|Intermediate Risk
1089709|NCT01617148|Exudative Macular Degeneration
1089710|NCT01617148|Aflibercept
1089711|NCT01617135|Parkinson's disease
1089712|NCT01617135|Motor fluctuations
1089713|NCT01617135|levodopa
1089714|NCT01617135|inhaled drugs
1089715|NCT01617135|"Motor fluctuation (off episodes)"
1089716|NCT01617122|PID
1089717|NCT01617122|PIDD
1089718|NCT01617122|antibody deficiency
1089719|NCT01617122|CVID
1089720|NCT01617122|recurrent infections
1089721|NCT01617109|Vitamin D
1089722|NCT01617109|Calcium
1089723|NCT01617109|Parathyroid hormone
1089724|NCT01617109|Bone
1089725|NCT01617109|Bone formation
1089726|NCT01617109|Bone resorption
1089727|NCT01617109|Micronutrients
1089728|NCT01617109|Trace Elements
1089729|NCT01617096|HIV Infections
1089730|NCT01617096|Anti-HIV agents
1089731|NCT01617096|HIV-1
1089732|NCT01617083|PANS
1089733|NCT01617083|PANDAS
1089734|NCT01617083|OCD
1089735|NCT01617083|Tics
1089736|NCT01617083|Azithromycin
1089737|NCT01617083|Antibiotic Treatment
1089738|NCT01617070|Tetrahydrobiopterin
1089739|NCT01617070|Kuvan
1089740|NCT01617070|Phenylketonuria (PKU)
1089741|NCT01617070|Large Neutral Amino Acids
1089742|NCT01617070|Serotonin
1089743|NCT01617070|Dopamine
1089744|NCT01617070|Melatonin
1089745|NCT01617057|otosclerosis
1089746|NCT01617057|inner ear
1089747|NCT01617057|tiludronic acid
1089748|NCT01617044|Iron
1089749|NCT01617044|Deficiency
1089750|NCT01617044|Restless
1089751|NCT01617044|Leg
1089752|NCT01617031|aspirin
1089753|NCT01617031|diabetes mellitus
1089754|NCT01617031|coronary artery disease
1089755|NCT01617018|Psoriasis; Biological therapy; Methotrexate; Cyclosporine
1089756|NCT01616979|Off-pump coronary artery bypass surgery
1089757|NCT01616979|Transesophageal echocardiography
1089758|NCT01616966|hoarseness
1089759|NCT01616966|sore throat
1089760|NCT01616966|vocal cord injuries
1089761|NCT01616953|dental implants
1089762|NCT01616940|HIV/AIDS
1089763|NCT01616940|Peer support
1089764|NCT01616927|ADPKD
1089765|NCT01616927|lanreotide
1089766|NCT01616927|polycystic kidney
1089767|NCT01616927|polycystic liver
1089768|NCT01616914|delirium
1089769|NCT01616914|outcome
1089770|NCT01616901|Obese
1089771|NCT01616901|Intensive Care
1089772|NCT01616901|Respiratory weaning
1089773|NCT01616901|Spontaneous Breathing trial
1089774|NCT01616901|Work of breathing
1089775|NCT01616888|drug eluting balloon with paclitaxel
1089776|NCT01616888|in stent restenosis
1089777|NCT01616888|femoropopliteal arteries
1089778|NCT01616888|angioplasty
1089779|NCT01616875|Bladder cancer
1089780|NCT01616875|Transitional cell carcinoma
1089781|NCT01616875|Urothelial cancer
1089782|NCT01616875|Cisplatin
1089783|NCT01616875|Cabazitaxel
1089784|NCT01616875|Chemotherapy
1089785|NCT01616875|Neo adjuvant chemotherapy
1089786|NCT01616862|Pseudomonas aeruginosa
1089787|NCT01616862|cystic fibrosis
1089788|NCT01616823|Human immunodeficiency virus (HIV) positive women
1089789|NCT01616810|urinary tract
1089790|NCT01616784|Adult
1089791|NCT01616784|Diabetes Mellitus
1089792|NCT01616784|Type 1
1089793|NCT01616784|Humans
1089794|NCT01616784|Hypoglycemic Agents
1089795|NCT01616784|Administration and Dosage
1089796|NCT01616784|Insulin
1089797|NCT01616784|Self Care
1089798|NCT01616784|Health Education
1089799|NCT01616784|Insulin Infusion Systems
1089800|NCT01616784|Randomised controlled trial
1089801|NCT01616784|Patient Education as Topic
1089802|NCT01616784|Hemoglobin A
1089803|NCT01616784|Glycosylated
1089804|NCT01616771|laryngoscopes
1089805|NCT01616745|NTM Lung disease
1089806|NCT01616745|NTM Lung disease patients enrolled in SNUH
1089807|NCT01616693|rotavirus
1089808|NCT01616693|polio
1089809|NCT01616693|zinc supplement
1089810|NCT01616693|probiotic supplement
1089811|NCT01616693|rotavirus vaccine shedding
1089812|NCT01616667|Controlled Clinical Trial
1089813|NCT01616667|Operative Surgical Procedures
1089814|NCT01616667|Treatment Outcome
1089815|NCT01616667|Pain Measurement
1089816|NCT01616667|Quality of Life
1089817|NCT01616667|Questionnaires/standards
1089818|NCT01616667|Activities of Daily Living
1089819|NCT01616667|Biomechanics
1089820|NCT01616667|Gait*
1089821|NCT01616667|Hip Joint/physiology*
1089822|NCT01616667|Hip Joint/surgery*
1089823|NCT01616667|Recovery of Function/physiology
1089824|NCT01616641|rheumatoid arthritis
1089825|NCT01616641|bite force
1089826|NCT01616641|grip strenght
1089827|NCT01616641|oral health
1089828|NCT01616641|quality of life
1089829|NCT01616628|Incentives
1089830|NCT01616628|Fruit
1089831|NCT01616628|Vegetables
1089832|NCT01616602|patients
1089833|NCT01616602|presenting
1089834|NCT01616602|elective
1089835|NCT01616602|colonoscopy.
1089836|NCT01616589|Fragile X syndrome
1089837|NCT01616589|Fragile X full mutation
1089838|NCT01616589|Fragile X premutation
1089839|NCT01616589|Fragile X intermediate
1089840|NCT01616589|CGG repeat length
1089841|NCT01616576|cochlear implant
1089842|NCT01616576|adults
1089843|NCT01616576|HiResolution™
1089844|NCT01616576|Fidelity 120™
1089845|NCT01616576|listening benefits
1089846|NCT01616576|noise
1089847|NCT01616576|cochlear implant benefit
1089848|NCT01616563|central obesity
1089849|NCT01616563|abdominal obesity
1089850|NCT01616563|hypertension
1089851|NCT01616563|cardiovascular disease
1089852|NCT01616563|high cholesterol
1089853|NCT01616563|high triglycerides
1089854|NCT01616563|insulin resistance
1089855|NCT01616563|diabetes mellitus
1089856|NCT01616550|analgesia
1089857|NCT01616550|thoracic surgery
1089858|NCT01616537|solid tumors
1089859|NCT01616537|hematological malignancy
1089860|NCT01616472|hypertension
1089861|NCT01616472|avascular necrosis
1089862|NCT01616472|systemic lupus erythematosus
1089863|NCT01616472|osteoporosis
1089864|NCT01616472|Steroid
1089865|NCT01616472|diabetes
1089866|NCT01616472|cataracts
1089867|NCT01616459|Streptococcus pneumoniae
1089868|NCT01616459|Haemophilus influenzae
1089869|NCT01616459|Pneumococcal vaccine
1089870|NCT01616459|Infants
1089871|NCT01616459|Safety
1089872|NCT01616459|Immunogenicity
1089873|NCT01616446|cyclosporin
1089874|NCT01616446|nephrotic syndrome
1089875|NCT01616446|pharmacokinetics
1089876|NCT01616446|children
1089877|NCT01616433|Arthritis
1089878|NCT01616433|Preventive Behaviors
1089879|NCT01616420|prevention
1089880|NCT01616420|treatment
1089881|NCT01616420|cost-effectiveness
1089882|NCT01616420|assisted partner notification services
1089883|NCT01616420|Kenya
1089884|NCT01616420|linkage to HIV care
1089885|NCT01616420|case-finding
1089886|NCT01616407|Effects of psychostimulants on emotion recognition and empathy
1089887|NCT01616355|denture, complete;
1089888|NCT01616355|sodium hypochlorite;
1089889|NCT01616355|disinfection;
1089890|NCT01616355|surface roughness;
1089891|NCT01616355|color stability.
1089892|NCT01616329|alloimmunization
1089893|NCT01616329|RBC
1089894|NCT01616329|clinicalfactors
1089895|NCT01616329|Risk
1089896|NCT01616303|ovarian
1089897|NCT01616303|cancer
1089898|NCT01616303|neoplasm
1089899|NCT01616303|adenocarcinoma
1089900|NCT01616303|CA125
1089901|NCT01616290|peripheral artery disease
1089902|NCT01616290|PAD
1089903|NCT01616290|claudication
1089904|NCT01616290|angioplasty
1089905|NCT01616290|percutaneous transluminal angioplasty
1089906|NCT01616290|PTA
1089907|NCT01616290|superficial femoral artery
1089908|NCT01616290|SFA
1089909|NCT01616290|popliteal artery
1089910|NCT01616290|PA
1089911|NCT01616290|PRT-201
1089912|NCT01616290|restenosis
1089913|NCT01616290|vonapanitase
1089914|NCT01616264|Tuberculosis
1089915|NCT01616264|Pleural Effusion
1089916|NCT01616264|Computed Tomography
1089917|NCT01616251|Protein sources
1089918|NCT01616251|Appetite
1089919|NCT01616251|Dietary fibers
1089920|NCT01616251|Meat
1089921|NCT01616251|Egg
1089922|NCT01616251|Legumes
1089923|NCT01616225|Infertility
1089924|NCT01616225|Poor Responder
1089925|NCT01616225|In Vitro Fertilization
1089926|NCT01616225|Growth Hormone
1089927|NCT01616212|Teens
1089928|NCT01616212|Parenting
1089929|NCT01616212|Substance Abuse
1089930|NCT01616212|Treatment Efficacy
1089931|NCT01616199|PX-866
1089932|NCT01616199|BRAF-mutant cancers
1089933|NCT01616199|Advanced melanoma
1089934|NCT01616199|BRAF inhibitor
1089935|NCT01616199|Vemurafenib
1089936|NCT01616199|Zelboraf
1089937|NCT01616199|PI-3K inhibitor
1089938|NCT01616186|Renal Cell Carcinoma
1089939|NCT01616173|Nerve Block
1089940|NCT01616173|Anesthesia Recovery Period
1089941|NCT01616160|Nasal polyps
1089942|NCT01616147|Intensive Lifestyle Intervention
1089943|NCT01616134|overweight,
1089944|NCT01616134|ginseng
1089945|NCT01616108|strabismus
1089946|NCT01616108|diplopia
1089947|NCT01616095|Growth hormone deficiency
1089948|NCT01616095|hrGH therapy
1089949|NCT01616095|metabolic health
1089950|NCT01616095|adipose tissue metabolism
1089951|NCT01616095|adipose tissue inflammation
1089952|NCT01616095|adipokines
1089953|NCT01616082|fatty acid oxidation
1089954|NCT01616082|Proton magnetic resonance spectroscopy
1089955|NCT01616069|CABG
1089956|NCT01616069|Echocardiography
1089957|NCT01616069|Heart Failure
1089958|NCT01616069|Heart Function
1089959|NCT01616056|Chronic graft-versus-host disease
1089960|NCT01616056|eye
1089961|NCT01616043|scar quality
1089962|NCT01616030|Hip fractures
1089963|NCT01616030|Strength training
1089964|NCT01616017|Cardiac output
1089965|NCT01616017|ultrasound dilution
1089966|NCT01616017|thermodilution
1089967|NCT01615965|prostate cancer
1089968|NCT01615965|lymph node
1089969|NCT01615965|micrometastasis
1089970|NCT01615952|Supraclavicular Block
1089971|NCT01615939|Sciatic Nerve Block
1089972|NCT01615939|Continuous Nerve Block
1089973|NCT01615926|dyspnea
1089974|NCT01615926|shortness of breath
1089975|NCT01615926|respiratory rate
1089976|NCT01615926|orthopnea
1089977|NCT01615913|onychomycosis
1089978|NCT01615913|terbinafine
1089979|NCT01615913|ketoconazole
1089980|NCT01615913|transdermal topical therapy
1089981|NCT01615900|Renal graft
1089982|NCT01615900|Teleconsultation
1089983|NCT01615900|Kidney transplant failure score
1089984|NCT01615848|polycystic Ovary syndrome (PCOS)
1089985|NCT01615848|diet
1089986|NCT01615848|mediterranean diet
1089987|NCT01615848|high protein diet
1089988|NCT01615822|Malaria
1089989|NCT01615822|PK
1089990|NCT01615822|OZ439
1089991|NCT01615822|Mefloquine
1089992|NCT01615822|Healthy Volunteers
1089993|NCT01615809|Invasive pulmonary aspergillosis
1089994|NCT01615809|IFI
1089995|NCT01615809|Leukaemia
1089996|NCT01615809|Leukemia
1089997|NCT01615809|Pediatric
1089998|NCT01615809|Paediatrics
1089999|NCT01615809|Amphotericin B
1090000|NCT01615809|Aspergillosis
1090001|NCT01615809|Pulmonary Aspergillosis
1090002|NCT01615809|Invasive Aspergillosis
1090003|NCT01615809|Antifungal agents
1090004|NCT01615809|Fungal infections
1090005|NCT01615809|Invasive Fungal Infection
1090006|NCT01615796|GSK2140944
1090007|NCT01615796|antibiotics
1090008|NCT01615796|first time in human
1090009|NCT01615796|pharmacokinetics
1090010|NCT01615796|intravenous
1090011|NCT01615796|safety
1090012|NCT01615796|absolute bioavailability
1090013|NCT01615796|Bacterial Type II
1090014|NCT01615796|tolerability
1090015|NCT01615796|infection
1090016|NCT01615783|Chronic Obstructive Pulmonary Disease
1090017|NCT01615783|Costs
1090018|NCT01615783|Resource utilization
1090019|NCT01615783|Medicaid
1090020|NCT01615757|AML
1090021|NCT01615757|Acute Myeloid Leukemia
1090022|NCT01615757|Cytarabine dose
1090023|NCT01615757|Ara-c dose
1090024|NCT01615757|Consolidation
1090025|NCT01615744|calcaneal fractures
1090026|NCT01615744|surgical treatment
1090027|NCT01615744|conservative treatment
1090028|NCT01615744|VAS scoring
1090029|NCT01615744|SF-36
1090030|NCT01615744|AOFAS
1090031|NCT01615744|Olerud-Molander score
1090032|NCT01615744|outcome
1090033|NCT01615731|Mifepristone
1090034|NCT01615731|Induced Abortion
1090035|NCT01615731|Dilation and Evacuation
1090036|NCT01615731|Cervical preparation
1090037|NCT01615731|Osmotic dilators
1090038|NCT01615718|noninvasive stimulation
1090039|NCT01615718|motor function
1090040|NCT01615718|transcranial stimulation
1090041|NCT01615718|transcranial ultrasound
1090042|NCT01615718|brain stimulation
1090043|NCT01615705|Postphlebitic Syndrome
1090044|NCT01615705|Post-Thrombotic Syndrome
1090045|NCT01615705|Biomarkers
1090046|NCT01615705|Markers of Inflammation
1090047|NCT01615705|Genetic Thrombophilia
1090048|NCT01615705|Coagulation Activation
1090049|NCT01615692|Elastic Stockings
1090050|NCT01615692|Stockings, Compression
1090051|NCT01615692|Randomized Controlled Trials
1090052|NCT01615692|Quality of Life
1090053|NCT01615679|Non-interventional study
1090054|NCT01615679|Attention Deficit/Hyperactivity Disorder
1090055|NCT01615679|ADHD
1090056|NCT01615666|Alzheimer's disease
1090057|NCT01615666|Mild Cognitive Impairment
1090058|NCT01615666|Frontotemporal dementia
1090059|NCT01615666|fMRI
1090060|NCT01615666|functional neuroimaging
1090061|NCT01615666|Memory
1090062|NCT01615653|Pancreatic cancer
1090063|NCT01615653|Pancreas cancer
1090064|NCT01615653|Pain
1090065|NCT01615653|Celiac Plexus
1090066|NCT01615653|Neurolysis
1090067|NCT01615640|Osteosarcoma
1090068|NCT01615640|Response of chemotherapy
1090069|NCT01615640|Dynamic contrast medium examination
1090070|NCT01615640|Diffusion-weighted MR imaging
1090071|NCT01615627|Subcutaneous Treprostinil
1090072|NCT01615614|Rilpivirine
1090073|NCT01615614|Rifabutin
1090074|NCT01615614|Pharmacokinetics
1090075|NCT01615614|Healthy participants
1090076|NCT01615601|Human Immunodeficiency Virus
1090077|NCT01615601|HIV
1090078|NCT01615601|HIV-1
1090079|NCT01615601|HIV type 1
1090080|NCT01615601|Darunavir
1090081|NCT01615601|PREZISTA
1090082|NCT01615601|Etravirine
1090083|NCT01615601|INTELENCE
1090084|NCT01615601|HIV symptom Distress Module
1090085|NCT01615601|HIV-SDM
1090086|NCT01615601|Antiretroviral therapy
1090087|NCT01615601|HIV Symptom Index (HSI),
1090088|NCT01615588|manuka honey
1090089|NCT01615588|glycaemic index
1090090|NCT01615588|blood glucose control
1090091|NCT01615588|individuals
1090092|NCT01615588|current disease
1090093|NCT01615588|medication use
1090094|NCT01615562|Polycystic Ovary Syndrome
1090095|NCT01615562|PCOS
1090096|NCT01615562|Infertility
1090097|NCT01615549|Cholecystectomy
1090098|NCT01615549|Virtual reality device
1090099|NCT01615549|Training
1090100|NCT01615536|chronic rhinosinusitis
1090101|NCT01615536|canine fossa trephine
1090102|NCT01615536|canine fossa puncture
1090103|NCT01615523|Executive functions
1090104|NCT01615497|cognitive behavior therapy
1090105|NCT01615497|computer assisted instruction
1090106|NCT01615497|alcohol abuse therapy
1090107|NCT01615497|educational resource design and development
1090108|NCT01615484|Lung Transplant
1090109|NCT01615484|Emphysema
1090110|NCT01615484|Chronic Obstructive Pulmonary Disease (COPD)
1090111|NCT01615484|Cystic Fibrosis
1090112|NCT01615484|Pulmonary Fibrosis
1090113|NCT01615484|Bronchiectasis
1090114|NCT01615484|Sarcoidosis
1090115|NCT01615484|Pulmonary Hypertension
1090116|NCT01615484|Alpha-1 Antitrypsin Deficiency
1090117|NCT01615471|Obesity
1090118|NCT01615471|Lifestyle Intervention
1090119|NCT01615471|Group treatment
1090120|NCT01615471|Internet Intervention
1090121|NCT01615458|Care Management
1090122|NCT01615458|Implementation
1090123|NCT01615458|Intervention
1090124|NCT01615458|Mood Disorders
1090125|NCT01615380|smoking cessation
1090126|NCT01615380|Aerobic Exercise
1090127|NCT01615380|Women
1090128|NCT01615380|YMCA
1090129|NCT01615367|Bipolar disorder
1090130|NCT01615367|Nutrition
1090131|NCT01615367|Exercise
1090132|NCT01615367|Symptoms
1090133|NCT01615367|Functioning
1090134|NCT01615341|Kidney transplantation
1090135|NCT01615341|Subclinical Viral Infection
1090136|NCT01615341|Renal Allograft Injury
1090137|NCT01615328|anterior cervical discectomy and fusion
1090138|NCT01615328|bone graft substitute
1090139|NCT01615328|PEEK cage
1090140|NCT01615328|hydroxyapatite
1090141|NCT01615328|demineralized bone matrix
1090142|NCT01615328|b-tricalcium phosphate
1090143|NCT01615328|Bonion
1090144|NCT01615328|Cervios ChronOs
1090145|NCT01615315|aspirin
1090146|NCT01615315|screening
1090147|NCT01615315|microscopic hematuria
1090148|NCT01615302|Rectal Fistula
1090149|NCT01615302|Peri-anal Fistula
1090150|NCT01615302|Platelet-Rich Plasma
1090151|NCT01615302|Mucosa advancement flap
1090152|NCT01615276|Neuromuscular Electrical Stimulation
1090153|NCT01615276|Ageing
1090154|NCT01615276|Protein ingestion
1090155|NCT01615263|Video-assisted thoracoscopic surgery (VATS)
1090156|NCT01615263|One lung ventilation
1090157|NCT01615263|Bronchial blocker
1090158|NCT01615263|Lung collapse
1090159|NCT01615263|Double lumen tube
1090160|NCT01615224|missed abortion
1090161|NCT01615224|miscarriage
1090162|NCT01615211|Abortion
1090163|NCT01615211|medical abortion
1090164|NCT01615211|termination of pregnancy
1090165|NCT01615211|Mifepristone
1090166|NCT01615211|misoprostol
1090167|NCT01615211|letrozole
1090168|NCT01615211|trilostane
1090169|NCT01615211|femara
1090170|NCT01615211|Modrenal
1090171|NCT01615198|Hypertension, blood pressure, LCZ696, dual inhibitor, neprilysin, NEP inhibition, vasopeptidase, ARNi, angiotensin receptor
1090172|NCT01615185|schizophrenia
1090173|NCT01615185|amisulpride
1090174|NCT01615185|sulpiride
1090175|NCT01615185|antipsychotic combination
1090176|NCT01615159|Sodium
1090177|NCT01615159|Diet
1090178|NCT01615159|Urinary sodium excretion
1090179|NCT01615159|Feeding study
1090180|NCT01615159|Diet maintenance
1090181|NCT01615146|Myelodysplasia
1090182|NCT01615146|Leukemia
1090183|NCT01615146|Thrombocytopenia
1090184|NCT01615146|Platelet
1090185|NCT01615146|transfusions
1090186|NCT01615146|Outpatient
1090187|NCT01615081|Malt extract
1090188|NCT01615081|carbohydrate
1090189|NCT01615081|glucose response
1090190|NCT01615081|insulin response
1090191|NCT01615081|Appetite
1090192|NCT01615081|Appetite regulating hormones
1090193|NCT01615055|Chemotherapy
1090194|NCT01615055|Cognitive
1090195|NCT01615055|Prozac
1090196|NCT01615055|Fluoxetine
1090197|NCT01615055|FDG
1090198|NCT01615055|PET
1090199|NCT01615042|Acute Leukemia
1090200|NCT01615042|Bone Marrow Transplant
1090201|NCT01615042|High Dose Lenalidomide
1090202|NCT01615029|Multiple Myeloma
1090203|NCT01615029|Daratumumab
1090204|NCT01615029|Lenalidomide
1090205|NCT01615029|Dexamethasone
1090206|NCT01615029|Dose-escalation
1090207|NCT01615029|Relapsed multiple myeloma
1090208|NCT01615029|Relapsed and refractory multiple myeloma
1090209|NCT01615016|Preterm infant
1090210|NCT01615016|Surfactant application
1090211|NCT01615016|Respiratory Distress Syndrome
1090212|NCT01615016|Minimally invasive Surfactant Application
1090213|NCT01615016|INSURE (Intubate-Surfactant-Extubate)
1090214|NCT01615003|MicroRNA
1090215|NCT01615003|coronary heart disease
1090216|NCT01615003|unstable angina
1090217|NCT01615003|blood stasis syndrome
1090218|NCT01615003|Xuesaitong soft capsule
1090219|NCT01614977|nontuberculous mycobacteria
1090220|NCT01614977|corticosteroids
1090221|NCT01614977|children
1090222|NCT01614977|lymphadeniti
1090223|NCT01614977|Therapeutic intervention in immunocompetent children with nontuberculous mycobacterial lymphadenitis.
1090224|NCT01614964|Plasmodium falciparum
1090225|NCT01614964|pharmacokinetics
1090226|NCT01614964|antimalarials (antimalarial drugs)
1090227|NCT01614964|chloroquine (chloroquine-resistant)
1090228|NCT01614964|QT (QTc) interval
1090229|NCT01614938|Nasopharyngeal carcinoma
1090230|NCT01614938|Locally advanced
1090231|NCT01614938|Cetuximab
1090232|NCT01614938|Weekly cisplatin chemotherapy
1090233|NCT01614938|Intensity-modulated radiotherapy
1090234|NCT01614886|Rivastigmine, Alzheimer's disease, Transdermal patch
1090235|NCT01614873|Breathing Pattern
1090236|NCT01614873|Mechanical Ventilation
1090237|NCT01614873|Pressure support ventilation
1090238|NCT01614873|Neurally Adjusted Ventilatory Assist
1090239|NCT01614860|Aldosterone
1090240|NCT01614860|Echocardiography
1090241|NCT01614860|Neurohormones
1090242|NCT01614847|dry eye
1090243|NCT01614847|artificial tears
1090244|NCT01614847|tear osmolarity
1090245|NCT01614847|residence time
1090246|NCT01614834|urticaria
1090247|NCT01614834|disease control
1090248|NCT01614834|severity
1090249|NCT01614834|test
1090250|NCT01614821|Relapsed
1090251|NCT01614821|Refractory
1090252|NCT01614743|Rosacea
1090253|NCT01614730|EMS
1090254|NCT01614730|Modified Device
1090255|NCT01614717|Hypertrophic Obstructive Cardiomyopathy
1090256|NCT01614717|Cardiac Resynchronization Therapy
1090257|NCT01614704|Breast cancer
1090258|NCT01614704|Fertility
1090259|NCT01614678|myopia
1090260|NCT01614665|Transplant
1090261|NCT01614665|Prograf
1090262|NCT01614665|Heart
1090263|NCT01614665|Advagraf
1090264|NCT01614665|Tacrolimus
1090265|NCT01614665|Immunosuppression
1090266|NCT01614665|Kidney
1090267|NCT01614665|Liver
1090268|NCT01614665|Pharmacokinetic
1090269|NCT01614665|Pediatric
1090271|NCT01614639|Acupuncture
1090272|NCT01614639|fMRI
1090273|NCT01614639|CLBP
1090274|NCT01614639|Pain
1090275|NCT01614639|Low Back Pain
1090276|NCT01614639|Back Pain
1090277|NCT01614626|HIV
1090278|NCT01614626|Alcohol Use
1090279|NCT01614626|Microbial Translocation
1090280|NCT01614626|Inflammation
1090281|NCT01614626|Altered Coagulation
1090282|NCT01614626|Russia
1090283|NCT01614600|contact lens
1090284|NCT01614600|dry eye syndrome
1090285|NCT01614600|symptomatic
1090286|NCT01614600|daily disposable
1090287|NCT01614600|myopia
1090288|NCT01614587|pelvic organ prolapse
1090289|NCT01614587|recurrence of pelvic organ prolapse
1090290|NCT01614587|genetic predisposition
1090291|NCT01614587|SNP microarray analysis
1090292|NCT01614587|pelvic floor
1090293|NCT01614587|genetic factors
1090294|NCT01614587|adequate prolapse repair
1090295|NCT01614587|polymorphisms
1090296|NCT01614587|surgical failure
1090297|NCT01614587|reoperation
1090298|NCT01614587|DNA
1090299|NCT01614587|buccal swabs
1090300|NCT01614587|TaqMan SNP allelic discriminiation assays
1090301|NCT01614587|duplex real-time PCR
1090302|NCT01614587|genome-wide SNP microarrays
1090303|NCT01614587|next-generation sequencing
1090304|NCT01614561|Hypercholesterolemia
1090305|NCT01614561|Lipid lowering drugs
1090306|NCT01614561|Cholesterol level in blood
1090307|NCT01614561|Target cholesterol levels guidelines for the management of high blood cholesterol
1090308|NCT01614548|Prostatic Neoplasms
1090309|NCT01614548|Prostate Cancer
1090310|NCT01614548|Disease Management
1090311|NCT01614548|Rural
1090312|NCT01614548|Urban
1090313|NCT01614522|Metastatic gastro-oesophageal carcinoma
1090314|NCT01614522|Recurrent gastro-oesophageal carcinoma
1090315|NCT01614522|Gastric cancer
1090316|NCT01614522|HER-1
1090317|NCT01614522|HER-2
1090318|NCT01614509|branch retinal vein occlusion
1090319|NCT01614509|bevacizumab
1090320|NCT01614509|triamcinolone acetonide
1090321|NCT01612702|postoperative nausea and vomiting
1090322|NCT01612702|postoperative pain
1090323|NCT01612689|Accelerometer
1090324|NCT01612689|EMU
1090325|NCT01612689|Ambulatory
1090326|NCT01612689|ECG
1090327|NCT01612689|Heart rate
1090328|NCT01612663|Knee pain
1090329|NCT01612663|Acupuncture
1090330|NCT01612663|Sham acupuncture
1090331|NCT01614483|Vitamin A deficiency
1090332|NCT01614483|Biofortification
1090333|NCT01614483|Cassava
1090334|NCT01614483|B-carotene
1090335|NCT01614483|School children
1090336|NCT01614483|Kenya
1090337|NCT01614431|renal function
1090338|NCT01614431|before and after N acetyl cysteine
1090339|NCT01614431|Cystinosis patients
1090340|NCT01614405|PBC
1090341|NCT01614392|Resistance Exercise
1090342|NCT01614392|Physical Activity
1090343|NCT01614392|Mobility disability
1090344|NCT01614392|Physical function
1090345|NCT01614392|Muscle Strength
1090346|NCT01614392|Older Adults
1090347|NCT01614392|Mobility-Limited
1090348|NCT01614392|Peak power and strength
1090349|NCT01614366|amlodipine
1090350|NCT01614366|DMTA07
1090351|NCT01614366|hypertension
1090352|NCT01614353|Multiple Chronic Conditions
1090353|NCT01614353|Older Adults
1090354|NCT01614353|New Prescription
1090355|NCT01614340|Home care
1090356|NCT01614340|Cognitive-Behavioral techniques
1090357|NCT01614340|Physical Therapy
1090358|NCT01614340|Pain
1090359|NCT01614340|Older Adults
1090360|NCT01614327|Diabetes Type One
1090361|NCT01614327|Diabetes Type Two
1090362|NCT01614327|PreDiabetes
1090363|NCT01614327|Retinal Screening
1090364|NCT01614327|RiskAnalyzer
1090365|NCT01614327|Retinal Imaging
1090366|NCT01614327|Algorithm
1090367|NCT01614327|Diabetic Retinopathy
1090368|NCT01614327|Microaneurysms
1090369|NCT01614327|Neovascularization
1090370|NCT01614327|Intraretinal microvascular abnormalities
1090371|NCT01614314|Preceptorship, simulation, nursing, catheters
1090372|NCT01614301|advanced Melanoma
1090373|NCT01614288|HTO
1090374|NCT01614288|Arthroscopy
1090375|NCT01614288|Quality-of-Life
1090376|NCT01614288|Gait Analysis
1090377|NCT01614275|Autism
1090378|NCT01614275|Early Intervention
1090379|NCT01614275|Parent Training
1090380|NCT01614275|EIBI
1090381|NCT01614275|Applied Behavior Analysis
1090382|NCT01614249|Omega-3
1090383|NCT01614249|EPA
1090384|NCT01614249|Depression
1090385|NCT01614249|HIV infected
1090386|NCT01614249|Pregnant women
1090387|NCT01614236|pregabalin
1090388|NCT01614236|analgesia
1090389|NCT01614236|postoperative pain
1090390|NCT01614236|orthopedic oncology patients
1090391|NCT01614223|Plantar fasciitis
1090392|NCT01614223|Autologous Conditioned Plasma
1090393|NCT01614197|Relapse
1090394|NCT01614197|Lymphoblastic
1090395|NCT01614197|Leukemia
1090396|NCT01614197|Refractory
1090397|NCT01614197|Temsirolimus
1090398|NCT01614197|Acute
1090399|NCT01614197|Childhood
1090400|NCT01614197|Pediatric
1090401|NCT01614197|ALL
1090402|NCT01614197|NHL
1090403|NCT01614197|LL
1090404|NCT01614197|PTL
1090405|NCT01614171|osteoporosis pseudoglioma
1090406|NCT01614171|OPPG
1090407|NCT01614171|growth hormone
1090408|NCT01614171|osteoporosis
1090409|NCT01614158|N-AION
1090410|NCT01614158|perimetry
1090411|NCT01614158|visual field loss
1090412|NCT01614158|Mean Defect
1090413|NCT01614158|Total Loss Volume
1090414|NCT01614158|D-BCVA
1090415|NCT01614158|RAPD
1090416|NCT01614158|retinal nerve fibre thickness/volume
1090417|NCT01614158|optic nerve head
1090418|NCT01614132|medulloblastoma
1090419|NCT01614132|CNS
1090420|NCT01614132|malignant neoplasm
1090421|NCT01614132|NOA
1090422|NCT01614132|neuroectodermal tumor
1090423|NCT01614132|Vincristin
1090424|NCT01614132|CCNU
1090425|NCT01614132|Cisplatin
1090426|NCT01614119|Cerebral
1090427|NCT01614119|Oxygenation
1090428|NCT01614119|Performance
1090429|NCT01614119|Exercise
1090430|NCT01614106|HIV/AIDS
1090431|NCT01614106|Drug Users
1090432|NCT01614106|Crack-Cocaine Use
1090433|NCT01614106|HIV Primary Care
1090434|NCT01614093|Schizophrenia
1090435|NCT01614093|Appetite
1090436|NCT01614093|Oxytocin
1090437|NCT01614080|Stroke
1090438|NCT01614080|Ischemic stroke
1090439|NCT01614080|thrombolysis
1090440|NCT01614080|toxicity of t-PA
1090441|NCT01614067|DOR
1090442|NCT01614067|Infertility
1090443|NCT01614067|IVF
1090444|NCT01614067|ART
1090445|NCT01614067|GnRHa
1090446|NCT01614067|GnRH Antagonist Protocol
1090447|NCT01614067|Ganirelix
1090448|NCT01614054|Smoking cessation
1090449|NCT01614054|Nicotine replacement therapy
1090450|NCT01614054|NRT
1090451|NCT01614054|Inpatient
1090452|NCT01614054|General Medicine
1090453|NCT01614041|Generalized Anxiety Disorder
1090454|NCT01614015|Recording
1090455|NCT01614015|Supervision
1090456|NCT01614015|Observation
1090457|NCT01614002|carcinoma
1090458|NCT01614002|breast cancer
1090459|NCT01614002|non-small cell lung cancer
1090460|NCT01614002|prostata cancer
1090461|NCT01614002|adenocarcinoma of the stomach
1090462|NCT01614002|squamous cell carcinoma of the head and neck region
1090463|NCT01614002|ambulant chemotherapy
1090464|NCT01614002|treatment cycles
1090465|NCT01614002|Docetaxel
1090466|NCT01614002|Doce onkovis
1090467|NCT01614002|Quantity of Docetaxel
1090468|NCT01614002|Packaging Sizes
1090469|NCT01613989|Hip arthroplasty
1090470|NCT01613989|navigation
1090471|NCT01613976|Myelodysplastic Syndromes
1090472|NCT01613976|MDS
1090473|NCT01613976|Chronic Myelomonocytic Leukemia
1090474|NCT01613976|CMML
1090475|NCT01613976|Acute Myeloid Leukemia
1090476|NCT01613976|AML
1090477|NCT01613976|Panobinostat
1090478|NCT01613976|LBH589
1090479|NCT01613976|5-Aza
1090480|NCT01613976|Azacitidine
1090481|NCT01613963|Uveitis
1090482|NCT01613963|Scleritis
1090483|NCT01613950|gastric cancer advanced gastric or metastatic gastric cancer PI3K PIK3CA mutation Her2 amplification HSP90 inhibitor PI3K inhibitor PIK3CA amplification
1090484|NCT01613937|Latinas
1090485|NCT01613937|Gestational Diabetes
1090486|NCT01613937|Prevention
1090487|NCT01613911|Epilepsy
1090488|NCT01613911|Invasive monitoring
1090489|NCT01613911|Human sensory perception
1090490|NCT01613898|Cerebrotendinous xanthomatosis (CTX),
1090491|NCT01613898|lipoprotein,atherosclerosis,
1090492|NCT01613898|carotid artery intima-media thickness (cIMT).
1090493|NCT01613833|Alpha2 macroglobulin
1090494|NCT01613833|Osteoarthritis
1090495|NCT01613833|plasma and synovium
1090496|NCT01613807|gestational diabetes mellitus
1090497|NCT01613807|insulin analogues in pregnancy
1090498|NCT01613794|Deep vein thrombosis
1090499|NCT01613794|Pulmonary embolism
1090500|NCT01613794|Rosuvastatin treatment
1090501|NCT01613794|Pharmacologic actions
1090502|NCT01613781|hemifacial spasm
1090503|NCT01613781|microvascular decompression
1090504|NCT01613781|neuromuscular blockade
1090505|NCT01613781|electromyography
1090506|NCT01613755|Effect Dipyridamole on pharmacokinetics of metformin
1090507|NCT01612650|breast cancer
1090508|NCT01612650|surveillance
1090509|NCT01612650|diagnosis
1090510|NCT01612650|2D mammography
1090511|NCT01612650|3D mammography
1090512|NCT01612637|Pelvic organ prolapse
1090513|NCT01612637|Pelvic floor muscle training
1090514|NCT01612637|Prolapse symptoms
1090515|NCT01612637|Pelvic organ prolapse quantification system
1090516|NCT01612637|Ultrasonography
1090517|NCT01612637|Predictors
1090518|NCT01612520|type 2 Diabetes Mellitus
1090519|NCT01612520|telenursing
1090520|NCT01612520|RCT
1090521|NCT01612520|economic analysis
1090522|NCT01612507|Phase 1
1090523|NCT01612507|healthy volunteers
1090524|NCT01612507|Parallel Group Study
1090525|NCT01612507|ceftaroline fosamil different doses
1090526|NCT01612507|safety
1090527|NCT01612507|Cmax
1090528|NCT01612507|tmax
1090529|NCT01612507|AUC
1090530|NCT01612481|soft tissue sarcoma
1090531|NCT01612481|lung metastasis
1090532|NCT01612481|surveillance
1090533|NCT01612468|Diabetes
1090534|NCT01612468|Liraglutide
1090535|NCT01612468|Hypoglycaemia
1090536|NCT01612468|Hyperglycaemia
1090537|NCT01612468|CIMT
1090538|NCT01612468|PWV
1090539|NCT01612468|Food preference
1090540|NCT01612468|Blood pressure
1090541|NCT01612455|HIV
1090542|NCT01612455|drug addiction
1090543|NCT01612455|Russia
1090544|NCT01612455|case management
1090545|NCT01613729|Dyslipidemia
1090546|NCT01613729|Rosuvastatin
1090547|NCT01613729|Efficacy
1090548|NCT01613729|Safety
1090549|NCT01613716|Diabetes
1090550|NCT01613716|Macular Edema
1090551|NCT01613716|Epiretinal Membrane
1090552|NCT01613716|Vitrectomy
1090553|NCT01613703|ONO-2952
1090554|NCT01613703|Healthy adult subjects
1090555|NCT01613703|single doe
1090556|NCT01613703|PET study
1090557|NCT01613703|Safety
1090558|NCT01613703|Tolerability
1090559|NCT01613690|Renal impairment
1090560|NCT01613690|NVA237
1090561|NCT01613690|Pharmacokinetics
1090562|NCT01613677|advanced cervical cancer, BKM 120, progression free survival
1090563|NCT01613664|obesity
1090564|NCT01613664|surgical management
1090565|NCT01613664|sleeve gastrectomy
1090566|NCT01613638|congenital malformation
1090567|NCT01613638|pollutants
1090568|NCT01613586|Interstitial Cystitis
1090569|NCT01613586|Bladder Pain Syndrome
1090570|NCT01613586|Painful Bladder Syndrome
1090571|NCT01613586|ASP3652
1090572|NCT01613573|pegylated Somatropin
1090573|NCT01613573|PEG-GH
1090574|NCT01613573|Phase 1 study
1090575|NCT01613573|Pharmacokinetics
1090576|NCT01613534|chronic radiation proctopathy
1090577|NCT01613534|argon plasma coagulation
1090578|NCT01613534|sucralfate
1090579|NCT01613521|DCE-MRI
1090580|NCT01613521|18F-FMISO PET
1090581|NCT01613521|11-174
1090582|NCT01613495|obesity
1090583|NCT01613469|fluorouracil
1090584|NCT01613469|leucovorin
1090585|NCT01613469|radiotherapy
1090586|NCT01613469|neoadjuvant therapy
1090587|NCT01613443|Dabigatran, Rivaroxaban, Point of Care-testing
1090588|NCT01613417|Have confirmed or are highly suspected of brain disease
1090589|NCT01613404|Chronic kidney disease
1090590|NCT01613404|Hemodialysis
1090591|NCT01613404|Eprex
1090592|NCT01613404|Aranesp
1090593|NCT01613404|ESA
1090594|NCT01613404|Anemia
1090595|NCT01613391|Visfatin
1090596|NCT01613391|Resistin
1090597|NCT01613391|Apelin
1090598|NCT01613391|roux-en-y gastric bypass
1090599|NCT01613391|laparoscopic adjustable gastric banding
1090600|NCT01613391|morbid obesity
1090601|NCT01613352|Early breast cancer surgery
1090602|NCT01613352|Psychosocial wellbeing
1090603|NCT01613352|Ambulatory surgery
1090604|NCT01613339|stroke
1090605|NCT01613339|postural control
1090606|NCT01613339|body awareness therapy
1090607|NCT01613326|COPD
1090608|NCT01613313|Lipoma
1090609|NCT01613313|Fatty Tumor
1090610|NCT01613300|hodgkin
1090611|NCT01613300|disease
1090612|NCT01613300|ofatumumab
1090613|NCT01613287|Pulmonary Hypertension
1090614|NCT01613287|Pulmonary Arterial Hypertension
1090615|NCT01613287|TheraSorb
1090616|NCT01613287|immunoadsorption
1090617|NCT01613274|colon resection
1090618|NCT01613261|TAK-733,
1090619|NCT01613261|alisertib,
1090620|NCT01613261|MLN8237,
1090621|NCT01613261|Oral MEK Inhibitor,
1090622|NCT01613261|Oral Aurora A Kinase Inhibitor
1090623|NCT01613235|subarachnoid hemorrhage
1090624|NCT01613235|ischemia
1090625|NCT01613235|vasospasm
1090626|NCT01613235|CT
1090627|NCT01613235|perfusion
1090628|NCT01613235|induced hypertension
1090629|NCT01613235|delayed cerebral ischemia
1090630|NCT01613209|Hypertension
1090631|NCT01613209|ABPM
1090632|NCT01613209|office blood pressure
1090633|NCT01613209|olmesartan
1090634|NCT01613209|amlodipine
1090635|NCT01613209|fixed combination
1090636|NCT01613209|time of intake
1090637|NCT01613196|Extrapulmonary tuberculosis
1090638|NCT01613196|FDG-TEP
1090639|NCT01613196|cohorts
1090640|NCT01613170|Overactive Bladder
1090641|NCT01613170|Vaginal Estrogen
1090642|NCT01613170|Anticholinergics
1090643|NCT01613170|Antimuscarinics
1090644|NCT01613157|pharmacokinetics
1090645|NCT01613157|HIV infected women
1090646|NCT01613118|Primary FSGS
1090647|NCT01613118|Nephrotic syndrome
1090648|NCT01613118|Steroid Resistant
1090649|NCT01613105|Diabetes Mellitus
1090650|NCT01613105|Type-2
1090651|NCT01613105|Acarbose
1090652|NCT01613105|Drug Therapy
1090653|NCT01613105|Combination
1090654|NCT01613092|Arrhythmia
1090655|NCT01613092|Device Procedure
1090656|NCT01613092|High risk patients
1090657|NCT01613092|Antibiotics
1090658|NCT01613092|Infection
1090659|NCT01613092|Cluster
1090660|NCT01613079|Rheumatoid Arthritis
1090661|NCT01613079|Methotrexate
1090662|NCT01613079|Tripterygium
1090663|NCT01613066|Haematological malignancies
1090664|NCT01613066|Allogeneic Cord Blood transplantation
1090665|NCT01613066|Intrabone
1090666|NCT01613053|Gastrointestinal Stromal Tumor, GIST
1090667|NCT01613014|Alcohol
1090668|NCT01613014|Alcohol Dependence
1090669|NCT01613014|Alcohol Abuse
1090670|NCT01613014|Alcohol Use Disorders
1090671|NCT01613014|Alcoholism
1090672|NCT01612988|B-cell chronic lymphocytic leukemia
1090673|NCT01612988|relapse
1090674|NCT01612988|Bendamustine
1090675|NCT01612988|Ofatumumab
1090676|NCT01612988|Méthylprednisolone
1090677|NCT01612975|Chest tubes
1090678|NCT01612975|Length of stay
1090679|NCT01612975|Pleural effusion
1090680|NCT01612975|Lung resection
1090681|NCT01612975|Post-operative
1090682|NCT01612975|Lung cancer
1090683|NCT01612949|endotracheal intubation
1090684|NCT01612949|facial structure
1090685|NCT01612949|Mallampati score
1090686|NCT01612949|computerized facial analysis
1090687|NCT01612936|Asthma
1090688|NCT01612936|Allergic
1090689|NCT01612936|Inflammation
1090690|NCT01612936|Constriction
1090691|NCT01612936|Airway
1090692|NCT01612936|Challenge
1090693|NCT01612936|Chemokines
1090694|NCT01612923|abortion
1090695|NCT01612923|medical abortion
1090696|NCT01612910|estrogen receptor-negative breast cancer
1090697|NCT01612910|HER2-negative breast cancer
1090698|NCT01612910|progesterone receptor-negative breast cancer
1090699|NCT01612910|recurrent breast cancer
1090700|NCT01612910|stage II breast cancer
1090701|NCT01612910|stage IIIA breast cancer
1090702|NCT01612910|stage IIIB breast cancer
1090703|NCT01612910|stage IIIC breast cancer
1090704|NCT01612910|triple-negative breast cancer
1090705|NCT01612897|autism
1090706|NCT01612897|well child care
1090707|NCT01612897|screening
1090708|NCT01612897|computer
1090709|NCT01612897|reminders
1090710|NCT01612871|Breast cancer,
1090711|NCT01612871|hormonotherapy,
1090712|NCT01612871|miRNAs,
1090713|NCT01612871|biomarkers
1090714|NCT01612871|hormone therapy
1090715|NCT01612858|Lipodystrophy
1090716|NCT01612858|Insulin resistance
1090717|NCT01612858|HIV infection
1090718|NCT01612845|rotator cuff
1090719|NCT01612845|shoulder
1090720|NCT01612845|platelet rich plasma
1090721|NCT01612845|fibrin
1090722|NCT01612793|COPD
1090723|NCT01612780|Sinusitis
1090724|NCT01612780|Sinus balloon dilation patients
1090725|NCT01612767|de novo coronary lesions
1090726|NCT01612767|restenotic coronary lesions
1090727|NCT01612767|coronary arteries
1090728|NCT01612754|Reduction of noise pollution
1090729|NCT01612754|Specifically enforced workplace rules
1090730|NCT01612754|Stress
1090731|NCT01612754|Sound Ears (TM)
1090732|NCT01612754|Error
1090733|NCT01612741|Diabetes Mellitus, Type-2
1090734|NCT01612741|Acarbose
1090735|NCT01612741|Drug Therapy
1090736|NCT01612741|Combination
1090737|NCT01612728|Aromatase Inhibitors
1090738|NCT01612715|Asthma, allergen challenge, T cells, Fel d 1.
1090739|NCT01612442|complementary feeding
1090740|NCT01612442|mothers
1090741|NCT01612442|6-24 months children
1090742|NCT01612442|community health volunteers
1090743|NCT01612442|nutrition education
1090744|NCT01612442|agricultural education
1090745|NCT01612429|Carbamylation
1090746|NCT01612429|Albumin
1090747|NCT01612429|Protein structure
1090748|NCT01612429|Kidney disease
1090749|NCT01612416|Ganglion Cell complex, Retinal Nerve Fiber Layer,Glaucoma
1090750|NCT01612403|zinc binding protein
1090751|NCT01612390|postpartum hemorrhage
1090752|NCT01612377|Moderate to Severe
1090753|NCT01612364|CRPS I
1090754|NCT01612351|Head and neck cancer
1090755|NCT01612351|Squamous Cell Carcinoma
1090756|NCT01612351|Phase II
1090757|NCT01612351|Transoral Surgery
1090758|NCT01612351|Induction Chemotherapy
1090759|NCT01612351|Carboplatin
1090760|NCT01612351|Paclitaxel
1090761|NCT01612351|Lapatinib
1090762|NCT01612338|breast cancer
1090763|NCT01612338|young age of onset
1090764|NCT01612338|family history
1090765|NCT01612338|screening interventions
1090766|NCT01612338|family support
1090767|NCT01612325|liver tumors
1090768|NCT01612312|Non-ST-elevation myocardial infarction
1090769|NCT01612312|thrombectomy
1090770|NCT01612312|magnetic resonance imaging
1090771|NCT01612312|microvascular obstruction
1090772|NCT01612286|Recombinant human endostatin
1090773|NCT01612286|nasopharyngeal carcinoma
1090774|NCT01612286|chemotherapy
1090775|NCT01612273|Vasospastic syndrome
1090776|NCT01612273|Vascular dysregulation
1090777|NCT01612260|heart failure
1090778|NCT01612260|ventricular premature complex
1090779|NCT01612260|Shensong Yangxin capsule
1090780|NCT01612247|Breast Cancer
1090781|NCT01612247|Neoadjuvant therapy
1090782|NCT01612234|humans
1090783|NCT01612234|lean
1090784|NCT01612234|obese
1090785|NCT01612234|saturated fat
1090786|NCT01612234|monounsaturated fat
1090787|NCT01612234|insulin sensitivity
1090788|NCT01612234|inflammation
1090789|NCT01612234|oxidant stress
1090790|NCT01612195|anal fistula
1090791|NCT01612195|anal continence
1090792|NCT01612195|health-related quality of life
1090793|NCT01612182|end-stage renal disease
1090794|NCT01612182|renal replacement therapy
1090795|NCT01612169|HIV patients
1090796|NCT01612169|Hospitalized patients
1090797|NCT01612169|Substance Users
1090798|NCT01612169|Drug Users
1090799|NCT01612156|Urodynamic testing
1090800|NCT01612156|pelvic floor examination
1090801|NCT01612156|Lidocaine gel
1090802|NCT01612156|Surgical lubricant
1090803|NCT01612156|Pain
1090804|NCT01612156|Embarrassment
1090805|NCT01612117|renal failure
1090806|NCT01612117|cardiology
1090807|NCT01612117|contrast-induced nephropathy
1090808|NCT01612104|Post Traumatic Stress Disorder
1090809|NCT01612104|Anxiety symptoms
1090810|NCT01612104|Depressive symptoms
1090811|NCT01612104|Externalizing behavior
1090812|NCT01612104|Reduced quality of life
1090813|NCT01612091|Expert System
1090814|NCT01612091|Intensive Care
1090815|NCT01612091|Telemedicine
1090816|NCT01612091|Equipment Design
1090817|NCT01612065|Office hysteroscopy
1090818|NCT01612065|Cervical priming
1090819|NCT01612065|Misoprostol
1090820|NCT01612052|Vascular Surgery
1090821|NCT01612039|ulcerative colitis
1090822|NCT01612013|N-acetylcysteine
1090823|NCT01612013|angiography
1090824|NCT01612013|contrast medium
1090825|NCT01612013|contrast-induced nephropathy
1090826|NCT01612013|sodium bicarbonate
1090827|NCT01612000|Influenza
1090828|NCT01611974|CMV
1090829|NCT01611974|cytomegalovirus
1090830|NCT01611974|resistant
1090831|NCT01611974|refractory
1090832|NCT01611974|transplant
1090833|NCT01611974|treatment
1090834|NCT01611961|Docetaxel
1090835|NCT01611961|Lipid Microsphere
1090836|NCT01611961|Neoplasms
1090837|NCT01611961|Antineoplastic Agents
1090838|NCT01611961|Pharmacologic Actions
1090839|NCT01611961|Therapeutic Uses
1090840|NCT01611935|trauma
1090841|NCT01611935|shock
1090842|NCT01611935|vasopressin
1090843|NCT01611935|blood transfusion
1090844|NCT01611922|eye
1090845|NCT01611922|eyelid
1090846|NCT01611922|contact lenses
1090847|NCT01611922|dry eye disease
1090848|NCT01611909|p-menthane-3,8-diol oil extract
1090849|NCT01611909|topical therapy
1090850|NCT01611896|Graves' hyperthyroidism
1090851|NCT01611896|Graves' disease
1090852|NCT01611896|Selenium
1090853|NCT01611896|Quality of Life
1090854|NCT01611896|ThyPRO
1090855|NCT01611896|Autoimmunity
1090856|NCT01611870|COPD
1090857|NCT01611857|Advanced solid tumors
1090858|NCT01611857|First-Line Metastatic GE cancer
1090859|NCT01611857|c-Met Inhibitor
1090860|NCT01611857|Tivantinib
1090861|NCT01611857|FOLFOX
1090862|NCT01611844|delayed-type hypersensitivity reaction to tuberculin intradermal injection
1090863|NCT01611844|tuberculosis skin test
1090864|NCT01611844|BD micro-needle
1090865|NCT01611844|medical device
1090866|NCT01611844|spectroscopy
1090867|NCT01611831|fibromyalgia
1090868|NCT01611831|Acceptation & Commitment Therapy
1090869|NCT01611831|randomized controlled trial
1090870|NCT01611818|Depression
1090871|NCT01611818|Computer-delivered psychotherapy
1090872|NCT01611818|Randomized-controlled trial
1090873|NCT01611792|Stabilization exercise
1090874|NCT01611792|Strength and conditioning exercise
1090875|NCT01611792|Physical therapy
1090876|NCT01611792|Rehabilitation
1090877|NCT01611779|obstructive sleep apnea
1090878|NCT01611779|tongue suspension
1090879|NCT01611766|secondary cytoreductive surgery
1090880|NCT01611766|Ovarian Cancer
1090881|NCT01611766|surgery
1090882|NCT01611766|recurrence
1090883|NCT01611753|Shock, Septic
1090884|NCT01611753|Erythrocyte Transfusion
1090885|NCT01611753|Ischemia
1090886|NCT01611740|Preterm infant
1090887|NCT01611740|Bacterial infection
1090888|NCT01611740|Diagnosis of proven or suspected bacterial infection
1090889|NCT01611727|BRCA1
1090890|NCT01611727|survival
1090891|NCT01611727|metastatic disease
1090892|NCT01611727|cisplatin
1090893|NCT01611714|Racial/ethnic disparities
1090894|NCT01611714|Imaging
1090895|NCT01611714|Emergency
1090896|NCT01611714|Headache
1090897|NCT01611675|Metastatic
1090898|NCT01611675|Unresectable
1090899|NCT01611675|Clearly progressive
1090900|NCT01611675|BRAF mutation
1090901|NCT01611649|infant formula
1090902|NCT01611649|dairy lipids
1090903|NCT01611649|omega-3
1090904|NCT01611636|allergy
1090905|NCT01611636|autoimmune diseases
1090906|NCT01611636|rheumatic diseases
1090907|NCT01611623|Solid tumor malignancy
1090908|NCT01611623|Hsp90
1090909|NCT01611610|outcome measures
1090910|NCT01611610|spinal muscular atrophy
1090911|NCT01611597|accelerometry
1090912|NCT01611597|neuromuscular disease
1090913|NCT01611584|ALA
1090914|NCT01611584|Florescence
1090915|NCT01611584|Lung cancer
1090916|NCT01611571|osteoporosis
1090917|NCT01611571|male
1090918|NCT01611545|Pharmacogenomics
1090919|NCT01611545|Pharmacogenetics
1090920|NCT01611545|Clopidogrel
1090921|NCT01611545|Plavix
1090922|NCT01611532|Acute pancreatitis
1090923|NCT01611532|Intraabdominal pressure
1090924|NCT01611532|Critical illness
1090925|NCT01611519|urinary bladder
1090926|NCT01611519|urinary catheterization
1090927|NCT01611519|epidural analgesia
1090928|NCT01611519|catheters, indwelling
1090929|NCT01611493|Dental Implants
1090930|NCT01611493|Jaw, Edentulous, Partially/rehabilitation
1090931|NCT01611493|Jaw, Edentulous, Partially/surgery
1090932|NCT01611493|randomised Clinical Trials
1090933|NCT01611493|Humans
1090934|NCT01611467|CC-223
1090935|NCT01611467|safety
1090936|NCT01611467|tolerability
1090937|NCT01611467|pharmacokinetic
1090938|NCT01611467|AME (Absorption, Metabolism, and Excretion)
1090939|NCT01611467|FE (Food Effect)
1090940|NCT01611454|Occupational Exposure to Radiation
1090941|NCT01611441|Osteoarthritis of the knee
1090942|NCT01611441|Biomarkers
1090943|NCT01611428|Ipragliflozin
1090944|NCT01611428|Healthy
1090945|NCT01611428|Absolute Bioavailability
1090946|NCT01611428|Pharmacokinetics
1090947|NCT01611415|Phase 1
1090948|NCT01611415|Ipragliflozin
1090949|NCT01611415|Furosemide
1090950|NCT01611415|Pharmacokinetics
1090951|NCT01611415|Pharmacodynamics
1090952|NCT01611402|Tuberculosis
1090953|NCT01611402|HIV Infection
1090954|NCT01611402|Transcriptional Signature
1090955|NCT01611402|IRIS
1090956|NCT01611376|impedance cardiography
1090957|NCT01611376|Flotrac/Vigileo
1090958|NCT01611376|cardiac output
1090959|NCT01611363|Phase 1
1090960|NCT01611363|Diabetes Mellitus
1090961|NCT01611363|Healthy
1090962|NCT01611363|Ipragliflozin
1090963|NCT01611363|Pharmacokinetics
1090964|NCT01611363|Pharmacodynamics
1090965|NCT01611350|Indoor Air Pollution
1090966|NCT01611350|Marketing Methods for Increasing Technology Adoption
1090967|NCT01611350|Optimal Contracts for Technology Adoption
1090968|NCT01611337|schizophrenia, insight
1090969|NCT01611324|Varicose Veins
1090970|NCT01611324|Phlebectomy
1090971|NCT01611324|Local Anesthesia
1090972|NCT01611298|allogeneic stem cell transplant
1090973|NCT01611298|malignant diseases
1090974|NCT01611298|Acute lymphoblastic leukemia
1090975|NCT01611298|acute myelogenous leukemia
1090976|NCT01611298|Chronic myelogenous leukemia
1090977|NCT01611298|myelodysplastic syndrome
1090978|NCT01611298|Hodgkin lymphoma
1090979|NCT01611298|non-Hodgkin lymphoma
1090980|NCT01611298|myeloproliferative disorder
1090981|NCT01611298|non-malignant disease
1090982|NCT01611285|UPHOLD
1090983|NCT01611285|robotic surgery
1090984|NCT01611285|decision analysis
1090985|NCT01611285|FDA
1090986|NCT01611285|decision node
1090987|NCT01611285|outcome node
1090988|NCT01611272|Unstable angina
1090989|NCT01611259|MALT Lymphoma
1090990|NCT01611259|Lenalidomide
1090991|NCT01611259|Rituximab
1090992|NCT01611233|metal on metal
1090993|NCT01611233|hip replacement
1090994|NCT01611233|ASR
1090995|NCT01611233|DePuy
1090996|NCT01611220|Anorexia Nervosa
1090997|NCT01611220|Relapse prevention
1090998|NCT01611220|Cognitive Dissonance
1090999|NCT01611220|Inpatient treatment
1091000|NCT01611220|Cognitive behavior therapy
1091001|NCT01611207|wound healing impairments,
1091002|NCT01611207|negative pressure wound therapy,
1091003|NCT01611207|health services research,
1091004|NCT01611207|germany
1091005|NCT01611194|HBO2
1091006|NCT01611194|HBOT
1091007|NCT01611194|mTBI
1091008|NCT01611194|Brain injury
1091009|NCT01611194|PCS
1091010|NCT01611194|PTSD
1091011|NCT01611194|hyperbaric oxygen
1091012|NCT01611181|Iron supplementation
1091013|NCT01611181|Iron deficiency
1091014|NCT01611181|Hip arthroplasty
1091015|NCT01611181|Knee arthroplasty
1091016|NCT01611142|Monoclonal antibody
1091017|NCT01611142|Peripheral T-cell Lymphoma
1091018|NCT01611142|cancer
1091019|NCT01611142|hematologic malignancy
1091020|NCT01611129|Disability Evaluation
1091021|NCT01611103|Cognitive Enhancement
1091022|NCT01611103|tDCS
1091023|NCT01611103|stimulation
1091024|NCT01611103|elderly
1091025|NCT01611103|older adults
1091026|NCT01611090|Chronic lymphocytic leukemia
1091027|NCT01611090|Small lymphocytic lymphoma
1091028|NCT01611090|Relapsed or refractory chronic lymphocytic leukemia
1091029|NCT01611090|Relapsed or refractory small lymphocytic lymphoma
1091030|NCT01611090|Ibrutinib
1091031|NCT01611090|PCI-32765
1091032|NCT01611090|JNJ-54179060
1091033|NCT01611090|Bruton's tyrosine kinase inhibitor
1091034|NCT01611090|Bendamustine
1091035|NCT01611090|Rituximab
1091036|NCT01611064|Hand
1091037|NCT01611064|Surgery
1091038|NCT01611064|Tourniquet
1091039|NCT01611064|Pain
1091040|NCT01611064|Oxygen
1091041|NCT01611051|breast cancer
1091042|NCT01611051|neutropenia
1091043|NCT01611051|febrile neutropenia
1091044|NCT01611012|Asthma
1091045|NCT01611012|Inflammation
1091046|NCT01611012|Phenotype
1091047|NCT01611012|Sputum
1091048|NCT01610986|Fructose
1091049|NCT01610986|Exercise
1091050|NCT01610986|Lactic acid
1091051|NCT01610986|Monocarboxylic Acid Transporters
1091052|NCT01610973|Fuch's dystrophy
1091053|NCT01610973|Corneal graft
1091054|NCT01610960|Non invasive ventilation
1091055|NCT01610960|Helmet
1091056|NCT01610960|NEXT Helmet
1091057|NCT01610960|Work of breathing
1091058|NCT01610960|Intensive care
1091059|NCT01610947|Spondyloarthritis
1091060|NCT01610947|Anti-TNF
1091061|NCT01610947|Adalimumab
1091062|NCT01610947|Etanercept
1091063|NCT01610947|Infliximab
1091064|NCT01610934|MODY
1091065|NCT01610934|Monogenic diabetes
1091066|NCT01610934|Non-autoimmune diabetes
1091067|NCT01610934|MODY3
1091068|NCT01610921|asthma
1091069|NCT01610921|small airways disease
1091070|NCT01610921|inflammation
1091071|NCT01610921|provocation
1091072|NCT01610921|adenosine
1091073|NCT01610908|Adolescent
1091074|NCT01610908|Idiopathic
1091075|NCT01610908|Scoliosis
1091076|NCT01610908|Schroth
1091077|NCT01610908|Exercises
1091078|NCT01610908|Conservative treatment
1091079|NCT01610895|Colonoscopy
1091080|NCT01610895|low fibre diet
1091081|NCT01610895|clear fluids
1091082|NCT01610895|Bowel Preparation
1091083|NCT01610869|Recurrence
1091084|NCT01610869|Ovarian Neoplasms
1091085|NCT01610869|Ovarian Diseases
1091086|NCT01610869|Fallopian Tube Neoplasms
1091087|NCT01610869|Neoplasms
1091088|NCT01610869|Carcinoma
1091089|NCT01610869|Neoplasms by site
1091090|NCT01610856|bowel preparation
1091091|NCT01610856|bowel purgative
1091092|NCT01610856|bowel cleansing
1091093|NCT01610856|colonoscopy
1091094|NCT01610843|Sarcoidosis
1091095|NCT01610843|WISE
1091096|NCT01610843|Sarcoid Study
1091097|NCT01610843|Worldwide Sarcoidosis Research Study
1091098|NCT01610830|Purpura, Schoenlein-Henoch
1091099|NCT01610830|adults
1091100|NCT01610830|children
1091101|NCT01610830|pronostic factors
1091102|NCT01610817|Patient information and active participation
1091103|NCT01610817|Patient safety
1091104|NCT01610817|Health education
1091105|NCT01610817|Adverse drug event
1091106|NCT01610817|Primary care
1091107|NCT01610817|Antihypertensive drugs
1091108|NCT01610765|HSV
1091109|NCT01610765|pharmacokinetics
1091110|NCT01610765|herpes
1091111|NCT01610765|neonates
1091112|NCT01610752|Pregnancy
1091113|NCT01610752|Gestational weight gain
1091114|NCT01610726|colon
1091115|NCT01610726|rectum
1091116|NCT01610726|recovery
1091117|NCT01610726|surgery
1091118|NCT01610674|Diabetes mellitus
1091119|NCT01610674|Surgery
1091120|NCT01610674|Implementation
1091121|NCT01610674|Quality of care
1091122|NCT01610674|Quality indicators
1091123|NCT01610661|carbohydrate
1091124|NCT01610661|inflammation
1091125|NCT01610661|glucose homeostasis
1091126|NCT01610661|gene expression
1091127|NCT01610648|OSA
1091128|NCT01610648|metabolic syndrome
1091129|NCT01610648|Apnea-hypopnea index
1091130|NCT01610648|Oxygen desaturation index
1091131|NCT01610635|RCT
1091132|NCT01610635|blood donation frequency
1091133|NCT01610635|quality of life
1091134|NCT01610635|iron deficiency
1091135|NCT01610622|Cardiac Output
1091136|NCT01610622|Blood volumes
1091137|NCT01610622|Neonates
1091138|NCT01610609|Statin treatment
1091139|NCT01610609|Cardiovascular disease
1091140|NCT01610609|High cholesterol
1091141|NCT01610609|Care management
1091142|NCT01610596|Psoriasis
1091143|NCT01610596|Skin Diseases
1091144|NCT01610596|Halobetasol
1091145|NCT01610596|Vasoconstrictor Agents
1091146|NCT01610596|Therapeutic Uses
1091147|NCT01610596|Pharmacologic Actions
1091148|NCT01610596|Anti-Inflammatory Agents
1091149|NCT01610596|Physiological Effects of Drugs
1091150|NCT01610583|Genetic Literacy
1091151|NCT01610583|Latino
1091152|NCT01610570|Dose Limiting Toxicity
1091153|NCT01610570|Maximum Tolerated Dose
1091154|NCT01610570|Radiographic Response
1091155|NCT01610570|Time to Progression
1091156|NCT01610570|Bone Tumors
1091157|NCT01610557|Diabetic Macular Edema
1091158|NCT01610557|Ranibizumab
1091159|NCT01610557|Bevacizumab
1091160|NCT01610544|Thymoma
1091161|NCT01610544|Insulin Growth Factor
1091162|NCT01610544|Cell Proliferation
1091163|NCT01610544|Non Small Cell Lung Cancer
1091164|NCT01610544|PET/CT Imaging Sessions
1091165|NCT01610531|Cohort
1091166|NCT01610531|Melanoma
1091167|NCT01610531|targeted screening
1091168|NCT01610531|risks function
1091169|NCT01610531|cost effectiveness
1091170|NCT01610518|postprandial blood glucose
1091171|NCT01610518|dietary fiber
1091172|NCT01610518|beta-glucan
1091173|NCT01610505|Knee Osteoarthritis
1091174|NCT01610505|Knee pain
1091175|NCT01610505|Arthritis
1091176|NCT01610505|KineSpring
1091177|NCT01610505|High Tibial Osteotomy
1091178|NCT01610492|IMGN
1091179|NCT01610492|anti-PLA2R antibodies
1091180|NCT01610492|pharmacokinetics
1091181|NCT01610492|belimumab
1091182|NCT01610492|Benlysta
1091183|NCT01610492|Idiopathic Membranous Glomerulonephropathy
1091184|NCT01610492|safety
1091185|NCT01610492|GSK1550188
1091186|NCT01610492|Lymphostat-B
1091187|NCT01610492|membrane attack complex
1091188|NCT01610466|Education
1091189|NCT01610466|Simulation
1091190|NCT01610466|Technical skills training
1091191|NCT01610466|Laparoscopy
1091192|NCT01610466|Bariatric Surgery
1091193|NCT01610453|prolonged labor
1091194|NCT01610453|cesarean section
1091195|NCT01610453|duration of labor
1091196|NCT01610440|Duchenne muscular dystrophy
1091197|NCT01610440|Human Umbilical Cord Mesenchymal Stem Cells
1091198|NCT01610427|CMI
1091199|NCT01610427|HIV
1091200|NCT01610427|Antiretroviral therapy-naïve
1091201|NCT01610414|Observer-blind
1091202|NCT01610414|Efficacy
1091203|NCT01610414|Immunogenicity
1091204|NCT01610414|Vaccination
1091205|NCT01610414|Safety
1091206|NCT01610414|Adult autologous haematopoietic cell transplant recipients
1091207|NCT01610414|Herpes Zoster
1091208|NCT01610388|healthy subjects
1091209|NCT01610388|double-blind
1091210|NCT01610388|FTIH
1091211|NCT01610388|dose-escalation
1091212|NCT01610388|absolute bioavailability
1091213|NCT01610388|GSK1322322
1091214|NCT01610388|BAL
1091215|NCT01610375|Endometrial cancer
1091216|NCT01610362|rabies
1091217|NCT01610362|immunoglobulin
1091218|NCT01610362|dosage
1091219|NCT01610336|EGFR
1091220|NCT01610336|c-MET
1091221|NCT01610336|Lung cancer
1091222|NCT01610336|Gefitinib
1091223|NCT01610336|Erlotinib
1091224|NCT01610323|Pregnancy
1091225|NCT01610323|Obesity
1091226|NCT01610323|Physical activity
1091227|NCT01610323|Cardiorespiratory fitness
1091228|NCT01610323|Muscular Fitness
1091229|NCT01610323|Weight gain
1091230|NCT01610323|Fetal growth
1091231|NCT01610310|SC
1091232|NCT01610310|PEG
1091233|NCT01610310|Inteferon
1091234|NCT01610310|PK
1091235|NCT01610310|Subcutaneous
1091236|NCT01610310|PEGylated
1091237|NCT01610310|Autoinjector
1091238|NCT01610310|Injectable
1091239|NCT01610310|MS
1091240|NCT01610297|hematopoietic stem cell transplantation, beta-thalassemia major, deferasirox, iron overload
1091241|NCT01610284|Breast cancer
1091242|NCT01610284|Hormone receptor positive
1091243|NCT01610284|HER2-negative
1091244|NCT01610284|Metastatic
1091245|NCT01610284|Locally advanced
1091246|NCT01610284|PI3K
1091247|NCT01610284|Fulvestrant
1091248|NCT01610284|Refractory
1091249|NCT01610284|Aromatase inhibitor
1091250|NCT01610271|Prevention
1091251|NCT01610271|Surgical Site Infection
1091252|NCT01610271|Air Barrier System
1091253|NCT01610271|Implant Infection
1091254|NCT01610258|pregnancy, chorioamnionitis, PPROM, Treg
1091255|NCT01610245|Influenza
1091256|NCT01610232|Infrared LED
1091257|NCT01610232|Treadmill Training
1091258|NCT01610232|Strength Muscle
1091259|NCT01610232|Fatigue Muscle
1091260|NCT01610232|Aerobic Capacity
1091261|NCT01610232|Cellulite
1091262|NCT01610232|Osteoporosis
1091263|NCT01610206|recurrent
1091264|NCT01610206|persistent
1091265|NCT01610193|Pancreatic Stone Protein
1091266|NCT01610193|Abdominal pain
1091267|NCT01610193|Acute appendicitis
1091268|NCT01610193|Alvarado score
1091269|NCT01610193|Appendectomy
1091270|NCT01610193|Sensitivity and specificity
1091271|NCT01610180|Eltrombopag
1091272|NCT01610180|ITP
1091273|NCT01610180|LPD
1091274|NCT01610180|leukemia
1091275|NCT01610180|Immune ThrombocytoPenia
1091276|NCT01610154|glucagon
1091277|NCT01610154|dipeptidyl peptidase-4 inhibitor
1091278|NCT01610141|warfarin metabolism
1091279|NCT01610141|pharmacogenetics
1091280|NCT01610141|CYP2C9
1091281|NCT01610141|genotyping
1091282|NCT01610141|VKORC1
1091283|NCT01610141|CYP4F2
1091284|NCT01610141|anticoagulation
1091285|NCT01610141|atrial fibrillation
1091286|NCT01610141|deep vein thrombosis
1091287|NCT01610141|pulmonary embolism
1091288|NCT01610141|Artificial Heart Valve
1091289|NCT01610128|urticaria, patient reported outcome
1091290|NCT01610115|Pregnancy
1091291|NCT01610102|clinical follow-up
1091292|NCT01610102|up to 7 years
1091293|NCT01610102|all patients enrolled in the main study
1091294|NCT01610089|citrullinemia
1091295|NCT01610089|argininosuccinate synthetase deficiency
1091296|NCT01610089|nitric oxide
1091297|NCT01610089|urea
1091298|NCT01610076|Code Status
1091299|NCT01610076|Do not resuscitate (DNR)
1091300|NCT01610076|Do not intubate (DNI)
1091301|NCT01610076|CPR
1091302|NCT01610076|Cardiopulmonary resuscitation
1091303|NCT01610076|video
1091304|NCT01610076|advanced directives
1091305|NCT01610063|Algorithm
1091306|NCT01610063|Depression
1091307|NCT01610063|Assurex
1091308|NCT01610063|GeneSight
1091309|NCT01610050|castration-resistant prostate cancer, advanced breast cancer
1091310|NCT01610037|chronic obstructive pulmonary disease
1091311|NCT01610037|COPD
1091312|NCT01610037|QVA149
1091313|NCT01610037|QAB149
1091314|NCT01610037|NVA237
1091315|NCT01610037|Indacaterol maleate
1091316|NCT01610037|Glycopyronnium bromide
1091317|NCT01610011|Schizophrenia
1091318|NCT01610011|Psychotic Disorders
1091319|NCT01610011|N-methyl-D-aspartate receptor
1091320|NCT01610011|Glycine augmentation
1091321|NCT01610011|Glycine
1091322|NCT01610011|Glycine Pharmacodynamics
1091323|NCT01610011|Glycine Bioavailability
1091324|NCT01610011|Magnetic Resonance Spectroscopy
1091325|NCT01610011|Glycine Decarboxylase
1091326|NCT01610011|Glycine Decarboxylase Mutation
1091327|NCT01609998|Influenza A (H1)
1091328|NCT01609998|Influenza A (H3)
1091329|NCT01609998|Influenza B
1091330|NCT01609998|DNA Vaccine
1091331|NCT01609998|Trivalent Inactivated Vaccine (TIV)
1091332|NCT01609998|Healthy Adolescents
1091333|NCT01609998|Healthy Children
1091334|NCT01609985|Cardiac Resynchronization Therapy Defibrillator (CRT-D) Devices
1091335|NCT01609972|Back pain
1091336|NCT01609972|Spinal Cord Stimulation
1091337|NCT01609959|Hypertension
1091338|NCT01609959|Angiotensin II Receptor Blocker
1091339|NCT01609959|Azilsartan
1091340|NCT01609959|Valsartan
1091341|NCT01609946|presenting for FNAB or surgery
1091342|NCT01609933|Hepatitis C
1091343|NCT01609933|Hepatitis C Genotype 1
1091344|NCT01609933|Chronic Hepatitis C
1091345|NCT01609933|HCV
1091346|NCT01609920|MRI
1091347|NCT01609920|lymph node metastases
1091348|NCT01609920|breast cancer
1091349|NCT01609920|gadofosveset
1091350|NCT01609907|Drug interaction
1091351|NCT01609907|YH14700
1091352|NCT01609907|Rosuvastatin
1091353|NCT01609907|Valsartan
1091354|NCT01609907|Yuhan
1091355|NCT01609894|Postnatal development
1091356|NCT01609894|Breast milk fortification
1091357|NCT01609894|Composition of breast milk
1091358|NCT01609881|Inflammation
1091359|NCT01609868|premature infant feeding protein
1091360|NCT01609855|Adenoma Detection Rate
1091361|NCT01609855|Anti-spasmotic drug
1091362|NCT01609842|Acute Coronary Syndrome
1091363|NCT01609842|adherence
1091364|NCT01609816|adult grade III lymphomatoid granulomatosis
1091365|NCT01609816|adult nasal type extranodal NK/T-cell lymphoma
1091366|NCT01609816|anaplastic large cell lymphoma
1091367|NCT01609816|angioimmunoblastic T-cell lymphoma
1091368|NCT01609816|contiguous stage II adult Burkitt lymphoma
1091369|NCT01609816|contiguous stage II adult diffuse large cell lymphoma
1091370|NCT01609816|contiguous stage II adult diffuse mixed cell lymphoma
1091371|NCT01609816|contiguous stage II adult diffuse small cleaved cell lymphoma
1091372|NCT01609816|contiguous stage II adult immunoblastic large cell lymphoma
1091373|NCT01609816|contiguous stage II adult lymphoblastic lymphoma
1091374|NCT01609816|contiguous stage II grade 1 follicular lymphoma
1091375|NCT01609816|contiguous stage II grade 2 follicular lymphoma
1091376|NCT01609816|contiguous stage II grade 3 follicular lymphoma
1091377|NCT01609816|contiguous stage II mantle cell lymphoma
1091378|NCT01609816|contiguous stage II marginal zone lymphoma
1091379|NCT01609816|contiguous stage II small lymphocytic lymphoma
1091380|NCT01609816|cutaneous B-cell non-Hodgkin lymphoma
1091381|NCT01609816|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1091382|NCT01609816|hepatosplenic T-cell lymphoma
1091383|NCT01609816|intraocular lymphoma
1091384|NCT01609816|nodal marginal zone B-cell lymphoma
1091385|NCT01609816|noncontiguous stage II adult Burkitt lymphoma
1091386|NCT01609816|noncontiguous stage II adult diffuse large cell lymphoma
1091387|NCT01609816|noncontiguous stage II adult diffuse mixed cell lymphoma
1091388|NCT01609816|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1091389|NCT01609816|noncontiguous stage II adult immunoblastic large cell lymphoma
1091390|NCT01609816|noncontiguous stage II adult lymphoblastic lymphoma
1091391|NCT01609816|noncontiguous stage II grade 1 follicular lymphoma
1091392|NCT01609816|noncontiguous stage II grade 2 follicular lymphoma
1091393|NCT01609816|noncontiguous stage II grade 3 follicular lymphoma
1091394|NCT01609816|noncontiguous stage II mantle cell lymphoma
1091395|NCT01609816|noncontiguous stage II marginal zone lymphoma
1091396|NCT01609816|noncontiguous stage II small lymphocytic lymphoma
1091397|NCT01609816|noncutaneous extranodal lymphoma
1091398|NCT01609816|peripheral T-cell lymphoma
1091399|NCT01609816|recurrent adult Burkitt lymphoma
1091400|NCT01609816|recurrent adult diffuse large cell lymphoma
1091401|NCT01609816|recurrent adult diffuse mixed cell lymphoma
1091402|NCT01609816|recurrent adult diffuse small cleaved cell lymphoma
1091403|NCT01609816|recurrent adult grade III lymphomatoid granulomatosis
1091404|NCT01609816|recurrent adult Hodgkin lymphoma
1091405|NCT01609816|recurrent adult immunoblastic large cell lymphoma
1091406|NCT01609816|recurrent adult lymphoblastic lymphoma
1091407|NCT01609816|recurrent adult T-cell leukemia/lymphoma
1091408|NCT01609816|recurrent cutaneous T-cell non-Hodgkin lymphoma
1091409|NCT01609816|recurrent grade 1 follicular lymphoma
1091410|NCT01609816|recurrent grade 2 follicular lymphoma
1091411|NCT01609816|recurrent grade 3 follicular lymphoma
1091412|NCT01609816|recurrent mantle cell lymphoma
1091413|NCT01609816|recurrent marginal zone lymphoma
1091414|NCT01609816|recurrent mycosis fungoides/Sezary syndrome
1091415|NCT01609816|recurrent small lymphocytic lymphoma
1091416|NCT01609816|refractory hairy cell leukemia
1091417|NCT01609816|refractory multiple myeloma
1091418|NCT01609816|small intestine lymphoma
1091419|NCT01609816|splenic marginal zone lymphoma
1091420|NCT01609816|stage I adult Burkitt lymphoma
1091421|NCT01609816|stage I adult diffuse large cell lymphoma
1091422|NCT01609816|stage I adult diffuse mixed cell lymphoma
1091423|NCT01609816|stage I adult diffuse small cleaved cell lymphoma
1091424|NCT01609816|stage I adult Hodgkin lymphoma
1091425|NCT01609816|stage I adult immunoblastic large cell lymphoma
1091426|NCT01609816|stage I adult lymphoblastic lymphoma
1091427|NCT01609816|stage I adult T-cell leukemia/lymphoma
1091428|NCT01609816|stage I cutaneous T-cell non-Hodgkin lymphoma
1091429|NCT01609816|stage I grade 1 follicular lymphoma
1091430|NCT01609816|stage I grade 2 follicular lymphoma
1091431|NCT01609816|stage I grade 3 follicular lymphoma
1091432|NCT01609816|stage I mantle cell lymphoma
1091433|NCT01609816|stage I marginal zone lymphoma
1091434|NCT01609816|stage I multiple myeloma
1091435|NCT01609816|stage I small lymphocytic lymphoma
1091436|NCT01609816|stage IA mycosis fungoides/Sezary syndrome
1091437|NCT01609816|stage IB mycosis fungoides/Sezary syndrome
1091438|NCT01609816|stage II adult Hodgkin lymphoma
1091439|NCT01609816|stage II adult T-cell leukemia/lymphoma
1091440|NCT01609816|stage II cutaneous T-cell non-Hodgkin lymphoma
1091441|NCT01609816|stage II multiple myeloma
1091442|NCT01609816|stage IIA mycosis fungoides/Sezary syndrome
1091443|NCT01609816|stage IIB mycosis fungoides/Sezary syndrome
1091444|NCT01609816|stage III adult Burkitt lymphoma
1091445|NCT01609816|stage III adult diffuse large cell lymphoma
1091446|NCT01609816|stage III adult diffuse mixed cell lymphoma
1091447|NCT01609816|stage III adult diffuse small cleaved cell lymphoma
1091448|NCT01609816|stage III adult Hodgkin lymphoma
1091449|NCT01609816|stage III adult immunoblastic large cell lymphoma
1091450|NCT01609816|stage III adult lymphoblastic lymphoma
1091451|NCT01609816|stage III adult T-cell leukemia/lymphoma
1091452|NCT01609816|stage III cutaneous T-cell non-Hodgkin lymphoma
1091453|NCT01609816|stage III grade 1 follicular lymphoma
1091454|NCT01609816|stage III grade 2 follicular lymphoma
1091455|NCT01609816|stage III grade 3 follicular lymphoma
1091456|NCT01609816|stage III mantle cell lymphoma
1091457|NCT01609816|stage III marginal zone lymphoma
1091458|NCT01609816|stage III multiple myeloma
1091459|NCT01609816|stage III small lymphocytic lymphoma
1091460|NCT01609816|stage IIIA mycosis fungoides/Sezary syndrome
1091461|NCT01609816|stage IIIB mycosis fungoides/Sezary syndrome
1091462|NCT01609816|stage IV adult Burkitt lymphoma
1091463|NCT01609816|stage IV adult diffuse large cell lymphoma
1091464|NCT01609816|stage IV adult diffuse mixed cell lymphoma
1091465|NCT01609816|stage IV adult diffuse small cleaved cell lymphoma
1091466|NCT01609816|stage IV adult Hodgkin lymphoma
1091467|NCT01609816|stage IV adult immunoblastic large cell lymphoma
1091468|NCT01609816|stage IV adult lymphoblastic lymphoma
1091469|NCT01609816|stage IV adult T-cell leukemia/lymphoma
1091470|NCT01609816|stage IV cutaneous T-cell non-Hodgkin lymphoma
1091471|NCT01609816|stage IV grade 1 follicular lymphoma
1091472|NCT01609816|stage IV grade 2 follicular lymphoma
1091473|NCT01609816|stage IV grade 3 follicular lymphoma
1091474|NCT01609816|stage IV mantle cell lymphoma
1091475|NCT01609816|stage IV marginal zone lymphoma
1091476|NCT01609816|stage IV small lymphocytic lymphoma
1091477|NCT01609816|stage IVA mycosis fungoides/Sezary syndrome
1091478|NCT01609816|stage IVB mycosis fungoides/Sezary syndrome
1091479|NCT01609816|T-cell large granular lymphocyte leukemia
1091480|NCT01609816|testicular lymphoma
1091481|NCT01609816|Waldenström macroglobulinemia
1091482|NCT01609751|probiotic
1091483|NCT01609751|lactobacillus
1091484|NCT01609751|colonic diseases
1091485|NCT01609751|dietary fibre
1091486|NCT01609738|Cardiac pacing
1091487|NCT01609738|Left ventricular septal pacing
1091488|NCT01609738|Feasibility and safety
1091489|NCT01609738|Lead stability
1091490|NCT01609738|Hemodynamics
1091491|NCT01609738|Left ventricular dyssynchrony
1091492|NCT01609738|Pacing for heart failure
1091493|NCT01609738|Cardiac resynchronization therapy
1091494|NCT01609725|Coronary artery disease
1091495|NCT01609725|C reactive protein
1091496|NCT01609725|Periodontitis
1091497|NCT01609725|Periodontal therapy
1091498|NCT01609725|Flow-mediated dilation
1091499|NCT01609712|Improvement of lung function (FEV1, PEF)
1091500|NCT01609712|Visual Analog Scale
1091501|NCT01609712|Oswestry Disability Index
1091502|NCT01609712|Radiographs pre and post Op
1091503|NCT01609699|body circumference
1091504|NCT01609699|Non-Invasive Reduction
1091505|NCT01609686|cardiac surgery
1091506|NCT01609686|renal dysfunction
1091507|NCT01609686|pharmacokinetics
1091508|NCT01609686|tranexamic acid
1091509|NCT01609673|Immunosuppression
1091510|NCT01609673|Chronic Kidney Disease
1091511|NCT01609673|Renal Transplant
1091512|NCT01609660|probiotics
1091513|NCT01609660|cytokine
1091514|NCT01609660|short chain fatty acids
1091515|NCT01609660|complications
1091516|NCT01609660|colorectal surgery
1091517|NCT01609647|High plate reactivity unit after loading dose of clopidogrel
1091518|NCT01609634|Healthy
1091519|NCT01609634|Term infants
1091520|NCT01609634|Growth
1091521|NCT01609634|Body composition
1091522|NCT01609595|Thalassemia
1091523|NCT01609595|Anemia
1091524|NCT01609595|Fetal hemoglobin
1091525|NCT01609582|Drug therapy
1091526|NCT01609556|FOLR solid tumors
1091527|NCT01609530|verruca
1091528|NCT01609530|vulgaris
1091529|NCT01609530|hands
1091530|NCT01609530|feet
1091531|NCT01609530|Nd:YAG
1091532|NCT01609530|laser
1091533|NCT01609530|cryotherapy
1091534|NCT01609517|Spinal anesthesia
1091535|NCT01609517|determinant
1091536|NCT01609517|duration
1091537|NCT01609504|Rectal cancer
1091538|NCT01609504|Radiochemotherapy
1091539|NCT01609504|Transanal Endoscopic Microsurgery
1091540|NCT01609504|Laparoscopic Resection
1091541|NCT01609478|asthma
1091542|NCT01609465|CAD
1091543|NCT01609465|stable angina
1091544|NCT01609465|STEMI
1091545|NCT01609465|NSTEMI
1091546|NCT01609465|CVD
1091547|NCT01609465|secondary prevention
1091548|NCT01609452|Immune Thrombocytopenic Purpura
1091549|NCT01609452|Idiopathic Thrombocytopenic Purpura
1091550|NCT01609452|Chronic ITP
1091551|NCT01609439|Permanent
1091552|NCT01609439|temporary
1091553|NCT01609439|hypocalcemia
1091554|NCT01609426|Proteinuria
1091555|NCT01609426|idiopathic
1091556|NCT01609426|nephrotic syndrome
1091557|NCT01609426|herpesvirus
1091558|NCT01609426|epidemiology
1091559|NCT01609426|immune response
1091560|NCT01609426|interferon
1091561|NCT01609426|steroid dependency
1091562|NCT01609426|nephrotic disease: Idiopathic nephrotic syndrome
1091563|NCT01609387|Vitamine
1091564|NCT01609387|mineral
1091565|NCT01609387|obese patients
1091566|NCT01609387|Vitamine en mineral shortage in obese patients
1091567|NCT01609374|Spinal Kinetics
1091568|NCT01609374|artificial cervical disc
1091569|NCT01609374|cervical radiculopathy
1091570|NCT01609374|ACDF
1091571|NCT01609374|neck pain
1091572|NCT01609374|cervical spine
1091573|NCT01609374|degenerative disc disease
1091574|NCT01609361|Rehabilitation program
1091575|NCT01609361|Fast track surgery
1091576|NCT01609361|Laparoscopic colorectal resection
1091577|NCT01609361|Colorectal cancer
1091578|NCT01609361|Morbidity
1091579|NCT01609348|Depression
1091580|NCT01609348|Alzheimer's Disease
1091581|NCT01609322|fear of falling
1091582|NCT01609322|agoraphobia
1091583|NCT01609309|Stomach Neoplasms
1091584|NCT01609309|Laparoscopy
1091585|NCT01609296|Peripheral Arterial Disease
1091586|NCT01609296|Drug coated balloon
1091587|NCT01609296|Superficial Femoral Artery
1091588|NCT01609296|Popliteal Femoral Artery
1091589|NCT01609296|Atherosclerosis
1091590|NCT01609244|Sleep apnea
1091591|NCT01609244|central sleep apnea
1091592|NCT01609244|bilevel
1091593|NCT01609244|servoventilation
1091594|NCT01609244|CPAP
1091595|NCT01609192|sickle-cell anemia
1091596|NCT01609192|spermatogenesis
1091597|NCT01609192|hydroxyurea
1091598|NCT01609166|Hand-foot Syndrome
1091599|NCT01609166|capecitabine
1091600|NCT01609166|allopurinol
1091601|NCT01609153|schizophrenia
1091602|NCT01609153|amisulpride
1091603|NCT01609153|olanzapine
1091604|NCT01609153|polypharmacy
1091605|NCT01609140|Hyperlipidemia
1091606|NCT01609140|Dyslipidemia
1091607|NCT01609114|phenomena and mechanism of RT-PK
1091608|NCT01609114|fact for different anticancer drugs
1091609|NCT01609114|different part in human
1091610|NCT01609101|Videolaryngoscopy
1091611|NCT01609101|Palatopharyngeal distance
1091612|NCT01609101|Trauma
1091613|NCT01609088|endothelium
1091614|NCT01609088|diabetes mellitus
1091615|NCT01609088|oxidative stress
1091616|NCT01609062|Mucopolysaccharidosis IVA Type A
1091617|NCT01609062|MPS IVA Type A
1091618|NCT01609062|Mucopolysaccharidosis IVA
1091619|NCT01609062|MPS IVA
1091620|NCT01609062|Morquio A Syndrome
1091621|NCT01609062|Lysosomal Storage Disorder
1091622|NCT01609062|LSD
1091623|NCT01609062|N-acetylgalactosamine-6-sulfatase
1091624|NCT01609062|N-acetylgalactosamine-6-sulfate
1091625|NCT01609062|sulfatase
1091626|NCT01609062|galactose-6-sulfatase
1091627|NCT01609062|GALNS
1091628|NCT01609062|enzyme replacement therapy
1091629|NCT01609062|ERT
1091630|NCT01609062|MOR-008
1091631|NCT01609062|CPET
1091632|NCT01609062|MST
1091633|NCT01609062|muscle strength test
1091634|NCT01609062|physiological effect
1091635|NCT01608984|remote ischemic preconditioning
1091636|NCT01608984|coronary artery bypass grafting
1091637|NCT01608984|myocardial injury
1091638|NCT01608971|Protamine
1091639|NCT01608971|heparin level
1091640|NCT01608971|haemostasis
1091641|NCT01608971|thromboelastometry
1091642|NCT01608971|cardiac surgery
1091643|NCT01608971|Patients undergoing cardiac surgery
1091644|NCT01608958|Postpartum hemorrhage
1091645|NCT01608958|Oxytocin
1091646|NCT01608958|Third stage of labor
1091647|NCT01608958|Hemoglobin
1091648|NCT01608958|Prevention
1091649|NCT01608958|Intravenous
1091650|NCT01608958|Intramuscular
1091651|NCT01608945|steroid
1091652|NCT01608945|liver function
1091653|NCT01608945|prognosis
1091654|NCT01608906|venous thrombosis
1091655|NCT01608906|heparin
1091656|NCT01608906|pulmonary embolism
1091657|NCT01608906|ICU
1091658|NCT01608867|Phase 1
1091659|NCT01608867|dose escalation
1091660|NCT01608867|histologically confirmed
1091661|NCT01608867|malignancy
1091662|NCT01608867|metastatic
1091663|NCT01608854|surgical site infection
1091664|NCT01608854|spinal surgery
1091665|NCT01608854|prophylactic antibiotics
1091666|NCT01608854|postoperative spinal drains
1091667|NCT01608815|Salmonella infections
1091668|NCT01608815|Typhoid fever
1091669|NCT01608815|Bacterial infections
1091670|NCT01608815|Typhoid vaccine
1091671|NCT01608802|HIV
1091672|NCT01608802|Antiretroviral therapy
1091673|NCT01608802|Palliative care
1091674|NCT01608802|Pain
1091675|NCT01608789|Male sling
1091676|NCT01608789|Stress Urinary Incontinence
1091677|NCT01608789|Urination Disorders
1091678|NCT01608789|Urologic Diseases
1091679|NCT01608724|Type 2 DM
1091680|NCT01608711|Gemcitabine
1091681|NCT01608711|ASP6182
1091682|NCT01608711|AGS-1C4D4
1091683|NCT01608711|Pancreatic Cancer
1091684|NCT01608698|chlormadinone acetate
1091685|NCT01608698|drospirenone
1091686|NCT01608698|contraceptive pills
1091687|NCT01608685|Tuberculosis
1091688|NCT01608685|Latent tuberculosis infection
1091689|NCT01608685|Immunosuppression
1091690|NCT01608685|Renal transplant recipient
1091691|NCT01608646|S-1
1091692|NCT01608646|Oxaliplatin
1091693|NCT01608646|Dihydropyrimidine Dehydrogenase
1091694|NCT01608620|Systematic review and meta-analysis
1091695|NCT01608620|Evidence-based medicine (EBM)
1091696|NCT01608620|Evidence-based nutrition (EBN)
1091697|NCT01608620|Clinical practice guidelines
1091698|NCT01608620|Clinical trials
1091699|NCT01608620|Dietary sugars
1091700|NCT01608620|Fructose
1091701|NCT01608620|High fructose corn syrup
1091702|NCT01608620|Fruit
1091703|NCT01608620|Isocaloric
1091704|NCT01608620|Hypercaloric
1091705|NCT01608620|Cardiometabolic risk factors
1091706|NCT01608620|Triglycerides
1091707|NCT01608620|Cholesterol
1091708|NCT01608620|Glycemic control
1091709|NCT01608620|Insulin resistance
1091710|NCT01608620|Body weight
1091711|NCT01608620|Uric acid
1091712|NCT01608620|Blood pressure
1091713|NCT01608607|Systematic review and meta-analysis
1091714|NCT01608607|Evidence-based medicine (EBM)
1091715|NCT01608607|Evidence-based nutrition (EBN)
1091716|NCT01608607|Clinical practice guidelines
1091717|NCT01608607|Clinical trials
1091718|NCT01608607|Dietary sugars
1091719|NCT01608607|Fructose
1091720|NCT01608607|High fructose corn syrup
1091721|NCT01608607|sucrose
1091722|NCT01608607|Isocaloric
1091723|NCT01608607|Hypercaloric
1091724|NCT01608607|Glycemic control
1091725|NCT01608607|Insulin resistance
1091726|NCT01608607|Body weight
1091727|NCT01608607|body mass index
1091728|NCT01608607|waist circumference
1091729|NCT01608581|prevention
1091730|NCT01608581|burn
1091731|NCT01608581|adult
1091732|NCT01608581|health promotion
1091733|NCT01608581|evaluation
1091734|NCT01608581|media
1091735|NCT01608568|Sutures
1091736|NCT01608568|Pelvic Organ Prolapse
1091737|NCT01608568|Sacrocolpopexy
1091738|NCT01608568|Robotic Assisted Laparoscopy
1091739|NCT01608555|cystic fibrosis
1091740|NCT01608555|bacterial load
1091741|NCT01608555|inhaled tobramycin
1091742|NCT01608542|fostamatinib
1091743|NCT01608542|FosD
1091744|NCT01608542|Japanese Healthy volunteers
1091745|NCT01608542|Phase 1
1091746|NCT01608542|Single and Multiple Dose Study
1091747|NCT01608529|Restriction device ventilatory nasal flow
1091748|NCT01608529|oronasal breathing
1091749|NCT01608529|nasal breathing.
1091750|NCT01608516|PET/CT
1091751|NCT01608516|68Ga-NODAGA-RGD
1091752|NCT01608516|18F-FDG
1091753|NCT01608516|MRI
1091754|NCT01608516|US ultrasound
1091755|NCT01608516|inflammatory atheromatous plaque
1091756|NCT01608516|endarterectomy
1091757|NCT01608503|subclavian vein
1091758|NCT01608503|ultrasound
1091759|NCT01608503|distance between the subclavian vein and the lung
1091760|NCT01608490|COPD
1091761|NCT01608490|RePneu
1091762|NCT01608477|Heart transplantation
1091763|NCT01608477|Medication adherence
1091764|NCT01608477|Behavior system factor
1091765|NCT01608464|Randomized trial,
1091766|NCT01608464|Pre-operative chemo-RT with CDDP and 5-FU
1091767|NCT01608464|Multicenter study
1091768|NCT01608438|Body-machine interface
1091769|NCT01608438|Customization
1091770|NCT01608438|Upper-body motion
1091771|NCT01608438|Motor learning
1091772|NCT01608438|Assistive Devices
1091773|NCT01608438|Wheelchair
1091774|NCT01608438|Computer keyboard
1091775|NCT01608425|diabetic foot ulcer
1091776|NCT01608425|ulcer monitoring
1091777|NCT01608425|telemedicine consultations
1091778|NCT01608425|cross-sectoral collaboration
1091779|NCT01608412|renal transplantation
1091780|NCT01608412|everolimus
1091781|NCT01608412|tacrolimus
1091782|NCT01608412|molecular evaluation
1091783|NCT01608399|major depressive disorder
1091784|NCT01608399|psychotherapy
1091785|NCT01608399|metacognitive therapy
1091786|NCT01608386|Anterior approach
1091787|NCT01608386|infrahepatic inferior vena cava clamping
1091788|NCT01608386|hepatic resection
1091789|NCT01608373|Pain
1091790|NCT01608373|Lidocaine
1091791|NCT01608373|Intravenous
1091792|NCT01608373|Intraperitoneum
1091793|NCT01608373|Laparoscopic cholecystectomy
1091794|NCT01608360|Pain
1091795|NCT01608360|Lidocaine
1091796|NCT01608360|Intravenous
1091797|NCT01608360|Thyroidectomy
1091798|NCT01608347|LMWH
1091799|NCT01608347|enoxaparin
1091800|NCT01608347|recurrent miscarriage
1091801|NCT01608347|continuing fetal viability beyond 20 weeks gestation
1091802|NCT01608321|Chronic Pain
1091803|NCT01608321|Gulf War Illness
1091804|NCT01608321|Gulf War Syndrome
1091805|NCT01608321|Fibromyalgia
1091806|NCT01608321|repetitive Transcranial Magnetic Stimulation
1091807|NCT01608321|Transcranial Magnetic Stimulation
1091808|NCT01608321|Veterans
1091809|NCT01608308|Chronic Sinusitis
1091810|NCT01608308|Pain Relief
1091811|NCT01608308|Post-Operative Opioid Requirement
1091812|NCT01608308|IV Acetaminophen
1091813|NCT01608308|Functional Endoscopic Sinus Surgery
1091814|NCT01608308|FESS
1091815|NCT01608295|depressed
1091816|NCT01608295|geriatric
1091817|NCT01608295|older adults
1091818|NCT01608295|antidepressants
1091819|NCT01608295|depression
1091820|NCT01608295|anxious
1091821|NCT01608295|major depressive disorder
1091822|NCT01608295|MDD
1091823|NCT01608282|Osteoarthritis
1091824|NCT01608282|Arthritis
1091825|NCT01608282|Knee
1091826|NCT01608282|Exercise
1091827|NCT01608282|Physical Activity
1091828|NCT01608282|Web-based
1091829|NCT01608256|mild cognitive impairment
1091830|NCT01608256|Automobile Driving
1091831|NCT01608256|cognitive aspects
1091832|NCT01608217|Behavioural disturbances
1091833|NCT01608217|Pain
1091834|NCT01608217|Dementia
1091835|NCT01608217|Alzheimer's dementia
1091836|NCT01608217|Vascular dementia
1091837|NCT01608217|THC
1091838|NCT01608217|Cannabis
1091839|NCT01608204|Pharmacokinetics
1091840|NCT01608204|Busulfan
1091841|NCT01608204|Polymorphism
1091842|NCT01608204|GST
1091843|NCT01608204|MDR-1(p-Glycoprotein)
1091844|NCT01608204|Acute Myeloid Leukemia adult patients
1091845|NCT01608178|Pediatric Neurotransmitter Disorders
1091846|NCT01608178|Succinic Semialdehyde Dehydrogenase
1091847|NCT01608178|GABA
1091848|NCT01608178|Epilepsy
1091849|NCT01608165|Small renal cancer mass
1091850|NCT01608152|Leukemia
1091851|NCT01608152|Lymphoma
1091852|NCT01608152|Game mechanics
1091853|NCT01608152|Stem cell transplant survivors
1091854|NCT01608152|Hematopoietic stem cell transplantation
1091855|NCT01608152|HSCT
1091856|NCT01608152|Internet-based
1091857|NCT01608152|Interactive and personalized intervention
1091858|NCT01608152|Questionnaires
1091859|NCT01608152|Focus groups
1091860|NCT01608152|Interviews
1091861|NCT01608139|Advanced Cancers
1091862|NCT01608139|Advanced Solid Tumors
1091863|NCT01608139|Curcumin
1091864|NCT01608139|Sorafenib
1091865|NCT01608139|Nexavar
1091866|NCT01608139|Bay 43-9006
1091867|NCT01608139|Vorinostat
1091868|NCT01608139|SAHA
1091869|NCT01608139|Suberoylanilide Hydroxamic Acid
1091870|NCT01608139|MSK-390
1091871|NCT01608139|Zolinza
1091872|NCT01608126|Ultrasound
1091873|NCT01608126|Cervical Plexus
1091874|NCT01608126|Anesthesia, Conduction
1091875|NCT01608126|Surgical Procedures, Elective
1091876|NCT01608126|Atherectomy
1091877|NCT01608113|neovascular AMD
1091878|NCT01608113|Optical coherence tomography
1091879|NCT01608113|reading acuity
1091880|NCT01608113|contrast sensitivity
1091881|NCT01608074|BRCA1
1091882|NCT01608074|BRCA2
1091883|NCT01608074|Prophylactic surgery
1091884|NCT01608074|Salpingectomy
1091885|NCT01608074|Fimbriectomy
1091886|NCT01608061|Mild probable Alzheimer's Disease
1091887|NCT01608048|In-vitro Fertilization
1091888|NCT01608048|transcutaneous electrical acupoint stimulation
1091889|NCT01608035|sciatic catheter
1091890|NCT01608035|stump catheter
1091891|NCT01608035|below knee amputation
1091892|NCT01608009|platinum resistant
1091893|NCT01608009|ovarian cancer
1091894|NCT01607996|Epidural anesthesia
1091895|NCT01607996|pancreatic perfusion
1091896|NCT01607996|pancreatic necrosectomy
1091897|NCT01607983|nitric oxide
1091898|NCT01607983|ventricular-arterial coupling
1091899|NCT01607983|congenital heart disease
1091900|NCT01607970|Oxytocin
1091901|NCT01607970|Startle
1091902|NCT01607970|moral dilemma
1091903|NCT01607970|oxytocin receptor gene
1091904|NCT01607957|Refractory, metastatic colorectal cancer
1091905|NCT01607931|Exercise
1091906|NCT01607931|Physical activity
1091907|NCT01607931|Type 2 diabetes
1091908|NCT01607931|Obesity
1091909|NCT01607931|Incretin effect
1091910|NCT01607931|GLP-1
1091911|NCT01607931|GIP
1091912|NCT01607931|Insulin secretion
1091913|NCT01607931|Glucagon
1091914|NCT01607931|Beta-cell function
1091915|NCT01607931|Disposition Index
1091916|NCT01607918|H pylori, eradication
1091917|NCT01607905|Selinexor
1091918|NCT01607905|KPT-330
1091919|NCT01607905|Squamous Cell Carcinoma
1091920|NCT01607905|Glioblastoma multiforme
1091921|NCT01607905|Adenocarcinoma
1091922|NCT01607905|Melanoma
1091923|NCT01607892|Selinexor
1091924|NCT01607892|KPT-330
1091925|NCT01607892|Multiple Myeloma
1091926|NCT01607892|non-Hodgkin Lymphoma
1091927|NCT01607892|Chronic Lymphocytic Leukemia
1091928|NCT01607892|Waldenström's macroglobulinemia
1091929|NCT01607892|Peripheral T-Cell Lymphoma
1091930|NCT01607892|Cutaneous T-Cell Lymphoma
1091931|NCT01607892|Chronic Myelocytic Leukemia
1091932|NCT01607892|Acute Lymphoblastic Leukemia
1091933|NCT01607879|Prostate Cancer
1091934|NCT01607879|Men
1091935|NCT01607879|Androgen Deprivation Therapy
1091936|NCT01607879|Elderly
1091937|NCT01607879|Geriatric
1091938|NCT01607879|Nutritional supplementation
1091939|NCT01607840|Schizophrenia
1091940|NCT01607840|Cognitive Improvement
1091941|NCT01607840|tDCS
1091942|NCT01607840|stimulation
1091943|NCT01607827|polypectomy
1091944|NCT01607827|colonoscopy
1091945|NCT01607827|polyp miss rate
1091946|NCT01607827|surveillance
1091947|NCT01607827|colorectal cancer
1091948|NCT01607814|cirrhosis
1091949|NCT01607814|oxidative stress
1091950|NCT01607814|NADPH oxidase
1091951|NCT01607814|isoprostanes
1091952|NCT01607814|PUFA balance
1091953|NCT01607814|platelet activation
1091954|NCT01607814|coagulation abnormalities
1091955|NCT01607801|umbilical hernia repair
1091956|NCT01607801|recurrence
1091957|NCT01607801|choice of suture
1091958|NCT01607801|mesh
1091959|NCT01607801|mesh/non-mesh
1091960|NCT01607788|Selection criteria
1091961|NCT01607788|Liver transplantation
1091962|NCT01607788|Hepatocellular carcinoma
1091963|NCT01607762|Healthy
1091964|NCT01607762|Antipsychotics
1091965|NCT01607762|Aripiprazole
1091966|NCT01607762|Paliperidone
1091967|NCT01607762|Risperidone
1091968|NCT01607762|Quetiapine
1091969|NCT01607762|Olanzapine
1091970|NCT01607749|Asthma Control
1091971|NCT01607749|Quality of life
1091972|NCT01607749|Children
1091973|NCT01607749|Asthma education
1091974|NCT01607736|falls
1091975|NCT01607736|walking
1091976|NCT01607736|healthy older individuals
1091977|NCT01607736|virtual gait training
1091978|NCT01607723|Sleep pattern
1091979|NCT01607723|Mechanical ventilation
1091980|NCT01607723|weaning
1091981|NCT01607723|Intensive Care
1091982|NCT01607723|NAVA (Neurally Adjusted Ventilatory Assist)
1091983|NCT01607723|PAV+ (Proportional Assist Ventilation Plus)
1091984|NCT01607710|fMRI
1091985|NCT01607710|Generalized Anxiety Disorder
1091986|NCT01607697|Parkinson's Disease
1091987|NCT01607671|Ischemic
1091988|NCT01607671|Optic Neuropathy
1091989|NCT01607671|Non-Arteritic Anterior Ischemic Optic Neuropathy
1091990|NCT01607671|NAION
1091991|NCT01607671|Ischemic Optic Neuropathy
1091992|NCT01607671|Intraocular Pressure
1091993|NCT01607658|Testosterone
1091994|NCT01607632|posttraumatic stress
1091995|NCT01607632|depression
1091996|NCT01607619|CRP
1091997|NCT01607593|Retrospective
1091998|NCT01607593|Sertraline
1092125|NCT01607047|diagnosis
1091999|NCT01607593|Posttraumatic stress disorder
1092000|NCT01607554|Lung
1092001|NCT01607554|non small cell
1092002|NCT01607554|NSCLC
1092003|NCT01607554|Irinotecan
1092004|NCT01607541|HIV/AIDS
1092005|NCT01607541|vulnerable populations
1092006|NCT01607541|heterosexuals at high risk
1092007|NCT01607541|peer-driven intervention
1092008|NCT01607541|tailored intervention
1092009|NCT01607541|African-American
1092010|NCT01607541|Latino/Hispanic
1092011|NCT01607541|Seek, test, treat, and retain (STTR)
1092012|NCT01607515|Pulmonary hypertension
1092013|NCT01607515|Cardiac index
1092014|NCT01607515|impedance cardiography
1092015|NCT01607502|Pulmonary hypertension
1092016|NCT01607502|database
1092017|NCT01607502|biomarker
1092018|NCT01607489|Early diagnosis of pulmonary arterial hypertension
1092019|NCT01607489|dynamic dual-energy computed tomography
1092020|NCT01607463|pain
1092021|NCT01607463|transcutaneous electrical nerve stimulation
1092022|NCT01607450|Type 2 diabetes mellitus
1092023|NCT01607450|lean healthy control
1092024|NCT01607424|cognitive rehabilitation
1092025|NCT01607424|schizophrenia
1092026|NCT01607398|Japan
1092027|NCT01607398|COPD
1092028|NCT01607398|CAT
1092029|NCT01607398|placebo
1092030|NCT01607398|serum
1092031|NCT01607398|Adoair250
1092032|NCT01607398|anti-inflammatory
1092033|NCT01607398|sputum
1092034|NCT01607385|pharmacokinetic
1092035|NCT01607385|intestinal bile acid transporter inhibitor
1092036|NCT01607385|GSK2330672
1092037|NCT01607385|pharmacodynamic
1092038|NCT01607385|GSK1614235
1092039|NCT01607385|dose escalation
1092040|NCT01607372|TLR7 agonist, Respiratory Allergies, Allergic Rhinitis, Mild Allergic Asthma, Repeat Dose Safety, Reduction of Allergic Reactivity
1092041|NCT01607359|atrial fibrillation
1092042|NCT01607359|catheter ablation
1092043|NCT01607359|dabigatran
1092044|NCT01607359|warfarin
1092045|NCT01607359|oral anticoagulation
1092046|NCT01607346|Urinary Retention
1092047|NCT01607333|Antiepileptics
1092048|NCT01607333|suicidality
1092049|NCT01607320|PCOS
1092050|NCT01607320|Infertility
1092051|NCT01607320|Anovulation
1092052|NCT01607307|daikenchuto
1092053|NCT01607307|postoperative ileus
1092054|NCT01607307|pancreaticoduodenectomy
1092055|NCT01607281|anatomical landmark
1092056|NCT01607281|internal jugular vein canulation
1092057|NCT01607268|autonomic failure
1092058|NCT01607268|mangenetic resonance
1092059|NCT01607268|neurochemistry
1092060|NCT01607268|neurotransmitter
1092061|NCT01607268|glutamate
1092062|NCT01607255|adenoma detection
1092063|NCT01607255|screening colonoscopy
1092064|NCT01607255|water exchange method
1092065|NCT01607255|chromoendoscopy
1092066|NCT01607242|total thyroidectomy
1092067|NCT01607242|voice handicap index
1092068|NCT01607242|swallowing disorders
1092069|NCT01607242|thyroid surgery
1092070|NCT01607242|voice disorders
1092071|NCT01607229|multi-frequency
1092072|NCT01607229|bioelectrical impedance
1092073|NCT01607229|body composition
1092074|NCT01607229|hydration
1092075|NCT01607216|Prematurity
1092076|NCT01607216|Respiratory Illness
1092077|NCT01607216|Lung Function
1092078|NCT01607216|Lung Disease
1092079|NCT01607203|ovarian hyper stimulation syndrome (OHSS)
1092080|NCT01607203|metaphase II oocytes (MII)
1092081|NCT01607203|good quality embryo's
1092082|NCT01607203|implantation
1092083|NCT01607203|pregnancy
1092084|NCT01607190|type 2 diabetes mellitus
1092085|NCT01607190|nonproliferative diabetic retinopathy
1092086|NCT01607164|Mood management
1092087|NCT01607164|self-help
1092088|NCT01607164|depression
1092089|NCT01607164|prevention
1092090|NCT01607164|cognitive behavioral
1092091|NCT01607151|hypothermia
1092092|NCT01607151|normothermia
1092093|NCT01607151|hyperthermia
1092094|NCT01607138|laryngectomy
1092095|NCT01607138|swallowing disturbances
1092096|NCT01607138|speech disturbances
1092097|NCT01607138|speech intelligibility
1092098|NCT01607138|voice prothesis
1092099|NCT01607112|Influenza
1092100|NCT01607112|Healthy
1092101|NCT01607112|Immunogenicity
1092102|NCT01607112|Elderly
1092103|NCT01607112|Safety
1092104|NCT01607112|Adults
1092105|NCT01607099|colonoscopy
1092106|NCT01607099|bowel cleansing
1092107|NCT01607099|bowel cleanness
1092108|NCT01607099|efficiency
1092109|NCT01607099|compatibility
1092110|NCT01607086|Lamotrigine
1092111|NCT01607086|placebo
1092112|NCT01607086|properties
1092113|NCT01607086|characteristics
1092114|NCT01607073|Dravet
1092115|NCT01607073|seizures
1092116|NCT01607073|verapamil
1092117|NCT01607060|Critically ill patients
1092118|NCT01607060|intestinal failure
1092119|NCT01607047|leptospirosis
1092120|NCT01607047|qPCR
1092121|NCT01607047|cohort
1092122|NCT01607047|french west indies
1092123|NCT01607047|blood sample collection
1092124|NCT01607047|pronostic
1092126|NCT01607021|Chronic hepatitis C
1092127|NCT01607021|interleukin 28
1092128|NCT01607021|Children
1092129|NCT01606995|Stroke
1092130|NCT01606995|Embolism
1092131|NCT01606995|Atrial fibrillation
1092132|NCT01606982|prostate
1092133|NCT01606982|MDV3100
1092134|NCT01606982|cancer
1092135|NCT01606969|Dexmedetomidine
1092136|NCT01606969|epinephrine
1092137|NCT01606969|lidocaine
1092138|NCT01606969|scalp infiltration
1092139|NCT01606969|craniotomy
1092140|NCT01606943|Aortic dissection
1092141|NCT01606943|Risk factor
1092142|NCT01606943|Feature
1092143|NCT01606943|Management
1092144|NCT01606943|Outcome
1092145|NCT01606930|Patient Satisfaction
1092146|NCT01606930|Patient Doctor Communication
1092147|NCT01606930|Shared Decision Making
1092148|NCT01606930|Patient Activation
1092149|NCT01606891|preschooler obesity prevention
1092150|NCT01606891|community home visiting parents
1092151|NCT01606891|preschooler excess BMI gain
1092152|NCT01606891|multi-setting/component intervention
1092153|NCT01606852|sedation
1092154|NCT01606852|mechanical ventilation
1092155|NCT01606852|anxiety
1092156|NCT01606852|respiratory failure
1092157|NCT01606826|Severe
1092158|NCT01606787|Kidney
1092159|NCT01606787|MANNITOL
1092160|NCT01606787|PLACEBO
1092161|NCT01606787|Partial Nephrectomy
1092162|NCT01606787|12-079
1092163|NCT01606761|Arthritis, Rheumatoid
1092164|NCT01606761|Active rheumatoid arthritis despite anti-TNF-alpha therapy
1092165|NCT01606761|Sirukumab
1092166|NCT01606761|Human Anti-IL-6 monoclonal antibody
1092167|NCT01606748|Advanced Malignant Solid Tumors
1092168|NCT01606748|Solid Cancers
1092169|NCT01606748|Non-small Cell Lung Cancer
1092170|NCT01606748|NSCLC
1092171|NCT01606748|Breast Cancer
1092172|NCT01606735|cataract surgery
1092173|NCT01606735|ocular inflammation
1092174|NCT01606722|Antiretroviral therapy
1092175|NCT01606722|Boosted-Darunavir monotherapy
1092176|NCT01606722|Resistance
1092177|NCT01606722|Proviral DNA-HIV
1092178|NCT01606709|GnRHa trigger
1092179|NCT01606709|endometrial gene profile
1092180|NCT01606709|quality of life
1092181|NCT01606696|CAD
1092182|NCT01606696|cardiac rehabilitation
1092183|NCT01606696|fitness
1092184|NCT01606683|Acidified milk
1092185|NCT01606683|Beta-palmitate
1092186|NCT01606683|Bifidobacteria
1092187|NCT01606683|Breastfeeding
1092188|NCT01606683|Infant formula
1092189|NCT01606683|Galacto-oligosaccharides
1092190|NCT01606683|Growth
1092191|NCT01606683|Infants
1092192|NCT01606683|Metabolomics
1092193|NCT01606683|Prebiotics
1092194|NCT01606670|Rotigotine
1092195|NCT01606670|Neupro®
1092196|NCT01606657|I&D
1092197|NCT01606657|Abscess
1092198|NCT01606657|Irrigation
1092199|NCT01606657|Cutaneous Abscess
1092200|NCT01606644|radiation sequelae
1092201|NCT01606644|hyperbaric oxygen
1092202|NCT01606631|severe sepsis
1092203|NCT01606631|toxic shock
1092204|NCT01606618|Self-esteem
1092205|NCT01606618|Spina Bifida
1092206|NCT01606618|Spinal cord injury
1092207|NCT01606605|Lymphoma
1092208|NCT01606605|Prognosis
1092209|NCT01606605|Relapse
1092210|NCT01606605|Gene
1092211|NCT01606605|microRNA
1092212|NCT01606579|Leukemia
1092213|NCT01606579|acute myeloid leukemia
1092214|NCT01606579|AML
1092215|NCT01606579|chronic myeloid leukemia
1092216|NCT01606579|CML
1092217|NCT01606579|MDS
1092218|NCT01606579|myelodysplastic syndrome
1092219|NCT01606579|myeloproliferative neoplasia
1092220|NCT01606579|MPN
1092221|NCT01606566|Recurrent
1092222|NCT01606566|Head and Neck
1092223|NCT01606566|Neoplasms
1092224|NCT01606566|Squamous Cell Carcinoma
1092225|NCT01606566|Amphinex
1092226|NCT01606566|Cancer
1092227|NCT01606566|Photodynamic therapy
1092228|NCT01606566|Chemotherapy
1092229|NCT01606566|Bleomycin
1092230|NCT01606553|chronic heart failure
1092231|NCT01606553|respiratory muscle weakness
1092232|NCT01606553|inspiratory muscle training
1092233|NCT01606540|Colles fracture
1092234|NCT01606540|Non-steroid antiinflammatory drugs
1092235|NCT01606540|Bone healing
1092236|NCT01606527|Spectrum of Altitude-associated acute mountain sickness
1092237|NCT01606527|hypoxia
1092238|NCT01606527|high altitude headache
1092239|NCT01606527|high altitude cerebral edemat is.....
1092240|NCT01606488|Postoperative Cognitive Dysfunction
1092241|NCT01606488|Postoperative Cognitive Decline
1092242|NCT01606488|POCD
1092243|NCT01606488|Alzheimer's disease
1092244|NCT01606488|Florbetapir F 18 (18F-AV-45)
1092245|NCT01606475|Islet transplant
1092246|NCT01606475|Diabetes Mellitus
1092247|NCT01606475|Hypoglycemia
1092248|NCT01606462|oxytocin
1092249|NCT01606462|social cognition
1092250|NCT01606462|fMRI
1092251|NCT01606462|oxytocin receptor gene
1092252|NCT01606449|Gastroesophageal reflux diseases
1092253|NCT01606449|Hiatal Hernia
1092254|NCT01606449|Paraesophageal Hernia
1092255|NCT01606358|Ovarian Cancer
1092256|NCT01606358|Patient with ovarian cancer
1092387|NCT01605682|adults
1092257|NCT01606345|Upper Tract Urothelial Carcinoma
1092258|NCT01606345|UTUC
1092259|NCT01606345|Kidney
1092260|NCT01606345|Cancer
1092261|NCT01606345|Renal
1092262|NCT01606319|Asthma
1092263|NCT01606319|Wheezing
1092264|NCT01606319|Ibuprofen
1092265|NCT01606319|Acetaminophen
1092266|NCT01606319|exacerbations
1092267|NCT01606319|pain
1092268|NCT01606319|fever
1092269|NCT01606306|Asthma
1092270|NCT01606306|Wheezing
1092271|NCT01606306|Fluticasone
1092272|NCT01606306|Montelukast
1092273|NCT01606306|Preschool-age
1092274|NCT01606293|Small cell carcinomas of the cervix
1092275|NCT01606293|Large cell carcinomas of the cervix
1092276|NCT01606293|Online surveys
1092277|NCT01606293|Electronic surveys
1092278|NCT01606293|Questionnaires
1092279|NCT01606293|Facebook
1092280|NCT01606293|Social networking support groups
1092281|NCT01606280|Amyloidosis
1092282|NCT01606267|Integrated Community Case Management
1092283|NCT01606267|Pneumonia
1092284|NCT01606267|Ethiopia
1092285|NCT01606254|Schizophrenia
1092286|NCT01606254|Paliperidone Palmitate
1092287|NCT01606254|JNS010
1092288|NCT01606228|Schizophrenia
1092289|NCT01606228|Paliperidone ER
1092290|NCT01606228|Treatment naive patients
1092291|NCT01606228|Newly diagnosed patients
1092292|NCT01606215|multiple sclerosis
1092293|NCT01606215|mesenchymal stem cells
1092294|NCT01606215|bone marrow
1092295|NCT01606215|rapidly evolving
1092296|NCT01606150|neonate
1092297|NCT01606150|late preterm
1092298|NCT01606150|lumbar puncture
1092299|NCT01606150|analgesia
1092300|NCT01606150|pain
1092301|NCT01606150|lidocaine
1092302|NCT01606098|Surgery
1092303|NCT01606098|Chemotherapy
1092304|NCT01606085|Diabetes
1092305|NCT01606085|Heart Failure
1092306|NCT01606085|Quality of Life
1092307|NCT01606085|Self Care
1092308|NCT01606072|DDAVP
1092309|NCT01606033|stress
1092310|NCT01606033|Life quality
1092311|NCT01606033|adjustment strategy
1092312|NCT01606033|receiving an antitumor treatment
1092313|NCT01606033|within a clinical trial (case)
1092314|NCT01606033|according to a standard treatment (control)
1092315|NCT01606020|effects of sleep deprivation
1092316|NCT01606020|Transcranial Magnetic Stimulation
1092317|NCT01606020|male, healthy volunteers
1092318|NCT01605981|Nilotinib
1092319|NCT01605981|CML patients
1092320|NCT01605981|accelerated phase
1092321|NCT01605968|Obstetrics
1092322|NCT01605968|Gynecology
1092323|NCT01605968|Wound healing
1092324|NCT01605955|SPO2
1092325|NCT01605929|Anesthetics, local/administration & dosage
1092326|NCT01605929|Brachial Plexus/ultrasonography
1092327|NCT01605929|Humans
1092328|NCT01605929|Nerve Block/methods
1092329|NCT01605929|Upper Extremity/surgery
1092330|NCT01605929|Catheters, Indwelling
1092331|NCT01605929|Anesthesia, Conduction/methods
1092332|NCT01605929|Analgesia/methods
1092333|NCT01605929|Nerve Block/adverse effects
1092334|NCT01605916|Cancer,
1092335|NCT01605916|Tumour,
1092336|NCT01605916|Metastatic,
1092337|NCT01605916|Lung cancer,
1092338|NCT01605916|Non-Small Cell Lung Cancer
1092339|NCT01605903|Tonsillectomy
1092340|NCT01605903|adenoidectomy
1092341|NCT01605903|bleeding
1092342|NCT01605903|bleeding rates
1092343|NCT01605903|Tonsillectomy with and without adenoidectomy
1092344|NCT01605890|HIV-2
1092345|NCT01605877|Cataracts
1092346|NCT01605877|Intraocular lens
1092347|NCT01605877|Multifocal
1092348|NCT01605877|Presbyopia
1092349|NCT01605864|pneumonia
1092350|NCT01605864|community acquired bacterial pneumonia
1092351|NCT01605864|CAP
1092352|NCT01605864|CABP
1092353|NCT01605864|bacterial pneumonia
1092354|NCT01605851|PFO
1092355|NCT01605851|closure
1092356|NCT01605838|TBI
1092357|NCT01605812|IOL;
1092358|NCT01605812|capsule；
1092359|NCT01605812|PCO;
1092360|NCT01605812|OCT
1092361|NCT01605799|PTSD
1092362|NCT01605799|Mental Health
1092363|NCT01605799|War
1092364|NCT01605799|Veterans
1092365|NCT01605786|Malaria
1092366|NCT01605786|Plasmodium falciparum
1092367|NCT01605786|vaccine
1092368|NCT01605786|ADCI
1092369|NCT01605786|sporozoite challenge
1092370|NCT01605786|pre-erythrocytic
1092371|NCT01605786|erythrocytic
1092372|NCT01605760|immunotherapy
1092373|NCT01605760|elderly
1092374|NCT01605734|hepatocellular carcinoma
1092375|NCT01605734|transarterial chemoembolization
1092376|NCT01605734|sorafenib
1092377|NCT01605721|Everolimus
1092378|NCT01605721|XIENCE PRIME
1092379|NCT01605721|Drug eluting stent
1092380|NCT01605708|Itching
1092381|NCT01605695|reference range
1092382|NCT01605695|plasma
1092383|NCT01605695|inducible nitric oxide synthase
1092384|NCT01605695|iNOS
1092385|NCT01605695|healthy adults
1092386|NCT01605682|effect of different berry doses on mood and cognition
1092388|NCT01605669|Auscultation
1092389|NCT01605669|Aortic stenosis
1092390|NCT01605669|computer assisted auscultation
1092391|NCT01605669|Aortic Stenosis Acceleration Index
1092392|NCT01605656|Cancer Prevention
1092393|NCT01605656|Cervix
1092394|NCT01605656|Questionnaires
1092395|NCT01605656|Focus groups
1092396|NCT01605656|Surveys
1092397|NCT01605656|Interviews
1092398|NCT01605643|cancer
1092399|NCT01605643|tobacco use
1092400|NCT01605643|pregnancy
1092401|NCT01605604|mindfulness EQ adolescents
1092402|NCT01605591|left-side double lumen bronchial tube
1092403|NCT01605591|bending type
1092404|NCT01605591|GlideScope videolaryngoscope
1092405|NCT01605552|Depression
1092406|NCT01605552|Depressive Symptoms
1092407|NCT01605552|Cardiovascular Disease (CVD)
1092408|NCT01605552|Coronary Artery Disease (CAD)
1092409|NCT01605552|Heart Disease
1092410|NCT01605513|recombinant interferon, tolerated, effective
1092411|NCT01605500|ICD
1092412|NCT01605474|foley catheter
1092413|NCT01605474|foley bulb
1092414|NCT01605474|induction of labor
1092415|NCT01605474|labor
1092416|NCT01605448|Mild Cognitive Impairment
1092417|NCT01605448|Alzheimer's disease
1092418|NCT01605448|Meditation
1092419|NCT01605448|Default Mode Network
1092420|NCT01605422|Systematic review and meta-analysis
1092421|NCT01605422|Evidence-based medicine (EBM)
1092422|NCT01605422|Evidence-based nutrition (EBN)
1092423|NCT01605422|Clinical practice guidelines
1092424|NCT01605422|Clinical trials
1092425|NCT01605422|Dietary pulses
1092426|NCT01605422|legumes
1092427|NCT01605422|Beans, peas, chickpeas, lentils
1092428|NCT01605422|glycemic index
1092429|NCT01605422|postprandial glycemia
1092430|NCT01605422|insulin resistance
1092431|NCT01605422|body weight
1092432|NCT01605422|appetite
1092433|NCT01605422|food intake regulation
1092434|NCT01605422|satiety
1092435|NCT01605422|satiation
1092436|NCT01605409|Refractory cardiac arrest
1092437|NCT01605409|Emergency cardiopulmonary bypass
1092438|NCT01605409|Extracorporeal life support in cardiac arrest
1092439|NCT01605383|Avascular Necrosis of Femur Head
1092440|NCT01605383|Osteonecrosis of the hip
1092441|NCT01605383|Osteonecrosis of the femoral head
1092442|NCT01605383|Mesenchymal Stem Cells
1092443|NCT01605383|Bone marrow
1092444|NCT01605383|Tissue engineering
1092445|NCT01605383|Bone Diseases
1092446|NCT01605383|Musculoskeletal Diseases
1092447|NCT01605370|Hypertension, Left Ventricular Mass
1092448|NCT01605357|Brain Injuries
1092449|NCT01605357|Hematoma, subdural
1092450|NCT01605357|Decompressive Craniectomy
1092451|NCT01605357|Saline solution, hypertonic
1092452|NCT01605357|Hypernatremia
1092453|NCT01605357|Intracranial hemorrhages
1092454|NCT01605357|Head Injuries, closed
1092455|NCT01605357|Intracranial pressure
1092456|NCT01605357|Brain edema
1092457|NCT01605357|Critical care
1092458|NCT01605357|Brain Diseases
1092459|NCT01605357|Central Nervous System Diseases
1092460|NCT01605357|Nervous System Diseases
1092461|NCT01605357|Wounds and Injuries
1092462|NCT01605357|Physiological Effects of Drugs
1092463|NCT01605357|Pharmacologic Actions
1092464|NCT01605344|Advanced colon cancer
1092465|NCT01605344|Advanced rectal cancer
1092466|NCT01605344|Metastatic colon cancer
1092467|NCT01605344|Metastatic rectal cancer
1092468|NCT01605344|Lipitor
1092469|NCT01605344|Atorvastatin
1092470|NCT01605344|FOLFIRI
1092471|NCT01605331|Adults
1092472|NCT01605331|GH deficiency
1092473|NCT01605318|metastatic colorectal cancer
1092474|NCT01605318|colon cancer
1092475|NCT01605318|rectal cancer
1092476|NCT01605318|previously treated
1092477|NCT01605292|Transradial catheterization
1092478|NCT01605292|Ultrasound
1092479|NCT01605292|Radial artery
1092480|NCT01605279|Low superior vena cava flow
1092481|NCT01605279|Functional echocardiography
1092482|NCT01605266|pediatric
1092483|NCT01605266|kidney disease
1092484|NCT01605266|minimal change disease
1092485|NCT01605266|focal segmental glomerulosclerosis
1092486|NCT01605266|nephrotic syndrome
1092487|NCT01605253|Post-traumatic stress disorder
1092488|NCT01605253|sleep disturbance
1092489|NCT01605253|insomnia
1092490|NCT01605253|cytokines
1092491|NCT01605253|anxiety
1092492|NCT01605253|traumatic event
1092493|NCT01605253|memory
1092494|NCT01605240|Fracture pain
1092495|NCT01605240|Fracture reduction
1092496|NCT01605240|Analgesia
1092497|NCT01605240|Acetaminophen
1092498|NCT01605240|Ibuprofen
1092499|NCT01605240|Codeine
1092500|NCT01605240|Pediatric
1092501|NCT01605240|Fracture Pain Analgesia in Pediatric population
1092502|NCT01605227|prostate cancer
1092503|NCT01605227|castration resistant prostate cancer
1092504|NCT01605227|bone pain
1092505|NCT01605227|CRPC
1092506|NCT01605214|Extravascular Lung Water
1092507|NCT01605214|Transpulmonary Thermodilution
1092508|NCT01605214|Primary Graft Dysfunction
1092509|NCT01605214|Ischemia Reperfusion Injury
1092510|NCT01605201|Chondral lesions in the knee after traumatic injury
1092511|NCT01605175|Inflammatory Bowel Disease
1092512|NCT01605175|Predictors Mucosal Healing
1092513|NCT01605149|Diabetes
1092514|NCT01605136|Erythropoietic Protoporphyria
1092515|NCT01605136|EPP
1092516|NCT01605136|Afamelanotide
1092517|NCT01605123|endothelial function
1092518|NCT01605123|children
1092519|NCT01605123|obesity
1092520|NCT01605123|cardiovascular dysfunction
1092521|NCT01605123|carotid intima media thickness
1092522|NCT01605123|blood pressure
1092523|NCT01605123|oral glucose tolerance test
1092524|NCT01605110|blepharoplasty
1092525|NCT01605110|hyperbaric
1092526|NCT01605110|oxygen
1092527|NCT01605110|ecchymosis
1092528|NCT01605110|edema
1092529|NCT01605110|wound
1092530|NCT01605110|healing
1092531|NCT01605097|prostate neoplasms
1092532|NCT01605097|interstitial radiation
1092533|NCT01605097|High dose rate prostate brachytherapy
1092534|NCT01605097|dose escalation
1092535|NCT01605071|menopause
1092536|NCT01605071|estrogen
1092537|NCT01605071|insulin sensitivity
1092538|NCT01605071|estrogen receptors
1092539|NCT01605045|Cardiac catheterization
1092540|NCT01605045|Radiation
1092541|NCT01605019|Ventricular Assist Devices
1092542|NCT01605019|Heart assist pumps
1092543|NCT01605019|heart pumps
1092544|NCT01605019|sealant agents
1092545|NCT01605006|amyotrophic lateral sclerosis
1092546|NCT01605006|ALS
1092547|NCT01605006|motor neuron disease
1092548|NCT01605006|diaphragm
1092549|NCT01605006|diaphragm pacing
1092550|NCT01605006|diaphragmatic pacing
1092551|NCT01605006|phrenic pacing
1092552|NCT01605006|phrenic nerve
1092553|NCT01605006|phrenic nerve stimulation
1092554|NCT01605006|NeuRx DPS
1092555|NCT01605006|DPS
1092556|NCT01605006|chronic hypoventilation
1092557|NCT01605006|respiration
1092558|NCT01605006|ventilation
1092559|NCT01605006|breathing
1092560|NCT01605006|Humanitarian Device Exemption
1092561|NCT01605006|HDE
1092562|NCT01605006|post-approval study
1092563|NCT01604993|Dietary Nitrates
1092564|NCT01604993|Arterial Stiffness
1092565|NCT01604993|Vascular
1092566|NCT01604993|Blood pressure
1092567|NCT01604954|Food labeling
1092568|NCT01604928|Overactive Bladder
1092569|NCT01604928|YM178
1092570|NCT01604928|Mirabegron
1092571|NCT01604928|Frequency
1092572|NCT01604928|Urinary urge incontinence
1092573|NCT01604928|Urgency
1092574|NCT01604928|Urinary incontinence
1092575|NCT01604928|Micturition
1092576|NCT01604902|Psoriasis mRNA and miRNA
1092577|NCT01604889|Melanoma, Skin Cancer, Oncology
1092578|NCT01604876|Parkinson's disease
1092579|NCT01604876|depression
1092580|NCT01604876|light therapy
1092581|NCT01604876|sleeping problems
1092582|NCT01604863|Solid Tumors
1092583|NCT01604863|Cancer
1092584|NCT01604863|Lung Cancer
1092585|NCT01604863|Prostate Cancer
1092586|NCT01604863|Mesothelioma
1092587|NCT01604863|Small Cell lung Cancer
1092588|NCT01604850|HCV genotype 2 (GT-2)
1092589|NCT01604850|HCV genotype 3 (GT-3)
1092590|NCT01604850|HCV
1092591|NCT01604850|Sustained Virologic Response
1092592|NCT01604850|Direct Acting Antiviral
1092593|NCT01604850|Combination Therapy
1092594|NCT01604850|Treatment Experienced
1092595|NCT01604850|GS-7977
1092596|NCT01604850|Ribavirin
1092597|NCT01604837|superior hypogastric plexus block
1092598|NCT01604837|pelvic malignancy
1092599|NCT01604837|chronic pelvic pain
1092600|NCT01604798|proteomics
1092601|NCT01604798|serum peptides
1092602|NCT01604798|colorectal cancer
1092603|NCT01604798|MALDI-TOF MS
1092604|NCT01604785|Migraine Headache
1092605|NCT01604785|Pediatric
1092606|NCT01604759|Mouth Neoplasms
1092607|NCT01604759|Mouth Diseases
1092608|NCT01604733|Multi-Center Survey
1092609|NCT01604733|patients currently on lipid-lowering pharmacological treatment
1092610|NCT01604733|level of Control of Hypercholesterolemia in Egypt
1092611|NCT01604720|sample size
1092612|NCT01604720|liver disease
1092613|NCT01604707|stress
1092614|NCT01604707|anxiety
1092615|NCT01604707|depression
1092616|NCT01604707|quality of life
1092617|NCT01604694|Abdominoplasty
1092618|NCT01604694|Transversus Abdominis Plane (TAP) Block
1092619|NCT01604694|levobupivacaine
1092620|NCT01604694|Placebo
1092621|NCT01604681|Linseed Oil
1092622|NCT01604681|Oxidative Stress
1092623|NCT01604681|Polymorphism, Genetic
1092624|NCT01604681|Cardiovascular Diseases
1092625|NCT01604655|Chest pain
1092626|NCT01604655|shortness of breath
1092627|NCT01604655|suspected acute coronary syndrome
1092628|NCT01604655|stress testing
1092629|NCT01604655|coronary computed tomography angiography
1092630|NCT01604629|Spondylarthropathies
1092631|NCT01604629|Persistent clinical remission with anti-TNF therapy
1092632|NCT01604629|Standardized protocol for dose reduction anti-TNF therapy
1092633|NCT01604590|Glioblastoma
1092634|NCT01604590|Imaging Biomarkers
1092635|NCT01604590|Bevacizumab
1092636|NCT01604590|MRI
1092637|NCT01604577|health literacy
1092638|NCT01604577|health numeracy
1092639|NCT01604564|Registry
1092640|NCT01604564|Colitis Ulcerosa (CU)
1092641|NCT01604564|Familial Adenomatous Polyposis(FAP)
1092642|NCT01604564|IPAA
1092643|NCT01604512|Brain tumor
1092644|NCT01604512|MRI Perfusion
1092645|NCT01604512|FDG PET/CT
1092646|NCT01604512|12-067
1092647|NCT01604499|Healthy eating
1092648|NCT01604499|Incentives
1092649|NCT01604499|Feedback
1092650|NCT01604486|Myocardial infarction
1092651|NCT01604486|Ischaemic preconditioning
1092652|NCT01604486|Myocardial Ischaemia National Audit Project
1092653|NCT01604486|General Practice Research Database
1092654|NCT01604486|Hospital Episode Statistics
1092655|NCT01604486|Office for National Statistics
1092656|NCT01604473|Chronic Kidney Disease
1092657|NCT01604473|CKD
1092658|NCT01604473|ESRD
1092659|NCT01604473|AV Fistula
1092660|NCT01604473|Arterio-venous fistula
1092661|NCT01604473|hemodialysis
1092662|NCT01604460|Hypothermia
1092663|NCT01604460|Newborn
1092664|NCT01604460|Plastic bag
1092665|NCT01604460|Resuscitation
1092666|NCT01604447|Hypothermia
1092667|NCT01604447|Newborn
1092668|NCT01604447|Incubator
1092669|NCT01604447|Plastic bag
1092670|NCT01604447|Normothermia
1092671|NCT01604434|Hypothermia
1092672|NCT01604434|Low birth Weight
1092673|NCT01604434|Newborn
1092674|NCT01604434|Incubator
1092675|NCT01604434|Plastic bag
1092676|NCT01604421|Hypothermia
1092677|NCT01604421|Low birth weight
1092678|NCT01604421|Newborn
1092679|NCT01604421|Plastic bag
1092680|NCT01604421|Thermoregulation
1092681|NCT01604395|GHD
1092682|NCT01604395|TS
1092683|NCT01604395|CRF
1092684|NCT01604395|SGA
1092685|NCT01604395|ISS
1092686|NCT01604382|Total Knee Arthroplasty (TKA)
1092687|NCT01604369|Atrial flutter
1092688|NCT01604369|Cryoablation
1092689|NCT01604369|Cavotricuspid isthmus
1092690|NCT01604369|Visual analogue scale
1092691|NCT01604356|retinitis pigmentosa
1092692|NCT01604343|Active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy
1092693|NCT01604343|Sirukumab
1092694|NCT01604343|Human Anti-IL-6 monoclonal antibody
1092695|NCT01604330|High dose baclofen
1092696|NCT01604330|Alcoholism
1092697|NCT01604330|Abstinence
1092698|NCT01604330|Low risk consumption
1092699|NCT01604330|Craving
1092700|NCT01604317|Hypothermia
1092701|NCT01604317|Low birth Weight
1092702|NCT01604317|Newborn
1092703|NCT01604317|Resuscitation
1092704|NCT01604317|Plastic bag
1092705|NCT01604304|stone
1092706|NCT01604304|calculi
1092707|NCT01604304|kidney
1092708|NCT01604304|renal treatment
1092709|NCT01604304|flexible ureteroscopy
1092710|NCT01604304|extracoporeal shockwave lithotripsy
1092711|NCT01604304|retrograde intra renal surgery
1092712|NCT01604278|Indacaterol
1092713|NCT01604278|Glycopyrronium Bromide
1092714|NCT01604278|COPD
1092715|NCT01604278|bronchodilation
1092716|NCT01604239|Osteoarthritis
1092717|NCT01604239|Shinbaro
1092718|NCT01604239|Herbal drug
1092719|NCT01604226|total intravenous anesthesia
1092720|NCT01604226|Bispectral index monitoring
1092721|NCT01604226|propofol
1092722|NCT01604226|remifentanil
1092723|NCT01604213|Type 2 diabetes mellitus
1092724|NCT01604213|vildagliptin
1092725|NCT01604213|metformin
1092726|NCT01604213|atherosclerosis
1092727|NCT01604213|inflammation
1092728|NCT01604213|interleukin-6
1092729|NCT01604213|TNF
1092730|NCT01604213|atherothrombosis
1092731|NCT01604213|adiponectin
1092732|NCT01604213|MMP-9
1092733|NCT01604213|hs-CRP
1092734|NCT01604200|hypertension
1092735|NCT01604200|dentistry
1092736|NCT01604200|blood pressure
1092737|NCT01604200|measurement
1092738|NCT01604200|screening
1092739|NCT01604200|qualitative research
1092740|NCT01604187|sublingual fentanyl
1092741|NCT01604187|pain in coloscopy
1092742|NCT01604187|The efficacy and safety of fentanyl transmucosal tablet to placebo in patients having colonoscopy.
1092743|NCT01604174|knee
1092744|NCT01604174|osteoarthritis
1092745|NCT01604174|arthroplasty
1092746|NCT01604174|rehabilitation
1092747|NCT01604148|Holmium Laser Enucleation of Prostate
1092748|NCT01604135|Collagen crosslinking
1092749|NCT01604135|Keratoconus
1092750|NCT01604122|Survey
1092751|NCT01604122|burden of illness
1092752|NCT01604122|caregivers
1092753|NCT01604122|TTR-FAP
1092754|NCT01604122|TTR-CM
1092755|NCT01604122|familial amyloid polyneuropathy
1092756|NCT01604122|observational
1092757|NCT01604122|transthyretin familial amyloidosis
1092758|NCT01604109|Caries detection/diagnosis/prevention
1092759|NCT01604109|Preventive Dentistry
1092760|NCT01604109|Casien Phosphopeptide
1092761|NCT01604109|Remineralization
1092762|NCT01604109|Clinical trial
1092763|NCT01604096|Information
1092764|NCT01604096|campaign
1092765|NCT01604096|antibiotics
1092766|NCT01604096|bacterial resistance
1092767|NCT01604096|primary care
1092768|NCT01604083|transfusion
1092769|NCT01604083|packed red blood cells (PRBC)
1092770|NCT01604083|Transfusion Practice
1092771|NCT01604083|Transfusion habits
1092772|NCT01604083|Outcome
1092773|NCT01604083|elective surgery
1092774|NCT01604083|ETPOS
1092775|NCT01604083|ESA
1092776|NCT01604083|European Society of Anaesthesiology
1092777|NCT01604070|Hammertoe deformity
1092778|NCT01604070|podiatry
1092779|NCT01604031|B-CLL
1092780|NCT01604031|vaccine
1092781|NCT01604031|Lenalidomide
1092782|NCT01604031|CTL
1092783|NCT01604018|Cat Allergy
1092784|NCT01604018|Rhinoconjunctivitis
1092785|NCT01604005|Mesothelioma
1092786|NCT01604005|radiotherapy
1092787|NCT01604005|prophylactic irradiation of tracts
1092788|NCT01603992|Cannabis
1092789|NCT01603992|Craving
1092790|NCT01603992|Questionnaire
1092791|NCT01603992|Non-Treatment
1092792|NCT01603992|Drug Use
1092793|NCT01603979|AV203
1092794|NCT01603979|Solid Tumors
1092795|NCT01603979|ERBB3
1092796|NCT01603979|Monoclonal Antibody
1092797|NCT01603979|HER3
1092798|NCT01603966|platelet
1092799|NCT01603966|aggregation
1092800|NCT01603966|aspirin
1092801|NCT01603966|inhibition
1092802|NCT01603966|reactivity
1092803|NCT01603940|Hypertension
1092804|NCT01603940|Diabetes Mellitus
1092805|NCT01603940|Vascular stiffness
1092806|NCT01603940|Endothelial function
1092807|NCT01603914|burns, catheter related bacteremia,
1092808|NCT01603914|infection, central venous catheter,
1092809|NCT01603914|catheter-related bloodstream, adult critically ill patients
1092810|NCT01603888|children with heart disease
1092811|NCT01603888|infants
1092812|NCT01603888|healthy newborns
1092813|NCT01603875|CPRV
1092814|NCT01603875|SPEEDA
1092815|NCT01603875|intradermal
1092816|NCT01603875|pre-exposure
1092817|NCT01603875|booster
1092818|NCT01603849|Prophylactic Cranial Irradiation
1092819|NCT01603849|Lung Cancer
1092820|NCT01603849|Non Small Cell Lung Cancer
1092821|NCT01603849|Carcinoembryonic Antigen
1092822|NCT01603836|Lumbar spine
1092823|NCT01603836|Posterolateral fusion
1092824|NCT01603836|Allograft
1092825|NCT01603836|Bone marrow concentrate
1092826|NCT01603836|Mesenchymal stem cells
1092827|NCT01603836|Fusion rate
1092828|NCT01603823|vitrectomy
1092829|NCT01603823|cataract
1092830|NCT01603823|macular edema
1092831|NCT01603810|Basal cell carcinoma
1092832|NCT01603810|Optical Coherence Tomography
1092833|NCT01603797|internetdelivered CBT
1092834|NCT01603797|chronic pain
1092835|NCT01603797|acceptance and commitment therapy
1092836|NCT01603797|mindfulness
1092837|NCT01603797|guided self help
1092838|NCT01603784|exercise
1092839|NCT01603784|cognition
1092840|NCT01603784|memory
1092841|NCT01603784|adult
1092842|NCT01603771|Adult
1092843|NCT01603771|Exercise
1092844|NCT01603771|Cognition
1092845|NCT01603771|MRI
1092846|NCT01603758|Cholesterol
1092847|NCT01603758|Spectrometry, mass
1092848|NCT01603758|Deuterium
1092849|NCT01603758|Kinetics
1092850|NCT01603758|Cholesterol absorption
1092851|NCT01603758|Coronary Heart Disease
1092852|NCT01603745|PCOS
1092853|NCT01603732|Strep exposure and heart defects
1092854|NCT01603719|infant formula
1092855|NCT01603719|prebiotics
1092856|NCT01603719|beta-palmitate
1092857|NCT01603719|stool flora
1092858|NCT01603719|bifidogenic
1092859|NCT01603706|Heart failure
1092860|NCT01603706|Cardiac Resynchronization Therapy
1092861|NCT01603706|CRT
1092862|NCT01603706|Radial strain echocardiography
1092863|NCT01603706|Ischemic cardiomyopathy
1092864|NCT01603693|Guided bone regeneration
1092865|NCT01603693|Bio Oss
1092866|NCT01603693|BondBone
1092867|NCT01603693|computerized tomography
1092868|NCT01603693|histological examination
1092869|NCT01603680|Ultrasonography
1092870|NCT01603680|Block nerve
1092871|NCT01603680|Anaesthesia
1092872|NCT01603680|Carpal tunnel syndrome
1092873|NCT01603654|Colon preparation
1092874|NCT01603654|Colonoscopy
1092875|NCT01603654|Polyethylene glycol
1092876|NCT01603654|Sodium Picosulphate
1092877|NCT01603589|coronary artery disease
1092878|NCT01603589|coronary artery bypass grafting
1092879|NCT01603589|cardiopulmonary bypass
1092880|NCT01603589|minimal extracorporeal circulation
1092881|NCT01603563|Stepped Care
1092882|NCT01603563|Trauma-Focused Cognitive Behavioral Therapy
1092883|NCT01603563|Preschool children
1092884|NCT01603550|energy restriction
1092885|NCT01603550|sleep deprivation
1092886|NCT01603550|cognitive performance
1092887|NCT01603550|brain function
1092888|NCT01603537|Traumatic injuries
1092889|NCT01603537|Prehospital Trauma Life Support
1092890|NCT01603537|Traffic accidents
1092891|NCT01603524|Ottawa Model for Smoking Cessation
1092892|NCT01603524|Primary Care
1092893|NCT01603511|rewarming
1092894|NCT01603511|core cooling
1092895|NCT01603511|afterdrop
1092896|NCT01603511|pre-hospital treatment
1092897|NCT01603511|hypothermia
1092898|NCT01603498|pain measurement,
1092899|NCT01603498|edema,
1092900|NCT01603498|trismus
1092901|NCT01603485|Bioavailability
1092902|NCT01603485|Pharmacokinetics
1092903|NCT01603485|Lersivirine
1092904|NCT01603485|Modified-release
1092905|NCT01603472|pediatric
1092906|NCT01603472|parenteral nutrition
1092907|NCT01603472|bone disease
1092908|NCT01603472|long-term PN
1092909|NCT01603446|pediatric
1092910|NCT01603446|MELAS
1092911|NCT01603446|mechanism of action of L-arginine
1092912|NCT01603420|prostate
1092913|NCT01603420|cancer
1092914|NCT01603420|radiation
1092915|NCT01603420|proton
1092916|NCT01603420|chemotherapy
1092917|NCT01603420|high risk
1092918|NCT01603407|prednisone
1092919|NCT01603407|deflazacort
1092920|NCT01603407|muscular dystrophy
1092921|NCT01603407|neuromuscular disease
1092922|NCT01603407|multi-center
1092923|NCT01603368|Probiotics
1092924|NCT01603368|Lactobacillus reuteri
1092925|NCT01603368|Prematures
1092926|NCT01603368|Enteral feeding
1092927|NCT01603368|Motility
1092928|NCT01603368|Necrotizing enterocolitis
1092929|NCT01603368|Sepsis
1092930|NCT01603368|Weight
1092931|NCT01603355|JIA
1092932|NCT01603329|medication adherence
1092933|NCT01603329|diabetes
1092934|NCT01603329|hypertension
1092935|NCT01603329|cholesterol
1092936|NCT01603329|statins
1092937|NCT01603316|Food pantry
1092938|NCT01603316|Food voucher
1092939|NCT01603316|Grocery delivery
1092940|NCT01603316|12-099
1092941|NCT01603303|Breast Cancer
1092942|NCT01603303|Localized breast cancer
1092943|NCT01603303|Postmenopausal women
1092944|NCT01603303|Aromatase inhibitor
1092945|NCT01603303|AI
1092946|NCT01603303|Questionnaires
1092947|NCT01603303|Surveys
1092948|NCT01603303|Luvena
1092949|NCT01603303|Internet based website
1092950|NCT01603303|Phone counseling
1092951|NCT01603303|Water-based vaginal lubricant
1092952|NCT01603303|Hyalo-Gyn
1092953|NCT01603290|Acute leukemia,
1092954|NCT01603290|Chemotherapy,
1092955|NCT01603290|Cancer-Related Fatigue,
1092956|NCT01603290|Physical Fitness
1092957|NCT01603277|Asthma
1092958|NCT01603277|GM-CSF
1092959|NCT01603277|Moderate-to-Severe Asthma
1092960|NCT01603264|Bioequivalence
1092961|NCT01603264|Biosimilarity
1092962|NCT01603264|Similarity
1092963|NCT01603264|PK
1092964|NCT01603264|Phase I
1092965|NCT01603264|Trastuzumab
1092966|NCT01603264|Healthy Male Volunteers
1092967|NCT01603264|Single-dose
1092968|NCT01603264|HER-2
1092969|NCT01603264|Oncology
1092970|NCT01603251|transmission
1092971|NCT01603251|anopheles
1092972|NCT01603225|Autism
1092973|NCT01603225|tDCS
1092974|NCT01603212|Melanoma
1092975|NCT01603212|Metastatic melanoma
1092976|NCT01603212|Advanced melanoma
1092977|NCT01603212|Vemurafenib
1092978|NCT01603212|PLX4032
1092979|NCT01603212|RO5185426
1092980|NCT01603212|IL-2
1092981|NCT01603212|Interleukin-2
1092982|NCT01603212|Aldesleukin
1092983|NCT01603212|Proleukin
1092984|NCT01603212|Interferon Alfa-2b
1092985|NCT01603212|Intron A
1092986|NCT01603160|Sickle Cell Disease
1092987|NCT01603160|Emergency Department
1092988|NCT01603160|Quality Improvement
1092989|NCT01603147|methamphetamine
1092990|NCT01603147|monoclonal antibody
1092991|NCT01603121|lisofylline
1092992|NCT01603108|Liver Transplant Recipient
1092993|NCT01603108|Recurrent Fibrosis
1092994|NCT01603095|Achondroplasia
1092995|NCT01603095|dwarfism
1092996|NCT01603069|Parkinson's disease
1092997|NCT01603069|Safety
1092998|NCT01603069|Tolerability
1092999|NCT01603056|House dust mite induced allergic rhinitis.
1093000|NCT01603043|Geographic Atrophy
1093001|NCT01603043|Age-Related Macular Degeneration
1093002|NCT01603043|Intravitreal injection
1093003|NCT01603030|Moxifloxacin
1093004|NCT01603030|Prednisolone
1093005|NCT01603030|LASIK
1093006|NCT01603017|Magnetic Resonance Therapy
1093007|NCT01603017|Osteoarthrosis
1093008|NCT01603017|Osteoarthritis
1093009|NCT01603004|MRI
1093010|NCT01603004|CT
1093011|NCT01603004|12-058
1093012|NCT01602991|Obesity
1093013|NCT01602991|Endoscopy
1093014|NCT01602991|Nasopharyngoesophagogastroscopy
1093015|NCT01602991|Bariatric Surgery
1093016|NCT01602991|Gastric Bypass Surgery
1093017|NCT01602965|obesity
1093018|NCT01602965|counselling
1093019|NCT01602965|weight loss
1093020|NCT01602952|Radotinib
1093021|NCT01602952|CML-CP, AP
1093022|NCT01602939|Mast cell
1093023|NCT01602939|Mastocytosis
1093024|NCT01602939|Mast cell disease
1093025|NCT01602926|hallux valgus
1093026|NCT01602913|Pravastatin
1093027|NCT01602913|Adverse Events
1093028|NCT01602913|Type II Diabetes Mellitus
1093029|NCT01602913|Incidence
1093030|NCT01602913|Paroxetine
1093031|NCT01602887|BA/BE
1093032|NCT01602887|PK
1093033|NCT01602887|PD-0332991
1093034|NCT01602887|PF-05089326
1093035|NCT01602887|Breast Cancer
1093036|NCT01602874|children
1093037|NCT01602874|pediatry
1093038|NCT01602874|pneumonia
1093039|NCT01602874|intra-abdominal
1093040|NCT01602874|infection
1093041|NCT01602861|Fibrosis
1093042|NCT01602861|calcineurin inhibitor
1093043|NCT01602861|kidney transplant
1093044|NCT01602861|chronic rejection
1093045|NCT01602848|Medicaid
1093046|NCT01602848|frequent users
1093047|NCT01602848|heavy users
1093048|NCT01602848|high risk
1093049|NCT01602848|high cost
1093050|NCT01602848|intervention to improve care and reduce Medicaid expenditures
1093051|NCT01602835|Alport syndrome
1093052|NCT01602835|proteinuria
1093053|NCT01602835|glomerular disease
1093054|NCT01602835|hereditary nephropathy
1093055|NCT01602835|nephropathy
1093056|NCT01602822|HIV Prevention
1093057|NCT01602822|NPEP
1093058|NCT01602822|PEP
1093059|NCT01602809|Perfusion
1093060|NCT01602809|Microvessels
1093061|NCT01602809|Ultrasound
1093062|NCT01602809|Sickle Cell Disease
1093063|NCT01602783|Radical Prostatectomy
1093064|NCT01602770|Oral contraceptives
1093065|NCT01602770|Adverse events
1093066|NCT01602770|Safety profile
1093067|NCT01602770|Contraceptive Agents
1093068|NCT01602744|STOPP screening tool
1093069|NCT01602744|START screening tool
1093070|NCT01602744|MIP-medication inappropriate prescription
1093071|NCT01602744|PIM-Potentially inappropriate medication
1093072|NCT01602731|medication adherence
1093073|NCT01602718|physical activity
1093074|NCT01602718|physical performance
1093075|NCT01602718|ESRD
1093076|NCT01602718|home dialysis
1093077|NCT01602705|Feedback (NOT MESH)
1093078|NCT01602705|Medication errors
1093079|NCT01602705|Medication review
1093080|NCT01602705|Inappropriate medication
1093081|NCT01602705|Randomised controlled trial
1093082|NCT01602705|Primary Health Care
1093083|NCT01602705|Family Practice
1093084|NCT01602692|Pain, postoperative
1093085|NCT01602692|Postoperative Nausea and Vomiting
1093086|NCT01602692|Patient Readmission
1093087|NCT01602692|Time to Discharge
1093088|NCT01602640|sedation
1093089|NCT01602640|critical care
1093090|NCT01602640|morphine
1093091|NCT01602640|fentanyl
1093092|NCT01602640|analgesic based sedation
1093093|NCT01602601|Hunter syndrome, immunogenicity, antibodies
1093094|NCT01602575|IBS, FMRI, MBSR
1093095|NCT01602562|Herpes simplex infection
1093096|NCT01602562|valaciclovir
1093097|NCT01602562|herpes simplex virus
1093098|NCT01602562|hematopoietic stem cell transplantation
1093099|NCT01602536|twitter
1093100|NCT01602536|quit smoking
1093101|NCT01602536|smoking cessation
1093102|NCT01602536|social media
1093103|NCT01602536|peer support
1093104|NCT01602523|Emphysema
1093105|NCT01602523|COPD
1093106|NCT01602523|Sleep
1093107|NCT01602497|Borderline personality disorder
1093108|NCT01602497|repetitive transcranial magnetic stimulation
1093109|NCT01602471|Endarterectomy
1093110|NCT01602471|K5-C200
1093111|NCT01602471|RGD-K5
1093112|NCT01602471|angiogenesis
1093113|NCT01602471|Carotid CT Angiogram
1093114|NCT01602458|Preventative Scar Management
1093115|NCT01602458|Skin Grafts
1093116|NCT01602458|Silicone Therapy
1093117|NCT01602458|Silicone Pressure Garment Therapy
1093118|NCT01602445|Venous Thrombosis
1093119|NCT01602445|Coagulation factors
1093120|NCT01602445|Cancer
1093121|NCT01602445|Blood
1093122|NCT01602432|Venous Thrombosis
1093123|NCT01602432|Cancer
1093124|NCT01602432|Coagulation factors
1093125|NCT01602432|Blood
1093126|NCT01602406|Advanced HER2-positive Breast cancer or Gastric cancer
1093127|NCT01602380|hormone receptor positive breast cancer
1093128|NCT01602380|endocrine
1093129|NCT01602380|no hormone therapy
1093130|NCT01602380|hormone
1093131|NCT01602380|breast
1093132|NCT01602380|cancer
1093133|NCT01602380|neoplasm
1093134|NCT01602380|metastatic
1093135|NCT01602380|tumour
1093136|NCT01602354|Endotoxin Activity Assay
1093137|NCT01602354|Gram negative
1093138|NCT01602354|Septic Shock
1093139|NCT01602354|EAA
1093140|NCT01602341|atopic dermatitis
1093141|NCT01602328|Acute Kidney Injury
1093142|NCT01602328|Acute renal failure
1093143|NCT01602328|Human mesenchymal stem cells
1093144|NCT01602328|Allogeneic stem cells
1093145|NCT01602315|BYL719
1093146|NCT01602315|PI3K inhibitor
1093147|NCT01602315|PIK3CA
1093148|NCT01602315|cetuximab
1093149|NCT01602315|EGFR
1093150|NCT01602315|HNSCC
1093151|NCT01602315|RM HNSCC
1093152|NCT01602315|platinum-based chemotherapy
1093153|NCT01602315|(RM HNSCC) patients
1093154|NCT01602315|resistant or ineligible/intolerant to platinum-based chemotherapy
1093155|NCT01602315|swallowing dysfunction
1093156|NCT01602315|G-tube
1093157|NCT01602302|rheumatoid arthritis
1093158|NCT01602302|ultrasound
1093159|NCT01602302|remission
1093160|NCT01602302|biological DMARD
1093161|NCT01602276|Parkinson's disease
1093162|NCT01602276|Lewy body dementia
1093163|NCT01602276|Korsakoff's syndrome
1093164|NCT01602276|Subcortical Dementia
1093165|NCT01602276|Huntington's Disease
1093166|NCT01602263|Normal cognitive function
1093167|NCT01602263|Aphasia
1093168|NCT01602263|Autism
1093169|NCT01602263|Schizophrenia
1093170|NCT01602250|Anesthetics, local
1093171|NCT01602250|Toxicity
1093172|NCT01602250|Adverse effects
1093173|NCT01602211|stem cell transplant
1093174|NCT01602211|cancer survivors
1093175|NCT01602211|internet
1093176|NCT01602211|social media
1093177|NCT01602211|distress
1093178|NCT01602211|health care adherence
1093179|NCT01602185|NMDA (N-Methyl-D-Aspartate) antagonists
1093180|NCT01602185|ketamine
1093181|NCT01602185|memantine
1093182|NCT01602185|dextromethorphan
1093183|NCT01602185|Neuropathic pain
1093184|NCT01602172|alcohol consumption
1093185|NCT01602172|inpatients
1093186|NCT01602172|risk reduction behavior
1093187|NCT01602172|counseling
1093188|NCT01602172|nurses
1093189|NCT01602172|brief intervention
1093190|NCT01602159|Claudication
1093191|NCT01602159|SFA
1093192|NCT01602159|Open Bypass
1093193|NCT01602159|Angioplasty
1093194|NCT01602159|Stenting
1093195|NCT01602146|ultramarathon central fatigue,
1093196|NCT01602133|venous puncture
1093197|NCT01602133|seldinger technique
1093198|NCT01602133|ultrasound guidance
1093199|NCT01602107|Stress
1093200|NCT01602107|Urinary
1093201|NCT01602107|Incontinence
1093202|NCT01602107|Pelvic
1093203|NCT01602107|Physiotherapy
1093204|NCT01602094|measles
1093205|NCT01602094|antibody
1093206|NCT01602094|prevalence
1093207|NCT01602094|predictors
1093208|NCT01602094|Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old
1093209|NCT01602094|Measles antibody levels
1093210|NCT01602094|Predictors of adequate measles antibody levels and inadequate measles antibody levels
1093211|NCT01602081|Anal fistula
1093212|NCT01602081|Ligation of the intersphincteric fistula tract
1093213|NCT01602081|LIFT
1093214|NCT01602081|Tissue graft
1093215|NCT01602068|Iontophoresis
1093216|NCT01602068|Cataract Surgery
1093217|NCT01602068|Ophthalmology
1093218|NCT01602042|essential tremor
1093219|NCT01602042|motion sensors
1093220|NCT01602042|tremor
1093221|NCT01602029|Anti inflammatory
1093222|NCT01602029|Schizophrenia
1093223|NCT01602029|Simvastatin
1093224|NCT01602029|Ondansetron
1093225|NCT01602016|ASD
1093226|NCT01602016|PDD-NOS
1093227|NCT01601977|COPD
1093228|NCT01601977|Respiratory failure
1093229|NCT01601977|NIV
1093230|NCT01601977|OSA
1093231|NCT01601964|VEGF, ectopic pregnancy.
1093232|NCT01601951|Osteoarthritis
1093233|NCT01601951|Stem Cell Injections
1093234|NCT01601951|Bone Marrow
1093235|NCT01601951|Autologous
1093236|NCT01601938|Sepsis
1093237|NCT01601938|Shock, Septic
1093238|NCT01601938|Selenium
1093239|NCT01601938|Survival
1093240|NCT01601912|Whiplash Injuries
1093241|NCT01601912|Chronic Pain
1093242|NCT01601912|Exercise
1093243|NCT01601912|Cognition
1093244|NCT01601899|trial
1093245|NCT01601899|stavudine
1093246|NCT01601899|tenofovir
1093247|NCT01601899|mitochondria
1093248|NCT01601899|insulin resistance
1093249|NCT01601899|lipids
1093250|NCT01601899|HOMA
1093251|NCT01601886|Intubation, Intratracheal
1093252|NCT01601886|Continuous Positive Airway Pressure
1093253|NCT01601886|Historical Cohort Studies
1093254|NCT01601886|Clinical Trial
1093255|NCT01601873|Arteriovenous graft
1093256|NCT01601873|Propaten
1093257|NCT01601873|Heparin-bonded
1093258|NCT01601873|hemodialysis vascular access
1093259|NCT01601873|Surgical
1093260|NCT01601873|Arteriovenous Shunt
1093261|NCT01601860|Labor
1093262|NCT01601860|vaginal delivery
1093263|NCT01601860|pain
1093264|NCT01601834|Phase 1
1093265|NCT01601834|Single Dose
1093266|NCT01601834|Pharmacokinetics
1093267|NCT01601834|Safety
1093268|NCT01601834|Toleration
1093269|NCT01601795|Cardioprotection
1093270|NCT01601769|Cervical preinvasive disease
1093271|NCT01601769|Colposcopy
1093272|NCT01601769|Exocolposcopy
1093273|NCT01601769|Leep
1093274|NCT01601756|revision knee arthroplasty
1093275|NCT01601756|navigation
1093276|NCT01601756|joint line
1093277|NCT01601743|Cocaine
1093278|NCT01601743|Exercise
1093279|NCT01601730|Cocaine
1093280|NCT01601730|Modafinil
1093281|NCT01601730|Escitalopram
1093282|NCT01601717|RTI-336
1093283|NCT01601717|Methamphetamine
1093284|NCT01601704|Body Weight
1093285|NCT01601704|Bupropion
1093286|NCT01601704|Cardiovascular Diseases
1093287|NCT01601704|Diabetes Mellitus
1093288|NCT01601704|Diabetes Mellitus, Type 2
1093289|NCT01601704|Endocrine System Diseases
1093290|NCT01601704|Glucose Metabolism Disorders
1093291|NCT01601704|Heart Diseases
1093292|NCT01601704|Metabolic Diseases
1093293|NCT01601704|Narcotic Antagonists
1093294|NCT01601704|Naltrexone
1093295|NCT01601704|Nutrition Disorders
1093296|NCT01601704|Obesity
1093297|NCT01601704|Overnutrition
1093298|NCT01601704|Overweight
1093299|NCT01601691|prostate cancer
1093300|NCT01601691|brachytherapy
1093301|NCT01601691|spacer
1093302|NCT01601691|side effect
1093303|NCT01601678|Achalasia
1093304|NCT01601678|Heller Myotomy
1093305|NCT01601678|Dysphagia
1093306|NCT01601678|Peroral Endoscopic Myotomy
1093307|NCT01601665|Intraocular lens
1093308|NCT01601665|Cataracts
1093309|NCT01601665|Astigmatism
1093310|NCT01601665|Toric
1093311|NCT01601652|cholestasis
1093312|NCT01601652|PNAC
1093313|NCT01601652|Parenteral Nutrition Associated Cholestasis
1093314|NCT01601652|PNALD
1093315|NCT01601652|Parenteral Nutrition Associated Liver Disease
1093316|NCT01601639|Gastric Antral Vascular Ectasia
1093317|NCT01601639|Argon plasma Coagulation
1093318|NCT01601639|Endoscopic Band Ligation
1093319|NCT01601639|GAVE
1093320|NCT01601587|Introductory Seminar
1093321|NCT01601587|Waiting list
1093322|NCT01601587|Community Mental Health Centre
1093323|NCT01601574|Type 2 diabetes
1093324|NCT01601574|HbA1c
1093325|NCT01601574|Overweight
1093326|NCT01601574|Obesity
1093327|NCT01601561|Insulin
1093328|NCT01601561|Protein metabolism
1093329|NCT01601561|Stress response
1093330|NCT01601483|AMD
1093331|NCT01601483|Dry AMD
1093332|NCT01601483|Nonexudative AMD
1093333|NCT01601483|MC-1101
1093334|NCT01601470|LCZ696, sildenafil, pharmacokinetics, mild to moderate hypertension
1093335|NCT01601444|To assess pleural effusion by measuring internal thoracic impedance
1093336|NCT01601431|Screening colonoscopy
1093337|NCT01601418|YF476
1093338|NCT01601418|gastrin receptor antagonist
1093339|NCT01601418|pentagastrin
1093340|NCT01601418|gastric acid
1093341|NCT01601418|healthy subjects
1093342|NCT01601405|YF476
1093343|NCT01601405|gastrin receptor antagonist
1093344|NCT01601405|gastrin
1093345|NCT01601405|gastric aspiration
1093346|NCT01601405|healthy subjects
1093347|NCT01601392|Ischemic stroke
1093348|NCT01601392|direct current stimulation
1093349|NCT01601392|motor threshold
1093350|NCT01601392|National institutes of Health Stroke Scale
1093351|NCT01601392|Barthel index scale
1093352|NCT01601392|Measurement of motor power improvement
1093353|NCT01601379|Observational
1093354|NCT01601379|GERD
1093355|NCT01601379|Gastroesophageal Reflux Disease
1093356|NCT01601379|Gastro-oesophageal Reflux
1093357|NCT01601379|Heartburn
1093358|NCT01601366|Adenomyosis
1093359|NCT01601366|Intrauterine levonorgestrel
1093360|NCT01601366|Dysmenorrhea
1093361|NCT01601366|Oral contraceptives
1093362|NCT01601366|Uterus
1093363|NCT01601353|Erectile Dysfunction
1093364|NCT01601327|hypogonadism
1093365|NCT01601327|treatment
1093366|NCT01601327|testis volume
1093367|NCT01601301|Limb
1093368|NCT01601301|Lengthening
1093369|NCT01601301|PRECICE
1093370|NCT01601301|Ellipse
1093371|NCT01601301|Technologies
1093372|NCT01601301|Distraction
1093373|NCT01601301|Osteogenesis
1093374|NCT01601301|Femur
1093375|NCT01601301|Tibia
1093376|NCT01601301|Intramedullary
1093377|NCT01601301|Nail
1093378|NCT01601301|Device
1093379|NCT01601301|Medical
1093380|NCT01601301|Orthopedic
1093381|NCT01601301|Implant
1093382|NCT01601288|obstructive lung disease
1093383|NCT01601288|restrictive lung disease
1093384|NCT01601288|cough
1093385|NCT01601288|dyspnea
1093386|NCT01601275|tuberculosis
1093387|NCT01601262|ED
1093388|NCT01601262|LI-ESWT
1093389|NCT01601249|IVF, embryo selection, polarized light
1093390|NCT01601236|H.P. Acthar Gel
1093391|NCT01601236|Acthar
1093392|NCT01601236|diabetic nephropathy
1093393|NCT01601236|proteinuria
1093394|NCT01601236|nephrotic syndrome
1093395|NCT01601223|Ventilatory Management
1093396|NCT01601223|Mechanical Ventilation
1093397|NCT01601223|Post Operative pulmonary complications
1093398|NCT01601223|Intra-operative complications
1093399|NCT01601223|General Anesthesia
1093400|NCT01601223|Surgery
1093401|NCT01601223|LAS VEGAS
1093402|NCT01601223|ESA (European Society of Anaesthesiology)
1093403|NCT01601223|European Society of Anaesthesiology
1093404|NCT01601197|immunization
1093405|NCT01601197|pain management
1093406|NCT01601197|infants
1093407|NCT01601197|tactile stimulation
1093408|NCT01601184|medulloblastoma
1093409|NCT01601184|sonic hedgehog pathway
1093410|NCT01601184|vismodegib
1093411|NCT01601171|GnRH deficiency
1093412|NCT01601171|hypogonadism
1093413|NCT01601171|anosmia
1093414|NCT01601171|infertility
1093415|NCT01601171|cleft lip
1093416|NCT01601171|cleft palate
1093417|NCT01601171|cryptorchidism
1093418|NCT01601171|microphallus
1093419|NCT01601158|Global developmental delay
1093420|NCT01601158|Umbilical cord blood
1093421|NCT01601158|Rehabilitation
1093422|NCT01601145|Lactobacillus Brevis CD2
1093423|NCT01601145|schoolchildren
1093424|NCT01601145|dental caries
1093425|NCT01601145|Gingivatis
1093426|NCT01601132|pharmacokinetics
1093427|NCT01601132|colchicine
1093428|NCT01601132|theophylline
1093429|NCT01601119|Multiple Sclerosis
1093430|NCT01601119|Patient reported outcome
1093431|NCT01601119|Patient reported experience
1093432|NCT01601106|Atherosclerosis, inflammation
1093433|NCT01601093|Respiratory and urinary tract infections
1093434|NCT01601093|Ceftazidime and Sulbactam Sodium for Injection (2:1)
1093435|NCT01601093|Phase Ⅱ
1093436|NCT01601080|Adherence
1093437|NCT01601080|Multiple Sclerosis
1093438|NCT01601067|posttraumatic stress disorder
1093439|NCT01601067|psychotherapy
1093440|NCT01601067|alcoholism
1093441|NCT01601054|spine
1093442|NCT01601054|deformity
1093443|NCT01601054|instrumentation
1093444|NCT01601054|ALIF
1093445|NCT01601041|Urinary Tract Infection
1093446|NCT01601041|Bacteriuria
1093447|NCT01601041|Pyuria
1093448|NCT01601041|Prostatitis
1093449|NCT01601041|Intermittent Catheterization
1093450|NCT01601041|Spinal Cord Injuries
1093451|NCT01601041|Residual Urine
1093452|NCT01601028|Autoimmune Diseases
1093453|NCT01601028|Sjogren's Syndrome
1093454|NCT01601028|Hydroxychloroquine
1093455|NCT01601015|Tension-type headache, Effectiveness, Manual therapy
1093456|NCT01601002|Mirtazapine
1093457|NCT01600989|shock septic
1093458|NCT01600989|monocytes
1093459|NCT01600989|lymphocytes
1093460|NCT01600989|mitochondria
1093461|NCT01600989|interleukins
1093462|NCT01600989|Tumor Necrosis Factor-alpha
1093463|NCT01600989|Hypoxia-Inducible Factor 1, alpha Subunit
1093464|NCT01600976|Hepatic impairment
1093465|NCT01600976|Hepatitis C
1093466|NCT01600976|Telaprevir
1093467|NCT01600976|VX-950
1093468|NCT01600976|Pharmacokinetics
1093469|NCT01600976|Safety
1093470|NCT01600976|Unbound plasma concentrations
1093471|NCT01600976|Child-Pugh score
1093472|NCT01600963|Multi-drug resistant tuberculosis
1093473|NCT01600963|Pre-extensively drug resistant tuberculosis
1093474|NCT01600963|TMC207
1093475|NCT01600963|Background regimen
1093476|NCT01600937|diabetes mellitus
1093477|NCT01600937|diabetes education
1093478|NCT01600937|behavioral therapy
1093479|NCT01600937|behavior modification
1093480|NCT01600937|physical activity
1093481|NCT01600937|supervised exercise
1093482|NCT01600937|physical fitness
1093483|NCT01600937|HbA1c
1093484|NCT01600937|modifiable cardiovascular risk factors
1093485|NCT01600937|quality of life
1093486|NCT01600924|diabetes mellitus
1093487|NCT01600924|muscle strength
1093488|NCT01600924|bone strength
1093489|NCT01600924|cardiovascular risk factors
1093490|NCT01600924|diabetic complications
1093491|NCT01600911|metabolomics
1093492|NCT01600911|nutri-metabolomics
1093493|NCT01600911|plant food
1093494|NCT01600911|blood pressure
1093495|NCT01600898|Asymptomatic carriers of a BMPR2 mutation
1093496|NCT01600898|follow up study
1093497|NCT01600885|Guanfacine
1093498|NCT01600885|Ketamine
1093499|NCT01600885|Functional Magnetic Resonance Imaging
1093500|NCT01600885|Prefrontal Cortex Activity
1093501|NCT01600885|Receptors, N-Methyl-D-Aspartate
1093502|NCT01600885|Receptors, Adrenergic, alpha-2
1093503|NCT01600885|Memory, Short-Term
1093504|NCT01600885|Schizophrenia
1093505|NCT01600872|EDCs
1093506|NCT01600872|PCOS
1093507|NCT01600872|TAS
1093508|NCT01600872|TOS
1093509|NCT01600872|ROS
1093510|NCT01600872|Oxidative Stress, Endocrine-Disrupting Chemicals, Polycystic Ovary syndrome
1093511|NCT01600846|Pharmacogenetic testing
1093512|NCT01600846|pharmacokinetics
1093513|NCT01600846|Pharmacogenomics
1093514|NCT01600846|genetics
1093515|NCT01600846|pharmacy
1093516|NCT01600846|drug response
1093517|NCT01600833|PCOS
1093518|NCT01600833|Ferritin
1093519|NCT01600833|Homocysteine
1093520|NCT01600833|Insulin Resistance
1093521|NCT01600833|Metabolic Syndrome
1093522|NCT01600820|Plant sterol
1093523|NCT01600820|Hypercholesterolemia
1093524|NCT01600820|diet
1093525|NCT01600820|dairy
1093526|NCT01600820|LDL-C
1093527|NCT01600820|Mildly hypercholesterolemic subjects
1093528|NCT01600807|Metastatic
1093529|NCT01600807|Pancreas
1093530|NCT01600807|Cancer
1093531|NCT01600807|Adenocarcinoma
1093532|NCT01600794|In Vitro Fertilization (IVF)
1093533|NCT01600794|androgens
1093534|NCT01600794|ovary function
1093535|NCT01600794|This study include the patients who are evaluated by the doctors and are sure to process the In Vitro Fertilization cycle.
1093536|NCT01600781|Improve the nutritional status
1093537|NCT01600781|QOL
1093538|NCT01600781|children
1093539|NCT01600781|enhance immune response
1093540|NCT01600781|induction chemotherapy
1093541|NCT01600781|fewer side effects
1093542|NCT01600768|focus of study
1093543|NCT01600755|Cell Therapy
1093544|NCT01600755|Autologous Cell Transplantation
1093545|NCT01600755|Muscle-derived Cell
1093546|NCT01600755|Anal Incontinence
1093547|NCT01600755|Rectal Diseases
1093548|NCT01600755|Intestinal Diseases
1093549|NCT01600755|Gastrointestinal Diseases
1093550|NCT01600755|Urinary Incontinence
1093551|NCT01600703|Intestinal lipoprotein
1093552|NCT01600703|Apolipoprotein B48 and apolipoprotein B100
1093553|NCT01600703|Pancreatic clamp
1093554|NCT01600703|DPPIV inhibitor
1093555|NCT01600690|Stem cells
1093556|NCT01600690|Regeneration
1093557|NCT01600690|Inflammation
1093558|NCT01600677|Experimental; Computerized medication delivery unit
1093559|NCT01600664|Type 1 diabetes
1093560|NCT01600664|"My Diabetic friend"
1093561|NCT01600664|interactive computer game
1093562|NCT01600651|Receptor for advanced glycation end products (RAGE)
1093563|NCT01600651|Soluble RAGE (sRAGE)
1093564|NCT01600651|Recruitment Maneuver
1093565|NCT01600651|Acute respiratory distress syndrome (ARDS)
1093566|NCT01600651|Alveolar epithelium
1093567|NCT01600651|Electrical Impedance Tomography
1093568|NCT01600651|Mechanical ventilation
1093569|NCT01600651|Intensive Care Unit (ICU)
1093573|NCT01600625|meibomian gland dysfunction
1093574|NCT01600625|inflammatory tear cytokine
1093575|NCT01600625|minocycline
1093576|NCT01600612|postpartum hemorrhage, oxytocin, carbetocin, misopristol
1093577|NCT01600586|NICU
1093578|NCT01600586|Music therapy
1093579|NCT01600586|Premature infant
1093580|NCT01600586|Oral feeds
1093581|NCT01600586|Non-Nutritive Sucking
1093582|NCT01600586|Suck rate
1093583|NCT01600586|Suck efficiency
1093584|NCT01600586|Contingent music
1093585|NCT01600586|Mother's voice
1093586|NCT01600573|ovarian cancer
1093587|NCT01600534|gestational diabetes
1093588|NCT01600508|stoma care
1093589|NCT01600508|videoconference
1093590|NCT01600508|costs
1093591|NCT01600508|quality of life
1093592|NCT01600495|pain
1093593|NCT01600495|electric stimulation
1093594|NCT01600495|nervous
1093595|NCT01600495|transcutaneous
1093596|NCT01600495|humanized childbirth
1093597|NCT01600482|Hemostasis.
1093598|NCT01600482|Percutaneous coronary interventions.
1093599|NCT01600482|Closure Device
1093600|NCT01600469|Alzheimer's disease
1093601|NCT01600469|mild cognitive impairment
1093602|NCT01600469|NMDA
1093603|NCT01600456|PTSD
1093604|NCT01600456|Antidepressants
1093605|NCT01600456|Cognitive behavior therapy
1093606|NCT01600430|Vitamin D
1093607|NCT01600430|Newborn
1093608|NCT01600430|Preterm
1093609|NCT01600430|Supplementation
1093610|NCT01600430|Respiratory
1093611|NCT01600417|low back pain
1093612|NCT01600417|spine
1093613|NCT01600417|lumbar spine
1093614|NCT01600417|lumbar instability
1093615|NCT01600417|radiology
1093616|NCT01600417|functional radiology
1093617|NCT01600404|Mild Cognitive Impairment
1093618|NCT01600404|Muscarinic Antagonists
1093619|NCT01600404|Spinal Cord Injuries
1093620|NCT01600404|Urinary Bladder, Neurogenic
1093621|NCT01600404|Urinary Bladder, Overactive
1093622|NCT01600404|Overactive Detrusor
1093623|NCT01600391|Stroke
1093624|NCT01600391|Visual cues
1093625|NCT01600391|Gait rehabilitation
1093626|NCT01600391|Walking adaptability
1093627|NCT01600391|Turning
1093628|NCT01600391|Overground walking
1093629|NCT01600391|Treadmill training
1093630|NCT01600378|diffuse parenchymal lung disease
1093631|NCT01600378|interstitial lung disease
1093632|NCT01600378|idiopathic pulmonary fibrosis
1093633|NCT01600365|Conjunctivitis
1093634|NCT01600365|adenovirus.
1093635|NCT01600352|interstitial lung disease
1093636|NCT01600352|idiopathic pulmonary fibrosis
1093637|NCT01600313|rice bran oil
1093638|NCT01600313|diet
1093639|NCT01600313|cardiovascular disease
1093640|NCT01600313|low density lipoprotein
1093641|NCT01600313|total cholesterol
1093642|NCT01600300|Age-related macular degeneration
1093643|NCT01600300|electrical stimulation
1093644|NCT01600300|randomized
1093645|NCT01600300|double blind
1093646|NCT01600287|bispectral index
1093647|NCT01600287|propofol
1093648|NCT01600287|paediatric cardiac surgery
1093649|NCT01600287|closed loop anaesthesia delivery system
1093650|NCT01600261|without eye disease
1093651|NCT01600248|Chronic Pain
1093652|NCT01600248|Military
1093653|NCT01600248|Veteran
1093654|NCT01600248|Online
1093655|NCT01600248|Acceptance
1093656|NCT01600235|Stroke, ischemic
1093657|NCT01600235|Progression
1093658|NCT01600235|Induced-hypertension
1093659|NCT01600235|Phenylephrine
1093660|NCT01600209|Cancer
1093661|NCT01600209|Colorectal Cancer
1093662|NCT01600209|Neoplasm
1093663|NCT01600209|Colorectal Neoplasm
1093664|NCT01600209|Intestinal Neoplasms
1093665|NCT01600209|Gastrointestinal Neoplasms
1093666|NCT01600209|Digestive System Neoplasms
1093667|NCT01600209|Neoplasms by Site
1093668|NCT01600209|Neoplasms
1093669|NCT01600209|Digestive System Diseases
1093670|NCT01600209|Gastrointestinal Diseases
1093671|NCT01600209|Colonic Diseases
1093672|NCT01600209|Intestinal Diseases
1093673|NCT01600209|Rectal Diseases
1093674|NCT01600196|Hepatectomy
1093675|NCT01600196|Thrombectomy
1093676|NCT01600196|Hepatocellular carcinoma
1093677|NCT01600196|Portal vein tumor thrombus
1093678|NCT01600183|MTA
1093679|NCT01600183|metatarsus
1093680|NCT01600183|Metatarsus Adductus, also known as Metatarsus Varus
1093681|NCT01600170|HIV
1093682|NCT01600170|monocytes
1093683|NCT01600170|CD16+
1093684|NCT01600170|statins
1093685|NCT01600170|mcp1
1093686|NCT01600170|inflammation
1093687|NCT01600144|data mammography
1093688|NCT01600118|tooth mobility
1093689|NCT01600118|periodontal status
1093690|NCT01600118|irregularity index
1093691|NCT01600118|pulpal blood flow
1093692|NCT01600105|liver fibrosis
1093693|NCT01600105|liver cirrhosis
1093694|NCT01600105|chronic hepatitis
1093695|NCT01600105|magnetic resonance imaging
1093696|NCT01600079|Varicella-zoster vaccine
1093697|NCT01600079|herpes zoster
1093698|NCT01600079|shingles
1093699|NCT01600079|Varicella-zoster virus
1093700|NCT01600079|postherpetic neuralgia
1093701|NCT01600079|Herpesviridae Infections
1093702|NCT01600079|DNA Virus Infections
1093703|NCT01600079|Virus Diseases
1093704|NCT01600053|Chronic
1093705|NCT01600053|Lymphocytic
1093706|NCT01600053|Leukemia
1093707|NCT01600040|metastatic
1093708|NCT01600027|Fascia iliaca block
1093709|NCT01600027|dexmetomidine
1093710|NCT01600027|fracture femur
1093711|NCT01600027|α2 agonist
1093712|NCT01600001|Chronic Idiopathic Constipation (CIC)
1093713|NCT01600001|Constipation
1093714|NCT01600001|Functional gastrointestinal disorders
1093715|NCT01599975|HAND
1093716|NCT01599975|HIV Associated Neurocognitive Disorder
1093717|NCT01599975|Methylphenidate
1093718|NCT01599975|HIV Dementia
1093719|NCT01599949|Mantle cell lymphoma
1093720|NCT01599949|Ibrutinib
1093721|NCT01599949|Bruton's tyrosine kinase inhibitor
1093722|NCT01599949|Rituximab
1093723|NCT01599949|Bortezomib
1093724|NCT01599936|scorpion sting
1093725|NCT01599936|envenomation
1093726|NCT01599936|Anascorp
1093727|NCT01599923|scorpion
1093728|NCT01599923|envenomation
1093729|NCT01599923|Alacramyn
1093730|NCT01599910|Scribes
1093731|NCT01599910|Physician Productivity
1093732|NCT01599910|Electronic Documentation
1093733|NCT01599897|Tuberculosis
1093734|NCT01599897|TB
1093735|NCT01599897|Pulmonary
1093736|NCT01599897|Vaccine
1093737|NCT01599884|Chronic obstructive pulmonary disease
1093738|NCT01599884|Chronic bronchitis
1093739|NCT01599884|N-acetylcysteine
1093740|NCT01599871|COPD
1093741|NCT01599858|YF476
1093742|NCT01599858|gastrin receptor antagonist
1093743|NCT01599858|gastric pH
1093744|NCT01599858|healthy subjects
1093745|NCT01599858|omeprazole
1093746|NCT01599845|Lung
1093747|NCT01599845|Alveoli
1093748|NCT01599845|Nanoparticles
1093749|NCT01599845|Particulate matter
1093750|NCT01599845|Exhaled breath condensate
1093751|NCT01599845|Induced sputum
1093752|NCT01599845|Forced expiratory volume
1093753|NCT01599845|Force vital capacity
1093754|NCT01599806|Ceftazidime, Avibactam, Doripenem, Ciprofloxacin, sulfamethoxazole/trimethoprim, Anti-Infective Agents, Complicated Urinary Tract Infection,Acute Pyelonephritis
1093755|NCT01599793|castrate resistant prostate cancer
1093756|NCT01599793|CRPC
1093757|NCT01599793|cabozantinib
1093758|NCT01599793|XL184
1093759|NCT01599780|preterm
1093760|NCT01599780|premature
1093761|NCT01599780|prematurity
1093762|NCT01599780|children
1093763|NCT01599780|child
1093764|NCT01599780|kid
1093765|NCT01599780|toddler
1093766|NCT01599780|infant
1093767|NCT01599780|baby
1093768|NCT01599780|language
1093769|NCT01599780|development
1093770|NCT01599780|skills
1093771|NCT01599780|listening
1093772|NCT01599780|talking
1093773|NCT01599780|communication
1093774|NCT01599780|speech
1093775|NCT01599780|processing
1093776|NCT01599767|transcranial stimulation
1093777|NCT01599767|direct current
1093781|NCT01599741|X-rays
1093782|NCT01599741|Endovascular angiography
1093783|NCT01599741|Image processing
1093784|NCT01599728|Urocortin 2
1093785|NCT01599728|Urocortin 3
1093786|NCT01599728|Forearm venous occlusion plethysmography
1093787|NCT01599728|Heart failure
1093788|NCT01599728|Endothelium
1093789|NCT01599728|Substance P
1093790|NCT01599715|Urinary Incontinence
1093791|NCT01599715|Weak bladder
1093792|NCT01599715|Frequent urination
1093793|NCT01599715|Overactive bladder
1093794|NCT01599715|Urine leakage
1093795|NCT01599715|Stress incontinence
1093796|NCT01599715|Urge Incontinence
1093797|NCT01599715|Pelvic Floor weakness
1093798|NCT01599715|Pelvic Floor Muscle Exercises
1093799|NCT01599715|Kegel exercises
1093800|NCT01599715|Self-Care
1093801|NCT01599702|IBD
1093802|NCT01599702|IDA
1093803|NCT01599702|Subjects
1093804|NCT01599702|diagnosis
1093805|NCT01599689|Delirium
1093806|NCT01599689|Delirium, Dementia, Amnestic, Cognitive Disorders
1093807|NCT01599689|Confusion
1093808|NCT01599689|Neurobehavioral Manifestations
1093809|NCT01599689|Neurologic Manifestations
1093810|NCT01599689|Nervous System Diseases
1093811|NCT01599689|Signs and Symptoms
1093812|NCT01599689|Mental Disorders
1093813|NCT01599689|Cardiac Surgery
1093814|NCT01599689|Mirrors
1093815|NCT01599676|Citrulline
1093816|NCT01599676|protein-energy malnutrition
1093817|NCT01599676|amino acids
1093818|NCT01599676|muscle strength
1093819|NCT01599676|resistance training
1093820|NCT01599663|Pain management
1093821|NCT01599663|Pain assessment
1093822|NCT01599663|Intensive care unit
1093823|NCT01599663|Adult
1093824|NCT01599650|Macular Edema, Branch Retinal Vein Occlusion, visual impairment
1093825|NCT01599637|Chronic idiopathic urticaria
1093826|NCT01599637|CIU
1093827|NCT01599637|Xolair
1093828|NCT01599637|IGE025
1093829|NCT01599637|FcεRI
1093830|NCT01599637|IgE
1093831|NCT01599624|Resilience
1093832|NCT01599624|Perceived stress
1093833|NCT01599624|PTSD symptoms
1093834|NCT01599624|Depression
1093835|NCT01599624|Anxiety
1093836|NCT01599624|Sleep quality
1093837|NCT01599624|United States Navy service members
1093838|NCT01599611|Neonatal hyperbilirubinemia
1093839|NCT01599611|Follow-up
1093840|NCT01599611|Motor development
1093841|NCT01599611|Hearing
1093842|NCT01599611|Executive function
1093843|NCT01599598|perceived stress
1093844|NCT01599598|depression
1093845|NCT01599598|anxiety
1093846|NCT01599598|posttraumatic stress disorder
1093847|NCT01599598|military
1093848|NCT01599598|school
1093849|NCT01599598|training environment
1093850|NCT01599598|heart rate variability
1093851|NCT01599598|progressive muscle relaxation
1093852|NCT01599598|psychophysiological coherence
1093853|NCT01599598|coherence advantage
1093854|NCT01599598|stress reduction
1093855|NCT01599598|stress regulation
1093856|NCT01599598|independent duty corpsmen
1093857|NCT01599585|Depression
1093858|NCT01599585|Behavioral Activation
1093859|NCT01599585|Tele-medicine
1093860|NCT01599572|zinc supplementation
1093861|NCT01599572|serum zinc concentration
1093862|NCT01599572|lymphocyte proliferation
1093863|NCT01599559|previously
1093864|NCT01599559|untreated
1093865|NCT01599546|Preterm
1093866|NCT01599546|Full term
1093867|NCT01599546|Reading
1093868|NCT01599546|Dyslexia
1093869|NCT01599546|Brain
1093870|NCT01599546|Diffusion tensor imaging
1093871|NCT01599520|cancer
1093872|NCT01599520|stress
1093873|NCT01599520|stress management
1093874|NCT01599520|Latinas
1093875|NCT01599520|Hispanics
1093876|NCT01599507|Anemia
1093877|NCT01599507|Renal
1093878|NCT01599481|Common mental illness
1093879|NCT01599481|Supported Employment
1093880|NCT01599481|Anxiety
1093881|NCT01599481|Depression
1093882|NCT01599481|Sickness absence
1093883|NCT01599468|post partum hemorrhage
1093884|NCT01599468|transfusion
1093885|NCT01599468|tranexamic acid
1093886|NCT01599455|pediatric spinal cord injury
1093887|NCT01599455|blood pressure
1093888|NCT01599455|heart rate
1093889|NCT01599455|baseline
1093890|NCT01599429|AML / LMA
1093891|NCT01599416|Oral Probiotics
1093892|NCT01599416|HPV DNA Index Test
1093893|NCT01599416|Vaginal infection
1093894|NCT01599403|Rib Fracture
1093895|NCT01599403|Intercostal Nerve Block
1093896|NCT01599403|Paravertebral Nerve Block
1093897|NCT01599390|United States
1093898|NCT01599390|Burden of Disease
1093899|NCT01599390|Influenza
1093900|NCT01599364|HIV infection
1093901|NCT01599364|Atazanavir
1093902|NCT01599364|Lamivudine
1093903|NCT01599364|Ritonavir
1093904|NCT01599364|virological suppression
1093905|NCT01599364|non-inferiority
1093906|NCT01599364|Combined antiretroviral therapy
1093907|NCT01599351|Radiation exposure
1093908|NCT01599351|ERCP
1093909|NCT01599338|Liraglutide
1093910|NCT01599338|GLP-1 analogue
1093911|NCT01599338|Food preference
1093912|NCT01599338|Gustative perception
1093913|NCT01599338|Liking
1093914|NCT01599338|wanting
1093915|NCT01599338|T2DM
1093916|NCT01599338|body mass composition
1093917|NCT01599338|leptin
1093918|NCT01599338|ghrelin
1093919|NCT01599312|Videolaryngoscopy
1093920|NCT01599312|Forces
1093921|NCT01599312|Teeth
1093922|NCT01599299|ultrasound
1093923|NCT01599299|left and right jugular vein
1093924|NCT01599299|comparison
1093925|NCT01599286|Hyperammonia
1093926|NCT01599286|propionic acidemia (PA)
1093927|NCT01599286|methylmalonic acidemia (MMA)
1093928|NCT01599286|late-onset CPS1 deficiency (CPSD)
1093929|NCT01599286|late-onset Ornithine transcarbamylase deficiency (OTCD)
1093930|NCT01599286|Carbaglu
1093931|NCT01599273|thyroid-associated ophthalmopathy
1093932|NCT01599273|triamcinolone
1093933|NCT01599273|retraction
1093934|NCT01599273|swelling
1093935|NCT01599247|Suicide
1093936|NCT01599247|Optimism
1093937|NCT01599247|Hopelessness
1093938|NCT01599221|Femoral fractures
1093939|NCT01599221|Nail
1093940|NCT01599221|Implant
1093941|NCT01599221|Elderly
1093942|NCT01599221|Orthopaedics
1093943|NCT01599195|carotid stenosis
1093944|NCT01599195|femoral artery ischemia
1093945|NCT01599195|carotid bruit asymptomatic
1093946|NCT01599195|carotid murmur
1093947|NCT01599169|Burnout syndrome
1093948|NCT01599169|Depression work-related
1093949|NCT01599169|Food supplement
1093950|NCT01599156|Chronic constipation
1093951|NCT01599156|Reflexology
1093952|NCT01599156|Complementary medicine
1093953|NCT01599143|Mindfulness
1093954|NCT01599143|Pain Disorder (Chronic physical or mental health complaints:
1093955|NCT01599143|Fibromyalgia; Migraines; Back Pain; etc)
1093956|NCT01599143|Anxiety Disorder/Anxiety State
1093957|NCT01599130|Hepatitis B
1093958|NCT01599130|sequential peg-interferon-2a to entecavir
1093959|NCT01599117|Heart Failure with Preserved Ejection Fraction
1093960|NCT01599117|Diastolic Heart Failure
1093961|NCT01599117|Exercise Capacity
1093962|NCT01599117|Cardiopulmonary Exercise Test
1093963|NCT01599117|Udenafil (Zydena)
1093964|NCT01599117|Phosphodiesterase Type 5 Inhibitors
1093965|NCT01599104|Essential hypertension
1093966|NCT01599104|LCZ696
1093967|NCT01599091|Fibroblasts
1093968|NCT01599091|Periodontal ligament
1093969|NCT01599091|Gingiva
1093970|NCT01599091|Porphyromonas gingivalis
1093971|NCT01599091|Chronic periodontitis
1093972|NCT01599091|( patients undergoing tooth extraction will be asked permission to use extracted tooth and gingiva for periodontal disease basic research)
1093973|NCT01599078|Restenosis
1093974|NCT01599078|Angioplasty
1093975|NCT01599078|Stent
1093976|NCT01599078|Atherectomy
1093977|NCT01599078|Femoral Artery
1093978|NCT01599078|Popliteal Artery
1093979|NCT01599078|Paclitaxel
1093980|NCT01599065|ICD
1093981|NCT01599065|internal cardioverter defibrillator
1093982|NCT01599065|electrocautery
1093983|NCT01599052|Social Cognition
1093984|NCT01599052|Theory of Mind
1093985|NCT01599052|Emotion Recognition
1093986|NCT01599052|Social competence
1093987|NCT01599052|Brain Tumour
1093988|NCT01599039|early diagnostics
1093989|NCT01599039|lymphedema
1093990|NCT01599039|breast cancer
1093991|NCT01599039|breast cancer related lymphedema
1093992|NCT01599039|measuring methods
1093993|NCT01599039|inverse water volumetry
1093994|NCT01599039|prevention
1093995|NCT01599026|cardiology
1093996|NCT01599026|fetus of diabetic mother
1093997|NCT01599013|urothelial carcinoma
1093998|NCT01599013|bladder cancer
1093999|NCT01599013|vinflunine
1094000|NCT01599013|transitional cell carcinoma
1094001|NCT01599013|advanced or metastatic
1094002|NCT01599013|unfit
1094003|NCT01599013|ineligible to cisplatin
1094004|NCT01599013|renal impairment
1094005|NCT01599013|renal insufficiency
1094006|NCT01599013|urologic neoplasms
1094007|NCT01599013|urogenital neoplasm
1094008|NCT01599013|urinary neoplasms
1094009|NCT01599013|cisplatin
1094010|NCT01599013|tubulin inhibitors
1094011|NCT01599000|malaria
1094012|NCT01599000|Plasmodium
1094013|NCT01599000|Papua New Guinea
1094014|NCT01599000|artemether/lumefantrine
1094015|NCT01598987|Paediatric liver transplantation
1094016|NCT01598987|Everolimus
1094017|NCT01598987|Reduced calcineurin inhibitor
1094018|NCT01598987|Cyclosporine, tacrolimus
1094019|NCT01598987|Renal function
1094020|NCT01598987|Composite efficacy endpoint (treated biopsy proven acute rejection death, graft loss)
1094021|NCT01598987|Liver transplant
1094022|NCT01598974|Lower Back Pain
1094023|NCT01598974|Acupuncture
1094024|NCT01598948|hypercholesterolemia
1094025|NCT01598948|apheresis
1094026|NCT01598948|coronary heart disease
1094027|NCT01598948|cerebrovascular disease
1094028|NCT01598948|peripheral arterial disease
1094029|NCT01598922|Depression
1094030|NCT01598922|Internet Cognitive Behavioral Therapy
1094031|NCT01598922|fMRI
1094032|NCT01598922|Neuroimaging
1094033|NCT01598909|blepharoplasty
1094034|NCT01598909|arnica
1094035|NCT01598909|homeopathy
1094036|NCT01598896|Cannabis Dependence
1094037|NCT01598896|Marijuana Dependence
1094038|NCT01598896|Cannabis Use Disorders
1094039|NCT01598896|Cannabis Withdrawal
1094040|NCT01598896|Dronabinol
1094041|NCT01598896|Clonidine
1094042|NCT01598896|Schizophrenia
1094043|NCT01598870|Spontaneous bacterial peritonitis.
1094044|NCT01598857|granulomatosis with polyangiitis
1094045|NCT01598857|microscopic polyangiitis
1094046|NCT01598857|anti-neutrophil cytoplasmic antibodies
1094047|NCT01598857|ANCA-associated vasculitis
1094048|NCT01598857|Wegener Granulomatosis
1094049|NCT01598831|sepsis
1094050|NCT01598818|Vision Nearsighted
1094051|NCT01598818|Vision Farsighted
1094052|NCT01598805|venous thromboembolism/prevention & control
1094053|NCT01598779|genital warts
1094054|NCT01598779|HPV types
1094055|NCT01598779|Sexually Transmitted Diseases
1094056|NCT01598779|Skin Diseases, Viral
1094057|NCT01598779|Tumor Virus Infections
1094058|NCT01598779|Skin Diseases, Infectious
1094059|NCT01598779|Skin Diseases
1094060|NCT01598779|Papillomavirus Infections
1094061|NCT01598779|DNA Virus Infections
1094062|NCT01598779|Virus Diseases
1094063|NCT01598779|Sexually Transmitted Diseases, Viral
1094064|NCT01598727|parathyroid surgery
1094065|NCT01598701|Acetaminophen
1094066|NCT01598701|Intravenous Acetaminophen
1094067|NCT01598701|Opioid Requirement
1094068|NCT01598701|Pain
1094069|NCT01598701|Post-Operative Pain
1094070|NCT01598701|Craniotomy
1094071|NCT01598701|Post-Craniotomy Pain
1094072|NCT01598688|Bone marrow transplantation
1094073|NCT01598688|Hematopoietic stem cell transplantation
1094074|NCT01598688|Medication management
1094075|NCT01598688|Nursing care
1094076|NCT01598675|stroke
1094077|NCT01598675|Gait
1094078|NCT01598675|walking
1094079|NCT01598662|IUD placement
1094080|NCT01598662|contraception
1094081|NCT01598662|postpartum
1094082|NCT01598662|intrauterine device
1094083|NCT01598662|expulsion
1094084|NCT01598649|Dietary protein
1094085|NCT01598649|Lupin protein
1094086|NCT01598649|Cholesterol metabolism
1094087|NCT01598649|Protein metabolism
1094088|NCT01598649|Hypercholesterolemia
1094089|NCT01598649|Protein-enriched foods
1094090|NCT01598584|Mirtazapine
1094091|NCT01598584|gemcitabine
1094092|NCT01598584|placebo
1094093|NCT01598584|RCT
1094094|NCT01598584|pancreatic cancer
1094095|NCT01598571|Phase 1
1094096|NCT01598571|Healthy male volunteers
1094097|NCT01598571|pharmacokinetics
1094098|NCT01598571|fostamatinib
1094099|NCT01598571|Bioavailability
1094100|NCT01598571|R406 plasma AUC and Cmax
1094101|NCT01598571|R406 plasma AUC0-t
1094102|NCT01598571|t1/2λz
1094103|NCT01598571|tmax
1094104|NCT01598532|mild traumatic brain injury
1094105|NCT01598532|mild TBI
1094106|NCT01598532|mTBI
1094107|NCT01598519|school-based
1094108|NCT01598519|adolescent suicide
1094109|NCT01598519|intervention
1094110|NCT01598519|screening
1094111|NCT01598493|Burns
1094112|NCT01598493|Wound Healing
1094113|NCT01598480|Burns
1094114|NCT01598480|Wound Healing
1094115|NCT01598467|pelvic organ prolapse
1094116|NCT01598467|POP
1094117|NCT01598467|sacrocolpopexy
1094118|NCT01598467|sacrohysteropexy
1094119|NCT01598467|promontofixation
1094120|NCT01598467|colpopexy
1094121|NCT01598467|robotic surgery
1094122|NCT01598467|surgical complications
1094123|NCT01598467|mesh
1094124|NCT01598467|prolapse repair
1094125|NCT01598441|pulmonary hypertension, pulmonary hypertensive crisis
1094126|NCT01598428|age related cataract
1094127|NCT01598428|phacoemulsification
1094128|NCT01598428|anterior capsule polishing
1094129|NCT01598428|optical coherence tomography
1094130|NCT01598428|anterior chamber depth
1094131|NCT01598402|LAHNC
1094132|NCT01598402|Locally Advanced Head and Neck Cancer
1094133|NCT01598376|entropion
1094134|NCT01598376|suture
1094135|NCT01598376|granuloma
1094136|NCT01598376|tissue reaction
1094137|NCT01598350|Gait
1094138|NCT01598350|Orthoses
1094139|NCT01598350|Down syndrome
1094140|NCT01598324|magnetic resonance imaging
1094141|NCT01598324|magnetic resonance spectroscopy
1094142|NCT01598324|depression
1094143|NCT01598324|escitalopram
1094144|NCT01598324|selective serotonin reuptake inhibitor
1094145|NCT01598324|treatment-resistant depression
1094146|NCT01598324|ziprasidone
1094147|NCT01598311|CDAD
1094148|NCT01598311|Clostridium difficile Associated Diarrhea
1094149|NCT01598311|CDI
1094150|NCT01598311|Clostridium difficile Infection
1094151|NCT01598311|Diarrhea
1094152|NCT01598298|estrogen receptor-positive breast cancer
1094278|NCT01597752|Skin prick test
1094153|NCT01598298|progesterone receptor-positive breast cancer
1094154|NCT01598298|stage IA breast cancer
1094155|NCT01598298|stage IB breast cancer
1094156|NCT01598298|stage II breast cancer
1094157|NCT01598298|stage IIIA breast cancer
1094158|NCT01598298|stage IIIB breast cancer
1094159|NCT01598298|stage IIIC breast cancer
1094160|NCT01598298|pain
1094161|NCT01598298|musculoskeletal complications
1094162|NCT01598285|Genome-Wide
1094163|NCT01598285|GWAS
1094164|NCT01598285|microRNA
1094165|NCT01598285|miRNA
1094166|NCT01598285|Bevacizumab Response Predictors
1094167|NCT01598285|Metastatic Breast Cancer
1094168|NCT01598272|Ginseng
1094169|NCT01598272|Cordyceps
1094170|NCT01598272|Pomegranate
1094171|NCT01598272|Red Orange
1094172|NCT01598272|Grape Seed
1094173|NCT01598272|Broccoli Seed
1094174|NCT01598246|Extubation failures
1094175|NCT01598246|Sedation
1094176|NCT01598220|schizophrenia
1094177|NCT01598220|cognitive remediation therapy
1094178|NCT01598220|cognition
1094179|NCT01598220|quality of life
1094180|NCT01598194|solid pancreatic mass lesions
1094181|NCT01598194|22-gauge core biopsy needle
1094182|NCT01598194|reverse bevel design
1094183|NCT01598194|endoscopic ultrasound
1094184|NCT01598194|EUS
1094185|NCT01598194|guided
1094186|NCT01598194|fine needle aspiration
1094187|NCT01598194|FNA
1094188|NCT01598168|rivaroxaban
1094189|NCT01598168|treatment
1094190|NCT01598168|venous thromboembolism
1094191|NCT01598168|arterial thromboembolism
1094192|NCT01598168|thrombocytopenia
1094193|NCT01598155|dental biofilm
1094194|NCT01598155|periodontitis
1094195|NCT01598155|maintenance
1094196|NCT01598155|randomized clinical trial
1094197|NCT01598155|biomarkers
1094198|NCT01598155|bacterias
1094199|NCT01598155|gingival crevicular fluid
1094200|NCT01598142|Endoscopic retrograde cholangiopancreatography (ERCP)
1094201|NCT01598142|Guidewires
1094202|NCT01598142|Cannulation
1094203|NCT01598142|Single-operator
1094204|NCT01598142|C-Hook
1094205|NCT01598129|Phase I
1094206|NCT01598129|Dose escalation
1094207|NCT01598129|oncolytic virus
1094208|NCT01598103|Neurogenic detrusor overactivity
1094209|NCT01598103|spinal cord lesions
1094210|NCT01598103|spinal cord injury
1094211|NCT01598077|Breast cancer, gastric cancer, squamous cell carcinoma of head and neck, esophageal squamous cell carcinoma
1094212|NCT01598077|Breast cancer
1094213|NCT01598077|Gastric cancer
1094214|NCT01598077|Squamous cell carcinoma of head and neck
1094215|NCT01598077|Esophageal squamous cell carcinoma
1094216|NCT01598051|Xarelto
1094217|NCT01598051|SPAF
1094218|NCT01598051|QOL
1094219|NCT01598038|cancer
1094220|NCT01598038|renal
1094221|NCT01598038|Afinitor
1094222|NCT01598038|pharmacokinetics
1094223|NCT01598025|ANTITHYMOCYTE GLOBULIN:ATG
1094224|NCT01598025|FLUDARABINE
1094225|NCT01598025|THI0TEPA
1094226|NCT01598025|CliniMACS-CD34 Reagent System
1094227|NCT01598025|12-053
1094228|NCT01598012|Ayurved Siriraj Prasaplai
1094229|NCT01598012|primary dysmenorrhea
1094230|NCT01597986|isavuconazole
1094231|NCT01597986|ethinyl estradiol
1094232|NCT01597986|norethindrone
1094233|NCT01597986|contraceptive
1094234|NCT01597986|Healthy Volunteers
1094235|NCT01597986|BAL8557
1094236|NCT01597986|BAL4815
1094237|NCT01597934|Chronic hepatitis B
1094238|NCT01597934|Partial virologic response
1094239|NCT01597934|YMDD mutation
1094240|NCT01597921|Breast conserving surgery
1094241|NCT01597921|Radiation dermatitis
1094242|NCT01597908|BRAF inhibitor
1094243|NCT01597908|Metastatic Melanoma
1094244|NCT01597908|Cancer
1094245|NCT01597908|MEK inhibitor
1094246|NCT01597895|maraviroc
1094247|NCT01597895|boceprevir
1094248|NCT01597895|telaprevir
1094249|NCT01597895|drug interaction
1094250|NCT01597895|pharmacokinetics
1094251|NCT01597895|HIV
1094252|NCT01597882|case management
1094253|NCT01597882|long term conditions
1094254|NCT01597882|aged sixty five and over
1094255|NCT01597843|education
1094256|NCT01597843|self care
1094257|NCT01597843|peer group
1094258|NCT01597843|Computers
1094259|NCT01597843|Attitude to computers
1094260|NCT01597830|knee
1094261|NCT01597830|osteoarthritis
1094262|NCT01597830|loading
1094263|NCT01597817|Atopic dermatitis
1094264|NCT01597817|Eczema
1094265|NCT01597817|Textiles
1094266|NCT01597791|Urinary Retention
1094267|NCT01597791|Urinary Catheter
1094268|NCT01597791|Bacteriuria
1094269|NCT01597778|Haplo identical transplant
1094270|NCT01597778|Cord blood transplant
1094271|NCT01597778|Reduced intensity conditioning regimen
1094272|NCT01597778|Lymphoma
1094273|NCT01597778|Leukemia
1094274|NCT01597765|Thalassemia
1094275|NCT01597765|Oxidative stress
1094276|NCT01597765|antioxidant cocktail
1094277|NCT01597752|Immunotherapy
1094279|NCT01597752|Standardization
1094280|NCT01597752|Blomia tropicalis
1094281|NCT01597739|Active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy
1094282|NCT01597739|Disease-modifying antirheumatic drugs
1094283|NCT01597726|Abortion, Induced
1094284|NCT01597726|Laminaria
1094285|NCT01597726|Misoprostol
1094286|NCT01597726|Pregnancy Trimester, Second
1094287|NCT01597687|pertussis infection
1094288|NCT01597687|Prevalence
1094289|NCT01597687|health economic burden
1094290|NCT01597687|prolonged cough
1094291|NCT01597674|YF476
1094292|NCT01597674|gastrin receptor antagonist
1094293|NCT01597674|gastric pH
1094294|NCT01597674|gastrin
1094295|NCT01597674|healthy subjects
1094296|NCT01597661|first trimester
1094297|NCT01597661|left outflow tract obstruction
1094298|NCT01597661|Bupropion
1094299|NCT01597661|cardiovascular malformation
1094300|NCT01597661|antidepressants
1094301|NCT01597661|pregnancy
1094302|NCT01597661|cardiovascular defect
1094303|NCT01597661|congenital malformation
1094304|NCT01597648|Combivir™, HIV, bioequivalence, Combined Formulated Tablet, Combined Formulated Tablet, HIV, bioequivalence, Combivir, Selzentry™, Celsentri™, lamivudine, zidov
1094305|NCT01597635|rhACE2
1094306|NCT01597635|Acute Respiratory Distress Syndrome (ARDS)
1094307|NCT01597635|Acute Lung Injury
1094308|NCT01597635|GSK2586881
1094309|NCT01597635|critical care
1094310|NCT01597622|SELENA
1094311|NCT01597622|belimumab
1094312|NCT01597622|Lupus
1094313|NCT01597622|systemic lupus erythematosus
1094314|NCT01597622|PGA
1094315|NCT01597622|BLys
1094316|NCT01597622|SLE Flare Index
1094317|NCT01597622|continuation
1094318|NCT01597622|phase III
1094319|NCT01597622|BILAG
1094320|NCT01597622|extension
1094321|NCT01597622|efficacy
1094322|NCT01597622|SRI
1094323|NCT01597622|B cell
1094324|NCT01597622|SLEDAI
1094325|NCT01597622|safety
1094326|NCT01597622|Asia
1094327|NCT01597622|B lymphocyte
1094328|NCT01597557|Atrial Fibrillation
1094329|NCT01597557|Electrical Cardioversion
1094330|NCT01597557|Magnesium Sulfate
1094331|NCT01597544|Voiding dysfunction
1094332|NCT01597544|bladder catheter
1094333|NCT01597544|prolapse surgery
1094334|NCT01597544|patient satisfaction
1094335|NCT01597531|Liraglutide
1094336|NCT01597531|Orlistat
1094337|NCT01597518|Riluzole
1094338|NCT01597518|spinal cord injury
1094339|NCT01597518|treatment
1094340|NCT01597505|CDAD
1094341|NCT01597505|Clostridium difficile Associated Diarrhea
1094342|NCT01597505|CDI
1094343|NCT01597505|Clostridium difficile Infection
1094344|NCT01597505|Diarrhea
1094345|NCT01597492|Antibodies
1094346|NCT01597492|Vaccines
1094347|NCT01597492|SLE
1094348|NCT01597492|Immune System Diseases
1094349|NCT01597492|Biological Therapy
1094350|NCT01597492|Autoimmune Diseases
1094351|NCT01597492|Pneumococcal Vaccines
1094352|NCT01597492|Lupus
1094353|NCT01597492|Immunoglobulins
1094354|NCT01597492|Vaccination
1094355|NCT01597492|Belimumab
1094356|NCT01597492|Biological Agents
1094357|NCT01597492|Immunization
1094358|NCT01597479|Ultrasound guided distal peripheral nerve blocks
1094359|NCT01597453|Young ischemic stroke
1094360|NCT01597453|Families
1094361|NCT01597453|Long-term follow-up
1094362|NCT01597440|Propionic acidemia (PA)
1094363|NCT01597440|Methylmalonic acidemia (MMA)
1094364|NCT01597440|Carbaglu NCG
1094365|NCT01597440|Hyperammonia
1094366|NCT01597427|Clonidine
1094367|NCT01597427|Hypertension Pulmonary
1094368|NCT01597427|Cardiac Surgical Procedures
1094369|NCT01597401|Antisickling Agents
1094370|NCT01597388|Estrogen receptor positive
1094371|NCT01597388|Advanced metastatic breast cancer
1094372|NCT01597388|Estrogen receptor positive advanced metastatic breast cancer
1094373|NCT01597375|Aspirin
1094374|NCT01597375|Prasugrel
1094375|NCT01597375|Asthma
1094376|NCT01597375|AERD
1094377|NCT01597375|Aspirin challenge
1094378|NCT01597375|Aspirin desensitization
1094379|NCT01597375|Aspirin induced asthma
1094380|NCT01597362|laparoscopy
1094381|NCT01597362|trocars
1094382|NCT01597362|veress
1094383|NCT01597362|open
1094384|NCT01597362|direct
1094385|NCT01597336|abscess
1094386|NCT01597336|tPA
1094387|NCT01597323|Wrinkle Reduction
1094388|NCT01597323|Skin Resurfacing
1094389|NCT01597323|Skin Texture Improvement
1094390|NCT01597284|Oral therapies
1094391|NCT01597284|Cancer
1094392|NCT01597284|cognitive function
1094393|NCT01597284|compliance
1094394|NCT01597258|Safety
1094395|NCT01597258|All cases surveillance in Japan
1094396|NCT01597258|ALK-positive unresectable advanced and/or recurrent non-small cell lung cancer
1094397|NCT01597232|Transfusion trigger
1094398|NCT01597232|Hemoglobin level
1094399|NCT01597219|Haploidentical transplant
1094400|NCT01597219|Haematological malignancy
1094401|NCT01597219|Myeloablative
1094402|NCT01597219|Reduced intensity
1094403|NCT01597206|randomized controlled trial
1094404|NCT01597206|intervention
1094405|NCT01597206|posterior reduced dental arch
1094406|NCT01597206|patient satisfaction
1094407|NCT01597206|sequential sampling
1094408|NCT01597193|enzalutamide
1094409|NCT01597193|MDV3100
1094410|NCT01597193|breast cancer
1094411|NCT01597180|contraception
1094412|NCT01597180|HIV
1094413|NCT01597180|pharmacokinetics
1094414|NCT01597180|pharmacodynamics
1094415|NCT01597167|mild moderate treatment-resistant depression
1094416|NCT01597167|magnesium sulfate
1094417|NCT01597154|Adolescent
1094418|NCT01597154|Type 2 Diabetes
1094419|NCT01597154|Peer mentorship
1094420|NCT01597141|Prodromal
1094421|NCT01597141|Schizophrenia
1094422|NCT01597141|Psychosis
1094423|NCT01597141|Family psychoeducation
1094424|NCT01597141|Assertive community treatment
1094425|NCT01597141|Supported employment
1094426|NCT01597141|Supported education
1094427|NCT01597128|Hernia
1094428|NCT01597128|human tissue
1094429|NCT01597128|mesh
1094430|NCT01597115|duplex study
1094431|NCT01597115|hemodialysis access
1094432|NCT01597115|maturation rate
1094433|NCT01597115|endovascular intervention
1094434|NCT01597102|encephalopathy, hepatic
1094435|NCT01597102|autoregulation, cerebrovascular
1094436|NCT01597102|liver failure
1094437|NCT01597102|liver transplantation
1094438|NCT01597089|Specificity
1094439|NCT01597089|Bronchoalveolar Lavage
1094440|NCT01597089|Film Array Assay
1094441|NCT01597089|Nasopharyngeal Swab
1094442|NCT01597089|Sensitivity
1094443|NCT01597076|Morinda citrifolia
1094444|NCT01597076|noni
1094445|NCT01597076|advanced glycation end products
1094446|NCT01597076|oxidative stress
1094447|NCT01597076|quality of life
1094448|NCT01597076|metabolic syndrome
1094449|NCT01597076|safety
1094450|NCT01597050|Discoid Lupus Erythematosus
1094451|NCT01597050|Systemic Lupus Erythematosus
1094452|NCT01597037|Aphasia
1094453|NCT01597037|Speech Rehabilitation
1094454|NCT01597024|appetite
1094455|NCT01597024|food
1094456|NCT01597024|gut
1094457|NCT01597024|brain
1094458|NCT01597024|satiety
1094459|NCT01597024|hunger
1094460|NCT01597024|gut hormones
1094461|NCT01597011|Hernia, Inguinal
1094462|NCT01597011|Hernia repair
1094463|NCT01597011|Fibrin Tissue Adhesive
1094464|NCT01597011|Tisseel
1094465|NCT01597011|Tissucol
1094466|NCT01597011|Recurrence
1094467|NCT01597011|Chronic Pain
1094468|NCT01597011|Dysejaculation
1094469|NCT01596998|anesthesia, conduction
1094470|NCT01596998|transversus abdominis plane block
1094471|NCT01596998|Vasoconstrictor Agents
1094472|NCT01596998|Ultrasonography
1094473|NCT01596985|Endometrioma
1094474|NCT01596985|Endometriosis
1094475|NCT01596985|Cystectomy
1094476|NCT01596985|Ablation
1094477|NCT01596985|Plasma energy
1094478|NCT01596959|atrial flutter
1094479|NCT01596959|ablation
1094480|NCT01596959|irrigation
1094481|NCT01596959|contact
1094482|NCT01596959|ECI
1094483|NCT01596946|contact tracing
1094484|NCT01596946|home sampling
1094485|NCT01596946|cluster randomisation
1094486|NCT01596933|head and neck cancer
1094487|NCT01596933|omega-3 fatty acid supplementation
1094488|NCT01596933|echium oil
1094489|NCT01596933|weight loss
1094490|NCT01596933|cancer cachexia
1094491|NCT01596933|body composition
1094492|NCT01596933|biomarker
1094493|NCT01596933|quality of life
1094494|NCT01596920|Chronic DFUs
1094495|NCT01596920|Diabetic Foot Ulcers
1094496|NCT01596907|resting energy expenditure
1094497|NCT01596907|fat free mass
1094498|NCT01596907|lean body mass
1094499|NCT01596907|bariatric surgery
1094500|NCT01596907|morbid obesity
1094501|NCT01596907|ephedrine
1094502|NCT01596907|caffeine
1094503|NCT01596907|Low metabolic rate
1094504|NCT01596907|Low lean body mass
1094505|NCT01596907|Weight loss rate
1094506|NCT01596894|Pediatric
1094507|NCT01596894|Crohn's disease
1094508|NCT01596894|Azithromycin
1094509|NCT01596894|Metronidazole
1094510|NCT01596894|Mild to moderate Crohn's Disease
1094511|NCT01596881|Multiple sclerosis
1094512|NCT01596881|Blood flow
1094513|NCT01596881|Optical Coherence Tomography
1094514|NCT01596881|Imaging
1094515|NCT01596868|Advanced Nasopharyngeal Carcinoma
1094516|NCT01596868|treatment
1094517|NCT01596868|Northwest China
1094518|NCT01596855|Anemia
1094519|NCT01596855|Renal
1094520|NCT01596842|Omega-3 fatty acid
1094521|NCT01596842|vitamin D
1094522|NCT01596842|ergocalciferol
1094523|NCT01596842|hemodialysis
1094524|NCT01596829|antibiotic
1094525|NCT01596829|probiotic
1094526|NCT01596829|antibiotic-associated diarrhoea
1094527|NCT01596829|faecal microbiota
1094528|NCT01596816|prostate cancer
1094529|NCT01596803|FSHD
1094530|NCT01596803|Antioxidants
1094531|NCT01596803|Oxidative stress
1094532|NCT01596803|Muscle function
1094533|NCT01596803|Quality of life
1094534|NCT01596803|Activity
1094535|NCT01596803|(FSHD;4q35)
1094536|NCT01596790|Bevacizumab
1094537|NCT01596790|Circulating tumor cells
1094538|NCT01596790|Treatment efficiency
1094539|NCT01596777|Loperamide-induced obstipation
1094540|NCT01596777|Methylnaltrexone
1094541|NCT01596777|oro-cecal transit time
1094542|NCT01596777|whole gut transit time
1094543|NCT01596777|Pharmacokinetics
1094544|NCT01596764|whole-gut transit time
1094545|NCT01596764|oro-cecal transit time
1094546|NCT01596764|colon transit time
1094547|NCT01596764|loperamide-induced obstipation
1094548|NCT01596764|pharmacokinetics
1094549|NCT01596764|Methylnaltrexone
1094550|NCT01596764|Naloxone
1094551|NCT01596751|metastatic
1094552|NCT01596751|breast
1094553|NCT01596751|cancer
1094554|NCT01596751|triple
1094555|NCT01596751|negative
1094556|NCT01596751|PLX
1094557|NCT01596751|Eribulin
1094558|NCT01596738|Coronary Artery Disease
1094559|NCT01596738|Coronary Artery Bypass Graft
1094560|NCT01596738|Platelet Aggregation Inhibitors
1094561|NCT01596738|Tranexamic Acid
1094562|NCT01596712|Allergy,
1094563|NCT01596712|Asthma,
1094564|NCT01596712|Atopic dermatitis,
1094565|NCT01596712|Japanese,
1094566|NCT01596712|QGE031,
1094567|NCT01596712|IgE
1094568|NCT01596699|conditioning
1094569|NCT01596699|allogeneic
1094570|NCT01596699|hematopoietic
1094571|NCT01596699|cell
1094572|NCT01596699|transplantation
1094573|NCT01596699|HCT
1094574|NCT01596660|Tap block
1094575|NCT01596660|laparoscopic hysterectomy
1094576|NCT01596660|pain
1094577|NCT01596647|cancer, tumors, phase I, drug-drug interaction, pharmacokinetic, probe drug, caffeine, diclofenac, omeprazole, midazolam, CYP1A2, CYP2C9, CYP2C19, CYP3A4
1094578|NCT01596621|Bendamustine hydrochloride
1094579|NCT01596621|CEP-18083
1094580|NCT01596621|Treanda®
1094581|NCT01596621|Non-Hodgkin Lymphoma
1094582|NCT01596608|Magnetic seizure therapy
1094583|NCT01596608|Treatment resistance
1094584|NCT01596608|Open-label trial
1094585|NCT01596608|Treatment resistant depression
1094586|NCT01596608|Treatment resistant schizophrenia
1094587|NCT01596608|Treatment resistant obsessive-compulsive disorder
1094588|NCT01596595|ICD
1094589|NCT01596595|CRT-D
1094590|NCT01596595|Defibrillation lead
1094591|NCT01596582|Colorectal cancer screening
1094592|NCT01596582|Shared decision-making
1094593|NCT01596582|Patient preferences
1094594|NCT01596582|Risk assessment
1094595|NCT01596582|Advanced colorectal neoplasia
1094596|NCT01596569|Blast Traumatic Brain Injury
1094597|NCT01596569|Cognitive Rehabilitation
1094598|NCT01596569|Transcranial Magnetic Stimulation
1094599|NCT01596569|Combined Treatment
1094600|NCT01596556|smoking
1094601|NCT01596556|exercise
1094602|NCT01596556|heat tolerance
1094603|NCT01596556|heat stroke
1094604|NCT01596543|sleep
1094605|NCT01596543|HTT
1094606|NCT01596543|heat illness
1094607|NCT01596530|Breast Neoplasm
1094608|NCT01596530|Breast Cancer
1094609|NCT01596530|Breast Tumour
1094610|NCT01596530|Cancer of Breast
1094611|NCT01596530|Cancer of the Breast
1094612|NCT01596491|peripheral nerve injury
1094613|NCT01596491|postherpetic neuralgia
1094614|NCT01596491|PNI
1094615|NCT01596491|PHN
1094616|NCT01596491|Capsaicin
1094617|NCT01596491|QST
1094618|NCT01596491|quantitative sensory testing
1094619|NCT01596491|sensory profile
1094620|NCT01596491|neuropathic pain
1094621|NCT01596478|Gambling
1094622|NCT01596478|Pathological Gambling
1094623|NCT01596439|Healthy women
1094624|NCT01596439|consisting of a friend or relative of the patient
1094625|NCT01596426|CINV
1094626|NCT01596413|CINV
1094627|NCT01596400|CINV
1094628|NCT01596387|anaesthetics iv
1094629|NCT01596387|propofol
1094630|NCT01596387|pharmacokinetics
1094631|NCT01596387|pharmacodynamic
1094632|NCT01596348|Exercise
1094633|NCT01596348|Barriers
1094634|NCT01596348|Benefits
1094635|NCT01596348|Preferences
1094636|NCT01596348|Stages of change
1094637|NCT01596335|Infliximab
1094638|NCT01596335|REMICADE
1094639|NCT01596335|TA-650
1094640|NCT01596335|intravenous immunoglobulin
1094641|NCT01596335|Kawasaki disease
1094642|NCT01596335|IVIG
1094643|NCT01596322|HIV/AIDS in resource limited setting
1094644|NCT01596322|HIV treatment outcomes in resource limited setting
1094645|NCT01596322|Adherence to HIV treatment in resource limited setting
1094646|NCT01596322|ART resistance in resource limited setting
1094647|NCT01596309|cardiovascular risk
1094648|NCT01596309|Elderly population
1094649|NCT01596309|cocoa extract
1094650|NCT01596309|overweight and obesity
1094651|NCT01596309|Glycemic profile
1094652|NCT01596309|lipid profile
1094653|NCT01596309|antioxidant status
1094654|NCT01596309|inflammatory state
1094655|NCT01596309|Cardiovascular Risk factors in elder population
1094656|NCT01596296|labor induction
1094657|NCT01596296|transcervical foley catheter
1094658|NCT01596296|dinoprostone
1094659|NCT01596296|parous women
1094660|NCT01596283|Perioperative Fluid Management
1094661|NCT01596283|liver resection
1094662|NCT01596283|12-056
1094663|NCT01596257|CliniMACS-CD34 Reagent System
1094664|NCT01596257|Acute Leukemia
1094665|NCT01596257|Myelodysplastic syndrome
1094666|NCT01596257|Non Hodgkins Lymphoma
1094667|NCT01596257|Hodgkins Disease
1094668|NCT01596257|Multiple Myeloma
1094669|NCT01596257|12-016
1094670|NCT01596244|Diabetes Mellitus, Type II
1094671|NCT01596244|Disease management
1094672|NCT01596244|Chronic disease
1094673|NCT01596244|Prevention and control
1094674|NCT01596244|Education
1094675|NCT01596231|Alcohol consumption
1094676|NCT01596231|Kudzu extract
1094677|NCT01596218|Steroid Refractory
1094678|NCT01596218|Acute
1094679|NCT01596205|cognitive therapy
1094680|NCT01596192|allogeneic transplantation, GVHD
1094681|NCT01596192|Patients with acute GVHD after allogeneic hematopoietic cell transplantation
1094682|NCT01596179|treatment adherence
1094683|NCT01596179|fatigue
1094684|NCT01596179|symptom management
1094685|NCT01596166|migraine
1094686|NCT01596166|pediatric
1094687|NCT01596166|childhood
1094688|NCT01596166|emergency department
1094689|NCT01596166|ketorolac
1094690|NCT01596166|metoclopramide
1094691|NCT01596166|intravenous
1094692|NCT01596140|Vemurafenib
1094693|NCT01596140|Everolimus
1094694|NCT01596140|Afinitor
1094695|NCT01596140|RAD001
1094696|NCT01596140|temsirolimus
1094697|NCT01596140|BRAF gene mutation
1094698|NCT01596140|solid tumor
1094699|NCT01596140|relapsed BRAF mutation positive malignant melanoma
1094700|NCT01596140|refractory BRAF mutation positive malignant melanoma
1094701|NCT01596127|relapsed CD20+ lymphoid malignancies
1094702|NCT01596127|refractory CD20+ lymphoid malignancies
1094703|NCT01596127|Rituximab
1094704|NCT01596127|Intrathecal Rituximab
1094705|NCT01596127|CNS
1094706|NCT01596127|Leptomeningeal disease
1094707|NCT01596127|LMD
1094708|NCT01596127|central nervous system disease
1094709|NCT01596127|Relapsed lymphoid malignancies
1094710|NCT01596127|refractory lymphoid malignancies
1094711|NCT01596127|CNS leukemia
1094712|NCT01596127|intrathecal chemotherapy
1094713|NCT01596127|cerebrospinal fluid
1094714|NCT01596127|CSF
1094715|NCT01596127|lumbar puncture
1094716|NCT01596127|LP
1094717|NCT01596114|TKI
1094718|NCT01596114|CML
1094719|NCT01596114|Stopping
1094720|NCT01596114|chronic phase
1094721|NCT01596114|in remission
1094722|NCT01596088|Extravasation
1094723|NCT01596088|Anthracyclines
1094724|NCT01596075|Cannabidiol
1094725|NCT01596075|GVHD
1094726|NCT01596075|Allogeneic transplantation
1094727|NCT01596062|Basiliximab
1094728|NCT01596062|renal transplantation
1094729|NCT01596062|CNI-free
1094730|NCT01596062|everolimus
1094731|NCT01596036|cardiac rehabilitation
1094732|NCT01596036|referral
1094733|NCT01596036|enrollment
1094734|NCT01596036|timing
1094735|NCT01596023|COPD
1094736|NCT01595997|safety tolerability and immunogenicity of two different doses of DLX105 applied intra-dermally into psoriatic lesion of mild-to-moderate psoriatic patients
1094737|NCT01595984|kidney
1094738|NCT01595984|transplantation
1094739|NCT01595984|graft
1094740|NCT01595984|creatinin
1094741|NCT01595971|Asthma
1094742|NCT01595971|Continuing education
1094743|NCT01595971|Primary health care
1094744|NCT01595958|Cardiac arrest
1094745|NCT01595958|heart arrest
1094746|NCT01595958|cyclosporine A
1094747|NCT01595958|post cardiac arrest syndrome
1094748|NCT01595958|protective agent
1094749|NCT01595958|multiple organ failure
1094750|NCT01595958|mitochondrial permeability transition pore
1094751|NCT01595958|mitochondria
1094752|NCT01595958|cardio-pulmonary resuscitation
1094753|NCT01595958|cardioprotection
1094754|NCT01595958|ischemia reperfusion
1094755|NCT01595958|postconditioning
1094756|NCT01595945|Caloric restriction
1094757|NCT01595945|Obesity
1094758|NCT01595945|Gastric bypass
1094759|NCT01595945|Resting metabolic rate
1094760|NCT01595932|irritable bowel syndrome (IBS)
1094761|NCT01595932|bloating
1094762|NCT01595932|abdominal distension
1094763|NCT01595932|flatulence
1094764|NCT01595932|α-Galactosidase
1094765|NCT01595906|Helmet
1094766|NCT01595906|Heat Tolerance Test
1094767|NCT01595906|ventilation System
1094768|NCT01595893|Polymorphic light eruption
1094769|NCT01595893|Vitamin D3
1094770|NCT01595893|Photo provocation
1094771|NCT01595893|Immune function
1094772|NCT01595867|abuse liability
1094773|NCT01595867|abuse potential
1094774|NCT01595867|morphine
1094775|NCT01595867|intranasal administration
1094776|NCT01595867|snorting
1094777|NCT01595867|opioid abuse
1094778|NCT01595867|pharmacodynamic
1094779|NCT01595867|recreational drug use
1094780|NCT01595841|hemodialysis
1094781|NCT01595841|stenosis
1094782|NCT01595841|angioplasty
1094783|NCT01595841|sirolimus
1094784|NCT01595815|Fertilization failure, calcium ionophore, SrCl2
1094785|NCT01595802|Cerebral vasospasm
1094786|NCT01595789|Coronary Artery Disease
1094787|NCT01595789|Diabetes Mellitus
1094788|NCT01595789|Left ventricular ejection fraction
1094789|NCT01595789|Beta-cell function
1094790|NCT01595776|CLI, PAD, Buerger disease
1094791|NCT01595763|Deep vein thrombosis
1094792|NCT01595763|Primary care
1094793|NCT01595763|Diagnosis
1094794|NCT01595763|Clinical model
1094795|NCT01595750|Post-bronchodilator FEV1<70% reference
1094796|NCT01595750|Chronic bronchitis
1094797|NCT01595750|Presence of estavlished CVD,
1094798|NCT01595750|CVD equivalent or diabetes mellitus
1094799|NCT01595724|Non-interventional study
1094800|NCT01595724|Endometriosis,
1094801|NCT01595724|Quality of life
1094802|NCT01595698|Physical exercise
1094803|NCT01595698|IGF-1
1094804|NCT01595698|Schizophrenia
1094805|NCT01595698|neuroplasticity
1094806|NCT01595685|HBeAg-positive
1094807|NCT01595672|severe acute pancreatitis
1094808|NCT01595672|organ failure
1094809|NCT01595672|multiple organ dysfunction syndrome
1094810|NCT01595672|systemic complications
1094811|NCT01595672|continuous veno-venous hemofiltration
1094812|NCT01595672|blood purification
1094813|NCT01595672|continuous renal replacement therapy
1094814|NCT01595659|Risk
1094815|NCT01595659|Young drivers
1094816|NCT01595659|Alcohol
1094817|NCT01595659|Passengers
1094818|NCT01595659|Gender
1094819|NCT01595646|Memory
1094820|NCT01595646|Intranasal insulin
1094821|NCT01595646|Alzheimer's disease
1094822|NCT01595646|Mild Cognitive Impairment
1094823|NCT01595633|nucleoside analogue
1094824|NCT01595633|adefovir
1094825|NCT01595633|tenofovir
1094826|NCT01595633|hepatitis B
1094830|NCT01595594|Periodontal Diseases
1094831|NCT01595594|Type 2 Diabetes Mellitus
1094832|NCT01595594|hemoglobin A1c protein
1094833|NCT01595581|Testosterone
1094834|NCT01595581|ACL Reconstruction
1094835|NCT01595581|Clinical outcomes
1094836|NCT01595581|Lean mass
1094837|NCT01595581|Strength
1094838|NCT01595581|Muscle atrophy
1094839|NCT01595568|Adolescents
1094840|NCT01595568|Dual Diagnosis
1094841|NCT01595568|Mental Disorders
1094842|NCT01595568|Substance Use Problems
1094843|NCT01595568|Prevention
1094844|NCT01595555|stress
1094845|NCT01595555|relaxation
1094846|NCT01595555|mindfulness
1094847|NCT01595555|web-based
1094848|NCT01595555|online
1094849|NCT01595555|social media
1094850|NCT01595555|discussion board
1094851|NCT01595529|Urinary tract infection
1094852|NCT01595529|Antibiotic resistance
1094853|NCT01595529|Short course antibiotics
1094854|NCT01595529|Pediatrics
1094855|NCT01595529|Controlled clinical trial
1094856|NCT01595529|Anti Infective Agents
1094857|NCT01595529|Trimethoprim Sulfamethoxazole Combination
1094858|NCT01595529|Cefixime
1094859|NCT01595529|Cephalexin
1094860|NCT01595529|Trimethoprim-Sulfamethoxazole Combination
1094861|NCT01595529|Trimethoprim
1094862|NCT01595529|Sulfamethoxazole
1094863|NCT01595503|Schizophrenia, auditory hallucination
1094864|NCT01595451|Acupuncture
1094865|NCT01595451|Back Pain
1094866|NCT01595451|Lower Back Pain
1094867|NCT01595451|Brigham and Women's Hospital
1094868|NCT01595451|Massachusetts General Hospital
1094869|NCT01595451|Effects of Acupuncture
1094870|NCT01595438|Ceftazidime, Avibactam, Doripenem, Ciprofloxacin, sulfamethoxazole/trimethoprim, Anti-Infective Agents, Complicated Urinary Tract Infection,Acute Pyelonephritis
1094871|NCT01595425|Bioequivalence,
1094872|NCT01595425|pharmacokinetics,
1094873|NCT01595425|safety,
1094874|NCT01595425|esomeprazole,
1094875|NCT01595425|Japanese,
1094876|NCT01595425|healthy subject,
1094877|NCT01595425|homo-EM
1094878|NCT01595412|Laparoscopic surgery
1094879|NCT01595412|Colorectal Surgery
1094880|NCT01595412|Quality of Life
1094881|NCT01595412|Rectal Prolapse
1094882|NCT01595412|Anorectal Physiology
1094883|NCT01595399|bradycardia
1094884|NCT01595399|hypoxemia
1094885|NCT01595399|intubation
1094886|NCT01595399|premedication
1094887|NCT01595373|Ghrelin
1094888|NCT01595373|Microdialysis
1094889|NCT01595373|Controls
1094890|NCT01595373|Metabolic effects of ghrelin
1094891|NCT01595360|TT-173
1094892|NCT01595360|Topical Hemostatics
1094893|NCT01595360|Hemostasis
1094894|NCT01595347|Pressure Ulcer
1094895|NCT01595347|Primary Prevention
1094896|NCT01595347|Fatty Acids
1094897|NCT01595347|Vegetable Fats
1094898|NCT01595347|Olive oil
1094899|NCT01595347|"Pressure Ulcer[prevention and control][Mesh]"
1094900|NCT01595334|IVF-ET
1094901|NCT01595334|ICSI
1094902|NCT01595334|Gonadotrophins
1094903|NCT01595334|rFSH
1094904|NCT01595334|rLH
1094905|NCT01595334|Cetrorelix
1094906|NCT01595334|Leuprolide acetate
1094907|NCT01595321|Adjuvant therapy
1094908|NCT01595321|Immunotherapy
1094909|NCT01595321|Cytoxan
1094910|NCT01595321|Cyclophosphamide
1094911|NCT01595321|Pancreatic Vaccine
1094912|NCT01595321|Stereotactic radiation therapy
1094913|NCT01595321|SBRT
1094914|NCT01595321|FOLFIRINOX
1094915|NCT01595308|Male infertility
1094916|NCT01595295|CMML
1094917|NCT01595295|MDS
1094918|NCT01595295|AML
1094919|NCT01595295|registry
1094920|NCT01595295|Vidaza
1094921|NCT01595282|pain
1094922|NCT01595282|suction curettage
1094923|NCT01595269|Diabetes
1094924|NCT01595269|eHealth
1094925|NCT01595269|Type 2 Diabetes
1094926|NCT01595269|Education
1094927|NCT01595269|Calgary Health Region
1094928|NCT01595256|colorectal cancer,fatigue,6-minute walking test
1094929|NCT01595243|hepatocellular carcinoma
1094930|NCT01595243|Needs
1094931|NCT01595243|Telephone consultation
1094936|NCT01595217|Biliary Tract Neoplasm
1094937|NCT01595217|Cholangiocarcinoma
1094938|NCT01595217|Diffusion magnetic resonance imaging
1094939|NCT01595217|Magnetic resonance imaging
1094940|NCT01595217|Magnetic resonance Cholangiopancreatography
1094941|NCT01595204|Cancer of Ovary, laparoscopy, operability , score.
1094942|NCT01595178|smoking
1094943|NCT01595178|drinking
1094944|NCT01595178|SBIRT
1094945|NCT01595178|BNI
1094946|NCT01595178|counseling intervention
1094947|NCT01595178|emergency department
1094948|NCT01595178|adults
1094949|NCT01595165|laparoscopic cholecystectomy
1094950|NCT01595165|ultrasound
1094951|NCT01595165|transversus abdominis plane block
1094952|NCT01595152|Urgency, urgency incontinence,USIQ
1094953|NCT01595100|Waist circumference
1094954|NCT01595100|Visceral adipose tissue
1094955|NCT01595100|Intra-abdominal fat
1094956|NCT01595100|Pediatrics
1094957|NCT01595087|CRPC
1094958|NCT01595035|Day surgery
1094959|NCT01595035|Orthopedic surgery
1094960|NCT01595035|Breast reconstruction surgery
1094961|NCT01594996|Seroquel XR
1094962|NCT01594996|Quetiapine XR
1094963|NCT01594996|Drug utilization
1094964|NCT01594996|Major depressive disorder (MDD)
1094965|NCT01594983|hypertriglyceridemia
1094966|NCT01594983|Non familial Chylocmicronemia Syndrome (non-FCS)
1094967|NCT01594957|LCQ908,
1094968|NCT01594957|Hepatic Impairment,
1094969|NCT01594957|Pharmacokinetics
1094970|NCT01594931|malaria
1094971|NCT01594931|antimalarial
1094972|NCT01594931|artemisinin based combination therapy
1094973|NCT01594918|metastatic
1094974|NCT01594918|CRPC
1094975|NCT01594918|prostate
1094976|NCT01594918|CAMP
1094977|NCT01594905|To explore
1094978|NCT01594905|adequate management
1094979|NCT01594905|CHB
1094980|NCT01594905|Multidrug resistance
1094981|NCT01594892|Spinal metastases
1094982|NCT01594892|Vertebral metastases
1094983|NCT01594892|Radiosurgery
1094984|NCT01594892|Radiotherapy
1094985|NCT01594892|Stereotactic body radiotherapy
1094986|NCT01594892|Pain
1094987|NCT01594879|Endometrial cancer
1094988|NCT01594879|LNG-IUS
1094989|NCT01594879|oral MPA
1094990|NCT01594866|Major depressive disorder, remission, escitalopram
1094991|NCT01594853|exercise
1094992|NCT01594853|women
1094993|NCT01594853|training
1094994|NCT01594853|rehabilitation
1094995|NCT01594853|leukodystrophy
1094996|NCT01594840|language development
1094997|NCT01594840|parental interaction
1094998|NCT01594827|Methicillin-resistant Staphylococcus aureus
1094999|NCT01594827|Vancomycin
1095000|NCT01594814|AVNRT
1095001|NCT01594814|AVRT
1095002|NCT01594814|WPW
1095003|NCT01594801|DM
1095004|NCT01594801|insulin
1095005|NCT01594801|injections
1095006|NCT01594762|Diabetic Foot Ulcer Infection
1095007|NCT01594749|NK-1 Receptor Antagonist, CINV, Emesis, MEC
1095008|NCT01594684|restenosis
1095009|NCT01594684|stent
1095010|NCT01594684|drug eltuing balloon
1095011|NCT01594684|peripheral arterial disease
1095012|NCT01594671|primary knee arthroplasty
1095013|NCT01594671|tranexamic acid
1095014|NCT01594671|topical
1095015|NCT01594658|Ultrasound-guided foam sclerotherapy; chronic venous ulcers
1095016|NCT01594632|AE adverse event
1095017|NCT01594632|AIDS acquired immunodeficiency syndrome
1095018|NCT01594632|ALT (SGPT) alanine aminotransferase
1095019|NCT01594632|ART antiretroviral therapy
1095020|NCT01594632|AST (SGOT) aspartate aminotransferase
1095021|NCT01594632|DCF data collection forms
1095022|NCT01594632|DMC Data Monitoring Committee
1095023|NCT01594632|FDA (U.S.) Food and Drug Administration
1095024|NCT01594632|GCP Good Clinical Practice guidelines
1095025|NCT01594632|HB sAg Hepatitis B surface antigen
1095026|NCT01594632|ICH International Conference of Harmonization
1095027|NCT01594632|IND Investigational New Drug Application
1095028|NCT01594632|IRB Institutional Review Board
1095029|NCT01594632|IU International units
1095030|NCT01594632|mg milligram(s)
1095031|NCT01594632|mm3 cubic millimeter(s)
1095032|NCT01594632|PCR polymerase chain reaction
1095033|NCT01594632|SAE serious adverse event
1095034|NCT01594632|µg microgram
1095035|NCT01594632|ULN upper limit of the normal range
1095036|NCT01594632|WB Western Blot
1095037|NCT01594619|Phase 1
1095038|NCT01594619|Healthy male and female volunteers
1095039|NCT01594619|Drug-drug interaction
1095040|NCT01594619|Pharmacokinetics
1095041|NCT01594619|Naloxegol
1095042|NCT01594606|Animal-assisted intervention
1095043|NCT01594606|adjudicated adolescents
1095044|NCT01594606|empathy
1095045|NCT01594593|prostate cancer
1095046|NCT01594593|behavioral
1095047|NCT01594593|acceptance and commitment therapy
1095048|NCT01594593|distress
1095049|NCT01594567|Systematic review and meta-analysis
1095050|NCT01594567|Evidence-based medicine (EBM)
1095051|NCT01594567|Evidence-based nutrition (EBN)
1095052|NCT01594567|Clinical practice guidelines
1095053|NCT01594567|Clinical trials
1095054|NCT01594567|Dietary pulses
1095055|NCT01594567|legumes
1095056|NCT01594567|Beans, peas, chickpeas, lentils
1095057|NCT01594567|Cardiometabolic risk factors
1095058|NCT01594567|Triglycerides
1095059|NCT01594567|Cholesterol
1095060|NCT01594567|Glycemic control
1095061|NCT01594567|Insulin resistance
1095062|NCT01594567|Body weight
1095063|NCT01594567|Uric acid
1095064|NCT01594567|Blood pressure
1095065|NCT01594554|HCV viral genotypes
1095066|NCT01594554|host genotypes
1095067|NCT01594554|IL28B
1095068|NCT01594554|Outcome
1095069|NCT01594554|Follow-Up
1095070|NCT01594554|ITPA
1095071|NCT01594554|RNA
1095072|NCT01594554|China
1095073|NCT01594541|hyperhomocysteinemia
1095074|NCT01594541|dementia
1095075|NCT01594541|depression
1095076|NCT01594541|vitamin B12
1095077|NCT01594541|mild cognitive impairment
1095078|NCT01594541|alzheimer's
1095079|NCT01594528|schizophrenia
1095080|NCT01594528|major depression
1095081|NCT01594528|pain
1095082|NCT01594528|behavior
1095083|NCT01594502|prostate cancer
1095084|NCT01594502|dutasteride
1095085|NCT01594476|Postpartum
1095086|NCT01594476|Contraception
1095087|NCT01594476|Intrauterine device
1095088|NCT01594476|Intrauterine system
1095089|NCT01594476|Mirena
1095090|NCT01594476|Paragard
1095091|NCT01594476|Uterine involution
1095092|NCT01594463|Intrauterine growth restriction
1095093|NCT01594463|Screening
1095094|NCT01594463|Ultrasound
1095095|NCT01594463|Perinatal morbidity
1095096|NCT01594463|Maternal complications
1095097|NCT01594450|incisional ventral hernia
1095098|NCT01594450|infected field
1095099|NCT01594450|biological mesh
1095100|NCT01594437|Cytomegalovirus
1095101|NCT01594437|Monoclonal antibody
1095102|NCT01594424|Donor-Specific Anti-HLA Antibodies
1095103|NCT01594424|Kidney Transplantation
1095104|NCT01594411|Coronary Artery Disease
1095105|NCT01594411|Chest Pain
1095106|NCT01594411|Diagnosis of cardiovascular disease
1095107|NCT01594398|carcinoma,non small cell lung
1095108|NCT01594398|lung diseases
1095109|NCT01594398|lung neoplasms
1095110|NCT01594398|Respiratory
1095111|NCT01594398|Carcinoma, Bronchogenic
1095112|NCT01594398|Bronchial Neoplasms
1095113|NCT01594398|Respiratory Tract Neoplasms
1095114|NCT01594398|Thoracic Neoplasms
1095115|NCT01594398|Neoplasms by Site
1095116|NCT01594398|Respiratory Tract Diseases
1095117|NCT01594398|Erlotinib
1095118|NCT01594398|Protein Kinase Inhibitors
1095119|NCT01594398|Breast Neoplasms
1095120|NCT01594398|Neoplasms
1095121|NCT01594398|Breast Diseases
1095122|NCT01594398|Exemestane
1095123|NCT01594398|Aromatase Inhibitors
1095124|NCT01594385|Open Abdomen
1095125|NCT01594385|Damage Control
1095126|NCT01594385|Trauma
1095127|NCT01594385|Wound healing
1095128|NCT01594385|Gun shot wounds
1095129|NCT01594385|Stab wounds
1095130|NCT01594385|Automobile accidents
1095131|NCT01594385|Wounds and Injury
1095132|NCT01594372|Uterine Prolapse
1095133|NCT01594372|Laparoscopy
1095134|NCT01594372|Hysterectomy, vaginal
1095135|NCT01594359|Ferritin
1095136|NCT01594346|Vitamin E
1095137|NCT01594346|alpha-tocopherol
1095138|NCT01594346|cognitive decline
1095139|NCT01594346|Down syndrome
1095140|NCT01594346|Aging
1095141|NCT01594346|Dementia
1095142|NCT01594333|Myocardial Infarction
1095143|NCT01594333|Stroke
1095144|NCT01594333|Cardiovascular death
1095145|NCT01594333|Type 2 Diabetes
1095146|NCT01594333|Metabolic Syndrome
1095147|NCT01594333|Cardiovascular Inflammation
1095148|NCT01594333|Atherothrombosis
1095149|NCT01594307|BP
1095150|NCT01594294|CLEAR CARE®
1095151|NCT01594294|AOSEPT® Plus
1095152|NCT01594294|ReNu MultiPlus®
1095153|NCT01594294|silicone hydrogel
1095154|NCT01594294|hydrogel
1095155|NCT01594294|ACUVUE® 2®
1095156|NCT01594294|AIR OPTIX® AQUA
1095157|NCT01594294|eyelid response
1095158|NCT01594294|wettability
1095159|NCT01594294|contamination
1095160|NCT01594294|contact lenses
1095161|NCT01594281|Panretinal photocoagulation
1095162|NCT01594281|Ranibizumab
1095163|NCT01594268|kidney transplant
1095164|NCT01594268|Certican
1095165|NCT01594255|Healthy volunteer
1095166|NCT01594255|QT intervals
1095167|NCT01594255|ECG
1095168|NCT01594255|QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs
1095169|NCT01594242|multiple myeloma
1095170|NCT01594242|bortezomib
1095171|NCT01594242|proteasome inhibitor
1095172|NCT01594229|ABT-199
1095173|NCT01594229|Cancer
1095174|NCT01594229|Preliminary Efficacy
1095175|NCT01594229|Non-Hodgkin's Lymphoma
1095176|NCT01594229|Rituximab
1095177|NCT01594229|Bendamustine
1095178|NCT01594229|Pharmacokinetics
1095179|NCT01594229|Maximum Tolerated Dose
1095180|NCT01594229|Safety
1095181|NCT01594216|Postmenopausal female
1095182|NCT01594203|Soft Tissue Sarcoma
1095183|NCT01594203|Pazopanib
1095184|NCT01594203|F18-FDG PET/CT
1095185|NCT01594177|DAFNE
1095186|NCT01594177|GBG 70
1095187|NCT01594177|GBG
1095188|NCT01594177|German Breast Group
1095189|NCT01594177|GBG Forschungs GmbH
1095190|NCT01594177|Afatinib
1095191|NCT01594177|neo-adjuvant
1095192|NCT01594177|HER-2 positive breast cancer
1095193|NCT01594177|BIBW 2992
1095194|NCT01594177|1200.159
1095195|NCT01594164|High Resolution Computed Tomography
1095196|NCT01594164|Cone Beam Computed Tomography
1095197|NCT01594164|upper airway
1095198|NCT01594164|geometry
1095199|NCT01594151|asthma
1095200|NCT01594151|controlled
1095201|NCT01594151|Cone Beam Computed Tomography
1095202|NCT01594151|upper airway
1095203|NCT01594151|paediatric
1095204|NCT01594112|Remote monitoring
1095205|NCT01594112|Home monitoring
1095206|NCT01594112|Defibrillators, Implantable cardioverter-defibrillator
1095207|NCT01594112|Shock
1095208|NCT01594112|Inappropriate diagnoses and Therapies
1095209|NCT01594112|Corrective actions
1095210|NCT01594112|ID recurrences
1095211|NCT01594112|Medical reaction time
1095212|NCT01594099|cervical cancer
1095213|NCT01594099|elderly women
1095214|NCT01594099|concurrent chemotherapy
1095215|NCT01594086|green tea
1095216|NCT01594086|aging
1095217|NCT01594086|atherosclerosis
1095218|NCT01594086|homocysteine
1095219|NCT01594086|cognitive impairment
1095220|NCT01594073|implantable defibrillator
1095221|NCT01594073|ventricular arrhythmias
1095222|NCT01594073|cardiac death
1095223|NCT01594047|hyperalgesia
1095224|NCT01594047|Patient controlled analgesia
1095225|NCT01594047|morphine
1095226|NCT01594047|methadone
1095227|NCT01594047|ketamine
1095228|NCT01594021|propofol
1095229|NCT01594021|anesthesia, induction
1095230|NCT01594021|hypotension
1095231|NCT01594021|cardiac output
1095232|NCT01594008|Toll like receptors
1095233|NCT01594008|Inflammation
1095234|NCT01594008|Anthocyanins
1095235|NCT01594008|Blueberries
1095236|NCT01593995|Erlotinib
1095237|NCT01593995|Skin side effect
1095238|NCT01593995|EGF ointment
1095239|NCT01593982|Repetitive Transcranial Magnetic Stimulation
1095240|NCT01593982|Cocaine Dependence
1095241|NCT01593982|Cocaine Addicts
1095242|NCT01593982|Attention Deficit Hyperactivity Disorder
1095243|NCT01593982|Cognitive Function
1095244|NCT01593969|Essential Fatty Acid
1095245|NCT01593969|Seed oil
1095246|NCT01593969|Fish oil
1095247|NCT01593969|Dietary deficiency
1095248|NCT01593943|contraception
1095249|NCT01593943|india
1095250|NCT01593943|rural
1095251|NCT01593930|Pulp Anesthesia
1095252|NCT01593930|Articaine
1095253|NCT01593930|Lidocaine
1095254|NCT01593917|Aortic valve
1095255|NCT01593917|Heart valve
1095256|NCT01593917|Tissue valve
1095257|NCT01593917|Bioprosthesis
1095258|NCT01593904|CCSVI, Flow, Perfusion in MS
1095259|NCT01593891|IVUS, CCSVI
1095260|NCT01593865|Coronary Artery Bypass Grafting
1095261|NCT01593865|Mammary Artery Grafts
1095763|NCT01591772|functional MRI
1095262|NCT01593865|Bilateral Mammary Artery Grafting
1095263|NCT01593865|Clinical Outcomes
1095264|NCT01593852|X-rays
1095265|NCT01593852|Cardiac Electrophysiology
1095266|NCT01593852|Image Processing, Computer-Assisted
1095267|NCT01593852|Catheter Ablation
1095268|NCT01593813|Pronator quadratus
1095269|NCT01593813|distal radius fracture
1095270|NCT01593813|volar plating
1095271|NCT01593800|Probiotics
1095272|NCT01593800|Lactose
1095273|NCT01593787|Hypertension
1095274|NCT01593787|Renal dysfunction
1095275|NCT01593787|LCZ696
1095276|NCT01593774|Melatonin
1095277|NCT01593774|Olanzapine
1095278|NCT01593774|Metabolic side effects
1095279|NCT01593774|Psychosis
1095280|NCT01593774|Hyperlipidemia
1095281|NCT01593774|Hyperglycemia
1095282|NCT01593774|Weight gain
1095283|NCT01593774|Diabetes
1095284|NCT01593761|cABSSSI
1095285|NCT01593761|MRSA
1095286|NCT01593748|Sarcoma
1095287|NCT01593748|Soft Tissue Sarcoma
1095288|NCT01593722|Loa loa
1095289|NCT01593722|Immune Response
1095290|NCT01593722|Therapy
1095291|NCT01593709|Healthy Volunteers
1095292|NCT01593696|CD 19 Expressing B Cells
1095293|NCT01593696|B Cell Lymphoma
1095294|NCT01593696|ALL
1095295|NCT01593696|Anti-CD19 Chimeric Antigen Receptor
1095296|NCT01593696|Adoptive Immunotherapy
1095297|NCT01593683|Oncology service
1095298|NCT01593683|Nursing staff
1095299|NCT01593683|Psychosocial intervention
1095300|NCT01593683|Coping skills
1095301|NCT01593670|high risk myelodysplastic syndrome
1095302|NCT01593670|natural killer cells
1095303|NCT01593644|Dipyridamole/adenosine combination given intravenously
1095304|NCT01593644|slow bolus and low doses
1095305|NCT01593644|coronary flow reserve assessment
1095306|NCT01593644|transthoracic echodoppler
1095307|NCT01593644|Patients
1095308|NCT01593644|stable
1095309|NCT01593631|lactose malabsorption
1095310|NCT01593631|lactose intolerance
1095311|NCT01593631|lactose digestion
1095312|NCT01593631|lactose maldigestion
1095313|NCT01593631|acid lactase
1095314|NCT01593631|yoghurt bacteria
1095315|NCT01593618|cancer survivor
1095316|NCT01593605|Impaired glucose tolerance, pre-diabetes,glycemic control,
1095317|NCT01593605|supplements
1095318|NCT01593592|Helicobacter pylori
1095319|NCT01593592|Lactobacillus reuteri
1095320|NCT01593592|dyspeptic patients
1095321|NCT01593592|eradication
1095322|NCT01593579|melanoma
1095323|NCT01593579|autonomic failure
1095324|NCT01593579|hypotension
1095325|NCT01593579|akt therapy
1095326|NCT01593566|femoral nerve block
1095327|NCT01593553|Screening
1095328|NCT01593553|Stroke prevention
1095329|NCT01593553|Cost effectiveness
1095330|NCT01593527|Frequent flares
1095331|NCT01593527|Frequent attacks
1095332|NCT01593527|gout
1095333|NCT01593527|gouty arthritis
1095334|NCT01593527|Chronic kidney disease
1095335|NCT01593527|renal impairment
1095336|NCT01593527|Anti-interleukin-1β monoclonal antibody
1095337|NCT01593527|anti-inflammatory therapy
1095338|NCT01593514|Vaccines
1095339|NCT01593514|Meningitis
1095340|NCT01593514|Meningococcal
1095341|NCT01593501|vitamin D
1095342|NCT01593501|cholecalciferol
1095343|NCT01593501|bone mineral density
1095344|NCT01593501|Magnesium deficiency
1095345|NCT01593501|Calcium metabolism disorders
1095346|NCT01593488|recurrent
1095347|NCT01593488|CNS disease
1095348|NCT01593488|intrathecal therapy
1095349|NCT01593436|insomnia,menopause, polysomnography, mindfulness
1095350|NCT01593410|Efficacy/Safety
1095351|NCT01593410|Lenalidomide and Low-Dose Dexamethasone
1095352|NCT01593410|Chinese Subjects
1095353|NCT01593410|Relapsed/Refractory Multiple Myeloma
1095354|NCT01593397|Obesity
1095355|NCT01593397|Insulin Resistance
1095356|NCT01593384|Breast Cancer
1095357|NCT01593384|Digital Breast Tomosynthesis (DBT)
1095358|NCT01593384|Digital Mammography (DM)
1095359|NCT01593371|Adipokines
1095360|NCT01593371|leptin
1095361|NCT01593371|chemerin
1095362|NCT01593371|omentin
1095363|NCT01593371|metformin
1095364|NCT01593371|type 2 diabetes mellitus
1095365|NCT01593358|CCSVI
1095366|NCT01593345|Elderly
1095367|NCT01593345|mobility limitations
1095368|NCT01593345|self-management
1095369|NCT01593345|exercise
1095370|NCT01593332|Rituximab
1095371|NCT01593332|Rheumatoid arthritis
1095372|NCT01593332|Biologics
1095373|NCT01593332|Anti-tumour necrosis factor
1095374|NCT01593332|Disease-modifying anti-rheumatic drugs
1095375|NCT01593332|DAS28
1095376|NCT01593332|European League Against Rheumatism response
1095377|NCT01593293|Elderly patients
1095378|NCT01593293|Non-squamous Non-small Cell Lung Cancer
1095379|NCT01593293|Pemetrexed
1095380|NCT01593293|Carboplatin
1095381|NCT01593280|anesthesia
1095382|NCT01593280|regional anesthetic techniques: transversus abdominis plane block,
1095383|NCT01593280|pain, postoperative
1095384|NCT01593280|surgery, cesarean section
1095385|NCT01593280|quality of recovery
1095386|NCT01593267|intracranial aneurysm
1095387|NCT01593267|subarachnoid hemorrhage
1095388|NCT01593267|randomized trial
1095389|NCT01593267|coil embolization
1095390|NCT01593267|clip occlusion
1095391|NCT01593267|vascular disorders
1095392|NCT01593241|Seminoma IIA/B
1095393|NCT01593241|Carboplatin
1095394|NCT01593241|RT
1095395|NCT01593215|genetics
1095396|NCT01593215|type 2 diabetes
1095397|NCT01593215|insulin secretion
1095398|NCT01593189|developmental disabilities
1095399|NCT01593189|school readiness
1095400|NCT01593189|literacy
1095401|NCT01593189|social emotional skills
1095402|NCT01593189|self regulation
1095403|NCT01593189|caregiver involvement
1095404|NCT01593176|Femur
1095405|NCT01593176|Fracture
1095406|NCT01593176|Radiostereometric Analysis
1095407|NCT01593163|Functional echocardiography
1095408|NCT01593163|power Doppler cranial ultrasonography
1095409|NCT01593163|N-terminal probrain natriuretic peptide
1095410|NCT01593163|Patent ductus arteriosus
1095411|NCT01593150|Atrial Fibrillation
1095412|NCT01593150|TEE
1095413|NCT01593150|Early versus late DC cardioversion.
1095414|NCT01593124|Vaginal innate immune and inflammatory responses
1095415|NCT01593111|Allergies
1095416|NCT01593111|Asthma
1095417|NCT01593111|Environmental
1095418|NCT01593111|NYC
1095419|NCT01593111|Manhattan
1095420|NCT01593111|Harlem
1095421|NCT01593111|Bronx
1095422|NCT01593111|Brooklyn
1095423|NCT01593111|Breathing
1095424|NCT01593111|eNO
1095425|NCT01593111|IgE
1095426|NCT01593111|Allergens
1095427|NCT01593111|Cockroach
1095428|NCT01593111|Dust mites
1095429|NCT01593111|Pets
1095430|NCT01593098|siblings
1095431|NCT01593098|advanced neoplasm
1095432|NCT01593098|mRNA
1095433|NCT01593098|TaqMan microRNA expression assays
1095434|NCT01593085|palliative cares
1095435|NCT01593085|cancer
1095436|NCT01593085|suicide risk
1095437|NCT01593072|Multiple Ascending Dose (MAD)
1095438|NCT01593072|Ebola Virus
1095439|NCT01593072|Post Exposure Prophylaxis
1095440|NCT01593072|EHF
1095441|NCT01593059|International
1095442|NCT01593059|Multicenter
1095443|NCT01593059|Observational registry
1095444|NCT01593059|Orsiro Drug Eluting Stent (DES)
1095445|NCT01593059|Stenting
1095446|NCT01593059|Treatment of Coronary Artery Disease
1095447|NCT01593059|Coronary revascularization
1095448|NCT01593059|Percutaneous Coronary Intervention
1095449|NCT01593059|STEMI
1095450|NCT01593059|NSTEMI
1095451|NCT01593059|Ischemia
1095452|NCT01593059|Angina
1095453|NCT01593059|Subgroups
1095454|NCT01593059|Acute Myocardial Infarction
1095455|NCT01593059|Diabetes
1095456|NCT01593059|Small Vessels
1095457|NCT01593059|Chronic Total Occlusion (CTO)
1095458|NCT01593046|GSK1265744 LAP
1095459|NCT01593046|integrase inhibitor
1095460|NCT01593046|healthy subjects
1095461|NCT01593046|TMC278 LA
1095462|NCT01593046|GSK1265744LAP
1095463|NCT01593046|long acting retroviral
1095464|NCT01593046|HIV-1 infection
1095465|NCT01593020|Breast cancer
1095466|NCT01593020|Early Stage Breast Cancer Not Overexpressing HER-2
1095467|NCT01593020|Primary invasive adenocarcinoma of the breast
1095468|NCT01593020|Paclitaxel
1095469|NCT01593020|Taxol
1095470|NCT01593020|Eribulin
1095471|NCT01593020|E7389
1095472|NCT01593020|5-Fluorouracil
1095473|NCT01593020|5-FU
1095474|NCT01593020|Adrucil
1095475|NCT01593020|Efudex
1095476|NCT01593020|Epirubicin
1095477|NCT01593020|Ellence
1095478|NCT01593020|Cyclophosphamide
1095479|NCT01593020|Cytoxan
1095480|NCT01593020|Neosar
1095481|NCT01593020|Doxorubicin
1095482|NCT01593020|Doxorubicin hydrochloride
1095483|NCT01593020|Adriamycin PFS
1095484|NCT01593020|Adriamycin RDF
1095485|NCT01593020|Adriamycin
1095486|NCT01593020|Rubex
1095487|NCT01593007|Heart failure
1095488|NCT01593007|respiratory muscles
1095489|NCT01593007|optoelectronic plethysmography
1095490|NCT01592994|HIV
1095491|NCT01592994|condom use
1095492|NCT01592994|India
1095493|NCT01592994|women
1095494|NCT01592981|Waldenstrom's macroglobulinaemia
1095495|NCT01592981|bortezomib
1095496|NCT01592981|cyclophosphamide
1095497|NCT01592981|rituximab
1095498|NCT01592968|Brain Neoplasms
1095499|NCT01592968|Non-melanoma brain metastases
1095500|NCT01592968|Stereotactic radiosurgery
1095501|NCT01592968|SRS
1095502|NCT01592968|Whole brain radiation therapy
1095503|NCT01592968|WBRT
1095504|NCT01592955|Glaucoma
1095505|NCT01592955|Cyclocoagulation
1095506|NCT01592955|HIFU High Intensity Focused Ultrasound
1095507|NCT01592942|inguinal hernia
1095508|NCT01592942|mesh fixation
1095509|NCT01592942|glue
1095510|NCT01592942|Lichtenstein
1095893|NCT01591200|Cirrhosis
1095511|NCT01592929|Functional Respiratory Imaging
1095512|NCT01592929|Magnetic Resonance Imaging
1095513|NCT01592929|MRI
1095514|NCT01592929|Pharyngometry
1095515|NCT01592929|Upper Airway
1095516|NCT01592929|Mouthpiece of Inhaler
1095517|NCT01592929|Cone Beam Computed Tomography
1095518|NCT01592929|CBCT
1095519|NCT01592929|Computed Tomography
1095520|NCT01592929|CT
1095521|NCT01592916|Fibromyalgia
1095522|NCT01592916|Pain
1095523|NCT01592916|Women
1095524|NCT01592916|Exercise
1095525|NCT01592916|IGF1
1095526|NCT01592903|Uterine fibroids
1095527|NCT01592903|somatic stem cell
1095528|NCT01592903|Side Population
1095529|NCT01592877|UWB
1095530|NCT01592877|non-contact
1095531|NCT01592877|patient monitor
1095532|NCT01592838|Belgium
1095533|NCT01592838|Quality of hospital care
1095534|NCT01592838|Rotavirus vaccination
1095535|NCT01592825|Breast Cancer
1095536|NCT01592825|Prognostic factor
1095537|NCT01592825|uPA/PA-1
1095538|NCT01592825|cohort
1095539|NCT01592799|Influenza
1095540|NCT01592799|Children
1095541|NCT01592799|Hospitalizations
1095542|NCT01592799|Spain
1095543|NCT01592799|Burden
1095544|NCT01592786|Autism Spectrum Disorder (ASD)
1095545|NCT01592786|Autism
1095546|NCT01592786|Autistic Disorder
1095547|NCT01592786|Asperger's Disorder
1095548|NCT01592786|Asperger's
1095549|NCT01592786|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
1095550|NCT01592786|Memantine
1095551|NCT01592786|Pediatric Disorder
1095552|NCT01592773|Autistic Disorder
1095553|NCT01592773|Asperger's Disorder
1095554|NCT01592773|Asperger's
1095555|NCT01592773|Pediatric Autism
1095556|NCT01592773|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
1095557|NCT01592773|Pervasive Child Development Disorder
1095558|NCT01592760|air-Q SP
1095559|NCT01592760|air-Q
1095560|NCT01592760|i-gel
1095561|NCT01592760|supraglottic airway device
1095562|NCT01592760|laryngeal mask airway
1095563|NCT01592747|Asperger's
1095564|NCT01592747|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
1095565|NCT01592747|Memantine
1095566|NCT01592747|Pervasive Child Development Disorder
1095567|NCT01592747|Pediatric Disorder
1095568|NCT01592747|Randomized Controlled Trial
1095569|NCT01592734|chronic constipation
1095570|NCT01592734|faecal impaction
1095571|NCT01592734|PEG-only laxative
1095572|NCT01592721|Carcinoma
1095573|NCT01592721|Squamous cell carcinoma
1095574|NCT01592721|Head and neck neoplasms
1095575|NCT01592721|Cetuximab
1095576|NCT01592708|orthognathic surgery
1095577|NCT01592708|maxillary osteotomy
1095578|NCT01592708|post operative nausea vomiting
1095579|NCT01592708|post discharge nausea vomiting
1095580|NCT01592708|anesthesia
1095581|NCT01592695|Nicotine dependence
1095582|NCT01592695|Smoking cessation
1095583|NCT01592695|Telehealth
1095584|NCT01592695|Alcohol use
1095585|NCT01592695|Depression
1095586|NCT01592695|Body weight
1095587|NCT01592682|tobacco
1095588|NCT01592682|secondhand smoke
1095589|NCT01592682|Chinese
1095590|NCT01592682|NNAL
1095591|NCT01592669|Passive leg raising, blood pressure, heart rate
1095592|NCT01592656|Chronic Obstructive Pulmonary Disease
1095593|NCT01592656|GOLD stages II, III and IV
1095594|NCT01592656|Computed Tomography scan
1095595|NCT01592656|Functional Respiratory Imaging
1095596|NCT01592656|Non-Invasive Ventilation
1095597|NCT01592656|Arterial Blood Gas
1095598|NCT01592656|Hypercapnic
1095599|NCT01592656|Health Related Quality of Life
1095600|NCT01592656|Lung compliance
1095601|NCT01592643|Corneal shield
1095602|NCT01592643|PRK
1095603|NCT01592643|Myopia
1095604|NCT01592643|Pain
1095605|NCT01592643|Vision
1095606|NCT01592617|cancer vaccine
1095607|NCT01592617|HLA-A*24:02
1095608|NCT01592617|lung cancer
1095609|NCT01592617|CTL
1095610|NCT01592604|fracture
1095611|NCT01592604|fifth metatarsal
1095612|NCT01592604|functioanl outcome
1095613|NCT01592578|gastroesophgeal variceal bleeding
1095614|NCT01592578|liver cirrhosis
1095615|NCT01592578|portal hypertension
1095616|NCT01592552|Alzheimer's Disease
1095617|NCT01592552|Multiple Sclerosis
1095618|NCT01592552|Parkinson's Disease
1095619|NCT01592552|Huntington's Disease
1095620|NCT01592552|Amyotrophic Lateral Sclerosis (ALS)
1095621|NCT01592539|Type 1 Diabetes
1095622|NCT01592539|Bone
1095623|NCT01592526|Systemic inflammatory response.
1095624|NCT01592526|Autonomic nervous regulation.
1095625|NCT01592526|Cholinergic antiinflammatory pathway
1095626|NCT01592500|GHD
1095627|NCT01592500|r-hGH
1095628|NCT01592500|Long-acting
1095629|NCT01592474|Multiple Sclerosis
1095630|NCT01592474|Avonex
1095631|NCT01592474|Brain atrophy
1095632|NCT01592474|MRI
1095633|NCT01592474|Interferon-beta 1a
1095634|NCT01592474|IFN Beta 1-a
1095635|NCT01592474|Clinically isolated syndrome
1095636|NCT01592474|CIS
1095637|NCT01592461|Substance abuse treatment outcomes
1095638|NCT01592461|Opioid dependence
1095639|NCT01592461|Suboxone
1095640|NCT01592461|Methadone
1095641|NCT01592448|Acetaminophen
1095642|NCT01592448|Patient Safety
1095643|NCT01592448|Health Literacy
1095644|NCT01592422|Small cell lung cancer
1095645|NCT01592422|Maintenance therapy
1095646|NCT01592422|Immunotherapy
1095647|NCT01592422|Autologous cytokine-induced killer cell
1095648|NCT01592409|cannabis impaired driving
1095649|NCT01592409|driving simulation
1095650|NCT01592409|acute psychopharmacologic effects of cannabis
1095651|NCT01592409|residual effects of cannabis
1095652|NCT01592409|young drivers
1095653|NCT01592396|Tralokinumab
1095654|NCT01592396|CAT-354
1095655|NCT01592396|Asthma
1095656|NCT01592357|cardiac rehabilitation
1095657|NCT01592357|gait speed
1095658|NCT01592357|mind body exercise
1095659|NCT01592357|tai chi
1095660|NCT01592357|cardiac disease
1095661|NCT01592357|frail elderly
1095662|NCT01592344|Chronic pain
1095663|NCT01592344|peripheral nerve
1095664|NCT01592344|neuralgia
1095665|NCT01592344|somatosensory nervous system
1095666|NCT01592266|FLT
1095667|NCT01592266|PET
1095668|NCT01592266|bone marrow
1095669|NCT01592266|AML
1095670|NCT01592240|PF-04950615
1095671|NCT01592240|RN316
1095672|NCT01592227|healthy volunteer
1095673|NCT01592227|pharmacokinetics
1095674|NCT01592227|paracetamol
1095675|NCT01592214|Staphylococcus aureus, nasal decolonization, XF-73, gel formulation
1095676|NCT01592201|Schizophrenia
1095677|NCT01592201|Paliperidone ER
1095678|NCT01592201|Antipsychotics
1095679|NCT01592201|Mental disorder
1095680|NCT01592201|Comparative study
1095681|NCT01592188|meditation, inflammation, children, attention
1095682|NCT01592149|Appetite
1095683|NCT01592136|Ponatinib
1095684|NCT01592136|Tyrosine kinase inhibitor
1095685|NCT01592123|anxiety
1095686|NCT01592123|septal surgery
1095687|NCT01592123|septum deviation
1095688|NCT01592123|sleep
1095689|NCT01592110|Schizophrenia
1095690|NCT01592097|Multiple Sclerosis
1095691|NCT01592097|MS
1095692|NCT01592097|Autoimmune
1095693|NCT01592084|lipid lowering therapy
1095694|NCT01592084|survival
1095695|NCT01592084|ALSFRS
1095696|NCT01592084|age
1095697|NCT01592084|BMI
1095698|NCT01592084|weight
1095699|NCT01592071|food sensitivity
1095700|NCT01592071|IgG
1095701|NCT01592071|obesity
1095702|NCT01592071|overweight
1095703|NCT01592071|body composition
1095704|NCT01592071|reactive foods
1095705|NCT01592058|weight change
1095706|NCT01592058|contraception
1095707|NCT01592058|birth control
1095708|NCT01592058|progestin
1095709|NCT01592058|progestin only
1095710|NCT01592058|weight gain
1095711|NCT01592058|depo
1095712|NCT01592058|Depo Provera
1095713|NCT01592058|DMPA
1095714|NCT01592058|IUD
1095715|NCT01592058|IUC
1095716|NCT01592058|Mirena
1095717|NCT01592058|Paragard
1095718|NCT01592058|Implanon
1095719|NCT01592058|implant
1095720|NCT01592032|Antibiotic-lock technique.
1095721|NCT01592032|In vivo antimicrobial concentration.
1095722|NCT01592032|Antimicrobial bioactivity.
1095723|NCT01592006|hepatitis C virus
1095724|NCT01592006|liver transplant recipient
1095725|NCT01591993|Sensitive skin
1095726|NCT01591993|Lactic acid test
1095727|NCT01591993|Transepidermal water loss
1095728|NCT01591993|Colorimetry
1095729|NCT01591993|Capacitance
1095730|NCT01591980|post-craniotomy pain
1095731|NCT01591980|pregabalin
1095732|NCT01591980|chronic post-craniotomy headache
1095733|NCT01591980|Craniotomy
1095734|NCT01591967|Chiropractic
1095735|NCT01591967|Blood pressure
1095736|NCT01591967|Pulse Rate
1095737|NCT01591967|Thoracic
1095738|NCT01591941|ACL, Knee , Injury,
1095739|NCT01591928|Pediatrics
1095740|NCT01591928|Congenital heart disease
1095741|NCT01591928|Heterotaxy syndrome
1095742|NCT01591928|Intestinal malrotation
1095743|NCT01591915|Breast cancer, Mindfulness Based Stress Reduction, RCT, mood, cooping, health related quality of life
1095744|NCT01591876|exercise
1095745|NCT01591876|kidney disease
1095746|NCT01591876|vascular function
1095747|NCT01591876|haemodialysis
1095748|NCT01591863|Clostridium difficile-associated diarrhea
1095749|NCT01591863|CDAD
1095750|NCT01591863|Pediatric
1095751|NCT01591798|Rectal cancer
1095752|NCT01591798|Robotic surgery
1095753|NCT01591798|Laparoscopic surgery
1095754|NCT01591785|Hand
1095755|NCT01591785|Foot
1095756|NCT01591785|Eczema
1095757|NCT01591785|Atopic Dermatitis
1095758|NCT01591772|FALLOPIAN TUBE
1095759|NCT01591772|OVARY
1095760|NCT01591772|PERITONEUM
1095761|NCT01591772|Quality of Life
1095762|NCT01591772|structural MRI
1095764|NCT01591772|neuropsychological assessment
1095765|NCT01591772|12-075
1095766|NCT01591759|citicoline
1095767|NCT01591759|cognitive function
1095768|NCT01591759|function magnetic resonance imaging
1095769|NCT01591759|magnetic resonance spectroscopy
1095770|NCT01591759|diffusion tensor imaging
1095771|NCT01591746|Mastectomy
1095772|NCT01591746|Mammaplasty
1095773|NCT01591746|Breast reconstruction
1095774|NCT01591746|Tissue expansion
1095775|NCT01591746|Botulinum toxins, Type A
1095776|NCT01591746|Quality of Life
1095777|NCT01591746|Acellular dermal matrix
1095778|NCT01591733|Borderline resectable
1095779|NCT01591707|autism spectrum disorders
1095780|NCT01591707|school
1095781|NCT01591707|language
1095782|NCT01591707|social
1095783|NCT01591694|child trauma
1095784|NCT01591694|maltreatment
1095785|NCT01591694|physical abuse
1095786|NCT01591694|sexual abuse
1095787|NCT01591694|emotional abuse
1095788|NCT01591694|abandonment
1095789|NCT01591694|domestic violence
1095790|NCT01591694|community violence
1095791|NCT01591681|Type 1 Diabetes
1095792|NCT01591681|Hypoglycemia
1095793|NCT01591681|Continuous Glucose Monitoring
1095794|NCT01591681|Pump Suspension
1095795|NCT01591668|Hepatitis
1095796|NCT01591668|Hepatitis C
1095797|NCT01591668|Chronic HCV
1095798|NCT01591668|HCV
1095799|NCT01591668|Treatment Naive
1095800|NCT01591668|Gilead
1095801|NCT01591668|GS-9620
1095802|NCT01591642|physical activity
1095803|NCT01591642|functional fitness
1095804|NCT01591642|quality of life
1095810|NCT01591590|Colorectal Cancer
1095811|NCT01591590|Cancer
1095812|NCT01591590|Colon Cancer
1095813|NCT01591590|Rectal Cancer
1095814|NCT01591590|PET
1095815|NCT01591590|PET-CT
1095816|NCT01591590|MRI
1095817|NCT01591590|Diffusion MRI
1095818|NCT01591590|Apparent Diffusion Coefficient
1095819|NCT01591590|ADC
1095820|NCT01591590|Metabolic Progression Index
1095821|NCT01591564|interpersonal psychotherapy
1095822|NCT01591564|severe mood dysregulation
1095823|NCT01591538|Prevalence
1095824|NCT01591538|MDRGNB
1095825|NCT01591538|Acquisition
1095826|NCT01591538|Middle stay
1095827|NCT01591538|Endemic area
1095828|NCT01591525|Type II Diabetes
1095829|NCT01591525|Minorities
1095830|NCT01591525|Diabetes Mellitus
1095831|NCT01591525|Community based screening
1095832|NCT01591512|Small Cell Lung Cancer
1095833|NCT01591512|SCLC
1095834|NCT01591512|Lung Cancer
1095835|NCT01591512|Subjects diagnosed with SCLC who will undergo treatment
1095836|NCT01591486|Helicobacter pylori (Hp)
1095837|NCT01591486|ASA users
1095838|NCT01591486|peptic ulcer bleeding
1095839|NCT01591486|cohorts
1095840|NCT01591473|Influenza
1095841|NCT01591473|Ampligen
1095842|NCT01591473|Poly I:Poly C12U
1095843|NCT01591473|Rintatolimod
1095844|NCT01591473|FluMist
1095845|NCT01591408|EEG biofeedback
1095846|NCT01591408|neurofeedback
1095847|NCT01591408|therapy
1095848|NCT01591408|adjunct
1095849|NCT01591395|inguinal hernia
1095850|NCT01591395|laparoscopy
1095851|NCT01591395|laparoendoscopic single-site surgery
1095852|NCT01591382|Ketamine
1095853|NCT01591382|Postoperative pain
1095854|NCT01591382|Opioid dependent patients
1095855|NCT01591382|Acute pain control
1095856|NCT01591356|Advanced Cancers
1095857|NCT01591356|Advanced solid tumors
1095858|NCT01591356|siRNA/EphA2
1095859|NCT01591343|Specific immunotherapy
1095860|NCT01591343|Allergic rhinitis
1095861|NCT01591343|Allergic rhinoconjunctivitis
1095862|NCT01591343|Asthma
1095863|NCT01591304|Ulthera® System
1095864|NCT01591304|Ultherapy™ Treatment
1095865|NCT01591304|Ulthera, Inc.
1095866|NCT01591291|alcohol dependence
1095867|NCT01591291|alcohol addiction
1095868|NCT01591265|Compensatory dental extraction
1095869|NCT01591265|Children 7-11 years old
1095870|NCT01591252|HIV
1095871|NCT01591252|Bone mineral density
1095872|NCT01591252|bone turnover
1095873|NCT01591252|fracture
1095874|NCT01591252|inflammation
1095875|NCT01591239|Adolescent
1095876|NCT01591239|Parent
1095877|NCT01591239|Substance Abuse
1095878|NCT01591239|Parent Training
1095879|NCT01591239|Addiction
1095880|NCT01591239|Family Intervention
1095881|NCT01591239|Brief Intervention
1095882|NCT01591239|Home Intervention
1095883|NCT01591226|caffeine
1095884|NCT01591226|sodium citrate
1095885|NCT01591226|exercise performance
1095886|NCT01591226|wheelchair athletes
1095887|NCT01591226|1500m
1095888|NCT01591213|Cancer education
1095889|NCT01591213|Prevention education
1095890|NCT01591213|Volunteers
1095891|NCT01591200|Alcoholic
1095892|NCT01591200|Liver
1095894|NCT01591200|Stem
1095895|NCT01591200|Cells
1095896|NCT01591187|Text messaging
1095897|NCT01591187|Secondhand smoke exposure
1095898|NCT01591174|Functional Dyspepsia
1095899|NCT01591174|Postprandial Distress Syndrome
1095900|NCT01591174|ghrelin
1095901|NCT01591174|C-13 acetate
1095902|NCT01591148|Pharmacokinetics
1095903|NCT01591148|Pharmacodynamics
1095904|NCT01591135|Esophageal squamous cell carcinoma
1095905|NCT01591135|chemoradiotherapy
1095906|NCT01591122|Prostate cancer
1095907|NCT01591122|Metastatic Castration Resistant Prostate Cancer
1095908|NCT01591122|Abiraterone acetate
1095909|NCT01591122|Prednisone
1095910|NCT01591122|Zytiga
1095911|NCT01591096|Stroke
1095912|NCT01591096|Childhood
1095913|NCT01591096|Thrombolysis
1095914|NCT01591083|Peptic ulcer rebleeding, double dose of esomeprazole
1095915|NCT01591070|Facial seborrhoeic dermatitis, tacrolimus
1095916|NCT01591057|fruit
1095917|NCT01591057|vegetables
1095918|NCT01591057|biomarkers
1095919|NCT01591057|randomised controlled feeding study
1095920|NCT01591057|Fruit and vegetable intake biomarkers in healthy adults
1095921|NCT01591031|laryngeal injuries
1095922|NCT01591031|vocal cord injuries
1095923|NCT01591031|hoarseness
1095924|NCT01591031|sore throat
1095925|NCT01591018|sonolysis, brain infarction, prevention, cardiac surgery
1095926|NCT01591005|sonolysis
1095927|NCT01591005|carotid
1095928|NCT01591005|endarterectomy
1095929|NCT01591005|stenting
1095930|NCT01590992|Somatoform disorder
1095931|NCT01590992|Functional Somatic Syndrome
1095932|NCT01590992|Functional Somatic Symptoms
1095933|NCT01590992|Somatic Symptom Disorder
1095934|NCT01590992|globus sensation
1095935|NCT01590992|globus pharynges
1095936|NCT01590992|globus hystericus
1095937|NCT01590979|Atrial Fibrillation New Onset
1095938|NCT01590979|Ranolazine
1095939|NCT01590979|CABG
1095940|NCT01590979|valve repair/replacement
1095941|NCT01590979|Cardiac Surgery
1095942|NCT01590966|spondyloarthritis
1095943|NCT01590966|Rheumatoid arthritis
1095944|NCT01590927|pelvic floor
1095945|NCT01590927|ultrasonography
1095946|NCT01590914|Roux-en-Y Bariatric surgery,
1095947|NCT01590914|Gastric banding,
1095948|NCT01590914|fMRI,
1095949|NCT01590914|food cues
1095950|NCT01590901|Pharmacokinetics
1095951|NCT01590901|Probucol
1095952|NCT01590901|healthy male subjects
1095953|NCT01590875|atrial fibrillation
1095954|NCT01590875|ablation
1095955|NCT01590875|pulmonary veins
1095956|NCT01590875|adenosine
1095957|NCT01590862|Obesessive Compulsive Disorder
1095958|NCT01590862|Major Depressive Disorder
1095959|NCT01590862|Deep Brain Stimulation
1095960|NCT01590849|contraceptive agents
1095961|NCT01590849|autonomic nervous system
1095962|NCT01590849|blood pressure
1095963|NCT01590849|risk
1095964|NCT01590823|pharmacokinetics
1095965|NCT01590784|Depression
1095966|NCT01590784|Schizophrenia
1095967|NCT01590758|Diabetic Foot Ulcer Infection
1095968|NCT01590745|Ultrasound therapy
1095969|NCT01590745|Nerve Conduction studies
1095970|NCT01590745|Boston and Levine Questionnaire
1095971|NCT01590745|Neutral Angle Wrist Splint
1095972|NCT01590745|Canterbury CTS scale
1095973|NCT01590732|Lymphoma
1095974|NCT01590732|Peripheral T-Cell Lymphoma
1095975|NCT01590732|PTCL
1095976|NCT01590732|Relapsed or refractory T-Cell Lymphoma
1095977|NCT01590732|TCL
1095978|NCT01590732|Peripheral TCL-NOS
1095979|NCT01590732|Angioimmunoblastic TCL
1095980|NCT01590732|Anaplastic large cell lymphoma
1095981|NCT01590732|Hepatosplenic TCL
1095982|NCT01590732|Enteropathy-associated TCL
1095983|NCT01590732|Romidepsin
1095984|NCT01590732|Istodax
1095985|NCT01590732|Depsipeptide
1095986|NCT01590732|FK228
1095987|NCT01590732|Etoposide
1095988|NCT01590732|VePesid
1095989|NCT01590732|Carboplatin
1095990|NCT01590732|Paraplatin
1095991|NCT01590732|Mesna
1095992|NCT01590732|Mesnex
1095993|NCT01590706|Genotype-Phenotype Association
1095994|NCT01590706|Aged
1095995|NCT01590706|Middle Aged
1095996|NCT01590706|Mild Cognitive Impairment
1095997|NCT01590706|Heart Rate Control
1095998|NCT01590706|Biomarkers
1095999|NCT01590693|Gait
1096000|NCT01590667|Fat excretion
1096001|NCT01590654|Hepatitis
1096002|NCT01590654|Hepatitis B
1096003|NCT01590654|Hepatitis B Virus
1096004|NCT01590654|HBV
1096005|NCT01590654|GS-9620
1096006|NCT01590654|Toll-like receptor (TLR)-7 Agonist
1096007|NCT01590641|Hepatitis
1096008|NCT01590641|Hepatitis B
1096009|NCT01590641|Hepatitis B Virus
1096010|NCT01590641|HBV
1096011|NCT01590641|GS-9620
1096012|NCT01590641|Toll-like receptor (TLR)-7 Agonist
1096013|NCT01590628|Sickle Cell Disease & Thalassemia
1096014|NCT01590628|Genetic disorder
1096015|NCT01590615|Hepatitis
1096016|NCT01590615|Hepatitis B
1096017|NCT01590615|HBV
1096018|NCT01590615|OLT
1096019|NCT01590615|MELD
1096020|NCT01590615|Renal Safety
1096021|NCT01590615|Liver Transplant
1096022|NCT01590602|Huntington's Disease
1096023|NCT01590602|European Huntington's Disease Network
1096024|NCT01590602|Juvenile HD
1096025|NCT01590602|EHDN
1096026|NCT01590602|REGISTRY
1096027|NCT01590589|Huntington Disease
1096028|NCT01590589|European HD Network
1096029|NCT01590589|Cohort
1096030|NCT01590589|REGISTRY
1096031|NCT01590589|EHDN
1096032|NCT01590576|women
1096033|NCT01590550|Pediatric hemodialysis
1096034|NCT01590550|Anticoagulation
1096035|NCT01590537|non-interventional
1096036|NCT01590537|Mirena
1096037|NCT01590537|Contraception
1096038|NCT01590537|Russian Federation
1096039|NCT01590524|Parent
1096040|NCT01590524|childhood cancer
1096041|NCT01590524|Complementary and Alternative
1096042|NCT01590511|mini fluid challenge
1096043|NCT01590511|subaortic velocity time integral
1096044|NCT01590498|Adenocarcinoma
1096045|NCT01590498|Prostatic Neoplasms
1096046|NCT01590498|Carcinoma
1096047|NCT01590498|Prostatic Diseases
1096048|NCT01590485|pain
1096049|NCT01590485|root canal therapy
1096050|NCT01590472|Genetics of Mesothelioma
1096051|NCT01590472|Mesothelioma Consortium
1096052|NCT01590472|GWAS
1096053|NCT01590472|Asbestos
1096054|NCT01590446|Achondroplasia
1096055|NCT01590433|Obesity
1096056|NCT01590433|Overweight
1096057|NCT01590433|Exenatide
1096058|NCT01590433|Diet
1096059|NCT01590433|Women
1096060|NCT01590420|OSA
1096061|NCT01590420|Sleep
1096062|NCT01590420|CPAP
1096063|NCT01590420|Cost
1096064|NCT01590394|obstruction
1096065|NCT01590394|bile duct
1096066|NCT01590394|malignant
1096067|NCT01590342|Pulmonary embolism
1096068|NCT01590342|Right ventricular dysfunction
1096069|NCT01590342|Prognosis
1096070|NCT01590342|Inflammation
1096071|NCT01590329|Skin surgery
1096072|NCT01590329|Micrografting
1096073|NCT01590329|Hypo-pigmentation
1096074|NCT01590316|Brain Injuries
1096075|NCT01590316|Infant, Premature
1096076|NCT01590316|Spectroscopy, Near-Infrared
1096077|NCT01590316|Randomized Controlled Trial
1096078|NCT01590303|severe sepsis
1096079|NCT01590264|tinnitus
1096080|NCT01590264|bimodal stimulation
1096081|NCT01590264|rTMS
1096082|NCT01590264|Repetitive Transcranial Magnetic Stimulation
1096083|NCT01590251|Pain
1096084|NCT01590251|Addiction
1096085|NCT01590251|Buprenorphine
1096086|NCT01590251|Counseling
1096087|NCT01590251|Methadone
1096088|NCT01590251|Yoga
1096089|NCT01590238|alopecia
1096090|NCT01590186|Pain
1096091|NCT01590186|Front foot
1096092|NCT01590186|Flat foot
1096093|NCT01590186|Metatarsalgia
1096094|NCT01590173|Low molecular weight heparin
1096095|NCT01590173|Prednisolone
1096096|NCT01590173|Glucocorticoids
1096097|NCT01590173|Recurrent implantation failure
1096098|NCT01590173|Pregnancy rate
1096099|NCT01590134|volunteers
1096100|NCT01590134|Pilot study
1096101|NCT01590134|There are no pre registration evaluations.
1096102|NCT01590134|Inclusion criteria: to be a healthy, consenting volunteer not currently receiving iron supplements.
1096103|NCT01590134|Exclusion criteria: 1) Needle phobia; 2) Currently receiving iron supplements; 3) Unable to provide informed consent
1096104|NCT01590121|Previous flight by aeroplane
1096105|NCT01590108|Idiopathic Pulmonary Arterial Hypertension
1096106|NCT01590108|IPAH
1096107|NCT01590108|Apelin
1096108|NCT01590108|APJ receptor
1096109|NCT01590095|Chlorine water treatment
1096110|NCT01590095|Point-of-use water treatment
1096111|NCT01590095|Household water treatment with safe storage
1096112|NCT01590095|Hand washing with soap
1096113|NCT01590095|Hand hygiene
1096114|NCT01590095|Latrines
1096115|NCT01590095|Child potties
1096116|NCT01590095|Point-of-use fortification
1096117|NCT01590095|Lipid-based nutrient supplement
1096118|NCT01590095|Environmental enteropathy
1096119|NCT01590095|Tropical enteropathy
1096120|NCT01590095|Gut function
1096121|NCT01590095|Intestinal parasitic infection
1096122|NCT01590095|Soil transmitted helminths
1096123|NCT01590095|Intestinal protozoans
1096124|NCT01590095|Antibody response
1096125|NCT01590095|Water
1096126|NCT01590095|Sanitation
1096127|NCT01590095|Hand washing
1096128|NCT01590095|Breast Feeding
1096129|NCT01590095|Complementary Feeding
1096130|NCT01590095|Micronutrients
1096131|NCT01590095|Malnutrition
1096132|NCT01590095|Nutrition Disorders
1096133|NCT01590095|Diarrhea
1096134|NCT01590095|Child Development
1096135|NCT01590082|Melanoma
1096136|NCT01590082|Metastatic Melanoma
1096137|NCT01590082|Advanced melanoma
1096138|NCT01590082|Doxycycline
1096139|NCT01590082|Ipilimumab
1096140|NCT01590082|Yervoy
1096141|NCT01590082|MDX010
1096142|NCT01590082|BMS-734016
1096143|NCT01590082|Temozolomide
1096144|NCT01590082|Temodar
1096145|NCT01590069|Sarcoma
1096146|NCT01590069|Solid Tumors
1096147|NCT01590069|Pulmonary Metastases
1096148|NCT01590069|Lung metastases
1096149|NCT01590069|Osteosarcomas
1096150|NCT01590069|Ewing sarcoma
1096151|NCT01590069|IL-2
1096152|NCT01590069|Interleukin-2
1096153|NCT01590069|Aldesleukin
1096154|NCT01590069|Proleukin
1096155|NCT01590069|Aerosol IL-2
1096156|NCT01590069|Spirometry
1096157|NCT01590069|Nebulizer
1096158|NCT01590069|Pulse oximeter
1096159|NCT01590056|Mapping limbic areas of the STN
1096160|NCT01590056|neuronal responses to stimuli during surgery
1096161|NCT01590017|stage IB cervical cancer
1096162|NCT01590017|stage IIA cervical cancer
1096163|NCT01590017|stage IIB cervical cancer
1096164|NCT01590017|stage III cervical cancer
1096165|NCT01590017|stage IVA cervical cancer
1096166|NCT01590017|cervical adenocarcinoma
1096167|NCT01590017|cervical adenosquamous cell carcinoma
1096168|NCT01590017|cervical squamous cell carcinoma
1096169|NCT01590017|HIV infection
1096170|NCT01590004|LumbarCool system
1096171|NCT01590004|Cooled radiofrequency medial ablation
1096172|NCT01590004|Cooled-RF neurotomy
1096173|NCT01589991|toothpastes
1096174|NCT01589991|bioavailability
1096175|NCT01589991|sodium fluoride
1096176|NCT01589991|monofluorphosphate
1096177|NCT01589991|low-fluoride
1096178|NCT01589978|drug-eluting stent
1096179|NCT01589978|DES
1096180|NCT01589978|atherosclerosis
1096181|NCT01589978|everolimus
1096182|NCT01589965|HIV/AIDS
1096183|NCT01589965|STIs
1096184|NCT01589965|Lottery
1096185|NCT01589952|Pegalyted interferon
1096186|NCT01589952|Entecavir
1096187|NCT01589939|Reduced Planning Target Volume
1096188|NCT01589939|radiation therapy
1096189|NCT01589939|Calypso
1096190|NCT01589913|Implantable Cardioverter Defibrillators
1096191|NCT01589913|Heart Failure
1096192|NCT01589913|Anxiety
1096193|NCT01589913|Depression
1096194|NCT01589913|Quality of Life
1096195|NCT01589913|Remote Care
1096196|NCT01589913|Prevention
1096197|NCT01589900|colorectal cancer
1096198|NCT01589900|invasion
1096199|NCT01589900|metastasis
1096200|NCT01589900|IHC
1096201|NCT01589874|hepcidin
1096202|NCT01589874|anemia
1096203|NCT01589874|acute inflammation
1096204|NCT01589874|IL-6
1096205|NCT01589874|cytokines
1096206|NCT01589848|vWD
1096207|NCT01589809|Congenital, familial and genetic disorders
1096208|NCT01589809|Nervous System Diseases
1096209|NCT01589796|anesthesia
1096210|NCT01589796|regional anesthetic techniques: transversus abdominis plane block, ilioinguinal nerve block, iliohypogastric nerve block
1096211|NCT01589796|surgery, inguinal herniorrhaphy
1096212|NCT01589796|pain, postoperative
1096213|NCT01589796|surgery, inguinal hernia repair
1096214|NCT01589783|Pregnancy
1096215|NCT01589783|Vitamin D
1096216|NCT01589770|rheumatoid arthritis
1096217|NCT01589770|inflammation
1096218|NCT01589757|"glycaemic index"
1096219|NCT01589757|"glycemic index"
1096220|NCT01589757|hyperglycaemia
1096221|NCT01589757|hyperglycemia
1096222|NCT01589757|pregnancy
1096223|NCT01589757|"dietary intervention"
1096224|NCT01589757|"education evaluation"
1096225|NCT01589757|antioxidant
1096226|NCT01589757|"Impaired Glucose Tolerance of Pregnancy"
1096227|NCT01589757|"Gestational Diabetes Mellitus"
1096228|NCT01589757|"Breast Milk"
1096229|NCT01589744|medical device
1096230|NCT01589731|Allergenicity
1096231|NCT01589731|Cow's milk allergy
1096232|NCT01589731|Leukocyte adherence inhibition test
1096233|NCT01589731|Polymerization
1096234|NCT01589718|Proliferative Diabetic Retinopathy
1096235|NCT01589718|Tractional Retinal Detachment
1096236|NCT01589718|Vitreous Hemorrhage
1096237|NCT01589705|Uric acid
1096238|NCT01589705|polycystic kidney disease
1096239|NCT01589692|WRIST
1096240|NCT01589692|Distal Radius Fracture
1096241|NCT01589692|DRF
1096242|NCT01589692|elderly
1096243|NCT01589692|internal fixation
1096244|NCT01589692|VLPS
1096245|NCT01589692|External Fixation
1096246|NCT01589692|Multi center randomized trial
1096247|NCT01589666|Entegrion
1096248|NCT01589666|Spray-dried Solvent/Detergent Plasma
1096249|NCT01589666|Fresh Frozen Plasma
1096250|NCT01589666|Transfusion
1096251|NCT01589666|Resuscitation
1096252|NCT01589666|Hemorrhage
1096253|NCT01589666|Coagulopathy
1096254|NCT01589627|distal radius fracture
1096255|NCT01589627|wrist contracture
1096256|NCT01589627|dynasplint
1096257|NCT01589601|Congestive Heart Failure
1096258|NCT01589601|Heart Failure
1096259|NCT01589601|Palliative Care
1096260|NCT01589601|Palliative Medicine
1096261|NCT01589588|acute treatment
1096262|NCT01589575|Intensive Care Unit
1096263|NCT01589549|Acute graft versus host disease
1096264|NCT01589549|Bone marrow transplantation
1096265|NCT01589549|Mesenchymal stromal cells
1096266|NCT01589536|psychocardiological
1096267|NCT01589536|interval intervention
1096268|NCT01589536|disability pension
1096269|NCT01589536|risk profile
1096270|NCT01589536|mental comorbidity
1096271|NCT01589484|Tomography
1096272|NCT01589484|Urinary Lithiasis
1096273|NCT01589484|Kidney Calculi
1096274|NCT01589471|Low anterior resection syndrome
1096275|NCT01589471|Botulinum toxin A
1096276|NCT01589471|Quality of life
1096277|NCT01589471|Incontinence
1096278|NCT01589471|Rectal cancer
1096279|NCT01589471|Anorectal manometry
1096280|NCT01589458|toothpastes
1096281|NCT01589458|saliva
1096282|NCT01589458|dental caries
1096283|NCT01589458|fluoride
1096284|NCT01589445|Bangladesh
1096285|NCT01589445|T2DM
1096286|NCT01589445|Pioglitazone
1096287|NCT01589445|Metformin
1096288|NCT01589445|Insulin secretion and Sensitivity
1096289|NCT01589432|Diabetic peripheral neuropathy
1096290|NCT01589419|DLT
1096291|NCT01589419|radiation
1096292|NCT01589419|veliparib
1096293|NCT01589419|locally advanced rectal cancer
1096294|NCT01589419|ABT-888
1096295|NCT01589419|capecitabine
1096296|NCT01589419|MTD
1096297|NCT01589419|PARP
1096298|NCT01589406|Gynaecological Cancer
1096299|NCT01589406|Quality of Life
1096300|NCT01589406|Sexuality
1096301|NCT01589393|Trauma
1096302|NCT01589393|Thromboprophylaxis
1096303|NCT01589393|Intracranial haemorrhage
1096304|NCT01589393|Deep vein Thrombosis
1096305|NCT01589380|Aortic stenosis
1096306|NCT01589380|Exercise performance
1096307|NCT01589380|cardiopulmonary exercise test
1096308|NCT01589380|fimasartan
1096309|NCT01589367|neoadjuvant endocrine therapy
1096310|NCT01589367|metformin
1096311|NCT01589367|postmenopausal breast cancer
1096312|NCT01589328|pancreatic cancer
1096313|NCT01589328|biliary tract cancer
1096314|NCT01589328|cancer pain
1096315|NCT01589328|depression
1096316|NCT01589315|ECT
1096317|NCT01589315|FEAST
1096318|NCT01589315|brain stimulation
1096319|NCT01589315|depression
1096320|NCT01589302|Bruton's Tyrosine Kinase
1096321|NCT01589302|CLL
1096322|NCT01589302|SLL
1096323|NCT01589302|B-PLL
1096324|NCT01589289|Diagnostic research
1096325|NCT01589289|Rapid diagnostic tests
1096326|NCT01589289|Neurological disorders
1096327|NCT01589289|Neglected Tropical Diseases
1096328|NCT01589289|Developing countries
1096329|NCT01589263|Benign Prostatic Hyperplasia
1096330|NCT01589263|Lower Urinary Track Symptoms
1096331|NCT01589263|BPH
1096332|NCT01589263|LUTS
1096333|NCT01589237|Familial Chylomicronemia Syndrome (FCS) (HLP type I)
1096334|NCT01589237|LCQ908
1096335|NCT01589211|smoking
1096336|NCT01589211|cessation
1096337|NCT01589211|intervention
1096338|NCT01589211|brief
1096339|NCT01589198|Asthma
1096340|NCT01589185|Pneumonia
1096341|NCT01589185|Monoclonal antibody
1096342|NCT01589185|Staphylococcus aureus
1096343|NCT01589146|colon-rectal cancer
1096344|NCT01589146|heparin
1096345|NCT01589146|prophylaxis
1096346|NCT01589146|laparoscopy
1096347|NCT01589133|Irregular antibody screening
1096348|NCT01589120|CHF
1096349|NCT01589120|video decision aid
1096350|NCT01589094|CISPLATIN
1096351|NCT01589094|GEMCITABINE
1096352|NCT01589094|GM-CSF
1096353|NCT01589094|radical cystectomy
1096354|NCT01589094|12-071
1096355|NCT01589003|low GI milk mood behaviour cognitive function children
1096356|NCT01588964|HIPEC
1096357|NCT01588964|ovarian cancer
1096358|NCT01588964|recurrence
1096359|NCT01588938|radiation therapy
1096360|NCT01588938|Calypso
1096361|NCT01588925|Cochlear implantation
1096362|NCT01588925|Dexamethasone
1096363|NCT01588925|Acid, Hyaluronic
1096364|NCT01588912|chronic hepatitis B
1096365|NCT01588912|HBeAg positive
1096366|NCT01588912|telbivudine
1096367|NCT01588912|tenofovir
1096368|NCT01588912|entecavir
1096369|NCT01588912|roadmap
1096370|NCT01588899|Uterine Leiomyomas
1096371|NCT01588899|Fibroids
1096372|NCT01588899|HIFU
1096373|NCT01588899|Ablation
1096374|NCT01588899|High Intensity Focused Ultrasound
1096375|NCT01588886|Proton pump inhibitors
1096376|NCT01588886|Pneumonia
1096377|NCT01588886|Retrospective cohort study
1096378|NCT01588873|Oral contraceptive pill
1096379|NCT01588873|Hormonal contraceptive ring
1096380|NCT01588873|Polycystic ovary syndrome
1096381|NCT01588847|perioperative immunoediting
1096382|NCT01588847|potential predictive biomarkers
1096383|NCT01588847|lymph node dissection
1096384|NCT01588821|Metastatic
1096385|NCT01588821|Refractory
1096386|NCT01588821|Relapsed
1096387|NCT01588808|Immobilization
1096388|NCT01588808|Protein supplementation
1096389|NCT01588795|Diabetic nephropathy
1096390|NCT01588795|renal denervation
1096391|NCT01588795|nephroprotection
1096392|NCT01588795|Renal failure
1096393|NCT01588795|Renal injury
1096394|NCT01588795|End stage renal disease
1096395|NCT01588782|Healthy volunteers
1096396|NCT01588782|Pharmacology
1096397|NCT01588782|Pharmacokinetics
1096398|NCT01588782|Pharmacodynamics
1096399|NCT01588782|Drug-drug interactions
1096400|NCT01588782|CYP3A4
1096401|NCT01588782|Abiraterone acetate
1096402|NCT01588782|JNJ-589485
1096403|NCT01588782|JNJ-212082
1096404|NCT01588782|Ketoconazole
1096405|NCT01588769|Glioblastoma Multiforme
1096406|NCT01588769|Brain cancer
1096407|NCT01588769|Immunotherapy
1096408|NCT01588769|Cell based therapy
1096409|NCT01588769|Autologous cell based therapy
1096410|NCT01588769|Adoptive immunotherapy
1096411|NCT01588769|Cytotoxic T cells
1096412|NCT01588769|Natural Killer cells
1096413|NCT01588756|Chronic kidney disease
1096414|NCT01588756|GFR
1096415|NCT01588756|Inulin
1096416|NCT01588756|51Cr-EDTA
1096417|NCT01588756|ASDKP-NH2
1096418|NCT01588756|Healthy male 18-35 yrs old, non smokers, non allergic
1096419|NCT01588756|Or Male/female 18-80 yrs old with chronic Kidney disease
1096420|NCT01588730|PF
1096421|NCT01588730|Dynasplint
1096422|NCT01588730|ADFD
1096423|NCT01588730|AFD
1096424|NCT01588730|Plantar Fasciitis
1096425|NCT01588730|plantar Fasciopathy
1096426|NCT01588717|Hyperhydrosis
1096427|NCT01588717|Excessive Sweating
1096428|NCT01588717|Sweating
1096429|NCT01588717|Depression
1096430|NCT01588717|Antidepressant
1096431|NCT01588704|lung cancer
1096432|NCT01588704|lung adenocarcinoma
1096433|NCT01588704|bevacizumab
1096434|NCT01588704|adjuvant chemotherapy
1096435|NCT01588704|surgical resection rate
1096436|NCT01588704|safety
1096437|NCT01588704|feasibility
1096438|NCT01588691|Traumatic Brain Injury
1096439|NCT01588678|endometrial
1096440|NCT01588678|prostate
1096441|NCT01588678|breast
1096442|NCT01588678|gastric
1096443|NCT01588678|cervical
1096444|NCT01588678|ovarian
1096445|NCT01588678|neuroendocrine cancers
1096446|NCT01588678|soft-tissue sarcoma
1096447|NCT01588678|squamous cell NSCLC
1096448|NCT01588678|renal cell carcinoma
1096449|NCT01588678|non-Hodgkin lymphoma
1096450|NCT01588665|pregnancy
1096451|NCT01588665|stable isotopes
1096452|NCT01588665|red blood cell catabolism
1096453|NCT01588639|Recombinant human insulin
1096454|NCT01588639|T2DM
1096455|NCT01588639|Safety
1096456|NCT01588639|Efficacy
1096457|NCT01588626|Healthy volunteer
1096458|NCT01588626|Japanese males
1096459|NCT01588626|PK study
1096460|NCT01588600|food intake, satiety, fiber
1096461|NCT01588548|Advanced solid malignancies
1096462|NCT01588548|Malignant lymphoma
1096463|NCT01588535|pain
1096464|NCT01588535|pain measurement
1096465|NCT01588535|ear, middle
1096466|NCT01588535|otitis media
1096467|NCT01588522|alopecia
1096468|NCT01588509|AMG 785, bone mineral density, alendronate
1096469|NCT01588496|hypercholesterolemia
1096470|NCT01588496|familial hypercholesterolemia
1096471|NCT01588496|homozygous familial hypercholesterolemia
1096472|NCT01588470|diastolic function
1096473|NCT01588470|intramyocellular fat
1096474|NCT01588470|mitochondria
1096475|NCT01588470|pioglitazone
1096476|NCT01588444|tooth extraction
1096477|NCT01588444|bone grafting
1096478|NCT01588431|Locally advanced head and neck cancer
1096479|NCT01588431|Squamous cell carcinoma of the head and neck
1096480|NCT01588418|Impaired glucose tolerance (IGT)
1096481|NCT01588418|Diabetes
1096482|NCT01588405|Pulmonary Arterial Hypertension
1096483|NCT01588405|UT-15C SR
1096484|NCT01588405|PAH
1096485|NCT01588392|Physical activity
1096486|NCT01588392|preschoolers
1096487|NCT01588353|AK160, collagenase clostridium histolyticum
1096488|NCT01588314|Fabry disease
1096489|NCT01588314|neuropathic pain
1096490|NCT01588314|gabapentin
1096491|NCT01588301|Cervical Cancer Screening
1096492|NCT01588301|Human Papillomavirus (HPV)
1096493|NCT01588301|Self-collected vaginal sample
1096494|NCT01588301|Cervical Smear
1096495|NCT01588288|Diagnosis
1096496|NCT01588288|Galectin 3
1096497|NCT01588288|Puncture
1096498|NCT01588288|Goiter, nodular
1096499|NCT01588288|Surgery
1096500|NCT01588275|cost-effectiveness
1096501|NCT01588275|effectiveness
1096502|NCT01588275|treatment
1096503|NCT01588275|CPAP
1096504|NCT01588275|MRA
1096505|NCT01588275|compliance
1096506|NCT01588210|caries
1096507|NCT01588210|sealant
1096508|NCT01588210|fluoride
1096509|NCT01588210|prevention
1096510|NCT01588210|community dentistry
1096511|NCT01588197|Pain
1096512|NCT01588197|fMRI
1096513|NCT01588197|real time
1096514|NCT01588171|Deep vein thrombosis
1096515|NCT01588171|Pulmonary embolism
1096516|NCT01588171|Low molecular weight heparin
1096517|NCT01588171|Enoxaparin
1096518|NCT01588171|Bemiparin
1096519|NCT01588158|carpal tunnel syndrome
1096520|NCT01588158|Tylenol
1096521|NCT01588158|Vicodin
1096522|NCT01588158|pain
1096523|NCT01588145|NSCLC
1096524|NCT01588145|HM61713
1096525|NCT01588145|EGFR-TKI
1096526|NCT01588145|Phase II
1096527|NCT01588145|olmutinib
1096528|NCT01588041|Microscope mounted SDOCT
1096529|NCT01587976|Health related quality of life
1096530|NCT01587976|Colorectal liver metastasis
1096531|NCT01587976|surveillance
1096532|NCT01587963|hypovolemic or septic
1096533|NCT01587950|dentinal sensitivity
1096534|NCT01587950|potassium nitrate
1096535|NCT01587950|dental pain
1096536|NCT01587937|Antibiotic stewardship.
1096537|NCT01587937|Clostridium difficile infection.
1096538|NCT01587937|Antibiotic resistance.
1096539|NCT01587924|Renal Impairment
1096540|NCT01587924|Anemia
1096541|NCT01587924|pharmacokinetics
1096542|NCT01587924|hemodialysis
1096543|NCT01587924|Chronic kidney disease
1096544|NCT01587924|GSK1278863
1096545|NCT01587924|hemoglobin
1096546|NCT01587924|Prolyl hydroxylase inhibitor
1096547|NCT01587924|recombinant human erythropoietin
1096548|NCT01587924|erythropoiesis stimulating agents
1096549|NCT01587924|Dialysis, Renal
1096550|NCT01587911|Satiety
1096551|NCT01587911|Food intake regulation
1096552|NCT01587911|Appetite regulation
1096553|NCT01587911|Dairy Protein
1096554|NCT01587898|Anemia
1096555|NCT01587898|Prolyl hydroxylase inhibitor
1096556|NCT01587898|Hemoglobin
1096557|NCT01587898|Chronic kidney disease
1096558|NCT01587898|pharmacokinetics
1096559|NCT01587898|recombinant human erythropoietin
1096560|NCT01587898|GSK1278863
1096561|NCT01587885|Frequent Heartburn
1096562|NCT01587885|Omeprazole
1096563|NCT01587885|Omeprazole, sodium bicarbonate drug combination
1096564|NCT01587885|Gastrointestinal Agents
1096565|NCT01587885|Therapeutic Uses
1096566|NCT01587885|Pharmacologic Actions
1096567|NCT01587885|Enzyme Inhibitors
1096568|NCT01587885|Molecular Mechanisms of Pharmacological Action
1096569|NCT01587885|Proton Pump Inhibitors
1096570|NCT01587872|Colonoscopy
1096571|NCT01587872|Colorectal cancer
1096572|NCT01587872|Screening colonoscopy
1096573|NCT01587859|esophagus
1096574|NCT01587859|gastro-esophageal reflux disease
1096575|NCT01587859|type II-IV hiatal hernia
1096576|NCT01587859|esophageal surgery
1096577|NCT01587859|minimally invasive surgery
1096578|NCT01587846|abdominal pain, constipation, Lactobacillus reuteri
1096579|NCT01587833|Benzodiazepines
1096580|NCT01587833|hip/femur fracture
1096581|NCT01587820|cisplatin
1096582|NCT01587820|RADPLAT
1096583|NCT01587820|intra-arterial chemotherapy
1096584|NCT01587820|head and neck cancer
1096585|NCT01587807|Infection, Quality of Life, lung injury
1096586|NCT01587794|Rhegmatogenous retinal detachment
1096587|NCT01587794|thickness of retinal layer
1096588|NCT01587794|outer nuclear layer
1096589|NCT01587794|photoreceptor layer
1096590|NCT01587781|Pharmacokinetics of enoxaparin
1096591|NCT01587768|Acute liver injury
1096592|NCT01587768|antibiotics
1096593|NCT01587742|Calcium channel blockers
1096594|NCT01587742|cancer
1096595|NCT01587729|Hip/femur fracture
1096596|NCT01587729|antidepressants
1096597|NCT01587716|Safety and tolerability, pharmacokinetics, cough, voltage gated sodium channels (VGSC), anaesthesia
1096598|NCT01587703|BRD3
1096599|NCT01587703|GSK525762
1096600|NCT01587703|NUT Midline Carcinoma
1096601|NCT01587703|MYCN-amplified Solid Tumor
1096602|NCT01587703|BRD4
1096603|NCT01587703|BET inhibitor
1096604|NCT01587703|bromodomains
1096605|NCT01587703|NMC
1096606|NCT01587703|Colorectal C ancer
1096607|NCT01587703|Small Cell Lung Cancer
1096608|NCT01587703|Multiple Myeloma
1096609|NCT01587703|Neuroblastoma
1096610|NCT01587703|Oncology
1096611|NCT01587677|Tuberculosis
1096612|NCT01587664|Swallowing disorders
1096613|NCT01587664|Aspiration
1096614|NCT01587651|CAD
1096615|NCT01587651|prasugrel
1096616|NCT01587651|ticagrelor
1096617|NCT01587651|antiplatelet
1096618|NCT01587651|thienopyridine
1096619|NCT01587651|P2Y12 Inhibitors
1096620|NCT01587638|new-onset diabetes
1096621|NCT01587638|carvedilol
1096622|NCT01587638|claims analysis
1096623|NCT01587638|beta-blocker
1096624|NCT01587638|Diabetes Mellitus
1096625|NCT01587625|Delayed labour
1096626|NCT01587625|dystocia
1096627|NCT01587625|oxytocin augmentation
1096628|NCT01587625|primiparous women
1096629|NCT01587625|childbirth
1096630|NCT01587625|childbirth experience
1096631|NCT01587625|progress
1096632|NCT01587612|Pain
1096633|NCT01587612|Foot
1096634|NCT01587599|pharmaceutical care
1096635|NCT01587599|drug-related problems
1096636|NCT01587599|elderly
1096637|NCT01587599|Pharmaceutical care of elderly patients with diabetes
1096638|NCT01587586|Hepatitis C, Chronic
1096639|NCT01587586|Interferon-alpha
1096640|NCT01587586|Hepatitis C Virus
1096641|NCT01587573|salivary biomarkers
1096642|NCT01587560|Shoulder
1096643|NCT01587560|Arthroplasty
1096644|NCT01587560|Pyrocarbon
1096645|NCT01587560|Randomized controlled trial
1096646|NCT01587560|Shoulder resurfacing
1096647|NCT01587547|ART
1096648|NCT01587547|IVF
1096649|NCT01587547|ICSI
1096650|NCT01587547|embryo selection
1096651|NCT01587534|Unresectable Pancreatic cancer
1096652|NCT01587521|Metabolic syndrome
1096653|NCT01587521|Prevalence
1096654|NCT01587521|Quality of life
1096655|NCT01587521|Depression
1096656|NCT01587521|Antipsychotics
1096657|NCT01587482|Superficial femoral artery
1096658|NCT01587482|endovascular
1096659|NCT01587482|Drug eluting balloon
1096660|NCT01587482|Paclitaxel
1096661|NCT01587456|Osteoporosis
1096662|NCT01587430|acute myeloid leukemia
1096663|NCT01587430|anthracyclines
1096664|NCT01587430|high dose cytarabine
1096665|NCT01587430|maintenance
1096666|NCT01587404|Atrial Fibrillation
1096667|NCT01587404|Electrogram
1096668|NCT01587404|Ablation
1096669|NCT01587404|Contact Force
1096670|NCT01587378|miscarriage
1096671|NCT01587378|preterm birth
1096672|NCT01587378|prevention
1096673|NCT01587326|cytokine, depression, escitalopram
1096674|NCT01587313|hydralazine
1096675|NCT01587313|isosorbide
1096676|NCT01587313|bidil
1096677|NCT01587313|volunteers
1096678|NCT01587313|pharmacokinetic profile
1096679|NCT01587287|Anterior corneal power
1096680|NCT01587287|Placido topographer
1096681|NCT01587287|Scheimpﬂug
1096682|NCT01587287|Precision
1096683|NCT01587287|Agreement
1096684|NCT01587274|low back pain
1096685|NCT01587261|Burns
1096686|NCT01587261|Vitamin C
1096687|NCT01587261|Thermal Injury
1096688|NCT01587261|Fluid Resuscitation
1096689|NCT01587248|Breast cancer,
1096690|NCT01587248|Harmonic scalpel,
1096691|NCT01587248|Electrocautery,
1096692|NCT01587248|Modified Radical Mastectomy,
1096693|NCT01587248|Randomized Controlled Trial
1096694|NCT01587209|decompression
1096695|NCT01587209|intravascular bubbles
1096696|NCT01587209|neutrophil activation
1096697|NCT01587196|prescription opiates/medications
1096698|NCT01587196|vivitrol
1096699|NCT01587196|brain imaging
1096700|NCT01587183|Running
1096701|NCT01587183|Blood pressure
1096702|NCT01587170|spasticity
1096703|NCT01587170|spinal cord injury
1096704|NCT01587170|zolmitriptan
1096705|NCT01587144|GBM
1096706|NCT01587131|Universal Influenza
1096707|NCT01587131|Intradermal DNA-Based Vaccine
1096708|NCT01587131|Senior
1096709|NCT01587131|Electroporation
1096710|NCT01587131|H1
1096711|NCT01587131|Influenza
1096712|NCT01587131|FVH1
1096713|NCT01587118|PTSD
1096714|NCT01587118|Posttraumatic Stress Disorder
1096715|NCT01587118|Asenapine
1096716|NCT01587118|Adjunctive
1096717|NCT01587118|antidepressant
1096718|NCT01587118|neuroleptic
1096719|NCT01587092|walking
1096720|NCT01587092|physical activity
1096721|NCT01587092|sedentary behavior
1096722|NCT01587092|workplace
1096723|NCT01587079|COPD
1096724|NCT01587027|Altitude Sickness
1096725|NCT01587027|High Altitude Sickness
1096726|NCT01587001|Sarcoidosis
1096727|NCT01587001|oxidative stress
1096728|NCT01587001|anti-oxidant
1096729|NCT01586988|HIV
1096730|NCT01586988|Parenting
1096731|NCT01586988|self-care
1096732|NCT01586988|disclosure
1096733|NCT01586988|medication adherence
1096734|NCT01586988|mother
1096735|NCT01586988|child
1096736|NCT01586988|adolescent
1096737|NCT01586962|paracetamol
1096738|NCT01586962|pseudoephedrine
1096739|NCT01586962|syrup
1096740|NCT01586962|upper respiratory tract infection
1096741|NCT01586949|well-being
1096742|NCT01586949|web-based intervention
1096743|NCT01586949|social networks
1096744|NCT01586923|Anemia
1096745|NCT01586923|Transfusion
1096746|NCT01586923|RBC storage age
1096747|NCT01586923|Tissue oxygenation
1096748|NCT01586923|Malaria
1096749|NCT01586897|health information technology
1096750|NCT01586897|primary care
1096751|NCT01586897|visit-independent
1096752|NCT01586897|medication monitoring
1096753|NCT01586884|LV Pacing
1096754|NCT01586884|LV Lead Placement
1096755|NCT01586884|LV Pacing Site
1096756|NCT01586884|CRT Device Placement
1096757|NCT01586871|MPS I
1096758|NCT01586871|MPS II
1096759|NCT01586871|MPS VI
1096760|NCT01586871|Mucopolysaccharidoses
1096761|NCT01586858|Vasculitis
1096762|NCT01586858|ANCA
1096763|NCT01586858|Rituximab
1096764|NCT01586858|Small vessel vasculitis
1096765|NCT01586845|Randomized Controlled Trials
1096766|NCT01586845|Immunosuppression
1096767|NCT01586845|Adult
1096768|NCT01586845|Kidney Transplantation
1096769|NCT01586845|Treatment Outcome
1096770|NCT01586832|Hospital Supplies
1096771|NCT01586832|Stocking of Supplies
1096772|NCT01586806|Dexamethasone
1096773|NCT01586806|Glucocorticoids
1096774|NCT01586806|Physiological Effects of Drugs
1096775|NCT01586806|Therapeutic Uses
1096776|NCT01586806|Anterior Cruciate Ligament Reconstruction
1096777|NCT01586806|Regional Anesthesia, nerve block
1096778|NCT01586806|Ultrasonic Imaging
1096779|NCT01586806|Post-Operative Complications: muscle weakness, pain, nausea and vomiting
1096780|NCT01586806|Dexamethasone (as local anesthetic additive)
1096781|NCT01586793|Repetitive transcranial magnetic stimulation
1096782|NCT01586793|Bipolar depression
1096783|NCT01586793|Randomized trial
1096784|NCT01586793|rTMS
1096785|NCT01586793|Neuromodulation
1096786|NCT01586780|Whey protein
1096787|NCT01586780|Soy protein
1096788|NCT01586780|Insulinogenic amino acids
1096789|NCT01586780|Incretins
1096790|NCT01586780|Glycaemia
1096791|NCT01586780|Insulinaemia
1096792|NCT01586767|Nasal cavity
1096793|NCT01586767|Salivary gland tumors
1096794|NCT01586767|Hard palate
1096795|NCT01586767|Sinus
1096796|NCT01586767|Soft Palate
1096797|NCT01586767|Lacrimal Apparatus
1096798|NCT01586754|metabolic syndrome
1096799|NCT01586754|obesity
1096800|NCT01586754|endothelial damage
1096801|NCT01586754|homocysteine
1096802|NCT01586754|microalbumin
1096803|NCT01586754|carotis intima-media thickness
1096804|NCT01586728|Cystic fibrosis
1096805|NCT01586728|oxygen therapy
1096806|NCT01586728|sleep
1096807|NCT01586715|Extremely complex perianal fistula
1096808|NCT01586715|Adipose Derived Stem Cells
1096809|NCT01586702|Stroke, TIA, secondary prevention, support program, multifactorial intervention
1096810|NCT01586689|Oxford House
1096811|NCT01586689|recovery
1096812|NCT01586689|substance abuse
1096813|NCT01586689|alcohol abuse
1096814|NCT01586689|addiction
1096815|NCT01586676|supervision
1096816|NCT01586676|motivational interviewing
1096817|NCT01586676|substance abuse
1096818|NCT01586676|dissemination
1096819|NCT01586663|Diffuse Systemic Sclerosis
1096820|NCT01586663|Hand
1096821|NCT01586663|Range of motion
1096822|NCT01586663|Splint
1096823|NCT01586650|ankylosing spondylitis
1096824|NCT01586650|aerobic exercise
1096825|NCT01586637|Fibromyalgia
1096826|NCT01586637|Art Therapy
1096827|NCT01586637|Pain
1096828|NCT01586637|Quality of life
1096829|NCT01586637|Body Image
1096830|NCT01586624|Phase I
1096831|NCT01586624|Drug evaluation
1096832|NCT01586624|Oncology
1096833|NCT01586624|Vandetanib
1096834|NCT01586624|Selumetinib
1096835|NCT01586624|Dose escalation
1096836|NCT01586624|Clinical trial
1096837|NCT01586624|Vascular Endothelial Growth Factor(VEGFR) inhibitor
1096838|NCT01586624|Epidermal Growth Factor Receptor(EGFR)inhibitor
1096839|NCT01586624|Mitogen Activated Kinase (MEK) inhibitor
1096840|NCT01586624|Non small cell lung cancer
1096841|NCT01586598|Mandibular Nerve
1096842|NCT01586598|Orthognathic Surgery
1096843|NCT01586598|Sagittal Split Osteotomy
1096844|NCT01586598|Sensory Retraining
1096845|NCT01586572|Polio virus type 1,2,3
1096846|NCT01586572|Poliovaccine-Oral
1096847|NCT01586572|Poliovaccine
1096848|NCT01586572|Trivalent Oral Polio vaccine
1096849|NCT01586572|Monovalent oral polio vaccine
1096850|NCT01586572|Bivalent Oral polio vaccine
1096851|NCT01586546|Mind-body
1096852|NCT01586546|Psychosocial
1096853|NCT01586546|Meditation
1096854|NCT01586546|Breathing Exercises
1096855|NCT01586546|Guided Imagery
1096856|NCT01586546|Visualization
1096857|NCT01586533|ulcerative colitis
1096858|NCT01586533|UC
1096859|NCT01586533|left-sided ulcerative colitis
1096860|NCT01586533|distal ulcerative colitis
1096861|NCT01586533|Zoenasa
1096862|NCT01586533|mesalamine
1096863|NCT01586533|mesalazine
1096864|NCT01586533|5-ASA
1096865|NCT01586533|5-aminosalicylic acid
1096866|NCT01586533|N-acetylcysteine
1096867|NCT01586533|acetylcysteine
1096868|NCT01586533|NAC
1096869|NCT01586533|enema
1096870|NCT01586533|rectal gel
1096871|NCT01586520|thyroid cancer, papillary, follicular, proteomics, genetic markers
1096872|NCT01586507|Pain
1096873|NCT01586507|ULTRAM ER
1096874|NCT01586507|Tramadol hydrochloride
1096875|NCT01586507|Adolescents
1096876|NCT01586494|Pain
1096877|NCT01586494|ULTRAM ER
1096878|NCT01586494|Tramadol hydrochloride
1096879|NCT01586494|Children
1096880|NCT01586481|Diabetic foot ulcer
1096881|NCT01586481|Off loading
1096882|NCT01586481|Compliance
1096883|NCT01586481|Healing duration
1096884|NCT01586481|Amputation rate
1096885|NCT01586455|umbilical cord blood
1096886|NCT01586455|stem cell transplantation
1096887|NCT01586455|placental stem cell
1096888|NCT01586455|inborn errors of metabolism
1096889|NCT01586455|marrow failure
1096890|NCT01586455|Severe Combined Immunodeficiency Disease
1096891|NCT01586455|AML
1096892|NCT01586455|ALL
1096893|NCT01586455|MDS
1096894|NCT01586429|comparing the analgesic efficacy of ultrasound-guided nerve block catheter compared with epidural analgesia
1096895|NCT01586416|Colonic neoplasms
1096896|NCT01586416|Older adults
1096897|NCT01586416|Psychosocial Intervention
1096898|NCT01586416|Chemotherapy adherence
1096899|NCT01586403|Melanoma
1096900|NCT01586403|Gene Therapy
1096901|NCT01586403|Adoptive T-Cell Transfer
1096902|NCT01586403|IL-2
1096903|NCT01586390|Ankle Sprain
1096904|NCT01586390|Ankle Distortion
1096905|NCT01586390|Functional treatment
1096906|NCT01586390|Brace treatment
1096907|NCT01586377|Complex regional pain syndrome
1096908|NCT01586377|Near Infrared Spectroscopy
1096909|NCT01586377|Vascular Occlusion Test
1096910|NCT01586364|Menopausal symptoms
1096911|NCT01586364|Vulvar and vaginal atrophy in menopausal women
1096912|NCT01586364|Vaginal atrophy
1096913|NCT01586364|Urogenital atrophy
1096914|NCT01586351|Rotator cuff tears
1096915|NCT01586351|ACP
1096916|NCT01586351|DX Reinforcement Matrix
1096917|NCT01586325|Chronic hepatitis C infection
1096918|NCT01586325|Asian genotype 1 chronic hepatitis C infection
1096919|NCT01586325|JNJ-47910382
1096920|NCT01586325|Non-structural protein 5A (NS5A) inhibitor
1096921|NCT01586312|Knee degenerative disease
1096922|NCT01586312|osteoarthritis
1096923|NCT01586312|gonarthrosis
1096924|NCT01586312|stem cell
1096925|NCT01586312|cellular therapy
1096926|NCT01586312|regenerative therapy
1096927|NCT01586312|Mesenchymal stem cells
1096928|NCT01586312|Bone marrow
1096929|NCT01586312|musculoskeletal Diseases
1096930|NCT01586312|Mesenchymal Stromal Cells (allogenic)
1096931|NCT01586299|pleuropneumonia children
1096932|NCT01586299|non steroidal anti inflammatory drugs
1096933|NCT01586299|pleural effusion
1096934|NCT01586299|severe pneumonia
1096935|NCT01586286|Levator Myalgia
1096936|NCT01586286|Pelvic Pain
1096937|NCT01586286|Vaginismus
1096938|NCT01586286|Myofascial pain syndromes
1096939|NCT01586260|Neuroblastoma in remission
1096940|NCT01586260|Relapsed Neuroblastoma
1096941|NCT01586260|Refractory Neuroblastoma
1096942|NCT01586234|Fuchs' endothelial dystrophy
1096943|NCT01586234|DSAEK
1096944|NCT01586234|Descemet's stripping automated endothelial keratoplasty
1096945|NCT01586221|Rehabilitation
1096946|NCT01586221|Fingers
1096947|NCT01586221|Grasp
1096948|NCT01586221|Strength
1096949|NCT01586221|Brain Function
1096950|NCT01586221|Physiopathology
1096951|NCT01586221|Functional Laterality
1096952|NCT01586221|Psychomotor Performance
1096953|NCT01586221|Biomechanis
1096954|NCT01586221|Touch
1096955|NCT01586221|Music Therapy
1096956|NCT01586221|Weight-Bearing
1096957|NCT01586208|refractory status epilepticus
1096958|NCT01586208|valproic acid
1096959|NCT01586208|phenytoin
1096960|NCT01586208|benzodiazepines
1096961|NCT01586208|Valproic acid initial dosage in status treatment
1096962|NCT01586182|poor prognosis
1096963|NCT01586169|Albendazole
1096964|NCT01586169|Ivermectin
1096965|NCT01586169|Azithromycin
1096966|NCT01586169|Lymphatic filariasis
1096967|NCT01586169|Trachoma
1096968|NCT01586169|Safety
1096969|NCT01586143|Paracetamol by permucosal route,
1096970|NCT01586143|Paracetamol by intraveinous route,
1096971|NCT01586143|Pain.
1096972|NCT01586143|Patient with minor trauma of lower limb and/or superior limb (sprains, muscle contusions, …).
1096973|NCT01586130|Knee Osteoarthritis
1096974|NCT01586130|Exercise
1096975|NCT01586130|Isokinetic
1096976|NCT01586130|Muscle strength
1096977|NCT01586130|Rehabilitation
1096978|NCT01586117|rectal cancer
1096979|NCT01586117|amifostine
1096980|NCT01586117|pre-operative chemo-radiation
1096981|NCT01586065|type 1 diabetes
1096982|NCT01586065|adolescents
1096983|NCT01586065|poor control
1096984|NCT01586065|CGM
1096985|NCT01586052|Cerebral Palsy
1096986|NCT01586052|Erythropoietin
1096987|NCT01586052|Rehabilitation
1096988|NCT01586039|Melatonin
1096989|NCT01586039|Sleep
1096990|NCT01586039|Light
1096991|NCT01586039|Alertness
1096992|NCT01586039|Circadian Rhythms
1096993|NCT01586026|Ports
1096994|NCT01586026|Catheters
1096995|NCT01586026|Distal Valved Catheters
1096996|NCT01586026|Maintenance Flush
1096997|NCT01586026|subjects
1096998|NCT01586026|routine maintenance flushes
1096999|NCT01586013|propofol
1097000|NCT01586013|pharmacodynamic
1097001|NCT01586013|age
1097002|NCT01586013|ke0
1097003|NCT01586000|vaginal ring
1097004|NCT01585974|Renal Cell Carcinoma
1097005|NCT01585974|TKI
1097006|NCT01585974|Turkey
1097007|NCT01585974|Observational
1097008|NCT01585961|Symptomatic paroxysmal
1097009|NCT01585961|Atrial fibrillation
1097010|NCT01585961|Observational
1097011|NCT01585961|Acute procedural outcomes
1097012|NCT01585961|Ablation
1097013|NCT01585961|Drug refractory
1097014|NCT01585961|Arrhythmia Recurrent
1097015|NCT01585961|Symptomatic
1097016|NCT01585935|Infant, Extremely Low Birth Weight
1097017|NCT01585935|Parenteral Nutrition
1097018|NCT01585935|Fish Oils
1097019|NCT01585935|Cholestasis
1097020|NCT01585935|Psychomotor Disorders, Developmental
1097021|NCT01585922|noninvasive positive pressure ventilation
1097022|NCT01585896|Hoarding
1097023|NCT01585896|Compulsive Hoarding
1097024|NCT01585896|Self-Help
1097025|NCT01585883|Lung cancer
1097026|NCT01585883|Breathlessness
1097027|NCT01585883|Self-management
1097028|NCT01585870|Safety
1097029|NCT01585870|Tolerability
1097030|NCT01585870|Pharmacokinetics
1097031|NCT01585870|Clinical benefit
1097032|NCT01585870|Sorafenib
1097033|NCT01585870|Eribulin
1097034|NCT01585870|advanced metastatic solid tumors
1097035|NCT01585844|sleep apnea
1097036|NCT01585844|pregnancy
1097037|NCT01585844|obesity
1097042|NCT01585818|Glycemic Index
1097043|NCT01585818|Type 2 Diabetes Mellitus
1097044|NCT01585818|Diet
1097045|NCT01585818|Glucose Variability
1097046|NCT01585818|Metabolic Response
1097047|NCT01585818|Glucose Response
1097048|NCT01585766|MAb, B cell, depletion, RMS
1097049|NCT01585753|cardiovascular function
1097050|NCT01585753|maraviroc
1097051|NCT01585740|Hyperchloraemic metabolic acidosis
1097052|NCT01585740|Neonatal acidosis
1097053|NCT01585740|Neonatal hyperchloraemia
1097054|NCT01585740|Base excess
1097055|NCT01585740|Metabolic acidosis
1097056|NCT01585740|Caesarean section
1097057|NCT01585740|Normal saline
1097058|NCT01585740|Ringer's Lactate
1097059|NCT01585740|Postoperative morbidity
1097060|NCT01585727|Rectal cancer
1097061|NCT01585727|total mesorectal excision
1097062|NCT01585727|pelvic autonomic nerve preservation
1097063|NCT01585727|neurostimulation
1097064|NCT01585727|urogenital function
1097065|NCT01585727|quality of life
1097066|NCT01585701|Phase I
1097067|NCT01585701|Oncology
1097068|NCT01585701|AGC Kinase inhibitor
1097069|NCT01585701|Protein Kinase inhibitor
1097070|NCT01585701|Clinical Trial
1097071|NCT01585701|Multiple protein kinases
1097072|NCT01585688|NHL
1097073|NCT01585688|CLL
1097074|NCT01585675|Lung Cancer
1097075|NCT01585662|EUS
1097076|NCT01585662|pancreatic pseudocyst
1097077|NCT01585662|drainage
1097078|NCT01585636|SQ109
1097079|NCT01585636|Tuberculosis
1097080|NCT01585610|smoking
1097081|NCT01585610|smoking cessation
1097082|NCT01585610|disabled persons
1097083|NCT01585610|behavioral research
1097084|NCT01585597|Ischemic Stoke
1097085|NCT01585597|Endovascular Reperfusion
1097086|NCT01585597|Reperfusion Injury
1097087|NCT01585597|Mild hypothermia
1097088|NCT01585584|Boceprevir
1097089|NCT01585584|Hepatitis C Genotype 3
1097090|NCT01585571|Balance
1097091|NCT01585571|Posture
1097092|NCT01585571|Virtual Environment
1097093|NCT01585571|Cerebral Palsy
1097094|NCT01585571|Adults
1097095|NCT01585558|Menopausal symptoms
1097096|NCT01585558|Urogenital atrophy
1097097|NCT01585558|Vulvar and vaginal atrophy in menopausal women
1097098|NCT01585558|Vaginal atrophy
1097099|NCT01585545|CT
1097100|NCT01585545|PET CT
1097101|NCT01585545|MRI
1097102|NCT01585545|cancer genomics
1097103|NCT01585545|Radiomics
1097104|NCT01585545|Radiogenomics
1097105|NCT01585532|Tuberculosis
1097106|NCT01585532|Urine
1097107|NCT01585532|Nucleic acid
1097108|NCT01585532|Alere
1097109|NCT01585532|Borstel
1097110|NCT01585519|High Epicatechin Apples
1097111|NCT01585519|Low Epicatechin Apples
1097112|NCT01585519|Apple Extract
1097113|NCT01585519|Apple Granules
1097114|NCT01585519|Blood Pressure
1097115|NCT01585519|Cholesterol
1097116|NCT01585493|Lifestyle
1097117|NCT01585493|Smoking
1097118|NCT01585493|Dietary
1097119|NCT01585493|Exercise
1097120|NCT01585480|Obesity
1097121|NCT01585480|Weight Gain Prevention
1097122|NCT01585480|Workplace
1097123|NCT01585480|Intervention
1097124|NCT01585480|Diet
1097125|NCT01585480|Exercise
1097126|NCT01585467|Anterior Shoulder Dislocation
1097127|NCT01585467|Shoulder Dislocation
1097128|NCT01585467|Shoulder Pain
1097129|NCT01585467|Shoulder Deformity
1097130|NCT01585454|Pregnancy
1097131|NCT01585454|Diabetes Mellitus
1097132|NCT01585454|Weight Gain
1097133|NCT01585454|Diabetes
1097134|NCT01585441|Finasteride
1097135|NCT01585441|Central Serous Chorioretinopathy
1097136|NCT01585428|Immunotherapy
1097137|NCT01585428|HPV-Associated Cancers
1097138|NCT01585428|Cervical Cancer
1097139|NCT01585428|Oropharyngeal Cancer
1097140|NCT01585428|HPV Infection
1097141|NCT01585415|Tumor Infiltrating Lymphocytes
1097142|NCT01585415|Immunotherapy
1097143|NCT01585415|Adoptive Cell Therapy
1097144|NCT01585415|B Raf Inhibitor
1097145|NCT01585402|NT5E
1097146|NCT01585402|Biphosphonates
1097147|NCT01585402|Vascular Calcifications
1097148|NCT01585402|Joint Capsule Calcifications
1097149|NCT01585402|Inherited Disease
1097150|NCT01585389|adult brain tumor
1097151|NCT01585389|childhood brain tumor
1097152|NCT01585376|alveolar childhood rhabdomyosarcoma
1097153|NCT01585376|embryonal childhood rhabdomyosarcoma
1097154|NCT01585350|melanoma
1097155|NCT01585350|peptide vaccine
1097156|NCT01585350|polyICLC
1097157|NCT01585350|lipopolysaccharide (LPS)
1097158|NCT01585350|immunotherapy
1097159|NCT01585311|Subarachnoid Hemorrhage (SAH)
1097160|NCT01585311|tachycardia
1097161|NCT01585311|Outcome
1097162|NCT01585298|Multiple Sclerosis
1097163|NCT01585298|MS
1097164|NCT01585298|Fingolimod
1097165|NCT01585298|Gilenya
1097166|NCT01585298|ECG
1097167|NCT01585298|Bradyarrythmia
1097168|NCT01585298|conduction abnormalities
1097169|NCT01585298|first dose observation
1097170|NCT01585285|Coronary artery bypass grafting
1097171|NCT01585285|Left internal mammary artery
1097172|NCT01585285|Composite grafting
1097173|NCT01585285|Multislice Spiral Computed Tomography Scanner
1097174|NCT01585285|Graft patency assessment
1097175|NCT01585272|Alzheimer's dementia, AD
1097176|NCT01585259|anti-platelet;
1097177|NCT01585259|safety;
1097178|NCT01585259|efficacy
1097179|NCT01585246|Prostate Cancer
1097180|NCT01585246|Radiation Therapy
1097181|NCT01585246|Quality of Life
1097182|NCT01585246|Symptom Management
1097183|NCT01585233|Moderate Psoriasis
1097184|NCT01585233|Severe Psoriasis
1097185|NCT01585233|Skin disease
1097186|NCT01585233|ASKP1240
1097187|NCT01585233|CD40 antigen
1097188|NCT01585233|Anti-CD40 monoclonal antibody
1097189|NCT01585220|WSRS
1097190|NCT01585220|GAIS
1097191|NCT01585220|HA filler
1097192|NCT01585220|filler
1097193|NCT01585207|Tourette's Disorder
1097194|NCT01585207|vigabatrin
1097195|NCT01585194|Melanoma
1097196|NCT01585194|History of Uveal Melanoma
1097197|NCT01585194|Metastatic
1097198|NCT01585194|Ipilimumab
1097199|NCT01585194|Yervoy
1097200|NCT01585194|BMS-734016
1097201|NCT01585194|MDX010
1097202|NCT01585194|Nivolumab
1097203|NCT01585194|BMS-936558
1097204|NCT01585194|Opdivo
1097205|NCT01585181|Vaccine, Bacterial disease condition, Cholera
1097206|NCT01585168|Reward Circuitry
1097207|NCT01585168|Impulsivity
1097208|NCT01585168|Family History of Alcoholism
1097209|NCT01585168|NMDA/DA Interactions
1097210|NCT01585155|Infliximab
1097211|NCT01585155|REMICADE
1097212|NCT01585155|TA-650
1097213|NCT01585090|Ankle positions
1097214|NCT01585090|pelvic floor muscles strength
1097215|NCT01585090|relaxation of pelvic floor muscles syndrome
1097216|NCT01585090|doing strengthening exercises of pelvic floor muscles
1097217|NCT01585077|Plasmodium vivax
1097218|NCT01585077|Malaria
1097219|NCT01585077|Challenge
1097220|NCT01585077|Anopheles albimanus
1097221|NCT01585064|Rheumatoid Arthritis (RA)
1097222|NCT01585064|Anti-TNF therapy
1097223|NCT01585064|Adalimumab
1097224|NCT01585064|Disease activity
1097225|NCT01585064|Treating to target
1097226|NCT01585051|vitamin D
1097227|NCT01585051|blood pressure
1097228|NCT01585051|typ 2 diabetes mellitus
1097229|NCT01585051|blood glucose
1097230|NCT01585051|HbA1c
1097231|NCT01585038|endothelium
1097232|NCT01585038|inflammation
1097233|NCT01585038|oxidative stress
1097234|NCT01585038|HIV-1
1097235|NCT01585025|Primary bile acid malabsorption
1097236|NCT01585025|Secondary bile acid malabsorption
1097237|NCT01585025|Chronic diarrhoea
1097238|NCT01585025|Obeticholic acid
1097239|NCT01585025|SeHCAT
1097240|NCT01585025|FXR
1097241|NCT01585025|FGF19
1097242|NCT01585012|Cervical cap insemination
1097243|NCT01585012|Collection condom
1097244|NCT01585012|Instructions for Use
1097245|NCT01585012|Safety during intercourse
1097246|NCT01585012|Acceptability of the cervical cap with condom sheath
1097247|NCT01585012|slip
1097248|NCT01585012|break
1097249|NCT01585012|ease of conversion
1097250|NCT01585012|adequate sample collection
1097251|NCT01584947|Oral pain
1097252|NCT01584947|Local anesthetic
1097253|NCT01584947|Bupivacaine hydrochloride
1097254|NCT01584934|fatigue
1097255|NCT01584934|sleep quality
1097256|NCT01584934|Chronic, disabling, unexplained fatigue with at least 4 minor criteria for CFS, according to the 1994 Fukuda case definition
1097257|NCT01584921|Erythropoietin
1097258|NCT01584921|Glomerular filtration rate
1097259|NCT01584921|Tubular reabsorption
1097260|NCT01584921|Renal function
1097261|NCT01584921|Renal perfusion
1097262|NCT01584908|kidney transplant recipients
1097263|NCT01584882|Clinical decision support (CDS)
1097264|NCT01584882|Tobacco
1097265|NCT01584882|Behavioral
1097266|NCT01584882|Dental hygienist
1097267|NCT01584882|Dentist
1097268|NCT01584882|Smoking
1097269|NCT01584882|Electronic health record
1097270|NCT01584869|GI-bleeding
1097271|NCT01584869|capsule endoscopy
1097272|NCT01584843|Neuromuscular Agents
1097273|NCT01584843|Strabismus
1097274|NCT01584843|Botulinum Toxin Type A
1097275|NCT01584830|Regorafenib
1097276|NCT01584830|Colorectal
1097277|NCT01584830|Metastatic
1097278|NCT01584817|colonoscopy
1097279|NCT01584817|bowel preparation
1097280|NCT01584817|education
1097281|NCT01584804|Su Huang antitussive capsule
1097282|NCT01584804|Cough variant asthma
1097283|NCT01584804|Placebo
1097284|NCT01584791|CAD
1097285|NCT01584791|PCI
1097286|NCT01584791|Percutaneous Coronary Intervention
1097287|NCT01584778|Behçet's disease
1097288|NCT01584778|Eosinophil cationic protein
1097289|NCT01584778|Eosinophils
1097290|NCT01584765|liver injury
1097291|NCT01584765|Rechallenge
1097292|NCT01584765|Kaiser Permanente California
1097293|NCT01584739|Safety
1097294|NCT01584739|tolerability
1097295|NCT01584739|healthy
1097296|NCT01584739|COPD (chronic obstructive pulmonary disease)
1097297|NCT01584739|pharmacokinetic
1097298|NCT01584739|pharmacodynamic
1097299|NCT01584739|inhaled
1097300|NCT01584726|magnesium
1097301|NCT01584726|nebulization
1097302|NCT01584726|asthma
1097303|NCT01584726|sulfate
1097304|NCT01584726|children
1097305|NCT01584726|pediatric
1097306|NCT01584713|Enterocutaneous fistula
1097307|NCT01584713|Adipose Derived Stem Cells
1097308|NCT01584700|NYHA class III or IV
1097309|NCT01584700|Maximal medical therapy
1097310|NCT01584700|Not eligible for CRT
1097311|NCT01584687|asthma
1097312|NCT01584687|difficult-to-control asthma
1097313|NCT01584687|mRNA expression
1097314|NCT01584687|biomarker
1097315|NCT01584687|real time PCR
1097316|NCT01584687|ACT
1097317|NCT01584687|ACQ
1097318|NCT01584648|Randomized study
1097319|NCT01584648|combination therapy
1097320|NCT01584648|BRAF inhibitor
1097321|NCT01584648|GSK1120212
1097322|NCT01584648|BRAF V600E/K mutation-positive cutaneous melanoma
1097323|NCT01584648|trametinib
1097324|NCT01584648|GSK2118436
1097325|NCT01584648|MEK inhibitor
1097326|NCT01584648|Phase III
1097327|NCT01584648|dabrafenib
1097328|NCT01584635|Less invasive treatment for Achalasia
1097329|NCT01584609|ischemic stroke
1097330|NCT01584609|large vessel occlusion
1097331|NCT01584609|mechanical thrombectomy
1097332|NCT01584609|revascularization
1097333|NCT01584609|Penumbra System
1097334|NCT01584609|Separator 3D
1097335|NCT01584596|physical activity
1097336|NCT01584596|dietary
1097337|NCT01584596|adults
1097338|NCT01584596|pedometer
1097339|NCT01584596|education
1097340|NCT01584583|BP
1097341|NCT01584570|dexmedetomidine
1097342|NCT01584570|heart rate variability
1097343|NCT01584570|QTc interval
1097344|NCT01584544|rectal neoplasms
1097345|NCT01584544|aged
1097346|NCT01584544|chemoradiotherapy
1097347|NCT01584544|clinical trials, phase I
1097348|NCT01584544|capecitabine
1097349|NCT01584531|rigosertib sodium
1097350|NCT01584531|rigosertib
1097351|NCT01584531|ON 01910.Na
1097352|NCT01584531|oral rigosertib
1097353|NCT01584505|COPD
1097354|NCT01584479|periodontitis
1097355|NCT01584466|Schizophrenia
1097356|NCT01584466|Substance Abuse
1097357|NCT01584427|Dietary fibers
1097358|NCT01584427|Resistent Starch
1097359|NCT01584427|Arabinoxylans
1097360|NCT01584427|Postprandial lipaemia
1097361|NCT01584427|Insulin sensitivity
1097362|NCT01584427|Body composition
1097363|NCT01584427|Gene expression
1097364|NCT01584427|Metabolic rate
1097365|NCT01584427|Blood pressure
1097366|NCT01584414|Zetiq CellDetect ® stain
1097367|NCT01584414|distinct red/purple color to the cytoplasm of neoplastic
1097368|NCT01584414|distinguishes green/blue stained non-neoplastic cells and tissues
1097369|NCT01584401|Body temperature
1097370|NCT01584401|Thermometers
1097371|NCT01584401|Non invasive
1097372|NCT01584401|Medisim's non invasive thermometers
1097373|NCT01584388|Type 1 autoimmune pancreatitis
1097374|NCT01584388|IgG4-related sclerosing cholangitis
1097375|NCT01584388|Chronic sclerosing sialadenitis
1097376|NCT01584388|Lacrimal glands
1097377|NCT01584388|Orbital pseudotumor
1097378|NCT01584388|IgG4-related tubulointerstitial nephritis
1097379|NCT01584388|Lymphadenopathy
1097380|NCT01584388|Pachymeningitis
1097381|NCT01584388|Aorta
1097382|NCT01584388|Peri-aortitis
1097383|NCT01584388|Retroperitoneal fibrosis
1097384|NCT01584388|Riedel's thyroiditis
1097385|NCT01584375|Intraventricular hemorrhage
1097386|NCT01584375|Preterm infant
1097387|NCT01584375|Midline head position
1097388|NCT01584375|Lateral head Position
1097389|NCT01584362|Taenia solium
1097390|NCT01584362|neurocysticercosis
1097391|NCT01584362|oxfendazole
1097392|NCT01584362|clinical trial, phase 1
1097393|NCT01584362|safety
1097394|NCT01584362|pharmacokinetics
1097520|NCT01583972|B lymphocyte
1097395|NCT01584336|Gastric cancer, laparoscopy-assisted total gastrectomy
1097396|NCT01584323|Preterm premature rupture of membranes
1097397|NCT01584323|pomgranate
1097398|NCT01584323|oxidative stress
1097399|NCT01584323|pregnant women with Preterm premature rupture of membranes
1097400|NCT01584310|Nutritional assessment
1097401|NCT01584310|children
1097402|NCT01584310|malnutrition
1097403|NCT01584297|Granulosa Cell Tumour
1097404|NCT01584284|Genelux
1097405|NCT01584284|Genelux Corporation
1097406|NCT01584284|GL-ONC1
1097407|NCT01584284|Vaccinia
1097408|NCT01584284|Vaccinia Virus
1097409|NCT01584284|Oncolytic virus
1097410|NCT01584284|Oncolytic Virotherapy
1097411|NCT01584284|Head and Neck Cancer
1097412|NCT01584284|Squamous Cell Carcinoma
1097413|NCT01584271|AOE
1097414|NCT01584271|Ear Comfort
1097415|NCT01584271|Dex Otic
1097416|NCT01584271|Otidin
1097417|NCT01584258|Prostate cancer
1097418|NCT01584258|Prostate adenocarcinoma
1097544|NCT01583842|imaging
1097419|NCT01584258|Early stage prostate cancer
1097420|NCT01584258|Organ-confined prostate cancer
1097421|NCT01584258|Low-risk prostate cancer
1097422|NCT01584258|Intermediate-risk prostate cancer
1097423|NCT01584232|Glucagon-like peptide-1 (GLP-1)
1097424|NCT01584206|Sitosterolemia
1097425|NCT01584206|Ezetimibe
1097426|NCT01584206|Plant sterol
1097427|NCT01584206|Cholesterol
1097428|NCT01584193|central venous access port
1097429|NCT01584193|ultrasound-guided venous puncture
1097430|NCT01584193|suclavian vein
1097431|NCT01584193|cephalic vein
1097432|NCT01584180|hypothermia
1097433|NCT01584180|induction of hypothermia
1097434|NCT01584180|cold infusion
1097435|NCT01584180|local neck cooling
1097436|NCT01584180|external cooling
1097437|NCT01584180|surface cooling
1097438|NCT01584180|non invasive cooling
1097439|NCT01584180|stroke
1097440|NCT01584180|intracranial hemorrhage
1097441|NCT01584180|cerebrovascular disease
1097442|NCT01584180|neuro intensive care
1097443|NCT01584167|hypothermia
1097444|NCT01584167|induction of hypothermia
1097445|NCT01584167|cold infusion
1097446|NCT01584167|whole-body cooling
1097447|NCT01584167|external cooling
1097448|NCT01584167|surface cooling
1097449|NCT01584167|non invasive cooling
1097450|NCT01584167|stroke
1097451|NCT01584167|intracranial hemorrhage
1097452|NCT01584167|cerebrovascular disease
1097453|NCT01584167|neuro intensive care
1097454|NCT01584141|Leukemia
1097455|NCT01584141|Lymphoma
1097456|NCT01584141|Occupational Epidemiology
1097457|NCT01584141|Molecular Epidemiology
1097458|NCT01584141|Genetic Polymorphisms
1097459|NCT01584115|Cancer.
1097460|NCT01584115|Melanoma.
1097461|NCT01584115|Ovarian cancer.
1097462|NCT01584115|Lung cancer.
1097463|NCT01584115|NY-ESO-1.
1097464|NCT01584115|MPLA (monophosphoryl lipid A).
1097465|NCT01584115|Tumor antigen.
1097466|NCT01584115|Bordetella pertussis.
1097467|NCT01584102|Randomized controlled trial
1097468|NCT01584102|obesity
1097469|NCT01584102|community-based participatory research
1097470|NCT01584102|minority health
1097471|NCT01584102|rural health
1097472|NCT01584102|health promotion
1097473|NCT01584076|Amblyopia
1097474|NCT01584076|Donepezil
1097475|NCT01584063|Mexican Americans
1097476|NCT01584063|Pregnancy
1097477|NCT01584063|Diabetes Mellitus Type 2
1097478|NCT01584063|Prevention
1097479|NCT01584063|Community health workers
1097480|NCT01584063|Community based participatory research
1097481|NCT01584063|Behavioral Intervention
1097482|NCT01584063|Lifestyle Intervention
1097483|NCT01584037|Adenovirus
1097484|NCT01584037|Adenovirus Type 4
1097485|NCT01584037|Adenovirus Type 7
1097486|NCT01584037|Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
1097487|NCT01584024|Dental caries
1097488|NCT01584024|Proximal surfaces
1097489|NCT01584024|Posterior teeth
1097490|NCT01584024|Carious lesions
1097491|NCT01584024|Tooth diseases
1097492|NCT01584024|Preventive therapy
1097493|NCT01584011|Taste
1097494|NCT01584011|Chorda tympani nerve
1097495|NCT01583998|Major Depressive Disorder
1097496|NCT01583998|MDD
1097497|NCT01583998|Depression
1097498|NCT01583998|Measurement Based Care
1097499|NCT01583998|MBC
1097500|NCT01583998|electronic health records
1097501|NCT01583998|EHR
1097502|NCT01583998|electronic medical records
1097503|NCT01583998|EMR
1097504|NCT01583985|opioid analgesics
1097505|NCT01583985|chronic pain
1097506|NCT01583985|musculoskeletal pain
1097507|NCT01583972|Vitamin A deficiency
1097508|NCT01583972|Vitamin A
1097509|NCT01583972|retinyl palmitate
1097510|NCT01583972|malnutrition
1097511|NCT01583972|vaccine
1097512|NCT01583972|vaccination
1097513|NCT01583972|BCG
1097514|NCT01583972|tuberculosis
1097515|NCT01583972|polio virus
1097516|NCT01583972|tetanus toxoid
1097517|NCT01583972|hepatitis B virus
1097518|NCT01583972|thymus
1097519|NCT01583972|T lymphocyte
1097521|NCT01583972|antibody
1097522|NCT01583972|bacterial translocation
1097523|NCT01583972|T-cell receptor excision circle
1097524|NCT01583959|rheumatoid arthritis
1097525|NCT01583959|folic acid
1097526|NCT01583959|methotrexate
1097527|NCT01583946|subjective well-being
1097528|NCT01583946|life transitions
1097529|NCT01583946|health-related quality of life
1097530|NCT01583946|health
1097531|NCT01583946|healthcare costs
1097532|NCT01583933|Dental stability
1097533|NCT01583933|Occlusal stability
1097534|NCT01583933|Retainers
1097535|NCT01583920|prostatic neoplasms
1097536|NCT01583920|brachytherapy
1097537|NCT01583920|salvage therapy
1097538|NCT01583920|recurrent prostate cancer
1097539|NCT01583907|cow's milk allergy
1097540|NCT01583881|Patients with diastolic heart failure and hypertension
1097541|NCT01583855|Remote catheter ablation
1097542|NCT01583855|Atrial fibrillation
1097543|NCT01583842|neuroblastoma
1097545|NCT01583842|124I-MIBG
1097546|NCT01583842|131I-MIBG
1097547|NCT01583842|PET/CT
1097548|NCT01583829|ADHD
1097549|NCT01583829|neurofeedback
1097550|NCT01583829|biofeedback
1097551|NCT01583829|computer attention training
1097552|NCT01583816|Actinic Keratosis
1097553|NCT01583816|Resiquimod
1097554|NCT01583790|Laparoscopic Sleeve Gastrectomy
1097555|NCT01583790|Bariatric surgery
1097556|NCT01583790|Morbid Obesity
1097557|NCT01583777|Belinostat
1097558|NCT01583751|pilonidal sinus
1097559|NCT01583751|new technique
1097560|NCT01583751|videoendoscopic
1097561|NCT01583725|Obesity
1097562|NCT01583725|Bariatric surgery
1097563|NCT01583725|Weight loss
1097564|NCT01583725|fMRI
1097565|NCT01583725|gut peptides
1097566|NCT01583712|Confocal laser endomicroscopy
1097567|NCT01583712|Small bowel imaging
1097568|NCT01583712|Graft-versus-host disease
1097569|NCT01583712|HSCT
1097570|NCT01583699|MALT-lymphoma
1097571|NCT01583699|Confocal laser endomicroscopy
1097572|NCT01583699|Gastrointestinal endoscopy
1097573|NCT01583686|Metastatic Cancer
1097574|NCT01583686|Immunotherapy
1097575|NCT01583686|Gene Therapy
1097576|NCT01583686|Mesothelioma
1097577|NCT01583686|Pancreatic Cancer
1097578|NCT01583660|NSAIDs
1097579|NCT01583660|Anti-inflammatory
1097580|NCT01583660|elderly hip fracture
1097581|NCT01583660|mortality
1097582|NCT01583608|Drug eluting stent
1097583|NCT01583608|Bioabsorbable
1097584|NCT01583608|Bioresorbable
1097585|NCT01583608|Coronary Stent
1097586|NCT01583608|Scaffold
1097587|NCT01583608|Stents
1097588|NCT01583608|Angioplasty
1097589|NCT01583608|Coronary Artery Disease
1097590|NCT01583608|Stentthrombosis
1097591|NCT01583595|Chronic Lung Disease
1097592|NCT01583595|Exercise
1097593|NCT01583595|Self-efficacy
1097594|NCT01583582|randomized double-blind placebo-controlled study
1097595|NCT01583582|peptide concentrate
1097596|NCT01583582|Coldwater Shrimp
1097597|NCT01583582|antihypertensive effect
1097598|NCT01583582|mild hypertension
1097599|NCT01583582|moderate hypertension
1097600|NCT01583582|blood pressure
1097601|NCT01583569|Complex Dynamic Systems
1097602|NCT01583569|Biomarkers
1097603|NCT01583569|Mood Disorders
1097604|NCT01583556|Adult
1097605|NCT01583556|English speaking
1097606|NCT01583556|Fractures
1097607|NCT01583556|Excellent prognosis
1097608|NCT01583556|Upper Extremity
1097609|NCT01583543|Recurrent
1097610|NCT01583543|Metastatic
1097611|NCT01583530|Belimumab
1097612|NCT01583530|Injections, Subcutaneous
1097613|NCT01583530|Drug Administration Routes
1097614|NCT01583530|Injections
1097615|NCT01583530|Lupus Erythematosus, Systemic
1097616|NCT01583530|Lupus
1097617|NCT01583530|SLE
1097618|NCT01583530|Systemic Lupus Erythematosus
1097619|NCT01583530|Antibodies
1097620|NCT01583530|Autoimmune Disease
1097621|NCT01583530|Biological Therapy
1097622|NCT01583530|Immune System Diseases
1097623|NCT01583530|Pharmacokinetics
1097624|NCT01583530|Biological Availability
1097625|NCT01583517|Acute pancreatitis
1097626|NCT01583517|ERCP
1097627|NCT01583517|Sphincterotomy
1097628|NCT01583517|Manometry
1097629|NCT01583517|Sphincter of Oddi dysfunction
1097630|NCT01583504|Achilles
1097631|NCT01583504|Tendinopathy
1097632|NCT01583504|Tendonitis
1097633|NCT01583504|Injection
1097634|NCT01583491|platelet rich fibrin
1097635|NCT01583491|mandibular third molar
1097636|NCT01583491|periodontal problem
1097637|NCT01583478|incobotulinumtoxinA
1097638|NCT01583478|wrinkles
1097639|NCT01583478|glabellar
1097640|NCT01583478|rhytids
1097641|NCT01583478|frown
1097642|NCT01583478|lines
1097643|NCT01583465|randomized controlled trial
1097644|NCT01583465|Blood loss, surgical
1097645|NCT01583465|Blood loss, postoperative
1097646|NCT01583465|Wound healing
1097647|NCT01583452|Post operative ileus
1097648|NCT01583452|Gastrointestinal surgery
1097649|NCT01583452|Chewing gum
1097650|NCT01583439|HIV Infections
1097651|NCT01583439|Acquired Immunodeficiency Syndrome
1097652|NCT01583439|Anti-HIV Agents
1097653|NCT01583439|Sexually Transmitted Diseases, Viral
1097654|NCT01583439|Immunologic Deficiency Syndromes
1097655|NCT01583439|Immune System Diseases
1097656|NCT01583439|Anti-Retroviral Agents
1097657|NCT01583439|Antiviral Agents
1097658|NCT01583426|GeparSepto
1097659|NCT01583426|GBG 69
1097660|NCT01583426|GBG
1097661|NCT01583426|German Breast Group
1097662|NCT01583426|neo-adjuvant
1097663|NCT01583426|GBG Forschungs GmbH
1097664|NCT01583426|Tubular breast cancer stage II
1097665|NCT01583426|Mucinous breast cancer stage II
1097666|NCT01583426|Invasive ductal breast cancer
1097667|NCT01583426|Tubular breast cancer stage III
1097668|NCT01583426|HER-2 positive breast cancer
1097669|NCT01583426|Inflammatory breast cancer
1097670|NCT01583413|Ventilator-associated pneumonia
1097671|NCT01583400|Depressive Disorder, Major
1097672|NCT01583400|Depressive Disorder, Minor
1097673|NCT01583400|Dysthymic Disorder
1097674|NCT01583387|healthy adults
1097675|NCT01583387|urinary adducts
1097676|NCT01583387|water intake
1097677|NCT01583374|spondylitis
1097678|NCT01583374|spondyloarthritis
1097679|NCT01583374|Spondyloarthropathy
1097680|NCT01583374|Oral preparation
1097681|NCT01583361|two arms
1097682|NCT01583361|D2 lymphadenectomy
1097683|NCT01583361|chemotherapy before and after surgery
1097684|NCT01583361|disease free survival
1097685|NCT01583348|transvaginal
1097686|NCT01583348|NOTES
1097687|NCT01583348|cholecystectomy
1097688|NCT01583348|cholangiography
1097689|NCT01583348|symptomatic gallstone disease
1097690|NCT01583335|Overweight
1097691|NCT01583335|Obesity
1097692|NCT01583335|Predisposition
1097693|NCT01583335|Prevention
1097694|NCT01583335|Diet
1097695|NCT01583335|Physical activity
1097696|NCT01583335|Sleep
1097697|NCT01583335|Family stress
1097698|NCT01583322|ovarian cancer
1097699|NCT01583322|debulking surgery
1097700|NCT01583322|interval debulking
1097701|NCT01583322|vargatef
1097702|NCT01583322|nintedanib
1097703|NCT01583322|maintenance
1097704|NCT01583322|first line
1097705|NCT01583322|paclitaxel
1097706|NCT01583322|carboplatin
1097707|NCT01583309|blood pressure
1097708|NCT01583309|cardiovascular instability
1097709|NCT01583309|symptomatic hypotension
1097710|NCT01583309|online hemofiltration
1097711|NCT01583309|online hemodiafiltration
1097712|NCT01583283|Multiple Myeloma
1097713|NCT01583283|Relapsed
1097714|NCT01583283|Refractory
1097715|NCT01583283|Histone deacetylase inhibitors
1097716|NCT01583283|Lenalidomide
1097717|NCT01583283|Revlimid
1097718|NCT01583283|Dexamethasone
1097719|NCT01583270|Arabinxylan
1097720|NCT01583270|Rye kernels
1097721|NCT01583270|whole grain
1097722|NCT01583270|Dietary fibre
1097723|NCT01583270|Metabolic syndrome
1097724|NCT01583270|Glycemic response
1097725|NCT01583270|Colon fermentation
1097726|NCT01583270|Second meal effekt
1097727|NCT01583270|Satiety
1097728|NCT01583218|Phase III
1097729|NCT01583205|ALS
1097730|NCT01583205|Coping Effectiveness Training
1097731|NCT01583205|Distress
1097732|NCT01583205|Care Giver
1097733|NCT01583192|infection
1097734|NCT01583192|skin preparation
1097735|NCT01583192|fore-foot surgery
1097736|NCT01583192|chloride-hexidine
1097737|NCT01583192|povidine-jodine
1097738|NCT01583192|alcohol
1097739|NCT01583179|nerve block
1097740|NCT01583179|outpatient surgery
1097741|NCT01583140|physical activity
1097742|NCT01583140|Latinas
1097743|NCT01583127|Problem Behavior
1097744|NCT01583114|dilated cardiomyopathy
1097745|NCT01583114|heart failure
1097746|NCT01583114|genetics
1097747|NCT01583114|mutation carrier
1097748|NCT01583114|ACE treatment
1097749|NCT01583114|preclinical
1097750|NCT01583088|Amyotrophic lateral sclerosis,
1097751|NCT01583088|Diaphragm
1097752|NCT01583088|Mechanical ventilation
1097753|NCT01583088|Phrenic nerve stimulation
1097754|NCT01583088|Respiratory insufficiency
1097755|NCT01583062|Surgical Wound Infection
1097756|NCT01583062|Facial Injuries
1097757|NCT01583062|Orbital Fractures
1097758|NCT01583062|Zygomatic Fractures
1097759|NCT01583062|Mandibular Fractures
1097760|NCT01583062|Jaw Injuries
1097761|NCT01583023|bipolar disorder
1097762|NCT01583023|repetitive transcranial magnetic stimulation (rtms)
1097763|NCT01583023|bupropion
1097764|NCT01583023|lithium a/o Epival
1097765|NCT01583010|ultrasound guided regional anaesthesia needle visualization
1097766|NCT01582997|BRAF
1097767|NCT01582997|Advance solid tumors
1097768|NCT01582984|consent
1097769|NCT01582984|Patient Understanding
1097770|NCT01582984|Knee Arthroplasty
1097771|NCT01582971|Breast Cancer
1097772|NCT01582971|Reflexology
1097773|NCT01582971|Complementary
1097774|NCT01582958|Osteopathic Manipulative Treatment
1097775|NCT01582958|Pulmonary Function Tests
1097776|NCT01582958|Biochemical Alterations
1097777|NCT01582945|Treatment resistant
1097778|NCT01582945|suicidal ideation
1097779|NCT01582945|major depressive disorder
1097780|NCT01582932|plaque psoriasis
1097781|NCT01582932|pediatric
1097782|NCT01582932|mild
1097783|NCT01582932|moderate
1097784|NCT01582919|dementia
1097785|NCT01582919|Alzheimer's Disease
1097786|NCT01582919|diagnostic
1097787|NCT01582919|biomarkers
1097788|NCT01582919|neuroimaging
1097789|NCT01582919|PET
1097790|NCT01582919|MRI
1097791|NCT01582919|mild cognitive impairment
1097792|NCT01582893|inflammation
1097793|NCT01582893|dialysis
1097794|NCT01582880|Keratoprosthesis
1097795|NCT01582880|sterile cornea ulcer
1097796|NCT01582867|Hemodiafiltration
1097797|NCT01582867|Hemodialysis
1097798|NCT01582867|Sodium
1097799|NCT01582867|Artis
1097800|NCT01582867|renal failure
1097801|NCT01582854|Post-Stroke Cognitive Impairment (PSCI)
1097802|NCT01582854|Stroke
1097803|NCT01582854|Actovegin
1097804|NCT01582854|Cognition disorders
1097805|NCT01582841|Colon Cancer
1097806|NCT01582841|Lynch Syndrome
1097807|NCT01582841|Genetic Screening
1097808|NCT01582828|atrial
1097809|NCT01582828|fibrillation
1097810|NCT01582828|pvi
1097811|NCT01582828|vats
1097812|NCT01582828|ablation
1097813|NCT01582828|hybrid
1097814|NCT01582815|Major Depressive Disorder
1097815|NCT01582815|Depression
1097816|NCT01582815|Anxiety symptoms
1097817|NCT01582815|JNJ-40411813
1097818|NCT01582763|Guillain-Barré syndrome
1097819|NCT01582763|Polyneuropathy
1097820|NCT01582763|Autoimmune Diseases
1097821|NCT01582763|Immune System Diseases
1097822|NCT01582763|Neuromuscular Diseases
1097823|NCT01582763|Outcome
1097824|NCT01582763|Quality of life
1097825|NCT01582763|Disability
1097826|NCT01582763|Prognostic Determinants
1097827|NCT01582763|Treatment
1097828|NCT01582763|Immunoglobulins
1097829|NCT01582763|Prognosis
1097830|NCT01582763|Infections
1097831|NCT01582763|Anti-ganglioside antibodies
1097832|NCT01582763|Genetic polymorphisms
1097833|NCT01582763|Electrophysiology
1097834|NCT01582763|Cerebrospinal Fluid
1097835|NCT01582763|Serum
1097836|NCT01582750|endoscopic ultrasound
1097837|NCT01582750|pre-operative concurrent chemoradiotherapy
1097838|NCT01582737|Xarelto
1097839|NCT01582737|SPAF
1097840|NCT01582724|Menstrual pain
1097841|NCT01582724|Primary dysmenorrhea
1097842|NCT01582724|Self-care acupressure
1097843|NCT01582711|LTBI
1097844|NCT01582711|LTB
1097845|NCT01582711|Latent TB
1097846|NCT01582711|TB infection
1097847|NCT01582685|Breast Cancer
1097848|NCT01582685|Obesity
1097849|NCT01582685|Exercise
1097850|NCT01582685|Angiogenesis
1097851|NCT01582672|RCC
1097852|NCT01582672|Kidney Cancer
1097853|NCT01582659|constipation
1097854|NCT01582659|children
1097855|NCT01582659|outpatient
1097856|NCT01582633|vaccine
1097857|NCT01582633|influenza
1097858|NCT01582633|needle free jet injector
1097859|NCT01582633|Intradermal
1097860|NCT01582633|sparing dose
1097861|NCT01582620|Cerebrovascular disorders
1097862|NCT01582620|Telemedicine
1097863|NCT01582620|remote consultation
1097864|NCT01582620|rural
1097865|NCT01582620|thrombolysis therapy
1097866|NCT01582620|plasminogen activators
1097867|NCT01582620|stroke care
1097868|NCT01582620|stroke management
1097869|NCT01582594|1000 residual serum/plasma samples
1097870|NCT01582594|anti-HCV seronegative or seropositive
1097871|NCT01582581|mental health
1097872|NCT01582581|depression
1097873|NCT01582581|behavioral health
1097874|NCT01582581|cognitive behavioral therapy
1097875|NCT01582581|CBT
1097876|NCT01582581|computer-assisted psychotherapy
1097877|NCT01582555|mucolysis
1097878|NCT01582555|QOL
1097879|NCT01582555|endoscopy
1097880|NCT01582555|sinus surgery
1097881|NCT01582529|Developmental Outcomes
1097882|NCT01582529|Psychosocial Outcomes
1097883|NCT01582529|Hypoplastic Left Heart Syndrome
1097884|NCT01582529|Congenital Heart Disease
1097885|NCT01582516|brain tumor
1097886|NCT01582516|virotherapy
1097887|NCT01582516|glioblastoma
1097888|NCT01582516|replication competent adenovirus
1097889|NCT01582490|Mammoplasty
1097890|NCT01582490|Postoperative pain
1097891|NCT01582490|Analgesia
1097892|NCT01582477|TAP, robot-assisted prostatectomy
1097893|NCT01582464|Protective Headwear
1097894|NCT01582464|Social Marketing
1097895|NCT01582464|Theory of Planned Behavior
1097896|NCT01582425|isavuconazole
1097897|NCT01582425|methadone
1097898|NCT01582425|Healthy Volunteers
1097899|NCT01582425|BAL8557
1097900|NCT01582412|Isavuconazole
1097901|NCT01582412|Digoxin
1097902|NCT01582412|Healthy Volunteers
1097903|NCT01582412|BAL8557
1097904|NCT01582399|Healthy Volunteers
1097905|NCT01582399|CD40 receptor occupancy
1097906|NCT01582399|Co-stimulation blockade
1097907|NCT01582399|CD40 antigen
1097908|NCT01582399|Anti-CD40
1097909|NCT01582399|ASKP1240
1097910|NCT01582360|critical illness
1097911|NCT01582360|pharmacokinetics
1097912|NCT01582360|CRRT
1097913|NCT01582360|CVVH
1097914|NCT01582360|CVVHD
1097915|NCT01582360|CVVHDF
1097916|NCT01582360|antiinfectives
1097917|NCT01582360|antibiotics
1097918|NCT01582360|minimum inhibitory concentration
1097919|NCT01582360|bacterial killing
1097920|NCT01582360|pharmacodynamics
1097921|NCT01582360|PK/PD index
1097922|NCT01582347|Opioid dependence
1097923|NCT01582334|Growth disorders
1097924|NCT01582334|Saizen
1097925|NCT01582334|Easypod
1097926|NCT01582334|Growth hormone
1097927|NCT01582334|Pediatric subject
1097928|NCT01582321|vascular ultrasound
1097929|NCT01582321|flow cytometry
1097930|NCT01582321|platelet aggregation
1097931|NCT01582295|Bone disease
1097932|NCT01582282|Type II NIDDM
1097933|NCT01582243|Diabetes Mellitus, type 2
1097934|NCT01582243|vildagliptin
1097935|NCT01582230|Type 2 diabetes mellitus
1097936|NCT01582230|Vildagliptin
1097937|NCT01582217|Bleeding
1097938|NCT01582217|Risk Score
1097939|NCT01582217|Outcomes
1097940|NCT01582217|Prasugrel
1097941|NCT01582204|clear cell carcinoma
1097942|NCT01582204|Kidney
1097943|NCT01582204|MAB-124I-CG250
1097944|NCT01582204|PET scan
1097945|NCT01582204|CT scan
1097946|NCT01582204|sunitinib
1097947|NCT01582204|pazopanib
1097948|NCT01582204|11-134
1097949|NCT01582191|Advanced Cancers
1097950|NCT01582191|Advanced solid cancer
1097951|NCT01582191|Metastatic cancer
1097952|NCT01582191|Vandetanib
1097953|NCT01582191|ZD 6474
1097954|NCT01582191|Zactima
1097955|NCT01582191|Caprelsa
1097956|NCT01582191|Everolimus
1097957|NCT01582191|Afinitor
1097958|NCT01582191|RAD001
1097959|NCT01582191|Multi-kinase Inhibitor
1097960|NCT01582178|colonoscopy
1097961|NCT01582178|warm water immersion
1097962|NCT01582178|cool water immersion
1097963|NCT01582152|Brain Neoplasms
1097964|NCT01582152|Central Nervous System Neoplasms
1097965|NCT01582152|Recurrent Glioblastoma
1097966|NCT01582152|Glioblastoma multiforme
1097967|NCT01582152|GBM
1097968|NCT01582152|Gliosarcoma
1097969|NCT01582152|TPI287
1097970|NCT01582152|Bevacizumab
1097971|NCT01582152|Avastin
1097972|NCT01582152|Anti-VEGF Monoclonal Antibody
1097973|NCT01582152|rhuMAb-VEGF
1097974|NCT01582139|Artificial Pancreas Project
1097975|NCT01582139|AP Platform
1097976|NCT01582139|Insulin Pump
1097977|NCT01582139|Continuous Glucose Monitor
1097978|NCT01582139|Closed-Loop Control
1097979|NCT01582139|Control-to-Range
1097980|NCT01582126|multiple sclerosis
1097981|NCT01582126|physical therapy
1097982|NCT01582126|postural control
1097983|NCT01582087|acute hepatic failure
1097984|NCT01582087|chronic hepatic failure
1097985|NCT01582087|coma
1097986|NCT01582074|Ultrasound Tomography
1097987|NCT01582074|Tamoxifen
1097988|NCT01582074|Breast Cancer
1097989|NCT01582074|Estrogen Receptor Positive
1097990|NCT01582074|Breast Density
1097991|NCT01582061|Cushing's disease
1097992|NCT01582061|Hormone disorder
1097993|NCT01582061|Cortisol
1097994|NCT01582061|Adrenocorticotropic hormone
1097995|NCT01582061|Pituitary tumor
1097996|NCT01582035|Hepatitis C
1097997|NCT01582035|TMC647055HPC1005
1097998|NCT01582035|TMC647055
1097999|NCT01582035|telaprevir
1098000|NCT01581996|Chronic renal failure
1098001|NCT01581996|End-stage renal disease
1098002|NCT01581996|Chronic peritoneal dialysis
1098003|NCT01581996|Serum phosphorus
1098004|NCT01581996|Hyperphosphatemia
1098005|NCT01581996|Phosphate binders
1098006|NCT01581996|Phosphate
1098007|NCT01581970|head and neck cancer
1098008|NCT01581970|metastatic squamous cell cancer
1098009|NCT01581957|Enteral nutrition, critically ill patients
1098010|NCT01581944|myomectomy
1098011|NCT01581944|GnRH
1098012|NCT01581944|blood loss
1098013|NCT01581905|Hysterectomy
1098014|NCT01581905|Laparoscopy
1098015|NCT01581905|Robotics
1098016|NCT01581892|bone nonunion
1098017|NCT01581892|bone marrow
1098018|NCT01581892|mononuclear
1098019|NCT01581892|fracture
1098020|NCT01581879|Bioequivalence
1098021|NCT01581879|Ziprasidone hydrochloride
1098022|NCT01581879|crossover
1098023|NCT01581866|Bioequivalence
1098024|NCT01581866|Ziprasidone hydrochloride
1098025|NCT01581866|crossover
1098026|NCT01581853|HIV
1098027|NCT01581853|AIDS
1098028|NCT01581853|MONOTHERAPY
1098029|NCT01581853|PILOT
1098030|NCT01581853|LOPINAVIR/RITONAVIR
1098031|NCT01581840|anus
1098032|NCT01581840|carcinoma
1098033|NCT01581840|panitumumab
1098034|NCT01581840|mitomycine
1098035|NCT01581840|5Fu
1098036|NCT01581840|radiotherapy
1098037|NCT01581827|Heart Failure
1098038|NCT01581827|BNP
1098039|NCT01581827|NT-proBNP
1098040|NCT01581814|PCOS
1098041|NCT01581801|gastric bypass
1098042|NCT01581801|sleeve gastrectomy
1098043|NCT01581801|reactive hypoglycemia
1098044|NCT01581788|Bioequivalence
1098045|NCT01581788|Divalproex Sodium
1098046|NCT01581788|Crossover
1098047|NCT01581775|Bioequivalence
1098048|NCT01581775|Divalproex Sodium
1098049|NCT01581775|Crossover
1098050|NCT01581762|EUS, FNA
1098051|NCT01581749|low risk prostate cancer
1098052|NCT01581749|intermediate risk prostate cancer
1098053|NCT01581749|stereotactic radiosurgery
1098054|NCT01581736|insulin resistance
1098055|NCT01581736|mitochondria
1098056|NCT01581723|urinary bladder tumor
1098057|NCT01581723|monopolar TURBT
1098058|NCT01581723|bipolar TURBT
1098059|NCT01581710|Leukotriene Antagonists
1098060|NCT01581710|Bronchial Hyperreactivity
1098061|NCT01581697|oat
1098062|NCT01581697|cholesterol
1098063|NCT01581697|children
1098064|NCT01581697|adolescent
1098065|NCT01581697|Level reduction of ceric cholesterol
1098066|NCT01581645|Parkinson's disease
1098067|NCT01581645|Parkinsonism
1098068|NCT01581645|Gait problems
1098069|NCT01581645|Freezing gait
1098070|NCT01581632|atherosclerosis
1098071|NCT01581632|endothelial dysfunction
1098072|NCT01581632|coronary vasospasm
1098073|NCT01581619|Early Invasive N0
1098074|NCT01581619|Non-Invasive
1098075|NCT01581606|Age Related Macular Degeneration
1098076|NCT01581606|Teleophthalmology
1098077|NCT01581606|Screening
1098078|NCT01581606|Diagnosis
1098079|NCT01581606|Timing
1098080|NCT01581606|Treatment
1098081|NCT01581593|Primary Immunodeficiency
1098082|NCT01581593|PID
1098083|NCT01581593|Agammaglobulinemia
1098084|NCT01581593|Hypogammaglobulinemia
1098085|NCT01581593|Antibody deficiency
1098086|NCT01581580|Parkinson's Disease
1098087|NCT01581580|Deep Brain Stimulation
1098088|NCT01581580|Neurophysiology
1098089|NCT01581580|Movement Disorder
1098090|NCT01581580|Essential Tremor
1098091|NCT01581580|Parkinson Disease
1098092|NCT01581567|Storage
1098093|NCT01581567|Repository
1098094|NCT01581567|Samples
1098095|NCT01581567|Data
1098096|NCT01581554|Hepatitis B
1098097|NCT01581554|Treatment
1098098|NCT01581554|Nucleoside/Nucleotide Analogue
1098099|NCT01581541|Targeted Therapy
1098100|NCT01581541|Solid Tumors
1098101|NCT01581541|Lymphoma
1098102|NCT01581541|Non-Hodgkin Lymphoma
1098103|NCT01581541|Solid Tumor
1098104|NCT01581528|T-cell childhood acute lymphoblastic leukemia
1098105|NCT01581528|untreated adult acute lymphoblastic leukemia
1098106|NCT01581528|T-cell adult acute lymphoblastic leukemia
1098107|NCT01581528|untreated childhood acute lymphoblastic leukemia
1098108|NCT01581502|Anticoagulation
1098109|NCT01581502|Recurrent stroke
1098110|NCT01581502|Bleeding
1098111|NCT01581489|Cord clamping
1098112|NCT01581489|iron deficiency
1098113|NCT01581489|Neurodevelopment
1098114|NCT01581476|Adolescence
1098115|NCT01581463|pharmacokinetics of oral T3
1098116|NCT01581450|Hyperalgesia and pain
1098117|NCT01581437|atrial fibrillation
1098118|NCT01581437|cardiac ablation
1098119|NCT01581424|Fabry disease
1098120|NCT01581424|kidney function
1098121|NCT01581424|kidney structure morphometry
1098122|NCT01581424|Fabry kidney disease
1098123|NCT01581424|Podocytes
1098124|NCT01581411|central retinal vein occlusion
1098125|NCT01581411|macular edema
1098126|NCT01581411|vision loss
1098127|NCT01581411|rtelative afferent papillary defect
1098128|NCT01581398|Peginterferon
1098129|NCT01581398|Pegasys
1098130|NCT01581398|Sustained virus response
1098131|NCT01581398|HCV
1098132|NCT01581385|atherosclerosis
1098133|NCT01581385|carotid artery
1098134|NCT01581385|carotid endarterectomy
1098135|NCT01581359|Endometriosis
1098136|NCT01581359|GnRH treatment
1098137|NCT01581359|Infertility
1098138|NCT01581359|IVF
1098139|NCT01581346|NSCLC
1098140|NCT01581346|exercise intervention
1098141|NCT01581346|quality of life
1098142|NCT01581333|febrile neutropenia
1098143|NCT01581333|antimicrobial treatment
1098144|NCT01581333|procalcitonin
1098145|NCT01581307|liver
1098146|NCT01581307|pancreas
1098147|NCT01581307|chemotherapy
1098148|NCT01581307|radiotherapy
1098149|NCT01581294|Rheumatoid arthritis
1098150|NCT01581294|Psoriatic arthritis
1098151|NCT01581294|Ankylosing spondylitis
1098152|NCT01581294|Spondyloarthritis
1098153|NCT01581281|Pediatric
1098154|NCT01581281|Children
1098155|NCT01581281|Adolescent
1098156|NCT01581281|Headache
1098157|NCT01581281|Migraine
1098158|NCT01581255|acute respiratory distress syndrome
1098159|NCT01581255|high frequency oscillation ventilation
1098160|NCT01581255|ventilator-induced lung injury
1098161|NCT01581255|biomarkers
1098162|NCT01581242|Clevudine and Adefovir dipivoxil
1098163|NCT01581242|pharmacokinetic drug drug interaction
1098164|NCT01581242|oral administration
1098165|NCT01581242|male subjects
1098166|NCT01581229|ALI;noninvasive positive pressure ventilation
1098167|NCT01581216|Fatigue
1098168|NCT01581216|Palliative Care
1098169|NCT01581216|Exercise
1098170|NCT01581190|Bananas
1098171|NCT01581190|Exercise
1098172|NCT01581190|Metabolomics
1098173|NCT01581190|Oxidative stress
1098174|NCT01581190|Inflammation
1098175|NCT01581190|Immune function
1098176|NCT01581177|asthma
1098177|NCT01581177|mild-to-moderate persistent asthma
1098178|NCT01581177|mild asthma
1098179|NCT01581177|moderate asthma
1098180|NCT01581177|persistent asthma
1098181|NCT01581164|blood
1098182|NCT01581164|hematopoietic
1098183|NCT01581164|stem
1098184|NCT01581164|cell
1098185|NCT01581164|transplant
1098186|NCT01581164|vaccine
1098187|NCT01581164|vaccination
1098188|NCT01581164|recovery
1098189|NCT01581164|immune
1098190|NCT01581164|system
1098191|NCT01581151|retinal vein occlusion
1098192|NCT01581151|ozurdex
1098193|NCT01581151|lucentis
1098194|NCT01581151|BCVA
1098195|NCT01581151|foveal thickness
1098196|NCT01581125|Inpatients
1098197|NCT01581125|Health Normalcy
1098198|NCT01581125|circadian rhythm
1098199|NCT01581099|Atherosclerosis
1098200|NCT01581099|Cardiovascular risk factors
1098201|NCT01581099|Calorie restriction
1098202|NCT01581099|Bariatric Surgery
1098206|NCT01581073|renal anemia
1098207|NCT01581073|erythropoiesis stimulating agent
1098208|NCT01581073|hemoglobin
1098209|NCT01581073|non-diabetes
1098210|NCT01581073|CKD
1098211|NCT01581073|Chronic Kidney Disease patients without diabetes
1098212|NCT01581047|amoxicillin
1098213|NCT01581047|clavulanic acid
1098214|NCT01581047|cefuroxime
1098215|NCT01581047|Patients in the intensive care unit, with an infection which requires amoxicillin/clavulanic acid or cefuroxime
1098216|NCT01581034|endothelial function
1098217|NCT01581034|biomarkers
1098218|NCT01581034|autonomic nervous system
1098219|NCT01581034|coronary artery disease
1098220|NCT01581021|randomized
1098221|NCT01581021|controlled
1098222|NCT01581021|hooks
1098223|NCT01581021|screws
1098224|NCT01581008|palliative care
1098225|NCT01581008|heart failure
1098226|NCT01581008|delivery of health care
1098227|NCT01580995|Chronic hepatitis C infection
1098228|NCT01580982|Oncogenes
1098229|NCT01580982|Lung and Other Thoracic Cancers
1098230|NCT01580969|glioma
1098231|NCT01580956|Acute respiratory failure
1098232|NCT01580956|Critical illness
1098233|NCT01580956|Mechanical ventilation
1098234|NCT01580956|Ventilation weaning
1098235|NCT01580956|Intensive Care Unit
1098236|NCT01580956|Variable (NOISY) PSV
1098237|NCT01580956|PSV
1098238|NCT01580943|Chlorhexidine
1098239|NCT01580943|Cetyl pyridinium chloride
1098240|NCT01580943|Mouth rinse
1098241|NCT01580943|Antiplaque Efficacy
1098242|NCT01580943|Self Efficacy
1098243|NCT01580943|Taste Sweet
1098244|NCT01580943|Side Effects
1098245|NCT01580930|physical inactivity
1098246|NCT01580930|exercise training
1098247|NCT01580930|sedentary time
1098248|NCT01580930|habitual physical activity
1098249|NCT01580917|laser doppler anemometry
1098250|NCT01580917|dynamic testing of tissue mechanical property
1098251|NCT01580917|diabetic foot complications
1098252|NCT01580917|ulcer genesis
1098253|NCT01580904|Pharmaceutical Care
1098254|NCT01580904|Diabetics patients
1098255|NCT01580904|Clinical trial
1098256|NCT01580891|Naftifine HCl Cream 1%
1098257|NCT01580891|Naftin® (Naftifine HCl) Cream 1%
1098258|NCT01580891|Tinea Pedis
1098259|NCT01580891|Efficacy and safety
1098260|NCT01580878|Butenafine Hydrochloride Cream, 1%
1098261|NCT01580878|Lotrimin Ultra® Cream, 1%
1098262|NCT01580878|Interdigital Tinea Pedis
1098263|NCT01580878|Safety and Bioequivalence
1098264|NCT01580865|Lupus nephritis
1098265|NCT01580865|Tacrolimus
1098266|NCT01580865|Mycophenolate mofetil
1098267|NCT01580865|Complete remission
1098268|NCT01580839|ischemic stroke
1098269|NCT01580839|ischemic penumbra
1098270|NCT01580839|magnetic resonance imaging
1098271|NCT01580839|MRI
1098272|NCT01580839|diffusion imaging
1098273|NCT01580839|DWI
1098274|NCT01580839|perfusion imaging
1098275|NCT01580839|PWI
1098276|NCT01580839|thrombolysis
1098277|NCT01580839|alteplase
1098278|NCT01580839|tPA
1098279|NCT01580839|EPITHET
1098280|NCT01580826|pasteurization
1098281|NCT01580826|human milk
1098282|NCT01580826|very low birth weight infants
1098283|NCT01580813|diabetes
1098284|NCT01580813|exercise
1098285|NCT01580813|cardiovascular
1098286|NCT01580813|heart
1098287|NCT01580813|insulin sensitivity
1098288|NCT01580787|Parkinson´s disease
1098289|NCT01580787|Postural Balance
1098290|NCT01580787|virtual reality
1098291|NCT01580735|NSCLC
1098292|NCT01580735|c-MET
1098293|NCT01580735|EGFR mutation-positive
1098294|NCT01580735|gefitinib
1098295|NCT01580735|erlotinib
1098296|NCT01580735|EGFR-TKI resistance
1098297|NCT01580722|Anterior Cruciate Ligament,Early,Delay,Reconstruction
1098298|NCT01580709|stricture
1098299|NCT01580709|cholangiocarcinoma
1098300|NCT01580709|pancreatic adenocarcinoma
1098301|NCT01580709|bile duct
1098302|NCT01580709|ERCP
1098303|NCT01580696|Folate binding protein
1098304|NCT01580696|E39 vaccine
1098305|NCT01580696|Stage I-IV ovarian cancer
1098306|NCT01580696|Stage I-IV endometrial cancer
1098307|NCT01580683|Atrial Fibrillation
1098308|NCT01580683|Ascorbic Acid
1098309|NCT01580683|Thoracic Surgery
1098310|NCT01580683|Cardiac Arrhythmias
1098311|NCT01580683|Cardiac Surgery
1098312|NCT01580683|Vitamin C
1098313|NCT01580683|Postoperative Complications
1098314|NCT01580683|Antioxidants
1098315|NCT01580683|Inflammation
1098316|NCT01580670|Infliximab
1098317|NCT01580670|REMICADE
1098318|NCT01580670|TA-650
1098319|NCT01580670|pediatric Crohn's disease
1098320|NCT01580657|HIV
1098321|NCT01580657|Prevention
1098322|NCT01580657|Methods
1098323|NCT01580657|Assessment reactivity
1098324|NCT01580657|South Africa
1098325|NCT01580657|Youth
1098326|NCT01580631|Narrow band imaging
1098327|NCT01580631|Barrett's esophagus
1098328|NCT01580631|Gastroesophageal reflux disease
1098329|NCT01580618|pleural effusion
1098330|NCT01580618|malignancy
1098331|NCT01580618|loculated
1098332|NCT01580579|Radiation pneumonitis
1098333|NCT01580579|locally advanced lung cancer
1098334|NCT01580579|Respiratory function tests
1098335|NCT01580566|Myocardial Infarction (MI)
1098336|NCT01580566|Kidney function
1098337|NCT01580566|bio-markers
1098338|NCT01580553|Heart failure
1098339|NCT01580553|L-carnitine
1098340|NCT01580553|injection
1098341|NCT01580553|safety
1098342|NCT01580553|efficacy
1098343|NCT01580527|postoperative artificial nutrition
1098344|NCT01580527|parenteral nutrition
1098345|NCT01580527|enteral nutrition
1098346|NCT01580527|postoperative complications
1098347|NCT01580527|cephalic pancreatoduodenectomy
1098348|NCT01580514|myocardial infarction
1098349|NCT01580514|percutaneous coronary intervention
1098350|NCT01580514|exenatide
1098351|NCT01580514|reperfusion injury
1098352|NCT01580514|cardiac magnetic resonance
1098353|NCT01580475|glycemic control,
1098354|NCT01580475|exercise training,
1098355|NCT01580475|detraining,
1098356|NCT01580475|retraining,
1098357|NCT01580475|body composition,
1098358|NCT01580475|strength and fitness
1098359|NCT01580462|continuous subcutaneous insulin infusion (CSII)
1098360|NCT01580462|children
1098361|NCT01580462|adolescent
1098362|NCT01580436|Tricuspid Valve Insufficiency
1098363|NCT01580436|Cardiac Valve Annuloplasty
1098364|NCT01580436|Outcome Assessment (Health Care)
1098365|NCT01580423|dyspnea
1098366|NCT01580397|Pancreatic cancer
1098367|NCT01580397|INNO-206
1098368|NCT01580397|Doxorubicin-EMCH
1098369|NCT01580358|cancer
1098370|NCT01580358|radiotherapy
1098371|NCT01580358|chemotherapy
1098372|NCT01580358|Traditional Chinese Medicine
1098373|NCT01580358|Safety
1098374|NCT01580345|DHA
1098375|NCT01580345|Omega 3 fatty acid
1098376|NCT01580345|Decosa hexaenoic acid
1098377|NCT01580345|Pregnancy
1098378|NCT01580345|Newborn outcome
1098379|NCT01580345|Supplementation
1098380|NCT01580345|Birth size
1098381|NCT01580345|gestational age
1098382|NCT01580345|India
1098383|NCT01580345|Randomized controlled trial
1098384|NCT01580345|RCT
1098385|NCT01580332|biomarkers
1098386|NCT01580332|lung cancer
1098387|NCT01580332|solitary pulmonary nodules
1098388|NCT01580332|SPN
1098389|NCT01580332|breath analysis
1098390|NCT01580332|VOC
1098391|NCT01580332|volatile organic compounds
1098392|NCT01580332|sputum
1098393|NCT01580332|auto-antibodies
1098394|NCT01580319|obesity
1098395|NCT01580319|cholesterol
1098396|NCT01580319|cholesterol, LDL
1098397|NCT01580319|cholesterol, HDL
1098398|NCT01580319|blood glucose
1098399|NCT01580319|Triglyceride
1098400|NCT01580319|C-Reactive Protein - hs
1098401|NCT01580319|blood pressure
1098402|NCT01580319|physical activity
1098403|NCT01580319|Sedentary Lifestyle
1098404|NCT01580293|Hemophilia A, factor VIII, prophylaxis
1098405|NCT01580280|Cervicogenic
1098406|NCT01580280|Headache
1098407|NCT01580280|Neck Pain
1098408|NCT01580280|Manipulation
1098409|NCT01580280|Mobilization
1098410|NCT01580280|Exercise
1098411|NCT01580267|Anemia in trauma
1098412|NCT01580254|Latanoprost
1098413|NCT01580254|IOP
1098414|NCT01580215|Valves
1098415|NCT01580215|Endobronchial
1098416|NCT01580215|Endoscopic lung volume reduction
1098417|NCT01580215|Pulmonx
1098418|NCT01580215|Zephyr
1098419|NCT01580215|Chartis
1098420|NCT01580215|Emphysema
1098421|NCT01580215|COPD
1098427|NCT01580189|Lean tissue
1098428|NCT01580189|Strength condition
1098429|NCT01580189|Protein
1098430|NCT01580189|Amino Acid
1098431|NCT01580163|the opioid dependence in rehabilitation phase
1098432|NCT01580163|community
1098433|NCT01580150|Berries
1098434|NCT01580150|Starch
1098435|NCT01580150|Sucrose
1098436|NCT01580150|Glucose
1098437|NCT01580150|Insulin
1098438|NCT01580150|Postprandial
1098439|NCT01580137|acute respiratory tract infection
1098440|NCT01580137|common cold
1098441|NCT01580137|acute bacterial rhinosinusitis
1098442|NCT01580137|adult
1098443|NCT01580137|conscript
1098444|NCT01580111|Blood
1098445|NCT01580111|Storage
1098446|NCT01580111|Age
1098447|NCT01580111|Transfusion
1098448|NCT01580111|Lactic acidosis
1098449|NCT01580085|Sleep disordered breathing
1098450|NCT01580085|gender
1098451|NCT01580085|hypercoagulability
1098452|NCT01580046|Chronic Kidney Disease
1098453|NCT01580046|Coronary Angiography
1098454|NCT01580046|Contrast Media
1098455|NCT01580046|Percutaneous Coronary Intervention
1098456|NCT01580046|Serum Creatinine
1098457|NCT01580046|Glomerular Filtration Rate
1098458|NCT01580046|Iodixanol
1098459|NCT01580046|Iopromide
1098460|NCT01580033|immunogenicity
1098461|NCT01580033|safety
1098462|NCT01580033|group A, C polysaccharide meningitis
1098463|NCT01580033|type b haemophilus Influenza
1098464|NCT01580020|Macular Degeneration
1098465|NCT01580020|Macular Edema
1098466|NCT01580020|Retinal Vein Occlusion
1098467|NCT01580020|Choroidal Neovascularization
1098468|NCT01580020|Signs and Symptoms
1098469|NCT01580020|Retinal Degeneration
1098470|NCT01580020|Retinal Diseases
1098471|NCT01580020|Eye Diseases
1098472|NCT01580020|Venous Thrombosis Sensation Disorders
1098473|NCT01580020|Dexamethasone acetate
1098474|NCT01580020|Dexamethasone
1098475|NCT01580020|Dexamethasone 21-phosphate
1098476|NCT01580020|BB 1101
1098477|NCT01580020|Anti-Inflammatory Agents
1098478|NCT01580020|Therapeutic Uses
1098479|NCT01580020|Vision, Low
1098480|NCT01580020|Signs
1098481|NCT01580020|Vision Disorders
1098482|NCT01580007|tuberculosis
1098483|NCT01580007|phenylbutyrate
1098484|NCT01580007|vitamin D
1098485|NCT01580007|cathelicidin
1098486|NCT01580007|antimicrobial peptide
1098487|NCT01580007|in adults
1098488|NCT01579994|adenocarcinoma
1098489|NCT01579994|Lung
1098490|NCT01579994|Metastatic
1098491|NCT01579994|Crizotinib
1098492|NCT01579994|Ganetespib
1098493|NCT01579994|STA-9090
1098494|NCT01579994|ALK Positive Lung Cancers
1098495|NCT01579994|12-015
1098496|NCT01579981|RYGB
1098497|NCT01579981|Bariatric Surgery
1098498|NCT01579981|Glucagon-like-peptide 1
1098499|NCT01579942|EEG
1098500|NCT01579942|Biomarker
1098501|NCT01579942|Major Depressive Disorder
1098502|NCT01579942|Healthy Control
1098503|NCT01579929|Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1098504|NCT01579929|CISPLATIN
1098505|NCT01579929|ETOPOSIDE (VP-16)
1098506|NCT01579929|LDE-225
1098507|NCT01579929|STAR
1098508|NCT01579929|Symptom Tracking and Reporting for Patients
1098509|NCT01579929|11-206
1098510|NCT01579916|Trivalent, Influenza, FluMist, Vaccine, Prevention
1098511|NCT01579903|Hemophilia A
1098512|NCT01579903|moroctocog alfa (AF-CC)
1098513|NCT01579903|ReFacto AF
1098514|NCT01579903|dual-chamber syringe
1098515|NCT01579903|bioavailability
1098516|NCT01579877|Xerostomia
1098517|NCT01579877|Yukmijihwang-tang
1098518|NCT01579877|Yin-Deficiency
1098519|NCT01579877|Visual analogue scale
1098520|NCT01579877|Dry mouth symptom questionnaire
1098521|NCT01579812|Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
1098522|NCT01579786|post operative pain
1098523|NCT01579786|acupuncture
1098524|NCT01579760|radiation
1098525|NCT01579760|retinopathy
1098526|NCT01579760|macular edema
1098527|NCT01579760|anti-VEGF
1098528|NCT01579760|VEGF-Trap
1098529|NCT01579760|aflibercept
1098530|NCT01579747|nerve stimulation
1098531|NCT01579747|ultrasound
1098532|NCT01579747|sciatic nerve block
1098533|NCT01579747|popliteal block
1098534|NCT01579747|obese
1098535|NCT01579734|breast cancer chemoprevention postmenopause
1098536|NCT01579708|Diet
1098537|NCT01579708|Physical activity
1098538|NCT01579708|Knowledge
1098539|NCT01579708|Attitudes
1098540|NCT01579708|Habits
1098541|NCT01579708|Lifestyle
1098542|NCT01579708|School-based
1098543|NCT01579695|HIV with lipohypertrophy
1098544|NCT01579682|Eating Disorder
1098545|NCT01579682|Anorexia Nervosa
1098546|NCT01579682|Eating Disorder Not Otherwise Specified
1098547|NCT01579682|Maudsley
1098548|NCT01579682|Family-Based Therapy
1098549|NCT01579682|FBT
1098550|NCT01579682|Family Therapy
1098551|NCT01579669|Autism Spectrum Disorder
1098552|NCT01579669|Primary Care Services
1098553|NCT01579669|Patient-Provider Communication
1098554|NCT01579669|Adults
1098555|NCT01579643|cornea
1098556|NCT01579643|opacity
1098557|NCT01579643|congenital
1098558|NCT01579630|NSCLC
1098559|NCT01579630|Nonsquamous
1098560|NCT01579630|Maintenance therapy
1098561|NCT01579617|pregnancy
1098562|NCT01579617|STI
1098563|NCT01579617|STD
1098564|NCT01579604|Loss of upper extremities functions
1098565|NCT01579604|Nerve transfer
1098690|NCT01579110|Treatment of autoimmune hemolytic anemia
1098566|NCT01579578|Metastatic Gastric Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status
1098567|NCT01579565|cataract
1098568|NCT01579565|lens replacement
1098569|NCT01579552|Questionnaires
1098570|NCT01579552|telephone counseling session
1098571|NCT01579552|10-104
1098572|NCT01579552|Childhood Cancer Survivor Women Post Chest Radiation
1098573|NCT01579539|Methylprednisolone
1098574|NCT01579539|Dry Eye Syndrome
1098575|NCT01579539|Tear Film
1098576|NCT01579539|Thyroid-associated ophthalmopathy
1098577|NCT01579526|Safety and Pharmacokinetics of FP01 in Healthy Volunteers
1098578|NCT01579513|Cardiopulmonary Bypass (CPB)
1098579|NCT01579513|System Inflammatory Response
1098580|NCT01579513|inflammation
1098581|NCT01579513|Methylprednisolone
1098582|NCT01579513|Neonates
1098583|NCT01579513|Steroid
1098584|NCT01579513|Cardiac Surgical Procedures
1098585|NCT01579513|Children
1098586|NCT01579513|Infants
1098587|NCT01579513|Pediatrics
1098588|NCT01579513|Glucocorticoid
1098589|NCT01579513|Heart Disease
1098590|NCT01579513|Heart Defects, Congenital
1098591|NCT01579513|Cardiovascular Diseases
1098592|NCT01579513|Cardiovascular Abnormalities
1098593|NCT01579513|Corticosteroid
1098594|NCT01579513|methylprednisolone Hemisuccinate
1098595|NCT01579513|Hormones
1098596|NCT01579513|Physiological Effects of Drugs
1098597|NCT01579513|Randomized Clinical Trial
1098601|NCT01579461|Pharmacokinetics
1098602|NCT01579461|mirabegron
1098603|NCT01579461|hepatic impairment
1098604|NCT01579461|Phase 1
1098605|NCT01579448|killed oral cholera vaccine
1098606|NCT01579448|boosting vaccine regimen
1098607|NCT01579448|safety and immunogenicity
1098608|NCT01579435|essential tremor
1098609|NCT01579435|primary motor cortex
1098610|NCT01579435|cerebellum
1098611|NCT01579435|transcranial direct current stimulation
1098612|NCT01579435|electrophysiology
1098613|NCT01579422|schizophrenia
1098614|NCT01579422|treatment
1098615|NCT01579422|social cognition
1098616|NCT01579409|Nutrition
1098617|NCT01579409|Arterial stiffness
1098618|NCT01579409|Endothelial dysfunction
1098619|NCT01579409|Microcirculation
1098620|NCT01579409|Cardiac autonomic system.
1098621|NCT01579396|septeX
1098622|NCT01579396|high cut-off
1098623|NCT01579396|Thoracic Surgery
1098624|NCT01579396|Renal Replacement Therapy
1098625|NCT01579383|Migraine Disorders
1098626|NCT01579383|Phase 1
1098627|NCT01579383|ALD403
1098628|NCT01579370|healthcare associated infections
1098629|NCT01579370|multidrug resistant organisms
1098630|NCT01579370|methicillin resistant staphylococcus aureus
1098631|NCT01579370|vancomycin resistant enterococcus
1098632|NCT01579370|clostridium difficile
1098633|NCT01579370|acinetobacter
1098634|NCT01579357|colorectal carcinoma
1098635|NCT01579357|K-ras wild type
1098636|NCT01579357|Capecitabine
1098637|NCT01579357|Cetuximab
1098638|NCT01579357|Oxaliplatin
1098639|NCT01579357|Pharmacokinetics
1098640|NCT01579357|exclude a possible influence of CETUX
1098641|NCT01579357|plasma disposition
1098642|NCT01579357|metabolic activation
1098643|NCT01579357|CCB
1098644|NCT01579357|OxPt
1098645|NCT01579344|Iodine Radioisotopes
1098646|NCT01579344|Nasolacrimal Duct
1098647|NCT01579344|radiation effects
1098648|NCT01579331|IOP
1098649|NCT01579331|Tonometry
1098650|NCT01579331|Pascal
1098651|NCT01579331|Goldmann
1098652|NCT01579331|DCT
1098653|NCT01579331|Dynamic Contour
1098654|NCT01579279|Diabetic neuropathic pain
1098655|NCT01579279|Active controlled phase 2 study
1098656|NCT01579266|Writer's Cramp
1098657|NCT01579266|Focal Hand Dystonia
1098658|NCT01579266|Writer Cramp
1098659|NCT01579266|Dystonia
1098660|NCT01579253|Recurrent glioblastoma
1098661|NCT01579253|Radiotherapy
1098662|NCT01579253|PET-MRI
1098663|NCT01579253|FET-PET
1098664|NCT01579240|physical activity
1098665|NCT01579240|older adults
1098666|NCT01579240|Internet
1098667|NCT01579240|sedentary
1098668|NCT01579240|multi-week
1098669|NCT01579240|internet intervention
1098670|NCT01579227|Healthy participants
1098671|NCT01579214|HIV
1098672|NCT01579214|Africa south of the sahara
1098673|NCT01579214|Knowledge of results
1098674|NCT01579214|Communication barriers
1098675|NCT01579214|Cellular Phones
1098676|NCT01579201|Postpartum Hemorrhage
1098677|NCT01579201|Uterine Atony
1098678|NCT01579201|Obstetric Anesthesia
1098679|NCT01579201|Cesarean Section
1098680|NCT01579201|Carbetocin
1098681|NCT01579188|NSCLC
1098682|NCT01579162|Hepatitis
1098683|NCT01579162|Fatty Liver
1098684|NCT01579123|Laser atherectomy
1098685|NCT01579123|Critical Limb Ischemia
1098686|NCT01579123|Angioplasty
1098687|NCT01579110|autoimmune hemolytic anemia
1098688|NCT01579110|hemolytic anemia
1098689|NCT01579110|Levamisole
1098941|NCT01577862|RESISTANCE
1098691|NCT01579110|warm antibody dependant autoimmune hemolytic anemia
1098692|NCT01579097|(PN) Parenteral nutrition
1098693|NCT01579097|oral/enteral not possible
1098694|NCT01579058|aortic stenosis
1098695|NCT01579058|beta-blocker
1098696|NCT01579032|CKD,
1098697|NCT01578980|Artificial Pancreas
1098698|NCT01578980|Type 1 Diabetes Mellitus
1098699|NCT01578980|Control-to-Range
1098700|NCT01578980|Closed-Loop Control
1098701|NCT01578980|Continuous Glucose Monitor
1098702|NCT01578967|Hodgkin's lymphoma
1098703|NCT01578967|Hodgkin lymphoma
1098704|NCT01578954|Leukemia
1098705|NCT01578954|Acute Myeloid Leukemia
1098706|NCT01578941|menstrual migraine
1098707|NCT01578941|migraine
1098708|NCT01578941|treximet
1098709|NCT01578928|renal, impairment, endstage renal disease
1098710|NCT01578928|renal
1098711|NCT01578928|impairment
1098712|NCT01578928|endstage renal disease
1098713|NCT01578902|Prostatic Neoplasms
1098714|NCT01578902|Radiotherapy
1098715|NCT01578902|Hypofractionation
1098716|NCT01578902|Low Risk Prostate Cancer
1098717|NCT01578876|coronary artery disease
1098718|NCT01578876|angina pectoris
1098719|NCT01578876|myocardial ischemia
1098720|NCT01578876|cardiac shock wave therapy
1098721|NCT01578863|Childhood obesity
1098722|NCT01578863|Adolescence
1098723|NCT01578863|Predictors
1098724|NCT01578863|Success
1098725|NCT01578863|Intervention program
1098726|NCT01578850|rheumatoid arthritis
1098727|NCT01578850|etanercept
1098728|NCT01578850|methotrexate
1098729|NCT01578850|DMARDs
1098730|NCT01578824|Rickets
1098731|NCT01578824|Vitamin D
1098732|NCT01578824|airway hyperreactivity
1098733|NCT01578824|Exhaled breath condensate
1098734|NCT01578772|HIV
1098735|NCT01578772|Flow-mediated dialation (FMD)
1098736|NCT01578772|Telmisartan
1098737|NCT01578772|Cardiovascular disease (CVD)
1098738|NCT01578772|HIV+ men and women age > 50 at risk for heart disease
1098739|NCT01578759|ovarian function tests
1098740|NCT01578746|Coxarthrosis
1098741|NCT01578746|Hip arthroplasty
1098742|NCT01578746|Anterior approach
1098743|NCT01578746|Direct lateral approach
1098744|NCT01578746|Hardinge approach
1098745|NCT01578746|Smith-Petersen approach
1098746|NCT01578746|Osteoarthrosis
1098747|NCT01578733|protein requirement
1098748|NCT01578733|female elderly
1098749|NCT01578733|healthy female subject's protein requirements
1098750|NCT01578707|Chronic
1098751|NCT01578707|SLL
1098752|NCT01578707|CLL
1098753|NCT01578707|Ofatumumab
1098754|NCT01578707|ibrutinib
1098755|NCT01578707|RESONATE
1098756|NCT01578707|Phase III
1098757|NCT01578707|Leukemia
1098758|NCT01578707|Lymphoma
1098759|NCT01578681|bronchiectasis
1098760|NCT01578681|respiratory therapy
1098761|NCT01578681|airway clearance
1098762|NCT01578668|lung adenocarcinoma
1098763|NCT01578668|brain metastases
1098764|NCT01578668|erlotinib
1098765|NCT01578668|pemetrexed
1098766|NCT01578655|custirsen sodium
1098767|NCT01578655|prostate cancer
1098768|NCT01578655|metastatic castrate resistant prostate cancer
1098769|NCT01578655|overall survival
1098770|NCT01578642|GERD
1098771|NCT01578642|LES Pressure
1098772|NCT01578642|Electrical Stimulation
1098773|NCT01578629|stroke
1098774|NCT01578629|ischemia
1098775|NCT01578629|TIA
1098776|NCT01578616|Coronary artery disease
1098777|NCT01578616|Endothelial function
1098778|NCT01578616|Optical coherence tomography
1098779|NCT01578616|Thin cap fibroatheroma
1098780|NCT01578603|prevention & control
1098781|NCT01578603|Xylitol
1098782|NCT01578603|casein phosphopeptide amorphous calcium phosphate complex
1098783|NCT01578603|Streptococcus mutans
1098784|NCT01578603|saliva
1098785|NCT01578603|dental plaque
1098786|NCT01578603|gingivitis
1098787|NCT01578577|Medication Therapy Management
1098788|NCT01578577|Hypertension
1098789|NCT01578577|Health Literacy
1098790|NCT01578577|Medication Reconciliation
1098791|NCT01578577|Medication Adherence
1098792|NCT01578564|Cancer
1098793|NCT01578564|Ovarian Cancer
1098794|NCT01578564|TRPV6 Calcium channel
1098795|NCT01578551|Carcinoma, Non-Small-Cell Lung
1098796|NCT01578551|Lung adenocarcinoma
1098797|NCT01578538|hernia, abdominal, strangulation, emergency, wall
1098798|NCT01578525|medication safety
1098799|NCT01578525|elderly
1098800|NCT01578525|pharmaceutical care
1098801|NCT01578525|hospital readmission
1098802|NCT01578525|drug-related readmission
1098803|NCT01578525|Health Services for the Aged
1098804|NCT01578499|brentuximab vedotin
1098805|NCT01578499|ALCANZA
1098806|NCT01578486|Schizophrenia
1098807|NCT01578486|Cognition
1098808|NCT01578486|Metabolism
1098809|NCT01578486|Antipsychotics
1098810|NCT01578486|Psychopathology
1098811|NCT01578473|low testosterone
1098812|NCT01578473|penile curvature
1098813|NCT01578460|Pregnancy
1098814|NCT01578460|Gestational Diabetes
1098815|NCT01578460|Type 2 Diabetes Mellitus
1098816|NCT01578460|Continuous Glucose Monitor
1098817|NCT01578460|Glucose
1098818|NCT01578447|injectable contraception
1098819|NCT01578447|acceptability
1098820|NCT01578447|intramuscular
1098821|NCT01578447|subcutaneous
1098822|NCT01578434|Nutritional Rickets
1098823|NCT01578434|Calcium
1098824|NCT01578434|Vitamin D
1098825|NCT01578408|Femoral neck fractures
1098826|NCT01578408|Uncemented
1098827|NCT01578408|Hydroxyapatite
1098828|NCT01578408|Coated
1098829|NCT01578408|Femoral
1098830|NCT01578408|Stems
1098831|NCT01578408|Hip fractures
1098832|NCT01578408|THA
1098833|NCT01578408|THR
1098834|NCT01578408|Cemented
1098835|NCT01578408|Fat embolism
1098836|NCT01578408|Cognition
1098837|NCT01578408|Inflammatory response
1098838|NCT01578408|Mobilization
1098839|NCT01578382|Martorell hypertensive ischemic leg ulcer
1098840|NCT01578382|Calciphylaxis (calcific uremic arteriolopathy)
1098841|NCT01578382|Ischemic subcutaneous arteriolosclerosis
1098842|NCT01578382|Hypertension
1098843|NCT01578382|Diabetes
1098844|NCT01578382|Medial calcinosis
1098845|NCT01578382|Wound healing
1098846|NCT01578369|Urinary incontinence
1098847|NCT01578369|Pregnancy
1098848|NCT01578369|Pelvic floor muscle training
1098849|NCT01578356|Prostate cancer
1098850|NCT01578343|fludarabine
1098851|NCT01578343|mitoxantrone
1098852|NCT01578343|dexamethasone
1098853|NCT01578343|relapsed or refractory mantle cell lymphoma
1098854|NCT01578343|FND regimen
1098855|NCT01578343|vorinostat
1098856|NCT01578343|autologous stem cell transplantation
1098857|NCT01578330|Relapsing remitting multiple sclerosis
1098858|NCT01578330|Fingolimod
1098859|NCT01578330|FTY720
1098860|NCT01578317|H5N1 Vaccine
1098861|NCT01578317|H5N1 Immunization
1098862|NCT01578317|MF59 Adjuvant
1098863|NCT01578317|Biologic Sample Collection
1098864|NCT01578317|Laboratory Research Specimens
1098865|NCT01578317|Healthy Volunteer
1098866|NCT01578317|HV
1098867|NCT01578304|Overactive bladder
1098868|NCT01578291|Play therapy
1098869|NCT01578291|Urinary tract infections
1098870|NCT01578291|Children
1098871|NCT01578291|Vesicoureteral reflux
1098872|NCT01578239|Neuroendocrine tumour
1098873|NCT01578239|177Lu-Dota0-Tyr3-octreotate
1098874|NCT01578226|Cirrhosis
1098875|NCT01578226|Ascites
1098876|NCT01578226|Decompensation
1098877|NCT01578226|Bacterial infection
1098878|NCT01578226|Sepsis
1098879|NCT01578226|Procalcitonin
1098880|NCT01578226|PCT
1098881|NCT01578200|CKD-MBD
1098882|NCT01578200|phosphate-binder
1098883|NCT01578200|vascular calcification
1098884|NCT01578200|mortality
1098885|NCT01578200|dialysis
1098886|NCT01578200|Hemodialysis patients with hyperphosphatemia
1098887|NCT01578187|hair reduction
1098888|NCT01578187|hair removal
1098889|NCT01578187|hair clearance
1098890|NCT01578148|Cervical pain
1098891|NCT01578148|Cervicalgia,
1098892|NCT01578148|Cervicodynia
1098893|NCT01578148|Neck ache
1098894|NCT01578148|Neckache
1098895|NCT01578148|Shoulder pain
1098896|NCT01578148|Shoulder impingement syndrome
1098897|NCT01578122|post-thrombotic syndrome
1098898|NCT01578122|prevention
1098899|NCT01578122|deep vein thrombosis
1098900|NCT01578122|elastic compression stockings
1098901|NCT01578122|compliance
1098902|NCT01578122|quality of life
1098903|NCT01578096|Type 2 Diabetes
1098904|NCT01578083|Chemotherapy
1098905|NCT01578083|Breast Cancer
1098906|NCT01578083|Cognitive Impairment
1098907|NCT01578083|Chemo brain
1098908|NCT01578070|Other and Unspecified Vaccines and Biological Substances Causing Adverse Effects in Therapeutic Use
1098909|NCT01578057|alcohol
1098910|NCT01578044|Anti-coagulation
1098911|NCT01578031|Sleep Apnea
1098912|NCT01578031|Obesity
1098913|NCT01578018|lung cancer
1098914|NCT01578018|smoking
1098915|NCT01578005|acute coronary syndrome
1098916|NCT01578005|IVUS
1098917|NCT01578005|atherosclerotic plaque
1098918|NCT01577992|subjective pain
1098919|NCT01577992|Multiple System Atrophy
1098920|NCT01577979|Vaccination
1098921|NCT01577979|Medical Home
1098922|NCT01577979|Adolescents
1098923|NCT01577966|Patients with brain tumors associated with seizures
1098924|NCT01577953|Antisense oligonucleotide
1098925|NCT01577953|Asthma
1098926|NCT01577953|Patients with asthma
1098927|NCT01577953|Phase 1b
1098928|NCT01577953|Transcription factor GATA-3
1098929|NCT01577953|Oral inhalation
1098930|NCT01577940|Transversus abdominis plane block
1098931|NCT01577940|postoperative pain
1098932|NCT01577940|Postoperative pain management
1098933|NCT01577927|weaning
1098934|NCT01577927|severe chronic diseases
1098935|NCT01577927|UTIR
1098936|NCT01577901|Pregnancy
1098937|NCT01577862|ACINETOBACTER BAUMANNII
1098938|NCT01577862|COLISTIN
1098939|NCT01577862|RIFAMPICIN
1098940|NCT01577862|THERAPY
1098942|NCT01577836|Radical prostatectomie
1098943|NCT01577836|Robotic assistance
1098944|NCT01577836|Laparotomy
1098945|NCT01577810|NIRS
1098946|NCT01577810|near infrared spectroscopy
1098947|NCT01577810|heart failure
1098948|NCT01577810|cardiac output
1098949|NCT01577810|outpatient
1098950|NCT01577810|pediatric
1098951|NCT01577797|Methamphetamine
1098952|NCT01577797|Drug Abuse
1098953|NCT01577797|Substance Abuse
1098954|NCT01577797|Amphetamine
1098955|NCT01577797|Dependence
1098956|NCT01577797|Addiction
1098957|NCT01577797|Craving
1098958|NCT01577797|Cognitive Behavioral Therapy
1098959|NCT01577797|Text Messaging
1098960|NCT01577784|Advanced renal cell carcinoma
1098961|NCT01577784|second-line treatment with pazopanib
1098962|NCT01577784|first line of treatment with a Tyrosine Kinase Inhibitor
1098963|NCT01577771|Pneumococcal conjugate vaccine
1098964|NCT01577771|Immunogenicity
1098965|NCT01577771|Reactogenicity
1098966|NCT01577758|Phase 1,
1098967|NCT01577758|Advanced gastrointestinal malignancies,
1098968|NCT01577758|MLN0264,
1098969|NCT01577758|Guanylyl Cyclase C(GCC),
1098970|NCT01577758|Antibody Drug Conjugate(ADC)
1098971|NCT01577745|Cancer
1098972|NCT01577732|booster
1098973|NCT01577732|Infanrix-IPV+HibTM
1098974|NCT01577732|DTPa-IPV/Hib
1098975|NCT01577732|Vietnamese toddlers
1098976|NCT01577719|Cardiovascular
1098977|NCT01577719|Prevention
1098978|NCT01577719|Ethnicity
1098979|NCT01577719|Culture
1098980|NCT01577719|Internet
1098981|NCT01577719|Text Message
1098982|NCT01577706|GABA
1098983|NCT01577706|glutamate
1098984|NCT01577706|glutamine
1098985|NCT01577706|spectroscopy
1098986|NCT01577706|brain
1098987|NCT01577706|imaging
1098988|NCT01577706|alprazolam
1098989|NCT01577706|dextroamphetamine
1098990|NCT01577706|placebo
1098994|NCT01577680|healthy subjects
1098995|NCT01577680|pharmacokinetics
1098996|NCT01577680|vilanterol
1098997|NCT01577680|tolerability
1098998|NCT01577680|safety
1098999|NCT01577680|hepatic impairment
1099000|NCT01577680|GW642444
1099001|NCT01577680|GSK573719
1099002|NCT01577667|automation
1099003|NCT01577667|closed loop
1099004|NCT01577667|oxygenation
1099005|NCT01577667|ventilation
1099006|NCT01577654|adenocarcinoma
1099007|NCT01577654|squamous
1099008|NCT01577654|adenosquamous
1099009|NCT01577654|adenocarcinoma with other NSCLC variants
1099010|NCT01577654|EC145
1099011|NCT01577654|EC20
1099012|NCT01577654|Vintafolide
1099013|NCT01577654|Etarfolatide
1099014|NCT01577628|Dermatitis
1099015|NCT01577628|Eczema
1099016|NCT01577628|Skin diseases
1099017|NCT01577628|Skin barrier
1099018|NCT01577628|Prevention
1099019|NCT01577628|Infant
1099020|NCT01577628|Moisturizer
1099021|NCT01577628|Emollient
1099022|NCT01577628|Asthma
1099023|NCT01577628|Food allergy
1099024|NCT01577628|Allergic rhinitis
1099025|NCT01577615|Preterm Infant
1099026|NCT01577615|Neurobehavioral
1099027|NCT01577615|Development
1099028|NCT01577602|Medication reconciliation
1099029|NCT01577602|Self report
1099030|NCT01577602|Electronic medical record medication list
1099031|NCT01577589|Phase 1
1099032|NCT01577589|healthy volunteers
1099033|NCT01577589|cross-over study
1099034|NCT01577589|ceftaroline fosamil
1099035|NCT01577589|various infusion volumes
1099036|NCT01577589|local tolerability
1099037|NCT01577589|Cmax
1099038|NCT01577589|tmax
1099039|NCT01577589|AUC
1099040|NCT01577576|Athletes
1099041|NCT01577576|Sedentary volunteers
1099042|NCT01577563|osteoarthritis (OA)
1099043|NCT01577563|rheumatoid arthritis (RA)
1099044|NCT01577563|ankylosing spondylitis (AS)
1099045|NCT01577563|gastrointestinal risk factors
1099046|NCT01577563|NSAIDs
1099047|NCT01577550|ABBV-066
1099048|NCT01577550|BI 655066
1099049|NCT01577550|risankizumab
1099050|NCT01577537|SPL7013
1099051|NCT01577537|VivaGel
1099052|NCT01577537|bacterial vaginosis
1099053|NCT01577537|BV
1099054|NCT01577511|invasive potential
1099055|NCT01577511|molecular characterisation of circulating cells
1099056|NCT01577498|Skeletal age
1099057|NCT01577498|Chronological age
1099058|NCT01577498|Adolescent
1099059|NCT01577472|female infertility
1099060|NCT01577472|poor ovarian response
1099061|NCT01577472|controlled ovarian hyperstimulation
1099062|NCT01577472|IVF
1099063|NCT01577472|Antagonist protocol
1099064|NCT01577446|CRT
1099065|NCT01577446|heart failure
1099066|NCT01577446|narrow QRS
1099067|NCT01577446|dyssynchrony
1099068|NCT01577433|HeartMate II
1099069|NCT01577433|heart-assist device
1099070|NCT01577433|left ventricular assist device
1099071|NCT01577433|driveline infection
1099072|NCT01577433|LVAD
1099073|NCT01577433|HMII LVAS driveline
1099074|NCT01577433|silicone portion
1099075|NCT01577433|Thoratec Corporation
1099076|NCT01577420|Reflexology
1099077|NCT01577420|Breast Cancer
1099078|NCT01577420|Complementary
1099079|NCT01577407|Dyspnea
1099080|NCT01577407|Pain
1099081|NCT01577394|Alzheimer disease
1099082|NCT01577394|Lewy Body Disease
1099083|NCT01577394|Cognitive Disorders
1099084|NCT01577394|Neurodegenerative Diseases
1099085|NCT01577394|Differential diagnosis
1099086|NCT01577394|Eye movement
1099087|NCT01577381|Phase 2
1099088|NCT01577381|Advanced Dry Age-Related Macular Degeneration
1099089|NCT01577381|Geographic Atrophy
1099090|NCT01577381|RN6G
1099091|NCT01577368|Pseudomonas
1099092|NCT01577368|Piperacillin
1099093|NCT01577368|Beta-lactams
1099094|NCT01577368|Continuous infusion
1099095|NCT01577368|Intermittent infusion
1099096|NCT01577368|Pharmacokinetics
1099097|NCT01577329|meditation
1099098|NCT01577329|Chronic Obstructive Pulmonary Disease
1099099|NCT01577329|Mindfulness
1099100|NCT01577329|Anxiety
1099101|NCT01577329|Breathing Patterns
1099102|NCT01577316|vaccination
1099103|NCT01577316|Influenza
1099104|NCT01577316|Immunogenicity
1099105|NCT01577316|Safety
1099106|NCT01577303|social phobia
1099107|NCT01577303|social anxiety
1099108|NCT01577303|cognitive bias modification
1099109|NCT01577290|Anxiety
1099110|NCT01577290|Depression
1099111|NCT01577290|Insomnia
1099112|NCT01577290|Mindfulness
1099113|NCT01577290|Internet
1099114|NCT01577277|Metabolic Syndrome X
1099115|NCT01577277|Fatty Acids, Omega-3
1099116|NCT01577277|Learning
1099117|NCT01577277|Attention
1099118|NCT01577277|Nutritional Status
1099119|NCT01577277|Nutrition Assessments
1099120|NCT01577277|Body Weight
1099121|NCT01577277|Physical Activity
1099122|NCT01577277|Sleep
1099123|NCT01577277|Child Nutrition Sciences
1099124|NCT01577264|Certolizumab Pegol
1099125|NCT01577264|Cimzia
1099126|NCT01577238|SPL7013
1099127|NCT01577238|VivaGel
1099128|NCT01577238|bacterial vaginosis
1099129|NCT01577238|BV
1099130|NCT01577225|Clean surgery
1099131|NCT01577212|stage III NSCLC
1099132|NCT01577212|(chemo)radiotherapy
1099133|NCT01577212|individualized dose-escalation
1099134|NCT01577199|IVF
1099135|NCT01577199|poor responder
1099136|NCT01577199|low ovarian reserve
1099137|NCT01577199|ART
1099138|NCT01577199|ovarian stimulation
1099139|NCT01577199|IVF protocols
1099140|NCT01577186|Schizophrenia
1099141|NCT01577186|Paliperidone Extended Release
1099142|NCT01577160|Schizophrenia
1099143|NCT01577160|Paliperidone Extended Release (ER)
1099144|NCT01577147|pregnancy
1099145|NCT01577134|multimorbidity
1099146|NCT01577134|autonomy
1099147|NCT01577134|older adults
1099148|NCT01577134|physical activity
1099149|NCT01577134|intervention
1099150|NCT01577134|behavior change
1099151|NCT01577121|Preterm labor
1099152|NCT01577108|31-32 Weeks of Gestation Completed
1099153|NCT01577108|Group B Streptococcal Infection
1099154|NCT01577108|Streptococcus Group B Infection of the Infant
1099155|NCT01577095|electroacupuncture
1099156|NCT01577095|rosiglitazone
1099157|NCT01577095|plasma glucose
1099158|NCT01577095|insulin resistance
1099159|NCT01577095|free fatty acid
1099160|NCT01577082|Adults, not adequately controlled, pre-dose morning PEF
1099161|NCT01577069|Hepatitis C
1099162|NCT01577069|Direct Antiviral agent (DAA)
1099163|NCT01577069|Ultra-deep pyrosequencing
1099164|NCT01577069|Single polynucleotide polymorphisms
1099165|NCT01577069|Treatment-resistant mutants
1099166|NCT01577069|Hepatitis C Virus Protease Inhibitor
1099167|NCT01577056|Familial hypercholesterolaemia
1099168|NCT01577056|Postprandial dyslipidaemia
1099169|NCT01577056|Fish oil treatment
1099170|NCT01577056|Cardiovascular disease
1099171|NCT01577043|acute diarrhea
1099172|NCT01577043|Racecadotril
1099173|NCT01577043|children
1099174|NCT01577017|ovulation induction, clomiphene citrate, letrozole
1099175|NCT01576978|LUMBAR BACK pain
1099176|NCT01576978|PELVIC PAIN
1099177|NCT01576978|PREGNANCY
1099178|NCT01576978|HATHA YOGA
1099179|NCT01576965|Laparoscopic hysterectomy,laparoscopic sacrocolpopexy,bowel prep
1099180|NCT01576926|Sleep apnea, obstructive
1099181|NCT01576926|Deglutition Disorders
1099182|NCT01576913|exercise testing
1099183|NCT01576913|music
1099184|NCT01576913|VO2 max
1099185|NCT01576900|behavior therapy
1099186|NCT01576900|nocturia
1099187|NCT01576900|polyuria
1099188|NCT01576874|nicotine dependence
1099189|NCT01576874|hormones
1099190|NCT01576848|muscle metabolism
1099191|NCT01576848|intrinsically labeled protein
1099192|NCT01576848|protein synthesis
1099193|NCT01576848|insulin
1099194|NCT01576848|perfusion
1099195|NCT01576835|Non-contrast
1099196|NCT01576822|Detoxification
1099197|NCT01576822|Sauna
1099198|NCT01576809|Paracetamol
1099199|NCT01576809|acetaminophen
1099200|NCT01576809|phenylephrine
1099201|NCT01576809|guaifenesin
1099202|NCT01576809|syrup
1099203|NCT01576809|URTI
1099204|NCT01576809|productive cough
1099205|NCT01576796|Radiotherapy
1099206|NCT01576796|Fmiso
1099207|NCT01576796|FDG PETSCAN
1099208|NCT01576796|FMISO PETSCAN
1099209|NCT01576796|complement dose
1099210|NCT01576796|lung cancer
1099211|NCT01576796|NSCLC
1099212|NCT01576796|hypoxic lesion
1099213|NCT01576770|propofol
1099214|NCT01576770|Pain
1099215|NCT01576770|Synera Patch
1099216|NCT01576770|Gebauer's Ethyl Chloride topical anesthetic
1099217|NCT01576757|Stem cell therapy
1099218|NCT01576744|HE4
1099219|NCT01576744|IVF
1099220|NCT01576744|Biomarker
1099221|NCT01576744|Ovarian cancer
1099222|NCT01576744|Infertility
1099223|NCT01576731|HIV Infection
1099224|NCT01576731|Postexposure prophylaxis
1099225|NCT01576718|Dose ranging
1099226|NCT01576718|Fluticasone Propionate
1099227|NCT01576718|Dry Powder Inhaler (DPI)
1099228|NCT01576718|High Dose ICS
1099229|NCT01576718|Asthma
1099230|NCT01576705|Down syndrome
1099231|NCT01576705|Young children
1099232|NCT01576705|Psychomotor development
1099233|NCT01576705|Thyroid hormone
1099234|NCT01576705|Folinic acid
1099235|NCT01576705|Psychometric tests
1099236|NCT01576705|GMDS
1099237|NCT01576705|Griffiths
1099238|NCT01576705|Genetic factors
1099239|NCT01576705|Biochemical factors
1099240|NCT01576692|recurrent neuroblastoma
1099241|NCT01576692|refractory neuroblastoma
1099242|NCT01576692|natural killer cells
1099243|NCT01576679|intra-abdominal
1099244|NCT01576679|abscess
1099245|NCT01576679|tPA
1099246|NCT01576679|alteplase
1099247|NCT01576679|cathflo
1099248|NCT01576666|Dose escalation
1099249|NCT01576666|Maximum Tolerated Dose
1099250|NCT01576666|MTD
1099251|NCT01576666|Safety Expansion
1099252|NCT01576666|Safety
1099253|NCT01576666|Preliminary Efficacy
1099254|NCT01576666|Objective Response Rate
1099255|NCT01576666|Early progression rate
1099256|NCT01576666|PI3K activation
1099257|NCT01576666|Combination Treatment
1099258|NCT01576666|Hedgehog Signaling Pathway
1099259|NCT01576666|Smoothened inhibitor
1099260|NCT01576666|Phosphoinositide-3' kinase
1099261|NCT01576666|Phosphatase signaling pathway
1099262|NCT01576666|Advanced solid tumors
1099263|NCT01576666|metastatic breast cancer
1099264|NCT01576666|advanced pancreatic adenocarcinoma
1099265|NCT01576666|metastatic colorectal cancer
1099266|NCT01576666|recurrent glioblastoma multiforme
1099267|NCT01576666|gastric cancer
1099268|NCT01576666|gastroesophageal junction cancer
1099269|NCT01576666|triple negative metastatic breast cancer
1099270|NCT01576666|hormone receptor positive (ER+/PR+, and Her2-) metastatic breast cancer
1099271|NCT01576653|IFI
1099272|NCT01576640|Nicotine Dependence
1099273|NCT01576640|Smoking Cessation
1099274|NCT01576640|Relapse Prevention
1099275|NCT01576640|Cognitive Behavioral Therapy
1099276|NCT01576640|Schizophrenia
1099277|NCT01576614|Comparing telephone VS RTP in SICU rounding practices
1099278|NCT01576601|pediatrics
1099279|NCT01576601|acute pain
1099280|NCT01576601|neurosurgery
1099281|NCT01576601|Pediatric patients (0-18)
1099282|NCT01576601|postoperative management
1099404|NCT01576146|Parathyroid hormone
1099283|NCT01576588|Chronic lymphocytic leukemia, relapsed, elderly or unfit patients, methylprednisolone, rituximab
1099284|NCT01576575|to determine how people absorb and break down (metabolize) and eliminate buprenorphine and if CYP3A is involved.
1099285|NCT01576562|Implantable Cardioverter Defibrillator
1099286|NCT01576562|Ventricular Assist Device
1099287|NCT01576536|Myocardial infarction
1099288|NCT01576536|Platelet aggregation
1099289|NCT01576536|cold pressor test
1099290|NCT01576536|Genetics
1099291|NCT01576497|EUS, EUS-FNA, Pancreatic masses
1099292|NCT01576471|T. suis ova
1099293|NCT01576471|Trichuris suis ova
1099294|NCT01576471|Inflammatory Bowel Disease
1099295|NCT01576471|TRUST-I
1099296|NCT01576471|TRUSTI
1099297|NCT01576471|TRUST-1
1099298|NCT01576471|TRUST1
1099299|NCT01576458|ursodeoxycholic acid
1099300|NCT01576458|intrahepatic cholestasis
1099301|NCT01576458|pregnancy
1099302|NCT01576445|Total Knee Arthroplasty
1099303|NCT01576445|function
1099304|NCT01576432|Pain
1099305|NCT01576432|Breastfeeding
1099306|NCT01576432|Heel prick
1099307|NCT01576432|Sucrose
1099308|NCT01576432|Skin-to-skin contact
1099309|NCT01576432|Newborn
1099310|NCT01576419|PG201
1099311|NCT01576419|Non-inferiority
1099312|NCT01576419|100mm pain VAS
1099313|NCT01576406|crizotinib
1099314|NCT01576406|xalkori
1099315|NCT01576406|PF-02341066
1099316|NCT01576406|hepatic impairment
1099317|NCT01576406|pharmacokinetics
1099318|NCT01576406|advanced cancer
1099319|NCT01576393|substance abuse
1099320|NCT01576393|treatment
1099321|NCT01576393|families
1099322|NCT01576380|Solid tumors
1099323|NCT01576380|Advanced scirrhous gastric carcinoma
1099324|NCT01576380|Gastric Cancer
1099325|NCT01576380|Second-line or third-line treatment
1099326|NCT01576380|VEGF
1099327|NCT01576380|FGFR
1099328|NCT01576380|Neoplasms
1099329|NCT01576380|Gastric Neoplasms
1099330|NCT01576380|Cancer
1099331|NCT01576380|Carcinoma
1099332|NCT01576380|Gastric Diseases
1099333|NCT01576380|Female Genital Diseases
1099334|NCT01576380|Tumors
1099335|NCT01576380|Oral Administration
1099336|NCT01576380|Capsules
1099337|NCT01576380|TKI258
1099338|NCT01576380|TKI-258
1099339|NCT01576380|TKI 258
1099340|NCT01576367|Cryopyrin-associated periodic syndromes (CAPS)
1099341|NCT01576367|Familial Cold Autoinflammatory Syndrome (FCAS)
1099342|NCT01576367|Muckle-Wells Syndrome (MWS)
1099343|NCT01576367|Neonatal Onset Multisystem Inflammatory Disease (NOMID)
1099344|NCT01576367|children, systemic autoinflammatory disease
1099345|NCT01576367|CIAS-1 gene
1099346|NCT01576367|NALP-3
1099347|NCT01576367|NLRP3
1099348|NCT01576367|ACZ885
1099349|NCT01576367|canakinumab
1099350|NCT01576367|human monoclonal anti-human interleukin-1 antibody
1099351|NCT01576367|autosomal dominant
1099352|NCT01576367|familial autoinflammatory syndrome
1099353|NCT01576367|childhood immunizations vaccinations
1099354|NCT01576354|Multiple Sclerosis
1099355|NCT01576354|walking function
1099356|NCT01576354|fampridine
1099357|NCT01576341|Epoetin alfa, ESA, HX575, CKD
1099358|NCT01576315|cystic fibrosis
1099359|NCT01576315|Aspergillus
1099360|NCT01576315|itraconazole
1099361|NCT01576315|voriconazole
1099362|NCT01576302|Rumination
1099363|NCT01576289|Esophagus
1099364|NCT01576289|Gastroesophageal reflux
1099365|NCT01576289|Reflux esophagitis
1099366|NCT01576289|Barrett's esophagus
1099367|NCT01576289|Stomach
1099368|NCT01576289|Intestinal metaplasia stomach
1099369|NCT01576289|Helicobacter pylori infection
1099370|NCT01576289|Proton pump inhibitor
1099371|NCT01576289|Duodenum
1099372|NCT01576289|Duodenal bulb
1099373|NCT01576289|Celiac disease diagnosis
1099374|NCT01576263|Anaesthesia
1099375|NCT01576263|Infiltration
1099376|NCT01576263|Blood transfusion
1099377|NCT01576263|Autologous
1099378|NCT01576263|Arthroplasty
1099379|NCT01576263|Replacement
1099380|NCT01576263|Ropivacaine
1099381|NCT01576237|hemovigilance
1099382|NCT01576237|hemapheresis
1099383|NCT01576237|donor vigilance
1099384|NCT01576237|plasmapheresis
1099385|NCT01576237|platelet apheresis
1099386|NCT01576237|leukapheresis
1099387|NCT01576237|stem cell apheresis
1099388|NCT01576237|granulocyte apheresis
1099389|NCT01576237|monocyte apheresis
1099390|NCT01576237|red cell apheresis
1099391|NCT01576224|Volar locking plate osteosynthesis
1099392|NCT01576224|Early mobilization
1099393|NCT01576224|DASH
1099394|NCT01576211|Wilms tumor and other childhood kidney tumors
1099395|NCT01576198|Wilms tumor and other childhood kidney tumors
1099396|NCT01576159|Biochemical Marker
1099397|NCT01576159|Fitness Exercises
1099398|NCT01576159|Impact
1099399|NCT01576159|Articular Cartilage
1099400|NCT01576146|Clinical Trial, Phase 2
1099401|NCT01576146|Renal Dialysis
1099402|NCT01576146|Secondary Hyperparathyroidism
1099403|NCT01576146|Chronic kidney disease-mineral and bone disorder
1099405|NCT01576133|Quality of Life
1099406|NCT01576120|Known, active Crohn's disease
1099407|NCT01576120|Iieocolonic or colonic involvement
1099408|NCT01576120|proven patency of the GI tract
1099409|NCT01576107|Different cancer entities
1099410|NCT01576094|congenital heart disease
1099411|NCT01576081|bone density
1099412|NCT01576081|weight bearing
1099413|NCT01576081|muscle atrophy
1099414|NCT01576081|vascular degeneration
1099415|NCT01576081|gravitational loading
1099416|NCT01576081|muscular unloading
1099417|NCT01576068|COPD
1099418|NCT01576068|Pharmacy
1099419|NCT01576068|Spirometry
1099420|NCT01576068|Case finding
1099421|NCT01576055|Peripheral Arterial Disease
1099422|NCT01576055|Superficial Femoral Artery
1099423|NCT01576055|Proximal Popliteal Artery
1099424|NCT01576055|PAD
1099425|NCT01576055|SFA
1099426|NCT01576055|PPA
1099427|NCT01576055|Stent
1099428|NCT01576055|Gore
1099429|NCT01576055|Bare Metal Stent
1099430|NCT01576055|LifeStent
1099431|NCT01576055|atherosclerosis
1099432|NCT01576055|Heparin
1099433|NCT01576055|claudication
1099434|NCT01576055|leg pain
1099435|NCT01576042|Ischemic heart disease
1099436|NCT01576042|Implantable Cardioverter Defibrillator
1099437|NCT01576042|Ventricular Tachycardia
1099438|NCT01576042|Patient with Implantable Cardioverter Defibrillator (ICD)
1099439|NCT01576016|bradycardia
1099440|NCT01576016|MRI scans
1099441|NCT01576003|Short Bowel Syndrome
1099442|NCT01576003|Necrotizing Entercolitis (NEC)
1099443|NCT01576003|Atresia
1099444|NCT01576003|Parenteral Nutrition
1099445|NCT01576003|Biological Markers
1099446|NCT01576003|Growth
1099447|NCT01575990|Colon cancer screening
1099448|NCT01575990|Decision support interventions
1099449|NCT01575990|Health status
1099450|NCT01575990|Patient-centered care
1099451|NCT01575990|Age
1099452|NCT01575990|Randomized controlled trial
1099453|NCT01575990|Double blind
1099454|NCT01575990|UNC
1099455|NCT01575938|HIV infection
1099456|NCT01575925|Pomalidomide for multiple myeloma
1099457|NCT01575925|renal impairment
1099458|NCT01575925|multiple myeloma patients with renal impairment
1099459|NCT01575925|Pomalidomide for patients with renal impairment due to multiple myeloma
1099460|NCT01575925|Pomalidomide
1099461|NCT01575925|dexamethasone
1099462|NCT01575925|RRMM
1099463|NCT01575925|impaired renal function in multiple myeloma
1099464|NCT01575925|hemodialysis
1099465|NCT01575925|dialysis
1099466|NCT01575925|POM
1099467|NCT01575925|Pomalyst
1099468|NCT01575925|MM
1099469|NCT01575925|severe renal impairment
1099470|NCT01575925|CrCl ≤ 30 mL/min
1099471|NCT01575925|Creatinine less than 30
1099472|NCT01575925|clinical trial in subjects with multiple myeloma with renal impairement
1099473|NCT01575912|Schizophrenia
1099474|NCT01575912|Major depression
1099475|NCT01575912|Pain
1099476|NCT01575912|Past pain experience
1099477|NCT01575899|Helicobacter pylori
1099478|NCT01575899|Levofloxacin
1099479|NCT01575899|Amoxicillin/clavulanate
1099480|NCT01575899|Rabeprazole
1099481|NCT01575899|Eastern Taiwan
1099482|NCT01575886|clinician patient communication
1099483|NCT01575886|smoking cessation
1099484|NCT01575886|weight management
1099485|NCT01575886|primary care
1099486|NCT01575886|health behavior change advice
1099487|NCT01575873|GIOP, Glucocorticoid, osteporosis, denosumab, BMD, Bone Mineral Density
1099488|NCT01575860|biopsy-proven diagnosis
1099489|NCT01575860|completed at least 2 cycles of salvage chemotherapy
1099490|NCT01575860|showing PET positive residual lesions
1099491|NCT01575847|Acetaminophen
1099492|NCT01575847|Acetaminophen Toxicity
1099493|NCT01575834|Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
1099494|NCT01575821|children, cough, honey
1099495|NCT01575808|Symptomatic PAD
1099496|NCT01575808|stenosed or occluded lesions
1099497|NCT01575808|totaling at least 10 cm in length
1099498|NCT01575808|Rutherford scores 2-5
1099499|NCT01575795|Ticagrelor
1099500|NCT01575795|ST elevation acute myocardial infarction
1099501|NCT01575795|Platelet reactivity
1099502|NCT01575782|small cell lung cancer
1099503|NCT01575782|stage I-III
1099504|NCT01575782|chloroquine
1099505|NCT01575782|Phase I
1099506|NCT01575730|Peritoneal carcinomatosis from colorectal or appendiceal origin
1099507|NCT01575717|Vitamin D
1099508|NCT01575717|hepatocellular carcinoma
1099509|NCT01575717|liver neoplasms
1099510|NCT01575717|liver transplantation
1099511|NCT01575704|Exercise
1099512|NCT01575704|Hematopoetic cell transplantation
1099513|NCT01575704|Children
1099514|NCT01575691|Combination Chemotherapy
1099515|NCT01575691|MDS
1099516|NCT01575691|High-Risk Myelodysplastic Syndrome
1099517|NCT01575691|AML
1099518|NCT01575691|Acute myelogenous leukemia
1099519|NCT01575691|valproic acid
1099520|NCT01575691|VPA
1099521|NCT01575691|Depakene
1099522|NCT01575691|5-azacytidine
1099523|NCT01575691|5-aza
1099524|NCT01575691|Azacitidine
1099525|NCT01575691|5-AZC
1099526|NCT01575691|Vidaza
1099527|NCT01575691|AZA-CR
1099528|NCT01575691|Ladakamycin
1099529|NCT01575691|NSC-102816
1099530|NCT01575691|All-trans retinoic acid
1099531|NCT01575691|ATRA
1099532|NCT01575691|Tretinoin
1099533|NCT01575691|Vesanoid
1099534|NCT01575678|enuresis
1099535|NCT01575678|melatonin
1099536|NCT01575678|circadian rhythm
1099537|NCT01575678|children
1099538|NCT01575678|blood pressure
1099539|NCT01575678|urine production
1099540|NCT01575678|activity
1099541|NCT01575678|sleep
1099542|NCT01575665|Hyperventilation
1099543|NCT01575665|Chronic Idiopathic Hyperventilation
1099544|NCT01575665|Dysfunctional Breathing
1099545|NCT01575665|Respiratory Alkalosis
1099546|NCT01575665|Respiratory Acidosis
1099547|NCT01575652|peritoneal dialysis
1099548|NCT01575652|protein losses
1099549|NCT01575613|malaria
1099550|NCT01575613|heterogeneity
1099551|NCT01575613|transmission
1099552|NCT01575613|elimination
1099553|NCT01575587|Pharmacology
1099554|NCT01575587|Pharmacokinetics
1099555|NCT01575587|Pharmacodynamics
1099556|NCT01575587|Abiraterone acetate
1099557|NCT01575587|Food intake
1099558|NCT01575587|Caucasion
1099559|NCT01575587|Japanese
1099560|NCT01575587|Healthy
1099561|NCT01575561|Lurasidone
1099562|NCT01575561|Latuda
1099563|NCT01575561|Bipolar Disorder
1099564|NCT01575535|untreated adult acute myeloid leukemia
1099565|NCT01575535|adult acute basophilic leukemia
1099566|NCT01575535|adult acute eosinophilic leukemia
1099567|NCT01575535|adult erythroleukemia (M6a)
1099568|NCT01575535|adult pure erythroid leukemia (M6b)
1099569|NCT01575535|adult acute megakaryoblastic leukemia (M7)
1099570|NCT01575535|adult acute minimally differentiated myeloid leukemia (M0)
1099571|NCT01575535|adult acute monoblastic leukemia (M5a)
1099572|NCT01575535|adult acute monocytic leukemia (M5b)
1099573|NCT01575535|adult acute myeloblastic leukemia with maturation (M2)
1099574|NCT01575535|adult acute myeloblastic leukemia without maturation (M1)
1099575|NCT01575535|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1099576|NCT01575535|adult acute myeloid leukemia with del(5q)
1099577|NCT01575535|adult acute myeloid leukemia with inv(16)(p13;q22)
1099578|NCT01575535|adult acute myeloid leukemia with t(16;16)(p13;q22)
1099579|NCT01575535|adult acute myeloid leukemia with t(8;21)(q22;q22)
1099580|NCT01575535|adult acute myelomonocytic leukemia (M4)
1099581|NCT01575496|Tinnitus
1099582|NCT01575496|Transcranial direct current stimulation
1099583|NCT01575496|Transcranial magnetic stimulation
1099584|NCT01575470|Traumatic Brain Injury
1099585|NCT01575470|TBI
1099586|NCT01575470|stem cells
1099587|NCT01575457|Adolescent Violence Prevention
1099588|NCT01575444|Pap test
1099589|NCT01575444|HPV testing
1099590|NCT01575444|cervical cancer
1099591|NCT01575431|coronary artery disease
1099592|NCT01575431|endothelial progenitor cells
1099593|NCT01575392|creatinine
1099594|NCT01575392|chronic kidney disease
1099595|NCT01575392|creatinine clearance
1099596|NCT01575392|estimated glomerular filtration rate
1099597|NCT01575379|allopurinol
1099598|NCT01575379|uric acid
1099599|NCT01575379|diabetes
1099600|NCT01575379|nephropathy
1099601|NCT01575340|inflammatory markers
1099602|NCT01575340|colorectal cancer
1099603|NCT01575340|cytokines
1099604|NCT01575340|fish oil
1099605|NCT01575314|stapling device
1099606|NCT01575314|lobectomy
1099607|NCT01575314|cost utility
1099608|NCT01575301|GLP-1R agonist
1099609|NCT01575301|biomarker
1099610|NCT01575288|arterial function
1099611|NCT01575288|cardiovascular
1099612|NCT01575288|aging
1099613|NCT01575288|endothelial function
1099614|NCT01575288|arterial stiffness
1099615|NCT01575288|vascular function
1099616|NCT01575288|Trehalose
1099617|NCT01575262|behaviour change
1099618|NCT01575262|incentives
1099619|NCT01575262|nudging
1099620|NCT01575262|physical activity
1099621|NCT01575262|self-monitoring
1099622|NCT01575249|progression
1099623|NCT01575249|moderate aortic stenosis
1099624|NCT01575249|asymptomatic
1099625|NCT01575249|symptomatic
1099626|NCT01575223|saline irrigation
1099627|NCT01575223|chronic rhinosinusitis
1099628|NCT01575223|endoscopic sinus surgery
1099629|NCT01575223|high volume saline irrigation
1099630|NCT01575184|internal jugular vein cannulation
1099631|NCT01575184|common carotid artery
1099632|NCT01575184|infants
1099633|NCT01575132|Parkinson's Disease
1099634|NCT01575132|Stimulation, Deep Brain
1099635|NCT01575132|Study, Follow-Up
1099636|NCT01575132|Adverse Effects
1099637|NCT01575119|Cigarette smoker
1099638|NCT01575119|Elective surgery
1099639|NCT01575093|Healthy volunteers
1099640|NCT01574040|Lifestyle
1099641|NCT01574040|Lifestyle modification
1099642|NCT01574040|Behavior
1099643|NCT01574040|Primary prevention
1099644|NCT01574040|Healthy staff and visitors of an Academic Hospital
1099645|NCT01574027|Assess the efficacy of vitamin D for preventing colorectal cancer and identifying the populations likely (or unlikely) to benefit from vitamin D-based therapy.
1099646|NCT01574027|Evaluate the ability of Vitamin D3 (cholecalciferol) to reduce ACF's in humans.
1099647|NCT01574014|Anxiety Disorder
1099648|NCT01574014|Phobic Disorders
1099649|NCT01574001|ischemic stroke
1099650|NCT01574001|smoking cessation
1099651|NCT01574001|antismoking interventions
1099652|NCT01573988|Nutrition
1099653|NCT01573988|Eating frequency
1099654|NCT01573988|Food intake
1099655|NCT01573988|Eating behavior
1099656|NCT01573988|Satiety
1099657|NCT01573988|Ghrelin
1099658|NCT01573975|Helicobacter pylori
1099659|NCT01573975|antibiotic resistance
1099660|NCT01573975|sequential therapy
1099661|NCT01573975|Taiwan
1099662|NCT01573962|Kidney Renal
1099663|NCT01573949|Heart Failure
1099664|NCT01573949|Diabetes
1099665|NCT01573949|Pre-diabetes
1099666|NCT01573949|Early type II diabetes
1099667|NCT01573949|Metformin
1099668|NCT01573949|Pharmacotherapy with metformin for prevention of DM in HF patients with pre-diabetes (pre-DM) and glycemic control in HF patients with early type II DM
1099669|NCT01573936|acquired brain injury
1099670|NCT01573936|health-related quality of life
1099671|NCT01573936|poliomyelitis survivor
1099672|NCT01573936|rehabilitation
1099673|NCT01573936|spinal cord injury
1099674|NCT01573936|completed the WHOQOL-BREF
1099675|NCT01575067|BP
1099676|NCT01575041|sodium
1099677|NCT01575041|salt
1099678|NCT01575041|potassium
1099679|NCT01575041|blood pressure
1099680|NCT01575041|flow-mediated dilatation
1099681|NCT01575041|endothelial function
1099682|NCT01575041|renal function
1099683|NCT01575041|controlled feeding study
1099684|NCT01575041|dietary intervention
1099685|NCT01575028|Transversus abdominis plane block
1099686|NCT01575028|TAP block
1099687|NCT01575028|Local anesthetic infiltration
1099688|NCT01575028|Appendectomy
1099689|NCT01575028|Laparoscopic appendectomy
1099690|NCT01575015|Liver transplantation (E04.210.650)
1099691|NCT01575015|Renal replacement therapy (E05.196.353)
1099692|NCT01575015|Intra-operative period (E04.614.374)
1099693|NCT01575015|Safety (N06.850.135.060.075)
1099694|NCT01575015|Efficacy
1099695|NCT01575002|transcranial stimulation
1099696|NCT01575002|direct current stimulation
1099697|NCT01574989|direct current stimulation
1099698|NCT01574989|magnetic stimulation
1099699|NCT01574989|transcranial stimulation
1099700|NCT01574976|ADHD
1099701|NCT01574976|probabilistic
1099702|NCT01574976|choice
1099703|NCT01574976|feedback
1099704|NCT01574976|practice
1099705|NCT01574963|Coronary artery disease
1099706|NCT01574963|OPG
1099707|NCT01574963|RANKL
1099708|NCT01574963|bone disease
1099709|NCT01574950|Delirium
1099710|NCT01574937|Castration Resistant
1099711|NCT01574937|Post Chemotherapy
1099712|NCT01574924|Personality change
1099713|NCT01574924|Perfectionism
1099714|NCT01574924|Coping
1099715|NCT01574924|Medical Specialty
1099716|NCT01574924|Medical Residency
1099717|NCT01574911|volumetry 3D
1099718|NCT01574911|Displacement of water
1099719|NCT01574911|lymphoedema
1099720|NCT01574911|Venous chronic insufficiency
1099721|NCT01574898|Smoking cessation
1099722|NCT01574898|Nicotine
1099723|NCT01574898|Tobacco Use Disorder
1099724|NCT01574898|Central Nervous System Agents
1099725|NCT01574885|sleep apnea
1099726|NCT01574885|adenotonsillar hypertrophy
1099727|NCT01574885|salt
1099728|NCT01574885|sodium chloride
1099729|NCT01574872|psoriasis
1099730|NCT01574872|salt
1099731|NCT01574872|sodium chloride
1099732|NCT01574859|central hypothyroidism
1099733|NCT01574859|hypopituitarism
1099734|NCT01574859|levothyroxine replacement
1099735|NCT01574859|lipids
1099736|NCT01574859|body composition
1099737|NCT01574820|prediabetes
1099738|NCT01574820|coronary artery disease
1099739|NCT01574820|insulin resistance
1099740|NCT01574820|glucose intolerance
1099741|NCT01574807|mepivacaine
1099742|NCT01574807|lidocaine
1099743|NCT01574807|inferior alveolar nerve block
1099744|NCT01574807|pulpal anesthesia
1099745|NCT01574807|pain of injection
1099746|NCT01574807|mepivacaine/lidocaine
1099747|NCT01574807|lidocaine/lidocaine
1099748|NCT01574781|Down syndrome
1099749|NCT01574781|Trisomy 13
1099750|NCT01574781|Trisomy 18
1099751|NCT01574781|Microdeletions
1099752|NCT01574781|Pregnancy
1099753|NCT01574781|Non-invasive
1099754|NCT01574755|gastric inlet patches
1099755|NCT01574755|argon plasma coagulation
1099756|NCT01574755|globus sensations
1099757|NCT01574729|p53 gene therapy
1099758|NCT01574729|non-small cell lung cancer
1099759|NCT01574729|post-surgery
1099760|NCT01574729|chemotherapy
1099761|NCT01574703|smoking cessation
1099762|NCT01574703|psychiatric disease
1099763|NCT01574703|cardiovascular events
1099764|NCT01574690|central venous pressure
1099765|NCT01574690|right heart catheter (RHC)
1099766|NCT01574690|non-invasive monitor
1099767|NCT01574690|physical exam of jugular venous pressure
1099768|NCT01574690|heart failure (HF)
1099769|NCT01574677|Colorectal cancer
1099770|NCT01574677|fecal immunochemical test
1099771|NCT01574677|Septin 9
1099772|NCT01574677|screening
1099773|NCT01574651|QVA149
1099774|NCT01574651|Health related quality of life
1099775|NCT01574651|Formoterol
1099776|NCT01574651|Tiotropium
1099777|NCT01574651|COPD
1099778|NCT01574612|Xerese
1099779|NCT01574612|acyclovir hydrocortisone cream
1099780|NCT01574612|herpes labialis
1099781|NCT01574612|pediatric
1099782|NCT01574599|Stroke
1099783|NCT01574599|weakness
1099784|NCT01574599|rehabilitation
1099785|NCT01574599|chronic stroke
1099786|NCT01574586|True Bifurcation stenosis
1099787|NCT01574573|Obesity
1099788|NCT01574573|GERD
1099789|NCT01574573|Weight loss
1099790|NCT01574560|smoke-free
1099791|NCT01574560|tobacco exposure
1099792|NCT01574560|biomarker feedback
1099793|NCT01574560|nicotine
1099794|NCT01574560|cotinine
1099795|NCT01574560|secondhand smoke
1099796|NCT01574547|Cat Scratch Colon.
1099797|NCT01574547|Mucosal tears.
1099798|NCT01574547|Mucosal erosion.
1099799|NCT01574547|Colonoscopy.
1099800|NCT01574508|efficacy
1099801|NCT01574508|safety
1099802|NCT01574508|intensive insulin therapy
1099803|NCT01574495|stroke
1099804|NCT01574495|error augmentation
1099805|NCT01574495|arm recovery
1099806|NCT01574495|massed practice
1099807|NCT01574482|Plant sterol - Hypercholesterolemia - diet - dairy
1099808|NCT01574469|Plant sterol - Cholesterol absorption - diet - dairy - LDL
1099809|NCT01574443|Epilepsy
1099810|NCT01574417|Plant stanols
1099811|NCT01574417|Gene expression profile
1099812|NCT01574417|Microbiota
1099813|NCT01574404|PGS,PGD, IVF, Polar Body Biopsy, FISH, Microarray analysis
1099814|NCT01574378|Abdominoplasty
1099815|NCT01574365|CKD patients with type 2 diabetes
1099816|NCT01574352|Children
1099817|NCT01574352|Overweight
1099818|NCT01574352|Obesity
1099819|NCT01574352|BMI
1099820|NCT01574352|Physical activity
1099821|NCT01574352|Cognitive function
1099822|NCT01574352|Intervention study
1099823|NCT01574352|Randomized controlled trial
1099824|NCT01574352|Day camp
1099825|NCT01574352|Risk factors
1099826|NCT01574339|GERD
1099827|NCT01574339|LES Pressure
1099828|NCT01574339|Electrical Stimulation
1099829|NCT01574326|Chronic Kidney Disease
1099830|NCT01574326|Pediatric
1099831|NCT01574326|Sevelamer Carbonate
1099832|NCT01574326|Hyperphosphatemia
1099833|NCT01574313|stellate ganglion block.
1099834|NCT01574313|Meniere's disease.
1099835|NCT01574313|electrocochleography.
1099836|NCT01574313|vertigo.
1099837|NCT01574313|hearing impairment.
1099838|NCT01574300|Small Cell Lung Cancer (SCLC)
1099839|NCT01574300|Non-Small Cell Lung Cancer (NSCLC)
1099840|NCT01574300|M1A or B NSCLC
1099841|NCT01574261|Polycystic Ovary Syndrome
1099842|NCT01574261|Cardiovascular risk
1099843|NCT01574261|Metabolic Syndrome
1099844|NCT01574248|ACE inhibitor
1099845|NCT01574248|Angioedema
1099846|NCT01574248|Bradykinin
1099847|NCT01574248|Swelling
1099848|NCT01574222|Stages IIIB, IV, and recurrent NSCLC
1099849|NCT01574222|Carcinoma, Non-small cell lung
1099850|NCT01574222|Lung Neoplasms
1099851|NCT01574222|Carcinoma, Bronchogenic
1099852|NCT01574222|Thoracic Neoplasms
1099853|NCT01574222|Neoplasms by Site
1099854|NCT01574222|Neoplasms
1099855|NCT01574222|Lung Diseases
1099856|NCT01574209|Celiac disease
1099857|NCT01574209|IBS
1099858|NCT01574209|Intestinal barrier
1099859|NCT01574209|Intestinal permeability
1099860|NCT01574209|GI peptides
1099861|NCT01574196|Childhood cancer
1099862|NCT01574196|Cancer
1099863|NCT01574196|Sequels
1099864|NCT01574196|Complications
1099865|NCT01574196|Chemotherapy
1099866|NCT01574196|Radiotherapy
1099867|NCT01574196|Surgery
1099868|NCT01574196|Autonomic nervous system
1099869|NCT01574196|Parasympathetic Nervous System
1099870|NCT01574196|Sympathetic Nervous System
1099871|NCT01574183|Marijuana
1099872|NCT01574183|Vilazodone
1099873|NCT01574183|Contingency management
1099874|NCT01574183|Motivational enhancement therapy
1099875|NCT01574170|Breast cancer,
1099876|NCT01574170|Third line metastatic
1099877|NCT01574170|Chemotherapy,
1099878|NCT01574170|Overall survival,
1099879|NCT01574170|Quality of life.
1099880|NCT01574144|Heart Failure
1099881|NCT01574131|Burn
1099882|NCT01574131|Fenofibrate
1099883|NCT01574131|PPAR alpha agonist
1099884|NCT01574131|insulin sensitivity
1099885|NCT01574131|mitochondrial
1099886|NCT01574118|PTSD
1099887|NCT01574118|Posttraumatic Stress Disorder
1099888|NCT01574118|Exposure Therapy
1099889|NCT01574118|Prolonged Exposure
1099890|NCT01574118|Fear Memory Retrieval
1099891|NCT01574118|Compound extinction
1099892|NCT01574118|Deepened extinction
1099893|NCT01574118|Psychotherapy
1099894|NCT01574105|Heparin Dose
1099895|NCT01574105|Heparin Resistance
1099896|NCT01574105|Chest Tube Losses
1099897|NCT01574105|Transfusion Events
1099898|NCT01574092|Pediatric
1099899|NCT01574092|Pediatrics
1099900|NCT01574092|Gliomas
1099901|NCT01574092|Glioma
1099902|NCT01574092|Brain tumor
1099903|NCT01574092|Brain cancer
1099904|NCT01574092|Cisplatin
1099905|NCT01574092|Cisplatino
1099906|NCT01574092|Irinotecan
1099907|NCT01574092|Brain stem tumor
1099908|NCT01574092|Brainstem gliomas
1099909|NCT01574092|Intrinsic brain stem tumor
1099910|NCT01574092|PAEDIATRIC HIGH GRADE GLIOMA
1099911|NCT01574092|Childhood brain stem glioma
1099912|NCT01574066|Community-acquired pneumonia
1099913|NCT01574066|Diagnosis
1099914|NCT01574066|Emergency medicine
1099915|NCT01574066|Chest CT-scan
1099916|NCT01574053|Huntington's Disease
1099917|NCT01574053|Huntington Disease
1099918|NCT01574053|Juvenile Huntington's Disease
1099919|NCT01574053|Registry
1099920|NCT01574053|Cohort
1099921|NCT01574053|CHDI
1099922|NCT01573923|Umbilical Mesenchymal Stem Cells; Liver cirrhosis
1099923|NCT01573910|Bacterial conjunctivitis
1099924|NCT01573910|Anti-infective
1099925|NCT01573910|Antibiotics
1099926|NCT01573897|Diabetes
1099927|NCT01573897|Sleep apnea
1099928|NCT01573897|Diabetic foot
1099929|NCT01573897|microcirculation
1099930|NCT01573858|Infertility
1099931|NCT01573858|Polycystic Ovary Syndrome
1099932|NCT01573858|Clomiphene citrate
1099933|NCT01573858|Acupuncture
1099934|NCT01573845|child
1099935|NCT01573845|communication
1099936|NCT01573845|diet
1099937|NCT01573845|food
1099938|NCT01573845|health communication
1099939|NCT01573845|nutrition
1099940|NCT01573845|parents
1099941|NCT01573845|primary schools
1099942|NCT01573845|school age population
1099943|NCT01573845|school health
1099944|NCT01573819|repeat dose
1099945|NCT01573819|PDE4
1099946|NCT01573819|healthy volunteers
1099947|NCT01573819|GSK356278
1099948|NCT01573806|sepsis
1099949|NCT01573806|septic shock
1099950|NCT01573806|children
1099951|NCT01573806|incretins
1099952|NCT01573806|exenatide
1099953|NCT01573806|pharmacokinetics
1099954|NCT01573806|pharmacodynamics
1099955|NCT01573806|glucose homeostasis
1099956|NCT01573806|inflammation
1099957|NCT01573806|cytokines
1099958|NCT01573806|health-related quality of life
1099959|NCT01573806|functional status
1099960|NCT01573754|Porphyria, rare disease, orphan disease, iron metabolism
1099961|NCT01573741|depressive ketamine antidepressant
1099962|NCT01573728|Depression
1099963|NCT01573728|Biomarkers
1099964|NCT01573728|Exercise
1099965|NCT01573702|Non small cell lung cancer
1099966|NCT01573702|EGFR mutant
1099967|NCT01573702|Phase II
1099968|NCT01573702|erlotinib
1099969|NCT01573702|tarceva
1099970|NCT01573702|cyberknife
1099971|NCT01573702|Lineberger
1099972|NCT01573689|bereaved children, mutual aid group, death, group intervention.
1099973|NCT01573676|bariatric surgery
1099974|NCT01573676|sleep apnea
1099975|NCT01573676|overweight
1099976|NCT01573663|Ambroxol
1099977|NCT01573663|Levodropropizine
1099978|NCT01573663|Drug-drug interaction
1099979|NCT01573637|schizophrenia
1099980|NCT01573637|negative schizophrenia
1099981|NCT01573637|schizophrenia in post-menopausal women
1099982|NCT01573637|schizophrenia in women
1099983|NCT01573637|ralixifene
1099984|NCT01573637|raloxifen
1099985|NCT01573637|raloxifeno
1099986|NCT01573637|negative symptoms of schizophrenia
1099987|NCT01573637|negative symptoms in schizophrenia
1099988|NCT01573637|schizophrenia symptoms
1099989|NCT01573637|negative symptoms of psychosis
1099990|NCT01573624|Vilanterol (VI),
1099991|NCT01573624|, Fluticasone Furoate (FF),
1099992|NCT01573624|Adults
1099993|NCT01573624|Asthma
1099994|NCT01573624|GSK573719,
1099995|NCT01573611|mild cognitive impairment
1099996|NCT01573611|dementia
1099997|NCT01573611|positron emission tomography (PET)
1099998|NCT01573611|F-18 Fluorodeoxyglucose (FDG)
1099999|NCT01573611|cerebral metabolism
1100000|NCT01573611|dietary supplement
1100001|NCT01573598|Major Depressive Disorder
1100002|NCT01573598|Depression
1100003|NCT01573585|Physical Therapy
1100004|NCT01573585|Exercise therapy
1100005|NCT01573559|Ambulatory adults with no apparent health conditions
1100006|NCT01573533|Treatment Resistant Idiopathic FSGS
1100007|NCT01573533|Glomerulosclerosis
1100008|NCT01573533|Proteinuria
1100009|NCT01573533|Rituximab
1100010|NCT01573520|compliance
1100011|NCT01573520|dialysis
1100012|NCT01573520|hyperparathyroidism
1100013|NCT01573507|traumatic brain injury
1100014|NCT01573507|lactate
1100015|NCT01573507|brain metabolism
1100016|NCT01573507|cerebral microdialysis
1100017|NCT01573507|subarachnoid hemorrhage
1100018|NCT01573507|transcranial doppler
1100019|NCT01573494|Cancer
1100020|NCT01573494|Melanoma
1100021|NCT01573494|Circulating Tumor Cells
1100022|NCT01573481|WEANING
1100023|NCT01573481|PRESSURE CONTROLLED CONTINOUS VENTILATION
1100024|NCT01573481|PRESSURE VENTILATION SUPPORT
1100025|NCT01573481|SLEEP
1100026|NCT01573481|POLYGRAPHIC RECORD
1100043|NCT01573416|Alcohol
1100044|NCT01573416|Abuse
1100045|NCT01573416|Drugs
1100046|NCT01573416|Brief intervention
1100047|NCT01573416|ASSIST
1100048|NCT01573403|Proton pump inhibitor (PPI)
1100049|NCT01573403|DLBS2411
1100050|NCT01573403|gastric pH
1100051|NCT01573390|Non-invasive
1100052|NCT01573390|tissue-oxygenation
1100053|NCT01573390|hyperspectral
1100054|NCT01573390|CWC imaging system
1100055|NCT01573377|polycystic ovary syndrome
1100056|NCT01573377|insulin resistance
1100057|NCT01573364|Distal Airways
1100058|NCT01573364|Hyperinflation
1100059|NCT01573364|Reversibility
1100060|NCT01573338|Cyclin dependent kinases
1100061|NCT01573338|Drug therapy, combination
1100062|NCT01573338|Small cell lung carcinoma
1100063|NCT01573338|Etoposide
1100064|NCT01573338|Cisplatin
1100065|NCT01573338|Carboplatin
1100066|NCT01573325|Cirrhosis of the liver
1100067|NCT01573325|Pre-liver transplant Candidate
1100068|NCT01573325|Depression
1100069|NCT01573325|Poor social support
1100070|NCT01573325|Liver disease symptoms
1100071|NCT01573325|Health releated quality of life
1100072|NCT01573312|influenza, vaccine, H5N1, monovalent, adjuvant, ASO3
1100073|NCT01573299|Cerebral Infarction, Mobilization, Recovery
1100074|NCT01573286|Infant Nutrition Disorders
1100075|NCT01573286|Childhood nutrition disorders
1100076|NCT01573286|malnutrition
1100077|NCT01573286|post surgical syndromes
1100078|NCT01573286|necrotising enterocolitis
1100079|NCT01573286|intestinal atresia
1100080|NCT01573286|gastroschisis
1100081|NCT01573273|cocaine
1100082|NCT01573273|substance abuse
1100083|NCT01573273|drug abuse
1100084|NCT01573273|cocaine dependence
1100085|NCT01573273|drug addiction
1100086|NCT01573260|Parkinson's Disease
1100087|NCT01573260|Tango
1100088|NCT01573247|Acute myeloid leukemia
1100089|NCT01573247|Refractory Acute myeloid leukemia
1100090|NCT01573247|FLT3 inhibitor
1100091|NCT01573247|kinase inhibitor
1100092|NCT01573234|MySkin patch
1100093|NCT01573234|Hydrogel bandage
1100094|NCT01573234|Occlusive dressing
1100095|NCT01573208|Knee osteoarthritis
1100096|NCT01573195|deescalation
1100097|NCT01573195|best practice alert
1100098|NCT01573195|antimicrobial stewardship
1100099|NCT01573182|Zostavax
1100100|NCT01573182|Herpes Zoster
1100101|NCT01573182|VZV vaccination
1100102|NCT01573182|Allogeneic haemopoietic stem cell transplantation
1100103|NCT01573169|hemorrhagic stroke
1100104|NCT01573169|venous thromboembolism
1100105|NCT01573169|prevention
1100106|NCT01573156|renal cancer
1100107|NCT01573156|photodynamic therapy
1100108|NCT01573156|wst 11
1100109|NCT01573143|Surgical Procedures, Cardiac
1100110|NCT01573143|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1100111|NCT01573143|Rosuvastatin
1100112|NCT01573143|Post operative atrial fibrillation
1100113|NCT01573130|Depression
1100114|NCT01573130|Physical exercise
1100115|NCT01573130|Internet
1100116|NCT01573117|hypothermia
1100117|NCT01573117|induction of hypothermia
1100118|NCT01573117|cold infusion
1100119|NCT01573117|nasopharyngeal cooling
1100120|NCT01573117|stroke
1100121|NCT01573117|intracranial hemorrhage
1100122|NCT01573117|cerebrovascular disease
1100123|NCT01573117|neuro intensive care
1100124|NCT01573104|Diagnosis
1100125|NCT01573104|Acute Kidney Injury
1100126|NCT01573091|Cardiac resynchronization therapy
1100127|NCT01573091|Heart failure
1100128|NCT01573078|Crohn's disease
1100129|NCT01573078|IBS
1100130|NCT01573078|Dissociation
1100131|NCT01573078|Emotional processing
1100132|NCT01573065|alcohol consumption
1100133|NCT01573065|sexual risk behaviors
1100134|NCT01573065|young, unhealthy drinkers
1100135|NCT01573039|Kidney transplantation
1100136|NCT01573039|PCR quantitative
1100137|NCT01573039|cytomegalovirus
1100138|NCT01573039|antigenemia
1100139|NCT01573026|Dental Implants
1100140|NCT01573026|Dental Implantation
1100141|NCT01573026|Osseointegration
1100142|NCT01573013|iron deficiency
1100143|NCT01573013|Lead poisoning
1100144|NCT01573013|cognitive development
1100145|NCT01573013|motor activity
1100146|NCT01573000|Bexxar
1100147|NCT01573000|Non-Hodgkin's Lymphoma
1100148|NCT01573000|Tositumomab
1100149|NCT01573000|Anti-B1 Antibody
1100150|NCT01573000|Radioimmunotherapy
1100151|NCT01573000|Iodine I-131
1100152|NCT01573000|Iodine-131
1100153|NCT01572987|Barrett's Esophagus
1100154|NCT01572987|Esophageal neoplasms
1100155|NCT01572987|Radiofrequency ablation
1100156|NCT01572987|Endoscopic mucosal resection
1100157|NCT01572974|Barrett's esophagus
1100158|NCT01572974|Gastroesophageal reflux disease
1100159|NCT01572974|Quality of life
1100160|NCT01572961|Laser Doppler flowmetry, skin, microcirculation
1100161|NCT01572935|childhood obesity prevalence
1100162|NCT01572922|Sickle cell disease
1100163|NCT01572922|Thalassemia
1100164|NCT01572922|Hemochromatosis
1100165|NCT01572922|Cancer
1100166|NCT01572909|Myocardial Reperfusion
1100167|NCT01572909|Primary PCI
1100168|NCT01572909|Stenting for ST-segment Elevation Myocardial Infarction
1100169|NCT01572896|adoloescent
1100170|NCT01572896|internet self-management
1100171|NCT01572896|managing JIA
1100172|NCT01572883|adjuvant treatment with Radiotherapy and trastuzumab
1100173|NCT01572870|Chit1
1100174|NCT01572870|Cystic Fibrosis
1100175|NCT01572870|Allergic Bronchopulmonary Aspergillosis (ABPA)
1100176|NCT01572870|Aspergillus
1100177|NCT01572857|multiple myeloma
1100178|NCT01572857|Proteinuria
1100179|NCT01572857|Albuminuria
1100180|NCT01572857|Urinary FLC
1100181|NCT01572857|Urine creatinine
1100182|NCT01572844|Dermatomyositis
1100183|NCT01572844|Superficial calcinosis
1100184|NCT01572844|Fractional carbon dioxide laser
1100185|NCT01572844|Sodium thiosulfate
1100186|NCT01572831|antibiotic cessation rules
1100187|NCT01572831|procalcitonin
1100188|NCT01572831|infection
1100189|NCT01572831|critical care
1100190|NCT01572818|Phlebotomy
1100191|NCT01572818|Insulin Resistance
1100192|NCT01572818|Iron Overload
1100193|NCT01572805|Post partum haemorrhage
1100194|NCT01572805|Cesarean
1100195|NCT01572805|Pain
1100196|NCT01572792|COPD
1100197|NCT01572792|Chronic Obstructive Pulmonary Disease
1100198|NCT01572792|Chronic Bronchitis
1100199|NCT01572792|Emphysema
1100200|NCT01572792|Airflow Obstruction, Chronic
1100201|NCT01572792|Chronic Airflow Obstruction
1100202|NCT01572792|Chronic Obstructive Airway Disease
1100203|NCT01572792|Chronic Obstructive Lung Disease
1100204|NCT01572779|dorsavi
1100205|NCT01572779|vimove
1100206|NCT01572779|biofeedback
1100207|NCT01572779|objective movement data
1100208|NCT01572779|back pain
1100209|NCT01572766|Osteoporosis
1100210|NCT01572766|Pharmacist
1100211|NCT01572766|Behavior Change
1100212|NCT01572766|FRAX
1100213|NCT01572766|Osteopenia
1100214|NCT01572727|BKM120
1100215|NCT01572727|paclitaxel
1100216|NCT01572727|breast cancer
1100217|NCT01572727|metastatic
1100218|NCT01572727|locally advanced
1100219|NCT01572727|PI3K
1100220|NCT01572727|PIK3CA
1100221|NCT01572727|PTEN
1100222|NCT01572714|Exercise
1100223|NCT01572714|Self Care
1100224|NCT01572714|Fatigue
1100225|NCT01572675|Pharmacoepidemiological
1100226|NCT01572675|Longitudinal
1100227|NCT01572675|Observational
1100228|NCT01572662|Leukemia
1100229|NCT01572662|Acute myeloid leukemia
1100230|NCT01572662|Acute lymphocytic leukemia
1100231|NCT01572662|Chronic myeloid leukemia
1100232|NCT01572662|Chronic lymphocytic leukemia
1100233|NCT01572662|Myeloproliferative Diseases
1100234|NCT01572662|Non-Hodgkins Lymphoma
1100235|NCT01572662|Hodgkins lymphoma
1100236|NCT01572662|Multiple myeloma
1100237|NCT01572662|Myelodysplastic syndrome
1100238|NCT01572662|MDS
1100239|NCT01572662|Fludarabine monophosphate
1100240|NCT01572662|Fludarabine phosphate
1100241|NCT01572662|Fludara
1100242|NCT01572662|Busulfan
1100243|NCT01572662|Busulfex
1100244|NCT01572662|Myleran
1100245|NCT01572662|Tacrolimus
1100246|NCT01572662|Prograf
1100247|NCT01572662|Methotrexate
1100248|NCT01572662|G-CSF
1100249|NCT01572662|Filgrastim
1100250|NCT01572662|Neupogen
1100251|NCT01572662|Stem cell transplant
1100252|NCT01572662|Allogeneic Transplantation
1100253|NCT01572636|Hurler Syndrome
1100254|NCT01572623|Therapeutic strategies for carotid artery stenting
1100255|NCT01572610|CKD patients with type 2 diabetes
1100256|NCT01572597|Helicobacter pylori
1100257|NCT01572597|antibiotic resistance
1100258|NCT01572597|N-acetylcystein
1100259|NCT01572597|biofilm
1100260|NCT01572597|second-line eradication treatment
1100261|NCT01572584|Pneumothorax
1100262|NCT01572584|Lung ultrasound
1100263|NCT01572584|Chest sonography
1100264|NCT01572571|Emergency ultrasound
1100265|NCT01572571|Focused ultrasound
1100266|NCT01572571|Point-of-care ultrasound
1100267|NCT01572571|Undifferentiated hypotension
1100268|NCT01572558|Appendectomy
1100269|NCT01572558|Nonsurgical treatment with antibiotics
1100270|NCT01572545|bone turnover
1100271|NCT01572545|denosumab
1100272|NCT01572545|postmenopausal osteoporosis
1100273|NCT01572545|sclerostin
1100274|NCT01572545|zolendronic acid
1100275|NCT01572532|Adverse Perinatal Outcomes
1100276|NCT01572532|Treatment of abnormal vaginal flora
1100290|NCT01572480|Proteasome Inhibitor
1100291|NCT01572480|Anti-Myeloma Inhibitor
1100292|NCT01572480|Immunomodulatory Agents
1100293|NCT01572480|Combination Therapy
1100294|NCT01572480|Smoldering Multiple Myeloma
1100295|NCT01572480|SMM
1100296|NCT01572467|Leydig cell tumor
1100297|NCT01572467|ovarian stromal cancer
1100298|NCT01572467|childhood malignant testicular germ cell tumor
1100299|NCT01572467|childhood malignant ovarian germ cell tumor
1100300|NCT01572454|coronary artery bypass graft
1100301|NCT01572454|hypokalemia
1100302|NCT01572454|cardiac arrhythmia
1100303|NCT01572454|dexmedetomidine
1100304|NCT01572454|remifentanil
1100305|NCT01572428|Proximal Colon Cancer
1100306|NCT01572428|Serrated Colon Lesions
1100307|NCT01572428|Narrow Band Imaging
1100308|NCT01572415|Screening for Type 2 diabetes
1100309|NCT01572402|Diet
1100310|NCT01572402|Gastrointestinal peptides
1100311|NCT01572402|Insulin secretion
1100312|NCT01572402|Oxidative stress
1100313|NCT01572402|Plasma lipids
1100314|NCT01572402|Postprandial
1100315|NCT01572402|Type 2 diabetes
1100316|NCT01572389|Diabetes Mellitus
1100317|NCT01572389|Depression
1100318|NCT01572389|Affective Symptoms
1100319|NCT01572389|Self Care
1100320|NCT01572389|Telemedicine
1100321|NCT01572389|Psychotherapy
1100322|NCT01572376|Pressure ulcers
1100323|NCT01572376|Chronic wounds
1100324|NCT01572376|Spinal cord injury patients
1100325|NCT01572376|Bone marrow
1100326|NCT01572376|Mononuclear
1100327|NCT01572376|Debridement
1100328|NCT01572363|Fontan
1100329|NCT01572363|Cardiac magnetic resonance imaging
1100330|NCT01572363|Sildenafil
1100331|NCT01572337|NIV
1100332|NCT01572337|acute respiratory failure
1100333|NCT01572337|hypoxia
1100334|NCT01572337|hypercapnia
1100335|NCT01572337|non-invasive ventilation
1100336|NCT01572337|hospital ward
1100337|NCT01572324|Cholangiocarcinoma
1100338|NCT01572324|gallbladder cancer
1100339|NCT01572324|Infusions
1100340|NCT01572324|Intra-Arterial
1100341|NCT01572311|Aerobic exercise
1100342|NCT01572311|Cognition
1100343|NCT01572311|Dual Task
1100344|NCT01572311|Gait Training
1100345|NCT01572311|Group-based exercise
1100346|NCT01572311|Older adults
1100347|NCT01572285|Hemiplegic
1100348|NCT01572285|Shoulder Pain
1100349|NCT01572285|Transforaminal
1100350|NCT01572285|Treatment
1100351|NCT01572285|Interventional
1100352|NCT01572272|Distal Capnography
1100353|NCT01572272|CO2
1100354|NCT01572272|neonates
1100355|NCT01572272|conventional ventilation
1100356|NCT01572246|electrosurgery
1100357|NCT01572246|Cardiac surgical procedures
1100358|NCT01572246|Surgical procedures, operative
1100359|NCT01572246|Defibrillators
1100360|NCT01572233|Fatigue,Physical Activity,Hepatitis C Virus Infection
1100361|NCT01572220|Hospitalized patients
1100362|NCT01572207|Multiple Sclerosis
1100363|NCT01572207|Exercise
1100364|NCT01572207|Physical activity
1100365|NCT01572207|Quality of life
1100366|NCT01572194|CF
1100367|NCT01572168|Fatigue
1100368|NCT01572142|Parkinson disease
1100369|NCT01572142|smell
1100370|NCT01572142|cognitive
1100371|NCT01572116|sufentanil
1100372|NCT01572116|irreversible pulpitis
1100373|NCT01572116|intra ligament injection
1100374|NCT01572090|Body mass index
1100375|NCT01572090|Body fat
1100376|NCT01572090|Obesity
1100377|NCT01572090|Bariatric surgery
1100378|NCT01572090|Conventional dietary treatment
1100379|NCT01572090|Diabetes Mellitus, Type 2
1100380|NCT01572090|Cardiometabolic risk factors
1100381|NCT01572090|Inflammation
1100382|NCT01572090|Adipokines
1100383|NCT01572090|Gastrointestinal hormones
1100384|NCT01572090|Comorbidity improvement
1100385|NCT01572090|Energy intake
1100386|NCT01572090|Energy expenditure
1100387|NCT01572090|Physical activity
1100388|NCT01572064|MRI
1100389|NCT01572064|liver biopsy
1100390|NCT01572064|serological markers
1100391|NCT01572051|osteoarthritis
1100392|NCT01572051|knee osteoarthritis
1100393|NCT01572051|education
1100394|NCT01572012|Pharmacokinetics
1100395|NCT01572012|Safety
1100396|NCT01572012|Healthy Volunteers
1100397|NCT01572012|tolerability
1100398|NCT01571999|pharmacokinetics
1100399|NCT01571999|GW642444
1100400|NCT01571999|GSK573719
1100401|NCT01571999|vilanterol
1100402|NCT01571999|renal impairment
1100403|NCT01571999|safety
1100404|NCT01571999|COPD
1100405|NCT01571986|NIV
1100406|NCT01571986|acute respiratory failure
1100407|NCT01571986|hypoxia
1100408|NCT01571986|hypercapnia
1100409|NCT01571986|non-invasive ventilation
1100410|NCT01571986|hospital ward
1100411|NCT01571973|pharmaceutical care
1100412|NCT01571973|depression
1100413|NCT01571973|compliance
1100414|NCT01571973|pharmacist's intervention
1100415|NCT01571973|Dáder
1100416|NCT01571947|Insulinaemia
1100417|NCT01571947|inflammatory markers
1100418|NCT01571947|gastrointestinal peptides
1100419|NCT01571947|SFA
1100420|NCT01571947|dietary fats
1100421|NCT01571947|carbohydrate
1100422|NCT01571947|insulin sensitivity
1100423|NCT01571934|Hemophilia A
1100424|NCT01571908|rocuronium
1100425|NCT01571908|succinylcholine
1100426|NCT01571908|magnesiumsulphate
1100427|NCT01571908|intubation conditions
1100428|NCT01571895|Autoimmune inflammatory blistering disorder
1100429|NCT01571882|Plant sterol - Policosanols - Hypercholesterolemia - Dairy
1100430|NCT01571869|Plant sterol - hypercholesterolemia - dairy - meal
1100431|NCT01571856|Acute Diarrhea
1100432|NCT01571856|Zinc
1100433|NCT01571856|Children
1100434|NCT01571843|Hyperparathyroidism, Primary
1100435|NCT01571843|Bone Diseases, Metabolic
1100436|NCT01571843|Osteoporosis, Postmenopausal
1100437|NCT01571843|Bone Loss, Postmenopausal
1100438|NCT01571830|food allergy
1100439|NCT01571830|nutrient intake
1100440|NCT01571830|growth
1100441|NCT01571817|Insulin Dependent
1100442|NCT01571804|Anesthesia
1100443|NCT01571804|pregabalin
1100444|NCT01571804|sevoflurane
1100445|NCT01571804|laparoscopic cholecystectomy
1100446|NCT01571791|Ketorolac
1100447|NCT01571791|lidocaine
1100448|NCT01571791|valvular hear diseases
1100449|NCT01571791|cesarean section
1100450|NCT01571778|Hand Hygiene
1100451|NCT01571778|Non-sterile Glove Use
1100452|NCT01571765|maternal
1100453|NCT01571765|newborn
1100454|NCT01571765|child
1100455|NCT01571752|Drug Abuse/Dependence
1100456|NCT01571752|Drug Abuse
1100457|NCT01571752|Drug Dependence
1100458|NCT01571739|Biomarker
1100459|NCT01571739|Latent Tuberculosis
1100460|NCT01571739|IGRA
1100461|NCT01571739|Isoniazid
1100462|NCT01571739|TB Lymphadenopathy
1100463|NCT01571739|Tuberculosis
1100464|NCT01571739|TB
1100465|NCT01571726|(18)-Fluciclatide PET/CT
1100466|NCT01571726|Serum M-Protein
1100467|NCT01571726|Percentage of Plasma Cells in the Bone Marrow
1100468|NCT01571726|Ratio of Normal/Abnormal Percentage of Plasma Cells in the Bone Marrow
1100469|NCT01571726|Multiple Myeloma
1100470|NCT01571700|Mechanical Dysynchrony
1100471|NCT01571700|Electrical Dysynchrony
1100472|NCT01571687|expedition
1100473|NCT01571687|hypoxia
1100474|NCT01571687|blood coagulation disorders
1100475|NCT01571687|cell-derived microparticles
1100476|NCT01571687|oxidative stress
1100477|NCT01571687|N-Acetylcystein
1100478|NCT01571687|vitamins
1100479|NCT01571674|Cervical
1100480|NCT01571674|Clinical Prediction Rule
1100481|NCT01571674|Exercise
1100482|NCT01571674|Manipulation
1100483|NCT01571674|Manual therapy
1100484|NCT01571674|Mobilization
1100485|NCT01571674|Physical Therapy
1100486|NCT01571674|Prognosis
1100487|NCT01571674|Shoulder pain
1100488|NCT01571674|Thoracic
1100489|NCT01571661|KGT-1142
1100490|NCT01571661|safety
1100491|NCT01571661|pharmacokinetics
1100492|NCT01571661|single-dose escalation
1100493|NCT01571661|tolerability
1100494|NCT01571635|Beta-Thalassaemia
1100495|NCT01571622|Whey protein
1100496|NCT01571622|type 2 diabetes
1100497|NCT01571596|XLH
1100498|NCT01571583|Chronic HCV infection
1100499|NCT01571583|Genotype 1 chronic HCV
1100500|NCT01571583|Liver transplantation
1100501|NCT01571583|Hepatitis C
1100502|NCT01571583|Hep C
1100503|NCT01571583|HCV
1100504|NCT01571583|Telaprevir
1100505|NCT01571583|Pegylated-Interferon-alfa-2a
1100506|NCT01571583|Ribavirin
1100507|NCT01571570|Healthy volunteers
1100508|NCT01571570|Food effect
1100509|NCT01571570|Capsule
1100510|NCT01571570|Formulations
1100511|NCT01571570|Liquid formulation
1100512|NCT01571570|Concept K
1100513|NCT01571570|Concept L
1100514|NCT01571570|Oral suspension
1100515|NCT01571570|Oral solution
1100516|NCT01571570|TMC435HPC1002
1100517|NCT01571570|TMC435
1100518|NCT01571570|HPC
1100519|NCT01571518|G-CSF
1100520|NCT01571518|neutropenia
1100521|NCT01571518|TAC
1100522|NCT01571505|Oral vaccines
1100523|NCT01571505|Vaccine Responsiveness
1100524|NCT01571505|Tropical Enteropathy
1100525|NCT01571492|Postoperative Pain
1100526|NCT01571492|Nerve block
1100527|NCT01571492|Total Hip Arthroplasty
1100528|NCT01571492|Postoperative analgesia
1100529|NCT01571492|Lumbar Plexus Catheters
1100530|NCT01571492|L2 Paravertebral Catheters
1100531|NCT01571479|laparoscopic cholecystectomy
1100532|NCT01571479|mini-instrument
1100533|NCT01571466|HIV Seronegativity
1100534|NCT01571466|HIV Preventive Vaccine
1100535|NCT01571453|MDD
1100536|NCT01571440|Bone
1100537|NCT01571440|adolescents
1100538|NCT01571440|fiber
1100539|NCT01571440|healthy
1100540|NCT01571440|boys
1100541|NCT01571440|girls
1100542|NCT01571440|camp
1100543|NCT01571440|calcium
1100544|NCT01571427|Behavioral intervention
1100545|NCT01571427|Social engagement
1100546|NCT01571427|Conversational engagement
1100547|NCT01571427|Social network
1100548|NCT01571427|Cognitive Reserve
1100549|NCT01571427|Alzheimer's disease
1100550|NCT01571401|Kidney cancer survivors
1100551|NCT01571401|Randomized Controlled Trial
1100552|NCT01571401|Physical Activity
1100553|NCT01571401|Theory of Planned Behaviour
1100554|NCT01571401|Quality of life
1100555|NCT01571388|dacomitinib
1100556|NCT01571388|PF-00299804
1100557|NCT01571388|hepatic impairment
1100558|NCT01571388|pharmacokinetics
1100559|NCT01571375|Traumatic Brain Injury
1100560|NCT01571375|HEMS
1100561|NCT01571375|Out-of-hospital
1100562|NCT01571375|Finland
1100563|NCT01571362|oxycodone
1100564|NCT01571362|naltrexone
1100565|NCT01571362|chronic pain
1100566|NCT01571362|low back pain
1100567|NCT01571349|rebalanced hemostasis
1100568|NCT01571349|idiopathic thrombocytopenic purpura
1100569|NCT01571349|coagulation status
1100570|NCT01571323|post partum haemorrhage at cesarean section
1100571|NCT01571297|Diabetes Mellitus
1100572|NCT01571297|Delayed Gastric Emptying
1100573|NCT01571297|Gastroparesis
1100574|NCT01571297|Gastrointestinal Motility Disorder
1100575|NCT01571271|biliary
1100576|NCT01571271|lithotripsy
1100577|NCT01571271|gall stones
1100578|NCT01571271|bile duct
1100579|NCT01571271|Biliary stones
1100580|NCT01571258|SMS
1100581|NCT01571258|Obesity
1100582|NCT01571258|Text Messaging
1100583|NCT01571258|Intervention
1100584|NCT01571258|Mobile Phone
1100585|NCT01571245|Heart rate variability
1100586|NCT01571245|Attentional Bias
1100587|NCT01571232|Macular Edema
1100588|NCT01571232|DME
1100589|NCT01571232|PDR
1100590|NCT01571232|NPDR
1100591|NCT01571232|Ozurdex
1100592|NCT01571232|Dexamethasone
1100593|NCT01571232|Avastin
1100594|NCT01571232|Bevacizumab
1100595|NCT01571219|RA
1100596|NCT01571219|Biosimilar
1100597|NCT01571206|AS
1100598|NCT01571206|Biosimilar
1100599|NCT01571180|Obesity
1100600|NCT01571180|Gastric bypass
1100601|NCT01571180|Medication
1100602|NCT01571180|Medication counseling
1100603|NCT01571180|Dietary pattern
1100604|NCT01571180|Follow-up of patients
1100605|NCT01571167|Methamphetamine
1100606|NCT01571167|Chantix
1100607|NCT01571167|Varenicline
1100608|NCT01571141|HPV
1100609|NCT01571141|polyhexamethylene biguanide
1100610|NCT01571141|intraepithelial lesions
1100611|NCT01571141|regression rate
1100612|NCT01571128|HIV
1100613|NCT01571128|Prevention & Control
1100614|NCT01571128|Intervention Studies
1100615|NCT01571128|Adolescent
1100616|NCT01571128|Gender
1100617|NCT01571128|Combination prevention
1100618|NCT01571128|Pre-Exposure Prophylaxis
1100619|NCT01571128|Cash Transfer
1100620|NCT01571128|Medical Male Circumcision
1100621|NCT01571128|HIV Testing
1100622|NCT01571128|Mobile Health
1100623|NCT01571115|insomnia
1100624|NCT01571115|resistance physical exercise
1100625|NCT01571115|stretching
1100626|NCT01571089|Dialectical behavior therapy
1100627|NCT01571089|cognitive behavioral therapy
1100628|NCT01571089|emotion regulation
1100629|NCT01571089|emotion dysregulation
1100630|NCT01571089|anxiety disorders
1100631|NCT01571089|skills training
1100632|NCT01571076|PGS
1100633|NCT01571076|CGH
1100634|NCT01571076|Aneuploidy
1100635|NCT01571076|Advanced maternal age
1100636|NCT01571076|Male factor
1100637|NCT01571050|toothpastes
1100638|NCT01571050|dental fluorosis
1100639|NCT01571050|fluoride
1100640|NCT01571050|bioavailability
1100641|NCT01571037|mechanical circulatory assist device
1100642|NCT01571024|FOLFOX6
1100643|NCT01571024|BKM120
1100644|NCT01571024|Advanced Solid Tumors
1100645|NCT01571024|Metastatic
1100646|NCT01571024|Colorectal Cancer
1100647|NCT01571024|Pancreatic Cancer
1100648|NCT01571011|Adolescent
1100649|NCT01571011|Randomized Trial
1100650|NCT01571011|Internet
1100651|NCT01571011|Depressive Disorder
1100652|NCT01571011|Primary Care
1100653|NCT01571011|Prevention
1100654|NCT01570985|shoulder capsulitis
1100655|NCT01570985|frozen shoulder
1100656|NCT01570985|adhesive capsulitis
1100657|NCT01570985|distension
1100658|NCT01570985|corticosteroid injection
1100659|NCT01570985|intraarticular injection
1100660|NCT01570972|schizophrenia
1100661|NCT01570972|schizoaffective disorder
1100662|NCT01570972|bipolar disorder with psychotic features
1100663|NCT01570972|major depression with psychotic features
1100664|NCT01570972|recent-onset psychosis
1100665|NCT01570972|first-episode psychosis
1100666|NCT01570972|cognitive behavioral therapy
1100667|NCT01570972|multifamily group psychoeducation
1100668|NCT01570946|Lifestyle changes to prevent type 2 diabetes
1100669|NCT01570933|cardio-pulmonary bypass
1100670|NCT01570920|Activity limitations
1100671|NCT01570920|restriction of participation
1100672|NCT01570920|chronic stroke survival
1100673|NCT01570920|physical activity
1100674|NCT01570920|walking
1100675|NCT01570881|postoperative delirium
1100676|NCT01570881|melatonin
1100677|NCT01570881|sevoflurane
1100678|NCT01570868|Leukemia
1100679|NCT01570868|Chronic Myeloid Leukemia
1100680|NCT01570868|CML
1100681|NCT01570868|Chronic Phase
1100682|NCT01570868|Cytogenetic response
1100683|NCT01570868|CCyR
1100684|NCT01570868|Major molecular response
1100685|NCT01570868|MMR
1100686|NCT01570868|Complete molecular response
1100687|NCT01570868|CMR
1100688|NCT01570868|Ponatinib
1100689|NCT01570868|AP24534
1100690|NCT01570855|Lung cancer
1100691|NCT01570855|chemosensitivity
1100692|NCT01570842|Gastroesophageal reflux disease
1100693|NCT01570842|GERD
1100694|NCT01570842|Barrett's esophagus
1100695|NCT01570816|spinal cord injury
1100696|NCT01570816|partial paralysis
1100697|NCT01570816|gait correction
1100698|NCT01570816|functional electrical stimulation
1100699|NCT01570816|paraplegia
1100700|NCT01570816|tetraplegia
1100701|NCT01570803|peripheral arterial disease,
1100702|NCT01570803|atherosclerosis,
1100703|NCT01570803|nitinol,
1100704|NCT01570803|stents
1100705|NCT01570777|Resistant hypertension
1100706|NCT01570777|Renal denervation
1100707|NCT01570777|Standardized medication regimen
1100708|NCT01570777|Endovascular
1100709|NCT01570777|Primary hypertension
1100710|NCT01570777|Cardiovascular diseases
1100711|NCT01570777|Vascular diseases
1100712|NCT01570764|Systemic sclerosis
1100713|NCT01570764|Interstitial lung disease
1100714|NCT01570764|Worsening
1100715|NCT01570764|Cyclophosphamide
1100716|NCT01570764|Intravenous
1100717|NCT01570738|sleep disorders
1100718|NCT01570738|sleep apnea
1100719|NCT01570738|ambulatory device
1100720|NCT01570738|polysomnography
1100721|NCT01570738|WatchPAT
1100722|NCT01570725|Immersive virtual reality
1100723|NCT01570725|e-health
1100724|NCT01570725|surgery
1100725|NCT01570725|anxiety
1100726|NCT01570725|relaxation
1100727|NCT01570725|Patients who undergo ambulatory surgical operations
1100728|NCT01570699|Cross-sectional observational study
1100729|NCT01570699|COMT polymorphism
1100730|NCT01570699|Opiate-users
1100731|NCT01570699|Opiate dependence
1100732|NCT01570686|Food effect, hypertension, aliskiren
1100733|NCT01570673|quality of life
1100734|NCT01570673|urinary bladder
1100735|NCT01570673|symptoms
1100736|NCT01570673|children
1100737|NCT01570634|Clostridium difficile
1100738|NCT01570634|infection
1100739|NCT01570634|diarrhea
1100740|NCT01570634|cramping
1100741|NCT01570621|achalasia
1100742|NCT01570621|peroral endoscopic myotomy
1100743|NCT01570621|LES pressure
1100744|NCT01570621|postoperative complication
1100745|NCT01570621|symptom relief
1100746|NCT01570621|esophageal barium
1100747|NCT01570608|Ranibizumab
1100748|NCT01570608|Bevacizumab
1100749|NCT01570608|Verteporfin
1100750|NCT01570608|age-related macular degeneration
1100751|NCT01570595|Tobacco Use Cessation
1100752|NCT01570595|Tobacco Cessation
1100753|NCT01570595|Tobacco Use Disorder
1100754|NCT01570595|Tobacco Dependence
1100755|NCT01570595|Tobacco-Use Disorder
1100756|NCT01570595|Virus, Human Immunodeficiency
1100757|NCT01570582|recurrent ovarian
1100758|NCT01570582|ECG
1100759|NCT01570582|GOG performance
1100760|NCT01570582|Hematologic g
1100761|NCT01570582|Blood chemistry and urinalysis h
1100762|NCT01570569|Volunteers
1100763|NCT01570556|Hemodialysis
1100764|NCT01570556|Inflammation
1100765|NCT01570556|Bacteriuria
1100766|NCT01570556|Interleukin 6
1100767|NCT01570556|C reactive protein
1100768|NCT01570543|implants
1100769|NCT01570543|knee implants
1100770|NCT01570543|hip implants
1100771|NCT01570543|metallic implants
1100772|NCT01570504|Strongyloidiasis
1100773|NCT01570504|Strongyloides stercoralis
1100774|NCT01570504|Ivermectin
1100775|NCT01570465|AML
1100776|NCT01570465|adult
1100777|NCT01570465|AML1310 GIMEMA study
1100778|NCT01570452|matrilysin
1100779|NCT01570452|MMP-7
1100780|NCT01570452|colorectal cancer
1100781|NCT01570452|adenoma
1100782|NCT01570452|lymph nodes
1100783|NCT01570426|Bipolar disorder
1100784|NCT01570426|Mood disorders
1100785|NCT01570426|ADHD
1100786|NCT01570426|Attention Deficit Disorder with Hyperactivity
1100787|NCT01570426|Attention Deficit Disorder without Hyperactivity
1100788|NCT01570426|Anxiety disorders
1100789|NCT01570426|Generalized anxiety disorder
1100790|NCT01570426|Magnetic resonance imaging
1100791|NCT01570426|Mental disorders
1100792|NCT01570426|Mental disorders diagnosed in childhood
1100793|NCT01570426|affective neuroscience
1100794|NCT01570426|emotion
1100795|NCT01570426|MRI
1100796|NCT01570426|fMRI
1100797|NCT01570426|neurocognitive tasks
1100798|NCT01570426|imaging
1100799|NCT01570426|Healthy controls
1100800|NCT01570426|typical development
1100801|NCT01570400|social phobia
1100802|NCT01570400|social anxiety
1100803|NCT01570400|cognitive bias modification
1100804|NCT01570374|Cognitive behavioral therapy
1100805|NCT01570374|Internet
1100806|NCT01570374|Anxiety
1100807|NCT01570374|Generalized anxiety disorder
1100813|NCT01570348|Crohn's Disease
1100814|NCT01570348|Allogeneic bone marrow transplantation
1100815|NCT01570348|Hematopoietic cell transplantation
1100816|NCT01570335|SBAR,
1100817|NCT01570335|SAQ,
1100818|NCT01570335|Team Resource Management
1100819|NCT01570322|Dementia - Alzheimer - Quality of life
1100820|NCT01570309|vitamin D,
1100821|NCT01570309|vitamin D deficiency
1100822|NCT01570309|coronary artery disease
1100823|NCT01570309|ergocalciferol
1100824|NCT01570309|endothelial function
1100825|NCT01570309|adhesion molecules
1100826|NCT01570309|inflammation
1100827|NCT01570309|IL-12
1100828|NCT01570309|interferon-gamma
1100829|NCT01570309|CXCL-10
1100830|NCT01570309|reactive hyperemia peripheral arterial tonometry
1100831|NCT01570309|endothelial dysfunction
1100832|NCT01570309|cytokines
1100833|NCT01570309|chemokines
1100834|NCT01570296|Advanced Non-Small Cell Lung Cancer
1100835|NCT01570296|tumors harbor molecular
1100836|NCT01570296|alterations of PI3K pathway
1100962|NCT01569698|acute renal failure
1100837|NCT01570296|known to overexpress EGFR
1100838|NCT01570283|post allogeneic hematopoietic stem cell transplant
1100839|NCT01570283|cytotoxic T lymphocytes
1100840|NCT01570283|Cytomegalovirus
1100841|NCT01570283|CMV
1100842|NCT01570283|adenovirus
1100843|NCT01570283|Epstein-Barr virus
1100844|NCT01570283|EBV
1100845|NCT01570283|Human polyomavirus type I
1100846|NCT01570283|BK virus
1100847|NCT01570283|Human herpesvirus 6
1100848|NCT01570283|HHV6
1100849|NCT01570270|Hypercholesterolemia
1100850|NCT01570270|Endocannabinoids
1100851|NCT01570257|normal pressure hydrocephalus
1100852|NCT01570257|ventriculoperitoneal shunt
1100853|NCT01570257|overdrainage
1100854|NCT01570257|subdural effusion
1100855|NCT01570231|remote ischemic preconditioning
1100856|NCT01570231|octogenarian
1100857|NCT01570231|intracranial arterial stenosis
1100858|NCT01570231|stroke recurrence
1100859|NCT01570218|breast cancer
1100860|NCT01570218|gynecological cancer
1100861|NCT01570218|radiotherapy
1100862|NCT01570218|fatigue
1100863|NCT01570218|musicotherapy
1100864|NCT01570192|gram negative pathogens
1100865|NCT01570192|Pseudomonas aeruginosa
1100866|NCT01570192|Acinetobacter
1100867|NCT01570192|HCAP
1100868|NCT01570192|VABP
1100869|NCT01570192|HABP
1100870|NCT01570179|bariatric surgery
1100871|NCT01570179|residual paralysis
1100872|NCT01570179|surgical conditions
1100873|NCT01570166|Hepatocellular Carcinoma
1100874|NCT01570166|RFA
1100875|NCT01570166|HR
1100876|NCT01570127|Individualized Acupuncture
1100877|NCT01570127|Standardized Acupuncture
1100878|NCT01570127|Low Back Pain
1100879|NCT01570127|Randomized Controlled Trial
1100880|NCT01570114|Covered metallic stent
1100881|NCT01570114|colon
1100882|NCT01570114|benign stricture
1100883|NCT01570075|Hepatocellular Carcinoma
1100884|NCT01570075|RFA
1100885|NCT01570075|HR
1100886|NCT01570062|Inflammation
1100887|NCT01570062|Pathologic Processes
1100888|NCT01570049|Single arm
1100889|NCT01570049|Open label
1100890|NCT01570049|Bendamustine HCl
1100891|NCT01570049|Non-hodgkin's lymphoma
1100892|NCT01570036|stage I breast cancer
1100893|NCT01570036|stage II breast cancer
1100894|NCT01570036|stage IIIA breast cancer
1100895|NCT01570036|stage IIIB breast cancer
1100896|NCT01570036|stage IIIC breast cancer
1100897|NCT01570036|male breast cancer
1100898|NCT01570023|Deglutition
1100899|NCT01570023|Exercise
1100900|NCT01569997|Dementia
1100901|NCT01569997|emergency hospitalization
1100902|NCT01569997|nursing home
1100903|NCT01569997|multidisciplinary meeting
1100904|NCT01569997|cognitive decline
1100905|NCT01569997|disability
1100906|NCT01569997|residents
1100907|NCT01569997|facilities
1100908|NCT01569997|long term care unit
1100909|NCT01569997|health policy
1100910|NCT01569997|general practitioner
1100911|NCT01569997|prevention
1100912|NCT01569984|Colorectal
1100913|NCT01569971|Transition Program
1100914|NCT01569971|Perspectives
1100915|NCT01569932|chemobrain, chemotherapy, cognitive impairments, fcMRI, neurocognitive Assessments
1100916|NCT01569919|Phase II
1100917|NCT01569919|Single arm
1100918|NCT01569919|Vaccine
1100919|NCT01569906|Atopic Dermatitis
1100920|NCT01569893|Telemonitoring
1100921|NCT01569893|Telemedicine
1100922|NCT01569893|Diabetes mellitus
1100923|NCT01569880|Blood gas response
1100924|NCT01569880|Exercise
1100925|NCT01569880|Gas exchange
1100926|NCT01569880|Hypoxia altitude simulation test
1100927|NCT01569880|Pulmonary function
1100928|NCT01569828|LCZ696
1100929|NCT01569828|pharmacokinetics
1100930|NCT01569815|Renal Impairment,
1100931|NCT01569815|LCZ696
1100932|NCT01569802|breast cancer screening
1100933|NCT01569802|tomosynthesis
1100934|NCT01569802|FFDM
1100935|NCT01569789|cytokines
1100936|NCT01569789|inflammation
1100937|NCT01569789|vagus nerve
1100938|NCT01569789|TNF
1100939|NCT01569776|Cow milk allergy
1100940|NCT01569776|CMA
1100941|NCT01569763|endometrial ablation
1100942|NCT01569750|CD20-positive B-cell non-Hodgkin lymphoma
1100943|NCT01569750|Diffuse large B-cell lymphoma
1100944|NCT01569750|Mantle cell lymphoma
1100945|NCT01569750|Follicular lymphoma
1100946|NCT01569750|Ibrutinib
1100947|NCT01569750|R-CHOP
1100948|NCT01569750|Rituximab
1100949|NCT01569750|Cyclophosphamide
1100950|NCT01569750|Doxorubicin
1100951|NCT01569750|Vincristine
1100952|NCT01569750|Prednisone
1100953|NCT01569737|ella
1100954|NCT01569737|ulipristal acetate
1100955|NCT01569737|pregnancy
1100956|NCT01569737|emergency contraception
1100957|NCT01569724|hypertriglyceridemia
1100958|NCT01569724|bexarotene
1100959|NCT01569711|chronic and resistant major depressive disorder
1100960|NCT01569711|deep brain stimulation
1100961|NCT01569698|pediatric
1100963|NCT01569698|acute extra renal replacement therapy
1100964|NCT01569698|Intermittent Hemodialysis
1100965|NCT01569698|Continuous Renal Replacement Therapies
1100966|NCT01569698|Peritoneal Dialysis
1100967|NCT01569685|PTSD
1100968|NCT01569685|Traumatic Stress
1100969|NCT01569685|Depressions
1100970|NCT01569685|Refugees
1100971|NCT01569672|Navigator
1100972|NCT01569659|Schizophrenia
1100973|NCT01569659|Refractory
1100974|NCT01569659|Treatment resistant
1100975|NCT01569659|Lurasidone
1100976|NCT01569646|monocytes
1100977|NCT01569646|culprit vessels
1100978|NCT01569620|Colorectal Cancer Screening
1100979|NCT01569620|CRC
1100980|NCT01569620|Screening Colonoscopy
1100981|NCT01569620|Hispanics
1100982|NCT01569620|Latinos
1100983|NCT01569607|Neurophysiology
1100984|NCT01569607|Transcranial Magnetic Stimulation (TMS)
1100985|NCT01569607|Neurology
1100986|NCT01569607|Stroke
1100987|NCT01569607|Physical Medicine and Rehabilitation
1100988|NCT01569581|Human Enterovirus 71 (EV71)
1100989|NCT01569581|Hand, Foot and Mouth Disease (HFMD)
1100990|NCT01569581|Inactivated Vaccine
1100991|NCT01569581|Human Diploid cell (KMB17)
1100992|NCT01569581|Adverse reactions associated with vaccine
1100993|NCT01569581|Efficacy
1100994|NCT01569568|Neuroimaging
1100995|NCT01569568|MRI
1100996|NCT01569568|Urea cycle
1100997|NCT01569568|hyperammonemia
1100998|NCT01569568|cognitive function
1100999|NCT01569568|ornithine transcarbamylase deficiency
1101000|NCT01569516|Alzheimer's Disease
1101001|NCT01569516|Octohydroaminoacridine Succinate
1101002|NCT01569503|Crohn's Disease
1101003|NCT01569503|VNS
1101004|NCT01569503|vagus nerve stimulation
1101005|NCT01569503|inflammation
1101006|NCT01569503|Inflammatory bowel diseases
1101007|NCT01569503|TNF
1101008|NCT01569464|Rotigotine
1101009|NCT01569464|Restless Legs Syndrome
1101010|NCT01569464|Neupro®
1101011|NCT01569451|Multiple Sclerosis
1101012|NCT01569451|Glatiramer Acetate
1101013|NCT01569451|Rituximab
1101014|NCT01569451|Relapsing forms of Multiple Sclerosis
1101015|NCT01569451|Relapsing Multiple Sclerosis
1101016|NCT01569425|PCOS
1101017|NCT01569399|Alcohol dependance
1101018|NCT01569399|rTMS
1101019|NCT01569399|craving
1101020|NCT01569399|alcohol consumption
1101021|NCT01569386|pulse wave velocity
1101022|NCT01569386|low intensity physical activity
1101023|NCT01569386|hemiplegia
1101024|NCT01569373|Allogeneic stem cell transplant
1101025|NCT01569373|Graft versus Host Disease
1101026|NCT01569373|GVHD
1101027|NCT01569360|Spinal cord injury
1101028|NCT01569360|Tetraplegia
1101029|NCT01569360|Paraplegia
1101030|NCT01569360|Respiratory function
1101031|NCT01569360|Corset
1101032|NCT01569347|Cocaine
1101033|NCT01569347|Cocaine-induced psychosis
1101034|NCT01569347|Genetic
1101035|NCT01569347|Clinical
1101036|NCT01569347|Biological
1101037|NCT01569334|identify early non invasive markers that index the endothelial lesion/ regeneration potential in association with CAV in heart transplanted recipients (HTR)
1101038|NCT01569308|Cardiac output
1101039|NCT01569308|Pulse pressure variation
1101040|NCT01569308|Fluid responsiveness
1101041|NCT01569308|Low tidal volume
1101042|NCT01569295|Zydelig
1101043|NCT01569295|CLL
1101044|NCT01569295|CAL 101
1101045|NCT01569295|CAL-101
1101046|NCT01569295|GS 1101
1101047|NCT01569295|GS-1101
1101048|NCT01569295|PI3K
1101049|NCT01569295|Rituxan
1101050|NCT01569295|Rituximab
1101051|NCT01569295|Bendamustine
1101052|NCT01569295|Leukemia
1101053|NCT01569295|idelalisib
1101054|NCT01569282|Surgical bypass
1101055|NCT01569282|Hepaticojejunostomy
1101056|NCT01569282|Gastrojejunostomy
1101057|NCT01569282|Biliary stent
1101058|NCT01569282|Enteral stent
1101059|NCT01569269|chemotherapy induced peripheral neuropathy
1101060|NCT01569269|cancer
1101061|NCT01569269|psychological distress
1101062|NCT01569269|mindfulness
1101063|NCT01569269|complementary and alternative
1101064|NCT01569243|Diabetes mellitus
1101065|NCT01569243|Text messaging
1101066|NCT01569243|Physical activity
1101067|NCT01569230|Knee osteoarthritis
1101068|NCT01569230|acupuncture
1101069|NCT01569230|sham acupuncture
1101070|NCT01569217|Diaphragm
1101071|NCT01569217|Abdomen
1101072|NCT01569217|Breathing pattern
1101073|NCT01569217|dyspnea
1101074|NCT01569191|Ocular allergy
1101075|NCT01569191|Tear supplement
1101076|NCT01569191|Cold compress
1101077|NCT01569178|stem cells
1101078|NCT01569178|acute myocardial infarction
1101079|NCT01569178|heart failure
1101080|NCT01569178|heart attack
1101081|NCT01569178|bone marrow
1101082|NCT01569178|intracoronary reinfusion
1101083|NCT01569178|bone marrow derived mononuclear cells
1101084|NCT01569178|Left ventricular function improvement
1101085|NCT01569178|mortality
1101086|NCT01569165|Acidogenicity
1101087|NCT01569165|Acidulated phosphate fluoride
1101088|NCT01569165|dental plaque
1101089|NCT01569165|water rinsing
1101090|NCT01569139|Validation
1101091|NCT01569139|Concordance
1101092|NCT01569139|Myocardial infarction
1101093|NCT01569139|Myocardial Ischaemia National Audit Project
1101094|NCT01569139|General Practice Research Database
1101095|NCT01569139|Hospital Episode Statistics
1101096|NCT01569139|ONS mortality
1101097|NCT01569113|ella
1101098|NCT01569113|ellaOne
1101099|NCT01569113|quickstart
1101100|NCT01569113|contraception
1101101|NCT01569113|combined oral pill
1101102|NCT01569113|microgynon
1101103|NCT01569087|empegfilgrastim
1101104|NCT01569087|pegylated filgrastim
1101105|NCT01569087|neutropenia
1101106|NCT01569087|febrile neutropenia
1101107|NCT01569087|chemotherapy-associated neutropenia
1101108|NCT01569087|breast cancer
1101109|NCT01569087|docetaxel
1101110|NCT01569087|doxorubicin
1101111|NCT01569074|Rheumatoid Arthritis
1101112|NCT01569061|overactive bladder
1101113|NCT01569061|laser therapy
1101114|NCT01569061|urinary incontinence
1101115|NCT01569061|urinary urgency
1101116|NCT01569035|oligohudramnios
1101117|NCT01569035|oral anti coagulant
1101118|NCT01569035|Dopplar ultrasound
1101122|NCT01569009|Bronchiectasis
1101123|NCT01569009|Physical activity
1101124|NCT01569009|Activity monitor
1101125|NCT01569009|Pedometer
1101126|NCT01568996|atypical nevi
1101127|NCT01568996|melanoma
1101128|NCT01568996|sulforaphane
1101129|NCT01568996|broccoli
1101130|NCT01568996|lesions
1101131|NCT01568996|STAT1
1101132|NCT01568996|STAT3
1101133|NCT01568970|rehabilitation
1101134|NCT01568970|return to work
1101135|NCT01568970|sick leave
1101136|NCT01568957|Gait
1101137|NCT01568957|Dual-task
1101138|NCT01568957|Obstacle avoidance
1101139|NCT01568957|Attention allocation
1101140|NCT01568944|periodontal
1101141|NCT01568944|disease
1101142|NCT01568944|dendritic
1101143|NCT01568944|cells
1101144|NCT01568944|antibiotics
1101145|NCT01568931|thrombectomy
1101146|NCT01568905|smoker
1101147|NCT01568905|smoking
1101148|NCT01568905|nicotine levels
1101149|NCT01568905|tobacco
1101150|NCT01568905|nicotine
1101151|NCT01568892|ART-experienced
1101152|NCT01568892|GSK1349572
1101153|NCT01568892|Integrase inhibitor resistance
1101154|NCT01568892|Dolutegravir
1101155|NCT01568879|Recurrent gout
1101156|NCT01568879|Tophaceous gout
1101157|NCT01568879|Gout flares
1101158|NCT01568879|Arthritis
1101159|NCT01568879|Joint Diseases
1101160|NCT01568879|Rheumatic Diseases
1101161|NCT01568866|multiple myeloma
1101162|NCT01568866|relapsed multiple myeloma
1101163|NCT01568840|Physical Therapy Modalities
1101164|NCT01568840|Posture
1101165|NCT01568840|Muscle Stretching Exercises
1101166|NCT01568840|Dyskinesias
1101167|NCT01568840|Neck pain
1101168|NCT01568814|colonoscopy
1101169|NCT01568814|bowel preparation
1101170|NCT01568814|polyethylene glycol
1101171|NCT01568814|low residue meal
1101172|NCT01568801|Integrated Services
1101173|NCT01568801|Health Services for the Elderly
1101174|NCT01568801|Community Services
1101175|NCT01568788|Respiratory Tract Infections; Orthomyxoviridae Infections
1101176|NCT01568775|End Stage Renal Disease
1101177|NCT01568775|Dialysis
1101178|NCT01568775|aliskiren
1101179|NCT01568775|SPP100A
1101180|NCT01568762|Asthma
1101181|NCT01568762|VAK694
1101182|NCT01568762|QAX576
1101183|NCT01568762|QBX258
1101184|NCT01568762|pharmacokinetics
1101185|NCT01568749|otc
1101186|NCT01568749|Analgesia
1101187|NCT01568749|Paracetamol
1101188|NCT01568736|Hyper IgD Syndrome (HIDS)
1101189|NCT01568736|Mevalonate Kinase Deficiency (MKD)
1101190|NCT01568723|Barrett's esophagus
1101191|NCT01568723|high grade dysplasia
1101192|NCT01568723|ablation
1101193|NCT01568723|radiofrequency ablation
1101194|NCT01568723|esophageal cancer
1101195|NCT01568710|Blood Flow
1101196|NCT01568710|Endothelium
1101197|NCT01568710|Nitric Oxide
1101198|NCT01568710|Oximetry
1101199|NCT01568710|Laser Doppler
1101200|NCT01568710|Sickle Cell Disease
1101201|NCT01568697|Oral Microbiome
1101202|NCT01568697|Periodontitis
1101203|NCT01568697|Oral Mucosal Immunity
1101204|NCT01568697|Oral Infection
1101205|NCT01568697|Immune Disorder
1101206|NCT01568697|Periodontal Disease
1101207|NCT01568697|Gum Disease
1101208|NCT01568697|Healthy Volunteer
1101209|NCT01568697|HV
1101210|NCT01568684|Magnetic Resonance Spectroscopy
1101211|NCT01568684|Depression
1101212|NCT01568684|Depression Treatment
1101213|NCT01568684|Major Depression
1101214|NCT01568684|Unipolar Depression
1101215|NCT01568671|Adult
1101216|NCT01568671|Body Fat Distribution
1101217|NCT01568671|Healthy
1101218|NCT01568671|Metabolic Rate
1101219|NCT01568671|Thermophysiology
1101220|NCT01568671|Brown Fat
1101221|NCT01568671|Healthy Volunteer
1101222|NCT01568671|HV
1101223|NCT01568658|Hereditary Myopathies
1101224|NCT01568658|Neuropathology
1101225|NCT01568658|Muscular Dystrophy
1101226|NCT01568658|Inherited Neuromuscular Condition
1101227|NCT01568658|Inherited Neuropathy
1101228|NCT01568658|Inherited Myopathy
1101229|NCT01568658|Hereditary Spastic Paraplegia
1101230|NCT01568658|Healthy Volunteer
1101231|NCT01568658|HV
1101232|NCT01568645|Sickle Cell Anemia
1101233|NCT01568645|Tyrosine Kinase Inhibitor
1101234|NCT01568645|Platelet Derived Growth Factor
1101235|NCT01568645|Beta Adrenergic Receptor Blocker
1101236|NCT01568645|Pulmonary Vascular Disease
1101237|NCT01568645|Sickle Cell Disease
1101238|NCT01568645|Pulmonary Hypertension
1101239|NCT01568632|Dose Limiting Toxicity
1101240|NCT01568632|Maximum Tolerated Dose
1101241|NCT01568632|Telomerase Inhibitor
1101242|NCT01568632|Safety
1101243|NCT01568632|Solid Tumor
1101244|NCT01568632|Lymphoma
1101245|NCT01568619|cardiopulmonary exercise test
1101246|NCT01568619|cardiac output
1101247|NCT01568606|Heart Failure
1101248|NCT01568606|Obesity
1101249|NCT01568606|Implantable Cardioverter Defibrillator
1101250|NCT01568580|Hemophilia A
1101251|NCT01568580|Factor VIII
1101252|NCT01568580|Recombinant
1101253|NCT01568567|safety
1101254|NCT01568567|tolerance
1101255|NCT01568567|lactobacillus Reuteri
1101256|NCT01568541|children
1101257|NCT01568541|dentifrice
1101258|NCT01568541|fluoride
1101259|NCT01568541|dental fluorosis
1101260|NCT01568515|HPV vaccine
1101261|NCT01568515|Vaccine adherence
1101262|NCT01568515|Vaccine utilization
1101263|NCT01568515|Electronic Messaging
1101264|NCT01568502|dobutamine stress
1101265|NCT01568502|inducible ischemia
1101266|NCT01568502|CAD
1101267|NCT01568476|Regional anesthesia
1101268|NCT01568476|Sciatic nerve block
1101269|NCT01568476|foot surgery
1101270|NCT01568476|ankle surgery
1101271|NCT01568476|Interneural local anesthetic
1101272|NCT01568463|Inter-scalene Block
1101273|NCT01568463|Regional Anesthesia
1101274|NCT01568463|shoulder surgeries
1101275|NCT01568450|Oxycodone, controlled release formulation
1101276|NCT01568437|Laparoscopic gastric-bypass surgery
1101277|NCT01568437|TAP block
1101278|NCT01568424|Heart Failure
1101279|NCT01568424|Right Ventricular Failure
1101280|NCT01568424|Levitronix
1101281|NCT01568424|Thoratec Corporation
1101282|NCT01568411|None - normal volunteers
1101283|NCT01568398|Gastric or duodenal ulcer
1101284|NCT01568385|Gastric or duodenal ulcer
1101285|NCT01568372|pediatric
1101286|NCT01568372|tonsillectomy
1101287|NCT01568372|pain management
1101288|NCT01568372|nurse follow-up
1101289|NCT01568346|Newly diagnosed
1101290|NCT01568346|Early stage
1101291|NCT01568333|Decitabine
1101292|NCT01568333|Immune thrombocytopenia
1101293|NCT01568320|Aorta
1101294|NCT01568320|Thoracic
1101295|NCT01568320|Aortic dissection
1101296|NCT01568320|Rupture
1101297|NCT01568320|Type B
1101298|NCT01568320|DeBakey type III
1101299|NCT01568320|Endovascular
1101300|NCT01568307|Major depressive disorder
1101301|NCT01568307|Serotonin transporter
1101302|NCT01568307|Sympathetic nervous system activation
1101303|NCT01568307|Cardiovascular risk factors
1101304|NCT01568307|Serotonin re-uptake inhibitor
1101305|NCT01568281|Bioequivalence
1101306|NCT01568281|pharmacokinetics
1101307|NCT01568281|safety
1101308|NCT01568281|anastrozole
1101309|NCT01568281|Arimidex
1101310|NCT01568281|Japanese
1101311|NCT01568281|healthy subject
1101312|NCT01568268|palonosetron
1101313|NCT01568268|postoperative nausea and vomiting
1101314|NCT01568255|myopathic symptoms
1101315|NCT01568242|Cataract
1101316|NCT01568242|Phacoemulsification
1101317|NCT01568242|Temperature
1101318|NCT01568242|Vitreous
1101319|NCT01568229|schizophrenia negative symptoms
1101320|NCT01568216|schizophrenia negative symptoms
1101321|NCT01568203|single dose, safety, healthy subjects, schizoaffective disorder, AMG 579
1101322|NCT01568190|House dust mites sensitisation
1101323|NCT01568177|MCD
1101324|NCT01568164|Epicardial Catheter-based Restoration
1101325|NCT01568164|Surgical/Left Ventricular Reconstruction
1101326|NCT01568164|Ventricular Remodeling
1101327|NCT01568164|Dor
1101328|NCT01568151|Colorectal Cancer
1101329|NCT01568151|Screening
1101330|NCT01568151|Education
1101331|NCT01568151|Testing
1101332|NCT01568138|Ventricular Remodeling
1101333|NCT01568112|BG00012
1101334|NCT01568112|gastrointestinal events
1101335|NCT01568112|flushing events
1101336|NCT01568112|dose titration
1101337|NCT01568112|pre-medication
1101338|NCT01568112|aspirin
1101339|NCT01568073|Parkinson
1101340|NCT01568073|PD
1101341|NCT01568073|Wearing-off
1101342|NCT01568073|Levodopa/DDCI
1101343|NCT01568060|Safety
1101344|NCT01568060|Infanrix-IPV
1101345|NCT01568060|Post-marketing surveillance
1101346|NCT01568060|Diphtheria, tetanus, pertussis and poliomyelitis
1101347|NCT01568047|Parkinson Disease
1101348|NCT01568047|BIA 9-1067
1101349|NCT01568034|Parkinson's Disease
1101350|NCT01568034|BIA 9-1067
1101351|NCT01567995|eczematous
1101352|NCT01567995|dermatitis
1101353|NCT01567982|tDCS
1101354|NCT01567982|brain stimulation
1101355|NCT01567982|addiction
1101356|NCT01567982|substance dependence
1101357|NCT01567982|craving
1101358|NCT01567982|cognition
1101359|NCT01567969|mental health services
1101360|NCT01567969|child behavior disorders
1101361|NCT01567969|child psychiatry
1101362|NCT01567956|Ulcerative colitis
1101363|NCT01567943|alcohol abuse
1101364|NCT01567943|drug abuse
1101365|NCT01567943|schizophrenia
1101366|NCT01567943|bipolar disorder
1101367|NCT01567943|major depressive disorder
1101368|NCT01567943|contingency management
1101369|NCT01567943|psychosocial treatment
1101370|NCT01567930|Temsirolimus
1101371|NCT01567930|HCC
1101372|NCT01567930|Advanced hepatocellular carcinoma
1101373|NCT01567917|Venous thromboembolism
1101374|NCT01567917|Colorectal cancer
1101375|NCT01567917|Postoperative period
1101376|NCT01567917|detected on 5th~14th days after surgery (by doppler US) or the follow-up period of postoperative 1 month
1101377|NCT01567904|thrombosis
1101378|NCT01567904|Central Venous Line
1101379|NCT01567904|CVL
1101380|NCT01567891|Ovarian Cancer
1101381|NCT01567891|Cell Therapy
1101382|NCT01567891|T Cell Therapy
1101383|NCT01567891|NY-ESO-1
1101384|NCT01567891|Immuno-oncology
1101385|NCT01567891|Metastatic
1101386|NCT01567891|Previously treated
1101387|NCT01567891|T Cell Receptor
1101388|NCT01567878|ultrasound
1101389|NCT01567878|MASEI index
1101390|NCT01567878|clinical and ultrasound correlation
1101391|NCT01567878|enthesis ultrasound
1101392|NCT01567878|articular ultrasound
1101393|NCT01567878|ankylosing spondylitis ultrasound
1101394|NCT01567878|radiographic and ultrasound correlation
1101395|NCT01567852|orientation
1101396|NCT01567852|post-anesthesia recovery
1101397|NCT01567852|electroconvulsive therapy
1101398|NCT01567839|degree of pulpal anesthesia obtained
1101399|NCT01567839|primary infiltration in the lower first molar
1101400|NCT01567826|YELLO
1101401|NCT01567826|Atorvastatin
1101402|NCT01567826|Simvastatin
1101403|NCT01567826|Rosuvastatin
1101404|NCT01567826|lipid therapy
1101405|NCT01567826|Statin therapy
1101406|NCT01567826|Coronary artery disease
1101407|NCT01567826|CHD
1101408|NCT01567813|Warts
1101409|NCT01567813|Papillomavirus infections
1101410|NCT01567813|DNA virus infections
1101411|NCT01567813|Virus diseases
1101412|NCT01567813|Skin diseases, viral
1101413|NCT01567813|Tumor virus infections
1101414|NCT01567813|Skin diseases, infectious
1101415|NCT01567813|Skin diseases
1101416|NCT01567800|Procedure/Surgery: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
1101417|NCT01567787|Proton Radiation Therapy
1101418|NCT01567787|Spinal tumors
1101419|NCT01567787|Neurofibroma(NF1)
1101420|NCT01567787|Malignant peripheral nerve sheath tumor(MPNST)
1101421|NCT01567774|Coronary artery disease
1101422|NCT01567774|dual antiplatelet therapy
1101423|NCT01567774|atorvastatin
1101424|NCT01567774|rosuvastatin
1101425|NCT01567761|IOP
1101426|NCT01567748|CABG
1101427|NCT01567748|Coronary Artery Bypass
1101428|NCT01567748|Central Aortic Pressure
1101429|NCT01567748|Peripheral Arterial Waveform
1101430|NCT01567735|Hepatitis C
1101431|NCT01567735|TMC435HPC3011
1101432|NCT01567735|TMC435
1101433|NCT01567722|HIV infection
1101434|NCT01567722|adult diffuse large cell lymphoma
1101435|NCT01567722|anal cancer
1101436|NCT01567722|cervical cancer
1101437|NCT01567722|non-small cell lung cancer
1101438|NCT01567722|AIDS-related diffuse large cell lymphoma
1101439|NCT01567696|Revision,
1101440|NCT01567683|Safety and Tolerability of Limtop and vehicle
1101441|NCT01567683|of Limtop and vehicle
1101442|NCT01567657|Sedation in TEE
1101443|NCT01567657|Blood pressure drop during TEE
1101444|NCT01567657|Safety of sedation in TEE
1101445|NCT01567644|Extracorporeal Shockwave Therapy
1101446|NCT01567644|Myocardial Ischemia
1101447|NCT01567644|Refractory Angina
1101448|NCT01567631|Classical Procedure
1101449|NCT01567631|Intrahepatic Glisson's Approach
1101450|NCT01567631|laparoscopic hepatectomy
1101451|NCT01567631|Minimal invasive surgery
1101452|NCT01567631|Endoscopic stapling devices
1101453|NCT01567618|Docetaxel
1101454|NCT01567618|Fluorouracil
1101455|NCT01567618|First line therapy
1101456|NCT01567618|Gastric cancer
1101457|NCT01567605|spinal cord injury
1101458|NCT01567605|autonomic dysreflexia
1101459|NCT01567605|blood pressure
1101460|NCT01567605|bowel care management
1101461|NCT01567605|defecation
1101462|NCT01567592|Extracorporeal Shockwave Therapy
1101463|NCT01567592|Myocardial Ischemia
1101464|NCT01567592|Refractory Angina
1101465|NCT01567579|congenital heart defects
1101466|NCT01567566|home based daily exercise program
1101467|NCT01567566|local lumbopelvic stabilizer muscles
1101468|NCT01567566|hip stabilizer muscles
1101469|NCT01567566|real time ultrasound imaging
1101470|NCT01567553|inflammatory disease of the central nervous system
1101471|NCT01567553|early clinical deficit
1101472|NCT01567553|multiple sclerosis (MS)
1101473|NCT01567540|Chronic Hepatitis C
1101474|NCT01567540|Interferon protein 10
1101475|NCT01567540|Chemokine gradients
1101476|NCT01567540|Sitagliptin
1101477|NCT01567527|Aripiprazole
1101478|NCT01567527|Intramuscular (IM) Depot
1101479|NCT01567527|Bipolar
1101480|NCT01567514|Deep occlusal caries restored with resin composite
1101481|NCT01567514|on Pit and Fissure Surface Penetrating Into Dentin
1101482|NCT01567488|Advanced
1101483|NCT01567488|Non functioning
1101484|NCT01567488|Well differentiated
1101485|NCT01567462|bladder cancer
1101486|NCT01567462|transurethral resection of bladder tumors
1101487|NCT01567423|Malaria
1101488|NCT01567423|Plasmodium falciparum
1101489|NCT01567423|Children
1101490|NCT01567423|Efficacy
1101491|NCT01567423|Uncomplicated malaria
1101492|NCT01567410|e-learning
1101493|NCT01567410|education
1101494|NCT01567384|cancer
1101495|NCT01567384|neoplasms
1101496|NCT01567384|tumors
1101497|NCT01567345|Pain
1101498|NCT01567345|cancer
1101499|NCT01567345|Intrathecal
1101500|NCT01567345|analgesia
1101501|NCT01567345|Morphine
1101502|NCT01567345|Implantable pump
1101503|NCT01567319|Sensitization
1101504|NCT01567319|Skin Prick Test
1101505|NCT01567319|Standardization
1101629|NCT01566812|Breast Feeding
1101506|NCT01567319|sources of: D. glomerata, L. perenne, S. cereale and O. europaea
1101507|NCT01567306|Allergy
1101508|NCT01567306|Allergic rhinoconjunctivitis
1101509|NCT01567306|Subcutaneous Immunotherapy
1101510|NCT01567306|Phleum pratense pollen extract
1101511|NCT01567267|Evidence-based Medicine
1101512|NCT01567267|Good Scientific Practice
1101513|NCT01567267|Problem-based Learning
1101514|NCT01567267|Critical health literacy
1101515|NCT01567267|Educational intervention
1101516|NCT01567254|guided imaginary
1101517|NCT01567241|clinical hypnosis
1101518|NCT01567241|relaxation music
1101519|NCT01567241|reproduction techniques
1101520|NCT01567241|insemination
1101521|NCT01567241|embryo transfer
1101522|NCT01567241|pregnancy rate
1101523|NCT01567228|obesity
1101524|NCT01567228|overweight
1101525|NCT01567228|dental caries
1101526|NCT01567228|school problems
1101527|NCT01567228|school failure
1101528|NCT01567228|child BMI > 85th percentile
1101529|NCT01567228|Needing dental preventive services
1101530|NCT01567228|Needing academic support for school problems
1101531|NCT01567215|granuloma umbilical
1101532|NCT01567202|Brain tumor
1101533|NCT01567202|Glioma
1101534|NCT01567202|Glioblastoma
1101535|NCT01567202|Tumor stem cells
1101536|NCT01567202|Immunotherapy
1101537|NCT01567202|Vaccine
1101538|NCT01567189|Exercise therapy
1101539|NCT01567189|cost effectiveness
1101540|NCT01567189|cardiac rehabilitation
1101541|NCT01567189|home-based exercise
1101542|NCT01567176|Sirtuins
1101543|NCT01567176|Aging
1101544|NCT01567176|Metabolic disease
1101545|NCT01567163|Advanced Malignant Solid Tumors
1101546|NCT01567124|Schizophrenia
1101547|NCT01567124|Moxonidine
1101548|NCT01567124|Sympathetic nervous system activation
1101549|NCT01567124|Cardiometabolic side effects of antipsychotics
1101550|NCT01567111|Primary aldosteronism
1101551|NCT01567111|Aldosterone producing adenoma
1101552|NCT01567111|Bilateral adrenal hyperplasia
1101553|NCT01567111|Metomidate-Positron emission tomography
1101554|NCT01567072|NSAID
1101555|NCT01567072|bone fracture
1101556|NCT01567072|heal
1101557|NCT01567033|Diabetes
1101558|NCT01567033|Obesity
1101559|NCT01567033|Home visiting
1101560|NCT01567020|Central Auditory Processing
1101561|NCT01567020|Traumatic Brain Injury
1101562|NCT01567020|Hearing Loss
1101563|NCT01567007|pedometer
1101564|NCT01567007|physical activity
1101565|NCT01567007|workplace
1101566|NCT01566994|smoking cessation
1101567|NCT01566981|Diabetes mellitus tip II
1101568|NCT01566981|eHealth solution
1101569|NCT01566981|Health Information Technology
1101570|NCT01566981|quality of life
1101571|NCT01566981|family medicine
1101572|NCT01566981|satisfaction with e-health care
1101573|NCT01566981|primary care
1101574|NCT01566968|COPD
1101575|NCT01566968|Asthma
1101576|NCT01566968|Healthy volunteers
1101577|NCT01566968|Chronic cough
1101578|NCT01566968|Smokers
1101579|NCT01566968|Cough challenge
1101580|NCT01566968|Cough challenge testing.
1101581|NCT01566955|transgastric
1101582|NCT01566955|NOTES
1101583|NCT01566955|Gastrotomy
1101584|NCT01566955|BRCA 1/2
1101585|NCT01566942|FOLFIRI
1101586|NCT01566942|FOLFOX
1101587|NCT01566942|adjuvant chemotherapy
1101588|NCT01566942|advanced colorectal cancer
1101589|NCT01566929|Obesity
1101590|NCT01566929|In vitro fertilization
1101591|NCT01566929|Low calorie diet (LCD)
1101592|NCT01566929|Obstetric outcome
1101593|NCT01566929|Weight reduction
1101594|NCT01566903|arterial stenosis
1101595|NCT01566903|arteriovenous malformations
1101596|NCT01566903|Post-treatment follow-up
1101597|NCT01566890|sickle cell
1101598|NCT01566890|sickle cell crisis
1101599|NCT01566890|sickle cell pain crisis
1101600|NCT01566890|vaso-occlusive crisis
1101601|NCT01566890|vaso-occlusion
1101602|NCT01566890|sickle cell anemia
1101603|NCT01566890|sickle cell disease
1101604|NCT01566890|genetic diseases
1101605|NCT01566890|adenosine 2A Receptor Agonists
1101606|NCT01566890|Lexiscan
1101607|NCT01566890|Regadenoson
1101608|NCT01566890|contrast-enhanced ultrasound
1101609|NCT01566890|Hydroxyurea
1101610|NCT01566877|Multiple Ascending Dose (MAD)
1101611|NCT01566877|Marburg Virus
1101612|NCT01566877|Post Exposure Prophylaxis
1101613|NCT01566864|hypertension
1101614|NCT01566864|disparities
1101615|NCT01566864|care management
1101616|NCT01566864|provider education
1101617|NCT01566864|audit and feedback
1101618|NCT01566864|Omron
1101619|NCT01566864|African Americans
1101620|NCT01566864|organizational change
1101621|NCT01566864|implementation research
1101622|NCT01566838|Visual analog pain score
1101623|NCT01566838|Length of stay
1101624|NCT01566838|Hospital Cost
1101625|NCT01566838|Subpleural pain catheter
1101626|NCT01566838|Bupivacaine
1101627|NCT01566825|amitriptyline
1101628|NCT01566825|sleep dependent memory consolidation
1101630|NCT01566812|Cardiovascular Risk
1101631|NCT01566799|Locally advanced breast cancer
1101632|NCT01566799|Neoadjuvant chemotherapy
1101633|NCT01566799|Metformin
1101634|NCT01566799|Pathologic Complete Response
1101635|NCT01566773|COPD
1101636|NCT01566760|food effect
1101637|NCT01566760|bioavailability
1101638|NCT01566760|pharmacokinetics
1101639|NCT01566760|fesoterodine
1101640|NCT01566760|5-hydroxymethyl tolterodine
1101641|NCT01566760|treatment of overactive bladder
1101642|NCT01566734|Surgical Wound Infection
1101643|NCT01566734|cefazolin
1101644|NCT01566734|Cesarean Section
1101645|NCT01566708|Acute Tinnitus
1101646|NCT01566708|Recent Onset Tinnitus
1101647|NCT01566708|Music Therapy
1101648|NCT01566708|fMRI
1101649|NCT01566708|Therapy Evaluation
1101650|NCT01566682|Lung Lesion
1101651|NCT01566682|Lung Mass
1101652|NCT01566682|Lung Nodule
1101653|NCT01566682|Lung Cancer
1101654|NCT01566682|Low-Dose CT
1101655|NCT01566682|CT
1101656|NCT01566682|Diagnostic
1101657|NCT01566682|Evaluation
1101658|NCT01566682|Bioconductance
1101659|NCT01566682|ProLung
1101660|NCT01566669|Cyclooxygenase inhibitors
1101661|NCT01566669|Morphine
1101662|NCT01566669|Analgesia
1101663|NCT01566669|patient-controlled
1101664|NCT01566669|Gynecologic surgical procedures
1101665|NCT01566656|Allogeneic hematopoietic stem cell transplantation
1101666|NCT01566656|Non-myeloablative preparative regimen
1101667|NCT01566656|Total lymphoid irradiation
1101668|NCT01566656|Anti-thymocyte globulin
1101669|NCT01566656|Lymphoid malignancies
1101670|NCT01566643|Helicobacter pylori
1101671|NCT01566643|antibiotic resistance
1101672|NCT01566643|sequential-concomitant hybrid therapy
1101673|NCT01566630|human recombinant RLX030
1101674|NCT01566630|Pre-eclampsia
1101675|NCT01566630|hemodynamics
1101676|NCT01566630|Pharmacokinetics
1101677|NCT01566604|Chronic obstructive pulmonary disease (COPD)
1101678|NCT01566604|NVA237
1101679|NCT01566591|Bipolar Depression
1101680|NCT01566552|AMBISOME
1101681|NCT01566552|VISCERAL LEISHMANIASIS
1101682|NCT01566552|SINGLE DOSE
1101683|NCT01566539|Social cooperation
1101684|NCT01566539|Oxytocin
1101685|NCT01566539|Vasopressin
1101686|NCT01566539|Prisoner's Dilemma game
1101687|NCT01566539|Empathy
1101688|NCT01566539|fMRI
1101689|NCT01566513|Peer Support
1101690|NCT01566513|Cost Effectiveness
1101691|NCT01566513|Reducing Hospital use
1101692|NCT01566513|Serious Mental Illness
1101693|NCT01566500|Epilepsy
1101694|NCT01566500|Medication Adherence
1101695|NCT01566487|Bioequivalence
1101696|NCT01566487|Quetiapine fumarate
1101697|NCT01566487|crossover
1101698|NCT01566461|Drug-Coated Angioplasty Balloon
1101699|NCT01566461|Drug Coated Angioplasty Balloon
1101700|NCT01566461|Peripheral Artery Disease
1101701|NCT01566461|Experimental
1101702|NCT01566461|Percutaneous Transluminal Angioplasty (PTA)
1101703|NCT01566448|Ketamine
1101704|NCT01566448|Mucositis
1101705|NCT01566448|Oral ketamine rinse
1101706|NCT01566409|Constipation
1101707|NCT01566409|Maintenance treatment
1101708|NCT01566409|Ultrasound of rectum
1101709|NCT01566396|Fractional,
1101710|NCT01566396|RF,
1101711|NCT01566396|Wrinkles
1101712|NCT01566396|Safety
1101713|NCT01566396|Efficacy
1101714|NCT01566396|treatment
1101715|NCT01566370|alcoholism
1101716|NCT01566370|alcohol use disorder
1101717|NCT01566370|alcohol dependence
1101718|NCT01566370|alcohol abuse
1101719|NCT01566370|bipolar
1101720|NCT01566370|anticonvulsant
1101721|NCT01566370|zonisamide
1101722|NCT01566357|dental erosion
1101723|NCT01566357|enamel
1101724|NCT01566357|dentin
1101725|NCT01566344|Premature Ventricular Complex
1101726|NCT01566344|Cardiomyopathy
1101727|NCT01566344|Left ventricular dysfunction
1101728|NCT01566344|Catheter Ablation
1101729|NCT01566344|Anti-Arrhythmic Agents
1101730|NCT01566344|Randomized Clinical Trial
1101731|NCT01566331|Safe Delivery
1101732|NCT01566331|reduction of pain
1101733|NCT01566331|reduction stage of labor
1101734|NCT01566318|Depression
1101735|NCT01566318|Anxiety
1101736|NCT01566318|Geriatric mental health
1101737|NCT01566279|solid tumors
1101738|NCT01566279|all comers
1101739|NCT01566279|everolimus
1101740|NCT01566279|biomarker
1101741|NCT01566279|next generation sequencing
1101742|NCT01566266|gut flora
1101743|NCT01566266|antibiotics
1101744|NCT01566266|lipid metabolism
1101745|NCT01566266|LDL cholesterol
1101746|NCT01566253|planned caesarian section, analgesic, PCOA
1101747|NCT01566240|cervical cancer
1101748|NCT01566240|Chemotherapy
1101749|NCT01566240|Paclitaxel
1101750|NCT01566240|Carboplatin
1101751|NCT01566240|Cisplatin
1101752|NCT01566240|Radiotherapy
1101753|NCT01566240|Chemoradiation
1101754|NCT01566240|Brachytherapy
1101755|NCT01566240|Stage IB2 Cervical Cancer
1101756|NCT01566240|Stage IIA Cervical Cancer
1101757|NCT01566240|Stage IIB Cervical Cancer
1101758|NCT01566240|Stage IIIB Cervical Cancer
1101759|NCT01566240|Stage IVA Cervical Cancer
1101760|NCT01566227|overdenture
1101761|NCT01566227|implant
1101762|NCT01566227|edentulism
1101763|NCT01566214|coronary heart disease (CHD)
1101764|NCT01566214|myocardial infarction (MI)
1101765|NCT01566214|acute coronary syndromes (ACS)
1101766|NCT01566201|Arterial stiffness
1101767|NCT01566201|Endothelial function
1101768|NCT01566201|Left ventricular function
1101769|NCT01566201|Apoptosis
1101770|NCT01566201|Nitrooxidative stress
1101771|NCT01566175|Neovasc Reducer
1101772|NCT01566175|Coronary Sinus
1101773|NCT01566175|Refractory Angina Pectoris
1101774|NCT01566175|angina class 3-4
1101775|NCT01566162|Lurasidone
1101776|NCT01566162|Latuda
1101777|NCT01566162|Schizophrenia
1101778|NCT01566136|hip fracture patients
1101779|NCT01566136|cognitive impairment
1101780|NCT01566136|rehabilitation model of care
1101781|NCT01566123|retroperitoneal soft tissue sarcoma
1101782|NCT01566123|IMRT
1101783|NCT01566123|IORT
1101784|NCT01566110|pediatric
1101785|NCT01566110|dietary treatment
1101786|NCT01566110|celiac disease
1101787|NCT01566110|T1D
1101788|NCT01566097|Cluster randomized trial
1101789|NCT01566097|Decision aids
1101790|NCT01566097|Culturally-appropriate decision aids
1101791|NCT01566058|Post partum
1101792|NCT01566058|mother-child relationships
1101793|NCT01566045|Prostate Cancer
1101794|NCT01566045|Biopsy
1101795|NCT01566032|pulmonary air leak
1101796|NCT01566032|Thopaz
1101797|NCT01566032|analog
1101798|NCT01566032|digital
1101799|NCT01566006|Mycophenolate mofetil (MMF)
1101800|NCT01566006|Diabetic Nephropathy
1101801|NCT01566006|proteinuria
1101802|NCT01566006|Diabetic Nephropathy in Chronic Kidney Disease patients stages 2-4
1101803|NCT01565980|Lung cancer
1101804|NCT01565980|mindfulness therapy
1101805|NCT01565980|active treatment (radiation and/or chemotherapy)
1101806|NCT01565967|AutoLog
1101807|NCT01565967|Post market release
1101808|NCT01565967|Non-interventional
1101809|NCT01565954|Sickle Cell Disease
1101810|NCT01565954|Respiration Disorders
1101811|NCT01565954|Polysomnography
1101812|NCT01565941|Cardiovascular
1101813|NCT01565941|Respiratory
1101814|NCT01565941|Failure
1101815|NCT01565941|Heart
1101816|NCT01565941|Lung
1101817|NCT01565941|Continuous glucose monitoring
1101818|NCT01565941|Tight glycemic control
1101819|NCT01565941|Subcutaneous
1101820|NCT01565941|Insulin
1101821|NCT01565941|Algorithm
1101822|NCT01565928|Prostate cancer
1101823|NCT01565928|docetaxel
1101824|NCT01565928|MDV3100
1101825|NCT01565928|enzalutamide
1101826|NCT01565928|Xtandi
1101827|NCT01565902|BAF312
1101828|NCT01565902|Pharmacokinetics
1101829|NCT01565902|Hepatic impairment
1101830|NCT01565876|weight bearing
1101831|NCT01565876|physiological load
1101832|NCT01565863|Perceived Disability
1101833|NCT01565863|Mental Wellness
1101834|NCT01565863|Employment
1101835|NCT01565863|Social Integration and Engagement
1101836|NCT01565863|Goal Achievement
1101837|NCT01565850|HIV-1
1101838|NCT01565850|HIV
1101839|NCT01565850|Treatment-Naive
1101840|NCT01565837|Melanoma
1101841|NCT01565837|Malignant Melanoma
1101842|NCT01565837|Metastatic
1101843|NCT01565837|Oligometastatic
1101844|NCT01565837|Radiosurgery
1101845|NCT01565837|Radiosurgery, Stereotactic
1101846|NCT01565837|Stereotactic Radiosurgery
1101847|NCT01565837|Ipilimumab
1101848|NCT01565837|Yervoy
1101849|NCT01565837|MDX-010
1101850|NCT01565837|Circulating Tumor Cells
1101851|NCT01565811|colon neoplasm, rectal neoplasm, liver metastasis
1101852|NCT01565798|healthcare-acquired infections
1101853|NCT01565798|colonization
1101854|NCT01565798|copper-alloy surfaces
1101855|NCT01565785|Child parent home self-management
1101856|NCT01565772|Lung cancer
1101857|NCT01565772|Stage III
1101858|NCT01565759|Gene expression
1101859|NCT01565759|Lithium
1101860|NCT01565759|Healthy volunteers
1101861|NCT01565759|Lymphoblastoid cell lines
1101862|NCT01565746|BAY88-8223
1101863|NCT01565746|radium-223 dichloride
1101864|NCT01565746|prostate cancer
1101865|NCT01565720|Isavuconazole
1101866|NCT01565720|Healthy Volunteers
1101867|NCT01565720|BAL8557
1101868|NCT01565707|Pediatric
1101869|NCT01565707|Solifenacin succinate suspension
1101870|NCT01565707|Phase 3
1101871|NCT01565707|Pharmacokinetics
1101872|NCT01565707|Overactive bladder (OAB)
1101873|NCT01565694|Cognitive Function
1101874|NCT01565694|Phase 3
1101875|NCT01565694|Neurogenic Detrusor Overactivity
1101876|NCT01565694|Pharmacokinetics
1101877|NCT01565694|Ocular Accommodation
1101878|NCT01565694|Urodynamics
1101879|NCT01565681|Healthy Volunteers
1101880|NCT01565681|B cell CD40 receptor occupancy
1101881|NCT01565681|anti-CD40 monoclonal antibody
1101882|NCT01565668|FLT3-ITD positive Acute Myeloid Leukemia (AML)
1101883|NCT01565668|AC220
1101884|NCT01565668|Relapse
1101885|NCT01565668|Refractory
1101886|NCT01565655|Rheumatoid Arthritis
1101887|NCT01565655|ASP015K
1101888|NCT01565642|Dementia, decision making
1101889|NCT01565629|Autism
1101890|NCT01565629|Asperger's Syndrome
1101891|NCT01565629|Treatment
1101892|NCT01565629|Cognitive-behavioral therapy
1101893|NCT01565629|Anxiety
1101894|NCT01565629|Children
1101895|NCT01565629|Therapy
1101896|NCT01565616|Severe Sickle Cell Disease
1101897|NCT01565616|Hematopoietic cell transplantation (HCT)
1101898|NCT01565616|Hematopoietic Stem Cell Therapy
1101899|NCT01565616|Bone Marrow Transplant
1101900|NCT01565616|Hematologic Diseases
1101901|NCT01565616|Genetic Diseases
1101902|NCT01565616|Anemia
1101903|NCT01565616|Hemolytic
1101904|NCT01565616|Congenital
1101905|NCT01565616|Human Leukocyte Antigen
1101906|NCT01565616|HLA
1101907|NCT01565603|Hypoxia
1101908|NCT01565603|Exercise
1101909|NCT01565603|Sleep
1101910|NCT01565603|Brain
1101911|NCT01565603|Neuromuscular function
1101912|NCT01565603|Heart
1101913|NCT01565590|aneurysmal subarachnoid hemorrhage
1101914|NCT01565590|dexmedetomidine
1101915|NCT01565590|cytokines
1101916|NCT01565577|Neisseria meningitidis B:14, P1-7, 16
1101917|NCT01565577|Serum bactericidal activity
1101918|NCT01565577|Menbvac
1101919|NCT01565564|Gestational diabetes mellitus
1101920|NCT01565564|intervention
1101921|NCT01565564|shared care
1101922|NCT01565564|pregnancy outcome
1101923|NCT01565564|macrosomia
1101924|NCT01565564|pregnancy-induced hypertension
1101925|NCT01565551|Traumatic Brain Injury
1101926|NCT01565551|Common Data Elements
1101927|NCT01565551|Prognostic Models
1101928|NCT01565551|Neuroimaging
1101929|NCT01565551|Biomarkers
1101930|NCT01565551|Genetic Variants
1101931|NCT01565551|Concussion
1101932|NCT01565551|Psychological Health
1101933|NCT01565538|Cancer
1101934|NCT01565538|Non-small-cell lung cancer
1101935|NCT01565538|Adenocarcinoma
1101936|NCT01565538|EGFR gene mutation
1101937|NCT01565538|Chemotherapy
1101938|NCT01565538|Pemetrexed
1101939|NCT01565538|Erlotinib
1101940|NCT01565525|well child visit
1101941|NCT01565525|anticipatory guidance
1101942|NCT01565525|obesity prevention
1101943|NCT01565525|infant feeding
1101944|NCT01565512|randomized trial
1101945|NCT01565512|robotic prostatectomy
1101946|NCT01565512|prostate cancer
1101947|NCT01565512|foley catheter discomfort
1101948|NCT01565499|Neoadjuvant nab-paclitaxel luminal breast cancer
1101949|NCT01565486|operation time
1101950|NCT01565486|complication rate
1101951|NCT01565486|costs
1101952|NCT01565486|admission time
1101953|NCT01565486|RFS
1101954|NCT01565486|OS
1101955|NCT01565473|non-motor symptoms
1101956|NCT01565460|pancreas
1101957|NCT01565460|biliary
1101958|NCT01565460|stricture
1101959|NCT01563510|Hepatolithiasis
1101960|NCT01563510|Minimal invasive surgery
1101961|NCT01563510|Laparoscopic hepatectomy
1101962|NCT01563510|Choledochoscope
1101963|NCT01563484|Primary Hepatocellular Carcinoma(HCC)
1101964|NCT01563484|Transarterial chemoembolization (TACE)
1101965|NCT01563484|Liver function
1101966|NCT01563484|Renal function
1101967|NCT01565421|Cancer
1101968|NCT01565421|Neoplasms
1101969|NCT01565421|Solid Tumor
1101970|NCT01565421|Ovarian Cancer
1101971|NCT01565421|Solid Malignancies
1101972|NCT01565395|ALS
1101973|NCT01565395|PD
1101974|NCT01565382|Amyloid imaging
1101975|NCT01565382|Positron Emission Tomography
1101976|NCT01565382|18F-AV-45
1101977|NCT01565382|florbetapir F 18
1101978|NCT01565382|Diagnostic imaging
1101979|NCT01565369|Amyloid imaging
1101980|NCT01565369|Positron Emission Tomography
1101981|NCT01565369|18F-AV-45
1101982|NCT01565369|florbetapir F 18
1101983|NCT01565369|Diagnostic imaging
1101984|NCT01565356|Amyloid imaging
1101985|NCT01565356|Positron Emission Tomography
1101986|NCT01565356|18F-AV-45
1101987|NCT01565356|florbetapir F 18
1101988|NCT01565356|Diagnostic imaging
1101989|NCT01565343|Amyloid imaging
1101990|NCT01565343|Positron Emission Tomography
1101991|NCT01565343|18F-AV-45
1101992|NCT01565343|florbetapir F 18
1101993|NCT01565343|Diagnostic imaging
1101994|NCT01565330|Amyloid imaging
1101995|NCT01565330|Positron Emission Tomography
1101996|NCT01565330|18F-AV-45
1101997|NCT01565330|florbetapir F 18
1101998|NCT01565330|Diagnostic imaging
1101999|NCT01565304|Teen pregnancy
1102000|NCT01565304|Sexually transmitted infections
1102001|NCT01565304|Sexual risk behaviors
1102002|NCT01565291|Amyloid imaging
1102003|NCT01565291|Positron Emission Tomography
1102004|NCT01565291|18F-AV-45
1102005|NCT01565291|florbetapir F 18
1102006|NCT01565291|Diagnostic imaging
1102007|NCT01565278|Parenteral nutrition
1102008|NCT01565278|fish oil
1102009|NCT01565278|liver disease
1102010|NCT01565278|Omegaven
1102011|NCT01565278|hepatic
1102012|NCT01565278|liver biopsy
1102013|NCT01565278|bilirubin
1102014|NCT01565265|ovarian hyperstimulation
1102015|NCT01565265|GnRH antagonist
1102016|NCT01565265|GnRH agonist
1102017|NCT01565265|assisted reproduction
1102018|NCT01565265|FSH
1102019|NCT01565265|LH
1102020|NCT01565252|Egg,Omega 3, Omega 6
1102021|NCT01565239|Warfarin
1102022|NCT01565239|Monitoring
1102023|NCT01565239|prothrombin time
1102024|NCT01565239|Fiix prothrombin time
1102025|NCT01565239|international normalized ratio (INR)
1102026|NCT01565239|new test
1102027|NCT01565226|Capnography
1102028|NCT01565226|CO2
1102029|NCT01565226|neonates
1102030|NCT01565226|High Frequency ventilation (HFV)
1102031|NCT01565213|primary health care,common mental disorders,
1102032|NCT01565213|group therapy
1102033|NCT01565200|HER2
1102034|NCT01565200|Metastatic Breast Cancer
1102035|NCT01565187|Hand Transplantation
1102036|NCT01565174|cannabis
1102037|NCT01565174|THC
1102038|NCT01565174|COMT
1102039|NCT01565174|psychosis
1102040|NCT01565174|D2
1102041|NCT01565161|Obesity
1102042|NCT01565161|Overweight
1102043|NCT01565148|DME
1102044|NCT01565109|NESC
1102045|NCT01565109|NEOADJUVANT
1102046|NCT01565109|GASTRIC
1102047|NCT01565070|Osteoarthritis
1102048|NCT01565070|Pain
1102049|NCT01565070|Quality of life
1102050|NCT01565057|emulsion
1102051|NCT01565057|emptying
1102052|NCT01565057|protein
1102053|NCT01565057|layering
1102054|NCT01565044|Stroke
1102055|NCT01565044|hemiplegia
1102056|NCT01565044|automatic pilot
1102057|NCT01565044|upper-limb rehabilitation
1102058|NCT01565031|Asthma
1102059|NCT01565018|Rotigotine
1102060|NCT01565018|Neupro®
1102061|NCT01565018|Transdermal Patch
1102062|NCT01565018|Bioequivalence
1102063|NCT01565005|MCPH
1102064|NCT01565005|FANCONI ANEMIA
1102068|NCT01564979|botulinum toxin
1102069|NCT01564979|facial nerve
1102070|NCT01564979|hemifacial spasm
1102071|NCT01564979|tears
1102072|NCT01564966|transplantation
1102073|NCT01564966|inflammation
1102074|NCT01564966|endothelial dysfunction
1102075|NCT01564953|vitamin D
1102076|NCT01564953|calcium
1102077|NCT01564953|magnesium
1102078|NCT01564953|COPD
1102079|NCT01564953|QoL
1102080|NCT01564940|Cervical cap insemination
1102081|NCT01564940|Usability Study
1102082|NCT01564927|deqi electroacupuncture
1102083|NCT01564927|BP HR HRV
1102084|NCT01564875|Simvast CR
1102085|NCT01564875|Zocor
1102086|NCT01564862|Drug Therapy
1102087|NCT01564849|Pomegranate fruit extract
1102088|NCT01564849|Sinusitis
1102089|NCT01564849|rhinitis
1102090|NCT01564849|nasal polyps
1102091|NCT01564823|Crohn´s disease
1102092|NCT01564823|Metronidazole
1102093|NCT01564823|Azathioprine
1102094|NCT01564823|Adalimumab
1102095|NCT01564823|post-chirurgic recurrence
1102096|NCT01564810|liver metastasis
1102097|NCT01564810|colorectal cancer
1102098|NCT01564810|cetuximab
1102099|NCT01564810|chemotherapy
1102100|NCT01564797|Diabetes
1102101|NCT01564797|haemoglobin A1C
1102102|NCT01564797|Hispanic
1102103|NCT01564797|Behavioural Intervention
1102104|NCT01564771|Pneumococcal serotypes
1102105|NCT01564771|Community Acquired Pneumonia (CAP)
1102106|NCT01564758|non-interventional
1102107|NCT01564758|non-comparative
1102108|NCT01564758|open-label study
1102109|NCT01564758|safety
1102110|NCT01564758|Linezolid
1102111|NCT01564758|gram positive infections
1102112|NCT01564758|Filipino
1102113|NCT01564732|morbid obesity
1102114|NCT01564732|gastric band
1102115|NCT01564719|clergy
1102116|NCT01564719|weight loss
1102117|NCT01564719|holistic
1102118|NCT01564719|stress
1102119|NCT01564719|spiritual
1102120|NCT01564706|Amyloid imaging
1102121|NCT01564706|Positron Emission Tomography
1102122|NCT01564706|18F-AV-45
1102123|NCT01564706|florbetapir F 18
1102124|NCT01564706|Diagnostic imaging
1102125|NCT01564693|anorexia
1102126|NCT01564693|cancer
1102127|NCT01564693|hypothalamus
1102128|NCT01564693|inflammation
1102129|NCT01564680|Lower abdominal surgery
1102130|NCT01564680|Paracetamol
1102131|NCT01564680|Lornoxicam
1102132|NCT01564680|Morphine
1102133|NCT01564667|PTSD
1102134|NCT01564667|Posttraumatic Stress
1102135|NCT01564667|Post Traumatic Stress
1102136|NCT01564667|Attention Bias
1102137|NCT01564667|Threat Bias
1102138|NCT01564667|Combat
1102139|NCT01564667|Warzone
1102140|NCT01564641|knee
1102141|NCT01564641|osteoarthritis
1102142|NCT01564641|bicompartmental
1102143|NCT01564641|arthroplasty
1102144|NCT01564641|joint diseases
1102145|NCT01564628|CAD
1102146|NCT01564615|Catheter related bloodstream infection
1102147|NCT01564615|Umbilical venous catheter
1102148|NCT01564615|Silver
1102149|NCT01564615|Preterm infants
1102150|NCT01564602|2-channel single port laparoscopy
1102151|NCT01564602|multiple-channel port laparoscopy
1102152|NCT01563432|crossover
1102153|NCT01563432|pharmacokinetic
1102154|NCT01563432|hyperuricemia
1102155|NCT01563432|gout
1102156|NCT01563419|Insulin
1102157|NCT01563419|Diabetes
1102158|NCT01563419|Low vision
1102159|NCT01563406|Needleless connectors
1102160|NCT01563406|catheter hubs
1102161|NCT01563393|tool for nutritional evaluation
1102162|NCT01563393|children
1102163|NCT01563393|malnutrition
1102164|NCT01563380|total knee arthroplasty
1102165|NCT01563380|osteoarthritis
1102166|NCT01563380|autologous Platelet rich plasma
1102167|NCT01563380|complications
1102168|NCT01563380|blood loss
1102169|NCT01563380|Pain
1102170|NCT01563380|functional outcome
1102171|NCT01563367|Anaemia
1102172|NCT01563367|Cardiac surgery
1102173|NCT01563354|neuroendocrine carcinoma; lung; thymus; pasireotide LAR; everolimus
1102174|NCT01563328|Dolutegravir, GSK1349572, DTG, BCV, TVR, drug interaction
1102175|NCT01564576|Laparoscopic surgery
1102176|NCT01564576|Anesthesiology
1102177|NCT01564576|Neuromuscular blockade
1102178|NCT01564550|Type 2 diabetes
1102179|NCT01564550|Very-low-density-lipoprotein(VLDL)
1102180|NCT01564550|VLDL1
1102181|NCT01564550|VLDL2
1102182|NCT01564550|hyperinsulinemia
1102183|NCT01564550|diet
1102184|NCT01564537|Drug therapy
1102185|NCT01564524|Craniomaxillofacial (CMF) Battle-injured (BI)
1102186|NCT01564524|Facial Trauma
1102187|NCT01564524|Fat Grafts
1102188|NCT01564524|Autogenous Fat Transfers (AFT)
1102189|NCT01564524|Wounded warriors
1102190|NCT01564511|Multiple Sclerosis
1102191|NCT01564511|Robotic Rahabilitation
1102192|NCT01564511|Fatigue
1102193|NCT01564511|Gait disorder
1102194|NCT01564498|anthocyanins
1102195|NCT01564498|antioxidant
1102196|NCT01564498|polyphenols
1102197|NCT01564498|bioavailability
1102198|NCT01564498|cholesterol
1102199|NCT01564498|insulin sensitivity
1102200|NCT01564498|glucose tolerance
1102201|NCT01564498|atherosclerosis
1102202|NCT01564498|metabolic syndrome
1102203|NCT01564446|medication
1102204|NCT01564446|discharge
1102205|NCT01564446|adherence
1102206|NCT01564446|compliance
1102207|NCT01564446|secure message
1102208|NCT01564433|robotics
1102209|NCT01564433|rehabilitation
1102210|NCT01564433|gait
1102211|NCT01564433|cerebral palsy
1102212|NCT01564420|pharmacokinetic/pharmacodynamic modeling
1102213|NCT01564420|intrathecal morphine
1102214|NCT01564420|postoperative analgesia
1102215|NCT01564420|patient-controlled analgesia device
1102216|NCT01564407|ICX‐RHY‐013
1102217|NCT01564407|Restrictive scar contracture
1102218|NCT01564407|Restrictive hypertrophic scar
1102219|NCT01564407|Burn Scar
1102220|NCT01564407|Burn Scar contractures
1102221|NCT01564407|Scar
1102222|NCT01564394|qigong
1102223|NCT01564394|mindfulness meditation
1102224|NCT01564394|fatigue
1102225|NCT01564394|prostate cancer
1102226|NCT01564381|Cardiovascular disease
1102227|NCT01564368|stage II breast cancer
1102228|NCT01564368|stage IIIA breast cancer
1102229|NCT01564368|stage IIIB breast cancer
1102230|NCT01564368|stage IIIC breast cancer
1102231|NCT01564368|stage IV breast cancer
1102232|NCT01564368|HER2-negative breast cancer
1102233|NCT01564368|HER2-positive breast cancer
1102234|NCT01564342|wound irrigation
1102235|NCT01564342|tap water irrigation
1102236|NCT01564342|wound infection
1102237|NCT01564342|wound irrigation solution
1102238|NCT01564329|endostar
1102239|NCT01564329|CT Perfusion
1102240|NCT01564329|Advanced Primary Lung Adenocarcinoma
1102241|NCT01564303|Carnitine
1102242|NCT01564303|Phosphodiesterase type 5 (PDE5) inhibitor
1102243|NCT01564303|Contrast Media-induced Nephropathy (CMN)
1102244|NCT01564290|acute diarrhea
1102245|NCT01564290|probiotics
1102246|NCT01564290|children
1102247|NCT01564264|Uterine Neoplasms
1102248|NCT01564264|Sentinel Lymph Node Biopsy
1102249|NCT01564238|calcium retention
1102250|NCT01564238|sodium retention
1102251|NCT01564225|XLHED
1102252|NCT01564212|heat loss
1102253|NCT01564212|laminar airflow
1102254|NCT01564212|operating rooms
1102255|NCT01564160|Fish Oil
1102256|NCT01564160|EPA
1102257|NCT01564160|DHA
1102258|NCT01564160|Omega-Score
1102259|NCT01564160|Omega-3 Fatty Acids
1102260|NCT01564160|Green-Lipped Mussel
1102261|NCT01564160|Omega-score < 5.2%
1102262|NCT01564147|Therapeutic Education, Rheumatoid Arthritis
1102263|NCT01564134|response vaccination
1102264|NCT01564108|Intravitreal Ranibizumab
1102265|NCT01564108|Non-infectious uveitis
1102266|NCT01564108|Refractory Cystoid Macular Oedema
1102267|NCT01564108|Lucentis
1102268|NCT01564108|LIMO
1102269|NCT01564095|Liver transplantation
1102270|NCT01564095|EDC
1102271|NCT01564095|IRI
1102272|NCT01564095|graft survival
1102273|NCT01564095|graft function
1102274|NCT01564095|graft preconditioning
1102275|NCT01564095|Tacrolimus rinse
1102276|NCT01564095|randomised multicenter trial
1102277|NCT01564082|endotracheal intubation
1102278|NCT01564082|GlideScope
1102279|NCT01564069|Chronic pain
1102280|NCT01564069|Intrathecal pain management
1102281|NCT01564056|Adjuvant systemic treatment
1102282|NCT01564056|Breast cancer
1102283|NCT01564056|Elderly patients
1102284|NCT01564030|Pregnancy
1102285|NCT01564030|Respiratory aspiration
1102286|NCT01564030|Gastric contents
1102287|NCT01564030|Ultrasound
1102288|NCT01564017|Allergy
1102289|NCT01564017|Allergic rhinoconjunctivitis
1102290|NCT01564017|Immunotherapy
1102291|NCT01564017|D. pteronyssinus
1102292|NCT01564017|house dust allergy
1102293|NCT01564004|breech presentation at term
1102294|NCT01564004|pregnancy
1102295|NCT01564004|external cephalic version (ECV)
1102296|NCT01564004|clinical hypnosis
1102297|NCT01564004|neuro-linguistic programming (NLP)
1102298|NCT01563991|surgery
1102299|NCT01563991|fluid
1102300|NCT01563991|morbidity
1102301|NCT01563978|Rheumatoid Arthritis
1102302|NCT01563965|Preoperative fasting
1102303|NCT01563965|Acute phase proteins
1102304|NCT01563965|Carbohydrates
1102305|NCT01563965|Protein hydrolizate
1102306|NCT01563965|Inflammatory response
1102307|NCT01563965|Surgery
1102308|NCT01563939|Labour analgesia
1102309|NCT01563939|Pregnancy
1102310|NCT01563939|IVPCA
1102311|NCT01563913|Parkinsons disease
1102312|NCT01563913|supplement
1102313|NCT01563913|DHA
1102314|NCT01563913|dyskinesia
1102315|NCT01563913|abnormal movements
1102316|NCT01563900|fatigue
1102317|NCT01563900|multiple sclerosis
1102318|NCT01563900|sleep apnea
1102319|NCT01563900|CPAP
1102320|NCT01563887|Type 1 Diabetes
1102321|NCT01563887|Hypoglycemia
1102322|NCT01563887|Driving
1102323|NCT01563887|Driving safety
1102324|NCT01563887|Internet
1102325|NCT01563887|Web
1102326|NCT01563887|Treatment
1102327|NCT01563887|Intervention
1102334|NCT01563861|contiguous stage II adult diffuse large cell lymphoma
1102335|NCT01563861|noncontiguous stage II adult diffuse large cell lymphoma
1102336|NCT01563861|stage III adult diffuse large cell lymphoma
1102337|NCT01563861|stage IV adult diffuse large cell lymphoma
1102338|NCT01563835|Termination of pregnancy
1102339|NCT01563835|Epidural
1102340|NCT01563835|IV PCA
1102341|NCT01563822|Follicular Fluid
1102342|NCT01563822|uterine cavity
1102343|NCT01563822|Implantation rates
1102344|NCT01563822|ICSI
1102345|NCT01563796|bladder cancer
1102346|NCT01563796|TCC
1102347|NCT01563796|urine
1102348|NCT01563796|protein ELISA
1102349|NCT01563783|Fibroids
1102350|NCT01563783|Myomas
1102351|NCT01563783|leiomyomata
1102352|NCT01563783|menorrhagia
1102353|NCT01563783|Acessa Procedure
1102354|NCT01563783|Radiofrequency Ablation
1102355|NCT01563783|RFA
1102356|NCT01563770|Hyperlipidemia
1102357|NCT01563770|Hypertension
1102358|NCT01563770|Vasodilation
1102359|NCT01563770|Oxidative stress
1102360|NCT01563770|Inflammation
1102361|NCT01563770|Hemostasis
1102362|NCT01563770|Hemorheology
1102363|NCT01563770|Cardiovascular diseases
1102364|NCT01563770|Cardiovascular agents
1102365|NCT01563770|Salvia miltiorrhiza
1102366|NCT01563770|Danshen
1102367|NCT01563770|Danshen root extract
1102368|NCT01563770|Molecular Mechanisms of Pharmacological Action
1102369|NCT01563770|Therapeutic Uses
1102370|NCT01563744|colonoscopy
1102371|NCT01563744|bowel preparation
1102372|NCT01563744|tolerability
1102373|NCT01563744|EGD-assisted
1102374|NCT01563731|Blood pressure medicines
1102375|NCT01563731|Lipid lowering medicines
1102376|NCT01563731|Hypertension
1102377|NCT01563731|Stroke
1102378|NCT01563731|Dementia
1102379|NCT01563731|Heart attack
1102380|NCT01563731|Heart failure
1102381|NCT01563705|Neuromuscular Disorders
1102382|NCT01563705|GSD III
1102383|NCT01563705|glycogen storage disease
1102384|NCT01563692|RSV
1102385|NCT01563692|Immune response
1102386|NCT01563679|cancer
1102387|NCT01563679|locoregional therapies
1102388|NCT01563679|RFA
1102389|NCT01563679|Cryoablation
1102390|NCT01563679|Microwave ablation
1102391|NCT01563679|chemical ablation
1102392|NCT01563679|Irreversible electroporation
1102393|NCT01563653|predicting surgical success
1102394|NCT01563653|simple diagnostic test device
1102395|NCT01563640|dengue
1102396|NCT01563588|breast cancer
1102397|NCT01563588|chemotherapy
1102398|NCT01563588|first line treatment
1102399|NCT01563588|treatments include a chemotherapy
1102400|NCT01563588|last treatment not performed more than 9 months earlier
1102401|NCT01563575|Recognition Process
1102402|NCT01563575|Health Promotion
1102403|NCT01563575|HPH
1102404|NCT01563575|WHO
1102405|NCT01563575|Hospitals
1102406|NCT01563575|Health Services
1102407|NCT01563575|Health Gain
1102408|NCT01563575|Service Delivery
1102409|NCT01563575|Quality Management
1102410|NCT01563536|Hepatitis C,Genotype 1
1102411|NCT01563315|Community-Acquired Infections
1102412|NCT01563315|Pneumonia/microbiology
1102413|NCT01563315|Pneumonia/diagnosis
1102414|NCT01563315|Prognosis
1102415|NCT01563315|Prospective Studies
1102416|NCT01563302|Advanced Cancers
1102417|NCT01563302|DLBCL
1102418|NCT01563302|Advanced Lymphoma
1102419|NCT01563276|Progressive Supranuclear Palsy
1102420|NCT01563276|PSP
1102421|NCT01563276|Falls
1102422|NCT01563276|Gait
1102423|NCT01563276|Balance
1102424|NCT01563276|Parkinson's Disease
1102425|NCT01563276|PD
1102426|NCT01563263|IC43
1102427|NCT01563263|Pseudomonas Aeruginosa
1102428|NCT01563263|mechanically ventilated ICU patients
1102429|NCT01563263|ICU patients
1102430|NCT01563250|Acute Coronary Syndrome
1102431|NCT01563250|Cardiac Biomarkers
1102432|NCT01563250|point of care testing
1102433|NCT01563224|GABA-B
1102434|NCT01563211|breast cancer therapy
1102435|NCT01563211|toxicity
1102436|NCT01563211|side effect profile
1102437|NCT01563198|MRI departments and facilities
1102438|NCT01563198|Noncompletion of MRI
1102439|NCT01563185|JIA
1102440|NCT01563185|ibuprofen
1102441|NCT01563185|famotidine
1102442|NCT01563185|pediatrics
1102443|NCT01563185|for > 1 month
1102444|NCT01563159|Belgium
1102445|NCT01563159|hospitals
1102446|NCT01563159|Rotavirus
1102447|NCT01563146|Rotavirus
1102448|NCT01563146|hospitals
1102449|NCT01563146|Belgium
1102450|NCT01563133|endomicroscopy
1102451|NCT01563133|needle-based
1102452|NCT01563133|pancreatic
1102453|NCT01563133|cyst
1102454|NCT01563133|mass
1102455|NCT01563133|EUSFNA
1102456|NCT01563107|Orthostatic Intolerance
1102457|NCT01563107|Tachycardia
1102458|NCT01563107|Orthostatic Hypotension
1102459|NCT01563107|Sodium
1102460|NCT01563094|Bone Density
1102461|NCT01563094|Lactation
1102462|NCT01563094|Bone Turnover Markers
1102463|NCT01563081|Allergic rhinitis
1102464|NCT01563081|Pediatric
1102465|NCT01563081|Pruritus
1102466|NCT01563081|Levocetirizine
1102467|NCT01563068|plaque psoriasis
1102468|NCT01563068|pediatric
1102469|NCT01563068|adolescent
1102475|NCT01563016|schizophrenia
1102476|NCT01563016|Psychotic Disorders
1102477|NCT01563016|Psychoses
1102478|NCT01563003|Autism
1102479|NCT01563003|Asperger's Syndrome
1102480|NCT01563003|Pervasive Developmental Disorder Not Otherwise Specified
1102481|NCT01563003|Treatment
1102482|NCT01563003|Cognitive-behavioral therapy
1102483|NCT01563003|Anxiety
1102484|NCT01563003|Children
1102485|NCT01563003|Therapy
1102486|NCT01562951|Crohn's disease
1102487|NCT01562951|mucosal inflammation
1102488|NCT01562951|lesions
1102489|NCT01562938|Respiratory Syncytial Virus
1102490|NCT01562912|radiofrequency
1102491|NCT01562912|ablation
1102492|NCT01562912|atrial fibrillation
1102493|NCT01562912|PVAC
1102494|NCT01562899|MEK162
1102495|NCT01562899|AMG 479
1102496|NCT01562899|Ganitumab
1102497|NCT01562899|colorectal adenocarcinoma
1102498|NCT01562899|pancreatic adenocarcinoma
1102499|NCT01562899|melanoma
1102500|NCT01562899|KRAS
1102501|NCT01562899|BRAF
1102502|NCT01562886|Rilpivirine CSF pharmacokinetics
1102503|NCT01562873|pSTAT3+
1102504|NCT01562860|median nerve
1102505|NCT01562860|carpal tunnel syndrome
1102506|NCT01562860|Pronator Teres Release
1102507|NCT01562782|Elevated triglycerides
1102508|NCT01562782|Diabetes Mellitus
1102509|NCT01562782|Dyslipidemia
1102510|NCT01562782|Lipid Metabolic Disorders
1102511|NCT01562782|Body Weight
1102512|NCT01562730|Coronary Artery Disease
1102513|NCT01562730|Myocardial Ischemia
1102514|NCT01562730|Coronary Disease
1102515|NCT01562730|Heart Diseases
1102516|NCT01562730|Cardiovascular Diseases
1102517|NCT01562730|Arteriosclerosis
1102518|NCT01562730|Arterial Occlusive Diseases
1102519|NCT01562730|Vascular Diseases
1102520|NCT01562730|iECG
1102521|NCT01562730|12 leads ECG
1102522|NCT01562704|mechanism of action of paracetamol in the brain structures
1102523|NCT01562691|nasal packing
1102524|NCT01562691|nasal airway
1102525|NCT01562691|septoplasty
1102526|NCT01562691|oxygen saturation
1102527|NCT01562691|postoperative pain
1102528|NCT01562678|fMRI
1102529|NCT01562678|Liraglutide
1102530|NCT01562678|diabetes
1102531|NCT01562678|GLP-1
1102532|NCT01562665|All patients with NSCLC attending participating hospitals
1102533|NCT01562639|maintenance therapy,
1102534|NCT01562639|repeatedly recurring,
1102535|NCT01562639|relapsing reflux oesophagitis,
1102536|NCT01562639|Nexium
1102537|NCT01562613|Stroke
1102538|NCT01562613|Hypertension
1102542|NCT01562548|upper back/neck/shoulder muscle spasm
1102543|NCT01562535|pulled elbow
1102544|NCT01562535|nursemaid elbow
1102545|NCT01562509|Non-Hodgkin lymphoma (NHL)
1102546|NCT01562509|Quality of health care
1102547|NCT01562509|Oncology Service Hospital
1102548|NCT01562509|Patient-centredness
1102549|NCT01562509|PROMs
1102550|NCT01562496|Parkinson's disease
1102551|NCT01562496|Neuroprotective
1102552|NCT01562496|Intensive exercise
1102553|NCT01562483|postsurgical pain
1102554|NCT01562483|abdominal pain
1102555|NCT01562483|visceral pain
1102556|NCT01562483|chronic pain
1102557|NCT01562470|cellulite
1102558|NCT01562470|reduction
1102559|NCT01562470|cream
1102560|NCT01562470|thighs
1102561|NCT01562470|women
1102562|NCT01562444|Long term immunogenicity study
1102563|NCT01562418|Ergonomics
1102564|NCT01562418|musculoskeletal symptoms
1102565|NCT01562418|kinematics
1102566|NCT01562405|Relapsed
1102567|NCT01562405|Refractory
1102568|NCT01562392|dietary prevention
1102569|NCT01562392|cognitive performance
1102570|NCT01562392|metabolic syndrome
1102571|NCT01562392|colonic fermentation
1102572|NCT01562392|sub clinical inflammation
1102573|NCT01562392|cognition and metabolism
1102574|NCT01562379|complementary food supplements
1102575|NCT01562379|stunting
1102576|NCT01562379|wasting
1102577|NCT01562379|growth
1102578|NCT01562379|Bangladesh
1102579|NCT01562379|infant feeding
1102580|NCT01562366|Iliotibial Band Release
1102581|NCT01562366|Trochanteric Bursectomy
1102582|NCT01562366|Micro debridement
1102583|NCT01562353|Opioid Dependence
1102584|NCT01562353|Opioids for the treatment of pain
1102585|NCT01562340|Hemodialysis
1102586|NCT01562340|End stage renal disease
1102587|NCT01562340|Oxidative stress
1102588|NCT01562340|Inflammation
1102589|NCT01562340|Endothelial dysfunction
1102590|NCT01562340|Cardiovascular disease
1102591|NCT01562340|Antioxidants
1102592|NCT01562340|Flavonoids
1102593|NCT01562314|Mild to Moderate Ulcerative Colitis
1102594|NCT01562301|chemotherapeutic agent toxicity
1102595|NCT01562301|recurrent non-small cell lung cancer
1102596|NCT01562301|stage IIIA non-small cell lung cancer
1102597|NCT01562301|stage IIIB non-small cell lung cancer
1102598|NCT01562301|stage IV non-small cell lung cancer
1102599|NCT01562301|carboplatin
1102600|NCT01562301|Paraplatin
1102601|NCT01562301|docetaxel
1102602|NCT01562301|Taxotere
1102603|NCT01562301|Anvirzel
1102604|NCT01562301|nerium oleander
1102605|NCT01562301|Advanced Non-Small Cell Lung Cancer
1102606|NCT01562301|NSCLC
1102607|NCT01562288|HER2-positive breast cancer
1102608|NCT01562288|HER2-negative breast cancer
1102609|NCT01562288|stage IA breast cancer
1102610|NCT01562288|stage IB breast cancer
1102611|NCT01562288|stage II breast cancer
1102612|NCT01562288|stage IIIA breast cancer
1102613|NCT01562275|GDC0973
1102614|NCT01562275|MEK
1102615|NCT01562275|MEK inhibitor
1102616|NCT01562275|GDC0068
1102617|NCT01562275|Akt
1102618|NCT01562275|Akt inhibitor
1102619|NCT01562262|Apnea
1102620|NCT01562262|PVT
1102621|NCT01562262|Reaction Time
1102622|NCT01562249|clinical evaluation
1102623|NCT01562249|controlled clinical trial
1102624|NCT01562249|electromyography
1102625|NCT01562249|exercise program
1102626|NCT01562249|motor control
1102627|NCT01562223|stage IIA prostate cancer
1102628|NCT01562223|stage IIB prostate cancer
1102629|NCT01562223|stage III prostate cancer
1102630|NCT01562223|stage IV prostate cancer
1102631|NCT01562223|adenocarcinoma of the prostate
1102632|NCT01562210|NSCLC
1102633|NCT01562210|Olaparib
1102634|NCT01562210|CCRT
1102635|NCT01562197|axitinib
1102636|NCT01562197|glioblastoma
1102637|NCT01562197|recurrent
1102638|NCT01562171|Overweight
1102639|NCT01562171|Obese
1102640|NCT01562171|Obesity
1102641|NCT01562171|Cholesterol
1102642|NCT01562171|Hypercholesterolemia
1102643|NCT01562171|LDL-Cholesterol
1102644|NCT01562145|Rotator cuff tear, matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, partial-thickness tear, full-thickness tear, plasma.
1102645|NCT01562132|cryptococcus
1102646|NCT01562132|HIV
1102647|NCT01562119|Burns
1102648|NCT01562119|Wound repair
1102649|NCT01562119|Skin substitutes
1102650|NCT01562106|Cancer of Endometrium
1102651|NCT01562106|Cancer of the Endometrium
1102652|NCT01562106|Carcinoma of Endometrium
1102653|NCT01562106|Endometrial Carcinoma
1102654|NCT01562106|Endometrium Cancer
1102655|NCT01562106|Neoplasms, Endometrial
1102656|NCT01562093|Adrenal Cortex Hormones
1102657|NCT01562093|Spirometry
1102658|NCT01562093|Administration, Intranasal
1102659|NCT01562093|Nasal blockage
1102660|NCT01562093|Nasal sprays
1102661|NCT01562080|hyperlipidemia
1102662|NCT01562080|metabolic syndrome
1102663|NCT01562080|yeast red
1102664|NCT01562080|berberine
1102665|NCT01562080|policosanol
1102666|NCT01562080|astaxanthin
1102667|NCT01562067|Cervical tumors,vascular changes,Sonographic characteristics
1102668|NCT01562041|Cardiovascular disease
1102669|NCT01562041|Exercise Treadmill Test
1102670|NCT01562041|Ranolazine
1102671|NCT01562041|Angina
1102672|NCT01562041|Myocardial ischemia
1102673|NCT01562028|non small cell lung cancer
1102674|NCT01562028|advanced
1102675|NCT01562028|non-squamous
1102676|NCT01562028|EGFR
1102677|NCT01562028|mutations
1102678|NCT01562002|limbus
1102679|NCT01562002|cornea
1102680|NCT01562002|insufficiency syndrome
1102681|NCT01562002|stem cell transplant
1102682|NCT01561963|Apremilast
1102683|NCT01561963|drug interaction
1102684|NCT01561963|pharmacokinetics
1102685|NCT01561911|Clinical Trial
1102686|NCT01561911|Phase I
1102687|NCT01561911|Antibodies
1102688|NCT01561911|Monoclonal
1102689|NCT01561898|Schizophrenia
1102690|NCT01561898|JNS007ER
1102691|NCT01561898|Paliperidone extended-release
1102692|NCT01561885|Clinical Pathways
1102693|NCT01561885|Length of Stay
1102694|NCT01561885|Patient-Centered Care
1102695|NCT01561885|Pragmatic Randomized Controlled Trial
1102696|NCT01561859|Early Course Schizophrenia
1102697|NCT01561859|Cognitive Enhancement Therapy
1102698|NCT01561859|Enriched Supportive Therapy
1102699|NCT01561846|Conjugated Linoleic Acid
1102700|NCT01561846|LDL-cholesterol
1102701|NCT01561846|Endocannabinoids
1102702|NCT01561833|relapsed or refractory T cell lymphoma
1102703|NCT01561820|mild cognitive impairment
1102704|NCT01561820|cognitive disorders
1102705|NCT01561820|exercise
1102706|NCT01561794|Ciprofloxacin
1102707|NCT01561794|Bacterial pneumonia
1102708|NCT01561794|Community Acquired Pneumonia (CAP)
1102709|NCT01561794|Hospital Acquired Pneumonia (HAP)
1102710|NCT01561794|Secondary infection of chronic respiratory disease
1102711|NCT01561794|400 mg BID/TID
1102712|NCT01561781|Phase 1
1102713|NCT01561781|healthy volunteers
1102714|NCT01561781|pharmacokinetics
1102715|NCT01561781|vandetanib
1102716|NCT01561781|digoxin
1102717|NCT01561755|HIV associated myelopathy
1102718|NCT01561742|minocycline, augmentation, schizophrenia
1102719|NCT01561729|nasogastric tube
1102720|NCT01561729|orogastric tube
1102721|NCT01561729|RightSpot pH Indicator
1102722|NCT01561729|suction tube
1102723|NCT01561729|RightBio Metrics
1102724|NCT01561729|RightLevel
1102725|NCT01561729|RightSpot Infant
1102726|NCT01561729|NG Tube
1102727|NCT01561729|pH
1102728|NCT01561729|Gastric Acidity
1102729|NCT01561716|video games
1102730|NCT01561716|energy expenditure
1102731|NCT01561716|physical activity
1102732|NCT01561716|exercise physiology
1102733|NCT01561703|Healthcare utilization
1102734|NCT01561703|Tonsillectomy
1102735|NCT01561703|Adenoidectomy/Tonsillectomy
1102736|NCT01561703|Antibiotics
1102737|NCT01561677|obstructive sleep apnea
1102738|NCT01561677|syndrome survival
1102739|NCT01561677|ischemic stroke
1102740|NCT01561677|continuous positive airway pressure
1102741|NCT01561677|handicap
1102742|NCT01561664|obesity
1102743|NCT01561664|insulin resistance
1102744|NCT01561651|cardiac surgery
1102745|NCT01561651|left atrial appendage
1102746|NCT01561651|atrial fibrillation
1102747|NCT01561651|stroke
1102748|NCT01561651|non-CNS systemic embolism
1102749|NCT01561638|Pulsed
1102750|NCT01561638|radiofrequency
1102751|NCT01561638|single-dose
1102752|NCT01561638|shoulder pain
1102753|NCT01561638|Pain lasts more than one month
1102754|NCT01561638|patients referred to the pain clinic from the shoulder clinic
1102755|NCT01561638|Failed all conservative therapies available
1102756|NCT01561625|COPD
1102757|NCT01561625|exercise training
1102758|NCT01561612|Breastfeeding
1102759|NCT01561612|Child Health
1102760|NCT01561612|Obesity
1102761|NCT01561612|Blood Pressure
1102762|NCT01561612|Asthma
1102763|NCT01561612|Cognitive Development
1102764|NCT01561612|Behavior
1102765|NCT01561612|Eczema
1102766|NCT01561612|Lung Function
1102767|NCT01561612|Spirometry
1102768|NCT01561599|hepatocyte growth factor mimetic
1102769|NCT01561599|hepatocyte growth factor(HGF)
1102770|NCT01561599|Delayed Graft Function (DGF)
1102771|NCT01561599|Kidney transplantation
1102772|NCT01561586|Cervical cancer
1102773|NCT01561586|Concurrent chemoradiation
1102774|NCT01561586|Cisplatin
1102775|NCT01561573|Point of Care Ultrasound
1102776|NCT01561573|Emergency Ultrasound
1102777|NCT01561573|Colles Fracture
1102778|NCT01561573|Fracture Reduction
1102779|NCT01561573|Bedside Ultrasound
1102780|NCT01561560|DAILIES TOTAL1
1102781|NCT01561560|contact lenses
1102782|NCT01561560|myopia
1102783|NCT01561547|pain
1102784|NCT01561547|preterm neonate
1102785|NCT01561547|sucrose
1102786|NCT01561547|kangaroo mother care
1102787|NCT01561534|fibula flap
1102788|NCT01561534|oral implants
1102789|NCT01561534|computer-guided
1102790|NCT01561508|diabetes mellitus
1102791|NCT01561508|children
1102792|NCT01561495|scheduled to receive RT either pre- or postoperatively
1102793|NCT01561482|Prostate carcinoma
1102794|NCT01561482|Prostate cancer
1102795|NCT01561482|Prostate Specific Antigen
1102796|NCT01561482|PSA
1102797|NCT01561482|Metformin
1102798|NCT01561482|Simvastatin
1102799|NCT01561482|Radiation therapy
1102800|NCT01561482|Prostatectomy
1102801|NCT01561469|Linezolid
1102802|NCT01561469|Vancomycin
1102803|NCT01561469|Ventilator-Associated Pneumonia
1102804|NCT01561469|Respiratory Tract Infections
1102805|NCT01561456|non-small-cell lung cancer
1102806|NCT01561456|squamous cell carcinoma
1102807|NCT01561456|adenocarcinoma of the lung
1102808|NCT01561456|IGF-1 inhibitor
1102809|NCT01561456|docetaxel
1102810|NCT01561456|AXL1717
1102811|NCT01561456|NSCLC
1102812|NCT01561456|SCC
1102813|NCT01561456|AC
1102814|NCT01561443|Breast cancer,
1102815|NCT01561443|hormone positive,
1102816|NCT01561430|beta-secretase inhibitor
1102817|NCT01561326|cervical cancer
1102818|NCT01561326|follow-up
1102819|NCT01561326|Pap test
1102820|NCT01561326|Medical management
1102821|NCT01561326|Colposcopy
1102822|NCT01561313|On label Humira users
1102823|NCT01561313|Pain
1102824|NCT01561313|Rheumatoid Arthritis,
1102825|NCT01561300|Black tea
1102826|NCT01561300|Flow Mediated Dilation
1102827|NCT01561300|Vascular function
1102828|NCT01561300|India
1102829|NCT01561261|fasciotomy
1102830|NCT01561261|ACS
1102831|NCT01561248|EHEC
1102832|NCT01561248|O104:H4
1102833|NCT01561248|German
1102834|NCT01561248|outbreak
1102835|NCT01561248|polyethylene glycol
1102836|NCT01561248|Bowel lavage
1102837|NCT01561235|Protein
1102838|NCT01561235|Appetite
1102839|NCT01561235|Satiety
1102840|NCT01561235|Energi intake
1102841|NCT01561235|Appetite regulating hormones
1102842|NCT01561235|Dose-response
1102843|NCT01561222|calcitrol
1102844|NCT01561222|Bone mineral density
1102845|NCT01561222|Osteoprotegin
1102846|NCT01561222|Vascular calcification
1102847|NCT01561209|amitryptiline
1102848|NCT01561209|Chronic pain
1102849|NCT01561209|Neck pain
1102850|NCT01561196|arteria cannulation
1102851|NCT01561196|Ultrasound
1102852|NCT01561196|pain
1102853|NCT01561196|complications
1102854|NCT01561183|Vital pulp therapy
1102855|NCT01561183|Pulp cap
1102856|NCT01561183|pulpotomy
1102857|NCT01561183|calcium enriched mixture
1102858|NCT01561183|CEM cement
1102859|NCT01561183|Endodontic
1102860|NCT01561170|Electromagnetic
1102861|NCT01561170|Field therapy
1102862|NCT01561170|Chronically venous ulcer
1102863|NCT01561170|Venous insufficiens
1102864|NCT01561157|porphyria
1102865|NCT01561157|acute intermittent
1102866|NCT01561157|coproporphyria
1102867|NCT01561157|variegate
1102868|NCT01561157|erythropoietic
1102869|NCT01561157|protoporphyria
1102870|NCT01561157|hepatoerythropoietic
1102871|NCT01561157|cutanea tarda
1102872|NCT01561157|AIP
1102873|NCT01561157|HCP
1102874|NCT01561157|VP
1102875|NCT01561157|ADP
1102876|NCT01561157|ALAD
1102877|NCT01561157|PCT
1102878|NCT01561157|HEP
1102879|NCT01561157|CEP
1102880|NCT01561157|EPP
1102881|NCT01561157|XLP
1102882|NCT01561144|Defibrillators, Implantable
1102883|NCT01561144|Cardiac arrhythmias
1102884|NCT01561144|Heart Disease
1102885|NCT01561131|Obesity
1102886|NCT01561131|Protein intake
1102887|NCT01561131|Calcium intake
1102888|NCT01561131|Weight loss
1102889|NCT01561131|Weight maintenance
1102890|NCT01561131|Blood lipid profile
1102891|NCT01561131|Diet induced thermogenesis
1102892|NCT01561118|hemodialysis
1102893|NCT01561118|dialysis efficacy
1102894|NCT01561118|cardiorespiratory capacity
1102895|NCT01561118|exercise capacity
1102896|NCT01561118|children and adolescents
1102897|NCT01561092|Stroke
1102898|NCT01561092|RCT
1102899|NCT01561092|SSRI
1102900|NCT01561092|Outcome
1102901|NCT01561079|Buprenorphine
1102902|NCT01561079|Methadone
1102903|NCT01561079|Fetal neurobehavior
1102904|NCT01561079|Infant neurobehavior
1102905|NCT01561066|Fibrin glue
1102906|NCT01561066|Platelet
1102907|NCT01561066|Autologous derivation
1102908|NCT01561066|Prospective randomized trial
1102909|NCT01561066|Fistulas
1102910|NCT01561053|Alzheimer's disease
1102911|NCT01561053|AB peptide
1102912|NCT01561053|Albumin
1102913|NCT01561053|Intravenous immune globulin
1102914|NCT01561053|IGIV
1102915|NCT01561040|Dry Eye syndrome
1102916|NCT01561040|tear film deficiency
1102917|NCT01561040|Essential Fatty Acid nutritional supplements
1102918|NCT01561040|Omega three supplements
1102919|NCT01560988|Asthma
1102920|NCT01560988|Borage
1102921|NCT01560988|Echium
1102922|NCT01560988|Botanical
1102923|NCT01560949|Pancreatic Cancer
1102924|NCT01560949|Adenocarcinoma of the Pancreas
1102925|NCT01560949|High Risk Resectable
1102926|NCT01560949|Borderline Resectable
1102927|NCT01560949|Chemotherapy
1102928|NCT01560949|Chemoradiation therapy
1102929|NCT01560949|Oxaliplatin
1102930|NCT01560949|Eloxatin
1102931|NCT01560949|Irinotecan
1102932|NCT01560949|CPT-11
1102933|NCT01560949|Camptosar
1102934|NCT01560949|5-FU
1102935|NCT01560949|5-Fluorouracil
1102936|NCT01560949|Adrucil
1102937|NCT01560949|Efudex
1102938|NCT01560949|Gemcitabine
1102939|NCT01560949|Gemcitabine Hydrochloride
1102940|NCT01560949|Gemzar
1102941|NCT01560949|Radiation Therapy
1102942|NCT01560949|XRT
1102943|NCT01560949|RT
1102944|NCT01560949|External Beam Radiation Therapy
1102945|NCT01560936|bacterial contamination
1102946|NCT01560923|hormone refractory prostate cancer
1102947|NCT01560910|with or without GERD symptoms
1102948|NCT01560910|presenting to gastrointestinal clinic of Maharaj Nakorn Chiangmai Hospital
1102949|NCT01560910|November 2009 to November 2010
1102950|NCT01560910|GERD
1102951|NCT01560910|NERD
1102952|NCT01560871|Heart failure
1102953|NCT01560871|inspiratory muscle training
1102954|NCT01560871|physical activity
1102955|NCT01560845|autologous bone marrow stem cells
1102956|NCT01560845|portal hypertension
1102957|NCT01560845|surgery
1102958|NCT01560845|liver cirrhosis
1102959|NCT01560819|ulcerative colitis, gut microbial transplantation
1102960|NCT01560806|hypertension
1102961|NCT01560806|cardiovascular risk factor
1102962|NCT01560806|lifestyle
1102963|NCT01560793|Influenza
1102964|NCT01560793|Vaccines
1102965|NCT01560793|H5N1
1102966|NCT01560780|Coronary Artery Bypass
1102967|NCT01560780|thrombosis
1102968|NCT01560780|prasugrel
1102969|NCT01560767|Pain relief
1102970|NCT01560767|Arthroplasty
1102971|NCT01560767|periarticular knee infiltration
1102972|NCT01560754|Randomized
1102973|NCT01560754|Placebo-controlled
1102974|NCT01560754|Double-blind
1102975|NCT01560754|Multi-center
1102976|NCT01560754|Disease-modifying potential
1102977|NCT01560754|transdermal nicotine
1102978|NCT01560741|Chronic respiratory failure
1102979|NCT01560741|Noninvasive Mechanical Ventilation
1102980|NCT01560741|Home-care
1102981|NCT01560741|Telemedicine
1102982|NCT01560741|COPD
1102983|NCT01560728|Post Traumatic Stress Disorder
1102984|NCT01560728|Major Depressive Disorder
1102985|NCT01560728|Dysthymia
1102986|NCT01560728|Generalized Anxiety Disorder
1102987|NCT01560728|Social Phobia
1102988|NCT01560728|Panic Disorder
1102989|NCT01560715|Retinitis pigmentosa
1102990|NCT01560715|stem cell
1102991|NCT01560715|bone marrow
1102992|NCT01560715|retinal dysprophy
1102993|NCT01560702|autologous blood
1102994|NCT01560702|epinephrine
1102995|NCT01560702|endoscopy
1102996|NCT01560702|ulcer
1102997|NCT01560702|hemostasis
1102998|NCT01560689|bone marrow transplantation
1102999|NCT01560689|obstructive lung disease
1103000|NCT01560689|bronchodilators
1103001|NCT01560689|inhaled steroids
1103002|NCT01560689|late-onset pulmonary complication
1103003|NCT01560676|Internet
1103004|NCT01560676|School based
1103005|NCT01560676|Obesity Prevention Program
1103006|NCT01560676|Adolescents
1103007|NCT01560663|Breast Cancer
1103008|NCT01560663|Neoadjuvant therapy
1103009|NCT01560663|Triple negative
1103010|NCT01560663|predictor of response
1103011|NCT01560663|predictor of resistance
1103012|NCT01560663|Continuous Renal Replacement Therapy
1103013|NCT01560650|CRRT
1103014|NCT01560650|cardiac surgery associated acute kidney injury
1103015|NCT01560650|Intensity
1103016|NCT01560637|PAH
1103017|NCT01560637|PH
1103018|NCT01560637|FREEDOM
1103019|NCT01560637|6 minute walk test
1103020|NCT01560637|treprostinil
1103021|NCT01560637|open label
1103022|NCT01560624|PAH
1103023|NCT01560624|PH
1103024|NCT01560624|Clinical Worsening
1103025|NCT01560624|Freedom
1103026|NCT01560624|Freedom-Ev
1103027|NCT01560624|Treprostinil
1103028|NCT01560624|UT-15C
1103029|NCT01560624|6 Minute walk test
1103030|NCT01560598|GERD
1103031|NCT01560598|reflux esophagitis
1103032|NCT01560598|adipokine
1103033|NCT01560598|especially
1103034|NCT01560598|endoscopically proven
1103035|NCT01560585|Isotretinoin
1103036|NCT01560585|Alzheimer's disease
1103037|NCT01560585|Dementia
1103038|NCT01560585|Retinoid
1103039|NCT01560572|kidney transplantation
1103040|NCT01560572|immunosuppression
1103041|NCT01560572|steroids
1103042|NCT01560572|tacrolimus OD
1103043|NCT01560559|Primary esophageal achalasia
1103044|NCT01560559|endoscopic myotomy
1103045|NCT01560559|high resolution manometry
1103046|NCT01560520|acute ischemic stroke
1103047|NCT01560520|accelerometer
1103048|NCT01560481|metformin glycinate
1103049|NCT01560481|pharmacokinetics
1103050|NCT01560481|pharmacodynamics
1103051|NCT01560468|Hepatitis C Virus Infection
1103052|NCT01560468|Liver Transplantation
1103053|NCT01560455|stent
1103054|NCT01560455|bifurcation
1103055|NCT01560455|coronary
1103056|NCT01560442|Analgesics, opioids
1103057|NCT01560442|Opiate substitution treatment
1103058|NCT01560442|Methadone
1103059|NCT01560442|Buprenorphine
1103060|NCT01560442|Hyperalgesia
1103061|NCT01560442|Pupil
1103062|NCT01560442|Pain
1103063|NCT01560442|Psychophysics
1103064|NCT01560442|previous illicit drug intake, under a substitution program
1103065|NCT01560429|anesthesia and analgesia
1103066|NCT01560429|Epidural Anesthesia
1103067|NCT01560429|administration schedules, drug
1103068|NCT01560416|Metastatic
1103069|NCT01560416|HR positive
1103070|NCT01560416|ER positive
1103071|NCT01560403|Short bowel syndrome
1103072|NCT01560403|Parenteral nutrition
1103073|NCT01560403|PN
1103074|NCT01560403|HPN
1103075|NCT01560403|TPN
1103076|NCT01560403|SBS
1103077|NCT01560390|Sedation
1103078|NCT01560390|ICU
1103079|NCT01560390|Ketamine
1103080|NCT01560390|Confusion
1103081|NCT01560390|Hyperalgesia
1103082|NCT01560377|Laparoscopic low anterior colon resection
1103083|NCT01560377|Laparoscopic left colectomy
1103084|NCT01560377|Colectomy
1103085|NCT01560377|Rectal cancer
1103086|NCT01560377|Colon cancer
1103087|NCT01560377|Crohn's Disease
1103088|NCT01560377|Polyp
1103089|NCT01560377|Procidentia
1103090|NCT01560377|Diverticulitis
1103091|NCT01560364|Renal replacement therapy
1103092|NCT01560364|Hemofilter clotting
1103093|NCT01560364|Clotting risk factor
1103094|NCT01560364|Hemofilter clotting prevention
1103095|NCT01560351|Pathological gambling
1103096|NCT01560351|craving
1103097|NCT01560351|repeated Transcranial Magnetic Stimulation
1103098|NCT01560351|craving cues
1103099|NCT01560338|Pharmacokinetics
1103100|NCT01560338|Midazolam
1103101|NCT01560338|Morphine
1103102|NCT01560338|Cardiac Arrest
1103103|NCT01560338|Hypothermia
1103104|NCT01560325|Solid Tumor, Tubulin inhibitor
1103105|NCT01560312|Renal denervation
1103106|NCT01560312|Resistant hypertension
1103107|NCT01560312|Spironolactone
1103108|NCT01560312|Long-term Outcome
1103109|NCT01560299|hyperthyroidism
1103110|NCT01560299|radio-iodine
1103111|NCT01560299|I-131
1103112|NCT01560299|methimazole
1103113|NCT01560299|graves disease
1103114|NCT01560286|PKU
1103115|NCT01560286|Injections
1103116|NCT01560286|PEG-PAL
1103117|NCT01560286|PAL
1103118|NCT01560247|Stroke
1103119|NCT01560247|Ischemic Stroke
1103120|NCT01560247|Revascularization
1103121|NCT01560247|Mechanical thrombectomy
1103122|NCT01560247|Neurothrombectomy
1103123|NCT01560234|Safety
1103124|NCT01560234|tolerability
1103125|NCT01560234|healthy
1103126|NCT01560234|pharmacokinetic
1103127|NCT01560234|pharmacodynamic
1103128|NCT01560234|inhaled
1103129|NCT01560208|infectious keratitis
1103130|NCT01560208|infective keratitis
1103131|NCT01560208|prospective multicentre study
1103132|NCT01560208|Asia
1103133|NCT01560195|neutropenia
1103134|NCT01560195|febrile neutropenia
1103135|NCT01560195|chemotherapy
1103136|NCT01560182|Lentiviral vector
1103137|NCT01560182|Metachromatic Leukodystrophy
1103138|NCT01560182|Gene Therapy
1103139|NCT01560169|Celiac Disease
1103140|NCT01560169|Coeliac Disease
1103141|NCT01560169|Celiac Sprue
1103142|NCT01560169|Keilakia Disease
1103143|NCT01560117|AGMT
1103144|NCT01560117|NHL
1103145|NCT01560104|Randomized
1103146|NCT01560104|metastatic
1103147|NCT01560104|ABT-888
1103148|NCT01560104|paclitaxel
1103149|NCT01560104|non-small cell lung cancer
1103150|NCT01560104|PARP
1103151|NCT01560104|veliparib
1103152|NCT01560104|progression free survival
1103153|NCT01560104|carboplatin
1103154|NCT01560091|clearance rate
1103155|NCT01560078|Tuberculosis
1103156|NCT01560078|Pleural effusion
1103157|NCT01560078|Category 3
1103158|NCT01560052|end stage kidney disease
1103159|NCT01560052|IgA nephropathy
1103160|NCT01560039|Neuropathic pain
1103161|NCT01560039|neurostimulation
1103162|NCT01560026|ovarian preservation
1103163|NCT01560013|Alcohol
1103164|NCT01560013|naltrexone
1103165|NCT01560013|cue reactivity
1103166|NCT01560013|PET
1103167|NCT01560000|The focus of this study is to determine satiety
1103168|NCT01559987|plaque removal methods
1103169|NCT01559987|oral hygiene devices
1103170|NCT01559974|Peripheral arterial disease
1103171|NCT01559974|PAOD
1103172|NCT01559974|Vitamin D
1103173|NCT01559974|Walking impairment
1103174|NCT01559961|bladder
1103175|NCT01559961|cystitis
1103176|NCT01559961|frequency
1103177|NCT01559961|nocturia
1103178|NCT01559961|pain
1103179|NCT01559961|urgency
1103180|NCT01559948|Low back pain
1103181|NCT01559948|Sacroiliac joint pain
1103182|NCT01559948|Lumbopelvic stabilization program
1103183|NCT01559948|Pelvic compression belt
1103184|NCT01559948|Deep abdominal muscles
1103185|NCT01559935|Multiple Myeloma
1103186|NCT01559922|Acne
1103187|NCT01559909|Lower limb loss
1103188|NCT01559909|Leg amputation
1103189|NCT01559909|walking study
1103190|NCT01559909|socket technology
1103191|NCT01559896|egg protein hydrolysate
1103192|NCT01559883|cancer
1103193|NCT01559883|thrombosis
1103194|NCT01559883|pulmonary embolism
1103195|NCT01559883|anticoagulation
1103196|NCT01559883|low molecular weight heparin
1103197|NCT01559870|cardiac surgery
1103198|NCT01559870|cytokine
1103199|NCT01559870|clinical scoring system
1103200|NCT01559870|risk factor
1103201|NCT01559857|Depression
1103202|NCT01559857|Insulin resistance
1103203|NCT01559857|Mood disorder
1103204|NCT01559844|Hepatitis
1103205|NCT01559844|Chronic
1103206|NCT01559844|hepatocellular carcinoma
1103207|NCT01559844|HCC
1103208|NCT01559844|transplant
1103209|NCT01559831|Japanese Encephalitis
1103210|NCT01559831|IXIARO
1103211|NCT01559831|Japanese Encephalitis Vaccine
1103212|NCT01559805|HIV
1103213|NCT01559805|Viral Load
1103214|NCT01559805|Risk
1103215|NCT01559805|Patient Compliance
1103216|NCT01559805|Homosexuality, Male
1103217|NCT01559805|Anti-Retroviral Agents
1103218|NCT01559779|Obesity
1103219|NCT01559779|Roux-en-Y gastric bypass
1103220|NCT01559779|Incretin hormones
1103221|NCT01559779|Beta cell function
1103222|NCT01559766|Vitamin A
1103223|NCT01559766|Dietary requirement
1103224|NCT01559766|Dietary records
1103225|NCT01559766|Deuterated retinol dilution technique
1103226|NCT01559766|Chinese children
1103227|NCT01559766|Dietary intake of vitamin A
1103228|NCT01559766|Vitamin A liver reserves
1103229|NCT01559753|Antibiotic
1103230|NCT01559753|treatment
1103231|NCT01559753|ventilator associated pneumonia
1103232|NCT01559753|duration
1103233|NCT01559740|regional anesthesia
1103234|NCT01559740|children
1103235|NCT01559740|postoperative pain relief
1103236|NCT01559727|heart failure
1103237|NCT01559727|diuresis
1103238|NCT01559727|prednisone
1103239|NCT01559714|Troponin
1103240|NCT01559714|Exercise
1103241|NCT01559714|MRI
1103242|NCT01559701|Safety
1103243|NCT01559701|PF-00345439
1103244|NCT01559701|Remoxy
1103245|NCT01559701|PTI-821
1103246|NCT01559675|Corticosteroids
1103247|NCT01559675|perioperative
1103248|NCT01559675|colorectal surgery
1103249|NCT01559662|chewing gum
1103250|NCT01559662|ileus
1103251|NCT01559662|gastrointestinal function
1103252|NCT01559662|colorectal surgery
1103253|NCT01559662|abdominal surgery
1103254|NCT01559649|Stroke
1103255|NCT01559649|Deglutition
1103256|NCT01559649|Deglutition Disorders
1103257|NCT01559649|Nurse Screening
1103258|NCT01559636|seroconversion
1103259|NCT01559636|oral polio vaccine
1103260|NCT01559636|OPV
1103261|NCT01559636|poliomyelitis
1103262|NCT01559636|diarrhea
1103263|NCT01559636|seroimmunity
1103264|NCT01559610|cardiac surgery
1103265|NCT01559610|orientation
1103266|NCT01559610|nursing
1103267|NCT01559597|controlled temperature chain
1103268|NCT01559597|outside the cold chain
1103269|NCT01559597|vaccination
1103270|NCT01559597|prevention of mother to child transmission
1103271|NCT01559584|Alopecia
1103272|NCT01559584|Areata
1103273|NCT01559584|Phototherapy
1103274|NCT01559584|Phototoxic
1103275|NCT01559584|Ultraviolet A
1103276|NCT01559584|Randomized controlled trial
1103277|NCT01559584|Interferon gamma
1103278|NCT01559584|Transforming growth factor beta-1
1103279|NCT01559584|Insulin like growth factor-1
1103280|NCT01559571|Retinopathy of Prematurity
1103281|NCT01559545|Clostridium difficile associated diarrhea
1103282|NCT01559545|Metronidazole
1103283|NCT01559545|CDAD
1103284|NCT01559532|Deep vein thrombosis
1103285|NCT01559532|Thromboembolism
1103286|NCT01559532|Tourniquet
1103287|NCT01559532|Knee prosthesis.
1103288|NCT01559519|TIPS
1103289|NCT01559519|albumin
1103290|NCT01559519|hepatic encephalopathy
1103291|NCT01559519|hyponatremia
1103292|NCT01559519|hypovolemia
1103293|NCT01559519|cirrhosis
1103294|NCT01559506|CFU
1103295|NCT01559506|surgery site
1103296|NCT01559493|atherosclerotic lesion assessment
1103297|NCT01559480|Endometriosis
1103298|NCT01559480|Desogestrel
1103299|NCT01559480|Placebo
1103300|NCT01559467|Myocardial infarction
1103301|NCT01559467|Randomized Controlled Trial
1103302|NCT01559467|Magnetic Resonance Imaging
1103303|NCT01559467|Coronary Angiography
1103304|NCT01559467|Tomography, X-Ray Computed
1103305|NCT01559467|Mortality
1103306|NCT01559467|Complications
1103307|NCT01559467|Quality of Life
1103308|NCT01559467|Cost-Benefit Analysis
1103309|NCT01559454|chronic pain
1103310|NCT01559454|opioid dependence
1103311|NCT01559454|methadone
1103312|NCT01559454|buprenorphine
1103313|NCT01559454|substance use disorder
1103314|NCT01559441|beetroot juice
1103315|NCT01559441|nitrate
1103316|NCT01559441|vascular activity
1103317|NCT01559441|postprandial state
1103318|NCT01559428|Plant sterols
1103319|NCT01559428|Plant stanols
1103320|NCT01559428|Oxyphytosterols
1103321|NCT01559428|Cardiovascular Disease
1103322|NCT01559415|Adipocytes
1103323|NCT01559389|Urge Urinary Incontinence
1103324|NCT01559389|Vesicare
1103325|NCT01559389|Urinary Incontinence
1103326|NCT01559389|Sexual function
1103327|NCT01559350|OPCAB
1103328|NCT01559337|defect
1103329|NCT01559337|dorsal branch of the proper digital nerve
1103330|NCT01559337|proper digital nerve
1103331|NCT01559337|nerve transfer
1103332|NCT01559337|finger sensory reconstruction
1103333|NCT01559311|Bradycardia
1103334|NCT01559298|Transcatheter aortic valve implantation
1103335|NCT01559298|Antithrombotic treatment
1103336|NCT01559298|Clopidogrel
1103337|NCT01559298|Aspirin
1103338|NCT01559298|Myocardial Infarction
1103339|NCT01559298|Ischemic stroke
1103340|NCT01559298|Major bleeding
1103341|NCT01559272|Schizophrenia
1103342|NCT01559272|Paliperidone palmitate
1103343|NCT01559272|R092670
1103344|NCT01559272|Paliperidone
1103345|NCT01559272|3-month formulation
1103346|NCT01559272|Pharmacokinetics
1103347|NCT01559259|ibuprofen
1103348|NCT01559259|acetaminophen
1103349|NCT01559259|pain
1103350|NCT01559259|molar extraction
1103351|NCT01559246|Cardiac Arrhythmia Monitoring
1103352|NCT01559246|Holter Monitoring
1103353|NCT01559246|Continuous ECG monitoring
1103354|NCT01559246|Event monitoring
1103355|NCT01559246|Observational
1103356|NCT01559207|nucleosome
1103357|NCT01559207|plasma nucleosome concentrations
1103358|NCT01559207|free DNA
1103359|NCT01559207|plasma free DNA concentrations
1103360|NCT01559181|Offspring of mothers with type 1 diabetes
1103361|NCT01559181|Pregnancy and programing
1103362|NCT01559181|Intrauterine hyperglycaemia
1103363|NCT01559181|Study focuses on offspring of mothers with type 1 diabetes
1103364|NCT01559155|proteasomes
1103365|NCT01559155|proteasome concentration
1103366|NCT01559155|disease activity
1103367|NCT01559155|proteolytic activity
1103368|NCT01559155|autoantibodies
1103369|NCT01559155|proteasome autoantibody
1103370|NCT01559142|Crohn Disease
1103371|NCT01559142|infliximab
1103372|NCT01559142|azathioprine
1103373|NCT01559103|Rheumatoid Arthritis
1103374|NCT01559103|Phase I
1103375|NCT01559103|Biologic
1103376|NCT01559090|Japan
1103377|NCT01559090|Phase2
1103378|NCT01559090|Safety
1103379|NCT01559090|Tolerability
1103380|NCT01559090|Systemic Lupus Erythematosus
1103381|NCT01559090|SLE, MEDI-546
1103382|NCT01559077|ATTR
1103383|NCT01559051|COPD
1103384|NCT01559051|Pulmonary
1103385|NCT01559051|Lungs
1103386|NCT01559038|Assessing Effectiveness in Psoriatic Arthritis
1103387|NCT01559025|Type 1 diabetes
1103388|NCT01559025|Vildagliptin
1103389|NCT01559025|Galvus
1103390|NCT01559012|Hyperemesis Gravidarum
1103391|NCT01559012|treatment
1103392|NCT01559012|transdermal clonidine
1103393|NCT01558986|Antibiotic prophylaxis
1103394|NCT01558986|surgical site infection
1103395|NCT01558986|modified radical mastectomy
1103396|NCT01558986|Prevention of surgical site infection (SSI) in patients undergoing MRM for breast cancer
1103397|NCT01558960|Retinoblastoma
1103398|NCT01558947|gastric cancer
1103399|NCT01558947|Peri-operative chemotherapy
1103400|NCT01558934|lofexidine
1103401|NCT01558934|methadone
1103402|NCT01558934|interaction
1103403|NCT01558934|pharmacodynamic
1103404|NCT01558934|ECG
1103405|NCT01558934|QTc
1103406|NCT01558921|rectal cancer
1103407|NCT01558921|radiotherapy
1103408|NCT01558921|chemotherapy
1103409|NCT01558921|5x5
1103410|NCT01558921|capecitbine
1103411|NCT01558921|oxaliplatin
1103412|NCT01558921|CAPOX
1103413|NCT01558921|FOLFOX
1103414|NCT01558921|folinic acid
1103415|NCT01558921|fluorouracil
1103416|NCT01558908|critical limb ischemia
1103417|NCT01558895|Infrared ray heat treatment
1103418|NCT01558895|liver cirrhosis
1103419|NCT01558895|refractory ascites
1103420|NCT01558882|Essure
1103421|NCT01558882|Change in uterine cytokines
1103422|NCT01558882|Change in uterine natural killer cells
1103423|NCT01558882|cytokine
1103424|NCT01558882|natural killer cell
1103425|NCT01558856|refractory overactive bladder
1103426|NCT01558856|neuromodulation
1103427|NCT01558856|sacral nerves
1103428|NCT01558843|Sodium Management
1103429|NCT01558843|Neurointensive Care
1103430|NCT01558843|Hyponatremia
1103431|NCT01558830|amiodarone
1103432|NCT01558830|ranolazine
1103433|NCT01558830|safety
1103434|NCT01558830|arrhythmia
1103435|NCT01558817|CPR
1103436|NCT01558817|Palliative
1103437|NCT01558817|Outcome
1103438|NCT01558804|Streptococcus pyogenes
1103439|NCT01558804|Streptococcus
1103440|NCT01558791|PTSD
1103441|NCT01558791|patient education handout
1103442|NCT01558765|Rehabilitation
1103443|NCT01558765|Integrated rehabilitation programme
1103444|NCT01558765|Exercise training
1103445|NCT01558765|Psycho-educational care
1103446|NCT01558752|Total hip replacement
1103447|NCT01558752|Bone mineral density (BMD)
1103448|NCT01558739|Ruxolitinib
1103449|NCT01558739|INC424
1103450|NCT01558739|myelofibrosis
1103451|NCT01558739|PMF
1103452|NCT01558739|post polycythemia myelofibrosis
1103453|NCT01558739|PPV MF
1103454|NCT01558739|post-essential thrombocythemia myelofibrosis
1103455|NCT01558739|PET-MF
1103456|NCT01558739|Primary Myelofibrosis
1103457|NCT01558739|Polycythemia
1103458|NCT01558739|Thrombocythemia
1103459|NCT01558739|Essential Thrombocytosis
1103460|NCT01558739|myeloproliferative Disorders
1103461|NCT01558739|Bone Marrow Diseases
1103462|NCT01558739|Haematologic Diseases
1103463|NCT01558739|Blood Coagulation Disorders
1103464|NCT01558739|Blood Platelet Disorders
1103465|NCT01558739|Haemorrhagic Disorders
1103466|NCT01558726|Case Management
1103467|NCT01558726|Crack abuse/dependents
1103468|NCT01558726|Evaluation
1103469|NCT01558726|Inpatient
1103470|NCT01558726|ASI
1103471|NCT01558726|Treatment retention
1103472|NCT01558726|Abstinence
1103473|NCT01558713|parturient
1103474|NCT01558700|osteoarthritis
1103475|NCT01558700|pain
1103476|NCT01558700|brain
1103477|NCT01558700|gray matter
1103478|NCT01558687|Oncology
1103479|NCT01558687|newly diagnosed inoperable glioblastoma
1103480|NCT01558687|temolozomide
1103481|NCT01558687|radiotherapy
1103482|NCT01558687|dynamic MRI
1103483|NCT01558687|Positron emission tomography
1103484|NCT01558687|[18]FET tracer
1103485|NCT01558687|cilengitide
1103486|NCT01558687|World Health Organization [WHO] Grade IV
1103487|NCT01558661|axitinib (AG-013736)
1103488|NCT01558661|recurrent
1103489|NCT01558661|metastatic
1103490|NCT01558661|12-004
1103491|NCT01558648|Minimally Invasive Esophagectomy
1103492|NCT01558648|Open Esophagectomy
1103493|NCT01558648|Quality of Life
1103494|NCT01558648|12-003
1103495|NCT01558635|Atrial Fibrillation
1103496|NCT01558635|Surgical ablation
1103497|NCT01558635|Maze procedure
1103498|NCT01558635|AF
1103499|NCT01558622|postoperative analgesia
1103500|NCT01558622|dexketoprofen trometamol
1103501|NCT01558622|tramadol hydrochloride
1103502|NCT01558622|pethidine
1103503|NCT01558622|laparoscopic Nissen fundoplication
1103504|NCT01555697|Schizophrenia
1103505|NCT01555697|prepulse inhibition
1103506|NCT01555697|neurocognition
1103507|NCT01555697|working memory
1103508|NCT01555697|memantine
1103509|NCT01555697|MATRICS Consensus Cognitive Battery
1103510|NCT01555684|MS
1103511|NCT01555684|CCSVI
1103512|NCT01555671|labor,
1103513|NCT01555671|meperidine,
1103514|NCT01555671|active phase,
1103515|NCT01555671|duration of labor
1103516|NCT01555658|Long Lesions
1103517|NCT01555658|Stent Implantation
1103518|NCT01555645|Breast cancer
1103519|NCT01555645|Stress management
1103520|NCT01555645|Stepped care
1103521|NCT01555645|Randomized
1103526|NCT01555606|Psoriasis
1103527|NCT01555606|Patient-reported outcome
1103528|NCT01555606|Quality of Life
1103529|NCT01555593|COPD
1103530|NCT01555593|FeNO
1103531|NCT01555593|Bronchial inflammation
1103532|NCT01555593|Small airways
1103533|NCT01555593|Decubitus
1103534|NCT01555580|myasthenia gravis
1103535|NCT01555580|autoimmune
1103536|NCT01555580|GM-CSF
1103537|NCT01558583|Colon
1103538|NCT01558583|Prostate
1103539|NCT01558583|Cancer
1103540|NCT01558544|Ovarian tissue cryopreservation
1103541|NCT01558544|Ovarian tissue transplantation
1103542|NCT01558544|Fertility preservation
1103543|NCT01558544|Risk of premature ovarian failure
1103544|NCT01558531|peripheral arterial disease
1103545|NCT01558531|drug-eluting balloon
1103546|NCT01558531|restenosis
1103547|NCT01558518|Handheld echocardiography
1103548|NCT01558518|V-scan
1103549|NCT01558518|Handheld ultrasound
1103550|NCT01558518|Portable ultrasound
1103551|NCT01558505|critical limb ischemia
1103552|NCT01558505|drug-eluting balloon
1103553|NCT01558505|restenosis
1103554|NCT01558492|Metastatic Castrate Resistant Prostate Cancer
1103555|NCT01558492|CRPC
1103556|NCT01558479|Parkinson's Disease
1103557|NCT01558479|Genetics
1103558|NCT01558479|Family Research
1103559|NCT01558479|Hereditary Neurodegenerative Diseases
1103560|NCT01558466|newborn
1103561|NCT01558466|INO
1103562|NCT01558466|Sildenafil
1103563|NCT01558466|PPHN
1103564|NCT01558440|Nutrition rehabilitation
1103565|NCT01558440|severe malnutrition
1103566|NCT01558440|infant formula
1103567|NCT01558440|F-100
1103568|NCT01558414|Cholecystectomy
1103569|NCT01558414|Minimally invasive surgery
1103570|NCT01558414|Laparoscopic surgery
1103571|NCT01558414|Single incision surgery
1103572|NCT01558401|physical activity
1103573|NCT01558401|elderly
1103574|NCT01558401|women
1103575|NCT01558401|efficiency
1103576|NCT01558362|myocardial perfusion imaging
1103577|NCT01558362|single photon emission tomography
1103578|NCT01558362|Coronary artery disease
1103579|NCT01558362|gamma camera imaging
1103580|NCT01558362|Phase 1 clinical trial
1103581|NCT01558362|cyclotron
1103582|NCT01558349|Epispot
1103583|NCT01558349|CellSearch
1103584|NCT01558349|Circulating melanoma cells
1103585|NCT01558349|circulating cells
1103586|NCT01558336|Schistosoma haematobium
1103587|NCT01558336|schoolchildren
1103588|NCT01558336|Central Sudan
1103589|NCT01558336|Praziquantel
1103590|NCT01558323|LCQ908, Renal Impairment, Pharmacokinetics
1103591|NCT01558284|Irritable bowel syndrome
1103592|NCT01558284|Neu-P11
1103593|NCT01558284|Melatonin
1103594|NCT01558284|D-IBS
1103595|NCT01558271|GLP-1
1103596|NCT01558245|ischemic stroke; in-stent restenosis; tissue kallikrein;
1103597|NCT01558245|the middle cerebral artery; atherosclerotic stenosis
1103598|NCT01558232|Stroke
1103599|NCT01558232|Tibion
1103600|NCT01558232|Bionics
1103601|NCT01558232|Rehab
1103602|NCT01558232|Therapy
1103603|NCT01558232|Robotics
1103604|NCT01558232|Intention
1103605|NCT01558219|Metastatic prostate cancer
1103606|NCT01558206|PTE
1103607|NCT01558206|Emergency bedside ultrasonography
1103608|NCT01558206|pulmonary CT Angiography
1103609|NCT01558206|Pulmonary Wedge infarction
1103610|NCT01558206|Pulmonary Thromboembolism
1103611|NCT01558193|Aggression DHA
1103612|NCT01558193|Docosahexaenoic acid
1103613|NCT01558193|Impulsivity
1103614|NCT01558193|Minerals
1103615|NCT01558193|Vitamins
1103616|NCT01558167|Dose limiting toxicity of Lenalidomide
1103617|NCT01558167|Chronic lymphocytic leukemia
1103618|NCT01558154|depression
1103619|NCT01558154|Chinese herb
1103620|NCT01558154|acupuncture
1103621|NCT01558154|Psychotherapy
1103622|NCT01558154|Transcranial magnetic stimulation
1103623|NCT01558141|IVF stimulation.
1103624|NCT01558141|Poor responders.
1103625|NCT01558141|IVF patients with poor response to stimulation
1103626|NCT01558115|Columbia University
1103627|NCT01558115|Primary hyperparathyroidism
1103628|NCT01558115|Low bone density
1103629|NCT01558115|Denosumab
1103630|NCT01558115|Prolia
1103631|NCT01558102|brain aneurysm PED Pipeline
1103632|NCT01558076|Sickle cell anemia
1103633|NCT01558076|exercise testing
1103634|NCT01558076|cardiopulmonary disease
1103635|NCT01558063|Ketamine
1103636|NCT01558063|Major Depressive Disorder
1103637|NCT01558063|Treatment
1103638|NCT01558063|Depression
1103639|NCT01558037|transplant
1103640|NCT01558037|solid organ transplant
1103641|NCT01558037|kidney transplant
1103642|NCT01558037|liver transplant
1103643|NCT01558037|pancreas transplant
1103644|NCT01558037|heart transplant
1103645|NCT01558037|CMV
1103646|NCT01558037|Cytomegalovirus
1103647|NCT01558024|compression stockings
1103648|NCT01558024|physiopathology
1103649|NCT01558011|gastric adenocarcinoma
1103650|NCT01558011|Capecitabine and oxaliplatin (XELOX)
1103651|NCT01558011|Docetaxel and capecitabine (TX)
1103652|NCT01558011|Using genetic polymorphisms
1103653|NCT01558011|drug metabolism and immunohistochemical stain
1103654|NCT01558011|predict the efficacy
1103655|NCT01557998|Test and linkage to care
1103656|NCT01557998|Injecting drug user (IDU)
1103657|NCT01557998|Prevention with positives
1103658|NCT01557998|ART adherence
1103659|NCT01557998|point of care CD4 counts
1103660|NCT01557998|Peer case management
1103661|NCT01557998|Conditional cash transfer
1103662|NCT01557985|children
1103663|NCT01557985|regional anesthesia
1103664|NCT01557985|postoperative pain management
1103665|NCT01557985|local anesthetic solution
1103666|NCT01557985|toxicity
1103667|NCT01557933|ECT
1103668|NCT01557933|Bipolar Disorder
1103669|NCT01557920|apnea
1103670|NCT01557920|airway collapsibility
1103671|NCT01557920|healthy
1103672|NCT01557920|hypercapnia
1103673|NCT01557920|general anesthesia
1103674|NCT01557920|breathing-swallow coordination
1103675|NCT01557920|aspiration
1103676|NCT01557907|Diabetes
1103677|NCT01557907|Diabetes Mellitus
1103678|NCT01557907|Type 1 diabetes
1103679|NCT01557907|Insulin Pump users
1103680|NCT01557907|Intradermal insulin
1103681|NCT01557894|Social anxiety disorders
1103682|NCT01557894|Social phobia
1103683|NCT01557894|Anxiety sensitivity
1103684|NCT01557894|Irrational thinking
1103685|NCT01557894|Guided self-help
1103686|NCT01557894|Internet-delivered treatment
1103687|NCT01557842|Ischemic
1103688|NCT01557842|Ventricular Tachycardia
1103689|NCT01557842|Implantable Cardioverter Defibrillators
1103690|NCT01557842|Antiarrhythmic Drug Therapy
1103691|NCT01557842|Ablation
1103692|NCT01557842|Electrophysiology
1103693|NCT01557829|spondylolisthesis
1103694|NCT01557829|disc degeneration
1103695|NCT01557829|lumbar interbody fusion
1103696|NCT01557829|randomized controlled trial
1103697|NCT01557829|ceramic interbody spacer
1103698|NCT01557816|osteoarthritis
1103699|NCT01557816|knee
1103700|NCT01557816|Naproxen
1103701|NCT01557803|Immune reconstitution inflammatory syndrome
1103702|NCT01557803|Biomarkers
1103703|NCT01557803|HIV
1103704|NCT01557803|ART
1103705|NCT01557803|predictive factors
1103706|NCT01557803|epidemiological pattern
1103707|NCT01557803|Gabon
1103708|NCT01557790|Adult male
1103709|NCT01557790|18 years or older
1103710|NCT01557790|clinical diagnosis
1103711|NCT01557751|Total knee arthroplasty
1103712|NCT01557751|Total knee replacement
1103713|NCT01557751|Genetics of pain
1103714|NCT01557738|Exercise
1103715|NCT01557738|Blood Flow
1103716|NCT01557738|Nitric Oxide
1103717|NCT01557738|Aging
1103718|NCT01557738|Antioxidant
1103719|NCT01557738|Flavanol
1103720|NCT01557738|Young (18-30 yrs)
1103721|NCT01557738|Aging (60 - 80 yrs)
1103722|NCT01557725|Knee Replacement, Total
1103723|NCT01557725|Hip Replacement, Total
1103724|NCT01557725|Thromboembolism, Venous
1103725|NCT01557725|prophylaxis
1103726|NCT01557725|Enhanced recovery
1103727|NCT01557686|Cancer Related fatigue
1103728|NCT01557686|Quality of Life
1103729|NCT01557686|Psychosocial Intervention
1103730|NCT01557686|Rehabilitation
1103731|NCT01557686|Physical Fitness
1103732|NCT01557686|Physical Activity
1103733|NCT01557686|Exercise Therapy
1103734|NCT01557686|Exercise
1103735|NCT01557686|Hematologic
1103736|NCT01557686|Hematological
1103737|NCT01557686|Leukemia, Myeloid, Acute
1103738|NCT01557686|Acute Myeloid Leukemia
1103739|NCT01557686|Acute Lymphoblastic Leukemia
1103740|NCT01557686|Acute Leukemia
1103741|NCT01557673|Nasogastric
1103742|NCT01557673|Small bowel water
1103743|NCT01557673|Diarrhoea
1103744|NCT01557673|Mesenteric blood flow
1103745|NCT01557673|Enteral feeding
1103746|NCT01555567|ACL
1103747|NCT01555567|muscle
1103748|NCT01555567|quadriceps
1103749|NCT01555567|strength
1103750|NCT01555554|Post-traumatic stress disorder
1103751|NCT01555554|Propranolol
1103752|NCT01555554|surgery
1103753|NCT01555554|anesthesia
1103754|NCT01555541|relapsed
1103755|NCT01555541|refractory
1103756|NCT01555541|DLBCL
1103757|NCT01555541|lymphoma
1103758|NCT01555541|B-cell
1103759|NCT01555541|diffuse
1103760|NCT01555528|Growth disorders
1103761|NCT01555528|Saizen
1103762|NCT01555528|Easypod
1103763|NCT01555528|Growth hormone
1103764|NCT01555528|Pediatric subject
1103765|NCT01555489|Pancreatic Neoplasms
1103766|NCT01555489|Pancreatic Cancer cells
1103767|NCT01555489|Digestive System Neoplasms
1103768|NCT01555489|Neoplasms by Site
1103769|NCT01555489|Neoplasms
1103770|NCT01555489|Endocrine Gland Neoplasms
1103771|NCT01555489|Digestive System Diseases
1103772|NCT01555489|Pancreatic Diseases
1103773|NCT01555489|Endocrine System Diseases
1103774|NCT01555489|Ascorbic Acid
1103775|NCT01555489|Gemcitabine Vitamins
1103776|NCT01555489|Vitamin C
1103777|NCT01555489|Antioxidants
1103778|NCT01555489|Molecular Mechanisms of Pharmacological Action
1103779|NCT01555489|Pharmacologic Actions
1103780|NCT01555489|Protective Agents
1103781|NCT01555489|Physiological Effects of Drugs
1103782|NCT01555489|Micronutrients
1103783|NCT01555489|Growth Substances
1103784|NCT01555489|Erlotinib
1103785|NCT01555489|Integrative Medicine
1103786|NCT01555489|Alternative Medicine
1103787|NCT01555489|Complementary Medicine
1103788|NCT01557621|Immunization reminder/recall
1103789|NCT01557621|Reminder/Recall systems
1103790|NCT01557621|Population based Recall
1103791|NCT01557621|Practice based Recall
1103792|NCT01557608|cancer
1103793|NCT01557608|chemotherapy
1103794|NCT01557608|photon stimulation
1103795|NCT01557608|neuropathy
1103796|NCT01557608|pain
1103797|NCT01557582|IPAH
1103798|NCT01557582|HPAH
1103799|NCT01557582|APAH CTD
1103800|NCT01557582|APAH HIV
1103801|NCT01557582|APAH PoPH
1103802|NCT01557582|APAH Drugs/Toxins
1103803|NCT01557582|APAH CHD repaired
1103804|NCT01557582|APAH CHD unrepaired
1103805|NCT01557569|methamphetamine
1103806|NCT01557569|addiction
1103807|NCT01557569|relapse
1103808|NCT01557569|atomoxetine
1103809|NCT01557556|CRH Antagonist
1103810|NCT01557556|Nicotine
1103811|NCT01557556|Nicotine Dependence
1103812|NCT01557556|Smoking
1103813|NCT01557556|Stress
1103814|NCT01557543|Coronary Artery Bypass Grafting
1103815|NCT01557543|Coronary Artery Disease
1103816|NCT01557543|Transmyocardial Revascularization
1103817|NCT01557543|Bone Marrow Stromal Cells
1103818|NCT01557517|cGVHD
1103819|NCT01557517|Oral cGVHD
1103820|NCT01557517|Topical
1103821|NCT01557517|Oral Rinse
1103822|NCT01557517|Clobetasol
1103823|NCT01557517|Oral Graft-Versus-Host Disease
1103824|NCT01557517|GVHD
1103825|NCT01557491|Alopecia
1103826|NCT01557491|Coronal Incision
1103827|NCT01557491|Scar Quality
1103828|NCT01557478|breast cancer
1103829|NCT01557478|melatonin
1103830|NCT01557478|adjuvant therapy
1103831|NCT01557478|quality of life
1103832|NCT01557478|pain
1103833|NCT01557478|sleep
1103834|NCT01557478|survival
1103835|NCT01557478|adverse events
1103836|NCT01557452|JIA
1103837|NCT01557426|skin
1103838|NCT01557426|soft tissue
1103839|NCT01557426|infection
1103840|NCT01557426|cellulitis
1103841|NCT01557426|abscess
1103842|NCT01557413|Humerus
1103843|NCT01557413|fracture
1103844|NCT01557413|nail
1103845|NCT01557413|plate
1103846|NCT01557413|tuberosity
1103847|NCT01557400|Duchenne muscular dystrophy
1103848|NCT01557400|Becker muscular dystrophy
1103849|NCT01557400|Nonsense mutation
1103850|NCT01557400|Premature stop codon
1103851|NCT01557400|DMD
1103852|NCT01557400|BMD
1103853|NCT01557400|nmDBMD
1103854|NCT01557400|DBMD
1103855|NCT01557400|Ataluren
1103856|NCT01557400|PTC124
1103857|NCT01557387|Pseudopolyp
1103858|NCT01557387|Inflammatory bowel disease
1103859|NCT01557374|Rheumatoid arthritis
1103860|NCT01557374|Disease activity
1103861|NCT01557374|Remission
1103862|NCT01557374|Lowest Effective DOse
1103863|NCT01557374|Abatacept Tocilizumab
1103864|NCT01557374|ACR-EULAR 2010
1103865|NCT01557361|renal replacement therapy
1103866|NCT01557361|dialysis
1103867|NCT01557361|acute kidney injury
1103868|NCT01557361|hemodialysis
1103869|NCT01557361|critical illness
1103870|NCT01557335|To evaluate adenosine diphosphate (ADP)-induced platelet aggregation
1103871|NCT01557309|traumatic rotator cuff tear
1103872|NCT01557309|arthroscopic rotator cuff repair
1103873|NCT01557309|age
1103874|NCT01557309|early rotator cuff repair
1103875|NCT01557296|Diet
1103876|NCT01557296|Dietary treatment
1103877|NCT01557296|Particle size
1103878|NCT01557296|Gastroparesis
1103879|NCT01557296|Diabetes Mellitus
1103880|NCT01557257|single- and multiple-dose pharmacokinetics
1103881|NCT01557257|ALO-02
1103882|NCT01557257|OxyContin
1103888|NCT01557231|OA
1103889|NCT01557231|osteoarthritis
1103890|NCT01557231|pain
1103891|NCT01557231|variability
1103892|NCT01557231|activity
1103893|NCT01557231|treatment
1103894|NCT01557218|Dietary variety
1103895|NCT01557218|Vegetable intake
1103896|NCT01557218|Fruit intake
1103897|NCT01557205|optical coherence tomography
1103898|NCT01557205|cell imaging
1103899|NCT01557192|Depression
1103900|NCT01557192|Bipolar Depression
1103901|NCT01557192|LFMS
1103902|NCT01557192|Electromagnetic Stimulation
1103903|NCT01557166|OSA
1103904|NCT01557153|Late-life Unremitted Depression
1103905|NCT01557140|Chagas cardiomyopathy,
1103906|NCT01557140|Renin-angiotensin system,
1103907|NCT01557140|Beta-blockers,
1103908|NCT01557140|Enalapril,
1103909|NCT01557140|Carvedilol,
1103910|NCT01557140|Renin-angiotensin system inhibitors,
1103911|NCT01557140|Brain natriuretic peptide level,
1103912|NCT01557140|Left ventricular ejection fraction,
1103913|NCT01557140|Chemokines
1103914|NCT01557127|Renal cell carcinoma,
1103915|NCT01557127|Sorafenib
1103916|NCT01557127|Dosing
1103917|NCT01557114|unresectable Stage III or stage IV advanced malignant melanoma
1103918|NCT01557088|coronary artery disease
1103919|NCT01557088|coronary artery spasm
1103920|NCT01557088|small vessel coronary artery disease
1103921|NCT01557075|High dose statin
1103922|NCT01557062|Fibromyalgia
1103923|NCT01557062|Hydrotherapy
1103924|NCT01557062|Sleep
1103925|NCT01557062|Pain
1103926|NCT01557062|Body Temperature
1103927|NCT01557049|chronic low back pain
1103928|NCT01557049|Postural global reeducation
1103929|NCT01557049|randomized
1103930|NCT01557049|physical rehabilitation
1103931|NCT01557036|Brain Aneurysm
1103932|NCT01556997|Hypertension
1103933|NCT01556997|Essential Hypertension
1103934|NCT01556984|diabetic foot
1103935|NCT01556984|digital subtraction angiography
1103936|NCT01556984|endothelial function
1103937|NCT01556984|Patients with diabetes
1103938|NCT01556984|Age 40 to 70 years old
1103939|NCT01556984|Endothelial function are determined
1103940|NCT01556945|P. falciparum
1103941|NCT01556945|vaccine
1103942|NCT01556945|healthy volunteers
1103943|NCT01556919|GERD
1103944|NCT01556919|Esophagitis
1103945|NCT01556893|Flap Creation
1103946|NCT01556893|Femtosecond Laser
1103947|NCT01556893|corneal flap prior to LASIK procedure
1103948|NCT01556880|Drivers
1103949|NCT01556880|Chinese
1103950|NCT01556880|Short Message Service
1103951|NCT01556880|Cellular Phone
1103952|NCT01556867|Umbilical cord care
1103953|NCT01556867|dry cord care
1103954|NCT01556867|antiseptic
1103955|NCT01556867|Omphalitis
1103956|NCT01556867|umbilical cord drop
1103957|NCT01556867|hospitalized in maternity hospital
1103958|NCT01556854|ginkgo leaves
1103959|NCT01556854|butylphthalide
1103960|NCT01556854|edaravone
1103961|NCT01556854|citicoline
1103962|NCT01556854|cerebrolysin
1103963|NCT01556854|piracetam
1103964|NCT01556854|Neuroprotectants
1103965|NCT01556841|Randomised
1103966|NCT01556841|Controlled
1103967|NCT01556841|Trovax
1103968|NCT01556841|MVA-5T4
1103969|NCT01556841|5T4
1103970|NCT01556841|Immunotherapy
1103971|NCT01556841|Relapsed
1103972|NCT01556841|Asymptomatic
1103973|NCT01556841|Epithelial
1103974|NCT01556841|Ovarian
1103975|NCT01556841|Fallopian
1103976|NCT01556841|Peritoneal
1103977|NCT01556815|Hepatocellular Carcinoma
1103978|NCT01556815|Sorafenib
1103979|NCT01556815|Transarterial Chemoembolization
1103980|NCT01556815|HBV
1103981|NCT01556802|stroke
1103982|NCT01556802|sequelaes
1103983|NCT01556802|minocicline
1103984|NCT01556789|ONT-10
1103985|NCT01556789|MUC1
1103986|NCT01556789|Vaccine
1103987|NCT01556789|Phase 1
1103988|NCT01556789|Solid Tumors
1103989|NCT01556789|Dose escalation
1103990|NCT01556776|CLL
1103991|NCT01556776|High Risk
1103992|NCT01556776|Maintenance
1103993|NCT01556763|Schizophrenia
1103994|NCT01556763|Schizoaffective
1103995|NCT01556763|CNS
1103996|NCT01555476|Pharmacokinetics
1103997|NCT01555463|Rosacea
1103998|NCT01555450|Colorectal cancer screening
1103999|NCT01555450|Social inequalities
1104000|NCT01555450|Patient Navigator
1104001|NCT01555437|capsule endoscopy scoring index
1104002|NCT01555437|Harvey-Bradshaw index
1104003|NCT01555437|C-reactive protein
1104004|NCT01555437|serum albumin
1104005|NCT01555437|hemoglobin
1104006|NCT01555424|25-hydroxyvitamin D
1104007|NCT01555424|Institutionalized seniors
1104008|NCT01555424|SF-36 survey
1104009|NCT01555424|Winter
1104010|NCT01556737|isoflavone
1104011|NCT01556737|supplement
1104012|NCT01556737|daidzein
1104013|NCT01556737|genistein
1104014|NCT01556737|gene expression
1104015|NCT01556724|Peripheral nerve blocks
1104016|NCT01556724|Ropivacaine concentrations in lumbar plexus catheters
1104017|NCT01556724|Postoperative pain
1104018|NCT01556724|Total hip replacement
1104019|NCT01556711|Head Injury
1104020|NCT01556711|Head Trauma
1104021|NCT01556711|TBI (Traumatic Brain Injury)
1104022|NCT01556711|Emergency Department
1104023|NCT01556698|Acne Vulgaris
1104024|NCT01556698|Acne
1104025|NCT01556672|small bowel lesions
1104026|NCT01556672|Crohn's Disease
1104027|NCT01556672|Plaque psoriasis
1104028|NCT01556672|adalimumab
1104029|NCT01556672|capsule endoscopy
1104030|NCT01556659|Left ventricular thrombus
1104031|NCT01556659|Acute myocardial infarction
1104032|NCT01556659|Anticoagulation
1104033|NCT01556646|Cirrhosis
1104034|NCT01556646|Hepatic Encephalopathy
1104035|NCT01556646|Hyponatremia
1104036|NCT01556646|Brain MRI
1104037|NCT01556646|Health-related quality of life
1104038|NCT01556646|cognitive function
1104039|NCT01556620|PtiO2
1104040|NCT01556620|NIRS
1104041|NCT01556607|Respiratory Syncytial Virus Infection
1104042|NCT01556607|RSV
1104043|NCT01556594|Hypoglycemia
1104044|NCT01556594|Diabetes mellitus
1104045|NCT01556581|back pain
1104046|NCT01556581|primary care
1104047|NCT01556581|physical therapy
1104048|NCT01556568|Noonan Syndrome, hypertrophic cardiomyopathy.
1104049|NCT01556555|Sclerosing cholangitis
1104050|NCT01556555|Spyglass
1104051|NCT01556555|Endoscopic retrograde cholangiopancreaticography
1104052|NCT01556542|peripheral arterial disease
1104053|NCT01556542|drug-eluting balloon
1104054|NCT01556542|restenosis
1104055|NCT01556477|MDS
1104056|NCT01556477|AML
1104057|NCT01556477|Azacitidine
1104058|NCT01556477|Lenalidomide
1104059|NCT01556477|del5q
1104060|NCT01556464|Obstructive sleep apnea
1104061|NCT01556464|CPAP
1104062|NCT01556412|endoscopic ultrasound
1104063|NCT01556412|primary sclerosing cholangitis
1104064|NCT01556412|EUS
1104065|NCT01556412|cholestatic hepatopathy
1104066|NCT01556399|Duodenal adenoma
1104067|NCT01556399|Ampullary adenoma
1104068|NCT01556386|acute lymphoblastic leukemia
1104069|NCT01556386|single nucleotide polymorphism
1104070|NCT01556373|acute systemic inflammation
1104071|NCT01556373|arterial stiffness
1104072|NCT01556373|Carotid-femoral pulse wave velocity
1104073|NCT01556360|genetic hemochromatosis
1104074|NCT01556360|Iron overload
1104075|NCT01556360|C282 homozygosity
1104076|NCT01556347|alloantibody
1104077|NCT01556347|immunologic
1104078|NCT01556347|memory
1104079|NCT01556347|heart
1104080|NCT01556347|transplant
1104081|NCT01556347|desensitization
1104082|NCT01556334|premature ruptured membranes
1104083|NCT01556334|azithromycin
1104084|NCT01556334|erythromycin
1104085|NCT01556334|latency
1104086|NCT01556334|antibiotics
1104087|NCT01556321|Obesity
1104088|NCT01556321|Body weight
1104089|NCT01556321|Gut flora
1104090|NCT01556321|Fat absorption
1104091|NCT01556308|Dowling Meara
1104092|NCT01556308|Epidermolysis bullosa
1104093|NCT01556308|inflammation
1104094|NCT01556295|Nurses
1104095|NCT01556295|Low back pain
1104096|NCT01556295|Gesture behavior
1104097|NCT01556295|Knowlegde
1104098|NCT01556282|Hepatocellular Carcinoma
1104099|NCT01556282|portal vein thrombosis
1104100|NCT01556282|HCC
1104101|NCT01556243|stage IA breast cancer
1104102|NCT01556243|stage IB breast cancer
1104103|NCT01556243|stage II breast cancer
1104104|NCT01556243|ductal breast carcinoma in situ
1104105|NCT01556243|lobular breast carcinoma in situ
1104106|NCT01556230|pituitary gland
1104107|NCT01556230|pituitary adenoma
1104108|NCT01556230|pituitary tumor
1104109|NCT01556230|hypophysis
1104110|NCT01556230|endocrine
1104111|NCT01556230|neuroendocrine
1104112|NCT01556230|hormone
1104113|NCT01556217|Healthy volunteers
1104114|NCT01556217|JNJ-39393406-aaa
1104115|NCT01556217|Pharmacokinetics
1104116|NCT01556217|Central brain penetrance
1104117|NCT01556217|Cerebral spinal fluid
1104118|NCT01556204|Endometriosis
1104119|NCT01556191|lung cancer
1104120|NCT01556191|women
1104121|NCT01556178|Hydrocephalus
1104122|NCT01556178|Survivin
1104123|NCT01556178|miRNA
1104124|NCT01556165|Rasagiline
1104125|NCT01556165|Azilect
1104126|NCT01556165|Parkinson´s Disease
1104127|NCT01556165|Motor fluctuations
1104128|NCT01556139|Endurance
1104129|NCT01556139|exercise training
1104130|NCT01556139|6-min walking test
1104131|NCT01556126|Coronary artery disease
1104132|NCT01556126|Drug Eluting Stent
1104133|NCT01556126|All comers patients
1104134|NCT01556113|fatty liver
1104135|NCT01556113|hypertriglyceridemia
1104136|NCT01556113|elevated liver enzymes
1104137|NCT01556100|18F-DTBZ AV-133 imaging
1104138|NCT01556087|opioids
1104139|NCT01556087|distress tolerance
1104140|NCT01556087|buprenorphine
1104141|NCT01556074|Post traumatic stress disorder
1104142|NCT01556074|PTSD
1104143|NCT01556074|Insomnia
1104144|NCT01556074|Sleep
1104145|NCT01556074|Yoga
1104146|NCT01556074|Meditation
1104147|NCT01556074|Mental Health
1104148|NCT01556074|Sleep Quality
1104149|NCT01556074|Actigraphy
1104150|NCT01556074|Sleep Diaries
1104151|NCT01556074|Autonomic
1104152|NCT01556074|Social Health
1104153|NCT01556074|Interoception
1104154|NCT01556074|Attention Regulation
1104155|NCT01556074|Emotion Regulation
1104156|NCT01556061|Laryngoscopy
1104157|NCT01556061|Airway Management
1104158|NCT01556061|Intubation
1104159|NCT01556048|Behavior therapy
1104160|NCT01556048|Bereavement
1104161|NCT01556048|Complicated grief
1104162|NCT01556048|Depression
1104163|NCT01556048|Posttraumatic Stress Disorder
1104164|NCT01556035|oncodermatology
1104165|NCT01556035|hematology
1104166|NCT01556035|cutaneous B cell lymphoma
1104167|NCT01556035|lenalidomide
1104168|NCT01556022|Ischemic heart disease
1104169|NCT01556022|Coronary artery disease
1104170|NCT01556022|Chronic heart failure
1104171|NCT01556022|Cardiovascular disease
1104172|NCT01556022|Adult stem cells
1104173|NCT01556022|Adipose derived regenerative cells
1104174|NCT01556009|Basal Cell Carcinoma
1104175|NCT01556009|Photodynamic Therapy
1104176|NCT01555996|older
1104177|NCT01555996|delirium
1104178|NCT01555996|cognitive status
1104179|NCT01555996|occupational therapy
1104180|NCT01555996|critically ill patients
1104181|NCT01555983|cannabis
1104182|NCT01555983|central neuropathic pain
1104183|NCT01555983|analgesia
1104184|NCT01555970|Obsessive-compulsive disorder
1104185|NCT01555970|Treatment
1104186|NCT01555970|Glutamate
1104187|NCT01555970|N-Acetylcysteine
1104188|NCT01555918|Pharmacokinetics
1104189|NCT01555918|Healthy volunteers
1104190|NCT01555918|Isavuconazole
1104191|NCT01555918|BAL4815
1104192|NCT01555918|BAL8728
1104193|NCT01555918|BAL8557
1104194|NCT01555905|Respiratory Muscle Strength
1104195|NCT01555892|EBV
1104196|NCT01555892|Hodgkin's Lymphoma
1104197|NCT01555892|Non-Hodgkin's Lymphoma
1104198|NCT01555892|Lymphoma Relapse
1104199|NCT01555892|Autologous or Syngeneic Stem Cell Transplant
1104200|NCT01555892|T/NK-lymphoproliferative disease
1104201|NCT01555892|LMP
1104202|NCT01555892|BARF1
1104203|NCT01555892|EBNA1
1104204|NCT01555879|Retrospective
1104205|NCT01555879|Database
1104206|NCT01555879|Data warehouse
1104207|NCT01555879|Data mining
1104208|NCT01555879|Collaborative effectiveness
1104209|NCT01555879|Comparative effectiveness
1104210|NCT01555879|Outcome based medicine
1104211|NCT01555879|Evidence based medicine
1104212|NCT01555866|isavuconazole
1104213|NCT01555866|BAL4815
1104214|NCT01555866|BAL8557
1104215|NCT01555866|BAL8728
1104216|NCT01555840|Magnetically guided capsule endoscopy (MGCE)
1104217|NCT01555840|Gastroscopy
1104218|NCT01555827|Retina
1104219|NCT01555827|ALzheimer's disease
1104220|NCT01555827|neurodegenerative signs
1104221|NCT01555814|dopamine
1104222|NCT01555814|first episode
1104223|NCT01555814|reward
1104224|NCT01555814|cognition
1104225|NCT01555814|MRI
1104226|NCT01555814|fMRI
1104227|NCT01555814|PPI
1104228|NCT01555814|P300
1104229|NCT01555814|P50 gating
1104230|NCT01555814|endophenotypes
1104231|NCT01555801|esophageal cancer
1104232|NCT01555801|early cancer
1104233|NCT01555801|ultrasonography (EUS)
1104234|NCT01555801|stage
1104235|NCT01555788|type 1 diabetes,
1104236|NCT01555788|diaport,
1104237|NCT01555788|artificial pancreas,
1104238|NCT01555788|zone mpc algorithm,
1104239|NCT01555788|ap system,
1104240|NCT01555788|intraperitoneal insulin
1104241|NCT01555775|exercise-induced muscle damage
1104242|NCT01555775|nutritional recovery
1104243|NCT01555775|nutritional supplement
1104244|NCT01555775|natural food
1104245|NCT01555736|allergic rhinitis
1104246|NCT01555736|perennial immunotherapy
1104247|NCT01555736|preseasonal immunotherapy
1104248|NCT01555411|Cardiovascular epidemiology
1104249|NCT01555411|Prospective, observational cohort study
1104250|NCT01555411|Biomarkers
1104251|NCT01555411|Cardio- and cerebrovascular imaging
1104252|NCT01555398|Fenofibric acid
1104253|NCT01555398|HIP0901
1104254|NCT01555398|food effect
1104255|NCT01555385|Mental workload
1104256|NCT01555385|Multitasking
1104257|NCT01555385|Protein
1104258|NCT01555385|Tryptophan
1104259|NCT01555372|unstable distal clavicular fractures (Neer 2b)
1104260|NCT01555372|Study Protocol
1104261|NCT01555372|Fracture Fixation
1104262|NCT01555346|Down syndrome
1104263|NCT01555346|fetal aneuploidy
1104264|NCT01555346|trisomy
1104265|NCT01555346|noninvasive prenatal test
1104266|NCT01555307|total hip arthroplasty
1104267|NCT01555307|total knee arthroplasty
1104268|NCT01555307|balance exercises
1104269|NCT01555307|force plate
1104270|NCT01555307|berg balance scale
1104271|NCT01555307|timed up and go test
1104272|NCT01555294|(subclinical)atherosclerosis
1104273|NCT01555294|non-invasive measurements
1104274|NCT01555294|intima-media thickness
1104275|NCT01555294|flow-mediated dilation
1104276|NCT01555294|pulse wave velocity and analysis
1104277|NCT01555294|fatal and non-fatal cardiovascular events
1104278|NCT01555294|ankle-brachial index (at rest and after exercise)
1104279|NCT01555294|general population
1104280|NCT01555294|Familial Combined Hyperlipidemia
1104281|NCT01555281|Multiple Myeloma
1104282|NCT01555281|Kahler Disease
1104283|NCT01555281|Lenalidomide
1104284|NCT01555281|Revlimid
1104285|NCT01555281|Nelfinavir
1104286|NCT01555281|Viracept
1104287|NCT01555281|Dexamethasone
1104288|NCT01555255|malaria
1104289|NCT01555255|pregnancy
1104290|NCT01555255|placental malaria
1104291|NCT01555255|malaria in pregnancy
1104292|NCT01555255|birth weight
1104293|NCT01555255|anemia
1104294|NCT01555242|Advanced Cancer
1104295|NCT01555242|Lymphoma
1104296|NCT01555242|Refractory
1104297|NCT01555229|Secretion drainage
1104298|NCT01555229|Ventilator-associated pneumonia
1104299|NCT01555229|Tracheal fibroscopy
1104300|NCT01555216|Forefoot surgery
1104301|NCT01555190|myo-inositol
1104302|NCT01555190|folic acid
1104303|NCT01555177|Peri-operative myocardial infarction
1104304|NCT01555177|Non-ST elevation myocardial infarction
1104305|NCT01555177|Optical coherence tomography
1104306|NCT01555151|Asthma
1104307|NCT01555138|Chronic Obstructive Pulmonary Disease
1104308|NCT01555138|Indacaterol
1104309|NCT01555138|Salmeterol/fluticasone propionate
1104310|NCT01555125|Psoriasis
1104311|NCT01555099|COPD, FEV1, AZD5423
1104312|NCT01555086|Lymphadenectomy
1104313|NCT01555086|Prostate cancer
1104314|NCT01555060|hemoglobin recovery
1104315|NCT01555060|iron recovery
1104316|NCT01555060|iron supplements
1104317|NCT01555034|obesity
1104318|NCT01555034|movement therapy
1104319|NCT01555034|exercise
1104320|NCT01555034|behaviour
1104321|NCT01554995|LCB01-0371
1104322|NCT01554982|Participation Limited
1104323|NCT01554982|Long Term
1104324|NCT01554982|Safety Extension
1104325|NCT01554956|Plasminogen Deficiency
1104326|NCT01554956|Ligneous Conjunctivitis
1104327|NCT01554956|Plasminogen
1104328|NCT01554956|Ligneous Conjunctivitis in Plasminogen Deficient Patients
1104329|NCT01554943|CMF
1104330|NCT01554943|HEC
1104331|NCT01554943|EC
1104332|NCT01554943|node positive
1104333|NCT01554943|breast cancer
1104334|NCT01554930|HFMD
1104335|NCT01554930|Traditional Chinese Medicine
1104336|NCT01554930|Xiyanping
1104337|NCT01554917|Rheumatoid Arthritis
1104338|NCT01554917|Iguratimod
1104339|NCT01554904|Sleep Study
1104340|NCT01554904|Snoring
1104341|NCT01554904|Sleep Apnea
1104342|NCT01554904|Muscle Laxity
1104343|NCT01554904|Oral Appliance
1104344|NCT01554904|Facial Muscles
1104345|NCT01554904|Neck Muscles
1104346|NCT01554904|Upper Airway
1104347|NCT01554904|Muscle Strength
1104348|NCT01554904|Dynamic Resistance
1104349|NCT01554904|Oral Exercise
1104350|NCT01554904|Facial Toning
1104351|NCT01554904|Facial Muscle Strength
1104352|NCT01554904|Strap Muscles of the Neck
1104353|NCT01554904|Apnea-Hypopnea
1104354|NCT01554891|brain injuries, traumatic
1104355|NCT01554891|military personnel
1104356|NCT01554891|classification
1104357|NCT01554891|diagnosis
1104358|NCT01554891|instrumentation
1104359|NCT01554878|osteochondral defect of the knee
1104360|NCT01554865|obesity
1104361|NCT01554865|men
1104362|NCT01554865|sexual function
1104363|NCT01554865|urinary tract symptoms
1104364|NCT01554865|endothelial function
1104365|NCT01554865|inflammation
1104366|NCT01554865|quality of life
1104367|NCT01554852|myeloma
1104368|NCT01554852|lenalidomide
1104369|NCT01554852|Revlimid
1104370|NCT01554852|cyclophosphamide
1104371|NCT01554852|dexamethasone
1104372|NCT01554852|bortezomib
1104373|NCT01554852|Velcade
1104374|NCT01554852|vorinostat
1104375|NCT01554852|Zolinza
1104376|NCT01554852|stem cell
1104377|NCT01554852|carfilzomib
1104378|NCT01554852|Kyprolis
1104379|NCT01554826|Pediatric influenza vaccine
1104380|NCT01554813|Influenza Vaccine, Vaccination,
1104381|NCT01554800|Lecithin Cholesterol Acyl Transferase
1104382|NCT01554800|LCAT
1104383|NCT01554800|rhLCAT
1104384|NCT01554800|Enzyme replacement therapy
1104385|NCT01554800|High-Density Lipoprotein (HDL)
1104386|NCT01554800|Cholesterol
1104387|NCT01554800|Cholesterol ester
1104388|NCT01554800|LCAT Deficiency
1104389|NCT01554787|After stroke with fatigue
1104390|NCT01554774|COPD
1104391|NCT01554774|PVR
1104392|NCT01554761|astigmatism
1104393|NCT01554761|pseudophakia
1104394|NCT01554748|total joint arthroplasty
1104395|NCT01554748|thumb
1104396|NCT01554748|trapeziometacarpal joint
1104397|NCT01554748|osteoarthritis
1104398|NCT01554735|obesity
1104399|NCT01554735|men
1104400|NCT01554735|sexual function
1104401|NCT01554735|urinary tract symptoms
1104402|NCT01554735|endothelial function
1104403|NCT01554735|inflammation
1104404|NCT01554735|quality of life
1104405|NCT01554722|Ultrasound guidance
1104406|NCT01554722|Femoral nerve block
1104407|NCT01554722|Needle placement
1104408|NCT01554722|Intraneural needle insertion
1104409|NCT01554709|bypass
1104410|NCT01554709|cannula
1104411|NCT01554696|Rheumatoid Arthritis
1104412|NCT01554696|ASP015K
1104413|NCT01554683|Alzheimer's Disease
1104414|NCT01554683|Seizures
1104415|NCT01554683|Memory
1104416|NCT01554683|Executive
1104417|NCT01554670|Arthroscopic subacromial decompression
1104418|NCT01554670|Bipolar radiofrequency
1104419|NCT01554670|Tendon debridement
1104420|NCT01554670|Shoulder surgery
1104421|NCT01554657|Pneumonia, Bacterial
1104422|NCT01554644|Cleansing
1104423|NCT01554644|Chronic Leg Ulcers
1104424|NCT01554644|Diabetic Patients
1104425|NCT01554631|Bioequivalence
1104426|NCT01554631|Acarbose
1104427|NCT01554631|ODT
1104428|NCT01554618|exenatide
1104429|NCT01554618|type 2 diabetes
1104430|NCT01554618|GLP-1 receptor agonist
1104431|NCT01554592|Heart Failure
1104432|NCT01554592|Statin withdrawal
1104433|NCT01554566|honey
1104434|NCT01554566|diabetes
1104435|NCT01554566|lipids
1104436|NCT01554566|c-peptide
1104437|NCT01554553|Sleeve gastrectomy
1104438|NCT01554553|Posterior crural repair
1104439|NCT01554540|Treprostinil
1104440|NCT01554540|Scleroderma
1104441|NCT01554540|Iontophoresis
1104442|NCT01554527|polysomnography
1104443|NCT01554527|child
1104444|NCT01554527|continuous positive airway pressure
1104445|NCT01554527|tonsillectomy
1104446|NCT01554527|neuropsychological tests
1104447|NCT01554527|cognition
1104448|NCT01554527|sleepiness
1104449|NCT01554527|behavior
1104450|NCT01554514|ADAMTS13
1104451|NCT01554514|Rituximab
1104452|NCT01554514|Thrombotic thrombocytopenic purpura
1104453|NCT01554514|TTP
1104454|NCT01554514|Plasma exchange
1104455|NCT01554501|stress
1104456|NCT01554501|self-control
1104457|NCT01554501|emotion regulation
1104458|NCT01554501|health
1104459|NCT01554488|asthma
1104460|NCT01554488|COPD
1104461|NCT01554488|sleep apnea, obstructive
1104462|NCT01554475|herbal drugs
1104463|NCT01554475|dietary supplements
1104464|NCT01554475|drug interactions
1104465|NCT01554462|Attention
1104466|NCT01554462|Cognitive control
1104467|NCT01554462|ADHD
1104468|NCT01554462|Healthy
1104469|NCT01554462|EPA
1104470|NCT01554462|Eicosapentaenoic acid
1104471|NCT01554462|DHA
1104472|NCT01554462|Docosahexaenoic acid
1104473|NCT01554462|PUFA
1104474|NCT01554462|Omega-3
1104475|NCT01554449|Stroke
1104476|NCT01554449|Upper arm
1104477|NCT01554449|Rehabilitation
1104478|NCT01554449|Motor function
1104479|NCT01554449|Video games
1104480|NCT01554449|Virtual reality
1104481|NCT01554449|Occupational Therapy
1104482|NCT01554449|Functional MRI
1104483|NCT01554436|Smoking
1104484|NCT01554436|Neuropsychology
1104485|NCT01554436|Abstinence
1104486|NCT01554436|Prognosis
1104487|NCT01554436|Nicotine Dependence, Cigarettes, with Other Nicotine-induced Disorders
1104488|NCT01554423|HIV Prevention Intervention
1104489|NCT01554410|Cervical
1104490|NCT01554410|Carcinoma
1104491|NCT01554410|Gemcitabine
1104492|NCT01554410|Gemzar
1104493|NCT01554410|Cisplatin
1104494|NCT01554410|IMRT
1104495|NCT01554410|Radiation
1104496|NCT01554410|External Beam
1104497|NCT01554410|Brachytherapy
1104498|NCT01554397|Cervical
1104499|NCT01554397|Carcinoma
1104500|NCT01554397|Cisplatin
1104501|NCT01554397|IMRT
1104502|NCT01554397|Radiation
1104503|NCT01554397|INTERTECC
1104504|NCT01554397|International
1104505|NCT01554397|External Beam
1104506|NCT01554397|Brachytherapy
1104507|NCT01554397|LDR
1104508|NCT01554397|HDR
1104509|NCT01554397|IGRT
1104510|NCT01554397|CBCT
1104511|NCT01554384|Tuberculosis
1104512|NCT01554384|diagnosis
1104513|NCT01554384|Xpert MTB/RIF
1104514|NCT01554384|point-of-treatment
1104515|NCT01554384|randomized controlled trial
1104516|NCT01554371|Solid tumor
1104517|NCT01554371|Metastatic breast cancer
1104518|NCT01554371|Unresectable or metastatic carcinoma
1104519|NCT01554371|Neuropathy
1104520|NCT01554371|Eribulin
1104521|NCT01554371|Cyclophosphamide
1104522|NCT01554358|Gestational diabetes mellitus
1104523|NCT01554358|Lifestyle intervention
1104524|NCT01554332|Motor Cortex Stimulation
1104525|NCT01554332|Neuropathic pain
1104526|NCT01554319|Antisense oligonucleotide
1104527|NCT01554319|Asthma
1104528|NCT01554319|Healthy subjects
1104529|NCT01554319|Phase 1
1104530|NCT01554319|Transcription factor GATA-3
1104531|NCT01554319|Oral inhalation
1104532|NCT01554280|Stricture
1104533|NCT01554280|Dysphagia
1104534|NCT01554267|Mastectomy skin flap necrosis
1104535|NCT01554267|Breast reconstruction
1104536|NCT01554267|Indocyanine Green Dye
1104537|NCT01554254|Cord blood transplant
1104538|NCT01554254|hematological malignancy
1104539|NCT01554254|inherited metabolic disease
1104540|NCT01554254|Mucositis
1104541|NCT01554254|Neutrophil engraftment
1104542|NCT01554254|Platelet recovery
1104543|NCT01554254|Immune reconstitution
1104544|NCT01554241|vitamin D3
1104545|NCT01554241|D3
1104546|NCT01554241|cholecalciferol
1104547|NCT01554241|25-OH vitamin D
1104548|NCT01554241|elderly
1104549|NCT01554241|nursing home resident
1104550|NCT01554215|parenting
1104551|NCT01554215|child behavior
1104552|NCT01554215|attachment
1104553|NCT01554202|Alzheimer's disease
1104554|NCT01554202|MCI
1104555|NCT01554202|genetic
1104556|NCT01554202|AV45-PET
1104557|NCT01554176|Current depressive episode
1104558|NCT01554176|moderate to severe
1104559|NCT01554163|Osteoarthritis
1104560|NCT01554163|Celecoxib
1104561|NCT01554163|Etoricoxib
1104562|NCT01554150|Primary Health Care
1104563|NCT01554150|Mental Health
1104564|NCT01554150|Cognitive Therapy
1104565|NCT01554124|Meningitis
1104566|NCT01554124|Neonates
1104567|NCT01554124|Meropenem
1104568|NCT01554111|Bowel Evacuants
1104569|NCT01554111|Purgatives
1104570|NCT01554098|Polyp detection
1104571|NCT01554098|Supine
1104572|NCT01554098|Colonoscope withdrawal
1104573|NCT01554098|Patient position
1104574|NCT01554098|Dynamic position change
1104575|NCT01554072|home-based
1104576|NCT01554072|pulmonary rehabilitation
1104577|NCT01554072|COPD
1104578|NCT01554059|Rectal cancer
1104579|NCT01554059|Adenocarcinoma
1104580|NCT01554059|Bevacizumab
1104581|NCT01554059|Chemoradiation
1104582|NCT01554046|Attention Deficit Hyperactivity Disorder (ADHD)
1104583|NCT01554046|Methylphenidate- RITALIN IR (Immediate Release)
1104584|NCT01554033|European Huntington's Disease Network
1104585|NCT01554033|Huntington patients in KOREA
1104586|NCT01554020|Blood glucose
1104587|NCT01554020|Insulin sensitivity
1104588|NCT01554020|Oral glucose tolerance
1104589|NCT01554007|Crohn's disease
1104590|NCT01553981|Interstitial lung disease
1104591|NCT01553981|Scleroderma
1104592|NCT01553955|PRP,
1104593|NCT01553955|Platelet
1104594|NCT01553955|Manual
1104595|NCT01553942|NSCLC
1104596|NCT01553929|MCI
1104597|NCT01553903|Hormonal therapy
1104598|NCT01553903|Breast Cancer
1104599|NCT01553903|AEBS
1104600|NCT01553903|Oxysterols
1104601|NCT01553890|SSc= scleroderma
1104602|NCT01553890|ICF+ informed consent form
1104603|NCT01553890|age 18 to 85
1104604|NCT01553890|healthy
1104605|NCT01553838|prostate biopsy
1104606|NCT01553838|MRI guided biopsy
1104607|NCT01553838|TRUS guided biopsy
1104608|NCT01553812|forced oscillation technique
1104609|NCT01553812|COPD
1104610|NCT01553812|elderly
1104611|NCT01553812|airway resistance
1104612|NCT01553812|airtrapping
1104613|NCT01553786|T-cell lymphoma
1104614|NCT01553786|CHOp
1104615|NCT01553786|lenalidomide
1104616|NCT01553773|Hyaluroic acid
1104617|NCT01553773|Estradiol
1104618|NCT01553773|Isoflavone
1104619|NCT01553773|Skin
1104620|NCT01553773|Postmenopause
1104621|NCT01553760|Cataract
1104622|NCT01553760|TRI-MICS
1104623|NCT01553760|ACM
1104624|NCT01553760|MICS
1104625|NCT01553760|phacoemulsification
1104626|NCT01553747|Irritable bowel syndrome with diarrhea
1104627|NCT01553747|Irritable bowel syndrome
1104628|NCT01553747|Diarrhea predominant irritable bowel syndrome
1104629|NCT01553747|Colonic diseases
1104630|NCT01553747|Colonic diseases, functional
1104631|NCT01553747|Digestive system disease
1104632|NCT01553747|Gastrointestinal disease
1104633|NCT01553747|Intestinal disease
1104634|NCT01553747|Colonic pseudo-obstruction
1104635|NCT01553747|Diarrhea
1104636|NCT01553747|Signs and symptoms, Digestive
1104637|NCT01553734|QT prolongation
1104638|NCT01553734|Azithromycin
1104639|NCT01553734|macrolide
1104640|NCT01553734|pneumonia
1104641|NCT01553734|ECG changes
1104642|NCT01553708|Wound healing
1104643|NCT01553708|Epithelialization
1104644|NCT01553708|Safety
1104645|NCT01553695|Touble
1104646|NCT01553695|deficit
1104647|NCT01553695|attention
1104648|NCT01553695|hyperactivity
1104649|NCT01553695|Touble deficit attention with hyperactivity
1104650|NCT01553682|HIV
1104651|NCT01553682|STDs
1104652|NCT01553682|African American Females
1104653|NCT01553682|Alcohol
1104654|NCT01553656|Advanced cancer
1104655|NCT01553656|Metastatic
1104656|NCT01553656|NSCLC
1104657|NCT01553643|Huang-Chi-Wu-Wu-Tang
1104658|NCT01553643|Intracranial arterial prominent stenosis
1104659|NCT01553630|Fractures
1104660|NCT01553630|distal femur fractures
1104661|NCT01553630|distal tibial fracures
1104662|NCT01553604|breast prosthesis implantation
1104663|NCT01553604|bandages
1104664|NCT01553604|skin colonization
1104665|NCT01553604|surgical site infection
1104666|NCT01553604|augmentation mammaplasty
1104667|NCT01553604|dressing wear time
1104668|NCT01553591|Irritable bowel syndrome with diarrhea
1104669|NCT01553591|Irritable bowel syndrome
1104670|NCT01553591|Diarrhea Predominant Irritable Bowel Syndrome
1104671|NCT01553591|Colonic diseases
1104672|NCT01553591|Colonic diseases, functional
1104673|NCT01553591|Digestive system disease
1104674|NCT01553591|Gastrointestinal disease
1104675|NCT01553591|Intestinal disease
1104676|NCT01553591|Colonic pseudo-obstruction
1104677|NCT01553591|Diarrhea
1104678|NCT01553591|Signs and symptoms, Digestive
1104679|NCT01553565|10 mm in diameter
1104680|NCT01553565|antithrombotic agents
1104681|NCT01553552|Schistosoma haematobium
1104682|NCT01553552|schistosoma mansoni
1104683|NCT01553552|Anemia
1104684|NCT01553552|Underweight
1104685|NCT01553552|stunting
1104686|NCT01553552|Blastocystis
1104687|NCT01553526|International
1104688|NCT01553526|Multicenter
1104689|NCT01553526|Observational registry
1104690|NCT01553526|All-comers open label registry
1104691|NCT01553526|Orsiro Drug Eluting Stent (DES)
1104692|NCT01553526|Stenting
1104693|NCT01553526|Treatment of Coronary Artery Disease
1104694|NCT01553526|Coronary revascularization
1104695|NCT01553526|Percutaneous Coronary Intervention
1104696|NCT01553526|STEMI
1104697|NCT01553526|NSTEMI
1104698|NCT01553526|Ischemia
1104699|NCT01553526|Angina
1104700|NCT01553526|Subgroups
1104701|NCT01553526|Acute Myocardial Infarction
1104702|NCT01553526|Diabetes
1104703|NCT01553526|Small Vessels
1104704|NCT01553526|Chronic Total Occlusion (CTO)
1104705|NCT01553513|PET
1104706|NCT01553513|Coronary Artery Disease
1104707|NCT01553513|Inflammation
1104708|NCT01553513|Plaque
1104709|NCT01553513|Atherosclerosis
1104710|NCT01553500|NAFLD
1104711|NCT01553500|insulin resistance
1104712|NCT01553500|children
1104713|NCT01553487|vibration
1104714|NCT01553487|muscle strength
1104715|NCT01553487|bone loss
1104716|NCT01553487|immobilization
1104717|NCT01553487|fracture
1104718|NCT01553474|Age-Related Macular Degeneration (AMD)
1104719|NCT01553474|Eye Diseases
1104724|NCT01553448|disseminated neuroblastoma
1104725|NCT01553448|hereditary neuroblastoma
1104726|NCT01553448|localized resectable neuroblastoma
1104727|NCT01553448|localized unresectable neuroblastoma
1104728|NCT01553448|stage 4S neuroblastoma
1104729|NCT01553435|Dextromethorphan
1104730|NCT01553435|Morphine
1104731|NCT01553435|Fentanyl
1104732|NCT01553435|Opioid
1104733|NCT01553435|analgesia
1104734|NCT01553435|Efficacy
1104735|NCT01553422|Intrabdominal Pressure
1104736|NCT01553422|Emergency Bedside Ultrasonography
1104737|NCT01553422|Abdominal Compartment Syndrome
1104738|NCT01553409|Hypertension
1104739|NCT01553409|Ferritin
1104740|NCT01553409|Phlebotomy
1104741|NCT01553409|Blood donation
1104742|NCT01553383|OSA
1104743|NCT01553357|Plasma cell leukemia
1104744|NCT01553357|Lenalidomide
1104745|NCT01553357|Dexamethasone
1104746|NCT01553357|Multiple myeloma
1104747|NCT01553357|Bortezomib
1104748|NCT01553357|Stem cell transplantation
1104749|NCT01553344|sclerostin
1104750|NCT01553344|osteomalacia
1104751|NCT01553344|vitamin D deficiency
1104752|NCT01553331|laparoscopic cholecystectomy
1104753|NCT01553318|Fibromyalgia
1104754|NCT01553318|FMS
1104755|NCT01553305|exercise programme
1104756|NCT01553292|Respiratory distress syndrome
1104757|NCT01553292|Preterm infants
1104758|NCT01553292|Vascular catheter
1104759|NCT01553292|Surfactant
1104760|NCT01553292|CPAP
1104761|NCT01553292|ECALMIST
1104762|NCT01553266|Diabetes Mellitus
1104763|NCT01553266|diabetes care
1104764|NCT01553266|diabetes self-management education
1104765|NCT01553266|primary care physicians
1104766|NCT01553266|interprofessional collaboration
1104767|NCT01553266|diabetes education programs
1104768|NCT01553266|qualitative
1104769|NCT01553266|quantitative
1104770|NCT01553266|implementation
1104771|NCT01553266|evaluation
1104772|NCT01553266|health services
1104773|NCT01553266|coordinated care
1104774|NCT01553266|integrated care
1104775|NCT01553266|patient care processes
1104776|NCT01553253|Postcholecystectomy Pain
1104777|NCT01553253|Chronic Postoperative Pain
1104778|NCT01553253|Visceral Pain
1104779|NCT01553253|Referred pain
1104780|NCT01553253|Somatic pain
1104781|NCT01553253|Quantitative Sensory Testing
1104782|NCT01553240|TMS
1104783|NCT01553240|functional MRI
1104784|NCT01553240|Supplementary motor cortex
1104785|NCT01553240|Right Temporoparietal junction( RTPJ)
1104786|NCT01553227|OSAHS: Obstructive Sleep Apnea hypopnea Syndrome
1104787|NCT01553227|OHS: Obesity Hypoventilation Syndrome
1104788|NCT01553227|Auto-trilevel ventilation
1104789|NCT01553227|BiPAP ventilation
1104790|NCT01553214|Healthy Volunteers
1104791|NCT01553214|Granulocyte Transfusion
1104792|NCT01553214|Granulocytapheresis
1104793|NCT01553214|Leukapheresis
1104794|NCT01553214|Cytokine Stimulation
1104795|NCT01553214|Healthy Volunteer
1104796|NCT01553214|HV
1104797|NCT01553201|Quality of Life
1104798|NCT01553201|Endometriosis
1104799|NCT01553201|Botulinum Toxin A
1104800|NCT01553201|Pelvic Pain Spasm
1104801|NCT01553201|Chronic Pelvic Pain
1104802|NCT01553188|Anti-Angiogenesis
1104803|NCT01553188|Ang 1
1104804|NCT01553188|Ang 2
1104805|NCT01553188|Peptide-Fc fusion protein
1104806|NCT01553188|Small Molecule
1104807|NCT01553175|childhood atypical teratoid/rhabdoid tumor
1104808|NCT01553175|rhabdoid tumor of the kidney
1104809|NCT01553162|B-cell childhood acute lymphoblastic leukemia
1104810|NCT01553162|untreated childhood acute lymphoblastic leukemia
1104811|NCT01553136|alcohol-related disorders
1104812|NCT01553136|Cholinergic Drugs
1104813|NCT01553136|varenicline
1104814|NCT01553136|Chantix
1104815|NCT01553123|Leiomyomas
1104816|NCT01553110|Cold
1104817|NCT01553110|Acute Rhinosinusitis
1104818|NCT01553110|Allergic Rhinitis
1104819|NCT01553097|Breast Cancer
1104820|NCT01553097|Neurocognitive Impairment
1104821|NCT01553097|Quality of Life
1104822|NCT01553097|Cytokines
1104823|NCT01553084|Smoking Cessation
1104824|NCT01553084|Smoking
1104825|NCT01553084|Nicotine
1104826|NCT01553071|Malignancy, Relapsed
1104827|NCT01553071|Chemotherapy, Intravenous
1104828|NCT01553058|Psoriasis
1104829|NCT01553058|Cardiovascular Disease
1104830|NCT01553058|FDG/PET-CT
1104831|NCT01553058|NB-UVB Phototherapy
1104832|NCT01553058|Vascular Inflammation
1104833|NCT01553058|Lipid Biomarkers
1104834|NCT01553045|symptom burden
1104835|NCT01553045|atrial fibrillation
1104836|NCT01553045|biomarkers
1104837|NCT01553045|intracardiac pressures
1104838|NCT01553032|Immuno-(Chemo-)and Radiotherapy
1104839|NCT01553032|Erbitux®
1104840|NCT01553032|Skin changes in Head and neck cancer
1104841|NCT01553019|Proton radiation
1104842|NCT01553019|Chemotherapy
1104843|NCT01553019|Pancreatic cancer
1104844|NCT01553019|Postoperative
1104845|NCT01553006|rhinosinusitis
1104846|NCT01553006|cefditoren pivoxil
1104847|NCT01552993|prematurity
1104848|NCT01552993|retinopathy
1104849|NCT01552993|pain
1104850|NCT01552993|acetaminophen
1104851|NCT01552980|Gastric cancer
1104852|NCT01552980|Adenocarcinoma
1104853|NCT01552980|SOX
1104854|NCT01552967|Colorectal cancer
1104855|NCT01552967|Adenocarcinoma
1104856|NCT01552967|XELOX
1104857|NCT01552954|hypertension
1104858|NCT01552954|Chronic kidney disease
1104859|NCT01552954|albuminuria
1104860|NCT01552954|low salt diet
1104861|NCT01552954|Angiotensin II receptor blocker
1104862|NCT01552941|Vagus Nerve
1104863|NCT01552941|Vagal Nerve Stimulation
1104864|NCT01552941|Rheumatoid Arthritis
1104865|NCT01552941|Implantable Medical Device
1104866|NCT01552915|ADHD
1104867|NCT01552902|ADHD
1104868|NCT01552863|pharmacokinetics
1104869|NCT01552863|bioavailability
1104870|NCT01552863|oxycodone.
1104871|NCT01552850|pharmacokinetics
1104872|NCT01552850|relative bioavailability
1104873|NCT01552850|oxycodone
1104874|NCT01552837|Diffusion Tensor Imaging,
1104875|NCT01552837|quetiapine
1104876|NCT01552837|Bipolar Disorder
1104877|NCT01552837|hippocampus
1104878|NCT01552837|Volume Brain Morphometry
1104879|NCT01552837|Magnetic Resonance Spectroscopy
1104880|NCT01552837|effect of quetiapine on hippocampal neurogenesis
1104881|NCT01552824|LUTO
1104882|NCT01552824|posterior urethral valves
1104883|NCT01552824|urethral atresia
1104884|NCT01552772|Safety
1104885|NCT01552772|Tolerability
1104886|NCT01552772|Schizophrenia
1104887|NCT01552772|Aripiprazole
1104888|NCT01552759|Appetite Hormones
1104889|NCT01552759|Binge Eating Disorder
1104890|NCT01552759|Obesity
1104891|NCT01552759|Cortisol
1104892|NCT01552759|Stress
1104893|NCT01552746|Postoperative shoulder pain
1104894|NCT01552746|Persisting postoperative pain
1104895|NCT01552720|aorta
1104896|NCT01552720|dissection
1104897|NCT01552720|feature
1104898|NCT01552707|Spondylolisthesis
1104899|NCT01552707|Degenerative discopathy
1104900|NCT01552707|Mesenchymal Stem Cells
1104901|NCT01552707|Bone marrow
1104902|NCT01552707|Tissue engineering
1104903|NCT01552707|Spinal fusion
1104904|NCT01552694|cardiometabolic complications
1104905|NCT01552681|baminercept treatment
1104906|NCT01552668|Clostridium difficile infection
1104907|NCT01552668|fidaxomicin
1104908|NCT01552655|Dual-time PET/CT
1104909|NCT01552655|Breast cancer recurrence
1104910|NCT01552655|Bone scintigraphy
1104911|NCT01552655|CT thorax upper abdomen
1104912|NCT01552642|Comprehensive Health Enhancement Support System (CHESS)
1104913|NCT01552629|Atopic dermatitis
1104914|NCT01552629|Atopic eczema
1104915|NCT01552629|Skin Diseases
1104916|NCT01552629|QGE031
1104917|NCT01552603|glucose sensors
1104918|NCT01552603|artificial pancreas
1104919|NCT01552603|Diabetes Mellitus
1104920|NCT01552577|Post-Concussion Syndrome
1104921|NCT01552577|Concussion
1104922|NCT01552577|Brain Injury
1104923|NCT01552577|TBI
1104924|NCT01552577|Military Personnel
1104925|NCT01552577|Eye-tracking
1104926|NCT01552577|Neurocognitive Function
1104927|NCT01552577|Assessment
1104928|NCT01552551|Falls
1104929|NCT01552551|exercise
1104930|NCT01552551|safety
1104931|NCT01552551|injury
1104932|NCT01552551|Older adults
1104933|NCT01552538|Rheumatoid Arthritis
1104934|NCT01552538|Vagus Nerve
1104935|NCT01552538|Vagal Nerve Stimulation
1104936|NCT01552525|acute kidney injury
1104937|NCT01552525|asymmetric dimethylarginine
1104938|NCT01552525|symmetric dimethylarginine
1104939|NCT01552525|l-arginine
1104940|NCT01552525|arterial stiffness
1104941|NCT01552525|augmentation index
1104942|NCT01552525|pulse wave velocity
1104943|NCT01552512|Stunting
1104944|NCT01552512|Hidden Hunger
1104945|NCT01552512|Diarrhea
1104946|NCT01552512|Vitamin A Deficiency
1104947|NCT01552486|chiropractic
1104948|NCT01552486|manipulation
1104949|NCT01552486|radiculopathy
1104950|NCT01552486|sciatica
1104951|NCT01552486|lumbar
1104952|NCT01552486|disc
1104953|NCT01552486|herniation
1104954|NCT01552486|protrusion
1104955|NCT01552473|TBI
1104956|NCT01552473|Traumatic Brain Injury
1104957|NCT01552473|combat related injury
1104958|NCT01552473|blast injury
1104959|NCT01552473|concussion
1104960|NCT01552473|sleep problems
1104961|NCT01552473|attention problems
1104962|NCT01552473|memory problems
1104963|NCT01552473|headaches
1104964|NCT01552473|dizziness
1104965|NCT01552473|OEF
1104966|NCT01552473|OIF
1104967|NCT01552473|Veterans
1104968|NCT01552473|Civilian
1104969|NCT01552460|Autism Spectrum Disorders
1104970|NCT01552460|Brain Imaging
1104971|NCT01552460|Genetics
1104972|NCT01552434|Advanced Cancers
1104973|NCT01552434|Advanced Malignancy
1104974|NCT01552434|Metastatic cancer
1104975|NCT01552434|Temsirolimus
1104976|NCT01552434|CCI-779
1104977|NCT01552434|Torisel
1104978|NCT01552434|Bevacizumab
1104979|NCT01552434|Avastin
1104980|NCT01552434|rhuMAb-VEGF
1104981|NCT01552434|Anti-VEGF Monoclonal Antibody
1104982|NCT01552434|Cetuximab
1104983|NCT01552434|C225
1104984|NCT01552434|Erbitux
1104985|NCT01552434|IMC-C225
1104986|NCT01552434|Valproic Acid
1104987|NCT01552434|Depakene
1104988|NCT01552421|Cholecystectomy
1104989|NCT01552421|Natural Orifice Transluminal Endoscopic Surgery
1104990|NCT01552421|Transvaginal cholecystectomy
1104991|NCT01552421|Postoperative outcome
1104992|NCT01552408|Non Proliferative Diabetic Retinopathy
1104993|NCT01552408|Diabetic Retinopathy
1104994|NCT01552408|Macular Edema
1104995|NCT01552408|Background Diabetic Retinopathy
1104996|NCT01552408|Pre Proliferative Diabetic Retinopathy
1104997|NCT01552382|vitamin D
1104998|NCT01552382|25-hydroxyvitamin D
1104999|NCT01552382|MACCE
1105000|NCT01552382|mortality
1105001|NCT01552382|cardiac
1105002|NCT01552382|cerebrovascular
1105003|NCT01552369|liver transplantation
1105004|NCT01552369|CMV disease
1105005|NCT01552369|valgancyclovir
1105006|NCT01552369|prophylaxis
1105007|NCT01552369|preemptive therapy
1105008|NCT01552330|Primaquine
1105009|NCT01552330|Pyronaridine-artesunate
1105010|NCT01552317|chronic kidney disease
1105011|NCT01552304|Obstructive sleep apnea
1105012|NCT01552304|Oxygen therapy
1105013|NCT01552304|Surgery
1105014|NCT01552304|Anesthesia
1105015|NCT01552291|Malnourishment
1105016|NCT01552291|Gastrointestinal tumors
1105017|NCT01552291|Immunocompetence
1105018|NCT01552265|Mild Cognitive Impairment
1105019|NCT01552265|Alzheimer's Disease
1105020|NCT01552252|POs-Ca
1105021|NCT01552252|calcium additives
1105022|NCT01552252|drink
1105023|NCT01552239|Soft tissue sarcoma
1105024|NCT01552239|Intensity-Modulated Radiation Therapy (IMRT)
1105025|NCT01552239|Tomotherapy
1105026|NCT01552239|Safety Margins
1105027|NCT01552239|Image-guided Radiation Therapy
1105028|NCT01552239|Brachytherapy
1105029|NCT01552239|interstitial
1105030|NCT01552200|Colorectal Cancer
1105031|NCT01552200|Polyp
1105032|NCT01552200|Adenoma
1105033|NCT01552200|Detection Rate
1105034|NCT01552200|Colonoscopy
1105159|NCT01551615|Cmax
1105035|NCT01552200|NaviAid™ G-Eye procedure
1105036|NCT01552200|NaviAid™ G-Eye system
1105037|NCT01552200|G-Eye procedure
1105038|NCT01552200|G-Eye system
1105039|NCT01552187|cardiac surgery
1105040|NCT01552187|post-pericardiotomy syndrome
1105041|NCT01552187|atrial fibrillation
1105042|NCT01552187|pericardial effusion
1105043|NCT01552187|pleural effusion
1105044|NCT01552187|prevention
1105045|NCT01552187|colchicine
1105046|NCT01552174|MGD
1105047|NCT01552174|ocular surface pathologies
1105048|NCT01552161|Angiography
1105049|NCT01552161|Atherosclerosis
1105050|NCT01552161|Asthma
1105051|NCT01552161|Tryptase
1105052|NCT01552161|Eosinophil cationic protein
1105053|NCT01552135|titanium dioxide
1105054|NCT01552135|nanoparticles
1105055|NCT01552135|skin
1105056|NCT01552135|penetrate
1105057|NCT01552109|symptomatic stable angina
1105058|NCT01552109|subjects with symptomatic stable angina visiting non-interventional consulting physicians for treatment and meets the inclusion/exclusion criteria
1105059|NCT01552096|Anaesthesia
1105060|NCT01552096|tonsillectomy
1105061|NCT01552096|inflammatory response
1105062|NCT01552096|stress response
1105063|NCT01552096|tramadol
1105064|NCT01552096|lidocaine
1105065|NCT01552083|sleep apnea
1105066|NCT01552083|screening
1105067|NCT01552083|community pharmacy
1105068|NCT01552044|retina
1105069|NCT01552031|COPD exacerbations
1105070|NCT01552031|FOT variability
1105071|NCT01551992|Sutures
1105072|NCT01551992|Pelvic Organ Prolapse
1105073|NCT01551992|Sacrocolpopexy
1105074|NCT01551992|Laparoscopy
1105075|NCT01551979|Schizophrenia
1105076|NCT01551979|repetitive Transcranial Magnetic Stimulation
1105077|NCT01551966|Esophageal varices
1105078|NCT01551966|Portal hypertension in children
1105079|NCT01551966|Wireless capsule endoscopy
1105080|NCT01551953|chronic bronchitis
1105081|NCT01551953|emphysema
1105082|NCT01551953|pulmonary
1105083|NCT01551953|COPD
1105084|NCT01551940|Sialorrhea
1105085|NCT01551940|Amyotrophic lateral sclerosis
1105086|NCT01551940|Botulinum toxin
1105087|NCT01551927|expectations
1105088|NCT01551914|Ultrasonic scissors
1105089|NCT01551914|thyroidectomy
1105090|NCT01551901|Back pain
1105091|NCT01551901|Spinal fusion
1105092|NCT01551901|Degenerative disc disease (DDD)
1105093|NCT01551901|Lower back pain
1105094|NCT01551901|Fusion
1105095|NCT01551888|COPD
1105096|NCT01551888|Chronic Obstructive Pulmonary Disease
1105097|NCT01551888|Chronic Bronchitis
1105098|NCT01551888|Emphysema
1105099|NCT01551888|Airflow Obstruction, Chronic
1105100|NCT01551888|Chronic Airflow Obstruction
1105101|NCT01551888|Chronic Obstructive Airway Disease
1105102|NCT01551888|Chronic Obstructive Lung Disease
1105103|NCT01551875|CIMT
1105104|NCT01551875|cardiovascular disease
1105105|NCT01551875|correlation with cardiovascular Risk factors
1105106|NCT01551862|lower body lift
1105107|NCT01551862|body contouring surgery
1105108|NCT01551862|massive weight loss
1105109|NCT01551836|pharmacokinetics
1105110|NCT01551836|paracetamol
1105111|NCT01551823|Influenza Virus Vaccine (Split Virion, Inactivated)
1105112|NCT01551823|Influenza
1105113|NCT01551810|Influenza Virus Vaccine (Split Virion, Inactivated)
1105114|NCT01551810|Influenza
1105115|NCT01551784|Statin treatment
1105116|NCT01551784|Cardiovascular disease
1105117|NCT01551784|Statin treatment induced HDL changes and the effect on cardiovascular disease
1105118|NCT01551771|CCR3 antagonist
1105119|NCT01551758|Exacerbation
1105120|NCT01551758|Adult
1105121|NCT01551758|COPD
1105122|NCT01551758|Respiratory
1105123|NCT01551745|Papillary Serous Ovarian Cancer
1105124|NCT01551745|Endometrioid Ovarian Cancer
1105125|NCT01551745|Epithelial Ovarian Cancer
1105126|NCT01551732|Anger
1105127|NCT01551732|Aggression
1105128|NCT01551732|Biofeedback
1105129|NCT01551732|Videogame
1105130|NCT01551719|Bacterial infection of skin or soft tissues
1105131|NCT01551706|Total antioxidant capacity
1105132|NCT01551706|SOD
1105133|NCT01551706|8-OHdG
1105134|NCT01551706|8-isoprostane
1105135|NCT01551706|oxLDL
1105136|NCT01551693|Stage III
1105137|NCT01551693|Stage IV
1105138|NCT01551693|Unresectable
1105139|NCT01551693|Metastatic
1105140|NCT01551667|S. aureus
1105141|NCT01551654|Pain
1105142|NCT01551654|Colonoscopy
1105143|NCT01551654|TENS
1105144|NCT01551654|Acupuncture
1105145|NCT01551641|Esophageal Cancer
1105146|NCT01551641|Chemoradiotherapy
1105147|NCT01551641|VEGF
1105148|NCT01551641|Thalidomide
1105149|NCT01551615|Phase 1
1105150|NCT01551615|healthy volunteers
1105151|NCT01551615|pharmacokinetics
1105152|NCT01551615|vandetanib
1105153|NCT01551615|metformin
1105154|NCT01551615|AUC(0-t)
1105155|NCT01551615|t1/2
1105156|NCT01551615|tmax
1105157|NCT01551615|CL/F
1105158|NCT01551615|Vz/F
1105160|NCT01551602|AK159
1105161|NCT01551602|teriparatide acetate
1105162|NCT01551589|Esophageal squamous cell carcinoma
1105163|NCT01551589|Concurrent chemoradiotherapy
1105164|NCT01551589|Clinical target volume
1105165|NCT01551589|Safety
1105166|NCT01551589|Prognosis
1105167|NCT01551550|Glaucoma Drainage Device, Tube Exposure, Amniotic Membrane
1105168|NCT01551537|Healthy females
1105169|NCT01551537|Post-marketing surveillance (PMS)
1105170|NCT01551537|Human papillomavirus vaccine
1105171|NCT01551537|Sri Lanka
1105172|NCT01551537|Cervarix
1105173|NCT01551524|Leukemia
1105174|NCT01551524|Lymphoma
1105175|NCT01551524|C240588.448
1105176|NCT01551524|C115.378.400
1105177|NCT01551511|chronic pancreatitis
1105178|NCT01551511|abdominal pain
1105179|NCT01551511|visceral pain
1105180|NCT01551511|chronic pain
1105181|NCT01551498|Hashimoto Disease
1105182|NCT01551498|Thyroiditis
1105183|NCT01551459|Uveal
1105184|NCT01551459|Melanoma
1105185|NCT01551459|Metastatic
1105186|NCT01551459|Sunitinib
1105187|NCT01551433|esophagectomy
1105188|NCT01551433|ESOPHAGUS
1105189|NCT01551433|Wipox instrument
1105190|NCT01551433|Tissue Oxygenation
1105191|NCT01551433|Anastomotic Leak
1105192|NCT01551433|11-192
1105193|NCT01551420|Amputation
1105194|NCT01551420|Prosthetic Design
1105195|NCT01551420|Upper Extremity
1105196|NCT01551407|Hexvix
1105197|NCT01551407|bladder cancer
1105198|NCT01551407|cystoscopy
1105199|NCT01551407|Patients with known or suspicion of bladder cancer
1105200|NCT01551394|sepsis
1105201|NCT01551394|neonates
1105202|NCT01551394|meropenem
1105203|NCT01551381|Safety
1105204|NCT01551381|Tolerability
1105205|NCT01551381|Pharmacokinetics
1105206|NCT01551381|Pharmacodynamics
1105207|NCT01551368|male factor
1105208|NCT01551368|intrauterine insemination
1105209|NCT01551368|LH surge
1105210|NCT01551368|controlled ovarian stimulation
1105211|NCT01551368|clomiphene citrate
1105212|NCT01551368|letrozole
1105213|NCT01551368|human menopausal gonadotropins
1105214|NCT01551355|behavioral modification
1105215|NCT01551355|health communication
1105216|NCT01551355|prevention
1105217|NCT01551342|bladder cancer
1105218|NCT01551342|Transitional cell carcinoma (TCC)
1105219|NCT01551329|depression
1105220|NCT01551329|alcohol
1105221|NCT01551329|comorbidity
1105222|NCT01551329|ketamine
1105223|NCT01551329|glutamate
1105224|NCT01551329|NMDA
1105225|NCT01551316|safety
1105226|NCT01551316|pharmacokinetics
1105227|NCT01551316|spirometry
1105228|NCT01551290|Ulcerative colitis
1105229|NCT01551290|UC
1105230|NCT01551290|Remicade
1105231|NCT01551290|Infliximab
1105232|NCT01551290|Chinese patients
1105233|NCT01551290|Mayo score
1105234|NCT01551290|Mucosal healing
1105235|NCT01551290|Rectal bleeding
1105236|NCT01551290|Inflammatory bowel disease
1105237|NCT01551290|IBD
1105238|NCT01551238|Energy expenditure
1105239|NCT01551238|Sleep
1105240|NCT01551238|Protein
1105241|NCT01551238|Carbohydrate
1105242|NCT01551225|Randomized controlled trial
1105243|NCT01551225|Escitalopram
1105244|NCT01551225|Irritable bowel syndrome
1105245|NCT01551225|Panic disorder
1105246|NCT01551212|Liver transplantation
1105247|NCT01551212|everolimus
1105248|NCT01551212|kidney function
1105249|NCT01551186|Probiotics
1105250|NCT01551173|Dyslipidemias
1105251|NCT01551173|Fluvastatin sodium
1105252|NCT01551173|Chinese
1105253|NCT01551160|Non-technical skills
1105254|NCT01551160|Crisis resource management
1105255|NCT01551160|Medical Emergency Team
1105256|NCT01551160|Rapid Response Team
1105257|NCT01551147|asthma
1105258|NCT01551147|ONO-6950
1105259|NCT01551147|asthma in adult patients
1105260|NCT01551134|Gastroesophageal Reflux
1105261|NCT01551134|Fundoplication
1105262|NCT01551134|Randomized Controlled Trial
1105263|NCT01551134|General Surgery
1105264|NCT01551134|Child
1105265|NCT01551134|Laparoscopy
1105266|NCT01551108|Children
1105267|NCT01551108|physical activity
1105268|NCT01551095|PEGJ
1105269|NCT01551095|PEG-J
1105270|NCT01551095|percutaneous endoscopic gastrostomy
1105271|NCT01551095|feeding tube
1105272|NCT01551095|gastroparesis
1105273|NCT01551095|acute pancreatitis
1105274|NCT01551095|stroke
1105275|NCT01551095|respiratory failure
1105276|NCT01551095|GERD
1105277|NCT01551095|balloon
1105278|NCT01551095|self-propelled
1105279|NCT01551043|adult patients
1105280|NCT01551043|aged 18
1105281|NCT01551043|CD19+ ALL relapsed
1105282|NCT01551043|after allogeneic SCT
1105283|NCT01551030|KIDNEY
1105284|NCT01551030|URETER
1105285|NCT01551030|URINARY BLADDER
1105286|NCT01551030|Buparlisib
1105287|NCT01551030|11-060
1105288|NCT01551017|total knee endoprostheses
1105289|NCT01551017|swelling
1105290|NCT01551017|mobilisation
1105291|NCT01551004|C. difficile, Clostridium difficile, C. diff, CRS3123
1105292|NCT01550965|Quality of Life
1105293|NCT01550965|Costs of Ulcerative Colitis
1105294|NCT01550965|Health Care Utilization
1105295|NCT01550939|Biometry of the Eye
1105296|NCT01550939|Intraocular Lens Implantation
1105297|NCT01550939|IOL
1105298|NCT01550926|orlistat
1105299|NCT01550926|overweight
1105300|NCT01550926|bioequivalence
1105301|NCT01550913|Substance use
1105302|NCT01550913|perinatal depression
1105303|NCT01550913|pregnant
1105304|NCT01550900|Colorectum
1105305|NCT01550900|Metachronous ctalColonic Neoplastic Polyps
1105306|NCT01550900|Chemoprevention
1105307|NCT01550900|Colonic adenoma(s)
1105308|NCT01550900|Pre-cancerous tumor(s) on the colon
1105309|NCT01550900|Metformin ER
1105310|NCT01550900|Extended Release
1105311|NCT01550900|Placebo
1105312|NCT01550900|Sugar pill
1105313|NCT01550874|Physical Activity
1105314|NCT01550874|Epilepsy
1105315|NCT01550874|Children
1105316|NCT01550861|infertility
1105317|NCT01550861|in vitro maturation (IVM)
1105318|NCT01550861|in vitro fertilization (IVF)
1105319|NCT01550861|natural cycle
1105320|NCT01550835|Symptomatic carotid artery stenosis
1105321|NCT01550822|stroke, lifestyle habits
1105322|NCT01550809|T1DM
1105323|NCT01550809|CSII
1105324|NCT01550809|CGM
1105325|NCT01550809|postprandial control
1105326|NCT01550809|glycemic variability
1105327|NCT01550809|Prandial insulin dosing in Type 1 diabetes treated with continuous subcutaneous insulin infusion
1105328|NCT01550796|Tinnitus
1105329|NCT01550796|Brain Fitness Program
1105330|NCT01550796|Posit Science
1105331|NCT01550796|D-cycloserine
1105332|NCT01550796|Cognitive Training
1105333|NCT01550783|Cervical cancer
1105334|NCT01550783|Atypical squamous cells of undetermined significance
1105335|NCT01550783|Stage 0 cervical cancer
1105336|NCT01550783|Cervical intraepithelial neoplasia grade 1
1105337|NCT01550783|Cervical
1105338|NCT01550783|intraepithelial neoplasia grade 2
1105339|NCT01550783|Cervical intraepithelial neoplasia grade 3
1105340|NCT01550783|Human papillomavirus
1105341|NCT01550783|HPV
1105342|NCT01550744|Psoriasis
1105343|NCT01550744|Ustekinumab
1105344|NCT01550744|STELARA
1105345|NCT01550744|Skin disease
1105346|NCT01550744|Monoclonal
1105347|NCT01550731|advance care planning
1105348|NCT01550731|health communication
1105349|NCT01550731|aging
1105350|NCT01550718|Aerobic Exercise
1105351|NCT01550718|Alzheimer's Disease
1105352|NCT01550718|Burden and Stress
1105353|NCT01550718|Caregiving Issues
1105354|NCT01550718|Quality of Life
1105355|NCT01550718|Early Stage Memory Loss
1105356|NCT01550705|Protoporphyria
1105357|NCT01550705|Porphyria
1105358|NCT01550705|Porphyrins
1105359|NCT01550666|negative symptoms
1105360|NCT01550653|Memory
1105361|NCT01550653|GLP-1
1105362|NCT01550653|Liraglutide
1105363|NCT01550653|energy output
1105364|NCT01550653|Memory facilitation
1105365|NCT01550653|GLP-1 analogue
1105366|NCT01550640|remifentanil
1105367|NCT01550640|Caesarean operation
1105368|NCT01550640|general anaesthesia
1105369|NCT01550640|hypertension
1105370|NCT01550640|newborn's adaptation
1105371|NCT01550640|pharmacogenetics
1105372|NCT01550627|preterm infants < 32 weeks of gestation
1105373|NCT01550614|Angina Pectoris
1105374|NCT01550614|Myocardial Ischemia
1105375|NCT01550614|Chest Pain
1105376|NCT01550614|Coronary Artery Disease
1105377|NCT01550614|Heart Diseases
1105378|NCT01550614|Cardiovascular Diseases
1105379|NCT01550614|Myocardial Perfusion
1105380|NCT01550614|Reversible Perfusion Defect Size
1105381|NCT01550614|SPECT-MIBI
1105382|NCT01550614|Anti-Anginal Medication
1105383|NCT01550614|Quality of Life
1105384|NCT01550601|morbid obesity
1105385|NCT01550601|gastrectomy
1105386|NCT01550601|gastrinaemia
1105387|NCT01550601|comorbidity
1105388|NCT01550601|gastric antrum
1105391|NCT01550549|Amyloid imaging
1105392|NCT01550549|Positron Emission Tomography
1105393|NCT01550549|18F-AV-45
1105394|NCT01550549|florbetapir F 18
1105395|NCT01550549|Diagnostic imaging
1105396|NCT01550536|basal metabolic rate
1105397|NCT01550536|resting energy expenditure
1105398|NCT01550536|menopause
1105399|NCT01550536|physical activity
1105400|NCT01550536|metabolic syndrome
1105401|NCT01550523|Brain Tumor
1105402|NCT01550510|Stage IV Colorectal cancer
1105403|NCT01550510|Colorectal Neoplasms
1105404|NCT01550510|Intestinal Neoplasms
1105405|NCT01550510|Gastrointestinal Neoplasms
1105406|NCT01550510|Digestive System Neoplasms
1105407|NCT01550510|Neoplasms by Site
1105408|NCT01550510|Neoplasms
1105409|NCT01550510|Digestive System Diseases
1105410|NCT01550510|Gastrointestinal Diseases
1105411|NCT01550510|Colonic Diseases
1105412|NCT01550510|Intestinal Diseases
1105413|NCT01550510|Rectal Diseases
1105414|NCT01550510|Ascorbic Acid
1105415|NCT01550510|Vitamins
1105416|NCT01550510|Irinotecan
1105417|NCT01550510|Integrative Medicine
1105418|NCT01550510|Complementary Medicine
1105419|NCT01550510|Alternative Medicine Antioxidants
1105420|NCT01550510|Molecular Mechanisms of Pharmacological Action
1105421|NCT01550510|Pharmacologic Actions
1105422|NCT01550510|Protective Agents
1105423|NCT01550510|Physiological Effects of Drugs
1105424|NCT01550510|Micronutrients
1105425|NCT01550510|Growth Substances
1105426|NCT01550510|Antineoplastic Agents, Phytogenic
1105427|NCT01550510|Antineoplastic Agents
1105428|NCT01550510|Therapeutic Uses
1105429|NCT01550510|Radiation-Sensitizing Agents
1105430|NCT01550510|Topoisomerase I Inhibitors
1105431|NCT01550510|Topoisomerase Inhibitors
1105432|NCT01550510|Enzyme Inhibitors
1105433|NCT01550497|back pain
1105434|NCT01550497|scoliosis
1105435|NCT01550497|home exercise program
1105436|NCT01550471|Mild asthma and allergic rhinitis
1105437|NCT01550458|Clinical Trial, Phase I
1105438|NCT01550458|Human Volunteers
1105439|NCT01550458|Healthy Volunteers
1105440|NCT01550458|mibefradil
1105441|NCT01550458|Posicor®
1105442|NCT01550445|Steroid withdrawal, Kidney transplantation
1105443|NCT01550419|Ventilator-associated pneumonia
1105444|NCT01550419|Ischemic stroke
1105445|NCT01550419|Atorvastatin
1105446|NCT01550419|Morbidity
1105447|NCT01550419|Mortality
1105448|NCT01550406|Pancreatic fistula
1105449|NCT01550406|distal Pancreatectomy
1105450|NCT01550393|stage II Wilms tumor
1105451|NCT01550393|stage III Wilms tumor
1105452|NCT01550393|recurrent Wilms tumor and other childhood kidney tumors
1105453|NCT01550380|Endometrial cancer
1105454|NCT01550341|HIV
1105455|NCT01550341|AIDS
1105456|NCT01550341|Opiate Addiction
1105457|NCT01550341|Drug Dependence
1105458|NCT01550341|Buprenorphine
1105459|NCT01550328|Screening for Type 2 diabetes
1105460|NCT01550315|POTS
1105461|NCT01550315|endothelial function
1105462|NCT01550315|high salt vs low salt diet
1105463|NCT01550315|PAT protocol
1105464|NCT01550315|Calf blood flow
1105465|NCT01550315|forearm mediated dilation
1105466|NCT01550302|Superficial Cervical Plexus Block
1105467|NCT01550302|Thoracic Surgery
1105468|NCT01550302|Thoracotomy
1105469|NCT01550302|Video-Assisted Thoracoscopic Surgery
1105470|NCT01550289|Dengue Fever
1105471|NCT01550289|Dengue Hemorrhagic Fever
1105472|NCT01550289|CYD Dengue Vaccine
1105473|NCT01550289|Dengue Virus
1105474|NCT01550289|Flavivirus
1105475|NCT01550276|Effectiveness
1105476|NCT01550276|Tension-type headache
1105477|NCT01550276|Manual therapy
1105478|NCT01550263|Hip Preservation
1105479|NCT01550263|Hip Arthroscopy
1105480|NCT01550263|Hip Pain
1105481|NCT01550263|Psychological distress
1105482|NCT01550250|Breast cancer
1105483|NCT01550250|Arm lymphedema
1105484|NCT01550250|Compression therapy
1105485|NCT01550237|radiotherapy, image-guided
1105486|NCT01550237|adverse effects
1105487|NCT01550237|position verification
1105488|NCT01550237|safety margins
1105489|NCT01550198|newborn
1105490|NCT01550198|shock
1105491|NCT01550198|hemodynamics
1105492|NCT01550198|cardiac output
1105493|NCT01550198|blood pressure
1105494|NCT01550172|dementia caregivers
1105495|NCT01550172|caregivers
1105496|NCT01550172|Alzheimer's caregivers
1105497|NCT01550172|caregiver sleep
1105498|NCT01550172|heart disease risk
1105499|NCT01550172|dementia
1105500|NCT01550172|Alzheimer's Disease
1105501|NCT01550159|Postoperative Cognitive Dysfunction
1105502|NCT01550159|Cardiac Surgery
1105503|NCT01550159|General Anesthesia
1105504|NCT01550159|Neuropsychological Tests
1105505|NCT01550146|Fractured neck of femur
1105506|NCT01550146|Dexamethasone
1105507|NCT01550133|Peptides
1105508|NCT01550133|Hormones
1105509|NCT01550133|Appetite
1105510|NCT01550133|Humans
1105511|NCT01550133|Obese
1105512|NCT01550133|Beverage
1105513|NCT01550133|Solid food
1105514|NCT01550133|cephalic phase
1105515|NCT01550120|taste
1105516|NCT01550120|fat
1105517|NCT01550120|threshold
1105518|NCT01550120|sensitivity
1105519|NCT01550120|human
1105520|NCT01550107|Sarcopenia
1105521|NCT01550107|Allopurinol
1105522|NCT01550107|Xanthine Oxidase
1105523|NCT01550107|MR Spectroscopy
1105524|NCT01550094|obese
1105525|NCT01550094|regional anesthesia
1105526|NCT01550094|anesthesia
1105527|NCT01550094|anesthesiology
1105528|NCT01550094|surgery
1105529|NCT01550094|foot
1105530|NCT01550094|foot surgery
1105531|NCT01550094|ankle
1105532|NCT01550094|ankle surgery
1105533|NCT01550094|orthopedics
1105534|NCT01550094|orthopedic surgery
1105535|NCT01550094|sports medicine
1105536|NCT01550094|sports medicine surgery
1105537|NCT01550094|Ochsner Hospital
1105538|NCT01550094|Ochsner Clinic
1105539|NCT01550094|New Orleans
1105540|NCT01550094|Louisiana
1105541|NCT01550094|Jefferson
1105542|NCT01550094|Soberon
1105543|NCT01550081|exercise intensity
1105544|NCT01550081|aerobic interval training
1105545|NCT01550081|cardiac rehabilitation
1105546|NCT01550081|group exercise
1105547|NCT01550068|Rheumatic Heart Disease
1105548|NCT01550055|KRAS wild-type
1105549|NCT01550055|Metastatic Colorectal Cancer
1105550|NCT01550055|CMAB009 Plus Irinotecan
1105551|NCT01550055|Phase II/III
1105552|NCT01550029|Smoking
1105553|NCT01550029|Tobacco
1105554|NCT01550029|Nicotine
1105555|NCT01550029|Bipolar
1105556|NCT01550016|dengue warning signs
1105557|NCT01550016|latin america
1105558|NCT01550016|south east asia
1105559|NCT01550016|other febrile illnesses
1105560|NCT01550016|dengue classification
1105561|NCT01550003|Cimzia
1105562|NCT01550003|JIA
1105563|NCT01550003|Polyarticular
1105564|NCT01550003|Oligoarticular
1105565|NCT01550003|Enthesitis-related-Arthritis
1105566|NCT01550003|Juvenile Idiopathic Arthritis
1105567|NCT01550003|Juvenile Psoriatic Arthritis
1105568|NCT01550003|Certolizumab Pegol
1105569|NCT01550003|PASCAL
1105570|NCT01550003|CDP870
1105571|NCT01549977|Drug Therapy
1105572|NCT01549964|Drug Therapy
1105573|NCT01549951|Metastatic castrate resistant prostate cancer, mCRPC, orteronel, TAK-700, Phase 2, QT, QTc
1105574|NCT01549938|Vitamin D
1105575|NCT01549938|Cholecalciferol
1105576|NCT01549938|Respiratory tract infection
1105577|NCT01549912|Rotator Cuff Tears
1105578|NCT01549912|Dislocation
1105579|NCT01549912|Shoulder Dislocation
1105580|NCT01549899|Insomnia
1105581|NCT01549899|Cognitive
1105582|NCT01549899|Behavioral
1105583|NCT01549899|Therapy
1105584|NCT01549899|Internet
1105585|NCT01549899|Depression
1105586|NCT01549899|Substance Use
1105587|NCT01549899|Post-Tramatic Stress Disorder
1105588|NCT01549886|Non-Hodgkin's Lymphoma
1105589|NCT01549886|Zevalin
1105590|NCT01549886|Motexafin Gadolinium
1105591|NCT01549860|Venous Insufficiency
1105592|NCT01549860|Reflux
1105593|NCT01549860|Lower Extremity Ulcer
1105594|NCT01549847|Postpoliomyelitis Syndrome
1105595|NCT01549847|Piracetam
1105596|NCT01549847|L-Carnitine
1105597|NCT01549808|ADL
1105598|NCT01549808|activities of daily living
1105599|NCT01549808|level of function
1105600|NCT01549795|Liver transplantation
1105601|NCT01549795|Neoadjuvant radio- chemo-therapy
1105602|NCT01549782|Prebiotics
1105603|NCT01549782|Microbiota
1105604|NCT01549782|Radiotherapy
1105605|NCT01549782|Gynaecological Cancer
1105606|NCT01549756|stage 4 stomach cancer
1105607|NCT01549756|stage 4 gastric cancer
1105608|NCT01549717|Early warning score
1105609|NCT01549717|Physiological score
1105610|NCT01549717|Track and trigger score
1105611|NCT01549717|Scoring system
1105612|NCT01549717|Physiological model
1105613|NCT01549717|Monitoring
1105614|NCT01549717|Patient monitoring
1105615|NCT01549717|Wireless monitoring
1105616|NCT01549717|Wearable monitor
1105617|NCT01549704|Total knee arthroplasty
1105618|NCT01549704|Adductor canal blockade (ACB)
1105619|NCT01549704|High pain responders
1105620|NCT01549704|US-guided nerve block
1105621|NCT01549691|Premedication
1105622|NCT01549691|Benzodiazepine
1105623|NCT01549691|Anti-anxiety agents
1105624|NCT01549691|Anxiety
1105625|NCT01549691|Surgery
1105626|NCT01549691|Adult
1105627|NCT01549691|Human
1105628|NCT01549678|Plantar fasciitis
1105629|NCT01549678|foot pain
1105630|NCT01549678|insoles
1105631|NCT01549678|foot function
1105632|NCT01549678|electronic baropodometer
1105633|NCT01549678|plantar pressure
1105634|NCT01549678|gait analysis
1105635|NCT01549665|Graft-Versus-Host Disease
1105636|NCT01549665|GVHD
1105637|NCT01549665|Hematopoietic Stem Cell Transplantation
1105638|NCT01549665|Stem Cell Transplantation
1105639|NCT01549665|Allogeneic hematopoietic transplant
1105640|NCT01549665|Mesenchymal Stem Cells
1105641|NCT01549665|Unrelated Donors
1105642|NCT01549665|Cord Blood Stem Cell Transplantation
1105643|NCT01549639|Propofol
1105644|NCT01549639|Target controlled infusion
1105645|NCT01549639|General anaesthesia
1105646|NCT01549626|Flaxseed
1105647|NCT01549626|Women
1105648|NCT01549626|Obesity
1105649|NCT01549626|No smokers
1105650|NCT01549574|crizotinib
1105651|NCT01549574|pharmacokinetics
1105652|NCT01549574|esomeprazole
1105653|NCT01549574|proton pump inhibitor
1105654|NCT01549574|drug drug interaction
1105655|NCT01549574|healthy volunteers
1105656|NCT01549561|behavior problems
1105657|NCT01549561|foster care
1105658|NCT01549561|parent training
1105659|NCT01549561|youth skills training
1105660|NCT01549548|CML
1105661|NCT01549522|patients or caregivers
1105662|NCT01549522|for caregivers, loved one must still be living
1105663|NCT01549496|HCV
1105664|NCT01549496|pharmacokinetics
1105665|NCT01549496|boceprevir
1105666|NCT01549496|hypertension
1105667|NCT01549496|amlodipine
1105668|NCT01549496|diltiazem
1105669|NCT01549483|asthma
1105670|NCT01549483|airway hyperresponsiveness
1105671|NCT01549483|asymptomatic airway hyperresponsiveness
1105672|NCT01549483|small airways
1105673|NCT01549457|latent tuberculosis
1105674|NCT01549457|text message interventions
1105675|NCT01549457|medication adherence
1105676|NCT01549444|renin
1105677|NCT01549444|aldosterone
1105678|NCT01549444|neonate
1105679|NCT01549431|Multiple Myeloma
1105680|NCT01549418|Gastrointestinal bleeding
1105681|NCT01549418|Lower gastrointestinal bleeding (LGIB)
1105682|NCT01549418|Polypectomy
1105683|NCT01549418|Large colorectal polyps
1105684|NCT01549418|ASA
1105685|NCT01549418|Aspirin
1105686|NCT01549418|Acetylsalicylic acid
1105687|NCT01549418|Colorectal Neoplasms
1105688|NCT01549418|Intestinal Neoplasms
1105689|NCT01549418|Gastrointestinal Neoplasms
1105690|NCT01549418|Digestive System Neoplasms
1105691|NCT01549418|Neoplasms by Site
1105692|NCT01549418|Neoplasms
1105693|NCT01549418|Digestive System Diseases
1105694|NCT01549418|Gastrointestinal Diseases
1105695|NCT01549418|Colonic Diseases
1105696|NCT01549418|Intestinal Diseases
1105697|NCT01549418|Rectal Diseases
1105698|NCT01549405|percutanous nephrolitotomy,intercostal nerve block, Ultrasound
1105699|NCT01549392|dynamic enhanced ct scan
1105700|NCT01549392|mri spectroscopy
1105701|NCT01549392|recurrent gliomas
1105702|NCT01549379|Head and neck cancer
1105703|NCT01549379|Radiation
1105704|NCT01549379|Chemotherapy
1105705|NCT01549379|Surgery
1105706|NCT01549379|Dynamic contrast enhanced computed tomography
1105707|NCT01549340|Rhinitis
1105708|NCT01549340|Allergen immunotherapy
1105709|NCT01549327|Virtual Patient Navigation
1105710|NCT01549327|Randomized Clinical Trial
1105711|NCT01549327|Empowerment
1105712|NCT01549327|Cost-Effectiveness
1105713|NCT01549327|Cancer Information Preferences
1105714|NCT01549314|Cystic fibrosis related bone disease
1105715|NCT01549314|Cystic fibrosis
1105716|NCT01549314|Ivacaftor
1105717|NCT01549249|cone outer segment tips line
1105718|NCT01549249|inner segment/outer segment junction line
1105719|NCT01549249|optical coherence tomography
1105720|NCT01549249|epiretinal membrane
1105721|NCT01549236|Chagas Disease
1105722|NCT01549236|Trypanosoma Cruzi
1105723|NCT01549236|T.Cruzi
1105724|NCT01549223|Uterine Atony
1105725|NCT01549223|Hypotension
1105726|NCT01549223|Cesarean Delivery
1105727|NCT01549223|Hemorrhage
1105728|NCT01549223|Phenylephrine
1105729|NCT01549223|Ephedrine
1105730|NCT01549210|gout
1105731|NCT01549210|gouty arthritis
1105732|NCT01549197|PTSD
1105733|NCT01549184|secondary ITP
1105734|NCT01549184|hydroxychloroquine
1105735|NCT01549184|Systemic Lupus Erythematosus
1105736|NCT01549171|Human ART
1105737|NCT01549171|Prostacyclin
1105738|NCT01549171|Iloprost
1105739|NCT01549171|Pregnancy
1105740|NCT01549158|loop diuretics
1105741|NCT01549158|torasemide prolonged release
1105742|NCT01549158|torasemide immediate release
1105743|NCT01549158|Sutril Neo
1105744|NCT01549158|pharmacodynamic profile of Torasemide-PR
1105745|NCT01549145|Severe
1105746|NCT01549145|Ongoing
1105747|NCT01549145|Unilateral
1105748|NCT01549145|present for more than 6 months
1105749|NCT01549132|Clinically significant macular oedema
1105750|NCT01549132|Retinal Oximetry
1105751|NCT01549132|Spectral imaging
1105752|NCT01549132|Retinal Laser therapy
1105753|NCT01549132|Intravitreal Anti-VEGF Injection therapy
1105754|NCT01549119|HIV-1
1105755|NCT01549119|HIV
1105756|NCT01549119|immunotherapy
1105757|NCT01549119|active immunotherapy
1105758|NCT01549119|vaccine
1105759|NCT01549119|virulence
1105760|NCT01549119|innate immunity
1105761|NCT01549119|NK cells
1105762|NCT01549093|Non-small cell lung cancer
1105763|NCT01549093|Endostar
1105764|NCT01549093|Continued Pumping into
1105765|NCT01549093|Gemcitabine
1105766|NCT01549093|Carboplatin
1105767|NCT01549080|traditional chinese medicine and thalassemia
1105768|NCT01549067|Advanced
1105769|NCT01549067|Colorectal Cancer
1105770|NCT01549067|Targeted chemotherapy
1105771|NCT01549067|Surgery
1105772|NCT01549067|Radiotherapy
1105773|NCT01549041|schizophrenia
1105774|NCT01549041|asenapine
1105775|NCT01549041|Once daily
1105776|NCT01549041|twice daily
1105777|NCT01549015|Urea Cycle Defects
1105778|NCT01549015|CPSD
1105779|NCT01549015|OTCD
1105780|NCT01549015|ASSD
1105781|NCT01549015|ASLD
1105782|NCT01549002|Abscess
1105783|NCT01549002|Pain
1105784|NCT01549002|Administration intranasal
1105785|NCT01549002|Infusions intravenous
1105786|NCT01548989|linguistic validation of a new questionnaire
1105787|NCT01548976|linguistic validation of the PISQ-R questionnaire
1105788|NCT01548963|Tight glycemia control
1105789|NCT01548963|Model Predictive Control algorithm
1105790|NCT01548963|Cardiac surgery patients
1105791|NCT01548950|Congenital heart disease
1105792|NCT01548950|Pulmonary arterial hypertension
1105793|NCT01548950|Sildenafil
1105794|NCT01548950|Bosentan
1105795|NCT01548950|Pediatric cardiac surgery
1105796|NCT01548937|I-123 ADAM Serotonin transporter imaging
1105797|NCT01548924|Patients with malignant solid tumors of any histologically confirmed, not susceptible of cure, which have received the standard treatment available
1105798|NCT01548872|HTk solution
1105799|NCT01548872|Cardioplegia
1105800|NCT01548872|myocardial protection
1105801|NCT01548872|pediatric cardiac surgery
1105802|NCT01548859|Myocardial protection
1105803|NCT01548859|Myocardial injury
1105804|NCT01548859|Anaesthetic preconditioning
1105805|NCT01548859|Pediatric cardiac surgery
1105806|NCT01548859|Troponin I
1105807|NCT01548859|Sevoflurane
1105808|NCT01548859|Midazolam
1105809|NCT01548846|tomotherapy
1105810|NCT01548846|xerostomy
1105811|NCT01548846|head and neck squamous cell carcinoma
1105812|NCT01548833|Myopia
1105813|NCT01548833|Contact Lenses
1105814|NCT01548820|Hepatitis B virus
1105815|NCT01548820|Lamivudine
1105816|NCT01548820|Resistance to treatment
1105817|NCT01548794|spinal anesthesia
1105818|NCT01548794|bupivacaine
1105819|NCT01548794|lidocaine
1105820|NCT01548794|local infiltration anesthesia
1105821|NCT01548794|recovery
1105822|NCT01548794|duration of anesthesia
1105823|NCT01548794|outpatient herniorrhaphy
1105824|NCT01548781|arm
1105825|NCT01548781|strength
1105826|NCT01548781|coordination
1105827|NCT01548781|physical therapy
1105828|NCT01548781|robotics
1105829|NCT01548781|stroke
1105830|NCT01548781|synergy
1105831|NCT01548768|Rheumatoid Arthritis
1105832|NCT01548768|Cardiovascular disease
1105833|NCT01548768|Myocardium
1105834|NCT01548768|TNF-alpha inhibitors
1105835|NCT01548768|ESCAPE
1105836|NCT01548768|Co-morbidities
1105837|NCT01548768|RHYTHM
1105838|NCT01548755|Home monitoring
1105839|NCT01548755|cardiomessenger
1105840|NCT01548755|ICD
1105841|NCT01548742|Meditation
1105842|NCT01548729|Cystic Fibrosis
1105843|NCT01548729|Diabetes Related Cystic Fibrosis
1105844|NCT01548729|Lung transplantation
1105845|NCT01548729|Pancreatic islets
1105846|NCT01548716|Pruritis in hemodialysis patients
1105847|NCT01548716|25-Vitamin D in chronic kidney disease
1105848|NCT01548703|metabotropic glutamate receptors 2 and 3
1105849|NCT01548703|antagonist
1105850|NCT01548703|mGluR
1105851|NCT01548703|ketamine
1105852|NCT01548703|BDNF
1105853|NCT01548703|Depression
1105854|NCT01548703|Major Depressive Disorder
1105855|NCT01548703|Treatment Resistant Depression
1105856|NCT01548703|Mood Disorder
1105857|NCT01548703|Phase 1 safety, tolerability and pharmacokinetics study
1105858|NCT01548690|ornithine
1105859|NCT01548690|phenylacetate
1105860|NCT01548690|acetaminophen toxicity
1105861|NCT01548690|acute liver failure
1105862|NCT01548690|hepatitis B
1105863|NCT01548690|autoimmune hepatitis
1105864|NCT01548690|drug-induced liver injury
1105865|NCT01548677|Circulating Tumour Cells
1105866|NCT01548677|HER2 negative primary breast cancer
1105867|NCT01548677|HER2 positive CTC
1105868|NCT01548677|Trastuzumab
1105869|NCT01548664|Total knee replacement
1105870|NCT01548664|Outpatient
1105871|NCT01548664|Randomized controlled trial
1105872|NCT01548664|Video games
1105873|NCT01548638|Tobacco
1105874|NCT01548638|Smoking
1105875|NCT01548638|Galantamine
1105876|NCT01548625|risk of cardiovascular events
1105877|NCT01548612|Schizophrenia
1105878|NCT01548612|Nitric oxide
1105879|NCT01548612|Sodium nitroprusside
1105880|NCT01548599|HIV
1105881|NCT01548599|Malnutrition
1105882|NCT01548599|Food Security
1105883|NCT01548599|Kenya
1105884|NCT01548586|tDCS
1105885|NCT01548586|Diaphragm
1105886|NCT01548586|Cortical Excitability
1105887|NCT01548586|MEPs
1105888|NCT01548586|TMS
1105889|NCT01548573|multiple myeloma
1105890|NCT01548573|POEMS (Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes)
1105891|NCT01548573|amyloidosis
1105892|NCT01548573|bone marrow transplant
1105893|NCT01548573|autologous
1105894|NCT01548560|HIV Infections
1105895|NCT01548560|Anti-HIV agents
1105896|NCT01548560|HIV-1
1105897|NCT01548547|intravenous line
1105898|NCT01548547|simulation education
1105899|NCT01548534|Metastatic Breast Cancer
1105900|NCT01548534|First-Line chemotherapy
1105901|NCT01548534|Taxane or Anthracycline
1105902|NCT01548534|DHA
1105903|NCT01548534|PUFA
1105904|NCT01548534|Dietary supplementation
1105905|NCT01548534|First-Line Taxane or Anthracycline based chemotherapy
1105906|NCT01548521|Prader-Willi, neonates, poor suckling
1105907|NCT01548508|Advanced Chronic Heart Failure, physical therapy, Exercise
1105908|NCT01548495|MDS
1105909|NCT01548495|Autoantibodies
1105910|NCT01548495|Erythropoietin
1105911|NCT01548495|Autoantibodies in MDS patients treated with EPO
1105912|NCT01548469|Mild periodontitis
1105913|NCT01548469|Bio Mineral toothpaste
1105914|NCT01548469|Geumjin Thermal Water
1105915|NCT01548456|femur fracture
1105916|NCT01548456|internal fixation
1105917|NCT01548456|intramedullary nailing
1105918|NCT01548443|Wound Healing
1105919|NCT01548443|hydrocolloid
1105920|NCT01548443|Wound Dressing
1105921|NCT01548443|Medifoam H
1105922|NCT01548443|Duoderm THIN
1105923|NCT01548443|Mild Acute Trauma
1105924|NCT01548417|Alcohol
1105925|NCT01548417|Relapse
1105926|NCT01548378|HGF
1105927|NCT01548378|Gene
1105928|NCT01548378|Critical Limb Ischemia
1105929|NCT01548365|Nursing Services
1105930|NCT01548365|Catheterization, Central Venous
1105931|NCT01548365|Catheters Indwelling
1105932|NCT01548365|Catheterization, Peripheral
1105933|NCT01548352|Syncope
1105934|NCT01548352|Unconsciousness
1105935|NCT01548352|Syncope, vasovagal, neurally-mediated
1105936|NCT01548352|Syncope, cardiogenic
1105937|NCT01548352|Cardiac arrhythmia
1105938|NCT01548352|Sudden cardiac death
1105939|NCT01548352|Syncopal episode
1105940|NCT01548326|Vaccination Failure
1105941|NCT01548326|Nonresponder
1105942|NCT01548326|Hepatitis B virus
1105943|NCT01548326|Atorvastatin
1105944|NCT01548326|Immunization against viral Hepatitis
1105945|NCT01548313|human milk
1105946|NCT01548313|nutrition
1105947|NCT01548313|breastfed child
1105948|NCT01548313|microbiota
1105949|NCT01548313|fatty acids
1105950|NCT01548313|intestinal microbiota
1105951|NCT01548313|probiotics
1105952|NCT01548300|cardiometabolic disease
1105953|NCT01548287|Mild Cognitive Impairment
1105954|NCT01548287|Mild Alzheimer's disease
1105955|NCT01548287|Safety
1105956|NCT01548287|Tolerability
1105957|NCT01548274|endothelial progenitor cells
1105958|NCT01548261|obtain the oral mucosal tissue from healthy donors
1105959|NCT01548222|type 2 diabetes
1105960|NCT01548222|continuous glucose
1105961|NCT01548222|basal insulin
1105962|NCT01548196|nephrolithotomy
1105963|NCT01548170|Pharmacokinetic
1105964|NCT01548170|Sunitinib
1105965|NCT01548170|Ketoconazol
1105966|NCT01548170|interaction, Phase I
1105967|NCT01548157|HCP1007
1105968|NCT01548157|Rosuvastatin
1105969|NCT01548157|Omega-3
1105970|NCT01548144|Advanced Cancers
1105971|NCT01548144|Advanced Malignancies
1105972|NCT01548144|Crizotinib
1105973|NCT01548144|PF-02341066
1105974|NCT01548144|Pazopanib
1105975|NCT01548144|Gw786034
1105976|NCT01548144|Pemetrexed
1105977|NCT01548144|LY231514
1105978|NCT01548144|Alimta
1105979|NCT01548144|MTA
1105980|NCT01548144|Multitargeted Antifolate
1105981|NCT01548144|NSC-698037
1105982|NCT01548131|fear of childbirth
1105983|NCT01548131|delivery mode
1105984|NCT01548131|delivery satisfaction
1105985|NCT01548118|Human papillomavirus
1105986|NCT01548118|vaccine
1105987|NCT01548118|cervical infection
1105988|NCT01548118|cervical cancer
1105989|NCT01548105|Pelvic organ prolapse
1105990|NCT01548105|smoking and collagen metabolism
1105991|NCT01548092|Recto-vaginal fistula
1105992|NCT01548092|Adipose Derived Stem Cells
1105993|NCT01548079|ursodeoxycholic acid
1105994|NCT01548079|fatty liver disease
1105995|NCT01548079|morbid obesity
1105996|NCT01548079|bariatric surgery
1105997|NCT01548079|NAFLD
1105998|NCT01548053|Primary care
1105999|NCT01548053|Dementia
1106000|NCT01548053|Knowledge translation
1106001|NCT01548053|Quality of care
1106002|NCT01548053|Qualitative methods
1106003|NCT01548053|Alzheimer's disease
1106004|NCT01548040|NMES
1106005|NCT01548040|Muscle
1106006|NCT01548040|strength
1106007|NCT01548040|TKA
1106008|NCT01548040|Focus to show shorter muscle recovery after Knee operation
1106009|NCT01548027|TAP block
1106010|NCT01548027|postoperative analgesia
1106011|NCT01548014|Crohn's disease
1106012|NCT01548014|VSL #3
1106013|NCT01548014|infliximab
1106014|NCT01548001|Rheumatoid Arthritis
1106015|NCT01548001|Iguratimod
1106016|NCT01548001|Methotrexate
1106017|NCT01547988|Aging
1106018|NCT01547988|Falls
1106019|NCT01547988|Balance Control
1106020|NCT01547988|Voluntary Step Execution Test
1106021|NCT01547988|Dual-Task
1106022|NCT01547988|Self-reported function
1106023|NCT01547975|surgical outcomes after corneal transplantation
1106024|NCT01547975|Retrospective analysis
1106025|NCT01547975|corneal transplantation
1106026|NCT01547949|pain
1106027|NCT01547949|inflammation
1106028|NCT01547949|muscle damage
1106029|NCT01547923|Colorectal Cancer
1106030|NCT01547923|DihydroPyrimidine Dehydrogenase
1106031|NCT01547923|Lethal toxicity
1106032|NCT01547923|Fluoropyrimidine
1106033|NCT01547910|fatty liver
1106034|NCT01547910|hepatitis
1106035|NCT01547910|insulin resistance
1106036|NCT01547910|unsaturated fatty acids
1106037|NCT01547910|NAFLD, children
1106038|NCT01547884|Immune Responses
1106039|NCT01547884|Mycobacterial Antigens
1106040|NCT01547884|Tissue-invasive Helminth Parasites
1106041|NCT01547871|Natural History Study
1106042|NCT01547871|Spinal Muscular Atrophy (SMA)
1106043|NCT01547871|Natural History
1106044|NCT01547858|Hematotoxicity
1106045|NCT01547858|Formaldehyde
1106046|NCT01547858|Cross-Sectional Study
1106047|NCT01547858|Occupational Exposure
1106048|NCT01547845|Disparities
1106049|NCT01547845|Patient Reported Outcomes
1106050|NCT01547845|Symptoms
1106051|NCT01547845|Symptom Surveillance
1106052|NCT01547832|Cholesterol
1106053|NCT01547832|Early Onset Parkinson's Disease
1106054|NCT01547832|Fat Metabolism
1106055|NCT01547832|Insulin Resistance
1106056|NCT01547832|PARK2 Mutations
1106057|NCT01547819|TBI
1106058|NCT01547819|Magnetic Resonance Imaging (MRI)
1106059|NCT01547819|PTSD
1106060|NCT01547819|PET Imaging
1106061|NCT01547819|11C-Flumazenil
1106062|NCT01547806|Autologous Hematopoietic Cell Transplantation
1106063|NCT01547806|Plasma Cell Myeloma
1106064|NCT01547806|Mobilization
1106065|NCT01547806|Apheresis
1106066|NCT01547806|Plerixafor
1106067|NCT01547793|Hemolytic Severity
1106068|NCT01547793|Erythrocyte
1106069|NCT01547793|Sickle Cell Disease
1106070|NCT01547793|SD
1106071|NCT01547780|MRI
1106072|NCT01547780|Positron Emission Tomograhy (PET)
1106073|NCT01547780|Inflammation
1106074|NCT01547780|Microglial Activation
1106075|NCT01547780|Traumatic Brain Injury
1106076|NCT01547780|TBI
1106082|NCT01547754|Neuroinflammation
1106083|NCT01547754|HIV
1106084|NCT01547754|Positron Emission Tomograhy (PET)
1106085|NCT01547754|Mild Neurocognitive Disorder
1106086|NCT01547754|P-Glycoprotein
1106087|NCT01547754|Mild Cognitive Disorder
1106088|NCT01547754|Healthy Volunteer
1106089|NCT01547754|HV
1106090|NCT01547741|estrogen receptor-negative breast cancer
1106091|NCT01547741|estrogen receptor-positive breast cancer
1106092|NCT01547741|HER2-negative breast cancer
1106093|NCT01547741|progesterone receptor-negative breast cancer
1106094|NCT01547741|progesterone receptor-positive breast cancer
1106095|NCT01547741|stage IA breast cancer
1106096|NCT01547741|stage IB breast cancer
1106097|NCT01547741|stage II breast cancer
1106098|NCT01547741|stage IIIA breast cancer
1106099|NCT01547741|stage IIIC breast cancer
1106100|NCT01547728|antithrombin
1106101|NCT01547728|Heparin Resistant
1106102|NCT01547728|Cardiac Surgery
1106103|NCT01547715|Meningococcal,
1106104|NCT01547715|ACWY,
1106105|NCT01547715|bacterial meningitis,
1106106|NCT01547715|conjugate vaccine,
1106107|NCT01547715|healthy, children,
1106108|NCT01547715|adolescents,
1106109|NCT01547715|adults,
1106110|NCT01547715|India
1106111|NCT01547702|ADHD
1106112|NCT01547702|attention
1106113|NCT01547702|inattention
1106114|NCT01547702|hyperactivity
1106115|NCT01547702|classroom intervention
1106116|NCT01547702|teacher education
1106117|NCT01547702|web-based intervention
1106118|NCT01547663|pain scale
1106119|NCT01547663|craniotomy
1106120|NCT01547637|Obturator nerve block
1106121|NCT01547637|Regional anesthesia
1106122|NCT01547637|TURBT
1106123|NCT01547624|Neck
1106124|NCT01547624|Spine
1106125|NCT01547624|Muscles
1106126|NCT01547624|Activity
1106127|NCT01547624|Coordination
1106128|NCT01547611|Rehabilitation
1106129|NCT01547611|Cervical Spine
1106130|NCT01547611|Radiculopathy
1106131|NCT01547611|Disc
1106132|NCT01547611|Surgery
1106133|NCT01547585|Cholesterol
1106134|NCT01547585|Cardiovascular disease
1106135|NCT01547585|Soy
1106136|NCT01547585|Dose-response
1106137|NCT01547572|Video education
1106138|NCT01547572|Enhanced recovery
1106139|NCT01547572|Reducing hospital stay
1106140|NCT01547572|Improving patient satisfaction
1106141|NCT01547533|Chagas disease
1106142|NCT01547533|lactation
1106143|NCT01547533|breastmilk
1106144|NCT01547533|postpartum period
1106145|NCT01547533|infants
1106146|NCT01547533|pediatric clinical pharmacology
1106147|NCT01547533|developmental clinical pharmacology
1106148|NCT01547533|parasitology
1106149|NCT01547533|trypanosoma cruzi
1106150|NCT01547520|meperidine
1106151|NCT01547520|esophagogastroduodenoscopy
1106152|NCT01547520|unsedated
1106153|NCT01547520|minimal sedation
1106154|NCT01547507|hemodynamics
1106155|NCT01547507|respiratory
1106156|NCT01547494|Migraines
1106157|NCT01547494|Diet, Vegetarian
1106158|NCT01547494|Diet, Fat-Restricted
1106159|NCT01547494|Pain
1106160|NCT01547468|hip fracture
1106161|NCT01547468|elderly
1106162|NCT01547468|delirium
1106163|NCT01547468|broken hip
1106164|NCT01547468|hip
1106165|NCT01547468|surgery
1106166|NCT01547468|orthopedic
1106167|NCT01547468|orthopedic surgery
1106168|NCT01547468|pain
1106169|NCT01547468|anesthesia
1106170|NCT01547468|Ochsner Clinic
1106171|NCT01547468|Ochsner Hospital
1106172|NCT01547468|Leslie Thomas MD
1106173|NCT01547468|New Orleans
1106174|NCT01547468|Louisiana
1106175|NCT01547455|Statin
1106176|NCT01547455|kidney function
1106177|NCT01547455|antiinflammatory effect
1106178|NCT01547442|aphakia
1106179|NCT01547442|secondary intraocular lens
1106180|NCT01547442|congenital cataract
1106181|NCT01547442|marfan syndrome
1106182|NCT01547442|pediatric cataract
1106183|NCT01547442|ectopia lentis
1106184|NCT01547442|subluxated lens
1106185|NCT01547429|aphakia
1106186|NCT01547429|secondary intraocular lens
1106187|NCT01547416|Diaphragmatic dysfunction
1106188|NCT01547416|General anesthesia
1106189|NCT01547416|Epidural Anesthesia
1106190|NCT01547403|Screening for Type 2 Diabetes
1106191|NCT01547390|preeclampsia
1106192|NCT01547390|Aspirin
1106193|NCT01547377|atherosclerosis
1106194|NCT01547377|zinc and selenium status
1106195|NCT01547377|rosuvastatin
1106196|NCT01547377|oxidative stress biomarkers
1106197|NCT01547377|inflammation biomarkers
1106198|NCT01547364|Caudal
1106199|NCT01547364|Epidural
1106200|NCT01547364|Dextrose
1106201|NCT01547364|Analgesia
1106202|NCT01547364|TRVP1
1106203|NCT01547351|Relapse in multiple sclerosis
1106204|NCT01547351|Psychometric properties of the patient self-report questionnaire
1106205|NCT01547351|Evaluation of ARMS questionnaire
1106206|NCT01547338|Breast
1106207|NCT01547338|Reconstruction
1106208|NCT01547299|prostate cancer
1106209|NCT01547299|prostatectomy
1106210|NCT01547299|neoadjuvant
1106211|NCT01547286|Asthma
1106212|NCT01547286|Allergen Challenge
1106213|NCT01547286|Cat allergen
1106214|NCT01547286|Dust mite allergen
1106215|NCT01547286|Airway Hyper-responsiveness
1106216|NCT01547286|Positron Emission Tomography - Computed Tomography
1106217|NCT01547286|Nitrogen isotopes
1106218|NCT01547286|Blood flow
1106219|NCT01547247|colonoscopy
1106220|NCT01547247|cap-assisted colonoscopy
1106221|NCT01547247|water immersion colonoscopy
1106222|NCT01547234|Multiple Sclerosis
1106223|NCT01547234|ambulation
1106224|NCT01547234|manual function
1106225|NCT01547234|Fampridine
1106226|NCT01547221|otomycosis
1106227|NCT01547221|3% boric acid
1106228|NCT01547221|1% clotrimazole ear drop
1106229|NCT01547208|ICD shocks
1106230|NCT01547208|Ventricular tachycardias ablation
1106231|NCT01547208|Timing of ablation
1106232|NCT01547208|Electrical storm
1106233|NCT01547208|Arrhythmic storm
1106234|NCT01547195|fibromyalgia
1106235|NCT01547195|swimming
1106236|NCT01547169|memory
1106237|NCT01547169|intranasal insulin
1106238|NCT01547169|Alzheimer's disease
1106239|NCT01547156|patient decision support
1106240|NCT01547156|telemonitoring
1106241|NCT01547156|self-management
1106242|NCT01547156|remote patient monitoring
1106243|NCT01547156|active assistance technology
1106244|NCT01547156|selfcare
1106245|NCT01547143|Secondary hemophagocytic lymphohistiocytosis of adults
1106246|NCT01547130|Colonoscopy
1106247|NCT01547130|Yoga
1106248|NCT01547130|Complementary and alternative medicine
1106249|NCT01547130|Bowel cleansing
1106250|NCT01547130|Large bowel preparation
1106251|NCT01547130|Cancer screening
1106252|NCT01547130|Colorectal cancer
1106253|NCT01547117|POTS
1106254|NCT01547117|Orthostatic Intolerance
1106255|NCT01547117|Orthostatic Tachycardia
1106256|NCT01547091|Mesenchymal Stem Cells
1106257|NCT01547091|Rheumatoid Arthritis
1106258|NCT01547065|TEE and renal resistive index
1106259|NCT01547052|DBT, child, emotion regulation, behavior problems, residential care
1106260|NCT01547039|Carotid endarterectomy
1106261|NCT01547039|Transcranial doppler
1106262|NCT01547039|Micro embolic signals
1106263|NCT01547039|Platelets
1106264|NCT01547039|Aspirin
1106265|NCT01547026|schizophrenia
1106266|NCT01547026|exercise
1106267|NCT01547026|sport
1106268|NCT01547026|weight control
1106269|NCT01547026|fitness
1106270|NCT01547000|Tourette Syndrome
1106271|NCT01547000|Tourette Disorder
1106272|NCT01547000|Tics
1106273|NCT01547000|Motor tics
1106274|NCT01547000|Vocal tics
1106275|NCT01547000|Intuniv
1106276|NCT01547000|Guanfacine
1106277|NCT01547000|Medication
1106278|NCT01547000|Drug
1106279|NCT01547000|Placebo
1106280|NCT01547000|Child
1106281|NCT01547000|Children
1106282|NCT01547000|Adolescent
1106283|NCT01546987|adenocarcinoma of the prostate
1106284|NCT01546987|stage I prostate cancer
1106285|NCT01546987|stage IIA prostate cancer
1106286|NCT01546987|stage IIB prostate cancer
1106287|NCT01546987|stage III prostate cancer
1106288|NCT01546987|stage IV prostate cancer
1106289|NCT01546974|Mechanical Ventilation
1106290|NCT01546974|Humidification system
1106291|NCT01546974|Patients submitted to mechanical ventilation for at least 48 hours
1106292|NCT01546961|Chloroquine
1106293|NCT01546961|Uncomplicated vivax malaria
1106294|NCT01546948|Methadone
1106295|NCT01546948|Hydromorphone
1106296|NCT01546948|Hepatobiliary surgery
1106297|NCT01546948|Postoperative pain
1106298|NCT01546935|Influenza
1106299|NCT01546935|Oseltamivir
1106300|NCT01546935|Lower tract respiratory infection
1106301|NCT01546922|Hydrocortisone
1106302|NCT01546922|Cognition
1106303|NCT01546922|Adrenal insufficiency
1106304|NCT01546922|Quality of Life
1106305|NCT01546922|Common Somatic Complaints
1106306|NCT01546922|Cardiovascular/Metabolic Profile
1106307|NCT01546922|Somatosensation
1106308|NCT01546883|Atrial fibrillation
1106309|NCT01546883|MRI
1106310|NCT01546857|orthopedic pain
1106311|NCT01546844|SMS
1106312|NCT01546844|text
1106313|NCT01546844|text messages
1106314|NCT01546844|text messaging
1106315|NCT01546844|diabetes
1106316|NCT01546844|diabetes mellitus
1106317|NCT01546844|type II diabetes
1106318|NCT01546844|type II diabetes mellitus
1106319|NCT01546844|type 2 diabetes
1106320|NCT01546844|type 2 diabetes mellitus
1106321|NCT01546844|Beacon
1106322|NCT01546818|HIV
1106323|NCT01546818|Vaccine
1106324|NCT01546818|HIV-1 infections
1106325|NCT01546805|Blepharospasm
1106326|NCT01546805|Hemifacial spasm
1106327|NCT01546805|Botox
1106328|NCT01546805|Zinc
1106329|NCT01546792|exercise
1106330|NCT01546792|diet
1106331|NCT01546792|lifestyle
1106332|NCT01546792|sleep apnoea
1106333|NCT01546792|obesity
1106334|NCT01546766|Diabetes
1106335|NCT01546766|Pupillary response
1106336|NCT01546766|Retinal disorders
1106337|NCT01546766|Midperipheral ischemia
1106338|NCT01546766|Fundus photography
1106339|NCT01546766|Optical coherence tomography
1106346|NCT01546740|Glaucoma, Compliance, Prevalence
1106347|NCT01546727|Preschoolers
1106348|NCT01546727|Obesity
1106349|NCT01546727|Behavioral Treatment
1106350|NCT01546675|Amputation
1106351|NCT01546675|Prosthesis Design
1106352|NCT01546675|Biomechanics
1106353|NCT01546662|Rhinitis
1106354|NCT01546636|Cerebral desaturation events
1106355|NCT01546636|Cerebral oximetry
1106356|NCT01546636|Beach chair position
1106357|NCT01546610|Rheumatoid foot
1106358|NCT01546610|foot pain
1106359|NCT01546610|insoles
1106360|NCT01546610|foot function
1106361|NCT01546610|electronic baropodometer
1106362|NCT01546610|plantar pressure
1106363|NCT01546610|gait analysis
1106364|NCT01546597|Metformin
1106365|NCT01546597|Ranolazine
1106366|NCT01546597|Type 2 Diabetes Mellitus
1106367|NCT01546558|Metformin
1106368|NCT01546558|Ranolazine
1106369|NCT01546558|Type 2 Diabetes Mellitus
1106370|NCT01546532|Heart failure
1106371|NCT01546532|RLX030
1106372|NCT01546532|hemodynamics
1106373|NCT01546532|cardiovascular diseases
1106374|NCT01546480|Chronic postoperative pain
1106375|NCT01546480|Postcholecystectomy pain
1106376|NCT01546480|Inflammation
1106377|NCT01546480|Interleukines
1106378|NCT01546467|Schizophrenia
1106379|NCT01546467|Schizoaffective disorder
1106380|NCT01546467|Psychosis
1106381|NCT01546467|Early phase
1106382|NCT01546467|Cognitive remediation
1106383|NCT01546467|Functional outcome
1106384|NCT01546454|Premenopausal women
1106385|NCT01546454|coronary heart disease
1106386|NCT01546454|menstrual cycle
1106387|NCT01546454|lipids
1106388|NCT01546441|primary care
1106389|NCT01546441|aging
1106390|NCT01546441|interprofessional care
1106391|NCT01546441|multimorbidity
1106392|NCT01546428|c-MET
1106393|NCT01546428|Advanced solid tumor
1106394|NCT01546415|Phase 4
1106395|NCT01546415|Desferasirox
1106396|NCT01546415|Iron Overload
1106397|NCT01546415|Aplastic Anemia
1106398|NCT01546389|Malaria, vaccine, PfSPZ, challenge
1106399|NCT01546350|infertility, recurrent pregnancy loss, miscarriage
1106400|NCT01546337|anemia
1106401|NCT01546337|non-myeloid haemopathy
1106402|NCT01546337|myelodysplastic syndrome
1106403|NCT01546337|Erythropoiesis stimulating agents
1106404|NCT01546337|predictive markers
1106405|NCT01546324|Maternal Blood
1106406|NCT01546324|PGD
1106407|NCT01546324|PGS
1106408|NCT01546324|Natera
1106409|NCT01546324|Gene Security Network
1106410|NCT01546324|Non-invasive prenatal diagnosis
1106411|NCT01546311|prosthetic socket
1106412|NCT01546311|residual limb volume fluctuation
1106413|NCT01546311|instantaneous bladder
1106414|NCT01546298|Contact Dermatitis
1106415|NCT01546285|The focus of this study is to demonstrate that DINAMAP® SuperSTATTM NIBP algorithm has been implemented correctly without performance losses to the B40 monitor
1106416|NCT01546272|Subcutaneous resorbable sutures
1106417|NCT01546272|Tolerance / effectiveness of subcutaneous suture
1106418|NCT01546272|Reduced operative time and anesthesia time
1106544|NCT01545726|CRTH2 receptor
1106419|NCT01546272|Medico-economic evaluation
1106420|NCT01546272|Accidental exposure to blood
1106421|NCT01546259|colonoscopy
1106422|NCT01546259|water
1106423|NCT01546259|female
1106424|NCT01546259|BMI
1106425|NCT01546259|unsedated
1106426|NCT01546259|low BMI female patients
1106427|NCT01546259|Intubation
1106428|NCT01546246|colonoscopy
1106429|NCT01546246|water
1106430|NCT01546246|incomplete
1106431|NCT01546246|failed
1106432|NCT01546246|unsedated
1106433|NCT01546233|Lung cancer
1106434|NCT01546233|Chemotherapy
1106435|NCT01546233|Multidisciplinary self care programme
1106436|NCT01546233|Fatigue
1106437|NCT01546220|colonoscopy
1106438|NCT01546220|elder patient
1106439|NCT01546220|water
1106440|NCT01546220|unsedated
1106441|NCT01546207|ventricular tachycardia
1106442|NCT01546207|catheter ablation
1106443|NCT01546207|VT
1106444|NCT01546194|Informed consent
1106445|NCT01546194|Perioperative period
1106446|NCT01546194|Morning of surgery
1106447|NCT01546194|Anesthesiology
1106448|NCT01546181|photoreceptors
1106449|NCT01546181|retinal pigment epithelium
1106450|NCT01546181|adaptive optics
1106451|NCT01546168|Atrial Fibrillation ablation
1106452|NCT01546168|Esophageal Deviation
1106453|NCT01546168|AF
1106454|NCT01546116|adefovir
1106455|NCT01546116|lamivudine
1106456|NCT01546116|entecavir resistance
1106457|NCT01546103|Vitamin D deficiency
1106458|NCT01546090|Alprazolam
1106459|NCT01546090|benzodiazepines
1106460|NCT01546090|Inferior alveolar nerve block
1106461|NCT01546090|irreversible pulpitis
1106462|NCT01546090|local anesthesia
1106463|NCT01546064|Bile duct anastomosis
1106464|NCT01546064|Biliary complications
1106465|NCT01546051|metabotropic glutamate receptors 2 and 3
1106466|NCT01546051|antagonist
1106467|NCT01546051|mGluR
1106468|NCT01546051|ketamine
1106469|NCT01546051|BDNF
1106470|NCT01546051|Depression
1106471|NCT01546051|Major Depressive Disorder
1106472|NCT01546051|Mood Disorder
1106473|NCT01546051|Treatment Resistant Depression
1106474|NCT01546051|Phase 1 safety, tolerability and pharmacokinetics study
1106475|NCT01546038|Hedgehog Inhibitor
1106476|NCT01546038|Acute Myeloid Leukemia
1106477|NCT01546038|Myelodysplastic syndrome
1106478|NCT01546038|Intensive chemotherapy
1106479|NCT01546038|LDAC
1106480|NCT01545999|Transcranial Magnetic Stimulation (TMS)
1106481|NCT01545999|Dorsolateral Prefrontal Cortex (DLPFC)
1106482|NCT01545999|Schizophrenia
1106483|NCT01545999|Working Memory
1106484|NCT01545999|Paired Associative Stimulation (PAS)
1106485|NCT01545999|Electroencephalography (EEG)
1106486|NCT01545999|Cognition
1106487|NCT01545986|Joint Replacement
1106488|NCT01545986|Exercise
1106489|NCT01545986|Power training
1106490|NCT01545947|Neoplasms
1106491|NCT01545947|Pulmonary
1106492|NCT01545947|Lung Cancer
1106493|NCT01545947|Cancer of the Lung
1106494|NCT01545947|Stage IIIB Non-Small Cell Lung Cancer
1106495|NCT01545947|IV Non-Small Cell Lung Cancer
1106496|NCT01545947|Non-Small Cell Lung Cancer
1106497|NCT01545934|Overweight
1106498|NCT01545934|Obese
1106499|NCT01545934|Pregnancy
1106500|NCT01545934|Weight Gain
1106501|NCT01545921|Quality Of Life
1106502|NCT01545921|Cancer
1106503|NCT01545921|End of life
1106504|NCT01545921|palliative setting
1106505|NCT01545908|Fecal transplant
1106506|NCT01545908|induction of remission
1106507|NCT01545908|active ulcerative colitis
1106508|NCT01545882|prostate
1106509|NCT01545882|hormone-resistant
1106510|NCT01545882|degarelix
1106511|NCT01545882|firmagon
1106512|NCT01545882|anti-androgens
1106513|NCT01545882|total androgen blockade
1106514|NCT01545882|injection
1106515|NCT01545869|carbon dioxide laser
1106516|NCT01545869|fractional resurfacing
1106517|NCT01545869|freckles
1106518|NCT01545869|melanosis
1106519|NCT01545856|Parkinson's Disease
1106520|NCT01545856|cardiovascular events
1106521|NCT01545856|Levodopa
1106522|NCT01545843|depression
1106523|NCT01545843|sleep
1106524|NCT01545843|treatment
1106525|NCT01545830|Metabolic syndrome
1106526|NCT01545830|Insulin resistance
1106527|NCT01545830|Vitamin D deficiency
1106528|NCT01545817|Renal cell carcinoma
1106529|NCT01545817|GW786034
1106530|NCT01545817|Everolimus
1106531|NCT01545817|Pazopanib
1106532|NCT01545804|Hepatocellular carcinoma
1106533|NCT01545778|Substance abuse detection
1106534|NCT01545778|Opioids abuse
1106535|NCT01545778|Tapentadol immediate-release (IR)
1106536|NCT01545778|Oxycodone immediate-release (IR)
1106537|NCT01545765|Healthy volunteers
1106538|NCT01545752|elearning
1106539|NCT01545752|CD-based education
1106540|NCT01545739|Pacemaker therapy
1106541|NCT01545739|Cardiac resynchronisation therapy (CRT)
1106542|NCT01545726|Asthma
1106543|NCT01545726|Sputum eosinophilia
1106545|NCT01545726|PGD2 antagonist
1106546|NCT01545713|renal
1106547|NCT01545713|kidney
1106548|NCT01545713|transplant
1106549|NCT01545713|living donor
1106550|NCT01545700|dexamethasone
1106551|NCT01545700|hyperglycemia
1106552|NCT01545700|gynecologic surgery
1106553|NCT01545687|pain
1106554|NCT01545687|oral complications of radiation therapy
1106555|NCT01545687|weight changes
1106556|NCT01545687|recurrent squamous cell carcinoma of the hypopharynx
1106557|NCT01545687|recurrent squamous cell carcinoma of the larynx
1106558|NCT01545687|recurrent squamous cell carcinoma of the nasopharynx
1106559|NCT01545687|recurrent squamous cell carcinoma of the oropharynx
1106560|NCT01545687|recurrent verrucous carcinoma of the larynx
1106561|NCT01545687|stage I squamous cell carcinoma of the hypopharynx
1106562|NCT01545687|stage I squamous cell carcinoma of the larynx
1106563|NCT01545687|stage I squamous cell carcinoma of the nasopharynx
1106564|NCT01545687|stage I squamous cell carcinoma of the oropharynx
1106565|NCT01545687|stage I verrucous carcinoma of the larynx
1106566|NCT01545687|stage II squamous cell carcinoma of the hypopharynx
1106567|NCT01545687|stage II squamous cell carcinoma of the larynx
1106568|NCT01545687|stage II squamous cell carcinoma of the nasopharynx
1106569|NCT01545687|stage II squamous cell carcinoma of the oropharynx
1106570|NCT01545687|stage II verrucous carcinoma of the larynx
1106571|NCT01545687|stage III squamous cell carcinoma of the hypopharynx
1106572|NCT01545687|stage III squamous cell carcinoma of the larynx
1106573|NCT01545687|stage III squamous cell carcinoma of the nasopharynx
1106574|NCT01545687|stage III squamous cell carcinoma of the oropharynx
1106575|NCT01545687|stage III verrucous carcinoma of the larynx
1106576|NCT01545687|stage IV squamous cell carcinoma of the hypopharynx
1106577|NCT01545687|stage IV squamous cell carcinoma of the nasopharynx
1106578|NCT01545687|stage IVA squamous cell carcinoma of the larynx
1106579|NCT01545687|stage IVA squamous cell carcinoma of the oropharynx
1106580|NCT01545687|stage IVA verrucous carcinoma of the larynx
1106581|NCT01545687|stage IVB squamous cell carcinoma of the larynx
1106582|NCT01545687|stage IVB squamous cell carcinoma of the oropharynx
1106583|NCT01545687|stage IVB verrucous carcinoma of the larynx
1106584|NCT01545687|stage IVC squamous cell carcinoma of the larynx
1106585|NCT01545687|stage IVC squamous cell carcinoma of the oropharynx
1106586|NCT01545687|stage IVC verrucous carcinoma of the larynx
1106587|NCT01545687|stage I squamous cell carcinoma of the lip and oral cavity
1106588|NCT01545687|stage I verrucous carcinoma of the oral cavity
1106589|NCT01545687|stage II squamous cell carcinoma of the lip and oral cavity
1106590|NCT01545687|stage II verrucous carcinoma of the oral cavity
1106591|NCT01545687|stage III squamous cell carcinoma of the lip and oral cavity
1106592|NCT01545687|stage III verrucous carcinoma of the oral cavity
1106593|NCT01545687|stage IVA squamous cell carcinoma of the lip and oral cavity
1106594|NCT01545687|stage IVA verrucous carcinoma of the oral cavity
1106595|NCT01545687|stage IVB squamous cell carcinoma of the lip and oral cavity
1106596|NCT01545687|stage IVB verrucous carcinoma of the oral cavity
1106597|NCT01545687|stage IVC squamous cell carcinoma of the lip and oral cavity
1106598|NCT01545687|stage IVC verrucous carcinoma of the oral cavity
1106599|NCT01545687|recurrent squamous cell carcinoma of the lip and oral cavity
1106600|NCT01545687|recurrent verrucous carcinoma of the oral cavity
1106601|NCT01545674|Aneuploidy
1106602|NCT01545674|Non-invasive Prenatal Diagnosis
1106603|NCT01545674|Prenatal Blood Test
1106604|NCT01545674|Prenatal Aneuploidy Screening
1106605|NCT01545674|Trisomy 13
1106606|NCT01545674|Trisomy 18
1106607|NCT01545674|Trisomy 21
1106608|NCT01545674|Trisomy
1106609|NCT01545674|Down Syndrome
1106610|NCT01545674|Turner Syndrome
1106611|NCT01545674|Edwards Syndrome
1106612|NCT01545661|Tuberculosis
1106613|NCT01545661|diagnosis
1106614|NCT01545661|sputum induction
1106615|NCT01545661|primary care
1106616|NCT01545648|breast
1106617|NCT01545648|cancer
1106618|NCT01545648|early
1106619|NCT01545648|DTC
1106620|NCT01545648|disseminated
1106621|NCT01545648|tumor
1106622|NCT01545648|cells
1106623|NCT01545635|Major trauma
1106624|NCT01545635|Injury Severity Score
1106625|NCT01545635|ISS > 15
1106626|NCT01545635|clinical signs
1106627|NCT01545635|risk of blood loss
1106628|NCT01545635|coagulopathy
1106629|NCT01545635|rotational thrombelastometry
1106630|NCT01545635|ROTEM
1106631|NCT01545609|Text messaging
1106632|NCT01545609|birth control
1106633|NCT01545609|adolescents
1106634|NCT01545596|Intraoperative Monitoring
1106635|NCT01545596|Decision Support Systems
1106636|NCT01545596|anesthesia outcomes
1106637|NCT01545557|Volume loss
1106638|NCT01545544|B-Cell Non Hodgkin Lymphomas
1106639|NCT01545544|Hepatitis C
1106640|NCT01545531|glomerular filtration rate
1106641|NCT01545531|iohexol
1106642|NCT01545531|hematopoietic cell transplant
1106643|NCT01545531|kidney function
1106644|NCT01545531|gold standard measure
1106645|NCT01545531|cystatin C.
1106646|NCT01545518|Refractory epilepsy
1106647|NCT01545518|Cryptogenic epilepsy
1106648|NCT01545518|Autoimmune disorders
1106649|NCT01545518|IVIG
1106650|NCT01545518|Immunomodulatory therapy
1106651|NCT01545518|Autoantibodies
1106652|NCT01545492|CHIPS
1106653|NCT01545492|famine
1106654|NCT01545492|reprogramming
1106655|NCT01545492|developmental
1106656|NCT01545492|blood
1106657|NCT01545492|pressure
1106658|NCT01545492|randomised
1106659|NCT01545492|randomized
1106660|NCT01545492|hypertension
1106661|NCT01545492|anthropometry
1106662|NCT01545492|measurement
1106663|NCT01545492|genetics
1106664|NCT01545492|epigenetics
1106665|NCT01545492|methylation
1106666|NCT01545492|cortisol
1106667|NCT01545492|stress
1106668|NCT01545492|DNA
1106669|NCT01545492|growth
1106670|NCT01545492|weight
1106671|NCT01545492|length
1106672|NCT01545492|height
1106673|NCT01545479|ECA
1106674|NCT01545479|BOLD-MRI
1106675|NCT01545479|kidney
1106676|NCT01545466|Migraines
1106677|NCT01545466|Behavioral
1106678|NCT01545466|Complementary and Alternative Medicine
1106679|NCT01545466|Mindfulness Meditation
1106680|NCT01545466|Mindfulness Based Stress Reduction
1106681|NCT01545427|Scleroderma
1106682|NCT01545427|Randomized controled trial
1106683|NCT01545427|Pilot study
1106684|NCT01545427|Gleevec (imatinib)
1106685|NCT01545427|Biomarkers
1106686|NCT01545414|Self-help treatment
1106687|NCT01545414|Internet treatment
1106688|NCT01545414|Cognitive Behavioral Therapy
1106689|NCT01545414|Internet-based Cognitive Behavioral Therapy
1106690|NCT01545401|chronic disease management
1106691|NCT01545401|Chronic Care Model
1106692|NCT01545401|multifaceted intervention
1106693|NCT01545401|primary care
1106694|NCT01545401|type 2 diabetes mellitus
1106695|NCT01545401|hypertension
1106696|NCT01545375|nasopharyngeal carriage
1106697|NCT01545375|safety
1106698|NCT01545375|immunogenicity
1106699|NCT01545375|US
1106700|NCT01545375|Pneumococcal vaccine
1106701|NCT01545375|efficacy
1106702|NCT01545375|Streptococcus pneumoniae
1106703|NCT01545375|infants
1106704|NCT01545349|LGG
1106705|NCT01545349|Immune response
1106706|NCT01545349|Influenza vaccine
1106707|NCT01545349|Elderly
1106708|NCT01545349|Healthy
1106709|NCT01545349|Microbiome
1106710|NCT01545323|Netherton syndrome
1106711|NCT01545323|Gene therapy
1106712|NCT01545323|SPINK5
1106713|NCT01545297|dexmedetomidine
1106714|NCT01545297|conscious sedation
1106715|NCT01545297|awake craniotomy
1106716|NCT01545297|brain mapping
1106717|NCT01545284|chronic hand dermatitis
1106718|NCT01545284|acitretin
1106719|NCT01545284|PGA
1106720|NCT01545271|Xenon
1106721|NCT01545271|Hypothermia
1106722|NCT01545271|Hypoxic Ischemic Encephalopathy
1106723|NCT01545271|Newborn
1106724|NCT01545271|Term
1106725|NCT01545271|Neuroprotection
1106726|NCT01545271|Cooling
1106727|NCT01545271|HIE
1106728|NCT01545245|atopic asthma
1106729|NCT01545245|recurrent wheezing
1106730|NCT01545245|preterm infants
1106731|NCT01545245|palivizumab
1106732|NCT01545245|respiratory syncytial virus
1106733|NCT01545245|RSV
1106734|NCT01545232|Massive Transfusion
1106735|NCT01545232|Trauma
1106736|NCT01545232|Coagulopathy
1106737|NCT01545232|Trauma Induced Coagulopathy
1106738|NCT01545232|Plasma
1106739|NCT01545232|Platelets
1106740|NCT01545232|Red Blood Cells
1106741|NCT01545232|Mortality
1106742|NCT01545232|Wounds and Injuries
1106743|NCT01545232|Shock, Hemorrhagic
1106744|NCT01545232|Shock
1106745|NCT01545232|Pathologic Processes
1106746|NCT01545232|Hemorrhage
1106747|NCT01545232|Hemostatics
1106748|NCT01545232|Coagulation
1106749|NCT01545232|Transfusion-related acute lung injury (TRALI)
1106750|NCT01545232|Inflammation
1106751|NCT01545193|Elderly
1106752|NCT01545193|Residual neuromuscular blockade
1106753|NCT01545180|Observatory
1106754|NCT01545180|Heart failure
1106755|NCT01545180|Post-capillary pulmonary hypertension
1106756|NCT01545180|HTPcap
1106757|NCT01545167|pancreatits
1106758|NCT01545141|metastatic
1106759|NCT01545141|recurrent
1106760|NCT01545141|peritoneal metastasis
1106761|NCT01545141|cytoreductive surgery
1106762|NCT01545141|hyperthermic intraperitoneal chemoperfusion
1106763|NCT01545141|HIPEC
1106764|NCT01545141|hepatic metastasis
1106765|NCT01545141|extrahepatic metastasis
1106766|NCT01545141|vaccine
1106767|NCT01544153|Web based behavioral intervention
1106768|NCT01544153|Adherence
1106769|NCT01544153|Smoking cessation
1106770|NCT01544153|Social network
1106771|NCT01544153|Nicotine replacement therapy
1106772|NCT01544153|Social support
1106773|NCT01544140|Phase 1
1106774|NCT01544140|healthy volunteers
1106775|NCT01544140|pharmacokinetics
1106776|NCT01544140|vandetanib
1106777|NCT01544140|midazolam
1106778|NCT01544127|Veterans
1106779|NCT01544127|Motivational Interviewing
1106780|NCT01544127|Inpatients
1106781|NCT01544127|Suicide, Attempted
1106782|NCT01544101|Rheumatoid Arthritis
1106783|NCT01544101|Diet, Vegetarian
1106784|NCT01544101|Diet, Fat-Restricted
1106785|NCT01544101|Pain
1106786|NCT01544088|randomized controlled trial
1106787|NCT01544088|PTSD
1106788|NCT01544088|cognitive behavioral treatment
1106789|NCT01544088|group treatment
1106790|NCT01544062|Cardiac surgery
1106791|NCT01544062|Acute Pain
1106792|NCT01544062|Wound Hyperalgesia
1106793|NCT01544062|Intravenous Acetaminophen
1106794|NCT01544062|Patient Satisfaction
1106795|NCT01544049|fallopian tube removal
1106796|NCT01544049|salpingectomy
1106797|NCT01544049|ovarian cancer prevention
1106798|NCT01544036|AKI
1106799|NCT01544036|contrast nephropathy
1106800|NCT01544036|renal blood flow
1106801|NCT01544023|breast reconstruction
1106802|NCT01544023|mesh
1106803|NCT01544023|implant reconstruction
1106804|NCT01544023|acellular dermal matrix
1106805|NCT01544023|titanized polypropylene mesh
1106806|NCT01544023|TiLOOP Bra
1106807|NCT01544023|TiLOOP
1106808|NCT01544023|implant based breast reconstruction
1106809|NCT01544010|Transtheoretical Model
1106810|NCT01544010|Tailored Print Intervention
1106811|NCT01544010|Population-based
1106812|NCT01544010|Behavioral Intervention
1106813|NCT01543984|health care workers
1106814|NCT01543984|tailored physical activity
1106815|NCT01543984|prevention
1106816|NCT01543984|spine
1106817|NCT01543984|upper body
1106818|NCT01543984|pain related to Spine or Upper body
1106819|NCT01545128|COPD
1106820|NCT01545128|Pulmonary rehabilitation
1106821|NCT01545115|Children
1106822|NCT01545115|Immunity
1106823|NCT01545115|Sub-Saharan
1106824|NCT01545115|Pertussis
1106825|NCT01545115|Malaria
1106826|NCT01545115|Nutrition
1106827|NCT01545115|antibodies
1106828|NCT01545011|Inspiratory muscle training
1106829|NCT01545011|COPD
1106830|NCT01545011|Conventional respiratory rehabilitation
1106831|NCT01545011|Dyspnea scale
1106832|NCT01544985|pediatrics
1106833|NCT01544985|emergency medicine
1106834|NCT01544985|pain
1106835|NCT01544985|bladder catheterization
1106836|NCT01544972|Patent Ductus Arteriosus
1106837|NCT01544972|Paracetamol
1106838|NCT01544972|Ibuprofen
1106839|NCT01544972|Serum levels
1106840|NCT01544972|Preterm infant
1106841|NCT01544959|Narcotic
1106842|NCT01544959|Opioid
1106843|NCT01544959|betablocking drug
1106844|NCT01544959|postoperative pain
1106845|NCT01544959|postoperative nausea and vomiting
1106846|NCT01544959|breast cancer
1106847|NCT01544959|hyperalgesia
1106848|NCT01544959|cancer recurrence
1106849|NCT01544959|anesthesia
1106850|NCT01544959|mastectomy
1106851|NCT01544959|chronic postsurgical pain syndrome
1106852|NCT01544959|acute postoperative pain
1106853|NCT01544959|postmastectomy pain syndrome
1106854|NCT01544959|pain
1106855|NCT01544959|ambulatory surgery
1106856|NCT01544946|pediatrics
1106857|NCT01544946|emergency medicine
1106858|NCT01544946|pain
1106859|NCT01544946|nasopharyngeal aspiration
1106860|NCT01544933|spinal fractures
1106861|NCT01544933|Thoracic vertebrae
1106862|NCT01544933|spinal canal
1106863|NCT01544933|kyphosis
1106864|NCT01544907|Drug Eluting Balloon
1106865|NCT01544907|Arteriovenous fistula or graft stenosis
1106866|NCT01544894|Postmenopausal osteoporosis
1106867|NCT01544894|Compliance
1106868|NCT01544894|Bone mineral density
1106869|NCT01544894|Bonemarkers
1106870|NCT01544881|Pharmacokinetics
1106871|NCT01544881|Pharmacodynamics
1106872|NCT01544881|Hyperglycemia
1106873|NCT01544881|Insulin
1106874|NCT01544868|Total Energy Expenditure
1106875|NCT01544868|Protein Balance
1106876|NCT01544868|Burns
1106877|NCT01544855|Health young participants
1106878|NCT01544842|Oral lichen planus
1106879|NCT01544842|Tacrolimus ointment
1106880|NCT01544842|Triamcinolone paste
1106881|NCT01544829|theobromine
1106882|NCT01544829|heart rate
1106883|NCT01544829|blood lipids
1106884|NCT01544803|Randomized Controlled Trial
1106885|NCT01544803|Alcohol
1106886|NCT01544803|Internet
1106887|NCT01544803|Screening
1106888|NCT01544803|Brief intervention
1106889|NCT01544803|Personalized feedback
1106890|NCT01544790|Esophageal carcinoma
1106891|NCT01544790|Esophageal cancer
1106892|NCT01544790|Robotic surgery
1106893|NCT01544790|Esophagectomy
1106894|NCT01544790|Minimally invasive
1106895|NCT01544777|Aphakia
1106896|NCT01544777|Cataract
1106897|NCT01544764|Diphtheria-Tetanus-Pertussis Vaccine
1106898|NCT01544764|Measles-Mumps-Rubella Vaccine
1106899|NCT01544764|Meningococcal Vaccines
1106900|NCT01544764|Hepatitis B Vaccines
1106901|NCT01544764|Chickenpox Vaccine
1106902|NCT01544764|Papillomavirus Vaccines
1106903|NCT01544751|NAFLD
1106904|NCT01544751|metformin
1106905|NCT01544751|atorvastatin
1106906|NCT01544751|metabolic syndrome
1106907|NCT01544738|Parkinson Disease
1106908|NCT01544738|sensory stimulation
1106909|NCT01544738|Bradykinesia
1106910|NCT01544725|Procedural sedation
1106911|NCT01544725|Ketamine-propofol
1106912|NCT01544725|Ketamine
1106913|NCT01544712|osteonecrosis
1106914|NCT01544712|cell-based therapy
1106915|NCT01544712|bone marrow
1106916|NCT01544712|mesenchymal stem cell
1106917|NCT01544712|hip
1106918|NCT01544712|core decompression
1106919|NCT01544699|stroke
1106920|NCT01544686|neutropenia
1106921|NCT01544686|cancer
1106922|NCT01544686|fever
1106923|NCT01544686|central venous catheter
1106924|NCT01544686|infection
1106925|NCT01544660|spine and hip scan
1106926|NCT01544660|BMD
1106927|NCT01544647|Knee osteoarthritis
1106928|NCT01544647|spa therapy
1106929|NCT01544647|spa modalities
1106930|NCT01544634|Asthma
1106931|NCT01544634|Propranolol
1106932|NCT01544634|Inhaled corticosteroids
1106933|NCT01544634|Steroid sparing agent
1106934|NCT01544634|Airway hyper-responsiveness
1106935|NCT01544621|Real life smoking cessation. NON-drug NON-intervention study
1106936|NCT01544608|Acute psychotic episode of Schizophrenia
1106937|NCT01544595|Psoriasis, inflammatory skin disease
1106938|NCT01544595|scaly patches
1106939|NCT01544595|secukinumab (AIN457)
1106940|NCT01544595|Psoriasis Area and Severity Index (PASI)
1106941|NCT01544595|Investigator Global Assessment (IGA) mod 2011
1106942|NCT01544582|Pegylated Interferon
1106943|NCT01544582|boceprevir
1106944|NCT01544582|telaprevir
1106945|NCT01544569|rhabdoid tumor of the kidney
1106946|NCT01544556|abdominoplasty
1106947|NCT01544543|COPD
1106948|NCT01544530|Brain-death
1106949|NCT01544530|organ donation
1106950|NCT01544517|Helicobacter pylori
1106951|NCT01544517|Concomitant therapy
1106952|NCT01544517|Sequential therapy
1106953|NCT01544517|levofloxacin
1106954|NCT01544504|Radiodermatitis
1106955|NCT01544504|Prevention
1106956|NCT01544504|Radiotherapy
1106957|NCT01544504|Breast
1106958|NCT01544504|Radiation Dermatitis
1106959|NCT01544491|Paediatric kidney transplantation
1106960|NCT01544491|Early MMF to everolimus conversion
1106961|NCT01544491|Composite efficacy (biopsy-proven acute rejection, graft loss or death)
1106962|NCT01544491|Renal function
1106963|NCT01544465|Parkinson's disease
1106964|NCT01544465|Sleep Quality
1106965|NCT01544465|Daytime sleepiness
1106966|NCT01544465|physical therapy
1106967|NCT01544465|exercise
1106968|NCT01544452|MR
1106969|NCT01544452|CT
1106970|NCT01544452|ultrasonography
1106971|NCT01544452|MR colonography
1106972|NCT01544452|MR rectum
1106973|NCT01544452|MR liver
1106974|NCT01544439|Temporomandibular joint disorders
1106975|NCT01544439|Stress psychological
1106976|NCT01544439|Depression
1106977|NCT01544439|Quality of Life
1106978|NCT01544426|Office hysteroscopy,
1106979|NCT01544426|intrauterine insemination
1106980|NCT01544426|endometrial scrap
1106981|NCT01544413|laparoscopic sentinel lymph node biopsy
1106982|NCT01544413|quality control study
1106983|NCT01544413|early gastric cancer
1106984|NCT01544400|reverse anorexia,
1106985|NCT01544400|anorexia athletics
1106986|NCT01544387|Preterm Premature Rupture Of Membranes
1106987|NCT01544387|PPROM
1106988|NCT01544387|Pregnancy
1106989|NCT01544387|Bed rest.
1106990|NCT01544374|Breast Cancer
1106991|NCT01544374|Treatment Disparities
1106992|NCT01544374|Tracking and Feedback
1106993|NCT01544374|Registry
1106994|NCT01544374|Cancer Therapy Disparities
1106995|NCT01544374|Adjuvant Treatment
1106996|NCT01544374|Racial Disparities
1106997|NCT01544374|Underuse of Adjuvant Treatment
1106998|NCT01544361|Healthy subjects
1106999|NCT01544361|MEDI7814
1107000|NCT01544361|FTiH
1107001|NCT01544348|Allergic
1107002|NCT01544348|Atopic Dermatitis
1107003|NCT01544348|MEDI4212
1107004|NCT01544322|solid tumors
1107005|NCT01544322|recurrent
1107006|NCT01544322|advanced
1107007|NCT01544322|metastatic
1107008|NCT01544322|refractory
1107009|NCT01544283|Shoulder Pain
1107010|NCT01544283|Shoulder Impingement Syndrome
1107011|NCT01544270|milk protein
1107012|NCT01544270|probiotics
1107013|NCT01544270|stress
1107014|NCT01544270|cortisol
1107015|NCT01544270|heart beat
1107016|NCT01544257|Osteopathic manipulative treatment
1107017|NCT01544257|alternative medicine
1107018|NCT01544257|complementary medicine
1107019|NCT01544257|neonatology
1107020|NCT01544257|neonatal care
1107021|NCT01544257|prematurity
1107022|NCT01544257|allied health care
1107023|NCT01544244|comparison of physical therapy strategies
1107024|NCT01544231|Neutrophil Gelatinase Associated Lipocalin
1107025|NCT01544231|predicting acute kidney failure
1107026|NCT01544231|emergency room
1107028|NCT01544192|Antioxidant
1107029|NCT01544192|α−tocopherol
1107030|NCT01544192|Vitamin E
1107031|NCT01544192|Gingko Biloba
1107032|NCT01544192|Glaucoma
1107033|NCT01544192|Neuroprotection
1107034|NCT01544192|Retina
1107035|NCT01544179|Non Small Cell Lung Cancer
1107036|NCT01544179|Gefitinib
1107037|NCT01544179|Pemetrexed
1107038|NCT01544179|Treatment Beyond Progression
1107039|NCT01544166|Gadolinium, Pediatrics, MRI, contrast
1107040|NCT01543971|Peripheral blood stem cell mobilization
1107041|NCT01543971|CD34+ count
1107042|NCT01543945|Postoperative Nausea and Vomiting
1107043|NCT01543945|Ambulatory
1107044|NCT01543945|Gynecologic laparoscopy
1107045|NCT01543945|Incidence of postoperative nausea and vomiting.
1107046|NCT01543932|antiplatelet effect
1107047|NCT01543932|prasugrel
1107048|NCT01543932|clopidogrel
1107049|NCT01543932|stable angina
1107050|NCT01543893|neck pain
1107051|NCT01543893|shoulder pain
1107052|NCT01543893|resistance training
1107053|NCT01543854|Heart failure
1107054|NCT01543854|RLX030
1107055|NCT01543854|Hemodynamics
1107056|NCT01543854|Cardiovascular Diseases
1107057|NCT01543841|advanced cancer
1107058|NCT01543841|healthy
1107059|NCT01543841|blood sample
1107060|NCT01543841|TEM
1107061|NCT01543841|TIE-2 expressing monocytes
1107062|NCT01543841|ANG1
1107063|NCT01543841|ANG2
1107064|NCT01543828|COPD
1107065|NCT01543828|Indacatarol
1107066|NCT01543828|placebo
1107067|NCT01543828|crossover
1107068|NCT01543828|patient perception
1107069|NCT01543815|Psychological Distress
1107070|NCT01543815|Depression
1107071|NCT01543815|Anxiety
1107072|NCT01543815|Well-Being Therapy
1107073|NCT01543815|Heart Failure
1107074|NCT01543815|Quality of Life
1107075|NCT01543815|Adherence
1107076|NCT01543802|soft-tissue sarcoma
1107077|NCT01543802|pazopanib
1107078|NCT01543802|antiangiogenetic treatment
1107079|NCT01543802|endothelial progenitor cells
1107080|NCT01543802|preoperative therapy
1107081|NCT01543789|Umbilical Hernia
1107082|NCT01543763|metastatic
1107083|NCT01543763|solid
1107084|NCT01543763|sarcoma
1107085|NCT01543763|progression
1107086|NCT01543750|episodic ataxia
1107087|NCT01543750|CACNA1A mutations
1107088|NCT01543711|Breast cancer
1107089|NCT01543711|persistent pain
1107090|NCT01543711|neuropathic pain
1107091|NCT01543711|lymphedema
1107092|NCT01543698|Advanced solid tumor,
1107093|NCT01543698|BRAF V600 mutation
1107094|NCT01543672|lung
1107095|NCT01543672|SBRT
1107096|NCT01543672|MLD
1107097|NCT01543672|toxicity
1107098|NCT01543659|89Zr-DFO-huJ591
1107099|NCT01543659|prostate
1107100|NCT01543659|Pet scan
1107101|NCT01543659|11-126
1107102|NCT01543646|Hepatology
1107103|NCT01543646|Liver Cirrhosis
1107104|NCT01543646|Fatty Liver
1107105|NCT01543620|kidney safety
1107106|NCT01543620|biomarkers
1107107|NCT01543620|serum creatinine
1107108|NCT01543620|BUN
1107109|NCT01543620|cystic fibrosis
1107110|NCT01543620|head and neck cancer
1107111|NCT01543620|renal injury
1107112|NCT01543620|drug induced acute kidney injury
1107113|NCT01543620|aminoglycoside
1107114|NCT01543620|cisplatin
1107115|NCT01543620|nephrotoxicity
1107116|NCT01543620|biomarker qualification
1107117|NCT01543607|Bile duct
1107118|NCT01543607|Cholangiocarcinoma
1107119|NCT01543607|Bile duct stenosis
1107120|NCT01543607|Malignant bile duct obstruction
1107121|NCT01543607|Malignant bile duct stricture
1107122|NCT01543607|Radiofrequency ablation
1107123|NCT01543607|RFA
1107124|NCT01543607|Endoscopic RFA catheter
1107125|NCT01543607|EndoHPB
1107126|NCT01543594|Rheumatoid arthritis
1107127|NCT01543594|Seronegative polyarthritis
1107128|NCT01543594|Biologic drugs
1107129|NCT01543594|Safety efficacy biologics polyarthritis
1107130|NCT01543581|Basal Cell Carcinoma
1107131|NCT01543581|Treatment of Skin Cancer
1107132|NCT01543568|Age related Macular Degeneration
1107133|NCT01543568|Recalcitrant Age Related Macular Degeneration
1107134|NCT01543555|myocardial infarction
1107135|NCT01543555|statin
1107136|NCT01543555|perioperative care
1107137|NCT01543555|peripheral vascular diseases
1107138|NCT01543555|anesthesiology
1107139|NCT01543542|1-3 brain metastases from any primary cancer
1107140|NCT01543516|Asthma
1107141|NCT01543516|Sputum
1107142|NCT01543516|Blood
1107143|NCT01543516|Inflammation
1107144|NCT01543516|adaptive immune system
1107145|NCT01543516|innate immune system
1107146|NCT01543464|Indeolamine 2,3 dioxygenase
1107147|NCT01543464|Survivin
1107148|NCT01543464|Montanide
1107149|NCT01543464|Imiquimod
1107150|NCT01543464|GMCSF
1107151|NCT01543438|ED utilization
1107152|NCT01543438|video education
1107153|NCT01543438|mobile health
1107154|NCT01543438|streaming media
1107155|NCT01543438|underserved populations
1107156|NCT01543425|Neuropathic Pain
1107157|NCT01543425|Adenocorticotrophic axis
1107158|NCT01543425|Psychological state
1107159|NCT01543412|FOLFIRI
1107160|NCT01543412|Metastases
1107161|NCT01543412|pancreatic adenocarcinoma
1107162|NCT01543412|locally advanced or metastatic pancreatic adenocarcinoma
1107163|NCT01543399|Tibolone
1107164|NCT01543399|climacteric
1107165|NCT01543399|Doppler
1107166|NCT01543399|hormone replacement therapy
1107167|NCT01543386|Polyphenol
1107168|NCT01543386|Curcumin
1107169|NCT01543386|Endothelium, vascular
1107170|NCT01543386|Endothelium-dependant relaxing factor
1107171|NCT01543386|Smoking
1107172|NCT01543386|Transcriptome
1107173|NCT01543373|Coronary artery disease
1107174|NCT01543373|Optical Coherence Tomography
1107175|NCT01543373|Tissue coverage
1107176|NCT01543373|DES
1107177|NCT01543360|axillary vein
1107178|NCT01543360|sub clavian vein
1107179|NCT01543360|comparison of strategies
1107180|NCT01543347|UTI
1107181|NCT01543347|ESBL
1107182|NCT01543347|AmpC Enterobacteriaceae
1107183|NCT01543334|intensive care
1107184|NCT01543334|antibiotic levels in blood samples
1107185|NCT01543321|tetrabenazine
1107186|NCT01543321|movement disorders
1107187|NCT01543321|tardive disorders
1107188|NCT01543295|Non-Treponemal
1107189|NCT01543295|Treponemal
1107190|NCT01543282|endoscopic ultrasonography
1107191|NCT01543282|fine needle aspiration cytology
1107192|NCT01543282|22 gauge
1107193|NCT01543282|25 gauge
1107194|NCT01543269|Obesity
1107195|NCT01543269|Lipid disorders
1107197|NCT01543243|postural balance
1107198|NCT01543243|strength
1107199|NCT01543230|Non-Inflammatory Degenerative Joint Disease
1107200|NCT01543217|COPD
1107201|NCT01543204|plaque psoriasis
1107202|NCT01543204|etanercept
1107203|NCT01543204|adalimumab
1107204|NCT01543191|Lung Diseases
1107205|NCT01543191|Respiratory Tract Diseases
1107206|NCT01543191|Fibrosis
1107207|NCT01543178|IBS
1107208|NCT01543178|IBS-D
1107209|NCT01543178|IBS with diarrhea
1107210|NCT01543178|Diarrhea
1107211|NCT01543178|Irritable bowel syndrome with diarrhea
1107212|NCT01543165|Renal colic
1107213|NCT01543165|Analgesia
1107214|NCT01543165|Nefopam
1107215|NCT01543165|Ketorolac
1107216|NCT01543152|HIV
1107217|NCT01543152|autologous cell therapy
1107218|NCT01543152|cyclophosphamide
1107219|NCT01543113|melanoma
1107220|NCT01543113|white-caucasian population
1107221|NCT01543100|MGUS
1107222|NCT01543074|HDAC
1107223|NCT01543074|histone acetylation
1107224|NCT01543074|broccoli sprout extract
1107225|NCT01543074|garlic oil
1107226|NCT01543074|PBMCs
1107227|NCT01543048|Human Papilloma Virus (HPV)
1107228|NCT01543048|Virological tests
1107229|NCT01543048|CIN3
1107230|NCT01543048|Cervical cancer
1107231|NCT01543048|Conization
1107232|NCT01543048|within women treated by conization for a CIN3
1107233|NCT01543035|HIV infection
1107234|NCT01543035|lipid lowering drugs
1107235|NCT01543035|etravirine
1107236|NCT01543035|patient
1107237|NCT01543035|statin treatment
1107238|NCT01543035|EFV or boosted PI antiretroviral treatment
1107239|NCT01543009|child
1107240|NCT01543009|venipuncture
1107241|NCT01543009|pain
1107242|NCT01542983|breast cancer
1107243|NCT01542983|bright light
1107244|NCT01542983|insomnia
1107245|NCT01542983|fatigue
1107246|NCT01542970|intervention
1107247|NCT01542970|lactobacillus reuteri
1107248|NCT01542970|omega-3 fatty acids
1107249|NCT01542970|pregnancy
1107250|NCT01542970|lactation
1107251|NCT01542970|allergic symptoms
1107252|NCT01542970|IgE associated disease
1107253|NCT01542970|gastrointestinal function
1107254|NCT01542957|Major Depressive Disorder
1107255|NCT01542957|Dysthymic Disorder
1107256|NCT01542957|Depression
1107257|NCT01542957|Cognitive Behavior Therapy
1107258|NCT01542957|Personal Construct Theory
1107259|NCT01542957|Repertory Grid Technique
1107260|NCT01542957|Cognitive Conflicts
1107261|NCT01542957|Personal dilemmas
1107262|NCT01542944|Acute myeloid leukemia
1107263|NCT01542944|Myelodysplastic syndrome
1107264|NCT01542944|Stem Cell Mobilization
1107265|NCT01542944|Allogeneic Stem Cell Transplantation
1107266|NCT01542931|Oral squamous cell carcinoma
1107267|NCT01542931|Induction chemotherapy
1107268|NCT01542931|Surgery
1107269|NCT01542931|Radiotherapy
1107270|NCT01542918|Recurrent
1107271|NCT01542918|Refractory
1107272|NCT01542918|CNS
1107273|NCT01542918|Intraocular
1107274|NCT01542918|Lymphoma
1107275|NCT01542892|Sarcopenia
1107276|NCT01542892|Nutrition
1107277|NCT01542892|Vitamin D
1107278|NCT01542892|Exercise
1107279|NCT01542866|ranibizumab
1107280|NCT01542866|Age related Macular Degeneration
1107281|NCT01542866|AMD
1107282|NCT01542866|Health Management Tool
1107283|NCT01542866|HMT
1107284|NCT01542866|Best Corrected Visual Acuity
1107285|NCT01542866|Investigator's Clinical Judgement of Change
1107286|NCT01542866|Choroidal Neovascularization
1107287|NCT01542866|Central Retinal Subfield Thickness
1107288|NCT01542866|visual function self test
1107289|NCT01542840|surgery
1107290|NCT01542840|orthopedic surgery
1107291|NCT01542840|foot surgery
1107292|NCT01542840|leg surgery
1107293|NCT01542840|ankle surgery
1107294|NCT01542840|leg
1107295|NCT01542840|foot
1107296|NCT01542840|ankle
1107297|NCT01542840|anesthesia
1107298|NCT01542840|local anesthesia
1107299|NCT01542840|regional anesthesia
1107300|NCT01542840|Ochsner Clinic
1107301|NCT01542840|Ochsner Hospital
1107302|NCT01542840|New Orleans
1107303|NCT01542840|Louisiana
1107304|NCT01542840|Kristie Osteen, MD
1107305|NCT01542827|neck pain
1107306|NCT01542827|menthol
1107307|NCT01542814|Screening Mammogram
1107308|NCT01542814|Diagnostic Mammogram
1107309|NCT01542814|Benign
1107310|NCT01542814|Malignant
1107311|NCT01542814|BI-RADS Categories
1107312|NCT01542801|Effect of Preventive Antibiotics
1107313|NCT01542788|HCV genotype 2 (GT-2)
1107314|NCT01542788|HCV genotype 3 (GT-3)
1107315|NCT01542788|HCV
1107316|NCT01542788|Sustained Virologic Response
1107317|NCT01542788|Direct Acting Antiviral
1107318|NCT01542788|Combination Therapy
1107319|NCT01542788|Interferon intolerant
1107320|NCT01542788|Interferon ineligible
1107321|NCT01542788|GS-7977
1107322|NCT01542788|Ribavirin
1107323|NCT01542762|Deep venous thrombosis
1107324|NCT01542762|Pulmonary Embolism
1107325|NCT01542762|Lower leg Cast immobilization
1107326|NCT01542749|BVA-100 Blood volume analyzer
1107327|NCT01542749|Human serum albumin labeled with Iodine 131
1107328|NCT01542723|Deep venous thrombosis
1107329|NCT01542723|Pulmonary Embolism
1107330|NCT01542723|Arthroscopy of the knee
1107331|NCT01542697|magnesium sulpahate
1107332|NCT01542697|postoperative analgesia
1107333|NCT01542684|Leukemia
1107334|NCT01542684|Myelodysplastic Syndrome
1107335|NCT01542684|MDS
1107336|NCT01542684|Azacytidine
1107337|NCT01542684|5-Azacytidine
1107338|NCT01542684|5-AZA
1107339|NCT01542684|Vidaza
1107340|NCT01542684|5-AZC
1107341|NCT01542684|Aza-CR
1107342|NCT01542684|Ladakamycin
1107343|NCT01542684|NSC-102816
1107344|NCT01542684|GM-CSF
1107345|NCT01542684|Sargramostim
1107346|NCT01542684|Leukine
1107347|NCT01542671|lifestyle change
1107348|NCT01542671|obesity treatment
1107349|NCT01542671|physical activity
1107350|NCT01542671|primary care
1107351|NCT01542671|quality of life
1107352|NCT01542645|Fentanyl
1107353|NCT01542645|Methadone
1107354|NCT01542645|Thoracic Surgery
1107355|NCT01542632|safety and immunogenicity of dengue vaccine
1107356|NCT01542606|PH
1107357|NCT01542606|SCREENING
1107358|NCT01542606|EARLY WARNING
1107359|NCT01542606|VAGINAL HEALTH
1107360|NCT01542606|VAGINAL SECRETION
1107361|NCT01542606|VAGINAL PH
1107362|NCT01542580|Revision surgery
1107363|NCT01542567|Diclofenac
1107364|NCT01542567|BCG
1107365|NCT01542567|BLADDER IRRIGATIONS
1107366|NCT01542554|Diabetes mellitus
1107367|NCT01542554|Chinese
1107368|NCT01542554|Glycaemic index
1107369|NCT01542528|ADHD
1107370|NCT01542528|Executive function
1107371|NCT01542528|Inhibitory control
1107372|NCT01542528|Computer games
1107373|NCT01542528|Sports activities
1107374|NCT01542528|Good Behavior Game
1107375|NCT01542515|Allograft
1107376|NCT01542515|Arthroplasty
1107377|NCT01542515|Basal Joint
1107378|NCT01542515|carpometacarpal joint
1107379|NCT01542515|Thumb
1107380|NCT01542515|meniscus
1107381|NCT01542515|osteoarthritis
1107382|NCT01542515|Patients with Stages I - III arthritis of the the thumb carpometacarpal joint
1107383|NCT01542502|Heart failure with preserved ejection fraction
1107384|NCT01542502|Diastolic heart failure
1107385|NCT01542502|Aerobic exercise performance
1107386|NCT01542437|Non-Small Cell Lung Cancer
1107387|NCT01542398|community-based
1107388|NCT01542398|war-affected
1107389|NCT01542398|psychosocial support
1107390|NCT01542398|family-focused
1107391|NCT01542398|psychological distress
1107392|NCT01542398|adolescents
1107393|NCT01542398|Democratic Republic of Congo
1107394|NCT01542398|family functioning
1107395|NCT01542398|community functioning
1107396|NCT01542398|daily functioning
1107397|NCT01542385|Delayed stenting
1107398|NCT01542385|Deferred stenting
1107399|NCT01542385|Late stenting
1107400|NCT01542385|postponed stenting
1107401|NCT01542385|Thrombectomy
1107402|NCT01542385|Percutaneous coronary intervention
1107403|NCT01542385|PCI
1107404|NCT01542385|Angioplasty
1107405|NCT01542385|STEMI
1107406|NCT01542385|acute myocardial infarction
1107407|NCT01542372|PTSD
1107408|NCT01542372|Cognitive behavioral therapy (CBT)
1107409|NCT01542372|Medication augmentation
1107410|NCT01542372|Treatment-resistant PTSD
1107411|NCT01542372|Cambodian refugees
1107412|NCT01542372|Culturally sensitive treatment
1107413|NCT01542359|Yoga, Hypertension
1107414|NCT01542359|Blood Pressure
1107415|NCT01542359|Autonomic Nervous system
1107416|NCT01542346|Wound closure
1107417|NCT01542346|cosmetic outcome
1107418|NCT01542333|recurrent Wilms tumor and other childhood kidney tumors
1107419|NCT01542333|stage I Wilms tumor
1107420|NCT01542333|stage II Wilms tumor
1107421|NCT01542333|stage III Wilms tumor
1107422|NCT01542333|stage IV Wilms tumor
1107423|NCT01542333|stage V Wilms tumor
1107424|NCT01542320|probiotic
1107425|NCT01542320|Lactobacillus reuteri DSM 17938
1107426|NCT01542320|healthy infants
1107427|NCT01542307|migraine
1107428|NCT01542307|oxygen therapy
1107429|NCT01542294|gastric cancer
1107430|NCT01542294|S-1
1107431|NCT01542294|oxaliplatin
1107432|NCT01542294|adjuvant chemotherapy
1107433|NCT01542281|liver resection
1107434|NCT01542281|hepatectomy
1107435|NCT01542281|pre-habilitation
1107436|NCT01542268|pentoxifylline
1107437|NCT01542268|tight junction signalling
1107438|NCT01542268|intestinal epithelial barrier
1107439|NCT01542268|irritable bowel syndrome
1107440|NCT01542255|Metronomic Therapy
1107441|NCT01542255|Metastatic Melanoma
1107442|NCT01542255|Vinblastine
1107443|NCT01542255|Cyclophosphamide
1107444|NCT01542255|Dacarbazine
1107445|NCT01542242|Diabetes Mellitus Type 2
1107446|NCT01542242|Prader Willi Syndrome
1107447|NCT01542229|Post Traumatic Stress Disorder
1107448|NCT01542229|Severe Mental Illness
1107449|NCT01542203|doxorubicin
1107450|NCT01542203|cyclophosphamide
1107451|NCT01542203|Breast Cancer
1107452|NCT01542203|BMI
1107453|NCT01542190|cataract surgery
1107454|NCT01542190|cystoid macular edema
1107455|NCT01542190|angiography
1107456|NCT01542177|hypoxia
1107457|NCT01542177|pancreas
1107458|NCT01542177|cancer
1107459|NCT01542177|pancreatic cancer
1107460|NCT01542177|18F-FAZA
1107461|NCT01542177|18F-Fluoroazomycin Arabinoside
1107462|NCT01542177|Positron Emission Tomography
1107463|NCT01542177|PET
1107464|NCT01542164|Calcium intake
1107465|NCT01542164|Fat excretion
1107466|NCT01542164|Energy excretion
1107467|NCT01542164|Gut micro flora
1107468|NCT01542151|Labor, induced
1107469|NCT01542151|Sleep
1107470|NCT01542151|Fatigue
1107471|NCT01542151|Patient satisfaction
1107472|NCT01542151|Circadian rhythm
1107473|NCT01542138|Inflammatory hyperpigmentation, axillar pigmentation
1107474|NCT01542125|Patients aged 3 to 16 years presenting for
1107475|NCT01542125|removal of smooth percutaneous interosseus pins
1107476|NCT01542125|after orthopeadic surgery
1107477|NCT01542112|Patient-Centered Care
1107478|NCT01542112|Patient Satisfaction
1107479|NCT01542112|Interventional study
1107480|NCT01542112|Patient Expectations
1107481|NCT01542112|Hospitalization
1107482|NCT01542086|intermediate pre-test
1107483|NCT01542086|probability of significant coronary heart disease
1107484|NCT01542073|myocardial infarction
1107485|NCT01542073|angiogenesis
1107486|NCT01542073|integrin receptor imaging
1107487|NCT01542073|68Ga-BNOTA-PRGD2
1107488|NCT01542047|Metastatic
1107489|NCT01542047|Solid tumors
1107490|NCT01542047|carboplatin
1107491|NCT01542047|Paraplatin
1107492|NCT01542047|Pazopanib
1107493|NCT01542047|Votrient
1107494|NCT01542047|Alkylating agent
1107495|NCT01542047|Tyrosine kinase inhibitor
1107496|NCT01542047|Metastatic disease
1107497|NCT01542021|prostate
1107498|NCT01542021|Degarelix
1107499|NCT01542021|injections
1107500|NCT01542021|radical prostatectomy
1107501|NCT01542021|11-182
1107502|NCT01541995|contrast medium enhanced post mortem CT
1107503|NCT01541995|virtual autopsy
1107504|NCT01541995|To evaluate the value of contrast medium enhanced post-mortem CT in virtual autopsy focussing on thromboembolic and vascular conditions
1107505|NCT01541969|Ear
1107506|NCT01541969|Hearing
1107507|NCT01541956|type 2 diabetes;
1107508|NCT01541956|vildagliptin;
1107509|NCT01541956|metformin;
1107510|NCT01541943|Atorvastatin
1107511|NCT01541943|Losartan
1107512|NCT01541943|Essential Hypertension
1107513|NCT01541943|Hyperlipidemia
1107514|NCT01541904|Ocular Allergy.
1107515|NCT01541904|Seasonal Allergic Conjunctivitis
1107516|NCT01541904|Perennial Allergic Conjunctivitis
1107517|NCT01541904|Conjunctivitis, Allergic
1107518|NCT01541904|Ocular Antihistamines.
1107519|NCT01541891|PRO-148
1107520|NCT01541891|Dry eye syndrome
1107521|NCT01541865|hypertension, renal denervation, uncontrolled hypertension, medication resistant hypertension
1107522|NCT01541852|Vascular Inflammation
1107523|NCT01541852|FDG PET-CT
1107524|NCT01541852|COPD
1107525|NCT01541852|Atherosclerosis
1107526|NCT01541852|p38 MAP kinase inhibitor
1107527|NCT01541839|Nasal septum
1107528|NCT01541839|Nasal surgical procedures
1107529|NCT01541826|aronia
1107530|NCT01541826|LDL cholesterol
1107531|NCT01541826|polyphenols
1107532|NCT01541826|bioavailability
1107533|NCT01541826|oxidative stress
1107534|NCT01541813|Rare iron overload
1107535|NCT01541813|hepcidin
1107536|NCT01541774|Atherectomy
1107537|NCT01541774|Atherosclerosis
1107538|NCT01541774|Peripheral artery disease
1107539|NCT01541761|Obesity
1107540|NCT01541761|Child
1107541|NCT01541761|Hispanic
1107542|NCT01541761|Prevention
1107543|NCT01541761|Nutrition
1107544|NCT01541761|Parenting
1107545|NCT01541735|Diabetes
1107546|NCT01541735|Insulin
1107547|NCT01541735|Pantoprazole
1107548|NCT01541722|Urea cycle disorders
1107549|NCT01541709|This is a single-center
1107550|NCT01541709|prospective
1107551|NCT01541709|single-arm
1107552|NCT01541709|open-label phase II study
1107553|NCT01541696|zinc
1107554|NCT01541696|zn
1107555|NCT01541696|EZP (exchangeable zinc pools)multivitamin MN
1107556|NCT01541683|PEG-electrolyte solution
1107557|NCT01541683|bowel cleansing
1107558|NCT01541683|Mentholyptus drops
1107559|NCT01541683|Palatability
1107560|NCT01541657|Ankle Instability
1107561|NCT01541657|Sensorimotor Control
1107562|NCT01541657|Sensory
1107563|NCT01541657|Postural Control
1107564|NCT01541657|Balance
1107565|NCT01541657|Gait
1107566|NCT01541644|Acupuncture Therapy
1107567|NCT01541644|bortezomib-induced peripheral neuropathy
1107568|NCT01541631|Human Immunodeficiency Virus-1
1107569|NCT01541631|Schistosoma mansoni
1107570|NCT01541631|Anemia
1107571|NCT01541631|Immune response
1107572|NCT01541631|Opportunistic infections
1107573|NCT01541631|Tanzania
1107574|NCT01541618|MS
1107575|NCT01541618|RRMS
1107576|NCT01541618|RR Multiple Sclerosis
1107577|NCT01541592|Insulin resistance
1107578|NCT01541592|Endothelial dysfunction
1107579|NCT01541592|saturated fat
1107580|NCT01541592|monounsaturated fat
1107581|NCT01541592|polyunsaturated fat
1107582|NCT01541579|Perianal fistulising Crohn's disease.
1107583|NCT01541566|arterial hypertension
1107584|NCT01541566|metabolic syndrome
1107585|NCT01541566|home blood pressure
1107586|NCT01541566|ambulatory blood pressure
1107587|NCT01541566|office blood pressure
1107588|NCT01541566|telemedicine
1107589|NCT01541527|non neutralizing antibody
1107590|NCT01541527|Epitopic profile
1107591|NCT01541527|Clinical relevance
1107592|NCT01541501|Central Corneal Thickness
1107593|NCT01541501|Pachymetry
1107594|NCT01541462|mechanical ventilation
1107595|NCT01541462|weaning
1107596|NCT01541462|pressure support
1107597|NCT01541462|spontaneous breathing
1107598|NCT01541462|Long-term acute care facility
1107599|NCT01541462|mortality
1107600|NCT01541449|AMD
1107601|NCT01541449|PLAQUENIL
1107602|NCT01541449|CNV
1107603|NCT01541436|Remote Ischemic Preconditioning
1107604|NCT01541436|Nociception
1107605|NCT01541436|Central Sensitization
1107606|NCT01541436|Peripheral Sensitization
1107607|NCT01541397|Hyperphenylalaninemia
1107608|NCT01541397|Phenylketonuria
1107609|NCT01541397|Adults
1107610|NCT01541397|Bone Mineral Density
1107611|NCT01541384|Kidney transplant
1107612|NCT01541384|Adherence
1107613|NCT01541384|Electronic pill bottles
1107614|NCT01541371|Schizophrenia
1107615|NCT01541371|Paliperidone extended-release tablets
1107616|NCT01541332|relapsed refractory
1107617|NCT01541332|multiple myeloma
1107618|NCT01541332|pomalidomide
1107619|NCT01541332|Doxil
1107620|NCT01541332|dexamethasone
1107621|NCT01541332|Oncotherapeutics
1107622|NCT01541319|Cardiac Surgery
1107623|NCT01541319|Erythrocyte Transfusion
1107624|NCT01541306|C-type natriuretic peptide
1107625|NCT01541306|dwarfism
1107626|NCT01541306|growth
1107627|NCT01541306|achondroplasia
1107628|NCT01541306|hypochondroplasia
1107629|NCT01541306|biomarker
1107630|NCT01541293|Abortion, Induced
1107631|NCT01541293|Laminaria
1107632|NCT01541293|Pain management
1107633|NCT01541293|Cervical preparation
1107634|NCT01541293|Dilation and Evacuation
1107635|NCT01541280|Allogreffe, LAM , MDS
1107636|NCT01541280|Azacitidine (VidazaÒ)
1107637|NCT01541280|Injection de lymphocytes de donneur (DLI)
1107638|NCT01541267|aliskiren
1107639|NCT01541267|eplerenon
1107640|NCT01541267|telmisartan
1107641|NCT01541267|direct renin inhibitor
1107642|NCT01541267|ACE inhibitor
1107643|NCT01541267|mineralocorticoid inhibitor
1107644|NCT01541267|proteinuria
1107645|NCT01541267|chronic kidney diseases
1107646|NCT01541267|renin-angiotensin-aldosterone system
1107647|NCT01541254|intracranial aneurysm
1107648|NCT01541254|wide-neck
1107649|NCT01541254|saccular
1107650|NCT01541254|endovascular treatment
1107651|NCT01541254|coil embolization
1107652|NCT01541254|stent
1107653|NCT01541254|bare platinum
1107775|NCT01540669|constipation
1107654|NCT01541241|Intrauterine contraceptive device (IUD) is one of the most frequently used methods of birth control around the world
1107655|NCT01541241|Uterine Hemodynamic changes
1107656|NCT01541228|actinic keratosis
1107657|NCT01541228|photodynamic therapy
1107658|NCT01541228|5-aminolevulinic acid
1107659|NCT01541202|chronic heart failure
1107660|NCT01541202|neuregulin
1107661|NCT01541202|mortality
1107662|NCT01541189|hypertension
1107663|NCT01541189|valsartan
1107664|NCT01541176|Corticotherapy
1107665|NCT01541176|Fibrosis
1107666|NCT01541176|Numerical reading
1107667|NCT01541176|18-70 years
1107668|NCT01541176|first renal transplant was lost due to rejection
1107669|NCT01541176|first or second renal transplant
1107670|NCT01541163|Ischemia
1107671|NCT01541163|Brain Infarction
1107672|NCT01541163|Acute Stroke
1107673|NCT01541163|Heart Diseases
1107674|NCT01541163|Myocardial Infarction
1107675|NCT01541150|Pedophilia
1107676|NCT01541150|Impaired Decision making
1107677|NCT01541150|Insight
1107678|NCT01541150|Cognitive Distorsions
1107679|NCT01541150|Impulsiveness
1107680|NCT01541137|thoracotomy
1107681|NCT01541137|pain
1107682|NCT01541137|NSAID
1107683|NCT01541137|PCA
1107684|NCT01541137|TEA
1107685|NCT01541137|chronic
1107686|NCT01541124|cancer pain
1107687|NCT01541124|analgesia
1107688|NCT01541124|morphine
1107689|NCT01541111|Cancer pain
1107690|NCT01541111|Magnesiun
1107691|NCT01541085|Human Immunodeficiency Virus; HIV; Highly Active Antiretroviral Therapy; HAART; Darunavir; Ritonavir; Efavirenz; Kinetics; Immunological Recovery
1107692|NCT01541072|Lymphoma, B-cell
1107693|NCT01541072|Lymphocyte reconstitution
1107694|NCT01541072|Lymphocyte subsets
1107695|NCT01541072|Peripheral stem cell transplantation
1107696|NCT01541072|Induction chemotherapy
1107697|NCT01541072|growth factor
1107698|NCT01541072|Granulocyte Colony-stimulating factor
1107699|NCT01541072|Pegfilgrastim
1107700|NCT01541072|Filgrastim
1107701|NCT01541059|Third molar extraction
1107702|NCT01541059|local anesthesia
1107703|NCT01541059|ropivacaine
1107704|NCT01541046|pediatric
1107705|NCT01541046|infantile colic
1107706|NCT01541046|probiotic treatment
1107707|NCT01541033|autism
1107708|NCT01541033|children
1107709|NCT01541007|Prostate Cancer
1107710|NCT01541007|Metastatic
1107711|NCT01541007|Castration Resistant
1107712|NCT01540994|Neoplasms
1107713|NCT01540994|Urogenital neoplasm
1107714|NCT01540994|Genital neoplasms, male
1107715|NCT01540955|Reduce Cognitive Complaints
1107716|NCT01540955|improve cognitive function
1107717|NCT01540955|post-treatment breast cancer patients
1107718|NCT01540942|Crohn's disease
1107719|NCT01540942|Nutrition
1107720|NCT01540942|Bowel resection
1107721|NCT01540942|Postoperative recurrence
1107722|NCT01540942|complication
1107723|NCT01540942|Active disease
1107724|NCT01540929|Smallpox
1107725|NCT01540929|ACAM2000®
1107726|NCT01540929|Smallpox vaccine
1107727|NCT01540916|acid-base equilibrium
1107728|NCT01540916|renal system
1107729|NCT01540916|urinary electrolytes
1107730|NCT01540903|Malaria Challenge
1107731|NCT01540903|Plasmodium falciparum
1107732|NCT01540903|PfSPZ Challenge
1107733|NCT01540903|Controlled
1107734|NCT01540903|human
1107735|NCT01540903|malaria infection
1107736|NCT01540864|Obesity
1107737|NCT01540864|Overweight
1107738|NCT01540864|Body Mass Index
1107739|NCT01540851|Osteoarthritis
1107740|NCT01540851|Total Knee Replacement
1107741|NCT01540851|total Knee Arthroplasty
1107742|NCT01540851|Post operative recovery, TKA
1107743|NCT01540851|Post-operative recovery TKR
1107744|NCT01540851|Care Navigator
1107745|NCT01540838|Bacterial meningitis
1107746|NCT01540838|infusion
1107747|NCT01540838|bolus
1107748|NCT01540838|paracetamol
1107749|NCT01540812|Acute Lymphoblastic Leukemia
1107750|NCT01540799|Migraine
1107751|NCT01540799|High disability migraine
1107752|NCT01540799|Sphenopalatine ganglion
1107753|NCT01540799|Neuromodulation
1107754|NCT01540799|Neurostimulation
1107755|NCT01540799|Autonomic nervous system
1107756|NCT01540786|OAB
1107757|NCT01540786|High Resolution Urodynamics
1107758|NCT01540773|growth hormone
1107759|NCT01540747|intrafollicular melatonin
1107760|NCT01540747|PCOS
1107761|NCT01540747|embryos quality
1107762|NCT01540747|oocytes quality
1107763|NCT01540734|paracetamol
1107764|NCT01540734|pharmacokinetic
1107765|NCT01540721|paracetamol
1107766|NCT01540721|pharmacokinetics
1107770|NCT01540695|Any patient with a routine basal cell or squamous cell carcinoma
1107771|NCT01540695|of the skin diagnosed on frozen histology during a Mohs procedure
1107772|NCT01540682|Male and female patients with HNSCC of the oral cavity, oropharynx, hypopharynx, larynx,
1107897|NCT01540019|Paullinia cupana
1107773|NCT01540682|nasopharynx or paranasal sinuses that is considered appropriate
1107774|NCT01540682|for definitive cetuximab-based radiation therapy.
1107776|NCT01540669|functional constipation
1107777|NCT01540669|polydextrose
1107778|NCT01540669|whole gut transit time
1107779|NCT01540656|Stress incontinence
1107780|NCT01540656|Incontinence
1107781|NCT01540656|prostate cancer
1107782|NCT01540656|Radical Prostatectomy vibration
1107783|NCT01540656|nerve stimulation
1107784|NCT01540643|abdominal aortic aneurysm
1107785|NCT01540643|iliac leg graft
1107786|NCT01540617|Low back pain
1107787|NCT01540617|Proprioception
1107788|NCT01540617|Postural control
1107789|NCT01540617|Spine
1107790|NCT01540617|Variability
1107791|NCT01540617|MRI
1107792|NCT01540617|Vibration
1107793|NCT01540617|Brain
1107794|NCT01540604|DMD
1107795|NCT01540604|BMD
1107796|NCT01540604|symptomatic carriers
1107797|NCT01540591|repeated implantation failure
1107798|NCT01540591|intralipid
1107799|NCT01540552|lung cancer
1107800|NCT01540552|precancerous condition
1107801|NCT01540552|lung nodules
1107802|NCT01540552|CT Scan
1107803|NCT01540500|Pharmacokinetics
1107804|NCT01540500|Drug Interaction
1107805|NCT01540474|Interference of malaria infection
1107806|NCT01540461|HCC
1107807|NCT01540435|Colorectal cancer
1107808|NCT01540435|Liver metastases
1107809|NCT01540435|Perioperative treatment
1107810|NCT01540435|Liver resection
1107811|NCT01540422|vein grafts
1107812|NCT01540422|coronary bypass
1107813|NCT01540422|endoscopic harvest
1107814|NCT01540422|endoscopic vein harvest
1107815|NCT01540409|DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
1107816|NCT01540396|Gestational Diabetes
1107817|NCT01540383|Communication
1107818|NCT01540383|Language
1107819|NCT01540383|Treatment
1107820|NCT01540383|Intervention
1107821|NCT01540383|Therapy
1107822|NCT01540383|Efficacy
1107823|NCT01540383|Maintenance
1107824|NCT01540383|Recovery
1107825|NCT01540383|Outcome
1107826|NCT01540383|Rehabilitation
1107827|NCT01540383|Treatment Intensity
1107828|NCT01540383|Language Impairment
1107829|NCT01540383|Intensive Language Therapy
1107830|NCT01540383|Functional Communication
1107831|NCT01540383|Functional Improvement
1107832|NCT01540383|Evidence-Based Intervention
1107833|NCT01540383|High-Frequency
1107834|NCT01540357|mindfulness-based therapy
1107835|NCT01540357|chronic tinnitus;
1107836|NCT01540344|peritoneal carcinomatosis
1107837|NCT01540344|cytoreductive surgery
1107838|NCT01540344|HIPEC
1107839|NCT01540344|colorectal cancer
1107843|NCT01540305|Obsessive Compulsive Disorder
1107844|NCT01540305|Transcranial Magnetic Stimulation
1107845|NCT01540305|Treatment
1107846|NCT01540292|Crohn's disease
1107847|NCT01540292|Mesenchymal Stem Cell
1107848|NCT01540292|Cell therapy
1107849|NCT01540292|Allogeneic
1107850|NCT01540292|Inflammatory disorders
1107851|NCT01540292|Autoimmune disorders
1107852|NCT01540266|physician-patient communication
1107853|NCT01540266|information structuring
1107854|NCT01540266|emergency department
1107855|NCT01540240|HIV treatment
1107856|NCT01540240|zidovudine
1107857|NCT01540240|dose reduction
1107858|NCT01540240|anaemia
1107859|NCT01540240|safety and efficacy comparison
1107860|NCT01540227|Syphilis
1107861|NCT01540227|Penicillin
1107862|NCT01540214|Urinary Bladder, Overactive
1107863|NCT01540214|Pelvic Organ Prolapse
1107864|NCT01540214|Gynecologic Surgical Procedures
1107865|NCT01540214|Urodynamics
1107866|NCT01540201|one lung ventilation
1107867|NCT01540201|gas exchange
1107868|NCT01540201|inverse-ratio ventilation
1107869|NCT01540188|Drug user
1107870|NCT01540188|Family member
1107871|NCT01540188|Intervention
1107872|NCT01540188|Community
1107873|NCT01540188|Support
1107874|NCT01540175|Autologous stem cell transplant
1107875|NCT01540175|Immune reconstitution
1107876|NCT01540162|preterm newborn
1107877|NCT01540162|neonatology
1107878|NCT01540162|EcN
1107879|NCT01540162|Nissle
1107880|NCT01540162|Mutaflor
1107881|NCT01540162|prophylaxis
1107882|NCT01540162|infection
1107883|NCT01540110|Locally Advanced or Node Positive Primary Breast Cancer
1107884|NCT01540084|Cocktail sedation
1107885|NCT01540084|ERCP
1107886|NCT01540071|Hormone refractory prostate cancer
1107887|NCT01540071|HRPC
1107888|NCT01540071|Androgen independent prostate cancer
1107889|NCT01540071|CRPC
1107890|NCT01540071|Castration and Taxane Resistant Prostate Cancer
1107891|NCT01540045|Non-Small Cell Lung Cancer
1107892|NCT01540045|Dysgeusia
1107893|NCT01540045|Antineoplastic Combined Chemotherapy Protocols
1107894|NCT01540045|Paclitaxel
1107895|NCT01540045|Cisplatin
1107896|NCT01540019|anorexia
1107898|NCT01540019|loss of weight
1107899|NCT01539993|Hepatocellular carcinoma
1107900|NCT01539993|Liver metastases
1107901|NCT01539993|Cholangiocarcinoma
1107902|NCT01539993|Percutaneous treatments
1107903|NCT01539993|RFA
1107904|NCT01539993|TACE
1107905|NCT01539993|DEB
1107906|NCT01539980|Sericin scaffold
1107907|NCT01539980|Wound healing
1107908|NCT01539980|Skin graft donor
1107909|NCT01539967|Laparoscopic Sleeve Gastrectomy
1107910|NCT01539967|Obesity follow-up
1107911|NCT01539954|Alcohol related disorders
1107912|NCT01539941|Co-occurring adolescent substance use and ADHD
1107913|NCT01539928|Dual time PET/CT
1107914|NCT01539928|glucose-6-phosphatase
1107915|NCT01539915|Psoriasis
1107916|NCT01539915|Stable plaque psoriasis
1107917|NCT01539915|lesions
1107918|NCT01539915|TNF-alpha
1107919|NCT01539915|BCT194
1107920|NCT01539902|MSC for the treatment of Lupus Nephritis
1107921|NCT01539876|locally advanced breast cancer patients
1107922|NCT01539850|obesity
1107923|NCT01539850|gastric stimulation
1107924|NCT01539850|morbid obesity
1107925|NCT01539837|Parkinson's disease
1107926|NCT01539837|Brain Iron
1107927|NCT01539837|Iron chelation
1107928|NCT01539837|Oxidative stress
1107929|NCT01539811|Foot Infections
1107930|NCT01539811|Diabetes
1107931|NCT01539811|Antibiotic
1107932|NCT01539798|Saline solution
1107933|NCT01539798|Sodium Chloride
1107934|NCT01539798|Hypoalbuminemia
1107935|NCT01539798|Weight Gain
1107936|NCT01539785|HIPEC
1107937|NCT01539785|Hyperthermic
1107938|NCT01539785|ovarian cancer
1107939|NCT01539785|recurrence
1107940|NCT01539759|Postpartum Contraception
1107941|NCT01539759|Intrauterine Devices
1107942|NCT01539746|Aortic stenosis
1107943|NCT01539746|Transcatheter aortic valve implantation
1107944|NCT01539746|TAVI
1107945|NCT01539746|Predilation
1107946|NCT01539746|Balloon valvuloplasty
1107947|NCT01539746|BAV
1107948|NCT01539746|CoreValve
1107949|NCT01539720|emergency contraception
1107950|NCT01539720|Ella
1107951|NCT01539720|Mirena IUD
1107952|NCT01539720|post-coital contraception
1107953|NCT01539720|Liletta IUD
1107954|NCT01539707|Neurogenic Detrusor Overactivity
1107955|NCT01539707|Solifenacin succinate suspension
1107956|NCT01539707|Pharmacokinetics
1107957|NCT01539707|Phase 1
1107958|NCT01539681|Hepatocellular Carcinoma
1107959|NCT01539681|Cancer, Liver
1107960|NCT01539681|Sorafenib
1107961|NCT01539681|Nexavar
1107962|NCT01539668|Cervical Cancer
1107963|NCT01539668|HPV
1107964|NCT01539668|Secondary prevention
1107965|NCT01539655|Phase 1
1107966|NCT01539655|healthy volunteers
1107967|NCT01539655|pharmacokinetics
1107968|NCT01539655|vandetanib
1107969|NCT01539655|omeprazole
1107970|NCT01539655|ranitidine
1107971|NCT01539642|In patient, post operative pain
1107972|NCT01539642|Adult post-operative inpatients who are expected to require parenteral opioid analgesia for at least 48 hours after open abdominal surgery
1107973|NCT01539629|Heart failure
1107974|NCT01539629|Autothreshold
1107975|NCT01539629|Pacing
1107976|NCT01539629|CRT-D recipients
1107977|NCT01539629|Left Ventricular evoked response signals
1107978|NCT01539616|Hypertriglyceridemia
1107979|NCT01539616|Dyslipidemia
1107980|NCT01539603|drug eluting balloon
1107981|NCT01539603|bare metal stent
1107982|NCT01539603|drug eluting stent
1107983|NCT01539603|coronary artery disease
1107984|NCT01539590|hepatocyte growth factor mimetic
1107985|NCT01539590|hepatocyte growth factor(HGF)
1107986|NCT01539590|Myocardial Infarction
1107987|NCT01539590|Acute ST Segment Elevation Myocardial Infarction (STEMI)
1107988|NCT01539590|Percutaneous Coronary Intervention (PCI)
1107989|NCT01539538|Adult post-operative inpatients who
1107990|NCT01539538|are expected to require parenteral
1107991|NCT01539538|opioid analgesia for at least 48
1107992|NCT01539538|hours after open abdominal surgery
1107993|NCT01539538|or hip/knee replacement surgery
1107994|NCT01539512|CLL
1107995|NCT01539512|CAL-101
1107996|NCT01539512|GS 1101
1107997|NCT01539512|PI3K
1107998|NCT01539512|GS-US-312-0117
1107999|NCT01539512|idelalisib
1108000|NCT01539460|Axillary osmidrosis
1108001|NCT01539460|liposuction
1108002|NCT01539460|minimally invasive surgery
1108003|NCT01539447|Hip arthroscopy
1108004|NCT01539447|Femoroacetabular impingement
1108005|NCT01539447|Heterotopic ossification
1108006|NCT01539447|Heterotopic bone formation
1108007|NCT01539434|COPD
1108008|NCT01539434|Behavioral intervention
1108009|NCT01539434|Physical capacity
1108010|NCT01539434|Physical activity
1108011|NCT01539421|COPD
1108012|NCT01539421|exercise endurance
1108013|NCT01539395|Relapsing Remitting
1108014|NCT01539395|MS
1108015|NCT01539382|cardiac surgery
1108016|NCT01539382|neurocognitive assessment
1108017|NCT01539382|neurocognitive function
1108018|NCT01539369|dietary intervention
1108019|NCT01539369|dietary fibre
1108020|NCT01539369|weight loss
1108021|NCT01539369|weight maintenance
1108022|NCT01539356|Hepcidin
1108023|NCT01539356|Preterm Infants
1108024|NCT01539356|Anemia
1108025|NCT01539356|Sepsis
1108026|NCT01539356|Ferritin
1108027|NCT01539343|Infection
1108028|NCT01539343|Catheter-related bloodstream infection
1108029|NCT01539343|CRBSI
1108030|NCT01539343|Antimicrobial Lock Therapy
1108031|NCT01539343|ALT
1108032|NCT01539343|Central Line Associated Bloodstream Infection
1108033|NCT01539343|CLABSI
1108034|NCT01539343|Central Venous Catheter
1108035|NCT01539343|CVC
1108036|NCT01539343|Quantitative blood cultures
1108037|NCT01539343|QBC
1108038|NCT01539330|voriconazole
1108039|NCT01539330|microdialysis
1108040|NCT01539330|sequence therapy
1108041|NCT01539330|pharmacokinetics
1108042|NCT01539330|Target Site Pharmacokinetics
1108043|NCT01539317|Vulvodynia
1108044|NCT01539317|Dyspareunia
1108045|NCT01539317|Breast Cancer
1108046|NCT01539317|Menopause
1108047|NCT01539317|Vaginal dryness
1108048|NCT01539317|Painful intercourse
1108049|NCT01539291|CLL
1108050|NCT01539291|CAL-101
1108051|NCT01539291|CAL 101
1108052|NCT01539291|GS-1101
1108053|NCT01539291|GS 1101
1108054|NCT01539291|PI3K
1108055|NCT01539291|Leukemia
1108056|NCT01539291|GS-US-312-0116
1108057|NCT01539291|idelalisib
1108058|NCT01539278|Sleep Apnea, Obstructive
1108059|NCT01539278|Child
1108060|NCT01539278|Tonsillectomy
1108061|NCT01539278|Adenoidectomy
1108062|NCT01539265|urinary calculus
1108063|NCT01539265|ureteral stones
1108064|NCT01539265|medical expulsive therapy
1108065|NCT01539252|hemodialysis
1108066|NCT01539252|adequacy
1108067|NCT01539252|phosphate clearance
1108068|NCT01539252|double dialyzer
1108069|NCT01539252|two dialyzers in parallel
1108070|NCT01539239|Glaucoma
1108071|NCT01539239|POAG
1108072|NCT01539239|Cataract
1108073|NCT01539226|HIV Infections
1108074|NCT01539226|Anti-HIV agents
1108075|NCT01539226|HIV-1
1108076|NCT01539213|Psoriasis
1108077|NCT01539213|interstitial fluid
1108078|NCT01539213|open flow microperfusion
1108079|NCT01539213|IL-17
1108080|NCT01539213|inflammatory skin disease
1108081|NCT01539213|scaly patches
1108082|NCT01539213|Healthy volunteers and psoriasis patients
1108083|NCT01539187|uterine fibroid RF ablation
1108084|NCT01539187|intrauterine ultrasound
1108085|NCT01539187|VizAblate
1108086|NCT01539161|Chagas Disease
1108087|NCT01539161|Chagasic
1108088|NCT01539161|Reveal XT
1108089|NCT01539161|Implantable Cardiac Monitor
1108090|NCT01539161|ICM
1108091|NCT01539148|Quality of Life
1108092|NCT01539148|Qol
1108093|NCT01539148|Questionnaire
1108094|NCT01539148|Survey
1108095|NCT01539148|Insulin Potentiation Targeted Low Dose Chemotherapy
1108096|NCT01539148|IPTLD
1108097|NCT01539148|Nutritional Therapy
1108098|NCT01539148|Chemotherapy
1108099|NCT01539148|Cancer Treatment
1108100|NCT01539148|Kotsanis Institute
1108101|NCT01539148|The Best Answer for Cancer Foundation
1108102|NCT01539148|Liberty IRB
1108103|NCT01539148|Texas
1108104|NCT01539135|Aspiration, Respiratory
1108105|NCT01539122|osteoarthritis
1108106|NCT01539122|shoulder replacement
1108107|NCT01539109|Incomplete Spinal Cord Injury
1108108|NCT01539109|Quadriplegia
1108109|NCT01539109|Tetraplegia
1108110|NCT01539109|SCI
1108111|NCT01539109|Spinal Cord Disease
1108112|NCT01539109|Spinal Cord Injury
1108113|NCT01539109|iSCI
1108114|NCT01539109|Transcranial Direct Current Stimulation
1108115|NCT01539109|tDCS
1108116|NCT01539109|SCI recovery
1108117|NCT01539109|brain stimulation
1108118|NCT01539109|rehabilitation
1108119|NCT01539096|Stroke
1108120|NCT01539096|Rehabilitation
1108121|NCT01539096|Paresis
1108122|NCT01539096|Paralysis
1108123|NCT01539096|Recovery
1108124|NCT01539096|tDCS
1108125|NCT01539096|Transcranial Direct Current Stimulation
1108126|NCT01539096|CIMT
1108127|NCT01539096|Constraint Induced Movement Therapy
1108128|NCT01539096|Stroke therapy
1108129|NCT01539096|MRI
1108130|NCT01539096|Hand
1108131|NCT01539096|CVA
1108132|NCT01539096|Cerebrovascular accident
1108133|NCT01539083|Multiple Myeloma
1108134|NCT01539083|Bortezomib
1108135|NCT01539083|VELCADE
1108136|NCT01539083|Consolidation therapy
1108137|NCT01539083|Subcutaneous
1108138|NCT01539083|Thalidomide
1108139|NCT01539083|Prednisolone
1108140|NCT01539083|Autologous stem cell transplant (ASCT)
1108141|NCT01539083|VELCADE, cyclophosphamide, dexamethasone (VCD) induction therapy
1108142|NCT01539070|Nutritional intervention
1108143|NCT01539070|Childhood obesity
1108144|NCT01539070|Physical activity
1108145|NCT01539070|Feeding practices
1108146|NCT01539057|Liver
1108147|NCT01539057|Surgery
1108148|NCT01539057|hemostasis
1108149|NCT01539057|coagulation
1108150|NCT01539057|Fibrinogen
1108151|NCT01539044|reversal
1108152|NCT01539044|muscle relaxant
1108153|NCT01539044|sugammadex
1108154|NCT01539031|Alzheimer Disease
1108155|NCT01539031|Dementia
1108156|NCT01539031|Delirium
1108157|NCT01539031|Amnestic
1108158|NCT01539031|Cognitive Disorders
1108159|NCT01539031|Donepezil
1108160|NCT01539031|Brain Diseases
1108161|NCT01539031|Central Nervous System Diseases
1108162|NCT01539031|Nervous System Diseases
1108163|NCT01539031|Tauopathies
1108164|NCT01539031|Neurodegenerative Diseases
1108165|NCT01539031|Mental Disorders
1108166|NCT01539031|Cholinesterase Inhibitors
1108167|NCT01539031|Enzy
1108168|NCT01539005|Recurrence
1108169|NCT01539005|Tuberculosis
1108170|NCT01538992|renal denervation
1108171|NCT01538992|heart failure
1108172|NCT01538979|Grass pollen allergy
1108173|NCT01538979|Immunotherapy
1108174|NCT01538979|Recombinant vaccine
1108175|NCT01538979|Rhinitis, allergic, seasonal
1108176|NCT01538966|acromegaly
1108177|NCT01538966|pituitary
1108178|NCT01538966|pegvisomant
1108179|NCT01538966|somavert
1108180|NCT01538966|lanreotide
1108181|NCT01538966|octreotide
1108182|NCT01538953|diarrhea
1108183|NCT01538953|handwashing
1108184|NCT01538953|point-of-use water treatment
1108185|NCT01538953|diarrhea longitudinal prevalence
1108186|NCT01538940|Influenza
1108187|NCT01538940|Vaccine
1108188|NCT01538940|Thailand
1108189|NCT01538927|fibrin sealant
1108190|NCT01538927|tissue adhesive
1108191|NCT01538927|wound healing
1108192|NCT01538927|interleukin 1 beta
1108193|NCT01538927|interleukin 8
1108194|NCT01538901|actinic keratoses
1108195|NCT01538901|organ transplant recipients
1108196|NCT01538901|photodynamic therapy
1108197|NCT01538901|imiquimod
1108198|NCT01538888|WHOLE BODY VIBRATION
1108199|NCT01538888|AGED
1108200|NCT01538888|VO2
1108201|NCT01538888|muscle strength
1108202|NCT01538875|Hypertension, pregnancy induced
1108203|NCT01538875|Hydralazine
1108204|NCT01538875|Labetalol
1108205|NCT01538823|Surgery, Renal Cell Cancer
1108206|NCT01538810|CT imaging
1108207|NCT01538797|YF476
1108208|NCT01538797|gastrin receptor antagonist
1108209|NCT01538797|gastric pH
1108210|NCT01538797|healthy subjects
1108211|NCT01538797|ranitidine
1108212|NCT01538784|YF476
1108213|NCT01538784|gastrin receptor antagonist
1108214|NCT01538784|gastric pH
1108215|NCT01538784|healthy subjects
1108216|NCT01538771|Myocardial infarction
1108217|NCT01538771|Erythropoietin
1108218|NCT01538771|Myocardial reperfusion injury
1108219|NCT01538758|calcifying tendinitis
1108220|NCT01538758|rotator cuff
1108221|NCT01538745|Pain
1108222|NCT01538745|Emergency Department
1108223|NCT01538745|Morphine
1108224|NCT01538745|Ketamine
1108225|NCT01538706|Hospital-based home care
1108226|NCT01538706|Pediatric oncology
1108227|NCT01538693|BDNF
1108228|NCT01538693|serotonin
1108229|NCT01538693|high-intensity
1108230|NCT01538693|exercise
1108231|NCT01538667|Lung
1108232|NCT01538667|Scintigraphy
1108233|NCT01538667|Pharmacokinetics
1108234|NCT01538667|Inhalation
1108235|NCT01538667|Ciprofloxacin
1108236|NCT01538654|obesity
1108237|NCT01538654|PSMF ( protein sparing modified fast)
1108238|NCT01538654|Enteral nutrition
1108239|NCT01538654|Tube feeding
1108240|NCT01538654|VLCD ( very low calorie diet)
1108241|NCT01538654|Pulmonary function tests
1108242|NCT01538654|body composition
1108243|NCT01538654|FFM ( fat free mass)
1108244|NCT01538654|Body fat
1108245|NCT01538654|Handgripstregth
1108246|NCT01538628|Prostate cancer
1108247|NCT01538628|Spacer
1108248|NCT01538615|Family meals
1108249|NCT01538615|Home food environment
1108250|NCT01538615|Electronic media
1108251|NCT01538602|PCOS
1108252|NCT01538602|cardiovascular disorders
1108256|NCT01538550|cancer
1108257|NCT01538550|colon
1108258|NCT01538550|rectum
1108259|NCT01538550|adenoma
1108260|NCT01538550|screening
1108261|NCT01538550|iFOBT
1108262|NCT01538550|flexible sigmoidoscopy
1108263|NCT01538550|randomized trial
1108267|NCT01538498|PCI
1108268|NCT01538498|Ovarian cancer
1108269|NCT01538485|Vitamin D
1108270|NCT01538485|regulatory T cells
1108271|NCT01538485|GUT
1108272|NCT01538472|Lymphoma
1108273|NCT01538472|Relapse B-cell CD20+ non-Hodgkin's lymphoma
1108274|NCT01538472|High-dose BEAM chemotherapy
1108275|NCT01538472|Y Zevalin
1108276|NCT01538472|In Zevalin
1108277|NCT01538472|Rituxan
1108278|NCT01538472|Rituximab
1108279|NCT01538472|BCNU
1108280|NCT01538472|1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea
1108281|NCT01538472|Carmustine
1108282|NCT01538472|BiCNU
1108283|NCT01538472|VP-16
1108284|NCT01538472|Ara-C
1108285|NCT01538472|Cytarabine
1108286|NCT01538472|Cytosar
1108287|NCT01538472|DepoCyt
1108288|NCT01538472|Cytosine Arabinosine Hydrochloride
1108289|NCT01538472|Melphalan
1108290|NCT01538472|Alkeran
1108291|NCT01538472|G-CSF
1108292|NCT01538472|Filgrastim
1108293|NCT01538472|Neupogen
1108294|NCT01538472|Stem cell infusion
1108295|NCT01538472|Autologous stem cell transplantation
1108296|NCT01538459|Blood Glucose
1108297|NCT01538459|Bupivacaine
1108298|NCT01538459|Interscalene Nerve Block
1108299|NCT01538459|Regional Anesthesia
1108300|NCT01538459|Pain Blockade
1108301|NCT01538459|Arthroscopic Surgery
1108302|NCT01538459|Arthroscopic rotator cuff repair
1108303|NCT01538459|Dexamethasone
1108304|NCT01538459|Anti-Inflammatory Agents
1108305|NCT01538459|Therapeutic Uses
1108306|NCT01538459|Physiological Effects of Drugs
1108307|NCT01538459|Glucocorticoids
1108308|NCT01538459|Anesthetics, Local
1108309|NCT01538459|Anesthetics
1108310|NCT01538459|Sensory System Agents
1108311|NCT01538459|Adjuvants, Anesthesia
1108312|NCT01538459|Anesthesiology
1108313|NCT01538459|Injections
1108314|NCT01538459|Adult
1108315|NCT01538459|Analgesia/methods
1108316|NCT01538459|Brachial Plexus/drug effects
1108317|NCT01538459|Brachial Plexus/surgery
1108318|NCT01538459|Brachial Plexus/ultrasonography
1108319|NCT01538459|Bupivacaine/administration & dosage
1108320|NCT01538459|Dexamethasone/administration & dosage
1108321|NCT01538459|Drug Therapy, Combination
1108322|NCT01538459|Female
1108323|NCT01538459|Humans
1108324|NCT01538459|Male
1108325|NCT01538459|Nerve Block/methods
1108326|NCT01538459|Pain, Postoperative/etiology
1108327|NCT01538459|Pain, Postoperative/prevention & control
1108328|NCT01538459|Prospective Studies
1108329|NCT01538459|Time Factors
1108330|NCT01538446|Elderly
1108331|NCT01538446|Acute coronary syndrome
1108332|NCT01538446|Percutaneous coronary intervention
1108333|NCT01538446|Prasugrel
1108334|NCT01538446|Platelet function test
1108335|NCT01538433|diagnosis
1108336|NCT01538433|IgA nephropathy
1108337|NCT01538420|Safety
1108338|NCT01538420|Tolerability
1108339|NCT01538420|Pharmacokinetics
1108340|NCT01538420|Pharmacodynamics
1108341|NCT01538407|Strength training
1108342|NCT01538407|Biomechanics
1108343|NCT01538407|Quadriceps
1108344|NCT01538407|Gait
1108345|NCT01538394|smoking cessation
1108346|NCT01538394|abstinence
1108347|NCT01538394|clinical trial
1108348|NCT01538394|varenicline
1108349|NCT01538394|nicotine
1108350|NCT01538381|Neoadjuvant targeted therapy
1108351|NCT01538381|Preoperative targeted therapy
1108352|NCT01538381|Afatinib
1108353|NCT01538368|MRCP
1108354|NCT01538368|ERCP
1108355|NCT01538368|EUS
1108356|NCT01538368|Image interpretation
1108357|NCT01538368|MRCP findings
1108358|NCT01538368|endoscopic intervention(s)
1108359|NCT01538355|multiple sclerosis
1108360|NCT01538355|diet
1108361|NCT01538355|prolonged fasting
1108362|NCT01538355|caloric restriction
1108363|NCT01538355|ketogenic low glycemic load treatment
1108364|NCT01538355|health related quality of life
1108365|NCT01538355|ketogenic diet
1108366|NCT01538355|neurodegeneration
1108367|NCT01538355|neuroinflammation
1108368|NCT01538329|Dyskinesia
1108369|NCT01538329|L-DOPA
1108370|NCT01538329|Early introduced treatment
1108371|NCT01538329|Amantadine
1108372|NCT01538316|Prostate cancer
1108373|NCT01538316|dietary supplements
1108374|NCT01538316|quercetin
1108375|NCT01538316|genistein
1108376|NCT01538316|prostate-specific antigen
1108377|NCT01538316|oxidative Status
1108378|NCT01538303|STEMI
1108379|NCT01538303|absolute flow
1108380|NCT01538303|microvascular resistance
1108381|NCT01538290|Calibration
1108382|NCT01538290|Validation
1108383|NCT01538290|Transfer function
1108384|NCT01538290|SphygmoCor
1108385|NCT01538290|Arteriograph
1108386|NCT01538277|contact force catheter
1108387|NCT01538277|loop recorder
1108388|NCT01538251|ulcerative colitis
1108389|NCT01538251|propionyl-l-carnitine
1108390|NCT01538225|Spasticity
1108391|NCT01538212|Alzheimer's disease
1108392|NCT01538212|retrospective
1108393|NCT01538212|Axona
1108394|NCT01538199|Device study
1108395|NCT01538199|Depression
1108396|NCT01538199|Major Depression
1108397|NCT01538199|Major Depressive Disorder
1108398|NCT01538199|MDD
1108399|NCT01538199|Device for depression
1108400|NCT01538199|Alternatives to medication for depression
1108401|NCT01538199|Massachusetts General Hospital
1108402|NCT01538199|Boston
1108403|NCT01538186|Coronary intervention
1108404|NCT01538186|PCI of the side branch
1108405|NCT01538173|surgical side infection
1108406|NCT01538173|breast reduction
1108407|NCT01538173|reduction mammaplasty
1108408|NCT01538173|prospective trial
1108409|NCT01538173|microcirculation
1108410|NCT01538173|breast surgery
1108411|NCT01538160|recombinant factor VIIa
1108412|NCT01538160|factor XI deficiency
1108413|NCT01538147|Restless Leg Syndrome
1108414|NCT01538147|Severe Preeclampsia
1108415|NCT01538134|Antibodies, anticardiolipin
1108416|NCT01538134|Antibodies, B2 Glycoprotein I
1108417|NCT01538134|Lupus Anticoagulant
1108418|NCT01538134|Fetal Growth Restriction
1108419|NCT01538121|Antibodies, anticardiolipin
1108420|NCT01538121|Antibodies, B2 Glycoprotein I
1108421|NCT01538121|Lupus Anticoagulant
1108422|NCT01538121|Severe Preeclampsia
1108423|NCT01538082|Anxiety disorders
1108424|NCT01538082|Depressive disorders
1108425|NCT01538082|Metabolic syndrome
1108426|NCT01538082|Stress disorders
1108427|NCT01538082|Primary care
1108428|NCT01538069|Heart failure
1108429|NCT01538069|Sleep apnea syndromes
1108430|NCT01538069|Exercise
1108431|NCT01538069|Continuous Positive Airway Pressure
1108432|NCT01538056|AAA
1108433|NCT01538043|Cost-effectiveness analysis
1108434|NCT01538043|Cost-utility analysis
1108435|NCT01538043|Osteoarthritis
1108436|NCT01538043|Spa therapy
1108437|NCT01538043|Randomized clinical trial
1108438|NCT01538043|Mechanisms of action
1108439|NCT01538030|Fetal membranes, premature rupture
1108440|NCT01538030|Cesarean section
1108441|NCT01538030|Perinatal mortality
1108442|NCT01538030|Neonatal sepsis
1108443|NCT01538030|Amniotic Fluid Volume
1108444|NCT01538004|Blood pressure determination
1108445|NCT01538004|Primary health care
1108446|NCT01538004|Office visits
1108447|NCT01538004|Reproducibility of results
1108448|NCT01537991|radiotherapy
1108449|NCT01537991|non small cell lung cancer
1108450|NCT01537991|isotoxic
1108451|NCT01537978|spinal cord injury, video gaming, functional improvement
1108452|NCT01537965|hepatitis
1108453|NCT01537965|fibrosis
1108454|NCT01537965|elastography
1108455|NCT01537952|facial paralysis, facial nerve, borreliosis, Bell's palsy
1108456|NCT01537939|Physical Activity
1108457|NCT01537939|Walking
1108458|NCT01537939|Pedometer
1108459|NCT01537939|Body Composition
1108460|NCT01537939|Aerobic Fitness
1108461|NCT01537926|HALT
1108462|NCT01537926|HCM
1108463|NCT01537874|Secondhand smoke
1108464|NCT01537874|Pediatric disease
1108465|NCT01537848|EUS
1108466|NCT01537848|Endoscopic ultrasound
1108467|NCT01537848|abdominal collection
1108468|NCT01537848|post-operative
1108469|NCT01537848|post-surgical
1108470|NCT01537835|healthcare
1108471|NCT01537835|worker
1108472|NCT01537835|uniforms
1108473|NCT01537835|bacterial
1108474|NCT01537835|contamination
1108475|NCT01537822|intrauterine polyps
1108476|NCT01537822|myomas
1108477|NCT01537822|residual placental tissue
1108478|NCT01537809|Vitamin D
1108479|NCT01537809|Vitamin D Deficiency
1108480|NCT01537809|Avitaminosis
1108481|NCT01537809|Deficiency Diseases
1108482|NCT01537809|Blood lipids
1108483|NCT01537796|Obesity
1108484|NCT01537796|Exercise
1108485|NCT01537783|abscess
1108486|NCT01537770|Vertebroplasty
1108487|NCT01537770|Low energy osteoporotic vertebral fractures
1108488|NCT01537770|of the thoracic and/or lumbar spine
1108489|NCT01537744|expansion cohort
1108490|NCT01537705|Medical food
1108491|NCT01537705|Neuropathy
1108492|NCT01537705|Diabetes
1108493|NCT01537705|Neuropathic Pain
1108494|NCT01537679|Caregiver
1108495|NCT01537679|meditation
1108496|NCT01537679|relaxation
1108497|NCT01537679|stress
1108498|NCT01537627|Motor activity
1108499|NCT01537627|Exercise
1108500|NCT01537627|Rehabilitation
1108501|NCT01537601|Posterior urethral valves
1108502|NCT01537601|Febrile urinary tract infection
1108503|NCT01537601|Circumcision
1108504|NCT01537601|Antibioprophylaxis
1108505|NCT01537601|Impact on family
1108506|NCT01537588|anterior cruciate ligament
1108507|NCT01537588|hamstring
1108508|NCT01537588|semitendinosus
1108509|NCT01537588|gracilis
1108510|NCT01537588|graft
1108511|NCT01537562|Copper IUD
1108512|NCT01537562|LNG-IUS
1108513|NCT01537562|intrauterine contraception
1108514|NCT01537562|medical abortion
1108515|NCT01537562|postabortion contraception
1108516|NCT01537549|Progressive supranuclear palsy
1108517|NCT01537549|alpha-lipoic acid
1108518|NCT01537549|L-acetyl carnitine
1108519|NCT01537549|antioxidant
1108520|NCT01537549|magnetic resonance spectroscopy
1108521|NCT01537549|neurodegeneration
1108522|NCT01537549|glutathione
1108523|NCT01537536|Breast cancer
1108524|NCT01537536|Neoadjuvant chemotherapy
1108525|NCT01537536|EndoTAG-1
1108526|NCT01537523|physical
1108527|NCT01537523|psychological
1108528|NCT01537523|fracture hip
1108529|NCT01537497|Phase 1
1108530|NCT01537497|Single Doses
1108531|NCT01537497|Pharmacodynamics
1108532|NCT01537497|Healthy Volunteers
1108533|NCT01537484|massage
1108534|NCT01537484|osteoarthritis
1108535|NCT01537484|light touch
1108536|NCT01537484|Swedish
1108537|NCT01537471|PPI
1108538|NCT01537471|Meclizine
1108539|NCT01537471|Startle
1108540|NCT01537471|Sensory processing
1108541|NCT01537471|antihistamines
1108542|NCT01537445|Diabetes Mellitus
1108543|NCT01537445|Pancreas
1108544|NCT01537445|Renal failure
1108545|NCT01537445|Transplantation
1108546|NCT01537432|Psoriasis, Plaque-type psoriasis
1108547|NCT01537432|Plaque
1108548|NCT01537432|Secukinumab
1108549|NCT01537432|AIN457A
1108550|NCT01537432|PASI
1108551|NCT01537432|DLQI
1108552|NCT01537432|IGA
1108553|NCT01537419|Suicide
1108554|NCT01537419|Depression
1108555|NCT01537419|Family Relationships
1108556|NCT01537406|BREAST IRRADIATION USING INTENSITY MODULATED RADIATION THERAPY
1108557|NCT01537393|cornea
1108558|NCT01537393|transplant
1108559|NCT01537393|preservation
1108560|NCT01537393|endothelial keratoplasty
1108561|NCT01537367|Human immunodeficiency virus
1108562|NCT01537367|HIV primary care
1108563|NCT01537328|Total knee arthroplasty
1108564|NCT01537328|quadriceps
1108565|NCT01537328|muscle
1108566|NCT01537328|arthroplasty
1108567|NCT01537328|joint diseases
1108568|NCT01537328|musculoskeletal diseases
1108569|NCT01537315|Kidney Failure, Chronic
1108570|NCT01537315|Cardiovascular Disease
1108571|NCT01537315|Arteriosclerosis
1108572|NCT01537302|Chronic Total Occlusion
1108573|NCT01537302|Optimal Coherence Tomography
1108574|NCT01537302|Lumivascular
1108575|NCT01537289|Trauma
1108576|NCT01537289|Pneumothorax
1108577|NCT01537276|hysterosalpingography
1108578|NCT01537276|Fluoroscopy
1108579|NCT01537276|diagnostic accuracy
1108580|NCT01537263|Aneurysmal Subarachnoid Hemorrhage
1108581|NCT01537263|SAB
1108582|NCT01537263|SAH
1108583|NCT01537263|Ultrasound
1108584|NCT01537263|Perfusion imaging
1108585|NCT01537250|CAP
1108586|NCT01537237|Atrial Fibrillation
1108587|NCT01537237|Catheter-based ablation
1108588|NCT01537237|Pulmonary vein isolation
1108589|NCT01537237|Electro-anatomical mapping
1108590|NCT01537237|Rotational angiography
1108591|NCT01537224|Electrophysiology
1108592|NCT01537224|Subthalamic nucleus
1108593|NCT01537224|Parkinson
1108594|NCT01537211|Dysvascular
1108595|NCT01537211|amputation
1108596|NCT01537211|above knee
1108597|NCT01537211|ambulation
1108598|NCT01537198|Postmarketing Drug Surveillance
1108599|NCT01537172|ONO-4053 healthy subjects
1108600|NCT01537172|3 part adaptive design
1108601|NCT01537159|AML
1108602|NCT01537146|unicompartmental
1108603|NCT01537146|osteoarthritis
1108604|NCT01537146|varus
1108605|NCT01537146|malalignment
1108606|NCT01537146|opening wedge
1108607|NCT01537146|HTO
1108608|NCT01537146|high
1108609|NCT01537146|tibia
1108610|NCT01537146|osteotomy
1108611|NCT01537094|low vitamin c
1108612|NCT01537094|reduced growth hormone secretion
1108613|NCT01537068|Dysthymic disorder
1108614|NCT01537068|Dysthymia
1108615|NCT01537068|Chronic non-major depression
1108616|NCT01537068|Non-major chronic depression
1108617|NCT01537068|Chronic depressive disorder
1108618|NCT01537068|Antidepressant treatment
1108619|NCT01537055|H pylori eradication
1108620|NCT01537042|Rotigotine
1108621|NCT01537042|Neupro
1108622|NCT01537042|Restless Legs Syndrome
1108623|NCT01537042|RLS
1108624|NCT01537042|End-Stage Renal Disease
1108625|NCT01537029|Breast cancer
1108626|NCT01537029|Pharmacokinetics
1108627|NCT01537029|Obesity
1108628|NCT01537029|Doxorubicin
1108629|NCT01537029|Cyclophosphamide
1108630|NCT01537029|Weight
1108631|NCT01536977|quality of life
1108632|NCT01536925|Behavioral Economics
1108633|NCT01536925|Drug self administration
1108634|NCT01536925|Opioid
1108635|NCT01536912|HIV positive
1108636|NCT01536899|HIV positive
1108637|NCT01536899|Medical Marijuana
1108638|NCT01536873|treatment experienced patients
1108639|NCT01536873|Integrase resistance
1108640|NCT01536821|Parkinson disease
1108641|NCT01536821|Parkinson's Disease
1108642|NCT01536821|PD
1108643|NCT01536821|LRRK2
1108644|NCT01536821|genetics
1108645|NCT01536821|genes
1108646|NCT01536808|Diabetes mellitus
1108647|NCT01536808|accelerated aging
1108648|NCT01536808|cellular senescence
1108649|NCT01536808|diabetic cardiomyopathy
1108650|NCT01536808|strain imaging
1108651|NCT01536808|strain rate imaging,
1108652|NCT01536808|echocardiography
1108653|NCT01536795|Ointment to treat leishmania skin lesions
1108654|NCT01536782|head and neck cancer
1108655|NCT01536782|chemoradiation therapy
1108656|NCT01536782|bolus feeding
1108657|NCT01536782|gravity feeding
1108658|NCT01536782|pump feeding
1108659|NCT01536782|optimal enteral feeding method
1108660|NCT01536782|To determine the optimal tube feeding method by analyzing percent weigtht loss.
1108661|NCT01536782|To determine the optimal tube feeding method by analyzing tolerance of enteral feeds.
1108662|NCT01536782|To determine the optimal tube feeding method by analyzing percent met of estimated calories and protein.
1108663|NCT01536769|Metagenomic analysis
1108664|NCT01536769|Microbiota
1108665|NCT01536756|Depressive disorder
1108666|NCT01536756|exercise
1108667|NCT01536756|pain
1108668|NCT01536756|physical
1108669|NCT01536756|psychological
1108670|NCT01536756|Chinese
1108671|NCT01536756|mild to severe depressive disorders
1108672|NCT01536717|atrial septal defect
1108673|NCT01536717|mitral valve annuloplasty
1108674|NCT01536717|aortic valve annuloplasty
1108675|NCT01536717|open heart surgery
1108676|NCT01536717|oxycodone consumption
1108677|NCT01536717|articain
1108678|NCT01536717|bupivacaine
1108679|NCT01536717|pain after sternotomy
1108680|NCT01536717|postoperative pain
1108681|NCT01536717|wound infusion
1108682|NCT01536704|nicotine lozenge
1108683|NCT01536704|nicotine
1108684|NCT01536704|nicotine replacement therapy
1108685|NCT01536691|ramosetron
1108686|NCT01536691|ondansetron
1108687|NCT01536691|aprepitant
1108688|NCT01536691|chemotherapy induced nausea & vomiting
1108689|NCT01536587|influence of bronchodilatation with salmeterol on the autonomic nervous systems in COPD patients will be measured using MSNA.
1108690|NCT01536587|Relation of COPD and sympathetic nerve activity is to be evaluated,
1108691|NCT01536561|Tositumomab and/or Iodine I 131 Tositumomab
1108692|NCT01536561|B-cell non-Hodgkin's lymphoma
1108693|NCT01536561|Dose-limiting toxicity
1108694|NCT01536561|Bexxar
1108695|NCT01536548|hemodialysis
1108696|NCT01536548|cannulation
1108697|NCT01536548|AV-fistula
1108698|NCT01536548|buttonhole technique
1108699|NCT01536535|Ulcerative Colitis
1108700|NCT01536535|mesalamine
1108701|NCT01536535|corticosteroids
1108702|NCT01536535|PROTECT
1108703|NCT01536522|Asthma
1108704|NCT01536522|Allergic Asthma
1108705|NCT01536522|Non-allergic Asthma
1108706|NCT01536496|trauma
1108707|NCT01536496|hemorrhagic shock
1108708|NCT01536496|thrombelastography
1108709|NCT01536496|coagulopathy
1108710|NCT01536496|transfusion
1108711|NCT01536496|resuscitation
1108712|NCT01536483|Butyrate
1108713|NCT01536483|Preterms
1108714|NCT01536483|Very Low Birth Weight (<1250g)
1108715|NCT01536483|Rectocolonic enemas
1108716|NCT01536483|Digestive maturation
1108717|NCT01536483|Parenteral nutrition weaning
1108718|NCT01536483|ECUN
1108719|NCT01536483|Whole gut transit time
1108720|NCT01536470|Intraoperative hemodynamic
1108721|NCT01536470|Arterial pressure
1108722|NCT01536470|Postoperative complications
1108723|NCT01536470|Intraoperative fluids
1108724|NCT01536470|Noradrenaline
1108725|NCT01536457|asthma
1108726|NCT01536457|children
1108727|NCT01536457|gastroesophageal reflux
1108728|NCT01536457|retrospective
1108729|NCT01536457|data analysis
1108730|NCT01536444|Mohs surgery
1108731|NCT01536444|Excisional skin surgery
1108732|NCT01536444|Micrografting
1108733|NCT01536431|Diabetes
1108734|NCT01536418|Crohn's disease, chemokine receptor 9 antagonist, Crohn's Disease Activity Index
1108735|NCT01536418|active treatment
1108736|NCT01536392|Cancer of the Cervix
1108737|NCT01536392|Anti-emetic therapy
1108738|NCT01536392|Granisetron
1108739|NCT01536392|Transdermal patch
1108740|NCT01536392|Ondansetron
1108741|NCT01536392|Zofran
1108742|NCT01536392|Questionnaires
1108743|NCT01536392|Surveys
1108744|NCT01536392|Study Drug Diary
1108745|NCT01536379|Infection
1108746|NCT01536379|Quality of Life
1108747|NCT01536366|Parkinson Disease
1108748|NCT01536366|BIA 9-1067
1108749|NCT01536340|post discharge adverse events
1108750|NCT01536340|discontinuities in care
1108751|NCT01536340|medical injury
1108752|NCT01536327|Metachromatic Leukodystrophy
1108753|NCT01536327|Demyelinating Diseases
1108754|NCT01536314|Pre-emptive administration
1108755|NCT01536314|Post-operative administration
1108756|NCT01536314|Prophylaxis
1108757|NCT01536314|Memantine
1108758|NCT01536314|Post-mastectomy/tumorectomy
1108759|NCT01536314|Neuropathic pain
1108760|NCT01536301|oxycodone
1108761|NCT01536301|morphine
1108762|NCT01536301|hip replacement
1108763|NCT01536301|analgesia
1108764|NCT01536301|post operative analgesia
1108765|NCT01536288|acute mountain sickness
1108766|NCT01536288|AMS
1108767|NCT01536288|Rhodiola Crenulata
1108768|NCT01536288|mountaineering
1108769|NCT01536288|pulse oximetry
1108770|NCT01536288|oxygen saturation
1108775|NCT01536236|Diabetes
1108776|NCT01536236|Polyneuropathy
1108777|NCT01536236|Spinal cord stimulation
1108778|NCT01536223|Nasopharyngeal Carcinoma (NPC)
1108779|NCT01536223|cisplatin and 5-fluorouracil (PF)
1108780|NCT01536223|docetaxel,cisplatin and 5-fluorouracil(TPF)
1108781|NCT01536223|Neoadjuvant Chemotherapy
1108782|NCT01536223|intensity modulated radiotherapy(IMRT)
1108783|NCT01536210|ADHD(attention Deficit Hyperactivity Disorder)
1108784|NCT01536197|obesity
1108785|NCT01536197|gastric bypass
1108786|NCT01536197|gastric banding
1108787|NCT01536197|weight loss
1108788|NCT01536197|taste perception
1108789|NCT01536184|Fetal Alcohol Spectrum Disorder
1108790|NCT01536184|FASD
1108791|NCT01536171|runners
1108792|NCT01536171|mid-foot strike
1108793|NCT01536171|fore foot strike
1108794|NCT01536171|metabolic costs
1108795|NCT01536171|trained runners (men,women) with a FM strike
1108796|NCT01536171|shod running
1108797|NCT01536171|barefoot running
1108798|NCT01536158|Patent Ductus Arteriosus
1108799|NCT01536158|Paracetamol
1108800|NCT01536158|Ibuprofen
1108801|NCT01536158|Preterm infant
1108802|NCT01536145|IGF-1R inhibitor
1108803|NCT01536145|CP-751871
1108804|NCT01536145|multiple myeloma
1108805|NCT01536132|Levosimendan
1108806|NCT01536132|chronic heart failure
1108807|NCT01536132|inotropic drug
1108808|NCT01536119|Breastfeeding
1108809|NCT01536119|Coparenting
1108810|NCT01536119|Infant feeding
1108811|NCT01536119|Fathers' support
1108812|NCT01536119|Breastfeeding support
1108813|NCT01536119|Breastfeeding support intervention
1108814|NCT01536119|clinical trial
1108815|NCT01536106|Cell therapy, Bone marrow stem cells, cardiac cell therapy
1108816|NCT01536041|asthma
1108817|NCT01536041|Adult
1108818|NCT01536015|Rotigotine
1108819|NCT01536015|Neupro®
1108820|NCT01536015|Levodopa
1108821|NCT01536015|Gastrointestinal Dysfunction
1108822|NCT01536002|Bariatric surgery
1108823|NCT01536002|Anesthetics, intravenous
1108824|NCT01536002|Propofol
1108825|NCT01536002|Pharmacokinetics
1108826|NCT01535989|B-cell Non Hodgkin's Lymphomas
1108827|NCT01535989|CD22 positive
1108828|NCT01535950|Age-related macular degeneration
1108829|NCT01535950|intravitreal, neovascular
1108830|NCT01535950|anti-vascular endothelial growth factor
1108831|NCT01535950|wet AMD
1108832|NCT01535950|Age-related
1108833|NCT01535950|Macular degeneration
1108834|NCT01535950|Intravitreal
1108835|NCT01535950|Neovascular
1108836|NCT01535924|Hodgkin's Lymphoma
1108837|NCT01535924|relapsed
1108838|NCT01535924|refractory
1108839|NCT01535911|ketogenic diet
1108840|NCT01535911|brain tumors
1108841|NCT01535898|MRI
1108842|NCT01535898|MR imaging Pulse Sequence
1108843|NCT01535898|High Resolution Diffusion-weighted
1108844|NCT01535898|Questionnaire
1108845|NCT01535898|12-033
1108846|NCT01535885|Cytoxic T Lymphocytes(CTL)
1108847|NCT01535885|T-cell Depleted
1108848|NCT01535885|Allogeneic Transplant
1108849|NCT01535885|Epstein Barr Virus
1108850|NCT01535885|Adenovirus
1108851|NCT01535885|Cytomegalovirus
1108852|NCT01535885|Hematopoietic progenitor cell transplantation
1108853|NCT01535846|taste
1108854|NCT01535846|mindful eating
1108855|NCT01535846|intuitive eating
1108856|NCT01535846|attitude
1108857|NCT01535846|behavior
1108858|NCT01535833|robotic sacral colpopexy
1108859|NCT01535833|Learning curve
1108860|NCT01535833|Pelvic Organ Prolapse
1108861|NCT01535833|Robotic Surgery
1108862|NCT01535820|Healthy volunteers
1108863|NCT01535820|ORTHO EVRA
1108864|NCT01535820|Contraceptive hormones
1108865|NCT01535820|Transdermal patch
1108866|NCT01535820|Progestin norelgestromin (NGMN)
1108867|NCT01535820|Estrogen ethinyl estradiol (EE)
1108868|NCT01535820|JNJ-93964
1108869|NCT01535820|JNJ-622206
1108870|NCT01535807|Atrial Fibrillation
1108871|NCT01535807|Cardiac surgery
1108872|NCT01535807|Coronary Artery Bypass Graft
1108873|NCT01535807|CorMatrix extra cellular matrix
1108874|NCT01535807|Heart surgery
1108875|NCT01535807|Inflammatory Biomarkers
1108876|NCT01535807|Myocardial Infarction
1108877|NCT01535807|identify proteomic inflammatory biomarkers
1108878|NCT01535794|HPV vaccine
1108879|NCT01535794|acceptability
1108880|NCT01535794|males
1108881|NCT01535794|men who have sex with men
1108882|NCT01535781|pertrochanteric fracture
1108883|NCT01535781|tranexamic acid
1108884|NCT01535781|postoperative blood loss
1108885|NCT01535781|blood loss
1108886|NCT01535781|hidden blood loss
1108887|NCT01535781|blood transfusions
1108888|NCT01535755|noninvasive mechanical ventilation
1108889|NCT01535755|ventilator weaning
1108890|NCT01535742|laryngeal mask airway
1108891|NCT01535742|children
1108892|NCT01535742|tracheal intubation
1108893|NCT01535742|fiberoptic bronchoscopy
1108894|NCT01535690|Laser
1108895|NCT01535690|Clinical trial
1108896|NCT01535690|Non-surgical periodontal therapy
1108897|NCT01535690|Periodontitis
1108898|NCT01535690|bleeding on probing and radiographic bone loss
1108899|NCT01535690|minimum of 2 teeth with probing depth (PD) ≥ 7 mm and
1108900|NCT01535690|2 other teeth with PD ≥ 5 mm
1108901|NCT01535690|mininum 16 teeth in both jaws
1108902|NCT01535677|Phase 1
1108903|NCT01535677|healthy volunteers
1108904|NCT01535677|cross-over study
1108905|NCT01535677|Bioavailability
1108906|NCT01535677|Bioequivalence
1108907|NCT01535677|Cmax
1108908|NCT01535677|tmax
1108909|NCT01535677|AUC
1108910|NCT01535677|AUC(0-t)
1108911|NCT01535677|λz
1108912|NCT01535677|tlast
1108913|NCT01535664|Multiple Sclerosis
1108914|NCT01535664|MS
1108915|NCT01535625|Coronary artery disease
1108916|NCT01535625|Atherosclerosis
1108917|NCT01535625|CAD
1108918|NCT01535599|Acute Otitis Externa
1108919|NCT01535586|CPAP
1108920|NCT01535586|MAD
1108921|NCT01535586|sleep apnea
1108922|NCT01535586|PTSD
1108923|NCT01535573|Cocaine
1108924|NCT01535573|citalopram
1108925|NCT01535573|treatment
1108926|NCT01535573|serotonin
1108927|NCT01535560|Acute otitis externa
1108928|NCT01535547|isavuconazole
1108929|NCT01535547|tacrolimus
1108930|NCT01535547|Healthy Volunteers
1108931|NCT01535547|BAL8557
1108932|NCT01535534|sepsis
1108933|NCT01535534|inflammation
1108934|NCT01535534|diagnosis
1108935|NCT01535534|prognosis
1108936|NCT01535534|survival
1108937|NCT01535534|mortality
1108938|NCT01535495|beta-antagonist
1108939|NCT01535495|propranolol
1108940|NCT01535495|diabetic retinopathy
1108941|NCT01535495|diabetes
1108942|NCT01535495|angiogenesis
1108943|NCT01535495|neovascularization
1108944|NCT01535482|Cognitive therapy
1108945|NCT01535482|Suicide
1108946|NCT01535482|Older men
1108947|NCT01535482|suicide ideation
1108948|NCT01535469|cryptococcal meningitis
1108949|NCT01535469|hiv
1108950|NCT01535469|aids
1108951|NCT01535469|implementation science
1108952|NCT01535469|stepped wedge design
1108953|NCT01535469|retention-in-care
1108954|NCT01535456|MDS
1108955|NCT01535456|AML
1108956|NCT01535456|5 azacitidine
1108957|NCT01535456|FLT PET
1108958|NCT01535443|PRO-155
1108959|NCT01535443|Ocular NSAIDs
1108960|NCT01535443|Safety and tolerability
1108961|NCT01535443|Ocular Inflammation
1108962|NCT01535443|Ocular Paint
1108963|NCT01535430|brain mapping
1108964|NCT01535430|brain tumor
1108965|NCT01535417|Osteoarthritis
1108966|NCT01535391|Chronic Myeloid Leukemia,
1108967|NCT01535391|Nilotinib,
1108968|NCT01535391|Philadelphia positive,
1108969|NCT01535391|BCR-ABL+
1108970|NCT01535391|Early chronic phase
1108971|NCT01535365|muscular sprain
1108972|NCT01535365|acute back pain
1108973|NCT01535365|acute neck pain
1108974|NCT01535365|heat treatment
1108975|NCT01535365|cold treatment
1108976|NCT01535339|mild Traumatic Brain Injury
1108977|NCT01535339|mTBI
1108978|NCT01535339|Concussion
1108979|NCT01535326|colonoscopy
1108980|NCT01535300|Ultrasound
1108981|NCT01535300|Minimal transverse tracheal diameter
1108982|NCT01535300|Endotracheal tube size
1108983|NCT01535300|Paediatric age-based formulas
1108984|NCT01535300|Sonographic measurement of the trachea
1108985|NCT01535287|Dexmedetomidine
1108986|NCT01535287|Emergence Agitation
1108987|NCT01535287|Myringotomy
1108988|NCT01535287|Children
1108989|NCT01535287|General Anesthesia
1108990|NCT01535274|Cerebral oxygenation
1108991|NCT01535274|Beach chair position
1108992|NCT01535274|General anesthetic technique
1108993|NCT01535274|Inspired oxygen fraction
1108994|NCT01535274|End tidal carbon dioxide
1108995|NCT01535261|Ophthalmology
1108996|NCT01535261|Ranibizumab
1108997|NCT01535261|Central Retinal Vein Occlusion
1108998|NCT01535248|ERCP
1108999|NCT01535248|Transthoracic Echocardiography
1109000|NCT01535248|Air Embolus
1109001|NCT01535248|ERCP associated air embolus
1109002|NCT01535235|HIV
1109003|NCT01535235|Lymphoid fibrosis
1109004|NCT01535222|cardiac surgery
1109005|NCT01535222|coronary artery bypass graft
1109006|NCT01535222|cardiopulmonary bypass
1109007|NCT01535222|haemostasis modulator
1109008|NCT01535222|blood loss
1109009|NCT01535222|direct inhibitor of plasmin and plasma kallikrein
1109010|NCT01535222|CABG
1109011|NCT01535222|CPB
1109012|NCT01535209|Stereotactic radiotherapy
1109013|NCT01535209|Whole-brain radiotherapy
1109014|NCT01535209|Resection cavity
1109015|NCT01535196|vitamin D
1109016|NCT01535196|heart failure
1109017|NCT01535183|irinotecan
1109018|NCT01535183|brain tumor
1109019|NCT01535183|pediatrics
1109020|NCT01535183|salvage therapy
1109021|NCT01535183|chemotherapy
1109022|NCT01535170|lactoferrin
1109023|NCT01535170|selective decontamination of digestive tract
1109024|NCT01535170|antimicrobial activity
1109025|NCT01535170|prolonged mechanical ventilation
1109026|NCT01535170|respiratory care center
1109027|NCT01535157|Chemotherapy
1109028|NCT01535131|otitis media
1109029|NCT01535131|cleft palate
1109030|NCT01535118|Allergies
1109031|NCT01535118|Immunotherapy
1109032|NCT01535092|HCV recurrence
1109033|NCT01535092|HCV reinfection
1109034|NCT01535092|Liver transplantation
1109035|NCT01535092|Legalon SIL
1109036|NCT01535092|silibinin
1109037|NCT01535092|viral load
1109038|NCT01535079|sore throat pain
1109039|NCT01535079|tonsillopharyngitis
1109040|NCT01535079|upper respiratory tract infection
1109041|NCT01535066|estrogen receptor-positive breast cancer
1109042|NCT01535066|progesterone receptor-positive breast cancer
1109043|NCT01535066|stage IA breast cancer
1109044|NCT01535066|stage IB breast cancer
1109045|NCT01535066|stage II breast cancer
1109046|NCT01535066|stage IIIA breast cancer
1109047|NCT01535066|stage IIIB breast cancer
1109048|NCT01535066|stage IIIC breast cancer
1109049|NCT01535066|pain
1109050|NCT01535040|cancer survivor
1109051|NCT01535040|stage I non-small cell lung cancer
1109052|NCT01535040|stage II non-small cell lung cancer
1109053|NCT01535040|tobacco use disorder
1109054|NCT01535040|stage IA breast cancer
1109055|NCT01535040|stage IB breast cancer
1109056|NCT01535040|stage II breast cancer
1109057|NCT01535040|stage IIIA breast cancer
1109058|NCT01535040|stage IIIB breast cancer
1109059|NCT01535040|stage IIIC breast cancer
1109060|NCT01535040|stage I prostate cancer
1109061|NCT01535040|stage IIA prostate cancer
1109062|NCT01535040|stage IIB prostate cancer
1109063|NCT01535040|stage III prostate cancer
1109064|NCT01535040|stage I colon cancer
1109065|NCT01535040|stage IIA colon cancer
1109066|NCT01535040|stage IIB colon cancer
1109067|NCT01535040|stage IIC colon cancer
1109068|NCT01535040|stage IIIA colon cancer
1109069|NCT01535040|stage IIIB colon cancer
1109070|NCT01535040|stage IIIC colon cancer
1109071|NCT01535040|stage I rectal cancer
1109072|NCT01535040|stage IIA rectal cancer
1109073|NCT01535040|stage IIB rectal cancer
1109074|NCT01535040|stage IIC rectal cancer
1109075|NCT01535040|stage IIIA rectal cancer
1109076|NCT01535040|stage IIIB rectal cancer
1109077|NCT01535040|stage IIIC rectal cancer
1109078|NCT01535027|teriparatide
1109079|NCT01535027|alendronate
1109080|NCT01535027|raloxifene
1109081|NCT01535027|bone mineral density
1109082|NCT01535001|Osteoarthritis, Knee
1109083|NCT01535001|Treatment Outcome
1109084|NCT01535001|Time Factors
1109085|NCT01535001|Rehabilitation
1109086|NCT01535001|Combined Modality Therapy
1109087|NCT01535001|Middle Aged
1109088|NCT01535001|Aged
1109089|NCT01535001|Aged, 80 and over
1109090|NCT01535001|Male
1109091|NCT01535001|Female
1109092|NCT01535001|Humans
1109093|NCT01535001|Analysis of Variance
1109094|NCT01534975|cardiac CT
1109095|NCT01534975|enhancement
1109096|NCT01534975|contrast
1109097|NCT01534975|safety
1109098|NCT01534975|image quality
1109099|NCT01534962|Atrial Fibrillation
1109100|NCT01534962|Ranolazine
1109101|NCT01534962|Arrhythmias, Cardiac
1109102|NCT01534962|Antiarrhythmic Agents
1109103|NCT01534962|Cardiac Electroversion
1109104|NCT01534962|Ranexa
1109105|NCT01534949|DLBCL, Biosimilar
1109106|NCT01534936|schizophrenia
1109107|NCT01534936|atypical antipsychotics
1109108|NCT01534936|depressive symptoms
1109109|NCT01534923|Doctor-Patient Communication
1109110|NCT01534923|questionnaire
1109111|NCT01534923|survey
1109112|NCT01534923|12-017
1109113|NCT01534910|garlic
1109114|NCT01534910|ct angiography
1109115|NCT01534910|atherosclerosis
1109116|NCT01534910|carotid IMT
1109117|NCT01534897|thyroid cancer
1109118|NCT01534897|Tall cell PTC
1109119|NCT01534897|Poorly differentiated thyroid carcinoma
1109120|NCT01534897|metastatic
1109121|NCT01534884|RA, Biosimilar
1109122|NCT01534871|Cardiac rehabilitation
1109123|NCT01534871|Exercise
1109124|NCT01534871|Systemic inflammation
1109125|NCT01534871|Cardiovascular disease risk
1109126|NCT01534858|polyhexanide, polihexanide, PHMB, Prontosan, burns, wounds
1109127|NCT01534832|surgical smoke
1109128|NCT01534832|laparoscopic surgery
1109129|NCT01534832|impaired vision
1109130|NCT01534819|Abdominal aortic aneurysm
1109131|NCT01534819|AAA
1109132|NCT01534819|Endograft
1109133|NCT01534819|interventional treatment of AAA
1109134|NCT01534806|Migraine
1109135|NCT01534793|Quality assessment
1109136|NCT01534793|Benign Prostatic Hyperplasia
1109137|NCT01534793|Enucleation of the prostate
1109138|NCT01534793|LUMENIS
1109139|NCT01534793|Laser
1109140|NCT01534793|Learning Curve
1109141|NCT01534728|Hepatitis C
1109142|NCT01534728|CD8 epitopes
1109143|NCT01534702|Acute Myeloid Leukemia
1109144|NCT01534702|chemotherapy
1109145|NCT01534702|clofarabine
1109146|NCT01534676|iron
1109147|NCT01534676|transfusion
1109148|NCT01534676|red blood cells
1109149|NCT01534676|sickle cell disease
1109150|NCT01534676|thalassemia
1109151|NCT01534676|blood donors
1109152|NCT01534663|Heart Failure
1109153|NCT01534663|Skeletal Muscle Function
1109154|NCT01534663|Metabolism
1109155|NCT01534663|Inflammation
1109156|NCT01534663|Glutamine
1109157|NCT01534663|Fish oil
1109158|NCT01534663|Muscle Function
1109159|NCT01534650|motion sensors
1109160|NCT01534650|tremor
1109161|NCT01534650|bradykinesia
1109162|NCT01534650|gait
1109163|NCT01534650|balance
1109164|NCT01534650|dyskinesia
1109165|NCT01534624|Induced Pluripotent Stem Cell (iPS) Cell Lines
1109166|NCT01534624|Addiction
1109167|NCT01534624|Addiction-Associated Human Gene Variants
1109168|NCT01534624|Dopamine Transporter
1109176|NCT01534585|nasopharyngeal carcinoma(NPC)
1109177|NCT01534585|Icotinib
1109178|NCT01534585|Intensity Modulation Radiation Therapy(IMRT)
1109179|NCT01534546|neoadjuvant chemotherapy
1109180|NCT01534546|adjuvant chemotherapy
1109181|NCT01534546|DFS
1109182|NCT01534546|OS
1109183|NCT01534546|safety
1109184|NCT01534546|resectable locally advanced gastric carcinoma
1109185|NCT01534546|potentially resectable locally advanced gastric carcinoma
1109186|NCT01534533|early atherosclerosis
1109187|NCT01534533|serum lutein
1109188|NCT01534533|serum lycopene
1109189|NCT01534533|intima-media thickness
1109190|NCT01534533|arterial stiffness
1109191|NCT01534533|combined effect
1109192|NCT01534520|Intrauterine Device
1109193|NCT01534520|Pain
1109194|NCT01534520|Lidocaine
1109195|NCT01534494|alcohol dependence
1109196|NCT01534494|psilocybin
1109197|NCT01534494|clinical trial
1109198|NCT01534494|motivational enhancement therapy
1109205|NCT01534455|German Breast Group
1109206|NCT01534455|GBG Forschungs GmbH
1109207|NCT01534455|GBG
1109208|NCT01534455|GBG 64
1109209|NCT01534455|E-VITA
1109210|NCT01534455|Breast Cancer
1109211|NCT01534455|Metastatic Breast Cancer
1109212|NCT01534455|Eribulin
1109213|NCT01534455|Lapatinib
1109214|NCT01534455|Halaven
1109215|NCT01534455|Tyverb
1109216|NCT01534429|pain
1109217|NCT01534416|Paracervical Block
1109218|NCT01534416|Laparoscopic Surgery
1109219|NCT01534416|Postoperative Pain
1109220|NCT01534416|Bupivacaine
1109221|NCT01534416|Hysterectomy
1109222|NCT01534416|Myomectomy
1109223|NCT01534416|Randomized Trial
1109224|NCT01534403|Lupus
1109225|NCT01534403|Monoclonal antibody
1109226|NCT01534403|B-cell immunotherapy
1109227|NCT01534403|Epratuzumab
1109228|NCT01534390|microparticles
1109229|NCT01534390|in-line microfilters
1109230|NCT01534390|systemic inflammation
1109231|NCT01534390|organ failure
1109232|NCT01534390|critical illness
1109233|NCT01534390|adult
1109234|NCT01534377|Depression
1109235|NCT01534377|Adolescents
1109236|NCT01534364|acute renal failure
1109237|NCT01534364|acute kidney injury
1109238|NCT01534364|diet
1109239|NCT01534364|caloric restriction
1109240|NCT01534364|cardiac surgery
1109241|NCT01534364|cardiothoracic surgery
1109242|NCT01534338|Sleep
1109243|NCT01534338|inflammation
1109244|NCT01534338|mindfulness
1109245|NCT01534338|meditation
1109246|NCT01534338|randomized controlled trial
1109247|NCT01534312|Glycopeptides
1109248|NCT01534312|Dietary proteins
1109249|NCT01534286|Prescription Medical Food
1109250|NCT01534286|Theramine
1109251|NCT01534286|Knee surgery
1109252|NCT01534273|Mild Cognitive Impairment
1109253|NCT01534247|Phase I
1109254|NCT01534247|drug to drug
1109255|NCT01534247|CAZ-AVI
1109256|NCT01534247|Healthy volunteer
1109257|NCT01534247|pharmacokinetics
1109258|NCT01534247|open label
1109259|NCT01534247|metronidazole
1109260|NCT01534247|safety
1109261|NCT01534234|CRT-D device
1109262|NCT01534234|Severe HF (NYHA Class III or ambulatory IV)
1109263|NCT01534234|stable, optimal drug regimen
1109264|NCT01534234|sinus rhythm
1109265|NCT01534221|Ischemic Heart Disease
1109266|NCT01534182|Relapsing Remitting Multiple Sclerosis (RRMS)
1109267|NCT01534182|Fingolimod
1109268|NCT01534182|Disease Modifying Therapy (DMT)
1109269|NCT01534182|TSQM-9
1109270|NCT01534169|Graves' disease
1109271|NCT01534169|Dexamethasone
1109272|NCT01534169|Function of regulatory T cells
1109273|NCT01534169|The proportion of Th1 and Th2 cells
1109274|NCT01534130|Chronic Fatigue Syndrome
1109275|NCT01534130|Sleep Disorder, Adjustment
1109276|NCT01534130|Acupuncture
1109277|NCT01534104|fMRI
1109278|NCT01534104|DTI
1109279|NCT01534104|DSI
1109280|NCT01534104|tractography
1109281|NCT01534104|neurological/physical testing
1109282|NCT01534104|Motor and Language Pathways
1109283|NCT01534104|resting state fMRI
1109284|NCT01534104|12-008
1109285|NCT01534091|overweight
1109286|NCT01534091|obese
1109287|NCT01534091|children
1109288|NCT01534091|exercise
1109289|NCT01534091|physical activity
1109290|NCT01534091|pedometer
1109291|NCT01534078|non-bulky
1109292|NCT01534078|limited stage
1109293|NCT01534065|Hernia
1109294|NCT01534065|Intervertebral Disk Displacement
1109295|NCT01534065|Pathological Conditions, Anatomical
1109296|NCT01534065|Spinal Diseases
1109297|NCT01534065|Bone Diseases
1109298|NCT01534065|Musculoskeletal Diseases
1109299|NCT01534052|Prostate Cancer
1109300|NCT01534052|Castration-Resistant Prostate Cancer (CRPC)
1109301|NCT01534052|MDV3100
1109302|NCT01534052|Androgen receptor signaling inhibitor
1109303|NCT01534013|Closed loop insulin delivery
1109304|NCT01534000|Cardiac CT
1109305|NCT01534000|Ischemic heat disease
1109306|NCT01534000|Stress test
1109307|NCT01533987|Male
1109308|NCT01533987|Overweight
1109309|NCT01533987|Juice Plus
1109310|NCT01533961|neglected disease
1109311|NCT01533961|africa
1109312|NCT01533961|new drug
1109313|NCT01533961|oral drug
1109314|NCT01533961|parasite
1109315|NCT01533896|Obesity prevention
1109316|NCT01533896|Primary care
1109317|NCT01533896|Education
1109318|NCT01533883|Mitral
1109319|NCT01533883|Valve
1109320|NCT01533883|Annuloplasty
1109321|NCT01533883|Transatrial
1109322|NCT01533883|Transapical
1109323|NCT01533883|Transfemoral
1109324|NCT01533883|Mitral valve insufficiency
1109325|NCT01533870|Phase 1
1109326|NCT01533870|Healthy male and female volunteers
1109327|NCT01533870|Drug-drug interaction
1109328|NCT01533870|Pharmacokinetics
1109329|NCT01533870|NKTR-118
1109330|NCT01533870|Bioavailability
1109331|NCT01533870|Plasma AUC and Cmax
1109332|NCT01533870|Plasma AUC0-t and t1/2λz and tmax
1109333|NCT01533857|Black tea
1109334|NCT01533857|phenolic acids
1109335|NCT01533844|CDAD
1109336|NCT01533844|Neonates
1109337|NCT01533844|Clostridium difficile
1109338|NCT01533818|Fast breathing
1109339|NCT01533818|Young infants
1109340|NCT01533818|Management
1109341|NCT01533818|Amoxicillin
1109342|NCT01533818|Placebo
1109343|NCT01533805|Lumbago
1109344|NCT01533805|Exercise therapy
1109345|NCT01533805|Spine
1109346|NCT01533792|Treatment
1109347|NCT01533792|pregnant women
1109348|NCT01533792|periodontitis
1109349|NCT01533792|dental scaling
1109350|NCT01533792|dental plaque
1109351|NCT01533779|children
1109352|NCT01533779|malignancy
1109353|NCT01533779|neutrophil
1109354|NCT01533779|neutrophil extracellular traps
1109355|NCT01533779|superoxide production
1109356|NCT01533779|hydrogen peroxide production
1109357|NCT01533779|chemotaxis
1109358|NCT01533779|myeloperoxidase
1109359|NCT01533779|immunosurveillance
1109360|NCT01533779|cancer cell lines
1109361|NCT01533753|hot flashes
1109362|NCT01533753|prostate cancer
1109363|NCT01533727|Cytokine-Induced Killer Cell
1109364|NCT01533727|NSCLC
1109365|NCT01533727|adjuvant therapy
1109366|NCT01533714|Rheumatoid Arthritis
1109367|NCT01533714|Monoclonal antibody
1109368|NCT01533714|Interleukin-6
1109369|NCT01533714|Olokizumab
1109370|NCT01533714|CDP6038
1109371|NCT01533701|Hypoxia
1109372|NCT01533701|Fetal blood sampling
1109373|NCT01533701|Lactate
1109374|NCT01533701|pH
1109375|NCT01533701|base deficit
1109376|NCT01533701|angiogenic factors
1109377|NCT01533701|suspected fetal hypoxia
1109378|NCT01533675|suture, tensile strength, wound care, saline, hydrogen peroxide, skin closure, wounds, wound healing, wound cleansing, antiseptics
1109379|NCT01533662|phenylephrine
1109380|NCT01533662|hypotension
1109381|NCT01533662|spinal anesthesia
1109382|NCT01533662|lower limb orthopedic surgery
1109383|NCT01533649|Behavioral intervention
1109384|NCT01533649|Seizure self-efficacy
1109385|NCT01533649|Psychosocial outcomes
1109386|NCT01533649|Quality of Life in Epilepsy
1109387|NCT01533636|Cystic Fibrosis, Healthy
1109388|NCT01533610|Post-Traumatic Stress disorder
1109389|NCT01533610|Stellate ganglion
1109390|NCT01533610|cervical plexus
1109391|NCT01533610|local anesthesia
1109392|NCT01533610|anxiety
1109393|NCT01533597|Overactive bladder
1109394|NCT01533597|Solifenacin succinate
1109395|NCT01533597|Tamsulosin
1109396|NCT01533571|Guided Bone Regeneration
1109397|NCT01533571|Dental Implant
1109398|NCT01533571|Alveolar Ridge Augmentation
1109399|NCT01533571|Socket graft
1109400|NCT01533558|caspofungin
1109401|NCT01533558|pharmacokinetics
1109402|NCT01533558|invasive fungal infection
1109403|NCT01533558|candidiasis
1109404|NCT01533558|aspergillosis
1109405|NCT01533558|intensive care
1109406|NCT01533545|Mepivacaine
1109407|NCT01533545|Epinephrine
1109408|NCT01533545|Brachial plexus block
1109409|NCT01533545|Renal insufficiency
1109410|NCT01533532|Gonadotropin-Releasing Hormone (GnRH) antagonist
1109411|NCT01533519|Neuropeptide Y
1109412|NCT01533519|Intranasal Administration
1109413|NCT01533519|PTSD
1109414|NCT01533519|Trauma
1109415|NCT01533506|treatment with stiripentol
1109416|NCT01533493|ADHD
1109417|NCT01533493|Executive Function
1109418|NCT01533493|Namenda
1109419|NCT01533493|Concerta
1109420|NCT01533480|Adenovirus
1109421|NCT01533480|Conjunctivitis
1109422|NCT01533480|keratoconjunctivitis
1109423|NCT01533480|viral shedding
1109424|NCT01533480|subepithelial infiltrate
1109425|NCT01533480|bulbar injection
1109426|NCT01533467|Delivery rupture
1109427|NCT01533467|perineal protection device
1109428|NCT01533467|reduce perineal tears
1109429|NCT01533454|Obesity
1109430|NCT01533454|Weight loss
1109431|NCT01533454|Incentives
1109432|NCT01533454|Motivation
1109433|NCT01533441|anticoagulant therapy
1109434|NCT01533441|INR
1109435|NCT01533441|vitamin K2
1109436|NCT01533441|vitamin K antagonist
1109437|NCT01533428|Painful Diabetic Peripheral Neuropathy,
1109438|NCT01533428|Capsaicin 8% transdermal delivery system
1109439|NCT01533415|Anxiety
1109440|NCT01533415|Anxiety Disorders
1109441|NCT01533402|Cognitive behavior therapy
1109442|NCT01533402|Internet
1109443|NCT01533402|Anxiety disorders
1109444|NCT01533402|Children
1109445|NCT01533376|Sturge Weber
1109446|NCT01533376|SWS
1109447|NCT01533376|Timolol
1109448|NCT01533376|Port wine mark
1109449|NCT01533363|Hemorrhoids
1109450|NCT01533363|Surgery
1109451|NCT01533363|Hemorrhoidopexy
1109452|NCT01533363|Milligan Morgan
1109453|NCT01533350|Ultrasonography
1109454|NCT01533350|late follicle phase
1109455|NCT01533350|homogeneous endometrium
1109456|NCT01533350|receptivity
1109457|NCT01533350|biochemical factor
1109458|NCT01533350|ultrastructure
1109459|NCT01533350|endometrial echo pattern
1109460|NCT01533337|dorsal digital free flap
1109461|NCT01533337|dorsal branch of proper digital nerve
1109462|NCT01533337|dorsal branch of proper digital artery
1109463|NCT01533337|proper digital artery
1109464|NCT01533324|hepatocellular carcinoma
1109465|NCT01533324|S-1
1109466|NCT01533324|Leucovorin
1109467|NCT01533324|fluorouracil
1109468|NCT01533311|nonpolypoid colorectal neoplasms(NP-CRN)
1109469|NCT01533311|prevalence
1109470|NCT01533311|histology
1109471|NCT01533285|Major depressive disorder
1109472|NCT01533285|MDD
1109473|NCT01533285|Psychiatry disorders
1109474|NCT01533285|Psychosocial stressor
1109475|NCT01533285|Psychosocial stress
1109476|NCT01533285|Typhoid vaccination
1109477|NCT01533285|Typhoid vaccine
1109478|NCT01533272|HIV infection
1109479|NCT01533272|Postexposure prophylaxis
1109480|NCT01533259|HIV-1
1109481|NCT01533259|HIV
1109482|NCT01533259|Treatment Experienced
1109483|NCT01533233|thoracoscopy
1109484|NCT01533233|lung cancer
1109485|NCT01533233|lobectomy
1109486|NCT01533233|epidural anesthesia
1109487|NCT01533220|nasal and nasopharyngeal congestion
1109488|NCT01533168|childhood acute lymphoblastic leukemia in remission
1109489|NCT01533168|recurrent childhood acute lymphoblastic leukemia
1109490|NCT01533168|B-cell childhood acute lymphoblastic leukemia
1109491|NCT01533155|Phase 1
1109492|NCT01533155|Healthy male and female volunteers
1109493|NCT01533155|Drug-drug interaction
1109494|NCT01533155|Pharmacokinetics
1109495|NCT01533155|NKTR-118
1109496|NCT01533142|lipids
1109497|NCT01533129|Hypogonadism
1109498|NCT01533129|Endothelial dysfunction
1109499|NCT01533129|Inflammation
1109500|NCT01533129|Insulin resistance
1109501|NCT01533129|Testosterone replacement therapy
1109502|NCT01533116|Parkinson Disease
1109503|NCT01533116|BIA 9-1067
1109504|NCT01533077|Parkinson Disease
1109505|NCT01533077|BIA 9-1067
1109506|NCT01533051|Chronic hepatitis B
1109507|NCT01533051|Nucleos(t)ide analogue
1109508|NCT01533051|Antiviral treatment
1109509|NCT01533051|Korea
1109510|NCT01533025|anterior cruciate ligament
1109511|NCT01533025|Achilles
1109512|NCT01533025|free tendon
1109513|NCT01533025|bone-tendon
1109514|NCT01533025|free tendon Achilles allograft
1109515|NCT01533025|Achilles allograft with calcaneal bone block on its end
1109516|NCT01532999|Posttraumatic Stress Disorder
1109517|NCT01532999|Meditation
1109518|NCT01532999|Present Centered Group Therapy
1109519|NCT01532999|mindfulness
1109520|NCT01532999|MBSR
1109521|NCT01532999|complementary alternative medicine
1109522|NCT01532986|Quality of Health Care
1109523|NCT01532986|Nursing Care Management
1109524|NCT01532986|Care Coordination
1109525|NCT01532986|Randomized Trials
1109526|NCT01532960|breast cancer
1109527|NCT01532960|peptide vaccine
1109528|NCT01532960|immunotherapy
1109529|NCT01532934|substance use
1109530|NCT01532934|psychopathy
1109531|NCT01532934|motivational enhancement
1109532|NCT01532934|criminal recidivism
1109533|NCT01532908|Liver Transplantation
1109534|NCT01532895|Pain
1109535|NCT01532895|Cancer pain
1109536|NCT01532895|Hydromorphone
1109537|NCT01532895|Hydromorphone OROS
1109538|NCT01532895|Narcotic analgesics
1109539|NCT01532895|Opioid-naive
1109540|NCT01532856|multiple myeloma
1109541|NCT01532856|thalidomide
1109542|NCT01532856|comparative
1109543|NCT01532856|elderly
1109544|NCT01532843|Hepatitis B
1109545|NCT01532843|sustained response
1109546|NCT01532843|peginterferon
1109547|NCT01532843|nucleos(t)ide analogues
1109548|NCT01532830|vagus nerve stimulation
1109549|NCT01532830|vagal nerve stimulation
1109550|NCT01532830|nVNS
1109551|NCT01532830|VNS
1109552|NCT01532830|migraine
1109553|NCT01532830|non invasive
1109554|NCT01532830|gammacore
1109555|NCT01532804|Unresectable metastases
1109556|NCT01532791|MELAS
1109557|NCT01532791|mitochondrial DNA mutation
1109558|NCT01532791|mtDNA mutation
1109559|NCT01532791|mitochondrial DNA
1109560|NCT01532791|mitochondria
1109561|NCT01532791|m.3243A>G mutation
1109562|NCT01532765|Internal limiting membrane
1109563|NCT01532765|Indocyanine green dye
1109564|NCT01531933|Prediabetic
1109565|NCT01531933|Primary prevention
1109566|NCT01531933|Type 2 diabetes mellitus
1109567|NCT01531907|GLP2
1109568|NCT01531907|Obesity
1109569|NCT01531907|Premenopausal
1109570|NCT01531907|Bone
1109571|NCT01531907|Formation
1109572|NCT01531907|Resorption
1109573|NCT01531894|solid tumor
1109574|NCT01531894|GSK2110183
1109575|NCT01531894|hematologic malignancy
1109576|NCT01531894|AKT inhibitor
1109577|NCT01531894|cancer
1109578|NCT01531894|safety
1109579|NCT01531868|Decision making
1109580|NCT01531868|Carotid stenosis
1109581|NCT01531855|T1DM, Exercise
1109582|NCT01531842|Conjunctival bacterial flora
1109583|NCT01531842|prophylactic topical antibiotic
1109584|NCT01531842|injection
1109585|NCT01531842|intravitreal injection
1109586|NCT01531842|bacterial resistance
1109587|NCT01531842|serial injection
1109588|NCT01531842|serial intravitreal injections
1109589|NCT01531842|CNV
1109590|NCT01531842|CRVO
1109591|NCT01531842|AMD
1109592|NCT01531842|BRVO
1109593|NCT01531829|pulmonary embolism
1109594|NCT01531829|right ventricular dysfunction
1109595|NCT01531829|Thrombolysis
1109596|NCT01531829|Heparin
1109597|NCT01531816|Pediatrics,
1109598|NCT01531816|Critically ill Children
1109599|NCT01531816|immobility
1109600|NCT01531790|Endostar
1109601|NCT01531790|Carboplatin
1109602|NCT01531790|Pemetrexed
1109603|NCT01531790|NSCLC
1109604|NCT01531790|Phase I
1109605|NCT01531777|Advanced Colorectal Cancer
1109606|NCT01531764|Metastatic breast cancer
1109607|NCT01531764|intermediate HER2 expression
1109608|NCT01531764|Afatinib
1109609|NCT01531751|HCO-HD
1109610|NCT01531751|survival
1109611|NCT01531751|cardiac biomarkers
1109612|NCT01531751|AL amyloidosis
1109613|NCT01531751|Light Chain Amyloidosis
1109614|NCT01531738|Taste
1109615|NCT01531738|bariatric surgery
1109616|NCT01531738|food preferences
1109617|NCT01531738|reward
1109618|NCT01531738|progressive ratio task
1109619|NCT01531725|Stents
1109620|NCT01532739|Mild Cognitive Impairment
1109621|NCT01532739|Aging
1109622|NCT01532739|Memory
1109623|NCT01532739|Executive Function
1109624|NCT01532739|Cognitive Intervention
1109625|NCT01532739|Memory Training
1109626|NCT01532739|Mental Health
1109627|NCT01532726|Partial-Onset Seizures
1109628|NCT01532726|Eslicarbazepine Acetate
1109629|NCT01532726|ESL
1109630|NCT01532726|BIA 2-093
1109631|NCT01532726|BIAL
1109632|NCT01532661|TRAUMA
1109633|NCT01532661|HAEMORRHAGIC
1109634|NCT01532661|rVIIa
1109635|NCT01532661|Complication of Trauma hemorrhage
1109636|NCT01532661|bleeding
1109637|NCT01532661|rFVIIa administration for hemorrhage after trauma
1109638|NCT01532648|Ulcerative Colitis
1109639|NCT01532635|hematologic malignancy
1109640|NCT01532635|leukemia
1109641|NCT01532635|Acute lymphoblastic leukemia
1109642|NCT01532635|ALL
1109643|NCT01532635|Acute myelogenous leukemia
1109644|NCT01532635|AML
1109645|NCT01532635|Chronic lymphocytic leukemia
1109646|NCT01532635|CLL
1109647|NCT01532635|lymphoma
1109648|NCT01532635|hodgkin's lymphoma
1109649|NCT01532635|non-hodgkin's lymphoma
1109650|NCT01532635|myeloma
1109777|NCT01532011|Tarceva
1109651|NCT01532635|allogeneic stem cell transplant
1109652|NCT01532635|TJU 2-step
1109653|NCT01532635|Hematopoietic stem cell transplant
1109654|NCT01532635|HSCT
1109655|NCT01532635|bone marrow transplant
1109656|NCT01532635|Cyclophosphamide
1109657|NCT01532635|MMF
1109658|NCT01532635|Mycophenolate Mofetil
1109659|NCT01532622|Blueberry
1109660|NCT01532609|Methadone maintenance therapy
1109661|NCT01532609|Behavioral intervention
1109662|NCT01532609|Service provider
1109663|NCT01532609|Drug use
1109664|NCT01532570|Behcet's disease
1109665|NCT01532570|intestinal Behcet's disease
1109666|NCT01532570|neuro-Behcet's disease
1109667|NCT01532570|vascular Behcet's disease
1109668|NCT01532544|Severe pneumonia
1109669|NCT01532531|Collateral Meridian Therapy
1109670|NCT01532531|Knee Osteoarthritis
1109671|NCT01532518|Feeding intolerance
1109672|NCT01532518|Infant
1109673|NCT01532518|tachykinin antagonist
1109674|NCT01532518|Infant colic
1109675|NCT01532518|Nepadutant
1109676|NCT01532505|cardiopulmonary bypass
1109677|NCT01532505|Postcardiotomy vasodilatory shock
1109678|NCT01532505|Microcirculation
1109679|NCT01532505|Catecholamines
1109680|NCT01532505|Vasopressin
1109681|NCT01532492|Questionnaire
1109682|NCT01532492|WORC
1109683|NCT01532492|Rotator cuff
1109684|NCT01532492|Reliability
1109685|NCT01532492|Validity
1109686|NCT01532492|Responsiveness
1109687|NCT01532479|Osteoradionecrosis
1109688|NCT01532479|Xerostomia
1109689|NCT01532466|fentanyl-induced coughing, rocuronium
1109690|NCT01532401|Blood pressure
1109691|NCT01532388|Randomized Controlled Trial
1109692|NCT01532388|Alcohol
1109693|NCT01532388|Drugs
1109694|NCT01532388|Internet
1109695|NCT01532388|Screening
1109696|NCT01532388|Brief intervention
1109697|NCT01532375|Kochujang,
1109698|NCT01532375|visceral fat
1109699|NCT01532375|population
1109700|NCT01532349|chronic kidney disease
1109701|NCT01532349|anemia
1109702|NCT01532336|adenovirus
1109703|NCT01532336|conjunctivitis
1109704|NCT01532336|pinkeye
1109705|NCT01532323|Oral disorders
1109706|NCT01532310|systemic lupus erythematosus
1109707|NCT01532310|belimumab
1109708|NCT01532310|pregnancy
1109709|NCT01532297|citrate dialysate
1109710|NCT01532297|dialysis
1109711|NCT01532297|calcium
1109712|NCT01532284|aneuploid oocytes
1109713|NCT01532284|ICSI
1109714|NCT01532284|IVF
1109715|NCT01532284|Polar Body Biopsy
1109716|NCT01532271|mild Traumatic Brain Injury
1109717|NCT01532271|mTBI
1109718|NCT01532271|Concussion
1109719|NCT01532258|BMI
1109720|NCT01532258|Weight loss
1109721|NCT01532258|Nutrition
1109722|NCT01532258|Diet
1109723|NCT01532258|Mediterranean diet
1109724|NCT01532258|Online program
1109725|NCT01532258|web-based program
1109726|NCT01532258|Oxidative stress
1109727|NCT01532258|F2 isoprostanes
1109728|NCT01532232|PLACEBO
1109729|NCT01532232|VARENICLINE (CHANTIX)
1109730|NCT01532232|Self-reported cigarettes smokers
1109731|NCT01532232|Smoking Cessation
1109732|NCT01532232|11-136
1109733|NCT01532206|Remote ischemic preconditioning
1109734|NCT01532206|inflammation
1109735|NCT01532180|Obstructive sleep apnea, neurostimulation, hypoglossal nerve
1109736|NCT01532141|Parkinson Disease
1109737|NCT01532141|BIA 9-1067
1109738|NCT01532128|Parkinson Disease
1109739|NCT01532128|BIA 9-1067
1109740|NCT01532115|Parkinson Disease
1109741|NCT01532115|BIA 9-1067
1109742|NCT01532102|Genital warts
1109743|NCT01532102|Anogenital warts
1109744|NCT01532102|HPV
1109745|NCT01532102|Human papillomavirus
1109746|NCT01532102|Antiviral
1109747|NCT01532076|osteoporosis
1109748|NCT01532076|prox. humeral fracture
1109749|NCT01532076|geriatric trauma
1109750|NCT01532076|mesenchymal stem cells
1109751|NCT01532063|Difficult intubation
1109752|NCT01532063|Intensive care units
1109753|NCT01532063|Risk factors
1109754|NCT01532063|Incidence
1109755|NCT01532063|Complications
1109756|NCT01532063|Intubation in Intensive Care Unit
1109757|NCT01532063|More than 2 attempts of intubation
1109758|NCT01532063|Intubation attempts lasting more than 10 minutes
1109759|NCT01532050|OSAS
1109760|NCT01532050|American Academy of Sleep Medicine Task Force
1109761|NCT01532037|Randomised controlled trial
1109762|NCT01532037|Multiple Sclerosis
1109763|NCT01532037|Fatigue
1109764|NCT01532037|Cognitive Behavioural Therapy
1109765|NCT01532037|Self Help
1109766|NCT01532024|Optical Imaging
1109767|NCT01532024|Neutrophil
1109768|NCT01532024|Elastase
1109769|NCT01532024|Molecular Imaging
1109770|NCT01532024|Acute Lung Injury
1109771|NCT01532024|ARDS
1109772|NCT01532011|Advanced Cancers
1109773|NCT01532011|Solid Tumors
1109774|NCT01532011|Erlotinib
1109775|NCT01532011|Erlotinib Hydrochloride
1109776|NCT01532011|OSI-774
1109778|NCT01532011|Pralatrexate
1109779|NCT01532011|Folotyn
1109780|NCT01532011|PDX-010
1109781|NCT01531998|Myeloma
1109782|NCT01531998|Multiple Myeloma
1109783|NCT01531998|MM
1109784|NCT01531998|Newly diagnosed
1109785|NCT01531998|Lenalidomide
1109786|NCT01531998|CC-5013
1109787|NCT01531998|Revlimid
1109788|NCT01531998|Bortezomib
1109789|NCT01531998|Velcade
1109790|NCT01531998|LDP-341
1109791|NCT01531998|MLN341
1109792|NCT01531998|PS-341
1109793|NCT01531998|Siltuximab
1109794|NCT01531998|CNTO 328
1109795|NCT01531998|Anti-IL-6 Antibody
1109796|NCT01531998|Dexamethasone
1109797|NCT01531998|Decadron
1109798|NCT01531998|M. D. Anderson Symptom Inventory Module
1109799|NCT01531998|MDASI-MM
1109800|NCT01531998|Questionnaires
1109801|NCT01531998|Surveys
1109802|NCT01531985|Congenital Heart Disease
1109803|NCT01531985|Acute Kidney Injury
1109804|NCT01531985|Cardiopulmonary Bypass
1109805|NCT01531985|Biomarkers
1109806|NCT01531972|Single-photon Emission Computed Tomography
1109807|NCT01531972|Healthy Volunteers
1109808|NCT01531972|Tomography
1109809|NCT01531959|Midodrine
1109810|NCT01531959|Hypotension
1109811|NCT01531959|Intensive care unit
1109812|NCT01531959|IV vasopressors
1109813|NCT01531959|ICU discharge
1109814|NCT01531946|Diffusion Tensor Imaging
1109815|NCT01531712|neoadjuvant treatment
1109816|NCT01531712|borderline resectability
1109817|NCT01531686|intraosseous vascular access
1109818|NCT01531686|CT examination
1109819|NCT01531634|Borderline Personality Disorder
1109820|NCT01531634|Women
1109821|NCT01531634|Dynamic Cognitive Intervention
1109822|NCT01531634|Recovery
1109823|NCT01531634|Hope Scale
1109824|NCT01531621|metastatic colorectal cancer
1109825|NCT01531608|melanoma
1109826|NCT01531608|imaging
1109827|NCT01531608|sentinel node
1109828|NCT01531608|biopsy
1109829|NCT01531595|metastatic colorectal cancer
1109830|NCT01531582|Angelman
1109831|NCT01531582|Minocycline
1109832|NCT01531582|cognitive
1109833|NCT01531582|children
1109834|NCT01531582|tetracycline
1109835|NCT01531569|Flaxseed
1109836|NCT01531569|Lignans
1109837|NCT01531569|Pharmacokinetics
1109838|NCT01531543|Vacuum Assisted Closure (VAC)
1109839|NCT01531543|Laparostomy
1109840|NCT01531543|Severe peritonitis
1109841|NCT01531530|Shigella
1109842|NCT01531530|Vaccine
1109843|NCT01531530|Mucosal immunity
1109844|NCT01531517|Pedyphar
1109845|NCT01531517|Ointment
1109846|NCT01531517|Healing
1109847|NCT01531517|Diabetic
1109848|NCT01531517|Foot Ulcer
1109849|NCT01531504|hysterectomies
1109850|NCT01531504|uterine manipulator
1109851|NCT01531491|Emergence
1109852|NCT01531491|Hypercapnia
1109853|NCT01531491|Hypocapnia
1109854|NCT01531491|Propofol
1109855|NCT01531478|Childhood cancer
1109856|NCT01531478|Cancer
1109857|NCT01531478|Sequels
1109858|NCT01531478|Complications
1109859|NCT01531478|Chemotherapy
1109860|NCT01531478|Radiotherapy
1109861|NCT01531478|Surgery
1109862|NCT01531465|Respiratory insufficiency
1109863|NCT01531465|Infants
1109864|NCT01531465|High Flow Nasal Cannula (HFNC)
1109865|NCT01531465|Nasal Continuous Positive Airway Pressure (NCPAP)
1109866|NCT01531452|Stomach Neoplasms
1109867|NCT01531452|drug therapy
1109868|NCT01531452|oxaliplatin
1109869|NCT01531452|s1
1109870|NCT01531439|Narcotic Antagonists
1109871|NCT01531439|Naloxone infusion
1109872|NCT01531439|Postoperative pruritis
1109873|NCT01531439|Patient controlled analgesia
1109874|NCT01531439|Pediatric
1109875|NCT01531439|Children
1109876|NCT01531426|resuscitation
1109877|NCT01531426|hypothermia
1109878|NCT01531426|outcome
1109879|NCT01531387|Phase III
1109880|NCT01531387|Sickle cell anemia
1109881|NCT01531387|Conditional transcranial doppler velocities
1109882|NCT01531387|Reduce risk of conversion to abnormally high transcranial doppler velocities
1109883|NCT01531387|Pediatric patients
1109884|NCT01531374|Valvular Heart Disease
1109885|NCT01531374|Critical Aortic Stenosis
1109886|NCT01531374|Severe Aortic Stenosis
1109887|NCT01531374|Extreme Risk
1109888|NCT01531374|High Risk
1109889|NCT01531374|Aortic Valve Replacement
1109890|NCT01531361|Advanced Cancers
1109891|NCT01531361|Advanced Malignancies
1109892|NCT01531361|Metastatic cancers
1109893|NCT01531361|Vemurafenib
1109894|NCT01531361|PLX4032
1109895|NCT01531361|R05185426
1109896|NCT01531361|Sorafenib
1109897|NCT01531361|Nexavar
1109898|NCT01531361|Bay 43-9006
1109899|NCT01531361|Crizotinib
1109900|NCT01531361|PF-02341066
1109901|NCT01531361|Xalkori
1109902|NCT01531361|Maximum tolerated dose
1109903|NCT01531361|MTD
1109904|NCT01531361|Dose limiting toxicity
1109905|NCT01531361|DLT
1109906|NCT01531348|Retinitis pigmentosa
1109907|NCT01531348|Bone marrow-derived mesenchymal stem cells
1109908|NCT01531348|Intravitreal injection
1109909|NCT01531335|adults
1109910|NCT01531322|13vPnC
1109911|NCT01531322|Healthy subjects
1109912|NCT01531322|China
1109913|NCT01531309|Liver impairment
1109914|NCT01531309|Major Depression Disorder
1109915|NCT01531309|Sublingual tablet
1109916|NCT01531296|MRI
1109917|NCT01531296|Lower Extremity Rotational
1109918|NCT01531296|Femoral Version
1109919|NCT01531296|Tibial Torsion
1109920|NCT01531283|unacylated ghrelin
1109921|NCT01531283|beta cell function
1109922|NCT01531231|heart disease
1109923|NCT01531231|unstable angina
1109924|NCT01531231|myocardial infarction
1109925|NCT01531231|behavioral
1109926|NCT01531231|cardiovascular
1109927|NCT01531231|emotions
1109928|NCT01531218|Campylobacter
1109929|NCT01531218|concisus
1109930|NCT01531218|diarrhea
1109931|NCT01531218|fever
1109932|NCT01531218|abdominal pain
1109933|NCT01531218|vomiting
1109934|NCT01531205|recurrent
1109935|NCT01531205|high risk
1109936|NCT01531192|Lactobacillus reuteri
1109937|NCT01531192|Nystatin
1109938|NCT01531192|Very Low Birth Weight Infants
1109939|NCT01531192|Candida Colonization
1109940|NCT01531166|Chronic hepatitis B
1109941|NCT01531166|pegylated Interferon-alpha 2a
1109942|NCT01531166|Korean
1109943|NCT01531153|Cocaine use decreases, increases or stays the same
1109944|NCT01531140|colonoscopy cleansing
1109945|NCT01531140|PEG
1109946|NCT01531140|sennosides
1109947|NCT01531140|children
1109954|NCT01531101|Transference work
1109955|NCT01531101|Psychodynamic
1109956|NCT01531101|Depression
1109957|NCT01531101|Treatment
1109958|NCT01531101|Adolescent
1109959|NCT01531088|Nursing Home
1109960|NCT01531075|HBV, Inflammatory bowel disease, immunosuppressor
1109961|NCT01531062|nigella sativa
1109962|NCT01531062|dyslipidemia
1109963|NCT01531062|elderly
1109964|NCT01531049|smoking cessation
1109965|NCT01531049|young adults
1109966|NCT01531049|motivational counselling
1109967|NCT01531049|smoking
1109968|NCT01531049|nicotine replacement therapy
1109969|NCT01531049|therapy
1109970|NCT01531023|Extended-Spectrum Beta-lactamase Producing Bacteria
1109971|NCT01531010|Neonate
1109972|NCT01531010|Premature
1109973|NCT01531010|Pressure limited ventilation
1109974|NCT01531010|Volume ventilation
1109975|NCT01530997|Human Papilloma Virus
1109976|NCT01530997|Oropharynx
1109977|NCT01530997|Oropharyngeal Squamous Cell Carcinoma
1109978|NCT01530997|Squamous Cell Carcinoma
1109979|NCT01530997|Radiation Therapy
1109980|NCT01530997|Chemotherapy
1109981|NCT01530997|p16
1109982|NCT01530984|prostate cancer
1109983|NCT01530984|metastatic castrate resistant prostate cancer
1109984|NCT01530984|Chemotherapy-naïve patients
1109985|NCT01530984|Anti-CTLA4 blockade
1109986|NCT01530984|systemic GM-CSF
1109987|NCT01530984|Ipilimumab
1109988|NCT01530971|oxygen
1109989|NCT01530971|pregnancy
1109990|NCT01530971|caesarean section
1109991|NCT01530971|anesthetic techniques
1109992|NCT01530958|CKD
1109993|NCT01530958|Automated Telephone Self Management
1109994|NCT01530958|Registry
1109995|NCT01530958|CKD awareness
1109996|NCT01530958|Self efficacy
1109997|NCT01530932|sepsis
1109998|NCT01530932|tissue oxygenation
1109999|NCT01530932|tissue perfusion
1110000|NCT01530932|immune reaction
1110001|NCT01530906|Eating disorders
1110002|NCT01530906|Bulimia
1110003|NCT01530906|rTMS
1110004|NCT01530906|Treatment
1110005|NCT01530893|flavonoids
1110006|NCT01530893|vascular function
1110007|NCT01530893|randomised controlled trial
1110008|NCT01530893|placebo controlled
1110009|NCT01530880|Fever reduction
1110010|NCT01530880|Fever burden
1110011|NCT01530880|intravenous ibuprofen
1110012|NCT01530867|Dietary Supplements
1110013|NCT01530867|Physician-patient communication
1110014|NCT01530867|Qualitative study
1110015|NCT01530867|Audio recorded office visits
1110016|NCT01530854|sepsis
1110017|NCT01530854|free fatty acids
1110018|NCT01530854|emergency department
1110019|NCT01530841|Myotonic dystrophy type 1
1110020|NCT01530841|Home ventilation
1110021|NCT01530841|Respiratory insufficiency
1110022|NCT01530841|Neuromuscular
1110023|NCT01530828|Immunoreactive Trypsinogen
1110024|NCT01530828|Nectrotizing Enterocolitis
1110025|NCT01530828|Premature Infants
1110026|NCT01530828|Serial IRT
1110027|NCT01530802|laparoscopic myomectomy, leiomyoma, blood loss, uterine artery
1110028|NCT01530789|Telemedecine
1110029|NCT01530789|Telemedecine nurse
1110030|NCT01530789|Delegation of tasks
1110031|NCT01530789|Type 1 diabetes
1110032|NCT01530776|Pregnancy
1110033|NCT01530776|Postpartum
1110034|NCT01530776|Weight Retention
1110035|NCT01530776|Behavioral
1110036|NCT01530776|Electronically-mediated
1110037|NCT01530763|Infections
1110038|NCT01530763|Pediatrics
1110039|NCT01530763|Teflaro
1110040|NCT01530763|cephalosporin
1110041|NCT01530750|postoperative atrial fibrillation
1110042|NCT01530750|internal loop recorder
1110043|NCT01530750|risk factors
1110044|NCT01530750|coronary artery bypass surgery
1110045|NCT01530737|pediatric
1110046|NCT01530737|Antithrombin
1110047|NCT01530737|anticoagulation efficiency
1110048|NCT01530737|cardiac surgery
1110049|NCT01530724|abdominal obesity
1110050|NCT01530698|dendritic cell vaccination
1110051|NCT01530698|melanoma
1110052|NCT01530698|toll like receptor ligands
1110053|NCT01530698|mRNA electroporation
1110054|NCT01530698|vaccines
1110055|NCT01530685|cinnamon
1110056|NCT01530685|chromium
1110057|NCT01530685|prediabete
1110058|NCT01530685|overweight
1110059|NCT01530672|HIV
1110060|NCT01530672|Syphilis
1110061|NCT01530672|Combination
1110062|NCT01530672|POC
1110063|NCT01530672|point-of-care
1110064|NCT01530672|MBIO
1110065|NCT01530659|Retinitis pigmentosa
1110066|NCT01530659|Usher syndrome type 2
1110067|NCT01530659|Usher syndrome type 3
1110068|NCT01530659|Cone photoreceptor
1110069|NCT01530659|Vision
1110070|NCT01530659|Blind
1110071|NCT01530646|obesity
1110072|NCT01530646|overweight
1110073|NCT01530646|muscle
1110074|NCT01530646|protein
1110075|NCT01530646|muscle protein synthesis
1110076|NCT01530646|muscle protein breakdown
1110077|NCT01530646|whey
1110078|NCT01530646|soy
1110079|NCT01530646|caloric restriction
1110080|NCT01530620|Antimuscarinics
1110081|NCT01530620|Neurogenic bladder
1110082|NCT01530620|Propiverine
1110083|NCT01530620|Urodynamics
1110084|NCT01530607|Early Stage Breast Cancer
1110085|NCT01530607|Reduce Ovarian Failure Following Chemotherapy
1110086|NCT01530594|Untreated
1110087|NCT01530594|Without intent for immediate autologous stem cell transplant
1110088|NCT01530568|Intensive care, TB, tracheal aspirates, Gene Xpert
1110089|NCT01530542|bioavailability
1110090|NCT01530542|food effect
1110091|NCT01530542|oxycodone
1110092|NCT01530542|management of acute and chronic moderate to severe pain
1110093|NCT01530529|PF-05180999
1110094|NCT01530529|safety
1110095|NCT01530529|pharmacokinetics
1110096|NCT01530529|relative bioavailability
1110097|NCT01530529|Mental Disorders
1110098|NCT01530529|Schizophrenia and Disorders with Psychotic Features
1110099|NCT01530529|Schizophrenia
1110100|NCT01530516|Malocclusion, Angle Class II
1110101|NCT01530503|biliary tract cancer
1110102|NCT01530503|advanced disease
1110103|NCT01530503|chemotherapy
1110104|NCT01530490|IVF
1110105|NCT01530490|ovarian hyperstimulation syndrome
1110106|NCT01530490|cabergoline
1110107|NCT01530490|hydroxyethyl starch
1110108|NCT01530490|prevention
1110109|NCT01530477|Bone mineral density
1110110|NCT01530477|weight
1110111|NCT01530477|body composition
1110112|NCT01530477|DEXA
1110113|NCT01530477|DXA
1110114|NCT01530464|High altitude induced fatigue
1110115|NCT01530464|High altitude induced pulmonary Hypertension
1110116|NCT01530451|Nocturia
1110117|NCT01530451|Obstructive sleep Apnoea
1110118|NCT01530451|Desmopressin
1110119|NCT01530438|Amyotrophic lateral sclerosis
1110120|NCT01530425|pediatric wheelchairs
1110121|NCT01530425|low-income
1110122|NCT01530425|comparisons
1110123|NCT01530412|Quality of Life
1110124|NCT01530412|Free-living activity
1110125|NCT01530412|Exacerbation
1110126|NCT01530412|Rehabilitation
1110127|NCT01530386|Lacosamide
1110128|NCT01530386|Vimpat
1110129|NCT01530373|hot flashes
1110130|NCT01530373|breast cancer
1110131|NCT01530373|aromatase inhibitors
1110132|NCT01530373|solifenacin
1110133|NCT01530373|clonidine
1110134|NCT01530373|quality of life
1110135|NCT01530347|Glucose monitoring
1110136|NCT01530347|non-invasive glucometer
1110137|NCT01530347|Self glucose monitoring
1110138|NCT01530321|cervicogenic headache
1110139|NCT01530321|spinal manipulation
1110140|NCT01530321|chiropractic
1110141|NCT01530321|randomized controlled trial
1110142|NCT01530321|dose-response
1110143|NCT01530321|efficacy
1110144|NCT01530308|Delirium
1110145|NCT01530282|Respiratory Insufficiency [C08.618.846]
1110146|NCT01530269|intermediate
1110147|NCT01530269|high
1110148|NCT01530269|risk
1110149|NCT01530269|radiation
1110150|NCT01530269|therapy
1110151|NCT01530269|planning
1110152|NCT01530269|surgical
1110153|NCT01530269|immunotherapy
1110154|NCT01530269|chemotherapy
1110155|NCT01530269|hormone
1110156|NCT01530256|allograph
1110157|NCT01530256|steroid refractory
1110158|NCT01530230|cesarean section
1110159|NCT01530230|electrocardiography
1110160|NCT01530230|heart
1110161|NCT01530230|hypotension
1110162|NCT01530230|ischemia
1110163|NCT01530230|oxytocin
1110164|NCT01530230|preeclampsia
1110165|NCT01530230|regional anesthesia
1110166|NCT01530230|ECG changes suggestive of myocardial ischemia
1110167|NCT01530217|Analgesics
1110168|NCT01530217|Ibuprofen
1110169|NCT01530217|Inflammation
1110170|NCT01530217|Tooth Bleaching
1110171|NCT01530204|knee arthritis
1110172|NCT01530204|knee osteoarthritis
1110173|NCT01530204|knee pain
1110174|NCT01530204|cognitive behavioral therapy
1110175|NCT01530204|physical therapy
1110176|NCT01530204|depression prevention
1110177|NCT01530191|depression
1110178|NCT01530191|anxiety
1110179|NCT01530191|pelvic organ prolapse
1110180|NCT01530191|POP
1110181|NCT01530178|Diabetes Mellitus, Type 1
1110182|NCT01530165|IFG
1110183|NCT01530165|IGTT
1110184|NCT01530152|Truwiev PCD laryngoscope
1110185|NCT01530152|Macintosh laryngoscope
1110186|NCT01530126|periodontitis
1110187|NCT01530113|Childhood sexual abuse
1110188|NCT01530113|Vaginismus
1110189|NCT01530113|Partial vaginismus
1110190|NCT01530113|Labor dystocia
1110191|NCT01530113|Depression
1110192|NCT01530100|Edema
1110193|NCT01530100|Pain
1110194|NCT01530100|Lower laser therapy
1110195|NCT01530100|orthognathics surgery
1110196|NCT01530087|colostomy
1110197|NCT01530087|ileostomy
1110198|NCT01530087|irritant dermatitis
1110199|NCT01530087|two piece barrier
1110200|NCT01530074|Mandibular nerve
1110201|NCT01530074|Mental nerve
1110202|NCT01530074|Mandibular incisive nerve
1110203|NCT01530074|Local anesthesia
1110204|NCT01530074|None, only healthy subjects will be enrolled in this study
1110205|NCT01530035|cardiac
1110206|NCT01530035|vascular
1110207|NCT01530035|muscular
1110208|NCT01530035|adaptations
1110209|NCT01530035|soccer training
1110210|NCT01530035|strength training
1110211|NCT01530022|Lacosamide
1110212|NCT01530022|Vimpat
1110213|NCT01530022|Cognition
1110214|NCT01530022|Mental Processes
1110215|NCT01530022|Adverse Effects
1110216|NCT01530009|Antroduodenal manometry
1110217|NCT01530009|Child
1110218|NCT01530009|Adolescent
1110219|NCT01530009|Amoxicillin
1110220|NCT01530009|Gastrointestinal Motility
1110221|NCT01529957|Volunteers
1110222|NCT01529918|Diabetes
1110223|NCT01529918|Self-screening
1110224|NCT01529918|Web-based technology
1110225|NCT01529918|follow-up clinical care
1110226|NCT01529918|randomized control trial
1110227|NCT01529905|depression
1110228|NCT01529905|mania
1110229|NCT01529905|bipolar
1110230|NCT01529905|outcome
1110231|NCT01529905|cognitive
1110232|NCT01529879|edentulism
1110233|NCT01529879|dental implants
1110234|NCT01529879|clinical study
1110235|NCT01529879|Nanotite Certain Tapered implant
1110236|NCT01529879|randomized
1110237|NCT01529879|crestal bone level
1110238|NCT01529866|clinical study
1110239|NCT01529866|edentulism
1110240|NCT01529866|dental implants
1110241|NCT01529866|Nanotite Certain Tapered implant
1110242|NCT01529866|randomized
1110243|NCT01529866|crestal bone level
1110244|NCT01529866|immediate loading
1110245|NCT01529814|edentulism
1110246|NCT01529814|dental implants
1110247|NCT01529814|clinical study
1110248|NCT01529814|Nanotite Certain Tapered implant
1110249|NCT01529814|randomized
1110250|NCT01529814|crestal bone level
1110251|NCT01529814|early loading
1110252|NCT01529801|edentulism
1110253|NCT01529801|dental implants
1110254|NCT01529801|clinical study
1110255|NCT01529801|randomized
1110256|NCT01529801|Osseotite Certain Tapered
1110257|NCT01529801|Crestal bone level
1110258|NCT01529788|abobotulinum toxin lateral orbital lines
1110259|NCT01529788|BotoxCosmetic
1110260|NCT01529788|Dysport
1110261|NCT01529788|onabotulinum toxin
1110262|NCT01529788|wrinkles
1110263|NCT01529788|lateral orbital lines
1110264|NCT01529775|partial edentulism
1110265|NCT01529775|dental implants
1110266|NCT01529775|Osseotite Certain Prevail Tapered
1110267|NCT01529775|Osseotite Certain Tapered
1110268|NCT01529775|Crestal bone level
1110269|NCT01529775|randomized
1110270|NCT01529775|clinical study
1110271|NCT01529762|edentulism
1110272|NCT01529762|dental implants
1110273|NCT01529762|Osseotite Certain Tapered
1110274|NCT01529762|randomized
1110275|NCT01529762|clinical study
1110276|NCT01529762|partial edentulism
1110277|NCT01529762|immediate loading
1110278|NCT01529762|crestal bone level
1110279|NCT01529736|edentulism
1110280|NCT01529736|dental implants
1110281|NCT01529736|early loading
1110282|NCT01529736|crestal bone level
1110283|NCT01529736|high torque insertion
1110284|NCT01529736|low torque insertion
1110285|NCT01529736|randomized
1110286|NCT01529736|Osseotite
1110287|NCT01529736|clinical study
1110288|NCT01529723|Stroke
1110289|NCT01529723|Dysphagia screening
1110290|NCT01529710|Schistosomiasis hematobium
1110291|NCT01529710|Schistosomiasis mansoni
1110292|NCT01529697|Asthma
1110293|NCT01529697|Inhaler use
1110294|NCT01529684|Cancer, solid tumors
1110295|NCT01529684|oncology patients
1110296|NCT01529684|OSI-906
1110297|NCT01529684|mass balance
1110298|NCT01529684|Absorption, Metabolism, and Excretion of OSI-906
1110299|NCT01529684|Metabolic profile of 906
1110300|NCT01529684|Pharmacokinetics of 14C-OSI-906
1110301|NCT01529658|Renal function
1110302|NCT01529658|Renal hypothermia
1110303|NCT01529658|Nephrology
1110304|NCT01529658|Nephrectomy
1110305|NCT01529658|Renal tumor
1110306|NCT01529658|Urology
1110307|NCT01529658|Kidney
1110308|NCT01529645|pertussis
1110309|NCT01529645|booster vaccine
1110310|NCT01529645|tetanus
1110311|NCT01529645|diphtheria in adults
1110312|NCT01529632|chronic obstructive pulmonary disease
1110313|NCT01529632|COPD
1110314|NCT01529632|QVA149
1110315|NCT01529632|QAB149
1110316|NCT01529632|NVA237
1110317|NCT01529632|indacaterol
1110318|NCT01529632|glycopyrronium bromide
1110319|NCT01529619|Rivastigmine
1110320|NCT01529619|Alzheimer's disease
1110321|NCT01529619|Transdermal patch
1110322|NCT01529606|dental restoration
1110323|NCT01529606|dental caries
1110324|NCT01529606|tooth cavity
1110325|NCT01529593|Advanced Cancers
1110326|NCT01529593|Metastatic cancer
1110327|NCT01529593|Tumor response
1110328|NCT01529593|Dose limiting toxicity
1110329|NCT01529593|DLT
1110330|NCT01529593|Maximum tolerated dose
1110331|NCT01529593|MTD
1110332|NCT01529593|Temsirolimus
1110333|NCT01529593|CCI-779
1110334|NCT01529593|Torisel
1110335|NCT01529593|Metformin
1110336|NCT01529580|Autism Spectrum Disorder
1110337|NCT01529580|language
1110338|NCT01529580|intervention
1110339|NCT01529580|school-age
1110340|NCT01529554|Acute Coronary Syndromes
1110341|NCT01529554|ST-Elevation Myocardial Infarction
1110342|NCT01529554|Infarct size
1110343|NCT01529554|inflammation
1110344|NCT01529554|everolimus
1110345|NCT01529541|CWP-0403
1110346|NCT01529541|Sitagliptin
1110347|NCT01529541|Metformin
1110348|NCT01529541|type 2 DM
1110349|NCT01529528|CWP-0403
1110350|NCT01529528|type 2 DM
1110351|NCT01529528|Efficacy
1110352|NCT01529528|Safety
1110353|NCT01529528|Phase 3
1110354|NCT01529515|Schizophrenia
1110355|NCT01529515|R092670
1110356|NCT01529515|Paliperidone Palmitate
1110357|NCT01529515|Paliperidone palmitate 3 month formulation (PP3M)
1110358|NCT01529502|Blood Transfusion, Autologous
1110359|NCT01529502|Blood Preservation/adverse effects
1110360|NCT01529502|Blood Transfusion/adverse effects
1110361|NCT01529502|Endothelium, Vascular/physiopathology
1110362|NCT01529502|Hemoglobins
1110363|NCT01529502|Nitric Oxide
1110364|NCT01529502|Pulmonary Hypertension
1110365|NCT01529489|Chronic Obstructive Pulmonary Disease
1110366|NCT01529489|Physical training
1110367|NCT01529489|Oxygen uptake kinetic
1110368|NCT01529489|Heart rate kinetic
1110369|NCT01529476|Ofloxacin
1110370|NCT01529476|Levofloxacin
1110371|NCT01529476|Ofloxacin hydrochloride
1110372|NCT01529463|Congestive Heart Failure
1110373|NCT01529450|basal cell carcinoma, sonidegib, smoothened inhibitor, hedgehog
1110374|NCT01529437|allergy
1110375|NCT01529437|immunology
1110376|NCT01529437|immune tolerance
1110377|NCT01529437|immunotherapy
1110378|NCT01529424|Hypertriglyceridemia
1110379|NCT01529411|urothelium
1110380|NCT01529411|transitional
1110381|NCT01529411|carcinoma
1110382|NCT01529411|cancer
1110383|NCT01529411|metastatic
1110384|NCT01529411|tract
1110385|NCT01529398|knee osteoarthritis
1110386|NCT01529398|exercise therapy
1110387|NCT01529398|resistance training
1110388|NCT01529398|proprioception
1110389|NCT01529385|swollen leg
1110390|NCT01529385|diabetes
1110391|NCT01529385|compression stockings
1110392|NCT01529385|edema
1110393|NCT01529372|Hypertension
1110394|NCT01529372|Blood pressure
1110395|NCT01529372|Renal denervation
1110396|NCT01529359|Irritable Bowel Syndrome
1110397|NCT01529359|Probiotics
1110398|NCT01529346|Postoperative dental pain
1110399|NCT01529307|Biologic,
1110400|NCT01529307|solid tumors,
1110401|NCT01529307|Death Receptor 5 agonist,
1110402|NCT01529307|caspase-8
1110403|NCT01529294|Hepatic impairment
1110404|NCT01529294|Iloperidone
1110405|NCT01529294|ILO522D
1110406|NCT01529294|Pharmacokinetics
1110407|NCT01529268|Nonalcoholic Fatty Liver Disease (NAFLD)
1110408|NCT01529268|Cysteamine bitartrate delayed release
1110409|NCT01529268|Children
1110410|NCT01529255|Chronic Hepatitis B
1110411|NCT01529255|Compensated Chronic hepatitis B
1110412|NCT01529216|DIAMOND System
1110413|NCT01529216|T2DM
1110414|NCT01529216|Randomized study
1110415|NCT01529216|Electrical stimulation
1110416|NCT01529216|Fundus
1110417|NCT01529190|pregabalin
1110418|NCT01529190|postoperative pain control
1110419|NCT01529190|interleukin-6
1110420|NCT01529190|acute pain
1110421|NCT01529177|Metformin
1110422|NCT01529177|Insulin resistance
1110423|NCT01529177|male infertility
1110424|NCT01529177|unexplained Oligozspermia
1110425|NCT01529177|Clomiphene citrate
1110426|NCT01529177|Unexplained azoospermia
1110427|NCT01529164|endostatin
1110428|NCT01529164|chemotherapy
1110429|NCT01529164|antiangiogenesis agent
1110430|NCT01529164|colorectal cancer
1110431|NCT01529151|Dizziness
1110432|NCT01529151|Vertigo
1110433|NCT01529151|Benign Paroxysmal Positional Vertigo
1110434|NCT01529151|Labyrinthitis
1110435|NCT01529151|Osteopathic Manipulative Treatment
1110436|NCT01529151|Vestibular Rehabilitation Therapy
1110437|NCT01529138|Cancer
1110438|NCT01529112|Locally Advanced
1110439|NCT01529112|Metastatic Non-Squamous Non-Small Cell Lung Cancer
1110440|NCT01529099|Osteoarthritis
1110441|NCT01529099|Knee
1110442|NCT01529099|Knee replacement
1110443|NCT01529099|Knee implant
1110444|NCT01529099|Knee arthroplasty
1110445|NCT01529099|Unicompartmental
1110446|NCT01529099|Primary
1110447|NCT01529099|Partial
1110448|NCT01529099|Patellofemoral
1110449|NCT01529099|Medial
1110450|NCT01529099|Lateral
1110451|NCT01529099|Bicompartmental
1110452|NCT01529099|Cemented
1110453|NCT01529099|Post-traumatic arthritis of the tibio-femoral and/or patellofemoral articular surfaces
1110454|NCT01529099|History of Gout or pseudo-gout.
1110455|NCT01529086|prostate cancer
1110456|NCT01529086|dutasteride
1110457|NCT01529086|for cause prostate biopsy
1110458|NCT01529073|HIV
1110459|NCT01529073|genotype 4 HCV
1110460|NCT01529073|pegylated interferon
1110461|NCT01529073|ribavirin
1110462|NCT01529073|nitazoxanide
1110463|NCT01529060|phenylbutyrate
1110464|NCT01529060|MSUD
1110465|NCT01529060|Buphenyl-TM
1110466|NCT01529034|Epilepsy
1110467|NCT01529034|seizure clusters
1110468|NCT01529034|acute repetitive seizures
1110469|NCT01529034|rescue treatment
1110470|NCT01529021|Pain management
1110471|NCT01529021|vaccination
1110472|NCT01529021|immunization
1110473|NCT01529021|pediatric
1110474|NCT01529021|robotics
1110475|NCT01529021|human-robot interaction
1110476|NCT01529008|Osteonecrosis
1110477|NCT01529008|Femoral Head
1110478|NCT01529008|Hip
1110479|NCT01529008|Orthopedics
1110480|NCT01529008|Bone
1110481|NCT01529008|Musculoskeletal Disorders
1110482|NCT01528995|fecal incontinence
1110483|NCT01528995|anal incontinence
1110484|NCT01528995|obstetric sphincter injuries
1110485|NCT01528995|OASIS
1110486|NCT01528995|double incontinence
1110487|NCT01528995|urinary incontinence
1110488|NCT01528995|sexual function
1110489|NCT01528995|sacral nerve modulation
1110490|NCT01528995|sacral nerve stimulation
1110491|NCT01528995|Interstim
1110492|NCT01528995|anal bulking injections
1110493|NCT01528995|Permacol
1110494|NCT01528969|oral microbiota
1110495|NCT01528969|mutans streptococci
1110496|NCT01528969|xylitol
1110497|NCT01528956|adrenocortical carcinoma
1110498|NCT01528943|To evaluate the effect of prostacycline on endothelial integrity during major abdominal surgery
1110499|NCT01528930|Lung Diseases
1110500|NCT01528930|Anti-Infective Agents
1110501|NCT01528930|Therapeutic Uses
1110502|NCT01528930|Amikacin
1110503|NCT01528917|Lysosomal Storage Disease
1110504|NCT01528917|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
1110505|NCT01528917|Acid cholesteryl ester hydrolase deficiency, type 2
1110506|NCT01528917|Acid lipase disease
1110507|NCT01528917|Cholesterol ester hydrolase deficiency
1110508|NCT01528917|LAL Deficiency
1110509|NCT01528917|LIPA Deficiency
1110510|NCT01528917|Wolman disease
1110511|NCT01528904|pregnancy
1110512|NCT01528904|autoimmune thyroid disease
1110513|NCT01528904|fetal thyroid hormones
1110514|NCT01528904|antithyroid antibodies
1110515|NCT01528904|ultrasound parameters
1110516|NCT01528891|tonsillectomy
1110517|NCT01528891|emergence agitation
1110518|NCT01528878|Liver Cancer
1110519|NCT01528878|Hepatocellular Carcinoma
1110520|NCT01528878|HCC
1110521|NCT01528878|Metastatic Cancer to Liver
1110522|NCT01528878|Metastatic Colon Cancer
1110523|NCT01528878|Metastatic Colo-rectal Cancer
1110524|NCT01528878|mCRC
1110525|NCT01528878|Liver Function
1110526|NCT01528878|Child-Pugh
1110527|NCT01528865|virus
1110528|NCT01528865|K(HML2)[HERV-K(HML2)]
1110529|NCT01528865|Lymphoma
1110530|NCT01528865|Human endogenous retrovirus-K(HLM2)[HERV-K(HML2)]
1110531|NCT01528852|neonatal Mortality
1110532|NCT01528852|chlorhexidine cord care
1110533|NCT01528852|cord infections
1110534|NCT01528852|african settings
1110535|NCT01528852|clinical trials
1110536|NCT01528839|Bipolar disorder
1110537|NCT01528839|Bipolar depression
1110538|NCT01528839|Thyroid abnormality
1110539|NCT01528839|mood stabilizer
1110540|NCT01528839|antidepressants
1110541|NCT01528839|currently depressed
1110542|NCT01528826|metastatic triple-negative breast cancer
1110543|NCT01528826|vinorebine
1110544|NCT01528826|oxaliplatin
1110545|NCT01528813|Erbium-doped yttrium aluminium garnet laser
1110546|NCT01528813|Er:YAG
1110547|NCT01528813|Amorolfine lacquer
1110548|NCT01528813|Dermatophytes
1110549|NCT01528813|Subungual distal lateral onychomycosis
1110550|NCT01528813|Drug delivery
1110551|NCT01528800|Vitamin K
1110552|NCT01528800|Chronic kidney disease
1110553|NCT01528800|vascular calcification
1110554|NCT01528800|hemodialysis
1110555|NCT01528800|coronary artery calcification
1110556|NCT01528787|Intraocular pressure
1110557|NCT01528787|visual field
1110558|NCT01528787|Ocular hypertension or open angle glaucoma
1110559|NCT01528774|Melanoma
1110560|NCT01528774|Circulating Tumor Cells
1110561|NCT01528774|Prostate cancer
1110562|NCT01528774|Sarcoma
1110563|NCT01528774|Renal Cancer
1110564|NCT01528774|Pancreatic neuroendocrine cancer
1110565|NCT01528774|Other solid tumor
1110566|NCT01528761|physical activity
1110567|NCT01528761|older adults
1110568|NCT01528761|physical function
1110569|NCT01528761|health-related quality of life
1110570|NCT01528761|prosocial behavior
1110571|NCT01528761|social cognitive theory
1110572|NCT01528722|Emergency laparoscopic cholecystectomy
1110573|NCT01528722|Pain scores
1110574|NCT01528722|Intraperitoneal local anaesthesia
1110575|NCT01528722|Cholecystitis
1110576|NCT01528709|Statin,
1110577|NCT01528709|CABG,
1110578|NCT01528709|saphenous vein graft,
1110579|NCT01528709|graft occlusion,
1110580|NCT01528709|lipids
1110581|NCT01528696|Obesity
1110582|NCT01528696|Cesarean Section
1110583|NCT01528696|Wound care
1110584|NCT01528657|Sick Sinus Syndrome
1110585|NCT01528657|Ventricular pacing
1110586|NCT01528657|Minimal ventricular pacing
1110587|NCT01528657|Ventricular pacing suppression
1110588|NCT01528657|Intrinsic rhythm support
1110589|NCT01528657|Long term AV
1110590|NCT01528644|iron
1110591|NCT01528644|fortification
1110592|NCT01528644|alginate
1110593|NCT01528644|iron deficiency
1110594|NCT01528618|Advanced Nasopharyngeal Carcinoma
1110595|NCT01528618|treatment
1110596|NCT01528605|lutein
1110597|NCT01528605|zeaxanthin
1110598|NCT01528605|age-related macular degeneration
1110599|NCT01528605|supplementation
1110600|NCT01528605|macular pigment optical density
1110601|NCT01528605|visual function
1110602|NCT01528605|serum concentration
1110603|NCT01528579|Whiplash
1110604|NCT01528579|Rehabilitation
1110605|NCT01528579|Physiotherapy
1110606|NCT01528579|Exercises
1110607|NCT01528566|osteoarthritis, knee
1110608|NCT01528566|Cognitive impairment
1110609|NCT01528566|Tai Chi
1110610|NCT01528553|genu valgus
1110611|NCT01528553|lower limb
1110612|NCT01528553|paediatric
1110613|NCT01528553|epiphysiodesis
1110614|NCT01528540|chronic pancreatitis
1110615|NCT01528540|pregabalin
1110616|NCT01528540|antioxidant
1110617|NCT01528514|Myocardial infarction
1110618|NCT01528514|Coronary artery bypass grafting
1110619|NCT01528514|Anti-oxidant
1110620|NCT01528514|Curcuminoids
1110621|NCT01528475|Therapeutic Hypothermia
1110622|NCT01528475|Cardiac arrest
1110623|NCT01528462|Stroke
1110624|NCT01528462|Ischemic Attack, Transient
1110625|NCT01528462|Sleep Disorders
1110626|NCT01528462|Sleep Apnea Syndromes
1110627|NCT01528462|Restless Legs Syndrome
1110628|NCT01528462|Chronobiology Disorders
1110629|NCT01528449|babesia
1110630|NCT01528449|blood donation
1110631|NCT01528449|transfusion transmitted babesiosis
1110632|NCT01528436|Cerebral Palsy
1110633|NCT01528436|Umbilical Cord Blood
1110634|NCT01528436|Rehabilitation
1110635|NCT01528423|XtremeCT
1110636|NCT01528423|Density
1110637|NCT01528423|pQCT
1110638|NCT01528423|Turnover
1110639|NCT01528423|Bone
1110640|NCT01528423|short-term reproducibility
1110641|NCT01528397|defect
1110642|NCT01528397|dorsal branch of the proper digital nerve
1110643|NCT01528397|proper digital nerve
1110644|NCT01528397|second dorsal metacarpal artery
1110645|NCT01528397|pedicled nerve graft.
1110646|NCT01528384|Arginine
1110647|NCT01528384|Arginine deiminase
1110648|NCT01528384|Argininosuccinate synthetase
1110649|NCT01528384|Phase 1
1110650|NCT01528384|Pediatric
1110651|NCT01528384|Failed other treatments
1110652|NCT01528384|Pediatric patients
1110653|NCT01528371|Intravenous sedation
1110654|NCT01528371|Midazolam
1110655|NCT01528371|Dental treatment
1110656|NCT01528371|White-coat hypertension
1110657|NCT01528371|STAI
1110658|NCT01528371|Dental patients
1110659|NCT01528371|Transient hypertension
1110660|NCT01528358|sepsis
1110661|NCT01528358|tissue oximetry
1110662|NCT01528358|NIRS
1110663|NCT01528358|VOT
1110664|NCT01528345|Breast Cancer
1110665|NCT01528345|HER2-, HR+
1110666|NCT01528345|post-menopausal
1110667|NCT01528345|Locally advanced or metastatic Breast Cancer (HER2-, HR+)
1110668|NCT01528332|Musculoskeletal pain
1110669|NCT01528332|Back pain
1110670|NCT01528332|Chronic pain
1110671|NCT01528319|Arthroscopic Bankart repair
1110672|NCT01528319|Suture anchor
1110673|NCT01528319|Shoulder dislocation
1110674|NCT01528306|HP802-247
1110675|NCT01528306|EB (epidermolysis bullosa)
1110676|NCT01528280|Shift work
1110677|NCT01528280|Hepatitis A vaccination
1110678|NCT01528280|humoral response
1110679|NCT01528280|cellular response
1110680|NCT01528267|Emphysema, lung volume reduction, autologous blood
1110681|NCT01528254|Type 2 Diabetes Mellitus,
1110682|NCT01528254|Vildagliptin,
1110683|NCT01528254|Elderly Patients
1110684|NCT01528241|ABP688
1110685|NCT01528241|Tracer
1110686|NCT01528241|Depression
1110687|NCT01528202|Sleep, circadian cycle, melatonin
1110688|NCT01528189|Insulin, surgery, infection
1110689|NCT01528176|FGF-23, CKD, Cyp24, 24,25(OH)2D, vitamin D metabolism
1110690|NCT01528163|Head and neck
1110691|NCT01528163|Squamous cell carcinoma
1110692|NCT01528163|Randomized
1110693|NCT01528163|palliative treatment
1110694|NCT01528098|polyethylene glycol
1110695|NCT01528098|bisacodyl
1110696|NCT01528085|Philadelphia chromsome
1110697|NCT01528085|BCR-ABL
1110698|NCT01528085|ALL
1110699|NCT01528085|acute lymphoblastic leukemia
1110700|NCT01528085|Nilotinib
1110701|NCT01528085|Tasigna
1110702|NCT01528072|Dynesys Dynamic Stabilization System
1110703|NCT01528072|Spondylolithesis
1110704|NCT01528072|pseudoarthrosis
1110705|NCT01528072|neurologic impairment
1110706|NCT01528072|failed fusion
1110707|NCT01528059|Diabetes
1110708|NCT01528059|Gastric cancer
1110709|NCT01528059|Gastric bypass
1110710|NCT01528046|central nervous system (CNS)
1110711|NCT01528046|malignancy
1110712|NCT01528046|relapsed
1110713|NCT01528046|refractory
1110714|NCT01528046|pediatric
1110715|NCT01528046|recurrent
1110716|NCT01528033|surgical wound
1110717|NCT01528033|wound healing disorder
1110718|NCT01528033|Wound healing impairment
1110719|NCT01528033|post surgical wound healing disorder
1110720|NCT01528033|abdominal wound healing impairment
1110721|NCT01528033|Vacuum Assisted Closure
1110722|NCT01528033|negative pressure wound therapy
1110723|NCT01528007|Pathological gambling
1110724|NCT01528007|Treatment intervention
1110725|NCT01527994|Aprepitant
1110726|NCT01527994|Intravenous heroin dependence
1110727|NCT01527981|Depression
1110728|NCT01527981|Diabetes
1110729|NCT01527981|Adherence
1110730|NCT01527981|Medication
1110731|NCT01527981|Glucose
1110732|NCT01527981|Insulin
1110733|NCT01527955|Kelee
1110734|NCT01527955|Meditation
1110735|NCT01527955|Stress
1110736|NCT01527955|Anxiety
1110737|NCT01527955|Depression
1110738|NCT01527955|Brain
1110739|NCT01527955|Mind
1110740|NCT01527942|Pain Management
1110741|NCT01527903|propofol
1110742|NCT01527903|midazolam
1110743|NCT01527903|sedation
1110744|NCT01527903|ICU
1110745|NCT01527890|intravenous patient-controlled analgesia
1110746|NCT01527890|IV PCA
1110747|NCT01527877|BKM120
1110748|NCT01527877|head and neck cancer
1110749|NCT01527877|squamous cell carcinoma
1110750|NCT01527864|NSCLC
1110751|NCT01527851|Post-bariatric surgery
1110752|NCT01527851|Excess skin
1110753|NCT01527851|Physical fitness
1110754|NCT01527851|Physical activity
1110755|NCT01527851|Barriers to physical activity
1110756|NCT01527851|Plastic surgery
1110757|NCT01527851|Quality of life
1110758|NCT01527851|Self-esteem
1110759|NCT01527838|Hematologic malignancies
1110760|NCT01527799|Sickle cell anemia
1110761|NCT01527799|Exercise testing
1110762|NCT01527799|Cardiopulmonary disease
1110763|NCT01527786|Major Depressive Disorder, Postpartum Onset
1110764|NCT01527773|COPD
1110765|NCT01527773|Cardiovascular disease
1110766|NCT01527773|Phenotypes
1110767|NCT01527760|Essential Hypertension
1110768|NCT01527760|Viscum album mother tincture
1110769|NCT01527760|one group pretest post-test study
1110770|NCT01527747|Type 2 Diabetes
1110771|NCT01527747|Hypertriglyceridemia
1110772|NCT01527747|dipeptidyl peptidase-4 (DPP-4)
1110773|NCT01527747|glucagon-like peptide-1 (glp-1)
1110774|NCT01527734|Comparison study
1110775|NCT01527721|keratoconus
1110776|NCT01527721|CxL
1110777|NCT01527721|CxL combined with t-PRK
1110778|NCT01527695|Phase IIa
1110779|NCT01527695|AZD3241
1110780|NCT01527695|microglia activation
1110781|NCT01527695|safety
1110782|NCT01527695|Pharmacodynamics and pharmacokinetics analyses
1110783|NCT01527695|Parkinson patients
1110784|NCT01527682|Intraocular pressure
1110785|NCT01527682|Latanoprost
1110786|NCT01527682|Dorzolamide
1110787|NCT01527669|Red yeast rice
1110788|NCT01527669|lovastatin
1110789|NCT01527669|Pharmacokinetics
1110790|NCT01527578|Healthy children
1110791|NCT01527578|Healthy adults
1110792|NCT01527578|individuals ages 7-60
1110793|NCT01527526|DMPA
1110794|NCT01527526|insulin resistance
1110795|NCT01527526|cardiovascular disease
1110796|NCT01527526|BMI
1110797|NCT01527526|weight gain
1110798|NCT01527526|thrombosis
1110799|NCT01527513|Partial Epilepsy
1110800|NCT01527513|eslicarbazepine acetate
1110801|NCT01527513|Children
1110802|NCT01527500|AMD
1110803|NCT01527500|Age-related Macular Degeneration
1110804|NCT01527500|geographic atrophy
1110805|NCT01527500|GA
1110806|NCT01527500|Dry AMD
1110807|NCT01527500|Blindness
1110808|NCT01527500|Drusen
1110809|NCT01527500|GA lesion
1110810|NCT01527487|breast cancer
1110811|NCT01527487|eribulin
1110812|NCT01527487|Halaven
1110813|NCT01527487|taxotere
1110814|NCT01527474|postpartum
1110815|NCT01527474|postpartum depression
1110816|NCT01527474|PPD
1110817|NCT01527474|escitalopram
1110818|NCT01527461|lung neoplasms
1110819|NCT01527461|dogs
1110820|NCT01527461|sweat
1110821|NCT01527461|smell
1110822|NCT01527448|postpartum
1110823|NCT01527448|postpartum depression
1110824|NCT01527448|PPD
1110825|NCT01527448|quetiapine XR
1110826|NCT01527448|quetiapine
1110827|NCT01527448|seroquel
1110828|NCT01527448|bipolar
1110829|NCT01527448|bipolar disorder
1110830|NCT01527448|bipolar disorder, type II
1110831|NCT01527435|Best corrected visual acuity
1110832|NCT01527435|Slit lamp examination
1110833|NCT01527435|Ophthalmoscopy with contact lens/indirect ophthalmoscope
1110834|NCT01527435|OCT assessment
1110835|NCT01527435|Fundus photos, fluorescein angiogram, ICG angiogram
1110836|NCT01527422|Aggressive Non-Hodgkin's Lymphoma
1110837|NCT01527409|Exercise
1110838|NCT01527409|Diet
1110839|NCT01527409|Posttraumatic growth
1110840|NCT01527396|endometrial cancer
1110841|NCT01527396|lymph node metastasis
1110842|NCT01527396|lymphadenectomy
1110843|NCT01527396|risk criteria
1110844|NCT01527383|Shingles
1110845|NCT01527357|fibrin sealant
1110846|NCT01527357|thrombin
1110847|NCT01527357|fibrinogen
1110848|NCT01527357|hemostasis
1110849|NCT01527344|OCT
1110850|NCT01527344|IVUS
1110851|NCT01527344|CAV
1110852|NCT01527318|NLSDM
1110853|NCT01527318|Lipid accumulation
1110854|NCT01527305|Schizophrenia
1110855|NCT01527305|Antipsychotics
1110856|NCT01527305|Paliperidone Palmitate
1110857|NCT01527305|Paliperidone
1110858|NCT01527305|Invega
1110859|NCT01527305|Sustenna
1110860|NCT01527305|Psychotic disorder
1110861|NCT01527305|Psychosis
1110862|NCT01527292|Vertebral Metastasis
1110863|NCT01527292|pain control
1110864|NCT01527292|VAP
1110865|NCT01527292|SRT+VAP
1110866|NCT01527279|atrial fibrillation
1110867|NCT01527279|paroxysmal
1110868|NCT01527279|cardioversion
1110869|NCT01527279|antazoline
1110870|NCT01527266|carbohydrate
1110871|NCT01527266|performance
1110872|NCT01527266|cycling
1110873|NCT01527253|Cardiometabolic risk
1110874|NCT01527253|Metabolic syndrome
1110875|NCT01527253|Prebiotics
1110876|NCT01527253|Legumes
1110877|NCT01527253|Wholegrain cereal
1110878|NCT01527253|Functional diet
1110879|NCT01527253|Low glycemic index diet
1110880|NCT01527240|Volume of cerebral infarction
1110881|NCT01527240|Stroke
1110882|NCT01527240|CsA
1110883|NCT01527240|NIHSS
1110884|NCT01527227|Children of mentally ill
1110885|NCT01527214|Lung cancer
1110886|NCT01527214|early detection
1110887|NCT01527214|CT scan
1110888|NCT01527214|General Practice
1110889|NCT01527214|Effect of Computed Tomography scans
1110890|NCT01527214|Clinical medical education
1110891|NCT01527201|Arthroscopy
1110892|NCT01527201|Debridement
1110893|NCT01527188|HDM
1110894|NCT01527188|allergic rhinitis
1110895|NCT01527162|Cerebral palsy
1110896|NCT01527162|orthotics
1110897|NCT01527162|solid ankle foot orthoses
1110898|NCT01527123|GSK2585823, benzoic acid, hippuric acid, acne vulgaris, pharmacokinetics
1110899|NCT01527110|zanamivir
1110900|NCT01527110|Seasonal Influenza
1110901|NCT01527110|H1N1
1110902|NCT01527110|intravenous
1110903|NCT01527110|neuraminidase inhibitor
1110904|NCT01527110|Pandemic
1110905|NCT01527110|Relenza
1110906|NCT01527110|Influenza B virus
1110907|NCT01527110|Influenza A virus
1110908|NCT01527097|Cardiovascular Diseases
1110909|NCT01527097|Pharmacologic Actions
1110910|NCT01527097|Endothelial Function
1110911|NCT01527097|Dermatology
1110912|NCT01527097|Inflammatory Disease
1110913|NCT01527097|Skin Disease
1110914|NCT01527058|lung cancer
1110915|NCT01527058|integrin receptor
1110916|NCT01527058|68Ga-BNOTA-PRGD2
1110917|NCT01527058|PET/CT
1110918|NCT01527058|efficacy and safety
1110919|NCT01527032|amyloidosis
1110920|NCT01527032|stem cell transplant
1110921|NCT01527019|Acute Cystitis
1110922|NCT01526967|ostomy
1110923|NCT01526967|peristomal skin breakdown
1110924|NCT01526967|ConvaTec Moldable Skin Barriers
1110925|NCT01526928|cancer
1110926|NCT01526928|metastatic
1110927|NCT01526928|locally advanced
1110928|NCT01526928|lung
1110929|NCT01526928|non-small cell lung cancer
1110930|NCT01526928|NSCLC
1110931|NCT01526928|epidermal growth factor receptor
1110932|NCT01526928|EGFR
1110933|NCT01526928|T790M
1110934|NCT01526928|CO-1686
1110935|NCT01526928|unresectable
1110936|NCT01526928|recurrent
1110937|NCT01526928|EGFR-directed therapy
1110938|NCT01526928|irreversible EGFR inhibitor
1110939|NCT01526928|TIGER
1110940|NCT01526928|Rociletinib
1110941|NCT01526915|PRF
1110942|NCT01526915|PLATELET RICH FIBRIN
1110943|NCT01526915|BISPHOSPHONATES
1110944|NCT01526902|contact lenses
1110945|NCT01526889|Non-infectious uveitis
1110946|NCT01526889|Panuveitis
1110947|NCT01526889|Vitreous haze
1110948|NCT01526889|Visual acuity
1110949|NCT01526876|Intracranial Pressure
1110950|NCT01526876|Cerebral Perfusion Pressure
1110951|NCT01526876|Clevidipine Butyrate
1110952|NCT01526863|Allergy
1110953|NCT01526863|Egg
1110954|NCT01526850|cGVHD
1110955|NCT01526837|Brain tumor
1110956|NCT01526837|GBM
1110957|NCT01526837|Brain cancer
1110958|NCT01526811|Endurant
1110959|NCT01526811|Stent Graft
1110960|NCT01526811|Abdominal Aortic Aneurysm
1110961|NCT01526798|End-Stage Renal Disease (ESRD)
1110962|NCT01526798|chronic Inflammation
1110963|NCT01526798|EPO Resistance
1110964|NCT01526798|ESA Resistance
1110965|NCT01526798|high cut-off dialysis
1110966|NCT01526798|hemodialysis
1110967|NCT01526772|Transnasal
1110968|NCT01526772|Transoral
1110969|NCT01526772|Roux en Y gastric bypass
1110970|NCT01526772|Upper Endoscopy
1110971|NCT01526772|Obesity
1110972|NCT01526759|dietary fiber
1110973|NCT01526759|energy intake
1110974|NCT01526759|satiety
1110975|NCT01526759|physicochemical properties
1110976|NCT01526759|men and women
1110977|NCT01526759|Healthy adults
1110978|NCT01526746|End stage renal disease
1110979|NCT01526746|ESRD
1110980|NCT01526746|kidney disease
1110981|NCT01526746|renal impairment
1110982|NCT01526746|renal
1110983|NCT01526733|Type 1 Diabetes
1110984|NCT01526733|Continuous Subcutaneous Insulin Infusion (CSII)
1110985|NCT01526720|Type 2 diabetes mellitus
1110986|NCT01526720|Beta cell function
1110987|NCT01526720|Insulin sensitivity
1110988|NCT01526720|Genetics of diabetes
1110989|NCT01526707|To identify changes in FKBP51 expression with inhaled steroid treatment in asthma
1110990|NCT01526694|relapsed or refractory multiple myeloma
1110991|NCT01526681|Sensory Nerve
1110992|NCT01526681|Mixed Nerve
1110993|NCT01526681|Motor Nerve
1110994|NCT01526668|Benign gynecological disease
1110995|NCT01526668|Surgery
1110996|NCT01526668|Postoperative follow-up strategy
1110997|NCT01526668|Pain threshold
1110998|NCT01526668|Chronic pelvic pain
1110999|NCT01526668|[E04.950.300.399]
1111000|NCT01526668|[C13.351.500]
1111001|NCT01526668|[F02.463.593.710.560]
1111002|NCT01526668|[N02.421.585.722.700]
1111003|NCT01526668|Postoperative Care
1111004|NCT01526655|Endometrial cancer
1111005|NCT01526655|Robot assisted laparoscopy
1111006|NCT01526655|Abdominal hysterectomy
1111007|NCT01526655|Fast track program
1111008|NCT01526629|ICD
1111009|NCT01526629|Remote follow-up
1111010|NCT01526616|PCOS
1111011|NCT01526616|metformin
1111012|NCT01526616|spironolactone
1111013|NCT01526616|metabolic syndrome
1111014|NCT01526616|hyperandrogenism
1111015|NCT01526603|peripheral blood stem cell transplantation
1111016|NCT01526603|autologous stem cell transplant
1111017|NCT01526577|phase1
1111018|NCT01526577|healthy subjects
1111019|NCT01526577|antiplatelet agent
1111020|NCT01526564|Chemotherapy-induced peripheral neuropathy (CIPN)
1111021|NCT01526551|Human Papillomavirus
1111022|NCT01526525|tramadol
1111023|NCT01526525|ketamine
1111024|NCT01526525|parecoxib
1111025|NCT01526525|paracetamol
1111026|NCT01526525|numerical rating scale (NRS)
1111027|NCT01526525|McGill (SF-MPQ)
1111028|NCT01526525|electronic pressure algometer
1111029|NCT01526525|Spielberger State Trait Anxiety Inventory STAI Y-6 item
1111030|NCT01526512|Metronomic cyclophosphamide
1111031|NCT01526512|Metronomic capecitabine
1111032|NCT01526512|HER2-negative breast cancer
1111033|NCT01526499|Metronomic cyclophosphamide
1111034|NCT01526499|metastatic breast cancer
1111035|NCT01526499|first line
1111036|NCT01526499|docetaxel
1111037|NCT01526486|melanoma
1111038|NCT01526486|urology
1111039|NCT01526486|inguinal
1111040|NCT01526486|lymph nodes
1111041|NCT01526486|groin
1111042|NCT01526486|lymphadenectomy
1111043|NCT01526486|groin dissection
1111044|NCT01526486|skin cancer
1111045|NCT01526486|penile cancer
1111046|NCT01526486|urethral cancer
1111047|NCT01526486|scrotal cancer
1111048|NCT01526486|Paget's disease
1111049|NCT01526473|Alphavirus
1111050|NCT01526473|Vaccine
1111051|NCT01526473|Immunotherapy
1111052|NCT01526473|HER2
1111053|NCT01526460|Platelet
1111054|NCT01526460|Atorvastatin
1111055|NCT01526460|Rosuvastatin
1111056|NCT01526460|Multiplate
1111057|NCT01526460|reactivity
1111058|NCT01526447|Neck Pain
1111059|NCT01526447|Craniosacral Manipulation
1111060|NCT01526447|Complementary Therapies
1111061|NCT01526447|Randomized Controlled Trial
1111062|NCT01526447|Sensory Thresholds
1111063|NCT01526447|Quality of Life
1111064|NCT01526434|Cimzia
1111065|NCT01526434|Non-interventional
1111066|NCT01526434|Multicenter
1111067|NCT01526434|Postmarketing
1111068|NCT01526434|Local
1111069|NCT01526421|HIV
1111070|NCT01526421|Antiretroviral therapy, highly active
1111071|NCT01526408|Meniere's Disease
1111072|NCT01526408|Vertigo
1111073|NCT01526408|Hearing loss
1111074|NCT01526408|Tinnitus
1111075|NCT01526408|Anti-viral
1111076|NCT01526408|Famciclovir
1111077|NCT01526395|electroconvulsive therapy
1111078|NCT01526395|ECT
1111079|NCT01526395|unmodified
1111080|NCT01526395|anesthesia
1111081|NCT01526395|propofol
1111082|NCT01526382|septic shock
1111083|NCT01526382|acute respiratory distress syndrome
1111084|NCT01526382|transpulmonary thermodilution technique
1111085|NCT01526382|mortality
1111086|NCT01526369|HER2-positive metastatic breast cancer.
1111087|NCT01526356|Angiofibroma
1111088|NCT01526356|Tuberous Sclerosis
1111089|NCT01526356|Rapamycin
1111090|NCT01526356|Sirolimus
1111091|NCT01526356|mTOR
1111092|NCT01526343|Patients
1111093|NCT01526330|Degenerative disc disease
1111094|NCT01526330|YH14618
1111095|NCT01526330|Penial 2000
1111096|NCT01526330|Penial 2K
1111097|NCT01526317|Drug interaction
1111098|NCT01526317|Rosuvastatin
1111099|NCT01526317|Metformin SR
1111100|NCT01526317|Pharmacokinetic
1111101|NCT01526291|Myopia
1111102|NCT01526291|Hyperopia
1111103|NCT01526291|Astigmatism
1111104|NCT01526291|Patient-reported outcomes
1111105|NCT01526291|Patient satisfaction
1111106|NCT01526291|Refractive Error
1111107|NCT01526291|Emmetropia
1111108|NCT01526291|Dry eyes
1111109|NCT01526291|glare
1111110|NCT01526291|halos
1111111|NCT01526291|patient expectations
1111112|NCT01526278|alendronate
1111113|NCT01526278|Maxmarvil®
1111114|NCT01526265|Smoking Cessation
1111115|NCT01526265|Work-site
1111116|NCT01526265|Incentives
1111117|NCT01526265|Health Behavior
1111118|NCT01526265|Smoking
1111119|NCT01526252|speckle tracking echocardiography
1111120|NCT01526252|database
1111121|NCT01526239|Colorectal cancer screening
1111122|NCT01526239|colon cancer screening
1111123|NCT01526239|colonoscopy
1111124|NCT01526226|High flow nasal cannula
1111125|NCT01526226|Discomfort
1111126|NCT01526200|CLM
1111127|NCT01526187|Public Health and Epidemiology
1111128|NCT01526187|Bacteriology
1111129|NCT01526187|Infectious and Tropical
1111130|NCT01526174|autoimmune
1111131|NCT01526174|hearing loss
1111132|NCT01526174|bilateral hearing loss
1111133|NCT01526174|steroid-dependent
1111134|NCT01526161|Asthma
1111135|NCT01526161|Children
1111136|NCT01526161|Therapy
1111137|NCT01526161|Fluticasone
1111138|NCT01526161|Salmeterol
1111139|NCT01526161|Montelukast
1111140|NCT01526135|National multicentric phase III superiority trial
1111141|NCT01526122|Clopidogrel
1111142|NCT01526122|Aspirin
1111143|NCT01526122|coadministration
1111144|NCT01526109|elderly
1111145|NCT01526109|quality of life
1111146|NCT01526109|functional capacity
1111147|NCT01526109|cognitive function
1111148|NCT01526109|physical exercise
1111149|NCT01526083|Male Healthy Volunteers
1111150|NCT01526057|rheumatoid arthritis
1111151|NCT01526057|rituximab
1111152|NCT01526057|methotrexate
1111153|NCT01526057|anti-TNF
1111154|NCT01526044|hyperglycemia
1111155|NCT01526044|hypoglycemia
1111156|NCT01526044|insulin
1111157|NCT01526044|critical illness
1111158|NCT01526044|intensive insulin therapy
1111159|NCT01526044|continuous glucose monitoring
1111160|NCT01526044|CGM
1111161|NCT01526044|interstitial fluid glucose
1111162|NCT01526044|intensive care unit
1111163|NCT01526044|Blood glucose
1111164|NCT01526031|frozen shoulder
1111165|NCT01526031|bee venom acupuncture
1111166|NCT01526018|Intake
1111167|NCT01526018|Formula feeding
1111168|NCT01525992|Community Pharmacy Services
1111169|NCT01525992|Pharmacists
1111170|NCT01525992|Diabetes Mellitus
1111171|NCT01525992|Diabetes Mellitus, Type 2
1111172|NCT01525992|Self Care
1111173|NCT01525992|Randomized Controlled Trial
1111174|NCT01525979|Stroke rehabilitation
1111175|NCT01525979|Unilateral arm training
1111176|NCT01525979|Bilateral arm training
1111177|NCT01525979|Robot-assisted arm training
1111178|NCT01525979|Kinematic analysis
1111179|NCT01525979|Functional magnetic resonance image
1111180|NCT01525979|Motor recovery
1111181|NCT01525979|Quality of life
1111182|NCT01525953|esophageal cancer
1111183|NCT01525953|radiochemotherapy
1111184|NCT01525953|prognosis
1111185|NCT01525940|colon capsule endoscopy
1111186|NCT01525940|CT-colonography
1111187|NCT01525940|Patients
1111188|NCT01525940|incomplete colonoscopy
1111189|NCT01525927|Oropharyngeal Neoplasms
1111190|NCT01525927|Neoplasms, Oropharyngeal
1111191|NCT01525927|Oropharynx Neoplasms
1111192|NCT01525914|prostate cancer
1111193|NCT01525914|PSA kinetics
1111194|NCT01525914|PSA doubling time
1111195|NCT01525914|active surveillance
1111196|NCT01525901|SHANK3
1111197|NCT01525901|IGF-1
1111198|NCT01525901|Autism
1111199|NCT01525888|Contrast induced nephropathy
1111200|NCT01525875|pseudoxanthoma elasticum
1111201|NCT01525875|calcification
1111202|NCT01525836|Purpura
1111203|NCT01525836|Idiopathic Thrombocytopenic Purpura
1111204|NCT01525797|Liver Transplant
1111205|NCT01525784|rtCGMS
1111206|NCT01525784|glycemic control
1111207|NCT01525784|type 1 diabetes mellitus
1111208|NCT01525784|youth
1111209|NCT01525771|Advanced Gastric cancer
1111210|NCT01525771|Xeloda (Capecitabine)
1111211|NCT01525771|Cisplatin
1111212|NCT01525771|Taxotere (Docetaxel)
1111213|NCT01525732|Achalasia, Hypertensive LES
1111214|NCT01525719|cholangiocarcinoma
1111215|NCT01525719|RAD001
1111216|NCT01525719|everolimus
1111217|NCT01525706|Endoscopic Ultrasound
1111218|NCT01525706|Pancreatic Mucinous Cystic Neoplasm
1111219|NCT01525706|Fine Needle Injection
1111220|NCT01525706|Ethanol Ablation
1111221|NCT01525706|Paclitaxel Ablation
1111222|NCT01525693|diabetes
1111223|NCT01525693|diabetics
1111224|NCT01525693|high glucose
1111225|NCT01525693|Chinese patients
1111226|NCT01525680|PTSD
1111227|NCT01525667|THA
1111228|NCT01525667|Muscle injury
1111229|NCT01525654|Rheumatoid Arthritis
1111230|NCT01525654|peer support
1111231|NCT01525654|self-efficacy
1111232|NCT01525654|medication adherence
1111233|NCT01525602|advanced, incurable solid tumors
1111234|NCT01525589|Breast cancer
1111235|NCT01525589|PM01183
1111236|NCT01525589|lurbinectedin
1111237|NCT01525589|Pharma Mar
1111238|NCT01525576|booster program
1111239|NCT01525576|internet
1111240|NCT01525576|cbt
1111241|NCT01525576|Study the specific effects of adding a booster program
1111242|NCT01525563|Duphaston Study
1111243|NCT01525550|neuroendocrine tumors
1111244|NCT01525550|adenoma islet cells
1111245|NCT01525550|carcinoma islet cells
1111246|NCT01525550|pancreatic neoplasms
1111247|NCT01525550|angiogenesis inhibitors
1111248|NCT01525550|sunitinib
1111249|NCT01525550|neoplasms
1111250|NCT01525550|carcinoma
1111251|NCT01525550|adenoma
1111252|NCT01525537|Anesthesia General
1111253|NCT01525537|Anesthetics Inhalation
1111254|NCT01525537|Diagnostic techniques and procedures
1111255|NCT01525524|tDCS
1111256|NCT01525524|Major Depression
1111257|NCT01525524|Stroke
1111258|NCT01525498|Pelvic Organ Prolapse
1111259|NCT01525498|Catheterization
1111260|NCT01525498|Urinary tract infection
1111261|NCT01525498|Urinary retention
1111262|NCT01525472|obesity
1111263|NCT01525472|adipose tissue
1111264|NCT01525472|angiogenesis
1111265|NCT01525472|senecence
1111266|NCT01525459|Glioma
1111267|NCT01525459|PBMC subpopulations
1111268|NCT01525459|Gene expression
1111269|NCT01525459|Metabolomics
1111270|NCT01525459|Immunological status
1111271|NCT01525459|miRNA
1111272|NCT01525459|Proteomics
1111273|NCT01525446|NSCLC
1111274|NCT01525446|Lung Cancer
1111275|NCT01525394|lymphomas
1111276|NCT01525394|Refractory solid tumors
1111277|NCT01525368|mild cognitive impairment
1111278|NCT01525368|Alzheimer's disease
1111279|NCT01525368|cognitive intervention
1111280|NCT01525368|cognitive reserve
1111281|NCT01525355|EUS
1111282|NCT01525355|ERCP
1111283|NCT01525355|Intraoperative cholangiogram
1111284|NCT01525355|Cholecystectomy
1111285|NCT01525355|Common Bile Duct Stones
1111286|NCT01525355|Strictures
1111287|NCT01525355|Stenosis
1111288|NCT01525355|Duodenum
1111289|NCT01525355|Dilated Bile duct
1111290|NCT01525355|Non-filling of the duodenum by contrast
1111291|NCT01525329|Actinic Keratosis
1111292|NCT01525329|Photodynamic Therapy
1111293|NCT01525316|Late Onset Neonatal Sepsis
1111294|NCT01525316|Neonates
1111295|NCT01525316|Lactoferrin
1111296|NCT01525316|Infections
1111297|NCT01525316|Prevention
1111298|NCT01525316|Neurodevelopment
1111299|NCT01525303|headaches
1111300|NCT01525303|behavioral treatment
1111301|NCT01525303|physical activity
1111302|NCT01525290|wake-up stroke
1111303|NCT01525290|thrombolysis
1111304|NCT01525290|magnetic resonance imaging (MRI)
1111305|NCT01525290|diffusion weighted imaging (DWI)
1111306|NCT01525290|fluid attenuated inversion recovery (FLAIR)
1111307|NCT01525264|Mammography
1111308|NCT01525251|primary caregiver
1111309|NCT01525251|neuroblastoma
1111310|NCT01525251|support group
1111311|NCT01525251|posttraumatic stress
1111312|NCT01525251|uncertainty
1111313|NCT01525199|Non-Small Cell Lung Cancer,
1111314|NCT01525199|Epidermal Growth Factor Receptor mutation,
1111315|NCT01525199|Lung cancer,
1111316|NCT01525199|Lung adenocarcinoma
1111317|NCT01525186|Weight
1111318|NCT01525186|Food intakes
1111319|NCT01525186|Feeding
1111320|NCT01525160|Clot structure
1111321|NCT01525160|Haemostasis
1111322|NCT01525160|Gel point
1111323|NCT01525160|Fractal dimension
1111324|NCT01525160|serum amyloid A
1111325|NCT01525160|C-reactive protein
1111326|NCT01525160|vascular cell adhesion molecule-1
1111327|NCT01525160|intercellular adhesion molecule-1
1111328|NCT01525134|Tests, Diagnostic
1111329|NCT01525134|Mycobacterium tuberculosis
1111330|NCT01525134|Mycobacterium tuberculosis antigens
1111331|NCT01525134|TB
1111332|NCT01525134|Tuberculosis
1111333|NCT01525134|Tuberculosis, Pulmonary
1111334|NCT01525134|Tuberculosis, Miliary
1111335|NCT01525134|Lipoarabinomannan
1111336|NCT01525121|mechanical ventilation
1111337|NCT01525121|chest physiotherapy
1111338|NCT01525121|critical care
1111339|NCT01525121|pneumonia
1111340|NCT01525121|Mechanically ventilated patients with pulmonary infection.
1111341|NCT01525108|Medication adherence
1111342|NCT01525108|Blood pressure
1111343|NCT01525108|Home-based blood pressure measurement
1111344|NCT01525108|Blood Pressure Determination
1111345|NCT01525108|Blood Pressure Monitors
1111346|NCT01525108|Blood Pressure Monitoring, Ambulatory
1111347|NCT01525095|Candida
1111348|NCT01525095|Diagnostic Assay
1111349|NCT01525095|Blood culture
1111350|NCT01525095|Sepsis
1111351|NCT01525095|T2 Magnetic Relaxation
1111352|NCT01525056|rectal cancer
1111353|NCT01525056|imaging
1111354|NCT01525056|PET
1111355|NCT01525056|MRI
1111356|NCT01525043|Epicondylitis
1111357|NCT01525004|Solid organ transplant
1111358|NCT01525004|Flu vaccine
1111359|NCT01524965|Locking Plate
1111360|NCT01524965|Physiotherapy
1111361|NCT01524926|Phase 2
1111362|NCT01524926|Crizotinib
1111363|NCT01524926|Anaplastic large cell lymphoma
1111364|NCT01524926|Inflammatory myofibroblastic tumor
1111365|NCT01524926|Papillary renal cell carcinoma type 1
1111366|NCT01524926|Alveolar soft part sarcoma
1111367|NCT01524926|Clear cell sarcoma
1111368|NCT01524926|Alveolar rhabdomyosarcoma
1111369|NCT01524874|vitamin d
1111370|NCT01524874|cholecalciferol
1111371|NCT01524874|nutritional supplements
1111372|NCT01524874|hypovitaminosis d
1111373|NCT01524874|klotho
1111374|NCT01524874|toll like receptor 4
1111375|NCT01524861|Tako-Tsubo
1111376|NCT01524861|Sympathetic heart innervation
1111377|NCT01524861|MIBG
1111378|NCT01524861|Alpha-lipoic acid
1111379|NCT01524861|L-acetyl carnitine
1111380|NCT01524848|Clinical trial
1111381|NCT01524848|Investigational drugs
1111382|NCT01524848|Gastrointestinal stromal tumors
1111383|NCT01524848|Pazopanib
1111384|NCT01524835|Tissue Donors
1111385|NCT01524835|Lung
1111386|NCT01524835|Transplants
1111387|NCT01524835|Transplantation
1111388|NCT01524822|Military
1111389|NCT01524822|Traumatic Brain Injury
1111390|NCT01524822|Cognitive Testing
1111391|NCT01524822|Neuroimaging
1111392|NCT01524822|Brain Function
1111393|NCT01524796|Real-life
1111394|NCT01524796|non-interventional
1111395|NCT01524796|observational
1111396|NCT01524796|peripheral neuropathic pain
1111397|NCT01524796|Lyrica
1111398|NCT01524796|pregabalin
1111399|NCT01524783|Neuroendocrine tumor
1111400|NCT01524783|NET
1111401|NCT01524783|progressive
1111402|NCT01524783|advanced
1111403|NCT01524783|gastrointestinal
1111404|NCT01524783|GI or lung origin
1111405|NCT01524783|nonfunctional
1111406|NCT01524783|everolimus
1111407|NCT01524783|Advanced NET of GI origin
1111408|NCT01524783|Advanced NET of lung origin
1111409|NCT01524744|oral lichen planus treatment pimecrolimus
1111410|NCT01524718|radiation
1111411|NCT01524718|time surgery
1111412|NCT01524705|Pilot Study
1111413|NCT01524705|Prospective Randomized Trial
1111414|NCT01524705|Comparative Effectiveness
1111415|NCT01524705|Glycemic Variability
1111416|NCT01524705|insulin glargine
1111417|NCT01524705|exenatide
1111418|NCT01524705|basal insulin
1111419|NCT01524705|bolus insulin
1111420|NCT01524679|chronic hepatitis B
1111421|NCT01524653|VTE
1111422|NCT01524653|DVT
1111423|NCT01524653|Chemo
1111424|NCT01524653|Metastatic
1111425|NCT01524653|Advanced
1111426|NCT01524653|Systemic therapy
1111427|NCT01524653|statin
1111428|NCT01524653|biomarkers
1111429|NCT01524640|oral cholera vaccine
1111430|NCT01524640|safety and immunogenicity
1111431|NCT01524640|bridging study
1111432|NCT01524640|ethiopia
1111433|NCT01524627|Smokers
1111434|NCT01524627|fMRI
1111435|NCT01524627|varenicline
1111436|NCT01524614|continuous positive airway pressure
1111437|NCT01524614|nasal mask
1111438|NCT01524614|upper airway obstruction
1111439|NCT01524601|Immunosuppression
1111440|NCT01524601|Everolimus
1111441|NCT01524601|rosuvastatin
1111442|NCT01524601|fluvastatin
1111443|NCT01524601|Lipid lowering
1111444|NCT01524588|Genotype
1111445|NCT01524588|Phenotype
1111446|NCT01524588|Genotypic Variation Between Patients
1111447|NCT01524588|Genotypic Phenotypic Relationships
1111448|NCT01524575|pancreatic cancer
1111449|NCT01524575|ERCC1
1111450|NCT01524575|oxaliplatin
1111451|NCT01524575|gemcitabine
1111452|NCT01524562|Fibrosis
1111453|NCT01524562|Cirrhosis
1111454|NCT01524562|Africa
1111455|NCT01524562|Schistosomiasis
1111456|NCT01524562|Aflatoxin
1111457|NCT01524562|Liver Disease
1111465|NCT01524536|Hypereosinophilia
1111466|NCT01524536|Hypereosinophilic Syndrome
1111467|NCT01524536|Corticosteroids
1111468|NCT01524536|Therapy
1111469|NCT01524536|HES
1111470|NCT01524523|Gene Expression
1111471|NCT01524523|Acute Pain
1111472|NCT01524523|Nitric Oxide
1111473|NCT01524523|Pain
1111474|NCT01524523|Bone Marrow
1111475|NCT01524510|OSAS
1111476|NCT01524510|AHI
1111477|NCT01524510|MRA
1111478|NCT01524510|CFD
1111479|NCT01524497|losing interest and feelings of guilt
1111480|NCT01524497|poor concentration
1111481|NCT01524497|loss of appetite
1111482|NCT01524497|suicide
1111483|NCT01524484|Data quality
1111484|NCT01524484|Anesthesia
1111485|NCT01524484|Quality assurance
1111486|NCT01524471|Hypertensive LES
1111487|NCT01524445|Bortezomib
1111488|NCT01524445|Velcade
1111489|NCT01524445|multiple myeloma
1111490|NCT01524445|retrospective study, response rate, medical resource utilization
1111491|NCT01524432|Clotrimazole
1111492|NCT01524432|Microcapsules
1111493|NCT01524419|spontaneous labor
1111494|NCT01524419|term
1111495|NCT01524419|surgical
1111496|NCT01524419|mechanical
1111497|NCT01524419|fetal or maternal complications
1111498|NCT01524406|Muscle Atrophy
1111499|NCT01524393|Assisted Reproductive Techniques
1111500|NCT01524393|Pregnancy
1111501|NCT01524393|Pulmonary Embolism
1111502|NCT01524393|Venous Thromboembolism
1111503|NCT01524380|Schizophrenia
1111504|NCT01524380|clinical trial
1111505|NCT01524380|risperidone
1111506|NCT01524380|ginkgo biloba extract
1111507|NCT01524380|antioxidant
1111508|NCT01524354|depth of anesthesia
1111509|NCT01524354|valve surgery
1111510|NCT01524341|Acute malaria
1111511|NCT01524341|KAE609
1111512|NCT01524328|Complementary and alternative medicine
1111513|NCT01524328|HRQoL, Inflammatory bowel disease
1111514|NCT01524315|Thiamine
1111515|NCT01524315|Vitamin B1
1111516|NCT01524315|Thiamine Deficiency
1111517|NCT01524315|Thiamine supplementation
1111518|NCT01524315|Cardiac surgery
1111519|NCT01524315|Lactic Acid
1111520|NCT01524302|pneumonia
1111521|NCT01524302|ceftaroline
1111522|NCT01524302|community-aquired
1111523|NCT01524250|Multiple Sclerosis
1111524|NCT01524250|relapse
1111525|NCT01524250|demyelination
1111526|NCT01524250|treatment
1111527|NCT01524250|corticosteroids
1111528|NCT01524224|Metastases
1111529|NCT01524224|Neoplasm
1111530|NCT01524224|Advanced Cancer
1111531|NCT01524224|Metastatic Cancer
1111532|NCT01524211|Aortic Aneurysms
1111533|NCT01524185|childhood trauma
1111534|NCT01524185|intergenerational trauma
1111535|NCT01524185|child neglect
1111536|NCT01524185|child maltreatment
1111537|NCT01524185|mental health
1111538|NCT01524172|child trauma exposure
1111539|NCT01524172|mental health
1111540|NCT01524172|yoga
1111541|NCT01524172|mood regulation
1111542|NCT01524172|child maltreatment
1111543|NCT01524159|cardiovascular disease
1111544|NCT01524146|Unresectable Cholangiocarcinoma
1111545|NCT01524146|Biliary obstruction
1111546|NCT01524146|Stent obstruction
1111547|NCT01524146|Biliary stricture
1111548|NCT01524146|Photodynamic therapy
1111549|NCT01524146|PDT
1111550|NCT01524146|Ablation
1111551|NCT01524133|combat-related PTSD
1111552|NCT01524133|Posttraumatic stress disorder
1111553|NCT01524133|prolonged exposure therapy
1111554|NCT01524133|sertraline
1111555|NCT01524133|military
1111556|NCT01524133|veterans
1111557|NCT01524133|VA hospital
1111558|NCT01524133|mental illness
1111559|NCT01524120|Mucosal healing
1111560|NCT01524107|Prophylaxis Antibiotics
1111561|NCT01524107|Maternal Complications
1111562|NCT01524107|Neonatal Complications
1111563|NCT01524107|Cord Prolapse
1111564|NCT01524107|Elective Caesarian Section
1111565|NCT01524107|Maternal Morbidity
1111566|NCT01524107|Neonatal Morbidity
1111567|NCT01524094|colorectal cancer
1111568|NCT01524094|cytoreductive surgery
1111569|NCT01524094|intraperitoneal chemotherapy
1111570|NCT01524094|systemic chemotherapy
1111571|NCT01524094|Peritoneal Metastatic Disease From the Colon or Rectum
1111572|NCT01524081|antibiotic prophylaxis
1111573|NCT01524081|emergent surgery
1111574|NCT01524081|surgical site infection
1111575|NCT01524068|Acute Idiopathic Pulmonary Fibrosis Exacerbations
1111576|NCT01524068|Idiopathic Pulmonary Fibrosis
1111577|NCT01524068|IPF
1111578|NCT01524042|Satisfaction
1111579|NCT01524042|colonoscopy
1111580|NCT01524042|double pants
1111581|NCT01524042|single pants
1111582|NCT01524029|Digital Breast Tomosynthesis
1111583|NCT01524029|Digital Mammography
1111584|NCT01524029|Breast cancer detection
1111585|NCT01524016|Oncogenic osteomalacia
1111586|NCT01524016|mesenchymal tumor
1111587|NCT01524016|Somatostatin receptor
1111588|NCT01524016|68Ga-DOTATATE
1111589|NCT01524016|PET/CT
1111590|NCT01524003|community based participatory research
1111591|NCT01523977|ALL
1111592|NCT01523977|pediatric
1111593|NCT01523977|relapse
1111594|NCT01523964|DMD
1111595|NCT01523964|EIM
1111596|NCT01523964|Duchenne Muscular Dystrophy
1111597|NCT01523964|electrical impedance myography
1111598|NCT01523951|topical local anaesthesia
1111599|NCT01523951|cooling
1111600|NCT01523951|capsaicin 8%
1111601|NCT01523951|epidermal nerve fiber density
1111602|NCT01523951|treatment pain
1111603|NCT01523925|Functional electrical therapy
1111604|NCT01523925|Bilateral arm training
1111605|NCT01523925|Constraint induced therapy
1111606|NCT01523925|Stroke rehabilitation
1111607|NCT01523925|Clinical evaluation
1111608|NCT01523925|Kinematic analysis
1111609|NCT01523912|radiofrequency ablation
1111610|NCT01523912|gastric dysplasia
1111611|NCT01523912|gastric neoplasia
1111612|NCT01523899|SSTI
1111613|NCT01523899|cutaneous abscess
1111614|NCT01523899|boil
1111615|NCT01523847|Hodgkin Lymphoma
1111616|NCT01523847|Cardiopathic
1111617|NCT01523847|elderly
1111618|NCT01523847|Myocet
1111619|NCT01523834|Diffuse Large B-cell Lymphoma (DLBCL)
1111620|NCT01523834|Panobinostat
1111621|NCT01523834|Patients with relapsed/refractory DLBCL.
1111622|NCT01523808|pancreatic cancer
1111623|NCT01523808|asparaginase
1111624|NCT01523795|Energy intake
1111625|NCT01523795|Video games
1111626|NCT01523795|Television
1111627|NCT01523795|Physical activity
1111628|NCT01523795|Obesity
1111629|NCT01523782|Acute Lymphoblastic leukemia
1111630|NCT01523782|Elderly patient
1111631|NCT01523782|Asparaginase
1111632|NCT01523769|prematurity
1111633|NCT01523769|umbilical cord milking
1111634|NCT01523769|delayed cord clamping
1111635|NCT01523769|neonatal transfusion
1111636|NCT01523730|Schizophrenia
1111637|NCT01523730|Nicotine
1111638|NCT01523730|Transcranial Magnetic Stimulation
1111639|NCT01523730|Cognition
1111640|NCT01523730|EEG
1111641|NCT01523717|procalcitonin
1111642|NCT01523717|decrease over 72 hours
1111643|NCT01523717|severe sepsis
1111644|NCT01523717|septic shock
1111645|NCT01523691|Healthy individuals
1111646|NCT01523678|Ovarian Cancer
1111647|NCT01523678|Endometrial Cancer
1111648|NCT01523678|Endometrial Carcinoma
1111649|NCT01523678|Uterine Cervical Cancer
1111650|NCT01523678|Paclitaxel
1111651|NCT01523678|Carboplatin
1111652|NCT01523678|Neupogen
1111653|NCT01523678|Filgrastim
1111654|NCT01523678|Ovarian Diseases
1111655|NCT01523678|Peritoneal Diseases
1111656|NCT01523678|Fallopian Tube Diseases
1111657|NCT01523678|Endocrine System Diseases
1111658|NCT01523678|Endometrial Diseases
1111659|NCT01523678|Uterine Cervical Diseases
1111660|NCT01523678|Neoplasms
1111661|NCT01523678|Neoplasms, Glandular and Epithelial
1111662|NCT01523678|Ovarian Neoplasms
1111663|NCT01523678|Peritoneal Neoplasms
1111664|NCT01523678|Fallopian Tube Neoplasms
1111665|NCT01523678|Neoplasms, Endometrial
1111666|NCT01523678|Cervical Neoplasms
1111667|NCT01523678|Genital Neoplasms, Female
1111668|NCT01523678|Urogenital Neoplasms
1111669|NCT01523678|Antineoplastic Agents, Phytogenic
1111670|NCT01523678|Genital Diseases, Female
1111671|NCT01523639|liver injury
1111672|NCT01523639|steatosis
1111673|NCT01523639|KRAS-Wild-Type
1111674|NCT01523639|metastatic colorectal cancer
1111675|NCT01523639|metformin
1111676|NCT01523639|placebo
1111677|NCT01523639|chemotherapy
1111678|NCT01523626|Trauma
1111679|NCT01523626|Injur*
1111680|NCT01523626|Emergen*
1111681|NCT01523626|Computed Tomography
1111682|NCT01523626|Total body
1111683|NCT01523626|TBCT
1111684|NCT01523626|Whole body
1111685|NCT01523626|WBCT
1111686|NCT01523626|Full body
1111687|NCT01523626|Pan CT
1111688|NCT01523613|Dental caries
1111689|NCT01523613|Proximal surfaces
1111690|NCT01523613|Posterior teeth
1111691|NCT01523613|Carious lesions
1111692|NCT01523613|Tooth diseases
1111693|NCT01523613|Dental restorations
1111694|NCT01523613|Glass-ionomer
1111695|NCT01523600|whole body vibration
1111696|NCT01523600|physical functioning
1111697|NCT01523600|falls
1111698|NCT01523600|older people
1111699|NCT01523600|prevention
1111700|NCT01523574|oxaliplatin
1111701|NCT01523574|vitamin e
1111702|NCT01523574|neuropathy
1111703|NCT01523574|peripheral
1111704|NCT01523574|prophylaxis
1111705|NCT01523561|dance
1111706|NCT01523561|intervention
1111707|NCT01523561|adolescent
1111708|NCT01523561|girls
1111709|NCT01523548|Carbon Monoxide
1111710|NCT01523548|Hypertension, Pulmonary
1111711|NCT01523522|Fecal incontinence
1111712|NCT01523522|Myoblast
1111713|NCT01523522|Surgery
1111714|NCT01523509|Dental Caries
1111715|NCT01523509|Radiography, Dental
1111716|NCT01523509|Contrast media
1111717|NCT01523509|Tooth
1111718|NCT01523496|HIV
1111719|NCT01523496|Vitamin D Deficiency
1111720|NCT01523483|preterm birth
1111721|NCT01523483|preterm labor
1111722|NCT01523483|progesterone
1111723|NCT01523483|uterine electromyography
1111724|NCT01523483|cervical length
1111725|NCT01523470|non-invasive ventilator
1111726|NCT01523457|metastatic pancreatic cancer
1111727|NCT01523457|locally advanced pancreatic cancer
1111728|NCT01523457|FOLFIRINOX
1111729|NCT01523457|phase II
1111730|NCT01523457|progression free survival
1111731|NCT01523444|Adolescents
1111732|NCT01523444|Screening
1111733|NCT01523444|Advice
1111734|NCT01523444|Referral
1111735|NCT01523431|Colorectal cancer
1111736|NCT01523431|Irinotecan
1111737|NCT01523431|UGT1A1 genotype
1111738|NCT01523431|Neutropenia
1111739|NCT01523431|diarrhea
1111740|NCT01523431|response
1111741|NCT01523431|pharmacokinetic
1111742|NCT01523418|Xarelto
1111743|NCT01523418|Thromboembolism, Venous
1111744|NCT01523418|Orthopedic surgery
1111745|NCT01523418|Factor Xa inhibitor
1111746|NCT01523418|Observational study
1111747|NCT01523405|Non Interventional Study, Type II Diabetes Mellitus, Quality of Life
1111748|NCT01523392|Stable Coronary Artery Disease, CAD
1111749|NCT01523379|Causalgia
1111750|NCT01523379|CRPS
1111751|NCT01523379|complex regional pain syndrome
1111752|NCT01523379|Dynastat
1111753|NCT01523379|Parecoxib
1111754|NCT01523366|Stable Coronary Artery Disease, CAD
1111755|NCT01523353|Prehabilitation
1111756|NCT01523353|Exercise
1111757|NCT01523353|Colorectal Cancer
1111758|NCT01523353|Surgery
1111759|NCT01523327|Uric acid
1111760|NCT01523314|diabetic macular edema
1111761|NCT01523314|intravitreal injection
1111762|NCT01523314|dexamethasone
1111763|NCT01523314|Cyclodextrin
1111764|NCT01523314|eye drops
1111765|NCT01523314|bevacizumab
1111766|NCT01523314|macular laser
1111767|NCT01523301|Rotigotine
1111768|NCT01523301|Neupro
1111769|NCT01523301|Depressive Symptom
1111770|NCT01523301|Idiopathic Parkinson's disease
1111771|NCT01523275|mitomycin-C
1111772|NCT01523275|laryngotracheal stenosis
1111773|NCT01523275|subglottic stenosis
1111774|NCT01523275|tracheal stenosis
1111775|NCT01523275|endoscopic airway surgery
1111776|NCT01523262|preconditioning
1111777|NCT01523262|aortic aneurysm
1111778|NCT01523249|3D ultrasonography
1111779|NCT01523249|epidural
1111780|NCT01523249|neuraxial anesthesia
1111781|NCT01523249|neuraxial analgesia
1111782|NCT01523249|pregnant woman
1111783|NCT01523249|parturients
1111784|NCT01523236|Allergic Rhinitis
1111785|NCT01523236|Bioequivalence
1111786|NCT01523210|spasticity
1111787|NCT01523210|Diffusor tensor imaging
1111788|NCT01523210|distribution
1111789|NCT01523210|botulinum toxin
1111790|NCT01523210|physiotherapy
1111791|NCT01523197|Obstructive Sleep Apnea hypopnea Syndrome
1111792|NCT01523197|COPD
1111793|NCT01523197|overlap syndrome
1111794|NCT01523197|Auto-trilevel ventilation
1111795|NCT01523197|BiPAP ventilation
1111796|NCT01523184|Chronic constipation (CC)
1111797|NCT01523184|Functional Constipation (FC)
1111798|NCT01523184|Gastric Emptying
1111799|NCT01523184|Colon Transit
1111800|NCT01523184|multiple doses of YKP10811
1111801|NCT01523184|gastrointestinal transit
1111802|NCT01523184|colonic transit
1111803|NCT01523158|Allergic Rhinitis
1111804|NCT01523158|Immunotherapy
1111805|NCT01523145|Atrial fibrillation
1111806|NCT01523145|Radio Frequency Ablation
1111807|NCT01523145|Rehabilitation
1111808|NCT01523145|Physical capacity
1111809|NCT01523145|Quality of life
1111810|NCT01523145|Integrated rehabilitation
1111811|NCT01523106|Crohn's disease
1111812|NCT01523106|carnitine
1111813|NCT01523067|Vasomera
1111814|NCT01523067|PB1046
1111815|NCT01523067|Hypertension
1111816|NCT01523054|metoprolol, acute myocardial infarction, pharmacokinetics, pharmacodynamics
1111817|NCT01523015|Adenocarcinoma
1111818|NCT01523015|esophago-gastric cancer
1111819|NCT01523015|chemotherapy
1111820|NCT01523015|chemoradiotherapy
1111821|NCT01523015|surgery
1111822|NCT01522989|Cancer
1111823|NCT01522989|Advanced
1111824|NCT01522989|Refractory
1111825|NCT01522950|hypertension
1111826|NCT01522950|prevention
1111827|NCT01522950|endothelial function
1111828|NCT01522924|tobacco cessation treatment
1111829|NCT01522924|standardized patients
1111830|NCT01522924|dental students
1111831|NCT01522924|tobacco cessation treatment education
1111832|NCT01522898|Heart Failure
1111833|NCT01522898|Atrial Fibrillation
1111834|NCT01522885|Chest tube
1111835|NCT01522885|placement
1111836|NCT01522885|mal positioning
1111837|NCT01522872|TH-302
1111838|NCT01522872|Relapsed/Refractory Multiple Myeloma
1111839|NCT01522872|Bortezomib
1111840|NCT01522872|Phase 1/2
1111841|NCT01522872|Hypoxia
1111842|NCT01522872|Myeloma
1111843|NCT01522872|Evofosfamide
1111844|NCT01522872|Pomalidomide
1111845|NCT01522872|Pimonidazole
1111846|NCT01522859|COPD
1111847|NCT01522859|Telehealth
1111848|NCT01522859|health related quality of life
1111849|NCT01522833|NSLCL
1111850|NCT01522833|Erlotinib
1111851|NCT01522833|Tarceva
1111852|NCT01522807|Phase 1
1111853|NCT01522807|Single Doses
1111854|NCT01522807|Biocomparison
1111855|NCT01522807|Pharmacokinetics
1111856|NCT01522807|Healthy Volunteers
1111857|NCT01522768|ESOPHAGUS
1111858|NCT01522768|STOMACH
1111859|NCT01522768|Afatinib
1111860|NCT01522768|paclitaxel
1111861|NCT01522768|trastuzumab
1111862|NCT01522768|11-166
1111863|NCT01522755|Pacing lead
1111864|NCT01522755|implant
1111865|NCT01522755|pacemaker
1111866|NCT01522742|psoriasis
1111867|NCT01522742|cardiovascular disease risk
1111868|NCT01522742|atherosclerosis
1111869|NCT01522742|etanercept (enbrel)
1111870|NCT01522729|Chronic pulmonary obstructive disease
1111871|NCT01522729|Muscle dysfunction
1111872|NCT01522729|Exercise intolerance
1111873|NCT01522729|Muscle afferents
1111874|NCT01522729|Ventilation
1111875|NCT01522703|asthma
1111876|NCT01522703|allergic rhinitis
1111877|NCT01522703|dietary interventions
1111878|NCT01522703|mouse allergy
1111879|NCT01522690|Accelerometer
1111880|NCT01522690|gait analysis
1111881|NCT01522690|Healthy subjects
1111882|NCT01522677|tumor immunology
1111883|NCT01522677|neoadjuvant
1111884|NCT01522677|colonoscopy
1111885|NCT01522677|photosensitization
1111886|NCT01522651|Atrial Fibrillation
1111887|NCT01522651|Ranolazine
1111888|NCT01522651|Dronedarone
1111889|NCT01522651|Dual Chamber Pacemakers
1111890|NCT01522625|chronic hepatitis B
1111891|NCT01522625|hepatitis B viral DNA
1111892|NCT01522625|antiviral therapy
1111893|NCT01522625|Tenofovir
1111894|NCT01522612|KRAS Wild Type
1111895|NCT01522612|Frail Elderly
1111896|NCT01522612|QLQ-C30
1111897|NCT01522612|QLQ-ELD14
1111898|NCT01522612|CGA
1111899|NCT01522612|EGFR
1111900|NCT01522612|Cetuximab
1111901|NCT01522612|5-FU
1111902|NCT01522599|ARDS: Acute Respiratory Distress Syndrome
1111903|NCT01522599|LOW FLOW ECCO2-R: EXTRA-CORPOREAL CO2 REMOVAL
1111904|NCT01522599|VILI: Ventilator Induced Lung Injury
1111905|NCT01522573|Cholangiocarcinoma
1111906|NCT01522573|Pancreatic Cancer
1111907|NCT01522573|Bile Duct Cancer
1111908|NCT01522573|Biliary Stricture
1111909|NCT01522573|Biliary obstruction
1111910|NCT01522573|Stent obstruction
1111911|NCT01522573|Proximal duct stricture
1111912|NCT01522573|Distal duct stricture
1111913|NCT01522573|Ampullary Cancer
1111914|NCT01522573|Biliary sphincter stenosis
1111915|NCT01522573|Impacted stones
1111916|NCT01522573|Chronic pancreatitis
1111917|NCT01522573|Peri-ampullary diverticula
1111918|NCT01522573|Altered anatomy
1111919|NCT01522573|Endoscopic ultrasound
1111920|NCT01522573|Endoscopic Retrograde Cholangiopancreatography
1111921|NCT01522573|Multicenter
1111922|NCT01522560|CA2 and CA3 residents
1111923|NCT01522560|Pediatric Anesthesia
1111924|NCT01522547|Pomalidomide
1111925|NCT01522547|Sickle Cell Disease
1111926|NCT01522547|Fetal Hemoglobin
1111927|NCT01522534|injuries
1111928|NCT01522534|pain
1111929|NCT01522534|Block, Nerve
1111930|NCT01522534|morphine
1111931|NCT01522534|Prehospital Emergency Care
1111932|NCT01522521|AK156
1111933|NCT01522508|Analgesia
1111934|NCT01522508|Anesthetics
1111935|NCT01522508|Diagnostic Techniques and Procedures
1111936|NCT01522482|fatty acids
1111937|NCT01522482|cardiovascular disease
1111938|NCT01522482|genotype
1111939|NCT01522482|apoE
1111940|NCT01522469|FLT3
1111941|NCT01522469|Crenolanib
1111942|NCT01522469|Acute
1111943|NCT01522469|myeloid
1111944|NCT01522469|leukemia
1111945|NCT01522469|relapsed
1111946|NCT01522469|refractory
1111947|NCT01522443|prostate cancer
1111948|NCT01522443|castration resistant prostate cancer
1111949|NCT01522443|bone pain
1111950|NCT01522443|CRPC
1111951|NCT01522430|Resistant hypertension
1111952|NCT01522430|Renal denervation
1111953|NCT01522430|Ambulatory blood pressure
1111954|NCT01522430|Renal function
1111955|NCT01522430|Simplicity catheter
1111956|NCT01522430|Sham procedure
1111957|NCT01522404|Mild Cognitive Impairment
1111958|NCT01522404|Memory Loss
1111959|NCT01522404|Alzheimer's Disease
1111960|NCT01522378|cardiac resynchronization therapy
1111961|NCT01522365|Dental implants
1111962|NCT01522365|XiVE CAD/CAM bridge
1111963|NCT01522352|Bioprosthesis,
1111964|NCT01522352|aortic valve replacement
1111965|NCT01522352|Magna Ease
1111966|NCT01522352|Mitroflow
1111967|NCT01522352|Trifecta
1111968|NCT01522339|NICU
1111969|NCT01522339|MRI
1111970|NCT01522339|Neonatal
1111971|NCT01522339|Safety
1111972|NCT01522339|Efficacy
1111973|NCT01522339|Cincinnati
1111974|NCT01522326|Acute Mountain Sickness
1111975|NCT01522326|High Altitude Headache
1111976|NCT01522326|Lake Louise AMS Score
1111977|NCT01522326|Visual Analog Scale
1111978|NCT01522326|Ibuprofen
1111979|NCT01522326|Metoclopramide
1111980|NCT01522326|Nepal
1111981|NCT01522300|Tomosynthesis
1111982|NCT01522300|breast cancer
1111983|NCT01522300|specificity
1111984|NCT01522300|sensitivity
1111985|NCT01522300|To assess efficacy of Tomosynthesis by evaluating its sensitivity and specificity in detecting the multicentricity of mammary tumor
1111986|NCT01522287|Obsessive Compulsive Disorder
1111987|NCT01522287|Computer Assisted Therapy
1111988|NCT01522287|Cognitive Behavior Therapy
1111989|NCT01522287|Cognitive Therapy
1111990|NCT01522261|Mechanical Bowel Prep
1111991|NCT01522248|influenza vaccine
1111992|NCT01522248|cytokines
1111993|NCT01522248|chemokines
1111994|NCT01522248|symptoms
1111995|NCT01522235|Autoimmune autonomic neuropathy
1111996|NCT01522235|Orthostatic hypotension
1111997|NCT01522235|Dysautonomia
1111998|NCT01522235|Autonomic failure
1111999|NCT01522235|Peripheral autonomic neuropathy
1112000|NCT01522222|cardiopulmonary bypass surgery
1112001|NCT01522222|CABG
1112002|NCT01522222|PEEP
1112003|NCT01522209|CRLM
1112004|NCT01522209|Primovist MRI
1112005|NCT01522209|CEIOUS
1112006|NCT01522196|SCD
1112007|NCT01522183|Atypical Hemolytic-Uremic Syndrome
1112008|NCT01522183|aHUS
1112009|NCT01522183|Thrombotic Microangiopathy
1112010|NCT01522183|TMA
1112011|NCT01522170|Atypical Hemolytic Uremic Syndrome
1112012|NCT01522170|aHUS
1112013|NCT01522170|Eculizumab
1112014|NCT01522157|Diet
1112015|NCT01522157|Low-carbohydrate
1112016|NCT01522157|Postprandial
1112017|NCT01522157|Type 2 diabetes mellitus
1112018|NCT01522131|bioresorbable membrane
1112019|NCT01522118|Prostate Cancer
1112020|NCT01522118|High Intensity Focused Ultrasound
1112021|NCT01522118|Magnetic Resonance guided Focused Ultrasound
1112022|NCT01522118|Non-invasive therapy
1112023|NCT01522118|Focal Disease
1112024|NCT01522105|Meningitis
1112025|NCT01522105|Central Nervous System Infections
1112026|NCT01522105|Pediatrics
1112027|NCT01522105|Daptomycin
1112028|NCT01522105|Anti-Bacterial Agents
1112029|NCT01522105|Therapeutic Use
1112030|NCT01522105|Pharmacologic Actions
1112031|NCT01522092|Exacerbations
1112032|NCT01522079|spinal muscular atrophy
1112033|NCT01522079|heart rate variability
1112034|NCT01522079|posture
1112035|NCT01522079|air stacking
1112036|NCT01522040|Asthma
1112037|NCT01522040|Magnesium
1112038|NCT01522040|Adrenergic Receptor
1112039|NCT01522014|Joint Replacement
1112040|NCT01522014|Health Related Quality of Life
1112041|NCT01522014|Functional Outcomes
1112042|NCT01522014|Revision Rate
1112043|NCT01522001|Acute Coronary Syndrome
1112044|NCT01522001|Myocardial Ischemia
1112045|NCT01522001|Shared Care
1112046|NCT01522001|Rehabilitation
1112047|NCT01522001|Community
1112048|NCT01522001|Cardiac Rehabilitation
1112049|NCT01522001|Hospital
1112050|NCT01521988|Atrial flutter
1112051|NCT01521988|Atrial fibrillation
1112052|NCT01521988|Catheter ablation
1112053|NCT01521975|HBV DNA
1112054|NCT01521975|LdT
1112055|NCT01521975|ADV
1112056|NCT01521975|HBeAg negative hepatitis
1112057|NCT01521975|CHB
1112058|NCT01521949|Prostate Cancer
1112059|NCT01521949|Nutraceutical
1112060|NCT01521949|Acai Juice
1112061|NCT01521923|Certolizumab Pegol - Cimzia
1112062|NCT01521923|Rheumatoid Arthritis
1112063|NCT01521910|survival
1112064|NCT01521910|protein restriction
1112065|NCT01521910|diabetic nephropathy
1112066|NCT01521910|type 1 diabetes
1112067|NCT01521910|GFR
1112068|NCT01521910|ESRD
1112069|NCT01521910|progressive renal disease
1112070|NCT01521897|Pneumococcal Vaccine
1112071|NCT01521897|Prevenar
1112072|NCT01521897|7-valent
1112073|NCT01521897|Special Use-result surveillance
1112074|NCT01521871|Tissue glue
1112075|NCT01521871|Cyanoacrylate
1112076|NCT01521871|Wound closure
1112077|NCT01521871|Living donor nephrectomy
1112078|NCT01521871|Surgical wound closure
1112079|NCT01521845|elective percutaneous coronary intervention
1112080|NCT01521845|hs-CRP
1112081|NCT01521845|CKMB and troponin I
1112082|NCT01521819|AMD
1112083|NCT01521819|V-Ped
1112084|NCT01521819|Vascularized Pigment Epithelial Detachment
1112085|NCT01521819|Iray
1112086|NCT01521819|radiation
1112087|NCT01521819|retina
1112088|NCT01521819|macula
1112089|NCT01521819|radiotherapy
1112090|NCT01521806|insulin sensitivity
1112091|NCT01521806|resistant starch
1112092|NCT01521780|hepatocellular carcinoma
1112093|NCT01521780|MRI
1112094|NCT01521780|pharmacogenomics
1112095|NCT01521780|beta-catenin
1112096|NCT01521767|pharmacokinetics
1112097|NCT01521767|relative bioavailability
1112098|NCT01521767|tolterodine microspheres in powder blend
1112099|NCT01521767|Overactive Urinary Bladder
1112100|NCT01521741|Breast Cancer
1112101|NCT01521741|Lymphedema
1112102|NCT01521741|symptoms
1112103|NCT01521728|ALS
1112104|NCT01521728|Exercise
1112105|NCT01521728|Resistance
1112106|NCT01521728|Endurance
1112107|NCT01521702|adenocarcinoma
1112108|NCT01521702|pancreatic head
1112109|NCT01521689|MRD negative CR
1112110|NCT01521676|breast cancer
1112111|NCT01521663|Moderate to severe idiopathic RLS
1112112|NCT01521650|Probiotics
1112113|NCT01521650|Anaesthesia
1112114|NCT01521650|Intubation
1112115|NCT01521650|Pathogenic bacteria
1112116|NCT01521611|Radioimmunotherapy
1112117|NCT01521611|Transplant
1112118|NCT01521611|BMT
1112119|NCT01521611|yttrium
1112120|NCT01521611|indium
1112121|NCT01521598|Diabetic Peripheral Neuropathy
1112122|NCT01521572|chronic obstructive pulmonary disease,
1112123|NCT01521572|bronchial reversibility,
1112124|NCT01521572|bronchodilator,
1112125|NCT01521572|respiratory impedance,
1112126|NCT01521572|forced oscillation technique,
1112127|NCT01521572|plethysmography,
1112128|NCT01521572|spirometry
1112129|NCT01521572|Diagnostic Techniques, Respiratory System
1112130|NCT01521546|Duchenne muscular dystrophy
1112131|NCT01521546|cardiomyopathy
1112132|NCT01521546|aldosterone antagonist
1112133|NCT01521533|Relapsed Multiple Myeloma
1112134|NCT01521533|NOX-A12
1112135|NCT01521533|Velcade
1112136|NCT01521533|Dexamethasone
1112137|NCT01521533|Spiegelmer
1112138|NCT01521533|Chemosensitization
1112139|NCT01521533|Stromal cell-derived factor-1 (SDF-1)
1112140|NCT01521533|CXCL12
1112141|NCT01521520|type 1 diabetes
1112142|NCT01521520|magnetic resonance imaging
1112143|NCT01521520|insulitis
1112144|NCT01521520|ferumoxytol
1112145|NCT01521494|Hemodialysis
1112146|NCT01521494|Hyperphosphatemia
1112147|NCT01521468|Coronary artery disease
1112148|NCT01521468|Diagnostic accuracy
1112149|NCT01521468|CT coronary angiography
1112150|NCT01521468|Positron emission tomography
1112151|NCT01521468|Single photon emission tomography
1112152|NCT01521468|Noninvasive techniques
1112153|NCT01521468|Cardiac catheterization
1112154|NCT01521468|Fractional flow reserve
1112155|NCT01521442|PTSD
1112156|NCT01521442|Yoga
1112157|NCT01521442|Complementary and Alternative Medicine (CAM)
1112158|NCT01521416|Illness
1112159|NCT01521416|Influenza
1112160|NCT01521416|Cost
1112161|NCT01521416|UK
1112162|NCT01521403|Blastocystis hominis
1112163|NCT01521403|Metronidazole
1112164|NCT01521377|LAMA
1112165|NCT01521377|Respiratory
1112166|NCT01521377|COPD
1112167|NCT01521377|Tolerability
1112168|NCT01521377|Beta-2 Agonist
1112169|NCT01521377|Safety
1112170|NCT01521377|Pharmacokinetics
1112171|NCT01521377|Pharmacodynamics
1112172|NCT01521377|LABA
1112173|NCT01521377|Muscarinic Receptor Agonist
1112174|NCT01521377|Healthy subjects
1112175|NCT01521377|Moxifloxacin
1112176|NCT01521377|Anticholinergic
1112177|NCT01521377|GW642444
1112178|NCT01521377|GSK573719
1112179|NCT01521377|QTc
1112180|NCT01521364|pharmacokinetic
1112181|NCT01521364|drug-interaction
1112182|NCT01521364|linezolid
1112183|NCT01521364|clarithromycin
1112184|NCT01521364|Mycobacterium tuberculosis
1112185|NCT01521351|microwave radiometry
1112186|NCT01521351|cardiovascular events
1112187|NCT01521351|carotid artery disease
1112188|NCT01521351|stroke
1112189|NCT01521351|myocardial infarction
1112190|NCT01521338|Cystic Fibrosis
1112191|NCT01521338|G551D
1112192|NCT01521338|G551D Mutation
1112193|NCT01521312|Impaired glucose tolerance
1112194|NCT01521312|Saxagliptin
1112195|NCT01521312|Cardiovascular risk integrators
1112196|NCT01521312|Vago-sympathetic activity
1112197|NCT01521312|Arterial stiffness
1112198|NCT01521312|Endothelial function
1112199|NCT01521299|hydroxyurea
1112200|NCT01521299|S phase
1112201|NCT01521299|G2 phase
1112202|NCT01521299|pharmacokinetics
1112203|NCT01521286|Spain
1112204|NCT01521286|cost
1112205|NCT01521286|complications
1112206|NCT01521286|incidence
1112207|NCT01521286|adults
1112208|NCT01521286|quality of life
1112209|NCT01521286|Herpes Zoster
1112210|NCT01521286|Surveillance
1112211|NCT01521273|beans
1112212|NCT01521273|biofortification
1112213|NCT01521273|phytic acid
1112214|NCT01521273|iron
1112215|NCT01521273|iron isotopes
1112216|NCT01521273|different phytic acid concentrations
1112217|NCT01521260|dental implants
1112218|NCT01521260|microbiology
1112219|NCT01521260|chlorhexidine
1112220|NCT01521247|Asthma
1112221|NCT01521247|Transition program
1112222|NCT01521247|Pediatric
1112223|NCT01521247|Adult
1112224|NCT01521208|Out-of-Hospital cardiac arrest (OHCA)
1112225|NCT01521208|Chest compressions
1112226|NCT01521208|LUCAS device
1112227|NCT01521195|pediatric
1112228|NCT01521195|ECMO
1112229|NCT01521195|extracorporeal blood flow
1112230|NCT01521195|VO2
1112231|NCT01521182|Probiotic - dairy product - influenza vaccination - healthy elderly
1112232|NCT01521169|Plant sterol - Hypercholesterolemia - Diet - Dairy
1112233|NCT01521156|Plant sterols - Hypercholesterolemia - Diet - Dairy
1112234|NCT01521143|EOC
1112235|NCT01521130|Benign Childhood Epilepsy With Centrotemporal Spikes
1112236|NCT01521130|Benign Rolandic Epilepsy
1112237|NCT01521117|donepezil
1112238|NCT01521117|parkinson's disease
1112239|NCT01521117|balance
1112240|NCT01521117|cholinesterase inhibitor
1112241|NCT01521104|narrow band imaging（NBI）
1112242|NCT01521104|colorectal lesions
1112243|NCT01521104|predicting histology
1112244|NCT01521091|narrow band imaging（NBI）
1112245|NCT01521091|indigo carmine
1112246|NCT01521091|acetic acid
1112247|NCT01521091|colorectal lesions
1112248|NCT01521091|predicting histology
1112249|NCT01521065|AMD
1112250|NCT01521065|Wet AMD
1112251|NCT01521039|aGVHD
1112252|NCT01521039|Acute Graft-versus-Host Disease
1112253|NCT01521039|allogeneic stem cell transplantation
1112254|NCT01521039|Hematopoietic stem cell transplantation
1112255|NCT01521039|MicroRNA Expression
1112256|NCT01521000|Breast Cancer
1112257|NCT01521000|Lymphedema
1112258|NCT01521000|Sentinel Node Biopsy
1112259|NCT01521000|Axillary Dissection
1112260|NCT01520987|Parkinson Disease
1112261|NCT01520987|BIA 9-1067
1112262|NCT01520961|Partial Hip Arthroplasty
1112263|NCT01520948|Parkinson disease
1112264|NCT01520948|Incontinence
1112265|NCT01520935|Office of National Statistics
1112266|NCT01520935|Burden of Disease
1112267|NCT01520935|Influenza
1112268|NCT01520935|Hospital Episode Statistics
1112269|NCT01520935|General Practitioners Research Database
1112270|NCT01520922|Relapsed or Refractory Chronic Lymphocytic Leukemia
1112271|NCT01520922|Chronic Lymphocytic Leukemia
1112272|NCT01520922|CLL
1112273|NCT01520922|Cancer
1112274|NCT01520922|Lymphoid leukemia
1112275|NCT01520922|Lymphoblastic leukemia
1112276|NCT01520909|immune thrombocytopenic purpura
1112277|NCT01520909|pediatrics
1112278|NCT01520909|chronic ITP
1112279|NCT01520909|idiopathic thrombocytopenic purpura
1112280|NCT01520909|eltrombopag
1112281|NCT01520909|Chronic Immune Thrombocytopenia
1112282|NCT01520909|platelet disorder
1112283|NCT01520909|thrombocytopenia
1112284|NCT01520896|Phase 1
1112285|NCT01520896|Healthy male and female volunteers
1112286|NCT01520896|Drug-drug interaction
1112287|NCT01520896|Pharmacokinetics
1112288|NCT01520896|NKTR-118
1112289|NCT01520870|Dacomitinib
1112290|NCT01520870|PF-299804
1112291|NCT01520870|Glioblastoma, Recurrent
1112292|NCT01520870|EGFR
1112293|NCT01520857|Laparoscopic inguinal hernia repair
1112294|NCT01520857|TAPP
1112295|NCT01520857|Spinal Anesthesia
1112296|NCT01520857|General Anesthesia
1112297|NCT01520805|acute myeloid leukemia
1112298|NCT01520805|myelodysplastic syndrome
1112299|NCT01520805|refractory
1112300|NCT01520805|relapsed
1112301|NCT01520805|hypomethylating agents
1112302|NCT01520792|pharmacogenetic of paracetamol
1112303|NCT01520792|Pain threshold
1112304|NCT01520779|Hepatocellular cacinoma
1112305|NCT01520779|Radiofrequancy ablation
1112306|NCT01520779|Intrahepatic recurrence
1112307|NCT01520766|glass fiber posts
1112308|NCT01520766|titanium posts
1112309|NCT01520766|postendodontic restoration
1112310|NCT01520766|self-adhesive resin cement
1112311|NCT01520740|Gold Stage III
1112312|NCT01520740|Gold Stage IV
1112313|NCT01520740|Chronic Obstructive Pulmonary Disease
1112314|NCT01520740|COPD
1112315|NCT01520740|Lung Volume Reduction Surgery
1112316|NCT01520740|LVRS
1112317|NCT01520740|Bronchoscopic Lung Volume Reduction
1112318|NCT01520740|BLVR
1112319|NCT01520740|Upper Lobe Predominant
1112320|NCT01520740|ULP
1112321|NCT01520740|Heterogeneous
1112322|NCT01520740|Homogeneous
1112323|NCT01520727|BIA 9-1067
1112324|NCT01520714|Congestive Heart Failure (CHF)
1112325|NCT01520714|Cardiac Resynchronization Therapy (CRT)
1112326|NCT01520714|BiVentricular Implantable Cardioverter Defibrillator (BiVICD)
1112327|NCT01520714|Fraction
1112328|NCT01520701|head and neck cancer
1112329|NCT01520701|Hydrotac®
1112330|NCT01520701|radiodermatitis
1112331|NCT01520701|algia
1112332|NCT01520701|radiotherapy
1112333|NCT01520688|Mild persistent or mild intermittent asthma
1112339|NCT01520662|patient-centered care
1112340|NCT01520662|wellness
1112341|NCT01520662|preventive services
1112342|NCT01520662|primary care
1112343|NCT01520662|To accomplish Aim 2, we will conduct a nine-month pre-post
1112344|NCT01520662|randomized controlled trial (RCT) in four primary care
1112345|NCT01520662|practices. The study will focus on the impact of a patient
1112346|NCT01520662|Wellness Portal on the quantity and quality of preventive
1112347|NCT01520662|care patients receive in primary care practices.
1112348|NCT01520649|Neurogenesis
1112349|NCT01520649|hippocampal stem cells
1112350|NCT01520649|depression
1112351|NCT01520649|stroke
1112352|NCT01520636|stroke
1112353|NCT01520636|early rehabilitation
1112354|NCT01520636|motor recovery
1112355|NCT01520636|functional recovery
1112356|NCT01520623|Allogeneic haematopoietic stem cell transplantation (HSCT)
1112357|NCT01520623|Myeloablative conditioning for an haematological malignancy
1112358|NCT01520623|Graft-versus-host disease (GvHD)
1112359|NCT01520623|Activation of complement system
1112360|NCT01520623|Gut GVHD
1112361|NCT01520610|Tako-TSUBO Cardiomyopathy
1112362|NCT01520610|Stress Cardiomyopathy
1112363|NCT01520610|Myocardiopathies
1112364|NCT01520610|Acute Coronary Syndrome
1112365|NCT01520610|Gene
1112366|NCT01520597|Multicentric
1112367|NCT01520597|National
1112368|NCT01520597|Prospective on
1112369|NCT01520597|Listeriosis
1112370|NCT01520597|Listeria
1112371|NCT01520571|Computer Assistance
1112372|NCT01520571|Total Knee Arthroplasty
1112373|NCT01520571|conventional
1112374|NCT01520558|Acute Myeloid Leukemia
1112375|NCT01520558|High Risk Relapse
1112376|NCT01520558|Complete Remission
1112377|NCT01520558|Allogeneic Natural Killer Cells
1112378|NCT01520545|Gablofen
1112379|NCT01520545|baclofen injection
1112380|NCT01520519|Leukemia
1112381|NCT01520519|Chronic Lymphocytic Leukemia
1112382|NCT01520519|CLL
1112383|NCT01520519|Small Lymphocytic Lymphoma
1112384|NCT01520519|SLL
1112385|NCT01520519|Rituximab
1112386|NCT01520519|Rituxan
1112387|NCT01520519|PCI-32765
1112388|NCT01520506|Hypertension
1112389|NCT01520506|Kidney Diseases
1112390|NCT01520506|Kidney Failure, Chronic
1112391|NCT01520506|Vascular Diseases
1112392|NCT01520506|Cardiovascular Diseases
1112393|NCT01520506|Urologic Diseases
1112394|NCT01520506|Renal Insufficiency, Chronic
1112395|NCT01520506|Renal Insufficiency
1112396|NCT01520493|pulmonary arterial hypertension
1112397|NCT01520493|skeletal muscle microcirculation
1112398|NCT01520493|exercise induced blood flow
1112399|NCT01520480|survival after surgery
1112400|NCT01520480|Pathological Subtrochanteric Fractures
1112401|NCT01520467|SRS
1112402|NCT01520467|PWS
1112403|NCT01520467|pathological adrenarche
1112404|NCT01520467|aromatase inhibitor
1112405|NCT01520467|Children
1112406|NCT01520454|Leptin resistance
1112407|NCT01520454|Free fatty acids
1112408|NCT01520454|Lipotoxicity
1112409|NCT01520441|Botulinum Toxin
1112410|NCT01520441|Prostate Cancer
1112411|NCT01520441|BPH
1112412|NCT01520441|LUTS
1112413|NCT01520402|Genetic Determinants of Warfarin Dose Variability
1112414|NCT01520389|cancer
1112415|NCT01520389|solid tumors
1112416|NCT01520389|oncology
1112417|NCT01520389|Phase I
1112418|NCT01520389|EGFR
1112419|NCT01520389|EGF receptor (ErbB1)
1112420|NCT01520389|irinotecan
1112421|NCT01520363|Rett syndrome
1112422|NCT01520363|RTT
1112423|NCT01520363|MECP2
1112424|NCT01520363|dextromethorphan
1112425|NCT01520363|DM
1112426|NCT01520311|Coronary Artery Disease
1112427|NCT01520311|Myocardial Ischemia
1112428|NCT01520311|Coronary Disease
1112429|NCT01520311|Heart Diseases
1112430|NCT01520311|Cardiovascular Diseases
1112431|NCT01520311|Arteriosclerosis
1112432|NCT01520311|Arterial Occlusive Diseases
1112433|NCT01520311|Vascular Diseases
1112434|NCT01520311|CABG
1112435|NCT01520311|SVG
1112436|NCT01520311|eSVS Mesh
1112437|NCT01520311|Bypass Grafting
1112438|NCT01520285|hypertension
1112439|NCT01520285|Blood pressure decrease
1112440|NCT01520285|efficacy
1112441|NCT01520272|HPV18 Immunogenicity
1112442|NCT01520272|HPV16 Immunogenicity
1112443|NCT01520272|Bivalent HPV16/18 Vaccine
1112444|NCT01520272|Less than 3 Dosed of the Bivalent HPV Vaccine
1112445|NCT01520272|HP Vaccine
1112446|NCT01520259|Gallbaldder
1112447|NCT01520259|Gallstones
1112448|NCT01520259|Inflammation
1112449|NCT01520259|Cholecystectomy
1112450|NCT01520259|Cancer
1112451|NCT01520259|Gallbaldder Cancer
1112452|NCT01520246|adult acute lymphoblastic leukemia
1112453|NCT01520246|childhood acute lymphoblastic leukemia
1112454|NCT01520246|adult T-cell leukemia/lymphoma
1112455|NCT01520233|disseminated neuroblastoma
1112456|NCT01520233|localized unresectable neuroblastoma
1112457|NCT01520233|recurrent neuroblastoma
1112458|NCT01520233|regional neuroblastoma
1112459|NCT01520233|stage 4S neuroblastoma
1112460|NCT01520194|genital warts
1112461|NCT01520194|HPV
1112462|NCT01520194|psychosocial burden
1112463|NCT01520194|economic burden
1112464|NCT01520194|female genital warts
1112465|NCT01520168|Incisional hernia
1112466|NCT01520168|Mesh
1112467|NCT01520168|Surgery
1112468|NCT01520168|Composix Kugel
1112469|NCT01520168|IPOM technique
1112470|NCT01520155|lupus erythematosus
1112471|NCT01520155|cardiovascular risk
1112472|NCT01520142|Healthy participants
1112473|NCT01520142|Pharmacodynamic
1112474|NCT01520142|Pharmacokinetics
1112475|NCT01520142|Intravenous Endotoxin-Induced Model
1112476|NCT01520142|Acute Inflammation
1112477|NCT01520142|JNJ-26528398
1112478|NCT01520142|Anti-inflammatory
1112479|NCT01520129|Bipolar Disorder
1112480|NCT01520129|Bipolar NOS
1112481|NCT01520129|Bipolar Depression
1112482|NCT01520103|Metastatic breast cancer
1112483|NCT01520103|locally advanced breast cancer
1112484|NCT01520103|Her2/new negative
1112485|NCT01520103|HER2 negative
1112486|NCT01520090|contraception
1112487|NCT01520090|family planning
1112488|NCT01520090|egyptian
1112489|NCT01520090|knowledge
1112490|NCT01520077|alopecia areata
1112491|NCT01520077|vytorin
1112492|NCT01520077|statin
1112493|NCT01520077|hair growth
1112494|NCT01520064|Emphysema
1112495|NCT01520064|GOLD Stage III
1112496|NCT01520064|GOLD Stage IV
1112497|NCT01520064|AeriSeal System
1112498|NCT01520064|Homogeneous
1112499|NCT01520064|Heterogeneous
1112500|NCT01520064|Upper Lobe Predominant
1112501|NCT01520064|ULP
1112502|NCT01520064|Chronic Obstructive Pulmonary Disease
1112503|NCT01520064|COPD
1112504|NCT01520064|Lung Volume Reduction Surgery
1112505|NCT01520064|LVRS
1112506|NCT01520064|Bronchoscopic Lung Volume Reduction
1112507|NCT01520064|BLVR
1112508|NCT01520051|Asthma
1112509|NCT01520051|Viral
1112510|NCT01520051|Infection
1112511|NCT01520051|Inflammation
1112512|NCT01520051|Mepolizumab
1112513|NCT01520051|Eosinophilia
1112514|NCT01520025|Radiopharmaceutical
1112515|NCT01520025|18FDG PET
1112516|NCT01520025|CTA
1112517|NCT01520025|Multi-modality imaging
1112518|NCT01520025|Metabolic Imaging of Ischemia
1112519|NCT01520025|Myocardial blood flow
1112520|NCT01520025|Myocardial blood flow reserve
1112521|NCT01519999|Shared decision making
1112522|NCT01519999|Ambulatory Care
1112523|NCT01519999|Patient-Centered Care
1112524|NCT01519999|Community-wide intervention
1112525|NCT01519999|Intervention Study
1112526|NCT01519999|Longitudinal Studies
1112527|NCT01519986|Vitamin D
1112528|NCT01519986|Cholecalciferol
1112529|NCT01519986|Supplementation
1112530|NCT01519986|Dietary Supplements
1112531|NCT01519986|Dietary Fats
1112532|NCT01519986|25-hydroxyvitamin D
1112533|NCT01519973|Diagnostic imaging
1112534|NCT01519973|Single Photon Emission Computed Tomography
1112535|NCT01519973|Positron emission tomography
1112536|NCT01519973|Computed tomography
1112537|NCT01519973|Attenuation
1112538|NCT01519973|Resolution
1112539|NCT01519973|Scatter
1112540|NCT01519973|Radiopharmaceutical
1112541|NCT01519934|Ulthera® System
1112542|NCT01519934|Ultherapy™ Treatment
1112543|NCT01519934|Ulthera, Inc.
1112544|NCT01519934|Ultrasound treatment for skin tightening
1112669|NCT01519362|Polyacrylamide hydrogel
1112545|NCT01519908|cardiac resynchronization therapy
1112546|NCT01519908|biomarkers
1112547|NCT01519908|response
1112548|NCT01519895|quality of life
1112549|NCT01519895|anxiety
1112550|NCT01519895|stress
1112551|NCT01519895|carers
1112552|NCT01519895|colorectal or colon cancer
1112553|NCT01519882|Rotigotine
1112554|NCT01519882|Neupro
1112555|NCT01519882|Polysomnography
1112556|NCT01519882|Sleep efficiency
1112557|NCT01519882|Advanced Idiopathic Parkinson's Disease
1112558|NCT01519882|Sleep Disorder
1112559|NCT01519869|peritoneal
1112560|NCT01519869|carcinoma
1112561|NCT01519869|ovarian
1112562|NCT01519869|fallopian tube
1112563|NCT01519869|neoadjuvant chemotherapy
1112564|NCT01519869|surgical debulking
1112565|NCT01519856|open
1112566|NCT01519856|non-intervention
1112567|NCT01519856|observational
1112568|NCT01519843|stroke
1112569|NCT01519830|Anemia, Iron-Deficiency
1112570|NCT01519830|Blood Donors
1112571|NCT01519817|Vaccine Therapy
1112572|NCT01519817|Dose-Limiting Toxicity
1112573|NCT01519817|Maximum Tolerated Dose
1112574|NCT01519817|Clinical Response
1112575|NCT01519817|Immune Response
1112576|NCT01519817|Cancer
1112577|NCT01519817|Solid Tumor
1112578|NCT01519791|Certolizumab Pegol - Cimzia
1112579|NCT01519791|Methotrexate
1112580|NCT01519791|Rheumatoid Arthritis
1112581|NCT01519752|Tinea Pedis
1112582|NCT01519713|Meningitis
1112583|NCT01519713|Meningococcal Meningitis
1112584|NCT01519713|Meningococcal Infections
1112585|NCT01519713|Meningococcal conjugate Vaccine
1112586|NCT01519713|Menactra®
1112587|NCT01519700|Filgrastim
1112588|NCT01519700|G-CSF, neutropenia
1112589|NCT01519700|supportive care
1112590|NCT01519700|breast cancer
1112591|NCT01519687|hyperuricemia
1112592|NCT01519687|gout
1112593|NCT01519687|levotofisopam
1112594|NCT01519661|Tobramycin Inhalation powder
1112595|NCT01519661|Cystic fibrosis
1112596|NCT01519661|Lung disease
1112597|NCT01519661|Anti-bacterial agents
1112598|NCT01519648|Invasive fungal infection
1112599|NCT01519648|Acute leukemia (AL)
1112600|NCT01519648|Hematopoietic stem cell transplantation
1112601|NCT01519648|Antifungal stewardship
1112602|NCT01519648|Neutropenia
1112603|NCT01519648|Hematological malignancies
1112604|NCT01519635|Kidney oxygenation
1112605|NCT01519635|Stage 1 or 2 hypertension
1112606|NCT01519635|BOLD-IRM
1112607|NCT01519622|End of life decisions
1112608|NCT01519622|Perception of illness
1112609|NCT01519609|Bowel prep
1112610|NCT01519609|Safety
1112611|NCT01519609|Efficacy
1112612|NCT01519583|walking
1112613|NCT01519583|physical activity
1112614|NCT01519583|sedentary behavior
1112615|NCT01519570|Herpes Zoster vaccine
1112616|NCT01519570|Electronic patient portal
1112617|NCT01519570|Electronic medical record
1112618|NCT01519570|Primary care
1112619|NCT01519570|Immunizations
1112620|NCT01519544|Sleep
1112621|NCT01519544|High Altitude
1112622|NCT01519544|High-altitude Sleep Disturbance
1112623|NCT01519544|Acute Mountain Sickness
1112624|NCT01519544|Difficulty Sleeping at High Altitude
1112625|NCT01519544|Periodic Breathing
1112626|NCT01519544|Actigraphy
1112627|NCT01519544|Acetazolamide
1112628|NCT01519544|Temazepam
1112629|NCT01519544|Groningen Sleep Quality Questionnaire survey
1112630|NCT01519544|Stanford Sleepiness Scale
1112631|NCT01519544|Lake Louise Acute Mountain Sickness Score
1112632|NCT01519518|ST elevation myocardial infarction
1112633|NCT01519518|Primary percutaneous coronary intervention
1112634|NCT01519518|Unfractionated heparin
1112635|NCT01519518|Bivalirudin
1112636|NCT01519518|primary angioplasty
1112637|NCT01519505|Prevention
1112638|NCT01519505|Diabetes mellitus
1112639|NCT01519505|Lifestyle changes
1112640|NCT01519505|Cardiovascular risk
1112641|NCT01519505|Cost-effectiveness
1112642|NCT01519492|Skin and Subcutaneous Tissue Bacterial Infections
1112643|NCT01519479|Congestive Heart Failure
1112644|NCT01519479|Heart Failure
1112645|NCT01519479|Palliative Care
1112646|NCT01519479|Palliative Medicine
1112647|NCT01519466|Diabetes
1112648|NCT01519466|SMBG
1112649|NCT01519466|Insulin calculator
1112650|NCT01519453|Asthma
1112651|NCT01519453|Preschool
1112652|NCT01519453|Health Disparities
1112653|NCT01519453|Implementation
1112654|NCT01519440|unintended extension
1112655|NCT01519440|blunt
1112656|NCT01519440|sharp
1112657|NCT01519440|maternal blood loss
1112658|NCT01519401|PCOS
1112659|NCT01519401|drospirenone ethinylestradiol
1112660|NCT01519401|androgens
1112661|NCT01519401|metabolism
1112662|NCT01519388|Neuromuscular disorder
1112663|NCT01519388|Respiratory failure
1112664|NCT01519388|Swallowing
1112665|NCT01519388|Mechanical ventilation
1112666|NCT01519375|Osteoarthritis
1112667|NCT01519375|Rheumatoid Arthritis
1112668|NCT01519375|Ankylosing Spondylitis
1112670|NCT01519362|leukocytopenia
1112671|NCT01519362|migration
1112672|NCT01519362|complication
1112673|NCT01519362|epicranial aponeurosis
1112674|NCT01519362|PAAG injection
1112675|NCT01519349|Becker muscular dystrophy
1112676|NCT01519349|BMD
1112677|NCT01519349|muscular dystrophy
1112678|NCT01519349|inclusion body myositis
1112679|NCT01519349|IBM
1112680|NCT01519349|Follistatin
1112681|NCT01519310|choline metabolism
1112682|NCT01519310|gut flora
1112683|NCT01519310|phosphatidylcholine
1112684|NCT01519310|lecithin
1112685|NCT01519297|Preeclampsia
1112686|NCT01519297|Pregnancy Induced Hypertension
1112687|NCT01519284|Parkinson Disease
1112688|NCT01519284|BIA 9-1067
1112689|NCT01519271|Parkinson's Disease
1112690|NCT01519271|Mild Cognitive Impairment
1112691|NCT01519271|Cognition
1112692|NCT01519271|Memory
1112693|NCT01519271|Attention
1112694|NCT01519271|Exelon
1112695|NCT01519271|Rivastigmine
1112696|NCT01519258|ARDS
1112697|NCT01519245|coronary artery bypass grafting
1112698|NCT01519245|tranexamic acid
1112699|NCT01519245|antifibrinolytic
1112700|NCT01519245|administration, topical
1112701|NCT01519245|operative blood salvage
1112702|NCT01519232|hepatocellular carcinoma
1112703|NCT01519219|hepatic irradiation
1112704|NCT01519219|IC-GREEN
1112705|NCT01519206|Ulthera® System
1112706|NCT01519206|Ultherapy™ Treatment
1112707|NCT01519206|Ulthera, Inc.
1112708|NCT01519193|Aggressive Behavior
1112709|NCT01519193|Appetitive Aggression
1112710|NCT01519193|Post-Traumatic Stress Disorder
1112711|NCT01519180|gastroparesis
1112712|NCT01519180|gastric emptying
1112713|NCT01519180|antro-duodenal manometry
1112714|NCT01519154|deep sedation
1112715|NCT01519154|propofol
1112716|NCT01519154|ketamine
1112717|NCT01519154|child
1112718|NCT01519154|preschool child
1112719|NCT01519154|infant
1112720|NCT01519154|recovery and quality of sedation
1112721|NCT01519141|Human Immunodeficiency Virus
1112722|NCT01519141|Atherosclerosis
1112723|NCT01519141|Inflammation
1112724|NCT01519141|Endothelial Function
1112725|NCT01519141|Thrombosis
1112726|NCT01519128|Healthy
1112727|NCT01519128|TMC278
1112728|NCT01519128|TMC278IFD1001
1112729|NCT01519128|Human immunodeficiency virus - type 1
1112730|NCT01519128|Pharmacokinetics
1112731|NCT01519128|Digoxin
1112732|NCT01519115|deep cervical flexors
1112733|NCT01519115|spine stabilization
1112734|NCT01519115|posture
1112735|NCT01519115|function
1112736|NCT01519115|neck pain
1112737|NCT01519089|chronic
1112738|NCT01519089|severe
1112739|NCT01519089|moderate
1112740|NCT01519089|treatment
1112741|NCT01519089|safety
1112742|NCT01519089|efficacy
1112743|NCT01519089|CP-690
1112744|NCT01519089|550
1112745|NCT01519089|Plaque psoriasis
1112746|NCT01519089|Psoriasis Vulgaris
1112747|NCT01519089|Psoriatic Arthritis
1112748|NCT01519089|tofacitinib
1112749|NCT01519089|Xeljanz
1112750|NCT01519076|stroke
1112751|NCT01519063|Alcohol
1112752|NCT01519063|Drinking
1112753|NCT01519063|Drinkers
1112754|NCT01519063|Alcohol Drinking
1112755|NCT01519063|Memantine
1112756|NCT01519063|Naltrexone
1112757|NCT01519063|Alcohol Dependence
1112758|NCT01519063|Alcohol Abuse
1112759|NCT01519063|Alcohol-Related Disorders
1112760|NCT01519063|Ethanol
1112761|NCT01519063|Alcoholism
1112762|NCT01519037|calcimimetic agent
1112763|NCT01519037|RAAS
1112764|NCT01519037|renin
1112765|NCT01519037|aldosterone
1112766|NCT01519024|hypertrophy
1112767|NCT01519024|breast
1112768|NCT01519024|postural balance
1112769|NCT01519011|Myelodysplastic Syndromes
1112770|NCT01519011|MDS
1112771|NCT01519011|Chronic Myelomonocytic Leukemia
1112772|NCT01519011|CMML
1112773|NCT01519011|Acute Myeloid Leukemia
1112774|NCT01519011|AML
1112775|NCT01519011|Vidaza
1112776|NCT01519011|oral azacitidine
1112777|NCT01519011|aza
1112778|NCT01519011|oral aza
1112779|NCT01519011|pharmacokinetics
1112780|NCT01519011|hematology
1112781|NCT01519011|myeloid disease
1112782|NCT01519011|PK
1112783|NCT01518998|Fimasartan
1112784|NCT01518998|Amlodipine
1112785|NCT01518998|antihypertension
1112786|NCT01518972|Alcohol
1112787|NCT01518972|Abuse
1112788|NCT01518972|Use
1112789|NCT01518972|Disorder
1112790|NCT01518972|Dependence
1112791|NCT01518972|Symptoms
1112792|NCT01518972|Alcoholic
1112793|NCT01518972|Alcoholism
1112794|NCT01518972|Prazosin
1112795|NCT01518972|Drug
1112796|NCT01518972|Medicine
1112797|NCT01518972|Medication
1112798|NCT01518972|Treatment
1112799|NCT01518972|Study
1112800|NCT01518972|Placebo
1112801|NCT01518972|Medical
1112802|NCT01518972|Management
1112803|NCT01518972|Craving
1112804|NCT01518972|Consumption
1112805|NCT01518972|Binge
1112806|NCT01518972|Drinking
1112807|NCT01518972|Drink
1112808|NCT01518972|Heavy
1112809|NCT01518972|PTSD
1112810|NCT01518972|Trauma
1112811|NCT01518972|Post
1112812|NCT01518972|Posttraumatic
1112813|NCT01518946|Symptomatic Orthostatic Hypotension
1112814|NCT01518933|HCV recurrence
1112815|NCT01518933|stable liver transplanted patients
1112816|NCT01518920|Age related sensorineural hearing loss
1112817|NCT01518920|PF-04958242
1112818|NCT01518907|cellulite
1112819|NCT01518907|Xiaflex
1112820|NCT01518894|PF-04958242
1112821|NCT01518894|multiple dose
1112822|NCT01518894|Safety
1112823|NCT01518894|schizophrenia
1112824|NCT01518842|ischemic retinopathy, stem cell,bone marrow
1112825|NCT01518829|hepatocellular carcinom
1112826|NCT01518829|postablation syndrom
1112827|NCT01518829|procalcitonin
1112828|NCT01518816|antioxidant preterm labor
1112829|NCT01518803|Obesity
1112830|NCT01518803|Adolescence
1112831|NCT01518803|Lipid metabolism
1112832|NCT01518803|Mediterranean diet
1112833|NCT01518803|Chylomicron
1112834|NCT01518803|Macrophages
1112835|NCT01518790|PEG 3350
1112836|NCT01518790|boston bowel preparation scale
1112837|NCT01518790|colonoscopy cleanout
1112838|NCT01518790|bowel preparation
1112839|NCT01518790|miralax
1112840|NCT01518790|gatorade
1112841|NCT01518790|cleanout efficacy
1112842|NCT01518790|Focus of study is efficacy of PEG 3350 cleanout for improving diagnostic yield of colonoscopy.
1112843|NCT01518777|Coronary Artery Disease
1112844|NCT01518725|Muscle Power
1112845|NCT01518725|Vitamin D
1112846|NCT01518725|Vitamins
1112847|NCT01518725|Cholecalciferol
1112848|NCT01518712|Healthy Volunteers
1112849|NCT01518712|Bioequivalence
1112850|NCT01518712|Canagliflozin (JNJ-28431754)
1112851|NCT01518712|Metformin IR
1112852|NCT01518686|Norm values
1112853|NCT01518686|semi-automated kinetic perimetry
1112854|NCT01518686|isopters
1112855|NCT01518686|mathematical model
1112856|NCT01518686|luminance
1112857|NCT01518686|test-retest reliability
1112858|NCT01518686|deviation
1112859|NCT01518686|age dependance
1112860|NCT01518686|different age groups
1112861|NCT01518686|Healthy subjects
1112862|NCT01518660|Resistance Training
1112863|NCT01518660|Strength Training
1112864|NCT01518647|Bodily Distress Syndrome
1112865|NCT01518647|Medically unexplained symptoms
1112866|NCT01518647|Functional somatic symptoms
1112867|NCT01518647|Functional somatic syndromes
1112868|NCT01518647|Treatment
1112869|NCT01518647|Acceptance and Commitment Therapy
1112870|NCT01518634|Bodily Distress Syndrome
1112871|NCT01518634|Medically unexplained symptoms
1112872|NCT01518634|Functional somatic symptoms
1112873|NCT01518634|Functional somatic syndromes
1112874|NCT01518634|Treatment
1112875|NCT01518634|Imipramine
1112876|NCT01518634|Tricyclic antidepressant
1112877|NCT01518608|Alfentanil
1112878|NCT01518608|Tracheal intubation
1112879|NCT01518608|Rapid sequence induction
1112880|NCT01518595|patients
1112881|NCT01518582|Cervicobrachial
1112882|NCT01518582|neuralgia
1112883|NCT01518582|symptomatic cervical discopathy
1112884|NCT01518569|ulinastatin
1112885|NCT01518569|systemic inflammation
1112886|NCT01518569|cardiac surgery
1112887|NCT01518569|cardiopulmonary bypass
1112888|NCT01518556|Idarubicin
1112889|NCT01518556|Remission Induction
1112890|NCT01518556|Maximum Tolerated Dose
1112891|NCT01518556|Survival
1112892|NCT01518543|arthrodesis
1112893|NCT01518543|arthrodesis in the following joints:Ankle, 1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid;
1112894|NCT01518530|Chronic Neck Pain, Occiflex, Computerized Mobilization
1112895|NCT01518517|acute lymphoblastic leukemia
1112896|NCT01518517|relapse
1112897|NCT01518517|asparaginase
1112898|NCT01518504|Thoracic
1112899|NCT01518504|Manipulation
1112900|NCT01518504|Manual Therapy
1112901|NCT01518504|Mobilization
1112902|NCT01518504|Shoulder
1112903|NCT01518504|Range of Motion
1112904|NCT01518452|working memory training, computerized
1112905|NCT01518452|clinical assessment
1112906|NCT01518452|quantitative EEG
1112907|NCT01518452|child, preschool
1112908|NCT01518439|neuromuscular
1112909|NCT01518439|cough
1112910|NCT01518439|restrictive
1112911|NCT01518426|Brain computer interface
1112912|NCT01518426|EEG recording
1112913|NCT01518426|Electrodes
1112914|NCT01518413|Sora./Irino. combination therapy
1112915|NCT01518400|Pediatric Cancer
1112916|NCT01518400|Cancer Late Effects
1112917|NCT01518400|Cancer Survivor
1112918|NCT01518400|Cancer Survivorship
1112919|NCT01518387|Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis
1112920|NCT01518374|Male or female subjects at least 18 years of age
1112921|NCT01518374|AD
1112922|NCT01518374|MCI
1112923|NCT01518348|Patch Test
1112924|NCT01518348|Contact Dermatitis
1112925|NCT01518348|Allergy
1112926|NCT01518348|Children
1112927|NCT01518348|PREA
1112928|NCT01518335|platelet rich plasma
1112929|NCT01518335|ankle
1112930|NCT01518335|sprain
1112931|NCT01518335|injection
1112932|NCT01518335|Platelet Rich Plasma therapy
1112933|NCT01518335|focal, invasive therapy for sprains
1112934|NCT01518322|Asthma
1112935|NCT01518322|Fractional Exhaled Nitric Oxide
1112936|NCT01518322|Respiratory Symptoms
1112937|NCT01518322|NIOX MINO
1112938|NCT01518322|Inhaled corticosteroids
1112939|NCT01518322|Nitric Oxide
1112940|NCT01518296|Pelvic Organ Prolapse Quantification (POPQ)
1112941|NCT01518296|POPQ
1112942|NCT01518296|Urodynamic test
1112943|NCT01518283|Weekly cabazitaxel.
1112944|NCT01518283|Advanced Hormone-refractory prostate Cancer.
1112945|NCT01518283|Unfit patients.
1112946|NCT01518244|Primary open angle-glaucoma
1112947|NCT01518244|Ocular hypertension
1112948|NCT01518244|Pigment dispersion glaucoma
1112949|NCT01518231|stroke
1112950|NCT01518231|hematopoietic stem cell transplantation
1112951|NCT01518218|Sickle cell disease
1112952|NCT01518218|laying-on-of-hands
1112953|NCT01518218|morbidity
1112954|NCT01518218|mortality
1112955|NCT01518205|diabetic foot ulcers,
1112956|NCT01518205|peripheral arterial disease,
1112957|NCT01518205|heparin-induced extracorporal lipid apheresis.
1112958|NCT01518205|inflammatory markers
1112959|NCT01518205|type 2 diabetes
1112960|NCT01518205|LDL-cholesterol
1112961|NCT01518192|erythema migrans
1112962|NCT01518192|doxycycline
1112963|NCT01518192|cefuroxime axetil
1112964|NCT01518192|post-Lyme disease symptoms
1112965|NCT01518192|background symptoms in general population
1112966|NCT01518179|Colles' Fracture
1112967|NCT01518179|Compression Bandages
1112968|NCT01518179|Occupational therapy
1112969|NCT01518179|Rehabilitation
1112970|NCT01518179|Smith's fracture
1112971|NCT01518153|Blood and Marrow Transplantation
1112972|NCT01518153|Lymphoma
1112973|NCT01518153|Myeloma
1112974|NCT01518153|Myeloproliferative Diseases
1112975|NCT01518153|Leukemia
1112976|NCT01518153|Myelodysplastic syndrome
1112977|NCT01518153|MDS
1112978|NCT01518153|Hodgkin disease
1112979|NCT01518153|Multiple myeloma
1112980|NCT01518153|Fludarabine
1112981|NCT01518153|Fludarabine Phosphate
1112982|NCT01518153|Fludara
1112983|NCT01518153|Melphalan
1112984|NCT01518153|Alkeran
1112985|NCT01518153|Tacrolimus
1112986|NCT01518153|Prograf
1112987|NCT01518153|Methotrexate
1112988|NCT01518153|G-CSF
1112989|NCT01518153|Filgrastim
1112990|NCT01518153|NeupogenTM
1112991|NCT01518153|Donor Lymphocyte Infusion
1112992|NCT01518153|DLI
1112993|NCT01518153|Allogeneic Stem Cell Transplantation
1112994|NCT01518153|Graft-vs-host disease
1112995|NCT01518153|GvHD
1112996|NCT01518153|T-lymphocytes
1112997|NCT01518153|T-cells
1112998|NCT01518153|Alemtuzumab
1112999|NCT01518153|CAMPATH-1H
1113000|NCT01518153|Campath
1113001|NCT01518140|Advanced Cancers
1113002|NCT01518140|Locally advanced
1113003|NCT01518140|Recurrent
1113004|NCT01518140|Metastatic disease
1113005|NCT01518140|Oxygen Delivery Modalities
1113006|NCT01518140|Shortness of breath
1113007|NCT01518140|Dyspnea
1113008|NCT01518140|VapoTherm
1113009|NCT01518140|Bilevel positive airway pressure
1113010|NCT01518140|BiPAP
1113011|NCT01518140|Non-rebreather mask
1113012|NCT01518127|Macular Degeneration
1113013|NCT01518114|Hypertrophic Cardiomyopathy
1113014|NCT01518114|Exercise Training
1113015|NCT01518114|Cardiac Rehabilitation
1113016|NCT01518114|Heart Failure
1113017|NCT01518101|patient preference
1113018|NCT01518101|vildagliptin
1113019|NCT01518101|liraglutide
1113020|NCT01518075|Chronic Obstructive Pulmonary Disease
1113021|NCT01518075|Non invasive mechanical ventilation
1113022|NCT01518075|Breathing-swallowing interaction
1113023|NCT01518075|Intensive Care Unit
1113024|NCT01518049|Affective Disorders, Psychotic
1113025|NCT01518049|Psychometrics
1113026|NCT01518049|Biological Markers
1113027|NCT01518023|diabetes mellitus
1113028|NCT01518023|prediabetes
1113029|NCT01518023|fasting blood glucose
1113030|NCT01518023|HbA1c
1113031|NCT01518023|Roux en Y gastric bypass
1113032|NCT01518023|Cancer gastrectomy
1113033|NCT01518023|Cancer colorectal surgery
1113034|NCT01518010|Brain injury
1113035|NCT01518010|Cognitive rehabilitation
1113036|NCT01518010|Video game
1113037|NCT01517997|Drug coated balloons
1113038|NCT01517997|Drug eluting stents
1113039|NCT01517984|recipients of living-donor kidney allografts
1113040|NCT01517984|antithymocyte globulin (ATG) induction
1113041|NCT01517984|calcineurin inhibitors (CNIs)
1113042|NCT01517984|CNI withdrawal
1113043|NCT01517971|stage IA non-small cell lung cancer
1113044|NCT01517971|stage IB non-small cell lung cancer
1113045|NCT01517971|adenocarcinoma of the lung
1113046|NCT01517971|squamous cell lung cancer
1113047|NCT01517958|Transient tachypnea of the newborn
1113048|NCT01517958|Respiratory Distress Syndrome
1113049|NCT01517958|Lung Ultrasound
1113050|NCT01517958|Neonates
1113051|NCT01517945|Survivors
1113052|NCT01517945|Quality of Life
1113053|NCT01517945|Questionnaire
1113054|NCT01517945|11-204
1113055|NCT01517919|peer support
1113056|NCT01517919|peer leader
1113057|NCT01517919|community health worker
1113058|NCT01517919|empowerment
1113059|NCT01517919|self-management
1113060|NCT01517906|eating disorder behaviors
1113061|NCT01517906|well being
1113062|NCT01517906|functional health
1113063|NCT01517893|vitiligo
1113064|NCT01517893|simvastatin
1113065|NCT01517880|Hereditary Inclusion Body Myopathy (HIBM)
1113066|NCT01517880|GNE myopathies
1113067|NCT01517880|distal myopathy with rimmed vacuoles [DMRV]
1113068|NCT01517880|Nonaka disease
1113069|NCT01517867|preschool children behavior problems
1113070|NCT01517867|child between 2 and 5 years old
1113071|NCT01517841|peritoneal dialysis
1113072|NCT01517841|modality choice
1113073|NCT01517841|kidney disease
1113074|NCT01517828|Intubation
1113075|NCT01517828|Delivery room
1113076|NCT01517828|Sedation
1113077|NCT01517828|Analgesia
1113078|NCT01517815|Septic shock
1113079|NCT01517815|overweight
1113080|NCT01517815|critically ill
1113081|NCT01517815|pharmacokinetic
1113082|NCT01517815|doripenem
1113083|NCT01517815|piperacillin-tazobactam
1113084|NCT01517802|Metastatic castration-resistant prostate cancer
1113085|NCT01517802|Metastatic breast cancer
1113086|NCT01517802|Abiraterone acetate
1113087|NCT01517802|Low-dose corticosteroid treatment
1113088|NCT01517802|Long-term access
1113089|NCT01517789|Surgery
1113090|NCT01517789|Optic Nerve and Pathway Injury
1113091|NCT01517789|visual event-related potential
1113092|NCT01517776|High grade glioma
1113093|NCT01517776|Glioblastoma multiforme
1113094|NCT01517776|Anaplastic astrocytoma
1113095|NCT01517776|Diffuse intrinsic pontine glioma
1113096|NCT01517776|Relapse
1113097|NCT01517776|refractory tumour disease
1113098|NCT01517776|Relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas
1113099|NCT01517763|Obstructive Sleep Apnea
1113100|NCT01517763|Humidification
1113101|NCT01517763|Continuous Positive Airway Pressure
1113102|NCT01517763|ICON
1113103|NCT01517763|ThermoSmart
1113104|NCT01517763|SensAwake
1113105|NCT01517750|Obstructive Sleep Apnea
1113106|NCT01517750|Humidification
1113107|NCT01517750|Continuous Positive Airway Pressure
1113108|NCT01517750|ICON
1113109|NCT01517750|ThermoSmart
1113110|NCT01517724|MM
1113111|NCT01517724|HDT
1113112|NCT01517724|ASCT
1113113|NCT01517724|consolidation
1113114|NCT01517724|bortezomib
1113115|NCT01517711|pharmacotherapy
1113116|NCT01517711|combat disorders
1113117|NCT01517685|Eicosapentaenoic acid
1113118|NCT01517685|EPA
1113119|NCT01517685|Docosahexaenoic acid
1113120|NCT01517685|DHA
1113121|NCT01517685|Omega 3 fat
1113122|NCT01517685|alpha-linoleic acid
1113123|NCT01517685|ALA
1113124|NCT01517685|fish oil
1113125|NCT01517685|flax seed oil
1113126|NCT01517672|PTSD
1113127|NCT01517672|domestic violence
1113128|NCT01517672|intimate partner violence
1113129|NCT01517672|functional MRI
1113130|NCT01517672|neuroimaging
1113137|NCT01517633|Amniotic fluid leakage
1113138|NCT01517633|Urinary incontinence
1113139|NCT01517581|Brown adipose tissue
1113140|NCT01517542|diet
1113141|NCT01517542|DASH
1113142|NCT01517542|Stroke
1113143|NCT01517542|Nutritional counseling
1113144|NCT01517529|Hepatitis C
1113145|NCT01517529|HCV
1113146|NCT01517516|fMRI
1113147|NCT01517516|resting state
1113148|NCT01517516|structural MRI
1113149|NCT01517516|functional MRI
1113150|NCT01517477|Open angle
1113151|NCT01517477|Glaucoma
1113152|NCT01517477|surgery
1113153|NCT01517477|Glaucoma, Open-Angle
1113154|NCT01517477|Ocular Hypertension
1113155|NCT01517477|Eye Diseases
1113156|NCT01517464|neoplasm
1113157|NCT01517464|bladder cancer
1113158|NCT01517464|advances solid tumors
1113159|NCT01516463|burn
1113160|NCT01516463|partial thickness burn
1113161|NCT01516463|second degree burn
1113162|NCT01516463|minor burn
1113163|NCT01516463|scar
1113164|NCT01516463|Santyl
1113165|NCT01516463|Bacitracin
1113166|NCT01516463|outpatient burn center
1113167|NCT01516463|scar appearance
1113168|NCT01516463|Kansas City
1113169|NCT01516463|University of Kansas Medical Center
1113170|NCT01516463|KUMC
1113171|NCT01516450|GSK1550188, belimumab, SLE, healthy, Japanese, pharmacokinetics, safety
1113172|NCT01516437|Chronic Obstructive Pulmonary disease (COPD)
1113173|NCT01516424|Blonanserin
1113174|NCT01516411|Health Promotion
1113175|NCT01516411|Physical Activity
1113176|NCT01516411|Sedentary Time
1113177|NCT01516411|Smartphones
1113178|NCT01516385|spinal cord injury
1113179|NCT01516385|biomarkers
1113180|NCT01516385|rehabilitation
1113181|NCT01516385|functional independence
1113182|NCT01516385|prognosis
1113183|NCT01516372|GEn, moxifloxacin, cardiac repolarisation, QT/QTc
1113184|NCT01516346|Heart Failure
1113185|NCT01516346|Heart failure with preserved ejection fraction (HFpEF)
1113186|NCT01516346|Vasodilators
1113187|NCT01516346|Isosorbide dinitrate
1113188|NCT01516346|Hydralazine
1113189|NCT01516346|wave reflections
1113190|NCT01516346|arterial stiffness
1113191|NCT01516346|hemodynamics
1113192|NCT01516333|glycemic Index
1113193|NCT01516320|Type 2 Diabetes
1113194|NCT01516320|Gastric Bypass
1113195|NCT01516320|Laparoscopic Banding
1113196|NCT01516320|Vertical Sleeve Gastrectomy
1113197|NCT01516294|AMD
1113198|NCT01516294|PCV
1113199|NCT01516294|Iray
1113200|NCT01516294|radiation
1113201|NCT01516294|retina
1113202|NCT01516294|macula
1113203|NCT01516294|radiotherapy
1113204|NCT01516281|TBI
1113205|NCT01516281|PD
1113206|NCT01516268|Cesarean Delivery
1113207|NCT01516268|TAP block
1113208|NCT01516268|sufentanyl
1113209|NCT01516268|Narcotic dosages
1113210|NCT01517438|agitation, desflurane, children
1113211|NCT01517399|Oncology
1113212|NCT01517399|pharmacokinetics
1113213|NCT01517399|PK interaction in advanced solid tumors with our drug and other drugs
1113214|NCT01517386|paravertebral space
1113215|NCT01517386|needle placement
1113216|NCT01517386|tissue identification
1113217|NCT01517386|regional
1113218|NCT01517373|T2DM
1113219|NCT01517373|PF-04937319
1113220|NCT01517373|Phase 2
1113221|NCT01517360|Schizophrenia
1113222|NCT01517360|Social Cognition
1113223|NCT01517360|Oxytocin
1113224|NCT01517347|IL2
1113225|NCT01517347|relapse
1113226|NCT01517347|GVHD
1113227|NCT01517347|survival
1113228|NCT01517347|allogeneic stem cell transplantation
1113229|NCT01517347|MRD
1113230|NCT01517347|CR
1113231|NCT01517308|HCV
1113232|NCT01517308|Hepatitis
1113233|NCT01517308|Genotype 2 or 3
1113234|NCT01517308|Pegylated Interferon
1113235|NCT01517308|Duration
1113236|NCT01517295|Pharmacokinetics
1113237|NCT01517295|Hydromorphone
1113238|NCT01517295|Hydrocodone
1113239|NCT01517295|APAP
1113240|NCT01517269|Parent education
1113241|NCT01517256|Chronic pain
1113242|NCT01517256|Primary care
1113243|NCT01517256|Multidisciplinary group therapy
1113244|NCT01517256|Embedded mixed-methods study
1113245|NCT01517243|Metastatic Renal Cell Carcinoma
1113246|NCT01517243|sunitinib
1113247|NCT01517243|alternating
1113248|NCT01517243|temsirolimus
1113249|NCT01517230|Cluster-randomised trial
1113250|NCT01517230|Comprehensive mass media campaign
1113251|NCT01517230|Rural community radio
1113252|NCT01517230|Under-five child mortality
1113253|NCT01517230|Preventive and curative behaviours
1113254|NCT01517230|Burkina Faso
1113255|NCT01517230|Health care seeking behavior
1113256|NCT01517230|Childbirth
1113257|NCT01517217|girdle
1113258|NCT01517217|laparotomy
1113259|NCT01517217|pulmonary function
1113260|NCT01517217|postoperative pain
1113261|NCT01517217|mobilisation
1113262|NCT01517204|Trachway(R) intubating stylet
1113263|NCT01517204|Left sided double lumen endobronchial tube
1113264|NCT01517204|Efficacy
1113265|NCT01517204|Intubation complication
1113266|NCT01517191|Influenza
1113267|NCT01517191|Respiratory Infection
1113268|NCT01517165|Opioid Dependence
1113269|NCT01517165|Pioglitazone
1113270|NCT01517165|Buprenorphine
1113271|NCT01517152|Symptoms
1113272|NCT01517152|Patient-Reported Outcomes
1113273|NCT01517152|Linguistic Validation
1113274|NCT01517152|Toxicity
1113275|NCT01517152|PRO-CTCAE
1113276|NCT01517152|Adverse Events
1113277|NCT01517152|Translation
1113278|NCT01517152|Questionnaire
1113279|NCT01517139|Diet and Nutrition
1113280|NCT01517139|Pregnancy Folic Acid
1113281|NCT01517139|In Utero Exposure
1113282|NCT01517139|DNA Methylation
1113283|NCT01517139|Physical Activity
1113284|NCT01517126|Youth Suicide
1113285|NCT01517126|Suicide Screening
1113286|NCT01517126|Developmental Delay
1113287|NCT01517126|Intellectual Disability
1113288|NCT01517126|Assessment Instrument
1113289|NCT01517126|Mental Retardation
1113290|NCT01517126|Suicidal Thoughts
1113291|NCT01517126|Suicidal Behavior
1113292|NCT01517113|Endothelial Dysfunction
1113293|NCT01517113|Hepatic
1113294|NCT01517113|Adiposity
1113295|NCT01517113|Cytokines
1113296|NCT01517113|Muscle Mass
1113297|NCT01517113|Coronary Artery Disease
1113298|NCT01517113|Aging
1113299|NCT01517113|Inflammation
1113300|NCT01517100|Glucose
1113301|NCT01517100|Insulin Secretion
1113302|NCT01517100|Insulin Action
1113303|NCT01517100|Endocannabinoids
1113304|NCT01517100|Insulin
1113305|NCT01517100|Metabolism
1113306|NCT01517087|Motor Function
1113307|NCT01517087|Magnetic Resonance Spectroscopy
1113308|NCT01517087|Transcranial Magnetic Stimulation (TMS)
1113309|NCT01517087|Diffusion Tensor Imaging
1113310|NCT01517087|Functional Magnetic Resonance Imaging (fMRI)
1113311|NCT01517087|Healthy Volunteer
1113312|NCT01517087|HV
1113313|NCT01517074|Sirolimus
1113314|NCT01517074|Scleritis
1113315|NCT01517074|Autoimmune Scleritis
1113316|NCT01517061|Phantom Limb Pain
1113317|NCT01517061|Genetic Polymorphisms
1113318|NCT01517061|Genetic Susceptibility
1113319|NCT01517061|Amputation
1113320|NCT01517048|Body Composition
1113321|NCT01517048|Obesity
1113322|NCT01517048|Overweight
1113323|NCT01517048|Energy Homeostasis
1113324|NCT01517048|Nociception
1113325|NCT01517048|Prader-Willi Syndrome
1113326|NCT01517048|Genetic Disorder
1113327|NCT01517048|Healthy Volunteer
1113328|NCT01517048|HV
1113329|NCT01517035|Peripheral Blood Stem Cell Transplantation
1113330|NCT01517035|Stem Cell Transplant
1113331|NCT01517035|Transplant
1113332|NCT01517035|Myelodyplastic Syndrome
1113333|NCT01517035|MDS
1113334|NCT01517035|Leukemia
1113335|NCT01517022|smoking cessation
1113336|NCT01517022|early sputum smear conversion
1113337|NCT01517009|Neo-adjuvant chemotherapy
1113338|NCT01517009|D1extra-resection
1113339|NCT01516996|Neoadjuvant
1113340|NCT01516996|Concurrent Chemoradiotherapy,CCRT
1113341|NCT01516996|Nimotuzumab
1113342|NCT01516996|Locoregionally Advanced Oropharynx
1113343|NCT01516996|Hypopharynx cancer
1113344|NCT01516996|Randomized
1113345|NCT01516996|Multicenter
1113346|NCT01516983|Safety
1113347|NCT01516983|EGFR-TKI
1113348|NCT01516983|NSCLC
1113349|NCT01516983|Icotinib
1113350|NCT01516983|WBRT
1113351|NCT01516970|Human Immunodeficiency Virus (HIV) Post exposure prophylaxis
1113352|NCT01516970|DRV/r
1113353|NCT01516970|Occupational injury
1113354|NCT01516970|Non-occupational exposure
1113355|NCT01516970|Prezista
1113356|NCT01516970|Darunavir/r
1113357|NCT01516957|Psoriatic Arthritis
1113358|NCT01516957|IL-17
1113359|NCT01516957|AMG 827
1113360|NCT01516957|AMG827
1113361|NCT01516957|Musculoskeletal Disease
1113362|NCT01516957|Spondylarthropathy
1113363|NCT01516944|Tegafur，Gimeracil and Oteracil Potassium Capsules
1113364|NCT01516944|Capecitabine
1113365|NCT01516944|Oxaliplatin
1113366|NCT01516944|perioperative Chemotherapy
1113367|NCT01516944|Gastric Cancer
1113368|NCT01516931|repetitive Transcranial Magnetic Stimulation (rTMS)
1113369|NCT01516931|Depression
1113370|NCT01516931|Venlafaxine
1113371|NCT01516931|Relapse
1113372|NCT01516879|Cholesterol
1113373|NCT01516879|High Cholesterol
1113374|NCT01516879|Elevated Cholesterol
1113375|NCT01516879|Raised Cholesterol
1113376|NCT01516866|Androgen receptor-directed therapy
1113377|NCT01516866|NaF PET/CT
1113378|NCT01516866|antimicrotubule directed chemotherapy
1113379|NCT01516840|acute symptomatic deep vein thrombosis
1113380|NCT01516827|PTSD
1113381|NCT01516827|Children and Adolescents
1113382|NCT01516827|Post-Traumatic Stress Disorder in Children and Adolescents
1113383|NCT01516814|acute symptomatic pulmonary embolism
1113384|NCT01516801|Prostate Cancer Screening
1113385|NCT01516801|Pragmatic Trial
1113386|NCT01516801|Health Literacy
1113387|NCT01516775|preoperative care
1113388|NCT01516775|preoperative period
1113389|NCT01516775|fasting
1113390|NCT01516762|Radium 223
1113391|NCT01516762|Alpharadin
1113392|NCT01516762|Prostate Cancer
1113393|NCT01516762|Bone metastases
1113394|NCT01516762|Castrate resistant prostate cancer
1113395|NCT01516762|Hormone refractory prostate cancer
1113396|NCT01516749|hidradenitis suppurativa
1113397|NCT01516749|anakinra
1113398|NCT01516736|Pegfilgrastim
1113399|NCT01516736|G-CSF
1113400|NCT01516736|neutropenia
1113401|NCT01516736|breast cancer
1113402|NCT01516736|myelosuppressive chemotherapy
1113403|NCT01516723|drug-eluting stent
1113404|NCT01516723|chronic total occlusion
1113405|NCT01516723|hybrid sirolimus-eluting stent
1113406|NCT01516723|everolimus-eluting stent
1113407|NCT01516710|Open liver resection
1113408|NCT01516710|Laparoscopic liver resection
1113409|NCT01516710|Colorectal cancer liver metastases
1113410|NCT01516697|thoracic electric bioimpedance
1113411|NCT01516697|cardiac output monitoring
1113412|NCT01516697|cesarean section
1113413|NCT01516697|spinal anesthesia
1113414|NCT01516671|Subarachnoid hemorrhage
1113415|NCT01516671|Cerebral vasospasm
1113416|NCT01516671|Neuroinflammation
1113417|NCT01516671|Bilateral Bispectral Index
1113418|NCT01516658|intracranial aneurysm
1113419|NCT01516658|endovascular therapy
1113420|NCT01516658|detachable coil
1113421|NCT01516658|recanalization
1113422|NCT01516645|Squamous cell type tumor
1113423|NCT01516632|Cellular Phone
1113424|NCT01516632|Mobile Phone
1113425|NCT01516632|Cognitive Behavior Therapy
1113426|NCT01516632|Technology
1113427|NCT01516632|Smoking cessation
1113428|NCT01516632|young adults
1113429|NCT01516619|NHL
1113430|NCT01516619|chemotherapy-induced grade-4 thrombocytopenia
1113431|NCT01516606|MALT
1113432|NCT01516606|refractory
1113433|NCT01516606|relapsed
1113434|NCT01516606|extranodal
1113435|NCT01516606|relapsed or refractory extranodal marginal zone lymphoma
1113436|NCT01516593|HIV
1113437|NCT01516593|Burkitt's lymphoma
1113438|NCT01516593|intensive
1113439|NCT01516593|short term
1113440|NCT01516593|immuno-chemotherapy
1113441|NCT01516593|HIV-positive patients with Burkitt's lymphoma
1113442|NCT01516554|Multiple Sclerosis
1113443|NCT01516554|Fatigue
1113444|NCT01516528|COPD
1113445|NCT01516528|exacerbation
1113446|NCT01516528|comorbidities
1113447|NCT01516528|lung function
1113448|NCT01516528|burden
1113449|NCT01516528|chronic bronchitis
1113450|NCT01516528|emphysema
1113451|NCT01516528|prevalence
1113452|NCT01516528|cardiovascular disease
1113453|NCT01516515|Actinic Keratosis
1113454|NCT01516515|AK
1113455|NCT01516502|laser therapy
1113456|NCT01516502|myofascial pain syndrome
1113457|NCT01516502|acupoint
1113458|NCT01516502|trigger point
1113459|NCT01516502|range of motion
1113460|NCT01516489|screening
1113461|NCT01516489|colon cancer
1113462|NCT01516489|incentives
1113463|NCT01516489|behavioral economics
1113464|NCT01516216|previously untreated
1113465|NCT01516203|AZD5847,dose-ranging,Mycobacterium tuberculosis,Rifafour,tuberculosis
1113466|NCT01516190|stage I-III breast cancer
1113467|NCT01516177|Kidney Transplantation
1113468|NCT01516177|kidney transplant
1113469|NCT01516177|renal transplant
1113470|NCT01516177|immunosuppression
1113471|NCT01516164|Laryngoscopy
1113472|NCT01516164|Videolaryngoscopy
1113473|NCT01516164|Ease of Intubation
1113474|NCT01516151|Hypertriglyceridemia
1113475|NCT01516138|Glucose-insulin-potassium
1113476|NCT01516138|Cardiac surgery
1113477|NCT01516125|healthy adult
1113478|NCT01516125|genetic variation
1113479|NCT01516125|botanical oils
1113480|NCT01516125|polyunsaturated fatty acid
1113481|NCT01516125|fish oil
1113482|NCT01516125|fat metabolism
1113483|NCT01516125|Genetic variation of fat metabolism in healthy adults
1113484|NCT01516112|ICD, home monitoring, cardiomessenger, implant
1113485|NCT01516099|Physical activity counselor
1113486|NCT01516099|Active and healthy lifestyle
1113487|NCT01516099|General Practitioner
1113488|NCT01516099|Social-cultural Organization
1113489|NCT01516086|Controlled
1113490|NCT01516086|uncontrolled
1113491|NCT01516073|partially controlled
1113492|NCT01516073|uncontrolled
1113493|NCT01516047|Hepatic impairment
1113494|NCT01516047|Pharmacology
1113495|NCT01516047|Pharmacokinetics
1113496|NCT01516047|Pharmacodynamics
1113497|NCT01516047|Abiraterone acetate suspension
1113498|NCT01516047|JNJ-212082
1113499|NCT01516034|Tattoo removal
1113500|NCT01516034|ultrasound
1113501|NCT01516021|Fat ingestion
1113502|NCT01516021|hypothalamus
1113503|NCT01516021|insula
1113504|NCT01516021|fMRI
1113505|NCT01516021|CBF
1113506|NCT01516008|Hallux Valgus
1113507|NCT01516008|Bunionectomy
1113508|NCT01516008|Bunion
1113509|NCT01516008|Acute pain
1113510|NCT01516008|Tapentadol
1113511|NCT01516008|Tapentadol IR
1113512|NCT01515995|Magnesium sulfate
1113513|NCT01515995|Childhood asthma
1113514|NCT01515995|Emergency department
1113515|NCT01515982|Alzheimer's disease
1113516|NCT01515982|Aerobic exercise
1113517|NCT01515982|Physical training
1113518|NCT01515982|Cognitive function
1113519|NCT01515982|Functional capacity.
1113520|NCT01515956|Mucopolysaccharidosis IVA type A
1113521|NCT01515956|MPS IVA Type A
1113522|NCT01515956|Mucopolysaccharidosis IVA
1113523|NCT01515956|MPS IVA
1113524|NCT01515956|Morquio A Syndrome
1113525|NCT01515956|Lysosomal Storage Disorder
1113526|NCT01515956|LSD
1113527|NCT01515956|N-acetylgalactosamine-6-sulfatase
1113528|NCT01515956|N-acetylgalactosamine-6-sulfate
1113529|NCT01515956|sulfatase
1113530|NCT01515956|galactose-6-sulfatase
1113531|NCT01515956|GALNS
1113532|NCT01515956|enzyme replacement therapy
1113533|NCT01515956|ERT
1113534|NCT01515943|Convergence insufficiency
1113535|NCT01515930|Parenting
1113536|NCT01515930|Parental Monitoring
1113537|NCT01515930|Diabetes
1113538|NCT01515930|Care
1113539|NCT01515917|Veterans
1113540|NCT01515917|Traumatic Brain Injury
1113541|NCT01515917|TBI
1113542|NCT01515917|Substance Abuse
1113543|NCT01515917|Substance Dependence
1113544|NCT01515917|Veterans with traumatic brain injury (TBI)
1113545|NCT01515917|Veterans with substance abuse or dependence
1113546|NCT01515904|obesity management
1113547|NCT01515904|adolescents
1113548|NCT01515904|body mass index
1113549|NCT01515904|treatment outcomes
1113550|NCT01515904|program evaluation
1113551|NCT01515891|Parkinson Disease
1113552|NCT01515891|BIA 9-1067
1113553|NCT01515852|stress level
1113554|NCT01515852|stereotactic biopsy
1113555|NCT01515852|brain lesion
1113556|NCT01515852|general anesthesia
1113557|NCT01515852|local anesthesia
1113558|NCT01515839|SPECT
1113559|NCT01515839|Imaging
1113560|NCT01515839|Football
1113561|NCT01515839|Traumatic brain injury
1113562|NCT01515839|Regional cerebral blood flow
1113563|NCT01515826|Cataract surgery
1113564|NCT01515826|Topical therapy
1113565|NCT01515826|Prevention of inflammation
1113566|NCT01515826|Inflammation of infection
1113567|NCT01515800|estrogen receptor-positive breast cancer
1113568|NCT01515800|progesterone receptor-positive breast cancer
1113569|NCT01515800|stage IA breast cancer
1113570|NCT01515800|stage IB breast cancer
1113571|NCT01515800|stage II breast cancer
1113572|NCT01515800|stage IIIA breast cancer
1113576|NCT01515774|Parkinson's disease
1113577|NCT01515774|Pramipexole
1113578|NCT01515722|Medication Persistence
1113579|NCT01515722|Compliance
1113580|NCT01515722|Health Education Intervention (HEI)
1113581|NCT01515709|Cohort Studies
1113582|NCT01515709|Longitudinal Studies
1113583|NCT01515696|VLBW infant
1113584|NCT01515696|Meconium
1113585|NCT01515696|Enteral nutrition
1113586|NCT01515696|Meconium passage
1113587|NCT01515683|Nervousness before anesthesia
1113588|NCT01515670|THA
1113589|NCT01515670|TKA
1113590|NCT01515670|Fast-track
1113591|NCT01515670|Enhanced recovery
1113592|NCT01515670|preoperative co-morbidity
1113593|NCT01515670|postoperative morbidity
1113594|NCT01515670|Arthroplasty
1113595|NCT01515670|Replacement
1113596|NCT01515670|Hip
1113597|NCT01515670|Knee
1113598|NCT01515670|Morbidity
1113599|NCT01515644|Healthy infants
1113600|NCT01515644|Infant formula
1113601|NCT01515644|Prebiotics
1113602|NCT01515566|Advanced Cancer
1113603|NCT01515566|Dyspnea
1113604|NCT01515566|Exercise-induced breakthrough dyspnea
1113605|NCT01515566|Shortness of breath
1113606|NCT01515566|Fentanyl
1113607|NCT01515566|Sublimaze
1113608|NCT01515566|Placebo
1113609|NCT01515566|Normal saline
1113610|NCT01515566|NS
1113611|NCT01515566|Questionnaires
1113612|NCT01515566|Surveys
1113613|NCT01515566|Walk test
1113614|NCT01515540|chronic back pain
1113615|NCT01515540|placebo
1113616|NCT01515540|fmri
1113617|NCT01515540|brain imaging
1113618|NCT01515527|Leukemia
1113619|NCT01515527|Acute myeloid leukemia
1113620|NCT01515527|AML
1113621|NCT01515527|myelodysplastic syndrome
1113622|NCT01515527|MDS
1113623|NCT01515527|Cytarabine
1113624|NCT01515527|Ara-C
1113625|NCT01515527|Cytosar
1113626|NCT01515527|DepoCyt
1113627|NCT01515527|Cytosine Arabinosine Hydrochloride
1113628|NCT01515527|Decitabine
1113629|NCT01515527|Dacogen
1113630|NCT01515527|Cladribine
1113631|NCT01515527|Leustatin
1113632|NCT01515527|2-CdA
1113633|NCT01515514|polyps
1113634|NCT01515514|inflammatory bowel disease
1113635|NCT01515514|associated neoplasia
1113636|NCT01515501|Constipation
1113637|NCT01515501|Hirschsprung Disease
1113638|NCT01515488|Triage
1113639|NCT01515488|Automated
1113640|NCT01515488|Admitting
1113641|NCT01515488|Pediatric ED
1113642|NCT01515475|Hyperopia
1113643|NCT01515475|Glasses
1113644|NCT01515462|Lentiviral vector
1113645|NCT01515462|Gene therapy
1113646|NCT01515462|Wiskott-Aldrich Syndrome
1113647|NCT01515436|Rolandic Epilepsy
1113648|NCT01515436|Benign Childhood Epilepsy with Centrotemporal Spikes (BCECTS)
1113649|NCT01515436|Epilepsy
1113650|NCT01515436|Seizures
1113651|NCT01515436|Music
1113652|NCT01515436|Mozart
1113653|NCT01515436|Beethoven
1113654|NCT01515423|Schizophrenia
1113655|NCT01515423|R092670
1113656|NCT01515423|Paliperidone Palmitate
1113657|NCT01515423|Paliperidone palmitate 1 month formulation (PP1M)
1113658|NCT01515423|Paliperidone palmitate 3 month formulation (PP3M)
1113659|NCT01515410|Parkinson's disease
1113660|NCT01515410|PD
1113661|NCT01515410|stage2/3Parkinson's
1113662|NCT01515410|Advanced Parkinson's Disease with Motor Fluctuations
1113663|NCT01515345|clopidogrel-nonresponder
1113664|NCT01515345|stent thrombosis
1113665|NCT01515319|Obesity
1113666|NCT01515319|Peptide YY
1113667|NCT01515319|Food intake
1113668|NCT01515319|Safety
1113669|NCT01515319|Pharmacokinetics
1113670|NCT01515306|Advanced Malignant Solid Tumors
1113671|NCT01515280|chronic cough
1113672|NCT01515267|EF
1113673|NCT01515267|EDV
1113674|NCT01515267|ESV
1113675|NCT01515267|Biplane
1113676|NCT01515267|Echocardiography
1113677|NCT01515254|Children
1113678|NCT01515254|Obesity Prevention
1113679|NCT01515254|Child Overweight
1113680|NCT01515254|Eating Behavior
1113681|NCT01515254|Energy Compensation
1113682|NCT01515254|Food Intake
1113683|NCT01515254|Parenting Behavior
1113684|NCT01515241|Heterozygous Familial Hypercholesterolemia
1113685|NCT01515241|Familial Hypercholesterolemia
1113686|NCT01515241|HDL mimetic
1113687|NCT01515241|ApoA-1
1113688|NCT01515228|requiring drug eluting stents
1113689|NCT01515215|Major Depression Disorder
1113690|NCT01515215|Treatment Resistance
1113691|NCT01515215|repetitive Transcranial Magnetic Stimulation
1113692|NCT01515150|diverticulitis
1113693|NCT01515150|Out-patient management
1113694|NCT01515150|Antibiotics
1113695|NCT01515137|Head and Neck
1113696|NCT01515137|Locally Advanced Head and Neck Squamous Cell Carcinoma
1113697|NCT01515124|Lymphedema
1113698|NCT01515124|Strength training intervention
1113699|NCT01515124|Weight loss intervention
1113700|NCT01515124|Breast cancer recurrence
1113701|NCT01515124|Cost Effectiveness
1113702|NCT01515111|Non-communicable diseases
1113703|NCT01515111|Preventive services
1113704|NCT01515111|Medical education
1113705|NCT01515111|Guatemala
1113706|NCT01515072|Remote Ischemic Preconditioning
1113707|NCT01515072|Brain death organ donors
1113708|NCT01515072|Delayed graft function
1113709|NCT01515072|Donor management
1113710|NCT01515072|Pulsatile perfusion
1113711|NCT01515059|obesity
1113712|NCT01515059|diabetes
1113713|NCT01515059|bariatric surgery
1113714|NCT01515059|gastric bypass
1113715|NCT01515059|insulin
1113716|NCT01515059|glucose
1113717|NCT01515059|incretins
1113718|NCT01515059|leptin
1113719|NCT01515059|ghrelin
1113720|NCT01515046|Vitamins
1113721|NCT01515046|Complementary medicine
1113722|NCT01515046|Pancreatic cancer
1113723|NCT01515046|Ascorbate
1113724|NCT01515046|Ascorbic Acid
1113725|NCT01515046|Antioxidants
1113726|NCT01515046|Gemcitabine
1113727|NCT01515046|Pharmacologic actions
1113728|NCT01515033|Coronary artery disease
1113729|NCT01515033|Exercise
1113730|NCT01515033|Ventilatory efficiency
1113731|NCT01515020|bacteremia
1113732|NCT01515020|meticillin-resistant Staphylococcus aureus
1113733|NCT01515020|nosocomial infection
1113734|NCT01515020|healthcare-associated infection
1113735|NCT01515020|rapid molecular diagnostic test
1113736|NCT01515007|Bronchiectasis, non-CF, Ciprofloxacin, Liposome
1113737|NCT01514981|Asthma
1113738|NCT01514942|PCOS
1113739|NCT01514942|Insulin resistance
1113740|NCT01514942|Myo-inositol
1113741|NCT01514942|D-chiro-inositol
1113742|NCT01514929|Thorough QT
1113743|NCT01514903|anti erectile dysfunction agent
1113744|NCT01514877|tumors metastatic to brain
1113745|NCT01514877|non-small cell lung cancer
1113746|NCT01514877|Icotinib
1113747|NCT01514851|Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis
1113748|NCT01514838|ASP1941
1113749|NCT01514838|ipragliflozin
1113750|NCT01514838|plasma glucose
1113751|NCT01514838|urine glucose
1113752|NCT01514825|YM150
1113753|NCT01514825|Plasma concentration
1113754|NCT01514825|darexaban
1113755|NCT01514825|Healthy elderly subject
1113756|NCT01514825|Pharmacokinetics of YM150
1113757|NCT01514812|YM150
1113758|NCT01514812|digoxin
1113759|NCT01514812|drug-drug interaction
1113760|NCT01514812|Plasma concentration
1113761|NCT01514812|darexaban
1113762|NCT01514812|Pharmacokinetics of digoxin
1113763|NCT01514799|gastric bypass
1113764|NCT01514799|morbid obesity
1113765|NCT01514799|gut function
1113766|NCT01514799|weight loss
1113767|NCT01514786|Colorectal Cancer
1113768|NCT01514786|Screening
1113769|NCT01514786|Prevention
1113770|NCT01514773|left ventricular systolic dysfunction
1113771|NCT01514773|implantable cardioverter defibrillator
1113772|NCT01514773|systolic heart failure
1113773|NCT01514773|congestive heart failure
1113774|NCT01514773|Ischemic cardiomyopathy
1113775|NCT01514773|Nonischemic cardiomyopathy
1113776|NCT01514773|ICD
1113777|NCT01514773|ICD utilization
1113778|NCT01514773|ICD implantation
1113779|NCT01514773|defibrillator
1113780|NCT01514773|defibrillator therapy
1113781|NCT01514773|sudden cardiac death
1113782|NCT01514760|Adolescents
1113783|NCT01514760|Mobile based applications
1113784|NCT01514760|Asthma action plan
1113785|NCT01514760|Self Efficacy
1113786|NCT01514734|Primary open-angle glaucoma
1113787|NCT01514734|Ocular hypertension
1113788|NCT01514734|Pigment dispersion glaucoma
1113789|NCT01514721|Open-angle glaucoma
1113790|NCT01514721|Ocular hypertension
1113791|NCT01514721|Pigment dispersion glaucoma
1113792|NCT01514708|Influenza
1113793|NCT01514708|Vaccination
1113794|NCT01514708|Vaccine
1113795|NCT01514708|Pregnancy
1113796|NCT01514695|endoscopy
1113797|NCT01514695|sedation
1113798|NCT01514695|opioid
1113799|NCT01514695|narcotic
1113800|NCT01514682|schizophrenia
1113801|NCT01514682|anti-inflammatory
1113802|NCT01514682|salsalate
1113803|NCT01514682|statins
1113804|NCT01514682|omega-3-fatty acids
1113805|NCT01514643|tibial plateau fracture
1113806|NCT01514643|tibial plafond fracture
1113807|NCT01514643|inflammatory cytokine profile
1113808|NCT01514643|synovial fluid
1113809|NCT01514643|blood serum
1113810|NCT01514643|Post-traumatic osteoarthritis (PTOA)
1113811|NCT01514617|Leiomyoma
1113812|NCT01514617|Diffusion weighted MRI
1113813|NCT01514617|Perfusion MRI
1113814|NCT01514617|Uterine artery embolization
1113815|NCT01514617|Volumetric Response
1113816|NCT01514617|Women with symptomatic leiomyomas
1113817|NCT01514604|Anesthesia and analgesia
1113818|NCT01514604|ultrasonography
1113819|NCT01514604|education
1113820|NCT01514578|safety
1113821|NCT01514578|tolerability
1113822|NCT01514578|TRV130A
1113823|NCT01514565|Triple negative Breast Cancer
1113824|NCT01514565|RB
1113825|NCT01514565|PTEN
1113826|NCT01514565|Chemotherapy
1113827|NCT01514565|Neoadjuvant
1113828|NCT01514552|Functional food
1113829|NCT01514552|Strawberries
1113830|NCT01514552|Gummies
1113831|NCT01514552|Smoker
1113832|NCT01514552|Nonsmoker
1113833|NCT01514539|Human milk, Ghrelin,PYY and maternal obesity.
1113834|NCT01514526|Adrenocortical carcinoma
1113835|NCT01514461|Hyperlipoproteinemia (HLP Type I)
1113836|NCT01514461|Fasting Triglycerides
1113837|NCT01514448|Kidney cancer
1113838|NCT01514448|mRCC
1113839|NCT01514448|metastic renal cell carcinoma
1113840|NCT01514448|everolimus
1113841|NCT01514448|sunitinib
1113842|NCT01514448|pazopanib
1113843|NCT01514435|depression
1113844|NCT01514435|FDG-PET
1113845|NCT01514435|Electroconvulsive therapy
1113846|NCT01514435|glucose metabolism
1113847|NCT01514422|Bipolar disorder
1113848|NCT01514422|depression
1113849|NCT01514422|minocycline
1113850|NCT01514422|mood disorders
1113851|NCT01514422|bipolar depression
1113852|NCT01514409|5-hydroxytryptophan
1113853|NCT01514409|Mood
1113854|NCT01514409|Emotional Processing
1113855|NCT01514409|Emotional Cognition
1113856|NCT01514409|Nutritional Supplement
1113857|NCT01514409|Low mood
1113858|NCT01514396|Pediatric
1113859|NCT01514396|Wounds
1113860|NCT01514383|wounds
1113861|NCT01514370|Multiple Sclerosis
1113862|NCT01514370|Relapsing
1113863|NCT01514370|Interferon beta 1a
1113864|NCT01514370|Curcumin
1113865|NCT01514344|OAL
1113866|NCT01514344|MALT
1113867|NCT01514344|conjunctiva
1113868|NCT01514344|indolent
1113869|NCT01514344|CD20+
1113870|NCT01514331|Ventilator Induced Lung Injury
1113871|NCT01514331|Neonatal respiratory distress
1113872|NCT01514331|Mechanical ventilation
1113873|NCT01514279|Overweight
1113874|NCT01514279|Obese
1113875|NCT01514279|Over Nutrition
1113876|NCT01514279|Nutrition Disorders
1113877|NCT01514279|Body weight
1113878|NCT01514279|Signs and Symptoms
1113879|NCT01514266|proven diagnosis
1113880|NCT01514266|COPD
1113881|NCT01514266|sputum
1113882|NCT01514253|glucose
1113883|NCT01514253|analgesic
1113884|NCT01514253|newborns
1113885|NCT01514240|mild to moderate active Crohn's disease
1113886|NCT01514240|affecting ileum
1113887|NCT01514240|ileocecal region
1113888|NCT01514240|ascending colon
1113889|NCT01514240|score of 180-400 on the CDAI
1113890|NCT01514214|ERCP
1113891|NCT01514214|biliary stricture
1113892|NCT01514214|viaduct
1113893|NCT01514214|cancer
1113894|NCT01514188|sarcoma
1113895|NCT01514188|soft-tissue sarcoma
1113896|NCT01514188|Metastatic,locally advanced, or unresectable soft tissue sarcoma
1113897|NCT01514175|Ketorolac
1113898|NCT01514175|Caldolor
1113899|NCT01514175|Chronic Pelvic Pain
1113900|NCT01514162|Trifecta Valve
1113901|NCT01514149|Type 2 Diabetes Mellitus
1113902|NCT01514149|T2DM
1113903|NCT01514149|diabetes
1113904|NCT01514149|ConjuChem
1113905|NCT01514149|GLP-1
1113906|NCT01514149|Glucagon-like peptide-1
1113907|NCT01514149|exendin-4
1113908|NCT01514149|modified exendin-4
1113909|NCT01514123|VGX-100
1113910|NCT01514123|Bevacizumab
1113911|NCT01514123|VEGF-C
1113912|NCT01514123|First-In-Human
1113913|NCT01514123|Dose Escalation
1113914|NCT01514123|Advanced Solid Tumors
1113915|NCT01514123|Angiogenesis Inhibitors
1113916|NCT01514123|Angiogenesis Modulating Agents
1113917|NCT01514123|Pharmacologic Actions
1113918|NCT01514123|Antibodies, Monoclonal
1113919|NCT01514123|Phase 1
1113920|NCT01514123|Oncology
1113921|NCT01514123|Advanced malignancy
1113922|NCT01514097|emergency
1113923|NCT01514097|pediatric
1113924|NCT01514097|fracture
1113925|NCT01514097|pain
1113926|NCT01514084|laceration
1113927|NCT01514084|emergency
1113928|NCT01514084|cosmetic outcomes
1113929|NCT01514084|patient satisfaction
1113930|NCT01514084|suture
1113931|NCT01514071|head injury
1113932|NCT01514071|CT
1113933|NCT01514071|emergency
1113934|NCT01514071|radiation
1113935|NCT01514045|Quality of Life
1113936|NCT01514019|SLCO2B1 genotype
1113937|NCT01514019|effect of apple juice
1113938|NCT01514006|Primary hip arthroplasty
1113939|NCT01514006|postoperative anemia
1113940|NCT01514006|functional outcomes
1113941|NCT01513993|CHF
1113942|NCT01513993|Telemonitoring
1113943|NCT01513980|Chronic Obstructive Pulmonary Disease
1113944|NCT01513980|Telemonitoring
1113945|NCT01513967|Alzheimer,
1113946|NCT01513967|dementia
1113947|NCT01513954|Infertility
1113948|NCT01513941|Chronic hepatitis C
1113949|NCT01513941|Genotype 1 chronic hepatitis C
1113950|NCT01513941|Treatment experienced with HCV-1/HIV-1 coinfection
1113951|NCT01513941|Telaprevir
1113952|NCT01513941|Pegylated-Interferon-alfa-2a
1113953|NCT01513941|Ribavirin
1113954|NCT01513941|HCV-1/HIV-1 coinfection
1113955|NCT01513941|Hepatitis C
1113956|NCT01513928|pharmacokinetics
1113957|NCT01513928|relative bioavailability
1113958|NCT01513928|formulation comparison
1113959|NCT01513915|parents
1113960|NCT01513915|group cognitive behavioral intervention
1113961|NCT01513915|anxiety disorder
1113962|NCT01513915|children
1113963|NCT01513915|FRIENDS program
1113964|NCT01513902|Arthritis
1113965|NCT01513902|Pediatric
1113966|NCT01513902|Tofacitinib
1113967|NCT01513902|JIA
1113968|NCT01513850|Liver Transplantation
1113969|NCT01513850|HBV
1113970|NCT01513850|HBV Recurrence
1113971|NCT01513850|HBsAg Positive
1113972|NCT01513824|stress
1113973|NCT01513824|biofeed back guided treatment
1113974|NCT01513824|acupressure
1113975|NCT01513824|ischemic heart disease
1113976|NCT01513811|bowel preparation
1113977|NCT01513811|constipation
1113978|NCT01513811|polyethylene glycol
1113979|NCT01513811|itopride
1113980|NCT01513798|Diet Therapy
1113981|NCT01513798|Exercise Therapy
1113982|NCT01513798|Insulin Resistance
1113983|NCT01513785|H. pylori
1113984|NCT01513785|Dual therapy
1113985|NCT01513785|Amoxicillin
1113986|NCT01513785|Rabeprazole
1113987|NCT01513759|Fibrinolysis
1113988|NCT01513759|catheter directed fibrinolysis
1113989|NCT01513759|ultrasound accelerated fibrinolysis
1113990|NCT01513759|recombinant t-PA
1113991|NCT01513759|Activase
1113992|NCT01513746|Type 1 Diabetes
1113993|NCT01513746|Type 1 Diabetes Mellitus
1113994|NCT01513746|Eating Disorders
1113995|NCT01513746|Insulin Omission
1113996|NCT01513720|Bioequivalence
1113997|NCT01513720|Lamotrigine
1113998|NCT01513720|crossover
1113999|NCT01513707|kidney transplantation
1114000|NCT01513707|hemodialysis
1114001|NCT01513707|peritoneal dialysis
1114002|NCT01513694|Mesenchymal Stem Cells
1114003|NCT01513694|Stem Cells
1114004|NCT01513694|Intervertebral disc disease
1114005|NCT01513681|Bioequivalence
1114006|NCT01513681|Lamotrigine
1114007|NCT01513681|crossover
1114008|NCT01513655|COPD
1114009|NCT01513655|Home NIV
1114010|NCT01513655|NIV
1114011|NCT01513642|physiotherapy
1114012|NCT01513642|cardiac surgery
1114013|NCT01513642|breath Stacking
1114014|NCT01513629|Autism spectrum disorders
1114015|NCT01513629|structural connectivity
1114016|NCT01513629|diffusion spectrum imaging
1114017|NCT01513629|sibling
1114018|NCT01513629|endophenotype
1114019|NCT01513616|COPD
1114020|NCT01513616|dyspnea
1114021|NCT01513616|exercise
1114022|NCT01513616|measurement
1114023|NCT01513616|respiratory physiology
1114024|NCT01513577|Lumbar fusion
1114025|NCT01513577|Pedicular screws
1114026|NCT01513577|Minimal invasive technique
1114027|NCT01513577|Randomized controlled trial
1114028|NCT01513564|Disc disease
1114029|NCT01513564|Spondylolisthesis
1114030|NCT01513538|Pacemaker programming
1114031|NCT01513538|Bradyarrhythmia
1114032|NCT01513499|Eating behavior
1114033|NCT01513499|Appetite
1114034|NCT01513499|Oxytocin
1114035|NCT01513499|Neuropeptide
1114036|NCT01513460|Chronic Obstructive Pulmonary Disease,
1114037|NCT01513460|NVA 237,
1114038|NCT01513460|glycopyrronium,
1114039|NCT01513460|COPD
1114040|NCT01513447|sterile water injections
1114041|NCT01513447|back labor
1114042|NCT01513421|Infected
1114043|NCT01513421|Intra-abdominal
1114044|NCT01513421|Collection
1114045|NCT01513421|Drainage
1114046|NCT01513421|Percutaneous
1114051|NCT01513395|Cervical assessment
1114052|NCT01513395|Focal myometrial contractions
1114053|NCT01513382|Pilonidal sinus
1114054|NCT01513382|Methylene blue
1114055|NCT01513382|Histopathology
1114056|NCT01513382|Surgery
1114057|NCT01513369|Diabetes
1114058|NCT01513369|iron deficiency
1114059|NCT01513356|breast
1114060|NCT01513356|cancer
1114061|NCT01513356|BKM120
1114062|NCT01513317|Myelodysplastic Syndrome
1114063|NCT01513317|MDS
1114064|NCT01513317|Blood and lymphatic diseases
1114065|NCT01513317|Siltuximab
1114066|NCT01513317|Anemic
1114067|NCT01513265|reduction polypharmacy
1114068|NCT01513265|clinical outcomes
1114069|NCT01513265|pharmaceutical care
1114070|NCT01513265|clinical pharmacy
1114071|NCT01513265|geriatrics
1114072|NCT01513265|medication review
1114073|NCT01513265|potentially inappropriate drugs
1114074|NCT01513252|Cognitive decline
1114075|NCT01513252|prevention
1114076|NCT01513252|omega-3 fatty acids
1114077|NCT01513252|nutrition exercise
1114078|NCT01513252|cognitive training
1114079|NCT01513252|social activities
1114080|NCT01513252|frailty
1114081|NCT01513239|Clostridium difficile
1114082|NCT01513239|Clostridium difficile infection (CDI)
1114083|NCT01513239|recurrent Clostridium difficile
1114084|NCT01513239|vancomycin
1114085|NCT01513239|metronidazole
1114086|NCT01513239|monoclonal antibody
1114087|NCT01513226|cycled light
1114088|NCT01513226|dim light
1114089|NCT01513226|circadian rhythm
1114090|NCT01513226|actigraphy, sleep
1114091|NCT01513226|premature infant
1114092|NCT01513213|Arterial cannulation
1114093|NCT01513213|Blood gas
1114094|NCT01513213|Carbon dioxide
1114095|NCT01513213|Arterial blood
1114096|NCT01513213|Oxygen
1114097|NCT01513213|Oxygen fractions
1114098|NCT01513187|Advanced renal cell carcinoma
1114099|NCT01513187|SOGUG
1114100|NCT01513187|Pazopanib
1114101|NCT01513187|Pazopanib in combination with interferon alpha 2A
1114102|NCT01513174|GOAL
1114103|NCT01513174|Lung
1114104|NCT01513174|Non small cell lung cancer
1114105|NCT01513174|EGFR mutations
1114106|NCT01513161|pruritus
1114107|NCT01513135|HIV,
1114108|NCT01513135|HAART-treated
1114109|NCT01513135|participants
1114110|NCT01513135|Tat protein,
1114111|NCT01513135|Therapeutic immunization
1114112|NCT01513109|WT1 positive Acute Myeloid Leukemia
1114113|NCT01513109|Antigen specific cancer immunotherapeutic
1114114|NCT01513109|Ex vivo regulatory T cell depletion
1114115|NCT01513109|In vivo regulatory T cell depletion
1114116|NCT01513096|colonoscopy
1114117|NCT01513096|bowel preparation
1114118|NCT01513096|PEG
1114119|NCT01513096|Prokinetics
1114120|NCT01513070|Quick-Acting Heart Reliever
1114121|NCT01513070|Coronary Artery Stenosis
1114122|NCT01513070|Coronary Heart Disease
1114123|NCT01513070|Suxiao Jiuxin Pill
1114124|NCT01513070|Chinese Herbal Drugs
1114125|NCT01513070|Traditional Chinese Medicine
1114126|NCT01513070|Chinese Medicine
1114127|NCT01513070|Angina Pectoris
1114128|NCT01513070|Isosorbide Dinitrate
1114129|NCT01513070|Myocardial Perfusion Imaging
1114130|NCT01513070|Clinical Trial
1114131|NCT01513057|bioequivalence
1114132|NCT01513057|Mycophenolate Mofetil
1114133|NCT01513057|crossover
1114134|NCT01513044|bioequivalence
1114135|NCT01513044|Mycophenolate Mofetil
1114136|NCT01513044|crossover
1114137|NCT01513031|Atrial fibrillation
1114138|NCT01513031|Anti-arrhythmic medication
1114139|NCT01513031|Medication adherence
1114140|NCT01513018|OLV
1114141|NCT01513018|one lung ventilation
1114142|NCT01513005|Laparoscopic Sleeve Gastrectomy
1114143|NCT01513005|obesity management
1114144|NCT01512966|Diabetic Macular Edema
1114145|NCT01512966|DME
1114146|NCT01512966|VEGF Trap-Eye
1114147|NCT01512966|best-corrected visual acuity (BCVA)
1114148|NCT01512953|PPI
1114149|NCT01512953|clopidogrel
1114150|NCT01512953|2C19
1114151|NCT01512953|Lansoprazole
1114152|NCT01512940|obesity
1114153|NCT01512940|Laparoscopic Greater Curvature Plication
1114154|NCT01512940|Percent Excess weight Loss
1114155|NCT01512940|comorbidities
1114156|NCT01512940|BMI
1114157|NCT01512940|Bariatric Surgery
1114158|NCT01512927|electronic stethoscope
1114159|NCT01512927|arteriovenous fistula
1114160|NCT01512927|hemodialysis,
1114161|NCT01512914|Gynecologic laparoscopic surgery
1114162|NCT01512914|Postoperative pain
1114163|NCT01512914|Nebulization
1114164|NCT01512914|Ropivacaine
1114165|NCT01512888|SCID
1114166|NCT01512888|SCID-X1
1114167|NCT01512888|X-linked SCID
1114168|NCT01512888|immunodeficiency
1114169|NCT01512888|gene therapy
1114170|NCT01512875|Helicobacter pylori
1114171|NCT01512875|water contamination
1114172|NCT01512875|Lima, Peru
1114173|NCT01512862|Calcitriol
1114174|NCT01512862|Off-label
1114175|NCT01512849|TA-7284
1114176|NCT01512849|JNJ-28431754
1114177|NCT01512849|Canagliflozin
1114178|NCT01512849|Renal Impairment
1114179|NCT01512849|Sodium Glucose Co-transporter2 (SGLT2) inhibitor
1114180|NCT01512836|COPD
1114181|NCT01512836|Case management
1114182|NCT01512836|CEA
1114183|NCT01512836|Health economy
1114184|NCT01512836|Quality of Life
1114185|NCT01512823|randomised controlled trial
1114186|NCT01512823|educational intervention
1114187|NCT01512823|occupational therapy
1114188|NCT01512810|Endometrial
1114189|NCT01512810|Cancer
1114190|NCT01512810|Intraoperative Consultation
1114191|NCT01512797|Januvia
1114192|NCT01512797|Sitagliptin
1114193|NCT01512797|Diabetes
1114194|NCT01512797|Gastric-Bypass
1114195|NCT01512784|Quadrivalent Human Papillomavirus Vaccine (HPV) Gardasil
1114196|NCT01512784|HIV infection
1114197|NCT01512784|Evaluation of quadrivalent HPV vaccine in adolescents and young adults.
1114198|NCT01512758|East Asian Patients
1114199|NCT01512758|Advanced solid tumors
1114200|NCT01512758|Lymphomas
1114201|NCT01512758|MLN8237
1114202|NCT01512758|Alisertib
1114203|NCT01512758|Aurora A Kinase Inhibitor
1114204|NCT01512706|Human Enterovirus 71 (EV71)
1114205|NCT01512706|Hand, Foot and Mouth Disease
1114206|NCT01512706|Inactivated Vaccine
1114207|NCT01512706|Human Diploid cell
1114208|NCT01512706|Safety
1114209|NCT01512706|Immunogenicity
1114210|NCT01512706|Adverse reactions associated with vaccine
1114211|NCT01512680|Functional Insulin Thearpy
1114212|NCT01512680|Carbs counting
1114213|NCT01512680|Type 1 diabetes mellitus
1114214|NCT01512680|Insulin pump
1114215|NCT01512680|Treatment by external insulin pump
1114216|NCT01512654|diabetes
1114217|NCT01512654|diadvisor
1114218|NCT01512654|type 1 diabetes
1114219|NCT01512654|type 2 diabetes
1114220|NCT01512654|glucose prediction
1114221|NCT01512654|cgm prediction
1114222|NCT01512654|algorithm
1114223|NCT01512654|therapy advices
1114224|NCT01512641|children dissociative disorders schizophrenia
1114225|NCT01512615|Rehabilitation
1114226|NCT01512615|Exercise training
1114227|NCT01512615|Psycho-educational care
1114228|NCT01512602|Borderline Personality Disorder traits
1114229|NCT01512602|Suicide prevention
1114230|NCT01512602|Self-harm
1114231|NCT01512602|Dialectical Behavior Therapy
1114232|NCT01512602|DBT
1114233|NCT01512602|Collaborative Assessment and Management of Suicidology
1114234|NCT01512602|CAMS
1114235|NCT01512589|Proton Beam Therapy
1114236|NCT01512589|PBT
1114237|NCT01512589|Intensity-Modulated Radiation Therapy
1114238|NCT01512589|IMRT
1114239|NCT01512589|Esophageal cancer
1114240|NCT01512589|Adenocarcinoma
1114241|NCT01512589|Squamous cell carcinoma
1114242|NCT01512589|Cervical esophagus
1114243|NCT01512589|Thoracic esophagus
1114244|NCT01512589|Gastroesophageal junction
1114245|NCT01512589|Cardia of stomach
1114246|NCT01512589|Questionnaires
1114247|NCT01512589|Surveys
1114248|NCT01512589|Symptom scores
1114249|NCT01512589|Quality of life
1114250|NCT01512589|QOL
1114251|NCT01512576|whiplash
1114252|NCT01512576|chronic pain
1114253|NCT01512576|sensitization
1114254|NCT01512576|treatment
1114255|NCT01512576|acupuncture
1114256|NCT01512576|relaxation
1114257|NCT01512563|paclitaxel
1114258|NCT01512563|drug eluting stent
1114259|NCT01512550|Radiostereometric Analysis (RSA)
1114260|NCT01512550|Total hip arthroplasty (THA)
1114261|NCT01512550|Hip anatomy
1114262|NCT01512550|Hip biomechanics
1114263|NCT01512537|Vitamin D
1114264|NCT01512537|UVB
1114265|NCT01512537|Vitamin D supplementation
1114266|NCT01512524|Traumatic Brain Injury
1114267|NCT01512524|Quality of Life (QoL)
1114268|NCT01512524|hypopituitarism,GH
1114269|NCT01512511|laparoscopic cholecystectomy
1114270|NCT01512511|pneumoperitoneum
1114271|NCT01512511|nitrous oxide
1114272|NCT01512511|carbon dioxide
1114273|NCT01512498|VV GVHD
1114274|NCT01512498|girls
1114275|NCT01512498|adolescents
1114276|NCT01512498|HSCT
1114277|NCT01512485|Bioequivalence
1114278|NCT01512485|Clopidogrel
1114279|NCT01512485|crossover
1114280|NCT01512472|localized prostate cancer
1114281|NCT01512472|degarelix
1114282|NCT01512472|intermittent androgen deprivation therapy
1114283|NCT01512459|Bioavailability
1114284|NCT01512459|Venlafaxine
1114285|NCT01512459|two way crossover
1114286|NCT01512446|Osteoporosis
1114287|NCT01512446|Osteoporotic fractures
1114288|NCT01512446|Bisphosphonate
1114289|NCT01512446|Pretreatment with bisphosphonates
1114290|NCT01512433|acupuncture
1114291|NCT01512433|methadone
1114292|NCT01512407|Hepatocellular Carcinoma
1114293|NCT01512407|Randomised controlled trial
1114294|NCT01512407|Transarterial chemoembolisation
1114295|NCT01512394|bowel preparation
1114296|NCT01512381|heart failure
1114297|NCT01512381|CRT
1114298|NCT01512381|atrial fibrillation
1114299|NCT01512381|AV junction ablation
1114300|NCT01512368|Fibroblast growth factor 21 (FGF21)
1114301|NCT01512368|Exercise
1114302|NCT01512368|Metabolic equivalents (METs)
1114303|NCT01512368|Lipolysis
1114304|NCT01512368|Glucose
1114305|NCT01512368|Free fatty acids (FFAs)
1114306|NCT01512368|Epinephrine
1114307|NCT01512342|pacing
1114308|NCT01512342|activity management
1114309|NCT01512342|relaxation
1114310|NCT01512342|physiotherapy
1114311|NCT01512342|occupational therapy
1114312|NCT01512342|autonomic nervous system
1114313|NCT01512329|neurology
1114314|NCT01512329|physiotherapy
1114315|NCT01512329|physical therapy
1114316|NCT01512329|occupational therapy
1114317|NCT01512329|stress management
1114318|NCT01512329|activity management
1114319|NCT01512329|treatment
1114320|NCT01512316|Fear
1114321|NCT01512316|Cycloserine
1114322|NCT01512316|Conditioning
1114323|NCT01512316|Functional neuroimaging
1114324|NCT01512316|Anxiety disorders
1114325|NCT01512303|PTSD
1114326|NCT01512303|Veterans' Health
1114327|NCT01512303|Meditation
1114328|NCT01512303|MRI, Functional
1114329|NCT01512290|Auditory verbal hallucinations
1114330|NCT01512290|Transcranial Magnetic stimulation
1114331|NCT01512290|Theta Burst frequency
1114332|NCT01512277|vaccines
1114333|NCT01512277|safety
1114334|NCT01512277|drug tolerance
1114335|NCT01512277|immunogenic protein
1114336|NCT01512277|antibody response
1114337|NCT01512277|cytokine
1114338|NCT01512264|Aphasia
1114339|NCT01512264|Stroke
1114340|NCT01512264|functional Magnetic resonance imaging
1114341|NCT01512264|fMRI
1114342|NCT01512264|Language recovery after stroke
1114343|NCT01512264|constraint induced aphasia therapy
1114344|NCT01512264|CIAT
1114345|NCT01512264|Repetitive transcranial magnetic stimulation
1114346|NCT01512264|rTMS
1114347|NCT01512251|BKM120
1114348|NCT01512251|BRAF
1114349|NCT01512251|Melanoma
1114350|NCT01512251|PI3K
1114351|NCT01512238|Medicine adherence
1114352|NCT01512238|Drug substitution
1114353|NCT01512238|Herb-drug interaction
1114354|NCT01512238|Herbal medicine
1114355|NCT01512238|Dietary supplements
1114356|NCT01512238|Over-the-counter products
1114357|NCT01512238|On-line prescription records
1114358|NCT01512238|Personal electronic medicine profile
1114359|NCT01512238|Intentional non-adherence
1114360|NCT01512238|Unintentional non-adherence
1114361|NCT01512225|breastmilk
1114362|NCT01512225|domperidone
1114363|NCT01512225|preterm
1114364|NCT01512212|thyroid
1114365|NCT01512212|fine
1114366|NCT01512212|needle
1114367|NCT01512212|aspiration
1114368|NCT01512212|biopsy
1114369|NCT01512212|new
1114370|NCT01512212|technique
1114371|NCT01512199|U3-1287
1114372|NCT01512199|Trastuzumab
1114373|NCT01512199|Paclitaxel
1114374|NCT01512199|newly diagnosed HER-2 positive
1114375|NCT01512199|breast cancer
1114376|NCT01512199|metastatic
1114377|NCT01512186|Clear cell renal cancer
1114378|NCT01512173|Propranolol gel
1114379|NCT01512173|Hemangioma
1114380|NCT01512173|capillary neoplasm
1114381|NCT01512173|vascular tissue
1114382|NCT01512173|neoplasm by histologic type
1114383|NCT01512173|neoplasm
1114384|NCT01512173|therapeutic uses
1114385|NCT01512173|pharmacologic actions
1114386|NCT01512173|adrenergic beta-antagonists
1114387|NCT01512173|adrenergic antagonist
1114388|NCT01512173|adrenergics agent
1114389|NCT01512173|neurotransmitter agent
1114390|NCT01512173|molecular mechanism of pharmacological action
1114391|NCT01512173|physiological effects of drugs
1114392|NCT01512160|Post-surgical dental pain
1114393|NCT01512147|SSEP measurements
1114394|NCT01512147|MEP measurements
1114395|NCT01512147|Pediatric Patients
1114396|NCT01512147|Neurosurgery
1114397|NCT01512147|General Anesthesia
1114398|NCT01512134|Obesity
1114399|NCT01512134|DBS
1114400|NCT01512082|Pain
1114401|NCT01512082|Delayed onset muscle soreness
1114402|NCT01512082|Pulsed electromagnetic field
1114403|NCT01512082|Marathon
1114404|NCT01512069|randomized controlled trial
1114405|NCT01512069|internet
1114406|NCT01512069|diet
1114407|NCT01512069|exercise
1114408|NCT01512069|health planning
1114409|NCT01512069|the TTM
1114410|NCT01512056|Influenza vaccine
1114411|NCT01512056|dialysis
1114412|NCT01512056|vaccine
1114413|NCT01512056|Seroprotection
1114414|NCT01512056|Seroresponse
1114415|NCT01512056|Seroconversion
1114416|NCT01512056|Safety of the vaccine
1114417|NCT01512043|Breathlessness
1114418|NCT01512043|Symptoms
1114419|NCT01512043|Quality of life
1114420|NCT01512017|skin lesions or defects
1114421|NCT01512004|Overactive Bladder
1114422|NCT01512004|urgent micturition
1114423|NCT01512004|frequent micturition
1114424|NCT01512004|urge urinary incontinence
1114425|NCT01511991|cardiac surgery
1114426|NCT01511991|sevoflurane
1114427|NCT01511991|tissue Doppler
1114428|NCT01511978|Lambert-Eaton
1114429|NCT01511978|Eaton-Lambert
1114430|NCT01511978|myasthenia
1114431|NCT01511978|myasthenic
1114432|NCT01511978|LEMS
1114433|NCT01511978|LES
1114434|NCT01511978|DAP
1114435|NCT01511978|diaminopyridine
1114436|NCT01511978|3,4-diaminopyridine
1114437|NCT01511978|3,4-DAP
1114438|NCT01511952|music therapy
1114439|NCT01511952|entrainment
1114440|NCT01511952|premature infants
1114441|NCT01511952|live music intervention
1114442|NCT01511952|parent preferred lullabies
1114443|NCT01511939|Knee pain
1114444|NCT01511939|Anticoagulant
1114445|NCT01511939|Warfarin
1114446|NCT01511939|Dabigatran
1114447|NCT01511939|Clopidogrel
1114448|NCT01511939|Aspirin
1114449|NCT01511939|Topical NSAID
1114450|NCT01511939|Osteoarthritis
1114451|NCT01511926|Vimovo™ treated patients and prescribing patterns
1114452|NCT01511926|Risk of gastrointestinal side effects
1114453|NCT01511913|Unresectable or metastatic cutaneous melanoma
1114454|NCT01511887|Patent Ductus Arteriosus
1114455|NCT01511887|PDA
1114456|NCT01511887|Term newborns
1114457|NCT01511887|Ibuprofen
1114458|NCT01511874|ELIGARD
1114459|NCT01511874|Prostate cancer
1114460|NCT01511848|Iron chelation
1114461|NCT01511848|Iron balance
1114462|NCT01511848|Secondary iron overload
1114463|NCT01511848|deferoxamine
1114464|NCT01511848|deferasirox
1114465|NCT01511848|Deferiprone
1114466|NCT01511848|1- Beta-thalassemia major patients;
1114467|NCT01511848|Patients with high iron stores
1114468|NCT01511848|Serum ferritin consistently > 2500 mcg/l and or increasing trend over previous 12 months
1114469|NCT01511848|Liver iron >14 mg/g dry weight- by R2 MRI
1114470|NCT01511848|2- Sickle cell disease
1114471|NCT01511848|3- Other causes of transfusional iron hemosiderosis
1114472|NCT01511835|diabetes
1114473|NCT01511835|pregnancy
1114474|NCT01511835|myo-inositol
1114475|NCT01511822|PCOS
1114476|NCT01511822|Insulin resistance
1114477|NCT01511822|Hyperandrogenism
1114478|NCT01511822|Myo-inositol
1114479|NCT01511809|HIV-1
1114480|NCT01511796|stroke
1114605|NCT01511354|critically ill children
1114481|NCT01511796|upper limb rehabilitation function
1114482|NCT01511770|Bioequivalence
1114483|NCT01511770|Fluconazole
1114484|NCT01511770|Crossover
1114485|NCT01511757|Bioequivalence
1114486|NCT01511757|Fluconazole
1114487|NCT01511757|Crossover
1114488|NCT01511744|Respiratory Tract Infections; Orthomyxoviridae Infections
1114489|NCT01511731|Bioequivalence
1114490|NCT01511731|famotidine
1114491|NCT01511731|Crossover
1114492|NCT01511718|Bioequivalence
1114493|NCT01511718|Ondansetron
1114494|NCT01511718|crossover
1114495|NCT01511705|Bioequivalence
1114496|NCT01511705|Ondansetron
1114497|NCT01511705|crossover
1114498|NCT01511679|Alcohol abuse
1114499|NCT01511666|cardiac arrest
1114500|NCT01511666|mechanical chest compressions
1114501|NCT01511666|intraarrest cooling
1114502|NCT01511666|ECLS
1114503|NCT01511653|screening colonoscopy
1114504|NCT01511653|colon cancer early detection
1114505|NCT01511653|rectal cancer early detection
1114506|NCT01511653|colorectal cancer prevention
1114507|NCT01511653|biomarker validation
1114508|NCT01511640|marijuana
1114509|NCT01511640|addiction
1114510|NCT01511640|treatment
1114511|NCT01511640|pharmacotherapy
1114512|NCT01511640|cannabinoid
1114513|NCT01511614|fMRI
1114514|NCT01511614|Nicotine Withdrawal
1114515|NCT01511601|Apheresis
1114516|NCT01511601|Leukocytes
1114517|NCT01511601|Plasma
1114518|NCT01511601|Plamodium Falciparum Malaria
1114519|NCT01511601|Immunology
1114520|NCT01511588|Kallmann Syndrome
1114521|NCT01511588|Delayed Puberty
1114522|NCT01511588|GnRH Deficiency
1114523|NCT01511588|Infertility
1114524|NCT01511588|Hypogonadotropic Hypogonadism
1114525|NCT01511588|Amenorrhea
1114526|NCT01511588|Hypogonadism
1114527|NCT01511575|childhood acute myeloid leukemia in remission
1114528|NCT01511575|childhood acute myeloid leukemia/other myeloid malignancies
1114529|NCT01511575|childhood acute megakaryocytic leukemia (M7)
1114530|NCT01511562|primary central nervous system non-Hodgkin lymphoma
1114531|NCT01511562|contiguous stage II adult diffuse large cell lymphoma
1114532|NCT01511562|noncontiguous stage II adult diffuse large cell lymphoma
1114533|NCT01511562|stage I adult diffuse large cell lymphoma
1114534|NCT01511562|stage III adult diffuse large cell lymphoma
1114535|NCT01511562|stage IV adult diffuse large cell lymphoma
1114536|NCT01511523|Liver
1114537|NCT01511523|Fatty
1114538|NCT01511523|Non Alcoholic
1114539|NCT01511523|Vitamin E
1114540|NCT01511523|Silymarin
1114541|NCT01511523|Carnitine
1114542|NCT01511523|Supplement
1114543|NCT01511523|NAFLD
1114544|NCT01511510|PF-04958242
1114545|NCT01511510|multiple dose
1114546|NCT01511510|safety
1114547|NCT01511510|schizophrenia
1114548|NCT01511497|Phase 1
1114549|NCT01511497|PF-04427429
1114550|NCT01511484|fruit
1114551|NCT01511484|vegetables
1114552|NCT01511484|appearance
1114553|NCT01511484|skin color
1114554|NCT01511484|carotenoids
1114555|NCT01511484|diet
1114556|NCT01511471|Ticagrelor
1114557|NCT01511471|platelet reactivity
1114558|NCT01511471|clopidogrel
1114559|NCT01511471|haemodialysis
1114560|NCT01511458|Pregnancy
1114561|NCT01511458|Fetal aneuploidy
1114562|NCT01511458|Trisomy 21
1114563|NCT01511458|Down Syndrome
1114564|NCT01511458|Prenatal screening
1114565|NCT01511458|Non-invasive prenatal testing
1114566|NCT01511458|First trimester
1114567|NCT01511458|Combined screening
1114568|NCT01511458|Nuchal translucency
1114569|NCT01511458|PAPP-A
1114570|NCT01511458|hCG
1114571|NCT01511458|cell free DNA
1114572|NCT01511458|cf DNA
1114573|NCT01511458|DNA
1114574|NCT01511458|Performance characteristics of non-invasive first trimester screening
1114575|NCT01511458|Harmony Prenatal Test
1114576|NCT01511445|Cervicobrachial pain
1114577|NCT01511445|radicular pain
1114578|NCT01511445|arm pain
1114579|NCT01511445|myelopathy
1114580|NCT01511445|radiculitis
1114581|NCT01511445|Radiating pain with or without signs of myelopathy.
1114582|NCT01511432|Relative bioavailability
1114583|NCT01511432|telaprevir formulations
1114584|NCT01511419|Influenza
1114585|NCT01511419|Vaccine
1114586|NCT01511419|Pandemic
1114587|NCT01511419|H7N3
1114588|NCT01511406|Psychosis
1114589|NCT01511406|Schizophrenia
1114590|NCT01511406|Cognitive behavioral therapy
1114591|NCT01511406|Self esteem
1114592|NCT01511406|Depression
1114593|NCT01511393|GLP1
1114594|NCT01511393|Glucagon like peptide
1114595|NCT01511393|liraglutide
1114596|NCT01511393|exenatide extended release
1114597|NCT01511393|albiglutide
1114598|NCT01511393|dulaglutide
1114599|NCT01511380|juvenile
1114600|NCT01511380|randomized trial
1114601|NCT01511380|substance abuse
1114602|NCT01511380|sexual risk
1114603|NCT01511380|contingency management
1114604|NCT01511367|moderate to severe persistent reversible asthma
1114606|NCT01511354|ICU
1114607|NCT01511354|24hr protein balance
1114608|NCT01511354|stable isotopes
1114609|NCT01511354|fed state
1114610|NCT01511341|Telenursing
1114611|NCT01511341|Children
1114612|NCT01511341|Chronic Illness
1114613|NCT01511341|Nursing
1114614|NCT01511328|HPV testing
1114615|NCT01511328|Primary screening
1114616|NCT01511328|Cervical Cancer
1114617|NCT01511315|Moderate to severe psoriasis
1114618|NCT01511289|Radotinib
1114619|NCT01511289|CML-CP
1114620|NCT01511289|Chronic Myeloid Leukemia, chronic phase
1114621|NCT01511276|Breast cancer
1114622|NCT01511276|Sex hormones
1114623|NCT01511276|Physical activity
1114624|NCT01511263|Epigallocatechin gallate
1114625|NCT01511263|AL amyloidosis
1114626|NCT01511250|normal healthy adults and children
1114627|NCT01511250|Safety and tolerability
1114628|NCT01511250|active vaccine
1114629|NCT01511250|placebo
1114630|NCT01511250|Dengue virus vaccine
1114631|NCT01511250|Immune response
1114632|NCT01511237|HIV-1 infection
1114633|NCT01511237|Prophylaxis
1114634|NCT01511237|Mother-to-child transmission HIV-1
1114635|NCT01511237|Thailand
1114636|NCT01511237|Developing Countries
1114637|NCT01511224|Bloodstream infections
1114638|NCT01511224|Acinetobacter
1114639|NCT01511224|Drug resistant Acinetobacter baumannii bacteremia
1114640|NCT01511211|Dexamethasone
1114641|NCT01511211|lower limb block
1114642|NCT01511211|ultrasound guided femoral nerve block
1114643|NCT01511211|ultrasound guided obturator nerve block
1114644|NCT01511211|ultrasound guided sciatic nerve block
1114645|NCT01511211|ropivacaine
1114646|NCT01511211|total knee arthroplasty
1114647|NCT01511211|Post surgical pain after total knee arthroplasty
1114648|NCT01511146|oxaliplatin
1114649|NCT01511146|mitomycin
1114650|NCT01511146|gemcitabine
1114651|NCT01511146|intrahepatic
1114652|NCT01511146|liver metastasis
1114653|NCT01511146|response in liver metastasis
1114654|NCT01511146|downsized to operation
1114655|NCT01511133|Laboratory evaluations
1114656|NCT01511133|infants
1114657|NCT01511133|Porcine circovirus type 1 (PCV-1)
1114658|NCT01511133|serologic response
1114659|NCT01511133|human rotavirus (HRV) vaccine
1114660|NCT01511107|acute otitis media
1114661|NCT01511107|ear infection
1114662|NCT01511107|antimicrobial therapy
1114663|NCT01511107|antimicrobial resistance
1114664|NCT01511094|ab-interno trabeculectomy,
1114665|NCT01511094|intraocular pressure,
1114666|NCT01511094|open angle glaucoma
1114667|NCT01511094|trabeculectomy
1114668|NCT01511094|Goniocurettage
1114669|NCT01511094|Non-Filtering Surgery
1114670|NCT01511081|Non-small-cell lung cancer
1114671|NCT01511081|NSCLC
1114672|NCT01511081|Centrally-located
1114673|NCT01511081|Recurrent
1114674|NCT01511081|Squamous cell carcinoma
1114675|NCT01511081|Adenocarcinoma
1114676|NCT01511081|Large cell carcinoma
1114677|NCT01511081|Bronchioloalveolar cell carcinoma
1114678|NCT01511081|Non-small cell carcinoma not otherwise specified
1114679|NCT01511081|Stereotactic Body Radiotherapy
1114680|NCT01511081|SBRT
1114681|NCT01511081|Stereotactic Body Proton Therapy
1114682|NCT01511081|SBPT
1114683|NCT01511068|PAP
1114684|NCT01511055|Ovarian Cancer
1114685|NCT01511016|lipid kinetics
1114686|NCT01511016|fat oxidation
1114687|NCT01511003|Tacrolimus
1114688|NCT01511003|Prograf
1114689|NCT01511003|calcineurin inhibitor
1114690|NCT01511003|Rheumatoid arthritis (RA)
1114691|NCT01510990|Non-small cell lung cancer
1114692|NCT01510990|Gefitinib
1114693|NCT01510990|FDG-PET
1114694|NCT01510977|colonoscopy
1114695|NCT01510977|bowel preparation
1114696|NCT01510964|Breast cancer
1114697|NCT01510964|Patient involvement
1114698|NCT01510964|Question prompt-sheet
1114699|NCT01510964|Doctor-patient communication
1114700|NCT01510964|RCT
1114701|NCT01510951|AMGEN
1114702|NCT01510951|PSORIASIS
1114703|NCT01510951|SAFETY
1114704|NCT01510938|Children
1114705|NCT01510938|Respiratory Tract Infections
1114706|NCT01510938|Prevention
1114707|NCT01510886|MDD, management, Andalusia, Database, PismaEP
1114708|NCT01510873|Health-related quality of life
1114709|NCT01510873|Fatigue
1114710|NCT01510873|pITO
1114711|NCT01510873|Primary Immune Thrombocytopenic Purpura
1114712|NCT01510834|Computerized Tailored Intervention
1114713|NCT01510834|CTI
1114714|NCT01510834|Post Traumatic Stress Disorder
1114715|NCT01510834|PTSD
1114716|NCT01510834|Smoking
1114717|NCT01510834|Anxiety
1114718|NCT01510834|Depression
1114719|NCT01510821|endoscopic vein harvest
1114720|NCT01510821|saphenous vein graft
1114721|NCT01510821|endothelial function
1114722|NCT01510808|aggressive periodontitis orthodontic stability
1114723|NCT01510795|Kidney transplantation
1114724|NCT01510795|Mineralocorticoid receptors
1114725|NCT01510795|Spironolactone
1114726|NCT01510743|open heart surgery
1114727|NCT01510743|lung surgery
1114728|NCT01510743|spine surgery
1114729|NCT01510743|hepatobiliary surgery
1114730|NCT01510730|gastric tumor
1114731|NCT01510730|Helicobacter pylori
1114732|NCT01510730|endoscopic resection
1114733|NCT01510730|metachronous neoplasms
1114734|NCT01510717|Intraocular Lens
1114735|NCT01510717|Monofocal
1114736|NCT01510717|Multifocal
1114737|NCT01510691|Oxygenation of the retinal vessels
1114738|NCT01510691|vitroretinal surgery
1114739|NCT01510678|Diet Quality
1114740|NCT01510665|Weight gain in pregnancy
1114741|NCT01510665|Metabolic and Inflammatory markers
1114742|NCT01510652|Cardiac Resynchronization therapy,
1114743|NCT01510652|Heart Failure,
1114744|NCT01510652|Left Ventricular Lead,
1114745|NCT01510652|Quadripolar Left ventricular Lead,
1114746|NCT01510652|Phrenic Nerve Stimulation,
1114747|NCT01510652|Intra and post operative related complications
1114748|NCT01510626|Multiple food allergies
1114749|NCT01510613|Pomalidomide
1114750|NCT01510613|Dexamethasone
1114751|NCT01510613|treatment
1114752|NCT01510613|AL amyloidosis
1114753|NCT01510600|stage 4S neuroblastoma
1114754|NCT01510600|localized resectable neuroblastoma
1114755|NCT01510600|localized unresectable neuroblastoma
1114756|NCT01510600|recurrent neuroblastoma
1114757|NCT01510600|regional neuroblastoma
1114758|NCT01510587|obesity
1114759|NCT01510587|prevention
1114760|NCT01510587|preteen
1114761|NCT01510587|nutrition
1114762|NCT01510587|physical activity
1114763|NCT01510587|body image
1114764|NCT01510587|family dynamics
1114765|NCT01510574|postpartum hemorrhage, PPH, misoprostol
1114766|NCT01510561|metastatic pancreatic adenocarcinoma
1114767|NCT01510561|pancreatic cancer
1114768|NCT01510561|metastatic pancreatic cancer
1114769|NCT01510548|Disc prolapse
1114770|NCT01510548|Pain
1114771|NCT01510548|Disability
1114772|NCT01510535|Osteoartritis
1114773|NCT01510535|Knee
1114774|NCT01510535|LBSA0103
1114775|NCT01510535|Hyruan Plus Inj.
1114776|NCT01510522|Diabetes
1114777|NCT01510522|Glucophage
1114778|NCT01510522|Metformin
1114779|NCT01510522|sachets
1114780|NCT01510522|tablets
1114781|NCT01510509|Drug Eluting Stent
1114782|NCT01510509|Bioactive Bare Metal Stent
1114783|NCT01510496|Chronic pain
1114784|NCT01510496|genetic polymorphisms
1114785|NCT01510496|postoperative pain
1114786|NCT01510483|obesity prevention
1114787|NCT01510483|tobacco prevention
1114788|NCT01510483|nutrition
1114789|NCT01510483|physical activity
1114790|NCT01510483|sedentary activity
1114791|NCT01510483|tobacco use
1114792|NCT01510483|tobacco exposure
1114793|NCT01510483|prevention
1114794|NCT01510483|clinician intervention
1114795|NCT01510483|preteen
1114796|NCT01510483|adolescents
1114797|NCT01510470|AstraTech Osseospeed Profile Implant
1114798|NCT01510470|Marginal bone level
1114799|NCT01510470|soft tissue
1114800|NCT01510470|soft tissue responds
1114801|NCT01510457|Knee Osteoarthritis
1114802|NCT01510457|Degenerative Joint Disease
1114803|NCT01510457|Chronic Pain
1114804|NCT01510457|Knee Pain
1114805|NCT01510418|Hemophilia
1114806|NCT01510418|Spouse
1114807|NCT01510418|Significant Other
1114808|NCT01510418|Quality of Life
1114809|NCT01510405|Subjects undergoing or who have undergone thoracic surgery for presumed lung cancer.
1114810|NCT01510405|The following procedures are allowed: Wedge resection, lobectomy, bilobectomy, segmentectomy and pneumonectomy thoracic surgical operations are permitted.
1114811|NCT01510392|Optical coherence tomography
1114812|NCT01510392|Glaucoma
1114813|NCT01510392|Macula
1114814|NCT01510392|Keratoconus
1114815|NCT01510392|Screening
1114816|NCT01510379|nausea
1114817|NCT01510379|vomiting
1114818|NCT01510379|post-operative
1114819|NCT01510379|foregut surgery
1114820|NCT01510366|Inactivated Poliomyelitis Vaccine
1114821|NCT01510366|Sabin Strains
1114822|NCT01510366|poliomyelitis
1114823|NCT01510340|adherence
1114824|NCT01510340|HIV
1114825|NCT01510340|antiretroviral therapy
1114826|NCT01510340|tailored web intervention
1114827|NCT01510327|drug-eluting stents
1114828|NCT01510327|DES
1114829|NCT01510327|atherosclerotic
1114830|NCT01510301|Self-report
1114831|NCT01510301|Self-management
1114832|NCT01510301|Hypertension
1114833|NCT01510301|Adherence
1114834|NCT01510301|Cell phone
1114835|NCT01510301|Drug treatment
1114836|NCT01510301|Medical Adherence
1114837|NCT01510288|GVAX
1114838|NCT01510288|Ipilimumab
1114839|NCT01510288|prostate cancer
1114840|NCT01510275|cardio-thoracic surgery
1114841|NCT01510275|patients
1114842|NCT01510275|pulmonary volume
1114843|NCT01510275|respiratory muscle performance
1114844|NCT01510262|Repeat STI patients
1114845|NCT01510262|HIV
1114846|NCT01510262|Cost effectiveness
1114847|NCT01510262|Resource scarce
1114848|NCT01510262|Urban clinics
1114849|NCT01510249|calcaneal spur
1114850|NCT01510249|shock wave therapy
1114851|NCT01510249|ultrasound therapy
1114852|NCT01510236|Adolescence
1114853|NCT01510236|Cancer
1114854|NCT01510236|Depression
1114855|NCT01510236|Anxiety
1114856|NCT01510236|Self-help via internet
1114857|NCT01510223|Fats
1114858|NCT01510223|Macronutrients
1114859|NCT01510223|appetite
1114860|NCT01510223|gastric emptying
1114861|NCT01510223|Gastrointestinal transit
1114862|NCT01510210|Atrial Fibrillation
1114863|NCT01510210|Arrhythmia
1114864|NCT01510210|Rhythm control
1114865|NCT01510197|Atrial Fibrillation
1114866|NCT01510197|Arrhythmia
1114867|NCT01510197|Rhythm control
1114868|NCT01510171|platelet inhibitor
1114869|NCT01510171|ST-segment elevation myocardial infarction
1114870|NCT01510171|stent
1114871|NCT01510171|prasugrel
1114872|NCT01510171|ticagrelor
1114873|NCT01510145|Glaucoma
1114874|NCT01510145|Open-angle glaucoma
1114875|NCT01510145|Ocular hypertension
1114876|NCT01510145|Hypertension
1114877|NCT01510145|Eye Diseases
1114878|NCT01510145|Vascular Diseases
1114879|NCT01510145|Cardiovascular Diseases
1114880|NCT01510145|Travoprost
1114881|NCT01510145|Antihypertensive Agents
1114882|NCT01510145|Cardiovascular Agents
1114883|NCT01510145|Therapeutic Uses
1114884|NCT01510145|Pharmacologic Actions
1114885|NCT01510132|OAG
1114886|NCT01510132|OHT
1114887|NCT01510093|type 2 diabetes mellitus, endogenous insulin
1114888|NCT01510080|Computer-assisted live supervision
1114889|NCT01510080|"Bug-in-the-eye supervision"
1114890|NCT01510080|Delayed video-based supervision
1114891|NCT01510080|Cognitive behavioral therapy supervision
1114892|NCT01510067|CLE
1114893|NCT01510067|Lupus
1114894|NCT01510067|Lupus Erythematosus
1114895|NCT01510054|miRNA in endometrium
1114896|NCT01510041|Chronic obstructive pulmonary disease
1114897|NCT01510041|Physical therapy
1114898|NCT01510041|Dyspnea
1114899|NCT01510041|Inspiratory muscle training
1114900|NCT01510041|Activities of daily living
1114901|NCT01510028|Intrathecal Drug Delivery Device (IDDD)
1114902|NCT01510028|Recombinant human arylsulfatase A (rhASA)
1114903|NCT01510028|Metachromatic Leukodystrophy (MLD)
1114904|NCT01510015|cannabis
1114905|NCT01510015|psychostimulants
1114906|NCT01510015|psychosis
1114907|NCT01510002|papillary thyroid cancer
1114908|NCT01510002|central neck dissection
1114909|NCT01510002|survival
1114910|NCT01510002|locoregional control
1114911|NCT01510002|morbidity
1114912|NCT01509989|Adherence
1114913|NCT01509989|Compliance
1114914|NCT01509989|Systemic Lupus Erythematosus
1114915|NCT01509989|Hydroxychloroquine
1114916|NCT01509989|Blood monitoring
1114917|NCT01509989|Flares
1114918|NCT01509976|Triclosan
1114919|NCT01509976|Triclocarban
1114920|NCT01509976|Microbial flora
1114921|NCT01509976|Obesity
1114922|NCT01509963|MSKCC nomogram
1114923|NCT01509963|Tenon score
1114924|NCT01509963|metastatic SN
1114925|NCT01509963|low risk of metastatic non-SN
1114926|NCT01509963|additional ALND
1114927|NCT01509937|end stage renal disease
1114928|NCT01509937|maintenance hemodialysis
1114929|NCT01509937|dry weight
1114930|NCT01509937|bioimpedance spectroscopy analysis
1114931|NCT01509937|body composition monitor
1114932|NCT01509937|Fresenius BCM
1114933|NCT01509937|Ultrafiltration
1114934|NCT01509924|Walking capacity
1114935|NCT01509924|Mental Fatigue
1114936|NCT01509924|Quality of Life
1114937|NCT01509924|Cognition
1114938|NCT01509924|Motor activity
1114939|NCT01509924|Exercise
1114940|NCT01509872|Trauma-Focused Cognitive Behavior Therapy
1114941|NCT01509872|War-affected Children
1114942|NCT01509872|Post-traumatic Stress Symptoms
1114943|NCT01509872|Psychosocial Distress
1114944|NCT01509859|proximal femur nail
1114945|NCT01509859|pfna
1114946|NCT01509859|intertan
1114947|NCT01509859|weight bearing
1114948|NCT01509859|pertrochanteric fracture
1114949|NCT01509859|femur neck fracture
1114950|NCT01509846|Shigella
1114951|NCT01509846|vaccine
1114952|NCT01509846|shigellosis
1114953|NCT01509846|dysentery
1114954|NCT01509846|whole cell
1114955|NCT01509833|ICSI Ovarian stimulation
1114956|NCT01509833|hCG low dose
1114957|NCT01509833|Oocyte maturity
1114958|NCT01509833|poor respond
1114959|NCT01509807|Ileostomy reversal
1114960|NCT01509794|CME
1114961|NCT01509794|Simulation
1114962|NCT01509794|Affective engagement
1114963|NCT01509794|Cognitive performance
1114964|NCT01509781|simple mastectomy
1114965|NCT01509781|modified radical mastectomy
1114966|NCT01509781|wound care
1114967|NCT01509781|suction drain
1114968|NCT01509781|adaptive suture
1114969|NCT01509768|MPS IIIB
1114970|NCT01509729|Knee
1114971|NCT01509729|Arthroscopy
1114972|NCT01509729|Lidocaine patch
1114973|NCT01509729|Pain management after knee arthroscopy
1114974|NCT01509716|Predialysis
1114975|NCT01509703|COPD
1114976|NCT01509703|Nasal High Flow Therapy
1114977|NCT01509703|tracheotomy stent
1114978|NCT01509703|tracheotomy
1114979|NCT01509690|Incident
1114980|NCT01509690|Hemodialysis
1114981|NCT01509677|Roflumilast
1114982|NCT01509677|Chronic Obstructive Pulmonary Disease
1114983|NCT01509677|COPD
1114984|NCT01509651|antagonists neuromuscular block
1114985|NCT01509651|neuromuscular block, monitoring
1114986|NCT01509651|neuromuscular function
1114987|NCT01509638|Ileostomy reversal
1114988|NCT01509625|Fulvestrant
1114989|NCT01509625|Faslodex
1114990|NCT01509612|cancer
1114991|NCT01509612|additive homeopathy
1114992|NCT01509612|patients with advanced malignant tumors
1114993|NCT01509599|Venous disease
1114994|NCT01509599|Venous disorders
1114995|NCT01509599|Venous insufficiency
1114996|NCT01509599|Venous ulcers
1114997|NCT01509599|Cryotherapy
1114998|NCT01509586|smoking
1114999|NCT01509586|smoking cessation
1115000|NCT01509586|Potentially Reduced Exposure Products (PREPs)
1115001|NCT01509573|prevention therapy
1115002|NCT01509573|depressive symptoms
1115003|NCT01509573|anxiety
1115004|NCT01509573|parenting
1115005|NCT01509573|family functioning
1115006|NCT01509573|resilience, psychological
1115007|NCT01509573|Developing countries
1115008|NCT01509573|Rwanda
1115009|NCT01509573|HIV/AIDS
1115010|NCT01509534|pacemaker
1115011|NCT01509534|implantable loop recorder
1115012|NCT01509534|syncope
1115013|NCT01509521|Spectroscopy, Near-Infrared
1115014|NCT01509521|Fetal heartrate
1115015|NCT01509521|Ephedrine
1115016|NCT01509521|Phenylephrine
1115017|NCT01509508|HIV
1115018|NCT01509508|Prevention
1115019|NCT01509508|Treatment
1115020|NCT01509508|South Africa
1115021|NCT01509495|Heart Failure
1115022|NCT01509495|HF
1115023|NCT01509482|insulin resistance
1115024|NCT01509482|unexplained azoospermia
1115025|NCT01509482|unexplained oligospermia
1115026|NCT01509469|Ileal brake
1115027|NCT01509469|Casein
1115028|NCT01509469|Sucrose
1115029|NCT01509469|Ileal infusion
1115030|NCT01509456|bone metabolism
1115031|NCT01509456|potassium bicarbonate
1115032|NCT01509456|alkaline salt
1115033|NCT01509456|acid base balance
1115034|NCT01509456|bed rest
1115035|NCT01509443|Asthma
1115036|NCT01509443|Obesity
1115037|NCT01509443|Breathing exercise
1115038|NCT01509417|pyloric stenosis
1115039|NCT01509404|CMV
1115040|NCT01509404|cytomegalovirus
1115041|NCT01509404|transplant
1115042|NCT01509378|ICD
1115043|NCT01509378|ATP therapy
1115044|NCT01509378|Rescue Shock therapy
1115045|NCT01509365|cardiovascular disease
1115046|NCT01509365|maintenance dose
1115047|NCT01509365|clopidogrel
1115048|NCT01509365|overweight
1115049|NCT01509365|antiplatelet agents
1115050|NCT01509352|fundoplication
1115051|NCT01509352|gastric reflux
1115052|NCT01509339|Vancomycin
1115053|NCT01509339|Inhalation
1115054|NCT01509339|Nebulization
1115055|NCT01509339|Pharmacokinetics
1115056|NCT01509326|headache
1115057|NCT01509326|chiropractic
1115058|NCT01509326|manipulation
1115059|NCT01509326|acupressure
1115060|NCT01509326|self-care
1115061|NCT01509313|endometrial polyps
1115062|NCT01509313|uterine polyps
1115063|NCT01509313|morcellator
1115064|NCT01509313|hysteroscopy
1115065|NCT01509300|TBI
1115066|NCT01509300|Fludarabine
1115067|NCT01509300|CD3 depletion
1115068|NCT01509300|Children and adolescents
1115069|NCT01509300|Haploidentical hematopoietic stem cell transplantation
1115070|NCT01509287|Donnai-Barrow Syndrome (DBS)
1115071|NCT01509287|metabolic testing
1115072|NCT01509287|genes
1115073|NCT01509287|genetic
1115074|NCT01509274|Plantar fasciitis
1115075|NCT01509274|Plasma
1115076|NCT01509274|PRP
1115077|NCT01509274|Heel pain
1115078|NCT01509261|Erosive Esophagitis
1115079|NCT01509261|Ilaprazole
1115080|NCT01509261|GERD
1115081|NCT01509248|Theophylline
1115082|NCT01509235|cystic fibrosis
1115083|NCT01509235|Lung function
1115084|NCT01509235|physical exercise
1115085|NCT01509222|Health promotion
1115086|NCT01509222|Dietary Counseling
1115087|NCT01509209|vasomotor
1115088|NCT01509209|pseudoephedrine
1115089|NCT01509209|levocetirizine
1115090|NCT01509196|Fenofibric acid
1115091|NCT01509196|HIP0901
1115092|NCT01509196|Lipidilsupra
1115093|NCT01509183|asthma
1115094|NCT01509183|healthcare utilization costs
1115095|NCT01509157|Type 1 diabetes
1115096|NCT01509157|Continuous Glucose Monitoring
1115097|NCT01509157|Nocturnal Hypoglycemia
1115098|NCT01509144|Safety of this HIV vaccine
1115099|NCT01509092|traumatic macular hole
1115100|NCT01509092|vitrectomy
1115101|NCT01509092|observation
1115102|NCT01509066|vegetarian
1115103|NCT01509066|vegan
1115104|NCT01509066|low calorie
1115105|NCT01509066|infertility
1115106|NCT01509066|PCOS
1115107|NCT01509053|Schizophrenia
1115108|NCT01509040|Resuscitated from Out-of-Hospital Cardiac Arrest
1115109|NCT01509027|hemodialysis
1115110|NCT01509027|hyperphoshatemia
1115111|NCT01509027|compliance
1115112|NCT01509014|Statins
1115113|NCT01509014|Adherence
1115114|NCT01509014|Pharmacists
1115115|NCT01509001|type 2 diabetes
1115116|NCT01509001|metformin
1115117|NCT01509001|glimepiride
1115118|NCT01509001|glucose control
1115119|NCT01509001|vascular reactivity
1115120|NCT01509001|Adverse Reaction to Other Drugs and Medicines
1115121|NCT01508988|ONO-9054
1115122|NCT01508988|adult healthy volunteers
1115123|NCT01508988|single dose
1115124|NCT01508988|phase 1
1115125|NCT01508975|satiety
1115126|NCT01508975|obesity
1115127|NCT01508975|food intake
1115128|NCT01508962|Disease onset
1115129|NCT01508962|Disease progression
1115130|NCT01508884|intradermal
1115131|NCT01508884|influenza
1115132|NCT01508884|vaccination
1115133|NCT01508845|vitamin D
1115134|NCT01508845|vitamin D absorption
1115135|NCT01508845|vitamin D deficiency
1115136|NCT01508819|Patients over 75
1115137|NCT01508819|acute pathology
1115138|NCT01508819|ICU admission
1115139|NCT01508793|Sleep
1115140|NCT01508793|Obesity
1115141|NCT01508793|Children
1115142|NCT01508793|Eating behaviors
1115143|NCT01508793|Activity
1115144|NCT01508754|Continuous positive airway pressure
1115145|NCT01508754|Ambulatory blood pressures
1115146|NCT01508741|Insomnia
1115147|NCT01508741|Frequent Nocturnal Awakening
1115148|NCT01508741|Irritability
1115149|NCT01508741|Moody
1115150|NCT01508741|Moodiness
1115151|NCT01508741|Coping Ability
1115152|NCT01508741|Coping Behavior
1115153|NCT01508741|Stress
1115154|NCT01508741|Feeling Overwhelmed
1115155|NCT01508728|unoperated severe sprain of the knee with partial or total rupture of the anterior
1115156|NCT01508728|cruciate ligament and medial or lateral collateral ligament
1115157|NCT01508715|subacromial
1115158|NCT01508715|rotator cuff
1115159|NCT01508715|impingement
1115160|NCT01508715|physical therapy
1115161|NCT01508715|eccentric exercise
1115162|NCT01508715|concentric exercise
1115163|NCT01508702|Gout
1115164|NCT01508689|Cereal bar
1115165|NCT01508689|Calcium-fortified
1115166|NCT01508689|Calcium intake
1115167|NCT01508676|neuropathic pain
1115168|NCT01508676|postherpetic neuralgia
1115169|NCT01508676|complex regional pain syndrome
1115170|NCT01508676|reflex sympathetic dystrophy
1115171|NCT01508663|Coronary artery disease 75years of age or older
1115172|NCT01508650|heart failure
1115173|NCT01508637|air pollution
1115174|NCT01508637|vasoconstriction
1115175|NCT01508637|blood pressure
1115176|NCT01508637|diesel exhaust
1115177|NCT01508624|Randomised controlled trial
1115178|NCT01508624|Pain
1115179|NCT01508624|Recovery
1115180|NCT01508624|Office based surgery
1115181|NCT01508611|dental caries
1115182|NCT01508611|permanent teeth
1115183|NCT01508611|silver diamine fluoride
1115184|NCT01508611|tooth eruption
1115185|NCT01508598|Pediatric
1115186|NCT01508598|Obesity
1115187|NCT01508598|Bariatric surgery
1115188|NCT01508598|Cardiovascular disease
1115189|NCT01508585|Bariatric surgery
1115190|NCT01508585|Cognitive Behavioral Therapy
1115191|NCT01508585|Telephone based CBT
1115192|NCT01508585|Obesity
1115193|NCT01508572|breast cancer
1115194|NCT01508572|VEGF
1115195|NCT01508572|optical imaging
1115196|NCT01508559|HIV
1115197|NCT01508559|Neurocognitive
1115198|NCT01508546|breast cancer
1115199|NCT01508546|axillary dissection
1115200|NCT01508533|Disease burden
1115201|NCT01508533|Rotavirus gastroenteritis
1115202|NCT01508520|early gastric cancer
1115203|NCT01508520|stomach neoplasms
1115204|NCT01508520|magnifying endoscopy
1115205|NCT01508520|narrow band imaging
1115206|NCT01508507|Oral
1115207|NCT01508507|Cholera
1115208|NCT01508507|Vaccine
1115209|NCT01508507|Herd
1115210|NCT01508507|Risk
1115211|NCT01508507|population
1115212|NCT01508507|Matched
1115213|NCT01508507|Control
1115214|NCT01508507|Case
1115215|NCT01508507|Bias
1115216|NCT01508494|modification of fMRI maps after galantamine/placebo
1115217|NCT01508481|Vitamin D
1115218|NCT01508481|Diabetes
1115219|NCT01508481|pancreas beta cell function
1115220|NCT01508481|insulin resistance
1115221|NCT01508481|Deficiency of Vitamin D3
1115222|NCT01508468|Rituximab
1115223|NCT01508468|membranous nephropathy
1115224|NCT01508468|anti-PLA2R antibody
1115225|NCT01508429|Postpartum hemorrhage
1115226|NCT01508429|PPH
1115227|NCT01508429|misoprostol
1115228|NCT01508429|home deliveries
1115229|NCT01508416|Multiple Myeloma
1115230|NCT01508416|Newly diagnosed
1115231|NCT01508416|Thrombin generation
1115232|NCT01508416|TFPI
1115233|NCT01508416|Tissue Factor pathway inhibitor
1115234|NCT01508416|Protein S
1115235|NCT01508416|Thrombosis
1115236|NCT01508416|Chemotherapy
1115237|NCT01508390|prostate
1115238|NCT01508377|posttraumatic stress disorder
1115239|NCT01508377|internet-based psychotherapy
1115240|NCT01508377|cognitive restructuring
1115241|NCT01508377|exposure
1115242|NCT01508364|renal cell carcinoma, first targeted therapy, observational study
1115243|NCT01508351|Propofol
1115244|NCT01508351|Induction
1115245|NCT01508351|Hypotension
1115246|NCT01508351|General population
1115247|NCT01508338|HMB beta-hydroxy-beta-methylbutyrate
1115248|NCT01508338|ATP (adenosine-triphosphate)
1115249|NCT01508338|trained athletes
1115250|NCT01508325|Bisoprolol
1115251|NCT01508325|Hypertension
1115252|NCT01508325|Blood pressure
1115253|NCT01508325|Heart rate
1115254|NCT01508312|CARBOPLATIN
1115255|NCT01508312|ETOPOSIDE (VP-16)
1115256|NCT01508312|IFOSFAMIDE
1115257|NCT01508312|SGN-35 (BRENTUXIMAB VEDOTIN)
1115258|NCT01508312|11-142
1115259|NCT01508299|skin test
1115260|NCT01508299|raw food
1115261|NCT01508299|commercial extract
1115262|NCT01508286|telaprevir
1115263|NCT01508286|hepatitis C
1115264|NCT01508286|early access program
1115265|NCT01508273|Breast Cancer
1115266|NCT01508273|Breast Cancer Survivors
1115267|NCT01508273|High risk cancer survivors
1115268|NCT01508273|Stage II to IIIC breast cancer
1115269|NCT01508273|African American
1115270|NCT01508273|AA
1115271|NCT01508273|Hispanic
1115272|NCT01508273|Non-Hispanic White
1115273|NCT01508273|Operable invasive breast carcinoma
1115274|NCT01508273|Aerobic and resistance training
1115275|NCT01508273|Pedometer
1115276|NCT01508273|Telephone Counseling Calls
1115277|NCT01508273|Physical activity report
1115278|NCT01508273|PAR
1115279|NCT01508273|Functional Assessment of Cancer Therapy-Breast
1115280|NCT01508273|FACT-B
1115281|NCT01508273|Health related quality of life
1115282|NCT01508273|HRQOL
1115283|NCT01508260|Leukemia
1115284|NCT01508260|Aquapheresis
1115285|NCT01508260|Ultrafiltration
1115286|NCT01508260|Aquadex pump
1115287|NCT01508260|Severe Fluid Overload
1115288|NCT01508260|Diuretic therapy
1115289|NCT01508260|Dyspnea
1115290|NCT01508260|Orthopnea
1115291|NCT01508260|Paroxysmal nocturnal dyspnea
1115292|NCT01508260|PND
1115293|NCT01508260|Peripheral edema
1115294|NCT01508260|Rales
1115295|NCT01508260|Jugular venous distension
1115296|NCT01508260|JVD
1115297|NCT01508260|Hypoxia
1115298|NCT01508260|Pulmonary edema by chest X-ray
1115299|NCT01508260|Furosemide
1115300|NCT01508260|Lasix
1115301|NCT01508247|efficacy
1115302|NCT01508247|safety
1115303|NCT01508247|inactivated vaccine (Vero Cell) against EV71
1115304|NCT01508247|EV71-associated diseases
1115305|NCT01508221|brain metastasis
1115306|NCT01508208|Hypertension
1115307|NCT01508208|24 hour urine protein
1115308|NCT01508208|Protein/creatinine ratio
1115309|NCT01508195|Healthy Volunteers
1115310|NCT01508195|Bioequivalence
1115311|NCT01508195|Canagliflozin (JNJ-28431754)
1115312|NCT01508195|Metformin IR
1115313|NCT01508182|Healthy Volunteers
1115314|NCT01508182|Bioequivalence
1115315|NCT01508182|Canagliflozin (JNJ-28431754)
1115316|NCT01508182|Metformin IR
1115317|NCT01508169|elderly
1115318|NCT01508169|balance
1115319|NCT01508169|insole
1115320|NCT01508169|foot orthosis
1115321|NCT01508169|orthotics
1115322|NCT01508156|Hepatitis C
1115323|NCT01508156|HCV
1115324|NCT01508156|treatment-naive
1115325|NCT01508143|Abortion
1115326|NCT01508143|Pregnancy
1115327|NCT01508143|Termination
1115328|NCT01508143|Misoprostol
1115329|NCT01508117|GBM
1115330|NCT01508117|brain tumor
1115331|NCT01508104|solid tumor
1115332|NCT01508104|glioblastoma multiforme
1115333|NCT01508104|GBM
1115334|NCT01508104|brain tumor
1115335|NCT01508104|neuroendocrine tumor
1115336|NCT01508091|Obesity
1115337|NCT01508091|ageing
1115338|NCT01508052|core temperature
1115339|NCT01508052|sequential compression device
1115340|NCT01508052|total intravenous anesthesia
1115341|NCT01508039|Intranasal
1115342|NCT01508039|Chitin Micro-particles
1115343|NCT01508039|Immunological Effects
1115344|NCT01508039|Nasal mucosa
1115345|NCT01508039|Cytokines
1115346|NCT01508039|Immunological Effects from Intranasal Chitin Micro-Particles
1115347|NCT01508026|Stage 1
1115348|NCT01508026|Stage 2
1115349|NCT01508026|Hypertension
1115350|NCT01508013|Melanoma
1115351|NCT01508013|Basal Cell Carcinoma
1115352|NCT01508013|Squamous Cell Carcinoma
1115353|NCT01508000|Liver metastases
1115354|NCT01508000|Colorectal Cancer
1115355|NCT01508000|KRAS wild type
1115356|NCT01508000|FOLFOX
1115357|NCT01508000|Bevacizumab
1115358|NCT01508000|Panitumumab
1115359|NCT01508000|Randomized
1115360|NCT01508000|Phase II
1115361|NCT01508000|Perioperative treatment
1115362|NCT01508000|Adjuvant
1115363|NCT01508000|Neo-adjuvant
1115364|NCT01508000|Surgery
1115365|NCT01508000|Progression Free Survival
1115366|NCT01507987|Externalized Conductors
1115367|NCT01507974|preventive
1115368|NCT01507974|antibiotic treatment
1115369|NCT01507974|urinary tract infection
1115370|NCT01507974|pregnancy
1115371|NCT01507974|puerperium
1115372|NCT01507948|Posttraumatic Stress Disorder (PTSD)
1115373|NCT01507948|Psychotherapy
1115374|NCT01507948|non-medication treatment
1115375|NCT01507948|Prolonged Exposure
1115376|NCT01507948|Transcranial Magnetic Stimulation (TMS)
1115377|NCT01507948|Anxiety Disorders
1115378|NCT01507948|emotion
1115379|NCT01507948|emotion regulation
1115380|NCT01507948|functional MRI
1115381|NCT01507948|Affective Symptoms
1115382|NCT01507935|Healthy infants
1115383|NCT01507935|Infant formula
1115384|NCT01507935|Prebiotics oligosaccharides
1115385|NCT01507935|Colonisation Resistance
1115386|NCT01507935|Gut Microbiota
1115387|NCT01507922|Fenoverine
1115388|NCT01507922|Irritable Bowel Syndrome
1115389|NCT01507922|Abdominal pain
1115390|NCT01507922|BSS
1115391|NCT01507909|EEG
1115392|NCT01507909|related visual
1115393|NCT01507909|and verbal cues
1115394|NCT01507883|Supervision
1115395|NCT01507883|embryos
1115396|NCT01507883|Resulting
1115397|NCT01507870|body mass index
1115398|NCT01507857|EV71 vaccine
1115399|NCT01507857|HFMD
1115400|NCT01507857|efficacy
1115401|NCT01507857|EV71 associated disease
1115402|NCT01507844|COPD
1115403|NCT01507844|CPAP
1115404|NCT01507844|Sham
1115405|NCT01507844|FEV1
1115406|NCT01507844|IC
1115407|NCT01507844|RV/TLC
1115408|NCT01507818|Arthroscopic Rotator Cuff Repair
1115409|NCT01507818|Electromagnetic field treatment
1115410|NCT01507818|Pulsed Radio Frequency treatment
1115411|NCT01507818|Non-invasive
1115412|NCT01507818|Non-thermal
1115413|NCT01507805|Electroacupuncture
1115414|NCT01507805|preconditioning
1115415|NCT01507805|Non-cardiac surgery
1115416|NCT01507805|Coronary heart disease
1115417|NCT01507792|Cough
1115418|NCT01507792|Laryngismus
1115419|NCT01507792|Bronchial spasm
1115420|NCT01507792|Deficiency diseases
1115421|NCT01507766|severe acute pancreatitis
1115422|NCT01507766|intra-abdominal pressure
1115423|NCT01507766|enteral nutrition
1115424|NCT01507753|childhood bipolar disorder
1115425|NCT01507727|hyponatremia
1115426|NCT01507727|Non-hypovolemic and Non-acute hyponatremia
1115427|NCT01507727|Tolvaptan
1115428|NCT01507714|Preventive
1115429|NCT01507714|tvt-o
1115430|NCT01507714|stress incontinence
1115431|NCT01507701|adolescents
1115432|NCT01507688|Stroke
1115433|NCT01507675|suicide
1115434|NCT01507675|psychometric properties
1115435|NCT01507675|military
1115436|NCT01507675|veterans
1115437|NCT01507675|Interpersonal needs questionnaire
1115438|NCT01507675|Acquired capability for suicide
1115439|NCT01507675|mental health
1115440|NCT01507675|Survey of Life Principles
1115441|NCT01507675|Risk assessment
1115442|NCT01507662|Bone Density
1115443|NCT01507662|Absorptiometry, Photon
1115444|NCT01507662|Osteoporosis
1115445|NCT01507662|Bone, Diseases, Metabolic
1115446|NCT01507662|Patient Education as Topic
1115447|NCT01507662|Fractures, Bone/Prevention and Control
1115448|NCT01507649|postnatal depression
1115449|NCT01507649|quality of life
1115450|NCT01507636|apraxia
1115451|NCT01507636|occupational therapy
1115452|NCT01507636|multiple sclerosis
1115453|NCT01507636|manual dexterity
1115454|NCT01507623|NAPS
1115455|NCT01507623|Hypoxia
1115456|NCT01507623|Propofol
1115457|NCT01507623|capnography
1115458|NCT01507623|endoscopy
1115459|NCT01507623|Sedation
1115460|NCT01507610|sumatriptan
1115461|NCT01507610|bioavailability
1115462|NCT01507597|Glucagon-like peptide-1
1115463|NCT01507597|Glucagon
1115464|NCT01507597|Normal physiology
1115465|NCT01507597|T2DM
1115466|NCT01507597|T1DM
1115467|NCT01507571|Incurable cancer
1115468|NCT01507571|Palliative care
1115469|NCT01507571|Dignity Therapy
1115470|NCT01507571|Loss of dignity
1115471|NCT01507571|Patient Dignity Intventory
1115472|NCT01507571|Eortc QLQ-C15-PAL
1115473|NCT01507571|Structured Interview for Symptoms and Concerns
1115474|NCT01507571|Hospital Anxiety and Depression Scale
1115475|NCT01507558|Peripheral Arterial Disease
1115476|NCT01507558|Femoral popliteal lesions
1115477|NCT01507545|mCRC
1115478|NCT01507545|chemorefractory metastatic colorectal cancer
1115479|NCT01507506|Glioblastoma
1115480|NCT01507506|Radiotherapy
1115481|NCT01507506|Intensity modulated radiation therapy (IMRT)
1115482|NCT01507506|Magnetic resonance spectroscopic imaging (MRSI)
1115483|NCT01507493|gene polymorphism
1115484|NCT01507493|SCN9A
1115485|NCT01507493|pain perception
1115486|NCT01507493|postoperative pain
1115487|NCT01507480|Hemorrhagic Hereditary Telangiectasia (HHT)
1115488|NCT01507480|Antiangiogenic therapies
1115489|NCT01507480|Bevacizumab
1115490|NCT01507467|Head and neck carcinoma
1115491|NCT01507467|Accelerated radiotherapy
1115492|NCT01507467|Hypoxic modification with Nimorazole
1115493|NCT01507441|childhood myelodysplastic syndromes
1115494|NCT01507441|childhood acute myeloid leukemia/other myeloid malignancies
1115495|NCT01507441|childhood acute megakaryocytic leukemia (M7)
1115496|NCT01507415|Cohort Studies
1115497|NCT01507415|Longitudinal Studies
1115498|NCT01507415|Patient Readmission
1115499|NCT01507415|Hospitalization
1115500|NCT01507415|Disability Evaluation
1115501|NCT01507376|Ovulation induction
1115502|NCT01507376|urinary
1115503|NCT01507376|hCG
1115504|NCT01507376|recombinant hCG
1115505|NCT01507350|obesity related glmerulopathy
1115506|NCT01507350|51 Cr-EDTA clearance
1115507|NCT01507350|impaired renal function
1115508|NCT01507350|gastric band
1115509|NCT01507350|GFR measurement
1115510|NCT01507350|gastric bypass
1115511|NCT01507350|sleeve gastrectomy
1115512|NCT01507298|Physical activity
1115513|NCT01507298|Accelerometry
1115514|NCT01507298|Oesophageal pH
1115515|NCT01507298|Capsule endoscopy
1115516|NCT01507259|Determine effect on cerebral vasculature
1115517|NCT01507246|open colectomy
1115518|NCT01507233|open colectomy
1115519|NCT01507233|colectomy
1115520|NCT01507220|open colectomy
1115521|NCT01507207|Dysphagia
1115522|NCT01507207|aspiration
1115523|NCT01507207|pediatric
1115524|NCT01507207|injection laryngoplasty
1115525|NCT01507181|suicidal ideation
1115526|NCT01507181|major depression
1115527|NCT01507181|treatment resistant
1115528|NCT01507181|ketamine
1115529|NCT01507181|glutamate
1115530|NCT01507155|Major
1115531|NCT01507155|Depressive
1115532|NCT01507155|Disorder
1115533|NCT01507155|Depression
1115534|NCT01507155|MDD
1115535|NCT01507155|Treatment Resistant
1115536|NCT01507155|Anxiety
1115537|NCT01507155|GAD
1115538|NCT01507142|saliva
1115539|NCT01507142|diagnostics
1115540|NCT01507142|HIV
1115541|NCT01507142|AIDS
1115542|NCT01507129|dehydration
1115543|NCT01507129|plasma
1115544|NCT01507129|osmolality
1115545|NCT01507129|saliva
1115546|NCT01507129|urine
1115547|NCT01507129|biomarkers
1115548|NCT01507129|hypertonic
1115549|NCT01507129|isotonic
1115550|NCT01507129|hydration
1115551|NCT01507103|Tecemotide (L-BLP25)
1115552|NCT01507103|Cyclophosphamide (CPA)
1115553|NCT01507103|Mode of action
1115554|NCT01507103|Neoplasms
1115555|NCT01507103|Neoplasms by Site
1115556|NCT01507103|Carcinomas
1115557|NCT01507103|Antineoplastic Agents
1115558|NCT01507103|Neoadjuvant
1115559|NCT01507103|Radiotherapy Pharmacologic Actions
1115560|NCT01507103|Immunosuppressive Agents
1115561|NCT01507103|Immunologic Function
1115562|NCT01507103|Therapeutic Uses
1115563|NCT01507103|Molecular Mechanisms of Pharmacological Action
1115564|NCT01507090|children for whom there is no scale to determine weight
1115565|NCT01507077|Obese
1115566|NCT01507077|Obesity
1115567|NCT01507077|Overweight
1115568|NCT01507064|hepatocellular carcinoma
1115569|NCT01507064|sorafenib
1115570|NCT01507064|laser ablation
1115571|NCT01507051|Rivaroxaban
1115572|NCT01507051|Xa-Factors
1115573|NCT01507051|Warfarin
1115574|NCT01507051|Thrombosis
1115575|NCT01507051|Embolism
1115576|NCT01507038|Diabetes Mellitus
1115577|NCT01507038|YH14617
1115578|NCT01507038|Exenatide
1115579|NCT01507038|Yuhan
1115580|NCT01507025|hinge position
1115581|NCT01507025|dry eye
1115582|NCT01507012|Berry phenolics
1115583|NCT01507012|mood
1115584|NCT01507012|cognition
1115585|NCT01507012|adults
1115586|NCT01506999|Angina Pectoris
1115587|NCT01506999|SNPs
1115588|NCT01506999|Genetic
1115589|NCT01506999|Myocardial Infarction
1115590|NCT01506999|Cardiovascular Risk Factors
1115591|NCT01506986|Ulcer bleeding
1115592|NCT01506986|Aspirin
1115593|NCT01506986|Helicobacter pylori
1115594|NCT01506986|H. pylori
1115595|NCT01506986|Hospitalisation for ulcer bleeding
1115596|NCT01506973|histologically or cytologically documented
1115597|NCT01506947|Hemodialysis
1115598|NCT01506947|Chronic kidney disease
1115599|NCT01506947|Secondary hyperparathyroidism,
1115600|NCT01506921|racemic ketamine
1115601|NCT01506921|S-ketamine
1115602|NCT01506921|Cerebral blood flow
1115603|NCT01506921|Magnetic resonance imaging
1115604|NCT01506921|arterial spin labeling
1115605|NCT01506921|healthy volunteers
1115606|NCT01506908|craving
1115607|NCT01506895|Diabetic Macular Edema
1115608|NCT01506856|Epithelial ovarian cancer
1115609|NCT01506856|Fallopian tube cancer
1115610|NCT01506856|peritoneal cancer
1115611|NCT01506856|intraperitoneal therapy
1115612|NCT01506856|Carboplatin
1115613|NCT01506856|Paclitaxel
1115614|NCT01506843|IgA antibody
1115615|NCT01506843|IgE antibody
1115616|NCT01506843|IgG1/IgG4 subclasses
1115617|NCT01506843|Mite allergy
1115618|NCT01506843|Sublingual immunotherapy
1115619|NCT01506843|Saliva
1115620|NCT01506830|Adhesives.
1115621|NCT01506830|Composites.
1115622|NCT01506830|Noncarious cervical lesions.
1115623|NCT01506830|Clinical performance.
1115624|NCT01506830|Treatment
1115625|NCT01506817|fibromyalgia
1115626|NCT01506817|DCE-MRI
1115627|NCT01506817|neurogenic inflammation
1115628|NCT01506817|contrast-enhancement patterns
1115629|NCT01506804|Shoulder
1115630|NCT01506804|Impingement
1115631|NCT01506804|Ultrasound
1115632|NCT01506804|injection of glucocorticosteroid
1115633|NCT01506804|exercise
1115634|NCT01506791|Bioequivalence
1115635|NCT01506791|Desloratadine and pseudoephedrine
1115636|NCT01506791|crossover
1115637|NCT01506778|Endometrial Sampling Procedure
1115638|NCT01506778|Likert Scala
1115639|NCT01506778|Pipelle
1115640|NCT01506778|Tenaculum
1115641|NCT01506778|Visual Analog Pain Scala
1115642|NCT01506765|Schizophrenia
1115643|NCT01506765|glutathione
1115644|NCT01506765|NAC
1115645|NCT01506765|Neurological scales
1115646|NCT01506765|Magnetic Resonance Spectroscopy (MRS)
1115647|NCT01506765|EEG/evoked potentials
1115648|NCT01506765|fibroblasts
1115649|NCT01506765|patients who receive NAC
1115650|NCT01506765|patients who receive placebo
1115651|NCT01506752|Bioequivalence
1115652|NCT01506752|Healthy Subjects
1115653|NCT01506752|Donepezil
1115654|NCT01506739|Bioequivalence
1115655|NCT01506739|Healthy Subjects
1115656|NCT01506739|Donepezil
1115657|NCT01506726|anemia
1115658|NCT01506726|unexplained anemia
1115659|NCT01506726|elderly
1115660|NCT01506726|geriatric
1115661|NCT01506726|older adults
1115662|NCT01506726|UAE
1115663|NCT01506726|over 65
1115664|NCT01506726|salsalate
1115665|NCT01506726|PACTTE
1115666|NCT01506726|pactee
1115667|NCT01506726|aging
1115668|NCT01506726|aged
1115669|NCT01506726|old
1115670|NCT01506726|older
1115671|NCT01506687|Colorectal cancer screening
1115672|NCT01506687|50 years or older
1115673|NCT01506661|Rheumatoid arthritis
1115674|NCT01506661|vaccination
1115675|NCT01506661|immune response
1115676|NCT01506661|varicella zoster
1115677|NCT01506609|temozolomide
1115678|NCT01506609|Temodar
1115679|NCT01506609|Paclitaxel
1115680|NCT01506609|BRCA1 mutation carrier
1115681|NCT01506609|Metastatic breast cancer
1115682|NCT01506609|TMZ
1115683|NCT01506609|Recurrent breast cancer
1115684|NCT01506609|Carboplatin
1115685|NCT01506609|ABT-888
1115686|NCT01506609|veliparib
1115687|NCT01506609|Breast cancer
1115688|NCT01506609|Locally recurrent
1115689|NCT01506609|Temodal
1115690|NCT01506609|BRCA2 mutation carrier
1115691|NCT01506609|PARP
1115692|NCT01506596|Liposarcoma
1115693|NCT01506583|cough
1115694|NCT01506583|myalgia
1115695|NCT01506583|nasal obstruction
1115696|NCT01506583|sore throat
1115697|NCT01506583|headache
1115698|NCT01506583|fatigue
1115699|NCT01506583|feverishness
1115700|NCT01506583|Patients who exhibit flu-like symptoms during a flu season, including cough, myalgia, nasal obstruction, sore throat, headache, fatigue, and/or feverishness.
1115701|NCT01506557|vitamin D
1115702|NCT01506557|vitamin D deficiency
1115703|NCT01506557|breastfeeding
1115704|NCT01506557|body composition
1115705|NCT01506557|bone mineral content
1115706|NCT01506544|HU
1115707|NCT01506544|Hydroxyurea
1115708|NCT01506544|Sickle cell
1115709|NCT01506544|Pediatric
1115710|NCT01506531|gastroschisis
1115711|NCT01506531|silo
1115712|NCT01506531|primary closure
1115713|NCT01506518|Muscular Dystrophy, Duchenne
1115714|NCT01506518|Ultrasound
1115715|NCT01506518|Imaging
1115716|NCT01506518|Acoustic Radiation Force
1115717|NCT01506518|Double Push
1115718|NCT01506505|Cardiovascular prevention
1115719|NCT01506505|Polypill
1115720|NCT01506505|Combination therapy
1115721|NCT01506492|Randomized controlled trial
1115722|NCT01506492|Depression
1115723|NCT01506492|Cancer
1115724|NCT01506492|Psychotherapy
1115725|NCT01506492|Quality of life
1115726|NCT01506479|Parkinson Disease
1115727|NCT01506479|Basal Ganglia Disease
1115728|NCT01506479|Central Nervous System Diseases
1115729|NCT01506479|Nervous System Diseases
1115730|NCT01506479|Movement Disorders
1115731|NCT01506479|Neurodegenerative Diseases
1115732|NCT01506479|Brain Diseases
1115733|NCT01506466|chemotherapy
1115734|NCT01506466|metabolism
1115735|NCT01506466|weight
1115736|NCT01506466|body composition
1115737|NCT01506453|Acute Lymphoblastic Leukemia
1115738|NCT01506453|Neuropathy
1115739|NCT01506453|Neuropathic Pain
1115740|NCT01506453|Vincristine
1115741|NCT01506453|TOTAL XVI Protocol
1115742|NCT01506427|Newly Diagnosed
1115743|NCT01506427|Head and Neck Cancer
1115744|NCT01506427|PET Imaging
1115745|NCT01506414|Purpura
1115746|NCT01506414|Idiopathic Thrombocytopenic Purpura
1115747|NCT01506401|ARDS
1115748|NCT01506401|ventilator-induced lung injury
1115749|NCT01506401|lung protective ventilation
1115750|NCT01506401|high frequency oscillation
1115751|NCT01506388|labour induction
1115752|NCT01506388|Foley catheter
1115753|NCT01506388|misoprostol
1115754|NCT01506388|isosorbide mononitrate
1115755|NCT01506375|seasonal allergic rhinoconjunctivitis
1115756|NCT01506375|grass pollen
1115757|NCT01506375|allergen specific immunotherapy
1115758|NCT01506362|Ulcerative Colitis
1115759|NCT01506362|IBD
1115760|NCT01506349|celiac disease
1115761|NCT01506349|gluten
1115762|NCT01506349|fog
1115763|NCT01506349|attention
1115764|NCT01506336|GIST
1115765|NCT01506336|resistant
1115766|NCT01506336|imatinib
1115767|NCT01506336|gastro intestinal stromal tumor resistant to imatinib
1115768|NCT01506323|Complementary Therapy
1115769|NCT01506323|Stress Disorders, Post-Traumatic
1115770|NCT01506323|Veterans Health
1115771|NCT01506323|Clinical Trials, Randomized
1115772|NCT01506323|Mindfulness
1115773|NCT01506323|Spirituality
1115774|NCT01506323|Meditation
1115775|NCT01506323|Mind-body therapy
1115776|NCT01506310|gestational diabetes mellitus
1115777|NCT01506310|fasting glucose
1115778|NCT01506310|insulin resistance
1115779|NCT01506310|birth-weight
1115780|NCT01506310|Glucose values
1115781|NCT01506310|Insulin concentrations
1115782|NCT01506310|Cesarean sections
1115783|NCT01506297|obesity
1115784|NCT01506297|satiety
1115785|NCT01506297|body weight management
1115786|NCT01506284|Forced oscillatory technique
1115787|NCT01506284|Laser interferometry
1115788|NCT01506284|Intravenous anesthesia
1115789|NCT01506284|Mechanical ventilation
1115790|NCT01506284|Pressure controlled ventilation
1115791|NCT01506284|Airways mechanical properties
1115792|NCT01506284|Respiratory system reactance
1115793|NCT01506284|Oscillatory mechanics
1115794|NCT01506284|Atelectasis
1115795|NCT01506271|Complicated Intra-abdominal Infections
1115796|NCT01506258|CD34+
1115797|NCT01506258|perinatal hypoxia
1115798|NCT01506258|autologous hematopoietic stem cells
1115799|NCT01506258|cord and placental blood
1115800|NCT01506258|cerebral palsy
1115801|NCT01506245|Obesity
1115802|NCT01506245|Children
1115803|NCT01506245|Behavior
1115804|NCT01506245|Family
1115805|NCT01506245|Exercise
1115806|NCT01506232|ADHD
1115807|NCT01506232|Pediatric Bipolar Disorder
1115808|NCT01506232|Autism
1115809|NCT01506232|Autism Spectrum Disorders
1115810|NCT01506232|EEG
1115811|NCT01506232|Brain Flow Analyses
1115812|NCT01506219|Randomized controlled trial
1115813|NCT01506219|Comprehensive geriatric care
1115814|NCT01506219|Hospital contacts
1115815|NCT01506219|Activity of daily living
1115816|NCT01506219|Quality of life
1115817|NCT01506219|Rehabilitation
1115818|NCT01506206|Deep Brain Stimulation
1115819|NCT01506206|Impulsivity
1115820|NCT01506193|safety
1115821|NCT01506193|healthy
1115822|NCT01506193|conjugated
1115823|NCT01506193|immunogenicity
1115824|NCT01506193|children
1115825|NCT01506193|MenC vaccine
1115826|NCT01506193|MMRV vaccine
1115827|NCT01506180|acute medical care
1115828|NCT01506180|comprehensive geriatric assessment
1115829|NCT01506180|Health Services for the Aged
1115830|NCT01506180|Geriatric Assessment
1115831|NCT01506180|Geriatrics
1115832|NCT01506180|Aged
1115833|NCT01506154|bursitis/tendonitis and/or subdeltoid bursitis
1115834|NCT01506141|MPS II
1115835|NCT01506141|MPS 2
1115836|NCT01506141|lysosomal storage disorder
1115837|NCT01506141|mps symptoms
1115838|NCT01506141|enlarged adenoids
1115839|NCT01506141|elaprase
1115840|NCT01506141|hunter's syndrome
1115841|NCT01506141|MPS2
1115842|NCT01506141|hunters disease
1115843|NCT01506141|hunter's disease treatment
1115844|NCT01506141|hunter syndrome therapy
1115845|NCT01506141|iduronate sulfatase
1115846|NCT01506141|mps society
1115847|NCT01506141|MPSII
1115848|NCT01506141|hunter syndrome treatment
1115849|NCT01506141|hunter's disease
1115850|NCT01506141|iduronate 2 sulfatase
1115851|NCT01506141|mucopolysaccharides
1115852|NCT01506141|mps diagnosis
1115853|NCT01506141|chronic ear infection
1115854|NCT01506141|hunters syndrome
1115855|NCT01506141|ert treatment
1115856|NCT01506141|lysosomal storage disease
1115857|NCT01506141|hunter disease
1115858|NCT01506141|enzyme replacement therapy
1115859|NCT01506141|idursulfase
1115860|NCT01506141|hunter's syndrome treatment
1115861|NCT01506128|HPV
1115862|NCT01506128|Menstrual blood
1115988|NCT01505478|Machine Learning
1115863|NCT01506128|HPV detection using menstrual blood
1115864|NCT01506115|Hepatocellular carcinoma
1115865|NCT01506115|Obstructive jaundice
1115866|NCT01506115|Photodynamic therapy
1115867|NCT01506089|IVF
1115868|NCT01506089|infertility
1115869|NCT01506089|PGD
1115870|NCT01506089|embryo
1115871|NCT01506089|temperature
1115872|NCT01506089|incubator
1115873|NCT01506089|CCS
1115874|NCT01506089|culture
1115875|NCT01506089|incubator-36 degrees Celsius
1115876|NCT01506089|incubator-37 degrees Celsius
1115877|NCT01506063|Bioequivalence
1115878|NCT01506063|Levocetirizine
1115879|NCT01506063|Crossover
1115880|NCT01506050|Bioequivalence
1115881|NCT01506050|Desloratadine
1115882|NCT01506050|crossover
1115883|NCT01506037|Bioequivalence
1115884|NCT01506037|Desloratadine
1115885|NCT01506037|crossover
1115886|NCT01506024|Arthroplasty, Replacement, Hip
1115887|NCT01506024|Surgical Procedures, Operative
1115888|NCT01506024|Surgical Procedures, Minimally Invasive
1115889|NCT01505985|Hip fracture
1115890|NCT01505985|SPPB
1115891|NCT01505985|Functional recovery
1115892|NCT01505972|screening colonoscopy
1115893|NCT01505972|attendance
1115894|NCT01505972|response
1115895|NCT01505972|colorectal cancer
1115896|NCT01505959|Obstructive Sleep Apnea Syndrome
1115897|NCT01505959|Apnea
1115898|NCT01505959|Sleep Apnea
1115899|NCT01505959|Telemedicine
1115900|NCT01505959|CPAP compliance
1115901|NCT01505946|Thrombin
1115902|NCT01505946|Hemophilia
1115903|NCT01505946|Inhibitors
1115904|NCT01505946|Immunotolerance
1115905|NCT01505946|Haemostatic
1115906|NCT01505946|FVIII
1115907|NCT01505946|Epitopes
1115908|NCT01505946|Moderately severe Hemophilia A with inhibitor
1115909|NCT01505933|upper
1115910|NCT01505933|airway
1115911|NCT01505933|dimensions
1115912|NCT01505933|propofol
1115913|NCT01505933|dexmedetomidine
1115914|NCT01505907|Pharmacokinetics
1115915|NCT01505907|Safety
1115916|NCT01505907|Healthy Males
1115917|NCT01505868|Prostate Cancer
1115918|NCT01505868|Metastatic Castration-Resistant Prostate Cancer
1115919|NCT01505868|mCRPC
1115920|NCT01505868|Prior treatment with docetaxel
1115921|NCT01505868|Cabazitaxel
1115922|NCT01505868|Jevtana
1115923|NCT01505868|Carboplatin
1115924|NCT01505868|Paraplatin
1115925|NCT01505868|Prednisone
1115926|NCT01505855|Crohn's disease
1115927|NCT01505855|Pneumococcal vaccination
1115928|NCT01505842|Ulcerative colitis
1115929|NCT01505842|Crohn's disease
1115930|NCT01505842|Chromoendoscopy
1115931|NCT01505842|Dysplasia
1115932|NCT01505842|Neoplasia
1115933|NCT01505842|Inflammatory Bowel Disease
1115934|NCT01505816|Cataract
1115935|NCT01505816|Vision
1115936|NCT01505816|Intraocular lens
1115937|NCT01505816|Multifocal
1115938|NCT01505816|Toric
1115939|NCT01505803|Type 2 diabetes mellitus
1115940|NCT01505803|Dietary supplements
1115941|NCT01505803|Hyperglycemia
1115942|NCT01505803|Insulin resistance
1115943|NCT01505803|Dyslipidemia
1115944|NCT01505803|Inflammation
1115945|NCT01505803|Oxidative stress
1115946|NCT01505803|Zinc
1115947|NCT01505803|Omega 3
1115948|NCT01505777|irritable bowel syndrome without predominant diarrhea
1115949|NCT01505777|Probiotics(Medirac) 10/mosapride 10mg
1115950|NCT01505777|Probiotics(Medirac) 15/mosapride 10mg
1115951|NCT01505777|Probiotics(Medirac) 15/mosapride 15mg
1115952|NCT01505777|Probiotics(Medirac) 30/mosapride 15mg
1115953|NCT01505777|Probiotics(Medirac) placebo/mosapride placebo
1115954|NCT01505764|Cachexia
1115955|NCT01505751|Outcome of cervical cancer
1115956|NCT01505725|Nicotine Reinforcement
1115957|NCT01505725|Tobacco Craving
1115958|NCT01505725|Behavior Genetics
1115959|NCT01505725|Smoking
1115960|NCT01505712|stage I adult Hodgkin lymphoma
1115961|NCT01505712|stage II adult Hodgkin lymphoma
1115962|NCT01505712|stage III adult Hodgkin lymphoma
1115963|NCT01505712|stage IV adult Hodgkin lymphoma
1115964|NCT01505699|adult acute lymphoblastic leukemia in remission
1115965|NCT01505699|B-cell adult acute lymphoblastic leukemia
1115966|NCT01505673|Insulin
1115967|NCT01505673|Glucagon-like peptide
1115968|NCT01505673|Liraglutide
1115969|NCT01505673|Beta-Cell
1115970|NCT01505673|pancreatic steatosis
1115971|NCT01505673|hepatic steatosis
1115972|NCT01505660|Adherence
1115973|NCT01505660|Depression
1115974|NCT01505660|Care management
1115975|NCT01505660|Stepped care
1115976|NCT01505660|HIV
1115977|NCT01505660|Patient reported outcomes
1115978|NCT01505660|Antiretroviral medication adherence
1115979|NCT01505621|Aging
1115980|NCT01505621|Protein accumulation
1115981|NCT01505621|Protein damage
1115982|NCT01505569|autologous transplantation
1115983|NCT01505569|high risk solid tumor
1115984|NCT01505569|relapsed solid tumor
1115985|NCT01505478|Sepsis
1115986|NCT01505478|Clinical Prediction Rule
1115987|NCT01505478|Clinical Informatics
1115989|NCT01505465|Total Knee Replacement
1115990|NCT01505465|Pain
1115991|NCT01505465|Confusion
1115992|NCT01505465|Sleep
1115993|NCT01505439|solifenacin
1115994|NCT01505439|bladder symptom
1115995|NCT01505426|ASP1941
1115996|NCT01505426|ipragliflozin
1115997|NCT01505426|metformin
1115998|NCT01505426|plasma glucose
1115999|NCT01505426|urine glucose
1116000|NCT01505413|advanced unresectable or metastatic Pancreatic Cancer
1116001|NCT01505400|Molecular profiling
1116002|NCT01505400|Advanced cancer
1116003|NCT01505400|Breast cancer
1116004|NCT01505400|Non-small cell lung cancer
1116005|NCT01505400|Colorectal cancer
1116006|NCT01505400|Genitourinary cancer
1116007|NCT01505400|Pancreatobiliary gastrointestinal cancer
1116008|NCT01505400|Upper aerodigestive tract cancer
1116009|NCT01505400|Gynecological cancers
1116010|NCT01505400|Phase I
1116011|NCT01505400|Phase I Clinical Trial Candidates
1116012|NCT01505400|melanoma cancer
1116013|NCT01505400|rare cancer
1116014|NCT01505400|unknown primary cancer
1116015|NCT01505387|Weight maintenance
1116016|NCT01505387|Overweight
1116017|NCT01505387|Obese
1116018|NCT01505387|Weight management
1116019|NCT01505374|Bilateral total knee replacement
1116020|NCT01505374|Femoral Nerve Block
1116021|NCT01505374|Saphenous Nerve Block
1116022|NCT01505361|probiotic
1116023|NCT01505361|Lactobacillus salivarius
1116024|NCT01505361|mastitis
1116025|NCT01505361|prevention
1116026|NCT01505361|group B streptococci
1116027|NCT01505361|intrapartum prophylaxis
1116028|NCT01505348|feeding patterns
1116029|NCT01505348|aerobic exercise
1116030|NCT01505348|osteoclasts
1116031|NCT01505335|alveolar nerve, inferior
1116032|NCT01505335|ultrasound
1116033|NCT01505335|digital radiography, dental
1116034|NCT01505335|nerve injury
1116035|NCT01505322|daily activities
1116036|NCT01505309|Aortic Diseases
1116037|NCT01505309|Vascular Diseases
1116038|NCT01505309|Cardiovascular Diseases
1116039|NCT01505309|Treatment Outcome
1116040|NCT01505309|Aorta Dissection
1116041|NCT01505309|Aorta Aneurysm
1116042|NCT01505309|Aorta pseudoaneurysm
1116043|NCT01505309|Endovascular aortic repair
1116044|NCT01505296|Catheter ablation
1116045|NCT01505257|Delirium
1116046|NCT01505257|Dementia
1116047|NCT01505257|Confusion Assessment Method
1116048|NCT01505231|Shock
1116049|NCT01505231|norepinephrine
1116050|NCT01505231|vasopressin
1116051|NCT01505231|cardiac surgery
1116052|NCT01505218|Sedation
1116053|NCT01505218|propofol
1116054|NCT01505218|patient-controlled
1116055|NCT01505218|safety
1116056|NCT01505205|Gist,c-KIT,PDGFRA,DOG1,mutation
1116057|NCT01505192|Those in Labor, Delivery and the Puerperium
1116058|NCT01505179|HFPEF
1116059|NCT01505179|Heart Failure
1116060|NCT01505179|HF w/ preserved EF
1116061|NCT01505179|Preserved EF
1116062|NCT01505179|Preserved Ejection Fraction
1116063|NCT01505179|Diastolic Dysfunction
1116064|NCT01505166|colorectal carcinoma
1116065|NCT01505166|colon cancer
1116066|NCT01505166|liver metastases
1116067|NCT01505153|Advanced cancer
1116068|NCT01505153|Metastatic cancer
1116069|NCT01505153|solid tumors
1116070|NCT01505153|Melanoma
1116071|NCT01505140|Andrology
1116072|NCT01505140|Fertility
1116073|NCT01505140|Reproduction
1116074|NCT01505140|Diet
1116075|NCT01505140|Nutritional Sciences
1116076|NCT01505140|Fatty Acids
1116077|NCT01505140|Antioxidants
1116078|NCT01505140|Body weight changes
1116079|NCT01505127|Drug Therapy
1116080|NCT01505114|HIV Prevention
1116081|NCT01505114|PrEP
1116082|NCT01505114|Maraviroc
1116083|NCT01505088|Iontophoresis
1116084|NCT01505088|Non-Infectious Anterior Segment Uveitis
1116085|NCT01505088|Ophthalmology
1116086|NCT01505075|prostatic neoplasms
1116087|NCT01505075|radiotherapy
1116088|NCT01505075|hypofractionated
1116089|NCT01505075|high risk prostate cancer
1116090|NCT01505062|Usher Syndrome Retinitis Pigmentosa
1116091|NCT01505062|Usher Syndrome associated Retinitis Pigmentosa
1116092|NCT01505049|immunology
1116093|NCT01505049|vaccination
1116094|NCT01505049|human papillomavirus
1116095|NCT01505036|Diabetes Mellitus
1116096|NCT01505036|smart-care
1116097|NCT01505036|U-health care
1116098|NCT01505010|Treatment-resistant hypertension
1116099|NCT01505010|Renal denervation
1116100|NCT01505010|Sympathetic nervous system
1116101|NCT01504997|DaVinci
1116102|NCT01504997|Robot assisted surgery
1116103|NCT01504997|Gastrectomy
1116104|NCT01504997|Safety
1116105|NCT01504997|Gastric Cancer
1116106|NCT01504984|Evaluation of the pharmacokinetics equivalence
1116107|NCT01504984|Healthy volunteers
1116108|NCT01504984|Single dose over the period I and II(crossover)
1116109|NCT01504984|Healthy male volunteers
1116110|NCT01504971|Gastroesophageal Reflux;
1116111|NCT01504971|Endoscopy;
1116237|NCT01504633|omega-3 PUFA (DHA)
1116112|NCT01504971|Esophageal pH monitoring;
1116113|NCT01504971|Narrow band imaging;
1116114|NCT01504971|Autofluorescence imaging;
1116115|NCT01504971|White light imaging;
1116116|NCT01504958|Alzheimer's disease
1116117|NCT01504958|Cognitive Training
1116118|NCT01504958|Transcranial Magnetic Stimulation
1116119|NCT01504945|chronic coronary artery disease
1116120|NCT01504932|black raspberry lozenges
1116121|NCT01504932|Appalachian
1116122|NCT01504932|Oral Cancer
1116123|NCT01504919|Psychosocial
1116124|NCT01504919|Behavioral intervention
1116125|NCT01504919|Nicotine patch
1116126|NCT01504919|Latinos
1116127|NCT01504919|Mexican American
1116128|NCT01504919|Motivation and Problem Solving
1116129|NCT01504919|MAPS
1116130|NCT01504919|Cancer risk reduction
1116131|NCT01504919|Smoking cessation
1116132|NCT01504919|Overweight/obese smokers
1116133|NCT01504919|BMI greater than or equal to 25
1116134|NCT01504919|Wellness program
1116135|NCT01504919|Questionnaires
1116136|NCT01504919|Surveys
1116137|NCT01504919|Self-help materials
1116138|NCT01504919|Pamphlets
1116139|NCT01504906|Phase 1
1116140|NCT01504906|Healthy male volunteers
1116141|NCT01504906|pharmacokinetics
1116142|NCT01504906|cyclosporine
1116143|NCT01504906|ticagrelor
1116144|NCT01504906|Bioavailability (plasma AUC, Cmax, plasma AUC0-t, t1/2λz, tmax)
1116145|NCT01504893|ventilation
1116146|NCT01504893|PEEP
1116147|NCT01504893|Acute Lung Injury
1116148|NCT01504893|pneumonectomy
1116149|NCT01504893|ARDS
1116150|NCT01504880|Mitral Regurgitation
1116151|NCT01504880|Tricuspid Regurgitation
1116152|NCT01504880|Vena Contracta
1116153|NCT01504867|Acute Respiratory Distress Syndrome
1116154|NCT01504867|Acute Lung Injury
1116155|NCT01504867|ARDS
1116156|NCT01504867|ALI
1116157|NCT01504867|aspirin
1116158|NCT01504867|prevention
1116159|NCT01504854|Alzheimer's disease
1116160|NCT01504854|Dementia
1116161|NCT01504854|Brain diseases
1116162|NCT01504854|Resveratrol
1116163|NCT01504854|Memory problems
1116164|NCT01504854|Mental disorders
1116165|NCT01504854|Cognitive disorders
1116166|NCT01504828|Energy Metabolism
1116167|NCT01504828|Ageing
1116168|NCT01504828|left ventricle
1116169|NCT01504828|energetics
1116170|NCT01504828|function
1116171|NCT01504815|advanced head and neck cancer
1116172|NCT01504815|adaptive radiotherapy
1116173|NCT01504815|cisplatinum
1116174|NCT01504802|Growth hormone
1116175|NCT01504802|C-type natriuretic peptide
1116301|NCT01504321|PCOS
1116176|NCT01504802|amino-terminal propeptide of C-type natriuretic peptide
1116177|NCT01504802|insulin-like growth factor-I
1116178|NCT01504802|bone specific alkaline phosphatase
1116179|NCT01504802|leptin
1116180|NCT01504802|deoxypyridinoline
1116181|NCT01504802|growth velocity
1116182|NCT01504802|pharmacodynamic
1116183|NCT01504802|biomarker
1116184|NCT01504789|Breast Cancer
1116185|NCT01504789|Breast Cancer Survivors
1116186|NCT01504789|Exercise
1116187|NCT01504789|Hispanic
1116188|NCT01504789|Mexican-American
1116189|NCT01504789|Puerto Rican
1116190|NCT01504789|Culturally tailored exercise
1116191|NCT01504789|Fitness tests
1116192|NCT01504789|Questionnaires
1116193|NCT01504789|Surveys
1116194|NCT01504789|Culturally tailored written material
1116195|NCT01504776|MCL
1116196|NCT01504776|Lymphoma
1116197|NCT01504776|Panobinostat
1116198|NCT01504763|Massage
1116199|NCT01504763|Chair massage
1116200|NCT01504763|Relaxation
1116201|NCT01504763|Nurses
1116202|NCT01504750|Length of Stay [E02.760.400.480]
1116203|NCT01504750|Activities of Daily Living [I03.050]
1116204|NCT01504737|Exercise
1116205|NCT01504737|Physical Activity
1116206|NCT01504737|Physiotherapy
1116207|NCT01504737|Exercise test
1116208|NCT01504737|Quality of Life
1116209|NCT01504737|Aortic Valve Replacement
1116210|NCT01504724|central macular thickness
1116211|NCT01504698|Manipulative treatment
1116212|NCT01504698|Children
1116213|NCT01504698|Neck pain
1116214|NCT01504698|Back pain
1116215|NCT01504698|Effect
1116216|NCT01504698|Adolescence
1116217|NCT01504698|Advise
1116218|NCT01504698|Exercise
1116219|NCT01504685|Morbid obesity
1116220|NCT01504685|Obesity surgery
1116221|NCT01504685|Gastric bypass
1116222|NCT01504685|Banded gastric bypass
1116223|NCT01504672|Drug related problems
1116224|NCT01504659|bipolar disorder
1116225|NCT01504659|treatment resistance
1116226|NCT01504659|depression
1116227|NCT01504659|ketamine
1116228|NCT01504659|intranasal
1116229|NCT01504659|child
1116230|NCT01504646|Asthma
1116231|NCT01504646|Exercise-Induced Bronchoconstriction
1116232|NCT01504646|lipids
1116233|NCT01504646|n-3 PUFA
1116234|NCT01504646|airway inflammation
1116235|NCT01504646|Bronchoconstriction
1116236|NCT01504633|cognitive function
1116238|NCT01504633|iron
1116239|NCT01504633|nutrigenomics
1116240|NCT01504633|under-two year old children
1116241|NCT01504633|Indonesia
1116242|NCT01504620|diabetes mellitus
1116243|NCT01504620|blood glucose self-assessment
1116244|NCT01504620|Accuracy
1116245|NCT01504620|Intra-Assay precision
1116246|NCT01504620|Hematocrit interference
1116247|NCT01504607|corneal endothelium
1116248|NCT01504607|congenital cataract surgery
1116249|NCT01504607|IOL implantation
1116250|NCT01504594|Dilated cardiomyopathy
1116251|NCT01504594|Idiopathic
1116252|NCT01504594|Bone Marrow
1116253|NCT01504594|Stem Cells
1116254|NCT01504594|CD34 +
1116255|NCT01504594|Autologous
1116256|NCT01504555|hypercortisolism, dexamethasone, alcoholism,obesity.
1116257|NCT01504542|Immunotherapy
1116258|NCT01504529|Rotigotine (Neupro)
1116259|NCT01504529|Non-Motor Symptoms
1116260|NCT01504529|Advanced Parkinson's Disease
1116261|NCT01504529|Local study
1116262|NCT01504529|Spain
1116263|NCT01504529|Observational study
1116264|NCT01504529|Non-interventional study
1116265|NCT01504529|Retrospective study
1116266|NCT01504529|Post-marketing study
1116267|NCT01504529|Multicenter study
1116268|NCT01504516|Bioequivalence
1116269|NCT01504516|Donepezil
1116270|NCT01504516|crossover
1116271|NCT01504503|Bioequivalence
1116272|NCT01504503|Donepezil
1116273|NCT01504503|crossover
1116274|NCT01504490|Advanced cancer
1116275|NCT01504477|colorectal cancer
1116276|NCT01504477|relapsed
1116277|NCT01504477|refractory
1116278|NCT01504477|Kras wild type
1116279|NCT01504464|knee joint osteoarthritis mesenchymal stem cell
1116280|NCT01504451|Atrial fibrillation
1116281|NCT01504451|Ablation
1116282|NCT01504451|Implantable loop recorder
1116283|NCT01504412|Pain
1116284|NCT01504412|Diabetic Peripheral Neuropathy
1116285|NCT01504399|Pituitary surgery
1116286|NCT01504399|Transsphenoidal surgery
1116287|NCT01504399|Anterior skull base surgery
1116288|NCT01504399|Endoscopic surgery
1116289|NCT01504399|Patient survey
1116290|NCT01504399|Nasal complications
1116291|NCT01504373|NAVA
1116292|NCT01504373|neurally adjusted ventilatory support
1116293|NCT01504373|lung injury
1116294|NCT01504373|ventilation
1116295|NCT01504373|lung volume distribution
1116296|NCT01504373|oxygen cost of breathing
1116297|NCT01504360|sarcoma
1116298|NCT01504360|radiation therapy
1116299|NCT01504360|predictive essay
1116300|NCT01504321|Polycystic Ovary syndrome
1116302|NCT01504321|sympathetic nervous system
1116303|NCT01504321|moxonidine
1116304|NCT01504308|uterine fibroids
1116305|NCT01504308|uterine leiomyomas
1116306|NCT01504308|magnetic resonance imaging
1116307|NCT01504308|focused ultrasound
1116308|NCT01504256|Adenocarcinoma
1116309|NCT01504256|Esophagogastric Junction
1116310|NCT01504256|Peritoneal Carcinomatosis
1116311|NCT01504256|Catumaxomab
1116312|NCT01504256|AIO-STO-0110
1116313|NCT01504243|CD163;
1116314|NCT01504243|SNPs;
1116315|NCT01504243|prognosis;
1116316|NCT01504243|control（normal person）
1116317|NCT01504230|To ascertain the mechanisms for effectively controlling balance in seniors with osteoporosis and to provide a basis for developing fall prevention programs.
1116318|NCT01504230|To develop biomechanical models that control the entire body's center of mass (CoM) during upright quiet stance in seniors with osteoporosis.
1116319|NCT01504230|To identify the mechanism to control the entire body's CoM after receiving a balance perturbation in seniors with osteoporosis.
1116320|NCT01504217|Healthy older people over 65 years old
1116321|NCT01504204|adherence
1116322|NCT01504204|adapalene
1116323|NCT01504204|benzoyl peroxide
1116324|NCT01504204|sample
1116325|NCT01504204|topical treatment
1116326|NCT01504191|myocardial infarction
1116327|NCT01504191|depression
1116328|NCT01504191|anxiety
1116329|NCT01504191|Internet‐based CBT
1116330|NCT01504191|genetic disposition
1116331|NCT01504178|Noradrenergic system and pain in Parkinson's disease
1116332|NCT01504165|Renal impairment
1116333|NCT01504165|Pharmacokinetic
1116334|NCT01504165|cilengitide
1116335|NCT01504165|subjects with mild
1116336|NCT01504165|moderate or severe renal impairment compared to subjects with normal renal function
1116337|NCT01504152|International travel
1116338|NCT01504152|cancer patients
1116339|NCT01504152|HSCT
1116340|NCT01504152|Quality of Life
1116341|NCT01504152|questionnaire
1116342|NCT01504152|11-176
1116343|NCT01504126|Ovarian Cancer
1116344|NCT01504126|Primary peritoneal carcinoma
1116345|NCT01504126|Fallopian tube cancer
1116346|NCT01504126|Invasive epithelial ovarian cancer
1116347|NCT01504126|Serous adenocarcinoma
1116348|NCT01504126|Endometrioid adenocarcinoma
1116349|NCT01504126|Mucinous adenocarcinoma
1116350|NCT01504126|Undifferentiated carcinoma
1116351|NCT01504126|Clear cell carcinoma
1116352|NCT01504126|Mixed epithelial carcinoma
1116353|NCT01504126|Adenocarcinoma not otherwise specified
1116604|NCT01502982|DLBCL
1116354|NCT01504126|Primary Müllerian epithelial adenocarcinoma
1116355|NCT01504126|Propranolol
1116356|NCT01504126|Beta-blocker
1116357|NCT01504113|Target therapy
1116358|NCT01504113|Biologics
1116359|NCT01504113|Psoriasis
1116360|NCT01504113|Latent virus
1116361|NCT01504113|Human papillomaviruses
1116362|NCT01504113|Cytomegalovirus
1116363|NCT01504113|Epstein-Barr virus
1116364|NCT01504113|Tumor necrosis factor
1116365|NCT01504087|patient in critical care
1116366|NCT01504074|Irvine Gass syndrome
1116367|NCT01504074|multimodal imaging
1116368|NCT01504074|SD-OCT
1116369|NCT01504074|CME secondary to cataract surgery
1116370|NCT01504074|in vivo correlation of morphology and function
1116371|NCT01504061|surgical
1116372|NCT01504061|scars
1116373|NCT01504061|Mederma
1116374|NCT01504048|Microscopic colitis
1116375|NCT01504048|Intestinal Diseases
1116376|NCT01504048|Inflammatory Bowel Diseases
1116377|NCT01504035|Donor site pain
1116378|NCT01504035|Iliac crest
1116379|NCT01504035|Bone graft
1116380|NCT01504035|Hemostatic putty
1116381|NCT01504035|lidocaine
1116382|NCT01504035|Donor site pain following harvest of iliac crest bone grafts
1116383|NCT01504022|Hypertension
1116384|NCT01504022|self-monitoring
1116385|NCT01504022|internet
1116386|NCT01504022|lifestyle modification
1116387|NCT01504009|Nervous System Disease
1116388|NCT01504009|Neurodegenerative Disease
1116389|NCT01504009|Motor Neuron Disease
1116390|NCT01504009|ALS
1116391|NCT01504009|Muscle training
1116392|NCT01504009|Muscle atrophy
1116393|NCT01503996|dehydration
1116394|NCT01503996|risk factor
1116395|NCT01503996|glaucoma
1116396|NCT01503996|Controls
1116397|NCT01503983|Gastric Cancer with Metastasis
1116398|NCT01503983|HER2-positive
1116399|NCT01503970|chondral lesions
1116400|NCT01503970|knee
1116401|NCT01503957|Allergic rhinitis
1116402|NCT01503957|Allergen
1116403|NCT01503957|Allergy
1116404|NCT01503957|Dustmite
1116405|NCT01503931|alcohol dependence, functional magnetic resonance imaging, genetics, endophenotypes, dopamine,
1116406|NCT01503931|glutamate
1116407|NCT01503918|Critical Illness
1116408|NCT01503918|Critical Care
1116409|NCT01503918|Valganciclovir
1116410|NCT01503918|Ganciclovir
1116411|NCT01503918|Aciclovir
1116412|NCT01503918|Valaciclovir
1116413|NCT01503918|Cytomegalovirus
1116414|NCT01503905|breast cancer
1116415|NCT01503905|neoadjuvant chemotherapy
1116416|NCT01503905|amenorrhea
1116417|NCT01503892|Small Fiber Neuropathy
1116418|NCT01503892|Metanx Effect on Small Fiber Neuropathy
1116419|NCT01503892|Metanx Effect on Diabetic Peripheral Neuropathy
1116420|NCT01503879|general anaesthesia
1116421|NCT01503879|invasive mechanical ventilation
1116422|NCT01503879|DLCO
1116423|NCT01503879|SPB
1116424|NCT01503853|Medical Costs
1116425|NCT01503853|Health Care
1116426|NCT01503853|Focus Groups
1116427|NCT01503827|Whole Brain Radiotherapy
1116428|NCT01503827|Brain metastases
1116429|NCT01503827|Melanoma
1116430|NCT01503827|Stage IV Metastatic Melanoma
1116431|NCT01503827|Neurocognitive function
1116432|NCT01503827|Quality of life
1116433|NCT01503814|hypertension
1116434|NCT01503814|primary care
1116435|NCT01503814|cardiovascular disease prevention
1116436|NCT01503814|high cardiovascular risk
1116437|NCT01503814|diuretics
1116438|NCT01503814|aspirin
1116439|NCT01503814|smoking cessation
1116440|NCT01503814|salt reduction
1116441|NCT01503814|Tibet
1116442|NCT01503801|Preterm neonates
1116443|NCT01503801|Bronchopulmonary dysplasia
1116444|NCT01503801|Chronic lung disease
1116445|NCT01503801|Inhaled nitric oxide
1116446|NCT01503801|Respiratory therapy
1116452|NCT01503762|Hand Flexor tendon Injuries
1116453|NCT01503762|hand Extensor Tendon Injuries
1116454|NCT01503762|Hand Joint Dislocations and subluxation
1116455|NCT01503736|Kidney Diseases
1116456|NCT01503736|Kidney Failure, Chronic
1116457|NCT01503736|Hyperphosphatemia
1116458|NCT01503736|Urologic Diseases
1116459|NCT01503736|Renal Insufficiency, Chronic
1116460|NCT01503736|Renal Insufficiency
1116461|NCT01503736|Phosphorus Metabolism Disorders
1116462|NCT01503710|Proteinuria predict outcome
1116463|NCT01503710|BNP and NGAL predict outcome
1116464|NCT01503710|Pre-operative GFR and proteinuria
1116465|NCT01503697|Breast Cancer
1116466|NCT01503697|High Risk
1116467|NCT01503697|Imaging
1116468|NCT01503697|Angiogenesis
1116469|NCT01503684|sepsis
1116470|NCT01503671|left ventricular diastolic function
1116471|NCT01503671|inflammation
1116472|NCT01503671|peritoneal dialysis
1116473|NCT01503671|LV diastolic function changes after statin intervention
1116474|NCT01503658|Clopidogrel,
1116475|NCT01503658|Aspirin,
1116476|NCT01503658|Pharmacogenomics
1116477|NCT01503645|kidney diseases
1116478|NCT01503645|drugs, Chinese herbal
1116479|NCT01503645|aristolochic acid
1116480|NCT01503645|polymorphism, genetic
1116482|NCT01503606|preterm premature rupture of membrane
1116483|NCT01503606|antibiotics
1116484|NCT01503606|duration
1116485|NCT01503606|cefazolin
1116486|NCT01503606|clarithromycin
1116487|NCT01503541|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1116488|NCT01503541|adult acute myeloid leukemia with del(5q)
1116489|NCT01503541|adult acute myeloid leukemia with inv(16)(p13;q22)
1116490|NCT01503541|adult acute myeloid leukemia with t(15;17)(q22;q12)
1116491|NCT01503541|adult acute myeloid leukemia with t(16;16)(p13;q22)
1116492|NCT01503541|adult acute myeloid leukemia with t(8;21)(q22;q22)
1116493|NCT01503541|adult acute myeloid leukemia
1116494|NCT01503528|arthroplasty
1116495|NCT01503528|wound
1116496|NCT01503528|catheter
1116497|NCT01503528|infusion
1116498|NCT01503528|local
1116499|NCT01503528|anesthesia
1116500|NCT01503528|infiltration
1116501|NCT01503502|Myelogenous Leukemia
1116502|NCT01503502|chronce
1116503|NCT01503502|Philadelphia Chromosome Positive
1116504|NCT01503502|Flumatinib
1116505|NCT01503489|Switch.
1116506|NCT01503476|gastro esophageal reflux disease
1116507|NCT01503463|Congestive Heart Failure
1116508|NCT01503463|Telemedicine
1116509|NCT01503385|Celecoxib
1116510|NCT01503385|phase II
1116511|NCT01503359|glutamic acid
1116512|NCT01503359|sarcosine
1116513|NCT01503359|NMDA
1116514|NCT01503359|schizophrenia
1116515|NCT01503346|Appetite Loss
1116516|NCT01503333|exercise
1116517|NCT01503333|adolescent
1116518|NCT01503333|intervention
1116519|NCT01503333|female
1116520|NCT01503333|counseling
1116521|NCT01503320|To evaluate
1116522|NCT01503320|efficacy
1116523|NCT01503320|enteral glutamine
1116524|NCT01503307|prenatal chd diagnosis
1116525|NCT01503307|postpartum chd diagnosis
1116526|NCT01503307|parenting
1116527|NCT01503307|internal working models
1116528|NCT01503294|Temporal artery thermometer
1116529|NCT01503294|Pulmonary artery thermistor
1116530|NCT01503281|Children
1116531|NCT01503281|Physical activity
1116532|NCT01503281|Home-based treatment
1116533|NCT01503281|Body mass index (z-BMI)
1116534|NCT01503281|Percentage body fat
1116535|NCT01503281|Waist circumference
1116536|NCT01503268|Atrial fibrillation
1116537|NCT01503268|Ablation
1116538|NCT01503268|Percutaneous ablation
1116539|NCT01503268|Minimally-invasive thoracoscopic ablation
1116540|NCT01503268|Implantable loop recorder
1116541|NCT01503255|CBT
1116542|NCT01503255|alcohol
1116543|NCT01503255|HIV
1116544|NCT01503255|Kenya
1116545|NCT01503255|paraprofessional
1116546|NCT01503216|randomized controlled trial
1116547|NCT01503216|vitamin D
1116548|NCT01503216|bioavailability
1116549|NCT01503203|Older
1116550|NCT01503203|virtual systems
1116551|NCT01503203|low back pain
1116552|NCT01503203|postural balance
1116553|NCT01503190|Breast Cancer
1116554|NCT01503190|Young Women
1116555|NCT01503190|Pregnancy Associated Breast Cancer
1116556|NCT01503190|Pregnancy
1116557|NCT01503190|Premenopausal Breast Cancer
1116558|NCT01503164|Obstructive sleep apnea
1116559|NCT01503164|Sleep Apnea
1116560|NCT01503164|Sleep-disordered breathing
1116561|NCT01503164|Insulin sensitivity
1116562|NCT01503164|Glucose tolerance
1116563|NCT01503164|Type 2 diabetes
1116564|NCT01503151|attention bias modification treatment
1116565|NCT01503151|interpretive bias modification
1116566|NCT01503151|cognitive bias modification
1116567|NCT01503151|attention training
1116568|NCT01503151|social anxiety
1116569|NCT01503138|Intimate Partner Violence
1116570|NCT01503138|Depressive Symptoms
1116571|NCT01503138|Intervention
1116572|NCT01503138|Randomized Controlled Trial
1116573|NCT01503138|Mainland Chinese
1116574|NCT01503138|Immigrants
1116575|NCT01503138|Women
1116576|NCT01503125|GAN
1116577|NCT01503125|Giant Axonal Neuropathy
1116578|NCT01503125|Neuromuscular Disease
1116579|NCT01503125|Natural History Study
1116580|NCT01503125|Observational Study
1116581|NCT01503112|Glucagon-Like Peptide 1, DPP4 protein, Therapeutics, Hypoglycemic Agents, C-Peptide, Type 2 Diabetes Mellitus,
1116582|NCT01503099|ITB
1116583|NCT01503099|PTB
1116584|NCT01503099|CD
1116585|NCT01503073|stroke
1116586|NCT01503060|pediatrics
1116587|NCT01503060|Pain
1116588|NCT01503060|Immunization
1116589|NCT01503034|Pregnant women
1116590|NCT01503021|Soluble ferric pyrophosphate
1116591|NCT01503021|Chronic kidney disease
1116592|NCT01503021|Chronic hemodialysis
1116593|NCT01503021|Ferric pyrophosphate citrate
1116594|NCT01502995|Assistive devices
1116595|NCT01502995|Freezing of gait
1116596|NCT01502995|Gait disorders
1116597|NCT01502995|Gait hesitation
1116598|NCT01502995|Gait ignition failure
1116599|NCT01502995|Laser light
1116600|NCT01502995|Parkinson's disease
1116601|NCT01502995|Rolling walker
1116602|NCT01502995|Visual Cue
1116603|NCT01502995|Walker
1116605|NCT01502982|high risk
1116606|NCT01502982|young
1116607|NCT01502969|diarrhea
1116608|NCT01502969|fever
1116609|NCT01502969|nausea
1116610|NCT01502969|vomit
1116611|NCT01502969|irritability
1116612|NCT01502956|Refractory Urinary Urge Incontinence
1116613|NCT01502956|Botox A®
1116614|NCT01502956|Interstim® Device
1116615|NCT01502943|Complementary Therapies
1116616|NCT01502943|Traditional Chinese Medicine
1116617|NCT01502943|Quality of life
1116618|NCT01502943|Seattle angina questionnaire (SAQ)
1116619|NCT01502943|SF-12
1116620|NCT01502943|Measure Your Medical Outcome Profile (MYMOP)
1116621|NCT01502943|Phlegm and blood stasis Syndrome
1116622|NCT01502943|Qi deficiency and blood stasis Syndrome
1116623|NCT01502943|Invigorating Spleen to Remove Phlegm or replenish Qi
1116624|NCT01502943|Activating blood and dissolving stasis
1116625|NCT01502943|Traditional Chinese medicine SYndrome Scale (TCMsys)
1116626|NCT01502943|Patients Report Outcomes(PRO)
1116627|NCT01502943|clinical efficacy
1116628|NCT01502943|evaluative index
1116629|NCT01502917|Brain stem glioma
1116630|NCT01502917|CNS
1116631|NCT01502917|MAB 124I-8H9
1116632|NCT01502917|infusion cannula
1116633|NCT01502917|DIPG
1116634|NCT01502917|Diffuse Intrinsic Pontine Glioma
1116635|NCT01502917|11-011
1116636|NCT01502904|SES vs BES
1116637|NCT01502891|Comparative Effectiveness Research
1116638|NCT01502891|Decision Support Techniques
1116639|NCT01502891|Decision Making
1116640|NCT01502878|Nut allergy
1116641|NCT01502878|Double-blind placebo-controlled (DBPC) oral nut challenge
1116642|NCT01502878|Nut oral immunotherapy (OIT)
1116643|NCT01502878|Nut oral desensitization
1116644|NCT01502852|OEF/OIF Veterans
1116645|NCT01502852|Traumatic Brain Injury
1116646|NCT01502852|Community Mental Health
1116647|NCT01502826|Childhood obesity
1116648|NCT01502826|Endothelial dysfunction
1116649|NCT01502826|Inflammation
1116650|NCT01502826|Insulin resistance
1116651|NCT01502813|Neuropsychological testing
1116652|NCT01502813|Dietary supplements
1116653|NCT01502800|Metastatic
1116654|NCT01502800|Unresectable
1116655|NCT01502800|Recurrent advanced
1116656|NCT01502787|hypertension
1116657|NCT01502787|blood pressure
1116658|NCT01502787|blood pressure medications
1116659|NCT01502787|metoprolol
1116660|NCT01502787|nebivolol
1116661|NCT01502787|handgrip exercise
1116662|NCT01502787|lower body negative pressure
1116663|NCT01502787|angiotensin II
1116664|NCT01502787|sympathetic nerve activity
1116665|NCT01502787|flow mediated dilation
1116666|NCT01502787|nitric oxide
1116667|NCT01502787|microneurography
1116668|NCT01502774|STEMI
1116669|NCT01502774|cyclosporine
1116670|NCT01502774|reperfusion injury
1116671|NCT01502761|stroke
1116672|NCT01502761|Magnesium
1116673|NCT01502761|endovascular
1116674|NCT01502748|stroke
1116675|NCT01502748|Magnesium
1116676|NCT01502748|Endovascular
1116677|NCT01502735|dengue
1116678|NCT01502735|dengue fever
1116679|NCT01502735|monovalent dengue vaccine
1116680|NCT01502709|Single blind
1116681|NCT01502709|Randomized
1116682|NCT01502709|Controlled clinical trial
1116683|NCT01502696|ulcerated primary cutaneous melanoma
1116684|NCT01502696|Stage II
1116685|NCT01502696|PEG IFN alfa-2b
1116686|NCT01502696|T(2-4)bN0M0
1116687|NCT01502683|Stroke
1116688|NCT01502683|neurocognitive dysfunction
1116689|NCT01502683|cerebral embolic events
1116690|NCT01502670|Pulmonary nodules
1116691|NCT01502657|percutaneous tracheostomy
1116692|NCT01502657|ultrasonography
1116693|NCT01502657|echography
1116694|NCT01502657|critical care
1116695|NCT01502644|low back pain
1116696|NCT01502644|opioids
1116697|NCT01502644|mood symptoms
1116698|NCT01502618|Adolescent Medicine Trials Network for HIV/AIDS Interventions
1116699|NCT01502618|Human Immunodeficiency Virus
1116700|NCT01502605|5-ALA
1116701|NCT01502605|Aminolevulinic Acid
1116702|NCT01502605|Craniotomy
1116703|NCT01502605|Brain Tumor
1116704|NCT01502605|Surgical Resection
1116705|NCT01502605|Neurosurgery
1116706|NCT01502592|MDX-010 (Ipilimumab)
1116707|NCT01502592|Cryoablation
1116708|NCT01502592|Total mastectomy planned
1116709|NCT01502592|11-202
1116710|NCT01502579|IgA nephropathy
1116711|NCT01502566|educational intervention
1116712|NCT01502566|dentals caries
1116713|NCT01502566|population
1116714|NCT01502566|new populational caries prevention strategies.
1116715|NCT01502553|blood pressure
1116716|NCT01502553|heart rate
1116717|NCT01502540|pain
1116718|NCT01502540|craniotomy
1116719|NCT01502527|Vulvo vaginal atrophy
1116720|NCT01502527|Femarelle
1116721|NCT01502514|CHF
1116722|NCT01502514|ischemia
1116723|NCT01502514|Heart Failure
1116724|NCT01502501|CHF
1116725|NCT01502501|Heart Failure
1116726|NCT01502501|Non-Ischemic
1116727|NCT01502501|nonischemic
1116728|NCT01502501|nonischemia
1116729|NCT01502488|Autistic
1116730|NCT01502488|ASC therapy
1116731|NCT01502488|ADSC
1116732|NCT01502475|Complementary Alternative Medicine
1116733|NCT01502475|Veteran
1116734|NCT01502475|Attitudes
1116735|NCT01502475|Beliefs
1116736|NCT01502462|Clinical course and prognostic factors in patients with severe isolated TR
1116737|NCT01502449|telemedicine, telephonic, PTSD
1116738|NCT01502436|posttraumatic stress disorder
1116739|NCT01502436|traumatic brain injury
1116740|NCT01502436|Suicide Attempt
1116741|NCT01502436|Veterans
1116742|NCT01502423|On label Humira users
1116743|NCT01502423|Rheumatoid Arthritis
1116744|NCT01502423|Pain
1116745|NCT01502397|hepatitis B
1116746|NCT01502397|anti-HBc
1116747|NCT01502397|HBsAg
1116748|NCT01502397|rituximab
1116749|NCT01502397|occult HBV
1116750|NCT01502384|healthy 1st degree relatives of pd patients
1116751|NCT01502371|Asthma
1116752|NCT01502371|Children
1116753|NCT01502371|Persistent
1116754|NCT01502358|dengue
1116755|NCT01502358|dengue fever
1116756|NCT01502358|dengue disease
1116757|NCT01502358|tetravalent dengue vaccine
1116758|NCT01502358|Vaxfectin®
1116759|NCT01502345|HFRS
1116760|NCT01502332|Mechanical ventilation
1116761|NCT01502332|Open lung approach
1116762|NCT01502332|Blood gases
1116763|NCT01502332|Cardiac surgery
1116764|NCT01502332|Pulmonary complications
1116765|NCT01502306|Smoking cessation
1116766|NCT01502306|Telephone
1116767|NCT01502306|Self-help
1116768|NCT01502306|Smoking abstinence
1116769|NCT01502306|Incentives
1116770|NCT01502306|Nicotine-replacement therapy
1116771|NCT01502306|Medi-Cal
1116772|NCT01502306|Medicaid
1116773|NCT01502280|extent of resection
1116774|NCT01502280|Glioma
1116775|NCT01502280|5-ALA
1116776|NCT01502280|tumor fluorescence
1116777|NCT01502280|confocal microscopy
1116778|NCT01502267|Waiting list
1116779|NCT01502267|Deceased donor kidney transplantation
1116780|NCT01502267|Desensitization
1116781|NCT01502267|anti HLA antibody
1116782|NCT01502254|Informed consent
1116783|NCT01502254|Cancer clinical trials
1116784|NCT01502254|Patient information
1116785|NCT01502254|Knowledge
1116786|NCT01502254|Questionnaire
1116787|NCT01502254|Patient Eligible for a Phase II or III Cancer Clinical Trial
1116788|NCT01502254|Scheduled Clinical Visit for Information About a Trial
1116789|NCT01502241|elderly
1116790|NCT01502241|brain tumors
1116791|NCT01502241|MGMT
1116792|NCT01502241|chemotherapy
1116793|NCT01502241|Newly diagnosed
1116794|NCT01502241|patients > 65 years
1116795|NCT01502202|lung adenocarcinoma
1116796|NCT01502202|never smoker
1116797|NCT01502202|1st line treatment
1116798|NCT01502202|Intercalation administration
1116799|NCT01502202|Gefitinib
1116800|NCT01502202|never smokers
1116801|NCT01502189|patient education as topic
1116802|NCT01502189|representational approach
1116803|NCT01502189|parents
1116804|NCT01502189|childhood cancer
1116805|NCT01502189|paediatric oncology
1116806|NCT01502189|nursing
1116807|NCT01502189|parents of children with cancer
1116808|NCT01502189|Stress
1116809|NCT01502189|Health Knowledge
1116810|NCT01502189|Attitudes
1116811|NCT01502189|Practice
1116812|NCT01502176|atrial fibrillation
1116813|NCT01502176|registry
1116814|NCT01502163|perioperative hypothermia
1116815|NCT01502163|prewarming
1116816|NCT01502163|forced air warming
1116817|NCT01502163|insulation
1116818|NCT01502150|Pediatric Cancer
1116819|NCT01502150|Proton Radiation Therapy
1116820|NCT01502150|Proton beam radiotherapy
1116821|NCT01502150|PBT
1116822|NCT01502150|Data Collection
1116823|NCT01502150|Database
1116824|NCT01502150|Acute and late normal tissue toxicities
1116825|NCT01502150|Dosimetric data
1116826|NCT01502150|Toxicity data
1116827|NCT01502111|decreased level of consciousness
1116828|NCT01502111|hypoxemia
1116829|NCT01502111|ineffective ventilation
1116830|NCT01502111|airway obstruction
1116831|NCT01502111|combative or unresponsive
1116832|NCT01502111|relief of pain or distress
1116833|NCT01502111|cardiopulmonary arrest
1116834|NCT01502085|multiple myeloma lenalidomide
1116835|NCT01502072|Ribavirin
1116836|NCT01502072|Ribavirin Aerosol
1116837|NCT01502072|Respiratory Syncytial Virus
1116838|NCT01502072|RSV
1116839|NCT01502072|upper respiratory tract infection
1116840|NCT01502072|URI
1116841|NCT01502072|Lower respiratory tract Infection
1116842|NCT01502072|LRI
1116843|NCT01502072|pneumonia
1116844|NCT01502072|aerosolized ribavirin
1116845|NCT01502072|HSCT
1116846|NCT01502072|Hematopoietic stem cell transplantation
1116847|NCT01502072|oral ribavirin therapy
1116848|NCT01502059|Pilates
1116849|NCT01502059|Exercise
1116850|NCT01502059|Treatment
1116851|NCT01502059|Low back pain
1116852|NCT01502059|Pain
1116853|NCT01502059|Function
1116854|NCT01502046|Huntington's disease, cannabinoids
1116855|NCT01502033|Adolescent Depression
1116856|NCT01502033|Transcranial Magnetic Stimulation
1116857|NCT01502020|actinic keratoses
1116858|NCT01502020|actinic keratosis
1116859|NCT01502020|imiquimod, 3.75%
1116860|NCT01502020|imiquimod
1116861|NCT01502020|Zyclara
1116862|NCT01502020|Actinic keratoses of the face or balding scalp
1116863|NCT01502007|Activity Level
1116864|NCT01502007|Overweight
1116865|NCT01502007|Obesity
1116866|NCT01501994|Activity level
1116867|NCT01501994|Weight
1116868|NCT01501994|Body Fat
1116869|NCT01501994|Well Being
1116870|NCT01501981|heart failure
1116871|NCT01501981|MR-proANP
1116872|NCT01501981|MR-proADM
1116873|NCT01501981|decompensation
1116874|NCT01501981|Copeptin
1116875|NCT01501981|CT-proET1
1116876|NCT01501981|NT-proBNP
1116877|NCT01501968|Colistin
1116878|NCT01501968|ascorbic acid
1116879|NCT01501968|renal toxicity
1116880|NCT01501955|Osteoarthritis
1116881|NCT01501942|Asthma
1116882|NCT01501942|Allergen induced asthma
1116883|NCT01501942|ATS Criteria (1)
1116884|NCT01501929|hypertension
1116885|NCT01501929|blood pressure
1116886|NCT01501929|blood pressure medications
1116887|NCT01501929|metoprolol
1116888|NCT01501929|nebivolol
1116889|NCT01501929|vascular oxidative stress
1116890|NCT01501929|nitric oxide
1116891|NCT01501929|nitric oxide synthase (eNOS)
1116892|NCT01501929|endothelium
1116893|NCT01501929|endothelial dysfunction
1116894|NCT01501929|endothelial cell protein expression
1116895|NCT01501929|microvascular blood flow
1116896|NCT01501929|flow mediated dilation
1116897|NCT01501929|handgrip exercise
1116898|NCT01501929|endothelial cell collection
1116899|NCT01501929|microbubbles
1116900|NCT01501929|Definity
1116901|NCT01501890|Threatened Abortion
1116902|NCT01501890|Progesterone
1116903|NCT01501890|Subchorionic Hematoma
1116904|NCT01501890|Pre-Eclampsia
1116905|NCT01501890|Abruptio Placentae
1116906|NCT01501890|Fetal Growth Retardation
1116907|NCT01501890|Premature Birth
1116908|NCT01501877|Smoking
1116909|NCT01501877|Type 2 Diabetes
1116910|NCT01501877|Smoking cessation
1116911|NCT01501864|HIV prevention
1116912|NCT01501864|HSV-2
1116913|NCT01501864|Schooling
1116914|NCT01501864|Kenya
1116915|NCT01501864|Orphans
1116916|NCT01501864|School support
1116917|NCT01501799|acne
1116918|NCT01501799|adapalene/benzoyl peroxide
1116919|NCT01501799|Epiduo
1116920|NCT01501799|Mild to severe acne vulgaris
1116921|NCT01501786|children
1116922|NCT01501786|sedation
1116923|NCT01501786|propofol
1116924|NCT01501786|ketamine
1116925|NCT01501773|Acute ischemic stroke
1116926|NCT01501747|Placebo effect
1116927|NCT01501747|drug half life
1116928|NCT01501747|pharmacokinetics
1116929|NCT01501734|CHF
1116930|NCT01501734|watch-pat
1116931|NCT01501734|embletta x
1116932|NCT01501734|endothelial function
1116933|NCT01501721|prevention
1116934|NCT01501721|workers
1116935|NCT01501721|clinical trials
1116936|NCT01501721|obesity
1116937|NCT01501708|caspofungin
1116938|NCT01501708|IFI
1116939|NCT01501708|allogeneic hematopoietic stem cell transplantation
1116940|NCT01501695|tic disorder
1116941|NCT01501695|pediatric
1116942|NCT01501682|ventralex
1116943|NCT01501682|ventral hernia
1116944|NCT01501669|irinotecan
1116945|NCT01501669|capecitabine
1116946|NCT01501669|metastatic breast cancer
1116947|NCT01501643|Non invasive positive pressure ventilation
1116948|NCT01501643|Spirometry
1116949|NCT01501643|Acute chest syndrome
1116950|NCT01501643|Sickle cell disease
1116951|NCT01501643|Vaso-occlusive crisis
1116952|NCT01501630|Comparison of imaging modalities
1116953|NCT01501630|Impact on patient management
1116954|NCT01501630|Optimisation of cost of the diagnostic strategy
1116955|NCT01501617|Hair Loss
1116956|NCT01501617|Androgenetic Alopecia
1116957|NCT01501617|Baldness
1116958|NCT01501617|Male pattern baldness
1116959|NCT01501617|Male pattern hair loss
1116960|NCT01501617|Hair Regrowth
1116961|NCT01501617|Alopecia
1116962|NCT01501617|Hair growth
1116963|NCT01501617|Regrow Hair
1116964|NCT01501604|PIK3CA mutation
1116965|NCT01501604|Advanced solid tumors
1116966|NCT01501591|Placebo effect
1116967|NCT01501591|placebo drug interaction
1116968|NCT01501591|placebo -controlled clinical trials
1116969|NCT01501578|Pulmonary fibrosis
1116970|NCT01501578|Telomerase mutation
1116971|NCT01501565|Postoperative pain
1116972|NCT01501565|Transverse abdominal blockade
1116973|NCT01501565|Efficacy
1116974|NCT01501565|Safety
1116975|NCT01501565|Urology
1116976|NCT01501552|Primary health care
1116977|NCT01501552|Identification and Brief Intervention Programmes
1116978|NCT01501552|Hazardous and harmful alcohol consumption
1116979|NCT01501539|Hypergranulation tissue
1116980|NCT01501539|Gastrostomy tube
1116981|NCT01501539|Hydrocolloid dressing
1116982|NCT01501539|Silver hydrocolloid dressing
1116983|NCT01501539|Gastrostomy tube dislodgement
1116984|NCT01501539|Wound infection
1116985|NCT01501539|Peristomal skin breakdown
1116986|NCT01501526|herpes esophagitis
1116987|NCT01501526|dysphagia
1116988|NCT01501526|vocal fold palsy
1116989|NCT01501526|immunocompetent
1116990|NCT01501526|husky voice
1116991|NCT01501513|colonoscopy
1116992|NCT01501513|bowel preparation
1116993|NCT01501513|endoscopy
1116994|NCT01501500|botulinum toxin type A
1116995|NCT01501500|hallux valgus angle
1116996|NCT01501500|foot function index
1116997|NCT01501500|VAS pain scale
1116998|NCT01501487|breast cancer
1116999|NCT01501487|neo adjuvant therapy
1117000|NCT01501474|Confocal
1117001|NCT01501474|malignant biliary stricture
1117002|NCT01501474|Sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
1117003|NCT01501474|sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
1117004|NCT01501435|Safety
1117005|NCT01501435|Pharmacokinetics
1117006|NCT01501422|postmenopause
1117007|NCT01501422|sleep quality
1117008|NCT01501422|estrogen
1117009|NCT01501422|objective sleep quality
1117010|NCT01501422|actigraph
1117011|NCT01501409|Sodium lauryl sulfate (SLS)
1117012|NCT01501409|recurrent aphthous stomatitis (RAS)
1117013|NCT01501409|dentifrice
1117014|NCT01501409|pain
1117015|NCT01501370|Myeloma
1117016|NCT01501370|Biochemical relapse
1117017|NCT01501357|caries
1117018|NCT01501357|primary molars
1117019|NCT01501357|plaque
1117020|NCT01501357|toothbrushing
1117021|NCT01501344|osteoporosis
1117022|NCT01501344|postmenopausal women
1117023|NCT01501344|bone remodelling
1117024|NCT01501344|bone turnover markers
1117025|NCT01501331|Congestive Heart Failure
1117026|NCT01501331|Cardiac Resynchronization Therapy
1117027|NCT01501331|Internal Cardioverter Defibrillators
1117028|NCT01501318|SBIRT
1117029|NCT01501318|brief intervention
1117030|NCT01501318|alcohol
1117031|NCT01501318|drug abuse
1117032|NCT01501305|influence
1117033|NCT01501305|carob powder
1117034|NCT01501305|probiotics
1117035|NCT01501305|duration
1117036|NCT01501279|pudendal nerve block
1117037|NCT01501279|postoperative pain
1117038|NCT01501279|bladder spasm
1117039|NCT01501266|postmenopausal breast cancer
1117040|NCT01501266|Faslodex
1117041|NCT01501266|cohort
1117042|NCT01501253|CKD-828
1117043|NCT01501253|Hypertension
1117044|NCT01501253|Primary Hypertension
1117045|NCT01501253|S-Amlodipine
1117046|NCT01501253|Telmisartan
1117047|NCT01501253|Non-Responder
1117048|NCT01501240|Magnetic resonance image
1117049|NCT01501240|gadoxetic acid
1117050|NCT01501240|hepatocellular carcinoma
1117051|NCT01501240|liver cirrhosis
1117052|NCT01501227|ventilator associated pneumonia
1117053|NCT01501214|atosiban
1117054|NCT01501214|in vitro fertilization
1117055|NCT01501214|subfertility
1117056|NCT01501201|Obesity
1117057|NCT01501201|Diabetes
1117058|NCT01501201|Bariatric Surgery
1117059|NCT01501188|Chronic Venous Insufficiency
1117060|NCT01501188|Kinesio Taping
1117061|NCT01501188|Electromyography
1117062|NCT01501188|Range of ankle motion
1117063|NCT01501175|superficial vein thrombosis
1117064|NCT01501175|Saint Etienne region
1117065|NCT01501162|hepatitis, alcohol
1117066|NCT01501149|NK/T cell lymphoma
1117067|NCT01501149|chemotherapy
1117068|NCT01501149|clinical trial
1117069|NCT01501149|RR
1117070|NCT01501149|PFS
1117071|NCT01501149|OS
1117072|NCT01501136|NK/T cell lymphoma
1117073|NCT01501136|chemotherapy
1117074|NCT01501136|clinical trial
1117075|NCT01501136|RR
1117076|NCT01501136|PFS
1117077|NCT01501136|OS
1117078|NCT01501123|Time to sedation of agitated patients
1117079|NCT01501110|Euthyroid Sick Syndrome
1117080|NCT01501110|low T3 syndrome
1117081|NCT01501110|deiodases
1117082|NCT01501110|oxidative stress
1117083|NCT01501110|ischemic heart disease
1117084|NCT01501084|functional MRI
1117085|NCT01501084|Structural MRI
1117086|NCT01501084|obesity
1117087|NCT01501084|resting state networks
1117088|NCT01501071|Laparoscopic Nissen fundoplication
1117089|NCT01501071|Esophageal calibration
1117090|NCT01501071|Postoperative dysphagia
1117091|NCT01501045|TMS
1117092|NCT01501045|CPM
1117093|NCT01501045|headache
1117094|NCT01501045|migraine
1117095|NCT01501045|EEG
1117096|NCT01501045|psychophysics
1117097|NCT01501032|Diabetes Type 1
1117098|NCT01501032|Artificial Pancreas
1117099|NCT01501006|Physicians
1117100|NCT01500993|Rectal cancer
1117101|NCT01500993|Chemoradiotherapy
1117102|NCT01500993|Capecitabine
1117103|NCT01500993|phase-III trial
1117104|NCT01500980|malaria
1117105|NCT01500980|challenge
1117106|NCT01500980|P. falciparum
1117107|NCT01500980|prevention
1117108|NCT01500928|Insulin Pump
1117109|NCT01500928|Glycemic Control
1117110|NCT01500928|Type 1 Diabetes
1117111|NCT01500915|AMD
1117112|NCT01500915|ranibizumab
1117113|NCT01500915|antiVEGF
1117114|NCT01500915|regimen of injections
1117115|NCT01500915|anti VEGF regimen
1117116|NCT01500915|PRN
1117117|NCT01500915|treat and extend
1117118|NCT01500902|Acute Coronary Syndrome (ACS)
1117119|NCT01500902|Percutaneous Intervention (PCI)
1117120|NCT01500902|Coronary Stent (CStent)
1117121|NCT01500902|Percutaneous Transluminal Coronary Angioplasty (PTCA)
1117122|NCT01500902|stent placement
1117123|NCT01500902|balloon angioplasty
1117124|NCT01500889|Anal fissure
1117125|NCT01500889|Advancement flap
1117126|NCT01500889|Internal sphincterotomy
1117127|NCT01500876|lung cancer
1117128|NCT01500863|endometrial receptivity
1117129|NCT01500863|gene arrays
1117130|NCT01500863|agonist triggering
1117131|NCT01500863|Endometrial gene expression
1117132|NCT01500863|OHSS
1117133|NCT01500850|Type 2 Diabetes mellitus
1117134|NCT01500850|NPH insulin
1117135|NCT01500850|Insulin Glargine
1117136|NCT01500850|cardiovascular biomarkers
1117137|NCT01500850|hsCRP, adiponectin
1117138|NCT01500850|intact proinsulin
1117139|NCT01500850|cardiovascular risk
1117140|NCT01500837|Staphylococcus aureus
1117141|NCT01500837|osteoarticular infection
1117142|NCT01500837|clindamycin
1117143|NCT01500837|serum concentration
1117144|NCT01500837|orthopedic surgery
1117145|NCT01500824|Crizotinib
1117146|NCT01500824|ALK
1117147|NCT01500824|NSCLC
1117148|NCT01500824|Non-Small Cell Lung Cancer
1117149|NCT01500824|Asian
1117150|NCT01500811|chondrocyte hip osteoarthritis intra articular injection
1117151|NCT01500772|Hepatitis C
1117152|NCT01500772|PI treatment failure
1117153|NCT01500759|chronic heart failure
1117154|NCT01500759|heart failure
1117155|NCT01500759|hf
1117156|NCT01500759|sleep-disordered breathing
1117157|NCT01500759|sdb
1117158|NCT01500759|nyha
1117159|NCT01500759|lvef
1117160|NCT01500759|cheyne stokes
1117161|NCT01500759|central sleep apnoea
1117162|NCT01500759|sleep apnoea
1117163|NCT01500746|chronic wound treatment
1117164|NCT01500746|pulse lavage
1117165|NCT01500746|serial pulse lavage
1117166|NCT01500746|wounds
1117167|NCT01500746|bacterial colonization of wounds
1117177|NCT01500668|Botox
1117178|NCT01500668|catocholamine
1117179|NCT01500668|shock
1117180|NCT01500668|vasomotor
1117181|NCT01500668|Vasopressin
1117182|NCT01500668|botulinum toxin
1117183|NCT01500655|burn
1117184|NCT01500655|skin graft donor site
1117185|NCT01500655|analgesia for donor site
1117186|NCT01500629|Allergic Rhinitis
1117187|NCT01500629|Hayfever
1117188|NCT01500629|Pollen Allergy
1117189|NCT01500616|Chronic Hepatitis C Infection
1117190|NCT01500616|Chronic Hepatitis C Co-Infected Patients
1117191|NCT01500616|Hepatitis C
1117192|NCT01500616|Severe Fibrosis
1117193|NCT01500616|Compensated Cirrhosis
1117194|NCT01500616|VX-950HPC3005
1117195|NCT01500603|post-radical prostatectomy
1117196|NCT01500603|stress urinary incontinence
1117197|NCT01500603|periurethral Pro-ACT balloons
1117198|NCT01500603|AdvanceXP retrourethral male sling
1117199|NCT01500590|Diabetes
1117200|NCT01500590|hypertensive
1117201|NCT01500590|without albuminuria
1117202|NCT01500577|Prevention
1117203|NCT01500577|Breast Cancer
1117204|NCT01500577|Proliferation
1117205|NCT01500577|Breast Cancer Prevention
1117206|NCT01500564|Stroke
1117207|NCT01500564|transcranial direct current stimulation (tDCS)
1117208|NCT01500564|motor function
1117209|NCT01500551|Arthritis
1117210|NCT01500551|Pediatric
1117211|NCT01500551|Tofacitinib
1117212|NCT01500551|Long-term
1117213|NCT01500551|JIA
1117214|NCT01500551|CP-690,550
1117215|NCT01500551|Xeljanz
1117216|NCT01500538|Follicular lymphoma
1117217|NCT01500538|Marginal zone lymphoma
1117218|NCT01500538|Mantle cell lymphoma
1117219|NCT01500538|thrombocytopenia
1117220|NCT01500538|eltrombopag
1117221|NCT01500538|vorinostat
1117222|NCT01500538|lymphoma
1117223|NCT01500525|asthma
1117224|NCT01500525|children
1117225|NCT01500525|accuracy of bronchodilator response
1117226|NCT01500499|adult acute myeloid leukemia
1117227|NCT01500499|childhood acute myeloid leukemia/other myeloid malignancies
1117238|NCT01500434|drug-eluting stents
1117239|NCT01500434|DES
1117240|NCT01500434|atherosclerotic
1117241|NCT01500421|Hypothermia, Induced
1117242|NCT01500395|Aortic Diseases
1117243|NCT01500395|Vascular Diseases
1117244|NCT01500395|Cardiovascular Diseases
1117245|NCT01500395|Treatment Outcome
1117246|NCT01500395|Aorta Dissection
1117247|NCT01500395|Aorta Aneurysm
1117248|NCT01500395|Aorta pseudoaneurysm
1117249|NCT01500395|Endovascular aortic repair
1117250|NCT01500395|Hybrid operation
1117251|NCT01500395|Debranching
1117252|NCT01500369|atrial fibrillation
1117253|NCT01500369|remote ischemic conditioning
1117254|NCT01500356|cardiovascular disease
1117255|NCT01500356|obesity
1117256|NCT01500356|exercise
1117257|NCT01500343|heart failure
1117258|NCT01500343|probiotics
1117259|NCT01500343|Saccharomyces boulardii
1117260|NCT01500343|cardio-intestinal syndrome
1117261|NCT01500343|gut
1117262|NCT01500343|inflammation
1117263|NCT01500317|tapentadol
1117264|NCT01500317|oxycodone
1117265|NCT01500317|mu-opiate
1117266|NCT01500317|stomach
1117267|NCT01500317|small intestine
1117268|NCT01500317|colon
1117269|NCT01500317|motility
1117270|NCT01500317|nausea
1117271|NCT01500317|constipation
1117272|NCT01500304|Melanoma
1117273|NCT01500304|Lymph Nodes
1117274|NCT01500304|Lymph Node Dissection
1117275|NCT01500304|Minimally invasive
1117276|NCT01500291|anesthesia stress
1117277|NCT01500278|Certolizumab Pegol
1117278|NCT01500278|Cimzia
1117279|NCT01500278|Adalimumab
1117280|NCT01500278|Humira
1117281|NCT01500278|Rheumatoid Arthritis
1117282|NCT01500265|hepatitis B virus
1117283|NCT01500265|early screening tools
1117284|NCT01500265|renal proximal tubular tolerance
1117285|NCT01500252|Total Knee Replacement
1117286|NCT01500252|Patellar Resurfacing
1117287|NCT01500252|Health Related Quality of Life
1117288|NCT01500226|Rolapitant
1117289|NCT01500226|Nausea
1117290|NCT01500226|Vomiting
1117291|NCT01500226|CINV
1117292|NCT01500226|Chemotherapy
1117293|NCT01500213|Rolapitant
1117294|NCT01500213|Nausea
1117295|NCT01500213|Vomiting
1117296|NCT01500213|CINV
1117297|NCT01500213|Chemotherapy
1117298|NCT01500187|white spot lesions
1117299|NCT01500187|fixed orthodontic brackets
1117300|NCT01500187|fluoride varnish
1117301|NCT01500187|fluoride gel
1117302|NCT01500174|skin
1117303|NCT01500174|decubitus
1117304|NCT01500174|pressure
1117305|NCT01500174|sore
1117306|NCT01500174|spinal cord injury
1117307|NCT01500161|Leukemia
1117308|NCT01500161|Lymphoma
1117309|NCT01500161|Myeloma
1117310|NCT01500161|Aplastic Anemia
1117311|NCT01500161|Myelodysplasia
1117312|NCT01500161|AML
1117313|NCT01500161|ALL
1117314|NCT01500161|CLL
1117315|NCT01500161|CML
1117316|NCT01500148|Mitral Valve Prolapse
1117317|NCT01500148|Mitral Valve Disease
1117318|NCT01500148|Mitral Valve Regurgitation
1117319|NCT01500148|Mitral Valve Insufficiency
1117320|NCT01500148|Mitral Valve Incompetence
1117321|NCT01500148|Percutaneous Mitral Valve Repair
1117322|NCT01500148|Posterior leaflet prolapse
1117323|NCT01500148|Mitral valve degeneration
1117324|NCT01500135|Vascular Surgery
1117325|NCT01500135|Secondary treatment of needle hole bleeding
1117326|NCT01500135|Subjects undergoing vascular surgery and who need supportive treatment in order to control bleeding
1117327|NCT01500109|cleft palate surgery
1117328|NCT01500109|post-operative pain management
1117329|NCT01500109|Acetaminophen
1117330|NCT01500096|Fatigue
1117331|NCT01500096|HIV/AIDS
1117332|NCT01500096|American ginseng
1117333|NCT01500096|Panax quinquefolius
1117334|NCT01500096|Fatigue Severity Scale
1117335|NCT01500096|CD4 count
1117336|NCT01500096|plasma HIV RNA
1117337|NCT01500096|cytokines
1117338|NCT01500096|IL-6
1117339|NCT01500096|sTNFR1
1117340|NCT01500096|sTNFR2
1117341|NCT01500083|iNHL
1117342|NCT01500083|CLL
1117343|NCT01500070|Peripheral Arterial Disease
1117344|NCT01500070|Claudication
1117345|NCT01500070|Drug-Eluting Stent
1117346|NCT01500070|BTK
1117347|NCT01500070|Everolimus
1117348|NCT01500070|CLI
1117349|NCT01500057|enlarged prostate
1117350|NCT01500044|Radiculopathy
1117351|NCT01500044|Rehabilitation
1117352|NCT01500044|Mobilization
1117353|NCT01500044|Exercise
1117354|NCT01500044|Physical Therapy
1117355|NCT01500018|Phase I
1117356|NCT01500018|healthy recreational polydrug users
1117357|NCT01500018|abuse liability
1117358|NCT01500018|TC-5214
1117359|NCT01500018|Single dose crossover study to evaluate the abuse potential of TC-5214
1117360|NCT01499992|Shoulder rehabilitation
1117361|NCT01499992|Rotator cuff tear
1117362|NCT01499992|Physiotherapy
1117363|NCT01499992|aqua therapy
1117364|NCT01499992|Therapy dosage
1117365|NCT01499992|adjunctive aquatic physical therapy
1117366|NCT01499979|Ischemia-reperfusion injury
1117367|NCT01499979|In situ hypothermic perfusion
1117368|NCT01499979|In situ hypothermic preservation
1117369|NCT01499966|Lateral Ankle Sprain
1117370|NCT01499966|Plaster of Paris
1117371|NCT01499966|Tubigrip
1117372|NCT01499953|superficial vein thrombosis
1117373|NCT01499953|thrombosis
1117374|NCT01499953|SVT
1117375|NCT01499940|peripheral neuropathy
1117376|NCT01499940|vitamin D status
1117377|NCT01499940|oxaliplatin
1117378|NCT01499927|Early reassessment of intravenous antiinfective therapy
1117379|NCT01499914|vaccination H1N1
1117380|NCT01499914|cystic fibrosis
1117381|NCT01499901|deafness
1117382|NCT01499901|unilateral implantation
1117383|NCT01499901|bilateral
1117384|NCT01499901|auditory perception
1117385|NCT01499888|Sickle Cell Disease
1117386|NCT01499888|Subtype Hgb SS
1117387|NCT01499888|Subtype Hgb SC
1117388|NCT01499888|Subtype Hgb SB
1117389|NCT01499888|Chronic Transfusion Therapy
1117390|NCT01499888|Prior Stroke
1117391|NCT01499888|Allogeneic
1117392|NCT01499888|Stem Cell Transplantation
1117393|NCT01499888|Alemtuzumab
1117394|NCT01499888|Sirolimus
1117395|NCT01499888|Total Body Irradiation
1117396|NCT01499888|Hydroxyurea Intolerant
1117397|NCT01499875|Pharmacokinetic
1117398|NCT01499875|Pharmacodynamic
1117399|NCT01499875|Phenoxymethylpenicillin
1117400|NCT01499875|Children
1117401|NCT01499862|Stroke
1117402|NCT01499862|Tibion
1117403|NCT01499862|Bionics
1117404|NCT01499862|Rehab
1117405|NCT01499862|Therapy
1117406|NCT01499862|Robotics
1117407|NCT01499862|Intention
1117408|NCT01499849|Rolapitant
1117409|NCT01499849|Nausea
1117410|NCT01499849|Vomiting
1117411|NCT01499849|CINV
1117412|NCT01499849|Chemotherapy
1117413|NCT01499823|Permeability Map
1117414|NCT01499823|High-Grade Glioma
1117415|NCT01499810|Hypertension
1117416|NCT01499810|Radiofrequency Catheter Ablation
1117417|NCT01499810|Renal Artery
1117418|NCT01499810|Sympathetic Nerve Block
1117419|NCT01499797|frailty
1117420|NCT01499797|frail elders
1117421|NCT01499797|multicomponent intervention
1117422|NCT01499797|overall functioning
1117423|NCT01499797|cost-effectiveness
1117424|NCT01499797|integrated care
1117425|NCT01499797|primary care
1117426|NCT01499797|community dwelling
1117427|NCT01499745|Idiopathic pulmonary fibrosis (IPF) patients
1117428|NCT01499732|Premature endothelial dysfunction
1117429|NCT01499732|Early Rheumatoid Arthritis
1117430|NCT01499732|established rheumatoid arthritis
1117431|NCT01499732|Premature endothelial dysfunction in early rheumatoid arthritis
1117432|NCT01499732|Premature endothelial dysfunction in established rheumatoid arthritis
1117433|NCT01499732|Endothelial function in healthy subjects
1117434|NCT01499719|Sinusitis
1117435|NCT01499719|Disease
1117436|NCT01499719|Chronic
1117437|NCT01499719|Sinonasal
1117438|NCT01499706|Motivational Interviewing
1117439|NCT01499706|Telephone
1117440|NCT01499706|HIV
1117441|NCT01499706|AIDS
1117442|NCT01499706|Older Adults
1117443|NCT01499693|Proton Pump Inhibitors
1117444|NCT01499693|gastric pH
1117445|NCT01499680|Degenerative Lumbar Conditions
1117446|NCT01499667|Relapsing remitting multiple sclerosis
1117447|NCT01499667|multiple sclerosis (MS)
1117448|NCT01499667|safety
1117449|NCT01499667|tolerability
1117450|NCT01499667|health outcomes
1117451|NCT01499667|fingolimod
1117452|NCT01499667|disease control
1117453|NCT01499667|MRI
1117454|NCT01499654|SPECT MPI
1117455|NCT01499654|Tomography, Emission-Computed, Single-Photon
1117456|NCT01499654|Wide Beam Reconstruction
1117457|NCT01499641|discectomy
1117458|NCT01499641|methylprednisolone
1117459|NCT01499641|randomized control trial
1117460|NCT01499615|adverse events
1117461|NCT01499615|adverse cardiovascular events
1117462|NCT01499615|early warning
1117463|NCT01499602|Endometrial hyperplasia,
1117464|NCT01499602|LNG-IUS,
1117465|NCT01499602|Progestin
1117466|NCT01499589|anesthesia-controlled time
1117467|NCT01499589|turnover time
1117468|NCT01499576|Mass Screening
1117469|NCT01499576|Endoscopy, Gastrointestinal
1117470|NCT01499576|Stomach Neoplasms
1117471|NCT01499576|Metaplasia
1117472|NCT01499576|Diagnosis
1117473|NCT01499576|Acetic acid
1117474|NCT01499576|Chromoendoscopy
1117475|NCT01499550|transnasal high flow therapy
1117476|NCT01499550|COPD
1117477|NCT01499537|Stenosis of biliary ways
1117478|NCT01499524|ICP, GDM
1117479|NCT01499511|Hypertension
1117480|NCT01499511|Mortality
1117481|NCT01499511|Morbidity
1117482|NCT01499511|Coronary Heart Disease
1117483|NCT01499511|Stroke
1117484|NCT01499511|Diabetes
1117485|NCT01499498|Healthy volunteers
1117486|NCT01499485|Pulmonary Disease, Chronic Obstructive
1117487|NCT01499485|Obesity Hypoventilation Syndrome
1117488|NCT01499485|Alkalosis
1117489|NCT01499485|Respiration, Artificial
1117490|NCT01499485|Acetazolamide
1117491|NCT01499485|Intensive care
1117492|NCT01499485|Adult
1117493|NCT01499459|liver cirrhosis
1117494|NCT01499459|autologous mesenchymal stem cell transplantation
1117495|NCT01499342|Stent
1117496|NCT01499342|Atherosclerotic occlusive disease
1117497|NCT01499342|Peripheral arterial disease
1117498|NCT01499342|Superficial femoral artery
1117499|NCT01499342|SFA
1117500|NCT01499329|Stent therapy
1117501|NCT01499316|Coronary artery disease
1117502|NCT01499316|Fractional flow reserve
1117503|NCT01499303|lymphoma
1117504|NCT01499303|DLBCL
1117505|NCT01499303|fostamatinib
1117506|NCT01499303|Diffuse Large B-Cell Lymphoma (DLBCL)
1117507|NCT01499290|Ceftazidime
1117508|NCT01499290|Meropenem
1117509|NCT01499290|Metronidazole
1117510|NCT01499290|Anti-Bacterial Agents
1117511|NCT01499290|Anti-Infective Agents
1117512|NCT01499290|Antiprotozoal Agents
1117513|NCT01499290|Antiparasitic Agents
1117514|NCT01499290|cIAI, Complicated Intra-Abdominal Infection
1117515|NCT01499277|complicated skin and soft tissue infections (cSSTI)
1117516|NCT01499277|skin infection
1117517|NCT01499277|ceftaroline
1117518|NCT01499277|wound infection
1117519|NCT01499277|cellulitis
1117520|NCT01499277|burn infection
1117521|NCT01499277|bacterial infection
1117522|NCT01499277|vancomycin
1117523|NCT01499264|MySkin patch
1117524|NCT01499251|glioblastoma
1117525|NCT01499238|Efficacy
1117526|NCT01499238|safety
1117527|NCT01499238|nasal SIMV
1117528|NCT01499238|nasal CPAP
1117529|NCT01499238|infants who are >35 gestational week with wet lung
1117530|NCT01499199|cerebrospinal fluid (CSF)
1117531|NCT01499199|ART-naive
1117532|NCT01499199|integrase inhibitor
1117533|NCT01499199|dolutegravir
1117534|NCT01499199|antiretroviral therapy naive
1117535|NCT01499186|Local vibration, elderly, bone, muscle, functionality
1117536|NCT01499160|endocrine resistant
1117537|NCT01499160|everolimus
1117538|NCT01499160|lapatinib
1117539|NCT01499160|letrozole
1117540|NCT01499147|Acute myeloid leukemia
1117541|NCT01499147|First remission
1117542|NCT01499147|Acute lymphocytic leukemia
1117543|NCT01499147|Acute leukemia
1117544|NCT01499147|Second remission
1117545|NCT01499147|Early relapse
1117546|NCT01499147|Partial remission
1117547|NCT01499147|Accelerated phase
1117548|NCT01499147|Blast-crisis
1117549|NCT01499147|Chronic myelogenous leukemia
1117550|NCT01499147|Chronic phase
1117551|NCT01499147|Recurrent malignant lymphoma
1117552|NCT01499147|Refractory malignant lymphoma
1117553|NCT01499147|Hodgkin's disease
1117554|NCT01499147|Multiple myeloma.
1117555|NCT01499147|Chronic lymphocytic leukemia
1117556|NCT01499147|Myeloproliferative disorder
1117557|NCT01499147|Polycythemia vera
1117558|NCT01499147|Myelofibrosis
1117559|NCT01499147|Severe aplastic anemia
1117560|NCT01499108|type 2 diabetes
1117561|NCT01499108|hypertension
1117562|NCT01499108|liraglutide
1117563|NCT01499108|kidney function
1117564|NCT01499056|osteoarthritis
1117565|NCT01499056|hip joint
1117566|NCT01499056|mesenchymal stem cell
1117567|NCT01499043|CRPC
1117568|NCT01499043|Prostate Cancer
1117569|NCT01499043|Bone metastasis
1117570|NCT01499043|Advanced Castration-Resistant Prostate Cancer (CRPC)
1117571|NCT01499017|Single Ascending Dose Study in healthy subjects
1117572|NCT01499004|tofacitinib
1117573|NCT01499004|CP-690
1117574|NCT01499004|550
1117575|NCT01499004|relative bioavailability
1117576|NCT01499004|modified release
1117577|NCT01499004|Phase 1
1117578|NCT01498991|Incomplete Spinal Cord Injury
1117579|NCT01498991|Rehabilitation
1117580|NCT01498991|AMES device
1117581|NCT01498991|Lower Extremity
1117582|NCT01498991|Gait
1117583|NCT01498991|Paraplegia
1117584|NCT01498965|food allergy
1117585|NCT01498965|eczema
1117586|NCT01498965|Vitamin D status
1117587|NCT01498965|body composition
1117588|NCT01498965|obesity
1117589|NCT01498965|neurodevelopmental and behavioural outcome
1117590|NCT01498952|HCC, liver cancer, hepatocellular carcinoma, MEDI-573, anti-IGF
1117591|NCT01498887|Multiple Sclerosis
1117592|NCT01498887|Relapsing Remitting Multiple Sclerosis
1117593|NCT01498887|Fingolimod
1117594|NCT01498887|Early multiple sclerosis
1117595|NCT01498887|Naive patients
1117596|NCT01498874|Acne
1117597|NCT01498874|Acne Vulgaris
1117598|NCT01498835|Soft tissue sarcoma
1117599|NCT01498835|Radiation therapy
1117600|NCT01498835|Sunitinib
1117601|NCT01498822|Levetiracetam
1117602|NCT01498822|Oxcarbazepine
1117603|NCT01498822|treatment failure
1117604|NCT01498822|partial epilepsy
1117605|NCT01498809|Orthostatic intolerance in people with spinal cord injury
1117606|NCT01498744|Skin and Soft Tissue Abscess
1117607|NCT01498744|Methicillin-resistant Staphylococcus aureus (MRSA)
1117608|NCT01498744|Incision and Drainage
1117609|NCT01498744|Clindamycin
1117610|NCT01498744|Trimethoprim-sulfamethoxazole
1117611|NCT01498744|Skin Infection
1117612|NCT01498731|Copeptin
1117613|NCT01498731|Troponin
1117614|NCT01498731|Acute Coronary Syndrome
1117615|NCT01498731|Rule-out of acute myocardial infarction
1117616|NCT01498731|Emergency Medicine
1117617|NCT01498718|Influenza A (H1N1)
1117618|NCT01498718|Influenza A (H3N2)
1117619|NCT01498718|Influenza B
1117620|NCT01498718|Trivalent Inactivated Vaccine (TIV)
1117621|NCT01498718|Healthy Adults
1117622|NCT01498705|Intraventricular Hemorrhage
1117623|NCT01498705|Intracerebral Hemorrhage
1117624|NCT01498705|Cerebrovascular Disorders
1117625|NCT01498705|Brain Diseases
1117626|NCT01498705|Central Nervous System Diseases
1117627|NCT01498705|Nervous System Diseases
1117628|NCT01498705|Vascular Diseases
1117629|NCT01498705|Procalcitonin Level
1117630|NCT01498692|drug-eluting stents
1117631|NCT01498692|DES
1117632|NCT01498692|atherosclerotic
1117633|NCT01498640|XIAFLEX
1117634|NCT01498640|XIAPEX
1117635|NCT01498640|Dupuytren's disease
1117636|NCT01498640|contracture
1117637|NCT01498627|Autoimmune diseases (AIDs)
1117638|NCT01498627|Cervarix
1117639|NCT01498627|PGRx information system
1117640|NCT01498614|Diabetes mellitus
1117641|NCT01498614|depression
1117642|NCT01498614|anxiety
1117643|NCT01498614|negative self image
1117644|NCT01498614|alexithymia
1117645|NCT01498614|metabolic control
1117646|NCT01498614|diabetes complications
1117647|NCT01498601|oral hygiene
1117648|NCT01498601|tracheostomy
1117649|NCT01498601|deglutition disorders
1117650|NCT01498601|enteral nutrition
1117651|NCT01498601|brain injury
1117652|NCT01498601|coma
1117653|NCT01498588|Breast Neoplasms
1117654|NCT01498588|Breast Cancer
1117655|NCT01498588|Breast Tumors
1117656|NCT01498588|Cancer of the Breast
1117657|NCT01498588|Neoplasms, Breast
1117658|NCT01498588|Tumors, Breast
1117659|NCT01498575|Teen driving
1117660|NCT01498575|Behind the wheel practice driving
1117661|NCT01498575|Parent supervision
1117662|NCT01498549|Abstinent cocaine users
1117663|NCT01498549|cognitive testing
1117664|NCT01498523|Camel milk
1117665|NCT01498523|Postprandial glycaemic response
1117666|NCT01498523|postprandial insulinaemic response
1117667|NCT01498523|Glycaemic index
1117668|NCT01498510|chronic pain
1117669|NCT01498510|cognitive behavior therapy
1117670|NCT01498510|web-based intervention
1117671|NCT01498484|EBV-specific T-cell lines
1117672|NCT01498484|11-130
1117673|NCT01498458|German Breast Group
1117674|NCT01498458|GBG Forschungs GmbH
1117675|NCT01498458|GBG
1117676|NCT01498458|GBG 62
1117677|NCT01498458|PazoX
1117678|NCT01498458|Breast Cancer
1117679|NCT01498458|Metastatic Breast Cancer
1117680|NCT01498458|Pazopanib
1117681|NCT01498458|Abraxane
1117682|NCT01498458|Capecitabine
1117683|NCT01498458|Xeloda
1117684|NCT01498445|Leukemia
1117685|NCT01498445|Chronic myelogenous leukemia
1117686|NCT01498445|Chronic myeloid leukemia
1117687|NCT01498445|CML
1117688|NCT01498445|Accelerated phase
1117689|NCT01498445|Blastic phase
1117690|NCT01498445|Dasatinib
1117691|NCT01498445|BMS-354825
1117692|NCT01498445|Sprycel
1117693|NCT01498445|Decitabine
1117694|NCT01498445|Dacogen
1117695|NCT01498419|Tuberculosis
1117696|NCT01498419|Serial Sputum Colony Counts
1117697|NCT01498419|Colony Forming Units
1117698|NCT01498419|Time to Sputum Culture Positivity
1117699|NCT01498419|PA824
1117700|NCT01498419|pretomanid
1117701|NCT01498406|cutaneous lupus erythematosus
1117702|NCT01498406|vitamin D
1117703|NCT01498406|quality of life
1117704|NCT01498393|fungal nail
1117705|NCT01498380|Dexmedetomidine
1117706|NCT01498380|Precedex
1117707|NCT01498380|TIVA
1117708|NCT01498380|Rapid bolus
1117709|NCT01498367|Diabetes Mellitus, Type 2
1117710|NCT01498367|Telemedicine
1117711|NCT01498354|Transanal endoscopic microsurgery
1117712|NCT01498354|Transanal endoscopic operations
1117713|NCT01498354|Rectal adenomas
1117714|NCT01498354|Transanal endoscopic surgery
1117715|NCT01498354|"Rectal adenocarcinomas in situ"
1117716|NCT01498341|Hypoparathyroidism
1117717|NCT01498341|Epidemiology
1117718|NCT01498341|Prognosis
1117719|NCT01498341|Symptoms
1117720|NCT01498328|EGFRvIII
1117721|NCT01498328|Glioblastoma
1117722|NCT01498328|Rindopepimut
1117723|NCT01498328|CDX-110
1117724|NCT01498328|Small cell
1117725|NCT01498328|Giant cell
1117726|NCT01498328|Brain Cancer
1117727|NCT01498328|Brain Tumor
1117728|NCT01498328|Gliosarcoma
1117729|NCT01498328|oligodendroglial
1117730|NCT01498328|radiotherapy
1117731|NCT01498328|chemoradiation
1117732|NCT01498328|Tumor
1117733|NCT01498328|Bevacizumab
1117734|NCT01498328|Relapsed
1117735|NCT01498328|Returned
1117736|NCT01498328|Recurrent
1117737|NCT01498328|EGFR variant III
1117738|NCT01498302|childhood acute myeloid leukemia/other myeloid malignancies
1117739|NCT01498289|recurrent esophageal cancer
1117740|NCT01498289|stage IV esophageal cancer
1117741|NCT01498289|recurrent gastric cancer
1117742|NCT01498289|stage IV gastric cancer
1117743|NCT01498289|adenocarcinoma of the gastroesophageal junction
1117744|NCT01498289|stage IIIB gastric cancer
1117745|NCT01498289|stage IIIC gastric cancer
1117746|NCT01498289|stage IIIB esophageal cancer
1117747|NCT01498289|stage IIIC esophageal cancer
1117748|NCT01498289|adenocarcinoma of the esophagus
1117749|NCT01498289|adenocarcinoma of the stomach
1117750|NCT01498276|Family History
1117751|NCT01498276|Family Health History
1117752|NCT01498276|Disease Risk Assessment
1117759|NCT01498237|Photoacoustic endoscopy
1117760|NCT01498224|Cataract surgery
1117761|NCT01498211|volunteer
1117762|NCT01498198|Rotator Cuff
1117763|NCT01498198|WCB
1117764|NCT01498172|Non muscle invasive bladder cancer
1117765|NCT01498159|Diabetes Mellitus
1117766|NCT01498159|Pharmacists
1117767|NCT01498159|Community Health Aides
1117768|NCT01498146|cryptogenic stroke
1117769|NCT01498146|atrial fibrillation
1117770|NCT01498146|longterm monitoring
1117771|NCT01498146|loop recorder
1117772|NCT01498133|Skin-to-skin contact
1117773|NCT01498133|Decolonization
1117774|NCT01498133|MRSA
1117775|NCT01498120|Rotigotine
1117776|NCT01498120|Restless Legs Syndrome
1117777|NCT01498120|RLS
1117778|NCT01498120|Long-term
1117779|NCT01498120|Adolescents
1117780|NCT01498107|online intervention
1117781|NCT01498107|computerized CBT
1117782|NCT01498107|e-health
1117783|NCT01498094|Bronchiolitis
1117784|NCT01498094|High
1117785|NCT01498094|Flow
1117786|NCT01498094|Oxygen
1117787|NCT01498094|Therapy
1117788|NCT01498094|Nasal
1117789|NCT01498094|Cannulae
1117790|NCT01498094|Prongs
1117791|NCT01498081|COPD, pulmonary disease
1117792|NCT01498068|Genotype 1 chronic Hepatitis C
1117793|NCT01498068|VX-950HPC3007
1117794|NCT01498068|VX-950
1117795|NCT01498068|Hepatitis C
1117796|NCT01498068|Telaprevir
1117797|NCT01498068|HCV
1117798|NCT01498055|lung cancer
1117799|NCT01498055|CIK cells
1117800|NCT01498055|therapy
1117801|NCT01498029|Cartilage, Articular
1117802|NCT01498016|acute leukemia
1117803|NCT01498016|allogeneic stem cell transplantation
1117804|NCT01498016|busulfan
1117805|NCT01498003|coronary disease
1117806|NCT01498003|stents
1117807|NCT01498003|thrombosis
1117808|NCT01498003|myocardial infarction
1117809|NCT01498003|prognosis
1117810|NCT01497990|Burns
1117811|NCT01497990|Ertapenem
1117812|NCT01497990|Pharmacokinetics
1117813|NCT01497977|phytoestrogens
1117814|NCT01497977|postmenopause
1117815|NCT01497977|serum lipids
1117816|NCT01497925|Arginine deiminase
1117817|NCT01497925|Arginine
1117818|NCT01497925|Solid tumors
1117819|NCT01497925|Prostate cancer
1117820|NCT01497925|Phase 1 study
1117821|NCT01497899|HIV-1
1117822|NCT01497899|HIV
1117823|NCT01497899|Treatment-Naive
1117824|NCT01497886|Stroke
1117825|NCT01497886|Children
1117826|NCT01497886|Hip Hop Stroke
1117827|NCT01497886|New York City
1117828|NCT01497873|Small Cell Lung Cancer
1117829|NCT01497873|Belotecan
1117830|NCT01497873|Topotecan
1117831|NCT01497860|pediatric
1117832|NCT01497860|children
1117833|NCT01497860|glioma
1117834|NCT01497860|low-grade
1117835|NCT01497860|vinorelbine
1117836|NCT01497860|recurrent
1117837|NCT01497860|progressive
1117838|NCT01497847|Post-Infectious Irritable Bowel Syndrome
1117839|NCT01497847|PI-IBS
1117840|NCT01497834|Hepatitis C Virus Infection
1117841|NCT01497821|Amgen
1117842|NCT01497821|Phase 1
1117843|NCT01497821|First in Human
1117844|NCT01497821|Relapsed / Refractory Renal Cell Carcinoma (RCC)
1117845|NCT01497821|Kidney Cancer
1117846|NCT01497821|Clinical Trial
1117847|NCT01497821|Antibody drug conjugate (ADC)
1117848|NCT01497821|Open-label
1117849|NCT01497821|Oncology
1117850|NCT01497808|previously untreated
1117851|NCT01497808|previously treated
1117852|NCT01497808|bone, lung, liver or subcutaneous involvement
1117853|NCT01497808|nodal involvement
1117854|NCT01497808|without evidence of brain involvement
1117855|NCT01497782|virtual reality, simulator, feedback, laparoscopy, training
1117856|NCT01497769|vaccine
1117857|NCT01497769|immunogenicity
1117858|NCT01497743|Scleroderma
1117859|NCT01497743|gastrointestinal
1117860|NCT01497743|bloating
1117861|NCT01497743|reflux
1117862|NCT01497730|Arthroplasty, Replacement, Knee,
1117863|NCT01497704|Cancer
1117864|NCT01497704|Tumor
1117865|NCT01497704|Oncology
1117866|NCT01497704|Antiangiogenesis
1117867|NCT01497691|Asthma
1117868|NCT01497691|Pediatrics
1117869|NCT01497691|BiPAP
1117870|NCT01497691|Noninvasive Positive Pressure Ventilation
1117871|NCT01497678|MTURR
1117872|NCT01497678|ECM
1117873|NCT01497678|Muscle Loss
1117874|NCT01497678|Tendon
1117875|NCT01497678|Tendon Repair
1117876|NCT01497678|Muscle Repair
1117877|NCT01497678|Soft Tissue Repair
1117878|NCT01497678|Scaffold
1117879|NCT01497678|Extracellular Matrix
1117880|NCT01497665|GRN1005
1117881|NCT01497665|ANG1005
1117882|NCT01497665|LRP-1
1117883|NCT01497665|Targeted Therapy
1117884|NCT01497665|Brain Tumor
1117885|NCT01497665|Blood Brain Barrier
1117886|NCT01497665|Peptide-Drug Conjugate (PDC)
1117887|NCT01497665|Brain Metastases
1117888|NCT01497665|Paclitaxel
1117889|NCT01497665|Taxol
1117890|NCT01497665|NSCLC
1117891|NCT01497665|Non-Small Cell Lung Cancer
1117892|NCT01497652|Parkinson's Disease
1117893|NCT01497652|Cognition
1117894|NCT01497652|Rasagiline
1117895|NCT01497652|MoCA
1117896|NCT01497652|Mild Cognitive Impairment in Parkinson's Disease
1117897|NCT01497639|dystonia
1117898|NCT01497639|pallidal stimulation
1117899|NCT01497639|deep brain stimulation
1117900|NCT01497639|deep brain stimulation of GPi
1117901|NCT01497639|GPi
1117902|NCT01497639|interleaving stimulation
1117903|NCT01497626|Advanced cancer
1117904|NCT01497626|Solid tumor
1117905|NCT01497613|Socialization
1117906|NCT01497613|Well-being
1117907|NCT01497613|Quality of Life
1117908|NCT01497613|Connectivity
1117909|NCT01497548|Depression
1117910|NCT01497548|cancer
1117911|NCT01497548|methylphenidate
1117912|NCT01497548|pharmacotherapy
1117913|NCT01497522|Vildagliptin
1117914|NCT01497522|Type 2 diabetes
1117915|NCT01497522|HbA1c
1117916|NCT01497522|Fasting plasma glucose
1117917|NCT01497496|leukemia
1117918|NCT01497496|lymphoma
1117919|NCT01497496|consolidative therapy
1117920|NCT01497496|combination regimen
1117921|NCT01497496|Chronic Lymphocytic Leukemia (CLL)
1117922|NCT01497496|Small Lymphocytic Lymphoma (SLL)
1117923|NCT01497470|paclitaxel
1117924|NCT01497470|carboplatin
1117925|NCT01497470|custirsen
1117926|NCT01497470|drug-drug interaction
1117927|NCT01497470|pharmacokinetics
1117928|NCT01497470|cancer
1117934|NCT01497405|Gender-based Violence
1117935|NCT01497405|HIV
1117936|NCT01497405|Randomized Controlled Trial
1117937|NCT01497405|Sexually Transmitted Diseases
1117938|NCT01497405|Substance Abuse Detection
1117939|NCT01497405|Test, Treat and Retain
1117940|NCT01497379|Hereditary retinal
1117941|NCT01497379|degeneration outer
1117942|NCT01497379|retinal layers
1117943|NCT01497379|photoreceptor rods cones
1117944|NCT01497379|Retinitis pigmentosa
1117945|NCT01497379|blindness
1117946|NCT01497379|reading ability
1117947|NCT01497379|retina implant
1117948|NCT01497379|subretinal
1117949|NCT01497366|HCV genotype 2 (GT-2)
1117950|NCT01497366|HCV genotype 3 (GT-3)
1117951|NCT01497353|Cord clamping
1117952|NCT01497353|newborn
1117953|NCT01497353|Skin contact
1117954|NCT01497353|Placental transfusion
1117955|NCT01497353|Delivery room
1117956|NCT01497340|Cord clamping
1117957|NCT01497340|newborn
1117958|NCT01497340|Placental trasfusion
1117959|NCT01497340|Delivery room
1117960|NCT01497327|HEPATITIS C, CHRONIC
1117961|NCT01497327|HCV
1117962|NCT01497327|hepatic impairment
1117963|NCT01497314|healthy term infants
1117964|NCT01497314|growth
1117965|NCT01497314|infant formula
1117966|NCT01497301|Diabetes
1117967|NCT01497301|Group Visit
1117968|NCT01497301|Shared Medical Appointment
1117969|NCT01497288|Intranasal fentanyl spray
1117970|NCT01497288|Population PK
1117971|NCT01497262|Multiple Sclerosis
1117972|NCT01497262|Relapsing-Remitting
1117973|NCT01497249|Dietary Fiber
1117974|NCT01497249|Blood glucose control
1117975|NCT01497249|Fermentability
1117976|NCT01497249|Tolerability
1117977|NCT01497223|Phase II
1117978|NCT01497223|Double-Blind
1117979|NCT01497223|Placebo-Controlled
1117980|NCT01497223|Vulvovaginal Candidiasis
1117981|NCT01497223|Moderate to Severe
1117982|NCT01497223|Acute
1117983|NCT01497223|Treatment of Moderate to Severe Vulvovaginal Candidiasis
1117984|NCT01497197|Reproduction Techniques
1117985|NCT01497197|Reproductive Medicine
1117986|NCT01497197|Assisted Reproductive Technics
1117987|NCT01497197|Pregnancy Rate
1117988|NCT01497197|Ovulation Induction
1117989|NCT01497197|Ovarian Stimulation
1117990|NCT01497197|Oocytes
1117991|NCT01497197|Implantation
1117992|NCT01497184|Leukemia
1117993|NCT01497184|Lymphoma
1117994|NCT01497184|Allogeneic donor lymphocyte infusion
1117995|NCT01497184|DLI
1117996|NCT01497184|Hematopoietic Stem Cell Transplantation
1117997|NCT01497184|HSCT
1117998|NCT01497184|Bone marrow transplant
1117999|NCT01497184|CD19-specific T cells
1118000|NCT01497184|T cell infusion
1118001|NCT01497184|B-Lineage lymphoid malignancies
1118002|NCT01497184|CD19+ lymphoid malignancies
1118003|NCT01497184|Acute lymphoblastic leukemia
1118004|NCT01497184|ALL
1118005|NCT01497184|Biphenotypic leukemia CD19+ in advanced remission
1118006|NCT01497184|Non-Hodgkin's Lymphoma
1118007|NCT01497184|NHL
1118008|NCT01497184|Diffuse large B-cell lymphoma
1118009|NCT01497184|Small lymphocytic lymphoma
1118010|NCT01497184|Follicular lymphoma
1118011|NCT01497184|Mantle cell lymphoma with active disease at time of transplant
1118012|NCT01497171|Cystocele
1118013|NCT01497171|Bladder prolapse
1118014|NCT01497171|Anterior prolapse
1118015|NCT01497171|Vaginal prolapse
1118016|NCT01497171|Uterine prolapse
1118017|NCT01497171|Urinary incontinence
1118018|NCT01497158|tobacco cessation
1118019|NCT01497119|Moderate atopic dermatitis
1118020|NCT01497119|JNJ-39758979
1118021|NCT01497119|Japanese patients
1118022|NCT01497106|Insulin resistance
1118023|NCT01497106|Abdominal obesity
1118024|NCT01497106|Calorie restriction
1118025|NCT01497093|Myeloma
1118026|NCT01497093|Multiple Myeloma
1118027|NCT01497093|Relapsed Multiple Myeloma
1118028|NCT01497093|Relapsed and Refractory Multiple Myeloma
1118029|NCT01497093|Refractory Myeloma
1118030|NCT01497093|Resistant Multiple Myeloma
1118031|NCT01497093|Treatment-resistant Multiple Myeloma
1118032|NCT01497093|Pomalidomide
1118033|NCT01497093|Lenalidomide-resistant
1118034|NCT01497080|distal radius fracture
1118035|NCT01497080|Condition
1118036|NCT01497080|risk factors
1118037|NCT01497080|adverse activity transitions following DRF
1118038|NCT01497080|optimal assessment approach
1118039|NCT01497054|B type natriuretic peptide
1118040|NCT01497054|Patent Ductus Arteriosus
1118041|NCT01497054|Preterm infant
1118042|NCT01497028|Co-morbid disease resolution
1118043|NCT01497002|AML
1118044|NCT01496989|HIV
1118045|NCT01496989|AIDS
1118046|NCT01496989|HIV vaccine
1118047|NCT01496989|HIV prevention
1118048|NCT01496976|leukemia
1118049|NCT01496976|lymphoma
1118050|NCT01496976|consolidative therapy
1118051|NCT01496976|combination regimen
1118052|NCT01496976|CLL
1118053|NCT01496976|SLL
1118054|NCT01496963|Thalassemia
1118055|NCT01496963|Pulmonary Arterial Hypertension
1118056|NCT01496950|migraine
1118057|NCT01496924|Dysphagia
1118058|NCT01496924|Intensive care units
1118059|NCT01496924|Deglutition disorders
1118060|NCT01496924|Rehabilitation
1118061|NCT01496911|Diving
1118062|NCT01496911|Drugs
1118063|NCT01496911|Antihistamines
1118064|NCT01496911|Performance
1118065|NCT01496898|Microflora
1118066|NCT01496898|Vaginal
1118067|NCT01496898|Cervical
1118068|NCT01496898|Uterine
1118069|NCT01496898|Inflammation
1118070|NCT01496898|Cytokine
1118071|NCT01496898|Intrauterine Device
1118072|NCT01496898|Levonorgestrel
1118073|NCT01496885|stroke
1118074|NCT01496872|Newborn cranial somatic dysfunction
1118075|NCT01496872|Newborn observational study
1118076|NCT01496872|Somatic dysfunction
1118077|NCT01496872|Cranial strain pattern
1118078|NCT01496872|Osteopathy
1118079|NCT01496859|Baska mask
1118080|NCT01496859|supraglottic airway
1118081|NCT01496859|airway management
1118082|NCT01496846|Articaine
1118083|NCT01496846|Lidocaine
1118084|NCT01496846|Anesthesia, Local
1118085|NCT01496846|Endodontics
1118086|NCT01496846|Molar
1118087|NCT01496846|Dental Pulp Diseases
1118088|NCT01496833|Aortic Diseases
1118089|NCT01496833|Vascular Diseases
1118090|NCT01496833|Cardiovascular Diseases
1118091|NCT01496833|Treatment Outcome
1118092|NCT01496833|Aorta Dissection
1118093|NCT01496833|Aorta Aneurysm
1118094|NCT01496833|Aorta pseudoaneurysm
1118095|NCT01496833|Endovascular aortic repair
1118096|NCT01496807|unresectable
1118097|NCT01496807|stage 3
1118098|NCT01496807|stage 4
1118099|NCT01496807|autoimmune
1118100|NCT01496807|antibodies
1118101|NCT01496781|Endoscopic Hemostasis
1118102|NCT01496781|metallic hemoclip
1118103|NCT01496781|EndoClot Absorbable Polysaccharide Hemostat
1118104|NCT01496781|Colonic Polyps
1118105|NCT01496729|Kidney transplantation
1118106|NCT01496729|Transversus abdominis plane (TAP) block
1118107|NCT01496716|Osteoarthritis
1118108|NCT01496716|obesity
1118109|NCT01496716|quality of life
1118110|NCT01496703|reasons for MMF dose reduction
1118111|NCT01496690|Anxiety-comorbidity to schizophrenia
1118112|NCT01496690|Double-blinded randomized placebo controlled trial
1118113|NCT01496690|Pregabalin
1118114|NCT01496677|volunteer
1118115|NCT01496651|Percutaneous coronary intervention
1118116|NCT01496651|Coronary artery bypass graft operation
1118117|NCT01496651|Left Main
1118118|NCT01496638|PCI
1118119|NCT01496638|Bifurcation lesion
1118120|NCT01496625|Biological Specimens
1118121|NCT01496625|Retinal Disease
1118122|NCT01496625|Phenotype
1118123|NCT01496625|Phenotype-Genotype correlation
1118124|NCT01496625|Age-Related Macular Degeneration (AMD)
1118125|NCT01496625|AMD
1118126|NCT01496625|Diabetic Retinopathy
1118127|NCT01496625|Healthy Volunteer
1118128|NCT01496625|HV
1118129|NCT01496612|Epilepsy
1118130|NCT01496612|Temporal Lobe Epilepsy
1118131|NCT01496612|Serotonin 1A Receptor
1118132|NCT01496612|Seizures
1118140|NCT01496586|Fatigue
1118141|NCT01496586|Traumatic Brain Injury
1118142|NCT01496586|Motivational Incentive
1118143|NCT01496586|TBI
1118144|NCT01496560|colonoscopy
1118145|NCT01496560|pain
1118146|NCT01496560|rectal balloon
1118147|NCT01496547|feasibility, effective and safety
1118148|NCT01496547|intensive chemotherapy
1118149|NCT01496547|RIC regimen
1118150|NCT01496547|refractory or relapse leukemia
1118151|NCT01496547|allogeneic stem cell transplantation
1118152|NCT01496534|advanced solid tumors
1118153|NCT01496534|bladder cancer
1118154|NCT01496534|gemcitabine
1118155|NCT01496534|cisplatin
1118156|NCT01496534|carboplatin
1118157|NCT01496534|solid tumors
1118158|NCT01496521|Aspirin
1118159|NCT01496521|polyphenols
1118160|NCT01496521|Chemoprevention
1118283|NCT01495923|radiculopathy
1118161|NCT01496508|high-frequency oscillatory ventilation
1118162|NCT01496508|respiratory distress syndrome
1118163|NCT01496508|preterm infants
1118164|NCT01496508|neurodevelopment
1118165|NCT01496508|preterm infants with severe respiratory distress syndrome
1118166|NCT01496482|Dry eye Syndromes
1118167|NCT01496469|Drug Therapy
1118168|NCT01496456|Dental caries
1118169|NCT01496456|Proximal surfaces
1118170|NCT01496456|Posterior teeth
1118171|NCT01496456|Carious lesions
1118172|NCT01496456|Tooth diseases
1118173|NCT01496456|Preventive therapy
1118174|NCT01496443|Drug Therapy
1118175|NCT01496430|Drug Therapy
1118176|NCT01496430|Hypertension and Diabetes
1118177|NCT01496417|Kidney Transplantation
1118178|NCT01496417|Biopsy
1118179|NCT01496417|Belatacept
1118180|NCT01496404|Electrocautery
1118181|NCT01496391|imaging
1118182|NCT01496391|renal function
1118183|NCT01496391|I-123 OIH
1118184|NCT01496391|Tc-99m MAG 3
1118185|NCT01496378|Chronic Pain
1118186|NCT01496378|Abdominal Pain
1118187|NCT01496378|Headache
1118188|NCT01496378|Adolescents
1118189|NCT01496378|Children
1118190|NCT01496378|Parents
1118191|NCT01496378|Problem-Solving Skills Training
1118192|NCT01496365|Keywords: pain, diabetes, neuropathy
1118193|NCT01496352|Surgical site infection
1118194|NCT01496352|Colorectal surgery
1118195|NCT01496326|Osteoarthritis
1118196|NCT01496326|knee pain
1118197|NCT01496313|medullary thyroid cancer
1118198|NCT01496313|metastatic
1118199|NCT01496313|thyroid cancer
1118200|NCT01496313|carcinoma of the thyroid
1118201|NCT01496313|receptor tyrosine kinase inhibitor
1118202|NCT01496313|VEGFR
1118203|NCT01496313|Unresectable locally advanced thyroid cancer
1118204|NCT01496300|Navigation OrthoPilot Hip TEP THA
1118205|NCT01496261|Clopidogrel
1118206|NCT01496261|Aspirin
1118207|NCT01496261|Combination
1118208|NCT01496261|Pharmacokinetics
1118209|NCT01496261|Phase 1
1118210|NCT01496248|Major depressive disorder
1118211|NCT01496248|Residual symptoms
1118212|NCT01496248|Korean red ginseng
1118213|NCT01496222|mild cognitive impairment
1118214|NCT01496222|Montreal Cognitive Assessment test
1118215|NCT01496209|Infarction
1118216|NCT01496209|Myocardial Infarction
1118217|NCT01496209|Ventricular Dysfunction, Left
1118218|NCT01496209|Heart Disease
1118219|NCT01496209|Cardiovascular Disease
1118220|NCT01496209|Chronic Ischemia
1118221|NCT01496196|hemoptisis
1118222|NCT01496196|bleeding
1118223|NCT01496196|tranexamic acid
1118224|NCT01496157|Primary Prostate Cancer
1118225|NCT01496144|Chronic non specific low back pain
1118226|NCT01496144|Manual therapy
1118227|NCT01496144|Active exercises
1118228|NCT01496144|Pain
1118229|NCT01496144|Disability
1118230|NCT01496131|Tecemotide
1118231|NCT01496131|Prostate Cancer
1118232|NCT01496131|Goserelin
1118233|NCT01496131|Cyclophosphamide
1118234|NCT01496131|Radiotherapy
1118235|NCT01496118|Relapsed/Refractory Multiple Myeloma
1118236|NCT01496118|carfilzomib
1118237|NCT01496118|panobinostat
1118238|NCT01496092|Keto Acid
1118239|NCT01496092|Peritoneal dialysis
1118240|NCT01496092|Insulin resistance
1118241|NCT01496079|Maternal immunization
1118242|NCT01496079|Infant immunization
1118243|NCT01496079|Influenza vaccine
1118244|NCT01496079|Passive transfer of immunity
1118245|NCT01496053|Cytokine levels in blood
1118246|NCT01496053|Calprotectin in feces
1118247|NCT01496053|Clinical symptom score.
1118248|NCT01496027|cerebral oxygenation
1118249|NCT01496027|NIRS
1118250|NCT01496027|tissue oximeters
1118251|NCT01496027|near infrared spectroscopy
1118252|NCT01496027|newborn
1118253|NCT01496014|open fracture wounds
1118254|NCT01496014|infections
1118255|NCT01496014|tibia fractures
1118256|NCT01496014|antibiotic therapies in severe fractures
1118257|NCT01496014|All severe open fracture of the tibia bone
1118258|NCT01496001|Early unilateral breast cancer
1118259|NCT01495988|Metastatic melanoma
1118260|NCT01495988|BRAF-mutant
1118261|NCT01495988|Stage IV melanoma
1118262|NCT01495988|Vemurafenib
1118263|NCT01495988|Bevacizumab
1118264|NCT01495988|Cobimetinib
1118265|NCT01495975|Diabetes Mellitus
1118266|NCT01495975|Diabetes Mellitus, Type 2
1118267|NCT01495975|Hospitalization
1118268|NCT01495975|Patient Discharge
1118269|NCT01495962|Damage Control Laparotomy
1118270|NCT01495962|Open Abdomen
1118271|NCT01495962|Botulinum Toxin A
1118272|NCT01495962|Primary Fascial Closure
1118273|NCT01495949|etomidate
1118274|NCT01495949|cortisol level
1118275|NCT01495949|inotrope
1118276|NCT01495949|cardiac patients
1118277|NCT01495936|One Lung Ventilation (OLV)
1118278|NCT01495936|Continuous Positive Airway Pressure (CPAP)
1118279|NCT01495936|Positive End Expiratory Pressure (PEEP)
1118280|NCT01495936|Lung recruitment maneuver
1118281|NCT01495936|Hypoxia
1118282|NCT01495923|low back pain
1118284|NCT01495923|injection
1118285|NCT01495910|21-hydroxylase deficiency
1118286|NCT01495910|Androstenedione
1118287|NCT01495910|Abiraterone acetate
1118288|NCT01495910|Pharmacokinetics
1118289|NCT01495910|Pharmacodynamics
1118290|NCT01495910|Dose-finding
1118291|NCT01495897|Dystonia
1118292|NCT01495897|Cerebellar
1118293|NCT01495897|ocular movements
1118294|NCT01495897|DYT 11
1118295|NCT01495897|sensorimotor integration
1118296|NCT01495858|Naproxen sodium
1118297|NCT01495858|Diphenhydramine
1118298|NCT01495845|pharmacogenomics
1118299|NCT01495845|feasibility
1118300|NCT01495845|community pharmacy
1118301|NCT01495845|personalized medicine
1118302|NCT01495845|clopidogrel
1118303|NCT01495845|Plavix
1118304|NCT01495832|Adult Obesity
1118305|NCT01495832|Cardiometabolic health
1118306|NCT01495832|Pulse Foods
1118307|NCT01495832|Beans, Peas, Lentils
1118308|NCT01495832|Cognitive Function
1118309|NCT01495819|Nicotine
1118310|NCT01495819|smokers
1118311|NCT01495819|vitals associated with smoking
1118312|NCT01495806|functional dyspepsia
1118313|NCT01495806|irritable bowel syndrome
1118314|NCT01495806|functional abdominal pain
1118315|NCT01495793|Rotigotine
1118316|NCT01495793|Restless Legs Syndrome
1118317|NCT01495793|RLS
1118318|NCT01495793|Children
1118319|NCT01495793|Adolescents
1118320|NCT01495780|Behavioral
1118321|NCT01495780|Remote monitoring
1118322|NCT01495767|childhood uveitis
1118323|NCT01495767|health-related quality of life
1118324|NCT01495767|gender
1118325|NCT01495754|coffee
1118326|NCT01495754|overweight/obese
1118327|NCT01495754|appetite
1118328|NCT01495754|energy intake
1118329|NCT01495754|inflammation
1118330|NCT01495754|glucose metabolism
1118331|NCT01495754|randomized controlled trial
1118332|NCT01495741|Mania
1118333|NCT01495741|Manic
1118334|NCT01495741|Depressive
1118335|NCT01495741|Manic Depressive
1118336|NCT01495728|Cervical Radiculopathy
1118337|NCT01495728|Neck Pain
1118338|NCT01495728|Manipulation
1118339|NCT01495702|HIV-1
1118340|NCT01495702|HIV
1118341|NCT01495702|Treatment Experienced
1118342|NCT01495689|Smoking Cessation
1118343|NCT01495689|respirology Out-patient setting
1118344|NCT01495689|SmartCard
1118345|NCT01495676|Bladder cancer
1118346|NCT01495676|Organ-conserving strategy
1118347|NCT01495676|Radiochemotherapy
1118348|NCT01495676|non metastatic
1118349|NCT01495663|refractory
1118350|NCT01495663|relapsed
1118351|NCT01495663|non-small cell lung cancer
1118352|NCT01495663|triple-negative breast cancer
1118353|NCT01495663|soft tissue sarcoma
1118354|NCT01495663|colorectal cancer
1118355|NCT01495663|esophageal cancer
1118356|NCT01495663|prostate cancer
1118357|NCT01495663|ovarian cancer
1118358|NCT01495650|Comprehensive Adjuvant Care
1118359|NCT01495650|Cancer-related fatigue
1118360|NCT01495650|Therapeutic patient education
1118361|NCT01495650|Physical Activity
1118362|NCT01495650|Nutritional counselling
1118363|NCT01495650|Rehabilitation
1118364|NCT01495637|pediatric
1118365|NCT01495637|trauma
1118366|NCT01495637|critical
1118367|NCT01495637|GM-CSF
1118368|NCT01495637|immune
1118369|NCT01495624|rotator cuff repair
1118370|NCT01495624|capsular shift
1118371|NCT01495624|shoulder arthroplasty
1118372|NCT01495624|subacromial decompression
1118373|NCT01495624|18 and 75 years
1118374|NCT01495611|postoperative,
1118375|NCT01495611|pediatric
1118376|NCT01495611|pharmacogenetic
1118377|NCT01495611|opioid
1118378|NCT01495611|morphine
1118379|NCT01495611|perioperative
1118380|NCT01495611|respiratory depression
1118381|NCT01495598|Human Herpesvirus-8/HHV8
1118382|NCT01495598|Immune Modulation
1118383|NCT01495598|CC-4047
1118384|NCT01495598|IMiD
1118385|NCT01495598|Kaposi Sarcoma
1118386|NCT01495585|Hepatitis
1118387|NCT01495585|Delta
1118388|NCT01495585|Treatment
1118389|NCT01495585|Lonafarnib
1118390|NCT01495585|Hepatitis D
1118391|NCT01495572|Malignant Melanoma
1118392|NCT01495572|Immunotherapy
1118393|NCT01495572|Cell Therapy
1118394|NCT01495572|HLA-A2 Positive
1118395|NCT01495572|Skin Cancer
1118396|NCT01495546|total hip arthroplasty
1118397|NCT01495546|THA
1118398|NCT01495546|prosthesis type Lepine
1118399|NCT01495520|Arrhythmias
1118400|NCT01495520|palpitations
1118401|NCT01495494|Nasal Strip
1118402|NCT01495481|Supraventricular Tachycardia
1118403|NCT01495481|SVT
1118404|NCT01495481|Reentrant Tachycardia
1118405|NCT01495481|Dexmedetomidine
1118406|NCT01495481|Adenosine
1118407|NCT01495468|pegylated somatropin
1118408|NCT01495468|PEG-rhGH
1118409|NCT01495468|growth hormone
1118410|NCT01495468|Growth Hormone Deficiency
1118411|NCT01495468|phase III study
1118786|NCT01493908|Placebo effect;
1118412|NCT01495429|catheter related large vein thrombosis
1118413|NCT01495429|upper extremity deep venous thrombosis
1118414|NCT01495429|central venous catheters
1118415|NCT01495429|upper extremity catheter related large vein thrombosis
1118416|NCT01495403|liver cirrhosis
1118417|NCT01495403|muscle cramps
1118418|NCT01495390|Biomarkers
1118419|NCT01495390|Biological Markers
1118420|NCT01495390|Surrogate Markers
1118421|NCT01495390|Clinical Markers
1118422|NCT01495390|Plasma
1118423|NCT01495390|Cerebrospinal Fluid
1118424|NCT01495390|DNA
1118425|NCT01495390|Serum
1118426|NCT01495390|RNA
1118427|NCT01495377|swallowing difficulties
1118428|NCT01495377|remifentanil
1118429|NCT01495377|pulmonary aspiration
1118430|NCT01495377|scintigraphy
1118431|NCT01495364|STEMI
1118432|NCT01495325|Firefighter
1118433|NCT01495325|Woodsmoke
1118434|NCT01495325|Vascular function
1118435|NCT01495325|Air Pollution
1118436|NCT01495325|Endothelial function
1118437|NCT01495325|Thrombosis
1118438|NCT01495312|IOP fluctuations
1118439|NCT01495312|during two 24-hour periods
1118440|NCT01495299|relationship
1118441|NCT01495299|IOP fluctuations
1118442|NCT01495299|glaucoma
1118443|NCT01495299|cataract surgery
1118444|NCT01495299|SENSIMED Triggerfish
1118445|NCT01495286|newborn infant
1118446|NCT01495286|acupuncture
1118447|NCT01495286|safety
1118448|NCT01495286|pain
1118449|NCT01495260|XALD
1118450|NCT01495260|AMN
1118451|NCT01495247|Locally advanced
1118452|NCT01495247|metastatic
1118453|NCT01495247|breast cancer
1118454|NCT01495247|HER2 negative
1118455|NCT01495247|PI3K pathway
1118456|NCT01495247|paclitaxel
1118457|NCT01495247|mTOR inhibitor
1118458|NCT01495234|Spinal degeneration
1118459|NCT01495195|Acetylcholine
1118460|NCT01495195|Cholinesterases
1118461|NCT01495195|Cocaine
1118462|NCT01495195|Self-Administration
1118463|NCT01495182|Dietary fiber
1118464|NCT01495182|Gastrointestinal toleration
1118465|NCT01495182|Fecal weight
1118466|NCT01495169|Antipsychotic
1118467|NCT01495169|Schizophrenia
1118468|NCT01495169|Bipolar disorder
1118469|NCT01495169|Iloperidone
1118470|NCT01495143|Glucose
1118471|NCT01495143|Lactate pyruvate ratio
1118472|NCT01495143|Glycerol
1118473|NCT01495143|Paraspinal muscle
1118474|NCT01495143|Microdialysis
1118475|NCT01495117|surgical site infection
1118476|NCT01495117|chlorhexidine gluconate
1118477|NCT01495117|povidone iodine
1118478|NCT01495091|coronary artery disease
1118479|NCT01495091|cardiovascular disease
1118480|NCT01495091|exercise stress testing
1118481|NCT01495091|biomarkers
1118482|NCT01495091|NT-pro-BNP
1118483|NCT01495078|telemonitoring
1118484|NCT01495078|heart failure
1118485|NCT01495065|GSK2251052, healthy volunteer, safety, tolerability, pharmacokinetics, single
1118486|NCT01495052|naked oat (Avena nuda L.)
1118487|NCT01495052|diabetes mellitus
1118488|NCT01495052|RCT
1118489|NCT01495026|Healthy male subjects
1118490|NCT01495026|North-East Asian ancestry
1118491|NCT01495026|Bioequivalence
1118492|NCT01495026|Food effect
1118493|NCT01495026|Tamsulosin hydrochloride
1118494|NCT01495026|Cross-over design
1118495|NCT01495026|Pilot bioequivalence
1118496|NCT01495026|Dutasteride (GI198745)
1118497|NCT01495013|non-inferiority
1118498|NCT01495013|glimepiride
1118499|NCT01495013|LDL cholesterol
1118500|NCT01495013|fixed dose combination
1118501|NCT01495013|atorvastatin
1118502|NCT01495013|Diabetes Mellitus
1118503|NCT01495000|India
1118504|NCT01495000|dual energy x-ray absorptiometry
1118505|NCT01495000|bone mineral density
1118506|NCT01495000|denosumab
1118507|NCT01494987|Type 2 Diabetes Mellitus
1118508|NCT01494974|Glaucoma
1118509|NCT01494974|Pediatric
1118510|NCT01494974|Ahmed
1118511|NCT01494974|Congenital
1118512|NCT01494974|FP7
1118513|NCT01494974|FP8
1118514|NCT01494961|Partner HIV testing
1118515|NCT01494961|Couple HIV counseling
1118516|NCT01494961|Couple communication on sexual and reproductive health
1118517|NCT01494961|HIV incidence
1118518|NCT01494961|Incidence of pregnancies
1118519|NCT01494961|Disclosure
1118520|NCT01494961|Condom use
1118521|NCT01494922|Skin scarring
1118522|NCT01494922|cicatrix
1118523|NCT01494922|hypertrophic scar
1118524|NCT01494922|hypertrophic scar prevention
1118525|NCT01494909|protein digestion
1118526|NCT01494909|fat absorption
1118527|NCT01494909|gut function
1118528|NCT01494909|glucose absorption
1118529|NCT01494909|CF
1118530|NCT01494909|pancreatic intake
1118531|NCT01494909|feeding
1118532|NCT01494896|Pulmonary Hypertension
1118533|NCT01494896|Pulmonary Arterial Hypertension
1118534|NCT01494896|COPD
1118535|NCT01494896|Chronic Obstructive Pulmonary Disease
1118536|NCT01494896|Tyvaso
1118537|NCT01494896|Inhaled Treprostinil Sodium
1118538|NCT01494896|Ventilation Perfusion Matching
1118539|NCT01494896|HO Group 1 Pulmonary Arterial Hypertension
1118540|NCT01494896|Concomitant Chronic Obstructive Pulmonary Disease
1118541|NCT01494883|Mindfulness Based Stress Reduction
1118542|NCT01494883|lung cancer
1118543|NCT01494883|psychological distress
1118544|NCT01494883|caretakers
1118545|NCT01494870|acute coronary syndrome
1118546|NCT01494870|percutaneous coronary intervention
1118547|NCT01494870|left bundle branch block
1118548|NCT01494857|Ulcerative colitis
1118549|NCT01494857|biological treatment
1118550|NCT01494857|anti-TNF
1118551|NCT01494844|Patient Monitoring
1118552|NCT01494844|Capnography
1118553|NCT01494844|Human Engineering
1118554|NCT01494818|Contact lenses
1118555|NCT01494818|Contact lens solutions
1118556|NCT01494805|Age-related Macular Degeneration
1118557|NCT01494805|AAV
1118558|NCT01494805|AMD
1118559|NCT01494805|Wet AMD
1118560|NCT01494805|Neovascular AMD
1118561|NCT01494805|Gene Therapy
1118562|NCT01494805|Ocular
1118563|NCT01494805|Ocular Gene Therapy
1118564|NCT01494805|Eye diseases
1118565|NCT01494805|Macular Degeneration
1118566|NCT01494805|Retinal Degeneration
1118567|NCT01494805|Retinal Neovascularization
1118568|NCT01494805|Wet Macular Degeneration
1118569|NCT01494805|Retinal Diseases
1118570|NCT01494779|children
1118571|NCT01494766|RLS
1118572|NCT01494740|H1N1
1118573|NCT01494740|Vaccine
1118574|NCT01494740|Immunogenicity
1118575|NCT01494740|Safety
1118576|NCT01494740|infants
1118577|NCT01494727|Safety
1118578|NCT01494727|Pharmacokinetics
1118579|NCT01494714|Healthy volunteers
1118580|NCT01494714|JNJ 10229570-AAA
1118581|NCT01494714|Skin irritation
1118582|NCT01494714|Skin photo irritation
1118583|NCT01494701|Spinal Muscular Atrophy
1118584|NCT01494701|SMA
1118585|NCT01494701|SMN
1118586|NCT01494701|SMNRx
1118587|NCT01494701|ISIS-SMNRx
1118588|NCT01494701|ISIS-SMN Rx
1118589|NCT01494701|ISIS 396443
1118590|NCT01494701|IONIS-SMNRx
1118591|NCT01494701|IONIS-SMN Rx
1118592|NCT01494701|Spinraza
1118593|NCT01494675|procalcitonin
1118594|NCT01494675|duration of the antibiotic therapy
1118595|NCT01494675|sepsis
1118596|NCT01494662|HER2 Positive
1118597|NCT01494662|BrCa
1118598|NCT01494649|dentinal
1118599|NCT01494649|hypersensitivity
1118608|NCT01494623|working memory
1118609|NCT01494623|schizophrenia
1118610|NCT01494623|cognition
1118611|NCT01494623|rTMS
1118612|NCT01494610|safety
1118613|NCT01494610|replicated cross-over design
1118614|NCT01494610|pharmacodynamics
1118615|NCT01494610|Fluticasone propionate/Salmeterol
1118616|NCT01494610|capsule-based inhaler
1118617|NCT01494610|COPD
1118618|NCT01494610|asthma
1118619|NCT01494610|multi dose dry powder inhaler
1118620|NCT01494610|bioavailability
1118621|NCT01494610|pharmacokinetics
1118622|NCT01494597|Isavuconazole
1118623|NCT01494597|Cyclosporine
1118624|NCT01494597|Healthy Volunteers
1118625|NCT01494597|BAL8557
1118626|NCT01494597|Pharmacokinetics of isavuconazole
1118627|NCT01494597|Pharmacokinetics of cyclosporine
1118628|NCT01494558|Overall survival
1118629|NCT01494545|DAILIES TOTAL1
1118630|NCT01494545|Alcon
1118631|NCT01494545|contact lens
1118632|NCT01494519|External ring fixation
1118633|NCT01494519|internal fixation
1118634|NCT01494519|traumatic tibia fracture
1118635|NCT01494506|Pancreatic cancer
1118636|NCT01494506|MM-398
1118637|NCT01494506|PEP02
1118638|NCT01494506|Metastatic pancreatic cancer
1118639|NCT01494506|Gemcitabine refractory pancreatic cancer
1118640|NCT01494506|Second line pancreatic cancer treatment
1118641|NCT01494506|Pancreatic cancer post gemcitabine therapy
1118642|NCT01494493|symptomatic degenerative disc disease
1118643|NCT01494480|ALS
1118644|NCT01494480|stem cell
1118645|NCT01494467|PPR
1118646|NCT01494454|Lumbar degenerative disc disease
1118647|NCT01494441|lumbar degenerative disc disease
1118648|NCT01494428|symptomatic degenerative disc disease
1118649|NCT01494415|Squamous Cell Lung Cancer
1118650|NCT01494415|radiation therapy
1118651|NCT01494415|chemotherapy
1118652|NCT01494402|Healthy volunteer, Japanese males, homo-EM
1118653|NCT01494389|CD4+T lymphocyte subsets
1118654|NCT01494389|sepsis
1118655|NCT01494389|immunoparalysis
1118656|NCT01493323|Psychic pain
1118657|NCT01493323|Social exclusion
1118658|NCT01493323|Mood disorders
1118659|NCT01493323|Suicide, attempted
1118660|NCT01493323|Magnetic Resonance Imaging, Functional
1118661|NCT01493323|Genetic
1118662|NCT01493323|Physic pain
1118663|NCT01493297|Retinyl palmitate, beta-carotene, stable isotopes, radio isotopes
1118664|NCT01494350|cutaneous leishmaniasis
1118665|NCT01494350|topical treatment
1118666|NCT01494350|Tunisia
1118667|NCT01494337|LASER
1118668|NCT01494337|BPH
1118669|NCT01494337|Prostate surgery
1118670|NCT01494337|HOLEP
1118671|NCT01494337|Green light PVP
1118672|NCT01494324|Liver
1118673|NCT01494324|Thermal Ablation
1118674|NCT01494324|Dynamic CT
1118675|NCT01494324|09-122
1118676|NCT01494311|Arterial catheter
1118677|NCT01494311|arterial cannula
1118678|NCT01494311|Rapydan
1118679|NCT01494311|lidocaine/tetracaine patch
1118680|NCT01494311|topical anaesthesia
1118681|NCT01494298|Type 2 diabetes
1118682|NCT01494298|African American
1118683|NCT01494298|cholesterol
1118684|NCT01494298|lipoprotein
1118685|NCT01494298|apolipoprotein
1118686|NCT01494285|Acne Vulgaris
1118687|NCT01494285|Topical
1118688|NCT01494285|Foam
1118689|NCT01494272|caudal epidural analgesia
1118690|NCT01494272|elective circumcision
1118691|NCT01494272|elective inguinal herniorrhaphy
1118692|NCT01494259|immediate breast reconstruction
1118693|NCT01494259|pain control
1118694|NCT01494259|post mastectomy pain control
1118695|NCT01494246|Adult
1118696|NCT01494246|computer-assisted instruction
1118697|NCT01494246|electronic mail
1118698|NCT01494246|program evaluation
1118699|NCT01494246|smoking cessation/methods
1118700|NCT01494246|continued abstinence
1118701|NCT01494220|Bispectral index; anesthesia
1118702|NCT01494220|liver transplantation
1118703|NCT01494220|independent factors
1118704|NCT01494220|outcome
1118705|NCT01494220|Living donor liver transplantation
1118706|NCT01494207|worksite
1118707|NCT01494207|interventions
1118708|NCT01494207|motivational interviewing
1118709|NCT01494207|physical activity
1118710|NCT01494194|Mold sensitized
1118711|NCT01494181|obstructive sleep apnea
1118712|NCT01494181|vascular events
1118713|NCT01494168|Hypertension
1118714|NCT01494168|Arterial stiffness
1118715|NCT01494168|Obesity
1118716|NCT01494168|Bariatric surgery
1118717|NCT01494155|resectable pancreatic cancer
1118718|NCT01494155|pancreaticoduodenectomy
1118719|NCT01494142|Registry
1118720|NCT01494142|Atopic Dermatitis
1118721|NCT01494142|Eczema Herpeticum
1118722|NCT01494142|GWAS
1118723|NCT01494142|Staphylococcus aureus
1118724|NCT01494116|Pediatrics
1118725|NCT01494116|Fluid
1118726|NCT01494116|Bolus
1118727|NCT01494116|Resuscitation
1118728|NCT01494116|Shock
1118729|NCT01494103|Acute lymphoblastic leukemia
1118730|NCT01494103|Myelodysplastic syndrome
1118731|NCT01494103|Acute myeloid leukemia
1118732|NCT01494103|Chronic myelogenous leukemia
1118733|NCT01494103|Non Hodgkin lymphoma
1118734|NCT01494103|Hemophagocytic lymphohistiocytosis
1118735|NCT01494103|Familial hemophagocytic lymphohistiocytosis
1118736|NCT01494103|Hemophagocytic syndrome
1118737|NCT01494103|Epstein Barr virus infection
1118738|NCT01494103|X-linked lymphoproliferative disease
1118739|NCT01494090|Venous thromboembolism
1118740|NCT01494090|Hip fracture
1118741|NCT01494090|Cardiovascular events
1118742|NCT01494090|Statin
1118743|NCT01494077|Pancreatic Cyst Fluid
1118744|NCT01494077|Dilution
1118745|NCT01494077|Carcinoembryonic Antigen (CEA)
1118746|NCT01494051|fatty acid oxidation disorders
1118747|NCT01494025|Diabetes
1118748|NCT01494025|Pre-diabetes
1118749|NCT01494025|Obese
1118750|NCT01493999|Clopidogrel
1118751|NCT01493999|prasugrel
1118752|NCT01493999|HPR
1118753|NCT01493999|loading dose
1118754|NCT01493999|maintenance dose
1118755|NCT01493999|stent thrombosis
1118756|NCT01493999|platelet reactivity
1118757|NCT01493999|Coronary intervention
1118758|NCT01493999|stent implantation
1118759|NCT01493986|Ropivacaine
1118760|NCT01493986|Brachial plexus
1118761|NCT01493973|Erythropoietin
1118762|NCT01493973|EPO
1118763|NCT01493973|Friedreich
1118764|NCT01493973|Ataxia
1118765|NCT01493973|Epoetin alfa
1118766|NCT01493973|VO2 max
1118767|NCT01493973|SARA
1118768|NCT01493973|EQ-5D
1118769|NCT01493973|frataxin
1118770|NCT01493960|Colitis, Ulcerative
1118771|NCT01493960|Gastrointestinal Diseases
1118772|NCT01493960|Inflammatory Bowel Diseases
1118773|NCT01493960|Immunomodulatory Therapy
1118774|NCT01493960|Glucocorticoids
1118775|NCT01493960|Anti-Inflammatory Agents
1118776|NCT01493960|Therapeutic uses
1118777|NCT01493934|metabolic syndrome
1118778|NCT01493934|type 2 diabetes mellitus
1118779|NCT01493934|insulin resistance
1118780|NCT01493934|Scintigraphy
1118781|NCT01493921|SR-T100 Clinical treatment against Actinic Keratosis
1118782|NCT01493921|Actinic keratosis skin lesion treatment with SR-T100 gel
1118783|NCT01493921|Skin lesion treatment with SR-T100 gel
1118784|NCT01493921|SR-T100 gel treatment against skin lesion
1118785|NCT01493921|Clinical efficacy study of SR-T100 gel
1118787|NCT01493908|Pain; Analgesic;
1118788|NCT01493908|Electrical shock
1118789|NCT01493908|control in healthy volunteers
1118790|NCT01493882|Uncontrolled Persistent Asthma, Dyspnea, Wheezing
1118791|NCT01493869|Normal healthy adult subjects
1118792|NCT01493869|Adult subjects with hepatic impairment
1118793|NCT01493830|neuroblastoma
1118794|NCT01493804|Near Infrared Spectroscopy
1118795|NCT01493804|EEG
1118796|NCT01493804|Brain Connectivity
1118797|NCT01493804|Healthy Volunteer
1118798|NCT01493804|HV
1118799|NCT01493791|CDB-2914
1118800|NCT01493791|Abnormal Urine Bleeding
1118801|NCT01493791|Abnormal Uterine Bleeding
1118802|NCT01493700|heated circuit
1118803|NCT01493700|body temperature
1118804|NCT01493674|folate
1118805|NCT01493674|homocysteine
1118806|NCT01493674|cognitive function
1118807|NCT01493674|eating disorders
1118808|NCT01493674|depression.
1118809|NCT01493661|Sleep
1118810|NCT01493661|Polysomnography
1118811|NCT01493661|Reaction Time
1118812|NCT01493661|Sleep Deprivation
1118813|NCT01493661|Psychophysiology
1118814|NCT01493661|Chronic sleep restriction
1118815|NCT01493661|healthy
1118816|NCT01493661|without sleep complaints
1118817|NCT01493648|statins
1118818|NCT01493648|side effects
1118819|NCT01493648|muscle
1118820|NCT01493648|vitamin D
1118821|NCT01493648|biopsy
1118822|NCT01493648|strength
1118823|NCT01493648|fatigue
1118824|NCT01493622|Schizophrenia minocycline cognition
1118825|NCT01493596|Safety
1118826|NCT01493596|Tolerability
1118827|NCT01493583|severely obese
1118828|NCT01493583|Roux-en Y gastric bypass surgery (RYGB)
1118829|NCT01493583|brain activity by fMRI
1118830|NCT01493583|visual presentation of food and non-food-related pictures
1118831|NCT01493544|COPD
1118832|NCT01493544|smokers
1118833|NCT01493544|primary care
1118834|NCT01493531|Gout
1118835|NCT01493518|SAFETY
1118836|NCT01493518|ADULT
1118837|NCT01493518|PSORIASIS
1118838|NCT01493518|INFLAMMATION
1118839|NCT01493505|Primary Peritoneal Cancer
1118840|NCT01493492|proteomics,urinary,sepsis,prognosis
1118841|NCT01493466|proteomics,
1118842|NCT01493466|serum,
1118843|NCT01493466|sepsis,
1118844|NCT01493466|potential biomarkers,
1118845|NCT01493466|dynamic changes
1118846|NCT01493466|normal
1118847|NCT01493440|atosiban
1118848|NCT01493440|clinical pregnancy
1118849|NCT01493440|implantation rate
1118850|NCT01493440|uterine contractility
1118851|NCT01493440|IVF-ET
1118852|NCT01493427|Glaucoma
1118853|NCT01493427|OAG
1118854|NCT01493427|OHT
1118855|NCT01493414|INC424
1118856|NCT01493414|Ruxolitinib
1118857|NCT01493414|myelofibrosis
1118858|NCT01493414|PMF
1118859|NCT01493414|post polycythemia myelofibrosis
1118860|NCT01493414|PPV MF
1118861|NCT01493414|post-essential thrombocythemia myelofibrosis
1118862|NCT01493414|PET-MF
1118863|NCT01493375|Contamination, hip operation, knee operation
1118864|NCT01493362|Bulimia Nervosa
1118865|NCT01493362|PET Imaging
1118866|NCT01493362|Dopamine
1118867|NCT01493349|Colonic diverticula
1118868|NCT01493349|Diverticulitis
1118869|NCT01493284|aortic stenosis
1118870|NCT01493284|aortic valve stenosis
1118871|NCT01493284|valvular heart disease
1118872|NCT01493284|aortic valve replacement
1118873|NCT01493284|transcatheter aortic valve implantation
1118874|NCT01493284|TAVI
1118875|NCT01493258|Diabetes
1118876|NCT01493258|Comparative Effectiveness Research
1118877|NCT01493258|Interactive computer-assisted education
1118878|NCT01493258|Informatics
1118879|NCT01493245|Chronic Pain
1118880|NCT01493245|JNS020QD
1118881|NCT01493245|Fentanyl
1118882|NCT01493245|Opioid analgesics
1118883|NCT01493232|Lingualized occlusion
1118884|NCT01493232|Complete denture occlusion
1118885|NCT01493232|Fully bilateral balanced occlusion
1118886|NCT01493232|Patient satisfaction of complete denture
1118887|NCT01493219|Glioblastoma
1118888|NCT01493219|Glioblastoma Multiforme
1118889|NCT01493219|Astrocytoma
1118890|NCT01493219|Gliosarcoma
1118891|NCT01493219|Glioma WHO grade IV
1118892|NCT01493206|intraoperative radiotherapy
1118893|NCT01493167|cast
1118894|NCT01493167|splint
1118895|NCT01493167|circumferential casting
1118896|NCT01493167|casting techniques
1118897|NCT01493167|fracture in extremity
1118898|NCT01493154|HPV
1118899|NCT01493154|Head and Neck Cancer
1118900|NCT01493154|Vaccine
1118901|NCT01493154|Immunotherapy
1118902|NCT01493154|Cyclophosphamide
1118903|NCT01493154|Sexually Transmitted Diseases, Viral
1118904|NCT01493141|MOMHR
1118905|NCT01493141|THA
1118906|NCT01493141|Osteoarthritis
1118907|NCT01493128|atrial fibrillation
1118908|NCT01493128|atrial cells
1118909|NCT01493128|myocardial tissue
1118910|NCT01493128|t-tubules
1118911|NCT01493128|immunofluorescence
1118912|NCT01493102|septic shock
1118913|NCT01493102|norepinephrine
1118914|NCT01493102|vasopressin
1118915|NCT01493102|hypotension
1118916|NCT01493076|ERCP
1118917|NCT01493076|Cannulation
1118918|NCT01493076|Precut
1118919|NCT01493076|Mini-spincterotome
1118920|NCT01493063|preterm newborns
1118921|NCT01493050|Diabetic Nephropathy
1118922|NCT01493050|Sevelamer Carbonate
1118923|NCT01493037|STEMI
1118924|NCT01493037|PICSO
1118925|NCT01493037|Coronary Sinus
1118926|NCT01493037|Involving Left Anterior Descending Coronary Artery
1118927|NCT01492998|Hepatitis C virus
1118928|NCT01492998|Biliary salts
1118929|NCT01492998|Farnesoid X receptor
1118930|NCT01492998|Guggulsterone
1118935|NCT01492946|Malnutrition
1118936|NCT01492946|Post-operative outcome
1118937|NCT01492946|Phase angle
1118938|NCT01492946|MUST
1118939|NCT01492946|Clavien Dindo classification
1118940|NCT01492946|Bioelectrical impedance analysis
1118941|NCT01492933|Ethanol
1118942|NCT01492933|Magnetic Resonance Spectroscopy
1118943|NCT01492933|Spectroscopy
1118944|NCT01492933|Alcohol Use
1118945|NCT01492907|Heterocyclic amine carcinogens
1118946|NCT01492907|meat-borne carcinogens
1118947|NCT01492881|relapsed multiple myeloma
1118948|NCT01492881|refractory multiple myeloma
1118949|NCT01492881|vorinostat
1118950|NCT01492881|bortezomib
1118951|NCT01492881|doxil
1118952|NCT01492868|sinusitis
1118953|NCT01492868|upper respiratory infection
1118954|NCT01492855|Meniscal lesions
1118955|NCT01492855|MRI
1118956|NCT01492855|arthroscopic treatment
1118957|NCT01492829|HIV prevention
1118958|NCT01492829|sexually transmitted infection prevention
1118959|NCT01492829|HIV knowledge
1118960|NCT01492829|relationship power
1118961|NCT01492829|depression
1118962|NCT01492829|coping
1118963|NCT01492829|social support
1118964|NCT01492829|internally displaced persons
1118965|NCT01492829|community health worker
1118966|NCT01492829|HIV/STI educational video
1118967|NCT01492829|substance use
1118968|NCT01492829|women's health
1118969|NCT01492816|HIV prevention
1118970|NCT01492816|HIV positive communities
1118971|NCT01492803|HIV infection
1118972|NCT01492803|Probiotics
1118973|NCT01492764|Ventricular Tachyarrhythmia
1118974|NCT01492764|Ablation
1118975|NCT01492764|Electrophysiology
1118976|NCT01492764|Human
1118977|NCT01492764|Mapping
1118978|NCT01492751|Prostatic Neoplasms
1118979|NCT01492751|Radiotherapy conformal
1118980|NCT01492751|brachytherapy
1118981|NCT01492751|radical prostatectomy
1118982|NCT01492751|Quality of life
1118983|NCT01492751|biochemical relapse
1118984|NCT01492751|biochemical failure
1118985|NCT01492751|survival
1118986|NCT01492751|Clinically localized prostate cancer
1118987|NCT01492738|Acupuncture
1118988|NCT01492738|anxiety
1118989|NCT01492738|memory
1118990|NCT01492712|Propofol
1118991|NCT01492712|Pharmacokinetics
1118992|NCT01492712|Pharmacodynamics
1118993|NCT01492712|Infusion Pumps
1118994|NCT01492699|PTSD
1118995|NCT01492699|Post Traumatic Stress Disorder
1118996|NCT01492686|Amyotrophic Lateral Sclerosis (ALS)
1118997|NCT01492673|Ewing's sarcoma
1118998|NCT01492673|BEVACIZUMAB (AVASTIN)
1118999|NCT01492673|CYCLOPHOSPHAMIDE (CYTOXAN)
1119000|NCT01492673|TOPOTECAN
1119001|NCT01492673|11-183
1119002|NCT01492673|POETIC
1119003|NCT01492660|Ultrasonography
1119004|NCT01492660|nerve block
1119005|NCT01492660|catheters
1119006|NCT01492660|needle
1119007|NCT01492660|anesthesia
1119008|NCT01492647|Acne vulgaris
1119009|NCT01492647|JNJ 10229570-AAA
1119010|NCT01492647|Japanese patients
1119011|NCT01492647|Topical treatment
1119012|NCT01492634|bioimpedance
1119013|NCT01492634|overhydration
1119014|NCT01492634|dry weight
1119015|NCT01492621|major depression
1119016|NCT01492621|DTI
1119017|NCT01492621|inflammatory markers
1119018|NCT01492621|cognition
1119019|NCT01492608|magnesium sulphate
1119020|NCT01492608|preterm birth
1119021|NCT01492608|cerebral palsy
1119022|NCT01492595|contact
1119023|NCT01492556|Recurrent
1119024|NCT01492556|Metastatic
1119025|NCT01492556|Breast cancer
1119026|NCT01492543|Advanced
1119027|NCT01492543|Metastatic
1119028|NCT01492543|Breast cancer
1119029|NCT01492530|Men who have sex with Men and Women
1119030|NCT01492530|HIV Prevention
1119031|NCT01492530|Behavioral Intervention
1119032|NCT01492530|Condom use
1119033|NCT01492530|African American MSMW
1119034|NCT01492517|Controlled Human exposure study
1119035|NCT01492517|Air Pollution
1119036|NCT01492517|Gene expression
1119037|NCT01492517|Epigenetic
1119038|NCT01492517|Cardiovascular
1119039|NCT01492491|SUPRA-HFR
1119040|NCT01492491|adsorpition
1119041|NCT01492491|vitamins
1119042|NCT01492491|large toxins
1119043|NCT01492465|Type 2 diabetes
1119044|NCT01492452|guidelines for nursing
1119045|NCT01492452|anxiety
1119046|NCT01492452|cardiac surgery
1119047|NCT01492452|pediatrics
1119048|NCT01492439|Psychosis
1119049|NCT01492439|Psychosis NOS
1119050|NCT01492439|Schizophrenia
1119051|NCT01492439|Schizoaffective Disorder
1119052|NCT01492439|Bipolar Disorder
1119053|NCT01492426|Hepatitis C Virus
1119054|NCT01492413|Overweight
1119055|NCT01492413|Obesity
1119056|NCT01492387|community-acquired pneumonia
1119057|NCT01492387|healthcare-associated pneumonia
1119058|NCT01492387|antibiotic therapy
1119059|NCT01492387|Duration of therapy
1119060|NCT01492361|Coronary Artery Disease
1119061|NCT01492361|Myocardial Ischemia
1119062|NCT01492361|Coronary Disease
1119063|NCT01492361|Heart Diseases
1119064|NCT01492361|Acute Coronary Syndrome
1119065|NCT01492361|Cardiovascular Diseases
1119066|NCT01492361|Arteriosclerosis
1119067|NCT01492361|Arterial Occlusive Diseases
1119068|NCT01492361|Vascular Diseases
1119069|NCT01492361|Angina Pectoris
1119070|NCT01492361|Chest Pain
1119071|NCT01492361|Anticholesteremic Agents
1119072|NCT01492361|Hypolipidemic Agents
1119073|NCT01492361|Lipid Regulating Agents
1119074|NCT01492361|hypertriglyceridemia
1119075|NCT01492361|omega-3 fatty acids
1119076|NCT01492361|statin
1119077|NCT01492361|triglycerides
1119078|NCT01492361|EPA
1119079|NCT01492361|docosahexaenoic acid
1119080|NCT01492361|fish
1119081|NCT01492361|fatty acids
1119082|NCT01492361|fibrates
1119083|NCT01492361|niacin
1119084|NCT01492361|lipids
1119085|NCT01492361|lipoprotein
1119086|NCT01492361|atorvastatin
1119087|NCT01492361|Lovaza
1119088|NCT01492361|simvastatin
1119089|NCT01492361|lovastatin
1119090|NCT01492361|pravastatin
1119091|NCT01492361|fluvastatin
1119092|NCT01492361|rosuvastatin
1119093|NCT01492361|Trilipix
1119094|NCT01492361|Vytorin
1119095|NCT01492361|Simcor
1119096|NCT01492361|ezetimibe
1119097|NCT01492361|Zetia
1119098|NCT01492361|ethyl-EPA
1119099|NCT01492361|ethyl icosapentate
1119100|NCT01492361|Crestor
1119101|NCT01492361|Zocor
1119102|NCT01492361|Lipitor
1119103|NCT01492361|LDL
1119104|NCT01492361|HDL
1119105|NCT01492361|cholesterol
1119106|NCT01492361|dyslipidemia
1119107|NCT01492361|AMR101
1119108|NCT01492361|Cardiovascular Disease, Unspecified
1119109|NCT01492361|VASCEPA
1119110|NCT01492361|icosapent ethyl
1119111|NCT01492348|collaborative care
1119112|NCT01492348|PTSD
1119113|NCT01492348|military
1119114|NCT01492348|Depression
1119115|NCT01492348|primary care
1119116|NCT01492348|care management
1119117|NCT01492348|stepped care
1119118|NCT01492348|telehealth
1119119|NCT01492348|OIF
1119120|NCT01492348|OEF
1119121|NCT01492348|preference-based treatment
1119122|NCT01492348|cost effectiveness
1119123|NCT01492348|web-based treatment
1119124|NCT01492348|telephonic CBT
1119125|NCT01492348|evidence-based treatment
1119126|NCT01492335|Cognitive decline
1119127|NCT01492335|Cognitive impairment
1119128|NCT01492322|Smoker
1119129|NCT01492322|SPECT
1119130|NCT01492322|Dopamine
1119131|NCT01492322|Nicotine Sated condition
1119132|NCT01492322|Nicotine withdrawal condition
1119133|NCT01492309|Major Depressive Disorder
1119134|NCT01492309|Pregnancy
1119135|NCT01492309|Brain Derived Neurotrophic Factor
1119136|NCT01492309|Transcranial Magnetic Stimulation
1119137|NCT01492283|NAFLD
1119138|NCT01492283|Incretin hormones
1119139|NCT01492270|Prostate Cancer
1119140|NCT01492270|Multi parametric MRI
1119141|NCT01492270|Prostate HistoScanning
1119142|NCT01492270|Transperineal prostate mapping biopsy
1119143|NCT01492257|shared decision making
1119144|NCT01492257|decision aids
1119145|NCT01492257|total joint arthroplasty
1119146|NCT01492257|osteoarthritis
1119147|NCT01492244|Knee pain
1119148|NCT01492244|map
1119149|NCT01492244|questionnaire
1119150|NCT01492244|survey
1119151|NCT01492231|gastroenterology
1119152|NCT01492231|Endoscopy, Digestive System
1119153|NCT01492231|Endosonography
1119154|NCT01492231|Endoscopic Retrograde Cholangiopancreatography
1119155|NCT01492231|gastrointestinal endoscopy
1119156|NCT01492192|Angiogenesis
1119157|NCT01492192|PET-CT
1119158|NCT01492192|Perfusion-CT
1119159|NCT01492179|Surgery: Abdominal hysterectomy
1119160|NCT01492179|Anesthetics: Local
1119161|NCT01492179|Postoperative: Pain
1119162|NCT01492179|Drugs: Morphine
1119163|NCT01492127|Hepatocellular carcinoma
1119164|NCT01492127|cirrhosis
1119165|NCT01492127|proteasome
1119166|NCT01492127|alpha-fetoprotein
1119167|NCT01492114|C-reactive protein
1119168|NCT01492114|Resveratrol
1119169|NCT01492114|Redox index
1119170|NCT01492088|Pediatric
1119171|NCT01492088|Lymphoma
1119172|NCT01492088|Hodgkin
1119173|NCT01492088|Anaplastic Large-cell
1119174|NCT01492088|Relapsed
1119175|NCT01492088|Refractory
1119176|NCT01492088|Drug therapy
1119177|NCT01492075|Postoperative pain
1119178|NCT01492075|Anesthetics: Local anesthetics
1119179|NCT01492075|Surgery: Hysterectomy
1119180|NCT01492062|Type 1 diabetes mellitus
1119181|NCT01492062|artificial pancreas
1119182|NCT01492062|closed-loop
1119183|NCT01492049|Colorectal Neoplasms
1119184|NCT01492049|Promoting Health Literacy
1119185|NCT01492049|Patient education program
1119186|NCT01492049|Colorectal Cancer Screening
1119187|NCT01492049|CRCS
1119188|NCT01492049|Patient decision aid
1119189|NCT01492049|PtDA
1119190|NCT01492049|Video
1119191|NCT01492049|Questionnaires
1119192|NCT01492049|Surveys
1119193|NCT01492036|Replication-Competent Retrovirus
1119194|NCT01492036|RCR
1119195|NCT01492036|Gene transfer therapy
1119196|NCT01492036|Registry
1119197|NCT01492036|Medical information database
1119198|NCT01492036|Vector or vector-treated cells
1119199|NCT01492036|Blood draw
1119200|NCT01492036|Computed tomography
1119201|NCT01492036|CT
1119202|NCT01492036|Questionnaires
1119203|NCT01492036|Surveys
1119204|NCT01492036|Gene Transfer Research
1119205|NCT01492036|National Gene Vector Biorepository and Coordinating Center
1119206|NCT01492036|NGVB
1119207|NCT01492023|neuropsychological
1119208|NCT01492023|rehabilitation
1119209|NCT01492023|multiple sclerosis
1119210|NCT01492023|RCT study
1119211|NCT01492010|skeletal muscle
1119212|NCT01492010|FSR
1119213|NCT01492010|resistance exercise
1119214|NCT01492010|leucine
1119215|NCT01492010|protein
1119216|NCT01491958|Leukemia
1119217|NCT01491958|AML
1119218|NCT01491958|ALL
1119219|NCT01491958|MDS
1119220|NCT01491945|Abdominal aortic aneurysm
1119221|NCT01491945|Renal stent
1119222|NCT01491945|Juxtarenal
1119223|NCT01491945|Pararenal
1119224|NCT01491945|Endovascular
1119225|NCT01491932|Parkinson Disease
1119226|NCT01491932|L-dopa
1119227|NCT01491932|Levodopa
1119228|NCT01491932|Dyskinesia
1119229|NCT01491919|High Blood Pressure
1119230|NCT01491919|Hypertension
1119231|NCT01491919|Renal Transplantation
1119232|NCT01491919|Kidney Transplantation
1119233|NCT01491893|GBM
1119234|NCT01491893|Brain Tumor
1119235|NCT01491893|Poliovirus Vaccine
1119236|NCT01491893|WHO Grade IV Malignant Glioma
1119237|NCT01491880|cognitive behavior therapy
1119238|NCT01491880|telemedicine
1119239|NCT01491880|rural
1119240|NCT01491880|Latinos
1119241|NCT01491880|children
1119242|NCT01491867|intraocular pressure
1119243|NCT01491854|Long-term
1119244|NCT01491854|safety
1119245|NCT01491854|follow-up
1119246|NCT01491854|growth hormone treatment
1119247|NCT01491854|short children
1119248|NCT01491854|Small for Gestational Age
1119249|NCT01491854|Somatropin
1119250|NCT01491828|Apnea
1119251|NCT01491828|Sleep apnea
1119252|NCT01491828|Snoring
1119253|NCT01491828|Hypoglossal nerve stimulation
1119254|NCT01491828|Laynx stimulation
1119255|NCT01491802|COPD
1119256|NCT01491802|Combination therapy
1119257|NCT01491802|Anticholinergic
1119258|NCT01491802|Beta2-agonist
1119259|NCT01491802|Exercise
1119260|NCT01491802|Dyspnea
1119261|NCT01491802|Respiratory mechanics
1119262|NCT01491789|spinal cord injury
1119263|NCT01491789|Virtual sailing
1119264|NCT01491789|Vsail
1119265|NCT01491776|Group A Streptococcus
1119266|NCT01491776|Strep A
1119267|NCT01491776|Rapid Test
1119268|NCT01491776|Pharyngitis
1119269|NCT01491750|SURGERY
1119270|NCT01491750|TOTAL JOINT REPLACEMENT
1119271|NCT01491750|TOTAL KNEE REPLACEMENT
1119272|NCT01491750|GUIDED IMAGERY
1119273|NCT01491750|COMPLEMENTARY AND ALTERNATIVE THERAPY
1119274|NCT01491711|Superficial basal cell carcinoma
1119275|NCT01491711|Carcinoma, Basal Cell
1119276|NCT01491711|Skin diseases
1119277|NCT01491711|Connective tissue diseases
1119278|NCT01491711|Treatment
1119279|NCT01491711|Drug therapy
1119280|NCT01491711|Efficacy
1119281|NCT01491711|Photodynamic therapy
1119282|NCT01491711|Photosensitizing Agents/therapeutic use
1119283|NCT01491711|Aminolevulinic acid
1119284|NCT01491711|Methylaminolevulinate
1119285|NCT01491711|Pain measurement
1119286|NCT01491711|Health Care Economics and Organizations
1119287|NCT01491698|stomach
1119288|NCT01491698|surgery
1119289|NCT01491698|Total Gastrectomy
1119290|NCT01491698|Roux-En-Y Pouch Reconstruction
1119291|NCT01491698|Conventional Roux-En-Y Reconstruction
1119292|NCT01491698|Quality of Life
1119293|NCT01491698|11-170
1119294|NCT01491672|Metastatic Renal Cell Carcinoma
1119295|NCT01491672|Second Line
1119296|NCT01491672|Everolimus
1119297|NCT01491672|RAD001
1119298|NCT01491646|pulmonary hypertension
1119299|NCT01491646|cardiac magnetic resonance imaging
1119300|NCT01491646|Characterize and quantify RV vortex flow
1119301|NCT01491646|Assess feasibility of cardiac MR for RVDD diagnosis
1119302|NCT01491646|Biomarker information to help diagnose
1119303|NCT01491633|Lung cancer
1119304|NCT01491633|NSCLC
1119305|NCT01491633|Stage IIIB
1119306|NCT01491633|Stage IV
1119307|NCT01491620|poikiloderma of Civatte
1119308|NCT01491620|red dyschromia
1119309|NCT01491620|brown dyschromia
1119310|NCT01491620|sun damage
1119311|NCT01491620|neck
1119312|NCT01491620|chest
1119313|NCT01491620|dyschromia
1119314|NCT01491620|pigmentation disorders
1119315|NCT01491620|erythema
1119316|NCT01491620|photosensitivity disorders
1119317|NCT01491620|sun exposure
1119318|NCT01491620|telangiectasia
1119319|NCT01491620|hyperpigmentation
1119320|NCT01491620|hypopigmentation
1119321|NCT01491607|post-exposure prophylaxis
1119322|NCT01491607|toxin neutralization assay
1119323|NCT01491594|Metastatic sarcoma
1119324|NCT01491594|Bone sarcoma
1119325|NCT01491581|anthropometry
1119326|NCT01491581|zinc
1119327|NCT01491581|iodine
1119328|NCT01491581|vitamin D
1119329|NCT01491581|calcium
1119330|NCT01491581|school children
1119331|NCT01491581|food supplement
1119332|NCT01491568|symptomatic degenerative disc disease at two levels
1119333|NCT01491555|Duchenne Muscular Dystrophy
1119334|NCT01491555|DMD
1119335|NCT01491555|controls
1119336|NCT01491555|EIM
1119337|NCT01491555|QUS
1119338|NCT01491542|Symptomatic Degenerative Disc Disease
1119339|NCT01491529|Parkinson Disease
1119340|NCT01491529|L-dopa
1119341|NCT01491529|Levodopa
1119342|NCT01491529|Dyskinesia
1119343|NCT01491529|Amantadine
1119344|NCT01491516|Lumbar degenerative disc disease
1119345|NCT01491503|montelukast
1119346|NCT01491503|levocetirizine
1119347|NCT01491503|interaction
1119348|NCT01491490|Schizophrenia
1119349|NCT01491490|Functional psychosis
1119350|NCT01491490|Schizophreniform
1119351|NCT01491490|Acute psychosis
1119352|NCT01491464|symptomatic degenerative disc disease
1119353|NCT01491451|Degenerative lumbar disc disease
1119354|NCT01491425|symptomatic degenerative disc disease
1119355|NCT01491412|Schizophrenia
1119356|NCT01491412|antipsychotics
1119357|NCT01491412|real life treatment
1119358|NCT01491412|non-interventional
1119359|NCT01491386|symptomatic degenerative disc disease
1119360|NCT01491373|Degenerative Disc Disease
1119361|NCT01491373|Symptomatic Degenerative Disc Disease
1119362|NCT01491360|Presbyopia
1119363|NCT01491360|sclera
1119364|NCT01491360|LaserACE
1119365|NCT01491347|BDNF
1119366|NCT01491347|withdrawal
1119367|NCT01491347|alcohol
1119368|NCT01491347|psychiatry
1119369|NCT01491334|POP
1119370|NCT01491334|Pelvic Floor
1119371|NCT01491334|Pelvic Organ Prolapse
1119372|NCT01491321|chronic low back pain
1119373|NCT01491321|bee venom acupuncture
1119374|NCT01491295|Lamivudine
1119375|NCT01491295|adefovir add on treatment
1119376|NCT01491295|tenofovir
1119377|NCT01491295|chronic hepatitis B
1119378|NCT01491282|human brown adipose tissue activity
1119379|NCT01491282|obesity
1119380|NCT01491282|energy metabolism
1119381|NCT01491282|adaptive thermogenesis
1119382|NCT01491269|chronic pain
1119383|NCT01491269|internet delivered CBT
1119384|NCT01491269|tertiary intervention
1119385|NCT01491269|mindfulness
1119386|NCT01491269|applied relaxation
1119387|NCT01491269|guided self help
1119388|NCT01491256|Index of microcirculatory resistance
1119389|NCT01491256|atorvastatin
1119390|NCT01491256|drug-eluting stent
1119391|NCT01491256|acute coronary syndrome
1119392|NCT01491243|contrast-induced nephropathy
1119393|NCT01491230|cancer
1119394|NCT01491230|neutrophil extracellular traps
1119395|NCT01491230|autologous hematopoietic stem cell transplantation
1119396|NCT01491230|allogeneic hematopoietic stem cell transplantation
1119397|NCT01491230|chemotaxis
1119398|NCT01491230|superoxide production
1119399|NCT01491230|hydrogen peroxide production
1119400|NCT01491230|myeloperoxidase
1119401|NCT01491217|Oraxol®
1119402|NCT01491217|oral paclitaxel
1119403|NCT01491217|paclitaxel
1119404|NCT01491217|HM30181A
1119405|NCT01491217|MTD
1119406|NCT01491217|DLT
1119407|NCT01491217|RD
1119408|NCT01491191|surgical pain
1119409|NCT01491191|chronic pain
1119410|NCT01491191|prevention
1119411|NCT01491191|palmitoylethanolamide
1119412|NCT01491165|umbilical cord mesenchyma stem cell
1119413|NCT01491152|Cerebral Palsy
1119414|NCT01491152|Whole Body Vibration
1119415|NCT01491152|Infant
1119416|NCT01491152|Motor development
1119417|NCT01491152|Physiotherapy
1119418|NCT01491139|Radiotherapy
1119419|NCT01491139|Biomarkers, pharmacological
1119420|NCT01491139|Pharmacokinetics
1119421|NCT01491139|Genetic Markers
1119422|NCT01491139|Cisplatin
1119423|NCT01491139|Poly(ADP-ribose) Polymerases
1119424|NCT01491139|AZD 2281
1119425|NCT01491139|Radiotherapy, Intensity-Modulated
1119426|NCT01491139|Head and Neck
1119427|NCT01491139|Chemoradiotherapy
1119428|NCT01491139|SCC
1119429|NCT01491126|Gastroscopy
1119430|NCT01491126|Colonoscopy
1119431|NCT01491126|Anesthesia
1119432|NCT01491126|Recovery
1119433|NCT01491113|Levetiracetam
1119434|NCT01491113|Oral administration
1119435|NCT01491113|Japanese
1119436|NCT01491113|Non-epileptic
1119437|NCT01491113|Healthy
1119438|NCT01491113|Renal impaired subjects
1119439|NCT01491100|Cognition
1119440|NCT01491100|Physical Activity
1119441|NCT01491100|Relapsing Remitting Multiple Sclerosis
1119442|NCT01491087|Pentaxim®
1119443|NCT01491087|Whole-cell Pertussis vaccine
1119444|NCT01491087|Acellular Pertussis vaccine
1119445|NCT01491087|Haemophilus influenzae type b polysaccharide
1119446|NCT01491087|Inactivated Polio vaccine
1119447|NCT01491087|Pentavac®
1119448|NCT01491061|periprocedural myocardial infarction
1119449|NCT01491061|ranolazine
1119450|NCT01491048|Hip osteoarthritis
1119451|NCT01491048|Physiotherapy
1119452|NCT01491048|THA
1119453|NCT01491035|Children
1119454|NCT01491035|Adolescents
1119455|NCT01491035|Pharmacokinetic
1119456|NCT01491035|Pharmacodynamic
1119457|NCT01491022|parkinson's
1119458|NCT01491022|gait dysfunction
1119459|NCT01491022|ampyra
1119460|NCT01491022|4-aminopyridine
1119461|NCT01491009|Dexmedetomidine
1119462|NCT01491009|midazolam
1119463|NCT01491009|remifentanil
1119464|NCT01491009|mini-mental state examination
1119465|NCT01491009|monitored anaesthesia care
1119466|NCT01491009|cystoscopy
1119467|NCT01491009|sedation
1119468|NCT01490996|Curcumin
1119469|NCT01490996|Colorectal cancer
1119470|NCT01490996|metastases
1119471|NCT01490996|FOLFOX
1119472|NCT01490983|Chronic Myeloid Leukemia
1119473|NCT01490983|Chronic Phase CML
1119474|NCT01489995|Food effect
1119475|NCT01489995|GR181413A
1119476|NCT01489995|AT1001
1119477|NCT01489995|migalastat hydrochloride
1119478|NCT01489995|Lysosomal storage disorders
1119479|NCT01489995|Pharmacokinetics
1119480|NCT01489982|Parkinson's disease
1119481|NCT01489982|insomnia
1119482|NCT01489969|sleep latency
1119483|NCT01489969|Sleep maintenance
1119484|NCT01489969|Sleep fragmentation
1119485|NCT01489969|Polysomnography
1119486|NCT01489956|Keyhole Limpet Hemocyanin (KLH)
1119487|NCT01489956|Immucothel
1119488|NCT01489956|Native KLH
1119489|NCT01489956|Healthy volunteers
1119490|NCT01489956|Oral tolerance
1119491|NCT01489956|Immunogenicity
1119492|NCT01489956|Autoimmune diseases
1119493|NCT01489930|Exercise
1119494|NCT01489930|Aging
1119495|NCT01489930|Sarcopenia
1119496|NCT01489930|Mitochondria
1119497|NCT01489917|radial artery occlusion
1119498|NCT01489917|hemostasis
1119499|NCT01489917|coronary intervention
1119500|NCT01489917|radial approach
1119501|NCT01489904|drooling
1119502|NCT01489904|cerebral palsy
1119503|NCT01489891|Esophagogastroduodenoscopy
1119504|NCT01489891|Lidocaine
1119505|NCT01489891|Propofol
1119506|NCT01489878|Coagulase-negative staphylococci
1119507|NCT01489878|Staphylococcus epidermidis
1119508|NCT01489878|Staphylococcus aureus
1119509|NCT01489878|Anti-bacterial agents
1119510|NCT01489878|Drug resistance, Microbial
1119511|NCT01489878|Methicillin resistance
1119512|NCT01489878|Β-lactams
1119513|NCT01489878|Fluoroquinolones
1119514|NCT01489878|Macrolides
1119515|NCT01489878|Synergistin
1119516|NCT01489878|General practitioners
1119517|NCT01489878|Antibiotic selection pressure
1119518|NCT01489878|Ambulatory antibiotherapy
1119519|NCT01489878|Community patients
1119520|NCT01489865|Pancreas cancer
1119521|NCT01489865|Veliparib
1119522|NCT01489865|oxaliplatin
1119523|NCT01489852|Assisted reproductive treatment
1119524|NCT01489852|GnRH antagonist
1119525|NCT01489852|Estrogen pre-treatment
1119526|NCT01489852|Ovarian stimulation
1119527|NCT01489839|periodontal disease
1119528|NCT01489839|biomarkers
1119529|NCT01489839|periodontal treatment
1119530|NCT01489839|clinical attachment level
1119531|NCT01489826|Cancer
1119532|NCT01489800|feeding
1119533|NCT01489800|complications
1119534|NCT01489800|radical cystectomy
1119535|NCT01490970|Sarcoma Database
1119536|NCT01490957|HD
1119537|NCT01490957|NHL
1119538|NCT01490931|acute pain
1119539|NCT01490931|dental pain
1119540|NCT01490931|intranasal ketorolac
1119541|NCT01490931|dental implant surgery
1119542|NCT01490918|Type-II diabetes mellitus
1119543|NCT01490918|Acarbose
1119544|NCT01490918|ACADEMIC
1119545|NCT01490905|Medical food
1119546|NCT01490905|Theramine
1119547|NCT01490905|Ibuprofen
1119548|NCT01490905|Amino acids
1119549|NCT01490905|Convenience Pack Kit
1119550|NCT01490892|breast abnormality
1119551|NCT01490892|ultrasound imaging
1119552|NCT01490892|ultrasound contrast agent
1119553|NCT01490892|subharmonic imaging
1119554|NCT01490879|DFU
1119555|NCT01490879|Diabetic Foot Ulcer
1119556|NCT01490879|Ulcers
1119557|NCT01490879|Foot Ulcers
1119558|NCT01490879|chronic wound
1119559|NCT01490879|wounds
1119560|NCT01490879|Nexagon
1119561|NCT01490879|CoDa
1119562|NCT01490866|Colorectal Cancer
1119563|NCT01490866|Axitinib
1119564|NCT01490866|FOLFOX/Bevacizumab
1119565|NCT01490853|Ph pos CML
1119566|NCT01490853|Philadelphia positive Chronic Myeloid Leukemia
1119567|NCT01490840|Fatigue
1119568|NCT01490840|MS
1119569|NCT01490840|Multiple Sclerosis
1119570|NCT01490840|Exercise
1119571|NCT01490840|Physical activity
1119572|NCT01490840|Physical training
1119573|NCT01490840|Fingolimod
1119574|NCT01490814|PAF
1119575|NCT01490814|two episodes within the last twelve months one episode documented
1119576|NCT01490814|Documented treatment failure of at least one antiarrhythmic
1119577|NCT01490814|drug AAD Type I or III including β-blocker and AAD intolerance
1119578|NCT01490801|childhood Hodgkin lymphoma
1119579|NCT01490801|childhood mixed cellularity Hodgkin lymphoma
1119580|NCT01490801|hemophagocytic lymphohistiocytosis
1119581|NCT01490801|Epstein-Barr virus infection
1119582|NCT01490775|Chronic Myeloid Leukemia
1119583|NCT01490762|PK
1119584|NCT01490762|PD
1119585|NCT01490749|Esophageal Cancer
1119586|NCT01490749|Neoplasms, Esophageal
1119587|NCT01490736|Acne
1119588|NCT01490736|Sebum gland disease
1119589|NCT01490723|Leukemia
1119590|NCT01490723|Chronic lymphocytic leukemia
1119591|NCT01490723|Lymphoma
1119592|NCT01490723|CD20+ lymphoid malignancies
1119593|NCT01490723|Diffuse large B-cell lymphoma
1119594|NCT01490723|Allogeneic transplantation
1119595|NCT01490723|Rituximab
1119596|NCT01490723|Rituxan
1119597|NCT01490723|In ibritumomab
1119598|NCT01490723|Y ibritumomab
1119599|NCT01490723|Zevalin
1119600|NCT01490723|Fludarabine Phosphate
1119601|NCT01490723|Fludara
1119602|NCT01490723|Bendamustine Hydrochloride
1119603|NCT01490723|Bendamustine HCL
1119604|NCT01490723|CEP-18083
1119605|NCT01490723|SDX-105
1119606|NCT01490723|Treanda
1119607|NCT01490723|Stem Cell Transplantation
1119608|NCT01490723|Planar Scintigraphy
1119609|NCT01490723|Spect Scan
1119610|NCT01490723|Single Photon Emission-Computed Tomography
1119611|NCT01490723|CT Scan
1119612|NCT01490723|Computed Tomography
1119613|NCT01490723|G-CSF
1119614|NCT01490723|Filgrastim
1119615|NCT01490723|Neupogen
1119616|NCT01490723|Thymoglobulin
1119617|NCT01490723|ATG
1119618|NCT01490723|Antithymocyte Globulin
1119619|NCT01490723|Methotrexate
1119620|NCT01490723|Mycophenolate
1119621|NCT01490723|MMF
1119622|NCT01490723|Mycophenolate Mofetil
1119623|NCT01490723|CellCept
1119624|NCT01490723|Tacrolimus
1119625|NCT01490723|Prograf
1119626|NCT01490710|NAVA
1119627|NCT01490710|Hemodynamic
1119628|NCT01490710|Cardiac Index
1119629|NCT01490710|Children with admission weight > 5kg
1119630|NCT01490697|stress disorders
1119631|NCT01490697|posttraumatic
1119632|NCT01490697|memory
1119633|NCT01490697|mifepristone
1119634|NCT01490697|d-cycloserine
1119635|NCT01490697|psychophysiology
1119636|NCT01490684|candidiasis
1119637|NCT01490684|critically ill
1119638|NCT01490684|outcomes
1119639|NCT01490645|ACS patients participating in a SCP
1119640|NCT01490645|QoL after ACS
1119641|NCT01490645|ASC Patients's needs
1119642|NCT01490632|Moderate
1119643|NCT01490632|Severe
1119644|NCT01490632|Plaque
1119645|NCT01490632|Chronic
1119646|NCT01490619|Type 1 diabetes
1119647|NCT01490619|Adolescent
1119648|NCT01490619|Resilience
1119649|NCT01490619|Prevention
1119650|NCT01490619|Depression
1119651|NCT01490593|Canadian
1119652|NCT01490593|Eye
1119653|NCT01490593|Injury
1119654|NCT01490593|Registry
1119655|NCT01490580|Pain
1119656|NCT01490580|Newborn
1119657|NCT01490580|Anaesthesia
1119658|NCT01490580|opioids
1119659|NCT01490580|propofol
1119660|NCT01490580|neuromuscular blocker
1119661|NCT01490580|atropine
1119662|NCT01490567|Impaired Cognition Schizophrenia
1119663|NCT01490554|Skin aging
1119664|NCT01490554|fibroblasts
1119665|NCT01490554|transplantation
1119666|NCT01490554|autologous
1119667|NCT01490541|Gastric intestinal metaplasia
1119668|NCT01490528|Pediatric IBD
1119669|NCT01490515|non-invasive,
1119670|NCT01490515|metabolomics,
1119671|NCT01490515|morphology,
1119672|NCT01490515|embryo selection,
1119673|NCT01490515|implantation rates
1119674|NCT01490489|EG-VEGF
1119803|NCT01489709|overactive bladder
1119675|NCT01490489|Endocrine Gland-derived Vascular Endothelial Growth Factor
1119676|NCT01490489|Pre-eclampsia
1119677|NCT01490489|intra-uterine growth retardation
1119678|NCT01490489|prognosis
1119679|NCT01490476|Neurofibromatosis Type 2 with Vestibular Schwannoma
1119680|NCT01490476|Vestibular Schwannoma
1119681|NCT01490476|Peripheral Nervous System Diseases
1119682|NCT01490476|Otorhinolaryngologic Diseases
1119683|NCT01490476|Vestibulocochlear Nerve Diseases
1119684|NCT01490463|Treatment of
1119685|NCT01490437|Advanced urothelial carcinoma
1119686|NCT01490424|TREM-1;
1119687|NCT01490424|SNPs;
1119688|NCT01490424|prognosis
1119689|NCT01490424|control（normal person）
1119690|NCT01490411|Specific immunotherapy
1119691|NCT01490411|SIT
1119692|NCT01490411|SCIT
1119693|NCT01490411|recombinant
1119694|NCT01490398|Hypertension
1119695|NCT01490398|Rosuvastatin
1119696|NCT01490398|Coronary flow reserve
1119697|NCT01490359|human immunodeficiency virus
1119698|NCT01490359|randomized controlled trial
1119699|NCT01490359|intervention studies
1119700|NCT01490359|South Africa
1119701|NCT01490359|men
1119702|NCT01490359|sexually behavior
1119703|NCT01490359|social cognitive theory
1119704|NCT01490346|HIV 1
1119705|NCT01490346|Pharmacokinetics
1119706|NCT01490346|Drug levels
1119707|NCT01490346|Treatment naive
1119708|NCT01490320|Violence prevention
1119709|NCT01490320|Media
1119710|NCT01490320|Primary care
1119711|NCT01490320|Parenting
1119712|NCT01490307|parenting intervention
1119713|NCT01490307|Family Check-Up
1119714|NCT01490307|Anxiety Disorders
1119715|NCT01490307|Depression
1119716|NCT01490307|Depressive Disorder
1119717|NCT01490307|Conduct Disorder
1119718|NCT01490307|Mental Disorders
1119719|NCT01490307|Behavioral Symptoms
1119720|NCT01490307|Mood Disorders
1119721|NCT01490307|Mental Disorders Diagnosed in Childhood
1119722|NCT01490307|Substance-Related Disorders
1119723|NCT01490294|Cardiac MRI
1119724|NCT01490294|gadobutrol
1119725|NCT01490281|Fibromyalgia
1119726|NCT01490281|exercise
1119727|NCT01490281|physical activity
1119728|NCT01490281|pain
1119729|NCT01490268|Pharmacokinetic-pharmacodynamic modeling
1119730|NCT01490268|Patient-controlled analgesia
1119731|NCT01490268|Target-controlled infusion
1119732|NCT01490268|Hydromorphone
1119733|NCT01490268|Sufentanil
1119734|NCT01490268|after thoracotomy
1119735|NCT01490268|cardiac surgery
1119736|NCT01490255|platelet reactivity
1119737|NCT01490255|aspirin
1119738|NCT01490255|clopidogrel
1119739|NCT01490229|nutraceuticals
1119740|NCT01490229|statin
1119741|NCT01490216|cocaine
1119742|NCT01490216|lisdexamfetamine
1119743|NCT01490216|vyvanse
1119744|NCT01490203|Gd-EOB-DTPA
1119745|NCT01490203|MRI
1119746|NCT01490203|Hepatectomy
1119747|NCT01490203|Hepatocellular Carcinoma
1119748|NCT01490203|Liver Function Tests
1119749|NCT01490177|Multiple food allergies
1119750|NCT01490151|Hormone
1119751|NCT01490151|Diabetes
1119752|NCT01490151|Mellitus
1119753|NCT01490151|Type 1
1119754|NCT01490151|Immune
1119755|NCT01490151|Metabolic disorder
1119756|NCT01490138|β-D-Glucan test
1119757|NCT01490138|IFI
1119758|NCT01490125|COPD
1119759|NCT01490125|Dyspnea
1119760|NCT01490125|QVA149
1119761|NCT01490125|tiotropium
1119762|NCT01490073|Intrauterine device
1119763|NCT01490073|Pain
1119764|NCT01490073|Contraception
1119765|NCT01490073|Nitroglycerin
1119766|NCT01490073|Nitric oxide donor
1119767|NCT01490073|Intrauterine device insertion
1119768|NCT01490060|cancer
1119769|NCT01490060|fosaprepitant
1119770|NCT01490060|Ifosfamide-based Multi-day Chemotherapy
1119771|NCT01490060|Chemotherapy-induced nausea and vomiting
1119772|NCT01490060|CINV
1119773|NCT01490060|multi-day chemotherapy regimens
1119774|NCT01490060|antiemetics
1119775|NCT01490060|adverse effect
1119776|NCT01490060|doxorubicin plus ifosfamide
1119777|NCT01490060|AI
1119778|NCT01490060|AI and vincristine
1119779|NCT01490060|VAI
1119780|NCT01490060|aprepitant
1119781|NCT01490060|prevention
1119782|NCT01490060|nausea
1119783|NCT01490060|vomiting
1119784|NCT01490060|emetogenic chemotherapy
1119785|NCT01490034|obesity
1119786|NCT01490034|energy intake
1119787|NCT01490034|appetite
1119788|NCT01490034|food form
1119789|NCT01490034|beverage
1119790|NCT01490034|learning
1119791|NCT01490034|dietary compensation
1119792|NCT01490021|Healthy young men
1119793|NCT01489787|Surgery
1119794|NCT01489787|Ultrasonic therapy
1119795|NCT01489787|Liver
1119796|NCT01489761|long lesions
1119797|NCT01489761|drug eluting stents
1119798|NCT01489735|GERD
1119799|NCT01489735|GERD Q QUESTIONNAIRE
1119800|NCT01489722|Leukemia
1119801|NCT01489722|AML
1119802|NCT01489722|AZD1208
1119804|NCT01489709|solifenacin
1119805|NCT01489709|Overactive bladder questionnaire
1119806|NCT01489709|Overactive Bladder Symptom Score
1119807|NCT01489709|satisfaction score
1119808|NCT01489696|Pharmacokinetics
1119809|NCT01489696|Mirabegron
1119810|NCT01489696|Tamsulosin
1119811|NCT01489696|Phase 1
1119812|NCT01489683|intubating conditions
1119813|NCT01489683|propofol
1119814|NCT01489683|remifentanil
1119815|NCT01489683|topical lidocaine
1119816|NCT01489657|Obesity
1119817|NCT01489657|Bariatric Surgery
1119818|NCT01489657|Sleeve Gastrectomy
1119819|NCT01489657|Metabolite Profiling
1119820|NCT01489631|Epidural
1119821|NCT01489631|Local infiltration
1119822|NCT01489631|Knee
1119823|NCT01489631|Arthroplasty
1119824|NCT01489618|Common variable immunodeficiency
1119825|NCT01489618|pneumococcal vaccine
1119826|NCT01489618|prime boost
1119827|NCT01489605|Orotracheal intubation, videolaryngoscopy
1119828|NCT01489566|Hepatocellular,Carcinoma,recurrence
1119829|NCT01489553|Egg hypersensitivity
1119830|NCT01489553|egg allergy
1119831|NCT01489553|egg protein allergy
1119832|NCT01489540|Burn
1119833|NCT01489540|Depth
1119834|NCT01489540|Diagnosis
1119835|NCT01489540|Laser Doppler Imaging
1119836|NCT01489527|Vaccine
1119837|NCT01489527|Placebo
1119838|NCT01489527|sexually transmitted infection (STI)
1119839|NCT01489527|HIV
1119840|NCT01489527|Human Immunodeficiency
1119841|NCT01489527|Gardasil
1119842|NCT01489527|HPV
1119843|NCT01489527|human papillomavirus
1119844|NCT01489514|peanut allergy
1119845|NCT01489514|hypoallergenic peanut extracts
1119846|NCT01489514|epicutaneous skin prick testing
1119847|NCT01489501|Caomecs, Transplantation, Limbal stem cell deficiency,
1119848|NCT01489488|Relative bioavailability study
1119849|NCT01489475|children
1119850|NCT01489475|congenital heart defects
1119851|NCT01489475|cardiopulmonary bypass
1119852|NCT01489475|modified ultrafiltration
1119853|NCT01489475|angiopoietins
1119854|NCT01489475|cytokines
1119855|NCT01489462|Arthritis
1119856|NCT01489462|Osteoarthritis
1119857|NCT01489462|Strength Training
1119858|NCT01489449|drug coated balloon
1119859|NCT01489449|NSTEMI
1119860|NCT01489436|gallstone disease
1119861|NCT01489436|cholecystectomy
1119862|NCT01489436|minimally invasive
1119863|NCT01489436|surgical
1119864|NCT01489436|laparoscopic
1119865|NCT01489436|single port
1119866|NCT01489436|cytokine
1119867|NCT01489423|stage IIIC melanoma
1119868|NCT01489423|stage IV melanoma
1119869|NCT01489423|recurrent melanoma
1119870|NCT01489397|Confocol laser endomicroscopy
1119871|NCT01489397|Feasibility of Confocol laser endomicroscopy
1119872|NCT01489384|Rheumatoid arthritis
1119873|NCT01489384|DAS28
1119874|NCT01489358|Vaccine-Mediated Protection
1119875|NCT01489358|Antibody Response
1119876|NCT01489358|Chikungunya Virus
1119877|NCT01489358|Immune Response
1119878|NCT01489358|Healthy Volunteer
1119879|NCT01489358|Humoral Inmunity
1119880|NCT01489358|Virus-like Particles
1119881|NCT01489345|ONO-2952
1119882|NCT01489345|Healthy adult subjects
1119883|NCT01489345|Multiple dose
1119884|NCT01489345|Safety
1119885|NCT01489345|Tolerability
1119886|NCT01489345|Pharmacokinetics
1119887|NCT01489332|rectal cancer
1119888|NCT01489332|capecitabine
1119889|NCT01489332|radiotherapy
1119890|NCT01489332|locally advanced rectal cancer
1119891|NCT01489319|inflammation
1119892|NCT01489319|body composition
1119893|NCT01489319|hyperandrogenism
1119894|NCT01489319|insulin resistance
1119895|NCT01489306|Respiratory Syncytial Virus Infection
1119896|NCT01489306|RSV
1119897|NCT01489280|Temple Touch Pro
1119898|NCT01489280|Medisim
1119899|NCT01489280|temperature
1119900|NCT01489280|surgery
1119901|NCT01489267|cerebellar ataxia
1119902|NCT01489267|hereditary disease
1119903|NCT01489267|stem cell
1119904|NCT01489254|Multiple Sclerosis,
1119905|NCT01489254|Relapsing-Remitting Multiple Sclerosis,
1119906|NCT01489254|glatiramer acetate,
1119907|NCT01489254|MRI,
1119908|NCT01489254|lesions,
1119909|NCT01489254|MS relapse rate,
1119910|NCT01489254|Copaxone
1119911|NCT01489241|Pulmonary Disease, Chronic Obstructive
1119912|NCT01489241|Telemedicine
1119913|NCT01489228|Chagas Disease
1119914|NCT01489202|drug-eluting stent
1119915|NCT01489202|percutaneous coronary intervention
1119916|NCT01489176|Stress Echocardiography
1119917|NCT01489176|Real-Time Perfusion Imaging
1119918|NCT01489176|Regadenoson
1119919|NCT01489176|Optison
1119920|NCT01489163|Gestational Diabetes
1119921|NCT01489163|Weight Loss
1119922|NCT01489163|Physical Activity
1119923|NCT01489163|Pregnancy
1119924|NCT01489163|Postpartum
1119925|NCT01489163|Intervention
1119926|NCT01489150|Acute respiratory failure
1119927|NCT01489150|Hypercapnia
1119928|NCT01489150|Non invasive ventilation
1119929|NCT01489150|End-tidal CO2
1119930|NCT01489124|Infection
1119931|NCT01489124|Imipenem
1119932|NCT01489124|Ventilator-Associated Pneumonia
1119933|NCT01489124|pharmacokinetic
1119934|NCT01489124|pharmacodynamic
1119935|NCT01489098|Body composition
1119936|NCT01489098|Protein Metabolism
1119937|NCT01489085|ventilation
1119938|NCT01489085|automated
1119939|NCT01489033|Allergic rhinitis
1119940|NCT01489033|Phleum pratense
1119941|NCT01489033|Timothy grass pollen allergy
1119942|NCT01489033|subcutaneous immunotherapy
1119943|NCT01489020|Allergy
1119944|NCT01489020|Immunotherapy
1119945|NCT01489020|Allergic Rhinoconjunctivitis
1119946|NCT01489020|D. pteronyssinus
1119947|NCT01489020|house dust allergy
1119948|NCT01489007|vegetarian
1119949|NCT01489007|children
1119950|NCT01489007|iron
1119951|NCT01489007|iron absorption
1119952|NCT01488981|Radio Frequency Microstimulator
1119953|NCT01488981|Traumatic Brain Injury
1119954|NCT01488981|TBI
1119955|NCT01488981|Arm Rehabilitation
1119956|NCT01488981|electrical stimulation
1119957|NCT01488981|FES
1119958|NCT01488968|high risk prostate cancer
1119959|NCT01488968|hypofractionated radiation treatment
1119960|NCT01488968|higher biological doses
1119961|NCT01488968|acceptable rectal toxicity
1119962|NCT01488968|Radiation Treatment
1119963|NCT01488955|bacterial infection
1119964|NCT01488942|HIV
1119965|NCT01488942|reinforcement
1119966|NCT01488942|medication adherence
1119967|NCT01488942|patient compliance
1119968|NCT01488942|antiretroviral therapy, highly active
1119969|NCT01488916|Vitamin D
1119970|NCT01488916|Postprandial Glucose
1119971|NCT01488916|Type 2 Diabetes
1119972|NCT01488903|genetic susceptibility
1119973|NCT01488903|obesity
1119974|NCT01488903|body composition
1119975|NCT01488903|the metabolic syndrome
1119976|NCT01488903|women
1119977|NCT01488890|Dengue fever
1119978|NCT01488890|Dengue Hemorrhagic Fever
1119979|NCT01488890|CYD dengue vaccine
1119980|NCT01488890|Yellow Fever
1119981|NCT01488890|Flavivirus
1119982|NCT01488877|Type 2 diabetes mellitus. albuminuria.
1119983|NCT01488864|Hot flashes
1119984|NCT01488864|Vasomotor symptoms
1119985|NCT01488864|Menopause
1119986|NCT01488864|Applied Relaxation
1119987|NCT01488864|Health Related Quality of Life
1119988|NCT01488864|Salivary cortisol
1119989|NCT01488851|Osteo necrosis of the Jaw
1119990|NCT01488812|Hip-fracture
1119991|NCT01488799|Anxiety
1119992|NCT01488799|Generalized Anxiety Disorder
1119993|NCT01488799|Motivational Interviewing
1119994|NCT01488799|Cognitive Behavioural Therapy
1119995|NCT01488799|Psychotherapy
1119996|NCT01488786|Assistive Technology
1119997|NCT01488786|Non-Surgical Visual Prosthetic
1119998|NCT01488786|Sensory Substitution
1119999|NCT01488773|asthma
1120000|NCT01488773|asthma control
1120001|NCT01488773|inhaled glucocorticosteroid
1120002|NCT01488773|ICS
1120003|NCT01488773|leukotriene antagonist
1120004|NCT01488773|LTRA
1120005|NCT01488773|montelukast
1120006|NCT01488773|fluticasone
1120007|NCT01488773|salmeterol
1120008|NCT01488773|observational study
1120009|NCT01488773|repeated measures
1120010|NCT01488773|retrospective
1120011|NCT01488747|Omega-3 fatty acids
1120012|NCT01488747|Phospholipid fatty acids
1120013|NCT01488747|chymlomicron fatty acids
1120014|NCT01488747|Bioavailability fo fish oil supplements in healthy adults
1120015|NCT01488734|Vitamin D
1120016|NCT01488734|Mushroom
1120017|NCT01488734|Cholecalciferol
1120018|NCT01488734|Prediabetes
1120019|NCT01488734|Metabolic Syndrome
1120020|NCT01488708|Lupus
1120021|NCT01488708|SLE
1120022|NCT01488708|Systemic Lupus Erythematosus
1120023|NCT01488708|Immune System Disease
1120024|NCT01488695|intubation
1120025|NCT01488695|double lumen tube
1120026|NCT01488682|Head and neck cancer
1120027|NCT01488682|Neck dissection
1120028|NCT01488682|Harmonic scalpel
1120029|NCT01488669|head and neck neoplasms
1120030|NCT01488669|neck dissection
1120031|NCT01488669|robotics
1120032|NCT01488656|Antioxidants
1120033|NCT01488656|Dietary supplements
1120034|NCT01488656|Forced vital lung capacity
1120035|NCT01488656|Exhaled nitric oxide
1120036|NCT01488656|Air pollution
1120037|NCT01488643|Bronchospasm
1120038|NCT01488643|Laparoscopic Gastrectomy
1120039|NCT01488643|Obesity
1120040|NCT01488630|substance abuse
1120041|NCT01488630|alcohol
1120042|NCT01488630|drug
1120043|NCT01488630|smoking
1120044|NCT01488630|HIV screening
1120045|NCT01488617|Surgery
1120046|NCT01488617|Psychosocial Factors
1120047|NCT01488617|Psychological Distress
1120048|NCT01488617|Outcome Assessment (Health Care)
1120049|NCT01488578|Overactive Bladder
1120050|NCT01488578|Japanese
1120051|NCT01488578|Tolterodine
1120052|NCT01488578|Detrusitol
1120053|NCT01488578|Detrol
1120054|NCT01488578|Postmarketing commitment plan.
1120055|NCT01488552|pancreatic cancer
1120056|NCT01488552|pancreatic adenocarcinoma
1120057|NCT01488552|Stage IV pancreatic cancer
1120058|NCT01488552|pancreas
1120059|NCT01488552|pancreatic
1120060|NCT01488539|Stress Disorders, Post-Traumatic
1120061|NCT01488539|PTSD
1120062|NCT01488539|Adult Survivors of Child Abuse
1120063|NCT01488539|Women
1120064|NCT01488539|Interpersonal violence
1120065|NCT01488539|psychological trauma
1120066|NCT01488526|Hepatitis B
1120067|NCT01488526|Vertical transmission
1120068|NCT01488526|Pregnancy
1120069|NCT01488526|Antiviral treatment
1120070|NCT01488513|ABC294640
1120071|NCT01488513|RedHill Biopharma, Ltd.
1120072|NCT01488513|ABC-101
1120073|NCT01488513|Medical University of South Carolina
1120074|NCT01488513|Apogee Biotechnology Corporation
1120075|NCT01488500|Wood smoke
1120076|NCT01488500|inflammation
1120077|NCT01488500|lung function
1120078|NCT01488500|arterial stiffness
1120079|NCT01488500|heart rate variability
1120080|NCT01488500|Respiratory and systemic inflammation following exposure to woodsmoke in healthy volunteers
1120081|NCT01488487|HCC
1120082|NCT01488487|Advanced Hepatocellular Carcinoma
1120083|NCT01488487|Metastatic Hepatocellular Carcinoma
1120084|NCT01488487|Liver Cancer
1120085|NCT01488474|regional anesthesia
1120086|NCT01488474|peripheral nerve stimulation
1120087|NCT01488474|diabetes
1120088|NCT01488474|diabetic neuropathy
1120089|NCT01488461|Congenital cerebellar ataxias
1120090|NCT01488461|Genetics
1120091|NCT01488461|Gene ATCAY
1120092|NCT01488461|Gene ABC7
1120093|NCT01488461|Cerebellar atrophy
1120094|NCT01488448|Hypertonic saline
1120095|NCT01488448|Bronchiolitis
1120096|NCT01488448|Infants
1120097|NCT01488448|Wheezing
1120098|NCT01488448|Nebulized
1120099|NCT01488448|Bronchodilator
1120100|NCT01488396|Cyclosporin
1120101|NCT01488396|Stevens-Johnson syndrome
1120102|NCT01488396|Dry eye
1120103|NCT01488383|Hyperglycemia
1120104|NCT01488383|Diabetes
1120105|NCT01488383|Blood glucose
1120106|NCT01488383|Hypertension
1120107|NCT01488383|Anti hypertensive agents
1120108|NCT01488383|Anti hypertensive drugs
1120109|NCT01488383|Anti hypertensive
1120110|NCT01488370|breathing tube placement
1120111|NCT01488357|Breast cancer
1120112|NCT01488357|UNC
1120113|NCT01488357|Lineberger
1120114|NCT01488357|Breast Reconstruction
1120115|NCT01488357|Mastectomy
1120116|NCT01488318|Cetuximab
1120117|NCT01488318|Dasatinib
1120118|NCT01488318|Squamous Cell
1120119|NCT01488318|Head and Neck
1120120|NCT01488318|After Cetuximab Containing Chemoradiotherapy
1120121|NCT01488318|Recurrent
1120122|NCT01488318|Metastatic
1120123|NCT01488305|MNP
1120124|NCT01488305|AAMA program
1120125|NCT01488305|Nepal
1120126|NCT01488305|HFP
1120127|NCT01488305|IYCF
1120128|NCT01488305|BCC
1120129|NCT01488292|mental health
1120130|NCT01488292|social skills
1120131|NCT01488279|Pre-diabetes
1120132|NCT01488279|Impaired fasting glucose
1120133|NCT01488279|Impaired glucose tolerance
1120134|NCT01488279|Steroid-induced hyperglycemia
1120135|NCT01488266|depression
1120136|NCT01488266|depressive
1120137|NCT01488266|major
1120138|NCT01488266|aripiprazole
1120139|NCT01488266|switching
1120140|NCT01488266|augmentation
1120141|NCT01488266|antidepressant
1120142|NCT01488253|Hematopoietic stem cell transplantation
1120143|NCT01488253|Graft vs Host disease
1120144|NCT01488253|Prevention
1120145|NCT01488253|Sirolimus
1120146|NCT01488253|Tacrolimus
1120147|NCT01488240|burn
1120148|NCT01488240|scar
1120149|NCT01488240|laser
1120150|NCT01488227|Vitamin D status in athletes
1120151|NCT01488227|Vitamin D
1120152|NCT01488227|25(OH)D
1120153|NCT01488227|athletes
1120154|NCT01488227|body composition
1120155|NCT01488227|inflammatory markers
1120156|NCT01488227|illness
1120157|NCT01488227|injury
1120158|NCT01488214|Systemic Sclerosis
1120159|NCT01488214|neuropsychiatric manifestations
1120160|NCT01488214|magnetic resonance imaging
1120161|NCT01488201|Psoriasis
1120162|NCT01488188|Influenza vaccine
1120163|NCT01488188|nasal route
1120164|NCT01488188|sublingual route
1120165|NCT01488188|immunogenicity
1120166|NCT01488188|safety
1120167|NCT01488175|TKA
1120168|NCT01488175|RSA
1120169|NCT01488175|Tourniquet
1120170|NCT01488175|Arthroplasty
1120171|NCT01488175|Knee
1120172|NCT01488149|Fentanyl
1120173|NCT01488149|Bupivacaine
1120174|NCT01488149|Nalbuphine
1120175|NCT01488136|Type 1 diabetes
1120176|NCT01488136|Hypoglycaemia
1120177|NCT01488136|Diazoxide
1120178|NCT01488123|Breast, Cancer, Survivorship, Integrative, Complementary
1120179|NCT01488097|Enzyme Replacement Therapy (ERT)
1120180|NCT01488097|Lysosomal Storage Disease
1120181|NCT01488097|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
1120182|NCT01488097|Acid cholesteryl ester hydrolase deficiency, type 2
1120183|NCT01488097|Acid lipase disease
1120184|NCT01488097|Cholesterol ester hydrolase deficiency
1120185|NCT01488097|LAL Deficiency
1120186|NCT01488097|LIPA Deficiency
1120187|NCT01488097|Wolman disease
1120188|NCT01488084|Saphenous vein graft patency
1120189|NCT01488084|Coronary artery bypass surgery
1120190|NCT01488084|Coronary artery disease
1120191|NCT01488071|Depression
1120192|NCT01488071|Multimodal antidepressant
1120193|NCT01488045|Colonoscopy
1120194|NCT01488045|Propofol
1120195|NCT01488045|Cancer Screening
1120196|NCT01488006|Primary Glenohumeral Osteoarthritis
1120197|NCT01488006|Total shoulder arthroplasty
1120198|NCT01488006|Total shoulder replacement
1120199|NCT01488006|Osteoarthritis
1120200|NCT01488006|Multicenter study
1120201|NCT01487993|Obesity
1120202|NCT01487993|Children
1120203|NCT01487993|Adolescents
1120204|NCT01487993|Metformin
1120205|NCT01487993|Insulin resistance
1120206|NCT01487967|Attention Deficit Hyperactivity Disorder
1120207|NCT01487967|ADHD
1120208|NCT01487967|Preferences
1120209|NCT01487967|Goals
1120210|NCT01487967|Decision Making
1120211|NCT01487954|skin reactions secondary to radiation therapy
1120212|NCT01487928|breastfed
1120213|NCT01487928|human milk cream
1120214|NCT01487928|human milk fat
1120215|NCT01487928|caloric supplement
1120216|NCT01487915|Cisplatin-unfit condition
1120217|NCT01487902|Chemotherapy-naive
1120218|NCT01487876|DNA vaccine
1120219|NCT01487876|HBV
1120220|NCT01487876|Chronic hepatitis B (CHB)
1120221|NCT01487876|T-cell
1120222|NCT01487863|prostate cancer
1120223|NCT01487863|prostate
1120224|NCT01487863|androgen independent prostate cancer (AIPC)
1120225|NCT01487863|androgen-independent
1120226|NCT01487863|androgen independent
1120227|NCT01487863|hormone insensitive
1120228|NCT01487863|hormone-insensitive
1120229|NCT01487863|prostate specific antigen (PSA)
1120230|NCT01487863|prostatic adenocarcinoma
1120231|NCT01487863|hormone-refractory
1120232|NCT01487863|hormone refractory
1120233|NCT01487863|hormone refractory prostate cancer (HRPC)
1120234|NCT01487863|immune therapy
1120235|NCT01487863|immunotherapy
1120236|NCT01487863|vaccine
1120237|NCT01487863|dendritic cells
1120238|NCT01487863|antigen-presenting cells
1120239|NCT01487863|antigen presenting cells
1120240|NCT01487863|cancer vaccine
1120241|NCT01487863|therapeutic vaccine
1120242|NCT01487863|therapeutic cancer vaccine
1120243|NCT01487863|recombinant
1120244|NCT01487863|biological
1120245|NCT01487863|biopharmaceutical
1120246|NCT01487863|biotechnology
1120247|NCT01487863|biotech
1120248|NCT01487863|castration resistant prostate cancer (CRPC)
1120249|NCT01487863|castration-resistant prostate cancer (CRPC)
1120250|NCT01487863|castration-resistance
1120251|NCT01487863|sipuleucel-T
1120252|NCT01487863|abiraterone
1120253|NCT01487863|prednisone
1120254|NCT01487863|sequence
1120255|NCT01487863|sequencing
1120256|NCT01487850|wind instruments
1120257|NCT01487850|molds
1120258|NCT01487850|hypersensitivity pneumonitis
1120259|NCT01487850|fungal contamination of wind instruments
1120260|NCT01487850|specific antibodies against molds in musicians' sera
1120261|NCT01487850|musicians
1120262|NCT01487837|Fibrinogen
1120263|NCT01487837|Blood coagulation disorders
1120264|NCT01487837|Postoperative bleeding
1120265|NCT01487837|Transfusions
1120266|NCT01487785|metastatic pancreatic cancer
1120267|NCT01487785|LDE225
1120268|NCT01487785|gemcitabine
1120269|NCT01487785|locally advanced
1120270|NCT01487785|adenocarcinoma
1120271|NCT01487746|APLA
1120272|NCT01487746|APS
1120273|NCT01487746|Stroke
1120274|NCT01487746|minor anti body
1120275|NCT01487746|major anti body
1120276|NCT01487746|APLA antibodies in Serum
1120277|NCT01487733|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1120278|NCT01487733|metastatic squamous neck cancer with occult primary
1120279|NCT01487733|recurrent metastatic squamous neck cancer with occult primary
1120280|NCT01487733|recurrent squamous cell carcinoma of the hypopharynx
1120281|NCT01487733|recurrent squamous cell carcinoma of the larynx
1120282|NCT01487733|recurrent squamous cell carcinoma of the lip and oral cavity
1120283|NCT01487733|recurrent squamous cell carcinoma of the nasopharynx
1120284|NCT01487733|recurrent squamous cell carcinoma of the oropharynx
1120285|NCT01487733|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1120286|NCT01487733|salivary gland squamous cell carcinoma
1120287|NCT01487733|stage III squamous cell carcinoma of the hypopharynx
1120288|NCT01487733|stage III squamous cell carcinoma of the larynx
1120289|NCT01487733|stage III squamous cell carcinoma of the lip and oral cavity
1120290|NCT01487733|stage III squamous cell carcinoma of the nasopharynx
1120291|NCT01487733|stage III squamous cell carcinoma of the oropharynx
1120409|NCT01487356|withdrawal time
1120292|NCT01487733|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1120293|NCT01487733|stage IV squamous cell carcinoma of the hypopharynx
1120294|NCT01487733|stage IVA squamous cell carcinoma of the larynx
1120295|NCT01487733|stage IVA squamous cell carcinoma of the lip and oral cavity
1120296|NCT01487733|stage IVA squamous cell carcinoma of the oropharynx
1120297|NCT01487733|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
1120298|NCT01487733|stage IVB squamous cell carcinoma of the larynx
1120299|NCT01487733|stage IVB squamous cell carcinoma of the lip and oral cavity
1120300|NCT01487733|stage IVB squamous cell carcinoma of the oropharynx
1120301|NCT01487733|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
1120302|NCT01487733|stage IVC squamous cell carcinoma of the larynx
1120303|NCT01487733|stage IVC squamous cell carcinoma of the lip and oral cavity
1120304|NCT01487733|stage IVC squamous cell carcinoma of the oropharynx
1120305|NCT01487733|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
1120306|NCT01487733|recurrent salivary gland cancer
1120307|NCT01487733|stage III salivary gland cancer
1120308|NCT01487733|stage IVA salivary gland cancer
1120309|NCT01487733|stage IVB salivary gland cancer
1120310|NCT01487733|stage IVC salivary gland cancer
1120311|NCT01487720|Castration-resistant prostate cancer
1120312|NCT01487720|Docetaxel-refractory status
1120313|NCT01487707|pregnancy
1120314|NCT01487707|maternal mortality
1120315|NCT01487707|neonatal mortality
1120316|NCT01487707|community intervention
1120317|NCT01487707|voluntary health worker
1120318|NCT01487707|safe birth kit
1120319|NCT01487707|maternal child health
1120320|NCT01487694|back cohosh
1120321|NCT01487694|cimicifuga racemosa
1120322|NCT01487694|menopausal symptoms
1120323|NCT01487694|hot flashes
1120324|NCT01487694|Kupperman index
1120325|NCT01487694|MENQOL
1120326|NCT01487668|chronic mental disorders
1120327|NCT01487668|cardiovascular disease
1120328|NCT01487668|behavior change
1120329|NCT01487655|Open-angle glaucoma
1120330|NCT01487655|Low tension glaucoma
1120331|NCT01487655|Color Doppler Imaging
1120332|NCT01487629|Diabetic Retinopathy
1120333|NCT01487629|Macular Edema
1120334|NCT01487629|Bevacizumab
1120335|NCT01487629|Ranibizumab
1120336|NCT01487616|Mullerian anomalies
1120337|NCT01487616|Congenital uterine malformations or anomalies
1120338|NCT01487616|Arcuate
1120339|NCT01487616|Septate
1120340|NCT01487616|Subseptate
1120341|NCT01487616|Bicornuate
1120342|NCT01487616|Unicornuate
1120343|NCT01487616|Didelphys
1120344|NCT01487616|T-shaped
1120345|NCT01487603|Patients
1120346|NCT01487603|undiagnosed enlarged
1120347|NCT01487603|lymph nodes
1120348|NCT01487590|pregnancy
1120349|NCT01487590|breech
1120350|NCT01487590|acupuncture
1120351|NCT01487590|moxibustion
1120352|NCT01487590|version
1120353|NCT01487577|Allogeneic blood and marrow transplantation (BMT)
1120354|NCT01487577|Graft versus host disease
1120355|NCT01487577|Mycophenolate mofetil
1120356|NCT01487577|Pharmacokinetics
1120357|NCT01487564|Healthy volunteers
1120358|NCT01487564|Pharmacokinetics
1120359|NCT01487564|OROS Hydromorphone
1120360|NCT01487564|Hydromorphone
1120361|NCT01487564|Taiwan
1120362|NCT01487564|UGT2B7 Gene
1120363|NCT01487551|Systemic sclerosis
1120364|NCT01487551|Biomarkers
1120365|NCT01487525|symptomatic knee osteoarthritis
1120366|NCT01487525|partial blood flow restriction
1120367|NCT01487525|knee extensor strength
1120368|NCT01487512|Healthy Volunteers
1120369|NCT01487512|Dose Proportionality
1120370|NCT01487512|Pharmacokinetics
1120371|NCT01487512|OROS Hydromorphone
1120372|NCT01487512|Hydromorphone
1120373|NCT01487512|Taiwan
1120374|NCT01487486|Polycystic Ovary Syndrome
1120375|NCT01487486|PCOS
1120376|NCT01487486|Follicular Fluid
1120377|NCT01487486|Proteomics
1120378|NCT01487486|Glyco-proteomics
1120379|NCT01487473|Meditation
1120380|NCT01487473|Mindfulness
1120381|NCT01487473|Attention
1120382|NCT01487473|Chronic Pain
1120383|NCT01487473|Depression
1120384|NCT01487473|Anxiety
1120385|NCT01487473|Stress
1120386|NCT01487473|Acceptance
1120387|NCT01487473|Pain intensity
1120388|NCT01487473|Pain disability
1120389|NCT01487460|High cholesterol levels
1120390|NCT01487460|Hyperlipidemia
1120391|NCT01487460|High-density Lipoprotein
1120392|NCT01487460|Low-density Lipoprotein
1120393|NCT01487460|Simvastatin
1120394|NCT01487434|Attendance
1120395|NCT01487434|Truancy
1120396|NCT01487434|Student engagement
1120397|NCT01487434|Mentoring
1120398|NCT01487434|Monitoring
1120399|NCT01487434|Case management
1120400|NCT01487395|Alzheimer
1120401|NCT01487395|Donepezil
1120402|NCT01487395|biomarkers
1120403|NCT01487395|battery
1120404|NCT01487395|cognition
1120405|NCT01487395|imaging
1120406|NCT01487395|neurophysiological
1120407|NCT01487356|Colonoscopy
1120408|NCT01487356|quality assurance
1120410|NCT01487356|polyp detection rate
1120411|NCT01487343|Oral Chemotherapy
1120412|NCT01487343|capecitabine
1120413|NCT01487343|questionnaire
1120414|NCT01487343|breast
1120415|NCT01487343|gastric
1120416|NCT01487343|11-194
1120417|NCT01487330|aortic stenosis
1120418|NCT01487330|aortic valve stenosis
1120419|NCT01487330|valvular heart disease
1120420|NCT01487330|aortic valve replacement
1120421|NCT01487330|transcatheter aortic valve implantation
1120422|NCT01487330|TAVI
1120423|NCT01487330|TAVR
1120424|NCT01487317|Delirium
1120425|NCT01487317|acetylcholinesterase inhibitor
1120426|NCT01487317|Elderly
1120427|NCT01487317|Emergency department
1120428|NCT01487291|Thrombophilia tests
1120429|NCT01487291|Hypofibrinolysis
1120430|NCT01487291|Fibrinolysis
1120431|NCT01487278|postpartum hemorrhage
1120432|NCT01487278|prevention
1120433|NCT01487278|misoprostol
1120434|NCT01487278|Uniject
1120435|NCT01487278|oxytocin
1120436|NCT01487265|Erlotinib
1120437|NCT01487265|BKM120
1120438|NCT01487265|NSCLC
1120439|NCT01487226|Cervical cancer
1120440|NCT01487213|Medical abortion
1120441|NCT01487213|Termination of pregnancy
1120442|NCT01487213|Mifepristone
1120443|NCT01487213|Misoprostol
1120444|NCT01487213|Urine hCG
1120445|NCT01487213|Follow Up
1120446|NCT01487213|Termination of unwanted pregnancy. Self assessment (follow up) after medical abortion
1120447|NCT01487200|Osteoarthritis
1120448|NCT01487200|Knee
1120449|NCT01487200|Steroid
1120450|NCT01487200|intra-articular
1120451|NCT01487200|injection
1120452|NCT01487187|Cord-milking
1120453|NCT01487187|hemodynamic
1120454|NCT01487187|preterm infants
1120455|NCT01487161|Osteoarthritis
1120456|NCT01487161|Knee
1120457|NCT01487161|pain
1120458|NCT01487161|steroid
1120459|NCT01487161|intra-articular
1120460|NCT01487161|injection
1120461|NCT01487135|Thorough QT (TQT)
1120462|NCT01487135|EVP-6124
1120463|NCT01487122|Diathermy
1120464|NCT01487122|Neck Pain
1120465|NCT01487109|Type 2 diabetes
1120466|NCT01487109|chronic kidney disease
1120467|NCT01487083|schizophrenia
1120468|NCT01487083|LY2140023
1120469|NCT01487083|pomaglumetad methionil
1120470|NCT01487057|thyroid cancer
1120471|NCT01487057|dislipidemia
1120472|NCT01487057|cardiovascular risk
1120473|NCT01487044|DME
1120474|NCT01487031|Autologous Stem Cell Transplantation
1120475|NCT01487031|multiple myeloma
1120476|NCT01487031|non-Hodgkin
1120477|NCT01487031|Hodgkin lymphoma
1120478|NCT01487031|Music Therapy
1120479|NCT01487031|Nausea
1120480|NCT01487031|Pain
1120481|NCT01487018|Zygomatic Fractures
1120482|NCT01487018|Surgery, Computer-Assisted
1120483|NCT01487018|Facial Asymmetry
1120484|NCT01487005|ozone
1120485|NCT01487005|air pollution
1120486|NCT01487005|vascular function
1120487|NCT01487005|cardiac function
1120488|NCT01487005|inflammation
1120489|NCT01486953|respiratory resistance
1120490|NCT01486953|lung compliance
1120491|NCT01486953|desflurane
1120492|NCT01486953|sevoflurane
1120493|NCT01486836|Cardiac disease (ICD indication)
1120494|NCT01486810|cocaine
1120495|NCT01486810|lisdexamfetamine
1120496|NCT01486797|Relapsed Chronic Lymphocytic Leukemia (CLL)
1120497|NCT01486797|NOX-A12
1120498|NCT01486797|Bendamustine
1120499|NCT01486797|Rituximab
1120500|NCT01486797|Spiegelmer
1120501|NCT01486797|Chemosensitization
1120502|NCT01486797|Stromal cell-derived factor-1 (SDF-1)
1120503|NCT01486797|CXCL12
1120504|NCT01486784|equal to or greater than age 60 years
1120505|NCT01486784|non-M3 AML
1120506|NCT01486784|relapsed disease
1120507|NCT01486784|primary refractory disease
1120508|NCT01486784|not appropriate or willing candidates for aggressive therapy
1120509|NCT01486784|AML
1120510|NCT01486771|Proliferative Diabetic Retinopathy
1120511|NCT01486732|Cerebral Palsy
1120512|NCT01486732|Umbilical Cord Blood
1120513|NCT01486732|FLT-PET
1120514|NCT01486719|Finger pulp reconstruction
1120515|NCT01486719|dorsal branch
1120516|NCT01486719|proper digital nerve
1120517|NCT01486719|palmar arterial arch
1120518|NCT01486719|dorsal digital island flap
1120519|NCT01486706|Overactive Bladder
1120520|NCT01486706|Gabapentin
1120521|NCT01486706|Quality of Life
1120522|NCT01486706|Urodynamic
1120523|NCT01486706|safety
1120524|NCT01486706|Efficacy
1120525|NCT01486693|cytomegalovirus
1120526|NCT01486693|uveitis
1120527|NCT01486680|Gastric bypass
1120528|NCT01486680|Silastic ring gastric bypass
1120529|NCT01486680|Roux-en-Y gastric bypass
1120530|NCT01486680|Sleeve gastrectomy
1120531|NCT01486680|Body composition analysis
1120532|NCT01486667|focus of study instead
1120533|NCT01486654|Cortical stimulation
1120534|NCT01486654|Ischemic Stroke
1120535|NCT01486654|Aphasia
1120536|NCT01486654|Speech and Language Rehabilitation
1120537|NCT01486641|femoral neck fracture
1120538|NCT01486641|arthroplasty
1120539|NCT01486641|surgical approach
1120540|NCT01486641|anterolateral
1120541|NCT01486641|posterolateral
1120542|NCT01486615|premedication
1120543|NCT01486615|premedicants
1120544|NCT01486615|preoperative anxiety
1120545|NCT01486615|melatonin
1120546|NCT01486615|alprazolam
1120549|NCT01486589|emergency care
1120550|NCT01486589|cardiac autonomic function
1120551|NCT01486589|deceleration capacity
1120552|NCT01486537|samples
1120553|NCT01486537|children
1120554|NCT01486537|the age group 3-13 years
1120555|NCT01486524|pharmacogenomic biomarker
1120556|NCT01486524|predictive marker
1120557|NCT01486524|prospective-retrospective
1120558|NCT01486524|propensity score
1120559|NCT01486524|matched-patients trial
1120560|NCT01486511|Liver disease
1120561|NCT01486511|Pulmonary embolism
1120562|NCT01486511|Thrombophilia
1120563|NCT01486511|Death
1120564|NCT01486485|renal replacement therapy
1120565|NCT01486472|Adjuvant chemotherapy
1120566|NCT01486446|IEM
1120567|NCT01486446|EM
1120568|NCT01486446|Erythromelalgia
1120569|NCT01486446|Erythermalgia
1120570|NCT01486446|Red neuralgia
1120571|NCT01486446|Peripheral Vascular Disease
1120572|NCT01486446|Vascular Disease
1120573|NCT01486446|Cardiovascular Disease
1120574|NCT01486433|eicosapentaenoic acid
1120575|NCT01486433|docosapentaenoic acid
1120576|NCT01486433|arachidonic acid
1120577|NCT01486433|hypertriglyceridemia
1120578|NCT01486433|simvastatin
1120579|NCT01486420|Quinell grade
1120580|NCT01486420|Open surgery
1120581|NCT01486420|corticosteroid injections
1120582|NCT01486420|randomized controlled trial
1120583|NCT01486420|Trigger finger
1120584|NCT01486407|Airway management
1120585|NCT01486355|Mortality
1120586|NCT01486355|Morbidity
1120587|NCT01486355|Hospitalisations/consultations
1120588|NCT01486355|Growth
1120589|NCT01486355|Measles infection
1120590|NCT01486329|Pancreatic cancer
1120591|NCT01486329|Cancer vaccine
1120592|NCT01486329|Gemcitabine
1120593|NCT01486329|Inoperable
1120594|NCT01486329|Gemcitabine chemotherapy
1120595|NCT01486329|Locally advanced
1120596|NCT01486303|Facial Cosmetic acupuncture
1120597|NCT01486303|Skin Rejuvenation
1120598|NCT01486303|Skin Aging
1120599|NCT01486290|Intervention
1120600|NCT01486290|Cost Effective
1120601|NCT01486290|Elderly
1120602|NCT01486290|Glycemic Control
1120603|NCT01486277|Lymphoma, T-Cell, Cutaneous
1120604|NCT01486277|T-cell lymphoma
1120605|NCT01486277|Lymphoma
1120606|NCT01486277|Histone Deacetylase Inhibitor
1120607|NCT01486277|JNJ-26481585
1120608|NCT01486238|Diabetic Macular Edema
1120609|NCT01486212|Ischemia-reperfusion injury
1120610|NCT01486212|Oxidative markers
1120611|NCT01486212|Inflammatory markers
1120612|NCT01486199|cystic fibrosis
1120613|NCT01486199|mucociliary clearance
1120614|NCT01486199|airway surface liquid
1120615|NCT01486199|nuclear medicine
1120616|NCT01486186|Pulmonary Disease, Chronic Obstructive
1120617|NCT01486186|Double-Blind Method
1120618|NCT01486186|Medicine, Chinese Traditional
1120619|NCT01486186|Humans
1120620|NCT01486186|Treatment Outcome
1120621|NCT01486173|PUFA
1120622|NCT01486173|Iron
1120623|NCT01486173|Neurological development
1120624|NCT01486173|Premature infant
1120625|NCT01486147|Food labeling
1120626|NCT01486147|Nutrition
1120627|NCT01486147|Memory
1120628|NCT01486147|Diet
1120629|NCT01486134|Hepatocellular carcinoma
1120630|NCT01486134|Radiofrequency ablation
1120631|NCT01486134|Multipolar mode
1120632|NCT01486134|Recurrence
1120633|NCT01486134|Cirrhosis
1120634|NCT01486134|MR temperature monitoring
1120635|NCT01486134|large tumor
1120636|NCT01486121|Surgery
1120637|NCT01486121|Critical illness
1120638|NCT01486121|Mechanical ventilation
1120639|NCT01486121|Organ dysfunction syndrome
1120640|NCT01486121|Intensive Care Units Sedation
1120641|NCT01486121|Analgesia
1120642|NCT01486121|Treatment protocol
1120643|NCT01486121|Nursing protocol
1120644|NCT01486121|Outcome
1120645|NCT01486121|Pain
1120646|NCT01486121|Neurological disorders
1120647|NCT01486121|Delirium
1120648|NCT01486121|Muscular weakness
1120649|NCT01486121|Psychological disorders
1120650|NCT01486121|Anxiety
1120651|NCT01486121|Depression
1120652|NCT01486121|Stress disorders
1120653|NCT01486121|Post-Traumatic
1120654|NCT01486108|tonic, burst and placebo stimulation
1120655|NCT01486082|OCA 10
1120656|NCT01486082|Antibiogram
1120657|NCT01486082|Eradication
1120658|NCT01486069|Dentofacial Deformity
1120659|NCT01486069|Orthognathic Surgery
1120660|NCT01486069|Mandible
1120661|NCT01486069|Orthognathic Surgical Procedures
1120662|NCT01486056|epilepsy
1120663|NCT01486056|ECG
1120664|NCT01486056|device placement
1120665|NCT01486043|Induction chemotherapy
1120666|NCT01486043|Transient hyperglycemia
1120667|NCT01486043|Metformin
1120668|NCT01486043|Acute lymphoblastic leukemia
1120669|NCT01486043|Insulin resistance
1120670|NCT01486043|Hyperglycemia
1120671|NCT01486043|Insulin
1120672|NCT01486030|Atherosclerosis
1120673|NCT01486017|ASP015K
1120674|NCT01486017|healthy subjects
1120675|NCT01486017|bioavailability
1120676|NCT01486017|rheumatoid arthritis
1120677|NCT01486017|psoriasis
1120678|NCT01486017|transplantation
1120679|NCT01486004|Hepatitis C Virus
1120680|NCT01486004|TMC435
1120681|NCT01486004|TMC435-TiDP16-C124
1120682|NCT01486004|TMC435-C124
1120683|NCT01486004|HCV
1120684|NCT01486004|Hepatitis C
1120685|NCT01486004|Hep C
1120686|NCT01486004|Healthy participants
1120687|NCT01485991|Hepatitis C
1120688|NCT01485991|TMC435HPC3001
1120689|NCT01485991|TMC435
1120690|NCT01485991|Hepatitis C Virus (HCV)
1120691|NCT01485991|HEP C
1120692|NCT01485991|Genotype 1
1120693|NCT01485991|Treatment experienced
1120694|NCT01485991|Null responders
1120695|NCT01485991|Partial responders
1120696|NCT01485978|Alport Syndrome
1120697|NCT01485978|chronic kidney disease
1120698|NCT01485978|renal fibrosis
1120699|NCT01485978|nephroprotection
1120700|NCT01485978|pediatric study
1120701|NCT01485965|Huntington Disease
1120702|NCT01485965|Basal Ganglia Diseases
1120703|NCT01485965|Brain Diseases
1120704|NCT01485965|Central Nervous System Diseases
1120705|NCT01485965|Nervous System Diseases
1120706|NCT01485965|Dementia
1120707|NCT01485965|Chorea
1120708|NCT01485965|Dyskinesias
1120709|NCT01485965|Movement Disorders
1120710|NCT01485965|Heredodegenerative Disorders, Nervous System
1120711|NCT01485965|Neurodegenerative Diseases
1120712|NCT01485965|Genetic Diseases, Inborn
1120713|NCT01485965|Cognition Disorders
1120714|NCT01485965|Mental Disorders
1120715|NCT01485952|Huntington Disease
1120716|NCT01485952|Basal Ganglia Diseases
1120717|NCT01485952|Brain Diseases
1120718|NCT01485952|Central Nervous System Diseases
1120719|NCT01485952|Nervous System Diseases
1120720|NCT01485952|Dementia
1120721|NCT01485952|Chorea
1120722|NCT01485952|Dyskinesias
1120723|NCT01485952|Movement Disorders
1120724|NCT01485952|Heredodegenerative Disorders, Nervous System
1120725|NCT01485952|Neurodegenerative Diseases
1120726|NCT01485952|Genetic Diseases, Inborn
1120727|NCT01485952|Cognition Disorders
1120728|NCT01485952|Mental Disorders
1120729|NCT01485939|lidocaine patch
1120730|NCT01485939|laparoscopic cholecystectomy
1120731|NCT01485913|Education
1120732|NCT01485913|Diabetes
1120733|NCT01485913|Prevention complications
1120734|NCT01485913|Prevention of complications of diabetes
1120735|NCT01485887|Venlafaxine ER
1120736|NCT01485887|long-term extension
1120737|NCT01485887|Japan
1120738|NCT01485874|BIBF 1120
1120739|NCT01485835|Multiple Myeloma
1120740|NCT01485835|Bortezomib
1120741|NCT01485835|Velcade
1120742|NCT01485835|Ganetespib
1120743|NCT01485822|Glaucoma
1120744|NCT01485822|Travatan
1120745|NCT01485822|Trabeculectomy
1120746|NCT01485796|PIDD
1120747|NCT01485783|Hypertension
1120748|NCT01485757|patients
1120749|NCT01485744|metastatic
1120750|NCT01485744|untreated
1120751|NCT01485744|advanced
1120752|NCT01485731|Cervical
1120753|NCT01485731|Cancer
1120754|NCT01485731|Uterine Cervix
1120755|NCT01485731|Squamous Cell
1120756|NCT01485731|Adenocarcinoma
1120757|NCT01485718|Obesity
1120758|NCT01485718|Overweight
1120759|NCT01485718|Weight loss
1120760|NCT01485705|severe bacterial infection
1120761|NCT01485692|Violence
1120762|NCT01485692|Aggression
1120763|NCT01485692|Psychiatric emergencies
1120764|NCT01485692|Psychomotor agitation
1120765|NCT01485692|Violent patient
1120766|NCT01485679|18 fluoro deoxy glucose positrons emission tomography combined with computed tomography,
1120767|NCT01485679|Patients with intraductal papillary mucinous tumor of the pancreas
1120768|NCT01485679|intraductal papillary mucinous
1120769|NCT01485679|pancreas
1120770|NCT01485666|Thoratec
1120771|NCT01485666|HeartMate II
1120772|NCT01485666|heart-assist devices
1120773|NCT01485666|driveline or percutaneous lead management
1120774|NCT01485666|HeartMate II Percutaneous Lead Management
1120775|NCT01485653|Brachial Plexus
1120776|NCT01485653|Mepivacaine
1120777|NCT01485653|Ultrasound
1120778|NCT01485653|Axillary
1120779|NCT01485653|Block
1120780|NCT01485640|Schizophrenia
1120781|NCT01485640|bipolar disorder
1120782|NCT01485640|Lurasidone
1120783|NCT01485640|Latuda
1120784|NCT01485627|Cancer
1120785|NCT01485627|Communication
1120786|NCT01485627|prognosis
1120787|NCT01485575|Chromovitrectomy
1120788|NCT01485575|Indocyanine green
1120789|NCT01485575|ICG
1120790|NCT01485575|Brilliant Blue G
1120791|NCT01485575|BBG
1120792|NCT01485575|Trypan blue
1120793|NCT01485575|TB
1120794|NCT01485575|Internal limiting membrane
1120795|NCT01485575|ILM
1120796|NCT01485562|postpartum haemorrhage
1120797|NCT01485562|misoprostol
1120798|NCT01485562|treatment
1120799|NCT01485562|prophylaxis
1120800|NCT01485562|home births
1120801|NCT01485549|Multiple system atrophy (MSA)
1120802|NCT01485549|alpha-synucleinopathies
1120803|NCT01485549|biological markers
1120804|NCT01485549|cerebrospinal fluid
1120805|NCT01485549|plasma
1120806|NCT01485536|Lymphoma
1120807|NCT01485536|Relapsed/refractory lymphoma
1120808|NCT01485536|AUY922
1120809|NCT01485523|Allergic rhinitis
1120810|NCT01485523|Nasal provocation test
1120811|NCT01485510|Maltreatment
1120812|NCT01485510|Infant Mental Health
1120813|NCT01485510|Infant mental health in maltreated children
1120814|NCT01485497|APNEA
1120815|NCT01485471|Middle Ear Infection
1120816|NCT01485458|Incomplete spinal cord injury
1120817|NCT01485458|Cervical canal stenosis
1120818|NCT01485458|Ossification of the posterior longitudinal ligament
1120819|NCT01485458|Surgery
1120820|NCT01485458|Decompression
1120821|NCT01485445|bioequivalence
1120822|NCT01485445|pharmacokinetics
1120823|NCT01485445|Fluticasone Furoate
1120824|NCT01485445|Vilanterol
1120825|NCT01485432|Renal transplant surgery
1120826|NCT01485432|hemodynamic management
1120827|NCT01485432|PiCCO
1120828|NCT01485432|delayed graft function
1120829|NCT01485419|Sex hormones
1120830|NCT01485419|Testosterone
1120831|NCT01485419|Estradiol
1120832|NCT01485406|Haemophilus influenzae
1120833|NCT01485406|Safety
1120834|NCT01485406|Pneumococcal vaccine
1120835|NCT01485406|Streptococcus pneumoniae
1120836|NCT01485406|Immunogenicity
1120837|NCT01485406|Toddlers
1120838|NCT01485380|Dexmedetomidine
1120839|NCT01485380|Sleep
1120840|NCT01485380|MRI-PET
1120841|NCT01485380|EEG
1120842|NCT01485367|Senile Purpura
1120843|NCT01485367|Adapalene 0.3%
1120844|NCT01485354|stroke
1120845|NCT01485354|Armeo
1120846|NCT01485341|gluten sensitivity
1120847|NCT01485328|Dyspepsia
1120848|NCT01485328|Flatulence
1120849|NCT01485328|Aerophagia
1120850|NCT01485328|Constipation
1120851|NCT01485302|mild to moderate Alzheimer's Disease
1120852|NCT01485276|Parkinson's Disease
1120853|NCT01485276|Deep Brain Stimulation
1120854|NCT01485276|Gait
1120855|NCT01485276|Electrophysiology
1120856|NCT01485276|Parkinson Disease
1120857|NCT01485276|PD
1120858|NCT01485263|Deep Brain Stimulation
1120859|NCT01485263|OCD
1120860|NCT01485250|Healthy Volunteers
1120861|NCT01485250|Motivations
1120862|NCT01485250|Decision Making
1120863|NCT01485250|Motivation
1120864|NCT01485224|Hereditary hemorrhagic telangiectasia
1120865|NCT01485224|Epistaxis
1120866|NCT01485224|Thalidomide
1120867|NCT01485211|progressive keratoconus
1120868|NCT01485211|thin corneas
1120869|NCT01485211|cross-linking
1120870|NCT01485211|hypo-osmolar riboflavin
1120871|NCT01485198|osteoarthritis
1120872|NCT01485198|knee
1120873|NCT01485198|stem cell therapy
1120874|NCT01485198|bone marrow
1120875|NCT01485198|G-CSF
1120876|NCT01485185|Donepezil
1120877|NCT01485185|allodynia
1120878|NCT01485185|Gabapentin
1120879|NCT01485185|Sural nerve stimulation
1120880|NCT01485185|Electrical hyperalgesia
1120881|NCT01485159|prevalence
1120882|NCT01485159|COPD
1120883|NCT01485159|emphysema
1120884|NCT01485159|co-morbidities
1120885|NCT01485159|ischemic heart disease
1120886|NCT01485159|chronic bronchitis
1120887|NCT01485159|spirometry
1120888|NCT01485159|burden
1120889|NCT01485133|colonoscopy
1120890|NCT01485133|water
1120891|NCT01485133|surgery
1120892|NCT01485133|unsedated
1120893|NCT01485120|Blood pressure (low, normal, high)
1120894|NCT01485107|Ulthera® System
1120895|NCT01485107|Ultherapy™ treatment
1120896|NCT01485107|Ulthera, Inc.
1120897|NCT01485107|Ultrasound treatment for skin tightening
1120898|NCT01485094|neuralgia
1120899|NCT01485094|postherpetic
1120900|NCT01485081|Bifurcation
1120901|NCT01485081|Drug-eluting balloon
1120902|NCT01485081|Paclitaxel-eluting balloon
1120903|NCT01485081|Angioplasty
1120904|NCT01485081|Coronary artery disease
1120905|NCT01485081|Coronary artery stenosis
1120906|NCT01485068|Restenosis
1120907|NCT01485068|Paclitaxel-eluting balloon
1120908|NCT01485068|Angioplasty
1120909|NCT01485068|Coronary artery disease
1120910|NCT01485068|Coronary artery stenosis
1120911|NCT01485055|aGVHD
1120912|NCT01485055|GVHD
1120913|NCT01485055|Graft versus host disease
1120914|NCT01485055|Acute graft versus host disease
1120915|NCT01485055|Steroid refractory graft versus host disease
1120916|NCT01485055|Bone marrow transplant
1120917|NCT01485055|BMT
1120918|NCT01485055|HSCT
1120919|NCT01485055|infliximab
1120920|NCT01485055|basiliximab
1120921|NCT01485055|Monoclonal antibody treatment
1120922|NCT01485042|Phase 1
1120923|NCT01485042|pazopanib
1120924|NCT01485042|TH-302
1120925|NCT01485042|advanced solid tumors
1120926|NCT01485016|epilepsy
1120927|NCT01485016|ECG
1120928|NCT01485016|accelerometer
1120929|NCT01484990|Parkinson's Disease
1120930|NCT01484990|levodopa
1120931|NCT01484990|carbidopa
1120932|NCT01484990|Duodopa
1120933|NCT01484990|intestinal gel
1120934|NCT01484977|Lacosamide
1120935|NCT01484977|Epilepsy
1120936|NCT01484977|Levetiracetam
1120937|NCT01484977|Sodium Channel Blockers
1120938|NCT01484964|ASP015K
1120939|NCT01484964|healthy subjects
1120940|NCT01484964|bioavailability
1120941|NCT01484964|food effect
1120942|NCT01484964|rheumatoid arthritis
1120943|NCT01484964|psoriasis
1120944|NCT01484964|transplantation
1120945|NCT01484951|Open-angle glaucoma
1120946|NCT01484951|Ocular hypertension
1120947|NCT01484951|Pigment dispersion glaucoma
1120948|NCT01484938|Soft contact lenses
1120949|NCT01484938|Multi-purpose solution
1120950|NCT01484938|Corneal staining
1120951|NCT01484925|Barrett's esophagus
1120952|NCT01484912|Green tea polyphenols
1120953|NCT01484912|Chronic Stable Angina
1120954|NCT01484899|Pulmonary arterial Hypertension
1120955|NCT01484899|Chronic thromboembolic pulmonary hypertension
1120956|NCT01484899|smoking
1120957|NCT01484886|Hemoglobin
1120958|NCT01484886|Congenital heart disease
1120959|NCT01484886|Cardiac surgery
1120960|NCT01484886|Red blood cell transfusion
1120961|NCT01484886|Number of red blood cell transfusions
1120962|NCT01484873|Exenatide
1120963|NCT01484873|Byetta
1120964|NCT01484873|Hypothalamic Obesity
1120965|NCT01484873|Obesity
1120966|NCT01484873|Craniopharyngioma
1120967|NCT01484860|AUY922
1120968|NCT01484860|Pancreas
1120969|NCT01484860|Pancreatic cancer
1120970|NCT01484860|Adenocarcinoma of the pancreas
1120971|NCT01484860|Cancer of the pancreas
1120972|NCT01484860|Metastatic
1120973|NCT01484860|Advanced
1120974|NCT01484860|Advanced disease
1120975|NCT01484860|Prior systemic anticancer therapy
1120976|NCT01484847|advanced
1120977|NCT01484847|PF-00299804
1120978|NCT01484847|head and neck
1120979|NCT01484847|pharmacokinetic
1120980|NCT01484847|squamous cell carcinoma
1120981|NCT01484847|gastrojejunostomy
1120982|NCT01484847|feeding tube
1120983|NCT01484834|Physical Activity
1120984|NCT01484834|Occupational Health
1120985|NCT01484834|Quality of Life
1120986|NCT01484834|Health Promotion
1120987|NCT01484834|Workplace Place or physical location of work or employment
1120988|NCT01484834|Exercise Physical activity which is usually regular and done with the intention of improving or maintaining PHYSICAL FITNESS or HEALTH
1120989|NCT01484821|Sarcopenia
1120990|NCT01484821|ARFI
1120991|NCT01484821|DEXA
1120992|NCT01484821|Cancer
1120993|NCT01484808|PSA Density
1120994|NCT01484808|Prostate Cancer
1120995|NCT01484808|Prostate Biopsy
1120996|NCT01484808|PSA
1120997|NCT01484795|noninvasive ventilation
1120998|NCT01484795|autonomic nervous system
1120999|NCT01484782|Hypertension
1121000|NCT01484782|Telephone Care Management
1121001|NCT01484782|Blood pressure
1121002|NCT01484782|Medication adherence
1121003|NCT01484782|Interactive Voice Response (IVR)
1121004|NCT01484782|Cloud computing
1121005|NCT01484756|respiratory infection
1121006|NCT01484756|independent elderly
1121007|NCT01484756|zinc
1121008|NCT01484756|vitamins
1121009|NCT01484743|recurrence
1121010|NCT01484743|readmission
1121011|NCT01484743|reoperation
1121012|NCT01484743|mortality
1121013|NCT01484743|morbidity
1121014|NCT01484704|Carcinoma ductale mammae
1121015|NCT01484678|Duchenne Muscular Dystrophy
1121016|NCT01484678|Magnetic Resonance Imaging
1121017|NCT01484678|Magnetic Resonance Spectroscopy
1121018|NCT01484678|Muscle
1121019|NCT01484665|PSA screening
1121020|NCT01484665|Decision aids
1121021|NCT01484652|Moderate Post-Operative Pain
1121022|NCT01484652|Severe Post-Operative Pain
1121023|NCT01484652|Bunionectomy
1121024|NCT01484639|transfusion
1121025|NCT01484639|cardiac surgery
1121026|NCT01484626|Relapsed Multiple Myeloma
1121027|NCT01484626|Refractory Multiple Myeloma
1121028|NCT01484626|Bendamustine
1121029|NCT01484626|Bortezomib
1121030|NCT01484626|Lenalidomide
1121031|NCT01484626|Dexamethasone
1121032|NCT01484626|Treanda
1121033|NCT01484626|Velcade
1121034|NCT01484626|Revlimid
1121035|NCT01484613|Hear Failure
1121036|NCT01484613|Cardiac resynchronization
1121037|NCT01484613|CRT-D
1121038|NCT01484613|quadripolar
1121039|NCT01484600|Volunteers
1121040|NCT01484587|Moderate to Severe Plaque-Type Psoriasis
1121041|NCT01484587|Psoriasis
1121042|NCT01484587|Plaque-type psoriasis
1121043|NCT01484587|CNTO 1959
1121044|NCT01484587|Japanese participants
1121045|NCT01484574|Critical limb ischemia
1121046|NCT01484574|Buerger's disease
1121047|NCT01484574|Critical limb ischemia due to Buerger's disease
1121048|NCT01484561|Phase 1
1121049|NCT01484522|Influenza
1121050|NCT01484522|Perinatal
1121051|NCT01484522|immunogenicity
1121052|NCT01484522|Monovalent vaccine
1121053|NCT01484522|Children
1121054|NCT01484522|Youth
1121055|NCT01484522|H1N1
1121056|NCT01484522|Adolescent
1121057|NCT01484522|Flu
1121058|NCT01484509|walking impairment
1121059|NCT01484509|claudication
1121060|NCT01484509|treadmill
1121061|NCT01484509|questionnaire
1121062|NCT01484496|Subcutaneous
1121063|NCT01484496|Lupus
1121064|NCT01484496|Systemic Lupus Erythematosus
1121065|NCT01484496|SLE
1121066|NCT01484496|Belimumab
1121067|NCT01484496|Autoimmune Disease
1121068|NCT01484496|Antibodies
1121069|NCT01484470|Stem cell transplantation
1121070|NCT01484470|Stem Cell expansion
1121071|NCT01484470|Elderly
1121072|NCT01484457|Diabetes Mellitus
1121073|NCT01484457|Closed Loop
1121074|NCT01484457|Artificial Pancreas
1121075|NCT01484418|Chronic Low Back Pain
1121076|NCT01484418|Cognitive Behavioural Therapy
1121077|NCT01484418|Exposure
1121078|NCT01484418|Fear avoidance
1121079|NCT01484418|Cognitive Behavioural Therapy in chronic low back pain
1121080|NCT01484418|Exposure in vivo in chronic low back pain
1121081|NCT01484405|surgical approach for total hip arthroplasty
1121082|NCT01484392|open angle glaucoma
1121083|NCT01484392|compliance
1121084|NCT01484392|adherence
1121085|NCT01484379|Primary Hyperparathyroidism
1121086|NCT01484379|multigland disease
1121087|NCT01484379|neck exploration
1121088|NCT01484379|elderly
1121089|NCT01484366|fractures of both radius and ulna
1121090|NCT01484353|Diabetes
1121091|NCT01484340|smoking
1121092|NCT01484340|administration, cutaneous
1121093|NCT01484327|Heart Failure
1121094|NCT01484327|Acute Myocardial Infarction
1121095|NCT01484327|LVEF
1121096|NCT01484314|Relapsed
1121097|NCT01484301|Chronic pain
1121098|NCT01484301|Opioids
1121099|NCT01484301|Tolerability
1121100|NCT01484275|High-risk smoldering multiple myeloma
1121101|NCT01484275|Multiple myeloma
1121102|NCT01484275|Siltuximab
1121103|NCT01484249|embolic
1121104|NCT01484249|filters
1121105|NCT01484249|brachiocephalic
1121106|NCT01484249|neurovasculature
1121107|NCT01484249|debris
1121108|NCT01484236|Lymphangioleiomyomatosis
1121109|NCT01484223|Primary Health Care
1121110|NCT01484223|Somatization symptoms
1121111|NCT01484223|Cognitive Behavioral Therapy
1121112|NCT01484223|Nursing intervention
1121113|NCT01484197|Asthma
1121114|NCT01484197|Indacaterol
1121115|NCT01484197|QAB149
1121116|NCT01484184|Completely paralyzed
1121117|NCT01484184|Chronically injured
1121118|NCT01484184|Central Pattern Generator
1121119|NCT01484184|Locomotion
1121120|NCT01484184|Secondary complications
1121121|NCT01484184|Activity-based training
1121122|NCT01484184|Treadmill training
1121123|NCT01484184|Spinal cord injury
1121124|NCT01484184|Paraplegia
1121125|NCT01484184|Tetraplegia
1121126|NCT01484171|Acute Myeloid Leukemia
1121127|NCT01484171|idarubicin
1121128|NCT01484171|Microtransplantation
1121129|NCT01484158|Myocardial Infarction
1121130|NCT01484145|Onychomycosis
1121131|NCT01484145|Nail fungus
1121132|NCT01484145|Tinea Unguium
1121133|NCT01484132|Dental Caries
1121134|NCT01484132|Dental Restorative Materials
1121135|NCT01484132|Dental Composite
1121136|NCT01484132|Bisphenol-A
1121137|NCT01484119|seasonal allergic rhinitis
1121138|NCT01484093|CYCLOPHOSPHAMIDE (CYTOXAN)
1121139|NCT01484093|CYTARABINE (ARA-C)
1121140|NCT01484093|DOXORUBICIN/ADRIAMYCIN
1121141|NCT01484093|PREDNISONE
1121142|NCT01484093|RITUXIMAB
1121143|NCT01484093|TOSITUMOMAB (BEXXAR)
1121144|NCT01484093|Iodine
1121145|NCT01484093|VINCRISTIN
1121146|NCT01484093|Lymphoma
1121147|NCT01484093|Chemo-Radioimmunotherapy
1121148|NCT01484093|Autologous Transplantation
1121149|NCT01484093|Untreated
1121150|NCT01484093|11-095
1121151|NCT01484067|Herpes Simplex Virus
1121152|NCT01484041|Breast cancer
1121153|NCT01484041|postmenopausal
1121154|NCT01484002|Hip replacement
1121155|NCT01484002|Crosslinked and conventional polyethylene
1121156|NCT01484002|Oxidation
1121157|NCT01484002|Crosslink density
1121158|NCT01484002|Outcome
1121159|NCT01483989|Dry Eye
1121160|NCT01483989|Epithelial changes
1121161|NCT01483950|Dyslipidemia
1121162|NCT01483950|Statins
1121163|NCT01483950|Total Cholesterol
1121164|NCT01483950|Low density lipoprotein (LDL) cholesterol
1121165|NCT01483950|High density lipoprotein (HDL) cholesterol
1121166|NCT01483937|Keywords provided by BalanceSense, LLC:
1121167|NCT01483937|Physical Therapy
1121168|NCT01483937|Rehabilitation
1121169|NCT01483937|Disequilibrium
1121170|NCT01483937|Balance dysfunction or disorder
1121171|NCT01483937|Vestibular
1121172|NCT01483937|Mild Traumatic Brain Injury (mTBI)
1121173|NCT01483937|Vibrotactile
1121174|NCT01483924|Mild to Moderate Chronic Plaque Psoriasis
1121175|NCT01483898|critical limb ischemia
1121176|NCT01483898|REVIVE
1121177|NCT01483898|peripheral vascular disease
1121178|NCT01483898|CLI
1121179|NCT01483898|PAD
1121180|NCT01483898|MSC
1121181|NCT01483898|stem cells
1121182|NCT01483898|cell therapy
1121183|NCT01483872|salvage infected hemodialysis catheters
1121184|NCT01483872|novel catheter lock solution
1121185|NCT01483846|Neuropathic Pain
1121186|NCT01483846|Capsaicin Induced Pain
1121187|NCT01483807|speech
1121188|NCT01483807|speech therapy
1121189|NCT01483807|apraxia of speech
1121190|NCT01483794|genital warts
1121191|NCT01483781|Diabetes Mellitus, Type 2
1121192|NCT01483781|Plasma Volume
1121193|NCT01483781|Canagliflozin
1121194|NCT01483781|Metformin
1121195|NCT01483781|Hemoglobin A1c
1121196|NCT01483781|Hypertension
1121197|NCT01483781|Angiotensin-Converting Enzyme Inhibitors (ACEIs)
1121198|NCT01483781|Angiotensin Receptor Blockers (ARBs)
1121199|NCT01483781|Pharmacodynamics
1121200|NCT01483781|Pharmacokinetics
1121201|NCT01483768|Sleeve gastrectomy
1121202|NCT01483768|Obesity surgery
1121203|NCT01483768|Iron deficiency
1121204|NCT01483768|HEPCIDINE
1121205|NCT01483755|Myocardial infarction
1121206|NCT01483755|Postconditioning
1121207|NCT01483690|Relapse
1121208|NCT01483690|Lymphoblastic
1121209|NCT01483690|Leukemia
1121210|NCT01483690|Decitabine
1121211|NCT01483690|Vorinostat
1121212|NCT01483690|Refractory
1121213|NCT01483690|Acute
1121214|NCT01483690|Childhood
1121215|NCT01483690|Pediatric
1121216|NCT01483690|ALL
1121217|NCT01483677|Laparoscopy
1121218|NCT01483677|video games
1121219|NCT01483677|Nintendo Wii
1121220|NCT01483677|Playstation
1121221|NCT01483664|patient outcomes
1121222|NCT01483664|Survivorship
1121223|NCT01483664|Communication Skills
1121224|NCT01483664|Communication strategies
1121225|NCT01483664|Physicians communication
1121226|NCT01483664|11-180
1121227|NCT01483651|diabetes
1121228|NCT01483651|glucagon
1121229|NCT01483651|insulin
1121230|NCT01483651|dideuterated glucose
1121231|NCT01483638|duration of disease response
1121232|NCT01483638|axitinib
1121233|NCT01483612|Body Weight
1121234|NCT01483612|Female
1121235|NCT01483612|Infertility, Female/therapy
1121236|NCT01483612|Infertility, Female/physiopathology
1121237|NCT01483612|Obesity/physiopathology
1121238|NCT01483612|Polycystic ovary syndrome
1121239|NCT01483612|Pregnancy
1121240|NCT01483612|Pregnancy Outcome
1121241|NCT01483612|Weight Loss
1121242|NCT01483599|Moderate to Severe Plaque-Type Psoriasis
1121243|NCT01483599|Psoriasis
1121244|NCT01483599|Plaque-type psoriasis
1121245|NCT01483599|CNTO 1959
1121246|NCT01483599|adalimumab
1121247|NCT01483573|low back pain
1121248|NCT01483573|straight leg raise
1121249|NCT01483560|REMOVAL
1121250|NCT01483560|metformin
1121251|NCT01483560|carotid IMT
1121252|NCT01483560|LDL Cholesterol
1121253|NCT01483560|endothelial function
1121254|NCT01483560|retinopathy
1121255|NCT01483560|HbA1c
1121256|NCT01483534|Chronic Obstructive Pulmonary Disease
1121257|NCT01483534|Pulmonary
1121258|NCT01483534|Intervention
1121259|NCT01483534|Device
1121260|NCT01483534|Denervation
1121261|NCT01483534|Lung
1121262|NCT01483534|Holaira, Inc.
1121263|NCT01483534|Innovative Pulmonary Solutions, Inc.
1121264|NCT01483521|Randomized
1121265|NCT01483521|Home visitation
1121266|NCT01483521|Externalizing disorder
1121267|NCT01483521|Parenting stress
1121268|NCT01483521|Childhood externalizing disorders
1121269|NCT01483521|Positional defiant
1121270|NCT01483508|flavanols
1121271|NCT01483508|procyanidins
1121272|NCT01483508|absorption
1121273|NCT01483508|cocoa polyphenols
1121274|NCT01483508|Flavanol and procyanidin absorption in healthy volunteers
1121275|NCT01483482|clavicle fractures
1121276|NCT01483482|midshaft clavicle fractures
1121277|NCT01483482|conservative treatment
1121278|NCT01483482|surgical treatment
1121279|NCT01483482|functional outcome
1121280|NCT01483482|clinical assessment
1121281|NCT01483482|adults
1121282|NCT01483456|Accidental falls
1121283|NCT01483456|safety management
1121284|NCT01483456|aged
1121285|NCT01483456|inpatient
1121286|NCT01483456|stepped wedge design
1121287|NCT01483443|oophrectomy
1121288|NCT01483443|survival
1121289|NCT01483430|Blood pressure
1121290|NCT01483430|Korea red ginseng
1121291|NCT01483430|Ambulatory blood pressure
1121292|NCT01483430|Pulse wave velocity
1121293|NCT01483417|SILS
1121294|NCT01483417|Laparoscopic hysterectomy
1121295|NCT01483417|Cosmetic outcome
1121296|NCT01483417|Pain
1121297|NCT01483404|microcirculation
1121298|NCT01483404|caput femoris
1121299|NCT01483391|Bipolar disorder
1121300|NCT01483391|Major depressive disorder
1121301|NCT01483391|Mania
1121302|NCT01483391|Depression
1121303|NCT01483391|Cyclothymic Disorder
1121304|NCT01483313|Anesthestics
1121305|NCT01483313|Minor surgery
1121306|NCT01483313|Wechsler Intelligence Scale for Children
1121307|NCT01483313|Cognitiion
1121308|NCT01483300|breast cancer
1121309|NCT01483300|gemcitabine
1121310|NCT01483300|lobaplatin
1121311|NCT01483300|cisplatin
1121312|NCT01483287|Gastrointestinal Symptoms
1121313|NCT01483287|Bloating
1121314|NCT01483287|Distention
1121315|NCT01483274|AML
1121316|NCT01483274|vaccine
1121317|NCT01483261|Trauma-Focused Cognitive Behavior Therapy
1121318|NCT01483261|Sexually Exploited Girls
1121319|NCT01483261|Post-traumatic Stress Symptoms
1121320|NCT01483261|Psychosocial Distress
1121321|NCT01483248|Menstrual blood
1121322|NCT01483248|Mesenchymal stem cell
1121323|NCT01483248|Liver cirrhosis
1121324|NCT01483235|cardiac rehabilitation
1121325|NCT01483235|prevention
1121326|NCT01483235|exercise capacity
1121327|NCT01483222|Low Back Pain
1121328|NCT01483222|Braces
1121329|NCT01483222|Prevention
1121330|NCT01483209|Digital ischemia
1121331|NCT01483209|Vasopressor
1121332|NCT01483183|Atrial fibrillation
1121333|NCT01483183|Paroxysmal Atrial fibrillation
1121334|NCT01483183|Persistent Atrial fibrillation
1121335|NCT01483183|A-fib
1121336|NCT01483144|Familial Adenomatous Polyposis
1121337|NCT01483144|Eflornithine
1121338|NCT01483144|Sulindac
1121339|NCT01483118|PCOS
1121340|NCT01483118|Insulin resistance
1121341|NCT01483118|Cinnamon extract
1121342|NCT01483118|Irregular menstrual cycles
1121343|NCT01483118|Ovarian cysts
1121344|NCT01483105|VCUG
1121345|NCT01483105|Child
1121346|NCT01483105|Hypnosis
1121347|NCT01483105|Relaxation
1121348|NCT01483105|Voiding cystourethrography
1121353|NCT01483053|Major depressive disorder
1121354|NCT01483053|Sympathetic nervous system activation
1121355|NCT01483053|Cardiovascular risk factors
1121356|NCT01483053|Agomelatine
1121357|NCT01483053|Escitalopram
1121358|NCT01483040|wide angle view colonoscopy
1121359|NCT01483040|PeerScope B System™
1121360|NCT01483014|Gastrointestinal,
1121361|NCT01483014|stromal,
1121362|NCT01483014|neoadjuvant,
1121363|NCT01483014|imatinib,
1121364|NCT01483014|mesylate,
1121365|NCT01483014|pre-operatory
1121366|NCT01483001|Cancer Stem Cells
1121367|NCT01483001|Chemo-Sensitivity Assay
1121368|NCT01483001|Cancer Treatment
1121369|NCT01482988|prevalence of the Dectin-1 polymorphism (Tyr238X)
1121370|NCT01482975|tobacco
1121371|NCT01482975|alcohol
1121372|NCT01482975|diet
1121373|NCT01482975|exercise
1121374|NCT01482949|RCC
1121375|NCT01482949|Kidney Cancer
1121376|NCT01482949|Renal Cancer
1121377|NCT01482949|Arcelis
1121378|NCT01482923|Tobacco Use Assessment
1121379|NCT01482923|smoke tobacco
1121380|NCT01482923|quit smoking
1121381|NCT01482923|tobacco cessation
1121382|NCT01482923|HIV/AIDS
1121383|NCT01482923|Community-Based Service Organizations
1121384|NCT01482923|11-173
1121385|NCT01482923|Low-Income Persons Living with HIV/AIDS
1121386|NCT01482897|Discal sciatica, infiltrations
1121387|NCT01482897|Subjects
1121388|NCT01482897|evolving
1121389|NCT01482884|tralokinumab
1121390|NCT01482884|inflammatory bowel disease
1121391|NCT01482884|moderate to severe ulcerative colitis
1121392|NCT01482871|Diabetic Macular Edema
1121393|NCT01482832|Randomized trial
1121394|NCT01482832|Postpartum depression
1121395|NCT01482832|Adolescent pregnancy
1121396|NCT01482832|Interpersonal psychotherapy
1121397|NCT01482806|Depression
1121398|NCT01482806|Anxiety
1121399|NCT01482806|Primary care
1121400|NCT01482806|Cognitive Behavioral Therapy
1121401|NCT01482806|Internet
1121402|NCT01482806|Support groups
1121403|NCT01482806|Technology assisted
1121404|NCT01482741|Quality of Life
1121405|NCT01482741|Focus groups
1121406|NCT01482741|Risks of Ionizing Radiation
1121407|NCT01482741|Risk of medical imaging
1121408|NCT01482741|11-185
1121409|NCT01482715|gBRCA ovarian cancer
1121410|NCT01482715|platinum sensitive
1121411|NCT01482715|PARP Inhibitor
1121412|NCT01482715|Rucaparib
1121413|NCT01482715|CO-338
1121414|NCT01482715|PF 01367338
1121415|NCT01482715|AG 14699
1121416|NCT01482715|BRCA1
1121417|NCT01482715|BRCA2
1121418|NCT01482715|platinum sensitive ovarian cancer
1121419|NCT01482715|platinum sensitive gBRCA ovarian cancer
1121420|NCT01482715|gynecological cancer
1121421|NCT01482715|relapsed disease
1121422|NCT01482715|homologous recombination deficiency
1121423|NCT01482715|HRD
1121424|NCT01482702|breast cancer survivor
1121425|NCT01482702|weight loss
1121426|NCT01482702|postmenopausal
1121427|NCT01482702|Weight loss for overweight postmenopausal breast cancer survivors
1121428|NCT01482689|Bioavailability
1121429|NCT01482689|Vitamin D metabolism
1121430|NCT01482689|Bone turnover
1121431|NCT01482663|Hand eczema
1121432|NCT01482663|Hand dermatitis
1121433|NCT01482663|Chronic hand eczema
1121434|NCT01482663|Chronic hand dermatitis
1121435|NCT01482663|Contact dermatitis
1121436|NCT01482663|Skin disease
1121437|NCT01482663|Self-management
1121438|NCT01482650|Baska mask
1121439|NCT01482650|LMA
1121440|NCT01482650|laryngeal mask airway
1121441|NCT01482650|supraglottic airway device
1121442|NCT01482624|hyaluronan
1121443|NCT01482624|hyaluronic acid
1121444|NCT01482611|Hepatitis C Virus
1121445|NCT01482611|JNJ-47910382
1121446|NCT01482611|47910382HPC1001
1121447|NCT01482611|HCV
1121448|NCT01482611|Hepatitis C
1121449|NCT01482611|Hep C
1121450|NCT01482611|Healthy participants
1121451|NCT01482611|Japanese
1121452|NCT01482611|Caucasians
1121453|NCT01482598|Heart Failure
1121454|NCT01482598|Cardiac Resynchronization Therapy
1121455|NCT01482598|Remote Care
1121456|NCT01482598|Disease Management
1121457|NCT01482585|lung adenocarcinoma
1121458|NCT01482585|prognosis
1121459|NCT01482585|tumor aggressiveness
1121460|NCT01482585|imaging biomarker
1121461|NCT01482585|genetic biomarker
1121462|NCT01482572|biopsy
1121463|NCT01482572|needle aspiration
1121464|NCT01482572|mutational analysis
1121465|NCT01482559|Dopamine
1121466|NCT01482559|Intraventricular haemorrhage
1121467|NCT01482559|Periventricular Leukomalacia
1121468|NCT01482559|Neurodisability
1121469|NCT01482559|Infant
1121475|NCT01482494|Myopathies
1121476|NCT01482494|Pompe disease
1121477|NCT01482494|Polymyositis
1121478|NCT01482494|Respiratory Insufficiency
1121479|NCT01482481|Patient Care Planning
1121480|NCT01482481|Type 2 Diabetes Mellitus
1121481|NCT01482481|Cardiovascular Risk Factors
1121482|NCT01482481|Primary Health Care
1121483|NCT01482481|Spain
1121484|NCT01482455|Insulin resistance
1121485|NCT01482455|vascular impairment
1121486|NCT01482455|diabetes
1121487|NCT01482442|Liver, HCC
1121488|NCT01482442|Liver, interventional procedures
1121489|NCT01482442|Liver, randomized studies
1121490|NCT01482442|Liver, targeted therapy
1121491|NCT01482442|Liver, RADIOEMBOLIZATION
1121492|NCT01482429|ventilator weaning
1121493|NCT01482429|protocol
1121494|NCT01482416|hormone replacement therapy
1121495|NCT01482416|Doppler velocimetry
1121496|NCT01482416|Flow-mediated dilation
1121497|NCT01482416|menopause
1121498|NCT01482364|HOTMAN System
1121499|NCT01482364|Hemodynamic integrated management
1121500|NCT01482351|apnea
1121501|NCT01482351|cognition
1121502|NCT01482351|memory
1121503|NCT01482351|function
1121504|NCT01482351|amnestic mild cognitive impairment
1121505|NCT01482351|older adults
1121506|NCT01482351|Alzheimer's Disease
1121507|NCT01482338|PMS
1121508|NCT01482338|Low-dose combine contraceptives pills
1121509|NCT01482338|COC
1121510|NCT01482299|pS6 Ser 240/4
1121511|NCT01482299|RAD001 (everolimus)
1121512|NCT01482299|second-line treatment
1121513|NCT01482299|advanced gastric cancer
1121514|NCT01482286|Exercise
1121515|NCT01482286|Diet
1121516|NCT01482286|Insulin resistance
1121517|NCT01482286|Weight
1121518|NCT01482273|catheter-directed thrombolysis
1121519|NCT01482273|ilio-femoral deep vein thrombosis
1121520|NCT01482273|Postthrombotic syndrome
1121521|NCT01482273|Phlebographic scores
1121522|NCT01482273|Phlebography
1121523|NCT01482273|Catheters
1121524|NCT01482234|physical activity
1121525|NCT01482234|exercise
1121526|NCT01482234|walking
1121527|NCT01482234|pedometers
1121528|NCT01482234|goal setting
1121529|NCT01482234|text messages
1121530|NCT01482234|motivation
1121531|NCT01482234|intrinsic motivation
1121532|NCT01482234|extrinsic motivation
1121533|NCT01482234|self determination theory
1121534|NCT01482234|prompts
1121535|NCT01482221|Major Depressive Disorder
1121536|NCT01482221|MDD
1121537|NCT01482221|Inadequate Response to Antidepressant Therapy
1121538|NCT01482221|Channel blocker of the NMDA class of glutamate receptors
1121539|NCT01482208|Dehydration
1121540|NCT01482208|Hydration
1121541|NCT01482208|Muscle composition
1121542|NCT01482208|Diarrhea
1121543|NCT01482208|Pediatrics
1121544|NCT01482208|Neonatology
1121545|NCT01482208|Ultrasound
1121546|NCT01482195|Retinal Disease
1121547|NCT01482182|Non-small cell lung cancer
1121548|NCT01482182|Diffusion-weighted MRI
1121549|NCT01482182|18F-FDG PET
1121550|NCT01482182|Treatment response
1121551|NCT01482182|Prognosis
1121552|NCT01482169|Left heart catheterization
1121553|NCT01482169|Fractional flow reserve
1121554|NCT01482169|Adenoscan®
1121555|NCT01482169|Regadenoson
1121556|NCT01482156|Advanced solid tumors
1121557|NCT01482156|Metastatic renal cell carcinoma (mRCC)
1121558|NCT01482156|ER+/HER2-Metastatic breast cancer (MBC)
1121559|NCT01482156|Dose finding study
1121560|NCT01482156|mTOR
1121561|NCT01482156|Pl3K
1121562|NCT01482156|BEZ235
1121563|NCT01482156|RAD001
1121564|NCT01482156|Everolimus
1121565|NCT01482156|Afinitor®
1121566|NCT01482156|ER+/HER2- metastatic breast cancer
1121567|NCT01482143|Fragile X Syndrome
1121568|NCT01482143|pharmacokinetics
1121569|NCT01482143|safety and tolerability
1121570|NCT01482130|Exercise
1121571|NCT01482130|osteoporosis
1121572|NCT01482130|prevention
1121573|NCT01482117|CYP2C19
1121574|NCT01482117|CYP3A5
1121575|NCT01482117|Clopidogrel
1121576|NCT01482117|Cilostazol
1121577|NCT01482117|Healthy
1121578|NCT01482104|Photochemotherapy
1121579|NCT01482104|methyl 5-aminolevulinate
1121580|NCT01482091|fentanyl
1121581|NCT01482091|intranasal
1121582|NCT01482091|sickle cell
1121583|NCT01482091|vasoocclusive crisis
1121584|NCT01482091|pain crisis
1121585|NCT01482091|pediatrics
1121586|NCT01482078|Magnesium Sulphate
1121587|NCT01482078|Neuroprotection
1121588|NCT01482078|Neuraxial Anesthesia
1121589|NCT01482078|Sedation
1121590|NCT01482078|Respiratory function
1121591|NCT01482078|Cesarean Section
1121592|NCT01482078|Obstetrical Anesthesia
1121593|NCT01482065|Non Alcoholic Fatty Liver Disease
1121594|NCT01482065|NAFLD
1121595|NCT01482065|Continuous Positive Airway Pressure
1121596|NCT01482065|CPAP
1121597|NCT01482065|CPAP Therapy
1121598|NCT01482065|Apnea Hypopnea Index
1121599|NCT01482065|Non alcoholic steatohepatitis
1121600|NCT01482065|NASH
1121601|NCT01482065|OSA
1121602|NCT01482065|Obstructive Sleep Apnea
1121603|NCT01482065|AHI
1121604|NCT01482052|Central Nervous System Infections
1121605|NCT01482052|Meningitis
1121606|NCT01482052|toxoid
1121607|NCT01482052|Meningococcal vaccine
1121608|NCT01482052|conjugate vaccines
1121609|NCT01482039|short cervix
1121610|NCT01482039|cervical shortening
1121611|NCT01482039|preterm birth
1121612|NCT01482026|Epilepsy
1121613|NCT01482026|Attention deficit
1121614|NCT01482026|ADHD rating scale IV
1121615|NCT01482000|Pulmonary Disease, Chronic Obstructive
1121616|NCT01482000|Adult
1121617|NCT01482000|therapeutic use
1121618|NCT01482000|Humans
1121619|NCT01482000|Treatment Outcome
1121620|NCT01482000|daoyin therapy
1121621|NCT01481987|Microperimetry
1121622|NCT01481987|OCT
1121623|NCT01481987|idiopathic epiretinal membrane
1121624|NCT01481974|liver transplantation
1121625|NCT01481974|treprostinil
1121626|NCT01481961|Alzheimer's disease
1121627|NCT01481961|rTMS
1121628|NCT01481961|cognition
1121629|NCT01481948|physical activity
1121630|NCT01481948|fruit and vegetable
1121631|NCT01481948|water
1121632|NCT01481948|girls
1121633|NCT01481948|African American
1121634|NCT01481948|online
1121635|NCT01481935|Antibiotic resistant bacteria
1121636|NCT01481935|Colonization
1121637|NCT01481935|Hospital cleaning
1121638|NCT01481935|Environmental cleaning
1121639|NCT01481935|Infection Control
1121640|NCT01481922|Lumbar puncture
1121641|NCT01481922|Flow rate
1121642|NCT01481922|Backache
1121643|NCT01481922|Pain
1121644|NCT01481922|Undifferentiated headache
1121645|NCT01481922|Post-lumbar puncture headache
1121646|NCT01481909|Assessment of wheal and flare development
1121647|NCT01481909|Assessment of life quality
1121648|NCT01481896|Hip replacement
1121649|NCT01481896|Metal-on-metal bearings
1121650|NCT01481896|Osteolysis
1121651|NCT01481896|Metal ion levels
1121652|NCT01481896|Outcome
1121653|NCT01481883|Schizophrenia
1121654|NCT01481883|Mental Illness
1121655|NCT01481883|SERM
1121656|NCT01481883|Raloxifene
1121657|NCT01481870|renal cell carcinoma
1121658|NCT01481870|sorafenib
1121659|NCT01481870|sunitinib
1121660|NCT01481870|crossover
1121661|NCT01481844|sequential therapy
1121662|NCT01481844|second line treatment
1121663|NCT01481844|H pylori
1121664|NCT01481792|Keratorefractive Surgical Procedures
1121665|NCT01481766|child development
1121666|NCT01481766|screening
1121667|NCT01481766|Non-anemic iron deficiency
1121668|NCT01481766|primary care pediatrics
1121669|NCT01481766|prevention and health promotion
1121670|NCT01481740|spinal induced hypotension
1121671|NCT01481740|nausea and vomiting
1121672|NCT01481740|cesarean delivery
1121673|NCT01481727|acute exacerbation of COPD number
1121674|NCT01481727|acute exacerbation of COPD severity
1121675|NCT01481714|Sodium picosulphate
1121676|NCT01481714|Split-dose
1121677|NCT01481714|Bowel cleansing
1121678|NCT01481714|colonoscopy
1121679|NCT01481714|Degree of bowel cleansing during colonoscopy
1121680|NCT01481701|ovarian carcinoma
1121681|NCT01481701|Bordet
1121682|NCT01481701|relapse
1121683|NCT01481688|Dialysis adequacy
1121684|NCT01481688|Urea clearance
1121685|NCT01481688|Phosphate clearance
1121686|NCT01481688|Beta 2 microglobulin clearance
1121687|NCT01481688|Intradialytic exercise
1121688|NCT01481688|Haemodialysis patients
1121689|NCT01481675|biliopancreatic diversion
1121690|NCT01481675|sleeve gastrectomy
1121691|NCT01481675|diabetes mellitus
1121692|NCT01481675|weight loss
1121693|NCT01481675|ghrelin
1121694|NCT01481675|PYY
1121695|NCT01481675|GLP-1
1121696|NCT01481662|SUSAC's Syndrome
1121697|NCT01481662|encephalopathy
1121698|NCT01481662|hearing loss
1121699|NCT01481662|retinal artery branch occlusions
1121700|NCT01481662|Diffusion tensor MRI
1121701|NCT01481649|hepatitis B
1121702|NCT01481649|anti-HBc
1121703|NCT01481649|HBsAg
1121704|NCT01481649|HSCT
1121705|NCT01481649|recipients
1121706|NCT01481636|Obstructive sleep apnea
1121707|NCT01481636|correlation
1121708|NCT01481636|AHI
1121709|NCT01481636|symptoms
1121710|NCT01481636|mechanisms
1121711|NCT01481623|Diabetes
1121712|NCT01481623|neonatal
1121713|NCT01481623|consanguinity
1121714|NCT01481623|monogenic
1121715|NCT01481623|metabolism
1121716|NCT01481610|Kidney Failure, Chronic
1121717|NCT01481610|Arthralgia
1121718|NCT01481610|NSAID
1121719|NCT01481610|Diclofenac
1121720|NCT01481610|Lumiracoxib
1121721|NCT01481610|Safety
1121722|NCT01481597|deuteporfin
1121723|NCT01481597|safety
1121724|NCT01481597|tolerability
1121725|NCT01481597|pharmacokinetics
1121726|NCT01481597|healthy volunteers
1121727|NCT01481584|Dietary protein
1121728|NCT01481584|Canola protein
1121729|NCT01481584|Protein metabolism
1121730|NCT01481584|Protein-enriched drinks
1121731|NCT01481584|Nitrogen balance
1121732|NCT01481571|Media for vitrification/warming of human oocytes
1121733|NCT01481558|Apathy
1121734|NCT01481558|Alzheimer's Disease
1121735|NCT01481558|Dementia
1121736|NCT01481545|locally advanced
1121737|NCT01481545|high risk
1121738|NCT01481545|preoperative therapy
1121739|NCT01481532|Antineoplastic agent
1121740|NCT01481519|Conjunctivitis
1121741|NCT01481519|Ocular diseases
1121742|NCT01481519|Artificial tears
1121743|NCT01481493|rheumatoid arthritis
1121744|NCT01481480|shoulder
1121745|NCT01481480|rotator cuff
1121746|NCT01481480|tendon transfer
1121747|NCT01481480|arthroscopic repair
1121748|NCT01481467|influenza vaccination
1121749|NCT01481467|intervention mapping
1121750|NCT01481467|hospital care
1121751|NCT01481467|respiratory infections
1121752|NCT01481467|vaccination
1121753|NCT01481454|Influenza
1121754|NCT01481454|Quadrivalent Inactivated Influenza Vaccine
1121755|NCT01481454|Trivalent Inactivated Influenza Vaccine
1121756|NCT01481441|Contrast Enhanced Ultrasound (CEUS)
1121757|NCT01481441|Prostate cancer
1121758|NCT01481441|Quantification
1121759|NCT01481441|Prostate biopsies
1121760|NCT01481441|Transrectal ultrasound (TRUS)
1121761|NCT01481441|Microbubbles
1121762|NCT01481428|High risk behavior
1121763|NCT01481428|Drug court clients
1121764|NCT01481428|Substance abuse
1121765|NCT01481428|HIV intervention
1121766|NCT01481428|Treatment Court Clients
1121767|NCT01481415|left atrial
1121768|NCT01481415|three-dimensional echocardioraphy
1121769|NCT01481415|left atrial function
1121770|NCT01481402|Heart failure
1121771|NCT01481402|Liothyronine
1121772|NCT01481402|Low T3 syndrome
1121773|NCT01481389|Blood lipids
1121774|NCT01481389|risk factor for cardiovascular diseases
1121775|NCT01481376|Parietex™ ProGrip™
1121776|NCT01481376|Laparoscopic Transabdominal preperitoneal
1121777|NCT01481376|TAPP
1121778|NCT01481376|Inguinal hernia repair
1121779|NCT01481363|dementia
1121780|NCT01481363|communication
1121781|NCT01481363|carers
1121782|NCT01481363|caregivers
1121783|NCT01481363|psychosocial support systems
1121784|NCT01481363|education
1121785|NCT01481337|colon
1121786|NCT01481337|endoscopy
1121787|NCT01481337|resection
1121788|NCT01481324|Clubfoot
1121789|NCT01481324|Compliance
1121790|NCT01481324|Brace wear
1121791|NCT01481285|Bioelectrical Impedance Measurement
1121792|NCT01481285|Adults
1122160|NCT01479738|graft
1121793|NCT01481272|Salvage therapy in DLBCL
1121794|NCT01481259|Nonsquamous non-small cell lung cancer
1121795|NCT01481259|Maintenance therapy
1121796|NCT01481259|Immunotherapy
1121797|NCT01481259|Autologous cytokine-induced killer cell
1121798|NCT01481259|Pemetrexed
1121799|NCT01481246|neurorehabilitation
1121800|NCT01481246|cognition
1121801|NCT01481246|aging
1121802|NCT01481246|MCI
1121803|NCT01481246|cognitive decline
1121804|NCT01481233|oral colchicine
1121805|NCT01481233|castrate-resistant prostate cancer
1121806|NCT01481233|failed taxotere based chemotherapy
1121807|NCT01481220|Myelodysplastic syndrome
1121808|NCT01481220|azacitidine
1121809|NCT01481220|Eltrombopag
1121810|NCT01481220|Thrombopoietin-receptor agonist
1121811|NCT01481220|Thrombocytopenia
1121812|NCT01481220|Transfusion dependency
1121813|NCT01481220|Safety study
1121814|NCT01481207|magnetic resonance spectroscopy
1121815|NCT01481207|magnetic resonance imaging
1121816|NCT01481194|Multiple Myeloma
1121817|NCT01481181|zinc water diarrhoea growth preschool children
1121818|NCT01481155|actinic keratosis
1121819|NCT01481155|field cancerisation
1121820|NCT01481116|Drug Therapy
1121821|NCT01481103|Over the counter medication
1121822|NCT01481103|Acupuncture
1121823|NCT01481090|Infertility
1121824|NCT01481090|acupuncture
1121825|NCT01481090|frozen embryos
1121826|NCT01481090|endometrium
1121827|NCT01481090|TCM
1121828|NCT01481064|Patient centredness
1121829|NCT01481064|Quality of life
1121830|NCT01481064|Multifaceted approach
1121831|NCT01481064|Fertility care
1121832|NCT01481038|early detection
1121833|NCT01481038|CRBSI
1121834|NCT01481025|Climacteric
1121835|NCT01481025|Depression
1121836|NCT01481025|Herbal treatment
1121837|NCT01481012|Heart transplantation
1121838|NCT01481012|Coronary artery bypass graft (CABG) surgery
1121839|NCT01481012|Left ventricular assist device implantation surgeries
1121840|NCT01480999|Laparotomy
1121841|NCT01480999|Open Surgery
1121842|NCT01480999|Laparoscopy
1121843|NCT01480999|Robotic surgery
1121844|NCT01480960|lung transplantation
1121845|NCT01480960|whole body vibration
1121846|NCT01480960|exercise training
1121847|NCT01480960|pulmonary rehabilitation
1121848|NCT01480947|probiotics
1121849|NCT01480947|pediatric
1121850|NCT01480947|salmonella
1121851|NCT01480947|rotavirus
1121852|NCT01480947|gastroenteritis
1121853|NCT01480934|Diabetes,posterior capsule opacification,case control study
1121854|NCT01480921|heart failure
1121855|NCT01480921|health related quality of life
1121856|NCT01480921|exercise capacity
1121857|NCT01480921|home based exercise training
1121858|NCT01480921|supervised exercise training
1121859|NCT01480908|Right bundle branch block
1121860|NCT01480908|Ventricular septal defect
1121861|NCT01480908|Echocardiography
1121862|NCT01480908|MRI
1121863|NCT01480908|Exercise testing
1121864|NCT01480895|Diabetes Mellitus Type 2
1121865|NCT01480895|Gestational Diabetes Mellitus
1121866|NCT01480895|Glucose Intolerance
1121867|NCT01480895|Physical exercise
1121868|NCT01480895|Nutritional Habits
1121869|NCT01480895|Dyslipidemia
1121870|NCT01480882|Manual percussion
1121871|NCT01480882|Mechanical percussion
1121872|NCT01480882|Chronic bronchiectasis
1121873|NCT01480882|Chronic Obstructive Pulmonary Disease
1121874|NCT01480882|Wet sputum weight
1121875|NCT01480882|Dry sputum weight
1121876|NCT01480869|Breast cancer
1121877|NCT01480869|Vitamin D supplementation
1121878|NCT01480869|in neoadjuvant
1121879|NCT01480869|adjuvant setting
1121880|NCT01480843|simplification
1121881|NCT01480843|glargine
1121882|NCT01480843|elderly
1121883|NCT01480830|Quality
1121884|NCT01480830|indicators
1121885|NCT01480804|Barriers
1121886|NCT01480804|Intervention
1121887|NCT01480804|Elderly
1121888|NCT01480804|glycemic control
1121889|NCT01480791|resistance arteries
1121890|NCT01480791|endothelial dysfunction
1121891|NCT01480791|aortic stiffness
1121892|NCT01480778|hormonal response, levonorgestrel, ethinyl estradiol
1121893|NCT01480752|In the patients with symptomatic Irreversible Pulpitis
1121894|NCT01480739|Phase 1, AZD5069, safety and tolerability, healthy volunteer,
1121895|NCT01480713|HIV-1
1121896|NCT01480713|protease inhibitors
1121897|NCT01480713|integrase inhibitors
1121898|NCT01480713|raltegravir
1121899|NCT01480713|viral replication
1121900|NCT01480713|treatment intensification
1121901|NCT01480713|viral pathogenesis
1121902|NCT01480713|immune activation
1121903|NCT01480700|eggs
1121904|NCT01480700|Optical Macular Pigment
1121905|NCT01480700|Age Macular Degeneration
1121906|NCT01480700|study for the Age Macular Degeneration prevention
1121907|NCT01480687|Hypertension
1121908|NCT01480687|Endothelial dysfunction
1121909|NCT01480687|Vascular stiffness
1121910|NCT01480661|Pulmonary Disease, Chronic Obstructive
1121911|NCT01480661|Computed Tomography scan
1121912|NCT01480661|Functional Respiratory Imaging
1121913|NCT01480661|Roflumilast
1121914|NCT01480661|Health Related Quality of Life
1121915|NCT01480635|Incomplete Colonoscopy
1121916|NCT01480635|Efficacy of PillCam Colon2
1121917|NCT01480622|healthy subjects
1121918|NCT01480622|Tenofovir disoproxil fumarate
1121919|NCT01480622|hepatitis
1121920|NCT01480622|pharmacokinetics
1121921|NCT01480583|GRN1005
1121922|NCT01480583|ANG1005
1121923|NCT01480583|Peptide-Drug Conjugate (PDC)
1121924|NCT01480583|LRP-1
1121925|NCT01480583|Targeted Therapy
1121926|NCT01480583|Breast Cancer
1121927|NCT01480583|Brain Metastases
1121928|NCT01480583|Brain Tumor
1121929|NCT01480583|Blood Brain Barrier
1121930|NCT01480583|Trastuzumab
1121931|NCT01480583|Herceptin
1121932|NCT01480583|Paclitaxel
1121933|NCT01480583|Taxol
1121934|NCT01480583|Breast cancer with brain metastases
1121935|NCT01480557|cataract
1121936|NCT01480557|phacoemulsification
1121937|NCT01480557|liquefaction
1121938|NCT01480557|torsional ip
1121939|NCT01480557|endothelial cell count
1121940|NCT01480557|central corneal edema
1121941|NCT01480557|central corneal sensitivity
1121942|NCT01480544|Institutional Deliveries
1121943|NCT01480544|Maternal Health
1121944|NCT01480544|Infant Health
1121945|NCT01480544|Private Medical Providers
1121946|NCT01480544|Provider Incentives
1121947|NCT01480544|Randomized Control Trial
1121948|NCT01480531|aorta
1121949|NCT01480531|aneurysm
1121950|NCT01480531|dissection
1121951|NCT01480518|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1121952|NCT01480505|Retinal detachment
1121953|NCT01480505|high myopia
1121954|NCT01480505|macular hole
1121955|NCT01480505|axial length
1121956|NCT01480505|Scleral buckling
1121957|NCT01480505|Vitrectomy
1121958|NCT01480505|Visual acuity
1121959|NCT01480505|fundus examination results
1121960|NCT01480492|HBV
1121961|NCT01480492|Immune
1121962|NCT01480492|antiviral therapy
1121963|NCT01480479|EGFRvIII
1121964|NCT01480479|Glioblastoma
1121965|NCT01480479|Small cell
1121966|NCT01480479|Giant cell
1121967|NCT01480479|Gliosarcoma
1121968|NCT01480479|oligodendroglial
1121969|NCT01480479|Brain Cancer
1121970|NCT01480479|Brain Tumor
1121971|NCT01480479|radiotherapy
1121972|NCT01480479|chemoradiation
1121973|NCT01480479|Tumor
1121974|NCT01480479|temozolomide
1121975|NCT01480479|EGFR variant III
1121976|NCT01480466|Overweight
1121977|NCT01480466|Obesity
1121978|NCT01480466|Body mass index
1121979|NCT01480466|Weight
1121980|NCT01480466|Primary care
1121981|NCT01480453|Osteoarthritis
1121982|NCT01480453|Rheumatoid arthritis
1121983|NCT01480453|Post-traumatic arthritis
1121984|NCT01480453|Ununited humeral head fracture
1121985|NCT01480453|Irreducible 3- and 4-part proximal humeral fractures
1121986|NCT01480453|Avascular necrosis
1121987|NCT01480440|Reverse Total Shoulder Arthroplasty
1121988|NCT01480440|Reverse TSA
1121989|NCT01480440|Osteoarthritis
1121990|NCT01480440|Rheumatoid Arthritis
1121991|NCT01480440|Post-traumatic arthritis
1121992|NCT01480440|Ununited humeral head fracture
1121993|NCT01480440|Irreducible 3-and 4-part proximal humeral fractures
1121994|NCT01480440|Avascular necrosis
1121995|NCT01480440|Gross rotator cuff deficiency
1121996|NCT01480440|Failed total shoulder arthroplasty (both glenoid and humeral components require revision
1121997|NCT01480427|Children aged 0-12 years
1121998|NCT01480427|IgE mediated food allergy
1121999|NCT01480414|bone marrow mono nuclear stem cell ischemic ulcer
1122000|NCT01480401|Patients with stable heart failure
1122001|NCT01480388|Rheumatoid arthritis
1122002|NCT01480388|Swollen and tender joints
1122003|NCT01480388|Dose range finding study
1122004|NCT01480388|Concurrent treatment with methotrexate
1122005|NCT01480375|prostate cancer detection
1122006|NCT01480375|prostate biopsy
1122007|NCT01480375|3d navigation
1122008|NCT01480375|trans rectal ultrasound
1122009|NCT01480362|Diabetic foot wound
1122010|NCT01480362|Amputation wound
1122011|NCT01480362|Chronic wound
1122012|NCT01480349|Post-Hemorrhagic Hydrocephalus
1122013|NCT01480349|Intraventricular Hemorrhage
1122014|NCT01480349|Low Birth Weight Premature Infants
1122015|NCT01480336|Arrhythmia
1122016|NCT01480323|Malignant melanoma
1122017|NCT01480297|Pain
1122018|NCT01480297|Neuropathy
1122019|NCT01480297|Diabetes type 1
1122020|NCT01480284|Tenofovir Disoproxil Fumarate
1122021|NCT01480284|Chronic Hepatitis B
1122027|NCT01480258|combination vaccine
1122028|NCT01480258|diphtheria
1122029|NCT01480258|pertussis
1122030|NCT01480258|tetanus
1122031|NCT01480258|hepatitis B
1122032|NCT01480258|Hep B
1122033|NCT01480258|Haemophilus influenzae b
1122034|NCT01480258|Hib
1122035|NCT01480258|polio
1122036|NCT01480258|poliovirus
1122037|NCT01480245|968
1122038|NCT01480245|Duchenne
1122039|NCT01480245|DMD
1122040|NCT01480245|drisapersen
1122041|NCT01480219|voriconazole
1122042|NCT01480219|non-melanoma skin cancer
1122043|NCT01480219|confounding
1122044|NCT01480219|statistical adjustment
1122045|NCT01480219|risk adjustment
1122046|NCT01480219|lung transplant
1122047|NCT01480219|heart/lung transplant
1122048|NCT01480219|immunosuppression
1122049|NCT01480193|Tinnitus
1122050|NCT01480167|VCF
1122051|NCT01480167|Osteoporosis
1122052|NCT01480167|Minimally Invasive
1122053|NCT01480167|Non-operative management
1122054|NCT01480167|Medical Management
1122055|NCT01480128|Single-port
1122056|NCT01480128|Laparoscopy
1122057|NCT01480128|colectomy
1122058|NCT01480128|Single port
1122059|NCT01480128|colon cancer
1122060|NCT01480128|minimally invasive surgery
1122061|NCT01480115|antral follicle count
1122062|NCT01480115|automated antral follicle count
1122063|NCT01480115|ovarian reserve
1122064|NCT01480102|Percutaneous nephrolithotomy
1122065|NCT01480102|Paravertebral block
1122066|NCT01480102|bupivacaine
1122067|NCT01480089|Surgical Pain Management
1122068|NCT01480089|Robotic surgery
1122069|NCT01480089|Ropivacaine
1122070|NCT01480076|Quality of Life
1122071|NCT01480076|Multiple Sclerosis
1122072|NCT01480050|adult giant cell glioblastoma
1122073|NCT01480050|adult glioblastoma
1122074|NCT01480050|adult anaplastic astrocytoma
1122075|NCT01480050|adult anaplastic ependymoma
1122076|NCT01480050|adult anaplastic oligodendroglioma
1122077|NCT01480050|adult mixed glioma
1122078|NCT01480050|recurrent adult brain tumor
1122084|NCT01480011|Lactobacillus CD2 lozenges
1122085|NCT01480011|high-dose chemotherapy induced
1122086|NCT01480011|hematopoietic stem cell transplantation
1122087|NCT01479998|smoking cessation
1122088|NCT01479998|NRT nicotine replacement therapy
1122089|NCT01479998|CBT cognitive behavioral therapy
1122090|NCT01479998|contingency management
1122091|NCT01479972|Tuberculosis
1122092|NCT01479972|Vaccine
1122093|NCT01479972|Live vaccine
1122094|NCT01479972|rBCG
1122095|NCT01479959|Tracheostomy
1122096|NCT01479959|positive end expiratory pressure
1122097|NCT01479959|speech
1122098|NCT01479959|respiratory failure
1122099|NCT01479959|ventilation
1122100|NCT01479959|neuromuscular disorders
1122101|NCT01479933|vitamin D
1122102|NCT01479933|cholecalciferol
1122103|NCT01479933|supplementation
1122104|NCT01479933|prediabetic state
1122105|NCT01479933|obesity
1122106|NCT01479933|glucose metabolism
1122107|NCT01479933|gene expression
1122108|NCT01479933|transcriptomics
1122109|NCT01479933|epigenomics
1122110|NCT01479933|immunological function
1122111|NCT01479933|insulin sensitivity
1122112|NCT01479933|peripheral mononuclear cells
1122113|NCT01479920|Depressive Disorder
1122114|NCT01479920|Depressive Symptoms
1122115|NCT01479920|Depressive Syndrome
1122116|NCT01479920|Emotional Depression
1122117|NCT01479881|Hepatitis C Virus
1122118|NCT01479881|TMC435
1122119|NCT01479881|TMC435-TiDP16-C120
1122120|NCT01479881|TMC435-C120
1122121|NCT01479881|HCV
1122122|NCT01479881|Hepatitis C
1122123|NCT01479881|Hep C
1122124|NCT01479881|Healthy participants
1122125|NCT01479868|Hepatitis C virus genotype-1
1122126|NCT01479868|Human immunodeficiency virus-type 1
1122127|NCT01479868|HCV-1
1122128|NCT01479868|HIV-1
1122129|NCT01479868|TMC435
1122130|NCT01479868|Pegylated interferon alpha-2a
1122131|NCT01479868|PegIFNα-2a
1122132|NCT01479868|Pegasys
1122133|NCT01479868|Ribavirin
1122134|NCT01479868|RBV
1122135|NCT01479868|Copegus
1122136|NCT01479855|Mild Cognitive Impairment (MCI)
1122137|NCT01479855|Alzheimers disease
1122138|NCT01479855|Vitamines
1122139|NCT01479855|Nutrients
1122140|NCT01479829|Bipolar depression
1122141|NCT01479829|Celecoxib
1122142|NCT01479829|Escitalopram
1122143|NCT01479829|Inflammation
1122144|NCT01479816|continence
1122145|NCT01479816|index
1122146|NCT01479790|Visante AS-OCT
1122147|NCT01479790|Cirrus AS-OCT
1122148|NCT01479790|Thermography
1122149|NCT01479790|Tear evaporation
1122150|NCT01479790|Tear evaporimetry
1122151|NCT01479777|Spinal Cord Injury
1122152|NCT01479777|Functional electrical stimulation
1122153|NCT01479777|Rehabilitation
1122154|NCT01479751|Rocuronium
1122155|NCT01479751|magnesium
1122156|NCT01479751|priming
1122157|NCT01479751|ketamine
1122158|NCT01479751|intubation
1122159|NCT01479738|arthroplasty
1122161|NCT01479738|capitate
1122162|NCT01479738|artery
1122163|NCT01479725|interstitial cystitis
1122164|NCT01479712|Irrigation
1122165|NCT01479712|Cesarean Section
1122166|NCT01479712|Nausea
1122167|NCT01479712|Infection
1122168|NCT01479699|Olive leaf extract
1122169|NCT01479699|Polyphenols
1122170|NCT01479699|Vascular function
1122171|NCT01479699|Bioavailability
1122172|NCT01479699|Cytokines
1122173|NCT01479686|GLIOMA
1122174|NCT01479686|NEURONAVIGATION
1122175|NCT01479686|INTERVENTIONAL MRI
1122176|NCT01479673|Enteral Nutrition
1122177|NCT01479673|Parenteral Nutrition
1122178|NCT01479673|Indirect Calorimetry
1122179|NCT01479673|Intravenous Feeding
1122180|NCT01479660|Probiotics
1122181|NCT01479660|ulcerative colitis
1122182|NCT01479660|inflammatory bowel disease
1122183|NCT01479634|HIV
1122184|NCT01479634|ART
1122185|NCT01479621|Dose Ranging
1122186|NCT01479621|Fluticasone Propionate
1122187|NCT01479621|Dry Powder Inhaler (DPI)
1122188|NCT01479621|Non-steroidal
1122189|NCT01479621|Asthma
1122190|NCT01479595|Asthma
1122191|NCT01479595|Interleukin
1122192|NCT01479595|QBX258
1122193|NCT01479595|QAX576
1122194|NCT01479595|VAK694
1122195|NCT01479582|Adult and Pediatric
1122196|NCT01479582|Unlicensed Cord Blood Unit IND
1122197|NCT01479582|NMDP
1122198|NCT01479582|Transplant
1122199|NCT01479582|Hematologic Malignancies
1122200|NCT01479582|Leukemia
1122201|NCT01479582|Multiple Myeloma
1122202|NCT01479582|Non-Hodgkin Lymphoma
1122203|NCT01479582|CML
1122204|NCT01479582|Chronic Myelogenous Leukemia
1122205|NCT01479582|Myelodyplastic Syndrome
1122206|NCT01479582|MDS
1122207|NCT01479582|Thalassemia
1122208|NCT01479582|Lysosomal Storage Diseases
1122209|NCT01479569|MRI Catheterization
1122210|NCT01479569|Pericardiocentesis
1122211|NCT01479569|MRI Safety
1122212|NCT01479569|Cardiac Magnetic Resonance Imaging
1122213|NCT01479556|Pregabalin
1122214|NCT01479556|Neuropathic pain
1122215|NCT01479556|At-level neuropathic pain
1122216|NCT01479556|Non-evoked neuropathic pain
1122217|NCT01479556|Evoked neuropathic pain
1122218|NCT01479556|Sub-acute spinal cord injury
1122219|NCT01479543|Probiotic
1122220|NCT01479543|Immunity
1122221|NCT01479543|Gastrointestinal symptoms
1122222|NCT01479530|Rasagiline
1122223|NCT01479530|Azilect
1122224|NCT01479530|Parkinson´s Disease
1122225|NCT01479530|Motor fluctuations
1122226|NCT01479517|operative
1122227|NCT01479517|dental procedure
1122228|NCT01479504|Nasopharyngeal Carcinoma
1122229|NCT01479504|neoadjuvant chemotherapy
1122230|NCT01479504|concurrent chemoradiotherapy
1122231|NCT01479504|Nedaplatin
1122232|NCT01479491|Japan
1122233|NCT01479491|Retrospective
1122234|NCT01479491|Observational
1122235|NCT01479491|Epidemiological study
1122236|NCT01479491|Children aged < 12 months
1122237|NCT01479491|Intussusception
1122238|NCT01479465|GSI
1122239|NCT01479465|Gilead
1122240|NCT01479465|Gilead Sciences
1122241|NCT01479465|GS-6624
1122242|NCT01479465|Colorectal Cancer
1122243|NCT01479465|KRAS
1122244|NCT01479465|Oncology
1122245|NCT01479465|monoclonal antibody
1122246|NCT01479452|obesity
1122247|NCT01479452|bariatric surgery
1122248|NCT01479452|weight loss
1122249|NCT01479426|Erectile dysfunction
1122250|NCT01479426|Korean Red Ginseng
1122251|NCT01479426|IIEF
1122252|NCT01479426|MSHQ
1122253|NCT01479413|Schizophrenia
1122254|NCT01479413|Oxidative stress
1122255|NCT01479413|Mitochondria
1122256|NCT01479400|antipsychotic
1122257|NCT01479400|schizophrenia
1122258|NCT01479400|infant development
1122259|NCT01479387|Zevalin
1122260|NCT01479387|CD20+
1122261|NCT01479387|Non-Hodgkin's lymphoma
1122262|NCT01479387|Mantle cell lymphoma
1122263|NCT01479374|Allergic Conjunctivitis
1122264|NCT01479374|Ocular Allergy
1122265|NCT01479361|Atovaquone
1122266|NCT01479361|Drug Interaction
1122267|NCT01479361|Pharmacokinetics
1122268|NCT01479361|Efavirenz
1122269|NCT01479361|Atazanavir-Ritonavir
1122270|NCT01479361|HIV
1122271|NCT01479348|Imaging
1122272|NCT01479348|Radiopharmaceutical
1122273|NCT01479348|Safety
1122274|NCT01479348|Dosimetry
1122275|NCT01479348|Drug Distribution
1122276|NCT01479348|Cancer
1122277|NCT01479322|Intima-media thickness
1122278|NCT01479322|Ghrelin
1122279|NCT01479322|Prader-Willi syndrome
1122280|NCT01479309|Advanced Malignancies
1122281|NCT01479309|Solid Tumors
1122282|NCT01479309|Melanoma
1122283|NCT01479309|Renal Cell Carcinoma
1122284|NCT01479309|Phase I Studies
1122285|NCT01479309|Sodium Stibogluconate
1122286|NCT01479309|Interferon Alpha-2b
1122287|NCT01479309|Intron A
1122288|NCT01479309|SSG
1122289|NCT01479283|Infection
1122290|NCT01479283|Bone Neoplasms
1122291|NCT01479283|Prosthesis
1122292|NCT01479283|Anti-Bacterial Agents
1122293|NCT01479283|Randomized
1122294|NCT01479270|recovery
1122295|NCT01479270|postoperative
1122296|NCT01479270|pain
1122297|NCT01479270|laparoscopy
1122298|NCT01479270|hysterectomy
1122299|NCT01479270|ropivacaine
1122300|NCT01479270|TAP block
1122301|NCT01479270|local anesthesia
1122302|NCT01479257|Cancer
1122303|NCT01479257|Risk factors
1122304|NCT01479257|Latinos
1122305|NCT01479257|Hispanic Americans
1122306|NCT01479257|Hispanics
1122307|NCT01479257|Latino resident
1122308|NCT01479257|Houston metropolitan area
1122309|NCT01479257|Spanish speaking
1122310|NCT01479257|Cancer risk behaviors
1122311|NCT01479257|Questionnaires
1122312|NCT01479257|Surveys
1122313|NCT01479257|Accelerometer
1122314|NCT01479244|HER2
1122315|NCT01479244|low or intermediate
1122316|NCT01479244|breast cancer
1122317|NCT01479244|node-positive tumors
1122318|NCT01479231|GERD
1122319|NCT01479231|Eosinophilic esophagitis
1122320|NCT01479231|Proton pump inhibitor
1122321|NCT01479231|dysphagia
1122322|NCT01479205|specific immunotherapy
1122323|NCT01479205|bronchial allergen provocation
1122324|NCT01479205|specific IgE
1122325|NCT01479205|specific IgG
1122326|NCT01479205|specific IgG4
1122327|NCT01479205|SIT
1122328|NCT01479192|breast
1122329|NCT01479192|cancer
1122330|NCT01479192|prevention
1122331|NCT01479192|fenretinide
1122332|NCT01479179|Breast Cancer
1122333|NCT01479179|Metastatic Breast Cancer
1122334|NCT01479179|HER-2-overexpressing breast cancer
1122335|NCT01479179|Human epidermal growth factor receptor
1122336|NCT01479179|AMG 479
1122337|NCT01479179|Trastuzumab
1122338|NCT01479179|Herceptin
1122339|NCT01479166|cystic fibrosis
1122340|NCT01479166|HRCT
1122341|NCT01479166|Sputum
1122342|NCT01479166|Blood
1122343|NCT01479166|Inflammation
1122344|NCT01479166|adaptive immune system
1122345|NCT01479166|innate immune system
1122346|NCT01479153|Central venous catheterization
1122347|NCT01479153|Major complications
1122348|NCT01479153|Internal Jugular
1122349|NCT01479153|Femoral
1122350|NCT01479153|Subclavian
1122351|NCT01479140|myocardial infarction
1122352|NCT01479140|dissection
1122353|NCT01479140|coronary Fibromuscular Dysplasia
1122354|NCT01479140|coronary ectasia
1122355|NCT01479140|atherosclerotic Coronary Artery Disease
1122356|NCT01479140|coronary vasculitis
1122357|NCT01479140|coronary embolism
1122358|NCT01479140|congenital coronary anomaly
1122359|NCT01479127|Levodopa-carbidopa intestinal gel
1122360|NCT01479127|Advanced Parkinson's disease
1122361|NCT01479127|Severe motor fluctuations
1122362|NCT01479127|Dyskinesia
1122363|NCT01479101|neo adjuvant, breast cancer
1122364|NCT01479088|Cinacalcet
1122365|NCT01479088|PK
1122366|NCT01479088|Secondary Hyperparathyroidism
1122367|NCT01479088|Paediatric
1122368|NCT01479088|Chronic Kidney Disease
1122369|NCT01479088|Dialysis
1122370|NCT01479075|central insulin
1122371|NCT01479075|insulin resistance
1122372|NCT01479075|energy metabolism
1122373|NCT01479062|behavior change
1122374|NCT01479062|pre-diabetes
1122375|NCT01479062|prevention
1122376|NCT01479062|diabetes prevention
1122377|NCT01479062|Hemoglobin A1c
1122378|NCT01479062|glucose
1122379|NCT01479062|physical activity
1122380|NCT01479062|nutrition
1122381|NCT01479062|email
1122382|NCT01479062|web
1122383|NCT01479062|obesity
1122384|NCT01479049|congenital heart disease
1122385|NCT01479049|cardiac surgery
1122386|NCT01479049|cardiopulmonary bypass
1122387|NCT01479049|cardioplegia
1122388|NCT01479036|breast cancer
1122389|NCT01479036|neoadjuvant chemotherapy
1122390|NCT01479036|recombinant human endostatin (endostar)
1122391|NCT01479036|docetaxel
1122392|NCT01479036|epirubicin
1122393|NCT01478984|NSTEMI
1122394|NCT01478984|PCI
1122395|NCT01478984|onestage
1122396|NCT01478984|multistaged
1122397|NCT01478971|Anemia
1122398|NCT01478971|Chronic Renal Failure
1122399|NCT01478971|CRF
1122400|NCT01478971|Chronic Kidney Disease
1122401|NCT01478971|CKD
1122402|NCT01478971|Erythropoietin
1122403|NCT01478971|Hematide
1122404|NCT01478971|Peginesatide
1122405|NCT01478971|Hemoglobin
1122406|NCT01478971|Hgb
1122407|NCT01478971|Red Blood Cell
1122408|NCT01478971|Red Blood Cell Production
1122409|NCT01478971|Dialysis
1122410|NCT01478958|fatty acids
1122411|NCT01478958|cardiovascular disease
1122412|NCT01478958|vascular function
1122413|NCT01478958|microparticles
1122414|NCT01478945|vitiligo
1122415|NCT01478945|early vitiligo
1122416|NCT01478945|focal vitiligo
1122417|NCT01478932|dyspnea
1122418|NCT01478932|diaphragmatic breathing
1122419|NCT01478932|Heart failure
1122420|NCT01478919|Endoscopic Mucosal Resection
1122421|NCT01478919|Laterally Spreading Tumor
1122422|NCT01478919|Local Residual Neoplasia
1122423|NCT01478919|Colonoscopy
1122424|NCT01478919|Therapy
1122425|NCT01478893|nicotine vaccine
1122426|NCT01478893|smoking vaccine
1122427|NCT01478893|smoking cessation
1122428|NCT01478893|SEL-068
1122429|NCT01478867|celiac disease
1122430|NCT01478867|gluten-free diet
1122431|NCT01478867|gluten peptides
1122432|NCT01478867|feces
1122433|NCT01478841|insulin resistance
1122434|NCT01478841|type 2 diabetes (T2D)
1122435|NCT01478841|cardiovascular complications
1122436|NCT01478841|polyphenolic compounds derived from red grape marc extracts
1122437|NCT01478841|oxidative stress
1122438|NCT01478802|Mechanical Ventilation
1122439|NCT01478802|High frequency oscillation
1122440|NCT01478802|Acute Respiratory Distress syndrome
1122441|NCT01478776|ASP
1122442|NCT01478776|LCN2
1122443|NCT01478776|RBP4
1122444|NCT01478776|C5L2
1122445|NCT01478763|PDRP
1122446|NCT01478763|vitreous
1122447|NCT01478763|protein
1122448|NCT01478763|vitrectomy
1122449|NCT01478750|obesity
1122450|NCT01478750|fat
1122451|NCT01478750|appetite
1122452|NCT01478750|digestion
1122453|NCT01478737|PDRP
1122454|NCT01478737|vitreous hemorrhage
1122455|NCT01478737|vitrectomy
1122456|NCT01478698|peritoneal dialysis
1122457|NCT01478698|peritoneal dialysis, continuous ambulatory
1122458|NCT01478698|peritonitis
1122459|NCT01478685|Relapsed or Refractory Solid Tumors
1122460|NCT01478672|Promotion health
1122461|NCT01478659|Diet
1122462|NCT01478659|Fiber
1122463|NCT01478659|Adult
1122464|NCT01478659|Fructooligosaccharide
1122465|NCT01478646|breathing therapy
1122466|NCT01478646|reflective breathing therapy
1122467|NCT01478646|COPD
1122468|NCT01478646|chronic obstructive pulmonary disease
1122469|NCT01478633|Alzheimer's disease
1122470|NCT01478633|Dementia
1122471|NCT01478633|Galantamine
1122472|NCT01478633|Donepezil
1122473|NCT01478607|Painful Diabetic Peripheral Neuropathy
1122474|NCT01478607|Qutenza
1122475|NCT01478594|metastatic colorectal cancer
1122476|NCT01478594|Avastin
1122477|NCT01478594|bevacizumab
1122478|NCT01478594|tivozanib
1122479|NCT01478594|mFOLFOX6
1122480|NCT01478594|BATON-CRC
1122481|NCT01478594|AV951
1122482|NCT01478594|ASP4130
1122483|NCT01478581|PCI-32765
1122484|NCT01478581|Multiple Myeloma
1122485|NCT01478581|Relapsed Refractory Multiple Myeloma
1122486|NCT01478581|Bruton's Tyrosine Kinase
1122487|NCT01478568|Pharmacokinetics
1122488|NCT01478568|Mirabegron
1122489|NCT01478568|Phase 1
1122490|NCT01478555|Dry Eye
1122491|NCT01478542|DLBCL
1122492|NCT01478542|Liposomal Vincristine (Marqibo)
1122493|NCT01478542|Optimised Rituximab
1122494|NCT01478542|Toxicity
1122495|NCT01478542|Elderly Patients
1122496|NCT01478542|FDG-PET
1122497|NCT01478542|Bulky Disease
1122498|NCT01478542|Radiation
1122499|NCT01478542|age >60 years
1122500|NCT01478542|First line Therapy
1122501|NCT01478542|Vitamin D
1122502|NCT01478529|Pharmacokinetics
1122503|NCT01478529|Mirabegron
1122504|NCT01478529|Phase 1
1122505|NCT01478516|autologous plasmin
1122506|NCT01478516|macular edema
1122507|NCT01478516|vitreous
1122508|NCT01478503|Pharmacokinetics
1122509|NCT01478503|Mirabegron
1122510|NCT01478503|Phase 1
1122511|NCT01478503|Dose-Escalation
1122512|NCT01478490|Pharmacokinetics,
1122513|NCT01478490|Mirabegron
1122514|NCT01478490|Metoprolol
1122515|NCT01478490|CYP2D6
1122516|NCT01478490|Phase 1
1122517|NCT01478477|Breast Cancer
1122518|NCT01478451|DOMS
1122519|NCT01478438|Unifocal
1122520|NCT01478438|20mm in diameter
1122521|NCT01478438|measures
1122522|NCT01478438|5mm away from the skin and chest
1122523|NCT01478425|Prevention
1122524|NCT01478425|Pollen
1122525|NCT01478425|Allergy
1122526|NCT01478425|Rhinitis
1122527|NCT01478412|Prostate cancer
1122528|NCT01478412|Low risk
1122529|NCT01478412|Intermediate risk
1122530|NCT01478412|T1
1122531|NCT01478412|T2a
1122532|NCT01478412|T2b
1122533|NCT01478412|Gleason 6
1122534|NCT01478412|Gleason 7
1122535|NCT01478412|PSA 10
1122536|NCT01478412|PSA 20
1122537|NCT01478373|GIST
1122538|NCT01478373|Dovitinib
1122539|NCT01478360|Asthma
1122540|NCT01478360|Secukinumab
1122541|NCT01478360|Therapeutic Uses
1122542|NCT01478360|Respiratory
1122543|NCT01478360|Lung
1122544|NCT01478360|Pulmonary
1122545|NCT01478360|inhaled
1122546|NCT01478360|corticosteroids
1122547|NCT01478347|Neisseria, Meningitis, Group B, Vaccine, At-risk, Adults
1122548|NCT01478334|High intensity exercise
1122549|NCT01478334|cardiovascular risk factors
1122550|NCT01478321|Information Not Provided
1122551|NCT01478308|prostate
1122552|NCT01478308|castration resistant
1122553|NCT01478308|hormone resistant
1122554|NCT01478308|CRPC
1122555|NCT01478295|Nursing intervention
1122556|NCT01478295|Primary Health care
1122557|NCT01478295|caregiver
1122558|NCT01478295|strain
1122559|NCT01478282|dabigatran
1122560|NCT01478282|rivaroxaban
1122561|NCT01478282|oral anticoagulants
1122562|NCT01478282|coagulation
1122563|NCT01478282|bleeding
1122564|NCT01478282|plasma concentrates
1122565|NCT01478269|Aggressive B-cell lymphoma
1122566|NCT01478269|R-CHOP
1122567|NCT01478256|blepharitis
1122568|NCT01478256|topical erythromycin
1122569|NCT01478256|topical besifloxocin
1122570|NCT01478243|Keloid
1122571|NCT01478230|Pharmacokinetics
1122572|NCT01478217|lung ultrasonography
1122573|NCT01478217|pressure-volume loops
1122574|NCT01478217|ARDS
1122575|NCT01478204|Alzheimer's disease
1122576|NCT01478204|Sleep quality
1122577|NCT01478204|Anticholinesterase drugs
1122578|NCT01478191|Hodgkin's Lymphoma
1122579|NCT01478191|Ifosfamide, Gemcitabine and Vinorelbine (IGEV)
1122580|NCT01478191|High Dose Chemotherapy (HDCT)
1122581|NCT01478191|Autologous Hematopoietic Stem Cells Transplantation (AHSCT)
1122582|NCT01478178|Glioma
1122583|NCT01478178|Glioblastoma
1122584|NCT01478178|Glioblastoma multiforme
1122585|NCT01478178|GBM
1122586|NCT01478178|brain tumor
1122587|NCT01478178|brain cancer
1122588|NCT01478178|recurrent brain tumor
1122589|NCT01478178|recurrent brain cancer
1122590|NCT01478178|refractory brain tumor
1122591|NCT01478178|refractory brain cancer
1122592|NCT01478178|recurrent GBM
1122593|NCT01478178|refractory GBM
1122594|NCT01478178|recurrent glioma
1122595|NCT01478178|refractory glioma
1122596|NCT01478178|recurrent glioblastoma
1122597|NCT01478178|refractory glioblastoma
1122598|NCT01478178|recurrent glioblastoma multiforme
1122599|NCT01478178|refractory glioblastoma multiforme
1122600|NCT01478178|failed temodar
1122601|NCT01478178|failed temozolomide
1122602|NCT01478178|temodar refractory
1122603|NCT01478178|temozolomide refractory
1122604|NCT01478178|failed avastin
1122605|NCT01478178|avastin refractory
1122606|NCT01478178|failed bevacizumab
1122607|NCT01478178|bevacizumab refractory
1122608|NCT01478178|avastin failure
1122609|NCT01478178|bevacizumab failure
1122610|NCT01478178|temodar failure
1122611|NCT01478178|temozolomide failure
1122612|NCT01478165|Palonosetron
1122613|NCT01478165|PONV(postoperative nausea and vomiting)
1122614|NCT01478165|TIVA(Total intravenous anesthesia)
1122615|NCT01478152|Asthma
1122616|NCT01478152|Ectoin
1122617|NCT01478152|Ectoine
1122618|NCT01478152|FeNO
1122619|NCT01478152|Metacholin
1122620|NCT01478152|sRaw
1122621|NCT01478139|anorectal fistula
1122622|NCT01478139|acellular dermal matrix
1122623|NCT01478139|ligation of intersphincteric fistula tract
1122624|NCT01478139|ligation of intersphincteric fistula tract and plug
1122625|NCT01478139|complications of treatment
1122626|NCT01478139|recurrence
1122627|NCT01478113|Major Depressive Disorder
1122628|NCT01478113|Therapy
1122629|NCT01478113|Medication study
1122630|NCT01478113|Depression
1122631|NCT01478113|Therapy study
1122632|NCT01478100|Coronary artery disease
1122633|NCT01478100|CT
1122634|NCT01478100|Computational flow dynamics
1122635|NCT01478074|Acute Myeloid Leukemia
1122636|NCT01478074|Relapsed leukemia
1122637|NCT01478074|Refractory leukemia
1122638|NCT01478074|Natural Killer Cells
1122639|NCT01478074|Adoptive immunotherapy
1122640|NCT01478074|NK cell infusion
1122641|NCT01478074|Haploidentical
1122642|NCT01478074|KIR mismatch
1122643|NCT01478074|Fludarabine
1122644|NCT01478074|Cytarabine
1122645|NCT01478074|Ara-C
1122646|NCT01478074|ALT-801
1122647|NCT01478048|Relapsed/Refractory Multiple Myeloma
1122648|NCT01478035|Phenytoin prophylaxis
1122649|NCT01478035|Pneumococcal meningitis
1122650|NCT01478035|Randomized
1122651|NCT01478035|Placebo-controlled
1122652|NCT01478035|Double blind
1122653|NCT01478035|Patient 50 years or older
1122654|NCT01478022|DMD
1122655|NCT01478022|Duchenne
1122656|NCT01478022|Muscular Dystrophy
1122657|NCT01477996|intravitreal therapy
1122658|NCT01477996|pain scales
1122659|NCT01477996|gauge
1122660|NCT01477996|Pain Scores
1122661|NCT01477996|Visual Analog Scale
1122662|NCT01477983|atrial fibrillation
1122663|NCT01477983|catheter ablation
1122664|NCT01477983|adenosine triphosphate
1122665|NCT01477983|antiarrhythmic drugs
1122666|NCT01477970|GnRH antagonists
1122667|NCT01477970|OHSS
1122668|NCT01477970|ovarian stimulation
1122669|NCT01477957|weight loss after bariatric surgery
1122670|NCT01477957|Insulin sensitivity
1122671|NCT01477957|insulin resistance
1122672|NCT01477944|Statins pattern of use
1122673|NCT01477944|Hypercholesterolemic patients
1122674|NCT01477944|Statins
1122675|NCT01477931|Bupropion hydrochloride extended release
1122676|NCT01477931|Wellbutrin XL
1122677|NCT01477931|Major Depressive Disorder with Atypical Features
1122678|NCT01477918|prevalence
1122679|NCT01477918|Korea
1122680|NCT01477905|priming
1122681|NCT01477905|remifentanil
1122682|NCT01477905|target-controlled infusion
1122683|NCT01477840|Misoprostol
1122684|NCT01477840|Oxytocin
1122685|NCT01477840|Cesarean Delivery
1122686|NCT01477840|Blood Loss
1122687|NCT01477814|colorectal cancer
1122688|NCT01477814|screening
1122689|NCT01477814|colonoscopy
1122690|NCT01477814|fecal immunochemical test
1122691|NCT01477814|clinical guidelines
1122692|NCT01477788|pelvic mass
1122693|NCT01477788|ovarian mass
1122694|NCT01477788|ultrasound
1122695|NCT01477788|serum markers
1122696|NCT01477788|ovarian malignancy
1122697|NCT01477775|myocardial infarction
1122698|NCT01477775|coronary stent
1122699|NCT01477775|Oral P2Y12 receptor blocker
1122700|NCT01477775|Platelet reactivity units (PRU)
1122701|NCT01477762|startle response
1122702|NCT01477762|fear conditioning
1122703|NCT01477762|PTSD
1122704|NCT01477749|prostate cancer
1122705|NCT01477749|prostate
1122706|NCT01477749|immune therapy
1122707|NCT01477749|immunotherapy
1122708|NCT01477749|vaccine
1122709|NCT01477749|dendritic cells
1122710|NCT01477749|antigen-presenting cells
1122711|NCT01477749|antigen presenting cells
1122712|NCT01477749|cancer vaccine
1122713|NCT01477749|PSA
1122714|NCT01477749|prostatic adenocarcinoma
1122715|NCT01477736|Neurogenic bladder
1122716|NCT01477736|Urodynamic
1122717|NCT01477736|Quality of life
1122718|NCT01477710|Mechanical ventilation
1122719|NCT01477710|Tidal volume
1122720|NCT01477710|Respiratory rate
1122721|NCT01477697|Trauma
1122722|NCT01477671|Dengue
1122723|NCT01477671|Dengue Fever
1122724|NCT01477671|Dengue Hemorrhagic Fever
1122725|NCT01477658|Congenital Complete Atrioventricular Heart Block
1122726|NCT01477658|Pacemaker
1122727|NCT01477658|Cardiac pacing
1122728|NCT01477658|Children
1122729|NCT01477658|Heart failure
1122730|NCT01477658|Ventricular dyssynchrony
1122731|NCT01477658|Echocardiography
1122732|NCT01477658|Quality of life
1122733|NCT01477658|Six-minute walk test
1122734|NCT01477658|Young adults
1122735|NCT01477619|Pharmacokinetics
1122736|NCT01477606|Acute myeloid leukemia
1122737|NCT01477606|FLT3-ITD
1122738|NCT01477606|midostaurin (PKC412)
1122739|NCT01477593|circumcision, chinese children, pain
1122740|NCT01477554|Women
1122741|NCT01477554|Maternal morbidity
1122742|NCT01477554|Maternal mortality
1122743|NCT01477554|Perinatal mortality
1122744|NCT01477554|Perinatal morbidity
1122745|NCT01477554|Training
1122746|NCT01477554|Obstetric Emergency
1122747|NCT01477554|Medical team
1122748|NCT01477554|Simulation
1122749|NCT01477541|Prenatal care
1122750|NCT01477541|Maternal mortality
1122751|NCT01477541|Perinatal mortality
1122752|NCT01477541|Perinatal
1122753|NCT01477541|Puerperium
1122754|NCT01477541|Puerperium care
1122755|NCT01477541|Midwives
1122756|NCT01477541|Midwife
1122757|NCT01477541|Obstetric
1122758|NCT01477541|Nurse
1122759|NCT01477541|Integration
1122760|NCT01477541|Alternative personnel
1122761|NCT01477541|Skilled attendant
1122762|NCT01477541|Birth attendant
1122763|NCT01477541|Delivery
1122764|NCT01477541|Delivery services
1122765|NCT01477541|Best practices
1122766|NCT01477541|Rural
1122767|NCT01477528|HeartMate II
1122768|NCT01477528|Anticoagulation
1122769|NCT01477528|Thoratec Corporation
1122770|NCT01477502|urinary tract infection
1122771|NCT01477502|spinal cord injury
1122772|NCT01477502|homeopathy
1122773|NCT01477502|prevention
1122774|NCT01477476|DKA
1122775|NCT01477476|Diabetes
1122776|NCT01477476|Type I Diabetes
1122777|NCT01477463|quality of life
1122778|NCT01477450|Hypobaric hypoxemia
1122779|NCT01477450|Altitude
1122780|NCT01477450|Oxygen
1122781|NCT01477450|oxygen concentrator
1122782|NCT01477437|teens
1122783|NCT01477437|adolescents
1122784|NCT01477437|Internet intervention
1122785|NCT01477437|Hemophilia
1122786|NCT01477424|Drug-drug interaction
1122787|NCT01477424|Pharmacokinetics
1122788|NCT01477424|PA21
1122789|NCT01477411|Drug-drug interaction
1122790|NCT01477411|Pharmacokinetics
1122791|NCT01477411|PA21
1122792|NCT01477385|dental caries
1122793|NCT01477385|primary teeth
1122794|NCT01477385|permanent teeth
1122795|NCT01477385|silver diamine fluoride
1122796|NCT01477372|Pregnancy
1122797|NCT01477372|Exercise
1122798|NCT01477372|Excessive weight gain
1122799|NCT01477372|Outcomes
1122800|NCT01477372|Urinary incontinence
1122801|NCT01477333|Tyvaso
1122802|NCT01477333|UT-15C SR
1122803|NCT01477333|PAH
1122804|NCT01477320|Enteral Nutrition
1122805|NCT01477320|Stress Ulcer Prophylaxis
1122806|NCT01477320|Critically Ill Patients
1122807|NCT01477320|Overt and significant GI bleeding
1122808|NCT01477320|Stress gastropathy
1122809|NCT01477320|Clostridium Difficile pseudomembranous colitis
1122810|NCT01477320|Vital AF
1122811|NCT01477320|Small peptide fish oil structured lipids
1122812|NCT01477320|Fructose oligosaccharide
1122813|NCT01477307|obesity
1122814|NCT01477307|non-alcoholic fatty liver disease
1122815|NCT01477294|Total
1122816|NCT01477294|Intra and Extracellular Water
1122817|NCT01477294|Energy Expenditure, Physical Activity
1122818|NCT01477294|Body Composition
1122819|NCT01477294|Dilution Techniques
1122820|NCT01477281|chronic venous insufficiency
1122821|NCT01477281|Daflon
1122822|NCT01477281|Venaflon
1122823|NCT01477268|antidepressants
1122824|NCT01477268|depression
1122825|NCT01477268|zoloft
1122826|NCT01477268|psychiatry
1122827|NCT01477268|psychology
1122828|NCT01477255|daily assessment
1122829|NCT01477255|electronic diary
1122830|NCT01477255|coping strategies
1122831|NCT01477255|resiliency of cancer patients
1122832|NCT01477255|psychology
1122833|NCT01477242|vomiting
1122834|NCT01477242|anti-emetics
1122835|NCT01477242|ketamine
1122836|NCT01477242|sedation
1122837|NCT01477229|Rectal cancer
1122838|NCT01477229|Quality of Life
1122839|NCT01477229|Abdominoperineal Resection
1122840|NCT01477229|Anterior Resection
1122841|NCT01477229|Palliative cancer treatment
1122842|NCT01477229|Radio chemotherapy
1122843|NCT01477216|Glycemic index
1122844|NCT01477216|Glycemic responses
1122845|NCT01477216|Insulin responses
1122846|NCT01477216|Insulinemic index
1122847|NCT01477216|Carbohydrates
1122848|NCT01477216|Methodology
1122849|NCT01477216|Glucose metabolism
1122850|NCT01477177|Barrett's esophagus dysplasia
1122851|NCT01477164|Exercise
1122852|NCT01477164|Aging
1122853|NCT01477164|Sarcopenia
1122854|NCT01477164|Muscle function
1122855|NCT01477151|isoflurane
1122856|NCT01477151|sevoflurane
1122857|NCT01477151|troponin
1122858|NCT01477151|anesthesia
1122859|NCT01477151|cardioprotection
1122860|NCT01477151|preconditioning
1122861|NCT01477151|cardiac surgery
1122862|NCT01477151|cardiac anesthesia
1122863|NCT01477138|Sick Sinus Syndrome
1122864|NCT01477138|Cardiac Pacing, Artificial
1122865|NCT01477138|Cardiac Resynchronization Therapy
1122866|NCT01477138|Pacemaker, Artificial
1122867|NCT01477138|SSS
1122868|NCT01477125|adhd
1122869|NCT01477125|adults
1122870|NCT01477125|working memory
1122871|NCT01477125|training
1122872|NCT01477125|RCT
1122873|NCT01477112|Type 2 diabetes
1122874|NCT01477112|β-carotene
1122875|NCT01477112|Oxidative balance
1122876|NCT01477112|Oxidants
1122877|NCT01477112|Antioxidants
1122878|NCT01477086|Sarcopenia
1122879|NCT01477086|Hip fracture
1122880|NCT01477086|Frailty
1122881|NCT01477073|in-vitro fertilization
1122882|NCT01477073|reproductive disorder
1122883|NCT01477034|Vitamin D deficiency
1122884|NCT01477034|Obesity
1122885|NCT01477034|Inflammation
1122886|NCT01477034|Low-grade, chronic inflammation
1122887|NCT01477034|Adipose tissue inflammation
1122888|NCT01477034|Diabetes
1122889|NCT01477034|Type 2 diabetes mellitus
1122890|NCT01477034|Insulin resistance
1122891|NCT01477034|Intestinal permeability
1122892|NCT01477008|Knee
1122893|NCT01477008|Cartilage repair
1122894|NCT01477008|Cartilage regeneration
1122895|NCT01477008|Chondral
1122896|NCT01477008|Osteochondral
1122897|NCT01477008|Biphasic scaffold
1122898|NCT01477008|Medical device
1122899|NCT01477008|Autologous
1122900|NCT01477008|Synthetic
1122901|NCT01477008|Medial condyle
1122902|NCT01477008|Lateral condyle
1122903|NCT01477008|Trochlea
1122904|NCT01476995|Cardiovascular system
1122905|NCT01476995|gastrointestinal system
1122906|NCT01476995|kidneys
1122907|NCT01476995|liver
1122908|NCT01476995|lungs
1122909|NCT01476969|Ischemia reperfusion injury
1122910|NCT01476969|Cardiopulmonary bypass
1122911|NCT01476969|Remote Ischemic Postconditioning
1122912|NCT01476969|Other Functional Disturbances Following Cardiac Surgery
1122913|NCT01476930|migraine
1122914|NCT01476930|prophylactic treatment
1122915|NCT01476930|cupping
1122916|NCT01476930|serkangabin
1122917|NCT01476904|Asthma
1122918|NCT01476904|Bronchial Asthma
1122919|NCT01476904|Shortness of breath
1122920|NCT01476891|MBSR
1122921|NCT01476891|Cancer
1122922|NCT01476891|Online
1122923|NCT01476891|Mindfulness Meditation
1122924|NCT01476891|Randomized Waitlist Controlled Trial
1122925|NCT01476878|Radiosurgery
1122926|NCT01476878|Frameless radiosurgery
1122927|NCT01476878|Accuracy
1122928|NCT01475786|nerve pain
1122929|NCT01475786|diabetic nerve pain
1122930|NCT01475786|throbbing
1122931|NCT01475786|burning
1122932|NCT01475786|painful feet
1122933|NCT01475786|tingling
1122934|NCT01475786|numbness
1122935|NCT01475773|self-esteem
1122936|NCT01475773|personality
1122937|NCT01475773|quality of life
1122938|NCT01475773|malocclusion
1122939|NCT01475773|orthodontics
1122940|NCT01475760|chronic kidney disease
1122941|NCT01475760|serum phosphorus
1122942|NCT01475760|salivary phosphorus
1122943|NCT01475760|FGF23
1122944|NCT01475734|glucose clamp
1122945|NCT01475734|hypoglycemia
1122946|NCT01475721|ADVAIR
1122947|NCT01475721|Asthma
1122948|NCT01475721|safety
1122949|NCT01475721|FLOVENT
1122950|NCT01475708|Lyme borreliosis
1122951|NCT01475708|Erythema migrans
1122952|NCT01475708|Doxycycline
1122953|NCT01475708|Subjective symptoms
1122954|NCT01475708|Outcome
1122961|NCT01475682|Obstructive sleep apnea
1122962|NCT01475682|cardiometabolic complications
1122963|NCT01475682|Effects of CPAP treatment
1122964|NCT01476800|Drugs, Investigational
1122965|NCT01476800|pharmacokinetics
1122966|NCT01476800|Urinary Bladder, Overactive
1122967|NCT01476800|YM178
1122968|NCT01476800|Mirabegron
1122969|NCT01476787|Follicular lymphoma
1122970|NCT01476787|Non-Hodgkins Follicular Lymphoma
1122971|NCT01476787|treatment for Follicular Lymphoma
1122972|NCT01476787|rituximab treatment
1122973|NCT01476787|rituximab and lenalidomide treatment
1122974|NCT01476761|Surgical tissue resection
1122975|NCT01476761|Tissue dissection
1122976|NCT01476761|Tissue transection
1122977|NCT01476761|Anastomosis of gastrointestina tissue
1122978|NCT01476722|Silicone Hydrogel
1122979|NCT01476722|Soft Contact Lenses
1122980|NCT01476722|Multi-Purpose Solution
1122981|NCT01476709|Puncture; Instrument
1122982|NCT01476709|Optics and Photonics
1122983|NCT01476709|Pain
1122984|NCT01476696|Sickle cell disease
1122985|NCT01476696|pediatrics
1122986|NCT01476696|SCD
1122987|NCT01476696|children
1122988|NCT01476696|child
1122989|NCT01476696|kids
1122990|NCT01476696|pain crisis
1122991|NCT01476696|sickle cell anemia
1122992|NCT01476696|sickle cell pain
1122993|NCT01476683|Antidiarrheals
1122994|NCT01476670|Posterior fossa brain tumor
1122995|NCT01476670|Cerebral blood flow
1122996|NCT01476670|Cerebral autoregulation
1122997|NCT01476670|Carbon dioxide reactivity
1122998|NCT01476670|Transcranial Doppler
1122999|NCT01476657|Phase 1
1123000|NCT01476644|Health related quality of life
1123001|NCT01476644|Clinical measures of vision
1123002|NCT01476618|Provider Perspectives
1123003|NCT01476618|Barriers
1123004|NCT01476618|OIF/OEF Veterans
1123005|NCT01476605|prolotherapy
1123006|NCT01476605|Platelet rich plasma
1123007|NCT01476605|tennis elbow
1123008|NCT01476605|lateral epicondylosis
1123009|NCT01476592|gastrointestinal neuroendocrine tumor
1123010|NCT01476579|Coronary CT
1123011|NCT01476579|Sensitivity
1123012|NCT01476579|Specificity
1123013|NCT01476579|Radiation
1123014|NCT01476579|Tomography, X-Ray Computed
1123015|NCT01476579|Coronary angiography
1123016|NCT01476566|aged
1123017|NCT01476566|family practice
1123018|NCT01476553|gastric cancer
1123019|NCT01476553|extensive intraperitoneal lavage
1123020|NCT01476553|EIPL
1123021|NCT01476553|intraperitoneal tumor cells
1123022|NCT01476553|peritoneal carcinomatosis
1123023|NCT01476514|Hyperekplexia
1123024|NCT01476514|Pain modulation
1123025|NCT01476514|Glycine receptors
1123026|NCT01476514|Hyperalgesia
1123027|NCT01476514|Spinal inhibitory interneurons
1123028|NCT01476501|vitamin D
1123029|NCT01476501|bone health
1123030|NCT01476501|diabetes
1123031|NCT01476501|nephropathy
1123032|NCT01476462|Acute lymphoblastic leukemia
1123033|NCT01476462|Ponte-di-Legno consortium
1123034|NCT01476462|Second cancer
1123035|NCT01476462|Survival
1123036|NCT01476449|Diabetic Macular Edema
1123037|NCT01476449|Diabetic Retinal Swelling
1123038|NCT01476449|DIabetic Eye Disease
1123039|NCT01476436|Cardio vascular risk factors
1123040|NCT01476423|Glanzmann's Thrombasthenia
1123041|NCT01476397|full-term
1123042|NCT01476397|formula-fed infants
1123043|NCT01476384|Glucose
1123044|NCT01476384|insulin
1123045|NCT01476384|Glycocalyx
1123046|NCT01476384|Muscle
1123047|NCT01476384|Vascularisation
1123048|NCT01476384|young
1123049|NCT01476384|elderly
1123050|NCT01476371|Group treatment
1123051|NCT01476371|Mindfulness
1123052|NCT01476371|Minor mental disorders
1123053|NCT01476371|Inflammation
1123054|NCT01476332|eyes
1123055|NCT01476332|cis-urocanic acid
1123056|NCT01476332|safety
1123057|NCT01476332|tolerability
1123058|NCT01476332|pharmacokinetics
1123059|NCT01476306|feasibility
1123060|NCT01476306|effectiveness
1123061|NCT01476306|Parkinson disease care
1123062|NCT01476306|care via telemedicine
1123063|NCT01476293|Infiltration
1123064|NCT01476293|Extravasation
1123065|NCT01476293|Leaking
1123066|NCT01476293|PIV Infiltration
1123067|NCT01476293|IV Infiltration
1123068|NCT01476293|Optical Detection of Infiltration
1123069|NCT01476293|Optical Monitoring
1123070|NCT01476280|antiemetics
1123071|NCT01476280|ramosetron
1123072|NCT01476280|palonosetron
1123073|NCT01476280|PONV(postoperative nausea and vomiting)
1123074|NCT01476254|Postoperative pulmonary complications
1123075|NCT01476254|Laparoscopic surgery
1123076|NCT01476215|paracetamol
1123077|NCT01476202|craving, provoked craving, smoking cessation, nicotine replacement therapy, NRT
1123078|NCT01476189|pharmacokinetic
1123079|NCT01476189|paracetamol
1123080|NCT01476189|Healthy volunteer
1123081|NCT01476189|steady state
1123082|NCT01476176|Bioequivalence
1123083|NCT01476176|Pharmacokinetics
1123084|NCT01476176|Healthy volunteers
1123085|NCT01476176|paracetamol
1123086|NCT01476176|caffeine
1123087|NCT01476163|AT1001
1123088|NCT01476163|Lysosomal storage disease
1123089|NCT01476163|Lysosomal Storage Disorder
1123090|NCT01476163|migalastat
1123091|NCT01476163|Fabry disease
1123092|NCT01476163|Fabry
1123093|NCT01476163|Amicus
1123094|NCT01476137|oncology
1123095|NCT01476137|solid tumors
1123096|NCT01476137|multiple myeloma
1123097|NCT01476137|AKT inhibitor
1123098|NCT01476137|MEK inhibitor
1123099|NCT01476111|tumor antigens
1123100|NCT01476111|observational
1123101|NCT01476111|breast cancer
1123102|NCT01476111|biomarkers
1123103|NCT01476111|Neoadjuvant
1123107|NCT01476046|Acute Lung Injury (ALI)
1123108|NCT01476046|Acute Respiratory Distress Syndrome (ARDS)
1123109|NCT01476033|Oxidative stress
1123110|NCT01476033|inflammation
1123111|NCT01476033|blood flow
1123112|NCT01476020|Drug eluting stent
1123113|NCT01476020|Dual antiplatelet therapy
1123114|NCT01476020|bleeding
1123115|NCT01476020|stent thrombosis
1123116|NCT01476020|follow-up of the drug eluting stent
1123117|NCT01476007|primary health care
1123118|NCT01476007|Vitamin B 12 Deficiency
1123119|NCT01475981|JTK-853
1123120|NCT01475981|single dose
1123121|NCT01475942|elderly
1123122|NCT01475942|probiotic
1123123|NCT01475942|bowel function
1123124|NCT01475942|pathogen
1123125|NCT01475942|constipation
1123126|NCT01475942|diarrhoea
1123127|NCT01475942|Subclinical levels
1123128|NCT01475929|irritable bowel syndrome
1123129|NCT01475929|probiotic
1123130|NCT01475916|Asthma
1123131|NCT01475916|Educational program
1123132|NCT01475916|Quality of life
1123133|NCT01475916|School-aged children
1123134|NCT01475903|Obesity
1123135|NCT01475903|Sleeve gastrectomy
1123136|NCT01475903|Nutritional impact
1123137|NCT01475903|Vitamin deficiency
1123138|NCT01475890|HIV/AIDS
1123139|NCT01475890|Nutrition
1123140|NCT01475877|bromfenac
1123141|NCT01475877|nepafenac
1123142|NCT01475877|PRK
1123143|NCT01475877|epithelial healing,
1123144|NCT01475864|Choledocholithiasis
1123145|NCT01475864|metal stents
1123146|NCT01475864|biliary duct stent
1123147|NCT01475851|Tenofovir disoproxil fumarate, compensated chronic hepatitis B
1123148|NCT01475838|HIV-1
1123149|NCT01475838|HIV
1123150|NCT01475838|Treatment Experienced
1123151|NCT01475812|COPD
1123152|NCT01475812|activities of daily living
1123153|NCT01475812|pulmonary hyperinflation
1123154|NCT01475812|exercise
1123155|NCT01475643|Pediatric cataract
1123156|NCT01475630|temporomandibular joint
1123157|NCT01475630|rehabilitation medicine
1123158|NCT01475630|joint diseases
1123159|NCT01475630|physical therapy
1123160|NCT01475604|Pulsed Radio Frequency, Electromagnetic Field therapy
1123161|NCT01475591|persistent neuromusculoskeletal pain
1123162|NCT01475591|neck
1123163|NCT01475591|shoulder
1123164|NCT01475591|back-area
1123165|NCT01475591|risk
1123166|NCT01475591|longlasting
1123167|NCT01475591|pain syndrome
1123168|NCT01475578|Vascular Dementia
1123169|NCT01475565|polycystic ovary syndrome (PCOS)
1123170|NCT01475565|insulin sensitivity
1123171|NCT01475565|insulin resistance
1123172|NCT01475565|gestational diabetes
1123173|NCT01475565|pregnancy
1123174|NCT01475565|estrogen
1123175|NCT01475565|glucose intolerance
1123176|NCT01475565|obesity
1123177|NCT01475565|ovulatory disorder
1123178|NCT01475565|racial differences
1123179|NCT01475565|hyperandrogenism
1123180|NCT01475552|platelet reactivity
1123181|NCT01475552|platelet function assay
1123182|NCT01475552|abciximab
1123183|NCT01475552|tailored therapy
1123184|NCT01475539|Polio
1123185|NCT01475539|Poliovirus
1123186|NCT01475539|Oral poliovirus vaccine
1123187|NCT01475539|IMOVAX Polio®
1123188|NCT01475526|grocery store
1123189|NCT01475526|nutrition
1123190|NCT01475526|Latino
1123191|NCT01475526|Hispanic
1123192|NCT01475513|oral contraceptive
1123193|NCT01475513|birth control pill
1123194|NCT01475513|women
1123195|NCT01475513|healthy volunteer
1123196|NCT01475513|insulin sensitivity
1123197|NCT01475513|insulin resistance
1123198|NCT01475513|cardiovascular risk factors
1123199|NCT01475513|endothelial function
1123200|NCT01475513|estrogen metabolism
1123201|NCT01475513|racial difference
1123202|NCT01475513|glucose intolerance
1123203|NCT01475474|incontinence
1123204|NCT01475474|bowel
1123205|NCT01475474|movement
1123206|NCT01475474|fecal
1123207|NCT01475474|anal
1123208|NCT01475474|diarrhea
1123209|NCT01475474|stool
1123210|NCT01475474|rectal
1123211|NCT01475474|feces
1123212|NCT01475474|uncontrolled
1123213|NCT01475474|loose
1123214|NCT01475474|leakage
1123215|NCT01475474|rectum
1123216|NCT01475474|BM
1123217|NCT01475474|watery
1123218|NCT01475474|urgent
1123219|NCT01475474|flatulence
1123220|NCT01475474|gas
1123221|NCT01475461|Phase 2
1123222|NCT01475461|type 2 diabetes mellitus
1123223|NCT01475461|PF-04937319
1123224|NCT01475448|biomechanics
1123225|NCT01475448|motor control
1123226|NCT01475448|movement
1123227|NCT01475448|walking
1123228|NCT01475448|running
1123229|NCT01475448|sedentarism
1123230|NCT01475448|joint moment
1123231|NCT01475409|anti-TNF
1123232|NCT01475409|tuberculosis
1123233|NCT01475409|QuantiFERON-TB Gold In-Tube
1123234|NCT01475409|tuberculin skin test
1123235|NCT01475409|rheumatoid arthritis
1123236|NCT01475409|spondyloarthritis
1123237|NCT01475396|exercise
1123238|NCT01475396|physical activity
1123239|NCT01475396|cognition
1123240|NCT01475396|brain
1123241|NCT01475396|aging
1123242|NCT01475396|BDNF
1123243|NCT01475383|Tourette's Syndrome in adults
1123244|NCT01475383|Safety and Efficacy
1123245|NCT01475383|Randomized
1123246|NCT01475383|Placebo Control
1123247|NCT01475383|Cross-over
1123248|NCT01475370|Acute myeloid leukemia
1123249|NCT01475370|WT1
1123250|NCT01475357|congenital heart defects
1123251|NCT01475357|growth failure
1123252|NCT01475344|Trauma patient with major bleeding
1123253|NCT01475331|pancreatic cyst
1123254|NCT01475331|chemotherapy
1123255|NCT01475331|ethanol
1123256|NCT01475331|ablation
1123257|NCT01475318|complete abortion rate
1123258|NCT01475318|side effects
1123259|NCT01475318|induction-to-abortion interval
1123260|NCT01475305|RSV, Healthy adults, MEDI-557, intranasal challenge, human model
1123261|NCT01475292|COPD
1123262|NCT01475279|Warfarin
1123263|NCT01475279|Dantonic
1123264|NCT01475279|Pharmacodynamics
1123265|NCT01475279|Pharmacokinetics
1123266|NCT01475279|Interaction
1123267|NCT01475266|Bladder Cancer
1123268|NCT01475266|NMIBC
1123269|NCT01475266|TURBT
1123270|NCT01475266|Apaziquone
1123271|NCT01475266|EOquin
1123272|NCT01475266|Immediate instillation
1123273|NCT01475240|HIV
1123274|NCT01475227|HIV
1123275|NCT01475227|Bilirubin
1123276|NCT01475214|potassium bicarbonate
1123277|NCT01475214|urinary N-telopeptide
1123278|NCT01475214|urinary nitrogen
1123279|NCT01475214|net acid excretion
1123280|NCT01475201|Type 2 diabetes
1123281|NCT01475201|Hypertension
1123282|NCT01475201|Primary Care
1123283|NCT01475201|Physical Activity
1123284|NCT01475201|Behavioural Intervention
1123285|NCT01475201|Pedometer
1123286|NCT01475201|Accelerometer
1123287|NCT01475201|Arterial Stiffness
1123288|NCT01475201|Carotid femoral pulse wave velocity
1123289|NCT01475201|Vascular disease risk
1123290|NCT01475201|Vascular disease prevention
1123291|NCT01475201|Intervention
1123292|NCT01475188|specific subcutaneous immunotherapy
1123293|NCT01475188|seasonal allergic rhinitis
1123294|NCT01475188|regulatory lymphocytes
1123295|NCT01475188|signal transduction
1123296|NCT01475188|histamine receptor
1123297|NCT01475162|acute Graft versus Host Disease (aGVHD)
1123298|NCT01475162|steroid refractory acute Graft versus Host Disease (aGVHD)
1123299|NCT01475162|chronic Graft versus Host Disease (cGVHD)
1123300|NCT01475162|corticosteroids
1123301|NCT01475162|allogeneic hematopoietic stem cell transplantation
1123302|NCT01475149|Antiphospholipid syndrome
1123303|NCT01475149|Antiphospholipid antibodies
1123304|NCT01475149|Systemic lupus erythematosus
1123305|NCT01475149|Annexin A5 and Annexin A5 resistance assay
1123306|NCT01475123|Nicorandil
1123307|NCT01475123|Randomized control study
1123308|NCT01475123|Hemodialysis
1123309|NCT01475123|Coronary Artery Disease
1123310|NCT01475110|Imatinib
1123311|NCT01475110|Chronic Myeloid Leukaemia
1123312|NCT01475110|Nilotinib
1123313|NCT01475110|Adult patients
1123314|NCT01475110|Imatinib resistant
1123315|NCT01475097|AE - Adverse event
1123316|NCT01475097|Arteriography
1123317|NCT01475097|IA - Intra-arterial
1123318|NCT01475097|IOCM - Iso-Osmolar Contrast Medium
1123319|NCT01475097|LOCM - Low-Osmolar Contrast Medium
1123320|NCT01475097|Patient Comfort
1123321|NCT01475097|Body Image Disturbance
1123322|NCT01475097|Patient
1123323|NCT01475084|Flex-rigid pleuroscopy
1123324|NCT01475084|cryobiopsy
1123325|NCT01475084|pleural biopsy
1123326|NCT01475084|pleural effusion
1123327|NCT01475084|safety
1123328|NCT01475084|thoracoscopy
1123329|NCT01475045|COPD
1123330|NCT01475032|Asthma
1123331|NCT01475032|children
1123332|NCT01475032|chronic treatment
1123333|NCT01475019|Obesity
1123334|NCT01475019|Polycystic Ovaries Syndrome
1123335|NCT01475019|Orlistat
1123336|NCT01475019|Sibutramine
1123337|NCT01475019|Androgen levels
1123338|NCT01475019|Insulin resistance
1123339|NCT01475006|Epidermal Growth Factor Receptor Variant III
1123340|NCT01475006|EGFRvIII
1123341|NCT01475006|Glioma
1123342|NCT01475006|Anaplastic Astrocytomas
1123343|NCT01475006|Glioblastoma Multiforme
1123344|NCT01475006|Antibody drug conjugate
1123345|NCT01475006|brain tumor
1123346|NCT01474980|Congenital Myasthenic Syndrome
1123347|NCT01474980|Pregnancy
1123348|NCT01474980|Outcome
1123349|NCT01474967|polycystic ovary syndrome
1123350|NCT01474967|lipid profile
1123351|NCT01474967|metformin
1123352|NCT01474954|HIV
1123353|NCT01474954|Antiretroviral Medication
1123354|NCT01474954|Cardiovascular Disease Risk
1123355|NCT01474941|Multiple Dose Study Overweight Healthy Subjects Body Weight Modified-Release Formulation
1123356|NCT01474928|Asthma
1123357|NCT01474928|Community-based participatory research
1123358|NCT01474928|Educational intervention
1123359|NCT01474928|Ethno-cultural community
1123360|NCT01474928|Video recording
1123361|NCT01474928|Patient education handout
1123362|NCT01474915|Neurosurgery
1123363|NCT01474902|pediatric
1123364|NCT01474902|asymptotic venous thrombosis
1123365|NCT01474902|Enoxaparin
1123366|NCT01474902|pediatric cardiac surgery
1123367|NCT01474889|Hypoglycemia, Unawareness, RT-CGM, Type 1 Diabetes
1123368|NCT01474876|Post-marketing observational study (PMOS) Protocol
1123369|NCT01474876|Effectiveness of Adalimumab (HUMIRA®)
1123370|NCT01474876|Psoriatic Arthritis
1123371|NCT01474876|Ankylosing Spondylitis
1123372|NCT01474850|mechanical ventilation
1123373|NCT01474850|pressure control ventilation
1123374|NCT01474850|lung recruitment
1123375|NCT01474850|positive end expiratory pressure
1123376|NCT01474850|opto-electronic plethysmography
1123377|NCT01474850|chest wall volume variation
1123378|NCT01474850|intravenous anesthesia
1123379|NCT01474837|depressive disorders
1123380|NCT01474837|exercise therapy
1123381|NCT01474824|Cardiac output
1123382|NCT01474824|Stroke volume
1123383|NCT01474811|Hepatitis
1123384|NCT01474811|Hepatitis C
1123385|NCT01474811|HCV-TARGET
1123386|NCT01474811|HCV
1123387|NCT01474811|Observational Study
1123388|NCT01474798|Acne Vulgaris
1123389|NCT01474785|Obesity
1123390|NCT01474785|Bariatric surgery
1123391|NCT01474785|Nashville, Tennessee
1123392|NCT01474772|Diabetic Peripheral Neuropathy
1123393|NCT01474772|Pain on Walking
1123394|NCT01474772|Pregabalin
1123395|NCT01474746|Fragile X Syndrome
1123396|NCT01474746|Pediatrics
1123397|NCT01474746|sertraline
1123398|NCT01474746|autism
1123399|NCT01474733|resident education
1123400|NCT01474733|health literacy
1123401|NCT01474733|curriculum
1123402|NCT01474720|Systemic Lupus Erythematosus
1123403|NCT01474720|Lupus
1123404|NCT01474720|SLE
1123405|NCT01474720|Zostavax
1123406|NCT01474720|shingles
1123407|NCT01474707|COPD
1123408|NCT01474707|Educational materials
1123409|NCT01474707|Cultural background
1123410|NCT01474707|Instructional videos
1123411|NCT01474707|Patient education handouts
1123412|NCT01474707|Lung age
1123413|NCT01474694|prospective study
1123414|NCT01474694|multicenter trial
1123415|NCT01474694|analysis, computer assisted image
1123416|NCT01474694|CE marked
1123417|NCT01474694|medical devices
1123418|NCT01474694|catheter ablation
1123419|NCT01474681|hematologic malignancies
1123420|NCT01474681|leukemia
1123421|NCT01474681|lymphoma
1123422|NCT01474655|epiretinal membrane
1123423|NCT01474655|visual acuity
1123424|NCT01474655|metamorphopsia
1123425|NCT01474655|thickness of retinal layers
1123426|NCT01474655|spectral domain optical coherence tomography
1123427|NCT01474642|Advanced or recurrent esophageal squamous cell carcinoma
1123428|NCT01474642|Randomizes phase II trial
1123429|NCT01474642|Capecitabine
1123430|NCT01474642|Cisplatin
1123431|NCT01474642|Genexol
1123432|NCT01474629|oxidative stress
1123433|NCT01474629|inflammation
1123434|NCT01474629|endotoxemia
1123435|NCT01474629|strenuous exercise
1123436|NCT01474616|Aging
1123437|NCT01474616|Health Services
1123438|NCT01474616|Knowledge Translation
1123439|NCT01474616|Long-Term Care Facilities
1123440|NCT01474616|Mobility
1123441|NCT01474616|Psychosocial And Health Behaviours
1123442|NCT01474603|observational study
1123443|NCT01474577|stress test
1123444|NCT01474577|cardiac issues
1123445|NCT01474577|Rb-82 PET Myocardial Perfusion Imaging
1123446|NCT01474577|11-150
1123574|NCT01474005|laryngectomy
1123447|NCT01474577|one or more 82Rb myocardial perfusion stress tests
1123448|NCT01474564|Blood draw
1123449|NCT01474564|pancreas
1123450|NCT01474564|Tumorigenic Cells
1123451|NCT01474564|11-141
1123452|NCT01474551|Vemurafenib
1123453|NCT01474551|skin cancer
1123454|NCT01474551|Stage IV
1123455|NCT01474551|advanced stage III
1123456|NCT01474551|11-091
1123457|NCT01474538|diabetes
1123458|NCT01474538|type 2 diabetes
1123459|NCT01474538|insulin pump
1123460|NCT01474538|continuous subcutaneous insulin infusion
1123461|NCT01474538|CSII
1123462|NCT01474538|A1C
1123463|NCT01474486|thiamin
1123464|NCT01474486|pyridoxine
1123465|NCT01474486|vitamin D
1123466|NCT01474486|zinc
1123467|NCT01474486|congestive heart failure (CHF)
1123468|NCT01474486|ischemic cardiomyopathy
1123469|NCT01474486|nutritional injury
1123470|NCT01474486|quality of life
1123471|NCT01474473|CACIPLIQ20
1123472|NCT01474473|Matrix Therapy
1123473|NCT01474473|Diabetic foot
1123474|NCT01474460|warfarin
1123475|NCT01474460|phytonadione
1123476|NCT01474460|INR
1123477|NCT01474447|low back pain
1123478|NCT01474434|coronary artery disease,
1123479|NCT01474434|LCQ908,
1123480|NCT01474434|hyperlipidemia,
1123481|NCT01474434|hypertriglyceridemia,
1123482|NCT01474434|pradigastat
1123483|NCT01474421|Parkinson's disease
1123484|NCT01474421|Dyskinesia
1123485|NCT01474421|Movement disorders
1123486|NCT01474421|L-dopa
1123487|NCT01474408|Coronary artery bypass
1123488|NCT01474408|Exercise therapy
1123489|NCT01474408|Revascularization (PCI)
1123490|NCT01474395|schizophrenia
1123491|NCT01474395|cognitive remediation
1123492|NCT01474395|NMDA
1123493|NCT01474382|OraVerse
1123494|NCT01474382|Safety
1123495|NCT01474382|Efficacy
1123496|NCT01474382|Pediatric
1123497|NCT01474382|Reversal of dental anesthesia
1123498|NCT01474369|Drug Therapy
1123499|NCT01474356|brachytherapy
1123500|NCT01474356|interstitial hyperthermia
1123501|NCT01474356|cervical cancer
1123502|NCT01474356|side effects
1123503|NCT01474356|Locally advanced cervical cancer patients
1123504|NCT01474343|Neurodegenerative Diseases
1123505|NCT01474343|Nervous System Diseases
1123506|NCT01474343|Genetic Diseases, Inborn
1123507|NCT01474343|Metabolic Diseases
1123508|NCT01474343|Gene Therapy
1123509|NCT01474343|Adenovirus Associated Vector
1123510|NCT01474330|Pomalidomide
1123511|NCT01474330|safety
1123512|NCT01474330|tolerability
1123513|NCT01474330|pharmacokinetics
1123514|NCT01474304|craniotomy
1123515|NCT01474304|tumor resection
1123516|NCT01474304|aneurysm
1123517|NCT01474304|revascularization
1123518|NCT01474304|opioid
1123519|NCT01474304|nausea
1123520|NCT01474304|vomiting
1123521|NCT01474304|acetaminophen
1123522|NCT01474265|smoking cessation
1123523|NCT01474265|varenicline
1123524|NCT01474265|sympathovagal balance
1123525|NCT01474265|quit attempts
1123526|NCT01474265|MSNA
1123527|NCT01474226|lysine
1123528|NCT01474226|rice
1123529|NCT01474226|bioavailability
1123530|NCT01474213|dexmedetomidine
1123531|NCT01474213|remifentanil
1123532|NCT01474213|awake nasotracheal fibreoptic intubation
1123533|NCT01474213|oral maxillofacial surgery
1123534|NCT01474213|difficult airway
1123535|NCT01474213|adult
1123536|NCT01474200|Ultrafiltration
1123537|NCT01474200|Aquapheresis
1123538|NCT01474200|Diuretics
1123539|NCT01474200|Loop Diuretics
1123540|NCT01474200|Aquadex Flexflow System
1123541|NCT01474200|Gambro UF Solutions
1123542|NCT01474187|Neoadjuvant chemotherapy
1123543|NCT01474187|rectal cancer
1123544|NCT01474187|phase I study
1123545|NCT01474187|irinotecan
1123546|NCT01474148|paraplegia
1123547|NCT01474148|tetraplegia
1123548|NCT01474148|Spinal cord injured
1123549|NCT01474148|FES
1123550|NCT01474135|Glaucoma
1123551|NCT01474135|Ocular Hypertension
1123552|NCT01474122|digital ulcers
1123553|NCT01474122|systemic sclerosis
1123554|NCT01474109|systemic sclerosis
1123555|NCT01474109|digital ulcers
1123678|NCT01473628|Radiation Therapy
1123556|NCT01474096|clinical practice guideline-primary health care
1123557|NCT01474083|Type 2 diabetes mellitus
1123558|NCT01474083|pharmacokinetics
1123559|NCT01474083|pharmacodynamics
1123560|NCT01474070|Glaucoma
1123561|NCT01474070|Goldmann Tonometry
1123562|NCT01474070|Dynamic Contour Tonometry
1123563|NCT01474057|PTSD
1123564|NCT01474057|combat trauma
1123565|NCT01474057|telemedicine
1123566|NCT01474057|primary care interventions
1123567|NCT01474057|CBT
1123568|NCT01474057|self-managed treatment
1123569|NCT01474057|web-based intervention
1123570|NCT01474057|internet treatment
1123571|NCT01474031|total hip arthroplasty
1123572|NCT01474031|biomechanics
1123573|NCT01474031|direct anterior approach
1123575|NCT01474005|artificial larynx
1123576|NCT01474005|breathing
1123577|NCT01474005|swallowing
1123578|NCT01474005|upper airway
1123579|NCT01473979|cardiac surgery
1123580|NCT01473979|poststernotomy wound infections
1123581|NCT01473979|delayed secondary closure of sternum
1123582|NCT01473927|Inflammatory bowel diseases
1123583|NCT01473927|Crohn disease
1123584|NCT01473927|Ficolin-2
1123585|NCT01473927|C-Reactive Protein
1123586|NCT01473927|Calprotectin
1123587|NCT01473927|Inflammatory markers
1123588|NCT01473927|SES-CD
1123589|NCT01473901|BKM120
1123590|NCT01473901|temozolomide
1123591|NCT01473901|glioblastoma multiforme
1123592|NCT01473901|GBM
1123593|NCT01473901|Newly diagnosed
1123594|NCT01473888|T89(Dantonic®)
1123595|NCT01473888|Cooperstown 5+1 cocktail probes
1123596|NCT01473888|CYP450
1123597|NCT01473875|LIPA
1123598|NCT01473875|Wolman Disease
1123599|NCT01473875|Wolman Phenotype
1123600|NCT01473875|Acid Lipase Deficiency
1123601|NCT01473875|Acid Cholesteryl Hydrolase
1123602|NCT01473875|Acid Lipase Disease Deficiency, type 2
1123603|NCT01473875|Cholesteryl Ester Storage Disease (CESD)
1123604|NCT01473875|Cholesteryl Ester Hydrolase Deficiency
1123605|NCT01473875|Early Onset LAL-Deficiency (Wolman Disease)
1123606|NCT01473875|LAL Deficiency
1123607|NCT01473875|Late Onset Lysosomal Acid Lipase Deficiency (CESD)
1123608|NCT01473875|Wolman Disease (early onset LAL Deficiency)
1123609|NCT01473875|Related Disorders:
1123610|NCT01473875|Non-alcoholic Fatty Liver Disease (NAFLD)
1123611|NCT01473875|Non-alcoholic Steatohepatitis (NASH)
1123612|NCT01473875|Alcoholic Liver Disease
1123613|NCT01473875|Cryptogenic Cirrhosis
1123614|NCT01473875|Niemann-Pick Disease (NPD) Type C
1123615|NCT01473875|Chanarin Dorfman Syndrome
1123616|NCT01473862|adolescent
1123617|NCT01473862|bereavement
1123618|NCT01473862|cancer
1123619|NCT01473862|coping skills
1123620|NCT01473849|Cytomegalovirus
1123621|NCT01473849|Liver transplantation
1123622|NCT01473849|Hepatitis C virus
1123623|NCT01473849|Patients who underwent first liver transplantation due to hepatopathy caused by HCV,confirmed by detection of HCV RNA previously to transplantation
1123624|NCT01473836|Metronidazole
1123625|NCT01473836|intra-abdominal infection
1123626|NCT01473836|pelvic inflammatory disease
1123627|NCT01473836|anaerobe
1123628|NCT01473823|food allergy
1123629|NCT01473823|eczema
1123630|NCT01473823|sensitisation
1123631|NCT01473823|omega-3 long chain polyunsaturated fatty acids
1123632|NCT01473823|prevention
1123633|NCT01473823|asthma
1123634|NCT01473810|HIV
1123635|NCT01473810|vaccination
1123636|NCT01473810|T cells
1123637|NCT01473810|mucosal immunity
1123638|NCT01473810|safety
1123639|NCT01473810|nasal administration
1123640|NCT01473810|DTH skin test
1123641|NCT01473771|Suicide
1123642|NCT01473771|Suicide, Attempted
1123643|NCT01473758|COPD
1123644|NCT01473758|Chronic obstructive pulmonary disease
1123645|NCT01473758|Roflumilast
1123646|NCT01473745|Alar Base Suture; Nasolabial Change; 3D stereogrammetry
1123647|NCT01473732|CNI toxicity
1123648|NCT01473732|CAI
1123649|NCT01473719|alcohol use
1123650|NCT01473719|marijuana use
1123651|NCT01473719|STI
1123652|NCT01473706|Malnutrition
1123653|NCT01473706|Nutrition status
1123654|NCT01473706|Elderly
1123655|NCT01473706|Nutrition screening
1123656|NCT01473693|Quality of Life
1123657|NCT01473693|Lung cancer
1123658|NCT01473693|MRI
1123659|NCT01473693|Surgery
1123660|NCT01473693|induction chemotherapy
1123661|NCT01473693|11-145
1123662|NCT01473680|minority breast cancer patients
1123663|NCT01473680|EEG
1123664|NCT01473680|Evaluation
1123665|NCT01473680|Questionnaires
1123666|NCT01473680|11-139
1123667|NCT01473641|Etonogestrel
1123668|NCT01473641|Contraceptive implant
1123669|NCT01473641|Safety
1123670|NCT01473628|early stage follicular lymphoma
1123671|NCT01473628|indolent non-Hodgkin's lymphomas
1123672|NCT01473628|Lymphoma
1123673|NCT01473628|Follicular Lymphoma
1123674|NCT01473628|FL
1123675|NCT01473628|Rituximab
1123676|NCT01473628|Rituxan
1123677|NCT01473628|Radiation
1123679|NCT01473628|XRT
1123680|NCT01473576|type II diabetes
1123681|NCT01473576|protein synthesis
1123682|NCT01473576|nitrate
1123683|NCT01473576|elderly
1123684|NCT01473550|Mental Health
1123685|NCT01473550|Smart Technology
1123686|NCT01473550|Mood disorder
1123687|NCT01473550|Psychotic disorder
1123688|NCT01473537|dental caries/prevention and control
1123689|NCT01473537|oral health
1123690|NCT01473537|cariostatic agents
1123691|NCT01473524|Primary Biliary Cholangitis
1123692|NCT01473524|Primary Biliary Cirrhosis
1123693|NCT01473524|PBC
1123694|NCT01473524|Cirrhosis
1123695|NCT01473524|Liver
1123696|NCT01473511|Behavioural intervention
1123697|NCT01473511|Distance intervention
1123698|NCT01473511|Parenting intervention
1123699|NCT01473498|Sepsis
1123700|NCT01473498|Acute kidney injury
1123701|NCT01473498|Mean arterial pressure
1123702|NCT01473498|Catecholamines
1123703|NCT01473498|Renal doppler
1123704|NCT01473485|Brain Tumor
1123705|NCT01473485|Glioma
1123706|NCT01473485|Brain Cancer
1123707|NCT01473485|Metastatic Brain Cancer
1123708|NCT01473472|Prophylaxis
1123709|NCT01473472|HIV infection
1123710|NCT01473472|tenofovir
1123711|NCT01473472|emtricitabine
1123712|NCT01473472|men who have sex with men
1123713|NCT01473459|best fertility protocol
1123714|NCT01473459|(BMI > 30)
1123715|NCT01473459|women
1123716|NCT01473459|PCOS
1123717|NCT01473446|Goal directed fluid therapy
1123718|NCT01473446|perioperative fluid therapy
1123719|NCT01473446|LiDCOrapid
1123720|NCT01473446|Postoperative outcome
1123721|NCT01473446|Open abdominal surgery
1123722|NCT01473433|Regenerative medicine
1123723|NCT01473433|Myocardial infarction
1123724|NCT01473394|Major depressive disorder
1123725|NCT01473394|Depression
1123726|NCT01473381|Major Depressive Disorder
1123727|NCT01473381|Depression
1123728|NCT01473368|human Gut Microbiota
1123729|NCT01473368|gut microbiota
1123730|NCT01473368|gut microbiome
1123731|NCT01473368|probiotic
1123732|NCT01473368|antibiotic
1123733|NCT01473368|antibiotic-associated diarrhea
1123734|NCT01473368|intestinal bacterial overgrowth
1123735|NCT01473342|Healthy survivorship
1123736|NCT01473342|Smartphones
1123737|NCT01473342|Treatment
1123738|NCT01473329|diabetes care
1123739|NCT01473329|diabetes education
1123740|NCT01473329|diabetes control
1123741|NCT01473303|stage IV pancreatic cancer
1123742|NCT01473303|duct cell adenocarcinoma of the pancreas
1123743|NCT01473290|diarrhea
1123744|NCT01473290|constipation, impaction, and bowel obstruction
1123745|NCT01473290|gastrointestinal complications
1123746|NCT01473290|fatigue
1123747|NCT01473290|psychosocial effects of cancer and its treatment
1123748|NCT01473290|cognitive/functional effects
1123749|NCT01473290|unspecified adult solid tumor, protocol specific
1123750|NCT01473277|Hemiplegic shoulder pain
1123751|NCT01473277|Botulinum toxin type A (BT-A)
1123752|NCT01473277|Steroid
1123753|NCT01473277|Intra-articular injection
1123754|NCT01473277|Pain score of 45 or greater on a 0-100 mm VAS
1123755|NCT01473277|Duration of HSP for at least one month
1123756|NCT01473277|Pain refractoriness to conventional treatment
1123757|NCT01473264|CC10
1123758|NCT01473264|BPD
1123759|NCT01473264|Bronchopulmonary dysplasia
1123760|NCT01473264|premature infants
1123761|NCT01473264|neonates
1123762|NCT01473264|pulmonary inflammation
1123763|NCT01473264|lung function
1123764|NCT01473264|RDS
1123765|NCT01473238|Desktop computer
1123766|NCT01473238|Mobile
1123767|NCT01473238|iPad
1123768|NCT01473238|Evaluation
1123769|NCT01473238|User experience
1123770|NCT01473238|Benefits
1123771|NCT01473238|Cost analysis
1123772|NCT01473199|focal defect
1123773|NCT01473199|focal lesion
1123774|NCT01473199|chondral lesion
1123775|NCT01473199|osteochondral lesion
1123776|NCT01473186|morbid obesity
1123777|NCT01473186|endometrial pathology
1123778|NCT01473186|menstrual irregularities
1123779|NCT01473173|Safety
1123780|NCT01473173|Tolerability
1123781|NCT01473173|Pharmacokinetics
1123782|NCT01473173|Pharmacodynamics
1123783|NCT01473147|GLP-1 analogue
1123784|NCT01473147|CSII
1123785|NCT01473147|insulin
1123786|NCT01473147|type 2 diabetes mellitus
1123787|NCT01473121|Hepatocellular carcinoma
1123788|NCT01473121|Registry
1123789|NCT01473121|Turkey
1123790|NCT01473108|Healthy volunteers, proof-of-concept trial, PK and PD
1123791|NCT01473095|AKT
1123792|NCT01473095|ARQ 092
1123793|NCT01473095|Targeted therapy
1123794|NCT01473095|Molecular therapy
1123795|NCT01473095|Biomarker
1123796|NCT01473095|Phase 1
1123797|NCT01473095|Phase I
1123798|NCT01473095|Endometrial cancer
1123799|NCT01473095|Lymphoma
1123800|NCT01473095|AKT pathway
1123801|NCT01473095|AKT signaling
1123802|NCT01473095|AKT inhibitor
1123803|NCT01473095|AKT pan inhibitor
1123804|NCT01473095|AKT1
1123805|NCT01473095|AKT2
1123806|NCT01473095|AKT3
1123807|NCT01473095|AKT1 mutation
1123808|NCT01473095|AKT1-E17K
1123809|NCT01473095|AKT1-E17K mutation
1123810|NCT01473095|AKT 2 inhibitor
1123811|NCT01473095|AKT 3 inhibitor
1123812|NCT01473095|AKT 3 amplification
1123813|NCT01473095|PI3K AKT mTOR signalling pathway
1123814|NCT01473095|mTOR inhibitor
1123815|NCT01473095|PI3K inhibitor
1123816|NCT01473095|Clinical oncology
1123817|NCT01473095|Tumor
1123818|NCT01473095|Tumour
1123819|NCT01473095|PIK3CA H1047R mutation
1123820|NCT01473069|JTK-853
1123821|NCT01473069|Healthy subjects
1123822|NCT01473056|Hepatitis C
1123823|NCT01473056|JTK-853
1123824|NCT01473043|Axitinib
1123825|NCT01473043|metastatic renal cell carcinoma
1123826|NCT01473030|Benign prostate
1123827|NCT01473030|serum DHT
1123828|NCT01473030|Dutasteride
1123829|NCT01473030|PSA
1123830|NCT01473030|Avodart
1123831|NCT01473004|Sir-spheres
1123832|NCT01473004|Liver Metastases
1123833|NCT01473004|Selective internal radiation
1123834|NCT01473004|Yttrium-90
1123835|NCT01473004|Uveal
1123836|NCT01473004|Melanoma
1123837|NCT01473004|Ocular melanoma
1123838|NCT01472991|ADHD
1123839|NCT01472978|C. difficile
1123840|NCT01472965|central line
1123841|NCT01472965|adolescents
1123842|NCT01472965|children
1123843|NCT01472965|bloodstream infection
1123844|NCT01472965|antibiotic lock therapy
1123845|NCT01472965|catheter lock therapy
1123846|NCT01472965|ethanol lock therapy
1123847|NCT01472952|sepsis
1123848|NCT01472952|immune cells
1123849|NCT01472952|immune reaction
1123850|NCT01472952|trauma
1123851|NCT01472952|Immune activation
1123852|NCT01472926|acute ischaemic stroke
1123853|NCT01472926|stroke
1123854|NCT01472926|thrombolysis
1123855|NCT01472926|thrombolytic drug therapy
1123856|NCT01472926|CT perfusion
1123857|NCT01472926|CT angiography
1123858|NCT01472926|brain imaging
1123859|NCT01472913|Prospective randomised double-blind study
1123860|NCT01472913|Fibrin sealant
1123861|NCT01472913|Bilateral simultaneous total knee arthroplasty
1123862|NCT01472913|Blood loss
1123863|NCT01472913|Postoperative pain
1123864|NCT01472913|Complications
1123865|NCT01472900|acne vulgaris
1123866|NCT01472874|Wilson Disease
1123867|NCT01472874|Trientine
1123868|NCT01472874|One Daily Dosage
1123869|NCT01472861|coculture
1123870|NCT01472861|endometrial biopsy
1123871|NCT01472861|IVF poor responders
1123872|NCT01472835|sedation
1123873|NCT01472835|sensitivity
1123874|NCT01472835|specificity
1123875|NCT01472835|validity
1123876|NCT01472835|diagnostic injection
1123877|NCT01472822|Omija
1123878|NCT01472822|knee osteoarthritis
1123879|NCT01472809|ZYGK1
1123880|NCT01472809|Cadila
1123881|NCT01472809|Zydus
1123882|NCT01472809|ZRC
1123883|NCT01472809|Zydus Research Center
1123884|NCT01472809|Phase 1
1123885|NCT01472809|Diabetes
1123886|NCT01472796|African American
1123887|NCT01472796|Vitamin D deficient
1123888|NCT01472783|BRCA1 mutation
1123889|NCT01472783|BRCA2 mutation
1123890|NCT01472783|Ovarian cancer
1123891|NCT01472783|PARP inhibitor
1123892|NCT01472770|Colorectal cancer
1123893|NCT01472770|Metastatic
1123894|NCT01472770|Treatment resistant
1123895|NCT01472744|Executive function
1123896|NCT01472744|Aging
1123897|NCT01472744|Physical activity
1123898|NCT01472731|GC1008
1123899|NCT01472731|PET imaging
1123900|NCT01472731|primary brain tumors
1123901|NCT01472731|recurrent high grade glioma's
1123902|NCT01472705|drug-eluting coronary stent
1123903|NCT01472705|percutaneous coronary intervention
1123904|NCT01472692|Prehypertension
1123905|NCT01472692|Gout
1123906|NCT01472692|Puls Wave Velocity
1123907|NCT01472692|Hypertension
1123908|NCT01472692|24 hour blood pressure
1123909|NCT01472679|fat mass
1123910|NCT01472679|fat free mass
1123911|NCT01472679|body mass index
1123912|NCT01472666|Medium chain fatty acids
1123913|NCT01472666|Saturated fatty acids
1123914|NCT01472666|Whey protein
1123915|NCT01472666|Casein protein
1123916|NCT01472666|Metabolic syndrome
1123917|NCT01472666|Type 2 diabetes
1123918|NCT01472666|Cardiovascular disease
1123919|NCT01472666|Dairy products
1123920|NCT01472666|Dietary intervention
1123921|NCT01472653|Head and neck Cancer
1123922|NCT01472653|Radiochemotherapy
1123923|NCT01472653|Radioimmunotherapy
1123924|NCT01472653|Skin rush
1123925|NCT01472653|locoregional control
1123926|NCT01472653|Survival
1123927|NCT01472653|Toxicity
1123928|NCT01472640|CHF, Diabetes; Liraglutid, Ecco
1123929|NCT01472627|MM
1123930|NCT01472627|Bortezomib
1123931|NCT01472627|Velcade
1123932|NCT01472614|Type-2 diabetes mellitus
1123933|NCT01472614|Add-on therapy
1123934|NCT01472575|rotavirus
1123935|NCT01472575|gastroenteritis
1123936|NCT01472575|vaccination
1123937|NCT01472575|hospitalisation
1123938|NCT01472562|mantle cell lymphoma
1123939|NCT01472549|Preoperative
1123940|NCT01472549|Antiseptics
1123941|NCT01472549|Comparative
1123942|NCT01472549|Cost
1123943|NCT01472549|Effectiveness
1123944|NCT01472536|Influenza
1123945|NCT01472536|Non pharmaceutical intervention
1123946|NCT01472536|Sequestration
1123947|NCT01472536|Social network
1123948|NCT01472510|Diabetic
1123949|NCT01472510|Macular
1123950|NCT01472510|Edema
1123951|NCT01472510|Ranibizumab
1123952|NCT01472510|anti-VEGF
1123953|NCT01472497|hypertension
1123954|NCT01472497|insulin resistance
1123955|NCT01472497|oral glucose tolerance test
1123956|NCT01472497|AGE
1123957|NCT01472497|inflammatory cytokine
1123958|NCT01472484|beans
1123959|NCT01472484|lpa mutant
1123960|NCT01472484|polyphenols
1123961|NCT01472484|phytic acid
1123962|NCT01472484|stable iron isotopes
1123963|NCT01472471|Childhood Asthma
1123964|NCT01472471|Oxidative stress
1123965|NCT01472471|Urinary 8-isoprostane
1123966|NCT01472458|Cardiac arrest
1123967|NCT01472458|Hypothermia
1123968|NCT01472458|Post Cardiac Arrest Care
1123969|NCT01472458|Survivors of cardiac arrest
1123970|NCT01472445|Vitamin D
1123971|NCT01472445|Obesity
1123972|NCT01472432|type 2 diabetes
1123973|NCT01472432|healing
1123974|NCT01472432|foot ulcers
1123975|NCT01472432|vildagliptin
1123976|NCT01472419|metastatic esophageal squamous cell carcinoma
1123977|NCT01472419|Fluoropyrimidine/platinum-based first-line chemotherapy
1123978|NCT01472419|prognosis
1123979|NCT01472406|type 1 diabetes mellitus
1123980|NCT01472406|closed-loop artificial pancreas
1123981|NCT01472393|creatine supplementation
1123982|NCT01472393|bone mass
1123983|NCT01472393|postmenopausal women
1123984|NCT01472393|muscle function
1123985|NCT01472393|bone markers
1123986|NCT01472354|HIV
1123987|NCT01472354|Hepatitis C
1123988|NCT01472354|Decision-Making
1123989|NCT01472354|chronic
1123990|NCT01472328|Oxidative stress
1123991|NCT01472328|Insulin resistance
1123992|NCT01472315|sleep apnea
1123993|NCT01472315|women
1123994|NCT01472315|postmenopause
1123995|NCT01472315|hormone treatment
1123996|NCT01472289|CLI
1123997|NCT01472289|Peripheral arterial disease
1123998|NCT01472276|Behaviour change
1123999|NCT01472276|Weight loss
1124000|NCT01472276|Cardiovascular risk
1124001|NCT01472276|Diet
1124002|NCT01472276|Physical activity
1124003|NCT01472276|Overweight
1124004|NCT01472276|Obesity
1124005|NCT01472276|Internet
1124006|NCT01472263|HTLV-1
1124007|NCT01472263|tropical spastic paraparesis
1124008|NCT01472263|Immune System Diseases
1124009|NCT01472263|Physical disability
1124010|NCT01472263|pentoxifylline
1124011|NCT01472250|Advanced Gastric Cancer
1124012|NCT01472250|chemotherapy
1124013|NCT01472250|quality of life
1124014|NCT01472250|treatment expense
1124015|NCT01472250|patients accepted first-line chemotherapy
1124016|NCT01472224|Transcranial ultrasound
1124017|NCT01472224|Haematoma expansion
1124018|NCT01472198|GSI
1124019|NCT01472198|Gilead
1124020|NCT01472198|Gilead Sciences
1124021|NCT01472198|Pancreatic Cancer
1124022|NCT01472198|PC
1124023|NCT01472198|Gemcitabine
1124024|NCT01472198|Phase 2
1124025|NCT01472198|Phase II
1124026|NCT01472198|GS-6624
1124027|NCT01472198|Oncology
1124028|NCT01472198|Monoclonal Antibody
1124029|NCT01472185|Type 2 Diabetes Mellitus
1124030|NCT01472172|Flex-rigid pleuroscopy
1124031|NCT01472172|cryobiopsy
1124032|NCT01472172|pleural biopsy
1124033|NCT01472172|pleural effusion
1124034|NCT01472172|safety
1124035|NCT01472172|thoracoscopy
1124036|NCT01472146|Neoadjuvant therapy
1124037|NCT01472146|Breast cancer HER2 positive
1124038|NCT01472146|zolendronic acid
1124039|NCT01472133|Respiration Rate
1124040|NCT01472133|ECG
1124041|NCT01472133|Pulse oximetry
1124042|NCT01472133|Photoplethysmograph
1124043|NCT01472133|PPG
1124044|NCT01472133|Physiology
1124045|NCT01472107|Pregnancy
1124046|NCT01472107|APL female patients
1124047|NCT01472068|Incontinence
1124048|NCT01472068|NMES
1124049|NCT01472055|Hematopoietic stem cell transplantation with fludarabine based conditioning
1124050|NCT01472042|Traumatic Brain Injury
1124051|NCT01472042|Sport Concussion
1124052|NCT01472042|Head Injury
1124053|NCT01472042|Sports Injury
1124054|NCT01472029|Adenocarcinoma
1124055|NCT01472029|Gastroesophageal junction
1124056|NCT01472029|Stomach
1124057|NCT01472029|HER2
1124058|NCT01472016|c-Met overexpression
1124059|NCT01472016|MET amplification
1124060|NCT01472016|Neoplasms
1124061|NCT01472016|h224G11
1124062|NCT01471990|PACAP38
1124063|NCT01471990|MMA
1124064|NCT01471990|migraine
1124065|NCT01471990|angiography
1124066|NCT01471990|VIP
1124067|NCT01471990|vasodilatation
1124068|NCT01471912|Macular Holes
1124069|NCT01471912|spectral domain optical coherence tomography
1124070|NCT01471912|elongation of foveal tissue
1124071|NCT01471912|M-score
1124072|NCT01471873|Posterior corneal surface elevation
1124073|NCT01471873|Pentacam-Scheimpflung imaging
1124074|NCT01471873|variability
1124075|NCT01471873|progressive keratoconus
1124076|NCT01471873|corneal cross-linking
1124077|NCT01471847|Locally advanced
1124078|NCT01471847|metastatic
1124079|NCT01471847|breast cancer
1124080|NCT01471847|HER2 positive
1124081|NCT01471847|PI3K
1124082|NCT01471847|mTOR
1124083|NCT01471847|trastuzumab
1124084|NCT01471847|targeted therapy
1124085|NCT01471847|LABC
1124086|NCT01471847|MBC
1124087|NCT01471782|ALL
1124088|NCT01471782|relapsed, refractory B-precursor ALL
1124089|NCT01471782|Leukemia
1124090|NCT01471782|Leukemia, Lymphoid
1124091|NCT01471782|Precursor Cell Lymphoblastic Leukemia
1124092|NCT01471782|Neoplasms by Histologic Type
1124093|NCT01471782|Neoplasms
1124094|NCT01471782|Lymphoproliferative Disorders
1124095|NCT01471782|Lymphatic Diseases
1124096|NCT01471782|Immunoproliferative Disorders
1124097|NCT01471782|Antibodies, Bispecific
1124098|NCT01471769|pediatric
1124099|NCT01471769|pain
1124100|NCT01471756|sessile neoplasms
1124101|NCT01471756|flat neoplasms
1124102|NCT01471756|gastric cancer
1124103|NCT01471743|nutrition
1124104|NCT01471743|surgery
1124105|NCT01471743|immune
1124106|NCT01471730|Transfusions
1124107|NCT01471730|Fresh Frozen Plasma
1124108|NCT01471730|Fibrinogen
1124109|NCT01471730|Prothrombin complex
1124110|NCT01471717|PK
1124111|NCT01471717|pharmacokinetics
1124112|NCT01471717|INX08189
1124113|NCT01471717|Victrelis
1124114|NCT01471717|Inhibitex
1124115|NCT01471704|Pharmacokinetics
1124116|NCT01471704|PK
1124117|NCT01471704|INX08189
1124118|NCT01471704|Verapamil
1124119|NCT01471704|Inhibitex
1124120|NCT01471678|Cross-over design
1124121|NCT01471678|Pilot bioequivalence
1124122|NCT01471678|North east Asian ancestry
1124123|NCT01471678|GI198745
1124124|NCT01471678|Tamsulosin hydrochloride
1124125|NCT01471678|healthy male subjects
1124126|NCT01471678|Bioequivalence
1124127|NCT01471678|Dutasteride
1124128|NCT01471652|myalgic encephalopathy
1124129|NCT01471652|chronic fatigue syndrome
1124130|NCT01471652|post viral infection
1124131|NCT01471652|fatigue
1124132|NCT01471652|muscle pain
1124133|NCT01471652|unrefreshing sleep
1124134|NCT01471652|fuzzy thought
1124135|NCT01471652|poor memory
1124136|NCT01471652|forgetfulness
1124137|NCT01471639|18 years and older,
1124138|NCT01471639|previously healthy
1124139|NCT01471639|men and nonpregnant women
1124140|NCT01471639|emergency department
1124141|NCT01471626|sleep apnea
1124142|NCT01471626|polysomnography
1124143|NCT01471626|telemedicine
1124144|NCT01471613|spinal cord injury
1124145|NCT01471613|umbilical cord blood cell
1124146|NCT01471613|cell transplant
1124147|NCT01471613|lithium carbonate
1124148|NCT01471600|upper gastrointestinal endoscopy
1124149|NCT01471600|general anesthesia
1124150|NCT01471561|Osmolarity
1124151|NCT01471561|Cataract
1124152|NCT01471561|Dry Eye
1124153|NCT01471548|tumor
1124154|NCT01471548|cancer
1124155|NCT01471548|phase1
1124156|NCT01471548|TKI258
1124157|NCT01471535|chronic hepatitis B
1124158|NCT01471509|Glycemic Index
1124159|NCT01471509|LoBAG Diet
1124160|NCT01471509|Insulin
1124161|NCT01471509|Glucagon
1124162|NCT01471496|duodenal ulcer
1124163|NCT01471496|upper gastrointestinal system bleeding
1124164|NCT01471496|injection therapy
1124165|NCT01471483|Geriatric Assessment
1124166|NCT01471483|Quality of Life
1124167|NCT01471483|11-164
1124168|NCT01471483|Fallopian Tubes
1124169|NCT01471470|Advanced gastric cancer
1124170|NCT01471470|Neoadjuvant
1124171|NCT01471470|Bevacizumab
1124172|NCT01471457|bacterial
1124173|NCT01471457|vaginosis
1124174|NCT01471457|pessary
1124175|NCT01471457|discharge
1124176|NCT01471444|Blood And Marrow Transplantation
1124177|NCT01471444|Leukemia
1124178|NCT01471444|Allogeneic hematopoietic stem cell transplantation
1124179|NCT01471444|Acute myeloid leukemia
1124180|NCT01471444|AML
1124181|NCT01471444|Myelodysplastic syndrome
1124182|NCT01471444|MDS
1124183|NCT01471444|Progression free survival
1124184|NCT01471444|Rate of engraftment
1124185|NCT01471444|Toxicity
1124186|NCT01471444|Relapse rate
1124187|NCT01471444|Graft-vs-host disease
1124188|NCT01471444|GvHD
1124189|NCT01471444|Progression-free survival
1124190|NCT01471444|PFS
1124191|NCT01471444|Overall survival
1124192|NCT01471444|OS
1124193|NCT01471444|Fludarabine
1124194|NCT01471444|Fludarabine Phosphate
1124195|NCT01471444|Fludara
1124196|NCT01471444|Clofarabine
1124197|NCT01471444|Clofarex
1124198|NCT01471444|Clolar
1124199|NCT01471444|Busulfan
1124200|NCT01471444|Busulfex
1124201|NCT01471444|Myleran
1124202|NCT01471444|Thymoglobulin
1124203|NCT01471444|ATG
1124204|NCT01471444|Antithymocyte Globulin
1124205|NCT01471444|Methotrexate
1124206|NCT01471444|Tacrolimus
1124207|NCT01471444|Prograf
1124208|NCT01471418|TMJ
1124209|NCT01471418|orofacial pain
1124210|NCT01471418|synovitis
1124211|NCT01471418|arthroscopy
1124212|NCT01471392|Identigene
1124213|NCT01471392|STD Test
1124214|NCT01471392|Chlamydia
1124215|NCT01471392|Gonorrhoeae
1124216|NCT01471392|APTIMA
1124217|NCT01471392|Sexually Transmitted Disease
1124218|NCT01471379|Irritable Bowel Syndrome
1124219|NCT01471379|IBS
1124220|NCT01471379|Savella
1124221|NCT01471379|Milnacipran
1124222|NCT01471379|Abdominal Pain
1124223|NCT01471366|Hyperlipidemias
1124224|NCT01471366|Dyslipidemias
1124225|NCT01471366|Fatty Acids, Omega-3
1124226|NCT01471366|Fish Oils
1124227|NCT01471353|Metastatic
1124228|NCT01471353|Colon Cancer
1124229|NCT01471353|Rectal Cancer
1124230|NCT01471301|systemic lupus erythematosus
1124231|NCT01471301|rheumatoid arthritis
1124232|NCT01471288|well differentiated thyroid cancer
1124233|NCT01471288|Carum Carvi
1124234|NCT01471288|Normal controls
1124235|NCT01471275|type 2 diabetes
1124236|NCT01471275|obesity
1124237|NCT01471275|hypertriglyceridemia
1124238|NCT01471262|Complications
1124239|NCT01471262|Mortality
1124240|NCT01471262|Liver
1124241|NCT01471262|Failure
1124242|NCT01471249|esophageal stenting
1124243|NCT01471249|palliative
1124244|NCT01471249|dysphagia
1124245|NCT01471236|cartilage
1124246|NCT01471236|bone
1124247|NCT01471184|Allergic Rhinitis
1124248|NCT01471184|Conjunctivitis
1124249|NCT01471184|Bitop
1124250|NCT01471184|Eye
1124251|NCT01471184|Eye Drops
1124252|NCT01471184|Nasal Spray
1124253|NCT01471184|Total Nasal Symptom Score
1124254|NCT01471184|Total Ocular Symptom Score
1124255|NCT01471184|AUC
1124256|NCT01471171|COPD
1124257|NCT01471171|Antimuscarinic
1124258|NCT01471158|Primary open-angle glaucoma
1124259|NCT01471158|ocular hypertension
1124260|NCT01471158|pigment dispersion glaucoma
1124261|NCT01471145|opioid dependence
1124262|NCT01471145|heroin dependence
1124263|NCT01471145|extended release depot naltrexone
1124264|NCT01471145|functional Magnetic Resonance Imaging
1124265|NCT01471145|dopamine transporter
1124266|NCT01471145|Single Photon Emission Computed Tomography
1124267|NCT01471119|sublingual immunotherapy
1124268|NCT01471119|atopic dermatitis
1124269|NCT01471119|Dermatophagoides Farinae Drops
1124270|NCT01471106|Breast Cancer
1124271|NCT01471106|Estrogen Receptor Negative Breast Cancer
1124272|NCT01471106|Biomarker studies
1124273|NCT01471106|Ki-67
1124274|NCT01471106|Dasatinib
1124275|NCT01471106|BMS-354825
1124276|NCT01471106|Sprycel
1124277|NCT01471080|laparoscopic hepatectomy
1124278|NCT01471080|radio-frequency ablation
1124279|NCT01471080|giant cavernous hemangiomas
1124280|NCT01471080|liver
1124281|NCT01471067|Blood And Marrow Transplantation
1124282|NCT01471067|Leukemia
1124283|NCT01471067|Lymphoma
1124284|NCT01471067|Pediatrics
1124285|NCT01471067|Cord blood transplant
1124286|NCT01471067|Cord Blood Fucosylation
1124287|NCT01471067|Hematologic Malignancies
1124288|NCT01471067|Acute Myelogenous Leukemia
1124289|NCT01471067|AML
1124290|NCT01471067|Myelodysplastic Syndrome
1124291|NCT01471067|MDS
1124292|NCT01471067|High-risk cytogenetics
1124293|NCT01471067|Secondary leukemia from prior chemotherapy
1124294|NCT01471067|Langerhan's cell histiocytosis
1124295|NCT01471067|Acute Lymphoblastic Leukemia
1124296|NCT01471067|ALL
1124297|NCT01471067|complete remission
1124298|NCT01471067|Philadelphia chromosome
1124299|NCT01471067|translocation 4;11
1124300|NCT01471067|Hypodiploidy
1124301|NCT01471067|Chronic Myeloid Leukemia
1124302|NCT01471067|CML
1124303|NCT01471067|Non-Hodgkin's Lymphoma
1124304|NCT01471067|NHL
1124305|NCT01471067|Hodgkin's Disease
1124306|NCT01471067|HD
1124307|NCT01471067|Chronic Lymphocytic Leukemia
1124308|NCT01471067|CLL
1124309|NCT01471067|Melphalan
1124310|NCT01471067|Alkeran
1124311|NCT01471067|Thiotepa
1124312|NCT01471067|Fludarabine
1124313|NCT01471067|Fludarabine Phosphate
1124314|NCT01471067|Fludara
1124315|NCT01471067|Mycophenolate Mofetil
1124316|NCT01471067|MMF
1124317|NCT01471067|CellCept
1124318|NCT01471067|Tacrolimus
1124319|NCT01471067|Prograf
1124320|NCT01471067|Rituximab
1124321|NCT01471067|Rituxan
1124322|NCT01471067|ATG
1124323|NCT01471067|Antithymocyte Globulin
1124324|NCT01471067|Thymoglobulin
1124325|NCT01471054|Plaque radiotherapy
1124326|NCT01471054|Brachytherapy
1124327|NCT01471054|Macular edema
1124328|NCT01471054|Cystoid macular edema
1124329|NCT01471054|Uveal melanoma
1124330|NCT01471054|Radiation maculopathy
1124331|NCT01471054|Radiation retinopathy
1124332|NCT01471054|Ozurdex
1124333|NCT01471054|Dexamethasone intravitreal implant
1124334|NCT01471041|End Stage Renal Disease
1124335|NCT01471041|Hemodialysis
1124336|NCT01471041|AV fistula
1124337|NCT01471041|Kidney failure
1124338|NCT01471028|Acute alcoholic hepatitis
1124339|NCT01471028|alcoholic
1124340|NCT01471028|hepatitis
1124341|NCT01471028|liver
1124342|NCT01471015|Hypoxic Ischemic Encephalopathy
1124343|NCT01471015|Cooling Therapy
1124344|NCT01471015|HIE
1124345|NCT01470989|gouty arthritis
1124346|NCT01470976|Goal-directed therapy
1124347|NCT01470976|Hemodynamic optimization
1124348|NCT01470976|Cardiac surgery
1124349|NCT01470963|Referral
1124350|NCT01470963|Quality of Health Care
1124351|NCT01470950|Functional Electrical Stimulation
1124352|NCT01470950|Signalling Pathways
1124353|NCT01470937|diabetes acarbose alphaglucosidase prevention
1124354|NCT01470924|acute lymphoblastic leukemia
1124355|NCT01470924|relapse
1124356|NCT01470924|salvage
1124357|NCT01470924|prognostic
1124358|NCT01470911|Antisense oligonucleotide
1124359|NCT01470911|Asthma
1124360|NCT01470911|Healthy subjects
1124361|NCT01470911|Phase 1
1124362|NCT01470911|Transcription factor GATA-3
1124363|NCT01470911|Oral inhalation
1124364|NCT01470898|bispectral index monitoring
1124365|NCT01470898|extubation
1124366|NCT01470898|analgesia
1124367|NCT01470898|abdominal surgery
1124368|NCT01470885|glucose
1124369|NCT01470885|prognosis
1124370|NCT01470885|glycated hemoglobin
1124371|NCT01470859|De Novo parkinson's disease
1124372|NCT01470859|initial treatment
1124373|NCT01470859|pramipexole
1124374|NCT01470859|Levodopa
1124375|NCT01470859|Parkinson's disease-related spatial covariance pattern
1124376|NCT01470846|epidural analgesia
1124377|NCT01470846|morphin analgesia
1124378|NCT01470846|laparotomy
1124379|NCT01470833|Achilles tendon
1124380|NCT01470833|rupture
1124381|NCT01470833|non-operative
1124382|NCT01470833|treatment
1124383|NCT01470820|Neonates
1124384|NCT01470820|Hyperbilirubinemia
1124385|NCT01470820|Phototherapy
1124386|NCT01470820|Light irradiance
1124387|NCT01470820|Saturation point
1124388|NCT01470807|Artificial Pancreas
1124389|NCT01470807|Insulin Pump
1124390|NCT01470807|Continuous Glucose Monitor
1124391|NCT01470807|Closed Loop
1124392|NCT01470794|GBM
1124393|NCT01470794|HGG
1124394|NCT01470794|High grade glioma
1124395|NCT01470794|Malignant glioma
1124396|NCT01470794|Grade III glioma
1124397|NCT01470794|Grad IV glioma
1124398|NCT01470781|Bipolar Disorder
1124399|NCT01470781|Psychosis
1124400|NCT01470781|Cognition
1124401|NCT01470781|Cognitive Remediation
1124402|NCT01470755|Pediatrics
1124403|NCT01470755|Bronchial wheeze
1124404|NCT01470755|bronchodilator
1124405|NCT01470755|lung function
1124406|NCT01470755|airway resistance
1124407|NCT01470729|Spinocerebellar ataxia, energy metabolism, NMR spectroscopy
1124408|NCT01470716|EGFR mutation
1124409|NCT01470716|NSCLC
1124410|NCT01470703|Acute Respiratory Distress Syndrome,
1124411|NCT01470703|ECMO, Extracorporeal Membrane Oxygenation
1124412|NCT01470703|Randomized controlled trial
1124413|NCT01470703|Positive-Pressure ventilation
1124414|NCT01470703|Survival Rate
1124415|NCT01470690|HVC infection
1124416|NCT01470690|gastric acid-related disorders
1124417|NCT01470690|proton pump inhibitor
1124418|NCT01470690|interaction
1124419|NCT01470690|pharmacokinetics
1124420|NCT01470690|boceprevir
1124421|NCT01470690|omeprazole
1124422|NCT01470677|lymph cyst
1124423|NCT01470677|lymphocele
1124424|NCT01470677|fibrin
1124425|NCT01470677|collagen
1124426|NCT01470677|prevention
1124427|NCT01470677|cancer
1124428|NCT01470651|HCV+
1124429|NCT01470651|HCV treatment
1124430|NCT01470651|Fatigue
1124431|NCT01470651|patients starting alpha interferon/ribavirin treatment
1124432|NCT01470638|Flt3-L
1124433|NCT01470638|CSF
1124434|NCT01470625|Dying
1124435|NCT01470625|Patients
1124436|NCT01470625|Hospice
1124437|NCT01470625|Liverpool Care Pathways
1124438|NCT01470612|Ulcerative colitis
1124439|NCT01470612|open-label
1124440|NCT01470612|long term treatment
1124441|NCT01470586|Colorectal cancer
1124442|NCT01470586|Surgical resection
1124443|NCT01470586|Oxidative Stress Markers
1124444|NCT01470586|Controls
1124445|NCT01470560|Mindfulness
1124446|NCT01470560|Mindfulness-Based Stress Reduction
1124447|NCT01470560|Meditation
1124448|NCT01470560|Yoga
1124449|NCT01470547|Liver Cirrhosis
1124450|NCT01470547|Portal Vein Thrombosis
1124451|NCT01470547|Cirrhosis Complications
1124452|NCT01470547|Registry
1124453|NCT01470547|Italian
1124454|NCT01470534|Dietary supplement
1124455|NCT01470534|Carbohydrate loading
1124456|NCT01470534|Insulin resistance
1124457|NCT01470534|Surgery
1124458|NCT01470521|Multiple sclerosis
1124459|NCT01470521|Hookworm larvae
1124460|NCT01470521|Necator americanus
1124461|NCT01470521|Treg cells
1124462|NCT01470508|Bulimia
1124463|NCT01470508|Binge-Eating Disorder
1124464|NCT01470508|Eating Disorders
1124465|NCT01470482|Total knee
1124466|NCT01470482|Tourniquet
1124467|NCT01470482|Blood loss
1124468|NCT01470482|pain
1124469|NCT01470482|range of motion
1124470|NCT01470391|Adductor-Canal-Blockade
1124471|NCT01470391|Femoral Nerve Block
1124472|NCT01470391|Postoperative Pain
1124473|NCT01470391|Total Knee Arthroplasty
1124474|NCT01470378|Lymphedema
1124475|NCT01470378|Magnetic Resonance Imaging
1124476|NCT01470378|Plastic Surgery
1124477|NCT01470352|migraine
1124478|NCT01470352|pain
1124479|NCT01470352|CPM
1124480|NCT01470352|offset analgesia
1124481|NCT01470352|fMRI
1124482|NCT01470339|endogenous pain modulation
1124483|NCT01470339|migraine
1124484|NCT01470339|fMRI
1124485|NCT01470339|duloxetine
1124486|NCT01470339|preventive migraine treatment
1124487|NCT01470326|Osteoporosis
1124488|NCT01470326|Post menopausal women
1124489|NCT01470326|SERM
1124490|NCT01470326|Japanese
1124491|NCT01470326|Viviant
1124492|NCT01470326|Regulatory Post Marketing Commitment Plan
1124493|NCT01470326|Long term treatment
1124494|NCT01470313|Safety and tolerability
1124495|NCT01470313|cutaneous lupus erythematosus
1124496|NCT01470313|efficacy
1124497|NCT01470287|Infants,
1124498|NCT01470287|Immunogenicity,
1124499|NCT01470287|Safety
1124500|NCT01470274|Blood volume
1124501|NCT01470274|CO-rebreathing
1124502|NCT01470274|COPD
1124503|NCT01470274|CVD
1124504|NCT01470261|methylphenidate
1124505|NCT01470261|ritalin
1124506|NCT01470261|Attention Deficit Disorder
1124507|NCT01470248|Lung Cancer
1124508|NCT01470248|Carcinoma, small cell
1124509|NCT01470248|Trisenox
1124510|NCT01470248|Arsenic trioxide
1124511|NCT01470248|phase II trial
1124512|NCT01470235|screening
1124513|NCT01470235|genetic
1124514|NCT01470235|cancer
1124515|NCT01470222|Worksite
1124516|NCT01470222|group weight loss
1124517|NCT01470222|behavioral components
1124518|NCT01470209|lung cancer with activated mTOR/PI3K pathway
1124519|NCT01470209|alterations in PIK3CA, NF1, TSC1/TSC2, mTOR, KRAS, LKB1, PTEN
1124520|NCT01470196|WM
1124521|NCT01470196|untreated
1124522|NCT01470196|symptomatic
1124523|NCT01470183|Lupus Nephritis
1124524|NCT01470170|Sedative bronchoscope
1124525|NCT01470170|Alfentanil doses
1124526|NCT01470170|Propofol
1124527|NCT01470170|Targeted controlled infusion
1124528|NCT01470170|Hypoxemia
1124529|NCT01470131|multiple myeloma
1124530|NCT01470131|relapse
1124531|NCT01470131|second line therapy
1124532|NCT01470131|bortezomib
1124533|NCT01470131|dexamethasone
1124534|NCT01470105|questionnaire
1124535|NCT01470105|11-121
1124536|NCT01470092|Menopause
1124537|NCT01470092|Depression
1124538|NCT01470066|peripheral T cell lymphomas
1124539|NCT01470066|interim PET/CT
1124540|NCT01470066|prognosis
1124541|NCT01470066|Positron-emission tomography/Computerized tomography
1124542|NCT01470053|mometasone furoate
1124543|NCT01470053|azelastine HCl
1124544|NCT01470053|perennial allergic rhinitis
1124545|NCT01470040|traumatic brain injury
1124546|NCT01470040|chronic subdural hematoma
1124547|NCT01470040|aspirin
1124548|NCT01470040|antiplatelet therapy
1124549|NCT01470027|magnetic resonance spectroscopy
1124550|NCT01470027|N-acetylcysteine
1124551|NCT01470027|antioxidant
1124552|NCT01470027|glutathione
1124553|NCT01470014|isolated left ventricular non-compaction
1124554|NCT01470014|cardiac computed tomography
1124555|NCT01470014|cardiac magnet resonance imaging
1124556|NCT01470014|echocardiography
1124557|NCT01469975|cancer
1124558|NCT01469975|relapse or refractory
1124559|NCT01469962|morbid obesity
1124560|NCT01469962|bariatric surgery
1124561|NCT01469962|NASH
1124562|NCT01469962|Liver fibrosis
1124563|NCT01469962|Fibrotest
1124564|NCT01469949|Improvement of the accuracy of Lumbar repositioning
1124565|NCT01469936|Fibromyalgia
1124566|NCT01469936|Irritable Bowel Syndrome
1124567|NCT01469923|Phase 1
1124568|NCT01469923|obese
1124569|NCT01469923|healthy male volunteers
1124570|NCT01469923|multiple doses
1124571|NCT01469923|dose escalation
1124572|NCT01469923|pharmacokinetics
1124573|NCT01469923|pharmakodynamics
1124574|NCT01469897|JIA
1124575|NCT01469897|Juvenile Idiopathic Arthritis
1124576|NCT01469897|Cost of Care
1124577|NCT01469897|Quality of Life
1124578|NCT01469897|QOL
1124579|NCT01469884|Renal allograft recipients
1124580|NCT01469884|Hepatitis C virus (HCV)
1124581|NCT01469884|Certican
1124582|NCT01469884|Calcineurin inhibitor(tacrolimus or cyclosporin)
1124583|NCT01469871|Dressing
1124584|NCT01469871|Blisters
1124585|NCT01469871|Silicone
1124586|NCT01469845|hospital admissions
1124587|NCT01469845|acute bronchiolitis
1124588|NCT01469845|under one year old
1124589|NCT01469845|requiring oxygen therapy
1124590|NCT01469832|fundus flavimaculatus
1124591|NCT01469832|Retinal Diseases
1124592|NCT01469832|Macular Degeneration
1124593|NCT01469832|SMD
1124594|NCT01469832|juvenile macular dystrophy
1124595|NCT01469819|chronic constipation
1124596|NCT01469819|constipation
1124597|NCT01469819|idiopathic constipation
1124598|NCT01469819|SmartPill
1124599|NCT01469819|Wireless Motility Capsule
1124600|NCT01469819|lubiprostone (Amitiza)
1124601|NCT01469819|small intestinal bacterial overgrowth
1124602|NCT01469780|Pain
1124603|NCT01469780|Health behavior change
1124604|NCT01469780|Coronary angioplasty
1124605|NCT01469780|Cardiovascular disease
1124606|NCT01469780|Outcomes
1124607|NCT01469780|Morbidity
1124608|NCT01469780|Mortality
1124609|NCT01469767|eczema
1124610|NCT01469767|itch
1124611|NCT01469767|scratching
1124612|NCT01469767|actigraphy
1124613|NCT01469767|adherence
1124614|NCT01469754|lymphoma
1124615|NCT01469754|survivors
1124616|NCT01469754|posttraumatic growth
1124617|NCT01469754|posttraumatic stress
1124618|NCT01469754|longitudinal
1124619|NCT01469728|VATS
1124620|NCT01469728|awake thoracic surgery
1124621|NCT01469728|pleurodesis
1124622|NCT01469728|talc
1124623|NCT01469728|TEA
1124624|NCT01469728|epidural anesthesia
1124625|NCT01469728|Video-Assisted
1124626|NCT01469728|Anesthesia Epidural
1124627|NCT01469715|Continuous Glucose Monitor
1124628|NCT01469702|cat-scratch disease
1124629|NCT01469702|Bartonella henselae
1124630|NCT01469702|corticosteroids
1124631|NCT01469702|treatment
1124632|NCT01469689|People
1124633|NCT01469689|living
1124634|NCT01469689|community
1124635|NCT01469676|Coronary Artery Bypass Surgery
1124636|NCT01469676|Cardiopulmonary Bypass
1124637|NCT01469676|Leukocyte Reduction Filtrations
1124638|NCT01469676|Pulmonary Function
1124639|NCT01469676|Systemic Inflammatory Response
1124640|NCT01469663|Borderline Personality Disorder
1124641|NCT01469663|Major Depression
1124642|NCT01469663|Electroencephalogram
1124643|NCT01469663|N2
1124644|NCT01469663|Error Related Negativity
1124645|NCT01469663|Emotional Processing
1124646|NCT01469663|Levels of Emotional Awareness
1124647|NCT01469650|vitamin D3
1124648|NCT01469650|prematurity
1124649|NCT01469650|parathyroid hormone
1124650|NCT01469650|25(OH)D
1124651|NCT01469650|NICU hospitalization
1124652|NCT01469624|Contrast Induced Nephropathy
1124653|NCT01469624|Pentoxifylline
1124654|NCT01469624|PCI
1124655|NCT01469611|advanced/metastatic colorectal carcinoma
1124656|NCT01469585|continuous oral contraceptives
1124657|NCT01469585|MMP expression
1124658|NCT01469572|Neuroendocrine hepatic tumors
1124659|NCT01469572|Liver cancer
1124660|NCT01469572|Metastatic liver cancer
1124661|NCT01469559|Insulin
1124662|NCT01469559|Diabetic neuropathy
1124663|NCT01469559|Intranasal administration
1124664|NCT01469559|Pilot project
1124665|NCT01469546|Squamous Cell Carcinoma of the Head and Neck
1124666|NCT01469533|Spine
1124667|NCT01469533|Manipulation
1124668|NCT01469533|Pain Threshold
1124669|NCT01469533|Electromyography.
1124670|NCT01469520|HIV
1124671|NCT01469520|AIDS
1124672|NCT01469520|Treatment
1124673|NCT01469494|DIEP flap
1124674|NCT01469494|SIEA flap
1124675|NCT01469494|breast reconstruction
1124676|NCT01469494|objective isokinetic abdominal strength testing
1124677|NCT01469494|fat necrosis
1124678|NCT01469494|flap loss
1124679|NCT01469494|seroma rate
1124680|NCT01469494|abdominal wound breakdown
1124681|NCT01469494|Breast-Q
1124682|NCT01469494|abdominal wall outcome questionnaire
1124683|NCT01469481|diabetes mellitus
1124684|NCT01469481|ADME
1124685|NCT01469455|Local metastatic melanoma
1124686|NCT01469455|relapsed cutaneous/subcutaneous tumors
1124687|NCT01469455|melanoma-in-transit
1124688|NCT01469442|Biliary fistula
1124689|NCT01469442|prevention
1124690|NCT01469442|hepatectomy
1124691|NCT01469442|external stent
1124692|NCT01469442|Hepatectomy of more 2 segments
1124693|NCT01469442|Not emergency or laparoscopy surgery
1124694|NCT01469429|oral cancer
1124695|NCT01469416|rosuvastatin
1124696|NCT01469416|clopidogrel
1124697|NCT01469416|pharmacokinetics
1124698|NCT01469416|drug interaction
1124699|NCT01469416|healthy volunteer
1124700|NCT01469416|drug transporter
1124701|NCT01469403|Osteoarthritis, knee
1124702|NCT01469403|Obesity
1124703|NCT01469403|Weight Loss
1124704|NCT01469403|Arthroplasty
1124705|NCT01469377|Major Depressive Disorder
1124706|NCT01469377|Depression
1124707|NCT01469364|Lung Transplant
1124708|NCT01469364|Lung Transplant Recipient
1124709|NCT01469351|Alzheimers disease
1124710|NCT01469325|Repetitive Transcranial Magnetic Stimulation
1124711|NCT01469325|Depression
1124712|NCT01469325|left prefrontal
1124713|NCT01469312|Low Biologically Available Glucose Diet (LoBAG diet)
1124714|NCT01469312|Diabetes
1124715|NCT01469312|Glycemic Index
1124716|NCT01469299|Ligament Balance, Total Knee Arthroplasty, Intra-operative Sensors
1124717|NCT01469286|delayed gastric emptying
1124718|NCT01469286|nausea
1124719|NCT01469286|vomiting
1124720|NCT01469286|abdominal discomfort
1124721|NCT01469273|Diarrhea
1124722|NCT01469273|EcN
1124723|NCT01469273|E. coli strain Nissle 1917
1124724|NCT01469273|Gastrointestinal infection
1124725|NCT01469273|Infant
1124726|NCT01469273|Newborn
1124727|NCT01469273|Probiotic drug
1124728|NCT01469273|Prevention
1124729|NCT01469273|Prophylaxis
1124730|NCT01469260|Overweight
1124731|NCT01469260|Obesity
1124732|NCT01469260|Pregnancy
1124733|NCT01469260|Weight gain
1124734|NCT01469260|Pedometer
1124735|NCT01469260|Exercise
1124736|NCT01469247|Brain cancer
1124737|NCT01469247|Recurrent or progressive brainstem glioma
1124738|NCT01469247|Diffuse Intrinsic Pontine Glioma
1124739|NCT01469247|DIPG
1124740|NCT01469247|Reirradiation
1124741|NCT01469247|ReRT
1124742|NCT01469247|Photon radiation therapy
1124743|NCT01469247|XRT
1124744|NCT01469221|Bladder Cancer
1124745|NCT01469221|Non-Muscle Invasive Bladder Cancer
1124746|NCT01469221|NMIBC
1124747|NCT01469221|Apaziquone
1124748|NCT01469221|EOquin
1124749|NCT01469221|GU Cancer
1124750|NCT01469221|TURBT
1124751|NCT01469208|Gastroschisis
1124752|NCT01469208|NICU inpatients
1124753|NCT01469208|Post surgical repair
1124754|NCT01469208|Music Therapy
1124755|NCT01469195|lead rectangle
1124756|NCT01469195|radiation exposure
1124757|NCT01469195|operators
1124758|NCT01469195|radial approach
1124759|NCT01469195|coronary procedures
1124760|NCT01469195|percutaneous coronary intervention
1124761|NCT01469182|Immunology
1124762|NCT01469169|Iloprost
1124763|NCT01469169|Inhalation
1124764|NCT01469169|Pulmonary Hypertension
1124765|NCT01469169|Pulmonary Artery Hypertension
1124766|NCT01469169|Japanese Patients
1124767|NCT01469156|polypoidal choroidal vasculopathy
1124768|NCT01469156|choroidal neovascularization
1124769|NCT01469156|ranibizumab
1124770|NCT01469156|Lucentis
1124771|NCT01469130|MEK, Advanced solid tumor
1124772|NCT01469117|Developmental disabilities
1124773|NCT01469117|Enteral Nutrition
1124774|NCT01469117|Tube feeding
1124775|NCT01469117|Nutrition support
1124776|NCT01469104|Diabetes
1124777|NCT01469091|Acute admittance
1124778|NCT01469091|Current smoker
1124779|NCT01469078|Chronic Kidney Disease
1124780|NCT01469078|CKD stage 5
1124781|NCT01469078|Iron deficiency
1124782|NCT01469065|inpatient
1124783|NCT01469065|diabetes
1124784|NCT01469065|phase 1
1124785|NCT01469039|Alkermes
1124786|NCT01469039|schizophrenia
1124787|NCT01469039|ALKS 9072
1124788|NCT01469039|ALKS 9070
1124789|NCT01469039|aripiprazole lauroxil
1124790|NCT01468948|Essential Tremor
1124791|NCT01468948|Tremor
1124792|NCT01468948|Octanol
1124793|NCT01468948|Octanoic Acid
1124794|NCT01468935|Uterus
1124795|NCT01468935|Endometrium
1124796|NCT01468935|Bone Marrow Transplant
1124797|NCT01468935|Gynecology
1124798|NCT01468935|Healthy Volunteer
1124799|NCT01468935|HV
1124800|NCT01468935|Stem Cell Transplant
1124801|NCT01468935|Endometriosis
1124802|NCT01468922|Pazopanib
1124803|NCT01468922|Tivantinib
1124804|NCT01468922|MET Inhibitor
1124805|NCT01468922|Advanced Cancer
1124806|NCT01468922|Anti-Angiogenesis
1124807|NCT01468922|Cancer
1124808|NCT01468922|Solid Tumor
1124809|NCT01468922|Sarcoma
1124810|NCT01468883|Breast Cancer
1124811|NCT01468883|Surgery
1124812|NCT01468883|Radiation
1124813|NCT01468857|Clinical Stress Markers
1124814|NCT01468857|Chronic Stress
1124815|NCT01468857|Allogeneic Hematopoietic Stem Cell Transplant
1124816|NCT01468857|HSCT Caregivers
1124817|NCT01468857|Cancer Caregivers
1124818|NCT01468857|Stress
1124819|NCT01468857|Family Caregivers
1124820|NCT01468844|Central Retinal Vein Occlusion
1124821|NCT01468844|Minocycline
1124822|NCT01468844|Retinal Vein Occlusion
1124823|NCT01468844|CRVO
1124824|NCT01468831|Branch Retinal Vein Occlusion
1124825|NCT01468831|Minocycline
1124826|NCT01468831|Macular Edema
1124827|NCT01468831|Retinal Vein Occlusion
1124828|NCT01468831|BRVO
1124829|NCT01468818|Metastatic Melanoma
1124830|NCT01468818|Adoptive Cell Therapy
1124831|NCT01468818|Skin Cancer
1124832|NCT01468805|Environmental Intervention
1124833|NCT01468805|Indoor Allergens
1124834|NCT01468805|Cockroach
1124835|NCT01468805|Health Disparities
1124836|NCT01468805|Multi-Center
1124837|NCT01468805|Asthma
1124838|NCT01468805|Environment
1124839|NCT01468792|systemic sclerosis
1124840|NCT01468792|pulmonary arterial hypertension
1124841|NCT01468779|Periampullary cancer
1124842|NCT01468779|Surgery
1124843|NCT01468779|Dietary supplementation
1124844|NCT01468779|Nutritional assessment
1124845|NCT01468753|Conception in HIV Discordant Couples
1124846|NCT01468753|Reproduction in HIV Discordant Couples
1124847|NCT01468753|Vaginal Insemination
1124848|NCT01468727|dental caries
1124849|NCT01468727|mutans streptococci
1124850|NCT01468727|lactobacilli
1124851|NCT01468727|bacterial transmission
1124852|NCT01468727|bacterial colonization
1124853|NCT01468714|Drug Interaction
1124854|NCT01468714|pharmacokinetics
1124855|NCT01468714|ketoconazole
1124856|NCT01468714|CYP3A
1124857|NCT01468688|Imatinib mesylate
1124858|NCT01468688|BKM120
1124859|NCT01468688|GIST
1124860|NCT01468649|Breast Cancer
1124861|NCT01468649|Sentinel Lymph Node Mapping
1124862|NCT01468649|Intraoperative Imaging
1124863|NCT01468636|Warts
1124864|NCT01468636|HPV
1124865|NCT01468636|Zinc
1124866|NCT01468623|Colorectal cancer, metastatic
1124867|NCT01468623|FOLFOX6
1124868|NCT01468623|5-FU
1124869|NCT01468623|First line
1124870|NCT01468623|bevacizumab
1124871|NCT01468610|depression
1124872|NCT01468610|cognition
1124873|NCT01468610|occupational functioning
1124874|NCT01468610|productivity
1124875|NCT01468610|neuropsychology
1124876|NCT01468610|desvenlafaxine
1124877|NCT01468610|antidepressants
1124878|NCT01468597|Emergent
1124879|NCT01468597|Cardiac surgery
1124880|NCT01468597|On-pump
1124881|NCT01468597|Platelet function
1124882|NCT01468584|Genotype 2
1124883|NCT01468571|Potassium Sparing Diuretics
1124884|NCT01468571|Right-sided heart failure
1124885|NCT01468571|Edema
1124886|NCT01468558|Drug Drug Interaction Study in Normal Healthy Volunteers
1124887|NCT01468545|Education
1124888|NCT01468545|Ventavis
1124889|NCT01468545|Adherence
1124890|NCT01468545|PAH
1124891|NCT01468545|Pulmonary artery hypertension
1124892|NCT01468519|Diabetes mellitus, type 2
1124893|NCT01468519|Erectile dysfunction
1124894|NCT01468519|continuous subcutaneous insulin infusion
1124895|NCT01468519|CSII
1124896|NCT01468519|insulin
1124897|NCT01468506|Chronic Kidney Disease
1124898|NCT01468506|arteriovenous fistula
1124899|NCT01468493|FSGS
1124900|NCT01468493|suPAR
1124901|NCT01468480|direct pulp capping
1124902|NCT01468480|MTA
1124903|NCT01468480|Single visit pulp cap
1124904|NCT01468480|Multical
1124905|NCT01468467|AC220
1124906|NCT01468467|Acute Myeloid Leukemia (AML)
1124907|NCT01468467|Transplantation
1124908|NCT01468467|Stem Cell Transplantation
1124909|NCT01468467|Allogeneic Transplantation
1124910|NCT01468467|FMS-like tyrosine kinase (FLT3)
1124911|NCT01468467|FMS-like tyrosine kinase (FLT3) Inhibitor
1124912|NCT01468467|Kinase
1124913|NCT01468467|Kinase Inhibitor
1124914|NCT01468467|Pharmacokinetics
1124915|NCT01468467|ASP2689
1124916|NCT01468467|quizartinib
1124917|NCT01468454|Congenital Hyperinsulinism (CHI)
1124918|NCT01468454|hyperinsulinism
1124919|NCT01468454|Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
1124920|NCT01468454|CHI
1124921|NCT01468454|PHHI
1124922|NCT01468454|Pancreatectomy
1124923|NCT01468454|18F-DOPA
1124924|NCT01468454|PET/CT scan
1124925|NCT01468441|ovarian stimulation
1124926|NCT01468441|GnRH agonist
1124927|NCT01468441|GnRH antagonist
1124928|NCT01468441|hCG microdose
1124929|NCT01468441|ICSI
1124930|NCT01468415|Methylprednisolone
1124931|NCT01468415|trans sacral block
1124932|NCT01468415|phenol
1124933|NCT01468402|Leiomyoma
1124934|NCT01468402|uterine artery embolization
1124935|NCT01468402|magnetic resonance imaging
1124936|NCT01468389|Gastric Cancer
1124937|NCT01468389|capecitabine
1124938|NCT01468389|maintenance treatment
1124939|NCT01468376|impaired glucose tolerance
1124940|NCT01468376|pre-diabetes
1124941|NCT01468363|Dry weight
1124942|NCT01468363|Body composition monitor
1124943|NCT01468363|Hemodialysis
1124944|NCT01468363|Zonguldak
1124945|NCT01468337|Central Serous Chorioretinopathy
1124946|NCT01468337|Interferon-Gamma (IFN-Gamma)
1124947|NCT01468337|Jakstat
1124948|NCT01468337|Retinal Eye Disease
1124949|NCT01468337|Macular Eye Disease
1124950|NCT01468337|CSC
1124951|NCT01468324|Brain
1124952|NCT01468324|Angiogenesis
1124953|NCT01468324|Radiotherapy
1124954|NCT01468324|Malignant
1124955|NCT01468324|Tumor
1124956|NCT01468324|Glioma
1124957|NCT01468324|Glioblastoma Multiforme
1124958|NCT01468324|Brain Tumor
1124959|NCT01468311|Immunotherapy
1124960|NCT01468311|Resistant Hodgkins Lymphoma
1124961|NCT01468311|Auto Stem Cell Transplant
1124962|NCT01468311|Combination Chemo and Radiolabeled Monoclonal Antibody
1124963|NCT01468311|Hodgkin Lymphoma
1124964|NCT01468298|back pain
1124965|NCT01468298|physical therapy
1124966|NCT01468298|spine
1124967|NCT01468298|rehabilitation
1124968|NCT01468298|exercise
1124969|NCT01468285|interventional,placebo controlled
1124970|NCT01468272|asthma children NEXT DPI LABA ICS inhalation
1124971|NCT01468246|Breast Cancer
1124972|NCT01468246|Cohort
1124973|NCT01468246|Young Women
1124974|NCT01468246|Survivorship
1124975|NCT01468246|Fertility
1124976|NCT01468233|placebo controlled
1124977|NCT01468233|double blind
1124978|NCT01468233|adalimumab
1124979|NCT01468233|TNF
1124980|NCT01468233|psoriasis
1124981|NCT01468233|HS
1124982|NCT01468233|PIONEER II
1124983|NCT01468233|hidradenitis suppurativa
1124984|NCT01468233|acne inversa
1124985|NCT01468233|boil
1124986|NCT01468233|acne
1124987|NCT01468220|tissue metabolism
1124988|NCT01468220|skeletal muscle
1124989|NCT01468220|adipose tissue
1124990|NCT01468220|HIF
1124991|NCT01468207|acne
1124992|NCT01468207|psoriasis
1124993|NCT01468207|hidradenitis suppurativa
1124994|NCT01468207|TNF
1124995|NCT01468207|HS
1124996|NCT01468207|PIONEER I
1124997|NCT01468207|acne inversa
1124998|NCT01468207|boil
1124999|NCT01468207|placebo controlled
1125000|NCT01468207|Double blind
1125001|NCT01468207|adalimumab
1125002|NCT01468194|AMS
1125003|NCT01468194|HAPE
1125004|NCT01468194|high altitude
1125005|NCT01468194|oxygen
1125006|NCT01468194|saturation
1125007|NCT01468194|mountain
1125008|NCT01468194|climbing
1125009|NCT01468194|breathing
1125010|NCT01468181|Type 2 diabetes mellitus
1125011|NCT01468181|Oral antihyperglycemic medications
1125012|NCT01468181|Long-Term Safety
1125013|NCT01468181|GLP 1
1125014|NCT01468181|Glucagon like peptide 1
1125015|NCT01468155|PVA
1125016|NCT01468155|peri procedural bleeding complications
1125017|NCT01468116|Type 2 diabetes
1125018|NCT01468116|Gastric bypass surgery
1125019|NCT01468116|Obesity
1125020|NCT01468116|Mitochondrial function
1125021|NCT01468103|intraocular pressure
1125022|NCT01468103|Peripheral anterior synechiae
1125023|NCT01468090|Inflammatory bowel disease
1125024|NCT01468090|Crohn's disease
1125025|NCT01468090|Ulcerative colitis
1125026|NCT01468090|Disease course
1125027|NCT01468090|Phenotype
1125028|NCT01468090|Biological treatment
1125029|NCT01468064|Central Nervous System Diseases
1125030|NCT01468064|Stroke
1125031|NCT01468064|Infarction, Middle Cerebral Artery
1125032|NCT01468064|Cerebral Infarction
1125033|NCT01468064|Cerebrovascular Accident
1125034|NCT01468064|Stem Cell Transplantation
1125035|NCT01468064|Mesenchymal Stem Cell Transplantation
1125036|NCT01468064|Bone marrow stromal cells
1125037|NCT01468064|Mesenchymal Stem Cells
1125038|NCT01468064|Endothelial progenitor cells
1125039|NCT01468064|Adult Stem Cells
1125040|NCT01468064|Cell Therapy
1125041|NCT01468051|predialysed
1125042|NCT01468051|chronic
1125043|NCT01468051|renal failure patients
1125044|NCT01468025|NSAIDs
1125045|NCT01468025|Theramine
1125046|NCT01468025|naproxen
1125047|NCT01468025|Low back pain
1125048|NCT01468025|amino acids
1125049|NCT01468025|CRP
1125050|NCT01468025|Medical Food
1125051|NCT01468012|cocaine dependence
1125052|NCT01468012|levodopa
1125053|NCT01468012|carbidopa
1125054|NCT01468012|entacapone
1125055|NCT01467999|cannabis dependence
1125056|NCT01467999|marijuana dependence
1125057|NCT01467999|guanfacine
1125058|NCT01467986|neuroblastoma
1125059|NCT01467986|molecular targeted therapy
1125060|NCT01467986|protein kinase inhibitor
1125061|NCT01467986|mTOR Inhibitor
1125062|NCT01467986|cytostatic topoisomerase-I-inhibitor
1125063|NCT01467986|temozolomide
1125064|NCT01467986|irinotecan
1125065|NCT01467986|dasatinib
1125066|NCT01467986|rapamycin
1125067|NCT01467973|Heart Failure
1125068|NCT01467973|Heart Failure, Diastolic
1125069|NCT01467973|Heart Failure, Systolic
1125070|NCT01467973|Middle-East
1125071|NCT01467908|Diagnosed vegetative state after stroke or traumatic brain injury
1125072|NCT01467869|abnormal semen
1125073|NCT01467869|assisted conception
1125074|NCT01467856|Tetraplegia
1125075|NCT01467843|Cognitive Behavioral Therapy
1125076|NCT01467843|Mindfulness Based Stress Reduction
1125077|NCT01467830|absorbable sutures efficacy
1125078|NCT01467830|reducing Adverse effect to be caused from surgery
1125079|NCT01467830|Inguinal Hernia repair with mesh
1125080|NCT01467817|body mass
1125081|NCT01467817|abdominal fat
1125082|NCT01467817|whole body lean mass
1125083|NCT01467817|insulin resistance
1125084|NCT01467817|caloric intake
1125085|NCT01467817|expenditure
1125086|NCT01467817|endurance
1125087|NCT01467817|Strength
1125088|NCT01467817|TC:HDL ratio
1125089|NCT01467817|LDL:HDL ratio
1125090|NCT01467817|area under the TG response curve
1125091|NCT01467817|feeding challenge
1125092|NCT01467817|fasting and post-prandial whole body fat oxidation
1125093|NCT01467817|HRQoL
1125094|NCT01467804|efficacy,
1125095|NCT01467804|safety,
1125096|NCT01467804|JWXYJN
1125097|NCT01467791|ambrisentan
1125098|NCT01467791|Bosentan
1125099|NCT01467791|Iloprost
1125100|NCT01467778|skin
1125101|NCT01467752|reconstruction
1125102|NCT01467752|metacarpophalangeal joint
1125103|NCT01467752|bone graft
1125104|NCT01467752|MCP joint
1125105|NCT01467726|Alzheimer's disease
1125106|NCT01467726|Elderly
1125107|NCT01467713|Drug Therapy
1125108|NCT01467700|Drug Therapy
1125109|NCT01467674|Diabetes mellitus
1125110|NCT01467674|Chronic periodontitis
1125111|NCT01467674|Malondialdehyde
1125112|NCT01467674|Glutathione peroxidase
1125113|NCT01467674|Paraoxonase
1125114|NCT01467648|Infection
1125115|NCT01467648|Doripenem
1125116|NCT01467648|Ventilator-Associated Pneumonia
1125117|NCT01467648|pharmacokinetic
1125118|NCT01467648|pharmacodynamic
1125119|NCT01467635|Endobronchial ultrasound
1125120|NCT01467635|Transbronchial needle aspiration
1125121|NCT01467635|Transbronchial biopsy forceps
1125122|NCT01467635|Mediastinal lymphadenopathy
1125123|NCT01467635|Hilar lymphadenopathy
1125124|NCT01467622|chest tube drainage
1125125|NCT01467622|pulmonary air leak
1125126|NCT01467622|lung resection
1125127|NCT01467609|Pillcam colon capsule endoscopy
1125128|NCT01467609|conventional colonoscopy
1125129|NCT01467609|ulcerative colitis
1125130|NCT01467609|endoscopic manifestation
1125131|NCT01467609|colonoscopy
1125132|NCT01467596|Ultrasound
1125133|NCT01467596|Brachial block
1125134|NCT01467596|Levobupivacaine
1125135|NCT01467596|Minimum
1125136|NCT01467596|Volume
1125137|NCT01467596|Minimum volume of Levobupivacaine 0,5%
1125138|NCT01467583|Fondaparinux
1125139|NCT01467583|Renal Failure
1125140|NCT01467583|Critically Ill
1125141|NCT01467570|diarrhea
1125142|NCT01467557|adverse events
1125143|NCT01467544|Tai Chi
1125144|NCT01467531|HIV, GSK1265744, GSK1349572, dolutegravir, rilpivirine, drug interaction, pharmacokinetics
1125145|NCT01467518|methadone
1125146|NCT01467518|Opiate-dependent
1125147|NCT01467492|VX-950, Incivek
1125148|NCT01467466|renal
1125149|NCT01467466|cardiovascular
1125150|NCT01467466|kidney
1125151|NCT01467466|heart
1125152|NCT01467466|clinical trial
1125153|NCT01467466|double-blind
1125154|NCT01467466|multi-site trial
1125155|NCT01467466|randomized
1125156|NCT01467466|drug treatment
1125157|NCT01467466|IV solutions
1125158|NCT01467466|antioxidant
1125159|NCT01467440|Glaucoma and Ocular Hypertension
1125160|NCT01467388|patients with glaucoma or ocular hypertension
1125161|NCT01467362|xerosis
1125162|NCT01467362|dry skin
1125163|NCT01467362|dermatitis
1125164|NCT01467362|pruritus
1125165|NCT01467362|eczema
1125166|NCT01467362|emollient
1125167|NCT01467362|corticosteroid
1125168|NCT01467349|Raltegravir
1125169|NCT01467349|efficacy
1125170|NCT01467349|safety
1125171|NCT01467349|raltegravir-containing regimens
1125172|NCT01467349|HIV urban clinic setting
1125173|NCT01467310|GSK1120212
1125174|NCT01467310|TNBC
1125175|NCT01467310|Triple Negative Breast Cancer
1125176|NCT01467310|Surgical Resection
1125177|NCT01467297|Chronic bronchitis
1125178|NCT01467297|exacerbations
1125179|NCT01467297|treatment
1125180|NCT01467297|ceftidoren
1125181|NCT01467297|levofloxacin
1125182|NCT01467297|inflammation
1125183|NCT01467284|Obesity
1125184|NCT01467284|Workplace
1125185|NCT01467284|Intervention
1125186|NCT01467284|Diet
1125187|NCT01467284|Exercise
1125188|NCT01467245|Thoracoscopy
1125189|NCT01467245|congenital diaphragmatic hernia
1125190|NCT01467245|oesophageal atresia
1125191|NCT01467245|hypercapnia
1125192|NCT01467245|acidosis
1125193|NCT01467245|cerebral oxygenation
1125194|NCT01467245|neonates
1125195|NCT01467219|early
1125196|NCT01467219|high risk
1125197|NCT01467206|Stroke
1125198|NCT01467206|Physiotherapy
1125199|NCT01467206|Motor training
1125200|NCT01467206|Rehabilitation
1125201|NCT01467206|Randomized Controlled Trial
1125202|NCT01467180|septeX
1125203|NCT01467180|CVVH
1125204|NCT01467180|CVHD
1125205|NCT01467180|myoglobin
1125206|NCT01467167|Anesthesia
1125207|NCT01467167|Smart Pilot View
1125208|NCT01467167|Pain control
1125209|NCT01467167|Recovery
1125210|NCT01467128|Elderly
1125211|NCT01467128|Hospital
1125212|NCT01467128|Adverse Drug
1125213|NCT01467128|Pharmacist
1125214|NCT01467128|Prevention
1125215|NCT01467115|loco regionally advanced
1125216|NCT01467115|head and neck cancer
1125217|NCT01467115|chemotherapy
1125218|NCT01467115|radiation
1125219|NCT01467102|chronic post surgical pain
1125220|NCT01467102|Pain
1125221|NCT01467102|Risk factors of chronic post surgical pain
1125222|NCT01467102|predictive risk factors
1125223|NCT01467102|chronic post-surgical pain (CPSP)
1125224|NCT01467102|international level
1125225|NCT01467102|epidemiology of CPSP
1125226|NCT01467102|Europe
1125227|NCT01467102|observational
1125228|NCT01467102|prospective
1125229|NCT01467089|Schizophrenia
1125230|NCT01467089|Extrapyramidal symptoms
1125231|NCT01467089|Tardive dyskinesia
1125232|NCT01467089|Two Way Video Assessment
1125233|NCT01467063|Type I Diabetes
1125234|NCT01467063|Insulin Resistance
1125235|NCT01467063|Glutamine
1125236|NCT01467063|Amino Acids
1125237|NCT01467063|Glucagon like peptide 1
1125238|NCT01467063|Glutathione
1125239|NCT01467063|Citrulline
1125240|NCT01467063|Arginine
1125241|NCT01467063|Nitric Oxide
1125242|NCT01467050|Adverse drug event
1125243|NCT01467050|Adverse drug reaction
1125244|NCT01467050|Inappropriate prescribing
1125245|NCT01467050|Elderly
1125246|NCT01467050|Hospital-acquired
1125247|NCT01467037|Rotavirus
1125248|NCT01467037|Gastroenteritis
1125249|NCT01467037|Vaccination
1125250|NCT01467037|Pediatrics
1125251|NCT01467024|HTLV
1125252|NCT01467024|Confirmatory
1125253|NCT01467024|Supplemental
1125254|NCT01467024|Blot
1125255|NCT01467024|HTLV-I
1125256|NCT01467024|HTLV-II
1125257|NCT01467011|Myfortic
1125258|NCT01467011|Mycophenolic acid
1125259|NCT01467011|Prograf
1125260|NCT01467011|Tacrolimus
1125261|NCT01467011|Liver transplantation
1125262|NCT01466972|Advanced
1125263|NCT01466972|Breast
1125264|NCT01466972|Cancer
1125265|NCT01466972|Hormone Resistance
1125266|NCT01466972|Pazopanib
1125267|NCT01466972|anastrozole
1125268|NCT01466972|arimidex
1125269|NCT01466972|letrozole
1125270|NCT01466972|femara
1125271|NCT01466959|hemodialysis
1125272|NCT01466959|dialysate
1125273|NCT01466959|acetate based dialysate
1125274|NCT01466959|citrasate dialysate
1125275|NCT01466959|heparin anticoagulation
1125276|NCT01466959|hemodynamic stability
1125277|NCT01466946|lung cancer
1125278|NCT01466946|Hispanic/Latino patients
1125279|NCT01466946|interviews
1125280|NCT01466946|11-109
1125281|NCT01466933|parenting intervention
1125282|NCT01466933|child development
1125283|NCT01466933|low and middle income countries
1125284|NCT01466920|Total knee arthroplasty
1125285|NCT01466907|complication
1125286|NCT01466907|depression
1125287|NCT01466907|follow-up
1125288|NCT01466907|intervention
1125289|NCT01466907|nurse-led
1125290|NCT01466907|outcome
1125291|NCT01466907|secondary prevention
1125292|NCT01466907|stroke
1125293|NCT01466894|Nonalcoholic fatty liver disease
1125294|NCT01466894|NAFLD
1125295|NCT01466894|Fatty liver
1125296|NCT01466894|NASH
1125297|NCT01466868|Diffuse Large B cell Lymphoma
1125298|NCT01466868|AKT
1125299|NCT01466868|MK 2206
1125300|NCT01466868|objective response rate
1125301|NCT01466868|progression free survival
1125302|NCT01466868|overall survival
1125303|NCT01466868|safety
1125304|NCT01466855|Retinoblastoma
1125305|NCT01466829|sternotomy
1125306|NCT01466829|parathyroid hormone
1125307|NCT01466829|bone healing
1125308|NCT01466816|Lipid metabolism
1125309|NCT01466803|Buprenorphine
1125310|NCT01466803|Vorikonazole
1125311|NCT01466803|Interactions
1125312|NCT01466803|Pharmacokinetics
1125313|NCT01466803|Pharmacodynamics
1125314|NCT01466803|Voriconazole
1125315|NCT01466790|Hepatitis C
1125316|NCT01466790|TMC435
1125317|NCT01466790|PSI-7977
1125318|NCT01466790|GS7977
1125319|NCT01466790|Ribavirin
1125320|NCT01466790|HCV
1125321|NCT01466790|Hep C
1125322|NCT01466790|Genotype 1
1125323|NCT01466777|Endometrium cancer
1125324|NCT01466777|Robotic-assisted laparoscopy
1125325|NCT01466777|Traditional laparoscopy
1125326|NCT01466777|Laparoscopic surgery
1125327|NCT01466777|Treatment
1125328|NCT01466777|Operation time
1125329|NCT01466777|Bleeding
1125330|NCT01466777|Complications
1125331|NCT01466777|Conversions
1125332|NCT01466777|Pelvic lymph node
1125333|NCT01466764|biomarkers
1125552|NCT01465997|Lacosamide
1125334|NCT01466751|Computerized neurobehavioral intervention
1125335|NCT01466738|Healthy volunteer
1125336|NCT01466738|Rhinovirus
1125337|NCT01466738|Cold virus
1125338|NCT01466738|HRV-16
1125339|NCT01466725|Lupus
1125340|NCT01466725|Discoid Lupus
1125341|NCT01466725|DLE
1125342|NCT01466725|Cutaneous Lupus
1125343|NCT01466686|Recurrent Glioblastoma Multiforme
1125344|NCT01466686|Recurrent Anaplastic Astrocytoma
1125345|NCT01466686|Surgery
1125346|NCT01466686|Adjuvant Radiation
1125347|NCT01466686|Adjuvant Temozolomide
1125348|NCT01466673|Acne Vulgaris
1125349|NCT01466673|Ethinyl estradiol
1125350|NCT01466673|Norgestimate
1125351|NCT01466673|Desogestrel
1125352|NCT01466673|Tricilest
1125353|NCT01466673|Oilezz
1125354|NCT01466647|NSCLC
1125355|NCT01466621|cardiac resynchronization therapy
1125356|NCT01466621|heart failure
1125357|NCT01466621|mortality
1125358|NCT01466608|OATP1B1
1125359|NCT01466608|Rosuvastatin
1125360|NCT01466608|lipidomics
1125361|NCT01466608|pharmacodynamics
1125362|NCT01466582|HIV-1-infection
1125363|NCT01466582|comorbidity
1125364|NCT01466582|ageing
1125365|NCT01466569|Advanced Solid Tumor
1125366|NCT01466569|Gastric Cancer
1125367|NCT01466569|Oncology
1125368|NCT01466569|monoclonal Antibody
1125369|NCT01466543|Vascular dementia
1125370|NCT01466543|Subcortical vascular dementia
1125371|NCT01466543|Phosphodiesterase 5
1125372|NCT01466543|Udenafil
1125373|NCT01466530|Full term pregnancy > 36 weeks
1125374|NCT01466530|Cesarean delivery
1125375|NCT01466530|General anesthesia
1125376|NCT01466517|Relative Bioavailability Study
1125377|NCT01466517|Ibuprofen
1125378|NCT01466517|Alivium
1125379|NCT01466504|P63
1125380|NCT01466504|Sorafenib
1125381|NCT01466504|Regorafenib
1125382|NCT01466504|rash
1125383|NCT01466504|skin toxicity
1125384|NCT01466504|RCC
1125385|NCT01466504|HCC
1125386|NCT01466504|colorectal carcinoma
1125387|NCT01466491|Pain during first-trimester surgical abortion
1125388|NCT01466465|Vitamin D
1125389|NCT01466465|SIT
1125390|NCT01466465|Grass pollen
1125391|NCT01466465|allergic rhinoconjunctivitis
1125392|NCT01466439|rTMS
1125393|NCT01466439|P50
1125394|NCT01466439|inhibitory
1125395|NCT01466439|facilitatory
1125396|NCT01466439|physiological process
1125397|NCT01466439|brain changes
1125398|NCT01466426|Venous thromboembolic disease
1125399|NCT01466426|Deep veinous thrombosis
1125400|NCT01466426|Pulmonary embolism
1125401|NCT01466413|Intrinsic Aging of Skin
1125402|NCT01466400|health benefits of infant formula
1125403|NCT01466387|Adults
1125404|NCT01466387|international travel vaccination
1125405|NCT01466387|Meningococcal disease
1125406|NCT01466387|meningococcal meningitis
1125407|NCT01466387|typhoid
1125408|NCT01466387|yellow fever
1125409|NCT01466387|rabies
1125410|NCT01466387|Japanese encephalitis
1125411|NCT01466361|Nicotine
1125412|NCT01466361|Nicotine craving
1125413|NCT01466348|Paracetomol
1125414|NCT01466348|Caffeine
1125415|NCT01466348|Common cold
1125416|NCT01466322|Healthy volunteers
1125417|NCT01466322|GSK2018682
1125418|NCT01466322|Pharmacokinetics
1125419|NCT01466322|Relapsing Remitting Multiple Sclerosis
1125420|NCT01466322|Pharmacodynamics
1125421|NCT01466309|AHI
1125422|NCT01466309|ESS
1125423|NCT01466309|VAS
1125424|NCT01466309|FOSQ
1125425|NCT01466309|SF-36
1125426|NCT01466296|CERBRAL PALSY
1125427|NCT01466296|Poststroke/CVA Paresis
1125428|NCT01466296|REHABILITATION
1125429|NCT01466296|WALKING
1125430|NCT01466296|PERUTURBATION
1125431|NCT01466283|childhood rhabdomyosarcoma
1125432|NCT01466270|fatigue
1125433|NCT01466270|sleep disorders
1125434|NCT01466270|depression
1125435|NCT01466270|anxiety disorder
1125436|NCT01466270|cognitive/functional effects
1125437|NCT01466270|breast cancer
1125438|NCT01466270|cancer survivor
1125439|NCT01466257|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1125440|NCT01466257|recurrent metastatic squamous neck cancer with occult primary
1125441|NCT01466257|recurrent squamous cell carcinoma of the hypopharynx
1125442|NCT01466257|recurrent squamous cell carcinoma of the larynx
1125443|NCT01466257|recurrent squamous cell carcinoma of the lip and oral cavity
1125444|NCT01466257|recurrent squamous cell carcinoma of the oropharynx
1125445|NCT01466257|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1125446|NCT01466257|stage III squamous cell carcinoma of the hypopharynx
1125447|NCT01466257|stage III squamous cell carcinoma of the larynx
1125448|NCT01466257|stage III squamous cell carcinoma of the lip and oral cavity
1125449|NCT01466257|stage III squamous cell carcinoma of the oropharynx
1125450|NCT01466257|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1125451|NCT01466257|stage IV squamous cell carcinoma of the hypopharynx
1125452|NCT01466257|stage IVA squamous cell carcinoma of the larynx
1125553|NCT01465984|Paracetamol
1125453|NCT01466257|stage IVA squamous cell carcinoma of the lip and oral cavity
1125454|NCT01466257|stage IVA squamous cell carcinoma of the oropharynx
1125455|NCT01466257|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
1125456|NCT01466257|stage IVB squamous cell carcinoma of the larynx
1125457|NCT01466257|stage IVB squamous cell carcinoma of the lip and oral cavity
1125458|NCT01466257|stage IVB squamous cell carcinoma of the oropharynx
1125459|NCT01466257|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
1125460|NCT01466257|stage IVC squamous cell carcinoma of the larynx
1125461|NCT01466257|stage IVC squamous cell carcinoma of the lip and oral cavity
1125462|NCT01466257|stage IVC squamous cell carcinoma of the oropharynx
1125463|NCT01466257|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
1125464|NCT01466257|untreated metastatic squamous neck cancer with occult primary
1125465|NCT01466244|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1125466|NCT01466244|recurrent metastatic squamous neck cancer with occult primary
1125467|NCT01466244|recurrent squamous cell carcinoma of the hypopharynx
1125468|NCT01466244|recurrent squamous cell carcinoma of the larynx
1125469|NCT01466244|recurrent squamous cell carcinoma of the lip and oral cavity
1125470|NCT01466244|recurrent squamous cell carcinoma of the oropharynx
1125471|NCT01466244|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1125472|NCT01466244|stage III squamous cell carcinoma of the hypopharynx
1125473|NCT01466244|stage III squamous cell carcinoma of the larynx
1125474|NCT01466244|stage III squamous cell carcinoma of the lip and oral cavity
1125475|NCT01466244|stage III squamous cell carcinoma of the oropharynx
1125476|NCT01466244|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1125477|NCT01466244|stage IVA squamous cell carcinoma of the larynx
1125478|NCT01466244|stage IVA squamous cell carcinoma of the lip and oral cavity
1125479|NCT01466244|stage IVA squamous cell carcinoma of the oropharynx
1125480|NCT01466244|stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity
1125481|NCT01466244|stage IVB squamous cell carcinoma of the larynx
1125482|NCT01466244|stage IVB squamous cell carcinoma of the lip and oral cavity
1125483|NCT01466244|stage IVB squamous cell carcinoma of the oropharynx
1125484|NCT01466244|stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity
1125485|NCT01466244|stage IVC squamous cell carcinoma of the larynx
1125486|NCT01466244|stage IVC squamous cell carcinoma of the lip and oral cavity
1125487|NCT01466244|stage IVC squamous cell carcinoma of the oropharynx
1125488|NCT01466244|stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity
1125489|NCT01466244|untreated metastatic squamous neck cancer with occult primary
1125490|NCT01466231|refractory germ cell cancer
1125491|NCT01466231|everolimus
1125492|NCT01466218|pulmonary function abnormalities
1125493|NCT01466218|pulmonary disease
1125494|NCT01466218|cardiac disease
1125495|NCT01466218|cardiopulmonary disease
1125496|NCT01466218|obstructive sleep apnea
1125497|NCT01466218|OSA
1125498|NCT01466218|cardiovascular disease
1125499|NCT01466218|CVD
1125500|NCT01466218|particulate matter
1125501|NCT01466205|schizotypal personality disorder
1125502|NCT01466205|cognitive impairment
1125503|NCT01466205|working memory
1125504|NCT01466192|Genotype 2
1125505|NCT01466179|B-ALL
1125506|NCT01466179|relapsed ALL
1125507|NCT01466179|refractory ALL
1125508|NCT01466179|adult ALL
1125509|NCT01466179|Leukemia
1125510|NCT01466179|Leukemia, Lymphoid
1125511|NCT01466179|precursor cell lymphoblastic leukemia-lymphoma
1125512|NCT01466179|Lymphatic diseases
1125513|NCT01466179|Lymphoproliferative disorders
1125514|NCT01466179|bispecific antibody
1125515|NCT01466179|anti-CD19
1125516|NCT01466179|Immunotherapeutic treatment
1125517|NCT01466179|immunoproliferative disorders
1125518|NCT01466153|Chronic lymphocytic leukemia; leukemia; B-Cell malignancy; anti-CD19; monoclonal antibody; CLL; Refractory; Relapse; Non-Hodgkin's Lymphoma
1125519|NCT01466140|Patient Satisfaction
1125520|NCT01466140|Request for help
1125521|NCT01466140|General practice
1125522|NCT01466127|Effect of oxytocin on learning
1125523|NCT01466114|multiple sclerosis
1125524|NCT01466114|MS
1125525|NCT01466114|relapsing remitting multiple sclerosis
1125526|NCT01466114|RRMS
1125527|NCT01466114|secondary progressive multiple sclerosis
1125528|NCT01466114|SPMS
1125529|NCT01466114|primary progressive multiple sclerosis
1125530|NCT01466114|estrogen
1125531|NCT01466114|estriol
1125532|NCT01466101|Hysterectomy
1125533|NCT01466101|Pain
1125534|NCT01466101|Pregabalin
1125535|NCT01466088|Alzheimer's Disease
1125536|NCT01466088|AD
1125537|NCT01466088|Dementia
1125538|NCT01466062|Immunocompromised medical conditions
1125539|NCT01466062|Respiratory Syncytial Virus Infection
1125540|NCT01466062|Infant
1125541|NCT01466062|Newborn
1125542|NCT01466062|Young children
1125543|NCT01466049|Ovarian Cancer
1125544|NCT01466049|Adnexal Mass
1125545|NCT01466049|Pelvic Mass
1125546|NCT01466036|metastatic
1125547|NCT01466023|thyroid metabolism during pregnancy
1125548|NCT01466023|impact on neonate
1125549|NCT01466010|osteoma, osteoid
1125550|NCT01466010|surgical procedures, operative
1125551|NCT01466010|bone neoplasms
1125554|NCT01465984|Morphine sulfates
1125555|NCT01465984|Acute pain
1125556|NCT01465971|high
1125557|NCT01465971|altitude
1125558|NCT01465971|acute
1125559|NCT01465971|mountain
1125560|NCT01465971|sickness
1125561|NCT01465971|sleep
1125562|NCT01465971|disorder
1125563|NCT01465971|periodic
1125564|NCT01465971|breathing
1125565|NCT01465971|hyperventilation
1125566|NCT01465971|apnea
1125567|NCT01465945|TEM for rectal lesions
1125568|NCT01465945|Sutured defect
1125569|NCT01465945|Unsutured defect
1125570|NCT01465932|Nursing staff
1125571|NCT01465932|Physical Therapy (Specialty)
1125572|NCT01465919|depression
1125573|NCT01465919|interferon
1125574|NCT01465919|chronic hepatitis C
1125575|NCT01465919|mirtazapine
1125576|NCT01465906|COPD
1125577|NCT01465893|vitamin d
1125578|NCT01465880|Smoking research study
1125579|NCT01465867|Selenium
1125580|NCT01465867|Pregnancy
1125581|NCT01465867|Auto-immune thyroiditis
1125582|NCT01465867|Post-partum thyroiditis
1125583|NCT01465867|Miscarriage
1125584|NCT01465867|Pre-eclampsia
1125585|NCT01465867|Implantation and Pregnancy rate
1125586|NCT01465867|Infertility
1125587|NCT01465854|lung cancer
1125588|NCT01465854|smoking
1125589|NCT01465854|molecular epidemiology
1125590|NCT01465854|genetic polymorphism
1125591|NCT01465854|risk factors
1125592|NCT01465854|never smokers
1125593|NCT01465854|histologically/cytologically confirmed
1125594|NCT01465841|intracranial aneurysms
1125595|NCT01465841|Peripheral aneurysms
1125596|NCT01465841|acute treatment
1125597|NCT01465841|PC 400 System
1125598|NCT01465841|packing density
1125599|NCT01465828|antiplatelet effect
1125600|NCT01465828|prasugrel
1125601|NCT01465828|clopidogrel
1125602|NCT01465828|ACS
1125603|NCT01465802|non-small cell lung cancer
1125604|NCT01465802|advanced
1125605|NCT01465802|previously treated
1125606|NCT01465776|SCC of the oral cavity
1125607|NCT01465776|black raspberries
1125608|NCT01465763|tofacitinib
1125609|NCT01465763|CP-690
1125610|NCT01465763|550
1125611|NCT01465763|Moderate to severe ulcerative colitis
1125612|NCT01465763|phase 3 clinical trial
1125613|NCT01465763|Mayo score
1125614|NCT01465737|epidemiology
1125615|NCT01465737|uterine cancer
1125616|NCT01465737|Taiwan
1125617|NCT01465724|Insulin resistance
1125618|NCT01465724|Insulin sensitivity
1125619|NCT01465724|HOMA-IR
1125620|NCT01465724|blood pressure
1125621|NCT01465724|Renal denervation
1125622|NCT01465724|renal sympathetic denervation
1125623|NCT01465724|renal ablation
1125624|NCT01465711|Peritonitis
1125625|NCT01465711|Sepsis
1125626|NCT01465711|General Surgery
1125627|NCT01465711|Intensive Care Units
1125628|NCT01465711|Sensitivity and Specificity
1125629|NCT01465698|exercise
1125630|NCT01465698|counseling
1125631|NCT01465698|movement control
1125632|NCT01465698|fear avoidance
1125633|NCT01465685|MDMA
1125634|NCT01465685|pharmacokinetics
1125635|NCT01465685|pharmacodynamics
1125636|NCT01465685|emotions
1125637|NCT01465685|Mechanism of action of MDMA
1125638|NCT01465685|Interaction study
1125639|NCT01465685|Effect of MDMA and methylphenidate on emotions
1125640|NCT01465672|copeptin
1125641|NCT01465672|SIADH
1125642|NCT01465672|Diabetes insipidus
1125643|NCT01465672|transphenoidal pituitary adenoma resection
1125644|NCT01465672|pituitary adenoma
1125645|NCT01465672|tumors close to pituitary gland
1125646|NCT01465672|tumors close to hypothalamus
1125647|NCT01465646|levothyroxine
1125648|NCT01465646|bioavailability
1125649|NCT01465633|bioavailability
1125650|NCT01465633|levothyroxine
1125651|NCT01465620|Peripheral Nervous System Diseases
1125652|NCT01465620|Diabetic Polyneuropathy
1125653|NCT01465620|Metabolic Syndrome X
1125654|NCT01465607|Condom use
1125655|NCT01465594|Pain Measurement
1125656|NCT01465581|incontinence
1125657|NCT01465581|dysfunctional voiding
1125658|NCT01465581|neurogenic bladder disturbance
1125659|NCT01465581|filum terminale
1125660|NCT01465581|spinal cord tethering
1125661|NCT01465581|conus
1125662|NCT01465568|osteoporosis
1125663|NCT01465568|denosumab
1125664|NCT01465568|RANKL
1125665|NCT01465568|glucocorticoids
1125666|NCT01465555|Clinical Alert
1125667|NCT01465555|Cognitive Behavioral Intervention
1125668|NCT01465555|Web-based
1125669|NCT01465555|Substance Abuse Treatment
1125670|NCT01465542|Acetaminophen Toxicity
1125671|NCT01465542|Acetaminophen Overdose
1125672|NCT01465542|N-acetylcysteine
1125673|NCT01465542|Liver Toxicity
1125674|NCT01465503|bleeding
1125675|NCT01465503|percutaneous coronary intervention
1125676|NCT01465503|heparin
1125677|NCT01465503|bivalirudin
1125678|NCT01465490|Monitoring
1125679|NCT01465490|Feedback
1125680|NCT01465490|Substance Abuse Treatment
1125681|NCT01465477|Fibromyalgia
1125682|NCT01465477|Influenza vaccination
1125683|NCT01465451|colorectal cancer
1125684|NCT01465451|curative resection
1125685|NCT01465451|intra-operative chemotherapy
1125686|NCT01465451|5-fluorouracil
1125687|NCT01465451|chemotherapy
1125688|NCT01465425|extracolonic findings
1125689|NCT01465425|ECFs
1125690|NCT01465425|CT colonography
1125691|NCT01465425|computed tomography colonography
1125692|NCT01465425|National CT Colonography Trial
1125693|NCT01465425|ACRIN 6664
1125694|NCT01465412|Parkinson disease
1125695|NCT01465373|In-Vitro Fertilization
1125696|NCT01465373|Donor Egg IVF
1125697|NCT01465360|Alzheimer's disease
1125698|NCT01465360|AD
1125699|NCT01465360|Non AD dementia
1125700|NCT01465360|Mild Cognitive Impairment
1125701|NCT01465360|MCI
1125702|NCT01465360|Vascular dementia
1125703|NCT01465360|Fronto-temporal dementia
1125704|NCT01465360|Primary progressive aphasia
1125705|NCT01465360|Parkinson's Disease dementia
1125706|NCT01465360|Mixed dementia
1125707|NCT01465360|Blood signature
1125708|NCT01465360|Diagnosis
1125709|NCT01465360|AclarusDx
1125710|NCT01465360|Alzheimer's Disease and other non-AD dementia
1125711|NCT01465360|Exonhit
1125712|NCT01465347|Primary brain tumor
1125713|NCT01465347|Glioblastoma
1125714|NCT01465347|Glioma
1125715|NCT01465347|GBM
1125716|NCT01465347|Radiation therapy
1125717|NCT01465334|17p Deletion CLL
1125718|NCT01465308|head and neck cancer
1125719|NCT01465308|radiotherapy induced xerostomia
1125720|NCT01465308|radiotherapy induced oral mucositis
1125721|NCT01465308|RCT
1125722|NCT01465308|symptom management
1125723|NCT01465295|Scoliosis
1125724|NCT01465295|Adolescent Idiopathic Scoliosis (AIS)
1125725|NCT01465295|Scoliosis treatment
1125726|NCT01465295|Fusionless spinal surgery
1125727|NCT01465295|Vertebral stapling
1125728|NCT01465295|Spinal stapling
1125729|NCT01465295|Non-fusion
1125730|NCT01465295|Spinal curvature
1125731|NCT01465295|Curvature of the spine
1125732|NCT01465295|Spinal bracing alternative
1125733|NCT01465295|HemiBridge
1125734|NCT01465295|SpineForm
1125735|NCT01465295|Dr. Eric Wall
1125736|NCT01465295|Dr. George Thompson
1125737|NCT01465295|Spinal clip
1125738|NCT01465295|Cincinnati Children's Hospital Medical Center
1125739|NCT01465295|University Hospitals Case Medical Center, Rainbow Babies
1125740|NCT01465282|psoriasis vulgaris
1125741|NCT01465282|topical ointment
1125742|NCT01465269|TBI
1125743|NCT01465269|Social Competence
1125744|NCT01465256|Aspirin
1125745|NCT01465256|Colon polypectomy
1125746|NCT01465256|Bleeding
1125747|NCT01465243|Efficacy
1125748|NCT01465243|Safety
1125749|NCT01465243|EGFR-TKI
1125750|NCT01465243|phase IV
1125751|NCT01465243|NSCLC
1125752|NCT01465243|Dose escalation
1125753|NCT01465230|chronic lymphocytic leukemia
1125754|NCT01465230|maintenance therapy
1125755|NCT01465217|medication adherence
1125756|NCT01465217|African Americans
1125757|NCT01465204|Behavior Change
1125758|NCT01465204|Hygiene & Sanitation Marketing
1125759|NCT01465191|cesarean
1125760|NCT01465191|postoperative
1125761|NCT01465191|morphine
1125762|NCT01465191|genetics
1125763|NCT01465191|opioid
1125764|NCT01465178|hypovitaminosis D
1125765|NCT01465178|vitamin D insufficiency
1125766|NCT01465178|low vitamin D
1125767|NCT01465165|Depression
1125768|NCT01465165|Positron emission tomography
1125769|NCT01465165|Magnetic resonance spectroscopy
1125770|NCT01465165|glucose metabolism
1125771|NCT01465165|ATP
1125772|NCT01465165|phosphocreatine
1125773|NCT01465113|Barrett's Esophagus
1125774|NCT01465113|Vitamin D3
1125775|NCT01465113|cholecalciferol
1125776|NCT01465113|15-Prostaglandin Dehydrogenase Expression
1125777|NCT01465113|metformin
1125778|NCT01465100|phenylketonuria
1125779|NCT01465100|hepatocyte
1125780|NCT01465087|Multiple Sclerosis
1125781|NCT01465087|Breath
1125782|NCT01465087|Diagnosis
1125783|NCT01465087|Discrimination MS/healthy subj. via exhaled breath samples
1125784|NCT01465087|Discrimination MS/other neurological and autoimmune diseases
1125785|NCT01465074|nicotine
1125786|NCT01465074|memory
1125787|NCT01465074|plasticity
1125788|NCT01465074|TMS
1125789|NCT01465074|Paired Associative Stimulation
1125790|NCT01465061|Online social network
1125791|NCT01465061|Psoriasis
1125792|NCT01465061|Filipino
1125793|NCT01465048|Malaria
1125794|NCT01465048|Protozoan Infections
1125795|NCT01465048|Parasitic Diseases
1125796|NCT01465048|Malaria Challenge
1125797|NCT01465022|Breastfeeding rates
1125798|NCT01465022|Contraceptive continuation
1125799|NCT01465022|Birth control pills
1125800|NCT01465022|Lactation
1125801|NCT01465009|Sore Throat
1125802|NCT01464996|non-carious cervical lesions
1125803|NCT01464996|bonded restorations
1125804|NCT01464996|composites
1125805|NCT01464996|adhesives
1125806|NCT01464970|DIEP perfusion
1125807|NCT01464970|Zone IV
1125808|NCT01464970|Free Flap
1125809|NCT01464970|Breast Cancer Reconstruction
1125810|NCT01464970|Perfusion of Zone IV of DIEP flaps
1125811|NCT01464957|skin cancer prevention
1125812|NCT01464957|precaution adoption process model
1125813|NCT01464957|semi-tailored newsletter
1125814|NCT01464957|pediatric
1125815|NCT01464957|behavioral intervention
1125816|NCT01464944|Upper Respiratory Tract Infections
1125817|NCT01464918|gastric cancer
1125818|NCT01464918|colon cancer
1125819|NCT01464918|endoscopic submucosal dissection
1125820|NCT01464905|RRMS
1125821|NCT01464892|Imagery rescripting
1125822|NCT01464892|Imagery rescripting and reprocessing therapy
1125823|NCT01464892|Skills Training in affective and interpersonal regulation
1125824|NCT01464892|Post-traumatic Stress Disorder
1125825|NCT01464892|Childhood abuse
1125826|NCT01464892|Childhood sexual abuse
1125827|NCT01464840|Pregnancy
1125828|NCT01464840|Cesarean section
1125829|NCT01464840|Antibiotic
1125830|NCT01464827|Hepatitis C Genotype 1
1125831|NCT01464827|Hepatitis C
1125832|NCT01464827|Interferon-Free
1125833|NCT01464827|HCV
1125834|NCT01464827|Chronic Hepatitis C
1125835|NCT01464814|probiotic
1125836|NCT01464814|fish oil
1125837|NCT01464814|digestion
1125838|NCT01464814|viability
1125839|NCT01464801|Non-alcoholic Fatty Liver Disease
1125840|NCT01464801|Non-alcoholic Steatohepatitis
1125841|NCT01464801|Resveratrol
1125842|NCT01464801|Human study
1125843|NCT01464788|stroke
1125844|NCT01464788|Argatroban
1125845|NCT01464788|thrombin-inhibition
1125846|NCT01464788|thrombolysis
1125847|NCT01464788|anticoagulation
1125848|NCT01464775|Endometriosis
1125849|NCT01464775|Laparoscopy
1125850|NCT01464775|Narrow Band Imaging
1125851|NCT01464762|Tuberculosis
1125852|NCT01464762|TMC207TBC3001
1125853|NCT01464762|TMC207
1125854|NCT01464762|Early access
1125855|NCT01464762|TB
1125856|NCT01464762|Drug resistant
1125857|NCT01464762|Multi drug-resistant
1125858|NCT01464762|Extensively drug-resistant
1125859|NCT01464749|multiple sclerosis
1125860|NCT01464749|gait rehabilitation
1125861|NCT01464736|aerobic exercise
1125862|NCT01464736|noninvasive ventilation
1125863|NCT01464736|functionality
1125864|NCT01464697|hot flushes/hot flashes
1125865|NCT01464697|night sweats
1125866|NCT01464697|sleep problems
1125867|NCT01464697|negative mood
1125868|NCT01464697|anxiety
1125869|NCT01464697|perimenopause
1125870|NCT01464697|progesterone
1125871|NCT01464697|vasomotor symptoms
1125872|NCT01464697|premenopause
1125873|NCT01464671|Coronary Artery Disease
1125874|NCT01464671|Stable Angina
1125875|NCT01464671|Percutaneous Coronary Intervention
1125876|NCT01464658|panniculitis
1125877|NCT01464658|panniculectomy
1125878|NCT01464632|medial knee replacement
1125879|NCT01464619|Parenting
1125880|NCT01464619|Early Child Development
1125881|NCT01464606|pleuropulmonary blastoma
1125882|NCT01464606|pediatric
1125883|NCT01464606|lung cysts
1125884|NCT01464593|Colorectal Liver Metastasis
1125885|NCT01464593|Colon Cancer
1125886|NCT01464593|Liver Cancer
1125887|NCT01464593|Liver Metastasis
1125888|NCT01464593|Liver metastases
1125889|NCT01464567|Weaning
1125890|NCT01464567|Chronic Obstructive Pulmonary Disease
1125891|NCT01464567|Spontaneous Breathing Trial
1125892|NCT01464554|adolescents
1125893|NCT01464554|alcohol
1125894|NCT01464554|drugs
1125895|NCT01464554|delinquency
1125896|NCT01464554|intervention
1125897|NCT01464541|Orbit
1125898|NCT01464541|Fracture
1125899|NCT01464541|measurement
1125900|NCT01464541|CT
1125901|NCT01464541|intraoperative
1125902|NCT01464528|hysteroscopy
1125903|NCT01464528|postoperative complications
1125904|NCT01464528|adhesions
1125905|NCT01464528|hyaluronic gel
1125906|NCT01464528|prevention
1125907|NCT01464515|Mild Cognitive Impairment, So Stated
1125908|NCT01464515|Deep Transcranial Magnetic Stimulation
1125909|NCT01464502|Heart failure
1125910|NCT01464502|Cardiac resynchronisation therapy
1125911|NCT01464502|Acute haemodynamic response
1125912|NCT01464502|Responder
1125913|NCT01464489|Intubation time
1125914|NCT01464489|Atropine
1125915|NCT01464489|Propofol anesthesia
1125916|NCT01464463|Depression
1125917|NCT01464463|Exercise
1125918|NCT01464463|Psychoneuroimmunology
1125919|NCT01464463|Cognitive Behavioral Therapy
1125920|NCT01464463|CBASP
1125921|NCT01464450|Pharmacokinetics
1125922|NCT01464450|Bioavailability
1125923|NCT01464450|Healthy Participants
1125924|NCT01464437|diabetes
1125925|NCT01464437|mellitus
1125926|NCT01464437|metformin
1125927|NCT01464424|Glaucoma
1125928|NCT01464424|Ocular Hypertension
1125929|NCT01464424|Open-Angle Glaucoma
1125930|NCT01464424|Intraocular Pressure
1125931|NCT01464411|chronic myelogenous leukemia
1125932|NCT01464411|chronic phase
1125933|NCT01464411|Phase II
1125934|NCT01464411|dasatinib
1125935|NCT01464398|Polycystic Ovary Syndrome
1125936|NCT01464398|stress
1125937|NCT01464398|mindfulness
1125938|NCT01464398|meditation
1125939|NCT01464398|health education
1125940|NCT01464398|women
1125941|NCT01464398|overweight
1125942|NCT01464398|obesity
1125943|NCT01464372|Urinary Incontinence, Urge
1125944|NCT01464372|Peripheral Nerve Stimulation
1125945|NCT01464359|umbilical cord blood transplant
1125946|NCT01464346|diabetes
1125947|NCT01464346|glucose sensor
1125948|NCT01464346|CGM
1125949|NCT01464333|Crohn's Disease
1125950|NCT01464320|Safety
1125951|NCT01464320|Type 2 diabetes
1125952|NCT01464320|Kidney disease
1125953|NCT01464294|CAD/CAM
1125954|NCT01464294|crowns
1125955|NCT01464294|onlays
1125956|NCT01464294|composite block
1125957|NCT01464294|milled restorations
1125958|NCT01464281|nucleoside
1125959|NCT01464281|peginterferon alfa-2a
1125960|NCT01464268|Keratoconus
1125961|NCT01464268|Corneal Ectasia
1125962|NCT01464268|Collagen Crosslinking
1125963|NCT01464268|Riboflavin
1125964|NCT01464255|contact lenses
1125965|NCT01464242|Cutaneous Leishmaniasis
1125966|NCT01464242|pentoxifylline
1125967|NCT01464242|immunomodulation
1125968|NCT01464216|Functional Magnetic Resonance Imaging
1125969|NCT01464216|Prostate cancer
1125970|NCT01464216|FACBC PET
1125971|NCT01464216|Hypoxia imaging
1125972|NCT01464203|Computed tomographic coronary angiography
1125973|NCT01464203|multi-slice CT
1125974|NCT01464203|angina
1125975|NCT01464203|cost-effectiveness
1125976|NCT01464190|PA21
1125977|NCT01464190|Phosphate Binder
1125978|NCT01464177|malignant glioma
1125979|NCT01464177|glioblastoma
1125980|NCT01464177|radiotherapy
1125981|NCT01464177|randomized
1125982|NCT01464164|Diamond Blackfan anemia
1125983|NCT01464164|DBA
1125984|NCT01464164|Blackfan Diamond anemia
1125985|NCT01464164|Congenital pure red cell aplasia
1125986|NCT01464164|Aase-Smith II Syndrome
1125987|NCT01464164|Aase Syndrome
1125988|NCT01464164|Anemia, Congenital Pure Red Cell
1125989|NCT01464164|Aplasia, Congenital Pure Red Cell
1125990|NCT01464164|BDA
1125991|NCT01464164|Congenital Hypoplastic Anemia
1125992|NCT01464164|Erythrogenesis Imperfecta
1125993|NCT01464164|Hypoplastic Congenital Anemia
1125994|NCT01464164|Inherited Erythroblastopenia
1125995|NCT01464164|pure red cell aplasia
1125996|NCT01464164|bone marrow failure syndrome
1125997|NCT01464151|IBD
1125998|NCT01464151|colitis
1125999|NCT01464151|dysplasia
1126000|NCT01464151|colorectal cancer
1126001|NCT01464138|Malaria
1126002|NCT01464125|Malaria
1126003|NCT01464125|Plasmodium falciparum
1126004|NCT01464125|acute uncomplicated
1126005|NCT01464112|Multiple myeloma that has relapsed or is progressive following prior therapy
1126006|NCT01464112|Relapsed Multiple Myeloma
1126007|NCT01464112|JNJ 26481585
1126008|NCT01464112|VELCADE
1126009|NCT01464112|Bortezomib
1126010|NCT01464112|Dexamethasone
1126011|NCT01464086|patients with Li Fraumeni syndrome
1126012|NCT01464073|NIDDM
1126013|NCT01464073|obesity
1126014|NCT01464073|lifestyle intervention
1126015|NCT01464073|physical exercise
1126016|NCT01464073|diet
1126017|NCT01464073|LIPOXmax
1126018|NCT01464073|FATmax
1126019|NCT01464073|fat oxydation rate
1126020|NCT01464060|Helicobacter pylori
1126021|NCT01464060|Quadruple therapy
1126022|NCT01464060|Clarithromycin resistance
1126023|NCT01464021|Study
1126024|NCT01464021|prospective
1126025|NCT01464021|Rheumatoid
1126026|NCT01464021|Observational study
1126027|NCT01464021|Arthritis
1126028|NCT01464021|Adalimumab
1126029|NCT01463995|severe neurological diseases
1126030|NCT01463995|neurological intensive care unit
1126031|NCT01463995|prediction
1126032|NCT01463995|long-term outcome
1126033|NCT01463995|biomarkers
1126034|NCT01463995|prediction of long-term outcome
1126035|NCT01463982|Advanced solid cancer
1126036|NCT01463969|PCOS and PTX3 levels
1126037|NCT01463956|Boceprevir
1126038|NCT01463956|HCV infection
1126039|NCT01463956|Antiviral therapy
1126040|NCT01463956|Liver transplantation
1126041|NCT01463930|Total Knee Replacement
1126042|NCT01463930|Expectations
1126043|NCT01463930|Audiovisual videodisc
1126044|NCT01463917|Coronary Artery Bypass
1126045|NCT01463917|Off-Pump
1126046|NCT01463917|Saline Solution
1126047|NCT01463917|Hypertonic
1126048|NCT01463904|Morbid obesity
1126049|NCT01463904|duodenal switch
1126050|NCT01463904|diabetes
1126051|NCT01463904|decrease in cardiac risk
1126052|NCT01463904|remission of T2DM
1126053|NCT01463891|Eribulin Mesylate
1126054|NCT01463891|inoperable or recurrent breast cancer
1126055|NCT01463878|glycemic control
1126056|NCT01463878|glycemic variability
1126057|NCT01463878|mean blood glucose level
1126058|NCT01463852|vincristine
1126059|NCT01463852|JNK
1126060|NCT01463852|phosphorylation
1126061|NCT01463852|cll
1126062|NCT01463852|vinca alkaloid
1126063|NCT01463852|apoptosis
1126064|NCT01463839|sleep disorder
1126065|NCT01463839|malocclusion
1126066|NCT01463839|children
1126067|NCT01463826|bruxism
1126068|NCT01463826|children
1126069|NCT01463826|oral breathing
1126070|NCT01463826|dental caries
1126071|NCT01463813|bone density conservation agents
1126072|NCT01463813|cancer
1126073|NCT01463813|cardiovascular disease
1126074|NCT01463813|cholecalciferol
1126075|NCT01463813|diabetes mellitus, type 2
1126076|NCT01463813|dietary supplements
1126077|NCT01463813|primary prevention
1126078|NCT01463813|vitamin D
1126079|NCT01463800|Heart Defects, congenital
1126080|NCT01463787|Infertility
1126081|NCT01463787|varicocelectomy
1126082|NCT01463787|microsurgery
1126083|NCT01463787|Chinese men
1126084|NCT01463787|pregnancy rate
1126085|NCT01463774|Healthy Volunteers
1126086|NCT01463774|Bioequivalence
1126087|NCT01463774|Canagliflozin (JNJ-28431754)
1126088|NCT01463774|Metformin
1126089|NCT01463761|High-level athlete
1126090|NCT01463761|ANS activity
1126091|NCT01463761|Overtraining
1126092|NCT01463735|Cirrhotic patients
1126093|NCT01463722|Respiratory distress syndrome
1126094|NCT01463722|Lung maturity
1126095|NCT01463722|lamellar body
1126096|NCT01463709|basal cell carcinoma
1126097|NCT01463709|Basal Cell Nevus Syndrome
1126098|NCT01463709|Electric Field
1126099|NCT01463709|Nanosecond pulse
1126100|NCT01463670|LENALIDOMIDE (CC-5013)
1126101|NCT01463670|BONE MARROW
1126102|NCT01463670|11-107
1126103|NCT01463657|Aging
1126104|NCT01463644|Mepolizumab
1126105|NCT01463644|COPD
1126106|NCT01463644|eosinophilic bronchitis
1126107|NCT01463644|exacerbation
1126108|NCT01463644|anti-interleukin 5 (IL5)
1126109|NCT01463605|radiotherapy
1126110|NCT01463605|targeted therapy
1126111|NCT01463605|esophageal cancer
1126112|NCT01463605|older
1126113|NCT01463592|Renessans
1126114|NCT01463592|HCV
1126115|NCT01463579|Intensive Care Unit
1126116|NCT01463579|Critical Illness
1126117|NCT01463579|Rehabilitation
1126118|NCT01463579|Exercise Programme
1126119|NCT01463566|arthritis
1126120|NCT01463553|primary spontaneous pneumothorax
1126121|NCT01463553|VATS
1126122|NCT01463553|pleurodesis
1126123|NCT01463553|recurrence rate
1126124|NCT01463540|Enteral nutrition
1126125|NCT01463540|Gastrostomy, adverse effects
1126126|NCT01463540|Gastrostomy, nursing
1126127|NCT01463540|Endoscopy,gastrointestinal
1126128|NCT01463540|Surgical wound infection
1126129|NCT01463527|Hypoventilation during sedation
1126130|NCT01463527|Hypoxia associated with hypoventilation
1126131|NCT01463514|Pulmonary Hypertension,
1126132|NCT01463514|NIRS,
1126133|NCT01463514|Near-infrared spectroscopy,
1126134|NCT01463514|cerebral tissue oxygenation,
1126135|NCT01463514|cerebral blood flow
1126136|NCT01463501|Esophageal cancer
1126137|NCT01463501|Resectable
1126138|NCT01463501|Neoadjuvant chemoradiotherapy
1126139|NCT01463501|Adjuvant chemoradiotherapy
1126140|NCT01463475|MSC
1126141|NCT01463475|Allogeneic
1126142|NCT01463475|Bone marrow cells
1126143|NCT01463475|Healthy subject donors
1126144|NCT01463475|Collection of MSC from bone marrow aspirate
1126145|NCT01463475|Bronchiolitis obliterans syndrome (BOS)
1126146|NCT01463449|Obesity
1126147|NCT01463449|Soluble-CD163
1126148|NCT01463449|Macrophage
1126149|NCT01463449|Inflammation
1126150|NCT01463436|endothelial function
1126151|NCT01463436|postmenopausal
1126152|NCT01463436|soy isoflavone supplementation
1126153|NCT01463436|osteoporosis
1126154|NCT01463384|Magnetic Resonance Imaging
1126155|NCT01463384|Magnetic Resonance Spectroscopy
1126156|NCT01463384|Neuroinflammation
1126157|NCT01463384|Mild Cognitive Impairment
1126158|NCT01463384|Alzheimer's Disease
1126159|NCT01463384|Minocycline
1126160|NCT01463371|Bronchiectasis
1126161|NCT01463371|Oxidative stress markers
1126162|NCT01463371|Airway inflammation
1126163|NCT01463358|Syncope
1126164|NCT01463358|Bifascicular block
1126165|NCT01463358|Bradycardia pacing
1126166|NCT01463345|Blood conservation
1126167|NCT01463345|Transfusion
1126168|NCT01463345|Hemoglobin trigger
1126169|NCT01463345|Transfusion trigger
1126170|NCT01463345|Cardiac surgery
1126171|NCT01463345|Transfusion triggers post cardiac surgery
1126172|NCT01463332|Propofol
1126173|NCT01463332|Pain
1126174|NCT01463332|Dexmedetomidine
1126175|NCT01463319|colonoscopy
1126176|NCT01463319|warm water method
1126177|NCT01463319|hydrocolonoscopy
1126178|NCT01463319|unsedated colonoscopy
1126179|NCT01463306|safety
1126180|NCT01463306|partial onset seizures
1126181|NCT01463306|primary generalized tonic-clonic seizures
1126182|NCT01463306|pregabalin
1126183|NCT01463306|pediatric
1126184|NCT01463306|adult
1126185|NCT01463306|open-label
1126186|NCT01463306|long term
1126187|NCT01463293|constipation
1126188|NCT01463293|probiotic
1126189|NCT01463293|functional constipation
1126190|NCT01463293|IBS-C
1126191|NCT01463280|Platelets
1126192|NCT01463280|Inhibition
1126193|NCT01463280|Lidocaine
1126194|NCT01463280|Thromboembolism
1126195|NCT01463280|Prevention
1126196|NCT01463280|Lidocaine effects on platelets
1126197|NCT01463267|Heart Failure
1126198|NCT01463254|Femplant
1126199|NCT01463254|AE adverse event
1126200|NCT01463254|AIDS acquired immunodeficiency syndrome
1126201|NCT01463254|ALT (SGPT) alanine aminotransferase
1126202|NCT01463254|ART antiretroviral therapy
1126203|NCT01463254|AST (SGOT) aspartate aminotransferase
1126204|NCT01463254|DCF data collection forms
1126205|NCT01463254|DMC Data Monitoring Committee
1126206|NCT01463254|FDA (U.S.) Food and Drug Administration
1126207|NCT01463254|GCP Good Clinical Practice guidelines
1126208|NCT01463254|HB sAg Hepatitis B surface antigen
1126209|NCT01463254|ICH International Conference of Harmonisation
1126210|NCT01463254|IND Investigational New Drug Application
1126211|NCT01463254|IRB Institutional Review Board
1126212|NCT01463254|IU international units
1126213|NCT01463254|mg milligram(s)
1126214|NCT01463254|mm3 cubic millimeter(s)
1126215|NCT01463254|PCR polymerase chain reaction
1126216|NCT01463254|SAE serious adverse event
1126217|NCT01463254|µg microgram
1126218|NCT01463254|ULN upper limit of the normal range
1126219|NCT01463254|WB Western Blot
1126220|NCT01463228|Healthy Volunteers
1126221|NCT01463228|Bioequivalence
1126222|NCT01463228|Canagliflozin (JNJ-28431754)
1126223|NCT01463228|Metformin IR
1126224|NCT01463215|Ambroxol
1126225|NCT01463215|Type I Gaucher Disease
1126226|NCT01463202|Postpartum contraception
1126227|NCT01463202|Contraceptive continuation
1126228|NCT01463202|Breastfeeding
1126229|NCT01463202|Postpartum depression
1126230|NCT01463202|Progestins
1126231|NCT01463189|arthritis
1126232|NCT01463189|self management
1126233|NCT01463176|Music Therapy
1126234|NCT01463176|Child Psychology
1126235|NCT01463176|Vaccination
1126236|NCT01463163|Platelet reactivity
1126237|NCT01463163|Ticagrelor
1126238|NCT01463163|Prasugrel
1126239|NCT01463150|Platelet reactivity
1126240|NCT01463150|Clopidogrel
1126241|NCT01463150|Prasugrel
1126242|NCT01463137|social phobia
1126243|NCT01463137|anxiety
1126244|NCT01463124|School Nurse
1126245|NCT01463124|Overweight
1126246|NCT01463124|Obesity
1126247|NCT01463124|Counseling
1126248|NCT01463124|Intervention
1126249|NCT01463124|Exercise
1126250|NCT01463111|Bipolar
1126251|NCT01463111|Manic depression
1126252|NCT01463111|Mood stabilizer
1126253|NCT01463111|Decision
1126254|NCT01463111|Neuroeconomics
1126255|NCT01463059|Rheumatoid Arthritis
1126256|NCT01463059|Monoclonal Antibody
1126257|NCT01463059|Interleukin-6
1126258|NCT01463059|Olokizumab
1126259|NCT01463059|CDP6038
1126260|NCT01463046|leukemia
1126261|NCT01463046|AML
1126262|NCT01463046|AMS
1126263|NCT01463046|panobinostat
1126264|NCT01463046|cytarabine
1126265|NCT01463046|daunorubicin
1126266|NCT01463046|HDAC
1126267|NCT01463033|Post-Traumatic epilepsy
1126268|NCT01463033|Traumatic brain injury
1126269|NCT01463033|Epilepsy prevention
1126270|NCT01463033|Levetiracetam
1126271|NCT01463020|Depression
1126272|NCT01463020|Smartphone
1126273|NCT01463020|Behavioural activation
1126274|NCT01463020|Mindfulness
1126275|NCT01463007|invasive ductal cancer
1126276|NCT01463007|tubular breast cancer
1126277|NCT01463007|breast cancer
1126278|NCT01463007|colloid
1126279|NCT01463007|ER positive
1126280|NCT01463007|radiation
1126281|NCT01462994|Patients with GIST treated with standard therapy harboring activating mutations of CKIT and PDGFRA
1126282|NCT01462968|Heparin treatment during cardiac surgery
1126283|NCT01462968|Heparin reversal after cardiac surgery
1126284|NCT01462968|Thrombin generation
1126285|NCT01462968|Endogenous Thrombin potential
1126286|NCT01462942|COPD
1126287|NCT01462942|Bronchitis
1126288|NCT01462942|Chronic
1126289|NCT01462942|Emphysema
1126290|NCT01462929|COPD
1126291|NCT01462929|antimuscarinic
1126292|NCT01462916|honey
1126293|NCT01462916|mucositis
1126294|NCT01462916|bee products
1126295|NCT01462903|TIL
1126296|NCT01462903|NPC
1126297|NCT01462903|hepatocellular carcinoma
1126298|NCT01462903|immunotherapy
1126299|NCT01462890|Ovarian Carcinoma
1126300|NCT01462890|Bevacizumab
1126301|NCT01462890|Paclitaxel
1126302|NCT01462890|Carboplatin
1126303|NCT01462877|Lipid Regulating Agents
1126304|NCT01462877|Drug Therapy
1126305|NCT01462877|cardiovascular diseases
1126306|NCT01462877|hypertriglyceridemia
1126307|NCT01462877|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1126308|NCT01462877|fenofibrate
1126309|NCT01462877|Dyslipidemias
1126310|NCT01462877|Combination
1126311|NCT01462864|Polycystic Ovary Syndrome
1126312|NCT01462864|Lifestyle
1126313|NCT01462864|Structured Education
1126314|NCT01462864|Walking Activity
1126315|NCT01462864|Exercise
1126316|NCT01462864|Overweight
1126317|NCT01462864|Impaired Glucose Regulation
1126318|NCT01462864|Diabetes Prevention
1126319|NCT01462851|healthy volunteer
1126320|NCT01462851|safety
1126321|NCT01462851|pharmacokinetic
1126322|NCT01462851|pharmacodynamic
1126323|NCT01462838|advanced HPV-
1126324|NCT01462838|p16INK4a-positive
1126325|NCT01462838|cervical
1126326|NCT01462838|vulvar,
1126327|NCT01462838|vaginal
1126328|NCT01462838|penile
1126329|NCT01462838|anal
1126330|NCT01462838|head
1126331|NCT01462838|neck
1126332|NCT01462825|Inflammation
1126333|NCT01462825|cytokines
1126334|NCT01462825|chemotaxis
1126335|NCT01462825|tomatoes
1126336|NCT01462825|cardiovascular disease
1126337|NCT01462812|Migraine
1126338|NCT01462812|Headache
1126339|NCT01462812|Sumatriptan
1126340|NCT01462799|PBL
1126341|NCT01462799|patient education
1126342|NCT01462799|coronary heart disease
1126343|NCT01462799|empowerment
1126344|NCT01462799|self-efficacy
1126345|NCT01462799|self-care
1126346|NCT01462799|Focus on to determine the long term effectiveness of PBL in patient education by comparison of standardized homesent information in patients with CHD.
1126347|NCT01462799|Further focus is on patients' self-care goals, beliefs, self-efficacy and empowerment to make lifestyle changes.
1126348|NCT01462773|malignant
1126349|NCT01462773|melanoma
1126350|NCT01462708|Parkinson Disease
1126351|NCT01462708|Molecular NeuroImaging
1126352|NCT01462682|focus group study
1126353|NCT01462682|sleep deprivation
1126354|NCT01462682|surgery
1126355|NCT01462669|Ezogabine
1126356|NCT01462669|Pharmacokinetics
1126357|NCT01462669|Retigabine
1126358|NCT01462656|anti-epileptic drug
1126359|NCT01462656|ezogabine
1126360|NCT01462656|AED polytherapy
1126361|NCT01462656|epilepsy
1126362|NCT01462656|AED monotherapy
1126363|NCT01462656|retigabine
1126364|NCT01462656|urinary retention
1126365|NCT01462643|Psoriasis Plaque Test
1126366|NCT01462643|topical
1126367|NCT01462643|ointment
1126368|NCT01462591|wave reflection
1126369|NCT01462591|augmentation Index
1126370|NCT01462591|heart rate variability
1126371|NCT01462591|wasted left ventricular energy
1126372|NCT01462578|Neoplasms benign, malignant and unspecified
1126373|NCT01462578|Acute myeloid leukemia
1126374|NCT01462578|AML
1126375|NCT01462578|Myelodysplastic syndrome
1126376|NCT01462578|MDS
1126377|NCT01462565|flolan
1126378|NCT01462565|pulmonary arterial hypertension
1126379|NCT01462565|thermo stable formulation
1126380|NCT01462565|epoprostenol sodium
1126381|NCT01462565|modified sterile diluent
1126382|NCT01462552|liver function testing
1126383|NCT01462552|Breast cancer
1126384|NCT01462552|lapatanib
1126385|NCT01462513|Colon carcinoma
1126386|NCT01462513|Rectum carcinoma
1126387|NCT01462513|Liver metastases
1126388|NCT01462500|Miltefosine
1126389|NCT01462500|pharmacokinetics
1126390|NCT01462500|cutaneous leishmaniasis
1126391|NCT01462487|Pregnancy safety
1126392|NCT01462487|zanamivir
1126393|NCT01462487|influenza
1126394|NCT01462474|Concurrent Chemoradiotherapy
1126395|NCT01462461|Phantom Limb
1126396|NCT01462461|Amputation, Traumatic
1126397|NCT01462461|Electromyography
1126398|NCT01462461|Visual Analog Pain Scale
1126399|NCT01462448|Phantom Limb
1126400|NCT01462448|Genetic Variation
1126401|NCT01462448|DNA Sequence Analysis
1126402|NCT01462448|Amputation, Traumatic
1126403|NCT01462448|Single Nucleotide Polymorphism
1126404|NCT01462448|Visual Analog Pain Scale
1126405|NCT01462448|Brain-Derived Neurotrophic Factor
1126406|NCT01462448|Inflammatory Antibody
1126407|NCT01462448|Peripheral Nerve Damage
1126408|NCT01462422|Postpartum hemorrhage
1126409|NCT01462422|Prevention
1126410|NCT01462422|Misoprostol
1126411|NCT01462422|Developing countries
1126412|NCT01462422|Nurse midwife
1126413|NCT01462409|obstructive sleep apnea
1126414|NCT01462409|humidification
1126415|NCT01462409|mask
1126416|NCT01462409|heated tubing
1126417|NCT01462396|Neuroblastoma
1126418|NCT01462396|Relapsed
1126419|NCT01462396|Refractory
1126420|NCT01462383|Advanced Cancer
1126421|NCT01462383|Malignancy
1126422|NCT01462383|Cardiac complications
1126423|NCT01462383|Electrocardiograms
1126424|NCT01462383|ECG
1126425|NCT01462383|Chart Review
1126426|NCT01462383|Data Review
1126427|NCT01462383|Data Analysis
1126428|NCT01462383|Phase I
1126429|NCT01462383|Clinical Research Study
1126430|NCT01462357|Human papillomavirus
1126431|NCT01462357|Safety
1126432|NCT01462357|HPV vaccine
1126433|NCT01462357|Immune response
1126434|NCT01462344|pediatric
1126435|NCT01462344|ADVAIR
1126436|NCT01462344|FLOVENT
1126437|NCT01462344|asthma
1126438|NCT01462331|Isomaltooligosaccharide
1126439|NCT01462331|Human Consumption
1126440|NCT01462331|Dose tolerance
1126441|NCT01462331|Prebiotic
1126442|NCT01462331|Short chain fatty acids
1126443|NCT01462331|Blood glucose
1126444|NCT01462331|Dose tolerance and prebiotic effect
1126445|NCT01462318|Pre-filled syringe
1126446|NCT01462318|Pharmacokinetic
1126447|NCT01462318|Daclizumab High Yield Process
1126448|NCT01462318|immunogenicity
1126449|NCT01462305|SAD
1126450|NCT01462305|Seasonal Affective Disorder
1126451|NCT01462305|Winter Blues
1126452|NCT01462305|Seasonal Depression
1126453|NCT01462292|968
1126454|NCT01462292|Duchenne Muscular Dystrophy
1126455|NCT01462292|Duchenne
1126456|NCT01462292|GSK
1126457|NCT01462292|DMD
1126458|NCT01462292|GSK2402968
1126459|NCT01462279|acute respiratory failure
1126460|NCT01462279|thiamine
1126461|NCT01462279|oxygen consumption
1126462|NCT01462279|VO2
1126463|NCT01462253|Adult patients
1126464|NCT01462253|Refractory
1126465|NCT01462253|Relapsed
1126466|NCT01462253|clofarabine
1126467|NCT01462253|cyclophosphamide
1126468|NCT01462253|refractory and relapsed acute lymphoblastic leukemia
1126469|NCT01462253|ALL
1126470|NCT01462240|arthritis
1126471|NCT01462227|Hypoglycemia
1126472|NCT01462227|Type 1 diabetes
1126473|NCT01462201|focused ultrasound
1126474|NCT01462201|mechanical fat destruction
1126475|NCT01462201|Body Sculpting
1126476|NCT01462188|ST-segment elevation myocardial infarction
1126477|NCT01462188|Primary angioplasty
1126478|NCT01462188|stent
1126479|NCT01462136|PK study
1126480|NCT01462097|Chronic kidney disease
1126481|NCT01462097|Exercise
1126482|NCT01462097|Aerobic capacity
1126483|NCT01462097|Learning and memory
1126484|NCT01462097|Executive function
1126485|NCT01462097|Endothelial function
1126486|NCT01462084|sleeping
1126487|NCT01462084|opioid medications
1126488|NCT01462084|positive airway pressure
1126489|NCT01462058|SPAQ
1126490|NCT01462058|Sigh-SAD
1126491|NCT01462058|Hamilton 29
1126492|NCT01462058|Vitamin D3
1126493|NCT01462058|p25(OH)D
1126494|NCT01462045|Exercise
1126495|NCT01462045|Stress
1126496|NCT01462045|PTSD
1126497|NCT01462045|Mindfulness
1126498|NCT01462045|Breathing
1126499|NCT01462045|Cortisol
1126500|NCT01462032|Preschool Children
1126501|NCT01462032|ADHD
1126502|NCT01462032|Treatment
1126503|NCT01462032|Non-pharmacological
1126504|NCT01462019|nipple trauma
1126505|NCT01462019|breast feeding
1126506|NCT01462019|phototherapy
1126507|NCT01462019|wound healing
1126508|NCT01461993|vaccine
1126509|NCT01461993|rLP2086
1126510|NCT01461993|Gardasil
1126511|NCT01461993|HPV
1126512|NCT01461993|meningitis B
1126513|NCT01461993|N. meningitidis serogroup B
1126514|NCT01461993|adolescents
1126515|NCT01461993|single-blind
1126516|NCT01461993|Meningococcal Vaccines
1126517|NCT01461980|vaccine
1126518|NCT01461980|rLP2086
1126519|NCT01461980|MCV4
1126520|NCT01461980|Tdap
1126521|NCT01461980|meningitis B
1126522|NCT01461980|N. meningitidis serogroup B
1126523|NCT01461980|adolescents
1126524|NCT01461980|observer-blind
1126525|NCT01461941|Dermatitis
1126526|NCT01461941|Atopic
1126527|NCT01461915|Pancreatic Cancer
1126528|NCT01461902|traumatic brain injury
1126529|NCT01461902|brain injury
1126530|NCT01461902|head injury
1126531|NCT01461902|vasospasm
1126532|NCT01461889|transfusion-related acute lung injury
1126533|NCT01461889|Blood Component Transfusion
1126534|NCT01461889|Gastrointestinal Hemorrhage
1126535|NCT01461889|Cirrhosis
1126536|NCT01461889|Fresh frozen plasma
1126537|NCT01461837|sickle cell disease
1126538|NCT01461837|stem cell transplantation
1126539|NCT01461837|haploidentical
1126540|NCT01461824|Birth Control
1126541|NCT01461824|Contraceptive Methods
1126542|NCT01461824|Female Contraception
1126543|NCT01461824|Weight Gain
1126544|NCT01461824|Bone Density
1126545|NCT01461811|toric
1126546|NCT01461811|contact lenses
1126547|NCT01461811|daily disposable contact lenses
1126548|NCT01461811|astigmatism
1126549|NCT01461811|soft contact lenses
1126550|NCT01461811|contact lens comfort
1126551|NCT01461798|plant stanols
1126552|NCT01461798|lipids
1126553|NCT01461798|cardiovascular disease
1126554|NCT01461785|Platelet rich plasma
1126555|NCT01461785|Dermal improvement
1126556|NCT01461785|Graft survival
1126557|NCT01461733|atrial fibrillation
1126558|NCT01461733|amiodarone
1126559|NCT01461720|Bone marrow
1126560|NCT01461720|Autologous
1126561|NCT01461720|Mesenchymal stem cells
1126562|NCT01461720|Unilateral middle cerebral artery infarct
1126563|NCT01461707|Cellular phone
1126564|NCT01461707|exercise
1126565|NCT01461707|pregnant women
1126566|NCT01461707|obesity
1126567|NCT01461707|overweight
1126568|NCT01461707|physical activity
1126569|NCT01461694|Hirsutism
1126570|NCT01461694|Laser
1126571|NCT01461694|Hair Reduction
1126572|NCT01461694|IPL
1126573|NCT01461694|Intense Pulsed Light
1126574|NCT01461681|Palliative care
1126575|NCT01461681|Symptom management
1126576|NCT01461681|Heart failure
1126577|NCT01461668|MRSA
1126578|NCT01461668|MRSA resistant to mupirocin
1126579|NCT01461642|Asthma
1126580|NCT01461642|ICT Support
1126581|NCT01461642|ACT
1126582|NCT01461642|PEF
1126583|NCT01461629|cognitive impairment
1126584|NCT01461629|cognitive function
1126585|NCT01461629|hospitalization
1126586|NCT01461629|self-management
1126587|NCT01461629|cardiac disease
1126588|NCT01461629|heart failure
1126589|NCT01461616|Diabetes Mellitus, Type 1
1126590|NCT01461603|critical illness
1126591|NCT01461603|protein metabolism
1126592|NCT01461603|pharmaconutrients
1126593|NCT01461564|screening
1126594|NCT01461564|colonoscopy
1126595|NCT01461564|carbon dioxide
1126596|NCT01461564|air
1126597|NCT01461564|pain score
1126598|NCT01461564|complications
1126599|NCT01461551|troponin I
1126600|NCT01461551|creatine kinase mb
1126601|NCT01461551|hospital days
1126602|NCT01461551|lymphocyte apoptosis
1126603|NCT01461551|intensive care unit days
1126604|NCT01461538|Acute Lymphoid Leukemia
1126605|NCT01461538|Myelodysplastic Syndrome
1126606|NCT01461538|Acute Myeloid Leukemia
1126607|NCT01461538|Solid Tumors
1126608|NCT01461538|Anemia, Refractory, with Excess of Blasts
1126609|NCT01461538|Antibodies, Monoclonal
1126610|NCT01461538|Antibody-Drug Conjugate
1126611|NCT01461538|Antigens, CD30
1126612|NCT01461538|Drug Therapy
1126613|NCT01461538|Hematologic Diseases
1126614|NCT01461538|Immunotherapy
1126615|NCT01461538|Monomethyl Auristatin E
1126616|NCT01461525|Low Rectal Cancer
1126617|NCT01461525|Sphincter preservation
1126618|NCT01461525|Abdominoperineal resection
1126619|NCT01461525|Quality of life
1126620|NCT01461525|Sexual function
1126621|NCT01461525|Urinary function
1126622|NCT01461525|Oncologic outcome
1126623|NCT01461499|Hypertension
1126624|NCT01461499|Albuminuria
1126625|NCT01461499|Direct renin inhibitor
1126626|NCT01461499|Angiotensin receptor blocker
1126627|NCT01461499|Type 2 diabetes
1126628|NCT01461486|Continuous positive airway pressure
1126629|NCT01461486|Oral appliance
1126630|NCT01461486|mild Obstructive Sleep Apnea Syndrome
1126631|NCT01461473|Obstructive Sleep Apnea
1126632|NCT01461473|Obstructive Sleep Apnea Syndrome
1126633|NCT01461473|Sleep Apnea Syndrome, Obstructive
1126634|NCT01461473|Syndrome, Obstructive Sleep Apnea
1126635|NCT01461473|Syndrome, Sleep Apnea, Obstructive
1126636|NCT01461473|Syndrome, Upper Airway Resistance, Sleep Apnea
1126637|NCT01461473|Upper Airway Resistance Sleep Apnea Syndrome
1126638|NCT01461460|volunteer
1126639|NCT01461434|atrial fibrillation
1126640|NCT01461434|biomarkers
1126641|NCT01461434|stroke prevention
1126642|NCT01461434|implantable loop recorder
1126643|NCT01461421|Obesity
1126644|NCT01461421|Primary Care
1126645|NCT01461421|Behavior Modification
1126646|NCT01461408|HPV Vaccination
1126647|NCT01461408|Beauty Salons
1126648|NCT01461408|Health Education
1126649|NCT01461408|Sexual Health
1126650|NCT01461395|IVF
1126651|NCT01461343|pulmonary hypertension, PET imaging, CT/PET
1126652|NCT01461330|diabetes
1126653|NCT01461330|exercise
1126654|NCT01461330|DASH diet
1126655|NCT01461330|ABPM
1126656|NCT01461304|fatty acid oxidation
1126657|NCT01461304|triheptanoin
1126658|NCT01461304|long-chain fatty acid oxidation disorders
1126659|NCT01461304|LCHADD
1126660|NCT01461304|VLCADD
1126661|NCT01461304|CPT1
1126662|NCT01461304|CPT2
1126663|NCT01461304|TFP
1126664|NCT01461304|Glycogen Storage Disorders
1126665|NCT01461304|GSD
1126666|NCT01461304|Pyruvate Carboxylase
1126667|NCT01461304|PC
1126668|NCT01461304|ACAD9
1126669|NCT01461304|Barth
1126670|NCT01461291|Primary open-angle glaucoma
1126671|NCT01461291|POAG
1126672|NCT01461291|Trabecular meshwork
1126673|NCT01461291|iStent inject
1126674|NCT01461278|Primary open-angle glaucoma
1126675|NCT01461278|POAG
1126676|NCT01461278|Cataract surgery
1126677|NCT01461278|Suprachoroidal space
1126678|NCT01461278|Suprachoroidal stent
1126679|NCT01461278|iStent supra
1126680|NCT01461265|Painful bone metastases
1126681|NCT01461265|Bone metastases
1126682|NCT01461265|Metastatic bone tumors
1126683|NCT01461265|Metastatic bone pain
1126684|NCT01461265|Cryoablation
1126685|NCT01461265|Cryotherapy
1126686|NCT01461265|Cryosurgery
1126687|NCT01461252|Painful bone metastases
1126688|NCT01461252|Bone metastases
1126689|NCT01461252|Metastatic bone tumors
1126690|NCT01461252|Metastatic bone pain
1126691|NCT01461252|Cryoablation
1126692|NCT01461252|Cryotherapy
1126693|NCT01461252|Cryosurgery
1126694|NCT01461252|Radiation therapy
1126695|NCT01461252|Radiotherapy
1126696|NCT01461239|survival
1126697|NCT01461239|debonding
1126698|NCT01461239|endodontic treated teeth
1126699|NCT01461226|overweight
1126700|NCT01461226|cardiovascular risk factors
1126701|NCT01461226|exercise training
1126702|NCT01461226|endothelial function
1126703|NCT01461226|endothelium
1126704|NCT01461226|endothelial progenitor cells
1126705|NCT01461213|Tapetoretinal degeneration, choroideraemia, X-linked
1126706|NCT01461213|retinitis pigmentosa
1126707|NCT01461187|Exercise
1126708|NCT01461187|Pregnancy
1126709|NCT01461187|Childbirth
1126710|NCT01461187|Vaginal
1126711|NCT01461187|Cesarean section
1126712|NCT01461174|Sleep deprivation
1126713|NCT01461174|Cognitive Functions
1126714|NCT01461174|young male
1126715|NCT01461148|UICC stage III/IV MSI-H colorectal cancer
1126716|NCT01461109|Parkinson Disease
1126717|NCT01461109|Alzheimer Disease
1126718|NCT01461109|[18F] CFPyPB
1126719|NCT01461109|GlyT1
1126720|NCT01461083|Parkinson Disease
1126721|NCT01461083|[18F]MPPF
1126722|NCT01461070|Breast Cancer
1126723|NCT01461070|Post Menopausal Estrogens
1126724|NCT01461070|Fecal Microbes
1126725|NCT01461031|pain
1126726|NCT01461031|orthognathic
1126727|NCT01461018|Immune globulin subcutaneous
1126728|NCT01461018|SCIG
1126729|NCT01461018|Primary immunodeficiency
1126730|NCT01461018|PID
1126731|NCT01461005|Spondylolisthesis
1126732|NCT01461005|Neurologic impairment
1126733|NCT01461005|Kyphosis
1126734|NCT01461005|Pseudarthrosis
1126735|NCT01460992|Pacemaker therapy
1126736|NCT01460992|Magnetic Resonance Imaging (MRI)
1126737|NCT01460992|EVIA/ENTOVIS
1126738|NCT01460979|Ovarian Cancer
1126739|NCT01460979|Endometrial Carcinoma
1126740|NCT01460979|Temsirolimus
1126741|NCT01460966|Distal protection device
1126742|NCT01460966|Thrombus aspiration
1126743|NCT01460966|Coronary Artery Disease
1126744|NCT01460966|Coronary Disease
1126745|NCT01460966|Acute Coronary Syndrome
1126746|NCT01460953|curriculum
1126747|NCT01460953|training
1126748|NCT01460953|Medical student Knowledge
1126749|NCT01460940|refractory Hodgkin's lymphoma
1126750|NCT01460940|panobinostat
1126751|NCT01460940|lenalidomide
1126752|NCT01460914|ECP
1126753|NCT01460914|CTCL
1126754|NCT01460914|Extracorporeal photopheresis
1126755|NCT01460914|Cutaneous T Cell Lymphoma
1126756|NCT01460914|GVHD
1126757|NCT01460914|Graft versus host disease
1126758|NCT01460901|Neuroblastoma
1126759|NCT01460901|Relapsed
1126760|NCT01460901|Refractory
1126761|NCT01460875|high risk melanoma
1126762|NCT01460875|lymph node disease
1126763|NCT01460862|Asthma
1126764|NCT01460862|Omalizumab
1126765|NCT01460849|Cystic fibrosis
1126766|NCT01460836|Cystic fibrosis
1126767|NCT01460823|Hearing loss
1126768|NCT01460823|Cochlear Implantation
1126769|NCT01460823|Image guided surgery
1126770|NCT01460797|Glycemic index
1126771|NCT01460797|Caloric restriction
1126772|NCT01460797|Energy intake
1126773|NCT01460797|Glucose
1126774|NCT01460797|Lipid Metabolism
1126775|NCT01460797|Cholesterol
1126776|NCT01460797|HDL Cholesterol
1126777|NCT01460797|LDL Cholesterol
1126778|NCT01460797|Obesity
1126779|NCT01460797|Metformin
1126780|NCT01460784|Metabolic dysfunction
1126781|NCT01460784|Insulin resistance
1126782|NCT01460784|Brown adipose tissue
1126783|NCT01460784|Dyslipidemia
1126784|NCT01460771|childhood dystonia
1126785|NCT01460758|Depression
1126786|NCT01460758|Transcranial magnetic stimulation
1126787|NCT01460758|rTMS
1126788|NCT01460758|DLPFC
1126789|NCT01460758|medial frontal cortex
1126790|NCT01460758|anterior cingulate complex
1126791|NCT01460745|Erbitux
1126792|NCT01460745|CRC
1126793|NCT01460745|mCRC
1126794|NCT01460745|Liver
1126795|NCT01460745|Metastases
1126796|NCT01460732|Hypertension
1126797|NCT01460732|Nocturnal BP dipping
1126798|NCT01460732|Home Blood pressure Monitoring
1126799|NCT01460732|Ambulatory Blood Pressure Monitoring
1126800|NCT01460706|Glioma
1126801|NCT01460706|68Ga-DOTATOC
1126802|NCT01460706|PET/CT
1126803|NCT01460706|Somatostatin receptor
1126804|NCT01460693|Leukemia
1126805|NCT01460693|Myeloid
1126806|NCT01460693|Chronic
1126807|NCT01460693|Chronic-Phase
1126808|NCT01460693|CML
1126809|NCT01460680|Fibromyalgia
1126810|NCT01460680|Systemic Lupus Erythematosus
1126811|NCT01460680|Omega-3 Fatty acids
1126812|NCT01460680|Magnesium
1126813|NCT01460667|Laparoscopic Roux-en-Y Gastric Bypass
1126814|NCT01460667|Post-Operative Pain
1126815|NCT01460667|IV Acetaminophen
1126816|NCT01460667|Post-Operative Nausea and Vomiting
1126817|NCT01460628|fatigue
1126818|NCT01460628|menopausal symptoms
1126819|NCT01460628|hot flashes
1126820|NCT01460628|Vasomotor symptoms
1126821|NCT01460628|perimenopause
1126822|NCT01460628|related Quality of life
1126823|NCT01460615|Postoperative pancreatitis
1126824|NCT01460615|Postoperative complications
1126825|NCT01460615|Delayed gastric emptying
1126826|NCT01460615|Leakage
1126827|NCT01460615|Fistula
1126828|NCT01460615|Acinar cell
1126829|NCT01460615|Risk patient
1126830|NCT01460615|Pancreaticoduodenectomy
1126831|NCT01460615|Whipple
1126832|NCT01460615|Cortisone
1126833|NCT01460602|Lymphoma
1126834|NCT01460602|Follicular
1126835|NCT01460602|Marginal Zone
1126836|NCT01460602|Mantle Cell
1126837|NCT01460602|Velcade
1126838|NCT01460602|bortezomib
1126839|NCT01460602|Nipent
1126840|NCT01460602|pentastatin
1126841|NCT01460602|Rituxan
1126842|NCT01460602|rituximab
1126843|NCT01460602|Turturro
1126844|NCT01460602|Shreveport
1126845|NCT01460589|colon cancer
1126846|NCT01460589|Chemotherapy
1126847|NCT01460589|adjuvant
1126848|NCT01460576|prematurity
1126849|NCT01460576|respiratory disease
1126850|NCT01460576|bronchopulmonary dysplasia
1126851|NCT01460563|craniotomy
1126852|NCT01460563|sodium valproate
1126853|NCT01460563|rocuronium
1126854|NCT01460550|delayed gastric emptying(DGE)
1126855|NCT01460550|pancreaticoduodenectomy(PD)
1126856|NCT01460550|randomized controlled trial(RCT)
1126857|NCT01460550|gastro- or duodeno- jejunostomy reconstruction
1126858|NCT01460550|morbidity
1126859|NCT01460537|phase I
1126860|NCT01460537|phosphatidylinositol-3 kinase inhibitor
1126861|NCT01460537|gemcitabine
1126862|NCT01460537|cisplatin
1126863|NCT01460537|maximum tolerated dose
1126864|NCT01460524|bronchiolitis
1126865|NCT01460524|saline
1126866|NCT01460524|nebulization
1126867|NCT01460524|hypertonic
1126868|NCT01460511|Mild bronchial asthma
1126869|NCT01460498|Leukemia
1126870|NCT01460498|Chronic Myeloid Leukemia
1126871|NCT01460498|CML
1126872|NCT01460498|Complete cytogenetic remission
1126873|NCT01460498|CCyR
1126874|NCT01460498|Minimal residual disease
1126875|NCT01460498|Philadelphia chromosome (Ph)-
1126876|NCT01460498|BCR/ABL-positive
1126877|NCT01460498|Tyrosine kinase inhibitor
1126878|NCT01460498|TKI
1126879|NCT01460498|Azacitidine
1126880|NCT01460498|5-Azacytidine
1126881|NCT01460498|5-AZA
1126882|NCT01460498|Vidaza
1126883|NCT01460498|5-AZC
1126884|NCT01460498|AZA-CR
1126885|NCT01460498|Ladakamycin
1126886|NCT01460498|NSC-102816
1126887|NCT01460472|NSCLC
1126888|NCT01460472|Lung cancer, small-cell
1126889|NCT01460472|advanced lung cancer
1126890|NCT01460472|therapeutic vaccine
1126891|NCT01460472|anti-idiotypic vaccine
1126892|NCT01460472|1E10
1126893|NCT01460459|diabetes
1126894|NCT01460459|self-monitoring of blood glucose
1126895|NCT01460459|frequency
1126896|NCT01460433|HIV 1
1126897|NCT01460433|Herpes Simplex Type 2
1126898|NCT01460433|Treatment experienced
1126899|NCT01460420|Allogeneic transplantation
1126900|NCT01460420|Hematologic malignancies
1126901|NCT01460420|Multiple myeloma
1126902|NCT01460420|RIC (Reduced Intensity Conditioning)
1126903|NCT01460394|Healthy
1126904|NCT01460394|Control
1126905|NCT01460355|strabismus surgery
1126906|NCT01460355|botulinum toxin
1126907|NCT01460355|esotropia
1126908|NCT01460355|exotropia
1126909|NCT01460355|blepharoptosis
1126910|NCT01460342|Prostatic hyperplasia
1126911|NCT01460342|Benign prostatic hyperplasia
1126912|NCT01460342|Lower urinary tract
1126913|NCT01460329|intensive care units
1126914|NCT01460329|pediatric
1126915|NCT01460329|cardiac index
1126916|NCT01460329|Doppler Ultrasonography
1126917|NCT01460316|Conotruncal cardiac defects
1126918|NCT01460316|methylation
1126919|NCT01460316|genotype
1126920|NCT01460316|cobalamin
1126921|NCT01460316|folates
1126922|NCT01460316|nutrition
1126923|NCT01460303|Transurethral catheterization
1126924|NCT01460303|Urinary retention
1126925|NCT01460303|Bladder dysfunction
1126926|NCT01460303|Patient comfort
1126927|NCT01460303|Pelvic Reconstructive Surgery
1126928|NCT01460303|Postoperative bladder dysfunction
1126929|NCT01460303|Postoperative urinary retention
1126930|NCT01460277|hemiplegic
1126931|NCT01460277|balance
1126932|NCT01460277|hydrotherapy
1126933|NCT01460264|Prospective Cohort Study
1126934|NCT01460264|Respiratory Function Tests
1126935|NCT01460264|Computed Tomography
1126936|NCT01460264|Electrocardiography
1126937|NCT01460264|Peripheral Arterial Disease
1126938|NCT01460251|type 1 diabetes
1126939|NCT01460251|beta cell
1126940|NCT01460251|immunomodulation
1126941|NCT01460251|immunointervention
1126942|NCT01460238|Lipoprotein Lipase
1126943|NCT01460238|Chronic Lymphocytic Leukemia
1126944|NCT01460238|CLL
1126945|NCT01460225|constipation
1126946|NCT01460225|chronic idiopathic constipation
1126947|NCT01460225|no prior history of surgery to the colon
1126948|NCT01460225|not on any type of medication that could alter gastrointestinal motility or transit
1126949|NCT01460212|Cognitive-Behavior Therapy
1126950|NCT01460212|Magnetic Resonance Imaging
1126951|NCT01460212|major depressive disorder
1126952|NCT01460186|Germ line polymorphisms
1126953|NCT01460173|alertness test
1126954|NCT01460173|sleepiness
1126955|NCT01460173|vigilance
1126956|NCT01460173|Sleep Apnea, Obstructive
1126957|NCT01460147|Hemophilia
1126958|NCT01460134|CD27 expressing Hematologic Malignancies
1126959|NCT01460134|CD27 expressing Solid Tumors
1126960|NCT01460134|chronic lymphocytic leukemia
1126961|NCT01460134|Burkett's lymphoma
1126962|NCT01460134|mantle cell lymphoma
1126963|NCT01460134|primary lymphoma of the central nervous system
1126964|NCT01460134|marginal zone B cell lymphoma
1126965|NCT01460134|solid tumor
1126966|NCT01460134|metastatic melanoma
1126967|NCT01460134|renal (clear) cell carcinoma
1126968|NCT01460134|hormone-refractory prostate adenocarcinoma
1126969|NCT01460134|ovarian cancer
1126970|NCT01460134|colorectal adenocarcinoma
1126971|NCT01460134|non-small cell lung cancer
1126972|NCT01460121|Phobic Postural Vertigo
1126973|NCT01460121|Visual Vertigo
1126974|NCT01460121|Chronic Subjective Dizziness
1126975|NCT01460121|Motion and Space Discomfort
1126976|NCT01460121|SpotOn
1126977|NCT01460108|PLVR
1126978|NCT01460108|AeriSeal
1126979|NCT01460108|Treatment
1126980|NCT01460108|Device
1126981|NCT01460108|Breathing
1126982|NCT01460108|COPD
1126983|NCT01460108|emphysema
1126984|NCT01460108|polymeric lung volume reduction
1126985|NCT01460108|heterogeneous
1126986|NCT01460108|homogeneous
1126987|NCT01460108|Chronic Obstructive Pulmonary Disease
1126988|NCT01460095|diabetes
1126989|NCT01460095|translational research
1126990|NCT01460095|HbA1c
1126991|NCT01460095|education
1126992|NCT01460082|chronic obstructive pulmonary disease
1126993|NCT01460082|acute exacerbation
1126994|NCT01460082|endothelial dysfunction
1126995|NCT01460082|flow mediated dilation
1126996|NCT01460082|systemic inflammation
1126997|NCT01460069|psoriasis
1126998|NCT01460069|liraglutide
1126999|NCT01460069|morbidity
1127000|NCT01460069|PASI
1127001|NCT01460069|DLQI
1127002|NCT01460056|peritoneal dialysis
1127003|NCT01460056|endotoxin-associated sterile peritonitis
1127004|NCT01460030|Hypercalcemia in patients with parathyroid carcinoma or intractable PHPT
1127005|NCT01460004|patellar tendinopathy
1127006|NCT01460004|jumper's knee
1127007|NCT01459991|walnut
1127008|NCT01459991|mediterranean
1127009|NCT01459978|CUmulative SUM (CUSUM)
1127010|NCT01459978|quality indicators
1127011|NCT01459978|obstetrics
1127012|NCT01459965|Jaundice
1127013|NCT01459965|Biliary stents
1127014|NCT01459965|Palliation
1127015|NCT01459965|Quality of Life
1127016|NCT01459965|Endoscopic Retrograde Cholangiography
1127017|NCT01459952|occurences of flu
1127018|NCT01459952|occurences of common cold
1127019|NCT01459939|Osteoarthritis
1127020|NCT01459926|Opioid induced constipation
1127021|NCT01459926|OIC
1127022|NCT01459926|Constipation
1127023|NCT01459926|Opioid side effects
1127024|NCT01459926|Morphine induced constipation
1127025|NCT01459926|Opioid therapy
1127026|NCT01459913|VX-950
1127027|NCT01459913|INCIVEK
1127028|NCT01459913|INCIVO
1127029|NCT01459900|Treatment Resistant Hypertension
1127030|NCT01459887|untreated, CD20-positive
1127031|NCT01459874|Home Monitoring
1127032|NCT01459874|Remote monitoring
1127033|NCT01459874|Telecardiology
1127034|NCT01459874|Organizational model
1127035|NCT01459874|Patient indicated for pacemaker, ICD, CRT-P, or CRT-D
1127036|NCT01459861|early ambulation
1127037|NCT01459861|knee arthroplasty
1127038|NCT01459848|Salivary cortisol measured after DVD watching or block play
1127039|NCT01459835|TV
1127040|NCT01459835|Violence
1127041|NCT01459835|DVDs
1127042|NCT01459835|Behavior
1127043|NCT01459835|Preschool children
1127044|NCT01459822|sepsis
1127045|NCT01459822|miRNA
1127046|NCT01459783|Caregivers
1127047|NCT01459783|Comparative Effectiveness Research
1127048|NCT01459783|Cost Effectiveness
1127049|NCT01459783|Patient Care Management
1127050|NCT01459783|Social Work
1127051|NCT01459770|glomerular filtration rate
1127052|NCT01459770|albuminuria
1127053|NCT01459770|medical therapy
1127054|NCT01459770|hospital discharge
1127055|NCT01459770|hospital readmission
1127056|NCT01459770|CKD complications
1127057|NCT01459770|CKD risk factors
1127058|NCT01459757|Retrospective
1127059|NCT01459757|GIST
1127060|NCT01459757|sunitinib
1127061|NCT01459757|mutational
1127062|NCT01459744|Heart failure
1127063|NCT01459744|Palliative care
1127064|NCT01459744|Communication
1127065|NCT01459718|Severe cardiac iron overload
1127066|NCT01459718|deferasirox
1127067|NCT01459718|β-thalassaemia
1127068|NCT01459718|cardiac dysfunction
1127069|NCT01459705|Combat Disorders
1127070|NCT01459705|Exposure Therapy
1127071|NCT01459705|Army Personnel
1127072|NCT01459692|Seizures
1127073|NCT01459692|Epilepsy
1127074|NCT01459692|Auditory Stimulation
1127075|NCT01459692|Music
1127076|NCT01459666|Scar
1127077|NCT01459666|Forehead
1127078|NCT01459666|Skin Cancer
1127079|NCT01459666|MOHS Surgery
1127080|NCT01459666|Dermatology
1127081|NCT01459653|Febrile neutropenia
1127082|NCT01459653|cancer
1127083|NCT01459653|chemotherapy,
1127084|NCT01459653|primary prophylaxis
1127085|NCT01459653|secondary prophylaxis
1127086|NCT01459653|filgrastim
1127087|NCT01459653|granulocyte colony stimulating factor
1127088|NCT01459653|observational study
1127089|NCT01459653|noninterventional study
1127090|NCT01459640|Osteoarthritis
1127091|NCT01459640|Bone marrow
1127092|NCT01459640|Mesenchymal stem cells
1127093|NCT01459640|Autologous
1127094|NCT01459640|Mild osteoarthritis
1127095|NCT01459640|Moderate osteoarthritis
1127096|NCT01459627|DAPT- Dual Antiplatelet Therapy
1127097|NCT01459627|STEMI
1127098|NCT01459601|diabetes mellitus
1127099|NCT01459601|FBS
1127100|NCT01459601|HbA1C
1127101|NCT01459601|Cabergoline
1127102|NCT01459575|Acquired Immunodeficiency Syndrome
1127103|NCT01459575|antiretroviral therapy
1127104|NCT01459575|China
1127105|NCT01459549|hepatolithiasis
1127106|NCT01459549|sphincter of oddi laxity
1127107|NCT01459549|choledochojejunostomy
1127108|NCT01459536|Aging
1127109|NCT01459523|Peripheral Nerve Block
1127110|NCT01459523|Perineural Catheter
1127111|NCT01459523|Orthopedic Surgery
1127112|NCT01459523|Ultrasound
1127113|NCT01459510|Violence prevention
1127114|NCT01459510|Parenting
1127115|NCT01459510|Discipline
1127116|NCT01459497|non-small cell lung cancer
1127117|NCT01459497|Stages II or III non-small cell lung cancer
1127118|NCT01459484|Non metastatic extremities high grade osteosarcoma
1127119|NCT01459458|intimate partner violence
1127120|NCT01459458|gender-based violence
1127121|NCT01459458|domestic violence
1127122|NCT01459458|unintended pregnancy
1127123|NCT01459445|ethinylestradiol 30µg-drospirenone
1127124|NCT01459445|flow-mediated dilatation
1127125|NCT01459445|endothelial dysfunction
1127126|NCT01459445|hsCRP
1127127|NCT01459445|metformin
1127128|NCT01459445|polycystic ovary syndrome
1127129|NCT01459406|Gastrointestinal physiology
1127130|NCT01459406|Gastrointestinal response to sugars
1127131|NCT01459406|MRI
1127132|NCT01459406|gastrointestinal
1127133|NCT01459406|stomach
1127134|NCT01459406|small bowel
1127135|NCT01459406|colon
1127136|NCT01459406|glucose
1127137|NCT01459406|fructose
1127138|NCT01459406|fructan
1127139|NCT01459406|FODMAP
1127144|NCT01459367|Drug Therapy
1127145|NCT01459341|CLI Critical limb ischemia
1127146|NCT01459341|PVD peripheral vascular disease
1127147|NCT01459341|NIRS near infrared spectroscopy
1127148|NCT01459341|TCPO2 - transcutaneous oxygen pressure
1127149|NCT01459328|rectal carcinoma
1127150|NCT01459328|long course chemo-radiation
1127151|NCT01459328|short course chemo-rdiation
1127152|NCT01459328|Locally Advanced Rectal Carcinoma
1127153|NCT01459315|Healthy
1127154|NCT01459315|Male
1127155|NCT01459315|GSK1349572
1127156|NCT01459315|Dolutegravir
1127157|NCT01459315|DTG
1127158|NCT01459315|Integrase
1127159|NCT01459315|HIV
1127160|NCT01459302|FALS
1127161|NCT01459302|ALS
1127162|NCT01459302|SALS
1127163|NCT01459302|MND
1127164|NCT01459302|SOD1
1127165|NCT01459302|ALS GENES
1127166|NCT01459302|PLS
1127167|NCT01459302|PMA
1127168|NCT01459302|ALS/FTD
1127169|NCT01459302|FAMILIAL ALS
1127170|NCT01459302|SPORADIC ALS
1127171|NCT01459302|GENETICS
1127172|NCT01459302|FTD
1127173|NCT01459302|Miyoshi myopathy
1127174|NCT01459276|seasonal
1127175|NCT01459276|prevention
1127176|NCT01459276|influenza
1127177|NCT01459276|infection
1127178|NCT01459276|influenza vaccine
1127179|NCT01459276|vaccine
1127180|NCT01459276|influenza in humans
1127181|NCT01459263|GSV
1127182|NCT01459263|insufficiency
1127183|NCT01459263|ClariVein device
1127184|NCT01459263|safety
1127185|NCT01459263|efficacy
1127186|NCT01459263|QOL
1127187|NCT01459250|AGO178C,
1127188|NCT01459250|renal impairment,
1127189|NCT01459250|ESRD,
1127190|NCT01459250|pharmacokinetics
1127191|NCT01459237|Cushing's Disease
1127192|NCT01459237|Microadenoma
1127193|NCT01459237|PET Imaging
1127194|NCT01459237|Cushing Disease Tumor
1127195|NCT01459237|Pituitary Tumors
1127196|NCT01459211|CLL
1127197|NCT01459185|Non-small cell lung cancer
1127198|NCT01459185|Adjuvant chemotherapy
1127199|NCT01459185|oral fluoropyrimidine
1127200|NCT01459185|S-1
1127201|NCT01459185|Feasibility study
1127202|NCT01459185|Surgery
1127203|NCT01459172|breast cancer prevention
1127204|NCT01459159|Hematology
1127205|NCT01459159|MDS
1127206|NCT01459159|Myelodysplastic Syndrome
1127207|NCT01459159|Low risk MDS
1127208|NCT01459159|Int-1 risk MDS
1127209|NCT01459159|Transfusion dependence
1127210|NCT01459159|Telintra
1127211|NCT01459159|ezatiostat
1127212|NCT01459159|ezatiostat hydrochloride
1127213|NCT01459159|TLK199
1127214|NCT01459159|Glutathione
1127215|NCT01459159|Glutathione analog
1127216|NCT01459159|Glutathione Transferase
1127217|NCT01459159|Glutathione Transferase P1-1 inhibitor
1127218|NCT01459159|GST P1-1 inhibitor
1127219|NCT01459159|Apoptosis
1127220|NCT01459159|Differentiation
1127221|NCT01459159|Enzyme inhibitor
1127222|NCT01459159|non-del (5q)
1127223|NCT01459159|non-deletion 5q
1127224|NCT01459146|IPT
1127225|NCT01459146|malaria
1127226|NCT01459146|ACT
1127227|NCT01459146|schistosomiasis
1127228|NCT01459146|Hemoglobin
1127229|NCT01459146|Anemia
1127230|NCT01459146|Sustained attention
1127231|NCT01459146|Recall
1127232|NCT01459146|Schoolchildren
1127233|NCT01459146|Kassena-Nankana
1127234|NCT01459133|investigational
1127235|NCT01459133|inhaled insulin product
1127236|NCT01459120|Home-based HIV-testing
1127237|NCT01459120|Voluntary Counseling and Testing
1127238|NCT01459120|Community based testing
1127239|NCT01459120|HIV/AIDS
1127240|NCT01459120|Lesotho
1127241|NCT01459107|Hand Transplant
1127242|NCT01459107|CTA
1127243|NCT01459107|VCA
1127244|NCT01459107|Composite Tissue
1127245|NCT01459107|Amputation
1127246|NCT01459107|Upper limb
1127247|NCT01459107|Immunosuppression
1127248|NCT01459094|Healthy Volunteers
1127249|NCT01459094|Oral bioavailability
1127250|NCT01459094|Canagliflozin (JNJ-28431754)
1127251|NCT01459094|Metformin IR
1127252|NCT01459029|Schizophrenia
1127253|NCT01459029|NMDA receptor
1127254|NCT01459029|D-serine
1127255|NCT01459029|Recent onset
1127256|NCT01459029|Negative symptoms
1127257|NCT01459029|Cognition
1127258|NCT01459016|Mild Cognitive Impairment
1127259|NCT01459016|Brain Imaging Biomarkers
1127260|NCT01459016|Magnetic resonance imaging biomarker
1127261|NCT01459016|Positron Emission Tomography
1127262|NCT01458977|Lípid-lowering effect
1127263|NCT01458977|Tenofovir
1127264|NCT01458977|Dyslipidemia
1127265|NCT01458964|Fibromyalgia
1127266|NCT01458951|Tofacitinib
1127267|NCT01458951|CP-690
1127268|NCT01458951|550
1127269|NCT01458951|Moderate to severe ulcerative colitis
1127270|NCT01458951|phase 3 clinical trial
1127271|NCT01458951|Mayo score
1127272|NCT01458925|Colorectal cancer
1127273|NCT01458925|Colonic polyps
1127274|NCT01458899|Phase 1
1127275|NCT01458899|healthy male
1127276|NCT01458899|nonpregnant female
1127277|NCT01458899|volunteers
1127278|NCT01458899|pharmacokinetics
1127279|NCT01458899|TC 5214
1127280|NCT01458899|The effect of food on the pharmacokinetics of TC-5214
1127281|NCT01458873|infiltration
1127282|NCT01458873|extravasation
1127283|NCT01458847|bladder cancer
1127284|NCT01458847|cis-urocanic acid
1127285|NCT01458847|primary
1127286|NCT01458847|recurrent
1127287|NCT01458847|non-muscle
1127288|NCT01458834|Smoking
1127289|NCT01458834|Attentional bias
1127290|NCT01458834|Craving
1127291|NCT01458821|Tinnitus
1127292|NCT01458808|salt
1127293|NCT01458808|inflammation
1127294|NCT01458808|hypervolemia
1127295|NCT01458808|diet
1127296|NCT01458782|Cartilage repair
1127297|NCT01458782|Chondrocytes
1127298|NCT01458782|Stemcells
1127299|NCT01458756|liver transplant patients
1127300|NCT01458756|hepatic transplantation
1127301|NCT01458743|pharmacokinetics
1127302|NCT01458730|PCNSL
1127303|NCT01458730|Immunochemotherapy
1127304|NCT01458730|Intraspinal Depocyt
1127305|NCT01458730|Maintenance temozolomide
1127306|NCT01458717|pancreas
1127307|NCT01458717|cancer
1127308|NCT01458717|borderline resectable
1127309|NCT01458717|locally advanced
1127310|NCT01458717|resectability
1127311|NCT01458717|chemotherapy
1127312|NCT01458717|radiation
1127313|NCT01458717|chemoradiation
1127314|NCT01458717|neoadjuvant
1127315|NCT01458717|survival
1127316|NCT01458717|prognosis
1127317|NCT01458717|recurrence
1127318|NCT01458717|response rate
1127319|NCT01458652|AST-120
1127320|NCT01458652|HDF
1127321|NCT01458652|Replacement Volume described above
1127322|NCT01458639|Pulmonary embolism
1127323|NCT01458639|PE
1127324|NCT01458626|mirtazapine
1127325|NCT01458626|paroxetine
1127326|NCT01458626|major depression
1127327|NCT01458626|early improvement
1127328|NCT01458613|Mucopolysaccharidoses
1127329|NCT01458613|Mucopolysaccharidosis VI
1127330|NCT01458613|Metabolism, Inborn Errors
1127331|NCT01458613|Genetic Diseases, Inborn
1127332|NCT01458613|Mucinoses
1127333|NCT01458613|Connective Tissue Diseases
1127334|NCT01458613|Metabolic Diseases
1127335|NCT01458600|ophthalmopathy
1127336|NCT01458600|prevention
1127337|NCT01458600|diclofenac
1127338|NCT01458587|Actinic keratosis
1127339|NCT01458574|Janus kinase inhibitor
1127340|NCT01458574|JAK 3 inhibitor
1127341|NCT01458574|inflammatory bowel disease
1127342|NCT01458574|ulcerative colitis
1127343|NCT01458574|OCTAVE
1127344|NCT01458574|CP-690
1127345|NCT01458574|550
1127346|NCT01458574|tofacitinib
1127347|NCT01458574|Xeljanz
1127348|NCT01458561|Hemostatic agent
1127349|NCT01458561|Liver surgery
1127350|NCT01458561|Hemostasis
1127351|NCT01458548|1st-line therapy
1127352|NCT01458548|single agent rituximab
1127353|NCT01458548|CHOP
1127354|NCT01458548|PTLD
1127355|NCT01458535|Genotype 1
1127356|NCT01458535|Genotype 2
1127357|NCT01458535|Genotype 3
1127358|NCT01458535|Hepatitis C Virus
1127359|NCT01458535|ABT-450/r
1127360|NCT01458535|Ribavirin
1127361|NCT01458535|ABT-267
1127362|NCT01458535|Ombitasvir
1127363|NCT01458535|Paritaprevir
1127364|NCT01458522|Nonconvulsive Seizures
1127365|NCT01458509|Quality of Life
1127366|NCT01458509|patient outcomes
1127367|NCT01458509|questionaires
1127368|NCT01458509|11-101
1127369|NCT01458470|huntington
1127370|NCT01458470|huntingtin
1127371|NCT01458470|memantine
1127372|NCT01458470|ebixa
1127373|NCT01458470|namenda
1127374|NCT01458444|Respiratory Insufficiency
1127375|NCT01458444|Cardiothoracic Surgery
1127376|NCT01458444|Ventilation system
1127377|NCT01458431|cesarean section
1127378|NCT01458431|wound infusion
1127379|NCT01458431|Local anesthetic levobupivacaine
1127380|NCT01458431|Pain management
1127381|NCT01458418|Eosinophil
1127382|NCT01458418|Esophagitis
1127383|NCT01458405|Myocardial Infarction
1127384|NCT01458405|Heart Attack
1127385|NCT01458405|Stem cell
1127386|NCT01458405|Left ventricular dysfunction
1127387|NCT01458405|Congestive heart failure
1127388|NCT01458366|Non-Hodgkin's Lymphoma
1127389|NCT01458366|Lymphoma
1127390|NCT01458366|B-Cell Lymphoma
1127391|NCT01458353|Right-sided colon cancer
1127392|NCT01458353|Ileocolonic anastomosis
1127393|NCT01458353|stapled anastomosis
1127394|NCT01458353|handsewn anastomosis
1127395|NCT01458353|peritoneal contamination
1127396|NCT01458353|microbiological spectrum
1127397|NCT01458340|Adult ADHD
1127398|NCT01458340|Attention-Deficit/Hyperactivity Disorder
1127399|NCT01458327|MDMA
1127400|NCT01458327|PTSD
1127401|NCT01458327|psychotherapy
1127402|NCT01458314|Physical exercise
1127403|NCT01458314|Rehabilitation
1127404|NCT01458314|NIV
1127405|NCT01458301|Drug Therapy
1127406|NCT01458275|Seasonal Allergic Rhinitis
1127407|NCT01458275|Ciclesonide
1127408|NCT01458275|Ciclesonide Nasal Aerosol
1127409|NCT01458262|cerebral oxymetry
1127410|NCT01458262|systemic oxymetry
1127411|NCT01458262|hepatic surgery
1127412|NCT01458262|liver transplantation
1127413|NCT01458249|Soft Tissue Sarcoma
1127414|NCT01458223|spine surgery
1127415|NCT01458223|postoperative infection
1127416|NCT01458223|postoperative antibiotics
1127417|NCT01458197|Overactive Bladder
1127418|NCT01458197|Tarafenacin
1127419|NCT01458184|risk factors for complications
1127420|NCT01458184|precarious medical situations
1127421|NCT01458171|Immune globulin subcutaneous
1127422|NCT01458171|SCIG
1127423|NCT01458171|Primary immunodeficiency
1127424|NCT01458171|PID
1127425|NCT01458158|Gelatinases
1127426|NCT01458158|kidney disease
1127427|NCT01458158|diabetes mellitus type 2
1127428|NCT01458132|subject follow-up
1127429|NCT01458132|HIV infection
1127430|NCT01458132|registry
1127431|NCT01458132|seizures
1127432|NCT01458132|GSK2248761
1127433|NCT01458119|Fabry disease
1127434|NCT01458119|Lysosomal storage disease
1127435|NCT01458119|migalastat HCl
1127436|NCT01458119|AT1001
1127437|NCT01458080|ENABLE
1127438|NCT01458080|invasive procedures
1127439|NCT01458080|Thrombocytopenia
1127440|NCT01458080|Thromboembolic events
1127441|NCT01458080|Eltrombopag
1127442|NCT01458080|Hepatitis C
1127443|NCT01458080|HCV
1127444|NCT01458054|pharmacokinetics
1127445|NCT01458054|omeprazole
1127446|NCT01458054|ritonavir
1127447|NCT01458054|healthy subjects
1127448|NCT01458054|drug interaction
1127449|NCT01458041|Critical limb ischaemia
1127450|NCT01458041|Iloprost
1127451|NCT01458041|Quality of life
1127452|NCT01458041|Visual analogue scale
1127453|NCT01458028|BAY85-3934
1127454|NCT01458028|pharmacokinetics
1127455|NCT01458028|age
1127456|NCT01458028|gender
1127457|NCT01458015|QST
1127458|NCT01458015|neuropathic pain
1127459|NCT01458015|tapentadol pr
1127460|NCT01458015|oxycodone
1127461|NCT01457989|retention rate
1127462|NCT01457989|epilepsy
1127463|NCT01457989|responder rate
1127464|NCT01457989|seizure freedom
1127465|NCT01457989|discontinuation rate
1127466|NCT01457989|safety assessment
1127467|NCT01457989|reduction in seizure frequency
1127468|NCT01457989|open-label
1127469|NCT01457976|cancer
1127470|NCT01457976|obesity
1127471|NCT01457976|personal responsibility
1127472|NCT01457950|denosumab
1127473|NCT01457950|Republic of Korea
1127474|NCT01457950|dual energy x-ray absorptiometry
1127475|NCT01457937|HCV
1127476|NCT01457937|Menopause
1127477|NCT01457937|Peg IFN
1127478|NCT01457937|Ribavirin
1127479|NCT01457937|Boceprevir
1127480|NCT01457924|Relapsing Remitting Multiple Sclerosis
1127481|NCT01457924|Ofatumumab
1127482|NCT01457898|Cardiac surgery
1127483|NCT01457898|Non-invasive ventilation
1127484|NCT01457885|AML
1127485|NCT01457872|Heroin addiction
1127486|NCT01457872|Substance use disorders
1127487|NCT01457872|Substitution treatment
1127488|NCT01457872|Syringe exchange
1127489|NCT01457846|gastro-oesophageal junction cancer
1127490|NCT01457846|gastric cancer
1127491|NCT01457846|lower third oesophageal cancer
1127492|NCT01457846|polysomy
1127493|NCT01457846|amplification
1127494|NCT01457846|FGFR
1127495|NCT01457820|Allopurinol
1127496|NCT01457820|Angina
1127497|NCT01457820|Acute coronary syndrome
1127498|NCT01457807|Phase 1
1127499|NCT01457807|Parkinson's disease
1127500|NCT01457807|pharmacodynamic
1127501|NCT01457807|biomarkers
1127502|NCT01457807|pharmacokinetics
1127503|NCT01457807|extended release formulation
1127504|NCT01457794|Metabolic Syndrome X
1127505|NCT01457794|Fatty Acids, Omega-3
1127506|NCT01457794|Learning
1127507|NCT01457794|Attention
1127508|NCT01457794|Nutritional Status
1127509|NCT01457794|Nutrition Assessments
1127510|NCT01457794|Body Weight
1127511|NCT01457794|Physical Activity
1127512|NCT01457794|Sleep
1127513|NCT01457794|Child Nutrition Sciences
1127514|NCT01457781|Inhaled nitric oxide
1127515|NCT01457781|pulmonary arterial hypertension
1127516|NCT01457781|pulmonary hypertension
1127517|NCT01457781|PAH
1127518|NCT01457768|Hepatitis C
1127519|NCT01457768|HCV
1127520|NCT01457768|Sustained Virologic Response
1127521|NCT01457768|Direct Acting Antiviral
1127522|NCT01457768|Combination Therapy
1127523|NCT01457768|Tegobuvir
1127524|NCT01457768|Registry
1127525|NCT01457768|HCV RNA
1127526|NCT01457768|Treatment experienced
1127527|NCT01457768|Treatment naive
1127528|NCT01457768|GS 9451
1127529|NCT01457768|GS 5885
1127530|NCT01457768|Sequence
1127531|NCT01457768|GS 5816
1127532|NCT01457768|GS 7977
1127533|NCT01457768|Sofosbuvir
1127534|NCT01457768|Sovaldi™
1127535|NCT01457768|SOF
1127536|NCT01457768|Ledipasvir
1127537|NCT01457768|LDV
1127538|NCT01457755|Hepatitis C
1127539|NCT01457755|HCV
1127540|NCT01457755|Sustained Virologic Response
1127541|NCT01457755|Direct Acting Antiviral
1127542|NCT01457755|Combination Therapy
1127543|NCT01457755|Tegobuvir
1127544|NCT01457755|Registry
1127545|NCT01457755|HCV RNA
1127546|NCT01457755|Treatment experienced
1127547|NCT01457755|Treatment naive
1127548|NCT01457755|GS 9451
1127549|NCT01457755|GS 5885
1127550|NCT01457755|GS 7977
1127551|NCT01457755|GS 5816
1127552|NCT01457755|Sofosbuvir
1127553|NCT01457755|Sovaldi™
1127554|NCT01457755|SOF
1127555|NCT01457755|Ledipasvir
1127556|NCT01457755|LDV
1127557|NCT01457742|Osteoarthritis
1127558|NCT01457729|ergometer
1127559|NCT01457729|training
1127560|NCT01457729|motivation
1127561|NCT01457729|telemonitoring
1127562|NCT01457729|sleep apnea
1127563|NCT01457716|Healthy volunteer study
1127564|NCT01457703|LH pulsatility
1127565|NCT01457703|Obesity
1127566|NCT01457703|Reproduction
1127567|NCT01457690|Vitamin E pegylated
1127568|NCT01457690|chylomicron retention
1127569|NCT01457690|Familial Hypocholesterolemia
1127570|NCT01457690|Hypobetalipoproteinemias
1127571|NCT01457651|Recruitment
1127572|NCT01457651|Coronary artery bypass grafting
1127573|NCT01457651|Postoperative period
1127574|NCT01457638|nasal obstruction
1127575|NCT01457638|rhinoplasty
1127576|NCT01457638|turbinate surgery
1127577|NCT01457638|quality of life
1127578|NCT01457638|acoustic rhinometry
1127579|NCT01457625|fetuin A liver fat content visceral obesity mortality
1127580|NCT01457612|Insulin Resistant
1127581|NCT01457612|Dietary Supplements
1127582|NCT01457612|Nutrition
1127583|NCT01457612|Antioxidant
1127584|NCT01457612|Inflammation
1127585|NCT01457599|liver-colorectal metastases-computertomography-guided-wire-chemotherapy-complete response
1127586|NCT01457599|Feasibility, safety
1127587|NCT01457586|Heart Surgery
1127588|NCT01457586|Blood Transfusion
1127589|NCT01457586|Postoperative Complications
1127590|NCT01457560|Oral polio vaccine (OPV)
1127591|NCT01457560|DTPa-HBV-IPV/Hib vaccine
1127592|NCT01457547|HEXAVACTM
1127593|NCT01457547|InfanrixTM HEXA
1127594|NCT01457547|DTPa-HBV-IPV-Hib
1127595|NCT01457547|DTPa-HBV-IPV/Hib
1127596|NCT01457521|pain
1127597|NCT01457521|medical abortion
1127598|NCT01457508|combination vaccine
1127599|NCT01457508|DTPa-HBV-IPV
1127600|NCT01457508|Hib
1127601|NCT01457495|Infants
1127602|NCT01457495|combined vaccine
1127603|NCT01457495|DTPa-HBV-IPV/Hib
1127604|NCT01457495|DTPa-IPV/Hib
1127605|NCT01457495|safety
1127606|NCT01457495|Immunogenicity
1127607|NCT01457495|HBV
1127608|NCT01457482|Fear
1127609|NCT01457482|Childbirth
1127610|NCT01457482|Art therapy
1127611|NCT01457482|Therapeutic conversations
1127612|NCT01457482|W-DEQ
1127613|NCT01457456|Mucopolysaccharidoses
1127614|NCT01457456|Mucopolysaccharidosis IV
1127615|NCT01457456|Carbohydrate Metabolism, Inborn Errors
1127616|NCT01457456|Metabolism, Inborn Errors
1127617|NCT01457456|Genetic Diseases, Inborn
1127618|NCT01457456|Lysosomal Storage Diseases
1127619|NCT01457456|Connective Tissue Diseases
1127620|NCT01457456|Metabolic Diseases
1127621|NCT01457456|Musculoskeletal Diseases
1127622|NCT01457443|Glycogen Storage Disease
1127623|NCT01457443|Glycogen Storage Disease Type II
1127624|NCT01457443|Metabolic Diseases
1127625|NCT01457443|Carbohydrate Metabolism, Inborn Errors
1127626|NCT01457443|Metabolism, Inborn Errors
1127627|NCT01457443|Genetic Diseases, Inborn
1127628|NCT01457443|Lysosomal Storage Diseases, Nervous System
1127629|NCT01457417|Cancer
1127630|NCT01457417|Oncology
1127631|NCT01457404|integrated cognitive behavioral therapy
1127632|NCT01457404|cognitive behavioral therapy
1127633|NCT01457404|addiction
1127634|NCT01457404|posttraumatic stress disorder (PTSD)
1127635|NCT01457391|cognitive behavioral therapy
1127636|NCT01457391|addiction
1127637|NCT01457391|posttraumatic stress disorder (PTSD)
1127638|NCT01457378|Gastrointestinal symptoms
1127639|NCT01457378|healthy subjects
1127640|NCT01457378|IBS
1127641|NCT01457378|HRQoL
1127642|NCT01457378|questionnaires
1127643|NCT01457352|Baclofen, spasticity
1127644|NCT01457339|Schizophrenia
1127645|NCT01457326|Immersion therapy
1127646|NCT01457326|early weight bearing physical therapy
1127647|NCT01457300|Rehabilitation outcome
1127648|NCT01457300|Aged
1127649|NCT01457300|Aged, 80 and over
1127650|NCT01457300|Activities of daily living
1127651|NCT01457274|AMBULATORY CARE
1127652|NCT01457274|AWARENESS AND RECALL
1127653|NCT01457274|Propofol
1127654|NCT01457274|Patient Safety and Satisfaction
1127655|NCT01457274|Colonoscopy
1127656|NCT01457274|Elective outpatient colonoscopy
1127657|NCT01457274|Procedural sedation
1127658|NCT01457261|interstitial lung disease
1127659|NCT01457261|drug deposition
1127660|NCT01457261|lung imaging
1127661|NCT01457261|respiratory
1127662|NCT01457248|after aortic surgery
1127663|NCT01457235|Bipolar disorder
1127664|NCT01457235|Cognitive Remediation
1127665|NCT01457235|Cognition
1127666|NCT01457235|Cognitive function
1127667|NCT01457235|Mood disorders
1127668|NCT01457235|Affective disorders
1127669|NCT01457222|Mindfulness
1127670|NCT01457222|Stress
1127671|NCT01457222|Cognition
1127672|NCT01457222|Psychological health
1127673|NCT01457222|Primary prevention
1127674|NCT01457209|PCOS
1127675|NCT01457209|Insulin resistance
1127676|NCT01457209|Acupuncture
1127677|NCT01457196|Cancer Genetics
1127678|NCT01457183|pulsed lavage
1127679|NCT01457183|evaluate containment
1127680|NCT01457183|evaluate tolerability
1127681|NCT01457170|Pulmonary Hypertension
1127682|NCT01457170|Heart Failure
1127683|NCT01457170|Apelin
1127684|NCT01457170|Haemodynamics
1127685|NCT01457170|pulmonary vascular resistance
1127686|NCT01457170|cardiac output
1127687|NCT01457144|Mantle cell lymphoma
1127688|NCT01457144|Rituximab
1127689|NCT01457144|bendamustine
1127690|NCT01457144|Velcade
1127691|NCT01457144|Dexamethasone
1127692|NCT01457131|Metastatic Cancer
1127693|NCT01457131|Immunotherapy
1127694|NCT01457131|Gene Therapy
1127695|NCT01457131|Metastatic Melanoma
1127696|NCT01457131|Metastatic Kidney Cancer
1127697|NCT01457118|Open Label multicenter extension study advanced solid tumors
1127698|NCT01457105|Malignant strictures of the main biliary duct
1127699|NCT01457092|benign biliary strictures
1127700|NCT01457092|chronic pancreatitis
1127701|NCT01457079|Keloid
1127702|NCT01457079|Radiation Therapy
1127703|NCT01457079|Hypertrophic Scar
1127704|NCT01457053|Acute decompensated heart failure
1127705|NCT01457053|Myocardial blood flow
1127706|NCT01457053|Coronary flow reserve
1127707|NCT01457053|Ultrafiltration
1127708|NCT01457053|Diuretics
1127709|NCT01457040|Acute Lymphoblastic leukemia
1127710|NCT01457040|Hematopoietic Stem Cell Transplantation
1127711|NCT01457027|Influenza
1127712|NCT01457027|Virus
1127713|NCT01457027|Vaccination
1127714|NCT01457027|Immunisation
1127715|NCT01457014|chronic pain
1127716|NCT01457014|sleep disordered breathing
1127717|NCT01457014|Opioids
1127718|NCT01457001|chronic haemodialysis
1127719|NCT01457001|25-OH-D vitamin
1127720|NCT01456975|Ascending aorta aneurism
1127721|NCT01456975|Aortic insufficiency
1127722|NCT01456962|Immune reconstitution
1127723|NCT01456962|CD4+ T cells
1127724|NCT01456949|Atrial fibrillation (AF)
1127725|NCT01456949|Paroxysmal atrial fibrillation (PAF)
1127726|NCT01456949|Arrythmias
1127727|NCT01456949|Cardiac Arrythmias
1127728|NCT01456949|Cardiac ablation
1127729|NCT01456949|Cryoablation
1127730|NCT01456936|smoking cessation
1127731|NCT01456936|psychiatric disease
1127732|NCT01456923|DNA damaging agents
1127733|NCT01456910|Physical education
1127734|NCT01456910|People with mental disabilities
1127735|NCT01456910|muscular strength dynamometer
1127736|NCT01456910|Performance Evaluation
1127737|NCT01456910|Occupational health
1127738|NCT01456884|Music therapy
1127739|NCT01456884|Infants
1127740|NCT01456884|Children
1127741|NCT01456884|Adolescents
1127742|NCT01456884|pediatric
1127743|NCT01456884|palliative care
1127744|NCT01456884|neurological impairment
1127745|NCT01456884|metabolic condition
1127746|NCT01456884|pain management
1127747|NCT01456871|Mechanoreceptors
1127748|NCT01456871|PIP joint
1127749|NCT01456871|Ligamento-muscular reflexes
1127750|NCT01456858|Malaria Prevention Refugee Emergency
1127751|NCT01456858|Malaria, Falciparum C03.752.530.650
1127752|NCT01456845|Plasma levels
1127753|NCT01456845|isoniazid
1127754|NCT01456845|rifampicin
1127755|NCT01456845|pyrazinamide
1127756|NCT01456845|hepatoxicity
1127757|NCT01456832|hyponatremia
1127758|NCT01456832|renal transplant
1127759|NCT01456819|autologous
1127760|NCT01456819|bone marrow
1127761|NCT01456819|critical limb ischemia
1127762|NCT01456819|efficacy
1127763|NCT01456819|mesenchymal stem cells
1127764|NCT01456819|mononuclear cells
1127765|NCT01456806|T2DM
1127766|NCT01456806|Cardiovascular risk factors
1127767|NCT01456806|Metabolic control
1127768|NCT01456806|Well-being
1127769|NCT01456806|Cost
1127770|NCT01456806|Cost-consequence
1127771|NCT01456793|Pregnancy prevention
1127772|NCT01456793|Pregnancy
1127773|NCT01456793|Birth
1127774|NCT01456793|Contraceptive use
1127775|NCT01456793|Adolescents
1127776|NCT01456780|Meibomian gland dysfunction
1127777|NCT01456780|Blepharitis
1127778|NCT01456780|Dry Eye
1127779|NCT01456780|Ocular Inflammation
1127780|NCT01456780|MGD
1127781|NCT01456780|Zylet
1127782|NCT01456780|Lotemax
1127783|NCT01456780|Artificial Tear
1127784|NCT01456754|Insulin Metabolism
1127785|NCT01456754|Glucose Metabolism
1127786|NCT01456754|Substrate Partitioning
1127787|NCT01456754|Muscle Biopsies
1127788|NCT01456754|Feeding Frequency
1127789|NCT01456754|Insulin
1127790|NCT01456741|endobronchial needle aspiration (EBNA)
1127791|NCT01456741|transbronchial needle aspiration (TBNA)
1127792|NCT01456741|rapid on-site evaluation (ROSE)
1127793|NCT01456741|lung cancer
1127794|NCT01456728|Helicobacter pylori
1127795|NCT01456728|Progastria
1127796|NCT01456728|Lactobacillus reuteri
1127797|NCT01456728|omeprazole
1127798|NCT01456728|triple therapy
1127799|NCT01456728|probiotic
1127800|NCT01456715|Human Papillomavirus Vaccines
1127801|NCT01456715|Immunogenicity Gardasil Cervarix
1127802|NCT01456715|Booster dose
1127803|NCT01456702|SVV
1127804|NCT01456702|hemodynamic monitoring
1127805|NCT01456702|goal-directed volume therapie
1127806|NCT01456689|Myeloma
1127807|NCT01456689|Multiple Myeloma
1127808|NCT01456689|MM
1127809|NCT01456676|LDE225
1127810|NCT01456676|nilotinib
1127811|NCT01456676|Chronic myeloid leukemia
1127812|NCT01456676|CML
1127813|NCT01456676|Philadelphia positive
1127814|NCT01456676|Ph+
1127815|NCT01456676|resistant
1127816|NCT01456676|Resistant Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
1127817|NCT01456663|AFQ056
1127818|NCT01456663|Hepatic impairment
1127819|NCT01456663|Hepatic impaired
1127820|NCT01456650|Type 2 diabetes
1127821|NCT01456650|ABCA1 alleles
1127822|NCT01456650|Glyburide
1127823|NCT01456637|Insomnia
1127824|NCT01456637|Intervention
1127825|NCT01456637|Self-help
1127826|NCT01456637|Internet
1127827|NCT01456598|Stomach neoplasm
1127828|NCT01456598|Laparoscopy
1127829|NCT01456585|Histological documentation
1127830|NCT01456585|primary adenocarcinoma of the pancreas
1127831|NCT01456585|surgically eligible
1127832|NCT01456585|tumor resection
1127833|NCT01456585|curative intent
1127834|NCT01456572|glucagon-like peptide-1
1127835|NCT01456572|peptide tyrosine tyrosine
1127836|NCT01456572|ghrelin
1127837|NCT01456572|stomach
1127838|NCT01456572|small intestine
1127839|NCT01456572|gastric emptying
1127840|NCT01456559|Hypovolemia
1127841|NCT01456559|Lower body negative pressure
1127842|NCT01456559|Photoplethysmography
1127843|NCT01456546|CYP2C19*17
1127844|NCT01456546|Pharmacokinetics
1127845|NCT01456546|Pharmacodynamics
1127846|NCT01456533|hyponatremia
1127847|NCT01456533|hypernatremia
1127848|NCT01456520|pharmacokinetics
1127849|NCT01456520|bioequivalence
1127850|NCT01456520|hydrocodone
1127851|NCT01456520|acetaminophen
1127852|NCT01456520|moderate to moderately severe pain
1127853|NCT01456507|Food effect
1127854|NCT01456507|bioavailability
1127855|NCT01456507|oxycodone
1127856|NCT01456507|sequestered Naltrexone
1127857|NCT01456507|management of moderate to severe pain
1127858|NCT01456494|Obstructive Lung Disease
1127859|NCT01456494|COPD
1127860|NCT01456494|Asthma
1127861|NCT01456494|Inhaler
1127862|NCT01456494|Metered-Dose Inhaler
1127863|NCT01456494|Education
1127864|NCT01456494|Hospital-based education
1127865|NCT01456481|reflex fainting
1127866|NCT01456481|vasovagal syncope
1127867|NCT01456481|midodrine
1127868|NCT01456468|Cholangitis, Sclerosing
1127869|NCT01456468|Tretinoin
1127870|NCT01456468|Ursodeoxycholic Acid
1127871|NCT01456455|Central nervous system
1127872|NCT01456455|pathological markers
1127873|NCT01456429|invasive staging
1127874|NCT01456429|mediastinal lymph nodes
1127875|NCT01456429|endosonography
1127876|NCT01456429|surgical staging
1127877|NCT01456429|lung cancer
1127878|NCT01456416|RRMS
1127879|NCT01456416|Multiple Sclerosis
1127880|NCT01456416|Glatiramer Acetate
1127881|NCT01456416|Autoimmune Comorbidities
1127882|NCT01456416|Psoriasis
1127883|NCT01456416|Autoimmune Thyroiditis
1127884|NCT01456416|Vasculitis
1127885|NCT01456416|Rheumatoid Arthritis
1127886|NCT01456403|Carotid
1127887|NCT01456403|endarterectomy
1127888|NCT01456403|vulnerable plaque
1127889|NCT01456403|Ultrasound
1127890|NCT01456403|MRI
1127891|NCT01456403|PET/CT
1127892|NCT01456390|Open angle glaucoma
1127893|NCT01456390|Prior trabeculectomy
1127894|NCT01456377|lumbar stenosis
1127895|NCT01456377|systemic corticosteroids
1127896|NCT01456377|outcome
1127897|NCT01456377|security
1127898|NCT01456364|clopidogrel low response
1127899|NCT01456364|ticagrelor
1127900|NCT01456364|prasugrel
1127901|NCT01456364|platelet aggregation
1127902|NCT01456351|Event free survival
1127903|NCT01456351|Remission rates
1127904|NCT01456351|Toxicity
1127905|NCT01456351|Overall survival
1127906|NCT01456351|Efficiency costs
1127907|NCT01456351|Recurrent low grade
1127908|NCT01456338|cognitive behavior therapy
1127909|NCT01456338|addiction
1127910|NCT01456338|posttraumatic stress disorder (PTSD)
1127911|NCT01456312|Peginterferon alfa 2a
1127912|NCT01456312|Entecavir
1127913|NCT01456312|Response Guided Therapy
1127914|NCT01456312|Chronic Hepatitis B
1127915|NCT01456299|laryngeal mask airway
1127916|NCT01456299|insertion
1127917|NCT01456299|sevoflurane
1127918|NCT01456299|remifentanil
1127919|NCT01456273|biopsychosocial model
1127920|NCT01456273|biomedical model
1127921|NCT01456273|functional dyspepsia
1127922|NCT01456260|Drug Therapy
1127923|NCT01456247|Drug Therapy
1127924|NCT01456221|Obesity
1127925|NCT01456221|Insulin resistance
1127926|NCT01456221|Omega3 long chain polyunsaturated fatty acids
1127927|NCT01456195|Drug Therapy
1127928|NCT01456169|High Blood Pressure
1127929|NCT01456169|Drug Therapy
1127930|NCT01456156|hepatocellular carcinoma
1127931|NCT01456156|postoperative radiotherapy
1127932|NCT01456143|Squamous Cell Carcinoma
1127933|NCT01456143|Neoplasia
1127934|NCT01456143|Optical imaging
1127935|NCT01456143|Head and Neck Cancer
1127936|NCT01456143|Oropharynx
1127937|NCT01456143|Larynx
1127938|NCT01456143|Oral Cavity
1127939|NCT01456117|Drug Therapy
1127940|NCT01456117|pharmacodynamics
1127941|NCT01456117|pharmacokinetics
1127942|NCT01456104|vaccine
1127943|NCT01456104|stage IIB
1127944|NCT01456104|stage IIC
1127945|NCT01456104|stage III
1127946|NCT01456104|stage IV (MIa)
1127947|NCT01456104|Langerhans-type dendritic cells
1127948|NCT01456104|Immune Responses
1127949|NCT01456104|10-229
1127950|NCT01456091|adolescent pregnancy
1127951|NCT01456091|adolescent birth
1127952|NCT01456091|rapid repeat pregnancy
1127953|NCT01456091|rapid repeat birth
1127954|NCT01456091|youth development
1127955|NCT01456091|Pregnancy in Adolescence
1127956|NCT01456078|Neuroendocrine tumor
1127957|NCT01456078|Liver metastases
1127958|NCT01456078|177Lu-DOTA-TATE
1127959|NCT01456078|Safety
1127960|NCT01456078|Kidney dosimetry
1127961|NCT01456078|Dose escalation
1127962|NCT01456078|Neuroendocrine tumors, with liver metastases.
1127963|NCT01456026|Diabetes
1127964|NCT01456026|Advanced glycation endproducts
1127965|NCT01456026|Endothelium
1127966|NCT01456000|atrial fibrillation
1127967|NCT01456000|AF
1127968|NCT01456000|PAF
1127969|NCT01456000|PVI
1127970|NCT01456000|ablation
1127971|NCT01456000|paroxysmal atrial fibrillation
1127972|NCT01456000|pulmonary vein isolation
1127973|NCT01455987|Osteochondritis dissecans
1127974|NCT01455987|Juvenile osteochondritis dissecans
1127975|NCT01455987|Knee
1127976|NCT01455987|Osteochondral
1127977|NCT01455987|Outcome
1127978|NCT01455974|hypertension
1127979|NCT01455974|arterial stiffness
1127980|NCT01455974|left ventricular hypertrophy
1127981|NCT01455961|Real life setting
1127982|NCT01455961|Bipolar Disorder
1127983|NCT01455961|Registry based Data Base Audit
1127984|NCT01455948|sinusitis
1127985|NCT01455948|chronic
1127986|NCT01455948|Functional endoscopic sinus surgery
1127987|NCT01455948|balloon sinuplasty
1127988|NCT01455844|Hypertriglyceridemia
1127989|NCT01455792|Biopsy
1127990|NCT01455792|MRI and ultrasound soft image fusion
1127991|NCT01455792|Gold standard TRUS biopsy
1127992|NCT01455779|Stress Urinary Incontinence
1127993|NCT01455779|Incontinence
1127994|NCT01455779|SUI
1127995|NCT01455779|Renessa
1127996|NCT01455766|postpneumonectomy pulmonary edema
1127997|NCT01455766|extravascular lung water
1127998|NCT01455753|Influenza
1127999|NCT01455753|Proximity
1128000|NCT01455740|Acquired Immunodeficiency Syndrome
1128001|NCT01455740|HIV
1128002|NCT01455740|Commitment
1128003|NCT01455740|Financial Incentives
1128004|NCT01455727|Pharmaceutical care
1128005|NCT01455727|Diabetes Mellitus
1128006|NCT01455714|hypertenion
1128007|NCT01455714|exertional dyspnoea
1128008|NCT01455714|heart failure
1128009|NCT01455714|biomarkers
1128010|NCT01455688|critically ill patients
1128011|NCT01455688|HIV infection
1128012|NCT01455688|HAART
1128013|NCT01455688|mortality
1128014|NCT01455675|cystic fibrosis
1128015|NCT01455662|cardiac arrest
1128016|NCT01455649|Kidney
1128017|NCT01455649|Transplant
1128018|NCT01455649|Immunosuppression
1128019|NCT01455649|Everolimus
1128020|NCT01455649|Graft function
1128021|NCT01455636|pediatric
1128022|NCT01455636|micronutrient powder
1128023|NCT01455636|hand hygiene
1128024|NCT01455636|low birth weight
1128025|NCT01455636|infant feeding
1128026|NCT01455636|hand sanitizers
1128027|NCT01455623|CMT
1128028|NCT01455610|Computed tomography
1128029|NCT01455610|Contrast enhancement
1128030|NCT01455610|Pancreas
1128031|NCT01455610|Cancer
1128032|NCT01455610|Resectability
1128033|NCT01455597|Postmenopausal Women
1128034|NCT01455597|Vaginal Dryness
1128035|NCT01455597|Postmenopausal Vulvovaginal Atrophy
1128036|NCT01455584|HM781-36B
1128037|NCT01455558|Pharmacokinetics
1128038|NCT01455545|Asthma
1128039|NCT01455545|Degree of Control
1128040|NCT01455545|Exhaled Nitric Oxide
1128041|NCT01455545|Asthma Control Test
1128042|NCT01455519|Low Back Pain
1128043|NCT01455519|Back Pain
1128044|NCT01455519|Chronic back pain
1128045|NCT01455506|Acute Myeloid Leukemia (AML)
1128046|NCT01455506|Myelodysplastic Syndrome (MDS)
1128047|NCT01455506|Bone Marrow Transplant
1128048|NCT01455506|Stem Cell Transplant
1128049|NCT01455480|Second Degree Burn
1128050|NCT01455480|partial thickness burns
1128051|NCT01455467|Open angle glaucoma
1128052|NCT01455467|Pigmentary glaucoma
1128053|NCT01455467|Pseudoexfoliative glaucoma
1128054|NCT01455441|GLP-1
1128055|NCT01455441|Training
1128056|NCT01455441|Exercise
1128057|NCT01455441|Type 2 Diabetes
1128058|NCT01455428|Pregabalin
1128059|NCT01455428|Postherpetic Neuralgia ( PHN )
1128060|NCT01455402|Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Observational
1128061|NCT01455389|Lung Cancer
1128062|NCT01455389|Non-small cell lung cancer
1128063|NCT01455389|NSCLC
1128064|NCT01455389|FUS1-nanoparticles
1128065|NCT01455389|DOTAP:Chol-fus1
1128066|NCT01455389|DOTAP:Cholesterol-Fus1 Liposome Complex
1128067|NCT01455389|Erlotinib
1128068|NCT01455389|Erlotinib Hydrochloride
1128069|NCT01455389|OSI-774
1128070|NCT01455389|Tarceva
1128071|NCT01455389|Dexamethasone
1128072|NCT01455389|Decadron
1128073|NCT01455389|Diphenhydramine
1128074|NCT01455389|Benadryl
1128075|NCT01455389|Benylin Cough SyrupPharmacokinetic
1128076|NCT01455389|PK
1128077|NCT01455376|brain injury
1128078|NCT01455376|cognitive function
1128079|NCT01455376|sodium lactate
1128080|NCT01455376|MMSE score
1128081|NCT01455350|provoked vestibulodynia
1128082|NCT01455350|multimodal physiotherapy
1128083|NCT01455350|lidocaine
1128084|NCT01455337|severe alcoholic hepatitis
1128085|NCT01455324|prosthetic socket
1128086|NCT01455324|residual limb volume fluctuation
1128087|NCT01455324|conformable socket liner
1128088|NCT01455311|cystic pancreatic tumors
1128089|NCT01455311|cystic pancreatic lesions
1128090|NCT01455311|gastrointestinal
1128091|NCT01455311|GI
1128092|NCT01455311|EUS-FNA
1128093|NCT01455311|EchoBrush®
1128094|NCT01455311|cytology brush
1128095|NCT01455311|endoscopic
1128096|NCT01455298|Alpha-1 AT deficiency
1128097|NCT01455298|liver injury
1128098|NCT01455298|Transient Elastography
1128099|NCT01455298|FibroTest
1128100|NCT01455285|dysmenorrhea
1128101|NCT01455285|transcutaneous electrical nerve stimulation (TENS
1128102|NCT01455285|analgesia
1128103|NCT01455285|pain visual analog scale
1128104|NCT01455285|McGill pain questionnaire
1128105|NCT01455259|AdCD40L
1128106|NCT01455259|Adenoviral vector
1128107|NCT01455259|CD40L
1128108|NCT01455259|CD154
1128109|NCT01455259|malignant melanoma
1128110|NCT01455246|Cirrhosis
1128111|NCT01455246|Nosocomial Spontaneous Bacterial Peritonitis
1128112|NCT01455246|Ascites
1128113|NCT01455246|Daptomycin
1128114|NCT01455246|Meropenem
1128115|NCT01455246|Ceftazidime
1128116|NCT01455246|Nosocomial infection
1128117|NCT01455246|Multi drug resistant bacteria
1128118|NCT01455246|Sepsis
1128119|NCT01455246|Albumin
1128120|NCT01455233|cornea
1128121|NCT01455233|ocular antibiotic
1128122|NCT01455233|cataract surgery
1128123|NCT01455220|Multiple Sclerosis
1128124|NCT01455220|Sexual Dysfunction
1128125|NCT01455220|Quality of Life
1128126|NCT01455207|Magnetic Resonance Imaging
1128127|NCT01455207|Positon Emission Tomography
1128128|NCT01455207|Behavior
1128129|NCT01455194|ciclesonide
1128130|NCT01455194|asthma
1128131|NCT01455181|Hypoparathyroidism
1128132|NCT01455181|NPSP558
1128133|NCT01455181|Parathyroid Hormone 1-84
1128134|NCT01455181|PTH 1-84
1128135|NCT01455168|anterior capsule shrinkage
1128136|NCT01455168|capsular tension ring
1128137|NCT01455168|exfoliation syndrome
1128138|NCT01455168|phacoemulsification and aspiration
1128139|NCT01455155|stroke
1128140|NCT01455155|Art therapy
1128141|NCT01455155|Music therapy
1128142|NCT01455155|Creative therapy
1128143|NCT01455155|Efficacy
1128144|NCT01455129|chronic obstructive pulmonary disease
1128145|NCT01455129|COPD
1128146|NCT01455129|COPD exacerbation
1128147|NCT01455129|treatment
1128148|NCT01455129|tiotropium
1128149|NCT01455129|anticholinergic
1128150|NCT01455129|acute exacerbation of COPD (AECOPD)
1128151|NCT01455116|Sepsis
1128152|NCT01455116|Multi organ dysfunction syndrome
1128153|NCT01455116|Mild Induced Hypothermia
1128154|NCT01455077|obesity
1128155|NCT01455077|sleep apnea
1128156|NCT01455077|portable monitoring
1128157|NCT01455025|Plerixafor granulocyte-colony stimulating factor
1128158|NCT01455025|Chemotherapy in relapse
1128159|NCT01455025|Acute Myeloid Leukemia
1128160|NCT01455012|Rotigotine
1128161|NCT01455012|Neupro
1128162|NCT01455012|RLS
1128163|NCT01455012|Cardiovascular Risk
1128164|NCT01455012|Nocturnal Blood Pressure
1128165|NCT01454999|veteran
1128166|NCT01454999|smoking
1128167|NCT01454999|stage of change
1128168|NCT01454999|cell phone
1128169|NCT01454999|computerized tailored intervention
1128170|NCT01454986|Healthy subjects
1128171|NCT01454973|type 2 diabetes
1128172|NCT01454973|beta cell function
1128173|NCT01454973|meal tolerance test
1128174|NCT01454973|maximum stimulation test
1128175|NCT01454973|method standardization
1128176|NCT01454973|insulin secretion
1128177|NCT01454960|Antibiotics
1128178|NCT01454960|Inappropriate Prescribing
1128179|NCT01454960|Respiratory Tract Infections
1128180|NCT01454960|Behavioral Research
1128181|NCT01454947|Antibiotics
1128182|NCT01454947|Inappropriate Prescribing
1128183|NCT01454947|Respiratory Tract Infections
1128184|NCT01454947|Behavioral Research
1128185|NCT01454921|HIV
1128186|NCT01454921|Adolescent Trials Network
1128187|NCT01454908|partial knee arthroplasty
1128188|NCT01454895|noise-induced hearing loss
1128189|NCT01454895|prevention
1128190|NCT01454895|farmers
1128191|NCT01454882|Direct calorimetry
1128192|NCT01454882|Indirect calorimetry
1128193|NCT01454882|Energy Expenditure
1128194|NCT01454869|heparin
1128195|NCT01454843|Myopia
1128196|NCT01454843|Astigmatism
1128197|NCT01454843|Aberrations
1128198|NCT01454843|Wavefront
1128199|NCT01454843|LASIK
1128200|NCT01454843|Wavefront LASIK
1128201|NCT01454830|Social support
1128202|NCT01454830|Cognition
1128203|NCT01454830|Adaptation, psychological
1128204|NCT01454830|Health behavior
1128205|NCT01454830|Patient education
1128206|NCT01454817|Quality of Life
1128207|NCT01454817|Implantable Cardiac Defibrillators
1128208|NCT01454817|ICDs
1128209|NCT01454804|Advanced Cancers
1128210|NCT01454804|Solid Tumors
1128211|NCT01454804|Pazopanib
1128212|NCT01454804|GW786034
1128213|NCT01454804|Lapatinib
1128214|NCT01454804|Tykerb
1128215|NCT01454804|GW572016
1128216|NCT01454804|Trastuzumab
1128217|NCT01454804|Herceptin
1128218|NCT01454791|multiple sclerosis
1128219|NCT01454791|diclofenac
1128220|NCT01454791|subcutaneous injection
1128221|NCT01454791|glatiramer acetate
1128222|NCT01454791|Copaxone
1128223|NCT01454778|restenosis
1128224|NCT01454778|peripheral vascular disease
1128225|NCT01454778|lower extremity ischemia
1128226|NCT01454778|claudication
1128227|NCT01454752|malaria
1128228|NCT01454752|anaemia
1128229|NCT01454752|cognition
1128230|NCT01454752|intermittent preventive treatment
1128231|NCT01454752|children
1128232|NCT01454752|schools
1128233|NCT01454752|insecticide-treated nets
1128234|NCT01454739|rFVIIIFc
1128235|NCT01454739|A-LONG Extension
1128236|NCT01454726|Dizziness
1128237|NCT01454726|Meniere's disease
1128238|NCT01454726|Diaoshi Jifa therapy
1128239|NCT01454700|Type 1 diabetes mellitus
1128240|NCT01454700|Albuminuria
1128241|NCT01454700|Late diabetes complications
1128242|NCT01454700|CSII
1128243|NCT01454700|CGM
1128244|NCT01454700|Glycaemic control
1128245|NCT01454661|Probiotics
1128246|NCT01454661|Premature infant
1128247|NCT01454661|Intestinal microbiota
1128248|NCT01454661|Intestinal immunity
1128249|NCT01454661|Breastfeeding
1128250|NCT01454648|Traumatic Brain Injury
1128251|NCT01454648|EMS
1128252|NCT01454648|Out-of-Hospital
1128253|NCT01454635|depression
1128254|NCT01454635|treatment response
1128255|NCT01454635|selective serotonin reuptake inhibitor
1128256|NCT01454622|Healthy Volunteers
1128257|NCT01454622|Bioequivalence
1128258|NCT01454622|Canagliflozin (JNJ-28431754)
1128259|NCT01454622|Metformin IR
1128260|NCT01454609|cervical plexus block
1128261|NCT01454609|thyroidectomy
1128262|NCT01454609|postoperative analgesia
1128263|NCT01454596|Cell Therapy
1128264|NCT01454596|Gene Therapy
1128265|NCT01454596|Immunotherapy
1128266|NCT01454596|Brain Cancer
1128267|NCT01454596|Glioma
1128268|NCT01454596|Glioblastoma
1128269|NCT01454583|renin inhibitor
1128270|NCT01454583|ACE inhibitor
1128271|NCT01454583|ARB (AT1 receptor blockers)
1128272|NCT01454583|RAS blockade
1128273|NCT01454570|exoskeleton walking system
1128274|NCT01454570|paraplegia
1128275|NCT01454570|paralysis
1128276|NCT01454557|Acquired Brain Injury
1128277|NCT01454557|Heart Rate Variability (HRV)
1128278|NCT01454557|Auditory Stimuli
1128279|NCT01454557|Physical Activity
1128280|NCT01454518|hip arthroscopy
1128281|NCT01454518|post operative analgesia
1128282|NCT01454505|Healthy subjects
1128283|NCT01454505|Nasal allergies
1128284|NCT01454505|Allergies
1128285|NCT01454505|Environmental Exposure Chamber
1128286|NCT01454505|EEC
1128287|NCT01454505|Ragweed
1128288|NCT01454492|Allergy rhinitis
1128289|NCT01454492|Geographic tongue
1128290|NCT01454479|Lapatinib
1128291|NCT01454479|Ixabepilone
1128292|NCT01454479|HER-2
1128293|NCT01454479|Endometrial Carcinoma
1128294|NCT01454466|prevention
1128295|NCT01454466|retinal break
1128296|NCT01454466|vitrectomy
1128297|NCT01454466|partial posterior hyaloidectomy
1128298|NCT01454453|amisulpride
1128299|NCT01454453|receptor occupancy
1128300|NCT01454453|antipsychotic sensitivity
1128301|NCT01454440|Coronary artery disease
1128302|NCT01454440|Eptifibatide
1128303|NCT01454440|Percutaneous coronary intervention
1128304|NCT01454440|stable coronary artery disease
1128305|NCT01454440|percutaneous coronary intervention (PCI)
1128306|NCT01454440|DES
1128307|NCT01454375|Smoking
1128308|NCT01454362|nicotine
1128309|NCT01454362|inhalator
1128310|NCT01454362|electronic cigarette
1128311|NCT01454362|tobacco
1128312|NCT01454349|Benign prostatic hyperplasia
1128313|NCT01454349|BPH
1128314|NCT01454349|Enlarged prostate
1128315|NCT01454349|Lower urinary tract symptoms (LUTS)
1128316|NCT01454336|MSCs
1128317|NCT01454336|Pioglitazon
1128318|NCT01454336|fibrosis
1128319|NCT01454336|liver
1128320|NCT01454323|Chronic Myocardial Ischemia
1128321|NCT01454323|Cell therapy
1128322|NCT01454323|Bone marrow mononuclear cells
1128323|NCT01454310|Skin substitutes
1128324|NCT01454310|Split-thickness skin graft
1128325|NCT01454310|Burn wound
1128326|NCT01454310|Scar formation
1128327|NCT01454310|Skin quality
1128328|NCT01454297|Myeloma
1128329|NCT01454297|Multiple Myeloma
1128330|NCT01454297|Observational
1128331|NCT01454297|Longitudinal
1128332|NCT01454271|Total Hip arthroplasty
1128333|NCT01454271|Hip Osteoarthritis
1128334|NCT01454271|Infection after Total Hip Arthroplasty
1128335|NCT01454245|39439335EDI1013
1128336|NCT01454245|Bioavailability
1128337|NCT01454245|Pharmacokinetics
1128338|NCT01454232|Obesity
1128339|NCT01454232|adipose tissue inflammation
1128340|NCT01454232|Low grade systemic inflammation
1128341|NCT01454232|gut microbiota
1128342|NCT01454232|Bariatric surgery
1128343|NCT01454206|cannabis abuse
1128344|NCT01454206|alcohol abuse
1128345|NCT01454206|substance abuse
1128346|NCT01454180|Therapeutic targets in Pancreas
1128347|NCT01454167|vacum drains
1128348|NCT01454167|operational wounds
1128349|NCT01454167|infections
1128350|NCT01454167|seroma
1128351|NCT01454167|acid base
1128352|NCT01454167|glucose
1128353|NCT01454167|lactate
1128354|NCT01454154|TBI
1128355|NCT01454154|Traumatic Brain Injury
1128356|NCT01454141|Depressed mood
1128357|NCT01454128|exercise base rehabilitation
1128358|NCT01454128|heart failure
1128359|NCT01454128|periodic breathing
1128360|NCT01454128|aerobic fitness
1128361|NCT01454089|bladder
1128362|NCT01454089|urinary tract
1128363|NCT01454089|transitional cell carcinoma
1128364|NCT01454089|metastatic bladder cancer
1128365|NCT01454089|chemotherapy
1128366|NCT01454076|Cmax: maximum plasma concentration
1128367|NCT01454076|AUC0-tlast: time zero to the time of the last quantifiable concentration
1128368|NCT01454063|cataract
1128369|NCT01454063|lens replacement
1128370|NCT01454050|ICD therapy
1128371|NCT01454050|RV/LV Capture Control
1128372|NCT01454050|Safety and Efficacy
1128373|NCT01454011|hypogonadism
1128374|NCT01454011|testosterone
1128375|NCT01454011|HDL cholesterol subgroups
1128376|NCT01454011|hsCRP
1128377|NCT01454011|HOMA-IR
1128378|NCT01453972|Exercise
1128379|NCT01453972|High-intensity
1128380|NCT01453972|Interval training
1128381|NCT01453959|hypertension
1128382|NCT01453959|salt sensitivity
1128383|NCT01453959|fludrocortisone
1128384|NCT01453946|Crohn's Disease
1128385|NCT01453933|Anti-HIV Agents
1128386|NCT01453933|Anti-Retroviral Agents
1128387|NCT01453933|Antiviral Agents
1128388|NCT01453933|Anti-Infective Agents
1128389|NCT01453933|Lopinavir/ritonavir
1128390|NCT01453920|Age Related Macular Degeneration
1128391|NCT01453920|Choroidal Neovascular Membrane
1128392|NCT01453894|Colorectal Cancer Screening
1128393|NCT01453894|Fecal Occult Blood Testing
1128394|NCT01453881|Asthma
1128395|NCT01453881|pMDI
1128396|NCT01453881|Beclomethasone
1128397|NCT01453881|Formoterol
1128398|NCT01453881|Efficacy
1128399|NCT01453868|Multiple Sclerosis
1128400|NCT01453868|non impact aerobics
1128401|NCT01453855|Open-Angle Glaucoma
1128402|NCT01453855|Ocular Hypertension
1128403|NCT01453842|Glucagon-like peptide-1
1128404|NCT01453842|Glucose-dependant insulinotropic polypeptide
1128405|NCT01453842|Glucagon
1128406|NCT01453842|Peptide PYY
1128407|NCT01453842|2-oleyl glycerol
1128408|NCT01453816|Renal insufficiency
1128409|NCT01453816|kidney failure
1128410|NCT01453803|Liposuction
1128411|NCT01453803|ADSC
1128412|NCT01453803|ASC
1128413|NCT01453803|stem cell
1128414|NCT01453803|Parkinson's Disease
1128415|NCT01453803|Parkinson's
1128416|NCT01453803|therapy
1128417|NCT01453790|depression
1128418|NCT01453790|treatment
1128419|NCT01453790|motivation to seek follow up
1128420|NCT01453777|diffuse brain lesion
1128421|NCT01453751|Diabetes
1128422|NCT01453751|Type 2 Diabetes
1128423|NCT01453738|Osteoarthritis
1128424|NCT01453738|Knee
1128425|NCT01453738|Stem cells
1128426|NCT01453738|Mesenchymal Stem Cells
1128427|NCT01453712|coronary artery disease
1128428|NCT01453712|coronary CT angiography
1128429|NCT01453712|radiation dose
1128430|NCT01453712|iterative image reconstruction
1128431|NCT01453712|detection
1128432|NCT01453699|Bereavement
1128433|NCT01453699|early parental death
1128434|NCT01453699|grief
1128435|NCT01453699|affective disorders
1128436|NCT01453699|depression, depressive symptoms
1128437|NCT01453699|socioeconomic factors
1128438|NCT01453699|suicide
1128439|NCT01453699|attempted suicide
1128440|NCT01453699|antidepressive agents
1128441|NCT01453699|cardiovascular diseases
1128442|NCT01453699|quality of life
1128443|NCT01453699|Long-term health effects
1128444|NCT01453699|Socioeconomic outcomes
1128445|NCT01453699|Psychosocial well-being
1128446|NCT01453686|Alopecia Areata
1128447|NCT01453686|Hydrocortisone
1128448|NCT01453686|Clobetasol Propionate
1128449|NCT01453686|Randomized Controlled Trial
1128450|NCT01452711|Drug Therapy
1128451|NCT01452698|Drug Therapy
1128452|NCT01452685|Drug Therapy
1128453|NCT01452672|Breast cancer
1128454|NCT01452672|Radiotherapy
1128455|NCT01452672|Post-mastectomy
1128456|NCT01452672|Molecular characterization
1128457|NCT01452659|Drug Therapy
1128458|NCT01452646|acute myeloid leukemia
1128459|NCT01452646|risk-adapted therapy
1128460|NCT01452646|MRD-directed therapy
1128461|NCT01452646|young adults
1128462|NCT01452633|pain
1128463|NCT01452633|laparoscopy
1128464|NCT01452633|reduction
1128465|NCT01452620|Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
1128466|NCT01452620|Abdominal Aortic aneurysm (AAA)
1128467|NCT01452607|Ebselen
1128468|NCT01452581|Transfusion
1128469|NCT01452581|Red blood cells
1128470|NCT01452581|Postoperative
1128471|NCT01452581|Dizziness
1128472|NCT01452581|Hip Arthroplasty
1128473|NCT01452568|Thromboembolic complications
1128474|NCT01452568|Bleeding complications
1128475|NCT01452568|Haemorrhagic complications
1128476|NCT01452568|Anticoagulant therapy
1128477|NCT01452568|Aspirin
1128478|NCT01452568|biological Aorta Valve
1128479|NCT01452555|HIV
1128480|NCT01452555|HIV Prevention
1128481|NCT01452555|HIV testing
1128482|NCT01452555|HIV Rapid Test
1128483|NCT01452542|Genz-112638
1128484|NCT01452529|Pain
1128485|NCT01452529|Opioid
1128486|NCT01453673|knee
1128487|NCT01453673|Cruciate Ligament
1128488|NCT01453673|Meniscus
1128489|NCT01453660|Endothelial Function
1128490|NCT01453660|Endo-PAT2000 system
1128491|NCT01453660|11-140
1128492|NCT01453647|Fibromyalgia
1128493|NCT01453647|self-efficacy
1128494|NCT01453647|fatigue
1128495|NCT01453647|stress
1128496|NCT01453647|cytokine
1128497|NCT01453634|chronic kidney disease (CKD)
1128498|NCT01453634|secondary hyperparathyroidism (SHPT)
1128499|NCT01453634|hemodialysis (HD)
1128500|NCT01453621|prediction rules
1128501|NCT01453621|computerized clinical decision support
1128502|NCT01453621|traumatic brain injury
1128503|NCT01453621|blunt head trauma
1128504|NCT01453595|Kidney
1128505|NCT01453595|renal cell carcinoma
1128506|NCT01453595|BEZ235
1128507|NCT01453595|11-080
1128508|NCT01453582|Chest stuffiness of TCM
1128509|NCT01453582|Qi deficiency and blood stasis of TCM
1128510|NCT01453556|Laparoscopic surgery
1128511|NCT01453556|Right colectomy
1128512|NCT01453556|Mechanical anastomosis
1128513|NCT01453556|Post-operative ileum
1128514|NCT01453530|Recovery
1128515|NCT01453530|Street fitness
1128516|NCT01453530|Sugammadex
1128517|NCT01453530|Alertness
1128518|NCT01453530|Ambulatory surgery
1128519|NCT01453517|bariatric
1128520|NCT01453517|obesity
1128521|NCT01453517|post-surgery
1128522|NCT01453517|intervention
1128523|NCT01453465|childhood atypical teratoid/rhabdoid tumor
1128524|NCT01453465|rhabdoid tumor of the kidney
1128525|NCT01453452|weight changes
1128526|NCT01453452|fatigue
1128527|NCT01453452|depression
1128528|NCT01453452|anxiety disorder
1128529|NCT01453452|pain
1128530|NCT01453452|cognitive/functional effects
1128531|NCT01453452|psychosocial effects of cancer and its treatment
1128532|NCT01453452|cancer survivor
1128533|NCT01453452|stage IA breast cancer
1128534|NCT01453452|stage IB breast cancer
1128535|NCT01453452|stage II breast cancer
1128536|NCT01453452|stage IIIA breast cancer
1128537|NCT01453452|stage IIIB breast cancer
1128538|NCT01453452|stage IIIC breast cancer
1128539|NCT01453452|stage I colon cancer
1128540|NCT01453452|stage IIA colon cancer
1128541|NCT01453452|stage IIB colon cancer
1128542|NCT01453452|stage IIC colon cancer
1128543|NCT01453452|stage IIIA colon cancer
1128544|NCT01453452|stage IIIB colon cancer
1128545|NCT01453452|stage IIIC colon cancer
1128546|NCT01453452|stage I rectal cancer
1128547|NCT01453452|stage IIA rectal cancer
1128548|NCT01453452|stage IIB rectal cancer
1128549|NCT01453452|stage IIC rectal cancer
1128550|NCT01453452|stage IIIA rectal cancer
1128551|NCT01453452|stage IIIB rectal cancer
1128552|NCT01453452|stage IIIC rectal cancer
1128553|NCT01453439|Body dysmorphic disorder
1128554|NCT01453439|Obsessive compulsive spectrum disorder
1128555|NCT01453439|Body image
1128556|NCT01453439|Appearance concerns
1128557|NCT01453400|aspirin
1128558|NCT01453400|acetylsalicylic acid
1128559|NCT01453400|pharyngitis
1128560|NCT01453400|sore throat
1128561|NCT01453387|MEK inhibitor
1128562|NCT01453387|Solid Tumor
1128563|NCT01453387|Phase I
1128564|NCT01453374|opioid dependence
1128565|NCT01453374|VIVITROL
1128566|NCT01453374|criminal justice
1128567|NCT01453361|FANG
1128568|NCT01453361|Melanoma
1128569|NCT01453361|Vigil
1128570|NCT01453348|meningococcal
1128571|NCT01453348|conjugate
1128572|NCT01453348|vaccine
1128573|NCT01453348|adults
1128574|NCT01453335|Veins
1128575|NCT01453335|Catheter Segments
1128576|NCT01453335|Vascular Access
1128577|NCT01453335|VeinViewer Vision
1128578|NCT01453322|Veins
1128579|NCT01453322|Vascular Access
1128580|NCT01453322|IV complications
1128581|NCT01453322|VeinViewer Vision
1128582|NCT01453309|lumbar fusion
1128583|NCT01453309|transfusion
1128584|NCT01453309|cell-saver
1128585|NCT01453309|cost-effectiveness
1128586|NCT01453296|Asthma
1128587|NCT01453296|Tolerability
1128588|NCT01453296|Safety
1128589|NCT01453296|Pharmacokinetics
1128590|NCT01453296|GW642444
1128591|NCT01453283|DNA Repair
1128592|NCT01453283|Nucleotide Excision Repair
1128593|NCT01453283|Trabectedine
1128594|NCT01453283|Phase I
1128595|NCT01453283|Sarcoma
1128596|NCT01453283|Cytotoxic
1128597|NCT01453283|Chemotherapy
1128598|NCT01453283|Solid Tumor
1128599|NCT01453283|Malignant Tumor
1128600|NCT01453283|Rhabdomyosarcoma
1128601|NCT01453283|Ewing Sarcoma
1128602|NCT01453283|Neuroblastoma
1128603|NCT01453283|Wilm's Tumor
1128604|NCT01453283|Hepatic Tumor
1128605|NCT01453283|Brain Tumor
1128606|NCT01453270|Sepsis
1128607|NCT01453270|Emergency medicine
1128608|NCT01453270|Cardiac output
1128609|NCT01453270|Stroke volume
1128610|NCT01453270|Lactate
1128611|NCT01453257|Molecular Targets
1128612|NCT01453257|Personalize Treatment
1128613|NCT01453257|Colon Cancer
1128614|NCT01453257|Complete Response Rate
1128615|NCT01453244|Chronic hepatitis C
1128616|NCT01453244|Pharmacogenomics
1128617|NCT01453244|IL28B
1128618|NCT01453244|ITPA
1128619|NCT01453231|bariatric surgery
1128620|NCT01453231|plastic surgery
1128621|NCT01453231|thigh
1128622|NCT01453231|obesity
1128623|NCT01453231|body image
1128624|NCT01453231|quality of life
1128625|NCT01453218|Renal insufficiency
1128626|NCT01453218|Liver transplant
1128627|NCT01453218|Acute rejection
1128628|NCT01453218|Infections
1128629|NCT01453218|Hepatitis C recurrence
1128630|NCT01453205|Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, B-Cell Malignancy, anti-CD19, monoclonal antibody, second line, ASCT, Refractory
1128631|NCT01453192|Raltegravir
1128632|NCT01453192|Renal transplantation
1128633|NCT01453192|HIV-1
1128634|NCT01453192|Acute renal graft rejection
1128635|NCT01453179|actinic keratosis
1128636|NCT01453179|invasive SCC
1128637|NCT01453179|in situ SCC
1128638|NCT01453179|histological classification
1128639|NCT01453179|histological progression
1128640|NCT01453179|clinical clearance
1128641|NCT01453179|cryotherapy
1128642|NCT01453153|pancreatic
1128643|NCT01453153|Cancer
1128644|NCT01453153|Stage IV
1128645|NCT01453153|untreated
1128646|NCT01453127|dementia
1128647|NCT01453127|parkinsonism
1128648|NCT01453127|mild cognitive impairment
1128649|NCT01453127|REM sleep behavior disorder
1128650|NCT01453114|Cognitive Behavioral Therapy
1128651|NCT01453114|CBT
1128652|NCT01453114|relapse
1128653|NCT01453114|postpartum depression
1128654|NCT01453114|depression recurrence
1128655|NCT01453114|depression relapse
1128656|NCT01453101|Multiple Myeloma
1128657|NCT01453101|Transplant
1128658|NCT01453088|multiple myeloma
1128659|NCT01453088|transplant
1128660|NCT01453075|hepatitis C
1128661|NCT01453075|herpes simplex type 2
1128662|NCT01453075|veterans
1128663|NCT01453062|Ofatumumab
1128664|NCT01453062|Chronic lymphocytic leukemia (CLL)
1128665|NCT01453062|Arzerra
1128666|NCT01453049|rosiglitazone/glimepiride, fix dose, type 2 diabetes
1128667|NCT01453036|Peptic ulcer
1128668|NCT01453036|Helicobacter pylori
1128669|NCT01453036|Clarithromycin
1128670|NCT01453036|23S rRNA
1128671|NCT01453036|Resistance
1128672|NCT01453023|pediatric ages 5 to 11 years
1128673|NCT01453010|SaeboFlex
1128674|NCT01453010|Stroke rehabilitation
1128675|NCT01453010|Upper Limb Rehabilitation
1128676|NCT01453010|Acute Stroke
1128677|NCT01452997|mosquito
1128678|NCT01452997|allergy
1128679|NCT01452997|bite
1128680|NCT01452997|ant-inflammatory
1128681|NCT01452997|Aedes aegypti mosquito bite
1128682|NCT01452984|Non-Melanoma skin cancer patients who have undergone or about to undergo Mohs surgery
1128683|NCT01452984|who are treated within the University of Pennsylvania Health System
1128684|NCT01452971|tumor susceptibility gene
1128685|NCT01452971|glycine N-methyltransferase (GNMT)
1128686|NCT01452971|polycyclic aromatic hydrocarbons (PAHs)
1128687|NCT01452971|lung cancer
1128688|NCT01452958|Endotoxin
1128689|NCT01452958|LPS
1128690|NCT01452958|TNF-α
1128691|NCT01452958|insulin resistance
1128692|NCT01452958|metabolism
1128693|NCT01452932|Chronic obstructive pulmonary disease
1128694|NCT01452932|Dyspnea
1128695|NCT01452932|Exercise test
1128696|NCT01452932|Endurance training
1128697|NCT01452919|schizophrenia, LY2140023, pomaglumetad methionil
1128698|NCT01452906|Drug-drug interaction
1128699|NCT01452906|Pharmacokinetics
1128700|NCT01452906|PA21
1128701|NCT01452906|Drug Interaction Potentiation
1128702|NCT01452880|Remifentanil
1128703|NCT01452880|Lithotripsy
1128704|NCT01452880|Conscious Sedation
1128705|NCT01452867|Airway
1128706|NCT01452867|Bag-Valve -Mask- Ventilation
1128707|NCT01452867|Laryngeal Mask - Ventilation
1128708|NCT01452867|Laryngeal Tube - Ventilation
1128709|NCT01452854|LGG
1128710|NCT01452854|Temozolomide
1128711|NCT01452854|Temodar
1128712|NCT01452854|Ovarian Aging
1128713|NCT01452854|Infertility
1128714|NCT01452854|Chemotherapy
1128715|NCT01452841|grapefruit
1128716|NCT01452841|weight loss
1128717|NCT01452841|blood pressure
1128718|NCT01452841|lipids
1128719|NCT01452841|inflammation
1128720|NCT01452828|Renal Impairment
1128721|NCT01452815|diabetic gastroparesis
1128722|NCT01452815|delayed gastric emptying
1128723|NCT01452815|gastroparesis
1128724|NCT01452815|diabetes mellitus, Type 1
1128725|NCT01452815|diabetes mellitus, Type 2
1128726|NCT01452802|HeartMate II
1128727|NCT01452802|heart-assist device
1128728|NCT01452802|medical management
1128729|NCT01452802|optimal medical management
1128730|NCT01452802|Heart Failure NYHA Class IIIB/IV
1128731|NCT01452802|Thoratec Corporation
1128732|NCT01452789|neonatal abstinence syndrome
1128733|NCT01452789|buprenorphine
1128734|NCT01452789|morphine
1128735|NCT01452789|pharmacokinetics
1128736|NCT01452776|Drug Therapy
1128737|NCT01452763|Drug Therapy
1128738|NCT01452750|Drug Therapy
1128739|NCT01452737|colonoscopy
1128740|NCT01452737|bowel preparation
1128741|NCT01452737|Golytely
1128742|NCT01452724|Drug Therapy
1128743|NCT01452516|PLF
1128744|NCT01452516|lumbar fusion
1128745|NCT01452516|bone graft
1128746|NCT01452516|biologics
1128747|NCT01452503|AE adverse event
1128748|NCT01452503|AIDS acquired immunodeficiency syndrome
1128749|NCT01452503|ALT (SGPT) alanine aminotransferase
1128750|NCT01452503|ART antiretroviral therapy
1128751|NCT01452503|AST (SGOT) aspartate aminotransferase
1128752|NCT01452503|DCF data collection forms
1128753|NCT01452503|DMC Data Monitoring Committee
1128754|NCT01452503|FDA (U.S.) Food and Drug Administration
1128755|NCT01452503|GCP Good Clinical Practice guidelines
1128756|NCT01452503|HB sAg Hepatitis B surface antigen
1128757|NCT01452503|ICH International Conference of Harmonization
1128758|NCT01452503|IND Investigational New Drug Application
1128759|NCT01452503|IRB Institutional Review Board
1128760|NCT01452503|IU International units
1128761|NCT01452503|mg milligram(s)
1128762|NCT01452503|mm3 cubic millimeter(s)
1128763|NCT01452503|PCR polymerase chain reaction
1128764|NCT01452503|SAE serious adverse event
1128765|NCT01452503|µg microgram
1128766|NCT01452503|ULN upper limit of the normal range
1128767|NCT01452503|WB Western Blot
1128768|NCT01452490|Onychomycosis
1128769|NCT01452490|Toenail Fungus
1128770|NCT01452477|Polycystic Ovary Syndrome
1128771|NCT01452477|Cryptotanshinone
1128772|NCT01452464|observational
1128773|NCT01452464|serogroup A, B, Y, W
1128774|NCT01452464|meningococcal meningitis
1128775|NCT01452464|meningococcal vaccines
1128776|NCT01452464|safety
1128777|NCT01452464|MenACYW-CRM
1128778|NCT01452464|post-marketing
1128779|NCT01452464|adolescents
1128780|NCT01452438|observational
1128781|NCT01452438|serogroup A, B, Y, W
1128782|NCT01452438|meningococcal meningitis
1128783|NCT01452438|meningococcal vaccines
1128784|NCT01452438|safety
1128785|NCT01452438|MenACYW-CRM
1128786|NCT01452438|post-marketing
1128787|NCT01452438|children
1128788|NCT01452425|Human volunteers
1128789|NCT01452412|Alkali
1128790|NCT01452412|Sodium bicarbonate
1128791|NCT01452412|Kidney disease
1128792|NCT01452412|Acidosis
1128793|NCT01452386|Constipation
1128794|NCT01452386|Stimulation Treatment
1128795|NCT01452373|Hot flush(es)
1128796|NCT01452373|Hot flash(es)
1128797|NCT01452373|Vasomotor symptoms
1128798|NCT01452373|Dehydroepiandrosterone (DHEA)
1128799|NCT01452373|Prasterone
1128800|NCT01452373|Acolbifene
1128801|NCT01452373|Selective estrogen receptor modulator (SERM)
1128802|NCT01452373|Antiestrogen
1128803|NCT01452373|Menopause
1128804|NCT01452373|Postmenopausal women
1128805|NCT01452360|chronic kidney disease
1128806|NCT01452321|Transcranial Magnetic Stimulation;
1128807|NCT01452321|Postpartum Depression;
1128808|NCT01452321|Clinical Performance;
1128809|NCT01452321|Cognitive Performance;
1128810|NCT01452321|Social Performance
1128811|NCT01452308|Gilead
1128812|NCT01452308|Gilead Sciences
1128813|NCT01452308|GSI
1128814|NCT01452308|Liver Fibrosis
1128815|NCT01452308|Liver
1128816|NCT01452308|Fibrosis
1128817|NCT01452295|liver
1128818|NCT01452295|liver failure
1128819|NCT01452295|acute liver failure
1128820|NCT01452295|ELAD
1128821|NCT01452295|alcoholic hepatitis
1128822|NCT01452295|acute on chronic hepatitis
1128823|NCT01452282|Ankle Brachial Index
1128824|NCT01452282|Perioperative care
1128825|NCT01452282|General Surgery
1128826|NCT01452282|Acute Coronary Syndromes
1128827|NCT01452282|Cardiovascular Complications
1128828|NCT01452243|Vitamin D
1128829|NCT01452243|Calcium
1128830|NCT01452243|Elderly
1128831|NCT01452230|Bariatric Surgery Candidate
1128832|NCT01452230|Severely obese
1128833|NCT01452230|Bariatric surgery
1128834|NCT01452230|Physical activity
1128835|NCT01452230|Physical fitness
1128836|NCT01452230|Comorbidities
1128837|NCT01452230|Quality of life
1128838|NCT01452230|Surgical complications
1128839|NCT01452217|Pancreas
1128840|NCT01452217|Chronic pancreatitis
1128841|NCT01452217|Perfusion
1128842|NCT01452217|Blood flow
1128843|NCT01452217|Magnetic resonance imaging
1128844|NCT01452204|PEMF
1128845|NCT01452204|magneto
1128846|NCT01452204|shoulder
1128847|NCT01452204|impingement
1128848|NCT01452191|Cluster Randomised Controlled Trial
1128849|NCT01452191|Community Health Services
1128850|NCT01452191|prevention & control
1128851|NCT01452191|Accidents, Home
1128852|NCT01452191|Child Health Services
1128853|NCT01452178|Cardiovascular diseases
1128854|NCT01452178|Glucometabolic disorders
1128855|NCT01452178|Type-D personality
1128856|NCT01452165|Cardiovascular diseases
1128857|NCT01452165|Hypertrophy, Left ventricle
1128858|NCT01452165|Echocardiography
1128859|NCT01452165|Prognosis
1128860|NCT01452152|Pharmacogenomics
1128861|NCT01452152|Platelet Aggregation Inhibitors
1128862|NCT01452139|STEMI
1128863|NCT01452139|Pharmacogenetics
1128864|NCT01452139|Prasugrel
1128865|NCT01452139|Clopidogrel
1128866|NCT01452139|Percutaneous Coronary Intervention
1128867|NCT01452113|Diabetes Mellitus
1128868|NCT01452113|DPP-IV protein
1128869|NCT01452113|Glucagon-Like Peptide 1
1128870|NCT01452113|autonomic neuropathy
1128871|NCT01452100|embolism
1128872|NCT01452100|cholesterol cristal
1128873|NCT01452100|creatinine
1128874|NCT01452100|renal insufficiency
1128875|NCT01452100|prednisone
1128876|NCT01452100|systemic atheroembolism
1128877|NCT01452087|insulin sensitivity
1128878|NCT01452087|exercise
1128879|NCT01452074|Insulin Sensitivity
1128880|NCT01452074|Exercise Training
1128881|NCT01452074|Weight Loss
1128882|NCT01452074|Fat Metabolism
1128883|NCT01452061|Autism Spectrum Disorder
1128884|NCT01452061|Attention Deficit/Hyperactivity Disorder
1128885|NCT01452061|Developmental Delay
1128888|NCT01452035|insulin sensitivity
1128889|NCT01452035|fatty acid metabolism
1128890|NCT01452035|exercise
1128891|NCT01452022|inductigraft
1128892|NCT01452022|osteoinductive
1128893|NCT01452022|synthetic bone graft
1128894|NCT01452022|posterolateral lumbar fusion
1128895|NCT01452022|post market
1128896|NCT01452022|lumbar spinal stenosis
1128897|NCT01452009|open angle glaucoma
1128898|NCT01452009|ocular hypertension
1128899|NCT01451996|direct-to-consumer advertising
1128900|NCT01451983|Autism
1128901|NCT01451983|PTEN
1128902|NCT01451983|macrocephaly
1128903|NCT01451970|high fat diet treatment
1128904|NCT01451970|insulin sensitivity
1128905|NCT01451957|exercise
1128906|NCT01451957|fatty acid metabolism
1128907|NCT01451957|insulin sensitivity
1128908|NCT01451944|Asthma
1128909|NCT01451944|Home Health Nursing
1128910|NCT01451944|Patient education
1128911|NCT01451931|kidney stone
1128912|NCT01451931|urolithiasis
1128913|NCT01451931|urinary tract infection
1128914|NCT01451931|ultrasound
1128915|NCT01451931|computed tomography
1128916|NCT01451931|safety
1128917|NCT01451931|cost
1128918|NCT01451931|accuracy
1128919|NCT01451918|Dyslipidaemia
1128920|NCT01451918|Insulin resistance
1128921|NCT01451918|Type 2 Diabetes
1128922|NCT01451892|Obesity
1128923|NCT01451892|dance
1128924|NCT01451892|gait
1128925|NCT01451892|balance
1128926|NCT01451892|posture
1128927|NCT01451892|dance therapy
1128928|NCT01451879|Pompe Disease
1128929|NCT01451879|Infusion Associated Reaction
1128930|NCT01451879|Immune-modulation regimen
1128931|NCT01451866|resistance training
1128932|NCT01451866|Healthy People Programs
1128933|NCT01451853|Lung Cancer
1128934|NCT01451853|Head and Neck Cancer
1128935|NCT01451853|Hearing Loss
1128936|NCT01451853|Ototoxicity
1128937|NCT01451853|Tinnitus
1128938|NCT01451853|Deafness
1128939|NCT01451853|SPI-1005
1128940|NCT01451853|Cisplatin
1128941|NCT01451853|Carboplatin
1128942|NCT01451853|Ebselen
1128943|NCT01451827|Kidney Disease
1128944|NCT01451827|Polycystic Kidney Disease
1128945|NCT01451827|Autosomal Dominant Polycystic Kidney Disease
1128946|NCT01451827|PKD
1128947|NCT01451827|ADPKD
1128948|NCT01451814|smoking cessation
1128949|NCT01451801|Hepatitis B
1128950|NCT01451801|non responders
1128951|NCT01451801|cellular immune response
1128952|NCT01451801|cytokines
1128953|NCT01451801|predictors
1128954|NCT01451801|HBsAg
1128955|NCT01451788|RCT
1128956|NCT01451788|Gelatin matrix
1128957|NCT01451788|thrombin
1128958|NCT01451788|idiopathic scoliosis
1128959|NCT01451788|Surgery
1128960|NCT01451762|pain
1128961|NCT01451762|anesthesia
1128962|NCT01451762|surgery
1128963|NCT01451762|postoperative
1128964|NCT01451749|Mild cognitive impairment
1128965|NCT01451736|First-episode Schizophrenia
1128966|NCT01451736|Schizoaffective Disorder, Depressed Type (recent-onset)
1128967|NCT01451736|Schizophreniform Disorder
1128968|NCT01451736|oral risperidone
1128969|NCT01451736|long-acting injectable paliperidone palmitate
1128970|NCT01451736|functional outcome
1128971|NCT01451723|Multiple Sclerosis
1128972|NCT01451723|Polyphenon E
1128973|NCT01451723|Green tea
1128974|NCT01451723|EGCG
1128975|NCT01451723|Epigallocatechin-galleate
1128976|NCT01451723|Placebo
1128977|NCT01451723|Randomized controlled trial
1128978|NCT01451710|enough steroids
1128979|NCT01451710|MCD
1128980|NCT01451710|efficacy
1128981|NCT01451684|pregnancy
1128982|NCT01451684|fetus
1128983|NCT01451684|euploid
1128984|NCT01451671|fetal
1128985|NCT01451671|aneuploidy
1128986|NCT01451671|non-invasive
1128987|NCT01451671|prenatal
1128988|NCT01451671|cell free DNA
1128989|NCT01451658|Variceal bleeding
1128990|NCT01451658|portal hypertension
1128991|NCT01451658|hepatocellular carcinoma
1128992|NCT01451658|endoscopic variceal ligation
1128993|NCT01451658|non-selective beta-blocker
1128994|NCT01451658|rebleeding
1128995|NCT01451645|Gout
1128996|NCT01451632|Metastatic Colorectal cancer
1128997|NCT01451632|Kras wild-type
1128998|NCT01451632|Squamous cell head and neck cancer
1128999|NCT01451632|Non-small cell lung cancer
1129000|NCT01451632|Triple negative breast cancer
1129001|NCT01451632|EGFR
1129002|NCT01451632|ErbB3
1129003|NCT01451632|MM-121
1129004|NCT01451632|Cetuximab
1129005|NCT01451632|Irinotecan
1129006|NCT01451606|Chronic Pelvic Pain
1129007|NCT01451606|CPP
1129008|NCT01451606|Pelvic Pain
1129009|NCT01451593|Optic neuritis
1129010|NCT01451593|Multiple sclerosis
1129011|NCT01451593|Retinal nerve fibre layer
1129012|NCT01451593|Axonal loss
1129013|NCT01451593|Neuroprotection
1129014|NCT01451593|Phenytoin
1129015|NCT01451593|MRI
1129016|NCT01451593|Optical coherence tomography
1129017|NCT01451593|Sodium Channel Blockers
1129018|NCT01451580|Phase II
1129019|NCT01451580|Metastatic Breast Cancer
1129020|NCT01451567|Nurses, Workload, Musculoskeletal System, Intervention
1129021|NCT01451554|weight
1129022|NCT01451554|body mass index
1129023|NCT01451554|obesity
1129024|NCT01451554|portion control plate
1129025|NCT01451554|diet
1129026|NCT01451554|exercise
1129027|NCT01451528|Umbilical Cord Blood
1129028|NCT01451528|Allogeneic
1129029|NCT01451528|Traumatic Brain Injury
1129030|NCT01451515|Lymphoblastic lymphoma
1129031|NCT01451502|umbilical cord blood
1129032|NCT01451489|FSGS
1129033|NCT01451489|FK506
1129034|NCT01451489|CTX
1129035|NCT01451476|Ageing
1129036|NCT01451463|Huntington's Disease
1129037|NCT01451463|Chorea
1129038|NCT01451463|Gait
1129039|NCT01451463|Balance
1129040|NCT01451450|Peanut Allergy
1129041|NCT01451411|Serum Sodium
1129042|NCT01451411|Euvolemia
1129043|NCT01451411|Hypervolemia
1129044|NCT01451411|Vaprisol®
1129045|NCT01451411|Conivaptan
1129046|NCT01451411|YM087
1129047|NCT01451372|Diabetes
1129048|NCT01451372|CGM
1129049|NCT01451372|CSII
1129050|NCT01451346|Pilot study
1129051|NCT01451333|HIV
1129052|NCT01451333|Efavirenz
1129053|NCT01451333|Central Nervous System (CNS)
1129054|NCT01451333|Lumbar puncture
1129055|NCT01451333|Dose reduction
1129056|NCT01451320|Prosthetic valve
1129057|NCT01451320|thrombosis
1129058|NCT01451320|TROIA
1129059|NCT01451320|tPA
1129060|NCT01451320|TEE
1129061|NCT01451307|Congenital abnormalities
1129062|NCT01451307|Digestive system abnormalities
1129063|NCT01451307|Neonatal surgery
1129064|NCT01451307|Neonatal anesthesia
1129065|NCT01451307|Bayley Scales of Infant Development II
1129066|NCT01451294|Cerebral autoregulation
1129067|NCT01451281|Ultrasonography
1129068|NCT01451281|Muscular Dystrophy
1129069|NCT01451281|Neuromuscular Disease
1129070|NCT01451281|Oligonucleotide
1129071|NCT01451281|Magnetic Resonance Imaging (MRI)
1129072|NCT01451281|Duchenne Muscular Dystrophy
1129073|NCT01451281|DND
1129074|NCT01451268|60 to 150 Days After Allogeneic Stem Cell Transplantation
1129075|NCT01451268|High Risk MDS
1129076|NCT01451268|MDS
1129077|NCT01451268|AML
1129078|NCT01451255|pulsatility
1129079|NCT01451255|normal subjects
1129080|NCT01451255|mild pulmonary hypertension
1129081|NCT01451255|exercise-associated pulmonary hypertension
1129082|NCT01451242|Heart Rate Variability
1129083|NCT01451242|Acquired Brain Injury
1129084|NCT01451242|Physical Activity
1129085|NCT01451229|pharmacokinetics
1129086|NCT01451229|pharmacodynamics
1129087|NCT01451216|Acquired brain injury
1129088|NCT01451216|Balance control
1129089|NCT01451216|Functional reach
1129090|NCT01451203|Early RA
1129091|NCT01451203|Certolizumab Pegol
1129092|NCT01451203|Cimzia
1129093|NCT01451190|Androgenetic Alopecia
1129094|NCT01451190|Male Pattern Baldness
1129095|NCT01451190|Female Pattern Baldness
1129096|NCT01451190|Hair Loss
1129097|NCT01451190|Baldness
1129098|NCT01451177|Androgenetic Alopecia
1129099|NCT01451177|Male Pattern Baldness
1129100|NCT01451177|Female Pattern Baldness
1129101|NCT01451177|Hair Loss
1129102|NCT01451177|Baldness
1129103|NCT01451151|Androgenetic Alopecia
1129104|NCT01451151|Male Pattern Baldness
1129105|NCT01451151|Female Pattern Baldness
1129106|NCT01451151|Hair Loss
1129107|NCT01451151|Baldness
1129108|NCT01451138|Androgenetic Alopecia
1129109|NCT01451138|Male Pattern Baldness
1129110|NCT01451138|Female Pattern Baldness
1129111|NCT01451138|Hair Loss
1129112|NCT01451138|Baldness
1129113|NCT01451125|Androgenetic Alopecia
1129114|NCT01451125|Male Pattern Baldness
1129115|NCT01451125|Female Pattern Baldness
1129116|NCT01451125|Hair Loss Baldness
1129117|NCT01451112|Androgenetic Alopecia
1129118|NCT01451112|Male Pattern Baldness
1129119|NCT01451112|Female Pattern Baldness
1129120|NCT01451112|Hair Loss
1129121|NCT01451112|Baldness
1129122|NCT01451099|Androgenetic Alopecia
1129123|NCT01451099|Male Pattern Baldness
1129124|NCT01451099|Female Pattern Baldness
1129125|NCT01451099|Hair Loss
1129126|NCT01451099|Baldness
1129127|NCT01451086|Safety
1129128|NCT01451086|Immunogenicity
1129129|NCT01451086|Pneumococcal vaccine
1129130|NCT01451073|Androgenetic Alopecia
1129131|NCT01451073|Male Pattern Baldness
1129132|NCT01451073|Female Pattern Baldness
1129133|NCT01451073|Hair Loss
1129134|NCT01451073|Baldness
1129135|NCT01451060|vasopressors
1129136|NCT01451060|cesarean anesthesia
1129137|NCT01451060|hypotension
1129138|NCT01451047|Androgenetic Alopecia
1129139|NCT01451047|Male Pattern Baldness
1129140|NCT01451047|Female Pattern Baldness
1129141|NCT01451047|Hair Loss
1129142|NCT01451047|Baldness
1129143|NCT01451034|WHYX lesion
1129144|NCT01451034|endoscopic resection
1129145|NCT01451034|complete resection
1129146|NCT01451034|complete resection rate
1129147|NCT01451034|endoscopic feature
1129148|NCT01451034|Average size discrepancy
1129149|NCT01451021|Androgenetic Alopecia
1129150|NCT01451021|Male Pattern Baldness
1129151|NCT01451021|Female Pattern Baldness
1129152|NCT01451021|Hair Loss
1129153|NCT01451021|Baldness
1129154|NCT01451008|Anastomosis
1129155|NCT01451008|Compression
1129156|NCT01451008|Colon
1129157|NCT01450995|Migraine
1129158|NCT01450995|Headache, Migraine
1129159|NCT01450982|Rheumatoid Arthritis
1129160|NCT01450982|JNJ-38518168
1129161|NCT01450982|Methotrexate
1129162|NCT01450969|Operator Comfort Assessment
1129163|NCT01450969|Radiation protection
1129164|NCT01450969|Measurement of Radiation Exposure
1129165|NCT01450969|Endovascular Interventional Radiology
1129166|NCT01450956|congenital heart diseases
1129167|NCT01450956|cardiopulmonary bypass
1129168|NCT01450956|Pediatric
1129169|NCT01450956|sevoflurane
1129170|NCT01450943|Diabetic Foot Ulcer
1129171|NCT01450943|Chronic wounds
1129172|NCT01450943|Chronic ulcers
1129173|NCT01450943|Oasis
1129174|NCT01450943|Dermagraft
1129175|NCT01450943|Adaptic
1129176|NCT01450930|Adrenal insufficiency
1129177|NCT01450930|Addison's disease
1129178|NCT01450891|Alzheimer's disease
1129179|NCT01450891|Diagnosis
1129180|NCT01450891|Costs
1129181|NCT01450891|Benefits
1129182|NCT01450891|subjective and/or objective memory complaints
1129183|NCT01450878|high dose of EPO
1129184|NCT01450878|transplant kidney
1129185|NCT01450878|cadaveric organ donor
1129186|NCT01450878|mono-organ (kidney) retrieval
1129187|NCT01450878|patient
1129188|NCT01450878|kidney graft
1129189|NCT01450865|neuropathy
1129190|NCT01450865|axonal excitability
1129191|NCT01450865|myelinated nerve
1129192|NCT01450865|human
1129193|NCT01450865|ectopic discharge
1129194|NCT01450865|flupirtine
1129195|NCT01450852|Melanocortin Receptor
1129196|NCT01450852|Monocyte
1129197|NCT01450852|Resistance Training
1129198|NCT01450852|Inflammation
1129199|NCT01450852|Markers of Inflammation
1129200|NCT01450839|Transdermal Administration
1129201|NCT01450839|Japanese
1129202|NCT01450839|elderly
1129203|NCT01450839|male
1129204|NCT01450839|volunteers
1129205|NCT01450826|Chemotherapy induced nausea and vomiting
1129206|NCT01450826|CINV
1129207|NCT01450826|Glioma
1129208|NCT01450826|Temozolomide
1129209|NCT01450826|Temodar
1129210|NCT01450826|Aprepitant
1129211|NCT01450826|Emend
1129212|NCT01450826|Ondansetron
1129213|NCT01450826|Zofran
1129214|NCT01450826|Pro00031206
1129215|NCT01450826|Affronti
1129216|NCT01450826|Peters
1129217|NCT01450826|Duke
1129218|NCT01450826|Preston Robert Tisch Brain Tumor Center
1129219|NCT01450800|urinary tract infection
1129220|NCT01450800|gynecologic surgery
1129221|NCT01450800|post-operative complications
1129222|NCT01450800|nitrofurantoin
1129223|NCT01450787|dry eyes
1129224|NCT01450787|diabetes
1129225|NCT01450748|sodium alginate
1129226|NCT01450748|laryngopharyngeal reflux
1129227|NCT01450748|combined impedance-pH monitoring
1129228|NCT01450722|Chronic lower limb ischemia
1129229|NCT01450722|claudication
1129230|NCT01450722|chronic critical ischemia
1129231|NCT01450709|Probiotics
1129232|NCT01450709|Kibow Biotics
1129233|NCT01450709|Dialysis
1129234|NCT01450709|Gut based uremic toxin removal
1129235|NCT01450670|Probiotics
1129236|NCT01450670|Kibow Biotics
1129237|NCT01450670|Dialysis
1129238|NCT01450670|Gut based uremic toxin removal
1129239|NCT01450657|Chronic Kidney failure stage three and four
1129240|NCT01450657|Probiotics
1129241|NCT01450657|Kibow Biotics
1129242|NCT01450657|Dialysis
1129243|NCT01450657|Gut based uremic toxin removal
1129244|NCT01450644|Advanced
1129245|NCT01450644|Progressive
1129246|NCT01450644|Idiopathic Fibrotic Interstitial Lung Disease
1129247|NCT01450644|Palliative Care
1129248|NCT01450644|Randomised
1129249|NCT01450644|Controlled
1129250|NCT01450631|surgical site infection
1129251|NCT01450631|nosocomial infection
1129252|NCT01450631|post-operative complication
1129253|NCT01450631|surgical incision risk
1129254|NCT01450631|surgical incision infection
1129255|NCT01450631|negative pressure wound therapy
1129256|NCT01450631|wound management
1129257|NCT01450631|cesarean section surgery
1129258|NCT01450631|wound dehiscence
1129259|NCT01450631|wound infection
1129260|NCT01450631|surgical closure
1129261|NCT01450631|wound disruption
1129262|NCT01450631|subcutaneous approximation
1129263|NCT01450631|wound separation
1129264|NCT01450631|seroma
1129265|NCT01450631|hematoma
1129266|NCT01450631|subcutaneous closure
1129267|NCT01450631|obesity
1129268|NCT01450631|cesarean
1129269|NCT01450631|incision
1129270|NCT01450631|massive obesity
1129271|NCT01450631|obese
1129272|NCT01450631|pregnancy
1129273|NCT01450631|cesarean delivery
1129274|NCT01450631|superobesity
1129275|NCT01450631|wound complication
1129276|NCT01450592|Carbohydrate, Dietary
1129277|NCT01450579|Recombinant Influenza HA vaccine
1129278|NCT01450579|Immunogenicity of ASP7373
1129279|NCT01450566|ureteroscopy (URS)
1129280|NCT01450566|ureteral stent placement
1129281|NCT01450566|Ureteral Calculi
1129282|NCT01450566|Renal Calculi
1129283|NCT01450553|Tissue Collection
1129284|NCT01450553|Lung Cancer
1129285|NCT01450553|Non-Small Cell Lung Cancer
1129286|NCT01450553|Early Stage Lung Cancer
1129287|NCT01450527|Etiology and outcomes of ARDS
1129288|NCT01450488|primary progressive multiple sclerosis
1129289|NCT01450488|relapse-free secondary progressive multiple sclerosis
1129290|NCT01450449|GBM, fractionation, short course, standard course
1129291|NCT01450423|Epilepsy
1129292|NCT01450423|Physical activity
1129293|NCT01450423|Cardio exercise
1129294|NCT01450423|Physical fitness
1129295|NCT01450423|Cognitive function
1129296|NCT01450410|Dyslipemia, HDL composition
1129297|NCT01450397|Dupuytren's Contracture
1129298|NCT01450384|protocol specific
1129299|NCT01450371|Autonomic Nervous System
1129300|NCT01450371|Neuromodulation
1129301|NCT01450371|Blood flow control
1129302|NCT01450371|Exercise
1129303|NCT01450358|Sepsis
1129304|NCT01450358|Real time PCR
1129305|NCT01450358|Blood culture
1129306|NCT01450358|Bacteremia diagnosis
1129307|NCT01450358|Fungemia diagnosis
1129308|NCT01450345|Clinical diagnosis of inguinal hernia
1129309|NCT01450345|Patient undergo operation under daycare basis
1129310|NCT01450345|ASA I-II
1129311|NCT01450345|Written consent
1129312|NCT01450332|ACL
1129313|NCT01450332|arthroscopy
1129314|NCT01450332|ligament
1129315|NCT01450332|rupture
1129316|NCT01450332|reconstruction
1129317|NCT01450332|ACLR
1129318|NCT01450332|accelerated rehabilitation program
1129319|NCT01450319|K-RAS
1129320|NCT01450319|FcγRII/IIIa genotypes
1129321|NCT01450319|CRC
1129322|NCT01450319|Colorectal cancer
1129323|NCT01450293|Immune response
1129324|NCT01450267|Cystic Fibrosis
1129325|NCT01450267|Glutathione
1129326|NCT01450254|Hip Osteoarthritis
1129327|NCT01450254|Gait Patterns
1129328|NCT01450254|Neuromuscular retraining
1129329|NCT01450241|Febrile neutropenia
1129330|NCT01450241|Unexplained fever
1129331|NCT01450241|Duration
1129332|NCT01450241|Short-term antibiotic treatment
1129333|NCT01450228|primary insomnia
1129334|NCT01450215|Relapsed and refractory Multiple Myeloma
1129335|NCT01450202|Carbon dioxide insufflation
1129336|NCT01450202|Colonoscopy
1129337|NCT01450202|Esophagogastroduodenoscopy
1129338|NCT01450202|Bowel insufflation
1129339|NCT01450202|Postprocedure pain
1129340|NCT01450202|Pain Due to Certain Specified Procedures
1129341|NCT01450189|Acute HIV
1129342|NCT01450189|Transmission Prevention
1129343|NCT01450189|Randomized Pilot study
1129344|NCT01450176|eye
1129345|NCT01450176|itching
1129346|NCT01450176|allergies
1129347|NCT01450163|Neuropathic pain
1129348|NCT01450163|prevention
1129349|NCT01450163|prophylaxis
1129350|NCT01450163|chemotherapy
1129351|NCT01450163|neuropathy
1129352|NCT01450163|Oxaliplatin
1129353|NCT01450163|pregabalin
1129354|NCT01450150|Major Depression
1129355|NCT01450150|Transcranial Direct Current Stimulation
1129356|NCT01450150|Randomized, Sham-Controlled Trial
1129357|NCT01450150|tDCS
1129358|NCT01450137|Giant Cell Arteritis
1129359|NCT01450137|Tocilizumab
1129360|NCT01450137|Antibodies, Monoclonal
1129361|NCT01450137|Glucocorticoids
1129362|NCT01450111|Lacosamide
1129363|NCT01450059|Human Immunodeficiency Virus
1129364|NCT01450059|Microchimerism
1129365|NCT01450059|Maternal-Fetal Exchange
1129366|NCT01450059|Gestation
1129367|NCT01450059|HiV-vertical transmission
1129368|NCT01450046|pancreas
1129369|NCT01450046|gastrointestinal
1129370|NCT01450046|GI
1129371|NCT01450046|prevention
1129372|NCT01450046|vitamin E
1129373|NCT01450033|kidney
1129374|NCT01450033|renal
1129375|NCT01450033|transplant
1129376|NCT01450033|transplantation
1129377|NCT01450033|adolescent
1129378|NCT01450033|pediatric
1129379|NCT01450033|mentor
1129380|NCT01450033|mentoring
1129381|NCT01450033|medication
1129382|NCT01450033|adherence
1129383|NCT01450033|immunosuppressant
1129384|NCT01450033|heart
1129385|NCT01450033|liver
1129386|NCT01450020|cancer survivor
1129387|NCT01450007|Pain blockade
1129388|NCT01450007|Ropivacaine
1129389|NCT01450007|Dexamethasone
1129390|NCT01449994|knee
1129391|NCT01449994|hip
1129392|NCT01449994|ankle
1129393|NCT01449994|foot
1129394|NCT01449994|pain
1129395|NCT01449994|lower limb
1129396|NCT01449994|activator
1129397|NCT01449994|instrumental
1129398|NCT01449994|chiropractic
1129399|NCT01449994|Painful functional conditions of the lower extremity
1129400|NCT01449981|Adolescents
1129401|NCT01449981|Alcohol Abuse
1129402|NCT01449981|Alcohol Dependence
1129403|NCT01449981|Drug Abuse
1129404|NCT01449981|Drug Dependence
1129405|NCT01449981|Substance Use Disorder
1129406|NCT01449981|Alcoholics Anonymous
1129407|NCT01449981|Motivational Enhancement Therapy
1129408|NCT01449981|Cognitive Behavioral Therapy
1129409|NCT01449955|PTSD
1129410|NCT01449942|Nasopharyngeal carcinoma
1129411|NCT01449942|EBV
1129412|NCT01449942|LMP1
1129413|NCT01449929|ritonavir
1129414|NCT01449929|HIV
1129415|NCT01449929|HAART
1129416|NCT01449929|darunavir
1129417|NCT01449929|antiretroviral
1129418|NCT01449929|dolutegravir
1129419|NCT01449929|GSK1349572
1129420|NCT01449916|Sepsis
1129421|NCT01449916|Severe Sepsis
1129422|NCT01449916|Protocol
1129423|NCT01449916|Zambia
1129424|NCT01449890|follow up care
1129425|NCT01449890|e-mail
1129426|NCT01449890|effectiveness
1129427|NCT01449890|depressive disorders
1129428|NCT01449877|Ocular Toxoplasmosis
1129429|NCT01449877|Retinochoroiditis
1129430|NCT01449877|Prophylaxis
1129431|NCT01449864|upper GI malignancies
1129432|NCT01449864|concurrent chemoradiation with continuous infusion 5-Fluorouracil chemotherapy
1129433|NCT01449825|hepatic safety
1129434|NCT01449825|prescriber compliance
1129435|NCT01449825|pazopanib
1129436|NCT01449825|epidemiology
1129437|NCT01449812|combination vaccine
1129438|NCT01449812|booster vaccination
1129439|NCT01449786|Mal d 1, Bet v 1, sublingual immunotherapy,
1129440|NCT01449760|Ankle sprain
1129441|NCT01449760|Balance
1129442|NCT01449760|Gait
1129443|NCT01449747|Type 2 diabetes mellitus
1129444|NCT01449747|Dipeptidyl peptidase IV inhibitors
1129445|NCT01449747|Glucagon-like peptide 1
1129446|NCT01449721|Sepsis
1129447|NCT01449721|Multiple organ failure
1129448|NCT01449721|Resuscitation
1129449|NCT01449708|Bariatric Surgery
1129450|NCT01449708|TIVA
1129451|NCT01449708|PONV
1129452|NCT01449708|non-opioid
1129453|NCT01449708|OSA
1129454|NCT01449695|PAD
1129455|NCT01449695|CVA
1129456|NCT01449695|ACS
1129457|NCT01449682|BRVO
1129458|NCT01449682|CRVO
1129459|NCT01449682|Macular Edema
1129460|NCT01449682|Anti-VEGF
1129461|NCT01449682|Ozurdex
1129462|NCT01449669|pharmacokinetics
1129463|NCT01449669|cefazolin
1129464|NCT01449669|microdialysis sampling
1129465|NCT01449669|interstitial fluid
1129466|NCT01449669|skeletal muscle
1129467|NCT01449669|plasma
1129468|NCT01449669|children
1129469|NCT01449643|Obesity
1129470|NCT01449643|Diaphragm
1129471|NCT01449643|Inspiratory muscular training
1129472|NCT01449617|Carotid stenosis
1129473|NCT01449617|Aspirin plus Clopidogrel
1129474|NCT01449617|Residual platelet reactivity
1129475|NCT01449604|Stereotactic radiotherapy
1129476|NCT01449604|SRS
1129477|NCT01449604|SRT
1129478|NCT01449604|vestibular schwannoma
1129479|NCT01449591|BFH772
1129480|NCT01449591|rosacea
1129481|NCT01449591|erythemato-telangiectatic rosacea
1129482|NCT01449565|methamphetamine
1129483|NCT01449565|high-risk sexual behavior
1129484|NCT01449565|HIV prevention
1129485|NCT01449539|Hyperbaric oxygen
1129486|NCT01449539|mobilize
1129487|NCT01449539|stem cells
1129488|NCT01449539|growth factor
1129489|NCT01449526|contact lens
1129490|NCT01449500|Dyspeptic H.pylori-infection
1129491|NCT01449487|Experimental pain
1129492|NCT01449487|IBS
1129493|NCT01449487|Rectum
1129494|NCT01449461|Advanced Malignancies
1129495|NCT01449461|Carcinoma, Non-Small-Cell Lung
1129496|NCT01449461|Anaplastic Large Cell Lymphoma
1129497|NCT01449461|Diffuse Large Cell Lymphoma
1129498|NCT01449461|Inflammatory Myofibroblastic Tumors
1129499|NCT01449461|Anaplastic Lymphoma Kinase (ALK)
1129500|NCT01449461|Epidermal Growth Factor Receptor (EGFR)
1129501|NCT01449461|Advanced Cancers
1129502|NCT01449461|AP26113
1129503|NCT01449448|pain relief
1129504|NCT01449448|Hypermobility, Joint
1129505|NCT01449448|increased strength
1129506|NCT01449448|increased patient satisfaction
1129507|NCT01449435|Asthma
1129508|NCT01449435|children
1129509|NCT01449435|predictors of exacerbation
1129510|NCT01449435|Methacholine challenge
1129511|NCT01449435|Pulmonary function testing
1129512|NCT01449409|Uncontrolled asthma
1129513|NCT01449409|Asthma risk
1129514|NCT01449409|Asthma impairment
1129515|NCT01449409|Real time asthma outreach program
1129516|NCT01449396|acupuncture
1129517|NCT01449396|in vitro fertilization
1129518|NCT01449396|embryo transfer
1129519|NCT01449383|cross over
1129520|NCT01449383|dietary intervention
1129521|NCT01449383|fibre
1129522|NCT01449383|red meat
1129523|NCT01449383|microbiota
1129524|NCT01449370|INK1117
1129525|NCT01449370|PIK3CA
1129526|NCT01449370|KINASE
1129527|NCT01449370|TUMOR
1129528|NCT01449370|CANCER
1129529|NCT01449370|Locally advanced or metastatic solid tumors
1129530|NCT01449370|not eligible for standard of care therapy
1129531|NCT01449357|NSCLC
1129532|NCT01449357|Zalutumumab
1129533|NCT01449357|Efficacy
1129534|NCT01449357|Safety
1129535|NCT01449344|relapsed
1129536|NCT01449344|refractory
1129537|NCT01449318|Pain
1129538|NCT01449318|quantitative sensory testing
1129539|NCT01449292|PLVR
1129540|NCT01449292|ELVR
1129541|NCT01449292|AeriSeal System
1129542|NCT01449292|foam sealant
1129543|NCT01449292|emphysematous lung sealant
1129544|NCT01449292|ELS
1129545|NCT01449292|COPD
1129546|NCT01449292|emphysema
1129547|NCT01449292|polymeric lung volume reduction
1129548|NCT01449292|heterogeneous
1129549|NCT01449292|Respiratory Tract Diseases
1129550|NCT01449292|Lung Diseases
1129551|NCT01449292|Chronic Obstructive Pulmonary Disease
1129552|NCT01449266|Dotarem
1129553|NCT01449266|Dialyses
1129554|NCT01449266|Dialysed
1129555|NCT01449266|Safety
1129556|NCT01449266|Safety and dialysability of Dotarem in dialysed patients
1129557|NCT01449240|Hunter syndrome
1129558|NCT01449240|Mucopolysaccharidosis II
1129559|NCT01449240|Iduronate 2-Sulfatase Deficiency
1129560|NCT01449240|Lumbar puncture
1129561|NCT01449240|Cerebrospinal fluid (CSF)
1129562|NCT01449240|Pediatric
1129563|NCT01449240|Adult
1129564|NCT01449240|Biomarkers
1129565|NCT01449227|adhesive capsulitis
1129566|NCT01449227|hip
1129567|NCT01449214|Thoracic epidural
1129568|NCT01449214|Epidural anesthesia
1129569|NCT01449214|Ultrasound
1129570|NCT01449214|Palpation
1129571|NCT01449214|Thoracic spine
1129572|NCT01449201|PF-00299804, head and neck cancer, squamous cell carcinoma
1129573|NCT01449188|ondansetron
1129574|NCT01449188|moxifloxacin
1129575|NCT01449188|Zofran
1129576|NCT01449188|thorough QT study
1129577|NCT01449188|IV
1129578|NCT01449175|AeriSeal
1129579|NCT01449175|treatment
1129580|NCT01449175|device
1129581|NCT01449175|breathing
1129582|NCT01449175|COPD
1129583|NCT01449175|emphysema
1129584|NCT01449175|polymeric lung volume reduction (PLVR)
1129585|NCT01449175|biologic lung volume reduction (BLVR)
1129586|NCT01449175|heterogeneous
1129587|NCT01449175|homogeneous
1129588|NCT01449175|Respiratory Tract Diseases
1129589|NCT01449175|Lung Diseases
1129590|NCT01449175|Pulmonary Disease, Chronic Obstructive
1129591|NCT01449162|severe persistent asthma
1129592|NCT01449162|patients treated with oral corticosteroids
1129593|NCT01449149|Age 18 or greater
1129594|NCT01449149|No prior radiation
1129595|NCT01449136|Antibacterial agents
1129596|NCT01449136|Deciduous Teeth
1129597|NCT01449136|Clinical Trial
1129598|NCT01449123|Asthma
1129599|NCT01449123|mannitol challenge test
1129600|NCT01449123|Sweden
1129601|NCT01449123|primary care
1129602|NCT01449110|Primary prevention
1129603|NCT01449110|Secondary prevention
1129604|NCT01449110|Resveratrol
1129605|NCT01449110|Grape
1129606|NCT01449110|Cardiovascular
1129607|NCT01449110|Nutraceutical
1129608|NCT01449110|Food complement
1129609|NCT01449097|Adductor-Canal-blockade,
1129610|NCT01449097|human volunteers,
1129611|NCT01449097|US-guided nerve block
1129612|NCT01449097|femoral nerve block
1129613|NCT01449084|Pancreatic duct stenting
1129614|NCT01449084|Post-endoscopic pancreatitis
1129615|NCT01449071|Lupus
1129616|NCT01449071|Monoclonal antibody
1129617|NCT01449071|B-cell immunotherapy
1129618|NCT01449071|Epratuzumab
1129619|NCT01449058|Advanced solid tumor,
1129620|NCT01449058|AML
1129621|NCT01449058|high risk and very high risk MDS
1129622|NCT01449058|dose escalation,
1129623|NCT01449058|RAS/BRAF mutation,
1129624|NCT01449058|PI3K inhibitor,
1129625|NCT01449058|MEK inhibitor,
1129626|NCT01449058|BYL719,
1129627|NCT01449058|MEK162
1129628|NCT01449045|IPTc
1129629|NCT01449045|Community Case Management
1129630|NCT01449045|Home Management for malaria
1129631|NCT01449032|Patients
1129632|NCT01449019|GLP-1
1129633|NCT01449019|Exendin(9-39)
1129634|NCT01449019|Insulin
1129635|NCT01449019|Glucagon
1129636|NCT01449019|T2DM
1129637|NCT01449019|incretin effect
1129638|NCT01449019|human physiology
1129639|NCT01449006|HIV
1129640|NCT01449006|HAND
1129641|NCT01449006|Maraviroc
1129642|NCT01449006|Neurocognitive
1129643|NCT01449006|Neurology
1129644|NCT01449006|Human Immunodeficiency Virus
1129645|NCT01449006|HIV Associated Neurocognitive Disorders
1129646|NCT01448980|massage
1129647|NCT01448980|stroke spasticity
1129648|NCT01448928|Zevalin
1129649|NCT01448928|CD20+
1129650|NCT01448928|Non-Hodgkin's Lymphoma
1129651|NCT01448928|Mantle Cell Lymphoma
1129652|NCT01448915|HIV
1129653|NCT01448915|Human immunodeficiency virus
1129654|NCT01448915|Acquired Immune Deficiency Syndrome Virus
1129655|NCT01448915|AIDS virus
1129656|NCT01448915|Immunodeficiency Virus, Human
1129657|NCT01448915|Virus, Human Immunodeficiency
1129658|NCT01448915|Hepatitis C
1129659|NCT01448915|Hepatitis C, chronic
1129660|NCT01448915|Hepatitis C virus
1129661|NCT01448915|Hepatitis C antibodies
1129662|NCT01448915|Hepatitis C antigens
1129663|NCT01448902|Allergic rhinitis
1129664|NCT01448902|CRTH2
1129665|NCT01448889|contrast induced nephropathy
1129666|NCT01448889|oxigen
1129667|NCT01448889|coronary angiography
1129668|NCT01448876|Chlamydia trachomatis
1129669|NCT01448876|anorectal
1129670|NCT01448876|cervicovaginal
1129671|NCT01448876|MSM
1129672|NCT01448876|women
1129673|NCT01448876|treatment
1129674|NCT01448876|RNA
1129675|NCT01448876|bacterial load
1129676|NCT01448876|sexual behaviour
1129677|NCT01448876|Azythromycin treated
1129678|NCT01448850|Chronic Obstructive Pulmonary Disease (COPD)
1129679|NCT01448850|MEDI8968
1129680|NCT01448824|Low High-density Lipoprotein (HDL)
1129681|NCT01448824|Cholesterol (HDL-C)
1129682|NCT01448798|radical prostatectomy
1129683|NCT01448798|robotic surgery
1129684|NCT01448798|erectile dysfunction
1129685|NCT01448798|continence
1129686|NCT01448785|obesity
1129687|NCT01448785|gastric stimulation
1129688|NCT01448785|morbid obesity
1129689|NCT01448772|Dronabinol
1129690|NCT01448772|fasting
1129691|NCT01448759|Patients receiving docetaxel or paclitaxel. All tumors.
1129692|NCT01448746|gastric cancer
1129693|NCT01448746|VTE
1129694|NCT01448746|incidence
1129695|NCT01448733|acne vulgaris
1129696|NCT01448720|Schizophrenia
1129697|NCT01448720|Paliperidone palmitate
1129698|NCT01448720|Long-acting injectable antipsychotic medication
1129699|NCT01448707|Darunavir (DRV)
1129700|NCT01448707|TMC114
1129701|NCT01448707|Prezista
1129702|NCT01448707|HIV
1129703|NCT01448707|virologic response
1129704|NCT01448707|neurocognitive function
1129705|NCT01448694|Hemorrhage
1129706|NCT01448681|Intracranial Hypertension
1129707|NCT01448681|Elevated ICP (Intracranial Pressure)
1129708|NCT01448668|pancreatic cancer
1129709|NCT01448668|mistletoe
1129710|NCT01448668|supportive treatment
1129711|NCT01448668|long-term study
1129712|NCT01448668|non-interventional cohort study
1129713|NCT01448668|controlled study with parallel groups
1129714|NCT01448655|colorectal cancer
1129715|NCT01448655|mistletoe
1129716|NCT01448655|supportive treatment
1129717|NCT01448655|long-term study
1129718|NCT01448655|non-interventional cohort study
1129719|NCT01448655|controlled study with parallel groups
1129720|NCT01448603|Ragweed allergy
1129721|NCT01448603|ToleroMune ragweed
1129722|NCT01448603|immunotherapy
1129723|NCT01448590|post dural puncture headache
1129724|NCT01448590|accidental dural puncture
1129725|NCT01448590|PDPH
1129726|NCT01448590|ADP
1129727|NCT01448590|spinal catheter
1129728|NCT01448590|epidural catheter
1129729|NCT01448590|intrathecal catheter
1129730|NCT01448590|dural puncture
1129731|NCT01448590|systemic review
1129732|NCT01448564|Chronic Obstructive Pulmonary Disease
1129733|NCT01448564|Fatigue
1129734|NCT01448564|laser therapy
1129735|NCT01448551|Obesity
1129736|NCT01448551|Treatment
1129737|NCT01448551|Adolescents
1129738|NCT01448551|Text Messages
1129739|NCT01448551|Mobile phones
1129740|NCT01448551|Multidisciplinary
1129741|NCT01448538|Medication Non-Adherence
1129742|NCT01448538|Medication Persistence
1129743|NCT01448538|wet macular degeneration
1129744|NCT01448512|HIV
1129745|NCT01448512|Pregnancy
1129746|NCT01448512|Prevention
1129747|NCT01448512|Couples
1129748|NCT01448499|schizophrenia
1129749|NCT01448499|clozapine
1129750|NCT01448499|amisulpride
1129751|NCT01448499|combination
1129752|NCT01448499|treatment resistant
1129753|NCT01448486|HIV
1129754|NCT01448486|HAND
1129755|NCT01448486|Human Immunodeficiency Virus
1129756|NCT01448486|Raltegravir
1129757|NCT01448486|HIV Associated Neurocognitive Disorders
1129758|NCT01448486|Neuro-HAART
1129759|NCT01448486|Neurocognitive
1129760|NCT01448486|Neurology
1129761|NCT01448473|Head trauma
1129762|NCT01448473|Children
1129763|NCT01448473|Radiography
1129764|NCT01448434|Osteoarthritis
1129765|NCT01448434|Knee
1129766|NCT01448434|Stem cell
1129767|NCT01448434|MSC
1129768|NCT01448421|TAVR
1129769|NCT01448408|Forme Fruste Keratoconus
1129770|NCT01448408|Corneal Biomechanical properties
1129771|NCT01448408|Anterior Segment Parameters
1129772|NCT01448408|Diagnostic Capacity
1129773|NCT01448395|Mass Balance
1129774|NCT01448395|Metabolite Identification and Profiling
1129775|NCT01448395|Metabolite profile and Identification of [14C]NXL104
1129776|NCT01448395|Mass Balance Recovery
1129777|NCT01448369|meibomian gland dysfunction
1129778|NCT01448369|hot compress
1129779|NCT01448369|eyelid warming
1129780|NCT01448369|meibum
1129781|NCT01448356|Controlled adverse chamber
1129782|NCT01448356|tear film stability
1129783|NCT01448356|tear film evaporation
1129784|NCT01448356|tear film break up time
1129785|NCT01448356|humidity
1129786|NCT01448356|temperature
1129787|NCT01448343|transfusion
1129788|NCT01448343|potassium
1129789|NCT01448330|clopidogrel
1129790|NCT01448330|aspinin
1129791|NCT01448330|combination
1129792|NCT01448291|Contraception
1129793|NCT01448291|Nuvaring
1129794|NCT01448291|Vaginal inflammation
1129795|NCT01448291|Bacterial vaginosis
1129796|NCT01448291|Nugent score
1129797|NCT01448278|Anterior cruciate ligament
1129798|NCT01448278|Arthroscopy
1129799|NCT01448278|Incomplete bone tunnels
1129800|NCT01448278|Anterior cruciate ligament reconstruction
1129801|NCT01448265|atrial fibrillation
1129802|NCT01448265|catheter ablation
1129803|NCT01448265|circular mapping catheter
1129804|NCT01448265|cryoballoon
1129805|NCT01448252|T cell vaccination
1129806|NCT01448252|Immunotherapy
1129807|NCT01448252|Tolerance
1129808|NCT01448252|safety
1129809|NCT01448252|clinical efficacy
1129810|NCT01448213|DMEK
1129811|NCT01448213|Rejection
1129812|NCT01448213|Corticosteroid
1129813|NCT01448200|hepatitis C
1129814|NCT01448200|NS5A inhibitor
1129815|NCT01448200|Phase 1
1129816|NCT01448200|genotype-1
1129817|NCT01448200|genotype-2
1129818|NCT01448200|genotype-3
1129819|NCT01448187|Lung cancer, France
1129820|NCT01448174|salusin-alpha
1129821|NCT01448174|atorvastatin
1129822|NCT01448174|CD36
1129823|NCT01448174|Hemodialysis
1129824|NCT01448161|Pediatric
1129825|NCT01448161|Adult
1129826|NCT01448161|ICU
1129827|NCT01448148|Mild cognitive impairment
1129828|NCT01448122|Prevention of pigmentation
1129829|NCT01448109|Sepsis
1129830|NCT01448109|Corticosteroid
1129831|NCT01448096|primary breast diffuse large B cell lymphoma
1129832|NCT01448096|rituximab
1130202|NCT01446757|geriatric competence
1129833|NCT01448096|prophylactic intrathecal chemotherapy
1129834|NCT01448096|CNS recurrence
1129835|NCT01448083|I-131 MIBG therapy
1129836|NCT01448083|whole body I-123 MIBG scintigraphy
1129837|NCT01448057|Paracetamol
1129838|NCT01448057|dimethindene maleate
1129839|NCT01448057|phenylephrine hydrochloride
1129840|NCT01448057|cold and flu symptoms
1129841|NCT01448044|hepatitis C virus
1129842|NCT01448031|Acetyl Salicylic Acid
1129843|NCT01448031|Bioavailability
1129844|NCT01448031|Healthy Volunteers
1129845|NCT01448005|Coronary Artery Bypass Grafting
1129846|NCT01448005|Resuscitation
1129847|NCT01448005|Sudden Cardiac Death
1129848|NCT01448005|Ventricular Dysfunction
1129849|NCT01447992|Artificial Pancreas
1129850|NCT01447992|Insulin Pump
1129851|NCT01447992|Continuous Glucose Monitor
1129852|NCT01447992|Closed Loop
1129853|NCT01447979|Artificial Pancreas
1129854|NCT01447979|Insulin Pump
1129855|NCT01447979|Continuous Glucose Monitor
1129856|NCT01447979|Closed Loop
1129857|NCT01447966|OCD
1129858|NCT01447966|Obsessive Compulsive Disorder
1129859|NCT01447966|Child
1129860|NCT01447966|Pediatric
1129861|NCT01447966|CBT
1129862|NCT01447966|Therapy
1129863|NCT01447966|ERP
1129864|NCT01447966|Exposure Response Prevention
1129865|NCT01447966|Preschool
1129866|NCT01447966|Cognitive Behavioral
1129867|NCT01447953|Activity
1129868|NCT01447953|disability
1129869|NCT01447953|life-role
1129870|NCT01447953|multimodal rehabilitation
1129871|NCT01447953|primary health care
1129872|NCT01447953|persistent pain
1129873|NCT01447953|randomized controlled trial
1129874|NCT01447953|Musculoskeletal back pain
1129875|NCT01447940|Telemedicine
1129876|NCT01447940|Type 1 diabetes
1129877|NCT01447940|economic cost of Type 1 diabetes
1129878|NCT01447940|ePortal Meos
1129879|NCT01447914|c-Met Inhibitor ARQ-197
1129880|NCT01447914|tivantinib
1129881|NCT01447914|multiple myeloma
1129882|NCT01447914|plasma cell proliferative disorder
1129883|NCT01447914|Hypercalcemia
1129884|NCT01447914|hematologic malignancy
1129885|NCT01447914|plasma cell dyscrasia
1129886|NCT01447914|cast nephropathy
1129887|NCT01447914|amyloidosis
1129888|NCT01447914|osteolysis
1129889|NCT01447914|Renal insufficiency
1129890|NCT01447914|Anemia
1129891|NCT01447914|Bone lytic lesions
1129892|NCT01447914|severe osteopenia
1129893|NCT01447914|pathologic fractures
1129894|NCT01447914|biopsy-proven plasmacytoma
1129895|NCT01447901|Hyperlipoproteinemia Type I
1129896|NCT01447888|Spine surgery
1129897|NCT01447888|Chronic pain
1129898|NCT01447888|Opioid tolerant
1129899|NCT01447888|Pain management in spine surgery patients
1129900|NCT01447862|recent-onset
1129901|NCT01447849|Chronic Constipation
1129902|NCT01447836|indocyanine green
1129903|NCT01447836|sepsis
1129904|NCT01447836|liver injury
1129905|NCT01447836|abdominal perfusion pressure
1129906|NCT01447823|Oesophageal bolus obstruction
1129907|NCT01447823|Gastroscopy
1129908|NCT01447823|phmetry
1129909|NCT01447810|Constraint-Induced Movement therapy
1129910|NCT01447810|Pediatric
1129911|NCT01447810|Hemiplegia
1129912|NCT01447810|Brain Tumor
1129913|NCT01447810|Rehabilitation
1129914|NCT01447797|Irbesartan
1129915|NCT01447797|Atorvastatin
1129916|NCT01447797|combination
1129917|NCT01447784|HDM allergy
1129918|NCT01447784|Rhinoconunctivitis
1129919|NCT01447784|Environmental Exposure Chamber
1129920|NCT01447784|Immunotherapy
1129921|NCT01447784|ToleroMune HDM
1129922|NCT01447771|Decision making
1129923|NCT01447771|Decisional aide
1129924|NCT01447745|Visceral obesity
1129925|NCT01447745|Cardiometabolic risk
1129926|NCT01447745|Atherosclerosis
1129927|NCT01447745|Ectopic fat
1129928|NCT01447745|Carotid plaque
1129929|NCT01447745|Magnetic resonance imaging (MRI)
1129930|NCT01447745|Computed tomography (CT)
1129931|NCT01447732|Monoclonal antibody (Mab)
1129932|NCT01447732|Antibody dependent cellular cytotoxicity (ADCC)
1129933|NCT01447732|Complement-dependent toxicity (CDC)
1129934|NCT01447732|Non-fucosylated immunoglobulin G
1129935|NCT01447706|Ovarian Cancer
1129936|NCT01447706|Platinum-resistant
1129937|NCT01447706|Platinum-refractory
1129938|NCT01447706|Fallopian tube cancer
1129939|NCT01447706|Peritoneal Cancer
1129940|NCT01447706|Paclitaxel
1129941|NCT01447706|ErbB3
1129942|NCT01447706|Phase II
1129943|NCT01447706|locally advanced/metastatic or recurrent
1129944|NCT01447693|uremia
1129945|NCT01447693|pruritus
1129946|NCT01447693|oliva-omega 3
1129947|NCT01447680|HIV infection
1129948|NCT01447680|HCV infection
1129949|NCT01447680|SMARTube
1129950|NCT01447680|SMARTplasma
1129951|NCT01447667|Hepatic fibrosis
1129952|NCT01447667|Magnetic resonance elastography
1129953|NCT01447667|Hepatocellular carcinoma
1129954|NCT01447667|Recurrence
1129955|NCT01447654|Hypertrophic cardiomyopathy
1129956|NCT01447654|Hypertrophic obstructive cardiomyopathy
1129957|NCT01447654|Hypertrophy
1129958|NCT01447654|Losartan
1129959|NCT01447654|Angiotensin II receptor antagonist
1129960|NCT01447641|Cluster Headache
1129961|NCT01447641|Trigeminal Autonomic Cephalalgias
1129962|NCT01447641|Sleep
1129963|NCT01447641|Circadian Rhythms
1129964|NCT01447628|Idiopathic pulmonary arterial hypertension (IPAH)
1129965|NCT01447628|Iron deficiency
1129966|NCT01447615|Orphaned children and youth
1129967|NCT01447615|Economic empowerment
1129968|NCT01447615|Uganda
1129969|NCT01447615|HIV/AIDS
1129970|NCT01447615|Sub-Saharan Africa
1129971|NCT01447602|Major Depressive Disorder (MDD)
1129972|NCT01447602|Dysthymia
1129973|NCT01447602|Depressive Disorder Not Otherwise Specified (DDNOS)
1129974|NCT01447589|Radiosensitiser
1129975|NCT01447563|Bioequivalence
1129976|NCT01447563|Bioavailability
1129977|NCT01447550|Bosentan
1129978|NCT01447550|Buerguer disease
1129979|NCT01447537|Cirrhosis
1129980|NCT01447537|Exercise
1129981|NCT01447537|Relaxation
1129982|NCT01447537|Muscle mass
1129983|NCT01447537|Effort tolerance
1129984|NCT01447511|Drug Interactions
1129985|NCT01447511|Warfarin
1129986|NCT01447511|Genetics
1129987|NCT01447511|CYP2C9
1129988|NCT01447511|Healthy Volunteers
1129989|NCT01447485|Hypertension, chronic kidney disease
1129990|NCT01447485|nephrotic syndrome
1129991|NCT01447485|pharmacokinetics
1129992|NCT01447472|MDMA,
1129993|NCT01447472|pharmacokinetics,
1129994|NCT01447472|pharmacodynamics,
1129995|NCT01447472|CYP2D6, COMT,
1129996|NCT01447472|SERT, 5-HTTLPR, gender,
1129997|NCT01447472|dextromethorphan,
1129998|NCT01447472|caffeine.
1129999|NCT01447459|Asthma
1130000|NCT01447459|Asthma Education
1130001|NCT01447433|Calcium Carbonate
1130002|NCT01447433|Vitamin D
1130003|NCT01447433|Body weight
1130004|NCT01447433|Body fat
1130005|NCT01447433|Metabolic parameters
1130006|NCT01447433|Energy restriction
1130007|NCT01447433|Very-low calcium consumers
1130008|NCT01447433|Obesity
1130009|NCT01447433|Overweight
1130010|NCT01447407|Staphylococcal infections
1130011|NCT01447407|Yeast infections
1130012|NCT01447407|Candidiasis
1130013|NCT01447368|chronic kidney disease
1130014|NCT01447368|peritoneal dialysis
1130015|NCT01447368|secondary hyperparathyroidism
1130016|NCT01447368|parathyroidectomy
1130017|NCT01447368|vascular calcification
1130018|NCT01447368|cinacalcet
1130019|NCT01447329|pain
1130020|NCT01447329|acupuncture
1130021|NCT01447329|knee
1130022|NCT01447329|debridement
1130023|NCT01447329|surgery
1130024|NCT01447329|arthroscopic knee surgery debridement
1130025|NCT01447316|body composition
1130026|NCT01447316|gait
1130027|NCT01447316|quality of life
1130028|NCT01447316|Patients
1130029|NCT01447316|undergoing
1130030|NCT01447316|bariatric surgery.
1130031|NCT01447303|knee
1130032|NCT01447303|osteoarthritis
1130033|NCT01447303|hyaluronic acid
1130034|NCT01447303|viscosupplementation
1130035|NCT01447290|preeclampsia
1130036|NCT01447290|protein
1130037|NCT01447290|creatinine
1130038|NCT01447290|protein:creatinine ratio
1130039|NCT01447277|ACL reconstruction
1130040|NCT01447277|Femoral Block
1130041|NCT01447277|Sciatic Block
1130042|NCT01447264|Rheumatoid arthritis
1130043|NCT01447264|Muscle strength
1130044|NCT01447264|Body composition
1130045|NCT01447264|Physical activity
1130046|NCT01447264|Water exercises
1130047|NCT01447264|Hydrotherapy
1130048|NCT01447264|Randomized controlled clinical trial
1130049|NCT01447251|Obstructive Sleep Apnea
1130050|NCT01447251|Diabetes Mellitus type 2
1130051|NCT01447251|DM2
1130052|NCT01447251|OSA
1130053|NCT01447251|CPAP
1130054|NCT01447251|continuous positive airway pressure
1130055|NCT01447238|pancreatic cysts
1130056|NCT01447238|EUS/FNA
1130057|NCT01447238|Needle-based Confocal Laser Endomicroscopy (nCLE)
1130058|NCT01447238|fiber optic imaging
1130059|NCT01447238|EUS/FNA of pancreatic cysts
1130060|NCT01447225|Advanced-stage
1130061|NCT01447225|Solid Tumors
1130062|NCT01447225|MM-121
1130063|NCT01447225|Carboplatin
1130064|NCT01447225|Pemetrexed
1130065|NCT01447225|Gemcitabine
1130066|NCT01447225|Cabazitaxel
1130067|NCT01447225|ErbB3
1130068|NCT01447225|Phase I
1130069|NCT01447225|Cancer
1130070|NCT01447212|Opioid Dependence
1130071|NCT01447212|Long-term Opioid Injectors
1130072|NCT01447212|Opioid Substitution Treatment
1130073|NCT01447212|Hydromorphone
1130074|NCT01447212|Diamorphine
1130075|NCT01447212|Diacetylmorphine
1130076|NCT01447199|Bladder cancer
1130077|NCT01447199|Colorectal cancer
1130078|NCT01447199|Endometrial cancer
1130079|NCT01447199|Kidney cancer
1130080|NCT01447199|Skin cancer
1130081|NCT01447199|Uterus cancer
1130082|NCT01447199|Molecular Predisposition
1130083|NCT01447199|Hereditary Nonpolyposis Colon Cancer
1130084|NCT01447199|HNPCC
1130085|NCT01447199|Molecular genetic testing
1130086|NCT01447199|Gene mutations
1130087|NCT01447199|Mutation analyses
1130088|NCT01447199|Genetic polymorphisms
1130089|NCT01447199|Family history of cancer
1130090|NCT01447199|Early age of cancer onset
1130091|NCT01447199|Little/no personal or family history of cancer
1130092|NCT01447199|Spouses
1130093|NCT01447199|Questionnaires
1130094|NCT01447199|Blood sample
1130095|NCT01447199|Saliva Sample
1130096|NCT01447186|Prostate cancer screening
1130097|NCT01447186|Prostate Cancer
1130098|NCT01447186|Patient Decision Aid
1130099|NCT01447186|Spanish Speaking Men
1130100|NCT01447186|Spanish-language slide set
1130101|NCT01447186|Focus group
1130102|NCT01447186|Interview
1130103|NCT01447186|Survey
1130104|NCT01447173|Asthma
1130105|NCT01447173|Pulmonary Function Test
1130106|NCT01447173|Vitamin D
1130107|NCT01447160|facet joint
1130108|NCT01447160|back pain
1130109|NCT01447160|osteoarthritis
1130110|NCT01447160|infiltration
1130111|NCT01447108|Trigeminal Neuralgia
1130112|NCT01447108|Tic Douloureux
1130113|NCT01447108|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound
1130114|NCT01447095|Subarachnoid hemorrhage
1130115|NCT01447095|vasospasm
1130116|NCT01447095|prostacyclin
1130117|NCT01447082|atypical
1130118|NCT01447082|antipsychotics
1130119|NCT01447082|quetiapine
1130120|NCT01447069|heart failure stage 3
1130121|NCT01447069|beta 2 agonist
1130122|NCT01447069|N-terminal pro-brain natriuretic peptide
1130123|NCT01447069|ejection fraction <35%
1130124|NCT01447056|Hodgkin lymphoma
1130125|NCT01447056|Non-Hodgkin lymphoma
1130126|NCT01447056|Lymphoproliferative disorder
1130127|NCT01447056|Nasopharyngeal carcinoma
1130128|NCT01447056|Leiomyosarcoma
1130129|NCT01447056|EBV Cytotoxic T Lymphocytes
1130130|NCT01447043|retrospective studies
1130131|NCT01447030|Biliary strictur
1130132|NCT01447030|Hepatojejunostomy
1130133|NCT01447030|Iatrogenic major bile duct injury
1130134|NCT01446991|prostate neoplasm
1130135|NCT01446991|brachytherapy
1130136|NCT01446991|androgen ablation
1130137|NCT01446991|benign prostatic hypertrophy
1130138|NCT01446991|prostate size reduction
1130139|NCT01446991|localized prostate cancer with prostate volume > 40 cc
1130140|NCT01446978|hepatitis A vaccine
1130141|NCT01446978|TNF-alfa inhibitory drugs
1130142|NCT01446978|Rheumatoid arthritis
1130143|NCT01446978|methotrexate
1130144|NCT01446965|myocardial infarction, acute
1130145|NCT01446965|myocardial infarction
1130146|NCT01446965|ventricular dysfunction
1130147|NCT01446965|death, sudden, cardiac
1130148|NCT01446965|death, sudden
1130149|NCT01446965|death
1130150|NCT01446965|ventricular tachycardia
1130151|NCT01446965|ventricular fibrillation
1130152|NCT01446965|defibrillation, electric
1130153|NCT01446965|cardioversion, electric
1130154|NCT01446965|electric countershock
1130155|NCT01446965|defibrillators, external
1130156|NCT01446952|prevention
1130157|NCT01446952|pancreas
1130158|NCT01446939|MRI
1130159|NCT01446939|Parkinson's disease
1130160|NCT01446939|Essential tremor
1130161|NCT01446939|Ultrasonography
1130162|NCT01446939|Diagnosis
1130163|NCT01446926|Pneumonia
1130164|NCT01446926|Pneumococcal Infections
1130165|NCT01446926|Streptococcus pneumoniae Infections
1130166|NCT01446926|Pneumococcal vaccines
1130167|NCT01446913|Sleep Apnea
1130168|NCT01446913|CPAP adherence
1130169|NCT01446913|behavioral adherence
1130170|NCT01446913|stroke
1130171|NCT01446900|Rituximab
1130172|NCT01446900|Cladribine
1130173|NCT01446900|Chronic Lymphocytic Leukaemia
1130174|NCT01446900|Small Lymphocytic Lymphoma
1130175|NCT01446887|Deep Vein Thrombosis
1130176|NCT01446887|total hip arthroplasty
1130177|NCT01446887|prophylactic anticoagulation
1130178|NCT01446887|randomized study
1130179|NCT01446874|Incidence of post-operative pneumonia in patients undergoing surgery for primary lung cancer or primary esophageal cancer
1130180|NCT01446861|Cystic fibrosis
1130181|NCT01446861|Pancreas
1130182|NCT01446861|Exocrine function
1130183|NCT01446861|Ultrasound
1130184|NCT01446861|Contrast ultrasound
1130185|NCT01446848|iron deficiency
1130186|NCT01446848|pulmonary hypertension
1130187|NCT01446848|iron supplements
1130188|NCT01446848|ferrous sulfate
1130193|NCT01446796|Ventricular assist device
1130194|NCT01446783|COL5A1
1130195|NCT01446783|Collagen disorders
1130196|NCT01446783|IGF-I
1130197|NCT01446783|Collagen synthesis
1130198|NCT01446757|quality of life
1130199|NCT01446757|feeling of security
1130200|NCT01446757|costs
1130201|NCT01446757|multiprofessional team
1130203|NCT01446731|Prostate cancer
1130204|NCT01446718|quadrivalent vaccine
1130205|NCT01446718|Human Papillomavirus
1130206|NCT01446692|Major depressive disorder
1130207|NCT01446692|primary care
1130208|NCT01446692|real-world evidence
1130209|NCT01446692|database
1130210|NCT01446679|Lipitor
1130211|NCT01446679|HMG-CoA reductase inhibitor
1130212|NCT01446666|hepatocellular carcinoma
1130213|NCT01446666|surveillance
1130214|NCT01446666|gadoxetic acid
1130215|NCT01446666|MRI
1130216|NCT01446653|Fetal Alcohol Spectrum Disorders
1130217|NCT01446653|FASDs
1130218|NCT01446653|AEP risk
1130219|NCT01446653|binge drinking
1130220|NCT01446653|ineffective contraception
1130221|NCT01446627|Absorbable vicryl subcuticular staples
1130222|NCT01446627|metal staples
1130223|NCT01446627|wound healing
1130224|NCT01446627|cesarean section
1130225|NCT01446601|Apnea
1130226|NCT01446601|OSA
1130227|NCT01446601|Sleep Apnea Syndromes
1130228|NCT01446601|Sleep Apnea, Obstructive
1130229|NCT01446601|Hypoglossal Nerve Stimulation
1130230|NCT01446601|Sleep Disorders
1130231|NCT01446601|Tongue
1130232|NCT01446536|Quality
1130233|NCT01446536|Improvement
1130234|NCT01446523|endotoxins HE
1130235|NCT01446510|VTE
1130236|NCT01446510|DVT
1130237|NCT01446510|PE
1130238|NCT01446510|Risk assessment
1130239|NCT01446510|risk score
1130240|NCT01446510|risk analysis
1130241|NCT01446510|Venous thromboembolism risk
1130242|NCT01446497|Normal tension glaucoma
1130243|NCT01446497|Antiglaucoma ophthalmic solution
1130244|NCT01446497|Brimonidine
1130245|NCT01446497|Timolol
1130246|NCT01446497|Combination drugs
1130247|NCT01446484|Renal transplantation
1130248|NCT01446484|Kidney transplantation
1130249|NCT01446484|CD4+CD25+CD127lowFoxP3+ T Regulatory Cells
1130250|NCT01446484|T reg
1130251|NCT01446484|Campath
1130252|NCT01446471|Bedside Ultrasound
1130253|NCT01446471|Point of care ultrasound
1130254|NCT01446471|cardiac arrest
1130255|NCT01446458|Cancer of Pancreas
1130256|NCT01446458|Cancer of the Pancreas
1130257|NCT01446458|Neoplasms, Pancreatic
1130258|NCT01446458|Pancreas Cancer
1130259|NCT01446458|Pancreas Neoplasms
1130260|NCT01446458|Entry Term Pancreatic Cancer
1130261|NCT01446445|Cytomegalovirus
1130262|NCT01446445|renal transplant
1130263|NCT01446432|Dupuytren's Contracture
1130264|NCT01446419|chronic axial low back pain
1130265|NCT01446419|vertebrogenic pain
1130266|NCT01446419|Radio frequency ablation
1130267|NCT01446406|Bipolar disorder
1130268|NCT01446406|Electronic daily monitoring
1130269|NCT01446406|Affective episodes
1130270|NCT01446354|Blood component transfusion
1130271|NCT01446354|Hypothermic
1130272|NCT01446341|Ankle sprain
1130273|NCT01446341|Functional rehabilitation
1130274|NCT01446341|Immobilization
1130275|NCT01446328|Antipsychotic Drugs
1130276|NCT01446328|Randomized Controlled Trial
1130277|NCT01446328|Treatment Effectiveness
1130278|NCT01446328|Translational Research
1130279|NCT01446315|asthma
1130280|NCT01446315|asthma care system
1130281|NCT01446315|effectiveness
1130282|NCT01446315|primary care
1130283|NCT01446315|practice based research network
1130284|NCT01446302|Dialysis
1130285|NCT01446302|Protein-energy wasting
1130286|NCT01446302|Insulin-Like Growth Factor I
1130287|NCT01446302|Insulin-Like Growth Factor Binding Protein 1
1130288|NCT01446302|Inflammation
1130289|NCT01446289|Group B streptococcus
1130290|NCT01446289|GBS
1130291|NCT01446289|Vaccine
1130292|NCT01446289|Prevention of group B streptococcus infection
1130293|NCT01446276|Obesity
1130294|NCT01446276|Resveratrol
1130295|NCT01446276|Nonalcoholic fatty liver disease
1130296|NCT01446276|Insulin sensitivity
1130297|NCT01446276|Lipid turnover
1130298|NCT01446276|Liver fat content
1130299|NCT01446263|Radial access
1130300|NCT01446263|Femoral access
1130301|NCT01446263|Coronary angiography
1130302|NCT01446263|Coronary artery bypass graft
1130303|NCT01446250|Chronic hepatitis C
1130304|NCT01446250|Cyclophilin inhibitor
1130305|NCT01446224|adverse events
1130306|NCT01446224|pazopanib
1130307|NCT01446224|Torsades des Pointes
1130308|NCT01446224|renal cell carcinoma
1130309|NCT01446224|anti-VEGF agents
1130310|NCT01446224|observational data
1130311|NCT01446224|cardiac ischemia
1130312|NCT01446211|gusperimus
1130313|NCT01446211|Wegeners granulomatosis
1130314|NCT01446211|relapse
1130315|NCT01446198|HPV
1130316|NCT01446185|HR+, N- or pN1(mi), Her2- breast cancer adjuvant population
1130317|NCT01446185|Early Breast cancer
1130318|NCT01446185|Gene Expression
1130319|NCT01446185|Node-Negative
1130320|NCT01446185|treatment options
1130321|NCT01446185|Hormone receptor positive
1130322|NCT01446172|Long term outcome
1130323|NCT01446159|MEDI-573, breast cancer, metastatic, aromatase inhibitor, anti-IGF
1130324|NCT01446146|Posttraumatic Stress Disorder
1130325|NCT01446146|PTSD Treatment
1130326|NCT01446146|Decision making
1130327|NCT01446146|Veterans
1130328|NCT01446133|Leukemia
1130329|NCT01446133|Lymphoma
1130330|NCT01446133|Chronic Lymphocytic Leukemia
1130331|NCT01446133|CLL
1130332|NCT01446133|Small Lymphocytic Lymphoma
1130333|NCT01446133|SLL
1130334|NCT01446133|Initial Treatment
1130335|NCT01446133|Subsequent Therapy
1130336|NCT01446133|Rituximab
1130337|NCT01446133|Rituxan
1130338|NCT01446133|Lenalidomide
1130339|NCT01446133|CC-5013
1130340|NCT01446133|Revlimid
1130341|NCT01446120|this is phase one study. The study population are healthy volunteers.
1130342|NCT01446107|tooth decay
1130343|NCT01446107|fluoride
1130344|NCT01446107|sealant
1130345|NCT01446107|prevention
1130346|NCT01446094|Coronary artery disease
1130347|NCT01446081|chemotherapy
1130348|NCT01446081|exercise
1130349|NCT01446081|quality of life
1130350|NCT01446081|cancer-related fatigue
1130351|NCT01446081|elderly
1130352|NCT01446081|physical fitness
1130353|NCT01446055|Peripheral arterial disease
1130354|NCT01446055|Buerger's disease
1130355|NCT01446055|atherosclerotic arterial occlusion
1130356|NCT01446055|bone marrow mononuclear cell
1130357|NCT01446055|chronic limb ischemia
1130358|NCT01446029|Telemonitoring
1130359|NCT01446029|Chronic Kidney Disease
1130360|NCT01446016|Breast Cancer
1130361|NCT01446016|Breast Tumors
1130362|NCT01446016|Cancer of Breast
1130363|NCT01446016|Cancer of the Breast
1130364|NCT01446016|Human Mammary Carcinoma
1130365|NCT01446016|Mammary Carcinoma, Human
1130366|NCT01446016|Mammary Neoplasm, Human
1130367|NCT01446016|Mammary Neoplasms, Human
1130368|NCT01446016|Neoplasms, Breast
1130369|NCT01446016|Tumors, Breast
1130370|NCT01446016|Taxotere
1130371|NCT01446016|Chloroquine
1130372|NCT01446016|Paclitaxel
1130373|NCT01446016|Taxol
1130374|NCT01446016|Ixabepilone
1130375|NCT01446016|Abraxane
1130376|NCT01446016|Metastatic Breast Cancer
1130377|NCT01446016|Advanced Breast Cancer
1130378|NCT01446016|Anthracycline
1130379|NCT01445990|free tissue flaps
1130380|NCT01445990|lactic acid
1130381|NCT01445990|glucose
1130382|NCT01445990|thrombosis
1130383|NCT01445990|diagnostic test
1130384|NCT01445990|Pedicle postoperative complications diagnosis
1130385|NCT01445977|Sonitus Medical
1130386|NCT01445977|SoundBite
1130387|NCT01445977|Single Sided Deafness
1130388|NCT01445977|Conductive Hearing Loss
1130389|NCT01445977|Unilateral Hearing Loss
1130390|NCT01445964|SLCO2B1 genotype
1130391|NCT01445964|effect of apple juice
1130392|NCT01445886|Nail Psoriasis
1130393|NCT01445886|Indigo Naturalis
1130394|NCT01445886|Indirubin
1130395|NCT01445886|Calcipotriol
1130396|NCT01445886|Nail Psoriasis Severity Index
1130397|NCT01445873|Pulmonary arterial hypertension
1130398|NCT01445873|sitaxentan sodium
1130399|NCT01445873|Thelin
1130400|NCT01445860|DDI
1130401|NCT01445860|pharmacokinetics
1130402|NCT01445847|Laryngospasm
1130403|NCT01445847|Lidocaine
1130404|NCT01445834|outcome of pelvic floor muscle physiotherapy
1130405|NCT01445834|female
1130406|NCT01445834|stress urinary incontinence
1130407|NCT01445834|urgency urinary incontinence
1130408|NCT01445834|mixed urinary incontinence
1130409|NCT01445821|systemic scleroderma
1130410|NCT01445821|autologous stem cell transplantation
1130411|NCT01445808|psychodynamic psychotherapy
1130412|NCT01445808|coronary heart disease
1130413|NCT01445808|physical activity
1130414|NCT01445808|secondary prevention
1130415|NCT01445795|Inhibitex
1130416|NCT01445795|Chronic Hepatitis
1130417|NCT01445795|Hepatitis C Virus
1130418|NCT01445782|Safety
1130419|NCT01445782|tolerability
1130420|NCT01445782|healthy
1130421|NCT01445782|inhaled
1130422|NCT01445769|Myelofibrosis
1130423|NCT01445769|Primary Myelofibrosis
1130424|NCT01445769|PMF
1130425|NCT01445769|Post-Polycythemia Vera Myelofibrosis
1130426|NCT01445769|PPV-MF
1130427|NCT01445769|Post-Essential Thrombocythemia Myelofibrosis
1130428|NCT01445769|PET-MF
1130429|NCT01445769|Open label
1130430|NCT01445769|Ruxolitinib
1130431|NCT01445769|18424
1130432|NCT01445769|Jak inhibitor
1130433|NCT01445756|Intrauterine Device
1130434|NCT01445743|Tdap Vaccine
1130435|NCT01445743|Pregnant woman
1130436|NCT01445743|Pertussis
1130437|NCT01445730|fructose
1130438|NCT01445730|hypertriglyceridemia
1130439|NCT01445730|postprandial lipids
1130440|NCT01445730|de novo lipogenesis
1130441|NCT01445730|stable isotopes
1130442|NCT01445717|GBS, Streptococcus, .
1130443|NCT01445717|Group B
1130444|NCT01445704|Weight loss
1130445|NCT01445704|Probiotics
1130446|NCT01445704|Gastric Bypass
1130447|NCT01445691|Benign Neoplasms, Brain
1130448|NCT01445691|Brain Cancer
1130449|NCT01445691|Brain Neoplasms, Benign
1130450|NCT01445691|Brain Neoplasms, Malignant
1130451|NCT01445691|Brain Tumor, Primary
1130452|NCT01445691|Brain Tumor, Recurrent
1130453|NCT01445691|Brain Tumors
1130454|NCT01445691|Intracranial Neoplasms
1130455|NCT01445691|Neoplasms, Brain
1130456|NCT01445691|Neoplasms, Intracranial
1130457|NCT01445691|Primary Brain Neoplasms
1130458|NCT01445691|Primary Malignant Brain Neoplasms
1130459|NCT01445691|Primary Malignant Brain Tumors
1130460|NCT01445691|Gliomas
1130461|NCT01445691|Glioblastoma
1130462|NCT01445691|Surgery
1130463|NCT01445691|5-ALA
1130464|NCT01445691|Aminolevulinic acid
1130465|NCT01445691|Fluorescence
1130466|NCT01445678|cIAI
1130467|NCT01445639|dexmedetomidine
1130468|NCT01445639|sedation
1130469|NCT01445639|neurosurgery
1130470|NCT01445639|postoperative care
1130471|NCT01445613|Carotid
1130472|NCT01445613|Stent
1130473|NCT01445613|Carotid Endarterectomy
1130474|NCT01445600|Impetigo
1130475|NCT01445600|secondarily-infected traumatic lesions
1130476|NCT01445600|retapamulin
1130477|NCT01445587|bortezomib
1130478|NCT01445587|AKT inhibitor
1130479|NCT01445587|multiple myeloma
1130480|NCT01445587|GSK2110183
1130481|NCT01445587|hematologic malignancies
1130482|NCT01445561|Interleukin-2
1130483|NCT01445561|IL-2
1130484|NCT01445561|Stem Cells
1130485|NCT01445561|Regulatory T Cells (T regs)
1130486|NCT01445561|Natural Killer Cells (NK cells)
1130487|NCT01445561|Healthy Volunteer
1130488|NCT01445561|HV
1130489|NCT01445548|Age-Related Macular Degeneration (AMD)
1130490|NCT01445548|Geographic Atrophy
1130491|NCT01445548|Bilateral Geographic Atrophy
1130492|NCT01445548|Sirolimus
1130493|NCT01445548|Age Related Macular Degeneration
1130494|NCT01445548|AMD
1130495|NCT01445535|CD2 Positive
1130496|NCT01445535|Toxicity
1130497|NCT01445535|EBV Lymphoma
1130498|NCT01445535|Chemotherapy Naive
1130499|NCT01445535|Maximum Tolerated Dose
1130500|NCT01445535|Lymphoma
1130501|NCT01445535|T-Cell Lymphoma
1130502|NCT01445535|NK T-Cell Lymphoma
1130503|NCT01445522|PARP Inhibitor
1130504|NCT01445522|DNA Damage
1130505|NCT01445522|Chemotherapy
1130506|NCT01445522|Advanced Cancer
1130507|NCT01445522|DNA Repair
1130508|NCT01445509|Angiogenesis
1130509|NCT01445509|VEGF
1130510|NCT01445509|SRC
1130511|NCT01445509|Targeted Therapy
1130512|NCT01445509|Cancer
1130513|NCT01445509|Solid Tumor
1130514|NCT01445483|Cancer
1130515|NCT01445483|Radiation
1130516|NCT01445483|Brain
1130517|NCT01445483|Neuropsychological Outcome
1130518|NCT01445483|Metastasis
1130519|NCT01445483|Brain Metastasis
1130520|NCT01445444|Habit Reversal Training
1130521|NCT01445444|Hair Pulling
1130522|NCT01445444|Children
1130523|NCT01445444|Trich
1130524|NCT01445444|cognitive behavioral therapy
1130525|NCT01445444|TTM
1130526|NCT01445444|psychotherapy
1130527|NCT01445418|Genetic
1130528|NCT01445418|BRCA
1130529|NCT01445418|Ovarian Cancer, sporadic epithelial ovarian cancer
1130530|NCT01445418|Breast Cancer, triple negative breast cancer
1130531|NCT01445418|Metastatic
1130532|NCT01445418|Breast Cancer
1130533|NCT01445418|Ovarian Cancer
1130534|NCT01445405|Proteasome
1130535|NCT01445405|Bortezomib
1130536|NCT01445405|NF-kappaB
1130537|NCT01445405|Cetuximab
1130538|NCT01445405|Epidermal Growth Factor
1130539|NCT01445405|Head and Neck Cancer
1130540|NCT01445405|Squamous Cell Carcinoma
1130541|NCT01445405|Oral Cancer
1130542|NCT01445392|Recombinant Immunotoxin
1130543|NCT01445392|Monoclonal Antibody
1130544|NCT01445392|Pseudomonas Exotoxin
1130545|NCT01445392|Targeted Therapy
1130546|NCT01445392|Pleural Mesothelioma
1130547|NCT01445392|Mesothelioma
1130548|NCT01445392|Epithelial Pleural Mesothelioma
1130549|NCT01445379|Solid Tumor
1130550|NCT01445379|Monoclonal Antibody
1130551|NCT01445379|Pediatrics
1130552|NCT01445379|Pharmacokinetics
1130553|NCT01445379|Immunotherapy
1130554|NCT01445379|Sarcoma
1130555|NCT01445379|Lymphoma
1130556|NCT01445379|Neuroblastoma
1130557|NCT01445340|Topical Depsi
1130558|NCT01445340|Cutaneous T Cell Lymphoma
1130559|NCT01445340|CTCL
1130560|NCT01445340|Mycosis Fungoides
1130561|NCT01445327|Blood
1130562|NCT01445327|Urine
1130563|NCT01445327|Stool
1130564|NCT01445327|Tumor Marker
1130565|NCT01445327|Radiation Therapy
1130566|NCT01445327|Gastrointestinal Cancer
1130567|NCT01445327|Esophageal Cancer
1130568|NCT01445327|Stomach
1130569|NCT01445327|Pancreatic Cancer
1130570|NCT01445314|Stored Data
1130571|NCT01445314|Neurobehavioral
1130572|NCT01445314|Behavior
1130573|NCT01445314|Quality of Life
1130574|NCT01445301|twice daily
1130575|NCT01445301|once daily
1130576|NCT01445301|CLDM 1%-BPO 3% gel
1130577|NCT01445301|Clindamycin (CLDM)
1130578|NCT01445301|benzoyl peroxide (BPO)
1130579|NCT01445301|inflammatory lesion
1130580|NCT01445301|non-inflammatory lesion
1130581|NCT01445301|acne vulgaris
1130582|NCT01445288|Neurotoxicity
1130583|NCT01445288|Brain Tumor
1130584|NCT01445288|Children
1130585|NCT01445288|Angiogenesis
1130586|NCT01445288|Imaging
1130587|NCT01445288|Central Nervous System Tumor
1130588|NCT01445288|CNS Tumor
1130589|NCT01445249|regional anaesthetic techniques
1130590|NCT01445249|surgery orthopaedic
1130591|NCT01445236|Operational tolerance
1130592|NCT01445236|Biomarkers
1130593|NCT01445236|Liver Transplantation
1130594|NCT01445223|HIV
1130595|NCT01445223|Antiretroviral therapy
1130596|NCT01445223|efavirenz
1130597|NCT01445223|lopinavir
1130598|NCT01445223|atazanavir
1130599|NCT01445223|randomised controlled clinical trial
1130600|NCT01445210|Postoperative pain
1130601|NCT01445210|Major ankle surgery
1130602|NCT01445210|Continuous nerve block
1130603|NCT01445210|Saphenous nerve
1130604|NCT01445210|Ropivacaine
1130605|NCT01445171|Aortic Valve Replacement
1130606|NCT01445158|ShopTalk
1130607|NCT01445158|Comprehension
1130608|NCT01445158|Donors
1130609|NCT01445158|Education
1130610|NCT01445158|Stem Cell Transplant
1130611|NCT01445158|Sibling Donor
1130612|NCT01445145|End-of-Life
1130613|NCT01445145|Advance Directive
1130614|NCT01445145|Pediatric Cancer
1130615|NCT01445145|Adolescents
1130616|NCT01445145|Young Adults
1130617|NCT01445132|Adoptive Immunotherapy
1130618|NCT01445132|Tumor Infiltrating Lymphocytes
1130619|NCT01445132|Refractory Tumor
1130620|NCT01445132|Resection
1130621|NCT01445132|B-Cell Malignancies
1130622|NCT01445132|Chronic Lymphocytic Leukemia
1130623|NCT01445132|BCL
1130624|NCT01445132|B-Cell Lymphoid Malignancy
1130625|NCT01445119|Brain
1130626|NCT01445119|Tumor
1130627|NCT01445119|Radiation
1130628|NCT01445119|Antiangiogenesis
1130629|NCT01445119|Chemotherapy
1130630|NCT01445119|Brain Tumor
1130631|NCT01445119|Glioma
1130632|NCT01445106|HIV Protease Inhibitor
1130633|NCT01445106|Drug Repositioning
1130634|NCT01445106|Akt/Mtor Inhibitor
1130635|NCT01445106|Targeted Therapy
1130636|NCT01445106|Off - Label Drugs
1130637|NCT01445106|Nelfinavir
1130638|NCT01445106|Protease Inhibitor
1130639|NCT01445106|Solid Tumor
1130640|NCT01445106|Phase I
1130641|NCT01445106|Malignant Tumor
1130642|NCT01445080|MTD
1130643|NCT01445080|Phase I/II
1130644|NCT01445080|Pediatric
1130645|NCT01445080|Solid Tumor
1130646|NCT01445080|Leukemia
1130647|NCT01445080|Chronic Myelogenous Leukemia
1130648|NCT01445080|CML
1130649|NCT01445080|Acute Lymphoblastic Leukemia
1130650|NCT01445080|ALL
1130651|NCT01445080|Acute Myeloid Leukemia
1130652|NCT01445080|AML
1130653|NCT01445080|Juevenile Myelomoncytic Leukemia
1130654|NCT01445080|JMML
1130655|NCT01445054|111 Indium Trastuzumab Imaging
1130656|NCT01445054|PET
1130657|NCT01445054|Breast Cancer
1130658|NCT01445041|Hypoplastic Left Heart Syndrome
1130659|NCT01445041|Autologous Umbilical Cord Blood
1130660|NCT01445041|Newborn Infants
1130661|NCT01445015|adolescents
1130662|NCT01445002|grass pollen allergy
1130663|NCT01445002|immunotherapy
1130664|NCT01445002|recombinant vaccine
1130665|NCT01444989|"Sun spots"
1130666|NCT01444989|"Pre-cancerous skin lesion"
1130667|NCT01444976|age range of 18-83
1130668|NCT01444924|Pain control
1130669|NCT01444924|Gynecologic Oncology
1130670|NCT01444924|Surgery
1130671|NCT01444911|Sexual Dysfunction
1130672|NCT01444911|Gynecologic cancer
1130673|NCT01444911|Cancer survivor
1130674|NCT01444911|Vaginal dilator
1130675|NCT01444898|Prader-Willi Syndrome
1130676|NCT01444898|Obesity
1130677|NCT01444898|Weight
1130678|NCT01444898|Exenatide
1130679|NCT01444898|Byetta
1130680|NCT01444898|Pediatrics
1130681|NCT01444898|Adolescents
1130682|NCT01444885|Variant angina
1130683|NCT01444885|Cilostazol
1130684|NCT01444846|Temporary Auditory Threshold Shift
1130685|NCT01444846|Hearing Loss
1130686|NCT01444846|Deafness
1130687|NCT01444846|SPI-1005
1130688|NCT01444846|Ebselen
1130689|NCT01444833|hypertension
1130690|NCT01444833|obesity
1130691|NCT01444833|metabolism
1130692|NCT01444833|angiotensin
1130693|NCT01444820|radiation therapy
1130694|NCT01444820|hypofractionation
1130695|NCT01444820|hormonal therapy
1130696|NCT01444820|high risk adenocarcinoma of the prostate
1130697|NCT01444807|sorafenib
1130698|NCT01444807|metastatic renal cell carcinoma
1130699|NCT01444807|metastasectomy
1130700|NCT01444794|Lower limb spasticity
1130701|NCT01444781|Diphtheria
1130702|NCT01444781|Tetanus
1130703|NCT01444781|Whooping Cough
1130704|NCT01444781|Hepatitis B
1130705|NCT01444781|Poliomyelitis
1130706|NCT01444781|Pediatric combined vaccine
1130707|NCT01444781|Invasive Hib infections
1130708|NCT01444768|Alert Systems, Medication
1130709|NCT01444768|Computerized Physician Order Entry System
1130710|NCT01444768|CPOE
1130711|NCT01444768|Medication Alert Systems
1130712|NCT01444768|Medical Order Entry Systems
1130713|NCT01444755|Locally advanced gastric cancer
1130714|NCT01444755|neoadjuvant chemotherapy
1130715|NCT01444742|Leukemia
1130716|NCT01444742|Myeloproliferative Diseases
1130717|NCT01444742|Myelodysplastic Syndrome
1130718|NCT01444742|(MDS)
1130719|NCT01444742|Relapsing
1130720|NCT01444742|Refractory
1130721|NCT01444742|Clofarabine
1130722|NCT01444742|Clofarex
1130723|NCT01444742|Clolar
1130724|NCT01444742|Cytarabine
1130725|NCT01444742|Ara-C
1130726|NCT01444742|Cytosar
1130727|NCT01444742|DepoCyt
1130728|NCT01444742|Cytosine Arabinosine Hydrochloride
1130729|NCT01444729|'Dupuytren's contracture'
1130730|NCT01444729|'xiapex'
1130731|NCT01444729|'surgery'
1130732|NCT01444716|Advanced Cancers
1130733|NCT01444716|Leukemia
1130734|NCT01444716|Chronic Lymphocytic Leukemia
1130735|NCT01444716|CLL
1130736|NCT01444716|Elderly
1130737|NCT01444716|Ofatumumab
1130738|NCT01444716|Arzerra
1130739|NCT01444703|Thoracic surgery
1130740|NCT01444703|double-lumen endotracheal tube
1130741|NCT01444703|intubation
1130742|NCT01444703|extubation
1130743|NCT01444703|sore throat
1130744|NCT01444703|prevention of post-extubation sore throat
1130745|NCT01444690|Antiretroviral therapy
1130746|NCT01444690|Acquired Immunodeficiency Syndrome/complications*
1130747|NCT01444690|Anti-HIV Agents/adverse effects
1130748|NCT01444677|Safety
1130749|NCT01444677|Tolerability
1130750|NCT01444677|Pharmacokinetic
1130751|NCT01444651|Tadalafil
1130752|NCT01444651|Phosphodiesterase 5 Inhibitors
1130753|NCT01444651|Cyclic Guanylyl Monophosphate Pathway
1130754|NCT01444651|Pharmacologic Actions
1130755|NCT01444651|Vasodilator Agents
1130756|NCT01444651|Cardiovascular Agents
1130757|NCT01444651|Obesity
1130758|NCT01444651|Glycemic Traits
1130759|NCT01444651|Insulin Resistance
1130760|NCT01444651|Glucose Metabolism
1130761|NCT01444638|pregnancy
1130762|NCT01444638|Caesarian
1130763|NCT01444638|section
1130764|NCT01444638|spinal
1130765|NCT01444625|UV radiation
1130766|NCT01444625|photoprotection
1130767|NCT01444625|flavanols rich chocolate
1130768|NCT01444612|cancer surgery
1130769|NCT01444612|venous thromboembolism
1130770|NCT01444612|hospitalization
1130771|NCT01444612|anticoagulants
1130772|NCT01444612|costs and cost analysis
1130773|NCT01444612|thromboprophylaxis
1130774|NCT01444599|coronary atherosclerosis
1130775|NCT01444599|virtual histology intravascular ultrasound
1130776|NCT01444599|fractional flow reserve
1130777|NCT01444586|non-interventional
1130778|NCT01444586|Xarelto
1130779|NCT01444586|knee replacement
1130780|NCT01444586|hip replecement
1130781|NCT01444586|Russia
1130782|NCT01444573|Rate control
1130783|NCT01444573|ILR
1130784|NCT01444547|esophageal cancer
1130785|NCT01444547|paclitaxel
1130786|NCT01444547|cisplatin
1130787|NCT01444534|mobile phone application
1130788|NCT01444534|diabetes type 1
1130789|NCT01444534|self-management
1130790|NCT01444534|telemedicin
1130791|NCT01444521|advanced gastric cancer
1130792|NCT01444521|irinotecan
1130793|NCT01444521|cisplatin
1130794|NCT01444495|rectal cancer
1130795|NCT01444495|radiotherapy
1130796|NCT01444495|overall survival
1130797|NCT01444495|recurrence rate
1130798|NCT01444495|downstaging
1130799|NCT01444469|Asthma exacerbations
1130800|NCT01444469|Respiratory disease
1130801|NCT01444469|Viral infection
1130802|NCT01444469|Macrolide/ketolide antibiotics
1130803|NCT01444469|Mycoplasma pneumoniae (M. pneumoniae)
1130804|NCT01444469|Chlamydophila pneumoniae (C. pneumoniae)
1130805|NCT01444456|Breast Cancer
1130806|NCT01444456|Lung Cancer
1130807|NCT01444456|Ovarian Cancer
1130808|NCT01444456|Prostate Cancer
1130809|NCT01444456|Colorectal Cancer
1130810|NCT01444456|Aranesp
1130811|NCT01444456|Chemotherapy induced anaemia
1130812|NCT01444456|Chemotherapy
1130813|NCT01444456|Bladder Cancer
1130814|NCT01444456|Endometrial Cancer
1130815|NCT01444456|Renal Cancer
1130816|NCT01444456|Pancreatic Cancer
1130817|NCT01444456|Esophageal Cancer
1130818|NCT01444456|Gastric Cancer
1130819|NCT01444443|Type 1 diabetes
1130820|NCT01444443|Glucose control
1130821|NCT01444443|Closed-loop
1130822|NCT01444443|Insulin pump
1130823|NCT01444443|Glucose sensor
1130824|NCT01444430|Symbicort pMDI
1130825|NCT01444430|Asthma
1130826|NCT01444430|safety
1130827|NCT01444430|budesonide
1130828|NCT01444417|Immune (Idiopathic) Thrombocytopenic Purpura
1130829|NCT01444417|Pediatric Immune (Idiopathic) Thrombocytopenic Purpura
1130830|NCT01444417|Immune Thrombocytopenia
1130831|NCT01444404|Solid Tumors
1130832|NCT01444404|Phase 1
1130833|NCT01444404|Clinical Trial
1130962|NCT01443767|Non-invasive Monitoring
1130834|NCT01444391|Tympanostomy tube placement
1130835|NCT01444391|iontophoresis
1130836|NCT01444378|Atherosclerosis
1130837|NCT01444378|Claudication
1130838|NCT01444378|Peripheral Arterial Occlusive Disease
1130839|NCT01444378|Stent
1130840|NCT01444365|Osteoarthritis of the knee
1130841|NCT01444352|Pneumococcal infections
1130842|NCT01444352|Streptococcus pneumoniae Infections
1130843|NCT01444352|Pneumococcal Vaccines
1130844|NCT01444339|Pneumococcal Infections
1130845|NCT01444339|Streptococcus Pneumoniae Infections
1130846|NCT01444339|Pneumococcal Vaccine
1130847|NCT01444326|Keywords;
1130848|NCT01444326|Cardiovascular disease
1130849|NCT01444326|Dairy
1130850|NCT01444326|Inflammation
1130851|NCT01444326|Blood lipids
1130852|NCT01444300|multiple sclerosis
1130853|NCT01444300|postural balance
1130854|NCT01444300|gait
1130855|NCT01444300|fatigue
1130856|NCT01444261|iron deficiency
1130857|NCT01444261|anemia
1130858|NCT01444248|Amaryl MEX
1130859|NCT01444235|CAD, ACVB
1130860|NCT01444222|Myocardial contractility
1130861|NCT01444222|Quantification of regurgitant flow
1130862|NCT01444222|exercise capacity
1130863|NCT01444209|pituitary gland
1130864|NCT01444196|ACU
1130865|NCT01444196|acquired cold urticaria
1130866|NCT01444183|Epilepsy
1130867|NCT01444183|seizures
1130868|NCT01444183|stress reduction
1130869|NCT01444170|eccentric exercise
1130870|NCT01444170|exercise induce muscle damage
1130871|NCT01444170|isometric strength
1130872|NCT01444170|range of motion
1130873|NCT01444170|self report symptoms
1130874|NCT01444170|mechanical pain threshold
1130875|NCT01444144|Ankle
1130876|NCT01444144|Fracture
1130877|NCT01444144|Elderly
1130878|NCT01444144|At-risk Population
1130879|NCT01444144|Ankle Fracture in at-risk elderly population
1130880|NCT01444131|Smoking
1130881|NCT01444131|Smoking cessation
1130882|NCT01444131|Pharmaceutical aids
1130883|NCT01444105|Open angle glaucoma
1130884|NCT01444105|Pseudoexfoliative glaucoma
1130885|NCT01444079|Liver transplantation
1130886|NCT01444079|Rejection
1130887|NCT01444079|Tolerance
1130888|NCT01444040|Open angle glaucoma
1130889|NCT01444040|POAG
1130890|NCT01444040|Ocular hypertension
1130891|NCT01444040|Pseudoexfoliative glaucoma
1130892|NCT01444040|Naïve to treatment
1130893|NCT01444014|YF476
1130894|NCT01444014|netazepide
1130895|NCT01444014|hypergastrinaemia
1130896|NCT01444014|gastric carcinoids
1130897|NCT01444001|Pneumococcal Infections
1130898|NCT01444001|Pneumococcal Vaccines
1130899|NCT01444001|pneumococcal protein
1130900|NCT01443988|Open angle glaucoma
1130901|NCT01443988|POAG
1130902|NCT01443988|Ocular hypertension
1130903|NCT01443988|Pseudoexfoliative glaucoma
1130904|NCT01443988|Naïve to treatment
1130905|NCT01443975|Total Hip Arthroplasty
1130906|NCT01443975|Osteoarthritis
1130907|NCT01443962|laparoscopic cholecystectomy
1130908|NCT01443962|PEEP
1130909|NCT01443962|rSO2
1130910|NCT01443949|fMRI
1130911|NCT01443949|Reward
1130912|NCT01443949|Adolescents
1130913|NCT01443949|Impulse Control
1130914|NCT01443949|Cabergoline
1130922|NCT01443923|Hepatitis
1130923|NCT01443923|Immunological Response
1130924|NCT01443923|Virological Response
1130925|NCT01443923|Resistance Mutations
1130926|NCT01443923|Viral Kinetics
1130927|NCT01443923|Hepatitis C
1130928|NCT01443923|HCV
1130929|NCT01443910|Body Weight
1130930|NCT01443910|Immersive Virtual Enviroment Technology
1130931|NCT01443897|Vitamin D
1130932|NCT01443871|Volunteer
1130933|NCT01443858|Smoking Cessation
1130934|NCT01443858|Cigarette Smoking
1130935|NCT01443858|Meclizine
1130936|NCT01443858|Nicotine Patch
1130937|NCT01443845|COPD
1130938|NCT01443845|Exacerbations
1130939|NCT01443845|Roflumilast
1130940|NCT01443845|Daliresp
1130941|NCT01443832|ferrous sulfate
1130942|NCT01443832|iron absorption
1130943|NCT01443832|Beninese women
1130944|NCT01443832|fonio
1130945|NCT01443819|Radiculopathy
1130946|NCT01443819|Transforaminal
1130947|NCT01443819|Disc Protrusion
1130948|NCT01443806|oseltamivir metabolism
1130949|NCT01443806|Carboxylesterase 1
1130950|NCT01443780|Selenium
1130951|NCT01443780|Q10
1130952|NCT01443780|dietary supplement
1130953|NCT01443780|elderly population
1130954|NCT01443780|intervention
1130955|NCT01443780|All-cause mortality
1130956|NCT01443780|cardiac function
1130957|NCT01443767|Cardiac Output
1130958|NCT01443767|esCCO
1130959|NCT01443767|Pulse Wave Transit Time
1130960|NCT01443767|PiCCO
1130961|NCT01443767|Pulse Contour Analysis
1130963|NCT01443767|Partial Liver Resection
1130964|NCT01443741|FIT Therapy
1130965|NCT01443741|Diabetes mellitus
1130966|NCT01443741|Insulin pump
1130967|NCT01443741|Pediatric
1130972|NCT01443715|MDD
1130973|NCT01443715|Dysthymia
1130974|NCT01443715|Depressive Disorder Not Otherwise Specified (DDNOS)
1130975|NCT01443702|Kidney Calculi
1130976|NCT01443702|Iranian traditional medicine
1130977|NCT01443702|Lapis judaicus
1130978|NCT01443689|Extensive Burn
1130979|NCT01443689|Human Cord Blood Mononuclear Cells
1130980|NCT01443689|Human Umbilical Cord Mesenchymal Stem Cells
1130981|NCT01443637|Coronary Artery Disease
1130982|NCT01443637|CAD
1130983|NCT01443637|Atherosclerosis
1130984|NCT01443637|Myocardial Infarction
1130985|NCT01443637|MI
1130986|NCT01443637|CONFIRM
1130987|NCT01443637|Coronary Computed Tomographic Angiography
1130988|NCT01443637|CCTA
1130989|NCT01443624|iron
1130990|NCT01443624|critical illness
1130991|NCT01443624|oxidative stress
1130992|NCT01443611|Infants
1130993|NCT01443598|Pulmonary arterial hypertension,
1130994|NCT01443598|Interstitial lung disease at HRCT
1130995|NCT01443585|Progressive Addition Lens
1130996|NCT01443585|Multifocal
1130997|NCT01443585|Presbyopia
1130998|NCT01443572|Kasai operation under general anesthesia
1130999|NCT01443559|Xenogenic
1131000|NCT01443546|oocyte donor
1131001|NCT01443546|oocyte recipient
1131002|NCT01443546|ovulation trigger
1131003|NCT01443533|Contraception
1131004|NCT01443533|Contraception behavior
1131005|NCT01443533|Postnatal care
1131006|NCT01443533|Health education
1131007|NCT01443533|Randomized controlled trial
1131008|NCT01443520|Pharmacokinetics
1131009|NCT01443520|Pharmacodynamics
1131010|NCT01443507|aerobic capacity
1131011|NCT01443507|maximal oxygen uptake
1131012|NCT01443507|aerobic endurance
1131013|NCT01443507|work economy
1131014|NCT01443507|lactate threshold
1131015|NCT01443507|endurance training
1131016|NCT01443507|exercise intensity
1131017|NCT01443494|septic shock
1131018|NCT01443494|microcirculation
1131019|NCT01443494|norepinephrine
1131020|NCT01443494|fluid
1131021|NCT01443481|solid tumors
1131022|NCT01443481|hepatic impairment
1131023|NCT01443481|Child-Pugh classification
1131024|NCT01443481|pharmacokinetics
1131025|NCT01443481|PK
1131026|NCT01443481|RECIST 1.1
1131027|NCT01443468|Tp53
1131028|NCT01443468|Cancer
1131029|NCT01443468|Hereditary
1131030|NCT01443468|Genetic Testing
1131031|NCT01443468|Screening
1131032|NCT01443468|Li-Fraumeni Syndrome
1131033|NCT01443468|LFS
1131034|NCT01443455|menopause
1131035|NCT01443455|sedentary
1131036|NCT01443455|overweight
1131037|NCT01443442|Conjunctivitis
1131038|NCT01443442|Allergic
1131039|NCT01443442|Bepotastine besilate
1131040|NCT01443442|Loteprednol etabonate
1131041|NCT01443429|TRK-100STP
1131042|NCT01443429|PK
1131043|NCT01443429|beraprost sodium
1131044|NCT01443429|Japanese males and females
1131045|NCT01443429|Subjects with mild/moderate/severe patients
1131046|NCT01443429|renal impairment
1131047|NCT01443416|pneumococcal conjugate vaccine
1131048|NCT01443416|invasive pneumococcal disease
1131049|NCT01443416|vaccination
1131050|NCT01443416|children
1131051|NCT01443403|Opioid Therapy
1131052|NCT01443403|Non-Malignant Chronic Pain
1131053|NCT01443403|Opioid-Induced Constipation
1131054|NCT01443390|Whole genome sequencing
1131055|NCT01443390|Advanced Refractory Cancer
1131056|NCT01443377|Neorec
1131057|NCT01443377|rectal cancer
1131058|NCT01443377|KRAS
1131059|NCT01443377|Panitumumab
1131060|NCT01443377|neoadjuvant
1131061|NCT01443377|Radiochemotherapy
1131062|NCT01443377|antibody
1131063|NCT01443377|locally advanced KRAS wild type rectal cancer
1131064|NCT01443364|Certolizumab pegol - Cimzia
1131065|NCT01443364|Rheumatoid Arthritis
1131066|NCT01443364|Power Doppler Ultrasonography
1131067|NCT01443364|Italy
1131068|NCT01443364|Moderate-severe Rheumatoid Arthritis
1131069|NCT01443351|ITP
1131070|NCT01443351|romiplostim
1131071|NCT01443351|eltrombopag
1131072|NCT01443351|bone marrow fibrosis
1131073|NCT01443351|long-term safety
1131074|NCT01443338|Triptergium wilfordii
1131075|NCT01443338|Acitretin
1131076|NCT01443338|psoriasis vulgaris
1131077|NCT01443325|Persistent Postherniorrhaphy inguinal Pain
1131078|NCT01443312|Beta globin gene
1131079|NCT01443312|Alfa globin gene
1131080|NCT01443312|xmn1 polymorphism
1131081|NCT01443273|Newborns
1131082|NCT01443260|oncolytic virus
1131083|NCT01443260|oncolytic
1131084|NCT01443260|GL-ONC1
1131085|NCT01443260|Vaccinia
1131086|NCT01443260|Vaccinia virus
1131087|NCT01443260|Genelux
1131088|NCT01443260|Genelux GmbH
1131089|NCT01443260|peritoneal
1131090|NCT01443260|peritoneal carcinomatosis
1131091|NCT01443260|cancer
1131092|NCT01443260|abdominal cancer
1131093|NCT01443260|imaging
1131094|NCT01443234|Depression
1131095|NCT01443234|Cognitive Bias
1131096|NCT01443234|Internet
1131097|NCT01443221|mitiglinide
1131098|NCT01443221|metformin
1131099|NCT01443221|Pharmacokinetics
1131100|NCT01443221|Safety
1131101|NCT01443208|pharmacokinetics
1131102|NCT01443208|safety
1131103|NCT01443208|desvenlafaxine
1131104|NCT01443208|Korean healthy subjects
1131105|NCT01443169|Pharmacokinetic
1131106|NCT01443169|relative oral bioavailability
1131107|NCT01443169|pregabalin
1131108|NCT01443156|Diet
1131109|NCT01443156|Sleep deficiency
1131110|NCT01443156|Cancer
1131111|NCT01443156|Obesity
1131112|NCT01443156|Diabetes
1131113|NCT01443156|Shift work
1131114|NCT01443156|Work schedule
1131115|NCT01443156|Cardiovascular disease
1131116|NCT01443156|Body composition
1131117|NCT01443156|Body mass index
1131118|NCT01443156|Body fat percentage
1131119|NCT01443143|Diabetes
1131120|NCT01443143|Obesity
1131121|NCT01443143|Glycemic
1131122|NCT01443143|Portion-control
1131123|NCT01443143|Commercial diet
1131124|NCT01443130|malaria,Malawi,pregnancy
1131125|NCT01443104|coronary artery disease
1131126|NCT01443104|drug-eluting stents
1131127|NCT01443104|polymers
1131128|NCT01443091|very low birth weight infants
1131129|NCT01443091|VLBW infants
1131130|NCT01443091|colostrum
1131131|NCT01443078|Carboplatin
1131132|NCT01443078|Cisplatin
1131133|NCT01443078|Pemetrexed (Altima)
1131134|NCT01443078|Taxotere (Docetaxel)
1131135|NCT01443078|Vinorelbine Tartrate (Navelbine)
1131136|NCT01443078|Stage IB-III
1131137|NCT01443078|non squamous
1131138|NCT01443078|non-small cell lung cancer
1131139|NCT01443078|11-106
1131140|NCT01443065|Adenocarcinoma
1131141|NCT01443065|Locally advanced (non operable) or metastatic
1131142|NCT01443065|First line treatment
1131143|NCT01443052|Gait stability
1131144|NCT01443052|Spatiotemporal parameters
1131145|NCT01443052|Walking
1131146|NCT01443052|Elderly people
1131147|NCT01443052|Stroke
1131148|NCT01443052|Fallers
1131149|NCT01443039|drug metabolizing enzymes and drug transporter
1131150|NCT01443039|Roux-en Y-Gastric Bypass
1131151|NCT01443039|Obesity
1131152|NCT01443039|Drug Availability
1131153|NCT01443039|BMI over 35kg/m² and comorbidities or >40kg/m²
1131154|NCT01443026|Intraepithelial Prostatic Neoplasia
1131155|NCT01443026|Prostatic neoplasms
1131156|NCT01443026|Male urogenital disease
1131157|NCT01443026|Prostate
1131158|NCT01443013|Tolerance
1131159|NCT01443013|Renal Transplantation
1131160|NCT01443013|Chronic allograft nephropathy
1131161|NCT01443000|Observational study
1131162|NCT01443000|IOIS
1131163|NCT01443000|Orbital Pseudotumor
1131164|NCT01443000|Outcome
1131165|NCT01443000|Treatment
1131166|NCT01442987|Irbesartan
1131167|NCT01442987|Atorvastatin
1131168|NCT01442987|Hypertension
1131169|NCT01442987|Hyperlipidemia
1131170|NCT01442974|nab-paclitaxel
1131171|NCT01442974|neoadjuvant treatment
1131172|NCT01442974|SPARC
1131173|NCT01442974|Pancreatic Cancer
1131174|NCT01442961|pain, postoperative
1131175|NCT01442961|hysterectomy, vaginal
1131176|NCT01442961|surgery, gynecological
1131177|NCT01442948|-CD16+ monocytes
1131178|NCT01442935|Adenocarcinoma
1131179|NCT01442935|Non-resectable hepatic metastases
1131180|NCT01442935|First-line treatment
1131181|NCT01442922|L3-L4
1131182|NCT01442922|L4-L5
1131183|NCT01442922|L5-S1
1131184|NCT01442922|Human Meniscus Allograft
1131185|NCT01442922|Nucleus pulposus
1131186|NCT01442922|Minimally invasive surgery
1131187|NCT01442922|Degeneration of L3-L4 Intervertebral Disc
1131188|NCT01442922|Degeneration of L4-L5 Intervertebral Disc
1131189|NCT01442922|Degeneration of L5-S1 Intervertebral Disc
1131190|NCT01442909|lung cancer
1131191|NCT01442909|docetaxel
1131192|NCT01442909|pemetrexed
1131193|NCT01442883|Treatment Resistant
1131194|NCT01442857|Magnetic Resonance Imaging
1131195|NCT01442857|Nerve Net
1131196|NCT01442857|Brachial Plexus
1131197|NCT01442857|Nerve block
1131198|NCT01442844|Mohs
1131199|NCT01442844|Scalp
1131200|NCT01442831|metabolic profile of TR-700 in plasma urine
1131201|NCT01442818|vaginal reconstructive surgery
1131202|NCT01442805|Cognitive Behavior Therapy
1131203|NCT01442805|Virtual Reality Exposure Therapy
1131204|NCT01442805|Psychophysiological Measures
1131205|NCT01442805|Driving Phobia
1131206|NCT01442805|Flying Phobia
1131207|NCT01442792|Angioplasty, Balloon, Coronary
1131208|NCT01442779|Idiopathic Pulmonary Fibrosis
1131209|NCT01442779|Interferon alpha
1131210|NCT01442766|cholinesterase inhibitor
1131211|NCT01442766|donepezil
1131212|NCT01442766|motor
1131213|NCT01442766|stroke
1131214|NCT01442753|Spanish speaking
1131215|NCT01442740|Functional Endoscopic Sinus Surgery
1131216|NCT01442740|Reverse Trendelenburg Position
1131217|NCT01442727|arsenical melanosis
1131218|NCT01442727|arsenical melanoses
1131219|NCT01442727|arsenical keratosis
1131220|NCT01442727|arsenical keratoses
1131221|NCT01442727|arsenical cancer
1131222|NCT01442727|arsenic cancers
1131223|NCT01442727|arsenic
1131224|NCT01442727|arsenicosis
1131225|NCT01442727|arsenic exposure
1131226|NCT01442727|arsenic toxicity
1131227|NCT01442727|arsenic poisoning
1131228|NCT01442727|drinking water
1131229|NCT01442727|selenium
1131230|NCT01442727|selenite
1131231|NCT01442727|sodium selenite
1131232|NCT01442675|Meningitis
1131233|NCT01442675|Meningococcal Infection
1131234|NCT01442675|Menactra®
1131235|NCT01442662|Metastatic or relapsed uterine or soft tissue leiomyosarcoma
1131236|NCT01442649|Adenocarcinoma
1131237|NCT01442649|Metastatic
1131238|NCT01442649|Second-line treatment
1131239|NCT01442649|Progressive disease after first-line treatment with bevacizumab
1131240|NCT01442649|Non-mutated (wild-type) KRAS.
1131241|NCT01442623|Vestibular Rehabilitation
1131242|NCT01442623|Balance
1131243|NCT01442623|Virtual Reality
1131244|NCT01442623|Gait
1131245|NCT01442623|Dizziness
1131246|NCT01442610|Rasagiline
1131247|NCT01442610|Sleep disorder
1131248|NCT01442610|Parkinson's disease
1131249|NCT01442610|Sleep Disturbances in patients with parkinsons's disease
1131250|NCT01442597|cognitive behavior therapy
1131251|NCT01442597|computer assisted instruction
1131252|NCT01442597|drug abuse therapy
1131253|NCT01442597|educational resource design and development
1131254|NCT01442584|ovary
1131255|NCT01442584|cortex
1131256|NCT01442584|transplantation
1131257|NCT01442571|Adult Men and Women, who underwent arthroscopy of the knee with cartilage injury of ICRS grade 2 or higher
1131258|NCT01442558|relief
1131259|NCT01442558|Intra-operative
1131260|NCT01442545|Rheumatoid Arthritis
1131261|NCT01442545|JNJ-39758979
1131262|NCT01442545|Methotrexate
1131263|NCT01442532|Healthy male volunteer
1131264|NCT01442532|JNJ-38518168
1131265|NCT01442532|Midazolam
1131266|NCT01442519|non-muscle invasive urothelial bladder cancer
1131267|NCT01442519|intravesical therapy
1131268|NCT01442519|BCG
1131269|NCT01442519|mitomycin
1131270|NCT01442519|electromotive drug administration
1131271|NCT01442519|Bladder Cancer Stage 0, Without Cancer in Situ
1131272|NCT01442506|acetic acid
1131273|NCT01442506|virtual chromoendosopy
1131274|NCT01442493|Methadone Treatment
1131275|NCT01442493|Opiate dependence
1131276|NCT01442493|Services research
1131277|NCT01442480|air pollution
1131278|NCT01442480|fatty acid supplementation
1131279|NCT01442467|mitral annular calcification
1131280|NCT01442467|MAC
1131281|NCT01442467|left atrial pressure
1131282|NCT01442467|LAP
1131283|NCT01442467|left ventricular end diastolic pressure
1131284|NCT01442467|LVEDP
1131285|NCT01442467|Echocardiogram
1131286|NCT01442454|chronic pancreatitis
1131287|NCT01442441|chronic pancreatitis
1131288|NCT01442428|TB
1131289|NCT01442428|AIDS
1131290|NCT01442428|HIV
1131291|NCT01442428|IRIS
1131292|NCT01442428|immune reconstitution inflammatory syndrome
1131293|NCT01442428|anti-inflammatory
1131294|NCT01442428|treatment
1131295|NCT01442376|Prevention of Chemotherapy-Induced Nausea and Vomiting
1131296|NCT01442376|Palonosetron
1131297|NCT01442376|Ondansetron
1131298|NCT01442376|Pediatric
1131299|NCT01442363|Crohn's disease
1131300|NCT01442363|perianal
1131301|NCT01442363|inflammatory bowel disease
1131302|NCT01442363|fistula
1131303|NCT01442350|Fabry disease
1131304|NCT01442350|annexin 5
1131305|NCT01442350|miosin
1131306|NCT01442350|sarcoma
1131307|NCT01442350|alfa-galactosidase
1131308|NCT01442350|fibrosis
1131309|NCT01442350|apoptosis
1131310|NCT01442350|biomarkers
1131311|NCT01442350|NT-proBNP
1131312|NCT01442337|de novo kidney transplant
1131313|NCT01442337|kidney transplant
1131314|NCT01442337|ASP8597
1131315|NCT01442337|diannexin
1131316|NCT01442337|ischemia-reperfusion injury
1131317|NCT01442324|Laparotomic surgery
1131318|NCT01442324|Laparoscopic surgery
1131319|NCT01442324|Percutaneos tumour ablation
1131320|NCT01442324|Irreversible electroporation (IRE)
1131321|NCT01442311|Hepatitis C Virus
1131322|NCT01442311|Chronic Hepatitis C
1131323|NCT01442311|Methadone
1131324|NCT01442311|Injection Drug User
1131325|NCT01442311|Adherence
1131326|NCT01442311|Directly Observed Treatment
1131327|NCT01442298|bloodless field
1131328|NCT01442298|cuff pressure
1131329|NCT01442298|limb occlusion pressure
1131330|NCT01442259|Renal impairment,
1131331|NCT01442259|pharmacokinetics,
1131332|NCT01442259|safety
1131333|NCT01442246|Benefit of
1131334|NCT01442246|adjuvant
1131335|NCT01442246|treatment
1131336|NCT01442246|prostatectomy
1131337|NCT01442233|multiple sclerosis
1131338|NCT01442233|plasma exchange
1131339|NCT01442207|Premature Birth
1131340|NCT01442207|Placenta Previa
1131341|NCT01442194|Multiple sclerosis
1131342|NCT01442194|fingolimod
1131343|NCT01442194|observational study
1131344|NCT01442168|Uncomplicated Falciparum Malaria
1131345|NCT01442168|Plasmodium falciparum
1131346|NCT01442168|Antimalarial treatment
1131347|NCT01442168|Sevuparin/DF02
1131348|NCT01442168|Adjuvant therapy
1131349|NCT01442168|Malanil
1131350|NCT01442168|Peripheral blood parasitemia
1131351|NCT01442168|Rosette formation
1131352|NCT01442168|Maximum tolerated dose
1131353|NCT01442155|Colorectal cancer
1131354|NCT01442155|Adjuvant setting
1131355|NCT01442155|Capecitabine
1131356|NCT01442155|Oxaliplatin
1131357|NCT01442142|obesity
1131358|NCT01442142|pediatric
1131359|NCT01442142|childhood
1131360|NCT01442142|overweight
1131361|NCT01442129|Heart Failure
1131362|NCT01442129|Left Ventricular Assist Device
1131363|NCT01442129|Heart Transplantation
1131364|NCT01442129|Cardiomyopathy
1131365|NCT01442129|Destination Therapy
1131366|NCT01442129|Cell Therapy
1131367|NCT01442064|CNV
1131368|NCT01442064|Lucentis
1131369|NCT01442064|AMD
1131370|NCT01442064|Age-related macular degeneration
1131371|NCT01442064|RVO
1131372|NCT01442064|Macular edema secondary to retinal vein occlusion
1131373|NCT01442051|Acute Normovolemic Hemodilution
1131374|NCT01442051|Cytoreductive Surgery
1131375|NCT01442051|laparotomy
1131376|NCT01442051|11-149
1131377|NCT01442051|advanced primary epithelial ovarian cancer
1131378|NCT01442025|Crohn's Disease
1131379|NCT01442025|IFX trough level
1131380|NCT01442012|PONV
1131381|NCT01442012|ACUPUNCTURE
1131382|NCT01441999|Rigid rods
1131383|NCT01441999|less rigid rods
1131384|NCT01441999|prevent kyphosis
1131385|NCT01441999|long constructs
1131386|NCT01441986|dextromethorphan
1131387|NCT01441986|amantadine
1131388|NCT01441986|blood glucose lowering effect
1131389|NCT01441986|oral glucose tolerance test
1131390|NCT01441960|Succinylcholine
1131391|NCT01441960|Rocuronium
1131392|NCT01441960|ECT
1131393|NCT01441947|ER+
1131394|NCT01441947|PR+
1131395|NCT01441947|Human Epidermal Growth Factor Receptor (HER) 2 negative
1131396|NCT01441947|metastatic
1131397|NCT01441921|pistachio intake
1131398|NCT01441921|insulin resistance
1131399|NCT01441921|type 2 diabetes mellitus
1131400|NCT01441908|Cardiovascular
1131401|NCT01441908|Multi-analyte
1131402|NCT01441908|Statin
1131403|NCT01441908|Dyslipidemia
1131404|NCT01441895|Refractive Cataract Extraction
1131405|NCT01441895|Femtosecond laser
1131406|NCT01441895|arcuate relaxing incisions
1131407|NCT01441895|Dry Eye post cataract refraction
1131408|NCT01441869|Phase 1, Healthy male volunteers, pharmacokinetics, saxagliptin/ metformin , Diabex
1131409|NCT01441856|Open
1131410|NCT01441856|Laparoscopic
1131411|NCT01441856|Hemihepatectomy
1131412|NCT01441856|Enhanced Recovery After Surgery
1131413|NCT01441856|Functional recovery
1131414|NCT01441843|quality of life
1131415|NCT01441843|lorazepam
1131416|NCT01441843|anxiety
1131417|NCT01441843|premedication
1131418|NCT01441843|surgery
1131419|NCT01441843|Adult patients
1131420|NCT01441843|Ambulatory Surgical Procedures
1131421|NCT01441843|Postoperative Period
1131422|NCT01441830|shoulder
1131423|NCT01441830|subacromial
1131424|NCT01441830|impingement
1131425|NCT01441830|tendinopathy
1131426|NCT01441830|rESWT
1131427|NCT01441830|shock wave
1131428|NCT01441830|ESWT
1131429|NCT01441830|RSWT
1131430|NCT01441791|PEEP
1131431|NCT01441791|Positive end-expiratory pressure
1131432|NCT01441791|Recruitment maneuver
1131433|NCT01441791|Open lung approach
1131434|NCT01441791|Post-operative complications
1131435|NCT01441791|Open abdominal surgery
1131436|NCT01441778|nasal irrigation
1131437|NCT01441778|allergic rhinitis
1131438|NCT01441778|children
1131439|NCT01441765|Kidney
1131440|NCT01441765|Metastatic
1131441|NCT01441765|Stage IV
1131442|NCT01441726|Advanced dementia
1131443|NCT01441726|Quality
1131444|NCT01441726|Terminal care
1131445|NCT01441713|Hormone treatment
1131446|NCT01441713|castration
1131447|NCT01441713|Orchiectomy
1131448|NCT01441713|treatment frequency
1131449|NCT01441713|treatment satisfaction
1131450|NCT01441713|side effects
1131451|NCT01441700|Prone emergence
1131452|NCT01441700|supine emergence
1131453|NCT01441700|coughing
1131454|NCT01441700|haemodynamic stimulation
1131455|NCT01441700|lumbar surgery
1131456|NCT01441687|Health status unknown
1131457|NCT01441687|healthy,no evidence of disease
1131458|NCT01441674|Occupational Therapy
1131459|NCT01441661|Sunitinib
1131460|NCT01441661|kidney diseases
1131461|NCT01441661|urogenital neoplasms
1131462|NCT01441661|kidney cancer
1131463|NCT01441648|conjunctival injection
1131464|NCT01441648|conjunctival papillary hypertrophy
1131465|NCT01441648|pannus formation
1131466|NCT01441648|corneal epitheliopathy
1131467|NCT01441648|Schirmer test
1131468|NCT01441648|Impression cytology
1131469|NCT01441648|confocal microscopy
1131470|NCT01441648|Scanning electronmicroscopy (SEM)
1131471|NCT01441648|bacterial adhesion determination
1131472|NCT01441635|Elagolix
1131473|NCT01441635|Uterine Fibroids
1131474|NCT01441635|Elagolix sodium
1131475|NCT01441635|Leiomyomata
1131476|NCT01441635|Heavy Uterine Bleeding
1131477|NCT01441635|Menorrhagia
1131478|NCT01441635|ABT-620
1131479|NCT01441622|Continuous Positive Airway Pressure (CPAP)
1131480|NCT01441622|AL539
1131481|NCT01441622|Home-monitoring
1131482|NCT01441609|Th9 cells
1131483|NCT01441609|IL9
1131484|NCT01441609|non/poor responsiveness to hepatitis B
1131485|NCT01441609|collect blood samples after vaccination
1131486|NCT01441583|pacemaker, CRT-P, auto threshold
1131487|NCT01441570|kidney
1131488|NCT01441570|transplant
1131489|NCT01441570|hypertension
1131490|NCT01441570|nebivolol
1131491|NCT01441570|metoprolol
1131492|NCT01441570|bystolic
1131493|NCT01441570|toprol
1131494|NCT01441557|mechanical ventilation
1131495|NCT01441544|active video games
1131496|NCT01441544|Energy expenditure
1131497|NCT01441531|narcotic use
1131498|NCT01441531|Other Acute Pain
1131499|NCT01441492|Distal pancreatectomy
1131500|NCT01441492|Pancreas resection
1131501|NCT01441466|bronchiolitis
1131502|NCT01441466|RSV
1131503|NCT01441453|Hepatocellular carcinoma
1131504|NCT01441453|Cirrhosis
1131505|NCT01441453|Liver resection
1131506|NCT01441453|FibroScan
1131507|NCT01441440|venlafaxine ER
1131508|NCT01441440|Major depressive disorder
1131509|NCT01441440|Japan
1131510|NCT01441440|placebo-controlled
1131511|NCT01441427|feeding intolerance
1131512|NCT01441427|recombinant growth factors
1131513|NCT01441427|G-CSF
1131514|NCT01441427|EPO
1131515|NCT01441427|necrotizing enterocolitis
1131516|NCT01441414|CVX-060
1131517|NCT01441414|PF-04856884
1131518|NCT01441414|AG-013736
1131519|NCT01441414|axitinib
1131520|NCT01441414|mRCC
1131521|NCT01441414|metastatic renal cell cancer
1131522|NCT01441414|second line
1131523|NCT01441414|anti-angiogenic
1131524|NCT01441414|Ang-2
1131525|NCT01441401|Gabapentin
1131526|NCT01441401|Epilepsies
1131527|NCT01441401|safety
1131528|NCT01441388|Phase 1b
1131529|NCT01441388|crizotinib
1131530|NCT01441388|sunitinib
1131531|NCT01441388|axitinib
1131532|NCT01441388|sorafenib
1131533|NCT01441388|bevacizumab
1131534|NCT01441388|cMET inhibitor
1131535|NCT01441388|VEGF inhibitor
1131536|NCT01441388|crizotinib combination
1131537|NCT01441375|Sickle cell anemia
1131538|NCT01441362|during double-lumen
1131539|NCT01441362|tube intubation
1131540|NCT01441349|Simvastatin
1131541|NCT01441349|SCLC
1131542|NCT01441349|Extensive Disease
1131543|NCT01441323|Obesity
1131544|NCT01441323|Type 2 Diabetes
1131545|NCT01441323|Cardiovascular Risk
1131546|NCT01441323|Cancer
1131547|NCT01441323|African American
1131548|NCT01441323|Adolescents
1131549|NCT01441323|Strength Training
1131550|NCT01441323|Nutrition
1131551|NCT01441310|Gastric cancer
1131552|NCT01441310|Sentinel node navigation surgery
1131553|NCT01441310|Dual method
1131554|NCT01441310|Recurrence
1131555|NCT01441297|recurrent small cell lung cancer
1131556|NCT01441284|pramipexole
1131557|NCT01441284|essential tremor
1131558|NCT01441284|cross-over
1131559|NCT01441245|acute heart failure
1131560|NCT01441245|diuretics
1131561|NCT01441245|BNP
1131562|NCT01441245|Renal function
1131563|NCT01441245|acute decompensated Heart Failure,
1131564|NCT01441245|volume overload
1131565|NCT01441206|rifampin
1131566|NCT01441206|infants
1131567|NCT01441193|HIV
1131568|NCT01441193|preventive vaccine
1131569|NCT01441193|Tat
1131570|NCT01441193|Env
1131571|NCT01441180|Direct Acting Antiviral
1131572|NCT01441180|Liver
1131573|NCT01441180|Hepatitis C
1131574|NCT01441180|HCV
1131575|NCT01441167|Healthy Subjects
1131576|NCT01441167|Immunogenicity
1131577|NCT01441167|Vaccine-Mediated Protection
1131578|NCT01441167|Sporozoites
1131579|NCT01441167|Parasitemia
1131580|NCT01441167|Healthy Volunteer
1131581|NCT01441167|HV
1131582|NCT01441154|Hypothyroidism
1131583|NCT01441154|Thyroid Cancer
1131584|NCT01441154|Triiodothyronine (T3)
1131585|NCT01441154|Energy Expenditure
1131586|NCT01441154|Thyroid Hormone
1131587|NCT01441141|GCH1
1131588|NCT01441141|Pain Sensitivity
1131589|NCT01441141|Quantitative Sensory Testing (QST)
1131590|NCT01441141|Genetic Variation
1131591|NCT01441141|Sickle Cell Anemia
1131592|NCT01441128|Lung Neoplasms
1131593|NCT01441128|Epithelial-Mesenchymal Transition Factor (c-Met)
1131594|NCT01441128|Tyrosine Kinase Inhibitor
1131595|NCT01441128|Hepatocyte Growth Factor Receptor
1131596|NCT01441128|Epidermal Growth Factor Receptor
1131597|NCT01441128|Non Small Cell Lung Cancer
1131598|NCT01441128|NSCLC
1131599|NCT01441115|Metastasis
1131600|NCT01441115|Cancer
1131601|NCT01441115|Radiation Therapy
1131602|NCT01441115|Locally Advanced
1131603|NCT01441115|Palliation
1131604|NCT01441115|Metastatic Cancer
1131605|NCT01441102|Diabetic Macular Edema
1131606|NCT01441102|Microglia
1131607|NCT01441102|Dextromethorphan
1131608|NCT01441089|Pharmacogenetics
1131609|NCT01441089|Pharmacokinetics
1131610|NCT01441089|Pharmacodynamics
1131611|NCT01441089|Clinical Outcome
1131612|NCT01441089|Drug Metabolism and Transport
1131613|NCT01441089|Cancer
1131614|NCT01441076|Behcet's Disease
1131615|NCT01441076|Aphthous Ulcer
1131616|NCT01441076|Uveitis
1131617|NCT01441076|IL-1
1131618|NCT01441076|Autoinflammation
1131619|NCT01441076|BD
1131620|NCT01441063|Kaposi Sarcoma Herpesvirus
1131621|NCT01441063|Human Immunodeficiency Virus
1131622|NCT01441063|Tocilizumab
1131623|NCT01441063|Multicentric Castleman Disease
1131624|NCT01441063|Interleukin-6
1131625|NCT01441063|Castleman Disease
1131626|NCT01441037|Aplastic Anemia
1131627|NCT01441037|Androgen
1131628|NCT01441037|Telomeres
1131629|NCT01441024|Immunocompromised
1131630|NCT01441024|Respiratory Tract Disease
1131631|NCT01441024|Viral Shedding
1131632|NCT01441024|Fever
1131633|NCT01441024|Pharmacokinetics
1131634|NCT01441024|Parainfluenza Infection
1131635|NCT01441024|Flu
1131636|NCT01441011|weight loss
1131637|NCT01441011|breast cancer
1131638|NCT01441011|obesity
1131639|NCT01441011|overweight
1131640|NCT01441011|rural women
1131641|NCT01441011|community based
1131642|NCT01441011|Secondary Prevention
1131643|NCT01440985|Tooth Staining
1131644|NCT01440972|knee osteoarthritis
1131645|NCT01440972|symptomatic knee osteoarthritis
1131646|NCT01440972|isotonic leg-press strength
1131647|NCT01440972|isokinetic knee extensor strength
1131648|NCT01440972|quadriceps volume
1131649|NCT01440959|This is a single-center
1131650|NCT01440959|prospective
1131651|NCT01440959|single-arm
1131652|NCT01440959|open-label phase II study
1131653|NCT01440933|sugammadex
1131654|NCT01440933|rocuronium
1131655|NCT01440933|magnesiumsulphate
1131656|NCT01440933|neuromuscular monitoring
1131657|NCT01440920|Acute myeloid leukemia
1131658|NCT01440920|WT1
1131659|NCT01440907|Health Information Technology
1131660|NCT01440907|Health Records, Personal
1131661|NCT01440907|Hospital Information Systems
1131662|NCT01440907|Patient Access to Records
1131663|NCT01440907|Medical Records
1131664|NCT01440907|Medical Record Systems, Computerized
1131665|NCT01440894|weight
1131666|NCT01440894|body fat
1131667|NCT01440894|total body water
1131668|NCT01440894|bone mass
1131669|NCT01440894|muscle mass
1131670|NCT01440881|renal failure
1131671|NCT01440881|cardiopulmonary bypass
1131672|NCT01440868|Respiratory Distress Syndrome, Newborn
1131673|NCT01440868|Delivery Rooms
1131674|NCT01440868|Resuscitation
1131675|NCT01440868|Premature Birth
1131676|NCT01440868|Infant, Newborn
1131677|NCT01440868|Respiration, Artificial
1131678|NCT01440855|Survivorship
1131679|NCT01440855|cancer control
1131680|NCT01440855|psychosocial interventions
1131681|NCT01440855|Facing Forward
1131682|NCT01440842|Stress hyperglycaemia
1131683|NCT01440829|Transjugular Intrahepatic Portosystemic Shunt
1131684|NCT01440829|TIPS
1131685|NCT01440829|Liver Cirrhosis
1131686|NCT01440829|LOLA
1131687|NCT01440829|L-ornithine-L-aspartate
1131688|NCT01440829|Refractory Ascites
1131689|NCT01440803|osteoporosis
1131690|NCT01440803|premenopausal
1131691|NCT01440803|forteo
1131692|NCT01440803|idiopathic
1131693|NCT01440803|Idiopathic Osteoporosis in Premenopausal Women
1131694|NCT01440777|Insomnia
1131695|NCT01440777|Sleep
1131696|NCT01440777|Stress
1131697|NCT01440777|Online program
1131698|NCT01440777|Web-based program
1131699|NCT01440777|Cognitive Behavioral Therapy for Insomnia (CBT-i)
1131700|NCT01440764|dyspnea
1131701|NCT01440764|Laboratory model of dyspnea in healthy subjects
1131702|NCT01440751|ologen collagen matrix
1131703|NCT01440751|mitomycin-C
1131704|NCT01440751|trabeculectomy
1131705|NCT01440751|glaucoma
1131706|NCT01440751|filtering surgery
1131707|NCT01440738|general population
1131708|NCT01440725|muscle
1131709|NCT01440725|injuries
1131710|NCT01440725|platelet-rich plasma
1131711|NCT01440725|autologous
1131712|NCT01440725|haematoma
1131713|NCT01440712|Gastrografin
1131714|NCT01440712|Postoperative ileus
1131715|NCT01440712|Colo-rectal surgery
1131716|NCT01440712|Effects on morbidity and mortality of postoperative ileus
1131717|NCT01440699|Crohn's fistula
1131718|NCT01440686|Pharmacokinetics
1131719|NCT01440686|Pharmacodynamics
1131720|NCT01440686|Safety
1131721|NCT01440686|Male
1131722|NCT01440673|Postoperative Nausea and Vomiting
1131723|NCT01440647|Respiration, Artificial
1131724|NCT01440647|Infant, Premature
1131725|NCT01440647|Bronchopulmonary Dysplasia
1131726|NCT01440647|Continuous Positive Airway Pressure
1131727|NCT01440647|Non-Invasive Positive-Pressure Ventilation
1131728|NCT01440647|Intermittent Positive-Pressure Ventilation
1131729|NCT01440647|High-Frequency Ventilation
1131730|NCT01440634|Peripheral arterial disease
1131731|NCT01440634|Community Medicine
1131732|NCT01440634|Exercise Test
1131733|NCT01440634|Exercise Therapy
1131734|NCT01440621|Cancer related fatigue
1131735|NCT01440621|Quality of life
1131736|NCT01440621|Modafinil
1131737|NCT01440621|Radiation therapy
1131738|NCT01440621|Radiotherapy
1131739|NCT01440582|Myeloma
1131740|NCT01440582|Multiple Myeloma
1131741|NCT01440582|MM
1131742|NCT01440582|Newly diagnosed
1131743|NCT01440582|Transplant eligible
1131744|NCT01440582|Panobinostat
1131745|NCT01440582|LBH589B
1131746|NCT01440582|Bortezomib
1131747|NCT01440582|Velcade
1131748|NCT01440582|LDP-341
1131749|NCT01440582|MLN341
1131750|NCT01440582|PS-341
1131751|NCT01440582|Lenalidomide
1131752|NCT01440582|CC-5013
1131753|NCT01440582|Revlimid
1131754|NCT01440582|Dexamethasone
1131755|NCT01440582|Decadron
1131756|NCT01440582|Symptom questionnaire
1131757|NCT01440582|Survey
1131758|NCT01440569|HIV-1
1131759|NCT01440569|HIV
1131760|NCT01440569|Treatment Naïve
1131761|NCT01440569|Treatment Experienced
1131762|NCT01440556|Allogeneic bone marrow transplantation
1131763|NCT01440556|Multiple myeloma
1131764|NCT01440543|colonoscopy
1131765|NCT01440543|water immersion
1131766|NCT01440543|CO2 insufflation
1131767|NCT01440543|patients referred for diagnostic outpatient colonoscopy
1131768|NCT01440543|(screening, surveillance, symptoms)
1131769|NCT01440543|patient discomfort associated with diagnostic colonoscopy
1131770|NCT01440530|Diabetes Internet Education
1131771|NCT01440530|Diabetes Education
1131772|NCT01440530|Diabetes Self-Care
1131773|NCT01440530|Diabetes Self-Management
1131774|NCT01440530|Diabetes Behavior Intervention
1131775|NCT01440517|CE-MRI - Contrast-enhanced magnetic resonance imaging
1131776|NCT01440517|DM - Diabetes mellitus
1131777|NCT01440517|EKG - Echocardiography
1131778|NCT01440517|HFPEF - Heart failure preserved left ventricular ejection fraction
1131779|NCT01440517|LVEF - Left Ventricular Ejection Fraction
1131780|NCT01440504|Cancer
1131781|NCT01440504|Ovarian
1131782|NCT01440504|chemotherapy
1131783|NCT01440504|BH3-mimetic
1131784|NCT01440504|platin
1131785|NCT01440504|ex-vivo
1131786|NCT01440491|low back pain
1131787|NCT01440491|exercise
1131788|NCT01440491|booklet
1131789|NCT01440465|chemotherapy
1131790|NCT01440465|cancer
1131791|NCT01440465|nausea
1131792|NCT01440465|vomiting
1131793|NCT01440452|TM
1131794|NCT01440452|MS
1131795|NCT01440452|Spinal Cord Injury
1131796|NCT01440452|Functional electrical stimulation
1131797|NCT01440452|Rehabilitation
1131798|NCT01440452|Growth factors
1131799|NCT01440452|Cytokines
1131800|NCT01440439|insulin glargine
1131801|NCT01440439|insulin detemir
1131802|NCT01440439|hypoglycaemia
1131803|NCT01440439|metabolism
1131804|NCT01440439|Exercise
1131805|NCT01440426|gingival recession
1131806|NCT01440426|root coverage
1131807|NCT01440426|periodontal surgery
1131808|NCT01440426|collagen matrix
1131809|NCT01440426|mucograft
1131810|NCT01440426|multiple exposed teeth
1131811|NCT01440413|anti-tumor immune response
1131812|NCT01440413|neo-adjuvant chemotherapy
1131813|NCT01440413|relapse
1131814|NCT01440413|long term survival
1131815|NCT01440413|histo-pathological response
1131816|NCT01440413|tumor cell death
1131817|NCT01440413|tumor associated antigens
1131818|NCT01440413|Calreticulin
1131819|NCT01440413|Localized breast cancer
1131820|NCT01440400|Ultrasound
1131821|NCT01440400|Spinal anesthesia
1131822|NCT01440400|Cesarean section
1131823|NCT01440387|Influenza
1131824|NCT01440387|Phase III
1131825|NCT01440387|Seasonal influenza
1131826|NCT01440374|acute myeloid leukemia (AML)
1131827|NCT01440374|acute myelogenous leukemia (AML)
1131828|NCT01440374|acute non lymphocytic leukemia (ANLL)
1131829|NCT01440374|myeloproliferative disease (MDS)
1131830|NCT01440374|myelodysplastic syndrome ( secondary acute myeloid leukemia)
1131831|NCT01440374|refractory acute myeloid leukemia
1131832|NCT01440348|Achilles allograft
1131833|NCT01440348|cruciate ligament
1131834|NCT01440348|reconstruction
1131835|NCT01440335|Fenoterol
1131836|NCT01440335|Pharmacodynamics
1131837|NCT01440335|Pharmacokinetics
1131838|NCT01440335|Safety
1131839|NCT01440335|Beta Adrenergic Agonist
1131840|NCT01440322|Myopia
1131841|NCT01440322|Contact lenses
1131842|NCT01440309|biliary cirrhosis
1131843|NCT01440283|Neuroblastoma
1131844|NCT01440283|Radiation Therapy
1131845|NCT01440270|Oral cancer
1131846|NCT01440270|Oropharyngeal cancer
1131847|NCT01440270|Induction chemotherapy
1131848|NCT01440270|Targeted chemotherapy
1131849|NCT01440270|Surgery
1131850|NCT01440270|Radiotherapy
1131851|NCT01440270|Effects of Chemotherapy
1131852|NCT01440244|mediastinoscopy
1131853|NCT01440244|pleural evaluation
1131854|NCT01440244|pleural biopsy
1131855|NCT01440244|pleurodesis
1131856|NCT01440231|Rheumatology
1131857|NCT01440231|Double-Blind
1131858|NCT01440231|Placebo-Controlled
1131859|NCT01440231|Multidose
1131860|NCT01440231|Dose-Response
1131861|NCT01440231|Phase II
1131862|NCT01440231|Systemic Lupus Erythematosus
1131863|NCT01440231|SLE
1131864|NCT01440231|Atacicept
1131865|NCT01440218|Idiopathic diseases
1131866|NCT01440218|family member of the affected individual
1131867|NCT01440218|unknown etiology
1131868|NCT01440205|Flu Shot
1131869|NCT01440192|Sarcoidosis
1131870|NCT01440192|Stem cells
1131871|NCT01440192|PDA001
1131872|NCT01440192|Celgene
1131873|NCT01440192|Human Placenta-Derived cells
1131874|NCT01440192|Cenplacel-L
1131875|NCT01440166|Human healthy volunteers
1131876|NCT01440153|Dance
1131877|NCT01440153|Injury
1131878|NCT01440153|Physical condition
1131879|NCT01440153|Exercise
1131880|NCT01440114|emergence agitation
1131881|NCT01440114|pediatric patient
1131882|NCT01440114|fentanyl
1131883|NCT01440114|incidence of emergence agitation
1131884|NCT01440114|severity of emergence agitation
1131885|NCT01440114|adverse outcome from intervention
1131886|NCT01440088|TH-302
1131887|NCT01440088|TH-CR-406
1131888|NCT01440088|SARC021
1131889|NCT01440088|Locally Advanced Soft Tissue Sarcoma
1131890|NCT01440088|Metastatic Soft Tissue Sarcoma
1131891|NCT01440088|Sarcoma
1131892|NCT01440088|Doxorubicin
1131893|NCT01440088|Evofosfamide
1131894|NCT01440075|Kawasaki disease
1131895|NCT01440049|patients with MI- on top of treatment add Eplerenone - assess LVEF and BP
1131896|NCT01440036|carotid artery
1131897|NCT01440036|Atherosclerotic plaque
1131898|NCT01440036|paraoxygenase 1 PON1
1131899|NCT01440036|Patients undergoing carotid artery endarterectomy CEA for carotid artery stenosis
1131900|NCT01440023|tic disorder
1131901|NCT01440023|tourette syndrome
1131902|NCT01440023|habit reversal
1131903|NCT01440023|response inhibition
1131904|NCT01440023|cognitive retraining
1131905|NCT01440010|IORT
1131906|NCT01440010|Boost
1131907|NCT01440010|Breast cancer
1131908|NCT01440010|Local recurrence
1131909|NCT01440010|Toxicity
1131910|NCT01440010|LENT SOMA
1131911|NCT01440010|TARGIT
1131912|NCT01440010|Quality Control Registry
1131913|NCT01439997|Nocturnal polyuria
1131914|NCT01439984|PE
1131915|NCT01439984|IELT
1131916|NCT01439984|DCIT
1131917|NCT01439971|Phase 1
1131918|NCT01439971|Safety
1131919|NCT01439971|Pharmacokinetic
1131920|NCT01439971|Pharmacodynamic
1131921|NCT01439958|Inhalation
1131922|NCT01439958|Lung Transplantation
1131923|NCT01439958|Cyclosporine
1131924|NCT01439945|hot flashes
1131925|NCT01439945|cancer survivor
1131926|NCT01439945|breast cancer
1131927|NCT01439932|plantar fasciitis
1131928|NCT01439932|heel pain
1131929|NCT01439932|manual treatment
1131930|NCT01439932|dorsi flexion
1131931|NCT01439906|Degenerative scoliosis
1131932|NCT01439906|Pain
1131933|NCT01439906|Deformity correction
1131934|NCT01439906|Instrumented arthrodesis
1131935|NCT01439893|Chronic heart failure
1131936|NCT01439893|rhNRG-1
1131937|NCT01439893|Cardiac remodeling
1131938|NCT01439880|High cholesterol
1131939|NCT01439880|Raised cholesterol
1131940|NCT01439880|Cholesterol
1131941|NCT01439880|Elevated Cholesterol
1131942|NCT01439867|Dialysis
1131943|NCT01439867|Sensipar
1131944|NCT01439867|Mimpara
1131945|NCT01439867|Hemodialysis
1131946|NCT01439867|Peritoneal Dialysis
1131947|NCT01439867|Renal
1131948|NCT01439867|Parathyroid hormone
1131949|NCT01439867|Pediatric
1131950|NCT01439854|Insulin sensitivity
1131951|NCT01439854|Mitochondrial function
1131952|NCT01439854|Glucose toxicity
1131953|NCT01439854|Glucosuria
1131954|NCT01439841|HIV
1131955|NCT01439841|microbial translocation
1131956|NCT01439841|immune activation
1131957|NCT01439841|probiotics
1131958|NCT01439828|Cannabis
1131959|NCT01439828|N-Acetylcystein
1131960|NCT01439828|Dependence
1131961|NCT01439828|Abuse
1131962|NCT01439828|Craving
1131963|NCT01439828|Genetic
1131964|NCT01439802|Postpartum IUD
1131965|NCT01439802|Cesarean Delivery
1131966|NCT01439802|6 months postpartum
1131967|NCT01439802|satisfaction
1131968|NCT01439789|Chronic Heart Failure
1131969|NCT01439789|rhNRG-1
1131970|NCT01439789|NT-proBNP
1131971|NCT01439776|chronic hepatitis C
1131972|NCT01439776|SVR
1131973|NCT01439776|Vit D
1131974|NCT01439776|Peginterferon alfa 2a
1131975|NCT01439776|Ribavirin
1131976|NCT01439763|Bullies
1131977|NCT01439763|Bully victims
1131978|NCT01439763|Psychiatric symptoms
1131979|NCT01439750|mantle cell lymphoma
1131980|NCT01439750|lymphoma
1131981|NCT01439737|Asthma
1131982|NCT01439737|metabolomics
1131983|NCT01439737|exhaled breath condensate
1131984|NCT01439724|Oral mucositis
1131985|NCT01439724|Low Level Laser Therapy
1131986|NCT01439724|Head and neck cancer
1131987|NCT01439711|ductal breast carcinoma in situ
1131988|NCT01439711|estrogen receptor-positive breast cancer
1131989|NCT01439698|Cholangiocarcinoma
1131990|NCT01439698|Pancreatic Cancer
1131991|NCT01439698|Bile Duct Cancer
1131992|NCT01439698|Biliary Stricture
1131993|NCT01439698|Bile duct obstruction
1131994|NCT01439698|ENDOHPB
1131995|NCT01439698|Radio Frequency Ablation
1131996|NCT01439698|RFA
1131997|NCT01439698|ERCP
1131998|NCT01439698|Endoscopic Retrograde Cholangiopancreatography
1131999|NCT01439698|Registry
1132000|NCT01439698|Multicenter
1132001|NCT01439685|Cholangiocarcinoma
1132002|NCT01439685|PDT
1132003|NCT01439685|Photodynamic Therapy
1132004|NCT01439685|Bile Duct
1132005|NCT01439685|Bile Duct Obstruction
1132006|NCT01439685|Jaundice
1132007|NCT01439685|Biliary Stent
1132008|NCT01439685|ERCP
1132009|NCT01439685|Obstructive Jaundice
1132010|NCT01439672|Type 1 Diabetes Mellitus
1132011|NCT01439659|Ovarian Cancer
1132012|NCT01439659|Epithelial ovarian cancer
1132013|NCT01439659|First clinical remission
1132014|NCT01439659|Nutritional Supplements
1132015|NCT01439659|Juice Plus +
1132016|NCT01439659|Juice Plus + Complete
1132017|NCT01439659|Dietary counseling
1132018|NCT01439646|empirical
1132019|NCT01439646|ICU
1132020|NCT01439646|high risk patient
1132021|NCT01439633|Barrett's Esophagus
1132022|NCT01439633|Esophagus
1132023|NCT01439633|OCT
1132024|NCT01439633|Imaging
1132025|NCT01439620|Biliary Stricture
1132026|NCT01439620|OCT
1132027|NCT01439620|Imaging
1132028|NCT01439607|Gaucher disease
1132029|NCT01439594|Barrett's Esophagus
1132030|NCT01439594|Esophagus
1132031|NCT01439594|OCT
1132032|NCT01439594|Imaging
1132033|NCT01439594|Radiofrequency Ablation
1132034|NCT01439594|BARRX
1132035|NCT01439581|patients
1132036|NCT01439581|susceptible to
1132037|NCT01439581|hospital
1132038|NCT01439581|acquired pressure
1132039|NCT01439568|Cancer
1132040|NCT01439568|Lung
1132041|NCT01439568|Metastasis
1132042|NCT01439555|Early Alzheimer
1132043|NCT01439555|Mild Cognitive Impairment
1132044|NCT01439555|Drug treatment
1132045|NCT01439555|Cerebral blood flow
1132046|NCT01439555|Endothelial facilitation
1132047|NCT01439555|Cognitive improvement
1132048|NCT01439542|High risk prostate cancer
1132049|NCT01439529|Cardiac
1132050|NCT01439529|Resynchronization
1132051|NCT01439529|Therapy
1132052|NCT01439477|exercise
1132053|NCT01439477|healthy eating
1132054|NCT01439477|heart disease
1132055|NCT01439477|prevention & control
1132056|NCT01439477|Middle aged
1132057|NCT01439477|Women
1132058|NCT01439477|Health promotion
1132059|NCT01439451|Balance control
1132060|NCT01439451|Aging
1132061|NCT01439451|Balance reactions
1132062|NCT01439451|Perturbation
1132063|NCT01439451|above seventy years old
1132064|NCT01439425|psoriasis
1132065|NCT01439425|obesity
1132066|NCT01439425|body mass index
1132067|NCT01439425|disease remission
1132068|NCT01439425|diet
1132069|NCT01439412|Low back pain
1132070|NCT01439412|Acupuncture
1132071|NCT01439412|General practice
1132072|NCT01439399|postoperative pain
1132073|NCT01439399|postoperative care
1132074|NCT01439399|intravenous lidocaine
1132075|NCT01439399|intravenous ketamine
1132076|NCT01439399|morphine consumption
1132077|NCT01439373|chronic hepatitis C
1132078|NCT01439373|NS5A inhibitor
1132079|NCT01439373|ribavirin
1132080|NCT01439373|pegylated interferon
1132081|NCT01439373|GSK2336805
1132082|NCT01439360|Vaccine
1132083|NCT01439360|Seasonal Flu
1132084|NCT01439360|Efficacy
1132085|NCT01439360|Children
1132086|NCT01439347|Marqibo
1132087|NCT01439347|HALLMARQ
1132088|NCT01439347|leukemia
1132089|NCT01439347|front-line
1132090|NCT01439347|ALL
1132091|NCT01439347|acute lymphoblastic leukemia
1132092|NCT01439334|Brief
1132093|NCT01439334|Online
1132094|NCT01439334|Image
1132095|NCT01439334|Interactive
1132096|NCT01439334|Young Adult
1132097|NCT01439334|Primary Care
1132098|NCT01439321|treatment satisfaction
1132099|NCT01439321|romiplostim
1132100|NCT01439321|eltrombopag
1132101|NCT01439321|chronic immune thrombocytopenic pupura
1132102|NCT01439308|NAR
1132103|NCT01439308|Capsaicin challenge
1132104|NCT01439295|Ascorbyl peroxide
1132105|NCT01439295|Bronchopulmonary dysplasia
1132106|NCT01439295|Redox status
1132107|NCT01439295|Necrotising entercolitis
1132108|NCT01439295|Retinopathy of prematurity
1132109|NCT01439295|Patent ductus arteriosus
1132110|NCT01439295|Intraventricular hemorrhage
1132111|NCT01439295|Periventricular leucomalacia
1132112|NCT01439282|Estrogen Receptor-Positive Early Stage Breast Cancer
1132113|NCT01439269|Separation stress
1132114|NCT01439269|Family Nurture
1132115|NCT01439269|Maternal Confidence
1132116|NCT01439269|Maternal Competence
1132117|NCT01439269|Calming Cycle
1132118|NCT01439269|Kangaroo Care
1132119|NCT01439269|Infant Neurodevelopment
1132120|NCT01439269|Infant Psychological Development
1132121|NCT01439269|Post-partum depression
1132122|NCT01439269|Mother-infant Co-regulation
1132123|NCT01439243|Bioequivalence
1132124|NCT01439243|Healthy Subjects
1132125|NCT01439243|Donepezil
1132126|NCT01439230|Bioequivalence
1132127|NCT01439230|Healthy Subjects
1132128|NCT01439230|Donepezil
1132129|NCT01439217|Acute lymphoblastic leukemia
1132130|NCT01439217|Survivor
1132131|NCT01439217|Sibling control
1132132|NCT01439191|HER2-Overexpressed
1132133|NCT01439165|Adacel vaccine
1132134|NCT01439165|Tetanus
1132135|NCT01439165|Diphtheria
1132136|NCT01439165|whooping cough
1132137|NCT01439152|Oncology
1132138|NCT01439152|solid tumors
1132139|NCT01439152|Antibody drug conjugate
1132140|NCT01439152|Maximum tolerable dose
1132141|NCT01439152|mesothelin
1132142|NCT01439139|Osteoporosis
1132143|NCT01439139|ultrasound
1132144|NCT01439139|sonometer
1132145|NCT01439139|DXA
1132146|NCT01439126|Attention Deficit Hyperactivity Disorder
1132147|NCT01439113|Ultrasound, Difficult access
1132148|NCT01439100|Parkinson's disease
1132149|NCT01439100|severe pain
1132150|NCT01439100|OXN PR
1132151|NCT01439100|randomised
1132152|NCT01439087|Colonic Polyps
1132153|NCT01439087|OCT
1132154|NCT01439087|Imaging
1132155|NCT01439087|Colon
1132156|NCT01439087|Polyp
1132157|NCT01439074|Burn injuries
1132158|NCT01439074|Mepilex Ag
1132159|NCT01439074|SSD Ag
1132160|NCT01439074|Partial thickness
1132161|NCT01439061|Growth disorders
1132162|NCT01439061|Saizen
1132163|NCT01439061|Easypod
1132164|NCT01439061|Growth hormone
1132165|NCT01439061|Pediatric subject
1132166|NCT01439048|Placenta
1132167|NCT01439048|Cord Blood
1132168|NCT01439048|PAH
1132169|NCT01439048|Environmental Markers
1132170|NCT01439048|Toll-Like Receptors
1132171|NCT01439035|Celiac Disease
1132172|NCT01439035|Duodenal
1132173|NCT01439035|OCT
1132174|NCT01439035|Imaging
1132175|NCT01439022|Parkinson's Disease
1132176|NCT01439022|Exercise
1132177|NCT01439022|Treatment Outcome
1132178|NCT01439022|Patient Adherence
1132179|NCT01439009|Heart failure
1132180|NCT01439009|Volume overload
1132181|NCT01439009|Tolvaptan
1132182|NCT01439009|loop diuretics
1132183|NCT01438996|Typhoid fever
1132184|NCT01438996|Glycoconjugate vaccine
1132185|NCT01438996|Vi polysaccharide
1132186|NCT01438996|Immunogenicity
1132187|NCT01438957|Dexmedetomidine
1132188|NCT01438957|Sedation
1132189|NCT01438957|Non-intubation
1132190|NCT01438957|epidural anesthesia
1132191|NCT01438957|spinal anesthesia
1132192|NCT01438944|NRT
1132193|NCT01438944|Patch
1132194|NCT01438944|smoking
1132195|NCT01438944|addiction
1132196|NCT01438931|Dexmedetomidine
1132197|NCT01438931|Sedation
1132198|NCT01438931|Non-intubation
1132199|NCT01438931|local anesthesia
1132200|NCT01438918|Knee
1132201|NCT01438918|Osteoarthritis
1132202|NCT01438918|X-ray
1132203|NCT01438918|Joint Space Narrowing
1132204|NCT01438905|Ankle Sprain
1132205|NCT01438905|Chronic Ankle Instability
1132206|NCT01438905|Ankle Mobilization
1132207|NCT01438905|Talocrural Joint Mobilization
1132208|NCT01438905|Cortical Muscle Activation
1132209|NCT01438905|Spinal Muscle Activation
1132210|NCT01438892|rheumatoid arthritis
1132211|NCT01438892|therapy compliance
1132212|NCT01438879|CSF
1132213|NCT01438879|PCR
1132214|NCT01438879|lymphocytic herpesvirus
1132215|NCT01438879|CNS
1132216|NCT01438866|Dental caries
1132217|NCT01438866|Fissure sealant
1132218|NCT01438866|Fluoride varnish
1132219|NCT01438866|Primary molar
1132220|NCT01438853|Sepsis
1132221|NCT01438853|Acute Lung Injury
1132222|NCT01438853|Acute Respiratory Distress Syndrome
1132223|NCT01438853|ALI/ARDS
1132224|NCT01438853|Lung Disease
1132225|NCT01438840|Chronic Immune Thrombocytopenia
1132226|NCT01438788|Bethlem myopathy
1132227|NCT01438788|Ullrich congenital muscular dystrophy
1132228|NCT01438788|Low protein diet
1132229|NCT01438788|Autophagy
1132230|NCT01438788|Pilot clinical trial
1132231|NCT01438775|Benign prostatic hyperplasia
1132232|NCT01438775|BPH
1132233|NCT01438775|Enlarged prostate
1132234|NCT01438775|Lower urinary tract symptoms
1132235|NCT01438775|LUTS
1132236|NCT01438775|LUTS secondary to BPH
1132237|NCT01438775|LUTS/BPH
1132238|NCT01438775|Benign prostatic obstruction
1132239|NCT01438775|BPO
1132240|NCT01438775|Bladder outlet obstruction
1132241|NCT01438775|BOO
1132242|NCT01438762|Anterior Knee Pain
1132243|NCT01438736|Focus:
1132244|NCT01438736|preceding
1132245|NCT01438736|desogestrel predicts
1132246|NCT01438736|pattern of following
1132247|NCT01438736|etonogestrel implant
1132248|NCT01438723|ischemia reperfusion injury
1132249|NCT01438723|CABG
1132250|NCT01438723|metformin
1132251|NCT01438723|Hs-troponin-I
1132252|NCT01438697|sleep
1132253|NCT01438697|insomnia
1132254|NCT01438697|internet
1132255|NCT01438697|CBT
1132256|NCT01438684|chronic vegetative state
1132257|NCT01438684|functional MRI
1132258|NCT01438671|WiiFit
1132259|NCT01438671|Standing Balance
1132260|NCT01438671|Neurological Population
1132261|NCT01438658|uveal melanoma
1132262|NCT01438658|metastatic uveal melanoma
1132263|NCT01438645|Colonoscopy
1132264|NCT01438645|Colon cancer screening
1132265|NCT01438632|Insulin action
1132266|NCT01438632|Jet injector
1132267|NCT01438632|Diabetes Mellitus
1132268|NCT01438632|Pharmacodynamics
1132269|NCT01438632|Pharmacokinetics
1132270|NCT01438632|Insulin analogs
1132271|NCT01438632|Insulin aspart
1132272|NCT01438619|sodium
1132273|NCT01438619|blood pressure
1132274|NCT01438619|pulse wave velocity
1132275|NCT01438619|random digit dialling
1132276|NCT01438593|Stroke
1132277|NCT01438593|Brain disease
1132278|NCT01438593|Ischemia
1132279|NCT01438593|Cerebral infraction
1132280|NCT01438593|Cord Blood
1132281|NCT01438580|atrial ﬁbrillation
1132282|NCT01438580|stroke
1132283|NCT01438580|warfarin
1132284|NCT01438580|aspirin
1132285|NCT01438567|oxycodone naloxone combination
1132286|NCT01438567|severe chronic and non-malignant pain
1132287|NCT01438567|Malignant and non-malignant pain that requires around-the clock opioid therapy
1132288|NCT01438567|Opioid related constipation
1132289|NCT01438541|No skin breakdown
1132290|NCT01438541|Prevention
1132291|NCT01438541|protection of the skin
1132292|NCT01438528|Growth disorders
1132293|NCT01438528|Saizen
1132294|NCT01438528|Easypod
1132295|NCT01438528|Growth hormone
1132296|NCT01438528|Pediatric subject
1132297|NCT01438515|MRSA
1132298|NCT01438515|doxycycline
1132299|NCT01438515|rifampin
1132300|NCT01438515|mupirocin
1132301|NCT01438515|chlorhexidine gluconate
1132302|NCT01438515|decolonization
1132303|NCT01438515|methicillin-resistant staphylococcus aureus
1132304|NCT01438502|cardiac surgery
1132305|NCT01438502|cardio-pulmonary-bypass
1132306|NCT01438489|MEDI-546
1132307|NCT01438489|Anifrolumab
1132308|NCT01438489|Systemic Lupus Erythematosus
1132309|NCT01438476|Liver Cancer
1132310|NCT01438476|Pancreatic Cancer
1132311|NCT01438476|Thoracic epidural analgesia
1132312|NCT01438476|TEA
1132313|NCT01438476|Intravenous patient-controlled analgesia
1132314|NCT01438476|IVPCA
1132315|NCT01438476|Pain control
1132316|NCT01438476|Quality of life
1132317|NCT01438476|QOL
1132318|NCT01438476|Surgical resection
1132319|NCT01438463|non-seasonal allergy
1132320|NCT01438463|house dust mite
1132321|NCT01438463|immunotherapy
1132322|NCT01438463|dose response
1132323|NCT01438450|Thalidomide
1132324|NCT01438450|Capecitabine
1132325|NCT01438450|Advanced hepatocellular carcinoma
1132326|NCT01438450|Therapy
1132327|NCT01438450|Supportive care
1132328|NCT01438437|Hepatocellular carcinoma
1132329|NCT01438437|Radiofrequency ablation
1132330|NCT01438437|Percutaneous acetic acid ablation
1132331|NCT01438437|Tumour response
1132332|NCT01438411|Cholic Acid
1132333|NCT01438411|Inborn Error
1132334|NCT01438411|Bile Acid Metabolism
1132335|NCT01438411|Inborn Error of Bile Acid Synthesis
1132336|NCT01438398|Submucosal endoscopic myotomy
1132337|NCT01438398|Per Oral Endoscopic Myotomy
1132338|NCT01438398|Natural Orifice Transluminal Endoscopic Surgery
1132339|NCT01438385|Pancreatico-biliary
1132340|NCT01438385|Biliary
1132341|NCT01438385|Bile Duct
1132342|NCT01438385|Gastrointestinal disorder
1132343|NCT01438385|Esophageal disorder
1132344|NCT01438372|Iron Deficiency Anemia
1132345|NCT01438372|Inflammatory Bowel Disease
1132346|NCT01438372|Children
1132347|NCT01438359|Drug-drug interaction
1132348|NCT01438359|Pharmacokinetics
1132349|NCT01438359|PA21
1132350|NCT01438359|Drug Interaction Potentiation
1132351|NCT01438346|Substance Abuse
1132352|NCT01438346|Substance Addiction
1132353|NCT01438346|Substance Dependence
1132354|NCT01438346|Treatment program
1132355|NCT01438333|Chronic Peridodontitis
1132356|NCT01438333|probiotics
1132357|NCT01438333|lactobacillus brevis
1132358|NCT01438333|full mouth disinfection
1132359|NCT01438320|Treatment naive
1132360|NCT01438320|Contraindications to standard therapies
1132361|NCT01438320|Alternative hepatitis C therapy
1132362|NCT01438307|Non-small cell lung cancer
1132363|NCT01438307|Cabazitaxel-XRP6258
1132364|NCT01438307|P-glycoprotein
1132365|NCT01438307|taxane
1132366|NCT01438307|Advanced NSCLC
1132367|NCT01438294|Asthma
1132368|NCT01438294|childhood
1132369|NCT01438294|exercise
1132370|NCT01438281|ocular pain
1132371|NCT01438281|dry eye
1132372|NCT01438281|siRNA
1132373|NCT01438242|Major
1132374|NCT01438242|Depressive
1132375|NCT01438242|Disorder
1132376|NCT01438242|Depression
1132377|NCT01438242|Treatment Resistant
1132378|NCT01438229|Catheter-based renal artery ablation
1132379|NCT01438229|Hypertension
1132380|NCT01438229|Resistant to Conventional Therapy
1132381|NCT01438216|Pharmacokinetics
1132382|NCT01438216|Intensive Care
1132383|NCT01438216|Candidemia
1132384|NCT01438216|Invasive candidiasis
1132385|NCT01438216|Anidulafungin
1132386|NCT01438203|manipulation
1132387|NCT01438203|mobilization
1132388|NCT01438203|low back pain
1132389|NCT01438203|treatment
1132390|NCT01438177|myeloma
1132391|NCT01438177|multiple myeloma
1132392|NCT01438177|relapsed myeloma
1132393|NCT01438177|refractory myeloma
1132394|NCT01438164|FDG-PET
1132395|NCT01438164|cancer
1132396|NCT01438164|staging
1132397|NCT01438164|Evaluate the cost impact in the evaluation of oncologic patients.
1132398|NCT01438151|Crohn's disease
1132399|NCT01438151|Remicade
1132400|NCT01438151|infliximab
1132401|NCT01438138|childhood acute myeloid leukemia in remission
1132402|NCT01438138|recurrent childhood acute myeloid leukemia
1132403|NCT01438138|untreated childhood acute myeloid leukemia and other myeloid malignancies
1132404|NCT01438138|childhood acute basophilic leukemia
1132405|NCT01438138|childhood acute eosinophilic leukemia
1132406|NCT01438138|childhood acute erythroleukemia (M6)
1132407|NCT01438138|childhood acute megakaryocytic leukemia (M7)
1132408|NCT01438138|childhood acute monoblastic leukemia (M5a)
1132409|NCT01438138|childhood acute monocytic leukemia (M5b)
1132410|NCT01438138|childhood acute myeloblastic leukemia with maturation (M2)
1132411|NCT01438138|childhood acute myeloblastic leukemia without maturation (M1)
1132412|NCT01438138|childhood acute myelomonocytic leukemia (M4)
1132413|NCT01438138|childhood acute minimally differentiated myeloid leukemia (M0)
1132414|NCT01438112|cancer
1132415|NCT01438112|bladder cancer
1132416|NCT01438112|transitional cell
1132417|NCT01438112|virus
1132418|NCT01438112|oncolytic
1132419|NCT01438112|GM-CSF
1132420|NCT01438112|adenovirus
1132421|NCT01438112|intravesical
1132422|NCT01438112|neoadjuvant
1132423|NCT01438112|cystectomy
1132424|NCT01438112|gene therapy
1132425|NCT01438112|oncolytic virus
1132426|NCT01438112|carcinoma in situ
1132427|NCT01438112|carcinoma in situ concurrent with papillary tumors
1132428|NCT01438099|epidural analgesia
1132429|NCT01438099|ultrasound
1132430|NCT01438099|labor analgesia
1132431|NCT01438099|labor
1132432|NCT01438086|Heart Failure
1132433|NCT01438086|Myocardial Infarction
1132434|NCT01438047|Port Wine Stain
1132435|NCT01438021|unspecified adult solid tumor, protocol specific
1132436|NCT01438008|Sucrose
1132437|NCT01438008|Pain
1132438|NCT01437995|Asthma
1132439|NCT01437995|Step down therapy
1132440|NCT01437995|Inhaled corticosteroids
1132441|NCT01437995|Long-acting beta agonists
1132442|NCT01437995|Fluticasone Salmeterol
1132443|NCT01437982|post-operative inflammation
1132444|NCT01437982|conjunctivitis
1132445|NCT01437982|safety
1132446|NCT01437982|Seasonal allergic conjunctivitis
1132447|NCT01437982|Giant papillary conjunctivitis
1132448|NCT01437969|Possible association
1132449|NCT01437969|between severity
1132450|NCT01437969|IL28B genetic variants
1132451|NCT01437969|patients
1132452|NCT01437969|different HCV genotypes
1132453|NCT01437956|Calcineurin
1132454|NCT01437956|Bronchiolitis
1132455|NCT01437956|Epithelial lung injury
1132456|NCT01437956|Rhinovirus
1132457|NCT01437956|Respiratory Syncytial Virus
1132458|NCT01437956|Asthma
1132459|NCT01437943|Transplant
1132460|NCT01437943|Failure
1132461|NCT01437943|Kidney
1132462|NCT01437930|n-3 LC-PUFA
1132463|NCT01437930|hypertriglyceridemic
1132464|NCT01437930|human
1132465|NCT01437930|TAG
1132466|NCT01437917|glycemic index
1132467|NCT01437904|Renal Calculi
1132468|NCT01437904|Percutaneous nephrolithotomy (PCNL)
1132469|NCT01437891|PTSD
1132470|NCT01437891|Military veteran
1132471|NCT01437891|Gulf War
1132472|NCT01437891|Fibromyalgia
1132473|NCT01437891|Gulf War Syndrome
1132474|NCT01437878|PH
1132475|NCT01437878|COPD
1132476|NCT01437865|MRI
1132477|NCT01437865|lymph node metastases
1132478|NCT01437865|breast cancer
1132479|NCT01437865|gadofosveset
1132480|NCT01437839|Food effect study
1132481|NCT01437839|Pharmacokinetics
1132482|NCT01437839|Apixaban
1132483|NCT01437826|chemoprevention
1132484|NCT01437826|colorectal cancer
1132485|NCT01437826|metachronous adenoma
1132486|NCT01437826|randomized trial
1132487|NCT01437813|DM2
1132488|NCT01437813|glimepiride
1132489|NCT01437813|metformin extended release
1132490|NCT01437800|DM2
1132491|NCT01437800|glimepiride
1132492|NCT01437800|metformin extended release
1132493|NCT01437774|Acute ischemic stroke
1132494|NCT01437748|Small Airways
1132495|NCT01437748|Closing volume
1132496|NCT01437748|Closing Capacity
1132497|NCT01437748|Tiotropium
1132498|NCT01437748|Indacaterol
1132499|NCT01437748|COPD
1132500|NCT01437735|Asthma
1132501|NCT01437735|QAW039
1132502|NCT01437722|BV
1132503|NCT01437722|Bacterial vaginosis
1132504|NCT01437722|recurrent
1132505|NCT01437722|SPL7013 Gel
1132506|NCT01437722|VivaGel
1132507|NCT01437709|Bendamustine HCL
1132508|NCT01437709|Ofatumumab (GSK 1841157)
1132509|NCT01437709|Immunotherapy
1132510|NCT01437709|Chemoimmunotherapy
1132511|NCT01437709|11-050
1132512|NCT01437696|Aging
1132513|NCT01437696|Vitamin D
1132514|NCT01437696|Bone health
1132515|NCT01437696|Inflammation
1132516|NCT01437696|Men
1132517|NCT01437683|Craniocerebral Trauma
1132518|NCT01437683|Quality of life
1132519|NCT01437683|Long term outcome
1132520|NCT01437683|Activities of Daily Living
1132521|NCT01437683|Cognitive Deficiency
1132522|NCT01437683|Health Care Quality, Access, and Evaluation
1132523|NCT01437644|Cerebral Palsy
1132524|NCT01437644|Hip displacement
1132525|NCT01437644|Hip surgery
1132526|NCT01437644|Post-operative pain
1132527|NCT01437644|Botulinum Toxin
1132528|NCT01437631|colon polyp
1132529|NCT01437631|endoscopic polypectomy
1132530|NCT01437631|postpolypectomy bleeding
1132531|NCT01437631|prophylactic clip application
1132532|NCT01437605|Resected
1132533|NCT01437605|Skin
1132534|NCT01437605|Stage IV
1132535|NCT01437579|interstitial cystitis
1132536|NCT01437579|bladder pain syndrome
1132537|NCT01437579|intratrigonal injection
1132538|NCT01437579|botulinum toxin
1132539|NCT01437553|IVUS
1132540|NCT01437553|iMAP
1132541|NCT01437553|Catheterization
1132542|NCT01437553|Acute Coronary Syndrome
1132543|NCT01437540|COPD
1132544|NCT01437540|Chronic Obstructive Pulmonary Disease
1132545|NCT01437540|Chronic Bronchitis
1132546|NCT01437540|Emphysema
1132547|NCT01437540|Airflow Obstruction, Chronic
1132548|NCT01437540|Chronic Airflow Obstruction
1132549|NCT01437540|Chronic Obstructive Airway Disease
1132550|NCT01437540|Chronic Obstructive Lung Disease
1132551|NCT01437527|anorexia nervosa
1132552|NCT01437527|CMME-TCA Unit
1132553|NCT01437527|Centre Hospitalier Sainte Anne
1132554|NCT01437514|rectal cancer
1132555|NCT01437514|Endosonography
1132556|NCT01437514|preoperative short-course radiotherapy
1132557|NCT01437514|preoperative adjuvant therapy
1132558|NCT01437514|neoadjuvant therapy
1132559|NCT01437514|short-term high-dose preoperative radiotherapy
1132560|NCT01437514|total mesorectal excision
1132561|NCT01437514|circumferential resection margin
1132562|NCT01437514|local recurrence
1132563|NCT01437514|overall survival
1132564|NCT01437514|metastasis
1132565|NCT01437514|complication
1132566|NCT01437501|glucoraphanin
1132567|NCT01437501|sulforaphane
1132568|NCT01437501|pharmacokinetics
1132569|NCT01437501|pharmacodynamics
1132570|NCT01437501|broccoli sprout
1132571|NCT01437501|carcinogens, environment
1132572|NCT01437488|Urothelial carcinoma
1132573|NCT01437488|Urothelial cancer
1132574|NCT01437475|HBV
1132575|NCT01437475|HIV
1132576|NCT01437475|Immunization
1132577|NCT01437475|HBV Immunization rate among HIV positive individuals
1132578|NCT01437462|Pain, Postoperative
1132579|NCT01437462|Anesthetics, intravenous
1132580|NCT01437462|Anesthetics, inhalation
1132581|NCT01437462|Otherwise healthy adults undergoing general anesthesia for gynecological disease.
1132582|NCT01437449|Quality of Life
1132583|NCT01437436|otitis media
1132584|NCT01437436|obesity
1132585|NCT01437436|ventilation tube
1132586|NCT01437423|Diphtheria
1132587|NCT01437423|Tetanus
1132588|NCT01437423|Pertussis
1132589|NCT01437423|Poliomyelitis
1132590|NCT01437423|TETRAXIM™
1132591|NCT01437397|COPD
1132592|NCT01437397|Chronic Obstructive Pulmonary Disease
1132593|NCT01437397|Chronic Bronchitis
1132594|NCT01437397|Emphysema
1132595|NCT01437397|Airflow Obstruction, Chronic
1132596|NCT01437397|Chronic Airflow Obstruction
1132597|NCT01437397|Chronic Obstructive Airway Disease
1132598|NCT01437397|Chronic Obstructive Lung Disease
1132599|NCT01437371|Heart failure
1132600|NCT01437371|Aged and over 80
1132601|NCT01437371|clinical trial
1132602|NCT01437371|quality of life
1132603|NCT01437358|Epidural catheter
1132604|NCT01437358|Epidural analgesia
1132605|NCT01437358|Intensive care unit
1132606|NCT01437358|Safety
1132607|NCT01437306|lofexidine
1132608|NCT01437306|food effect
1132609|NCT01437306|pharmacokinetics
1132610|NCT01437306|healthy volunteer
1132611|NCT01437293|cocaine
1132612|NCT01437280|Tumors
1132613|NCT01437280|Solid Tumors
1132614|NCT01437254|99mTc Pertechnetate
1132615|NCT01437254|thyroidectomy
1132616|NCT01437241|HIV-infection
1132617|NCT01437241|Etravirine
1132618|NCT01437241|Treatment
1132619|NCT01437241|Non-nucleoside reverse-transcriptase inhibitor
1132620|NCT01437215|aneurysm
1132621|NCT01437215|renal stent
1132622|NCT01437215|juxtarenal
1132623|NCT01437215|pararenal
1132624|NCT01437202|imatinib
1132625|NCT01437202|drug resistance
1132626|NCT01437202|pharmacogenetics
1132627|NCT01437189|Parkinson's disease
1132628|NCT01437189|depression
1132629|NCT01437189|sertraline
1132630|NCT01437189|intervention
1132631|NCT01437176|surgery
1132632|NCT01437176|fixation
1132633|NCT01437176|intramedullary nail
1132634|NCT01437150|surgery
1132635|NCT01437150|fixation
1132636|NCT01437150|bone plate
1132637|NCT01437137|elective surgery of short duration (less than 2 hr) undergoing general anesthesia using supraglottic airway
1132638|NCT01437111|Osteoporosis
1132639|NCT01437111|Postmenopausal
1132640|NCT01437098|Valvular Heart Disease
1132641|NCT01437098|Severe Aortic Stenosis
1132642|NCT01437098|Aortic Valve Replacement
1132643|NCT01437085|Needle deflection
1132644|NCT01437085|Prostate Deformation
1132645|NCT01437085|Prostate Brachytherapy
1132646|NCT01437085|Needles
1132647|NCT01437046|Alcohol drinking
1132648|NCT01437046|Alcohol craving
1132649|NCT01437033|Breath Tests
1132650|NCT01437033|Human Volunteers
1132651|NCT01437033|Pilot Study
1132652|NCT01437033|Breath Test
1132653|NCT01437020|IL-10
1132654|NCT01437020|Leishmaniasis
1132655|NCT01437020|Immunotherapy
1132656|NCT01437007|SNALP
1132657|NCT01437007|Regional Therapy
1132658|NCT01437007|Stage IV Disease
1132659|NCT01437007|Adenocarcinoma
1132660|NCT01437007|Unresectable
1132661|NCT01437007|Liver Metastases
1132662|NCT01437007|Colorectal Cancer
1132663|NCT01437007|Stomach Cancer
1132664|NCT01437007|Gastric Cancer
1132665|NCT01437007|Breast Cancer
1132666|NCT01437007|Ovarian Cancer
1132667|NCT01437007|Pancreatic Cancer
1132668|NCT01437007|Liver Cancer
1132669|NCT01436994|thyrotoxic
1132670|NCT01436994|thyrotoxicosis
1132671|NCT01436994|paediatric
1132672|NCT01436994|endocrinology
1132673|NCT01436994|block and replace
1132674|NCT01436994|dose titration
1132675|NCT01436994|carbimazole
1132676|NCT01436981|papaverine
1132677|NCT01436981|pharmacokinetic
1132678|NCT01436981|CABG
1132679|NCT01436981|Injury of Internal Mammary Artery
1132680|NCT01436981|Complications Due to Coronary Artery Bypass Graft
1132681|NCT01436968|immunotherapy, cytotoxicity, tumor vaccine, prostate cancer, radiotherapy
1132682|NCT01436929|silymarin
1132683|NCT01436929|hepatotoxicity
1132684|NCT01436929|tuberculosis
1132685|NCT01436929|HREZ
1132686|NCT01436916|prediabetes
1132687|NCT01436916|oral cholecalciferol
1132688|NCT01436903|menorrhagia
1132689|NCT01436903|dysfunctional uterine bleeding
1132690|NCT01436903|endometrial ablation
1132691|NCT01436903|cavatermTM
1132692|NCT01436903|probe
1132693|NCT01436890|Chronic Persistent Asthma
1132694|NCT01436877|BPH
1132695|NCT01436877|bladder neck obstruction
1132696|NCT01436877|Bladder neck obstruction secondary to BPH
1132697|NCT01436864|Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902
1132698|NCT01436864|)
1132699|NCT01436864|age-related macular degeneration (AMD)
1132700|NCT01436864|choroidal neovascularization (CNV)
1132701|NCT01436864|intravitreal injection
1132702|NCT01436864|best corrected visual acuity (BCVA)
1132703|NCT01436864|central retinal thickness
1132704|NCT01436851|rhinitis
1132705|NCT01436851|allergy
1132706|NCT01436851|occupational
1132707|NCT01436851|storage mites
1132708|NCT01436851|nasal lavage
1132709|NCT01436851|challenge test
1132710|NCT01436851|ECP
1132711|NCT01436851|alfa2Macroglobuline
1132712|NCT01436838|Relapsing-Remitting Multiple Sclerosis
1132713|NCT01436838|Secondary Progressive Multiple Sclerosis
1132714|NCT01436825|Haemophilia A
1132715|NCT01436825|Factor VIII
1132716|NCT01436825|Pharmacokinetic
1132717|NCT01436825|Computer Tool validation
1132718|NCT01436812|cerebral oxymetry
1132719|NCT01436812|laparoscopy
1132720|NCT01436812|PEEP
1132721|NCT01436799|propofol
1132722|NCT01436799|desflurane
1132723|NCT01436799|cerebrovascular circulation
1132724|NCT01436799|sitting
1132725|NCT01436786|cytokines
1132726|NCT01436786|Guided imagery
1132727|NCT01436760|IBS
1132728|NCT01436747|Kidney transplantation
1132729|NCT01436747|Proteinuria
1132730|NCT01436747|Albuminuria
1132731|NCT01436747|Vitamin D
1132732|NCT01436747|Paricalcitol
1132733|NCT01436721|Effectiveness
1132734|NCT01436721|Device success
1132735|NCT01436721|Hepatectomy
1132736|NCT01436708|pelvic organ prolapse
1132737|NCT01436708|urinary symptoms
1132738|NCT01436708|sexual function
1132739|NCT01436695|seizure early detection
1132740|NCT01436682|Nerve Blocks
1132741|NCT01436656|BRAF mutant,
1132742|NCT01436656|BRAF mutated,
1132743|NCT01436656|melanoma,
1132744|NCT01436656|metastatic,
1132745|NCT01436656|advanced,
1132746|NCT01436656|RAF kinase inhibitor
1132747|NCT01436656|BRAF V600 mutation
1132748|NCT01436643|Depression
1132749|NCT01436643|Multiple Sclerosis
1132750|NCT01436643|Fingolimod
1132751|NCT01436643|Venlafaxine
1132752|NCT01436643|Fluoxetine
1132753|NCT01436630|Exercise Tolerance
1132754|NCT01436630|Step Test
1132755|NCT01436630|Stroke
1132756|NCT01436630|Walking
1132757|NCT01436617|cancer
1132758|NCT01436617|colon
1132759|NCT01436617|Head and neck
1132760|NCT01436617|cetuximab
1132761|NCT01436617|anti-cetuximab dosage
1132762|NCT01436604|cardiac MRI
1132763|NCT01436604|Cancer
1132764|NCT01436604|Breast
1132765|NCT01436604|Herceptin
1132766|NCT01436604|LV dysfunction
1132767|NCT01436591|Cancer
1132768|NCT01436591|Breast
1132769|NCT01436591|18FDG
1132770|NCT01436591|Axillary
1132771|NCT01436591|Positron Emission Tomography
1132772|NCT01436552|MCI
1132773|NCT01436552|Depression
1132774|NCT01436552|Alzheimer
1132775|NCT01436552|Life events
1132776|NCT01436526|Bioequivalence
1132777|NCT01436513|bioequivalence
1132778|NCT01436513|menometrorrhagia
1132779|NCT01436513|climacteric disturbance
1132780|NCT01436513|Estrogen Replacement Therapy
1132781|NCT01436513|Estrogens Conjugated
1132782|NCT01436500|Hepatorenal Syndrome
1132783|NCT01436500|HRS
1132784|NCT01436500|ifetroban
1132785|NCT01436487|ischemic stroke
1132786|NCT01436487|adult stem cells
1132787|NCT01436474|Varenicline
1132788|NCT01436474|Chantix
1132789|NCT01436474|Chronic Pain
1132790|NCT01436474|Opioid dependence
1132791|NCT01436448|efficacy
1132792|NCT01436448|Lactobacillus Rhamnosus
1132793|NCT01436448|glucose intolerance
1132794|NCT01436448|feasibility
1132795|NCT01436448|compliance and safety
1132796|NCT01436448|reducing glucose intolerance during and after pregnancy
1132797|NCT01436435|PAD
1132798|NCT01436435|peripheral artery disease
1132799|NCT01436435|atherectomy
1132800|NCT01436422|Dengue Virus
1132801|NCT01436422|Dengue Fever
1132802|NCT01436422|Dengue Vaccine
1132803|NCT01436422|Dengue Hemorrhagic Fever
1132804|NCT01436422|Dengue Shock Syndrome
1132805|NCT01436409|vaginal touch
1132806|NCT01436409|deliveries assisted
1132807|NCT01436409|echography
1132808|NCT01436409|assisted delivery
1132809|NCT01436396|Dengue
1132810|NCT01436396|Dengue Hemorrhagic Fever
1132811|NCT01436396|CYD Dengue Vaccines
1132812|NCT01436396|Yellow Fever
1132813|NCT01436396|Stamaril®
1132814|NCT01436396|Flavivirus Infections
1132815|NCT01436383|high altitude
1132816|NCT01436383|hypobaric hypoxia
1132817|NCT01436383|metabolomics
1132818|NCT01436383|oxidative stress
1132819|NCT01436383|acute mountain sickness
1132820|NCT01436370|influenza, rheumatoid arthritis, TNF-alpha-inhibitor, Fluzone®, Fluzone® High Dose
1132821|NCT01436357|AdCh3NSmut1
1132822|NCT01436357|Hepatitis C
1132823|NCT01436357|MVA-NSmut
1132824|NCT01436357|vaccine
1132825|NCT01436344|esophageal electrocardiography
1132826|NCT01436344|electrocardiography
1132827|NCT01436344|atrial electrogram
1132828|NCT01436344|atrial function, left
1132829|NCT01436331|First episode psychosis
1132830|NCT01436331|Early Psychosis
1132831|NCT01436331|Cognitive Behavioural therapy
1132832|NCT01436331|Psychosocial Intervention
1132833|NCT01436331|Assertive Community treatment
1132834|NCT01436331|Family Intervention
1132835|NCT01436331|Mental Disorders
1132836|NCT01436331|Psychotic Disorders
1132837|NCT01436331|Schizophrenia and Disorders with Psychotic Features
1132838|NCT01436331|Affective Disorders, Psychotic
1132839|NCT01436318|Healthy Kids
1132840|NCT01436318|Respiratory
1132841|NCT01436318|Volunteers
1132842|NCT01436305|immunosuppressive (IS) regimens
1132843|NCT01436305|long-term graft function
1132844|NCT01436305|CNI (calcineurin Inhibitor )-free IS regimen
1132845|NCT01436305|CNI (calcineurin Inhibitor ) IS regimen
1132846|NCT01436305|corticosteroids
1132847|NCT01436292|Hypoalbuminemia
1132848|NCT01436292|Burns
1132849|NCT01436292|Albumin
1132850|NCT01436292|Organ dysfunction
1132851|NCT01436292|Outcome
1132852|NCT01436240|Patient-Reported Outcomes
1132853|NCT01436240|Common Terminology Criteria for Adverse Events
1132854|NCT01436240|PRO-CTCAE
1132855|NCT01436240|Native Spanish Speaking
1132856|NCT01436240|Spanish Translation
1132857|NCT01436240|Cognitive Interview
1132858|NCT01436240|Questionnaire
1132859|NCT01436240|11-133
1132860|NCT01436240|Adverse Events
1132861|NCT01436240|chemotherapy
1132862|NCT01436240|radiation therapy
1132863|NCT01436240|treatment in previous 6 months
1132864|NCT01436227|Von Hippel-Lindau Syndrome
1132865|NCT01436227|VHL
1132866|NCT01436227|Von Hippel-Lindau related lesion
1132867|NCT01436227|Pazopanib
1132868|NCT01436227|GW786034
1132869|NCT01436188|Biological Markers
1132870|NCT01436188|Healthy Volunteer
1132871|NCT01436188|Alzheimer's Disease (AD)
1132872|NCT01436188|Mild Cognitive Impairment (MCI)
1132873|NCT01436188|Cerebrospinal fluid (CSF)
1132874|NCT01436188|CSF proteins
1132875|NCT01436136|Cardiovascular disease
1132876|NCT01436136|HIV
1132877|NCT01436136|Antiretroviral treatment
1132878|NCT01436136|team interventions
1132879|NCT01436136|Framingham risk score
1132880|NCT01436123|Plasmonic Photothermal Therapy
1132881|NCT01436123|Nanoparticles
1132882|NCT01436123|Stem cells
1132883|NCT01436123|Atherosclerosis
1132884|NCT01436123|Bioengineering
1132885|NCT01436123|Biodegradable stenting
1132886|NCT01436123|Repair disease
1132887|NCT01436097|Healthy Eating
1132888|NCT01436097|Health Behavior
1132889|NCT01436097|Incentive
1132890|NCT01436097|Work-site
1132891|NCT01436084|Leukemia
1132892|NCT01436084|Myelodysplastic syndrome
1132893|NCT01436084|MDS
1132894|NCT01436084|SB1518
1132895|NCT01436058|side effect
1132896|NCT01436058|mesenchymal stem cell
1132897|NCT01436058|ankle
1132898|NCT01436058|osteoarthritis
1132899|NCT01436045|Memory
1132900|NCT01436045|Insulin glulisine
1132901|NCT01436045|Alzheimer's Disease
1132902|NCT01436019|Juvenile idiopathic arthritis
1132903|NCT01436019|Rheumatic diseases
1132904|NCT01436019|Antibodies
1132905|NCT01436019|Biological therapy
1132906|NCT01436006|MDCT
1132907|NCT01436006|radiation
1132908|NCT01436006|dose
1132910|NCT01435980|type 2 diabetes
1132911|NCT01435980|Gastric Bypass
1132912|NCT01435980|GLP-1
1132913|NCT01435980|adiponectin
1132914|NCT01435967|Rotarix™
1132915|NCT01435967|Observational
1132916|NCT01435967|ecological
1132917|NCT01435954|benign prostatic hyperplasia
1132918|NCT01435954|surgery
1132919|NCT01435954|5-alpha-reductase inhibitor
1132920|NCT01435954|enlarged prostate
1132921|NCT01435954|acute urinary retention
1132922|NCT01435941|mailed survey
1132923|NCT01435941|non-steroidal anti-inflammatory drug
1132924|NCT01435941|migraine disorders
1132925|NCT01435941|headache
1132926|NCT01435928|Schizophrenia
1132927|NCT01435928|Lurasidone
1132928|NCT01435928|Latuda
1132929|NCT01435902|exercise-induced bronchospasm
1132930|NCT01435902|Activity/Exercise induced bronchospasm
1132931|NCT01435902|asthma
1132932|NCT01435889|Acute respiratory distress syndrome
1132933|NCT01435889|Children
1132934|NCT01435889|Long term respiratory sequelae
1132935|NCT01435889|Pulmonary function tests
1132936|NCT01435889|Computed tomography, lung
1132937|NCT01435850|hip arthroplasty
1132938|NCT01435850|primary stability
1132939|NCT01435850|secondary stability
1132940|NCT01435850|EBRA
1132941|NCT01435837|Voice
1132942|NCT01435837|aerodynamics
1132943|NCT01435837|acoustics
1132944|NCT01435824|healthy adult volunteers
1132945|NCT01435824|comparative bioavailability
1132946|NCT01435824|amoxicillin
1132947|NCT01435824|breast milk
1132948|NCT01435824|Amoxicillin Bioavailability in breast milk
1132949|NCT01435811|Norovirus
1132950|NCT01435798|chronic pain
1132951|NCT01435798|central neuropathic pain
1132952|NCT01435798|spinal cord injury
1132953|NCT01435798|dextromethorphan
1132954|NCT01435798|lidocaine
1132955|NCT01435798|combination therapy
1132956|NCT01435798|analgesia
1132957|NCT01435785|PKPD
1132958|NCT01435785|Propofol
1132959|NCT01435785|TCI
1132960|NCT01435785|Elderly patients
1132961|NCT01435746|liver transplantation
1132962|NCT01435746|intensive care
1132963|NCT01435746|red blood cell transfusion
1132964|NCT01435733|ASD
1132965|NCT01435733|Divorce
1132966|NCT01435720|Multiple myeloma
1132967|NCT01435720|B cell lymphoma
1132968|NCT01435720|Hematologic disease
1132969|NCT01435720|Blood protein disorder
1132970|NCT01435720|Neoplasm, plasma cell
1132971|NCT01435720|Mantle Cell Lymphoma
1132972|NCT01435720|Diffuse Large B Cell Lymphoma
1132973|NCT01435720|Plasma Cell Leukemia
1132974|NCT01435720|B cell malignancy
1132975|NCT01435707|epidural steroid injection
1132976|NCT01435707|triamcinolone
1132977|NCT01435707|fasting blood glucose
1132978|NCT01435707|diabetes mellitus
1132979|NCT01435694|multiple sclerosis
1132980|NCT01435694|gait rehabilitation
1132981|NCT01435681|DYT-1
1132982|NCT01435681|DYT1
1132983|NCT01435681|DYT 1
1132984|NCT01435681|dystonia
1132985|NCT01435681|DBS
1132986|NCT01435681|deep brain stimulation
1132987|NCT01435681|TMS
1132988|NCT01435681|transcranial magnetic stimulation
1132989|NCT01435668|alcohol
1132990|NCT01435668|hazardous or harmful drinking
1132991|NCT01435668|emergency department (ED)
1132992|NCT01435616|diabetes mellitus
1132993|NCT01435616|type 2 diabetes mellitus
1132994|NCT01435616|insulin naive
1132995|NCT01435616|insulin treatment
1132996|NCT01435603|Prevention & Control
1132997|NCT01435603|Hyperglycemia
1132998|NCT01435603|Obesity
1132999|NCT01435603|Diabetes Mellitus
1133000|NCT01435603|Cost Benefit Analysis
1133001|NCT01435577|Bunionectomy
1133002|NCT01435577|Postsurgical Pain
1133003|NCT01435577|Acute Pain
1133004|NCT01435564|Mobile phone
1133005|NCT01435564|Sedentary lifestyle
1133006|NCT01435564|Physical activity
1133007|NCT01435564|Prevention
1133008|NCT01435564|Health Promotion
1133009|NCT01435564|Exercise
1133010|NCT01435564|eHealth
1133011|NCT01435564|Electronic diary
1133012|NCT01435551|Alzheimer
1133013|NCT01435551|Dementia
1133014|NCT01435538|interprofessional teamwork
1133015|NCT01435538|care pathways
1133016|NCT01435538|team communication
1133017|NCT01435538|team coordination
1133018|NCT01435538|Chronic Obstructive Pulmonary Disease Teams
1133019|NCT01435538|Proximal Femur Fracture Teams
1133020|NCT01435525|triple therapy
1133021|NCT01435525|Helicobacter pylori
1133022|NCT01435525|eradication
1133023|NCT01435525|Nexium
1133024|NCT01435512|PTSD
1133025|NCT01435512|CBT
1133026|NCT01435512|Intimate Partner Violence
1133027|NCT01435512|Treatment
1133028|NCT01435499|immunotherapy
1133029|NCT01435499|vaccine
1133030|NCT01435499|GVAX
1133031|NCT01435499|GM-CSF
1133032|NCT01435486|caffeine
1133033|NCT01435486|apnea
1133034|NCT01435486|bronchiolitis
1133035|NCT01435473|pediatrics
1133036|NCT01435473|thrombosis
1133037|NCT01435473|thromboembolic complications
1133038|NCT01435473|pediatric cardiac surgery
1133039|NCT01435460|ocular allergy
1133040|NCT01435447|efficacy
1133041|NCT01435447|safety
1133042|NCT01435447|conditioning
1133043|NCT01435447|fludarabine
1133044|NCT01435447|busulfan
1133045|NCT01435447|cyclophosphamide
1133046|NCT01435447|adult
1133047|NCT01435434|subjects sustaining Non union/delayed fractures and requiring surgical intervention for treatment
1133048|NCT01435408|STEMI
1133049|NCT01435408|Ischemic postconditioning
1133050|NCT01435408|Deferred stenting
1133051|NCT01435408|Primary PCI
1133052|NCT01435356|Urinary Bladder neoplasms
1133053|NCT01435356|Lymphoproliferative Disorders
1133054|NCT01435356|Immune System Diseases
1133055|NCT01435356|Cystectomy
1133056|NCT01435356|Adjuvants, Immunologic
1133057|NCT01435356|Immunologic Factors
1133058|NCT01435330|Safety
1133059|NCT01435330|BVS857
1133060|NCT01435330|insulin resistance
1133061|NCT01435317|Acoustic CR®-neuromodulation
1133062|NCT01435317|ANM T30 CR®-System
1133063|NCT01435278|Weight maintenance
1133064|NCT01435278|BMI
1133065|NCT01435278|Body weight
1133066|NCT01435278|Overweight
1133067|NCT01435278|Obesity
1133068|NCT01435278|Satiety
1133069|NCT01435265|Psoriasis
1133070|NCT01435265|Dermatology
1133071|NCT01435265|Phase IV
1133072|NCT01435265|Nurse Education
1133073|NCT01435265|Adalimumab
1133074|NCT01435265|Humira
1133075|NCT01435226|Hepatitis C
1133076|NCT01435226|HCV
1133077|NCT01435226|Rapid Virologic Response
1133078|NCT01435226|Sustained Virologic Response
1133079|NCT01435226|Direct Acting Antiviral
1133080|NCT01435226|Combination Therapy
1133081|NCT01435226|Tegobuvir
1133082|NCT01435226|Treatment Experienced
1133083|NCT01435226|HCV RNA
1133084|NCT01435226|Polymerase inhibitor
1133085|NCT01435226|Protease inhibitor
1133086|NCT01435226|Interferon intolerant
1133087|NCT01435226|Interferon ineligible
1133088|NCT01435226|GS-9190
1133089|NCT01435226|GS-9451
1133090|NCT01435226|GS-5885
1133091|NCT01435226|Chronic Genotype 1a or 1b
1133092|NCT01435213|alpha2-adrenoceptor
1133093|NCT01435213|receptor occupancy
1133094|NCT01435213|positron emission tomography
1133095|NCT01435213|[11C]ORM-13070
1133096|NCT01435213|striatum
1133097|NCT01435213|brain
1133098|NCT01435213|noradrenaline
1133099|NCT01435213|norepinephrine
1133100|NCT01435213|endogenous
1133101|NCT01435213|binding
1133102|NCT01435213|Validation studies
1133103|NCT01435200|Intravenous iron
1133104|NCT01435200|gynecologic cancer blood transfusion
1133105|NCT01435174|ranolazine
1133106|NCT01435174|end-stage renal disease
1133107|NCT01435174|pharmacokinetics
1133108|NCT01435174|cardiovascular disease
1133109|NCT01435161|paroxysmal atrial fibrillation, hypertension
1133110|NCT01435148|Deep Brain Stimulation
1133111|NCT01435148|Treatment Resistant Depression
1133112|NCT01435122|progressive advanced carcinoid tumors
1133113|NCT01435122|advanced
1133114|NCT01435122|unresectable
1133115|NCT01435122|metastatic
1133116|NCT01435122|cancerous tumors
1133117|NCT01435122|neuroendocrine
1133118|NCT01435122|digestive tract
1133119|NCT01435122|lungs
1133120|NCT01435122|renal
1133121|NCT01435122|ovarian
1133122|NCT01435122|thymic
1133123|NCT01435122|hepatic
1133124|NCT01435109|Osteoarthritis
1133125|NCT01435109|Exercise
1133126|NCT01435109|Diet
1133127|NCT01435109|Coping Skills
1133128|NCT01435109|Education, Medical
1133129|NCT01435083|Nocturia
1133130|NCT01435070|Colles' fracture
1133131|NCT01435070|Radius fracture
1133132|NCT01435070|grip strength
1133133|NCT01435070|pinch strength
1133134|NCT01435070|range of movement
1133135|NCT01435070|PRWE
1133136|NCT01435070|DASH
1133137|NCT01435070|EQ-5D
1133138|NCT01435070|Kirschner wire
1133139|NCT01435070|Volar locking plate
1133140|NCT01435057|Abdominal Obesity
1133141|NCT01435057|training
1133142|NCT01435057|fat
1133143|NCT01435057|insulin
1133144|NCT01435057|glucose
1133145|NCT01435057|diet
1133146|NCT01435044|Hepatitis C
1133147|NCT01435044|Chronic
1133148|NCT01435044|HCV
1133149|NCT01435031|Angioplasty
1133150|NCT01435031|Chronic Total Occlusion (CTO)
1133151|NCT01435031|Chronic total coronary occlusions
1133152|NCT01435031|Coronary Artery Disease (CAD)
1133153|NCT01435031|Coronary artery stenosis
1133154|NCT01435031|Total coronary occlusion
1133155|NCT01435005|Prevention and control
1133156|NCT01435005|Exercise
1133157|NCT01435005|Sedentary lifestyle
1133158|NCT01435005|Biological markers
1133159|NCT01434966|Lumbopelvic Manipulation
1133160|NCT01434966|Lumbosacral Manipulation
1133161|NCT01434966|Sacroiliac Manipulation
1133162|NCT01434966|TENS Spine
1133163|NCT01434966|TENS Knee
1133164|NCT01434966|Knee Pain
1133165|NCT01434966|Chronic Knee Pain
1133166|NCT01434953|Prehypertension
1133167|NCT01434953|Blood pressure screening
1133168|NCT01434953|White coat effect
1133169|NCT01434940|Alzheimer disease
1133170|NCT01434940|Depression
1133171|NCT01434940|Differential diagnosis
1133172|NCT01434940|Eye movement
1133173|NCT01434914|Ulcus cruris
1133174|NCT01434914|chronic wounds
1133175|NCT01434914|octenisept®
1133176|NCT01434901|Diabetes
1133177|NCT01434901|Blood Sugar
1133178|NCT01434901|Xenin-25
1133179|NCT01434901|GIP
1133180|NCT01434901|Muscarinic
1133181|NCT01434888|pharmacokinetics
1133182|NCT01434862|Type 1 Diabetes Mellitus
1133183|NCT01434849|infantile hemangioma
1133184|NCT01434849|very low birth weight infants
1133185|NCT01434849|premature infants
1133186|NCT01434836|Anti-depressant effects
1133187|NCT01434823|nocturnal staffing
1133188|NCT01434823|intensivist staffing
1133189|NCT01434823|intensivist coverage
1133190|NCT01434823|ICU patient-centered outcomes
1133191|NCT01434823|ICU resource utilization
1133192|NCT01434823|patients admitted to the medical intensive care unit
1133193|NCT01434823|Sleep Deprivation
1133194|NCT01434823|Inattention
1133195|NCT01434823|Work Hours
1133196|NCT01434810|Hyperbilirubinemia, Neonatal
1133197|NCT01434797|Infection
1133198|NCT01434797|Permanent central venous catheter
1133199|NCT01434797|Device Related
1133200|NCT01434784|lung cancer
1133201|NCT01434784|quality of life
1133202|NCT01434758|Mycobacterium tuberculosis
1133203|NCT01434758|Culture yield
1133204|NCT01434745|SLOS
1133205|NCT01434745|Cholesterol Supplementation
1133206|NCT01434745|Simvastatin
1133207|NCT01434732|Superior vena cava flow
1133208|NCT01434732|umbilical cord milking
1133209|NCT01434732|hemodynamics
1133210|NCT01434732|systemic blood flow
1133211|NCT01434719|Streptococcus suis
1133212|NCT01434719|Sepsis
1133213|NCT01434719|Porcine Respiratory and Reproductive System virus
1133214|NCT01434719|Pig disease
1133215|NCT01434719|Epidemiology
1133216|NCT01434706|HIV
1133217|NCT01434706|acute infection
1133218|NCT01434706|primary infection
1133219|NCT01434706|seroconverters
1133220|NCT01434693|T. suis ova
1133221|NCT01434693|Crohn's disease
1133222|NCT01434680|Meningococcal disease
1133223|NCT01434680|vaccines
1133224|NCT01434680|toddlers
1133225|NCT01434680|prevention
1133226|NCT01434680|Meningitis
1133227|NCT01434667|Mild Cognitive Impairment (MCI)
1133228|NCT01434667|Alzheimer's disease (AD)
1133229|NCT01434667|APOE
1133230|NCT01434667|genetics
1133231|NCT01434667|risk assessment
1133232|NCT01434667|education
1133233|NCT01434667|genetic counseling
1133234|NCT01434667|Mild Cognitive Impairment, So Stated
1133235|NCT01434654|HAND
1133236|NCT01434654|HIV
1133237|NCT01434654|Neurology
1133238|NCT01434654|Neurocognitive
1133239|NCT01434654|Neuro-HAART
1133240|NCT01434654|HIV Associated Neurocognitive Disorders (HAND)
1133241|NCT01434641|myocardial perfusion SPECT
1133242|NCT01434641|wide beam reconstruction
1133243|NCT01434641|Tc-99m sestamibi
1133244|NCT01434628|Male Circumcision
1133245|NCT01434628|HIV Prevention
1133246|NCT01434628|HIV Infections
1133247|NCT01434615|Cardiac Resynchronization Therapy
1133248|NCT01434615|Moderate to advanced
1133249|NCT01434615|patients
1133250|NCT01434615|current consensus guidelines
1133251|NCT01434602|Chemotherapy
1133252|NCT01434602|Brain Tumor
1133253|NCT01434602|Glioblastoma
1133254|NCT01434602|Anaplastic Glioma
1133255|NCT01434589|internet addiction
1133256|NCT01434589|computer game addiction
1133257|NCT01434589|STICA
1133258|NCT01434589|short-term treatment
1133259|NCT01434589|psychotherapy
1133260|NCT01434589|internet and computer game addiction
1133261|NCT01434563|HIV
1133262|NCT01434563|neurocognitive disorder
1133263|NCT01434563|primary care
1133264|NCT01434563|HIV negative
1133265|NCT01434563|HAND
1133266|NCT01434563|CNS
1133267|NCT01434550|pancreas
1133268|NCT01434550|pancreatic cancer
1133269|NCT01434550|SBRT
1133270|NCT01434550|stereotactic body radiation
1133271|NCT01434550|radiation therapy
1133272|NCT01434550|unresectable
1133273|NCT01434550|non-metastatic
1133274|NCT01434550|tissue, blood, research imaging
1133275|NCT01434550|TBRI
1133276|NCT01434537|pediatric anesthesia
1133277|NCT01434537|venepuncture
1133278|NCT01434537|peripheral venous access
1133279|NCT01434511|hemophilia A
1133280|NCT01434511|haemophilia A
1133281|NCT01434511|blood coagulation disorders
1133282|NCT01434511|hemorrhagic disorders
1133283|NCT01434511|coagulation protein disorder
1133284|NCT01434511|hematologic diseases
1133285|NCT01434511|congenital hemophilia A
1133286|NCT01434498|Hepatitis C
1133287|NCT01434498|HCV
1133288|NCT01434498|Rapid Virologic Response
1133289|NCT01434498|Sustained Virologic Response
1133290|NCT01434498|Direct Acting Antiviral
1133291|NCT01434498|Combination Therapy
1133292|NCT01434498|Tegobuvir
1133293|NCT01434498|Treatment naïve
1133294|NCT01434498|HCV RNA
1133295|NCT01434498|Polymerase inhibitor
1133296|NCT01434498|Protease inhibitor
1133297|NCT01434498|Interferon intolerant
1133298|NCT01434498|Interferon ineligible
1133299|NCT01434498|GS-9190
1133300|NCT01434498|GS-9451
1133301|NCT01434498|GS-5885
1133302|NCT01434485|gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome, Nexium
1133303|NCT01434459|Pancreatic neoplasms
1133304|NCT01434459|Cholangiocarcinoma
1133305|NCT01434420|triple negative breast cancer
1133306|NCT01434407|Advanced glycation endproducts
1133307|NCT01434407|Satiety
1133308|NCT01434407|Obesity
1133309|NCT01434407|Inflammation
1133310|NCT01434407|Insulin resistance
1133311|NCT01434394|Oral cancer
1133312|NCT01434394|Oropharyngeal cancer
1133313|NCT01434394|Induction chemotherapy
1133314|NCT01434394|Targeted chemotherapy
1133315|NCT01434394|Surgery
1133316|NCT01434394|Radiotherapy
1133317|NCT01434381|Recombinant
1133318|NCT01434381|Proteins
1133319|NCT01434381|Antigen
1133320|NCT01434381|Membrane
1133321|NCT01434381|Assay
1133322|NCT01434381|Malaria
1133323|NCT01434368|Functional Magnetic Resonance Imaging (fMRI)
1133324|NCT01434368|Normal Development
1133325|NCT01434368|Puberty
1133326|NCT01434368|Brain Function
1133327|NCT01434368|Gonadal Steroids
1133328|NCT01434368|Brain Structure
1133329|NCT01434368|Healthy Volunteer
1133330|NCT01434368|HV
1133331|NCT01434342|stage IA non-small cell lung cancer
1133332|NCT01434342|stage IB non-small cell lung cancer
1133333|NCT01434342|stage IIA non-small cell lung cancer
1133334|NCT01434342|stage IIB non-small cell lung cancer
1133335|NCT01434342|stage IIIA non-small cell lung cancer
1133336|NCT01434342|stage IIIB non-small cell lung cancer
1133337|NCT01434342|limited stage small cell lung cancer
1133338|NCT01434342|tobacco use disorder
1133339|NCT01434342|Breast Cancer
1133340|NCT01434342|Cervical Cancer
1133341|NCT01434342|head & neck cancer
1133342|NCT01434342|Prostate Cancer
1133343|NCT01434342|All histologies
1133344|NCT01434329|untreated adult acute myeloid leukemia
1133345|NCT01434290|radiation toxicity
1133346|NCT01434290|sexual dysfunction
1133347|NCT01434290|psychosocial effects of cancer and its treatment
1133348|NCT01434290|adenocarcinoma of the prostate
1133349|NCT01434290|stage I prostate cancer
1133350|NCT01434290|stage IIA prostate cancer
1133351|NCT01434277|Preservative
1133352|NCT01434277|Eye Drops
1133353|NCT01434264|rehabilitation
1133354|NCT01434251|Hypotension
1133355|NCT01434251|premature infants
1133356|NCT01434251|near infrared spectroscopy
1133357|NCT01434238|infant feeding
1133358|NCT01434238|HIV
1133359|NCT01434238|growth
1133360|NCT01434238|anemia
1133361|NCT01434225|Neonatal seizures
1133362|NCT01434225|Hypoxic Ischemic Encephalopathy
1133363|NCT01434225|Electroencephalography
1133364|NCT01434225|Bumetanide
1133365|NCT01434212|HCV dynamics
1133366|NCT01434212|Mathematical model
1133367|NCT01434212|Interferon
1133368|NCT01434212|Predict
1133369|NCT01434212|Hepatitis C Virus
1133370|NCT01434199|magnetic endoscope imaging
1133371|NCT01434199|colonoscopy
1133372|NCT01434199|caecal intubation
1133373|NCT01434173|Liver Diseases
1133374|NCT01434173|Anti-Bacterial Agents
1133375|NCT01434173|Fluoroquinolones
1133376|NCT01434173|Amoxicillin
1133377|NCT01434173|Amoxicillin-Potassium Clavulanate Combination
1133378|NCT01434173|Clarithromycin
1133379|NCT01434173|Doxycycline
1133380|NCT01434173|Cefuroxime
1133381|NCT01434173|Case-Control Studies
1133382|NCT01434173|Retrospective Studies
1133383|NCT01434173|Cohort Studies
1133384|NCT01434173|Epidemiologic Research Design
1133385|NCT01434173|Epidemiologic Studies
1133386|NCT01434173|HealthCore Integrated Research Database (non-MESH)
1133387|NCT01434173|United States
1133388|NCT01434173|Human
1133389|NCT01434173|Insurance Claim Review
1133390|NCT01434160|Intrauterine
1133391|NCT01434160|contraception
1133392|NCT01434160|adolescent
1133393|NCT01434147|locally advanced rectal cancer
1133394|NCT01434147|preoperative induction chemotherapy chemoradiotherapy
1133395|NCT01434134|Anthracyclines
1133396|NCT01434134|Trastuzumab
1133397|NCT01434108|cirrhosis, gastrointestinal bleeding
1133398|NCT01434095|microperimetry
1133399|NCT01434095|fixation point
1133400|NCT01434095|retinal sensitivity
1133401|NCT01434095|photodynamic therapy
1133402|NCT01434095|chronic central serous chorioretinopathy
1133403|NCT01434082|sleep
1133404|NCT01434082|school-age children
1133405|NCT01434082|Children with and without arthritis
1133406|NCT01434069|colon
1133407|NCT01434069|rectum
1133408|NCT01434069|small bowel
1133409|NCT01434069|pancreas
1133410|NCT01434069|gastric
1133411|NCT01434069|esophageal
1133412|NCT01434069|metastatic
1133413|NCT01434069|unresectable
1133414|NCT01434069|GI
1133415|NCT01434069|combination therapy
1133416|NCT01434069|dose escalation
1133417|NCT01434069|solid tumor
1133418|NCT01434056|Liver disease
1133419|NCT01434056|Hepatic encephalopathy
1133420|NCT01434056|MELD
1133421|NCT01434056|Liver transplantation
1133422|NCT01434043|Cardiac CT perfusion
1133423|NCT01434043|Positron emission tomography perfusion
1133424|NCT01434043|Quantitative perfusion
1133425|NCT01434017|PONV
1133426|NCT01434017|Dexamethasone
1133427|NCT01434017|Droperidol
1133428|NCT01434017|Ondansetron
1133429|NCT01434017|Tonsillectomy
1133430|NCT01434004|prostate cancer
1133431|NCT01433965|Bone marrow transplantation
1133432|NCT01433965|Maintenance lenalidomide
1133433|NCT01433939|colonoscopy
1133434|NCT01433939|position changes
1133435|NCT01433939|patient comfort
1133436|NCT01433926|Breast cancer.
1133437|NCT01433926|Trastuzumab.
1133438|NCT01433926|Complete remission.
1133439|NCT01433900|glaucoma
1133440|NCT01433900|intraocular pressure
1133441|NCT01433900|ocular surface
1133442|NCT01433900|benzalkonium chloride
1133443|NCT01433887|Peginterferon alfa-2a
1133444|NCT01433887|ribavirin
1133445|NCT01433874|Shoulder pain
1133446|NCT01433874|Upper abdominal pain
1133447|NCT01433874|Laparoscopic surgery
1133448|NCT01433874|Abdominal fullness
1133449|NCT01433861|gastric cancer
1133450|NCT01433861|proximal gastrectomy
1133451|NCT01433861|total gastrectomy
1133452|NCT01433861|laparoscopy
1133453|NCT01433861|reflux esophagitis
1133454|NCT01433861|double tract reconstruction
1133455|NCT01433835|Cytomegalovirus
1133456|NCT01433835|Antiviral
1133457|NCT01433835|Safety
1133458|NCT01433835|Healthy
1133459|NCT01433809|thyroid cancer
1133460|NCT01433809|thyroid neoplasm
1133461|NCT01433809|thyroid adenoma
1133462|NCT01433796|antiretroviral therapy
1133463|NCT01433796|tuberculosis
1133464|NCT01433796|health centres
1133465|NCT01433796|Ethiopia
1133466|NCT01433757|dystonia
1133467|NCT01433757|DYT-1
1133468|NCT01433757|AMPICILLIN
1133469|NCT01433744|C-Reactive protein
1133470|NCT01433744|risk
1133471|NCT01433731|CTCL
1133472|NCT01433731|Cutaneous T-Cell Lymphoma
1133473|NCT01433718|Effectivness
1133474|NCT01433718|Neuromuscular Training
1133475|NCT01433718|Resistance Training
1133476|NCT01433718|Modification
1133477|NCT01433718|Anterior Cruciate Ligament Risk Factors
1133478|NCT01433718|Drop-Jump
1133479|NCT01433718|Knee Separation
1133480|NCT01433718|Resistance training program
1133481|NCT01433705|heart
1133482|NCT01433705|perfusion
1133483|NCT01433705|glucose
1133484|NCT01433692|Addictions
1133485|NCT01433692|Adolescents
1133486|NCT01433692|Primary Health Care
1133487|NCT01433692|Brief Intervention
1133488|NCT01433679|Health Behavior
1133489|NCT01433679|Exercise
1133490|NCT01433679|Adolescent Behavior
1133491|NCT01433679|Motivation
1133492|NCT01433679|Biological Markers
1133493|NCT01433653|Comorbid
1133494|NCT01433653|Complicated
1133495|NCT01433640|image on multi-modalities
1133496|NCT01433640|visualize cancer lesions
1133497|NCT01433640|highly suspicious lesions
1133498|NCT01433627|acute coronary syndromes
1133499|NCT01433627|myocardial infarction
1133500|NCT01433627|access site
1133501|NCT01433627|bivalirudin
1133502|NCT01433627|bleedings
1133503|NCT01433601|Adherence
1133504|NCT01433601|Peer support
1133505|NCT01433601|Treatment failure
1133506|NCT01433588|Managing infant pain
1133507|NCT01433588|27 - 36+6 weeks gestation
1133508|NCT01433588|Preterm infants
1133509|NCT01433562|breast cancer
1133510|NCT01433562|neoadjuvant therapy
1133511|NCT01433562|Stage II/III
1133512|NCT01433536|cranial trauma with or without high velocity fracture to inferior limb
1133513|NCT01433536|spinal trauma with or without high velocity fracture to inferior limb
1133514|NCT01433536|high velocity fracture to inferior limb
1133515|NCT01433523|HDM
1133516|NCT01433523|AIT
1133517|NCT01433523|asthma
1133518|NCT01433523|asthma exacerbation
1133519|NCT01433523|House dust mite induced asthma
1133520|NCT01433510|Allergic
1133521|NCT01433510|Rhinoconjunctivitis
1133522|NCT01433510|Immunotherapy
1133523|NCT01433497|multiple sclerosis
1133524|NCT01433497|primary progressive
1133525|NCT01433497|relapse-free
1133526|NCT01433497|secondary progressive
1133527|NCT01433484|cardiovascular disease
1133528|NCT01433484|coronary heart disease
1133529|NCT01433484|obesity
1133530|NCT01433484|weight loss
1133531|NCT01433484|genomics
1133532|NCT01433471|Ulcerative Colitis
1133533|NCT01433471|Trichuris Suis Ova
1133534|NCT01433471|Inflammatory Bowel Disease
1133535|NCT01433471|Mucus
1133536|NCT01433458|Hepatic impairment
1133537|NCT01433458|healthy volunteers
1133538|NCT01433458|RLX030
1133539|NCT01433458|pharmacokinetics
1133540|NCT01433445|Myelofibrosis
1133541|NCT01433445|Panobinostat
1133542|NCT01433445|Ruxolitinib
1133543|NCT01433445|MF
1133544|NCT01433445|PMF
1133545|NCT01433445|PPV
1133546|NCT01433445|PPV-MF
1133547|NCT01433445|PET
1133548|NCT01433445|PET-MF
1133549|NCT01433445|JAK2
1133550|NCT01433445|DACi
1133551|NCT01433432|Crohn's Disease
1133552|NCT01433419|Drug Therapy
1133553|NCT01433406|Drug Therapy
1133554|NCT01433393|Drug Therapy
1133555|NCT01433380|Phase 1
1133556|NCT01433380|Single Doses
1133557|NCT01433380|Pharmacodynamics
1133558|NCT01433380|Healthy Volunteers
1133559|NCT01433367|total disc replacement
1133560|NCT01433367|cervical disc disease
1133561|NCT01433354|Fragile X Syndrome
1133562|NCT01433354|Martin-Bell Syndrome
1133563|NCT01433354|Genetic Diseases
1133564|NCT01433354|X-Linked
1133565|NCT01433354|Escalante's syndrome
1133566|NCT01433341|Normal young athletes
1133567|NCT01433328|Remodulin
1133568|NCT01433328|Treprostinil
1133569|NCT01433315|sleep deprivation
1133570|NCT01433315|sleep restriction
1133571|NCT01433302|Breast cancer
1133572|NCT01433302|Genitourinary cancer
1133573|NCT01433302|Gynecological cancer
1133574|NCT01433302|Malignant Female Reproductive System Neoplasm
1133575|NCT01433302|Melanoma
1133576|NCT01433302|Sarcoma
1133577|NCT01433302|Inflammatory Response
1133578|NCT01433302|Inflammatory proteins
1133579|NCT01433302|Tissue Fibrosis
1133580|NCT01433302|Lymphatico-venous Bypass Surgery
1133581|NCT01433302|Punch biopsy
1133582|NCT01433302|Lab collections
1133583|NCT01433302|Th2 immune phenotype
1133584|NCT01433302|Lymphedema
1133585|NCT01433289|HIV
1133586|NCT01433289|safety
1133587|NCT01433289|toxicity
1133588|NCT01433289|pharmacokinetics
1133589|NCT01433289|Polyphenon E
1133590|NCT01433289|EGCG
1133591|NCT01433289|green tea
1133592|NCT01433289|CD4
1133593|NCT01433289|viral load
1133594|NCT01433276|Fluid resuscitation
1133595|NCT01433276|hemorrhagic shock
1133596|NCT01433276|Totilac
1133597|NCT01433276|Ringer's
1133598|NCT01433276|trauma
1133599|NCT01433263|Wasting syndrome
1133600|NCT01433263|emaciation
1133601|NCT01433263|lung cancer
1133602|NCT01433263|adenocarcinoma
1133603|NCT01433263|pancreatic cancer
1133604|NCT01433250|Multiple Sclerosis,
1133605|NCT01433250|demyelinating autoimmune diseases,
1133606|NCT01433250|interleukin-17,
1133607|NCT01433250|monoclonal human antibody
1133608|NCT01433237|embryonal childhood rhabdomyosarcoma
1133609|NCT01433237|adult rhabdomyosarcoma
1133610|NCT01433237|alveolar childhood rhabdomyosarcoma
1133611|NCT01433237|adult soft tissue sarcoma
1133612|NCT01433237|childhood rhabdomyosarcoma
1133613|NCT01433224|recurrent childhood malignant germ cell tumor
1133614|NCT01433224|recurrent extragonadal germ cell tumor
1133615|NCT01433224|recurrent malignant testicular germ cell tumor
1133616|NCT01433224|recurrent ovarian germ cell tumor
1133617|NCT01433185|PMTCT
1133618|NCT01433185|SMS
1133619|NCT01433185|HIV Infections
1133620|NCT01433185|Acquired Immunodeficiency Syndrome
1133621|NCT01433185|Prevention & Control
1133622|NCT01433185|Patient Compliance
1133623|NCT01433185|Cellular Phone
1133624|NCT01433185|Randomized Controlled Trial
1133625|NCT01433172|stage IV
1133626|NCT01433172|adenocarcinoma
1133627|NCT01433172|vaccine therapy
1133628|NCT01433172|immunology
1133629|NCT01433172|tumor vaccine
1133630|NCT01433172|colony stimulating factor(CSF)
1133631|NCT01433172|granulocyte-macrophage colony-stimulating factor (GM-CSF)
1133632|NCT01433172|CC chemokine ligand 21 (CCL21)
1133633|NCT01433172|Chemokine [C-C motif] ligand 21 (CCL21)
1133634|NCT01433172|human leukocyte antigen serotype (HLA)
1133635|NCT01433159|Pressure Ulcers
1133636|NCT01433159|Spinal Cord Injury
1133637|NCT01433159|Healthpoint
1133638|NCT01433159|Xenaderm
1133639|NCT01433159|011-101
1133640|NCT01433146|Temperament
1133641|NCT01433146|Anxiety
1133642|NCT01433146|Depression
1133643|NCT01433146|Colorectal Cancer
1133644|NCT01433120|Obesity
1133645|NCT01433120|Insulin resistance
1133646|NCT01433120|Microbiota
1133647|NCT01433120|Probiotic
1133648|NCT01433120|Prebiotic
1133649|NCT01433107|Tinea pedis
1133650|NCT01433107|Terbinafine film forming solution
1133651|NCT01433094|Adherence
1133652|NCT01433094|Psychoeducation
1133653|NCT01433094|Pharmacotherapy
1133654|NCT01433094|Schizophrenia
1133655|NCT01433094|Family support
1133656|NCT01433068|Adult Soft Tissue Sarcoma of the extremities and Trunk wall
1133657|NCT01433055|Schizophrenia
1133658|NCT01433055|Cognitive Symptoms
1133659|NCT01433055|Clozapine
1133660|NCT01433042|small bowel disease
1133661|NCT01433029|Surgical Procedure
1133662|NCT01433029|Assessment
1133663|NCT01433029|Cardiothoracic Surgery
1133664|NCT01433029|Coronary artery bypass
1133665|NCT01433029|CAB
1133666|NCT01433029|Video recordings
1133667|NCT01433029|Global rating scale
1133668|NCT01433029|GRS
1133669|NCT01433029|Cardiothoracic surgeon
1133670|NCT01433029|Surgical trainees
1133671|NCT01433016|HCC Hepatocellular carcinoma
1133672|NCT01433016|OBT Octanoate Breath Test
1133673|NCT01433003|Thrombotic thrombocytopenia purpura
1133674|NCT01433003|hemolytic uremic syndrome
1133675|NCT01433003|plasma exchange
1133676|NCT01433003|Improve treatment response
1133677|NCT01433003|TTP/HUS
1133678|NCT01432990|SCI
1133679|NCT01432990|gait
1133680|NCT01432990|rehabilitation
1133681|NCT01432990|robotic
1133682|NCT01432964|Orbital Fractures
1133683|NCT01432964|Fracture Fixation
1133684|NCT01432964|Blow-out Fractures
1133685|NCT01432964|Surgical Mesh
1133686|NCT01432964|Titanium
1133687|NCT01432964|Computer-assisted Image Processing
1133688|NCT01432925|Buruli ulcer
1133689|NCT01432925|Mycobacterium ulcerans
1133690|NCT01432925|Streptomycin
1133691|NCT01432925|Rifampicin
1133692|NCT01432925|Functional limitations
1133693|NCT01432925|surgery
1133694|NCT01432925|Bénin
1133695|NCT01432899|Neurophysiology
1133696|NCT01432899|Hemidystonia
1133697|NCT01432899|Childhood-onset
1133698|NCT01432899|Motion Analysis
1133699|NCT01432899|Neuroimaging
1133700|NCT01432899|Childhood Onset Hemidystonia
1133701|NCT01432899|Healthy Volunteer
1133702|NCT01432899|HV
1133703|NCT01432886|Breast Cancer
1133704|NCT01432873|BMT
1133705|NCT01432873|HSCT
1133706|NCT01432860|Skin Self Examination
1133707|NCT01432847|Best Disease
1133708|NCT01432847|Late-Onset Retinal Degeneration (L-ORD)
1133709|NCT01432847|Age-Related Macular Degeneration (AMD)
1133710|NCT01432847|Induced Pluripotent Stem Cell (iPS) Cell Lines
1133711|NCT01432847|Retinal Degeneration
1133712|NCT01432847|Age-Related Macular Degeneration
1133713|NCT01432847|AMD
1133714|NCT01432834|non-anterior astigmatism correction
1133715|NCT01432834|Allegretto Wave excimer laser
1133716|NCT01432834|wavefront optimized ablation profile (WFO)
1133717|NCT01432834|LASIK
1133718|NCT01432834|PRK
1133719|NCT01432821|Epilepsy,
1133720|NCT01432821|dopamine
1133721|NCT01432821|yawning,
1133722|NCT01432821|blinking eyelids,
1133723|NCT01432821|electroencephalography
1133724|NCT01432795|chronic venous insufficiency
1133725|NCT01432795|post-thrombotic syndrome
1133726|NCT01432795|medical compression therapy
1133727|NCT01432795|compression stocking
1133728|NCT01432795|gliding aid
1133729|NCT01432795|stocking butler
1133730|NCT01432795|adherence to treatment
1133731|NCT01432782|Weight loss
1133732|NCT01432782|Dysphagia
1133733|NCT01432782|Esophageal hypermotility
1133734|NCT01432782|Chest Pain
1133735|NCT01432769|enteral nutrition
1133736|NCT01432769|malnutrition
1133737|NCT01432769|cardiac surgery
1133738|NCT01432756|HIV
1133739|NCT01432743|3D mapping
1133740|NCT01432743|Image integration
1133741|NCT01432743|Atrial fibrillation
1133742|NCT01432743|Catheter Ablation
1133743|NCT01432704|MS
1133744|NCT01432704|vitamin D
1133745|NCT01432704|environment
1133746|NCT01432691|Hip-fracture
1133747|NCT01432691|RSA
1133748|NCT01432678|vitamin D
1133749|NCT01432678|asthma
1133750|NCT01432665|HSDD
1133751|NCT01432639|Myocardial infarction
1133752|NCT01432639|Autonomic function
1133753|NCT01432639|Arterial Stiffness
1133754|NCT01432639|Endothelial function
1133755|NCT01432639|Inflammation
1133756|NCT01432639|Rehabilitation program
1133757|NCT01432639|Exercise
1133758|NCT01432626|stress induced cardiomyopathy
1133759|NCT01432626|broken heart syndrome
1133760|NCT01432626|Takotsubo cardiomyopathy
1133761|NCT01432626|transient apical ballooning syndrome
1133762|NCT01432626|apical ballooning cardiomyopathy
1133763|NCT01432626|stress cardiomyopathy
1133764|NCT01432626|non-ischemic cardiomyopathy
1133765|NCT01432613|Myositis
1133766|NCT01432613|Magnetic Resonance Imaging
1133767|NCT01432613|Muscle biopsy
1133768|NCT01432613|Sensitivity and Specificity
1133769|NCT01432600|Multiple Myeloma
1133770|NCT01432600|Relapsed
1133771|NCT01432600|Refractory
1133772|NCT01432600|Corticosteroids
1133773|NCT01432587|Amyloidosis
1133774|NCT01432587|Transthyretin
1133775|NCT01432587|Neuropathies
1133776|NCT01432587|Diflunisal
1133777|NCT01432587|Familial
1133778|NCT01432574|HPV
1133779|NCT01432561|Lysosomal Storage Diseases
1133780|NCT01432561|Metabolic Diseases
1133781|NCT01432561|Metabolism, Inborn Errors
1133782|NCT01432548|Ischemic
1133783|NCT01432548|preconditioning
1133784|NCT01432548|liver
1133785|NCT01432548|resection
1133786|NCT01432522|Intranasal epinephrine
1133787|NCT01432522|Plasma epinephrine level
1133788|NCT01432509|Pre-diabetes
1133789|NCT01432509|Type 2 diabetes
1133790|NCT01432509|Biomarkers
1133791|NCT01432509|Cohort
1133792|NCT01432509|Diabetes Risk Score
1133793|NCT01432509|Diabetes Mellitus, Type 2
1133794|NCT01432509|Glucose Intolerance
1133795|NCT01432509|Prediabetic State
1133796|NCT01432509|Glucose Metabolism Disorders
1133797|NCT01432509|Metabolic Diseases
1133798|NCT01432509|Endocrine System Diseases
1133799|NCT01432509|Hyperglycemia
1133800|NCT01432496|Laparoscopic
1133801|NCT01432496|Colectomy
1133802|NCT01432496|Nebulization
1133803|NCT01432496|Ropivacaine
1133804|NCT01432483|Cancer
1133805|NCT01432483|ONTAK
1133806|NCT01432483|Denileukin diftitox
1133807|NCT01432483|persistent or recurrent disease
1133808|NCT01432483|requiring continued delivery of essential cancer therapy
1133809|NCT01432470|vaginal atrophy
1133810|NCT01432444|Schizophrenia
1133811|NCT01432418|rehabilitation
1133812|NCT01432418|wheelchairs
1133813|NCT01432418|safety
1133814|NCT01432418|disability evaluation
1133815|NCT01432418|motor skills
1133816|NCT01432405|Diabetes
1133817|NCT01432392|gastroesophageal reflux disease
1133818|NCT01432392|GERD questionnaire
1133819|NCT01432392|primary care setting
1133820|NCT01432340|Influenza
1133821|NCT01432340|Influenza vaccine
1133822|NCT01432340|Influenza vaccine effectiveness study
1133823|NCT01432327|motor activity
1133824|NCT01432327|randomized controlled trial
1133825|NCT01432327|feedback
1133826|NCT01432314|patient's survival
1133827|NCT01432314|tumor response
1133828|NCT01432314|safety
1133829|NCT01432301|fluorouracil overdose
1133830|NCT01432301|fluorouracil toxicity
1133831|NCT01432301|capecitabine overdose
1133832|NCT01432301|capecitabine toxicity
1133833|NCT01432275|Diabetes
1133834|NCT01432275|SMBG
1133835|NCT01432275|Insulin calculator
1133836|NCT01432262|prevention of pneumococcal diseases
1133837|NCT01432249|pediatric psoriasis
1133838|NCT01432249|enbrel
1133839|NCT01432249|safety
1133840|NCT01432249|efficacy
1133841|NCT01432236|Pregabalin
1133842|NCT01432236|Lyrica
1133843|NCT01432236|depression
1133844|NCT01432223|Trastuzumab
1133845|NCT01432223|Neoadjuvant chemotherapy
1133846|NCT01432223|Primary chemotherapy
1133847|NCT01432210|post-prandial absorption
1133848|NCT01432210|provitamin A carotenoids
1133849|NCT01432210|vitamin A
1133850|NCT01432210|avocado
1133851|NCT01432210|tomato
1133852|NCT01432210|carrot
1133853|NCT01432197|HRQOL
1133854|NCT01432197|Occupational therapy
1133855|NCT01432197|ADL intervention
1133856|NCT01432197|Cancer patients
1133857|NCT01432184|cerebral
1133858|NCT01432184|hypoxia
1133859|NCT01432171|Brain cancer
1133860|NCT01432171|Central nervous system
1133861|NCT01432171|Seizure prophylaxis
1133862|NCT01432171|High-Grade Gliomas
1133863|NCT01432171|HGG
1133864|NCT01432171|Supratentorial high-grade glioma
1133865|NCT01432171|Malignant glioma
1133866|NCT01432171|Lacosamide
1133867|NCT01432171|Vimpat
1133868|NCT01432171|Placebo
1133869|NCT01432171|Sugar pill
1133870|NCT01432158|Invasive pneumococcal disease
1133871|NCT01432145|BRCA defective
1133872|NCT01432132|Head and Neck Cancer
1133873|NCT01432132|Body Image Adaptation
1133874|NCT01432132|Post surgical body image
1133875|NCT01432132|Audio-recorded interview
1133876|NCT01432132|Questionnaire
1133877|NCT01432132|Survey
1133878|NCT01432119|Advanced Cancers
1133879|NCT01432119|Advanced Malignancies
1133880|NCT01432119|Liver Metastases
1133881|NCT01432119|SIR-Spheres
1133882|NCT01432119|Selective internal radiation
1133883|NCT01432119|Yttrium-90
1133884|NCT01432119|Cetuximab
1133885|NCT01432119|C225
1133886|NCT01432119|Erbitux
1133887|NCT01432119|Erlotinib
1133888|NCT01432119|Erlotinib Hydrochloride
1133889|NCT01432119|Tarceva
1133890|NCT01432119|OSI-774
1133891|NCT01432106|Hypertension
1133892|NCT01432106|Metabolic Syndrome
1133893|NCT01432106|African American
1133894|NCT01432093|liver transplant
1133895|NCT01432093|high blood sugars
1133896|NCT01432093|hospital hyperglycemia
1133897|NCT01432093|post-transplant hyperglycemia
1133898|NCT01432093|post liver transplant
1133899|NCT01432093|post liver-kidney transplant
1133900|NCT01432080|Pulmonary disease, chronic obstructive
1133901|NCT01432080|Viral respiratory tract infections
1133902|NCT01432080|Respiratory syncytial viruses
1133903|NCT01432080|Influenza virus A
1133904|NCT01432080|Influenza virus B
1133905|NCT01432080|Transplantation, Allogeneic
1133906|NCT01432067|cancer
1133907|NCT01432067|geriatry
1133908|NCT01432067|curative care
1133909|NCT01432067|physical activity
1133910|NCT01432054|Human Tissue Repository
1133911|NCT01432041|Injury prevention
1133912|NCT01432041|smoke alarms
1133913|NCT01432041|car seats
1133914|NCT01432015|aprepitant
1133915|NCT01432015|fosaprepitant
1133916|NCT01432015|gynecologic cancer
1133917|NCT01432015|emesis
1133918|NCT01432002|breast carcinoma
1133919|NCT01432002|FDG
1133920|NCT01432002|PET/CT
1133921|NCT01432002|PET/IRM
1133922|NCT01431950|fluticasone furoate
1133923|NCT01431937|Pharmacodynamics
1133924|NCT01431937|Pharmacokinetics
1133925|NCT01431924|outcomes
1133926|NCT01431924|observational
1133927|NCT01431924|retrospective
1133928|NCT01431924|database
1133929|NCT01431924|asthma
1133930|NCT01431898|HCV RNA
1133931|NCT01431898|Polymerase inhibitor
1133932|NCT01431898|Treatment naïve and Treatment experienced
1133933|NCT01431898|GS-9669
1133934|NCT01431898|Hepatitis C
1133935|NCT01431898|HCV
1133936|NCT01431885|fibronectin
1133937|NCT01431885|cervical length
1133938|NCT01431872|Aromatase Inhibitors
1133939|NCT01431859|pollen
1133940|NCT01431859|allergy
1133941|NCT01431859|food
1133942|NCT01431859|immunotherapy
1133943|NCT01431833|Hepatic Impairment
1133944|NCT01431833|Matched control subjects
1133945|NCT01431820|Onychomycosis
1133946|NCT01431820|Toenail Fungus
1133947|NCT01431820|luliconazole
1133948|NCT01431820|Antifungal
1133949|NCT01431820|Topical
1133950|NCT01431794|Pancreatic ductal adenocarcinoma (PDA)Neoplasms
1133951|NCT01431794|LDE225
1133952|NCT01431794|nab-paclitaxel
1133953|NCT01431794|abraxane
1133954|NCT01431794|gemcitabine
1133955|NCT01431794|neoadjuvant
1133956|NCT01431794|cytotoxic
1133957|NCT01431794|hedgehog (Hh) inhibitors
1133958|NCT01431794|stromal cells
1133959|NCT01431794|resectable PDA
1133960|NCT01431794|Pancreatic Diseases
1133961|NCT01431794|Carcinoma
1133962|NCT01431768|Influenza
1133963|NCT01431768|Human
1133964|NCT01431768|Orthomyxoviridae infections
1133965|NCT01431768|RNA Virus Infections
1133966|NCT01431768|Virus Diseases
1133967|NCT01431768|Respiratory Tract infections
1133968|NCT01431768|Respiratory Tract Diseases
1133969|NCT01431742|buccal soluble film
1133970|NCT01431742|Pain
1133971|NCT01431742|Back Pain
1133972|NCT01431742|Low Back Pain
1133973|NCT01431742|Buprenorphine
1133974|NCT01431742|Analgesics, Opioid
1133975|NCT01431742|Analgesics
1133976|NCT01431703|narrow band imaging
1133977|NCT01431703|learning curve
1133978|NCT01431703|colorectal
1133979|NCT01431703|differential diagnosis
1133980|NCT01431703|with colorectal lesion
1133981|NCT01431703|NBI with magnification
1133982|NCT01431690|Eicosapentaenoic Acid
1133983|NCT01431690|Docosahexaenoic Acid
1133984|NCT01431690|Warfarin
1133985|NCT01431690|Hypertriglyceridemia
1133986|NCT01431690|Omega-3 free fatty acids
1133987|NCT01431690|Omega-3 ethyl ester acids
1133988|NCT01431690|Epanova
1133989|NCT01431690|Lovaza
1133990|NCT01431690|pharmacokinetics
1133991|NCT01431690|low-fat meal
1133992|NCT01431677|Muscle
1133993|NCT01431677|Biopsy
1133994|NCT01431677|Energetics
1133995|NCT01431677|Sarcopenia
1133996|NCT01431677|Frailty
1133997|NCT01431664|recurrent childhood acute lymphoblastic leukemia
1133998|NCT01431664|recurrent childhood acute myeloid leukemia
1133999|NCT01431664|acute leukemias of ambiguous lineage
1134000|NCT01431664|acute undifferentiated leukemia
1134001|NCT01431664|secondary acute myeloid leukemia
1134002|NCT01431651|Food and beverages
1134003|NCT01431651|Food
1134004|NCT01431651|Dietary supplements
1134005|NCT01431638|Gout
1134006|NCT01431638|arthritis
1134007|NCT01431638|gout flare
1134008|NCT01431638|acute gout
1134009|NCT01431638|gouty
1134010|NCT01431638|rheumatic disease
1134011|NCT01431638|uric acid
1134012|NCT01431638|podagra
1134013|NCT01431625|COPD
1134014|NCT01431625|Exercise Training
1134015|NCT01431612|Pharmacokinetics, kidney;
1134016|NCT01431612|Receptors, adrenergic;
1134017|NCT01431612|Fluids, i.v.;
1134018|NCT01431612|Sympathetic nervous system, esmolol;
1134019|NCT01431612|Sympathetic nervous system, phenylephrine
1134020|NCT01431599|Locally advanced rectal cancer
1134021|NCT01431586|JDTic
1134022|NCT01431586|cocaine dependence
1134023|NCT01431586|kappa-opioid antagonist
1134024|NCT01431573|Depression
1134025|NCT01431560|ankle
1134026|NCT01431560|metallic
1134027|NCT01431560|biodegradable
1134028|NCT01431560|Freedom
1134029|NCT01431508|Hypertension
1134030|NCT01431495|platelet agregation
1134031|NCT01431495|clopidogrel
1134032|NCT01431495|major adverse cardiac events (MACE)
1134033|NCT01431482|skin symptoms
1134034|NCT01431456|Prevention
1134035|NCT01431456|venous thromboembolism after knee arthroplasty
1134036|NCT01431443|Randomized double blind trial
1134037|NCT01431443|Cocoa flavonoids
1134038|NCT01431443|Endothelial function
1134039|NCT01431443|Blood pressure
1134040|NCT01431443|Pregnant women
1134041|NCT01431443|Preeclampsia
1134042|NCT01431443|Uterine artery flow
1134043|NCT01431443|Pulsatility index
1134044|NCT01431430|Vitamine D
1134045|NCT01431430|renal transplantation
1134046|NCT01431430|diabetes mellitus
1134047|NCT01431430|cancer
1134048|NCT01431430|cardiovascular complications
1134049|NCT01431417|Shoulder
1134050|NCT01431417|Outcome treatment
1134051|NCT01431417|Validation Studies as topic
1134052|NCT01431417|Biomechanics
1134053|NCT01431417|Shoulder, Joint Instability
1134054|NCT01431391|Immune therapy
1134055|NCT01431391|Cancer vaccine
1134056|NCT01431391|Therapeutic vaccine
1134057|NCT01431391|Therapeutic cancer vaccine
1134058|NCT01431391|Vaccine
1134059|NCT01431391|Dendritic cells
1134060|NCT01431391|PSA
1134061|NCT01431391|Androgen deprivation therapy
1134062|NCT01431391|Prostatic Neoplasms
1134063|NCT01431391|Genital Neoplasms, Male
1134064|NCT01431391|Urogenital Neoplasms
1134065|NCT01431391|Neoplasms
1134066|NCT01431391|Prostatic Diseases
1134067|NCT01431391|Androgens
1134068|NCT01431391|Hormones
1134069|NCT01431391|Adenocarcinoma
1134070|NCT01431391|Carcinoma
1134071|NCT01431391|Neoplasms, Glandular and Epithelial
1134072|NCT01431391|Immunology
1134073|NCT01431391|Hormone therapy
1134074|NCT01431391|Immunotherapy
1134075|NCT01431391|Luteinizing hormone-releasing hormone (LHRH)
1134076|NCT01431378|CT scan
1134077|NCT01431378|CNS
1134078|NCT01431378|Thorax
1134079|NCT01431378|Abdomen
1134080|NCT01431378|staging of a known or suspected lung cancer
1134081|NCT01431378|suspected urolithiasis
1134082|NCT01431378|known or suspected focal liver lesion
1134083|NCT01431365|exercise
1134084|NCT01431365|topography
1134085|NCT01431365|cravings
1134086|NCT01431365|smoking behaviour
1134087|NCT01431352|Polycystic ovary syndrome
1134088|NCT01431352|Randomized controlled trial
1134089|NCT01431352|Chinese herbal medicine
1134090|NCT01431352|Chinese herbal medicine granules
1134091|NCT01431352|Letrozole
1134092|NCT01431352|Live birth
1134093|NCT01431326|adenovirus
1134094|NCT01431326|adrenal insufficiency
1134095|NCT01431326|afterload inducer
1134096|NCT01431326|amnestic
1134097|NCT01431326|anaesthetic
1134098|NCT01431326|anesthesia
1134099|NCT01431326|angina
1134100|NCT01431326|anticoagulant
1134101|NCT01431326|anti-epileptic
1134102|NCT01431326|anti-inflammatory
1134103|NCT01431326|antimicrobial
1134104|NCT01431326|anti-psychotic
1134105|NCT01431326|antiviral
1134106|NCT01431326|anxiety
1134107|NCT01431326|anxiolysis
1134108|NCT01431326|anxiolytic
1134109|NCT01431326|autism
1134110|NCT01431326|autistic disorder
1134111|NCT01431326|benzodiazepine
1134112|NCT01431326|bipolar disorder
1134113|NCT01431326|convulsions
1134114|NCT01431326|edema
1134115|NCT01431326|epilepsy
1134116|NCT01431326|headaches
1134117|NCT01431326|herpes simplex virus
1134118|NCT01431326|HSV
1134119|NCT01431326|hypertension
1134120|NCT01431326|infantile hemangioma
1134121|NCT01431326|infection
1134122|NCT01431326|inflammation
1134123|NCT01431326|influenza
1134124|NCT01431326|LRTI
1134125|NCT01431326|meningitis
1134126|NCT01431326|migraines
1134127|NCT01431326|muscle spasms
1134128|NCT01431326|pain
1134129|NCT01431326|pneumonia
1134130|NCT01431326|prophylaxis
1134131|NCT01431326|retinitis
1134132|NCT01431326|schizophrenia
1134133|NCT01431326|sedation
1134134|NCT01431326|sedative
1134135|NCT01431326|seizures
1134136|NCT01431326|septicemia
1134137|NCT01431326|swelling
1134138|NCT01431326|thromboprophylaxis
1134139|NCT01431326|thrombosis
1134140|NCT01431326|urinary tract infection
1134141|NCT01431326|UTI
1134142|NCT01431326|withdrawal
1134143|NCT01431313|pulmonary hypertension
1134144|NCT01431300|central veins
1134145|NCT01431300|thorax
1134146|NCT01431300|superior vena cava
1134147|NCT01431300|Central vein imaging
1134148|NCT01431261|Chronic neck pain
1134149|NCT01431261|Whiplash
1134150|NCT01431261|Whiplash Associated Disorders
1134151|NCT01431261|Chronic Pain
1134152|NCT01431261|Neck exercises
1134153|NCT01431261|Training
1134154|NCT01431261|Pacing
1134155|NCT01431261|Patient Education
1134156|NCT01431261|Pain Management
1134157|NCT01431261|Whiplash Injuries
1134158|NCT01431261|Musculoskeletal
1134159|NCT01431248|Preterm Premature Rupture of Membranes
1134160|NCT01431248|Erythromycin
1134161|NCT01431248|Azithromycin
1134162|NCT01431235|ADHD
1134163|NCT01431235|SUD
1134164|NCT01431235|cognitive behavioral therapy
1134165|NCT01431222|severe mitral regurgitation
1134166|NCT01431222|interventional mitral valve reconstruction
1134167|NCT01431222|inoperable
1134168|NCT01431222|EuroSCORE
1134169|NCT01431222|STS Risk Score
1134170|NCT01431222|MitraClip
1134171|NCT01431222|fluoroscopy
1134172|NCT01431222|echocardiography
1134173|NCT01431222|percutaneous treatment of mitral regurgitation
1134174|NCT01431196|breast cancer
1134175|NCT01431196|neoadjuvant chemotherapy
1134176|NCT01431196|autologous dendritic cell vaccination
1134177|NCT01431183|influenza
1134178|NCT01431183|vaccine
1134179|NCT01431183|reminder / recall
1134180|NCT01431183|immunization registry
1134181|NCT01431183|immunization information systems
1134182|NCT01431157|Sleep Apnea Syndrome
1134183|NCT01431157|Heart Failure
1134184|NCT01431157|Oxygen Inhalation Therapy
1134185|NCT01431144|soft tissue thickness
1134186|NCT01431144|dental implant
1134187|NCT01431144|soft tissue recession
1134188|NCT01431144|implant exposure
1134189|NCT01431131|graft placement
1134190|NCT01431131|bone resorption
1134191|NCT01431118|iron metabolism
1134192|NCT01431118|hepcidin
1134193|NCT01431118|dragon boating
1134194|NCT01431118|sport-specific stress
1134195|NCT01431118|iron
1134196|NCT01431118|anaemia
1134197|NCT01431118|sport
1134198|NCT01431105|Kawasaki disease
1134199|NCT01431079|HPV
1134200|NCT01431079|College men
1134201|NCT01431079|HPV vaccine
1134202|NCT01431079|Health belief model
1134203|NCT01431079|HPV vaccine acceptance
1134204|NCT01431053|exemestane
1134205|NCT01431053|aspirin
1134206|NCT01431053|quality of life
1134207|NCT01431040|Bowel Prep
1134208|NCT01431040|No bowel prep
1134209|NCT01431040|Vaginal reconstructive or obliterative surgery
1134210|NCT01431027|Heart Failure
1134211|NCT01431027|Diastolic Heart Failure
1134212|NCT01431027|Heart Failure with Normal Ejection Fraction
1134213|NCT01431014|orthognathic surgery
1134214|NCT01431014|steroid
1134215|NCT01431014|swelling
1134216|NCT01431014|3-dimensional photogrammetry
1134217|NCT01431001|Depression
1134218|NCT01431001|MDD
1134219|NCT01431001|Transcranial Magnetic Stimulation
1134220|NCT01431001|Depressive Disorder
1134221|NCT01431001|TMS
1134222|NCT01430988|Head Injuries
1134223|NCT01430988|Head Trauma
1134224|NCT01430988|TBI (Traumatic Brain Injury)
1134225|NCT01430988|Emergency Department
1134226|NCT01430988|Accident & Emergency
1134227|NCT01430975|Radiation Exposure
1134228|NCT01430975|Rubidium 82
1134229|NCT01430975|Strontium 82
1134230|NCT01430975|Strontium 85
1134231|NCT01430962|EBUS
1134232|NCT01430962|mediastinal lymph nodes
1134233|NCT01430962|mediastinal masses
1134234|NCT01430962|anesthesia
1134235|NCT01430962|moderate sedation
1134236|NCT01430949|Paroxysmal Atrial Fibrillation
1134237|NCT01430949|Catheter Ablation
1134238|NCT01430949|Pulmonary Vein Isolation
1134239|NCT01430949|Radio Frequency Ablation
1134240|NCT01430936|Vascular Diseases
1134241|NCT01430936|Hypertension
1134242|NCT01430936|Chronic Kidney Disease
1134243|NCT01430936|COPD
1134244|NCT01430923|Refrigeration free latanoprost
1134245|NCT01430910|Phase 1
1134246|NCT01430910|open label
1134247|NCT01430910|ceftazidime
1134248|NCT01430910|pharmacokinetics
1134249|NCT01430910|urinary tract infection
1134250|NCT01430910|intra-abdominal infection
1134251|NCT01430897|d-TGA
1134252|NCT01430897|dextro Transposition of the great arteries
1134253|NCT01430897|systemic right ventricle
1134254|NCT01430897|right ventricular failure
1134255|NCT01430897|Atrial switch procedure
1134256|NCT01430884|coronary aspirate blood
1134257|NCT01430884|particular debris / microemboli
1134258|NCT01430884|distal occlusion device
1134259|NCT01430858|Fracture
1134260|NCT01430858|Anabolic
1134261|NCT01430858|Vibration
1134262|NCT01430858|Strain Gauge
1134263|NCT01430858|Focus - Osteoporosis
1134264|NCT01430845|GDD
1134265|NCT01430845|CP
1134266|NCT01430845|MR
1134267|NCT01430845|PDD
1134268|NCT01430845|ASD
1134269|NCT01430845|BSID
1134270|NCT01430832|PTSD
1134271|NCT01430832|Preterm
1134272|NCT01430832|Premature
1134273|NCT01430832|VLBW
1134274|NCT01430819|Influenza
1134275|NCT01430819|Influenza Virus Vaccine
1134276|NCT01430819|Fluzone® 2011-2012 Formulation
1134277|NCT01430819|Fluzone® High-Dose 2011-2012 Formulation
1134278|NCT01430819|Trivalent Inactivated Influenza Vaccine
1134279|NCT01430780|Coronary artery disease
1134280|NCT01430780|nitrate
1134281|NCT01430780|endothelium
1134282|NCT01430767|adherence
1134283|NCT01430754|Blindness
1134284|NCT01430754|Eye Diseases
1134285|NCT01430754|Nap Disorders
1134286|NCT01430754|Circadian Rhythm Disorders
1134287|NCT01430754|Sleep Disorders
1134288|NCT01430754|Circadian Rhythm Sleep Disorders
1134289|NCT01430754|Dyssomnias
1134290|NCT01430754|Nervous System Diseases
1134291|NCT01430741|Implementation Science
1134292|NCT01430741|Supportive Housing
1134293|NCT01430741|Co-occurring disorders
1134294|NCT01430741|Cluster randomized controlled trial
1134295|NCT01430741|Hybrid implementation-effectiveness trial
1134296|NCT01430715|active video game
1134297|NCT01430715|video gaming
1134298|NCT01430715|accelerometery
1134299|NCT01430715|MVPA
1134300|NCT01430715|outdoor play
1134301|NCT01430715|children
1134302|NCT01430715|unstructured
1134303|NCT01430715|energy expenditure
1134304|NCT01430689|Influenza
1134305|NCT01430689|Pregnancy
1134306|NCT01430689|Neonates
1134307|NCT01430676|Incisional hernia
1134308|NCT01430676|recurrence
1134309|NCT01430676|longterm
1134310|NCT01430663|aspergillosis
1134311|NCT01430663|bronchoalveolar lavage
1134312|NCT01430663|galactomannan
1134313|NCT01430663|pcr
1134314|NCT01430663|hematological patients
1134315|NCT01430650|Oral estrogens
1134316|NCT01430650|transdermal estrogens
1134317|NCT01430650|endometrial priming
1134318|NCT01430637|childhood desmoplastic small round cell tumor
1134319|NCT01430637|metastatic childhood soft tissue sarcoma
1134320|NCT01430637|nonmetastatic childhood soft tissue sarcoma
1134321|NCT01430637|recurrent childhood soft tissue sarcoma
1134322|NCT01430637|recurrent adult soft tissue sarcoma
1134323|NCT01430637|stage I adult soft tissue sarcoma
1134324|NCT01430637|stage II adult soft tissue sarcoma
1134325|NCT01430637|stage III adult soft tissue sarcoma
1134326|NCT01430637|stage IV adult soft tissue sarcoma
1134327|NCT01430637|adult desmoplastic small round cell tumor
1134328|NCT01430624|Rape
1134329|NCT01430624|Secondary prevention
1134330|NCT01430624|Intervention
1134331|NCT01430611|Meningitis
1134332|NCT01430611|Neisseria meningitidis
1134333|NCT01430611|Meningo A+C®
1134334|NCT01430611|Meng Ling Kang®
1134335|NCT01430598|Full Thickness Rotator Cuff Tear and Acromial Spur
1134336|NCT01430585|Ki-67
1134337|NCT01430585|postmenopausal early breast cancer
1134338|NCT01430585|ER positive/HER2 negative early breast cancer
1134339|NCT01430572|Advanced Cancers
1134340|NCT01430572|Solid Tumors
1134341|NCT01430572|PI3KCA Mutation Positive/PTEN
1134342|NCT01430572|Refractory to standard therapy
1134343|NCT01430572|Relapsed after standard therapy
1134344|NCT01430572|Pazopanib
1134345|NCT01430572|GW786034
1134346|NCT01430572|Everolimus
1134347|NCT01430572|Afinitor
1134348|NCT01430572|RAD001
1134349|NCT01430559|Validation of the WOMAC in Chinese subjects with osteoarthritis of the knee
1134350|NCT01430546|Relapsed and Refractory Multiple Myeloma
1134351|NCT01430533|dermal sensitization potential
1134352|NCT01430507|Anti-inflammatory drugs, DMARD
1134353|NCT01430481|rosehip
1134354|NCT01430481|osteoarthritis
1134355|NCT01430481|pain
1134356|NCT01430481|knee
1134357|NCT01430481|RCT
1134358|NCT01430468|Glenoid component position
1134359|NCT01430468|patient specific instruments
1134360|NCT01430455|Major Depressive Episode
1134361|NCT01430455|Depression NOS
1134362|NCT01430455|Bipolar Disorder
1134363|NCT01430455|Bipolar Disorder I
1134364|NCT01430455|Bipolar Disorder II
1134365|NCT01430455|Bipolar Depression
1134366|NCT01430455|Major Depression
1134367|NCT01430416|Uveal melanoma
1134368|NCT01430416|phase 1
1134369|NCT01430416|AEB071
1134370|NCT01430416|Metastatic
1134371|NCT01430403|persistent allergic asthma
1134372|NCT01430403|asthma exacerbations reduction
1134373|NCT01430403|Xolair® (omalizumab)
1134374|NCT01430403|Flovent® Diskus® (fluticasone)
1134375|NCT01430403|placebo
1134376|NCT01430403|inhaled corticosteroid therapy
1134377|NCT01430403|anti-immunoglobulin E therapy
1134378|NCT01430403|anti-IgE therapy
1134379|NCT01430390|In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic
1134380|NCT01430390|T-Lymphocytes (EBV-CTLs)
1134381|NCT01430390|CD19 specific T-cells
1134382|NCT01430390|11-038
1134383|NCT01430377|periprocedural myonecrosis
1134384|NCT01430377|procedure time
1134385|NCT01430377|fluoroscopy time
1134386|NCT01430364|coronary bifurcation stenosis
1134387|NCT01430364|dedicated bifurcation stent
1134388|NCT01430364|sirolymus
1134389|NCT01430364|PTS
1134390|NCT01430364|BiOSS Lym
1134391|NCT01430351|Brain cancer
1134392|NCT01430351|Central nervous system
1134393|NCT01430351|Glioblastoma Multiforme
1134394|NCT01430351|GBM
1134395|NCT01430351|Post Radiation Therapy
1134396|NCT01430351|Post-RT
1134397|NCT01430351|External beam radiotherapy
1134398|NCT01430351|XRT
1134399|NCT01430351|Supratentorial glioblastoma
1134400|NCT01430351|Gliosarcoma
1134401|NCT01430351|Grade IV astrocytoma
1134402|NCT01430351|Temozolomide
1134403|NCT01430351|Temodar
1134404|NCT01430351|Memantine
1134405|NCT01430351|Namenda
1134406|NCT01430351|Mefloquine
1134407|NCT01430351|Apo-Mefloquine
1134408|NCT01430351|Lariam
1134409|NCT01430351|Metformin
1134410|NCT01430325|Hyperbaric oxygen
1134411|NCT01430312|dermal irritative potential
1134412|NCT01430286|Caregivers
1134413|NCT01430286|Alzheimer Disease
1134414|NCT01430286|Psychological stress
1134415|NCT01430286|Psychological adaptation
1134416|NCT01430286|Self-efficacy
1134417|NCT01430286|Randomized controlled trial
1134418|NCT01430273|Antiplatelet therapy
1134419|NCT01430273|Surgery
1134420|NCT01430273|Bleeding
1134421|NCT01430273|Platelet aggregation
1134422|NCT01430260|efficacy
1134423|NCT01430260|ciclesonide
1134424|NCT01430260|levocetirizine
1134425|NCT01430260|allergic rhinitis
1134426|NCT01430247|amblyopia
1134427|NCT01430247|amblyogenic factors
1134428|NCT01430247|screening
1134429|NCT01430247|preschool children
1134430|NCT01430247|visual acuity
1134431|NCT01430247|prevalence
1134432|NCT01430234|Chronic pancreatitis
1134433|NCT01430234|Exocrine insufficiency
1134434|NCT01430234|Pancreatic enzyme replacement therapy
1134435|NCT01430234|Self-administration
1134436|NCT01430221|prediabetes
1134437|NCT01430221|severity of depressive symptoms
1134438|NCT01430221|mindfulness
1134439|NCT01430221|personalized health planning
1134440|NCT01430221|cardiometabolic diseases prevention
1134441|NCT01430208|endometrial pathology
1134442|NCT01430195|vitiligo
1134443|NCT01430195|depigmentation
1134444|NCT01430195|phototherapy
1134445|NCT01430195|non-segmental vitiligo
1134446|NCT01430182|Adult
1134447|NCT01430182|Female
1134448|NCT01430182|Humans
1134449|NCT01430182|Intraoperative Care/methods
1134450|NCT01430182|Male
1134451|NCT01430182|Methadone/administration & dosage
1134452|NCT01430182|Analgesics/therapeutic use
1134453|NCT01430182|Methadone/therapeutic use
1134454|NCT01430182|Morphine/therapeutic use
1134455|NCT01430182|Middle Aged
1134456|NCT01430182|Pain Measurement/drug effects
1134457|NCT01430182|Pain Measurement/methods
1134458|NCT01430182|Pain, Postoperative/prevention & control
1134459|NCT01430182|Prospective Studies
1134460|NCT01430182|Double-Blind Method
1134461|NCT01430182|Tibial Fractures/surgery
1134462|NCT01430182|Young Adult
1134463|NCT01430182|Orthopedics
1134464|NCT01430169|Xiaflex
1134465|NCT01430169|Xiapex
1134466|NCT01430169|Collagenase clostridium histolyticum
1134467|NCT01430156|Renal Transplantation
1134468|NCT01430156|Ischemia-reperfusion injury
1134469|NCT01430156|Heme-oxygenase 1
1134470|NCT01430156|Heme arginate
1134471|NCT01430143|Exercise
1134472|NCT01430130|scar
1134473|NCT01430130|incision
1134474|NCT01430130|wound healing
1134475|NCT01430130|scarring
1134476|NCT01430130|scar revision
1134477|NCT01430117|Immunotherapy
1134478|NCT01430117|Skin prick test
1134479|NCT01430117|Standardization
1134480|NCT01430117|Poa pratensis
1134481|NCT01430078|ASP015K
1134482|NCT01430078|Healthy subjects
1134483|NCT01430078|Pharmacokinetics of ASP015K
1134484|NCT01430065|transplant
1134485|NCT01430065|ASP015K
1134486|NCT01430065|tacrolimus
1134487|NCT01430065|Prograf
1134488|NCT01430065|healthy volunteers
1134489|NCT01430039|Crohn's disease
1134490|NCT01430039|ulcerative colitis
1134491|NCT01430039|Syndecan-1
1134492|NCT01430026|chronic sinusitis
1134493|NCT01430026|gentamicin nasal irrigation
1134494|NCT01429987|Chronic Idiopathic Constipation
1134495|NCT01429987|Constipation
1134496|NCT01429987|Sign and Symptoms: Digestive
1134497|NCT01429974|amniotic fluid
1134498|NCT01429974|post term pregnancies
1134499|NCT01429948|Stroke, Ischemic
1134500|NCT01429948|Patent foramen ovale
1134501|NCT01429948|Magnetic resonance imaging
1134502|NCT01429948|Paradoxical embolism
1134503|NCT01429948|Transcranial Doppler
1134504|NCT01429948|Silent cerebral infarct
1134505|NCT01429935|dental pain model
1134506|NCT01429935|Ginger powder
1134507|NCT01429935|CRP
1134508|NCT01429909|Functional magnetic resonance imaging
1134509|NCT01429909|T2*
1134510|NCT01429909|cortex and basal ganglia
1134511|NCT01429909|Parkinson's disease
1134512|NCT01429896|peanut allergy
1134513|NCT01429896|food allergy
1134514|NCT01429896|thresholds
1134515|NCT01429896|anaphylaxis
1134516|NCT01429896|food labelling
1134517|NCT01429896|food challenges
1134518|NCT01429896|peanut challenges
1134519|NCT01429857|Troponin concentration in heart failure
1134520|NCT01429844|Calcineurin inhibitors
1134521|NCT01429844|Bronchiolitis obliterans
1134522|NCT01429844|Lung transplantation
1134523|NCT01429844|Cyclosporine
1134524|NCT01429844|Tacrolimus
1134525|NCT01429844|Mycophenolate
1134526|NCT01429844|Steroids
1134527|NCT01429844|Chronic rejection
1134528|NCT01429844|Acute rejection
1134529|NCT01429844|Obliterative bronchiolitis
1134530|NCT01429818|Endothelial dysfunction
1134531|NCT01429818|Diabetes mellitus
1134532|NCT01429818|glimepiride
1134533|NCT01429818|metformin
1134534|NCT01429805|Hip arthroscopy
1134535|NCT01429779|General surgery
1134536|NCT01429766|Breath holding times
1134537|NCT01429766|Phases of respiration
1134538|NCT01429766|Radiotherapy
1134539|NCT01429753|Cardiac resychronisation therapy
1134540|NCT01429753|Heart failure
1134541|NCT01429753|Imaging guided LV lead placement
1134542|NCT01429740|PF 05180999
1134543|NCT01429740|safety
1134544|NCT01429740|pharmacokinetics
1134545|NCT01429727|Spontaneous coronary artery dissection
1134546|NCT01429727|SCAD
1134547|NCT01429727|coronary artery disease
1134548|NCT01429727|myocardial infarction
1134549|NCT01429727|coronary dissection
1134550|NCT01429714|Elastic Compression Stockings
1134551|NCT01429714|Deep Venous Thrombosis
1134552|NCT01429714|Post Thrombotic Syndrome
1134553|NCT01429701|Dermatitis
1134554|NCT01429701|Dermatitis, Atopic
1134555|NCT01429662|postmenopause
1134556|NCT01429662|hypertension
1134557|NCT01429662|relaxation
1134558|NCT01429662|SBP 140-159 mmHg
1134559|NCT01429662|DBP 90-99 mmHg
1134560|NCT01429662|stage 1 or mild hypertension
1134561|NCT01429649|pure pulmonary ground glass opacity
1134562|NCT01429636|perimenopause
1134563|NCT01429636|postmenopause
1134564|NCT01429636|vasomotor symptoms
1134565|NCT01429636|relaxation
1134566|NCT01429623|Mild Cognitive Impairment
1134567|NCT01429623|Early Stage Dementia
1134568|NCT01429623|Conversion to Alzheimer's disease
1134569|NCT01429623|Memory Impairment
1134570|NCT01429610|acute lymphoblastic leukemia
1134571|NCT01429610|rituximab
1134572|NCT01429610|VPDL
1134573|NCT01429610|CD20
1134574|NCT01429597|Cerebrovascular Accident
1134575|NCT01429597|Cerebrovascular Accident, Acute
1134576|NCT01429597|Fabry Disease
1134577|NCT01429597|Fabry´s Disease
1134578|NCT01429597|Anderson-Fabry Disease
1134579|NCT01429597|CVA (Cerebrovascular Accident)
1134580|NCT01429597|Stroke, Acute
1134581|NCT01429597|Cerebral Stroke
1134582|NCT01429584|bupivacaine concentration
1134583|NCT01429584|interscalene nerve block
1134584|NCT01429584|diaphragm function
1134585|NCT01429584|diaphragm weakness
1134586|NCT01429558|treatment resistant obsessive-compulsive disorder
1134587|NCT01429545|Tocolysis
1134588|NCT01429545|atosiban
1134589|NCT01429545|nifedipine
1134590|NCT01429545|combination
1134591|NCT01429532|Cataract
1134592|NCT01429519|chronic wound
1134593|NCT01429519|ulcerated wound
1134594|NCT01429519|venous insufficiency
1134595|NCT01429519|lymphatic insufficiency
1134596|NCT01429519|neuropathic wound
1134597|NCT01429519|diabetic ulcer
1134598|NCT01429519|post- operative
1134599|NCT01429519|post-traumatic chronic wound
1134600|NCT01429506|Sleeve gastrectomy
1134601|NCT01429506|Intensive medical management
1134602|NCT01429480|Analgesia, postoperative
1134603|NCT01429467|Glucose Variability
1134604|NCT01429467|Continuous Glucose Monitoring
1134605|NCT01429467|Hypoxia-inducible Factor (HIF)
1134606|NCT01429467|Vascular Endothelial Growth Factor (VEGF)
1134607|NCT01429467|Erythropoietin
1134608|NCT01429467|Cortisol
1134609|NCT01429454|Prodromal
1134610|NCT01429454|Schizophrenia
1134611|NCT01429454|Psychosis
1134612|NCT01429454|Omega
1134613|NCT01429428|Cellulitis
1134614|NCT01429428|Skin ultra-sound images
1134615|NCT01429428|Treatment
1134616|NCT01429428|Infra-red light
1134617|NCT01429415|pediatric
1134618|NCT01429415|Acute Asthma
1134619|NCT01429415|Inhaled Magnesium
1134620|NCT01429402|Botulinum toxin A.
1134621|NCT01429402|Cleft lip scar
1134622|NCT01429389|Down syndrome
1134623|NCT01429389|fetal aneuploidy
1134624|NCT01429389|trisomy
1134625|NCT01429389|noninvasive screening test
1134626|NCT01429376|Chronic heart failure
1134627|NCT01429376|Pulmonary function abnormalities/impairment
1134628|NCT01429376|Restriction
1134629|NCT01429376|Airway obstruction
1134630|NCT01429376|Diffusion impairment
1134631|NCT01429376|Pulmonary function tests
1134632|NCT01429376|Chronic obstructive pulmonary disease (COPD)
1134633|NCT01429376|Prevalence
1134634|NCT01429376|Overdiagnosis
1134635|NCT01429376|Underdiagnosis
1134636|NCT01429376|Systemic inflammation
1134637|NCT01429376|Diagnostic Errors
1134638|NCT01429363|contained herniated lumbar discs
1134639|NCT01429363|TDD
1134640|NCT01429363|Case series
1134641|NCT01429363|RCT
1134642|NCT01429350|ischemic stroke
1134643|NCT01429350|acute intervention
1134644|NCT01429350|thrombolysis
1134645|NCT01429350|rtPA
1134646|NCT01429350|internal carotid artery
1134647|NCT01429350|middle cerebral artery
1134648|NCT01429350|mechanical thrombectomy
1134649|NCT01429350|Penumbra System
1134650|NCT01429350|clot length
1134651|NCT01429350|mRS
1134652|NCT01429350|NIHSS
1134653|NCT01429337|Pharmacokinetics
1134654|NCT01429337|Hepatic impaired patients
1134655|NCT01429337|Healthy volunteers
1134656|NCT01429337|Varying degrees of hepatic impairment
1134657|NCT01429324|Near infrared spectroscopy
1134658|NCT01429324|neuromonitoring
1134659|NCT01429324|aortic arch surgery
1134660|NCT01429311|Atopic Dermatitis
1134661|NCT01429311|Eczema herpeticum
1134662|NCT01429311|Interferon gamma
1134663|NCT01429311|IFNγ
1134664|NCT01429298|Acute
1134665|NCT01429298|Pain
1134666|NCT01429298|Emergency Department
1134667|NCT01429298|Hydromorphone
1134668|NCT01429298|Protocol
1134669|NCT01429285|Pain
1134670|NCT01429285|Hydromorphone
1134671|NCT01429285|Acute
1134672|NCT01429285|Emergency Department
1134673|NCT01429272|Bipolar Disorder
1134674|NCT01429272|Minocycline
1134675|NCT01429259|Cystic Fibrosis
1134676|NCT01429259|Acute Pulmonary Exacerbations
1134677|NCT01429259|Pseudomonas aeruginosa
1134678|NCT01429246|Hypertension
1134679|NCT01429246|Diet Therapy
1134680|NCT01429246|Sodium Chloride, Dietary
1134681|NCT01429246|Tibet
1134682|NCT01429246|Aged
1134683|NCT01429233|Observational
1134684|NCT01429233|Colombia
1134685|NCT01429220|deep brain stimulation
1134686|NCT01429220|monopolar review
1134687|NCT01429220|motion sensors
1134688|NCT01429220|tremor
1134689|NCT01429220|bradykinesia
1134690|NCT01429207|levodopa
1134691|NCT01429207|tremor
1134692|NCT01429207|bradykinesia
1134693|NCT01429207|motion sensors
1134694|NCT01429194|Weight Loss
1134695|NCT01429194|Trans-oral Endoscopic Procedure
1134696|NCT01429194|Gastric Plication
1134697|NCT01429181|Peripheral Neuropathic Pain
1134698|NCT01429155|End stage liver disease
1134699|NCT01429155|Living donor liver transplantation
1134700|NCT01429155|Hepatitis C
1134701|NCT01429155|Interleukin 28B
1134702|NCT01429129|Smoking
1134703|NCT01429129|Nicotine
1134704|NCT01429129|Nicotine Replacement Therapy
1134705|NCT01429129|Nicotine Patch
1134706|NCT01429129|Nicoderm
1134707|NCT01429129|Mass Distribution
1134708|NCT01429129|Tobacco Control
1134709|NCT01429129|Randomized Controlled Trial
1134710|NCT01429116|Blindness
1134711|NCT01429116|Eye Diseases
1134712|NCT01429116|Nap Disorders
1134713|NCT01429116|Circadian Rhythm Disorders
1134714|NCT01429116|Sleep Disorders
1134715|NCT01429116|Circadian Rhythm Sleep Disorders
1134716|NCT01429116|Dyssomnias
1134717|NCT01429116|Nervous System Diseases
1134718|NCT01429090|Pharmacokinetics
1134719|NCT01429090|Accommodation, Ocular
1134720|NCT01429090|Reflex, Pupillary
1134721|NCT01429090|Salivation
1134722|NCT01429077|Levodopa
1134723|NCT01429077|Ischemic Stroke
1134724|NCT01429077|Aphasia
1134725|NCT01429077|Speech Rehabilitation
1134726|NCT01429051|Break through pain
1134727|NCT01429051|BTP
1134728|NCT01429051|Cancer
1134729|NCT01429051|Intranasal Fentanyl Spray
1134730|NCT01429051|INFS
1134731|NCT01429051|cancer patients
1134732|NCT01429038|end-stage
1134733|NCT01429038|liver diseases
1134734|NCT01429038|cirrhosis
1134735|NCT01429038|cancer
1134736|NCT01429038|fulminant hepatic failure
1134737|NCT01429038|metabolic hepatic diseases
1134738|NCT01429038|congenital hepatic diseases
1134739|NCT01429038|renal diseases
1134740|NCT01429025|recurrent grade 1 follicular lymphoma
1134741|NCT01429025|recurrent grade 2 follicular lymphoma
1134742|NCT01429025|recurrent marginal zone lymphoma
1134743|NCT01429025|recurrent small lymphocytic lymphoma
1134744|NCT01429025|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1134745|NCT01429025|Waldenström macroglobulinemia
1134746|NCT01429025|nodal marginal zone B-cell lymphoma
1134747|NCT01429025|splenic marginal zone lymphoma
1134748|NCT01429012|bone
1134749|NCT01429012|nonunion fracture
1134750|NCT01429012|atrophic nonunion fracture
1134751|NCT01429012|callus
1134752|NCT01429012|mesenchymal stem cells
1134753|NCT01429012|cell therapy
1134754|NCT01429012|autologous
1134755|NCT01429012|indium
1134756|NCT01429012|Pet-scan
1134757|NCT01428999|probiotics
1134758|NCT01428999|gastrointestinal function
1134759|NCT01428999|intestinal bacteria flora
1134760|NCT01428986|maraviroc
1134761|NCT01428986|osteoclasts
1134762|NCT01428986|Receptors, CCR5
1134763|NCT01428986|Chemokine CCL5
1134764|NCT01428973|Allogeneic hematopoeitic cell transplantation
1134765|NCT01428973|Graft-Versus-Host Disease
1134766|NCT01428973|Prophylaxis
1134767|NCT01428973|Reduced-intensity conditioning
1134768|NCT01428973|Immunosuppressive regimen
1134769|NCT01428973|HLA-matched donor
1134770|NCT01428973|Progression free survival
1134771|NCT01428973|Overall survival
1134772|NCT01428960|Palm mid fraction
1134773|NCT01428960|Shea butter
1134774|NCT01428960|sn-1, sn-3 fatty acids
1134775|NCT01428960|Cholesterol
1134776|NCT01428960|Postprandial lipemia,
1134777|NCT01428960|Inflammatory markers
1134778|NCT01428960|Satiety
1134779|NCT01428960|Gut hormone
1134780|NCT01428960|Insulin
1134781|NCT01428921|Long-term efficacy
1134782|NCT01428921|Education programme
1134783|NCT01428921|Adherence
1134784|NCT01428921|OSA
1134785|NCT01428921|CPAP
1134786|NCT01428908|immunogenicity
1134787|NCT01428908|safety
1134788|NCT01428908|group A, C polysaccharide meningitis
1134789|NCT01428908|type b haemophilus Influenza
1134790|NCT01428908|conjugate vaccine
1134791|NCT01428895|Bone Metastases
1134792|NCT01428895|Femoral Metastases
1134793|NCT01428882|Propofol
1134794|NCT01428882|Midazolam
1134795|NCT01428882|Moderate sedation
1134796|NCT01428882|Deep sedation
1134797|NCT01428882|Colonoscopy
1134798|NCT01428869|Statins
1134799|NCT01428869|acetylsalicylic acid
1134800|NCT01428869|dutasteride
1134801|NCT01428869|Prostate Cancer
1134802|NCT01428869|Lower urinary tract symptoms
1134803|NCT01428869|prevention
1134804|NCT01428869|drug interactions
1134805|NCT01428843|Inflammatory Bowel Disease
1134806|NCT01428843|Anemia
1134807|NCT01428843|Anti-TNF alpha theray
1134808|NCT01428843|Ferrisat perfusion
1134809|NCT01428830|fistula
1134810|NCT01428830|catheter
1134811|NCT01428830|surgery
1134812|NCT01428830|obstetrics
1134813|NCT01428830|gynecology
1134814|NCT01428830|urology
1134815|NCT01428817|pregnancy
1134816|NCT01428817|postpartum hemorrhage
1134817|NCT01428817|Cesarean delivery
1134818|NCT01428817|carbetocin
1134819|NCT01428804|Resistant Major Depression
1134820|NCT01428804|Mood disorders
1134821|NCT01428804|tDCS
1134822|NCT01428791|Geriatrics
1134823|NCT01428791|Older adults
1134824|NCT01428791|Health Disparities
1134825|NCT01428791|Health Services for the Aged
1134826|NCT01428791|Interdisciplinary Health Team
1134827|NCT01428791|Depressive symptoms
1134828|NCT01428791|Metabolic Syndrome X
1134829|NCT01428791|Overweight
1134830|NCT01428791|Obesity
1134831|NCT01428791|Hypertension
1134832|NCT01428791|Hyperglycemia
1134833|NCT01428791|Dyslipidemias
1134834|NCT01428778|Marathon running
1134835|NCT01428778|Brain MRI
1134836|NCT01428778|ECG recording
1134837|NCT01428778|Blood tests
1134838|NCT01428752|colonoscopy
1134839|NCT01428752|colorectal neoplasms
1134840|NCT01428752|screening
1134841|NCT01428752|family history
1134842|NCT01428739|cancer
1134843|NCT01428739|MRS
1134844|NCT01428739|Treatment response
1134845|NCT01428726|NT-KO-003
1134846|NCT01428726|RRMS
1134847|NCT01428726|efficacy
1134848|NCT01428726|safety
1134849|NCT01428726|Phase IIa
1134850|NCT01428713|menorrhagia
1134851|NCT01428713|oral contraceptives
1134852|NCT01428713|oral tranexamic acid
1134853|NCT01428687|Weight loss
1134854|NCT01428687|Sleep duration
1134855|NCT01428674|Interpersonal mindful compassion
1134856|NCT01428674|Loving kindness meditation
1134857|NCT01428674|Autonomic Nervous System
1134858|NCT01428674|Heart rate variability
1134859|NCT01428674|Respiratory rate
1134860|NCT01428674|Relaxation
1134861|NCT01428661|tasimelteon
1134862|NCT01428661|Major Depressive Disorder
1134863|NCT01428661|MDD
1134864|NCT01428661|depression
1134865|NCT01428648|Parkinson
1134866|NCT01428648|ballroom dancing
1134867|NCT01428635|Leukemia
1134868|NCT01428635|Thrombocytopenia
1134869|NCT01428635|Tyrosine kinase therapy
1134870|NCT01428635|TKI
1134871|NCT01428635|Chronic myeloid leukemia
1134872|NCT01428635|CML
1134873|NCT01428635|Platelet count
1134874|NCT01428635|Clonal evolution
1134875|NCT01428635|Eltrombopag
1134876|NCT01428635|Promacta
1134877|NCT01428635|Myelofibrosis
1134878|NCT01428635|MF
1134879|NCT01428609|Amalgam
1134880|NCT01428609|Mercury
1134881|NCT01428609|Endodontics
1134882|NCT01428609|Apicoectomy
1134883|NCT01428596|HIV-1
1134884|NCT01428596|therapeutic vaccine
1134885|NCT01428596|immunotherapy
1134886|NCT01428596|AIDS
1134887|NCT01428583|Chronic noncancer pain
1134888|NCT01428583|oxycodone
1134889|NCT01428583|naltrexone
1134890|NCT01428570|sleep apnea, obstructive
1134891|NCT01428570|intubation
1134892|NCT01428557|Heart Failure
1134893|NCT01428557|Epidemiology
1134894|NCT01428557|Evidence-Based Practice
1134895|NCT01428492|AKT Inhibitor
1134896|NCT01428492|hematologic malignancies
1134897|NCT01428492|GSK2110183
1134898|NCT01428492|bortezomib
1134899|NCT01428492|multiple myeloma
1134900|NCT01428492|dexamethasone
1134901|NCT01428453|Alzheimer's disease
1134902|NCT01428427|Gemcitabine
1134903|NCT01428427|MEK inhibitor
1134904|NCT01428427|GSK1120212
1134905|NCT01428414|HER2
1134906|NCT01428414|Breast cancer
1134907|NCT01428414|neoadjuvant chemotherapy
1134908|NCT01428414|efficacy
1134909|NCT01428414|safety
1134910|NCT01428401|Complementary therapies
1134911|NCT01428401|Acute hemorrhagic stroke
1134912|NCT01428388|macular edema
1134913|NCT01428388|vein occlusion
1134914|NCT01428388|bevacizumab
1134915|NCT01428388|ranibizumab
1134916|NCT01428388|vascular endothelial growth factor
1134917|NCT01428375|intravenous paracetamol
1134918|NCT01428375|intrapartum analgesia
1134919|NCT01428375|labor pain
1134920|NCT01428375|intrapartum pains
1134921|NCT01428362|donepezil
1134922|NCT01428362|VI-1121
1134923|NCT01428349|Incarcerated offenders
1134924|NCT01428349|emotionally reactive
1134925|NCT01428349|emotionally stable
1134926|NCT01428349|psychopathy
1134927|NCT01428310|dietary supplement
1134928|NCT01428310|nutraceutical
1134929|NCT01428297|Atopic dermatitis
1134930|NCT01428297|Eczema
1134931|NCT01428297|Skin Diseases, Eczematous
1134932|NCT01428297|Netherton syndrome
1134933|NCT01428297|Skin Diseases, Genetic
1134934|NCT01428297|BPR277
1134935|NCT01428284|Healthy Volunteers
1134936|NCT01428284|Canagliflozin (JNJ-28431754)
1134937|NCT01428284|Pharmacokinetic
1134938|NCT01428284|Probenecid
1134939|NCT01428258|Diet therapy
1134940|NCT01428258|Low phenylalanine diet
1134941|NCT01428258|Attention
1134942|NCT01428258|Executive function
1134943|NCT01428232|Breastfeeding
1134944|NCT01428232|Baby Friendly Hospital Initiative
1134945|NCT01428232|Well-child clinics
1134946|NCT01428219|Prostate
1134947|NCT01428219|Cancer
1134948|NCT01428219|Metastatic
1134949|NCT01428206|palliative care
1134950|NCT01428206|nursing homes
1134951|NCT01428206|Liverpool care pathway
1134952|NCT01428193|PCOS
1134953|NCT01428193|hyperandrogenemia
1134954|NCT01428180|preterm neonates
1134955|NCT01428180|hemodynamically relevant patent ductus arteriosus
1134956|NCT01428167|Thyroid cancer
1134957|NCT01428167|Hashimotos thyroiditis
1134958|NCT01428167|Thyroidectomy
1134959|NCT01428167|Anti-inflammatory factors
1134960|NCT01428154|paediatric
1134961|NCT01428154|dialysis
1134962|NCT01428154|CKD
1134963|NCT01428154|pediatric
1134964|NCT01428141|Cancer
1134965|NCT01428141|Gastrointestinal Cancer
1134966|NCT01428115|monoclonal
1134967|NCT01428115|anxiety
1134968|NCT01428115|antibodies
1134969|NCT01428115|adalimumab
1134970|NCT01428115|severe crohn's disease
1134971|NCT01428115|quality of life
1134972|NCT01428115|biological products
1134973|NCT01428102|Thromboelastography
1134974|NCT01428102|TEG
1134975|NCT01428102|Coagulation
1134976|NCT01428102|RapidTEG
1134977|NCT01428102|Kaolin
1134978|NCT01428089|hyperandrogenemia
1134979|NCT01428076|Varicose Veins
1134980|NCT01428076|SFJ Reflux
1134981|NCT01428050|whipple
1134982|NCT01428050|hypertonic saline
1134983|NCT01428050|pancreaticoduodenectomy
1134984|NCT01428050|fluid restriction
1134985|NCT01428050|resuscitation strategy
1134986|NCT01428037|Vaginal Misoprostol
1134987|NCT01428037|Cervical Ripening
1134988|NCT01428037|Labor Induced
1134989|NCT01428024|efficacy
1134990|NCT01428024|safety
1134991|NCT01428024|Restylane
1134992|NCT01428024|Lip products
1134993|NCT01428024|injection techniques
1134994|NCT01428011|Hypertension
1134995|NCT01428011|Patient-Provider Communication
1134996|NCT01428011|Medication Adherence
1134997|NCT01428011|Race Concordance
1134998|NCT01427998|diabetes
1134999|NCT01427998|blood glucose
1135000|NCT01427998|olive leaf extract
1135001|NCT01427946|KRAS mutant
1135002|NCT01427946|Non-Small Cell Lung Cancer
1135003|NCT01427946|NSCLC
1135004|NCT01427933|Breast Cancer
1135005|NCT01427907|Serum phosphorus levels
1135006|NCT01427894|Prematurity
1135007|NCT01427894|Music
1135008|NCT01427894|Kangaroo Care
1135009|NCT01427894|Bonding Mother infant
1135010|NCT01427868|LB80380
1135011|NCT01427868|bioequivalence
1135012|NCT01427855|Dietary Protein
1135013|NCT01427855|Red Meat
1135014|NCT01427855|White Meat
1135015|NCT01427855|Vegetable Protein
1135016|NCT01427855|Saturated Fat
1135017|NCT01427855|LDL Subclasses
1135018|NCT01427855|Cholesterol
1135019|NCT01427855|Atherogenic Dyslipidemia
1135020|NCT01427842|Trough concentration
1135021|NCT01427842|Vancomycin
1135022|NCT01427842|Pharmacokinetics
1135023|NCT01427829|pilot
1135024|NCT01427829|randomized controlled trial
1135025|NCT01427829|RCT
1135026|NCT01427829|computer
1135027|NCT01427829|screening
1135028|NCT01427829|community heath center
1135029|NCT01427829|psychosocial
1135030|NCT01427829|immigrant
1135031|NCT01427816|Dry eye syndromes
1135032|NCT01427816|Corneal diseases
1135033|NCT01427816|Conjunctival diseases
1135034|NCT01427803|Actual Use Trial
1135035|NCT01427764|Dentin sensitivity
1135036|NCT01427764|Dental scaling
1135037|NCT01427764|Ultrasonic
1135038|NCT01427764|manual and ultrasonic instrumentation
1135039|NCT01427725|Digestive System Diseases
1135040|NCT01427725|Therapeutic Uses
1135041|NCT01427725|Pancreatectomy
1135042|NCT01427725|Gastrointestinal Agents
1135043|NCT01427725|Pancreatic Diseases
1135044|NCT01427725|Pancrelipase
1135045|NCT01427725|Exocrine Pancreatic Insufficiency
1135046|NCT01427712|Digestive System Diseases
1135047|NCT01427712|Cystic Fibrosis
1135048|NCT01427712|Therapeutic Uses
1135049|NCT01427712|Gastrointestinal Agents
1135050|NCT01427712|Pancreatic Diseases
1135051|NCT01427712|Pancrelipase
1135052|NCT01427712|Exocrine Pancreatic Insufficiency
1135053|NCT01427673|Chronic Obstructive Pulmonary Disease
1135054|NCT01427673|Obstructive Sleep Apnea
1135055|NCT01427673|Overlap Syndrome
1135056|NCT01427673|COPD
1135057|NCT01427673|OSA
1135058|NCT01427660|Diabetes
1135059|NCT01427660|Decision Aid
1135060|NCT01427660|AntiHyperglycemic Medication
1135061|NCT01427660|Tailored health information
1135062|NCT01427660|Medication information
1135063|NCT01427647|Laparoscopy
1135064|NCT01427647|Anesthesia, Epidural
1135065|NCT01427634|Heart Failure
1135066|NCT01427634|Ventricular Assist Device
1135067|NCT01427634|Palliative Care
1135068|NCT01427595|hyperandrogenemia
1135069|NCT01427569|Diabetes
1135070|NCT01427569|Chronic wound
1135071|NCT01427556|Food intake
1135072|NCT01427556|Breakfast eating
1135073|NCT01427543|behavioral intervention
1135074|NCT01427543|HIV risk reduction
1135075|NCT01427543|African Americans
1135076|NCT01427543|incarceration
1135077|NCT01427543|bisexual
1135078|NCT01427543|reduce risk behaviors
1135079|NCT01427530|brain activity
1135080|NCT01427530|implanted with DBS electrodes
1135081|NCT01427517|Parkinson's disease
1135082|NCT01427517|Gaucher's disease
1135083|NCT01427517|Control
1135084|NCT01427504|HCV
1135085|NCT01427504|HIV
1135086|NCT01427478|Head and neck squamous cell carcinoma
1135087|NCT01427478|Post operative radio-chemotherapy
1135088|NCT01427478|Randomisation
1135089|NCT01427478|Maintenance treatment
1135090|NCT01427478|Afatinib
1135091|NCT01427465|Brief
1135092|NCT01427465|Image
1135093|NCT01427465|Intervention
1135094|NCT01427465|Adolescents
1135095|NCT01427465|School
1135096|NCT01427452|Live Donor
1135097|NCT01427452|Kidney Donation
1135098|NCT01427452|Living Donation
1135099|NCT01427452|Live Donor Kidney Transplantation
1135100|NCT01427452|Donor Nephrectomy
1135101|NCT01427439|MDD
1135102|NCT01427439|Non-interventional study
1135103|NCT01427439|Observational study
1135104|NCT01427426|Health
1135105|NCT01427426|Vitality
1135106|NCT01427426|Well-being
1135107|NCT01427426|Nutritional Supplement
1135108|NCT01427426|Phytonutrient
1135109|NCT01427426|Greens
1135110|NCT01427413|blastocoele fluid
1135111|NCT01427413|mass spectrometry
1135112|NCT01427413|metabolomics
1135113|NCT01427400|Breast expander
1135114|NCT01427400|Breast reconstruction
1135115|NCT01427400|Implants
1135116|NCT01427400|Botox
1135117|NCT01427387|ASP0456
1135118|NCT01427387|Pharmacokinetics
1135119|NCT01427387|safety
1135120|NCT01427387|tolerability
1135121|NCT01427387|food effect
1135122|NCT01427374|hemodialysis
1135123|NCT01427374|peritoneal dialysis
1135124|NCT01427374|chronic kidney disease
1135125|NCT01427374|cardiovascular risk factors
1135126|NCT01427374|cardiac imaging
1135127|NCT01427374|dialysis
1135128|NCT01427374|parathyroid hormone
1135129|NCT01427374|vitamin D
1135130|NCT01427374|coronary artery calcification
1135131|NCT01427374|left ventricular hypertrophy
1135132|NCT01427374|genetic predisposition
1135133|NCT01427374|biochemical markers
1135134|NCT01427374|infection
1135135|NCT01427374|pharmacogenomics
1135136|NCT01427335|OHSS
1135137|NCT01427335|ICSI
1135138|NCT01427335|calcium injection
1135139|NCT01427322|lapatinib
1135140|NCT01427322|radiation therapy
1135141|NCT01427322|metastases
1135142|NCT01427309|Influenza
1135143|NCT01427309|Trivalent Inactivated Influenza Vaccine
1135392|NCT01426282|Nurse, Heath Education
1135144|NCT01427309|High-Dose Trivalent Inactivated Influenza Vaccine
1135145|NCT01427309|Fluzone® High-Dose
1135146|NCT01427309|Influenza vaccines
1135147|NCT01427296|Colon Cleansing
1135148|NCT01427296|Bowel Prep
1135149|NCT01427296|Colonoscopy
1135150|NCT01427283|Low back pain
1135151|NCT01427283|Chronic pain
1135152|NCT01427283|Opioid
1135153|NCT01427283|Constipation
1135154|NCT01427283|Moderate to severe
1135155|NCT01427270|Low back pain
1135156|NCT01427270|Chronic pain
1135157|NCT01427270|Opioid
1135158|NCT01427270|Constipation
1135159|NCT01427270|Moderate to severe chronic low back pain
1135160|NCT01427244|HER2+
1135161|NCT01427244|Histologic confirmation
1135162|NCT01427244|measurable disease
1135163|NCT01427244|HER2 positive
1135164|NCT01427244|HER2 overexpression
1135165|NCT01427244|persistent vulvar Paget's disease
1135166|NCT01427244|recurrent vulvar Paget's disease
1135167|NCT01427231|Cognitive performance
1135168|NCT01427231|Attention
1135169|NCT01427231|Memory
1135170|NCT01427231|Glucose
1135171|NCT01427231|Sacharose
1135172|NCT01427231|Elderly
1135173|NCT01427231|Memory complaints
1135174|NCT01427218|pharmacist
1135175|NCT01427218|medication therapy management
1135176|NCT01427218|evidence based medicine
1135177|NCT01427205|Head and Neck Squamous Cell Carcinoma
1135178|NCT01427205|HNSCC
1135179|NCT01427205|recurrent
1135180|NCT01427205|metastatic
1135181|NCT01427205|oral cavity
1135182|NCT01427205|Cetuximab
1135183|NCT01427205|C225
1135184|NCT01427205|Erbitux
1135185|NCT01427205|IMC-C225
1135186|NCT01427205|OSI-906
1135187|NCT01427205|Placebo
1135188|NCT01427205|sugar pill
1135189|NCT01427205|oropharynx
1135190|NCT01427205|larynx
1135191|NCT01427205|hypopharynx
1135192|NCT01427192|Breathing-Related Sleep Disorder
1135193|NCT01427192|Pulmonary Hypertension
1135194|NCT01427179|Spontaneous coronary artery dissection
1135195|NCT01427179|SCAD
1135196|NCT01427166|Breast Cancer
1135197|NCT01427166|Cording
1135198|NCT01427166|Lymphedema
1135199|NCT01427166|upper extremity cording
1135200|NCT01427166|following treatment
1135201|NCT01427153|knee osteoarthritis
1135202|NCT01427153|physical therapy
1135203|NCT01427153|corticosteroid
1135204|NCT01427153|treatment
1135205|NCT01427140|Liver fat
1135206|NCT01427140|Polyunsaturated fatty acids (PUFA)
1135207|NCT01427140|Saturated fatty acids (SFA)
1135208|NCT01427140|Weight gain
1135209|NCT01427140|Overfeed
1135210|NCT01427140|Dietary fatty acids
1135211|NCT01427140|Palm oil
1135212|NCT01427140|Sunflower oil
1135213|NCT01427114|extranodal marginal zone lymphoma
1135214|NCT01427114|ocular adnexal lymphoma
1135215|NCT01427114|mucosa associated lymphoid tissue
1135216|NCT01427114|cyclophosphamide
1135217|NCT01427114|vincristine
1135218|NCT01427114|prednisolone
1135219|NCT01427101|Pseudomyxoma Peritonei
1135220|NCT01427101|Cytoreductive surgery
1135221|NCT01427101|Debulking surgery
1135222|NCT01427101|Intraperitoneal chemotherapy
1135223|NCT01427088|rTMS-induced cumulative pattern of sBDNF
1135224|NCT01427075|Magnetic Resonance Imaging
1135225|NCT01427075|Sleep Apnea, Obstructive
1135226|NCT01427075|Pharyngeal Muscles
1135227|NCT01427062|parkinson's disease
1135228|NCT01427062|balance
1135229|NCT01427062|anticipatory postural adjustment
1135230|NCT01427062|componsatory postural adjustment
1135231|NCT01427062|falls
1135232|NCT01427049|renal denervation
1135233|NCT01427049|renal sympathetic denervation
1135234|NCT01427049|renal ablation
1135235|NCT01427049|resistant hypertension
1135236|NCT01427049|hypertension
1135237|NCT01427049|renal oxygenation
1135238|NCT01427049|renal perfusion
1135239|NCT01427023|APTIMA Trichomonas vaginalis Assay
1135240|NCT01427023|APTIMA
1135241|NCT01427023|trichomonas
1135242|NCT01427023|trichomonas vaginalis
1135243|NCT01426997|Major Depressive Disorder
1135244|NCT01426997|Depression
1135245|NCT01426971|Migraine
1135246|NCT01426945|alveolar childhood rhabdomyosarcoma
1135247|NCT01426945|previously treated childhood rhabdomyosarcoma
1135248|NCT01426945|previously untreated childhood rhabdomyosarcoma
1135249|NCT01426945|recurrent childhood rhabdomyosarcoma
1135250|NCT01426945|embryonal childhood rhabdomyosarcoma
1135251|NCT01426932|Vestibular Function Tests
1135252|NCT01426932|Caloric Test
1135253|NCT01426932|Electronystagmography
1135254|NCT01426932|Prediction
1135255|NCT01426919|Traumatic Brain Injury
1135256|NCT01426919|Head Injury
1135257|NCT01426893|Respiratory disease
1135258|NCT01426893|COPD
1135259|NCT01426880|GBG
1135260|NCT01426880|German Breast Group
1135261|NCT01426880|neo-adjuvant
1135262|NCT01426880|GBG Forschungs GmbH
1135263|NCT01426880|Tubular breast cancer stage II
1135264|NCT01426880|Mucinous breast cancer stage II
1135265|NCT01426880|Invasive ductal breast cancer
1135393|NCT01426282|Cardiovascular Diseases
1135266|NCT01426880|Tubular breast cancer stage III
1135267|NCT01426880|HER-2 positive breast cancer
1135268|NCT01426880|Inflammatory breast cancer stage IV
1135269|NCT01426880|Inflammatory breast cancer
1135270|NCT01426867|Open-Angle Glaucoma
1135271|NCT01426867|Ocular Hypertension
1135272|NCT01426867|Intraocular Pressure
1135273|NCT01426867|Brinzolamide
1135274|NCT01426867|Brimonidine
1135275|NCT01426854|Cataract Surgery
1135276|NCT01426854|Anti-ocular Inflammation
1135277|NCT01426854|Anti-ocular Pain
1135278|NCT01426841|Small cell lung cancer
1135279|NCT01426841|Adaptive radiotherapy
1135280|NCT01426841|Thoracic radiotherapy
1135281|NCT01426828|adult
1135282|NCT01426828|symptomatic multiple myeloma
1135283|NCT01426828|myeloma
1135284|NCT01426828|diagnosis within 12 months of initiation of systemic therapy
1135285|NCT01426815|Peripheral spondylarthritis according to ASAS- criteria
1135286|NCT01426802|metformin
1135287|NCT01426802|vildagliptin
1135288|NCT01426802|T2DM
1135289|NCT01426789|Rheumatoid Arthritis
1135290|NCT01426789|IgG1K monoclonal antibody
1135291|NCT01426789|Interleukin-17A neutralizing
1135292|NCT01426776|Cheyne-Stokes respiration
1135293|NCT01426776|Heart valve disease
1135294|NCT01426776|Central Sleep Apnea
1135295|NCT01426763|HAE
1135296|NCT01426763|C1 esterase inhibitor
1135297|NCT01426763|C1 INH
1135298|NCT01426763|Subcutaneous
1135299|NCT01426763|hyaluronidase
1135300|NCT01426763|rHuPH20
1135301|NCT01426750|Nutritional support.
1135302|NCT01426750|Cancer.
1135303|NCT01426750|Malnutrition.
1135304|NCT01426750|Child.
1135305|NCT01426750|Adolescent
1135306|NCT01426724|Vitamin D
1135307|NCT01426724|Chronic Kidney Disease
1135308|NCT01426724|Hyperparathyroidism
1135309|NCT01426724|Renal Blood Flow
1135310|NCT01426724|Proteinuria
1135311|NCT01426724|Inflammation
1135312|NCT01426724|Renin Angiotensin System
1135313|NCT01426698|delayed cord clamping
1135314|NCT01426698|developmental delay
1135315|NCT01426685|sudden death
1135316|NCT01426685|coronary artery disease
1135317|NCT01426685|diabetes
1135318|NCT01426672|Strabismic deviation less than 12 prism diopeters
1135319|NCT01426659|language
1135320|NCT01426659|constraints
1135321|NCT01426659|premature
1135322|NCT01426659|phonology
1135323|NCT01426659|implied
1135324|NCT01426659|early development (< 5 years)
1135325|NCT01426646|gastric cancer
1135326|NCT01426646|S-1
1135327|NCT01426646|cisplatin
1135328|NCT01426646|adjuvant chemotherapy
1135329|NCT01426633|L-sarcomas
1135330|NCT01426620|NSCLC
1135331|NCT01426620|blueberry
1135332|NCT01426620|salvage therapy
1135333|NCT01426620|docetaxel
1135334|NCT01426620|non-small cell lung cancer
1135335|NCT01426620|second-line
1135336|NCT01426620|polyphenol
1135337|NCT01426594|Observational
1135338|NCT01426594|Colombia
1135339|NCT01426594|Metpure XL
1135340|NCT01426581|Asthma
1135341|NCT01426581|Chronic Obstructive Pulmonary Disease (COPD)
1135342|NCT01426581|Pulmonary Disease, Chronic Obstructive
1135343|NCT01426581|Lung Disease, Obstructive
1135344|NCT01426581|Self-management
1135345|NCT01426581|Health Literacy
1135346|NCT01426568|Multi-Convergent Therapy
1135347|NCT01426568|Mindfulness Meditation
1135348|NCT01426568|Functional Abdominal Symptoms
1135349|NCT01426568|Irritable Bowel Syndrome
1135350|NCT01426568|Inflammatory Bowel Disease
1135351|NCT01426568|Psychological Stress
1135352|NCT01426555|Disorder of Bone Density and Structure, Unspecified
1135353|NCT01426555|Weakening of the bone structure
1135358|NCT01426516|Treatment Resistant
1135359|NCT01426516|Depression
1135360|NCT01426477|Ventral hernia
1135361|NCT01426477|Abdominal wall hernia
1135362|NCT01426477|Incisional hernia
1135363|NCT01426477|Biologic mesh
1135364|NCT01426477|Veritas Collagen Matrix
1135365|NCT01426477|Veritas
1135366|NCT01426464|Glaucoma
1135367|NCT01426464|Xalatan
1135368|NCT01426464|Transdermal
1135369|NCT01426451|Dramatherapy
1135370|NCT01426451|Group tutoring activities
1135371|NCT01426451|Impairment
1135372|NCT01426451|Emotional and behavioural problems
1135373|NCT01426451|Learning difficulties
1135374|NCT01426425|Cardiac cryoablation
1135375|NCT01426425|AVNRT
1135376|NCT01426425|heart disease
1135377|NCT01426425|tachycardia
1135378|NCT01426425|AtrioVentricular Nodal Reentrant Tachycardia
1135379|NCT01426425|Supraventricular tachycardia
1135380|NCT01426425|SVT
1135381|NCT01426360|dentifrice
1135382|NCT01426360|potassium nitrate
1135383|NCT01426360|strontium chloride
1135384|NCT01426347|Rheumatoid Arthritis
1135385|NCT01426347|Vitamin D deficiency
1135386|NCT01426347|Disability
1135387|NCT01426321|Cardiac resynchronization therapy
1135388|NCT01426321|Echocardiography
1135389|NCT01426321|Cardiac computed tomography
1135390|NCT01426295|hematologic disease candidates for autologous or allogeneic bone marrow
1135391|NCT01426282|Out-patient Compliance
1135394|NCT01426282|Treatment and Prevention
1135395|NCT01426256|vitamin D
1135396|NCT01426256|cholecalciferol
1135397|NCT01426256|cystic fibrosis
1135398|NCT01426256|respiratory tract infection
1135399|NCT01426256|immunity
1135400|NCT01426256|intervention studies
1135401|NCT01426256|inflammation
1135402|NCT01426256|dietary supplements
1135403|NCT01426256|alpha-Defensins
1135404|NCT01426256|Cytokines
1135405|NCT01426256|mortality
1135406|NCT01426256|biological markers
1135407|NCT01426256|Biomedical Research
1135408|NCT01426230|PHN
1135409|NCT01426230|Post Herpetic Neuralgia
1135410|NCT01426230|Shingles
1135411|NCT01426230|HZ roster
1135412|NCT01426204|Hepatitis C
1135413|NCT01426204|Retreatment
1135414|NCT01426204|Failures
1135415|NCT01426204|Infergen
1135416|NCT01426204|Interferon Alfacon-1
1135417|NCT01426191|Cefotaxime sulbactam sodium
1135418|NCT01426191|Phase IV clinical studies
1135419|NCT01426191|Respiratory and urinary tract infections
1135420|NCT01426178|Respiratory Insufficiency
1135421|NCT01426178|Respiration, Artificial
1135422|NCT01426178|Intermittent Positive-Pressure Ventilation
1135423|NCT01426178|Neurally Adjusted Ventilatory Assist
1135424|NCT01426178|Non Invasive Ventilation
1135425|NCT01426165|hypomagnesemia
1135426|NCT01426165|magnesium
1135427|NCT01426165|magnesium sulfate
1135428|NCT01426152|IVF
1135429|NCT01426152|progesterone
1135430|NCT01426152|ovulation induction
1135431|NCT01426152|pregnancy rates
1135432|NCT01426152|Female Infertility Due to Nonimplantation
1135433|NCT01426126|urothelial carcinoma
1135434|NCT01426126|gemcitabine
1135435|NCT01426126|platinum
1135436|NCT01426126|refractory
1135437|NCT01426126|salvage chemotherapy
1135438|NCT01426100|CKD-828
1135439|NCT01426100|Hypertension
1135440|NCT01426100|Primary Hypertension
1135441|NCT01426100|S-Amlodipine
1135442|NCT01426100|Telmisartan
1135443|NCT01426100|Amlodipine
1135444|NCT01426100|Non-Responder
1135445|NCT01426061|Complementary and alternative medicine
1135446|NCT01426061|Reflexology
1135447|NCT01426061|Homeopathy
1135448|NCT01426061|Asthma
1135449|NCT01426061|Randomized controlled trial
1135450|NCT01426035|SUPERFICIAL VARICOSE VEINS
1135451|NCT01426022|alcohol
1135452|NCT01426022|mood
1135453|NCT01426022|postprandial
1135454|NCT01426009|COPD
1135455|NCT01425996|HCC
1135456|NCT01425996|PVTT
1135457|NCT01425983|stress
1135458|NCT01425983|lability and irritative disturbances
1135459|NCT01425983|dietary supplement
1135460|NCT01425983|amino acid composition
1135461|NCT01425983|psychological neurological questionnaire (PNF)
1135462|NCT01425970|Inhibitex
1135463|NCT01425970|Chronic Hepatitis
1135464|NCT01425970|Hepatitis C Virus
1135465|NCT01425957|MEMORY and COGNITIVE IMPAIRMENT
1135466|NCT01425957|ALZHEIMER DISEASE CONVERSION
1135467|NCT01425957|Amyloid beta-Peptides
1135468|NCT01425944|Sturge Weber Syndrome
1135469|NCT01425944|Biomarkers
1135470|NCT01425944|DNA arrays
1135471|NCT01425944|brain vessel malformations
1135472|NCT01425918|Autism Spectrum Disorder
1135473|NCT01425918|language
1135474|NCT01425918|social
1135475|NCT01425918|toddlers
1135476|NCT01425905|Female
1135477|NCT01425905|Depression
1135478|NCT01425905|Obesity
1135479|NCT01425905|Insulin Resistance
1135480|NCT01425905|Adolescents
1135481|NCT01425905|Overweight
1135482|NCT01425905|Type 2 Diabetes Risk
1135483|NCT01425905|Mood
1135484|NCT01425892|Salivary Gland
1135485|NCT01425892|Pathogenesis
1135486|NCT01425892|Sj(SqrRoot)(Delta)gren s Syndrome
1135487|NCT01425892|Sjogren Syndrome
1135488|NCT01425866|Diabetes Mellitus
1135489|NCT01425866|Diabetes Mellitus, Type 2
1135490|NCT01425866|Structured self-management education
1135491|NCT01425866|Therapeutic patient education
1135492|NCT01425866|Lifestyle changes
1135493|NCT01425866|Self-management Blood glucose
1135494|NCT01425866|Empowerment
1135495|NCT01425866|Adult learning
1135496|NCT01425866|Socio-constructivism
1135497|NCT01425866|Health management network
1135498|NCT01425866|Reunion island
1135499|NCT01425840|Lidocaine,
1135500|NCT01425840|liposome encapsulation,
1135501|NCT01425840|topical anesthesia,
1135502|NCT01425840|palatal mucosa
1135503|NCT01425827|duloxetine
1135504|NCT01425827|osteoarthritis
1135505|NCT01425827|pain
1135506|NCT01425827|function
1135507|NCT01425814|COPD
1135508|NCT01425801|COPD
1135509|NCT01425788|Grass pollen induced allergic rhinoconjunctivitis
1135510|NCT01425775|SLE
1135511|NCT01425775|disease activity markers
1135512|NCT01425775|vitamin D
1135513|NCT01425749|melanoma
1135514|NCT01425749|MAGE-A3
1135515|NCT01425749|immunotherapy
1135516|NCT01425749|adjuvant
1135517|NCT01425749|skin cancer
1135518|NCT01425749|skin diseases
1135519|NCT01425749|immunology
1135520|NCT01425736|Nimotuzumab
1135521|NCT01425736|Chemotherapy
1135522|NCT01425736|Head and Neck Squamous Cell Carcinoma
1135523|NCT01425723|B-LONG
1135524|NCT01425723|B-YOND
1135525|NCT01425723|B-LONG Extension
1135526|NCT01425723|rFIXFc
1135527|NCT01425723|Severe Hemophilia B
1135528|NCT01425710|Pheochromocytoma
1135529|NCT01425710|Adrenalectomy
1135530|NCT01425710|Cardiac output
1135531|NCT01425710|Fluid managment
1135532|NCT01425710|Esopagheal doppler sonography
1135533|NCT01425697|Adult Cardiac surgery
1135534|NCT01425697|Surgery site infections
1135535|NCT01425684|MRI
1135536|NCT01425684|Smoking
1135537|NCT01425684|Schizophrenia
1135538|NCT01425671|Schizophrenia
1135539|NCT01425671|Family
1135540|NCT01425671|Psychosis
1135541|NCT01425658|Fentanyl
1135542|NCT01425658|clonidine
1135543|NCT01425658|intrathcal
1135544|NCT01425658|bupivacaine
1135545|NCT01425645|gestational diabetes
1135546|NCT01425645|GDM
1135547|NCT01425645|prevention
1135548|NCT01425632|TAU-284
1135549|NCT01425632|Bepotastine besilate
1135550|NCT01425632|Histamine H1 receptor antagonists
1135551|NCT01425619|Anxiety Disorder due to Allergy Skin Testing
1135552|NCT01425580|Congestive Heart Failure
1135553|NCT01425580|Type 2 Diabetes Mellitus
1135554|NCT01425580|GLP-1
1135555|NCT01425580|Liraglutide
1135556|NCT01425567|cholestasis
1135557|NCT01425567|parenteral nutrition
1135558|NCT01425554|Vascular malformations in the internal jugular veins
1135559|NCT01425515|hypertension
1135560|NCT01425515|genomics
1135561|NCT01425502|High risk prescribing
1135562|NCT01425502|Primary care
1135563|NCT01425502|Non-steroidal anti-inflammatory drugs
1135564|NCT01425502|Anti-platelet agents
1135565|NCT01425502|Stepped wedge design
1135566|NCT01425502|Cluster randomised controlled trial
1135567|NCT01425502|United Kingdom
1135568|NCT01425489|Leukodystrophy, Globoid Cell
1135569|NCT01425489|Hereditary Central Nervous System Demyelinating Diseases
1135570|NCT01425489|Brain Diseases, Metabolic, Inborn
1135571|NCT01425489|Central Nervous System Diseases
1135572|NCT01425489|Nervous System Diseases
1135573|NCT01425489|Sphingolipidoses
1135574|NCT01425489|Leukoencephalopathies
1135575|NCT01425489|Demyelinating Diseases
1135576|NCT01425489|Metabolism, Inborn Errors
1135577|NCT01425489|Genetic Diseases, Inborn
1135578|NCT01425489|Lipidoses
1135579|NCT01425489|Lipid Metabolism, Inborn Errors
1135580|NCT01425489|Lysosomal Storage Diseases
1135581|NCT01425489|Metabolic Diseases
1135582|NCT01425489|Lipid Metabolism DisordersLeukodystrophy, Globoid Cell
1135583|NCT01425476|breast
1135584|NCT01425476|high risk women
1135585|NCT01425476|biomarkers
1135586|NCT01425476|vitamin D
1135587|NCT01425463|Ferrous (II) Glycine Sulphate Complex
1135588|NCT01425463|Polyferose
1135589|NCT01425463|Ferro Sanol duodenal
1135590|NCT01425463|Niferex
1135591|NCT01425463|Iron Deficiency Anemia
1135592|NCT01425437|Keloid
1135593|NCT01425424|Vitamin D
1135594|NCT01425424|Prediabetes
1135595|NCT01425424|Prehypertension
1135596|NCT01425411|hypertension
1135597|NCT01425411|left ventricular hypertrophy
1135598|NCT01425411|angiotensin receptor blocker
1135599|NCT01425411|midwall mechanics
1135600|NCT01425411|tissue Doppler imaging
1135601|NCT01425411|Hypertension with left ventricular hypertrophy
1135602|NCT01425385|liver failure
1135603|NCT01425385|liver transplantation
1135604|NCT01425372|vaccine
1135605|NCT01425372|pneumococcal conjugate vaccine
1135606|NCT01425372|immune responses
1135607|NCT01425372|primary immunisation
1135608|NCT01425372|Vaccine responses to primary immunisation in the UK
1135609|NCT01425359|Chronic angina
1135610|NCT01425359|Angina pectoris
1135611|NCT01425359|Coronary artery disease
1135612|NCT01425359|Type 2 Diabetes Mellitus
1135613|NCT01425346|Ophthalmic, healthy eye, fluorescence, lens
1135614|NCT01425333|Ovarian endometriomas
1135615|NCT01425333|Laparoscopy
1135616|NCT01425333|Cystectomy
1135617|NCT01425333|Ablation
1135618|NCT01425307|Phase III
1135619|NCT01425307|Sickle cell anemia
1135620|NCT01425307|Abnormally high Transcranial Doppler velocities.
1135621|NCT01425307|Reduce risk of primary stroke
1135622|NCT01425307|Pediatric patients
1135623|NCT01425307|Chelation therapy
1135624|NCT01425294|Chinese post-menopausal women
1135625|NCT01425294|oestrogen receptor-positive locally advanced
1135626|NCT01425294|metastatic breast cancer
1135627|NCT01425294|fulvestrant 250 mg
1135628|NCT01425294|failure to adjuvant anti-oestrogen therapy
1135629|NCT01425281|Bioabsorbable
1135630|NCT01425281|Coronary scaffold
1135631|NCT01425281|Coronary Stent
1135632|NCT01425281|Everolimus
1135633|NCT01425281|Drug eluting stents
1135634|NCT01425281|Angioplasty
1135635|NCT01425281|Coronary artery disease
1135636|NCT01425281|Total coronary occlusion
1135637|NCT01425281|Coronary artery restenosis
1135638|NCT01425281|Stent thrombosis
1135639|NCT01425281|Myocardial ischemia
1135640|NCT01425281|Coronary artery stenosis
1135641|NCT01425268|Tissue Expansion
1135642|NCT01425268|Tissue Expander
1135643|NCT01425268|Breast Tissue Expansion
1135644|NCT01425268|Breast Tissue Expander
1135645|NCT01425268|Breast Reconstruction
1135646|NCT01425268|Two Stage Breast Reconstruction
1135647|NCT01425268|2 Stage Breast Reconstruction
1135648|NCT01425255|Type 1 diabetes
1135649|NCT01425255|Sleep quality
1135650|NCT01425255|Parents
1135651|NCT01425242|inflammation
1135652|NCT01425242|aneurysm
1135653|NCT01425242|hypertension
1135654|NCT01425242|aliskiren
1135655|NCT01425229|steady state
1135656|NCT01425229|bosentan
1135657|NCT01425229|clarithromycin
1135658|NCT01425216|Keloid
1135659|NCT01425216|Patient who have extensive or massive keloids
1135660|NCT01425177|Retained CBD Stones
1135661|NCT01425177|Recurrent CBD Stones
1135662|NCT01425164|hemodialysis
1135663|NCT01425164|coronary heart disease
1135664|NCT01425164|angina
1135665|NCT01425164|betablocker
1135666|NCT01425164|carvedilol
1135667|NCT01425164|ivabradine
1135668|NCT01425138|psoriasis
1135669|NCT01425138|systematic review
1135670|NCT01425138|meta-analyses
1135671|NCT01425125|nonedematous hyponatremia
1135672|NCT01425125|fractional urate excretion
1135673|NCT01425112|trabeculectomy
1135674|NCT01425112|bevacizumab
1135675|NCT01425112|anti-VEGF
1135676|NCT01425112|Efficacy
1135677|NCT01425086|Incubator,
1135678|NCT01425086|hypothermia,
1135679|NCT01425086|preterm,
1135680|NCT01425086|low-birthweight infants,
1135681|NCT01425086|embrace device,
1135682|NCT01425086|phase change materials
1135683|NCT01425086|PCM
1135684|NCT01425073|HIV
1135685|NCT01425073|Co-Infections
1135686|NCT01425073|Malaria
1135687|NCT01425073|Pneumonia
1135688|NCT01425073|Diarrhea
1135689|NCT01425060|Contraception
1135690|NCT01425060|Unintended pregnancy
1135691|NCT01425060|HIV
1135692|NCT01425060|HIV Risk
1135693|NCT01425060|Sexually Transmitted Infections
1135694|NCT01425060|Women
1135695|NCT01425060|Pregnancy
1135696|NCT01425060|Neonatal Health
1135697|NCT01425060|Drug Use
1135698|NCT01425060|Drug Treatment
1135699|NCT01425060|Opioids
1135700|NCT01425047|mangosteen
1135701|NCT01425047|xanthones
1135702|NCT01425047|dietary supplement
1135703|NCT01425047|botanical supplement
1135704|NCT01425047|bioavailability
1135705|NCT01425047|Determine bioavailability of mangosteen xanthones in adults
1135706|NCT01425034|Cast
1135707|NCT01425034|motion
1135708|NCT01425034|thumb CMC arthritis
1135709|NCT01425034|Collateral Ligament of Metacarpophalangeal Joint
1135710|NCT01424995|trigger thumb
1135711|NCT01424995|flexor pollicis longus tendon of the thumb
1135712|NCT01424995|stenosis tenosynovitis
1135713|NCT01424982|Leukemia
1135714|NCT01424982|Ph-positive acute lymphoblastic leukemia
1135715|NCT01424982|ALL
1135716|NCT01424982|Philadelphia (Ph) chromosome
1135717|NCT01424982|BCR-ABL
1135718|NCT01424982|Depo-Medrol
1135719|NCT01424982|Medrol
1135720|NCT01424982|Solu-Medrol
1135721|NCT01424982|Methylprednisolone
1135722|NCT01424982|Vincristine
1135723|NCT01424982|Dexamethasone
1135724|NCT01424982|Decadron
1135725|NCT01424982|Ponatinib
1135726|NCT01424982|G-CSF
1135727|NCT01424982|Filgrastim
1135728|NCT01424982|NeupogenTM
1135729|NCT01424982|Cyclophosphamide
1135730|NCT01424982|Cytoxan
1135731|NCT01424982|Neosar
1135732|NCT01424982|Doxorubicin
1135733|NCT01424982|Doxorubicin Hydrochloride
1135734|NCT01424982|Adriamycin PFS
1135735|NCT01424982|Adriamycin RDF
1135736|NCT01424982|Adriamycin
1135737|NCT01424982|Rubex
1135738|NCT01424982|Rituximab
1135739|NCT01424982|Rituxan
1135740|NCT01424982|Mesna
1135741|NCT01424982|Mesnex
1135742|NCT01424982|Cytarabine
1135743|NCT01424982|Ara-C
1135744|NCT01424982|Cytosar
1135745|NCT01424982|DepoCyt
1135746|NCT01424982|Cytosine Arabinosine Hydrochloride
1135747|NCT01424982|Methotrexate
1135748|NCT01424982|Leucovorin
1135749|NCT01424982|Wellcovorin
1135750|NCT01424982|Citrovorum
1135751|NCT01424982|Prednisone
1135752|NCT01424982|NeulastaTM
1135753|NCT01424982|PEG-G-CSF
1135754|NCT01424969|rotator cuff repair
1135755|NCT01424969|arthroscopic
1135756|NCT01424969|platelet-rich plasma
1135757|NCT01424969|platelet-rich fibrin matrix
1135758|NCT01424969|outcomes
1135759|NCT01424969|tendon healing
1135760|NCT01424969|magnetic resonance imaging
1135761|NCT01424956|breast
1135762|NCT01424956|breast cancer
1135763|NCT01424956|breast screening
1135764|NCT01424956|breast cancer screening
1135765|NCT01424956|ultrasound
1135766|NCT01424956|ultrasonography
1135767|NCT01424956|mammogram
1135768|NCT01424956|mammography
1135769|NCT01424956|breast density
1135770|NCT01424956|dense breasts
1135771|NCT01424956|early detection
1135772|NCT01424956|somo v
1135773|NCT01424956|somo•v
1135774|NCT01424956|U-Systems
1135775|NCT01424956|Automated Breast Ultrasound
1135776|NCT01424956|Ultrasonography, Mammary
1135777|NCT01424956|Breast Neoplasms
1135778|NCT01424956|Breast Density > 50% (BI-RADS III & IV)
1135779|NCT01424943|prevention
1135780|NCT01424943|evidence-based parenting intervention
1135781|NCT01424943|children
1135782|NCT01424943|disabilities
1135783|NCT01424943|IDEA Part C
1135784|NCT01424943|Stepping Stones Triple P
1135785|NCT01424930|Metastatic castration-resistant prostate cancer
1135786|NCT01424930|CRPC
1135787|NCT01424930|Abiraterone Acetate
1135788|NCT01424930|Prednisone
1135789|NCT01424930|Food Safety
1135790|NCT01424917|Cardiac Allograft Vasculopathy
1135791|NCT01424904|Ergogenic aid
1135792|NCT01424904|Exercise endurance
1135793|NCT01424904|High performance
1135794|NCT01424904|Time trial performance
1135795|NCT01424904|Glutathione
1135796|NCT01424878|Molecular Analysis of Medullary Thyroid Carcinoma Tissues
1135797|NCT01424865|HER2-positive breast cancer
1135798|NCT01424865|stage II breast cancer
1135799|NCT01424865|stage IIIA breast cancer
1135800|NCT01424852|Probiotics
1135801|NCT01424852|Caries
1135802|NCT01424852|Oral flora
1135803|NCT01424839|SIOP CNS GCT II
1135804|NCT01424839|Patients with the primary disease of an Intracranial Germ Cell Tumors
1135805|NCT01424826|Healthy volunteers
1135806|NCT01424813|Asthma
1135807|NCT01424813|dry powder inhaler
1135808|NCT01424813|short-acting beta2-agonist
1135809|NCT01424813|SABA
1135810|NCT01424813|bronchoconstriction
1135811|NCT01424813|bronchodilation
1135812|NCT01424813|bronchodilator
1135813|NCT01424813|metered dose inhaler
1135814|NCT01424774|Radiation Exposure
1135815|NCT01424774|Rubidium 82
1135816|NCT01424774|Strontium 82
1135817|NCT01424774|Strontium 85
1135818|NCT01424748|Noni juice
1135819|NCT01424748|Safety
1135820|NCT01424735|Best corrected Visual Acuity
1135821|NCT01424735|Pupillary Reaction
1135822|NCT01424735|Colour vision
1135823|NCT01424735|Disc edema
1135824|NCT01424722|ICD Indicated patients
1135825|NCT01424722|documented CAD
1135826|NCT01424709|Chemotherapy
1135827|NCT01424709|Individual therapy
1135828|NCT01424709|RRM1
1135829|NCT01424709|BRCA1
1135830|NCT01424696|growth measures
1135831|NCT01424696|nutritional status
1135832|NCT01424696|pulmonary infection
1135833|NCT01424696|inflammatory markers
1135834|NCT01424696|pancreatic enzyme replacement therapy
1135835|NCT01424683|Qol
1135836|NCT01424683|Quality of life
1135837|NCT01424683|VAS
1135838|NCT01424683|Visual Analogue Scale
1135839|NCT01424683|CABG
1135840|NCT01424683|Coronary Artery Bypass Graft
1135841|NCT01424683|Qol conversion
1135842|NCT01424683|post hoc HTA
1135843|NCT01424670|Multidrug resistant tuberculosis
1135844|NCT01424657|MRCP
1135845|NCT01424657|ERCP
1135846|NCT01424657|BILIARY OBSTRUCTION
1135847|NCT01424657|EFFECTIVENESS
1135848|NCT01424644|meningitis
1135849|NCT01424644|human papillomavirus
1135850|NCT01424644|tetanus
1135851|NCT01424644|diptheria
1135852|NCT01424644|pertussis
1135853|NCT01424618|Donor eggs
1135854|NCT01424618|Donor oocytes
1135855|NCT01424618|Pregnancy
1135856|NCT01424618|Embryo Implantation
1135857|NCT01424618|Infertility
1135858|NCT01424618|IVF
1135859|NCT01424605|left-sided double lumen bronchial tube
1135860|NCT01424605|GlideScope videolaryngoscope
1135861|NCT01424605|direct laryngoscope
1135862|NCT01424592|Portable sleep apnea testing
1135863|NCT01424592|Positive airway pressure therapy
1135864|NCT01424592|Polysomnography
1135865|NCT01424566|cancer pain
1135866|NCT01424566|opioid therapy
1135867|NCT01424566|inadequate analgesia
1135868|NCT01424566|optimized chronic opioid therapy
1135869|NCT01424553|Low birthweight
1135870|NCT01424553|Bronchopulmonary dysplasia
1135871|NCT01424553|Lung development
1135872|NCT01424553|Airway obstruction
1135873|NCT01424553|Asthma
1135874|NCT01424527|Chronic Obstructive Pulmonary Disease(COPD)
1135875|NCT01424527|COPD Assessment Test(CAT)
1135876|NCT01424501|Tuberculosis vaccine
1135877|NCT01424501|HIV-negative
1135878|NCT01424501|tuberculosis treatment
1135879|NCT01424488|sugammadex
1135880|NCT01424488|reversal
1135881|NCT01424488|pipecuronium-induced neuromuscular blockade
1135886|NCT01424436|CSF sampling
1135887|NCT01424436|Alzheimer's disease
1135888|NCT01424436|Amyloid beta levels
1135889|NCT01424423|Safety
1135890|NCT01424423|GSK1223249
1135891|NCT01424423|Pharmacokinetics
1135892|NCT01424423|Single dose escalation
1135893|NCT01424423|anti-GSK1223249 antibodies
1135894|NCT01424423|Multiple Sclerosis
1135895|NCT01424410|paediatric schistosomiasis morbidity immunology
1135896|NCT01424384|healthy volunteers
1135897|NCT01424384|Anxiety Disorder
1135898|NCT01424384|neuropsychological tests
1135899|NCT01424345|Kidney Transplantation
1135900|NCT01424345|Immunosuppression
1135901|NCT01424345|Immune monitoring
1135902|NCT01424332|Pharmacodynamics
1135903|NCT01424332|pharmacokinetics
1135904|NCT01424332|darexaban
1135905|NCT01424332|Acetyl Salicylic Acid
1135906|NCT01424332|darexaban glucuronide
1135907|NCT01424332|YM150
1135908|NCT01424332|YM-222714
1135909|NCT01424332|Phase 1
1135910|NCT01424319|Endothelin Receptor Antagonists
1135911|NCT01424319|Proteinuria
1135912|NCT01424306|Inflammation
1135913|NCT01424306|Intestinal permeability
1135914|NCT01424306|Type 2 diabetes mellitus
1135915|NCT01424306|Cardiovascular disease
1135916|NCT01424306|Obesity
1135917|NCT01424306|Sweetened beverages
1135918|NCT01424306|Sugar
1135919|NCT01424306|Fructose
1135920|NCT01424306|Glucose
1135921|NCT01424306|High-fructose corn syrup
1135922|NCT01424293|Rectal Cancer
1135923|NCT01424293|Colon Cancer
1135924|NCT01424293|Diverticulitis
1135925|NCT01424293|Anastamosis
1135926|NCT01424293|colectomy
1135927|NCT01424293|low anterior resection
1135928|NCT01424267|low profile
1135929|NCT01424267|endovascular graft
1135930|NCT01424267|endovascular procedure
1135931|NCT01424267|aortic aneurysm, abdominal aortic aneurysm
1135932|NCT01424254|Gastrointestinal Bleeding of Obscure Origin
1135933|NCT01424241|Sandostatin LAR
1135934|NCT01424228|Long term
1135935|NCT01424228|Constipation
1135936|NCT01424228|Digestive signs and symptoms
1135937|NCT01424202|Post extubation failure
1135938|NCT01424202|Mechanical Insufflation-Exsufflation
1135939|NCT01424202|Noninvasive Ventilation
1135940|NCT01424202|Weaning
1135941|NCT01424189|Cataract surgery
1135942|NCT01424189|Intraocular lens
1135943|NCT01424150|Postoperative fluid
1135944|NCT01424150|surgery
1135945|NCT01424150|anaesthesia
1135946|NCT01424150|fluid
1135947|NCT01424150|mortality
1135948|NCT01424150|morbidity
1135949|NCT01424111|Biomarkers
1135950|NCT01424111|Depression
1135951|NCT01424111|Major Depressive Disorder
1135952|NCT01424111|Escitalopram
1135953|NCT01424072|stress psychological
1135954|NCT01424072|coping behavior
1135955|NCT01424059|fear
1135956|NCT01424059|labor
1135957|NCT01424059|induction
1135958|NCT01424059|amniotomy
1135959|NCT01424059|WEDQ-B
1135960|NCT01424059|parous
1135961|NCT01424059|cesarean section
1135962|NCT01424046|type 1 diabetes
1135963|NCT01424046|basal insulin
1135964|NCT01424046|developing world
1135965|NCT01424046|comparative effectiveness
1135966|NCT01424033|Interstitial lung disease
1135967|NCT01424033|Connective tissue disease
1135968|NCT01424033|Scleroderma
1135969|NCT01424033|Rheumatoid arthritis
1135970|NCT01424033|Sjogren's syndrome
1135971|NCT01424033|Mixed connective tissue disease
1135972|NCT01424033|Dermatomyositis
1135973|NCT01424033|Polymyositis
1135974|NCT01424033|Systemic lupus erythematosis
1135975|NCT01424020|Questionnaire
1135976|NCT01424020|peripheral artery disease
1135977|NCT01424020|execise
1135978|NCT01424007|Obese
1135979|NCT01424007|Women
1135980|NCT01424007|Weight loss
1135981|NCT01424007|Exercise
1135982|NCT01424007|Physical activity
1135983|NCT01424007|Diet
1135984|NCT01424007|Female
1135985|NCT01423994|syncope
1135986|NCT01423994|fainting
1135987|NCT01423994|implantable loop recorder
1135988|NCT01423994|pacemaker
1135989|NCT01423994|heart block
1135990|NCT01423994|bifascicular heart block
1135991|NCT01423981|Keloid
1135992|NCT01423981|Scar
1135993|NCT01423981|hypertrophic scar
1135994|NCT01423981|familial keloid
1135995|NCT01423968|Sepsis
1135996|NCT01423968|Inflammation
1135997|NCT01423968|Lipopolysaccharide
1135998|NCT01423968|Muscle protein turnover
1135999|NCT01423968|Insulin resistance
1136000|NCT01423955|Erythropoietin
1136001|NCT01423955|Erythropoetin
1136002|NCT01423955|Cardiac surgery
1136003|NCT01423955|Ischemia
1136004|NCT01423955|Reperfusion
1136005|NCT01423955|Renal function
1136006|NCT01423955|Cystatin C
1136007|NCT01423955|Creatinine
1136008|NCT01423955|Safety
1136009|NCT01423929|Oxygen
1136010|NCT01423929|Myocardial infarction
1136011|NCT01423929|Ambulance
1136012|NCT01423929|Percutaneous coronary intervention
1136013|NCT01423929|Cardiac magnetic resonance imaging
1136014|NCT01423916|Schizophrenia
1136015|NCT01423916|QTc Interval
1136016|NCT01423903|Phase I
1136017|NCT01423903|STAT-3 inhibitor
1136018|NCT01423903|solid tumors
1136019|NCT01423890|Breast Cancer
1136020|NCT01423890|Oncotype DX
1136021|NCT01423890|Adjuvant! Online
1136022|NCT01423890|Decisional Conflict Scale
1136023|NCT01423877|bariatric surgery
1136024|NCT01423877|diabetes
1136025|NCT01423877|sleeve gastrectomy
1136026|NCT01423877|gastric bypass
1136027|NCT01423877|gastric banding
1136028|NCT01423864|Acute Respiratory Distress Syndrome
1136029|NCT01423864|Multi-organ Dysfunction Syndrome
1136030|NCT01423864|Extracorporeal Membrane Oxygenation
1136031|NCT01423851|Keywords provided by NS Pharma, Inc.:
1136032|NCT01423851|JAK2 kinase inhibitor
1136033|NCT01423851|NS-018
1136034|NCT01423851|Myeloproliferative Neoplasms
1136035|NCT01423851|Primary Myelofibrosis
1136036|NCT01423851|post-Polycythemia Vera Myelofibrosis
1136037|NCT01423851|post-Essential Thrombocythemia Myelofibrosis
1136038|NCT01423851|Additional relevant MeSH terms:
1136039|NCT01423851|Bone Marrow Diseases
1136040|NCT01423851|Hematologic Diseases
1136041|NCT01423851|Polycythemia Vera
1136042|NCT01423851|Thrombocythemia, Essential
1136043|NCT01423851|PMF
1136044|NCT01423851|post-PV MF
1136045|NCT01423851|post-ET MF
1136046|NCT01423838|Overactive bladder
1136047|NCT01423838|Solifenacin
1136048|NCT01423838|Oxybutynin
1136049|NCT01423812|HIV
1136050|NCT01423812|treatment-experienced
1136051|NCT01423812|protease inhibitor
1136052|NCT01423812|adherence
1136053|NCT01423812|lipids
1136054|NCT01423799|Quality of life
1136055|NCT01423799|Cancer
1136056|NCT01423799|Immunonutrition
1136057|NCT01423760|Vaccine
1136058|NCT01423760|Stimuvax
1136059|NCT01423760|Tecemotide
1136060|NCT01423760|L-BLP25
1136061|NCT01423760|Non-Small Cell Lung Carcinoma
1136062|NCT01423760|Multiple Myeloma
1136063|NCT01423747|ALL
1136064|NCT01423747|HSCT
1136065|NCT01423747|children
1136066|NCT01423747|adolescents
1136067|NCT01423734|ADRENAL GLAND
1136068|NCT01423734|MRI
1136069|NCT01423734|11-122
1136070|NCT01423708|Liver Transplantation
1136071|NCT01423708|Graft Rejection
1136072|NCT01423708|Graft Survival
1136073|NCT01423708|Transplantation Immunology
1136074|NCT01423708|Anti-Rejection Therapy
1136075|NCT01423708|Immunosuppression
1136076|NCT01423708|Organ Transplantation
1136077|NCT01423708|Host vs Graft Reaction
1136078|NCT01423708|Gastroenterology
1136079|NCT01423708|Hepatology
1136080|NCT01423669|Psychotic Disorders
1136081|NCT01423643|HIV
1136082|NCT01423643|Human immunodeficiency virus
1136083|NCT01423643|Acquired Immune Deficiency Syndrome Virus
1136084|NCT01423643|AIDS Virus
1136085|NCT01423643|Immunodeficiency Virus, Human
1136086|NCT01423643|Virus, Human Immunodeficiency
1136087|NCT01423643|Hepatitis C
1136088|NCT01423643|Hepatitis C, chronic
1136089|NCT01423643|Hepatitis C virus
1136090|NCT01423643|Hepatitis C antibodies
1136091|NCT01423643|Hepatitis C antigens
1136092|NCT01423630|fatty liver
1136093|NCT01423630|probiotics
1136094|NCT01423630|Lactobacillus
1136095|NCT01423630|fruit
1136096|NCT01423630|fibre
1136097|NCT01423630|dietary intervention
1136098|NCT01423630|obesity
1136099|NCT01423617|overweight
1136100|NCT01423617|weight loss
1136101|NCT01423617|body fat
1136102|NCT01423617|waist circumference
1136103|NCT01423617|satiety
1136104|NCT01423617|appetite
1136105|NCT01423604|Metastatic pancreatic cancer
1136106|NCT01423591|Infliximab
1136107|NCT01423591|polymyalgia rheumatica
1136108|NCT01423591|refractory
1136109|NCT01423591|double blind
1136110|NCT01423591|placebo controlled
1136111|NCT01423591|trial
1136112|NCT01423578|craving
1136113|NCT01423578|mood
1136114|NCT01423578|cue reactivity
1136115|NCT01423578|smoking behavior
1136116|NCT01423578|quit smoking
1136117|NCT01423578|prevention
1136118|NCT01423578|Hatha yoga
1136119|NCT01423578|cardiovascular exercise
1136120|NCT01423565|Deep Brain Stimulation
1136121|NCT01423565|Parkinson's Disease
1136122|NCT01423565|Subthalamic Nucleus
1136123|NCT01423565|Constant Current
1136124|NCT01423552|Heart transplantation
1136125|NCT01423552|Immunosuppression
1136126|NCT01423552|Pharmacokinetics
1136127|NCT01423552|Pharmacogenetics
1136128|NCT01423513|ankle tape
1136129|NCT01423513|Hoffmann reflex
1136130|NCT01423513|Balance
1136131|NCT01423500|ALL
1136132|NCT01423500|HSCT
1136133|NCT01423500|children
1136134|NCT01423500|adolescents
1136135|NCT01423487|Metformin
1136136|NCT01423487|Risperidone
1136137|NCT01423487|Prevention
1136138|NCT01423487|weight gain
1136139|NCT01423487|Amenorrhea
1136140|NCT01423474|Radiotherapy
1136141|NCT01423474|Hypofractionation
1136142|NCT01423448|Depression
1136143|NCT01423448|mental health
1136144|NCT01423448|wellbeing
1136145|NCT01423448|online bulletin board
1136146|NCT01423448|online support group
1136147|NCT01423435|TRK-100STP
1136148|NCT01423435|PK
1136149|NCT01423435|beraprost sodium
1136150|NCT01423422|Exercise stress test
1136151|NCT01423422|Effort Angina
1136152|NCT01423422|Exercise induced angina
1136153|NCT01423409|visual analog pain scale
1136154|NCT01423409|Deaf persons
1136155|NCT01423409|clinical trial
1136156|NCT01423409|multicentric
1136157|NCT01423396|Alzheimer's disease
1136158|NCT01423396|cardiovascular risk factors
1136159|NCT01423383|Keloid
1136160|NCT01423370|Erectile Dysfunction
1136161|NCT01423370|YHD1023
1136162|NCT01423370|YCD190
1136163|NCT01423370|Cialis
1136164|NCT01423370|Yuhan
1136165|NCT01423357|HIV prevention
1136166|NCT01423357|condom distribution
1136167|NCT01423357|youth peer education
1136168|NCT01423357|high risk places
1136169|NCT01423357|condom use
1136170|NCT01423357|prevention through increased condom use
1136171|NCT01423344|multiple myeloma
1136172|NCT01423344|Free light chains
1136173|NCT01423331|Postpartum depression
1136174|NCT01423331|maternal mental health
1136175|NCT01423305|Asthma
1136176|NCT01423266|High Protein Diet in heart failure
1136177|NCT01423266|obesity and heart failure
1136178|NCT01423266|Weight management in Heart failure
1136179|NCT01423266|heart failure, diabetes and obesity
1136180|NCT01423253|Depression
1136181|NCT01423253|Lurasidone
1136182|NCT01423253|Latuda
1136183|NCT01423240|Depression
1136184|NCT01423240|Lurasidone
1136185|NCT01423240|Latuda
1136186|NCT01423227|COPD
1136187|NCT01423227|exercise
1136188|NCT01423227|rehabilitation
1136189|NCT01423227|dyspnea
1136190|NCT01423227|quality of life
1136191|NCT01423227|economic evaluation
1136192|NCT01423214|rectal cancer
1136193|NCT01423214|robot
1136194|NCT01423214|laparoscopy
1136195|NCT01423214|total mesorectal excision
1136196|NCT01423214|robotic surgery
1136197|NCT01423201|TIA
1136198|NCT01423201|triage
1136199|NCT01423201|Lp-PLA2
1136200|NCT01423201|Proteomic
1136201|NCT01423201|Genomic
1136202|NCT01423188|ApolipoproteinA1
1136203|NCT01423188|HDL-C
1136204|NCT01423188|Atherosclerosis
1136205|NCT01423175|high risk acute myeloid leukemia
1136206|NCT01423175|advanced myelodysplastic syndrome
1136207|NCT01423175|allogenic stem cell transplantation
1136208|NCT01423175|clofarabine
1136209|NCT01423162|Iron absorption
1136210|NCT01423162|Oats
1136211|NCT01423162|fortified oat beverages
1136212|NCT01423149|subfoveal choroidal neovascularization
1136213|NCT01423149|pathologic myopia
1136214|NCT01423136|Patients undergoing non-cardiac Surgery
1136215|NCT01423123|Paclitaxel
1136216|NCT01423123|Trastuzumab
1136217|NCT01423123|Neratinib
1136218|NCT01423123|Breast Cancer
1136219|NCT01423123|HER2-positive
1136220|NCT01423110|sporadic Inclusion Body Myositis
1136221|NCT01423097|osteoarthritis symptoms
1136222|NCT01423084|Meningococcal Meningitis
1136223|NCT01423084|prevention, vaccination
1136224|NCT01423084|adolescents
1136225|NCT01423071|Pulmonary Hypertension
1136226|NCT01423071|Chronic obstructive pulmonary disease
1136227|NCT01423071|Prevalence
1136228|NCT01423071|Quality of life
1136229|NCT01423045|Chronic kidney disease
1136230|NCT01423045|Urine osmolarity
1136231|NCT01423045|Glomerular filtration rate
1136232|NCT01423032|relapsed
1136233|NCT01423019|Weight Loss
1136234|NCT01423019|Body Composition
1136235|NCT01423019|Fat Free Mass
1136236|NCT01423019|Bone Mineral Density
1136237|NCT01423019|Adipose Tissue
1136238|NCT01423019|Dual-Energy X-Ray Absorptiometry
1136239|NCT01423019|Body Fat
1136240|NCT01423019|Eating and appetite control
1136241|NCT01423019|Basal Metabolic Rate
1136242|NCT01423006|Pilot
1136243|NCT01423006|Ablation
1136244|NCT01423006|Low Risk
1136245|NCT01423006|Radio Frequency
1136246|NCT01423006|RFA
1136247|NCT01423006|minimally invasive
1136248|NCT01423006|prostate gland
1136249|NCT01422993|Oxaliplatin Induced
1136250|NCT01422993|Peripheral Neuropathy
1136251|NCT01422993|Strength
1136252|NCT01422993|Balance
1136253|NCT01422993|Training Program
1136254|NCT01422993|Colon
1136255|NCT01422993|Rectal
1136256|NCT01422980|dairy product
1136257|NCT01422980|upper gastric discomfort
1136258|NCT01422980|adult
1136259|NCT01422967|Osteoarthritis
1136260|NCT01422967|Sleep
1136261|NCT01422967|muscle strength
1136262|NCT01422967|balance
1136263|NCT01422928|Radiotherapy
1136264|NCT01422928|Acupuncture
1136265|NCT01422928|Immune System
1136266|NCT01422915|Sorbent
1136267|NCT01422915|Resin
1136268|NCT01422915|EPP
1136269|NCT01422915|Cutaneous porphyria
1136270|NCT01422915|Adult
1136271|NCT01422915|over age 21
1136272|NCT01422915|without intercurrent illness
1136273|NCT01422915|not pregnant
1136274|NCT01422915|willing to participate
1136275|NCT01422902|Schizophrenia
1136276|NCT01422902|Cognitive deficits
1136277|NCT01422902|Cognitive remediation
1136278|NCT01422902|Software
1136279|NCT01422902|Brain Plasticity
1136280|NCT01422889|Atherosclerosis
1136281|NCT01422889|Coronary Artery Disease
1136282|NCT01422863|weight loss
1136283|NCT01422863|exercise
1136284|NCT01422863|diet
1136285|NCT01422863|sleep apnea
1136286|NCT01422863|aging
1136287|NCT01422850|hormone-refractory prostate cancer
1136288|NCT01422850|Immunotherapy
1136289|NCT01422837|opioid
1136290|NCT01422837|dependence
1136291|NCT01422837|VIVITROL
1136292|NCT01422811|Public health
1136293|NCT01422811|Policy
1136294|NCT01422811|Training
1136295|NCT01422785|Acne Vulgaris
1136296|NCT01422720|Epilepsy
1136297|NCT01422720|ESL
1136298|NCT01422720|Eslicarbazepine Acetate
1136299|NCT01422720|BIAL
1136300|NCT01422720|BIA
1136301|NCT01422720|Partial-onset Seizures
1136302|NCT01422694|Sacroiliitis
1136303|NCT01422694|Ankylosing Spondylitis
1136304|NCT01422694|Spondyloarthritis
1136305|NCT01422694|HLA-B27
1136306|NCT01422694|Enthesitis-Related Arthritis
1136307|NCT01422681|COPD
1136308|NCT01422668|Glycemic index
1136309|NCT01422668|Dates
1136310|NCT01422668|Diabetes
1136311|NCT01422668|Coffee
1136312|NCT01422629|Breast Fibroadenoma
1136313|NCT01422629|High Intensity Focused Ultrasound
1136314|NCT01422616|Ischemic stroke
1136315|NCT01422616|High blood pressure
1136316|NCT01422616|Thrombolysis
1136317|NCT01422616|Antihypertensive drugs
1136318|NCT01422616|Disability
1136319|NCT01422616|Clinical trial
1136320|NCT01422603|High risk
1136321|NCT01422603|AML
1136322|NCT01422603|MDS
1136323|NCT01422590|sitagliptin
1136324|NCT01422590|mitiglinide
1136325|NCT01422590|type 2 diabetes mellitus
1136326|NCT01422590|Pharmacodynamics
1136327|NCT01422590|Safety
1136328|NCT01422551|stress management intervention
1136329|NCT01422551|breast cancer
1136330|NCT01422551|quality of life
1136331|NCT01422551|psychosocial adaptation
1136332|NCT01422538|Ulthera® System
1136333|NCT01422538|Ultherapy™ treatment
1136334|NCT01422538|Ulthera, Inc.
1136335|NCT01422538|Ultrasound treatment for skin tightening
1136336|NCT01422538|Skin laxity on the face and neck.
1136337|NCT01422512|seasonal influenza
1136338|NCT01422512|vaccine
1136339|NCT01422499|pediatric oncology
1136340|NCT01422499|relapsed solid tumor
1136341|NCT01422499|lymphoma
1136342|NCT01422499|leukemia
1136343|NCT01422499|vorinostat
1136344|NCT01422486|Hematology
1136345|NCT01422486|MDS
1136346|NCT01422486|Myelodysplastic Syndrome
1136347|NCT01422486|Low risk MDS
1136348|NCT01422486|Intermediate-1 risk MDS
1136349|NCT01422486|Int-1 risk MDS
1136350|NCT01422486|Transfusion dependence
1136351|NCT01422486|Lenalidomide refractory
1136352|NCT01422486|Revlimid refractory
1136353|NCT01422486|Lenalidomide resistant
1136354|NCT01422486|Revlimid resistant
1136355|NCT01422486|Telintra
1136356|NCT01422486|ezatiostat
1136357|NCT01422486|ezatiostat hydrochloride
1136358|NCT01422486|TLK199
1136359|NCT01422486|Glutathione
1136360|NCT01422486|Glutathione analog
1136361|NCT01422486|Glutathione Transferase
1136362|NCT01422486|Glutathione Transferase P1-1 inhibitor
1136363|NCT01422486|GST P1-1 inhibitor
1136364|NCT01422486|Apoptosis
1136365|NCT01422486|Differentiation
1136366|NCT01422486|Enzyme inhibitor
1136367|NCT01422473|Hemorrhoids
1136368|NCT01422473|Rectal Diseases
1136369|NCT01422473|Intestinal Diseases
1136370|NCT01422473|Gastrointestinal Diseases
1136371|NCT01422473|Digestive System Diseases
1136372|NCT01422460|Osteoarthritis
1136373|NCT01422460|PRP
1136374|NCT01422460|PRGF
1136375|NCT01422447|mental health education
1136376|NCT01422447|community-based
1136377|NCT01422434|A national
1136378|NCT01422434|multi-centre
1136379|NCT01422434|prospective
1136380|NCT01422434|randomised
1136381|NCT01422434|double-blind
1136382|NCT01422434|active-controlled
1136383|NCT01422434|3-arm
1136384|NCT01422434|parallel group
1136385|NCT01422434|4 week study
1136386|NCT01422421|type 2 diabetes
1136387|NCT01422421|coronary artery disease
1136388|NCT01422421|hypertension
1136389|NCT01422421|dyslipidemia
1136390|NCT01422395|Vitrification
1136391|NCT01422395|Egg Freezing
1136392|NCT01422395|Oocyte Cryopreservation
1136393|NCT01422382|Healthy Volunteers
1136394|NCT01422369|Healthy Volunteers
1136395|NCT01422356|cohort study
1136396|NCT01422356|men who have sex with men
1136397|NCT01422343|peripheral arterial disease
1136398|NCT01422343|cell-derived microparticles
1136399|NCT01422343|immunity, innate
1136400|NCT01422343|blood coagulation
1136401|NCT01422330|Human Immunodeficiency Virus (HIV) infection
1136402|NCT01422330|TMC125IFD3002
1136403|NCT01422330|TMC125
1136404|NCT01422330|Intelence
1136405|NCT01422330|HIV
1136406|NCT01422317|n-3 fatty acids
1136407|NCT01422317|randomized double-blind study
1136408|NCT01422317|coronary events
1136409|NCT01422317|serum lipids
1136410|NCT01422317|antithrombotic effects of omega-3 fatty acids
1136411|NCT01422317|anti-inflammatory effects of omega-3 fatty acids
1136412|NCT01422317|prognostic biomarkers in myocardial infarction (MI)-patients
1136413|NCT01422291|Low back pain
1136414|NCT01422291|paracetamol
1136415|NCT01422291|dexketoprofen
1136416|NCT01422291|morphine
1136417|NCT01422252|Falls Elderly persons
1136418|NCT01422252|Isolated At risk for falls
1136419|NCT01422252|Fall detection device
1136420|NCT01422252|Precocious detection Vigi'Fall®
1136421|NCT01422239|smoking
1136422|NCT01422239|treatment
1136423|NCT01422239|perceived risks
1136424|NCT01422226|IUD
1136425|NCT01422226|contraception
1136426|NCT01422226|nulliparous
1136427|NCT01422226|women
1136428|NCT01422213|MDD
1136429|NCT01422213|Cognitive dysfunction
1136430|NCT01422200|DMD
1136431|NCT01422200|SMA
1136432|NCT01422200|CMD
1136433|NCT01422200|flu vaccine
1136434|NCT01422187|enzyme replacement therapy
1136435|NCT01422174|Primary prevention
1136436|NCT01422174|Latin America
1136437|NCT01422174|Sudden death
1136438|NCT01422174|Myocardial infarction
1136439|NCT01422174|Ejection Fraction
1136440|NCT01422174|ICD
1136441|NCT01422161|Rehabilitation
1136442|NCT01422161|Fingers
1136443|NCT01422161|Grasp
1136444|NCT01422161|Hand
1136445|NCT01422161|Strength
1136446|NCT01422161|Brain Infraction
1136447|NCT01422161|Pathology
1136448|NCT01422161|Physiopathology
1136449|NCT01422161|Functional Laterality
1136450|NCT01422161|Neuronal Plasticity
1136451|NCT01422161|Psychomotor Performance
1136452|NCT01422161|Biomechanics
1136453|NCT01422161|Touch
1136454|NCT01422161|Weight-Bearing
1136455|NCT01422148|cardiac surgery
1136456|NCT01422148|atrial fibrillation
1136457|NCT01422148|minocycline
1136458|NCT01422148|amiodarone
1136459|NCT01422135|PK and safety
1136460|NCT01422135|Pharmacokinetic profile (PK) and safety
1136461|NCT01422122|vitamin D
1136462|NCT01422122|pregnancy
1136463|NCT01422122|periodontal health
1136464|NCT01422122|biomarkers
1136465|NCT01422109|YH14659
1136466|NCT01422109|Aspirin
1136467|NCT01422109|Clopidogrel
1136468|NCT01422109|Yuhan
1136469|NCT01422070|mortality
1136470|NCT01422070|intensive care
1136471|NCT01422070|critical care
1136472|NCT01422070|intermediate care
1136473|NCT01422057|diabetes
1136474|NCT01422057|coronary artery disease
1136475|NCT01422057|ischemic heart disease
1136476|NCT01422057|autonomic function
1136477|NCT01422057|heart rate turbulence
1136478|NCT01422057|deceleration capacity
1136479|NCT01422057|severe autonomic failure
1136480|NCT01422044|aortic stenosis
1136481|NCT01422044|autonomic function
1136482|NCT01422031|Primary care
1136483|NCT01422031|Family doctor
1136484|NCT01422031|Consultation
1136485|NCT01422031|utilization
1136486|NCT01422031|Non-drug managements
1136487|NCT01422031|Patient enablement index
1136488|NCT01422018|clinically significant macular edema
1136489|NCT01422018|diabetic macular edema
1136490|NCT01422018|focal edema
1136491|NCT01422018|focal laser photocoagulation
1136492|NCT01422018|hard exudates
1136493|NCT01422018|intravitreal bevacizumab
1136494|NCT01422005|Rehabilitation
1136495|NCT01422005|Fingers
1136496|NCT01422005|Grasp
1136497|NCT01422005|Hand
1136498|NCT01422005|Strength
1136499|NCT01422005|Brain Infraction
1136500|NCT01422005|Hand Function
1136501|NCT01422005|Post Stroke
1136502|NCT01422005|Neural mechanisms
1136503|NCT01422005|Motor Control
1136504|NCT01422005|Motor Function
1136505|NCT01421992|randomized
1136506|NCT01421992|double-blind
1136507|NCT01421992|crossover
1136508|NCT01421992|methylphenidate
1136509|NCT01421992|excessive daytime sleepiness
1136510|NCT01421966|chronic ulcers
1136511|NCT01421966|diabetic foot ulcers
1136512|NCT01421953|Positron Emission Tomography
1136513|NCT01421953|Computed Tomography
1136514|NCT01421953|Lung cancer
1136515|NCT01421940|Udenafil
1136516|NCT01421940|rectal cancer
1136517|NCT01421940|penile rehabilitation
1136518|NCT01421940|total mesorectal excision
1136519|NCT01421927|lenalidomide
1136520|NCT01421914|Ultrasound
1136521|NCT01421914|Axillary block
1136522|NCT01421914|Bupivacaine
1136523|NCT01421914|Minimum
1136524|NCT01421914|Volume
1136525|NCT01421914|Minimum volume of bupivacaine 0,5%
1136526|NCT01421901|Acute appendicitis
1136527|NCT01421901|Surgery
1136528|NCT01421901|Antibiotics
1136529|NCT01421901|comparison surgery and antibiotics
1136530|NCT01421901|resolutions of symptoms
1136531|NCT01421888|Immunity
1136532|NCT01421888|Urea Cycle Disorder
1136533|NCT01421888|Nutrition
1136534|NCT01421888|Vaccination
1136535|NCT01421888|Influenza
1136536|NCT01421875|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1136537|NCT01421875|adult acute myeloid leukemia with del(5q)
1136538|NCT01421875|adult acute myeloid leukemia with inv(16)(p13;q22)
1136539|NCT01421875|adult acute myeloid leukemia with t(16;16)(p13;q22)
1136540|NCT01421875|adult acute myeloid leukemia with t(8;21)(q22;q22)
1136541|NCT01421875|untreated adult acute myeloid leukemia
1136542|NCT01421875|adult acute myeloblastic leukemia without maturation (M1)
1136543|NCT01421875|adult acute myeloblastic leukemia with maturation (M2)
1136544|NCT01421875|adult acute myelomonocytic leukemia (M4)
1136545|NCT01421875|adult acute monoblastic leukemia (M5a)
1136546|NCT01421875|adult acute monocytic leukemia (M5b)
1136547|NCT01421875|adult erythroleukemia (M6a)
1136548|NCT01421875|adult pure erythroid leukemia (M6b)
1136549|NCT01421875|adult acute megakaryoblastic leukemia (M7)
1136550|NCT01421875|adult acute minimally differentiated myeloid leukemia (M0)
1136551|NCT01421862|adult acute basophilic leukemia
1136552|NCT01421862|adult acute eosinophilic leukemia
1136553|NCT01421862|adult erythroleukemia (M6a)
1136554|NCT01421862|adult pure erythroid leukemia (M6b)
1136555|NCT01421862|adult acute minimally differentiated myeloid leukemia (M0)
1136556|NCT01421862|adult acute monoblastic leukemia (M5a)
1136557|NCT01421862|adult acute monocytic leukemia (M5b)
1136558|NCT01421862|adult acute myeloblastic leukemia with maturation (M2)
1136559|NCT01421862|adult acute myelomonocytic leukemia (M4)
1136560|NCT01421862|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1136561|NCT01421862|adult acute myeloid leukemia with del(5q)
1136562|NCT01421862|adult acute myeloid leukemia with inv(16)(p13;q22)
1136563|NCT01421862|adult acute myeloid leukemia with t(16;16)(p13;q22)
1136564|NCT01421862|adult acute myeloid leukemia with t(8;21)(q22;q22)
1136565|NCT01421862|untreated adult acute myeloid leukemia
1136566|NCT01421862|adult acute myeloblastic leukemia without maturation (M1)
1136567|NCT01421862|adult acute megakaryoblastic leukemia (M7)
1136568|NCT01421849|single implant denture
1136569|NCT01421849|Elderly with an unstable mandibular denture
1136570|NCT01421836|stent patency
1136571|NCT01421836|EUS guided insertion
1136572|NCT01421836|ERCP guided insertion
1136573|NCT01421823|Fecal Incontinence
1136574|NCT01421823|Alpha agonist
1136575|NCT01421732|Dengue fever
1136576|NCT01421732|severe dengue fever
1136577|NCT01421732|NS1 detection assay
1136578|NCT01421732|Prognosis
1136579|NCT01421732|Diagnosis
1136580|NCT01421719|Parkinson's Disease
1136581|NCT01421719|Neurogenic Bladder
1136582|NCT01421719|Urinary Incontinence
1136583|NCT01421719|botulinum toxin
1136584|NCT01421719|cystoscopy
1136585|NCT01421719|Effect of Other Parasympatholytics [Anticholinergics and Antimuscarinics] and Spasmolytics
1136586|NCT01421706|clarithromycin
1136587|NCT01421706|sibutramine
1136588|NCT01421706|clopidogrel
1136589|NCT01421693|Gatifloxacin
1136590|NCT01421693|Ceftriaxone
1136591|NCT01421693|Enteric fever
1136592|NCT01421693|Typhoid fever
1136593|NCT01421667|Lymphoma, Large B-Cell, Diffuse
1136594|NCT01421667|Antigens, CD30
1136595|NCT01421667|Antibody-Drug Conjugate
1136596|NCT01421667|Antibodies, Monoclonal
1136597|NCT01421667|Lymphoma, Non-Hodgkin
1136598|NCT01421667|Monomethyl auristatin E
1136599|NCT01421667|Drug Therapy
1136600|NCT01421667|Immunotherapy
1136601|NCT01421667|Hematologic Diseases
1136602|NCT01421667|Lymphoma
1136603|NCT01421667|Lymphoma, B-Cell
1136604|NCT01421667|Lymphoma, T-Cell
1136605|NCT01421654|OSA
1136606|NCT01421654|Sleep Apnea
1136607|NCT01421654|PAP
1136608|NCT01421654|positive airway pressure
1136609|NCT01421641|Tenaculum
1136610|NCT01421641|Pain
1136611|NCT01421641|Lidocaine
1136612|NCT01421628|older adults
1136613|NCT01421628|exercise
1136614|NCT01421628|stretching
1136615|NCT01421628|mobility
1136616|NCT01421615|Bacterial vaginosis
1136617|NCT01421615|Probiotics
1136618|NCT01421615|Lactobacilli
1136619|NCT01421615|Pregnancy outcome
1136620|NCT01421615|Randomized controlled trial
1136621|NCT01421602|Inguinal Hernia
1136622|NCT01421602|Self-fixating mesh
1136623|NCT01421602|Progrip
1136624|NCT01421602|Hernia Recurrence
1136625|NCT01421602|Mesh, Surgical
1136626|NCT01421602|Recurrence
1136627|NCT01421589|Growth hormone
1136628|NCT01421589|GH
1136629|NCT01421589|Obesity
1136630|NCT01421589|Mitochondrial function
1136631|NCT01421589|reduced growth hormone secretion
1136632|NCT01421550|umbilical
1136633|NCT01421550|hernia
1136634|NCT01421550|cirrhosis
1136635|NCT01421550|ascites
1136636|NCT01421550|conservative
1136637|NCT01421550|surgery
1136638|NCT01421550|optimal management
1136639|NCT01421537|Thromboprophylaxis
1136640|NCT01421537|enoxaparin
1136654|NCT01421511|ABSSSI
1136655|NCT01421511|Tedizolid Phosphate
1136656|NCT01421511|TR-701
1136657|NCT01421511|Acute Bacterial Skin and Skin Structure Infections
1136658|NCT01421498|Dry Eye
1136659|NCT01421498|ophthalmic delivery
1136660|NCT01421472|Breast Cancer
1136661|NCT01421472|Neoadjuvant
1136662|NCT01421472|Her2 negative
1136663|NCT01421472|Her2 non-overexpressing
1136664|NCT01421472|Estrogen Receptor Positive
1136665|NCT01421472|Triple Negative
1136666|NCT01421472|MM-121
1136667|NCT01421472|Paclitaxel
1136668|NCT01421459|Diabetes
1136669|NCT01421459|Type 2 Diabetes
1136670|NCT01421446|Neuropsychology
1136671|NCT01421433|Clonixin
1136672|NCT01421433|Anti-Inflammatory Agents, Non-Steroidal
1136673|NCT01421433|Cyclooxygenase Inhibitors
1136674|NCT01421433|Lysine
1136675|NCT01421433|L-Lysine
1136676|NCT01421433|Lysine Acetate
1136677|NCT01421433|Lysine Hydrochloride
1136678|NCT01421433|Amitriptyline
1136679|NCT01421420|Alzheimer's
1136680|NCT01421420|Dementia
1136681|NCT01421420|Mild Cognitive Impairment
1136682|NCT01421407|Secondary hyperparathyroidism
1136683|NCT01421407|End stage renal disease
1136684|NCT01421407|Parathyroid hyperplasia
1136685|NCT01421407|High Intensity Focused Ultrasound
1136686|NCT01421394|spinal cord injury(SCI)
1136687|NCT01421394|diffusion tensor imaging(DTI)
1136688|NCT01421394|tractography
1136689|NCT01421381|leber's hereditary optic neuropathy
1136690|NCT01421381|idebenone
1136691|NCT01421342|Mood Disorder
1136692|NCT01421342|Depression
1136693|NCT01421342|Depressive Disorder
1136694|NCT01421342|Depressive Disorder, Major
1136695|NCT01421342|Bupropion
1136696|NCT01421342|Aripiprazole
1136697|NCT01421342|Remission
1136698|NCT01421342|Relapse
1136699|NCT01421342|Cost-Effectiveness
1136700|NCT01421342|Atypical Antipsychotic
1136701|NCT01421342|Antidepressant
1136702|NCT01421342|Augmentation
1136703|NCT01421342|Veterans
1136704|NCT01421342|Mental Health
1136705|NCT01421329|Interest in Exercising More
1136706|NCT01421316|Patients treated with whole brain radiotherapy in the setting of brain metastases
1136707|NCT01421316|Patients treated with whole brain radiotherapy in the prophylactic treatment for small cell lung cancer (extended disease).
1136708|NCT01421290|Cartilage lesions in the knee joint
1136709|NCT01421264|concussion
1136710|NCT01421264|gabapentin
1136711|NCT01421264|neurontin
1136712|NCT01421264|insomnia
1136713|NCT01421251|H1N1
1136714|NCT01421251|Flu
1136715|NCT01421251|Influenza
1136716|NCT01421251|Vaccine
1136717|NCT01421251|Manitoba
1136718|NCT01421251|Canada
1136719|NCT01421251|Safety
1136720|NCT01421238|Decision Making
1136721|NCT01421238|Premature infant
1136722|NCT01421238|Informed consent
1136723|NCT01421238|Prematurity
1136724|NCT01421238|Framing
1136725|NCT01421238|Negotiation Model
1136726|NCT01421225|Closed Loop Insulin Delivery
1136727|NCT01421225|Diabetes
1136728|NCT01421225|Type 1 Diabetes
1136729|NCT01421225|Artificial pancreas
1136730|NCT01421212|Liver Transplantation
1136731|NCT01421212|Liver Disease
1136732|NCT01421212|Hepatitis B
1136733|NCT01421212|Hepatitis B Infection
1136734|NCT01421212|Hepatitis B Associated Liver Disease
1136735|NCT01421212|HBV
1136736|NCT01421199|Otitis Media with Effusion
1136737|NCT01421199|Middle Ear Effusion
1136738|NCT01421186|Multiple Myeloma
1136739|NCT01421186|MOR03087 (MOR202)
1136740|NCT01421186|Lenalidomide
1136741|NCT01421186|Pomalidomide
1136742|NCT01421186|CD38
1136743|NCT01421173|Lymphoma
1136744|NCT01421173|Lymphoid malignancies
1136745|NCT01421173|Relapsed
1136746|NCT01421173|Refractory
1136747|NCT01421173|Autologous hematopoietic cell support
1136748|NCT01421173|Stem cell infusion
1136749|NCT01421173|Hodgkin's lymphoma
1136750|NCT01421173|non-Hodgkin's lymphoma
1136751|NCT01421173|Vorinostat
1136752|NCT01421173|SAHA
1136753|NCT01421173|Suberoylanilide Hydroxamic Acid
1136754|NCT01421173|MSK-390
1136755|NCT01421173|Zolinza
1136756|NCT01421173|Busulfan
1136757|NCT01421173|Busulfex
1136758|NCT01421173|Myleran
1136759|NCT01421173|Gemcitabine
1136760|NCT01421173|Gemcitabine Hydrochloride
1136761|NCT01421173|Gemzar
1136762|NCT01421173|Melphalan
1136763|NCT01421173|Alkeran
1136764|NCT01421173|Rituximab
1136765|NCT01421173|Rituxan
1136766|NCT01421173|Dexamethasone
1136767|NCT01421173|Decadron
1136768|NCT01421173|G-CSF
1136769|NCT01421173|Filgrastim
1136770|NCT01421173|NeupogenTM
1136771|NCT01421173|Palifermin
1136772|NCT01421173|Kepivance
1136773|NCT01421160|Chronic
1136774|NCT01421160|Inflammatory
1136775|NCT01421160|Joint
1136776|NCT01421160|Pain
1136777|NCT01421147|Diabetes
1136778|NCT01421147|Type 1 Diabetes
1136779|NCT01421147|Diabetes Mellitus
1136780|NCT01421134|depression
1136781|NCT01421134|Lurasidone
1136782|NCT01421134|Latuda
1136783|NCT01421108|oral health
1136784|NCT01421108|dental brushing
1136785|NCT01421108|dental flossing
1136786|NCT01421095|Fertility
1136787|NCT01421095|adolescent
1136788|NCT01421095|young adult
1136789|NCT01421095|cancer survivors
1136790|NCT01421082|LVRS (Lung Volume Reduction Surgery)
1136791|NCT01421082|LVRC (Lung Volume Reduction Coil)
1136792|NCT01421082|Emphysema
1136793|NCT01421082|coil
1136794|NCT01421082|RePneu
1136795|NCT01421069|Use of etanercept to treat pediatric subjects with extended oligoarticular JIA
1136796|NCT01421069|enthestitis related arthritis (ERA)
1136797|NCT01421069|or psoriatic arthritis (PsA).
1136798|NCT01421043|bioequivalence study
1136799|NCT01421043|triazolam
1136800|NCT01421043|liquid oral drops
1136801|NCT01421043|tablet
1136802|NCT01421030|quality of life
1136803|NCT01421030|congenital heart disease
1136804|NCT01421030|open heart surgery
1136805|NCT01421030|percutaneous pulmonary valve implantation
1136806|NCT01421030|costs
1136807|NCT01421017|radiation therapy
1136808|NCT01421017|combination therapy
1136809|NCT01421017|immunotherapy
1136810|NCT01421017|immune response modifier
1136811|NCT01421017|immunostimulatory
1136812|NCT01421017|immunomodulator
1136813|NCT01421004|cancer
1136814|NCT01421004|tumors
1136815|NCT01421004|phase I
1136816|NCT01421004|crossover
1136817|NCT01421004|bioequivalence
1136818|NCT01420965|Anti PD-1 Monoclonal Antibody
1136819|NCT01420965|Vaccine
1136820|NCT01420965|Autologous Cellular Immunotherapy
1136821|NCT01420965|Prostate Cancer
1136822|NCT01420952|Positron Emission Tomograhy (PET)
1136823|NCT01420952|Metabolic Glutamate Receptors
1136824|NCT01420952|Brain
1136825|NCT01420939|TBI
1136826|NCT01420939|Brain
1136827|NCT01420939|Traumatic Brain Injury
1136828|NCT01420939|Biomarkers
1136829|NCT01420939|Healthy Volunteer
1136830|NCT01420939|HV
1136831|NCT01420913|To evaluate the pharmacokinetic characteristics of Lyrica, YHD1119 A,B,C
1136832|NCT01420887|CPM
1136833|NCT01420887|elbow joint surgery
1136834|NCT01420887|continuous passive motion
1136835|NCT01420887|Recovery after surgery to restore elbow motion
1136836|NCT01420861|castrate resistant
1136837|NCT01420848|stress disorders
1136838|NCT01420848|anxiety disorders
1136839|NCT01420835|Stress
1136840|NCT01420835|Quality of life
1136841|NCT01420796|Parkinson's disease
1136842|NCT01420796|dysphagia
1136843|NCT01420796|swallowing treatment
1136844|NCT01420757|operation time
1136845|NCT01420757|length of hospital stay
1136846|NCT01420744|Endotracheal ventilation
1136847|NCT01420744|Bacterial pneumonia
1136848|NCT01420731|sexual life, back pain
1136849|NCT01420718|partial pulpotomy
1136850|NCT01420718|Cvek pulpotomy
1136851|NCT01420718|MTA
1136852|NCT01420718|iRootBP
1136853|NCT01420718|dentin bridge
1136854|NCT01420705|Bacille Calmette-Guérin
1136855|NCT01420705|DTP
1136856|NCT01420705|Vaccination
1136857|NCT01420705|Allergy
1136858|NCT01420705|Atopy
1136859|NCT01420705|Guinea-Bissau
1136860|NCT01420692|Tip 2 DM
1136861|NCT01420692|Endothelium
1136862|NCT01420692|Gliclazide
1136863|NCT01420692|Insulin detemir
1136864|NCT01420679|Lymphoproliferative Disorders
1136865|NCT01420679|Lymphoma
1136866|NCT01420679|Non-Hodgkin's Lymphoma
1136867|NCT01420679|T-cell Lymphoma
1136868|NCT01420640|Fibromyalgia
1136869|NCT01420640|Tai Chi
1136870|NCT01420640|mind-body exercise
1136871|NCT01420640|aerobic exercise
1136872|NCT01420640|exercise
1136873|NCT01420640|pain
1136874|NCT01420614|radial access
1136875|NCT01420614|primary angioplasty
1136876|NCT01420614|trial
1136877|NCT01420614|randomization
1136878|NCT01420614|outcome
1136879|NCT01420601|Torisel
1136880|NCT01420601|Long-term use
1136881|NCT01420601|Regulatory Post Marketing Commitment Plan
1136882|NCT01420588|Oncologic Investigations
1136883|NCT01420588|Gastric Diseases
1136884|NCT01420588|Gastric Cancer
1136885|NCT01420588|Gastric Ulcer
1136886|NCT01420588|Breath Analysis
1136887|NCT01420588|Volatile Biomarkers
1136888|NCT01420588|Nanosensors Array
1136889|NCT01420588|Discriminant Factor Analysis
1136890|NCT01420588|GC-MS
1136891|NCT01420588|Breath Tests
1136892|NCT01420575|Schizophrenia
1136893|NCT01420575|Schizoaffective Disorder
1136894|NCT01420575|Shared Decision
1136895|NCT01420575|Decision Aid
1136896|NCT01420575|Antipsychotic
1136897|NCT01420575|Weight Gain
1136898|NCT01420575|Olanzapine
1136899|NCT01420575|Lexapro
1136900|NCT01420575|Perphenazine
1136901|NCT01420562|allogeneic HSCT
1136902|NCT01420562|posaconazole
1136903|NCT01420562|prophylaxis
1136904|NCT01420562|mucositis
1136905|NCT01420562|pharmacokinetics
1136906|NCT01420549|Hypercholesterolemia
1136907|NCT01420549|Dyslipidemia
1136908|NCT01420536|Bilateral Balanced Occlusion
1136909|NCT01420536|Canine Guidance
1136910|NCT01420536|Complete Denture
1136911|NCT01420536|Denture Retention
1136912|NCT01420536|Dental Occlusion
1136913|NCT01420536|Edentulous
1136914|NCT01420536|Edentulism
1136915|NCT01420536|Mandibular movement
1136916|NCT01420536|Mastication
1136917|NCT01420536|Patient Acceptance of Health Care
1136918|NCT01420536|Patient Satisfaction
1136919|NCT01420523|HIV
1136920|NCT01420523|Lipohypertrophy
1136921|NCT01420510|Patients satisfaction
1136922|NCT01420510|Side effects
1136923|NCT01420497|methylprednisolone
1136924|NCT01420497|intra articular infiltration
1136925|NCT01420497|glycemia
1136926|NCT01420497|epidural infiltration
1136927|NCT01420497|diabetes
1136928|NCT01420484|CNAP
1136929|NCT01420484|continuous non-invasive arterial pressure
1136930|NCT01420484|IAP
1136931|NCT01420484|blood pressure
1136932|NCT01420484|analgosedation
1136933|NCT01420484|high-risk patients
1136934|NCT01420484|rapid-pacing
1136935|NCT01420471|Endoscopic Sinus Surgery
1136936|NCT01420471|Triamcinolone
1136937|NCT01420471|Merocel Middle Meatus Spacers
1136938|NCT01420458|bioequivalence
1136939|NCT01420432|Ankylosing Spondylitis
1136940|NCT01420432|Umbilical Cord/placenta-Derived MSC
1136941|NCT01420432|Transplantation
1136942|NCT01420419|nipple pain
1136943|NCT01420419|breastfeeding
1136944|NCT01420419|nipple damage
1136945|NCT01420419|lanolin
1136946|NCT01420419|clinical trial
1136947|NCT01420406|lactation
1136948|NCT01420406|cryptoxanthin
1136949|NCT01420406|beta-carotene
1136950|NCT01420406|vitamin A
1136956|NCT01420367|Paediatric
1136957|NCT01420367|Simple
1136958|NCT01420367|Non-perforated
1136959|NCT01420354|Metabolic stones
1136960|NCT01420354|kidney stones
1136961|NCT01420354|renal calculi
1136962|NCT01420354|metabolic evaluation
1136963|NCT01420341|Meliodosis
1136964|NCT01420341|Co-trimoxazole
1136965|NCT01420341|Relapse
1136966|NCT01420315|vitamin D
1136967|NCT01420315|deficiency
1136968|NCT01420315|alzheimer's disease
1136969|NCT01420302|critical illness
1136970|NCT01420302|intensive care
1136971|NCT01420302|insulin
1136972|NCT01420302|glucose
1136973|NCT01420302|algorithm
1136974|NCT01420302|blood glucose control
1136975|NCT01420289|Ischemic ulcers
1136976|NCT01420289|PAD
1136977|NCT01420289|Intermittent Claudication Pain
1136978|NCT01420276|Female sexual function
1136979|NCT01420263|premature infant
1136980|NCT01420263|feeding
1136981|NCT01420263|residuals
1136982|NCT01420263|fresh feeds
1136983|NCT01420263|full feeds
1136984|NCT01420263|digestive system
1136985|NCT01420250|Prostate cancer
1136986|NCT01420250|Adenocarcinoma of the prostate
1136988|NCT01420224|Air travel
1136989|NCT01420224|Aircraft cabin hypoxia
1136990|NCT01420224|Pulmonary artery pressure
1136991|NCT01420224|Hypoxic pulmonary vasoconstriction
1136992|NCT01420224|Pulmonary hypertension
1136993|NCT01420211|pharmacokinetics
1136994|NCT01420211|MRI
1136995|NCT01420211|liver
1136996|NCT01420211|drug transporter
1136997|NCT01420211|Gd-EOB-DTPA
1136998|NCT01420198|Diabetes type 2
1136999|NCT01420198|Lifestyle intervention
1137000|NCT01420198|QALY
1137001|NCT01420198|Ethnic group
1137002|NCT01420198|Impaired glucose tolerance
1137003|NCT01420198|Impaired fasting glucose
1137004|NCT01420185|estrogen receptor-positive breast cancer
1137005|NCT01420185|stage II breast cancer
1137006|NCT01420185|stage IIIA breast cancer
1137007|NCT01420159|Pain
1137008|NCT01420159|Trauma
1137009|NCT01420159|Analgesia
1137010|NCT01420133|Corticosteroids
1137011|NCT01420133|Diet low in sugar and salt
1137012|NCT01420133|Dermatological disease
1137013|NCT01420133|Corticosteroids Allergy
1137014|NCT01420133|3 Months
1137015|NCT01420120|Biodegradable stent, PAD
1137016|NCT01420107|Infant, Premature
1137017|NCT01420107|Delivery Rooms
1137018|NCT01420107|Video Recording
1137019|NCT01420107|Outcome Assessment (Health Care)
1137020|NCT01420094|Drugs, Investigational
1137021|NCT01420094|Acetylsalicylic Acid
1137022|NCT01420094|Aspirin
1137023|NCT01420094|dental pain
1137024|NCT01420081|uterine neoplasms
1137025|NCT01420081|endometrial
1137026|NCT01420081|uterine
1137027|NCT01420081|cancer
1137028|NCT01420081|PI3K
1137029|NCT01420081|mTOR
1137030|NCT01420081|PI3K/mTOR
1137031|NCT01420081|recurrent
1137032|NCT01420081|metastatic
1137033|NCT01420068|Pediatric
1137034|NCT01420068|hypertension
1137035|NCT01420068|aliskiren
1137036|NCT01420055|Multiple sclerosis
1137037|NCT01420055|Fingolimod
1137038|NCT01420055|Coping
1137039|NCT01420055|Anxiety
1137040|NCT01420055|France
1137041|NCT01420055|Treatment Satisfaction Questionnaire for Medication-9 items (TSQM 9)
1137042|NCT01420055|Active
1137043|NCT01420029|Low birth weight neonates
1137044|NCT01420029|Neurodevelopmental outcome
1137045|NCT01420029|Thyroid dysfunction
1137046|NCT01420029|Extrauterine growth
1137047|NCT01420029|Plasticizers
1137048|NCT01420016|Cardiovascular risk
1137049|NCT01420003|Allergen Challenge
1137050|NCT01420003|B cell activation
1137051|NCT01420003|M1 prime related biomarkers
1137052|NCT01419977|sickle cell disease
1137053|NCT01419977|vaso-occlusive crisis
1137054|NCT01419977|anticoagulation
1137055|NCT01419964|Vitiligo
1137056|NCT01419964|Macular depigmentation
1137057|NCT01419964|Stachytarpheta cayensensis
1137058|NCT01419951|Behavioral treatment
1137059|NCT01419951|Preschool aged children
1137060|NCT01419951|Obesity
1137061|NCT01419938|Light therapy
1137062|NCT01419938|circadian rhythm
1137063|NCT01419938|CBT
1137064|NCT01419925|influenza vaccine
1137065|NCT01419925|peptide
1137066|NCT01419925|universal
1137067|NCT01419925|prime
1137068|NCT01419925|boost
1137069|NCT01419925|TIV
1137070|NCT01419925|HAI
1137071|NCT01419925|Hemagglutination Inhibition
1137072|NCT01419925|elderly
1137073|NCT01419899|Brief intervention
1137074|NCT01419899|Rapid testing
1137075|NCT01419873|Hyperglycaemia
1137076|NCT01419873|Very low birthweight infants
1137077|NCT01419873|Insulin
1137078|NCT01419860|Microcirculation
1137079|NCT01419860|Colon
1137080|NCT01419860|Anastomosis
1137081|NCT01419860|ICG
1137082|NCT01419860|Gastro surgery
1137083|NCT01419860|benign colon diseases requiring resection
1137084|NCT01419834|CNS
1137085|NCT01419834|Brain
1137086|NCT01419834|MAB 3F8
1137087|NCT01419834|Hu3F8
1137088|NCT01419834|11-009
1137089|NCT01419821|Vitamin D
1137090|NCT01419821|Bone densitometry
1137091|NCT01419821|Vitamin D supplementation
1137092|NCT01419821|Growth
1137093|NCT01419808|Scaphoid
1137094|NCT01419808|Non-Union
1137095|NCT01419808|Proximal pole
1137096|NCT01419808|Bone Graft
1137097|NCT01419808|Vascularized
1137098|NCT01419808|Non-Vascularized
1137099|NCT01419808|PREE
1137100|NCT01419782|bone
1137101|NCT01419782|osteocyte
1137102|NCT01419782|rest muscle electrical activity
1137103|NCT01419782|whole-body vibration
1137104|NCT01419782|sclerostin
1137105|NCT01419769|symptomatic pancreatic pseudocyst
1137106|NCT01419769|pancreatic pseudocyst
1137107|NCT01419769|transluminal drainage
1137108|NCT01419769|minimally invasive
1137109|NCT01419769|Nitinol stent
1137110|NCT01419769|transmural endoscopic drainage
1137111|NCT01419769|catheter based
1137112|NCT01419743|Vitamin D deficiency
1137113|NCT01419743|Supplementation
1137114|NCT01419743|Infertility
1137115|NCT01419743|Clinical pregnancy rates
1137116|NCT01419717|cancer
1137117|NCT01419717|bone metastases
1137118|NCT01419717|breast cancer
1137119|NCT01419717|prostate cancer
1137120|NCT01419704|other hemoglobinopathies
1137121|NCT01419704|chimerism
1137122|NCT01419704|sickle cell
1137123|NCT01419704|thalassemia
1137124|NCT01419704|Marrow/Enriched Hematopoetic Stem Cell Transplant
1137125|NCT01419691|auranofin
1137126|NCT01419691|chronic lymphocytic leukemia
1137127|NCT01419691|relapsed
1137128|NCT01419691|refractory
1137129|NCT01419691|CLL
1137130|NCT01419691|SLL
1137131|NCT01419691|PLL
1137132|NCT01419678|posaconazole
1137133|NCT01419678|PK blood sampling
1137134|NCT01419665|Follicular Lymphoma
1137135|NCT01419665|Biosimilar
1137136|NCT01419665|GP13-301
1137137|NCT01419665|rituximab
1137138|NCT01419665|Antibodies
1137139|NCT01419665|CD20
1137140|NCT01419652|percutaneous coronary intervention
1137141|NCT01419639|Neurofibromatosis Type II
1137142|NCT01419639|cranial nerve schwannomas
1137143|NCT01419639|meningiomas
1137144|NCT01419639|ependymomas
1137145|NCT01419613|healthy lifestyle
1137146|NCT01419613|physical activity
1137147|NCT01419613|behavior
1137148|NCT01419613|motivational
1137149|NCT01419613|interview
1137150|NCT01419613|breast cancer survivor
1137151|NCT01419600|Phase 1
1137152|NCT01419600|healthy volunteers
1137153|NCT01419600|safety
1137154|NCT01419600|tolerability
1137155|NCT01419600|pharmacokinetics
1137156|NCT01419600|single ascending dose study
1137157|NCT01419587|Carcinoma, Non-Small-Cell Lung
1137158|NCT01419587|Non small cell lung cancer
1137159|NCT01419587|NSCLC
1137160|NCT01419587|Ketogenic Diet
1137161|NCT01419587|radiotherapy
1137162|NCT01419587|paclitaxel
1137163|NCT01419587|carboplatin
1137164|NCT01419574|Carotid Artery Plaque
1137165|NCT01419574|Contrast Agents
1137166|NCT01419574|Vasa Vasorum
1137167|NCT01419574|MRI
1137168|NCT01419574|Intraplaque Hemorrhage
1137169|NCT01419574|Solid Tumor
1137170|NCT01419574|Metastatic Solid Tumor
1137171|NCT01419561|KSHV
1137172|NCT01419561|KICS
1137173|NCT01419561|HIV
1137174|NCT01419561|Cytokines
1137175|NCT01419561|HHV-8
1137176|NCT01419561|KSHV Inflammatory Cytokine Syndrome
1137295|NCT01419119|Parathyroid Hormone
1137177|NCT01419561|Kaposi Sarcoma Heres Virus
1137178|NCT01419548|ABT-888
1137179|NCT01419548|Liver Dysfunction
1137180|NCT01419548|Kidney Dysfunction
1137181|NCT01419548|PARP Inhibitor
1137182|NCT01419548|Pharmacokinetics
1137183|NCT01419548|Cancer
1137184|NCT01419535|Metabolism
1137185|NCT01419535|Cortisol
1137186|NCT01419535|Hypercortisolism
1137187|NCT01419535|Glucose Intolerance
1137188|NCT01419522|Traumatic Brain Injury
1137189|NCT01419522|Walking Impairment
1137190|NCT01419522|Gait Training
1137191|NCT01419522|TBI
1137192|NCT01419509|alveolar childhood rhabdomyosarcoma
1137193|NCT01419509|embryonal childhood rhabdomyosarcoma
1137194|NCT01419509|embryonal-botryoid childhood rhabdomyosarcoma
1137195|NCT01419509|mixed childhood rhabdomyosarcoma
1137196|NCT01419509|pleomorphic childhood rhabdomyosarcoma
1137197|NCT01419509|previously untreated childhood rhabdomyosarcoma
1137198|NCT01419509|nonmetastatic childhood soft tissue sarcoma
1137199|NCT01419496|recurrent adult acute myeloid leukemia
1137200|NCT01419496|recurrent childhood acute myeloid leukemia
1137201|NCT01419496|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1137202|NCT01419496|adult acute myeloid leukemia with inv(16)(p13;q22)
1137203|NCT01419496|adult acute myeloid leukemia with t(15;17)(q22;q12)
1137204|NCT01419496|adult acute myeloid leukemia with t(16;16)(p13;q22)
1137205|NCT01419496|adult acute myeloid leukemia with t(8;21)(q22;q22)
1137206|NCT01419496|adult acute myeloid leukemia with del(5q)
1137207|NCT01419483|Pancreatic neoplasms
1137208|NCT01419483|Pancreatic cancer
1137209|NCT01419483|Ketogenic Diet
1137210|NCT01419483|radiotherapy
1137211|NCT01419483|gemcitabine
1137212|NCT01419457|Healthy
1137213|NCT01419457|hepatic impairment
1137214|NCT01419457|T-705a
1137215|NCT01419457|Favipiravir
1137216|NCT01419444|Voice
1137217|NCT01419444|Muscle Tension Dysphonia
1137218|NCT01419444|Hyperfunction
1137219|NCT01419444|Treatment
1137220|NCT01419431|Colon cancer
1137221|NCT01419418|Peripheral Arterial Disease (PAD)
1137222|NCT01419418|Qualitative analysis
1137223|NCT01419418|Patients' perspective
1137224|NCT01419405|analgesia
1137225|NCT01419405|acute experimental pain
1137226|NCT01419405|cold pressor test
1137227|NCT01419405|pregabalin
1137228|NCT01419405|remifentanil
1137229|NCT01419392|sildenafil citrate
1137230|NCT01419392|Doppler Ultrasonography
1137231|NCT01419392|nitric oxide
1137232|NCT01419392|total antioxidant capacity
1137233|NCT01419379|COPD exacerbation rate
1137234|NCT01419353|Infertility, IVF, Estrogen
1137235|NCT01419327|Fosrenol
1137236|NCT01419327|Hyperphosphatemia
1137237|NCT01419327|Hemodialysis
1137238|NCT01419314|Physical Therapy
1137239|NCT01419314|Splint
1137240|NCT01419314|Sleep
1137241|NCT01419314|Pain
1137242|NCT01419314|6 min walk
1137243|NCT01419314|forward reach
1137244|NCT01419314|Function
1137245|NCT01419301|multiple sclerosis
1137246|NCT01419301|glatiramer acetate
1137247|NCT01419301|stress reduction
1137248|NCT01419301|medication adherence
1137249|NCT01419288|Amputees
1137250|NCT01419262|Vitamin D
1137251|NCT01419262|Randomized Controlled Trial
1137252|NCT01419262|Child, Preschool
1137253|NCT01419262|Dietary Supplements
1137254|NCT01419262|Respiratory Tract Infections
1137255|NCT01419262|Asthma
1137256|NCT01419249|Growth Hormone Deficiency
1137257|NCT01419249|Turner syndrome
1137258|NCT01419249|Pharmacogenetics
1137259|NCT01419249|Recombinant Human Growth Hormone therapy
1137260|NCT01419236|Ejaculatory Dysfunction
1137261|NCT01419236|Orgasmic Dysfunction
1137262|NCT01419236|Sexual Dysfunction
1137263|NCT01419236|Climax Dysfunction
1137264|NCT01419236|Erectile Dysfunction
1137265|NCT01419236|Impotence
1137266|NCT01419236|Hypogonadism
1137267|NCT01419236|Low testosterone
1137268|NCT01419236|Low t
1137269|NCT01419223|Qualitative research
1137270|NCT01419223|Health Knowledge, Attitudes, Practice
1137271|NCT01419223|Refusal to Participate
1137272|NCT01419210|Complementary Medicine
1137273|NCT01419210|Traditional Medicine
1137274|NCT01419184|Complicated Skin and Skin Structure Infections (cSSSI)
1137275|NCT01419184|Methicillin-resistant Staphylococcus aureus (MRSA)
1137276|NCT01419184|Daptomycin
1137277|NCT01419184|Vancomycin
1137278|NCT01419184|Antibiotics
1137279|NCT01419158|Alpha-1 antitrypsin
1137280|NCT01419158|Alpha-1 antitrypsin deficiency
1137281|NCT01419158|Chronic obstructive pulmonary disease
1137282|NCT01419145|cachexia
1137283|NCT01419145|neoplasms
1137284|NCT01419145|complications
1137285|NCT01419145|combined modality therapy
1137286|NCT01419145|exercise therapy
1137287|NCT01419145|diet therapy
1137288|NCT01419145|anti-inflammatory agents
1137289|NCT01419132|furosemide
1137290|NCT01419132|hypertonic saline solution
1137291|NCT01419132|troponin I
1137292|NCT01419119|vitamin D insufficiency
1137293|NCT01419119|Cholecalciferol
1137294|NCT01419119|D3
1137296|NCT01419119|25-hydroxyvitamin D3
1137297|NCT01419119|RDA, recommended daily intake (nutrition policy)
1137298|NCT01419119|Vitamin D
1137299|NCT01419119|Hypovitaminosis-D
1137300|NCT01419119|Pharmacologic treatment
1137301|NCT01419106|Hypotension
1137302|NCT01419106|Emergency care
1137303|NCT01419106|Point of care Ultrasound
1137304|NCT01419106|Shock
1137305|NCT01419093|Physical Activity
1137306|NCT01419093|Exercise
1137307|NCT01419080|Peripheral Arterial Disease
1137308|NCT01419080|Quality of Life
1137309|NCT01419080|Quality of Care
1137310|NCT01419067|Proton Therapy
1137311|NCT01419067|Radical resection
1137312|NCT01419041|renal impairment
1137313|NCT01419041|crizotinib
1137314|NCT01419041|pharmacokinetics
1137315|NCT01419028|Hypophosphatasia
1137316|NCT01419028|HPP
1137317|NCT01419028|Bone disease
1137318|NCT01419028|Soft bones
1137319|NCT01419028|Low alkaline phosphatase
1137320|NCT01419028|Genetic metabolic disorder
1137321|NCT01419028|Alkaline phosphatase
1137322|NCT01419028|Tissue non-specific alkaline phosphatase
1137323|NCT01419028|Rickets
1137324|NCT01419028|Osteomalacia
1137325|NCT01419015|SAPIEN XT Valve (20mm)
1137326|NCT01419015|Cardiovascular Disease
1137327|NCT01419015|Valvular Heart Disease
1137328|NCT01419015|Aortic Stenosis
1137329|NCT01419015|Heart Valve Therapy
1137330|NCT01419015|Transcatheter
1137331|NCT01419015|Transfemoral
1137332|NCT01419015|Efficacy endpoints
1137333|NCT01419015|Indexed Aortic Valve Area
1137334|NCT01419015|NYHA
1137335|NCT01419002|Pancreatic Cancer
1137336|NCT01419002|Adenocarcinoma
1137337|NCT01419002|Neoadjuvant Radiotherapy
1137338|NCT01418976|physical therapy techniques
1137339|NCT01418976|brain injuries, traumatic
1137340|NCT01418976|walking
1137341|NCT01418976|gait
1137342|NCT01418976|postural balance
1137343|NCT01418950|Prematurity Counseling for pregnant women and their family
1137344|NCT01418937|HPV vaccine
1137345|NCT01418937|serious adverse events (SAEs)
1137346|NCT01418937|medically significant conditions
1137347|NCT01418937|cervical neoplasia
1137348|NCT01418924|sclerostin
1137349|NCT01418924|estradiol
1137350|NCT01418924|progesterone
1137351|NCT01418924|testosteron
1137352|NCT01418924|sex hormones
1137353|NCT01418898|Iron deficiency anemia
1137354|NCT01418898|iron
1137355|NCT01418898|zinc
1137356|NCT01418898|vitamin A
1137357|NCT01418898|vitamin C
1137358|NCT01418898|oats
1137359|NCT01418885|subcortical ischemic vascular disease
1137360|NCT01418872|Obesity
1137361|NCT01418872|Cardiovascular Diseases Prevention
1137362|NCT01418872|Paediatrics
1137363|NCT01418859|cervical cancer
1137364|NCT01418859|postoperation
1137365|NCT01418859|chemotherapy
1137366|NCT01418859|radiotherapy
1137367|NCT01418846|voriconazole
1137368|NCT01418846|saliva
1137369|NCT01418846|pharmacokinetics
1137370|NCT01418833|voriconazole
1137371|NCT01418833|therapeutic drug monitoring
1137372|NCT01418833|plasma levels
1137373|NCT01418833|dose adjustment
1137374|NCT01418820|hemianopia
1137375|NCT01418820|visual field defect
1137376|NCT01418820|stroke
1137377|NCT01418820|non-invasive brain stimulation
1137378|NCT01418820|alternating current stimulation
1137379|NCT01418794|Acute Coronary Syndromes
1137380|NCT01418794|Drug eluting stent
1137381|NCT01418794|Diffused lesion
1137382|NCT01418781|gout
1137383|NCT01418781|cost
1137384|NCT01418781|utilization
1137385|NCT01418768|COPD
1137386|NCT01418768|CAT
1137387|NCT01418768|Rehabilitation
1137388|NCT01418768|chronic obstructive pulmonary disease GOLD III/IV
1137389|NCT01418755|Platelet-Rich Plasma
1137390|NCT01418755|Knee
1137391|NCT01418755|Tibiofemoral Chondromalacia
1137392|NCT01418755|Injection
1137393|NCT01418742|skin toxicity
1137394|NCT01418716|Disease Management
1137395|NCT01418716|Quality Improvement
1137396|NCT01418716|Cooperative Behavior (collaboration)
1137397|NCT01418677|Unspecified Advance Solid Tumor, Protocol Specific
1137398|NCT01418664|vitamin D
1137399|NCT01418664|adverse pregnancy outcome
1137400|NCT01418664|Pakistan
1137401|NCT01418638|Major Depressive Disorder
1137402|NCT01418638|Antidepressants
1137403|NCT01418573|glucose, insulin, post prandial
1137404|NCT01418560|renal artery
1137405|NCT01418560|sympathetic nerves
1137406|NCT01418560|modification
1137407|NCT01418560|chronic renal failure
1137408|NCT01418521|Cardiac surgery
1137409|NCT01418521|Balanced 3rd generation Hydroxyethyl starch
1137410|NCT01418521|Tetraspan
1137411|NCT01418521|Ringer-albumin
1137412|NCT01418469|COPD
1137413|NCT01418469|protein metabolism
1137414|NCT01418469|branched-chain amino acid metabolism
1137415|NCT01418469|exercise
1137416|NCT01418469|protein feeding
1137417|NCT01418456|diabetes
1137418|NCT01418456|antibiotics
1137419|NCT01418456|clean foot ulcers
1137420|NCT01418404|Stroke
1137421|NCT01418404|Effects of TS in U/E motor recovery
1137422|NCT01418404|Brain mapping
1137423|NCT01418404|Kinematics analysis
1137424|NCT01418391|minimal laparotomy
1137425|NCT01418391|TAP block
1137426|NCT01418391|morphine consumption
1137427|NCT01418391|post-operative analgesia
1137428|NCT01418378|Sigma
1137429|NCT01418378|cruciate
1137430|NCT01418378|retaining
1137431|NCT01418378|fixed
1137432|NCT01418378|primary
1137433|NCT01418378|total
1137434|NCT01418378|knee
1137435|NCT01418378|arthroplasty
1137436|NCT01418378|cemented
1137437|NCT01418378|osteoarthritis
1137438|NCT01418352|Tourette's Disorder
1137439|NCT01418352|tic disorders
1137440|NCT01418339|Tourette's Disorder
1137441|NCT01418339|tic disorders
1137442|NCT01418326|Cancer - breast
1137443|NCT01418326|colo-rectal
1137444|NCT01418326|skin
1137445|NCT01418313|Atherosclerosis
1137446|NCT01418313|Non-invasive imaging
1137447|NCT01418313|Magnetic Resonance Imaging
1137448|NCT01418313|MRI
1137449|NCT01418313|Positron Emission Tomography
1137450|NCT01418313|PET/CT
1137451|NCT01418313|PET/MRI
1137452|NCT01418313|Inflammation
1137453|NCT01418313|Neovascularization
1137454|NCT01418261|uncontrolled hypertension
1137455|NCT01418261|renal denervation
1137456|NCT01418248|cardiac catheterization
1137457|NCT01418248|echocardiography
1137458|NCT01418235|HIV Infections
1137459|NCT01418235|Acquired Immunodeficiency Syndrome
1137460|NCT01418235|Lentivirus Infections
1137461|NCT01418235|Retroviridae Infections
1137462|NCT01418235|RNA Virus Infections
1137463|NCT01418235|Virus Diseases
1137464|NCT01418235|Sexually Transmitted Diseases, Viral
1137465|NCT01418235|Sexually Transmitted Diseases
1137466|NCT01418235|Immunologic Deficiency Syndromes
1137467|NCT01418235|Immune System Diseases
1137468|NCT01418235|Slow Virus Diseases
1137469|NCT01418209|Menopause
1137470|NCT01418209|Vasomotor
1137471|NCT01418209|Symptoms
1137472|NCT01418209|Estradiol
1137473|NCT01418209|Venlafaxine
1137474|NCT01418196|TMAO
1137475|NCT01418196|Children
1137476|NCT01418196|Dietary choline
1137477|NCT01418196|Cardiovascular disease risk
1137478|NCT01418196|Atherogenic dyslipidemia
1137479|NCT01418183|Orthognathic surgery
1137480|NCT01418183|Pain control
1137481|NCT01418183|Trigeminal nerve
1137482|NCT01418183|Levobupivacaine
1137483|NCT01418170|myofascial pain syndrome
1137484|NCT01418170|myofascial trigger points
1137485|NCT01418170|spinal manipulative therapy
1137486|NCT01418170|algometer
1137487|NCT01418170|pressure pain thresholds
1137488|NCT01418157|Acute mountain sickness
1137489|NCT01418157|Rapid ascent
1137490|NCT01418157|High altitude headache
1137491|NCT01418157|Mountain Medicine Society Nepal
1137492|NCT01418131|Proctitis
1137493|NCT01418131|resistant
1137494|NCT01418131|ulcerative colitis
1137495|NCT01418131|inflammatory bowel disease
1137496|NCT01418118|noradrenaline
1137497|NCT01418118|norepinephrine
1137498|NCT01418118|epinephrine
1137499|NCT01418118|adrenaline
1137500|NCT01418118|dobutamine
1137501|NCT01418118|dopexamine
1137502|NCT01418118|inotrope
1137503|NCT01418118|pressor
1137504|NCT01418118|sympathomimetic
1137505|NCT01418118|free flap
1137506|NCT01418118|transplantation
1137507|NCT01418118|free tissue transfer
1137508|NCT01418118|microsurgery
1137509|NCT01418118|survival
1137510|NCT01418105|spine injuries
1137511|NCT01418105|brain lesions
1137512|NCT01418105|dysphagia
1137513|NCT01418079|Spectroscopy, near infrared
1137514|NCT01418079|cerebral oxygenation
1137515|NCT01418027|NAFLD
1137516|NCT01418027|exercise
1137517|NCT01418027|hepatic triglycerides
1137518|NCT01418001|GEMCITABINE
1137519|NCT01418001|GW786034 (PAZOPANIB)
1137520|NCT01418001|TAXOTERE (DOCETAXEL)
1137521|NCT01418001|11-104
1137522|NCT01417988|TB
1137523|NCT01417975|exercise
1137524|NCT01417975|smoking satisfaction
1137525|NCT01417975|topography
1137526|NCT01417975|cravings
1137527|NCT01417962|Autopsy
1137528|NCT01417962|MRI
1137529|NCT01417962|Stillbirths
1137530|NCT01417962|Neonatal death
1137531|NCT01417962|Sudden Infant death
1137532|NCT01417923|chronic musculo-skeletal pain
1137533|NCT01417923|therapeutic&serology effects of vitamin D
1137534|NCT01417923|CRP, IL-6, IL-8, TNF and prostaglandin E2
1137535|NCT01417923|patients suffering from chronic musculo-skeletal pain
1137536|NCT01417884|molecular cardiology
1137537|NCT01417884|molecular epidemiology
1137538|NCT01417884|platelets
1137539|NCT01417884|cardiovascular disease
1137540|NCT01417858|intra-ocular pressure
1137541|NCT01417858|iridectomy
1137542|NCT01417858|gonioscopy
1137543|NCT01417858|ocular tonometry
1137544|NCT01417832|Dental caries
1137545|NCT01417832|Proximal surfaces
1137546|NCT01417832|Preventive therapy
1137547|NCT01417832|Dental radiography
1137548|NCT01417832|Treatment efficacy
1137549|NCT01417832|Young adults
1137550|NCT01417806|small cell lung cancer
1137551|NCT01417806|somatostatin
1137552|NCT01417806|topotecan
1137553|NCT01417793|Smoking cessation rate
1137554|NCT01417767|myelodysplastic syndromes
1137555|NCT01417767|Decitabine
1137556|NCT01417767|homoharringtonine
1137557|NCT01417767|cytarabine
1137558|NCT01417767|G-CSF
1137559|NCT01417754|toremifene
1137560|NCT01417728|endomicroscopy
1137561|NCT01417728|inflammatory bowel disease
1137562|NCT01417728|mucosal healing
1137563|NCT01417728|infliximab
1137564|NCT01417689|glaucoma
1137565|NCT01417689|randomized controlled trial
1137566|NCT01417689|eye drops
1137567|NCT01417689|instillation
1137568|NCT01417689|compliance
1137569|NCT01417676|prostate cancer
1137570|NCT01417676|locally advanced
1137571|NCT01417676|lymph node positive
1137572|NCT01417676|radiation therapy
1137573|NCT01417676|morbidity
1137574|NCT01417676|early morbidity
1137575|NCT01417676|late morbidity
1137576|NCT01417663|Aging
1137577|NCT01417663|Cardiovascular disease
1137578|NCT01417663|Endothelial function
1137579|NCT01417663|Physical activity
1137580|NCT01417663|Advanced Glycation Endproducts
1137581|NCT01417663|AGE crosslink breakers
1137582|NCT01417650|temporomandibular disorder
1137583|NCT01417650|laser therapy
1137584|NCT01417650|osteoarthritis
1137585|NCT01417637|TMD
1137586|NCT01417637|myofacial pain syndrome
1137587|NCT01417637|low level laser therapy
1137588|NCT01417637|LLLT
1137589|NCT01417624|Heart Failure
1137590|NCT01417624|Cardiac Resynchronisation Therapy
1137591|NCT01417611|screening colonoscopy
1137592|NCT01417598|Balance
1137593|NCT01417598|Gait
1137594|NCT01417598|Physical activity
1137595|NCT01417585|Activities of daily living
1137596|NCT01417585|Caregiver burden
1137597|NCT01417585|Client centered
1137598|NCT01417585|Life satisfaction
1137599|NCT01417585|Participation
1137600|NCT01417585|Patient satisfaction
1137601|NCT01417585|Rehabilitation
1137602|NCT01417585|Self rated impact of stroke
1137603|NCT01417585|Stroke
1137604|NCT01417546|Dose-Limiting Toxicity
1137605|NCT01417546|Maximum Tolerated Dose
1137606|NCT01417546|Immune Response
1137607|NCT01417546|Pharmacokinetics
1137608|NCT01417546|Dose Escalation
1137609|NCT01417546|Cancer
1137610|NCT01417546|Metastatic Solid Tumor
1137611|NCT01417546|Solid Tumor
1137612|NCT01417533|Hereditary Inclusion Body Myopathy
1137613|NCT01417533|N-Acetyl-D-mannosamine (ManNAc)
1137614|NCT01417533|UDP-N-acetyglucosamine 2-epimerase (GNE)
1137615|NCT01417533|Sialic Acid
1137616|NCT01417533|Muscular Dystrophy
1137617|NCT01417533|HIBM
1137618|NCT01417520|Histiocytosis
1137619|NCT01417520|Xanthomatosis
1137620|NCT01417520|Fibrosis
1137621|NCT01417520|Osteosclerosis
1137622|NCT01417520|Erdheim-Chester Disease
1137623|NCT01417520|ECD
1137624|NCT01417494|adenocarcinoma of the colon
1137625|NCT01417494|stage IVA colon cancer
1137626|NCT01417494|stage IVB colon cancer
1137627|NCT01417494|adenocarcinoma of the rectum
1137628|NCT01417494|stage IVA rectal cancer
1137629|NCT01417494|stage IVB rectal cancer
1137630|NCT01417481|cystic fibrosis
1137631|NCT01417481|glycine
1137632|NCT01417481|airway inflammation
1137633|NCT01417468|Cognitive Rehabilitation
1137634|NCT01417468|Learning Styles
1137635|NCT01417468|Learning Modes
1137636|NCT01417468|Learning Modalities
1137637|NCT01417468|Multiple Intelligences
1137638|NCT01417468|Educational Intervention
1137639|NCT01417468|Instructional Design
1137640|NCT01417455|Rheumatoid arthritis
1137641|NCT01417455|Ankylosing spondylitis
1137642|NCT01417455|Osteoclasts
1137643|NCT01417455|TNF antagonists
1137644|NCT01417442|papillary thyroid carcinoma
1137645|NCT01417442|BRAF V600E
1137646|NCT01417442|poor prognosis
1137647|NCT01417442|aggressive
1137648|NCT01417429|galantamine
1137649|NCT01417429|subjective nicotine
1137650|NCT01417429|tobacco withdrawal symptoms
1137651|NCT01417429|nicotine
1137652|NCT01417390|Nasopharyngeal Carcinoma
1137653|NCT01417364|Sarcopenia
1137654|NCT01417364|Aging muscle
1137655|NCT01417364|Testosterone administration
1137656|NCT01417364|Bone metabolism
1137657|NCT01417351|pregnancy
1137658|NCT01417351|immune function
1137659|NCT01417338|Hypertension,pulmonary
1137660|NCT01417338|Mortality
1137661|NCT01417338|Risk factors
1137662|NCT01417312|Multiple sclerosis
1137663|NCT01417312|Green tea extract
1137664|NCT01417312|Metabolism
1137665|NCT01417299|chronic vegetative state
1137666|NCT01417299|RPh201
1137667|NCT01417299|functional MRI
1137668|NCT01417273|Multiple sclerosis
1137669|NCT01417273|immune system
1137670|NCT01417273|vitamin A
1138047|NCT01415778|Japanese
1137671|NCT01417273|(MSFC)Multiple Sclerosis Functional Composite
1137672|NCT01417273|(EDSS)Expanded Disability Status Scale
1137673|NCT01417273|(MRI)Magnetic resonance imaging
1137674|NCT01417247|renal artery
1137675|NCT01417247|sympathetic nerves
1137676|NCT01417247|modification
1137677|NCT01417247|metabolic syndrome
1137678|NCT01417221|renal artery
1137679|NCT01417221|sympathetic nerves
1137680|NCT01417221|modification
1137681|NCT01417221|essential hypertension
1137682|NCT01417221|primary hypertension
1137683|NCT01417195|Assisted Reproductive Technology
1137684|NCT01417182|Patients with Advanced Prostate Cancer
1137685|NCT01417143|dovitinib
1137686|NCT01417130|Naproxen
1137687|NCT01417130|Celecoxib
1137688|NCT01417130|Anti-Inflammatory Agents, Non-Steroidal
1137689|NCT01417117|Intracerebral Hemorrhage
1137690|NCT01417117|Ischemic Stroke
1137691|NCT01417117|Diffusion Weight Imaging Abnormalities
1137692|NCT01417117|Neurologic Outcome
1137693|NCT01417104|plaque
1137694|NCT01417104|magnetic resonance imaging (MRI)
1137695|NCT01417104|high blood pressure
1137696|NCT01417104|MI
1137697|NCT01417104|heart attack
1137698|NCT01417104|CVA
1137699|NCT01417104|stroke
1137700|NCT01417104|PAD
1137701|NCT01417091|Brittle bone disease
1137702|NCT01417091|inherited
1137703|NCT01417091|connective tissue disorder
1137704|NCT01417091|fracture
1137705|NCT01417065|Cancer
1137706|NCT01417065|mTOR inhibitor Temsirolimus
1137707|NCT01417065|Torisel
1137708|NCT01417065|CCI-779
1137709|NCT01417065|pharmacodynamic targets
1137710|NCT01417026|Autism Spectrum Disorders
1137711|NCT01417026|Oxytocin
1137712|NCT01417026|Clinical Trial
1137713|NCT01417026|Computer-based Intervention
1137714|NCT01417026|Social Perception
1137715|NCT01417026|Social Motivation
1137716|NCT01417026|Social Cognition
1137717|NCT01417013|Dry eye or lubricant eye drops
1137718|NCT01417000|Cancer
1137719|NCT01417000|Cancer vaccine
1137720|NCT01417000|Listeria monocytogenes
1137721|NCT01417000|Listeria-based vaccines
1137722|NCT01417000|GVAX
1137723|NCT01417000|Cyclophosphamide
1137724|NCT01417000|Cytoxan
1137725|NCT01417000|T regulatory cells
1137726|NCT01417000|Heterologous Prime-Boost
1137727|NCT01417000|Immunotherapy
1137728|NCT01417000|Mesothelin
1137729|NCT01417000|Pancreatic cancer
1137730|NCT01416974|19-28Z RETROVIRUS
1137731|NCT01416974|CYCLOPHOSPHAMIDE (CYTOXAN)
1137732|NCT01416974|autologous T cells
1137733|NCT01416974|Leukapheresis
1137734|NCT01416974|11-048
1137735|NCT01416961|Squamous Cell
1137736|NCT01416961|Non-squamous cell
1137737|NCT01416948|Cognitive Complaints, TBI, PTSD
1137738|NCT01416935|Atrial Fibrillation
1137739|NCT01416935|Anti-Arrhythmic Medication
1137740|NCT01416909|Medication-induced
1137741|NCT01416909|Constipation in Cancer
1137742|NCT01416896|End stage Renal Disease
1137743|NCT01416896|Hemodialysis
1137744|NCT01416896|Oxidative Stress
1137745|NCT01416896|Inflammation
1137746|NCT01416883|oral mucosal absorption
1137747|NCT01416883|pharmacokinetics
1137748|NCT01416883|safety
1137749|NCT01416883|bicalutamide
1137750|NCT01416883|Japanese
1137751|NCT01416883|healthy subject
1137752|NCT01416870|Bioequivalence
1137753|NCT01416870|pharmacokinetics
1137754|NCT01416870|safety
1137755|NCT01416870|bicalutamide
1137756|NCT01416870|Casodex
1137757|NCT01416870|Japanese
1137758|NCT01416870|healthy subject
1137759|NCT01416857|Medicare
1137760|NCT01416844|Metastatic melanoma
1137761|NCT01416844|anti-OX40
1137762|NCT01416844|Immunostimulatory
1137763|NCT01416831|metastatic melanoma
1137764|NCT01416831|IL-2
1137765|NCT01416831|Interleukin 2
1137766|NCT01416831|Radiation
1137767|NCT01416831|Stereotactic Body Radiation Treatment
1137768|NCT01416831|SBRT
1137769|NCT01416831|Immunotherapy
1137770|NCT01416818|Depression;
1137771|NCT01416818|Parkinson's disease;
1137772|NCT01416818|antidepressant
1137773|NCT01416805|childhood anxiety disorders
1137774|NCT01416805|cognitive behavioral therapy
1137775|NCT01416805|CBT
1137776|NCT01416805|Generalized Anxiety Disorder
1137777|NCT01416805|Social Phobia
1137778|NCT01416805|Separation Anxiety Disorder
1137779|NCT01416805|Psychotherapy
1137780|NCT01416805|Counseling
1137781|NCT01416805|Social Anxiety Disorder
1137782|NCT01416779|Writing Intervention
1137783|NCT01416779|Bereaved Caregivers
1137784|NCT01416779|Older Adults
1137785|NCT01416779|hope
1137786|NCT01416779|inventory of daily widowed life
1137787|NCT01416766|Blood Pressure Monitors
1137788|NCT01416766|Medical Informatics
1137789|NCT01416766|Disease Management
1137790|NCT01416766|Comparative Effectiveness Research
1137791|NCT01416753|hemodialysis
1137792|NCT01416753|blood volume monitoring
1137793|NCT01416740|Indirect magnetic resonance arthrogram
1137794|NCT01416740|Direct magnetic resonance arthrogram
1137795|NCT01416740|Diagnostic tests for shoulder pain
1137796|NCT01416727|Patient Simulation
1137797|NCT01416727|Education, Medical, Graduate
1137798|NCT01416727|Internship and Residency
1137799|NCT01416727|Psychiatry
1137800|NCT01416701|COPD
1137801|NCT01416701|Vitamin D
1137802|NCT01416701|Pulmonary rehabilitation
1137803|NCT01416688|therapy-related toxicity
1137804|NCT01416688|dermatologic complications
1137805|NCT01416688|stage I colon cancer
1137806|NCT01416688|stage IIA colon cancer
1137807|NCT01416688|stage IIB colon cancer
1137808|NCT01416688|stage IIC colon cancer
1137809|NCT01416688|stage IIIA colon cancer
1137810|NCT01416688|stage IIIB colon cancer
1137811|NCT01416688|stage IIIC colon cancer
1137812|NCT01416688|stage IVA colon cancer
1137813|NCT01416688|stage IVB colon cancer
1137814|NCT01416688|stage I rectal cancer
1137815|NCT01416688|stage IIA rectal cancer
1137816|NCT01416688|stage IIB rectal cancer
1137817|NCT01416688|stage IIC rectal cancer
1137818|NCT01416688|stage IIIA rectal cancer
1137819|NCT01416688|stage IIIB rectal cancer
1137820|NCT01416688|stage IIIC rectal cancer
1137821|NCT01416688|stage IVA rectal cancer
1137822|NCT01416688|stage IVB rectal cancer
1137823|NCT01416688|stage IA non-small cell lung cancer
1137824|NCT01416688|stage IB non-small cell lung cancer
1137825|NCT01416688|stage IIA non-small cell lung cancer
1137826|NCT01416688|stage IIB non-small cell lung cancer
1137827|NCT01416688|stage IIIA non-small cell lung cancer
1137828|NCT01416688|stage IIIB non-small cell lung cancer
1137829|NCT01416688|stage IV non-small cell lung cancer
1137830|NCT01416688|extensive stage small cell lung cancer
1137831|NCT01416688|limited stage small cell lung cancer
1137832|NCT01416688|recurrent small cell lung cancer
1137833|NCT01416688|recurrent colon cancer
1137834|NCT01416688|recurrent rectal cancer
1137835|NCT01416688|recurrent non-small cell lung cancer
1137836|NCT01416662|adenocarcinoma of the pancreas
1137837|NCT01416662|stage IA pancreatic cancer
1137838|NCT01416662|stage IB pancreatic cancer
1137839|NCT01416662|stage IIA pancreatic cancer
1137840|NCT01416623|Advanced solid cancer
1137841|NCT01416623|Henatinib
1137842|NCT01416623|phase I
1137843|NCT01416597|Influenza
1137844|NCT01416597|Systematic review
1137845|NCT01416597|Meta-analysis
1137846|NCT01416597|Mismatched strains
1137847|NCT01416597|Cross-protection
1137848|NCT01416571|H5N1
1137849|NCT01416571|Influenza vaccine
1137850|NCT01416571|influenza infection
1137851|NCT01416571|GSK1557484A
1137852|NCT01416558|German Breast Group
1137853|NCT01416558|GBG Forschungs GmbH
1137854|NCT01416558|GBG
1137855|NCT01416558|GBG 65
1137856|NCT01416558|Tiffany
1137857|NCT01416558|Breast Cancer
1137858|NCT01416558|Metastatic Breast Cancer
1137859|NCT01416558|Nab-Paclitaxel
1137860|NCT01416558|Abraxane
1137861|NCT01416558|Taxane Failure
1137862|NCT01416545|Primary Prevention
1137863|NCT01416545|Cardiovascular disease
1137864|NCT01416545|Child
1137865|NCT01416545|Behavior modification
1137866|NCT01416545|Activities, Educational
1137867|NCT01416532|coronary Atheroslcerosis
1137868|NCT01416532|Computed Tomography
1137869|NCT01416519|Continuous Positive Airway Pressure
1137870|NCT01416519|Cough
1137871|NCT01416519|Oxygen Inhalation Therapy
1137872|NCT01416506|Pneumonia, surveillance
1137873|NCT01416493|acute rheumatoid arthritis
1137874|NCT01416480|Theobromine
1137875|NCT01416480|cough
1137876|NCT01416480|acute bronchitis
1137877|NCT01416467|lysosomal storage disease
1137878|NCT01416467|AAV vector
1137879|NCT01416467|gene transfer
1137880|NCT01416467|disease characterization
1137881|NCT01416441|Tourette's Disorder
1137882|NCT01416441|tic disorders
1137883|NCT01416428|multiple myeloma
1137884|NCT01416428|waldenstrom macroglobulinemia
1137885|NCT01416415|Glaucoma, Open-Angle
1137886|NCT01416415|Ophthalmic Solutions, Eye drops
1137887|NCT01416415|Instructional Films and Videos
1137888|NCT01416402|Hyperuricemia
1137889|NCT01416402|gout
1137890|NCT01416402|serum uric acid
1137891|NCT01416389|Locally
1137892|NCT01416389|Recurrent
1137893|NCT01416389|Breast
1137894|NCT01416389|Cancer
1137895|NCT01416363|firategrast
1137896|NCT01416363|pharmacokinetics, modified release, firategrast,
1137897|NCT01416363|simulated gastro-retentive
1137898|NCT01416363|pharmacokinetics
1137899|NCT01416363|healthy volunteers, simulated gastro-retentive
1137900|NCT01416363|healthy volunteers
1137901|NCT01416363|modified release
1137905|NCT01416298|Acute Kidney Injury
1137906|NCT01416298|Critically ill children
1137907|NCT01416298|Biomarkers
1137908|NCT01416298|NGAL
1137909|NCT01416298|Fluid Overload
1137910|NCT01416298|Continuous Renal Replacement Therapy (CRRT)
1137911|NCT01416285|Congestive heart failure (CHF)
1137912|NCT01416285|CHF education
1137913|NCT01416285|self-care training
1137914|NCT01416285|CHF center
1137915|NCT01416259|QTc Prolongation
1137916|NCT01416246|Stem cell Infusions
1137917|NCT01416246|Autologous Stem Cell Transplant
1137918|NCT01416246|11-105
1137919|NCT01416233|autologous
1137920|NCT01416233|fat
1137921|NCT01416233|orbit
1137922|NCT01416233|atrophy
1137923|NCT01416233|cannula
1137924|NCT01416220|depression
1137925|NCT01416220|bipolar disorder
1137926|NCT01416220|manic depressive illness
1137928|NCT01416181|Natalizumab
1137929|NCT01416181|secondary
1137930|NCT01416181|multiple sclerosis
1137931|NCT01416181|MS
1137932|NCT01416181|SPMS
1137933|NCT01416181|Tysabri
1137934|NCT01416168|Colon
1137935|NCT01416168|Geriatric
1137936|NCT01416168|McCorkle Model
1137937|NCT01416168|Questionnaire
1137938|NCT01416116|QUTENZA
1137939|NCT01416116|Pre-treatment
1137940|NCT01416116|Tramadol
1137941|NCT01416116|Tolerability
1137942|NCT01416090|syndactyly
1137943|NCT01416077|fluid
1137944|NCT01416077|goal-directed
1137945|NCT01416077|FloTrac
1137946|NCT01416077|pulse contour analysis
1137947|NCT01416077|postoperative complications
1137948|NCT01416077|anesthesia
1137949|NCT01416077|esophagus
1137950|NCT01416038|vaccine
1137951|NCT01416038|immunotherapy
1137952|NCT01416038|ovarian
1137953|NCT01416038|fallopian tube
1137954|NCT01416038|peritoneal
1137955|NCT01416038|cancer
1137956|NCT01416038|tumor
1137957|NCT01416038|Phase 1
1137958|NCT01416038|Phase I
1137959|NCT01416038|combination therapy
1137960|NCT01416025|Voriconazole
1137961|NCT01416025|Therapeutic drug monitoring
1137962|NCT01416025|Hematopoietic stem cell transplant
1137963|NCT01416025|Hematologic malignancy
1137964|NCT01416025|Invasive mould infection
1137965|NCT01415999|anthracycline
1137966|NCT01415999|cardiac function
1137967|NCT01415999|echocardiography
1137968|NCT01415999|biomarkers
1137969|NCT01415986|Advanced head and neck cancer
1137970|NCT01415986|Squamous cell carcinoma
1137971|NCT01415986|SCC
1137972|NCT01415986|HNSCC
1137973|NCT01415973|beef
1137974|NCT01415973|protein
1137975|NCT01415973|synergy
1137976|NCT01415973|intact beef constituents
1137977|NCT01415973|protein constituent
1137978|NCT01415973|Nutrient Synergy
1137979|NCT01415960|Prostate Cancer
1137980|NCT01415960|androgen deprivation therapy.
1137981|NCT01415960|Leuprolide Acetate Depot Formulation
1137982|NCT01415960|Pharmacokinetics
1137983|NCT01415960|testosterone
1137984|NCT01415960|serum luteinizing hormone
1137985|NCT01415960|follicle-stimulating hormone
1137986|NCT01415960|prostate-specific antigen
1137987|NCT01415947|Heart disease
1137988|NCT01415947|Device
1137989|NCT01415947|Mitral valve
1137990|NCT01415947|leaflet prolapse
1137991|NCT01415947|Heart valve disease
1137992|NCT01415947|Cardiovascular disease
1137993|NCT01415947|Neochordae
1137994|NCT01415921|heart failure
1137995|NCT01415921|autonomic function
1137996|NCT01415921|sympathovagal balance
1137997|NCT01415921|cholinesterase inhibitors
1137998|NCT01415921|pharmacology
1137999|NCT01415908|advanced degenerative disease of the lumbosacral spine
1138000|NCT01415908|lumbosacral spine
1138001|NCT01415908|radiculopathy
1138002|NCT01415908|degenerative instability
1138003|NCT01415908|spondylolisthesis
1138004|NCT01415908|retrolisthesis
1138005|NCT01415908|lateral listhesis
1138006|NCT01415908|spinal stenosis
1138007|NCT01415908|disc herniation
1138008|NCT01415908|INFUSE Bone Graft
1138009|NCT01415908|CD HORIZON Spinal System
1138010|NCT01415908|CAPSTONE Spinal System
1138011|NCT01415895|back pain
1138012|NCT01415895|cervical pain
1138013|NCT01415895|neuropathic pain
1138014|NCT01415895|radicular pain
1138015|NCT01415869|Ventricular Assist Device
1138016|NCT01415869|Gastrointestinal Bleeding
1138017|NCT01415869|VAD
1138018|NCT01415856|pulsed electromagnetic fields device
1138019|NCT01415856|Torino II
1138020|NCT01415856|postoperative knee pain
1138021|NCT01415856|knee replacement
1138022|NCT01415830|Anti-Scorpion venom serum
1138023|NCT01415830|venom
1138024|NCT01415830|efficacy
1138025|NCT01415830|safety
1138026|NCT01415830|children
1138027|NCT01415817|Quality Improvement
1138028|NCT01415817|Adenoma Detection Rate
1138029|NCT01415817|Polyp detection rate
1138030|NCT01415817|Colonoscopy
1138031|NCT01415817|Training
1138032|NCT01415817|Colorectal cancer screening
1138033|NCT01415804|Dissection
1138034|NCT01415804|Aorta
1138035|NCT01415804|Surgery
1138036|NCT01415791|oral mucosal absorption
1138037|NCT01415791|pharmacokinetics
1138038|NCT01415791|safety
1138039|NCT01415791|bicalutamide
1138040|NCT01415791|Japanese
1138041|NCT01415791|healthy subject
1138042|NCT01415778|Bioequivalence
1138043|NCT01415778|pharmacokinetics
1138044|NCT01415778|safety
1138045|NCT01415778|bicalutamide
1138046|NCT01415778|Casodex
1138048|NCT01415778|healthy subject
1138049|NCT01415765|Germinal Center Like B-Cell (GCB) DLBCL
1138050|NCT01415765|Activated B-Cell Like (ABC) DLBCL
1138051|NCT01415765|NF-KappaB Pathway
1138052|NCT01415765|Drug Resistance
1138053|NCT01415765|Nedd-8 Activating Enzyme Inhibitor
1138054|NCT01415765|Diffuse Large B-Cell Lymphoma
1138055|NCT01415765|Lymphoma
1138056|NCT01415752|neurotoxicity
1138057|NCT01415752|therapy-related toxicity
1138058|NCT01415752|contiguous stage II mantle cell lymphoma
1138059|NCT01415752|noncontiguous stage II mantle cell lymphoma
1138060|NCT01415752|stage I mantle cell lymphoma
1138061|NCT01415752|stage III mantle cell lymphoma
1138062|NCT01415752|stage IV mantle cell lymphoma
1138063|NCT01415739|stage IA non-small cell lung cancer
1138064|NCT01415739|stage IB non-small cell lung cancer
1138065|NCT01415739|adenocarcinoma of the lung
1138066|NCT01415739|squamous cell lung cancer
1138067|NCT01415726|Cord blood stem cells
1138068|NCT01415726|inflammation
1138069|NCT01415726|type 2 diabetes
1138070|NCT01415726|stem cell educator
1138071|NCT01415726|autoimmunity
1138072|NCT01415726|immune modulation
1138073|NCT01415713|enroll the 80 patients in this trial
1138074|NCT01415700|feet STEPPAGE of central neurological origin
1138075|NCT01415700|implanted functional electrical stimulation
1138076|NCT01415700|feet orthosis
1138077|NCT01415687|preoperative care
1138078|NCT01415687|colonoscopy
1138079|NCT01415687|cathartics
1138080|NCT01415674|Squamous cell carcinoma of the head and neck
1138081|NCT01415674|pre operative treatment
1138082|NCT01415674|Afatinib
1138083|NCT01415674|BIBW2992
1138084|NCT01415674|Biological markers
1138085|NCT01415648|with surgical indication
1138086|NCT01415648|Cerebral oximetry
1138087|NCT01415648|carotid endarterectomy
1138088|NCT01415648|MRI
1138089|NCT01415648|ischemic lesion
1138090|NCT01415648|cost/effectiveness analysis
1138091|NCT01415648|Neurocognitive Outcome
1138092|NCT01415648|protein S-100B
1138093|NCT01415635|Nutritional risk, Hospital food, Nutritional Intervention
1138094|NCT01415622|plasma therapy
1138095|NCT01415622|ulcus cruris
1138096|NCT01415609|Gastrointestinal neoplasia
1138097|NCT01415609|Submucosal resection
1138098|NCT01415570|Protein-energy wasting (PEW)
1138099|NCT01415570|racial disparities
1138100|NCT01415570|hemodialysis
1138101|NCT01415570|survival paradoxes
1138102|NCT01415570|Stage 5
1138103|NCT01415557|micronutrient
1138104|NCT01415557|healthy children
1138105|NCT01415557|vitamins
1138106|NCT01415557|minerals
1138107|NCT01415557|cognition
1138108|NCT01415557|physical performance
1138109|NCT01415557|iron
1138110|NCT01415557|Micronutrient status
1138111|NCT01415557|Cognitive Performance
1138112|NCT01415544|Diabetes
1138113|NCT01415531|Stage 1
1138114|NCT01415531|Stage 2
1138115|NCT01415531|Hypertension
1138116|NCT01415518|Severe chronic obstructive pulmonary disease (COPD) patients
1138117|NCT01415505|Stage 1
1138118|NCT01415505|Stage 2
1138119|NCT01415505|Hypertension
1138120|NCT01415505|1 year open label safety study
1138121|NCT01415492|Exercise
1138122|NCT01415492|Physical activity
1138123|NCT01415492|Cigarette Smoking
1138124|NCT01415492|Smoking cessation
1138125|NCT01415492|Multi Vitamin intake
1138126|NCT01415492|Vegetable consumption
1138127|NCT01415492|Fruit consumption
1138128|NCT01415492|Meat consumption
1138129|NCT01415479|Colon cancer
1138130|NCT01415479|Screening
1138131|NCT01415479|Decision-making
1138132|NCT01415453|retinitis pigmentosa
1138133|NCT01415453|acoustic radiation force ultrasound
1138134|NCT01415453|RP
1138135|NCT01415453|visual field loss
1138136|NCT01415453|Photoreceptor
1138137|NCT01415453|Vision loss
1138138|NCT01415453|retina
1138139|NCT01415453|progressive vision loss
1138140|NCT01415453|ultrasound
1138145|NCT01415427|Mucopolysaccharidosis IV type A
1138146|NCT01415427|MPS IV Type A
1138147|NCT01415427|Mucopolysaccharidosis IVA
1138148|NCT01415427|MPS IVA
1138149|NCT01415427|Morquio A Syndrome
1138150|NCT01415427|Lysosomal Storage Disorder
1138151|NCT01415427|LSD
1138152|NCT01415427|N-acetylgalactosamine-6-sulfatase
1138153|NCT01415427|N-acetylgalactosamine-6-sulfate sulfatase
1138154|NCT01415427|galactose-6-sulfatase
1138155|NCT01415427|GALNS
1138156|NCT01415427|enzyme replacement therapy
1138157|NCT01415427|ERT
1138158|NCT01415414|Image quality
1138159|NCT01415414|CNR
1138160|NCT01415414|SNR
1138161|NCT01415414|Abdominal
1138162|NCT01415414|Pelvic
1138163|NCT01415401|Glaucoma
1138164|NCT01415401|Ocular hypertension
1138165|NCT01415401|Intraocular pressure (IOP)
1138166|NCT01415401|Open angle glaucoma
1138167|NCT01415401|Pigment dispersion glaucoma
1138168|NCT01415401|Pigmentary
1138169|NCT01415388|Maintenance of normal blood triglyceride levels
1138170|NCT01415375|prostate-specific antigen (146-154)
1138171|NCT01415375|prostate-specific antigen (154-163)
1138172|NCT01415362|transcranial direct current stimulation
1138173|NCT01415362|electroencephalography
1138174|NCT01415323|Emergency services, psychiatric
1138175|NCT01415323|Psychomotor agitation
1138176|NCT01415323|Suicide
1138177|NCT01415323|Violence
1138178|NCT01415310|Geriatric Psychiatry
1138179|NCT01415310|Quality register
1138180|NCT01415310|Quality improvement
1138181|NCT01415310|Quality control
1138182|NCT01415310|Research elderly patients with psychiatric disorders
1138183|NCT01415297|Phase 1
1138184|NCT01415297|advanced solid tumors
1138185|NCT01415284|Obstetric anesthesia
1138186|NCT01415284|Spinal anesthesia
1138187|NCT01415284|Hypotension
1138188|NCT01415284|Fluid therapy
1138189|NCT01415284|Cesarean section
1138190|NCT01415284|phenylephrine
1138191|NCT01415284|cardiac output
1138192|NCT01415271|diabetes
1138193|NCT01415271|A1c
1138194|NCT01415271|internet
1138195|NCT01415271|long term care
1138196|NCT01415258|cancer
1138197|NCT01415258|vulnerability
1138198|NCT01415258|frail
1138199|NCT01415232|Obesity
1138200|NCT01415232|Ultrasound
1138201|NCT01415219|rehabilitation
1138202|NCT01415219|exercise
1138203|NCT01415219|efficacy
1138204|NCT01415219|functional status
1138205|NCT01415206|Behavioral changes
1138206|NCT01415206|Multiple risks
1138207|NCT01415180|sepsis
1138208|NCT01415180|health related quality of life
1138209|NCT01415180|functional status
1138210|NCT01415180|chronic comorbid conditions
1138211|NCT01415180|organ dysfunction
1138212|NCT01415154|TMS
1138213|NCT01415154|Major Depressive Disorder
1138214|NCT01415154|NeuroStar TMS
1138215|NCT01415141|genotype 1
1138216|NCT01415141|IL28B CC polymorphism
1138217|NCT01415141|telaprevir
1138218|NCT01415141|peginterferon
1138219|NCT01415141|ribavirin
1138220|NCT01415115|diabetes
1138221|NCT01415115|hypertension
1138222|NCT01415089|Cancer
1138223|NCT01415089|Quality of life
1138224|NCT01415089|Family caregiver
1138225|NCT01415089|Stress and coping
1138226|NCT01415089|Web-based intervention
1138227|NCT01415089|Communication
1138228|NCT01415063|Hepatocellular Carcinoma
1138229|NCT01415063|RFA
1138230|NCT01415063|TACE
1138231|NCT01415050|Osteoporosis
1138232|NCT01415050|Menopause
1138233|NCT01415050|Raloxifane
1138234|NCT01415050|Alendronate
1138235|NCT01415037|Annular Array Ultrasound
1138236|NCT01415037|Ultrasound Exam
1138237|NCT01415037|Posterior Vitreous Detachment
1138238|NCT01415037|PVD
1138239|NCT01415037|Diabetic Retinopathy
1138240|NCT01415024|CRT
1138241|NCT01415024|Dual LV
1138242|NCT01415024|Triple Ventricle stimulation
1138243|NCT01415024|two leftventricular leads
1138244|NCT01415024|Av VV optimization
1138245|NCT01415024|Lv dp/dt measurement
1138246|NCT01415011|Afatinib (BIBW2992)
1138247|NCT01415011|EGFR Mutation
1138248|NCT01415011|Non Small Cell Lung Cancer
1138249|NCT01415011|Poor performance status
1138250|NCT01415011|Elderly
1138251|NCT01414985|Batten Disease
1138252|NCT01414972|Atherosclerosis
1138253|NCT01414972|Coronary Artery Disease
1138254|NCT01414972|Vitamin A
1138255|NCT01414972|CD4-Positive T-Lymphocytes
1138256|NCT01414972|gene expression
1138257|NCT01414959|intensive care patient
1138258|NCT01414959|intubation
1138259|NCT01414959|(please change wording as you like!)
1138260|NCT01414920|Drug Therapy
1138261|NCT01414907|Drinking Behavior
1138262|NCT01414907|Harm Reduction
1138263|NCT01414907|Tobacco Use Cessation
1138264|NCT01414907|Smoking Cessation
1138265|NCT01414907|Rehabilitation
1138266|NCT01414907|Health Promotion
1138267|NCT01414907|Nutrition Therapy
1138268|NCT01414907|Feeding Behavior
1138269|NCT01414907|Exercise
1138270|NCT01414881|ApoB (Apolipoprotein B)
1138271|NCT01414881|LDL (low density lipoprotein)
1138272|NCT01414881|mipomersen
1138273|NCT01414868|Leukotriene
1138274|NCT01414868|leukotriene receptor antagonist
1138275|NCT01414868|bronchial provocation test
1138276|NCT01414868|therapeutic outcome
1138277|NCT01414829|Peptic disease
1138278|NCT01414829|Helicobacter pylori
1138279|NCT01414829|Different methods
1138280|NCT01414816|Multiple Sclerosis
1138281|NCT01414816|Clinical Isolated Syndrome (CIS)
1138282|NCT01414803|rosuvastatin, fenofibrate, creatine kinase, alanine aminotransferase
1138283|NCT01414790|human acellular dermal matrix
1138284|NCT01414790|parotid tumor
1138285|NCT01414790|total parotidectomy
1138286|NCT01414777|c-section
1138287|NCT01414777|Hypotension after spinal anesthesia for C-section
1138288|NCT01414764|rotator cuff tendon repair surgery
1138289|NCT01414764|supraspinatus tendon repair
1138290|NCT01414751|Risk communication
1138291|NCT01414751|Shared decision making
1138292|NCT01414751|Cardiovascular diseases
1138293|NCT01414751|Hypercholesterolemia
1138294|NCT01414751|Prevention
1138295|NCT01414725|Multiple Sclerosis
1138296|NCT01414725|Mobility
1138297|NCT01414725|Balance
1138298|NCT01414725|Core Stability
1138299|NCT01414725|Physiotherapy
1138300|NCT01414712|Low- and Intermediate-Risk Prostate Cancer
1138301|NCT01414699|dietary variety
1138302|NCT01414699|course sequence
1138303|NCT01414699|preschool
1138304|NCT01414699|child feeding
1138305|NCT01414673|IUI
1138306|NCT01414673|HCG
1138307|NCT01414673|Spontaneous LH
1138308|NCT01414673|pregnancy
1138309|NCT01414660|interleukin 7
1138310|NCT01414660|transplantation
1138311|NCT01414660|liver
1138312|NCT01414660|kidney
1138313|NCT01414660|islet
1138314|NCT01414660|diabetes
1138315|NCT01414647|Bilberry
1138316|NCT01414647|Vaccinium myrtillus
1138317|NCT01414647|Metabolic syndrome
1138318|NCT01414647|Glucose metabolism
1138319|NCT01414647|Lipid metabolism
1138320|NCT01414647|Inflammation
1138321|NCT01414647|Gene expression
1138322|NCT01414621|CABG
1138327|NCT01414582|tDCS
1138328|NCT01414582|Stroke
1138329|NCT01414582|Functional MRI
1138330|NCT01414582|Motor Learning
1138331|NCT01414543|violence
1138332|NCT01414517|Prebiotics
1138333|NCT01414517|Acute Intestinal Injury
1138334|NCT01414517|Chronic radiation enteritis
1138335|NCT01414504|pneumococcal,
1138336|NCT01414504|pneumococcal polysaccharide vaccine,
1138337|NCT01414504|challenge dose,
1138338|NCT01414504|hyporesponsiveness,
1138339|NCT01414504|Papua New Guinea
1138340|NCT01414478|emesis
1138341|NCT01414478|nausea
1138342|NCT01414465|Fatty acids
1138343|NCT01414465|orlistat
1138344|NCT01414465|lipase
1138345|NCT01414465|BMC (Body Mass Index) between 30 to 40 kg/m2
1138346|NCT01414465|Women
1138347|NCT01414465|18 to 45 years
1138348|NCT01414465|Premenopausal stage
1138349|NCT01414452|Myocardial Infarction
1138350|NCT01414452|Reperfusion injury
1138351|NCT01414452|Adiponectin
1138352|NCT01414452|endothelial progenitor cells
1138353|NCT01414413|HIV
1138354|NCT01414413|AIDS
1138355|NCT01414413|Antiretroviral therapy
1138356|NCT01414413|Community-based study
1138357|NCT01414413|Cluster-randomised trial
1138358|NCT01414413|HIV testing
1138359|NCT01414413|Africa
1138360|NCT01414400|Bacteremia
1138361|NCT01414400|Spyglass
1138362|NCT01414400|Cholangioscopy
1138363|NCT01414387|carotid stenosis
1138364|NCT01414387|cerebral embolization
1138365|NCT01414387|stents
1138366|NCT01414387|stroke
1138367|NCT01414374|iron
1138368|NCT01414374|anemia
1138369|NCT01414374|herbal medicine
1138370|NCT01414374|phytotherapy
1138371|NCT01414374|Centella asiatica
1138372|NCT01414374|Hibiscus sabdariffa
1138373|NCT01414361|Coronary artery stenosis
1138374|NCT01414361|Fractional flow reserve
1138375|NCT01414361|Intravascular ultrasonography
1138376|NCT01414348|participation
1138377|NCT01414348|activities of daily living
1138378|NCT01414348|brain injuries
1138379|NCT01414348|executive function
1138380|NCT01414335|amino acids
1138381|NCT01414335|immune system
1138382|NCT01414335|vitamins
1138383|NCT01414335|chronic infection
1138384|NCT01414335|common cold
1138385|NCT01414335|ear
1138386|NCT01414335|nose
1138387|NCT01414335|throat
1138388|NCT01414309|Heart Failure
1138389|NCT01414309|Central Sleep Apnea
1138390|NCT01414309|Sleep Disordered Breathing
1138391|NCT01414309|Cardiac Dysfunction
1138392|NCT01414257|Rheumatrex
1138393|NCT01414257|High Dose
1138394|NCT01414231|AML
1138395|NCT01414231|acute myeloid leukaemia
1138396|NCT01414231|low vs intermediate dose AraC
1138397|NCT01414231|CR rate
1138398|NCT01414231|patients <60 years
1138399|NCT01414218|elderly
1138400|NCT01414218|humor
1138401|NCT01414218|general well being
1138402|NCT01414218|psychological distress
1138403|NCT01414218|health quality of life
1138404|NCT01414179|nutrition
1138405|NCT01414179|environnement
1138406|NCT01414179|cardiovascular pathology
1138407|NCT01414153|choroidal neovascularization
1138408|NCT01414153|age-related macular degeneration
1138409|NCT01414153|iSONEP
1138410|NCT01414153|sonepcizumab
1138411|NCT01414153|Lucentis
1138412|NCT01414153|ranibizumab
1138413|NCT01414153|Avastin
1138414|NCT01414153|bevacizumab
1138415|NCT01414153|Eylea
1138416|NCT01414153|aflibercept
1138417|NCT01414140|Mirena, contraception
1138418|NCT01414114|Clinical Trial, Phase 2
1138419|NCT01414114|Renal Dialysis
1138420|NCT01414114|Secondary Hyperparathyroidism
1138421|NCT01414114|Chronic kidney disease-mineral and bone disorder
1138422|NCT01414114|Parathyroid hormone
1138423|NCT01414101|Rheumatoid Arthritis
1138424|NCT01414088|Nephrology
1138425|NCT01414088|ENaC
1138426|NCT01414088|NCC
1138427|NCT01414088|NKCC
1138428|NCT01414088|Sodium channels
1138429|NCT01414088|renal biomarkers
1138430|NCT01414075|Kidney
1138431|NCT01414075|ESRD
1138432|NCT01414075|Renal
1138433|NCT01414075|End-Stage Renal Disease
1138434|NCT01414075|Anemia
1138435|NCT01414075|Oral anemia treatment
1138436|NCT01414075|Hemoglobin levels
1138437|NCT01414075|Hemodialysis
1138438|NCT01414075|Peritoneal
1138439|NCT01414075|HD
1138440|NCT01414075|PD
1138441|NCT01414075|Hb
1138442|NCT01414075|Erythropoietin
1138443|NCT01414075|Blood count
1138444|NCT01414062|Breast Cancer
1138445|NCT01414062|Healthy meals
1138446|NCT01414062|Cocinar
1138447|NCT01414062|Dietary
1138448|NCT01414062|Dietary Intervention
1138449|NCT01414062|fruits and vegetables
1138450|NCT01414062|Cancer survivor
1138451|NCT01414062|Nutrition
1138452|NCT01414049|CABG
1138453|NCT01414049|Off-pump CABG
1138454|NCT01414049|Beating heart
1138455|NCT01414049|Graft patency
1138456|NCT01414049|Computed tomography angiography
1138457|NCT01414049|Angiographic evaluation of coronary graft patency
1138458|NCT01414036|cigarette smoking
1138459|NCT01414036|patient navigation
1138460|NCT01414036|primary care
1138461|NCT01414023|High OCI-R scores
1138462|NCT01414010|healthy volunteers
1138463|NCT01414010|gut microbiota
1138464|NCT01414010|gut microbiome
1138465|NCT01414010|prebiotic
1138466|NCT01414010|probiotic
1138467|NCT01414010|antibiotic
1138468|NCT01414010|antibiotic-associated diarrhea
1138469|NCT01414010|intestinal bacterial overgrowth
1138470|NCT01413984|Trauma
1138471|NCT01413984|incarceration
1138472|NCT01413984|treatment
1138473|NCT01413984|substance abuse
1138474|NCT01413958|Nasal Decongestants
1138475|NCT01413958|Rhinitis, Allergic, Seasonal
1138476|NCT01413958|Rhinitis
1138477|NCT01413958|Nose Conditions
1138478|NCT01413958|Respiratory Tract Diseases
1138479|NCT01413958|Phenylephrine
1138480|NCT01413945|Ileocecal valve
1138481|NCT01413945|Irritable bowel syndrome
1138482|NCT01413945|small bowel bacteria
1138483|NCT01413867|hemorrhoids
1138484|NCT01413867|circular staplers
1138485|NCT01413867|mucosal resection
1138486|NCT01413867|hemostatic suture
1138487|NCT01413841|PCI
1138488|NCT01413841|oxygen
1138489|NCT01413828|breast cancer
1138490|NCT01413828|adjuvant chemotherapy
1138491|NCT01413828|trastuzumab
1138492|NCT01413828|anthracycline
1138493|NCT01413815|peri-operative
1138494|NCT01413815|cardiovascular risk
1138495|NCT01413815|oral supplementation
1138496|NCT01413815|amino acid L-arginine
1138497|NCT01413802|Thyroid surgery
1138498|NCT01413763|Actinic keratosis
1138499|NCT01413763|Atrial ectopy
1138500|NCT01413724|Administered analgesic therapy
1138501|NCT01413711|IS
1138502|NCT01413711|Pharmacokinetics
1138503|NCT01413711|Area under the curve
1138504|NCT01413711|Maximum plasma concentration
1138505|NCT01413711|Time to maximum concentration
1138506|NCT01413685|tacrolimus
1138507|NCT01413685|calcineurin
1138508|NCT01413685|pharmacodynamic
1138509|NCT01413685|TDM
1138510|NCT01413685|pharmacokinetics
1138511|NCT01413672|ostomy
1138512|NCT01413672|colostomy
1138513|NCT01413672|ileostomy
1138514|NCT01413672|barrier
1138515|NCT01413672|irritation
1138516|NCT01413659|Colorectal surgery
1138517|NCT01413659|Surgical site infection
1138518|NCT01413659|Symbiotic
1138519|NCT01413646|obesity
1138520|NCT01413646|walnuts
1138521|NCT01413646|endothelial function
1138522|NCT01413620|Vitamin E
1138523|NCT01413620|Burn
1138524|NCT01413620|Oxidation
1138525|NCT01413620|Lung Dysfunction
1138526|NCT01413620|Fatty Liver
1138527|NCT01413620|Lipid Peroxidation
1138528|NCT01413607|nephrectomy
1138529|NCT01413607|self retaining sutures
1138530|NCT01413607|laparoscopy
1138531|NCT01413594|cerebral palsy
1138532|NCT01413594|constraint-induced therapy
1138533|NCT01413594|constraint-induced movement therapy
1138534|NCT01413594|CP
1138535|NCT01413594|hemiplegia
1138536|NCT01413594|hand
1138537|NCT01413594|forced use
1138538|NCT01413594|motor control
1138539|NCT01413594|children
1138540|NCT01413594|HABIT
1138541|NCT01413594|Hand-arm bimanual intensive therapy
1138542|NCT01413594|bilateral training
1138543|NCT01413594|bimanual training
1138544|NCT01413594|functional therapy
1138545|NCT01413594|physical therapy
1138546|NCT01413594|occupational therapy
1138547|NCT01413594|intensive
1138548|NCT01413594|pediatric
1138549|NCT01413594|development
1138550|NCT01413594|upper extremity
1138551|NCT01413594|hemiplegic
1138552|NCT01413594|childhood stroke
1138553|NCT01413581|rhBSSL
1138554|NCT01413581|preterm infants
1138555|NCT01413581|Swedish Orphan Biovitrum
1138556|NCT01413581|growth velocity
1138557|NCT01413581|Prevention of growth restriction
1138558|NCT01413555|blood culture
1138559|NCT01413555|emergency department
1138560|NCT01413555|quality improvement
1138561|NCT01413542|DPPIV inhibitors
1138562|NCT01413542|ACE inhibitors
1138563|NCT01413542|Bradykinin
1138564|NCT01413542|glucagon-like peptide (GLP-1)
1138565|NCT01413542|BNP
1138566|NCT01413542|diabetes
1138567|NCT01413542|hypertension
1138568|NCT01413529|HIV infected persons with co-occurring drug use
1138569|NCT01413516|Varenicline
1138570|NCT01413516|Placebo
1138571|NCT01413516|Inpatient
1138572|NCT01413503|Pheochromocytoma
1138573|NCT01413503|Paraganglioma
1138574|NCT01413503|MIBG
1138575|NCT01413503|131I-MIBG
1138576|NCT01413503|Resistant
1138577|NCT01413503|Relapsed
1138578|NCT01413503|Treatment
1138579|NCT01413503|UCSF
1138580|NCT01413503|Pediatric
1138581|NCT01413503|Adult
1138582|NCT01413503|Oncology
1138583|NCT01413490|hepatitis C virus
1138584|NCT01413490|Interferon
1138585|NCT01413490|rimantadine
1138586|NCT01413490|liver
1138587|NCT01413477|Allergic contact dermatitis
1138588|NCT01413477|Nickel allergy
1138589|NCT01413477|Desensitization therapy
1138590|NCT01413464|Renal Transplant
1138591|NCT01413464|Venous Thrombosis
1138592|NCT01413464|Deep Vein Thrombosis
1138593|NCT01413464|Prophylaxis
1138594|NCT01413464|Bleeding
1138595|NCT01413451|Monoclonal IgG Antibody
1138596|NCT01413451|Biodistribution
1138597|NCT01413451|Pharmacokinetics
1138598|NCT01413451|HACA
1138599|NCT01413451|Safety
1138600|NCT01413451|Mesothelioma
1138601|NCT01413451|Ovarian Cancer
1138602|NCT01413451|Pancreatic Duct Cancer
1138603|NCT01413451|Non-Small Cell Lung Cancer
1138604|NCT01413438|Bevacizumab
1138605|NCT01413438|Quality of Life
1138606|NCT01413438|Glioblastoma Multiforme
1138607|NCT01413438|Neurosurgery
1138608|NCT01413438|Glioblastoma
1138609|NCT01413438|GBM
1138610|NCT01413438|Brain Tumor
1138611|NCT01413425|Smith-Lemli-Opitz Syndrome
1138612|NCT01413425|Cholesterol
1138613|NCT01413425|SLOS
1138614|NCT01413412|Ventral Hernia
1138615|NCT01413412|Postoperative Pain
1138616|NCT01413412|Ventral Hernia Pain Questionnaire
1138617|NCT01413412|Postoperative Abdominal wall and muscle function
1138618|NCT01413412|Biodex
1138619|NCT01413386|paclitaxel
1138620|NCT01413386|drug eluting stent
1138621|NCT01413373|cephalometry
1138622|NCT01413373|three-dimensional
1138623|NCT01413373|CT scan
1138624|NCT01413373|lateral radiography
1138625|NCT01413373|facial symmetry
1138626|NCT01413373|maxillomandibular dysmorphoses
1138627|NCT01413334|Coronary artery disease
1138628|NCT01413334|CT
1138629|NCT01413321|Brain Injuries
1138630|NCT01413321|Post Traumatic Encephalopathy
1138631|NCT01413321|TBI (Traumatic Brain Injury)
1138632|NCT01413321|Cerebral Stroke
1138633|NCT01413321|Vascular Accidents, Brain
1138634|NCT01413321|Cerebrovascular Apoplexy
1138635|NCT01413321|Cerebrovascular Accident
1138636|NCT01413321|hemiparesis
1138637|NCT01413308|Fontan
1138638|NCT01413308|lung function test
1138639|NCT01413308|nitric oxide production
1138640|NCT01413308|NYHA class 1-2 without acute or chronic specified lung disease
1138641|NCT01413295|Colorectal Neoplasms
1138642|NCT01413295|Dendritic Cells
1138643|NCT01413282|Acute coronary syndrome
1138644|NCT01413269|breast cancer patients
1138645|NCT01413269|breast conservation surgery
1138646|NCT01413269|hypofractionated radiotherapy
1138647|NCT01413243|Multipe sclerosis, Trichuris suis ova
1138648|NCT01413230|Systemic lupus erythematosus
1138649|NCT01413230|vitamin D supplementation
1138650|NCT01413230|regulatory T cells
1138651|NCT01413230|Th17 cells
1138652|NCT01413204|TA-7284
1138653|NCT01413204|JNJ-28431754
1138654|NCT01413204|Canagliflozin
1138655|NCT01413204|Sodium Glucose Co-transporter (SGLT2 inhibitor)
1138656|NCT01413178|Myeloma
1138657|NCT01413178|Multiple Myeloma
1138658|NCT01413178|Light chain Multiple Myeloma
1138659|NCT01413178|MM
1138660|NCT01413178|Autologous Hematopoietic Stem Cell Transplantation
1138661|NCT01413178|Busulfan
1138662|NCT01413178|Busulfex
1138663|NCT01413178|Myleran
1138664|NCT01413178|Melphalan
1138665|NCT01413178|Alkeran
1138666|NCT01413178|G-CSF
1138667|NCT01413178|Filgrastim
1138668|NCT01413178|NeupogenTM
1138669|NCT01413178|Questionnaire
1138670|NCT01413178|Survey
1138671|NCT01413178|Quality of Life
1138672|NCT01413178|QOL
1138673|NCT01413152|men having sex with men
1138674|NCT01413139|peripheral Vascular Disease
1138675|NCT01413139|claudication
1138676|NCT01413139|rest pain
1138677|NCT01413126|Peanut
1138678|NCT01413126|Blood glucose
1138679|NCT01413126|Insulin
1138680|NCT01413126|Non-esterified free fatty acids
1138681|NCT01413126|Glucagon-like peptide-1
1138682|NCT01413126|Peptide YY
1138683|NCT01413126|Cholecystokinin
1138684|NCT01413126|Appetitive
1138685|NCT01413126|Food intake
1138686|NCT01413087|Pancreatic cancer
1138687|NCT01413087|Gemcitabine
1138688|NCT01413087|BC-819
1138689|NCT01413087|Adenocarcinoma
1138690|NCT01413087|Resectable
1138691|NCT01413087|H19 gene
1138692|NCT01413087|DTA-H19
1138693|NCT01413087|BioCancell
1138694|NCT01413074|End Stage Renal Disease
1138695|NCT01413074|ESRD
1138696|NCT01413074|Peritoneal Dialysis
1138697|NCT01413074|PD
1138698|NCT01413074|Hemodialysis
1138699|NCT01413074|HD
1138702|NCT01413048|Essential Hypertension
1138703|NCT01413048|Hypertension
1138704|NCT01413035|Diabetes
1138705|NCT01413035|Diabetes Medicines: Oral Hypoglycemic Drugs and Insulins.
1138706|NCT01413035|Umbilical Cord/placenta-Derived MSC
1138707|NCT01413035|Transplantation
1138708|NCT01413009|delirium
1138709|NCT01413009|ICU
1138710|NCT01413009|spontaneous awakening trials
1138711|NCT01413009|spontaneous breathing trials
1138712|NCT01413009|early mobility
1138713|NCT01412970|hemodynamic monitoring
1138714|NCT01412970|volume responsiveness
1138715|NCT01412970|electrical impedance tomography
1138716|NCT01412957|Best Supportive Care
1138717|NCT01412957|Panitumumab
1138718|NCT01412957|Chemorefractory
1138719|NCT01412957|Wild-type KRAS
1138720|NCT01412957|Overall Survival
1138721|NCT01412957|Phase 3
1138722|NCT01412944|Psoriasis
1138723|NCT01412944|plaque
1138724|NCT01412944|inflammatory skin disease
1138725|NCT01412944|scaly patches
1138726|NCT01412944|AIN457
1138727|NCT01412944|secukinumab
1138728|NCT01412944|Moderate to severe
1138729|NCT01412918|Tinnitus
1138730|NCT01412918|Inhibitor Device
1138731|NCT01412918|SCN9 gene
1138732|NCT01412918|Ringing in the ears
1138733|NCT01412918|Milwaukee
1138734|NCT01412918|Medical College of Wisconsin
1138735|NCT01412905|screening
1138736|NCT01412905|diabetic retinopathy
1138737|NCT01412892|Neurofibromatosis type 1
1138738|NCT01412892|Everolimus
1138739|NCT01412892|Plexiform neurofibromas
1138740|NCT01412892|Rapamycin
1138741|NCT01412879|contiguous stage II mantle cell lymphoma
1138742|NCT01412879|noncontiguous stage II mantle cell lymphoma
1138743|NCT01412879|stage III mantle cell lymphoma
1138744|NCT01412879|stage IV mantle cell lymphoma
1138745|NCT01412866|schizophrenia
1138746|NCT01412866|severe mental illness
1138747|NCT01412866|nicotine
1138748|NCT01412866|smoking
1138749|NCT01412866|motivation
1138750|NCT01412866|electronic decision support system
1138751|NCT01412866|motivational interviewing
1138753|NCT01412840|Ureterolithiasis
1138754|NCT01412840|Pain
1138755|NCT01412840|Complementary
1138756|NCT01412840|RCT
1138757|NCT01412827|Single-photon emission computed tomography
1138758|NCT01412827|myocardial perfusion imaging
1138759|NCT01412827|rest/stress
1138760|NCT01412827|treadmill
1138761|NCT01412827|persantine
1138762|NCT01412827|half-dose
1138763|NCT01412827|radiotracer
1138764|NCT01412827|tetrofosmin
1138765|NCT01412827|Thallium
1138766|NCT01412827|cadmium zinc telluride
1138767|NCT01412827|diagnostic
1138768|NCT01412827|prognostic
1138769|NCT01412814|Total knee arthroplasty
1138770|NCT01412814|Total knee replacement
1138771|NCT01412814|End-stage knee osteoarthritis
1138772|NCT01412814|Gait patterns
1138773|NCT01412814|Neuromuscular education
1138774|NCT01412801|Group B streptococcus
1138775|NCT01412801|GBS
1138776|NCT01412801|Vaccine
1138777|NCT01412801|Prevention of group B streptococcus infection
1138778|NCT01412788|breast cancer
1138779|NCT01412788|Breast Conserving Surgery
1138780|NCT01412788|Peri-areolar Incision
1138781|NCT01412775|stress
1138782|NCT01412775|burnout
1138783|NCT01412775|exhaustion
1138784|NCT01412762|Surgery
1138785|NCT01412762|interview
1138786|NCT01412762|11-087
1138787|NCT01412749|registry
1138788|NCT01412749|database
1138789|NCT01412749|eHNS
1138790|NCT01412749|Endoscopic Head and Neck Surgery
1138791|NCT01412749|Transoral Endoscopic Surgery Trial
1138792|NCT01412749|TEST
1138793|NCT01412749|melanoma
1138794|NCT01412749|head and neck surgery
1138795|NCT01412723|Iron Deficiency
1138796|NCT01412723|Child, Preschool
1138797|NCT01412723|Dietary Iron
1138798|NCT01412723|Ferrous sulfate
1138799|NCT01412723|Bis-glycino iron II
1138800|NCT01412710|Type 2 Diabetes
1138801|NCT01412710|Cholecalciferol
1138802|NCT01412710|Vitamin D
1138803|NCT01412710|Insulin resistance
1138804|NCT01412710|Cardiovascular disease risk
1138805|NCT01412710|Minorities
1138806|NCT01412697|Rural youth
1138807|NCT01412697|Theory-based intervention
1138808|NCT01412697|Randomized by schools
1138809|NCT01412697|Fruit and vegetable intake
1138810|NCT01412697|Health classes
1138811|NCT01412671|Nexavar
1138812|NCT01412671|unresectable or advanced renal cell carcinoma
1138813|NCT01412645|Obesity
1138814|NCT01412645|Inflammation
1138815|NCT01412645|Metabolic Syndrome
1138816|NCT01412645|Insulin sensitivity
1138817|NCT01412645|Osteoporosis
1138818|NCT01412645|Bone turnover
1138819|NCT01412645|Ectopic fat accumulation
1138820|NCT01412645|Resveratrol
1138821|NCT01412619|Neurological Outcome
1138822|NCT01412619|Intraoperative intracerebral Oxygen level
1138823|NCT01412619|Mean arterial blood pressure
1138824|NCT01412619|Central venous blood pressure
1138825|NCT01412619|Cardiac output
1138826|NCT01412619|Serum Lactate
1138827|NCT01412619|Venous oxygen saturation
1138828|NCT01412619|Fluid balance
1138829|NCT01412606|Unexplained infertility-endometrial scratching
1138830|NCT01412606|effect of endometrial biopsy (scratching) on clinical pregnancy rates in women with unexplained infertility
1138831|NCT01412567|Hepatitis B
1138832|NCT01412567|HBsAg
1138833|NCT01412567|Antenatal
1138834|NCT01412567|Pregnancy
1138835|NCT01412567|Vertical transmission
1138836|NCT01412567|Placenta
1138837|NCT01412567|HBV DNA
1138838|NCT01412554|Insulin resistance
1138839|NCT01412554|Diabetes mellitus
1138840|NCT01412554|Adipositas
1138841|NCT01412541|Arms
1138842|NCT01412541|Experimental
1138843|NCT01412541|Drug Coated Angioplasty Balloon
1138844|NCT01412541|Active Comparator
1138845|NCT01412541|Standard Angioplasty Balloon
1138846|NCT01412515|mTOR inhibitors
1138847|NCT01412502|Tissue Donors
1138848|NCT01412502|Tissue and Organ Procurement
1138849|NCT01412502|Brain death
1138850|NCT01412502|Withdrawal of life support
1138851|NCT01412489|Uterine synechiae
1138852|NCT01412489|HyalobarrierR Gel Endo
1138853|NCT01412489|Operative hysteroscopy
1138854|NCT01412489|submucous myoma
1138855|NCT01412450|symptomatic popliteal artery stenosis or occlusion
1138856|NCT01412437|PKU
1138857|NCT01412437|MRI
1138858|NCT01412437|neurocognition
1138859|NCT01412437|sapropterin dihydrochloride
1138860|NCT01412424|acromegaly
1138861|NCT01412424|IGF-1
1138862|NCT01412424|growth hormone
1138863|NCT01412424|Octreolin
1138864|NCT01412424|octreotide
1138865|NCT01412424|somatostatin analog
1138866|NCT01412411|Anemia
1138867|NCT01412411|Growth
1138868|NCT01412411|Infants
1138869|NCT01412411|Focus of the study is to assess the level of anemia and growth indicators among the infants
1138870|NCT01412398|Fosrenol
1138871|NCT01412398|Hyperphosphatemia
1138872|NCT01412398|Continuous Cyclic Peritoneal Dialysis
1138873|NCT01412372|Irritable Bowel Syndrome
1138874|NCT01412372|Diarrhea
1138875|NCT01412372|Mesalamine
1138876|NCT01412372|Gastroenteritis
1138877|NCT01412372|abdominal pain
1138878|NCT01412372|hypersensitivity
1138879|NCT01412359|TPN Cholestasis
1138880|NCT01412346|human
1138881|NCT01412346|clinical trial
1138882|NCT01412346|dietary intervention study
1138883|NCT01412346|blood pressure
1138884|NCT01412346|cardiovascular biomarkers
1138885|NCT01412346|nutritional biomarkers
1138886|NCT01412346|gene expression
1138887|NCT01412307|Hodgkin Lymphoma
1138888|NCT01412307|Lenalidomide
1138889|NCT01412307|Bendamustine
1138890|NCT01412307|Salvage therapy
1138891|NCT01412307|Palliation
1138892|NCT01412294|gastric cancer
1138893|NCT01412294|recurrent gastric cancer
1138894|NCT01412294|adenocarcinoma of the stomach
1138895|NCT01412294|capecitabine
1138896|NCT01412294|xp
1138897|NCT01412281|Influenza
1138898|NCT01412281|Virus
1138899|NCT01412281|Vaccination
1138900|NCT01412281|Immunisation
1138901|NCT01412268|Obesity
1138902|NCT01412268|Bariatric surgery
1138903|NCT01412268|Behavioral changes
1138904|NCT01412268|Eating habits
1138905|NCT01412268|Eating addiction
1138906|NCT01412242|Deep vein thrombosis
1138907|NCT01412242|Ultrasonography
1138908|NCT01412242|Pulmonary embolism
1138909|NCT01412242|D-dimer
1138910|NCT01412242|Pre-test probability
1138911|NCT01412229|Head and neck cancer
1138912|NCT01412229|Phase II
1138913|NCT01412229|Locally advanced
1138914|NCT01412229|Squamous Cell
1138915|NCT01412229|Carboplatin
1138916|NCT01412229|Nab-paclitaxel
1138917|NCT01412229|Abraxane
1138918|NCT01412229|Cetuximab
1138919|NCT01412229|Induction
1138920|NCT01412229|Chemotherapy
1138921|NCT01412216|Sedentarism
1138922|NCT01412216|Physical inactivity
1138923|NCT01412216|Fish oil
1138924|NCT01412216|Omega-3 fatty acids
1138925|NCT01412216|Endothelial dysfunction
1138926|NCT01412216|Insulin resistance
1138927|NCT01412216|Metabolic syndrome
1138928|NCT01412216|peripheral arterial disease
1138929|NCT01412203|Physical activity
1138930|NCT01412203|Healthy weight
1138931|NCT01412203|Healthy eating
1138932|NCT01412203|Physical fitness
1138933|NCT01412203|Children
1138934|NCT01412203|School based
1138935|NCT01412203|Community based
1138936|NCT01412203|Obesity
1138937|NCT01412203|Health promotion
1138938|NCT01412203|Socio-ecological
1138939|NCT01412203|Environment based
1138940|NCT01412190|Skin rejuvenation
1138941|NCT01412177|Meniere's Disease
1138942|NCT01412177|Vertigo
1138943|NCT01412177|Definitive vertigo
1138944|NCT01412177|Vertigo episodes
1138945|NCT01412177|Vertigo frequency
1138946|NCT01412177|Tinnitus
1138947|NCT01412177|Hearing loss
1138948|NCT01412177|Aural fullness
1138949|NCT01412164|DES
1138950|NCT01412164|CAD
1138951|NCT01412164|FIREHAWK
1138952|NCT01412164|MicroPort
1138953|NCT01412164|PCI
1138954|NCT01412151|Symptomatic
1138955|NCT01412151|Huntington's Disease
1138956|NCT01412151|HD
1138957|NCT01412125|Biomarkers
1138958|NCT01412125|Genetic polymorphism
1138959|NCT01412125|Neuroimaging markers
1138960|NCT01412125|Neuropsychology
1138961|NCT01412099|Exercise
1138962|NCT01412099|Fast Foods
1138963|NCT01412099|Fruits
1138964|NCT01412099|Vegetables
1138965|NCT01412099|Beverages
1138966|NCT01412099|Non-traditional college students
1138967|NCT01412099|Motivational Interviewing
1138968|NCT01412099|Peer Counselors
1138969|NCT01412099|Cancer Prevention
1138970|NCT01412073|caesarean section, intrapartum haemorrhage
1138971|NCT01412060|Schizophrenia
1138972|NCT01412060|Schizophrenic Disorder
1138973|NCT01412047|Paroxysmal Nocturnal Hemoglobinuria
1138974|NCT01412047|PNH
1138975|NCT01412047|Human Anti-Human Antibody
1138976|NCT01412047|HAHA
1138977|NCT01412047|Soliris
1138978|NCT01412047|eculizumab
1138979|NCT01412034|Homozygous Familial Hypercholesterolemia
1138980|NCT01412034|Familial Hypercholesterolemia
1138981|NCT01412034|HDL mimetic
1138982|NCT01412034|ApoA-1
1138983|NCT01412021|Arthritis, Juvenile Rheumatoid
1138984|NCT01412008|MRI
1138985|NCT01412008|Magnetic Resonance Imaging
1138986|NCT01412008|Botox
1138987|NCT01412008|botulinum toxin
1138988|NCT01412008|neurological
1138989|NCT01412008|stroke
1138990|NCT01412008|spasticity
1138991|NCT01412008|muscle stiffness
1138992|NCT01412008|diffusion
1138993|NCT01412008|Weill Cornell
1138994|NCT01412008|New York Presbyterian Hospital
1138995|NCT01412008|O'Dell
1138996|NCT01411995|intrauterine device
1138997|NCT01411995|pain
1138998|NCT01411995|lidocaine gel
1138999|NCT01411982|PACAP (pituitary adenylate cyclase-activating polypeptide)
1139000|NCT01411982|Nephrotic syndrome
1139001|NCT01411982|Thrombosis
1139002|NCT01411982|Platelets
1139003|NCT01411969|external nasal dilator strip
1139004|NCT01411969|nasal valve
1139005|NCT01411969|acoustic rhinometry
1139006|NCT01411956|Health Behavior Theory
1139007|NCT01411956|Patient Education
1139008|NCT01411956|Hypertension
1139009|NCT01411956|Health beliefs related to hypertension and hypertension treatment
1139010|NCT01411943|Epigenetics
1139011|NCT01411943|Inflammatory
1139012|NCT01411943|Psychoneurologic Symptoms
1139013|NCT01411943|Cognitive Dysfunction
1139014|NCT01411943|Pain
1139015|NCT01411943|Fatigue
1139016|NCT01411943|Sleep Disturbance
1139017|NCT01411943|Depression
1139018|NCT01411943|Depressive Symptoms
1139019|NCT01411943|Anxiety
1139020|NCT01411943|Breast Cancer
1139021|NCT01411930|Insulin resistance
1139022|NCT01411930|Antipsychotics
1139023|NCT01411930|Olanzapine
1139024|NCT01411930|Aripiprazole
1139025|NCT01411917|surgical stomas
1139026|NCT01411917|Nerve block
1139027|NCT01411904|Leukemia
1139028|NCT01411904|magnetic needle
1139029|NCT01411904|magnetic nanoparticles
1139030|NCT01411904|CD34
1139031|NCT01411891|Arthroplasty
1139032|NCT01411891|Infection Control
1139033|NCT01411878|Teen Pregnancy Prevention
1139034|NCT01411865|Pragmatic randomized controlled trial
1139035|NCT01411865|Cardiovascular risk reduction
1139036|NCT01411865|Knowledge translation
1139037|NCT01411865|Clinical practice guidelines
1139038|NCT01411865|Administrative databases
1139039|NCT01411852|fluid volume resuscitation
1139040|NCT01411852|trauma
1139041|NCT01411852|hemorrhagic shock
1139042|NCT01411839|Depression
1139043|NCT01411839|Latinos
1139044|NCT01411839|Adherence
1139045|NCT01411839|Cognitive-Behavioral Therapy
1139046|NCT01411839|HIV/AIDS
1139047|NCT01411826|Colon cancer screening
1139048|NCT01411787|Breast cancer
1139049|NCT01411787|neoadjuvant chemotherapy
1139050|NCT01411787|exercise
1139051|NCT01411787|Ki-67
1139052|NCT01411774|Obsessive-compulsive disorder
1139053|NCT01411774|OCD
1139054|NCT01411761|indirect hyperbilirubinemia
1139055|NCT01411761|very low birth weight infants
1139056|NCT01411722|Electrical Activity of Diaphragm
1139057|NCT01411722|Weaning outcome
1139058|NCT01411722|NAVA
1139059|NCT01411683|Cost estimates
1139060|NCT01411683|Complete Denture
1139061|NCT01411683|Dental Economics
1139062|NCT01411683|Dental Implants
1139063|NCT01411683|Dental Prosthesis, Implant-Supported
1139064|NCT01411683|Denture Retention
1139065|NCT01411683|Edentulous
1139066|NCT01411683|Edentulism
1139067|NCT01411683|Mini dental implant
1139068|NCT01411683|Oral Health-Related Quality of Life
1139069|NCT01411683|Overdenture
1139070|NCT01411683|Patient Acceptance of Health Care
1139071|NCT01411683|Quality of Health Care
1139072|NCT01411683|Quality of Life
1139073|NCT01411683|Patient Satisfaction
1139074|NCT01411670|Human Protein C
1139075|NCT01411670|Activated protein C
1139076|NCT01411670|Microcirculation
1139077|NCT01411670|Septic Shock
1139078|NCT01411670|Sepsis
1139079|NCT01411644|POF
1139080|NCT01411644|IOF
1139081|NCT01411644|Poor response
1139082|NCT01411644|early menopause
1139083|NCT01411644|Primary amenorrhea
1139084|NCT01411631|Polyphenols
1139085|NCT01411631|Cognition
1139086|NCT01411631|Cognitive function
1139087|NCT01411631|Driving performance
1139088|NCT01411631|Stress
1139089|NCT01411618|Antiplaque agents
1139090|NCT01411618|chemical plaque control
1139091|NCT01411618|oral hygiene
1139092|NCT01411618|essential oils
1139093|NCT01411618|alcohol
1139094|NCT01411618|mouthwash
1139095|NCT01411605|Obesity
1139096|NCT01411605|Adolescent
1139097|NCT01411605|Exercise training
1139098|NCT01411605|Exercise tolerance
1139099|NCT01411592|All-Ceramic
1139100|NCT01411592|Resin-bonded Fixed Dental Protheses
1139101|NCT01411592|Single Retainer
1139102|NCT01411592|Randomized Clinical Trial
1139103|NCT01411592|Resin Bond
1139104|NCT01411592|Bonding System
1139105|NCT01411579|liver
1139106|NCT01411579|metastases
1139107|NCT01411579|hepatocarcinoma
1139108|NCT01411579|MR
1139109|NCT01411579|DWI
1139110|NCT01411579|chemotherapy
1139111|NCT01411566|KLIPS
1139112|NCT01411553|ICU
1139113|NCT01411553|Telemetry
1139114|NCT01411553|ECG lead wire monitoring
1139115|NCT01411553|Infection
1139116|NCT01411553|Nuisance alarms
1139117|NCT01411540|Body composition
1139118|NCT01411540|Health markers
1139119|NCT01411540|Diet
1139120|NCT01411527|Hormones
1139121|NCT01411527|Endocrine Disrupters
1139122|NCT01411527|Polymorphism, Genetic
1139123|NCT01411514|Relapsing remittent multipse sclerosis
1139124|NCT01411514|Secondary progressive multiple sclerosis
1139125|NCT01411514|Clinically isolated syndrome
1139126|NCT01411514|Primary progressive multiple sclerosis
1139127|NCT01411501|Acupuncture
1139128|NCT01411501|Functional constipation
1139129|NCT01411488|Focus: anal erosion
1139130|NCT01411449|Primovist
1139131|NCT01411449|MRI agent
1139132|NCT01411436|Nexavar
1139133|NCT01411436|unresectable hepatocellular carcinoma
1139134|NCT01411423|Nexavar
1139135|NCT01411423|Unresectable or advanced renal cell carcinoma
1139136|NCT01411410|phase I
1139137|NCT01411410|phosphatidylinositol 3΄-kinase (PI3K)
1139138|NCT01411410|paclitaxel
1139139|NCT01411410|Maximum tolerated Dose
1139140|NCT01411397|Infection
1139141|NCT01411397|Prosthesis
1139142|NCT01411397|Recurrence
1139143|NCT01411397|Strangulation
1139144|NCT01411384|Keratoconus (KC)
1139145|NCT01411384|Corneal collagen cross-linking (CXL)
1139146|NCT01411384|Corneal hysteresis (CH)
1139147|NCT01411384|Corneal resistance factor (CRF)
1139148|NCT01411384|Ocular Response Analyzer (ORA)
1139149|NCT01411371|Atrial fibrillation
1139150|NCT01411371|Heart failure
1139151|NCT01411371|Catheter ablation
1139152|NCT01411358|influenza
1139153|NCT01411358|vaccine
1139154|NCT01411358|immunogenicity
1139155|NCT01411345|Prostate Cancer
1139156|NCT01411345|Prostate Adenocarcinoma
1139157|NCT01411332|Prostate Cancer
1139158|NCT01411332|Prostate Adenocarcinoma
1139159|NCT01411319|Prostate Cancer
1139160|NCT01411319|Prostate Adenocarcinoma
1139161|NCT01411293|cardiovascular disease
1139162|NCT01411293|oxidative stress
1139163|NCT01411293|dairy consumption
1139164|NCT01411293|metabolic syndrome
1139165|NCT01411293|obesity
1139166|NCT01411293|endothelial function
1139167|NCT01411267|Relapse
1139168|NCT01411267|Lymphoblastic
1139169|NCT01411267|Leukemia
1139170|NCT01411267|AC220
1139171|NCT01411267|Refractory
1139172|NCT01411267|Myelogenous
1139173|NCT01411267|Acute
1139174|NCT01411267|Childhood
1139175|NCT01411267|Pediatric
1139176|NCT01411267|ALL
1139177|NCT01411267|AML
1139178|NCT01411254|DME
1139179|NCT01411241|Dengue
1139180|NCT01411241|Dengue Hemorrhagic Fever
1139181|NCT01411241|CYD Dengue Vaccines
1139182|NCT01411241|Pentaxim™
1139183|NCT01411228|Gaucher disease
1139184|NCT01411228|pediatrics
1139185|NCT01411215|Rheumatoid arthritis
1139186|NCT01411215|ankylosing spondylitis
1139187|NCT01411215|observational study
1139188|NCT01411202|Malignant Pleural Effusion
1139189|NCT01411202|Doxycycline
1139190|NCT01411202|Pleurodesis
1139191|NCT01411202|Pleurx catheter
1139192|NCT01411189|therapeutic upper gastrointestinal endoscopy
1139449|NCT01410214|complete resection
1139193|NCT01411189|percutaneous endoscopic gastrostomy
1139194|NCT01411189|endoscopic mucosal resection
1139195|NCT01411189|endoscopic submucosal dissection
1139196|NCT01411189|PEG
1139197|NCT01411189|EMR
1139198|NCT01411189|ESD
1139199|NCT01411189|endoscopic hemostasis
1139200|NCT01411176|upper gastrointestinal endoscopy
1139201|NCT01411176|suspected gastric cancer
1139202|NCT01411163|Premanifest
1139203|NCT01411163|At-Risk
1139204|NCT01411163|Huntington's Disease
1139205|NCT01411163|HD
1139206|NCT01411150|Premanifest
1139207|NCT01411150|At-Risk
1139208|NCT01411150|Huntington's Disease
1139209|NCT01411150|HD
1139210|NCT01411124|gabapentin
1139211|NCT01411124|restless leg syndrome
1139212|NCT01411111|Drug-drug interaction
1139213|NCT01411111|rosuvastatin
1139214|NCT01411111|asthma
1139215|NCT01411111|FLAP inhibitor
1139216|NCT01411085|Schizophrenia
1139217|NCT01411085|Alcoholism
1139218|NCT01411085|Dual Diagnosis
1139219|NCT01411085|Desipramine
1139220|NCT01411085|Risperidone
1139221|NCT01411072|Biomarker directed adjuvant chemotherapy
1139222|NCT01411072|resected pancreas cancer
1139223|NCT01411059|yoga biomechanics seniors
1139224|NCT01411046|Glucocorticoid
1139225|NCT01411046|polymorphism
1139226|NCT01411046|Glucocorticoid receptor gene
1139227|NCT01411046|rheumatoid arthritis
1139228|NCT01411046|adrenal insufficiency
1139229|NCT01411046|prednisolone treatment
1139230|NCT01411007|Nicotine
1139231|NCT01411007|Cigarettes
1139232|NCT01411007|Smoker
1139233|NCT01411007|realtime fMRI
1139234|NCT01411007|brain imaging
1139235|NCT01411007|imaging
1139236|NCT01410994|glomerular filtration rate
1139237|NCT01410955|probiotics
1139238|NCT01410955|diarrhoea
1139239|NCT01410955|prevention
1139240|NCT01410955|colon cancer
1139241|NCT01410955|irinotecan
1139242|NCT01410942|Prostate Cancer
1139243|NCT01410942|Multimodal Therapy
1139244|NCT01410942|MMT
1139245|NCT01410942|Fatigue
1139246|NCT01410942|Cognitive Behavioral Therapy
1139247|NCT01410942|CBT
1139248|NCT01410942|Radiation therapy
1139249|NCT01410942|Radiotherapy
1139250|NCT01410942|RT
1139251|NCT01410942|Functional Assessment of Chronic Illness Therapy - Fatigue
1139252|NCT01410942|FACIT-F
1139253|NCT01410942|Androgen deprivation therapy
1139254|NCT01410942|Methylphenidate
1139255|NCT01410942|Methylphenidate Hydrochloride
1139256|NCT01410942|Ritalin
1139257|NCT01410942|Concerta
1139258|NCT01410942|Placebo
1139259|NCT01410942|Sugar Pill
1139260|NCT01410929|multiple myeloma
1139261|NCT01410929|VCF
1139262|NCT01410929|Vertebral Compression Fracture
1139263|NCT01410929|Spine
1139264|NCT01410929|Kyphoplasty
1139265|NCT01410929|Back pain
1139266|NCT01410929|Cancer
1139267|NCT01410916|STEC-HUS
1139268|NCT01410916|Shiga-like toxin-producing Escherichia Coli Hemolytic-Uremic Syndrome
1139269|NCT01410916|uncontrolled complement activation
1139270|NCT01410864|cerebrospinal fluid leaks
1139271|NCT01410864|dural opening
1139272|NCT01410864|dural sealing
1139273|NCT01410838|Obesity
1139274|NCT01410838|Food preferences
1139275|NCT01410838|Eating Behavior
1139276|NCT01410825|WAS
1139277|NCT01410825|Wiskott
1139278|NCT01410825|Gene Transfer
1139279|NCT01410825|Gene Therapy
1139280|NCT01410812|Interest in exercising more
1139281|NCT01410799|Growth Hormone Releasing Hormone
1139282|NCT01410799|Growth Hormone Insufficiency
1139283|NCT01410799|Aging
1139284|NCT01410799|Growth Hormone
1139285|NCT01410799|Physiologic Effects of Drugs
1139286|NCT01410799|Hormones, Hormone Substitutes, and Hormone Antagonists
1139287|NCT01410799|Hormones
1139288|NCT01410760|Imaging study
1139289|NCT01410760|Perfusion Computerised Tomography
1139290|NCT01410747|long-term treatment
1139291|NCT01410747|tacrolimus
1139292|NCT01410747|renal failure
1139293|NCT01410734|cholecystectomy
1139294|NCT01410734|chronic right upper quadrant pain
1139295|NCT01410721|TBI
1139296|NCT01410721|PTSD
1139297|NCT01410721|Veterans
1139298|NCT01410708|Human Breast Cancer Tissue
1139299|NCT01410708|Dasatinin
1139300|NCT01410695|Rheumatoid Arthritis
1139301|NCT01410695|RA
1139302|NCT01410695|masitinib
1139303|NCT01410695|DMARD
1139304|NCT01410695|methotrexate
1139305|NCT01410682|oral hygiene
1139306|NCT01410682|ventilator-associated pneumonia
1139307|NCT01410682|infection control
1139308|NCT01410682|intensive care
1139309|NCT01410682|pediatric nursing
1139310|NCT01410682|pediatrics
1139311|NCT01410669|Self-efficacy
1139312|NCT01410669|Intimate partner violence
1139313|NCT01410669|Randomized clinical trial
1139314|NCT01410669|Depression
1139315|NCT01410656|Survivors
1139316|NCT01410643|puberty
1139317|NCT01410643|body composition
1139318|NCT01410643|metabolism
1139319|NCT01410643|obesity
1139320|NCT01410643|optimization of body composition
1139321|NCT01410643|pubertal transition
1139322|NCT01410604|Metformin
1139323|NCT01410604|Obesity
1139324|NCT01410604|Insulin resistance
1139325|NCT01410604|Interleukin six
1139326|NCT01410604|Adiponectin
1139327|NCT01410604|High sensitivity C reactive protein.
1139328|NCT01410604|Tumour Necrosis Factor alpha
1139329|NCT01410591|transjugular intrahepatic portosystemic shunt
1139330|NCT01410591|TIPS
1139331|NCT01410591|liver cirrhosis
1139332|NCT01410591|variceal bleeding
1139333|NCT01410591|8- or 10-mm covered stent
1139334|NCT01410578|sTRE-1
1139335|NCT01410578|PCT
1139336|NCT01410578|CRP
1139337|NCT01410578|sepsis
1139338|NCT01410578|bacteremia
1139339|NCT01410578|FUO
1139340|NCT01410578|diagnosis
1139341|NCT01410578|prognosis
1139342|NCT01410565|Bladder Cancer
1139343|NCT01410565|Non-Muscle Invasive Bladder Cancer
1139344|NCT01410565|NMIBC
1139345|NCT01410565|Apaziquone
1139346|NCT01410565|EOquin
1139347|NCT01410565|GU Cancer
1139348|NCT01410565|TURBT
1139349|NCT01410552|Primary prevention
1139350|NCT01410552|Secondary prevention
1139351|NCT01410539|Stent Thrombosis
1139352|NCT01410539|Percutaneous Coronary Intervention
1139353|NCT01410539|Bare Metal Stent
1139354|NCT01410539|Drug Eluting Stent
1139355|NCT01410539|Residual Platelet Reactivity
1139356|NCT01410539|Optical Coherence Tomography
1139357|NCT01410539|OCT
1139358|NCT01410526|VAC
1139359|NCT01410526|Severe abdominal sepsis
1139360|NCT01410526|Peritoneal immune reaction
1139361|NCT01410526|Peritonitis
1139362|NCT01410526|Immune peritoneal reaction when abdominal sepsis is treated with VAC
1139363|NCT01410500|multiple myeloma
1139364|NCT01410487|pulmonary circulation
1139365|NCT01410474|Meningococcal
1139366|NCT01410474|ACWY
1139367|NCT01410474|bacterial meningitis
1139368|NCT01410474|conjugate vaccine
1139369|NCT01410474|healthy
1139370|NCT01410474|children
1139371|NCT01410474|adolescents
1139372|NCT01410474|Taiwan
1139373|NCT01410461|painful bladder
1139374|NCT01410461|physical therapy
1139375|NCT01410461|levator ani
1139376|NCT01410448|Immunosuppression
1139377|NCT01410448|Kidney transplantation
1139378|NCT01410448|everolimus
1139379|NCT01410448|safety
1139380|NCT01410422|COPD
1139381|NCT01410422|Bronchiectasis
1139382|NCT01410422|Metabolomics
1139383|NCT01410409|Osteoarthritis, Knee
1139384|NCT01410409|Treatment Outcome
1139385|NCT01410409|Time Factors
1139386|NCT01410409|Arthroplasty, Replacement
1139387|NCT01410409|Rehabilitation
1139388|NCT01410409|Combined Modality Therapy
1139389|NCT01410409|Middle Aged
1139390|NCT01410409|Aged
1139391|NCT01410409|Aged, 80 and over
1139392|NCT01410409|Male
1139393|NCT01410409|Female
1139394|NCT01410409|Humans
1139395|NCT01410409|Analysis of Variance
1139396|NCT01410396|Atrial Fibrillation
1139397|NCT01410396|Stroke
1139398|NCT01410383|hypercholesterolemia,
1139399|NCT01410383|dyslipidemia,
1139400|NCT01410383|thyroid,
1139401|NCT01410383|safety,
1139402|NCT01410383|Heterozygous Familial Hypercholesterolaemia
1139403|NCT01410383|coronary artery disease
1139404|NCT01410370|Endostar
1139405|NCT01410370|Radiotherapy
1139406|NCT01410370|Brain Metastases
1139407|NCT01410357|serious mental illness
1139408|NCT01410357|diabetes
1139409|NCT01410344|HIV
1139410|NCT01410344|ALL
1139411|NCT01410344|AML
1139412|NCT01410344|MDS
1139413|NCT01410344|Non-Hodgkin Lymphoma
1139414|NCT01410331|CLI
1139415|NCT01410331|peripheral vascular disease
1139416|NCT01410331|PVD
1139417|NCT01410331|PAD
1139418|NCT01410331|SDF-1
1139419|NCT01410318|Atherosclerosis
1139420|NCT01410318|PESA
1139421|NCT01410318|Subclinical
1139422|NCT01410318|Cardiovascular diseases
1139423|NCT01410318|Coronary disease
1139424|NCT01410318|Heart diseases
1139425|NCT01410318|Heart Failure
1139426|NCT01410318|Myocardial Infarction
1139427|NCT01410318|Stroke
1139428|NCT01410318|Arteriosclerosis
1139429|NCT01410305|Vitamin D Deficiency
1139430|NCT01410305|HIV+ Children
1139431|NCT01410305|HIV+ Young Adults
1139432|NCT01410292|fiber
1139433|NCT01410292|glycemic index
1139434|NCT01410292|glycemic response
1139435|NCT01410292|diabetes
1139436|NCT01410292|ghrelin
1139437|NCT01410279|pulmonary hypertension
1139438|NCT01410279|inspiratory muscle training
1139439|NCT01410279|inspiratory muscle weakness
1139440|NCT01410279|pulmonary functional
1139441|NCT01410279|functional capacity
1139442|NCT01410279|quality of life
1139443|NCT01410266|medical abortion
1139444|NCT01410266|first trimester
1139445|NCT01410266|follow-up
1139446|NCT01410266|pregnancy test
1139447|NCT01410214|NSCLC
1139448|NCT01410214|EGFR Mutation Positive
1139450|NCT01410214|Erlotinib Versus NVB/Cisplatin as Adjuvant treatment
1139451|NCT01410201|Epiretinal Membrane
1139452|NCT01410201|Macular Edema
1139453|NCT01410201|Dexamethasone Intravitreal Implant (Ozurdex)
1139454|NCT01410201|Pars Plana Vitrectomy
1139455|NCT01410188|open-angle glaucoma
1139456|NCT01410188|glaucoma
1139457|NCT01410188|ocular hypertension
1139458|NCT01410188|intraocular pressure
1139459|NCT01410162|Renal
1139460|NCT01410162|Kidney/Pancreas
1139461|NCT01410162|Transplant
1139462|NCT01410162|conversion
1139463|NCT01410162|bioequivalence
1139464|NCT01410162|Mycophenolate Acid
1139465|NCT01410149|PAV (proportional assist ventilation); sleep; polysomnography; mechanical ventilation
1139466|NCT01410136|Knee
1139467|NCT01410136|Femur
1139468|NCT01410136|Articular cartilage
1139469|NCT01410136|Lesions
1139470|NCT01410136|Defects
1139471|NCT01410136|Osteochondral graft
1139472|NCT01410136|Cartilage treatments
1139473|NCT01410136|Osteochondritis Dissecans
1139474|NCT01410136|OCD
1139475|NCT01410110|Substance Abuse
1139476|NCT01410110|Substance Dependence
1139477|NCT01410110|Cognitive Impairment
1139478|NCT01410084|vitamin D
1139479|NCT01410084|falls
1139480|NCT01410084|deficiency
1139481|NCT01410084|insufficiency
1139482|NCT01410071|Sphincter of Oddi Dysfunction
1139483|NCT01410058|HIV
1139484|NCT01410058|antiretroviral drug interaction
1139485|NCT01410058|herbal medicine
1139486|NCT01410058|pharmacokinetics
1139487|NCT01410058|herbal pharmacology
1139488|NCT01410045|Turner syndrome
1139489|NCT01410045|infertility
1139490|NCT01410045|ovarian insufficiency
1139491|NCT01410045|ovarian cryopreservation
1139492|NCT01410032|clavicle
1139493|NCT01410032|clavicular
1139494|NCT01410032|fracture
1139495|NCT01410032|midshaft
1139496|NCT01410032|plate
1139497|NCT01410032|ESIN
1139498|NCT01410032|intramedullary
1139499|NCT01410032|flexible
1139500|NCT01410032|nailing
1139501|NCT01410019|X-linked Severe Combined Immunodeficiency (SCID-X1)
1139502|NCT01410019|severe infection
1139503|NCT01410019|gene therapy
1139504|NCT01410019|HLA identical family donor
1139505|NCT01410019|without HLA identical unrelated donor
1139506|NCT01410006|NF1
1139507|NCT01410006|neurofibromatosis
1139508|NCT01410006|NF
1139509|NCT01409993|BMI greater than 25
1139510|NCT01409993|Elevated fasting blood sugar (100-125mg/dL)
1139511|NCT01409980|delta phalanx
1139512|NCT01409980|thumb reconstructed
1139513|NCT01409980|triphalangeal thumbs
1139514|NCT01409967|Anemia
1139515|NCT01409967|Transfusion
1139516|NCT01409967|Biological markers
1139517|NCT01409954|Fusion
1139518|NCT01409954|Spine
1139519|NCT01409954|Decompression
1139520|NCT01409954|Pseudarthrosis
1139521|NCT01409954|bone harvest
1139522|NCT01409954|Instrumented posterolateral fusion
1139523|NCT01409941|cerebral oxygen saturation,
1139524|NCT01409941|NTproBNP
1139525|NCT01409941|hsTNT
1139526|NCT01409941|GDF-15
1139527|NCT01409928|obesity
1139528|NCT01409928|adolescent
1139529|NCT01409928|pediatric
1139530|NCT01409928|weight loss
1139531|NCT01409928|bariatric surgery
1139532|NCT01409928|gastric banding
1139533|NCT01409915|Alzheimer's disease
1139534|NCT01409915|neuropsychological assessment
1139535|NCT01409915|Granulocyte-Macrophage Colony-Stimulating Factor
1139536|NCT01409915|Leukine
1139537|NCT01409876|histoscanning
1139538|NCT01409876|brachytherapy
1139539|NCT01409863|post surgical or post traumatic scar on face or scalp
1139540|NCT01409837|Oligospermia
1139541|NCT01409837|Male infertility
1139542|NCT01409837|Lisinopril
1139543|NCT01409824|clinical decision support system
1139544|NCT01409824|performance based incentives
1139545|NCT01409824|quality of maternal health care services
1139546|NCT01409798|Hyperparathyroidism
1139547|NCT01409798|Hypercalcemia
1139548|NCT01409785|supraglottic airway devices in children
1139549|NCT01409759|Perforators
1139550|NCT01409759|Interposition plasty
1139551|NCT01409759|Contracture release
1139552|NCT01409746|twin
1139553|NCT01409746|brain development
1139554|NCT01409746|MRI
1139555|NCT01409720|bony metastases
1139556|NCT01409720|physical exercise
1139557|NCT01409694|Alzheimer Disease
1139558|NCT01409694|Vitamin D
1139559|NCT01409694|Cholecalciferol
1139560|NCT01409694|Memantine
1139561|NCT01409694|Cognition Disorders
1139562|NCT01409655|AIDS, HIV, Adherence, Compliance, Contingency management
1139563|NCT01409616|Pharmacodynamics
1139564|NCT01409616|darexaban
1139565|NCT01409616|Acetyl Salicylic Acid
1139566|NCT01409616|clopidogrel
1139567|NCT01409616|YM150
1139568|NCT01409616|Phase 1
1139569|NCT01409603|Pharmacodynamics
1139570|NCT01409603|darexaban
1139571|NCT01409603|naproxen
1139572|NCT01409603|YM150
1139573|NCT01409603|Phase 1
1139574|NCT01409590|Schizophrenia
1139575|NCT01409590|weight gain
1139576|NCT01409590|atypical neuroleptics
1139577|NCT01409577|Coronary stenosis
1139578|NCT01409577|stent
1139579|NCT01409577|fractional flow reserve
1139580|NCT01409564|Alzheimer's dementia
1139581|NCT01409564|Cilostazol
1139582|NCT01409551|Pleural effusion
1139583|NCT01409551|VATS
1139584|NCT01409551|hyperthermia
1139585|NCT01409551|thoracostomy
1139586|NCT01409551|pleurodesis
1139587|NCT01409512|Heart rate variability, anti cholinergic medication
1139588|NCT01409499|hepatocellular carcinoma, treatments, survival
1139589|NCT01409486|Pompe disease
1139590|NCT01409486|Alpha glucosidase
1139591|NCT01409486|Newborn screening
1139592|NCT01409486|Tandem Mass Spectrometry (LC-MS-MS)
1139593|NCT01409486|The study aims:
1139594|NCT01409486|To establish the control mean values of alpha glucosidase activity in Dry blood spots of Newborn babies from Israel.
1139595|NCT01409486|To include the alpha glucosidase assay in the newborn screening program in Israel
1139596|NCT01409473|Prostate cancer
1139597|NCT01409473|Stereotactic body radiotherapy
1139598|NCT01409473|Radiosurgery
1139599|NCT01409473|Intensity-modulated radiotherapy
1139600|NCT01409473|SBRT
1139601|NCT01409473|IMRT
1139602|NCT01409473|Early-stage prostate cancer
1139603|NCT01409473|Low-risk prostate cancer
1139604|NCT01409473|Intermediate-risk prostate cancer
1139605|NCT01409473|Intraprostatic lesions
1139606|NCT01409473|IPL
1139607|NCT01409421|adherence
1139608|NCT01409421|glaucoma
1139609|NCT01409421|motivational interviewing
1139610|NCT01409408|Hypertension
1139611|NCT01409408|Diabetes Mellitus
1139612|NCT01409408|Vascular stiffness
1139613|NCT01409408|Endothelial function
1139614|NCT01409395|Drug drug interaction
1139615|NCT01409382|neonatal hypoglycemia
1139616|NCT01409382|pregnancy
1139617|NCT01409382|physical activity
1139618|NCT01409382|sedentary lifestyle
1139619|NCT01409382|high-glycemic index diet
1139620|NCT01409382|take-home baby
1139621|NCT01409382|recurrent miscarriages
1139622|NCT01409382|preterm delivery
1139623|NCT01409356|Obesity
1139624|NCT01409356|Portal hypertension
1139625|NCT01409356|Cirrhosis
1139626|NCT01409356|Diet
1139627|NCT01409356|Exercise
1139628|NCT01409343|advanced solid cancers
1139629|NCT01409343|metastatic solid cancers
1139630|NCT01409330|insulin sensitivity
1139631|NCT01409330|type 2 diabetes
1139632|NCT01409330|diet intervention
1139633|NCT01409317|Major Depression
1139634|NCT01409317|Functional Magnetic Resonance Imaging
1139635|NCT01409317|Deep Transcranial Magnetic Stimulation
1139636|NCT01409317|Repetitive Transcranial Magnetic Stimulation
1139637|NCT01409317|rTMS
1139638|NCT01409317|DTMS
1139639|NCT01409317|fMRI
1139640|NCT01409317|Randomized, Sham-Controlled Trial
1139641|NCT01409304|Major depression
1139642|NCT01409304|Deep Transcranial Magnetic Stimulation
1139643|NCT01409304|Naturalistic Trial
1139644|NCT01409304|DTMS
1139645|NCT01409291|low socioeconomic status
1139646|NCT01409291|stress
1139647|NCT01409291|women
1139648|NCT01409291|children
1139649|NCT01409291|cortisol
1139650|NCT01409265|stroke rehabilitation
1139651|NCT01409265|perceptual deficits
1139652|NCT01409252|Stroke
1139653|NCT01409252|intracerebral hemorrhage
1139654|NCT01409252|surgery
1139655|NCT01409239|hospital
1139656|NCT01409239|diabetes
1139657|NCT01409239|glycemic variability
1139658|NCT01409239|autonomic tone
1139659|NCT01409226|high-risk of breast cancer
1139660|NCT01409226|BRCA1 mutation carrier
1139661|NCT01409226|BRCA2 mutation carrier
1139662|NCT01409226|diagnostic
1139663|NCT01409226|MRI
1139664|NCT01409226|BI-RADS 4
1139665|NCT01409226|mammographically occult
1139682|NCT01409187|Melanoma
1139683|NCT01409187|Metastatic Melanoma
1139684|NCT01409187|Cytotoxic Drugs
1139685|NCT01409187|IPI-Biotherapy
1139686|NCT01409187|Ipilimumab
1139687|NCT01409187|Yervoy
1139688|NCT01409187|BMS-734016
1139689|NCT01409187|MDX010
1139690|NCT01409187|Interferon
1139691|NCT01409187|IFN Alpha-2b
1139692|NCT01409187|Intron A
1139693|NCT01409187|Interferon Apha-2b
1139694|NCT01409187|Interleukin-2
1139695|NCT01409187|IL-2
1139696|NCT01409187|Aldesleukin
1139697|NCT01409187|Proleukin
1139698|NCT01409174|Melanoma
1139699|NCT01409174|Metastatic
1139700|NCT01409174|IPI-Biochemotherapy
1139701|NCT01409174|Chemonaive
1139702|NCT01409174|Advanced stage IV
1139703|NCT01409174|Unresectable stage III melanoma
1139704|NCT01409174|1.0 cm or larger
1139705|NCT01409174|Ipilimumab
1139706|NCT01409174|Yervoy
1139707|NCT01409174|BMS-734016
1139708|NCT01409174|MDX010
1139709|NCT01409174|Interferon Alpha-2b
1139710|NCT01409174|Intron A
1139711|NCT01409174|Temozolomide
1139712|NCT01409174|Temodar
1139713|NCT01409174|Cisplatin
1139714|NCT01409174|Platinol-AQ
1139715|NCT01409174|Platinol
1139716|NCT01409174|CDDP
1139717|NCT01409174|Interleukin-2
1139718|NCT01409174|IL-2
1139719|NCT01409174|Aldesleukin
1139720|NCT01409174|Proleukin
1139721|NCT01409161|Leukemia
1139722|NCT01409161|Acute Promyelocytic Leukemia
1139723|NCT01409161|APL
1139724|NCT01409161|ATRA
1139725|NCT01409161|Tretinoin
1139726|NCT01409161|All-trans retinoic acid
1139727|NCT01409161|Vesanoid
1139728|NCT01409161|ATO
1139729|NCT01409161|Arsenic trioxide
1139730|NCT01409161|Trisenox
1139731|NCT01409161|GO
1139732|NCT01409161|Gemtuzumab
1139733|NCT01409161|Mylotarg
1139734|NCT01409161|Gemtuzumab ozogamicin
1139735|NCT01409161|Methylprednisolone
1139736|NCT01409161|Depo-Medrol
1139737|NCT01409161|Medrol
1139738|NCT01409161|Solu-Medrol
1139739|NCT01409148|Radioimmunoimaging
1139740|NCT01409148|AL Amyloidosis
1139741|NCT01409148|PET/CT
1139742|NCT01409135|Nectin 4 protein, humans
1139743|NCT01409135|Cancer
1139744|NCT01409135|Pharmacokinetics of AGS-22M6E
1139745|NCT01409135|Pharmacokinetics of ASG-22CE
1139746|NCT01409135|Safety
1139747|NCT01409135|Clinical Trial, Phase 1
1139748|NCT01409135|ASG-22ME
1139749|NCT01409135|AGS-22M6E
1139750|NCT01409135|ASG-22CE
1139751|NCT01409135|ASG-22C3
1139752|NCT01409122|vasodilator
1139753|NCT01409122|nitric oxide
1139754|NCT01409122|sodium nitrite
1139755|NCT01409122|sildenafil
1139756|NCT01409122|PDE-5
1139757|NCT01409122|pulmonary hypertension
1139758|NCT01409122|pulmonary arterial hypertension
1139759|NCT01409109|Schizophrenia
1139760|NCT01409109|Schizoaffective
1139761|NCT01409109|Neuroimaging
1139762|NCT01409109|Magnetic Resonance Imaging (MRI)
1139763|NCT01409109|Functional Magnetic Resonance Imaging (fMRI)
1139764|NCT01409109|Spectroscopy
1139765|NCT01409083|infiltration
1139766|NCT01409083|extravasation
1139767|NCT01409083|end-tidal carbon dioxide
1139768|NCT01409083|sodium bicarbonate
1139769|NCT01409070|MDS
1139770|NCT01409057|Inflammation parameters
1139771|NCT01409057|Various blood values
1139772|NCT01409057|Clinical Outcome
1139773|NCT01409057|Residence in ICU/ Hospital
1139774|NCT01409057|SAPS-Score
1139775|NCT01409057|SOFA-Score
1139776|NCT01409057|Duration of artificial respiration
1139782|NCT01409031|newborns
1139783|NCT01409031|respiratory failure
1139784|NCT01409031|pulmonary hypertension
1139785|NCT01409031|treatment
1139786|NCT01409018|pediatric
1139787|NCT01409018|cancer
1139788|NCT01409018|invasive fungal disease
1139789|NCT01409018|antifungal agent
1139790|NCT01408992|Hearing screening
1139791|NCT01408992|Questionnaire
1139792|NCT01408992|Hearing disability
1139793|NCT01408979|Severe preeclampsia
1139794|NCT01408979|magnesium sulfate
1139795|NCT01408979|anticonvulsivant
1139796|NCT01408966|Dark chocolate
1139797|NCT01408966|Catechins
1139798|NCT01408966|Intrahepatic endothelial dysfunction
1139799|NCT01408966|Cirrhosis
1139800|NCT01408966|Portal Hypertension
1139801|NCT01408953|Keloid
1139802|NCT01408927|Thienopyridine resistance
1139803|NCT01408927|Aspirin resistance
1139804|NCT01408927|Platelet reactivity
1139805|NCT01408901|peripheral arterial disease
1139806|NCT01408901|granulocyte macrophage colony stimulating factor
1139807|NCT01408901|PAD
1139808|NCT01408901|GM-CSF
1139809|NCT01408901|sargramostim
1139810|NCT01408901|leukine
1139811|NCT01408901|treadmill exercise
1139812|NCT01408875|Chronic Heart Failure
1139813|NCT01408875|Cardiac rehabilitation
1139814|NCT01408875|Exercise training
1139815|NCT01408875|Peak VO2
1139816|NCT01408875|Electrical myostimulation
1139817|NCT01408862|GLP1
1139818|NCT01408862|GIP
1139819|NCT01408862|platelets
1139820|NCT01408862|human
1139821|NCT01408862|aggregation
1139822|NCT01408849|Endoscopy
1139823|NCT01408849|Herbal medicine
1139824|NCT01408849|Phytotherapy
1139825|NCT01408836|Vasculitis
1139826|NCT01408836|ANCA
1139827|NCT01408836|Therapy
1139828|NCT01408836|Plasma exchange
1139829|NCT01408836|Immunosuppression
1139830|NCT01408823|Pediatrics
1139831|NCT01408823|Scoliosis
1139832|NCT01408823|Pharmacokinetics
1139833|NCT01408823|Hemorrhage
1139834|NCT01408823|Orthopedic Surgery
1139835|NCT01408810|infliximab
1139836|NCT01408810|ulcerative colitis
1139837|NCT01408810|histologic remission
1139838|NCT01408797|clonal deletion
1139839|NCT01408797|kidney transplantation
1139840|NCT01408784|calories
1139841|NCT01408784|counting
1139842|NCT01408784|obesity
1139843|NCT01408784|overweight
1139844|NCT01408784|categories
1139845|NCT01408784|calorie
1139846|NCT01408784|method
1139847|NCT01408784|counting calories
1139848|NCT01408784|lose weight
1139849|NCT01408784|diet
1139850|NCT01408784|energy balance
1139851|NCT01408784|energy intake
1139852|NCT01408784|24 hours recall
1139853|NCT01408784|food intake
1139854|NCT01408771|Urodynamics
1139855|NCT01408771|Overactive Bladder
1139856|NCT01408745|medical device
1139857|NCT01408745|sternal closure
1139858|NCT01408745|sternotomy
1139859|NCT01408745|dehiscence
1139860|NCT01408745|sternal wound healing
1139861|NCT01408745|randomized trial
1139862|NCT01408745|steel wire
1139863|NCT01408732|Epistaxis
1139864|NCT01408732|Hereditary Hemorrhagic Telangiectasia
1139865|NCT01408732|HHT
1139866|NCT01408732|Sclerotherapy
1139867|NCT01408732|Epistaxis (nosebleeds) due to Hereditary Hemorrhagic Telangiectasia
1139868|NCT01408719|Beta-Glucan
1139869|NCT01408719|Barley
1139870|NCT01408719|Molecular Weight
1139871|NCT01408719|Viscosity
1139872|NCT01408719|Cholesterol
1139873|NCT01408719|Stable isotope
1139874|NCT01408719|Gene-nutrient interaction
1139875|NCT01408719|Gut microbiota
1139876|NCT01408693|hip fracture
1139877|NCT01408693|hemiarthroplasty
1139878|NCT01408693|endoprosthesis
1139879|NCT01408693|elderly
1139880|NCT01408693|minimally invasive surgery
1139881|NCT01408693|anterior approach
1139882|NCT01408693|geriatric patients
1139883|NCT01408680|End-stage Renal Disease
1139884|NCT01408680|Hemodialysis
1139885|NCT01408680|Cardiovascular Disease
1139886|NCT01408680|Antioxidants
1139887|NCT01408680|Atherosclerosis
1139888|NCT01408680|Coenzyme Q10
1139889|NCT01408667|insulin sensitivity
1139890|NCT01408667|cardiometabolic risk
1139891|NCT01408667|hyperinsulinemic euglycemic clamp
1139892|NCT01408654|Suicidal Ideation
1139893|NCT01408654|Loneliness
1139894|NCT01408654|Social Support
1139895|NCT01408654|Voluntary Workers
1139896|NCT01408654|Friends/Companions
1139897|NCT01408654|Prevention
1139898|NCT01408654|Aged
1139899|NCT01408641|topiramate
1139900|NCT01408641|PTSD
1139901|NCT01408641|drinking
1139902|NCT01408641|alcohol
1139903|NCT01408602|Rheumatoid Arthritis
1139904|NCT01408589|alcohol
1139905|NCT01408589|craving
1139906|NCT01408589|mood
1139907|NCT01408589|optimum dose of atomoxetine
1139908|NCT01408576|Lupus
1139909|NCT01408576|Monoclonal antibody
1139910|NCT01408576|B-Cell immunotherapy
1139911|NCT01408576|Epratuzumab
1139912|NCT01408563|NHL
1139913|NCT01408563|lymphoma
1139914|NCT01408563|leukemia
1139915|NCT01408563|myelodysplastic disorder
1139916|NCT01408563|aplastic anemia
1139917|NCT01408550|IVIG in pemphigoid
1139918|NCT01408550|Patients with bullous pemphigoid unresponsive to corticosteroids
1139919|NCT01408537|inactivated Japanese encephalitis vaccine
1139920|NCT01408537|vero cell
1139921|NCT01408537|children
1139922|NCT01408537|immunogenicity
1139923|NCT01408537|safety
1139924|NCT01408524|Hypertension
1139925|NCT01408524|emergence
1139926|NCT01408524|craniotomy
1139927|NCT01408524|Hypertension during the emergence after craniotomy
1139928|NCT01408498|Testosterone
1139929|NCT01408498|Social psychology
1139930|NCT01408498|Human behavior
1139931|NCT01408459|Prostate cancer prevention
1139932|NCT01408446|Hypertension
1139933|NCT01408446|Menthol
1139934|NCT01408446|Metabolism
1139935|NCT01408433|embryo transfer
1139936|NCT01408433|in-vitro fertilization (IVF)
1139937|NCT01408433|pre-implantation diagnosis (PGD)
1139938|NCT01408433|infertility
1139939|NCT01408433|single embryo transfer
1139940|NCT01408433|two embryo transfer
1139941|NCT01408433|double embryo transfer
1139942|NCT01408420|Renal insufficiency
1139943|NCT01408420|Acute Kidney Injury
1139944|NCT01408420|Postoperative
1139945|NCT01408420|Extracorporeal Circulation
1139946|NCT01408420|Heart surgery
1139947|NCT01408407|Patients with anal canal, low rectal or gynecological cancer
1139948|NCT01408394|safety
1139949|NCT01408394|pharmacokinetics
1139950|NCT01408394|controlled release
1139951|NCT01408394|formulation
1139952|NCT01408381|Critical Limb Ischemia (CLI)
1139953|NCT01408381|Cell Therapy
1139954|NCT01408381|Bone marrow mononuclear cells
1139955|NCT01408368|Graves' disease
1139956|NCT01408368|total thyroidectomy
1139957|NCT01408368|bilateral subtotal thyroidectomy
1139958|NCT01408368|Graves' ophthalmopathy
1139959|NCT01408368|morbidity rate
1139960|NCT01408342|Alemtuzumab
1139961|NCT01408342|Rituximab
1139962|NCT01408342|Aplastic anemia
1139963|NCT01408342|cyclosporine
1139964|NCT01408316|Healthy Volunteer
1139965|NCT01408316|PX-866
1139966|NCT01408316|PI3K Inhibitor
1139967|NCT01408303|dyslipidemia
1139968|NCT01408303|hyperlipidemia
1139969|NCT01408303|cardiovascular risk
1139970|NCT01408290|seasonal
1139971|NCT01408290|prevention
1139972|NCT01408290|influenza
1139973|NCT01408290|infection
1139974|NCT01408290|influenza vaccine
1139975|NCT01408290|vaccine
1139976|NCT01408290|influenza in humans
1139977|NCT01408277|Diabetic Foot Ulcers
1139978|NCT01408277|Diabetic Foot Wounds
1139979|NCT01407484|Infertility
1139980|NCT01407484|Assisted reproductive technology
1139981|NCT01407484|Double blind therapeutical trial
1139982|NCT01407484|Multicentric study
1139983|NCT01407484|Prospective randomized study
1139984|NCT01407471|aldosterone
1139985|NCT01407471|clobetasol
1139986|NCT01407471|atrophy
1139987|NCT01407471|skin
1139988|NCT01407471|epidermis
1139989|NCT01407471|wound healing
1139990|NCT01407471|mineral corticoid receptor
1139991|NCT01407471|spironolactone
1139992|NCT01407445|Menopause
1139993|NCT01407445|Sexual dysfunction
1139994|NCT01407445|Tribulus
1139995|NCT01407445|Sexuality
1139996|NCT01407445|Phytotherapeutic Drugs
1139997|NCT01407432|Male infertility
1139998|NCT01407432|folic acid
1139999|NCT01407432|in VITRO fertilization
1140000|NCT01407432|sperm parameters
1140001|NCT01407432|MTHFR genotype
1140002|NCT01407419|Rheumatoid Arthritis
1140003|NCT01407393|overweight
1140004|NCT01407393|obesity
1140005|NCT01407393|weight loss
1140006|NCT01407393|body fat
1140007|NCT01407393|waste cirumference
1140008|NCT01407393|satiety
1140009|NCT01407393|appetite
1140010|NCT01407380|Advanced malignancies
1140011|NCT01407380|solid tumors
1140012|NCT01407380|cancer
1140013|NCT01407367|patient safety
1140014|NCT01407367|chronic kidney disease
1140015|NCT01407367|medical errors
1140016|NCT01407354|robotic weight support
1140017|NCT01407354|aquatic exercise
1140018|NCT01407354|incomplete motor spinal cord injury
1140019|NCT01407354|ASIA C and D
1140020|NCT01407328|shoulder arthroscopic surgery
1140021|NCT01407328|respiratory discomfort
1140022|NCT01407328|airway obstruction
1140023|NCT01407328|restrictive pathology
1140024|NCT01407328|diaphragm palsy
1140025|NCT01407315|Continuous subcutaneous glucose monitoring
1140026|NCT01407315|Type 1 Diabetes
1140027|NCT01407302|Laryngeal mask airway
1140028|NCT01407302|internal jugular vein cannulation
1140029|NCT01408238|Immunotherapy
1140030|NCT01408238|Skin prick test
1140031|NCT01408238|Standardization
1140032|NCT01408238|Secale cereale
1140033|NCT01408225|MGUS
1140034|NCT01408225|Multiple Myeloma
1140035|NCT01408225|Tissue Bank
1140036|NCT01408199|Lenalidomide
1140037|NCT01408199|Refractory Cutaneous Lupus
1140038|NCT01408186|aspirin
1140039|NCT01408186|PPI
1140040|NCT01408186|H2RA
1140041|NCT01408173|caffeine
1140042|NCT01408173|apnea
1140043|NCT01408173|prematurity
1140044|NCT01408147|Postpartum weight retention
1140045|NCT01408147|Low income women
1140046|NCT01408147|WIC
1140047|NCT01408147|Online
1140048|NCT01408134|Inter-reader variability of myocardial viability imaging
1140049|NCT01408121|Platelet reactivity
1140050|NCT01408121|Genotyping
1140051|NCT01408108|Hiatal hernia
1140052|NCT01408108|Gastro-oesophageal reflux disease
1140053|NCT01408108|Laparoscopic hiatal repair
1140054|NCT01408108|Laparoscopic anti-reflux surgery
1140055|NCT01408108|Partially absorbable lightweight mesh
1140056|NCT01408095|diabetes
1140057|NCT01408095|glimepiride
1140058|NCT01408095|diabetes type II
1140059|NCT01408095|diabetes type 2
1140060|NCT01408095|Type 2 diabetes
1140061|NCT01408095|diabetes mellitus
1140062|NCT01408069|headache
1140063|NCT01408069|migraine
1140064|NCT01408056|Hemangioma
1140065|NCT01408056|Infantile Hemangioma
1140066|NCT01408056|Ulcerated Hemangioma
1140067|NCT01408056|Timolol
1140068|NCT01408056|Beta blocker
1140069|NCT01408056|Vascular anomaly
1140070|NCT01408030|epistaxis
1140071|NCT01408030|HHT
1140072|NCT01408030|bevacizumab
1140073|NCT01408030|tranexamic acid
1140074|NCT01408030|nosebleed
1140075|NCT01408030|estrogen
1140076|NCT01408004|Renal carcinoma
1140077|NCT01408004|Resistance
1140078|NCT01408004|Reversible
1140079|NCT01408004|Translational
1140080|NCT01407991|Enteral tube placement
1140081|NCT01407978|Influenza
1140082|NCT01407978|Pandemic vaccine
1140083|NCT01407978|Seasonal vaccine
1140084|NCT01407978|Prevention
1140085|NCT01407978|Influenza vaccine
1140086|NCT01407978|Influenza in humans
1140087|NCT01407978|Pandemic influenza in humans
1140088|NCT01407978|Influenza vaccine for children
1140089|NCT01407978|Influenza vaccine for adolescents
1140090|NCT01407978|Seasonal vaccine for children
1140091|NCT01407978|Seasonal vaccine for adolescents
1140092|NCT01407965|obesity
1140093|NCT01407965|pharmacokinetic
1140094|NCT01407965|ertapenem
1140095|NCT01407965|meropenem
1140096|NCT01407952|treatment trial
1140097|NCT01407952|cerebral aneurysm
1140098|NCT01407952|randomized
1140099|NCT01407952|coils
1140100|NCT01407952|endovascular
1140101|NCT01407952|HEAT
1140102|NCT01407952|bare platinum
1140103|NCT01407952|Hydrogel
1140104|NCT01407952|Hydrocoil
1140105|NCT01407939|Bitter Taste
1140106|NCT01407939|Bitter Blockers
1140107|NCT01407939|Pediatric Medications
1140108|NCT01407939|Sensory methodology
1140109|NCT01407939|Children
1140110|NCT01407926|Depression
1140111|NCT01407926|Aging
1140112|NCT01407926|Clinical Effectiveness
1140113|NCT01407926|Home Care
1140114|NCT01407926|Nurse-Led
1140115|NCT01407900|CD NP
1140116|NCT01407900|dual receptor
1140117|NCT01407900|NPR A
1140118|NCT01407900|NPR B
1140119|NCT01407900|Adult, aged over 45
1140120|NCT01407887|children
1140121|NCT01407874|Gout
1140122|NCT01407874|Hyperuricemia
1140123|NCT01407874|Arthritis
1140124|NCT01407874|Joint Disease
1140125|NCT01407874|Allopurinol
1140126|NCT01407874|Renal Insufficiency
1140127|NCT01407835|Immunotherapy
1140128|NCT01407835|Skin prick test
1140129|NCT01407835|Standardization
1140130|NCT01407835|Dactylis glomerata
1140131|NCT01407822|Lung cancer
1140132|NCT01407822|IIIA-N2
1140133|NCT01407822|Neo-adjuvant treatment
1140134|NCT01407822|EGFR mutations
1140135|NCT01407822|Tyrosine kinase inhibitor
1140136|NCT01407796|lung inflammation
1140137|NCT01407796|positron emission tomography (PET)
1140138|NCT01407796|fluorodeoxyglucose (FDG)
1140139|NCT01407796|inducible nitric oxide synthase (iNOS)
1140140|NCT01407796|lung anti-inflammatory therapy
1140141|NCT01407783|Post-partum depression
1140142|NCT01407783|Low-income mothers
1140143|NCT01407783|home nurse visitation
1140144|NCT01407770|radiation toxicity
1140145|NCT01407770|skin reactions secondary to radiation therapy
1140146|NCT01407770|pain
1140147|NCT01407770|fatigue
1140148|NCT01407770|psychosocial effects of cancer and its treatment
1140149|NCT01407770|depression
1140150|NCT01407770|cognitive/functional effects
1140151|NCT01407770|stage IA breast cancer
1140152|NCT01407770|stage IB breast cancer
1140153|NCT01407770|stage II breast cancer
1140154|NCT01407770|stage IIIA breast cancer
1140155|NCT01407770|ductal breast carcinoma in situ
1140156|NCT01407757|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1140157|NCT01407757|adult acute myeloid leukemia with del(5q)
1140158|NCT01407757|adult acute myeloid leukemia with inv(16)(p13;q22)
1140159|NCT01407757|adult acute myeloid leukemia with t(16;16)(p13;q22)
1140160|NCT01407757|adult acute myeloid leukemia with t(8;21)(q22;q22)
1140161|NCT01407757|untreated adult acute myeloid leukemia
1140162|NCT01407757|untreated childhood acute myeloid leukemia and other myeloid malignancies
1140163|NCT01407757|adult acute basophilic leukemia
1140164|NCT01407757|childhood acute basophilic leukemia
1140165|NCT01407757|adult acute eosinophilic leukemia
1140166|NCT01407757|childhood acute eosinophilic leukemia
1140167|NCT01407757|adult acute myeloblastic leukemia without maturation (M1)
1140168|NCT01407757|childhood acute myeloblastic leukemia without maturation (M1)
1140169|NCT01407757|adult acute minimally differentiated myeloid leukemia (M0)
1140170|NCT01407757|childhood acute minimally differentiated myeloid leukemia (M0)
1140171|NCT01407757|adult acute myeloblastic leukemia with maturation (M2)
1140172|NCT01407757|childhood acute myeloblastic leukemia with maturation (M2)
1140173|NCT01407757|adult acute myelomonocytic leukemia (M4)
1140174|NCT01407757|childhood acute myelomonocytic leukemia (M4)
1140175|NCT01407757|adult acute monoblastic leukemia (M5a)
1140176|NCT01407757|adult acute monocytic leukemia (M5b)
1140177|NCT01407757|childhood acute monoblastic leukemia (M5a)
1140178|NCT01407757|childhood acute monocytic leukemia (M5b)
1140179|NCT01407757|adult erythroleukemia (M6a)
1140180|NCT01407757|adult pure erythroid leukemia (M6b)
1140181|NCT01407757|childhood acute erythroleukemia (M6)
1140182|NCT01407757|adult acute megakaryoblastic leukemia (M7)
1140183|NCT01407757|childhood acute megakaryocytic leukemia (M7)
1140184|NCT01407757|recurrent adult acute myeloid leukemia
1140185|NCT01407757|recurrent childhood acute myeloid leukemia
1140186|NCT01407731|disseminated neuroblastoma
1140187|NCT01407731|localized resectable neuroblastoma
1140188|NCT01407731|localized unresectable neuroblastoma
1140189|NCT01407731|stage 4S neuroblastoma
1140190|NCT01407718|Knee pain
1140191|NCT01407718|tibial nailing
1140192|NCT01407705|spinal cord injury with traumatic event
1140193|NCT01407692|menstrual cycle
1140194|NCT01407692|estrogen
1140195|NCT01407679|cutaneous lupus erythematosus
1140196|NCT01407679|discoid lupus erythematosus
1140197|NCT01407679|subacute cutaneous lupus erythematosus
1140198|NCT01407679|lupus erythematosus tumidus
1140199|NCT01407666|paravertebral block
1140200|NCT01407666|epidural block
1140201|NCT01407666|pain management
1140202|NCT01407666|liver resection
1140203|NCT01407666|comparison
1140204|NCT01407653|Low back pain
1140205|NCT01407653|virtual reality
1140206|NCT01407640|Insulin allergy
1140207|NCT01407640|adverse drug reaction
1140208|NCT01407640|diabetes
1140209|NCT01407640|type 1 hypersensitivity
1140210|NCT01407640|immediate hypersensitivity
1140211|NCT01407640|type 4 hypersensitivity
1140212|NCT01407640|insulin analogs
1140213|NCT01407640|intradermal testing
1140214|NCT01407640|insulin antibody
1140215|NCT01407640|mast cell
1140216|NCT01407640|CD+ TCELL
1140217|NCT01407627|human
1140218|NCT01407627|fructose
1140219|NCT01407627|dextrose
1140220|NCT01407627|renin angiotensin system
1140221|NCT01407627|kidney
1140222|NCT01407627|renal hemodynamics
1140223|NCT01407614|Subarachnoid hemorrhage
1140224|NCT01407614|delayed cerebral ischemia
1140225|NCT01407614|external lumbar drainage
1140226|NCT01407614|vasospasm
1140227|NCT01407601|vitamin K
1140228|NCT01407601|MK-7
1140229|NCT01407601|Hemodialysis
1140230|NCT01407601|vascular calcification
1140231|NCT01407601|Matrix Gla protein
1140232|NCT01407601|Osteocalcin
1140233|NCT01407588|Atrial fibrillation
1140234|NCT01407588|Ablation
1140235|NCT01407575|Buprenorphine
1140236|NCT01407575|Receptors, opioid
1140237|NCT01407575|Receptors, opioid, kappa
1140238|NCT01407536|Stroke
1140239|NCT01407536|Thermal Stimulation
1140240|NCT01407536|Upper Extremity
1140241|NCT01407536|Motor Recovery
1140242|NCT01407536|Transcranial Magnetic Stimulation
1140243|NCT01407523|Levetiracetam
1140244|NCT01407523|Infusion
1140245|NCT01407523|Epilepsy
1140246|NCT01407523|Partial Onset Seizures
1140247|NCT01407497|HIV
1140248|NCT01407497|Vaccine
1140249|NCT01407497|DNA
1140250|NCT01407497|Prevention
1140251|NCT01407263|radical prostatectomy
1140252|NCT01407263|anastomotic suturing
1140253|NCT01407263|lymph node dissection
1140254|NCT01407263|11-096
1140255|NCT01407237|HIV-infection
1140256|NCT01407237|renin
1140257|NCT01407237|aldosterone
1140258|NCT01407237|visceral fat
1140259|NCT01407224|Exclusive Breastfeeding
1140260|NCT01407224|Skin to skin contact
1140261|NCT01407224|Cord Clumping
1140262|NCT01407224|Prelactial feeding
1140263|NCT01407211|multiple sclerosis
1140264|NCT01407211|Myelin Oligodendrocyte Glycoprotein(MOG)
1140265|NCT01407211|Vitamin A
1140266|NCT01407211|CD4-Positive T-Lymphocytes
1140267|NCT01407211|gene expression
1140268|NCT01407211|Th1 Cells
1140269|NCT01407211|Th2 Cells
1140270|NCT01407198|High Risk Chordoma
1140271|NCT01407185|heart failure
1140272|NCT01407185|quality of life
1140273|NCT01407185|fall prevention
1140274|NCT01407185|endurance
1140275|NCT01407185|resistive training
1140276|NCT01407172|PAD
1140277|NCT01407172|Peripheral arterial disease
1140278|NCT01407172|Hydrogen Sulfide
1140279|NCT01407172|Gasotransmitter
1140280|NCT01407159|type b dissection
1140281|NCT01407159|thoracic stentgraft
1140282|NCT01407159|aortic stent
1140283|NCT01407159|clinical and technical success
1140284|NCT01407159|safety and feasibility of E-XL aortic stent
1140285|NCT01407146|acute myocardial infarction
1140286|NCT01407146|care-seeking behavior
1140287|NCT01407146|acute coronary syndrome
1140288|NCT01407146|care-seeking delay
1140289|NCT01407146|cardiac delay
1140290|NCT01407146|prehospital delay
1140291|NCT01407146|acute myocardial infarction & PTSD
1140292|NCT01407146|help seeking behaviors
1140293|NCT01407146|seeking treatment
1140294|NCT01407146|cardiac patients
1140295|NCT01407146|decision time
1140296|NCT01407133|Neuro-otology
1140297|NCT01407133|Chronic tinnitus
1140298|NCT01407133|Sensory disability
1140299|NCT01407133|Repetitive transcranial magnetic stimulation
1140300|NCT01407133|Dose escalation
1140301|NCT01407120|Prevention
1140302|NCT01407120|Divorce
1140303|NCT01407107|nitroglycerin
1140304|NCT01407107|5-flourouracil
1140305|NCT01407107|radiation therapy
1140306|NCT01407107|neo-adjuvant treatment
1140307|NCT01407094|Depression, Major Depressive Disorder, Mood Disorder
1140308|NCT01407081|cognitive rehabilitation
1140309|NCT01407081|SMART goals
1140310|NCT01407081|telehealth
1140311|NCT01407055|Coronary Artery Bypass Graft Surgery (CABG)
1140312|NCT01407055|Patients' Expectations
1140313|NCT01407055|Coronary Heart Disease
1140314|NCT01407055|Illness Perception Intervention
1140315|NCT01407055|Randomized Controlled Trial
1140316|NCT01407042|unicondylar knee arthroplasty
1140317|NCT01407042|mobile-bearing
1140318|NCT01407042|patellofemoral pain
1140319|NCT01407016|metronidazole infusion
1140320|NCT01407003|T2DM, blood glucose, OGTT, LIK066
1140321|NCT01406990|aspirin resistance
1140322|NCT01406990|hyporesponsive
1140323|NCT01406990|CAD
1140324|NCT01406990|women
1140325|NCT01406977|Hypophosphatasia
1140326|NCT01406977|HPP
1140327|NCT01406977|Rathbun's disease
1140328|NCT01406964|Chlamidia Antibody test, Hysterosalpyngography, Tubal disease
1140329|NCT01406951|sTREM-1
1140330|NCT01406951|PCT
1140331|NCT01406951|CPIS
1140332|NCT01406951|VAP
1140333|NCT01406951|EVC
1140334|NCT01406951|diagnosis
1140335|NCT01406951|prognosis
1140336|NCT01406938|Psoriasis
1140337|NCT01406938|plaque
1140338|NCT01406938|inflammatory skin disease
1140339|NCT01406938|scaly patches
1140340|NCT01406938|AIN457
1140341|NCT01406938|secukinumab
1140342|NCT01406938|Moderate to Severe Plaque-type Psoriasis
1140343|NCT01406912|Stroke Rehabilitation
1140344|NCT01406912|Ischemic Stroke
1140345|NCT01406912|Virtual Reality
1140346|NCT01406912|Nintendo Wii
1140347|NCT01406912|Recreational Activity
1140348|NCT01406912|Motor Function
1140349|NCT01406886|Modifiable environmental
1140350|NCT01406886|behavioral factors
1140351|NCT01406873|Myotonic Dystrophy
1140352|NCT01406873|Myotonic Dystrophy Type 1 (DM1)
1140353|NCT01406873|Muscular Dystrophy
1140354|NCT01406873|Mexiletine
1140355|NCT01406860|Headaches
1140356|NCT01406860|Migraines
1140357|NCT01406860|Tension headaches
1140358|NCT01406860|Cluster headaches
1140359|NCT01406847|Spinal Manipulation
1140360|NCT01406847|Body-based intervention
1140361|NCT01406847|Experimental pain
1140362|NCT01406834|PTSD
1140363|NCT01406834|Veterans
1140364|NCT01406834|Killing
1140365|NCT01406834|Military
1140366|NCT01406821|PRP
1140367|NCT01406821|platelet-rich-plasma
1140368|NCT01406821|platelet
1140369|NCT01406821|tendinosis
1140370|NCT01406821|tendinitis
1140371|NCT01406821|tendonitis
1140372|NCT01406821|tendinopathy
1140373|NCT01406821|enthesopathy
1140374|NCT01406821|muscle
1140375|NCT01406821|sport
1140376|NCT01406821|tendon
1140377|NCT01406821|patella
1140378|NCT01406821|patellar tendon
1140379|NCT01406808|genetic
1140380|NCT01406808|atherosclerosis
1140381|NCT01406808|myocardial infarction
1140382|NCT01406808|risk
1140383|NCT01406808|preventive cardiology
1140384|NCT01406795|Post Thrombotic Syndrome
1140385|NCT01406795|Venous Stasis
1140386|NCT01406795|Venous Occlusions
1140387|NCT01406795|Venous Stenosis
1140388|NCT01406782|stage III grade 1 follicular lymphoma
1140389|NCT01406782|stage III grade 2 follicular lymphoma
1140390|NCT01406782|stage IV grade 1 follicular lymphoma
1140391|NCT01406782|stage IV grade 2 follicular lymphoma
1140392|NCT01406743|Spine and pelvis parameters
1140393|NCT01406743|Sagittal balance
1140394|NCT01406743|Database
1140395|NCT01406730|running exercise
1140396|NCT01406730|cardiac hypertrophy
1140397|NCT01406730|blood
1140398|NCT01406730|maximum oxygen uptake
1140399|NCT01406730|intervention
1140400|NCT01406730|untrained
1140401|NCT01406730|males
1140402|NCT01406717|SPIL1033
1140403|NCT01406717|type 2 diabetes mellitus
1140404|NCT01406691|sleep
1140405|NCT01406691|delayed sleep phase disorder
1140406|NCT01406691|circadian
1140407|NCT01406691|teen
1140408|NCT01406691|adolescent
1140409|NCT01406678|remote ischemic preconditioning
1140410|NCT01406678|coronary artery bypass grafting
1140411|NCT01406678|myocardial injury
1140412|NCT01406665|diabetes
1140413|NCT01406665|impaired glucose tolerance
1140414|NCT01406652|septic bursitis
1140415|NCT01406652|bursectomy
1140416|NCT01406652|primary closure
1140417|NCT01406639|Hereditary Hemorrhagic Telangiectasia (HHT)
1140418|NCT01406639|Nosebleeds
1140419|NCT01406639|Ranibizumab
1140420|NCT01406639|Lucentis
1140421|NCT01406626|HIV
1140422|NCT01406626|AIDS
1140423|NCT01406626|Health navigation
1140424|NCT01406626|Viral load
1140425|NCT01406626|Corrections
1140426|NCT01406613|Observational
1140427|NCT01406613|Bone Density
1140428|NCT01406613|alendronate
1140429|NCT01406613|ibandronate
1140430|NCT01406613|risedronate
1140431|NCT01406613|postmenopausal
1140432|NCT01406613|osteoporosis
1140433|NCT01406600|recombinant hCG
1140434|NCT01406600|poor responder
1140435|NCT01406600|oocyte maturity
1140436|NCT01406587|Burning
1140437|NCT01406587|Dysuria
1140438|NCT01406587|Frequency
1140439|NCT01406587|Pain
1140440|NCT01406587|Uncomplicated Urinary Tract Infection
1140441|NCT01406587|Uncomplicated UTI
1140442|NCT01406587|Urinary Tract Infection
1140443|NCT01406587|UTI
1140444|NCT01406587|Burning during urination associated with uncomplicated urinary tract infection
1140445|NCT01406587|Urination frequency associated with uncomplicated urinary tract infection
1140446|NCT01406587|Pain associated with uncomplicated urinary tract infection
1140447|NCT01406574|Hepatocellular carcinoma
1140448|NCT01406561|Meniscectomy
1140449|NCT01406561|Knee Pain
1140450|NCT01406561|Postoperative Pain
1140451|NCT01406548|Osteopenia
1140452|NCT01406548|osteoporosis
1140453|NCT01406548|low bone mineral density
1140454|NCT01406535|Phosphodiesterase 5 inhibition
1140455|NCT01406535|myocardial perfusion
1140456|NCT01406535|angiogenesis
1140457|NCT01406535|coronary artery disease
1140458|NCT01406535|therapy refractory
1140459|NCT01406522|Acetylcholine
1140460|NCT01406522|Cholinesterases
1140461|NCT01406522|Cocaine
1140462|NCT01406522|Self-Administration
1140463|NCT01406509|Safety
1140464|NCT01406509|Conjugate vaccine
1140465|NCT01406496|Insulin bolus
1140466|NCT01406496|glucose excursions
1140467|NCT01406496|post-prandial
1140468|NCT01406496|timing
1140469|NCT01406496|meal content
1140470|NCT01406483|Platelet reactivity
1140471|NCT01406483|CABG
1140472|NCT01406483|Perioperative and in hospital bleeding
1140473|NCT01406470|IGIV
1140474|NCT01406470|Primary Immune Deficiency
1140475|NCT01406470|Immunoglobulin G
1140476|NCT01406457|Subarachnoid Hemorrhage
1140477|NCT01406444|Anorexia Nervosa
1140478|NCT01406444|Osteopenia
1140479|NCT01406444|Osteoporosis
1140480|NCT01406444|Bone density
1140481|NCT01406431|pitavastatin
1140482|NCT01406431|Livalo
1140483|NCT01406418|Influenza
1140484|NCT01406418|Virus
1140485|NCT01406418|Monoclonal
1140486|NCT01406418|Antibody
1140487|NCT01406418|Immunization
1140488|NCT01406418|Treatment
1140489|NCT01406405|Degenerative disc disease
1140490|NCT01406405|spinal stenosis
1140491|NCT01406405|herniated disc
1140492|NCT01406392|Misoprostol
1140493|NCT01406392|Sublingual
1140494|NCT01406392|Induced
1140495|NCT01406392|Labor
1140496|NCT01406366|Pediatric oral health
1140497|NCT01406366|Bright Futures
1140498|NCT01406366|Health promotion
1140499|NCT01406353|Mitral Stenosis
1140500|NCT01406353|Mitral Valvuloplasty
1140501|NCT01406314|Phase 1
1140502|NCT01406314|Patient
1140503|NCT01406314|Systemic Amyloidosis
1140504|NCT01406314|Amyloidosis
1140505|NCT01406301|prescribing information
1140506|NCT01406288|hemolytic-uremic syndrome
1140507|NCT01406288|shiga-toxin-producing E. Coli
1140508|NCT01406262|albiglutide
1140509|NCT01406262|QT interval
1140510|NCT01406262|cardiac repolarization
1140511|NCT01406262|ECG study
1140512|NCT01406249|unresectable gastric cancer
1140513|NCT01406249|recurrent gastric cancer
1140514|NCT01406249|StageIV gastric cancer
1140515|NCT01406249|adenocarcinoma of the stomach
1140516|NCT01406249|XP
1140517|NCT01406249|SP
1140518|NCT01406236|Female
1140519|NCT01406236|urgent or elective percutaneous coronary intervention
1140520|NCT01406236|PCI
1140521|NCT01406236|diagnostic angiography
1140522|NCT01406223|Nicotine addiction
1140523|NCT01406223|Cigarette smoking
1140524|NCT01406223|Smoking cessation
1140525|NCT01406223|Zyban
1140526|NCT01406223|Chantix
1140527|NCT01406223|Nicotine patches
1140528|NCT01406223|varenicline
1140529|NCT01406223|bupropion
1140530|NCT01406223|fMRI
1140531|NCT01406210|Lung Transplant
1140532|NCT01406210|REflux Surgery
1140533|NCT01406210|Gastroesophageal Reflux Disease (GERD)
1140534|NCT01406210|Fundoplication
1140535|NCT01406197|Progesterone
1140536|NCT01406197|Progestins
1140537|NCT01406197|Preterm labor
1140538|NCT01406197|Premature birth
1140539|NCT01406197|Uterine electromyography
1140540|NCT01406197|Uterine contractility
1140541|NCT01406184|Child Abuse
1140542|NCT01406184|Child Neglect
1140543|NCT01406184|Child Hospital Emergency Room Presentations
1140544|NCT01406184|Child Well-Care Compliance
1140545|NCT01406184|Child Immunization Compliance
1140546|NCT01406171|Isavuconazole
1140547|NCT01406171|ASP9766
1140548|NCT01406171|BAL8557
1140549|NCT01406171|Midazolam
1140550|NCT01406171|Healthy volunteers
1140551|NCT01406158|Solifenacin succinate
1140552|NCT01406158|VESIcare
1140553|NCT01406158|Healthy Volunteers
1140554|NCT01406158|YM905
1140555|NCT01406145|Alzheimer's Disease
1140556|NCT01406145|ASP0777
1140557|NCT01406132|ASP015K
1140558|NCT01406132|Healthy volunteers
1140559|NCT01406106|Hypercholesterolemia
1140560|NCT01406106|Lipids
1140561|NCT01406106|Cardiovascular disease
1140562|NCT01406106|Risks factors
1140563|NCT01406106|Primary Care
1140564|NCT01406093|Candidemia
1140565|NCT01406093|Early-onset
1140566|NCT01406093|Late-onset
1140567|NCT01406093|Health-care associated
1140568|NCT01406093|Nosocomial
1140569|NCT01406080|Photoaging
1140570|NCT01406080|Photodamage
1140571|NCT01406080|Adapalene
1140572|NCT01406080|Differin
1140573|NCT01406067|social skills training,
1140574|NCT01406067|social competence training,
1140575|NCT01406067|Oppositional Defiant Disorder
1140576|NCT01406067|peer related aggressive behavior
1140577|NCT01406067|randomized controlled trial
1140578|NCT01406054|athletes
1140579|NCT01406054|injury prevention
1140580|NCT01406054|neuromuscular training
1140581|NCT01406054|public school
1140582|NCT01406054|physical education
1140583|NCT01406054|knee
1140584|NCT01406054|sports
1140585|NCT01406054|ACL
1140586|NCT01406054|KIPP
1140587|NCT01406041|Fluid and electrolyte imbalance
1140588|NCT01406041|Hyponatremia
1140589|NCT01406041|Hypernatremia
1140590|NCT01406041|Electrolytes disorder
1140591|NCT01406028|IVF
1140592|NCT01406028|Stress
1140593|NCT01406028|Infertility
1140594|NCT01406015|Obesity
1140595|NCT01406015|Insulin resistance
1140596|NCT01406015|Mineralocorticoid receptor
1140597|NCT01406002|Pharmacokinetics
1140598|NCT01406002|darexaban
1140599|NCT01406002|YM150
1140600|NCT01406002|rifampicin
1140601|NCT01406002|Phase 1
1140602|NCT01405989|Pharmacokinetics
1140603|NCT01405989|darexaban
1140604|NCT01405989|ketoconazole
1140605|NCT01405989|Phase 1
1140606|NCT01405976|sleep apneas
1140607|NCT01405976|noninvasive ventilation
1140608|NCT01405976|CPAP
1140609|NCT01405963|Amgen
1140610|NCT01405963|AMG 157
1140611|NCT01405963|Asthma
1140612|NCT01405898|hypertension
1140613|NCT01405898|nitrite
1140614|NCT01405898|blood pressure
1140615|NCT01405898|endothelial function
1140616|NCT01405885|Universal Influenza
1140617|NCT01405885|Intradermal DNA vaccine
1140618|NCT01405885|Electroporation
1140619|NCT01405885|H1 and H5
1140620|NCT01405885|DNA Vaccination
1140621|NCT01405885|Influenza
1140622|NCT01405885|INO-3510
1140623|NCT01405859|Tourette
1140624|NCT01405859|tic
1140625|NCT01405859|Tourette's
1140626|NCT01405859|Tourette syndrome
1140627|NCT01405859|Tourette's syndrome
1140628|NCT01405807|Vasculitis
1140629|NCT01405807|ANCA
1140630|NCT01405807|Refractory
1140631|NCT01405742|Hemophilia
1140632|NCT01405742|Prophylaxis
1140633|NCT01405742|Recombinant factor VIII
1140634|NCT01405716|Mindfulness
1140635|NCT01405716|Back Pain
1140636|NCT01405716|Older adults
1140637|NCT01405703|Clavicle Fractures
1140638|NCT01405703|Numbness
1140639|NCT01405703|Percutaneous plate fixation
1140640|NCT01405703|open plate fixation
1140641|NCT01405703|incision related numbness
1140642|NCT01405703|union rates
1140643|NCT01405703|subjective
1140644|NCT01405703|questionnaire based outcomes
1140645|NCT01405703|Diaphyseal
1140646|NCT01405690|CAD
1140647|NCT01405690|CTCA
1140648|NCT01405690|multidetector computer tomography (MDCT)
1140649|NCT01405677|Hepatitis A
1140650|NCT01405677|Vaccination
1140651|NCT01405677|Immunisation
1140652|NCT01405651|ONO-6950
1140653|NCT01405651|Healthy adult subjects
1140654|NCT01405625|Asthma
1140655|NCT01405625|Health literacy
1140656|NCT01405625|Parent knowledge of appropriate action plan steps
1140657|NCT01405599|Ulimorelin
1140658|NCT01405599|Hepatic Impairment
1140659|NCT01405586|elderly
1140660|NCT01405586|chemotherapy
1140661|NCT01405573|Child Pugh B
1140662|NCT01405573|first line
1140663|NCT01405547|Gestational Diabetes
1140664|NCT01405547|Gestational Hyperglycemia
1140665|NCT01405547|Gestational Insulinemia
1140666|NCT01405547|Maternal Obesity
1140667|NCT01405547|Human Milk
1140668|NCT01405547|Lactogenesis
1140669|NCT01405547|Obstetrics
1140670|NCT01405547|Nutrition
1140671|NCT01405547|Infant Growth
1140672|NCT01405534|Catheterization, Central Venous
1140673|NCT01405521|typhoid vaccine M01ZH09
1140674|NCT01405521|Ty21a typhoid vaccine
1140675|NCT01405508|N01258
1140676|NCT01405508|Brivaracetam
1140677|NCT01405508|Epilepsy
1140678|NCT01405508|IV
1140679|NCT01405508|intravenous
1140680|NCT01405495|Posttraumatic Stress Disorder
1140681|NCT01405495|Working Memory
1140682|NCT01405495|Attentional Bias
1140683|NCT01405495|Connectivity
1140684|NCT01405495|Structural Neuroimaging
1140685|NCT01405495|Functional Neuroimaging
1140686|NCT01405495|Diffusion Tensor Imaging
1140687|NCT01405495|Arterial Spin Labelling
1140688|NCT01405495|Cortisol
1140689|NCT01405495|Psychophysiology
1140690|NCT01405495|Early development of
1140691|NCT01405482|Botulinum Toxin Type A
1140692|NCT01405482|Thoracic Outlet Syndrome
1140693|NCT01405469|Achalasia
1140694|NCT01405469|Heller myotomy
1140695|NCT01405469|Dysphagia
1140696|NCT01405469|Peroral Endoscopic Myotomy
1140697|NCT01405456|HIV-infection
1140698|NCT01405456|eplerenone
1140699|NCT01405456|aldosterone
1140700|NCT01405456|visceral fat
1140701|NCT01405456|lipodystrophy
1140702|NCT01405443|Simulator training
1140703|NCT01405443|Flexible endoscopy
1140704|NCT01405443|Gastrointestinal endoscopy
1140705|NCT01405443|Colonoscopy
1140706|NCT01405443|Training
1140707|NCT01405443|Performance
1140708|NCT01405417|Achalasia
1140709|NCT01405417|Heller myotomy
1140710|NCT01405417|Dysphagia
1140711|NCT01405417|Peroral Endoscopic Myotomy
1140712|NCT01405404|parenting childcare discounts child behavior
1140713|NCT01405404|No Intervention Control
1140714|NCT01405404|Intervention no childcare discount
1140715|NCT01405404|Intervention with childcare discount
1140716|NCT01405391|Pharma Mar
1140717|NCT01405391|PM01183
1140718|NCT01405391|Non-Colorectal Cancer (non-CRC)
1140719|NCT01405391|Dose finding phase I
1140720|NCT01405365|Periodontitis
1140721|NCT01405365|Periodontal diseases
1140722|NCT01405365|Obesity
1140723|NCT01405365|Metronidazole
1140724|NCT01405365|Prognosis
1140725|NCT01405365|Probing depth
1140726|NCT01405365|Periodontal attachment loss
1140727|NCT01405352|obesity
1140728|NCT01405352|vitamin A
1140729|NCT01405352|immune system
1140730|NCT01405326|rheumatoid arthritis
1140731|NCT01405326|biological therapy
1140732|NCT01405326|adalimumab
1140733|NCT01405326|ability to work
1140734|NCT01405326|sick leaves
1140735|NCT01405287|stent
1140736|NCT01405287|drug eluting stent
1140737|NCT01405287|healing
1140738|NCT01405287|endothelium
1140739|NCT01405287|DES
1140740|NCT01405287|OCT
1140741|NCT01405287|MI
1140742|NCT01405287|ACS
1140743|NCT01405248|Butylphthalide
1140744|NCT01405235|Paclitaxel/Topotecan
1140745|NCT01405235|Cisplatin/Topotecan
1140746|NCT01405222|exacerbation
1140747|NCT01405222|COPD
1140748|NCT01405222|Cough
1140749|NCT01405209|EKG
1140750|NCT01405209|AF
1140751|NCT01405209|biosignals
1140752|NCT01405196|double-blind
1140753|NCT01405196|placebo-controlled
1140754|NCT01405196|multicenter
1140755|NCT01405196|dose-ranging
1140756|NCT01405196|efficacy
1140757|NCT01405196|safety
1140758|NCT01405196|lupus.
1140759|NCT01405183|Hepatitis C
1140760|NCT01405183|Renal Cell Carcinoma
1140761|NCT01405183|Colorectal Cancer
1140762|NCT01405170|bioequivalence study
1140763|NCT01405170|methylprednisolone
1140764|NCT01405170|suspension
1140765|NCT01405170|tablets
1140766|NCT01405170|fed
1140767|NCT01405157|bioequivalence study
1140768|NCT01405157|methylprednisolone
1140769|NCT01405157|suspension
1140770|NCT01405157|tablets
1140771|NCT01405157|fasting
1140772|NCT01405144|Photoaging
1140773|NCT01405144|Actinic keratosis
1140774|NCT01405144|5-fluoruracil
1140775|NCT01405144|Carcinogenesis
1140776|NCT01405131|bioequivalence study
1140777|NCT01405131|methylprednisolone
1140778|NCT01405131|suspension
1140779|NCT01405131|tablets
1140780|NCT01405118|Drug-Drug Interaction Healthy Volunteers CP-690
1140781|NCT01405118|550 Metformin
1140782|NCT01405092|volume
1140783|NCT01405092|acute kidney injury
1140784|NCT01405092|continuous renal replacement
1140785|NCT01405079|Lung cancer
1140786|NCT01405079|II-IIIA(N1-N2)
1140787|NCT01405079|Adjuvant treatment
1140788|NCT01405079|EGFR mutations
1140789|NCT01405079|Tyrosine kinase inhibitor
1140790|NCT01405066|Computed Tomography (CT)
1140791|NCT01405066|Ionizing radiation
1140792|NCT01405066|Advanced medical imaging
1140793|NCT01405066|Radiation Dose Audit Reports
1140794|NCT01405053|Central Nervous System
1140795|NCT01405040|Cardiac
1140796|NCT01405040|Output
1140797|NCT01405040|Preload
1140798|NCT01405040|Lung
1140799|NCT01405040|Water
1140800|NCT01405027|HCV
1140801|NCT01405027|Genotype1
1140802|NCT01405027|Naive
1140803|NCT01405027|Partial responder
1140804|NCT01405027|Relapser
1140805|NCT01405014|Hold Me Tight
1140806|NCT01405014|Emotionally Focused Therapy
1140807|NCT01405014|Relationship enhancement
1140808|NCT01405014|Couples counseling
1140809|NCT01405014|Marital therapy
1140810|NCT01405014|Acquired brain injury
1140811|NCT01405014|Traumatic brain injury
1140812|NCT01405014|Stroke
1140813|NCT01405001|Emergencies
1140814|NCT01405001|War
1140815|NCT01405001|Intubation, Intratracheal
1140816|NCT01404988|Heart Failure
1140817|NCT01404988|Telemedicine
1140818|NCT01404988|Medication Adherence
1140819|NCT01404975|Delirium
1140820|NCT01404975|PVB
1140821|NCT01404975|PCA
1140822|NCT01404975|Opioid
1140823|NCT01404975|Aortic Valve replacement
1140824|NCT01404962|Haemophilus influenza type b
1140825|NCT01404962|children
1140826|NCT01404962|Korea
1140827|NCT01404962|vaccine
1140828|NCT01404962|Prevention of haemophilus influenza type b
1140829|NCT01404949|Tretinoin
1140830|NCT01404949|all-trans retinoic acid
1140831|NCT01404949|ATRA
1140832|NCT01404949|Vesanoid
1140833|NCT01404949|Arsenic Trioxide
1140834|NCT01404949|ATO
1140835|NCT01404949|Trisenox
1140836|NCT01404949|11-040
1140837|NCT01404936|Lymphoma
1140838|NCT01404936|Hodgkin's Disease
1140839|NCT01404936|Stage III and IV
1140840|NCT01404936|Adriamycin
1140841|NCT01404936|Doxorubicin
1140842|NCT01404936|Rubex
1140843|NCT01404936|Bleomycin
1140844|NCT01404936|Bleomycin Sulfate
1140845|NCT01404936|BLM
1140846|NCT01404936|Dacarbazine
1140847|NCT01404936|DTIC-DOME
1140848|NCT01404936|Interferon-2A
1140849|NCT01404936|Interferon-Alfa-2a
1140850|NCT01404936|Roferon-A
1140851|NCT01404936|Velban
1140852|NCT01404936|Vinblastine
1140853|NCT01404910|Pregnancy
1140854|NCT01404910|Preeclampsia
1140855|NCT01404910|Pre-term
1140856|NCT01404910|sFlt-1
1140857|NCT01404910|Apheresis
1140858|NCT01404910|Hypertension
1140859|NCT01404910|Proteinuria
1140860|NCT01404910|VEGF
1140861|NCT01404897|carbohydrate
1140862|NCT01404897|DASH diet
1140863|NCT01404897|blood pressure
1140864|NCT01404897|cholesterol
1140865|NCT01404884|myopia
1140866|NCT01404884|astigmatism
1140867|NCT01404884|presbyopia
1140868|NCT01404884|SUPRACOR
1140869|NCT01404884|multifocal
1140870|NCT01404871|OCD
1140871|NCT01404871|pharmacogenetics
1140872|NCT01404871|cortical inhibition
1140873|NCT01404871|genetics
1140874|NCT01404858|IVF
1140875|NCT01404858|Lifestyle habits
1140876|NCT01404845|exudative AMD
1140877|NCT01404845|dietary supplements
1140878|NCT01404845|macular pigment
1140879|NCT01404845|lutein
1140880|NCT01404845|zeaxanthin
1140881|NCT01404845|Nutrof total
1140882|NCT01404845|in one eye
1140883|NCT01404832|Gastroesophageal reflux
1140884|NCT01404832|Proton pump inhibitor
1140885|NCT01404832|Eosinophilic esophagitis
1140886|NCT01404793|Liver Transplantation
1140887|NCT01404793|Solid Phase Micro Extraction
1140888|NCT01404793|Rocuronium
1140889|NCT01404793|Metabolomics
1140890|NCT01404793|Pharmacokinetics
1140891|NCT01404793|Clinical Marker
1140892|NCT01404780|Double lumen ET intubation
1140893|NCT01404780|Laryngoscope
1140894|NCT01404780|Lung Surgery
1140895|NCT01404767|Vascular surgery
1140896|NCT01404767|esmolol
1140897|NCT01404767|hemodynamic control
1140898|NCT01404754|MDMA
1140899|NCT01404754|mood
1140900|NCT01404754|subjective effects
1140901|NCT01404754|interpersonal closeness
1140902|NCT01404741|MDS
1140903|NCT01404741|CMML
1140904|NCT01404741|allogeneic stem cell transplantation
1140905|NCT01404741|5-azacytidine
1140906|NCT01404728|Vaginal length
1140907|NCT01404728|Sexual dysfunction
1140908|NCT01404715|Drug drug interaction
1140909|NCT01404702|Neuroblastoma
1140910|NCT01404702|Pediatrics
1140911|NCT01404702|Refractory
1140912|NCT01404702|Immunotherapy
1140913|NCT01404702|Biological therapy
1140914|NCT01404702|Lymphocytes
1140915|NCT01404702|Cancer
1140916|NCT01404702|Bisphosphonate
1140917|NCT01404689|dexmedetomidine
1140918|NCT01404689|midazolam
1140919|NCT01404689|ERCP
1140920|NCT01404689|cholangiopancreatography
1140921|NCT01404689|sedation
1140922|NCT01404689|propofol
1140923|NCT01404676|Glucose variability
1140924|NCT01404676|Oxidative stress
1140925|NCT01404676|Endothelial cell function
1140926|NCT01404663|bone marrow CD133 transplantation side effects
1140927|NCT01404663|side effects
1140928|NCT01404650|GIST
1140929|NCT01404650|Refractory
1140930|NCT01404650|Gastrointestinal
1140931|NCT01404650|Stromal
1140932|NCT01404650|Tumor
1140933|NCT01404611|with tubes
1140934|NCT01404559|Amputee
1140935|NCT01404559|Transtibial
1140936|NCT01404559|Military
1140937|NCT01404559|Gait
1140938|NCT01404559|Rehabilitation
1140939|NCT01404546|stroke smoking cessation cost-free pharmacotherapy
1140940|NCT01404533|NTBI
1140941|NCT01404533|Iron
1140942|NCT01404533|Absorption
1140943|NCT01404520|#14 Cancer Related fatigue
1140944|NCT01404520|#13 Quality of Life
1140945|NCT01404520|"#12 Psychosocial Intervention[ti/ab]"
1140946|NCT01404520|#11 Rehabilitation[tw]
1140947|NCT01404520|"#10 Physical Fitness[tw]"
1140948|NCT01404520|"#9 Physical Activity[tw]"
1140949|NCT01404520|"#8 Exercise Therapy[tw]"
1140950|NCT01404520|#7 Exercise[tw]
1140951|NCT01404520|#6 Hematologic[tw]
1140952|NCT01404520|#5 Hematological[tw]
1140953|NCT01404520|#4 Leukemia, Myeloid, Acute[mh]
1140954|NCT01404520|"#3 Acute Myeloid Leukemia[tw]"
1140955|NCT01404520|"#2 Acute Lymphoblastic Leukemia[tw]"
1140956|NCT01404520|"#1 Acute Leukemia[tw]"
1140957|NCT01404507|Acute Myocardial Infarction
1140958|NCT01404494|Haptic Skills
1140959|NCT01404494|Computer Assisted Interface
1140960|NCT01404494|TBI
1140961|NCT01404494|Traumatic Brain Injury
1140962|NCT01404481|Urinary retention
1140963|NCT01404481|CISC
1140964|NCT01404481|Single use
1140965|NCT01404481|Re use
1140966|NCT01404442|midazolam
1140967|NCT01404442|ketamine
1140968|NCT01404442|intrathecal
1140969|NCT01404442|pain
1140970|NCT01404429|Rheumatoid arthritis
1140971|NCT01404429|Active
1140972|NCT01404390|Phase I
1140973|NCT01404390|Japanese
1140974|NCT01404377|breast surgery : postoperative pain; ropivacaine
1140975|NCT01404364|Triamcinolone
1140976|NCT01404364|Chlorpromazine
1140977|NCT01404364|Refractory glaucoma
1140978|NCT01404364|Blind painful eye
1140979|NCT01404351|Reduction mammaplasty
1140980|NCT01404351|Breast reduction
1140981|NCT01404351|PlasmaBlade
1140982|NCT01404351|PEAK
1140983|NCT01404325|Lung transplantation
1140984|NCT01404325|everolimus
1140985|NCT01404325|kidney function
1140986|NCT01404299|Frailty,
1140987|NCT01404299|nutritional supplementation,
1140988|NCT01404299|functional status
1140989|NCT01404260|chemotherapy
1140990|NCT01404260|maintenance therapy
1140991|NCT01404260|gefitinib
1140992|NCT01404247|retina
1140993|NCT01404247|optic nerve
1140994|NCT01404247|fovea
1140995|NCT01404247|Eyes
1140996|NCT01404247|Neonates
1140997|NCT01404234|Cystic fibrosis
1140998|NCT01404234|CF
1140999|NCT01404234|PA
1141000|NCT01404234|Pseudomonas aeruginosa
1141001|NCT01404234|AZLI
1141002|NCT01404234|aztreonam
1141003|NCT01404234|Chronic Pseudomonas aeruginosa
1141004|NCT01404195|Nutritional supplement
1141005|NCT01404195|CaHMB
1141006|NCT01404195|Barthel index
1141007|NCT01404195|Frailty
1141008|NCT01404182|seasonal
1141009|NCT01404182|prevention
1141010|NCT01404182|influenza
1141011|NCT01404182|infection
1141012|NCT01404182|influenza vaccine
1141013|NCT01404182|vaccine
1141014|NCT01404182|influenza in humans
1141015|NCT01404169|Alzheimer Disease
1141016|NCT01404169|Dementia
1141017|NCT01404169|Delirium
1141018|NCT01404169|Amnestic
1141019|NCT01404169|Cognitive Disorders
1141020|NCT01404169|Donepezil
1141021|NCT01404169|Brain Diseases
1141022|NCT01404169|Central Nervous System Diseases
1141023|NCT01404169|Nervous System Diseases
1141024|NCT01404169|Tauopathies
1141025|NCT01404169|Neurodegenerative Diseases
1141026|NCT01404169|Mental Disorders
1141027|NCT01404169|Cholinesterase Inhibitors
1141028|NCT01404169|Enzy
1141029|NCT01404156|Esophageal cancer
1141030|NCT01404156|Neoadjuvant
1141031|NCT01404156|Chemotherapy
1141032|NCT01404156|Chemoradiation
1141033|NCT01404156|Surgery
1141034|NCT01404156|Esophagectomy
1141035|NCT01404156|Adenocarcinoma
1141036|NCT01404156|Gastroesophageal
1141037|NCT01404130|isotretinoin
1141038|NCT01404130|hippocampus
1141039|NCT01404130|memory
1141040|NCT01404130|learning
1141041|NCT01404130|CANTAB
1141042|NCT01404065|transcranial direct current stimulation
1141043|NCT01404052|transcranial direct current stimulation
1141044|NCT01404052|transcranial ultrasound
1141045|NCT01404039|learning
1141046|NCT01404039|pain perception
1141047|NCT01404026|Transcranial Direct Current Stimulation
1141048|NCT01404013|Montelukast
1141049|NCT01404013|Cough variant asthma
1141050|NCT01404013|Inhaled Corticosteroid
1141051|NCT01403987|Education
1141052|NCT01403987|Ascites
1141053|NCT01403987|Liver
1141054|NCT01403987|Guidelines
1141055|NCT01403922|Phase I, Randomised, Placebo-Controlled, Double-Blind,Hypertensive Patients, Blood Pressure, Calcium Channel Blockers, Beta Blockers, ACE Inhibitors
1141056|NCT01403922|Scientific terminology: To determine if treatment with TC5214 alone or in combination with Anti-Hypertensive Medications has an effect on sitting blood pressure
1141057|NCT01403922|Laymen terminology: Hypertension
1141058|NCT01403896|Hematopoietic Stem Cell Transplantation
1141059|NCT01403896|Plerixafor
1141060|NCT01403896|Healthy Donors
1141061|NCT01403896|Stem Cell Graft
1141062|NCT01403883|Rectal cancer
1141063|NCT01403883|Temporary stoma
1141064|NCT01403883|Psychological disorders
1141065|NCT01403870|Low Back Pain
1141066|NCT01403857|Acceptability
1141067|NCT01403857|liking
1141068|NCT01403844|resonance Raman spectroscopy
1141069|NCT01403844|Dietary Guidelines
1141070|NCT01403844|fruits
1141071|NCT01403844|biomarkers
1141072|NCT01403844|carotenoids
1141073|NCT01403844|MyPlate
1141074|NCT01403844|vegetables
1141075|NCT01403818|ASP1941
1141076|NCT01403818|ipragliflozin
1141077|NCT01403818|Mitiglinide calcium hydrate
1141078|NCT01403818|Drug-Drug interaction
1141079|NCT01403818|Pharmacokinetics
1141080|NCT01403805|Oral care
1141081|NCT01403805|Vaccine
1141082|NCT01403805|Pneumonia
1141083|NCT01403805|Elderly
1141084|NCT01403805|Prevention
1141085|NCT01403805|Primary care
1141086|NCT01403792|Human Immunodeficiency Virus
1141087|NCT01403792|Neutralising monoclonal antibody
1141088|NCT01403779|Intensity-Modulated Radiation Therapy (IMRT)
1141089|NCT01403779|Breast cancer
1141090|NCT01403779|Hypofractionation
1141091|NCT01403766|pediatric
1141092|NCT01403766|kidney
1141093|NCT01403766|transplant
1141094|NCT01403766|GFR
1141095|NCT01403766|creatinine
1141096|NCT01403766|cystatin C
1141097|NCT01403766|iohexol
1141098|NCT01403753|Obesity
1141099|NCT01403753|Child
1141100|NCT01403753|Dietary Habits
1141101|NCT01403740|acquired haemophilia
1141102|NCT01403740|factor VIII
1141103|NCT01403727|Biopsy of liver tumors
1141104|NCT01403714|acute heart failure
1141105|NCT01403701|physical therapy
1141106|NCT01403701|pelvic prolapse
1141107|NCT01403701|incontinence
1141108|NCT01403701|quality of life
1141109|NCT01403688|fertility high risk, controlled ovarian stimulation, breast cancer
1141110|NCT01403675|women with cancer whose ovarian tissue has been collected and stored in liquid nitrogen before cancer therapy (surgery, chemotherapy, radiotherapy),
1141111|NCT01403675|who are in remission (no recurrence of disease for 5 years),
1141112|NCT01403675|who are in normal organ function and have no contraindication for surgery or pregnancy, and
1141113|NCT01403675|who wish to restore ovarian function using stored ovarian tissue.
1141114|NCT01403662|bipolar disorder
1141115|NCT01403662|depression
1141116|NCT01403662|major depression
1141117|NCT01403662|bipolar I depression
1141118|NCT01403662|bipolar II depression
1141119|NCT01403662|bipolar I disorder
1141120|NCT01403662|bipolar II disorder
1141121|NCT01403662|minocycline
1141122|NCT01403662|minocin
1141123|NCT01403623|Hypothermia
1141124|NCT01403623|Newborn
1141125|NCT01403623|Resuscitation
1141126|NCT01403623|Plastic bag
1141127|NCT01403610|TH-302
1141128|NCT01403610|Bevacizumab
1141129|NCT01403610|Phase 2
1141130|NCT01403610|Glioma
1141131|NCT01403610|High Grade Glioma
1141132|NCT01403610|CNS
1141133|NCT01403597|Skin wrinkling
1141134|NCT01403597|Skin aging
1141135|NCT01403597|Skin pigmentation
1141136|NCT01402544|AMD
1141137|NCT01402544|Choroidal neovascularization
1141138|NCT01402544|Ranibizumab
1141139|NCT01402544|Age-related Macular Degeneration
1141140|NCT01402544|Genome
1141141|NCT01402531|Hereditary hemorrhagic telangiectasia (HHT)
1141142|NCT01402531|nosebleed
1141143|NCT01402531|Bevacizumab
1141144|NCT01402531|Avastin
1141145|NCT01402518|achalasia
1141146|NCT01402518|myotomy
1141147|NCT01402518|endoscopic myotomy
1141148|NCT01402518|difficulty swallowing
1141149|NCT01402505|obesity
1141150|NCT01402505|sleeve gastrectomy
1141151|NCT01402505|transvaginal NOTES
1141152|NCT01402492|Cocaine-Related disorders
1141153|NCT01402492|Cocaine
1141154|NCT01402492|Substance-Related disorders
1141155|NCT01402492|Opioid abuse
1141156|NCT01402492|Opioid dependence
1141157|NCT01402492|abuse
1141158|NCT01402492|addiction
1141159|NCT01402492|treatment
1141160|NCT01402492|buprenorphine
1141161|NCT01402492|naltrexone
1141162|NCT01402492|Suboxone
1141163|NCT01402492|Vivitrol
1141164|NCT01402479|migraine,
1141165|NCT01402479|ramipril,
1141166|NCT01402479|hypertension
1141167|NCT01402466|Drug users
1141168|NCT01402466|criminal justice
1141169|NCT01402466|HIV care
1141170|NCT01402466|HAART
1141171|NCT01402466|incarceration
1141172|NCT01402453|Incentives
1141173|NCT01402453|Social psychology
1141174|NCT01402453|Randomized trial
1141175|NCT01402453|Hypertension
1141176|NCT01402453|Intervention
1141177|NCT01402453|Pilot Study
1141178|NCT01402440|Diffuse Large B-Cell Lymphoma,
1141179|NCT01402440|Phase 1,
1141180|NCT01402440|CD79 Mutation
1141181|NCT01403545|Safety
1141182|NCT01403545|Tolerability
1141183|NCT01403545|Pharmacokinetics
1141184|NCT01403545|Liposomal Curcumin
1141185|NCT01403532|Hypogonadotropic Hypogonadism
1141186|NCT01403532|Kallmann Syndrome
1141187|NCT01403532|LH
1141188|NCT01403532|FSH
1141189|NCT01403506|kidney transplantation
1141190|NCT01403506|N-Acetyl Cysteine
1141191|NCT01403506|living donor
1141192|NCT01403506|delayed graft function
1141193|NCT01403493|Irritable bowel syndrome
1141194|NCT01403493|Patient education
1141195|NCT01403480|Basal Cell Carcinoma
1141196|NCT01403467|Bronchial disease
1141197|NCT01403467|asthma
1141198|NCT01403467|continuous positive airway pressure (CPAP)
1141199|NCT01403467|Bronchoconstriction
1141200|NCT01403454|chronic kidney disease
1141201|NCT01403454|web-based application
1141202|NCT01403454|dialysis education
1141203|NCT01403441|Refractory Bipolar Depression
1141204|NCT01403428|Asthma
1141205|NCT01403428|non invasive ventilation
1141206|NCT01403428|pediatrics
1141207|NCT01403428|noninvasive positive pressure ventilation (NPPV)
1141208|NCT01403402|Congenital Muscular Dystrophy
1141209|NCT01403402|Congenital Myopathy
1141210|NCT01403402|Neuromuscular Diseases
1141211|NCT01403402|Musculoskeletal Diseases
1141212|NCT01403389|Kidney Transplant
1141213|NCT01403389|Delayed Graft Function
1141214|NCT01403350|Malaria
1141215|NCT01403350|Fever
1141216|NCT01403350|Acute febrile illness
1141217|NCT01403350|Pneumonia
1141218|NCT01403350|Community health worker
1141219|NCT01403350|Rapid diagnostic test
1141220|NCT01403337|peripheral arterial disease
1141221|NCT01403337|myocardial infarction
1141222|NCT01403324|metastatic or locally advanced differentiated thyroid cancer
1141223|NCT01403324|planned for a therapeutic activity of 131I after thyroid hormone withdrawal
1141224|NCT01403311|Anaplastic astrocytoma
1141225|NCT01403311|Astrocytoma
1141226|NCT01403311|Brain stem glioma
1141227|NCT01403311|Ependymoma
1141228|NCT01403311|Glioblastoma
1141229|NCT01403311|Glioblastoma multiforme
1141230|NCT01403311|Gliosarcoma
1141231|NCT01403311|oligodendroglioma
1141232|NCT01403311|Medulloblastoma
1141233|NCT01403311|Mixed astrocytoma-ependymoma
1141234|NCT01403311|ALA
1141235|NCT01403298|Adolescent
1141236|NCT01403298|HIV
1141237|NCT01403298|AIDS
1141238|NCT01403298|Sexual risk
1141239|NCT01403298|Family
1141240|NCT01403298|Prevention
1141241|NCT01403298|Juvenile Drug Court
1141242|NCT01403298|Juvenile Justice
1141243|NCT01403298|Drug Use
1141244|NCT01403298|Marijuana
1141245|NCT01403285|Glioblastoma
1141246|NCT01403285|stable disease
1141247|NCT01403272|pressure ulcers
1141248|NCT01403272|stage 1
1141249|NCT01403272|stage 2
1141250|NCT01403272|stage 3
1141251|NCT01403272|stage 4
1141252|NCT01403272|wounds
1141253|NCT01403272|sores
1141254|NCT01403272|infection
1141255|NCT01403272|bioburden
1141256|NCT01403272|bacterial contamination
1141257|NCT01403272|bed linen
1141258|NCT01403272|sheets
1141259|NCT01403272|underpad
1141260|NCT01403272|skin assessment
1141261|NCT01403272|microclimate
1141262|NCT01403272|shear
1141263|NCT01403272|friction
1141264|NCT01403272|moisture
1141265|NCT01403272|fabrics
1141266|NCT01403272|long term care
1141267|NCT01403272|nursing home
1141268|NCT01403272|decubitus ulcer
1141269|NCT01403272|bed ridden
1141270|NCT01403272|anti-microbial
1141271|NCT01403259|Nasopharyngeal carcinoma
1141272|NCT01403259|S-1
1141273|NCT01403259|Oxaliplatin
1141274|NCT01403246|CLL
1141275|NCT01403246|Lenalidomide
1141276|NCT01403246|Chlorambucil
1141277|NCT01403246|No previous treatment
1141278|NCT01403233|Pharmacokinetics
1141279|NCT01403233|Safety
1141280|NCT01403207|Sex differences
1141281|NCT01403207|knee joint
1141282|NCT01403207|inflammatory mediators
1141283|NCT01403207|Vitamin D
1141284|NCT01403207|osteoarthritis
1141285|NCT01403194|Sleep Disordered Breathing
1141286|NCT01403194|CPAP
1141287|NCT01403194|BiPAP
1141288|NCT01403194|Cardiovascular risk markers
1141289|NCT01403181|HCV
1141290|NCT01403181|T cells
1141291|NCT01403181|cytokines
1141292|NCT01403181|cytotoxicity
1141293|NCT01403181|proliferation
1141294|NCT01403168|Osteopathy
1141295|NCT01403168|Breast cancer
1141296|NCT01403168|Pain
1141297|NCT01403155|H5N1
1141298|NCT01403155|Avian Influenza
1141299|NCT01403155|DNA Vaccine
1141300|NCT01403155|Intradermal (ID) Injection
1141301|NCT01403155|Electroporation
1141302|NCT01403155|Healthy Adults
1141303|NCT01403142|heart transplant
1141304|NCT01403142|vasculopathy
1141305|NCT01403129|keratoconus
1141306|NCT01403129|keratoconus-suspect
1141307|NCT01403129|ultrasound exam
1141308|NCT01403129|acoustic radiation force ultrasound exam
1141309|NCT01403116|testosterone
1141310|NCT01403116|male hypogonadism
1141311|NCT01403116|low testosterone
1141312|NCT01403090|Pulmonary Embolism
1141313|NCT01403090|Deep Vein Thrombosis
1141314|NCT01403090|Venous Thromboembolism
1141315|NCT01403090|Central Line Catheter
1141316|NCT01403090|Vena Cava Filters
1141317|NCT01403077|Superficial femoral artery
1141318|NCT01403077|Peripheral arterial disease
1141319|NCT01403077|Atherosclerosis
1141320|NCT01403077|Intermittent Claudication
1141321|NCT01403077|Vascular Diseases
1141322|NCT01403077|Cardiovascular Diseases
1141323|NCT01403064|Oral mucositis; head and neck cancer; chemotherapy; radiotherapy
1141324|NCT01403038|healthy volunteers
1141325|NCT01403038|elagolix
1141326|NCT01403038|endometriosis
1141327|NCT01403038|ovarian reserve
1141328|NCT01403038|gonadotropin-releasing hormone antagonist
1141329|NCT01403038|ovulation
1141330|NCT01403038|ovarian activity
1141331|NCT01403012|To identify clinical and metabolomic markers that underlie variability in response to systemic therapy in psoriasis
1141332|NCT01403012|To identify metabolomic signatures associated with psoriasis
1141333|NCT01403012|To identify possible treatment-specific metabolomic signatures
1141334|NCT01402999|Growth disorders
1141335|NCT01402999|Saizen
1141336|NCT01402999|Easypod
1141337|NCT01402999|Growth hormone
1141338|NCT01402999|Pediatric subject
1141339|NCT01402986|Asthma
1141340|NCT01402986|Tralokinumab
1141341|NCT01402986|CAT-354
1141342|NCT01402960|High-Definition Transcranial Direct Current Stimulation
1141343|NCT01402908|Hepatocellular Carcinoma
1141344|NCT01402908|PI-88
1141345|NCT01402908|Phase III
1141346|NCT01402908|Adjuvant Therapy
1141347|NCT01402908|Hepatoma
1141348|NCT01402908|Liver Cancer
1141349|NCT01402895|Nerve conduction
1141350|NCT01402895|H-reflex, mobilizations
1141351|NCT01402895|with neurodynamic component
1141352|NCT01402882|traumatic brain injury
1141353|NCT01402882|tranexamic acid
1141354|NCT01402882|antifibrinolytic
1141355|NCT01402882|randomised
1141356|NCT01402882|clinical trial
1141357|NCT01402869|Methemoglobin
1141358|NCT01402869|Methemoglobinemia
1141359|NCT01402869|Prilocaine
1141360|NCT01402869|Lidocaine
1141361|NCT01402856|Prevention
1141362|NCT01402856|Adolescent
1141363|NCT01402856|Trauma
1141364|NCT01402856|Driving
1141365|NCT01402843|phase III combination study
1141366|NCT01402830|cancer
1141367|NCT01402830|depression
1141368|NCT01402830|pain
1141369|NCT01402817|NF1
1141370|NCT01402817|plexiform neurofibromas
1141371|NCT01402817|Sunitinib
1141372|NCT01402817|Sutent®
1141373|NCT01402739|PoC
1141374|NCT01402739|ROTEM
1141375|NCT01402739|Multiplate
1141376|NCT01402739|transfusion
1141377|NCT01402739|cardiac surgery
1141378|NCT01402739|drainage blood loss
1141379|NCT01402739|chest tube output
1141380|NCT01402726|renal artery
1141381|NCT01402726|sympathetic nerves
1141382|NCT01402726|modification
1141383|NCT01402726|heart failure
1141384|NCT01402700|Peripheral arterial disease
1141385|NCT01402700|claudication
1141386|NCT01402700|stent
1141387|NCT01402700|VISI-Pro
1141388|NCT01402700|Iliac artery
1141389|NCT01402687|Stem Cell Transplant
1141390|NCT01402687|Mucositis
1141391|NCT01402674|Obesity treatment
1141392|NCT01402674|Phentermine
1141393|NCT01402674|Withholding treatment
1141394|NCT01402674|Phentermine dependence
1141395|NCT01402661|rheumatoid arthritis
1141396|NCT01402661|psoriatic arthritis
1141397|NCT01402661|disease registry
1141398|NCT01402648|Non adenomatous mucosa
1141399|NCT01402648|Estrogen Receptor beta and apoptosis
1141400|NCT01402648|Adenoma recurrence
1141401|NCT01402648|Screening colonoscopy every 3-5 years
1141402|NCT01402648|patients at intermediate risk for CRC
1141403|NCT01402635|crowding
1141404|NCT01402635|Point-of-Care Systems
1141405|NCT01402635|emergency medicine
1141406|NCT01402609|Continuity of care
1141407|NCT01402609|Patient safety
1141408|NCT01402609|Communication between acute and community care providers
1141409|NCT01402596|Deep Sedation
1141410|NCT01402596|Pediatrics
1141411|NCT01402596|Emergency Hospital Services
1141412|NCT01402596|Midazolam
1141413|NCT01402596|Chloral hydrate
1141414|NCT01402596|Randomized controlled trial
1141415|NCT01402583|Hepatitis C
1141416|NCT01402583|Gender
1141417|NCT01402583|Menopause
1141418|NCT01402583|Sustained viral response
1141419|NCT01402583|Cytokines
1141420|NCT01402570|disability
1141421|NCT01402570|polio
1141422|NCT01402570|rehabilitation
1141423|NCT01402570|wellness
1141424|NCT01402557|Obesity
1141425|NCT01402557|Body Weight Changes
1141426|NCT01402557|Internet
1141427|NCT01402427|Coronary Artery Disease
1141428|NCT01402427|Coronary Angiography
1141429|NCT01402427|Percutaneous Coronary Intervention
1141430|NCT01402427|Transradial
1141431|NCT01402427|Radial Artery Spasm
1141432|NCT01402427|Verapamil
1141433|NCT01402427|Adverse Effects
1141434|NCT01402414|atopic dermatitis
1141435|NCT01402414|NB-UVB
1141436|NCT01402414|phototherapy
1141437|NCT01402414|balneophototherapy
1141438|NCT01402414|Bath-PUVA
1141439|NCT01402414|SCORAD index
1141440|NCT01402401|HER2+,
1141441|NCT01402401|Gastric Cancer,
1141442|NCT01402401|HSP90,
1141443|NCT01402401|2nd-line,
1141444|NCT01402401|Trastuzumab
1141445|NCT01402375|Pain Management
1141446|NCT01402375|Emergency Medicine
1141447|NCT01402375|Extremity Injuries
1141448|NCT01402362|Ethiopians
1141449|NCT01402362|Diabetes Mellitus
1141450|NCT01402362|Glucose tolerance
1141451|NCT01402362|Israel
1141452|NCT01402362|Included in the year 2000 study
1141453|NCT01402349|Chronic rhinosinusitis, SNOT 22, Quality of life
1141454|NCT01402336|Polycystic ovary syndrome
1141455|NCT01402336|ovulation induction
1141456|NCT01402336|In vitro fertilization-embryo transfer
1141457|NCT01402310|Onset of labor
1141458|NCT01402310|Bishop score
1141459|NCT01402310|Cervical length
1141460|NCT01402310|Multiple proteins
1141461|NCT01402310|Cervicovaginal fluid
1141462|NCT01402297|apocynin
1141463|NCT01402297|COPD
1141464|NCT01402284|Novel Drug Combinations
1141465|NCT01402284|Protease Inhibitors
1141466|NCT01402284|Decreased Peripheral Neuropathy
1141467|NCT01402284|Auto Stem Cell Transplant
1141468|NCT01402284|Multiple Myeloma
1141469|NCT01402271|recurrent ovarian epithelial cancer
1141470|NCT01402271|recurrent fallopian tube cancer
1141471|NCT01402271|recurrent primary peritoneal cavity cancer
1141472|NCT01402245|pneumonia
1141473|NCT01402245|pneumococcal polysaccharide vaccine
1141474|NCT01402245|pneumococcal conjugate vaccine
1141475|NCT01402232|contrast-induced nephropathy
1141476|NCT01402232|contrast medium
1141477|NCT01402232|creatinine clearance
1141478|NCT01402232|coronary angiography
1141479|NCT01402232|diabetes
1141480|NCT01402232|chronic kidney disease
1141481|NCT01402232|predictive model
1141482|NCT01402219|contrast-induced nephropathy
1141483|NCT01402219|contrast medium
1141484|NCT01402219|creatinine clearance
1141485|NCT01402219|coronary angiography
1141486|NCT01402219|chronic kidney disease
1141487|NCT01402206|Depression
1141488|NCT01402206|Intervention
1141489|NCT01402206|Primary health care
1141490|NCT01402193|Breast Cancer
1141491|NCT01402193|Timing of Radiotherapy
1141492|NCT01402193|TGF-beta1
1141493|NCT01402180|Esophageal squamous cell carcinoma
1141494|NCT01402180|lymph nodes recurrence
1141495|NCT01402180|chemoradiation
1141496|NCT01402180|Nimotuzumab
1141497|NCT01402141|Chungkookjang
1141498|NCT01402141|histamine
1141499|NCT01402141|skin reaction
1141500|NCT01402141|wheal
1141501|NCT01402128|Soluble fiber
1141502|NCT01402128|Polycan
1141503|NCT01402128|Overweight
1141504|NCT01402128|LDL-C(Low Density Lipoprotein-cholesterol)
1141505|NCT01402115|Polycan
1141506|NCT01402115|Bone metabolism
1141507|NCT01402115|Osteocalcin
1141508|NCT01402115|Deoxypyridinoline
1141509|NCT01402102|Aged garlic
1141510|NCT01402102|Hyperlipidemic
1141511|NCT01402102|LDL
1141512|NCT01402102|HDL
1141513|NCT01402102|Triglyceride
1141514|NCT01402089|phenotyping
1141515|NCT01402089|cytochrome p450
1141516|NCT01402089|erlotinib
1141517|NCT01402089|sunitinib
1141518|NCT01402089|lung cancer
1141519|NCT01402089|renal-cell cancer
1141520|NCT01402089|gastrointestinal stromal tumor
1141521|NCT01402076|Pharmacokinetics
1141522|NCT01402076|Drug Interaction
1141523|NCT01402063|Brain Tumors
1141524|NCT01402063|Glioblastoma Multiforme
1141525|NCT01402063|GBM
1141526|NCT01402050|Time from the start of the induction to delivery
1141527|NCT01402037|type 1 diabetes
1141528|NCT01402037|Prevention
1141529|NCT01402037|First degree relatives
1141530|NCT01402037|High risk for type 1 diabetes
1141531|NCT01402011|Prolotherapy
1141532|NCT01402011|regenerative injection therapy
1141533|NCT01402011|dextrose injections
1141534|NCT01401998|cystic kidney disease
1141535|NCT01401998|polycystic kidney disease
1141536|NCT01401998|congenital hepatic fibrosis
1141537|NCT01401998|genetic disease
1141538|NCT01401985|Opioid induced constipation
1141539|NCT01401985|OIC
1141540|NCT01401985|Constipation
1141541|NCT01401985|Opioid side effects
1141542|NCT01401985|morphine induced constipation
1141543|NCT01401972|prostate
1141544|NCT01401972|cancer
1141545|NCT01401972|ultrasound
1141546|NCT01401972|spectroscopy
1141547|NCT01401959|Metastatic Breast Cancer
1141548|NCT01401959|Adjuvant
1141549|NCT01401959|Residual Disease
1141550|NCT01401959|eribulin
1141551|NCT01401959|Trastuzumab
1141552|NCT01401920|internal jugular vein cannulation
1141553|NCT01401920|cross-sectional area
1141554|NCT01401920|passive leg elevation
1141555|NCT01401920|trendelenburg position
1141556|NCT01401920|open heart surgery
1141557|NCT01401907|Palliative care
1141558|NCT01401907|Lung
1141559|NCT01401907|Gastric
1141560|NCT01401907|Liver
1141561|NCT01401907|Pancreatic
1141562|NCT01401907|Esophageal
1141563|NCT01401907|Caregiver
1141564|NCT01401894|advanced cancer
1141565|NCT01401868|solid tumor
1141566|NCT01401868|recurrent
1141567|NCT01401868|advanced
1141568|NCT01401868|metastatic
1141569|NCT01401855|Diagnosis
1141570|NCT01401855|Fine Needle Aspiration Biopsy
1141571|NCT01401842|low back muscular strength and endurance
1141572|NCT01401829|endometrial cancer
1141573|NCT01401829|aerobic walking
1141574|NCT01401829|stretching/flexibility exercises
1141575|NCT01401829|quality of life
1141576|NCT01401816|Adolescents
1141577|NCT01401816|Sexually Active
1141578|NCT01401816|Unprotected Sex
1141579|NCT01401816|Emergency Contraception
1141580|NCT01401803|periorbital
1141581|NCT01401803|glabella
1141582|NCT01401803|ptosis
1141583|NCT01401803|eyelid
1141584|NCT01401803|brow
1141585|NCT01401790|Children
1141586|NCT01401790|Adolescents
1141587|NCT01401790|Telehomecare
1141588|NCT01401777|Kidney Tumors, Cryoablation, Biopsy
1141589|NCT01401751|Type 1 Diabetes Mellitus
1141590|NCT01401751|Artificial Pancreas
1141591|NCT01401738|Shoulder Arthroscopic Surgery
1141592|NCT01401725|venous thromboembolism
1141593|NCT01401725|thromboprophylaxis
1141594|NCT01401725|anticoagulants
1141595|NCT01401725|hospitalized medical patients
1141596|NCT01401725|electronic order sets
1141597|NCT01401725|decision support
1141598|NCT01401725|knowledge translation
1141599|NCT01401725|patient safety
1141600|NCT01401712|ON-Q
1141601|NCT01401712|epidural
1141602|NCT01401712|analgesia
1141603|NCT01401699|Barrett's
1141604|NCT01401699|esophagus
1141605|NCT01401699|OCT
1141606|NCT01401699|imaging
1141607|NCT01401673|Chronic Cough
1141608|NCT01401673|Indantadol
1141609|NCT01401660|low back pain
1141610|NCT01401647|cardiac arrest
1141611|NCT01401647|cardiopulmonary resuscitation
1141612|NCT01401647|ventricular fibrillation
1141613|NCT01401647|pulseless ventricular tachycardia
1141614|NCT01401647|Non-traumatic Out of Hospital Cardiac Arrest (OOHCA)
1141615|NCT01401634|Hyperglycemia Hydration
1141616|NCT01401621|behavioral economics
1141617|NCT01401621|nudge
1141618|NCT01401621|scratch off
1141619|NCT01401621|blood pressure check
1141620|NCT01401621|cholesterol test
1141621|NCT01401608|VT
1141622|NCT01401608|ventricular tachycardia
1141623|NCT01401608|ablation
1141624|NCT01401608|magnetic navigation
1141625|NCT01401608|robotic
1141626|NCT01401582|health care
1141627|NCT01401582|dementia care
1141628|NCT01401582|caregiver support
1141629|NCT01401582|epidemiological study
1141630|NCT01401569|Exercise,
1141631|NCT01401569|counseling,
1141632|NCT01401569|smoking cessation,
1141633|NCT01401569|depressive disorders
1141634|NCT01401556|osteoporosis
1141635|NCT01401556|fracture
1141636|NCT01401556|treatment
1141637|NCT01401556|guidelines
1141638|NCT01401556|quality
1141639|NCT01401543|testosterone
1141640|NCT01401543|energy
1141641|NCT01401543|libido
1141642|NCT01401543|erectile function
1141643|NCT01401543|weak muscles
1141644|NCT01401530|Neoplasms
1141645|NCT01401530|Neoplasms by Histologic Type
1141646|NCT01401530|Lymphoma
1141647|NCT01401530|Non-Hodgkin
1141648|NCT01401530|T- Cell
1141649|NCT01401530|Lymphatic Diseases
1141650|NCT01401530|Lymphoproliferative Disorders
1141651|NCT01401530|lmmune System Diseases
1141652|NCT01401530|lmmunoproliferative Disorders
1141653|NCT01401504|Anti-cancer
1141654|NCT01401504|ASP3026
1141655|NCT01401504|Anaplastic Lymphoma Kinase (ALK)
1141656|NCT01401491|schizophrenia
1141657|NCT01401491|clozapine
1141658|NCT01401491|fluvoxamine
1141659|NCT01401491|metabolic syndrome
1141660|NCT01401478|Secondary Hyperparathyroidism
1141661|NCT01401478|Chronic Renal Insufficiency
1141662|NCT01401465|perennial allergic rhinitis
1141663|NCT01401465|PAR
1141664|NCT01401452|Monoclonals
1141665|NCT01401452|Moderate to severe plaque psoriasis
1141666|NCT01401452|Psoriasis Area & Severity Index (PASI)
1141667|NCT01401452|Adalimumab
1141668|NCT01401452|Biological disease modifying anti-rheumatic drugs (BDMARD)
1141669|NCT01401452|Co-morbidities
1141670|NCT01401452|Antibodies
1141671|NCT01401452|Disease Life Quality Index (DLQI)
1141672|NCT01401439|cystic fibrosis
1141673|NCT01401439|body mass index
1141674|NCT01401439|fat free mass
1141675|NCT01401439|Children with cystic fibrosis
1141676|NCT01401426|overweight
1141677|NCT01401426|Obesity, Morbid
1141678|NCT01401374|Vitiligo Vulgaris
1141679|NCT01401374|Autoimmunity
1141680|NCT01401374|Thyroid Disease
1141681|NCT01401296|Depression
1141682|NCT01401296|Online-Therapy
1141683|NCT01401296|Deprexis
1141684|NCT01401296|Self-help
1141685|NCT01401257|PXT3003
1141686|NCT01401257|Charcot-Marie-Tooth Disease
1141687|NCT01401257|Hereditary Motor and Sensory Neuropathies
1141688|NCT01401231|depression
1141689|NCT01401231|pregnancy
1141690|NCT01401218|thoracic aortic surgery
1141691|NCT01401218|acute kidney injury
1141692|NCT01401205|shoulder arthroscopic surgery
1141693|NCT01401205|dyspnea
1141694|NCT01401205|airway diameter
1141695|NCT01401192|thymidylate synthase
1141696|NCT01401179|Preterm Premature Rupture of Fetal Membranes
1141697|NCT01401179|antibiotic therapy
1141698|NCT01401140|Coronary Artery Bypass
1141699|NCT01401140|Coronary Artery Surgery
1141700|NCT01401140|Coronary Artery Bypass Graft
1141701|NCT01401140|Coronary Revascularization
1141702|NCT01401140|Cardiac microdialysis
1141703|NCT01401140|Custodiol
1141704|NCT01401140|St Thomas
1141705|NCT01401140|Cardioplegic solutions
1141706|NCT01401127|Type 1 Diabetes Mellitus
1141707|NCT01401127|Exercise
1141708|NCT01401127|Continuous Subcutaneous Insulin Infusion
1141709|NCT01401127|CSII
1141710|NCT01401127|Insulin Pump Therapy
1141711|NCT01401114|Wellnara
1141712|NCT01401114|Postmenopausal osteoporosis
1141713|NCT01401101|mental health
1141714|NCT01401101|PTSD
1141715|NCT01401101|primary care
1141716|NCT01401101|quality improvement
1141717|NCT01401101|collaborative care
1141718|NCT01401088|patient with refractory glaucoma
1141719|NCT01401075|Quality of Life
1141720|NCT01401075|QoL
1141721|NCT01401075|EORTC QLQ-C30
1141722|NCT01401075|EORTC QLQ-STO22
1141723|NCT01401075|5-FU
1141724|NCT01401075|Viscum album
1141725|NCT01401062|metastatic breast cancer
1141726|NCT01401062|TGF-beta
1141727|NCT01401062|fresolimumab
1141728|NCT01401062|monoclonal antibody
1141729|NCT01401062|radiation therapy
1141730|NCT01401062|abscopal response
1141731|NCT01401049|Fospropofol
1141732|NCT01401049|Propofol
1141733|NCT01401049|Colonoscopy
1141734|NCT01401049|Lusedra
1141735|NCT01401036|acute myocardial infarction
1141736|NCT01401036|stents
1141737|NCT01401036|angioplasty
1141738|NCT01401036|thrombosis
1141739|NCT01401010|neutropenia
1141740|NCT01401010|doripenem
1141741|NCT01400997|Growth disorders
1141742|NCT01400997|Saizen
1141743|NCT01400997|Easypod
1141744|NCT01400997|Growth hormone
1141745|NCT01400997|Pediatric subject
1141746|NCT01400984|Growth disorders
1141747|NCT01400984|Saizen
1141748|NCT01400984|Easypod
1141749|NCT01400984|Growth hormone
1141750|NCT01400984|Pediatric subject
1141751|NCT01400971|Diabetes
1141752|NCT01400971|Insulin
1141753|NCT01400971|Progression
1141754|NCT01400971|Patient Reported Measures
1141755|NCT01400971|Adherence
1141756|NCT01400971|Heterogeneity
1141757|NCT01400971|Hypoglycemia
1141758|NCT01400958|fatigue
1141759|NCT01400958|external beam radiation
1141760|NCT01400958|EBRT
1141761|NCT01400958|radiation therapy
1141762|NCT01400958|placebo
1141763|NCT01400958|cognitive function
1141764|NCT01400958|TMZ
1141765|NCT01400958|Temozolomide
1141766|NCT01400945|GERD
1141767|NCT01400945|endoscopy
1141768|NCT01400945|LA grade
1141769|NCT01400945|heartburn
1141770|NCT01400932|inflammatory lesion
1141771|NCT01400932|Benzoyl peroxide (BPO)
1141772|NCT01400932|once daily
1141773|NCT01400932|acne vulgaris
1141774|NCT01400932|vehicle gel
1141775|NCT01400932|clindamycin (CLDM) 1%-BPO 3% gel
1141776|NCT01400932|non-inflammatory lesion
1141777|NCT01400919|Peripheral arterial disease
1141778|NCT01400919|claudication
1141779|NCT01400919|stent
1141780|NCT01400919|EverFlex
1141781|NCT01400919|GPS
1141782|NCT01400919|Iliac Artery
1141783|NCT01400893|Acute Renal Failure
1141784|NCT01400893|Acute kidney injury
1141785|NCT01400893|Acute tubular necrosis
1141786|NCT01400893|Continuous Renal Replacement Therapy
1141787|NCT01400893|Severe sepsis
1141788|NCT01400893|Selective cytopheretic device
1141789|NCT01400880|Maternal Fetal Monitoring
1141790|NCT01400867|Infections
1141791|NCT01400867|Pediatrics
1141792|NCT01400867|Teflaro
1141793|NCT01400867|cephalosporin
1141794|NCT01400854|breakthrough cancer pain
1141795|NCT01400841|Aortic Insufficiency, Aortic Regurgitation, Aortic Valve Repair
1141796|NCT01400815|smoking
1141797|NCT01400815|smoking cessation
1141798|NCT01400815|quitting smoking
1141799|NCT01400776|Postmenopausal Women, Vaginal Dryness
1141800|NCT01400763|focus of study
1141801|NCT01400750|cystic fibrosis- P aeruginosa- eradication-child
1141802|NCT01400737|ibuprofen
1141803|NCT01400737|prophylaxis
1141804|NCT01400737|VELBW
1141805|NCT01400724|menopause
1141806|NCT01400724|metabolic syndrome
1141807|NCT01400724|myo-inositol
1141808|NCT01400724|insulin resistance
1141809|NCT01400724|cocoa polyphenols
1141810|NCT01400724|isoflavones
1141811|NCT01400711|Fast-tract surgery, Enhanced recovery after surgery, multimodal surgery.
1141812|NCT01400698|Intra-uterine growth retardation (IUGR)
1141813|NCT01400698|Saizen
1141814|NCT01400698|Recombinant human growth hormone (r-hGH)
1141815|NCT01400698|Final height
1141816|NCT01400698|Bone age
1141817|NCT01400698|SGA (Small for Gestational Age)
1141823|NCT01400672|Diffuse intrinsic pontine glioma
1141824|NCT01400659|CSII
1141825|NCT01400659|prandial insulin requirements
1141826|NCT01400659|bolus calculation
1141827|NCT01400659|dual-wave bolus
1141828|NCT01400646|Rivaroxaban
1141829|NCT01400646|JNJ-39039039
1141830|NCT01400646|BAY59-7939
1141831|NCT01400646|Warfarin
1141832|NCT01400646|Transition
1141833|NCT01400633|Myelodysplastic Syndrome
1141834|NCT01400633|Dacogen
1141835|NCT01400633|decitabine
1141836|NCT01400633|epigenetic therapy
1141837|NCT01400633|hypomethylating agent
1141838|NCT01400620|oral mucositis
1141839|NCT01400620|chemoradiation
1141840|NCT01400620|head and neck cancer
1141841|NCT01400607|cartilage
1141842|NCT01400607|knee surgery
1141843|NCT01400607|cartilage injury
1141844|NCT01400607|knee pain
1141845|NCT01400607|cartilage repair
1141846|NCT01400607|cartilage damage
1141847|NCT01400607|cartilage lesion
1141848|NCT01400607|cartilage defect
1141849|NCT01400607|articular cartilage lesion
1141850|NCT01400607|articular cartilage defect
1141851|NCT01400607|juvenile
1141852|NCT01400607|cells
1141853|NCT01400607|ISTO Technologies
1141854|NCT01400607|Neocartilage
1141855|NCT01400607|RevaFlex
1141856|NCT01400594|Onychomycosis
1141857|NCT01400555|Prostate Cancer
1141858|NCT01400555|Metastatic Castration-Resistant Prostate Cancer
1141859|NCT01400555|Abiraterone Acetate
1141860|NCT01400555|Docetaxel
1141861|NCT01400555|Prednisone
1141862|NCT01400555|Dexamethasone
1141863|NCT01400542|Early Onset Alzheimer Disease
1141864|NCT01400542|Alzheimer Disease
1141865|NCT01400542|Sleep Apnea Syndromes
1141866|NCT01400542|Obstructive Sleep Apnea Syndromes
1141867|NCT01400542|Cognitive functions
1141868|NCT01400542|Continuous Positive Airway Pressure (CPAP) treatment
1141869|NCT01400529|Osteoarthritis
1141870|NCT01400529|knee
1141871|NCT01400529|hip
1141872|NCT01400529|population based
1141873|NCT01400516|Rheumatoid Arthritis
1141874|NCT01400516|Bone erosion
1141875|NCT01400516|Osteopenia
1141876|NCT01400503|Multicentric Castleman's Disease
1141877|NCT01400503|Multicentric
1141878|NCT01400503|Castleman
1141879|NCT01400503|Siltuximab
1141880|NCT01400503|Long term safety
1141881|NCT01400477|Drug Trial
1141882|NCT01400477|Smoking
1141883|NCT01400477|Smoking Cessation
1141884|NCT01400477|Cognition
1141885|NCT01400477|Mental Focus
1141886|NCT01400464|Giant Cell Arteritis
1141887|NCT01400464|prednisone
1141888|NCT01400464|pharmacokinetics
1141889|NCT01400438|Herceptin
1141890|NCT01400438|Breast cancer
1141891|NCT01400438|Quality of life
1141892|NCT01400438|fatigue
1141893|NCT01400399|AJCC DCIS or T1- T2, N0
1141894|NCT01400373|Hypothermia, induced
1141895|NCT01400373|Intra-arrest cooling
1141896|NCT01400373|Cardiac arrest
1141897|NCT01400373|Prehospital emergency care
1141898|NCT01400373|Emergency Medical Services
1141899|NCT01400360|cerebral vasospasm
1141900|NCT01400360|subarachnoid hemorrhage
1141901|NCT01400360|transluminal balloon angioplasty
1141902|NCT01400360|intraarterial treatment
1141903|NCT01400347|Motor activity, lower extremity, physical exercise
1141904|NCT01400334|Ischemic Cardiomyopathy
1141905|NCT01400334|Sudden Cardiac Death
1141906|NCT01400334|Positron Emission Tomography
1141907|NCT01400334|Hibernating Myocardium
1141908|NCT01400334|Denervated Myocardium
1141909|NCT01400321|dental implant
1141910|NCT01400321|soft tissue maintenance
1141911|NCT01400321|bone remodelling
1141912|NCT01400321|inclined atrophy
1141913|NCT01400308|Methicillin Resistant Staphylococcus Aureus colonization.
1141914|NCT01400308|Methicillin Resistant Staphylococcus Aureus infection.
1141915|NCT01400295|contrast-induced nephropathy
1141916|NCT01400295|contrast medium
1141917|NCT01400295|creatinine clearance
1141918|NCT01400295|coronary angiography
1141919|NCT01400295|diabetes
1141920|NCT01400295|chronic kidney disease
1141921|NCT01400269|PACE
1141922|NCT01400256|diagnostic
1141923|NCT01400243|Marijuana
1141924|NCT01400243|Drug withdrawal symptoms
1141925|NCT01400243|Nicotine
1141926|NCT01400230|computed tomography
1141927|NCT01400230|intravascular ultrasound
1141928|NCT01400230|coronary stenosis
1141929|NCT01400230|fractional flow reserve
1141930|NCT01400217|Primary Care
1141931|NCT01400217|Particle size
1141932|NCT01400217|beclomethasone dipropionate
1141933|NCT01400217|Asthma Management
1141934|NCT01400217|Maintenance Therapy
1141935|NCT01400217|Metered-Dose Inhaler
1141936|NCT01400204|hangover
1141937|NCT01400204|next day effects
1141938|NCT01400204|MDMA
1141939|NCT01400204|Alcohol
1141940|NCT01400191|Metformin
1141941|NCT01400191|Hypoglycemic Agents
1141942|NCT01400191|Diabetes Mellitus, Type 2
1141943|NCT01400191|Gluconeogenesis
1141944|NCT01400191|Pharmacodynamics
1141945|NCT01400191|Pharmacogenetics
1141946|NCT01400178|cochlear implant
1141947|NCT01400178|children
1141948|NCT01400178|follow up
1141949|NCT01400178|results
1141950|NCT01400165|Therapeutic Equivalency
1141951|NCT01400165|Human Experimentation
1141952|NCT01400165|Bioequivalence
1141953|NCT01400165|Brand name
1141954|NCT01400165|Generic
1141955|NCT01400165|Healthy volunteers
1141956|NCT01400152|Hypothermia, body temperature regulation,thermal comfort, active warming, passive warming, prehospital trauma care
1141957|NCT01400139|Pain
1141958|NCT01400139|Nonmalignant pain
1141959|NCT01400139|Nonneuropathic Pain
1141960|NCT01400139|Opioid
1141961|NCT01400126|Ultrapure water,hemodialysis, CRP, blood pressure
1141962|NCT01400113|Acute Agitation
1141963|NCT01400113|schizophrenia
1141964|NCT01400113|bipolar
1141965|NCT01400113|psychosis
1141966|NCT01400113|panss-ec
1141967|NCT01400100|octreotide
1141968|NCT01400100|intraarterial
1141969|NCT01400100|pancreatic hardness
1141970|NCT01400100|pancreatoduodenectomy
1141971|NCT01400100|durometer
1141972|NCT01400100|dynamometer
1141973|NCT01400087|colonoscopy
1141974|NCT01400087|Lower Gastrointestinal Tract
1141975|NCT01400087|Cecal intubation
1141976|NCT01400087|Cap-attached colonoscopy
1141977|NCT01400087|Trainee
1141978|NCT01400061|obesity, etiology, pathogenesis, treatment
1141979|NCT01400035|acute cerebral infarction, Vinpocetine
1141980|NCT01400022|lichen
1141981|NCT01400022|sclerosus
1141982|NCT01400022|genital
1141983|NCT01400022|vulvar
1141984|NCT01400022|UVA1
1141985|NCT01400009|Statin
1141986|NCT01400009|HMG COA Reductase Inhibitor
1141987|NCT01400009|myalgia
1141988|NCT01400009|vitamin D
1141989|NCT01399996|probiotic
1141990|NCT01399996|microbiota
1141991|NCT01399996|transit time
1141992|NCT01399996|immunity
1141993|NCT01399996|immune function
1141994|NCT01399996|constipation
1141995|NCT01399996|bowel function
1141996|NCT01399983|six minute walk
1141997|NCT01399970|Mobile Teledermatology
1141998|NCT01399970|Telemedicine
1141999|NCT01399970|Acne
1142000|NCT01399957|Multiple Sclerosis
1142001|NCT01399957|Dalfampridine-ER
1142002|NCT01399957|Walking speed
1142003|NCT01399944|bitter taste
1142004|NCT01399944|psychophysics
1142005|NCT01399944|genetics
1142006|NCT01399944|epigenetics
1142007|NCT01399944|bitterness sensitivity
1142008|NCT01399931|Early stage
1142009|NCT01399918|Kidney
1142010|NCT01399918|Everolimus
1142011|NCT01399918|Bevacizumab
1142012|NCT01399918|10-226
1142013|NCT01399918|non-clear cell histology
1142014|NCT01399918|Advanced
1142015|NCT01399905|Parkinson's disease
1142016|NCT01399905|Levodopa
1142017|NCT01399905|Carbidopa
1142018|NCT01399905|Blood brain barrier
1142019|NCT01399879|Surface potential
1142020|NCT01399879|Electrical
1142021|NCT01399879|Motion stabilization
1142022|NCT01399866|D-cycloserine
1142023|NCT01399866|Smoking cues
1142024|NCT01399866|Cognitive remediation
1142025|NCT01399866|physiologic reactivity
1142026|NCT01399866|craving
1142027|NCT01399853|immunogenicity
1142028|NCT01399853|safety
1142029|NCT01399853|inactivated EV71 vaccine
1142030|NCT01399801|Cardiac Resynchronization Therapy
1142031|NCT01399801|medically refractory heart failure patients
1142032|NCT01399788|Bioequivalence
1142033|NCT01399788|Healthy Volunteers
1142034|NCT01399775|Atrophy of Edentulous Alveolar Ridge
1142035|NCT01399775|Dental Prosthesis, Implant-Supported
1142036|NCT01399775|Dental Implants, Single-Tooth
1142037|NCT01399762|stroke, acute
1142038|NCT01399762|mechanical recanalization
1142039|NCT01399762|interventional neuroradiology
1142040|NCT01399762|clinical registry
1142041|NCT01399749|Cartilage
1142042|NCT01399749|Articular
1142043|NCT01399749|Femoral
1142044|NCT01399749|Knee
1142045|NCT01399749|Chondrocytes
1142046|NCT01399749|Adipose tissue-derived mesenchymal stem cells
1142047|NCT01399736|PCI FFR STEMI MVD
1142048|NCT01399736|FFR guided PCI in acute STEMI patients with MVD
1142049|NCT01399723|Severe pneumonia
1142050|NCT01399710|colorectal cancer
1142051|NCT01399710|CT colonography
1142052|NCT01399710|CAD
1142053|NCT01399671|depression
1142054|NCT01399671|vestibular
1142055|NCT01399658|Brachytherapy
1142056|NCT01399658|Gynecological cancer
1142057|NCT01399645|Randomized trial
1142058|NCT01399645|Open label
1142059|NCT01399645|Pilot study
1142060|NCT01399645|Single center
1142061|NCT01399606|Excessive Daytime Sleepiness (EDS)
1142062|NCT01399606|Narcolepsy
1142063|NCT01399593|Antibody Mediated Rejection
1142064|NCT01399593|AMR
1142065|NCT01399593|Acute Humoral Rejection
1142066|NCT01399593|AHR
1142067|NCT01399593|Living Donor
1142068|NCT01399593|Kidney Transplant
1142069|NCT01399580|endothelin receptor antagonists
1142070|NCT01399567|pain
1142071|NCT01399567|depression
1142072|NCT01399567|nursing homes
1142073|NCT01399567|diffusion of innovations
1142074|NCT01399567|clinical trial
1142075|NCT01399541|Symptoms
1142076|NCT01399541|Symptoms cluster
1142077|NCT01399541|Fatigue
1142078|NCT01399541|Depression
1142079|NCT01399541|Sleeplessness
1142080|NCT01399541|Social support
1142081|NCT01399541|Stigma
1142082|NCT01399515|Retinitis pigmentosa
1142083|NCT01399515|Valproic acid
1142084|NCT01399502|Depression
1142085|NCT01399502|Self Care
1142086|NCT01399489|Aerobic exercise
1142087|NCT01399489|Moderate intensity
1142088|NCT01399489|Ambulatory blood pressure
1142089|NCT01399489|Post exercise hypotension
1142090|NCT01399476|Achalasia
1142091|NCT01399463|Drug Eluting Stent, Drug Eluting Balloon, Fractional Flow Reserve, DES, DEB, FFR
1142092|NCT01399450|Schizophrenia, depressive symptom, paliperidone
1142093|NCT01399437|Default Network
1142094|NCT01399437|Schizophrenia
1142095|NCT01399437|fMRI
1142096|NCT01399437|Spatial Attention
1142097|NCT01399437|Sentinel Function
1142098|NCT01399424|Shigellosis
1142099|NCT01399424|Safety and Immunogenicity
1142100|NCT01399424|Conjugate Vaccine
1142101|NCT01399424|Shigella
1142102|NCT01399424|Vaccine
1142103|NCT01399411|Self-Reported
1142104|NCT01399411|Farming
1142105|NCT01399411|Agriculture
1142106|NCT01399411|Disease Validation
1142107|NCT01399411|Autoimmune Disorders
1142108|NCT01399398|Brain Scan
1142109|NCT01399398|Kinetic Analysis
1142110|NCT01399398|Healthy Subjects
1142111|NCT01399398|Healthy Volunteer
1142112|NCT01399398|HV
1142113|NCT01399385|Arteriosclerosis
1142114|NCT01399385|Arteriosclerosis, Narrowing of Vessels
1142115|NCT01399385|Endothelial Dysfunction
1142116|NCT01399385|Hardening of the arteries
1142117|NCT01399385|Noninvasive Plaque Imaging
1142118|NCT01399385|Cardiovascular Disease
1142119|NCT01399385|Heart Disease
1142120|NCT01399385|Healthy Volunteer
1142121|NCT01399385|HV
1142122|NCT01399372|neurotoxicity
1142123|NCT01399372|chemotherapeutic agent toxicity
1142124|NCT01399372|radiation toxicity
1142125|NCT01399372|cognitive/functional effects
1142126|NCT01399372|primary central nervous system non-Hodgkin lymphoma
1142127|NCT01399359|breast cancer
1142128|NCT01399346|Insulin aspart
1142129|NCT01399346|Type 1 diabetes
1142130|NCT01399346|Glucose clamp
1142131|NCT01399346|Pharmacodynamics
1142132|NCT01399346|Pharmacokinetics
1142133|NCT01399346|Rapid Acting Insulin Analog
1142134|NCT01399333|PDCAAS
1142135|NCT01399333|Bariatric patient
1142136|NCT01399320|Pilonidal disease
1142137|NCT01399320|Excision
1142138|NCT01399320|cyanoacrylate
1142139|NCT01399307|Stem
1142140|NCT01399307|Cell
1142141|NCT01399307|Antria
1142142|NCT01399307|Adipose
1142143|NCT01399307|Stromal
1142144|NCT01399307|Vascular
1142145|NCT01399307|Fraction
1142146|NCT01399307|Shahram
1142147|NCT01399307|Shah
1142148|NCT01399307|Rahimian
1142149|NCT01399294|Palliative Care
1142150|NCT01399294|Advanced Cancer
1142151|NCT01399294|Constipation
1142152|NCT01399294|Traditional Chinese Medicine
1142153|NCT01399294|Syndrome Distribution
1142154|NCT01399281|juvenile idiopathic arthritis, biologics, methotrexate
1142155|NCT01399268|Bilateral total knee replacement
1142156|NCT01399268|cytokine
1142157|NCT01399268|desmosine
1142158|NCT01399242|Disorder Related to Renal Transplantation
1142159|NCT01399203|contrast-induced nephropathy
1142160|NCT01399203|contrast medium
1142161|NCT01399203|creatinine clearance
1142162|NCT01399203|percutaneous coronary intervention
1142163|NCT01399164|Vitamin B-12
1142164|NCT01399151|Vitamin D
1142165|NCT01399151|Immune function
1142166|NCT01399138|Pre-diabetes
1142167|NCT01399138|Metabolic syndrome
1142168|NCT01399138|Diabetes
1142169|NCT01399138|Hypertension
1142170|NCT01399138|Blueberries
1142171|NCT01399138|Anthocyanins
1142172|NCT01399138|Insulin sensitivity
1142173|NCT01399138|Insulin resistance
1142174|NCT01399125|Alzheimer's
1142175|NCT01399125|Rivastigmine
1142176|NCT01399125|Patch
1142177|NCT01399125|Dementia
1142178|NCT01399112|Smoking Cessation
1142179|NCT01399112|First episode psychosis
1142180|NCT01399112|Electronic Decision Support System
1142181|NCT01399099|scar
1142182|NCT01399099|incision
1142183|NCT01399099|wound healing
1142184|NCT01399099|scarring
1142185|NCT01399099|post-surgical
1142186|NCT01399086|Cancer
1142187|NCT01399086|Breast
1142188|NCT01399086|Metastatic
1142189|NCT01399086|Hormonotherapy
1142190|NCT01399073|stroke
1142191|NCT01399073|neglect
1142192|NCT01399073|hemianopsia
1142193|NCT01399073|virtual reality
1142194|NCT01399060|Cough
1142195|NCT01399060|tobacco smoke exposure
1142196|NCT01399047|Batten Disease
1142197|NCT01399034|Epigenomics
1142198|NCT01399034|DNA methylation
1142199|NCT01399034|MicroRNA
1142200|NCT01399034|Periodontitis
1142201|NCT01399034|Inflammation
1142202|NCT01399034|Obesity
1142203|NCT01399021|Parotidectomy
1142204|NCT01399021|Drain removal
1142205|NCT01399021|Timing
1142206|NCT01399021|Hematoma
1142207|NCT01399021|Surgical wound infection
1142208|NCT01399008|Hyperuricemia
1142209|NCT01398995|Type 1 Diabetes
1142210|NCT01398995|Exercise
1142211|NCT01398995|continuous subcutaneous insulin infusion
1142212|NCT01398969|Randomized
1142213|NCT01398969|Double Blind
1142214|NCT01398969|Fecal Transplant
1142215|NCT01398969|Recurrent
1142216|NCT01398969|Clostridium difficile infection
1142217|NCT01398969|CDI
1142218|NCT01398969|HBT
1142219|NCT01398969|Diarrhea
1142220|NCT01398969|Frozen HBT
1142221|NCT01398969|Thawed HBT
1142222|NCT01398969|Fecal Enema
1142223|NCT01398956|Levetiracetam
1142224|NCT01398956|Epilepsy
1142225|NCT01398956|Generalized tonic-clonic seizures
1142226|NCT01398943|flow-mediated dilation
1142227|NCT01398943|arterial stiffness
1142228|NCT01398943|intima-media thickness
1142229|NCT01398943|pulse wave velocity
1142230|NCT01398943|dual energy x-ray absorptiometry
1142231|NCT01398943|inflammatory markers
1142232|NCT01398943|blood lipids
1142233|NCT01398943|tetrahydrobiopterin
1142234|NCT01398943|Salsalate
1142235|NCT01398943|body mass index
1142236|NCT01398943|hemoglobin A1c
1142237|NCT01398943|complete blood count
1142238|NCT01398943|oxidative stress biomarkers
1142239|NCT01398943|pulmonary function test
1142240|NCT01398943|ankle brachial index
1142241|NCT01398930|acupuncture; knee osteoarthritis; adjunctive therapy; chronic pain; algometer; etoricoxib.
1142242|NCT01398917|psc
1142243|NCT01398917|dominant stricture
1142244|NCT01398904|BDD
1142245|NCT01398878|Medical education, graduate
1142246|NCT01398878|Patient care
1142247|NCT01398878|Outcome assessment (Health care)
1142248|NCT01398878|Work schedule tolerance
1142249|NCT01398865|BDD
1142250|NCT01398826|Type 1 Diabetes
1142251|NCT01398826|Exercise
1142252|NCT01398826|Continuous glucose monitoring
1142253|NCT01398813|HED
1142254|NCT01398813|XLHED
1142255|NCT01398774|Pseudohypoparathyroidism
1142256|NCT01398774|Albright Hereditary Osteodystrophy
1142257|NCT01398761|Continuity of patient care
1142258|NCT01398761|Workflow
1142259|NCT01398761|Quality of signout
1142260|NCT01398761|Web based
1142261|NCT01398761|Handoffs
1142262|NCT01398761|Multi disciplinary
1142263|NCT01398761|Written signout
1142264|NCT01398761|Information science
1142265|NCT01398748|Parkinson's disease
1142266|NCT01398748|Neuroprotection
1142267|NCT01398748|Glutathione
1142268|NCT01398748|Intranasal
1142269|NCT01398722|cardiac surgery
1142270|NCT01398722|prognosis
1142271|NCT01398722|intensive insulin therapy
1142272|NCT01398709|Cardiopulmonary Bypass
1142273|NCT01398709|Prognosis
1142274|NCT01398709|Cardiac Surgery
1142275|NCT01398709|Rewarming Rate
1142276|NCT01398696|Patient Information Leaflets
1142277|NCT01398696|primary care
1142278|NCT01398696|patient behaviour
1142279|NCT01398696|pharyngitis
1142280|NCT01398696|gastroenteritis
1142281|NCT01398670|Type I Diabetes
1142282|NCT01398670|Wockhardt's Insulin analogue Lispro
1142283|NCT01398670|Humalog®
1142284|NCT01398670|Humalog Mix
1142285|NCT01398670|Wockhardt
1142286|NCT01398670|Biosimilar
1142287|NCT01398670|Phase 3
1142288|NCT01398657|localized
1142289|NCT01398657|High risk
1142290|NCT01398657|Prostate Cancer
1142291|NCT01398657|Randomized
1142292|NCT01398657|Cryotherapy
1142293|NCT01398657|Cryoablation
1142294|NCT01398657|Adjuvant
1142295|NCT01398657|Androgen Deprivation Therapy
1142296|NCT01398657|Hormone therapy
1142297|NCT01398657|ADT
1142298|NCT01398644|Phlebotomy
1142299|NCT01398644|Therapeutic erythrocytapheresis
1142300|NCT01398644|Hereditary Hemochromatosis
1142301|NCT01398644|maintenance therapy
1142302|NCT01398631|Risk scores
1142303|NCT01398631|ACS
1142304|NCT01398631|HEART-score
1142305|NCT01398618|latent tuberculosis infection
1142306|NCT01398618|tuberculosis
1142307|NCT01398618|interferon-gamma release assay
1142308|NCT01398618|preventive therapy
1142309|NCT01398618|9-month isoniazid
1142310|NCT01398618|4-month rifampin
1142311|NCT01398605|Postmenopausal women
1142312|NCT01398605|Physical activity
1142313|NCT01398605|Cardiovascular risks
1142314|NCT01398605|Cardiac function
1142315|NCT01398605|Dose-response
1142316|NCT01398592|Diabetes mellitus Type two
1142317|NCT01398592|T2DM
1142318|NCT01398592|vildagliptin
1142319|NCT01398592|sitagliptin
1142320|NCT01398592|FPG
1142321|NCT01398592|DPP-4
1142322|NCT01398579|intestinal metaplasia
1142323|NCT01398579|dysplasia
1142324|NCT01398579|probe-based confocal endomicroscopy
1142325|NCT01398566|TBI
1142326|NCT01398566|concussion
1142327|NCT01398566|brain injury
1142328|NCT01398553|stroke
1142329|NCT01398553|tbi
1142330|NCT01398553|rehabilitation
1142331|NCT01398553|upper limb
1142332|NCT01398527|Long-Term Care
1142333|NCT01398527|Vitamin D
1142334|NCT01398501|AML
1142335|NCT01398501|FLT3-ITD
1142336|NCT01398501|Stem cell transplant
1142337|NCT01398488|Trough levels
1142338|NCT01398488|Education
1142339|NCT01398488|Adherence
1142340|NCT01398449|thoracic esophageal squamous cell carcinoma
1142341|NCT01398449|esophagectomy
1142342|NCT01398449|elective nodal irradiation
1142343|NCT01398449|adjuvant chemotherapy
1142344|NCT01398436|Central venous saturation
1142345|NCT01398436|Mixed venous saturation
1142346|NCT01398436|Right atrium
1142347|NCT01398436|Central Venous Catheter position
1142348|NCT01398423|Hypertension
1142349|NCT01398423|Diabetes mellitis
1142350|NCT01398423|Nephropathy
1142351|NCT01398423|Albuminuria
1142352|NCT01398410|Rabeprazole
1142353|NCT01398410|proton pump inhibitor
1142354|NCT01398410|Acetylsalicylic Acid
1142355|NCT01398410|Aspirin
1142356|NCT01398410|Gastric Ulcer
1142357|NCT01398410|Duodenal Ulcer
1142358|NCT01398397|HED
1142359|NCT01398397|XLHED
1142360|NCT01398397|X-linked Hypohidrotic Ectodermal Dysplasia (XLHED)
1142361|NCT01398384|ST Elevation MI
1142362|NCT01398384|STEMI
1142363|NCT01398371|Heart failure
1142364|NCT01398371|Digoxin withdrawal
1142365|NCT01398358|obesity
1142366|NCT01398358|prevention
1142367|NCT01398358|children
1142368|NCT01398319|prevention
1142369|NCT01398319|alcohol abuse
1142370|NCT01398306|Angiogenesis Inhibitors
1142371|NCT01398306|Neoplasms, Glandular and Epithelial
1142372|NCT01398306|Neoplasms by Histologic Type
1142373|NCT01398306|Neoplasms
1142374|NCT01398306|Adenocarcinoma
1142375|NCT01398306|Kidney Neoplasms
1142376|NCT01398306|Urologic Neoplasms
1142377|NCT01398306|Urogenital Neoplasms
1142378|NCT01398306|Neoplasms by Site
1142379|NCT01398306|Kidney Diseases
1142380|NCT01398306|Angiogenesis Inducing Agents
1142381|NCT01398306|Biological Markers
1142382|NCT01398280|Rosacea
1142383|NCT01398280|Dermatology
1142384|NCT01398280|UCSD
1142385|NCT01398280|Skin disease
1142386|NCT01398254|ST-Elevation Myocardial Infarction
1142387|NCT01398254|Mortality
1142388|NCT01398228|Quality of care
1142389|NCT01398228|Acute Coronary Syndromes (ACS)
1142390|NCT01398215|umbilical hernia
1142391|NCT01398215|ventral hernia
1142392|NCT01398202|Vitamin D status
1142393|NCT01398202|25-hydroxyvitamin D
1142394|NCT01398202|Vitamin D3
1142395|NCT01398202|RCT
1142396|NCT01398202|Bio-efficacy
1142397|NCT01398189|clozapine
1142398|NCT01398189|PET
1142399|NCT01398189|schizophrenia
1142400|NCT01398189|schizoaffective disorder
1142401|NCT01398176|gamma delta T cell
1142402|NCT01398176|proliferation
1142403|NCT01398163|probiotics
1142404|NCT01398163|digestive well-being
1142405|NCT01398163|fMRI
1142406|NCT01398163|brain-gut axis
1142407|NCT01398150|gamma delta T cell
1142408|NCT01398150|proliferation
1142409|NCT01398150|cytokine secretion
1142410|NCT01398150|immune function
1142411|NCT01398150|antioxidant status
1142412|NCT01398137|Ragweed allergy
1142413|NCT01398124|early stage non-small cell lung cancer
1142414|NCT01398124|non-small cell lung cancer
1142415|NCT01398085|Papillary thyroid carcinoma
1142416|NCT01398085|Follicular thyroid carcinoma
1142417|NCT01398085|Hurthle cell carcinoma of the thyroid
1142418|NCT01398085|Iodine Radioisotopes
1142419|NCT01398059|Sedentary Behavior
1142420|NCT01398059|Cardiometabolic Risk
1142421|NCT01398059|Pediatrics
1142422|NCT01398046|dasatinib
1142423|NCT01398046|betaine
1142424|NCT01398046|betaine hydrochloride
1142425|NCT01398046|pharmacokinetics
1142426|NCT01398046|healthy volunteer
1142427|NCT01398033|infrapopliteal arteries
1142428|NCT01398033|In-stent stenosis
1142429|NCT01398033|long lesions
1142430|NCT01398033|drug-coated balloon
1142431|NCT01398020|Bowel Preparation
1142432|NCT01398020|Patient comfort
1142433|NCT01398020|Bi-Peglyte
1142434|NCT01397994|Nicorandil therapy in patients of chronic stable angina
1142435|NCT01397968|partial onset seizures
1142436|NCT01397968|treatment resistant
1142437|NCT01397968|partial epilepsy
1142438|NCT01397955|Julina
1142439|NCT01397955|Postmenopausal osteoporosis
1142440|NCT01397942|Diet intervention
1142441|NCT01397942|Type 2 diabetes
1142442|NCT01397942|Vegetables
1142443|NCT01397942|Phytochemicals
1142444|NCT01397916|CLL
1142445|NCT01397916|IDO
1142446|NCT01397903|antidepressant therapy, inadequate control, add-on therapy
1142447|NCT01397890|Severe chronic obstructive pulmonary disease (COPD) patients
1142448|NCT01397877|endometrial cancer
1142449|NCT01397877|BKM
1142450|NCT01397877|monotherapy
1142451|NCT01397877|metastatic
1142452|NCT01397877|initial treatment
1142453|NCT01397864|Hereditary Angioedema
1142454|NCT01397864|HAE
1142455|NCT01397864|Angioedema
1142456|NCT01397864|Recombinant C1 Inhibitor
1142457|NCT01397864|rhC1INH
1142458|NCT01397864|registry
1142459|NCT01397838|Osteopenia
1142460|NCT01397812|Rejection of the Heart Transplant
1142461|NCT01397812|Heart Transplant Rejection, an immune-mediated allograft injury
1142462|NCT01397812|Non-cellular or humoral rejection in cardiac transplant recipients
1142463|NCT01397812|Right ventricular endomyocardial biopsy to detect Heart transplant rejection
1142464|NCT01397799|Acute Myelogenous Leukemia
1142465|NCT01397799|AML
1142466|NCT01397799|Refractory
1142467|NCT01397799|Elderly
1142468|NCT01397773|Hemodialysis
1142469|NCT01397773|peritoneal dialysis
1142470|NCT01397773|chronic kidney disease
1142471|NCT01397773|inflammation
1142472|NCT01397773|carotis intima media thickness
1142473|NCT01397760|DIFFICULT TO CONTROL ASTHMA
1142474|NCT01397760|OMALIZUMABE
1142475|NCT01397747|Cancer
1142476|NCT01397747|Colorectal Cancer
1142477|NCT01397747|Neoplasm
1142478|NCT01397747|Colorectal Neoplasm
1142479|NCT01397747|Intestinal Neoplasms
1142480|NCT01397747|Gastrointestinal Neoplasms
1142481|NCT01397747|Digestive System Neoplasms
1142482|NCT01397747|Neoplasms by Site
1142483|NCT01397747|Neoplasms
1142484|NCT01397747|Digestive System Diseases
1142485|NCT01397747|Gastrointestinal Diseases
1142486|NCT01397747|Colonic Diseases
1142487|NCT01397747|Intestinal Diseases
1142488|NCT01397747|Rectal Diseases
1142489|NCT01397734|CML
1142490|NCT01397734|Chronic myelogenous leukemia
1142491|NCT01397734|Chronic Myeloid leukemia
1142492|NCT01397734|Arsenic
1142493|NCT01397734|Arsenic trioxide
1142494|NCT01397734|Imatinib
1142495|NCT01397734|Dasatinib
1142496|NCT01397734|Nilotinib
1142497|NCT01397734|TKI
1142498|NCT01397734|Tyrosine kinase inhibitor
1142499|NCT01397721|Chronic Obstructive Pulmonary Disease (COPD)
1142500|NCT01397721|pulmonary vasculature
1142501|NCT01397721|pulmonary hypertension
1142502|NCT01397721|atherosclerosis
1142503|NCT01397721|smokers
1142504|NCT01397721|emphysema
1142505|NCT01397708|Melanoma
1142506|NCT01397708|Unresectable
1142507|NCT01397682|Comprehensive Geriatric Assessment
1142508|NCT01397682|Frail elderly
1142509|NCT01397682|Italy/epidemiology
1142510|NCT01397682|Geriatric Health Service
1142511|NCT01397682|Polypharmacy
1142512|NCT01397682|Biological Markers
1142513|NCT01397682|Epidemiologic Research Design
1142514|NCT01397656|cardiac arrest
1142515|NCT01397656|CPR
1142516|NCT01397656|resuscitation
1142517|NCT01397656|fatigue
1142518|NCT01397656|quality
1142519|NCT01397565|Cholecystectomy
1142520|NCT01397565|Laparoscopy
1142521|NCT01397565|Minilaparoscopic surgery
1142522|NCT01397565|Post-operative pain
1142523|NCT01397565|Recovery time
1142524|NCT01397526|Congenital heart disease
1142525|NCT01397526|Cardiopulmonary bypass
1142526|NCT01397526|Capillary leak
1142527|NCT01397526|Colloid osmotic pressure
1142528|NCT01397526|Children
1142529|NCT01397513|Fibrin network structure
1142530|NCT01397513|Aspirin treatment
1142531|NCT01397513|Platelet microparticles
1142532|NCT01397487|morphometric parameters, embryo biopsy
1142533|NCT01397474|peripheral perfusion
1142534|NCT01397474|critically ill patients
1142535|NCT01397474|fluid administration
1142536|NCT01397448|Rabeprazole
1142537|NCT01397448|proton pump inhibitor
1142538|NCT01397448|Acetylsalicylic Acid
1142539|NCT01397448|Aspirin
1142540|NCT01397448|Gastric Ulcer
1142541|NCT01397448|Duodenal Ulcer
1142542|NCT01397435|Lysosomal diseases
1142543|NCT01397435|Magnetic resonance Spectroscopy
1142544|NCT01397435|MRI
1142545|NCT01397422|Levodopa-induced dyskinesia
1142546|NCT01397422|Parkinsonism
1142547|NCT01397370|Safety
1142548|NCT01397370|Tolerability
1142549|NCT01397370|Pharmacokinetics
1142550|NCT01397370|Pharmacodynamics
1142551|NCT01397357|Cardiac magnetic resonance
1142552|NCT01397357|Myocardial Ischemia
1142553|NCT01397357|Coronary Artery Disease
1142554|NCT01397357|suspected Myocardial Ischemia
1142555|NCT01397344|People in the outpatient waiting room
1142556|NCT01397331|inhalational anesthesia
1142557|NCT01397331|intravenous anesthesia
1142558|NCT01397331|cardiac surgery
1142559|NCT01397318|TaiChi Exercise
1142560|NCT01397318|pregnant women
1142561|NCT01397305|5,10-methylenetetrahydrofolate
1142562|NCT01397305|neoadjuvant therapy
1142563|NCT01397305|pemetrexed
1142564|NCT01397305|Neoplasms
1142565|NCT01397305|Rectal Neoplasms
1142566|NCT01397305|Colorectal Neoplasms
1142567|NCT01397305|Intestinal Neoplasms
1142568|NCT01397305|Gastrointestinal Neoplasms
1142569|NCT01397305|Digestive System Neoplasms
1142570|NCT01397305|Neoplasms by Site
1142571|NCT01397305|Rectal Diseases
1142572|NCT01397305|Digestive System Diseases
1142573|NCT01397305|Gastrointestinal Diseases
1142574|NCT01397305|Intestinal Diseases
1142575|NCT01397305|Pharmacologic Actions
1142576|NCT01397305|Therapeutic Uses
1142577|NCT01397305|Antineoplastic Agents
1142578|NCT01397305|Enzyme Inhibitors
1142579|NCT01397305|Molecular Mechanisms of Pharmacological Action
1142580|NCT01397305|Folic Acid Antagonists
1142581|NCT01397305|Antimetabolites, Antineoplastic
1142582|NCT01397305|Antimetabolites
1142583|NCT01397292|Bronchoscopy
1142584|NCT01397292|Interventional Pulmonary
1142585|NCT01397292|Pleuroscopy
1142586|NCT01397292|Tracheostomy
1142587|NCT01397279|type 2 diabetes
1142588|NCT01397279|insulin sensitivity
1142589|NCT01397279|hyperinsulinemic euglycemic clamp
1142590|NCT01397266|Transcranial Magnetic Stimulation
1142591|NCT01397266|Cocaine
1142592|NCT01397266|impulsivity
1142593|NCT01397266|rating scale
1142594|NCT01397253|Automated Communication Tools
1142595|NCT01397253|Medication errors
1142596|NCT01397253|PCP communication
1142597|NCT01397227|Malaria
1142598|NCT01397227|Plasmodium falciparum
1142599|NCT01397227|Vaccination
1142600|NCT01397227|Prophylaxis
1142601|NCT01397227|Adenovirus
1142602|NCT01397188|PiCCO
1142603|NCT01397175|Coronary artery disease
1142604|NCT01397175|Percutaneous coronary intervention
1142605|NCT01397175|Drug-eluting stent
1142606|NCT01397149|Chronic lymphocytic leukemia
1142607|NCT01397149|Thrombocytopenia
1142608|NCT01397149|Alkylating agents
1142609|NCT01397149|Purine derivatives
1142610|NCT01397149|TPO receptor agonist
1142611|NCT01397136|Human embryo
1142612|NCT01397136|Culture media
1142613|NCT01397136|Cell-free DNA
1142614|NCT01397136|In vitro fertilization
1142615|NCT01397136|Infertility
1142616|NCT01397123|BMI z-score
1142617|NCT01397123|children
1142618|NCT01397123|overweight
1142619|NCT01397123|school-based intervention
1142620|NCT01397123|trained teachers
1142621|NCT01397123|fruit
1142622|NCT01397123|vegetables
1142623|NCT01397123|Low nutrition energy dense foods
1142624|NCT01397084|esomeprazole 20mg
1142625|NCT01397084|heartburn
1142626|NCT01397084|rabeprazole 10mg
1142627|NCT01397084|reflux esophagitis
1142628|NCT01397084|Phase IV
1142629|NCT01397071|Avocado, antioxidant
1142630|NCT01397045|Lung
1142631|NCT01397045|Nodule
1142632|NCT01397045|Rehabilitation
1142633|NCT01397045|VATS
1142634|NCT01397045|Thoracotomy
1142635|NCT01397032|attention bias modification treatment
1142636|NCT01397032|cognitive bias modification
1142637|NCT01397032|attention training
1142638|NCT01397032|social anxiety
1142639|NCT01397019|Pancreatic cancer
1142640|NCT01397019|Chemotherapy
1142641|NCT01397019|Chemoradiotherapy
1142642|NCT01397006|Fibromyalgia
1142643|NCT01397006|pregabalin
1142644|NCT01397006|Lyrica
1142645|NCT01396980|hemodialysis
1142646|NCT01396980|intensive care
1142647|NCT01396980|microcirculation
1142648|NCT01396967|capsulorhexis
1142649|NCT01396954|Liver cirrhosis
1142650|NCT01396954|Diabetes mellitus
1142651|NCT01396954|Hepatogenous diabetes
1142652|NCT01396954|Oral glucose tolerance test
1142653|NCT01396954|Insulin resistance.
1142654|NCT01396941|Diabetes
1142655|NCT01396928|Low rectal adenocarcinoma
1142656|NCT01396915|Skeletal muscle lipid content
1142657|NCT01396915|whole muscle volume
1142658|NCT01396915|fasting glucose
1142659|NCT01396915|insulin
1142660|NCT01396915|blood urea nitrogen
1142661|NCT01396889|Upper Respiratory Tract Infections
1142662|NCT01396889|Echinacea
1142663|NCT01396889|viral infections
1142664|NCT01396876|Medical clown
1142665|NCT01396876|Pediatric emergency medicine
1142666|NCT01396876|Emergency procedures
1142667|NCT01396863|Renal dialysis
1142668|NCT01396863|Hemodiafiltration
1142669|NCT01396863|Hemodialysis
1142670|NCT01396863|MRI
1142671|NCT01396850|Psychotic Patients
1142672|NCT01396837|Diabetic Foot Ulcer
1142673|NCT01396837|Diabetic Ulcer
1142674|NCT01396837|Diabetic Wound
1142675|NCT01396837|Chronic Ulcer
1142676|NCT01396837|Chronic Wound
1142677|NCT01396837|Neuropathic Diabetic Foot Ulcer
1142678|NCT01396837|Neuropathic DFU
1142679|NCT01396837|DFU
1142680|NCT01396824|Malnutrition
1142681|NCT01396824|Undernutrition
1142682|NCT01396824|Nutrition Assessment
1142683|NCT01396824|Nutritional Assessment
1142684|NCT01396824|Nutritional Index
1142685|NCT01396824|Prognostic Nutritional Index
1142686|NCT01396824|Prognostic Nutritional Index (PNI)
1142687|NCT01396824|Nutritional Status
1142688|NCT01396824|Prognosis
1142689|NCT01396824|Heart Failure
1142690|NCT01396824|Cardiovascular Diseases
1142691|NCT01396824|Body Composition
1142692|NCT01396824|Body Weights and Measures
1142693|NCT01396811|Tinea Pedis
1142694|NCT01396811|Antifungal
1142695|NCT01396798|serious infections
1142696|NCT01396798|meningitis
1142697|NCT01396785|Tinea Pedis
1142698|NCT01396785|Antifungal
1142699|NCT01396772|prediabetes
1142700|NCT01396772|diabetes prevention
1142701|NCT01396772|adults
1142702|NCT01396772|lifestyle intervention
1142703|NCT01396772|Social Cognitive Theory
1142704|NCT01396772|dietary intake
1142705|NCT01396772|physical activity
1142706|NCT01396759|Bubble CPAP
1142707|NCT01396759|Humidified high flow
1142708|NCT01396759|Hypoxaemia
1142709|NCT01396759|Nasal prong
1142710|NCT01396759|Severe pneumonia
1142711|NCT01396733|thyroid
1142712|NCT01396733|cancer
1142713|NCT01396733|redifferentiation
1142714|NCT01396733|lipoic acid
1142715|NCT01396707|HER2
1142716|NCT01396707|Trastuzumab
1142717|NCT01396707|XELOX
1142718|NCT01396707|PHASE 2
1142719|NCT01396681|resected pancreatic cancer
1142720|NCT01396668|locally advanced
1142721|NCT01396655|breast cancer
1142722|NCT01396655|neoadjuvant chemotherapy
1142723|NCT01396655|molecular marker
1142724|NCT01396655|FDG PET
1142725|NCT01396655|locally advanced breast cancer
1142726|NCT01396642|Topical Emollient Therapy
1142727|NCT01396642|Emollient
1142728|NCT01396642|Preterm
1142729|NCT01396642|Hospital Acquired Infection
1142730|NCT01396629|cartridge IOL
1142731|NCT01396603|Optical Frequency Domain Imaging
1142732|NCT01396603|Optical Coherence Tomography
1142733|NCT01396603|Optical biopsy
1142734|NCT01396603|Comprehensive Microscopy
1142735|NCT01396590|Central Nervous System
1142736|NCT01396577|Central Nervous System
1142737|NCT01396564|Type 2 diabetes
1142738|NCT01396564|Resistin
1142739|NCT01396564|Inflammation
1142740|NCT01396564|Insulin Resistance
1142741|NCT01396551|Anchored Beacon Transponder
1142742|NCT01396551|Anchored Transponder
1142743|NCT01396551|Lung cancer
1142744|NCT01396551|Calypso system
1142745|NCT01396551|Realtime tracking
1142746|NCT01396538|anti-HBc alone ；occult HBV infection
1142747|NCT01396525|Atherosclerosis
1142748|NCT01396525|Peripheral artery disease
1142749|NCT01396525|Peripheral vascular disease
1142750|NCT01396525|PAD
1142751|NCT01396525|Claudication
1142752|NCT01396525|Peripheral Arterial Occlusive Disease
1142753|NCT01396525|Stent
1142754|NCT01396525|PAOD
1142755|NCT01396525|PVD
1142756|NCT01396512|Japanese Encephalitis
1142757|NCT01396512|Japanese Encephalitis Virus Disease
1142758|NCT01396512|IMOJEV™
1142759|NCT01396512|CD.JEVAX™
1142760|NCT01396499|Leukemia
1142761|NCT01396499|Acute leukemias
1142762|NCT01396499|Relapsed/refractory leukemias
1142763|NCT01396499|Acute myelogenous leukemia
1142764|NCT01396499|AML
1142765|NCT01396499|Acute lymphoblastic leukemia
1142766|NCT01396499|ALL
1142767|NCT01396499|BKM120
1142776|NCT01396473|afterschool
1142777|NCT01396473|accelerometers
1142778|NCT01396473|plate waste
1142779|NCT01396473|policy
1142780|NCT01396473|environment
1142781|NCT01396460|respiratory quotient
1142782|NCT01396460|fat oxidation
1142783|NCT01396460|morbid obesity
1142784|NCT01396460|bariatric
1142785|NCT01396460|Bariatric Surgery
1142786|NCT01396447|Bipolar I Disorder
1142787|NCT01396447|Bipolar Depression
1142788|NCT01396447|Depression
1142789|NCT01396447|Bipolar Disorder
1142790|NCT01396395|Nicorandil
1142791|NCT01396395|Stable angina
1142792|NCT01396382|neuroendocrine
1142793|NCT01396382|neuroendocrine carcinoma
1142794|NCT01396382|neuroendocrine tumor
1142795|NCT01396382|carcinoid
1142796|NCT01396382|carcinoid tumor
1142797|NCT01396382|islet cell tumor
1142798|NCT01396382|APUDoma
1142799|NCT01396382|Gallium
1142800|NCT01396382|PET Scan
1142801|NCT01396343|Pediatric Multiple Sclerosis
1142802|NCT01396343|Relapsing Remitting Multiple Sclerosis
1142803|NCT01396343|Clinically Isolated Syndrome
1142804|NCT01396343|Demyelinating Disease
1142805|NCT01396317|PMR
1142806|NCT01396317|POLYMYALGIA RHEUMATICA
1142807|NCT01396317|Tocilizumab
1142808|NCT01396317|Hospital for Special Surgery
1142809|NCT01396317|HSS
1142810|NCT01396317|Robert Spiera
1142811|NCT01396304|leg ulcer
1142812|NCT01396304|infection
1142813|NCT01396304|closure
1142814|NCT01396304|wound dressings
1142815|NCT01396239|DMD
1142816|NCT01396226|Atrial refractoriness
1142817|NCT01396226|cardiac electrophysiology
1142818|NCT01396226|IKACh
1142819|NCT01396213|celiac disease
1142820|NCT01396213|gastrointestinal symptoms
1142821|NCT01396213|gluten-free diet
1142822|NCT01396213|patients with biopsy-proven celiac disease with symptoms
1142823|NCT01396187|Type 2 diabetes
1142824|NCT01396187|safety
1142825|NCT01396187|multiple dose
1142826|NCT01396187|intravenous
1142827|NCT01396174|breast cancer
1142828|NCT01396174|breast tumor
1142829|NCT01396161|Phase 1
1142830|NCT01396161|Multiple Doses
1142831|NCT01396161|Safety
1142832|NCT01396161|Pharmacokinetics
1142833|NCT01396161|Pharmacodynamics
1142834|NCT01396161|Healthy Volunteers
1142835|NCT01396161|Type 2 Diabetic Patients
1142836|NCT01396148|Children and young adults with GIST
1142837|NCT01396148|sunitinib malate
1142838|NCT01396148|pharmacokinetics
1142839|NCT01396148|tumor response
1142840|NCT01396148|overall survival
1142841|NCT01396148|tumor KIT mutation status
1142842|NCT01396135|Phase 1
1142843|NCT01396135|Pharmacokinetics
1142844|NCT01396135|Healthy
1142845|NCT01396135|Japanese
1142846|NCT01396135|Non-smokers
1142847|NCT01396135|Major Depressive Disorder
1142848|NCT01396135|CP-601
1142849|NCT01396135|927
1142850|NCT01396096|Bariatric Surgery
1142851|NCT01396083|Visual impairment
1142852|NCT01396083|macular edema
1142853|NCT01396083|Central retinal vein occlusion
1142854|NCT01396083|Dexamethasone implant
1142855|NCT01396083|Ranibizumab
1142856|NCT01396057|Visual impairment
1142857|NCT01396057|macular edema
1142858|NCT01396057|branch retinal vein occlusion
1142859|NCT01396057|Dexamethasone implant
1142860|NCT01396057|Ranibizumab
1142861|NCT01396044|Quality improvement
1142862|NCT01396044|Checklist
1142863|NCT01396044|Critical care
1142864|NCT01396044|Anti-bacterial agents
1142865|NCT01396044|Mechanical ventilation
1142866|NCT01395966|with tubes
1142867|NCT01395953|Buspirone
1142868|NCT01395953|Buspar
1142869|NCT01395953|Autism Spectrum Disorders
1142870|NCT01395953|Pervasive Developmental Disorders
1142871|NCT01395953|Children
1142872|NCT01395953|Adolescents
1142873|NCT01395953|Anxiety
1142874|NCT01395940|Gonadotropin-Releasing Hormone (GnRH) antagonist
1142875|NCT01395927|Canagliflozin
1142876|NCT01395927|Rifampin
1142877|NCT01395927|Pharmacokinetics
1142878|NCT01395901|Prevention of Postoperative Nausea and Vomiting
1142879|NCT01395901|Palonosetron
1142880|NCT01395901|Ondansetron
1142881|NCT01395901|Pediatric
1142882|NCT01395836|Coronary Artery Bypass Grafting
1142883|NCT01395836|Cardiology
1142884|NCT01395836|Cardiac Electrophysiology
1142885|NCT01395836|Cardiac Surgery
1142886|NCT01395784|Oxycodone
1142887|NCT01395784|Opioid abuse
1142888|NCT01395771|Effect
1142889|NCT01395771|Phone call
1142890|NCT01395771|Intervention
1142891|NCT01395771|Promote
1142892|NCT01395771|HAART adherence
1142893|NCT01395758|KRAS mutation
1142894|NCT01395758|metastatic NSCLC
1142895|NCT01395745|SLE
1142896|NCT01395745|Lupus
1142897|NCT01395745|Lupus Erythematosus, Systemic
1142898|NCT01395745|Autoimmune Diseases
1142899|NCT01395745|A-623
1142900|NCT01395745|Blisibimod
1142901|NCT01395719|renal transplantation
1142902|NCT01395719|glomerular filtration rate
1142903|NCT01395719|remote ischemic preconditioning
1142904|NCT01395719|remote ischemic conditioning
1142905|NCT01395706|Malignant Neoplasm of Breast
1142906|NCT01395706|Sentinel lymph node detection
1142907|NCT01395706|ICG fluorescence technique
1142908|NCT01395706|Population of male and female patients with mamma carcinoma
1142909|NCT01395680|cancer adolescent
1142910|NCT01395680|resilience
1142911|NCT01395641|Aromatic Amino Acid Decarboxylase
1142912|NCT01395641|AADC
1142913|NCT01395641|DDC
1142914|NCT01395641|Gene Therapy
1142915|NCT01395641|AAV2-AADC
1142916|NCT01395641|Viral Vector
1142917|NCT01395641|Gene Transfer
1142918|NCT01395641|Aromatic L-Amino Acid Decarboxylase Deficiency
1142919|NCT01395628|chronic phase chronic myelogenous leukemia
1142920|NCT01395628|childhood acute promyelocytic leukemia (M3)
1142921|NCT01395628|childhood acute myeloid leukemia/other myeloid malignancies
1142922|NCT01395628|adult acute myeloid leukemia with t(8;21)(q22;q22)
1142923|NCT01395628|adult acute myeloid leukemia with del(5q)
1142924|NCT01395628|adult acute promyelocytic leukemia (M3)
1142925|NCT01395589|vitamin D
1142926|NCT01395589|emergency visits in patients with moderate to severe asthma after correction of vitamin D status.
1142927|NCT01395576|Genu recurvatum
1142928|NCT01395576|Knee hyper extension
1142929|NCT01395576|Orthosis
1142930|NCT01395576|Gait analysis
1142931|NCT01395576|Post stroke
1142932|NCT01394510|insulin secretion
1142933|NCT01394510|beta-cell function
1142934|NCT01394510|oxidative stress
1142935|NCT01394510|type 2 diabetes
1142936|NCT01394497|Liver Transplantation
1142937|NCT01394497|Graft Survival
1142938|NCT01394497|Graft Rejection
1142939|NCT01394497|Primary Graft Dysfunction
1142940|NCT01394497|Tissue and Organ Harvesting
1142941|NCT01394497|Tissue and Organ Procurement
1142942|NCT01394497|Tissue Donors
1142943|NCT01394497|Cold Ischemia
1142944|NCT01394471|schizophrenia
1142945|NCT01394471|schizoaffective disorder
1142946|NCT01394471|oxytocin
1142947|NCT01394471|OT
1142948|NCT01394471|social cognition
1142949|NCT01394471|social functioning
1142950|NCT01394471|paranoia
1142951|NCT01394471|psychosis
1142952|NCT01394471|psychotic symptoms
1142953|NCT01394471|social deficits
1142954|NCT01394471|intranasal administration
1142955|NCT01394458|catheter related infection
1142956|NCT01394458|bacteremia
1142957|NCT01394458|hemodialysis
1142958|NCT01394432|Endocardial Stem Cells Injection
1142959|NCT01394432|Percutaneous Coronary Intervention
1142960|NCT01394393|obesity treatment
1142961|NCT01394393|evidence based intervention
1142962|NCT01394393|cognitive behavioral treatment
1142963|NCT01394393|virtual reality environments
1142964|NCT01394380|sugar
1142965|NCT01394380|sweetened beverages
1142966|NCT01394380|hepatic steatosis
1142967|NCT01394380|visceral obesity
1142968|NCT01394380|metabolic syndrome
1142969|NCT01395524|Non-Cancer-Related Pain
1142970|NCT01395524|Opioid-Induced Constipation.
1142971|NCT01395511|whiplash associated disorder,
1142972|NCT01395511|Intractable Traumatic Cervical Syndrome,
1142973|NCT01395511|Acupuncture,
1142974|NCT01395511|Randomized controlled trial
1142975|NCT01395498|CMV
1142976|NCT01395498|PCP
1142977|NCT01395498|bronchoalveolar lavage
1142978|NCT01395485|Amgen
1142979|NCT01395485|Adolescent
1142980|NCT01395485|Single Dose
1142981|NCT01395485|Safety
1142982|NCT01395485|Pharmacokinetics
1142983|NCT01395472|TBI
1142984|NCT01395472|Acute physical exercise
1142985|NCT01395472|Cognitive functions
1142986|NCT01395472|Mood
1142987|NCT01395459|screening
1142988|NCT01395459|cancer prevention
1142989|NCT01395459|IVR
1142990|NCT01395433|Assessing the bioequivalence of escitalopram dosage forms
1142991|NCT01395420|Phase 1
1142992|NCT01395420|open label
1142993|NCT01395420|healthy male and female (post menopausal) volunteers
1142994|NCT01395420|Pharmacokinetics
1142995|NCT01395420|CAZ104
1142996|NCT01395420|Avibactam
1142997|NCT01395420|Ceftazidime
1142998|NCT01395420|open label, at least 2 different regimens, concentration of investigational product (IP), CAZ104, Avibactam, Ceftazidime, Cmax, tmax
1142999|NCT01395407|Brain
1143000|NCT01395407|Neoplasm
1143001|NCT01395407|Neoplasm Metastasis
1143002|NCT01395407|Radiosurgery
1143003|NCT01395394|Phenylketonuria
1143004|NCT01395394|PKU
1143005|NCT01395394|tetrahydrobiopterin
1143006|NCT01395394|sapropterin dihydrochloride
1143007|NCT01395394|BH4
1143008|NCT01395394|Kuvan
1143009|NCT01395394|Oxidative stress
1143010|NCT01395368|subjective
1143011|NCT01395368|unilateral
1143012|NCT01395368|bilateral
1143013|NCT01395368|non-pulsatile
1143014|NCT01395368|6 month's duration or longer
1143015|NCT01395355|binge eating
1143016|NCT01395355|loss of control eating
1143017|NCT01395355|eating in the absence of hunger
1143018|NCT01395355|emotional eating
1143019|NCT01395342|Pregnant women
1143020|NCT01395342|Pre-eclampsia
1143021|NCT01395342|Exercise
1143022|NCT01395342|Hypertension, Pregnancy-Induced
1143023|NCT01395342|Parturition
1143024|NCT01395303|infarction
1143025|NCT01395303|stroke
1143026|NCT01395303|diabetes
1143027|NCT01395303|fracture
1143028|NCT01395303|aortic stenosis
1143029|NCT01395303|cancer
1143030|NCT01395303|death
1143031|NCT01395303|vitamin D
1143032|NCT01395303|androgens
1143033|NCT01395303|thyroid hormones
1143034|NCT01395290|staphylococcus aureus
1143035|NCT01395290|vitamin D
1143036|NCT01395277|Nitric Oxide
1143037|NCT01395277|Vascular Function
1143038|NCT01395277|Aging
1143039|NCT01395277|Blood Pressure
1143040|NCT01395277|Arterial Stiffness
1143041|NCT01395277|Cardiovascular Disease
1143042|NCT01395277|Cerebral Blood Flow
1143043|NCT01395251|rheumatoid arthritis
1143044|NCT01395251|diagnosis
1143045|NCT01395251|sensitivity
1143046|NCT01395251|glucocorticoids
1143047|NCT01395238|fathers
1143048|NCT01395238|parenting
1143049|NCT01395238|high-risk
1143050|NCT01395238|child maltreatment
1143051|NCT01395238|prevention
1143052|NCT01395225|Fat Emulsifying
1143053|NCT01395225|Radical Cystectomy
1143054|NCT01395225|Pelvic Lymph Node Dissection
1143055|NCT01395225|Pathological Lymph Node Processing
1143056|NCT01395225|Bladder Cancer
1143057|NCT01395225|Transitional Cell Carcinoma
1143058|NCT01395225|Urothelial Cell Carcinoma
1143059|NCT01395212|Cell-based cardiac regenerative therapy
1143060|NCT01395212|Intramyocardial injections
1143061|NCT01395212|NOGA procedure
1143062|NCT01395212|Acute myocardial infarction
1143063|NCT01395199|Magnetic resonance imaging
1143064|NCT01395199|Thalassemia
1143065|NCT01395199|Iron overload
1143066|NCT01395186|varicocele
1143067|NCT01395186|pain
1143068|NCT01395173|detection
1143069|NCT01395160|Attention deficit hyperactivity disorder
1143070|NCT01395160|ADHD
1143071|NCT01395160|Bipolar Disorder
1143072|NCT01395160|Electrophysiological
1143073|NCT01395160|EEG
1143074|NCT01395160|ERP
1143075|NCT01395160|Attention
1143076|NCT01395160|Motivation
1143077|NCT01395160|Mood instability
1143078|NCT01395147|Drug Therapy
1143079|NCT01395134|External branch of the superior laryngeal nerve,
1143080|NCT01395134|Recurrent laryngeal nerve,
1143081|NCT01395134|Intraoperative neuromonitoring,
1143082|NCT01395134|Thyroid surgery
1143083|NCT01395121|c-KIT mutation
1143084|NCT01395121|advanced disease
1143085|NCT01395121|tyrosine kinase inhibitors
1143086|NCT01395095|cardiac rehabilitation
1143087|NCT01395095|risk factor
1143088|NCT01395095|lifestyle
1143094|NCT01395069|Post-cataract surgery
1143095|NCT01395069|macular edema
1143096|NCT01395056|breast neoplasm
1143097|NCT01395056|Neoplasm Metastasis
1143098|NCT01395056|Drug Therapy
1143099|NCT01395043|Transversus Abdominis Plane catheter
1143100|NCT01395043|TAP catheter
1143101|NCT01395030|Liver
1143102|NCT01395030|Cancer
1143103|NCT01395017|Pancreatic cancer
1143104|NCT01395017|Dasatinib
1143105|NCT01395017|chemotherapy
1143106|NCT01395017|Locally advanced
1143107|NCT01394991|Epoetin alfa (EPREX, ERYPO)
1143108|NCT01394978|Pleural air leak
1143109|NCT01394978|Pulmonary resection
1143110|NCT01394978|Open thoracotomy
1143111|NCT01394965|ECG
1143112|NCT01394965|Mapping
1143113|NCT01394965|ecg mapping
1143114|NCT01394965|arrythmias
1143115|NCT01394952|Cardiovascular disease
1143116|NCT01394952|Diabetes Mellitus
1143117|NCT01394952|Dulaglutide
1143118|NCT01394939|Vaccinia
1143119|NCT01394939|Vaccinia Virus
1143120|NCT01394939|JX-594
1143121|NCT01394939|Jennerex
1143122|NCT01394939|Colorectal Carcinoma
1143123|NCT01394939|Colorectal cancer
1143124|NCT01394939|Colon Cancer
1143125|NCT01394939|Rectal Cancer
1143126|NCT01394939|oncolytic virus
1143127|NCT01394939|viral therapy
1143128|NCT01394939|RAS mutant
1143129|NCT01394939|Erbitux failure
1143130|NCT01394939|Oxaliplatin failure
1143131|NCT01394939|FOLFOX failure
1143132|NCT01394939|FOLFIRI failure
1143133|NCT01394939|Irinotecan failure
1143134|NCT01394939|Pexa-Vec
1143135|NCT01394926|CE-U/S - Contrast-Enhanced U/S
1143136|NCT01394926|U/S - Ultrasound
1143137|NCT01394926|Assess effectiveness
1143138|NCT01394900|HIV
1143139|NCT01394900|sexually transmitted infection
1143140|NCT01394900|STI
1143141|NCT01394900|men who have sex with men
1143142|NCT01394900|MSM
1143143|NCT01394900|couples
1143144|NCT01394900|African American
1143145|NCT01394900|Black
1143146|NCT01394887|Metformin, inflammation
1143147|NCT01394887|resistin
1143148|NCT01394887|impaired glucose tolerance
1143149|NCT01394887|children
1143150|NCT01394874|osteoarthritis
1143151|NCT01394874|exercise
1143152|NCT01394861|Endoscopic Submucosal Dissection
1143153|NCT01394861|ESD
1143154|NCT01394861|EMR
1143155|NCT01394861|Early Gastric Cancer
1143156|NCT01394861|Flexible Endoscopic Robotic System
1143157|NCT01394861|Master Slave Robot
1143158|NCT01394861|Ease & Safety of ESD by Flexible Master Slave Robotic System
1143159|NCT01394835|Patient after lung transplantation
1143160|NCT01394809|osteoporosis
1143161|NCT01394809|wrist fracture
1143162|NCT01394809|mental practice
1143163|NCT01394809|mirror therapy
1143164|NCT01394809|immobilization
1143165|NCT01394809|elderly
1143166|NCT01394783|Endotracheal intubation, Teaching, Videolaryngoscope
1143167|NCT01394770|hypertension
1143168|NCT01394770|dialysis
1143169|NCT01394770|aliskiren
1143170|NCT01394770|amlodipine
1143171|NCT01394770|outcome
1143172|NCT01394744|metal
1143173|NCT01394744|ion
1143174|NCT01394744|cytokine
1143175|NCT01394744|hip arthroplasty
1143176|NCT01394744|blood
1143177|NCT01394744|Assessment
1143178|NCT01394744|cytokine profile
1143179|NCT01394718|analgesic adjunct
1143180|NCT01394718|acetaminophen
1143181|NCT01394718|spine fusion surgery
1143182|NCT01394718|opiate reduction
1143183|NCT01394718|pain management after elective surgical operation
1143184|NCT01394705|patients at increased risk for atherosclerosis
1143185|NCT01394692|intraoperative MRI
1143186|NCT01394692|glioma surgery
1143187|NCT01394692|extent of resection
1143188|NCT01394679|Lung Cancer
1143189|NCT01394679|Recurrent Lung Cancer no treatment within 3 months
1143190|NCT01394653|YM060
1143191|NCT01394653|ramosetron
1143192|NCT01394653|orally-disintegrating tablet
1143193|NCT01394653|OD tablet
1143194|NCT01394653|bioequivalence
1143195|NCT01394614|Cataplexy
1143196|NCT01394614|MSLT
1143197|NCT01394614|Hypocretin
1143198|NCT01394614|HLA typing
1143199|NCT01394614|Polysomnography
1143200|NCT01394614|A/H1N1 vaccine
1143201|NCT01394601|Antipsychotics
1143202|NCT01394601|schizophrenia
1143203|NCT01394601|acute inpatient
1143204|NCT01394588|Cardiac Surgery
1143205|NCT01394588|Perioperative Glucose Control
1143206|NCT01394575|breast cancer
1143207|NCT01394575|radiotherapy
1143208|NCT01394575|simultaneous integrated boost
1143209|NCT01394575|tumor bed
1143210|NCT01394575|IMRT
1143211|NCT01394536|Post-operative
1143212|NCT01394536|post-op
1143213|NCT01394536|nausea
1143214|NCT01394536|vomiting
1143215|NCT01394367|respiratory therapy
1143216|NCT01394367|exercise therapy
1143217|NCT01394367|oxygen uptake
1143218|NCT01394367|quality of life
1143219|NCT01394367|right ventricular function
1143220|NCT01394367|severe pulmonary hypertension
1143221|NCT01394354|Multiple Myeloma relapsed refractory
1143222|NCT01394341|Liraglutide
1143223|NCT01394341|Uremia
1143224|NCT01394341|Dialysis
1143225|NCT01394341|Type 2 diabetes mellitus
1143226|NCT01394341|Safety
1143227|NCT01394341|Efficacy
1143228|NCT01394328|Delirium
1143229|NCT01394328|Dementia
1143230|NCT01394328|Confusion Assessment Method
1143231|NCT01394328|Elderly
1143232|NCT01394315|diffuse optical tomography
1143233|NCT01394315|response
1143234|NCT01394315|neoadjuvant chemotherapy
1143235|NCT01394315|breast cancer
1143236|NCT01394302|Trigger Finger
1143237|NCT01394289|Standardization
1143238|NCT01394289|Immunotherapy
1143239|NCT01394289|Skin prick test
1143240|NCT01394263|prostate cancer
1143241|NCT01394263|PSA
1143242|NCT01394263|testosterone suppression
1143243|NCT01394250|Pain
1143244|NCT01394250|Anxiety
1143245|NCT01394250|IV Cannulation
1143246|NCT01394250|Topical Lidocaine
1143247|NCT01394250|Buzzy
1143248|NCT01394250|Face, Legs, Activity, Crying, Consolability (FLACC) scale
1143249|NCT01394250|Faces Pain Scale Revised (FPS-R)
1143250|NCT01394250|Child Rating of Anxiety Scale
1143251|NCT01394224|Healthy volunteers
1143252|NCT01394224|Japanese
1143253|NCT01394198|Osteopathic Manipulative Medicine (OMM)
1143254|NCT01394198|Neuromuscular Medicine (NMM)
1143255|NCT01394198|Somatic Dysfunction
1143256|NCT01394198|Correlational Study
1143257|NCT01394198|Endoscopy
1143258|NCT01394185|marijuana
1143259|NCT01394185|dronabinol
1143260|NCT01394185|pharmacotherapy
1143261|NCT01394172|Tidal Volume
1143262|NCT01394172|Pediatric
1143263|NCT01394172|Difficult airway
1143264|NCT01394172|Ventilation
1143265|NCT01394172|Airway management
1143266|NCT01394159|passes required to establish diagnosis
1143267|NCT01394146|phosphorus-based food additives
1143268|NCT01394146|phosphorus metabolism
1143269|NCT01394133|HIV Infected Women
1143270|NCT01394120|Pancreas cancer
1143271|NCT01394120|Targeted Therapy
1143272|NCT01394107|Thromboprophylaxis
1143273|NCT01394107|Effect of LMWH on coagulation
1143274|NCT01394107|Pregnancy
1143275|NCT01394107|Neuraxial anesthesia
1143276|NCT01394107|Spinal haematoma
1143277|NCT01394094|Gum chewing
1143278|NCT01394094|Bowel function
1143279|NCT01394094|benign gynecologic surgery
1143280|NCT01394081|Veterans
1143281|NCT01394081|Health Care Utilization
1143282|NCT01394081|Rural Health
1143283|NCT01394081|Patient Navigation
1143284|NCT01394081|Motivational Interviewing
1143285|NCT01394068|Selenium level
1143286|NCT01394068|Various blood values
1143287|NCT01394068|Duration of artificial respiration
1143288|NCT01394068|Residence in ICU/ Hospital
1143289|NCT01394068|SOFA-Score
1143290|NCT01394068|SAPS-Score
1143291|NCT01394055|Diabetes Mellitus Type 1 and 2
1143292|NCT01394055|Delayed Gastric Emptying
1143293|NCT01394055|Gastroparesis
1143294|NCT01394055|Gastrointestinal Motility Disorder
1143295|NCT01394042|Biopsy proven primary prostate cancer
1143296|NCT01394029|iron overload
1143297|NCT01394029|iron chelation
1143298|NCT01394029|deferasirox
1143299|NCT01394029|observational
1143300|NCT01394003|Advanced cancer
1143301|NCT01393977|Spinal Cord Injuries
1143302|NCT01393977|Stem Cell Transplantation
1143303|NCT01393977|Rehabilitation
1143304|NCT01393951|Recombinant Influenza hemagglutinin vaccine
1143305|NCT01393938|Mullerian Duct Anomaly
1143306|NCT01393938|3-dimensional Ultrasound
1143307|NCT01393938|Magnetic Resonance Imaging
1143308|NCT01393912|crenolanib
1143309|NCT01393912|radiation therapy
1143310|NCT01393912|malignant brain tumors
1143311|NCT01393912|pediatric
1143312|NCT01393899|tofacitinib
1143313|NCT01393899|Xeljanz
1143314|NCT01393899|CP-690,550
1143315|NCT01393899|maintenance therapy
1143316|NCT01393886|Obesity Surgery
1143317|NCT01393873|Obesity
1143318|NCT01393873|Type 2 DM
1143319|NCT01393860|Diabetes
1143320|NCT01393860|aliskiren
1143321|NCT01393860|hypertension
1143322|NCT01393860|renal impairment
1143323|NCT01393847|Sickle Cell
1143324|NCT01393847|Pain
1143325|NCT01393847|Genetics
1143326|NCT01393847|Sickle Cell Disease
1143327|NCT01393847|Healthy Volunteer
1143328|NCT01393847|HV
1143329|NCT01393834|Delayed cord clamping
1143330|NCT01393834|Umbilical cord
1143331|NCT01393834|Preterm
1143332|NCT01393834|Cord milking
1143333|NCT01393808|Type 2 diabetes
1143334|NCT01393808|Paricalcitol
1143335|NCT01393808|Proteinuria
1143336|NCT01393808|Sodium intake
1143337|NCT01393795|Pulmonary Hypertension
1143338|NCT01393795|Pain
1143339|NCT01393782|high output shock
1143340|NCT01393782|distributive shock
1143341|NCT01393782|warm shock
1143342|NCT01393782|septic shock
1143343|NCT01393782|pressor
1143344|NCT01393782|angiotensin
1143345|NCT01393782|ATII
1143346|NCT01393782|vasopressor
1143347|NCT01393769|Retinoblastoma
1143348|NCT01393769|RTB
1143349|NCT01393769|Ocular tumour
1143350|NCT01393769|Melfalan
1143351|NCT01393769|Enucleation
1143352|NCT01393769|Tumor of the eye
1143353|NCT01393769|Eye
1143354|NCT01393769|Ocular cancer
1143355|NCT01393769|Ocular chemotherapy
1143356|NCT01393769|Ophthalmic artery
1143357|NCT01393769|Intra-arterial chemotherapy
1143358|NCT01393743|Central Nervous System
1143359|NCT01393730|prostate
1143360|NCT01393730|metastatic
1143361|NCT01393730|castrate resistant
1143362|NCT01393704|myomectomy
1143363|NCT01393704|vasopressin
1143364|NCT01393704|blood loss
1143365|NCT01393691|nighttime fears
1143366|NCT01393691|anxiety
1143367|NCT01393691|sleep
1143368|NCT01393691|actigraphy
1143369|NCT01393691|intervention
1143370|NCT01393652|Pharmacokinetics Safety Tolerability Pharmacodynamics
1143371|NCT01393639|treatment of rheumatoid arthritis
1143372|NCT01393639|treatment of RA
1143373|NCT01393639|patients on methotrexate for rheumatoid arthritis
1143374|NCT01393639|prednisone for rheumatoid arthritis
1143375|NCT01393587|Oxidative Stress
1143376|NCT01393587|Laproscopy
1143377|NCT01393561|Rhinitis
1143378|NCT01393561|Common cold
1143379|NCT01393561|Nasal symptoms
1143380|NCT01393561|Children
1143381|NCT01393548|Rhinitis
1143382|NCT01393548|common cold
1143383|NCT01393548|nasal symptoms
1143384|NCT01393548|children
1143385|NCT01393535|Adiponectin
1143386|NCT01393535|Prognosis
1143387|NCT01393535|Cardiac Surgery
1143388|NCT01393522|headache
1143389|NCT01393522|migraine
1143390|NCT01393509|PU-H71
1143391|NCT01393509|Solid Tumor
1143392|NCT01393509|Lymphoma
1143393|NCT01393509|11-041
1143394|NCT01393509|incurable, locally advanced or metastatic solid tumor malignancy or lymphoma
1143395|NCT01393496|prematurity
1143396|NCT01393496|anemia
1143397|NCT01393496|transfusion
1143398|NCT01393483|esophagectomy
1143399|NCT01393483|endoscopy
1143400|NCT01393483|biopsy
1143401|NCT01393483|Tissue mesothelin
1143402|NCT01393483|Serum mesothelin
1143403|NCT01393483|11-037
1143404|NCT01393470|HPV
1143405|NCT01393470|Vaccine
1143406|NCT01393470|long-term efficacy
1143407|NCT01393470|registry-based study
1143408|NCT01393470|Evaluation of long-term HPV vaccine efficacy: a population-based, registry-based cohort study in Finland.
1143409|NCT01393457|cocaine
1143410|NCT01393457|cognition
1143411|NCT01393457|medication
1143412|NCT01393457|treatment
1143413|NCT01393444|Electrocorticography
1143414|NCT01393444|Tetraplegia
1143415|NCT01393444|Spinal cord injury
1143416|NCT01393444|Brainstem stroke
1143417|NCT01393444|Neuroprosthetic
1143418|NCT01393444|Brain-computer interface
1143419|NCT01393444|Direct brain interface
1143420|NCT01393444|Neural activity
1143421|NCT01393444|Motor cortex
1143422|NCT01393431|Exhaled breath condensate pH
1143423|NCT01393431|Predictive value of pH
1143424|NCT01393418|Erythropoietin
1143425|NCT01393418|Cardiac Surgery
1143426|NCT01393418|Renal Biomarker
1143427|NCT01393418|Acute Kidney Injury
1143428|NCT01393418|Hypothermic Circulatory Arrest
1143429|NCT01393392|smoking cessation
1143430|NCT01393392|methadone treatment
1143431|NCT01393392|nicotine addiction
1143432|NCT01393392|drug treatment
1143433|NCT01393392|drug addiction
1143434|NCT01393392|tobacco dependence
1143435|NCT01393327|physical training
1143436|NCT01393327|remaining post-operative pulmonary vascular changes
1143437|NCT01393327|right ventricular pump function
1143438|NCT01393327|PEA
1143439|NCT01393301|Nicotine dependence
1143440|NCT01393301|Smoking, cessation
1143441|NCT01393301|Quitting
1143442|NCT01393301|Anxiety symptoms
1143443|NCT01393301|Cognitive-behavioral therapy
1143444|NCT01393275|diabetes
1143445|NCT01393275|exercise
1143446|NCT01393275|intervention
1143447|NCT01393275|rehabilitation
1143448|NCT01393275|metabolic rate
1143449|NCT01393275|sport
1143450|NCT01393249|Acute Lymphoblastic Leukemia
1143451|NCT01393249|Pediatric
1143452|NCT01393249|Asparaginase
1143453|NCT01393249|Pancreatitis
1143454|NCT01393223|Interstitial Cystitis
1143455|NCT01393223|Painful Bladder Syndrome
1143456|NCT01393223|Bladder Pain Syndrome
1143457|NCT01393223|Liposome
1143458|NCT01393223|LP-08
1143459|NCT01393210|insulin sensitivity
1143460|NCT01393210|adipose tissue
1143461|NCT01393210|inflammation
1143462|NCT01393197|HCC
1143463|NCT01393197|TACE
1143464|NCT01393184|Target therapy
1143465|NCT01393171|Anterior Vaginal Prolapse
1143466|NCT01393171|Cystocele
1143467|NCT01393171|Pelvic Organ Prolapse
1143468|NCT01393145|Chronic obstructive pulmonary disease (COPD)
1143469|NCT01393145|salmeterol
1143470|NCT01393145|fluticasone
1143471|NCT01393145|formoterol
1143472|NCT01393145|FEV1
1143473|NCT01393145|Moderate-to-severe
1143474|NCT01393132|Dry Eye
1143475|NCT01393132|Sjogren's Syndrome
1143476|NCT01393132|Graft vs. Host Disease
1143477|NCT01393132|Rheumatoid arthritis
1143478|NCT01393132|Systemic lupus erythematosus
1143479|NCT01393132|Scleroderma
1143480|NCT01393106|HL
1143481|NCT01393106|idelalisib
1143482|NCT01393106|CAL-101
1143483|NCT01393106|GS-1101
1143484|NCT01393106|PI3K
1143485|NCT01393093|HCC
1143486|NCT01393093|TACE
1143487|NCT01393080|nimotuzumab
1143488|NCT01393080|non-small cell lung cancer
1143489|NCT01393080|chemotherapy
1143490|NCT01393067|cSEMS
1143491|NCT01393067|NEPS
1143492|NCT01393067|ERCP
1143493|NCT01393067|biliary stricture
1143494|NCT01393067|biliary stenosis
1143495|NCT01393067|liver transplantation
1143496|NCT01393054|Nigella sativa seed extract
1143497|NCT01393054|hypertension
1143498|NCT01393054|elderly
1143499|NCT01393028|coronary artery disease
1143500|NCT01393028|angina pectoris
1143501|NCT01393028|Stable chest pain complaints
1143502|NCT01393015|automatic
1143503|NCT01393015|automation
1143504|NCT01393015|oxygen
1143505|NCT01393015|weaning
1143506|NCT01393015|COPD
1143507|NCT01393015|exacerbation
1143508|NCT01393002|intensive care
1143509|NCT01393002|candidemia
1143510|NCT01393002|fungal infection
1143511|NCT01392976|cancer
1143512|NCT01392976|advanced
1143513|NCT01392976|solid
1143514|NCT01392976|tumor
1143515|NCT01392976|gemcitabine
1143516|NCT01392976|human equilibrative nucleoside transporter-1 (hENT1)
1143517|NCT01392976|CO-1.01
1143518|NCT01392976|CO-101
1143519|NCT01392976|CO101
1143520|NCT01392963|botox
1143521|NCT01392963|depression
1143522|NCT01392950|silicone hydrogel contact lenses for daily wear
1143523|NCT01392937|AIOL
1143524|NCT01392937|multipurpose solution
1143525|NCT01392937|silicone hydrogel lenses
1143526|NCT01392937|The safety and efficacy of the All-in-One Light multipurpose care regimen by comparison with the Aquify care regimen
1143527|NCT01392911|Dose Ranging
1143528|NCT01392911|Extended Early Bactericidal Activity
1143529|NCT01392911|Maximum tolerable dose
1143530|NCT01392911|Pharmacokinetics
1143531|NCT01392911|Pulmonary Tuberculosis
1143532|NCT01392911|Rifampicin
1143533|NCT01392911|Rifafour
1143534|NCT01392911|Safety
1143535|NCT01392911|Tolerability
1143536|NCT01392911|Max Tolerable Dose
1143537|NCT01392898|liraglutide
1143538|NCT01392898|insulin
1143539|NCT01392898|type 2 diabetes mellitus
1143540|NCT01392885|Schizophrenia
1143541|NCT01392885|Schizoaffective Disorder
1143542|NCT01392885|Brain Health
1143543|NCT01392885|Exercise
1143544|NCT01392885|Mental Health
1143545|NCT01392885|Poor memory
1143546|NCT01392872|Immunosuppressant
1143547|NCT01392872|Quality of life
1143548|NCT01392872|Cognitive function
1143549|NCT01392872|Relapsing Multiple Sclerosis
1143550|NCT01392846|Coronary artery disease requiring drug eluting stents
1143551|NCT01392833|iga nephropathy
1143552|NCT01392833|chronic kidney disease
1143553|NCT01392833|proteinuria
1143554|NCT01392833|steroids
1143555|NCT01392833|azathioprine
1143556|NCT01392820|Phase I
1143557|NCT01392820|Japan
1143558|NCT01392820|Elderly
1143559|NCT01392820|PK
1143560|NCT01392820|SAD
1143561|NCT01392820|MAD
1143562|NCT01392807|Phase 1
1143563|NCT01392807|volunteers with hepatic impairment
1143564|NCT01392807|pharmacokinetics
1143565|NCT01392807|NKTR-118
1143566|NCT01392807|Child-Pugh scale
1143567|NCT01392807|AUC
1143568|NCT01392807|Cmax
1143569|NCT01392807|tmax
1143570|NCT01392807|t1/2
1143571|NCT01392794|YM060
1143572|NCT01392794|ramosetron
1143573|NCT01392794|orally-disintegrating tablet
1143574|NCT01392794|OD tablet
1143575|NCT01392794|bioequivalence
1143576|NCT01392781|PCOS
1143577|NCT01392781|hsC-RP
1143578|NCT01392781|Lp-PLA2
1143579|NCT01392781|cardiovascular risk
1143580|NCT01392768|Epilepsy
1143581|NCT01392768|Partial
1143582|NCT01392768|Seizures
1143583|NCT01392768|Adjunctive
1143584|NCT01392690|No condition
1143585|NCT01392690|Primary prevention
1143586|NCT01392690|Anxiety
1143587|NCT01392677|dapagliflozin
1143588|NCT01392677|diabetes
1143589|NCT01392677|hyperglycaemia
1143590|NCT01392651|Urinary stress incontinence
1143591|NCT01392651|TVT
1143592|NCT01392638|Sildenafil
1143593|NCT01392638|Nitric oxide synthase
1143594|NCT01392638|Polymorphism
1143595|NCT01392638|Hemodynamics
1143596|NCT01392625|Non ischemic dilated cardiomyopathy
1143597|NCT01392625|Dilated cardiomyopathy
1143598|NCT01392625|Heart failure
1143599|NCT01392625|Cardiac Stem Cell Transplantation
1143600|NCT01392625|Stem Cells
1143601|NCT01392612|thrombosis
1143602|NCT01392612|hypertension
1143603|NCT01392612|gender
1143604|NCT01392612|endothelium
1143605|NCT01392599|CRPS Type II
1143606|NCT01392599|Pain
1143607|NCT01392599|Surgery
1143608|NCT01392599|Regional Subcutaneous Venous Sympathectomy(RSVS)
1143609|NCT01392599|Sudeck
1143610|NCT01392599|Reflex sympathetic dystrophy (RSD)
1143611|NCT01392599|Causalgia
1143612|NCT01392599|Algodystrophy
1143613|NCT01392586|survival
1143614|NCT01392586|systemic therapy
1143615|NCT01392586|upfront surgery
1143616|NCT01392534|Hypertension
1143617|NCT01392534|Telmisartan
1143618|NCT01392534|Hydrochlorothiazide
1143619|NCT01392534|Potassium
1143620|NCT01392534|Glucose metabolism
1143621|NCT01392534|Lipid metabolism
1143622|NCT01392521|Safety
1143623|NCT01392521|Tolerability
1143624|NCT01392521|Pharmacokinetics
1143625|NCT01392495|Pulmonary arterial hypertension
1143626|NCT01392495|imatinib
1143627|NCT01392495|6MWD
1143628|NCT01392482|Schizophrenia
1143629|NCT01392482|Bipolar Disorder
1143630|NCT01392469|Pulmonary arterial hypertension
1143631|NCT01392469|pulmonary vascular resistance
1143632|NCT01392469|imatinib
1143633|NCT01392469|bosentan
1143634|NCT01392469|sildenafil
1143635|NCT01392456|OHIP-EDENT, VALIDATION, OVERDENTURE, ROMANIAN
1143636|NCT01392443|INC424
1143637|NCT01392443|Ruxolitinib
1143638|NCT01392443|Myelofibrosis
1143639|NCT01392443|MF
1143640|NCT01392430|Primary prophylaxis
1143641|NCT01392430|Secondary prophylaxis
1143642|NCT01392430|Discontinuation
1143643|NCT01392391|Stroke
1143644|NCT01392391|Exercise
1143645|NCT01392391|Protein synthesis
1143646|NCT01392391|Protein breakdown
1143647|NCT01392391|Muscle atrophy
1143648|NCT01392391|Muscle phenotype
1143649|NCT01392391|Inflammation
1143650|NCT01392391|Insulin resistance
1143651|NCT01392391|Fitness
1143652|NCT01392378|Prevenar 13
1143653|NCT01392378|13vPnC
1143654|NCT01392378|Antipyretic medication
1143655|NCT01392378|Healthy subjects
1143656|NCT01392365|Crohn's disease
1143657|NCT01392365|Intestinal tuberculosis
1143658|NCT01392365|Diagnosis, Differential
1143659|NCT01392352|pazopanib
1143660|NCT01392352|hypertension
1143661|NCT01392352|forearm blood flow
1143662|NCT01392339|Obstructive Sleep Apnea
1143663|NCT01392339|CPAP
1143664|NCT01392339|hypoxia
1143665|NCT01392339|sleep
1143666|NCT01392339|translational science
1143667|NCT01392339|gene expression
1143668|NCT01392326|Psoriatic arthritis
1143669|NCT01392326|PsA
1143670|NCT01392326|ACR
1143671|NCT01392326|CASPAR
1143672|NCT01392313|carnitine, kidney
1143673|NCT01392287|Geriatric
1143674|NCT01392287|Older adults
1143675|NCT01392287|Major Depressive Disorder
1143676|NCT01392287|Magnetic Resonance Spectroscopy
1143677|NCT01392287|memantine hydrochloride
1143678|NCT01392287|N-Acetylaspartylglutamate
1143679|NCT01392287|NAAG
1143680|NCT01392287|Cognitive impairment
1143681|NCT01390324|Migraine
1143682|NCT01390324|Naratriptan
1143683|NCT01390324|Naproxen
1143684|NCT01390298|chronic pain after knee replacement surgery
1143685|NCT01390272|Hypertension
1143686|NCT01390272|Telephone
1143687|NCT01390272|Disease Management
1143688|NCT01390272|Veterans
1143689|NCT01390272|Pharmacists
1143690|NCT01390272|Nurses
1143691|NCT01390246|Pregnancy
1143692|NCT01390246|Tobacco use disorder
1143693|NCT01390246|Smoking cessation
1143694|NCT01390246|Bupropion SR
1143695|NCT01390246|Zyban
1143696|NCT01390233|Labor, obstetric
1143697|NCT01390233|Labor, induced
1143698|NCT01390220|Epilepsy
1143699|NCT01390220|seizure clusters
1143700|NCT01390220|acute repetitive seizures
1143701|NCT01390220|rescue treatment
1143702|NCT01390220|ARTEMIS
1143703|NCT01390207|hCG triggering
1143704|NCT01390207|pregnancy
1143705|NCT01390207|GnRH antagonist
1143706|NCT01390194|liver disease
1143707|NCT01390194|hepatocellular carcinoma
1143708|NCT01392248|EEG
1143709|NCT01392248|breast cancer surgery
1143710|NCT01392248|prediction
1143711|NCT01392248|acute postoperative pain
1143712|NCT01392248|chronic pain
1143713|NCT01392235|Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
1143716|NCT01392209|BEVACIZUMAB
1143717|NCT01392209|HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY
1143718|NCT01392209|Brain
1143719|NCT01392209|CNS
1143720|NCT01392209|anti-VEGF antibody
1143721|NCT01392209|11-057
1143722|NCT01392196|Renal Impairment
1143723|NCT01392183|Kidney cancer
1143724|NCT01392183|Renal Cell Carcinoma
1143725|NCT01392183|Poor-Risk Clear-Cell Renal Cell Carcinoma
1143726|NCT01392183|RCC
1143727|NCT01392183|Metastatic
1143728|NCT01392183|Locally advanced
1143729|NCT01392183|Complete response
1143730|NCT01392183|CR
1143731|NCT01392183|Partial Response
1143732|NCT01392183|PR
1143733|NCT01392183|Overall survival
1143734|NCT01392183|OS
1143735|NCT01392183|Time to progression
1143736|NCT01392183|TTP
1143737|NCT01392183|Pazopanib
1143738|NCT01392183|GW786034
1143739|NCT01392183|Temsirolimus
1143740|NCT01392183|CCI-779
1143741|NCT01392183|Torisel
1143742|NCT01392183|Benadryl
1143743|NCT01392183|Diphenhydramine
1143744|NCT01392183|TemPa
1143745|NCT01392170|Leukemia
1143746|NCT01392170|Chronic Myeloid Leukemia
1143747|NCT01392170|CML
1143748|NCT01392170|Tyrosine Kinase Inhibitors
1143749|NCT01392170|TKI
1143750|NCT01392170|Complete cytogenetic remission
1143751|NCT01392170|CCyR
1143752|NCT01392170|Minimal residual disease
1143753|NCT01392170|MRD
1143754|NCT01392170|PEG-IFNa-2a
1143755|NCT01392170|Pegasys
1143756|NCT01392170|Peginterferon Alpha-2a
1143757|NCT01392170|Philadelphia chromosome (Ph)-positive
1143758|NCT01392170|BCR-ABL1-positive
1143759|NCT01392144|Radiation pneumonitis
1143760|NCT01392144|RP
1143761|NCT01392144|Nitric oxide
1143762|NCT01392144|NO
1143763|NCT01392144|Thoracic
1143764|NCT01392144|Esophagus cancer
1143765|NCT01392144|Lung cancer
1143766|NCT01392144|Radiation therapy
1143767|NCT01392144|radiotherapy
1143768|NCT01392144|RT
1143769|NCT01392144|XRT
1143770|NCT01392144|Airway
1143771|NCT01392144|Alveolar
1143772|NCT01392144|Nitric oxide breath analyzer
1143773|NCT01392144|Questionnaires
1143774|NCT01392131|Oncoxin
1143775|NCT01392131|Safety of Oncoxin
1143776|NCT01392131|Therapeutic efficacy of Oncoxin
1143777|NCT01392131|Improvement of quality of life with Oncoxin
1143778|NCT01392131|Survival benefit with Oncoxin
1143779|NCT01392105|Mesenchymal stem cells
1143780|NCT01392105|Myocardial infarction
1143781|NCT01392105|Left ventricular dysfunction
1143782|NCT01392092|Contingency Management
1143783|NCT01392092|Drug Self-Administration
1143784|NCT01392079|CLL
1143785|NCT01392079|17p deletion
1143786|NCT01392079|refractory to fludarabine
1143787|NCT01392079|subcutaneous alemtuzumab
1143788|NCT01392079|CLL with 17p- or refractory to fludarabine
1143789|NCT01392066|breast neoplasms
1143790|NCT01392066|spouses/partners
1143791|NCT01392066|couples
1143792|NCT01392066|interpersonal relations
1143793|NCT01392066|psychosocial adjustment
1143794|NCT01392066|psychological adaptation
1143795|NCT01392066|depression
1143796|NCT01392066|quality of life
1143797|NCT01392066|dyadic coping
1143798|NCT01392066|coping behavior
1143799|NCT01392066|cohort
1143800|NCT01392066|questionnaire
1143801|NCT01392053|labor
1143802|NCT01392053|pain
1143803|NCT01392053|massage
1143804|NCT01392027|Pancreatic Cancer
1143805|NCT01392027|Chronic Pancreatitis
1143806|NCT01392027|Diseases of the pancreas
1143807|NCT01392014|malaria
1143808|NCT01392014|DHP
1143809|NCT01392014|PQ
1143810|NCT01392014|gametocytes
1143811|NCT01391975|arteriovenous fistula
1143812|NCT01391975|surveillance
1143813|NCT01391975|arterial stenosis
1143814|NCT01391975|venous stenosis
1143815|NCT01391962|Pharmacodynamics
1143816|NCT01391962|VEGF Inhibitor
1143817|NCT01391962|Alveolar Soft Part Sarcoma
1143818|NCT01391962|Anti-Angiogenesis
1143819|NCT01391962|Gene Expression Profiling
1143820|NCT01391949|disability
1143821|NCT01391949|walking
1143822|NCT01391949|feedback
1143823|NCT01391949|exercise
1143827|NCT01391910|rhinosinusitis
1143828|NCT01391897|somatoform disorders
1143829|NCT01391897|PTSD
1143830|NCT01391897|epigenetics
1143831|NCT01391897|psychotherapy
1143832|NCT01391897|psychosomatics
1143833|NCT01391884|Incretin hormones
1143834|NCT01391884|GLP-1
1143835|NCT01391884|GIP
1143836|NCT01391884|Uremia
1143837|NCT01391884|Dialysis
1143838|NCT01391858|Pregabalin
1143839|NCT01391858|Postoperative pain
1143840|NCT01391858|Mastectomy
1143841|NCT01391845|progesterone
1143842|NCT01391845|glycodelin-A
1143843|NCT01391845|ulipristal acetate
1143844|NCT01391832|rTMS
1143845|NCT01391832|PTSD
1143846|NCT01391832|Post Traumatic Stress Disorder
1143847|NCT01391832|repetitive transcranial magnetic stimulation
1143848|NCT01391832|combat related PTSD
1143849|NCT01391832|OEF
1143850|NCT01391832|OIF
1143851|NCT01391832|Veterans
1143852|NCT01391832|operation enduring freedom
1143853|NCT01391832|operation iraqi freedom
1143854|NCT01391832|CPT
1143855|NCT01391832|cognitive processing therapy
1143856|NCT01391819|Brazil
1143857|NCT01391819|Incidence
1143858|NCT01391819|Dengue virus
1143859|NCT01391819|Dengue
1143860|NCT01391819|Dengue infection
1143861|NCT01391806|Breast cancer
1143862|NCT01391806|Preoperative breast MRI
1143863|NCT01391806|Breast-conserving surgery
1143864|NCT01391806|Mastectomy
1143865|NCT01391806|Prospective study
1143866|NCT01391793|Renal scarring
1143867|NCT01391793|Dexamethasone
1143868|NCT01391793|Child
1143869|NCT01391793|Corticosteroids
1143870|NCT01391793|Pediatric
1143871|NCT01391793|Urinary tract infection
1143872|NCT01391793|Escherichia Coli Urinary Tract Infection
1143873|NCT01391780|pelvic floor evaluation,
1143874|NCT01391780|women,
1143875|NCT01391780|stress urinary incontinence;
1143876|NCT01391780|urgency urinary incontinence.
1143877|NCT01391767|Ridge Preservation
1143878|NCT01391767|Dental Implant
1143879|NCT01391767|Histology
1143880|NCT01391754|child abuse
1143881|NCT01391741|Parkinson´s Disease
1143882|NCT01391741|Walking
1143883|NCT01391741|Exercise
1143884|NCT01391741|Automaticity
1143885|NCT01391741|Dual Task
1143886|NCT01391741|Visual Cues
1143887|NCT01391741|Cueing
1143888|NCT01391741|Neuroplasticity
1143889|NCT01391741|Gait analysis
1143890|NCT01391715|Gastroesophageal reflux disease
1143891|NCT01391715|Proton pump inhibitor
1143892|NCT01391715|standard dose
1143893|NCT01391715|Double dose
1143894|NCT01391676|glaucoma
1143895|NCT01391676|trabeculectomy
1143896|NCT01391676|filtering bleb
1143897|NCT01391676|spectral domain optical coherence tomography
1143898|NCT01391663|Drug Therapy
1143899|NCT01391650|ACL
1143900|NCT01391650|double-bundle
1143901|NCT01391650|navigation system
1143902|NCT01391637|Long term follow-up
1143903|NCT01391637|HuCNS-SC cells
1143904|NCT01391637|human central nervous system stem cells
1143905|NCT01391624|chocolate
1143906|NCT01391624|craving
1143907|NCT01391624|addiction
1143908|NCT01391624|compulsion
1143909|NCT01391598|fibromyalgia
1143910|NCT01391598|intravenous lidocaine
1143911|NCT01391598|substance P
1143912|NCT01391598|interleukins
1143913|NCT01391585|Text
1143914|NCT01391585|SMS
1143915|NCT01391585|diabetes
1143916|NCT01391585|self-monitoring
1143917|NCT01391585|self-management
1143918|NCT01391585|adherence
1143919|NCT01391572|thoracic esophageal squamous cell carcinoma
1143920|NCT01391572|esophagectomy
1143921|NCT01391572|radiation
1143922|NCT01391572|tumor bed
1143923|NCT01391572|elective nodal irradiation
1143924|NCT01391559|breathing difficulty
1143925|NCT01391520|Acute Kidney Injury
1143926|NCT01391520|Contrast-Induced Nephropathy
1143927|NCT01391520|Labile Iron
1143928|NCT01391520|Iron Chelation
1143929|NCT01391520|Deferiprone
1143930|NCT01391507|Anti-beta1-receptor autoantibodies
1143931|NCT01391507|COR-1
1143932|NCT01391507|Heart failure
1143933|NCT01391494|Human Enterovirus 71 (EV71)
1143934|NCT01391494|Hand, Foot and Mouth Disease
1143935|NCT01391494|Inactivated Vaccine
1143936|NCT01391494|Human Diploid cell
1143937|NCT01391494|Safety
1143938|NCT01391494|Immunogenicity
1143939|NCT01391494|Adverse reactions associated with vaccine
1143940|NCT01391481|Perfluorocarbon
1143941|NCT01391481|Acute Respiratory Distress Syndrome
1143942|NCT01391481|Acute lung injury
1143943|NCT01391455|Inguinal hernia repair
1143944|NCT01391455|Mesh
1143945|NCT01391455|Groin pain
1143946|NCT01391455|Testicular pain
1143947|NCT01391442|follow up of troop,
1143948|NCT01391442|MRI, Echocardiography, Functional indices
1143949|NCT01391416|Hyperhomocysteinemia
1143950|NCT01391416|Chronic kidney disease
1143951|NCT01391403|Schizophrenia
1143952|NCT01391403|Risperidone
1143953|NCT01391403|Artemisinin
1143954|NCT01391403|Toxoplasma
1143955|NCT01391403|Immune
1143956|NCT01391390|Tardive Dyskinesia
1143957|NCT01391390|Schizophrenia
1143958|NCT01391390|Melatonin
1143959|NCT01391390|Oxidative Stress
1143960|NCT01391390|Antioxidant
1143961|NCT01391377|HDL
1143962|NCT01391377|High density Lipoprotein
1143963|NCT01391377|Peripheral arterial disease
1143964|NCT01391377|Tredaptive
1143965|NCT01391377|Niacin
1143966|NCT01391377|Laropiprant
1143967|NCT01391377|Plaque
1143968|NCT01391377|Atherosclerosis
1143969|NCT01391377|Lipid content
1143970|NCT01390155|Electrocardiography
1143971|NCT01390155|Coronary Artery Disease
1143972|NCT01390155|Atrial Fibrillation
1143973|NCT01390155|Heart Atria
1143974|NCT01390155|Coronary Circulation
1143975|NCT01390155|Ischemia
1143976|NCT01390116|gamma delta T cell
1143977|NCT01390116|natural killer cell
1143978|NCT01390116|proliferation
1143979|NCT01390116|cytokine secretion
1143980|NCT01390116|Improvement in immune cell function in healthy humans
1143981|NCT01390103|hip pain
1143982|NCT01390090|piriformis muscle
1143983|NCT01390077|homogentisic acid
1143984|NCT01390051|birth weight
1143985|NCT01390051|thrombosis
1143986|NCT01390051|anticoagulant therapy
1143987|NCT01391351|carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage
1143988|NCT01391351|chemotherapy with Taxol and Carboplatin
1143989|NCT01391351|predictors of therapeutic response
1143990|NCT01391351|serum miRNA
1143991|NCT01391351|identification of polymorphisms or SNPs (Single Nucleotide Polymorphism)
1143992|NCT01391338|Prostatitis
1143993|NCT01391338|Chronic
1143994|NCT01391338|Pelvic Pain
1143995|NCT01391338|NIH-CPSI
1143996|NCT01391338|Pain domain score in NIH-CPSI
1143997|NCT01391260|Locally Advanced NSCLC
1143998|NCT01391260|EGFR Mutation Positive
1143999|NCT01391260|Radiotherapy combined Gefitinib
1144000|NCT01391247|open angle glaucoma
1144001|NCT01391247|low tension glaucoma
1144002|NCT01391247|oximetry
1144003|NCT01391234|Metastatic bone disease
1144004|NCT01391234|Bone metastases
1144005|NCT01391234|Radiation therapy
1144006|NCT01391234|TomoTherapy
1144007|NCT01391221|Depression
1144008|NCT01391221|Inflammation
1144009|NCT01391221|Cognition
1144010|NCT01391221|Pain
1144011|NCT01391221|Allostatic load
1144012|NCT01391208|Barrett's Esophagus with High Grade Dysplasia
1144013|NCT01391208|Esophageal adenocarcinoma
1144014|NCT01391195|low level laser therapy
1144015|NCT01391195|muscle performance
1144016|NCT01391195|fatigue index
1144017|NCT01391195|endurance training
1144018|NCT01391195|ventilatory threshold
1144019|NCT01391195|VO2Max
1144020|NCT01391195|VO2Peak
1144021|NCT01391182|Epsilon Aminocaproic Acid
1144022|NCT01391182|blood loss
1144023|NCT01391182|total hip arthroplasty
1144024|NCT01391182|reduction in blood transfusions
1144025|NCT01391182|Amicar
1144026|NCT01391156|minoxidil
1144027|NCT01391156|finasteride
1144028|NCT01391156|topical
1144029|NCT01391156|lotion
1144030|NCT01391156|male pattern hair loss
1144031|NCT01391156|androgenetic alopecia
1144032|NCT01391143|Prostate cancer
1144033|NCT01391143|Melanoma
1144034|NCT01391143|Renal cell carcinoma
1144035|NCT01391143|Triple-negative breast cancer
1144036|NCT01391143|Head and neck cancer
1144037|NCT01391143|Bladder cancer
1144038|NCT01391143|Non-small cell lung cancer
1144039|NCT01391143|Squamous cell carcinoma
1144040|NCT01391130|Cancer
1144041|NCT01391130|Tumor
1144042|NCT01391130|Metastasis
1144043|NCT01391117|TMC649128
1144044|NCT01391117|HCV
1144045|NCT01391117|TMC649128HPC1002
1144046|NCT01391117|Hepatitis C
1144047|NCT01391117|Hep C
1144048|NCT01391104|Pulmonary Hypertension
1144049|NCT01391104|Pulmonary Arterial Hypertension
1144050|NCT01391104|Exercise
1144051|NCT01391104|Six-minute walk test
1144052|NCT01391104|sildenafil
1144053|NCT01391078|glaucoma
1144054|NCT01391078|IOP
1144055|NCT01391078|Sensimed Triggerfish
1144056|NCT01391078|Goldmann Applanation Tonometry
1144057|NCT01391078|fluctuation
1144058|NCT01391078|comparison
1144059|NCT01391065|Diffusion Weighted MRI
1144060|NCT01391065|FLT PET
1144061|NCT01391065|F-Miso PET
1144062|NCT01391065|Image Guided Brachytherapy
1144063|NCT01391065|Cervix
1144064|NCT01391065|Postoperative Residual Disease/Postoperative recurrences
1144065|NCT01391052|Intrauterine system
1144066|NCT01391052|reproductive age
1144067|NCT01391052|menstrual bleeding
1144068|NCT01391039|Ductal Carcinoma In-situ
1144069|NCT01391039|Contrast Ultrasound
1144070|NCT01391039|Microinvasion
1144071|NCT01391039|Elastography
1144072|NCT01391026|Medical informatics
1144073|NCT01391026|Health services accessibility
1144074|NCT01391013|Human immunodeficiency virus 1
1144075|NCT01391013|Acquired immunodeficiency syndrome
1144076|NCT01391013|Immunologic deficiency syndrome
1144077|NCT01391013|Darunavir/ritonavir
1144078|NCT01391013|Darunavir
1144079|NCT01391013|Ritonavir
1144080|NCT01391013|Nucleoside reverse transcriptase inhibitors (NRTIs)
1144081|NCT01391013|Prezista
1144082|NCT01391000|rotator cuff surgery
1144083|NCT01391000|pain
1144084|NCT01391000|exercise therapy
1144085|NCT01390974|ACS
1144086|NCT01390974|PCI
1144087|NCT01390974|thienopyridines
1144088|NCT01390974|prasugrel therapy
1144089|NCT01390974|clopidogrel therapy
1144090|NCT01390961|Allergic conjunctivitis
1144091|NCT01390935|guideline adherence
1144092|NCT01390935|systolic heart failure
1144093|NCT01390909|epilepsy
1144094|NCT01390909|anti-epileptic drug
1144095|NCT01390909|polytherapy
1144096|NCT01390909|adherence
1144097|NCT01390909|Medicaid
1144098|NCT01390870|Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, adherence
1144099|NCT01390818|MEK inhibitor (Pimasertib)
1144100|NCT01390818|PI3K/mTOR Inhibitor
1144101|NCT01390818|Solid Tumor
1144102|NCT01390818|Phase I
1144103|NCT01390766|Antirejection
1144104|NCT01390740|Transthoracic echocardiography
1144105|NCT01390727|hypertension
1144106|NCT01390727|device-guided breathing
1144107|NCT01390727|autonomic function
1144108|NCT01390727|Resperate
1144109|NCT01390714|Proton Pump Inhibitors
1144110|NCT01390714|Gastroesophageal Reflux Disease
1144111|NCT01390714|pharmacokinetics
1144112|NCT01390714|pharmacodynamics
1144113|NCT01390701|randomized
1144114|NCT01390701|cross-over
1144115|NCT01390701|transcutaneous electrical nerve stimulation
1144116|NCT01390701|felodipin
1144117|NCT01390701|hypertension
1144118|NCT01390701|blood pressure
1144119|NCT01390701|treatment
1144120|NCT01390688|Brain-derived Neurotrophic factor
1144121|NCT01390688|Low-grade inflammation
1144122|NCT01390688|Cognitive dysfunction
1144123|NCT01390662|serum 25-hydroxyvitamin d,vitamin D supplement, depression,
1144124|NCT01390662|parathyroid hormone
1144125|NCT01390649|ITP
1144126|NCT01390636|Continuous Glucose Monitoring
1144127|NCT01390636|Type 1 Diabetes and an Eating Disorder
1144128|NCT01390636|Eating Disorder Only
1144129|NCT01390623|Acute Uncomplicated Pyelonephritis
1144130|NCT01390623|Short-term antibiotic
1144131|NCT01390623|Ceftriaxone
1144132|NCT01390623|Cefixime
1144133|NCT01390623|Women
1144134|NCT01390623|Efficacy
1144135|NCT01390610|Continuous Glucose Monitoring
1144136|NCT01390610|Self Monitored Blood Glucose
1144137|NCT01390610|Type 2 Diabetes
1144138|NCT01390597|peripheral T-cell lymphoma
1144139|NCT01390597|stage I adult T-cell leukemia/lymphoma
1144140|NCT01390597|stage II adult T-cell leukemia/lymphoma
1144141|NCT01390597|stage III adult T-cell leukemia/lymphoma
1144142|NCT01390597|stage IV adult T-cell leukemia/lymphoma
1144143|NCT01390597|anaplastic large cell lymphoma
1144151|NCT01390571|adult glioblastoma
1144152|NCT01390571|adult giant cell glioblastoma
1144153|NCT01390571|adult gliosarcoma
1144154|NCT01390571|recurrent adult brain tumor
1144155|NCT01390558|Down Syndrome
1144156|NCT01390558|Orthotics
1144157|NCT01390558|Gait Analysis
1144158|NCT01390545|Rheumatoid arthritis
1144159|NCT01390545|anti-CD20 antibody
1144160|NCT01390545|subcutaneous
1144161|NCT01390532|Left Ventricular Dyssynchrony
1144162|NCT01390532|Gated blood-pool
1144163|NCT01390532|D-SPECT
1144164|NCT01390532|Pharmacological stress
1144165|NCT01390532|NYHA III/IV
1144166|NCT01390532|LVEF < 35 %
1144167|NCT01390532|QRS > 120 ms
1144168|NCT01390532|optimal medical treatment
1144169|NCT01390532|cardiac resynchronization therapy
1144170|NCT01390519|mRCC,
1144171|NCT01390519|observational,
1144172|NCT01390519|Afinitor,
1144173|NCT01390519|everolimus,
1144174|NCT01390519|2.line
1144175|NCT01390506|cardiac arrest
1144176|NCT01390506|resuscitation
1144177|NCT01390506|neurological outcome
1144178|NCT01390493|neurofeedback, alpha, anorexia nervosa
1144179|NCT01390480|vitamin D
1144180|NCT01390480|Autoimmune disease
1144181|NCT01390480|diabetes
1144182|NCT01390467|Paracetamol
1144183|NCT01390467|Cognitive impact
1144184|NCT01390441|Rheumatoid arthritis
1144185|NCT01390441|RA
1144186|NCT01390441|Rituximab
1144187|NCT01390441|Rituxan
1144188|NCT01390441|MabThera
1144189|NCT01390441|Methotrexate
1144190|NCT01390441|Rheumatrex
1144191|NCT01390441|Trexall
1144192|NCT01390441|MK-8808
1144193|NCT01390402|Alloreactive haploidentical NK cells
1144194|NCT01390402|Natural killer cells
1144195|NCT01390402|Stem Cell Transplantation
1144196|NCT01390402|Immune cells
1144197|NCT01390402|Chronic myelogenous leukemia
1144198|NCT01390402|CML
1144199|NCT01390402|Human leukocyte antigen
1144200|NCT01390402|HLA
1144201|NCT01390402|Graft-vs-host disease
1144202|NCT01390402|GVHD
1144203|NCT01390402|Antithymocyte globulin
1144204|NCT01390402|ATG
1144205|NCT01390402|Thymoglobulin
1144206|NCT01390402|Interleukin-2
1144207|NCT01390402|IL-2
1144208|NCT01390402|Aldesleukin
1144209|NCT01390402|Proleukin
1144210|NCT01390402|Fludarabine
1144211|NCT01390402|Fludarabine phosphate
1144212|NCT01390402|Fludara
1144213|NCT01390402|Tacrolimus
1144214|NCT01390402|Prograf
1144215|NCT01390402|Busulfan
1144216|NCT01390402|Busulfex
1144217|NCT01390402|Myleran
1144218|NCT01390402|Methotrexate
1144219|NCT01390389|Geriatric bipolar depression
1144220|NCT01390389|MR Spectroscopy
1144221|NCT01390389|Coenzyme Q10
1144222|NCT01390389|Mitochondrial Dysfunction
1144223|NCT01390376|Schizophrenia
1144224|NCT01390376|NMDA
1144225|NCT01390376|DAAOI
1144226|NCT01390376|Clozapine resistant schizophrenia
1144227|NCT01390363|immunization
1144228|NCT01390363|reminder systems
1144229|NCT01390350|Schnitzler syndrome
1144230|NCT01390350|autoinflammatory syndrome
1144231|NCT01390337|AC220
1144232|NCT01390337|Acute Myeloid Leukemia (AML)
1144233|NCT01390337|De Novo Acute Myeloid Leukemia (AML)
1144234|NCT01390337|Newly diagnosed Acute Myeloid Leukemia (AML)
1144235|NCT01390337|FMS-like tyrosine kinase (FLT3)
1144236|NCT01390337|FMS-like tyrosine kinase (FLT3) Inhibitor
1144237|NCT01390337|Kinase
1144238|NCT01390337|Kinase Inhibitor
1144239|NCT01390337|Pharmacokinetics
1144240|NCT01390337|ASP2689
1144241|NCT01390337|quizartinib
1144242|NCT01390025|Influenza
1144243|NCT01390025|Monoclonal antibody
1144244|NCT01389973|Diseases [C] - Digestive System Diseases [C06]
1144245|NCT01389973|primary biliary cirrhosis
1144246|NCT01389973|ursodeoxycholic acid (UDCA)
1144247|NCT01389973|STELARA
1144248|NCT01389973|ustekinumab
1144249|NCT01389947|mesenteric ischemia
1144250|NCT01389947|extracorporeal circulation
1144251|NCT01389947|microcirculation
1144252|NCT01389947|cardiac surgery
1144253|NCT01389947|IFABP
1144254|NCT01389947|citrullinemia
1144255|NCT01389947|glycocalyx
1144256|NCT01389947|vascular occlusion test
1144257|NCT01389947|NIRS probe on thenar eminence
1144258|NCT01389934|levo-bupicaine
1144259|NCT01389934|Radical
1144260|NCT01389934|Mastectomy
1144261|NCT01389921|lower urinary tract
1144262|NCT01389921|sensory evoked potential
1144263|NCT01389921|contact heat evoked potential stimulation
1144264|NCT01389921|electroencephalogram
1144265|NCT01389921|cortical processing
1144266|NCT01389921|bladder sensations
1144267|NCT01389921|lower urinary tract dysfunction
1144268|NCT01389921|overactive bladder
1144269|NCT01389895|Lupus
1144270|NCT01389895|Cutaneous lupus
1144271|NCT01389882|mechanical ventilation
1144272|NCT01389882|diaphragm electrical activity
1144273|NCT01389882|pressure support
1144274|NCT01389869|Emotional tears
1144275|NCT01389869|Postprandial plasma
1144276|NCT01389869|Chemosignal
1144277|NCT01389869|Obesity
1144278|NCT01389869|Appetite
1144279|NCT01389869|Food intake
1144280|NCT01389856|Persistent pulmonary hypertension, newborn
1144281|NCT01389856|PPHN
1144282|NCT01389843|Heart failure
1144283|NCT01389843|Registry
1144284|NCT01389843|Cohort
1144285|NCT01389843|Heart Disease
1144286|NCT01389843|Cardiovascular Diseases
1144287|NCT01389830|End of Life
1144288|NCT01389830|EOL
1144289|NCT01389830|Latinos
1144290|NCT01389830|Hispanic American
1144291|NCT01389830|Medicare beneficiaries
1144292|NCT01389830|stage III diagnosis
1144293|NCT01389830|Breast cancer
1144294|NCT01389830|Colorectal cancer
1144295|NCT01389830|Prostate cancer
1144296|NCT01389830|Lung cancer
1144297|NCT01389830|Cancer Prevention and Treatment Demonstration
1144298|NCT01389830|CPTD
1144299|NCT01389804|transplant, pediatric
1144300|NCT01389791|muscle relaxation
1144301|NCT01389791|magnesium sulfate
1144302|NCT01389791|rocuronium
1144303|NCT01389739|continuity of care
1144304|NCT01389739|interprofessional collaboration
1144305|NCT01389726|custodial grandparents
1144306|NCT01389726|kinship caregivers
1144307|NCT01389726|grandparents raising grandchildren
1144308|NCT01389726|grandmothers
1144309|NCT01389726|grandchildren
1144310|NCT01389726|psychological well-being
1144311|NCT01389713|ovarian reserve
1144312|NCT01389713|ovarian stimulation
1144313|NCT01389713|clomifene citrate
1144314|NCT01389713|high doses Follicle Stimulating Hormone (FSH)
1144315|NCT01389687|Poliomyelitis
1144316|NCT01389687|Inactivated polio vaccine
1144317|NCT01389687|Polio
1144318|NCT01389687|Poliovirus
1144319|NCT01389674|coronary stenosis
1144320|NCT01389674|Angina pectoris
1144321|NCT01389674|left ventricular wall motion abnormalities
1144322|NCT01389661|Maxillary bone cysts
1144323|NCT01389661|Cell therapy
1144324|NCT01389661|Mesenchymal stem cells
1144325|NCT01389661|Autologous serum scaffold
1144326|NCT01389648|adult
1144327|NCT01389635|Abdominoplasty
1144328|NCT01389635|Epidural
1144329|NCT01389622|Acupuncture
1144330|NCT01389622|smoking cessation
1144331|NCT01389609|Bioequivalence
1144332|NCT01389609|Orally-disintegrating Tablet
1144333|NCT01389596|safety
1144334|NCT01389596|efficacy
1144335|NCT01389596|partial onset seizures
1144336|NCT01389596|pediatric
1144337|NCT01389596|pregabalin
1144338|NCT01389596|placebo-controlled
1144339|NCT01389596|double-blind
1144340|NCT01389583|GIST(Gastrointestinal stromal tumor)
1144341|NCT01389583|HSP(Heat Shock Protein)
1144342|NCT01389583|Biomarker
1144343|NCT01389557|malaria
1144344|NCT01389557|DHP
1144345|NCT01389557|PQ
1144346|NCT01389557|MST
1144347|NCT01389518|Symptomatic treatment
1144348|NCT01389518|Common Cold
1144349|NCT01389518|flu syndrome
1144350|NCT01389505|Proliferative Diabetic Retinopathy
1144351|NCT01389505|Bevacizumab
1144352|NCT01389505|Panretinal Photocoagulation
1144353|NCT01389492|meat
1144354|NCT01389492|LDL
1144355|NCT01389492|MDA
1144356|NCT01389466|Avian influenza
1144357|NCT01389453|umbilical cord mesenchyma stem cell transplantation
1144358|NCT01389440|Resectable pancreatic adenocarcinoma
1144359|NCT01389440|Gemcitabine
1144360|NCT01389440|Erlotinib
1144361|NCT01389440|Radiotherapy
1144362|NCT01389440|Neoadjuvant treatment
1144363|NCT01389414|cholangiocarcinoma
1144364|NCT01389414|biliary
1144365|NCT01389414|gallbladder
1144366|NCT01389414|intrahepatic
1144367|NCT01389414|extrahepatic
1144368|NCT01389401|Larynx
1144369|NCT01389401|GERD
1144370|NCT01389401|saliva
1144371|NCT01389401|epidermal growth factor
1144372|NCT01389388|Carotid plaques
1144373|NCT01389388|inflammatory joint disease
1144374|NCT01389388|statins
1144375|NCT01389388|inflammation
1144376|NCT01389388|lipoprotein components
1144377|NCT01389375|Closure Device
1144378|NCT01389375|Coronary Angiography
1144379|NCT01389362|Diabetes
1144380|NCT01389362|foot ulcer
1144381|NCT01389362|Chinese herbal medicine
1144382|NCT01389349|tonsillectomy
1144383|NCT01389349|adenotonsillectomy
1144384|NCT01389349|acupuncture
1144385|NCT01389349|children
1144386|NCT01389349|postoperative pain
1144387|NCT01389349|postoperative nausea
1144388|NCT01389336|Fibromyalgia Syndrome
1144389|NCT01389336|Fibromyalgia
1144390|NCT01389336|Ayurveda
1144391|NCT01389336|Traditional Indian Medicine
1144392|NCT01389336|CAM
1144393|NCT01389336|Pain
1144394|NCT01389336|Chronic Widespread Pain
1144395|NCT01389297|alcohol dependence intervention
1144396|NCT01389297|Internet delivered intervention
1144397|NCT01389297|alcohol dependence treatment
1144398|NCT01389297|Internet delivered treatment
1144399|NCT01389284|Naproxen Sodium,
1144400|NCT01389284|dental pain
1144401|NCT01389271|Pulmonary hypertension
1144402|NCT01389271|Inhaled iloprost
1144403|NCT01389271|Efficacy
1144404|NCT01389271|Safety
1144405|NCT01389271|Tolerability
1144406|NCT01389271|Survival
1144407|NCT01389271|NYHA class III and IV
1144408|NCT01389219|Post partum
1144409|NCT01389219|Neonate
1144410|NCT01389219|community health care workers
1144411|NCT01389193|ibudilast
1144412|NCT01389193|migraine
1144413|NCT01389193|glial cell
1144414|NCT01389154|diagnostic yield
1144415|NCT01389154|Electromagnetic Tip Tracked
1144416|NCT01389154|peripheral lung lesion
1144417|NCT01389141|ovary
1144418|NCT01389141|follicle
1144419|NCT01389141|hormones
1144420|NCT01389141|bone
1144421|NCT01389141|muscle
1144422|NCT01389128|labor
1144423|NCT01389128|pain
1144424|NCT01389128|massage
1144425|NCT01389128|natural birth
1144426|NCT01389115|liver cirrhosis
1144427|NCT01389115|oxidative stress
1144428|NCT01389115|liver transplant
1144429|NCT01389102|Postmenopause
1144430|NCT01389102|Hot Flashes
1144431|NCT01389102|Estradiol
1144432|NCT01389102|Polyestradiol phosphate
1144433|NCT01389102|Estradiol valerate
1144434|NCT01389102|Estradiol 3-benzoate
1144435|NCT01389102|Estradiol 17 beta-cypionate
1144436|NCT01389102|Estrogens
1144437|NCT01389102|Hormones
1144438|NCT01389102|Hormones, Hormone Substitutes
1144439|NCT01389102|Hormone Antagonists
1144440|NCT01389089|edema reduction
1144441|NCT01389089|ice
1144442|NCT01389089|multi-layer compression bandage
1144443|NCT01389089|A-V Impulse compression
1144444|NCT01389089|ankle
1144445|NCT01389076|Previously Untreated, Advanced-Stage, Follicular Lymphoma
1144446|NCT01389063|endothelial function
1144447|NCT01389063|CCR5 receptor
1144448|NCT01389063|Maraviroc
1144449|NCT01389063|Abacavir
1144450|NCT01389063|Flow Mediated Dilatation
1144451|NCT01389063|EndoPAT
1144452|NCT01389037|African American
1144453|NCT01389037|High blood pressure
1144454|NCT01389024|sickle cell disease
1144455|NCT01389024|stroke
1144456|NCT01389024|silent cerebral infarct
1144457|NCT01389024|children
1144458|NCT01389011|PI
1144459|NCT01389011|PVI
1144460|NCT01389011|Interscalene block
1144461|NCT01388998|fluid management
1144462|NCT01388998|fluid therapy
1144463|NCT01388998|dPP
1144464|NCT01388998|difference in pulse pressure
1144465|NCT01388998|PVI
1144466|NCT01388998|pleth variability index
1144467|NCT01388998|external pressure applied on the caval vein
1144468|NCT01388985|Rabies
1144469|NCT01388985|Vaccination
1144470|NCT01388985|Boostability
1144471|NCT01388972|Community nutritional environment
1144472|NCT01388972|Physical activity
1144473|NCT01388946|acute postoperative pain
1144474|NCT01388946|late pain
1144475|NCT01388946|chronic pain
1144476|NCT01388946|wound irrigation with local anesthetic
1144477|NCT01388933|Crohn's Disease
1144478|NCT01388933|natural
1144479|NCT01388933|herbal
1144480|NCT01388933|Kampo
1144481|NCT01388933|inflammatory bowel disease
1144482|NCT01388933|Adult ages 18 to 75
1144483|NCT01388933|Male and female subjects
1144484|NCT01388920|COPD
1144485|NCT01388920|Muscle wasting
1144486|NCT01388907|myomectomy
1144487|NCT01388907|adhesion prevention
1144488|NCT01388907|pregnancy rate
1144489|NCT01388881|reading difficulties
1144490|NCT01388868|infusion dose
1144491|NCT01388868|vecuronium
1144492|NCT01388868|motor evoked potential
1144493|NCT01388868|neuromuscular blocking agent
1144494|NCT01388855|Heart Failure
1144495|NCT01388855|Vitamin D
1144496|NCT01388855|Pain
1144497|NCT01388855|Pilot Study
1144498|NCT01388855|RCT
1144499|NCT01388842|severe malaria
1144500|NCT01388842|children
1144501|NCT01388842|adjunctive treatment
1144502|NCT01388829|formulation comparison
1144503|NCT01388816|Randomized
1144504|NCT01388816|Double-Blind
1144505|NCT01388816|Placebo Controlled
1144506|NCT01388816|Parallel Arm
1144507|NCT01388816|Type II Hyperlipidemia
1144508|NCT01388816|Cholesteryl Ester Transferase Protein Inhibitor
1144509|NCT01388816|CETP Inhibitor
1144510|NCT01388803|bronchial blocker
1144511|NCT01388803|VATS
1144512|NCT01388790|Gastric Cancer
1144513|NCT01388790|Cetuximab
1144514|NCT01388790|EMD271786
1144515|NCT01388790|TS-1
1144516|NCT01388790|Cisplatin
1144523|NCT01388764|L-arginine supplement study
1144524|NCT01388751|Mallet Finger splinting
1144525|NCT01388738|Navigation Brain Stimulation (NEXSTIM)
1144526|NCT01388738|cerebroprotective drug effectiveness
1144527|NCT01388738|acute ischemic stroke
1144528|NCT01388725|sTREM-1
1144529|NCT01388725|sCD163
1144530|NCT01388725|PCT
1144531|NCT01388725|CRP
1144532|NCT01388725|WBC count
1144533|NCT01388725|SOFA score
1144534|NCT01388725|SIRS
1144535|NCT01388725|sepsis
1144536|NCT01388725|severity
1144537|NCT01388725|prognosis
1144538|NCT01388712|Probiotics
1144539|NCT01388712|constipation
1144540|NCT01388712|children
1144541|NCT01388699|Migraine with aura
1144542|NCT01388686|sepsis
1144543|NCT01388686|catheter
1144544|NCT01388686|blood stream infection
1144545|NCT01388686|blood culture
1144546|NCT01388673|prior RYGB procedure
1144547|NCT01388673|regained weight over time
1144548|NCT01388673|dilated pouch and/or stoma
1144549|NCT01388660|Healthy
1144550|NCT01388660|Platelet Aggregation Inhibitors
1144551|NCT01388660|Pharmacokinetics
1144552|NCT01388647|Neoadjuvant Treatment
1144553|NCT01388647|HER-2 Positive Breast Cancer
1144554|NCT01388634|Length of hospital stay
1144555|NCT01388634|readmission
1144556|NCT01388634|ventral hernia
1144557|NCT01388621|ovarian cancer
1144558|NCT01388621|fallopian cancer
1144559|NCT01388621|recurrent
1144560|NCT01388621|platinum-sensitive
1144561|NCT01388621|KRAS-Wildtype
1144562|NCT01388608|rheumatoid arthritis
1144563|NCT01388608|etanercept
1144564|NCT01388608|step activity measure
1144565|NCT01388582|contraceptives
1144566|NCT01388582|hormonal
1144567|NCT01388582|breastfeeding
1144568|NCT01388582|infant weight
1144569|NCT01388569|stage IV melanoma
1144570|NCT01388556|exercise
1144571|NCT01388556|Parkinson disease
1144572|NCT01388556|motor symptoms
1144573|NCT01388556|gait
1144574|NCT01388556|balance
1144575|NCT01388543|Pharmacokinetics
1144576|NCT01388543|Clinical Pharmacology
1144577|NCT01388543|Pharmacogenomics
1144578|NCT01388543|HIV
1144579|NCT01388517|Pityriasis alba
1144580|NCT01388517|Tacrolimus
1144581|NCT01388517|Calcitriol
1144582|NCT01388517|Petrolatum
1144583|NCT01388491|Contraception
1144584|NCT01388491|Hemostasis
1144585|NCT01388491|Blood Coagulation
1144586|NCT01388478|Safety
1144587|NCT01388478|Tolerability
1144588|NCT01388478|R(+)Pramipexole
1144589|NCT01388478|Alzheimer's
1144590|NCT01388465|Adherence
1144591|NCT01388465|Intervention
1144592|NCT01388452|HIV
1144593|NCT01388452|routine HIV testing
1144594|NCT01388452|provider-initiated HIV testing and counseling
1144595|NCT01388452|early infant diagnosis
1144596|NCT01388452|Africa South of the Sahara
1144597|NCT01388439|oseltamivir
1144598|NCT01388439|influenza
1144599|NCT01388439|neonate
1144600|NCT01388439|premature
1144601|NCT01388439|pharmacokinetics
1144602|NCT01388413|neurogenic bladder
1144603|NCT01388413|urinary tract infection
1144604|NCT01388400|stroke
1144605|NCT01388400|rehabilitation
1144606|NCT01388400|virtual reality
1144607|NCT01388400|upper limb
1144608|NCT01388387|pharmacogenetics
1144609|NCT01388387|pharmacokinetics
1144610|NCT01388387|tacrolimus
1144611|NCT01388387|genetic polymorphism
1144612|NCT01388387|CYP3A5
1144613|NCT01388387|liver transplantation
1144614|NCT01388374|Delivery of Health Care
1144615|NCT01388374|Nurse Practitioners
1144616|NCT01388374|Out of Hours Medical Care
1144617|NCT01388374|Primary Health Care
1144618|NCT01388374|Emergency Medical Services
1144619|NCT01388348|benign prostatic hyperplasia (BPH)
1144620|NCT01388348|acoustic vibration
1144621|NCT01388322|Pregnancy
1144622|NCT01388322|Preeclampsia
1144623|NCT01388322|Placental insufficiency
1144624|NCT01388283|prognostic marker
1144625|NCT01388270|Hemodialysis
1144626|NCT01388270|Anticoagulation
1144627|NCT01388270|Clotting
1144628|NCT01388270|Coagulation
1144629|NCT01388270|dalteparin
1144630|NCT01388270|Clotting in the extracorporeal system during HD
1144631|NCT01388270|Antithrombogenic property of Evodial HD filter
1144632|NCT01388270|Anticoagulation during HD
1144633|NCT01388257|Crohn Disease
1144634|NCT01388257|Anoperineal fistula
1144635|NCT01388257|Anal fistula
1144636|NCT01388257|Proctology
1144637|NCT01388257|Drainage
1144638|NCT01388257|Colorectal Surgery
1144639|NCT01388257|Fistulotomy
1144640|NCT01388257|Plug
1144641|NCT01388257|Advancement flap
1144642|NCT01388257|Glue
1144643|NCT01388257|Anti Tumor Necrosis Factor-alpha
1144644|NCT01388257|Adalimumab
1144645|NCT01388244|Screening
1144646|NCT01388244|Risk Assessment
1144647|NCT01388244|Fractures
1144648|NCT01388244|Absorptiometry, Photon
1144649|NCT01388244|Fracture prevention
1144650|NCT01388244|Women
1144651|NCT01388244|Patient prespective
1144652|NCT01388231|social phobia, cognitive-behavioral therapy, treatment
1144653|NCT01388218|Physical Activity
1144654|NCT01388218|Patient Reported Outcome (PRO)
1144655|NCT01388218|Chronic obstructive pulmonary disease (COPD)
1144656|NCT01388218|Innovative Medicines Initiative - Joint Undertaking (IMI-JU)
1144657|NCT01388205|Myopia
1144658|NCT01388205|Outdoor activity
1144659|NCT01388205|Physical activity
1144660|NCT01388205|Randomized Controlled Trial
1144661|NCT01388205|Pedometer
1144662|NCT01388205|Behavior modification
1144663|NCT01388205|Obesity
1144664|NCT01388192|Pancreaticoduodenectomy
1144665|NCT01388192|diabetes
1144666|NCT01388192|sugar metabolism
1144667|NCT01388179|Autism
1144668|NCT01388179|TMS
1144669|NCT01388153|Bioequivalence, acarbose, ODT
1144670|NCT01388140|dissociation
1144671|NCT01388140|psychosis
1144672|NCT01388140|trauma
1144673|NCT01388140|parenting
1144674|NCT01388140|executive functions
1144675|NCT01388114|Procalcitonin Measurement
1144676|NCT01388101|LECT2
1144677|NCT01388088|Hypertension
1144678|NCT01388088|Potassium
1144679|NCT01388088|Blood-pressure
1144680|NCT01388075|induction
1144681|NCT01388075|CYP2C9
1144682|NCT01388075|Genetic variability
1144683|NCT01388075|Expression
1144684|NCT01388062|influenza virus
1144685|NCT01388049|EV71
1144686|NCT01388036|heart rate
1144687|NCT01388023|SmellX
1144688|NCT01388023|malodor
1144689|NCT01388023|halitosis
1144690|NCT01388023|herbal formulation
1144691|NCT01388023|natural medicinals
1144692|NCT01388023|slow release delivery system
1144693|NCT01388023|gingivitis
1144694|NCT01388023|Bad Breath
1144695|NCT01388010|probiotics
1144696|NCT01388010|gastrointestinal well being
1144697|NCT01388010|digestive symptoms
1144698|NCT01388010|healthy population
1144699|NCT01387997|HPV
1144700|NCT01387984|Type 2 diabetes mellitus
1144701|NCT01387984|Diabetic complications
1144702|NCT01387984|YKL-40
1144703|NCT01387971|impression cytology
1144704|NCT01387971|ocular surface disorders
1144705|NCT01387971|ocular surface cells' variation
1144706|NCT01387971|Limbal insufficiency
1144707|NCT01387958|Hepatitis C virus
1144708|NCT01387958|Chronically infected
1144709|NCT01387958|treatment naive
1144710|NCT01387958|non responders to prior therapy
1144711|NCT01387945|Home blood pressure monitoring
1144712|NCT01387945|Patient activation
1144713|NCT01387945|Patient-centered care
1144714|NCT01387945|Community Health Aides
1144715|NCT01387945|Primary Health Care
1144716|NCT01387932|Hepatocellular carcinoma
1144717|NCT01387932|TACE
1144718|NCT01387932|HepaSphere Microspheres
1144719|NCT01387932|QuadraSphere Microspheres
1144720|NCT01387932|Doxorubicin
1144721|NCT01387919|Set time points during 48 hours of fasting
1144722|NCT01387906|mild
1144723|NCT01387906|moderate
1144724|NCT01387893|Benign Prostatic Hyperplasia
1144725|NCT01387893|BPH
1144726|NCT01387893|Lower Urinary Tract Symptoms
1144727|NCT01387893|LUTS
1144728|NCT01387893|Self-Administered Maneuver
1144729|NCT01387893|Symptomatic Relief
1144730|NCT01387893|Digital Repetitive Infrapubic Pressure maneuver
1144731|NCT01387880|Metastatic colorectal cancer
1144732|NCT01387880|Third line therapy
1144733|NCT01387880|Fourth line therapy
1144734|NCT01387880|KRAS mutation status
1144735|NCT01387880|Cetuximab
1144736|NCT01387880|Everolimus
1144737|NCT01387880|Irinotecan
1144738|NCT01387867|Exercise
1144739|NCT01387867|Hip osteoarthritis
1144740|NCT01387867|Randomized controlled trial
1144741|NCT01387841|yoga
1144742|NCT01387841|chemotherapy
1144743|NCT01387841|nausea
1144744|NCT01387841|vomiting
1144745|NCT01387828|Splenic artery
1144746|NCT01387828|Aneurysm
1144747|NCT01387828|laparoscopic
1144748|NCT01387828|Vascular reconstruction
1144749|NCT01387828|Splenectomy
1144750|NCT01387815|Adalimumab
1144751|NCT01387815|Psoriasis
1144752|NCT01387815|Topical Agents
1144753|NCT01387815|Observational
1144754|NCT01387815|Traditional Systemic Agents
1144755|NCT01387815|Prospective
1144756|NCT01387815|Comparative
1144757|NCT01387815|Effectiveness
1144758|NCT01387802|Assessing Effectiveness in Ankylosing Spondylitis
1144759|NCT01387789|Product Surveillance
1144760|NCT01387789|Postmarketing
1144761|NCT01387750|Acute Pain
1144762|NCT01387750|Musculoskeletal Pain
1144763|NCT01387750|Topical Analgesic
1144764|NCT01387737|TA-7284
1144765|NCT01387737|JNJ-28431754
1144766|NCT01387737|Canagliflozin
1144767|NCT01387737|Sodium Glucose Co-Transporter (SGLT2 inhibitor)
1144768|NCT01387724|disseminated neuroblastoma
1144769|NCT01387724|localized resectable neuroblastoma
1144770|NCT01387724|localized unresectable neuroblastoma
1144771|NCT01387724|regional neuroblastoma
1144772|NCT01387724|stage 4S neuroblastoma
1144773|NCT01387672|postmenopausal
1144774|NCT01387672|osteoporosis
1144775|NCT01387672|bone turnover
1144776|NCT01387672|nitrate
1144777|NCT01387672|headache
1144778|NCT01387659|Myfortic
1144779|NCT01387659|Simulect
1144780|NCT01387659|Steroids
1144781|NCT01387659|Diabetes
1144782|NCT01387659|Transplant
1144783|NCT01387659|Gastric emptying
1144784|NCT01387659|Gastric motility
1144785|NCT01387646|STI, abuse, substance use, unintended pregnancy
1144786|NCT01387633|Nursing care
1144787|NCT01387633|Diabetes mellitus
1144788|NCT01387633|Health Education
1144789|NCT01387633|Patient compliance
1144790|NCT01387633|Social support
1144791|NCT01387633|Self-efficacy
1144792|NCT01387633|Adaptation strategy
1144793|NCT01387620|Phacoemulsification
1144794|NCT01387620|Corneal Edema
1144795|NCT01387620|Corneal Endothelium
1144796|NCT01387620|Viscoelastic Substances
1144797|NCT01387607|Pregabalin
1144798|NCT01387607|fibromyalgia
1144799|NCT01387594|Crohn's disease lumbar puncture anti-MAdCAM monoclonal antibody PF-00547659 Ulcerative Colitis
1144800|NCT01387555|liver cancer
1144801|NCT01387555|liver tumor
1144802|NCT01387555|advanced hcc
1144803|NCT01387555|hepatocellular cancer
1144804|NCT01387555|Jennerex
1144805|NCT01387555|HCC
1144806|NCT01387555|sorafenib
1144807|NCT01387555|sorafenib failure
1144808|NCT01387555|sorafenib intolerant
1144809|NCT01387555|Nexavar
1144810|NCT01387555|Nexavar failure
1144811|NCT01387555|JX594
1144812|NCT01387555|oncolytic virus
1144813|NCT01387555|vaccinia
1144814|NCT01387555|viral therapy
1144815|NCT01387555|JX
1144816|NCT01387555|Biotherapeutics
1144817|NCT01387555|HEP018
1144818|NCT01387555|traverse
1144819|NCT01387555|biologic
1144820|NCT01387555|Pexa-Vec
1144821|NCT01387542|Schizophrenia
1144822|NCT01387542|Paliperidone Extended Release (ER)
1144823|NCT01387542|INVEGA
1144824|NCT01387529|Reference Values
1144825|NCT01387516|nicotine
1144826|NCT01387516|juveniles
1144827|NCT01387516|detention
1144828|NCT01387503|Hepatocellular Carcinoma
1144829|NCT01387503|Liver Transplantation
1144830|NCT01387503|Downstaging
1144831|NCT01387503|Trans-arterial chemoembolization (TACE)
1144832|NCT01387503|Radiofrequency ablation (RFA)
1144833|NCT01387503|Liver resection
1144834|NCT01387503|Sorafenib
1144835|NCT01387490|Mild Traumatic Brain Injury
1144836|NCT01387490|Telephone counseling
1144837|NCT01387477|hypoglycemia
1144838|NCT01387477|lactate
1144839|NCT01387477|glucose
1144840|NCT01387477|ICU
1144841|NCT01387464|bromfenac concentrations
1144842|NCT01387464|ISV-303
1144843|NCT01387464|Bromday
1144844|NCT01387451|Brown adipose tissue
1144845|NCT01387451|Different regions
1144846|NCT01387451|Chinese adults
1144847|NCT01387438|Brown Adipose Tissue
1144848|NCT01387438|Cross sectional study
1144849|NCT01387438|Chinese Adults
1144850|NCT01387438|Factor
1144851|NCT01387425|Smoking cessation of diabetic smoker
1144852|NCT01387412|genital warts
1144853|NCT01387412|HIV
1144854|NCT01387412|MSM
1144855|NCT01387412|Peru
1144856|NCT01387412|HPV
1144857|NCT01387399|ovarian cancer
1144858|NCT01387399|recurrence
1144859|NCT01387399|platinum-sensitive recurrent ovarian cancer
1144860|NCT01387399|HIPEC
1144861|NCT01387399|intraperitoneal chemotherapy
1144862|NCT01387399|hyperthermic intraperitoneal chemoperfusion
1144863|NCT01387399|cisplatin
1144864|NCT01387373|breast cancer
1144865|NCT01387373|metastatic
1144866|NCT01387373|liver metastases
1144867|NCT01387373|intrahepatic
1144868|NCT01387373|chemotherapy
1144869|NCT01387360|Myopia
1144870|NCT01387360|Hyperopia
1144871|NCT01387360|Presbyopia
1144872|NCT01387360|Pseudophakia
1144873|NCT01387360|LASIK
1144874|NCT01387347|Thymosin beta 4
1144875|NCT01387347|Dry eye syndrome
1144876|NCT01387347|Dry eye
1144877|NCT01387334|resistive exercise
1144878|NCT01387334|Resistance Exercise Training Program
1144879|NCT01387334|Rubber Bands
1144880|NCT01387334|Glycemic Control
1144881|NCT01387334|Type 2 Diabetes Mellitus
1144882|NCT01387321|Pi3K
1144883|NCT01387321|Advanced solid tumor
1144884|NCT01387308|Phase 1
1144885|NCT01387308|Healthy male volunteers
1144886|NCT01387308|pharmacokinetics
1144887|NCT01387308|fostamatinib
1144888|NCT01387308|Scientific Terminology: Bioavailability, R406 plasma AUC and C_maxR406 plasma AUC0-t, t1/2λz and t_max
1144889|NCT01387308|Laymen Terminology: Amount of R406 in blood
1144890|NCT01387295|breast cancer
1144891|NCT01387295|liver metastases
1144892|NCT01387295|intrahepatic chemotherapy
1144893|NCT01387256|abortion
1144894|NCT01387256|mifepristone
1144895|NCT01387256|misoprostol
1144896|NCT01387256|with gestations > 63 days LMP
1144897|NCT01387243|behavior modification
1144898|NCT01387243|overweight
1144899|NCT01387243|orlistat
1144900|NCT01387230|chronic obstructive pulmonary disease
1144901|NCT01387230|long acting muscarinic antagonist
1144902|NCT01387217|GSK2018682
1144903|NCT01387217|First Time in Human
1144904|NCT01387217|Healthy Volunteer
1144905|NCT01387204|MEK inhibitor
1144906|NCT01387204|elimination
1144907|NCT01387204|Phase 1
1144908|NCT01387204|GSK1120212
1144909|NCT01387204|cancer
1144910|NCT01387204|Pharmacokinetics
1144911|NCT01387204|oncology
1144912|NCT01387204|radiolabeled ADME
1144913|NCT01387178|chronic obstructive pulmonary disease
1144914|NCT01387178|cost and cost analysis
1144915|NCT01387178|bronchodilators
1144916|NCT01387178|healthcare utilization
1144917|NCT01387178|fluticasone propionate/salmeterol
1144918|NCT01387178|tiotropium
1144919|NCT01387165|Latin America
1144920|NCT01387165|diabetes complications
1144921|NCT01387165|patient compliance
1144922|NCT01387165|Diabetes mellitus, type 2
1144923|NCT01387165|health services accessibility
1144924|NCT01387152|chest pain
1144925|NCT01387152|myocardial perfusion scintigraphy
1144926|NCT01387152|nuclear stress testing
1144927|NCT01387152|low radiation dose
1144928|NCT01387139|Ketamine
1144929|NCT01387139|Propofol
1144930|NCT01387139|Procedural Sedation and Analgesia
1144931|NCT01387113|stroke
1144932|NCT01387113|tPA
1144933|NCT01387113|Thrombolysis
1144934|NCT01387113|rt-PA
1144935|NCT01387113|Ischemic
1144936|NCT01387113|CTP
1144937|NCT01387113|Imaging
1144938|NCT01387113|CT Perfusion Imaging
1144939|NCT01387113|Perfusion
1144940|NCT01387113|CTA
1144941|NCT01387113|CT Angiography
1144942|NCT01387113|Acute ischemic stroke
1144943|NCT01387113|Acute stroke therapy
1144944|NCT01387113|(AIS)
1144945|NCT01387100|supportive employment
1144946|NCT01387100|vocational rehabilitation
1144947|NCT01387087|ASP015K
1144948|NCT01387087|Healthy subjects
1144949|NCT01387087|Pharmacodynamics
1144950|NCT01387087|Maximum tolerated dose
1144951|NCT01387061|liver resection
1144952|NCT01387061|hepatic resection
1144953|NCT01387061|intraoperative ultrasound
1144954|NCT01387048|acne vulgaris
1144955|NCT01387048|late-type acne
1144956|NCT01387048|Skinoren
1144957|NCT01387048|maintenance
1144958|NCT01387022|Antiretroviral treatment
1144959|NCT01387022|Tenofovir
1144960|NCT01387022|Drug resistance
1144961|NCT01387022|Treatment outcome
1144962|NCT01386983|Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, acute urinary retention, surgery, early, costs
1144963|NCT01386983|benign prostatic hyperplasia
1144964|NCT01386970|Pharmacokinetics
1144965|NCT01386970|antiretroviral therapy
1144966|NCT01386970|nucleoside analogs
1144967|NCT01386970|mitochondrial toxicity
1144968|NCT01386970|clinical pharmacology
1144969|NCT01386970|cellular pharmacology
1144970|NCT01386970|pharmacogenetics
1144971|NCT01386957|Nephrotic Syndrome
1144972|NCT01386957|Steroid treatment
1144973|NCT01386957|Proteinuria
1144974|NCT01386957|Child
1144975|NCT01386944|Rotigotine
1144976|NCT01386944|Neupro®
1144977|NCT01386944|Augmentation
1144978|NCT01386944|Restless Legs Syndrome
1144979|NCT01386944|Moderate to severe
1144980|NCT01386944|idiopathic
1144981|NCT01386944|adults
1144982|NCT01386931|Biopsy, Fine-Needle
1144983|NCT01386931|Endoscopic Ultrasonography
1144984|NCT01386931|cytopathology
1144985|NCT01386918|Hallucinations
1144986|NCT01386918|Schizophrenia
1144987|NCT01386905|Obesity
1144988|NCT01386879|suction
1144989|NCT01386879|aspiration
1144990|NCT01386879|general anesthesia
1144991|NCT01386879|intubation
1144992|NCT01386879|endotracheal tube
1144993|NCT01386879|respiratory complications
1144994|NCT01386866|AMG 706
1144995|NCT01386866|Motesanib
1144996|NCT01386866|Amgen
1144997|NCT01386866|Phase 1
1144998|NCT01386853|Hyperlipidemia
1144999|NCT01386853|Pitavastatin
1145000|NCT01386853|Atorvastatin
1145001|NCT01386840|Efficacy of Treatment
1145002|NCT01386840|Severe
1145003|NCT01386840|home treatment
1145004|NCT01386840|treatment at hospital
1145005|NCT01386827|Ixiaro
1145006|NCT01386827|japanese encephalitis vaccine
1145007|NCT01386827|booster
1145008|NCT01386801|Diabetes
1145009|NCT01386801|Controls
1145010|NCT01386801|Biospecimen
1145011|NCT01386788|Smoke, cyanide, closed space fires
1145012|NCT01386775|X-Linked Hypohidrotic Ectodermal Dysplasia
1145013|NCT01386775|XLHED
1145014|NCT01386775|Hypohidrotic Ectodermal Dysplasia
1145015|NCT01386775|HED
1145016|NCT01386762|paralysis
1145017|NCT01386762|paraplegia
1145018|NCT01386762|obesity
1145019|NCT01386749|Vibration treatment
1145020|NCT01386749|Fracture healing
1145021|NCT01386749|Muscular function
1145022|NCT01386736|insulin resistance
1145023|NCT01386736|obesity
1145024|NCT01386736|adolescence
1145025|NCT01386736|vitamin D supplementation
1145026|NCT01386723|eltrombopag
1145027|NCT01386723|promacta
1145028|NCT01386723|immune thrombocytopenia (ITP)
1145029|NCT01386710|GBM
1145030|NCT01386710|AA
1145031|NCT01386710|AO
1145032|NCT01386710|Brain
1145033|NCT01386710|Tumors
1145034|NCT01386710|Malignant
1145035|NCT01386710|Glioblastoma
1145036|NCT01386710|Multiforme
1145037|NCT01386710|Anaplastic
1145038|NCT01386710|Astrocytoma
1145039|NCT01386684|Prostate Cancer
1145040|NCT01386671|Type 2 Diabetes
1145041|NCT01386671|metformin glycinate
1145042|NCT01386671|metabolic control
1145043|NCT01386658|Efficacy
1145044|NCT01386658|Hereditary angioedema
1145045|NCT01386658|HAE
1145046|NCT01386658|Pediatric
1145047|NCT01386658|Children
1145048|NCT01386658|Pharmacokinetics
1145049|NCT01386658|Safety
1145050|NCT01386658|Firazyr
1145051|NCT01386658|icatibant
1145052|NCT01386645|impaired glucose tolerance
1145053|NCT01386645|prediabetes
1145054|NCT01386645|dietary glycemic index
1145055|NCT01386645|beta-cell function
1145056|NCT01386645|insulin secretion
1145057|NCT01386645|oxidative stress
1145058|NCT01386645|glycemic variability
1145059|NCT01386632|Stage III-IV Squamous Cell Carcinoma
1145060|NCT01386593|Cytochrome
1145061|NCT01386593|Phenotyping
1145062|NCT01386593|Pharmacokinetics
1145063|NCT01386580|Brain Neoplasms
1145064|NCT01386580|Neoplasm Metastasis
1145065|NCT01386580|Neoplasms
1145066|NCT01386580|Central Nervous System Neoplasms
1145067|NCT01386580|Nervous System Neoplasms
1145068|NCT01386580|Neoplasms by Site
1145069|NCT01386580|Brain Diseases
1145070|NCT01386580|Central Nervous System Diseases
1145071|NCT01386580|Nervous System Diseases
1145072|NCT01386580|Neoplastic Processes
1145073|NCT01386580|Pathologic Processes
1145074|NCT01386567|hypogonadism
1145075|NCT01386567|low testosterone
1145076|NCT01386567|low T
1145077|NCT01386554|H.P. Acthar Gel
1145078|NCT01386554|Acthar
1145079|NCT01386554|nephrotic syndrome
1145080|NCT01386554|idiopathic membranous nephropathy
1145081|NCT01386554|proteinuria
1145082|NCT01386515|Adaptation
1145083|NCT01386515|Duchenne Muscular Dystrophy
1145084|NCT01386515|Communication about Duchenne Muscular Dystrophy
1145085|NCT01386515|Sibling
1145086|NCT01386502|Solid Tumors
1145087|NCT01386502|Monoclonal Antibody
1145088|NCT01386502|Peptide Vaccine
1145089|NCT01386502|Toxicity
1145090|NCT01386502|PD-1 ligand
1145091|NCT01386502|Solid Tumor
1145092|NCT01386502|Breast Cancer
1145093|NCT01386502|Ovarian Cancer
1145094|NCT01386502|Pancreatic Cancer
1145095|NCT01386502|Colon Cancer
1145096|NCT01386502|Sarcoma
1145097|NCT01386489|HIV-uninfected
1145098|NCT01386489|Mucosal Immunity
1145099|NCT01386489|Kinetics
1145100|NCT01386489|Cytokines
1145101|NCT01386489|Chemokines
1145102|NCT01386489|Healthy Volunteer
1145103|NCT01386489|HV
1145104|NCT01386476|5-HT1A Receptors
1145105|NCT01386476|Blood Brain Barrier
1145106|NCT01386476|Drug Resistance
1145107|NCT01386476|Healthy Volunteer
1145108|NCT01386476|HV
1145109|NCT01386437|Fungal Infection
1145110|NCT01386437|Immunopathogenesis
1145111|NCT01386437|Genetics
1145112|NCT01386437|Fungal Infections
1145113|NCT01386437|Mucocutaneous Fungal Infection
1145114|NCT01386437|Invasive Fungal Infection
1145115|NCT01386424|Influenza
1145116|NCT01386424|Human
1145117|NCT01386424|Challenge Study
1145118|NCT01386424|Healthy Volunteer
1145119|NCT01386424|HV
1145120|NCT01386411|Genetic testing
1145121|NCT01386411|BRCA testing
1145122|NCT01386411|Ashkenazi descent
1145123|NCT01386411|11-086
1145124|NCT01386398|stage II mycosis fungoides/Sezary syndrome
1145125|NCT01386398|stage III mycosis fungoides/Sezary syndrome
1145126|NCT01386398|stage IV mycosis fungoides/Sezary syndrome
1145127|NCT01386398|stage II cutaneous T-cell non-Hodgkin lymphoma
1145128|NCT01386398|stage III cutaneous T-cell non-Hodgkin lymphoma
1145129|NCT01386398|stage IV cutaneous T-cell non-Hodgkin lymphoma
1145130|NCT01386398|recurrent mycosis fungoides/Sezary syndrome
1145131|NCT01386398|recurrent cutaneous T-cell non-Hodgkin lymphoma
1145132|NCT01386372|Hyponatremia
1145133|NCT01386372|Vasopressin
1145134|NCT01386372|Tolvaptan
1145135|NCT01386372|SIADH
1145136|NCT01386346|gastroesophageal junction
1145137|NCT01386346|GEJ
1145138|NCT01386346|esophageal
1145139|NCT01386346|esophagus
1145140|NCT01386333|Frontotemporal Dementia
1145141|NCT01386333|oxytocin
1145142|NCT01386333|Pick's disease
1145143|NCT01386320|anaesthetic techniques, regional; surgery orthopaedic
1145144|NCT01386307|Pain
1145145|NCT01386307|Hospitalization
1145146|NCT01386281|Julina
1145147|NCT01386281|Postmenopausal osteoporosis
1145148|NCT01386268|Kogenate FS
1145149|NCT01386268|Hemophilia A
1145150|NCT01386255|GERD
1145151|NCT01386242|Colorectal Cancer
1145152|NCT01386242|Novaferon
1145153|NCT01386229|hemodynamic stability
1145154|NCT01386229|etomidate
1145155|NCT01386229|ketamine
1145156|NCT01386229|coronary artery bypass surgery after induction of anesthesia, hemodynamic stability
1145157|NCT01386216|Critical limb ischemia
1145158|NCT01386216|Peripheral vascular disease
1145159|NCT01386216|platelet-rich plasma
1145160|NCT01386203|lung cancer
1145161|NCT01386203|biomarkers
1145162|NCT01386203|breath
1145163|NCT01386203|early detection
1145164|NCT01386190|preterm infant, body composition, exercise
1145165|NCT01386177|MDMA
1145166|NCT01386177|doxazosin
1145167|NCT01386177|norepinephrine
1145168|NCT01386177|alpha1- receptor
1145169|NCT01386177|ecstasy
1145170|NCT01386177|stimulants
1145171|NCT01386151|Moderate asthmatic, uncontrolled
1145172|NCT01386138|HIV
1145173|NCT01386138|HIV Risk
1145174|NCT01386138|Sexually Transmitted Infections
1145175|NCT01386138|Women
1145176|NCT01386138|Pregnancy
1145177|NCT01386138|Neonatal Health
1145178|NCT01386138|Drug Use
1145179|NCT01386138|Drug Treatment
1145180|NCT01386138|Gender-specific Treatment
1145181|NCT01386138|Methamphetamine
1145182|NCT01386138|Opioids
1145183|NCT01386138|Cocaine
1145184|NCT01386138|Injection Drugs
1145185|NCT01386138|Stimulants
1145186|NCT01386138|Alcohol
1145187|NCT01386138|Mandrax
1145188|NCT01386138|Marijuana
1145189|NCT01386138|Nicotine
1145190|NCT01386086|Aripiprazole
1145191|NCT01386086|adjunctive therapy
1145192|NCT01386086|mood stabilizers
1145193|NCT01386086|major depressive disorder
1145194|NCT01386086|postpartum
1145195|NCT01386086|Augmentation therapy
1145196|NCT01386086|resistant
1145197|NCT01386060|Stress
1145198|NCT01386060|Mindfulness
1145199|NCT01386060|Meditation
1145200|NCT01386047|Clinical Prediction Rules
1145201|NCT01386047|Electronic Health Records
1145202|NCT01386047|Walsh Clinical Prediction Rule
1145203|NCT01386047|Heckerling Clinical Prediction Rule
1145204|NCT01386034|Nutrition, protein metabolism, stable isotopes, mass spectrometry, intestinal failure
1145205|NCT01386021|allograft
1145206|NCT01386021|coronary
1145207|NCT01386021|patency
1145208|NCT01386021|morbidity
1145209|NCT01385969|overinflation of LMAs
1145210|NCT01385956|metastatic
1145211|NCT01385956|locally advanced
1145212|NCT01385956|combination therapy
1145213|NCT01385956|dose escalation
1145214|NCT01385956|epithelial cancer
1145215|NCT01385956|adenocarcinoma
1145216|NCT01385956|exocrine pancreas
1145217|NCT01385943|Reflectance Confocal Microscopy
1145218|NCT01385943|Dermoscopy
1145219|NCT01385943|Clinical Photos
1145220|NCT01385943|Telemedicine
1145221|NCT01385930|Overweight
1145222|NCT01385930|Obesity
1145223|NCT01385930|lifestyle counseling
1145224|NCT01385917|Duchenne Muscular Dystrophy
1145225|NCT01385917|strength and function tests
1145226|NCT01385917|MRI
1145227|NCT01385878|Microcoaxial phacoemulsification, 1.8mm, 2.2mm
1145228|NCT01385852|CME
1145229|NCT01385852|OCT
1145230|NCT01385852|Optical coherence tomography
1145231|NCT01385852|macular thickness
1145232|NCT01385839|Alopecia
1145233|NCT01385839|Hair transplantation
1145234|NCT01385839|Needle irritation
1145235|NCT01385839|Medical needling
1145236|NCT01385826|Uveitis
1145237|NCT01385826|Juvenile arthritis
1145238|NCT01385826|Anti-tumor necrosis factor alpha monoclonal antibody
1145239|NCT01385826|treatment
1145240|NCT01385813|pre-eclampsia
1145241|NCT01385813|inflammatory markers
1145242|NCT01385813|serological biobank
1145243|NCT01385813|To assess whether the inflammatory markers could be useful
1145244|NCT01385813|in order to identify pregnant women at risk to
1145245|NCT01385813|develop preeclampsia
1145246|NCT01385800|Grass allergy
1145247|NCT01385800|Rhinoconjunctivitis
1145248|NCT01385800|Environmental Exposure Unit
1145249|NCT01385800|Immunotherapy
1145250|NCT01385800|ToleroMune Grass
1145251|NCT01385787|Pediatric (ages 0-21 years)
1145252|NCT01385787|myeloablative HCT
1145253|NCT01385787|PBMTC sites
1145254|NCT01385774|Intermittent Claudication
1145255|NCT01385774|Percutaneous Transluminal Angioplasty
1145256|NCT01385774|Supervised Exercise Therapy
1145257|NCT01385774|Peripheral Arterial Disease
1145258|NCT01385761|Supraglottic airway devices
1145259|NCT01385735|Parkinson Disease
1145260|NCT01385735|Emotion
1145261|NCT01385735|mood
1145262|NCT01385735|executive function
1145263|NCT01385709|Lithium
1145264|NCT01385709|Sertraline
1145265|NCT01385683|Healthy volunteer
1145266|NCT01385683|Pharmacokinetic
1145267|NCT01385683|pharmacodynamic
1145268|NCT01385683|Polymorphism, Genetic
1145269|NCT01385670|Patent Foramen Ovale
1145270|NCT01385670|PFO
1145271|NCT01385644|Mesenchymal stem cells
1145272|NCT01385644|Idiopathic pulmonary fibrosis
1145273|NCT01385631|ST-Segment Elevation Myocardial Infarction
1145274|NCT01385631|Intravascular ultrasound
1145275|NCT01385631|IVUS
1145276|NCT01385631|Optical coherence tomography
1145277|NCT01385631|OCT
1145278|NCT01385631|Ezetimibe
1145279|NCT01385631|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1145280|NCT01385631|Atorvastatin
1145281|NCT01385631|Randomized trial
1145282|NCT01385631|Hypolipidemic Agents
1145283|NCT01385631|Molecular Mechanisms of Pharmacological Action
1145284|NCT01385631|Pharmacologic Actions
1145285|NCT01385631|Enzyme Inhibitors
1145286|NCT01385631|Lipid Regulating Agents
1145287|NCT01385631|Therapeutic Uses
1145288|NCT01385592|Parkinson Disease
1145289|NCT01385592|L-dopa
1145290|NCT01385592|Levodopa
1145291|NCT01385592|Dyskinesia
1145292|NCT01385592|Anti-Dyskinesia Agents
1145293|NCT01385579|colorectal cancer screening
1145294|NCT01385579|fecal occult blood testing (FOBT)
1145295|NCT01385579|vulnerable populations
1145296|NCT01385579|community health center
1145297|NCT01385540|Tinnitus, fMRI, task-based fMRI, attention network
1145298|NCT01385488|lymphedema
1145299|NCT01385488|breast cancer
1145300|NCT01385488|self care
1145301|NCT01385488|bioelectrical impedance
1145302|NCT01385488|monitoring
1145303|NCT01385475|Resistance Training
1145304|NCT01385475|Physical Function
1145305|NCT01385475|Older Adults
1145306|NCT01385449|nerve block
1145307|NCT01385449|shoulder surgery
1145308|NCT01385449|physical therapy
1145309|NCT01385436|human papillomavirus (HPV)
1145310|NCT01385436|cervical cancer
1145311|NCT01385436|high grade cervical squamous intraepithelial lesion (HSIL)
1145312|NCT01385423|acute myelogenous leukemia
1145313|NCT01385423|natural killer cells
1145314|NCT01385423|haploidentical donor
1145315|NCT01385410|breastfeeding exclusively
1145316|NCT01385397|Health system organization
1145317|NCT01385345|Vitamin D deficiency
1145318|NCT01385345|Insulin resistance
1145319|NCT01385332|Metaphase II
1145320|NCT01385332|Ovarian stimulation
1145321|NCT01385332|Egg donors
1145322|NCT01385319|Bare metal stent
1145323|NCT01385319|zotarolimus eluting stent
1145324|NCT01385319|triple anti-thrombotic therapy
1145325|NCT01385319|high bleeding riskduration of dual anti-platelet therapy
1145326|NCT01385293|BKM120
1145327|NCT01385293|prostate cancer
1145328|NCT01385293|metastatic castrate-resistant prostate cancer (mCRPC)
1145329|NCT01385254|very low birthweight
1145330|NCT01385254|premature
1145331|NCT01385254|sibling adjustment
1145332|NCT01385254|preterm
1145333|NCT01385241|Human Immunodeficiency Virus (HIV)
1145334|NCT01385241|Stigma
1145335|NCT01385241|Safe disclosure of seropositive status
1145336|NCT01385241|HIV positive women
1145337|NCT01385241|Self-efficacy
1145338|NCT01385228|prostate cancer
1145339|NCT01385228|metastatic
1145340|NCT01385228|pazopanib
1145341|NCT01385228|docetaxel
1145342|NCT01385228|metastatic prostate cancer
1145343|NCT01385215|Vaccination
1145344|NCT01385215|Mucosal Immunity
1145345|NCT01385215|Nasal Immunization
1145346|NCT01385202|Atrial Fibrillation
1145347|NCT01385202|Paroxysmal Atrial Fibrillation
1145348|NCT01385189|Human Hookworm Vaccine Initiative
1145349|NCT01385189|HHVI
1145350|NCT01385189|Human Hookworm
1145351|NCT01385189|Hookworm
1145352|NCT01385189|Hookworm Disease
1145353|NCT01385189|N. americanus
1145354|NCT01385189|Soil-transmitted helminth infection
1145355|NCT01385189|Intestinal blood loss
1145356|NCT01385189|Iron deficiency anemia
1145357|NCT01385176|Heart failure
1145358|NCT01385176|Congestive heart failure
1145359|NCT01385176|New York Heart Association Class II-III
1145360|NCT01385176|Vagal therapy
1145361|NCT01385176|Vagal nerve stimulation
1145362|NCT01385163|mental health
1145363|NCT01385163|gender-based violence
1145364|NCT01385163|Africa
1145365|NCT01385150|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1145366|NCT01385150|adult acute myeloid leukemia with inv(16)(p13;q22)
1145367|NCT01385150|adult acute myeloid leukemia with t(16;16)(p13;q22)
1145368|NCT01385150|adult acute myeloid leukemia with t(8;21)(q22;q22)
1145369|NCT01385150|untreated adult acute myeloid leukemia
1145370|NCT01385150|adult acute basophilic leukemia
1145371|NCT01385150|adult acute eosinophilic leukemia
1145372|NCT01385150|adult erythroleukemia (M6a)
1145373|NCT01385150|adult pure erythroid leukemia (M6b)
1145374|NCT01385150|adult acute minimally differentiated myeloid leukemia (M0)
1145375|NCT01385150|adult acute monoblastic leukemia (M5a)
1145376|NCT01385150|adult acute monocytic leukemia (M5b)
1145377|NCT01385150|adult acute myeloblastic leukemia with maturation (M2)
1145378|NCT01385150|adult acute myeloblastic leukemia without maturation (M1)
1145379|NCT01385150|adult acute myelomonocytic leukemia (M4)
1145380|NCT01385137|estrogen receptor-positive breast cancer
1145381|NCT01385137|progesterone receptor-positive breast cancer
1145382|NCT01385137|stage I breast cancer
1145383|NCT01385137|stage II breast cancer
1145384|NCT01385137|stage IIIA breast cancer
1145385|NCT01385137|pain
1145386|NCT01385137|arthralgia
1145387|NCT01385124|Cannabidiol
1145388|NCT01385124|GVHD
1145389|NCT01385124|Allogeneic transplantation
1145390|NCT01385124|Prophylaxis
1145391|NCT01385111|endobronchial ultrasound
1145392|NCT01385111|endoscopic ultrasound
1145393|NCT01385111|EBUS-TBNA
1145394|NCT01385111|EUS-FNA
1145395|NCT01385111|EUS-B-FNA
1145396|NCT01385111|lung cancer
1145397|NCT01385111|staging
1145398|NCT01385098|Vitamin D
1145399|NCT01385098|Bariatric surgery
1145400|NCT01385098|Roux-en Y surgery
1145401|NCT01385098|Gastric sleeve surgery
1145402|NCT01385098|Parathyroid Hormone
1145403|NCT01385085|Vitamin D
1145404|NCT01385085|Sunlight
1145405|NCT01385085|Deficiency
1145406|NCT01385072|acute leukemia
1145407|NCT01385072|relapse
1145408|NCT01385072|induction failure
1145409|NCT01385072|allogeneic transplantation
1145410|NCT01385072|graft versus leukemia effect
1145411|NCT01385046|physical inactivity
1145412|NCT01385046|poor diet
1145413|NCT01385020|Red yeast rice
1145414|NCT01385020|Gemfibrozil
1145415|NCT01385020|Drug-drug interaction
1145416|NCT01385020|Pharmacokinetics
1145417|NCT01385007|Rural
1145418|NCT01385007|Veterans
1145419|NCT01385007|Dementia
1145420|NCT01385007|Pain
1145421|NCT01385007|Aggression
1145422|NCT01385007|residence in a VA designated rural area
1145423|NCT01385007|presence of a caregiver
1145424|NCT01384994|Colorectal Cancer
1145425|NCT01384994|PARLIM
1145426|NCT01384994|KRAS Wildtype
1145427|NCT01384994|Liver metastases
1145428|NCT01384981|chronic obstructive pulmonary rehabilitation
1145429|NCT01384981|COPD
1145430|NCT01384981|non invasive ventilation
1145431|NCT01384981|NIV
1145432|NCT01384981|exercise capacity
1145433|NCT01384981|pulmonary rehabilitation
1145434|NCT01384968|nitrite
1145435|NCT01384968|exercise
1145436|NCT01384968|cycling
1145437|NCT01384955|scoliosis
1145438|NCT01384955|physical therapy
1145439|NCT01384955|long term outcome
1145440|NCT01384955|pulmonary function
1145441|NCT01384955|physical fitness
1145442|NCT01384955|health related quality of life
1145443|NCT01384955|psychopathology
1145444|NCT01384942|Bereavement
1145445|NCT01384942|Grief
1145446|NCT01384942|Mourning
1145447|NCT01384942|Loss
1145448|NCT01384942|Death
1145449|NCT01384942|Meaning
1145450|NCT01384942|Group
1145451|NCT01384942|Counseling
1145452|NCT01384942|Psychotherapy
1145453|NCT01384942|Uncomplicated
1145454|NCT01384942|Support
1145455|NCT01384916|depression
1145456|NCT01384916|yoga
1145457|NCT01384916|health education
1145458|NCT01384916|antidepressant
1145459|NCT01384877|Pain
1145460|NCT01384877|Cancer
1145461|NCT01384877|Lidocaine
1145462|NCT01384877|Sodium Channel Blockers
1145463|NCT01384864|barrett's esophagus
1145464|NCT01384864|intraepithelial neoplasia
1145465|NCT01384864|cross polarized reflectance examination
1145466|NCT01384864|vital-dye enhanced fluorescence examination
1145467|NCT01384838|breast cancer
1145468|NCT01384838|physical activity
1145469|NCT01384838|sports
1145470|NCT01384838|exercise
1145471|NCT01384825|Multiple Sclerosis
1145472|NCT01384825|Other Neurodegenerative Diseases
1145473|NCT01384825|Chronic CerebroSpinal Venous Insufficiency
1145474|NCT01384825|Prevalence
1145475|NCT01384825|Case-control
1145476|NCT01384773|Keratoconus
1145477|NCT01384773|Ectasia
1145478|NCT01384773|UVA light
1145479|NCT01384773|riboflavin
1145480|NCT01384773|post-LASIK (laser in situ keratomileusis)
1145481|NCT01384773|pellucid marginal degeneration
1145482|NCT01384773|irregular astigmatism
1145483|NCT01384721|Computed Tomography Coronary Angiography
1145484|NCT01384721|Coronary Artery Disease
1145485|NCT01384721|Prevalence Of Disease
1145486|NCT01384721|Prognosis
1145487|NCT01384721|Risk Stratification
1145488|NCT01384708|squamous cell cancer
1145489|NCT01384708|squamous cell neoplasia
1145490|NCT01384695|Barrett's esophagus
1145491|NCT01384695|confocal microendoscopy
1145492|NCT01384617|distal pancreatectomy
1145493|NCT01384617|pancreatic fistula
1145494|NCT01384617|pancreaticojejunostomy
1145495|NCT01384617|Roux-en-Y anastomosis
1145496|NCT01384617|stapling closure
1145497|NCT01384604|Schizophrenia
1145498|NCT01384604|Schizoaffective disorder
1145499|NCT01384604|Bipolar disorder
1145500|NCT01384604|Psychosis
1145501|NCT01384604|Genetics
1145502|NCT01384604|Phenotype
1145503|NCT01384591|oxidative stress
1145504|NCT01384591|blood flow
1145505|NCT01384591|antioxidant
1145506|NCT01384591|muscle
1145507|NCT01384591|elderly
1145508|NCT01384552|normal weight
1145509|NCT01384552|overweight
1145510|NCT01384552|dietary restraint
1145511|NCT01384552|package unit size
1145512|NCT01384552|food intake
1145513|NCT01384539|chronic kidney disease
1145514|NCT01384539|vitamin D deficiency
1145515|NCT01384526|hormone therapy
1145516|NCT01384526|ovarian aging
1145517|NCT01384526|ovarian reserve
1145518|NCT01384526|fertility
1145519|NCT01384526|breast cancer
1145520|NCT01384513|Allogeneic HSCT
1145521|NCT01384513|Hematopoietic stem cell transplantation
1145522|NCT01384487|Viewing and axial cross sectional imaging of ocular
1145523|NCT01384487|structures, including the anterior chamber
1145524|NCT01384474|Crew Resource Management
1145525|NCT01384474|Surgical safety checklist
1145526|NCT01384474|Postoperative complications
1145527|NCT01384448|stress echocardiography
1145528|NCT01384448|coronary ct angiography
1145529|NCT01384435|Spinocerebellar degeneration (SCD)
1145530|NCT01384435|Thyrotropin-Releasing Hormone (TRH)
1145531|NCT01384422|methotrexate-refractory
1145532|NCT01384383|Chronic Hepatitis C
1145533|NCT01384383|IL28B CC Genotype
1145534|NCT01384383|Treatment naive
1145535|NCT01384383|Peginterferon α-2a (PEG)
1145536|NCT01384383|Genotype 1a/b
1145537|NCT01384383|GS 9451
1145538|NCT01384383|GS 5885
1145539|NCT01384383|Ribavirin (RBV)
1145540|NCT01384383|HCV NS5A inhibitor
1145541|NCT01384383|HCV NS3 protease inhibitor
1145542|NCT01384357|lymphadenopathy
1145543|NCT01384357|needle biopsy
1145544|NCT01384357|sonography
1145545|NCT01384331|Implanon users
1145546|NCT01384331|Frequent bleeding
1145547|NCT01384331|Prolonged bleeding
1145548|NCT01384331|Comparison of treatments
1145549|NCT01384331|Placebo controlled
1145550|NCT01384331|Randomly allocated tretment
1145551|NCT01384292|Cancer-Related Pain
1145552|NCT01384292|Opioid-Induced Constipation
1145553|NCT01384292|OIC
1145554|NCT01384279|metformin
1145555|NCT01384279|topiramate
1145556|NCT01384279|obesity
1145557|NCT01384279|metabolic syndrome
1145559|NCT01384253|HER2+
1145560|NCT01384253|HER-2 positive
1145561|NCT01384253|intraperitoneal
1145562|NCT01384253|intra-abdominal
1145563|NCT01384253|Lead 212
1145564|NCT01384253|Radio Immunotherapy
1145565|NCT01384253|Alpha particle
1145566|NCT01384253|Antibodies
1145567|NCT01384253|Immunoglobulins
1145568|NCT01384253|Antibodies, Monoclonal
1145569|NCT01384253|Immunologic Factors
1145570|NCT01384253|Physiological Effects of Drugs
1145571|NCT01384253|Pharmacologic Actions
1145572|NCT01384253|RIT
1145573|NCT01384240|colon polyps
1145574|NCT01384240|colonic dysplasia
1145575|NCT01384240|anal dysplasia
1145576|NCT01384240|microendoscopy
1145577|NCT01384227|Barrett's esophagus
1145578|NCT01384227|in vivo imaging
1145579|NCT01384227|image guide microscope
1145580|NCT01384201|intestinal metaplasia, gastric cancer
1145581|NCT01384175|Epidural Analgesia
1145582|NCT01384175|OPCAB
1145583|NCT01384175|PCEA
1145584|NCT01384162|ALS
1145585|NCT01384162|VEGF165
1145586|NCT01384162|Safety
1145587|NCT01384162|Intracerebroventricular
1145588|NCT01384162|Infusion
1145589|NCT01384162|Implantable
1145590|NCT01384149|intra ocular pressure
1145591|NCT01384149|open angle glaucoma
1145592|NCT01384149|selective laser trabeculoplasty
1145593|NCT01384149|external laser treatment
1145594|NCT01384123|stable pulmonary sarcoidosis with no change in medication during the last 3 months/
1145595|NCT01384110|Amylase
1145596|NCT01384110|Glucosidase
1145597|NCT01384110|Glycemic response
1145598|NCT01384110|Sucrose
1145599|NCT01384110|Seaweed
1145600|NCT01384097|haemodynamic
1145601|NCT01384097|goal-directed therapy
1145602|NCT01384097|surgery
1145603|NCT01384097|anaesthesia
1145604|NCT01384084|pelvic organ prolapse
1145605|NCT01384084|urinary incontinence
1145606|NCT01384084|sacropexy
1145607|NCT01384084|sling
1145608|NCT01384071|Low back pain
1145609|NCT01384071|Unstable shoes
1145610|NCT01384071|Gait
1145611|NCT01384071|Balance
1145612|NCT01384058|atherogenic lipoprotein
1145613|NCT01384058|cardiovascular disease
1145614|NCT01384058|coronary artery disease
1145615|NCT01384058|type 2 diabetes
1145616|NCT01384058|small, dense LDL
1145617|NCT01384045|Type II Diabetes
1145618|NCT01384045|Diabetes
1145619|NCT01384032|CVD, LDL-C, apoE, SFA, DHA
1145620|NCT01384019|ST-elevation myocardial infarction
1145621|NCT01384019|percutaneous coronary intervention
1145622|NCT01384019|cardiac magnetic resonance imaging
1145623|NCT01384019|microvascular occlusion
1145624|NCT01384019|myocardial salvage
1145625|NCT01384006|Pancreas transplantation
1145626|NCT01384006|extended donor criteria
1145627|NCT01384006|organ survival
1145628|NCT01383993|Open-Label
1145629|NCT01383993|Pharmacokinetics
1145630|NCT01383993|Intravenous to oral switch
1145631|NCT01383993|Safety
1145632|NCT01383993|Voriconazole
1145633|NCT01383993|Immunocompromise
1145634|NCT01383993|Children
1145635|NCT01383993|High Risk For Systemic Fungal Infection
1145636|NCT01383980|Enteral Nutrition
1145637|NCT01383980|Enteral Feeding
1145638|NCT01383980|nasogastric tubes
1145639|NCT01383980|gastrostomy tubes
1145640|NCT01383980|jejunostomy tubes
1145641|NCT01383954|knee osteoarthritis
1145642|NCT01383941|asthma
1145643|NCT01383941|rhinitis
1145644|NCT01383941|difficult-to-treat asthmatic
1145645|NCT01383941|phenotypes
1145646|NCT01383889|Physical exercise
1145647|NCT01383889|Pregnancy
1145648|NCT01383889|Fetal well being
1145649|NCT01383876|cervical
1145650|NCT01383876|laminectomy
1145651|NCT01383876|fusion
1145652|NCT01383876|neurological compression
1145653|NCT01383876|spondylosis
1145654|NCT01383850|preterm infants
1145655|NCT01383850|nasal continuous positive airway pressure
1145656|NCT01383850|heliox
1145657|NCT01383850|bronchopulmonary dysplasia.
1145658|NCT01383837|HIV/STI
1145659|NCT01383837|Prevention
1145660|NCT01383837|Adolescents
1145661|NCT01383837|Substance Use Disorders
1145662|NCT01383837|Family-based intervention
1145663|NCT01383824|Hip Replacement
1145664|NCT01383824|Femoral Component
1145665|NCT01383811|Treatment Resistant Depression
1145666|NCT01383811|Exercise
1145667|NCT01383798|iron deficiency, physical performance, female athletes
1145668|NCT01383785|Primary PTCA
1145669|NCT01383785|Thrombus Aspiration Catheter
1145670|NCT01383785|Intracoronary Abciximab
1145671|NCT01383772|Proliferative diabetic retinopathy
1145672|NCT01383772|Pan retinal photocoagulation
1145673|NCT01383772|Multi-spot Photocoagulator
1145674|NCT01383772|Visual field tests
1145675|NCT01383759|BORTEZOMIB (VELCADE)
1145676|NCT01383759|CYCLOPHOSPHAMIDE (CYTOXAN)
1145677|NCT01383759|DEXAMETHASONE
1145678|NCT01383759|MELPHALAN
1145679|NCT01383759|11-061
1145680|NCT01383746|Cholangiocarcinoma
1145681|NCT01383746|RADIOEMBOLIZATION
1145682|NCT01383746|tumor response
1145683|NCT01383746|progression-free survival
1145684|NCT01383746|safety
1145685|NCT01383746|second-line therapy
1145686|NCT01383720|Aortic Valve Stenosis
1145687|NCT01383720|Transcatheter Aortic Valve Replacement
1145688|NCT01383655|wheezy bronchitis
1145689|NCT01383655|asthma
1145690|NCT01383655|rhinovirus
1145691|NCT01383655|magnesium
1145692|NCT01383629|Vitrectomy
1145693|NCT01383629|Local anaesthesia
1145694|NCT01383629|Counselling
1145695|NCT01383629|Fear
1145696|NCT01383629|Visual perception
1145697|NCT01383616|osteoporosis
1145698|NCT01383616|vertebral compression fractures
1145699|NCT01383603|Cat Allergy
1145700|NCT01383603|Rhinoconjunctivitis
1145701|NCT01383603|Immunotherapy
1145702|NCT01383603|Cat-PAD
1145703|NCT01383590|Cat allergy
1145704|NCT01383590|Rhinoconjunctivitis
1145705|NCT01383590|Immunotherapy
1145706|NCT01383590|Cat-PAD
1145707|NCT01383577|Hemorrhoids
1145708|NCT01383577|Ligation
1145709|NCT01383577|Pain
1145710|NCT01383577|Morbidity
1145711|NCT01383577|Patient Satisfaction
1145712|NCT01383577|Cost-Benefit Analysis
1145713|NCT01383551|Depression
1145714|NCT01383551|Marital relationship
1145715|NCT01383551|Parental competence
1145716|NCT01383538|pancreas
1145717|NCT01383538|cancer
1145718|NCT01383538|adenocarcinoma
1145719|NCT01383538|Oxaliplatin
1145720|NCT01383538|Leucovorin
1145721|NCT01383538|Irinotecan
1145722|NCT01383538|5-FU
1145723|NCT01383538|IPI-926
1145724|NCT01383525|SLT, LTP
1145725|NCT01383525|non contact
1145726|NCT01383525|Trabeculoplasty
1145727|NCT01383525|Laser
1145728|NCT01383525|intraocular pressure
1145729|NCT01383512|stroke
1145730|NCT01383512|rehabilitation
1145731|NCT01383512|robotics
1145732|NCT01383512|motor control
1145733|NCT01383512|upper limb
1145734|NCT01383486|Self Selection Tria
1145735|NCT01383473|cancer therapy
1145736|NCT01383473|school attendance
1145737|NCT01383473|cancer diagnosis
1145738|NCT01383473|perception
1145739|NCT01383460|Acute-on-chronic liver failure
1145740|NCT01383460|ACLF
1145741|NCT01383460|cirrhosis
1145742|NCT01383460|acute hepatitis
1145743|NCT01383421|Rheumatoid Arthritis
1145744|NCT01383421|Patient Support Program
1145745|NCT01383421|adalimumab
1145746|NCT01383408|breath sample analysis
1145747|NCT01383408|exhalation analysis
1145748|NCT01383408|volatile organic compounds
1145749|NCT01383408|screening
1145750|NCT01383408|lung cancer
1145751|NCT01383408|breast cancer
1145752|NCT01383408|ovarian cancer
1145753|NCT01383408|canine scent detection
1145754|NCT01383382|Heart Diseases
1145755|NCT01383382|Cardiovascular Diseases
1145756|NCT01383382|Acute Myocardial Infarction
1145757|NCT01383382|Decision Making
1145758|NCT01383382|Percutaneous Coronary Intervention
1145759|NCT01383382|Informed Consent
1145760|NCT01383382|Quality of Care
1145761|NCT01383330|megesterol
1145762|NCT01383317|Remote Ischemic Preconditioning
1145763|NCT01383317|Acute Pain
1145764|NCT01383304|Platelet aggregation
1145765|NCT01383304|Aspirin
1145766|NCT01383304|Drug resistance
1145767|NCT01383304|Thromboxane B2
1145768|NCT01383304|Pharmacologic Actions
1145769|NCT01383304|Platelet Aggregation Inhibitors
1145770|NCT01383291|pelvic floor prolapse
1145771|NCT01383291|prolift
1145772|NCT01383291|IVS
1145773|NCT01383291|Surgery
1145774|NCT01383278|tobacco
1145775|NCT01383278|smoking
1145776|NCT01383278|smoking cessation
1145777|NCT01383265|screening colonoscopy
1145778|NCT01383265|adenoma
1145779|NCT01383265|water method
1145780|NCT01383252|water method
1145781|NCT01383252|air method
1145782|NCT01383252|unsedated colonoscopy
1145783|NCT01383252|adenoma detection
1145784|NCT01383239|Rotator Cuff Tear Repair
1145785|NCT01383239|Rotator Cuff Tear Repair and postoperative treatment
1145786|NCT01383226|endosonography
1145787|NCT01383226|enlarged thoracic lymph adenopathies
1145788|NCT01383226|non-cancer patient
1145789|NCT01383213|Acute Respiratory Failure
1145790|NCT01383213|Pneumonia
1145791|NCT01383213|Continuous Positive Airway Pressure
1145792|NCT01383200|efficacy
1145793|NCT01383200|comfort
1145794|NCT01383187|Deep Burn Trauma
1145795|NCT01383187|Dermo-Epidermal Graft
1145796|NCT01383187|Platelet Rich Plasma Concentrate (PRP)
1145797|NCT01383187|Vancouver Scar Score
1145798|NCT01383187|Scarring
1145799|NCT01383187|Hypertrophic Scarring
1145800|NCT01383174|Breast cancer
1145801|NCT01383174|Latinas
1145802|NCT01383174|Peer support counselor
1145803|NCT01383174|Spanish speaking
1145804|NCT01383174|Community based
1145805|NCT01383161|Curcumin
1145806|NCT01383161|Turmeric
1145807|NCT01383161|Memory
1145808|NCT01383161|Cognitive Impairment
1145809|NCT01383161|Brain Imaging
1145810|NCT01383161|Supplement
1145811|NCT01383148|NSCLC
1145812|NCT01383135|Healthy volunteers
1145813|NCT01383122|Pulsed electromagnetic field device
1145814|NCT01383122|Cesarean section
1145815|NCT01383109|Mass Balance
1145816|NCT01383109|Accelerated Mass Spectrometry (AMS)
1145817|NCT01383109|microdose
1145818|NCT01383109|Focus of the study: ADME
1145819|NCT01383096|OZ439
1145820|NCT01383096|Bioavailability
1145821|NCT01383096|Food Effect
1145822|NCT01383083|Pulmonary arterial hypertension
1145823|NCT01383083|Congenital heart disease
1145824|NCT01383083|Eisenmenger physiology
1145825|NCT01383070|Timely initiation of breast feeding
1145826|NCT01383070|Exclusive breast feeding
1145827|NCT01383070|Timely introduction of complimentary feeding
1145828|NCT01383070|Breast Feeding, Exclusive
1145829|NCT01383070|Childbirth and the Puerperium
1145830|NCT01383044|Carvedilol
1145831|NCT01383044|Banding ligation with Carvedilol
1145832|NCT01383044|the efficacy & safety of combining EVL and carvedilol in prevention of first variceal bleeding
1145833|NCT01383031|laparoscopic cholecystectomy
1145834|NCT01383031|single site
1145835|NCT01383031|randomized controlled trail
1145836|NCT01383018|Erectile Dysfunction (ED)
1145837|NCT01383018|Penile Implant
1145838|NCT01383018|Impotence
1145839|NCT01383018|Penile Prosthesis
1145840|NCT01383018|Registry
1145841|NCT01383005|Treatment satisfaction
1145842|NCT01383005|Adherence to treatment
1145843|NCT01382992|Carcinoma, Non-Small-Cell Lung
1145844|NCT01382992|erbB-1
1145845|NCT01382979|Alcohol misuse prevention
1145846|NCT01382979|College students
1145847|NCT01382979|Intervention and control
1145848|NCT01382966|sclerostin
1145849|NCT01382966|arteriovenous fistula thrombosis
1145850|NCT01382966|carpal tunnel syndrome
1145851|NCT01382966|echocardiography
1145852|NCT01382953|Holter Monitor, Ambulatory Electrocardiography Monitoring
1145853|NCT01382888|Haemodialysis
1145854|NCT01382888|Arteriovenous fistula
1145855|NCT01382888|Severe chronic kidney disease
1145856|NCT01382888|Newly constructed primary arteriovenous fistulas in patients planned for haemodialysis
1145857|NCT01382875|Multi-disciplinary management program
1145858|NCT01382875|Conventional care program
1145859|NCT01382875|Balance Ability
1145860|NCT01382875|Quality of Life
1145861|NCT01382862|acute ischemic stroke
1145862|NCT01382862|thrombolysis
1145863|NCT01382862|prehospital
1145864|NCT01382862|emergency medicine
1145865|NCT01382862|suspected acute stroke
1145866|NCT01382862|telemedicine
1145867|NCT01382849|amyloid
1145868|NCT01382849|cerebral amyloid angiopathy
1145869|NCT01382849|hemorrhages
1145870|NCT01382849|cerebral spot sign
1145871|NCT01382810|dry eye signs and symptoms
1145872|NCT01382771|low back pain
1145873|NCT01382771|zygapophysial joint pain
1145874|NCT01382771|medial branch block
1145875|NCT01382771|> 6 months duration
1145876|NCT01382771|non-radicular
1145877|NCT01382758|Near Infrared Spectroscopy (NIRS)
1145878|NCT01382758|Acute kidney injury (AKI)
1145879|NCT01382732|Pre-eclampsia
1145880|NCT01382732|Postpartum hemorrhage
1145881|NCT01382732|Carbetocin
1145882|NCT01382732|Oxytocin
1145883|NCT01382719|FSAD
1145884|NCT01382719|HSDD
1145885|NCT01382719|female sexual dysfunction
1145886|NCT01382719|FSD
1145887|NCT01382719|Female Sexual Arousal Disorder
1145888|NCT01382719|Hypoactive Sexual Desire Disorder
1145889|NCT01382693|Behavioral symptoms
1145890|NCT01382693|Long-term care
1145891|NCT01382667|mucositis
1145892|NCT01382667|dyspepsia
1145893|NCT01382667|chemotherapy
1145894|NCT01382667|GLP-2
1145895|NCT01382667|questionnaire
1145896|NCT01382641|Cataract surgery
1145897|NCT01382628|Diabetes
1145898|NCT01382628|Ulcers
1145899|NCT01382628|Equinus Deformity
1145900|NCT01382628|Amputation
1145901|NCT01382628|Achilles Tendon
1145902|NCT01382628|Limb Loss
1145903|NCT01382615|Multiple Myeloma
1145904|NCT01382602|Urinary Incontinence, Stress
1145905|NCT01382602|Tissue Therapy (Cell Therapy)
1145906|NCT01382602|Transplantation, Autologous
1145907|NCT01382589|vitiligo
1145908|NCT01382589|depigmentation
1145909|NCT01382589|phototherapy
1145910|NCT01382589|non-segmental vitiligo
1145911|NCT01382576|polycystic ovary syndrome
1145912|NCT01382576|chitotriosidase activity
1145913|NCT01382563|Eosinophilic Gastrointestinal Disorders
1145914|NCT01382563|EGID
1145915|NCT01382563|Eosinophilic Esophagitis
1145916|NCT01382563|Registry
1145917|NCT01382563|Eosinophils
1145918|NCT01382563|Eosinophilia
1145919|NCT01382563|Eosinophilic enteropathy
1145920|NCT01382563|Eosinophilic enteritis
1145921|NCT01382563|Eosinophilic gastritis
1145922|NCT01382563|Eosinophilic gastroenteritis
1145923|NCT01382563|Eosinophilic gastroenteropathy
1145924|NCT01382550|antithrombin
1145925|NCT01382550|venous thrombosis
1145926|NCT01382550|thrombosis risk factors
1145927|NCT01382550|thrombophilia
1145928|NCT01382537|Neck
1145929|NCT01382537|Chronic
1145930|NCT01382537|Musculoskeletal
1145931|NCT01382537|Shoulder
1145932|NCT01382524|PIV therapy
1145933|NCT01382498|Endothelin-1 high sensitivity CRP
1145934|NCT01382485|non union
1145935|NCT01382485|bone defect
1145936|NCT01382485|tibia non union
1145937|NCT01382485|femur non union
1145938|NCT01382485|bone graft
1145939|NCT01382472|STEMI
1145940|NCT01382472|PPCI
1145941|NCT01382472|Statins
1145942|NCT01382472|Infarct size
1145943|NCT01382459|children
1145944|NCT01382446|Trauma
1145945|NCT01382446|Mechanical Ventilation
1145946|NCT01382446|Ventilator Associated Pneumonia
1145947|NCT01382446|Oral Care
1145948|NCT01382433|Chronic Cannabis Users
1145949|NCT01382433|negative symptoms
1145950|NCT01382433|cognitive electrophysiology functions
1145951|NCT01382420|subclinical cushing syndrome
1145952|NCT01382420|hypercortisolism
1145953|NCT01382420|adrenal incidentaloma
1145954|NCT01382420|adrenalectomy
1145955|NCT01382407|skin rash reaction
1145956|NCT01382407|ERBITUX® (cetuximab)
1145957|NCT01382407|acne
1145958|NCT01382394|Sepsis
1145959|NCT01382394|heart failure
1145960|NCT01382394|BNP
1145961|NCT01382394|IL-6
1145962|NCT01382394|Procalcitonin
1145963|NCT01382394|Prognosis
1145964|NCT01382368|Post Pneumonectomy Patients
1145965|NCT01382368|IPF
1145966|NCT01382368|COPD
1145967|NCT01382355|Kidney transplant
1145968|NCT01382355|Kidney/Pancreas transplant
1145969|NCT01382355|Antibody
1145970|NCT01382355|Monitoring
1145971|NCT01382342|Parkinson's disease
1145972|NCT01382342|cognition
1145973|NCT01382342|executive function
1145974|NCT01382342|rasagiline
1145975|NCT01382329|Prophylaxis of influenza infection caused by a pandemic influenza virus (H5N1)
1145976|NCT01382316|12-step facilitation
1145977|NCT01382316|Alcoholics Anonymous
1145978|NCT01382316|Narcotics Anonymous
1145979|NCT01382316|AA
1145980|NCT01382316|Self-help
1145981|NCT01382303|Type 2 Diabetes
1145982|NCT01382303|pentoxifylline
1145983|NCT01382303|proteinuria
1145984|NCT01382290|MRI
1145985|NCT01382290|Spine
1145986|NCT01382290|Diffusion
1145987|NCT01382264|Poorly controlled diabetes Type 2
1145988|NCT01382264|Computer Assisted Decision Support
1145989|NCT01382264|Primary Care Providers
1145990|NCT01382251|Activities of Daily Living
1145991|NCT01382251|Caregivers
1145992|NCT01382251|Ambulatory Surgical Procedures
1145993|NCT01382238|dolutegravir
1145994|NCT01382238|pediatric
1145995|NCT01382238|granule formulation
1145996|NCT01382238|GSK1349572
1145997|NCT01382238|HIV
1145998|NCT01382225|Dry eyes
1145999|NCT01382225|Ocular discomfort
1146000|NCT01382212|Evaluate safety through the evaluation of the incidence of hypercalcemia in pediatric subjects
1146001|NCT01382199|Antibiotic Associated Diarrhea in Adult Patients
1146002|NCT01382186|Qualitative
1146003|NCT01382186|User, Computer Interface
1146004|NCT01382186|quantitative
1146005|NCT01382186|survey
1146006|NCT01382186|telemedicine
1146007|NCT01382173|Knee injury
1146008|NCT01382173|Osteoarthritis
1146009|NCT01382173|Anterior Cruciate Ligament injury
1146010|NCT01382173|Patellar dislocation
1146011|NCT01382160|Rheumatoid arthritis
1146012|NCT01382160|adalimumab
1146013|NCT01382160|pharmacokinetic-pharmacodynamic relationship
1146014|NCT01382160|immunogenicity
1146015|NCT01382160|Fc gamma receptors polymorphisms
1146016|NCT01382134|Platelet dysfunction
1146017|NCT01382134|Hemodilution
1146018|NCT01382134|Mild hypothermia
1146019|NCT01382134|NSAID
1146020|NCT01382134|Desmopressin
1146021|NCT01382121|Peer modeling
1146022|NCT01382121|Observational learning
1146023|NCT01382121|Obesity
1146024|NCT01382121|Adolescents
1146025|NCT01382121|Maximum ventilatory oxygen
1146026|NCT01382121|Aerobic fitness
1146027|NCT01382121|Health behaviour
1146028|NCT01382095|ETEC
1146029|NCT01382095|Diarrhea
1146030|NCT01382095|Vaccine
1146031|NCT01382082|cognitive function
1146032|NCT01382082|memory
1146033|NCT01382082|attention
1146034|NCT01382082|breast cancer
1146035|NCT01382082|lymphoma
1146036|NCT01382069|androgen
1146037|NCT01382069|male contraception
1146038|NCT01382069|dimethandrolone
1146039|NCT01382069|healthy men
1146040|NCT01382056|Peripheral Artery Disease
1146041|NCT01382056|Pulses
1146042|NCT01382056|Beans
1146043|NCT01382056|PAD
1146044|NCT01382043|percutaneous coronary angioplasty
1146045|NCT01382043|zotarolimus-eluting stent
1146046|NCT01382043|sirolimus-eluting stent
1146047|NCT01382043|biodegradable polymer
1146048|NCT01382043|biocompatible polymer
1146049|NCT01382030|Soft tissue sarcoma
1146050|NCT01382030|High-risk
1146051|NCT01382030|Neoadjuvant
1146052|NCT01382030|Adjuvant
1146053|NCT01382030|Chemotherapy
1146054|NCT01382030|Radiotherapy
1146055|NCT01382017|lacosamide
1146056|NCT01382017|carbamazepine
1146057|NCT01382017|placebo
1146058|NCT01382017|transcranial magnetic stimulation
1146059|NCT01382017|TMS
1146060|NCT01382017|motor cortex
1146061|NCT01382017|sodium channel
1146062|NCT01382017|inhibition
1146063|NCT01382017|threshold
1146064|NCT01382004|Neglected diseases
1146065|NCT01382004|Children
1146066|NCT01381991|Gastroesophageal Reflux Disease
1146067|NCT01381991|Reflux esophagitis
1146068|NCT01381991|i-scan
1146069|NCT01381978|Nutritional status of scholars
1146070|NCT01381978|Risk factors of obesity
1146071|NCT01381978|Socioeconomical status
1146072|NCT01381978|Physical activity habits
1146073|NCT01381965|spectral-domain optical coherence tomography
1146074|NCT01381965|idiopathic macular hole
1146075|NCT01381965|cone outer segment tips line
1146076|NCT01381965|vitrectomy
1146077|NCT01381952|X-ray
1146078|NCT01381952|Image processing
1146079|NCT01381952|Neuro angiography
1146080|NCT01381952|Radiation exposure
1146081|NCT01381939|Intrahepatic Cholestasis of Pregnancy
1146082|NCT01381939|Induction of labor
1146083|NCT01381939|Pregnancy
1146084|NCT01381939|Caesarian section
1146085|NCT01381939|Pruritus
1146086|NCT01381939|IUFD
1146087|NCT01381926|Type 2 diabetes
1146088|NCT01381926|exenatide
1146089|NCT01381926|Byetta
1146090|NCT01381913|Gastric cancer
1146091|NCT01381913|Chemoradiotherapy
1146092|NCT01381913|Adjacent tissue invasion
1146093|NCT01381913|Feasibility trial
1146094|NCT01381900|Canagliflozin
1146095|NCT01381900|Placebo
1146096|NCT01381900|Type 2 diabetes mellitus
1146097|NCT01381887|Canagliflozin
1146098|NCT01381887|Placebo
1146099|NCT01381887|Type 2 diabetes mellitus
1146100|NCT01381874|Breast cancer
1146101|NCT01381874|Abiraterone
1146102|NCT01381874|Postmenopausal
1146103|NCT01381874|Metastatic
1146104|NCT01381848|Doripenem
1146105|NCT01381848|DORIPED1003
1146106|NCT01381848|Intravenous
1146107|NCT01381848|Infection
1146108|NCT01381848|Colonization
1146109|NCT01381848|Prophylaxis
1146110|NCT01381848|Pediatric
1146111|NCT01381848|Antibiotic
1146112|NCT01381848|Pharmacokinetics
1146113|NCT01381835|TMC435-TiDP16-C126
1146114|NCT01381835|TMC435-C126
1146115|NCT01381835|TMC435
1146116|NCT01381835|HCV
1146117|NCT01381835|Hepatitis C
1146118|NCT01381835|Hep C
1146119|NCT01381835|severe renal impairement
1146120|NCT01381822|TH-302
1146121|NCT01381822|Advanced Renal Cell Carcinoma
1146122|NCT01381822|RCC
1146123|NCT01381822|Gastrointestinal Stromal Tumors
1146124|NCT01381822|GIST
1146125|NCT01381822|Phase 1
1146126|NCT01381822|Sunitinib
1146127|NCT01381822|Pancreatic Neuroendocrine Tumors
1146128|NCT01381822|PNET
1146129|NCT01381809|Myelodysplastic Syndromes
1146130|NCT01381809|Myeloproliferative Disorders
1146131|NCT01381809|Bone Marrow disease
1146132|NCT01381809|Anemia
1146133|NCT01381809|Epoetin Alfa
1146134|NCT01381809|Eprex
1146135|NCT01381809|Erypo
1146136|NCT01381809|Erythropoiesis-stimulating agent
1146137|NCT01380821|clinical indication for myocardial SPECT
1146138|NCT01380821|suspected or known coronary artery disease
1146139|NCT01380795|non-small cell lung cancer carcinoma
1146140|NCT01380795|circulating tumor cells
1146141|NCT01380795|EGFR
1146142|NCT01380795|K-ras
1146143|NCT01381783|topical anaesthesia
1146144|NCT01381783|Phacoemulsification
1146145|NCT01381770|muscular lesions grade 2
1146146|NCT01381770|muscular lesions grade 3
1146147|NCT01381757|Extensively Drug-Resistant Tuberculosis
1146148|NCT01381757|First-Line Antituberculous Drugs
1146149|NCT01381757|Second-Line Antituberculous Drugs
1146150|NCT01381757|Middlebrook Culture
1146151|NCT01381757|Agar Proportion Method
1146152|NCT01381744|Yersinia pestis, vaccine, plague, Flagellin/F1/V, Parent Protocol of 15-0104
1146153|NCT01381731|post PRK wound healing
1146154|NCT01381718|childhood brain tumor
1146155|NCT01381718|neurotoxicity
1146156|NCT01381718|fatigue
1146157|NCT01381718|cognitive/functional effects
1146158|NCT01381718|psychosocial effects of cancer and its treatment
1146159|NCT01381705|recurrent grade 1 follicular lymphoma
1146160|NCT01381705|recurrent grade 2 follicular lymphoma
1146161|NCT01381653|sexual risk
1146162|NCT01381653|substance use
1146163|NCT01381653|HIV prevention
1146164|NCT01381653|intervention acceptability and feasibility
1146165|NCT01381653|young men who have sex with men
1146166|NCT01381640|paracetamol
1146167|NCT01381640|healthy volunteer
1146168|NCT01381640|pharmacoscintography
1146169|NCT01381627|EBUS-TBNA
1146170|NCT01381627|Dexmedetomidine
1146171|NCT01381627|Precedex
1146172|NCT01381627|Remifentanil
1146173|NCT01381627|Ultiva
1146174|NCT01381627|Monitored Anesthesia Care
1146175|NCT01381627|Sedation
1146176|NCT01381627|Bronchoscopy
1146177|NCT01381627|Lung cancer
1146178|NCT01381627|Mediastinal node
1146179|NCT01381627|Cancer staging
1146180|NCT01381627|Anesthesia
1146181|NCT01381627|Remote location
1146182|NCT01381614|retrospective database analysis
1146183|NCT01381614|economic burden
1146184|NCT01381601|retrospective database analysis
1146185|NCT01381601|economic burden
1146186|NCT01381575|HPV infection
1146187|NCT01381575|Human Papillomavirus
1146188|NCT01381575|Cervical cancer
1146189|NCT01381575|HPV-16
1146190|NCT01381575|HPV-18
1146191|NCT01381575|vaccine
1146192|NCT01381562|intra-abdominal infection
1146193|NCT01381562|belly
1146194|NCT01381562|Gram-negative pathogen
1146195|NCT01381562|abscess
1146196|NCT01381562|peritonitis
1146197|NCT01381549|Gram-negative
1146198|NCT01381549|uropathogens
1146199|NCT01381549|complicated lower urinary tract infection
1146200|NCT01381549|pyelonephritis
1146201|NCT01381536|Anti Blys Antibody
1146202|NCT01381523|resource utilization
1146203|NCT01381523|naproxen sodium
1146204|NCT01381523|cost and cost analysis
1146205|NCT01381523|triptan
1146206|NCT01381523|migraine
1146207|NCT01381510|Benign prostatic hyperplasia
1146208|NCT01381510|Adherence
1146209|NCT01381510|Acute urinary retention
1146210|NCT01381510|Enlarged prostate
1146211|NCT01381510|5-alpha reductase inhibitor
1146212|NCT01381510|Surgery
1146213|NCT01381510|Cost and cost analysis
1146214|NCT01381497|presenteeism
1146215|NCT01381497|migraine disorders
1146216|NCT01381497|work productivity
1146217|NCT01381497|triptan
1146218|NCT01381497|sumatriptan and naproxen sodium
1146219|NCT01381497|absenteeism
1146220|NCT01381484|Periorbital wrinkles
1146221|NCT01381484|Efficacy and safety
1146222|NCT01381432|Antirejection
1146223|NCT01381419|pharmacokinetics
1146224|NCT01381419|safety
1146225|NCT01381419|positron emission tomography (PET)
1146226|NCT01381419|single ascending dose
1146227|NCT01381393|osteoporosis
1146228|NCT01381393|ibandronate
1146229|NCT01381380|myofascial pain
1146230|NCT01381380|trigger point injection
1146231|NCT01381380|manual therapy
1146232|NCT01381367|Chronic obstructive pulmonary disease
1146233|NCT01381367|Inhaled corticosteroid
1146234|NCT01381367|Pneumococcal vaccine
1146235|NCT01381367|Acute exacerbation
1146236|NCT01381367|High-dose daily inhaled corticosteroid usage
1146237|NCT01381367|Efficacy of the PPSV23 pneumococcal vaccine
1146238|NCT01381354|Secondary Progressive Multiple Sclerosis, primary progressive multiple sclerosis
1146239|NCT01381328|HIV-1 infected patients
1146240|NCT01381328|RALTEGRAVIR regimen
1146241|NCT01381328|genotypic evaluations
1146242|NCT01381328|phenotypic evaluations
1146243|NCT01381315|Sentinel lymph node biopsy
1146244|NCT01381315|Axillary lymph node dissection
1146245|NCT01381315|Prevention of lymphedema
1146246|NCT01381302|Severity of disease
1146247|NCT01381276|Vitamin A
1146248|NCT01381250|Pathological gambling according to DSM and having gambled at least once the past month.
1146249|NCT01381250|Being atleast 18 years old
1146250|NCT01381237|Balance
1146251|NCT01381237|Postural
1146252|NCT01381237|Rehabilitation
1146253|NCT01381237|Therapy
1146254|NCT01381237|computer-assisted
1146255|NCT01381237|Video Games
1146256|NCT01381237|Center of Pressure
1146257|NCT01381224|low back pain
1146258|NCT01381224|lumbar
1146259|NCT01381224|injection
1146260|NCT01381224|lumbar pain
1146261|NCT01381211|Intermediate stage hepatocellular carcinoma
1146262|NCT01381198|cerebral palsy
1146263|NCT01381198|distal rectus femoris transfer
1146264|NCT01381198|stiff knee gait pattern
1146265|NCT01381198|gait analysis
1146266|NCT01381198|single event multilevel surgery
1146267|NCT01381198|randomized trial
1146268|NCT01381198|crouch gait
1146269|NCT01381185|myocardial infarction
1146270|NCT01381185|percutaneous coronary intervention (PCI)
1146271|NCT01381185|high platelet reactivity (HPR)
1146272|NCT01381172|Heart Failure
1146273|NCT01381172|Congestive Heart Failure
1146274|NCT01381172|Chronic heart disease
1146275|NCT01381172|Cardiac contractility modulation
1146276|NCT01381172|CCM
1146277|NCT01381172|CHF
1146278|NCT01381159|Adherence
1146279|NCT01381159|Asthma Control
1146280|NCT01381159|Asthma Quality Of Life
1146281|NCT01381159|Motivational Communication
1146282|NCT01381159|Motivational Interviewing
1146283|NCT01381146|criminal behavior
1146284|NCT01381146|substance abuse
1146285|NCT01381146|HIV risk behavior
1146286|NCT01381146|criminogenic thinking
1146287|NCT01381146|shame
1146288|NCT01381146|guilt
1146289|NCT01381146|empathy
1146290|NCT01381146|jail inmates
1146291|NCT01381146|restorative justice
1146292|NCT01381146|Crime
1146293|NCT01381133|Substance abuse
1146294|NCT01381133|Adolescent outpatient treatment
1146295|NCT01381133|Continuing care
1146296|NCT01381133|Outcomes
1146297|NCT01381120|Flank Pain
1146298|NCT01381120|Lower Urinary Tract Symptoms
1146299|NCT01381120|LUTS
1146300|NCT01381120|Urgency
1146301|NCT01381120|Nocturia
1146302|NCT01381120|Frequency
1146303|NCT01381120|Ureteroscopy
1146304|NCT01381120|Kidney Stones
1146305|NCT01381120|Stent
1146306|NCT01381120|Incontinence
1146307|NCT01381120|VESIcare
1146308|NCT01381120|Ureter
1146309|NCT01381120|Urinary Bladder, Overactive
1146310|NCT01381120|OAB
1146311|NCT01381120|Overactive Bladder Syndrome
1146312|NCT01381094|anemia
1146313|NCT01381094|chronic kidney disease
1146314|NCT01381094|CKD
1146315|NCT01381094|chronic renal insufficiency
1146316|NCT01381094|renal impairment
1146317|NCT01381094|erythropoietin
1146318|NCT01381094|safety
1146319|NCT01381094|efficacy
1146320|NCT01381094|tolerability
1146321|NCT01381094|pharmacokinetics
1146322|NCT01381081|knee osteoarthritis
1146323|NCT01381081|comparing platelet-rich plasma
1146324|NCT01381081|intra-articular knee injections
1146325|NCT01381068|ventilation
1146326|NCT01381068|end tidal carbon dioxide
1146327|NCT01381068|hypercapnia
1146328|NCT01381068|hypocapnia
1146329|NCT01381068|positive pressure ventilation
1146330|NCT01381068|neonates
1146331|NCT01381068|delivery room resuscitation
1146332|NCT01381055|Cutaneous leishmaniasis
1146333|NCT01381055|Pentoxifylline
1146334|NCT01381055|Meglumine antimoniate
1146335|NCT01381055|L. braziliensis
1146336|NCT01381042|Brown Adipose Tissue
1146337|NCT01381042|Incidence
1146338|NCT01381042|Factor
1146339|NCT01381042|Human
1146340|NCT01381016|LH pulsatility
1146341|NCT01381016|Obesity
1146342|NCT01381016|Reproduction
1146343|NCT01381003|Chronic Granulomatous Disease
1146344|NCT01381003|Gene therapy
1146345|NCT01381003|X-CGD
1146346|NCT01381003|NADPH-oxidase
1146347|NCT01381003|gp91-phox
1146348|NCT01380977|crime
1146349|NCT01380977|substance abuse
1146350|NCT01380977|HIV risk
1146351|NCT01380977|criminogenic thinking
1146352|NCT01380977|shame
1146353|NCT01380977|guilt
1146354|NCT01380977|restorative justice
1146355|NCT01380977|victim impact group
1146356|NCT01380964|Duchenne Muscular Dystrophy
1146357|NCT01380964|biomarkers
1146358|NCT01380964|transcriptomics
1146359|NCT01380964|mironics
1146360|NCT01380964|proteomics
1146361|NCT01380951|liver cirrhosis
1146362|NCT01380951|chronic hepatitis B
1146363|NCT01380951|antiviral therapy
1146364|NCT01380951|telbivudine
1146365|NCT01380938|genotypes 2 and 3
1146366|NCT01380938|combination treatment
1146367|NCT01380938|individualized treatment
1146368|NCT01380912|breast cancer
1146369|NCT01380912|mastectomy
1146370|NCT01380912|methylprednisoloneacetate
1146371|NCT01380912|seroma
1146372|NCT01380912|numbers of punctures
1146373|NCT01380899|Parkinson Disease
1146374|NCT01380899|Parkinsonian Disorders
1146375|NCT01380899|Lewy Bodies
1146376|NCT01380899|alpha-Synuclein
1146377|NCT01380860|mesh
1146378|NCT01380860|hernia
1146379|NCT01380847|Kidney Transplantation
1146380|NCT01380847|Allograft
1146381|NCT01380847|Kidney failure
1146382|NCT01380847|Chronic allograft nephropathy
1146383|NCT01380847|Monitoring
1146384|NCT01380847|Urine
1146385|NCT01380834|paravertebral nerve blocks
1146386|NCT01380834|laparoscopic cholecystectomy
1146387|NCT01380782|brain tumor
1146388|NCT01380782|recurrent disease
1146389|NCT01380756|Amgen
1146390|NCT01380756|Phase 1
1146391|NCT01380756|Clinical Trial
1146392|NCT01380756|Aurora kinase inhibitor
1146393|NCT01380756|Open label
1146394|NCT01380756|Oncology
1146395|NCT01380756|Hematology
1146396|NCT01380743|Pompe disease
1146397|NCT01380730|Hypercholesterolemia
1146398|NCT01380730|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
1146399|NCT01380704|Depression
1146400|NCT01380678|bevacizumab
1146401|NCT01380678|pterygium
1146402|NCT01380678|treatment
1146403|NCT01380678|elevation
1146404|NCT01380665|Prevena
1146405|NCT01380665|Incision
1146406|NCT01380665|Management
1146407|NCT01380665|System
1146408|NCT01380665|total
1146409|NCT01380665|knee
1146410|NCT01380665|hip
1146411|NCT01380665|replacement
1146412|NCT01380665|Surgery
1146413|NCT01380665|Negative
1146414|NCT01380665|Pressure
1146415|NCT01380665|dressing
1146416|NCT01380665|KCI
1146417|NCT01380652|COPD III/IV
1146418|NCT01380652|Activity Monitoring
1146419|NCT01380652|SenseWear
1146420|NCT01380652|Vibration training
1146421|NCT01380652|Galileo
1146422|NCT01380652|Pulmonary rehabilitation
1146423|NCT01380639|COPD III/IV
1146424|NCT01380639|6-Minutes-Walking-Distance
1146425|NCT01380639|Vibration training
1146426|NCT01380639|Galileo
1146427|NCT01380639|Pulmonary rehabilitation
1146428|NCT01380626|alpha-1-antitrypsin-deficiency
1146429|NCT01380626|COPD
1146430|NCT01380626|exercise training
1146431|NCT01380626|muscle biopsy
1146432|NCT01380613|HIV
1146433|NCT01380613|depression
1146434|NCT01380613|drug use,
1146435|NCT01380613|risk reduction
1146436|NCT01380600|Vaccinia
1146437|NCT01380600|Vaccinia Virus
1146438|NCT01380600|JX-594
1146439|NCT01380600|Jennerex
1146440|NCT01380600|Colorectal Carcinoma
1146441|NCT01380600|Colorectal cancer
1146442|NCT01380600|Colon Cancer
1146443|NCT01380600|Rectal Cancer
1146444|NCT01380600|Pexa-Vec
1146445|NCT01380587|ALL
1146446|NCT01380587|XCL1
1146447|NCT01380587|Cytokines
1146448|NCT01380587|Prognosis
1146449|NCT01380574|atrial fibrillation
1146450|NCT01380574|cardioversion
1146451|NCT01380574|stroke
1146452|NCT01380574|thromboembolism
1146453|NCT01380561|asimadoline
1146454|NCT01380561|pharmacokinetic
1146455|NCT01380561|excretion of 14C-derived radioactivity
1146456|NCT01380561|metabolite profile
1146457|NCT01380561|14C-asimadoline
1146458|NCT01380561|metabolites
1146459|NCT01380561|single and multiple oral doses
1146460|NCT01380535|Extracorporeal photopheresis therapy
1146461|NCT01380535|Methoxsalen
1146462|NCT01380535|UVADEX
1146463|NCT01380535|Chronic graft versus host disease (cGvHD): National Institute Health Consensus Criteria
1146464|NCT01380522|Bioequivalence, single-dose, fed
1146465|NCT01380509|Bioequivalence, single-dose, fasting
1146466|NCT01380496|bioequivalence
1146467|NCT01380496|doxycycline monohydrate
1146468|NCT01380496|fed
1146469|NCT01380483|bioequivalence
1146470|NCT01380483|doxycycline monohydrate
1146471|NCT01380483|fasting
1146472|NCT01380470|Chronic Obstructive Pulmonary Disease
1146473|NCT01380470|Diagnosis differential
1146474|NCT01380470|Dyspnea/classification
1146475|NCT01380470|Dyspnea/etiology
1146476|NCT01380457|bioequivalence
1146477|NCT01380457|dronabinol
1146478|NCT01380457|fasting
1146479|NCT01380444|Intertrochanteric fracture
1146480|NCT01380444|Gamma3 intramedullary nail
1146481|NCT01380444|Sliding hip screw
1146482|NCT01380431|bioequivalence, lisinopril, fed
1146483|NCT01380418|Obesity
1146484|NCT01380405|Inhalators
1146485|NCT01380405|Education
1146486|NCT01380405|Primary care
1146487|NCT01380392|Liver cancer
1146488|NCT01380392|Uncertainty
1146489|NCT01380392|Personality
1146490|NCT01380392|coping strategies
1146491|NCT01380379|physical violence
1146492|NCT01380379|sexual violence
1146493|NCT01380366|Malabsorption
1146494|NCT01380353|Women undergoing total mastectomy
1146495|NCT01380353|Breast cancer prevention
1146496|NCT01380340|Seniors
1146497|NCT01380340|Driving
1146498|NCT01380340|Group work
1146499|NCT01380327|cockroach
1146500|NCT01380327|immunotherapy
1146501|NCT01380327|sublingual immunotherapy (SLIT)
1146502|NCT01380327|inner city asthma
1146503|NCT01380314|leishmaniasis
1146504|NCT01380314|cutaneois leishmaniasis
1146505|NCT01380314|miltefosine
1146506|NCT01380314|oral therapy
1146507|NCT01380314|treatment
1146508|NCT01380314|imiquimod
1146509|NCT01380301|Leishmaniasis
1146510|NCT01380301|Miltefosine
1146511|NCT01380301|Antimony
1146512|NCT01380301|Therapy
1146513|NCT01380288|Alzheimer's disease
1146514|NCT01380288|rivastigmine patch
1146515|NCT01380288|white matter change
1146516|NCT01380275|recurrent, refractory, bone, soft tissue, sarcomas
1146517|NCT01380262|Colorectal Cancer
1146518|NCT01380262|Skin Rash
1146519|NCT01380262|Pre-emptive treatment
1146520|NCT01380262|Doxycycline
1146521|NCT01380262|Anti-EGFR antibody
1146522|NCT01380262|Cetuximab
1146523|NCT01380262|Panitumumab
1146524|NCT01380249|Phase I
1146525|NCT01380249|Phase I multiple doses
1146526|NCT01380249|PDM08
1146527|NCT01380249|Cancer Treatment
1146528|NCT01380249|Pharmacokinetics and Pharmacodynamics
1146529|NCT01380249|Advanced Solid Tumors
1146530|NCT01380249|Prodimed
1146531|NCT01380210|Carbon dioxide intoxication
1146532|NCT01380210|Diffusion weighted images(DWI)
1146533|NCT01380197|pain
1146534|NCT01380197|sickle cell
1146535|NCT01380197|nubain
1146536|NCT01380197|morphine
1146537|NCT01380197|acute chest
1146538|NCT01380197|side effects
1146539|NCT01380184|Relapsed cancer
1146540|NCT01380158|pessary
1146541|NCT01380158|preterm birth
1146542|NCT01380158|short cervix
1146543|NCT01380158|cervical incompetence
1146544|NCT01380145|multiple myeloma
1146545|NCT01380145|MAGE-A3
1146546|NCT01380145|autologous stem cell transplant
1146547|NCT01380132|Fecal incontinence
1146548|NCT01380132|Treatment
1146549|NCT01380132|Surgery
1146550|NCT01380119|sputum conversion
1146551|NCT01380119|liver biochemistry
1146552|NCT01380119|weight loss
1146553|NCT01380119|quality of life
1146554|NCT01380106|Multiple myeloma
1146555|NCT01380106|Relapsed
1146556|NCT01380106|Revlimid
1146557|NCT01380093|abuse potential
1146558|NCT01380093|abuse liability
1146559|NCT01380093|recreational opioid use
1146560|NCT01380093|morphine
1146561|NCT01380067|Inguinal hernia
1146562|NCT01380067|Lateral umbilicus ligament
1146563|NCT01380067|Recurrence
1146564|NCT01380054|Pulmonary Hypertension
1146565|NCT01380054|Quality of life
1146566|NCT01380054|Coping
1146567|NCT01380054|Depression
1146568|NCT01380054|Anxiety
1146569|NCT01380054|Social support
1146570|NCT01380054|Control beliefs
1146571|NCT01380041|Multiple sclerosisCerebrospinal fluidBiomarkerCytokineArray
1146572|NCT01380028|chronic subdural hematomas
1146573|NCT01380028|corticosteroid
1146574|NCT01380028|treatment
1146575|NCT01380028|neurosurgery
1146576|NCT01380028|recurrence, adjuvant
1146577|NCT01380015|osteoarthritis
1146578|NCT01380015|spearmint
1146579|NCT01380015|rosmarinic acid
1146580|NCT01380002|care needs
1146581|NCT01379976|lung
1146582|NCT01379976|cancer
1146583|NCT01379976|non small cell lung cancer
1146584|NCT01379976|Advanced or metastatic non small cell lung cancer
1146585|NCT01379937|influenza
1146586|NCT01379937|H5N1
1146587|NCT01379937|vaccine
1146588|NCT01379937|children
1146589|NCT01379911|Satiety
1146590|NCT01379911|Food intake
1146591|NCT01379911|Yogurt
1146592|NCT01379898|Pheochromocytoma
1146593|NCT01379898|Doxazosin
1146594|NCT01379898|Phenoxybenzamine
1146595|NCT01379885|Pain
1146596|NCT01379885|immunization
1146597|NCT01379885|distraction
1146598|NCT01379885|hypnosis
1146599|NCT01379885|injections
1146600|NCT01379885|anxiety
1146601|NCT01379872|Prostate
1146602|NCT01379872|Head and Neck
1146603|NCT01379872|Anal
1146604|NCT01379846|Immunostimulation
1146605|NCT01379846|Haemophilus b conjugate vaccine
1146606|NCT01379846|HIB
1146607|NCT01379833|Chronic Inflammatory Demyelinating Polyneuropathy
1146608|NCT01379833|Neurotrophic corneal ulcer
1146609|NCT01379820|NEONATAL RESPIRATORY FAILURE
1146610|NCT01379820|OROTRACHEAL cpap
1146611|NCT01379820|NASAL cpap
1146612|NCT01379820|MECHANICAL VENTILATION
1146613|NCT01379820|PNEUMOTHORAX
1146614|NCT01379820|COMPENSATION BAG
1146615|NCT01379781|prevention
1146616|NCT01379781|postpartum depression
1146617|NCT01379755|stability
1146618|NCT01379755|single-radius
1146619|NCT01379755|multi-radius
1146620|NCT01379755|total knee arthroplasty
1146621|NCT01379742|prostate cancer
1146622|NCT01379742|prostate brachytherapy
1146623|NCT01379729|Type 1 Diabetes
1146624|NCT01379729|Transplantation
1146625|NCT01379729|Beta Cells
1146626|NCT01379729|Encapsulation
1146627|NCT01379703|HIV-1 infected patients
1146628|NCT01379703|Protease inhibitor
1146629|NCT01379703|Kaletra®
1146630|NCT01379690|HbA1c
1146631|NCT01379677|Coronary Artery Disease
1146632|NCT01379677|Myocardial perfusion imaging
1146633|NCT01379677|Rubidium
1146634|NCT01379677|Technetium
1146635|NCT01379664|Sevoflurane
1146636|NCT01379664|Isoflurane
1146637|NCT01379664|volatile anesthetic
1146638|NCT01379664|duration of hospitalization
1146639|NCT01379651|Egg allergy,specific oral tolerance induction
1146640|NCT01379638|cardiopulmonary bypass
1146641|NCT01379638|cardiac output
1146642|NCT01379638|flow rate
1146643|NCT01379638|lactate
1146644|NCT01379625|fatty acid oxidation
1146645|NCT01379625|triheptanoin
1146646|NCT01379625|long-chain fatty acid oxidation disorders
1146647|NCT01379625|LCHADD
1146648|NCT01379625|VLCADD
1146649|NCT01379625|CPT2
1146650|NCT01379625|TFP
1146651|NCT01379612|Ultrasound elastography
1146652|NCT01379612|Rectal cancer
1146653|NCT01379612|Preoperative chemoradiation
1146654|NCT01379599|cocaine
1146655|NCT01379599|heroin
1146656|NCT01379599|STIs
1146657|NCT01379599|HIV
1146658|NCT01379599|brief motivational intervention
1146659|NCT01379599|voluntary testing and counseling
1146660|NCT01379586|ONO-4053
1146661|NCT01379586|Healthy adult subjects
1146662|NCT01379586|First time in humans
1146663|NCT01379573|hydroxychloroquine
1146664|NCT01379573|Plaquenil
1146665|NCT01379573|congenital heart block
1146666|NCT01379573|neonatal lupus
1146667|NCT01379573|systemic lupus erythematosus
1146668|NCT01379573|Sjogren's syndrome
1146669|NCT01379573|autoantibodies
1146670|NCT01379573|SSA/Ro
1146671|NCT01379573|SSB/La
1146672|NCT01379573|autoimmunity
1146673|NCT01379573|pregnancy
1146674|NCT01379573|immunoglobulin
1146675|NCT01379547|Procalcitonin
1146676|NCT01379547|sepsis
1146677|NCT01379547|ICU
1146678|NCT01379547|antibiotic
1146679|NCT01379547|antibiotic duration
1146680|NCT01379547|Antibiotic treatment duration
1146681|NCT01379534|Solid tumors,
1146682|NCT01379534|advanced endometrial cancer,
1146683|NCT01379534|Endometrial Cancer,
1146684|NCT01379534|Second-line treatment,
1146685|NCT01379534|VEGF,
1146686|NCT01379534|Neoplasms,
1146687|NCT01379534|Endometrial Neoplasms,
1146688|NCT01379534|Uterine Neoplasms,
1146689|NCT01379534|Female Genital Neoplasms,
1146690|NCT01379534|Cancer,
1146691|NCT01379534|Carcinoma,
1146692|NCT01379534|Uterine Diseases,
1146693|NCT01379534|Female Genital Diseases,
1146694|NCT01379534|Tumors,
1146695|NCT01379534|Oral Administration,
1146696|NCT01379534|Capsules,
1146697|NCT01379534|Tablets,
1146698|NCT01379534|CHIR258,
1146699|NCT01379534|CHIR-258,
1146700|NCT01379534|CHIR 258,
1146701|NCT01379534|TKI258,
1146702|NCT01379534|TKI-258,
1146703|NCT01379534|TKI 258
1146704|NCT01379521|Localised
1146705|NCT01379521|unresectable
1146706|NCT01379521|chemoembolization
1146707|NCT01379495|burns
1146708|NCT01379495|rehabilitation
1146709|NCT01379482|Peritoneal carcinomatosis from gastric cancer
1146710|NCT01379469|Carbamazepine (Tegretol) use
1146711|NCT01379469|severe liver disease
1146712|NCT01379469|alpha-1-antitrypsin deficiency
1146713|NCT01379443|Children
1146714|NCT01379443|Rehabilitation
1146715|NCT01379443|Family Functioning
1146716|NCT01379443|Mental Health
1146717|NCT01379443|Costs
1146718|NCT01379443|Integration
1146719|NCT01379430|Vaccine
1146720|NCT01379430|Immune response
1146721|NCT01379417|Prematurity
1146722|NCT01379417|Nutrition
1146723|NCT01379417|Growth
1146724|NCT01379404|sepsis, fluid status, BIA, CVP
1146725|NCT01379391|Allogeneic Hematopoietic Stem Cell Transplantation
1146726|NCT01379391|Platelet Engraftment
1146727|NCT01379391|TPO
1146728|NCT01379365|wrinkle rhytid aging
1146729|NCT01379352|liver transplantation
1146730|NCT01379352|vecuronium
1146731|NCT01379339|Cabazitaxel
1146732|NCT01379339|Cabazitaxel and Cisplatin
1146733|NCT01379339|Phase I
1146734|NCT01379339|PF Induction Chemotherapy
1146735|NCT01379339|Squamous Cell Carcinoma
1146736|NCT01379339|Head and Neck
1146737|NCT01379339|Sanofi-Aventis Oncology
1146738|NCT01379339|Locally Advanced
1146739|NCT01379313|laparoscopic gynecologic surgery
1146740|NCT01379313|gas exchange
1146741|NCT01379313|inspiratory time
1146742|NCT01379313|expiratory time
1146743|NCT01379313|I:E ratio
1146744|NCT01379300|Hemophilia B
1146745|NCT01379287|Iso-Fludelone
1146746|NCT01379287|KOS-1803
1146747|NCT01379287|Dose-Escalation
1146748|NCT01379287|10-202
1146749|NCT01379274|MDS
1146750|NCT01379274|Low risk disease
1146751|NCT01379274|IPSS
1146752|NCT01379261|STEMI
1146753|NCT01379261|primary PCI
1146754|NCT01379261|Hypothermia
1146755|NCT01379261|Endovascular cooling
1146756|NCT01379261|Cardiac MRI
1146757|NCT01379235|independent 65 years old and above
1146758|NCT01379222|AAA
1146759|NCT01379222|Abdominal Aortic Aneurysm
1146760|NCT01379222|EVAR
1146761|NCT01379222|Endovascular aneurysm repair
1146762|NCT01379209|AHSCT
1146763|NCT01379209|Bone Marrow Transplant
1146764|NCT01379209|Leukemia
1146765|NCT01379209|myelodysplastic syndrome
1146766|NCT01379209|hematological malignancies
1146767|NCT01379209|Graft-versus-host-disease
1146768|NCT01379209|GvHD
1146769|NCT01379209|Hematopoietic Stem Cell Transplantation
1146770|NCT01379209|Stem Cell
1146771|NCT01379209|Transplantation
1146772|NCT01379196|Graves Orbitopathy
1146773|NCT01379196|Macrolide antibiotics
1146774|NCT01379196|Inflammation
1146775|NCT01379196|Clinical Activity Score
1146776|NCT01379183|Healthy
1146777|NCT01379183|Men
1146778|NCT01379183|Women
1146779|NCT01379183|No known gastrointestinal disease
1146780|NCT01379183|Aged between 18-70 years
1146781|NCT01379170|brown adipose tissue
1146782|NCT01379170|mitochondrial dysfunction
1146783|NCT01379170|insulin resistance
1146784|NCT01379157|Patients with ventilator-associated pneumonia
1146785|NCT01379131|Manifestation
1146786|NCT01379131|Coronary Heart Disease
1146787|NCT01379131|Myocardial infarction
1146788|NCT01379131|Angina pectoris
1146789|NCT01379131|Unheralded
1146790|NCT01379131|General Practice Research Database
1146791|NCT01379131|Myocardial Ischaemia National Audit Project
1146792|NCT01379131|CALIBER
1146793|NCT01379118|Total knee replacement
1146794|NCT01379105|Electromyography
1146795|NCT01379105|Muscle Stretching Exercises
1146796|NCT01379105|Neuromuscular agents
1146797|NCT01379105|Sedentary Lifestyle
1146798|NCT01379092|Radiography
1146799|NCT01379092|Breast Specimen Imaging
1146800|NCT01379066|Mycobacterium tuberculosis
1146801|NCT01379066|Pulmonary tuberculosis
1146802|NCT01379066|Electronic nose
1146803|NCT01379066|Gas chromatography
1146804|NCT01379053|Staphylococcus aureus
1146805|NCT01379053|Methicillin-resistant staphylococcus aureus
1146806|NCT01379053|Nosocomial disease
1146807|NCT01379053|Electronic nose
1146808|NCT01379053|Gas chromatography
1146809|NCT01379040|Cystic Fibrosis
1146810|NCT01379040|Pseudomonas aeruginosa
1146811|NCT01379040|Volatile Organic Compounds
1146812|NCT01379040|Electronic nose
1146813|NCT01379040|Gas Chromatography
1146814|NCT01379027|Depression
1146815|NCT01379027|Website intervention
1146816|NCT01379027|CBT
1146817|NCT01379014|Decisional conflict
1146818|NCT01379014|Disclosure
1146819|NCT01379014|Mental Health history
1146820|NCT01379014|Mental health service users
1146821|NCT01379014|Decision Aid Tool
1146822|NCT01379014|Vocational Specialists
1146823|NCT01379001|cholinergic function
1146824|NCT01379001|aging
1146825|NCT01379001|pharmacologic MRI
1146826|NCT01378949|pain score
1146827|NCT01378936|criminal behavior
1146828|NCT01378936|substance abuse
1146829|NCT01378936|HIV risk behavior
1146830|NCT01378936|criminogenic thinking
1146831|NCT01378936|shame
1146832|NCT01378936|guilt
1146833|NCT01378936|empathy
1146834|NCT01378936|jail inmates
1146835|NCT01378936|restorative justice
1146836|NCT01378936|crime
1146837|NCT01378923|Mindfulness
1146838|NCT01378923|Values
1146839|NCT01378923|Jail Inmates
1146840|NCT01378923|Impulsivity
1146841|NCT01378923|Substance Abuse
1146842|NCT01378923|HIV risk behavior
1146843|NCT01378923|Anxiety
1146844|NCT01378923|Depression
1146845|NCT01378923|Criminogenic Thinking
1146846|NCT01378910|HIV
1146847|NCT01378910|TROPISM
1146848|NCT01378910|PBMC
1146849|NCT01378910|GENOTYPE
1146850|NCT01378910|454 SEQUENCING
1146851|NCT01378897|bariatric surgery
1146852|NCT01378897|gastric bypass surgery
1146853|NCT01378884|Gastroparesis
1146854|NCT01378884|Domperidone
1146855|NCT01378884|Motilium
1146856|NCT01378871|T Cell
1146857|NCT01378871|T-Cell
1146858|NCT01378871|Leukemia
1146859|NCT01378871|Lymphoma
1146860|NCT01378871|Leukemia/Lymphoma
1146861|NCT01378871|ATL
1146862|NCT01378858|Smoking
1146863|NCT01378858|Substance-Related Disorders
1146864|NCT01378858|medication adherence
1146865|NCT01378858|Methadone
1146866|NCT01378845|Morbus Raynaud
1146867|NCT01378845|Ulcera Hands, Toes
1146868|NCT01378845|Vasospastic disorder
1146869|NCT01378845|Raynaud's phenomenon
1146870|NCT01378832|Intra-abdominal abscess
1146871|NCT01378832|wound infection
1146872|NCT01378832|colorectal surgery
1146873|NCT01378819|laparoscopic cholecystectomy
1146874|NCT01378819|Postoperative pain
1146875|NCT01378806|overweight
1146876|NCT01378806|obesity
1146877|NCT01378806|adults
1146878|NCT01378806|children
1146879|NCT01378793|Acupressure
1146880|NCT01378793|Insomnia
1146881|NCT01378793|Sleep Disorders
1146882|NCT01378780|Stroke
1146883|NCT01378780|hypertension
1146884|NCT01378780|diet
1146885|NCT01378780|sodium
1146886|NCT01378780|physical activity
1146887|NCT01378767|Dietary restriction
1146888|NCT01378767|oxidative stress
1146889|NCT01378767|fasting
1146890|NCT01378754|hydrodilation
1146891|NCT01378754|general anesthetic
1146892|NCT01378741|delirium
1146893|NCT01378741|cardiac surgery
1146894|NCT01378741|postoperative sedation
1146895|NCT01378728|Optical imaging
1146896|NCT01378728|Fluorescence imaging
1146897|NCT01378728|Chronic and acute wounds
1146898|NCT01378728|Wound bacteria
1146899|NCT01378728|Bacterial biofilms
1146900|NCT01378728|Pathogenic bacteria
1146901|NCT01378728|Microorganisms
1146902|NCT01378728|Wound infection
1146903|NCT01378728|Wound healing
1146904|NCT01378728|Treatment response assessment
1146905|NCT01378715|coronary artery disease
1146906|NCT01378715|percutaneous coronary intervention
1146907|NCT01378715|statins
1146908|NCT01378715|periprocedural myocardial infarction
1146909|NCT01378702|Mistletoe
1146910|NCT01378702|Anthroposophical medicine
1146911|NCT01378663|Congenital cardiac surgery
1146912|NCT01378663|Postoperative pain management
1146913|NCT01378650|Tinnitus
1146914|NCT01378650|Medication therapy management
1146915|NCT01378650|Cilostazol
1146916|NCT01378650|Antiplatelet agents
1146917|NCT01378637|Leg
1146918|NCT01378637|Robotic device
1146919|NCT01378637|AMES
1146920|NCT01378637|Stroke
1146921|NCT01378637|Cerebrovascular Accident
1146922|NCT01378637|Rehabilitation
1146923|NCT01378611|intractable childhood epilepsy
1146924|NCT01378611|VNS
1146925|NCT01378611|immune system
1146926|NCT01378598|erlotinib
1146927|NCT01378598|educational intervention
1146928|NCT01378598|direct care nurse
1146929|NCT01378585|DLBS1033
1146930|NCT01378585|safety
1146931|NCT01378585|fibrinolytic
1146932|NCT01378585|fibrinogenolytic
1146933|NCT01378585|antiplatelet
1146934|NCT01378572|ICD
1146935|NCT01378572|sudden cardiac death
1146936|NCT01378572|mapping
1146937|NCT01378559|Penis prosthesis
1146938|NCT01378559|Titan
1146939|NCT01378559|Satisfaction
1146940|NCT01378559|Complications
1146941|NCT01378533|triple-negative breast cancer
1146942|NCT01378533|dose-dense
1146943|NCT01378533|epirubicin and cyclophosphamide followed by paclitaxel（AC-T）
1146944|NCT01378533|paclitaxel plus carboplatin（PC）
1146945|NCT01378533|3 years DFS
1146946|NCT01378533|the tolerance
1146947|NCT01378520|breathlessness
1146948|NCT01378520|resistive load breathing
1146949|NCT01378520|beta-endorphins
1146950|NCT01378507|endoscopic submucosal dissection
1146951|NCT01378507|gastrointestinal neoplasm
1146952|NCT01378494|osteoporosis
1146953|NCT01378494|bone
1146954|NCT01378494|HIV
1146955|NCT01378494|antiretrovirals
1146956|NCT01378494|inflammation
1146957|NCT01378455|handwriting
1146958|NCT01378455|cerebral palsy
1146959|NCT01378455|visual perception
1146960|NCT01378455|sensory function
1146961|NCT01378455|motor function
1146962|NCT01378455|computerized handwriting programs
1146963|NCT01378442|Cerebral palsy
1146964|NCT01378442|bone density
1146965|NCT01378442|bone strength
1146966|NCT01378429|Perennial Allergic Rhinitis
1146967|NCT01378429|PAR
1146968|NCT01378416|Acute myelogenous leukemia
1146969|NCT01378416|myelodysplastic Syndrome
1146970|NCT01378416|cancer
1146971|NCT01378403|Schizophrenia
1146972|NCT01378403|Cognitive deficites
1146973|NCT01378403|Degraded objects
1146974|NCT01378403|Magnocellular pathway
1146975|NCT01378390|Complex perianal fistula
1146976|NCT01378390|Crohn disease
1146977|NCT01378390|Adipose-derived stem cells
1146978|NCT01378390|Liposuction
1146979|NCT01378377|MEK inhibitor
1146980|NCT01378377|Temsirolimus
1146981|NCT01378377|Solid Tumor
1146982|NCT01378377|Phase I
1146983|NCT01378377|Pimasertib
1146984|NCT01378338|GERD
1146985|NCT01378338|Comparison between ERD and NERD
1146986|NCT01378338|Rate of complete resolution
1146987|NCT01378338|rate of recurrence
1146988|NCT01378338|QOL
1146989|NCT01378338|To investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI
1147116|NCT01377792|pulmonary inflammation
1146990|NCT01378338|The aim of this study is to investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI
1146991|NCT01378325|spinal
1146992|NCT01378325|cesarean delivery
1146993|NCT01378325|phenylephrine
1146994|NCT01378325|hypotension
1146995|NCT01378312|vaccine
1146996|NCT01378312|TB
1146997|NCT01378312|tuberculosis
1146998|NCT01378299|testosterone
1146999|NCT01378273|neuroprotection
1147000|NCT01378273|erythropoietin
1147001|NCT01378273|Epo
1147002|NCT01378273|ELGANs
1147003|NCT01378273|preterm
1147004|NCT01378273|neonate
1147005|NCT01378260|Peripheral Arterial Disease
1147006|NCT01378260|Claudication
1147007|NCT01378260|Comparative Effectiveness Research
1147008|NCT01378260|PAD Study
1147009|NCT01378260|PAD
1147010|NCT01378260|atherosclerosis
1147011|NCT01378260|Intermittent claudication
1147012|NCT01378260|leg pain
1147013|NCT01378247|Heart Failure
1147014|NCT01378247|Family Nursing
1147015|NCT01378247|Health-Related Quality of Life
1147016|NCT01378247|Heart Failure Clinic
1147017|NCT01378221|vitamin D
1147018|NCT01378221|cardiac surgery
1147019|NCT01378221|inflammation
1147020|NCT01378221|immune system
1147021|NCT01378221|age
1147022|NCT01378208|Intermittent fasting
1147023|NCT01378208|Meal frequency
1147024|NCT01378208|body composition
1147025|NCT01378208|cognitive function
1147026|NCT01378208|glucose metabolism
1147027|NCT01378195|Alzheimer's Disease
1147028|NCT01378195|Dementia
1147029|NCT01378195|caregiving
1147030|NCT01378195|caregiver
1147031|NCT01378195|coping
1147032|NCT01378195|coping with caregiving
1147033|NCT01378195|stress
1147034|NCT01378182|Transplantation,Stem Cell
1147035|NCT01378182|Wilson's Disease
1147036|NCT01378169|SIRS
1147037|NCT01378169|Sepsis
1147038|NCT01378169|Severe Sepsis
1147039|NCT01378169|Septic Shock
1147040|NCT01378169|Inflammatory processes
1147041|NCT01378169|Cytokines
1147042|NCT01378169|HLA-DR
1147043|NCT01378169|HLA type II
1147044|NCT01378169|Chemokines
1147045|NCT01378169|TLR expression
1147046|NCT01378169|mRNA expression in whole blood
1147047|NCT01378169|Bacterial DNA detection
1147048|NCT01378169|Prognosis factors
1147049|NCT01378169|Infection
1147050|NCT01378169|Diagnosis
1147051|NCT01378156|Therapy for HIV Infection
1147052|NCT01378156|Suppressive ART with no failures
1147053|NCT01378156|Treatment interruption
1147054|NCT01378143|Colorectal Cancer
1147055|NCT01378143|Pentamidine bis(2-hydroxyethanesulfonate)
1147056|NCT01378143|OCZ103-OS
1147057|NCT01378143|Standard of Care
1147058|NCT01378130|CCS
1147059|NCT01378130|CSC
1147060|NCT01378130|Subretinal Fluid
1147061|NCT01378130|multimodal imaging
1147062|NCT01378117|diabetes
1147063|NCT01378117|non critical care setting
1147064|NCT01378117|hyperglycemia
1147065|NCT01378117|treatment
1147066|NCT01378117|oral antidiabetic agents
1147067|NCT01378117|subcutaneous insulin
1147068|NCT01378104|reducing dose of peginterferon
1147069|NCT01378104|chronic hepatitis c
1147070|NCT01378104|Koreans
1147071|NCT01378104|IL28B polymorphism
1147072|NCT01378091|Androgen Independent Prostate Cancer
1147073|NCT01378078|schizophrenia
1147074|NCT01378078|negative syndrome
1147075|NCT01378078|PANSS
1147076|NCT01378065|POP
1147077|NCT01378065|pelvic organ prolapse
1147078|NCT01378065|anterior prolapse
1147079|NCT01378065|posterior prolapse
1147080|NCT01378065|vaginal prolapse
1147081|NCT01378065|vaginal floor reconstruction
1147082|NCT01378039|COPD
1147083|NCT01378039|Asthma
1147084|NCT01378039|Pathophysiology
1147085|NCT01378039|Genetics
1147086|NCT01378039|Phenotype
1147087|NCT01378039|Treatment response
1147088|NCT01378026|Amyotrophic Lateral Sclerosis
1147089|NCT01378026|G72
1147090|NCT01378026|SNP
1147091|NCT01378013|Metabonomics
1147092|NCT01378013|Systems biology
1147093|NCT01378013|Intelligent knife
1147094|NCT01378013|Colorectal cancer
1147095|NCT01378013|NMR
1147096|NCT01378013|Mass spectrometry
1147097|NCT01377974|Leishmaniasis
1147098|NCT01377974|Mucocutaneous Leishmaniasis
1147099|NCT01377974|Therapeutics
1147100|NCT01377974|meglumine antimoniate
1147101|NCT01377974|miltefosine
1147102|NCT01377948|Anger
1147103|NCT01377948|Aggression
1147104|NCT01377948|CBT
1147105|NCT01377948|Videogame
1147106|NCT01377948|biofeedback
1147107|NCT01377909|chronic hepatitis C, interferon
1147108|NCT01377883|Needle, Anxiety, Pain, Clowns
1147109|NCT01377870|multiple sclerosis mesenchymal stem cell intravenous injection
1147110|NCT01377844|Diabetes mellitus
1147111|NCT01377818|COPD
1147112|NCT01377818|Exercise trainig
1147113|NCT01377805|Multiple Sclerosis hydrocephalus
1147114|NCT01377792|hypertonic saline
1147115|NCT01377792|cystic fibrosis
1147117|NCT01377792|pulmonary exacerbation
1147118|NCT01377779|Oxiplex/AP gel
1147119|NCT01377779|Prevention of Asherman's syndrome
1147120|NCT01377779|Intra uterine adhesions
1147121|NCT01377766|Bell's palsy
1147122|NCT01377766|psychological stress
1147123|NCT01377766|personality factors
1147124|NCT01377766|psychological factors
1147125|NCT01377753|Toxicity
1147126|NCT01377753|Thermal Ablation/Damage
1147127|NCT01377753|Localized Prostate Cancer
1147128|NCT01377753|Laser Ablation
1147129|NCT01377753|PSA Levels
1147130|NCT01377753|Prostate Cancer
1147134|NCT01377701|pituitary adenomas
1147135|NCT01377701|recovery of vision
1147136|NCT01377701|trans-sphenoidal surgery
1147137|NCT01377688|DKD
1147138|NCT01377636|Isoproterenol
1147139|NCT01377636|Bispectral index (BIS)
1147140|NCT01377636|electrophysiology studies (EPS)
1147141|NCT01377623|Spinal fusion
1147142|NCT01377623|Inflammatory response
1147143|NCT01377623|Inflammatory markers
1147144|NCT01377623|Dexmedetomidine
1147145|NCT01377610|Outpatient detoxification
1147146|NCT01377610|Opioid dependence
1147147|NCT01377610|Naltrexone
1147148|NCT01377610|Vivitrol
1147149|NCT01377610|Buprenorphine
1147150|NCT01377597|retinal vein occlusion
1147151|NCT01377597|branch retinal vein occlusion
1147152|NCT01377597|central retinal vein occlusion
1147153|NCT01377597|visual impairment
1147154|NCT01377597|macular edema
1147155|NCT01377597|ranibizumab
1147156|NCT01377584|Continuous Positive Airway Pressure
1147157|NCT01377584|Patient Compliance
1147158|NCT01377584|Intervention Studies
1147159|NCT01377584|Spouses
1147160|NCT01377571|diarrhea
1147161|NCT01377571|fever
1147162|NCT01377571|nausea
1147163|NCT01377571|vomit
1147164|NCT01377571|irritability
1147165|NCT01377558|aerobic training
1147166|NCT01377558|resistance training
1147167|NCT01377558|combination of aerobic and resistance training
1147168|NCT01377558|diabetes
1147169|NCT01377558|type 2 diabetes
1147170|NCT01377558|HbA1c
1147171|NCT01377558|endothelial dysfunction
1147172|NCT01377558|inflammation markers
1147173|NCT01377558|Parodontitis
1147174|NCT01377558|Exercise intervention
1147175|NCT01377558|training
1147176|NCT01377545|Infraclavicular
1147177|NCT01377545|Nerve Block
1147178|NCT01377545|Needle
1147179|NCT01377545|Perineural Catheter
1147180|NCT01377545|Volunteer
1147181|NCT01377545|Upper Extremity Nerve Block
1147182|NCT01377545|Sensation
1147183|NCT01377545|Strength
1147184|NCT01377532|Pheochromocytoma
1147185|NCT01377532|Paraganglioma
1147186|NCT01377532|MIBG
1147187|NCT01377532|131I-MIBG
1147188|NCT01377532|Resistant
1147189|NCT01377532|Relapsed
1147190|NCT01377532|Treatment
1147191|NCT01377532|UCSF
1147192|NCT01377532|Pediatric
1147193|NCT01377532|Adult
1147194|NCT01377532|Oncology
1147195|NCT01377519|Fibroids
1147196|NCT01377519|Uterine
1147197|NCT01377519|Focused Ultrasound
1147198|NCT01377519|Magnetic Resonance focused ultrasound
1147199|NCT01377519|HIFU
1147200|NCT01377519|NOninvasive
1147201|NCT01377519|Treatment
1147202|NCT01377506|behavioral weight control
1147203|NCT01377506|lifestyle intervention
1147204|NCT01377506|memory training
1147205|NCT01377506|cognitive training
1147206|NCT01377506|community-based
1147207|NCT01377493|chewing-gum
1147208|NCT01377493|enamel subsurface lesion
1147209|NCT01377493|calcium additives
1147210|NCT01377493|fluoride
1147211|NCT01377493|in situ
1147212|NCT01377467|Osteoporosis
1147213|NCT01377467|Osteopenia
1147214|NCT01377467|Denosumab
1147215|NCT01377467|Transplantation
1147216|NCT01377467|Kidney
1147217|NCT01377454|mTBI
1147218|NCT01377454|concussion
1147219|NCT01377454|mild Traumatic Brain Injury
1147220|NCT01377454|balance
1147221|NCT01377454|sensors
1147222|NCT01377441|Ibuprofen
1147223|NCT01377441|Cytokines
1147224|NCT01377441|Recovery
1147225|NCT01377441|IV ibuprofen
1147226|NCT01377441|major surgery
1147227|NCT01377428|COPD
1147228|NCT01377428|Indacaterol
1147229|NCT01377428|Formoterol
1147230|NCT01377415|arthroscopy
1147231|NCT01377415|shoulder surgery
1147232|NCT01377415|subacromial
1147233|NCT01377415|continuous bupivacaine
1147234|NCT01377389|Prostate cancer
1147235|NCT01377389|Castrate sensitive prostate carcinoma
1147236|NCT01377389|Metastatic prostate carcinoma
1147237|NCT01377389|Androgen deprivation therapy
1147238|NCT01377389|ADT
1147239|NCT01377389|Prostate-specific antigen
1147240|NCT01377389|PSA
1147241|NCT01377389|Ipilimumab
1147242|NCT01377389|Yervoy
1147243|NCT01377389|BMS-734016
1147244|NCT01377389|MDX010
1147245|NCT01377389|Leuprolide
1147246|NCT01377389|Lupron Depot
1147247|NCT01377389|Leuprolide Acetate
1147248|NCT01377389|Goserelin
1147249|NCT01377389|Zoladex
1147250|NCT01377389|Degarelix
1147251|NCT01377389|Firmagon
1147252|NCT01377363|metastatic breast cancer
1147253|NCT01377363|primary breast cancer
1147254|NCT01377350|Heart failure
1147255|NCT01377350|monitoring
1147256|NCT01377337|cardiac arrest
1147257|NCT01377337|cardiopulmonary resuscitation
1147258|NCT01377337|(sodium) bicarbonate
1147259|NCT01377337|return of spontaneous circulation
1147260|NCT01377337|outcome
1147261|NCT01377324|Breast cancer
1147262|NCT01377324|Fulvestrant
1147263|NCT01377324|FES
1147264|NCT01377324|PET
1147265|NCT01377324|Positron
1147266|NCT01377324|Emission
1147267|NCT01377324|Tomography
1147268|NCT01377324|Fluoroestradiol
1147269|NCT01377324|FES-PET
1147270|NCT01377324|Molecular Imaging
1147271|NCT01377324|Estrogen Receptor
1147272|NCT01377311|limbal stem cell
1147273|NCT01377311|amniotic membrane
1147274|NCT01377311|ex vivo expansion of autologous limbal stem cell
1147275|NCT01377311|unilateral limbal stem cell insufficiency
1147276|NCT01377285|chronic kidney disease
1147277|NCT01377285|pentoxifylline
1147278|NCT01377285|angiotensin receptor blockers(ARB)
1147279|NCT01377272|HIV/AIDS
1147280|NCT01377272|spatial epidemiology
1147281|NCT01377272|geographic information system
1147282|NCT01377272|HIV-infection/Aids
1147283|NCT01377259|changes
1147284|NCT01377259|tissue
1147285|NCT01377259|oxygenation
1147286|NCT01377259|saturation
1147287|NCT01377259|between
1147288|NCT01377259|upper
1147289|NCT01377259|lower
1147290|NCT01377259|extremities
1147291|NCT01377259|patients
1147292|NCT01377259|Adverse Effect
1147293|NCT01377259|Spinal and Epidural
1147294|NCT01377246|Somatostatin.
1147295|NCT01377246|Polycystic kidney disease.
1147296|NCT01377246|Renal insufficiency.
1147297|NCT01377233|Schizophrenia
1147298|NCT01377233|Antipsychotic
1147299|NCT01377233|Zicronapine
1147300|NCT01377233|Lu 31-310
1147301|NCT01377220|Hepatocellular carcinoma
1147302|NCT01377220|Positron Emission Tomography/computed tomography (PET-CT)
1147303|NCT01377220|11C-Choline
1147304|NCT01377220|alpha fetoprotein
1147305|NCT01377220|Dynamic magnetic resonance imaging
1147306|NCT01377220|Abdomen computed tomography
1147307|NCT01377220|Tumoral liver biopsy
1147308|NCT01377207|ST segment Elevation Myocardial Infarction
1147309|NCT01377207|Optical Coherence Tomography
1147310|NCT01377207|Percutaneous Coronary Intervention
1147311|NCT01377207|Thrombus hystopathology
1147312|NCT01377207|Gender differences
1147313|NCT01377194|Depression
1147314|NCT01377194|Major Depressive Disorder
1147315|NCT01377181|Inguinal hernia
1147316|NCT01377181|Laparoscope
1147317|NCT01377181|Lateral us ligament
1147318|NCT01377181|Recurrence
1147319|NCT01377181|Pediatric
1147320|NCT01377181|unilateral inguinal hernia
1147321|NCT01377155|basal insulin
1147322|NCT01377155|hypoglycemia
1147323|NCT01377155|diabetes mellitus type two
1147324|NCT01377142|Uterovaginal prolapse
1147325|NCT01377142|hysteropexy
1147326|NCT01377142|mesh
1147327|NCT01377129|Residual Rotational Laxity
1147328|NCT01377103|heart failure
1147329|NCT01377103|hypogonadism
1147330|NCT01377103|testosterone
1147331|NCT01377077|vitiligo
1147332|NCT01377077|piebaldism
1147333|NCT01377077|punchgrafting
1147334|NCT01377077|minigrafting
1147335|NCT01377077|stable for at least 12 months
1147336|NCT01377064|HIV
1147337|NCT01377064|physical activity
1147338|NCT01377064|cardiovascular disease risk
1147339|NCT01377051|COPD
1147340|NCT01377051|Inspiratory capacity
1147341|NCT01377051|Residual volume
1147342|NCT01377051|Total lung resistance
1147343|NCT01377051|Arterial Oxygen
1147344|NCT01377038|Osteoarthritis
1147345|NCT01377038|Chronic pain
1147346|NCT01377038|Central pain
1147347|NCT01377012|Rheumatoid Arthritis
1147348|NCT01377012|RA
1147349|NCT01377012|ACR
1147350|NCT01377012|inflammatory joints
1147351|NCT01376999|Sterility
1147352|NCT01376999|FSH-r
1147353|NCT01376999|intrauterine insemination
1147354|NCT01376999|unexplained sterility
1147355|NCT01376973|stress, temporomandibular disorders.
1147356|NCT01376960|forefoot surgery
1147357|NCT01376960|Ankle Block
1147358|NCT01376960|Popliteal Fossa Block
1147359|NCT01376947|IUD device insertion
1147360|NCT01376947|Nulliparous
1147361|NCT01376947|Multiparous
1147362|NCT01376947|Pain
1147363|NCT01376934|hysteroscopy
1147364|NCT01376934|saline solution
1147365|NCT01376934|carbon dioxide
1147366|NCT01376934|compare two techniques in office hysteroscopy co2 and saline solution
1147367|NCT01376921|Growth disorders
1147368|NCT01376921|Saizen
1147369|NCT01376921|Easypod
1147370|NCT01376921|Growth hormone
1147371|NCT01376921|Pediatric subject
1147372|NCT01376908|Phenylketonuria (PKU)
1147373|NCT01376908|Kuvan® (Sapropterin)
1147374|NCT01376908|Phe-restricted diet
1147375|NCT01376908|Paediatric <4 years old
1147376|NCT01376908|responders to BH4
1147377|NCT01376908|Phe tolerance
1147378|NCT01376895|Black MSM/W
1147379|NCT01376895|HIV
1147380|NCT01376882|Caffeine
1147381|NCT01376882|Withdrawal
1147382|NCT01376882|Cognitive function
1147383|NCT01376882|Mood
1147384|NCT01376882|Cerebral haemodynamics
1147385|NCT01376869|Hops
1147386|NCT01376869|Mood
1147387|NCT01376869|Cognitive Function
1147388|NCT01376869|Bioavailability
1147389|NCT01376869|Satiety
1147390|NCT01376869|Blood Pressure
1147391|NCT01376869|Heart rate
1147392|NCT01376856|mediastinal lymph node with false positive FDG PET/CT results in lung cancer staging
1147393|NCT01376843|latent tuberculosis in health care workers
1147394|NCT01376830|COPD
1147395|NCT01376830|Exacerbations
1147396|NCT01376830|Viruses
1147397|NCT01376817|Severe acute pancreatitis
1147398|NCT01376817|total parenteral nutrition
1147399|NCT01376817|fat emulsions
1147400|NCT01376817|omega 3 fatty acids
1147401|NCT01376791|Periodontal disease
1147402|NCT01376791|Atherosclerosis
1147403|NCT01376791|Oral Pathogens
1147404|NCT01376791|Native Americans
1147405|NCT01376791|Inflammatory cytokines
1147406|NCT01376791|Microbial metagenomics
1147407|NCT01376778|Perinatology
1147408|NCT01376778|Cytomegalovirus immune globulin
1147409|NCT01376778|Cytogam
1147410|NCT01376778|CMVIG infusions
1147411|NCT01376765|SARS, coronavirus, vaccine, adjuvant, Alhydrogel®, severe acute respiratory syndrome
1147412|NCT01376739|Magnevist
1147413|NCT01376739|MR angiography
1147414|NCT01376713|Melanoma
1147415|NCT01376687|Osteopathic Medicine
1147416|NCT01376687|Cervical Spine
1147417|NCT01376687|Kinetics
1147418|NCT01376674|localised
1147419|NCT01376674|prostate cancer
1147420|NCT01376674|radiotherapy
1147421|NCT01376674|immunology
1147422|NCT01376661|Prostate Cancer
1147423|NCT01376661|Active Surveillance
1147424|NCT01376661|Low risk prostate cancer
1147425|NCT01376635|Chronic Kidney Disease
1147426|NCT01376635|Autonomic Dysfunction
1147427|NCT01376609|Stroke
1147428|NCT01376609|Ischaemic Stroke
1147429|NCT01376609|Cerebral Infarction
1147430|NCT01376609|Cerebrovascular Disorders
1147431|NCT01376609|Brain Diseases
1147432|NCT01376609|Nervous System Diseases
1147433|NCT01376609|Vascular Diseases
1147434|NCT01376609|Brain Infarction
1147435|NCT01376609|Brain Ischemia
1147436|NCT01376609|mismatch
1147437|NCT01376609|PWI/DWI mismatch
1147438|NCT01376609|ischaemic penumbra
1147439|NCT01376609|image analysis
1147440|NCT01376596|Remission
1147441|NCT01376596|Psychosocial Functioning
1147442|NCT01376596|Symptoms reduction
1147443|NCT01376583|Breast cancer
1147444|NCT01376583|Exercise
1147445|NCT01376583|Myokines
1147446|NCT01376583|AMPK
1147447|NCT01376570|HIV
1147448|NCT01376570|Opiate dependence
1147449|NCT01376570|Opiate replacement therapy
1147450|NCT01376570|Cocaine-related disorders
1147451|NCT01376570|Risk Reduction Behavior
1147452|NCT01376570|Medication Adherence
1147453|NCT01376570|Motivation
1147454|NCT01376557|diabetes mellitus
1147455|NCT01376544|Neonate
1147456|NCT01376544|Weaning
1147457|NCT01376544|Assist control ventilation
1147458|NCT01376544|Pressure support ventilation
1147459|NCT01376531|acute renal failure
1147460|NCT01376531|cerebrovascular autoregulation
1147461|NCT01376531|transcranial Doppler
1147462|NCT01376531|continuous veno-venous hemodialysis
1147463|NCT01376518|acute respiratory distress syndrome
1147464|NCT01376518|acute lung injury
1147465|NCT01376518|cerebrovascular autoregulation
1147466|NCT01376518|transcranial Doppler
1147467|NCT01376518|ventilation
1147468|NCT01376505|Vaccine Therapy
1147469|NCT01376492|Schizophrenia
1147470|NCT01376492|Sleep disturbances
1147471|NCT01376492|Quality of sleep
1147472|NCT01376492|Functioning level
1147473|NCT01376492|Antipsychotic therapy.
1147474|NCT01376479|HFMD
1147475|NCT01376479|EV71
1147476|NCT01376479|Enterovirus
1147477|NCT01376479|INV21
1147478|NCT01376479|Encephalitis
1147479|NCT01376466|acute appendicitis
1147480|NCT01376466|diagnosis
1147481|NCT01376466|computed tomography
1147482|NCT01376453|External Radiation Therapy
1147483|NCT01376453|Locally Advanced Rectal
1147484|NCT01376453|Adenocarcinoma
1147485|NCT01376440|three or more loss stools in 24 hours
1147486|NCT01376414|dyspepsia
1147487|NCT01376414|abdominal
1147488|NCT01376414|pain
1147489|NCT01376414|helicobacter
1147490|NCT01376414|pylori
1147491|NCT01376414|[C06.405.748.398]
1147492|NCT01376414|[C06.405.748.586]
1147493|NCT01376414|[C06.405.748.586.698]
1147494|NCT01376414|[C06.405.748.586.849]
1147495|NCT01376388|Chronic Obstructive Pulmonary Disease (COPD)
1147496|NCT01376388|Pharmacogenetics
1147497|NCT01376388|GSK573719/GW642444
1147498|NCT01376375|Acupuncture
1147499|NCT01376375|Low Back Pain
1147500|NCT01376362|Cystoid Macular Edema
1147501|NCT01376362|Intermediate Uveitis
1147502|NCT01376362|Uveitis
1147503|NCT01376362|OCT
1147504|NCT01376362|Interferon-Gamma (IFN-Gamma)
1147505|NCT01376349|depression
1147506|NCT01376349|anxiety disorder
1147507|NCT01376349|cognitive/functional effects
1147508|NCT01376349|sexual dysfunction
1147509|NCT01376349|cancer survivor
1147510|NCT01376349|breast cancer
1147511|NCT01376349|cervical cancer
1147512|NCT01376349|fallopian tube cancer
1147513|NCT01376349|uterine sarcoma
1147514|NCT01376349|vaginal cancer
1147515|NCT01376349|vulvar cancer
1147516|NCT01376349|ovarian epithelial cancer
1147517|NCT01376349|ovarian germ cell tumor
1147518|NCT01376349|ovarian sarcoma
1147519|NCT01376349|ovarian stromal cancer
1147520|NCT01376349|primary peritoneal cavity cancer
1147521|NCT01376349|endometrial cancer
1147522|NCT01376336|environmental health
1147523|NCT01376336|diarrhea
1147524|NCT01376336|water
1147525|NCT01376336|HIV
1147526|NCT01376323|Safety
1147527|NCT01376323|Dose Ranging
1147528|NCT01376323|Efficacy
1147529|NCT01376258|benign prostatic hyperplasia
1147530|NCT01376258|acute urinary retention
1147531|NCT01376258|adherence
1147532|NCT01376258|5-alpha reductase inhibitor
1147533|NCT01376258|enlarged prostate
1147534|NCT01376258|surgery
1147535|NCT01376232|Anaemia
1147536|NCT01376232|Drug- Drug Interaction
1147537|NCT01376219|GINA
1147538|NCT01376219|direct / indirect costs
1147539|NCT01376219|exacerbations
1147540|NCT01376219|European
1147541|NCT01376219|asthma control
1147542|NCT01376219|Asthma Control Test (TM - QualityMetric Incorporated)
1147543|NCT01376102|osteoporosis
1147544|NCT01376102|ibandronate
1147545|NCT01376089|Safety
1147546|NCT01376076|schizophrenia
1147547|NCT01376076|QTc
1147548|NCT01376076|cardiac repolarization
1147549|NCT01376050|venous stasis ulcer
1147550|NCT01376050|leg ulcer
1147551|NCT01376037|upper arm
1147552|NCT01376037|body contouring
1147553|NCT01376037|body shaping
1147554|NCT01376024|Carpometacarpal arthritis
1147555|NCT01376024|Basal joint arthritis
1147556|NCT01376024|CMC arthritis
1147557|NCT01376024|Osteoarthritis
1147558|NCT01376011|quercetin
1147559|NCT01376011|brain blood flow
1147560|NCT01376011|aging
1147561|NCT01376011|memory
1147562|NCT01375998|YAZ
1147563|NCT01375998|Dysmenorrhea
1147564|NCT01375972|biliary cancer
1147565|NCT01375972|systemic chemotherapy
1147566|NCT01375972|S-1
1147567|NCT01375972|gemcitabine
1147568|NCT01375972|cisplatin
1147569|NCT01375959|resveratrol
1147570|NCT01375959|glucose intolerance
1147571|NCT01375959|insulin resistance
1147572|NCT01375959|endothelial function
1147573|NCT01375946|Pharmacokinetic Profile (PK) and Safety
1147574|NCT01375946|PK analysis of EE and LNG
1147575|NCT01375933|Smoking
1147576|NCT01375933|NicVAX
1147577|NCT01375933|Smoking vaccine
1147578|NCT01375920|Depression
1147579|NCT01375920|Antiglucocorticoid
1147580|NCT01375920|Anti-depressants
1147581|NCT01375907|blood cell counts
1147582|NCT01375907|BUN
1147583|NCT01375907|ALT
1147584|NCT01375907|AST
1147585|NCT01375907|diarrhea
1147586|NCT01375907|fever
1147587|NCT01375907|vomit
1147588|NCT01375907|nausea
1147589|NCT01375907|loss of appetite
1147590|NCT01375907|irritability
1147591|NCT01375881|HIV
1147592|NCT01375881|darunavir
1147593|NCT01375881|ritonavir
1147594|NCT01375881|Prezista
1147595|NCT01375881|naive
1147596|NCT01375881|experienced
1147597|NCT01375868|HPV
1147598|NCT01375868|recurrent respiratory papillomatosis
1147599|NCT01375868|antibodies
1147600|NCT01375855|Late stent malapposition
1147601|NCT01375855|stent thrombosis
1147602|NCT01375855|IVUS
1147603|NCT01375855|non-polimeric stent
1147604|NCT01375842|PD-L1
1147605|NCT01375842|PD-1
1147606|NCT01375842|lymphoma
1147607|NCT01375842|esophageal cancer
1147608|NCT01375842|antiPD-L1
1147609|NCT01375842|MPDL3280A
1147610|NCT01375842|Solid tumor
1147611|NCT01375842|Renal cell Carcinoma (RCC)
1147612|NCT01375842|Melanoma (MEL)
1147613|NCT01375842|Non-small Cell Lung Cancer (NSCLC)
1147614|NCT01375842|Breast Cancer
1147615|NCT01375842|Gastric Cancer
1147616|NCT01375842|Head and Neck Cancer
1147617|NCT01375842|Colorectal Cancer
1147618|NCT01375842|Heme Malignancies
1147619|NCT01375842|Non-Hodgkin Lymphoma
1147620|NCT01375842|Multiple Myeloma
1147621|NCT01375842|MPDL320A
1147622|NCT01375816|adenocarcinoma of the colon
1147623|NCT01375816|recurrent colon cancer
1147624|NCT01375816|stage IV colon cancer
1147625|NCT01375816|adenocarcinoma of the rectum
1147626|NCT01375816|recurrent rectal cancer
1147627|NCT01375816|stage IV rectal cancer
1147628|NCT01375803|dietary fiber
1147629|NCT01375803|fiber
1147630|NCT01375803|insulin sensitivity
1147631|NCT01375803|insulin resistance
1147632|NCT01375803|glucose metabolism
1147633|NCT01375790|whole-body vibration
1147634|NCT01375790|older people
1147635|NCT01375790|exercise
1147636|NCT01375790|body balance
1147637|NCT01375790|muscle performance
1147638|NCT01375790|falls
1147639|NCT01375790|physiotherapy
1147640|NCT01375777|High cholesterol
1147641|NCT01375777|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
1147642|NCT01375777|Treatment for high cholesterol
1147643|NCT01375777|Lowering cholesterol
1147644|NCT01375777|Lowering high cholesterol
1147645|NCT01375777|Hypercholesterolemia
1147646|NCT01375764|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
1147647|NCT01375764|Cholesterol
1147648|NCT01375764|High Cholesterol
1147649|NCT01375764|Raised Cholesterol
1147650|NCT01375764|Elevated Cholesterol
1147651|NCT01375764|Statin intolerant
1147652|NCT01375764|Hypercholesterolemia
1147653|NCT01375751|Heterozygous Familial Hypercholesterolemia
1147654|NCT01375751|Proprotein convertase subtilisin/kexin type 9 (PCSK9)
1147655|NCT01375738|Early gastric cancer
1147656|NCT01375712|Hard or lumpy stools
1147657|NCT01375712|Stool consistency
1147658|NCT01375712|Stool frequency
1147659|NCT01375712|Constipation related symptoms
1147660|NCT01375712|Constipation related quality of life
1147661|NCT01375699|Breast cancer
1147662|NCT01375699|Gastrointestinal cancer
1147663|NCT01375699|Genitourinary cancer
1147664|NCT01375699|Sarcoma
1147665|NCT01375699|Gynecologic cancer
1147666|NCT01375686|Diabetes
1147667|NCT01375673|Exercise
1147668|NCT01375673|Heart Failure
1147669|NCT01375673|Mixed Effects Modeling
1147670|NCT01375660|Vitamin D
1147671|NCT01375660|Glucose intolerance
1147672|NCT01375660|African American men
1147673|NCT01375647|Oral Vaccines
1147674|NCT01375647|Vaccine Responsiveness
1147675|NCT01375647|Tropical Enteropathy
1147676|NCT01375634|Intubation
1147677|NCT01375634|Gastrointestinal
1147678|NCT01375621|Farming
1147679|NCT01375621|Antibiotic Resistant
1147680|NCT01375621|Bacteria
1147681|NCT01375608|Neutropenia
1147682|NCT01375608|Hemaglobin
1147683|NCT01375608|Coagulation Disorders
1147684|NCT01375608|Thrombocytosis
1147685|NCT01375608|Red Blood Cells
1147686|NCT01375608|Sickle Cell Disease
1147687|NCT01375595|Working Memory
1147688|NCT01375595|Repetitive TMS (rTMS)
1147689|NCT01375595|Language
1147690|NCT01375595|Healthy Volunteer
1147691|NCT01375595|HV
1147692|NCT01375582|Dry Eye
1147693|NCT01375582|tear film
1147694|NCT01375582|lipid
1147695|NCT01375582|tear volume
1147696|NCT01375582|environmental chamber
1147697|NCT01375582|thermal imaging
1147698|NCT01375569|CD105
1147699|NCT01375569|Monoclonal Antibody
1147700|NCT01375569|Anti-Angiogenic
1147701|NCT01375569|Chimeric
1147702|NCT01375569|Apoptosis
1147703|NCT01375569|Liver Cancer
1147704|NCT01375556|Alcohol Clamp
1147705|NCT01375556|Pharmacogenetics
1147706|NCT01375556|Family History of Alcoholism
1147707|NCT01375556|Pharmacodynamics
1147708|NCT01375556|Healthy Volunteer
1147709|NCT01375556|HV
1147713|NCT01375530|Prevention
1147714|NCT01375530|Vaccine
1147715|NCT01375530|Immunity
1147716|NCT01375530|Evaluate
1147717|NCT01375530|Screen
1147718|NCT01375530|Healthy Volunteer
1147719|NCT01375530|HV
1147720|NCT01375504|Obesity
1147721|NCT01375504|Body Mass Index
1147722|NCT01375504|Mindfulness Training
1147723|NCT01375504|Attention and Interpretation Therapy
1147724|NCT01375491|doxycycline
1147725|NCT01375491|insulin resistance
1147726|NCT01375491|obesity
1147727|NCT01375491|inflammation
1147728|NCT01375439|Pregnancy
1147729|NCT01375439|vulvovaginitis
1147730|NCT01375439|uterine cervicitis
1147731|NCT01375439|pregnancy outcome
1147732|NCT01375426|Non-severe pneumonia
1147733|NCT01375426|Treatment failure
1147734|NCT01375426|Double dose amoxicillin
1147735|NCT01375426|Children
1147736|NCT01375413|Parkinson's disease
1147737|NCT01375413|Gait
1147738|NCT01375413|Rehabilitation
1147739|NCT01375413|Cognition
1147740|NCT01375413|Freezing of gait
1147741|NCT01375400|aspirin
1147742|NCT01375400|platelet
1147743|NCT01375387|Vimpat
1147744|NCT01375387|Pharmacokinetics
1147745|NCT01375387|Healthy Japanese male
1147746|NCT01375387|Healthy Chinese male
1147747|NCT01375374|Vimpat
1147748|NCT01375374|Partial seizures
1147749|NCT01375374|Carbamazepine
1147750|NCT01375374|Hormone levels
1147751|NCT01375374|Lipid levels
1147752|NCT01375374|Lacosamide
1147753|NCT01375361|albuterol
1147754|NCT01375348|Cognitive function
1147755|NCT01375348|Experimental pain
1147756|NCT01375335|Postoperative
1147757|NCT01375335|Dobutamine
1147758|NCT01375335|Inotropes
1147759|NCT01375335|Stunning
1147760|NCT01375335|Heart failure
1147761|NCT01375309|probiotics
1147762|NCT01375309|preterm infants
1147763|NCT01375309|enteral feeding
1147764|NCT01375309|Bifidobacterium on enteral feeding
1147765|NCT01375270|diabetes
1147766|NCT01375270|incretin
1147767|NCT01375270|beta-cell function
1147768|NCT01375270|glucolipotoxicity
1147769|NCT01375270|glucagon-like peptide 1
1147770|NCT01375270|glucose-dependent insulinotropic polypeptide
1147771|NCT01375244|bioequivalence
1147772|NCT01375244|lisinopril
1147773|NCT01375244|fasting
1147774|NCT01375205|atopic dermatitis
1147775|NCT01375205|skin care
1147776|NCT01375179|Inflammatory Bowel disease
1147777|NCT01375179|Ulcerative colitis
1147778|NCT01375153|BNP administration
1147779|NCT01375153|appetite
1147780|NCT01375153|ghrelin
1147781|NCT01375153|PYY
1147793|NCT01375127|Observational
1147794|NCT01375127|clinical follow-up data
1147795|NCT01375114|Advanced Cancers
1147796|NCT01375114|Solid Tumors
1147797|NCT01375114|Cancer related fatigue
1147798|NCT01375114|CRF
1147799|NCT01375114|Panax ginseng
1147800|NCT01375114|Placebo
1147801|NCT01375114|Sugar pill
1147802|NCT01375114|Functional Assessment of Chronic Illness Therapy-Fatigue
1147803|NCT01375114|FACIT-F
1147804|NCT01375114|Quality of life
1147805|NCT01375114|QOL
1147806|NCT01375114|FACT-G
1147807|NCT01375114|Hospital Anxiety and Depression Inventory
1147808|NCT01375114|Neurocognitive function
1147809|NCT01375114|SDMT
1147810|NCT01375114|Global Symptom Evaluation
1147811|NCT01375114|GSE
1147812|NCT01375101|lichen planus
1147813|NCT01375101|quercetin
1147814|NCT01375088|propolis
1147815|NCT01375088|mucositis
1147816|NCT01375088|radiotherapy
1147817|NCT01375088|cancer
1147818|NCT01375049|Cystic fibrosis
1147819|NCT01375049|CF
1147820|NCT01375049|PA
1147821|NCT01375049|Pseudomonas aeruginosa
1147822|NCT01375049|AZLI
1147823|NCT01375049|aztreonam
1147824|NCT01375036|Cystic fibrosis
1147825|NCT01375036|PA
1147826|NCT01375036|Pseudomonas aeruginosa
1147827|NCT01375036|CF
1147828|NCT01375036|aztreonam
1147829|NCT01375023|Allogenic Haematopoietic Cell Transplantation
1147830|NCT01375023|Total Lymphoid Irradiation
1147831|NCT01375023|Anti-Thymocyte Globulin
1147832|NCT01375023|Triple Negative Breast Cancer
1147833|NCT01375010|HIV
1147834|NCT01375010|Postmenopausal women
1147835|NCT01375010|Vitamin D
1147836|NCT01374984|smallpox
1147837|NCT01374984|vaccination
1147838|NCT01374984|complications
1147839|NCT01374971|Rheumatoid Arthritis
1147840|NCT01374971|Cimzia
1147841|NCT01374971|Certolizumab Pegol
1147842|NCT01374971|Arthroscopic Synovial biopsy
1147843|NCT01374971|Office Based Procedure
1147844|NCT01374971|Biologic
1147845|NCT01374971|Tumor Necrosis Factor (TNF)
1147846|NCT01374971|Anti-TNF
1147847|NCT01374932|Asthma
1147848|NCT01374932|Obstructive Sleep Apnea Syndrome
1147849|NCT01374919|Intravenous iron
1147850|NCT01374919|ferumoxytol
1147851|NCT01374919|iron deficiency anemia
1147852|NCT01374919|Treatment of iron deficiency
1147853|NCT01374919|Intolerance of or ineffectiveness of oral iron
1147854|NCT01374906|Cushing's Disease
1147855|NCT01374906|Mean Urinary Free Cortisol
1147856|NCT01374906|Pasireotide
1147857|NCT01374893|Function, hospitalization, elderly
1147858|NCT01374880|Heart failure
1147859|NCT01374880|Dyspnea
1147860|NCT01374880|Heart disease
1147861|NCT01374880|Pulmonary disease
1147862|NCT01374880|Natriuretic peptide
1147863|NCT01374880|Rehabilitation
1147864|NCT01374867|Cardiogenic shock
1147865|NCT01374867|Myocardial infarction
1147866|NCT01374867|Low-output syndrome
1147867|NCT01374867|Prognosis
1147868|NCT01374867|Biomarkers
1147869|NCT01374867|Pathophysiology
1147870|NCT01374854|type 1 diabetes mellitus
1147871|NCT01374854|umbilical mesenchymal stem cell
1147872|NCT01374854|mononuclear cell
1147873|NCT01374841|Hematopoietic Stem Cell Transplantation
1147874|NCT01374841|High-Risk Hematologic Neoplasms
1147875|NCT01374841|Haploidentical Donors
1147876|NCT01374841|Cyclophosphamide
1147877|NCT01374828|Toradol
1147878|NCT01374828|Ketorolac
1147879|NCT01374828|Normal saline
1147880|NCT01374828|Laparoscopic
1147881|NCT01374828|Postoperative pain control
1147882|NCT01374828|Incisional analgesia
1147883|NCT01374815|Children's diet quality
1147884|NCT01374815|Health-related social problems
1147885|NCT01374763|Naloxone
1147886|NCT01374763|Oxycodone
1147887|NCT01374763|Constipation
1147888|NCT01374763|Pain, postoperative
1147889|NCT01374763|Physiological effects of drugs
1147890|NCT01374763|Analgesics, Opioid
1147891|NCT01374724|Tobacco Use
1147892|NCT01374724|Relapse Prevention
1147893|NCT01374724|Military
1147894|NCT01374724|Smokeless Tobacco Use
1147895|NCT01374724|Dual Use
1147896|NCT01374711|Endotoxin
1147897|NCT01374711|Inflammation
1147898|NCT01374711|Sepsis
1147899|NCT01374711|GM-CSF
1147900|NCT01374711|IFN-y
1147901|NCT01374698|PCI
1147902|NCT01374698|Aspirin
1147903|NCT01374698|Reload
1147904|NCT01374685|BRCA1
1147905|NCT01374685|BRCA2
1147906|NCT01374685|Breast Cancer
1147907|NCT01374685|African American
1147908|NCT01374685|Women
1147909|NCT01374659|124-I PET
1147910|NCT01374659|FDG-PET
1147911|NCT01374659|PET/CT
1147912|NCT01374659|recurrence
1147913|NCT01374659|differentiated thyroid carcinoma
1147914|NCT01374659|diagnostic value
1147915|NCT01374646|Childhood Obesity
1147916|NCT01374646|Group Treatment
1147917|NCT01374646|Community-based Programs
1147918|NCT01374633|Sevoflurane
1147919|NCT01374633|Brain injury
1147920|NCT01374633|Intra cranial pressure
1147921|NCT01374633|Sedation
1147922|NCT01374633|Brain injury with initial Glasgow score less than 9
1147923|NCT01374620|Cancer
1147924|NCT01374607|acute coronary syndrome
1147925|NCT01374607|myocardial ischemia
1147926|NCT01374607|high-sensitivity cardiac troponin T
1147927|NCT01374581|retreatment
1147928|NCT01374581|artemisinin-based combination
1147929|NCT01374581|malaria
1147930|NCT01374581|resistant
1147931|NCT01374568|Type 2 diabetes
1147932|NCT01374568|sitagliptin
1147933|NCT01374568|Januvia
1147934|NCT01374555|Coronary artery disease
1147935|NCT01374542|Bronchoscopy
1147936|NCT01374542|Thoracoscopy
1147937|NCT01374516|Dengue Virus
1147938|NCT01374516|Dengue fever
1147939|NCT01374516|Dengue Hemorrhagic Fever
1147940|NCT01374516|CYD dengue vaccine
1147941|NCT01374516|Flavivirus
1147942|NCT01374516|Dengue Disease
1147943|NCT01374490|HIV +
1147944|NCT01374490|HIV positive
1147945|NCT01374490|HIV associated diarrhea
1147946|NCT01374490|AIDS
1147947|NCT01374490|Diarrhea
1147948|NCT01374477|Preeclampsia in Adolescence
1147949|NCT01374477|Adolescent
1147950|NCT01374477|Primipaternity
1147951|NCT01374464|Interscalene brachial plexus nerve block
1147952|NCT01374464|Nerve block
1147953|NCT01374451|Pancreatic
1147954|NCT01374451|Neuroendocrine tumors
1147955|NCT01374451|PNET
1147956|NCT01374451|Pasireotide
1147957|NCT01374451|Everolimus
1147958|NCT01374451|Advanced progressive pancreatic neuroendocrine tumor
1147959|NCT01374438|Alzheimer's disease
1147960|NCT01374438|cognitive function
1147961|NCT01374438|brain glucose utilization
1147962|NCT01374438|FDG-PET
1147963|NCT01374399|allogeneic stem cell transplantation
1147964|NCT01374399|exercise
1147965|NCT01374399|survival
1147966|NCT01374399|fatigue
1147967|NCT01374399|quality of life
1147968|NCT01374399|cancer
1147969|NCT01374399|physical performance
1147970|NCT01374386|adolescent obesity
1147971|NCT01374373|Chemotherapy
1147972|NCT01374373|Anemia
1147973|NCT01374373|Epoetin alfa
1147974|NCT01374373|Erythropoiesis stimulating agent (ESA)
1147975|NCT01374360|PNH
1147976|NCT01374360|Paroxysmal Nocturnal hemoglobinuria
1147977|NCT01374360|Soliris
1147978|NCT01374360|Eculizumab
1147979|NCT01374308|NASVAC
1147980|NCT01374308|Pegylated Interferon-2b
1147981|NCT01374308|CHB
1147982|NCT01373723|Uterine Cervical Neoplasms
1147983|NCT01373723|cancer screening
1147984|NCT01373723|Costs and Cost Analysis
1147985|NCT01373723|cost-effectiveness analysis
1147986|NCT01373723|Clinical Trial
1147987|NCT01373723|Primary Health Care
1147988|NCT01373710|Adverse Reaction to Trastuzumab Administered by intrathecal
1147989|NCT01373697|Ibuprofen
1147990|NCT01373697|muscle pain
1147991|NCT01373697|sprains
1147992|NCT01373697|contusions
1147993|NCT01373697|tendonitis
1147994|NCT01373684|Chronic hepatitis B
1147995|NCT01373684|HBeAg-negative
1147996|NCT01373671|Mammography
1147997|NCT01373671|Screening
1147998|NCT01373671|Diagnostic
1147999|NCT01373632|significant stenosis (>70% of lumen stenosis)
1148000|NCT01373632|epicardial coronary arteries
1148001|NCT01373632|clinical ischemic
1148002|NCT01374269|NSAIDS (Nonsteroidal anti-inflammatory drugs)
1148003|NCT01374269|Exercise
1148004|NCT01374269|Physiotherapy
1148005|NCT01374269|Subacute Low Back Pain
1148006|NCT01374269|Pain
1148007|NCT01374269|Visual Analogue Scale
1148008|NCT01374269|oswesrty
1148009|NCT01374269|Roland Morris
1148010|NCT01374269|SF-36
1148011|NCT01374269|Quality of life
1148012|NCT01374256|carbapenem
1148013|NCT01374256|sulbactam
1148014|NCT01374256|Acinetobacter baumannii
1148015|NCT01374230|clinical outcomes
1148016|NCT01374230|radiographic outcomes
1148017|NCT01374230|total knee arthroplasty
1148018|NCT01374230|survivorship
1148019|NCT01374204|Epilepsy
1148020|NCT01374204|Stigma
1148021|NCT01374191|botox
1148022|NCT01374191|neuroma pain
1148023|NCT01374191|pain
1148024|NCT01374191|chronic pain
1148025|NCT01374191|botulinum toxin
1148026|NCT01374191|botulinum toxin A
1148027|NCT01374191|botox and pain
1148028|NCT01374191|botox and neuroma
1148029|NCT01374191|botox treatment
1148030|NCT01374191|onabotulinum
1148031|NCT01374191|onabotulinum toxin
1148032|NCT01374191|onabotulinum toxin type A
1148033|NCT01374165|SCD
1148034|NCT01374152|stroke
1148035|NCT01374152|upper extremity
1148036|NCT01374152|rehabilitation
1148037|NCT01374152|perfetti
1148038|NCT01374139|Bosutinib
1148039|NCT01374139|Bioequivalence and Food Effect Studies
1148040|NCT01374113|safinamide
1148041|NCT01374113|pharmacokinetics
1148042|NCT01374113|renal impairment
1148043|NCT01374113|Moderate and Severe Renal Impairment
1148044|NCT01374100|Qigong
1148045|NCT01374100|Complementary Medicine
1148046|NCT01374100|Exercise
1148047|NCT01374100|Traditional Chinese Medicine
1148048|NCT01374100|Meditation
1148049|NCT01374100|Standard Exercise
1148050|NCT01374100|Chemotherapy
1148051|NCT01374100|Advanced cancer
1148052|NCT01374100|Quality of Life
1148053|NCT01374100|Functional Assessment of Cancer Therapy
1148054|NCT01374100|Hospital Anxiety and Depression Scale
1148055|NCT01374100|Anxiety
1148056|NCT01374100|Depression
1148057|NCT01374100|Cancer Nutrition-Rehabilitation Program
1148058|NCT01374100|Edmonton Symptom Assessment Scale
1148059|NCT01374100|Simmonds Functional Assessment
1148060|NCT01374087|Recurrent Prostate Carcinoma
1148061|NCT01374087|Brachytherapy
1148062|NCT01374087|Triptorelin
1148063|NCT01374087|Hormone Therapy
1148064|NCT01374074|Barrett's Esophagus (BE)
1148065|NCT01374074|Intestinal metaplasia
1148066|NCT01374074|Gastroesophageal reflux disease (GERD)
1148067|NCT01374074|Racial Disparity
1148068|NCT01374061|Emergency intubation
1148069|NCT01374061|Glide scope Ranger
1148070|NCT01374061|Pre hospital
1148071|NCT01374035|Health Service
1148072|NCT01374035|Coordination
1148073|NCT01374035|Referral letters
1148074|NCT01374035|Mental Health
1148075|NCT01374035|Adults
1148076|NCT01374022|Respiratory Distress Syndrome, Adult
1148077|NCT01374022|Randomized Controlled Trial
1148078|NCT01374022|Respiration, Artificial
1148079|NCT01373996|Invasive blood pressure monitoring
1148080|NCT01373996|Intensive care unit
1148081|NCT01373996|Wireless Technology
1148082|NCT01373983|Neuropathic pain
1148083|NCT01373983|Intrathecal analgesia
1148084|NCT01373983|Ziconotide
1148085|NCT01373983|Bolus
1148086|NCT01373983|trauma
1148087|NCT01373983|central
1148088|NCT01373983|severe
1148089|NCT01373983|chronic
1148090|NCT01373970|Functional Dyspepsia
1148091|NCT01373970|Protonpump inhibitor
1148092|NCT01373970|Rebound Acid HyperSecretion
1148093|NCT01373957|Acute Coronary Syndrome
1148094|NCT01373957|antithrombotic management
1148095|NCT01373957|STEMI
1148096|NCT01373957|NSTE-ACS
1148097|NCT01373944|MPI
1148098|NCT01373944|SPECT
1148099|NCT01373944|Stress-Only
1148100|NCT01373944|Spectrum Dynamics Camera
1148101|NCT01373944|Anger
1148102|NCT01373918|cholestasis
1148103|NCT01373918|neonates
1148104|NCT01373918|parenteral nutrition
1148105|NCT01373918|gastrointestinal disorders
1148106|NCT01373905|ARDS
1148107|NCT01373905|PEEP
1148108|NCT01373905|Recruitment maneuver
1148109|NCT01373879|Vaccine
1148110|NCT01373879|Immune response
1148111|NCT01373866|Repetitive Transcranial Magnetic Stimulation
1148112|NCT01373866|Neuronavigation
1148113|NCT01373866|Functional Magnetic Resonance Imaging
1148114|NCT01373866|Diffusion Tensor Imaging
1148115|NCT01373853|Lens Fragmentation
1148116|NCT01373853|Cataract
1148117|NCT01373853|Phacoemulsification
1148118|NCT01373853|Femtosecond Laser
1148119|NCT01373840|focal
1148120|NCT01373840|dystonia
1148121|NCT01373840|dopamine
1148122|NCT01373840|receptor
1148123|NCT01373827|VASER
1148124|NCT01373827|VASERShape
1148125|NCT01373827|MC1
1148126|NCT01373827|ultrasound
1148127|NCT01373801|Postpartum women, after surgical repair of vaginal and cervical lacerations
1148128|NCT01373775|Heart failure
1148129|NCT01373775|Revisit
1148130|NCT01373775|Emergency room
1148131|NCT01373762|Adherence
1148132|NCT01373762|Motivation
1148133|NCT01373762|Health-related fitness
1148134|NCT01373762|Exercise videogames
1148135|NCT01373762|Physical Activity
1148136|NCT01373749|PPHN
1148137|NCT01373749|NO inhalation
1148138|NCT01373749|Sildenafil
1148139|NCT01373749|Treatment
1148140|NCT01373749|Safety
1148141|NCT01373619|Heart failure with normal ejection fraction
1148142|NCT01373619|hemodialysis patients
1148143|NCT01373619|ivabradine
1148144|NCT01373619|Echocardiography
1148145|NCT01373619|NYHA class
1148146|NCT01373619|6-minutes walking test
1148147|NCT01373593|persistent postherniorrhaphy pain
1148148|NCT01373580|presbyopia
1148149|NCT01373580|LASIK
1148150|NCT01373580|loss of accommodation
1148151|NCT01373580|Emmetrope
1148152|NCT01373567|Plaque Psoriasis
1148153|NCT01373528|Sinonasal Budesonide
1148154|NCT01373528|Endoscopic sinus surgery
1148155|NCT01373528|Hypothalamic-Pituitary-Adrenal Axis Function
1148156|NCT01373515|DCOne
1148157|NCT01373515|DCP-001
1148158|NCT01373515|Second complete remission of AML
1148159|NCT01373515|Relapse AML
1148160|NCT01373489|type 2 diabetes
1148161|NCT01373489|nurse case management
1148162|NCT01373489|telemedicine
1148163|NCT01373476|Diabetic Retinopathy
1148164|NCT01373476|Traditional Chinese medicine
1148165|NCT01373476|Diabetic Eye Problems
1148166|NCT01373476|Retinal Disorders
1148167|NCT01373463|resectable
1148168|NCT01373437|Ultrasonography
1148169|NCT01373437|US
1148170|NCT01373437|Confirming
1148171|NCT01373437|Confirmation
1148172|NCT01373437|Proper
1148173|NCT01373437|Position
1148174|NCT01373437|Endotracheal tube
1148175|NCT01373437|ETT
1148176|NCT01373437|Emergency department
1148177|NCT01373437|ED
1148178|NCT01373437|Applicability
1148179|NCT01373437|Accuracy
1148180|NCT01373424|Observational study
1148181|NCT01373424|Cross-sectional and Prospective study
1148182|NCT01373424|Cohort and case-control study
1148183|NCT01373411|CABG
1148184|NCT01373411|Ticagrelor
1148185|NCT01373411|Coronary Artery Bypass Surgery
1148186|NCT01373398|bladder cancer
1148187|NCT01373398|EO9
1148188|NCT01373398|Apaziquone
1148189|NCT01373385|pediatric urology
1148190|NCT01373385|vesicoureteral reflux
1148191|NCT01373385|ureteral reimplant
1148192|NCT01373385|Deflux
1148193|NCT01373372|functional dyspepsia
1148194|NCT01373372|GI
1148195|NCT01373359|Misoprostol, oxytocin, postpartum blood loss, hemoglobin
1148196|NCT01373346|type II diabetes
1148197|NCT01373346|Gastric cancer
1148198|NCT01373346|Long limb Roux-en Y
1148199|NCT01373320|Smoking cessation
1148200|NCT01373320|Cancer screening
1148201|NCT01373320|Appalachia
1148202|NCT01373320|Group-randomized trial
1148203|NCT01373320|Faith-placed
1148204|NCT01373307|Overweight
1148205|NCT01373307|obesity
1148206|NCT01373307|Appalachian
1148207|NCT01373307|intergenerational
1148208|NCT01373307|families
1148209|NCT01373307|energy balance
1148210|NCT01373307|group-randomized trial
1148211|NCT01373294|non-muscle-invasive
1148212|NCT01373294|transitional cell
1148213|NCT01373294|oral lenalidomide
1148214|NCT01373294|intravesical
1148215|NCT01373281|Dengue
1148216|NCT01373281|Dengue fever
1148217|NCT01373281|Dengue Hemorrhagic Fever
1148218|NCT01373281|CYD dengue vaccine
1148219|NCT01373281|Flavivirus
1148220|NCT01373255|Placenta accreta
1148221|NCT01373255|Internal iliac artery catheterization
1148222|NCT01373255|Post partum bleeding
1148223|NCT01373229|Chronic Lymphocytic Leukemia
1148224|NCT01373229|CLL
1148225|NCT01373203|Acute Lung Injury(ALI)
1148226|NCT01373190|epilepsy
1148227|NCT01373190|thermography
1148228|NCT01373164|Neoplasms
1148229|NCT01373164|Neoplasm Metastasis
1148230|NCT01373164|Pancreatic Cancer
1148231|NCT01373138|Bioequivalence
1148232|NCT01373138|Desloratadine and pseudoephedrine
1148233|NCT01373138|crossover
1148234|NCT01373125|Barrett's Esophagus
1148235|NCT01373125|Intestinal metaplasia
1148236|NCT01373125|Gastroesophageal reflux disease (GERD)
1148237|NCT01373125|Neosquamous epithelium
1148238|NCT01373125|Radiofrequency ablation (RFA)
1148239|NCT01373112|arthroplasty
1148240|NCT01373112|knee replacement
1148241|NCT01373112|Osteoarthritis
1148242|NCT01373112|knee Infection
1148243|NCT01373112|Prosthetic Joint Infection
1148244|NCT01373112|Complications; Arthroplasty, Infection or Inflammation
1148245|NCT01373112|Complications; Arthroplasty
1148246|NCT01373099|arthroplasty
1148247|NCT01373099|hip replacement
1148248|NCT01373099|Osteoarthritis
1148249|NCT01373099|knee Infection
1148250|NCT01373099|Prosthetic Joint Infection
1148251|NCT01373099|Complications; Arthroplasty, Infection or Inflammation
1148252|NCT01373099|Complications; Arthroplasty
1148253|NCT01373086|Hypertension,
1148254|NCT01373086|mild hypertension,
1148255|NCT01373086|moderate hypertension,
1148256|NCT01373086|high blood pressure,
1148257|NCT01373086|uncomplicated hypertension.
1148258|NCT01373060|ASP1941
1148259|NCT01373060|ipragliflozin
1148260|NCT01373060|plasma glucose
1148261|NCT01373060|urine glucose
1148262|NCT01373047|liver metastases
1148263|NCT01373047|immunotherapy
1148264|NCT01373047|regional therapy
1148265|NCT01373047|T cells
1148266|NCT01373008|Inhaled steroids
1148267|NCT01373008|bronchopulmonary dysplasia
1148268|NCT01373008|Infants with moderate to severe BPD
1148269|NCT01372995|critical care
1148270|NCT01372995|nosocomial infection
1148271|NCT01372995|antiAntimicrobial peptide expression
1148272|NCT01372995|LL-37
1148273|NCT01372995|hBD-2
1148274|NCT01372995|cathelicidin
1148275|NCT01372995|microbial peptide
1148276|NCT01372956|LDL-C, cholesterol, risk factor
1148277|NCT01372943|Clostridium difficile
1148278|NCT01372943|recurrent
1148279|NCT01372943|infection
1148280|NCT01372930|Etanercept
1148281|NCT01372930|acute ST segment elevated myocardial infarction
1148282|NCT01372930|percutaneous coronary intervention
1148283|NCT01372930|myocardial reperfusion injury
1148284|NCT01372904|Cisplatin
1148285|NCT01372904|Hearing loss
1148286|NCT01372904|Ototoxicity
1148287|NCT01372904|Intratympanic injection
1148288|NCT01372904|Dexamethasone
1148289|NCT01372904|Steroids
1148290|NCT01372904|Prevention
1148291|NCT01372891|Contrast Induced Nephropathy
1148292|NCT01372891|percutaneous coronary interventions
1148293|NCT01372878|Polyps
1148294|NCT01372878|Capsule endoscopy
1148295|NCT01372878|Colonoscopy
1148296|NCT01372852|Diabetes mellitus
1148297|NCT01372839|Myocardial Infarction
1148298|NCT01372839|Unstable Angina
1148299|NCT01372826|Phase 1
1148300|NCT01372826|Pharmacokinetics
1148301|NCT01372826|NKTR-118
1148302|NCT01372826|renal impairment
1148303|NCT01372826|parallel study
1148304|NCT01372826|QTcF Interval
1148305|NCT01372826|AUC(0-t)
1148306|NCT01372826|Cmax
1148307|NCT01372826|tmax
1148308|NCT01372813|Advanced Clear Cell Renal Cell Carcinoma
1148309|NCT01372813|Cancer
1148310|NCT01372813|Renal
1148311|NCT01372813|Renal Cell Carcinoma
1148312|NCT01372813|Kidney Cancer
1148313|NCT01372800|adiponectin
1148314|NCT01372800|cardiovascular diseases
1148315|NCT01372800|cerebrovascular diseases
1148316|NCT01372774|neurotoxicity
1148317|NCT01372774|radiation toxicity
1148318|NCT01372774|cognitive/functional effects
1148319|NCT01372774|tumors metastatic to brain
1148320|NCT01372774|unspecified adult solid tumor, protocol specific
1148321|NCT01372761|Obese
1148322|NCT01372761|Obesity
1148323|NCT01372761|Overweight
1148324|NCT01372748|cardiac arrest
1148325|NCT01372748|cardiopulmonary resuscitation
1148326|NCT01372735|pancreatic cancer
1148327|NCT01372735|intensity-modulated radiation therapy
1148328|NCT01372735|intraoperative radiation therapy
1148329|NCT01372722|treatment resistant
1148330|NCT01372709|abdominal
1148331|NCT01372709|aortic
1148332|NCT01372709|aneurysm
1148333|NCT01372683|Appetite
1148334|NCT01372683|Satiety
1148335|NCT01372683|Subjective energy
1148336|NCT01372683|Oats
1148337|NCT01372670|Treating meal related anxiety
1148338|NCT01372657|cataract
1148339|NCT01372657|refraction
1148340|NCT01372657|iol
1148341|NCT01372657|calculation
1148342|NCT01372657|formula
1148343|NCT01372631|Reduction mammoplasty
1148344|NCT01372631|mastectomy
1148345|NCT01372631|partial mastectomy
1148346|NCT01372631|lumpectomy
1148347|NCT01372631|breast conserving surgery
1148348|NCT01372631|breast cancer
1148349|NCT01372605|Depression
1148350|NCT01372605|HIV
1148351|NCT01372605|Adherence
1148352|NCT01372605|Collaborative care
1148353|NCT01372605|Measurement-Based Care
1148354|NCT01372553|Primary care
1148355|NCT01372553|Family History
1148356|NCT01372553|Risk Stratification
1148357|NCT01372553|Cancer
1148358|NCT01372553|Thrombosis
1148359|NCT01372540|Relapsed/Refractory Multiple Myeloma
1148360|NCT01372540|MM
1148361|NCT01372540|Plasma Cell Leukemia
1148362|NCT01372540|PCL
1148363|NCT01372540|Arry-520
1148364|NCT01372540|Carfilzomib
1148365|NCT01372540|Dexamethasone
1148366|NCT01372540|Decadron
1148367|NCT01372540|Filgrastim
1148368|NCT01372540|G-CSF
1148369|NCT01372540|Neupogen
1148370|NCT01372527|medical informatics
1148371|NCT01372527|health IT
1148372|NCT01372527|primary care
1148373|NCT01372527|screening
1148374|NCT01372527|cervical cancer
1148375|NCT01372527|colorectal cancer
1148376|NCT01372527|breast cancer
1148377|NCT01372527|mammography
1148378|NCT01372527|colonoscopy
1148379|NCT01372527|pap smear
1148380|NCT01372514|Thromboembolism
1148381|NCT01372514|Venous Thromboembolism
1148382|NCT01372514|Pulmonary Embolism
1148383|NCT01372501|Obesity
1148384|NCT01372488|Suture self removal
1148385|NCT01372488|non-absorbable sutures
1148386|NCT01372475|Osteoarthritis
1148387|NCT01372475|Knee
1148388|NCT01372475|Hyaluronan
1148389|NCT01372475|Hyaluronic Acid
1148390|NCT01372475|Viscoelastic
1148391|NCT01372475|Hydrogel
1148392|NCT01372462|COPD
1148393|NCT01372462|Ventilator
1148394|NCT01372462|Constant work rate
1148395|NCT01372449|Autism
1148396|NCT01372449|Psychopharmacology
1148397|NCT01372449|Clinical Trial
1148398|NCT01372449|Children
1148399|NCT01372436|dental decay
1148400|NCT01372436|DMFT
1148401|NCT01372436|Individual Caries Risk
1148402|NCT01372436|Risk factors
1148403|NCT01372410|Long acting muscarinic antagonist
1148404|NCT01372410|Tiotropium
1148405|NCT01372410|Chronic Bronchitis
1148406|NCT01372410|Emphysema
1148407|NCT01372410|Chronic Obstructive Pulmonary Disease
1148408|NCT01372371|Vancomycin, Gentamycin
1148409|NCT01372371|Local Powder Antibiotic's Efficacy in Controlling Post Surgical Infection
1148410|NCT01372332|homonymous hemianopia
1148411|NCT01372332|quality of life (QoL)
1148412|NCT01372332|visual exploration
1148413|NCT01372332|on-road car driving
1148414|NCT01372332|driving simulator
1148415|NCT01372332|useful field of view (UFOV)
1148416|NCT01372332|modified field of view (MAFOV)
1148417|NCT01372319|glaucoma
1148418|NCT01372319|binocular visual field loss
1148419|NCT01372319|semi-automated kinetic perimetry (SKP)
1148420|NCT01372319|quality of life (QoL)
1148421|NCT01372319|visual exploration
1148422|NCT01372319|on-road car driving
1148423|NCT01372319|driving simulator
1148424|NCT01372293|PCOS
1148425|NCT01372293|oral contraceptive pill
1148426|NCT01372293|polymorphisms
1148427|NCT01372267|Cognitive Behavioral Therapy
1148428|NCT01372267|Chronic Pain
1148429|NCT01372267|Substance Use Disorders
1148550|NCT01371760|Multiple sclerosis
1148430|NCT01372267|Psychoeducational control group
1148431|NCT01372254|Cigarette Smoking
1148432|NCT01372254|Drug Use
1148433|NCT01372254|Depressed Mood
1148434|NCT01372241|Papanicolaou test
1148435|NCT01372241|Cervical cancer screening
1148436|NCT01372241|Randomized controlled trial
1148437|NCT01372241|Faith-placed
1148438|NCT01372241|Appalachia
1148439|NCT01372228|hematopoietic stem cell transplant, chimerism, leukodystrophy
1148440|NCT01372215|Breast mass
1148441|NCT01372215|Breast lesion
1148442|NCT01372202|Operable
1148443|NCT01372202|Based on CHFR Methylation Status
1148444|NCT01372202|Diagnostic Biopsies
1148445|NCT01372189|molecular imaging
1148446|NCT01372189|epidermal growth factor receptor
1148447|NCT01372189|colorectal neoplasia
1148448|NCT01372189|confocal laser endomicroscopy
1148449|NCT01372176|Intensive care unit
1148450|NCT01372176|Critical illness
1148451|NCT01372176|Mortality
1148452|NCT01372176|Reduced quality of life
1148453|NCT01372176|Loss of lean body mass
1148454|NCT01372176|Loss of physical function
1148455|NCT01372176|Optimised nutritional support
1148456|NCT01372176|Early initiation of nutrition
1148457|NCT01372176|Indirect calorimetry
1148458|NCT01372163|Phase 1
1148459|NCT01372163|Multiple Ascending Doses
1148460|NCT01372163|Safety
1148461|NCT01372163|Pharmacokinetics
1148462|NCT01372163|Healthy Volunteers
1148463|NCT01372163|Type 2 Diabetic Patients
1148464|NCT01372150|major depressive disorder
1148465|NCT01372150|MDD
1148466|NCT01372150|depression
1148467|NCT01372137|NOX-H94
1148468|NCT01372137|Hepcidin
1148469|NCT01372137|Anemia
1148470|NCT01372137|Inflammation
1148471|NCT01372124|Renal impairment
1148472|NCT01372124|NOX-E36
1148473|NCT01372111|Stg III or IVa Squamous Cell Carcinoma.
1148474|NCT01372111|Advanced
1148475|NCT01372098|Domestic Violence
1148476|NCT01372098|Spouse Abuse
1148477|NCT01372072|chronic respiratory hypercapnic failure
1148478|NCT01372046|technology transfer
1148479|NCT01372046|skill development
1148480|NCT01372046|organizational change
1148481|NCT01372033|drug treatment
1148482|NCT01372033|substance abuse
1148483|NCT01372033|offenders
1148484|NCT01372033|high risk
1148485|NCT01372020|Varicose ulcer
1148486|NCT01372020|wound healing
1148487|NCT01372020|electrical stimulation
1148488|NCT01372007|Rectal carcinoma
1148489|NCT01371994|Radical Robotic Arm
1148490|NCT01371994|Post Prostatectomy Incontinence
1148491|NCT01371994|Vesicare
1148492|NCT01371994|YM905
1148493|NCT01371968|Alfentanil
1148494|NCT01371968|optimal dose
1148495|NCT01371968|laryngeal mask airway
1148496|NCT01371955|diabetic nephropathy
1148497|NCT01371955|CYBA
1148498|NCT01371955|p22phox
1148499|NCT01371955|RAGE
1148500|NCT01371955|12LOX
1148501|NCT01371955|genetic
1148502|NCT01371955|Type 1 Diabetes Mellitus with Diabetic Dermatitis
1148503|NCT01371955|caucasian
1148504|NCT01371955|more than twenty years of diabetes duration
1148505|NCT01371955|older than 18 years
1148506|NCT01371955|no nephropathy other than diabetic nephropathy
1148507|NCT01371942|Colorectal cancer(CRC)
1148508|NCT01371916|tuberculous meningitis
1148509|NCT01371916|early secretory antigenic target 6
1148510|NCT01371916|diagnosis
1148511|NCT01371903|morphine
1148512|NCT01371903|fentanyl
1148513|NCT01371903|dilaudid
1148514|NCT01371903|opioid
1148515|NCT01371903|capnography
1148516|NCT01371890|hemodialysis
1148517|NCT01371890|end-stage renal disease
1148518|NCT01371890|hypertension
1148519|NCT01371877|urticaria
1148520|NCT01371877|angioedema
1148521|NCT01371877|hive
1148522|NCT01371877|swelling
1148523|NCT01371864|Congenital cardiac disease
1148524|NCT01371864|Teamwork
1148525|NCT01371864|Communication
1148526|NCT01371864|Peri-operative
1148527|NCT01371838|Community-Acquired Bacterial Pneumonia
1148528|NCT01371825|LIPA
1148529|NCT01371825|Wolman Disease
1148530|NCT01371825|Wolman Phenotype
1148531|NCT01371825|Acid Lipase Deficiency
1148532|NCT01371825|Acid Cholesteryl Hydrolase
1148533|NCT01371825|Acid Lipase Disease Deficiency, type 2
1148534|NCT01371825|Cholesteryl Ester Storage Disease (CESD)
1148535|NCT01371825|Cholesteryl Ester Hydrolase Deficiency
1148536|NCT01371825|Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
1148537|NCT01371825|LAL Deficiency
1148538|NCT01371825|Late Onset Lysosomal Acid Lipase Deficiency (CESD)
1148539|NCT01371825|Wolman Disease (early onset LAL Deficiency)
1148540|NCT01371825|Related Disorders:
1148541|NCT01371825|Non-alcoholic Fatty Liver Disease (NAFLD)
1148542|NCT01371825|Non-alcoholic Steatohepatitis (NASH)
1148543|NCT01371825|Alcoholic Liver Disease
1148544|NCT01371825|Cryptogenic Cirrhosis
1148545|NCT01371825|Niemann-Pick Disease (NPD) Type C
1148546|NCT01371825|Chanarin Dorfman Syndrome
1148547|NCT01371799|Schizophrenia
1148548|NCT01371786|Ciclesonide
1148549|NCT01371786|Allergic Rhinitis
1148551|NCT01371760|Chronic cerebrospinal venous insufficiency
1148552|NCT01371760|Percutaneous Transluminal Angioplasty (PTA)
1148553|NCT01371760|Internal jugular vein
1148554|NCT01371760|Azygous vein
1148555|NCT01371747|Hyperkalemia
1148556|NCT01371747|Chronic Kidney Disease
1148557|NCT01371747|Treatment of Hyperkalemia
1148558|NCT01371747|Hypertension
1148559|NCT01371747|Diabetic Nephropathy
1148560|NCT01371734|Major Depressive Disorder
1148561|NCT01371734|MDD
1148562|NCT01371734|Depression
1148563|NCT01371721|Major Depressive Disorder
1148564|NCT01371721|MDD
1148565|NCT01371721|Depression
1148566|NCT01371708|Major Depressive Disorder
1148567|NCT01371708|MDD
1148568|NCT01371708|Depression
1148569|NCT01371695|IGF-II levels
1148570|NCT01371669|Pulmonary arterial hypertension
1148571|NCT01371669|Chronic post embolic disease
1148572|NCT01371669|Sleep hypoxemia
1148573|NCT01371669|polysomnography
1148574|NCT01371669|sleep apnea
1148575|NCT01371669|periodic respiration
1148576|NCT01371630|Leukemia
1148577|NCT01371630|Acute Lymphoblastic Leukemia
1148578|NCT01371630|ALL
1148579|NCT01371630|pre-B, Philadelphia chromosome (Ph-) negative
1148580|NCT01371630|Maximum tolerated dose
1148581|NCT01371630|Inotuzumab Ozogamycin
1148582|NCT01371630|CMC-544
1148583|NCT01371630|Vincristine
1148584|NCT01371630|Rituximab
1148585|NCT01371630|Rituxan
1148586|NCT01371630|Cyclophosphamide
1148587|NCT01371630|Cytoxan
1148588|NCT01371630|Neosar
1148589|NCT01371630|Dexamethasone
1148590|NCT01371630|Decadron
1148591|NCT01371630|Mesna
1148592|NCT01371630|Mesnex
1148593|NCT01371630|Pegfilgrastim
1148594|NCT01371630|Neulasta
1148595|NCT01371630|PEG-G-CSF
1148596|NCT01371630|Ara-C
1148597|NCT01371630|Cytarabine
1148598|NCT01371630|Cytosar
1148599|NCT01371630|DepoCyt
1148600|NCT01371630|Cytosine Arabinosine Hydrochloride
1148601|NCT01371630|6-Mercaptopurine
1148602|NCT01371630|Mercaptopurine
1148603|NCT01371630|Purinethol
1148604|NCT01371630|6-MP
1148605|NCT01371630|Methotrexate
1148606|NCT01371630|Otrexup
1148607|NCT01371630|Rasuvo
1148608|NCT01371630|Rheumatrex
1148609|NCT01371630|Trexall
1148610|NCT01371630|Amethopterin
1148611|NCT01371630|Methotrexate Sodium
1148612|NCT01371630|MTX
1148613|NCT01371630|Oncovin
1148614|NCT01371630|Vincristine Sulfate
1148615|NCT01371630|Vincasar Pfs
1148616|NCT01371630|Prednisone
1148617|NCT01371630|Deltasone
1148618|NCT01371630|Sterapred
1148619|NCT01371630|Rayos
1148620|NCT01371630|Meticorten
1148621|NCT01371630|Citrovorum
1148622|NCT01371630|Leucovorin
1148623|NCT01371630|Wellcovorin
1148624|NCT01371630|Calcium Leucovorin
1148625|NCT01371630|Folinic Acid
1148626|NCT01371630|Citrovorum Factor
1148627|NCT01371617|IPI-926
1148628|NCT01371617|926
1148629|NCT01371617|Myelofibrosis
1148630|NCT01371617|Hedgehog
1148631|NCT01371617|Infinity Pharmaceuticals
1148632|NCT01371617|Post Essential thrombocythemia
1148633|NCT01371617|Post Polycythemia vera
1148634|NCT01371604|Hepatitis C
1148635|NCT01371604|HCV
1148636|NCT01371604|treatment-naive
1148637|NCT01371591|Bleeding
1148638|NCT01371591|gastrointestinal
1148639|NCT01371591|hemorrhage
1148640|NCT01371591|ulcer
1148641|NCT01371591|varix
1148642|NCT01371591|varices
1148643|NCT01371591|ulcers
1148644|NCT01371591|GI
1148645|NCT01371591|stomach
1148646|NCT01371591|esophagus
1148647|NCT01371591|duodenum
1148648|NCT01371591|melena
1148649|NCT01371591|hematemesis
1148650|NCT01371591|coffee-ground
1148651|NCT01371578|Hepatitis C
1148652|NCT01371578|HCV
1148653|NCT01371578|Rapid Virologic Response
1148654|NCT01371578|Sustained Virologic Response
1148655|NCT01371578|Direct Acting Antiviral
1148656|NCT01371578|Combination Therapy HCV RNA
1148657|NCT01371578|Polymerase inhibitor
1148658|NCT01371578|Protease inhibitor
1148659|NCT01371578|Treatment naïve
1148660|NCT01371578|GS-5885
1148661|NCT01371578|GS-9190
1148662|NCT01371578|Tegobuvir
1148663|NCT01371578|GS-9451
1148664|NCT01371565|Cushing's Disease
1148665|NCT01371565|Cushing's Syndrome
1148666|NCT01371565|Cushings
1148667|NCT01371565|Pituitary
1148668|NCT01371565|Ectopic ACTH secretion
1148669|NCT01371539|Myopia
1148670|NCT01371539|Presbyopia
1148671|NCT01371513|Serum prostate specific antigen
1148672|NCT01371422|Paravertebral nerve blockade
1148673|NCT01371422|Percutaneous nephrolithotomy/nephrolithotripsy
1148674|NCT01371422|opioids
1148675|NCT01371422|pain
1148676|NCT01371409|Stroke
1148677|NCT01371409|TMS
1148678|NCT01371409|Paired Pulse
1148679|NCT01371409|EEG
1148680|NCT01371409|Motor Learning
1148681|NCT01371396|Metabolic syndrome
1148808|NCT01370928|Pain
1148682|NCT01371396|Non-alcoholic fatty liver disease
1148683|NCT01371396|Obesity Metabolism
1148684|NCT01371396|Stable isotopes
1148685|NCT01371396|Dietary weight loss
1148686|NCT01371370|low intensity resistance exercise training
1148687|NCT01371370|hypocaloric diet
1148688|NCT01371370|prehypertension
1148689|NCT01371370|hypertension
1148690|NCT01371370|obesity
1148691|NCT01371370|arterial function
1148692|NCT01371370|arterial stiffness
1148693|NCT01371370|pulse wave velocity
1148694|NCT01371370|autonomic function
1148695|NCT01371370|endothelial function
1148696|NCT01371370|adipocytokines
1148697|NCT01371357|Remethylation
1148698|NCT01371357|Human Subjects
1148699|NCT01371357|Clinical Trial
1148700|NCT01371357|B-vitamin
1148701|NCT01371357|Creatine
1148702|NCT01371344|Liver Transplantation
1148703|NCT01371344|Kidney Transplantation
1148704|NCT01371344|Heart Transplantation
1148705|NCT01371344|Pharmacokinetics
1148706|NCT01371331|Kidney Transplantation
1148707|NCT01371331|Pharmacokinetics
1148708|NCT01371331|Heart Transplantation
1148709|NCT01371331|Liver Transplantation
1148710|NCT01371318|diabetic foot ulcer
1148711|NCT01371318|amputation
1148712|NCT01371318|wounds
1148713|NCT01371318|diabetic foot
1148714|NCT01371318|diabetes complications
1148715|NCT01371292|Physical activity
1148716|NCT01371292|Transformational leadership
1148717|NCT01371292|Physical education
1148718|NCT01371266|Glucose intolerance
1148719|NCT01371266|Insulin resistance
1148720|NCT01371266|Insulin
1148721|NCT01371266|metabolic syndrome
1148722|NCT01371266|honey
1148723|NCT01371266|Inflammation
1148724|NCT01371266|oxidative stress
1148725|NCT01371253|Nintendo wii
1148726|NCT01371253|postural balance
1148727|NCT01371253|muscle strength
1148728|NCT01371253|elderly
1148729|NCT01371240|pancreas cancer
1148730|NCT01371240|MRI
1148731|NCT01371240|CT scan
1148732|NCT01371227|Multiple myeloma
1148733|NCT01371227|Relapsed or refractory multiple myeloma
1148734|NCT01371227|JNS002
1148735|NCT01371227|Bortezomib
1148736|NCT01371214|exercise
1148737|NCT01371214|exercise movement techniques
1148738|NCT01371214|activities of daily living
1148739|NCT01371175|HIV
1148740|NCT01371123|serum aluminum
1148741|NCT01371123|parenteral nutrition
1148742|NCT01371123|children
1148743|NCT01371110|OCD
1148744|NCT01371110|Obsessive-Compulsive Disorder
1148745|NCT01371110|ketamine
1148746|NCT01371110|treatment
1148747|NCT01371097|Barthel Index
1148748|NCT01371097|elderly hospitalised patients
1148749|NCT01371097|progressive resistance training
1148750|NCT01371071|Clinically isolated syndrome (CIS)
1148751|NCT01371071|Multiple sclerosis (MS)
1148752|NCT01371071|Immunomodulatory therapy
1148753|NCT01371071|Prognostic markers
1148754|NCT01371071|MRI
1148755|NCT01371071|OCT
1148756|NCT01371058|high on-treatment platelet reactivity
1148757|NCT01371058|percutaneous coronary intervention
1148758|NCT01371058|stent thrombosis
1148759|NCT01371045|Acromegaly
1148760|NCT01371045|Growth Hormone
1148761|NCT01371045|Carcinoid Syndrome
1148762|NCT01371045|Somatostatin
1148763|NCT01371019|Preterm Birth, Proteomics
1148764|NCT01370993|Hypoxemia
1148765|NCT01370993|Model
1148766|NCT01370993|Bronchoscopes
1148767|NCT01370993|Monitored anesthesia care
1148768|NCT01370980|Medication Adherence
1148769|NCT01370980|Patient Compliance
1148770|NCT01370980|Patient Acceptance of Health Care
1148771|NCT01370980|Administration, Oral
1148772|NCT01370980|Cancer
1148773|NCT01370980|Letrozol
1148774|NCT01370980|Exemestan
1148775|NCT01370980|Imatinib
1148776|NCT01370980|Sunitinib
1148777|NCT01370980|Nilotinib
1148778|NCT01370980|Everolimus
1148779|NCT01370980|Deferasirox
1148780|NCT01370967|infant
1148781|NCT01370967|term birth
1148782|NCT01370967|human milk
1148783|NCT01370967|infant formula
1148784|NCT01370967|breast feeding
1148785|NCT01370967|bottle feeding
1148786|NCT01370967|gastrointestinal tract
1148787|NCT01370967|quality of life
1148788|NCT01370967|infant development
1148789|NCT01370954|CerefolinNAC
1148790|NCT01370954|early memory loss
1148791|NCT01370954|pre-alzheimer's disease
1148792|NCT01370954|cognitive function
1148793|NCT01370954|folic acid
1148794|NCT01370954|folate
1148795|NCT01370954|L-methylfolate
1148796|NCT01370954|vitamin B12
1148797|NCT01370954|methylcobalamin
1148798|NCT01370954|N-acetylcysteine
1148799|NCT01370954|NAC
1148800|NCT01370954|oxidative stress
1148801|NCT01370954|memory deficit
1148802|NCT01370954|antioxidant
1148803|NCT01370941|Chymosin
1148804|NCT01370941|24H urine calcium excretion
1148805|NCT01370941|Calcium absorption
1148806|NCT01370941|Intestinal Absorption of Calcium
1148807|NCT01370928|Colonoscopy performance
1148809|NCT01370928|Discomfort
1148810|NCT01370928|Screening
1148811|NCT01370928|Colorectal cancer
1148812|NCT01370928|Colorectal cancer screening, diagnostics of adenomas
1148813|NCT01370915|postoperative pain, nasal septum surgery, pregabalin
1148814|NCT01370876|Oxaliplatin
1148815|NCT01370876|Head and Neck cancer
1148816|NCT01370863|GERD
1148817|NCT01370863|Gastroesophageal reflux disease
1148818|NCT01370863|SPD557
1148819|NCT01370863|Proton pump inhibitors
1148820|NCT01370850|Retina pathology
1148821|NCT01370824|Diagnosis
1148822|NCT01370824|Clinical
1148823|NCT01370824|Punch biopsy
1148824|NCT01370824|Surgical excision
1148825|NCT01370824|Histology
1148826|NCT01370824|Histopathology
1148827|NCT01370824|Observed agreement
1148828|NCT01370824|Diagnostic value
1148829|NCT01370824|Accuracy
1148830|NCT01370824|Interobserver variability
1148831|NCT01370824|Intraobserver variability
1148832|NCT01370811|oxybutynin
1148833|NCT01370811|clonidine
1148834|NCT01370811|OC Oral Solution
1148835|NCT01370811|sialorrhoea
1148836|NCT01370811|Parkinson's disease
1148837|NCT01370798|Severe hypospadias
1148838|NCT01370798|local oestrogen
1148839|NCT01370798|promestriene
1148840|NCT01370798|Onlay-tube-onlay urethroplasty
1148841|NCT01370798|post-operative complications
1148842|NCT01370798|fistula dehiscence
1148843|NCT01370772|B CLL
1148844|NCT01370772|Fist line treatment
1148845|NCT01370759|bowel prep
1148846|NCT01370759|PillCam
1148847|NCT01370733|TMS,
1148848|NCT01370733|MDD,
1148849|NCT01370733|Depression,
1148850|NCT01370733|sTMS,
1148851|NCT01370733|NEST,
1148852|NCT01370733|NeoSync,
1148853|NCT01370733|EEG,
1148854|NCT01370733|synchronous,
1148855|NCT01370733|non-invasive neuromodulation,
1148856|NCT01370733|transcranial magnetic stimulation,
1148857|NCT01370733|antidepressant,
1148858|NCT01370720|IBS
1148859|NCT01370720|mast cell activation
1148860|NCT01370720|low grade inflammation
1148861|NCT01370720|visceral hyperalgesia
1148862|NCT01370668|functional remediation
1148863|NCT01370668|psychoeducation
1148864|NCT01370668|neurocognition
1148865|NCT01370629|atrial fibrillation
1148866|NCT01370629|cardioversion
1148867|NCT01370616|Infection
1148868|NCT01370616|Diabetes complications
1148869|NCT01370616|Diabetes wound infection
1148870|NCT01370616|Soft tissue infection
1148871|NCT01370616|Osteomyelitis
1148872|NCT01370616|Diabetes mellitus
1148873|NCT01370577|Predictors for asthma control
1148874|NCT01370577|Asthma Exacerbation rate
1148875|NCT01370577|Mean frequency of PFT
1148876|NCT01370577|sputum assessments
1148877|NCT01370577|refill adherence(%)
1148878|NCT01370577|prescription persistence
1148879|NCT01370564|Heart failure
1148880|NCT01370564|Cardiac filling pressure
1148881|NCT01370538|Heartburn
1148882|NCT01370525|Heartburn
1148883|NCT01370486|Lennox-Gastaut syndrome
1148884|NCT01370486|Epileptic encephalopathy
1148885|NCT01370486|Melatonin
1148886|NCT01370486|Tonic seizures
1148887|NCT01370486|Interictal discharges
1148888|NCT01370486|Quality of sleep
1148889|NCT01370473|Hyponatremia
1148890|NCT01370460|Tranexamic Acid
1148891|NCT01370460|Blood transfusion
1148892|NCT01370460|Total knee arthroplasty
1148893|NCT01370447|Leigh syndrome
1148894|NCT01370447|MELAS
1148895|NCT01370447|Kearns-Sayre
1148896|NCT01370447|Alper's
1148897|NCT01370447|Inherited mitochondrial disease
1148898|NCT01370447|Friedreich's ataxia
1148899|NCT01370447|POLG1 deficiency
1148900|NCT01370434|MM
1148901|NCT01370408|Autologous stem cell transplant
1148902|NCT01370408|BEAM
1148903|NCT01370408|Oral busulfan
1148904|NCT01370408|Cyclophosphamide
1148905|NCT01370408|Etoposide
1148906|NCT01370408|Carboplatin
1148907|NCT01370408|melphalan
1148908|NCT01370395|geriatrics
1148909|NCT01370395|troponin
1148910|NCT01370395|electrocardiography
1148911|NCT01370395|diagnosis
1148912|NCT01370395|myocardial infarction
1148913|NCT01370382|geriatrics
1148914|NCT01370382|troponin
1148915|NCT01370382|electrocardiography
1148916|NCT01370382|diagnosis
1148917|NCT01370382|myocardial infarction
1148918|NCT01370356|smoking reduction
1148919|NCT01370356|smoking cessation
1148920|NCT01370330|Neuroblastoma
1148921|NCT01370330|MIBG
1148922|NCT01370330|131I-MIBG
1148923|NCT01370330|Resistant
1148924|NCT01370330|Relapsed
1148925|NCT01370330|Treatment
1148926|NCT01370330|UCSF
1148927|NCT01370330|Pediatric
1148928|NCT01370330|Oncology
1148929|NCT01370304|repetitive Transcranial Magnetic Stimulation (rTMS)
1148930|NCT01370304|Depression
1148931|NCT01370304|Venlafaxine
1148932|NCT01370304|fMRI
1148933|NCT01370291|rTMS
1148934|NCT01370291|Risperidone
1148935|NCT01370278|Central airway obstruction
1148936|NCT01370278|lumen obstruction
1148937|NCT01370278|Sodium bicarbonate
1148938|NCT01370278|Baking soda
1148939|NCT01370278|Normal saline
1148940|NCT01370278|Salt water
1148941|NCT01370278|Airway stents
1148942|NCT01370278|Bronchoscopy
1148943|NCT01370278|mucus obstruction
1148944|NCT01370265|Regadenoson (Lexiscan)
1148945|NCT01370265|PET N-13 ammonia imaging
1148946|NCT01370265|Myocardial Blood Flow (MBF)
1148947|NCT01370265|Regadenoson Stress
1148948|NCT01370252|ankle arthrodesis
1148949|NCT01370252|pain
1148950|NCT01370252|arthroscopic technique
1148951|NCT01370252|ankle osteoarthritis
1148952|NCT01370239|monoclonal antibody
1148953|NCT01370239|Lewis
1148954|NCT01370239|breast cancer
1148955|NCT01370213|non-myeloablative haploidentical transplant
1148956|NCT01370213|hematopoietic cell transplant
1148957|NCT01370213|natural killer cells
1148958|NCT01370213|adoptive cellular therapy
1148959|NCT01370200|citrate
1148960|NCT01370200|anticoagulation
1148961|NCT01370200|plasma exchange
1148962|NCT01370200|efficacy
1148963|NCT01370187|Bronchiolitis
1148964|NCT01370187|Postbronchiolitis wheezing
1148965|NCT01370187|Montelukast
1148966|NCT01370174|Falls
1148967|NCT01370174|Balance
1148968|NCT01370174|Protective Stepping
1148969|NCT01370174|Lateral Balance
1148970|NCT01370174|Elderly
1148971|NCT01370161|transjugular intrahepatic portosystemic shunt
1148972|NCT01370161|TIPS
1148973|NCT01370161|variceal bleeding
1148974|NCT01370161|liver cirrhosis
1148975|NCT01370161|hepatitis B
1148976|NCT01370148|Pharmacokinetics
1148977|NCT01370148|Protein Binding
1148978|NCT01370148|Conivaptan
1148979|NCT01370148|Vaprisol
1148980|NCT01370148|Liver Disease
1148981|NCT01370148|YM087
1148982|NCT01370135|neovascular glaucoma
1148983|NCT01370135|rubeosis
1148984|NCT01370135|anterior chamber
1148985|NCT01370135|intraocular
1148986|NCT01370135|intravitreal injections
1148987|NCT01370135|Lucentis
1148988|NCT01370135|Ranibizumab
1148989|NCT01370135|short ans longterm effects
1148990|NCT01370135|best corrected visual acuity
1148991|NCT01370135|gonioscopy
1148992|NCT01370135|BCVA
1148993|NCT01370135|quality of life
1148994|NCT01370122|Women over the age of 20
1148995|NCT01370083|Dysphagia
1148996|NCT01370083|Viscosity
1148997|NCT01370083|Tongue
1148998|NCT01370083|Pressure
1148999|NCT01370057|Adolescent Idiopathic Scoliosis
1149000|NCT01370057|Scoliosis
1149001|NCT01370057|AIS
1149002|NCT01370057|Brace
1149003|NCT01370057|TLSO
1149004|NCT01370044|Febrile Seizure
1149005|NCT01370044|Carbon Dioxide
1149006|NCT01370044|Carbogen
1149007|NCT01370044|Respiratory Alkalosis
1149008|NCT01370031|Asthma
1149009|NCT01370031|PK
1149010|NCT01370031|Adults
1149011|NCT01370018|CD4 counts
1149012|NCT01369992|Metastatic Cancer
1149013|NCT01369979|Lumped constant
1149014|NCT01369979|FDG
1149015|NCT01369979|PET
1149016|NCT01369966|Smoking Cessation
1149017|NCT01369966|Schizophrenic Smokers
1149018|NCT01369966|fMRI
1149019|NCT01369966|Neural Circuits
1149020|NCT01369953|Civic Ideals/Social Norms
1149021|NCT01369953|Genetic Counseling
1149022|NCT01369953|Genetic Disorders
1149023|NCT01369953|Genetic Testing
1149024|NCT01369953|Whole Genome Sequencing
1149025|NCT01369940|Growth Discordancy
1149026|NCT01369940|Fetal Growth
1149027|NCT01369940|Twin Growth
1149028|NCT01369927|Shigellosis
1149029|NCT01369927|Safety and Immunogenicity
1149030|NCT01369927|Conjugate Vaccine
1149031|NCT01369914|Graft-Versus-Host Disease
1149032|NCT01369914|Natural History Study
1149033|NCT01369914|Hematopoietic Stem Cell Transplant
1149034|NCT01369914|GVHD
1149040|NCT01369888|Immunotherapy
1149041|NCT01369888|Cell Therapy
1149042|NCT01369888|IL-15 Cytokine
1149043|NCT01369888|Melanoma
1149044|NCT01369888|Metastatic Melanoma
1149045|NCT01369888|Skin Cancer
1149046|NCT01369875|Immunotherapy
1149047|NCT01369875|Cell Therapy
1149048|NCT01369875|Metastatic Cancer
1149049|NCT01369875|Melanoma
1149050|NCT01369875|Metastatic Melanoma
1149051|NCT01369875|Skin Cancer
1149052|NCT01369862|live attenuated flu vaccines
1149053|NCT01369862|influenza A (H1N1)
1149054|NCT01369862|intranasal application
1149055|NCT01369862|replication-deficient influenza virus
1149056|NCT01369836|Tafamidis
1149057|NCT01369836|Pharmacokinetics
1149058|NCT01369836|TTR stabilization
1149059|NCT01369823|HbA1c
1149060|NCT01369823|Paradigm 522/722 Infusion Pump
1149061|NCT01369823|Transmitter (MMT-7703WW)
1149062|NCT01369823|Sensor MMT-7002 (i.e. Glucose Sensor)
1149063|NCT01369823|Levels of HbA1c at enrollment higher than 7
1149064|NCT01369810|Epidemiological
1149065|NCT01369810|asthma
1149066|NCT01369810|COPD
1149067|NCT01369810|reimbursement
1149068|NCT01369810|switch
1149069|NCT01369810|outcomes associated with the change in reimbursement
1149070|NCT01369797|UPSAV
1149071|NCT01369797|autonomy
1149072|NCT01369797|the elderly of 75 years and older
1149073|NCT01369784|Diffuse large B-cell Lymphoma
1149074|NCT01369784|R-IPI
1149075|NCT01369771|Confocal microscopic findings
1149076|NCT01369771|Ocular Hypertension
1149077|NCT01369771|Open-Angle Glaucoma
1149078|NCT01369771|Preservative-free eye drops
1149079|NCT01369758|morcellator
1149080|NCT01369758|hysteroscope
1149081|NCT01369758|myomectomy
1149082|NCT01369758|polypectomy
1149083|NCT01369758|uterine fibroids
1149084|NCT01369758|uterine polyps
1149085|NCT01369745|Rheumatoid Arthritis
1149086|NCT01369745|Moderate to severe
1149087|NCT01369719|Thalassemia
1149088|NCT01369719|Iron overload
1149089|NCT01369719|transfusion
1149090|NCT01369719|osveral
1149091|NCT01369719|desferal
1149092|NCT01369706|electromagnetic interference
1149093|NCT01369706|hand-held metal detector
1149094|NCT01369706|pacemaker
1149095|NCT01369706|cardioverter-defibrillator
1149096|NCT01369693|smokeless tobacco
1149097|NCT01369693|Nicotine
1149098|NCT01369693|Cadmium
1149099|NCT01369693|lead
1149100|NCT01369693|Tobacco Specific Nitrosamines
1149101|NCT01369680|Ketamine
1149102|NCT01369680|Chronic pain
1149103|NCT01369680|Children
1149104|NCT01369680|Oral pain medication
1149105|NCT01369654|hysterectomy with Bilateral Salpingo Oophorectomy
1149106|NCT01369654|Oophorectomy
1149107|NCT01369654|Gynecologic condition
1149108|NCT01369641|cisplatin
1149109|NCT01369641|STS
1149110|NCT01369641|sodium thiosulfate
1149111|NCT01369641|Adults
1149112|NCT01369641|dose range of 80-120mg/m2
1149113|NCT01369628|Open label
1149114|NCT01369628|Dose Escalating
1149115|NCT01369628|Phase Ib
1149116|NCT01369615|Malignant pain
1149117|NCT01369615|Nonmalignant pain
1149118|NCT01369615|Pain
1149119|NCT01369615|Pediatric
1149120|NCT01369615|Opioid
1149121|NCT01369615|Moderate to severe
1149122|NCT01369589|Xerostomia
1149123|NCT01369589|dry mouth
1149124|NCT01369589|Sjogren's Syndrome
1149125|NCT01369563|rhinitis
1149126|NCT01369563|ciclesonide
1149127|NCT01369563|intermittent rhinitis
1149128|NCT01369563|persistent rhinitis
1149129|NCT01369524|fluid responsiveness
1149130|NCT01369524|microcirculation
1149131|NCT01369524|Intensive Care
1149132|NCT01369511|Disuse Atrophy
1149133|NCT01369511|Muscle
1149134|NCT01369511|Strength
1149135|NCT01369511|Arthroplasty
1149136|NCT01369511|Hip
1149137|NCT01369511|Joint Replacement
1149138|NCT01369498|Hematology
1149139|NCT01369498|Myelofibrosis
1149140|NCT01369498|Thrombocythemia Myelofibrosis
1149141|NCT01369498|Bone Marrow Diseases
1149142|NCT01369498|Hematologic Diseases
1149143|NCT01369498|Blood Diseases
1149144|NCT01369498|Leukemia
1149145|NCT01369498|Blood Disorders
1149146|NCT01369485|Urinary Incontinence
1149147|NCT01369485|Overactive Bladder
1149148|NCT01369485|Frequency
1149149|NCT01369485|Urgency
1149150|NCT01369459|Comorbid
1149151|NCT01369459|ADHD
1149152|NCT01369459|SUD
1149153|NCT01369459|ASU
1149154|NCT01369446|In vitro fertilization
1149155|NCT01369446|Assisted reproduction
1149156|NCT01369446|Noninvasive imaging of embryos
1149157|NCT01369446|Time lapse imaging of embryos
1149158|NCT01369446|Traditional morphological grading of embryos
1149159|NCT01369446|Prediction of blastocysts
1149161|NCT01369420|locoregional cancer therapy
1149162|NCT01369420|pancreatic cancer
1149163|NCT01369420|unresectable pancreatic cancer
1149164|NCT01369420|pancreatic adenocarcinoma
1149165|NCT01369420|locally advanced, unresectable pancreatic cancer
1149166|NCT01369420|pancreatic cancer tumor ablation
1149167|NCT01369420|NanoKnife tumor ablation for pancreatic cancer
1149168|NCT01369420|NanoKnife LEDC system tumor ablation
1149169|NCT01369420|Non thermal ablation
1149170|NCT01369420|Irreversible electroporation for pancreatic cancer treatment
1149171|NCT01369420|IRE for unresectable pancreatic cancer
1149172|NCT01369407|Heart failure
1149173|NCT01369407|HF
1149174|NCT01369407|Heart Diseases
1149175|NCT01369407|Cardiovascular Diseases
1149176|NCT01369407|Heart Failure NYHA class III
1149177|NCT01369407|Advanced heart failure
1149178|NCT01369407|Systolic Heart Failure
1149179|NCT01369394|Measles
1149180|NCT01369394|Mumps
1149181|NCT01369394|Rubella
1149182|NCT01369394|MMR
1149183|NCT01369394|Prevention
1149184|NCT01369394|Tailoring
1149185|NCT01369394|Persuasive communication
1149186|NCT01369394|Children
1149187|NCT01369381|Cervical spine
1149188|NCT01369381|Endotracheal intubation
1149189|NCT01369381|Laryngoscope
1149190|NCT01369381|Biomechanics
1149191|NCT01369368|Acute myeloid leukemia
1149192|NCT01369368|Allogeneic stem cell transplantation
1149193|NCT01369368|Relapse
1149194|NCT01369368|Disease stabilization, survival
1149195|NCT01369355|Ustekinumab
1149196|NCT01369355|Stelara, Moderately to severely active Crohn's Disease
1149197|NCT01369355|IBD, Crohn's
1149198|NCT01369355|UNITI
1149199|NCT01369355|colitis
1149200|NCT01369355|IL-12
1149201|NCT01369355|IL-23
1149202|NCT01369342|ustekinumab
1149203|NCT01369342|moderately to severely active Crohn's Disease
1149204|NCT01369342|Stelara
1149205|NCT01369342|IBD
1149206|NCT01369342|colitis
1149207|NCT01369342|crohn
1149208|NCT01369342|UNITI
1149209|NCT01369342|Crohn's
1149210|NCT01369329|ustekinumab
1149211|NCT01369329|moderately to severely active Crohn's Disease
1149212|NCT01369329|tumor necrosis factor, Stelara
1149213|NCT01369329|Crohn
1149214|NCT01369329|Crohn's
1149215|NCT01369329|IBD
1149216|NCT01369329|UNITI
1149217|NCT01369303|HIV
1149218|NCT01369290|Depression
1149219|NCT01369290|Antidepressant Medication
1149220|NCT01369290|CBT
1149221|NCT01369277|PF-04991532
1149222|NCT01369277|safety and tolerability
1149223|NCT01369277|PK
1149224|NCT01369277|Japanese and Western population
1149225|NCT01369264|Repetitive Transcranial Magnetic Stimulation (rTMS)
1149226|NCT01369264|Electroencephalography (EEG)
1149227|NCT01369264|Magnetic Resonance Imaging
1149228|NCT01369264|Quantitative EEG (QEEG)
1149229|NCT01369238|bee venom acupuncture
1149230|NCT01369238|east west collaborative medicine
1149231|NCT01369238|whiplash associated disorder
1149232|NCT01369225|Randomized
1149233|NCT01369225|Safety Study
1149234|NCT01369225|Open Label
1149235|NCT01369199|Hepatitis B
1149236|NCT01369199|immune-tolerant hepatitis b
1149237|NCT01369199|HBV
1149238|NCT01369173|Healthy
1149239|NCT01369147|SICU
1149240|NCT01369147|calories
1149241|NCT01369147|TPN
1149242|NCT01369147|tube feeding
1149243|NCT01369147|Optimum Energy Dose in SICU
1149244|NCT01369134|self-etch adhesive
1149245|NCT01369134|selective enamel etching
1149246|NCT01369134|Adper Easy Bond
1149247|NCT01369134|Supreme Ultra
1149248|NCT01369134|Molar and premolar teeth
1149249|NCT01369134|Adult
1149250|NCT01369134|Class I and II cavities
1149251|NCT01369121|peritumoral brain edema
1149252|NCT01369121|edema
1149253|NCT01369121|malignant brain tumor
1149254|NCT01369121|brain tumor
1149255|NCT01369121|dexamethasone
1149256|NCT01369121|Decadron
1149257|NCT01369108|small Class I
1149258|NCT01369108|molar and premolar
1149259|NCT01369108|low stress flowable composite
1149260|NCT01369108|adult
1149261|NCT01369108|Restoration
1149262|NCT01369108|small caries lesions
1149263|NCT01369082|islet allograft function
1149264|NCT01369082|c-peptide production
1149265|NCT01369082|maintenance immunosuppressive medications
1149266|NCT01369069|stroke
1149267|NCT01369069|diabetes
1149268|NCT01369069|hyperglycemia
1149269|NCT01369056|antiretroviral therapy, highly active
1149270|NCT01369056|treatment adherence
1149271|NCT01369043|Vitamin E
1149272|NCT01369043|Vitamin C
1149273|NCT01369043|Exercise
1149274|NCT01369043|Antioxidant
1149275|NCT01369030|L-methylfolate
1149276|NCT01369030|Deplin
1149277|NCT01369030|depression
1149278|NCT01369030|antidepressant
1149279|NCT01369030|combination therapy
1149280|NCT01369030|augmentation
1149281|NCT01369030|folate
1149282|NCT01369030|folic acid
1149283|NCT01369030|homocysteine
1149284|NCT01369030|methionine
1149285|NCT01369030|MTHFR genotype
1149286|NCT01369030|C677T mutation
1149287|NCT01369030|vitamin B6
1149288|NCT01369030|vitamin B12
1149289|NCT01369017|healthy volunteer
1149290|NCT01369017|endotoxin
1149291|NCT01369004|self-weighing
1149292|NCT01369004|self-monitoring
1149293|NCT01369004|weight loss
1149294|NCT01369004|obesity
1149295|NCT01368991|Coronary Artery Bypass Grafts
1149296|NCT01368991|Sternal Closure
1149297|NCT01368991|Biologic Bone cement
1149298|NCT01368978|TIDM
1149299|NCT01368952|Obstructive Sleep Apnea
1149300|NCT01368952|Prone positioning
1149301|NCT01368952|Positional Treatment
1149302|NCT01368952|Hypoxemia
1149303|NCT01368939|breast imaging
1149304|NCT01368939|MBI
1149305|NCT01368939|dose reduction
1149306|NCT01368939|Tc-99m
1149307|NCT01368939|imaging
1149308|NCT01368939|cardiac
1149309|NCT01368900|Ultherapy™ Treatment
1149310|NCT01368900|Ulthera, Inc.
1149311|NCT01368900|Ultrasound treatment for skin tightening
1149312|NCT01368887|psoriasis
1149313|NCT01368887|scalp psoriasis
1149314|NCT01368861|infant
1149315|NCT01368861|immunizations
1149316|NCT01368861|pain
1149317|NCT01368861|pain management
1149318|NCT01368861|vaccines
1149319|NCT01368861|analgesia
1149320|NCT01368848|AGMT
1149321|NCT01368848|NSCLC
1149322|NCT01368848|non-small cell lung cancer
1149323|NCT01368848|bevacizumab
1149324|NCT01368848|Avastin
1149325|NCT01368848|Cisplatin
1149326|NCT01368848|Docetaxel
1149327|NCT01368848|Taxotere
1149328|NCT01368848|Inoperable
1149329|NCT01368848|stages IIIB and IV
1149330|NCT01368809|Ambulatory surgery
1149331|NCT01368809|Pain management
1149332|NCT01368809|Perioperative outcomes
1149333|NCT01368809|Fentanyl
1149334|NCT01368809|Coughing during insertion of an LMA
1149335|NCT01368809|Ambulatory surgery procedures
1149336|NCT01368796|Vaccine
1149337|NCT01368796|Influenza vaccine
1149338|NCT01368796|Adjuvanted Influenza vaccine
1149339|NCT01368796|Intradermal Influenza vaccine
1149340|NCT01368796|Seniors
1149341|NCT01368796|Acceptability of vaccines
1149342|NCT01368796|Influenza
1149343|NCT01368757|Chronic myelomonocytic leukemia
1149344|NCT01368757|CMML
1149345|NCT01368757|Lenalidomide
1149346|NCT01368757|Revlimid
1149347|NCT01368744|Breast Neoplasms
1149348|NCT01368744|Breast Diseases
1149349|NCT01368705|Infants
1149350|NCT01368705|Nitrogen Balance
1149351|NCT01368705|Cardiothoracic surgery
1149352|NCT01368705|Congenital heart disease
1149353|NCT01368705|Malnutrition
1149354|NCT01368692|subclavian vein catheterization success rate
1149355|NCT01368679|Aortic Aneurysm, Abdominal
1149356|NCT01368679|Abdominal Aortic
1149357|NCT01368666|Aortic valve replacement
1149358|NCT01368666|Aortic stenosis
1149359|NCT01368666|Biological valve
1149360|NCT01368666|Sutureless valve
1149361|NCT01368666|Stented valve
1149362|NCT01368666|Aortic Valve Disease
1149363|NCT01368653|Tobacco
1149364|NCT01368653|Smoking
1149365|NCT01368653|Smoking Cessation
1149366|NCT01368653|Tobacco Dependence
1149367|NCT01368653|Tobacco Use
1149368|NCT01368653|Nicotine Dependence
1149369|NCT01368627|Coronary Artery Disease
1149370|NCT01368627|Restenosis
1149371|NCT01368627|Stent thrombosis
1149372|NCT01368627|Coronary stents
1149373|NCT01368627|Angioplasty
1149374|NCT01368627|Drug Eluting Stents(DES)
1149375|NCT01368614|OHS
1149376|NCT01368601|Lung Cancer
1149377|NCT01368601|CPAP
1149378|NCT01368601|PPC
1149379|NCT01368601|lobectomy
1149380|NCT01368601|One-lung ventilation
1149381|NCT01368588|adenocarcinoma of the prostate
1149382|NCT01368588|stage I prostate cancer
1149383|NCT01368588|stage IIA prostate cancer
1149384|NCT01368588|stage IIB prostate cancer
1149385|NCT01368588|stage III prostate cancer
1149386|NCT01368575|Ischemic
1149387|NCT01368575|Mitral
1149388|NCT01368575|Valve
1149389|NCT01368575|Insufficiency
1149390|NCT01368575|SVR
1149391|NCT01368549|Metanx
1149392|NCT01368549|diabetes
1149393|NCT01368549|neuropathy
1149394|NCT01368549|folic acid
1149395|NCT01368549|folate
1149396|NCT01368549|L-methylfolate
1149397|NCT01368549|vitamin B6
1149398|NCT01368549|Pyridoxal 5'-phosphate
1149399|NCT01368549|vitamin B12
1149400|NCT01368549|methylcobalamin
1149401|NCT01368549|DPN
1149402|NCT01368536|High blood pressure
1149403|NCT01368536|diabetes
1149404|NCT01368523|Chronic Myelogenous Leukemia
1149405|NCT01368523|chronic phase
1149406|NCT01368523|accelerated phase
1149407|NCT01368523|blastic phase
1149408|NCT01368523|nilotinib
1149409|NCT01368510|obsessive-compulsive disorder (OCD)
1149410|NCT01368510|cognitive-behavioral therapy (CBT)
1149411|NCT01368510|magnetic resonance spectroscopy (MRS)
1149412|NCT01368510|glutamate
1149413|NCT01368510|cingulate gyrus
1149414|NCT01368471|STEMI
1149415|NCT01368471|myocardial infarction
1149416|NCT01368471|stent
1149417|NCT01368432|TBI
1149418|NCT01368432|Depression
1149419|NCT01368432|Mood
1149420|NCT01368432|Behavior
1149421|NCT01368419|Endostar
1149422|NCT01368419|Radiotherapy
1149423|NCT01368419|Esophageal Cancer
1149424|NCT01368406|schizophrenia
1149425|NCT01368406|weight gain
1149426|NCT01368406|intervention
1149427|NCT01368380|Breast cancer
1149428|NCT01368380|Partners
1149429|NCT01368380|Couples
1149430|NCT01368380|Attachment
1149431|NCT01368380|Intervention
1149432|NCT01368367|Burns
1149433|NCT01368354|Community Led Total Sanitation
1149434|NCT01368354|Open Defecation
1149435|NCT01368354|Cysticercosis
1149436|NCT01368354|Soil transmitted helminths
1149437|NCT01368354|Zambia
1149438|NCT01368341|Antibiotics
1149439|NCT01368341|General Practice
1149440|NCT01368341|Erythema migrans
1149441|NCT01368341|Borrelia
1149442|NCT01368341|Ticks
1149443|NCT01368328|Type 2 Diabetes
1149444|NCT01368328|Chromium
1149445|NCT01368328|Insulin resistance
1149446|NCT01368302|attention bias modification treatment
1149447|NCT01368302|cognitive bias modification
1149448|NCT01368302|attention training
1149449|NCT01368302|anxiety
1149450|NCT01368276|Melanoma
1149451|NCT01368276|Stage IIIb, IIIc and IV Disease
1149452|NCT01368276|oncolytic
1149453|NCT01368276|OncoVex
1149454|NCT01368276|OncoVEX^GM-CSF
1149455|NCT01368250|Aortic
1149456|NCT01368250|Stenosis
1149457|NCT01368250|Valve
1149458|NCT01368250|VARC
1149459|NCT01368250|Transcatheter
1149460|NCT01368250|Minimal-invasive
1149461|NCT01368237|Computed tomography
1149462|NCT01368237|Myocardial perfusion
1149463|NCT01368237|Coronary heart disease
1149464|NCT01368224|Skin sensitivity
1149465|NCT01368224|Trans-epidermal water loss
1149466|NCT01368224|Clinical score
1149467|NCT01368224|skin moisturization factors
1149468|NCT01368224|serum immune-regulatory cytokine
1149469|NCT01368224|Evaluation of intestinal flora composition
1149470|NCT01368211|Mirasol
1149471|NCT01368211|Thrombocytopenic
1149472|NCT01368211|Pathogen reduction
1149473|NCT01368211|Platelets
1149474|NCT01368211|Thromboelastography
1149475|NCT01368211|CCI
1149476|NCT01368211|Corrected Count Increment
1149477|NCT01368198|Ocular Emulsion
1149478|NCT01368198|OPTIVE™ Lubricant
1149479|NCT01368198|Tear Film Break Up Time
1149480|NCT01368185|Essential hypertension Uric acid Retrospective Hyzaar
1149481|NCT01368172|spinal cord injury
1149482|NCT01368172|physical activity
1149483|NCT01368172|physical fitness
1149484|NCT01368133|acromegaly
1149485|NCT01368133|pituitary tumor
1149486|NCT01368107|IL-7
1149487|NCT01368107|metastatic breast cancer patients
1149488|NCT01368107|lymphopenia
1149489|NCT01368094|Pancreaticoduodenectomy
1149490|NCT01368094|Drainage
1149491|NCT01368094|Surgical site infection
1149492|NCT01368068|Perimenopause
1149493|NCT01368068|Depression
1149494|NCT01368055|Proton Radiation, Prostate Cancer
1149495|NCT01368042|Quality of Life changes
1149496|NCT01368042|Secondary Hyperparathyroidism
1149497|NCT01368042|Chronic Kidney Disease
1149498|NCT01368042|Hemodialysis
1149499|NCT01368042|Paricalcitol intravenous treatment
1149500|NCT01368029|LGG
1149501|NCT01368029|Immune response
1149502|NCT01368029|Influenza vaccine
1149503|NCT01368029|Elderly
1149504|NCT01368029|Healthy
1149505|NCT01368029|Microbiome
1149506|NCT01368016|Smoking Cessation
1149507|NCT01368016|Nicotine Pharmacodynamics
1149508|NCT01368003|Castration resistant prostate cancer
1149509|NCT01367990|alopecia
1149510|NCT01367990|hair loss
1149511|NCT01367990|prevention
1149512|NCT01367990|radiotherapy
1149513|NCT01367990|head & neck cancer
1149514|NCT01367990|radiodermatitis
1149515|NCT01367990|radiation dermatitis
1149516|NCT01367990|radiation-induced alopecia
1149517|NCT01367977|Ehlers Danlos Syndrome
1149518|NCT01367977|External Communicating Hydrocephalus
1149519|NCT01367977|Dysautonomia
1149520|NCT01367977|Postural orthostatic tachycardia syndrome
1149521|NCT01367977|Chronic cerebrospinal venous insufficiency
1149522|NCT01367964|Hypsarrhythmia
1149523|NCT01367964|Spasms, Infantile
1149524|NCT01367964|West Syndrome
1149525|NCT01367951|unstable chest injury
1149526|NCT01367951|flail chest
1149527|NCT01367951|chest wall injury
1149528|NCT01367951|rib fracture
1149529|NCT01367938|Osteoarthritis
1149530|NCT01367938|Total Knee Replacement
1149531|NCT01367925|Osteoarthritis
1149532|NCT01367925|Total Knee Replacement
1149533|NCT01367912|Luteal phase support
1149534|NCT01367912|estradiol supplementation
1149535|NCT01367912|IVF/ICSI
1149536|NCT01367912|clinical pregnancy rate
1149537|NCT01367899|Safety
1149538|NCT01367899|Efficacy
1149539|NCT01367886|Urine proteomics
1149540|NCT01367886|overactive bladder
1149541|NCT01367860|spine surgery
1149542|NCT01367860|low back pain
1149543|NCT01367860|herniated disk
1149544|NCT01367847|Parenting
1149545|NCT01367847|Parent-Child Relations
1149546|NCT01367847|Child Behavior
1149547|NCT01367834|Turner Syndrome
1149548|NCT01367834|growth hormone
1149549|NCT01367834|brain development
1149550|NCT01367821|Obstructive jaundice
1149551|NCT01367821|ERCP
1149552|NCT01367821|Immune dysfunction
1149553|NCT01367821|Endotoxin tolerance
1149554|NCT01367821|Quorum sensing
1149555|NCT01367808|Buprenorphine
1149556|NCT01367808|Vorikonazole
1149557|NCT01367808|Posakonazole
1149558|NCT01367808|Interactions
1149559|NCT01367795|palliation
1149560|NCT01367795|quality of life
1149561|NCT01367795|surgery
1149562|NCT01367795|surgery; palliative
1149563|NCT01367795|lifestyle
1149564|NCT01367782|UPDRS
1149565|NCT01367769|Deep vein thrombosis
1149566|NCT01367769|superficial thrombophlebitis
1149567|NCT01367769|contrast ultrasound
1149568|NCT01367743|myocardial infarction
1149569|NCT01367743|epinephrine
1149570|NCT01367743|norepinephrine
1149571|NCT01367743|cardiac output
1149572|NCT01367730|osteopenia and osteoporosis
1149573|NCT01367717|Creatine
1149574|NCT01367717|Creatinine
1149575|NCT01367717|Serum Creatinine
1149576|NCT01367717|Urine Creatinine
1149577|NCT01367717|Creatine Monohydrate
1149578|NCT01367717|Creatine Ethyl Ester
1149579|NCT01367717|Acute Kidney Injury
1149580|NCT01367717|Renal
1149581|NCT01367717|Kidney
1149582|NCT01367704|gender-based violence
1149583|NCT01367704|intimate partner violence
1149584|NCT01367704|relationship abuse
1149585|NCT01367704|sexual harassment
1149586|NCT01367704|sexual violence
1149587|NCT01367691|CRT
1149588|NCT01367691|heart failure
1149589|NCT01367691|CMR
1149590|NCT01367691|safety
1149591|NCT01367639|BRCA 1/2 Carriers
1149592|NCT01367639|IBSR
1149593|NCT01367639|The Work
1149594|NCT01367639|Randomized clinical trial
1149595|NCT01367613|Advanced medical illness
1149596|NCT01367600|Advanced medical illness
1149597|NCT01367574|Opioid-induced bowel dysfunction
1149598|NCT01367444|Stargardt Disease
1149599|NCT01367431|Xanthohumol
1149600|NCT01367431|Metabolic syndrome
1149601|NCT01367418|Analgesia: Thoracic epidural, patient controlled
1149602|NCT01367418|Surgery: Radical retropubic prostatectomy
1149603|NCT01367418|Immune system
1149604|NCT01367418|Inflammation
1149605|NCT01367405|Surgical decompression
1149606|NCT01367405|conservative treatment
1149607|NCT01367405|incomplete spinal cord lesion
1149608|NCT01367405|recovery
1149609|NCT01367379|Physician
1149610|NCT01367379|duty loading
1149611|NCT01367379|stress response
1149612|NCT01367379|Physician with different amount of duty area
1149613|NCT01367366|malignant mediastinal lymphadenopathy
1149614|NCT01367366|positron emission tomography
1149615|NCT01367366|endobronchial ultrasound
1149616|NCT01367366|transbronchial needle aspiration
1149617|NCT01367327|Exercise
1149618|NCT01367288|locally advanced breast cancer
1149619|NCT01367288|neoadjuvant chemotherapy
1149620|NCT01367288|HER2-negative breast cancer
1149621|NCT01367288|stage IIb breast cancer
1149622|NCT01367288|stage IIIa breast cancer
1149623|NCT01367288|Zoledronic acid
1149624|NCT01367288|bisphosphonate
1149625|NCT01367288|zometa
1149626|NCT01367288|therapeutic response
1149627|NCT01367288|VEGF serum
1149628|NCT01367288|tumors markers
1149629|NCT01367288|neoangiogenesis
1149630|NCT01367288|apoptosis
1149631|NCT01367288|proliferation
1149632|NCT01367288|disseminated tumors cells
1149633|NCT01367288|gamma-delta T cells activation
1149634|NCT01367275|colon
1149635|NCT01367275|Colorectum
1149636|NCT01367275|Colorectal Cancer
1149637|NCT01367275|Plasma FGF
1149638|NCT01367275|Colorectal adenocarcinoma
1149639|NCT01367275|Bevacizumab
1149640|NCT01367275|Brivanib
1149641|NCT01367275|BMS-582664
1149642|NCT01367275|Irinotecan
1149643|NCT01367275|CPT-11
1149644|NCT01367275|Camptosar
1149645|NCT01367275|Fibroblast Growth Factor
1149646|NCT01367275|bFGF
1149647|NCT01367275|tyrosine kinase receptors
1149648|NCT01367275|vascular endothelial growth factor receptors
1149649|NCT01367275|VEGFR
1149650|NCT01367275|fibroblast growth factor receptors
1149651|NCT01367275|FGFR
1149652|NCT01367262|Absorption
1149653|NCT01367262|Distribution
1149654|NCT01367262|Metabolism
1149655|NCT01367262|Excretion
1149656|NCT01367249|cataract surgery
1149657|NCT01367223|inflammatory response
1149658|NCT01367223|parenteral nutrition
1149659|NCT01367223|glutamine
1149660|NCT01367223|amino acid
1149661|NCT01367223|pediatric
1149662|NCT01367223|intensive care
1149663|NCT01367223|systemic infection
1149664|NCT01367223|abdominal surgery
1149665|NCT01367223|polytraumatised
1149666|NCT01367223|mortality
1149667|NCT01367223|mean stay in the intensive care unit
1149668|NCT01367223|occurrence of infections
1149669|NCT01367210|HIV
1149670|NCT01367210|AIDS
1149671|NCT01367210|Highly Active AntiRetroviral Therapy
1149672|NCT01367210|Simplification
1149673|NCT01367210|Maraviroc
1149674|NCT01367210|Darunavir
1149675|NCT01367210|Treatment experienced
1149676|NCT01367210|Tropism
1149677|NCT01367197|exercise training
1149678|NCT01367197|atrial fibrillation
1149679|NCT01367184|VTE
1149680|NCT01367184|Inferior vena cava
1149681|NCT01367184|Venous thrombo-embolism
1149682|NCT01367184|Outcome data
1149683|NCT01367184|IVC Filters
1149684|NCT01367158|Meningococcal disease
1149685|NCT01367158|vaccines
1149686|NCT01367158|adolescents
1149687|NCT01367158|prevention
1149688|NCT01367158|Meningitis
1149689|NCT01367145|OMEGA-3 polyunsaturated fatty-acids
1149690|NCT01367145|Peripheral Arterial Disease
1149691|NCT01367145|Endothelial Function
1149692|NCT01367145|Inflammation
1149693|NCT01367145|Platelet Function
1149694|NCT01367132|ultrasound
1149695|NCT01367132|first trimester
1149696|NCT01367132|umbilical cord
1149697|NCT01367119|Depression
1149698|NCT01367119|Electroconvulsive therapy
1149699|NCT01367119|Ketamine
1149700|NCT01367119|Methohexital
1149701|NCT01367106|offspring of 21-hydroxylase enzyme block
1149702|NCT01367093|BIOLOGICAL MARKERS
1149703|NCT01367093|INTENSIVE CARE UNIT
1149704|NCT01367093|MORTALITY
1149705|NCT01367093|QUALITY OF LIFE
1149706|NCT01367093|CARDIOVASCULAR
1149707|NCT01367080|depression
1149708|NCT01367067|claustrophobia
1149709|NCT01367067|magnetic resonance imaging
1149710|NCT01367067|MRI
1149711|NCT01367067|anxiety
1149712|NCT01367067|anxious patients
1149713|NCT01367067|phobic disorders
1149714|NCT01367067|anxiety disorders
1149715|NCT01367067|mental disorders
1149716|NCT01367054|Metformine
1149717|NCT01367054|adverse events
1149718|NCT01367054|bioequivalence
1149719|NCT01367041|bone
1149720|NCT01367041|muscle electrical activity
1149721|NCT01367041|whole-body vibration
1149722|NCT01367028|HER2-positive early breast cancer
1149723|NCT01367015|Preterm
1149724|NCT01367015|SGA
1149725|NCT01367015|AREDF
1149726|NCT01367015|Early feeding
1149727|NCT01367015|Late feeding
1149728|NCT01367015|Feed intolerance
1149729|NCT01367015|Necrotizing enterocolitis
1149730|NCT01367015|Days to achieve Full Feeds defined as 150 mL/kg
1149731|NCT01367002|Uterine serous papillary carcinoma
1149732|NCT01367002|Type II endometrial cancer
1149733|NCT01367002|HER2/neu
1149734|NCT01367002|Paclitaxel, Carboplatin, Trastuzumab
1149735|NCT01366989|Total Ankle Arthroplasty
1149736|NCT01366976|oxidative stress
1149737|NCT01366976|cardiopulmonary bypass
1149738|NCT01366976|acetaminophen
1149739|NCT01366976|hemolysis
1149740|NCT01366963|postural tachycardia syndrome
1149741|NCT01366963|brain fog
1149742|NCT01366963|cognitive dysfunction
1149743|NCT01366937|vitamin B12
1149744|NCT01366937|egg
1149745|NCT01366937|14C
1149746|NCT01366937|fecal excretion
1149747|NCT01366924|protein turnover
1149748|NCT01366924|whole body protein turnover
1149749|NCT01366924|essential amino acids
1149750|NCT01366924|leucine
1149751|NCT01366911|stem cells
1149752|NCT01366911|QCT testing
1149753|NCT01366911|Bone density findings
1149754|NCT01366911|mesenchymal stem cells
1149755|NCT01366885|Autism
1149756|NCT01366885|Pregnancy
1149757|NCT01366885|Newborn siblings
1149758|NCT01366872|ankle
1149759|NCT01366872|arthritis
1149760|NCT01366872|total ankle arthroplasty
1149761|NCT01366872|Agility LP,
1149762|NCT01366859|Autism
1149763|NCT01366859|Children
1149764|NCT01366859|Behavior
1149765|NCT01366859|Glutathione
1149766|NCT01366859|Whey Protein
1149767|NCT01366859|Immunocal
1149768|NCT01366859|Antioxidant
1149769|NCT01366846|Peanut
1149770|NCT01366833|Dysphagia
1149771|NCT01366833|Esophagus
1149772|NCT01366833|Cancer
1149773|NCT01366833|Esophageal Cancer
1149774|NCT01366794|Gut hormones
1149775|NCT01366794|Insulin secretion
1149776|NCT01366781|Gut hormones
1149777|NCT01366781|Insulin secretion
1149778|NCT01366768|Gut hormones
1149779|NCT01366768|Insulin secretion
1149780|NCT01366768|Normal physiology
1149781|NCT01366729|hemiplegia
1149782|NCT01366729|walking
1149783|NCT01366729|canes
1149784|NCT01366729|TheraTogs
1149785|NCT01366729|EMG
1149786|NCT01366729|balance
1149787|NCT01366729|Timed up and go
1149788|NCT01366716|Contingency Management
1149789|NCT01366716|Cash
1149790|NCT01366716|Substance Abuse
1149791|NCT01366716|Ethics
1149792|NCT01366703|heart failure
1149793|NCT01366703|implantable loop recorder
1149794|NCT01366690|HIV
1149795|NCT01366690|community health workers
1149796|NCT01366690|randomized trial
1149797|NCT01366690|task shifting
1149798|NCT01366690|Uganda
1149799|NCT01366690|retention
1149800|NCT01366690|operations research
1149801|NCT01366690|implementation research
1149802|NCT01366664|Premature Ejaculation
1149803|NCT01366664|Selective Serotonin Reuptake Inhibitor
1149804|NCT01366664|Dapoxetine
1149805|NCT01366664|PRILIGY
1149806|NCT01366664|Terazosin
1149807|NCT01366664|Pharmacodynamic
1149808|NCT01366664|Pharmacokinetic
1149809|NCT01366651|Doripenem
1149810|NCT01366651|DORIPED1002
1149811|NCT01366651|Intravenous
1149812|NCT01366651|Pediatric
1149813|NCT01366651|Antibiotic
1149814|NCT01366651|Meningitis
1149815|NCT01366638|Hepatitis C, Chronic
1149816|NCT01366638|TMC435
1149817|NCT01366638|Hepatitis C
1149818|NCT01366638|Hepatitis C virus
1149819|NCT01366638|Interferon Alfa-2b
1149820|NCT01366638|Ribavirin
1149821|NCT01366638|Viral ribonucleic acid
1149822|NCT01366625|hypertension, resistant
1149823|NCT01366625|obstructive sleep apnea
1149824|NCT01366625|renal denervation
1149825|NCT01366625|continuous positive airway pressure therapy
1149826|NCT01366612|Allogeneic Stem Cell Transplant
1149827|NCT01366612|AML
1149828|NCT01366612|CML
1149829|NCT01366612|MDS
1149830|NCT01366599|highly emetogenic chemotherapy
1149831|NCT01366599|HEC
1149832|NCT01366599|moderately emetogenic chemotherapy
1149833|NCT01366599|MEC
1149834|NCT01366573|Pharmacokinetics
1149835|NCT01366573|mu-opioid receptors
1149836|NCT01366573|Addiction
1149837|NCT01366573|Pharmacodynamics
1149838|NCT01366573|Alcohol
1149839|NCT01366547|Bioavailability
1149840|NCT01366547|Lamivudine
1149841|NCT01366547|Dolutegravir
1149842|NCT01366547|integrase
1149843|NCT01366547|Abacavir
1149844|NCT01366534|safety
1149845|NCT01366534|Vaccine
1149846|NCT01366534|Phase 1/2
1149847|NCT01366534|immunogenicity
1149848|NCT01366534|Malaria
1149849|NCT01366534|efficacy
1149850|NCT01366534|sporozoite challenge
1149851|NCT01366495|Seek
1149852|NCT01366495|Test
1149853|NCT01366495|Treat
1149854|NCT01366482|Peripheral arterial disease,
1149855|NCT01366482|claudication,
1149856|NCT01366482|atherectomy,
1149857|NCT01366482|plaque excision,
1149858|NCT01366482|drug-coated balloon
1149859|NCT01366482|drug-eluting balloon
1149860|NCT01366469|coronary artery bypass grafting
1149861|NCT01366469|coronary artery disease
1149862|NCT01366469|chronic obstructive pulmonary disease
1149863|NCT01366456|Temperature Change
1149864|NCT01366456|Moxibustion
1149865|NCT01366456|Warming effect
1149866|NCT01366443|ROM PLUS
1149867|NCT01366443|conventional clinical tests of rupture of membranes (ROM)
1149868|NCT01366443|speculum exam
1149869|NCT01366443|visualization of leakage
1149870|NCT01366443|pooling of amniotic fluid in the posterior fornix
1149871|NCT01366443|nitrazine testing
1149872|NCT01366443|ferning
1149873|NCT01366430|BPPV(benign paroxysmal positional vertigo)
1149874|NCT01366430|HC-BPPV(BPPV involving the horizontal semicircular canal)
1149875|NCT01366430|Nystagmus
1149876|NCT01366430|Treatment outcome
1149877|NCT01366430|Horizontal Canal Benign Paroxysmal Positional Vertigo
1149878|NCT01366404|FFR
1149879|NCT01366391|polycystic ovary syndrome
1149880|NCT01366391|metformin
1149881|NCT01366391|pharmacokinetic
1149882|NCT01366313|paracetamol
1149883|NCT01366313|morphine
1149884|NCT01366313|median effective dose
1149885|NCT01366313|pain
1149886|NCT01366287|Relative bioavailability
1149887|NCT01366287|food effect
1149888|NCT01366287|tablet
1149889|NCT01366287|suspension
1149890|NCT01366287|single dose
1149891|NCT01366287|crossover
1149892|NCT01366287|healthy subjects
1149893|NCT01366274|Trauma
1149894|NCT01366261|Flex-rigid pleuroscopy
1149895|NCT01366261|pleural biopsy
1149896|NCT01366261|pleural effusion
1149897|NCT01366261|safety
1149898|NCT01366261|thoracoscopy
1149899|NCT01366222|asthma
1149900|NCT01366209|Pirfenidone
1149901|NCT01366209|ASCEND
1149902|NCT01366209|IPF
1149903|NCT01366209|FVC
1149904|NCT01366196|Orthopedic Procedures
1149905|NCT01366196|Spinal Fusions
1149906|NCT01366196|Pregabalin
1149907|NCT01366196|Gamma-Aminobutyric Acid
1149908|NCT01366196|Analgesics
1149909|NCT01366196|Sensory System Agents
1149910|NCT01366196|Peripheral Nervous System Agents
1149911|NCT01366196|Physiological Effects of Drugs
1149912|NCT01366196|Pharmacologic Actions
1149913|NCT01366196|Central Nervous System Agents
1149914|NCT01366196|Therapeutic Uses
1149915|NCT01366196|Anticonvulsants
1149916|NCT01366196|GABA Agents
1149917|NCT01366196|Neurotransmitter Agents
1149918|NCT01366196|Molecular Mechanisms of Pharmacological Action
1149919|NCT01366170|childhood anaplastic large cell lymphoma
1149920|NCT01366157|childhood favorable prognosis Hodgkin lymphoma
1149921|NCT01366157|stage I childhood Hodgkin lymphoma
1149922|NCT01366157|stage II childhood Hodgkin lymphoma
1149923|NCT01366157|stage III childhood Hodgkin lymphoma
1149924|NCT01366157|stage IV childhood Hodgkin lymphoma
1149925|NCT01366157|childhood lymphocyte depletion Hodgkin lymphoma
1149926|NCT01366157|childhood lymphocyte predominant Hodgkin lymphoma
1149927|NCT01366157|childhood mixed cellularity Hodgkin lymphoma
1149928|NCT01366157|childhood nodular lymphocyte predominant Hodgkin lymphoma
1149929|NCT01366157|childhood nodular sclerosis Hodgkin lymphoma
1149930|NCT01366118|Rectal cancer, Chemoradiotherapy, target therapy
1149931|NCT01366105|Wound healing
1149932|NCT01366105|Negative Pressure Wound Therapy
1149933|NCT01366105|V.A.C.
1149934|NCT01366105|Incision
1149935|NCT01366092|stem cell transplant
1149936|NCT01366092|GVHD
1149937|NCT01366092|bone marrow transplant
1149938|NCT01366092|cord blood transplant
1149939|NCT01366092|regulatory T cell
1149940|NCT01366092|interleukin
1149941|NCT01366066|Stress incontinence
1149942|NCT01366066|urge incontinence
1149943|NCT01366066|overactive bladder syndrome
1149944|NCT01366066|vibration
1149945|NCT01366066|nerve stimulation
1149946|NCT01366053|Prostate Cancer
1149947|NCT01366053|Androgen Deprivation Therapy
1149948|NCT01366053|Agonist
1149949|NCT01366053|Antagonist
1149950|NCT01366053|PSA Failure
1149951|NCT01366053|PSA Rise
1149952|NCT01366040|Patient Satisfaction
1149953|NCT01366040|Multiple Sclerosis
1149954|NCT01366040|Autoinjector
1149955|NCT01366040|Avonex
1149956|NCT01366027|pseudobulbar affect
1149957|NCT01366014|osteoarthritis
1149958|NCT01366014|knee
1149959|NCT01366014|pain
1149960|NCT01366014|NSAID
1149961|NCT01366001|Opioid
1149962|NCT01366001|Cocaine
1149963|NCT01366001|Dependence
1149964|NCT01366001|Abuse
1149965|NCT01366001|Intravenous
1149966|NCT01366001|Buprenorphine
1149967|NCT01365988|fMRI
1149968|NCT01365988|Risk-Taking
1149969|NCT01365988|Decision-Making
1149970|NCT01365988|Memory
1149971|NCT01365988|Resting-State Functional Connectivity
1149972|NCT01365975|Cohort Study
1149973|NCT01365975|Folinic Acid, peri-conception
1149974|NCT01365975|Pediatric Leukemia
1149975|NCT01365975|Pediatric Cancer
1149976|NCT01365962|alveolar childhood rhabdomyosarcoma
1149977|NCT01365962|embryonal childhood rhabdomyosarcoma
1149978|NCT01365962|previously treated childhood rhabdomyosarcoma
1149979|NCT01365962|previously untreated childhood rhabdomyosarcoma
1149980|NCT01365962|recurrent childhood rhabdomyosarcoma
1149981|NCT01365949|Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
1149982|NCT01365936|IVF
1149983|NCT01365936|ICSI
1149984|NCT01365936|OHSS
1149985|NCT01365936|PCOS
1149986|NCT01365936|recFSH
1149987|NCT01365936|HMG
1149988|NCT01365897|Modafinil
1149989|NCT01365897|Memory
1149990|NCT01365897|Executive Functions
1149991|NCT01365897|Memory, Short-Term
1149992|NCT01365897|Attention
1149993|NCT01365897|University Students
1149994|NCT01365897|Stroop Effect
1149995|NCT01365897|Digit Span
1149996|NCT01365897|Backwards Digit Span
1149997|NCT01365897|Biber Cognitive Estimation Test
1149998|NCT01365871|prostate biopsy
1149999|NCT01365871|pain
1150000|NCT01365845|Proton Radiation
1150001|NCT01365845|Breast Cancer
1150002|NCT01365819|Crystal meth dependence
1150003|NCT01365819|crystal meth
1150004|NCT01365819|methamphetamine dependence
1150005|NCT01365819|substance abuse
1150006|NCT01365806|heart transplantation
1150007|NCT01365806|allograft rejection
1150008|NCT01365806|QT interval
1150009|NCT01365806|electrocardiogram (ECG)
1150010|NCT01365793|cerebral edema
1150011|NCT01365793|diabetic ketoacidosis
1150012|NCT01365793|pediatric diabetes
1150013|NCT01365793|fluid therapy
1150014|NCT01365780|microcirculation, O2c
1150015|NCT01365767|Crohn disease
1150016|NCT01365767|Ultrasonography, contrast enhanced
1150017|NCT01365767|Elasticity Imaging Techniques
1150018|NCT01365767|Small intestine
1150019|NCT01365767|Magnetic Resonance Imaging
1150020|NCT01365767|CDAI
1150021|NCT01365767|Calprotectin
1150022|NCT01365767|IBD
1150023|NCT01365767|Sonography
1150024|NCT01365754|Lumbar degenerative disease
1150025|NCT01365741|PCI
1150026|NCT01365741|STEMI
1150027|NCT01365741|Interventions
1150028|NCT01365741|Heart disease
1150029|NCT01365741|Thrombocytic inhibition
1150030|NCT01365741|Cross-over study
1150031|NCT01365741|Percutaneous coronary intervention
1150032|NCT01365728|Femtosecond Laser
1150033|NCT01365728|FS60
1150034|NCT01365728|iFS
1150035|NCT01365728|Intralase
1150036|NCT01365728|Wavefront-guided LASIK
1150037|NCT01365728|IntraLASIK
1150038|NCT01365728|LASIK
1150039|NCT01365728|Myopia
1150040|NCT01365728|Nearsightedness
1150041|NCT01365715|Preoperative embolization
1150042|NCT01365715|Transcatheter arterial embolization
1150043|NCT01365715|Therapeutic angiography
1150044|NCT01365715|Embolization
1150045|NCT01365715|Surgical blood loss
1150046|NCT01365715|Spinal metastases
1150047|NCT01365715|Spinal neoplasms
1150048|NCT01365715|Vertebral metastases
1150049|NCT01365715|metastatic spine surgery
1150050|NCT01365715|Spinal surgery
1150051|NCT01365702|COPD
1150052|NCT01365702|tiotropium
1150053|NCT01365702|tuberculous destroyed lung
1150054|NCT01365676|Edema
1150055|NCT01365676|Depression
1150056|NCT01365676|Hot Flashes
1150057|NCT01365676|Anxiety
1150058|NCT01365676|Irritability
1150059|NCT01365676|PMS
1150060|NCT01365663|Hypercholesterolemia
1150061|NCT01365663|LDL
1150062|NCT01365663|HDL
1150063|NCT01365663|apoB
1150064|NCT01365663|hyperlipidemia
1150065|NCT01365663|LNA-oligonucleotide
1150066|NCT01365637|safety
1150067|NCT01365637|tolerability
1150068|NCT01365637|pharmacokinetics
1150069|NCT01365637|PF-05089771
1150070|NCT01365598|malaria
1150071|NCT01365598|uncomplicated malaria
1150072|NCT01365598|gametocytocidal drug
1150073|NCT01365598|gametocytocidal
1150074|NCT01365598|gametocyte
1150075|NCT01365598|primaquine
1150076|NCT01365598|transmission blocking
1150077|NCT01365598|malaria transmission
1150078|NCT01365598|sexual parasite
1150079|NCT01365598|sexual stage
1150080|NCT01365598|Uganda
1150081|NCT01365598|Africa
1150082|NCT01365585|Pulmonary arterial hypertension
1150083|NCT01365585|sildenafil citrate
1150084|NCT01365585|Revatio
1150085|NCT01365572|Drug-eluting stent
1150086|NCT01365559|multiple myeloma
1150087|NCT01365559|carfilzomib
1150088|NCT01365559|relapsed
1150089|NCT01365559|refractory
1150090|NCT01365559|bortezomib
1150091|NCT01365559|Oncotherapeutics
1150092|NCT01365533|Airway Inflammation
1150093|NCT01365533|Roflumilast
1150094|NCT01365494|Rabies
1150095|NCT01365494|rabies vaccines
1150096|NCT01365494|post-exposure prophylaxis
1150097|NCT01365481|Hypertension, pediatric
1150098|NCT01365481|Hypertension with or without chronic kidney disease
1150099|NCT01365468|RAD001,
1150100|NCT01365468|Everolimus,
1150101|NCT01365468|Plexiform Neurofibroma,
1150102|NCT01365468|Neurofibromatosis Type 1
1150103|NCT01365455|Psoriasis
1150104|NCT01365455|plaque
1150105|NCT01365455|plaque-type psoriasis
1150106|NCT01365455|IL-17 blocker
1150107|NCT01365455|subcutaneous
1150108|NCT01365455|psoriatic arthritis
1150109|NCT01365455|injection
1150110|NCT01365455|AIN457
1150111|NCT01365455|AIN457A
1150112|NCT01365455|secukinumab
1150113|NCT01365442|Cholera
1150114|NCT01365442|Vaccination
1150115|NCT01365442|Oral cholera vaccine
1150116|NCT01365442|Mass vaccination
1150117|NCT01365442|Oral whole cell cholera vaccine
1150118|NCT01365429|Lung Transplant, Transplantation Lung
1150119|NCT01365416|diabetes
1150120|NCT01365416|diabetes remission
1150121|NCT01365416|obesity
1150122|NCT01365416|bariatric surgery
1150123|NCT01365416|gene expression
1150124|NCT01365416|genetic variation
1150125|NCT01365416|metabolomics
1150126|NCT01365416|metabonomics
1150127|NCT01365416|epigenetic variation
1150128|NCT01365416|mutations
1150129|NCT01365390|prospective
1150130|NCT01365390|Incidence
1150131|NCT01365390|otitis
1150132|NCT01365390|observational
1150133|NCT01365390|Epidemiological
1150134|NCT01365390|retrospective
1150135|NCT01365377|Anxiety
1150136|NCT01365377|Depression
1150137|NCT01365377|Post-traumatic stress disorders
1150138|NCT01365377|Quality of life
1150139|NCT01365377|Family
1150140|NCT01365377|ICU
1150141|NCT01365364|PLM
1150142|NCT01365364|dopamine
1150143|NCT01365364|physical exercise
1150144|NCT01365338|schizophrenia fMRI cognition working memory ASL
1150145|NCT01365312|Central line associated infection
1150146|NCT01365312|PICC associated infection
1150147|NCT01365312|Neonatal central line associated sepsis
1150148|NCT01365312|Central line colonization
1150149|NCT01365312|Ethanol Lock
1150150|NCT01365286|asthma, chronic obstructive pulmonary disease, COPD, ivabradine, heart rate
1150151|NCT01365273|Split thickness skin grafts
1150152|NCT01365273|Mepitel One
1150153|NCT01365273|Bridal Veil and staples
1150154|NCT01365273|Pain
1150155|NCT01365247|Co-morbid substance disorders and PTSD
1150156|NCT01365247|Trauma
1150157|NCT01365247|Alcohol and other drug use disorders
1150158|NCT01365247|Treatment outcome
1150159|NCT01365247|Post-Traumatic Stress Disorder (PTSD)
1150160|NCT01365247|Co-morbid Alcohol and other drug use disorders (AOD)
1150161|NCT01365247|Behavioral Treatment
1150162|NCT01365221|Acute Coronary Syndrome
1150163|NCT01365221|Clopidogrel
1150164|NCT01365221|Prasugrel
1150165|NCT01365195|opioid
1150166|NCT01365195|Fentanyl
1150167|NCT01365195|Anesthetic adjuvant
1150168|NCT01365195|Pain management
1150169|NCT01365195|Perioperative outcomes
1150170|NCT01365195|Constipation
1150171|NCT01365195|Ileus
1150172|NCT01365195|Colorectal
1150173|NCT01365182|prostate cancer
1150174|NCT01365182|urinary incontinence
1150175|NCT01365182|pelvic floor muscle exercise
1150176|NCT01365182|self-management
1150177|NCT01365182|behavioral intervention
1150178|NCT01365182|quality of life
1150195|NCT01365156|locally advanced cervical cancer
1150196|NCT01365156|pretherapeutic para-aortic surgical staging
1150197|NCT01365156|radiologic staging
1150198|NCT01365156|pretherapeutic surgical staging
1150199|NCT01365156|para-aortic metastatic disease
1150200|NCT01365130|esophageal cancer
1150201|NCT01365130|gastroesophageal cancer
1150202|NCT01365130|gastric cancer
1150203|NCT01365104|brain blood flow
1150204|NCT01365104|stroke
1150205|NCT01365104|cerebrovascular
1150206|NCT01365104|aging
1150207|NCT01365104|cerebrovascular hemodynamics
1150208|NCT01365078|n-3 polyunsaturated fatty acids
1150209|NCT01365078|Stearidonic acid
1150210|NCT01365078|Lipid metabolism
1150211|NCT01365078|Serum triacylglycerol
1150212|NCT01365052|Maximum Use Safety Trial
1150213|NCT01365039|contact lens
1150214|NCT01365026|Healthy Lifestyle
1150215|NCT01365026|Health promotion
1150216|NCT01365026|Counselling
1150217|NCT01365026|Action Plan
1150218|NCT01365026|Primary Health Care
1150219|NCT01365013|Lifestyle
1150220|NCT01365013|Prediabetic State
1150221|NCT01365013|Patient Education
1150222|NCT01365013|Primary Health Care
1150223|NCT01365000|Phase 1
1150224|NCT01365000|Pharmacokinetics
1150225|NCT01365000|NKTR-118
1150226|NCT01365000|fasting or fed state
1150227|NCT01365000|cross-over study
1150228|NCT01365000|AUC(0-t)
1150229|NCT01365000|Cmax
1150230|NCT01365000|tmax
1150231|NCT01365000|QTcF Interval
1150232|NCT01364987|transplant
1150233|NCT01364987|ASP015K
1150234|NCT01364987|healthy subjects
1150235|NCT01364974|ASP015K
1150236|NCT01364974|Healthy subjects
1150237|NCT01364961|Resveratrol
1150238|NCT01364961|FMD
1150239|NCT01364961|PWV
1150240|NCT01364961|HDL-cholesterol
1150241|NCT01364961|Macrovasculature
1150242|NCT01364961|Microvasculature
1150243|NCT01364948|Preterm
1150244|NCT01364948|VLBW
1150245|NCT01364948|Coconut Oil application
1150246|NCT01364948|Trans epidermal water loss
1150247|NCT01364948|Weight gain
1150248|NCT01364909|Sepsis
1150249|NCT01364909|Severe sepsis
1150250|NCT01364909|Septic shock
1150251|NCT01364909|Septicaemia
1150252|NCT01364909|Bacteremia
1150253|NCT01364896|Non-corticosteroid immunosuppressive agent
1150254|NCT01364883|Vaccine
1150255|NCT01364883|Immune response
1150256|NCT01364870|Knee OA
1150257|NCT01364870|TENS
1150258|NCT01364870|Total knee replacement
1150259|NCT01364870|Knee arthroplasty
1150260|NCT01364870|total unilateral knee replacement
1150261|NCT01364857|port wine stain of a limb
1150262|NCT01364831|sleep time
1150263|NCT01364831|athletic performance
1150264|NCT01364792|schizophrenia
1150265|NCT01364792|treatment
1150266|NCT01364792|inflammation
1150267|NCT01364792|neuroinflammation
1150268|NCT01364792|hippocampal
1150269|NCT01364779|aspirin
1150270|NCT01364779|Chronic kidney disease
1150271|NCT01364753|Memory
1150272|NCT01364753|Aviation
1150273|NCT01364714|ICU acquired weakness
1150274|NCT01364701|Erectile dysfunction
1150275|NCT01364701|combination therapy
1150276|NCT01364701|Sildenafil
1150277|NCT01364701|tadalafil
1150278|NCT01364701|PDE5i
1150279|NCT01364701|No Conditions
1150280|NCT01364688|coronary calcification
1150281|NCT01364688|vascular calcification
1150282|NCT01364688|active vitamin D
1150283|NCT01364688|alfacalcidol
1150284|NCT01364675|Impaired fasting glucose
1150285|NCT01364675|Impaired glucose tolerance
1150286|NCT01364675|Pre-diabetes
1150287|NCT01364675|Pre-hypertensives
1150288|NCT01364675|Cardiovascular events
1150289|NCT01364662|Impulsive Aggression
1150290|NCT01364662|Attention Deficit Hyperactivity Disorder
1150291|NCT01364662|ADHD
1150292|NCT01364649|Sexual Dysfunction, Physiological
1150293|NCT01364649|Depressive Disorder, Major
1150294|NCT01364649|Depression
1150295|NCT01364649|Antidepressive Agents
1150296|NCT01364649|Drug Therapy
1150297|NCT01364636|1-Heart Failure
1150298|NCT01364636|2-Acute Heart Failure
1150299|NCT01364636|3-Acute Decompensated Heart Failure
1150300|NCT01364636|4-Worsening Renal Function
1150301|NCT01364636|5-Acute Kidney Injury
1150302|NCT01364636|6-Cardiorenal Syndrome
1150303|NCT01364623|testosterone
1150304|NCT01364623|pharmacokinetics
1150305|NCT01364610|diagnosis
1150306|NCT01364610|pH measurement
1150307|NCT01364610|catheter
1150308|NCT01364610|wireless
1150309|NCT01364597|Brivaracetam
1150310|NCT01364597|Epilepsy
1150311|NCT01364597|Child
1150312|NCT01364597|Infant
1150313|NCT01364597|Adolescents
1150314|NCT01364571|Staphylococcus aureus
1150315|NCT01364571|vaccine
1150316|NCT01364571|staphylococcal infection
1150317|NCT01364532|transulnar arterial access
1150318|NCT01364532|transradial arterial access
1150319|NCT01364532|percutaneous coronary intervention
1150320|NCT01364519|COPD
1150321|NCT01364506|Cardiovascular capacity
1150322|NCT01364506|Water exercise
1150323|NCT01364506|Hydrokinetic Therapy
1150324|NCT01364506|Pregnancy
1150325|NCT01364506|Perinatal outcomes
1150326|NCT01364493|HER2-positive
1150327|NCT01364493|adenocarcinoma of the stomach or gastro-esophageal junction
1150328|NCT01364493|Inoperable
1150329|NCT01364493|locally advanced
1150330|NCT01364493|recurrent
1150331|NCT01364493|metastatic
1150332|NCT01364480|Tetraplegia
1150333|NCT01364480|Spinal cord injury
1150334|NCT01364480|Brainstem or spinal stroke
1150335|NCT01364480|Neuroprosthetic
1150336|NCT01364480|Brain-machine interface
1150337|NCT01364480|Brain-computer interface
1150338|NCT01364480|Neural activity
1150339|NCT01364454|Colorectal Cancer Screening
1150340|NCT01364454|Faecal Occult Blood test
1150341|NCT01364454|General Practitioners Involvement
1150342|NCT01364454|Patient's Participation
1150343|NCT01364454|Reminder
1150344|NCT01364441|ONO-2950
1150345|NCT01364441|healthy adult subjects
1150346|NCT01364441|first in human
1150347|NCT01364441|safety
1150348|NCT01364441|tolerability
1150349|NCT01364441|pharmacokinetics
1150350|NCT01364415|MTD
1150351|NCT01364415|pasireotide
1150352|NCT01364415|LAR
1150353|NCT01364415|NETs
1150354|NCT01364415|advanced neuroendocrine tumors
1150355|NCT01364402|scheduled for PCI
1150356|NCT01364389|Polymyalgia Rheumatica
1150357|NCT01364389|Inflammatory Disease
1150358|NCT01364389|Rheumatic Disease
1150359|NCT01364376|Gastric Cancer
1150360|NCT01364363|Transplant
1150361|NCT01364363|Allogeneic
1150362|NCT01364363|Allogeneic transplant
1150363|NCT01364363|Unrelated donor transplant
1150364|NCT01364363|MUD
1150365|NCT01364363|HSCT
1150366|NCT01364363|Stem cell transplant
1150367|NCT01364350|type 2 diabetes mellitus
1150368|NCT01364350|pediatrics
1150369|NCT01364350|post-intervention study
1150370|NCT01364350|metformin
1150371|NCT01364350|complications
1150372|NCT01364337|Hypertension
1150373|NCT01364324|tuberculosis
1150374|NCT01364324|pharmacokinetics
1150375|NCT01364324|first-line drugs
1150376|NCT01364324|gastrectomy
1150377|NCT01364311|Dry Eye Syndromes
1150378|NCT01364311|Dietary Supplements
1150379|NCT01364311|Vitamac® Tag and Nacht capsules
1150380|NCT01364311|Lutein
1150381|NCT01364311|Vitamin C
1150382|NCT01364311|Zinc
1150383|NCT01364311|ginkgo biloba
1150384|NCT01364311|Flavinoids
1150385|NCT01364311|Fishoil
1150386|NCT01364311|Zeaxanthin
1150387|NCT01364311|Vitamin E
1150388|NCT01364311|Copper
1150389|NCT01364311|Selen
1150390|NCT01364311|Alpha Lipon acid
1150391|NCT01364311|Break up time (BUT)
1150392|NCT01364311|Improvement of subjective symptoms of dry eye syndrome
1150393|NCT01364311|Visual Acuity
1150394|NCT01364311|Tear film osmolarity
1150395|NCT01364311|OSI (Objective Scattering Index)
1150396|NCT01364311|Schirmer I test
1150397|NCT01364311|Staining of the cornea with fluorescein
1150398|NCT01364311|Impression cytology
1150399|NCT01364311|Tear cytokines/chemokines
1150400|NCT01364311|Data from patient diary how often Hylo-Comod® eye drops were used
1150401|NCT01364298|Gabapentin/B complex
1150402|NCT01364298|Pregabalin
1150403|NCT01364298|Pain
1150404|NCT01364298|Neuropathic
1150405|NCT01364298|Gavindo
1150406|NCT01364298|Lyrica
1150407|NCT01364259|tic douloureux
1150408|NCT01364246|Progressive Multiple Sclerosis
1150409|NCT01364246|neuromyelitis optica
1150410|NCT01364246|Umbilical Cord Mesenchymal Stem Cell
1150411|NCT01364220|Additional relevant MeSH terms
1150412|NCT01364220|Stroke
1150413|NCT01364220|Cerebral Infarction
1150414|NCT01364220|Cerebrovascular Disorders
1150415|NCT01364220|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1150416|NCT01364220|Magnetic Resonance Imaging
1150417|NCT01364220|Recurrence
1150418|NCT01364194|Post operative pain
1150419|NCT01364194|Total knee replacement
1150420|NCT01364194|Total knee arthroplasty
1150421|NCT01364194|Bupivacaine
1150422|NCT01364194|Periarticular injection
1150423|NCT01364194|Placebo
1150424|NCT01364194|Morphine consumption
1150425|NCT01364181|Udenafil
1150426|NCT01364181|Chronic obstructive pulmonary disease
1150427|NCT01364181|pulmonary hypertension
1150428|NCT01364181|Phosphodiesterase 5 inhibitors
1150429|NCT01364181|Exercise
1150430|NCT01364181|Dyspnea
1150431|NCT01364129|Diabetes
1150432|NCT01364129|Diabetic Retinopathy Screening
1150433|NCT01364129|Ophthalmic Telemedicine
1150434|NCT01364129|Comparative Effectiveness Research
1150435|NCT01364116|Pulse CO-Oximetry™
1150436|NCT01364116|children
1150437|NCT01364116|noninvasive
1150438|NCT01364103|pulse pressure variation
1150439|NCT01364103|systolic pressure variation
1150440|NCT01364103|central venous pressure
1150441|NCT01364103|aortic blood flow velocity variation
1150442|NCT01364103|pleth variability index
1150443|NCT01364090|hepatitis C
1150444|NCT01364090|treatment
1150445|NCT01364090|injection drug users or receiving opiate substitution therapy
1150446|NCT01364077|Heart rate
1150447|NCT01364077|Dialysis
1150448|NCT01364077|ESRD
1150449|NCT01364077|ivabradine
1150450|NCT01363973|oropharyngeal dysphagia
1150451|NCT01363973|post-stroke
1150452|NCT01363960|Incidence
1150453|NCT01363960|neonatal care
1150454|NCT01363960|retinopathy of prematurity
1150455|NCT01363960|risk factors
1150456|NCT01363934|Erythropoietin
1150457|NCT01363934|EPO-hFC
1150458|NCT01363921|CKD5
1150459|NCT01363921|dialysis
1150460|NCT01363921|high porous membranes
1150461|NCT01363921|micro-inflammation
1150462|NCT01363908|Beta-Thalassemia
1150463|NCT01363908|Sickle Cell Anemia
1150464|NCT01363908|Transfusional iron overload
1150465|NCT01363908|Iron Overload
1150466|NCT01363908|Iron Chelation
1150467|NCT01363895|atrial fibrillation
1150468|NCT01363895|catheter ablation
1150469|NCT01363895|percutaneous closure of LAA
1150470|NCT01363895|intervention
1150471|NCT01363882|Amyotrophic Lateral Sclerosis
1150472|NCT01363882|Noninvasive Ventilation
1150473|NCT01363882|Respiratory Dysfunction
1150474|NCT01363882|Positive Pressure Ventilation
1150475|NCT01363869|hyperuricemia
1150476|NCT01363869|gout
1150477|NCT01363869|uric acid
1150478|NCT01363869|xanthine oxidase inhibitor
1150479|NCT01363869|green tea
1150480|NCT01363869|catechins
1150481|NCT01363869|antioxidant
1150482|NCT01363856|first ever stroke
1150483|NCT01363843|neoadjuvant
1150484|NCT01363843|chemo/radiation
1150485|NCT01363843|rectal cancer
1150486|NCT01363843|rectum cancer
1150487|NCT01363843|colon cancer
1150488|NCT01363843|colorectal cancer
1150489|NCT01363830|Disc
1150490|NCT01363830|lumbar
1150491|NCT01363830|herniation
1150492|NCT01363804|AV-951
1150493|NCT01363804|Tivozanib
1150494|NCT01363804|Healthy Subjects
1150495|NCT01363804|rifampin
1150496|NCT01363804|Pharmacokinetics
1150497|NCT01363791|Systematic review and meta-analysis
1150498|NCT01363791|Evidence-based medicine (EBM)
1150499|NCT01363791|Evidence-based nutrition (EBN)
1150500|NCT01363791|Clinical practice guidelines
1150501|NCT01363791|Clinical trials
1150502|NCT01363791|Dietary sugars
1150503|NCT01363791|Fructose
1150504|NCT01363791|High fructose corn syrup
1150505|NCT01363791|Fruit
1150506|NCT01363791|Isocaloric
1150507|NCT01363791|Hypercaloric
1150508|NCT01363791|Cardiometabolic risk factors
1150509|NCT01363791|Triglycerides
1150510|NCT01363791|Cholesterol
1150511|NCT01363791|Glycemic control
1150512|NCT01363791|Insulin resistance
1150513|NCT01363791|Body weight
1150514|NCT01363791|Uric acid
1150515|NCT01363791|Blood pressure
1150516|NCT01363791|Fatty liver
1150517|NCT01363791|Fasting
1150518|NCT01363791|Postprandial
1150519|NCT01363778|AV-951
1150520|NCT01363778|Tivozanib
1150521|NCT01363778|Healthy Subjects
1150522|NCT01363778|ketoconazole
1150523|NCT01363778|Pharmacokinetics
1150524|NCT01363765|diagnosis
1150525|NCT01363765|polymerase chain reaction
1150526|NCT01363765|sputum smear
1150527|NCT01363765|stepped-wedge design
1150528|NCT01363765|cost-effectiveness
1150529|NCT01363765|Xpert MTB/Rif
1150530|NCT01363752|Kidney
1150531|NCT01363752|Transplant
1150532|NCT01363752|Immunosuppression
1150533|NCT01363752|Kidney Failure, Acute
1150534|NCT01363752|Advagraf
1150535|NCT01363752|Tacrolimus
1150536|NCT01363752|Astagraf XL
1150537|NCT01363739|VEGF polymorphism Bevacizumab
1150538|NCT01363726|surveillance Rotavirus Gastroenteritis Children
1150539|NCT01363726|< 5 years of age
1150540|NCT01363726|southern Israel
1150541|NCT01363726|Signed informed concent
1150542|NCT01363674|Growth disorders
1150543|NCT01363674|Saizen
1150544|NCT01363674|Easypod
1150545|NCT01363674|Growth hormone
1150546|NCT01363674|Pediatric subject
1150547|NCT01363661|angina pectoris
1150548|NCT01363661|atherosclerosis
1150549|NCT01363661|endothelial dysfunction
1150550|NCT01363648|VCI-HS
1150551|NCT01363648|stroke
1150552|NCT01363648|choline alphoscerate
1150553|NCT01363635|severe sepsis/septic shock
1150554|NCT01363635|organ failure
1150555|NCT01363635|AKI
1150556|NCT01363635|PMI
1150557|NCT01363635|ALI
1150558|NCT01363635|Stroke
1150559|NCT01363635|ICU death
1150560|NCT01363622|Vaspin
1150561|NCT01363622|LGA
1150562|NCT01363622|SGA
1150563|NCT01363622|Insulin
1150564|NCT01363622|Blood glucose
1150565|NCT01363596|Infertility
1150566|NCT01363596|Fertility
1150567|NCT01363596|Reproductive Medicine
1150568|NCT01363596|Pregnancy
1150569|NCT01363596|Conception
1150570|NCT01363596|Miscarriage
1150571|NCT01363596|Ovulation Detection
1150572|NCT01363596|Cervical Mucus
1150573|NCT01363596|IVF Alternative
1150574|NCT01363583|traumatic brain injury
1150575|NCT01363570|Macular Degeneration
1150576|NCT01363570|Age related macular degeneration
1150577|NCT01363570|Macula Risk
1150578|NCT01363570|Genetic test
1150579|NCT01363570|Anti-inflammatory
1150580|NCT01363570|Anti-vascular endothelial growth factor (Anti-VEGF)
1150581|NCT01363570|Lucentis
1150582|NCT01363570|Ranibizumab
1150583|NCT01363570|Vision loss
1150584|NCT01363557|Randomized
1150585|NCT01363557|Brain Radiation Therapy
1150586|NCT01363557|Lung Cancer
1150587|NCT01363557|Brain Metastasis
1150588|NCT01363557|Gefitinib
1150589|NCT01363544|ADHD
1150590|NCT01363544|neurofeedback
1150591|NCT01363544|exercise
1150592|NCT01363544|neurophysiology
1150593|NCT01363531|Prescription
1150594|NCT01363531|Antibiotic
1150595|NCT01363531|Acute respiratory infections
1150596|NCT01363531|Satisfaction
1150597|NCT01363531|Perception
1150598|NCT01363531|Pharyngitis and/or acute tonsillitis
1150599|NCT01363531|Rhinosinusitis
1150600|NCT01363531|Acute bronchitis
1150601|NCT01363531|Acute exacerbation of chronic obstructive pulmonary disease (mild to moderate)
1150602|NCT01363518|humerus
1150603|NCT01363518|fracture
1150604|NCT01363518|operative treatment
1150605|NCT01363518|non-operative treatment
1150606|NCT01363492|agalsidase alfa
1150607|NCT01363492|Replagal
1150608|NCT01363492|Enzyme Replacement Therapy
1150609|NCT01363440|Diabetic Macular Edema
1150610|NCT01363440|Diabetic Retinopathy
1150611|NCT01363414|Dry eye
1150612|NCT01363414|Ocular aberration
1150613|NCT01363401|Amyotrophic lateral sclerosis
1150614|NCT01363401|ALS
1150615|NCT01363401|Motor neuron disease
1150616|NCT01363401|MND
1150617|NCT01363401|HYNR-CS inj
1150618|NCT01363401|Autologous bone marrow derived stem cell
1150619|NCT01363401|Intrathecal injection
1150620|NCT01363375|Plantar fascia
1150621|NCT01363375|Plantar fasciitis
1150622|NCT01363375|Foot orthosis
1150623|NCT01363375|Finite element analysis
1150624|NCT01363375|Gait analysis
1150625|NCT01363375|Plantar pressure measurement
1150626|NCT01363362|Selective Laser Trabeculoplasty
1150627|NCT01363362|pulsatile ocular blood flow
1150628|NCT01363336|Adalat
1150629|NCT01363336|Hypertension
1150630|NCT01363336|Diabetes
1150631|NCT01363336|Chronic kidney disease
1150632|NCT01363297|Relapsed/Refractory Acute Lymphocytic Leukemia (ALL)
1150633|NCT01363258|Elderly
1150634|NCT01363258|Dementia
1150635|NCT01363258|Care-resistant behavior
1150636|NCT01363258|Oral health
1150637|NCT01363258|Long-term care
1150638|NCT01363245|cost effectiveness
1150639|NCT01363245|behavioral health counseling
1150640|NCT01363232|BKM120
1150641|NCT01363232|MEK162
1150642|NCT01363232|RAS RAF mutations
1150643|NCT01363232|triple negative breast cancer
1150644|NCT01363232|pancreatic cancer, ovarian cancer
1150645|NCT01363232|NSCLC progressed on EGFR TKI
1150646|NCT01363232|PI3K inhibitor
1150647|NCT01363232|MEK inhibitor
1150648|NCT01363206|Melanoma
1150649|NCT01363206|GM-CSF
1150650|NCT01363206|Ipilimumab
1150651|NCT01363206|Immunologic Response
1150652|NCT01363193|Weight-based heparin dosing
1150653|NCT01363193|Obesity
1150654|NCT01363193|Body Mass Index
1150655|NCT01363193|Venous thromboembolism
1150656|NCT01363193|Atrial fibrillation
1150657|NCT01363193|Lean body weight
1150658|NCT01363193|Unfractionated heparin
1150659|NCT01363193|heparin
1150660|NCT01363167|vitamin D
1150661|NCT01363167|preterm infants
1150662|NCT01363167|calcium
1150663|NCT01363167|bone
1150664|NCT01363167|parathyroid hormone
1150665|NCT01363154|Children's Health
1150666|NCT01363154|Pediatrics
1150667|NCT01363154|Epilepsy
1150668|NCT01363154|Photoparoxysmal
1150669|NCT01363154|Photosensitive
1150670|NCT01363154|Music
1150671|NCT01363154|Mozart
1150672|NCT01363154|K-448
1150673|NCT01363141|Cardiovascular Diseases
1150674|NCT01363141|Type 2 Diabetes Mellitus
1150675|NCT01363141|Abdominal Fat
1150676|NCT01363141|Atherogenic Dyslipidemia
1150677|NCT01363141|Hypertension
1150678|NCT01363141|Hyperglycemia
1150679|NCT01363141|Insulin Resistance
1150680|NCT01363141|Thrombosis state
1150681|NCT01363128|Leukemia
1150682|NCT01363128|Acute Lymphoblastic Leukemia
1150683|NCT01363128|CD-20 Positive Acute Lymphoblastic Leukemia
1150684|NCT01363128|Any level of CD20 expression
1150685|NCT01363128|Lymphoblastic lymphoma
1150686|NCT01363128|Central Venous Catheter
1150687|NCT01363128|CVC
1150688|NCT01363128|HCVAD
1150689|NCT01363128|Cyclophosphamide
1150690|NCT01363128|Cytoxan
1150691|NCT01363128|Neosar
1150692|NCT01363128|Mesna
1150693|NCT01363128|Mesnex
1150694|NCT01363128|Doxorubicin
1150695|NCT01363128|Adriamycin
1150696|NCT01363128|Rubex
1150697|NCT01363128|Vincristine
1150698|NCT01363128|Dexamethasone
1150699|NCT01363128|Decadron
1150700|NCT01363128|Ofatumumab
1150701|NCT01363128|Arzerra
1150702|NCT01363128|Methotrexate
1150703|NCT01363128|Cytarabine
1150704|NCT01363128|Ara-C
1150705|NCT01363128|Cytosar
1150706|NCT01363128|DepoCyt
1150707|NCT01363128|Cytosine Arabinosine Hydrochloride
1150708|NCT01363115|Body Weight
1150709|NCT01363115|Dietary Supplement
1150710|NCT01363115|Calcium
1150711|NCT01363115|Vitamin D
1150712|NCT01363102|Muscle strength
1150713|NCT01363102|functional mobility
1150714|NCT01363102|outcome
1150715|NCT01363102|intensive care unit
1150716|NCT01363102|quality of life
1150717|NCT01363037|HIV infections
1150718|NCT01363037|Anti-HIV agents
1150719|NCT01363037|HIV-1
1150720|NCT01363024|Solid Cancers
1150721|NCT01363011|HIV-1
1150722|NCT01363011|Treatment Naive
1150723|NCT01363011|Treatment Experienced
1150724|NCT01362998|fentanyl, morphine, duramorph, Cesarean section, epidural
1150725|NCT01362959|Delirium
1150726|NCT01362959|Psychomotor Agitation
1150727|NCT01362959|Substance Withdrawal Syndrome
1150728|NCT01362959|Nicotine replacement therapy
1150729|NCT01362946|Conduct problems
1150730|NCT01362946|callous-unemotional traits
1150731|NCT01362946|disruptive behavior disorders
1150732|NCT01362933|PE
1150733|NCT01362933|DVT
1150734|NCT01362933|SVT
1150735|NCT01362933|LMWH
1150736|NCT01362933|VKA
1150737|NCT01362933|international Venous Thromboembolism Recommendations
1150738|NCT01362920|Sepsis
1150739|NCT01362920|Septic shock
1150740|NCT01362920|Procalcitonin
1150741|NCT01362920|PCT
1150742|NCT01362881|Early
1150743|NCT01362881|Onset
1150744|NCT01362881|Scoliosis
1150745|NCT01362868|Glaucoma
1150746|NCT01362868|Triggerfish
1150747|NCT01362868|Water drinking test
1150748|NCT01362855|Advance Care Planning
1150749|NCT01362855|End of life
1150750|NCT01362855|Knowledge translation
1150751|NCT01362855|Goals of care
1150752|NCT01362855|Advance directive
1150753|NCT01362855|Lining will
1150754|NCT01362842|Lung Cancer
1150755|NCT01362842|Symptom distress
1150756|NCT01362842|Post-operation
1150757|NCT01362842|Anxiety
1150758|NCT01362842|Depression
1150759|NCT01362842|Uncertainty
1150760|NCT01362842|Fear of recurrence
1150761|NCT01362842|Self-efficacy
1150762|NCT01362842|Needs
1150763|NCT01362803|Maximum Tolerated Dose
1150764|NCT01362803|Pharmacokinetics
1150765|NCT01362803|Pharmacodynamics
1150766|NCT01362803|Response Rate
1150767|NCT01362803|pain, quality of life and physical functioning
1150768|NCT01362803|Neurofibromatosis Type 1
1150769|NCT01362803|NF1
1150770|NCT01362803|Plexiform Neurofibroma
1150771|NCT01362790|Immune Therapy
1150772|NCT01362790|Immunotoxin
1150773|NCT01362790|T-Cell Depletion
1150774|NCT01362790|Mesothelioma
1150775|NCT01362777|Obstructive Sleep Apnea/Hypopnea Syndrome
1150776|NCT01362777|Exercise training program
1150777|NCT01362777|Inflammation
1150778|NCT01362777|Oxidative Stress
1150779|NCT01362777|Resistance to insulin
1150780|NCT01362764|Abiraterone Acetate
1150781|NCT01362764|ZYTIGA
1150782|NCT01362738|Long-standing persistent atrial fibrillation
1150783|NCT01362725|spinal cord stimulation
1150784|NCT01362725|systolic heart failure
1150785|NCT01362712|breast cancer
1150786|NCT01362712|radiotherapy
1150787|NCT01362712|chemoradiotherapy
1150788|NCT01362712|radiation
1150789|NCT01362712|chemoradiation
1150790|NCT01362712|[F-18]
1150791|NCT01362699|Alcoholism
1150792|NCT01362699|Alcohol-Related Disorders
1150793|NCT01362699|Substance-Related Disorders
1150794|NCT01362699|Mental Disorders
1150795|NCT01362699|Alcohol Dependence
1150796|NCT01362699|JNJ-31001074
1150797|NCT01362699|Bavisant
1150798|NCT01362686|diagnosis of Alzheimer's disease
1150799|NCT01362686|medication adherence
1150800|NCT01362673|Phase 1
1150801|NCT01362673|Pharmacokinetics
1150802|NCT01362673|food effect
1150803|NCT01362673|Healthy Japanese
1150804|NCT01362673|rheumatoid arthritis
1150805|NCT01362660|post-natal monitoring
1150806|NCT01362660|exposure in utero
1150807|NCT01362647|Muscle Relaxation
1150808|NCT01362634|HIV/AIDS
1150809|NCT01362634|substance use
1150810|NCT01362634|club drugs
1150811|NCT01362634|sexual risk
1150812|NCT01362621|Allergic asthma
1150813|NCT01362621|Pediatrics
1150814|NCT01362621|Exacerbations
1150815|NCT01362621|Perennial aeroallergens
1150816|NCT01362621|Inhaled corticosteroids
1150817|NCT01362608|Gout
1150818|NCT01362608|Inflammatory gout
1150819|NCT01362608|acute gout
1150820|NCT01362595|leucine administration
1150821|NCT01362595|red blood cell transfusion
1150822|NCT01362595|Diamond Blackfan anemia
1150823|NCT01362582|Pancreatic cancer
1150824|NCT01362582|progression under chemotherapy
1150825|NCT01362582|parenteral nutrition
1150826|NCT01362582|pancreatic adenocarcinoma
1150827|NCT01362582|chemotherapy
1150828|NCT01362569|endotoxin
1150829|NCT01362569|neutrophil function
1150830|NCT01362569|albumin function
1150831|NCT01362543|PTSD
1150832|NCT01362543|Depression
1150833|NCT01362543|Refugees
1150834|NCT01362543|Trauma
1150835|NCT01362517|Vaccination
1150836|NCT01362517|Immunisation
1150837|NCT01362517|Virus
1150838|NCT01362517|Diphtheria
1150839|NCT01362517|Pertussis
1150840|NCT01362517|Tetanus
1150841|NCT01362517|Hepatitis B
1150842|NCT01362517|Haemophilus Influenzae
1150843|NCT01362517|Immunity
1150844|NCT01362504|Pro-adrenomedullin
1150845|NCT01362504|Neonatal sepsis
1150846|NCT01362504|Prognosis
1150847|NCT01362504|Sepsis marker
1150848|NCT01362504|Clinical sepsis
1150849|NCT01362504|Proven sepsis
1150850|NCT01362491|Headache
1150851|NCT01362478|schizophrenia
1150852|NCT01362478|gene promoter
1150853|NCT01362478|methylation
1150854|NCT01362478|endophenotype
1150855|NCT01362478|epigenetic
1150856|NCT01362452|Leukemia
1150857|NCT01362452|Lymphoma
1150858|NCT01362452|CD19-specific T cells
1150859|NCT01362452|Umbilical cord blood transplantation
1150860|NCT01362452|B-Lineage Lymphoid Malignancies
1150861|NCT01362452|B-cell leukemia
1150862|NCT01362452|Acute Lymphoblastic Leukemia
1150863|NCT01362452|ALL
1150864|NCT01362452|Biphenotypic Leukemia
1150865|NCT01362452|Non-Hodgkin's Lymphoma
1150866|NCT01362452|NHL
1150867|NCT01362452|Small Lymphocytic Lymphoma
1150868|NCT01362452|SLL
1150869|NCT01362452|Chronic Lymphocytic Leukemia
1150870|NCT01362452|CLL
1150871|NCT01362452|White blood cells
1150872|NCT01362452|T cells
1150873|NCT01362452|Melphalan
1150874|NCT01362452|Alkeran
1150875|NCT01362452|Thiotepa
1150876|NCT01362452|Fludarabine
1150877|NCT01362452|Fludarabine Phosphate
1150878|NCT01362452|Fludara
1150879|NCT01362452|ATG
1150880|NCT01362452|Antithymocyte Globulin
1150881|NCT01362452|Thymoglobulin
1150882|NCT01362452|Rituxan
1150883|NCT01362452|Rituximab
1150884|NCT01362452|Cyclophosphamide
1150885|NCT01362452|Cytoxan
1150886|NCT01362452|Neosar
1150887|NCT01362439|Schizophrenia
1150888|NCT01362439|Paliperidone
1150889|NCT01362426|schizophrenia
1150890|NCT01362426|paliperidone palmitate
1150891|NCT01362426|INVEGA SUSTENNA
1150892|NCT01362426|registries
1150893|NCT01362426|quality of healthcare
1150894|NCT01362413|pseudarthrosis
1150895|NCT01362413|mineralization
1150896|NCT01362413|platelet-rich-plasma
1150897|NCT01362413|serum
1150898|NCT01362400|LUNG NEOPLASMS
1150899|NCT01362400|LARGE CELL CARCINOMA
1150900|NCT01362400|SQUAMOUS CELL CARCINOMA
1150901|NCT01362387|Medical abortion
1150902|NCT01362387|abortion follow-up
1150903|NCT01362361|Second line colorectal cancer
1150904|NCT01362348|Age-related Macular Degeneration
1150905|NCT01362322|dTpa
1150906|NCT01362322|Boostrix
1150907|NCT01362309|Alcohol
1150908|NCT01362309|Cues
1150909|NCT01362309|Extinction
1150910|NCT01362309|D-Cycloserine
1150911|NCT01362296|NRAS
1150912|NCT01362296|docetaxel
1150913|NCT01362296|NSCLC
1150914|NCT01362296|GSK1120212
1150915|NCT01362296|MEK inhibitor
1150916|NCT01362296|targeted therapy
1150917|NCT01362296|KRAS
1150918|NCT01362296|BRAF
1150919|NCT01362270|Anxiolytics
1150920|NCT01362270|Sedatives
1150921|NCT01362270|Acupuncture Therapy
1150922|NCT01362244|Quality of Life
1150923|NCT01362244|Intranasal Steroids
1150924|NCT01362244|Severe Nasal Polyposis
1150925|NCT01362244|Polyp Relapse
1150926|NCT01362244|Endoscopic Polyp Score
1150927|NCT01362244|Surgery
1150928|NCT01362231|Fibrosis
1150929|NCT01362231|Pulmonary Fibrosis
1150930|NCT01362231|Lung Diseases
1150931|NCT01362231|Interstitial
1150932|NCT01362205|Severe Alcohol Withdrawal Delirium Tremens
1150933|NCT01362192|Telangiectasis
1150934|NCT01362192|Spider Veins
1150935|NCT01362192|Excel V
1150936|NCT01362192|Cutera
1150937|NCT01362192|Laser
1150938|NCT01362192|Leg Veins
1150939|NCT01362192|Venulectasia
1150940|NCT01362192|Lower Extremity veins
1150941|NCT01362192|Laser light
1150942|NCT01362192|KTP
1150943|NCT01362192|532nm
1150944|NCT01362179|malignant myeloid hematologic disorders
1150945|NCT01362179|filgrastim
1150946|NCT01362179|long term incidence
1150947|NCT01362179|donors who received and in those who did not receive filgrastim.
1150948|NCT01362166|Chinese medicine
1150949|NCT01362166|channel
1150950|NCT01362166|acupuncture
1150951|NCT01362166|ZuSanLi
1150952|NCT01362166|XianGu
1150953|NCT01362166|frequency response
1150954|NCT01362166|resonance
1150955|NCT01362166|male volunteer
1150956|NCT01362166|aged within 20-35 years old
1150957|NCT01362153|Golimumab
1150958|NCT01362153|Simponi
1150959|NCT01362153|Rheumatoid Arthritis
1150960|NCT01362153|PK
1150961|NCT01362153|PD
1150962|NCT01362140|Randomized
1150963|NCT01362140|Darbepoetin alfa
1150964|NCT01362140|Myelodysplastic Syndromes
1150965|NCT01362140|Placebo-controlled
1150966|NCT01362140|low risk MDS
1150967|NCT01362140|intermediate-1 risk MDS
1150968|NCT01362140|International Prognostic Scoring System
1150969|NCT01362127|Histologically confirmed squamos cell carcinoma or adenocarcinoma of the esophagus and gastric cardia.Suitable for surgery.
1150970|NCT01362114|Hwa-byung
1150971|NCT01362114|Sihogayonggolmoryeo-tang
1150972|NCT01362114|Anxiety
1150973|NCT01362101|cue reactivity
1150974|NCT01362101|physiologic activation
1150975|NCT01362101|craving
1150976|NCT01362101|smoking cues
1150977|NCT01362101|Behavioral therapy
1150978|NCT01362088|microcirculation
1150979|NCT01362088|intensive care
1150980|NCT01362088|ultrafiltration
1150981|NCT01362088|CVVH
1150982|NCT01362075|Shoulder Arthroplasty
1150983|NCT01362075|Local infiltration analgesia
1150984|NCT01362049|Stabilization exercise
1150985|NCT01362049|Physical therapy
1150986|NCT01362049|Rehabilitation
1150987|NCT01362049|Movement System Impairment exercise
1150988|NCT01362010|Acne
1150989|NCT01362010|Acne Vulgaris
1150990|NCT01362010|Topical
1150991|NCT01362010|Minocycline
1150992|NCT01362010|Foam
1150993|NCT01362010|Phase II
1150994|NCT01361997|Antiseptics
1150995|NCT01361997|Hemoculture contamination
1150996|NCT01361997|Anti-infecting agents, local
1150997|NCT01361984|Chronic Obstructive Pulmonary Disease
1150998|NCT01361984|COPD
1150999|NCT01361984|Emphysema
1151000|NCT01361984|Chronic Bronchitis
1151001|NCT01361984|Brovana
1151002|NCT01361984|Serevent
1151003|NCT01361971|Insulin resistance
1151004|NCT01361971|Inflammation
1151005|NCT01361971|Hypoxia
1151006|NCT01361945|ER+
1151007|NCT01361945|HER2+
1151008|NCT01361945|Breast
1151009|NCT01361919|compressions
1151010|NCT01361919|quality
1151011|NCT01361919|teaching method
1151012|NCT01361919|feedback
1151013|NCT01361919|CPR performance - how well do students perform CPR when taught with feedback?
1151014|NCT01361919|Cardiopulmonary resuscitation (CPR)
1151015|NCT01361906|Musculoskeletal and Neural Physiological Phenomena
1151016|NCT01361906|Postural Balance
1151017|NCT01361906|Eye/hand coordination
1151018|NCT01361893|SIDS
1151019|NCT01361893|African American
1151020|NCT01361893|Infants
1151021|NCT01361893|Disparity
1151022|NCT01361880|African American
1151023|NCT01361880|Anticipatory Guidance
1151024|NCT01361880|Health Promotion
1151025|NCT01361880|Infant Mortality
1151026|NCT01361880|Injury Prevention
1151027|NCT01361880|Nurses
1151028|NCT01361880|Parent Education
1151029|NCT01361880|sudden Infant Death Syndrome
1151030|NCT01361867|motor adaptation
1151031|NCT01361867|lower extremity motor learning
1151032|NCT01361854|polysomnography
1151033|NCT01361854|portable monitoring
1151034|NCT01361854|sleep
1151035|NCT01361854|sleep disordered breathing
1151036|NCT01361854|home based polysomnography
1151037|NCT01361841|Latanoprost
1151038|NCT01361841|bimatoprost
1151039|NCT01361841|travoprost
1151040|NCT01361841|non responders
1151041|NCT01361828|Bevacizumab
1151042|NCT01361828|VEP
1151043|NCT01361828|ERG
1151044|NCT01361828|Optic nerve and retinal functions following intravitreal bevacizumab
1151045|NCT01361815|Depression
1151046|NCT01361815|MDD
1151047|NCT01361815|SSRIs
1151048|NCT01361815|TMS
1151049|NCT01361789|Arthroscopic reconstruction
1151050|NCT01361789|Anterior crucial ligament
1151051|NCT01361789|Coxib
1151052|NCT01361789|Dexamethasone
1151053|NCT01361776|immune response
1151054|NCT01361776|TBE-vaccine
1151055|NCT01361776|elderly
1151056|NCT01361776|additional doses
1151057|NCT01361763|Dabigatran
1151058|NCT01361763|Microbleeds
1151059|NCT01361763|Microthrombi
1151060|NCT01361763|CADASIL
1151061|NCT01361763|Small Vessel Disease
1151062|NCT01360762|Secondary prophylaxis
1151063|NCT01360762|Visceral leishmaniasis
1151064|NCT01360762|Relapses
1151065|NCT01360762|HIV co-infection
1151066|NCT01360762|Pentamidine
1151067|NCT01360762|Ethiopia
1151068|NCT01360749|Pain management
1151069|NCT01360749|Lidocaine
1151070|NCT01360736|Suicide Prevention
1151071|NCT01360736|Suicide Attempt
1151072|NCT01360736|Suicide Ideation
1151073|NCT01360736|Randomized Controlled Trial
1151074|NCT01360736|Safety Planning
1151075|NCT01360710|male age 18-30 years old
1151076|NCT01360710|presence of central obesity
1151077|NCT01360710|no history of cardiovascular disease, depression
1151078|NCT01360710|not on any medication
1151079|NCT01360697|Diabetes
1151080|NCT01360697|Structured care
1151081|NCT01360671|PPHN
1151082|NCT01360671|persistent pulmonary hypertension of the newborn
1151083|NCT01360671|sildenafil
1151084|NCT01360671|iv
1151085|NCT01360658|Intravenous immunoglobulins
1151086|NCT01360658|Solar urticaria
1151087|NCT01360658|Minimal urticaria dose
1151088|NCT01360658|Quality of life
1151089|NCT01360658|Safety
1151090|NCT01360645|OPC-34712
1151091|NCT01360645|brexpiprazole
1151092|NCT01360645|Major Depressive Disorder
1151093|NCT01360645|Adjunctive Treatment
1151094|NCT01360632|OPC-34712
1151095|NCT01360632|brexpiprazole
1151096|NCT01360632|Major Depressive Disorder
1151097|NCT01360632|Adjunctive Treatment
1151098|NCT01361737|Preeclampsia
1151099|NCT01361737|serological bio-bank
1151100|NCT01361737|adiponectin
1151101|NCT01361737|suPAR
1151102|NCT01361724|Parkinson's disease
1151103|NCT01361724|PD
1151104|NCT01361724|Exercise
1151105|NCT01361724|Balance
1151106|NCT01361724|Mobility
1151107|NCT01361698|recovery
1151108|NCT01361698|illness management
1151109|NCT01361698|rehabilitation
1151110|NCT01361698|mental illness
1151111|NCT01361698|psychosocial intervention
1151112|NCT01361698|Clinical recovery (increase in functioning, decrease in symptoms)
1151113|NCT01361698|Personal recovery (Hope, optimism, living a fulfilling life)
1151114|NCT01361659|anginal complaints
1151115|NCT01361659|Lithotripsy
1151116|NCT01361659|no option patients
1151117|NCT01361633|d-cycloserine
1151118|NCT01361633|geriatric
1151119|NCT01361633|neuropsychology
1151120|NCT01361633|cognition
1151121|NCT01361633|cognitive-enhancer
1151122|NCT01361633|aging
1151123|NCT01361633|neuropsychological functioning
1151124|NCT01361620|genomic markers
1151125|NCT01361620|aspirin resistance
1151126|NCT01361607|Cancer pain
1151127|NCT01361607|Opioid therapy
1151128|NCT01361607|Inadequate analgesia
1151129|NCT01361607|Optimized chronic opioid therapy
1151130|NCT01361594|Diabetes
1151131|NCT01361594|Coronary Artery Bypass Surgery
1151132|NCT01361594|Glycemic control
1151133|NCT01361594|Insulin infusion
1151134|NCT01361581|Acute renal failure
1151135|NCT01361581|Anticoagulation
1151136|NCT01361581|Citrate
1151137|NCT01361581|Haemodiafiltration
1151138|NCT01361581|Haemofiltration
1151139|NCT01361581|Renal replacement therapy
1151140|NCT01361568|pain
1151141|NCT01361568|acute pain
1151142|NCT01361568|visceral pain
1151143|NCT01361568|kappa agonist
1151144|NCT01361568|opioid analgesics
1151145|NCT01361568|peripheral nervous system agents
1151146|NCT01361568|physiological effects of drugs
1151147|NCT01361568|surgery
1151148|NCT01361568|hysterectomy
1151149|NCT01361568|post-operative
1151150|NCT01361568|post-operative complications
1151151|NCT01361542|TNF
1151152|NCT01361542|BMD
1151153|NCT01361542|Ankylosing spondylitis
1151154|NCT01361542|bone health
1151155|NCT01361542|Anti TNF therapy
1151156|NCT01361542|Disease activity
1151157|NCT01361529|dose escalation
1151158|NCT01361516|Urolithiasis
1151159|NCT01361516|ESWL
1151160|NCT01361516|Stone Fragmentation efficacy
1151161|NCT01361516|Sedation
1151162|NCT01361516|General Anaesthesia
1151163|NCT01361503|Autism Spectrum Disorders
1151164|NCT01361503|Pervasive Developmental Disorders
1151165|NCT01361503|Asperger's Syndrome
1151166|NCT01361503|Adolescents
1151167|NCT01361503|Magnetic Resonance Spectroscopy
1151168|NCT01361503|Diffusion Tensor Imaging
1151169|NCT01361477|General surgical ICU
1151170|NCT01361477|ICU Siamitra
1151171|NCT01361477|ICU Salad-Samung
1151172|NCT01361477|Data registry
1151173|NCT01361477|ICU refusal
1151174|NCT01361477|ICU complications
1151175|NCT01361477|ICU resource utilization
1151176|NCT01361477|Adverse events
1151177|NCT01361477|ICU readmission
1151178|NCT01361451|parasternal electromyogram
1151179|NCT01361451|neural respiratory drive
1151180|NCT01361451|chronic obstructive pulmonary disease
1151181|NCT01361451|respiratory physiology
1151182|NCT01361451|Acute exacerbation
1151183|NCT01361425|hypertension
1151184|NCT01361425|ultrasonography
1151185|NCT01361425|preeclampsia
1151186|NCT01361425|clinical trials
1151187|NCT01361425|treatment
1151188|NCT01361425|methyldopa
1151189|NCT01361412|ragweed allergy
1151190|NCT01361412|immunotherapy
1151191|NCT01361399|Sore Throat
1151192|NCT01361386|Long-term follow up
1151193|NCT01361386|Antithrombotic management patterns
1151194|NCT01361386|Acute Coronary Syndrome
1151195|NCT01361386|Asia
1151196|NCT01361386|quality of life
1151197|NCT01361347|milk allergy
1151198|NCT01361347|desensitization
1151199|NCT01361347|anaphylaxis
1151200|NCT01361347|school-age
1151201|NCT01361334|(other than AML M3)
1151202|NCT01361321|follow up
1151203|NCT01361321|Guided bone regeneration
1151204|NCT01361321|Micro computerized tomography
1151205|NCT01361321|histological examination
1151206|NCT01361308|Menopause
1151207|NCT01361308|Vasomotor Symptoms
1151208|NCT01361308|Hot Flashes Perimenopause
1151209|NCT01361308|Climacteric Symptoms
1151210|NCT01361308|Mesafem
1151211|NCT01361308|Low-Dose Mesylate salt of Paroxetine (LDMP)
1151212|NCT01361295|Atrial fibrillation
1151213|NCT01361295|cerebral embolism
1151214|NCT01361295|catheter ablation
1151215|NCT01361282|Total Corneal Power
1151216|NCT01361282|Optical Coherence Tomography
1151217|NCT01361282|Descemet Stripping Endothelial Keratoplasty
1151218|NCT01361256|Macular Degeneration
1151219|NCT01361256|Visual Impairment
1151220|NCT01361256|Implantable Telescope
1151221|NCT01361243|Pediatric Overweight
1151222|NCT01361243|Pediatric Obesity
1151223|NCT01361217|Fluoxetine
1151224|NCT01361217|CYP3A4
1151225|NCT01361217|CYP2D6
1151226|NCT01361217|CYP2C19
1151227|NCT01361217|Drug-Drug Interaction
1151228|NCT01361217|Multi-CYP Inhibition
1151229|NCT01361204|stress
1151230|NCT01361204|students
1151231|NCT01361204|pharmacy practice
1151232|NCT01361204|theanine
1151233|NCT01361204|pharmacy training
1151234|NCT01361191|DLBCL
1151235|NCT01361191|PET
1151236|NCT01361191|IPI
1151237|NCT01361191|R-MegaCHOP
1151238|NCT01361191|Autologous stem cell transplantation
1151239|NCT01361165|Pediatric
1151240|NCT01361165|Data Analysis
1151241|NCT01361152|total knee arthroplasty
1151242|NCT01361152|fixed-bearing
1151243|NCT01361152|mobile-bearing
1151244|NCT01361152|long-term
1151245|NCT01361139|Chronic obstructive lung disease
1151246|NCT01361139|Interstitial lung disease
1151247|NCT01361139|Asthma
1151248|NCT01361139|Sarcoidosis
1151249|NCT01361139|Pulmonary hypertension
1151250|NCT01361139|Ultrasound
1151251|NCT01361139|Doppler
1151252|NCT01361139|Lung disease diagnosis
1151253|NCT01361113|Renal Cell Carcinoma
1151254|NCT01361113|RCC
1151255|NCT01361113|Votrient
1151256|NCT01361113|Pazopanib
1151257|NCT01361113|Nephrectomy
1151258|NCT01361113|Neoadjuvant
1151259|NCT01361113|Phase II
1151260|NCT01361113|LCCC 1028
1151261|NCT01361113|Lineberger Comprehensive Cancer Center
1151262|NCT01361100|Otolaryngology
1151263|NCT01361087|TGF-B blood levels Atenolol vs, Losartan Study, NIH, NIHLB and NMF
1151264|NCT01361074|Virtual reality
1151265|NCT01361074|Augmented reality
1151266|NCT01361074|In vivo exposure
1151267|NCT01361074|One session treatment
1151268|NCT01361074|ICT
1151269|NCT01361074|Efficacy
1151270|NCT01361074|Specific phobia
1151271|NCT01361074|Anxiety disorders
1151272|NCT01361061|liver cirrhosis
1151273|NCT01361061|screening
1151274|NCT01361061|hepatocellular carcinoma
1151275|NCT01361061|liver cancer markers: AFP, AFP-L3% and DCP
1151276|NCT01361048|trichomonas
1151277|NCT01361035|health literacy
1151278|NCT01361035|cancer screening
1151279|NCT01361035|doctor-patient communication
1151280|NCT01361035|standardized patient
1151281|NCT01361035|continuing medical education
1151282|NCT01360996|PCOS
1151283|NCT01360970|hepatitis A vaccine
1151284|NCT01360970|TNF-alfa inhibitory drugs
1151285|NCT01360970|Rheumatoid arthritis
1151286|NCT01360970|methotrexate
1151287|NCT01360957|Obesity
1151288|NCT01360944|PPT, topical, psoriasis
1151289|NCT01360931|Lung cancer
1151290|NCT01360931|Chronic obstructive pulmonary disease
1151291|NCT01360905|PTL
1151292|NCT01360905|Multiples
1151293|NCT01360892|Hepatitis B virus
1151294|NCT01360892|Hepatitis C virus
1151295|NCT01360892|Chronic hepatitis
1151296|NCT01360892|Liver chlorosis
1151297|NCT01360892|Liver stiffness
1151298|NCT01360892|Liver fibrosis
1151299|NCT01360879|Hepatitis B virus
1151300|NCT01360879|Hepatitis C virus
1151301|NCT01360879|Chronic hepatitis
1151302|NCT01360879|Liver cirrhosis
1151303|NCT01360879|Liver stiffness
1151304|NCT01360879|Liver fibrosis
1151305|NCT01360866|OPC-34712
1151306|NCT01360866|brexpiprazole
1151307|NCT01360866|Major Depressive Disorder
1151308|NCT01360866|Adjunctive Treatment
1151309|NCT01360853|pancreatic cancer
1151310|NCT01360853|gemcitabine
1151311|NCT01360853|ON 01910.Na
1151312|NCT01360853|rigosertib sodium
1151313|NCT01360840|Asymptomatic
1151314|NCT01360840|mildly symptomatic
1151315|NCT01360840|metastatic castrate-resistant prostate cancer
1151316|NCT01360840|mCRPC
1151317|NCT01360827|Safety
1151318|NCT01360827|tolerability
1151319|NCT01360827|maximum tolerated dose of EMD 1201081
1151320|NCT01360827|TLR9 agonists
1151321|NCT01360827|squamous cell carcinoma of the head and neck
1151322|NCT01360827|First line subjects
1151323|NCT01360827|recurrent/metastatic
1151324|NCT01360788|chronic obstructive pulmonary disease
1151325|NCT01360788|lung function
1151326|NCT01360788|symptoms
1151327|NCT01360788|activity-related dyspnea
1151328|NCT01360788|quadriceps muscle function
1151329|NCT01360788|exercise capacity
1151330|NCT01360788|physical activity in daily life
1151331|NCT01360788|muscle biopsy
1151332|NCT01360788|systemic inflammation
1151333|NCT01360788|GOLD stage I
1151334|NCT01360788|pulmonary function
1151335|NCT01360775|Nutritional status
1151336|NCT01360775|Dependent patients
1151337|NCT01360775|Nutritional educational intervention
1151338|NCT01360775|Caregivers
1151339|NCT01360775|Clinical assay
1151340|NCT01360619|To demonstrate that multifunction Keito is as effective, as safe and accurate as the predicate K014009 on its body fat measurement.
1151341|NCT01360606|Liver
1151342|NCT01360606|Mets
1151343|NCT01360593|Pancreas
1151344|NCT01360567|green tea
1151345|NCT01360567|EGCG
1151346|NCT01360567|type 2 diabetes
1151347|NCT01360567|hyperlipidemia
1151348|NCT01360554|comparative study of PF-00299804 and Erlotinib
1151349|NCT01360554|Double-Blind Phase 3 trial of TKI
1151350|NCT01360541|Barrett oesophagus
1151351|NCT01360541|Low grade dysplasia
1151352|NCT01360541|Radiofrequency ablation
1151353|NCT01360528|Folic acid replacement
1151354|NCT01360528|Folic acid
1151355|NCT01360528|Preterm neonate
1151356|NCT01360515|esophagoscope
1151357|NCT01360515|esophageal disease
1151358|NCT01360515|gastroesophageal reflux
1151359|NCT01360515|esophageal varices
1151360|NCT01360502|capsule endoscopy
1151361|NCT01360502|cardiac pacemaker
1151362|NCT01360502|implantable cardiac defibrillator
1151363|NCT01360476|hypertension
1151364|NCT01360476|left ventricular hypertrophy
1151365|NCT01360476|Vitamin D
1151366|NCT01360476|African-Americans
1151367|NCT01360463|drug abuse counseling
1151368|NCT01360463|HIV risk reduction counseling
1151369|NCT01360463|HIV infection
1151370|NCT01360463|injection drug users
1151371|NCT01360463|AIDS
1151372|NCT01360450|opioid withdrawal
1151373|NCT01360450|NPASS
1151374|NCT01360450|duraclon
1151375|NCT01360437|coronary angioplasty
1151376|NCT01360437|clopidogrel hyporesponsiveness
1151377|NCT01360437|prasugrel
1151378|NCT01360437|ticagrelor
1151379|NCT01360437|CAD
1151380|NCT01360437|ACS
1151381|NCT01360424|osteoporosis
1151382|NCT01360424|teriparatide
1151383|NCT01360424|bone turnover
1151384|NCT01360424|New forms of inherited low-turnover osteoporosis
1151385|NCT01360411|elastography
1151386|NCT01360411|strain ratio
1151387|NCT01360411|pancreas
1151388|NCT01360411|GI wall lesions
1151389|NCT01360411|lymph nodes
1151390|NCT01360398|pathogen
1151391|NCT01360398|Chronic Obstructive Pulmonary Disease
1151392|NCT01360398|Acute Exacerbations of Chronic Obstructive Pulmonary Disease
1151393|NCT01360398|COPD
1151394|NCT01360398|respiratory
1151395|NCT01360398|AECOPD
1151396|NCT01360398|exacerbation
1151397|NCT01360385|Central retinal rein occlusion
1151398|NCT01360385|Retinal oximetry
1151399|NCT01360385|Oxymap Retinal Oximeter
1151400|NCT01360385|Visual acuity
1151401|NCT01360385|Central retinal thickness
1151402|NCT01360372|Hydrogen breath test value and gastric residual volume measurements
1151403|NCT01360372|Tube feeding tolerance while taking a stable dose of opiate
1151404|NCT01360359|low back pain
1151405|NCT01360359|core stabilization
1151406|NCT01360359|trunk muscle exercises
1151407|NCT01360359|physical therapy
1151408|NCT01360359|RCT
1151409|NCT01360346|Enteral Sedation
1151410|NCT01360346|Intravenous Sedation
1151411|NCT01360346|Critically ill ICU patient
1151412|NCT01360346|Conscious Sedation
1151413|NCT01360346|Deep Sedation
1151414|NCT01360346|RASS
1151415|NCT01360346|CAM-ICU
1151416|NCT01360346|VNR
1151417|NCT01360346|BPS
1151418|NCT01360346|Propofol
1151419|NCT01360346|Midazolam
1151420|NCT01360346|Hydroxyzine
1151421|NCT01360346|Lorazepam
1151422|NCT01360346|Melatonin
1151423|NCT01360333|Dehydration
1151424|NCT01360333|Hydration
1151425|NCT01360320|Green tea
1151426|NCT01360320|polyphenol
1151427|NCT01360320|catechin
1151428|NCT01360320|EGCG
1151429|NCT01360320|Epigallocatechin gallate
1151430|NCT01360320|colorectal adenoma
1151431|NCT01360320|adenoma prevention
1151432|NCT01360320|colon cancer prevention
1151433|NCT01360307|psychometric validation
1151434|NCT01360307|major depressive disorder
1151435|NCT01360307|patient-reported outcome
1151436|NCT01360294|Asthma
1151437|NCT01360294|Small airways disease
1151438|NCT01360294|Questionnaire
1151439|NCT01360281|Quadriceps strength
1151440|NCT01360281|osteoarthritis rehabilitation
1151441|NCT01360281|NMES
1151442|NCT01360255|Hepatocellular Carcinoma
1151443|NCT01360255|transarterial chemoembolisation
1151444|NCT01360255|liver cancer markers: AFP, AFP-L3% and DCP
1151445|NCT01360242|Acute STEMI
1151446|NCT01360242|Thrombus aspiration
1151447|NCT01360242|Angioplasty
1151448|NCT01360242|Primary Percutaneous Coronary Intervention
1151449|NCT01360229|Parkinsons Disease
1151450|NCT01360229|Fatigue
1151451|NCT01360216|Long-acting reversible contraception
1151452|NCT01360216|Intrauterine contraception
1151453|NCT01360216|Intrauterine devices
1151454|NCT01360216|Single-rod implant
1151455|NCT01360216|Hormonal contraception
1151456|NCT01360190|MDD
1151457|NCT01360190|major depressive disorder
1151458|NCT01360190|QEEG
1151459|NCT01360190|electroencephalograph
1151460|NCT01360190|fluoxtine
1151461|NCT01360190|placebo
1151462|NCT01360164|Human Umbilical Cord Mesenchymal Stem Cells
1151463|NCT01360151|VEGF (Vascular endothelial growth factor)
1151464|NCT01360125|adult acute basophilic leukemia
1151465|NCT01360125|adult acute eosinophilic leukemia
1151466|NCT01360125|adult acute erythroid leukemia (M6)
1151467|NCT01360125|adult acute megakaryoblastic leukemia (M7)
1151468|NCT01360125|adult acute minimally differentiated myeloid leukemia (M0)
1151469|NCT01360125|adult acute monoblastic leukemia (M5a)
1151470|NCT01360125|adult acute monocytic leukemia (M5b)
1151471|NCT01360125|adult acute myeloblastic leukemia with maturation (M2)
1151593|NCT01358669|Total Hip Arthroplasty
1151472|NCT01360125|adult acute myeloblastic leukemia without maturation (M1)
1151473|NCT01360125|adult acute myeloid leukemia in remission
1151474|NCT01360125|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1151475|NCT01360125|adult acute myeloid leukemia with del(5q)
1151476|NCT01360125|adult acute myeloid leukemia with inv(16)(p13;q22)
1151477|NCT01360125|adult acute myeloid leukemia with t(16;16)(p13;q22)
1151478|NCT01360125|adult acute myeloid leukemia with t(8;21)(q22;q22)
1151479|NCT01360125|adult acute myelomonocytic leukemia (M4)
1151480|NCT01360112|Mosquito
1151481|NCT01360112|Membrane
1151482|NCT01360112|Feeding
1151483|NCT01360112|Parasites
1151484|NCT01360112|Infection
1151485|NCT01360112|Malaria
1151486|NCT01360099|Atypical Hip Fracture
1151487|NCT01360099|Biosphosphonates
1151488|NCT01360099|Subtrochanteric Hip Fracture
1151489|NCT01360099|Osteoporosis
1151490|NCT01360086|adenocarcinoma of the gastroesophageal junction
1151491|NCT01360086|adenocarcinoma of the stomach
1151492|NCT01360086|stage IB gastric cancer
1151493|NCT01360086|stage IIA gastric cancer
1151494|NCT01360086|stage IIB gastric cancer
1151495|NCT01360086|stage IIIA gastric cancer
1151496|NCT01360086|stage IIIB gastric cancer
1151497|NCT01360086|stage IIIC gastric cancer
1151498|NCT01360073|MI
1151499|NCT01360073|low dose aspirin
1151500|NCT01360073|PPI
1151501|NCT01360073|epidemiology
1151502|NCT01360073|Nonfatal MI and coronary death
1151503|NCT01360047|MI
1151504|NCT01360047|low dose aspirin
1151505|NCT01360047|PPI
1151506|NCT01360047|epidemiology
1151507|NCT01360034|Obstetric labor, premature
1151508|NCT01360034|Short cervix
1151509|NCT01360034|Nifedipine
1151510|NCT01360034|Indomethacin
1151511|NCT01360008|Cardiac arrhythmia
1151512|NCT01360008|Catheter ablation
1151513|NCT01360008|Cohort Study
1151514|NCT01360008|cryoballoon
1151515|NCT01360008|radiofrequency
1151516|NCT01359995|cytomegalovirus endotheliitis
1151517|NCT01359982|Advanced Solid Tumors
1151518|NCT01359982|Lymphomas
1151519|NCT01359982|Safety
1151520|NCT01359982|Blood flow
1151521|NCT01359982|Nitric oxide
1151522|NCT01359982|Cancer
1151523|NCT01359982|Dynamic contrast enhanced MRI (DCE-MRI)
1151524|NCT01359982|Contrast Enhanced Ultrasound (CEUS)
1151525|NCT01359969|Hereditary Angioedema
1151526|NCT01359969|HAE
1151527|NCT01359969|Angioedema
1151528|NCT01359969|Recombinant C1 Inhibitor
1151529|NCT01359969|rhC1INH
1151530|NCT01359969|Pediatrics
1151531|NCT01359943|Rheumatoid Arthritis
1151532|NCT01359943|RA
1151533|NCT01359943|secukinumab
1151534|NCT01359943|AIN457
1151535|NCT01359943|inflammatory joints
1151536|NCT01359943|American College of Rheumatology
1151537|NCT01359943|ACR
1151538|NCT01359904|dialysate glucose
1151539|NCT01359904|glycemic control
1151540|NCT01359904|hypoglycemic episodes
1151541|NCT01359878|Postpartum haemorrhage
1151542|NCT01359878|Postpartum bleeding
1151543|NCT01359878|Postnatal bleeding
1151544|NCT01359878|Fibrinogen concentrate
1151545|NCT01359878|Transfusion
1151546|NCT01359878|Haemostatis
1151547|NCT01359878|Thrombelastography
1151548|NCT01359865|Total hip arthroplasty
1151549|NCT01359865|lumbar plexus block
1151550|NCT01359865|spinal anesthesia
1151551|NCT01359865|range of motion
1151552|NCT01359865|Anesthetic Technique
1151553|NCT01359865|Post-operative Pain Scores
1151554|NCT01359852|JNJ-42491293
1151555|NCT01359852|JNJ-40411813
1151556|NCT01359852|Metabotropic glutamate subtype 2 receptor (mGlu2R)
1151557|NCT01359852|Positive allosteric modulator (PAM)
1151558|NCT01359852|positron emission tomography (PET)
1151559|NCT01359826|Systemic Lupus Erythematosus
1151560|NCT01359826|Widespread Pain
1151561|NCT01359826|Fibromyalgia
1151562|NCT01359826|Fatigue
1151563|NCT01359826|Pain
1151564|NCT01359826|Quality of Life
1151565|NCT01359800|HIV
1151566|NCT01359800|HAART
1151567|NCT01359774|Energy
1151568|NCT01359774|Metabolism
1151569|NCT01359774|Spectroscopy
1151570|NCT01359761|Suicide
1151571|NCT01359761|Cognitive Therapy
1151572|NCT01359761|Inpatient
1151573|NCT01359761|Military
1151574|NCT01359748|Non Invasive Blood Pressure measurement study.
1151575|NCT01359735|Wound
1151576|NCT01359735|non-melanoma skin cancer
1151577|NCT01359735|Mohs micrographic surgery
1151578|NCT01359735|Head or neck
1151579|NCT01359722|N-acetylcysteine
1151580|NCT01359722|Myocardial Revascularization
1151581|NCT01359722|Acute Renal Failure
1151582|NCT01359722|Oxidative Stress
1151583|NCT01359696|solid cancers
1151584|NCT01359670|Duchenne
1151585|NCT01359670|muscular dystrophy
1151586|NCT01359670|tadalafil
1151587|NCT01359670|sildenafil
1151588|NCT01359670|muscle ischemia
1151589|NCT01359670|exercise
1151590|NCT01359657|Relapsed
1151591|NCT01359657|Refractory
1151592|NCT01358669|Denosumab
1151594|NCT01358643|OEF/OIF
1151595|NCT01358643|Physical Activity
1151596|NCT01358643|Preferences
1151597|NCT01358630|Periodontitis
1151598|NCT01358630|Vascular disease
1151599|NCT01358630|Proinflammatory cytokines
1151600|NCT01359631|Chronic Cluster Headache
1151601|NCT01359618|Phase I
1151602|NCT01359618|Safety
1151603|NCT01359618|tolerability
1151604|NCT01359618|healthy
1151605|NCT01359618|major depressive disorder
1151606|NCT01359618|thorough QT
1151607|NCT01359618|maximum tolerated dose
1151608|NCT01359618|elimination
1151609|NCT01359618|heart electrical signal
1151610|NCT01359605|ADME
1151611|NCT01359605|Healthy volunteers
1151612|NCT01359592|stage I adult diffuse large cell lymphoma
1151613|NCT01359592|contiguous stage II adult diffuse large cell lymphoma
1151614|NCT01359592|noncontiguous stage II adult diffuse large cell lymphoma
1151615|NCT01359592|stage III adult diffuse large cell lymphoma
1151616|NCT01359592|stage IV adult diffuse large cell lymphoma
1151617|NCT01359579|renal impairment
1151618|NCT01359579|phase 1
1151619|NCT01359579|healthy volunteers
1151620|NCT01359540|Total Hip Arthroplasty
1151621|NCT01359540|Bone Loss
1151622|NCT01359540|Femoral Remodeling
1151623|NCT01359527|Total Hip Replacement
1151624|NCT01359527|Hip Resurfacing
1151625|NCT01359527|Femoral Remodeling
1151626|NCT01359527|Bone Loss
1151627|NCT01359501|patients receiving chemotherapy
1151628|NCT01359488|Growth Hormone Deficiency
1151629|NCT01359488|rhGH
1151630|NCT01359488|hGH
1151631|NCT01359488|Versartis
1151632|NCT01359488|AGHD
1151633|NCT01359488|Hormones
1151634|NCT01359488|Hormone substitute
1151635|NCT01359488|Endocrin System disease
1151636|NCT01359488|Bone disease
1151637|NCT01359488|Bone disease, developmental
1151638|NCT01359488|Bone diseases
1151639|NCT01359488|Musculoskeletal diseases
1151640|NCT01359488|Bone diseases, endocrine
1151641|NCT01359488|Metabolism diseases
1151642|NCT01359488|Hypopituitarism
1151643|NCT01359488|Pituitary disease
1151644|NCT01359488|Hypothalmic disease
1151645|NCT01359488|Brain disease
1151646|NCT01359488|Growth Hormone Releasing Hormone
1151647|NCT01359488|Hormone replacement therapy
1151648|NCT01359488|IGF-I
1151649|NCT01359488|IGFBP-3
1151650|NCT01359475|Acetal crowns
1151651|NCT01359475|Primary molars
1151652|NCT01359475|The retention of acetal crowns in primary dentition
1151653|NCT01359475|Color changes of acetal crowns
1151654|NCT01359462|hepatic cirrhosis patients with ascites
1151655|NCT01359449|Meningitis
1151656|NCT01359449|Meningococcal Infection
1151657|NCT01359449|Menactra®
1151658|NCT01359449|MenC
1151659|NCT01359410|Pancreas adenocarcinoma
1151660|NCT01359410|Precancerous lesions of the pancreas (mucinous cystic neoplasms, IPMN)
1151661|NCT01359410|Pancreas neuroendocrine cancer
1151662|NCT01359397|Adenoca. stomach/gastr. Junct.
1151663|NCT01359384|severe primary immune deficieny
1151664|NCT01359371|Smoking Cessation
1151665|NCT01359371|Telephone
1151666|NCT01359371|Hospital Volunteers
1151667|NCT01359358|MRSA
1151668|NCT01359358|MLST
1151669|NCT01359358|PFGE
1151670|NCT01359358|Resistance
1151671|NCT01359358|isolated from colonization
1151672|NCT01359345|NSF
1151673|NCT01359345|ESRD
1151674|NCT01359345|MRA
1151675|NCT01359345|MRI
1151676|NCT01359345|occurrence of NSF
1151677|NCT01359345|Use of Gadollinum
1151678|NCT01359332|Convulsive status EPILEPTICUS
1151679|NCT01359332|hypothermia therapy
1151680|NCT01359332|(defined as continuous SEIZURING for longer than 5 min or three seizures
1151681|NCT01359332|not separated by recovery of normal consciousness
1151682|NCT01359332|or of the level of consciousness present before the
1151683|NCT01359332|seizures)
1151684|NCT01359319|Phase 1 Safety and Pharmacokinetic Study
1151685|NCT01359306|Acute myocardial infarction
1151686|NCT01359306|Right ventricular infarction
1151687|NCT01359306|Cardiovascular Magnetic Resonance
1151688|NCT01359306|Prognosis
1151689|NCT01359280|HIV
1151690|NCT01359280|AIDS
1151691|NCT01359280|Medication
1151692|NCT01359280|Adherence
1151693|NCT01359241|dysglycemia
1151694|NCT01359241|diabetes
1151695|NCT01359241|closed loop insulin delivery
1151696|NCT01359228|Rosacea
1151697|NCT01359202|Stroke
1151698|NCT01359202|ICH
1151699|NCT01359202|Intracerebral hemorrhage
1151700|NCT01359202|acute stroke
1151701|NCT01359202|rfVIIa
1151702|NCT01359202|Niastase
1151703|NCT01359189|Suspected Primary Prostate Cancer
1151704|NCT01359163|bioequivalence study
1151705|NCT01359163|marketed vs reformulation tablets
1151706|NCT01359163|Femulen
1151707|NCT01359137|Behavior
1151708|NCT01359137|Drug users
1151709|NCT01359137|Criminal Justice
1151710|NCT01359137|Probation
1151711|NCT01359124|Osteoarthritis, Knee
1151712|NCT01359124|Exercise Therapies
1151713|NCT01359111|Intradermal injections
1151714|NCT01359111|Vaccination
1151715|NCT01359098|swimmer's ear
1151716|NCT01359098|ear drops
1151717|NCT01359098|ear foam
1151718|NCT01359098|otic foam
1151719|NCT01359098|ear infection
1151720|NCT01359098|ear pain
1151721|NCT01359098|ear inflammation
1151722|NCT01359085|To compare postoperative pain relief by pregabalin versus ISBPB following arthroscopic rotator cuff repair
1151723|NCT01359085|To compare postoperative opioid consumption and opioid related AEs
1151724|NCT01359085|To compare patients recovery profile and patients satisfaction
1151725|NCT01359072|coping
1151726|NCT01359072|psychological distress
1151727|NCT01359072|self-administered intervention
1151728|NCT01359059|assess the beneficial effects of PGL administered either pre or post surgery
1151729|NCT01359059|assess the satisfaction rate in the orthopedic oncologic patients
1151730|NCT01359046|CAUTI
1151731|NCT01359046|UTI
1151732|NCT01359033|Myocardial Infarction
1151733|NCT01359033|UK
1151734|NCT01359033|Sweden
1151735|NCT01359033|National audit registry
1151736|NCT01359033|MINAP
1151737|NCT01359033|RIKS-HIA
1151738|NCT01359020|Fever
1151739|NCT01359020|Ibuprofen
1151740|NCT01359020|Acetaminophen
1151741|NCT01359020|Dipyrone
1151742|NCT01359007|Locally advanced unresectable adenocarcinoma of pancreas
1151743|NCT01359007|Borderline resectable adenocarcinoma of pancreas
1151744|NCT01358994|metformin
1151745|NCT01358994|type 2 diabetes
1151746|NCT01358994|e-GFR
1151747|NCT01358994|creatinine
1151748|NCT01358994|lactic acidosis
1151749|NCT01358955|mild cognitive impairment
1151750|NCT01358955|cognitive therapy
1151751|NCT01358955|prevention
1151752|NCT01358916|antimicrobial resistance
1151753|NCT01358916|antibiotic prescription
1151754|NCT01358916|primary health care
1151755|NCT01358916|cluster-randomized trial
1151756|NCT01358890|over weight
1151757|NCT01358890|obesity
1151758|NCT01358838|Patients with either hypertrophic or atrophic scars
1151759|NCT01358838|Efficacy of ablative 10600nm fractional laser therapy
1151760|NCT01358838|Laser therapy compared to no treatment of (part of) the scar
1151761|NCT01358825|Infanrix-IPV/Hib
1151762|NCT01358825|Long-term follow up
1151763|NCT01358825|Persistence
1151764|NCT01358825|Infanrix hexa
1151765|NCT01358812|RAS Wild-Type
1151766|NCT01358812|BRAF Wild-Type
1151767|NCT01358799|Chlamydia trachomatis
1151768|NCT01358799|APTIMA Assay for Chlamydia trachomatis
1151769|NCT01358786|Quilting suture
1151770|NCT01358786|seroma
1151771|NCT01358786|Procedure
1151772|NCT01358786|Surgery
1151773|NCT01358773|Obesity
1151774|NCT01358773|Therapy
1151775|NCT01358773|Interdisciplinary
1151776|NCT01358760|Vulvar/vaginal atrophy
1151777|NCT01358760|Atrophic Vaginitis
1151778|NCT01358760|Dehydroepiandrosterone
1151779|NCT01358760|DHEA
1151780|NCT01358760|Prasterone
1151781|NCT01358760|Vaginorm
1151782|NCT01358760|Menopause
1151783|NCT01358760|Intrarosa
1151784|NCT01358734|AML
1151785|NCT01358734|elderly
1151786|NCT01358734|acute myelogenous leukemia
1151787|NCT01358734|vidaza
1151788|NCT01358734|azacitidine
1151789|NCT01358734|elderly AML
1151790|NCT01358734|revlimid
1151791|NCT01358734|lenalidomide
1151792|NCT01358695|Lateral Canthal Lines
1151793|NCT01358695|Crow's Feet
1151794|NCT01358604|localized resectable neuroblastoma
1151795|NCT01358604|recurrent neuroblastoma
1151796|NCT01358604|regional neuroblastoma
1151797|NCT01358604|stage 4S neuroblastoma
1151798|NCT01358604|localized unresectable neuroblastoma
1151799|NCT01358578|Psoriasis,
1151800|NCT01358578|inflammatory skin disease,
1151801|NCT01358578|scaly patches
1151802|NCT01358578|Psoriasis
1151803|NCT01358578|inflammatory skin disease
1151804|NCT01358552|Neevo
1151805|NCT01358552|Neevo DHA
1151806|NCT01358552|L-methylfolate
1151807|NCT01358552|anemia during pregnancy
1151808|NCT01358552|folic acid
1151809|NCT01358552|vitamin B12
1151810|NCT01358552|prenatal vitamins
1151811|NCT01358552|hemoglobin
1151812|NCT01358552|iron deficiency
1151813|NCT01358552|Pregnancy
1151814|NCT01358539|palliation
1151815|NCT01358539|pain education
1151816|NCT01358526|Low back pain
1151817|NCT01358526|Chronic pain
1151818|NCT01358526|Opioid
1151819|NCT01358526|Moderate to severe chronic low back pain
1151820|NCT01358513|Positron Emission Tomography
1151821|NCT01358513|Inflammation
1151822|NCT01358513|Calcification
1151823|NCT01358500|opioid dependence
1151824|NCT01358500|tolerant
1151825|NCT01358500|dependent
1151826|NCT01358487|Major depression
1151827|NCT01358487|Cognitive Behavioral preventive intervention
1151828|NCT01358487|Mood Management
1151829|NCT01358487|Self-help
1151830|NCT01358487|Internet
1151831|NCT01358474|Parkinson disease
1151832|NCT01358474|idiopathic rapid eye movement sleep disorder
1151833|NCT01358474|Gaucher disease
1151834|NCT01358474|healthy volunteer
1151835|NCT01358448|Treatment of childhood obesity
1151836|NCT01358422|Prospective observational study
1151837|NCT01358422|major adverse cardiac events (MACE)
1151838|NCT01358422|clinically significant bleeding events
1151839|NCT01358422|Dual anti-platelet therapy
1151840|NCT01358422|aspirin alone therapy
1151841|NCT01358422|non-cardiac surgery
1151842|NCT01358422|percutaneous coronary intervention (PCI)
1151843|NCT01358422|placement of a bare metal or drug eluting stent
1151844|NCT01358422|OBTAIN
1151845|NCT01358422|Simon Howell
1151846|NCT01358422|ESA
1151847|NCT01358422|European Society of Anaesthesiology
1151848|NCT01358409|steatosis
1151849|NCT01358409|MR spectroscopy
1151850|NCT01358409|Nebivolol
1151851|NCT01358409|cardiac MRI
1151852|NCT01358396|Diabetic Macular Edema, Glycemic Control
1151853|NCT01358383|Juvenile Idiopathic Arthritis
1151854|NCT01358383|Pharmacokinetics
1151855|NCT01358383|VIMOVO
1151856|NCT01358383|fasting state
1151857|NCT01358383|Amount of VIMOVO in the blood
1151858|NCT01358383|taken on empty stomach
1151859|NCT01358370|LAL Deficiency
1151860|NCT01358370|LIPA
1151861|NCT01358370|Wolman disease
1151862|NCT01358370|Wolman Phenotype
1151863|NCT01358370|Early Onset LAL Deficiency
1151864|NCT01358370|Acid Lipase Deficiency
1151865|NCT01358357|Lurasidone
1151866|NCT01358357|Latuda
1151867|NCT01358357|Bipolar I
1151868|NCT01358318|obesity
1151869|NCT01358318|satiety
1151870|NCT01358318|soy protein
1151871|NCT01358318|soy fiber
1151872|NCT01358318|control appetite
1151873|NCT01358318|reduce food intake
1151874|NCT01358305|muscle
1151875|NCT01358305|synthesis
1151876|NCT01358305|mTOR
1151877|NCT01358305|antioxidant
1151878|NCT01358305|inflammatory markers
1151879|NCT01358305|soy protein
1151880|NCT01358305|whey
1151881|NCT01358305|casein
1151882|NCT01358292|Intramedullary tibia nailing
1151883|NCT01358292|Anterior Knee Pain
1151884|NCT01358292|Nail positioning
1151885|NCT01358253|Rituximab
1151886|NCT01358253|HyperCVAD
1151887|NCT01358240|Econazole Nitrate
1151888|NCT01358240|Foam
1151889|NCT01358240|Quinnova
1151890|NCT01358240|Tinea Pedis
1151891|NCT01358214|Sub-urethral Sling
1151892|NCT01358214|Treatment Outcome
1151893|NCT01358214|Quality of Life
1151894|NCT01358201|Acute Lymphoblastic Leukemia
1151895|NCT01358188|Gaucher disease
1151896|NCT01358188|immunity
1151897|NCT01358188|inflammation
1151898|NCT01358188|macrophage activation
1151899|NCT01358175|Ankylosing spondylitis
1151900|NCT01358175|AS
1151901|NCT01358175|ASAS
1151902|NCT01358175|inflammatory back pain
1151903|NCT01358162|Tuberculosis
1151904|NCT01358136|Thyroidectomy
1151905|NCT01358136|Mitochondria
1151906|NCT01358123|liver cirrhosis
1151907|NCT01358123|portal hypertension
1151908|NCT01358123|survival
1151909|NCT01358123|von willebrand factor
1151910|NCT01358123|hepatic venous pressure gradient
1151911|NCT01358110|palliative care
1151912|NCT01358110|cancer
1151913|NCT01358110|emergency medicine
1151914|NCT01358110|end- of- life care
1151915|NCT01358097|Head and neck cancer
1151916|NCT01358097|Oropharyngeal cancer
1151917|NCT01358097|Human papillomavirus
1151918|NCT01358097|Squamous cell carcinoma
1151919|NCT01358097|Radiation treatment
1151920|NCT01358097|Chemotherapy
1151921|NCT01358097|Induction chemotherapy
1151922|NCT01358097|Immune status
1151923|NCT01358097|Immune monitoring
1151924|NCT01358097|head and neck robotic surgery
1151925|NCT01358084|Malignant Pleural Mesothelioma
1151926|NCT01358084|MPM
1151927|NCT01358084|Maintenance treatment
1151928|NCT01358084|NGR-hTNF
1151929|NCT01358071|NGR-hTNF
1151930|NCT01358071|Pegylated liposomal doxorubicin
1151931|NCT01358071|Doxorubicin
1151932|NCT01358071|Platinum-resistant
1151933|NCT01358071|Progression or recurrence Ovarian Cancer
1151934|NCT01358071|Ovarian Cancer
1151935|NCT01358071|Advanced or metastatic
1151936|NCT01358058|Brain tumors
1151937|NCT01358058|Radiation
1151938|NCT01358058|Proton
1151939|NCT01358058|Gliomas
1151940|NCT01358045|Topical
1151941|NCT01358045|Diclofenac
1151942|NCT01358045|Vitamin D3
1151943|NCT01358032|Fear of falling
1151944|NCT01358032|Cognitive behavioral therapy
1151945|NCT01358032|Randomized controlled trial
1151946|NCT01358032|Frailty
1151947|NCT01358032|Accidental Falls
1151948|NCT01358006|JNJ-40411813
1151949|NCT01358006|Positron Emission Tomography (PET)
1151950|NCT01358006|Serotonin-2A (5-HT2A) receptor antagonist
1151951|NCT01358006|Male Volunteers
1151952|NCT01357993|Methylphenidate hydrochloride
1151953|NCT01357993|Concerta
1151954|NCT01357993|Adults
1151955|NCT01357993|Attention-Deficit / Hyperactivity Disorder
1151956|NCT01357993|ADHD
1151957|NCT01357993|Long term safety
1151958|NCT01357980|Detrusor Muscle Overactivity
1151959|NCT01357954|Postural control
1151960|NCT01357954|Targeted Training
1151961|NCT01357954|Gross motor function
1151962|NCT01357954|Cerebral palsy
1151963|NCT01357941|venous thromboembolism
1151964|NCT01357941|thromboembolism
1151965|NCT01357941|deep vein thrombosis
1151966|NCT01357941|pulmonary embolism
1151967|NCT01357941|thromboprophylaxis
1151968|NCT01357941|thrombosis
1151969|NCT01357941|embolism and thrombosis
1151970|NCT01357941|cardiovascular diseases
1151971|NCT01357941|venous thrombosis
1151972|NCT01357941|vascular diseases
1151973|NCT01357941|anticoagulants
1151974|NCT01357941|hematologic agents
1151975|NCT01357941|cardiovascular agents
1151976|NCT01357941|enoxaparin
1151977|NCT01357941|dalteparin
1151978|NCT01357941|tinzaparin
1151979|NCT01357941|pregnancy complications
1151980|NCT01357928|TEG
1151981|NCT01357928|Thromboelastography
1151982|NCT01357928|Coagulation
1151983|NCT01357915|Cytomegalovirus
1151984|NCT01357915|Vaccine
1151985|NCT01357889|pharmacokinetics
1151986|NCT01357889|pharmacodynamics
1151987|NCT01357889|GSK716155
1151988|NCT01357889|albiglutide
1151989|NCT01357863|Lapatinib
1151990|NCT01357863|Observational Study
1151991|NCT01357863|Trastuzumab
1151992|NCT01357863|Brazil
1151993|NCT01357863|Metastatic Breast Cancer
1151994|NCT01357837|Osteoarthritis, knee
1151995|NCT01357837|Analgesia
1151996|NCT01357837|Pain
1151997|NCT01357837|Painful
1151998|NCT01357824|Intubation
1151999|NCT01357824|Sellick´s maneuver
1152000|NCT01357824|aspiration
1152001|NCT01357824|[E05.497.578]
1152002|NCT01357811|Genz-112638
1152003|NCT01357811|digoxin
1152004|NCT01357798|Headache
1152005|NCT01357798|Allodynia
1152006|NCT01357798|Botulinum Toxin Type A
1152007|NCT01357785|Periodontal ligament stem cells
1152008|NCT01357785|Periodontal regeneration
1152009|NCT01357785|Clinical trial
1152010|NCT01357785|Deep intraosseous defects
1152011|NCT01357746|Pulmonary arterial blood pressure doppler
1152012|NCT01357733|Diffuse, Large B-Cell, Lymphoma
1152013|NCT01357733|18F Fluorodeoxyglucose
1152142|NCT01357018|Disease activity
1152014|NCT01357733|Radionuclide-Emission Computed Tomography
1152015|NCT01357720|Vaccination
1152016|NCT01357720|Immunisation
1152017|NCT01357720|Virus
1152018|NCT01357720|Diphtheria
1152019|NCT01357720|Pertussis
1152020|NCT01357720|Tetanus
1152021|NCT01357720|Hepatitis B
1152022|NCT01357720|Haemophilus Influenzae
1152023|NCT01357720|Immunity
1152024|NCT01357694|psychotherapy
1152025|NCT01357694|depression
1152026|NCT01357694|anxiety
1152027|NCT01357694|surgical patients
1152028|NCT01357681|Huntington Disease
1152029|NCT01357681|Cognition
1152030|NCT01357681|Motor
1152031|NCT01357681|Behaviour
1152032|NCT01357681|Functional Capacity
1152033|NCT01357681|Quality of Life
1152034|NCT01357681|Biomarker
1152035|NCT01357681|MRI
1152036|NCT01357681|Huntingtin
1152037|NCT01357681|EGCG
1152038|NCT01357655|Myelogenous
1152039|NCT01357655|Chronic
1152040|NCT01357655|BCR-ABL Positive
1152041|NCT01357642|asthma
1152042|NCT01357642|bronchial asthma
1152043|NCT01357642|shortness of breath
1152044|NCT01357629|Vaccination follow-up
1152045|NCT01357616|Glaucoma
1152046|NCT01357616|Open-angle glaucoma
1152047|NCT01357616|Ocular hypertension
1152048|NCT01357616|OAG
1152049|NCT01357616|OH
1152050|NCT01357590|aneurysm, penetrating ulcer, descending thoracic aorta
1152051|NCT01357577|PTSD
1152052|NCT01357577|Substance Use Disorders
1152053|NCT01357564|dementia
1152054|NCT01357564|caregivers
1152055|NCT01357564|tailored activity
1152056|NCT01357551|obesity
1152057|NCT01357551|intervention studies
1152058|NCT01357551|patient adherence
1152059|NCT01357538|Bibrocathol
1152060|NCT01357538|eye ointment
1152061|NCT01357538|blepharitis
1152062|NCT01357538|eye lid
1152063|NCT01357525|Pancreas
1152064|NCT01357525|Resected
1152065|NCT01357512|prostate cancer diagnosis
1152066|NCT01357512|magnetic resonance imaging
1152067|NCT01357512|prostate biopsy
1152068|NCT01357486|Hepatocellular Carcinoma
1152069|NCT01357486|CHILD B
1152070|NCT01357486|palliative management
1152071|NCT01357486|Sorafenib
1152072|NCT01357486|Pravastatin
1152073|NCT01357473|hormonal values
1152074|NCT01357473|menstruations
1152075|NCT01357473|pregnancy
1152076|NCT01357473|antagonist
1152077|NCT01357460|Emphysema
1152078|NCT01357460|alpha1 antitrypsin deficiency
1152079|NCT01357460|endoscopic lung volume reduction
1152080|NCT01357447|Sjogren's syndrome
1152081|NCT01357447|Cough
1152082|NCT01357408|without an indication for ICD or CRT
1152083|NCT01357408|left ventricular function greater than or equal to 40%
1152084|NCT01357395|Small Cell Lung Carcinoma
1152085|NCT01357382|low fat diet
1152086|NCT01357382|low carbohydrate diet
1152087|NCT01357369|bacteria infections
1152088|NCT01357343|Low back pain
1152089|NCT01357343|Chiropractic
1152090|NCT01357343|Acupuncture
1152091|NCT01357343|Integrated care
1152092|NCT01357330|locally advanced or metastatic
1152093|NCT01357317|Kidney disease
1152094|NCT01357317|Hyperphosphatemia
1152095|NCT01357317|Parathyroid hormone
1152096|NCT01357304|Group treatment
1152097|NCT01357304|Physical activity referral
1152098|NCT01357304|Type 2 diabetes
1152099|NCT01357304|Hypertension
1152100|NCT01357291|Behavior
1152101|NCT01357291|Drug users
1152102|NCT01357291|Inmates
1152103|NCT01357278|osteoporosis
1152104|NCT01357278|exercise
1152105|NCT01357278|intervention
1152106|NCT01357278|rehabilitation
1152107|NCT01357278|bone mineral density
1152108|NCT01357278|muscle strength
1152109|NCT01357265|Seasonal Influenza
1152110|NCT01357265|vaccine
1152111|NCT01357252|Diabetes mellitus
1152112|NCT01357252|vildagliptin
1152113|NCT01357239|Fragile X Syndrome
1152114|NCT01357239|Martin-Bell Syndrome
1152115|NCT01357239|Genetic Diseases
1152116|NCT01357239|X-Linked
1152117|NCT01357239|Escalante's syndrome
1152118|NCT01357226|measurement in two environments
1152119|NCT01357213|Botulism, Clostridium
1152120|NCT01357187|Lumbar pathology
1152121|NCT01357187|requiring elective lumbar interbody fusion
1152122|NCT01357096|intervention
1152123|NCT01357096|CABG or PTCA
1152124|NCT01357083|Melatonin
1152125|NCT01357083|Periodicity
1152126|NCT01357083|Depressive disorder, major
1152127|NCT01357083|Serum
1152128|NCT01357083|Depression
1152129|NCT01357057|Medical records
1152130|NCT01357057|Outcome scale
1152131|NCT01357057|Biological biomarkers
1152132|NCT01357044|Semen quality
1152133|NCT01357044|Plant extracts
1152134|NCT01357031|Amitriptyline
1152135|NCT01357031|Placebo
1152136|NCT01357031|Melatonin
1152137|NCT01357031|Migraine
1152138|NCT01357031|Headache
1152139|NCT01357031|Drug therapy
1152140|NCT01357031|Preventive treatment of migraine
1152141|NCT01357018|Ankylosing spondylitis
1152143|NCT01357018|EQ-5D
1152144|NCT01357018|Quality of life
1152145|NCT01357018|Rheumatoid arthritis
1152146|NCT01356992|non-inferiority phase III study
1152147|NCT01356992|Low-Molecular Weight Heparin
1152148|NCT01356992|Versa® (enoxaparin - Eurofarma)
1152149|NCT01356992|Clexane® (enoxaparin - Sanofi-Aventis)
1152150|NCT01356992|Acute coronary syndrome without ST-segment elevation
1152151|NCT01356979|Medical thoracoscopy
1152152|NCT01356979|Pleural effusion
1152153|NCT01356979|Malignant pleural diseases
1152154|NCT01356979|Tuberculous pleuritis
1152155|NCT01356979|Fibrinous pleuritis
1152156|NCT01356953|Aerobic Exercise
1152157|NCT01356953|Blood Pressure
1152158|NCT01356940|Ambulation
1152159|NCT01356927|long acting reversible contraception
1152160|NCT01356927|medical abortion
1152161|NCT01356927|DMPA
1152162|NCT01356927|etonogestrel implant
1152163|NCT01356927|Implanon
1152164|NCT01356927|contraceptive continuation
1152165|NCT01356875|myelodysplastic syndrome
1152166|NCT01356875|Transfusion
1152167|NCT01356875|Hydralazine
1152168|NCT01356875|valproic acid
1152169|NCT01356862|mastectomy
1152170|NCT01356862|axillary node dissection
1152171|NCT01356862|adjuvant or neoadjuvant
1152172|NCT01356849|Endothelin Receptor Antagonists
1152173|NCT01356849|Proteinuria
1152174|NCT01356836|Coronary collateral development
1152175|NCT01356836|monocyte subsets
1152176|NCT01356836|collateralization
1152177|NCT01356823|Human Papilloma Virus 16
1152178|NCT01356823|Human Papilloma Virus 18
1152179|NCT01356823|vaccine
1152180|NCT01356823|Cervical Intraepithelial Neoplasia
1152181|NCT01356823|cervical Cancer
1152182|NCT01356810|Delirium
1152183|NCT01356810|Primary Prevention
1152184|NCT01356810|Elderly
1152185|NCT01356797|knee arthroscopy
1152186|NCT01356797|hyperbaric bupivacaine
1152187|NCT01356797|hypobaric levobupivacaine plus fentanyl
1152188|NCT01356784|Sick-listed
1152189|NCT01356784|Tailored physical activity
1152190|NCT01356784|Patient education
1152191|NCT01356784|Returning to work
1152192|NCT01356784|DK-Sønderborg Municipality
1152193|NCT01356784|columna
1152194|NCT01356784|upper body
1152195|NCT01356771|Risk Assessment
1152196|NCT01356771|Intervention
1152197|NCT01356745|premixed nitrous oxide and oxygen
1152198|NCT01356745|acute pain
1152199|NCT01356745|prehospital setting
1152200|NCT01356732|mechanical ventilation
1152201|NCT01356732|Midazolam
1152202|NCT01356732|Ramsay
1152203|NCT01356732|Sufentanil
1152204|NCT01356719|Tracheostomy
1152205|NCT01356719|adverse effects
1152206|NCT01356719|Critical Care
1152207|NCT01356719|standards
1152208|NCT01356719|safety
1152209|NCT01356706|liver metastases
1152210|NCT01356706|colorectal cancer
1152211|NCT01356706|surgery
1152212|NCT01356706|prognosis
1152213|NCT01356693|Cough
1152214|NCT01356693|Common cold
1152215|NCT01356693|Child
1152216|NCT01356693|Adolescent
1152217|NCT01356680|Hodgkin Lymphoma
1152218|NCT01356680|intermediate stage
1152219|NCT01356680|PET
1152220|NCT01356667|American Indians
1152221|NCT01356667|Native Americans
1152222|NCT01356667|substance abuse
1152223|NCT01356667|culture
1152224|NCT01356654|Stroke
1152225|NCT01356654|TDCS
1152226|NCT01356654|Gait
1152227|NCT01356654|Balance
1152228|NCT01356654|loss of postural balance
1152229|NCT01356641|Antibiotic treatment
1152230|NCT01356641|Non perforated appendicitis
1152231|NCT01356641|Children
1152232|NCT01356628|Advanced Hepatocellular Carcinoma
1152233|NCT01356628|HCC
1152234|NCT01356628|Liver Cancer
1152235|NCT01356628|PD-0332991
1152236|NCT01356615|anticoagulation
1152237|NCT01356615|hemodialysis
1152238|NCT01356615|heparin
1152239|NCT01356615|lipids
1152240|NCT01356615|low molecular weight heparins
1152241|NCT01356602|Gout
1152242|NCT01356602|arthritis
1152243|NCT01356602|gout flare
1152244|NCT01356602|acute gout
1152245|NCT01356602|gouty
1152246|NCT01356602|rheumatic disease
1152247|NCT01356602|uric acid
1152248|NCT01356563|hemodialysis
1152249|NCT01356563|pharmacist
1152250|NCT01356563|medication-related problems
1152251|NCT01356563|compliance
1152252|NCT01356511|Purpura, Thrombocytopenic, Idiopathic
1152253|NCT01356498|gout
1152254|NCT01356498|chronic gout
1152255|NCT01356485|Sickle cell anemia
1152256|NCT01356485|Sickle cell disease
1152257|NCT01356485|Sickling crisis
1152258|NCT01356485|Vaso-occlusive crisis
1152259|NCT01356485|Carboxyhemoglobin
1152260|NCT01356485|Oxygen therapeutic
1152261|NCT01356485|Hemoglobin solutions
1152262|NCT01356485|Pegylated hemoglobin
1152263|NCT01356472|Methicillin-resistant Staphylococcus aureus
1152264|NCT01356472|Pneumonia, Ventilator-Associated
1152265|NCT01356472|linezolid
1152266|NCT01356472|imipenem/cilastatin
1152267|NCT01356459|Pressure ulcers
1152268|NCT01356459|ICU
1152269|NCT01356459|Prevention
1152270|NCT01356446|safety
1152271|NCT01356446|team
1152272|NCT01356446|team performance
1152273|NCT01356446|surgery
1152274|NCT01356446|outcome
1152275|NCT01356433|dialysis,inflammation,vitamin C
1152276|NCT01356420|SLOS
1152277|NCT01356394|Obesity
1152278|NCT01356394|Metabolic Syndrome
1152279|NCT01356394|Microalbuminuria
1152280|NCT01356394|Chronic Kidney Disease
1152281|NCT01356381|Diabetes mellitus
1152282|NCT01356381|vildagliptin
1152283|NCT01356368|Lung cancer
1152284|NCT01356355|Stent discomfort
1152285|NCT01356355|Herbmed plus
1152286|NCT01356355|Tolterodine
1152287|NCT01356342|Influenza
1152288|NCT01356342|Vaccine
1152289|NCT01356342|Immunogenicity
1152290|NCT01356329|Gynecologic malignancy ,major surgery
1152291|NCT01356316|Influenza
1152292|NCT01356316|Vaccine
1152293|NCT01356316|Immunogenicity
1152294|NCT01356303|Lung cancer
1152295|NCT01356290|Medulloblastoma
1152296|NCT01356290|Relapse
1152297|NCT01356290|Children
1152298|NCT01356290|antiangiogenic
1152299|NCT01356290|metronomic
1152300|NCT01356290|intrathecal
1152301|NCT01356277|renal
1152302|NCT01356277|allograft
1152303|NCT01356277|immunosuppressive
1152304|NCT01356277|immunosuppression
1152305|NCT01356277|adherence
1152306|NCT01356277|medication
1152307|NCT01356277|compliance
1152308|NCT01356264|colorectal cancer
1152309|NCT01356264|colorectal surgery
1152310|NCT01356264|prehabilitation
1152311|NCT01356264|surgical recovery
1152312|NCT01356264|exercise
1152313|NCT01356264|referred for scheduled resection
1152314|NCT01356251|Quality of life
1152315|NCT01356251|support group
1152316|NCT01356251|questionnaires
1152317|NCT01356251|Internet-based support group
1152318|NCT01356251|11-066
1152319|NCT01356225|pain following dental impaction surgery
1152320|NCT01356199|Gonalgia
1152321|NCT01356199|Quality of Life
1152322|NCT01356199|Dietary supplement
1152323|NCT01356199|Nutrition
1152324|NCT01356186|Suicide
1152325|NCT01356186|Cognitive Therapy
1152326|NCT01356186|Inpatient
1152327|NCT01356186|Military
1152328|NCT01356173|solid cancers
1152329|NCT01356160|Hepatitis C
1152330|NCT01356160|HCV
1152331|NCT01356160|Rapid Virologic Response
1152332|NCT01356160|Sustained Virologic Response
1152333|NCT01356160|Direct Acting Antiviral
1152334|NCT01356160|Combination Therapy HCV RNA
1152335|NCT01356160|Protease inhibitor
1152336|NCT01356160|Treatment naïve
1152337|NCT01356160|GS-5885
1152338|NCT01356160|GS-9451
1152339|NCT01356147|ventilator associated pulmonary infections
1152340|NCT01356134|multiple sclerosis
1152341|NCT01356134|ehlers danlos syndrome
1152342|NCT01356134|CCSVI
1152343|NCT01356134|chronic cerebrospinal venous insufficiency
1152344|NCT01356134|fundus
1152345|NCT01356134|retina
1152346|NCT01356108|Conduit
1152347|NCT01356108|Pulmonic
1152348|NCT01356108|Stenosis
1152349|NCT01356108|Regurgitation
1152350|NCT01356108|Dysfunctional
1152351|NCT01356095|Tuberculosis
1152352|NCT01356095|Treatment Adherence
1152353|NCT01356095|knowledge translation
1152354|NCT01356095|Educational outreach
1152355|NCT01356069|BPD
1152356|NCT01356069|MHS
1152357|NCT01356069|heavy users
1152358|NCT01356069|sequential psychotherapy
1152359|NCT01356004|severe resistant
1152360|NCT01355991|Spinal Cord Injury
1152361|NCT01355991|Tetraplegia
1152362|NCT01355991|Pulmonary Function
1152363|NCT01355991|Bronchodilator
1152364|NCT01355965|completed standard first line therapy
1152365|NCT01355965|platinum based double regimen
1152366|NCT01355965|Progressive Disease
1152367|NCT01355965|chosen not to pursue primary standard of care therapy
1152368|NCT01355952|Obesity
1152369|NCT01355952|Weight Loss
1152370|NCT01355952|Schizophrenia
1152371|NCT01355952|Alpha Lipoic Acid
1152372|NCT01355939|Hernia
1152373|NCT01355939|Adhesiolysis
1152374|NCT01355939|Adhesions
1152375|NCT01355939|Intraperitoneal Mesh
1152376|NCT01355939|Abdominal Re-exploration
1152377|NCT01355939|Mesh
1152378|NCT01355939|Barrier-Coated Mesh
1152379|NCT01355939|Non-Barrier-Coated Mesh
1152380|NCT01355939|Laparoscopic Approach
1152381|NCT01355939|Open Approach
1152382|NCT01355939|Abdominal Re-Exploration Surgery
1152383|NCT01355926|Flexible Fiber-based CO2 Laser
1152384|NCT01355926|Monopolar Cautery
1152385|NCT01355926|Oral Cavity Lesions
1152386|NCT01355926|Quality of life
1152387|NCT01355926|Assessing Pain
1152388|NCT01355926|11-034
1152389|NCT01355913|Myelodysplastic syndromes (MDS)
1152390|NCT01355913|chromosmal aberrations
1152391|NCT01355913|cytogenetics
1152392|NCT01355913|Fluorescence in situ hybridization (FISH)
1152393|NCT01355913|CD34+ cells
1152394|NCT01355913|peripheral blood
1152395|NCT01355900|Total knee arthroplasty
1152396|NCT01355900|Tourniquet
1152397|NCT01355900|Blood loss
1152398|NCT01355900|Volume loading test
1152399|NCT01355887|blood loss
1152400|NCT01355887|hepatectomy
1152401|NCT01355887|prospective study
1152402|NCT01355887|PTC
1152403|NCT01355874|Internal Symptomatic Hemorrhoids
1152404|NCT01355861|sarcopenia
1152405|NCT01355861|aging
1152406|NCT01355861|rehabilitation
1152407|NCT01355861|exercise
1152408|NCT01355848|Suicide
1152409|NCT01355848|Brief Intervention
1152410|NCT01355848|Youth
1152411|NCT01355848|Acute Medical Setting
1152412|NCT01355848|Readiness to Change
1152413|NCT01355848|Suicidality
1152414|NCT01355835|Parkinson's disease
1152415|NCT01355835|gait
1152416|NCT01355835|deep brain stimulation
1152417|NCT01355835|substantia nigra pars reticulata
1152418|NCT01355835|subthalamic nucleus
1152419|NCT01355822|abortion
1152420|NCT01355822|perinatal death
1152421|NCT01355822|IUGR
1152422|NCT01355822|preterm birth
1152423|NCT01355822|placental abruption
1152424|NCT01355822|preeclampsia
1152425|NCT01355809|Six-Minute Walk Test
1152426|NCT01355757|shoulder arthroscopy
1152427|NCT01355757|24-week follow-up
1152428|NCT01355757|quality of life
1152429|NCT01355757|rehabilitation achievement
1152430|NCT01355757|rotator cuff repair
1152431|NCT01355744|humans
1152432|NCT01355744|insect bites
1152433|NCT01355731|Registered Nurse
1152434|NCT01355731|Behaviors
1152435|NCT01355731|Attitudes
1152436|NCT01355692|DME
1152437|NCT01355692|Laser
1152438|NCT01355692|Selective laser therapy
1152439|NCT01355692|photocoagulation
1152440|NCT01355666|pressure ulcers
1152441|NCT01355666|stage 1
1152442|NCT01355666|stage 2
1152443|NCT01355666|stage 3
1152444|NCT01355666|stage 4
1152445|NCT01355666|wounds
1152446|NCT01355666|sores
1152447|NCT01355666|infection
1152448|NCT01355666|bioburden
1152449|NCT01355666|bacterial contamination
1152450|NCT01355666|bed linen
1152451|NCT01355666|sheets
1152452|NCT01355666|underpad
1152453|NCT01355666|skin assessment
1152454|NCT01355666|microclimate
1152455|NCT01355666|shear
1152456|NCT01355666|friction
1152457|NCT01355666|moisture
1152458|NCT01355666|fabrics
1152459|NCT01355666|long term care
1152460|NCT01355666|nursing home
1152461|NCT01355666|decubitus ulcer
1152462|NCT01355666|bed ridden
1152463|NCT01355666|anti-microbial
1152464|NCT01355653|heat
1152465|NCT01355653|device
1152466|NCT01355653|safety
1152467|NCT01355653|performance
1152468|NCT01355653|heatwrap
1152469|NCT01355653|elderly
1152470|NCT01355653|overweight
1152471|NCT01355640|heel lance
1152472|NCT01355640|pain
1152473|NCT01355640|newborn
1152474|NCT01355627|CSF leaks
1152475|NCT01355627|Skull base surgery
1152476|NCT01355627|pseudomeningocele
1152477|NCT01355627|TachoSil®
1152478|NCT01355627|Prevention
1152479|NCT01355627|post-operative
1152480|NCT01355614|Crohn's Disease
1152481|NCT01355614|Fistula
1152482|NCT01355575|Microbiota
1152483|NCT01355575|Insulin resistance
1152484|NCT01355575|Bacterial endotoxin
1152485|NCT01355575|Hepatic triglyceride
1152486|NCT01355575|Inflammation
1152487|NCT01355549|Shoulder pain
1152488|NCT01355549|Rotator cuff disease
1152489|NCT01355549|Spinal cord injuries
1152490|NCT01355549|Platelet-rich plasma therapy
1152491|NCT01355549|Rehabilitation
1152492|NCT01355536|Preterm birth
1152493|NCT01355536|Preterm labour
1152494|NCT01355536|Polycystic Ovary Syndrome
1152495|NCT01355536|PCOS
1152496|NCT01355536|Diabetes Mellitus
1152497|NCT01355536|Hyperandrogenism
1152498|NCT01355536|Hirsutism
1152499|NCT01355536|Ovarian cysts
1152500|NCT01355536|Anti Muller Hormone
1152501|NCT01355536|Hypertension
1152502|NCT01355523|Breast cancer surgery
1152503|NCT01355523|Melatonin
1152504|NCT01355523|Depression
1152505|NCT01355523|Anxiety
1152506|NCT01355523|Sleep disturbances
1152507|NCT01355523|Cognitive function
1152508|NCT01355471|rosacea
1152509|NCT01355458|rosacea
1152510|NCT01355419|Obstructive sleep apnea
1152511|NCT01355419|CPAP
1152512|NCT01355419|actigraphy
1152513|NCT01355419|sleep
1152514|NCT01355419|physical activity
1152515|NCT01355406|FlexStent
1152516|NCT01355406|Superficial Femoral Artery or SFA
1152517|NCT01355406|Self Expanding Stent
1152518|NCT01355406|Stent
1152519|NCT01355406|Bare Metal Stent
1152520|NCT01355393|Breast Cancer
1152521|NCT01355393|HER2+
1152522|NCT01355393|Vaccine
1152523|NCT01355393|Stage II
1152524|NCT01355393|Stage III
1152525|NCT01355393|Stage IV
1152526|NCT01355380|Pulmonary arterial hypertension
1152527|NCT01355380|Inhaled iloprost
1152528|NCT01355380|Quality of life
1152529|NCT01355367|BAYA1040 CR
1152530|NCT01355367|Nifedipine
1152531|NCT01355367|Essential hypertension
1152532|NCT01355367|Japanese Patients
1152533|NCT01355367|Phase III
1152534|NCT01355367|Extension study
1152535|NCT01355354|Phase 1
1152536|NCT01355354|healthy volunteers
1152537|NCT01355354|pharmacokinetics
1152538|NCT01355354|Rheumatoid arthritis
1152539|NCT01355354|RA, Fostamatinib
1152540|NCT01355354|Digoxin, drug-drug interaction
1152541|NCT01355354|Scientific terminology: Rheumatoid arthritis
1152542|NCT01355354|Fostamatinib
1152543|NCT01355354|Digoxin
1152544|NCT01355354|drug-drug interaction
1152545|NCT01355354|Laymen terminology: Rheumatoid arthritis
1152546|NCT01355354|Amount of Digoxin in blood
1152547|NCT01355341|RENAL CALCULI HERBMED PLUS
1152548|NCT01355328|light
1152549|NCT01355315|EECP
1152550|NCT01355315|ischemic cardiomyopathy
1152551|NCT01355315|endothelin-1
1152552|NCT01355315|ischemia coronary artery diseases
1152553|NCT01355315|congestive heart failure not amenable to standard procedures
1152554|NCT01355302|Cancer
1152555|NCT01355302|Solid Tumors
1152556|NCT01355302|Gastric
1152557|NCT01355302|Phase I
1152558|NCT01355302|Phase II
1152559|NCT01355289|Chronic Hepatitis C related
1152560|NCT01355276|Cinitapride
1152561|NCT01355276|efficacy
1152562|NCT01355276|safety
1152563|NCT01355276|mild to moderate functional dyspepsia
1152564|NCT01355263|vitamin a
1152565|NCT01355263|preschool children
1152566|NCT01355263|iron metabolic homeostasis
1152567|NCT01355263|supplementation effect
1152568|NCT01355237|Complementary and alternative medicine (CAM)
1152569|NCT01355224|obesity
1152570|NCT01355224|genetics
1152571|NCT01355224|risk assessment
1152572|NCT01355224|health behaviors
1152573|NCT01355224|randomized controlled trial
1152574|NCT01355211|Altered Mental Status
1152575|NCT01355211|non-convulsive seizure
1152576|NCT01355211|status epilepticus
1152577|NCT01355211|electroencephalography
1152578|NCT01355185|Seed movement
1152579|NCT01355185|implants
1152580|NCT01355185|prostate brachytherapy
1152581|NCT01355185|localized
1152582|NCT01355172|Influenza
1152583|NCT01355172|Vaccine
1152584|NCT01355172|Immunogenicity
1152585|NCT01355159|Pregnancy
1152586|NCT01355159|Folic Acid supplementation
1152587|NCT01355159|Preeclampsia
1152588|NCT01355146|Patients with proven Fabry's Disease
1152589|NCT01355133|Urinary incontinence
1152590|NCT01355133|Myoblasts
1152591|NCT01355133|Muscle derived cells
1152592|NCT01355133|Stem cells
1152593|NCT01355120|advanced ocular melanoma
1152594|NCT01355107|selenium level measurement
1152595|NCT01355094|temporary abdomen closure
1152596|NCT01355094|peritoneal vacuum therapy
1152597|NCT01355094|open abdomen
1152598|NCT01355094|abdominal compartment syndrome
1152599|NCT01355094|intra-abdominal sepsis
1152600|NCT01355094|intra-abdominal hypertension
1152601|NCT01355094|critical care
1152602|NCT01355081|Drug Therapy
1152603|NCT01355068|phenytoin
1152604|NCT01355068|chewable tablets
1152605|NCT01355068|dilantin
1152606|NCT01355068|epanutin
1152607|NCT01355068|infatabs
1152608|NCT01355068|bioequivalence
1152609|NCT01355068|Partial seizure
1152610|NCT01355068|Tonic-clonic seizure
1152611|NCT01355029|Stroke caregivers
1152612|NCT01355029|Family Caregivers
1152613|NCT01355029|Stroke
1152614|NCT01355016|RSV
1152615|NCT01354977|Diabetes Mellitus, Type 2
1152616|NCT01354977|Glucose Metabolism Disorders
1152617|NCT01354977|Metabolic Diseases
1152618|NCT01354977|Diabetes Mellitus
1152619|NCT01354977|Endocrin System Diseases
1152620|NCT01354977|Resveratrol
1152621|NCT01354977|Therapeutic Uses
1152622|NCT01354964|Glucose Metabolism Disorders
1152623|NCT01354964|Insulin Resistance
1152624|NCT01354964|Endocrine System
1152625|NCT01354964|Vitamin D
1152626|NCT01354951|Focal Brachytherapy
1152627|NCT01354951|Endorectal coil MRI
1152628|NCT01354951|Quality of Life
1152629|NCT01354951|11-056
1152630|NCT01354938|Bronchitis
1152631|NCT01354925|Diabetes type 2
1152632|NCT01354925|Fasting
1152633|NCT01354925|Ramadan
1152634|NCT01354925|Insulin analogues
1152635|NCT01354912|mycobacterial infection
1152636|NCT01354912|culture
1152637|NCT01354912|ct scan
1152638|NCT01354886|in-vitro fertilization
1152639|NCT01354886|reproductive disorder
1152640|NCT01354873|Colonoscopy
1152641|NCT01354873|Colon Polyps
1152642|NCT01354860|knee osteoarthritis
1152643|NCT01354847|extracorporeal circulation
1152644|NCT01354847|platelet dysfunction
1152645|NCT01354847|Multiplate electrode aggregometry analyses
1152646|NCT01354847|Multiplate
1152647|NCT01354821|Aorta
1152648|NCT01354821|Aneurysm
1152649|NCT01354821|endovascular
1152650|NCT01354821|stent-graft
1152651|NCT01354808|Cilostazol
1152652|NCT01354808|Platelet
1152653|NCT01354808|Inflammation
1152654|NCT01354808|Myonecrosis
1152655|NCT01354795|EUS FNA
1152656|NCT01354795|stylet
1152657|NCT01354795|suction
1152658|NCT01354782|Pharmacokinetic
1152659|NCT01354782|Roflumilast
1152660|NCT01354756|sleep apnea
1152661|NCT01354756|polysomnography
1152662|NCT01354756|obesity
1152663|NCT01354756|bariatric surgery
1152664|NCT01354743|atrophy
1152665|NCT01354743|rhytids
1152666|NCT01354743|glabellar
1152667|NCT01354743|periorbital
1152668|NCT01354730|incidence
1152669|NCT01354730|nature
1152670|NCT01354730|seriousness
1152671|NCT01354730|ADRs
1152672|NCT01354730|vaccination
1152673|NCT01354704|deep veinous thrombosis
1152674|NCT01354704|enoxaparin
1152675|NCT01354691|Alzheimer's Disease
1152676|NCT01354691|Dementia
1152677|NCT01354691|Memory Loss
1152678|NCT01354691|Cognitive Impairment
1152679|NCT01354691|Brain Diseases
1152680|NCT01354691|Central Nervous System Diseases
1152681|NCT01354691|Nervous System Diseases
1152682|NCT01354691|Neurodegenerative Diseases
1152683|NCT01354691|Delirium, Dementia, Amnestic, Cognitive Disorders
1152684|NCT01354691|Mental Disorders
1152685|NCT01354691|Depression
1152686|NCT01354691|Anxiety
1152687|NCT01354678|heart failure
1152688|NCT01354678|bone marrow mononuclear cells
1152689|NCT01354665|Multiple sclerosis
1152690|NCT01354665|Interferon beta-1b
1152691|NCT01354665|Fatigue
1152692|NCT01354665|Depression
1152693|NCT01354652|lactic acidosis
1152694|NCT01354652|entecavir
1152695|NCT01354652|lamivudine
1152696|NCT01354626|Hepatic fat accumulation
1152697|NCT01354626|Dietary protein
1152698|NCT01354626|NAFLD
1152699|NCT01354600|Obesity
1152700|NCT01354600|Appetite
1152701|NCT01354600|Hormones
1152702|NCT01354600|Exercise
1152703|NCT01354600|Body Weight
1152704|NCT01354587|immunodeficiency
1152705|NCT01354574|energy metabolism
1152706|NCT01354574|lipids
1152707|NCT01354574|lipoproteins
1152708|NCT01354574|satiety
1152709|NCT01354574|glycemic load
1152710|NCT01354574|insulin
1152711|NCT01354561|respiratory physiotherapy
1152712|NCT01354561|cardiac autonomic modulation
1152713|NCT01354561|paediatric patients
1152714|NCT01354548|Trismus
1152715|NCT01354548|Cancer
1152716|NCT01354548|Radiotherapy
1152717|NCT01354548|Quality of life
1152718|NCT01354535|periprosthetic
1152719|NCT01354535|femur fractures
1152720|NCT01354535|Vancouver B1
1152721|NCT01354509|Normothermia
1152722|NCT01354509|fever control
1152723|NCT01354509|Outcome study
1152724|NCT01354496|Healthy Volunteers
1152725|NCT01354496|Bioavailability
1152726|NCT01354483|spinal cord injury
1152727|NCT01354483|umbilical cord blood mononuclear cell
1152728|NCT01354483|lithium carbonate
1152729|NCT01354470|Meth
1152730|NCT01354470|Methamphetamine Addiction
1152731|NCT01354470|Methamphetamine Treatment
1152732|NCT01354470|Modafinil
1152733|NCT01354457|Patient with relapsing or refractory CD22+B-acute lymphoblastic leukemia (ALL)
1152734|NCT01354444|Memory problems
1152735|NCT01354444|Alzheimer's Disease
1152736|NCT01354431|Advanced/Metastatic
1152737|NCT01354431|clear cell component
1152738|NCT01354392|Relapsed or refractory
1152739|NCT01354392|Large B-Cell
1152740|NCT01354392|Diffuse
1152741|NCT01354340|Cholesterol
1152742|NCT01354340|LDL-cholesterol
1152743|NCT01354340|Coronary artery disease
1152744|NCT01354340|Red yeast rice
1152745|NCT01354340|Plants extract
1152746|NCT01354340|Cholesterol excess
1152747|NCT01354340|Delivery of Health Care
1152748|NCT01354327|Delivery of Health Care
1152749|NCT01354327|Cholesterol
1152750|NCT01354327|LDL-cholesterol
1152751|NCT01354327|Coronary artery disease
1152752|NCT01354327|Red yeast rice
1152753|NCT01354327|Plants extract
1152754|NCT01354327|Cholesterol excess
1152755|NCT01354314|HIV
1152756|NCT01354314|Neurocognitive impairment
1152757|NCT01354314|Memory
1152758|NCT01354314|Dementia
1152759|NCT01354314|CSF marker
1152760|NCT01354314|Functional assessment
1152761|NCT01354314|MRS
1152762|NCT01354314|Magnetic resonance spectroscopy
1152763|NCT01354314|Arterial spin labeling
1152764|NCT01354314|SSRI
1152765|NCT01354301|kidney transplantation
1152766|NCT01354301|thymoglobulin
1152767|NCT01354301|everolimus
1152768|NCT01354288|Diabetes
1152769|NCT01354288|Children
1152770|NCT01354288|Disease management
1152771|NCT01354288|Ketosis
1152772|NCT01354288|Hypoglycemia
1152773|NCT01354288|Parents
1152774|NCT01354288|Education
1152775|NCT01354275|PCOS
1152776|NCT01354275|IVF/ICSI
1152777|NCT01354275|Clinical Pregnancy rates
1152778|NCT01354275|GnRH Antagonist
1152779|NCT01354275|GnRH Agonist
1152780|NCT01354262|Diabetes
1152781|NCT01354262|Vitamin D deficiency
1152782|NCT01354262|Hemoglobin A1c
1152783|NCT01354249|preoperative fasting
1152784|NCT01354249|insulin resistance
1152785|NCT01354249|carbohydrates
1152786|NCT01354249|whey protein
1152787|NCT01354249|inflammatory response
1152788|NCT01354223|silicone hydrogel contact lens
1152789|NCT01354223|SHCL
1152790|NCT01354223|stenfilcon A
1152791|NCT01354223|ocufilcon B
1152792|NCT01354223|daily disposable
1152793|NCT01354223|substantial equivalence
1152794|NCT01354223|CooperVision ClearSight™ 1 Day SCL
1152795|NCT01354210|Patient Adherence
1152796|NCT01354210|HIV
1152797|NCT01354197|Adverse events
1152798|NCT01354197|Mortality
1152799|NCT01354197|Readmission
1152800|NCT01354197|Surgical intensive care unit
1152801|NCT01354171|active surveillance
1152802|NCT01354171|low risk prostate cancer
1152803|NCT01354132|schizophrenia
1152804|NCT01354132|schizoaffective
1152805|NCT01354132|schizophreniform
1152806|NCT01354132|early schizophrenia spectrum psychosis
1152807|NCT01354106|Skin condition after wear
1152810|NCT01354080|constipation
1152811|NCT01354080|massage
1152812|NCT01354080|tensegrity
1152813|NCT01354067|Pulmonary Disease, Chronic Obstructive
1152814|NCT01354067|Lung Diseases, Obstructive
1152815|NCT01354067|Single Limb
1152816|NCT01354067|Elastic Resistance
1152817|NCT01354067|Resistance Training
1152818|NCT01354067|Minor Muscle Mass
1152819|NCT01354067|Local muscle training
1152820|NCT01354054|Knee OA
1152821|NCT01354054|TENS
1152822|NCT01354041|fear and health worries about cancer recurrence
1152823|NCT01354028|premature infant
1152824|NCT01354028|massage therapy
1152825|NCT01354028|sleep induction
1152826|NCT01354028|relaxation
1152827|NCT01354015|Diabetes
1152828|NCT01354015|Technology
1152829|NCT01354002|human biological samples
1152830|NCT01354002|tissue banking
1152831|NCT01353989|hepatitis A
1152832|NCT01353989|vaccination
1152833|NCT01353989|elderly
1152834|NCT01353989|protection to hepatitis A after vaccination
1152835|NCT01353976|Econazole Nitrate
1152836|NCT01353976|Foam
1152837|NCT01353976|Quinnova
1152838|NCT01353976|Tinea Pedis
1152839|NCT01353950|Costimulatory molecules
1152840|NCT01353950|Cystic Fibrosis
1152841|NCT01353950|Biomarkers
1152842|NCT01353937|wound healing
1152843|NCT01353924|Allergy
1152844|NCT01353924|Vaccine
1152845|NCT01353924|rBet v 1
1152846|NCT01353924|Prevention
1152847|NCT01353885|Primary Osteoarthritis, Hip
1152848|NCT01353885|Total Hip Arthroplasty
1152849|NCT01353885|Anterior Approach
1152850|NCT01353885|Posterior Approach
1152851|NCT01353885|Anterolateral Approach
1152852|NCT01353885|Cohort Study
1152853|NCT01353885|Outcomes, Complication Rate
1152854|NCT01353885|Outcomes, Quality of Life
1152855|NCT01353872|Fatigue
1152856|NCT01353872|Tennis
1152857|NCT01353872|Nutrition
1152858|NCT01353872|Tournament simulation
1152859|NCT01353872|Delivery of Health Care
1152860|NCT01353846|oocyte donation program
1152861|NCT01353846|natural cycle
1152862|NCT01353846|hormone replacement therapy
1152863|NCT01353820|Midly hypercholesterolemic subjects
1152864|NCT01353820|Probiotic
1152865|NCT01353820|Cholesterol lowering
1152866|NCT01353820|Dairy
1152867|NCT01353807|Fish oil
1152868|NCT01353807|Pregnancy
1152869|NCT01353807|RCT
1152870|NCT01353807|Birth weight
1152871|NCT01353807|Gestational age
1152872|NCT01353807|Asthma and allergies
1152873|NCT01353807|Metabolic syndrome
1152874|NCT01353807|Obesity
1152875|NCT01353794|SORAFENIB
1152876|NCT01353794|RENAL CELL CARCINOMA
1152877|NCT01353794|TYROSINE KINASE INHIBITOR
1152878|NCT01353794|OBSERVATIONAL STUDY
1152879|NCT01353781|Phase 1
1152880|NCT01353781|advanced solid tumor
1152881|NCT01353781|AKT
1152882|NCT01353781|Ascending
1152883|NCT01353781|Japanese
1152884|NCT01353768|Influenza
1152885|NCT01353755|specific immunotherapy
1152886|NCT01353755|SIT
1152887|NCT01353729|12-lead ECG
1152888|NCT01353729|cardiac repolarization
1152889|NCT01353729|QTc
1152890|NCT01353729|influenza
1152891|NCT01353729|GR121167
1152892|NCT01353729|zanamivir
1152893|NCT01353703|Infanrix hexa™
1152894|NCT01353703|Primary vaccination
1152895|NCT01353703|India
1152896|NCT01353703|combination vaccine
1152897|NCT01353703|infants
1152898|NCT01353690|Cell Therapy
1152899|NCT01353690|Heart Failure
1152900|NCT01353690|Heart Disease
1152901|NCT01353690|Myocardial Infarction
1152902|NCT01353690|Myocardial Ischemia
1152903|NCT01353690|Autologous
1152904|NCT01353690|Muscle-derived Cell
1152905|NCT01353677|Hematopoietic stem cell transplantation
1152906|NCT01353677|QOL
1152907|NCT01353664|rollover protocol
1152908|NCT01353664|romidepsin
1152909|NCT01353664|Gloucester Pharmaceuticals
1152910|NCT01353664|Celgene Corporation
1152911|NCT01353664|continuing treatment
1152912|NCT01353638|Peritoneal dialysis
1152913|NCT01353638|Alanyl-Glutamine-Dipeptide
1152914|NCT01353638|Heat shock protein
1152915|NCT01353638|Peritoneal cells
1152916|NCT01353638|functional maintenance of the peritoneal membrane
1152917|NCT01353625|Neoplasm
1152918|NCT01353625|Malignancy
1152919|NCT01353625|Carcinoma
1152920|NCT01353625|Lymphoma
1152921|NCT01353625|Leukemia
1152922|NCT01353625|Multiple myeloma
1152923|NCT01353625|mTOR kinase inhibitor
1152924|NCT01353625|Castration-resistant prostate cancer
1152925|NCT01353625|Hormone-resistant prostate cancer
1152926|NCT01353625|Diffuse Large B-cell lymphoma
1152927|NCT01353599|Spinal Cord Injury
1152928|NCT01353599|Tetraplegia
1152929|NCT01353599|Pulmonary Function
1152930|NCT01353573|Brain Neoplasms
1152931|NCT01353573|Neoplasm Metastasis
1152932|NCT01353573|Neoplasms
1152933|NCT01353560|integrative medicine
1152934|NCT01353560|barriers to utilization
1152935|NCT01353560|communication
1152936|NCT01353534|Immunogenicity and Safety
1152937|NCT01353521|complex renal cysts
1152938|NCT01353521|Contrast enhanced ultrasound
1152939|NCT01353508|Sodium excretion,
1152940|NCT01353508|LCZ696
1152941|NCT01353495|Diabetic Foot Ulcers
1152942|NCT01353482|mesothelioma
1152943|NCT01353482|vorinostat
1152944|NCT01353456|Ambulation
1152945|NCT01353456|Side effects
1152946|NCT01353456|Serum sCD40L
1152947|NCT01353456|Bowel function
1152948|NCT01353456|Postoperative pain
1152949|NCT01353443|Abdominal Aortic Aneurysm
1152950|NCT01353443|AAA
1152951|NCT01353430|IBMPFD - Inclusion Body Myopathy associated with
1152952|NCT01353430|Paget's disease of bone and Frontotemporal Dementia
1152953|NCT01353430|VCP gene - Valosin-containing protein gene
1152954|NCT01353417|Grafting, kidney
1152955|NCT01353417|Transplantation, kidney
1152956|NCT01353391|Diabetes
1152957|NCT01353391|MiTy
1152958|NCT01353391|Metformin in Women
1152959|NCT01353391|Type 2 Diabetes Pregnancy
1152960|NCT01353378|dexmedetomidine
1152961|NCT01353378|emergence delirium
1152962|NCT01353378|sevoflurane anesthesia
1152963|NCT01353378|preschool children
1152964|NCT01353378|oral maxillofacial surgery
1152965|NCT01353352|Evaluation
1152966|NCT01353352|C-Spine
1152967|NCT01353352|Nursing
1152968|NCT01353352|Clinical Decision Rule
1152969|NCT01353339|Kidney Transplant
1152970|NCT01353339|BK Polyomavirus Infection
1152971|NCT01353326|non-inflammatory degenerative joint disease
1152972|NCT01353326|hip resurfacing
1152973|NCT01353326|bone mineral density
1152974|NCT01353326|cemented
1152975|NCT01353326|cementless
1152983|NCT01353300|embryonal childhood rhabdomyosarcoma
1152984|NCT01353300|cystic nephroma
1152985|NCT01353300|neuroblastoma
1152986|NCT01353300|childhood medulloblastoma
1152987|NCT01353300|childhood hepatoblastoma
1152988|NCT01353300|stromal predominant Wilms tumor
1152989|NCT01353300|hereditary Wilms tumor
1152990|NCT01353300|pleuropulmonary blastoma
1152991|NCT01353287|Transcatheter Aortic Valve Intervention (TAVI)
1152992|NCT01353287|Live case transmission
1152993|NCT01353261|Platelet reactivity
1152994|NCT01353248|Hepatitis C
1152995|NCT01353248|HCV
1152996|NCT01353248|Rapid Virologic Response
1152997|NCT01353248|Sustained Virologic Response
1152998|NCT01353248|Direct Acting Antiviral
1152999|NCT01353248|Combination Therapy
1153000|NCT01353248|HCV RNA
1153001|NCT01353248|Polymerase inhibitor
1153002|NCT01353248|Protease inhibitor
1153003|NCT01353248|Treatment naïve
1153004|NCT01353248|GS-5885
1153005|NCT01353248|GS-9451
1153006|NCT01353248|Tegobuvir
1153007|NCT01353235|COPD
1153008|NCT01353235|acute respiratory failure
1153009|NCT01353235|mechanical ventilation
1153010|NCT01353235|non invasive ventilation
1153011|NCT01353235|steroids
1153012|NCT01353222|Bladder cancer
1153013|NCT01353222|Renal pelvis cancer
1153014|NCT01353222|Ureteral cancer
1153015|NCT01353222|Urethral cancer
1153016|NCT01353222|Bladder
1153017|NCT01353222|Renal pelvis
1153018|NCT01353222|Ureter
1153019|NCT01353222|Urethra
1153020|NCT01353222|Immune therapy
1153021|NCT01353222|Immunotherapy
1153022|NCT01353222|Vaccine
1153023|NCT01353222|Dendritic cells
1153024|NCT01353222|Antigen-presenting cells
1153025|NCT01353222|Antigen presenting cells
1153026|NCT01353222|Cancer vaccine
1153027|NCT01353222|Urothelial carcinoma
1153028|NCT01353222|Urothelial neoplasms
1153029|NCT01353222|Neoplasms by site
1153030|NCT01353222|Neoplasms
1153031|NCT01353196|carotid
1153032|NCT01353196|atherosclerosis
1153033|NCT01353196|cognitive function
1153034|NCT01353183|biopsies, enteric nervous system, biomarker
1153035|NCT01353170|Serum calcium
1153036|NCT01353170|Dialysate
1153037|NCT01353170|Mass balance
1153038|NCT01353170|Blood pressure
1153039|NCT01353157|cytokine
1153040|NCT01353157|cardiac surgery
1153041|NCT01353157|clinical scoring system
1153042|NCT01353144|aspirin
1153043|NCT01353144|peptic ulcer
1153044|NCT01353131|electrocardiogram,
1153045|NCT01353131|cardiac magnetic resonance
1153046|NCT01353131|heart failure
1153047|NCT01353131|sudden cardiac death
1153048|NCT01353131|ECG scoring
1153049|NCT01353131|Delayed enhancement
1153050|NCT01353118|diabetes
1153051|NCT01353118|bariatric surgery
1153052|NCT01353118|Roux-en-y gastric bypass
1153053|NCT01353118|retinopathy
1153054|NCT01353118|neuropathy
1153055|NCT01353118|nephropathy
1153056|NCT01353105|cystic fibrosis
1153057|NCT01353105|chronic obstructive pulmonary disease
1153058|NCT01353105|pulmonary fibrosis
1153059|NCT01353092|Randomized Controlled Trial
1153060|NCT01353092|Major depression
1153061|NCT01353092|Hamilton
1153062|NCT01353092|PEMF
1153063|NCT01353066|Type 2 Diabetes Mellitus
1153064|NCT01353066|BMI 30.0-34.9 kg/m2
1153065|NCT01353053|Immunosuppression
1153066|NCT01353053|Cytomegalovirus
1153067|NCT01353053|Renal Transplant
1153068|NCT01353053|Atrophy/interstitial
1153069|NCT01353053|Conversion of tacrolimus everolimus
1153070|NCT01353014|Nutrigenomics
1153071|NCT01353014|Diet
1153072|NCT01353014|Nutrition
1153073|NCT01353001|Intervention Studies
1153074|NCT01353001|Magnetic Resonance Imaging
1153075|NCT01353001|C-Reactive Protein
1153076|NCT01352988|C17.300.475
1153077|NCT01352988|C17.800.480
1153078|NCT01352975|Age Related Macular Degeneration (AMD)
1153079|NCT01352975|Dark Adaptation
1153080|NCT01352975|Age Related Macular Degeneration
1153081|NCT01352975|AMD
1153082|NCT01352962|Dose Limiting Toxicity
1153083|NCT01352962|Urethra Cancer
1153084|NCT01352962|Carcinoma of the Bladder
1153085|NCT01352962|Cancer of the Renal Pelvis
1153086|NCT01352962|Ureter Cancer
1153087|NCT01352962|Urethral Cancer
1153088|NCT01352962|Solid Tumor
1153089|NCT01352962|Pancreatic Cancer
1153090|NCT01352962|Ovarian Cancer
1153091|NCT01352962|Non-Small Cell Lung Cancer
1153092|NCT01352949|Anthropometry
1153093|NCT01352949|Stereophotogrammetry
1153094|NCT01352949|Torso
1153095|NCT01352949|Spinal Deformity
1153096|NCT01352949|Chest Wall Deformity
1153097|NCT01352949|Overweight
1153098|NCT01352949|Obese
1153099|NCT01352949|Healthy Volunteer
1153100|NCT01352949|HV
1153101|NCT01352936|nephrotoxicity
1153102|NCT01352936|hospital cost
1153103|NCT01352936|Staphylococcus aureus
1153104|NCT01352936|bacteremia
1153105|NCT01352936|vancomycin
1153106|NCT01352936|teicoplanin
1153107|NCT01352923|PEAR1 gene
1153108|NCT01352923|whether and how PEAR 1 modulate intracellular signaling pathways relevant for platelet function
1153109|NCT01352897|Cholesterol
1153110|NCT01352897|rosuvastatin
1153111|NCT01352897|retrospective
1153112|NCT01352884|Cancer
1153113|NCT01352884|Carcinoma
1153114|NCT01352884|Tumor
1153115|NCT01352884|Solid tumor
1153116|NCT01352884|Metastatic
1153117|NCT01352884|Melanoma
1153118|NCT01352871|Immunity, Innate
1153119|NCT01352871|Attention
1153120|NCT01352871|Concentration
1153121|NCT01352858|Arthritis
1153122|NCT01352858|RA
1153123|NCT01352858|Auto-immune disorders
1153124|NCT01352832|Chronic NSAID use
1153125|NCT01352806|accuracy of identifying intralaminar space
1153126|NCT01352793|phase 3 safety study
1153127|NCT01352793|5700 healthy subjects
1153128|NCT01352793|3 vaccine doses at month 0
1153129|NCT01352793|2
1153130|NCT01352793|and 6
1153131|NCT01352793|control HAV/saline/HAV
1153132|NCT01352780|motivational interviewing
1153133|NCT01352780|psoriasis
1153134|NCT01352780|self management
1153135|NCT01352767|insulin injection
1153136|NCT01352754|Hip fracture
1153137|NCT01352754|Troponin T
1153138|NCT01352754|myocardial infarction
1153139|NCT01352741|low back pain
1153140|NCT01352741|neuropathic
1153141|NCT01352741|pain assessment
1153142|NCT01352741|centrally acting tapentadol pregabalin
1153143|NCT01352741|severe chronic
1153144|NCT01352728|Unresectable
1153145|NCT01352689|CKD-828
1153146|NCT01352689|Hypertension
1153147|NCT01352689|Primary Hypertension
1153148|NCT01352689|Healthy Volunteer
1153149|NCT01352689|S-Amlodipine
1153150|NCT01352689|Telmisartan
1153151|NCT01352689|Amlodipine
1153152|NCT01352689|Pharmacokinetic
1153153|NCT01352689|Phase 1
1153154|NCT01352676|renal colic
1153155|NCT01352676|flank pain
1153156|NCT01352676|back pain
1153157|NCT01352663|Type I Diabetes
1153158|NCT01352663|Wockhardt
1153159|NCT01352663|Insulin Analogue
1153160|NCT01352650|leukemia
1153161|NCT01352637|Traumatic Event
1153162|NCT01352637|Trauma Survivor
1153163|NCT01352637|Exposure Therapy
1153164|NCT01352637|PTSD DCS
1153165|NCT01352637|Virtual Reality Exposure
1153166|NCT01352637|Veteran
1153167|NCT01352637|Combat-related PTSD
1153168|NCT01352611|Tactile Defensiveness
1153169|NCT01352611|Autistic Disorder
1153170|NCT01352598|prostate cancer
1153171|NCT01352598|stereotactic radiotherapy
1153172|NCT01352572|Antidepressant Response
1153173|NCT01352572|Signal Transduction
1153174|NCT01352572|Lymphocyte
1153175|NCT01352572|Biomarkers
1153176|NCT01352572|Depressed Patients
1153177|NCT01352572|Antidepressant Drug Adverse Reaction
1153178|NCT01352559|Pharmacogenomics
1153179|NCT01352559|Prediction of Antidepressant Response
1153180|NCT01352559|Depressed Patients
1153181|NCT01352559|biomarkers
1153182|NCT01352559|phenotype
1153183|NCT01352559|Antidepressant Response
1153184|NCT01352559|Adverse Reaction to Drug
1153185|NCT01352546|vaginismus
1153186|NCT01352546|painful sex
1153187|NCT01352546|painful intercourse
1153188|NCT01352546|dyspareunia
1153189|NCT01352546|inability to have intercourse
1153190|NCT01352546|inability to consummate marriage
1153191|NCT01352546|vaginal spasm
1153192|NCT01352546|"hitting a wall"
1153193|NCT01352546|pain during sex
1153194|NCT01352546|pain during intercourse
1153195|NCT01352546|burning with intercourse
1153196|NCT01352520|systemic therapy
1153197|NCT01352520|cutaneous anaplastic large T cell lymphoma
1153198|NCT01352520|ALCL
1153199|NCT01352520|lymphomatoid papulosis
1153200|NCT01352520|LyP
1153201|NCT01352520|mycosis fungoides
1153202|NCT01352520|MF
1153203|NCT01352520|SGN-35 (brentuximab vedotin)
1153204|NCT01352520|skin lymphomas
1153205|NCT01352520|CD30-positive lymphoproliferative disorders
1153206|NCT01352520|tumor lymphocytes
1153207|NCT01352520|cutaneous lymphomas
1153208|NCT01352520|CD30+ expression
1153209|NCT01352520|Hematologic Disorder
1153210|NCT01352520|Lymphoma
1153211|NCT01352494|locally advanced breast cancer
1153212|NCT01352494|docetaxel
1153213|NCT01352494|gemcitabine
1153214|NCT01352481|Speech sound development
1153215|NCT01352468|ADHD
1153216|NCT01352468|cognitive training
1153217|NCT01352455|Hemodialysis
1153218|NCT01352455|Pediatric
1153219|NCT01352455|Outcomes
1153220|NCT01352455|Comparative Effectiveness
1153221|NCT01352455|End Stage Renal Disease
1153222|NCT01352442|Presbyopia
1153223|NCT01352442|Accommodation
1153224|NCT01352442|Near visual acuity
1153225|NCT01352442|LASIK
1153226|NCT01352429|adult
1153227|NCT01352429|histologically confirmed
1153228|NCT01352416|Suppress Atrial Fibrillation
1153229|NCT01352416|heart bypass surgery
1153230|NCT01352416|heart valve surgery
1153231|NCT01352403|obesity
1153232|NCT01352403|bariatric surgery
1153233|NCT01352403|gastric bypass
1153234|NCT01352403|life style intervention
1153235|NCT01352403|cardiac function
1153236|NCT01352390|behavioral economics
1153237|NCT01352390|nudge
1153238|NCT01352390|artwork
1153239|NCT01352390|Pap smear
1153240|NCT01352390|Blood pressure check
1153241|NCT01352390|Cholesterol test
1153242|NCT01352390|Fasting plasma glucose test
1153243|NCT01352364|Physiotherapy.
1153244|NCT01352364|Deafness.
1153245|NCT01352364|Postural balance.
1153246|NCT01352364|Motor skills.
1153247|NCT01352351|Breast feeding Exclusive
1153248|NCT01352351|Initiation of breastfeeding
1153249|NCT01352338|REPEAT
1153250|NCT01352338|multiple myeloma
1153251|NCT01352338|revlimid
1153252|NCT01352338|lenalidomide
1153253|NCT01352338|cyclophosphamide
1153254|NCT01352338|endoxan
1153255|NCT01352338|prednisone
1153256|NCT01352338|lenalidomide refractory
1153257|NCT01352312|Chronic Lymphocytic Leukemia
1153258|NCT01352312|Non-Hodgkin's Lymphoma
1153259|NCT01352312|B-cell
1153260|NCT01352312|leukemia
1153261|NCT01352312|lymphoma
1153262|NCT01352312|bendamustine
1153263|NCT01352312|pentostatin
1153264|NCT01352312|ofatumumab
1153265|NCT01352312|NHL
1153266|NCT01352312|CLL
1153267|NCT01352299|Macintosh laryngoscope blade
1153268|NCT01352299|MacCoy laryngoscope blade
1153269|NCT01352299|Miller laryngoscope blade
1153270|NCT01352299|TrueView laryngoscope
1153271|NCT01352286|Multiple myeloma
1153272|NCT01352286|Autologous stem cell transplantation
1153273|NCT01352286|Received initial treatment previously
1153274|NCT01352273|advanced Solid tumors
1153275|NCT01352273|harboring RAS
1153276|NCT01352273|harboring BRAFV600E
1153277|NCT01352260|Near Infrared Spectroscopy
1153278|NCT01352260|Neuromonitoring
1153279|NCT01352260|Aortic Arch Replacement
1153280|NCT01352221|iron deficiency
1153281|NCT01352221|anaemia
1153282|NCT01352221|inflammatory bowel disease
1153283|NCT01352221|Crohn's Disease
1153284|NCT01352208|ASP9521
1153285|NCT01352208|Castrate Resistant Prostate Cancer
1153286|NCT01352208|Phase 1/2
1153287|NCT01352195|Forever Free
1153288|NCT01352143|Neonates
1153289|NCT01352130|Postoperative nausea and vomiting
1153290|NCT01352130|Ondansetron
1153291|NCT01352130|Granisetron
1153292|NCT01352130|QTc interval
1153293|NCT01352104|Externalizing Problem Behaviour in Preschoolers
1153294|NCT01352091|breast cancer
1153295|NCT01352091|adjuvant endocrine therapy
1153296|NCT01352091|AI
1153297|NCT01352091|Zoladex
1153298|NCT01352078|Non healing ulcer
1153299|NCT01352078|Wound
1153300|NCT01352065|Pharmacokinetics
1153301|NCT01352065|Exercise performance
1153302|NCT01352065|Athletes
1153303|NCT01352052|chronic widespread pain
1153304|NCT01352052|fibromyalgia
1153305|NCT01352052|outcome assessment
1153306|NCT01352052|functional ability
1153307|NCT01352052|AMPS
1153308|NCT01352052|rehabilitation
1153309|NCT01352039|Heparin Sodium
1153310|NCT01352039|Thromboprophylaxis
1153311|NCT01352039|Hip Fracture Surgery.
1153312|NCT01352013|Fibromyalgia
1153313|NCT01352013|Omega-3
1153314|NCT01352013|Chronic Pain
1153315|NCT01352013|Fatigue
1153316|NCT01352013|Mood
1153317|NCT01352013|docosahexaenoic acid (DHA)
1153318|NCT01352013|eicosapentaenoic acid (EPA)
1153319|NCT01352000|self help
1153320|NCT01352000|smoking cessation
1153321|NCT01352000|cancer prevention
1153322|NCT01351987|Benign Prostatic Hyperplasia
1153323|NCT01351974|breast cancer
1153324|NCT01351974|sentinel lymph node biopsy
1153325|NCT01351974|axillary recurrence
1153326|NCT01351961|Hypertension
1153327|NCT01351961|Cognitive function
1153328|NCT01351948|Immune response
1153329|NCT01351935|non-hodgkin's lymphoma
1153330|NCT01351935|lymphoma
1153331|NCT01351935|leukemia
1153332|NCT01351935|chronic lymphocytic leukemia
1153333|NCT01351935|b-cell malignancies
1153334|NCT01351935|Btk inhibitor
1153335|NCT01351935|Phase 1b
1153336|NCT01351935|Avila Therapeutics
1153337|NCT01351935|Waldenstrom Macroglobulinemia
1153338|NCT01351883|immunomodulating diet
1153339|NCT01351883|postoperative infection
1153340|NCT01351857|Type 1 Diabetes
1153341|NCT01351857|17 to 20 years of age
1153342|NCT01351844|Aromatase inhibitor
1153343|NCT01351844|Arthralgia Syndrome
1153344|NCT01351844|Exercise
1153345|NCT01351831|Arthroplasty, Replacement, Knee
1153346|NCT01351831|Resistance training
1153347|NCT01351831|Physical Therapy Modalities
1153348|NCT01351831|Randomized Controlled Trial
1153349|NCT01351805|vitamin D
1153350|NCT01351805|omega-3 fatty acid
1153351|NCT01351805|fish oil
1153352|NCT01351805|prevention
1153353|NCT01351805|trial
1153354|NCT01351805|autoimmune disease
1153355|NCT01351805|rheumatoid arthritis
1153356|NCT01351805|psoriasis
1153357|NCT01351805|systemic inflammation
1153358|NCT01351805|Interleukin-6
1153359|NCT01351805|C-reactive peptide
1153360|NCT01351805|tumor necrosis factor
1153361|NCT01351805|osteoarthritis
1153362|NCT01351779|Intraocular pressure
1153363|NCT01351779|Contact lens sensor
1153364|NCT01351779|Optic disc hemorrhage
1153365|NCT01351766|Behavioral Activation
1153366|NCT01351753|Obesity
1153367|NCT01351753|Metabolic Syndrome X
1153368|NCT01351753|Hypertension
1153369|NCT01351753|Dyslipidemia
1153370|NCT01351753|Impaired glucose tolerance
1153371|NCT01351740|HIV
1153372|NCT01351740|Anti-HIV Agents
1153373|NCT01351740|HIV Protease Inhibitors
1153374|NCT01351727|seniors
1153375|NCT01351727|seizures
1153376|NCT01351727|epilepsy
1153377|NCT01351727|quality of life
1153378|NCT01351714|D3 resection
1153379|NCT01351714|right colectomy
1153380|NCT01351714|MDCT angiography
1153381|NCT01351714|lymphadenectomy
1153382|NCT01351714|safe
1153383|NCT01351714|right colon
1153384|NCT01351714|preoperative
1153385|NCT01351701|Diabetic foot
1153386|NCT01351701|Bacteriological epidemiology
1153387|NCT01351701|Wagner's Grading
1153388|NCT01351701|eastern India
1153389|NCT01351688|Phase 1
1153390|NCT01351688|Metastatic
1153391|NCT01351688|Castration resistant
1153392|NCT01351688|Prostate cancer
1153393|NCT01351688|Androgen receptor
1153394|NCT01351688|Down regulation
1153395|NCT01351688|Japanese
1153396|NCT01351675|Chronic kidney disease
1153397|NCT01351675|Type 2 diabetes
1153398|NCT01351675|Diabetic nephropathy
1153399|NCT01351662|Lupus
1153400|NCT01351662|stress
1153401|NCT01351649|exercise
1153402|NCT01351649|adolescent
1153403|NCT01351649|intervention
1153404|NCT01351649|female
1153405|NCT01351649|counseling
1153406|NCT01351636|chronic kidney disease
1153407|NCT01351636|hypertension
1153408|NCT01351623|PR-171 (CARFILZOMIB)
1153409|NCT01351623|Chemotherapy
1153410|NCT01351623|10-228
1153411|NCT01351610|Critical Limb Ischemia
1153412|NCT01351610|Peripheral Arterial Occlusive Disease
1153413|NCT01351610|Peripheral Artery Disease
1153414|NCT01351610|Peripheral Vascular Disease
1153415|NCT01351610|Stem Cell Therapy
1153416|NCT01351610|Mesenchymal Stem Cells
1153417|NCT01351597|recurrent breast cancer
1153418|NCT01351597|metastatic breast cancer
1153419|NCT01351597|docetaxel
1153420|NCT01351597|oxaliplatin
1153421|NCT01351584|Breast Cancer
1153422|NCT01351584|Advanced Breast Cancer
1153423|NCT01351584|Epidemiology
1153424|NCT01351584|Registry
1153425|NCT01351584|Health Services Research
1153426|NCT01351584|Germany
1153427|NCT01351584|Palliative Treatment
1153428|NCT01351584|Adjuvant Drug Therapy
1153429|NCT01351584|Nutrition Assessment
1153430|NCT01351584|Physical Activity
1153431|NCT01351519|Glioma
1153432|NCT01351519|Glioblastoma
1153433|NCT01351519|Glioblastoma Multiforme
1153434|NCT01351519|Astrocytoma
1153435|NCT01351519|Brain Tumor
1153436|NCT01351506|Body weight
1153437|NCT01351506|Body mass index
1153438|NCT01351506|Weight change
1153439|NCT01351506|ICU outcomes
1153440|NCT01351493|pressure sore
1153441|NCT01351493|nitric oxide
1153442|NCT01351480|Auto-immune Disease
1153443|NCT01351480|Arthritis
1153444|NCT01351480|Rheumatoid Arthritis
1153445|NCT01351467|Parkinson's
1153446|NCT01351467|genetic
1153447|NCT01351467|online
1153448|NCT01351467|GWAS
1153449|NCT01351467|genome wide association
1153450|NCT01351454|Depression
1153451|NCT01351454|Substance Use
1153452|NCT01351454|HIV Medication Adherence
1153453|NCT01351454|Behavioral Activation
1153454|NCT01351441|Geriatric
1153455|NCT01351441|Pharmacoeconomics
1153456|NCT01351441|Health Literacy
1153457|NCT01351441|Adherence
1153458|NCT01351428|Non invasive cardiac output monitor
1153459|NCT01351428|NICOM
1153460|NCT01351428|Hypertension
1153461|NCT01351428|Pregnancy
1153462|NCT01351428|Pre-Eclampsia
1153463|NCT01351402|Massage
1153464|NCT01351402|Rest
1153465|NCT01351389|Brief
1153466|NCT01351389|Alcohol
1153467|NCT01351389|Intervention
1153468|NCT01351389|Sex
1153469|NCT01351389|Risk
1153470|NCT01351376|Lymphedema, Low Level Laser, Breast Cancer
1153471|NCT01351363|Arthroscopic shoulder surgery
1153472|NCT01351363|Pain threshold
1153473|NCT01351350|Solid tumor, mTORC1/2 inhibitors, HER2
1153474|NCT01351337|Diffusion tensor imaging, Glioma, Intraoperative monitoring, Pyramidal tract, Subcortical
1153475|NCT01351337|stimulation, Tractography
1153476|NCT01351324|Endothelial function
1153477|NCT01351324|Non-esterified fatty acids
1153478|NCT01351324|Insulin sensitivity
1153479|NCT01351311|treatment
1153480|NCT01351311|exercise
1153481|NCT01351311|resistance training
1153482|NCT01351311|swiss ball
1153483|NCT01351311|functional capacity
1153484|NCT01351259|Mechanical ventilation
1153485|NCT01351259|Intubation
1153486|NCT01351259|Cuff pressure
1153487|NCT01351259|Microaspiration
1153488|NCT01351246|Program Evaluation
1153489|NCT01351246|ADHD
1153490|NCT01351233|Cataract
1153491|NCT01351220|CRC screening
1153492|NCT01351220|Prevention and early detection of CRC
1153493|NCT01351220|Filipino
1153494|NCT01351220|Dissemination
1153495|NCT01351194|Hepatocellular Carcinoma
1153496|NCT01351194|RFA
1153497|NCT01351194|HR
1153498|NCT01351181|Diabetes
1153499|NCT01351168|Parkinson's disease
1153500|NCT01351168|zolpidem
1153501|NCT01351155|acute respiratory failure
1153502|NCT01351155|noninvasive ventilation
1153503|NCT01351129|formulation comparison
1153504|NCT01351116|brachytherapy
1153505|NCT01351116|external beam radiation
1153506|NCT01351116|high dose rate intraluminal brachytherapy
1153507|NCT01351116|lung cancer
1153508|NCT01351116|quality of life
1153509|NCT01351116|radiation treatment
1153510|NCT01351116|bronchus
1153511|NCT01351103|LGK974
1153512|NCT01351103|pancreatic adenocarcinoma
1153513|NCT01351103|BRAF mutant colorectal cancer
1153514|NCT01351103|other tumor types with documented genetic alterations upstream in the Wnt signaling pathway
1153515|NCT01351103|RNF43 mutation
1153516|NCT01351103|RSPO fusion
1153517|NCT01351103|melanoma
1153518|NCT01351103|triple negative breast cancer
1153519|NCT01351103|PDR001
1153520|NCT01351103|immunotherapy
1153521|NCT01351103|head and neck cancer
1153522|NCT01351077|Developmental Delay
1153523|NCT01351064|ADHD
1153524|NCT01351012|Canola oil
1153525|NCT01351012|High oleic canola oil
1153526|NCT01351012|Flax oil
1153527|NCT01351012|ALA
1153528|NCT01351012|DHA
1153529|NCT01351012|Metabolic syndrome
1153530|NCT01351012|Cardiovascular disease
1153531|NCT01351012|Endothelial function
1153532|NCT01351012|FADS1
1153533|NCT01351012|Gut microbiome
1153534|NCT01351012|Body composition
1153535|NCT01351012|Psychosocial status
1153536|NCT01351012|Cholesterol
1153537|NCT01351012|Lipids
1153538|NCT01351012|Lipoproteins
1153539|NCT01351012|Inflammation
1153540|NCT01351012|Lipid peroxidation
1153541|NCT01350999|Drug Therapy
1153542|NCT01350986|Controlled Clinical Trials, Randomized
1153543|NCT01350973|Drug Therapy
1153544|NCT01350960|hypercholesterolemia
1153545|NCT01350960|hyperlipidemia
1153546|NCT01350960|LDL
1153547|NCT01350960|HDL
1153548|NCT01350960|PCSK9
1153549|NCT01350960|LNA-oligonucleotide
1153550|NCT01350947|Chronic Myelomonocytic Leukemia
1153551|NCT01350947|CMML
1153552|NCT01350921|phase 1
1153553|NCT01350921|ticagrelor
1153554|NCT01350921|venlafaxine
1153555|NCT01350895|Polycystic ovarian syndrome (PCOS)
1153556|NCT01350882|kidney transplantation
1153557|NCT01350882|acute humoral rejection
1153558|NCT01350882|rituximab
1153559|NCT01350856|Uncomplicated P. falciparum malaria
1153560|NCT01350843|Men
1153561|NCT01350843|Orange Juice
1153562|NCT01350843|Cholesterol
1153563|NCT01350843|Obesity
1153564|NCT01350830|inguinal hernia
1153565|NCT01350830|groin hernia
1153566|NCT01350830|chronic pain
1153567|NCT01350830|mesh repair
1153568|NCT01350804|Rheumatoid Arthritis
1153569|NCT01350804|RA
1153570|NCT01350804|ACR
1153571|NCT01350804|inflammatory joints
1153572|NCT01350778|Coronary artery disease requiring drug eluting stents
1153573|NCT01350765|Birth asphyxia
1153574|NCT01350765|Low birth weight
1153575|NCT01350765|neonatal sepsis
1153576|NCT01350765|mortality
1153577|NCT01350765|community based interventions
1153578|NCT01350752|cost effectiveness
1153579|NCT01350752|provider knowledge
1153580|NCT01350752|schools
1153581|NCT01350726|Cirrhosis
1153582|NCT01350726|Hepatic Carcinoma
1153583|NCT01350713|skin
1153584|NCT01350713|burn
1153585|NCT01350713|povidone iodine
1153586|NCT01350713|cold water
1153587|NCT01350700|QOL
1153588|NCT01350687|Calcium Phosphore
1153589|NCT01350687|Renagel
1153590|NCT01350674|mediastinal tuberculosis
1153591|NCT01350674|endoscopy
1153592|NCT01350674|EBUS
1153593|NCT01350674|tuberculous lymphadenopathy
1153594|NCT01350674|endobronchial ultrasound
1153595|NCT01350661|Asthma
1153596|NCT01350661|Questionnaires
1153597|NCT01350648|Viral Hepatitis
1153598|NCT01350648|Prospective Cohort
1153599|NCT01350648|Hepatocellular Carcinoma
1153600|NCT01350648|HIV-HCV Co-Infection
1153601|NCT01350648|HIV-HBV Co-Infection
1153602|NCT01350648|Hepatitis B
1153603|NCT01350648|Hepatitis C
1153604|NCT01350648|Hepatitis
1153605|NCT01350635|Specific Immunotherapy
1153606|NCT01350635|Grass pollen vaccine
1153607|NCT01350635|Allergy
1153608|NCT01350635|Grass Pollen Allergy
1153609|NCT01350622|pain management
1153610|NCT01350609|essential hypertension, blood pressure, nifedipine, candesartan, FDC
1153611|NCT01350596|Bioequivalence Study
1153612|NCT01350596|Ibuprofen
1153613|NCT01350596|Alivium
1153614|NCT01350583|tumor related pain
1153615|NCT01350570|acupuncture
1153616|NCT01350570|loperamide
1153617|NCT01350570|functional diarrhea
1153618|NCT01350570|IBS
1153619|NCT01350557|Elderly
1153620|NCT01350557|Hip fracture
1153621|NCT01350557|Intervention program
1153622|NCT01350544|HIV
1153623|NCT01350544|Adherence
1153624|NCT01350544|African American/Black
1153625|NCT01350544|Disparities
1153626|NCT01350531|Obesity
1153627|NCT01350531|African American adolescents
1153628|NCT01350531|Motivation
1153629|NCT01350518|Intra-Abdominal Fat
1153630|NCT01350518|Metabolic Syndrome
1153631|NCT01350518|Hepatic steatosis
1153632|NCT01350505|Postural Balance
1153633|NCT01350505|Sleep Initiation and Maintenance Disorders
1153634|NCT01350492|pain
1153635|NCT01350492|brain imaging
1153636|NCT01350492|exercise
1153637|NCT01350479|Cross infection
1153638|NCT01350479|Long term care
1153639|NCT01350466|Chronic rhinosinusitis
1153640|NCT01350453|CIT
1153641|NCT01350453|Stroke
1153642|NCT01350427|leucine supplementation
1153643|NCT01350427|BCCA supplementation
1153644|NCT01350427|resistance exercise-induced muscle remodeling
1153645|NCT01350401|Melanoma
1153646|NCT01350401|Cell Therapy
1153647|NCT01350401|T Cell Therapy
1153648|NCT01350401|NY-ESO-1
1153649|NCT01350401|Immuno-oncology
1153650|NCT01350401|Metastatic
1153651|NCT01350401|Previously treated
1153652|NCT01350401|T Cell Receptor
1153653|NCT01350388|Chronic Kidney Disease
1153654|NCT01350388|Diabetes
1153655|NCT01350388|Febuxostat
1153656|NCT01350388|Inflammation
1153657|NCT01350388|Hyperuricemia
1153658|NCT01350362|tideglusib
1153659|NCT01350362|Alzheimer
1153660|NCT01350362|NP-12
1153661|NCT01350362|NP031112
1153662|NCT01350362|ARGO
1153663|NCT01350362|Noscira
1153664|NCT01350349|Depression
1153665|NCT01350349|Dementia
1153666|NCT01350349|Geriatrics
1153667|NCT01350310|Heart failure
1153668|NCT01350310|Dilated cardiomyopathy
1153669|NCT01350310|Stem cells
1153670|NCT01350297|tetraplegia
1153671|NCT01350297|reinnervation
1153672|NCT01350297|phrenic nerve
1153673|NCT01350284|Antioxidants
1153674|NCT01350284|Glucose Intolerance prevention and control
1153675|NCT01350284|Diabetes Mellitus prevention and control
1153676|NCT01350271|Hookworm
1153677|NCT01350271|Necator americanus
1153678|NCT01350271|Mebendazole
1153679|NCT01350258|allogeneic HSCT
1153680|NCT01350258|Hematopoietic stem cell transplantation
1153681|NCT01350245|Acute Myeloid Leukemia
1153682|NCT01350245|Myelodysplastic Syndromes
1153683|NCT01350245|Biphenotypic Leukemia
1153684|NCT01350245|Acute Lymphocytic Leukemia
1153685|NCT01350245|Chronic Myeloid Leukemia
1153686|NCT01350245|Chronic Lymphocytic Leukemia
1153687|NCT01350245|Plasma Cell Neoplasms
1153688|NCT01350245|Lymphoma
1153689|NCT01350245|Hodgkin's Disease
1153690|NCT01350245|Aplastic Anemia
1153691|NCT01350245|Hematopoietic stem cell transplant (HSCT)
1153692|NCT01350245|myeloablative haploidentical HSCT
1153693|NCT01350245|graft versus host disease (GVHD)
1153694|NCT01350232|sickle cell
1153695|NCT01350232|SS disease
1153696|NCT01350232|SC disease
1153697|NCT01350232|S-thalassemia
1153698|NCT01350232|transplant
1153699|NCT01350232|bone marrow transplant
1153700|NCT01350232|stem cell transplant
1153701|NCT01350232|matched sibling
1153702|NCT01350232|haploidentical
1153703|NCT01350232|hemoglobinopathy
1153704|NCT01350232|anemia
1153705|NCT01350232|desensitization
1153706|NCT01350219|Cord blood stem cells
1153707|NCT01350219|Immune modulation
1153708|NCT01350219|Stem cell educator
1153709|NCT01350219|Autoimmunity
1153710|NCT01350219|Islet beta cell regeneration
1153711|NCT01350219|Type 1 diabetes
1153712|NCT01350206|Carcinoma,Hepatocellular
1153713|NCT01350206|Liver Neoplasms
1153714|NCT01350206|Therapeutic
1153715|NCT01350206|Chemoembolization,
1153716|NCT01350206|TACE
1153717|NCT01350206|hepatic resection
1153718|NCT01350193|Manuka Honey
1153719|NCT01350193|Irrigation
1153720|NCT01350193|Endoscopic Sinus Surgery
1153721|NCT01350180|biochemical failure
1153722|NCT01350180|hormonal therapy
1153723|NCT01350167|Hepatocellular Carcinoma
1153724|NCT01350167|Liver Cancer
1153725|NCT01350167|Ultrasound
1153726|NCT01350167|Computed Tomography
1153727|NCT01350167|Alpha fetoprotein
1153728|NCT01350167|Cirrhosis
1153729|NCT01350167|Screening
1153730|NCT01350167|Advanced Liver Disease
1153731|NCT01350154|clinical trial
1153732|NCT01350154|sildenafil
1153733|NCT01350154|revatio
1153734|NCT01350154|muscular dystrophy
1153735|NCT01350154|adult
1153736|NCT01350154|nNOS
1153737|NCT01350141|Hypercholesterolemia
1153738|NCT01350141|dyslipidemia
1153739|NCT01350141|high cholesterol
1153740|NCT01350141|LDL
1153741|NCT01350141|antibody
1153742|NCT01350141|PCSK9
1153743|NCT01350141|PF-04950615
1153744|NCT01350141|RN316
1153745|NCT01350128|COPD
1153746|NCT01350115|Basal Cell Carcinoma
1153747|NCT01350115|Gorlin Syndrome,
1153748|NCT01350115|Gorlin-Goltz Syndrome,
1153749|NCT01350115|Basal Cell Nevus Syndrome,
1153750|NCT01350115|Nevoid Basal Cell Carcinoma Syndrome,
1153751|NCT01350115|Basal Cell Carcinoma Nevus Syndrome
1153752|NCT01350115|Smo inhibitor,
1153753|NCT01350115|Hedgehog pathway inhibitor
1153754|NCT01350115|BCCs
1153755|NCT01350102|Adult
1153756|NCT01350089|energy drinks
1153757|NCT01350089|alcohol intoxication
1153758|NCT01350076|intraoperative fluid
1153759|NCT01350076|pediatric
1153760|NCT01350076|goal directed therapy
1153761|NCT01350076|pediatric with major abdominal surgery
1153762|NCT01350076|ASA less than or equal to 3
1153763|NCT01350076|Duration of surgery less than 2 hours
1153764|NCT01350076|Body weight more than or equal to 15 kg
1153765|NCT01350063|water
1153766|NCT01350063|tubewell
1153767|NCT01350063|diarrhea
1153768|NCT01350063|chlorination
1153769|NCT01350063|safe storage
1153770|NCT01350050|topical pharyngeal anesthesia
1153771|NCT01350050|articaine
1153772|NCT01350037|patient-controlled sedation
1153773|NCT01350037|propofol
1153774|NCT01350037|alfentanil
1153775|NCT01350037|remifentanil
1153776|NCT01350037|endoscopic retrograde cholangiopancreatography
1153777|NCT01350024|Conjunctival Mullerectomy
1153778|NCT01350024|Blepharoptosis
1153779|NCT01350024|Ptosis surgery
1153780|NCT01350024|Pain Control
1153781|NCT01350011|Nicotine Replacement Therapy
1153782|NCT01350011|Buprenorphine
1153783|NCT01350011|Varenicline
1153784|NCT01350011|Smoking Cessation
1153785|NCT01350011|Addiction
1153786|NCT01350011|The Innovative System (IS) Treatment
1153914|NCT01349478|CVD risk factors
1153787|NCT01350011|The Standard Treatment Control (STC)
1153788|NCT01349985|Naltrexone
1153789|NCT01349985|problem drinking
1153790|NCT01349985|medication adherence
1153791|NCT01349985|adherence
1153792|NCT01349985|smartphone
1153793|NCT01349920|biological markers
1153794|NCT01349920|endoscopy
1153795|NCT01349920|gastrointestinal
1153796|NCT01349881|Eflornithine/sulindac prevention trial
1153797|NCT01349868|COPD
1153798|NCT01349829|Hepatitis A
1153799|NCT01349829|Vaccination
1153800|NCT01349829|Immunity
1153801|NCT01349816|COPD
1153802|NCT01349803|COPD
1153803|NCT01349790|ITP
1153804|NCT01349790|Primary immune thrombocytopenia
1153805|NCT01349777|antiplatelet therapy post drug eluting stents
1153806|NCT01349764|vitamin D replacement
1153807|NCT01349764|Urolithiasis
1153808|NCT01349764|deficiency
1153809|NCT01349764|insufficiency
1153810|NCT01349751|abdominal incision
1153811|NCT01349751|hyperbaric
1153812|NCT01349751|isobaric
1153813|NCT01349751|levobupivacaine
1153814|NCT01349751|spinal anaesthesia
1153815|NCT01349725|Safety
1153816|NCT01349699|endotoxemia
1153817|NCT01349699|inflammation
1153818|NCT01349699|iron
1153819|NCT01349699|iron chelation
1153820|NCT01349699|cytokines
1153821|NCT01349686|Food
1153822|NCT01349686|Fluids
1153823|NCT01349686|Labor
1153824|NCT01349673|Open-label
1153825|NCT01349673|Proctitis
1153826|NCT01349673|Proctosigmoiditis
1153827|NCT01349673|Ulcerative
1153828|NCT01349673|Salix
1153829|NCT01349673|Budesonide foam
1153830|NCT01349673|Budesonide
1153831|NCT01349673|Rectal
1153832|NCT01349673|Gastrointestinal
1153833|NCT01349673|Colitis
1153834|NCT01349673|UC
1153835|NCT01349673|UP
1153836|NCT01349673|UPS
1153837|NCT01349673|Additional relevant MeSH terms:
1153838|NCT01349673|Proctocolitis
1153839|NCT01349673|Ulcer
1153840|NCT01349673|Colitis, Ulcerative
1153841|NCT01349673|Gastroenteritis
1153842|NCT01349673|Gastrointestinal Diseases
1153843|NCT01349673|Digestive System Diseases
1153844|NCT01349673|Rectal Diseases
1153845|NCT01349673|Intestinal Diseases
1153846|NCT01349673|Colonic Diseases
1153847|NCT01349673|Sigmoid Diseases
1153848|NCT01349673|Pathologic Processes
1153849|NCT01349673|Inflammatory Bowel Diseases
1153850|NCT01349673|Bronchodilator Agents
1153851|NCT01349673|Autonomic Agents
1153852|NCT01349673|Peripheral Nervous System Agents
1153853|NCT01349673|Physiological Effects of Drugs
1153854|NCT01349673|Pharmacologic Actions
1153855|NCT01349673|Anti-Asthmatic Agents
1153856|NCT01349673|Respiratory System Agents
1153857|NCT01349673|Therapeutic Uses
1153858|NCT01349673|Glucocorticoids
1153859|NCT01349673|Hormones
1153860|NCT01349673|Hormones, Hormone Substitutes and Hormone Antagonists
1153861|NCT01349673|Anti-inflammatory Agents
1153862|NCT01349660|Glioblastoma multiforme
1153863|NCT01349660|GBM
1153864|NCT01349660|Bevacizumab
1153865|NCT01349660|PI3K Pathway
1153866|NCT01349660|BKM120
1153867|NCT01349647|FUCOSYL-GM1-KLH
1153868|NCT01349647|GLOBO H-KLH CONJUGATE
1153869|NCT01349647|OPT-821
1153870|NCT01349647|POLYSIALIC ACID - KLH
1153871|NCT01349647|Vaccine
1153872|NCT01349647|08-095
1153873|NCT01349634|iodine
1153874|NCT01349634|goiter
1153875|NCT01349634|cretinism
1153876|NCT01349634|child nutrition
1153877|NCT01349634|cognition
1153878|NCT01349621|Abnormal Pap results
1153879|NCT01349621|Colposcopy
1153880|NCT01349608|Chronic Obstructive Pulmonary Disease
1153881|NCT01349608|Motivational Interviewing
1153882|NCT01349608|Health Coaching
1153883|NCT01349608|Physical Activity
1153884|NCT01349582|flow diversion
1153885|NCT01349582|endovascular treatment
1153886|NCT01349582|symptomatic aneurysm
1153887|NCT01349582|cavernous carotid aneurysm
1153888|NCT01349582|ophthalmic aneurysm
1153889|NCT01349582|vertebral aneurysm
1153890|NCT01349556|cancer
1153891|NCT01349556|chemotherapy
1153892|NCT01349556|EGFR inhibitors
1153893|NCT01349556|tretinoin
1153894|NCT01349556|EGFRi drug rash
1153895|NCT01349543|Respiratory syncytial virus
1153896|NCT01349543|RSV
1153897|NCT01349543|Immunology
1153898|NCT01349543|Viral infection
1153899|NCT01349543|Bronchiolitis
1153900|NCT01349543|Viral challenge
1153901|NCT01349543|Viral lung disease
1153902|NCT01349530|Usual medical care
1153903|NCT01349530|Anticoagulation by VKAs: COUMADINE® & PREVISCAN®
1153904|NCT01349530|Anticoagulation clinic care, CREATIF
1153905|NCT01349517|health-related quality of life(HRQL)
1153906|NCT01349517|Esophageal Cancer
1153907|NCT01349491|Atrial Fibrillation
1153908|NCT01349491|Ranolazine
1153909|NCT01349478|paraplegia
1153910|NCT01349478|tetraplegia
1153911|NCT01349478|passive gait training
1153912|NCT01349478|O2 consumption
1153913|NCT01349478|exercise capacity
1153915|NCT01349478|spasticity
1153916|NCT01349478|pain
1153917|NCT01349478|bladder, bowel
1153918|NCT01349478|well being
1153919|NCT01349465|Hepatitis C
1153920|NCT01349465|Hepatitis
1153921|NCT01349465|TMC435
1153922|NCT01349465|Liver disease
1153923|NCT01349465|Virus Infection
1153924|NCT01349452|Conjunctivitis, Viral
1153925|NCT01349452|Adenoviridae Infections
1153926|NCT01349452|Ganciclovir
1153927|NCT01349452|Adenovirus Keratoconjunctivitis
1153928|NCT01349452|Treatment of viral conjunctivitis
1153929|NCT01349426|Lung resection
1153930|NCT01349426|Parenchymal pneumostasis, haemostasis
1153931|NCT01349426|Fissure closure
1153932|NCT01349426|Automatic staplers,LigaSure, Force Triad Generator
1153933|NCT01349426|Bipolar fusion
1153934|NCT01349426|Procedure cost
1153935|NCT01349413|Functional dyspepsia
1153936|NCT01349413|symptom response
1153937|NCT01349413|postprandial fullness
1153938|NCT01349413|gastroesophageal reflux disease
1153939|NCT01349413|acid suppression
1153940|NCT01349400|asymptomatic
1153941|NCT01349400|minimally symptomatic
1153942|NCT01349348|Tolvaptan treatment to ascites and hepatic cirrhosis
1153943|NCT01349322|stage IA breast cancer
1153944|NCT01349322|stage IB breast cancer
1153945|NCT01349322|stage II breast cancer
1153946|NCT01349322|estrogen receptor-negative breast cancer
1153947|NCT01349322|estrogen receptor-positive breast cancer
1153948|NCT01349322|progesterone receptor-negative breast cancer
1153949|NCT01349322|progesterone receptor-positive breast cancer
1153950|NCT01349322|ductal breast carcinoma in situ
1153951|NCT01349309|Prophylactic Swallowing Exercises
1153952|NCT01349309|Head and Neck Cancer
1153953|NCT01349309|Dysphagia
1153954|NCT01349296|Solid Tumors
1153955|NCT01349283|Hepatitis B Vaccine
1153956|NCT01349283|Hepatitis B Virus
1153957|NCT01349283|Antigen
1153958|NCT01349283|Antibody
1153959|NCT01349283|Vaccination
1153960|NCT01349270|chronic inflammatory demyelinating polyneuropathy
1153961|NCT01349270|immunoglobulin
1153962|NCT01349270|prednisone
1153963|NCT01349257|Asthmatic patients
1153964|NCT01349244|hydronephrosis
1153965|NCT01349244|CT
1153966|NCT01349244|POC US
1153967|NCT01349231|obsessive-compulsive disorder
1153968|NCT01349231|ketamine
1153969|NCT01349231|glutamate
1153970|NCT01349218|Potassium
1153971|NCT01349218|Infants
1153972|NCT01349218|Heel Stick
1153973|NCT01349218|Less than or equal to 6 months of age
1153974|NCT01349218|IV catheter blood samples
1153975|NCT01349218|perioperatively
1153976|NCT01349218|elective surgical procedures
1153977|NCT01349205|OSA
1153978|NCT01349205|Caffeine
1153979|NCT01349205|Tonsillectomy
1153980|NCT01349205|Adenoidectomy
1153981|NCT01349205|Sleep Study
1153982|NCT01349192|MRSA
1153983|NCT01349192|Cystic Fibrosis
1153984|NCT01349192|Early Infection
1153985|NCT01349192|Treatment
1153986|NCT01349179|Hip
1153987|NCT01349179|Arthroplasty
1153988|NCT01349179|Metal on metal
1153989|NCT01349179|operated on 2002
1153990|NCT01349166|Obesity
1153991|NCT01349166|Type 2 diabetes
1153992|NCT01349166|glucose intolerance
1153993|NCT01349166|Physical Activity
1153994|NCT01349166|Inflammation
1153995|NCT01349166|HPA axis
1153996|NCT01349166|Cytokines
1153997|NCT01349153|Physical Activity
1153998|NCT01349153|Young Adults
1153999|NCT01349153|Cancer Survivors
1154000|NCT01349127|Vitamin D
1154001|NCT01349127|Cholecalciferol
1154002|NCT01349127|Nutrient requirements
1154003|NCT01349127|Randomised Controlled Trial
1154004|NCT01349127|Lactation
1154005|NCT01349127|pregnancy
1154006|NCT01349127|Cord blood
1154007|NCT01349127|Human milk
1154008|NCT01349127|serum 25-hydroxyvitamin D
1154009|NCT01349127|deficiency
1154010|NCT01349127|insufficiency
1154011|NCT01349127|nutrition
1154012|NCT01349114|aliskiren
1154013|NCT01349114|endothelial function
1154014|NCT01349114|hypertension
1154015|NCT01349101|hematopoietic stem cell transplantation
1154016|NCT01349101|HSCT
1154017|NCT01349101|allogeneic marrow transplantation
1154018|NCT01349101|cyclophosphamide
1154019|NCT01349101|graft-versus-host disease
1154020|NCT01349101|GVHD
1154021|NCT01349088|breast cancer
1154022|NCT01349088|metastatic breast cancer
1154023|NCT01349088|stage IV breast cancer
1154024|NCT01349088|motesanib
1154025|NCT01349088|ixabepilone
1154026|NCT01349088|capecitabine
1154027|NCT01349075|Unresectable
1154028|NCT01349075|Hepatocellular Carcinoma
1154029|NCT01349075|TheraSphere
1154030|NCT01349075|Yttrium-90
1154031|NCT01349062|Prolonged Viral Suppression
1154032|NCT01349062|HIV Infections
1154033|NCT01349049|AML
1154034|NCT01349049|relapsed
1154035|NCT01349049|refractory
1154036|NCT01349036|GBM
1154037|NCT01349036|Glioblastoma
1154038|NCT01349036|brain cancer
1154039|NCT01349023|energy content
1154040|NCT01349023|energy density
1154041|NCT01349023|energy intake
1154042|NCT01349023|pre-portioned entrees
1154043|NCT01349010|hyperlipidemia
1154044|NCT01348997|cancer
1154045|NCT01348997|cancer survivors
1154046|NCT01348997|internet
1154047|NCT01348997|depression
1154048|NCT01348997|anxiety
1154049|NCT01348984|postoperative
1154050|NCT01348984|pain score
1154051|NCT01348984|morphine consumption
1154052|NCT01348971|sodium nitrate
1154053|NCT01348971|coronary artery bypass surgery
1154054|NCT01348971|ischemia-reperfusion
1154055|NCT01348971|myocardial injury
1154059|NCT01348945|Partial tear ACL
1154060|NCT01348945|Stump preserved ACL surgery
1154061|NCT01348932|asthma
1154062|NCT01348932|Chitinase 3-like 1 (CHI3L1)
1154063|NCT01348932|YKL-40
1154064|NCT01348932|single nucleotide polymorphism(SNP)
1154065|NCT01348932|Real time PCR
1154066|NCT01348932|gene
1154067|NCT01348919|Cancer
1154068|NCT01348919|Multiple myeloma
1154069|NCT01348919|CEP-18770
1154070|NCT01348919|Lenalidomide
1154071|NCT01348919|Dexamethasone
1154072|NCT01348906|cardiopulmonary bypass
1154073|NCT01348893|Mental health
1154074|NCT01348893|Education
1154075|NCT01348893|Mind Body Therapies
1154076|NCT01348880|drug-drug interaction
1154077|NCT01348867|Diabetes
1154078|NCT01348867|Structured Care
1154079|NCT01348854|astigmatism
1154080|NCT01348841|community wound care
1154081|NCT01348841|systematic wound team referral
1154082|NCT01348841|Advanced in-home nurse wound training
1154083|NCT01348828|Abdominal Aortic Aneurysm
1154084|NCT01348828|Fenestrated
1154085|NCT01348828|Renal Stent
1154086|NCT01348828|Juxtarenal
1154087|NCT01348828|Pararenal
1154088|NCT01348828|Endologix
1154089|NCT01348828|Renal
1154090|NCT01348802|Knowledge Translation
1154091|NCT01348802|Push-out Evidence
1154092|NCT01348802|Technology-Based Knowledge Translation
1154093|NCT01348802|Pain
1154094|NCT01348802|Interdisciplinary
1154095|NCT01348802|Physician
1154096|NCT01348802|Rehabilitation
1154097|NCT01348802|Nursing
1154098|NCT01348802|Knowledge Uptake
1154099|NCT01348789|Hair removal
1154100|NCT01348789|Hair Clearance
1154101|NCT01348789|Epilation
1154102|NCT01348776|hair reduction
1154103|NCT01348776|hair removal
1154104|NCT01348776|hair clearance
1154105|NCT01348750|PTSD
1154106|NCT01348750|Healing Touch
1154107|NCT01348750|Guided Imagery
1154108|NCT01348750|Military
1154109|NCT01348750|Complementary Medicine
1154110|NCT01348737|Phase 1
1154111|NCT01348737|healthy volunteers
1154112|NCT01348737|double-blind
1154113|NCT01348737|placebo-controlled
1154114|NCT01348737|AZD3839
1154115|NCT01348737|pharmacokinetics
1154116|NCT01348737|Alzheimer's Disease
1154117|NCT01348724|Radioactive carbon
1154118|NCT01348724|Absorption
1154119|NCT01348724|Distribution
1154120|NCT01348724|Metabolism
1154121|NCT01348724|Excretion
1154122|NCT01348724|Healthy Volunteers
1154123|NCT01348711|Pre-eclampsia
1154124|NCT01348698|Adrenal Cancer
1154125|NCT01348698|Pheochromocytoma
1154126|NCT01348698|Functioning Tumor
1154127|NCT01348698|Nonfunctioning Tumor
1154128|NCT01348698|Gene Expression
1154129|NCT01348698|Adrenal Tumor
1154130|NCT01348672|Age related macular degeneration
1154131|NCT01348672|Glaucoma
1154132|NCT01348672|Diabetic retinopathy
1154133|NCT01348672|Retinal oxygen saturation
1154134|NCT01348672|Blood flow
1154135|NCT01348672|Vascular function
1154136|NCT01348672|High resolution imaging
1154137|NCT01348659|Hypertonic saline
1154138|NCT01348659|Extracellular fluid
1154139|NCT01348659|cardiopulmonary bypass
1154140|NCT01348646|Smoking
1154141|NCT01348646|Adolescence
1154142|NCT01348646|Brief intervention
1154143|NCT01348633|Doppler SD-OCT Blood Flow Technology
1154144|NCT01348633|Retinal and choroidal blood flow
1154145|NCT01348633|Canon Laser Blood Flowmeter
1154146|NCT01348620|single port cholecystectomy
1154147|NCT01348607|psychosocial effects of cancer and its treatment
1154148|NCT01348607|sleep disorders
1154149|NCT01348607|fatigue
1154150|NCT01348607|childhood craniopharyngioma
1154151|NCT01348594|Vitamin D
1154152|NCT01348594|In vitro Fertilization
1154153|NCT01348581|Adult
1154154|NCT01348581|Aged
1154155|NCT01348581|Aged, 80 and over
1154156|NCT01348581|Bandages
1154157|NCT01348581|Biological Dressings
1154158|NCT01348581|Chronic Disease
1154159|NCT01348581|Collagen
1154160|NCT01348581|Epithelium
1154161|NCT01348581|Extracellular Matrix
1154162|NCT01348581|Fibroblasts
1154163|NCT01348581|Granulation Tissue
1154164|NCT01348581|Humans
1154165|NCT01348581|Leg Ulcer
1154166|NCT01348581|Middle Aged
1154167|NCT01348581|Prospective Studies
1154168|NCT01348581|Soft Tissue Injuries
1154169|NCT01348581|Treatment Outcome
1154170|NCT01348581|Varicose Ulcer
1154171|NCT01348581|Wound Healing
1154172|NCT01348581|Wounds and Injuries
1154173|NCT01348555|COPD
1154174|NCT01348542|Chronic Insomnia
1154175|NCT01348542|Short Sleep Duration
1154176|NCT01348542|Trazodone
1154177|NCT01348542|Cognitive Behavioral Therapy
1154178|NCT01348542|Efficacy
1154179|NCT01348529|OCD
1154180|NCT01348529|CBT
1154181|NCT01348529|Reducing OCD symptoms
1154182|NCT01348516|HIV
1154183|NCT01348490|PMF
1154184|NCT01348490|PPV-MF
1154185|NCT01348490|PET-MF
1154186|NCT01348477|inguinal
1154187|NCT01348477|hernia
1154188|NCT01348477|pain
1154189|NCT01348477|inguinodynia
1154190|NCT01348477|mesh
1154191|NCT01348464|appendectomy
1154192|NCT01348464|appendicitis
1154193|NCT01348464|laparoscopic surgery
1154194|NCT01348451|Human spinal cord derived neural stem cell transplantation
1154195|NCT01348451|ALS
1154196|NCT01348438|high risk
1154197|NCT01348438|surgical valve replacement
1154198|NCT01348425|PAD
1154202|NCT01348399|Coronary artery disease requiring drug eluting stents
1154203|NCT01348386|Potassium hydroxide.
1154204|NCT01348386|Molluscum Contagiosum
1154205|NCT01348373|drug eluting stents
1154206|NCT01348334|Sling surgery
1154207|NCT01348334|synthetic meshes
1154208|NCT01348334|ultrapromesh®
1154209|NCT01348334|mix mesh
1154210|NCT01348334|incontinence
1154211|NCT01348334|The Ultrapromesh® synthetic sling procedures have lower complications incidence and higher success rates than the other synthetic slings in 3-year follow-up.
1154212|NCT01348308|Late diagnosed HIV-1 infected patients
1154213|NCT01348308|AIDS-defining events
1154214|NCT01348308|Immune restoration
1154215|NCT01348295|Mechanical ventilation
1154216|NCT01348295|Children
1154217|NCT01348295|Neonates
1154218|NCT01348295|Pediatric intensive care
1154219|NCT01348282|Neurocognitive Impairment
1154220|NCT01348282|Controlled Randomized Trial
1154221|NCT01348282|Coadjunctive Treatments
1154222|NCT01348282|Lithium; Rivastigmine
1154223|NCT01348282|Antiretroviral Therapy
1154224|NCT01348282|HIV Infection
1154225|NCT01348269|bone marrow edema
1154226|NCT01348269|Aclasta
1154227|NCT01348256|colorectal carcinoma
1154228|NCT01348256|resectable hepatic metastasis
1154229|NCT01348256|adjuvant treatment
1154230|NCT01348256|dendritic cells
1154231|NCT01348230|Premature prolonged rupture of membranes
1154232|NCT01348230|Premature labor
1154233|NCT01348230|Uromodulin
1154234|NCT01348230|Glycosylation
1154239|NCT01348204|Cystic Fibrosis
1154240|NCT01348191|Thyrotrophin
1154241|NCT01348191|Pregnancy
1154242|NCT01348191|Human myometrium
1154243|NCT01348191|Relaxation
1154244|NCT01348191|Contractility
1154245|NCT01348152|Gastric Emptying
1154246|NCT01348139|Asthma
1154247|NCT01348139|patients
1154248|NCT01348139|lung function
1154249|NCT01348126|Advanced non-small cell lung cancer
1154250|NCT01348126|NSCLC
1154251|NCT01348126|Lung cancer
1154252|NCT01348113|Alcohol Use Disorders Identification Test
1154253|NCT01348113|alcohol dependence
1154254|NCT01348113|Alcohol problem
1154255|NCT01348100|Schizophrenia
1154256|NCT01348100|Iloperidone
1154257|NCT01348100|Depot
1154258|NCT01348100|Injection
1154259|NCT01348087|Fragile X Syndrome
1154260|NCT01348087|Martin-Bell Syndrome
1154261|NCT01348087|Genetic Diseases
1154262|NCT01348087|X-Linked
1154263|NCT01348087|Escalante's syndrome
1154264|NCT01348074|warfarin
1154265|NCT01348074|surgery
1154266|NCT01348074|management
1154267|NCT01348074|thromboembolism
1154268|NCT01348074|bleeding
1154269|NCT01348061|Alzheimers Disease
1154270|NCT01348061|Progressive Supranuclear Palsy
1154271|NCT01348061|CSF
1154272|NCT01348061|Cerebrospinal Fluid
1154273|NCT01348061|Biomarker
1154274|NCT01348061|Heavy Water
1154275|NCT01348061|Cargo proteins
1154276|NCT01348048|palliative care
1154277|NCT01348048|end-of-life care
1154278|NCT01348048|randomized clinical trial
1154279|NCT01348048|quality of life
1154280|NCT01348048|needs assessment
1154281|NCT01348048|patient satisfaction
1154282|NCT01348048|cost-effectiveness
1154283|NCT01348048|Screening
1154284|NCT01348035|Autosomal Dominant Polycystic Kidney Disease.
1154285|NCT01348035|Arginine vasopressin
1154286|NCT01348035|Total Kidney Volume
1154287|NCT01348035|Glomerular Filtration Rate
1154288|NCT01348009|Gastric cancer
1154289|NCT01348009|First-line therapy
1154290|NCT01348009|Tesetaxel
1154291|NCT01348009|Taxane
1154292|NCT01348009|Capecitabine
1154293|NCT01348009|Oral fluoropyrimidine
1154294|NCT01348009|Cisplatin
1154295|NCT01348009|Platinum
1154296|NCT01347996|AML
1154297|NCT01347996|Leukemia
1154298|NCT01347996|Acute Myeloid Leukemia
1154299|NCT01347996|Minimal Residual Disease
1154300|NCT01347996|Ceplene
1154301|NCT01347996|Histamine
1154302|NCT01347996|interleukin 2
1154303|NCT01347983|RA
1154304|NCT01347970|childhood cancer survivor
1154305|NCT01347970|CHF
1154306|NCT01347970|risk of congestive heart failure
1154307|NCT01347944|MORE
1154308|NCT01347944|Monitoring Revlimid
1154309|NCT01347944|Myelodysplastic Syndrome
1154310|NCT01347944|Transfusion-dependent anemia
1154311|NCT01347944|5q deletion
1154312|NCT01347944|lenalidomide
1154313|NCT01347918|Fluorine MRI, small intestinal transit and motor activity
1154314|NCT01347892|Talar injury
1154315|NCT01347892|ankle
1154316|NCT01347892|lesion
1154317|NCT01347892|defect
1154318|NCT01347892|cartilage repair
1154319|NCT01347879|Acne vulgaris
1154320|NCT01347879|PDT
1154321|NCT01347866|Advanced metastatic cancer (solid tumors)
1154322|NCT01347866|PI3K
1154323|NCT01347866|mTOR
1154324|NCT01347866|MEK
1154325|NCT01347840|Obesity Gastric Bypass Roux en Y
1154326|NCT01347827|Coronary artery bypass surgery
1154327|NCT01347827|Oximetry
1154328|NCT01347827|Brain metabolism
1154329|NCT01347814|Domperidone
1154330|NCT01347814|gastric emptying
1154331|NCT01347814|obesity
1154332|NCT01347814|diabetes mellitus
1154333|NCT01347814|Domperidone/pharmacology
1154334|NCT01347814|Pharmacologic Actions
1154335|NCT01347814|Physiological Effects of Drugs
1154336|NCT01347814|Gastrointestinal Agents
1154337|NCT01347814|Humans
1154338|NCT01347801|GLP-1
1154339|NCT01347801|Inflammation
1154340|NCT01347801|Glucose
1154341|NCT01347788|Prostate cancer
1154342|NCT01347788|Castration Resistant
1154343|NCT01347788|Bone Metastases
1154344|NCT01347775|Renal failure
1154345|NCT01347775|Respiratory muscles
1154346|NCT01347775|Resistance training
1154347|NCT01347762|cannabis dependence
1154348|NCT01347762|marijuana dependence
1154349|NCT01347762|cannabis use disorders
1154350|NCT01347762|cannabis withdrawal
1154351|NCT01347762|nabilone
1154352|NCT01347749|Meditation
1154353|NCT01347749|Mindfulness
1154354|NCT01347749|Compassion
1154355|NCT01347749|Group Psychotherapy
1154356|NCT01347749|Emotional Regulation
1154357|NCT01347749|fMRI
1154358|NCT01347710|Coronary Artery Disease.
1154359|NCT01347710|Positron Emission Tomography Myocardial Perfusion Imaging.
1154360|NCT01347710|Single Positron Emission Computed Tomography.
1154361|NCT01347710|Flurpiridaz F18 Injection.
1154362|NCT01347697|rectal neoplasms
1154363|NCT01347697|reconstructive surgical procedure
1154364|NCT01347697|bioprosthesis
1154365|NCT01347697|surgical flaps
1154366|NCT01347697|locomotion
1154367|NCT01347697|lesser pelvis
1154368|NCT01347684|headache
1154369|NCT01347684|elavil
1154370|NCT01347684|splints
1154371|NCT01347684|physical therapy
1154372|NCT01347684|behavioral therapy
1154373|NCT01347671|analgesia
1154374|NCT01347671|analgesics
1154375|NCT01347671|pain
1154376|NCT01347671|chronic pain
1154377|NCT01347671|neuropathic pain
1154378|NCT01347658|etravirine
1154379|NCT01347658|Echinacea purpurea
1154380|NCT01347658|interaction
1154381|NCT01347645|locally advanced
1154382|NCT01347645|metastatic colon
1154383|NCT01347645|rectal cancer
1154384|NCT01347632|Bacterial Vaginosis
1154385|NCT01347632|Vaginal discharge
1154386|NCT01347632|Vaginal infections
1154387|NCT01347619|Comparative Effectiveness Research Summary Guide (CERSG)
1154388|NCT01347619|anti-psychotic use
1154389|NCT01347619|Nursing Home
1154390|NCT01347619|Long-term care
1154391|NCT01347619|Qualitative assessment of influences on CERSG adoption in NH
1154392|NCT01347619|Development of toolkit of CERSG-based products for NHs
1154393|NCT01347619|Evaluation of 3 implementation strategies of the toolkit
1154394|NCT01347606|thyroid
1154395|NCT01347606|secure
1154396|NCT01347606|surgery
1154397|NCT01347606|methylene
1154398|NCT01347606|blue
1154399|NCT01347593|ceftizoxime
1154400|NCT01347593|Cesarean
1154401|NCT01347593|post caesarean febrile morbidity
1154402|NCT01347580|Heart attack
1154403|NCT01347580|heart disease
1154404|NCT01347580|cardiovascular disease
1154405|NCT01347580|stroke
1154406|NCT01347580|reperfusion
1154407|NCT01347580|pre hospital settings
1154408|NCT01347580|ticagrelor
1154409|NCT01347580|Percutaneous Coronary Intervention
1154410|NCT01347567|Fingerstick BNP test
1154411|NCT01347567|Home Health Management System
1154412|NCT01347567|Acute Decompensated Heart Failure
1154413|NCT01347567|Hospital Readmission
1154414|NCT01347567|Prevention
1154415|NCT01347554|drug-eluting stent
1154416|NCT01347554|everolimus
1154417|NCT01347554|zotarolimus
1154418|NCT01347554|myocardial ischemia
1154419|NCT01347554|cardiovascular diseases
1154420|NCT01347554|MACE
1154421|NCT01347554|safety
1154422|NCT01347541|PTSD
1154423|NCT01347528|Medication adherence
1154424|NCT01347528|Heart failure
1154425|NCT01347528|Telemonitoring
1154426|NCT01347528|Determinants of adherence
1154427|NCT01347515|Phenol-enriched olive oil
1154428|NCT01347515|bioavailability
1154429|NCT01347515|bioactivity
1154430|NCT01347489|gender
1154431|NCT01347476|prostate-specific antigen
1154432|NCT01347476|radical prostatectomy
1154433|NCT01347450|Flavonoids
1154434|NCT01347450|cacao
1154435|NCT01347450|lipid peroxidation
1154436|NCT01347450|plasma
1154437|NCT01347437|HIV
1154438|NCT01347437|antiretroviral medication
1154439|NCT01347437|adherence
1154440|NCT01347437|adolescent
1154441|NCT01347424|NSCLC
1154442|NCT01347424|NPC
1154443|NCT01347398|Sleep apnoea
1154444|NCT01347398|Diagnosis
1154445|NCT01347398|Blood pressure
1154446|NCT01347398|Body mass index
1154447|NCT01347398|Breath analysis
1154448|NCT01347385|Fibroids
1154449|NCT01347385|Laparoscopic myomectomy
1154450|NCT01347385|Barbed suture
1154451|NCT01347372|peer support
1154452|NCT01347372|peer mentoring
1154453|NCT01347372|peer counselling
1154454|NCT01347372|arthritis
1154455|NCT01347372|chronic disease
1154456|NCT01347372|inflammatory arthritis
1154457|NCT01347372|early inflammatory arthritis
1154458|NCT01347372|rheumatoid arthritis
1154459|NCT01347359|Peer support
1154460|NCT01347359|Peer mentoring
1154461|NCT01347359|Peer counselling
1154462|NCT01347359|Arthritis
1154463|NCT01347359|Inflammatory arthritis
1154464|NCT01347359|Early inflammatory arthritis
1154465|NCT01347359|Rheumatoid arthritis
1154466|NCT01347359|Chronic disease
1154467|NCT01347346|Wiskott-Aldrich Syndrome
1154468|NCT01347346|Primary immune deficiency
1154469|NCT01347346|ex vivo gene therapy
1154470|NCT01347346|hematopoietic stem cells
1154471|NCT01347333|liver metastases
1154472|NCT01347333|stereotactic radiosurgery
1154473|NCT01347320|Prostate cancer
1154474|NCT01347320|preoperative staging
1154475|NCT01347320|MRI
1154476|NCT01347320|Free surgical margins
1154477|NCT01347307|stereotactic radiotherapy
1154478|NCT01347307|spinal metastases
1154479|NCT01347307|vertebral metastases
1154480|NCT01347307|benign spinal tumors
1154481|NCT01347281|Cancer of the Head and Neck
1154482|NCT01347281|[18F]HX4
1154483|NCT01347281|hypoxia
1154484|NCT01347281|PET
1154485|NCT01347281|phase II trial
1154486|NCT01347268|coasting
1154487|NCT01347268|withdrawing GnRH agonist
1154488|NCT01347268|GnRH antagonist
1154489|NCT01347268|IVF
1154490|NCT01347242|Wiskott-Aldrich Syndrome
1154491|NCT01347242|Primary immune deficiency
1154492|NCT01347242|ex vivo gene therapy
1154493|NCT01347242|hematopoietic stem cells
1154494|NCT01347229|Glaucoma
1154495|NCT01347229|Triggerfish
1154496|NCT01347229|body position
1154497|NCT01347216|Drug treatment
1154498|NCT01347216|Treatment pathways
1154499|NCT01347216|Clinical routine
1154500|NCT01347216|Registry
1154501|NCT01347216|Treatment outcomes
1154502|NCT01347216|Endothelin receptor antagonist
1154503|NCT01347216|Phosphodiesterase-V inhibitor
1154504|NCT01347216|Prostanoid
1154505|NCT01347216|Sildenafil
1154506|NCT01347216|Bosentan
1154507|NCT01347216|Macitentan
1154508|NCT01347216|Sitaxentan
1154509|NCT01347216|Ambrisentan
1154510|NCT01347216|Imatinib
1154511|NCT01347216|Epoprostenol
1154512|NCT01347216|Treprostinil
1154513|NCT01347216|Iloprost
1154514|NCT01347216|Infusion pump
1154515|NCT01347216|Riociguat
1154516|NCT01347216|soluble guanylate cyclase stimulator
1154517|NCT01347216|Quality of life
1154518|NCT01347216|Patient-related outcomes
1154519|NCT01347216|Economic model
1154520|NCT01347216|Adverse event
1154521|NCT01347216|Safety
1154522|NCT01347216|Combination therapy
1154523|NCT01347216|Internet
1154524|NCT01347216|Europe
1154525|NCT01347216|Australia
1154526|NCT01347216|Japan
1154527|NCT01347216|Eisenmenger
1154528|NCT01347216|Adults
1154529|NCT01347216|Children
1154530|NCT01347216|Selexipag
1154531|NCT01347203|phase I
1154532|NCT01347203|healthy volunteers
1154533|NCT01347203|crossover study
1154534|NCT01347203|pharmacokinetics
1154535|NCT01347203|pharmacodynamics
1154536|NCT01347190|Cystic Fibrosis
1154537|NCT01347164|bisexual
1154538|NCT01347164|HIV prevention
1154539|NCT01347151|Glide scope
1154540|NCT01347151|Pentax
1154541|NCT01347151|C spine movement
1154542|NCT01347138|Screening
1154543|NCT01347138|depression
1154544|NCT01347138|case management
1154545|NCT01347125|DHF (diastolic heart failure)
1154546|NCT01347125|HFNEF (heart failure with normal ejection fraction
1154547|NCT01347112|smoking
1154548|NCT01347112|tobacco dependence
1154549|NCT01347112|alcohol dependence
1154550|NCT01347099|CBT
1154551|NCT01347099|OCD
1154552|NCT01347099|Internet
1154553|NCT01347099|Reduce symptom burden
1154554|NCT01347073|Urea Cycle Disorder
1154555|NCT01347073|UCD
1154556|NCT01347073|GT4P
1154557|NCT01347073|Buphenyl
1154558|NCT01347073|hyperammonemia
1154559|NCT01347073|sodium phenylbutyrate
1154560|NCT01347060|Asthma
1154561|NCT01347060|treatment
1154562|NCT01347060|Advair and inhaled corticosteroids
1154563|NCT01347060|Medicare
1154564|NCT01347060|Outcomes
1154565|NCT01347060|costs
1154566|NCT01347047|Amyloidosis
1154567|NCT01347047|Known or Suspected
1154568|NCT01347034|radiation
1154569|NCT01347034|neoadjuvant
1154570|NCT01347034|intratumoral
1154571|NCT01347034|autologous
1154572|NCT01347034|dendritic cells
1154573|NCT01347021|vaginal colpopexy sacrospinous
1154574|NCT01347021|vaginal colpopexy uterosacral
1154575|NCT01347008|Sildenafil
1154576|NCT01347008|Endothelial Progenitor Cells
1154577|NCT01347008|Laser Doppler Imaging
1154578|NCT01346982|Darunavir
1154579|NCT01346982|Silimarine
1154580|NCT01346982|interaction
1154581|NCT01346969|Skin scarring
1154582|NCT01346969|cicatrix
1154583|NCT01346969|breast scar
1154584|NCT01346956|Cigarette
1154585|NCT01346956|Smoking
1154586|NCT01346956|Cardiovascular Effects
1154587|NCT01346956|2D Echocardiography
1154588|NCT01346956|Doppler
1154589|NCT01346943|Abdominal Aortic Aneurysms, AAA
1154590|NCT01346930|Idiopathic pulmonary fibrosis
1154591|NCT01346930|IPF
1154592|NCT01346930|pulmonary fibrosis
1154593|NCT01346917|Colorectal cancer
1154594|NCT01346917|Laparoscopic surgery
1154595|NCT01346917|Postoperative ileus
1154596|NCT01346917|Lidocaine
1154597|NCT01346917|Early oral feeding
1154598|NCT01346878|Ultra deep sequencing
1154599|NCT01346878|Virological failure
1154600|NCT01346878|Salvage antiretroviral therapy
1154601|NCT01346865|triple anti-platelet therapy
1154602|NCT01346865|dual antiplatelet therapy
1154603|NCT01346865|DES
1154604|NCT01346865|Coronary Artery Disease
1154605|NCT01346852|pediatrics
1154606|NCT01346852|Medicaid
1154607|NCT01346852|asthma
1154608|NCT01346852|outcomes
1154609|NCT01346852|asthma medication ratio
1154610|NCT01346839|Diagnostic delay
1154611|NCT01346839|Prevention
1154612|NCT01346839|Diagnostic errors
1154613|NCT01346826|Crohn's disease
1154614|NCT01346826|Ulcerative colitis
1154615|NCT01346826|Infliximab
1154616|NCT01346826|Infusion reaction
1154617|NCT01346813|Newborns
1154618|NCT01346813|Premature
1154619|NCT01346813|Pain
1154620|NCT01346813|Pain assessment
1154621|NCT01346813|Painful Procedures
1154622|NCT01346813|Stressful Procedures
1154623|NCT01346813|Endotracheal Intubation
1154624|NCT01346813|Analgesia
1154625|NCT01346813|Sedation
1154626|NCT01346813|Longterm effects of pain
1154627|NCT01346813|Epidemiology
1154628|NCT01346787|carfilzomib
1154629|NCT01346787|dexamethasone
1154630|NCT01346787|cyclophosphamide
1154631|NCT01346787|multiple myeloma
1154632|NCT01346787|newly diagnosed
1154633|NCT01346774|cystitis
1154634|NCT01346774|pyelonephritis
1154635|NCT01346774|bladder infection
1154636|NCT01346774|kidney infection
1154637|NCT01346761|Genetic Counseling
1154638|NCT01346761|Genetic Counseling Interventions
1154639|NCT01346761|Genetic Testing
1154640|NCT01346761|BRCA1 gene
1154641|NCT01346761|BRCA2 gene
1154642|NCT01346761|Risk Communication
1154643|NCT01346748|vasospasm prevention
1154644|NCT01346735|Ventilator associated pneumonia
1154645|NCT01346735|Catheter related blood stream infection
1154646|NCT01346735|Catheter associated urinary tract infection
1154647|NCT01346735|ICU-related infections (VAP, CAUTI and CRBSI)
1154648|NCT01346735|India
1154649|NCT01346709|Operative surgical procedures
1154650|NCT01346709|Postoperative pulmonary complications (PPC)
1154651|NCT01346709|Epidemiological Study
1154652|NCT01346709|ARISCAT score
1154653|NCT01346709|Risk Score
1154654|NCT01346709|Europe
1154655|NCT01346709|PERISCOPE
1154656|NCT01346709|observational study
1154657|NCT01346709|Mild respiratory failure
1154658|NCT01346709|Severe respiratory failure
1154659|NCT01346709|acute lung injury (ALI)
1154660|NCT01346709|Acute respiratory distress syndrome (ARDS)
1154661|NCT01346709|Suspected pulmonary infection
1154662|NCT01346709|Pulmonary infiltrate
1154663|NCT01346709|Pleural effusion
1154664|NCT01346709|Atelectasis
1154665|NCT01346709|Pneumothorax
1154666|NCT01346709|Bronchospasm
1154667|NCT01346709|Aspiration Pneumonitis
1154668|NCT01346709|Cardiopulmonary edema
1154669|NCT01346709|Prospective Evaluation
1154670|NCT01346709|nonobstetric in-hospital surgical procedure
1154671|NCT01346709|general or regional anaesthesia
1154672|NCT01346709|continued 7-day period recruitment
1154673|NCT01346670|Red yeast rice
1154674|NCT01346670|Lovastatin
1154675|NCT01346670|Bioavailability
1154676|NCT01346657|Nifidipine
1154677|NCT01346657|red yeast rice
1154678|NCT01346657|drug-drug interaction
1154679|NCT01346644|Probiotic
1154680|NCT01346644|infant nutrition
1154681|NCT01346644|safety
1154682|NCT01346644|infections
1154683|NCT01346618|bone age
1154684|NCT01346618|children
1154685|NCT01346618|x-ray
1154686|NCT01346618|ultrasound
1154687|NCT01346618|ultrasound based method
1154688|NCT01346618|safe
1154689|NCT01346618|valid
1154690|NCT01346618|reproducable
1154691|NCT01346605|Cardiac CT, heart disease
1154692|NCT01346592|Adjuvanted Trivalent Subunit Influenza Vaccine
1154693|NCT01346592|vaccine
1154694|NCT01346592|influenza
1154695|NCT01346592|adjuvant
1154696|NCT01346592|MF-59
1154697|NCT01346592|pediatric
1154698|NCT01346579|stage IA breast cancer
1154699|NCT01346579|stage IB breast cancer
1154700|NCT01346579|estrogen receptor-positive breast cancer
1154701|NCT01346566|Cionni Ring
1154702|NCT01346566|In-the-bag IOL
1154703|NCT01346566|Subluxated lenses
1154704|NCT01346566|Intraoperative Performance
1154705|NCT01346566|Postoperative Outcome
1154706|NCT01346553|Chronic Venous Insufficiency (CVI)
1154707|NCT01346527|diabetes
1154708|NCT01346527|pregnancy
1154709|NCT01346527|left ventricular dysfunction
1154710|NCT01346527|neonatal
1154711|NCT01346527|lipid
1154712|NCT01346527|lipotoxicity
1154713|NCT01346527|neurodevelopment
1154714|NCT01346514|Homeless Persons
1154715|NCT01346514|Housing
1154716|NCT01346514|Case Management
1154717|NCT01346514|Veterans
1154718|NCT01346514|Substance Related Disorders
1154719|NCT01346514|Mental Disorders
1154720|NCT01346514|Social Adjustment
1154721|NCT01346501|Rheumatoid arthritis
1154722|NCT01346488|Rheumatoid arthritis
1154723|NCT01346449|Obesity
1154724|NCT01346423|Sick leave
1154725|NCT01346423|musculoskeletal pain
1154726|NCT01346423|return to work
1154727|NCT01346423|multidisciplinary intervention
1154728|NCT01346423|randomised controlled trial
1154729|NCT01346410|pancreatic cancer
1154730|NCT01346397|rejection
1154731|NCT01346397|survival
1154732|NCT01346397|alemtuzumab
1154733|NCT01346397|cyclosporine
1154734|NCT01346397|tacrolimus
1154735|NCT01346384|intracuff pressure
1154736|NCT01346384|laryngeal tube
1154737|NCT01346384|nitrous oxide
1154738|NCT01346371|Allergic
1154739|NCT01346371|conjunctivitis
1154740|NCT01346371|Allergic conjunctivitis
1154741|NCT01346358|Advanced Solid Tumors
1154742|NCT01346345|Recession
1154743|NCT01346319|dose escalating
1154744|NCT01346293|Tetanus
1154745|NCT01346293|Diphtheria
1154746|NCT01346293|Pertussis
1154747|NCT01346293|DTap-IPV
1154748|NCT01346293|DAPTACEL®
1154749|NCT01346293|VARIVAX®
1154750|NCT01346280|Adherence to Evidence-Based Guidelines
1154751|NCT01346280|Multidisciplinary Care
1154752|NCT01346280|Patient Experiences
1154753|NCT01346280|Quality of Care Outcomes
1154754|NCT01346267|nausea and vomiting
1154755|NCT01346267|unspecified childhood solid tumor
1154756|NCT01346267|childhood central nervous system embryonal tumor
1154757|NCT01346267|childhood central nervous system germ cell tumor
1154758|NCT01346267|childhood central nervous system germinoma
1154759|NCT01346267|childhood central nervous system mixed germ cell tumor
1154760|NCT01346267|childhood central nervous system teratoma
1154761|NCT01346267|childhood central nervous system yolk sac tumor
1154762|NCT01346267|childhood mixed glioma
1154763|NCT01346267|childhood oligodendroglioma
1154764|NCT01346267|untreated childhood brain stem glioma
1154765|NCT01346267|untreated childhood visual pathway and hypothalamic glioma
1154766|NCT01346267|untreated childhood visual pathway glioma
1154767|NCT01346267|childhood high-grade cerebellar astrocytoma
1154768|NCT01346267|childhood high-grade cerebral astrocytoma
1154769|NCT01346267|childhood low-grade cerebellar astrocytoma
1154770|NCT01346267|childhood low-grade cerebral astrocytoma
1154771|NCT01346267|untreated childhood cerebellar astrocytoma
1154772|NCT01346267|untreated childhood cerebral astrocytoma
1154773|NCT01346267|untreated childhood subependymal giant cell astrocytoma
1154774|NCT01346267|childhood ependymoblastoma
1154775|NCT01346267|untreated childhood medulloblastoma
1154776|NCT01346267|untreated childhood pineoblastoma
1154777|NCT01346267|childhood choroid plexus tumor
1154778|NCT01346267|childhood craniopharyngioma
1154779|NCT01346267|childhood supratentorial ependymoma
1154780|NCT01346267|childhood supratentorial primitive neuroectodermal tumor
1154781|NCT01346267|childhood medulloepithelioma
1154782|NCT01346267|childhood infratentorial ependymoma
1154783|NCT01346267|newly diagnosed childhood ependymoma
1154784|NCT01346267|childhood meningioma
1154785|NCT01346254|after
1154786|NCT01346241|Panic
1154787|NCT01346241|Anxiety
1154788|NCT01346228|Panic
1154789|NCT01346228|Panic Disorder
1154790|NCT01346228|Anxiety
1154791|NCT01346215|heparin
1154792|NCT01346215|renal insufficiency, chronic
1154793|NCT01346215|extracorporeal dialysis
1154794|NCT01346215|fibrinolytic agents
1154795|NCT01346215|anticoagulants
1154796|NCT01346215|aPTT
1154797|NCT01346202|multi-modal pain therapy, chronic pain
1154798|NCT01346189|Cardiovascular Disease
1154799|NCT01346163|Schizophrenia
1154800|NCT01346163|Cognitive Impairment
1154801|NCT01346163|Electrophysiology
1154802|NCT01346163|H3 receptor antagonist
1154803|NCT01346137|ovulation
1154804|NCT01346137|unruptured luteinized follicle
1154805|NCT01346137|meloxicam
1154806|NCT01346124|radiation
1154807|NCT01346124|IMRT
1154808|NCT01346124|IMPT
1154809|NCT01346098|diabetes
1154810|NCT01346098|islet transplantation
1154811|NCT01346098|pancreas
1154812|NCT01346098|pancreatectomy
1154813|NCT01346085|islet transplantation
1154814|NCT01346085|brittle diabetes
1154815|NCT01346085|type 1 diabetes
1154816|NCT01346072|tolvaptan
1154817|NCT01346072|copeptin
1154818|NCT01346072|heart failure
1154819|NCT01346072|vasopressin antagonist
1154820|NCT01346059|Clostridium
1154821|NCT01346059|Colitis
1154822|NCT01346059|Intracolonic vancomycin
1154823|NCT01346059|psuedomembranous colitis
1154824|NCT01346046|Type 2 Diabetes
1154825|NCT01346046|Adults 18 years and older
1154826|NCT01346046|Taking Control of Your Diabetes Health Fair
1154827|NCT01346033|Type 2 Diabetes
1154828|NCT01346033|Adults 18 years and older
1154829|NCT01346033|Taking Control of Your Diabetes Health Fair
1154830|NCT01345968|anemia
1154831|NCT01345968|transfusion
1154832|NCT01345968|intravenous ferric carboxymaltose
1154833|NCT01345929|cUTI
1154834|NCT01345890|swallowing
1154835|NCT01345890|stroke
1154836|NCT01345890|aspiration
1154837|NCT01345890|human
1154838|NCT01345890|electrical stimulation
1154839|NCT01345890|post stroke dysphagia
1154840|NCT01345877|burn injury
1154841|NCT01345877|cold pressor test
1154842|NCT01345877|gender
1154843|NCT01345877|pain
1154844|NCT01345877|pain sensitivity
1154845|NCT01345877|pain prediction
1154846|NCT01345877|psychometrics
1154847|NCT01345877|quantitative sensory testing
1154848|NCT01345864|attention cognition memory problem solving scopolamine challenge
1154849|NCT01345825|osteoarthrosis
1154850|NCT01345825|unicompartmental knee replacement
1154851|NCT01345825|knee
1154852|NCT01345825|resistance training
1154853|NCT01345825|Muscle power
1154854|NCT01345825|gait analysis
1154855|NCT01345825|gait
1154856|NCT01345825|physiotherapy
1154857|NCT01345825|Gyro sensor
1154858|NCT01345812|ART
1154859|NCT01345812|IVF
1154860|NCT01345812|Timelapse
1154861|NCT01345799|Crohn's Disease Activity Index
1154862|NCT01345799|Crohn's Disease
1154863|NCT01345799|Inflammatory Bowel Disease
1154864|NCT01345760|Basal Cell Carcinoma
1154865|NCT01345760|Squamous Cell Carcinoma
1154866|NCT01345760|Actinic Keratosis
1154867|NCT01345760|microRNA
1154868|NCT01345760|Dicer
1154869|NCT01345760|Drosha
1154870|NCT01345760|RISC
1154871|NCT01345760|microprocessor complex
1154872|NCT01345760|Argonaute
1154873|NCT01345760|DGCR8
1154874|NCT01345760|TARBP
1154875|NCT01345747|laryngeal tube suction
1154876|NCT01345747|gynecology
1154877|NCT01345747|laparoscopic surgery
1154878|NCT01345721|Meningococcal
1154879|NCT01345721|ACWY
1154880|NCT01345721|Conjugate Vaccine
1154881|NCT01345721|Meningitis
1154882|NCT01345721|Toddlers
1154883|NCT01345721|Children
1154884|NCT01345721|Persistence
1154885|NCT01345721|Boost
1154886|NCT01345708|Low dose rituximab
1154887|NCT01345708|WAIHA
1154888|NCT01345708|CHD
1154889|NCT01345695|Childhood diarrhea
1154890|NCT01345695|childhood pneumonia
1154891|NCT01345695|telemedicine
1154892|NCT01345695|cluster
1154893|NCT01345695|treatment-control trial
1154894|NCT01345656|Chronic Heart Failure
1154895|NCT01345643|Transfusion
1154896|NCT01345643|Hemoglobin level
1154897|NCT01345630|Double-blind
1154898|NCT01345630|comparative
1154899|NCT01345630|trial
1154900|NCT01345630|maraviroc
1154901|NCT01345630|versus
1154902|NCT01345630|emtricitabine/tenofovir
1154903|NCT01345630|both with darunavir/ritonavir
1154904|NCT01345630|antiretroviral-naive
1154905|NCT01345630|Ccr5 tropic
1154906|NCT01345630|Hiv 1
1154907|NCT01345630|patients.
1154908|NCT01345591|BTI
1154909|NCT01345591|Craniomaxillofacial (CMF) Battle-injured (BI)
1154910|NCT01345591|Facial Trauma
1154911|NCT01345591|Fat Grafts
1154912|NCT01345591|Autogenous Fat Transfers (AFT)
1154913|NCT01345591|Wounded warriors
1154914|NCT01345578|Urea Cycle Disorders
1154915|NCT01345578|Carbamoyl-Phosphate Synthase I Deficiency Disease
1154916|NCT01345578|Citrullinemia
1154917|NCT01345578|Ornithine Carbamoyltransferase Deficiency Disease
1154918|NCT01345578|Crigler-Najjar Syndrome
1154919|NCT01345565|fulminant hepatic failure
1154920|NCT01345552|Oligo mets
1154921|NCT01345552|Oligometastatic disease
1154922|NCT01345539|Oligo mets
1154923|NCT01345539|Oligometastatic disease
1154924|NCT01345513|Genomic Analysis
1154925|NCT01345513|Sequencing
1154926|NCT01345513|Genetic
1154927|NCT01345513|Biopsy
1154928|NCT01345513|Solid tumors
1154929|NCT01345500|Overweight
1154930|NCT01345500|Obese
1154931|NCT01345500|Type 2 Diabetic
1154932|NCT01345500|Diabetes
1154933|NCT01345500|Weight loss
1154934|NCT01345500|Physical activity
1154935|NCT01345500|Diet
1154936|NCT01345500|Prepackaged meals
1154937|NCT01345487|appetite
1154938|NCT01345487|protein
1154939|NCT01345487|legumes
1154940|NCT01345487|meat
1154941|NCT01345474|noise-induced hearing loss
1154942|NCT01345474|hearing loss
1154943|NCT01345474|tinnitus
1154944|NCT01345474|weapons training
1154945|NCT01345474|hearing protection
1154946|NCT01345474|impulse noise
1154947|NCT01345448|Glaucoma
1154948|NCT01345448|Brimonidine
1154949|NCT01345448|Transdermal
1154950|NCT01345435|telemonitoring
1154951|NCT01345435|usual care
1154952|NCT01345435|telemedicine
1154953|NCT01345435|telehealth
1154954|NCT01345435|home care
1154955|NCT01345435|Health Care Quality
1154956|NCT01345435|Access
1154957|NCT01345435|Evaluation
1154958|NCT01345409|Musculoskeletal pain
1154959|NCT01345409|Chronic pain
1154960|NCT01345409|Acupuncture
1154961|NCT01345409|Chiropractic
1154962|NCT01345396|Asthma
1154963|NCT01345396|Health education
1154964|NCT01345396|Pregnancy
1154965|NCT01345383|smoking
1154966|NCT01345383|bronchoscopy
1154967|NCT01345383|cough
1154968|NCT01345370|Glioblastoma
1154969|NCT01345357|Solid tumors
1154970|NCT01345357|mantle cell lymphoma
1154971|NCT01345357|Gemcitabine
1154972|NCT01345357|Cisplatin
1154973|NCT01345357|Cancer
1154974|NCT01345357|Neoplasms
1154975|NCT01345357|Antineoplastic agents
1154976|NCT01345318|Crohn's Disease
1154977|NCT01345318|safety
1154978|NCT01345318|efficacy
1154979|NCT01345318|pharmacokinetics
1154980|NCT01345318|pharmacodynamics
1154981|NCT01345318|Crohn's Disease Activity Index (CDAI)
1154982|NCT01345305|Sturge-Weber Syndrome
1154983|NCT01345305|Biomarkers
1154984|NCT01345305|Quantitative EEG
1154985|NCT01345305|Transcranial Doppler Ultrasound
1154986|NCT01345305|Medical Rehabilitation Scales
1154987|NCT01345305|Optical Coherence Tomography
1154992|NCT01345253|SLEDAI
1154993|NCT01345253|Asia
1154994|NCT01345253|placebo
1154995|NCT01345253|BLys
1154996|NCT01345253|PGA
1154997|NCT01345253|BILAG
1154998|NCT01345253|systemic lupus erythematosus
1154999|NCT01345253|SELENA
1155000|NCT01345253|Lupus
1155001|NCT01345253|SRI
1155002|NCT01345253|efficacy
1155003|NCT01345253|B cell
1155004|NCT01345253|SLE Flare Index
1155005|NCT01345253|belimumab
1155006|NCT01345253|safety
1155007|NCT01345253|phase III
1155008|NCT01345253|B lymphocyte
1155009|NCT01345240|Africa
1155010|NCT01345240|Plasmodium falciparum
1155011|NCT01345240|Malaria vaccine
1155012|NCT01345240|hepatitis B
1155013|NCT01345240|EPI
1155014|NCT01345227|Type 1 diabetes
1155015|NCT01345227|islet transplantation
1155016|NCT01345227|autotransplantation
1155017|NCT01345214|ONO-7746
1155018|NCT01345214|Chemotherapy Induced Thrombocytopenia
1155019|NCT01345214|Thrombocytopenia
1155020|NCT01345201|Phase 1
1155021|NCT01345201|dose escalation
1155022|NCT01345201|histologically confirmed
1155023|NCT01345201|malignancy metastatic
1155024|NCT01345175|rectal
1155025|NCT01345175|colon
1155026|NCT01345175|PLACEBO
1155027|NCT01345175|RIFAXIMIN
1155028|NCT01345175|metronidazole
1155029|NCT01345175|11-045
1155030|NCT01345162|Herniotomy
1155031|NCT01345149|Obesity
1155032|NCT01345149|Pregnancy
1155033|NCT01345149|Intervention
1155034|NCT01345149|Diet
1155035|NCT01345149|Physical activity
1155036|NCT01345136|Neurofibromatosis Type 2
1155037|NCT01345136|Vestibular schwannoma
1155038|NCT01345136|Hearing
1155039|NCT01345110|dementia
1155040|NCT01345110|mild cognitive impairment
1155041|NCT01345110|prevalence
1155042|NCT01345110|incidence
1155043|NCT01345110|elderly
1155044|NCT01345110|longitudinal study
1155045|NCT01345110|population study
1155046|NCT01345097|short, metaphyseal-fitting femoral stem
1155047|NCT01345097|cementless anatomical femoral stem
1155048|NCT01345097|young patient
1155049|NCT01345097|elderly patient
1155050|NCT01345071|Rheumatoid Arthritis
1155051|NCT01345071|Pregnancy
1155052|NCT01345071|Anti-TNF
1155053|NCT01345071|Preconceptional counselling
1155054|NCT01345071|Disease activity
1155055|NCT01345058|Epilepsy
1155056|NCT01345058|antiepileptic drug
1155057|NCT01345058|polytherapy
1155058|NCT01345045|Diabetic Asymmetric Polyneuropathy
1155059|NCT01345045|Symmetric Diabetic Proximal Motor Neuropathy
1155060|NCT01345045|Diabetic Mononeuropathy Simplex,
1155061|NCT01345045|Diabetic Autonomic Neuropathy,
1155062|NCT01345045|Diabetic Amyotrophy
1155063|NCT01345045|Mononeuropathy
1155064|NCT01345045|Diabetic Neuropathy
1155065|NCT01345045|Asymmetric Diabetic Proximal Motor Neuropathy
1155066|NCT01345045|Diabetic Polyneuropathy
1155067|NCT01345045|Painful
1155068|NCT01345045|Diabetic Mononeuropathy
1155069|NCT01345045|Neuralgia
1155070|NCT01345019|zoledronic acid
1155071|NCT01345019|hematologic malignancies
1155072|NCT01345019|SRE
1155073|NCT01345019|skeletal-related event
1155074|NCT01345019|blood cancer
1155075|NCT01345019|lytic bone lesions
1155076|NCT01345019|bone metastases
1155077|NCT01345019|myeloma
1155078|NCT01345019|fractures
1155079|NCT01345019|spinal cord compression
1155080|NCT01345019|radiation to bone
1155081|NCT01345019|surgery to bone
1155082|NCT01345019|bisphosphonates
1155083|NCT01345019|Neoplasms, Plasma Cell
1155084|NCT01345019|Paraproteinemias
1155085|NCT01345019|Neoplasms
1155086|NCT01345019|Neoplasm Metastasis
1155087|NCT01345019|Bone Neoplasms
1155088|NCT01345019|Bone Marrow Diseases
1155089|NCT01345019|Blood Protein Disorders
1155090|NCT01345019|Hematologic Diseases
1155091|NCT01345019|multiple myeloma
1155092|NCT01345019|denosumab
1155093|NCT01345019|Neoplastic Processes
1155094|NCT01345019|Bone Diseases
1155095|NCT01345019|Diphosphonates
1155096|NCT01345019|Bone Density Conservation Agents
1155097|NCT01345006|juvenile macular dystrophy
1155098|NCT01345006|SMD
1155099|NCT01345006|fundus flavimaculatus
1155100|NCT01344993|Dry AMD
1155101|NCT01344993|Geographic atrophy
1155102|NCT01344941|Vaccine response
1155103|NCT01344941|Human Lymphocytes
1155104|NCT01344915|Patella
1155105|NCT01344915|Knee
1155106|NCT01344915|Brace
1155107|NCT01344876|multiple myeloma [MM]
1155108|NCT01344876|non-Hodgkin lymphoma [NHL]
1155109|NCT01344876|acute myeloid leukemia [AML]
1155110|NCT01344876|acute lymphoid leukemia [ALL]
1155111|NCT01344876|chronic myeloid leukemia [CML]
1155112|NCT01344824|recurrent non-small cell lung cancer
1155113|NCT01344824|stage IIIB non-small cell lung cancer
1155114|NCT01344824|stage IV non-small cell lung cancer
1155115|NCT01344824|adenocarcinoma of the lung
1155116|NCT01344824|bronchoalveolar cell lung cancer
1155117|NCT01344824|large cell lung cancer
1155118|NCT01344811|telemonitoring
1155119|NCT01344811|usual care
1155120|NCT01344811|telehealth
1155121|NCT01344811|home care
1155122|NCT01344811|Health Care Quality
1155123|NCT01344811|Access
1155124|NCT01344811|Evaluation
1155125|NCT01344798|limb girdle muscular dystrophy type 2C
1155126|NCT01344798|gamma-sarcoglycanopathy
1155127|NCT01344798|gene therapy
1155128|NCT01344798|AAV vector
1155129|NCT01344798|neuromuscular disease
1155130|NCT01344798|orphan disease
1155131|NCT01344785|Intertrochanteric Fractures
1155132|NCT01344785|Intramedullary nailing
1155133|NCT01344785|Hip function
1155134|NCT01344785|Pain
1155135|NCT01344772|femoral neck fracture
1155136|NCT01344772|total hip arthroplasty
1155137|NCT01344772|internal fixation
1155138|NCT01344759|Obstructive Sleep Apnea
1155139|NCT01344759|MRI
1155140|NCT01344759|Pediatrics
1155141|NCT01344759|Dexmedetomidine
1155142|NCT01344759|Propofol
1155143|NCT01344759|Anesthesia
1155144|NCT01344746|sleep-disordered breathing
1155145|NCT01344733|Major Depressive Disorder
1155146|NCT01344733|MDD
1155147|NCT01344720|Low Back Pain
1155148|NCT01344720|Etoricoxib
1155149|NCT01344720|Oxycodone
1155150|NCT01344707|Hematologic Malignancies
1155151|NCT01344707|Acute Myeloid Leukemia (AML)
1155152|NCT01344707|Acute Lymphocytic Leukemia (ALL)
1155153|NCT01344707|Chronic Lymphocytic Leukemia (CLL)
1155154|NCT01344707|Multiple Myeloma (MM)
1155155|NCT01344707|Myelodysplastic Syndrome (MDS)
1155156|NCT01344707|Malignant Lymphomas
1155157|NCT01344707|Histone Deacetylase (HDAC)
1155158|NCT01344707|4SC-202
1155159|NCT01344707|Phase I
1155160|NCT01344694|Epicardial fat
1155161|NCT01344694|Visceral fat
1155162|NCT01344694|atherosclerosis
1155163|NCT01344694|coronary computed tomography angiography
1155164|NCT01344694|Carotid Doppler ultrasound
1155165|NCT01344668|Diabetes
1155166|NCT01344642|HIV
1155167|NCT01344642|RNA
1155168|NCT01344616|computer-based behavioral support
1155169|NCT01344603|cardiac surgery
1155170|NCT01344603|cardiac anesthesia
1155171|NCT01344603|epidural
1155172|NCT01344590|central line associated blood stream infections
1155173|NCT01344577|Buccal Plate Augmentation technique
1155174|NCT01344577|socket preservation
1155175|NCT01344577|porcine biomaterial
1155176|NCT01344564|Prostate cancer
1155177|NCT01344564|Hormone therapy
1155178|NCT01344564|Testosterone measures
1155179|NCT01344538|ginger
1155180|NCT01344538|Zingiber officinale
1155181|NCT01344538|Cancer Risk Reductive
1155182|NCT01344538|Eicosanoids
1155183|NCT01344538|Colorectal Cancer
1155184|NCT01344538|Inflammation
1155185|NCT01344525|obesity therapy
1155186|NCT01344525|metabolic syndrome
1155187|NCT01344525|gastrointestinal tract
1155188|NCT01344525|microbiota
1155189|NCT01344525|metabolomics
1155190|NCT01344525|micronutrients
1155191|NCT01344525|outcome
1155192|NCT01344525|sustainability
1155193|NCT01344512|Pharmacokinetic
1155194|NCT01344512|Population
1155195|NCT01344512|Children
1155196|NCT01344512|Ceftazidime
1155197|NCT01344512|Ciprofloxacin
1155198|NCT01344512|Voriconazole
1155199|NCT01344512|Pediatric
1155200|NCT01344499|women
1155201|NCT01344499|laparoscopic subtotal hysterectomy
1155202|NCT01344486|women undergoing laparoscopic surgery
1155203|NCT01344473|Remineralisation
1155204|NCT01344473|White Spot Lesions
1155205|NCT01344473|Orthodontic treatment
1155206|NCT01344473|Tooth Mousse creme
1155207|NCT01344473|Casein Phosphopeptide
1155208|NCT01344460|magnetic resonance angiography (MRA) of the renal arteries
1155209|NCT01344447|Supra-aortic vascular disease
1155210|NCT01344447|MRA
1155211|NCT01344447|CTA
1155212|NCT01344447|Males and females aged 18 years or older
1155213|NCT01344447|Stroke
1155214|NCT01344447|Transient Ischemic Attack (TIA)
1155215|NCT01344421|Movement capture system
1155216|NCT01344421|Movement analysis
1155217|NCT01344421|Hip dysplasia
1155218|NCT01344421|Hip pain
1155219|NCT01344421|Quality of life
1155220|NCT01344421|Physical function
1155221|NCT01344408|Dizziness
1155222|NCT01344408|rehabilitation
1155223|NCT01344408|geriatric
1155224|NCT01344408|IT-technology
1155225|NCT01344382|Adolescent
1155226|NCT01344382|Parent
1155227|NCT01344382|Substance Abuse
1155228|NCT01344382|Parent Training
1155229|NCT01344382|Community Reinforcement and Family Training
1155230|NCT01344382|CRAFT
1155231|NCT01344382|Community Reinforcement Approach
1155232|NCT01344382|Addiction
1155233|NCT01344382|Family Intervention
1155234|NCT01344369|Healthy Subjects
1155235|NCT01344369|Bioequivalence
1155236|NCT01344356|stereotactic radiosurgery
1155237|NCT01344356|head and neck tumors
1155238|NCT01344356|squamous cell carcinoma of head and neck
1155239|NCT01344330|Colon cancer
1155240|NCT01344330|Prevention
1155241|NCT01344330|Cruciferous vegetables
1155242|NCT01344330|Histone status
1155243|NCT01344304|aprepitant therapy
1155244|NCT01344304|fosaprepitant therapy
1155245|NCT01344304|5HT3-receptor antagonist
1155246|NCT01344304|dexamethasone
1155247|NCT01344304|colorectal cancer
1155248|NCT01344304|FOLFOX
1155249|NCT01344304|XELOX
1155250|NCT01344304|SOX
1155251|NCT01344291|hyperprolactinoma
1155252|NCT01344291|turmeric
1155253|NCT01344291|amenorrhea
1155254|NCT01344265|B-type natriuretic peptide
1155255|NCT01344265|global end diastolic volume
1155256|NCT01344239|aortic aneurysm
1155257|NCT01344239|ischemia/reperfusion
1155258|NCT01344239|preconditioning
1155259|NCT01344239|pulmonary injury
1155260|NCT01344239|intestinal injury
1155261|NCT01344226|steroid responder
1155262|NCT01344213|Pregabalin
1155263|NCT01344213|Celecoxib
1155264|NCT01344213|Intrathecal morphine
1155265|NCT01344213|Total knee arthroplasty
1155266|NCT01344200|Pharmacokinetics
1155267|NCT01344200|Celecoxib
1155268|NCT01344200|Pediatric
1155269|NCT01344200|Peds QL
1155270|NCT01344200|CYP2C9
1155271|NCT01344174|Acute-on-chronic liver failure
1155272|NCT01344174|HBV
1155273|NCT01344174|Dexamethasone
1155274|NCT01344174|Prognosis
1155275|NCT01344161|Vitamin D
1155276|NCT01344161|Metabolic profile
1155277|NCT01344161|Overweight
1155278|NCT01344161|Obesity
1155279|NCT01344148|Anti- TB
1155280|NCT01344148|HAART
1155281|NCT01344148|choice of the right moment
1155282|NCT01344135|Pulmonary Disease, Chronic Obstructive
1155283|NCT01344135|Muscular Atrophy
1155284|NCT01344135|Nutritional rehabilitation
1155285|NCT01344135|Counselling
1155286|NCT01344096|Gaucher disease
1155287|NCT01344096|Thrombocytopathy
1155288|NCT01344096|Imiglucerase
1155289|NCT01344070|innovator formulations
1155290|NCT01344070|generic formulations
1155291|NCT01344070|bioequivalence
1155292|NCT01344070|interchangeability
1155293|NCT01344070|inter-patch variation
1155294|NCT01344070|quality of generic drug formulations on the market
1155295|NCT01344070|Interchangeability between marketed generic formulations
1155296|NCT01344070|prevalence of large intrasubject variability despite average bioequivalence
1155297|NCT01344070|Causes of large intrasubject variability
1155298|NCT01344057|Seasonal Influenza, vaccine
1155299|NCT01344044|Brain-Computer Interface
1155300|NCT01344018|adult angiosarcoma
1155301|NCT01344018|adult fibrosarcoma
1155302|NCT01344018|adult leiomyosarcoma
1155303|NCT01344018|adult liposarcoma
1155304|NCT01344018|adult malignant fibrous histiocytoma
1155305|NCT01344018|adult malignant mesenchymoma
1155306|NCT01344018|stage I adult soft tissue sarcoma
1155307|NCT01344018|stage II adult soft tissue sarcoma
1155308|NCT01344018|stage III adult soft tissue sarcoma
1155309|NCT01344005|non-small cell lung cancer
1155310|NCT01344005|small cell lung cancer
1155311|NCT01344005|tobacco use disorder
1155312|NCT01343992|Embryo transfer
1155313|NCT01343992|Implantation rate
1155314|NCT01343992|Pregnancy rate
1155315|NCT01343992|bedrest
1155316|NCT01343992|neutral
1155317|NCT01343992|benevolent
1155318|NCT01343992|deterious
1155319|NCT01343992|implantation
1155320|NCT01343992|gestation rates
1155321|NCT01343953|severe aplastic anemia
1155322|NCT01343953|cord blood transplantation
1155323|NCT01343940|RCT
1155324|NCT01343940|randomized block repeated measures design
1155325|NCT01343940|efficacy trial
1155326|NCT01343940|high risk population
1155327|NCT01343927|Chronic low back pain
1155328|NCT01343927|Community health center
1155329|NCT01343927|Yoga
1155330|NCT01343927|Physical therapy
1155331|NCT01343927|Minority populations
1155332|NCT01343927|Health education
1155333|NCT01342900|tissue oxygenation
1155334|NCT01342900|higk risk surgery
1155335|NCT01342900|high risk patient
1155336|NCT01342900|postoperative complications
1155337|NCT01342874|inositol
1155338|NCT01342874|gestational diabetes mellitus
1155339|NCT01342874|obstetric adverse outcomes
1155340|NCT01342861|protein supplementation
1155341|NCT01342861|caloric intake
1155342|NCT01342861|breakfast
1155343|NCT01342861|transthyretin (prealbumin)
1155344|NCT01342861|albumin
1155345|NCT01342861|Length of stay
1155346|NCT01342848|NSTE-ACS
1155347|NCT01342848|PCI
1155348|NCT01342848|Thrombus Aspiration
1155349|NCT01342848|IVUS
1155350|NCT01342848|Periprocedural Myocardial Infarction
1155351|NCT01342835|propofol
1155352|NCT01342835|sevoflurane
1155353|NCT01342835|postoperative pain
1155354|NCT01342835|children
1155355|NCT01342822|Heart disease
1155356|NCT01342822|Coronary Revascularization
1155357|NCT01342809|Depression
1155358|NCT01342809|Hopelessness
1155359|NCT01342809|Suicidal ideation
1155360|NCT01342796|Cell mediated immunity
1155361|NCT01342796|cell mediated immune response
1155362|NCT01342796|Children
1155363|NCT01342796|adjuvanted
1155364|NCT01342783|metastatic childhood soft tissue sarcoma
1155365|NCT01342783|nonmetastatic childhood soft tissue sarcoma
1155366|NCT01342783|recurrent childhood soft tissue sarcoma
1155367|NCT01342783|previously treated childhood rhabdomyosarcoma
1155368|NCT01342783|previously untreated childhood rhabdomyosarcoma
1155369|NCT01342783|recurrent childhood rhabdomyosarcoma
1155370|NCT01342744|Cardiovascular risk factors
1155371|NCT01342731|Tigecycline
1155372|NCT01342731|A.baumannii
1155373|NCT01342731|Drug safety
1155374|NCT01342718|Irritable bowel syndrome
1155375|NCT01342718|Herbal medicine
1155376|NCT01342718|Probiotics
1155377|NCT01343862|moderate traumatic brain injury
1155378|NCT01343862|brain contusion
1155379|NCT01343849|breast cancer
1155380|NCT01343849|auto antibodies
1155381|NCT01343836|autologous tenocytes
1155382|NCT01343836|cell therapy
1155383|NCT01343836|eccentric exercises
1155384|NCT01343810|Mindfulness-Based Stress Reduction
1155385|NCT01343810|Meditation
1155386|NCT01343810|Psychological stress
1155387|NCT01343810|Sleep quality
1155388|NCT01343810|Cardiovascular disease
1155389|NCT01343810|Inflammation
1155390|NCT01343797|Glycemic index
1155391|NCT01343797|Insulinemic index
1155392|NCT01343797|Fructo-oligosaccharide syrup
1155393|NCT01343797|Fructose syrup
1155394|NCT01343797|Aged between eighteen and fifty years old
1155395|NCT01343797|BMI between nineteen and twenty five kg/m²
1155396|NCT01343797|Non diabetic or pre-diabetic
1155397|NCT01343797|Without liver, renal or gastro-intestinal disorder
1155398|NCT01343797|Non-smoker
1155399|NCT01343784|Voiding trial
1155400|NCT01343784|sling
1155401|NCT01343784|post-operative assessment
1155402|NCT01343784|urinary retention
1155403|NCT01343771|Anorexia Nervosa (AN)
1155404|NCT01343771|bone density
1155405|NCT01343771|DHEA
1155406|NCT01343771|estrogen therapy
1155407|NCT01343771|eating disorder
1155408|NCT01343693|DDD
1155409|NCT01343693|Deformity
1155410|NCT01343693|Tumor
1155411|NCT01343693|Fracture
1155412|NCT01343693|Cervical
1155413|NCT01343667|GORE Neuro Protection System
1155414|NCT01343667|GORE Flow Reversal System
1155415|NCT01343667|carotid artery stenosis
1155416|NCT01343667|embolic protection device
1155417|NCT01343667|reverse flow
1155418|NCT01343667|proximal occlusion device
1155419|NCT01343667|GNPS
1155420|NCT01343667|Parodi
1155421|NCT01343667|EMPiRE
1155422|NCT01343667|distal embolization
1155423|NCT01343667|minimizing risks of CAS
1155424|NCT01343667|PAES
1155425|NCT01343667|embolic filter
1155426|NCT01343654|HIV medication adherence
1155427|NCT01343654|drug use
1155428|NCT01343654|rural
1155429|NCT01343654|nonadherence to HIV medications
1155430|NCT01343641|Kidney Disease
1155431|NCT01343641|Chronic Kidney Disease
1155432|NCT01343641|Growth Hormone
1155433|NCT01343628|Alcohol, atomoxetine, Strattera, alcohol dependence, alcoholism
1155434|NCT01343602|stroke
1155435|NCT01343602|Constraint Induced Movement Therapy
1155436|NCT01343602|participation
1155437|NCT01343602|Physical Therapy
1155438|NCT01343602|Occupational Therapy
1155439|NCT01343563|Depression
1155440|NCT01343563|Major Depressive Disorder (MDD)
1155441|NCT01343563|EEG
1155442|NCT01343563|Trigeminal Nerve Stimulation
1155443|NCT01343550|Borderline Personality Disorder
1155444|NCT01343550|Borderline Personality
1155445|NCT01343550|Borderline
1155446|NCT01343537|Brain Bleed
1155447|NCT01343537|SAH
1155448|NCT01343537|Vasospasm
1155449|NCT01343524|cystic fibrosis
1155450|NCT01343524|spirometry
1155451|NCT01343524|PFT's
1155452|NCT01343524|pulmonary function test
1155453|NCT01343511|Autism
1155454|NCT01343511|human cord blood mononuclear cells
1155455|NCT01343511|human umbilical cord mesenchymal stem cells
1155456|NCT01343498|Solid Tumor Malignancy
1155457|NCT01343498|Advanced Solid Tumors
1155458|NCT01343498|BEZ235
1155459|NCT01343498|mTOR Inhibitor
1155460|NCT01343485|Human papillomavirus (HPV) vaccine
1155461|NCT01343485|Gardasil vaccine
1155462|NCT01343472|Behavior
1155463|NCT01343472|Drug users
1155464|NCT01343459|Hypofractionated Whole breast irradiation
1155465|NCT01343459|Hypofractionated Whole breast irradiation long term results
1155466|NCT01343459|Breast conserving therapy
1155467|NCT01343459|IORT with electrons in breast cancer
1155468|NCT01343459|IOERT as anticipated Boost
1155469|NCT01343459|IOERT and hypofractionated whole breast irradiation
1155470|NCT01343446|Sleep impairment, Coping Style, Diabetes Mellitus
1155471|NCT01343433|Delirium
1155472|NCT01343433|Intensive Care Unit Syndrome
1155473|NCT01343433|Bright light therapy
1155474|NCT01343433|Intensive Care Unit
1155475|NCT01343420|Skin tests
1155476|NCT01343420|Dog Hair
1155477|NCT01343420|Allergy Extract
1155478|NCT01343394|Autologous
1155479|NCT01343394|Stem Cells
1155480|NCT01343394|Hearing Loss
1155481|NCT01343394|Children
1155482|NCT01343381|Heparin
1155483|NCT01343381|Coronary artery bypass graft surgery
1155484|NCT01343381|Anti-coagulation efficacy
1155485|NCT01343368|Post-menarchal
1155486|NCT01343355|Tropical Spastic Paraparesis
1155487|NCT01343355|HAM
1155488|NCT01343355|TSP
1155489|NCT01343342|omega-3
1155490|NCT01343342|PUFA
1155491|NCT01343342|fatty acids
1155492|NCT01343342|cardiovascular disease
1155493|NCT01343342|gene expression
1155494|NCT01343329|Traumatic Brain Injury
1155495|NCT01343329|Dysautonomia
1155496|NCT01343329|Brain Injury
1155497|NCT01343329|Sympathetic hyperactivity
1155498|NCT01343316|Enteral Feeds
1155499|NCT01343316|Supplemental Feeds
1155500|NCT01343316|Transpyloric Tube
1155501|NCT01343316|Nasogastric Tube
1155502|NCT01343303|Osteoarthritis, knee
1155503|NCT01343303|knee pain
1155504|NCT01343303|pain measurement
1155505|NCT01343290|Canagliflozin (JNJ-28431754)
1155506|NCT01343290|Pharmacokinetic
1155507|NCT01343290|Oral Bioavailability
1155508|NCT01343290|Food effect
1155509|NCT01343277|Advanced Liposarcoma or Leiomyosarcoma
1155510|NCT01343277|Trabectedin
1155511|NCT01343277|Yondelis
1155512|NCT01343277|Dacarbazine
1155513|NCT01343277|Anthracycline
1155514|NCT01343277|L-sarcoma
1155515|NCT01343264|Radical Pleurectomy
1155516|NCT01343264|Pleurectomy/decortication
1155517|NCT01343264|Cisplatin
1155518|NCT01343264|Pemetrexed
1155519|NCT01343264|Radiation
1155520|NCT01343251|dialysis
1155521|NCT01343251|HeRO graft
1155522|NCT01343251|catheter
1155523|NCT01343251|chronic renal failure
1155524|NCT01343251|end stage renal disease
1155525|NCT01343251|renal insufficiency
1155526|NCT01343238|obesity
1155527|NCT01343238|diet
1155528|NCT01343238|exercise
1155529|NCT01343225|African american vitamin d bone density
1155530|NCT01343225|African American male or female treatment naive
1155531|NCT01343212|hepatocellular carcinoma
1155532|NCT01343212|stiffness
1155533|NCT01343186|Peginterferon
1155534|NCT01343186|Healthy subject
1155535|NCT01343186|Pharmacokinetics
1155536|NCT01343186|Pharmacodynamics
1155537|NCT01343186|Safety
1155538|NCT01343173|Leukemia
1155539|NCT01343173|Adult Chronic
1155540|NCT01343173|Myeloid
1155541|NCT01343147|Hyperthermia
1155542|NCT01343147|Microwave diathermy
1155543|NCT01343147|Hot packs
1155544|NCT01343147|Pain
1155545|NCT01343147|Physical function
1155546|NCT01343134|Retina
1155547|NCT01343134|Rhegmatogenous retinal detachment
1155548|NCT01343134|Macular detachment
1155549|NCT01343134|Spectral domain OCT
1155550|NCT01343134|Microperimetry
1155551|NCT01343121|Radiotherapy
1155552|NCT01343121|GemX Chemoradiotherapy
1155553|NCT01343121|Bladder Cancer
1155554|NCT01343108|Emotional Labor
1155555|NCT01343108|Burnout
1155556|NCT01343108|Job Satisfaction
1155557|NCT01343108|Emotional Intelligence
1155558|NCT01343108|Job stress
1155559|NCT01343108|Job involvement
1155560|NCT01343095|ICU Delirium
1155561|NCT01343095|Delirium
1155562|NCT01343095|Sleep Quality
1155563|NCT01343095|Sleep Efficiency
1155564|NCT01343095|ICU Noise
1155565|NCT01343095|Noise Reduction
1155566|NCT01343095|Earplugs
1155567|NCT01343095|Noise Canceling Headphones
1155568|NCT01343069|safety
1155569|NCT01343069|team
1155570|NCT01343069|team performance
1155571|NCT01343069|surgery
1155572|NCT01343069|outcome
1155573|NCT01343056|Diabetes Self Management Education (DSME)
1155574|NCT01343056|Diabetes
1155575|NCT01343056|Self Management Support (SMS)
1155576|NCT01343043|Sarcoma
1155577|NCT01343043|Cell Therapy
1155578|NCT01343043|T Cell Therapy
1155579|NCT01343043|NY-ESO-1
1155580|NCT01343043|Immuno-oncology
1155581|NCT01343043|Metastatic
1155582|NCT01343043|Previously treated
1155583|NCT01343043|T Cell Receptor
1155584|NCT01343017|Anaesthesia
1155585|NCT01343017|Pulmonary gas exchange
1155586|NCT01343017|Functional residual capacity
1155587|NCT01343017|Cardiac output
1155588|NCT01343017|Sevoflurane
1155589|NCT01343004|BA058
1155590|NCT01343004|abaloparatide
1155591|NCT01343004|Abaloparatide-SC
1155592|NCT01343004|osteoporosis
1155593|NCT01343004|postmenopausal
1155594|NCT01343004|bone loss
1155595|NCT01343004|ACTIVE
1155596|NCT01343004|fracture
1155597|NCT01342991|Haemorrhoids
1155598|NCT01342991|Haemorrhoidectomy
1155599|NCT01342991|Laser Haemorrhoidectomy
1155600|NCT01342991|Milligan-Morgan Haemorrhoidectomy
1155601|NCT01342991|Open Haemorrhoidectomy
1155602|NCT01342978|HPV
1155603|NCT01342978|HNSCC
1155604|NCT01342952|pulmonary arterial hypertension
1155605|NCT01342952|pediatrics
1155606|NCT01342939|Monogenetic diabetes
1155607|NCT01342939|Diabetes mellitus
1155608|NCT01342926|age-related macular degeneration
1155609|NCT01342926|geographic atrophy
1155610|NCT01342926|dry AMD
1155611|NCT01342679|chronic myeloid leukemia
1155612|NCT01342679|dasatinib
1155613|NCT01342679|complete molecular response
1155614|NCT01342666|High density lipoprotein cholesterol
1155615|NCT01342666|Tomato
1155616|NCT01342666|Lycopene
1155617|NCT01342666|Hypoalphalipoproteinemia
1155618|NCT01342666|Dyslipidemia
1155619|NCT01342653|Peritoneal
1155620|NCT01342653|Carcinomatosis
1155621|NCT01342653|Gastric
1155622|NCT01342653|Cancer
1155623|NCT01342653|NIPS
1155624|NCT01342653|HIPEC
1155625|NCT01342627|Renal Carcinoma
1155626|NCT01342627|Metastatic
1155627|NCT01342627|Sorafenib
1155628|NCT01342627|Elderly
1155629|NCT01342614|Hypertension
1155630|NCT01342614|Insulin Resistance
1155631|NCT01342614|Hyperinsulinemia
1155632|NCT01342614|Metformin
1155633|NCT01342614|Fosinopril
1155634|NCT01342588|Pedicle screws
1155635|NCT01342588|safety
1155636|NCT01342575|ACDF
1155637|NCT01342549|Alcohol Use Disorders
1155638|NCT01342549|Traumatic Brain Injury
1155639|NCT01342549|Mood and Anxiety Disorders
1155640|NCT01342536|Depression
1155641|NCT01342523|Smoking Cessation
1155642|NCT01342523|Smoking
1155643|NCT01342523|Nicotine
1155644|NCT01342510|Intravenous Anesthesia
1155645|NCT01342510|General Anesthesia
1155646|NCT01342497|diabetic foot ulcer
1155647|NCT01342471|Physical activity intervention
1155648|NCT01342471|walking
1155649|NCT01342471|TV
1155650|NCT01342471|sedentary
1155651|NCT01342458|Knee osteoarthritis
1155652|NCT01342458|Shoes
1155653|NCT01342458|Gait
1155654|NCT01342458|Biomechanics
1155655|NCT01342432|low back pain
1155656|NCT01342432|balance reeducation
1155657|NCT01342432|pain
1155658|NCT01342432|function
1155659|NCT01342367|Prostate cancer
1155660|NCT01342367|Quality of Life
1155661|NCT01342354|Pancreatic Cancer
1155662|NCT01342354|Stereotactic Radiation
1155663|NCT01342328|Sleep disruption
1155664|NCT01342328|Sleep hygiene
1155665|NCT01342328|Sedative agents and sleep
1155666|NCT01342328|Electroencephalography
1155667|NCT01342328|REM sleep
1155668|NCT01342328|Magnetoencephalography
1155669|NCT01342315|Tinea Cruris, antifungal
1155670|NCT01342302|Breast Cancer
1155671|NCT01342302|Couples
1155672|NCT01342302|Distress
1155673|NCT01342302|Online Support
1155674|NCT01342302|e-health
1155675|NCT01342302|Intervention
1155676|NCT01342302|Relationships
1155677|NCT01342289|Nonmyeloablative
1155678|NCT01342289|Allogeneic
1155679|NCT01342289|Bone Marrow Transplant (BMT)
1155680|NCT01342289|Tacrolimus
1155681|NCT01342289|Cyclophosphamide
1155682|NCT01342276|Heart failure
1155683|NCT01342276|Self-management
1155684|NCT01342276|Telehealth
1155685|NCT01342276|Internet
1155686|NCT01342263|Chronic disease management
1155687|NCT01342263|Ischemic heart disease
1155688|NCT01342263|Heart failure
1155689|NCT01342263|Chronic kidney disease
1155690|NCT01342263|Diabetes
1155691|NCT01342263|Chronic obstructive pulmonary disease
1155692|NCT01342263|Telehealth
1155693|NCT01342263|Internet
1155694|NCT01342250|Decompensated Liver Cirrhosis
1155695|NCT01342250|Umbilical Cord Mesenchymal Stem Cells
1155696|NCT01342237|Brain tumors
1155697|NCT01342237|Stem cell transplantation
1155698|NCT01342237|topotecan
1155699|NCT01342237|thiotepa
1155700|NCT01342237|carboplatin
1155701|NCT01342237|melphalan
1155702|NCT01342237|etoposide
1155703|NCT01342224|pancreatic
1155704|NCT01342224|cancer
1155705|NCT01342224|adenocarcinoma
1155706|NCT01342224|vaccine
1155707|NCT01342211|PF-04950615
1155708|NCT01342211|RN316
1155709|NCT01342198|pregabalin
1155710|NCT01342198|pharmacokinetics
1155711|NCT01342198|bioavailability
1155712|NCT01342198|bioequivalence
1155713|NCT01342185|Medical ozone therapy
1155714|NCT01342185|chronic hepatitis B
1155715|NCT01342172|Bladder Cancer
1155716|NCT01342172|Urothelial Cancer
1155717|NCT01342172|Chemotherapy
1155718|NCT01342172|First-line
1155719|NCT01342172|Metastatic
1155720|NCT01342159|bevacizumab, diabetic macular edema, triamcinolone
1155721|NCT01342146|pegylated Somatropin
1155722|NCT01342146|PEG-GH
1155723|NCT01342146|Growth hormone
1155724|NCT01342146|PEG-rhGH
1155725|NCT01342146|Growth hormone deficiency (GHD)
1155726|NCT01342146|Phase 2 study
1155727|NCT01342120|atypical antipsychotics
1155728|NCT01342120|quetiapine
1155729|NCT01342107|Contact Lenses
1155730|NCT01342107|Contact Lens Care
1155731|NCT01342107|Multi-Purpose Solution Wettability
1155732|NCT01342107|Myopia
1155733|NCT01342094|Primary open angle glaucoma or ocular hypertension
1155734|NCT01342081|Primary open angle glaucoma or ocular hypertension
1155735|NCT01342068|Thoracic outlet syndrome
1155736|NCT01342068|Osteopathic medicine
1155737|NCT01342068|Osteopathic Manual Manipulations
1155738|NCT01342068|OMT
1155739|NCT01342068|Wright's Test
1155740|NCT01342068|Adson's Test
1155741|NCT01342068|Halstead's Maneuver
1155742|NCT01342068|TOS
1155743|NCT01342068|Vascular Sonography
1155744|NCT01342042|diabetes
1155745|NCT01342042|rRE-4
1155746|NCT01342042|exenatide
1155747|NCT01342042|metformin
1155748|NCT01342042|CSPC ZhongQi
1155749|NCT01342029|Microvascular Coronary Dysfunction (MCD)
1155750|NCT01342016|prograf
1155751|NCT01342016|nephritis
1155752|NCT01342016|leflunomide
1155753|NCT01342016|immunosuppressant
1155754|NCT01342003|HCV infection
1155755|NCT01342003|genotype 1a
1155756|NCT01342003|genotype 1 b
1155757|NCT01341990|Contact Lenses
1155758|NCT01341990|Contact Lens Care
1155759|NCT01341990|Multi-Purpose Solution
1155760|NCT01341977|Contact Lenses
1155761|NCT01341977|Contact Lens Care
1155762|NCT01341977|Multi-Purpose Solution
1155763|NCT01341964|Clopidogrel
1155764|NCT01341964|Aspirin
1155765|NCT01341964|Interaction
1155766|NCT01341951|liver failure, Acute
1155767|NCT01341938|Smokeless Tobacco Use
1155768|NCT01341925|childhood depression
1155769|NCT01341899|Type 1 diabetes
1155770|NCT01341899|stem cell
1155771|NCT01341899|C-peptide
1155772|NCT01341899|Immune function
1155773|NCT01341886|differentiated thyroid cancer
1155774|NCT01341886|THS suppression
1155775|NCT01341886|metformin
1155776|NCT01341834|Nasopharyngeal carcinoma, antiangiogenesis, HDACi, mTOR, Phase Ib
1155777|NCT01341821|Leadership Style
1155778|NCT01341821|Team Climate
1155779|NCT01341808|Crohn's disease
1155780|NCT01341808|Ulcerative colitis
1155781|NCT01341808|Hepatitis A
1155782|NCT01341808|vaccine
1155783|NCT01341795|Newly diagnosed type 2 diabetes patients
1155784|NCT01341782|Secondary hyperparathyroidism
1155785|NCT01341782|Paricalcitol
1155786|NCT01341782|Hemodialysis
1155787|NCT01341782|Maxacalcitol
1155788|NCT01341756|Gastric Cancer
1155789|NCT01341756|Radiotherapy
1155790|NCT01341756|palliation
1155791|NCT01341756|bleeding
1155792|NCT01341756|pain
1155793|NCT01341756|obstruction
1155794|NCT01341743|chronic hepatitis B
1155795|NCT01341743|inadequate response
1155796|NCT01341743|NUC therapy
1155797|NCT01341730|Atherosclerosis
1155798|NCT01341730|Pioglitazone
1155799|NCT01341730|Atorvastatin
1155800|NCT01341730|PET CT
1155801|NCT01341717|Diabetes Mellitus, Type 2
1155802|NCT01341717|Sitagliptin
1155803|NCT01341717|Insulin
1155804|NCT01341704|malaria
1155805|NCT01341704|vaccine
1155806|NCT01341704|clinical trials
1155807|NCT01341704|proof of concept
1155808|NCT01341704|efficacy
1155809|NCT01341691|chronic kidney disease
1155810|NCT01341691|K2CG chewing gum
1155811|NCT01341691|phosphorus
1155812|NCT01341691|saliva
1155813|NCT01341678|chronic kidney disease
1155814|NCT01341678|phosphorus
1155815|NCT01341678|circadian rhythm
1155816|NCT01341678|saliva
1155817|NCT01341665|hyponatremia
1155818|NCT01341665|SIADH
1155819|NCT01341665|copeptin
1155820|NCT01341639|combination vaccine
1155821|NCT01341639|diphtheria
1155822|NCT01341639|pertussis
1155823|NCT01341639|tetanus
1155824|NCT01341639|hepatitis B
1155825|NCT01341639|Hep B
1155826|NCT01341639|Haemophilus influenzae b
1155827|NCT01341639|Hib
1155828|NCT01341639|polio
1155829|NCT01341639|poliovirus
1155830|NCT01341626|delinquency
1155831|NCT01341626|drug use
1155832|NCT01341626|HIV risk behavior
1155833|NCT01341626|economic costs
1155834|NCT01341600|Clopidogrel
1155835|NCT01341600|Pharmacogenetics
1155836|NCT01341600|Platelets
1155837|NCT01341600|Healthy Subjects
1155838|NCT01341587|SMBG (self monitoring of blood glucose)
1155839|NCT01341587|diabetes
1155840|NCT01341587|mobile technology
1155841|NCT01341574|spatial neglect
1155842|NCT01341574|stroke
1155843|NCT01341548|Nasal
1155844|NCT01341548|Cluster Headache
1155845|NCT01341548|Episodic Cluster
1155846|NCT01341548|Headache
1155847|NCT01341548|Phase 3
1155848|NCT01341548|Civamide
1155849|NCT01341548|TRPV-1 Receptor
1155850|NCT01341509|Surgical Treatment of Insertional Achilles Tendinopathy
1155851|NCT01341496|Metastatic Cancer
1155852|NCT01341496|Cancer Vaccine
1155853|NCT01341496|Immunotherapy
1155854|NCT01341496|Chest Metastases
1155855|NCT01341496|Sarcoma
1155856|NCT01341496|Melanoma
1155857|NCT01341483|erectile dysfunction
1155858|NCT01341483|internal pudendal artery
1155859|NCT01341483|erection
1155860|NCT01341483|coronary artery disease
1155861|NCT01341483|peripheral atherosclerotic disease
1155862|NCT01341431|Parkinson disease
1155863|NCT01341431|Bee venom
1155864|NCT01341431|Motor fluctuations
1155865|NCT01341431|Disease progression
1155866|NCT01341418|tibia
1155867|NCT01341418|suprapatellar
1155868|NCT01341392|Drug-Drug interaction between the CKD-501 and Amlodipine
1155869|NCT01341379|Ureagenesis
1155870|NCT01341379|Urea cycle
1155871|NCT01341379|Inborn errors of metabolism
1155872|NCT01341366|Laparoscopic surgery
1155873|NCT01341340|Stent
1155874|NCT01341340|Infrapopliteal
1155875|NCT01341340|Tibial
1155876|NCT01341340|Limb Salvage
1155877|NCT01341327|Left Main
1155878|NCT01341314|joint pain
1155879|NCT01341314|stiffness
1155880|NCT01341301|allogeneic stem cell transplant
1155881|NCT01341301|TJU 2 Step
1155882|NCT01341301|HSCT
1155883|NCT01341301|Hematopoietic stem cell transplantation
1155884|NCT01341288|prostate cancer
1155885|NCT01341288|EUCLIDIAN
1155886|NCT01341288|Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing
1155887|NCT01341288|robot
1155888|NCT01341288|brachytherapy
1155889|NCT01341288|seed implantation
1155890|NCT01341275|hepatitis B vaccine
1155891|NCT01341275|duration of protection
1155892|NCT01341275|adolescent immunization
1155893|NCT01341275|anamnestic response
1155894|NCT01341275|booster dose
1155895|NCT01341275|Immunity to hepatitis B as measured by anti-HBSAg titers
1155896|NCT01341262|autologous stem cell transplantation
1155897|NCT01341262|thalidomide
1155898|NCT01341262|induction therapy
1155899|NCT01341236|VLBW
1155900|NCT01341236|IUGR
1155901|NCT01341236|NIRS
1155902|NCT01341236|enteral nutrition
1155903|NCT01341236|superior mesenteric artery doppler
1155904|NCT01341210|Patients Satisfaction
1155905|NCT01341210|Decision Making
1155906|NCT01341210|Informed Consent
1155907|NCT01341197|Fecal immunochemical test
1155908|NCT01341197|Guaiac fecal occult blood test
1155909|NCT01341197|Helicobacter pylori stool antigen test
1155910|NCT01341197|Mass screening
1155911|NCT01341197|Bidirectional endoscopy
1155912|NCT01341184|rifabutin
1155913|NCT01341184|rifampin
1155914|NCT01341184|TMC207
1155915|NCT01341184|tuberculosis
1155916|NCT01341171|tamoxifen
1155917|NCT01341171|aromatase inhibitors
1155918|NCT01341171|breast cancer
1155919|NCT01341171|platelets
1155920|NCT01341158|Malignatn Melanoma
1155921|NCT01341145|hypertension
1155922|NCT01341145|aerobic exercise
1155923|NCT01341145|relaxation
1155924|NCT01341145|functional magnetic resonance imaging (fMRI)
1155925|NCT01341145|magnetic resonance spectroscopy (MRS)
1155926|NCT01341145|brain health
1155927|NCT01341132|HCC
1155928|NCT01341132|Hepatocellular Carcinoma
1155929|NCT01341132|MRI
1155930|NCT01341132|Liver
1155931|NCT01341106|chronic hepatitis B
1155932|NCT01341106|liver fibrosis
1155933|NCT01341106|treatment with Entecavir
1155934|NCT01341080|Balance
1155935|NCT01341080|Postural impairment
1155936|NCT01341080|Falls
1155937|NCT01341080|Parkinson Disease
1155938|NCT01341054|mucositis
1155939|NCT01341054|chamomilla
1155940|NCT01341054|therapeutics
1155941|NCT01341028|weight loss
1155942|NCT01341028|appetite
1155943|NCT01341028|ghrelin
1155944|NCT01341028|PYY
1155945|NCT01341028|GLP-1
1155946|NCT01341028|insulin
1155947|NCT01341028|laparoscopic
1155948|NCT01341028|Roux-en-Y gastric bypass
1155949|NCT01341028|gastric fundus resection
1155950|NCT01341002|Postoperative Care
1155951|NCT01341002|red blood cell transfusion
1155952|NCT01341002|venous oxygen saturation
1155953|NCT01340989|women undergoing laparoscopic surgery for: hysterectomy, colpopexy, endometriosis, adhesions or myomas
1155954|NCT01340976|Cancer Related Anemia
1155955|NCT01340963|Chagas heart disease
1155956|NCT01340963|ventricular tachycardia
1155957|NCT01340963|atrial fibrillation
1155958|NCT01340963|stroke
1155959|NCT01340963|cardiac death
1155960|NCT01340963|signal averaged electrocardiogram
1155961|NCT01340950|Prevention
1155962|NCT01340950|Anti-Retroviral Agents
1155963|NCT01340950|Neuropsychological Tests
1155964|NCT01340937|Diphtheria
1155965|NCT01340937|Tetanus
1155966|NCT01340937|Whooping Cough (pertussis)
1155967|NCT01340937|Poliomyelitis
1155968|NCT01340937|Hepatitis B infection
1155969|NCT01340937|Haemophilus influenzae type b infection
1155970|NCT01340924|Gestational diabetes
1155971|NCT01340924|Type 2 diabetes
1155972|NCT01340898|meningococcal conjugate vaccine
1155973|NCT01340898|serogroups A,C, W-135 or Y
1155974|NCT01340898|meningococcal diseases
1155975|NCT01340898|Immunogenicity
1155976|NCT01340898|Neisseria meningitidis
1155977|NCT01340898|co-administration
1155978|NCT01340898|routine vaccines
1155979|NCT01340885|attention
1155980|NCT01340885|mild cognitive impairment
1155981|NCT01340885|dementia
1155982|NCT01340872|iron deficiency
1155983|NCT01340872|anaemia
1155984|NCT01340872|inflammatory bowel disease
1155985|NCT01340872|ulcerative colitis
1155986|NCT01340859|Suicide
1155987|NCT01340859|Cognitive Therapy
1155988|NCT01340859|Inpatient
1155989|NCT01340859|Military
1155990|NCT01340846|ketoconazole
1155991|NCT01340846|GSK2118436
1155992|NCT01340846|warfarin
1155993|NCT01340846|gemfibrozil
1155994|NCT01340846|oncology
1155995|NCT01340846|BRAF inhibitor
1155996|NCT01340846|BRAF
1155997|NCT01340846|BRAF positive tumor
1155998|NCT01340846|Drug Interactions
1155999|NCT01340833|GSK2118436
1156000|NCT01340833|BRAF inhibitor
1156001|NCT01340833|BRAF-mutation positive tumor
1156002|NCT01340833|Oncology
1156003|NCT01340833|absolute bioavailability
1156004|NCT01340833|microtracer
1156005|NCT01340781|inpatients
1156006|NCT01340781|medical
1156007|NCT01340781|polysomnogram
1156008|NCT01340781|questionnaires
1156009|NCT01340768|Glucose metabolism disorders Metabolic diseases Peptidase inhibitors
1156010|NCT01340755|Rectal cancer
1156011|NCT01340742|Remote ischemic preconditioning
1156012|NCT01340742|Abdominal surgery
1156013|NCT01340742|Perioperative complications
1156014|NCT01340729|melanoma
1156015|NCT01340729|TPI 287
1156016|NCT01340729|tumor recurrence
1156017|NCT01340729|tumor progression
1156018|NCT01340729|novel taxane analog
1156019|NCT01340703|optic disc pit
1156020|NCT01340703|retinal detachment
1156021|NCT01340703|retinoschisis
1156022|NCT01340703|vitrectomy
1156023|NCT01340703|posterior vitreous detachment
1156024|NCT01340690|ADHD
1156025|NCT01340690|children
1156026|NCT01340690|adolescents
1156027|NCT01340690|Polyunsaturated Fatty Acids
1156028|NCT01340690|ADHDRS - IV
1156029|NCT01340677|Canagliflozin (JNJ-28431754)
1156030|NCT01340677|Pharmacokinetic
1156031|NCT01340677|Dose proportionality
1156032|NCT01340664|Canagliflozin
1156033|NCT01340664|Placebo
1156034|NCT01340664|Metformin
1156035|NCT01340664|Hemoglobin A1c
1156036|NCT01340664|Type 2 diabetes mellitus
1156037|NCT01340651|myelofibrosis
1156038|NCT01340651|myeloproliferative neoplasms
1156039|NCT01340651|PMF
1156040|NCT01340651|PET-MF
1156041|NCT01340651|PPV-MF
1156042|NCT01340638|Seal pressure
1156043|NCT01340638|Cookgas
1156044|NCT01340638|AirQ
1156045|NCT01340638|LMA
1156046|NCT01340638|supraglottic device
1156047|NCT01340625|Healthy Subjects
1156048|NCT01340612|large aneurysm
1156049|NCT01340612|wide-necked aneurysm
1156050|NCT01340612|recurring aneurysm
1156051|NCT01340586|PHARMACOKINETIC
1156052|NCT01340586|NOS
1156053|NCT01340573|Chronic Hepatitis C
1156054|NCT01340573|pegylated interferon
1156055|NCT01340573|PegIntron Pen
1156056|NCT01340573|Ribavirin
1156057|NCT01340560|Endometrium, local injury, implantation, pregnancy, in vitro fertilization
1156058|NCT01340547|Phase I
1156059|NCT01340547|Safety
1156060|NCT01340547|PK
1156061|NCT01340547|ECG QTc
1156062|NCT01340547|Efficacy
1156063|NCT01340547|Palifosfamide-tris
1156064|NCT01340547|non-randomized
1156065|NCT01340534|Surgical wound infection
1156066|NCT01340534|Oxygen
1156067|NCT01340534|Cesarean
1156068|NCT01340521|Pituitary Hormone Response
1156069|NCT01340521|Clomiphene Citrate
1156070|NCT01340521|Follicle Stimulating Hormone
1156071|NCT01340521|Luteinizing Hormone
1156072|NCT01340508|Pathological complete response
1156073|NCT01340508|Intensity modulated radiotherapy
1156074|NCT01340508|Rectal cancer
1156075|NCT01340495|Breast Cancer
1156076|NCT01340495|Mastectomy
1156077|NCT01340482|XLH
1156078|NCT01340469|nosocomial infections
1156079|NCT01340469|necrotizing enterocolitis
1156080|NCT01340469|preterm infants
1156081|NCT01340469|ver low birth weight
1156082|NCT01340469|probiotics
1156083|NCT01340456|4beta-OHcholesterol
1156084|NCT01340456|Midazolam
1156085|NCT01340456|CYP3A4
1156086|NCT01340456|Enzyme induction
1156087|NCT01340456|Drug metabolism
1156088|NCT01340430|her2 positive breast cancer
1156089|NCT01340430|her2 positive non operable breast cancer
1156090|NCT01340430|her2 positive locally advanced breast cancer
1156091|NCT01340430|neoadjuvant trastuzumab
1156092|NCT01340430|pathologic complete response
1156093|NCT01340417|melatonin
1156094|NCT01340417|preterm
1156095|NCT01340417|deficiency
1156096|NCT01340417|neuroprotection
1156097|NCT01340391|cast, radius fracture
1156098|NCT01340378|neonatal surgery
1156099|NCT01340378|Blalock-Taussig shunt
1156100|NCT01340339|Jaundice
1156101|NCT01340339|Hyperbilirubinemia
1156102|NCT01340339|Phototherapy and Super-LED Fluorescent lamps
1156103|NCT01340326|Post myocardial infarction ventricular remodeling
1156104|NCT01340326|valsartan
1156105|NCT01340313|caudal block, children, ultrasound, urological surgery
1156106|NCT01340300|Colorectal
1156107|NCT01340300|Breast
1156108|NCT01340300|Insulin
1156109|NCT01340300|Exercise
1156110|NCT01340287|Plant sterol
1156111|NCT01340287|Hypercholesterolemia
1156112|NCT01340287|diet
1156113|NCT01340287|dairy
1156114|NCT01340287|isoprostanes
1156115|NCT01340287|Midly hypercholesterolemic subjects
1156116|NCT01340274|Community Reinforcement and Family Training
1156117|NCT01340274|Concerned Significant Others
1156118|NCT01340274|Identified Problem Gambler
1156119|NCT01340274|Therapeutics
1156120|NCT01340248|food effect
1156121|NCT01340248|pharmacokinetics
1156122|NCT01340248|healthy male volunteers
1156123|NCT01340222|Preterm labour
1156124|NCT01340222|monocyte
1156125|NCT01340222|lymphocyte
1156126|NCT01340222|MCP-1
1156127|NCT01340222|Treg Lymphocytes
1156128|NCT01340222|biologic markers
1156129|NCT01340222|immunology
1156130|NCT01340222|HLA-DR
1156131|NCT01340222|Th17
1156132|NCT01340183|Phase I
1156133|NCT01340183|safety
1156134|NCT01340183|tolerability
1156135|NCT01340183|pharmacokinetics
1156136|NCT01340183|AZD5099
1156137|NCT01340183|volunteers
1156138|NCT01340183|safety of the drug AZD5099
1156139|NCT01340183|blood and urine levels of AZD5099
1156140|NCT01340183|single intravenous doses
1156141|NCT01340183|healthy volunteers
1156142|NCT01340157|Fexinidazole
1156143|NCT01340157|Phase I
1156144|NCT01340157|Bioavailability study
1156145|NCT01340157|Food effect
1156146|NCT01340157|Human African Trypanosomiasis
1156147|NCT01340144|total knee replacement
1156148|NCT01340144|patellar crepitus
1156149|NCT01340144|Replacement of knee joint
1156150|NCT01340131|CKD-828
1156151|NCT01340131|Hypertension
1156152|NCT01340131|Primary Hypertension
1156153|NCT01340131|Healthy Volunteer
1156154|NCT01340131|S-Amlodipine
1156155|NCT01340131|Telmisartan
1156156|NCT01340131|Amlodipine
1156157|NCT01340131|Pharmacokinetic
1156158|NCT01340131|Phase 1
1156159|NCT01340118|Asthma
1156160|NCT01340118|FEF25-75
1156161|NCT01340118|exhaled nitric oxide
1156162|NCT01340118|inhaled corticosteroid
1156163|NCT01340118|children
1156164|NCT01340105|Microwave ablation
1156165|NCT01340105|Radiofrequency ablation
1156166|NCT01340105|Randomised controlled trial
1156167|NCT01340092|Family Navigator
1156168|NCT01340092|Autistic Disorder
1156169|NCT01340092|Early Intervention
1156170|NCT01340092|Developmental Disabilities
1156171|NCT01340092|Child Development Disorders
1156172|NCT01340079|diabetes mellitus, non-insulin dependent
1156173|NCT01340066|urinary incontinence
1156174|NCT01340066|stress incontinence
1156175|NCT01340066|urge incontinence
1156176|NCT01340066|mixed incontinence
1156177|NCT01340040|Phase I
1156178|NCT01340040|cancer
1156179|NCT01340040|solid tumours
1156180|NCT01340040|advanced solid malignancies
1156181|NCT01340040|dose escalation
1156182|NCT01340040|Insulin like growth factor
1156183|NCT01340040|Japanese
1156184|NCT01340027|Overactive bladder (OAB)
1156185|NCT01340027|Frequency
1156186|NCT01340027|Micturition
1156187|NCT01340027|Urgency
1156188|NCT01340027|Urinary incontinence
1156189|NCT01340027|Urgency incontinence
1156190|NCT01340027|YM178
1156191|NCT01340014|Glaucoma
1156192|NCT01340014|Intraocular pressure
1156193|NCT01340014|Tonometry, ocular
1156194|NCT01340001|Dementia with Lewy bodies
1156195|NCT01340001|Nucleus basalis of Meynert
1156196|NCT01340001|Deep brain stimulation
1156197|NCT01339988|Stem-cells
1156198|NCT01339988|Transplantation
1156199|NCT01339988|Busulfex
1156200|NCT01339988|Cyclophosphamide
1156201|NCT01339988|Total-Body-Ittadiation
1156202|NCT01339975|Renal Cell Carcinoma
1156203|NCT01339975|Nephrectomy
1156204|NCT01339975|Antiangiogenics
1156205|NCT01339975|Chemokines
1156206|NCT01339975|Prognostic value
1156207|NCT01339975|Carcinoma
1156208|NCT01339975|Carcinoma, Renal Cell
1156209|NCT01339975|Kidney Neoplasms
1156210|NCT01339975|Kidney Diseases
1156211|NCT01339975|Neoplasms, Glandular and Epithelial
1156212|NCT01339975|Neoplasms by Histologic Type
1156213|NCT01339975|Neoplasms
1156214|NCT01339975|Adenocarcinoma
1156215|NCT01339975|Urologic Neoplasms
1156216|NCT01339975|Urogenital Neoplasms
1156217|NCT01339975|Neoplasms by Site
1156218|NCT01339975|Urologic Diseases
1156219|NCT01339975|Adjuvants, Immunologic
1156220|NCT01339975|Physiological Effects of Drugs
1156221|NCT01339975|Pharmacologic Actions
1156222|NCT01339975|Biomarkers
1156223|NCT01339975|Targeted therapies
1156224|NCT01339975|Surgery
1156225|NCT01339962|Metastatic renal cell carcinoma
1156226|NCT01339949|AMD
1156227|NCT01339949|wet AMD
1156228|NCT01339949|Macular Degeneration
1156229|NCT01339949|wet Age-related Macular Degeneration
1156230|NCT01339949|Age-Related Macular Degeneration
1156231|NCT01339949|IRay
1156232|NCT01339949|radiation
1156233|NCT01339949|Oraya
1156234|NCT01339949|Oraya Therapeutics, Inc
1156235|NCT01339949|Low-voltage stereotactic radiosurgery
1156236|NCT01339949|radiosurgery
1156237|NCT01339949|x-ray
1156238|NCT01339949|Lucentis
1156239|NCT01339949|external beam radiation
1156240|NCT01339923|Meningococcal disease
1156241|NCT01339923|Vaccines
1156242|NCT01339923|intercalated administration
1156243|NCT01339910|Acute Myelogenous Leukemia
1156244|NCT01339910|Myelodysplastic Syndrome
1156245|NCT01339897|N6022, GSNORi
1156246|NCT01339884|Friedreich ataxia
1156247|NCT01339884|Resveratrol
1156248|NCT01339884|Frataxin
1156249|NCT01339884|Cardiomyopathy
1156250|NCT01339884|Oxidative stress
1156251|NCT01339871|Pazopanib
1156252|NCT01339871|Vorinostat
1156253|NCT01339871|Advanced Malignancies
1156254|NCT01339845|Cholera vaccine
1156255|NCT01339845|Behaviour change intervention
1156256|NCT01339845|Cost effectiveness and cost-benefit
1156257|NCT01339845|Prevention of cholera
1156258|NCT01339845|Control of Cholera
1156259|NCT01339845|Vaccination
1156260|NCT01339806|mTBI
1156261|NCT01339806|Concussion
1156262|NCT01339793|corporate social responsibility
1156263|NCT01339793|social identity theory
1156264|NCT01339793|stakeholder theory
1156265|NCT01339793|organizational commitment
1156266|NCT01339793|organizational performance
1156267|NCT01339767|Autism
1156268|NCT01339767|Language Acquisition
1156269|NCT01339767|Language Development
1156270|NCT01339767|Toddlers
1156271|NCT01339754|recurrent pancreatic cancer
1156272|NCT01339754|stage IV pancreatic cancer
1156273|NCT01339754|adenocarcinoma of the pancreas
1156274|NCT01339741|Psoriasis Vulgaris
1156275|NCT01339741|Vitamin D Deficiency
1156276|NCT01339741|Vitamin D Insufficiency
1156277|NCT01339741|Vitamin D Supplement
1156278|NCT01339741|Psoriasis Area and Severity Index (PASI Score)
1156279|NCT01339741|Dermatologic Life Qualify Index (DLQI)
1156280|NCT01339715|Ryodoraku
1156281|NCT01339715|Heart Rate Variability
1156282|NCT01339715|Traditional medicine
1156283|NCT01339715|Autonomic Nervous System
1156284|NCT01339715|Acupuncture
1156285|NCT01339715|Far Infrared Ray
1156286|NCT01339715|CV12 Acupoint
1156287|NCT01339702|Traumatic Brain Injury
1156288|NCT01339702|TBI
1156289|NCT01339702|Head Trauma
1156290|NCT01339702|Acute Traumatic Brain Injury
1156291|NCT01339702|Trauma, Brain
1156292|NCT01339689|PTSD
1156293|NCT01339689|Posttraumatic Stress Disorder
1156294|NCT01339689|pharmacotherapy
1156295|NCT01339689|ganaxolone
1156296|NCT01339676|Vitamin D
1156297|NCT01339676|Multiple Sclerosis
1156298|NCT01339676|MRI
1156299|NCT01339676|Randomised Trial
1156300|NCT01339676|Finland
1156301|NCT01339650|Solid Tumor
1156302|NCT01339650|BRCA 1 and BRCA 2 Mutations
1156303|NCT01339650|Breast Cancer 1
1156304|NCT01339650|Breast Cancer 2
1156305|NCT01339650|High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
1156306|NCT01339650|Solid Tumors
1156307|NCT01339637|Impaired Glucose Tolerance
1156308|NCT01339637|Diabetes Risk Factors
1156309|NCT01339637|Dark Skin
1156310|NCT01339624|analgesia
1156311|NCT01339624|renal colic
1156312|NCT01339624|ketorolac
1156313|NCT01339624|nasal fentanyl
1156314|NCT01339624|morphine.
1156315|NCT01339624|treatment of acute renal colic
1156316|NCT01339611|quality of life
1156317|NCT01339611|medical adherence
1156318|NCT01339611|warfarin
1156319|NCT01339611|Health education
1156320|NCT01339572|autologous transplantation
1156321|NCT01339572|peripheral stem cell mobilization
1156322|NCT01339559|Epilepsy
1156323|NCT01339559|Brivaracetam
1156324|NCT01339559|Partial Onset Seizures
1156325|NCT01339559|Adjunctive treatment
1156326|NCT01339546|ecologic
1156327|NCT01339546|cross sectional
1156328|NCT01339546|trend analysis
1156329|NCT01339533|ALI
1156330|NCT01339533|ARDS
1156331|NCT01339481|Orencia
1156332|NCT01339481|Abatacept
1156333|NCT01339481|Rheumatoid Arthritis
1156334|NCT01339481|Infusion
1156335|NCT01339468|living donor liver transplantation
1156336|NCT01339468|FK506
1156337|NCT01339468|prograf
1156338|NCT01339468|advagraf
1156339|NCT01339468|Immunosuppressant
1156340|NCT01339455|Neuromyelitis Optica
1156341|NCT01339455|NMO
1156342|NCT01339455|Devic's Disease
1156343|NCT01339455|Stem Cell Transplant
1156344|NCT01339429|wound
1156345|NCT01339429|negative pressure wound therapy
1156346|NCT01339429|non-powered negative pressure wound therapy
1156347|NCT01339390|Obesity
1156348|NCT01339390|Veteran
1156349|NCT01339390|Self Care
1156350|NCT01339390|Patient Education
1156351|NCT01339390|Peer Group
1156352|NCT01339377|Ozone
1156353|NCT01339377|Oxygen
1156354|NCT01339377|Oxygen-Ozone
1156355|NCT01339377|AO-1000
1156356|NCT01339377|ActiveO
1156357|NCT01339377|Herniated Disc
1156358|NCT01339377|Disc
1156359|NCT01339377|Lumbar
1156360|NCT01339351|breast cancer
1156361|NCT01339351|social connection
1156362|NCT01339325|Laparo-endoscopic single site cholecystectomy
1156363|NCT01339325|Quality of Life
1156364|NCT01339325|Postoperative Pain
1156365|NCT01339325|Cosmetics
1156366|NCT01339325|Complication
1156367|NCT01339312|Rabies
1156368|NCT01339312|Rabies virus
1156369|NCT01339312|Purified Vero Rabies Vaccine - Serum Free
1156370|NCT01339299|COS
1156371|NCT01339299|ART
1156372|NCT01339299|Infertility
1156373|NCT01339273|TAP block
1156374|NCT01339273|Laparoscopic hemicolectomy
1156375|NCT01339273|Laparoscopic anterior resection
1156376|NCT01339273|laparoscopic colonic resection
1156377|NCT01339247|Bioequivalence
1156378|NCT01339247|Paroxetine reference/test
1156379|NCT01339247|healthy volunteers
1156380|NCT01339247|Fed condition
1156381|NCT01339234|treadmill exercise
1156382|NCT01339234|rehabilitation
1156383|NCT01339234|progressive multiple sclerosis
1156384|NCT01339234|functional ability
1156385|NCT01339234|quality of life
1156386|NCT01339234|fatigue
1156387|NCT01339221|Observational
1156388|NCT01339221|Rotarix™
1156389|NCT01339221|post-marketing
1156390|NCT01339208|Type 2 Diabetes
1156391|NCT01339195|Dementia
1156392|NCT01339195|Alzheimer disease
1156393|NCT01339195|stroke
1156394|NCT01339195|cognitive impairment
1156395|NCT01339182|somatropin
1156396|NCT01339182|PK
1156397|NCT01339182|PD
1156398|NCT01339182|male
1156399|NCT01339182|pharmacokinetics
1156400|NCT01339182|pharmacodynamics
1156401|NCT01339182|safety
1156402|NCT01339169|YF476
1156403|NCT01339169|Hypergastrinaemia
1156404|NCT01339169|netazepide
1156405|NCT01339169|gastric carcinoids
1156406|NCT01339156|Safety
1156407|NCT01339156|Tolerability
1156408|NCT01339156|Food Effect
1156409|NCT01339156|Pharmacokinetics
1156410|NCT01339143|Vildagliptin
1156411|NCT01339130|Alzheimer disease
1156412|NCT01339130|Stroke
1156413|NCT01339130|Frontotemporal Lobar Degeneration
1156414|NCT01339130|Lewy Body Dementia
1156415|NCT01339130|Huntington Disease
1156416|NCT01339130|mild cognitive impairment
1156417|NCT01339130|vascular injury
1156418|NCT01339130|Parkinson's disease
1156419|NCT01339117|irritable bowel syndrome
1156420|NCT01339117|children
1156421|NCT01339117|chronic abdominal pain
1156422|NCT01339117|recurrent abdominal pain
1156423|NCT01339104|Cardiovascular safety
1156424|NCT01339078|Biliary strictures
1156425|NCT01339078|liver transplantation
1156426|NCT01339065|ketamine
1156427|NCT01339065|inflammatory
1156428|NCT01339065|pro inflammatory
1156429|NCT01339065|pro inflammatory markers IL-6 and IL-1beta
1156430|NCT01339052|BKM120
1156431|NCT01339052|Brain tumor
1156432|NCT01339039|AMD3100
1156433|NCT01339039|plerixafor
1156434|NCT01339039|Mozobil
1156435|NCT01339039|bevacizumab
1156436|NCT01339026|Acute coronary syndrome
1156437|NCT01339026|Platelet reactivity
1156438|NCT01339026|Clopidogrel
1156439|NCT01339026|Percutaneous coronary intervention
1156440|NCT01339013|Quantification
1156441|NCT01339013|ventilatory requirements
1156442|NCT01339013|charcoal filter
1156443|NCT01339000|Colorectal Cancer
1156444|NCT01339000|Breast Cancer
1156445|NCT01339000|Immunization
1156446|NCT01339000|Immunocompromised Host
1156447|NCT01339000|Bladder Cancer
1156448|NCT01339000|Colon Cancer
1156449|NCT01338987|FLT
1156450|NCT01338987|Lupron
1156451|NCT01338987|Thymic Renewal
1156452|NCT01338987|Stem Cell Transplant
1156453|NCT01338987|Acute Lymphocytic Leukemia
1156454|NCT01338987|Acute Myelogenous Leukemia
1156455|NCT01338987|Myelodyplastic Syndrome
1156456|NCT01338974|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1156457|NCT01338974|adult acute myeloid leukemia with del(5q)
1156458|NCT01338974|adult acute myeloid leukemia with inv(16)(p13;q22)
1156459|NCT01338974|adult acute myeloid leukemia with t(16;16)(p13;q22)
1156460|NCT01338974|adult acute myeloid leukemia with t(8;21)(q22;q22)
1156461|NCT01338974|recurrent adult acute myeloid leukemia
1156462|NCT01338974|untreated adult acute myeloid leukemia
1156463|NCT01338974|adult acute minimally differentiated myeloid leukemia (M0)
1156464|NCT01338974|adult acute myeloblastic leukemia without maturation (M1)
1156465|NCT01338974|adult acute myeloblastic leukemia with maturation (M2)
1156466|NCT01338974|adult acute myelomonocytic leukemia (M4)
1156467|NCT01338974|adult acute monoblastic leukemia (M5a)
1156468|NCT01338974|adult acute monocytic leukemia (M5b)
1156469|NCT01338974|adult erythroleukemia (M6a)
1156470|NCT01338974|adult pure erythroid leukemia (M6b)
1156471|NCT01338974|adult acute megakaryoblastic leukemia (M7)
1156472|NCT01338961|Cardiopulmonary Bypass
1156473|NCT01338961|Hypothermia
1156474|NCT01338961|Normothermia
1156475|NCT01338961|Troponin I
1156476|NCT01338961|Bleeding
1156477|NCT01338935|CW 002
1156478|NCT01338935|Phase I trial
1156479|NCT01338935|safety
1156480|NCT01338935|efficacy
1156481|NCT01338935|pharmacokinetics
1156482|NCT01338935|estimated dose
1156483|NCT01338935|Neuromuscular Blocking Agents
1156484|NCT01338935|Treatment Effectiveness
1156485|NCT01338935|Drug Antagonism
1156486|NCT01338909|prasugrel
1156487|NCT01338909|clopidogrel
1156488|NCT01338909|primary percutaneous coronary intervention
1156489|NCT01338909|high platelet reactivity
1156490|NCT01338896|Rotigotine
1156491|NCT01338896|Neupro
1156492|NCT01338883|HIV-1 Infection
1156493|NCT01338883|CCR5-tropic
1156494|NCT01338883|Anti-retroviral naive
1156495|NCT01338870|Phase 2
1156496|NCT01338870|safety and efficacy study with PF-04991532
1156497|NCT01338870|Type 2 diabetes
1156498|NCT01338857|neurofibromatosis1 (NF1)
1156499|NCT01338857|Recurrent or progressive optic pathway gliomas (OPG)
1156500|NCT01338857|Recurrent or progressive low-grade glioma
1156501|NCT01338857|sorafenib
1156502|NCT01338857|low-grade astrocytoma
1156503|NCT01338844|Poor oocyte quality
1156504|NCT01338844|IVF failure
1156505|NCT01338831|prostate cancer,
1156506|NCT01338831|breast cancer,
1156507|NCT01338831|prolactin,
1156508|NCT01338831|prolactin receptor
1156509|NCT01338831|uterine leiomyoma
1156510|NCT01338818|Attention Deficit /Hyperactivity Disorder,
1156511|NCT01338818|hyperactivity
1156512|NCT01338805|Partial onset seizure
1156513|NCT01338805|seizure frequency
1156514|NCT01338805|nervous system diseases
1156515|NCT01338805|central nervous system diseases
1156516|NCT01338805|CNS
1156517|NCT01338805|brain diseases
1156518|NCT01338805|neurologic manifestations
1156519|NCT01338805|adjunctive treatment
1156520|NCT01338805|AEDs
1156521|NCT01338805|antiepileptic drug
1156522|NCT01338779|Tolerance
1156523|NCT01338779|Renal
1156524|NCT01338779|Allograft
1156525|NCT01338779|B Cell Signature
1156526|NCT01338766|spondylolisthesis
1156527|NCT01338766|lumbar spinal stenosis
1156528|NCT01338753|breast
1156529|NCT01338753|cancer
1156530|NCT01338753|Pharmacogenomics
1156531|NCT01338753|bevacizumab
1156532|NCT01338740|Chrohn's disease
1156533|NCT01338740|Moderate to severely active Crohn's disease patients
1156534|NCT01338714|HBV carrier
1156535|NCT01338714|HBV DNA title
1156536|NCT01338714|Chinese Medicine
1156537|NCT01338714|Liver function
1156538|NCT01338714|RHD-1
1156539|NCT01338701|TBI
1156540|NCT01338701|Headaches
1156541|NCT01338701|Military
1156542|NCT01338701|Acupuncture
1156543|NCT01338701|Walter Reed Army Medical Center
1156544|NCT01338701|Fort Belvoir Community Hospital
1156545|NCT01338675|Chronic granulomatous disease
1156546|NCT01338675|Hematopoietic Stem Cell Transplantation
1156547|NCT01338662|Parkinson`s disease
1156548|NCT01338649|Parkinson's disease
1156549|NCT01338649|Daytime somnolence
1156550|NCT01338649|Sleepiness
1156551|NCT01338649|Light therapy
1156552|NCT01338636|Exercise-induced pulmonary arterial hypertension (EIPAH)
1156553|NCT01338636|Pulmonary arterial hypertension (PAH)
1156554|NCT01338636|ambrisentan
1156555|NCT01338636|Advanced cardiopulmonary exercise test (CPET)
1156556|NCT01338623|bioequivalence
1156557|NCT01338623|tansulosine
1156558|NCT01338610|Ocular discomfort
1156559|NCT01338597|thyroidectomy
1156560|NCT01338597|invasiveness
1156561|NCT01338584|Pelvic floor muscle training
1156562|NCT01338584|Post prostatectomy
1156563|NCT01338584|Early regaining of urinary continence
1156564|NCT01338584|Positive improvement in quality of life
1156565|NCT01338571|stool fatty acid
1156566|NCT01338532|Hip osteoarthritis
1156567|NCT01338532|Exercise
1156568|NCT01338532|Patient Education
1156569|NCT01338532|Total Hip Replacement
1156570|NCT01338506|Military
1156571|NCT01338506|Posttraumatic Stress Disorder
1156572|NCT01338506|PTSD
1156573|NCT01338506|PostTraumatic Stress Disorders
1156574|NCT01338506|Combat
1156575|NCT01338506|Psychological Treatment
1156576|NCT01338506|Psychotherapy
1156577|NCT01338506|Trauma
1156578|NCT01338506|Posttraumatic Stress
1156579|NCT01338506|Prolonged Exposure
1156580|NCT01338506|Exposure therapy
1156581|NCT01338506|Behavior Therapy
1156582|NCT01338506|Cognitive Behavior Therapy
1156583|NCT01338506|Stress Disorders
1156584|NCT01338506|Drug Abuse
1156585|NCT01338506|Drug Dependence
1156586|NCT01338506|Alcohol Abuse
1156587|NCT01338506|Alcohol Dependence
1156588|NCT01338506|Substance Use Disorders
1156589|NCT01338506|Alcoholism
1156590|NCT01338480|trauma
1156591|NCT01338480|surgery
1156592|NCT01338480|informed consent
1156593|NCT01338467|Glaucoma
1156594|NCT01338467|Refractory glaucoma
1156595|NCT01338467|Cyclocoagulation
1156596|NCT01338467|High Intensity Focused Ultrasound
1156597|NCT01338441|Drug induced QT prolongation
1156598|NCT01338428|rape
1156599|NCT01338428|sexual assault
1156600|NCT01338428|intervention
1156601|NCT01338428|female university students
1156602|NCT01338415|pediatric
1156603|NCT01338415|pulmonary arterial hypertension
1156604|NCT01338415|bosentan
1156605|NCT01338415|Tracleer
1156606|NCT01338363|acid suppressing drugs
1156607|NCT01338363|pharmacoepidemiology
1156608|NCT01338363|children
1156609|NCT01338350|safety
1156610|NCT01338350|tolerability
1156611|NCT01338350|pharmacokinetics
1156612|NCT01338350|pharmacodynamics
1156613|NCT01338350|AZD5423
1156614|NCT01338350|Japanese
1156615|NCT01338337|Low risk International Prognostic Scoring System (IPSS) (0 or Int-1)
1156616|NCT01338337|Patients who have not responded to previous treatment with erythropoietin (EPO)
1156617|NCT01338337|Eastern Cooperative Oncology Group (ECOG) score ≤ 3
1156618|NCT01338324|Biomarker
1156619|NCT01338324|Pharmacokinetics
1156620|NCT01338324|Villous
1156621|NCT01338324|Simvastatin
1156622|NCT01338324|Celiac disease
1156623|NCT01338298|Schizophrenia
1156624|NCT01338298|Symptomatic Hyperprolactinemia
1156625|NCT01338298|Hormone
1156626|NCT01338298|Menstrual
1156627|NCT01338285|Industry Hygiene
1156628|NCT01338285|Molecular Epidemiology
1156629|NCT01338285|Cancer Susceptability
1156630|NCT01338285|Genotoxocity
1156631|NCT01338285|FISH
1156632|NCT01338142|postmenopausal
1156633|NCT01338142|women
1156634|NCT01338142|absorption
1156635|NCT01338142|calcium
1156636|NCT01338142|amorphous calcium
1156637|NCT01338129|vitamin c
1156638|NCT01338129|ascorbic acid
1156639|NCT01338129|ankle fracture
1156640|NCT01338129|crps
1156641|NCT01338129|rds
1156642|NCT01338129|crps prevention
1156643|NCT01338116|computerized decision support system
1156644|NCT01338116|PCR
1156645|NCT01338116|antibiotic treatment
1156646|NCT01338103|Pemphigus
1156647|NCT01338103|Rituximab
1156648|NCT01338103|Cylex
1156649|NCT01338090|VEGF imaging
1156650|NCT01338090|neuroendocrine tumors
1156651|NCT01338090|biomarker
1156652|NCT01338090|mTOR inhibition
1156653|NCT01338077|Alginate
1156654|NCT01338077|Gastroesophageal reflux disease
1156655|NCT01338064|Silicosis
1156656|NCT01338051|Community based participatory research
1156657|NCT01338025|HIV
1156658|NCT01338025|Bridging
1156659|NCT01338025|Strategy
1156660|NCT01338012|metastatic castrate resistant prostate cancer
1156661|NCT01338012|prostate cancer
1156662|NCT01338012|prostate
1156663|NCT01338012|immune therapy
1156664|NCT01338012|immunotherapy
1156665|NCT01338012|vaccine
1156666|NCT01338012|dendritic cells
1156667|NCT01338012|antigen-presenting cells
1156668|NCT01338012|antigen presenting cells
1156669|NCT01338012|cancer vaccine
1156670|NCT01338012|prostatic adenocarcinoma
1156671|NCT01338012|Sipuleucel-T
1156672|NCT01338012|castration resistant prostate cancer (CRPC)
1156673|NCT01338012|booster
1156674|NCT01338012|retreatment
1156675|NCT01338012|immune memory
1156676|NCT01338012|immune response
1156677|NCT01337986|Multiple Sclerosis
1156678|NCT01337986|Optic Neuritis
1156679|NCT01337986|Ampyra
1156680|NCT01337986|Dalfampridine
1156681|NCT01337986|Fampridine
1156682|NCT01337986|Remote Optic Neuritis
1156683|NCT01337986|Contrast Sensitivity
1156684|NCT01337986|Treatment
1156685|NCT01337973|violence
1156686|NCT01337973|aggression
1156687|NCT01337973|Substance-Related Disorders
1156688|NCT01337973|Alcohol-Related Disorders
1156689|NCT01337973|Drug-Related Disorders
1156690|NCT01337960|Stroke
1156691|NCT01337960|Robotics
1156692|NCT01337960|Neurorehabilitation
1156693|NCT01337947|Type 1 diabetes
1156694|NCT01337947|adolescents
1156695|NCT01337947|exercise
1156696|NCT01337947|vascular function
1156697|NCT01337934|Septic shock
1156698|NCT01337934|Sepsis
1156699|NCT01337934|Albumin
1156700|NCT01337934|Lactated Ringer
1156701|NCT01337908|depression
1156702|NCT01337908|quality of life
1156703|NCT01337908|disability
1156704|NCT01337895|Dairy
1156705|NCT01337895|obesity
1156706|NCT01337895|overweight
1156707|NCT01337895|weight loss
1156708|NCT01337895|adults
1156709|NCT01337882|Air Pollution
1156710|NCT01337882|Diesel exhaust
1156711|NCT01337882|Biodiesel exhaust
1156712|NCT01337882|Vascular function
1156713|NCT01337882|Fibrinolysis
1156714|NCT01337882|Acute vascular and endothelial responses
1156715|NCT01337869|Bascom Procedure, Limberg, Pilonidal Disease
1156716|NCT01337856|time-effectiveness
1156717|NCT01337856|hand hygiene protocols
1156718|NCT01337843|Chronic low back pain
1156719|NCT01337843|cognitive behavioral pain management
1156720|NCT01337843|coping
1156721|NCT01337843|mindfulness
1156722|NCT01337843|physical activity
1156723|NCT01337843|Back Pain Lower Back Chronic
1156724|NCT01337830|smoking
1156725|NCT01337830|smokeless
1156726|NCT01337830|aversion
1156727|NCT01337830|nicotine
1156728|NCT01337830|nicotine replacement
1156729|NCT01337817|smoking
1156730|NCT01337817|smokeless
1156731|NCT01337817|aversion
1156732|NCT01337817|nicotine
1156733|NCT01337817|nicotine replacement
1156734|NCT01337791|chronic hepatitis B
1156735|NCT01337791|hepatitis B virus
1156736|NCT01337791|perinatal transmission
1156737|NCT01337791|Telbivudine
1156738|NCT01337778|gender based violence
1156739|NCT01337778|maternal and child health
1156740|NCT01337778|women
1156741|NCT01337778|India
1156742|NCT01337765|BEZ235,
1156743|NCT01337765|MEK162
1156744|NCT01337765|RAS RAF mutations,
1156745|NCT01337765|triple negative breast cancer
1156746|NCT01337765|pancreatic cancer,
1156747|NCT01337765|NSCLC progressed on EGFR TKI
1156748|NCT01337765|PI3K/mTOR inhibitor,
1156749|NCT01337765|MEK inhibitor
1156750|NCT01337765|Advanced and selected solid tumors
1156751|NCT01337752|multiple myeloma
1156752|NCT01337752|renal insufficiency
1156880|NCT01337258|cost effectiveness
1156753|NCT01337752|untreated multiple myeloma
1156754|NCT01337739|Hysteroscopic Surgery
1156755|NCT01337739|Dexmedetomidine
1156756|NCT01337739|Sedation
1156757|NCT01337739|Opioids
1156758|NCT01337726|Depression
1156759|NCT01337726|Heart Failure
1156760|NCT01337726|Chronic Obstructive Pulmonary Disease
1156761|NCT01337726|Quality of Life
1156762|NCT01337726|Functional Impairment
1156763|NCT01337713|Anxiety, GAD, Massage
1156764|NCT01337700|ASD
1156765|NCT01337700|Autism
1156766|NCT01337700|Autism Spectrum Disorder
1156767|NCT01337700|Asperger Syndrome
1156768|NCT01337700|Asperger
1156769|NCT01337700|PDD
1156770|NCT01337700|PDD-NOS
1156771|NCT01337687|Autism
1156772|NCT01337687|Autism Spectrum Disorders
1156773|NCT01337687|Oxytocin
1156774|NCT01337687|Hollander
1156775|NCT01337687|ASD
1156776|NCT01337687|Asperger Syndrome
1156777|NCT01337687|Asperger
1156778|NCT01337661|Chronic Obstructive Pulmonary Disease
1156779|NCT01337661|COPD
1156780|NCT01337661|Acute Exacerbation of COPD
1156781|NCT01337661|AECOPD
1156782|NCT01337648|Fecal biomarkers
1156783|NCT01337648|Radiation biodosimetry
1156784|NCT01337648|Total-body irradiation (TBI)
1156785|NCT01337648|Hematopoietic stem cell transplantation
1156786|NCT01337648|Gene expression profiles
1156787|NCT01337648|Fecal metabolites
1156788|NCT01337609|Depression
1156789|NCT01337609|Irritable Bowel Syndrome
1156790|NCT01337609|Probiotic
1156791|NCT01337609|Bacillus Coagulans
1156792|NCT01337596|pain
1156793|NCT01337596|neuropathic pain
1156794|NCT01337596|headaches
1156795|NCT01337583|HIV Infections
1156796|NCT01337583|Anti-HIV agents
1156797|NCT01337583|HIV-1
1156798|NCT01337570|HIV Infections
1156799|NCT01337570|Anti-HIV agents
1156800|NCT01337570|HIV-1
1156801|NCT01337557|Allergic conjunctivitis
1156802|NCT01337544|HAPLOIDENTICAL STEM CELL TRANSPLANTATION
1156803|NCT01337544|NK CELL
1156804|NCT01337544|IL-15
1156805|NCT01337531|Ovarian Response in PCOS
1156806|NCT01337531|pregnancy rate in PCOS
1156807|NCT01337531|miscarriage rate in PCOS
1156808|NCT01337518|Prostate Specific Antigen
1156809|NCT01337518|Castration Resistant Prostate Cancer
1156810|NCT01337518|Adenocarcinoma
1156811|NCT01337518|Androgen Receptor
1156812|NCT01337518|Metastases
1156813|NCT01337505|INNO-206
1156814|NCT01337505|Phase 1
1156815|NCT01337505|DOXO-EMCH
1156816|NCT01337505|Advanced solid tumors
1156817|NCT01337492|Hepatocellular Carcinoma
1156818|NCT01337492|Orthotopic Liver Transplant
1156819|NCT01337466|Phase I
1156820|NCT01337466|FIAU
1156821|NCT01337466|Fialuridine
1156822|NCT01337466|Biodistribution
1156823|NCT01337466|Dosimetry
1156824|NCT01337466|Prosthetic
1156825|NCT01337466|Joint
1156826|NCT01337466|Infection
1156827|NCT01337466|PET-CT
1156828|NCT01337453|botulinum toxin
1156829|NCT01337453|flu like symptoms
1156830|NCT01337453|frequency of FLS
1156831|NCT01337453|Botox
1156832|NCT01337440|Ursodeoxycholic Acid
1156833|NCT01337440|sitagliptin
1156834|NCT01337440|bile acids
1156835|NCT01337440|GLP-1
1156836|NCT01337427|multiple sclerosis
1156837|NCT01337427|relapsing
1156838|NCT01337427|MS
1156839|NCT01337427|injectable
1156840|NCT01337427|subcutaneous
1156841|NCT01337427|SC
1156842|NCT01337427|PEGylated
1156843|NCT01337427|interferon
1156844|NCT01337427|PEG
1156845|NCT01337427|OCT
1156846|NCT01337427|Optical Coherence Tomography
1156847|NCT01337414|age-related macular degeneration
1156848|NCT01337414|screening
1156849|NCT01337414|monitoring
1156850|NCT01337414|diagnosis
1156851|NCT01337414|dry or non-neovascular age-related macular degeneration (high risk, intermediate, geographic atrophy or AREDS grade 3/4 AMD)
1156852|NCT01337401|Cediranib
1156853|NCT01337401|ASPS
1156854|NCT01337401|Sarcoma
1156855|NCT01337362|Diabetes
1156856|NCT01337362|Hypoglycaemia
1156857|NCT01337362|EEG
1156858|NCT01337362|Thermography
1156859|NCT01337362|Hypoglycaemia-associated autonomic failure
1156860|NCT01337362|QTc interval
1156861|NCT01337362|Hypoglycemic alarm device
1156862|NCT01337362|Hormone response
1156863|NCT01337349|Pentoxifylline
1156864|NCT01337349|Chronic Congestive Heart Failure
1156865|NCT01337349|Left Systolic Function
1156866|NCT01337349|Biomarkers
1156867|NCT01337323|allergic rhinitis, allergies, concomitant medications, allergy symptoms
1156868|NCT01337310|Advanced solid tumors
1156869|NCT01337297|crack cocaine
1156870|NCT01337297|addiction
1156871|NCT01337297|tDCS
1156872|NCT01337297|ERP
1156873|NCT01337297|P300
1156874|NCT01337297|attention
1156875|NCT01337297|inhibitory control
1156876|NCT01337297|working memory
1156877|NCT01337271|artificial, ventilation
1156878|NCT01337271|mechanical ventilation
1156879|NCT01337271|weaning
1156881|NCT01337258|dutasteride
1156882|NCT01337258|elevated risk population
1156883|NCT01337258|Prostate cancer
1156884|NCT01337258|prevention
1156885|NCT01337245|Envenomation
1156886|NCT01337245|Coral Snake
1156887|NCT01337245|Antivenom
1156888|NCT01337245|Micrurus fulvius
1156889|NCT01337232|language development disorders
1156890|NCT01337232|learning disorders
1156891|NCT01337232|sentences
1156892|NCT01337232|syntax
1156893|NCT01337232|school-age
1156894|NCT01337232|language
1156895|NCT01337219|cystic fibrosis
1156896|NCT01337219|bioequivalence
1156897|NCT01337219|pharmacokinetic
1156898|NCT01337219|sputum
1156899|NCT01337219|plasma
1156900|NCT01337206|Esophageal Stenosis
1156901|NCT01337206|Esopageal Strictures
1156902|NCT01337206|Esophageal Dysphagia
1156903|NCT01337193|stress urinary incontinence
1156904|NCT01337193|exercise
1156905|NCT01337193|pelvic floor muscles
1156906|NCT01337193|biofeedback
1156907|NCT01337193|rehabilitative ultrasound imaging
1156908|NCT01337180|lung function
1156909|NCT01337180|respiratory symptoms
1156910|NCT01337180|dust
1156911|NCT01337180|inflammation
1156912|NCT01337180|prospective
1156913|NCT01337167|Diphtheria
1156914|NCT01337167|Tetanus
1156915|NCT01337167|Whooping Cough (pertussis)
1156916|NCT01337167|Poliomyelitis
1156917|NCT01337167|Hepatitis B infection
1156918|NCT01337167|Haemophilus influenzae type b infection
1156919|NCT01337154|NSCLC
1156920|NCT01337154|non-small cell lung cancer
1156921|NCT01337154|tamibarotene
1156922|NCT01337141|Telemedicine
1156923|NCT01337141|Type 1 diabetes
1156924|NCT01337141|Metabolic control optimisation
1156925|NCT01337141|Health care costs
1156926|NCT01337141|Intervention study
1156927|NCT01337141|Access to internet
1156928|NCT01337115|Postoperative pain
1156929|NCT01337115|Knee arthroplasty
1156930|NCT01337115|Peripheral nerve blocks
1156931|NCT01337115|Sciatic nerve block
1156932|NCT01337115|Femoral nerve block
1156933|NCT01337102|Lung Cancer
1156934|NCT01337102|Stage 3b
1156935|NCT01337102|Stage 4
1156936|NCT01337102|First Line Chemotherapy Treatment
1156937|NCT01337102|Quality Of Life
1156938|NCT01337102|Palliative Care
1156939|NCT01337102|Randomized
1156940|NCT01337102|Lung Cancer Scale
1156941|NCT01337089|cancer pain
1156942|NCT01337089|opioid therapy
1156943|NCT01337089|inadequate analgesia
1156944|NCT01337089|optimized chronic opioid therapy
1156945|NCT01337063|Adverse drug events
1156946|NCT01337050|Hepatocellular Carcinoma
1156947|NCT01337050|Advanced/Metastatic solid tumors
1156948|NCT01337037|video-assisted thoracic surgery
1156949|NCT01337037|Lung cancer
1156950|NCT01337037|lobectomy
1156951|NCT01337024|HRV
1156952|NCT01337024|NDO
1156953|NCT01337024|BoNT/A,
1156954|NCT01337024|adverse effects
1156955|NCT01337011|Chronic Ischemic Cardiomyopathy
1156956|NCT01336998|necrotizing enterocolitis
1156957|NCT01336998|arginine supplementation
1156958|NCT01336998|calprotectin
1156959|NCT01336985|Chemoembolization
1156960|NCT01336985|Hepatic Metastases
1156961|NCT01336985|Irinotecan
1156962|NCT01336985|Drug Eluding Beads
1156963|NCT01336985|Colorectal Cancer
1156964|NCT01336985|Liver Cancer
1156965|NCT01336985|Hepatic Cancer
1156966|NCT01336985|Melanoma
1156967|NCT01336959|Acute Kidney Injury
1156968|NCT01336959|Cardiopulmonary Bypass
1156969|NCT01336959|CABG
1156970|NCT01336959|Cardiac Surgery
1156971|NCT01336946|lifestyle
1156972|NCT01336946|mental disorder
1156973|NCT01336907|CNV
1156974|NCT01336907|AMD
1156975|NCT01336907|Wet-treated CNV
1156976|NCT01336894|stage IA non-small cell lung cancer
1156977|NCT01336894|stage IB non-small cell lung cancer
1156978|NCT01336855|HIV
1156979|NCT01336855|Observational
1156980|NCT01336855|Pathogenesis
1156981|NCT01336855|Immunology
1156982|NCT01336855|Virology
1156983|NCT01336855|Control
1156984|NCT01336855|Healthy control
1156985|NCT01336855|Men who have sex with men
1156986|NCT01336842|panobinostat
1156987|NCT01336842|cisplatin
1156988|NCT01336842|pemetrexed
1156989|NCT01336842|dose escalation
1156990|NCT01336829|Hepatitis C
1156991|NCT01336829|HIV
1156992|NCT01336829|TMC125IFD1001
1156993|NCT01336829|TMC125
1156994|NCT01336829|Intelence
1156995|NCT01336829|etravirine
1156996|NCT01336829|ETR
1156997|NCT01336829|TMC278
1156998|NCT01336829|telaprevir
1156999|NCT01336829|TVR
1157000|NCT01336829|VX-950
1157001|NCT01336829|healthy volunteers
1157002|NCT01336829|crossover
1157003|NCT01336816|smoking
1157004|NCT01336816|smokeless
1157005|NCT01336816|aversion
1157006|NCT01336816|nicotine
1157007|NCT01336816|nicotine replacement
1157008|NCT01336790|Lymphatic disease
1157009|NCT01336790|Lymphedema
1157010|NCT01336790|Lymphangiomatosis
1157011|NCT01336790|Lymphangiectasia
1157012|NCT01336790|Protein-losing enteropathy
1157013|NCT01336790|Vascular Anomalies
1157014|NCT01336777|obesity
1157015|NCT01336777|adipocyte differentiation
1157016|NCT01336777|inflammation
1157017|NCT01336777|insulin resistance
1157018|NCT01336777|visceral fat
1157019|NCT01336777|regional fat depots
1157020|NCT01336764|driving distress
1157021|NCT01336764|veterans
1157022|NCT01336764|OEF/OIF
1157023|NCT01336738|Phase 2
1157024|NCT01336738|safety and efficacy study with PF-04991532
1157025|NCT01336738|Type 2 diabetes
1157026|NCT01336725|Morbid obesity
1157027|NCT01336725|Patient education
1157028|NCT01336712|CML
1157029|NCT01336712|CLL
1157030|NCT01336712|AML
1157031|NCT01336712|ALL
1157032|NCT01336712|MDS
1157033|NCT01336712|HD
1157034|NCT01336712|NHL
1157035|NCT01336712|MFB
1157036|NCT01336712|P.vera
1157037|NCT01336712|Essential Thrombocytosis
1157038|NCT01336699|shigellosis, vaccine, Shigella sonnei, WRSs2, WRSs3
1157039|NCT01336673|Glucophage XR
1157040|NCT01336673|Tolerability
1157041|NCT01336660|Effectiveness
1157042|NCT01336660|New Antivenom
1157043|NCT01336660|North Africa and Middle East Scorpio Envenomation
1157044|NCT01336634|BRAF V600E
1157045|NCT01336634|trametinib
1157046|NCT01336634|dabrafenib
1157047|NCT01336634|GSK2118436
1157048|NCT01336634|GSK1120212
1157049|NCT01336634|Oncology
1157050|NCT01336634|Non-Small Cell Lung Cancer
1157051|NCT01336621|Partial-onset seizures
1157052|NCT01336621|retigabine IR
1157053|NCT01336621|Open Label Extension
1157054|NCT01336621|GW582892
1157055|NCT01336621|Epilepsy
1157056|NCT01336595|total knee arthroplasty
1157057|NCT01336595|oxidized zirconium
1157058|NCT01336595|genesis II
1157059|NCT01336595|femoral component
1157060|NCT01336595|cobalt chrome
1157061|NCT01336582|suitable candidate
1157062|NCT01336582|single agent docetaxel therapy
1157063|NCT01336582|Advanced Solid Tumor
1157064|NCT01336569|Primary Open-Angle Glaucoma
1157065|NCT01336569|Ocular Hypertension
1157066|NCT01336569|Pigment Dispersion Glaucoma
1157067|NCT01336569|IOP
1157068|NCT01336556|Oral appliance
1157069|NCT01336556|Continuous positive airway pressure
1157070|NCT01336556|Obstructive Sleep Apnea Syndrome
1157071|NCT01336556|Snore
1157072|NCT01336543|Non small cell lung cancer
1157073|NCT01336543|Inoperable Stage III
1157074|NCT01336543|Inoperable
1157075|NCT01336543|Stage III
1157076|NCT01336530|Oesophageal pain
1157077|NCT01336530|Radiotherapy
1157078|NCT01336530|Combined radio-chemotherapy
1157079|NCT01336530|Oesophageal symptoms
1157080|NCT01336517|Stroke
1157081|NCT01336517|Hemiplegia
1157082|NCT01336517|AFO
1157083|NCT01336517|Gait
1157084|NCT01336478|NK
1157085|NCT01336478|natural killer
1157086|NCT01336478|immunotherapy
1157087|NCT01336478|leukemia
1157088|NCT01336478|hematological malignancies
1157089|NCT01336478|stem cell transplantation
1157090|NCT01336478|adoptive therapy
1157091|NCT01336439|Bruxism
1157092|NCT01336439|Polysomnography
1157093|NCT01336439|Botulinum toxin type A
1157094|NCT01336439|Masseter muscle
1157095|NCT01336439|Temporal muscle
1157096|NCT01336426|Peripheral Artery Disease
1157097|NCT01336426|PAD
1157098|NCT01336413|brain injuries, traumatic
1157099|NCT01336413|pregnenolone
1157100|NCT01336413|Veteran
1157101|NCT01336413|OEF/OIF
1157102|NCT01336413|neurosteroid
1157103|NCT01336400|Single cell haplotyping
1157104|NCT01336400|Preimplantation genetic diagnosis
1157105|NCT01336361|Palliative Care
1157106|NCT01336361|Physical Therapy
1157107|NCT01336361|Functionally Dependent Elderly
1157108|NCT01336348|Prasugrel
1157109|NCT01336348|Tirofiban
1157110|NCT01336348|Clopidogrel
1157111|NCT01336348|glycoprotein IIa/IIIa inhibitors
1157112|NCT01336348|P2Y12 blockers
1157113|NCT01336335|sleep apnea, obstructive
1157114|NCT01336335|sympathetic nerve activity
1157115|NCT01336335|treatment
1157116|NCT01336322|beta-cell function
1157117|NCT01336322|insulin resistance
1157118|NCT01336309|Yoga
1157119|NCT01336283|COPD
1157120|NCT01336283|Exercise Training
1157121|NCT01336270|Melanoma
1157122|NCT01336270|NK cells
1157123|NCT01336270|T lymphocytes
1157124|NCT01336270|macrophages
1157125|NCT01336257|Decision Support Techniques
1157126|NCT01336257|Electronic Health Records
1157127|NCT01336257|Reminder Systems
1157128|NCT01336257|Early Detection of Cancer
1157129|NCT01336257|Mammography
1157130|NCT01336257|Women
1157131|NCT01336244|Safety
1157132|NCT01336244|Tolerability
1157133|NCT01336244|Pharmacokinetics
1157134|NCT01336231|quality of life
1157135|NCT01336231|cognitive functions
1157136|NCT01336231|antiangiogenic agents
1157137|NCT01336231|kidney cancer
1157138|NCT01336231|metastatic
1157139|NCT01336218|Phase 1
1157140|NCT01336218|healthy volunteers
1157141|NCT01336218|Rheumatoid arthritis
1157142|NCT01336218|RA
1157143|NCT01336218|Fostamatinib
1157144|NCT01336218|Rifampicin
1157145|NCT01336218|drug-drug interaction
1157146|NCT01336218|Pharmacokinetics
1157147|NCT01336218|Amount of Rifampicin in blood
1157148|NCT01336205|Non-Cancer-Related Pain
1157149|NCT01336205|Opioid-Induced Constipation
1157150|NCT01336192|Advanced NSCLC
1157151|NCT01336192|Maintenance therapy
1157152|NCT01336192|Gemcitabine
1157153|NCT01336179|gingivitis
1157154|NCT01336179|dental plaque
1157155|NCT01336179|oral hygiene
1157156|NCT01336179|toothbrush
1157157|NCT01336179|chewing sticks
1157158|NCT01336166|H1N1
1157159|NCT01336166|Vaccine
1157160|NCT01336166|Immunogenicity
1157161|NCT01336166|Safety
1157162|NCT01336153|Safety
1157163|NCT01336153|Efficacy
1157164|NCT01336153|MLC601
1157165|NCT01336153|motor recovery
1157166|NCT01336140|regadenoson
1157167|NCT01336140|chronic kidney disease
1157168|NCT01336140|renal failure
1157169|NCT01336140|lexiscan
1157170|NCT01336140|aminophylline
1157171|NCT01336140|SPECT
1157172|NCT01336140|Myocardial Perfusion Imaging
1157173|NCT01336140|pharmacologic stress test
1157174|NCT01336140|Patients with stage IV or V chronic kidney disease being assessed with nuclear stress testing of the heart using the stress agent regadenoson (Lexiscan ®)
1157175|NCT01336127|Occupational Therapy
1157176|NCT01336127|Parkinson's Disease
1157177|NCT01336127|Effectiveness
1157178|NCT01336127|RCT
1157179|NCT01336127|Activities of daily living
1157180|NCT01336127|Participation
1157181|NCT01336127|Caregiver's Burden
1157182|NCT01336127|Economic evaluation
1157183|NCT01336101|PAD
1157184|NCT01336101|SFA
1157185|NCT01336088|dyskinesia
1157186|NCT01336088|Parkinson's disease
1157187|NCT01336075|Percutaneous radiofrequency catheter ablation
1157188|NCT01336075|Mini invasive thoracoscopic radiofrequency ablation
1157189|NCT01336062|advanced
1157190|NCT01336062|resistant to prior chemotherapy
1157191|NCT01336010|Hepatitis C
1157192|NCT01336010|Acute Hepatitis C
1157193|NCT01336010|Early chronic Hepatitis C
1157194|NCT01335997|Low-density lipoprotein
1157195|NCT01335997|LDL
1157196|NCT01335997|High-density lipoprotein
1157197|NCT01335997|HDL
1157198|NCT01335997|Niacin
1157199|NCT01335997|Lipid modifying therapy
1157200|NCT01335997|Cholesterol
1157201|NCT01335997|High cholesterol
1157202|NCT01335997|Triglycerides
1157203|NCT01335984|telemonitoring
1157204|NCT01335984|usual care
1157205|NCT01335984|telemedicine
1157206|NCT01335984|telehealth
1157207|NCT01335984|home care
1157208|NCT01335984|Health Care Quality
1157209|NCT01335984|Access
1157210|NCT01335984|Evaluation
1157211|NCT01335971|COPD
1157212|NCT01335971|Nrf2
1157213|NCT01335971|Sulforaphane
1157214|NCT01335945|Cryoablation
1157215|NCT01335945|Cryotherapy
1157216|NCT01335945|Cryosurgery
1157217|NCT01335945|Pancreas
1157218|NCT01335945|Pancreatic Cancer
1157219|NCT01335945|Celiac Plexus
1157220|NCT01335945|Pain
1157221|NCT01335945|Abdominal pain
1157222|NCT01335932|Acute Lung Injury
1157223|NCT01335932|Acute Respiratory Distress Syndrome
1157224|NCT01335932|Respiratory Failure
1157225|NCT01335932|Cytomegalovirus seropositive
1157226|NCT01335932|Infection
1157227|NCT01335932|Intravenous Ganciclovir
1157228|NCT01335932|Non-immunocompromised
1157229|NCT01335932|Valganciclovir
1157230|NCT01335919|Hemoglobin
1157231|NCT01335919|Monitoring, Physiologic
1157232|NCT01335919|Blood Gas Monitoring, Transcutaneous
1157233|NCT01335906|Cancer Screening Tests
1157234|NCT01335906|Early Diagnosis of Cancer
1157235|NCT01335906|Mammography
1157236|NCT01335906|Informed Consent
1157237|NCT01335906|Consent Forms
1157238|NCT01335893|Imaging
1157239|NCT01335893|Indocyanine Green
1157240|NCT01335893|Lung Cancer
1157241|NCT01335893|Lung Neoplasms
1157242|NCT01335893|Preliminary Study
1157243|NCT01335880|Obesity
1157244|NCT01335880|Heart Disease
1157245|NCT01335880|Seniors
1157246|NCT01335880|Elderly
1157247|NCT01335880|Chronic Disease
1157248|NCT01335880|Prevention
1157249|NCT01335854|Apnea-hypopnea index
1157250|NCT01335854|Continuous positive airway pressure
1157251|NCT01335854|CPAP adherence
1157252|NCT01335828|Echography
1157253|NCT01335828|Elastography
1157254|NCT01335828|Thyroid nodules
1157255|NCT01335828|Needles punction
1157256|NCT01335828|Thyroid surgery
1157257|NCT01335828|Patients with thyroids nodules
1157258|NCT01335802|Abortion, Spontaneous
1157259|NCT01335802|Pre-eclampsia
1157260|NCT01335802|Gestational hypertension
1157261|NCT01335802|Pregnancy Complications
1157262|NCT01335802|Subclinical hypothyroidism
1157263|NCT01335802|Thyroperoxidase antibodies (TPOab)
1157264|NCT01335802|Mitochondrial dysfunction
1157265|NCT01335789|marijuana
1157266|NCT01335789|substance abuse
1157267|NCT01335789|drug abuse
1157268|NCT01335789|marijuana dependence
1157269|NCT01335789|drug addiction
1157270|NCT01335776|Mindfulness-Based Stress Reduction
1157271|NCT01335776|Cognitive Behavior Therapy
1157272|NCT01335776|Actigraphy
1157273|NCT01335776|Noninferiority
1157274|NCT01335776|MBSR
1157275|NCT01335776|CBT-I
1157276|NCT01335763|HbA1c
1157277|NCT01335763|Multicentre before-after design
1157278|NCT01335763|Glycemic control
1157279|NCT01335763|Community pharmacists
1157280|NCT01335750|corneal staining
1157281|NCT01335698|Pediatric
1157282|NCT01335672|Myocardial infarction
1157283|NCT01335672|chronic obstructive pulmonary disease
1157284|NCT01335672|General Practice Research Database
1157285|NCT01335672|Myocardial Ischaemia National Audit Project
1157286|NCT01335672|CALIBER
1157287|NCT01335659|FFR
1157288|NCT01335659|IVUS
1157289|NCT01335659|QCA
1157290|NCT01335633|MS
1157291|NCT01335633|Neuropsychological tests
1157292|NCT01335607|HCV
1157293|NCT01335607|Hepatitis C Virus
1157294|NCT01335594|Sleep apnea, obstructive
1157295|NCT01335594|Deglutition Disorders
1157296|NCT01335594|Manometry
1157297|NCT01335594|Endoscopy
1157298|NCT01335568|Hepatocyte
1157299|NCT01335568|Scaffold
1157300|NCT01335568|Matrix
1157301|NCT01335568|Liver cirrhosis
1157302|NCT01335568|Liver insufficiency
1157303|NCT01335529|HCV infection
1157304|NCT01335529|HIV-1 infection
1157305|NCT01335503|gluten
1157306|NCT01335451|AZD5213
1157307|NCT01335451|safety
1157308|NCT01335451|pharmacokinetics
1157309|NCT01335451|single dose
1157310|NCT01335451|repeated dose
1157311|NCT01335451|young
1157312|NCT01335451|elderly
1157313|NCT01335451|Japanese
1157314|NCT01335451|healthy subject
1157315|NCT01335438|total knee arthroplasty
1157316|NCT01335438|cemented
1157317|NCT01335438|cementless
1157318|NCT01335438|fixation
1157319|NCT01335438|posterior stabilized
1157320|NCT01335438|cruciate retaining
1157321|NCT01335425|Language problems
1157322|NCT01335425|childhood epilepsy
1157323|NCT01335425|bening (rolandic) epilepsy (of childhood) with centro temporal spikes
1157324|NCT01335425|brain maturation
1157325|NCT01335425|structral connectivity
1157326|NCT01335425|functional connectivity
1157327|NCT01335399|Newly Diagnosed
1157328|NCT01335399|Previously Untreated
1157329|NCT01335373|Vaginal candidiasis
1157330|NCT01335373|Bacterial vaginosis (also known as non-specific, or Gardnerellosis, or anaerobic vaginosis)
1157331|NCT01335373|Trichomonal vaginitis
1157332|NCT01335373|Vaginitis due to mixed infection
1157333|NCT01335360|nevirapine
1157334|NCT01335360|pharmacokinetics
1157335|NCT01335347|Influenza
1157336|NCT01335347|pandemic
1157337|NCT01335347|avian influenza
1157338|NCT01335347|H5N1
1157339|NCT01335347|flu
1157340|NCT01335334|Effectiveness
1157341|NCT01335334|eradication
1157342|NCT01335334|Asymptomatic
1157343|NCT01335321|viscosupplementation
1157344|NCT01335321|intra-articular injection
1157345|NCT01335321|hyaluronic acid
1157346|NCT01335321|osteoarthritis
1157347|NCT01335321|knee
1157348|NCT01335308|Pediatric Obesity
1157349|NCT01335308|Motivational Interviewing
1157350|NCT01335308|Overweight
1157351|NCT01335308|Behavior Change
1157352|NCT01335295|Flavocoxid
1157353|NCT01335295|Duchenne muscular dystrophy
1157354|NCT01335295|pilot study
1157355|NCT01335256|Phase I, dose escalation, kinase inhibitor, cyclin-dependent kinase inhibitor, target therapy, small molecule
1157356|NCT01335243|Orthopedic Procedures
1157357|NCT01335243|Spine
1157358|NCT01335243|Interbody fusion
1157359|NCT01335243|Arthrodesis
1157360|NCT01335243|Lumbar Vertebrae
1157361|NCT01335243|CT Scan
1157362|NCT01335243|Spine balance
1157363|NCT01335243|Instrumented fusion
1157364|NCT01335243|Posterior fusion
1157365|NCT01335243|Degenerative spine
1157366|NCT01335243|painful
1157367|NCT01335230|HIV
1157368|NCT01335230|HCV
1157369|NCT01335230|Hepatitis C
1157370|NCT01335230|HIV and Hepatitis C coinfection
1157371|NCT01335230|HIV/HCV
1157372|NCT01335217|Depression
1157373|NCT01335217|Major Depressive Disorder (MDD)
1157374|NCT01335217|Trigeminal Nerve Stimulation
1157375|NCT01335217|Post Traumatic Stress Disorder
1157376|NCT01335204|Castration-resistant prostate cancer
1157377|NCT01335204|Prostate Cancer
1157378|NCT01335204|JEVTANA
1157379|NCT01335204|Cabazitaxel
1157380|NCT01335204|Bavituximab
1157381|NCT01335191|HIV
1157382|NCT01335191|vaccine
1157383|NCT01335191|lipopeptide
1157384|NCT01335191|Tat
1157385|NCT01335191|TUTI-16
1157386|NCT01335191|THYMON
1157387|NCT01335178|Tobacco smoke exposure
1157511|NCT01334658|Corneal endothelium
1157388|NCT01335178|Secondhand smoke exposure
1157389|NCT01335178|Passive smoking
1157390|NCT01335178|Child health
1157391|NCT01335178|Prevention
1157392|NCT01335178|Tobacco control
1157393|NCT01335178|Motivational Interviewing
1157394|NCT01335178|Air quality
1157395|NCT01335178|Pilot Study
1157396|NCT01335165|PNH
1157397|NCT01335152|stress
1157398|NCT01335152|depression
1157399|NCT01335152|anxiety
1157400|NCT01335152|web
1157401|NCT01335152|internet
1157402|NCT01335152|coping
1157403|NCT01335139|sublingual immunotherapy
1157404|NCT01335139|subcutaneous immunotherapy
1157405|NCT01335126|Artificial tears
1157406|NCT01335100|Functional outcome
1157407|NCT01335100|Quality of life
1157408|NCT01335100|Global Positioning System (GPS)
1157409|NCT01335100|Advanced tracking technologies
1157410|NCT01335100|Time-space activity.
1157411|NCT01335100|walking speed
1157412|NCT01335100|distances
1157413|NCT01335100|number of walking events and destinations
1157414|NCT01335087|sleep apnea
1157415|NCT01335087|secondary prevention
1157416|NCT01335087|cardiovascular endpoint
1157417|NCT01335061|Hemophilia B
1157418|NCT01335061|on-demand
1157419|NCT01335061|prophylaxis
1157420|NCT01335061|nonacog alfa
1157421|NCT01335061|BeneFIX
1157422|NCT01335061|FIX
1157423|NCT01335048|Clopidogrel
1157424|NCT01335048|Statins
1157425|NCT01335048|Platelet reactivity
1157426|NCT01335048|Point-of-care platelet function test
1157427|NCT01335035|Iron metabolism,
1157428|NCT01335035|Allogenetic Hematopoietic Stem Cell Transplant,
1157429|NCT01335035|haematological diseases
1157430|NCT01335009|melanoma
1157431|NCT01335009|malignant
1157432|NCT01335009|metastatic
1157433|NCT01334983|cancer
1157434|NCT01334983|function
1157435|NCT01334983|fatigue
1157436|NCT01334983|late stage
1157437|NCT01334983|metastases
1157438|NCT01334983|quality of life
1157439|NCT01334983|functional decline in cancer
1157440|NCT01334944|Pain
1157441|NCT01334944|Fever
1157442|NCT01334931|Exposure to Ionizing Radiation
1157443|NCT01334931|Occupational Exposure to Radiation
1157444|NCT01334918|Coronary Artery Disease (CAD)
1157445|NCT01334918|ischemia
1157446|NCT01334918|pharmacologic stress
1157447|NCT01334918|regadenoson
1157448|NCT01334905|Overactive Bladder
1157449|NCT01334905|Urinary incontinence
1157450|NCT01334905|YM178
1157451|NCT01334905|mirabegron
1157452|NCT01334905|Food effect
1157453|NCT01334879|radiation
1157454|NCT01334879|retinopathy
1157455|NCT01334879|anti-VEGF
1157456|NCT01334879|eye
1157457|NCT01334866|Minimally invasive coronary surgery
1157458|NCT01334866|Coronary artery bypass grafting
1157459|NCT01334866|MICS CABG
1157460|NCT01334840|Cardiovascular risk
1157461|NCT01334840|Cholecystokinin
1157462|NCT01334840|Gallbladder emptying
1157463|NCT01334840|Lipid absorption
1157464|NCT01334840|Postprandial triacylglycerols
1157465|NCT01334840|Sodium-bicarbonated mineral water
1157466|NCT01334827|topical microbicide
1157467|NCT01334827|primary prevention
1157468|NCT01334827|HIV
1157469|NCT01334827|AIDS
1157470|NCT01334827|drug delivery systems
1157471|NCT01334801|aortic stenosis
1157472|NCT01334801|von Willebrand factor
1157473|NCT01334801|mitral valve replacement
1157474|NCT01334801|aortic valve replacement
1157475|NCT01334801|prosthetic valve dysfunction
1157476|NCT01334801|brain natriuretic peptide
1157477|NCT01334801|mitral valve regurgitation
1157478|NCT01334801|aortic valve regurgitation
1157479|NCT01334801|hypertrophic cardiomyopathy
1157480|NCT01334801|tricuspid insufficiency
1157481|NCT01334788|sleep deprivation
1157482|NCT01334788|sleep restriction
1157483|NCT01334775|Inguinal hernia
1157484|NCT01334775|Postoperative pain
1157485|NCT01334775|Surgical mesh
1157486|NCT01334762|minimal to mild endometriosis
1157487|NCT01334762|letrozole
1157488|NCT01334762|clomiphene citrate
1157489|NCT01334762|IUI
1157490|NCT01334749|Stroke
1157491|NCT01334749|Dementia
1157492|NCT01334749|Dementia, Vascular
1157493|NCT01334749|Alzheimer's Disease
1157494|NCT01334749|Intracranial Hemorrhage
1157495|NCT01334749|Brain Ischemia
1157496|NCT01334736|smoking cessation
1157497|NCT01334736|contingency management
1157498|NCT01334736|spirometry
1157499|NCT01334736|lung age
1157500|NCT01334723|Benign prostatic hyperplasia, enlarged prostate, 5-alpha-reductase inhibitor, adherence, surgery, acute urinary retention
1157501|NCT01334710|Liver cancer
1157502|NCT01334697|Cardiotrophin-1
1157503|NCT01334697|CT-1
1157504|NCT01334684|Type 2 Diabetes Mellitus
1157505|NCT01334684|Metformin Efficacy
1157506|NCT01334684|Gene Expression Profiles
1157507|NCT01334684|Personalized Medicine
1157508|NCT01334671|ST-elevation myocardial infarction(STEMI)
1157509|NCT01334671|emergency percutaneous coronary intervention(PCI)
1157510|NCT01334671|lipitor or Atorvastatin
1157512|NCT01334658|Cataract surgery
1157513|NCT01334658|Irrigation solutions intraocular
1157514|NCT01334658|Phacoemulsification
1157515|NCT01334645|Copeptin
1157516|NCT01334645|Troponin
1157517|NCT01334645|Diagnosis
1157518|NCT01334645|Chest pain
1157519|NCT01334645|Acute Coronary Syndrome
1157520|NCT01334645|Acute Myocardial Infarction
1157521|NCT01334645|Unstable Angina
1157522|NCT01334632|Electrophysiological study
1157523|NCT01334632|Nerve block
1157524|NCT01334632|Analgesia, patient-controlled
1157525|NCT01334632|Shoulder surgery
1157526|NCT01334619|Anesthetic techniques,regional
1157527|NCT01334619|Drug delivery,volume
1157528|NCT01334619|Anesthetic, local: ropivacaine
1157529|NCT01334606|diabetes
1157530|NCT01334606|pen needle
1157531|NCT01334606|basal insulin
1157532|NCT01334606|long-acting insulin
1157533|NCT01334554|African American
1157534|NCT01334554|Women
1157535|NCT01334554|Metabolic Syndrome
1157536|NCT01334554|Endothelial function
1157537|NCT01334554|Sildenafil citrate
1157538|NCT01334528|Deployment Acquired Mild Traumatic Brain Injury
1157539|NCT01334528|Persistent Post-Concussive Symptoms
1157540|NCT01334528|Repeated measures
1157541|NCT01334502|contiguous stage II adult diffuse large cell lymphoma
1157542|NCT01334502|noncontiguous stage II adult diffuse large cell lymphoma
1157543|NCT01334502|stage III adult diffuse large cell lymphoma
1157544|NCT01334502|stage IV adult diffuse large cell lymphoma
1157545|NCT01334489|Monochorionic pregnancy
1157546|NCT01334489|Twin to twin transfusion syndrome
1157547|NCT01334489|Cervical pessary
1157548|NCT01334489|Cervical lenght
1157549|NCT01334476|Data Repository
1157550|NCT01334476|Facilitate Recruitment of Participants for Ongoing and Future Research
1157551|NCT01334450|Improvement of ADAS-COG
1157552|NCT01334437|blood test
1157553|NCT01334437|ovarian cancer
1157554|NCT01334437|Associated Auto Antibodies
1157555|NCT01334424|Robot assisted laparoscopic radical prostatectomy
1157556|NCT01334424|Hypoperfusion reperfusion injury,
1157557|NCT01334424|Propofol
1157558|NCT01334424|oxidative stress
1157559|NCT01334398|Traumatic Brain Injury
1157560|NCT01334372|suicide
1157561|NCT01334372|veterans
1157562|NCT01334372|assessment
1157563|NCT01334372|CAMS
1157564|NCT01334359|physical activity
1157565|NCT01334359|fitness
1157566|NCT01334359|brain health
1157567|NCT01334359|cognition
1157568|NCT01334359|scholastic achievement
1157569|NCT01334359|preadolescent children
1157570|NCT01334346|Running
1157571|NCT01334346|Footwear
1157572|NCT01334346|Injury incidence
1157573|NCT01334346|injury risk
1157574|NCT01334346|pain
1157575|NCT01334333|kidney transplant
1157576|NCT01334333|tacrolimus
1157577|NCT01334333|medication adherence
1157578|NCT01334333|depression
1157579|NCT01334333|neuropsychological
1157580|NCT01334333|cognition
1157581|NCT01334333|Self-efficacy
1157582|NCT01334333|everyday problem solving
1157583|NCT01334320|oral squamous cell carcinoma
1157584|NCT01334320|elective neck dissection
1157585|NCT01334320|"watchful waiting"
1157586|NCT01334320|survival benefit
1157587|NCT01334320|recurrence rate
1157588|NCT01334307|Emphysema
1157589|NCT01334307|RePneu
1157590|NCT01334294|CNV
1157591|NCT01334294|AMD
1157592|NCT01334281|Panel Reactive Antibody (PRA)
1157593|NCT01334281|Sensitization
1157594|NCT01334281|Organ Transplant
1157595|NCT01334268|In-stent Late Lumen Loss (LLL)
1157596|NCT01334268|TARGET VESSEL FAILURE (TVF)
1157597|NCT01334268|MYOCARDIAL INFARCTION (MI)
1157598|NCT01334268|TARGET VESSEL REVASCULARIZATION (TVR)
1157599|NCT01334268|TARGET LESION REVASCULARIZATION (TLR)
1157600|NCT01334268|TARGET LESION FAILURE (TLF)
1157601|NCT01334268|STENT THROMBOSIS
1157602|NCT01334268|RESTENOTIC LESION
1157603|NCT01334268|PERCUTANEOUS CORONARY INTERVENTION (PCI)
1157604|NCT01334268|REAL-WORLD
1157605|NCT01334268|THE RANDOMIZED CONTROLLED TRIAL
1157606|NCT01334255|Pigment epithelial detachment
1157607|NCT01334255|Exudative age-related macular degeneration
1157608|NCT01334255|Polypoidal choroidal vasculopathy
1157609|NCT01334242|Pharmacodynamics
1157610|NCT01334229|sitagliptin
1157611|NCT01334229|diabetes
1157612|NCT01334229|apolipoprotein B48 and B100
1157613|NCT01334216|smoking
1157614|NCT01334216|quitting
1157615|NCT01334216|tobacco
1157616|NCT01334216|Parental
1157617|NCT01334203|Chronic angina
1157618|NCT01334203|Angina pectoris
1157619|NCT01334203|Coronary artery disease
1157620|NCT01334203|Type 2 Diabetes Mellitus
1157621|NCT01334203|ETT
1157622|NCT01334190|AE adverse event
1157623|NCT01334190|AIDS acquired immunodeficiency syndrome
1157624|NCT01334190|ALT (SGPT) alanine aminotransferase
1157625|NCT01334190|ART antiretroviral therapy
1157626|NCT01334190|AST (SGOT) aspartate aminotransferase
1157627|NCT01334190|DCF data collection forms
1157628|NCT01334190|DMC Data Monitoring Committee
1157754|NCT01333683|tinnitus
1157629|NCT01334190|FDA (U.S.) Food and Drug Administration
1157630|NCT01334190|GCP Good Clinical Practice guidelines
1157631|NCT01334190|HB sAg Hepatitis B surface antigen
1157632|NCT01334190|ICH International Conference of Harmonisation
1157633|NCT01334190|IND Investigational New Drug Application
1157634|NCT01334190|IRB Institutional Review Board
1157635|NCT01334190|IU international units
1157636|NCT01334190|mg milligram(s)
1157637|NCT01334190|mm3 cubic millimeter(s)
1157638|NCT01334190|PCR polymerase chain reaction
1157639|NCT01334190|SAE serious adverse event
1157640|NCT01334190|µg microgram
1157641|NCT01334190|ULN upper limit of the normal range
1157642|NCT01334190|WB Western Blot
1157643|NCT01334190|post-marketing monitoring
1157644|NCT01334190|safety
1157645|NCT01334190|efficacy
1157646|NCT01334190|acceptability
1157647|NCT01334164|substance use disorder
1157648|NCT01334164|offenders
1157649|NCT01334164|reentry
1157650|NCT01334164|HIV risk behavior
1157651|NCT01334164|recidivism
1157652|NCT01334138|hypertension
1157653|NCT01334138|sodium
1157654|NCT01334138|diet
1157655|NCT01334125|Double Diabetes
1157656|NCT01334125|Type 1 diabetes
1157657|NCT01334125|Type 2 diabetes
1157658|NCT01334125|Obesity
1157659|NCT01334125|Acanthosis nigricans
1157660|NCT01334125|Diabetes associated autoantibodies
1157661|NCT01334112|Hepatocellular Carcinoma
1157662|NCT01334112|Advanced Hepatocellular Carcinoma
1157663|NCT01334112|Liver Cancer
1157664|NCT01334112|Axitinib
1157665|NCT01334112|AG-013736
1157666|NCT01334086|AML
1157667|NCT01334073|Phase I
1157668|NCT01334073|Axitinib
1157669|NCT01334073|Everolimus
1157670|NCT01334073|Maximum tolerated dose (MTD)
1157671|NCT01334073|solid tumor
1157672|NCT01334073|Renal cell cancer (RCC)
1157673|NCT01334073|Pharmacokinetics (PK/PD)
1157674|NCT01334021|Genomic Testing
1157675|NCT01334021|Genetic Testing
1157676|NCT01334021|HER2 Negative
1157677|NCT01334021|Primary Invasive Breast Cancer
1157678|NCT01334021|Stage I
1157679|NCT01334021|Stage II
1157680|NCT01334021|Stage III
1157681|NCT01334021|Registry
1157682|NCT01334021|Biopsy
1157683|NCT01334021|Tumor sampling
1157684|NCT01334008|Circulating tumor DNA
1157685|NCT01334008|Choroidal Melanoma
1157686|NCT01333995|Peer counselling
1157687|NCT01333995|Infant
1157688|NCT01333995|Intervention
1157689|NCT01333995|breastfeeding
1157690|NCT01333995|complementary feeding
1157691|NCT01333995|stunting
1157692|NCT01333982|Neonatal Sepsis
1157693|NCT01333982|Evaluation
1157694|NCT01333982|Bangladesh
1157695|NCT01333982|Drying
1157696|NCT01333982|Wrapping
1157697|NCT01333982|Bathing
1157698|NCT01333943|Total Knee Replacement
1157699|NCT01333943|Regional Anesthesia
1157700|NCT01333943|Quadriceps
1157701|NCT01333943|Muscle Strength
1157702|NCT01333943|Muscle Strength Dynamometer
1157703|NCT01333943|Quadriceps muscle strength after regional anesthesia for TKA
1157704|NCT01333930|immunological effects
1157705|NCT01333930|Active O2
1157706|NCT01333930|strenuous exercise
1157707|NCT01333930|procedures
1157708|NCT01333930|pharmacodynamic parameters
1157709|NCT01333930|blood sampling scheme
1157710|NCT01333917|Curcumin
1157711|NCT01333917|Colorectal Cancer
1157712|NCT01333917|GWAS
1157713|NCT01333865|Memantine
1157714|NCT01333865|Namenda
1157715|NCT01333865|Autism Spectrum Disorders
1157716|NCT01333865|Pervasive Developmental Disorders
1157717|NCT01333865|Adults
1157718|NCT01333852|head and neck cancer
1157719|NCT01333852|paclitaxel
1157720|NCT01333852|metformin
1157721|NCT01333852|squamous cell carcinoma
1157722|NCT01333839|CABG surgery
1157723|NCT01333839|exercise intervention
1157724|NCT01333839|insulin sensitivity
1157725|NCT01333839|muscle mass
1157726|NCT01333813|immune response
1157727|NCT01333813|Engerix-B™Kinder
1157728|NCT01333813|Persistence
1157729|NCT01333813|challenge dose
1157730|NCT01333787|dietary fiber
1157731|NCT01333787|clinical trial
1157732|NCT01333787|constipation
1157733|NCT01333787|children
1157734|NCT01333774|Diabetes
1157735|NCT01333774|Acarbose
1157736|NCT01333774|Diet
1157737|NCT01333774|Compliance
1157738|NCT01333774|Advising
1157739|NCT01333761|right to left cardiac shunt finding
1157740|NCT01333748|breast cancer
1157741|NCT01333748|ovarian cancer
1157742|NCT01333748|BRCA 1 and BRCA 2
1157743|NCT01333735|cognitive functions
1157744|NCT01333735|quality of life
1157745|NCT01333735|breast cancer
1157746|NCT01333735|chemotherapy
1157747|NCT01333735|ages patients
1157748|NCT01333709|locally advanced rectal carcinoma
1157749|NCT01333709|Tailored treatment strategy
1157750|NCT01333709|MRI volumetry
1157751|NCT01333709|Early tumor response
1157752|NCT01333696|Squamous cell carcinoma of head and neck
1157753|NCT01333696|Pemetrexed
1157755|NCT01333683|hearing loss
1157756|NCT01333683|arterial hypertension
1157757|NCT01333683|ototoxicity
1157758|NCT01333657|sTREM-1
1157759|NCT01333657|sepsis
1157760|NCT01333657|SIRS
1157761|NCT01333657|blood
1157762|NCT01333657|urine
1157763|NCT01333657|diagnosis
1157764|NCT01333657|prognosis
1157765|NCT01333644|HIV Infection
1157766|NCT01333644|Endothelial function
1157767|NCT01333644|Cardiovascular Disease
1157768|NCT01333644|Inflammation
1157769|NCT01333644|Antiretroviral medication
1157770|NCT01333644|Treatment naive
1157771|NCT01333644|Treatment experienced
1157772|NCT01333631|Locally advanced unresectable pancreatic cancer
1157773|NCT01333618|Filter Tilt
1157774|NCT01333618|Preventional efficiency
1157775|NCT01333618|Günther Tulip filter
1157776|NCT01333618|Transfemoral Approach
1157777|NCT01333605|Hodgkin lymphoma
1157778|NCT01333605|Chemotherapy
1157779|NCT01333605|IGEV
1157780|NCT01333605|Autologous stem cell transplantation
1157781|NCT01333592|Type 2 diabetes
1157782|NCT01333592|HbA1c
1157783|NCT01333592|Long-term study
1157784|NCT01333553|birthmark
1157785|NCT01333540|constipation
1157786|NCT01333540|opioid induced
1157787|NCT01333514|diabetes
1157788|NCT01333514|prandial
1157789|NCT01333514|insulin
1157790|NCT01333514|aspart
1157791|NCT01333514|carbohydrate
1157792|NCT01333514|inpatient
1157793|NCT01333514|novolog
1157794|NCT01333501|Multiple sclerosis
1157795|NCT01333501|cognitive symptoms
1157796|NCT01333501|relapsing-remitting multiple sclerosis (RRMS)
1157797|NCT01333501|fingolimod
1157798|NCT01333501|Magnetic resonance imaging (MRI)
1157799|NCT01333488|Traumatic
1157800|NCT01333488|Brain
1157801|NCT01333488|Injury
1157802|NCT01333475|Targeted Therapy
1157803|NCT01333475|KRAS Mutation
1157804|NCT01333475|Metastatic Colorectal Cancer
1157805|NCT01333475|Colorectal Cancer
1157806|NCT01333449|Decitabine
1157807|NCT01333449|MDS, myelodysplastic syndrome
1157808|NCT01333449|prospective open label, phaseII
1157809|NCT01333449|Allogeneic Hematopoietic cell transplant
1157810|NCT01333423|Breast Cancer
1157811|NCT01333423|Metastatic Triple Negative
1157812|NCT01333423|ER/PR/HER2 negative
1157813|NCT01333423|Locally advanced
1157814|NCT01333423|Stage IV
1157815|NCT01333423|Metastatic
1157816|NCT01333423|Seliciclib
1157817|NCT01333423|Liposomal Doxorubicin
1157818|NCT01333423|Doxil
1157819|NCT01333423|Doxorubicin Hydrochloride (Liposomal)
1157820|NCT01333410|vitiligo
1157821|NCT01333410|tacrolimus
1157822|NCT01333410|mometasone furoate
1157823|NCT01333371|Distal Radius
1157824|NCT01333371|Volar locked plating
1157825|NCT01333371|Cost Effectiveness
1157826|NCT01333371|Randomization
1157827|NCT01333371|Outcomes
1157828|NCT01333358|Relapsing
1157829|NCT01333358|remitting
1157830|NCT01333345|Cataract replacement surgery
1157831|NCT01333345|implantation
1157832|NCT01333345|EC-3 IOL
1157833|NCT01333332|Pancreas
1157834|NCT01333332|Radiation
1157835|NCT01333319|liver transplantation
1157836|NCT01333319|acute kidney injury
1157837|NCT01333306|tDCS
1157838|NCT01333306|cognitive training
1157839|NCT01333293|mastocytosis
1157840|NCT01333293|omalizumab
1157841|NCT01333267|Endocrine System Diseases
1157842|NCT01333267|MusculoSkeletal System Disease
1157843|NCT01333267|Hormones
1157844|NCT01333267|Postmenopausal Women
1157845|NCT01333267|Bone metabolism
1157846|NCT01333267|Physiologic Properties
1157847|NCT01333267|African-Americans
1157848|NCT01333254|urinary tract infections
1157849|NCT01333254|urinary catheterisation
1157850|NCT01333241|Hispanic Americans
1157851|NCT01333241|Cardiovascular disease
1157852|NCT01333241|Obesity
1157853|NCT01333241|Intervention
1157854|NCT01333215|Suicide, Attempted
1157855|NCT01333215|Cognitive Symptoms
1157856|NCT01333202|Fresh lime
1157857|NCT01333202|nicotine gum
1157858|NCT01333202|smoking cessation
1157859|NCT01333202|craving
1157860|NCT01333189|total knee arthroplasty
1157861|NCT01333189|osteoarthritis
1157862|NCT01333189|biomechanics
1157863|NCT01333189|gait
1157864|NCT01333176|Type 2 Diabetes
1157865|NCT01333176|Hb A1c screening for diabetes in aboriginals
1157866|NCT01333150|Temporomandibular disorders
1157867|NCT01333150|Orofacial pain
1157868|NCT01333137|Triple negative breast cancer
1157869|NCT01333124|Preoperative chemoradiotherapy with Gemcitabine
1157870|NCT01333098|anxiety
1157871|NCT01333098|older adult
1157872|NCT01333098|memory
1157873|NCT01333098|cognitive
1157874|NCT01333098|Saint Louis
1157875|NCT01333098|treatment
1157876|NCT01333098|Non-dementia cognitive impairment in older adults with anxiety disorders.
1157877|NCT01333085|stage IV squamous cell carcinoma of the hypopharynx
1157878|NCT01333085|stage IV squamous cell carcinoma of the larynx
1158005|NCT01332565|pharmacokinetics
1157879|NCT01333085|stage IV verrucous carcinoma of the larynx
1157880|NCT01333085|stage IV squamous cell carcinoma of the lip and oral cavity
1157881|NCT01333085|stage IV verrucous carcinoma of the oral cavity
1157882|NCT01333085|stage IV squamous cell carcinoma of the oropharynx
1157883|NCT01333085|tongue cancer
1157884|NCT01333072|Autistic Disorder
1157885|NCT01333059|Sedation
1157886|NCT01333059|Cycling
1157887|NCT01333059|Pediatric
1157888|NCT01333046|Hodgkin Lymphoma
1157889|NCT01333046|Non-Hodgkin Lymphoma
1157890|NCT01333046|CTL
1157891|NCT01333033|adenocarcinoma of the gastroesophageal junction
1157892|NCT01333033|adenocarcinoma of the esophagus
1157893|NCT01333033|stage IB esophageal cancer
1157894|NCT01333033|stage IIA esophageal cancer
1157895|NCT01333033|stage IIB esophageal cancer
1157896|NCT01333033|stage IIIA esophageal cancer
1157897|NCT01333033|stage IIIB esophageal cancer
1157898|NCT01333033|stage IIIC esophageal cancer
1157899|NCT01333020|emulsion
1157900|NCT01333020|protein
1157901|NCT01333020|cross-linking
1157902|NCT01333020|gastric emptying
1157903|NCT01332955|Hepatitis C, Chronic
1157904|NCT01332955|HIV Infection
1157905|NCT01332955|Telaprevir
1157906|NCT01332955|Peginterferon alfa-2a
1157907|NCT01332955|Ribavirin
1157908|NCT01332955|Pharmacokinetic
1157909|NCT01332955|Pharmacogenetic
1157910|NCT01332955|Previous peginterferon-ribavirin regimen failure
1157911|NCT01332942|Anemia
1157912|NCT01332929|brain radiation therapy
1157913|NCT01332929|Bevacizumab
1157914|NCT01332929|brain metastasis
1157915|NCT01332929|solid tumor
1157916|NCT01332916|No metastatic breast cancer
1157917|NCT01332916|cognitive troubles
1157918|NCT01332916|adjuvant chemotherapy
1157919|NCT01332890|Drug interaction
1157920|NCT01332890|revaprazan
1157921|NCT01332890|Itopride HCI
1157922|NCT01332877|Obesity
1157923|NCT01332877|Weight loss
1157924|NCT01332877|Ghrelin
1157925|NCT01332877|Satiety
1157926|NCT01332877|Hunger
1157927|NCT01332864|headache
1157928|NCT01332864|migraine
1157929|NCT01332864|cephalgia
1157930|NCT01332864|osteopathic manipulative treatment
1157931|NCT01332851|child welfare
1157932|NCT01332851|child protective services
1157933|NCT01332851|child abuse
1157934|NCT01332851|child neglect
1157935|NCT01332851|infant
1157936|NCT01332851|parenting
1157937|NCT01332825|olfaction
1157938|NCT01332825|smell dysfunction
1157939|NCT01332812|Dexamethasone
1157940|NCT01332812|Postoperative cognitive dysfunction
1157941|NCT01332812|General Anesthesia
1157942|NCT01332812|neuropsychological tests
1157943|NCT01332799|cardiovascular disease
1157944|NCT01332799|kidney transplantation
1157945|NCT01332786|AML
1157946|NCT01332760|ergonomics
1157947|NCT01332760|workplace
1157948|NCT01332760|occupational
1157949|NCT01332760|tool
1157950|NCT01332760|dental
1157951|NCT01332760|dentist
1157952|NCT01332747|TC
1157953|NCT01332747|TG
1157954|NCT01332747|HDL
1157955|NCT01332747|LDL
1157956|NCT01332747|VLDL
1157957|NCT01332734|microcirculation
1157958|NCT01332734|SDF
1157959|NCT01332734|magnesium sulfate
1157960|NCT01332721|TRC105
1157961|NCT01332721|CD105
1157962|NCT01332721|Endoglin
1157963|NCT01332721|Solid Tumors
1157964|NCT01332721|Avastin
1157965|NCT01332721|Bevacizumab
1157966|NCT01332708|high complex carbohydrates
1157967|NCT01332708|hypocaloric diet
1157968|NCT01332708|cholinergic status
1157969|NCT01332708|overweight
1157970|NCT01332708|obese
1157971|NCT01332695|tremor
1157972|NCT01332695|WHIGET
1157973|NCT01332695|Fahn Tolosa Marin Scale
1157974|NCT01332682|head and neck cancer
1157975|NCT01332682|resistance training
1157976|NCT01332682|nutrition counseling
1157977|NCT01332682|pharyngeal or laryngeal cancer
1157978|NCT01332669|hepatocellular carcinoma
1157979|NCT01332669|chemoembolization
1157980|NCT01332669|drug eluting beads
1157981|NCT01332669|HCC
1157982|NCT01332669|Liver cancer
1157983|NCT01332669|Korea
1157984|NCT01332643|Preimplantation Genetic Diagnosis
1157985|NCT01332643|recurrent pregnancy loss
1157986|NCT01332643|infertility
1157987|NCT01332643|genetic screening
1157988|NCT01332643|trisomy 21
1157989|NCT01332643|Down syndrome
1157990|NCT01332630|Breast cancer
1157991|NCT01332630|Brain metastases
1157992|NCT01332630|TPI 287
1157993|NCT01332630|Computed Tomography
1157994|NCT01332630|CT
1157995|NCT01332630|Magnetic Resonance Imaging
1157996|NCT01332630|MRI
1157997|NCT01332617|Multiple Myeloma
1157998|NCT01332617|Simvastatin
1157999|NCT01332617|Zoledronic
1158000|NCT01332617|Bortezomib
1158001|NCT01332617|Bendamustine
1158002|NCT01332617|Methylprednisolone
1158003|NCT01332591|STEMI, primary PCI, non-infarct, non-culprit lesion, CABG
1158004|NCT01332565|GSK1349572
1158006|NCT01332565|Japanese
1158007|NCT01332565|HIV
1158008|NCT01332552|pharmacokinetics
1158009|NCT01332552|First administration to human
1158010|NCT01332552|antiviral activity
1158011|NCT01332552|safety
1158012|NCT01332552|hepatitis C
1158013|NCT01332526|FFT
1158014|NCT01332526|inflammation
1158015|NCT01332526|lipid metabolism
1158016|NCT01332526|hyperuricemia
1158017|NCT01332526|Agents Affecting Uric Acid Metabolism
1158018|NCT01332513|Healthy Volunteers
1158019|NCT01332500|Triptans
1158020|NCT01332500|Migraine
1158021|NCT01332487|5-alpha-reductase inhibitor
1158022|NCT01332487|prostate surgery
1158023|NCT01332487|alpha-blocker
1158024|NCT01332487|enlarged prostate
1158025|NCT01332487|acute urinary retention
1158026|NCT01332487|Benign prostatic hyperplasia
1158027|NCT01332474|Botox
1158028|NCT01332474|JCP
1158029|NCT01332448|Xenical
1158030|NCT01332448|Alli
1158031|NCT01332448|safety
1158032|NCT01332448|meta-analysis
1158033|NCT01332448|liver-function test
1158034|NCT01332448|Roche
1158035|NCT01332448|orlistat
1158164|NCT01331863|Malignant
1158036|NCT01332435|Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, early, costs
1158037|NCT01332370|Retrospective
1158038|NCT01332370|Type 2 Diabetes
1158039|NCT01332370|Cost Analysis
1158040|NCT01332370|Rosiglitazone
1158041|NCT01332370|Sitagliptin
1158042|NCT01332357|fluticasone/propionate salmeterol combination
1158043|NCT01332357|hospitalization
1158044|NCT01332357|emergency department
1158045|NCT01332357|asthma
1158046|NCT01332344|fluticasone propionate/salmeterol combination
1158047|NCT01332344|Asthma
1158048|NCT01332344|inhaled corticosteroids
1158049|NCT01332344|outcomes
1158050|NCT01332331|pulmonary arterial hypertension
1158051|NCT01332331|pediatric
1158052|NCT01332292|inhalation profiles
1158053|NCT01332292|pharmacokinetics
1158054|NCT01332292|pharyngometry
1158055|NCT01332292|asthma
1158056|NCT01332292|pediatric subjects
1158057|NCT01332292|GW685698
1158058|NCT01332292|Fluticasone furoate
1158059|NCT01332292|safety
1158060|NCT01332266|Cancer
1158061|NCT01332266|head and neck
1158062|NCT01332266|squamous cell carcinoma of the head and neck
1158063|NCT01332266|phase I
1158064|NCT01332266|phase II
1158065|NCT01332253|Tonsillectomy, Pediatric
1158066|NCT01332240|staging
1158067|NCT01332240|endosonography
1158068|NCT01332240|lung cancer
1158069|NCT01332240|stage III
1158070|NCT01332214|Phase 1
1158071|NCT01332214|healthy male volunteers
1158072|NCT01332214|dose escalation
1158073|NCT01332214|pharmacokinetics
1158074|NCT01332214|Single Ascending Dose
1158075|NCT01332214|AZD2820 Cmax
1158076|NCT01332214|tmax
1158077|NCT01332214|t1/2λz
1158078|NCT01332201|Advagraf
1158079|NCT01332201|Heart
1158080|NCT01332201|Lung
1158081|NCT01332201|Pancreas
1158082|NCT01332201|Transplant
1158083|NCT01332201|Immunosuppression
1158084|NCT01332201|Pharmacokinetics
1158085|NCT01332162|Hypertrophic Obstructive Cardiomyopathy (HOCM)
1158086|NCT01332162|Pacing
1158087|NCT01332149|Diabetic Neuropathies
1158088|NCT01332149|Pain
1158089|NCT01332149|Efficacy of pregabalin
1158090|NCT01332149|Placebo controlled
1158091|NCT01332110|Footwear
1158092|NCT01332110|Motion Analysis
1158093|NCT01332110|Running Injury
1158094|NCT01332097|Chronic Obstructive Pulmonary Disease
1158095|NCT01332097|Exacerbation
1158096|NCT01332097|Pulmonary Inflammation
1158097|NCT01332084|SOTI
1158098|NCT01332084|tolerance
1158099|NCT01332084|desensitization
1158100|NCT01332084|challenge test
1158101|NCT01332084|HA wheat cereals
1158102|NCT01332071|Metformin
1158103|NCT01332071|Rosiglitazone
1158104|NCT01332071|Healthy volunteers
1158105|NCT01332071|Avandamet
1158106|NCT01332071|Fed conditions
1158107|NCT01332071|Bioequivalence
1158108|NCT01332058|Peripheral arterial disease
1158109|NCT01332058|Walking
1158110|NCT01332058|Motivational Interviewing
1158111|NCT01332032|cost effectiveness
1158112|NCT01332032|screening mammography
1158113|NCT01332032|repeat mammography
1158114|NCT01332032|telephone counseling
1158115|NCT01332032|computerized reminders
1158116|NCT01332032|compliance
1158117|NCT01332019|Subcutaneous
1158118|NCT01332019|Extension
1158119|NCT01332019|Interferon
1158120|NCT01332019|MS
1158121|NCT01332019|PEGylated
1158122|NCT01332019|Injectable
1158123|NCT01332019|SC
1158124|NCT01332019|PEG
1158125|NCT01332019|peginterferon beta-1a
1158126|NCT01332019|Relapsing
1158127|NCT01331993|Phase 1
1158128|NCT01331993|crossover
1158129|NCT01331993|bioequivalence
1158130|NCT01331993|naproxen
1158131|NCT01331993|esomeprazole
1158132|NCT01331993|vimovo
1158133|NCT01331993|healthy volunteers
1158134|NCT01331980|cystic fibrosis
1158135|NCT01331980|bone
1158136|NCT01331967|pioglitazone
1158137|NCT01331967|optical coherence tomography
1158138|NCT01331967|microRNA
1158139|NCT01331967|neointima
1158140|NCT01331967|major adverse cardiovascular event
1158141|NCT01331941|AMG 386
1158142|NCT01331941|Pharmacokinetic
1158143|NCT01331941|Renal Impairment
1158144|NCT01331928|Sequential chemotherapy, gastric cancer
1158145|NCT01331915|Metastatic Melanoma
1158146|NCT01331915|Safety
1158147|NCT01331915|Theravac vaccine
1158148|NCT01331915|HLA-A2 typing
1158149|NCT01331915|Tyrosinase.A2 gene expression
1158150|NCT01331902|Adenosine
1158151|NCT01331902|Nicorandil
1158152|NCT01331902|Fractional Flow Reserve
1158153|NCT01331902|Maximal Hyperemia
1158154|NCT01331889|transfusion
1158155|NCT01331889|liver transplantation
1158156|NCT01331889|potassium
1158157|NCT01331876|Cognitive and Behavioral Therapy
1158158|NCT01331863|Bronchial disease
1158159|NCT01331863|Lung cancer surgery
1158160|NCT01331863|Aorta/aortic Allograft
1158161|NCT01331863|homograft
1158162|NCT01331863|Tracheal disease
1158163|NCT01331863|Benign
1158165|NCT01331824|Bladder Cancer
1158166|NCT01331824|Urothelial Cancer
1158167|NCT01331824|Chemotherapy
1158168|NCT01331824|Second-line
1158169|NCT01331824|Metastatic
1158170|NCT01331811|HIV
1158171|NCT01331811|Tuberculosis
1158172|NCT01331811|Diagnosis
1158173|NCT01331811|Pediatrics
1158174|NCT01331811|Asia
1158175|NCT01331811|Africa
1158176|NCT01331798|Abdominoplasty
1158177|NCT01331785|paracentesis
1158178|NCT01331785|ascites
1158179|NCT01331785|hypotension
1158180|NCT01331772|Breast cancer
1158181|NCT01331772|Adapted Physical activity
1158182|NCT01331772|Nutrition
1158183|NCT01331772|Assessment
1158184|NCT01331772|Patient education
1158185|NCT01331759|Burnout
1158186|NCT01331759|Subthreshold Disorder
1158187|NCT01331707|drug-eluting stent
1158188|NCT01331707|Zotarolimus
1158189|NCT01331707|Everolimus
1158190|NCT01331707|all comers population
1158191|NCT01331707|target vessel failure
1158192|NCT01331707|coronary artery disease
1158193|NCT01331681|Diabetic Macular Edema (DME)
1158194|NCT01331681|VEGF Trap-Eye
1158195|NCT01331681|Best-corrected visual acuity (BCVA)
1158196|NCT01331642|Lymphatic Diseases
1158197|NCT01331642|Metabolism, Inborn Errors
1158198|NCT01331642|Genetic Diseases, Inborn
1158199|NCT01331642|Lipidoses
1158200|NCT01331642|Lipid Metabolism, Inborn Errors
1158201|NCT01331642|Metabolic Diseases
1158202|NCT01331642|Lipid Metabolism Disorders
1158203|NCT01331629|breast cancer
1158204|NCT01331629|fatigue
1158205|NCT01331629|quality of life
1158206|NCT01331629|art-therapie
1158207|NCT01331629|adjuvant radiotherapy
1158208|NCT01331616|Prospective study
1158209|NCT01331616|Glioblastoma
1158210|NCT01331616|Avastin
1158211|NCT01331616|Visual Evoked Potential
1158212|NCT01331616|Optic neuropathy
1158213|NCT01331616|Chemo-radiotherapy
1158214|NCT01331603|MDS
1158215|NCT01331603|primary myelofibrosis
1158216|NCT01331603|low+high risk MDS patients
1158217|NCT01331603|patients
1158218|NCT01331577|Healthy
1158219|NCT01331577|Primary Prevention
1158220|NCT01331577|Stress
1158221|NCT01331577|Kinesiology
1158222|NCT01331577|cognitive behavioural therapy
1158223|NCT01331577|Prevention
1158224|NCT01331564|Pregnancy
1158225|NCT01331564|Postpartum
1158226|NCT01331564|Weight gain
1158227|NCT01331564|Weight retention
1158228|NCT01331564|Behavior
1158229|NCT01331564|Electronic Media
1158230|NCT01331564|Randomized Clinical Trial
1158231|NCT01331551|Inflammatory Bowel disease
1158232|NCT01331538|temporomandibular dysfunction
1158233|NCT01331538|posture
1158234|NCT01331525|Small cell lung cancer
1158235|NCT01331525|Chemotherapy
1158236|NCT01331525|Immunotherapy
1158237|NCT01331525|CTLA-4
1158238|NCT01331525|Ipilimumab
1158239|NCT01331512|Clinical Geriatrics
1158240|NCT01331512|Biomechanics
1158241|NCT01331512|Epidemiology
1158242|NCT01331512|Decline in Ambulation
1158243|NCT01331499|Blood loss
1158244|NCT01331499|transfusions
1158245|NCT01331499|instrumented spinal fusion
1158246|NCT01331486|Prehypertension
1158247|NCT01331486|Mild hypertension
1158248|NCT01331486|Flow mediated dilation
1158249|NCT01331486|Hawthorn
1158250|NCT01331473|Carotid Artery
1158251|NCT01331473|Stenting
1158252|NCT01331473|CAS
1158253|NCT01331473|proximal protection
1158254|NCT01331460|HIV
1158255|NCT01331460|HIV risk
1158256|NCT01331460|Sexually Transmitted Diseases
1158257|NCT01331460|Drug Use
1158258|NCT01331460|Women
1158259|NCT01331460|Drug Treatment
1158260|NCT01331460|opioids
1158261|NCT01331460|injection drug use
1158262|NCT01331460|stimulants
1158263|NCT01331460|gender-specific treatment
1158264|NCT01331395|Infertility
1158265|NCT01331395|IVF
1158266|NCT01331395|Acupuncture
1158267|NCT01331382|Resveratrol
1158268|NCT01331382|Piperine
1158269|NCT01331382|Cerebral blood flow
1158270|NCT01331382|Near- infrared spectroscopy
1158271|NCT01331382|Bioavailability
1158272|NCT01331369|adherence
1158273|NCT01331369|compliance
1158274|NCT01331369|persistence
1158275|NCT01331369|drop out
1158276|NCT01331369|abandon
1158277|NCT01331356|Chronic proctalgia
1158278|NCT01331356|Botulinum toxin type A
1158279|NCT01331356|Ganglion Impar
1158280|NCT01331356|Perineal pain
1158281|NCT01331356|Pudendal neuralgia
1158282|NCT01331356|Refractory chronic proctalgia
1158283|NCT01331343|Diabetes
1158284|NCT01331343|Glycemic Control
1158285|NCT01331343|Continuous Glucose Monitoring
1158286|NCT01331330|Depressive Disorder
1158287|NCT01331330|Unipolar
1158288|NCT01331330|Implantable Stimulation Electrodes
1158289|NCT01331317|Cardiovascular disease and mortality
1158290|NCT01331317|Plasma NTproBNP
1158291|NCT01331317|UAER
1158292|NCT01331304|Bipolar disorder
1158293|NCT01331304|Comparative effectiveness trial
1158294|NCT01331304|Lithium
1158295|NCT01331304|Quetiapine
1158296|NCT01331291|bosutinib
1158297|NCT01331291|SKI-606
1158298|NCT01331278|total joint replacement
1158299|NCT01331278|knee
1158300|NCT01331265|perceived lactose intolerance
1158301|NCT01331265|calcium/dairy consumption
1158302|NCT01331265|specific health outcomes
1158303|NCT01331239|Cushing Disease
1158304|NCT01331239|LCI699
1158305|NCT01331239|Pituitary Gland
1158306|NCT01331239|Adrenocorticotropic Hormone
1158307|NCT01331213|Pregabalin
1158308|NCT01331213|Irritable Bowel Syndrome
1158309|NCT01331213|motor
1158310|NCT01331213|sensation
1158311|NCT01331213|colon
1158312|NCT01331213|human
1158313|NCT01331200|ischemic stroke
1158314|NCT01331200|tissue plasminogen activator
1158315|NCT01331200|early mobilization
1158316|NCT01331200|patient safety
1158317|NCT01331200|length of stay
1158318|NCT01331187|Echocardiography
1158319|NCT01331187|Heart failure
1158320|NCT01331187|Ultrasonography
1158321|NCT01331187|pocket-size device
1158322|NCT01331187|Aorta
1158323|NCT01331187|Education
1158324|NCT01331174|knee
1158325|NCT01331174|osteoarthritis
1158326|NCT01331174|physical therapy
1158327|NCT01331174|pulsed short wave
1158328|NCT01331161|shingles vaccine
1158329|NCT01331161|immune responses
1158330|NCT01331148|sickle cell disease
1158331|NCT01331148|vitamin D
1158332|NCT01331148|pediatrics
1158333|NCT01331148|pain
1158334|NCT01331135|pediatrics
1158335|NCT01331135|sirolimus
1158336|NCT01331135|relapse
1158337|NCT01331109|Fibromyalgia
1158338|NCT01331109|Pediatric Fibromyalgia
1158339|NCT01331109|Adolescent Fibromyalgia
1158340|NCT01331109|milnacipran
1158341|NCT01331109|Savella
1158342|NCT01331109|loss of therapeutic response
1158343|NCT01331109|Forest Research Institute
1158344|NCT01331109|Pain
1158345|NCT01331109|Fatigue
1158346|NCT01331109|Serotonin Norepinephrine Reuptake Inhibitors
1158347|NCT01331096|thyroid gland resection surgery
1158348|NCT01331096|total intravenous anesthesia
1158349|NCT01331070|Chronic obstructive pulmonary disease (COPD)
1158350|NCT01331057|Bilingualism
1158351|NCT01331057|Language
1158352|NCT01331057|Evaluation transcultural
1158353|NCT01331057|Intra Familial Relationship
1158354|NCT01331057|Transmissions mother
1158355|NCT01331057|Tongue french
1158356|NCT01331057|Language tamil
1158357|NCT01331057|Language arabic
1158358|NCT01331057|Language soninke
1158359|NCT01331057|Language cultural
1158360|NCT01331057|Affiliations crossbreeding
1158361|NCT01331044|RUTF
1158362|NCT01331044|Severe Acute Malnutrition
1158363|NCT01331044|Children
1158364|NCT01331044|Body composition
1158365|NCT01331044|Microbiota
1158366|NCT01331044|Short Chain Fatty Acid
1158367|NCT01331044|Acceptability of RUTF
1158368|NCT01331044|Edema free 15 percent weight gain
1158369|NCT01331044|Changes in body composition
1158370|NCT01331044|Gut microbiota
1158371|NCT01331044|Genome wide association
1158372|NCT01331031|temporomandibular disorder
1158373|NCT01331031|adolescents
1158374|NCT01331005|Macular Edema
1158375|NCT01331005|Non steroidal anti-inflammatories
1158376|NCT01330992|Circadian rhythms
1158377|NCT01330992|Melatonin
1158378|NCT01330992|Ocular light exposure
1158379|NCT01330992|Darkness Exposure
1158380|NCT01330992|Performance
1158381|NCT01330992|Alertness
1158382|NCT01330979|Intraocular pressure
1158383|NCT01330966|surgically unresectable chondrosarcoma
1158384|NCT01330953|Anemia
1158385|NCT01330940|Kidney stones
1158386|NCT01330940|Calcium
1158387|NCT01330940|citrate
1158388|NCT01330927|VA106483
1158389|NCT01330927|Nocturia
1158390|NCT01330927|Benign Prostatic Hypertrophy
1158391|NCT01330927|BPH
1158392|NCT01330927|Elderly
1158393|NCT01330927|Males
1158394|NCT01330927|Nocturnal voids
1158395|NCT01330927|Anti-diuretic
1158396|NCT01330914|Obesity, Morbid
1158397|NCT01330914|Bariatric Surgery
1158398|NCT01330914|Gastric Bypass
1158399|NCT01330914|Calcium Metabolism Disorders
1158400|NCT01330914|Vitamin D
1158401|NCT01330914|Bone Density
1158402|NCT01330914|Body Composition
1158403|NCT01330914|Weight Loss
1158404|NCT01330888|war
1158405|NCT01330888|religion
1158406|NCT01330888|caregiver
1158407|NCT01330888|combat stress disorder
1158408|NCT01330862|patient outcomes
1158409|NCT01330849|Attention-deficit/hyperactivity disorder
1158410|NCT01330849|School
1158411|NCT01330849|Behavioral Intervention
1158412|NCT01330849|RCT
1158413|NCT01330823|pancreatic carcinoma
1158414|NCT01330823|L-Carnitine
1158415|NCT01330823|quality of life
1158416|NCT01330823|survival
1158417|NCT01330823|malnutrition
1158418|NCT01330823|cancer cachexia
1158419|NCT01330823|fatigue
1158420|NCT01330810|Pharmacokinetics
1158421|NCT01330810|Dietary Supplements
1158422|NCT01330810|Curcumin
1158423|NCT01330797|Cataract
1158424|NCT01330797|Intravitreal
1158425|NCT01330797|Ranibizumab
1158426|NCT01330797|LOCS III
1158427|NCT01330758|Phase I
1158428|NCT01330758|Healthy male and non-fertile female volunteers
1158429|NCT01330758|Bioavailability
1158430|NCT01330758|AZD8931
1158431|NCT01330745|cardiopulmonary bypass
1158432|NCT01330745|mesenteric
1158433|NCT01330745|microcirculatory function
1158434|NCT01330732|SPINESCAN®
1158435|NCT01330732|kyphosis
1158436|NCT01330719|Periodontitis
1158437|NCT01330706|Skin Diseases [C17.800]
1158438|NCT01330706|Nail Diseases [C17.800.529]
1158439|NCT01330706|Nails, Ingrown [C17.800.529.406]
1158440|NCT01330693|ADHD
1158441|NCT01330693|Atomoxetine
1158442|NCT01330693|Biomarker
1158443|NCT01330680|coffee
1158444|NCT01330680|caffeine
1158445|NCT01330680|blood pressure
1158446|NCT01330680|nutrigenetics
1158447|NCT01330680|gene polymorphisms
1158448|NCT01330680|Acute Cardiovascular and Neuropsychologic Effects
1158449|NCT01330667|Hyperbilirubinemia
1158450|NCT01330667|Breastfeeding
1158451|NCT01330667|Limited Formula
1158452|NCT01330654|Intermediate risk of adverse cardiac event
1158453|NCT01330654|Undergoing laparoscopic surgical procedure
1158454|NCT01330654|Age forty to seventy five
1158455|NCT01330641|Tendonitis
1158456|NCT01330641|Rotator Cuff
1158457|NCT01330641|Shoulder
1158458|NCT01330641|Injection
1158459|NCT01330628|peripheral arterial disease
1158460|NCT01330628|in stent restenosis
1158461|NCT01330628|peripheral vascular disease
1158462|NCT01330615|EMLA
1158463|NCT01330615|plantar warts
1158464|NCT01330615|cryotherapy
1158465|NCT01330589|Percutaneous coronary intervention
1158466|NCT01330589|Clopidogrel
1158467|NCT01330589|St. John's Wort
1158468|NCT01330589|CYP 2C19 loss-of-function allele
1158469|NCT01330576|Hypothermia
1158470|NCT01330576|cooling
1158471|NCT01330576|necrotizing enterocolitis
1158472|NCT01330576|NEC
1158473|NCT01330576|neonates
1158474|NCT01330576|preterm
1158475|NCT01330563|Drug-Drug interaction between the CKD-501 and ketoconazole
1158476|NCT01330550|High fiber sugar free biscuit
1158477|NCT01330550|pre-diabetics
1158478|NCT01330537|perceptual development
1158479|NCT01330537|topological perception theory
1158480|NCT01330537|familiarization/novelty preference method
1158481|NCT01330537|Discriminate a disk and a ring (topologically different),
1158482|NCT01330537|Discriminate a disk and a triangle (geometrically different)
1158483|NCT01330537|Detect a change in the number of holes
1158484|NCT01330537|Detect the size of the hole
1158485|NCT01330511|Newborn infant
1158486|NCT01330511|Congenital hydronephrosis
1158487|NCT01330511|Postnatal imaging evaluation
1158488|NCT01330511|Diagnostic algorithm
1158489|NCT01330498|Longitudinal assessment of biomarkers
1158490|NCT01330498|duration of natalizumab
1158491|NCT01330498|stratification of risk for PML
1158492|NCT01330472|Alprazolam
1158493|NCT01330472|Xanax
1158494|NCT01330472|Bioequivalence
1158495|NCT01330472|Panic disorder with or without agoraphobia.
1158496|NCT01330459|Pain during first trimester surgical abortion
1158497|NCT01330446|Head and Neck Cancer
1158498|NCT01330446|HNC
1158499|NCT01330446|Fatigue
1158500|NCT01330446|Patient-Reported Fatigue
1158501|NCT01330446|Fatigue-Symptom Intervention
1158502|NCT01330446|Postoperative Radiation Therapy
1158503|NCT01330446|Postoperative Chemoradiation Therapy
1158504|NCT01330446|Armodafinil
1158505|NCT01330446|Nuvigil
1158506|NCT01330446|Placebo
1158507|NCT01330446|Sugar Pill
1158508|NCT01330446|Questionnaires
1158509|NCT01330446|Surveys
1158510|NCT01330394|Alcoholism
1158511|NCT01330394|Lesch's typology
1158512|NCT01330394|tDCS
1158513|NCT01330394|ERP
1158514|NCT01330394|P300
1158515|NCT01330394|FAB
1158516|NCT01330394|MMSE
1158517|NCT01330394|Cognitive tasks
1158518|NCT01330368|Systemic Lupus Erythematosus
1158519|NCT01330368|SLE
1158520|NCT01330368|Lupus
1158521|NCT01330368|children with SLE
1158522|NCT01330355|Ocular infections, bacterial
1158523|NCT01330329|Obesity
1158524|NCT01330329|Weight loss
1158525|NCT01330329|Exercise
1158526|NCT01330329|Intervention studies
1158527|NCT01330303|Bioequivalence
1158528|NCT01330303|Healthy volunteers
1158529|NCT01330303|tamsulosin hydrochloride
1158530|NCT01330303|Fed administration
1158531|NCT01330290|Rotigotine
1158532|NCT01330290|Neupro®
1158533|NCT01330290|Parkinson
1158534|NCT01330290|Treatment preference
1158535|NCT01330290|Care-giving
1158536|NCT01330277|Metabolic Diseases
1158537|NCT01330277|Biomarker
1158538|NCT01330277|Mucopolysaccharidosis II
1158539|NCT01330277|Lysosomal Storage Diseases
1158540|NCT01330277|Morbus Hunter
1158541|NCT01330277|Mucopolysaccharidoses
1158542|NCT01330264|Intracranial Pressure (ICP) Monitoring
1158543|NCT01330264|Admission to Intensive Care Unit (ICU)
1158544|NCT01330238|Low back pain
1158545|NCT01330238|Modic changes
1158546|NCT01330238|Vertebral endplate signal changes
1158547|NCT01330238|Efficacy
1158548|NCT01330238|Zoledronic acid
1158549|NCT01330238|Bisphosphonates
1158550|NCT01330238|RCT
1158551|NCT01330199|Healthy
1158552|NCT01330199|Female
1158553|NCT01330199|Volunteer
1158554|NCT01330160|stroke
1158555|NCT01330160|Brain ischemia
1158556|NCT01330160|Intracranial hemorrhage
1158557|NCT01330160|Dementia, Vascular
1158558|NCT01330160|Alzheimer's disease
1158559|NCT01330147|HPV
1158560|NCT01330147|oral cancer
1158561|NCT01330147|oropharyngeal cancer
1158562|NCT01330147|tonsillectomy
1158563|NCT01330134|procedural
1158564|NCT01330121|Adherence with discharge diabetes medications
1158565|NCT01330121|Diabeted mellitus type 2 greater than one year
1158566|NCT01330121|Patient with provider and prescriptions filled within CCHS
1158567|NCT01330108|Pulmonary Arterial Hypertension
1158568|NCT01330108|PAH
1158569|NCT01330108|WHO Group 1
1158570|NCT01330095|Bifidobacterium bifidum
1158571|NCT01330095|Very low birth weight infant
1158572|NCT01330095|Enteral feeding
1158573|NCT01330095|Growth
1158574|NCT01330095|amount of enteral feeding
1158575|NCT01330082|Photodynamic therapy
1158576|NCT01330082|Light-emitting diode
1158577|NCT01330082|toluidine blue
1158578|NCT01330082|scaling and root planing
1158579|NCT01330056|Laryngeal and pharyngeal preservation, survivals
1158580|NCT01330043|smoking cessation intervention
1158581|NCT01330017|Seasonal allergies
1158582|NCT01329991|RA
1158583|NCT01329991|Methotrexate
1158584|NCT01329978|Hepatitis C
1158585|NCT01329978|HCV
1158586|NCT01329978|Chronic Hepatitis C
1158587|NCT01329965|Cardiovascular disease
1158588|NCT01329965|Inflammation
1158589|NCT01329965|LPS
1158590|NCT01329965|Endotoxin
1158591|NCT01329939|Asthma
1158592|NCT01329939|Obesity
1158593|NCT01329939|Pediatric
1158594|NCT01329939|Inflammation
1158595|NCT01329939|Leukotriene
1158596|NCT01329939|Montelukast
1158597|NCT01329926|Parkinson's disease
1158598|NCT01329926|Neural stem cells
1158599|NCT01329900|Chemotherapy
1158600|NCT01329900|Stem Cell Collection
1158601|NCT01329900|Ofatumumab
1158602|NCT01329900|Arzerra
1158603|NCT01329900|Ifosfamide
1158604|NCT01329900|Ifex
1158605|NCT01329900|Etoposide
1158606|NCT01329900|VePesid
1158607|NCT01329900|Mesna
1158608|NCT01329900|Mesnex
1158609|NCT01329900|G-CSF
1158610|NCT01329900|Filgrastim
1158611|NCT01329900|Neupogen
1158612|NCT01329900|Apheresis
1158613|NCT01329887|microcirculation
1158614|NCT01329887|SDF
1158615|NCT01329887|ketanserin
1158616|NCT01329887|severe sepsis
1158617|NCT01329861|chronic back pain
1158618|NCT01329861|internet based treatment
1158619|NCT01329861|pain management programme
1158620|NCT01329861|cognitive behavioural therapy
1158621|NCT01329861|minimal therapist contact
1158622|NCT01329848|Accommodation
1158623|NCT01329848|Reading
1158624|NCT01329848|Autorefraction
1158625|NCT01329822|type 2 diabetes
1158626|NCT01329822|overweight
1158627|NCT01329809|metastatic colorectal cancer
1158628|NCT01329809|colon cancer
1158629|NCT01329809|liver metastasis
1158630|NCT01329809|Pexa-vec
1158631|NCT01329809|JX-594
1158632|NCT01329796|dysmenorrhea,
1158633|NCT01329796|pelvic pain
1158634|NCT01329796|dyspareunia
1158635|NCT01329796|endometriosis
1158636|NCT01329770|Neurodevelopmental disability
1158637|NCT01329770|Hyperactivity
1158638|NCT01329770|Anxiety
1158639|NCT01329770|Cognitive problems
1158640|NCT01329770|Behavioural symptoms
1158641|NCT01329770|Fragile X syndrome
1158642|NCT01329770|Autism
1158643|NCT01329770|inherited Genetic condition
1158644|NCT01329757|Spinal Cord Injury
1158645|NCT01329757|Growth Hormone
1158646|NCT01329757|Trauma
1158647|NCT01329757|Incomplete
1158648|NCT01329757|ASIA
1158649|NCT01329744|HIV lipodystrophy
1158650|NCT01329731|white spot lesion
1158651|NCT01329731|initial caries
1158652|NCT01329731|fluoride
1158653|NCT01329731|amine fluoride
1158654|NCT01329731|orthodontics
1158655|NCT01329731|remineralization
1158656|NCT01329731|brackets
1158657|NCT01329718|Stability of the Septin 9 biomarker
1158658|NCT01329718|Epi Pro Colon Test
1158659|NCT01329718|CRC
1158660|NCT01329692|RYGB
1158661|NCT01329692|Intervention
1158662|NCT01329692|follow-up
1158663|NCT01329692|standard-of-care
1158664|NCT01329692|Back on Track program
1158665|NCT01329692|poor weight loss
1158666|NCT01329692|morbidly obese
1158667|NCT01329666|Primary Hyperparathyroidism
1158668|NCT01329666|Endocrinology
1158669|NCT01329666|Hypercalcemia
1158670|NCT01329666|Vitamin D deficiency
1158671|NCT01329666|Parathyroid Hormone
1158672|NCT01329666|Osteoporosis
1158673|NCT01329666|Bone Density
1158674|NCT01329666|Vitamin D repletion
1158675|NCT01329666|Vitamin D Supplements
1158676|NCT01329653|cerebral blood volume
1158677|NCT01329653|aging
1158678|NCT01329653|exercise
1158679|NCT01329640|Metronimic chemotherapy
1158680|NCT01329640|Locally Advanced HER2-positive Breast Cancer
1158681|NCT01329601|cognitive training
1158682|NCT01329601|Alzheimer disease
1158683|NCT01329601|tertiary prevention
1158684|NCT01329588|Female sex workers
1158685|NCT01329588|West Africa
1158686|NCT01329588|Presumptive treatment
1158687|NCT01329588|Sexually transmitted infections
1158688|NCT01329575|endoluminal ultrasound
1158689|NCT01329575|Mediastinal LN invasion
1158690|NCT01329562|Menstrual migraine
1158691|NCT01329562|Menstrually-related migraine
1158692|NCT01329562|Treximet
1158693|NCT01329562|CGRP
1158694|NCT01329562|calcitonin gene-related peptide
1158695|NCT01329536|Alzheimer's Disease
1158696|NCT01329536|Agitation
1158697|NCT01329536|Genetics
1158698|NCT01329536|Apolipoprotein
1158699|NCT01329536|ApoE4
1158700|NCT01329523|Dementia
1158701|NCT01329523|Insulin-like growth factor
1158702|NCT01329523|IGF
1158703|NCT01329523|APO E4
1158704|NCT01329523|Genetics
1158705|NCT01329510|ADHD
1158706|NCT01329510|Adult
1158707|NCT01329484|Alzheimer
1158708|NCT01329484|Dementia
1158709|NCT01329484|Computer
1158710|NCT01329484|Cognitive training
1158711|NCT01329484|Reminiscence therapy
1158712|NCT01329458|FLL
1158713|NCT01329458|CEUS
1158714|NCT01329458|SonoVue
1158715|NCT01329458|HCC
1158716|NCT01329458|Liver metastases
1158717|NCT01329458|Hemangiomas
1158718|NCT01329458|FNH
1158719|NCT01329445|Cartilage repair
1158720|NCT01329445|Articular cartilage defects
1158721|NCT01329432|surfactant
1158722|NCT01329432|intubation
1158723|NCT01329432|spontaneous breathing
1158724|NCT01329432|bronchopulmonary dysplasia
1158725|NCT01329406|Osteoarthritis (OA)
1158726|NCT01329406|Milnacipran
1158727|NCT01329406|Serotonin-norepinephrine reuptake inhibitor (SNRI)
1158728|NCT01329406|Knee pain
1158729|NCT01329393|Disability
1158730|NCT01329393|Social Security
1158731|NCT01329393|Representative Payee
1158732|NCT01329380|Ankylosing Spondylitis
1158733|NCT01329367|EVASYON
1158734|NCT01329367|GENOI
1158735|NCT01329367|antioxidants
1158736|NCT01329367|legume
1158737|NCT01329367|fish
1158738|NCT01329354|Follicular lymphoma
1158739|NCT01329354|Follicular non-Hodgkin´s lymphoma
1158740|NCT01329354|Autologous effector lymphocytes
1158741|NCT01329354|Cell Therapy
1158742|NCT01329354|Maintenance therapy
1158743|NCT01329354|Rituximab
1158744|NCT01329341|PTSD
1158745|NCT01329341|Service Dogs
1158746|NCT01329328|whole-body vibration
1158747|NCT01329328|radiofrequency
1158748|NCT01329328|hormonal status
1158749|NCT01329328|muscular strength
1158750|NCT01329328|balance
1158751|NCT01329276|COPD
1158752|NCT01329276|Symbicort
1158753|NCT01329276|Turbohaler
1158754|NCT01329276|Computational Fluid Dynamics
1158755|NCT01329276|Functional Imaging
1158756|NCT01329276|Budesonide
1158757|NCT01329276|Formoterol
1158758|NCT01329263|menthol cigarettes
1158759|NCT01329250|Tuberculosis
1158760|NCT01329250|Moxifloxacin
1158761|NCT01329250|Pharmacokinetics
1158762|NCT01329250|Safety
1158763|NCT01329237|drug-eluting stent
1158764|NCT01329237|coronary endothelial function
1158765|NCT01329237|coronary imaging
1158766|NCT01329224|acetylsalicylic acid resistance
1158767|NCT01329211|Gastroparesis
1158768|NCT01329211|Quality of Life
1158769|NCT01329198|tourette
1158770|NCT01329198|tourette's
1158771|NCT01329198|TS
1158772|NCT01329198|tourette syndrome
1158773|NCT01329198|tourette's syndrome
1158774|NCT01329185|EBV Viremia in posttransplant kidney recipients
1158775|NCT01329185|CMV viremia in posttransplant kidney recipients
1158776|NCT01329172|PUFA
1158777|NCT01329172|Cystic Fibrosis
1158778|NCT01329172|Nasal brushing
1158779|NCT01329172|Mucins
1158780|NCT01329172|Mucin production
1158781|NCT01329159|High altitude
1158782|NCT01329159|respiratory function
1158783|NCT01329159|cardiorespiratory health
1158784|NCT01329159|indoor pollution
1158785|NCT01329146|pulse pressure variation
1158786|NCT01329146|preload dependency
1158787|NCT01329146|one-lung ventilation
1158788|NCT01329146|thoracic surgery
1158789|NCT01329133|Deep brain stimulation (DBS)
1158790|NCT01329133|Obsessive compulsive disorder
1158791|NCT01329133|ventral striatum
1158792|NCT01329133|subthalamic nucleus
1158793|NCT01329107|Rehabilitation
1158794|NCT01329107|Enhanced Recovery
1158795|NCT01329107|Health related Qouality of Life
1158796|NCT01329107|Patient outcomes
1158797|NCT01329094|Severe mental illness
1158798|NCT01329094|physical activity
1158799|NCT01329094|evaluation
1158800|NCT01329081|Rehabilitation
1158801|NCT01329081|Strength training
1158802|NCT01329081|Long-term effect
1158803|NCT01329081|Activity and participation after fast-track knee arthroplasty
1158804|NCT01329068|breast cancer
1158805|NCT01329042|Potassium sodium citrate
1158806|NCT01329042|stone recurrence
1158807|NCT01329042|ESWL
1158808|NCT01329042|PCNL
1158809|NCT01329042|Hypocitraturia
1158810|NCT01329042|intervention
1158811|NCT01329029|COPD
1158812|NCT01329029|Roflumilast
1158813|NCT01329029|Daxas
1158814|NCT01329016|Pregnancy
1158815|NCT01329016|Glyburide
1158816|NCT01329016|Metformin
1158817|NCT01329016|Pharmacokinetics
1158818|NCT01329016|Pharmacodynamics
1158819|NCT01329003|Silicosis
1158820|NCT01328990|IPTc
1158821|NCT01328990|malaria
1158822|NCT01328990|children
1158823|NCT01328990|pharmacokinetics
1158824|NCT01328990|amodiaquiane
1158825|NCT01328990|sulfadoxine-pyrimethamine
1158826|NCT01328964|pediatric
1158827|NCT01328964|asthma
1158828|NCT01328964|outcomes
1158829|NCT01328964|inhaled cortcosteroids
1158830|NCT01328938|Pegfilgrastim
1158831|NCT01328938|neutropenia
1158832|NCT01328925|Rotavirus
1158833|NCT01328925|Viral gastroenteritis
1158834|NCT01328925|Gastroenteritis
1158835|NCT01328912|ischemic preconditioning
1158836|NCT01328912|cardiac surgery
1158837|NCT01328912|vascular surgery
1158838|NCT01328899|Emphysema
1158839|NCT01328899|COPD
1158840|NCT01328899|RePneu
1158841|NCT01328886|omalizumab
1158842|NCT01328886|allergic asthma
1158843|NCT01328886|pediatric patients
1158844|NCT01328873|Pulmonary infiltrates
1158845|NCT01328873|stem cell transplant
1158846|NCT01328873|leukemia
1158847|NCT01328860|Autologous
1158848|NCT01328860|Stem Cells
1158849|NCT01328860|Spinal Cord Injury
1158850|NCT01328860|Children
1158851|NCT01328834|Nephritis, Lupus
1158852|NCT01328834|Tacrolimus
1158853|NCT01328821|Safety
1158854|NCT01328821|Tolerability
1158855|NCT01328821|Pharmacokinetics
1158856|NCT01328821|Healthy volunteers
1158857|NCT01328808|Acetaminophen
1158858|NCT01328808|Preterm Infants
1158859|NCT01328795|Cardiogoniometry
1158860|NCT01328795|Chest Pain Unit
1158861|NCT01328795|ST-elevation
1158862|NCT01328795|Troponin
1158863|NCT01328795|Catheter intervention
1158864|NCT01328795|Fast Track
1158865|NCT01328782|elbow fracture
1158866|NCT01328782|supracondylar elbow fracture
1158867|NCT01328782|elbow
1158868|NCT01328782|fracture
1158869|NCT01328782|pain management
1158870|NCT01328782|pediatric
1158871|NCT01328769|uric acid
1158872|NCT01328769|febuxostat
1158873|NCT01328769|hypertension
1158874|NCT01328769|intra-renal renin-angiotensin system
1158875|NCT01328769|renal plasma flow
1158876|NCT01328769|angiotensin II
1158877|NCT01328756|ADHD
1158878|NCT01328730|significant stenosis (>70% of lumen stenosis)
1158879|NCT01328730|epicardial coronary arteries.
1158880|NCT01328704|Iron deficiency
1158881|NCT01328704|Vitamin D deficiency
1158882|NCT01328704|Anemia
1158883|NCT01328704|Athletes
1158884|NCT01328704|Triathletes
1158885|NCT01328704|Triathlon
1158886|NCT01328691|Carcinoma, Renal Cell
1158887|NCT01328691|thrombus
1158888|NCT01328691|body mass index
1158889|NCT01328691|grade
1158890|NCT01328678|Alopecia Areata
1158891|NCT01328678|Vitamin D
1158892|NCT01328678|Parathyroid
1158893|NCT01328678|Calcium
1158894|NCT01328652|LPR
1158895|NCT01328652|LTH
1158896|NCT01328639|Collaborative care
1158897|NCT01328639|Diabetes management
1158898|NCT01328639|Depression management
1158899|NCT01328639|Primary care
1158900|NCT01328626|Chronic Lymphocytic Leukemia
1158901|NCT01328626|Maximum Tolerated Dose
1158902|NCT01328626|ABT-199
1158903|NCT01328626|Safety
1158904|NCT01328626|Preliminary Efficacy
1158905|NCT01328626|Cancer
1158906|NCT01328626|Non-Hodgkin Lymphoma
1158907|NCT01328626|Pharmacokinetics
1158908|NCT01328613|BDNF
1158909|NCT01328613|Homeosis
1158910|NCT01328613|Women
1158911|NCT01328613|Childbirth
1158912|NCT01328613|Major Depressive Disorder
1158913|NCT01328600|Placenta
1158914|NCT01328600|Pregnancy
1158915|NCT01328600|Hypertension
1158916|NCT01328600|Supplementation
1158917|NCT01328600|Antibody
1158918|NCT01328587|Eltrombopag
1158919|NCT01328587|Aplastic Anemia
1158920|NCT01328587|Aplastic Anemia Treatment
1158921|NCT01328587|Moderate Aplastic Anemia
1158922|NCT01328587|Moderate Aplastic Anemia Treatment
1158923|NCT01328574|Progression-Free Survival
1158924|NCT01328574|Carcinoma of the Bladder
1158925|NCT01328574|Cancer of the Renal Pelvis
1158926|NCT01328574|Ureter Cancer
1158927|NCT01328574|Survival
1158928|NCT01328574|Bladder Cancer
1158929|NCT01328574|Renal Pelvis Cancer
1158930|NCT01328574|Urothelial Cancer
1158931|NCT01328561|Arginine
1158932|NCT01328561|Oxytocin
1158933|NCT01328561|Vasopressin
1158934|NCT01328561|Placebo
1158935|NCT01328561|Analgesia
1158936|NCT01328561|Healthy Volunteer
1158937|NCT01328561|HV
1158938|NCT01328548|varicella-zoster virus
1158939|NCT01328548|vaccine
1158940|NCT01328548|T-cell
1158941|NCT01328548|genes
1158942|NCT01328548|frail elderly
1158943|NCT01328548|immunosenescence
1158944|NCT01328548|immune and genetic correlates of response to zoster vaccine in the elderly
1158945|NCT01328509|Zinc
1158946|NCT01328496|Hematologic Malignancies
1158947|NCT01328496|Umbilical Cord Blood transplantation
1158948|NCT01328496|Hematopoietic Cell Transplantation
1158949|NCT01328483|Neonates
1158950|NCT01328483|Intrapartum Oropharyngeal Suctioning
1158951|NCT01328483|Meconium Aspiration Syndrome
1158952|NCT01328470|platelet
1158953|NCT01328470|cilostazol
1158954|NCT01328470|clopidogrel
1158955|NCT01328470|chronic kidney disease
1158956|NCT01328457|Leishmaniasis, Visceral
1158957|NCT01328457|kala-azar
1158958|NCT01328457|Paromomycin
1158959|NCT01328457|Bangladesh
1158960|NCT01328457|Injections, Intramuscular
1158961|NCT01328457|Treatment Outcome
1158962|NCT01328457|Patient compliance
1158963|NCT01328457|Medication adherence
1158964|NCT01328457|Drug toxicity
1158965|NCT01328431|Tobacco Use Cessation
1158966|NCT01328431|Smoking Cessation
1158967|NCT01328431|Nicotine Replacement Therapy
1158968|NCT01328431|Brief Intervention
1158969|NCT01328418|Lengthening
1158970|NCT01328392|LPR
1158971|NCT01328392|GERD
1158972|NCT01328366|Quality of Life
1158973|NCT01328366|Psychosocial factors
1158974|NCT01328353|triage
1158975|NCT01328353|aprn
1158976|NCT01328353|telehealth
1158977|NCT01328353|CCHCN
1158978|NCT01328353|advanced practice nurse
1158979|NCT01328353|improve family quality of life
1158980|NCT01328353|reduce unplanned use of health care services
1158981|NCT01328353|telehealth triage intervention
1158982|NCT01328340|muscle power, exercise, aging
1158983|NCT01328301|gait
1158984|NCT01328301|hemiplegia
1158985|NCT01328301|treadmill
1158986|NCT01328301|physiotherapy
1158987|NCT01328301|rehabilitation
1158988|NCT01328288|HIV related adverse events
1158989|NCT01328288|Immunological failure
1158990|NCT01328288|virological failure
1158991|NCT01328288|quality of life
1158992|NCT01328288|depression
1158993|NCT01328288|genotypic resistance
1158994|NCT01328275|HIV related adverse events
1158995|NCT01328275|immunological failure
1158996|NCT01328275|virological failure
1158997|NCT01328275|quality of life
1158998|NCT01328275|depression
1158999|NCT01328275|genotypic resistance
1159000|NCT01328262|Hemoglobins
1159001|NCT01328249|Breast Cancer
1159002|NCT01328249|HER2-normal Stage I to III invasive breast cancer
1159003|NCT01328236|Bortezomib
1159004|NCT01328236|PCL
1159005|NCT01328223|Hepatocellular carcinoma
1159006|NCT01328223|radiotherapy
1159007|NCT01328223|sorafenib
1159008|NCT01328210|metabolic syndrome
1159009|NCT01328210|Phlebotomy
1159010|NCT01328210|blood letting
1159011|NCT01328210|hypertension
1159012|NCT01328210|insulin sensitivity
1159013|NCT01328197|Treovance
1159014|NCT01328197|aneurysm
1159015|NCT01328197|AAA
1159016|NCT01328158|Kaletra, Lopinavir (LPV)/Ritonavir (RTV), Human Immunodeficiency Virus (HIV) infection
1159017|NCT01328132|Liver
1159018|NCT01328132|transplant
1159019|NCT01328132|albumin
1159020|NCT01328067|MRgFus
1159021|NCT01328067|Uterine Fibroids
1159022|NCT01328067|Pelvic Pain
1159023|NCT01328067|Quality of Life
1159024|NCT01328067|Symptomatic Uterine Fibroids
1159025|NCT01328054|cancer
1159026|NCT01328054|cardiac repolarization
1159027|NCT01328054|Holter monitor
1159028|NCT01328054|pharmacokinetics
1159029|NCT01328054|GW572016
1159030|NCT01328054|lapatinib
1159031|NCT01328054|QTc interval
1159032|NCT01328054|safety
1159033|NCT01328054|ECG
1159034|NCT01328041|GSK1349572
1159035|NCT01328041|resistance to raltegravir or elvitegravir
1159036|NCT01328041|Integrase inhibitor
1159037|NCT01328041|ART-experienced
1159038|NCT01328041|dolutegravir
1159039|NCT01328028|Invasive cervical cancer
1159040|NCT01328028|Human papillomavirus
1159041|NCT01328015|hyperhidrosis
1159042|NCT01328015|oxybutynin
1159043|NCT01328015|plantar sweating
1159044|NCT01328015|compensatory sweating
1159045|NCT01328002|Fibromyalgia
1159046|NCT01328002|Pediatric Fibromyalgia
1159047|NCT01328002|Adolescent Fibromyalgia
1159048|NCT01328002|milnacipran
1159049|NCT01328002|Savella
1159050|NCT01328002|loss of therapeutic response
1159051|NCT01328002|Forest Research Institute
1159052|NCT01328002|Pain
1159053|NCT01328002|Fatigue
1159054|NCT01328002|Serotonin Norepinephrine Reuptake Inhibitors
1159055|NCT01328002|Randomized Withdrawal
1159056|NCT01327989|Solitaire FR Device
1159057|NCT01327989|Mechanical Thrombectomy
1159058|NCT01327989|Recanalization
1159059|NCT01327989|Brain artery recanalization
1159060|NCT01327989|Neurovascular intervention
1159061|NCT01327989|Interventional Neuroradiology
1159062|NCT01327989|STAR
1159063|NCT01327989|Acute Ischemic Stroke
1159064|NCT01327976|Obesity
1159065|NCT01327976|Bariatric surgery
1159066|NCT01327976|Excess weight loss
1159067|NCT01327976|Vagus nerve
1159068|NCT01327976|Vagal blocking
1159069|NCT01327976|vBloc Therapy
1159070|NCT01327963|Gastroesophageal reflux disease
1159071|NCT01327963|GERD
1159072|NCT01327963|Heartburn
1159073|NCT01327963|Reflux
1159074|NCT01327963|Regurgitation
1159075|NCT01327963|Hoarseness
1159076|NCT01327963|Cough
1159077|NCT01327950|Percutaneous treatment
1159078|NCT01327950|Superficial Femoral Artery lesions
1159079|NCT01327950|EPIC Nitinol Vascular Stent System
1159080|NCT01327911|Mactel
1159081|NCT01327911|Macular Telangiectasia Type 2
1159082|NCT01327898|MSM
1159083|NCT01327898|HIV/AIDS
1159084|NCT01327898|sexual risk
1159085|NCT01327898|substance use
1159086|NCT01327872|Idiopathic Thrombocytopenia Purpura(ITP)
1159087|NCT01327872|Acute and Chronic Thrombocytopenia Associated with Chronic Liver Disease
1159088|NCT01327872|TLD
1159089|NCT01327846|Cardiovascular Death
1159090|NCT01327846|Myocardial Infarction
1159091|NCT01327846|Stroke
1159092|NCT01327846|Canakinumab
1159093|NCT01327846|IL-1B
1159094|NCT01327846|hsCRP
1159095|NCT01327820|Oxygen consumption
1159096|NCT01327820|Aortic Aneurysm
1159097|NCT01327820|Peripheral Arterial Disease
1159098|NCT01327807|Registries
1159099|NCT01327807|Cystinosis
1159100|NCT01327807|Nephropathic Cystinosis
1159101|NCT01327807|Renal Fanconi Syndrome
1159102|NCT01327807|Cystine
1159103|NCT01327807|Kidney
1159104|NCT01327807|Rare Diseases
1159105|NCT01327794|recurrent pancreatic cancer
1159106|NCT01327794|stage III pancreatic cancer
1159107|NCT01327794|stage IV pancreatic cancer
1159108|NCT01327768|Stroke,
1159109|NCT01327768|Stem Cell,
1159110|NCT01327768|Olfactory Ensheathing Cells,
1159111|NCT01327768|Intracerebral Implantation of Olfactory Ensheathing Cells.
1159112|NCT01327755|Selenium
1159113|NCT01327755|HIV/ AIDS
1159114|NCT01327755|CD4 counts
1159115|NCT01327755|Antiretroviral therapy
1159116|NCT01327742|Relay
1159117|NCT01327742|Thoracic
1159118|NCT01327742|Aneurysm
1159119|NCT01327729|pegylated interferon
1159120|NCT01327729|interferon
1159121|NCT01327729|HCV
1159122|NCT01327729|genotype 4
1159123|NCT01327703|Exocrine Pancreatic Insufficiency
1159124|NCT01327703|Cystic Fibrosis
1159125|NCT01327703|Steatorrhea
1159126|NCT01327703|Malabsorption
1159127|NCT01327703|Malnutrition
1159128|NCT01327677|pain management
1159129|NCT01327677|opioid analgesic therapy
1159130|NCT01327677|safety
1159131|NCT01327677|craniotomy
1159132|NCT01327664|Quiescent uveitis
1159133|NCT01327664|intermediate uveitis
1159134|NCT01327664|panuveitis
1159135|NCT01327664|posterior uveitis
1159136|NCT01327664|uveitis
1159137|NCT01327651|Drug Administration Schedule
1159138|NCT01327651|Nucleoside Reverse Transcriptase Inhibitors
1159139|NCT01327651|Pharmacokinetics
1159140|NCT01327625|Allogeneic hematopoietic cell transplantation
1159141|NCT01327625|Graft versus host disease
1159142|NCT01327625|Bronchiolitis obliterans
1159143|NCT01327625|Azithromycin
1159144|NCT01327625|N-acetylcystein
1159145|NCT01327625|Fluticasone
1159146|NCT01327625|Inhaled steroid
1159147|NCT01327612|AMG 655
1159148|NCT01327612|AMG 479
1159149|NCT01327612|Apoptosis
1159150|NCT01327612|Monoclonal Antibody
1159151|NCT01327612|Tumor Necrosis Factor
1159152|NCT01327612|Insulin-like Growth Factor
1159153|NCT01327612|Bevacizumab
1159154|NCT01327612|Modified FOLFOX6
1159155|NCT01327612|mFOLFOX6
1159156|NCT01327612|FOLFOX
1159157|NCT01327612|Lymphoma
1159158|NCT01327612|Trail Receptor
1159159|NCT01327612|ganitumab
1159160|NCT01327612|conatumumab
1159161|NCT01327599|Open-angle glaucoma
1159162|NCT01327599|Ocular hypertension
1159163|NCT01327599|Pigment dispersion glaucoma
1159164|NCT01327599|Intraocular pressure
1159165|NCT01327586|disability
1159166|NCT01327586|substance abuse
1159167|NCT01327586|cocaine abuse
1159168|NCT01327586|dual diagnosis
1159169|NCT01327586|representative payee
1159170|NCT01327586|HIV risk reduction
1159171|NCT01327573|chronic kidney allograft injury
1159172|NCT01327573|complement protein
1159173|NCT01327573|eculizumab
1159174|NCT01327573|Kidney transplantation
1159175|NCT01327560|hemodialysis patients
1159176|NCT01327560|sleep quality
1159177|NCT01327560|restless legs syndrome
1159178|NCT01327560|excessive daytime sleepiness
1159179|NCT01327560|sleep apnea syndrome
1159180|NCT01327547|HIV coinfection
1159181|NCT01327547|maraviroc
1159182|NCT01327547|CCR5 blocker
1159183|NCT01327547|entry inhibitor
1159184|NCT01327547|liver disease
1159185|NCT01327547|viral hepatitis
1159186|NCT01327534|STEMI
1159187|NCT01327534|clopidogrel
1159188|NCT01327534|prasugrel
1159189|NCT01327534|platelet reactivity index
1159190|NCT01327534|ST resolution
1159191|NCT01327495|Androgen replacement in men
1159192|NCT01327482|Raltegravir
1159193|NCT01327482|Pharmacokinetics
1159194|NCT01327456|health literacy
1159195|NCT01327456|self-management
1159196|NCT01327456|inhaler technique
1159197|NCT01327443|NAFLD
1159198|NCT01327443|NASH
1159199|NCT01327443|Weight loss
1159200|NCT01327443|Exercise
1159201|NCT01327443|NAS scores
1159202|NCT01327443|Mitochondrial dysfunction
1159203|NCT01327430|glycerophosphates
1159204|NCT01327430|sphingomyelins
1159205|NCT01327417|Depression
1159206|NCT01327404|Depression
1159207|NCT01327404|Diabetes Mellitus
1159208|NCT01327391|on line hemodiafiltration
1159209|NCT01327391|tolerance
1159210|NCT01327391|quality of life
1159211|NCT01327391|cardiovascular risk
1159212|NCT01327391|Hemodialysis patients
1159213|NCT01327365|significant coronary artery disease
1159214|NCT01327365|PCI
1159215|NCT01327365|radial approach
1159216|NCT01327365|women
1159217|NCT01327365|bifurcation lesion
1159218|NCT01327365|ostial lesion
1159219|NCT01327365|7 Fr guiding catheter
1159220|NCT01327365|percutaneous coronary intervention
1159221|NCT01327352|lupus
1159222|NCT01327326|Pain modulation
1159223|NCT01327326|Experimental pain
1159224|NCT01327313|alpha v integrin
1159225|NCT01327313|antibody
1159226|NCT01327313|solid tumor
1159227|NCT01327313|Japanese
1159228|NCT01327313|EMD525797
1159229|NCT01327300|Irritable Bowel Syndrome
1159230|NCT01327300|Irritable Bowel Syndrome Treatment
1159231|NCT01327300|Mesalamine
1159232|NCT01327300|Anti-inflammatory drugs
1159233|NCT01327300|5-ASA drugs
1159234|NCT01327300|Apriso ™
1159235|NCT01327287|thoracic epidural
1159236|NCT01327287|blunt
1159237|NCT01327287|blunt thoracic injury
1159238|NCT01327274|Pectus excavatum
1159239|NCT01327274|Chest wall deformity
1159240|NCT01327274|Magnetic Mini-Mover Procedure
1159241|NCT01327274|Pectus Severity Index
1159242|NCT01327274|pediatric medical device
1159243|NCT01327274|magnetic alteration
1159244|NCT01327274|sunken chest
1159245|NCT01327261|levodopa
1159246|NCT01327261|benserazide
1159247|NCT01327261|bioequivalence
1159248|NCT01327261|pharmacokinetics
1159249|NCT01327261|A Single - Dose
1159250|NCT01327261|Randomized- Sequence
1159251|NCT01327261|Open -Label Crossover Study
1159252|NCT01327248|Bronchiolitis obliterans
1159253|NCT01327248|HRCT
1159254|NCT01327248|Sputum
1159255|NCT01327248|Blood
1159256|NCT01327248|Inflammation
1159257|NCT01327248|adaptive immune system
1159258|NCT01327248|innate immune system
1159259|NCT01327222|age-related macular degeneration
1159260|NCT01327222|bevacizumab
1159261|NCT01327196|dementia
1159262|NCT01327196|cardiovascular risk
1159263|NCT01327196|elderly
1159264|NCT01327196|aging
1159265|NCT01327196|older 65-100 years
1159266|NCT01327157|Facial Paralysis / rehabilitation.
1159267|NCT01327157|Dental Occlusion.
1159268|NCT01327157|Occlusal Adjustment.
1159269|NCT01327157|Malocclusion / therapy.
1159270|NCT01327092|Injury
1159271|NCT01327092|Injury Prevention
1159272|NCT01327092|Cincinnati Home Injury Prevention
1159273|NCT01327092|Injury Hazards
1159274|NCT01327092|Modifiable Injury Hazards
1159275|NCT01327092|CHIP
1159276|NCT01327092|Literacy Promotion
1159277|NCT01327092|Reduce exposure to injury hazards
1159278|NCT01327092|preventable and medically attended injury
1159279|NCT01327092|young children
1159280|NCT01327079|NICU
1159281|NCT01327079|Methadone
1159282|NCT01327079|neonates
1159283|NCT01327066|QTc
1159284|NCT01327066|ECG Effects
1159285|NCT01327053|locally advanced basal cell carcinoma,
1159286|NCT01327053|metastatic basal cell carcinoma
1159287|NCT01327040|light
1159288|NCT01327040|melatonin
1159289|NCT01327040|circadian
1159290|NCT01327040|delayed sleep phase disorder
1159291|NCT01327040|circadian light sensitivity
1159292|NCT01327040|circadian timing system
1159293|NCT01327027|vasopressin
1159294|NCT01327027|antisocial
1159295|NCT01327027|affiliation
1159296|NCT01327014|Hyperlipidemia
1159297|NCT01327014|Cholesterol
1159298|NCT01327014|Lipids
1159299|NCT01327014|Lipoproteins
1159300|NCT01327014|XueZhiKang
1159301|NCT01327014|Botanical
1159302|NCT01327001|Asthma bronchiale, fixed combination
1159303|NCT01326988|Spinal anesthesia
1159304|NCT01326988|ultrasound
1159305|NCT01326988|real-time
1159306|NCT01326975|infant, premature
1159307|NCT01326975|infant, very low birth weight
1159308|NCT01326975|diaphragm
1159309|NCT01326975|apnea
1159310|NCT01326975|continuous positive airway pressure
1159311|NCT01326936|Online education
1159312|NCT01326936|Medical education
1159313|NCT01326936|Substance abuse training
1159314|NCT01326936|Drug abuse training
1159315|NCT01326923|Head
1159316|NCT01326923|Neck
1159317|NCT01326923|Locally advanced
1159318|NCT01326923|Squamous Cell
1159319|NCT01326923|Hypopharynx
1159320|NCT01326923|Larynx
1159321|NCT01326923|Oral Cavity
1159322|NCT01326923|Base of Tongue
1159323|NCT01326923|Tonsil
1159324|NCT01326923|Neck lymph node
1159325|NCT01326923|Resection
1159326|NCT01326910|Eczema
1159327|NCT01326884|aortic aneurysm
1159328|NCT01326884|iliac aneurysm
1159329|NCT01326884|endovascular procedures
1159330|NCT01326871|cancer
1159331|NCT01326871|immunotherapy
1159332|NCT01326871|immunochemotherapy
1159333|NCT01326871|combinational therapy
1159334|NCT01326871|targeted
1159335|NCT01326871|metastatic
1159336|NCT01326871|muscle invasive
1159337|NCT01326871|interleukin-2
1159338|NCT01326871|cisplatin
1159339|NCT01326871|gemcitabine
1159340|NCT01326871|antitumor
1159341|NCT01326871|TCR
1159342|NCT01326871|T-cell receptor
1159343|NCT01326871|p53
1159344|NCT01326871|p53 gene
1159345|NCT01326871|p53 tumor supressor protein
1159346|NCT01326871|urothelial cancer
1159347|NCT01326871|bladder cancer
1159348|NCT01326871|renal pelvis cancer
1159349|NCT01326871|ureters cancer
1159350|NCT01326871|urethra cancer
1159351|NCT01326871|HLA-A2 positive
1159352|NCT01326871|HLA-A*0201/p53 aa264-272
1159353|NCT01326871|HLA complex
1159354|NCT01326871|Muscle Invasive or Metastatic
1159355|NCT01326858|Ocular discomfort
1159356|NCT01326858|AL-4943A Ophthalmic Solution
1159357|NCT01326845|Gastrointestinal adverse events,
1159358|NCT01326845|myelodysplastic syndrome,
1159359|NCT01326845|transfusional iron overload diarrhea,
1159360|NCT01326845|constipation abdominal pain,
1159361|NCT01326845|vomiting
1159362|NCT01326832|THA
1159363|NCT01326819|Near infrared spectroscopy
1159364|NCT01326819|Skin pigmentation
1159365|NCT01326819|Regional oxygen saturation
1159366|NCT01326806|Parent-based intervention
1159367|NCT01326806|Sexual risk behavior
1159368|NCT01326806|Adolescents
1159369|NCT01326793|telepsychiatry
1159370|NCT01326793|MDD
1159371|NCT01326793|Depression
1159372|NCT01326793|Major Depressive Disorder
1159373|NCT01326793|Skype
1159374|NCT01326793|college
1159375|NCT01326793|university
1159376|NCT01326780|Acne
1159377|NCT01326780|Irritation
1159378|NCT01326780|Safety
1159379|NCT01326780|Sebum
1159380|NCT01326741|clonal mast cell disorder
1159381|NCT01326741|exercise-induced anaphylaxis
1159382|NCT01326741|hypotension
1159383|NCT01326728|Relapse
1159384|NCT01326728|Hematologic Malignancy
1159385|NCT01326728|Allogeneic
1159386|NCT01326728|Hematopoietic Stem Cell Transplantation
1159387|NCT01326728|Leukemia
1159388|NCT01326728|Lymphoma
1159389|NCT01326728|Hodgkin Lymphoma
1159395|NCT01326676|Polypill
1159396|NCT01326676|Red Heart Pill
1159397|NCT01326676|Cardiovascular disease
1159398|NCT01326676|Secondary prevention
1159399|NCT01326676|carotid intima media thickness
1159400|NCT01326663|Veterans
1159401|NCT01326663|TBI
1159402|NCT01326663|Alcoholism
1159403|NCT01326663|Mood
1159404|NCT01326650|vitamin D, mortality, event-free survival, heart failure
1159405|NCT01326637|primary health care
1159406|NCT01326637|aged
1159407|NCT01326624|heart failure
1159408|NCT01326624|ventricular dysfunction
1159409|NCT01326624|sudden death
1159410|NCT01326624|sudden cardiac arrest
1159411|NCT01326624|ventricular tachycardia
1159412|NCT01326624|ventricular fibrillation
1159413|NCT01326624|wearable defibrillator
1159414|NCT01326611|Chronic lung disease
1159415|NCT01326611|Clarithromycin
1159416|NCT01326611|Ureaplasma urealyticum
1159417|NCT01326598|V Go™
1159418|NCT01326598|Type 2 Diabetes
1159419|NCT01326598|Insulin
1159420|NCT01326598|Oral Anti Hypoglycemic Drugs
1159421|NCT01326585|Scleral Buckling
1159422|NCT01326585|Dexamethasone
1159423|NCT01326585|Post-operative Nausea and Vomiting
1159424|NCT01326572|HIV
1159425|NCT01326572|Pulmonary disease
1159426|NCT01326572|emphysema
1159427|NCT01326572|COPD
1159428|NCT01326559|induction chemotherapy
1159429|NCT01326559|docetaxel
1159430|NCT01326559|cisplatin
1159431|NCT01326559|fluorouracil
1159432|NCT01326559|cetuximab
1159433|NCT01326559|intensity-modulated radiotherapy
1159434|NCT01326546|Therapeutic HBV Vaccine
1159435|NCT01326546|Chronic Hepatitis B
1159436|NCT01326546|HBeAg positive
1159437|NCT01326533|pre-diabetes
1159438|NCT01326533|hydroxychloroquine
1159439|NCT01326533|frequently sampled intravenous glucose tolerance testing
1159440|NCT01326533|insulin resistance
1159441|NCT01326533|insulin secretion
1159442|NCT01326533|glucose tolerance
1159443|NCT01326507|pulmonary embolism
1159444|NCT01326507|Heart-type fatty acid-binding protein
1159445|NCT01326507|cardiac biomarkers
1159446|NCT01326507|risk stratification
1159447|NCT01326494|Upper Respiratory Tract Infection
1159448|NCT01326494|Asthma
1159449|NCT01326494|URTI induced exacerbation of Asthma
1159450|NCT01326481|TRC105
1159451|NCT01326481|Breast Cancer
1159452|NCT01326481|CD105
1159453|NCT01326481|Endoglin
1159454|NCT01326481|TRACON Pharma
1159455|NCT01326481|Roswell Park Cancer Institute
1159456|NCT01326481|Department of Defense
1159457|NCT01326468|head and neck cancer
1159458|NCT01326468|temsirolimus
1159459|NCT01326468|cetuximab
1159460|NCT01326468|cisplatin
1159461|NCT01326468|radiation therapy
1159462|NCT01326455|transradial
1159463|NCT01326455|angiogram
1159464|NCT01326455|device
1159465|NCT01326455|Care of the radial artery post transradial angiogram
1159466|NCT01326442|weight loss
1159467|NCT01326442|overweight
1159468|NCT01326442|body composition
1159469|NCT01326442|visceral obesity
1159470|NCT01326442|insulin
1159471|NCT01326442|glucose tolerance
1159472|NCT01326442|cholesterol
1159473|NCT01326442|hypertriglyceridemia
1159474|NCT01326429|Sodium
1159475|NCT01326429|Hyponatremia
1159476|NCT01326429|Hypernatremia
1159477|NCT01326429|Emergency department
1159478|NCT01326416|obesity
1159479|NCT01326416|metabolic syndrome
1159480|NCT01326416|leucine
1159481|NCT01326416|arginine
1159482|NCT01326416|physical activity
1159483|NCT01326403|proximal
1159484|NCT01326403|hip
1159485|NCT01326403|fractures
1159486|NCT01326338|Diarrhea
1159487|NCT01326325|Cancer
1159488|NCT01326325|Refractory pain
1159489|NCT01326325|Uncontrolled pain
1159490|NCT01326325|Ketamine
1159491|NCT01326286|Comparative Effectiveness Research
1159492|NCT01326286|Prostatectomy
1159493|NCT01326286|radiotherapy
1159494|NCT01326286|quality of life
1159495|NCT01326273|CMV
1159496|NCT01326273|cytomegalovirus
1159497|NCT01326273|autologous
1159498|NCT01326273|leukemia
1159499|NCT01326273|hematological malignancies
1159500|NCT01326273|stem cell transplantation
1159501|NCT01326273|CMV reactivation
1159502|NCT01326273|adoptive therapy
1159503|NCT01326260|resuscitation
1159504|NCT01326260|trauma
1159505|NCT01326260|THAM
1159506|NCT01326260|colloids
1159507|NCT01326260|crystalloids
1159508|NCT01326234|Smoking
1159509|NCT01326234|Motivation
1159510|NCT01326234|Cessation
1159511|NCT01326221|Truvada
1159512|NCT01326221|tenofovir
1159513|NCT01326221|emtricitabine
1159514|NCT01326221|Pharmacokinetics
1159515|NCT01326221|Healthy Volunteers
1159516|NCT01326208|electrical impedance tomography
1159517|NCT01326208|positive end-expiratory pressure
1159518|NCT01326208|regional ventilation delay index
1159519|NCT01326195|HIV Prevention
1159520|NCT01326195|Dating Violence
1159521|NCT01326195|Females
1159522|NCT01326195|Romantic relationships
1159523|NCT01326195|Adolescents
1159524|NCT01326195|Sexuality
1159525|NCT01326195|Underserved youth
1159526|NCT01326182|asthma
1159527|NCT01326182|depression
1159528|NCT01326182|Latino
1159529|NCT01326169|Alcohol
1159530|NCT01326169|brief intervention
1159531|NCT01326169|injuries
1159532|NCT01326156|Osteoarthritis
1159533|NCT01326156|Knee
1159534|NCT01326156|Knee cap
1159535|NCT01326156|Patella
1159536|NCT01326156|Patellofemoral
1159537|NCT01326143|MRD
1159538|NCT01326143|Narval
1159539|NCT01326143|Oral appliance
1159540|NCT01326143|Obstructive Sleep apnea
1159541|NCT01326143|OSAH
1159542|NCT01326143|OSA treatment
1159543|NCT01326130|Integrated care network
1159544|NCT01326130|Chronic care model
1159545|NCT01326130|Health services research
1159546|NCT01326117|gastroparesis
1159547|NCT01326117|gastric emptying
1159548|NCT01326117|diabetes
1159549|NCT01326117|Stomach Diseases
1159550|NCT01326117|Gastrointestinal Diseases
1159551|NCT01326117|Digestive System Diseases
1159552|NCT01326117|Phosphodiesterase Inhibitors
1159553|NCT01326117|Neurologic Manifestations
1159554|NCT01326117|Paralysis
1159555|NCT01326117|Signs and Symptoms
1159556|NCT01326117|Pharmacologic Actions
1159557|NCT01326104|Medulloblastoma
1159558|NCT01326104|Primitive Neuroectodermal Tumor
1159559|NCT01326091|Lumbar fusion surgery
1159560|NCT01326078|sedation
1159561|NCT01326078|children
1159562|NCT01326078|leukemia
1159563|NCT01326078|bone marrow biopsy
1159564|NCT01326013|Stool
1159565|NCT01326013|Feces
1159566|NCT01326013|Gastrointestinal
1159567|NCT01326013|Pathogen
1159568|NCT01326013|Panel
1159569|NCT01326013|xTAG GPP
1159570|NCT01326013|Infectious colitis
1159571|NCT01326013|Gastroenteritis
1159572|NCT01326013|Detection
1159573|NCT01325987|Type 2 diabetes
1159574|NCT01325987|Vitamin D deficiency
1159575|NCT01325987|Glycemic control
1159576|NCT01325974|Malaria
1159577|NCT01325974|Plasmodium falciparum
1159578|NCT01325974|Diagnosis
1159579|NCT01325974|Rapid diagnostic test
1159580|NCT01325974|malaria transmission
1159581|NCT01325961|prostate, cervical and anal canal cancers with pelvic lymph node irradiation
1159582|NCT01325948|COPD
1159583|NCT01325935|Coronary Artery Disease
1159584|NCT01325935|Coronary Disease
1159585|NCT01325935|Myocardial Ischemia
1159586|NCT01325935|Heart Disease
1159587|NCT01325935|Cardiovascular Disease
1159588|NCT01325935|Arteriosclerosis
1159589|NCT01325935|Arterial Occlusive Disease
1159590|NCT01325935|Vascular Disease
1159591|NCT01325935|Clopidogrel
1159592|NCT01325935|Platelet Aggregation Inhibitors
1159593|NCT01325896|Multiple Mieloma, PEG-Intron
1159594|NCT01325870|cardiopulmonary resuscitation
1159595|NCT01325818|Coronary Artery Disease
1159596|NCT01325818|Coronary Disease
1159597|NCT01325818|Dyslipidemia
1159598|NCT01325818|Stable Angina Pectoris
1159599|NCT01325818|Heart Diseases
1159600|NCT01325818|Cardiovascular Diseases
1159601|NCT01325818|Arteriosclerosis
1159602|NCT01325818|Arterial Occlusive Diseases
1159603|NCT01325818|Vascular Diseases Pravastatin
1159604|NCT01325818|Rosuvastatin
1159605|NCT01325818|Anticholesteremic Agents
1159606|NCT01325818|Antilipemic Agents
1159607|NCT01325818|Antimetabolites
1159608|NCT01325818|Molecular Mechanisms of Pharmacological Action
1159609|NCT01325818|Pharmacologic Actions
1159610|NCT01325818|Therapeutic Uses
1159611|NCT01325818|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1159612|NCT01325805|Miscarriage
1159613|NCT01325805|Recurrent Pregnancy Loss
1159614|NCT01325805|Obesity
1159615|NCT01325805|Overweight
1159616|NCT01325805|Diet
1159617|NCT01325792|Complex ventral incisional hernia repair
1159618|NCT01325792|reapproximation of the rectus abdominis muscle
1159619|NCT01325792|retrorectus or intraperitoneal placement technique
1159620|NCT01325792|mobility for midline fascial closure
1159621|NCT01325779|deep venous thrombosis
1159622|NCT01325779|DVT
1159623|NCT01325779|enoxaparin
1159624|NCT01325779|heparin
1159625|NCT01325779|surgical intensive care
1159626|NCT01325766|Cystic Fibrosis
1159627|NCT01325766|Yoga
1159628|NCT01325701|PCI-32765
1159629|NCT01325701|Lymphoma, B-Cell
1159630|NCT01325701|Bruton's Tyrosine Kinase
1159631|NCT01325701|Non Hodgkin's Lymphoma
1159632|NCT01325701|Germinal Center B-Cell
1159633|NCT01325701|Activated B-Cell
1159634|NCT01325688|PEP005
1159635|NCT01325688|Peplin
1159636|NCT01325688|sBCC
1159637|NCT01325675|Atrial fibrillation
1159638|NCT01325675|Motor activity
1159639|NCT01325649|rectal cancer
1159640|NCT01325649|MRI
1159641|NCT01325649|selective preoperative radiochemotherapy
1159642|NCT01325649|involvement of circumferential resection margin
1159643|NCT01325649|locoregional recurrence rate
1159644|NCT01325636|Allogenic haematopoietic stem cell transplant
1159645|NCT01325636|Cytomegalovirus or Adenovirus infection
1159646|NCT01325636|Graft versus Host
1159647|NCT01325623|Automatic Magnet Mode (AMM)
1159648|NCT01325623|Vagal Nerve Stimulation
1159649|NCT01325610|vitamin D
1159650|NCT01325610|kidney
1159651|NCT01325610|renal
1159652|NCT01325597|Heart failure
1159653|NCT01325597|Electric stimulation
1159654|NCT01325597|Breathing exercises
1159655|NCT01325571|prograf
1159656|NCT01325571|immunosuppressant
1159657|NCT01325558|cancer
1159658|NCT01325558|tissue factor
1159659|NCT01325558|solid tumor
1159660|NCT01325558|ovarian cancer
1159661|NCT01325558|breast cancer
1159662|NCT01325558|non-small cell lung cancer
1159663|NCT01325558|colon cancer
1159664|NCT01325558|pancreatic cancer
1159665|NCT01325558|head and neck cancer
1159666|NCT01325558|prostate cancer
1159667|NCT01325558|soft-tissue sarcoma
1159668|NCT01325558|metastatic
1159669|NCT01325558|gemcitabine
1159670|NCT01325558|anti-tumor
1159671|NCT01325558|venous thromboembolism
1159672|NCT01325545|Stroke
1159673|NCT01325545|Atrial Fibrillation
1159674|NCT01325532|depression
1159675|NCT01325532|Major Depressive Disorder
1159676|NCT01325532|MDD
1159677|NCT01325532|Cranial Electrical Stimulation
1159678|NCT01325532|CES
1159679|NCT01325506|Prostatectomy
1159680|NCT01325493|opioid tolerance
1159681|NCT01325493|hyperalgesia
1159682|NCT01325493|scoliosis
1159683|NCT01325493|pupillometry
1159684|NCT01325480|Cardiac Resynchronization Therapy
1159685|NCT01325480|Pacing
1159686|NCT01325480|His Bundle
1159687|NCT01325467|coronary artery disease
1159688|NCT01325467|high frequency QRS analysis
1159689|NCT01325467|ischemia
1159690|NCT01325467|exercise testing
1159691|NCT01325467|diagnosis of coronary artery disease
1159692|NCT01325454|Pleural effusion
1159693|NCT01325454|angiogenic cytokine
1159694|NCT01325454|fibrinolytic activity
1159695|NCT01325441|BBI608
1159696|NCT01325415|Phase 1
1159697|NCT01325415|healthy male volunteers
1159698|NCT01325415|cross-over study
1159699|NCT01325415|NKTR-118
1159700|NCT01325402|Radioligand
1159701|NCT01325402|Alzheimers disease
1159702|NCT01325402|Maximum Diagnostic Mass
1159703|NCT01325402|Beta amyloid
1159704|NCT01325376|overweight
1159705|NCT01325376|obesity
1159706|NCT01325363|Schizophrenia
1159707|NCT01325363|Novel metaphor
1159708|NCT01325298|Keratoconus
1159709|NCT01325298|Ectasia
1159710|NCT01325298|cross linking
1159711|NCT01325298|collagen cross linking
1159712|NCT01325298|corneal crosslinking
1159713|NCT01325298|corneal diseases
1159714|NCT01325298|eye diseases
1159715|NCT01325285|Intraocular pressure
1159716|NCT01325285|Hypercapnia
1159717|NCT01325285|Hyperoxia
1159718|NCT01325285|Rebreathing circuit
1159719|NCT01324310|ROMI-001
1159720|NCT01324310|romi
1159721|NCT01324310|Romidepsin
1159722|NCT01324310|Istodax
1159723|NCT01324310|advanced malignancy
1159724|NCT01324310|PK
1159725|NCT01324310|pharmacokinetics
1159726|NCT01324297|Diagnostic Techniques and Procedures
1159727|NCT01324297|Sensitivity and Specificity
1159728|NCT01324297|Skin Tests
1159729|NCT01324297|Biological Markers
1159730|NCT01324284|Lubiprostone
1159731|NCT01324284|Bowel preparation regime
1159732|NCT01324271|Tympanostomy tube placement
1159733|NCT01325272|otoacoustic emissions in newborns
1159734|NCT01325246|ventral hernia
1159735|NCT01325246|repair
1159736|NCT01325246|clinical
1159737|NCT01325246|reoperation
1159738|NCT01325233|Astragulus polysaccharides
1159739|NCT01325233|Hemorrhagic stroke
1159740|NCT01325207|Breast Cancer
1159741|NCT01325194|DLBCL
1159742|NCT01325194|FL grade 3B
1159743|NCT01325194|high risk
1159744|NCT01325194|CNS prophylaxis
1159745|NCT01325194|chemoimmunotherapy
1159746|NCT01325181|Chronic central serous chorioretinopathy
1159747|NCT01325181|Ranibizumab
1159748|NCT01325181|Photodynamic therapy
1159749|NCT01325168|PTSD
1159750|NCT01325168|empathy
1159751|NCT01325168|oxytocin
1159752|NCT01325155|Air Pollution
1159753|NCT01325155|particulate matter
1159754|NCT01325155|cardiovascular Disease
1159755|NCT01325142|Osteonecrosis of the Jaw (ONJ)
1159756|NCT01325129|ESIN
1159757|NCT01325129|Clavicular Fracture
1159758|NCT01325129|Dislocation
1159759|NCT01325129|Children
1159760|NCT01325129|Adolescents
1159761|NCT01325116|STEMI
1159762|NCT01325116|Medication Adherence
1159763|NCT01325116|Quality Improvement
1159764|NCT01325103|Spinal cord injury
1159765|NCT01325103|Mesenchymal stem cells
1159766|NCT01325103|Bone marrow
1159767|NCT01325090|neuropathic pain due to thoracotomy
1159768|NCT01325090|Neuropathic Pain Due to Thoracoscopy
1159769|NCT01325077|Nurse-based, acute pain service, pediatric, postoperative,
1159770|NCT01325077|pain
1159771|NCT01325064|Carotid Artery Diseases
1159772|NCT01325064|Blood Pressure
1159773|NCT01325064|Blood Pressure Monitoring, Ambulatory
1159774|NCT01325064|Peripheral Vascular Diseases
1159775|NCT01325064|Retinal Vessels
1159776|NCT01325051|raltegravir
1159777|NCT01325051|pharmacokinetics
1159778|NCT01325051|healthy
1159779|NCT01325051|male
1159780|NCT01325051|volunteers
1159781|NCT01325051|gastrointestinal
1159782|NCT01325051|tract
1159783|NCT01325038|resting metabolic rate
1159784|NCT01325025|Metachromatic Leukodystrophy
1159785|NCT01325025|Demyelinating Diseases
1159786|NCT01325025|Magnetic Resonance Imaging
1159787|NCT01325025|Diffusion Tensor Imaging
1159788|NCT01325025|Relaxometry
1159789|NCT01325025|Spectroscopy
1159790|NCT01325025|Longitudinal Studies
1159791|NCT01325012|Pain
1159792|NCT01325012|Surgery
1159793|NCT01325012|Catheter
1159794|NCT01325012|Nerve Block
1159795|NCT01325012|Popliteal
1159796|NCT01325012|Subgluteal
1159797|NCT01325012|Sciatic
1159798|NCT01325012|UCSD
1159799|NCT01325012|Moderate-to-severe pain
1159800|NCT01325012|Perineural Catheter
1159801|NCT01325012|Orthopedic Surgery
1159802|NCT01325012|foot surgery surgery
1159803|NCT01325012|sciatic perineural catheter
1159804|NCT01325012|age =>18
1159805|NCT01324999|Sarcoidosis Associated Pulmonary Hypertension
1159806|NCT01324986|extraesophageal symptoms of gastroesophageal reflux disease
1159807|NCT01324973|Medical Informatics
1159808|NCT01324973|Therapy, Computer-Assisted
1159809|NCT01324973|Health Education
1159810|NCT01324973|Diet
1159811|NCT01324973|Exercise
1159812|NCT01324960|IPSS
1159813|NCT01324960|High risk
1159814|NCT01324960|Azacitidine
1159815|NCT01324960|Ceplene
1159816|NCT01324947|Myeloma
1159817|NCT01324947|Multiple Myeloma
1159818|NCT01324947|Relapsed Multiple Myeloma
1159819|NCT01324947|Relapsed and Refractory Multiple Myeloma
1159820|NCT01324947|Refractory Myeloma
1159821|NCT01324947|Resistant Multiple Myeloma
1159822|NCT01324947|Treatment-resistant Multiple Myeloma
1159823|NCT01324947|Pomalidomide
1159824|NCT01324947|Lenalidomide-resistant
1159825|NCT01324947|Bortezomib-resistant
1159826|NCT01324947|Companion
1159827|NCT01324934|acute rejection
1159828|NCT01324934|chronic rejection
1159829|NCT01324934|subclinical rejection
1159830|NCT01324934|renal transplantation
1159831|NCT01324934|steroid-free
1159832|NCT01324934|kidney transplantation
1159833|NCT01324895|Small intestinal bacterial overgrowth syndrome (SIBO)
1159834|NCT01324895|bacterial overgrowth syndrome
1159835|NCT01324895|Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
1159836|NCT01324895|14-Co2 D-Xylose Breath Testing
1159837|NCT01324895|Antibiotics
1159838|NCT01324895|Prokinteics
1159839|NCT01324895|Prokinetic Agents
1159840|NCT01324882|colonoscopy
1159841|NCT01324869|KH902
1159842|NCT01324869|Diabetic macular Edema
1159843|NCT01324869|Intravitreal injection
1159844|NCT01324869|Multiple injections
1159845|NCT01324869|20 patients
1159846|NCT01324869|0.5mg/eye/time
1159847|NCT01324856|pancreatic cancer
1159848|NCT01324856|periampulary cancer
1159849|NCT01324856|pancreaticogastro vs pancreaticojejuno anastomosis
1159850|NCT01324843|Safety and Tolerability
1159851|NCT01324843|Intradermal Electroporation
1159852|NCT01324817|Non-Contact
1159853|NCT01324817|Radar
1159854|NCT01324817|Doppler
1159855|NCT01324817|Respiratory
1159856|NCT01324817|Respiration
1159857|NCT01324817|Breathing
1159858|NCT01324817|Rate
1159859|NCT01324817|Frequency
1159860|NCT01324817|Respiratory Mechanics
1159861|NCT01324817|Respiratory Rate Measurement
1159862|NCT01324817|Apnea
1159863|NCT01324817|Sleep Apnea
1159864|NCT01324804|postoperative wound healing
1159865|NCT01324778|Edentulism in the Upper Jaw
1159866|NCT01324765|Women
1159867|NCT01324765|PTSD
1159868|NCT01324765|Group Therapy
1159869|NCT01324765|Incarceration
1159870|NCT01324752|Drug-drug interaction
1159871|NCT01324752|Pharmacokinetics
1159872|NCT01324752|PA21
1159873|NCT01324726|Bacterial colonization
1159874|NCT01324726|Extended spectrum beta lactamase producing organisms
1159875|NCT01324687|Telemedicine
1159876|NCT01324687|Geriatrics
1159877|NCT01324674|Common Mental Disorder
1159878|NCT01324674|Efficacy of Bach´s flower remedy
1159879|NCT01324674|Spiritual well-being
1159880|NCT01324648|Guided self-help
1159881|NCT01324648|Telephone delivery
1159882|NCT01324648|Cognitive behavior therapy
1159883|NCT01324648|Bibliotherapy
1159884|NCT01324635|glioma
1159885|NCT01324635|meningioma
1159886|NCT01324635|brain metastasis
1159887|NCT01324635|stereotactic
1159888|NCT01324635|radiotherapy
1159889|NCT01324635|radiosurgery
1159890|NCT01324622|Spinal Cord Diseases
1159891|NCT01324622|Myelopathy
1159892|NCT01324622|Myeloradiculopathy
1159893|NCT01324622|Laminectomy
1159894|NCT01324622|Laminoplasty
1159895|NCT01324609|choroidal nevus
1159896|NCT01324609|vitrectomy
1159897|NCT01324596|Lymphoma, Large B-Cell, Diffuse
1159898|NCT01324596|Bortezomib
1159899|NCT01324596|R-CHOP
1159900|NCT01324596|Molecular profiling
1159901|NCT01324596|Chemotherapy
1159902|NCT01324570|Pain
1159903|NCT01324570|Opioid
1159904|NCT01324570|Analgesia
1159905|NCT01324570|Moderate to severe pain
1159906|NCT01324557|Continuous glucose monitoring
1159907|NCT01324557|CAPD patients
1159908|NCT01324557|Insulin pump
1159909|NCT01324544|Acute Pain
1159910|NCT01324544|Opioid
1159911|NCT01324544|Analgesia
1159912|NCT01324531|Bankart repair
1159913|NCT01324531|remplissage
1159914|NCT01324531|Hill-Sachs defect
1159915|NCT01324531|shoulder instability
1159916|NCT01324531|anterior shoulder instability
1159917|NCT01324492|phase Ib,
1159918|NCT01324492|RAD001,
1159919|NCT01324492|advanced pulmonary neuroendocrine tumor
1159920|NCT01324479|Non-small cell lung cancer,
1159921|NCT01324479|hepatocellular,
1159922|NCT01324479|gastric,
1159923|NCT01324479|renal cell,
1159924|NCT01324479|c-MET,
1159925|NCT01324479|refractory,
1159926|NCT01324479|glioblastoma,
1159927|NCT01324479|breast,
1159928|NCT01324479|nasopharyngeal,
1159929|NCT01324479|confirmed evidence of c-MET dysregulation
1159930|NCT01324453|Acute Myocardial Infarction
1159931|NCT01324453|STEMI
1159932|NCT01324453|Post Conditioning
1159933|NCT01324453|Primary Percutaneous Coronary Intervention
1159934|NCT01324440|Bacterial Vaccines
1159935|NCT01324440|Staphylococcus Aureus
1159936|NCT01324440|Adjuvanted Vaccine
1159937|NCT01324427|Telemedicine
1159938|NCT01324427|Virtual Medical Visit
1159939|NCT01324427|Quality of Life
1159940|NCT01324427|11-022
1159941|NCT01324401|Peanut Allergy
1159942|NCT01324401|Peanut Hypersensitivity
1159943|NCT01324362|FP
1159944|NCT01324362|Asthma
1159945|NCT01324362|Sont
1159946|NCT01324362|FSC
1159947|NCT01324362|BHR
1159948|NCT01324349|Hepatic
1159949|NCT01324349|Topical Hemostat
1159950|NCT01324336|ALL
1159951|NCT01324336|acute lymphoblastic leukemia
1159952|NCT01324336|6-Mercaptopurine
1159953|NCT01324336|Pediatric
1159954|NCT01324323|ROMI-001
1159955|NCT01324323|romi
1159956|NCT01324323|Romidepsin
1159957|NCT01324323|Istodax
1159958|NCT01324323|advanced malignancy
1159959|NCT01324323|PK
1159960|NCT01324323|pharmacokinetics
1159961|NCT01324258|pancreatic cancer (combination with gemcitabine)
1159962|NCT01324258|Non-small cell lung cancer (combination with gemcitabine)
1159963|NCT01324258|solid tumors (single agent)
1159964|NCT01324258|MEK inhibitor
1159965|NCT01324258|GSK1120212
1159966|NCT01324258|biliary cancer (combination with gemcitabine)
1159967|NCT01324258|urothelial cancer (combination with gemcitabine)
1159968|NCT01324245|Salt
1159969|NCT01324245|Balance
1159970|NCT01324245|Renin Angiotensin System
1159971|NCT01324245|Fenoldopam\blood Pressure
1159972|NCT01324245|Sodium
1159973|NCT01324219|nursing staff
1159974|NCT01324219|residents
1159975|NCT01324206|Whole-Body
1159976|NCT01324206|Development
1159977|NCT01324206|Exposure
1159978|NCT01324206|Magnetic
1159979|NCT01324206|Resonance
1159980|NCT01324180|ALL
1159981|NCT01324180|Relapsed
1159982|NCT01324180|Refractory
1159983|NCT01324167|schizophrenia
1159984|NCT01324167|schizoaffective disorder
1159985|NCT01324141|Anal Cancer
1159986|NCT01324141|Radioprotector
1159987|NCT01324141|Topical
1159988|NCT01324141|Radiation
1159989|NCT01324141|Dermatitis
1159990|NCT01324128|PA21
1159991|NCT01324128|Phosphate Binder
1159992|NCT01324115|unspecified adult solid tumor, protocol specific
1159993|NCT01324102|Neoplasms
1159994|NCT01324089|Resveratrol
1159995|NCT01324089|Piperine
1159996|NCT01324076|adult primary hepatocellular carcinoma
1159997|NCT01324076|localized unresectable adult primary liver cancer
1159998|NCT01324076|advanced adult primary liver cancer
1159999|NCT01324063|untreated adult acute myeloid leukemia
1160000|NCT01324037|suspected upper extremity deep vein thrombosis
1160001|NCT01324037|diagnostic algorithm
1160002|NCT01324024|Menopause
1160003|NCT01324024|Aging
1160004|NCT01324024|Memory
1160005|NCT01324024|Women
1160006|NCT01323998|enlarged prostate
1160007|NCT01323998|Benign prostatic hyperplasia
1160008|NCT01323998|alpha-blocker
1160009|NCT01323998|5-alpha-reductase inhibitor
1160010|NCT01323972|Malaria
1160011|NCT01323972|Plasmodium falciparum
1160012|NCT01323959|BoostrixTM Polio
1160013|NCT01323959|dTpa-IPV
1160014|NCT01323959|booster
1160015|NCT01323946|H5N1
1160016|NCT01323946|influenza infection
1160017|NCT01323946|Influenza vaccine GSK1562902A
1160018|NCT01323933|Solid tumors
1160019|NCT01323933|Oncology
1160020|NCT01323933|Cancer
1160021|NCT01323920|Stem Cell Transplant
1160022|NCT01323920|Allogeneic Transplant
1160023|NCT01323920|Donors
1160024|NCT01323907|Total Parenteral Nutrition-induced Cholestasis
1160025|NCT01323907|Omegaven
1160026|NCT01323907|liver disease
1160027|NCT01323907|Cholestasis
1160028|NCT01323907|Fat emulsions
1160029|NCT01323881|theta burst stimulation, stroke, motor, plasticity
1160030|NCT01323842|renal colic
1160031|NCT01323842|hydronephrosis
1160032|NCT01323842|abdominal aortic aneurysm
1160033|NCT01323842|ultrasound
1160034|NCT01323842|emergency medicine
1160035|NCT01323842|urolithiasis
1160036|NCT01323829|High Tone Pelvic Floor Dysfunction
1160037|NCT01323829|Botulinum toxin type A
1160038|NCT01323829|EMG
1160039|NCT01323803|Eosinophilic Esophagitis
1160040|NCT01323790|Non-Cancer-Related Pain
1160041|NCT01323790|Opioid-Induced Constipation
1160042|NCT01323777|Cataracts
1160043|NCT01323777|Intraocular lens
1160044|NCT01323777|Multifocal
1160045|NCT01323777|Toric
1160046|NCT01323777|Astigmatism
1160047|NCT01323777|Presbyopia
1160048|NCT01323764|Hydrocephalus
1160049|NCT01323764|CSF shunts
1160050|NCT01323764|Normal Pressure Hydrocephalus
1160051|NCT01323764|NPH
1160052|NCT01323764|ShuntCheck
1160053|NCT01323764|Shunt Malfunction
1160054|NCT01323764|Suspected shunt malfunction in adult hydrocephalus patients
1160055|NCT01323738|Psychoeducation
1160056|NCT01323738|Group Control
1160057|NCT01323725|Team-based financial incentives
1160058|NCT01323725|Smoking cessation
1160059|NCT01323712|CKD
1160060|NCT01323712|LV mass
1160061|NCT01323712|Vitamin D
1160062|NCT01323712|LV function
1160063|NCT01323699|Parkinson Disease
1160064|NCT01323699|Anxiety
1160065|NCT01323699|Depression
1160066|NCT01323647|IPV
1160067|NCT01323647|PoliorixTM
1160068|NCT01323647|China
1160069|NCT01323608|Thalassemia
1160070|NCT01323608|hypercalciuria
1160071|NCT01323608|vitamin D
1160072|NCT01323608|To conduct a pilot study to determine the effect of various doses of
1160073|NCT01323608|vitamin D supplementation on vitamin D stores and their association with calcium excretion
1160074|NCT01323595|Pain control
1160075|NCT01323595|testicular sperm extraction
1160076|NCT01323595|sperm
1160077|NCT01323582|Gastroparesis
1160078|NCT01323582|Gastroparesis Treatment
1160079|NCT01323582|Gastric Emptying
1160080|NCT01323582|Prokinetic Agents
1160081|NCT01323582|Macrolides
1160082|NCT01323582|Erythromycin
1160083|NCT01323582|Azithromycin
1160084|NCT01323582|Erythromycin Cardiac Side-effects
1160085|NCT01323582|Erythromycin drug interactions
1160086|NCT01323582|AZI
1160087|NCT01323569|Sativex
1160088|NCT01323569|Cannabinoids
1160089|NCT01323569|Abuse potential
1160090|NCT01323569|Addiction
1160091|NCT01323556|Panic disorder
1160092|NCT01323556|agoraphobia
1160093|NCT01323556|panic attacks
1160094|NCT01323556|exposure based learning
1160095|NCT01323556|interoceptive exposure exercises
1160096|NCT01323556|fear augmentation
1160097|NCT01323556|in vivo exposure
1160098|NCT01323543|Back Pain,
1160099|NCT01323543|Back Pains, Low
1160100|NCT01323543|Low Back Pains
1160101|NCT01323543|Pain, Low Back
1160102|NCT01323543|Pains, Low Back
1160103|NCT01323543|Lumbago
1160104|NCT01323543|Lower Back Pain
1160105|NCT01323543|Back Pain, Lower
1160106|NCT01323543|Back Pains, Lower
1160107|NCT01323543|Lower Back Pains
1160108|NCT01323543|Pain, Lower Back
1160109|NCT01323543|Pains, Lower Back
1160110|NCT01323543|Low Back Ache
1160111|NCT01323543|Ache, Low Back
1160112|NCT01323543|Aches, Low Back
1160113|NCT01323543|Back Ache, Low
1160114|NCT01323543|Back Aches, Low
1160115|NCT01323543|Low Back Aches
1160116|NCT01323543|Low Backache
1160117|NCT01323543|Backache, Low
1160118|NCT01323543|Backaches, Low
1160119|NCT01323543|Low Backaches
1160120|NCT01323543|Low Back Pain, Recurrent
1160121|NCT01323543|Recurrent Low Back Pain
1160122|NCT01323543|Low Back Pain, Postural
1160123|NCT01323543|Postural Low Back Pain
1160124|NCT01323543|Low Back Pain, Mechanical
1160125|NCT01323543|Mechanical Low Back Pain
1160126|NCT01323543|Low Back Pain, Posterior Compartment
1160127|NCT01323530|metastatic breast cancer
1160128|NCT01323517|skin
1160129|NCT01323517|DACTINOMYCIN
1160130|NCT01323517|MDX-010 (Ipilimumab)
1160131|NCT01323517|MELPHALAN
1160132|NCT01323517|Isolated Limb Infusion
1160133|NCT01323517|10-101
1160134|NCT01323504|Stage 5 arteritis
1160135|NCT01323504|Stage 6 arteritis
1160136|NCT01323504|rutherford classification
1160137|NCT01323491|smoking cessation
1160138|NCT01323491|nicotine replacement therapy
1160139|NCT01323491|routine smokers
1160140|NCT01323478|Depressive Disorder
1160141|NCT01323478|Depression
1160142|NCT01323478|Depressive Disorder, Major
1160143|NCT01323478|Mood Disorders
1160144|NCT01323478|Mental Disorders
1160145|NCT01323478|Behavioural Symptoms
1160146|NCT01323465|Sativex
1160147|NCT01323465|Cytochrome P450
1160148|NCT01323465|Pharmacokinetics
1160149|NCT01323465|Cannabinoids
1160150|NCT01323465|ketoconazole
1160151|NCT01323465|omeprazole
1160152|NCT01323465|rifampicin
1160153|NCT01323452|entecavir
1160154|NCT01323452|hepatitis B
1160155|NCT01323439|Patients presenting with an intracranial aneurysm
1160156|NCT01323426|urinary incontinence, stress
1160157|NCT01323426|autologous
1160158|NCT01323413|stroke
1160159|NCT01323413|penumbra
1160160|NCT01323413|determinants
1160161|NCT01323413|CT perfusion
1160162|NCT01323400|GIST
1160163|NCT01323400|Resistant
1160164|NCT01323400|Pazopanib
1160165|NCT01323400|Tyrosine kinase inhibitor
1160166|NCT01323400|Best supportive care
1160167|NCT01323400|Progression-free survival
1160168|NCT01323400|Overall survival
1160169|NCT01323400|Objective response rate
1160170|NCT01323400|Best response
1160171|NCT01323400|Tolerance profile
1160172|NCT01323374|Fibromyalgia
1160173|NCT01323374|FMS
1160174|NCT01323374|droxidopa
1160175|NCT01323374|pain
1160176|NCT01323361|inflammation
1160177|NCT01323361|laparoscopy
1160178|NCT01323361|hernia
1160179|NCT01323361|incisional
1160180|NCT01323361|trauma
1160181|NCT01323348|Diabetes
1160182|NCT01323348|Diabetes Education
1160183|NCT01323348|Diabetic Retinopathy
1160184|NCT01323348|HbA1c
1160185|NCT01323335|Uric Acid
1160186|NCT01323335|Rasburicase
1160187|NCT01323335|Inflammatory Markers
1160192|NCT01323309|Supportive Psychotherapy
1160193|NCT01323309|Therapy
1160194|NCT01323309|11-021
1160195|NCT01323296|Myocardial infarction
1160196|NCT01323296|Magnetic resonance
1160197|NCT01323296|Nanoparticle
1160198|NCT01323296|Iron
1160199|NCT01323296|Inflammation
1160200|NCT01323283|Omega-3
1160201|NCT01323283|physical activity
1160202|NCT01323283|children
1160203|NCT01323283|obesity
1160204|NCT01323283|sedentary
1160205|NCT01323283|accelerometry
1160206|NCT01323283|BMI
1160207|NCT01323283|fatty acids
1160208|NCT01323283|inflammatory markers
1160209|NCT01323283|intervention
1160210|NCT01323283|randomized
1160211|NCT01323283|double blind
1160212|NCT01323270|Healthy adolescents
1160213|NCT01323257|TMC435-TiDP16-C115
1160214|NCT01323257|TMC435-C115
1160215|NCT01323257|TMC435
1160216|NCT01323257|HCV
1160217|NCT01323257|Hepatitis C
1160218|NCT01323257|Hep C
1160219|NCT01323257|healthy volunteers
1160220|NCT01323244|TMC435-TiDP16-C213
1160221|NCT01323244|TMC435-C213
1160222|NCT01323244|TMC435
1160223|NCT01323244|HCV
1160224|NCT01323244|Hepatitis C
1160225|NCT01323231|XY-Zone
1160226|NCT01323231|school drop-out risk
1160227|NCT01323231|protective factors
1160228|NCT01323231|truancy
1160229|NCT01323218|Obstructive sleep apnea-hypopnea syndrome
1160230|NCT01323218|OSAHS
1160231|NCT01323218|Vitamin D
1160232|NCT01323205|JNJ-40411813
1160233|NCT01323192|Concerta
1160234|NCT01323192|Adults
1160235|NCT01323192|Attention-Deficit/Hyperactivity Disorder
1160236|NCT01323192|ADHD
1160237|NCT01323192|Methylphenidate hydrochloride
1160238|NCT01323179|Postoperative pain
1160239|NCT01323179|Postoperative opioid requirements
1160240|NCT01323166|rectal cancer
1160241|NCT01323140|hypogonadism, testosterone, transdermal system
1160242|NCT01323114|type 2 diabetes mellitus
1160243|NCT01323114|non-morbidly obese
1160244|NCT01323114|laparoscopic duodenal exclusion
1160245|NCT01323088|Childhood obesity
1160246|NCT01323088|Visceral fat
1160247|NCT01323088|Insulin resistance
1160248|NCT01323088|Liver fat
1160249|NCT01323088|Skeletal muscle lipid
1160250|NCT01323088|Regular exercise
1160251|NCT01323062|chemotherapy naive
1160252|NCT01323062|stage IV non squamous non small cell lung cancer
1160253|NCT01323062|Phase 1b
1160254|NCT01323062|Bavituximab
1160255|NCT01323062|Chimeric 3G4
1160256|NCT01323062|U of North Carolina at Chapel Hill
1160257|NCT01323049|extubation strategy
1160258|NCT01323010|asthma
1160259|NCT01323010|albuterol
1160260|NCT01323010|metered dose inhalers
1160261|NCT01322984|ASD
1160262|NCT01322984|Startle
1160263|NCT01322971|Bacterial Vaginosis
1160264|NCT01322971|Infertility
1160265|NCT01322971|Miscarriage
1160266|NCT01322971|Metronidazole
1160267|NCT01322958|bedside ultrasound
1160268|NCT01322932|Medication Adherence
1160269|NCT01322932|HIV Infection
1160270|NCT01322932|efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination [Substance Name]
1160271|NCT01322932|efavirenz
1160272|NCT01322932|emtricitabine
1160273|NCT01322932|Patient Satisfaction
1160274|NCT01322932|tenofovir disoproxil fumarate
1160275|NCT01322919|PresbyLASIK
1160276|NCT01322919|Presbyopia
1160277|NCT01322919|LASIK
1160278|NCT01322919|Supracor
1160279|NCT01322919|refractive
1160280|NCT01322919|Myopia
1160281|NCT01322919|Hyperopia
1160282|NCT01322906|ABMLF
1160283|NCT01322906|Allogenic Bone marrow Mesenchymal Stem Cells
1160284|NCT01322906|Liver Failure
1160285|NCT01322906|Transplantation
1160286|NCT01322893|Metastatic breast cancer
1160287|NCT01322893|Circulating tumour cells
1160288|NCT01322893|CTC
1160289|NCT01322893|Prognostic factors
1160290|NCT01322893|Treatment response
1160291|NCT01322880|domestic violence
1160292|NCT01322867|bioequivalence study
1160293|NCT01322867|alprazolam
1160294|NCT01322867|frontal
1160295|NCT01322854|IMRT
1160296|NCT01322854|Integrated boost
1160297|NCT01322854|adjuvant radiotherapy
1160298|NCT01322854|breast cancer
1160299|NCT01322854|breast conserving surgery
1160300|NCT01322841|CHICA
1160301|NCT01322841|clinical decision support
1160302|NCT01322828|Bicep
1160303|NCT01322828|Tendon
1160304|NCT01322828|Distal
1160305|NCT01322828|Ruptures
1160306|NCT01322828|Randomized
1160307|NCT01322828|Surgery
1160308|NCT01322815|colon cancer
1160309|NCT01322815|metastatic
1160310|NCT01322815|vaccine
1160311|NCT01322802|Ovarian Cancer
1160312|NCT01322802|Vaccine
1160313|NCT01322802|Stage III
1160314|NCT01322802|Stage IV
1160315|NCT01322802|Remission
1160316|NCT01322789|Diabetes mellitus
1160317|NCT01322789|Stem cells
1160318|NCT01322789|Autologous stem cell transplantation
1160319|NCT01322789|Autoimmune diseases
1160320|NCT01322776|Mantle Cell Lymphoma
1160321|NCT01322776|Recurrent
1160322|NCT01322776|Bortezomib
1160323|NCT01322776|Combination Treatment
1160324|NCT01322737|resection
1160325|NCT01322737|open
1160326|NCT01322737|laparoscopic
1160327|NCT01322737|benign
1160328|NCT01322737|malignant
1160329|NCT01322737|disease
1160330|NCT01322737|colon
1160331|NCT01322737|gastric
1160332|NCT01322724|colonoscopy
1160333|NCT01322724|colon cancer screening
1160334|NCT01322724|patient discomfort scores
1160335|NCT01322724|sedation medication requirements
1160336|NCT01322724|water insertion method
1160337|NCT01322711|Thromboxane
1160338|NCT01322711|Aspirin
1160339|NCT01322711|Atorvastatin
1160340|NCT01322711|Platelet activation
1160341|NCT01322711|Thrombin Activation
1160342|NCT01322711|Oxidative stress
1160343|NCT01322698|ICU
1160344|NCT01322685|Tuberculosis
1160345|NCT01322685|Lung cancer
1160346|NCT01322672|Anesthetic Agents
1160347|NCT01322672|POCD
1160348|NCT01322672|Delirium
1160349|NCT01322672|Cognitive Testing
1160350|NCT01322672|Aging
1160351|NCT01322672|Surgery
1160352|NCT01322672|fMRI
1160353|NCT01322672|Diffusion Tensor Imaging
1160354|NCT01322672|White Matter
1160355|NCT01322659|Mechanical ventilation
1160356|NCT01322659|Weaning
1160357|NCT01322659|Noninvasive ventilation
1160358|NCT01322659|Acute respiratory failure
1160359|NCT01322659|Helmet
1160360|NCT01322646|ADHD
1160361|NCT01322646|Driving
1160362|NCT01322646|Behavior modification
1160363|NCT01322633|Pantoprazole
1160364|NCT01322633|proton pump inhibitor
1160365|NCT01322633|gastric cancer
1160366|NCT01322633|digestive system cancer
1160367|NCT01322633|cancer
1160368|NCT01322607|Exercise
1160369|NCT01322607|Rehabilitation
1160370|NCT01322607|Stroke
1160371|NCT01322594|Chronic Obstructive Pulmonary Disease
1160372|NCT01322594|COPD
1160373|NCT01322581|Plasmodium Falciparum
1160374|NCT01322581|Genome-Wide Expression
1160375|NCT01322581|Antibody Profiling by Protein Microarray
1160376|NCT01322581|Multiplex Cytokine Analysis
1160377|NCT01322581|Children and Adults
1160378|NCT01322581|Malaria
1160379|NCT01322568|Aging
1160380|NCT01322568|Gene
1160381|NCT01322568|Environment
1160382|NCT01322568|Inflammation
1160383|NCT01322568|Iceland
1160384|NCT01322555|PBR28
1160385|NCT01322555|Positron Emission Tomography (PET)
1160386|NCT01322555|Propofol
1160387|NCT01322555|Autism
1160388|NCT01322555|Immune Response
1160389|NCT01322555|Autism Spectrum Disorders
1160390|NCT01322555|ASD
1160391|NCT01322555|Healthy Volunteer
1160392|NCT01322555|HV
1160393|NCT01322529|nulliparity
1160394|NCT01322529|pregnant women
1160395|NCT01322529|pregnancy outcomes
1160396|NCT01322529|pregnancy complications
1160397|NCT01322490|PROSTVAC
1160398|NCT01322490|metastatic
1160399|NCT01322490|prostate cancer
1160400|NCT01322490|castrate-resistant
1160401|NCT01322490|vaccine
1160402|NCT01322490|immunotherapy
1160403|NCT01322490|Phase 3
1160404|NCT01322477|Identification of treatment efficacy in patients with advanced HCC by PET/CT F18-FDG
1160405|NCT01322464|Sativex
1160406|NCT01322464|bio-availability
1160407|NCT01322464|cannabinoid
1160408|NCT01322464|pharmacokinetics
1160409|NCT01322451|Safety
1160410|NCT01322451|Tolerability
1160411|NCT01322451|Pharmacokinetics
1160412|NCT01322438|healthy volunteers
1160413|NCT01322438|rifampin
1160414|NCT01322438|pharmacokinetics
1160415|NCT01322438|single dose
1160416|NCT01322412|Adapted physical activity
1160417|NCT01322412|breast cancer
1160418|NCT01322399|low back pain
1160419|NCT01322399|chronic pain
1160420|NCT01322399|manual therapy
1160421|NCT01322399|Structural Integration
1160422|NCT01322386|PSC
1160423|NCT01322386|BA
1160424|NCT01322373|Alzheimer's disease
1160425|NCT01322373|magnetoencephalography
1160426|NCT01322373|MEG
1160427|NCT01322373|SNI
1160428|NCT01322347|End Stage Renal Disease
1160429|NCT01322347|Hemodialysis
1160430|NCT01322347|SFP
1160431|NCT01322347|Hemodialysis-dependent chronic renal failure
1160432|NCT01322334|Snoring
1160433|NCT01322334|Sleep apnea
1160434|NCT01322334|Pharyngeal muscle tone
1160435|NCT01322321|ACZ885
1160436|NCT01322321|diabetes
1160437|NCT01322321|type 1
1160438|NCT01322321|C-peptide
1160439|NCT01322308|lupus
1160440|NCT01322308|HDL particles
1160441|NCT01322308|endothelial function
1160442|NCT01322308|pioglitazone
1160443|NCT01322243|Anxiety
1160444|NCT01322243|Metabolic state
1160445|NCT01322243|Stress
1160446|NCT01322230|Instructional Design
1160447|NCT01322230|Online learning module
1160448|NCT01322230|Surgical education
1160449|NCT01322217|Medication adherence
1160450|NCT01322217|Substance use
1160451|NCT01322217|Sexual risk behaviors
1160452|NCT01322204|codeine, neonates, pediatric pharmacology
1160453|NCT01322191|pain, pain management, pediatrics, morphine pharmacokinetics
1160454|NCT01322178|cetuximab
1160455|NCT01322178|colorectal carcinoma
1160456|NCT01322165|Marfan syndrome
1160457|NCT01322165|Turner syndrome
1160458|NCT01322165|Bicuspid aortic valve
1160459|NCT01322165|Ehlers-Danlos Syndrome
1160460|NCT01322165|Loeys-Dietz syndrome
1160461|NCT01322165|Aneurysm
1160462|NCT01322165|Genetic
1160463|NCT01322165|aortic
1160464|NCT01322165|thoracic
1160465|NCT01322165|mutation
1160466|NCT01322165|dissection
1160467|NCT01322152|metastases
1160468|NCT01322152|neoplasm
1160469|NCT01322139|Sativex
1160470|NCT01322139|Cannabinoid
1160471|NCT01322139|Electrocardiogram
1160472|NCT01322139|QT interval
1160473|NCT01322113|BIPOLAR
1160474|NCT01322113|MANIA
1160475|NCT01322113|DEPRESSION
1160476|NCT01322100|Brain Metastases, CNS Metastases
1160477|NCT01322087|Nutrition
1160478|NCT01322087|new energy dense food concept
1160479|NCT01322074|Acute postoperative pain
1160480|NCT01322074|systemic inflammation
1160481|NCT01322074|CRP
1160482|NCT01322074|IL6
1160483|NCT01322061|Gallbladder removal
1160484|NCT01322061|acute cholecystitis
1160485|NCT01322061|Laparoscopic cholecestectomy
1160486|NCT01322048|Sympathetic Hyperactivity
1160487|NCT01322048|Traumatic Brain Injury
1160488|NCT01322048|Agitation
1160489|NCT01322048|Severe TBI
1160490|NCT01322048|TBI
1160491|NCT01322048|Catecholamines
1160492|NCT01322048|Heart rate variability
1160493|NCT01322048|Adrenergic alpha-Agonists
1160494|NCT01322048|Adrenergic beta-Antagonists
1160495|NCT01322048|Cognitive Impairment
1160496|NCT01322022|Autism
1160497|NCT01322022|Autism Spectrum Disorders
1160498|NCT01322022|Sleep Problems
1160499|NCT01322022|Sleep Disturbances
1160500|NCT01322022|Interventions
1160501|NCT01322009|Children
1160502|NCT01322009|Brain injury
1160503|NCT01322009|Trauma
1160504|NCT01321996|PET/CT
1160505|NCT01321996|68Ga-DOTANOC
1160506|NCT01321996|IPF
1160507|NCT01321996|NSIP
1160508|NCT01321996|Idiopathic pulmonary fibrosis
1160509|NCT01321931|Smoking Cessation
1160510|NCT01321931|Nicotine pharmacokinetics
1160511|NCT01321892|HRME
1160512|NCT01321892|High-resolution microendoscope
1160513|NCT01321892|Optical imaging technology
1160514|NCT01321892|Non-invasive fluorescence and reflectance imaging
1160515|NCT01321892|Upper aerodigestive tract
1160516|NCT01321892|Cancer surgery
1160517|NCT01321892|Squamous cell carcinoma
1160518|NCT01321892|Oral cavity
1160519|NCT01321892|Oropharynx
1160520|NCT01321892|Larynx
1160521|NCT01321892|Hypopharynx
1160522|NCT01321892|Squamous cell carcinoma of the oral cavity, oropharynx, larynx, and/or hypopharynx
1160523|NCT01321879|Gram Positive Bloodstream Infections
1160524|NCT01321879|Sepsis
1160525|NCT01321879|Staphylococcus aureus
1160526|NCT01321879|Enterococci
1160527|NCT01321879|Streptococci
1160528|NCT01321879|Pneumococci
1160529|NCT01321879|Corynebacterium
1160530|NCT01321879|Propionibacterium or Bacillus species
1160531|NCT01321879|Telavancin
1160532|NCT01321879|Vibativ
1160533|NCT01321866|Angioplasty
1160534|NCT01321866|cutting balloon
1160535|NCT01321853|Home health care
1160536|NCT01321853|Medication Management
1160537|NCT01321853|Cognitive impairment
1160538|NCT01321853|Medication adherence
1160539|NCT01321853|Older adults
1160540|NCT01321853|Care Coordination management
1160541|NCT01321840|Endometriosis
1160542|NCT01321840|pain
1160543|NCT01321840|sart
1160544|NCT01321840|autonomic nervous system
1160545|NCT01321840|fMRI
1160546|NCT01321840|perfusion
1160547|NCT01321840|connectivity
1160548|NCT01321840|hypnotherapy
1160549|NCT01321840|traditional Chinese medicine
1160550|NCT01321827|ABPA
1160551|NCT01321814|Hyperacusis
1160552|NCT01321814|Personality
1160553|NCT01321814|Comorbidity
1160554|NCT01321814|Treatment
1160555|NCT01321814|Cognitive behavioral therapy
1160556|NCT01321801|Pregabalin
1160557|NCT01321801|Laparoscopic cholecystectomy
1160558|NCT01321801|Postoperative pain
1160559|NCT01321801|Opioid consumption
1160560|NCT01321788|thromboprophylaxis
1160561|NCT01321788|pregnancy
1160562|NCT01321788|post-cesarian section
1160563|NCT01321762|Prolapse
1160564|NCT01321762|Childbirth
1160565|NCT01321762|Pregnancy
1160566|NCT01321749|ischemic cerebral vascular disease
1160567|NCT01321749|stroke secondary prevention
1160568|NCT01321749|remote ischemic preconditioning
1160569|NCT01321736|dietary fiber
1160570|NCT01321736|enteral nutrition
1160571|NCT01321736|laxation
1160572|NCT01321723|Osteoporosis
1160573|NCT01321723|Bone Diseases, Metabolic
1160574|NCT01321723|Bone Diseases
1160575|NCT01321723|Bone Density Conservation Agents
1160576|NCT01321710|sleep hygiene
1160577|NCT01321710|actigraphy
1160578|NCT01321710|maternal
1160579|NCT01321710|infant
1160580|NCT01321710|postpartum period
1160581|NCT01321710|immunization
1160582|NCT01321710|acetaminophen
1160583|NCT01321697|Being seen in the Winthrop P. Rockefeller Cancer Institute for vulvar
1160584|NCT01321697|cancer requiring lymph node evaluation for the ipsilateral or contralateral
1160585|NCT01321697|groin
1160586|NCT01321671|pregabalin
1160587|NCT01321671|pharmacokinetics
1160588|NCT01321671|bioavailability
1160589|NCT01321671|bioequivalence
1160590|NCT01321658|Geriatric Assessment
1160591|NCT01321658|Perioperative Care
1160592|NCT01321658|Colorectal Neoplasms
1160593|NCT01321658|Frail Elderly
1160594|NCT01321645|Acne Vulgaris
1160595|NCT01321645|Homoeopathy
1160596|NCT01321645|Homeopathy
1160597|NCT01321645|Azadirachta Indica
1160598|NCT01321632|Acne Vulgaris
1160599|NCT01321632|Homoeopathy
1160600|NCT01321632|Zingiber officinalis
1160601|NCT01321619|Chronic venous insufficiency
1160602|NCT01321619|Hemorrhoidal syndrome
1160603|NCT01321619|Varicell
1160604|NCT01321606|infection
1160605|NCT01321606|probiotics
1160606|NCT01321567|rabeprazole sodium
1160607|NCT01321567|refractory reflux esophagitis
1160608|NCT01321541|non-hodgkin lymphoma
1160609|NCT01321541|DLBCL
1160610|NCT01321541|relapsed
1160611|NCT01321541|aggressive NHL
1160612|NCT01321541|Diffuse large B-cell lymphoma
1160613|NCT01321541|Rituximab
1160614|NCT01321541|Rituxan
1160615|NCT01321541|Pixantrone
1160616|NCT01321541|NHL
1160617|NCT01321541|non hodgkin's lymphoma
1160618|NCT01321541|de novo DLBCL
1160619|NCT01321541|DLBCL transformed from Indolent Lymphoma
1160620|NCT01321541|Follicular Grade 3 Lymphoma
1160621|NCT01321502|treatment of herpes
1160622|NCT01321489|Phase III
1160623|NCT01321489|Sildenafil Citrate Tablet Sublingual
1160624|NCT01321489|Erectile dysfunction
1160625|NCT01321437|Melanoma
1160626|NCT01321437|Axitinib
1160627|NCT01321437|Anti-angiogenesis
1160628|NCT01321437|Neoadjuvant Melanoma
1160629|NCT01321424|Dry Eye
1160630|NCT01321424|Tear Osmolarity
1160631|NCT01321424|Meibomain Gland Disease
1160632|NCT01321424|Aqueous Dificiency
1160633|NCT01321424|Tear film abnormality
1160634|NCT01321411|Respiratory Muscle Blood Flow
1160635|NCT01321411|Work of Breathing
1160636|NCT01321411|Near Infrared Spectroscopy
1160637|NCT01321398|High Frequency Oscillation
1160638|NCT01321398|Oscillation
1160639|NCT01321398|HFO
1160640|NCT01321398|Transpulmonary pressure
1160641|NCT01321385|childhood acute myeloid leukemia in remission
1160642|NCT01321385|recurrent childhood acute myeloid leukemia
1160643|NCT01321385|untreated childhood acute myeloid leukemia and other myeloid malignancies
1160644|NCT01321385|childhood acute erythroleukemia (M6)
1160645|NCT01321385|childhood acute megakaryocytic leukemia (M7)
1160646|NCT01321385|childhood acute monoblastic leukemia (M5a)
1160647|NCT01321385|childhood acute monocytic leukemia (M5b)
1160648|NCT01321385|childhood acute myeloblastic leukemia with maturation (M2)
1160649|NCT01321385|childhood acute myeloblastic leukemia without maturation (M1)
1160650|NCT01321385|childhood acute myelomonocytic leukemia (M4)
1160651|NCT01321385|childhood acute minimally differentiated myeloid leukemia (M0)
1160652|NCT01321346|Relapse
1160653|NCT01321346|Lymphoblastic
1160654|NCT01321346|Leukemia
1160655|NCT01321346|Panobinostat
1160656|NCT01321346|LBH589
1160657|NCT01321346|Refractory
1160658|NCT01321346|Hodgkin's
1160659|NCT01321346|Non-Hodgkin's Lymphoma
1160660|NCT01321346|Lymphoma
1160661|NCT01321346|Myelogenous
1160662|NCT01321346|Acute
1160663|NCT01321346|Childhood
1160664|NCT01321346|Pediatric
1160665|NCT01321346|ALL
1160666|NCT01321346|AML
1160667|NCT01321346|NHL
1160668|NCT01321346|HD
1160669|NCT01321333|thoracic spinal cord injury
1160670|NCT01321333|spinal cord injury thoracic
1160671|NCT01321333|sub-acute spinal cord injury
1160672|NCT01321333|human neural stem cells
1160673|NCT01321333|stem cells
1160674|NCT01321333|stem cells transplant
1160675|NCT01321333|stem cells transplant spinal cord injury
1160676|NCT01321320|ICUAP
1160677|NCT01321320|Critical illness
1160678|NCT01321320|Muscle wasting
1160679|NCT01321320|ICU
1160680|NCT01321307|Aphtostomatitis
1160681|NCT01321307|Mucositis
1160682|NCT01321307|Mouth sores
1160683|NCT01321307|Natural
1160684|NCT01321307|Herbal
1160685|NCT01321281|Osteoarthritis
1160686|NCT01321268|orange peel skin
1160687|NCT01321268|cellulite
1160688|NCT01321255|Myocardial Infarction
1160689|NCT01321255|Treatment Adherence
1160690|NCT01321242|Resting heart rate
1160691|NCT01321242|Stable Angina
1160692|NCT01321242|Hypertension
1160693|NCT01321242|beta-blockers
1160694|NCT01321229|Sleep apnea
1160695|NCT01321229|NIHSS scale
1160696|NCT01321229|FIM scale
1160697|NCT01321229|FUGL-MEYER scale
1160698|NCT01321216|rotavirus
1160699|NCT01321216|gastroenteritis
1160700|NCT01321216|children
1160701|NCT01321216|Pediatric
1160702|NCT01321216|dehydration
1160703|NCT01321216|vaccine
1160704|NCT01321203|carbon dioxide insufflation
1160705|NCT01321177|Schizophrenia
1160706|NCT01321177|Schizoaffective Disorder
1160707|NCT01321177|Schizophreniform Disorder
1160708|NCT01321177|Brief Psychotic Disorder
1160709|NCT01321177|Psychotic Disorder NOS
1160710|NCT01321177|First Episode
1160711|NCT01321151|Mild Brain Injury
1160712|NCT01321151|Concussions
1160713|NCT01321151|Resveratrol
1160714|NCT01321151|Boxers
1160715|NCT01321151|ImPACT
1160716|NCT01321151|MRI
1160717|NCT01321138|Electrophysiological study
1160718|NCT01321138|Nerve block
1160719|NCT01321138|Analgesia, Patient-Controlled
1160720|NCT01321138|Anterior cruciate ligament
1160721|NCT01321125|Antiseptics
1160722|NCT01321125|Administration cutaneously
1160723|NCT01321125|Chlorine compounds
1160724|NCT01321125|Anti-infecting agents, local
1160725|NCT01321112|Conversion
1160726|NCT01321112|Mycophenolate mofetil
1160727|NCT01321112|Calcineurin inhibitors
1160728|NCT01321112|Liver transplantation
1160729|NCT01321112|Gene expression
1160730|NCT01321099|Iron absorption
1160731|NCT01321099|Complementary food fortificant
1160732|NCT01321099|Young children
1160733|NCT01321086|PAD
1160734|NCT01321060|severe acute pancreatitis
1160735|NCT01321060|acute fluid collection
1160736|NCT01321060|catheter drainage
1160737|NCT01321060|repeated aspiration
1160738|NCT01321047|sedation
1160739|NCT01321047|benzodiazepine
1160740|NCT01321047|opioid
1160741|NCT01321047|propofol
1160742|NCT01321034|Lipoprotein (a)
1160743|NCT01321034|LPA
1160744|NCT01321034|Niacin
1160745|NCT01321034|Kringle IV-2 repeats
1160746|NCT01321008|NK cell lymphoma-nasal type
1160747|NCT01321008|Stage I/II
1160748|NCT01321008|Radiation therapy
1160749|NCT01321008|XRT
1160750|NCT01321008|chemotherapy
1160751|NCT01321008|CHOP
1160752|NCT01321008|Cyclophosphamide
1160753|NCT01321008|Cytoxan
1160754|NCT01321008|Neosar
1160755|NCT01321008|Adriamycin
1160756|NCT01321008|Doxorubicin
1160757|NCT01321008|Rubex
1160758|NCT01321008|Vincristine
1160759|NCT01321008|Oncovin
1160760|NCT01321008|Prednisone
1160761|NCT01320995|Second degree vaginal tear
1160762|NCT01320995|Perineal ultrasound
1160763|NCT01320995|Anal incontinence
1160764|NCT01320982|Schizophrenia
1160765|NCT01320982|schizoaffective disorder
1160766|NCT01320969|mindfulness, fear conditioning
1160767|NCT01320956|hypnosis
1160768|NCT01320956|HYPNOANALGESIA
1160769|NCT01320956|surgery
1160770|NCT01320956|children
1160771|NCT01320956|anxiety
1160772|NCT01320956|morphine
1160773|NCT01320956|pain
1160774|NCT01320956|A-VAS
1160775|NCT01320956|orthopaedics
1160776|NCT01320956|osteotomy
1160777|NCT01320956|tenotomy
1160778|NCT01320956|arthrodesis
1160779|NCT01320956|spinal column surgery
1160780|NCT01320943|stopping oral antiviral therapy
1160781|NCT01320943|HBsAg loss
1160782|NCT01320943|seroconversion
1160783|NCT01320943|restarting oral antiviral therapy
1160784|NCT01320930|Effect of Pulmonary rehabilitation.
1160785|NCT01320930|Exercise capacity
1160786|NCT01320930|Quality of life
1160787|NCT01320917|obesity
1160788|NCT01320917|contraceptives hormonal
1160789|NCT01320917|levonorgestrel-releasing intrauterine device
1160790|NCT01320917|cardiovascular risk
1160791|NCT01320904|Closed Kinetic Chain
1160792|NCT01320904|NMES
1160793|NCT01320904|Knee Osteoarthritis
1160794|NCT01320891|general anaesthesia for major abdominal surgery
1160795|NCT01320878|pulmonary hypertension
1160796|NCT01320852|Transplant
1160797|NCT01320826|colonoscopy
1160798|NCT01320826|primary care physicians
1160799|NCT01320826|quality assurance
1160800|NCT01320813|da vinci robot
1160801|NCT01320813|Thyroidectomy
1160802|NCT01320787|Brain
1160803|NCT01320787|Adenocarcinoma of the prostate
1160804|NCT01320787|Locally advanced breast cancer
1160805|NCT01320787|Estrogen receptor
1160806|NCT01320787|ER
1160807|NCT01320787|Progesterone receptor
1160808|NCT01320787|PR
1160809|NCT01320787|Negative for ErbB2
1160810|NCT01320787|Malignant tumor of the central nervous system
1160811|NCT01320787|CNS
1160812|NCT01320761|Formulation Comparison
1160813|NCT01320748|Abstinence from alcohol
1160814|NCT01320748|Substance Abuse and Mental Health Services
1160815|NCT01320748|Social Support
1160816|NCT01320748|Psychosocial Support Systems
1160817|NCT01320748|Psychological support
1160818|NCT01320748|Cognitive Support
1160819|NCT01320748|Emotional Support
1160820|NCT01320748|Mental Support
1160821|NCT01320748|Psychosocial Support
1160822|NCT01320748|Intervention Studies
1160823|NCT01320748|Prevention & control
1160824|NCT01320748|Preventive therapy
1160825|NCT01320748|Treatment
1160826|NCT01320748|Therapy
1160827|NCT01320748|Magnetic Resonance Imaging
1160828|NCT01320748|fMRI
1160829|NCT01320748|Imaging
1160830|NCT01320748|Magnetic Resonance Imaging, Functional
1160831|NCT01320748|MRI Scans
1160832|NCT01320748|MRI, Functional
1160833|NCT01320748|Clinical Protocols
1160834|NCT01320748|Protocols, Treatment
1160835|NCT01320748|Drug Abuse Treatment Center
1160836|NCT01320748|Substance Abuse Treatment Center
1160837|NCT01320735|Lucrin Depot
1160838|NCT01320735|intermittent adjuvant regimen
1160839|NCT01320735|advanced prostate cancer
1160840|NCT01320735|Leuprorelin
1160841|NCT01320722|renin angiotensin system
1160842|NCT01320722|vitamin D
1160843|NCT01320722|uric acid
1160844|NCT01320722|allopurinol
1160845|NCT01320722|probenecid
1160846|NCT01320722|endothelial function
1160847|NCT01320709|Emergency contraception
1160848|NCT01320709|Contraception
1160849|NCT01320670|pharmacoresistance
1160850|NCT01320657|Self-ligating
1160851|NCT01320657|orthodontic
1160852|NCT01320657|appliance
1160853|NCT01320657|expansion
1160854|NCT01320657|dental inclination
1160855|NCT01320657|Expansion and inclination changes arising with orthodontic treatment
1160856|NCT01320644|Uterine prolapse
1160857|NCT01320644|vaginal prolapse
1160858|NCT01320644|mesh erosion
1160859|NCT01320644|urinary incontinence
1160860|NCT01320644|bowel symptoms
1160861|NCT01320631|uterine prolapse
1160862|NCT01320631|vaginal prolapse
1160863|NCT01320618|uterine prolapse
1160864|NCT01320618|vaginal prolapse
1160865|NCT01320618|mesh erosion
1160866|NCT01320618|urinary incontinence
1160867|NCT01320618|bowel symptoms
1160868|NCT01320592|Patient must have histologically or cytologically-confirmed metastatic
1160869|NCT01320592|breast cancer
1160870|NCT01320592|Any ER, PR or Her2 status is allowed.
1160871|NCT01320592|Tumor must express Retinoblastoma (Rb) protein, defined as
1160872|NCT01320592|any measurable staining by immunohistochemistry on the invasive tumor component
1160873|NCT01320592|<3 prior cyttoxic chemotherapy regimens for metastatic disease.
1160874|NCT01320592|Performance status of 0-1 on the ECOG Performance Scale and life expectancy > 3 months.
1160875|NCT01320592|Patient must have evaluable disease. Measureable disease is not required.
1160876|NCT01320592|The subject has adequate organ function
1160877|NCT01320579|atopic dermatitis
1160878|NCT01320579|cis-urocanic acid
1160879|NCT01320566|Polymeric Lung Volume Reduction (PLVR)
1160880|NCT01320566|Bolilogic Lung Volume Reduction (BLVR)
1160881|NCT01320566|AeriSeal
1160882|NCT01320566|treatment
1160883|NCT01320566|device
1160884|NCT01320566|breathing
1160885|NCT01320566|COPD
1160886|NCT01320566|emphysema
1160887|NCT01320566|heterogeneous
1160888|NCT01320566|homogeneous
1160889|NCT01320566|Pathologic Processes
1160890|NCT01320566|Respiratory Tract Diseases
1160891|NCT01320566|Lung Diseases
1160892|NCT01320566|Pulmonary Disease, Chronic Obstructive
1160893|NCT01320527|dietary supplement
1160894|NCT01320527|cognition
1160895|NCT01320527|mood
1160896|NCT01320527|Alzheimer's disease
1160897|NCT01320527|memory loss
1160898|NCT01320501|Lung Cancer
1160899|NCT01320488|Breast Cancer
1160900|NCT01320475|thoracic epidural analgesia
1160901|NCT01320475|epidural opioid
1160902|NCT01320475|ketamine
1160903|NCT01320475|adverse effect
1160904|NCT01320462|Smoking
1160905|NCT01320462|quit
1160906|NCT01320462|surgery
1160907|NCT01320462|anesthesia
1160908|NCT01320462|champix
1160909|NCT01320449|EPO
1160910|NCT01320449|Proteomics
1160911|NCT01320449|Carbohydrate metabolism
1160912|NCT01320449|Fat metabolism
1160913|NCT01320449|Protein metabolism
1160914|NCT01320436|Ulcerative colitis
1160915|NCT01320436|Curcumin
1160916|NCT01320423|Intracerebral Haemorrhage
1160917|NCT01320384|ALI
1160918|NCT01320371|barbed sutures
1160919|NCT01320371|knotted sutures
1160920|NCT01320371|total knee arthroplasty
1160921|NCT01320371|knee surgery
1160922|NCT01320358|Patient compliance
1160923|NCT01320358|ECMPS-IEM
1160924|NCT01320358|transplantation
1160925|NCT01320358|renal maintenance
1160926|NCT01320358|Proteus
1160927|NCT01320345|Diabetes Mellitus
1160928|NCT01320345|Type 1 Diabetes Mellitus
1160929|NCT01320345|Retinopathy
1160930|NCT01320345|Diabetic Nephropathy
1160931|NCT01320345|Fenofibrate
1160932|NCT01320332|Ulcerative colitis
1160933|NCT01320332|ASP3291
1160934|NCT01320293|Moderate to Severe Chronic plaque type psoriasis
1160935|NCT01320280|Prostate cancer, BIBW 2992 (Afatinib) , HER inhibitor
1160936|NCT01320267|Resectable right colon cancer
1160937|NCT01320254|Palliative treatment
1160938|NCT01320254|Panitumumab
1160939|NCT01320254|Cisplatin
1160940|NCT01320254|Cisplatinum
1160941|NCT01320254|Gemcitabine
1160942|NCT01320254|Vectibix
1160943|NCT01320228|Obesity
1160944|NCT01320228|orlistat
1160945|NCT01320228|fat excretion
1160946|NCT01320228|fiber
1160947|NCT01320228|dairy calcium
1160948|NCT01320215|da Vinci Robot
1160949|NCT01320215|uterine prolapse
1160950|NCT01320215|vaginal prolapse
1160951|NCT01320215|sacrohysteropexy
1160952|NCT01320202|End Stage Renal Disease
1160953|NCT01320202|Hemodialysis
1160954|NCT01320202|SFP
1160955|NCT01320202|Hemodialysis-dependent chronic renal failure
1160956|NCT01320189|Energy intake
1160957|NCT01320189|Protein requirement
1160958|NCT01320189|Satiety
1160959|NCT01320189|Protein leverage hypothesis
1160960|NCT01320150|persistent postsurgical pain (PPP)
1160961|NCT01320137|Immunological assay
1160962|NCT01320137|Birch allergy
1160963|NCT01320124|Contractures
1160964|NCT01320124|Total knee arthroplasty
1160965|NCT01320124|Tissue bank
1160966|NCT01320124|Osteoarthritis
1160967|NCT01320124|Gene expressions
1160968|NCT01320111|progression free survival
1160969|NCT01320111|paclitaxel
1160970|NCT01320111|sorafenib
1160971|NCT01320111|metastatic breast cancer
1160972|NCT01320098|Attention
1160973|NCT01320098|Behavior Problems
1160974|NCT01320098|Compliance
1160975|NCT01320098|Evaluation
1160976|NCT01320098|Preschool
1160977|NCT01320098|ADHD
1160978|NCT01320098|Overactive
1160979|NCT01320098|Inattentive
1160980|NCT01320098|Attention Deficit Hyperactivity Disorder in Preschoolers
1160981|NCT01320085|Metastatic melanoma,
1160982|NCT01320085|BRAF-mutant,
1160983|NCT01320085|NRAS-mutant
1160984|NCT01320072|aspirin
1160985|NCT01320072|asthma
1160986|NCT01320072|diagnosis
1160987|NCT01320072|prostaglandins
1160988|NCT01320072|leukotrienes
1160989|NCT01320059|18F-Fluoro-PEG6-IPQA
1160990|NCT01320059|Radioactive Imaging Solution
1160991|NCT01320059|Non-Small Cell Lung Cancer
1160992|NCT01320059|Positron Emission Tomography
1160993|NCT01320059|PET Scan
1160994|NCT01320059|CT
1160995|NCT01320059|Computed Tomography
1160996|NCT01320046|Urinary Incontinence
1160997|NCT01320046|Vulvar pruritus
1160998|NCT01320046|Vulvar contact dermatitis
1160999|NCT01320033|acne vulgaris
1161000|NCT01320033|inflammatory lesions
1161001|NCT01320020|Cancer
1161002|NCT01320020|Neoplasm
1161003|NCT01320020|Carcinoma
1161004|NCT01320020|intravenous
1161005|NCT01320020|Monoclonal Antibody
1161006|NCT01320020|Removab
1161007|NCT01319994|glucocorticoid
1161008|NCT01319981|Acute Lymphoblastic Leukemia
1161009|NCT01319981|ALL
1161010|NCT01319981|Lymphoblastic lymphoma
1161011|NCT01319981|Cytoxan
1161012|NCT01319981|Neosar
1161013|NCT01319981|Mesnex
1161014|NCT01319981|Liposomal Vincristine
1161015|NCT01319981|Vincristine Sulfate Liposomes Injection
1161016|NCT01319981|Marqibo
1161017|NCT01319981|Dexamethasone
1161018|NCT01319981|Adriamycin
1161019|NCT01319981|Rubex
1161020|NCT01319981|Cytarabine
1161021|NCT01319981|Cytosar
1161022|NCT01319981|DepoCyt
1161023|NCT01319981|Cytosine Arabinosine Hydrochloride
1161024|NCT01319981|Imatinib Mesylate
1161025|NCT01319981|Gleevec
1161026|NCT01319981|ST1571
1161027|NCT01319981|NSC-716051
1161028|NCT01319981|Filgrastim
1161029|NCT01319981|Neupogen
1161030|NCT01319968|Postpartum dyspareunia
1161031|NCT01319968|Vaginal atrophy
1161032|NCT01319955|Pneumonia
1161033|NCT01319955|Influenza
1161034|NCT01319955|Child
1161035|NCT01319955|Respiratory
1161036|NCT01319955|Pathogen
1161037|NCT01319942|Radiotherapy
1161038|NCT01319942|Sorafenib
1161039|NCT01319942|Treatment outcome
1161040|NCT01319929|Osteoarthritis, knee pain, osteoarthritic knee pain
1161041|NCT01319903|sepsis
1161042|NCT01319903|inflammation
1161043|NCT01319903|complement
1161044|NCT01319903|immune system
1161045|NCT01319890|all histologic subtypes
1161046|NCT01319890|benign
1161047|NCT01319890|malignant
1161048|NCT01319864|leukemia
1161049|NCT01319851|bone marrow transplant
1161050|NCT01319851|sickle cell disease
1161051|NCT01319851|thalassemia
1161052|NCT01319851|Glanzmann thrombasthenia
1161053|NCT01319851|Wiskott-Aldrich syndrome
1161054|NCT01319851|chronic-granulomatous disease
1161055|NCT01319851|severe congenital neutropenia
1161056|NCT01319851|leukocyte adhesion deficiency
1161057|NCT01319851|Schwachman-Diamond syndrome
1161058|NCT01319851|Diamond-Blackfan anemia
1161059|NCT01319851|Fanconi anemia
1161060|NCT01319851|dyskeratosis-congenita
1161061|NCT01319851|Chediak-Higashi syndrome
1161062|NCT01319851|severe aplastic anemia
1161063|NCT01319838|neuroblastoma
1161064|NCT01319838|isotretinoin
1161065|NCT01319812|Vascular intervention
1161066|NCT01319812|Endovascular
1161067|NCT01319812|Peripheral stent
1161068|NCT01319799|Embolism
1161069|NCT01319799|Nervous system
1161070|NCT01319799|Aorta
1161071|NCT01319799|Valves
1161072|NCT01319799|Ultrasonics
1161073|NCT01319786|Hypertension
1161074|NCT01319786|Microvascular function
1161075|NCT01319760|STEMI
1161076|NCT01319747|atrial
1161077|NCT01319747|fibrillation
1161078|NCT01319747|pvi
1161079|NCT01319747|vats
1161080|NCT01319747|ablation
1161081|NCT01319734|Vitamin C
1161082|NCT01319734|Oxidative stress
1161083|NCT01319734|Type 2DM
1161084|NCT01319721|Amniotic membrane
1161085|NCT01319721|Limbal conjunctival autograft
1161086|NCT01319721|Limbal
1161087|NCT01319721|Conjunctival
1161088|NCT01319721|Mitomycin C
1161089|NCT01319721|Recurrent pterygium
1161090|NCT01319721|Pterygium
1161091|NCT01319708|ovarian stimulation
1161092|NCT01319708|climiphene citrate
1161093|NCT01319708|Gonadotropin-Releasing Hormone agonists/antagonists
1161094|NCT01319708|Follicle Stimulating Hormone
1161095|NCT01319695|corifollitropin alfa
1161096|NCT01319695|FSH ovarian stimulation
1161097|NCT01319695|IVF
1161098|NCT01319682|Pain
1161099|NCT01319682|Preemptive
1161100|NCT01319682|Lidocaine
1161101|NCT01319682|Intravenous
1161102|NCT01319682|Lumbar fusion
1161103|NCT01319656|Chronic diseases
1161104|NCT01319656|Primary care
1161105|NCT01319656|Rehabilitation
1161106|NCT01319656|Chronic Care Model
1161107|NCT01319656|Patient centered medical home
1161108|NCT01319643|Oxygen
1161109|NCT01319643|Hyperoxia
1161110|NCT01319643|Intensive care unit
1161111|NCT01319643|Mortality
1161112|NCT01319643|Organ dysfunction
1161113|NCT01319643|Postoperative care
1161114|NCT01319630|sepsis
1161115|NCT01319630|microcirculation
1161116|NCT01319630|saline
1161117|NCT01319630|crystalloid
1161118|NCT01319630|colloid
1161119|NCT01319630|albumin
1161120|NCT01319630|hydroxyethyl starch
1161121|NCT01319578|chronic kidney disease
1161122|NCT01319578|phosphorus
1161123|NCT01319578|phosphate
1161124|NCT01319578|saliva
1161125|NCT01319578|K2CG
1161126|NCT01319578|medical food
1161127|NCT01319578|chitosan
1161133|NCT01319552|red blood cells
1161134|NCT01319552|transfusion
1161135|NCT01319552|storage
1161136|NCT01319552|sickle cell disease
1161137|NCT01319552|β-thalassemia
1161138|NCT01319552|hemoglobin-associated iron
1161139|NCT01319526|stage III adult Hodgkin lymphoma
1161140|NCT01319526|stage IV adult Hodgkin lymphoma
1161141|NCT01319526|HIV infection
1161142|NCT01319500|Drug Utilization
1161143|NCT01319500|Oral Contraceptives
1161144|NCT01319474|Deep vein thrombosis
1161145|NCT01319474|Pulmonary embolism
1161146|NCT01319474|Ultrasound
1161147|NCT01319474|Pregnancy
1161148|NCT01319461|Osteoarthritis
1161149|NCT01319461|Hyalgan
1161150|NCT01319448|Sickle cell disease
1161151|NCT01319448|Malaria
1161152|NCT01319448|Intermittent Preventive Treatment (IPT)
1161153|NCT01319448|prophylaxis
1161154|NCT01319435|Ciprofloxacin
1161155|NCT01319435|Neonates
1161156|NCT01319435|Gram negative infection
1161157|NCT01319422|myeloma
1161158|NCT01319422|multiple myeloma
1161159|NCT01319422|pomalidomide
1161160|NCT01319422|immunomodulatory
1161161|NCT01319409|Anterior cruciate ligament surgery
1161162|NCT01319409|Anterior cruciate ligament reconstruction
1161163|NCT01319409|Single bundle anterior cruciate ligament reconstruction
1161164|NCT01319409|Double bundle anterior cruciate ligament reconstruction
1161165|NCT01319409|Randomized clinical trial
1161166|NCT01319396|breathing rate
1161167|NCT01319383|HIV-1 Infection
1161168|NCT01319383|HIV RNA <50 copies/mL
1161169|NCT01319383|Stable ART
1161170|NCT01319383|Resting CD4+ T cells
1161171|NCT01319383|Leukapheresis
1161172|NCT01319383|Vorinostat
1161173|NCT01319383|HIV RNA expression
1161174|NCT01319383|PK visits
1161175|NCT01319331|diabetes
1161176|NCT01319331|type 1 diabetes
1161177|NCT01319331|AAT
1161178|NCT01319331|Alpha-1 Antitrypsin
1161179|NCT01319279|Pharmacokinetics
1161180|NCT01319279|Hydrocodone
1161181|NCT01319279|Extended Release
1161182|NCT01319279|Hepatic impairment
1161183|NCT01319266|hydrocodone
1161184|NCT01319266|extended release
1161185|NCT01319266|pharmacokinetics
1161186|NCT01319266|renal impairment
1161187|NCT01319253|Cystic Fibrosis
1161188|NCT01319253|Pseudomonas aeruginosa
1161189|NCT01319227|Periprosthetic bone remodeling
1161190|NCT01319227|Stress shielding
1161191|NCT01319227|Short femoral stem
1161192|NCT01319227|Porous Titanium Construct
1161193|NCT01319227|Polyethylene wear
1161194|NCT01319214|cocaine addiction treatment craving
1161195|NCT01319188|Age-related macular degeneration
1161196|NCT01319188|ranibizumab
1161197|NCT01319188|acute thromboembolic events
1161198|NCT01319188|coronary artery disease
1161199|NCT01319188|cerebrovascular disease
1161200|NCT01319175|hip flexion strength training
1161201|NCT01319175|elastic bands
1161202|NCT01319175|external resistance
1161203|NCT01319162|PCOS
1161204|NCT01319149|molecular methods
1161205|NCT01319136|new infusion test method
1161206|NCT01319136|reference method
1161207|NCT01319136|cerebrospinal fluid dynamics
1161208|NCT01319123|dressing for venous leg ulcers
1161209|NCT01319110|Cardiac Arrest
1161210|NCT01319110|Post Cardiac Arrest
1161211|NCT01319110|CoQ10
1161212|NCT01319110|Ubiquinone
1161213|NCT01319110|Post Arrest
1161214|NCT01319097|Reduction on local soft tissue edema
1161215|NCT01319058|obstructive sleep apnea
1161216|NCT01319058|Tonsillectomy
1161217|NCT01319058|Tonsillotomy
1161218|NCT01319058|Inflammation
1161219|NCT01319058|Pain
1161220|NCT01319058|Post tonsillectomy bleeding
1161221|NCT01319045|Pulmonary Arterial Hypertension
1161222|NCT01319045|Congenital Heart Disease
1161223|NCT01319045|Eisenmenger's Syndrome
1161224|NCT01319045|Prostacyclin
1161225|NCT01319045|Iloprost
1161226|NCT01319019|lung function
1161227|NCT01319019|bronchodilator
1161228|NCT01319019|COPD, dose response, dosing interval, efficacy, safety, PD, PK
1161229|NCT01319006|relative bioavailability
1161230|NCT01318993|GSK1605786A; Inflammatory Bowel Disease; Crohn's disease; long-term treatment; quality of life; CCR9 antagonist
1161231|NCT01318980|ADME
1161232|NCT01318980|IV radiolabelled
1161233|NCT01318980|pharmacokinetics
1161234|NCT01318967|Renal blood flow
1161235|NCT01318967|Regional renal blood flow
1161236|NCT01318967|MRI
1161237|NCT01318941|Ophthalmology, age-related macular degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, ranibizumab
1161238|NCT01318941|Ophthalmology
1161239|NCT01318941|Age-related macular degeneration
1161240|NCT01318941|Diabetic Macular Edema
1161241|NCT01318941|Retinal Vein Occlusion
1161242|NCT01318941|LUMINOUS
1161243|NCT01318941|Ranibizumab
1161244|NCT01318928|Periodontitis
1161245|NCT01318928|antibiotics
1161246|NCT01318928|treatment period
1161247|NCT01318928|microbiology
1161248|NCT01318915|Kidney transplantation
1161249|NCT01318915|Immunosuppression
1161250|NCT01318915|Graft rejection
1161251|NCT01318915|Graft loss
1161252|NCT01318915|Renal transplant
1161253|NCT01318915|Transplantation
1161254|NCT01318915|kidney disease
1161255|NCT01318915|Renal disease
1161256|NCT01318915|Organ transplant
1161257|NCT01318915|Living donor transplant
1161258|NCT01318915|Living-donor
1161259|NCT01318889|Dexpanthenol
1161260|NCT01318889|Radiotherapy
1161261|NCT01318889|chemotherapy
1161262|NCT01318889|Mucositis
1161263|NCT01318876|influenza
1161264|NCT01318876|vaccine safety
1161265|NCT01318876|adverse events
1161266|NCT01318876|health care workers
1161267|NCT01318863|aged matched normal control samples
1161268|NCT01318850|schizophrenia
1161269|NCT01318850|cognitive remediation
1161270|NCT01318850|fMRI
1161271|NCT01318837|OABSS
1161272|NCT01318837|IPSS
1161273|NCT01318837|PPBC
1161274|NCT01318837|Solifenacin
1161275|NCT01318824|Neonatal Respiratory Failure
1161276|NCT01318824|Newborn Infant
1161277|NCT01318824|BiPAP
1161278|NCT01318824|NIPPV
1161279|NCT01318811|Heparin
1161280|NCT01318811|CRRT
1161281|NCT01318811|Continuous renal replacement therapy
1161282|NCT01318811|CVVHD
1161283|NCT01318811|Anticoagulation
1161284|NCT01318798|Development
1161285|NCT01318798|Pre- and intra-operative predictors
1161286|NCT01318798|Acute renal failure
1161287|NCT01318798|Liver Surgery
1161288|NCT01318798|Prediction score
1161289|NCT01318798|Validation
1161290|NCT01318798|Clinical consequences
1161291|NCT01318798|Decision curve analysis
1161292|NCT01318798|predictors of acute renal failure after liver resection
1161293|NCT01318785|secondary arm-lymphedema
1161294|NCT01318785|breast cancer related arm-lymphedema
1161295|NCT01318746|change of potassium amount, circadian and day-to-day variability
1161296|NCT01318733|Rosacea
1161297|NCT01318720|Neck Pain
1161298|NCT01318720|Thrust Manipulation
1161299|NCT01318720|Non-Thrust Manipulation
1161300|NCT01318707|Severe Hemophilia A
1161301|NCT01318707|Hemophilia A Patients
1161302|NCT01318707|Serum collection vs a method of added FVIII to blood samples
1161303|NCT01318694|Chronic hepatitis C
1161304|NCT01318694|Cyclophilin inhibitor
1161305|NCT01318681|driving, memory, cognition
1161306|NCT01318668|fmri smoking vaccination mood
1161307|NCT01318655|Phase I
1161308|NCT01318655|Japan
1161309|NCT01318655|SAD
1161310|NCT01318655|MAD
1161311|NCT01318642|Adenocarcinoma
1161312|NCT01318642|pancreas
1161313|NCT01318642|pancreatic cancer
1161314|NCT01318642|local
1161315|NCT01318642|unresectable
1161316|NCT01318642|stage II
1161317|NCT01318642|stage III
1161318|NCT01318616|hip adduction strength training
1161319|NCT01318616|Improvement in adductor strength
1161320|NCT01318590|Pancreatitis, Chronic
1161321|NCT01318590|Abdominal Pain
1161322|NCT01318590|Celiac bloc
1161323|NCT01318590|Endosonography
1161324|NCT01318564|Type II Diabetes
1161325|NCT01318564|Unit dose packaging devices
1161326|NCT01318564|Metformin
1161327|NCT01318564|Lisinopril
1161328|NCT01318564|Enalapril
1161329|NCT01318564|Atorvastatin
1161330|NCT01318564|Lipitor
1161331|NCT01318564|Simvastatin
1161332|NCT01318564|Aspirin
1161333|NCT01318564|Questionnaires
1161334|NCT01318551|Anemia
1161335|NCT01318538|Substance use disorders, Gender differences, women, treatment outcomes, group therapy
1161336|NCT01318499|cataract
1161337|NCT01318499|inflammation
1161338|NCT01318499|pain
1161339|NCT01318499|inflammatory cells
1161340|NCT01318499|aqueous flare
1161341|NCT01318473|cancer
1161342|NCT01318460|coronary artery disease
1161343|NCT01318460|levosimendan
1161344|NCT01318460|coronary artery bypass grafting
1161345|NCT01318460|cardiac surgery
1161346|NCT01318447|Hepatic metastases
1161347|NCT01318447|Liver metastases
1161348|NCT01318447|Colorectal cancer
1161349|NCT01318447|Colorectal adenocarcinoma
1161350|NCT01318447|Accuray
1161351|NCT01318447|CyberKnife
1161352|NCT01318434|Outpatient
1161353|NCT01318421|Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS)
1161354|NCT01318356|Q fever
1161355|NCT01318356|Cognitive behavioral therapy
1161356|NCT01318356|Doxycycline
1161357|NCT01318356|Fatigue
1161358|NCT01318356|Coxiella
1161359|NCT01318343|Cryolipolysis
1161360|NCT01318343|Abdominal Fat
1161361|NCT01318343|Adipose Tissue
1161362|NCT01318343|Fat Reduction
1161363|NCT01318343|Non Invasive
1161364|NCT01318304|innate immunity
1161365|NCT01318304|HIV
1161366|NCT01318304|pregnancy
1161367|NCT01318304|vaginal immunity
1161368|NCT01318291|IVF
1161369|NCT01318291|Drop out
1161370|NCT01318278|Hypotension
1161371|NCT01318278|Low blood pressure
1161372|NCT01318278|Neonate
1161373|NCT01318278|Dopamine
1161374|NCT01318278|Vasopressin
1161375|NCT01318278|Extremely Low Birth Weight Infant
1161376|NCT01318265|drug interactions
1161377|NCT01318265|ketoconazole
1161378|NCT01318265|pharmacokinetics
1161379|NCT01318265|human volunteers
1161380|NCT01318252|Elevated IOP
1161381|NCT01318226|postherpetic neuralgia
1161382|NCT01318226|shingles
1161383|NCT01318226|analgesia
1161384|NCT01318226|neuropathic pain
1161385|NCT01318213|VRE
1161386|NCT01318213|MRSA
1161387|NCT01318200|Primary liver cancer
1161388|NCT01318200|Hepatocellular carcinoma
1161389|NCT01318200|CyberKnife
1161390|NCT01318200|Accuray
1161391|NCT01318200|TACE
1161392|NCT01318200|Transarterial chemoembolization
1161393|NCT01318187|renal colic
1161394|NCT01318187|paracetamol
1161395|NCT01318187|morphine
1161396|NCT01318187|emergency department
1161397|NCT01318174|Pulmonary embolism
1161398|NCT01318174|Pulmonary Disease, Chronic Obstructive
1161399|NCT01318161|Epidural analgesia
1161400|NCT01318161|Patient controlled analgesia
1161401|NCT01318161|Colorectal cancer
1161402|NCT01318161|Morbidity
1161403|NCT01318161|Mortality
1161404|NCT01318148|Echinocandins
1161405|NCT01318148|Caspofungin
1161406|NCT01318148|Pharmacokinetics
1161407|NCT01318148|Prophylaxis
1161408|NCT01318148|Antifungal
1161409|NCT01318148|Aspergillosis
1161410|NCT01318148|Acute Leucemia
1161411|NCT01318135|Diabetes Mellitus - Type 2
1161412|NCT01318135|Diabetes Mellitus
1161413|NCT01318135|Drug Therapy
1161414|NCT01318122|Diabetes Mellitus - Type 2
1161415|NCT01318122|Diabetes Mellitus
1161416|NCT01318122|Drug Therapy
1161417|NCT01318109|Diabetes Mellitus - Type 2
1161418|NCT01318109|Diabetes Mellitus
1161419|NCT01318109|Drug Therapy
1161420|NCT01318096|safety
1161421|NCT01318096|efficacy
1161422|NCT01318096|raltegravir
1161423|NCT01318096|HBV/HIV co-infection
1161424|NCT01318083|Diabetes Mellitus - Type 2
1161425|NCT01318083|Diabetes Mellitus
1161426|NCT01318083|Drug Therapy
1161427|NCT01318070|Diabetes Mellitus - Type2
1161428|NCT01318070|Diabetes Mellitus
1161429|NCT01318070|Drug Therapy
1161430|NCT01318057|Pharmacogenetics
1161431|NCT01318057|Warfarin
1161432|NCT01318057|Personalized Medicine
1161433|NCT01318057|Puerto Ricans
1161434|NCT01318057|Physiogenomics
1161435|NCT01318057|Hispanics
1161436|NCT01318057|Anticoagulants
1161437|NCT01318057|Cardiovascular
1161438|NCT01318057|Deep Vein Thrombosis with or without Pulmonary Embolism
1161439|NCT01318057|Cardiac Valvular Replacement
1161440|NCT01318044|thiopental
1161441|NCT01318044|propofol
1161442|NCT01318044|sedation
1161443|NCT01318044|MRI
1161444|NCT01318031|DDI
1161445|NCT01318031|Healthy Volunteers
1161446|NCT01318018|depression
1161447|NCT01318018|bispectral index
1161448|NCT01318018|electroconvulsive therapy
1161449|NCT01318018|magnetic seizure therapy
1161450|NCT01317992|Medication overuse headache
1161451|NCT01317992|ibudilast
1161452|NCT01317992|glia
1161453|NCT01317940|Leukemia
1161454|NCT01317940|ALL
1161455|NCT01317940|Vitamin D
1161456|NCT01317940|Bone Density
1161457|NCT01317940|Body Fat
1161458|NCT01317940|Obesity
1161459|NCT01317940|Adipose
1161460|NCT01317927|belionstat
1161461|NCT01317927|warfarin
1161462|NCT01317927|hematological malignancy
1161463|NCT01317927|solid tumors
1161464|NCT01317927|PK/PD study
1161470|NCT01317888|high grade gliomas of the brain
1161471|NCT01317888|anti-body treatment
1161472|NCT01317888|survival
1161473|NCT01317862|labor induction, transcervical foley catheter, prostaglandin
1161474|NCT01317849|folic acid
1161475|NCT01317849|B vitamins
1161476|NCT01317849|secondary prevention
1161477|NCT01317849|stroke
1161478|NCT01317849|randomized controlled trial
1161479|NCT01317849|homocysteine
1161480|NCT01317836|pancreatic cystic lesion
1161481|NCT01317836|PET
1161482|NCT01317836|PET-CT
1161483|NCT01317836|diagnosis
1161484|NCT01317823|Multiparas, Bishop score, Cervical length, Cervical ripening
1161485|NCT01317810|Overactive Bladder (OAB)
1161486|NCT01317810|Observational
1161487|NCT01317810|Registry
1161488|NCT01317797|Rheumatoid Arthritis
1161489|NCT01317797|MT203
1161490|NCT01317797|Human IgG1 monoclonal antibody
1161491|NCT01317797|GM-CSF monoclonal antibody
1161492|NCT01317784|diagnosis screening
1161493|NCT01317784|HIV serodiagnosis
1161494|NCT01317784|HCV antibodies
1161495|NCT01317784|serologic tests
1161496|NCT01317784|Bedside testing
1161497|NCT01317784|diagnostic test kits
1161498|NCT01317784|syphilis serodiagnosis
1161499|NCT01317771|Proximal Biceps Pathology
1161500|NCT01317758|influenza, vaccine, H5N1
1161501|NCT01317745|H5N1, vaccine, influenza
1161502|NCT01317732|Energy expenditure, physical activity, accelerometer, magnetometer, monitoring
1161503|NCT01317719|Rupture of Distal Bicep Tendon
1161504|NCT01317706|Bishop score, Cervical length, Cervical ripening, Labor induction
1161505|NCT01317693|LI-ESWT
1161506|NCT01317693|Erectile Dysfunction
1161507|NCT01317693|ED
1161508|NCT01317693|Shock waves
1161509|NCT01317693|Therapy
1161510|NCT01317680|Erectile Dysfunction
1161511|NCT01317680|ED
1161512|NCT01317680|PDE5 inhibitors
1161513|NCT01317680|LI-ESWT
1161514|NCT01317667|Ricin
1161515|NCT01317667|RVEc
1161516|NCT01317654|Tuberculosis meningitis
1161517|NCT01317628|tobacco smoke, intervention program
1161518|NCT01317615|Large cell carcinoma,
1161519|NCT01317615|Lung cancer,
1161520|NCT01317615|Neuroendocrine Tumors,
1161521|NCT01317615|RAD001
1161522|NCT01317602|Atrial Fibrillation
1161523|NCT01317602|AF
1161524|NCT01317589|Pain
1161525|NCT01317589|Cancer of Head and Neck
1161526|NCT01317589|methadone
1161527|NCT01317589|Fentanyl
1161528|NCT01317576|Magnetic Resonance Spectroscopy
1161529|NCT01317576|Exercise
1161530|NCT01317563|asthma
1161531|NCT01317563|obesity
1161532|NCT01317563|nutrition
1161533|NCT01317563|antioxidant
1161534|NCT01317550|Non-Small Cell Lung Cancer
1161535|NCT01317550|NSCLC
1161536|NCT01317550|Symptoms
1161537|NCT01317550|Concurrent Chemoradiation
1161538|NCT01317550|CXRT
1161539|NCT01317550|Fatigue
1161540|NCT01317550|Pain
1161541|NCT01317550|Disturbed Sleep
1161542|NCT01317550|Lack of Appetite
1161543|NCT01317550|Drowsiness
1161544|NCT01317550|Armodafinil
1161545|NCT01317550|Nuvigil
1161546|NCT01317550|Minocycline
1161547|NCT01317550|Dynacin
1161548|NCT01317550|Minocin
1161549|NCT01317550|Minocin PAC
1161550|NCT01317550|Myrac
1161551|NCT01317550|Solodyn
1161552|NCT01317550|Placebo
1161553|NCT01317537|personal health records
1161554|NCT01317524|Milk
1161555|NCT01317524|Homogenization
1161556|NCT01317524|Postprandial hyperlipidemia
1161557|NCT01317524|Postprandial inflammation
1161558|NCT01317524|Overweight
1161559|NCT01317498|ART
1161560|NCT01317498|antiretroviral
1161561|NCT01317498|treatment
1161562|NCT01317498|Vietnam
1161563|NCT01317498|Asia
1161564|NCT01317498|viral load
1161565|NCT01317485|diverticulitis
1161566|NCT01317485|perforation
1161567|NCT01317485|sigmoidectomy
1161568|NCT01317485|sigmoid resection
1161569|NCT01317485|lavage
1161570|NCT01317485|laparoscopic
1161571|NCT01317485|wash-out
1161572|NCT01317485|rinsing
1161573|NCT01317485|hartmann
1161574|NCT01317485|end-colostomy
1161575|NCT01317485|primary anastomosis
1161576|NCT01317472|laryngopharyngeal reflux, acid reflux, throat reflux
1161577|NCT01317459|Self management
1161578|NCT01317459|Diabetes type one
1161579|NCT01317459|Empowerment
1161580|NCT01317459|Intrinsic motivation
1161581|NCT01317446|gingivitis index
1161582|NCT01317446|plaque index
1161583|NCT01317446|discoloration index
1161584|NCT01317446|mouth rinse
1161585|NCT01317446|amine fluoride/stannous fluoride
1161586|NCT01317446|clinical trial
1161587|NCT01317433|Metastatic Colorectal Cancer
1161588|NCT01317433|K-RAS wild-type
1161589|NCT01317433|FOLFIRI
1161590|NCT01317433|Cetuximab
1161591|NCT01317407|postoperative delirium
1161592|NCT01317394|non-albicans candidemia
1161593|NCT01317368|Postoperative analgesic treatment
1161594|NCT01317368|TAP block
1161595|NCT01317368|Prostatectomy
1161596|NCT01317368|Double blinded randomized clinical trial
1161597|NCT01317355|Cancer
1161598|NCT01317355|Symptom burden
1161599|NCT01317355|Symptom cluster
1161600|NCT01317355|Distress
1161601|NCT01317355|Pain
1161602|NCT01317355|Fatigue
1161603|NCT01317355|Sleep disorder
1161604|NCT01317355|HRQoL
1161605|NCT01317342|liver transplantation
1161606|NCT01317342|machine liver perfusion
1161607|NCT01317342|extended criteria liver grafts
1161608|NCT01317342|donation after cardiac death
1161609|NCT01317342|hypothermic machine liver perfusion
1161610|NCT01317342|liver reperfusion injury
1161611|NCT01317303|paired associative stimulation
1161612|NCT01317303|theta burst stimulation
1161613|NCT01317303|transcranial magnetic stimulation
1161614|NCT01317303|neuroplasticity
1161615|NCT01317303|healthy controls
1161616|NCT01317290|Conversion of ALA
1161617|NCT01317277|interventions
1161618|NCT01317277|technology
1161619|NCT01317277|drug abuse
1161620|NCT01317277|methamphetamine
1161621|NCT01317264|β-glucan
1161622|NCT01317264|cholesterol
1161623|NCT01317264|bile acids
1161624|NCT01317264|blood glucose
1161625|NCT01317264|appetite
1161626|NCT01317251|Obesity prevention
1161627|NCT01317251|appetite regulation
1161628|NCT01317251|hyperlipidemia
1161629|NCT01317238|Smallpox vaccine efficacy
1161630|NCT01317225|Progesterone
1161631|NCT01317225|Obstetric labor, premature
1161632|NCT01317225|Short cervix
1161633|NCT01317212|Glioblastoma multiforme
1161634|NCT01317212|Carboplatin
1161635|NCT01317212|Convection-enhanced delivery
1161636|NCT01317199|Rising psa
1161637|NCT01317186|FGF 23
1161638|NCT01317186|ADMA
1161639|NCT01317186|chronic kidney disease
1161640|NCT01317186|Ca-P metabolism disorder
1161641|NCT01317173|Chronic kidney disease progression
1161642|NCT01317173|FGF 23
1161643|NCT01317173|Klotho
1161644|NCT01317160|Achilles Tendon
1161645|NCT01317160|Immobilization
1161646|NCT01317160|Wound Healing
1161647|NCT01317160|Intermittent Pneumatic Compression
1161648|NCT01317160|Ultrasonography
1161649|NCT01317160|Microdialysis
1161650|NCT01317147|pharmacokinetics
1161651|NCT01317147|serotonin reuptake inhibitors
1161652|NCT01317147|gastric bypass
1161653|NCT01317147|depression
1161654|NCT01317147|bioavailability
1161655|NCT01317147|drug absorption
1161656|NCT01317147|area under curve
1161657|NCT01317134|Pulmonary Arterial Hypertension
1161658|NCT01317134|Prognostic factors
1161659|NCT01317134|Signal transduction
1161660|NCT01317134|Genetics
1161661|NCT01317121|Patients with a first episode of schizophrenia
1161662|NCT01317121|Subjects at risk for psychosis
1161663|NCT01317108|node-negative
1161664|NCT01317095|Rigid fixation
1161665|NCT01317095|Sternal closure
1161666|NCT01317095|Open heart surgery
1161667|NCT01317082|Postoperative Nausea & Vomiting.
1161668|NCT01317017|Psoriasis
1161669|NCT01317004|Multiple sclerosis
1161670|NCT01317004|Fingolimod
1161671|NCT01317004|Disease Modifying Therapy
1161672|NCT01317004|TSQM-9
1161673|NCT01316991|chewing gum
1161674|NCT01316991|appetite
1161675|NCT01316991|hunger
1161676|NCT01316991|satiety
1161677|NCT01316991|metabolic
1161678|NCT01316991|nutrition
1161679|NCT01316991|gut peptide hormones
1161680|NCT01316991|psychological phenomena and processes
1161681|NCT01316965|Postoperative delirium
1161682|NCT01316965|elderly
1161683|NCT01316965|prevention
1161684|NCT01316965|stepped wedge design
1161685|NCT01316965|healthcare workers
1161686|NCT01316952|carvedilol
1161687|NCT01316952|propranolol
1161688|NCT01316952|hypersensitivity reactions
1161689|NCT01316952|beta- blockers
1161690|NCT01316952|Coreg
1161691|NCT01316939|Crohn's disease, oral CCR9 antagonist, placebo-controlled, maintenance of remission, 52-week treatment, quality of life
1161692|NCT01316926|fast condition
1161693|NCT01316926|Paroxetine reference/test
1161694|NCT01316926|healthy volunteers
1161695|NCT01316926|Bioequivalence
1161696|NCT01316913|tiotropium
1161697|NCT01316913|long-acting muscarinic antagonist
1161698|NCT01316913|COPD
1161699|NCT01316913|long-acting beta agonist
1161700|NCT01316900|long-acting muscarinic antagonist
1161701|NCT01316900|tiotropium
1161702|NCT01316900|COPD
1161703|NCT01316900|long-acting beta agonist
1161704|NCT01316887|Chronic Obstructive Pulmonary Disease
1161705|NCT01316887|COPD
1161706|NCT01316887|nDPI
1161707|NCT01316887|long-acting beta agonist
1161708|NCT01316887|long-acting muscarinic antagonist
1161709|NCT01316887|tolerability
1161710|NCT01316887|safety
1161711|NCT01316874|Valrubicin
1161712|NCT01316874|CIS
1161713|NCT01316874|AD 32, BCG-refractory CIS
1161714|NCT01316874|Carcinoma in situ (CIS) previously treated with BCG
1161715|NCT01316848|AV-951
1161716|NCT01316848|tivozanib
1161717|NCT01316848|healthy Subjects
1161718|NCT01316848|food Effect
1161719|NCT01316848|pharmacokinetics
1161720|NCT01316835|retrospective,sitagliptin, glycemia control,real world
1161721|NCT01316822|CSF1R
1161722|NCT01316822|M-CSF
1161723|NCT01316822|CSF-1
1161724|NCT01316822|c-FMS
1161725|NCT01316822|Tumor-associated macrophage
1161726|NCT01316822|Macrophage-Colony Stimulating Factor-1
1161727|NCT01316822|Receptor tyrosine kinase inhibitor
1161728|NCT01316822|Tumor cell-induced osteolysis
1161729|NCT01316809|Brain
1161730|NCT01316809|Tumor
1161731|NCT01316809|Recurrent
1161732|NCT01316809|Surgery
1161733|NCT01316809|Radiation
1161734|NCT01316809|Glioma
1161735|NCT01316809|Brain Tumor
1161736|NCT01316809|Glioblastoma Multiforme
1161737|NCT01316809|Astrocytoma
1161738|NCT01316809|Brainstem Glioma
1161739|NCT01316796|Sickle Cell Disease
1161740|NCT01316796|Hemolysis
1161741|NCT01316796|Anemia
1161742|NCT01316796|Nitric Oxide
1161743|NCT01316796|Blood Flow
1161744|NCT01316796|Leg Ulcer
1161745|NCT01316796|Sickle Cell Anemia
1161746|NCT01316796|Thalassemia
1161747|NCT01316796|Hemolytic Blood Disorder
1161748|NCT01316783|Africans
1161749|NCT01316783|Obesity
1161750|NCT01316783|Diabetes
1161751|NCT01316783|Heart Disease
1161752|NCT01316783|Genetic
1161753|NCT01316783|African Descent
1161754|NCT01316783|Cardiovascular Disease
1161755|NCT01316770|Xerostomia
1161756|NCT01316770|Sj(SqrRoot)(Delta)gren s Syndrome
1161757|NCT01316770|Interventional Study
1161758|NCT01316770|Sjogren Syndrome
1161759|NCT01316770|Dry Mouth
1161760|NCT01316744|long-term effects secondary to cancer therapy in adults
1161761|NCT01316744|anxiety disorder
1161762|NCT01316744|depression
1161763|NCT01316744|pain
1161764|NCT01316744|unspecified adult solid tumor, protocol specific
1161765|NCT01316744|neuropathy
1161766|NCT01316744|accelerated phase chronic myelogenous leukemia
1161767|NCT01316744|acute undifferentiated leukemia
1161768|NCT01316744|adult acute lymphoblastic leukemia in remission
1161769|NCT01316744|adult acute myeloid leukemia in remission
1161770|NCT01316744|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1161771|NCT01316744|adult acute myeloid leukemia with inv(16)(p13;q22)
1161772|NCT01316744|adult acute myeloid leukemia with t(15;17)(q22;q12)
1161773|NCT01316744|adult acute myeloid leukemia with t(16;16)(p13;q22)
1161774|NCT01316744|adult acute myeloid leukemia with t(8;21)(q22;q22)
1161775|NCT01316744|atypical chronic myeloid leukemia, BCR-ABL1 negative
1161776|NCT01316744|blastic phase chronic myelogenous leukemia
1161777|NCT01316744|chronic myelomonocytic leukemia
1161778|NCT01316744|chronic phase chronic myelogenous leukemia
1161779|NCT01316744|mast cell leukemia
1161780|NCT01316744|meningeal chronic myelogenous leukemia
1161781|NCT01316744|progressive hairy cell leukemia, initial treatment
1161782|NCT01316744|prolymphocytic leukemia
1161783|NCT01316744|recurrent adult acute lymphoblastic leukemia
1161784|NCT01316744|recurrent adult acute myeloid leukemia
1161785|NCT01316744|recurrent adult T-cell leukemia/lymphoma
1161786|NCT01316744|refractory chronic lymphocytic leukemia
1161787|NCT01316744|refractory hairy cell leukemia
1161788|NCT01316744|relapsing chronic myelogenous leukemia
1161789|NCT01316744|secondary acute myeloid leukemia
1161790|NCT01316744|stage I adult T-cell leukemia/lymphoma
1161791|NCT01316744|stage I chronic lymphocytic leukemia
1161792|NCT01316744|stage II adult T-cell leukemia/lymphoma
1161793|NCT01316744|stage II chronic lymphocytic leukemia
1161794|NCT01316744|stage III adult T-cell leukemia/lymphoma
1161795|NCT01316744|stage III chronic lymphocytic leukemia
1161796|NCT01316744|stage IV adult T-cell leukemia/lymphoma
1161797|NCT01316744|stage IV chronic lymphocytic leukemia
1161798|NCT01316744|T-cell large granular lymphocyte leukemia
1161799|NCT01316744|AIDS-related diffuse large cell lymphoma
1161800|NCT01316744|AIDS-related diffuse mixed cell lymphoma
1161801|NCT01316744|AIDS-related diffuse small cleaved cell lymphoma
1161802|NCT01316744|AIDS-related immunoblastic large cell lymphoma
1161803|NCT01316744|AIDS-related lymphoblastic lymphoma
1161804|NCT01316744|AIDS-related peripheral/systemic lymphoma
1161805|NCT01316744|AIDS-related primary CNS lymphoma
1161806|NCT01316744|AIDS-related small noncleaved cell lymphoma
1161807|NCT01316744|HIV-associated Hodgkin lymphoma
1161808|NCT01316744|recurrent adult Hodgkin lymphoma
1161809|NCT01316744|stage I adult Hodgkin lymphoma
1161810|NCT01316744|stage II adult Hodgkin lymphoma
1161811|NCT01316744|stage III adult Hodgkin lymphoma
1161812|NCT01316744|stage IV adult Hodgkin lymphoma
1161813|NCT01316744|anaplastic large cell lymphoma
1161814|NCT01316744|angioimmunoblastic T-cell lymphoma
1161815|NCT01316744|cutaneous B-cell non-Hodgkin lymphoma
1161816|NCT01316744|recurrent cutaneous T-cell non-Hodgkin lymphoma
1161817|NCT01316744|stage I cutaneous T-cell non-Hodgkin lymphoma
1161818|NCT01316744|stage II cutaneous T-cell non-Hodgkin lymphoma
1161819|NCT01316744|stage III cutaneous T-cell non-Hodgkin lymphoma
1161820|NCT01316744|stage IV cutaneous T-cell non-Hodgkin lymphoma
1161821|NCT01316744|recurrent mycosis fungoides/Sezary syndrome
1161822|NCT01316744|stage I mycosis fungoides/Sezary syndrome
1161823|NCT01316744|stage II mycosis fungoides/Sezary syndrome
1161824|NCT01316744|stage III mycosis fungoides/Sezary syndrome
1161825|NCT01316744|stage IV mycosis fungoides/Sezary syndrome
1161826|NCT01316744|adult grade III lymphomatoid granulomatosis
1161827|NCT01316744|adult nasal type extranodal NK/T-cell lymphoma
1161828|NCT01316744|Waldenstrom macroglobulinemia
1161829|NCT01316744|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1161830|NCT01316744|nodal marginal zone B-cell lymphoma
1161831|NCT01316744|splenic marginal zone lymphoma
1161832|NCT01316744|contiguous stage II adult Burkitt lymphoma
1161833|NCT01316744|contiguous stage II adult diffuse large cell lymphoma
1161834|NCT01316744|contiguous stage II adult diffuse mixed cell lymphoma
1161835|NCT01316744|contiguous stage II adult diffuse small cleaved cell lymphoma
1161836|NCT01316744|contiguous stage II adult immunoblastic large cell lymphoma
1161837|NCT01316744|contiguous stage II adult lymphoblastic lymphoma
1161838|NCT01316744|contiguous stage II grade 1 follicular lymphoma
1161839|NCT01316744|contiguous stage II grade 2 follicular lymphoma
1161840|NCT01316744|contiguous stage II grade 3 follicular lymphoma
1161841|NCT01316744|contiguous stage II mantle cell lymphoma
1161842|NCT01316744|contiguous stage II marginal zone lymphoma
1161843|NCT01316744|contiguous stage II small lymphocytic lymphoma
1161844|NCT01316744|stage I adult Burkitt lymphoma
1161845|NCT01316744|stage I adult diffuse large cell lymphoma
1161846|NCT01316744|stage I adult diffuse mixed cell lymphoma
1161847|NCT01316744|stage I adult diffuse small cleaved cell lymphoma
1161848|NCT01316744|stage I adult immunoblastic large cell lymphoma
1161849|NCT01316744|stage I adult lymphoblastic lymphoma
1161850|NCT01316744|stage I grade 1 follicular lymphoma
1161851|NCT01316744|stage I grade 2 follicular lymphoma
1161852|NCT01316744|stage I grade 3 follicular lymphoma
1161853|NCT01316744|stage I mantle cell lymphoma
1161854|NCT01316744|stage I marginal zone lymphoma
1161855|NCT01316744|stage I small lymphocytic lymphoma
1161856|NCT01316744|noncontiguous stage II adult Burkitt lymphoma
1161857|NCT01316744|noncontiguous stage II adult diffuse large cell lymphoma
1161858|NCT01316744|noncontiguous stage II adult diffuse mixed cell lymphoma
1161859|NCT01316744|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1161860|NCT01316744|noncontiguous stage II adult immunoblastic large cell lymphoma
1161861|NCT01316744|noncontiguous stage II adult lymphoblastic lymphoma
1161862|NCT01316744|noncontiguous stage II grade 1 follicular lymphoma
1161863|NCT01316744|noncontiguous stage II grade 2 follicular lymphoma
1161864|NCT01316744|noncontiguous stage II grade 3 follicular lymphoma
1161865|NCT01316744|noncontiguous stage II mantle cell lymphoma
1161866|NCT01316744|noncontiguous stage II marginal zone lymphoma
1161867|NCT01316744|noncontiguous stage II small lymphocytic lymphoma
1161868|NCT01316744|stage III adult Burkitt lymphoma
1161869|NCT01316744|stage III adult diffuse large cell lymphoma
1161870|NCT01316744|stage III adult diffuse mixed cell lymphoma
1161871|NCT01316744|stage III adult diffuse small cleaved cell lymphoma
1161872|NCT01316744|stage III adult immunoblastic large cell lymphoma
1161873|NCT01316744|stage III adult lymphoblastic lymphoma
1161874|NCT01316744|stage III grade 1 follicular lymphoma
1161875|NCT01316744|stage III grade 2 follicular lymphoma
1161876|NCT01316744|stage III grade 3 follicular lymphoma
1161877|NCT01316744|stage III mantle cell lymphoma
1161878|NCT01316744|stage III marginal zone lymphoma
1161879|NCT01316744|stage III small lymphocytic lymphoma
1161880|NCT01316744|stage IV adult Burkitt lymphoma
1161881|NCT01316744|stage IV adult diffuse large cell lymphoma
1161882|NCT01316744|stage IV adult diffuse mixed cell lymphoma
1161883|NCT01316744|stage IV adult diffuse small cleaved cell lymphoma
1161884|NCT01316744|stage IV adult immunoblastic large cell lymphoma
1161885|NCT01316744|stage IV adult lymphoblastic lymphoma
1161886|NCT01316744|stage IV grade 1 follicular lymphoma
1161887|NCT01316744|stage IV grade 2 follicular lymphoma
1161888|NCT01316744|stage IV grade 3 follicular lymphoma
1161889|NCT01316744|stage IV mantle cell lymphoma
1161890|NCT01316744|stage IV marginal zone lymphoma
1161891|NCT01316744|stage IV small lymphocytic lymphoma
1161892|NCT01316744|recurrent adult Burkitt lymphoma
1161893|NCT01316744|recurrent adult diffuse large cell lymphoma
1161894|NCT01316744|recurrent adult diffuse mixed cell lymphoma
1161895|NCT01316744|recurrent adult diffuse small cleaved cell lymphoma
1161896|NCT01316744|recurrent adult grade III lymphomatoid granulomatosis
1161897|NCT01316744|recurrent adult immunoblastic large cell lymphoma
1161898|NCT01316744|recurrent adult lymphoblastic lymphoma
1161899|NCT01316744|recurrent grade 1 follicular lymphoma
1161900|NCT01316744|recurrent grade 2 follicular lymphoma
1161901|NCT01316744|recurrent grade 3 follicular lymphoma
1161902|NCT01316744|recurrent mantle cell lymphoma
1161903|NCT01316744|recurrent marginal zone lymphoma
1161904|NCT01316744|recurrent small lymphocytic lymphoma
1161905|NCT01316744|intraocular lymphoma
1161906|NCT01316744|primary central nervous system non-Hodgkin lymphoma
1161907|NCT01316744|primary central nervous system Hodgkin lymphoma
1161908|NCT01316744|post-transplant lymphoproliferative disorder
1161909|NCT01316744|chronic eosinophilic leukemia
1161910|NCT01316744|chronic neutrophilic leukemia
1161911|NCT01316744|primary myelofibrosis
1161912|NCT01316744|essential thrombocythemia
1161913|NCT01316744|polycythemia vera
1161914|NCT01316744|extramedullary plasmacytoma
1161915|NCT01316744|isolated plasmacytoma of bone
1161916|NCT01316744|stage I multiple myeloma
1161917|NCT01316744|stage II multiple myeloma
1161918|NCT01316744|stage III multiple myeloma
1161919|NCT01316744|primary systemic amyloidosis
1161920|NCT01316744|refractory multiple myeloma
1161921|NCT01316744|de novo myelodysplastic syndromes
1161922|NCT01316744|previously treated myelodysplastic syndromes
1161923|NCT01316744|secondary myelodysplastic syndromes
1161924|NCT01316744|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1161925|NCT01316718|IBS
1161926|NCT01316718|diarrhoea
1161927|NCT01316679|HCC
1161928|NCT01316679|Liver Disease without HCC
1161929|NCT01316666|orthostatic hypotension
1161930|NCT01316666|Multiple System Atrophy
1161931|NCT01316666|Pure Autonomic Failure
1161932|NCT01316666|Parkinson's Disease
1161933|NCT01316627|Body Dysmorphic Disorder (BDD)
1161934|NCT01316627|Cognitive Behavior Therapy (CBT)
1161935|NCT01316627|Obsessive Compulsive Disorder (OCD)
1161936|NCT01316627|Mirror Retraining
1161937|NCT01316627|Crooked Mirror Externalization Therapy
1161938|NCT01316614|Fine-Needle Aspiration
1161939|NCT01316614|Stylet
1161940|NCT01316614|Solid Mass
1161941|NCT01316614|Endoscopic Ultrasound (EUS)
1161942|NCT01316588|recolonization
1161943|NCT01316588|Plastic adhesive drape
1161944|NCT01316588|microbial sealant
1161945|NCT01316588|SSI
1161946|NCT01316588|bacterial growth
1161947|NCT01316575|Continuous Positive Airway Pressure
1161948|NCT01316575|Postoperative Complications
1161949|NCT01316575|Respiratory Insufficiency
1161950|NCT01316575|Colorectal Surgery
1161951|NCT01316549|fludarabine
1161952|NCT01316549|pharmacokinetics
1161953|NCT01316549|pediatric
1161954|NCT01316549|allogeneic
1161955|NCT01316549|hematopoietic cell transplantation
1161956|NCT01316536|pain, agitation, music
1161957|NCT01316523|Lenalidomide
1161958|NCT01316523|Rituximab
1161959|NCT01316523|untreated indolent Non-Hodgkin's Lymphoma
1161960|NCT01316510|Probiotic
1161961|NCT01316510|bifidobacteria
1161962|NCT01316510|intestinal motility
1161963|NCT01316497|Acute kidney injury
1161964|NCT01316497|Ischemic preconditioning
1161965|NCT01316497|Congenital heart defects
1161966|NCT01316497|Cardiac surgical procedures
1161967|NCT01316497|Infant
1161968|NCT01316497|Child
1161969|NCT01316484|Cognitive Debriefing
1161970|NCT01316471|Chronic Pain
1161971|NCT01316471|Abdominal Pain
1161972|NCT01316471|Headache
1161973|NCT01316471|Adolescents
1161974|NCT01316471|Internet Interventions
1161975|NCT01316471|Behavioral Interventions
1161976|NCT01316458|Prostate cancer,
1161977|NCT01316458|radical prostatectomy,
1161978|NCT01316458|PSA rise
1161979|NCT01316445|Electroencephalography
1161980|NCT01316445|Benzodiazepines
1161981|NCT01316445|Midazolam
1161982|NCT01316432|Cenderitide
1161983|NCT01316432|CD-NP
1161984|NCT01316432|Natriuretic peptide
1161985|NCT01316432|Heart failure
1161986|NCT01316432|Chronic heart failure
1161987|NCT01316432|HF
1161988|NCT01316432|CHF
1161989|NCT01316406|safety
1161990|NCT01316406|efficacy
1161991|NCT01316406|treatment
1161992|NCT01316406|PPES
1162119|NCT01315990|first-line treatment
1161993|NCT01316406|Palmar-Plantar Erythrodysesthesia Syndrome
1161994|NCT01316406|Hand-foot syndrome
1161995|NCT01316406|capecitabine
1161996|NCT01316393|xerostomia, saliva, mucoprotection, oral health
1161997|NCT01316367|Health Promotion Education
1161998|NCT01316367|Type 2 Diabetes Mellitus
1161999|NCT01316367|Cardiovascular Risk Factors
1162000|NCT01316367|Spain
1162001|NCT01316354|Arabinoxylan
1162002|NCT01316354|Beta glucan
1162003|NCT01316354|Whole grain
1162004|NCT01316354|Dietary fibre
1162005|NCT01316354|Metabolic syndrome
1162006|NCT01316354|Glycemic index
1162007|NCT01316354|Satiety
1162008|NCT01316328|toxicity after single shot partial breast irradiation (SSPBI)
1162009|NCT01316302|Social Anxiety Disorder
1162010|NCT01316302|Social Phobia
1162011|NCT01316302|SAD
1162012|NCT01316289|tibial fractures
1162013|NCT01316289|pilon
1162014|NCT01316289|pilon fractures
1162015|NCT01316289|tibial plafond
1162016|NCT01316289|reduction quality
1162017|NCT01316289|anatomical reduction
1162018|NCT01316289|functional outcome
1162019|NCT01316289|ankle joint
1162020|NCT01316276|Cystic Fibrosis
1162021|NCT01316276|Respiratory Infections
1162022|NCT01316276|Pulmonary Cystic Fibrosis
1162023|NCT01316276|CFTR
1162024|NCT01316276|Anti-bacterial Agent
1162025|NCT01316250|chronic myelogenous leukemia
1162026|NCT01316250|nilotinib
1162027|NCT01316250|complete cytogenetic response
1162028|NCT01316250|imatinib mesylate
1162029|NCT01316237|Hepatitis C
1162030|NCT01316237|HCV
1162031|NCT01316237|HCV RNA
1162032|NCT01316237|Polymerase inhibitor
1162033|NCT01316237|Treatment naïve
1162034|NCT01316237|GS-6620
1162035|NCT01316224|Psoriasis
1162036|NCT01316224|Incidence
1162037|NCT01316224|Quality of Life
1162038|NCT01316224|Psoriatic Arthritis
1162039|NCT01316224|Prevalence
1162040|NCT01316211|Back Pains
1162041|NCT01316211|Pain, Back
1162042|NCT01316211|Pains, Back
1162043|NCT01316211|Backache
1162044|NCT01316211|Backaches
1162045|NCT01316211|Back Ache
1162046|NCT01316211|Ache, Back
1162047|NCT01316211|Aches, Back
1162048|NCT01316211|Back Aches
1162049|NCT01316211|Back Pain without Radiation
1162050|NCT01316211|Vertebrogenic Pain Syndrome
1162051|NCT01316211|Pain Syndrome, Vertebrogenic
1162052|NCT01316211|Pain Syndromes, Vertebrogenic
1162053|NCT01316211|Syndrome, Vertebrogenic Pain
1162054|NCT01316211|Syndromes, Vertebrogenic Pain
1162055|NCT01316211|Vertebrogenic Pain Syndromes
1162056|NCT01316211|Back Pain with Radiation
1162057|NCT01316211|Stenosis, spinal
1162058|NCT01316211|Caudal stenosis
1162059|NCT01316211|Spondylopathy
1162060|NCT01316211|Spondylopathies
1162061|NCT01316211|Low back pain
1162062|NCT01316211|Lower back pain
1162063|NCT01316198|human study
1162064|NCT01316198|AMD
1162065|NCT01316198|lutein
1162066|NCT01316198|zeaxanthin
1162067|NCT01316198|optical density
1162068|NCT01316185|Hepatitis D
1162069|NCT01316185|HDV
1162070|NCT01316185|Hepatitis
1162071|NCT01316172|consultation
1162072|NCT01316146|Hodgkin's Lymphoma
1162073|NCT01316146|Non-Hodgkin's Lymphoma
1162074|NCT01316146|Lymphoma
1162075|NCT01316146|T lymphocytes
1162076|NCT01316133|Tacrolimus
1162077|NCT01316133|Prograf
1162078|NCT01316133|FK506
1162079|NCT01316133|Proteinuria
1162080|NCT01316133|Calcineurin inhibitor
1162081|NCT01316120|Self-collected vaginal samples
1162082|NCT01316120|HPV
1162083|NCT01316120|HPV self-obtained sample
1162084|NCT01316120|HPV specimen transport medium
1162085|NCT01316107|ASP1941
1162086|NCT01316107|Diabetes mellitus
1162087|NCT01316107|nateglinide
1162088|NCT01316107|long-term safety
1162089|NCT01316094|Renal impairment
1162090|NCT01316094|ASP1941
1162091|NCT01316094|Pharmacokinetics
1162092|NCT01316081|antioxidant supplementation
1162093|NCT01316081|childhood obesity
1162094|NCT01316081|hepcidin
1162095|NCT01316081|iron status
1162096|NCT01316081|oxidative stress
1162097|NCT01316081|inflammation
1162098|NCT01316068|diabetic nephropathy
1162099|NCT01316068|albuminuria
1162100|NCT01316068|type 2 diabetes
1162101|NCT01316068|sulodexide
1162102|NCT01316042|Puberty
1162103|NCT01316042|Hormones
1162104|NCT01316029|Laying-on-of-hands
1162105|NCT01316029|Therapeutic touch
1162106|NCT01316029|cross-sectional study
1162107|NCT01316029|healing environment
1162108|NCT01316029|safety and effectiveness
1162109|NCT01316029|optimal condition for the intervention
1162110|NCT01316016|obesity
1162111|NCT01316016|glucose intolerance
1162112|NCT01316016|cholesterol
1162113|NCT01316016|blood pressure
1162114|NCT01316003|cone outer segment tips line
1162115|NCT01316003|Optical coherence tomography
1162116|NCT01315990|Phase IV Study
1162117|NCT01315990|Metastatic Colorectal Cancer (mCRC
1162118|NCT01315990|Cetuximab (Erbitux)
1162120|NCT01315990|acneiform follicular exanthema
1162121|NCT01315990|rash
1162122|NCT01315990|vitamin K1
1162123|NCT01315977|Type 2 Diabetes Mellitus
1162124|NCT01315977|Antioxidant oxidant balance
1162125|NCT01315977|Activation of Antioxidant Response Element
1162126|NCT01315964|cholesterol
1162127|NCT01315964|plant sterols
1162128|NCT01315964|atherosclerosis
1162129|NCT01315964|arterial stiffness
1162130|NCT01315951|Non scalp Seborrheic Dermatitis
1162131|NCT01315925|Acute myeloid leukemia
1162132|NCT01315925|invasive fungal infection
1162133|NCT01315925|Aspergillosis
1162134|NCT01315925|candidiasis
1162135|NCT01315912|clomiphene citrate
1162136|NCT01315912|infertility
1162137|NCT01315912|letrozole
1162138|NCT01315899|Raynaud's phenomenon
1162139|NCT01315899|Systemic sclerosis
1162140|NCT01315886|sublingual
1162141|NCT01315886|fentanyl
1162142|NCT01315886|titration
1162143|NCT01315886|conversion
1162144|NCT01315886|breakthrough cancer pain
1162145|NCT01315886|pain intensity difference
1162146|NCT01315886|PID
1162147|NCT01315886|Edmonton Symptom Assessment System
1162148|NCT01315886|ESAS
1162149|NCT01315873|myeloma
1162150|NCT01315873|multiple myeloma
1162151|NCT01315873|relapsed myeloma
1162152|NCT01315873|refractory myeloma
1162153|NCT01315860|Low Back Pain
1162154|NCT01315860|Pregnancy
1162155|NCT01315860|Biomechanics
1162156|NCT01315821|Saccharomyces boulardii
1162157|NCT01315821|necrotizing enterocolitis
1162158|NCT01315795|polycystic liver disease
1162159|NCT01315782|Sepsis
1162160|NCT01315782|Severe sepsis
1162161|NCT01315782|Septic shock
1162162|NCT01315782|Alveolar dead space
1162163|NCT01315782|Multi-organ failure
1162164|NCT01315730|stuttering
1162165|NCT01315730|haptic
1162166|NCT01315730|feedback
1162167|NCT01315730|fluency
1162168|NCT01315691|Cystic Fibrosis
1162169|NCT01315691|Respiratory Infections
1162170|NCT01315691|Pulmonary Cystic Fibrosis
1162171|NCT01315691|Amikacin
1162172|NCT01315691|Anti-bacterial agents
1162173|NCT01315678|Cystic Fibrosis
1162174|NCT01315678|Respiratory Infections
1162175|NCT01315678|Pulmonary Cystic Fibrosis
1162176|NCT01315678|CFTR
1162177|NCT01315678|Amikacin
1162178|NCT01315678|Anti-bacterial Agents
1162179|NCT01315665|broccoli sprouts
1162180|NCT01315665|sulforaphane
1162181|NCT01315665|triterpenoid
1162182|NCT01315665|Nrf2 activation
1162183|NCT01315665|cystic fibrosis
1162184|NCT01315665|healthy volunteers
1162185|NCT01315665|anti-inflammatory
1162186|NCT01315652|1 Rheumatoid arthritis
1162187|NCT01315652|2 Education
1162188|NCT01315652|3 Co-morbidities
1162189|NCT01315652|4 Nurse
1162190|NCT01315639|Dementia
1162191|NCT01315639|Cognitive impairment
1162192|NCT01315639|Memory impairment
1162193|NCT01315639|Mild Cognitive Impairment
1162194|NCT01315639|Cerebrospinal fluid
1162195|NCT01315639|Plasma
1162196|NCT01315639|Biomarker
1162197|NCT01315639|Longitudinal
1162198|NCT01315639|Abeta peptide amyloid, saPP alpha
1162199|NCT01315639|Oculomotor impairment
1162200|NCT01315626|Bronchiectasis
1162201|NCT01315626|pulmonary exacerbations
1162202|NCT01315626|pulmonary infections
1162203|NCT01315574|Glaucoma
1162204|NCT01315574|Xalatan
1162205|NCT01315574|Travatan Z
1162206|NCT01315574|Latanoprost
1162207|NCT01315574|Travoprost
1162208|NCT01315574|Dry Eye
1162209|NCT01315561|acute low back pain
1162210|NCT01315561|motion stlye acupuncture treatment
1162211|NCT01315561|disability
1162212|NCT01315561|MSAT
1162213|NCT01315548|Contrast enhanced harmonic endoscopic ultrasound
1162214|NCT01315548|Pancreatic adenocarcinoma
1162215|NCT01315548|Chronic pancreatitis
1162216|NCT01315535|Mandibular Advancement
1162217|NCT01315535|Oral Appliance
1162218|NCT01315535|TMD
1162219|NCT01315522|Stents
1162220|NCT01315522|Endoscopy
1162221|NCT01315522|Cholangiopancreatography
1162222|NCT01315522|Endoscopic Retrograde
1162223|NCT01315509|Severe mental illness
1162224|NCT01315509|Dental measures
1162225|NCT01315509|Resistant depression
1162226|NCT01315496|Human Immunoglobulin G
1162227|NCT01315496|Sepsis
1162228|NCT01315496|Septic shock
1162229|NCT01315483|Breast cancer
1162230|NCT01315483|survivors
1162231|NCT01315483|weight lose
1162232|NCT01315483|dietary pattern
1162233|NCT01315470|improving pregnancy rate and endometrial thickness
1162234|NCT01315457|alemtuzumab, infection, prophylaxis, treatment
1162235|NCT01315431|Solid tumor malignancy, excluding lymphoma
1162236|NCT01315418|Probiotic - Lactobacillus casei DN-114 001 - dairy product -
1162237|NCT01315418|infections - firemen
1162238|NCT01315418|Common infectious diseases, occuring in healthy subjects,
1162239|NCT01315418|including upper respiratory tract infections (defined as
1162240|NCT01315418|rhinopharyngitis, sore throat, sinusitis and otitis)
1162241|NCT01315418|lower respiratory tract infections (defined as bronchitis
1162242|NCT01315418|pneumopathy and flu and flu-like syndromes)
1162243|NCT01315418|gastrointestinal tract infection defined as gastroenteritis
1162244|NCT01315405|Emotional facial expression
1162245|NCT01315405|Apathy
1162246|NCT01315405|Mirror neurons
1162247|NCT01315379|Prolonged Exposure
1162248|NCT01315379|CBT
1162249|NCT01315379|PTSD
1162250|NCT01315379|Mild Traumatic Brain Injury
1162251|NCT01315379|Post Concussive Syndrome
1162252|NCT01315366|Vitamin D
1162253|NCT01315366|Elderly
1162254|NCT01315366|Cardiovascular profile
1162255|NCT01315366|Insulin resistance
1162256|NCT01315366|Gene polymorphisms
1162257|NCT01315327|Tourette's Disorder, Obsessive-Compulsive Disorder, tics
1162258|NCT01315314|Glucose degradation products
1162259|NCT01315314|Inflammation
1162260|NCT01315314|Endothelial dysfunction
1162261|NCT01315314|Soluble adhesion molecules
1162262|NCT01315314|Peritoneal dialysis
1162263|NCT01315301|Efavirenz
1162264|NCT01315301|Rifampicin
1162265|NCT01315301|HAART
1162266|NCT01315301|Anti Tuberculosis
1162267|NCT01315288|Medical decision making
1162268|NCT01315288|Asymptomatic Carotid Stenosis
1162269|NCT01315275|visual impairment
1162270|NCT01315275|macular edema
1162271|NCT01315275|ranibizumab
1162272|NCT01315275|visual impairment due to macular edema
1162273|NCT01315262|Sildenafil 100
1162274|NCT01315262|restoring erectile function after radical prostatectomy
1162275|NCT01315249|QVA149
1162276|NCT01315249|indacaterol
1162277|NCT01315249|NVA237
1162278|NCT01315249|COPD
1162279|NCT01315249|fluticasone/salmeterol
1162280|NCT01315210|Fibromyalgia
1162281|NCT01315210|Fatigue
1162282|NCT01315210|D-Ribose
1162283|NCT01315197|Low back Pain
1162284|NCT01315184|Interactive Voice Response
1162285|NCT01315184|Computer-based Treatment
1162286|NCT01315184|Opioid Agonist
1162287|NCT01315184|Buprenorphine
1162288|NCT01315184|Methadone
1162289|NCT01315171|medium chain triglycerides
1162290|NCT01315171|hypoglycemia
1162291|NCT01315171|cognitive function
1162292|NCT01315171|functional MRI
1162293|NCT01315158|Obstructive Sleep Apnea
1162294|NCT01315158|Body Mass Index
1162295|NCT01315132|Myeloablative Hematopoietic Stem Cell Transplant
1162296|NCT01315132|Cyclophosphamide tolerization
1162297|NCT01315132|2 Step Approach
1162298|NCT01315132|Hematological malignancies
1162299|NCT01315132|leukemia
1162300|NCT01315132|lymphoma
1162301|NCT01315132|multiple myeloma
1162302|NCT01315132|Hodgkin's Disease
1162303|NCT01315093|In Vitro Fertilisation
1162304|NCT01315093|poor responders
1162305|NCT01315080|mammillary fistula
1162306|NCT01315080|triamcinolone
1162307|NCT01315080|ultrasound management
1162308|NCT01315080|percutaneous treatment
1162309|NCT01315067|kidney transplantation
1162310|NCT01315067|acute rejection
1162311|NCT01315067|diagnosis
1162312|NCT01315067|urine analysis
1162313|NCT01315067|urinary peptides
1162314|NCT01315067|mass spectrometry
1162315|NCT01315067|allograft biopsy
1162316|NCT01315067|pathology
1162317|NCT01315067|diagnostic study
1162318|NCT01315054|IDUs
1162319|NCT01315054|high risk behaviors
1162320|NCT01315054|HIV
1162321|NCT01315054|MMT dosage and retention
1162322|NCT01315054|psychosocial services
1162323|NCT01315028|mania
1162324|NCT01315028|hypomania
1162325|NCT01315028|bipolar affective disorder
1162326|NCT01315028|psychological intervention
1162327|NCT01315028|cognitive therapy
1162328|NCT01315015|Breast cancer
1162329|NCT01315015|Breast neoplasm
1162330|NCT01315015|Magnetic Resonance Imaging
1162331|NCT01315015|Breast density
1162332|NCT01315015|Early detection of cancer
1162333|NCT01315015|Cancer screening test
1162334|NCT01315015|Secondary prevention
1162335|NCT01315002|nicotine
1162336|NCT01315002|schizophrenia
1162337|NCT01315002|endophenotype
1162338|NCT01314976|Children
1162339|NCT01314976|parasite
1162340|NCT01314976|intestinal
1162341|NCT01314976|treatment
1162342|NCT01314976|RCT
1162343|NCT01314937|preschool-age children
1162344|NCT01314937|soil-transmitted helminths
1162345|NCT01314937|growth
1162346|NCT01314937|development
1162347|NCT01314937|deworming
1162348|NCT01314924|Hypertension
1162349|NCT01314924|Endothelial dysfunction
1162350|NCT01314924|Vascular stiffness
1162351|NCT01314924|Use of one or two antihypertensive drugs
1162352|NCT01314911|H1N1
1162353|NCT01314911|Complications
1162354|NCT01314911|PCR
1162355|NCT01314911|Seasonal Influenza
1162356|NCT01314911|Viral Shedding
1162357|NCT01314898|Single dose
1162358|NCT01314898|cross-over
1162359|NCT01314898|active-control
1162360|NCT01314898|placebo control
1162361|NCT01314898|antimineralocorticoid activity
1162362|NCT01314885|Healthy
1162363|NCT01314872|Overactive bladder
1162364|NCT01314872|MK-4618
1162365|NCT01314872|tolterodine
1162366|NCT01314859|Nifedipine
1162367|NCT01314859|Obstetric Labor
1162368|NCT01314859|Premature
1162369|NCT01314859|Tocolysis
1162370|NCT01314833|Luminal A
1162371|NCT01314833|Luminal B
1162372|NCT01314833|Her-2 overexpression
1162373|NCT01314833|DFS
1162374|NCT01314833|DDFS
1162375|NCT01314833|OS
1162376|NCT01314820|Knee
1162377|NCT01314820|Osteoarthritis
1162378|NCT01314820|Effusion.
1162379|NCT01314807|COPD
1162380|NCT01314781|Overactive Bladder
1162381|NCT01314781|urinary frequency
1162382|NCT01314755|Head and Neck neoplasm
1162383|NCT01314755|Nutrition
1162384|NCT01314755|Carcinoma
1162385|NCT01314755|Infection
1162386|NCT01314755|Post-operative
1162387|NCT01314755|Surgery
1162388|NCT01314755|Immune-enhancing
1162389|NCT01314742|neonates
1162390|NCT01314742|mechanical ventilation
1162391|NCT01314742|oral care
1162392|NCT01314742|duration of mechanical ventilation
1162393|NCT01314742|feasibility
1162394|NCT01314742|ventilator-associated pneumonia
1162395|NCT01314729|Orthodontic fixed retainer
1162396|NCT01314729|fiber-reinforced-composite retainer
1162397|NCT01314729|composite-wire retainer
1162398|NCT01314690|obesity
1162399|NCT01314690|low calorie diet
1162400|NCT01314690|intestinal microbiota
1162401|NCT01314690|inflammation (systemic and in adipose tissue)
1162402|NCT01314690|fat mass
1162403|NCT01314690|Impact of nutritional transition on intestinal microbiota
1162404|NCT01314690|relation between food intake, clinical parameters and intestinal microbiota
1162405|NCT01314664|Non-Muscle Invasive Bladder Cancer
1162406|NCT01314664|CIS
1162407|NCT01314664|BCG Refractory
1162408|NCT01314651|Migraine Disorders
1162409|NCT01314651|Chronic migraine
1162410|NCT01314651|Insomnia
1162411|NCT01314651|Behavioral sleep management
1162412|NCT01314612|Insomnia
1162413|NCT01314612|group psychotherapy
1162414|NCT01314612|nightmares
1162415|NCT01314612|PTSD
1162416|NCT01314612|posttraumatic stress disorder
1162417|NCT01314612|Veterans
1162418|NCT01314612|cognitive-behavioral intervention
1162419|NCT01314599|Leukemia
1162420|NCT01314599|lurbinectedin
1162421|NCT01314599|PM01183
1162422|NCT01314599|Pharma Mar
1162423|NCT01314599|Acute Leukemia in Relapse and Primary Refractory
1162424|NCT01314586|hypercholesterolemia
1162425|NCT01314586|postmenopause
1162426|NCT01314586|secoisolariciresinol diglucoside
1162427|NCT01314586|flaxseed
1162428|NCT01314586|lignans
1162429|NCT01314586|enterolactone
1162430|NCT01314586|enterodiol
1162431|NCT01314586|serum cholesterol
1162432|NCT01314586|LDL cholesterol
1162433|NCT01314573|High intensity exercise training
1162434|NCT01314573|Vascular health
1162435|NCT01314573|Endothelial function
1162436|NCT01314573|Circulating angiogenic cells
1162437|NCT01314573|endothelial progenitor cells
1162438|NCT01314573|Aerobic capacity
1162439|NCT01314573|Arterial stiffness
1162440|NCT01314573|Traditional and emerging cardiovascular disease risk factors
1162441|NCT01314560|Lowe syndrome
1162442|NCT01314560|OCRL
1162443|NCT01314560|Haemostasis
1162444|NCT01314560|Bleeding Disorders
1162445|NCT01314560|Platelet Function Tests
1162446|NCT01314547|Environment
1162447|NCT01314547|spondylarthritis
1162448|NCT01314547|vasculitis
1162449|NCT01314547|stress
1162450|NCT01314547|life event
1162451|NCT01314547|vaccine
1162452|NCT01314534|Kabuki syndrome
1162453|NCT01314534|Genetic
1162454|NCT01314534|CGH-array
1162455|NCT01314521|Suicide
1162456|NCT01314521|Depression
1162457|NCT01314521|Adolescents
1162458|NCT01314508|pre-pubertal children
1162459|NCT01314508|pre-transplant
1162460|NCT01314508|not treated with growth hormone for at least 3 months
1162461|NCT01314495|Alopecia Areata
1162462|NCT01314482|Neuropathic pain
1162463|NCT01314482|Minocycline
1162464|NCT01313468|NEAT
1162465|NCT01313468|maximal oxygen uptake
1162466|NCT01313468|stroke volume
1162467|NCT01313455|Oligomenorrhea
1162468|NCT01313455|Adrenal Hyperplasia
1162469|NCT01313455|Obesity
1162470|NCT01313455|Hyperandrogenism
1162471|NCT01313455|Polycystic Ovarian Syndrome
1162472|NCT01313455|PCOS
1162473|NCT01313455|Polycystic Ovary
1162474|NCT01313455|Healthy Volunteer
1162475|NCT01313455|HV
1162476|NCT01313442|Tissue Acquisition
1162477|NCT01313442|Gastrointestinal Cancer
1162478|NCT01313442|Immune Suppressor
1162479|NCT01313442|Immune Monitoring
1162480|NCT01313442|Samples
1162481|NCT01313442|Gastrointestinal Tract Cancer
1162482|NCT01313429|Metastatic Cancer
1162483|NCT01313429|Cancer Vaccine
1162484|NCT01313429|Immunotherapy
1162485|NCT01313429|Adjuvant Therapy
1162486|NCT01313429|Chest Metastases
1162487|NCT01313429|Cancer
1162488|NCT01313429|Melanoma
1162489|NCT01313429|Lung Cancer
1162490|NCT01313429|Sarcoma
1162491|NCT01313416|Adjuvant Therapy
1162492|NCT01313416|Recombinant Monoclonal Antibody
1162493|NCT01313416|Adenocarcinoma of the Pancreas
1162494|NCT01313416|Vaccination
1162495|NCT01313416|PD-1 Receptor
1162496|NCT01313416|Pancreas Cancer
1162497|NCT01313416|Pancreatic Cancer
1162498|NCT01313403|5-HT1A Receptors
1162499|NCT01313403|Major Depression
1162500|NCT01313403|PET Imaging
1162501|NCT01313403|Depression
1162502|NCT01313403|Healthy Volunteer
1162503|NCT01313403|HV
1162504|NCT01313390|recurrent squamous cell carcinoma of the hypopharynx
1162505|NCT01313390|stage III squamous cell carcinoma of the hypopharynx
1162506|NCT01313390|stage IV squamous cell carcinoma of the hypopharynx
1162507|NCT01313390|stage III squamous cell carcinoma of the larynx
1162508|NCT01313390|stage III verrucous carcinoma of the larynx
1162509|NCT01313390|stage IV squamous cell carcinoma of the larynx
1162510|NCT01313390|stage IV verrucous carcinoma of the larynx
1162511|NCT01313390|recurrent squamous cell carcinoma of the larynx
1162512|NCT01313390|recurrent verrucous carcinoma of the larynx
1162513|NCT01313390|recurrent squamous cell carcinoma of the lip and oral cavity
1162514|NCT01313390|stage III squamous cell carcinoma of the lip and oral cavity
1162515|NCT01313390|stage IV squamous cell carcinoma of the lip and oral cavity
1162516|NCT01313390|recurrent verrucous carcinoma of the oral cavity
1162517|NCT01313390|stage III verrucous carcinoma of the oral cavity
1162518|NCT01313390|stage IV verrucous carcinoma of the oral cavity
1162519|NCT01313390|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1162520|NCT01313390|recurrent metastatic squamous neck cancer with occult primary
1162521|NCT01313390|recurrent squamous cell carcinoma of the nasopharynx
1162522|NCT01313390|stage III squamous cell carcinoma of the nasopharynx
1162523|NCT01313390|stage IV squamous cell carcinoma of the nasopharynx
1162524|NCT01313390|recurrent squamous cell carcinoma of the oropharynx
1162525|NCT01313390|stage III squamous cell carcinoma of the oropharynx
1162526|NCT01313390|stage IV squamous cell carcinoma of the oropharynx
1162527|NCT01313390|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1162528|NCT01313390|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1162529|NCT01313390|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1162530|NCT01313390|recurrent salivary gland cancer
1162531|NCT01313390|salivary gland squamous cell carcinoma
1162532|NCT01313390|stage III salivary gland cancer
1162533|NCT01313390|stage IV salivary gland cancer
1162534|NCT01313390|tongue cancer
1162535|NCT01313377|adenocarcinoma of the extrahepatic bile duct
1162536|NCT01313377|cholangiocarcinoma of the extrahepatic bile duct
1162537|NCT01313377|liver and intrahepatic biliary tract cancer
1162538|NCT01313377|localized extrahepatic bile duct cancer
1162539|NCT01313377|adenocarcinoma of the gallbladder
1162540|NCT01313377|cholangiocarcinoma of the gallbladder
1162541|NCT01313377|localized gallbladder cancer
1162542|NCT01312740|obesity
1162543|NCT01312740|dietary treatment
1162544|NCT01312740|high protein diet
1162545|NCT01312740|Low glycaemic index
1162546|NCT01312740|adipocytes
1162547|NCT01312740|fat mass
1162548|NCT01312740|systemic inflammatory markers
1162549|NCT01312740|improvement of complications
1162550|NCT01312740|effect on weight loss
1162551|NCT01312727|Tubulointerstitial renal diseases
1162552|NCT01312727|Hereditary renal diseases
1162553|NCT01312727|Uromodulin
1162554|NCT01312727|Renin gene
1162555|NCT01312714|Hemodialysis
1162556|NCT01312714|Peritoneal dialysis
1162557|NCT01312714|Vitamin D Deficiency
1162558|NCT01312714|blood pressure
1162559|NCT01312714|arterial stiffness
1162560|NCT01312714|Heart function
1162561|NCT01312714|Renin-angiotensin system
1162562|NCT01312714|Calcium
1162563|NCT01312714|FGF-23
1162564|NCT01312714|Brain natriuretic peptide
1162565|NCT01312701|cancer
1162566|NCT01312701|immunomonitoring
1162567|NCT01312701|CD247 -zeta chain
1162568|NCT01312701|chronic inflamation
1162569|NCT01312701|anticancertherapy
1162570|NCT01312688|Early Goal Directed Hemodunamic Therapy in Sepsis
1162571|NCT01312675|severe sepsis
1162572|NCT01312675|mechanical ventilation
1162573|NCT01314469|Quality of life in patients with macular edema compared to patients without macular edema.
1162574|NCT01314456|Prostate biopsy
1162575|NCT01314456|Trans-rectal ultrasound
1162576|NCT01314456|Prostate cancer
1162577|NCT01314443|smoking cessation
1162578|NCT01314443|gamma-tocopherol
1162579|NCT01314443|nicotine-replacement therapy
1162580|NCT01314443|oxidative stress
1162581|NCT01314417|Uveitis
1162582|NCT01314417|Macular Edema
1162583|NCT01314417|Methotrexate
1162584|NCT01314404|Human papillomavirus
1162585|NCT01314404|Prevalence
1162586|NCT01314404|Knowledge Attitude and Practice
1162587|NCT01314404|Willingness to Participate
1162588|NCT01314404|Vaccine
1162589|NCT01314404|HPV
1162590|NCT01314391|stage I Wilms tumor
1162591|NCT01314391|stage II Wilms tumor
1162592|NCT01314391|stage III Wilms tumor
1162593|NCT01314391|stage IV Wilms tumor
1162594|NCT01314391|stage V Wilms tumor
1162595|NCT01314391|renal failure
1162596|NCT01314378|Mindfulness
1162597|NCT01314378|Cognitive behavioral therapy
1162598|NCT01314378|Smoking
1162599|NCT01314378|Impulsivity
1162600|NCT01314378|Inhibitory Control
1162601|NCT01314326|Optical Coherence Tomography
1162602|NCT01314326|Glaucoma
1162603|NCT01314326|Advanced Imaging
1162604|NCT01314313|SAPIEN XT
1162605|NCT01314313|SAPIEN 3
1162606|NCT01314313|Transfemoral
1162607|NCT01314313|Transapical
1162608|NCT01314313|Transaortic
1162609|NCT01314313|NovaFlex
1162610|NCT01314313|TAVI
1162611|NCT01314313|Aortic Stenosis
1162612|NCT01314313|THV
1162613|NCT01314313|Aortic Valve
1162614|NCT01314313|Transcatheter Heart Valve
1162615|NCT01314313|tAVR
1162616|NCT01314300|Child, adolescent, young adult
1162617|NCT01314300|Plaster
1162618|NCT01314300|Lidocaine
1162619|NCT01314287|Anaesthesia
1162620|NCT01314287|pulmonary complications
1162621|NCT01314287|Atelectasis
1162622|NCT01314274|Epistaxis
1162623|NCT01314274|Osler
1162624|NCT01314274|Weber
1162625|NCT01314274|Rendu
1162626|NCT01314274|HHT
1162627|NCT01314274|Hereditary haemorrhagic telangiectasia
1162628|NCT01314248|airway sealing pressure
1162629|NCT01314248|fiberoptic assessment
1162630|NCT01314248|ease and time for successful insertion
1162631|NCT01314248|incidence of gastric insufflation
1162632|NCT01314248|complications were also evaluated
1162633|NCT01314235|anticoagulation with ASS
1162634|NCT01314235|anticoagulation with clopidogrel
1162635|NCT01314209|dexmedetomidine
1162636|NCT01314209|pharmacokinetics
1162637|NCT01314209|critical illness
1162638|NCT01314209|continuous renal replacement therapy
1162639|NCT01314196|biceps
1162640|NCT01314196|resistance training
1162641|NCT01314196|rehabilitation
1162642|NCT01314196|impact syndrome
1162643|NCT01314183|Knee
1162644|NCT01314183|Physical Therapy
1162645|NCT01314183|Exercise
1162646|NCT01314170|Implant, glaucoma, refractory glaucoma.
1162647|NCT01314157|low back pain
1162648|NCT01314157|pain
1162649|NCT01314157|incapacity
1162650|NCT01314157|life quality
1162651|NCT01314157|rehabilitation
1162652|NCT01314144|axillary clearance
1162653|NCT01314144|wound infiltration
1162654|NCT01314144|wound infusion
1162655|NCT01314144|local anaesthetic wound infusion
1162656|NCT01314118|abiraterone acetate
1162657|NCT01314118|prednisone
1162658|NCT01314118|zytiga
1162659|NCT01314092|crohn's disease
1162660|NCT01314092|fistula
1162661|NCT01314092|complex
1162662|NCT01314079|Crohn's fistula
1162663|NCT01314079|Autologous adipose derived stem cell
1162664|NCT01314053|Daptomycin
1162665|NCT01314053|Serious Gram-positive Infections
1162666|NCT01314040|Dietary protein
1162667|NCT01314040|Biomarkers
1162668|NCT01314040|filtration rate
1162669|NCT01314040|urinary acid excretion
1162670|NCT01314014|Non Hodgkin's Lymphoma
1162671|NCT01314014|Lymphoma, Low Grade
1162672|NCT01314014|Lymphoma, Intermediate Grade
1162673|NCT01314014|Lymphoma, High Grade
1162674|NCT01314014|Lymphoma, B Cell
1162675|NCT01314001|Tobacco, Smoking, Varenicline, Nicotine Patch
1162676|NCT01313988|dose-response study
1162677|NCT01313988|blood lipid profile
1162678|NCT01313988|plant sterols
1162679|NCT01313988|fish oil
1162680|NCT01313975|Electrolyte disturbances
1162681|NCT01313975|Fluid balance
1162682|NCT01313975|subarachnoid hemorrhage
1162683|NCT01313975|traumatic brain injury
1162684|NCT01313975|Cerebral salt wasting
1162685|NCT01313975|SIADH
1162686|NCT01313975|Diabetes insipidus
1162687|NCT01313962|antiviral
1162688|NCT01313962|intranasal
1162689|NCT01313962|influenza
1162690|NCT01313949|Diabetes
1162691|NCT01313949|Peer Support
1162692|NCT01313949|Structured Care
1162693|NCT01313936|Neuroblastoma
1162694|NCT01313936|MIBG
1162695|NCT01313936|131I-MIBG
1162696|NCT01313936|Irinotecan
1162697|NCT01313936|Vincristine
1162698|NCT01313936|Resistant
1162699|NCT01313936|Relapsed
1162700|NCT01313936|Treatment
1162701|NCT01313936|UCSF
1162702|NCT01313936|Pediatric
1162703|NCT01313936|Oncology
1162704|NCT01313923|Pemphigus
1162705|NCT01313910|HIV
1162706|NCT01313910|diarrhea
1162707|NCT01313897|Multiple Myeloma
1162708|NCT01313832|ventricular septal defect
1162709|NCT01313832|remote ischemic preconditioning
1162710|NCT01313832|pulmonary hypertension
1162711|NCT01313832|infant with ventricular septal defect and pulmonary hypertension
1162712|NCT01313819|Freezing
1162713|NCT01313806|dementia
1162714|NCT01313806|memory loss
1162715|NCT01313806|cognitive decline
1162716|NCT01313793|Bioequivalence (BE) Study
1162717|NCT01313793|Healthy Volunteers
1162718|NCT01313780|cancer related pain
1162719|NCT01313767|spasticity
1162720|NCT01313767|upperlimb
1162721|NCT01313767|Botulinum toxin
1162722|NCT01313754|Skin closure
1162723|NCT01313754|dermabond
1162724|NCT01313754|vicryl
1162725|NCT01313754|monocryl
1162726|NCT01313754|Suburethral sling
1162727|NCT01313754|Transobturator Sling
1162728|NCT01313754|Pain
1162729|NCT01313754|Discomfort
1162730|NCT01313754|Skin irritation
1162731|NCT01313728|Acne
1162732|NCT01313728|Irritation
1162733|NCT01313715|Safety
1162734|NCT01313715|Immunogenicity
1162735|NCT01313715|inactivated EV71 vaccine
1162736|NCT01313702|polypill, compliance, cardiovascular disease
1162737|NCT01313689|Safety
1162738|NCT01313689|Refractory
1162739|NCT01313689|Chronic Lymphocytic Leukemia
1162740|NCT01313689|Oncology
1162741|NCT01313689|Ofatumumab
1162742|NCT01313689|Efficacy
1162743|NCT01313676|COPD
1162744|NCT01313676|Cardiovascular disease
1162745|NCT01313676|Novel Dry Powder Inhaler
1162746|NCT01313676|Survival
1162747|NCT01313663|GW786034
1162748|NCT01313663|non-small cell lung cancer
1162749|NCT01313663|NSCLC
1162750|NCT01313663|pemetrexed
1162751|NCT01313663|pazopanib
1162752|NCT01313650|long-acting beta agonist
1162753|NCT01313650|anticholinergic
1162754|NCT01313637|anticholinergic
1162755|NCT01313637|long-acting beta agonist
1162756|NCT01313598|Patients with solid tumors
1162757|NCT01313598|Treatment-refractory
1162758|NCT01313585|Primary care
1162759|NCT01313585|asthma management
1162760|NCT01313585|inhaler device
1162761|NCT01313585|maintenance therapy
1162762|NCT01313585|reliever therapy
1162763|NCT01313585|Easibreathe salbutamol
1162764|NCT01313572|Coronary Artery Disease
1162765|NCT01313572|Myocardial Perfusion Imaging
1162766|NCT01313559|Castrate Resistant
1162767|NCT01313559|Chemotherapy Naive
1162768|NCT01313559|Prostate Cancer
1162769|NCT01313559|SOM230
1162770|NCT01313559|Everolimus
1162771|NCT01313546|Femoral nerve block
1162772|NCT01313546|total knee arthroplasty
1162773|NCT01313533|Atherosclerosis of Autologous Vein Bypass Graft
1162774|NCT01313507|Primary Immunodeficiency Disease
1162775|NCT01313507|PID
1162776|NCT01313494|COPD
1162777|NCT01313494|Roflumilast
1162778|NCT01313494|FEV1
1162779|NCT01313494|China
1162780|NCT01313481|Older persons
1162781|NCT01313481|Exercise
1162782|NCT01313481|Balance
1162783|NCT01313325|hippotherapy
1162784|NCT01313325|neuromuscular disorders
1162785|NCT01313325|balance deficits
1162786|NCT01313325|participation
1162787|NCT01313286|Diabetes Mellitus, Type 2
1162788|NCT01313260|Refractory partial epilepsies
1162789|NCT01313247|Paracetamol
1162790|NCT01313247|opioids
1162791|NCT01313247|cancer pain
1162792|NCT01313221|plaque psoriasis
1162793|NCT01313221|moderate
1162794|NCT01313221|severe
1162795|NCT01313221|etanercept
1162796|NCT01313221|Enbrel
1162797|NCT01313221|topical
1162798|NCT01313208|RA
1162799|NCT01313208|Enbrel
1162800|NCT01313208|DMARD
1162801|NCT01313208|Joint Count
1162802|NCT01313208|Rheumatoid Arthritis
1162803|NCT01313208|Etanercept
1162804|NCT01313208|disease modifying anti-rheumatic drug
1162805|NCT01313169|Electronic medical record reminders, Panel management
1162806|NCT01313156|Metabolic Syndrome, Syndrome X, MetS,
1162807|NCT01313156|Type 2 Diabetes
1162808|NCT01313143|AOP200704, Esmolol, Pharmacokinetics, Pharmacodynamics
1162809|NCT01313130|traumatic brain injury
1162810|NCT01313130|post traumatic stress disorder
1162811|NCT01313130|Diffusion tensor imaging
1162812|NCT01313130|resting state functional connectivity
1162813|NCT01313130|genetic factors
1162814|NCT01313117|chemotherapy
1162815|NCT01313117|peripheral neuropathy
1162816|NCT01313117|paclitaxel
1162817|NCT01313117|breast cancer
1162818|NCT01313078|Ovarian Cancer
1162819|NCT01313078|Fallopian Tube Cancer
1162820|NCT01313078|Primary Peritoneal Cancer
1162821|NCT01313078|Relapsed or Refractory
1162822|NCT01313078|Pegaspargase
1162823|NCT01313078|Pegylated L-Asparaginase
1162824|NCT01313065|VX15/2503
1162825|NCT01313065|Semaphorin 4D
1162826|NCT01313065|SEMA4D
1162827|NCT01313065|CD100
1162828|NCT01313065|safety
1162829|NCT01313065|tolerability
1162830|NCT01313065|pharmacokinetics
1162831|NCT01313065|pharmacodynamics
1162832|NCT01313065|advanced solid tumors
1162833|NCT01313052|Psychotic
1162834|NCT01313052|Criminal
1162835|NCT01313039|Breast Cancer
1162836|NCT01313039|ER-negative
1162837|NCT01313039|Allred Score
1162838|NCT01313026|Percutaneous nerve evaluation
1162839|NCT01313026|Transanal irrigation
1162840|NCT01313026|Low anterior resection syndrome
1162841|NCT01313000|fat, transfer, autologous fat transfer, bicep
1162842|NCT01312948|Obstructive sleep apnea
1162843|NCT01312948|OSA
1162844|NCT01312948|CPAP
1162845|NCT01312948|CPAP mask
1162846|NCT01312948|Non-invasive ventilation
1162847|NCT01312948|NIV
1162848|NCT01312935|Percutaneous Coronary Intervention
1162849|NCT01312935|Heparin
1162850|NCT01312935|Angioplasty
1162851|NCT01312935|LMWH
1162852|NCT01312909|smoking cessation in adolescents
1162853|NCT01312857|colon
1162854|NCT01312857|rectal
1162855|NCT01312857|liver
1162856|NCT01312857|AMG 954 (Panitumumab)
1162857|NCT01312857|DEXAMETHASONE
1162858|NCT01312857|FLOXURIDINE
1162859|NCT01312857|FLUOROURACIL
1162860|NCT01312857|IRINOTECAN (CPT-11) CAMPTOSAR
1162861|NCT01312857|LEUCOVORIN
1162862|NCT01312857|10-137
1162863|NCT01312831|cobalamin
1162864|NCT01312831|B12
1162865|NCT01312831|homocysteine
1162866|NCT01312831|MMA
1162867|NCT01312831|holotranscobalamin
1162868|NCT01312831|Eligen
1162869|NCT01312805|asthma
1162870|NCT01312805|clinical decision support
1162871|NCT01312805|CHICA
1162872|NCT01312792|Severe Pneumonia
1162873|NCT01312792|Pneumonia
1162874|NCT01312792|ARI
1162875|NCT01312792|IMCI
1162876|NCT01312792|Modified IMCI
1162877|NCT01312792|1st level Health facilities
1162878|NCT01312792|Children
1162879|NCT01312792|Operational Research
1162880|NCT01312792|Bangladesh
1162881|NCT01312792|Treatment of Severe Pneumonia
1162882|NCT01312779|Mitral Valve Replacement
1162883|NCT01312779|23mm CEP
1162884|NCT01312779|Magna
1162885|NCT01312610|orange juice
1162886|NCT01312610|cognitive function
1162887|NCT01312610|flavonoids
1162888|NCT01312610|flavanones
1162889|NCT01312597|Flavonoid
1162890|NCT01312597|Cognitive performance
1162891|NCT01312597|Cognitive function
1162892|NCT01312597|Executive function
1162893|NCT01312597|fMRI
1162894|NCT01312597|Cerebral blood flow
1162895|NCT01312597|Acute
1162896|NCT01312584|Flavanol
1162897|NCT01312584|Cocoa
1162898|NCT01312584|Vascular function
1162899|NCT01312584|Absorption
1162900|NCT01312584|Metabolism
1162901|NCT01312584|Alkalisation
1162902|NCT01312558|obstructive sleep apnoea/hypopnoea syndrome
1162903|NCT01312558|Mediterranean diet
1162904|NCT01312558|exercise
1162905|NCT01312558|weight loss
1162906|NCT01312558|continuous positive airway pressure
1162907|NCT01312558|lipid peroxidation
1162908|NCT01312545|orbital implant
1162909|NCT01312545|evisceration
1162910|NCT01312545|economic
1162911|NCT01312545|polyethylene
1162912|NCT01312545|porous
1162913|NCT01312532|Total knee arthroplasty
1162914|NCT01312532|Fixed-bearing
1162915|NCT01312532|Mobile-bearing
1162916|NCT01312519|Bone marrow biopsy of iliac crest
1162917|NCT01312506|metastatic
1162918|NCT01312506|melanoma
1162919|NCT01312506|CNS
1162920|NCT01312493|Head and neck cancer
1162921|NCT01312493|Phase II
1162922|NCT01312493|Locally advanced
1162923|NCT01312493|Panitumumab
1162924|NCT01312493|Vectibix
1162925|NCT01312493|Lineberger
1162926|NCT01312493|Radiation Therapy
1162927|NCT01312493|Intensity modulated radiation therapy (IMRT)
1162928|NCT01312493|Stage III to IVB
1162929|NCT01312480|Tobacco
1162930|NCT01312480|Tobacco Prevention
1162931|NCT01312480|Tobacco Cessation
1162932|NCT01312480|5A's Model
1162933|NCT01312480|Adolescence
1162934|NCT01312480|Media Use
1162935|NCT01312454|intravitreal injection
1162936|NCT01312454|intraocular pressure
1162937|NCT01312454|open-angle glaucoma
1162938|NCT01312454|ocular hypertension
1162939|NCT01312441|Vitamin D
1162940|NCT01312441|Ergocalciferol
1162941|NCT01312415|total knee arthroplasty
1162942|NCT01312415|total knee replacement
1162943|NCT01312415|local infiltration analgesia
1162944|NCT01312415|intra-articular local anaesthesia
1162945|NCT01312415|patients undergoing total knee arthroplasty (total knee replacement)
1162946|NCT01312363|Alzheimer's disease
1162947|NCT01312363|Rivastigmine
1162948|NCT01312363|Patch
1162949|NCT01312363|Tolerability
1162950|NCT01312350|neoadjuvant chemotherapy
1162951|NCT01312350|definitive chemoradiation therapy
1162952|NCT01312350|head and neck cancer
1162953|NCT01312350|base of tongue
1162954|NCT01312350|Locally advanced
1162955|NCT01312337|gefitinib
1162956|NCT01312337|EGFR mutation negative
1162957|NCT01312337|NSCLC
1162958|NCT01312324|neoadjuvant chemotherapy
1162959|NCT01312324|thymic cancer
1162960|NCT01312311|nasopharyngeal cancer
1162961|NCT01312311|weekly docetaxel
1162962|NCT01312311|cisplatin
1162963|NCT01312298|Arthritis
1162964|NCT01312298|General anaesthesia
1162965|NCT01312298|Spinal anaesthesia
1162966|NCT01312285|osteoarthritis
1162967|NCT01312285|painful hips
1162968|NCT01312272|Schizophrenia
1162969|NCT01312272|Social Intelligence
1162970|NCT01312272|Perception, Social
1162971|NCT01312272|Oxytocin
1162972|NCT01312259|Painful Bladder Syndrome
1162973|NCT01312259|Interstitial Cystitis
1162974|NCT01312259|Pelvic Floor dysfunction
1162975|NCT01312259|Fecal incontinence
1162976|NCT01312259|Constipation
1162977|NCT01312259|Sexual dysfunction
1162978|NCT01312259|Dyspareunia
1162979|NCT01312259|Vulvodynia
1162980|NCT01312246|vessel ligation
1162981|NCT01312246|colon resection
1162982|NCT01312207|tractional retinoschisis
1162983|NCT01312207|traction retinal detachment
1162984|NCT01312194|Periapical Periodontitis
1162985|NCT01312194|Dental Pulp Necrosis
1162986|NCT01312194|Root canal Therapy
1162987|NCT01312194|Adolescent
1162988|NCT01312181|Technology based intervention
1162989|NCT01312181|HIV primary care clinic
1162990|NCT01312181|Brief behavioral intervention
1162991|NCT01312181|Drug abuse
1162992|NCT01312168|Cardiovascular disease
1162993|NCT01312168|Continuous positive airway pressure
1162994|NCT01312168|Endothelium
1162995|NCT01312168|Vascular function
1162996|NCT01312168|Inflammation
1162997|NCT01312168|Sleep Apnea
1162998|NCT01312168|Obstructive
1162999|NCT01312155|endotracheal
1163000|NCT01312155|intubation
1163001|NCT01312155|video
1163002|NCT01312155|time
1163003|NCT01312129|Alcohol
1163004|NCT01312129|Sulfasalazine
1163005|NCT01312116|Internet treatment
1163006|NCT01312116|GAD
1163007|NCT01312116|guided self-help
1163008|NCT01312103|Safety Planning
1163009|NCT01312090|Weight loss
1163010|NCT01312090|brown adipose tissue
1163011|NCT01312090|white adipose tissue
1163012|NCT01312090|muscle, metabolism
1163013|NCT01312090|cold exposure
1163014|NCT01312077|total hip arthroplasty
1163015|NCT01312077|total hip replacement
1163016|NCT01312077|local infiltration analgesia
1163017|NCT01312077|wound infusion
1163018|NCT01312077|patients undergoing total hip replacement (total hip arthroplasty)
1163019|NCT01312064|rituximab
1163020|NCT01312064|everolimus
1163021|NCT01312038|Eustachian tube
1163022|NCT01312038|otitis
1163023|NCT01312038|middle-ear pressure
1163024|NCT01312038|simethicone
1163025|NCT01312012|hepatitis B virus,mother-infant transmission, nucleoside analog,pregnant women
1163026|NCT01311999|latent tuberculosis, renal failure, dialysis, interferon-gamma release assay
1163027|NCT01311986|atopic dermatitis
1163028|NCT01311986|nummular eczema
1163029|NCT01311986|chemokines
1163030|NCT01311973|Chronic kidney disease, phosphorus, salivary phosphorus
1163031|NCT01311960|pterygium
1163032|NCT01311960|recurrent pterygium
1163033|NCT01311960|bevacizumab
1163034|NCT01311960|VEGF
1163035|NCT01311960|anti-VEGF
1163036|NCT01311947|Chronic hepatitis B
1163037|NCT01311947|Peginterferon alfa-2a
1163038|NCT01311921|enterovirus 71, host genetics, social, behavior, environmental factors
1163039|NCT01311908|Pancreaticoduodenectomy
1163040|NCT01311908|Roux-en-Y reconstruction
1163041|NCT01311908|Reflux esophagitis
1163042|NCT01311895|acute
1163043|NCT01311895|pain
1163044|NCT01311895|emergency department
1163045|NCT01311895|hydromorphone
1163046|NCT01311856|Behavioral intervention
1163047|NCT01311856|Exercise
1163048|NCT01311856|Physical Assessment
1163049|NCT01311856|Questionnaire
1163050|NCT01311856|Survey
1163051|NCT01311856|Telephone counseling
1163052|NCT01311856|Internet interventions
1163053|NCT01311856|Overweight cancer survivors
1163054|NCT01311856|Exercise and weight management program
1163055|NCT01311791|Left ventricular augmentation
1163056|NCT01311791|Left ventricular restoration
1163057|NCT01311765|Postoperative peritonitis
1163058|NCT01311765|Intra-abdominal infection
1163059|NCT01311765|Surgery
1163060|NCT01311765|Laparotomy
1163061|NCT01311765|Nosocomial infection
1163062|NCT01311765|Antibiotic therapy
1163063|NCT01311765|Duration of treatment
1163064|NCT01311765|Multidrug resistant bacteria
1163065|NCT01311752|human papillomavirus
1163066|NCT01311752|follow up
1163067|NCT01311739|Pharmacokinetics
1163068|NCT01310959|Aplastic Anemia Marrow Failure Syndrome
1163069|NCT01310946|Acute Lymphocytic Leukemia
1163070|NCT01310894|Prostatic Disease
1163071|NCT01310894|Genital Neoplasm,male
1163072|NCT01310894|Urogenital neoplasm
1163073|NCT01310894|Genital disease,male
1163074|NCT01310894|Male urogenital disease
1163075|NCT01310894|Neoplasms
1163076|NCT01310894|Neoplasms by site
1163077|NCT01310894|Prostatic neoplasm
1163078|NCT01310894|Carcinoma
1163079|NCT01310881|Neurogenesis
1163080|NCT01310881|hippocampal stem cells
1163081|NCT01310881|depression
1163082|NCT01310881|stroke
1163083|NCT01310868|adult giant cell glioblastoma
1163084|NCT01310868|adult gliosarcoma
1163085|NCT01310868|adult glioblastoma
1163086|NCT01310855|adult giant cell glioblastoma
1163087|NCT01310855|adult glioblastoma
1163088|NCT01310855|adult gliosarcoma
1163089|NCT01310855|recurrent adult brain tumor
1163090|NCT01310842|Smoker
1163091|NCT01310842|Smoking Cessation
1163092|NCT01310842|Social Determinants
1163093|NCT01310842|Environmental Effects
1163094|NCT01310842|Individual-level effects
1163095|NCT01310842|Nicotine patch
1163096|NCT01310842|Smart Phone
1163097|NCT01310842|SP
1163098|NCT01310842|Global Positioning System
1163099|NCT01310842|GPS
1163100|NCT01310842|Questionnaires
1163101|NCT01310842|Saliva samples
1163102|NCT01310829|Genetic counselor
1163103|NCT01310829|Genetic counseling degree program
1163104|NCT01310829|Genetic counseling students
1163105|NCT01310829|Virtual reality-based intervention
1163106|NCT01310829|VR
1163107|NCT01310829|Genetic counseling
1163108|NCT01310829|hereditary cancers
1163109|NCT01310829|Questionnaires
1163110|NCT01310829|Physiological measurements
1163111|NCT01310829|Skin sensors
1163112|NCT01310816|malignant neoplasms of the bone
1163113|NCT01310816|bone sarcoma
1163114|NCT01311713|cancer
1163115|NCT01311713|tumors
1163116|NCT01311713|PARP
1163117|NCT01311700|Ischemia
1163118|NCT01311700|Reperfusion
1163119|NCT01311700|Myocardial infarction
1163120|NCT01311700|Beta blockers
1163121|NCT01311700|Metoprolol
1163122|NCT01311700|Acute myocardial infarction
1163123|NCT01311700|Necrosis
1163124|NCT01311700|Salvaged Myocardium
1163125|NCT01311687|Myeloma
1163126|NCT01311687|Multiple Myeloma
1163127|NCT01311687|Relapsed Multiple Myeloma
1163128|NCT01311687|Relapsed and Refractory Multiple Myeloma
1163129|NCT01311687|Refractory Myeloma
1163130|NCT01311687|Resistant Multiple Myeloma
1163131|NCT01311687|Treatment-resistant Multiple Myeloma
1163132|NCT01311687|Pomalidomide
1163133|NCT01311687|Lenalidomide-resistant
1163134|NCT01311687|Bortezomib-resistant
1163135|NCT01311648|recombinant factor VIII
1163136|NCT01311648|pediatric use
1163137|NCT01311635|Phase 1
1163138|NCT01311635|bioavailability study
1163139|NCT01311635|AZD1981
1163140|NCT01311635|tablets
1163141|NCT01311635|To study the relative bioavailability of single dose AZD1981 via three different tablets
1163142|NCT01311635|To compare the bioavailability between three different AZD1981 tablets
1163143|NCT01311622|drug-drug interaction
1163144|NCT01311622|Phase 1
1163145|NCT01311622|healthy subjects
1163146|NCT01311622|warfarin
1163147|NCT01311622|Rheumatoid arthritis
1163148|NCT01311622|RA
1163149|NCT01311622|fostamatinib open-label
1163150|NCT01311622|pharmacokinetics
1163151|NCT01311622|pharmacodynamics
1163152|NCT01311622|level of Warfarin in the blood
1163153|NCT01311609|Systane, Dry Eye
1163154|NCT01311596|icons in clinic or office for patients with Autism
1163155|NCT01311583|Self-care
1163156|NCT01311583|Teach Back
1163157|NCT01311557|Tetanus
1163158|NCT01311557|Diphtheria
1163159|NCT01311557|Pertussis
1163160|NCT01311557|Tdap vaccine
1163161|NCT01311557|Adacel®
1163162|NCT01311531|Fracture
1163163|NCT01311531|Radius
1163164|NCT01311531|Surgery
1163165|NCT01311531|Osteosynthesis
1163166|NCT01311518|Thymosin Beta 4
1163167|NCT01311518|Thymosin β4 (Tβ4) Injectable Solution
1163168|NCT01311518|RGN-352
1163169|NCT01311505|bioequivalence; rifampicin
1163170|NCT01311492|Alzheimer's Disease
1163171|NCT01311492|exercise
1163172|NCT01311492|physical activity
1163173|NCT01311492|intervention
1163174|NCT01311479|Osteopathic Manipulation
1163175|NCT01311479|Interstitial Cystitis
1163176|NCT01311479|Sacroiliac Joint Dysfunction
1163177|NCT01311466|Liver transplantation
1163178|NCT01311466|Overall survival
1163179|NCT01311440|RCT
1163180|NCT01311440|modified Atkins diet
1163181|NCT01311440|epilepsy
1163182|NCT01311440|adults
1163183|NCT01311440|ketogenic diet
1163184|NCT01311401|2 diabetes mellitus,Circassians, High fasting glucose
1163185|NCT01311388|cancer
1163186|NCT01311375|spinal,, bone, cord injury, lipid,antioxidant
1163187|NCT01311362|Steady-state
1163188|NCT01311362|Ambrisentan
1163189|NCT01311362|St. Johns Wort
1163190|NCT01311349|Susceptibility of tigecycline
1163191|NCT01311349|Drug Resistance, Bacterial
1163192|NCT01311336|Pegfilgrastim
1163193|NCT01311336|Loratadine
1163194|NCT01311336|Myalgia/arthralgia
1163195|NCT01311323|Multivessel Coronary Artery Disease
1163196|NCT01311323|Left Main Narrowing
1163197|NCT01311323|Percutaneous Coronary Intervention
1163198|NCT01311323|Coronary Artery Bypass Grafting
1163199|NCT01311323|Drug-Eluting Stent
1163200|NCT01311310|troponin, open heart surgery, children
1163201|NCT01311284|Nasotracheal intubation
1163202|NCT01311284|Macintosh laryngoscope
1163203|NCT01311284|Airtraq
1163204|NCT01311284|McGrath
1163205|NCT01311284|Manikin
1163206|NCT01311284|airway management
1163207|NCT01311271|Stroke
1163208|NCT01311271|Cerebrovascular disease
1163209|NCT01311271|hemiplegia
1163210|NCT01311271|Transcranial magnetic stimulation
1163211|NCT01311271|repetitive transcranial magnetic stimulation
1163212|NCT01311271|rTMS
1163213|NCT01311271|rehabilitation
1163214|NCT01311271|Upper Extremity
1163215|NCT01311258|AML
1163216|NCT01311258|MDS
1163217|NCT01311245|Risky drinking
1163218|NCT01311245|Brief intervention
1163219|NCT01311245|Computer-generated feedback
1163220|NCT01311245|Stage-tailored
1163221|NCT01311245|Non-stage-tailored
1163222|NCT01311232|rituximab, lymphoma, hepatitis B virus
1163223|NCT01311206|knee osteoarthritis
1163224|NCT01311206|isokinetic knee extensor strength
1163225|NCT01311206|quadriceps volume
1163226|NCT01311206|symptomatic knee osteoarthritis
1163227|NCT01311193|Circadian rhythms
1163228|NCT01311193|Sleep-wake cycles
1163229|NCT01311193|Melatonin
1163230|NCT01311193|Borderline Personality Disorder
1163231|NCT01311193|Light therapy
1163232|NCT01311167|Dexamethasone
1163233|NCT01311167|Sodium
1163234|NCT01311154|carriers
1163235|NCT01311154|resistant Enterobacteriaceae
1163236|NCT01311154|AMR
1163237|NCT01311154|antibiotic
1163238|NCT01311128|Blood pressure
1163239|NCT01311128|Heart rate
1163240|NCT01311128|Cardiac output
1163241|NCT01311128|Critical care
1163242|NCT01311128|Perioperative care
1163243|NCT01311102|Pain score
1163244|NCT01311102|IUD placement
1163245|NCT01311076|Type 1 Diabetes Mellitus
1163246|NCT01311076|Insulin
1163247|NCT01311076|Glucose
1163248|NCT01311076|Drug Therapy
1163249|NCT01311050|Metastatic Colorectal Cancer
1163250|NCT01311037|Premenopausal Women with Advanced Breast Cancer
1163251|NCT01311024|Children
1163252|NCT01311024|Pneumococcal Vaccines
1163253|NCT01311011|Critical Limb Ischemia
1163254|NCT01310998|Schizophrenia
1163255|NCT01310998|high intensity exercise
1163256|NCT01310998|interval training exercise
1163257|NCT01310985|Rectal Cancer
1163258|NCT01310972|Adjuvant Colon Cancer
1163259|NCT01310803|Urinary Bladder Neoplasms
1163260|NCT01310803|Neoplasms
1163261|NCT01310803|Urologic Neoplasms
1163262|NCT01310803|Urogenital Neoplasms
1163263|NCT01310803|Neoplasms by Site
1163264|NCT01310803|Urinary Bladder Diseases
1163265|NCT01310803|Urologic Diseases
1163266|NCT01310803|TURBT
1163267|NCT01310803|Valstar
1163268|NCT01310790|septic shock
1163269|NCT01310790|lactic acid clearance
1163270|NCT01310790|ScVO2
1163271|NCT01310777|Open-Angle glaucoma
1163272|NCT01310777|Ocular Hypertension
1163273|NCT01310777|OAG
1163274|NCT01310777|OHT
1163275|NCT01310764|Intraocular pressure
1163276|NCT01310764|Trabeculectomy
1163277|NCT01310764|Mitomycin C
1163278|NCT01310764|Bevacizumab
1163279|NCT01310738|Visceral leishmaniasis
1163280|NCT01310738|Leishmania infantum
1163281|NCT01310738|Leishmania chagasi
1163282|NCT01310725|CABG
1163283|NCT01310725|LIMA
1163284|NCT01310725|saphenous vein
1163285|NCT01310725|radial artery
1163286|NCT01310712|hyperhidrosis
1163287|NCT01310712|oxybutynin
1163288|NCT01310699|Colonoscopy
1163289|NCT01310699|Diagnostic imaging
1163290|NCT01310699|Colorectal Neoplasm
1163291|NCT01310699|Tandem Colonoscopy
1163292|NCT01310699|Flat Polyp
1163293|NCT01310699|Nonpolypoid
1163294|NCT01310699|Flat and Depressed Lesions
1163295|NCT01310699|Primary Prevention
1163296|NCT01310699|Endoscopy
1163297|NCT01310686|wet AMD anti-VEGF
1163298|NCT01310686|Genetic analysis of patients with Wet AMD who have not responded fully to anti-VEGF treatments
1163299|NCT01310673|Gout
1163300|NCT01310673|Allopurinol
1163301|NCT01310673|Acute gout
1163302|NCT01310647|estradiol
1163303|NCT01310647|testosterone
1163304|NCT01310647|combined oral contraceptive
1163305|NCT01310647|low responders
1163306|NCT01310647|ICSI
1163307|NCT01310634|Neonates
1163308|NCT01310634|Parenting
1163309|NCT01310634|Anxiety
1163310|NCT01310634|Depression
1163311|NCT01310621|Neonate
1163312|NCT01310621|Meconium aspiration syndrome
1163313|NCT01310621|surfactant lung lavage
1163314|NCT01310608|Atherosclerosis aorta
1163315|NCT01310608|A-View
1163316|NCT01310608|Distal ascending aorta
1163317|NCT01310608|Transoesophageal echocardiography
1163318|NCT01310608|CABG
1163319|NCT01310608|Cerebral embolisation
1163320|NCT01310595|Musculoskeletal manipulations
1163321|NCT01310595|Proprioception
1163322|NCT01310595|Postural balance
1163323|NCT01310582|Sevoflurane
1163324|NCT01310582|Desflurane
1163325|NCT01310569|PCOS, Skinfold thickness, HOMA-IR
1163326|NCT01310556|OGTT
1163327|NCT01310556|coronary artery disease
1163328|NCT01310543|Teenage pregnancy
1163329|NCT01310543|Adolescent
1163330|NCT01310543|Sexual health
1163331|NCT01310543|Youth development
1163332|NCT01310530|Breast Cancer
1163333|NCT01310530|Partial Breast
1163334|NCT01310530|Proton Beam
1163335|NCT01310517|Angiogram
1163336|NCT01310517|Injected Contrast
1163337|NCT01310517|Heart Function
1163338|NCT01310517|contrast dye
1163339|NCT01310478|Recombinant human endostatin
1163340|NCT01310478|Metastatic colorectal cancer
1163341|NCT01310478|DLT
1163342|NCT01310478|MTD
1163343|NCT01310478|Pharmacokinetics
1163344|NCT01310452|diabetes, basal insulin, metformin, liver fat, visceral fat
1163345|NCT01310426|Anal Sphincter injury
1163346|NCT01310426|Fecal Incontinence
1163347|NCT01310413|Influenza
1163348|NCT01310413|H5N1
1163349|NCT01310413|Pandemic
1163350|NCT01310400|Influenza
1163351|NCT01310400|Virus
1163352|NCT01310400|Vaccination
1163353|NCT01310400|Immunisation
1163354|NCT01310387|Lung cancer
1163355|NCT01310387|Cancer pain
1163356|NCT01310387|Opioid
1163357|NCT01310374|influenza vaccine
1163358|NCT01310374|immune response
1163359|NCT01310374|dynamic changes
1163360|NCT01310361|Pharyngitis
1163361|NCT01310361|Group A β-hemolytic Streptococci
1163362|NCT01310361|Exudate
1163363|NCT01310361|Erythema Penicillin
1163364|NCT01310361|Amoxicillin
1163365|NCT01310348|Bone
1163366|NCT01310348|Muscle strength
1163367|NCT01310348|whole-body vibration
1163368|NCT01310335|sclerostin
1163369|NCT01310335|whole-body vibration
1163370|NCT01310322|Phase I
1163371|NCT01310322|Healthy male volunteers
1163372|NCT01310322|mild asthmatics
1163373|NCT01310322|pharmacokinetics
1163374|NCT01310322|Bioavailability and AUC
1163375|NCT01310322|Level of AZD5423 in your blood
1163376|NCT01310309|Stents
1163377|NCT01310309|Drug-eluting Stent
1163378|NCT01310309|Angioplasty
1163379|NCT01310309|Coronary Artery stenosis
1163380|NCT01310309|Coronary Artery Stent Restenosis
1163381|NCT01310309|Stent Thrombosis
1163382|NCT01310296|Phase 1
1163383|NCT01310296|Normal Healthy Volunteers
1163384|NCT01310296|Mass Balance
1163385|NCT01310296|ADME
1163386|NCT01310296|Absolute Bioavailability
1163387|NCT01310283|dental caries
1163388|NCT01310283|children
1163389|NCT01310283|mutans streptococci
1163390|NCT01310283|lactobacilli
1163391|NCT01310283|cariogenic bacteria
1163392|NCT01310244|Phase 1/2
1163393|NCT01310244|MTD
1163394|NCT01310244|stage IV
1163395|NCT01310244|NSCLC
1163396|NCT01310244|chemo-naive
1163397|NCT01310244|Mixed-cell dose escalation
1163398|NCT01310244|lung cancer
1163399|NCT01310244|non-small-cell
1163400|NCT01310244|phase I
1163401|NCT01310244|Belinostat
1163402|NCT01310244|Carboplatin
1163403|NCT01310244|Paclitaxel
1163404|NCT01310244|adenocarcinoma
1163405|NCT01310244|PXD-101
1163406|NCT01310231|Metastatic Breast Cancer
1163407|NCT01310231|Metformin
1163408|NCT01310218|orthopedics, carpal tunnel syndrome, postoperative care
1163409|NCT01310205|HCV
1163410|NCT01310205|Genotype 1
1163411|NCT01310205|relapsers
1163412|NCT01310205|non cirrhotic
1163413|NCT01310205|Chronic Hepatitis C
1163414|NCT01310179|gene therapy
1163415|NCT01310179|advanced solid tumors
1163416|NCT01310179|Head and Neck cancer
1163417|NCT01310179|intratumoral therapy
1163418|NCT01310166|Multiple sclerosis
1163419|NCT01310166|RRMS
1163420|NCT01310166|relapsing-remitting
1163421|NCT01310166|fingolimod
1163422|NCT01310166|biomarkers
1163423|NCT01310140|Metabolic Syndrome
1163424|NCT01310140|Insulin Resistance
1163425|NCT01310140|Massachusetts General Hospital
1163426|NCT01310140|Major Depressive Disorder
1163427|NCT01310140|Major Depressive Disorder with Psychotic Features
1163428|NCT01310140|Cortisol
1163429|NCT01310140|Dexamethasone Suppression Test
1163430|NCT01310127|NSAID
1163431|NCT01310127|Ocular Inflammation
1163432|NCT01310127|bromfenac
1163433|NCT01310114|Human Placenta-Derived Cells
1163434|NCT01310114|Stem cells
1163435|NCT01310114|Stroke
1163436|NCT01310114|PDA001
1163437|NCT01310114|Celgene
1163438|NCT01310114|cenplacel-L
1163439|NCT01310101|Chronic Lymphocytic Leukemia
1163440|NCT01310101|Refractory
1163441|NCT01310101|Relapse
1163442|NCT01310101|Ofatumumab
1163443|NCT01310101|Dexamethasone
1163444|NCT01310088|Childhood
1163445|NCT01310088|Child
1163446|NCT01310088|adolescent
1163447|NCT01310088|central blood pressure
1163448|NCT01310088|ambulatory blood pressure monitoring
1163449|NCT01310088|ABPM
1163450|NCT01310088|clinic blood pressure
1163451|NCT01310088|pulse wave velocity
1163452|NCT01310088|PWV
1163453|NCT01310088|Pulse cave analysis
1163454|NCT01310088|PWA
1163455|NCT01310088|heart rate variability
1163456|NCT01310088|HRV
1163457|NCT01310088|Echocardiography
1163458|NCT01310088|Urine microalbuminuria
1163459|NCT01310088|blood samples
1163460|NCT01310075|Mastectomy
1163461|NCT01310075|Bioprosthetic Mesh
1163462|NCT01310075|Breast Reconstruction
1163463|NCT01310075|Tissue Expander
1163464|NCT01310075|Alloderm
1163465|NCT01310075|Surgimend
1163466|NCT01310062|hepatocellular carcinoma
1163467|NCT01310062|microarray
1163468|NCT01310062|gene expression profiling
1163469|NCT01310062|biomarkers
1163470|NCT01310049|Exploratory study in healthy subjects
1163866|NCT01308294|IMP321
1163471|NCT01310023|Conditions and diagnoses potentially related to perinatal exposure to antiretroviral medications
1163472|NCT01309997|Imatinib
1163473|NCT01309997|Rituximab
1163474|NCT01309997|Chronic Graft-vs-Host Disease
1163475|NCT01309984|Monitored anesthesia care
1163476|NCT01309971|Assessment
1163477|NCT01309971|Questionable Caries
1163478|NCT01309958|Dental Caries
1163479|NCT01309958|Intervention
1163480|NCT01309958|Non-invasive treatment for early caries
1163481|NCT01309919|intrauterine device
1163482|NCT01309919|Mirena
1163483|NCT01309919|levonorgestrel intrauterine system
1163484|NCT01309919|postpartum contraception
1163485|NCT01309893|Contact lens
1163486|NCT01309880|Contact lens
1163487|NCT01308814|Perimenopause
1163488|NCT01308814|Menopause
1163489|NCT01308814|Depression
1163490|NCT01308814|Cardiovascular health
1163491|NCT01308801|fibromyalgia
1163492|NCT01308801|pain
1163493|NCT01308801|repetitive transcranial magnetic stimulation
1163494|NCT01308801|rehabilitation exercise
1163495|NCT01308801|quality of life
1163496|NCT01308788|glaucoma blood flow
1163497|NCT01308775|SIS.NET
1163498|NCT01308736|tobacco
1163499|NCT01308736|nicotine
1163500|NCT01308736|cigarette smoking
1163501|NCT01309854|Phase 1
1163502|NCT01309854|healthy volunteers
1163503|NCT01309854|pharmacokinetics
1163504|NCT01309854|Rheumatoid arthritis
1163505|NCT01309854|RA
1163506|NCT01309854|fostamatinib
1163507|NCT01309854|pioglitazone
1163508|NCT01309854|drug-drug interaction
1163509|NCT01309841|Non-Cancer-Related Pain, Opioid-Induced Constipation
1163510|NCT01309828|Renal Insufficiency
1163511|NCT01309828|Kidney Diseases
1163512|NCT01309828|Hypertension
1163513|NCT01309828|Drug Therapy
1163514|NCT01309815|neoplasms
1163515|NCT01309815|existentialism
1163516|NCT01309815|existential concerns
1163517|NCT01309815|Meaning making
1163518|NCT01309815|early palliative phase
1163519|NCT01309815|elderly
1163520|NCT01309802|botox
1163521|NCT01309802|raynaud's
1163522|NCT01309802|botulinum toxin
1163523|NCT01309802|botulinum toxin A
1163524|NCT01309802|raynaud's disease
1163525|NCT01309802|raynaud's syndrome
1163526|NCT01309802|raynaud's phenomenon
1163527|NCT01309802|ischemic digits
1163528|NCT01309802|ischemia
1163529|NCT01309802|botox treatment
1163530|NCT01309802|onabotulinum
1163531|NCT01309802|onabotulinum toxin
1163532|NCT01309802|onabotulinum toxin type A
1163543|NCT01309737|Xeljanz
1163544|NCT01309737|tofacitinib
1163545|NCT01309737|Jak-inhibitor
1163546|NCT01309737|oral treatment
1163547|NCT01309737|chronic
1163548|NCT01309737|severe
1163549|NCT01309737|moderate
1163550|NCT01309737|Pruritus
1163551|NCT01309737|Itch
1163552|NCT01309737|DLQI
1163553|NCT01309737|treatment
1163554|NCT01309737|safety
1163555|NCT01309737|efficacy
1163556|NCT01309737|CP-690,550
1163557|NCT01309737|Plaque Psoriasis
1163558|NCT01309737|Psoriasis Vulgaris
1163559|NCT01309724|Hypotension
1163560|NCT01309724|Fluid
1163561|NCT01309711|MRI
1163562|NCT01309711|Biomarkers
1163563|NCT01309711|Neonatal encephalopathy
1163564|NCT01309711|Therapeutic hypothermia
1163565|NCT01309698|Drug interaction
1163566|NCT01309685|Cognition
1163567|NCT01309685|Smoking
1163568|NCT01309685|Nicotine
1163569|NCT01309685|Varenicline
1163570|NCT01309685|Withdrawal
1163571|NCT01309672|adenocarcinoma of the prostate
1163572|NCT01309672|hormone-resistant prostate cancer
1163573|NCT01309672|stage IV prostate cancer
1163574|NCT01309672|recurrent prostate cancer
1163575|NCT01309659|Anemia
1163576|NCT01309659|Unexplained anemia
1163577|NCT01309659|elderly
1163578|NCT01309659|geriatric
1163579|NCT01309659|older adults
1163580|NCT01309659|UAE
1163581|NCT01309659|over 65
1163582|NCT01309659|iron
1163583|NCT01309659|pactte
1163584|NCT01309659|pactee
1163585|NCT01309659|aging
1163586|NCT01309659|aged
1163587|NCT01309659|old
1163588|NCT01309659|older
1163589|NCT01309646|Primary vaccination
1163590|NCT01309646|combination vaccine
1163591|NCT01309646|South Korea
1163592|NCT01309633|locally advanced
1163593|NCT01309633|metastatic
1163594|NCT01309620|zinc, oxidative stress, vascular indices, type 2 diabetes
1163595|NCT01309581|depression
1163596|NCT01309581|electroconvulsive therapy
1163597|NCT01309581|ketamine
1163598|NCT01309581|antidepressant
1163599|NCT01309555|Growth disorders
1163600|NCT01309555|Saizen
1163601|NCT01309555|easypod™
1163602|NCT01309555|Growth hormone
1163603|NCT01309555|Pediatric subject
1163604|NCT01309542|major depressive disorder
1163605|NCT01309542|desvenlafaxine
1163606|NCT01309542|antidepressant
1163607|NCT01309529|general thoracic surgery
1163608|NCT01309529|epidural analgesia
1163609|NCT01309529|postoperative retention of urine
1163610|NCT01309529|postoperative urinary tract infection
1163611|NCT01309529|catheter associated urinary tract infection
1163612|NCT01309516|Postnatal depression
1163613|NCT01309516|Maternal depression
1163614|NCT01309516|Psychosocial intervention
1163615|NCT01309490|high eIF4E expression
1163616|NCT01309490|solid tumor cancer
1163617|NCT01309477|Refractory Nephrotic Syndrome
1163618|NCT01309477|Tacrolimus
1163619|NCT01309451|diabetic macular edema
1163620|NCT01309451|DME
1163621|NCT01309438|Healthy
1163622|NCT01309438|Renal Insufficiency
1163623|NCT01309438|Rivaroxaban (BAY 59-7939, JNJ-39039039)
1163624|NCT01309438|Erythromycin
1163625|NCT01309438|Pharmacokinetic
1163626|NCT01309438|Pharmacodynamic
1163627|NCT01309425|tapentadol
1163628|NCT01309425|NUCYNTA
1163629|NCT01309425|CG5503
1163630|NCT01309425|R331333
1163631|NCT01309425|pharmacokinetics
1163632|NCT01309425|healthy volunteer
1163633|NCT01309412|Relapsed or refractory multiple myeloma
1163634|NCT01309412|CNTO 328
1163635|NCT01309412|siltuximab
1163636|NCT01309412|bortezomib
1163637|NCT01309412|dexamethasone
1163638|NCT01309399|bone formation rate
1163639|NCT01309399|total hip arthroplasty
1163640|NCT01309386|Tapentadol
1163641|NCT01309386|Tumor related pain
1163642|NCT01309386|Opioid
1163643|NCT01309386|Cancer related pain
1163644|NCT01309386|Morphine
1163645|NCT01309373|Schizophrenia
1163646|NCT01309373|Schizoaffective Disorder
1163647|NCT01309373|Remission
1163648|NCT01309373|Psychosocial
1163649|NCT01309373|Symtomatic
1163650|NCT01309373|Integration
1163651|NCT01309373|Schizoaffective
1163652|NCT01309373|Adherence
1163653|NCT01309360|ultrasound
1163654|NCT01309360|methaemoglobin
1163655|NCT01309360|prilocaine
1163656|NCT01309360|regional anesthesia
1163657|NCT01309360|ASA risk groups I-II
1163658|NCT01309360|adult outpatients
1163659|NCT01309360|surgical spectrum covered procedures
1163660|NCT01309360|distal forearm
1163661|NCT01309360|hand
1163662|NCT01309347|prosthetic socket, residual limb volume fluctuation
1163663|NCT01309334|MRI
1163664|NCT01309334|PET-scan
1163665|NCT01309334|multiple myeloma
1163666|NCT01309334|prognosis
1163667|NCT01309334|pharmacoeconomic analysis
1163668|NCT01309321|Perinatal
1163669|NCT01309321|Handwashing
1163670|NCT01309321|Neonatal
1163671|NCT01309321|Morbidity
1163672|NCT01309321|Mortality
1163673|NCT01309321|Primiparous
1163674|NCT01309321|Health behavior
1163675|NCT01309321|Developing countries
1163676|NCT01309321|Sepsis
1163677|NCT01309321|Omphalitis
1163678|NCT01309321|Infectious disease
1163679|NCT01309321|Bangladesh
1163680|NCT01309308|cervical length
1163681|NCT01309308|sweeping the membranes
1163682|NCT01309256|distal gastrectomy
1163683|NCT01309256|Robotic gastrectomy
1163684|NCT01309256|registry
1163685|NCT01309256|learning curve
1163686|NCT01309256|cost-effectiveness
1163687|NCT01309256|quality of life
1163688|NCT01309256|acute inflammatory reaction
1163689|NCT01309256|Robotic and laparoscopic surgery
1163690|NCT01309243|HIV
1163691|NCT01309243|HIV-1
1163692|NCT01309243|Antiretroviral Treatment-Naïve
1163693|NCT01309230|Stage III
1163694|NCT01309230|Stage IV
1163695|NCT01309230|epithelial ovarian cancer
1163696|NCT01309230|ovarian cancer
1163697|NCT01309230|Adjuvant
1163698|NCT01309230|immunotherapy
1163699|NCT01309204|open-angle glaucoma
1163700|NCT01309204|ocular hypertension
1163701|NCT01309204|OAG
1163702|NCT01309204|OHT
1163703|NCT01309191|Androgenetic Alopecia
1163704|NCT01309191|Minoxidil
1163705|NCT01309191|Microarray
1163706|NCT01309165|stroke
1163707|NCT01309165|cognition
1163708|NCT01309165|cognitive strategies
1163709|NCT01309165|motor skill acquisition
1163710|NCT01309165|participation
1163711|NCT01309152|cefazolin
1163712|NCT01309152|microdialysis
1163713|NCT01309152|morbid obesity
1163714|NCT01309152|pharmacokinetics
1163715|NCT01309126|Colorectal Cancer
1163716|NCT01309126|KRAS Wild Type
1163717|NCT01309126|Imprime PGG
1163718|NCT01309126|Cetuximab
1163719|NCT01309126|Phase 3
1163720|NCT01309126|Efficacy
1163721|NCT01309126|Safety
1163722|NCT01309126|Recurrent or Progressive KRAS Wild Type Colorectal Cancer
1163723|NCT01309087|Gene Expression
1163724|NCT01309087|Lung Cancer
1163725|NCT01309087|Smoking
1163726|NCT01309074|Anxiety
1163727|NCT01309074|Epilepsy
1163728|NCT01309048|bone metastasis
1163729|NCT01309048|Patients with bone metastasis
1163730|NCT01309035|Prothesis fixation
1163731|NCT01309035|Bloodlessness
1163732|NCT01309022|Diabetes Mellitus, Type 1
1163733|NCT01309022|T1D
1163734|NCT01309022|T1DM
1163735|NCT01309022|Islets of Langerhans Transplantation
1163736|NCT01309022|Pancreatic Islets Transplantation
1163737|NCT01309022|Islet Transplant
1163738|NCT01309022|Tacrolimus
1163739|NCT01309022|Sirolimus
1163740|NCT01309022|Mycophenolate mofetil
1163741|NCT01309022|Mycophenolic acid
1163742|NCT01309009|Infantile Colic
1163743|NCT01309009|Tachykinin antagonist
1163744|NCT01309009|Nepadutant
1163745|NCT01308996|alveolar ridge augmentation
1163746|NCT01308996|edentulous ridge
1163747|NCT01308996|alveolar ridge defect
1163748|NCT01308996|posterior mandible defect
1163749|NCT01308996|bone morphogenic protein
1163750|NCT01308996|osseointegration
1163751|NCT01308983|Prehypertension
1163752|NCT01308983|Flow mediated dilation
1163753|NCT01308983|Pulse wave velocity
1163754|NCT01308983|carotid compliance
1163755|NCT01308983|Prehypertension and amiloride
1163756|NCT01308944|invasive epithelial ovarian cancer,
1163757|NCT01308944|primary peritoneal carcinoma,
1163758|NCT01308944|fallopian tube cancer
1163759|NCT01308931|Contraception
1163760|NCT01308931|IUD
1163761|NCT01308931|Essure
1163762|NCT01308931|Tubal ligation
1163763|NCT01308931|Anti-Mullerian hormone
1163764|NCT01308918|Thoracic surgery
1163765|NCT01308918|Double lumen tube intubation
1163766|NCT01308918|GlideScope
1163767|NCT01308918|Stylet
1163768|NCT01308905|Neuroblastoma
1163769|NCT01308879|Contextualized Feedback System (CFS)
1163770|NCT01308879|Mental health outcomes
1163771|NCT01308879|Quality improvement
1163772|NCT01308879|Feedback
1163773|NCT01308879|Clinical trial
1163774|NCT01308866|cardiovascular diseases
1163775|NCT01308866|patient education
1163776|NCT01308866|primary health care
1163777|NCT01308866|consumer participation
1163778|NCT01308866|decision aids
1163779|NCT01308840|Unresectable
1163780|NCT01308840|metastatic
1163781|NCT01308840|biliary tract
1163782|NCT01308840|gallbladder cancer
1163783|NCT01308827|Children 28 days to 36 months of age with suspected pneumococcal disease
1163784|NCT01308710|endothelial function
1163785|NCT01308710|lipids
1163786|NCT01308710|pediatrics
1163787|NCT01308697|Flail
1163788|NCT01308697|Chest
1163789|NCT01308671|coronary artery disease
1163790|NCT01308671|varenicline
1163791|NCT01308671|clopidogrel
1163792|NCT01308658|TMC114-C176
1163793|NCT01308658|TMC114
1163794|NCT01308658|DRV
1163795|NCT01308658|HIV
1163796|NCT01308658|Healthy volunteers
1163797|NCT01308645|SBP Injection
1163798|NCT01308645|HCC
1163799|NCT01308632|glioblastoma
1163800|NCT01308632|temozolamide
1163801|NCT01308632|radiotherapy
1163802|NCT01308632|TMZ
1163803|NCT01308632|irinotecan
1163804|NCT01308606|TMC435-TiDP16-C116
1163805|NCT01308606|TMC435-C116
1163806|NCT01308606|TMC435
1163807|NCT01308606|HCV
1163808|NCT01308606|Hepatitis C
1163809|NCT01308606|Hep C
1163810|NCT01308606|healthy volunteers
1163811|NCT01308554|TAP block
1163812|NCT01308554|Pain
1163813|NCT01308554|Obesity
1163814|NCT01308554|Surgery
1163815|NCT01308554|Laparoscopic gastric bypass
1163816|NCT01308528|Venous Thromboembolism
1163822|NCT01308502|laryngopharyngeal reflux
1163823|NCT01308502|LPR
1163824|NCT01308502|GERD
1163825|NCT01308502|gastroesophageal reflux
1163826|NCT01308502|nasopharyngeal probe
1163827|NCT01308463|elbow long-term Survivorship
1163828|NCT01308463|Study participant Discovery Elbow Multi-center Study who
1163829|NCT01308463|consent for the Discovery Elbow Long-term SurvivorshipStudy
1163830|NCT01308450|ADHD Normative Control Group
1163831|NCT01308424|Herpes Labialis
1163832|NCT01308424|Herpes Simplex
1163833|NCT01308424|Herpes
1163834|NCT01308411|Asthma
1163835|NCT01308411|Inhaled Corticosteroids
1163836|NCT01308411|Exhaled Nitric oxide
1163837|NCT01308411|Airways inflammation
1163838|NCT01308411|Step down
1163839|NCT01308411|Predicting response
1163840|NCT01308372|cardiovascular risk
1163841|NCT01308372|France
1163842|NCT01308372|General practice
1163843|NCT01308372|Primary prevention
1163844|NCT01308372|Non treated patients
1163845|NCT01308359|fetal movement
1163846|NCT01308346|Bioabsorbable
1163847|NCT01308346|Coronary Stent
1163848|NCT01308346|Everolimus
1163849|NCT01308346|drug eluting stents
1163850|NCT01308346|stents
1163851|NCT01308346|angioplasty
1163852|NCT01308346|coronary artery disease
1163853|NCT01308346|total coronary occlusion
1163854|NCT01308346|coronary artery restenosis
1163855|NCT01308346|stent thrombosis
1163856|NCT01308346|myocardial ischemia
1163857|NCT01308346|coronary artery stenosis
1163858|NCT01308307|Non-cycloplegic photorefraction
1163859|NCT01308307|cycloplegic refraction,
1163860|NCT01308307|Amblyopia
1163861|NCT01308294|Melanoma
1163862|NCT01308294|Stage II-IV
1163863|NCT01308294|Immunotherapy
1163864|NCT01308294|Vaccination
1163865|NCT01308294|HLA class I and II tumor-specific peptides
1163867|NCT01308294|Montanide ISA-51 VG
1163868|NCT01308268|STH
1163869|NCT01308268|Soil-transmitted Helminthiasis
1163870|NCT01308268|mass drug administration
1163871|NCT01308229|Bifurcation
1163872|NCT01308229|Dedicated
1163873|NCT01308229|Drug-eluting stent
1163874|NCT01308229|Angioplasty
1163875|NCT01308229|Coronary artery disease
1163876|NCT01308229|Coronary artery stenosis
1163877|NCT01308216|Transcranial Laser Therapy
1163878|NCT01308216|Hemiplegia
1163879|NCT01308216|Rehabilitation
1163880|NCT01308216|Physiotherapy
1163881|NCT01308216|Ischemic stroke
1163882|NCT01308190|Preoperative chemoradiotherapy
1163883|NCT01308190|Transanal endoscopic microsurgery
1163884|NCT01308190|Rectal Cancer
1163885|NCT01308190|T2-T3s-N0
1163886|NCT01308164|Type 1 diabetes
1163887|NCT01308164|Insulin Pump Therapy
1163888|NCT01308151|CBT, self harm, depression, cultural adaptation, Pakistan
1163889|NCT01308138|Physical Activity
1163890|NCT01308138|pathology
1163891|NCT01308138|Physical Deconditioning
1163892|NCT01308125|Stable Angina
1163893|NCT01308125|Coronary artery disease
1163894|NCT01308125|PCI
1163895|NCT01308125|Reperfusion
1163896|NCT01308125|Myocardial Infarction
1163897|NCT01308125|collateral flow pressure index
1163898|NCT01308125|CFpI
1163899|NCT01308125|pressure controlled intermittent coronary sinus occlusion
1163900|NCT01308125|PICSO
1163901|NCT01308112|Iron
1163902|NCT01308112|Plasmodium
1163903|NCT01308112|Malaria
1163904|NCT01308112|Pregnancy
1163905|NCT01308112|Kenya
1163906|NCT01308099|POTS
1163907|NCT01308099|Vascular Endothelial Function
1163908|NCT01308086|Cancer
1163909|NCT01308086|colorectal cancer
1163910|NCT01308086|adjuvant chemotherapy
1163911|NCT01308086|capecitabine
1163912|NCT01308086|oxaliplatin
1163913|NCT01308086|5 fluorouracil
1163914|NCT01308060|Canthal lines
1163915|NCT01308034|non GIST sarcomas
1163916|NCT01308034|sunitinib
1163917|NCT01308034|radiotherapy
1163918|NCT01308034|dose escalation
1163919|NCT01308021|Rhinoconjunctivitis
1163920|NCT01308021|Allergy
1163921|NCT01308021|Grass pollen
1163922|NCT01308021|Hypersensitivity
1163923|NCT01308021|Immune system disorder
1163924|NCT01308008|Type 2 Diabetes Mellitus
1163925|NCT01308008|Mobility Limitation
1163926|NCT01307995|GDM
1163927|NCT01307995|incretin effect
1163928|NCT01307995|gestation
1163929|NCT01307995|reversibility
1163930|NCT01307982|Gastroesophageal Reflux
1163931|NCT01307982|Nervous System Diseases
1163932|NCT01307982|Fundoplication
1163933|NCT01307982|Enteral Nutrition
1163934|NCT01307969|liposomes
1163935|NCT01307969|ropivacaine
1163936|NCT01307969|dental anesthesia
1163937|NCT01307969|dentistry
1163938|NCT01307943|MBSR
1163939|NCT01307943|adolescent
1163940|NCT01307943|mental health
1163941|NCT01307930|Echinocandin
1163942|NCT01307930|Obesity
1163943|NCT01307930|Pharmacokinetics
1163944|NCT01307930|Pharmacodynamics
1163945|NCT01307930|Fungal infection
1163946|NCT01307917|diabetes mellitus
1163947|NCT01307917|diabetic nephropathy
1163948|NCT01307917|vascular endothelial dysfunction
1163949|NCT01307917|flavonoids
1163950|NCT01307917|flow-mediated dilation
1163951|NCT01307904|Glycemic index
1163952|NCT01307904|Dates
1163953|NCT01307904|Blood glucose
1163954|NCT01307891|Triple negative breast cancer (TNBC)
1163955|NCT01307891|Metastatic breast cancer
1163956|NCT01307891|Tigatuzumab (CS-1008)
1163957|NCT01307891|Abraxane (ABI-007)
1163958|NCT01307891|HER-2-neu negative
1163959|NCT01307891|ER negative, PR negative
1163960|NCT01307865|midface volume loss
1163961|NCT01307865|aging of midface
1163962|NCT01307865|sculptra
1163963|NCT01307865|sculptra aesthetic
1163964|NCT01307865|poly-L-lactic acid
1163965|NCT01307852|Fiber optic radiation detectors
1163966|NCT01307852|Enhanced endorectal balloon
1163967|NCT01307852|Radiation treatment
1163968|NCT01307852|Radiotherapy
1163969|NCT01307852|External beam radiation
1163970|NCT01307852|Dosimetry
1163971|NCT01307839|labor
1163972|NCT01307839|epidural
1163973|NCT01307826|massage
1163974|NCT01307826|shoulder
1163975|NCT01307826|pain
1163976|NCT01307826|range of motion
1163977|NCT01307826|restricted range of motion
1163978|NCT01307813|colon distal
1163979|NCT01307813|surgical resection
1163980|NCT01307787|exercise
1163981|NCT01307787|education
1163982|NCT01307787|self-management
1163983|NCT01307787|rehabilitation
1163984|NCT01307774|parental acceptability of HPV vaccine
1164103|NCT01307332|Alemtuzumab
1163985|NCT01307761|fine needle aspiration; predictor; ultrasonography; thyroid cancer
1163986|NCT01307748|aromatherapy
1163987|NCT01307748|stress
1163988|NCT01307748|older adults
1163989|NCT01307748|stress-related change
1163990|NCT01307735|myocarditis
1163991|NCT01307735|edema
1163992|NCT01307735|hyperemia
1163993|NCT01307735|fibrosis
1163994|NCT01307735|necrosis
1163995|NCT01307735|cardiovascular magnetic resonance imaging
1163996|NCT01307722|left atrial distensibility
1163997|NCT01307722|advanced chronic heart failure
1163998|NCT01307722|decompensation
1163999|NCT01307722|rehospitalization
1164000|NCT01307722|prognosis
1164001|NCT01307722|all-cause mortality
1164002|NCT01307722|heart failure with hospitalization
1164003|NCT01307722|the duration of hospitalization
1164004|NCT01307696|Umbilical Hernia Repair
1164005|NCT01307696|PVP Mesh
1164006|NCT01307683|Pregnancy
1164007|NCT01307683|Overweight
1164008|NCT01307683|Obese
1164009|NCT01307683|Stress
1164010|NCT01307683|Mindfulness
1164011|NCT01307657|clopidogrel
1164012|NCT01307657|platelet
1164013|NCT01307657|platelet function test
1164014|NCT01307657|healthy
1164015|NCT01307657|Platelet function tests
1164016|NCT01307644|Overweight
1164017|NCT01307644|Obesity
1164018|NCT01307644|Rural Health
1164019|NCT01307644|Weight Loss
1164020|NCT01307644|Weight Maintenance
1164021|NCT01307644|Rural Middle Aged and Older Women
1164022|NCT01307644|Web Intervention Weight Loss
1164023|NCT01307644|Class I, II, & III obese (BMI 28 to 45)
1164024|NCT01307605|contiguous stage II grade 1 follicular lymphoma
1164025|NCT01307605|contiguous stage II grade 2 follicular lymphoma
1164026|NCT01307605|contiguous stage II grade 3 follicular lymphoma
1164027|NCT01307605|noncontiguous stage II grade 1 follicular lymphoma
1164028|NCT01307605|noncontiguous stage II grade 2 follicular lymphoma
1164029|NCT01307605|noncontiguous stage II grade 3 follicular lymphoma
1164030|NCT01307605|stage III grade 1 follicular lymphoma
1164031|NCT01307605|stage III grade 2 follicular lymphoma
1164032|NCT01307605|stage III grade 3 follicular lymphoma
1164033|NCT01307605|stage IV grade 1 follicular lymphoma
1164034|NCT01307605|stage IV grade 2 follicular lymphoma
1164035|NCT01307605|stage IV grade 3 follicular lymphoma
1164036|NCT01307592|peripheral T-cell lymphoma
1164037|NCT01307592|recurrent adult Burkitt lymphoma
1164038|NCT01307592|recurrent adult diffuse large cell lymphoma
1164039|NCT01307592|recurrent adult lymphoblastic lymphoma
1164040|NCT01307592|recurrent grade 3 follicular lymphoma
1164041|NCT01307514|DIABETES
1164042|NCT01307514|PHARMACOKINETICS
1164043|NCT01307514|PHARMACODYNAMICS
1164044|NCT01307514|INSULIN
1164045|NCT01307501|Cryoablation
1164046|NCT01307501|Cryotherapy
1164047|NCT01307501|Cryosurgery
1164048|NCT01307501|Metastatic
1164049|NCT01307501|Lung
1164050|NCT01307501|Pleura
1164051|NCT01307501|Tumors
1164052|NCT01307488|HIV
1164053|NCT01307488|AIDS
1164054|NCT01307488|Atazanavir
1164055|NCT01307488|Simplification
1164056|NCT01307475|Chronic Post-Traumatic Stress Disorder
1164057|NCT01307475|Delayed Onset Post-Traumatic Stress Disorder
1164058|NCT01307475|Post-Traumatic Neuroses
1164059|NCT01307475|Posttraumatic Neuroses
1164060|NCT01307475|Post-Traumatic Stress Disorders
1164061|NCT01307475|Posttraumatic Stress Disorders
1164062|NCT01307475|PTSD
1164063|NCT01307475|Post TraumaticStress Disorder
1164064|NCT01307475|Endogenous Depression
1164065|NCT01307475|Neurotic Depression
1164066|NCT01307475|Depressive Syndrome
1164067|NCT01307475|Melancholia
1164068|NCT01307475|Depressive Neurosis
1164069|NCT01307475|Unipolar Depression
1164070|NCT01307475|Depressive Symptoms
1164071|NCT01307475|Emotional Depression
1164072|NCT01307475|Quality of Life
1164073|NCT01307449|pneumococcal vaccine
1164074|NCT01307449|immune responses
1164075|NCT01307436|Hepatitis A Vaccine
1164076|NCT01307436|Combined Vaccines
1164077|NCT01307436|DTP Vaccine
1164078|NCT01307436|MMR Vaccine
1164079|NCT01307423|psoriasis
1164080|NCT01307423|Arthritis
1164081|NCT01307423|Psoriatic Arthritis
1164082|NCT01307423|inflammation
1164083|NCT01307423|skin condition
1164084|NCT01307423|inflammatory cells
1164085|NCT01307423|apremilast
1164086|NCT01307423|CC-10004
1164087|NCT01307423|phosphodiesterase type 4
1164088|NCT01307410|Patients with type 2 diabetes and participated in 3B Study
1164089|NCT01307384|Total hip Arthroplasty
1164090|NCT01307384|Total Hip Replacement (THR)
1164091|NCT01307384|Primary Hip Arthroplasty
1164092|NCT01307384|THA
1164093|NCT01307384|THR
1164094|NCT01307371|Bone Marrow Mononuclear cells;
1164095|NCT01307371|Diabetes;
1164096|NCT01307371|ST-segment Elevation Myocardial Infarction;
1164097|NCT01307371|Percutaneous Coronary Intervention;
1164098|NCT01307371|Left Ventricular Function
1164099|NCT01307332|Multiple Sclerosis
1164100|NCT01307332|MS
1164101|NCT01307332|Relapsing Remitting Multiple Sclerosis
1164102|NCT01307332|RRMS
1164104|NCT01307332|Demyelination
1164105|NCT01307332|Remyelination
1164106|NCT01307332|Tolerogenic
1164107|NCT01307332|T cells
1164108|NCT01307332|Demyelinating Autoimmune Diseases, CNS
1164109|NCT01307332|Autoimmune Diseases of the Nervous System
1164110|NCT01307332|Nervous System Diseases
1164111|NCT01307332|Demyelinating Diseases
1164112|NCT01307332|Autoimmune Diseases
1164113|NCT01307332|Immune System Diseases
1164114|NCT01307319|Allergies
1164115|NCT01307319|Hayfever
1164116|NCT01307306|Thermal injury
1164117|NCT01307306|Chemical Burn
1164118|NCT01307306|Flame Burn
1164119|NCT01307280|Behavioral Weight Management Intervention
1164120|NCT01307280|weight loss
1164121|NCT01307280|cost-effective analysis
1164122|NCT01307280|high blood pressure
1164123|NCT01307280|randomized clinical trial
1164124|NCT01307280|behavioral interventions
1164125|NCT01307280|physical activity
1164126|NCT01307280|dietary change
1164127|NCT01307280|obesity
1164128|NCT01307267|Phase 1
1164129|NCT01307267|Non-Hodgkin's Lymphoma
1164130|NCT01307267|Advanced malignancies
1164131|NCT01307241|Acute lymphoblastic leukemia
1164132|NCT01307241|prognostic factor
1164133|NCT01307241|pharmacogenetics.
1164134|NCT01307228|Knowledge translation
1164135|NCT01307228|Policymakers
1164136|NCT01307228|Health systems
1164137|NCT01307215|TAP block
1164138|NCT01307215|incision pain
1164139|NCT01307215|total hysterectomy
1164140|NCT01307202|knee
1164141|NCT01307202|arthroplasty
1164142|NCT01307202|postoperative pain
1164143|NCT01307202|gabapentin
1164144|NCT01307189|Chronic Obstructive Pulmonary Disease (COPD)
1164145|NCT01307189|Exercise
1164146|NCT01307189|Endurance shuttle walking test
1164147|NCT01307189|Bronchodilation
1164148|NCT01307189|Tiotropium
1164149|NCT01307176|ataxia
1164150|NCT01307176|exercise
1164151|NCT01307176|training
1164152|NCT01307176|cerebellar
1164153|NCT01307176|rehabilitation
1164154|NCT01307163|saliva
1164155|NCT01307163|liver transplantation
1164156|NCT01307163|children
1164157|NCT01307163|In this prospective study 60 subjects will be examined
1164158|NCT01307163|children and adolescents
1164159|NCT01307163|after a successful liver transplantation
1164160|NCT01307163|informed consent forms signed be the examinees parents
1164161|NCT01307150|Atopic Dermatitis
1164162|NCT01307150|Dead Sea
1164163|NCT01307150|Climatotherapy
1164164|NCT01307150|SCORAD
1164165|NCT01307124|safety and efficacy
1164166|NCT01307124|low dose LPV/r
1164167|NCT01307124|standard dose LPV/r
1164168|NCT01307124|HIV infected children
1164169|NCT01307111|Misoprostol
1164170|NCT01307111|IUD insertion
1164171|NCT01307111|Nulliparous Women
1164172|NCT01307111|Contraception
1164173|NCT01307111|Family Planning
1164174|NCT01307111|IUD insertion in nulliparous women
1164175|NCT01307098|Enzyme Replacement Therapy (ERT)
1164176|NCT01307098|Lysosomal Storage Disease
1164177|NCT01307098|Late Onset Lysosomal Acid Lipase (LAL) Deficiency
1164178|NCT01307098|Acid cholesteryl ester hydrolase deficiency, type 2
1164179|NCT01307098|Acid lipase disease
1164180|NCT01307098|Cholesterol ester hydrolase deficiency
1164181|NCT01307098|LAL Deficiency
1164182|NCT01307098|LIPA Deficiency
1164183|NCT01307098|Wolman disease
1164184|NCT01307085|remote ischemic preconditioning
1164185|NCT01307085|lung injury
1164186|NCT01307085|pulmonary resection
1164187|NCT01307072|periodic examinations, compliance
1164188|NCT01307059|Growth disorders
1164189|NCT01307059|Saizen
1164190|NCT01307059|Easypod
1164191|NCT01307059|Growth hormone
1164192|NCT01307059|Pediatric subject
1164193|NCT01307046|Essential hypertension
1164194|NCT01307046|Uncontrolled hypertension
1164195|NCT01307046|Antihypertensive agents
1164196|NCT01307046|Blood pressure
1164197|NCT01307033|Essential hypertension
1164198|NCT01307033|Uncontrolled hypertension
1164199|NCT01307033|Antihypertensive agents
1164200|NCT01307033|Blood pressure
1164201|NCT01307020|Moderate to severe pain
1164202|NCT01307020|Postoperative pain
1164203|NCT01307020|Analgesics
1164204|NCT01307020|Dexketoprofen
1164205|NCT01307020|Tramadol
1164206|NCT01306994|Exercise Test
1164207|NCT01306994|Bicycle Ergometry Test
1164208|NCT01306994|Stress Test
1164209|NCT01306981|Diabetes Mellitus
1164210|NCT01306981|Diabetes Complications
1164211|NCT01306981|Retinal Diseases
1164212|NCT01306981|Endothelial Growth Factors
1164213|NCT01306981|Monoclonal Antibodies
1164214|NCT01306981|Ranibizumab
1164215|NCT01306981|Vitrectomy
1164216|NCT01306981|Vitreoretinal Surgery
1164217|NCT01306968|mild tramatic brain injury
1164218|NCT01306968|mTBI
1164219|NCT01306968|hyperbaric oxygen
1164220|NCT01306968|post concussive symptoms
1164221|NCT01306968|active duty military
1164222|NCT01306968|veterans
1164223|NCT01306955|retinal vasculitis
1164224|NCT01306955|posterior uveitis
1164225|NCT01306955|methylprednisolone
1164226|NCT01306942|HER2+ metastatic breast cancer
1164227|NCT01306942|first line treatment
1164228|NCT01306929|Huntington Disease.
1164229|NCT01306916|thyroid disease, hyperthyroidism
1164230|NCT01306903|Minimizing Cardiopulmonary Bypass MECC damage organ failure
1164231|NCT01306877|hemorrhoid
1164232|NCT01306877|hemorrhoid stapler
1164233|NCT01306864|Endoscopic Hemostasis
1164234|NCT01306864|Peptic Ulcer
1164235|NCT01306864|Recurrent Bleeding
1164236|NCT01306864|Injection Therapy
1164237|NCT01306864|Thermal Probe
1164238|NCT01306851|fibrin glue
1164239|NCT01306851|anastomotic leak
1164240|NCT01306851|gastrointestinal high risk anastomosis
1164241|NCT01306838|Short bowel syndrome
1164242|NCT01306838|Necrotizing enterocolitis
1164243|NCT01306838|Small intestine perforation
1164244|NCT01306838|Enterostomy
1164245|NCT01306838|Intralipid
1164246|NCT01306838|Microlipid
1164247|NCT01306838|Fish oil
1164248|NCT01306825|Daptomycin
1164249|NCT01306825|Bone disease,infectious
1164250|NCT01306825|Osteomyelitis
1164251|NCT01306825|Diabetic foot
1164252|NCT01306825|Staphylococcus aureus
1164253|NCT01306812|Adolescent
1164254|NCT01306812|Alcohol
1164255|NCT01306812|Criminology
1164256|NCT01306812|Genes
1164257|NCT01306812|Environment
1164258|NCT01306812|Mono amine Oxidase
1164259|NCT01306812|Serotonin
1164260|NCT01306812|Social Support
1164261|NCT01306799|Barrett's Esophagus
1164262|NCT01306799|Erosive Esophagitis
1164263|NCT01306799|Proton Pump Inhibitor (PPI)
1164264|NCT01306799|Bone
1164265|NCT01306799|Bone Density
1164266|NCT01306799|GERD
1164267|NCT01306799|ulcer prophylaxis
1164268|NCT01306773|Influenza A
1164269|NCT01306773|convalescent plasma
1164270|NCT01306773|death
1164271|NCT01306760|depression
1164272|NCT01306760|electroconvulsive therapy
1164273|NCT01306760|ketamine
1164274|NCT01306747|Chronic pain
1164275|NCT01306747|Stanford chronic pain self-management programme
1164276|NCT01306747|Patient education
1164277|NCT01306734|Extracorporeal circulation
1164278|NCT01306734|Deep Hypothermic Circulatory Arrest
1164279|NCT01306734|aortic aneurism
1164280|NCT01306734|neurological injury
1164281|NCT01306734|inflammation
1164282|NCT01306734|coagulation
1164283|NCT01306708|Adhesive Capsulitis
1164284|NCT01306708|Shoulder
1164285|NCT01306708|SPADI
1164286|NCT01306695|Dementia
1164287|NCT01306695|Depressive symptoms
1164288|NCT01306695|Caregiver Burden
1164289|NCT01306695|Hispanic
1164290|NCT01306695|Latino
1164291|NCT01306695|Intervention
1164292|NCT01306695|Geriatric Depression Scale
1164293|NCT01306695|Zarit Caregiver Burden Scale
1164294|NCT01306656|Endocrinology
1164295|NCT01306656|Metabolic Bone Disease
1164296|NCT01306656|Primary Hyperparathyroidism
1164297|NCT01306656|PHPT
1164298|NCT01306656|Vitamin D Deficiency
1164299|NCT01306656|Bone Mineral Density
1164300|NCT01306656|Hyper-calcemia
1164301|NCT01306643|Indolent Non-Hodgkin's Lymphoma
1164302|NCT01306643|Non-Hodgkin Lymphoma
1164303|NCT01306643|iNHL
1164304|NCT01306643|NHL
1164305|NCT01306643|CAL-101
1164306|NCT01306643|PI3K
1164307|NCT01306643|Phosphatidylinositol 3-kinase
1164308|NCT01306643|Follicular Lymphoma (FL)
1164309|NCT01306643|Small Lymphocytic Lymphoma (SLL)
1164310|NCT01306643|Marginal Zone Lymphoma (MZL)
1164311|NCT01306630|AV-951
1164312|NCT01306630|tivozanib
1164313|NCT01306630|capecitabine (Xeloda®)
1164314|NCT01306604|Genetic Diseases
1164315|NCT01306604|Lipidoses
1164316|NCT01306604|Lipid Metabolism
1164317|NCT01306604|Lysosomal Storage Diseases
1164318|NCT01306604|Metabolic Diseases
1164319|NCT01306604|Lipid Metabolism Disorders
1164320|NCT01306591|neovascular age-related macular degeneration
1164321|NCT01306591|Bevacizumab
1164322|NCT01306591|Multicenter Randomized Study
1164323|NCT01306578|Guillain Barre syndrome
1164324|NCT01306578|IVIG
1164325|NCT01306578|Plasma exchange
1164326|NCT01306565|Unstable angina
1164327|NCT01306565|NSTMI
1164328|NCT01306565|Statin
1164329|NCT01306565|Atorvastatin
1164330|NCT01306552|Tobacco use
1164331|NCT01306552|Adolescents
1164332|NCT01306552|Primary prevention
1164333|NCT01306552|Program effectiveness
1164334|NCT01306552|Parental component
1164335|NCT01306539|deep brain stimulation
1164336|NCT01306539|subthalamic nucleus
1164337|NCT01306526|Thin-cap fibroatheroma
1164338|NCT01306526|Vulnerable plaque
1164339|NCT01306526|Coronary artery disease
1164340|NCT01306526|Obstructive sleep apnea
1164341|NCT01306526|Intravascular Ultrasound
1164342|NCT01306513|emphysema
1164343|NCT01306513|lung volume reduction surgery
1164344|NCT01306513|mesenchymal stromal cells
1164345|NCT01306500|Gastric lavage
1164346|NCT01306500|Neonate
1164347|NCT01306500|Meconium stained amniotic fluid
1164348|NCT01306500|Feeding problems
1164349|NCT01306487|macular hole
1164350|NCT01306474|CD4/CD25 Tr cell,TNF,IFN-γ,IL-2
1164351|NCT01306448|constipation
1164352|NCT01306448|gastro
1164353|NCT01306448|vibrating capsule
1164354|NCT01306448|safety
1164355|NCT01306435|Osteoarthritis
1164356|NCT01306435|Low Power Laser Therapy
1164357|NCT01306435|Exercise
1164358|NCT01306435|Knee
1164359|NCT01306422|hoodia gordonii
1164360|NCT01306422|energy intake
1164361|NCT01306422|food intake
1164362|NCT01306422|efficacy
1164363|NCT01306422|body weight
1164364|NCT01306422|functional food
1164365|NCT01306422|plant extract
1164366|NCT01306422|safety
1164367|NCT01306422|steroid glycosides
1164368|NCT01306422|tolerability
1164369|NCT01306409|anemia
1164370|NCT01306409|kidney disease
1164371|NCT01306396|NAFLD
1164372|NCT01306396|metabolic syndrome
1164373|NCT01306396|children
1164374|NCT01306396|fructose
1164375|NCT01306383|SODIS
1164376|NCT01306383|waterborne
1164377|NCT01306383|Disease
1164378|NCT01306383|Diarrhoea
1164379|NCT01306383|dysentery
1164380|NCT01306370|primary knee arthroplasty
1164381|NCT01306370|fibrin glue
1164382|NCT01306370|tranexamic acid
1164383|NCT01306370|topic
1164384|NCT01306357|Turner's syndrome
1164385|NCT01306357|somatropin
1164386|NCT01306357|human growth hormone deficiency
1164387|NCT01306344|Qualitative Research
1164388|NCT01306344|Interview, Psychological
1164389|NCT01306344|Patients
1164390|NCT01306344|Nurses
1164391|NCT01306344|Physicians
1164392|NCT01306305|Influenza
1164393|NCT01306305|Virus
1164394|NCT01306305|Vaccination
1164395|NCT01306305|Immunisation
1164396|NCT01306292|Pulmonary hypertension
1164397|NCT01306292|Right heart Catheterization
1164398|NCT01306279|Cystic Fibrosis
1164399|NCT01306279|Infection
1164400|NCT01306279|Pulmonary exacerbation
1164401|NCT01306279|Hypermutators
1164402|NCT01306279|Bacterial diversity
1164403|NCT01306279|Quorum sensing
1164404|NCT01306266|active duty
1164405|NCT01306266|blast induced
1164406|NCT01306266|headache
1164407|NCT01306253|Influenza
1164408|NCT01306253|Virus
1164409|NCT01306253|Vaccination
1164410|NCT01306253|Immunisation
1164411|NCT01306240|Infant newborn
1164412|NCT01306240|Infant preterm
1164413|NCT01306240|Acute respiratory distress syndrome
1164414|NCT01306240|surfactant
1164415|NCT01306240|Hyaline Membrane disease
1164416|NCT01306240|Newborn acute respiratory distress syndrome (ARDS)
1164417|NCT01306227|Infant, newborn
1164418|NCT01306227|Infant, preterm
1164419|NCT01306227|Thyroid
1164420|NCT01306227|Outcome
1164421|NCT01306227|Newborns less than 32 weeks of gestation
1164422|NCT01306227|TSH < 20 mIU/L and a FT4 < 0.80 ng/dL
1164423|NCT01306201|Hospital Setting
1164424|NCT01306188|metastatic cancer
1164425|NCT01306188|lymphopenia
1164426|NCT01306188|T cell receptor diversity
1164427|NCT01306149|biochemical parameters
1164428|NCT01306149|mineral metabolism
1164429|NCT01306149|protein-bound uremic retention solutes
1164430|NCT01306149|incident PD patients
1164431|NCT01306136|Posttraumatic stress disorder
1164432|NCT01306136|Prolonged exposure
1164433|NCT01306136|Cognitive behavior therapy
1164434|NCT01306123|bioavailability
1164435|NCT01306123|pharmacokinetics
1164436|NCT01306123|cyanocobalamin
1164437|NCT01306123|intranasal
1164438|NCT01306123|intramuscular
1164439|NCT01306110|Liver fibrosis
1164440|NCT01306110|diabetes
1164441|NCT01306110|Fibroscan
1164442|NCT01306110|Fibrotest
1164443|NCT01306110|noninvasive fibrosis biomarkers
1164444|NCT01306097|Zinc Supplement
1164445|NCT01306097|Diarrhea
1164446|NCT01306097|Sever Diarrhea
1164447|NCT01306084|Respiratory Infections
1164448|NCT01306084|Norovirus
1164449|NCT01306084|Adenovirus
1164450|NCT01306084|Viral Infection
1164451|NCT01306084|Respiratory Viruses
1164452|NCT01306071|Cirrhosis
1164453|NCT01306071|Natural History
1164454|NCT01306071|Hepatitis B
1164455|NCT01306058|Hepatocellular Carcinoma
1164456|NCT01306058|TRC105
1164457|NCT01306058|Sorafenib
1164458|NCT01306058|Liver Cancer
1164459|NCT01306058|Monoclonal Antibody
1164469|NCT01306032|PARP Inhibitor
1164470|NCT01306032|BRCA Mutations
1164471|NCT01306032|DNA Damage Repair
1164472|NCT01306032|Pharmacodynamics
1164473|NCT01306032|Metronomic Cyclophosphamide
1164474|NCT01306032|Ovarian Cancer
1164475|NCT01306032|Breast Cancer
1164476|NCT01306032|Fallopian Tube Cancer
1164477|NCT01306032|Peritoneal Cancer
1164605|NCT01305564|Vena cava filter
1164478|NCT01306019|X-Linked Severe Combined Immunodeficiency (XSCID)
1164479|NCT01306019|Gene Transfer
1164480|NCT01306019|Peripheral Blood Stem Cells
1164481|NCT01306019|Common Gamma Chain (GC), Immune Reconstitution
1164482|NCT01306019|Immune Reconstitution
1164483|NCT01306019|X-Linked Severe Combined Immunodeficiency
1164484|NCT01306019|SCID
1164485|NCT01306006|Mortality
1164486|NCT01306006|Vaccines
1164487|NCT01305954|Breast
1164488|NCT01305954|Cancer
1164489|NCT01305954|Breast Cancer
1164490|NCT01305954|New Diagnosis
1164491|NCT01305954|Treatment
1164492|NCT01305954|Chemotherapy
1164493|NCT01305954|Blood
1164494|NCT01305954|Blood Draw
1164495|NCT01305954|Lab Draw
1164496|NCT01305954|Gene
1164497|NCT01305954|Gene Therapy
1164498|NCT01305954|Geriatric
1164499|NCT01305954|Oncology
1164500|NCT01305954|Muss
1164501|NCT01305954|UNC
1164502|NCT01305954|North Carolina Cancer Hospital
1164503|NCT01305954|Initial Treatment
1164504|NCT01305954|CBC
1164514|NCT01305915|single-session group
1164515|NCT01305915|psychoeducational intervention
1164516|NCT01305889|Depression
1164517|NCT01305889|Cerebral perfusion
1164518|NCT01305889|Brain derived neurotropic factor
1164519|NCT01305889|Problem Solving Therapy
1164520|NCT01305889|Sertraline
1164521|NCT01305876|yoga
1164522|NCT01305876|emotional behavioral disorder
1164523|NCT01305876|intervention
1164524|NCT01305876|school
1164525|NCT01305876|meditation
1164526|NCT01305876|focus: yoga intervention in students with emotional behavioral disorders in an urban school
1164527|NCT01305863|Peripheral Vascular Disease (PVD)
1164528|NCT01305850|Aliskiren
1164529|NCT01305850|Losartan
1164530|NCT01305850|Peritoneal membrane dysfunction
1164531|NCT01305837|multiple sclerosis
1164532|NCT01305837|methylprednisolone
1164533|NCT01305837|osteopontin
1164534|NCT01305837|inflammation
1164535|NCT01305837|demyelinating
1164536|NCT01305824|arteriovenous fistula
1164537|NCT01305824|AVF
1164538|NCT01305824|hemodialysis
1164539|NCT01305824|vascular access
1164540|NCT01305824|dialysis
1164541|NCT01305824|fistula
1164542|NCT01305824|PRT-201
1164543|NCT01305824|vonapanitase
1164544|NCT01305824|kidney
1164545|NCT01305824|renal
1164546|NCT01305811|Complex Medical Illness
1164547|NCT01305811|Gulf War Illness
1164548|NCT01305811|Veteran
1164549|NCT01305798|Biometric Screenings
1164550|NCT01305798|Active Choice
1164551|NCT01305798|Behavioral Economics
1164552|NCT01305798|Default
1164553|NCT01305772|SCCHN
1164554|NCT01305772|untreated
1164555|NCT01305772|Stage III or IVa-b (M0)
1164556|NCT01305759|Total knee arthroplasty
1164557|NCT01305759|Total hip arthroplasty
1164558|NCT01305759|Peri acetabular osteotomy
1164559|NCT01305759|Social class
1164560|NCT01305759|Health related quality of life
1164561|NCT01305746|SLE
1164562|NCT01305746|Lupus
1164563|NCT01305746|Lupus Erythematosus, Systemic
1164564|NCT01305746|A-623
1164565|NCT01305746|Autoimmune Diseases
1164566|NCT01305746|Blisibimod
1164567|NCT01305733|Pain relief
1164568|NCT01305720|mydriatic
1164569|NCT01305720|NIRS
1164570|NCT01305720|preterm
1164571|NCT01305720|eye drops
1164572|NCT01305720|cerebral
1164573|NCT01305720|mesenteric oxygenation
1164574|NCT01305707|Consolidation ECT
1164575|NCT01305707|Pharmacotherapy
1164576|NCT01305707|Efficacy
1164577|NCT01305707|Depression
1164578|NCT01305707|Prevention
1164579|NCT01305707|Electroconvulsive therapy
1164580|NCT01305707|Drug therapy
1164581|NCT01305668|COPD
1164582|NCT01305668|Emphysema phenotype
1164583|NCT01305655|Drug: Glucarpidase
1164584|NCT01305642|Postnatal development
1164585|NCT01305642|Breast milk fortification
1164586|NCT01305642|Composition of breast milk
1164587|NCT01305629|HIV
1164588|NCT01305629|Medication Adherence
1164589|NCT01305629|Substance Use
1164590|NCT01305629|Older adults
1164591|NCT01305629|Treatment
1164592|NCT01305616|Open angle Glaucoma
1164593|NCT01305616|Yellow-tinted intraocular lens
1164594|NCT01305616|Short-wavelength Automated Perimetry (SWAP)
1164595|NCT01305616|Standard Automated Perimetry (SAP)
1164596|NCT01305616|cataract
1164597|NCT01305590|HIV
1164598|NCT01305590|AIDS
1164599|NCT01305590|Medication Adherence
1164600|NCT01305590|Commitment Devices
1164601|NCT01305590|Behavioral Economics
1164602|NCT01305564|Pulmonary embolism (PE)
1164603|NCT01305564|Deep vein thrombosis (DVT)
1164604|NCT01305564|Vena cava
1164606|NCT01305564|Inferior vena cava
1164607|NCT01305564|Venous thromboembolic disease (VTED)
1164608|NCT01305525|SCS
1164609|NCT01305525|St. Jude Medical
1164610|NCT01305525|Neuromodulation
1164611|NCT01305512|Solid
1164612|NCT01305512|Tumor
1164613|NCT01305512|Taxane
1164614|NCT01305499|AML
1164615|NCT01305447|smoking cessation
1164616|NCT01305447|exercise maintenance
1164617|NCT01305447|preventing relapse
1164618|NCT01305447|weight gain
1164619|NCT01305447|group-mediated cognitive behavioural therapy
1164620|NCT01305434|diabetes mellitus type 2
1164621|NCT01305434|mulberry leaf extract
1164622|NCT01305434|post prandial blood glucose
1164623|NCT01305421|ICU
1164624|NCT01305421|muscle strength
1164625|NCT01305421|mechanical ventilation
1164626|NCT01305421|weaning
1164627|NCT01305408|Bipolar I Disorder
1164628|NCT01305395|Cardiac Allograft Vasculopathy in Heart Transplant
1164629|NCT01305382|Cardiac Allograft Vasculopathy
1164630|NCT01305369|ASTHMA
1164631|NCT01305369|PLATELET RECEPTOR P2Y12
1164632|NCT01305369|PRASUGREL
1164633|NCT01305369|INFLAMMATION
1164634|NCT01305356|degenerative joint disease
1164635|NCT01305356|DJD
1164636|NCT01305356|joint fusion
1164637|NCT01305356|hindfoot
1164638|NCT01305356|congenital deformity
1164639|NCT01305356|osteoarthritis
1164640|NCT01305356|rheumatoid arthritis
1164641|NCT01305356|post-traumatic arthritis
1164642|NCT01305356|ankylosing spondylitis
1164643|NCT01305356|Augment(tm) Injectable Bone Graft
1164644|NCT01305356|autologous bone graft
1164645|NCT01305356|autogenous bone graft
1164646|NCT01305356|beta-TCP
1164647|NCT01305356|bovine collagen
1164648|NCT01305356|rhPDGF(bb)
1164649|NCT01305343|Spinal Deformity
1164650|NCT01305343|Scoliosis
1164651|NCT01305343|Neurologic complications
1164652|NCT01305330|small renal mass
1164653|NCT01305330|active surveillance
1164654|NCT01305330|kidney mass
1164655|NCT01305330|kidney tumour
1164656|NCT01305317|Statin
1164657|NCT01305291|dietary fiber
1164658|NCT01305291|satiety response
1164659|NCT01305291|hunger
1164660|NCT01305291|CCK
1164661|NCT01305291|PYY
1164662|NCT01305291|ghrelin
1164663|NCT01305291|GIP
1164664|NCT01305291|GLP-1
1164665|NCT01305278|Balance
1164666|NCT01305278|Rehabilitation
1164667|NCT01305278|Vestibular
1164668|NCT01305265|sore throat
1164669|NCT01305265|dysphagia
1164670|NCT01305265|hoarseness
1164671|NCT01305265|post operative
1164672|NCT01305265|endotracheal intubation
1164673|NCT01305239|Observational
1164674|NCT01305239|epidemiological
1164675|NCT01305239|cohort
1164676|NCT01305239|cross-sectional
1164677|NCT01305239|prospective
1164678|NCT01305239|multicenter
1164679|NCT01305239|survey
1164680|NCT01305239|France.
1164681|NCT01305226|THR 100
1164682|NCT01305174|Common Iliac Artery and External Iliac Artery
1164683|NCT01305161|1Allergy
1164684|NCT01305161|2 Neuromuscular blockers
1164685|NCT01305148|warfarin
1164686|NCT01305148|genetic testing
1164687|NCT01305148|personalized medicine
1164688|NCT01305148|anti-coagulants
1164689|NCT01305148|coumadin
1164690|NCT01305135|myelodysplastic syndrome, azacitidine, idarubicin
1164691|NCT01305122|Glioma
1164692|NCT01305122|Neurocognitive functions
1164693|NCT01305096|heart rate variability
1164694|NCT01305096|oxygen uptake
1164695|NCT01305096|heart rate recovery
1164696|NCT01305096|perceived stress
1164697|NCT01305096|sleep
1164698|NCT01305096|blood pressure
1164699|NCT01305096|body mass index
1164700|NCT01305096|body weight
1164701|NCT01305096|hand grip strength
1164702|NCT01305096|sleep quality
1164703|NCT01305096|subjective health complaints
1164704|NCT01305096|blood lipids
1164705|NCT01305096|salivary cortisol
1164706|NCT01305096|blood sugar
1164707|NCT01305096|HbA1C
1164708|NCT01305096|Adiponectin
1164709|NCT01305096|Leptin
1164710|NCT01305096|Adipolipoproteins
1164711|NCT01305096|blood proteins
1164712|NCT01305096|cytokines
1164713|NCT01305096|insomnia
1164714|NCT01305096|sleeplessness
1164715|NCT01305096|yoga
1164716|NCT01305070|Standard balloon angioplasty
1164717|NCT01305070|POBA
1164718|NCT01305070|Angioplasty with paclitaxel-eluting balloon
1164719|NCT01305070|Superficial femoral artery
1164720|NCT01305057|dry skin condition
1164721|NCT01305044|tai chi
1164722|NCT01305044|elderly cancer survivor
1164723|NCT01305044|mind body intervention
1164724|NCT01305031|Asphyxia
1164725|NCT01305031|Resuscitation
1164726|NCT01305031|Room Air
1164727|NCT01305018|Branched-chain amino acids
1164728|NCT01305018|Leucine
1164729|NCT01305018|Muscle damage
1164730|NCT01305018|Inflammation
1164731|NCT01305018|supplementation
1164732|NCT01305018|resistance exercise-induced
1164733|NCT01305005|blood flow
1164734|NCT01304992|Dietary protein
1164735|NCT01304992|Lupin protein
1164736|NCT01304992|Cholesterol metabolism
1164737|NCT01304992|Protein metabolism
1164738|NCT01304992|Hypercholesterolemia
1164739|NCT01304992|Protein-enriched drinks
1164740|NCT01304979|acupuncture
1164741|NCT01304979|auricular acu-therapy
1164742|NCT01304979|gua sha therapy
1164743|NCT01304979|low back 'spine fusion'
1164744|NCT01304979|post surgical pain
1164745|NCT01304979|post surgical recovery
1164746|NCT01304979|Pain and recovery from 'spine fusion' surgery
1164747|NCT01304966|RRP
1164748|NCT01304966|HPV
1164749|NCT01304953|General anaesthetics
1164750|NCT01304953|gynaecological laparoscopy
1164751|NCT01304953|anaesthetic i.v.
1164752|NCT01304953|propofol
1164753|NCT01304953|anaesthetic volatile
1164754|NCT01304953|evoflurane
1164755|NCT01304953|antiemetics
1164756|NCT01304953|reopisetron
1164757|NCT01304953|postoperative pain
1164758|NCT01304940|Stress
1164759|NCT01304940|Stress Disorders, Post-Traumatic
1164760|NCT01304940|Stress Disorders, Traumatic
1164761|NCT01304927|Reproduction
1164762|NCT01304927|Sex hormones
1164763|NCT01304927|Glucose metabolism
1164764|NCT01304927|Bone metabolism
1164765|NCT01304927|Calcium
1164766|NCT01304927|Sperm
1164767|NCT01304927|testis
1164768|NCT01304927|bone
1164769|NCT01304927|endocrinology
1164770|NCT01304914|Respiratory tract infections
1164771|NCT01304914|Gastrointestinal tract infections
1164772|NCT01304914|Pediatrics
1164773|NCT01304914|Specimen collection
1164774|NCT01304901|Acute asthma
1164775|NCT01304901|Children
1164776|NCT01304901|Montelukast
1164777|NCT01304901|Emergency room
1164778|NCT01304888|Food consumption
1164779|NCT01304875|Fabry disease
1164780|NCT01304875|alpha-galactosidase deficiency
1164781|NCT01304875|exercise
1164782|NCT01304875|pulmonary
1164783|NCT01304849|Hodgkin's Lymphoma
1164784|NCT01304849|PET CT scan
1164785|NCT01304849|Escalated BEACOPP
1164786|NCT01304849|ABVD
1164787|NCT01304849|Response adapted therapy
1164788|NCT01304836|Kidney
1164789|NCT01304836|Transplant
1164790|NCT01304836|Immunosuppression
1164791|NCT01304836|Diabetes Mellitus
1164792|NCT01304823|T1R2/T1R3
1164793|NCT01304823|gastric emptying
1164794|NCT01304823|gut
1164795|NCT01304823|lactisole
1164796|NCT01304823|nutrient sensing
1164797|NCT01304810|NicVAX
1164798|NCT01304810|Smoking cessation
1164799|NCT01304797|MM302
1164800|NCT01304797|Breast Cancer
1164801|NCT01304797|Locally advanced/unresectable
1164802|NCT01304797|metastatic
1164803|NCT01304784|Solid tumors
1164804|NCT01304784|Failed at least one line of standard therapy
1164805|NCT01304771|Safety
1164806|NCT01304771|AKSB
1164807|NCT01304771|probiotic
1164808|NCT01304771|synbiotic
1164809|NCT01304771|enterococcus
1164810|NCT01304771|Saccharomyces
1164811|NCT01304771|elderly
1164812|NCT01304771|influenza
1164813|NCT01304771|vaccine
1164814|NCT01304771|immune
1164815|NCT01304771|response
1164816|NCT01304693|AMD
1164817|NCT01304693|Wet AMD
1164818|NCT01304693|Exudative
1164819|NCT01304693|CNV
1164820|NCT01304667|Vulvar cancer
1164821|NCT01304667|Radiotherapy
1164822|NCT01304667|Chemotherapy
1164823|NCT01304654|acute lung injury
1164824|NCT01304654|respiratory distress syndrome
1164825|NCT01304654|neoplasms
1164826|NCT01304654|child
1164827|NCT01304641|Dyslipidemia
1164828|NCT01304641|Cardiovascular
1164829|NCT01304641|Statin
1164830|NCT01304628|asthma
1164831|NCT01304615|Overweight
1164832|NCT01304615|Obesity
1164833|NCT01304615|Young Adults
1164834|NCT01304615|Energy Density
1164835|NCT01304615|Culinary Skills
1164836|NCT01304615|Physical Activity
1164837|NCT01304615|Consumption of Self-made Meals
1164838|NCT01304615|Family History of diabetes
1164839|NCT01304602|colorectal cancer
1164840|NCT01304602|BKM120
1164841|NCT01304602|irinotecan
1164842|NCT01304589|provoked vestibulodynia
1164843|NCT01304589|vulvodynia
1164844|NCT01304589|PVD
1164845|NCT01304576|stroke
1164846|NCT01304576|parietal lesions
1164847|NCT01304550|non-invasive
1164848|NCT01304550|hemoglobin
1164849|NCT01304524|CIN 2/3 or CIN 3
1164850|NCT01304524|Cervical cancer
1164851|NCT01304524|Papillomavirus
1164852|NCT01304485|Recurrent Prostate Carcinoma
1164853|NCT01304485|sodium acetate c11
1164854|NCT01304485|PET
1164855|NCT01304485|prostate cancer
1164856|NCT01304485|rising PSA
1164857|NCT01304485|PSA recurrence
1164858|NCT01304485|biochemical recurrence
1164859|NCT01304472|coronary angioplasty
1164860|NCT01304472|clopidogrel resistance
1164861|NCT01304472|prasugrel
1164862|NCT01304446|Nutritional support
1164863|NCT01304446|Cancer
1164864|NCT01304446|Malnutrition
1164865|NCT01304446|Child
1164866|NCT01304446|Adolescent
1164867|NCT01304446|pediatric
1164868|NCT01304420|Juvenile idiopathic arthritis
1164869|NCT01304420|Ultrasonography
1164870|NCT01304420|Cartilage
1164871|NCT01304420|Cartilage biomarkers
1164872|NCT01304420|Bone biomarkers
1164873|NCT01304407|Rothmund-Thomson Syndrome
1164874|NCT01304407|Calcium absorption
1164875|NCT01304407|Bone density
1164876|NCT01304394|Parenteral Nutrition
1164877|NCT01304394|Multi Chamber Bag
1164878|NCT01304381|Heart failure
1164879|NCT01304381|Palliative care
1164880|NCT01304381|Integrated care
1164881|NCT01304368|Hyperthermia, Induced
1164882|NCT01304368|Randomized Controlled Trial
1164883|NCT01304368|Neck Pain
1164884|NCT01304368|Sensory Thresholds
1164885|NCT01304368|Pain Measurements
1164886|NCT01304355|IBS
1164887|NCT01304355|Cognition
1164888|NCT01304355|Kynurenine Pathway
1164889|NCT01304355|Gastrointestinal
1164890|NCT01304342|Propofol
1164891|NCT01304342|remifentanil
1164892|NCT01304342|fentanyl
1164893|NCT01304342|ERCP
1164894|NCT01304342|Quality of sedation
1164895|NCT01304342|recovery
1164896|NCT01304342|satisfaction
1164897|NCT01304342|respiratory depression
1164898|NCT01304303|solid
1164899|NCT01304303|tumor
1164900|NCT01304303|taxane
1164901|NCT01304303|platinum
1164902|NCT01304290|inflammatory process
1164903|NCT01304290|hyperglycaemia
1164904|NCT01304290|inflammatory cytokine response
1164905|NCT01304290|organ survival
1164906|NCT01304290|hyperinsulinemic clamp
1164907|NCT01304277|Replagal
1164908|NCT01304264|glaucoma, ocular, blood flow, fluctuations
1164909|NCT01304251|short-term fasting
1164910|NCT01304251|adjuvant chemotherapy
1164911|NCT01304251|toxicity
1164912|NCT01304251|side-effects
1164913|NCT01304238|Retrospective evaluation of patients with acute Heparin-induced Thrombocytopenia type II treated with Fondaparinux
1164914|NCT01304225|diabetic retinopathy
1164915|NCT01304225|photocoagulation
1164916|NCT01304225|PASCAL laser
1164917|NCT01304212|total knee arthroplasty
1164918|NCT01304212|intraarticular infiltration
1164919|NCT01304212|femoral block
1164920|NCT01304199|Cancer survivor
1164921|NCT01304199|Neoplasms
1164922|NCT01304199|Treatments
1164923|NCT01304199|Physical status
1164924|NCT01304199|Psychosocial status
1164925|NCT01304199|Survivorship survey
1164926|NCT01304199|Survivorship care
1164927|NCT01304199|Research
1164928|NCT01304199|Cancer patient
1164929|NCT01304186|Health literacy
1164930|NCT01304186|HIV
1164931|NCT01304186|Medication Adherence
1164932|NCT01304186|IMB Model
1164933|NCT01304173|BCG
1164934|NCT01304173|refractory
1164935|NCT01304173|NMIBC
1164936|NCT01304173|CIS
1164937|NCT01304173|non-muscle invasive
1164938|NCT01304160|pancreatic cancer
1164939|NCT01304160|stereotactic body radiotherapy
1164940|NCT01304160|radiation
1164941|NCT01304160|gemcitabine
1164942|NCT01304160|locally advanced
1164943|NCT01304147|ketamine
1164944|NCT01304147|depression
1164945|NCT01304147|treatment resistance
1164946|NCT01304147|intranasal, antidepressant
1164947|NCT01304147|glutamate
1164948|NCT01304147|NMDA receptor
1164949|NCT01304121|Bone tumors
1164950|NCT01304121|Bioactive glass
1164951|NCT01304121|Autogenous bone grafting
1164952|NCT01304121|Allogeneic bone grafting
1164953|NCT01304121|PET imaging
1164954|NCT01304108|Venous Thromboembolism
1164955|NCT01304108|Delivery of Health Care
1164956|NCT01304108|Quality Improvement
1164957|NCT01304108|Evidence-Based Practice
1164958|NCT01304095|Coronary Artery Disease, Angina, Metabolic Syndrome
1164959|NCT01304082|pain pH local anesthetics
1164960|NCT01304069|Pharmacokinetics
1164961|NCT01304069|Pharmacodynamics
1164962|NCT01304056|Ventilatory physiology
1164963|NCT01304043|ovarian tumors
1164964|NCT01304043|rare ovarian tumors
1164965|NCT01304043|germinal tumors
1164966|NCT01304043|sexual cords tumors
1164967|NCT01304043|observatory
1164968|NCT01304043|forum
1164969|NCT01304030|Empathy
1164970|NCT01304017|rehabilitation
1164971|NCT01304017|stroke
1164972|NCT01304017|intervention
1164973|NCT01304017|physical activity
1164974|NCT01304017|participation
1164975|NCT01304004|Obesity
1164976|NCT01304004|Yogurt
1164977|NCT01304004|Proteins
1164978|NCT01304004|Fibres
1164979|NCT01304004|Women
1164980|NCT01304004|Satiety
1164981|NCT01303952|cold agglutinin disease
1164982|NCT01303952|hemolysis
1164983|NCT01303952|eculizumab
1164984|NCT01303952|terminal complement inhibition
1164985|NCT01303939|Glaucoma
1164986|NCT01303939|MRI Brain Scan
1164987|NCT01303939|Voxel-Based Morphometry
1164988|NCT01303926|QoL
1164989|NCT01303926|EQ5D score
1164990|NCT01303926|cisplatin pemetrexed
1164991|NCT01303926|carboplatin paclitaxel bevacizumab
1164992|NCT01303926|maintenance
1164993|NCT01303913|COPD
1164994|NCT01303913|Oxygen desaturation
1164995|NCT01303913|Walking test
1164996|NCT01303900|Haemophilia
1164997|NCT01303900|Cardiovascular disease
1164998|NCT01303900|Cardiovascular disease risk factors
1164999|NCT01303900|Prospective
1165000|NCT01303900|QRISK2
1165001|NCT01303900|Hypertension
1165002|NCT01303900|Hypercholesterolaemia
1165003|NCT01303900|Diabetes
1165004|NCT01303900|Obesity
1165005|NCT01303887|PACIFICO
1165006|NCT01303887|Follicular Lymphoma
1165007|NCT01303887|Non-Hodgkin's Lymphoma
1165008|NCT01303887|Rituximab
1165009|NCT01303887|R-CVP
1165010|NCT01303887|R-FC
1165011|NCT01303887|Older
1165012|NCT01303874|Rheumatoid arthritis
1165013|NCT01303874|Inflammatory arthritis
1165140|NCT01303458|community resource
1165014|NCT01303874|Undifferentiated arthritis
1165015|NCT01303874|Etanercept
1165016|NCT01303874|Combination Therapy
1165017|NCT01303861|Nicotine addiction
1165018|NCT01303861|Cigarette smoking
1165019|NCT01303861|Smoking cessation
1165020|NCT01303861|Zyban
1165021|NCT01303861|Chantix
1165022|NCT01303861|Nicotine patches
1165023|NCT01303861|Nicotrol Inhaler
1165024|NCT01303861|varenicline
1165025|NCT01303861|bupropion
1165026|NCT01303848|Blood lactate
1165027|NCT01303848|Lipid transfer proteins
1165028|NCT01303848|Lactate
1165029|NCT01303848|PLTP
1165030|NCT01303848|CETP
1165031|NCT01303848|PPARs
1165032|NCT01303848|CLOCk
1165033|NCT01303848|Bal1
1165034|NCT01303835|malignant glioma
1165035|NCT01303835|glioblastoma multiforme
1165036|NCT01303835|quality of life
1165037|NCT01303835|naltrexone
1165038|NCT01303809|Perioperative care
1165039|NCT01303809|Fast-track
1165040|NCT01303809|Enhanced Recovery After Surgery
1165041|NCT01303809|ERAS
1165042|NCT01303809|Obesity
1165043|NCT01303809|Bariatric surgery
1165044|NCT01303809|Laparoscopic Sleeve Gastrectomy
1165045|NCT01303796|AML
1165046|NCT01303783|Nifedipine GITS
1165047|NCT01303783|Candesartan
1165048|NCT01303783|mild to moderate Hypertension
1165049|NCT01303783|Combination therapy
1165050|NCT01303770|Multiple Sclerosis
1165051|NCT01303770|Cognitive impairment
1165052|NCT01303770|Self-management programs
1165053|NCT01303770|Occupational Therapy
1165054|NCT01303770|Rehabilitation
1165055|NCT01303757|obesity
1165056|NCT01303731|Spinal anesthesia
1165057|NCT01303731|Cesarean section
1165058|NCT01303731|Marcaine Spinal 0.5% Heavy minidose
1165059|NCT01303731|Fentanyl
1165060|NCT01303731|Local Anesthetics
1165061|NCT01303718|LV Dysfunction
1165062|NCT01303718|Heart Failure
1165063|NCT01303705|progressive metastatic prostate cancer
1165064|NCT01303705|cancer of the prostate
1165065|NCT01303705|prostate cancer
1165066|NCT01303692|bone mineral loss
1165067|NCT01303692|prostate cancer
1165068|NCT01303692|GnRH agonist alone vs. GnRH agonist plus anti-androgen combination
1165069|NCT01303679|First line metastatic breast cancer
1165070|NCT01303679|Positive estrogen receptors
1165071|NCT01303679|Negative HER2 receptors
1165072|NCT01303679|At least stable disease after 4 months of paclitaxel-bevcizumab induction chemotheray
1165073|NCT01303653|endoscopic tissue closure,
1165074|NCT01303653|gastro-gastric fistulas,
1165075|NCT01303653|gastrointestinal perforations
1165076|NCT01303640|Coronary stent
1165077|NCT01303627|Remifentanil
1165078|NCT01303627|Laryngeal mask airway removal
1165079|NCT01303627|Hemodynamic changing
1165080|NCT01303627|Infusion
1165081|NCT01303627|Ureterorenoscopy
1165082|NCT01303614|hysterosalpingography
1165083|NCT01303614|prilocaine
1165084|NCT01303614|local anaesthetic
1165085|NCT01303614|pain relief
1165086|NCT01303614|gynecological pathology
1165087|NCT01303601|Olanzapine
1165088|NCT01303601|Monotherapy
1165089|NCT01303601|bipolar Ⅰ depression
1165090|NCT01303588|elderly patients
1165091|NCT01303575|Adolescents
1165092|NCT01303575|Youth
1165093|NCT01303575|Sexual Health
1165094|NCT01303575|Sex Education
1165095|NCT01303575|Pregnancy Prevention
1165096|NCT01303575|Abstinence Education
1165097|NCT01303575|HIV
1165098|NCT01303575|Human Immunodeficiency Virus
1165099|NCT01303575|STI
1165100|NCT01303575|Chlamydia
1165101|NCT01303575|Gonorrhea
1165102|NCT01303575|Sexually Transmitted Infections
1165103|NCT01303575|American Indian
1165104|NCT01303575|Alaska Native
1165105|NCT01303575|Native American
1165106|NCT01303575|Internet-Based
1165107|NCT01303575|Computer-based Education
1165108|NCT01303575|Computer-based learning
1165109|NCT01303562|oat
1165110|NCT01303562|barley
1165111|NCT01303562|whole grain
1165112|NCT01303562|bioavailability
1165113|NCT01303562|phytochemical
1165114|NCT01303549|Liver transplantation
1165115|NCT01303549|Hepatic transplant
1165116|NCT01303549|Antifungal prophylaxis
1165117|NCT01303549|Anidulafungin
1165118|NCT01303549|Liposomal Amphotericin B
1165119|NCT01303523|LMWH
1165120|NCT01303523|heparin
1165121|NCT01303523|immobilization
1165122|NCT01303523|anticoagulant prophylaxis
1165123|NCT01303523|leg injuries
1165124|NCT01303523|thromboembolism
1165125|NCT01303510|Influenza
1165126|NCT01303510|Virus
1165127|NCT01303510|Vaccination
1165128|NCT01303510|Immunisation
1165129|NCT01303497|Angiosarcoma
1165130|NCT01303497|Paclitaxel
1165131|NCT01303497|bevacizumab
1165132|NCT01303471|pain assessment
1165133|NCT01303471|anesthesia
1165134|NCT01303471|analgesia
1165135|NCT01303471|opioid
1165136|NCT01303471|HRV
1165137|NCT01303471|APV
1165138|NCT01303471|autonomic nervous system (ANS)
1165139|NCT01303471|pupil size
1165141|NCT01303458|well-child care visit
1165142|NCT01303458|low-income
1165143|NCT01303432|Joint discomfort
1165144|NCT01303432|Functional Food
1165145|NCT01303432|Joint function
1165146|NCT01303432|Mobilee
1165147|NCT01303419|mammography
1165148|NCT01303406|randomized withdrawal
1165149|NCT01303406|idebenone
1165150|NCT01303406|friedreich's ataxia
1165151|NCT01303406|Miconos
1165152|NCT01303406|Patient reported outcome
1165153|NCT01303406|ICARS
1165154|NCT01303393|Patient education. Patient discharge. Needs assessment.
1165155|NCT01303380|Hyper IgD syndrome
1165156|NCT01303380|canakinumab
1165157|NCT01303380|HIDS
1165158|NCT01303380|mevalonate kinase deficiency
1165159|NCT01303380|MKD
1165160|NCT01303367|Dementia
1165161|NCT01303367|behavioral and psychological symptoms of dementia
1165162|NCT01303354|Epidural, Transforaminal, Steroid Injection, Dexamethasone
1165163|NCT01303315|C19 246 300
1165164|NCT01303302|C19 246 300
1165165|NCT01303289|Total Enteral Nutrition
1165166|NCT01303289|Severe insufficient nutrition
1165167|NCT01303289|T-Diet plus Standard
1165168|NCT01303289|Lipidic profile
1165169|NCT01303289|Quality of life
1165170|NCT01303276|retinal vein occlusion
1165171|NCT01303276|anti-VEGF
1165172|NCT01303276|blood flow
1165173|NCT01303263|efficiency
1165174|NCT01303263|cost-awareness
1165175|NCT01303263|hospitals
1165176|NCT01303263|graduate medical education
1165177|NCT01303250|goal-directed fluid optimization
1165178|NCT01303250|hemodynamic optimization
1165179|NCT01303250|crystalloid
1165180|NCT01303250|colloid
1165181|NCT01303237|LA SCCHN
1165182|NCT01303237|Cetuximab
1165183|NCT01303237|RT
1165184|NCT01303237|PMS
1165185|NCT01303224|Irritable Bowel Syndrome
1165186|NCT01303224|Colon, irritable
1165187|NCT01303224|Bowel disease
1165188|NCT01303211|Meningococcal serogroup A conjugate vaccine
1165189|NCT01303211|Vaccine efficacy
1165190|NCT01303211|Serogroup A meningococcal diseases
1165191|NCT01303198|CPAP
1165192|NCT01303198|APAP
1165193|NCT01303198|sleep apnea
1165194|NCT01303185|Psoriatic Nail
1165195|NCT01303185|Pulsed dye laser
1165196|NCT01303159|Cholangiocarcinoma
1165197|NCT01303159|Pancreatic Cancer
1165198|NCT01303159|Radiofrequency
1165199|NCT01303159|Ablation
1165200|NCT01303146|Metachromatic Leukodystrophy
1165201|NCT01303146|Enzyme replacement therapy
1165202|NCT01303146|Allogeneic hematopoietic stem cell transplantation
1165203|NCT01303133|beta amyloid, Down Syndrome, Alzheimer's Disease
1165204|NCT01303081|Smoking Cessation
1165205|NCT01303081|Work-site
1165206|NCT01303081|Incentives
1165207|NCT01303081|Health Behavior
1165208|NCT01303081|Smoking
1165209|NCT01303068|CF
1165210|NCT01303055|Pancreatic beta Cell
1165211|NCT01303055|Diabetes Mellitus, Type 2
1165212|NCT01303055|Glucose Metabolism Disorders
1165213|NCT01303055|Metabolic Diseases
1165214|NCT01303055|Endocrine System Diseases
1165215|NCT01303055|Metformin
1165216|NCT01303055|Hypoglycemic Agents
1165217|NCT01303055|Physiological Effects of Drugs
1165218|NCT01303055|Pharmacologic Actions
1165219|NCT01303055|hemoglobin A1c protein, human
1165220|NCT01303055|Oral Glucose Tolerance Test
1165221|NCT01303042|insulin LISPRO
1165222|NCT01303042|Insulin therapy
1165223|NCT01303042|hemoglobin A1c protein, human
1165224|NCT01303042|Blood Glucose Self-Monitoring
1165225|NCT01303042|Quality of Life
1165226|NCT01303042|Hypoglycemia
1165227|NCT01303042|Diabetes Mellitus
1165228|NCT01303042|1,5-Anhydroglucitol
1165229|NCT01303029|Pancreatic cancer
1165230|NCT01303029|gemcitabine
1165231|NCT01303029|erlotinib
1165232|NCT01303029|capecitabine
1165233|NCT01302990|Influenza
1165234|NCT01302990|Respiratory disease
1165235|NCT01302990|Prevention
1165236|NCT01302977|Congenital diaphragmatic hernia
1165237|NCT01302977|Fetal anomalies
1165238|NCT01302964|Autistic Disorder
1165239|NCT01302964|Asperger's Disorder
1165240|NCT01302964|Pervasive Developmental Disorder
1165241|NCT01302951|pharmacokinetics
1165242|NCT01302951|liver resection
1165243|NCT01302938|Double-blind
1165244|NCT01302938|Placebo-controlled
1165245|NCT01302938|frequency
1165246|NCT01302938|urgency
1165247|NCT01302938|web-based
1165248|NCT01302938|incontinence
1165249|NCT01302938|methodology
1165250|NCT01302938|ediary
1165251|NCT01302938|safety
1165252|NCT01302938|efficacy
1165253|NCT01302938|tolerability ER
1165254|NCT01302938|overactive bladder
1165255|NCT01302912|ocular adnexal lymphomas
1165256|NCT01302886|High risk Smoldering multiple myeloma,
1165257|NCT01302886|BHQ880,
1165258|NCT01302886|MM
1165259|NCT01302873|Tinnitus
1165260|NCT01302873|AMPA Receptor antagonist
1165261|NCT01302860|Cryopyrin-associated periodic syndromes (CAPS)
1165262|NCT01302860|Familial Cold Autoinflammatory Syndrome (FCAS)
1165263|NCT01302860|Muckle-Wells Syndrome (MWS) or Neonatal Onset Multisystem Inflammatory Disease (NOMID)
1165264|NCT01302860|children
1165265|NCT01302860|systemic autoinflammatory disease
1165266|NCT01302860|CIAS-1 gene
1165267|NCT01302860|NALP-3
1165268|NCT01302860|NLRP3
1165269|NCT01302860|ACZ885
1165270|NCT01302860|Ilaris
1165271|NCT01302860|human monoclonal anti-human interleukin-1 beta (IL-beta)
1165272|NCT01302860|antibody
1165273|NCT01302860|autosomal dominant
1165274|NCT01302860|familial autoinflammatory syndrome
1165275|NCT01302847|Integrase Inhibitors
1165276|NCT01302847|Infant
1165277|NCT01302847|Child
1165278|NCT01302847|Adolescent
1165279|NCT01302834|stage III squamous cell carcinoma of the oropharynx
1165280|NCT01302834|stage IV squamous cell carcinoma of the oropharynx
1165281|NCT01302834|human papilloma virus infection
1165282|NCT01302821|breast - male
1165283|NCT01302821|breast - female
1165284|NCT01302821|metastatic
1165285|NCT01302821|invasive
1165286|NCT01302808|recurrent non-small cell lung cancer
1165287|NCT01302808|stage IIIB non-small cell lung cancer
1165288|NCT01302808|stage IV non-small cell lung cancer
1165289|NCT01302808|malignant pleural effusion
1165290|NCT01302808|adenocarcinoma of the lung
1165291|NCT01302808|adenosquamous cell lung cancer
1165292|NCT01302808|bronchoalveolar cell lung cancer
1165293|NCT01302808|large cell lung cancer
1165294|NCT01302808|squamous cell lung cancer
1165295|NCT01302795|Interleukin 1 beta
1165296|NCT01302795|Canakinumab
1165297|NCT01302795|autoinflammatory syndrome
1165298|NCT01302782|Altitude
1165299|NCT01302782|Glucose
1165300|NCT01302769|Acute Sore Throat
1165301|NCT01302769|Ear Acupuncture
1165302|NCT01302756|gestational diabetes
1165303|NCT01302756|gestational hypertension
1165304|NCT01302756|folic acid
1165305|NCT01302743|Diabetes
1165306|NCT01302743|Metformin
1165307|NCT01302743|Cinnamon
1165308|NCT01302730|ankylosing spondylitis
1165309|NCT01302730|spondylarthritis
1165310|NCT01302730|inflammatory back pain
1165311|NCT01302730|seronegative
1165312|NCT01302717|Left ventricular pacing
1165313|NCT01302704|Vitamin D
1165314|NCT01302704|Proton Pump Inhibitors
1165315|NCT01302691|Essential hypertension
1165316|NCT01302691|Uncontrolled hypertension
1165317|NCT01302691|Antihypertensive agents
1165318|NCT01302691|Blood pressure
1165319|NCT01302652|acromegaly
1165320|NCT01302652|growth hormone
1165321|NCT01302652|growth hormone deficiency
1165322|NCT01302626|NSCLC
1165323|NCT01302626|SCLC
1165324|NCT01302626|lung cancer
1165325|NCT01302626|RNA
1165326|NCT01302626|DNA
1165327|NCT01302626|imaging
1165328|NCT01302626|genomics
1165329|NCT01302626|proteomics
1165330|NCT01302626|predictive model
1165331|NCT01302626|prospective study
1165332|NCT01302613|rectal cancer
1165333|NCT01302574|T1R2/T1R3
1165334|NCT01302574|gastric emptying
1165335|NCT01302574|gut
1165336|NCT01302574|lactisole
1165337|NCT01302574|nutrient sensing
1165338|NCT01302561|adults
1165339|NCT01302561|fiber
1165340|NCT01302561|cold
1165341|NCT01302561|flu
1165342|NCT01302561|immune function
1165343|NCT01302561|microbiota
1165344|NCT01302548|Abscess
1165345|NCT01302548|Wound Irrigation
1165346|NCT01302548|Wound Debridement
1165347|NCT01302548|Wound Healing
1165348|NCT01302548|Incision and drainage
1165349|NCT01302548|Chlorhexidine
1165350|NCT01302535|Yoga
1165351|NCT01302535|Hypertension
1165352|NCT01302535|Quality of Life
1165353|NCT01302535|Primary Health Care
1165354|NCT01302509|Nutritional support.
1165355|NCT01302509|Cancer.
1165356|NCT01302509|Malnutrition.
1165357|NCT01302509|Child.
1165358|NCT01302509|Adolescent
1165359|NCT01302496|Previously Treated
1165360|NCT01302496|Unresectable
1165361|NCT01302496|Stage III or IV Melanoma
1165362|NCT01302470|biventricular pacing
1165363|NCT01302457|Thermal Burn Trauma
1165364|NCT01302444|treprostinil
1165365|NCT01302444|pulmonary hypertension, tadalafil
1165366|NCT01302431|experimental
1165367|NCT01302431|intervention
1165368|NCT01302431|nurse-led
1165369|NCT01302431|nurse specialist
1165370|NCT01302431|multiple sclerosis
1165371|NCT01302431|support of caregivers
1165372|NCT01302418|Respiratory Virus
1165373|NCT01302418|Influenza
1165374|NCT01302418|RSV
1165375|NCT01302418|Parainfluenza
1165376|NCT01302418|Metapneumovirus
1165377|NCT01302418|Rhinovirus
1165378|NCT01302418|Coxsackie virus
1165379|NCT01302418|Echo virus
1165380|NCT01302418|Adenovirus
1165381|NCT01302418|Coronavirus
1165382|NCT01302418|Bocavirus
1165383|NCT01302405|Advanced solid tumor
1165384|NCT01302405|cancer
1165385|NCT01302405|phase 1
1165386|NCT01302405|pancreatic cancer
1165387|NCT01302405|colon cancer
1165388|NCT01302405|unresectable neoplastic disease
1165389|NCT01302405|Progressive cancer
1165390|NCT01302405|metastatic solid tumor
1165391|NCT01302379|Obesity
1165392|NCT01302379|Survival
1165393|NCT01302379|Weight loss
1165394|NCT01302379|Metformin
1165395|NCT01302379|Biological markers
1165396|NCT01302366|multiple myeloma
1165397|NCT01302366|myeloma
1165398|NCT01302366|asymptomatic myeloma
1165399|NCT01302366|smoldering myeloma
1165400|NCT01302366|Asymptomatic (smoldering) myeloma
1165401|NCT01302353|Phase I trial
1165402|NCT01302353|Emulsified Isoflurane
1165403|NCT01302353|Health volunteer
1165404|NCT01302340|Dementia
1165405|NCT01302340|Alzheimer
1165406|NCT01302340|Cannabis
1165407|NCT01302340|THC
1165408|NCT01302340|Behavioral Disturbances
1165409|NCT01302340|Neuropsychiatric Inventory
1165410|NCT01302327|Wolfram syndrome
1165411|NCT01302327|Diabetes mellitus
1165412|NCT01302327|Exenatide
1165413|NCT01302327|GLP-1 analog
1165414|NCT01302327|beta cell function
1165415|NCT01302301|endolumenal myotomy, per oral endoscopic myotomy
1165416|NCT01302288|endolumenal myotomy, per oral endoscopic myotomy
1165417|NCT01302275|neuropathic pain
1165418|NCT01302275|oxcarbazepine
1165419|NCT01302275|pain mechanism
1165420|NCT01302262|Smoking-induced dopamine release
1165421|NCT01302262|[11C]-(+)-PHNO PET Study
1165422|NCT01302249|Glaucoma
1165423|NCT01302249|Intraocular pressure
1165424|NCT01302249|Ocular hypertension
1165425|NCT01302236|Elderly
1165426|NCT01302236|Early stage chronic kidney disease
1165427|NCT01302236|Hypertension
1165428|NCT01302236|Eplerenone
1165429|NCT01302223|burns
1165430|NCT01302223|Growth Factors, Combined Defect of
1165431|NCT01302223|inflammation
1165432|NCT01302223|Cytokine Storm
1165433|NCT01302210|MRSA
1165434|NCT01302210|Cluster Randomized Trial
1165435|NCT01302210|Infection Control Intervention
1165436|NCT01302197|Stroke
1165437|NCT01302197|Body Composition
1165438|NCT01302197|Glucose Tolerance
1165439|NCT01302171|dilated cardiomyopathy
1165440|NCT01302171|adult stem cells
1165441|NCT01302171|bone marrow progenitor cells
1165442|NCT01302171|bone marrow stem cells
1165443|NCT01302171|autologous
1165444|NCT01302171|granulocyte-colony stimulating factor
1165445|NCT01302171|intracoronary injection
1165446|NCT01302171|left ventricular function
1165447|NCT01302171|To determine if patient's own bone marrow derived stem cells can be used to improve cardiac function
1165448|NCT01302158|Drug-Drug interaction
1165449|NCT01302158|ASP1941
1165450|NCT01302158|Glimepiride
1165451|NCT01302158|Healthy subjects
1165452|NCT01302145|ASP1941
1165453|NCT01302145|Drug to drug interaction
1165454|NCT01302145|metformin
1165455|NCT01302145|pharmacokinetics
1165456|NCT01302132|Mass Balance
1165457|NCT01302132|ASP1941
1165458|NCT01302132|Pharmacokinetics
1165459|NCT01302119|Onychomycosis
1165460|NCT01302119|nail fungus
1165461|NCT01302119|toenail fungus
1165462|NCT01302119|fungal nail
1165463|NCT01302119|hyperkeratosis
1165464|NCT01302119|nail infection
1165465|NCT01302119|nail treatment
1165466|NCT01302119|toenail infection
1165467|NCT01302119|toenail treatment
1165468|NCT01302119|foot dermatoses
1165469|NCT01302119|fungal culture
1165470|NCT01302119|onycholysis
1165471|NCT01302119|podiatrist
1165472|NCT01302119|podiatry
1165473|NCT01302119|subungual
1165474|NCT01302119|tinea unguium
1165475|NCT01302119|antifungal
1165476|NCT01302119|anti-fungal
1165477|NCT01302119|dermatologist
1165478|NCT01302119|dermatology
1165479|NCT01302119|dermatophyte
1165480|NCT01302119|distal subungual onychomycosis
1165481|NCT01302119|yellow nail
1165482|NCT01302119|thick nail
1165483|NCT01302119|brittle nail
1165484|NCT01302119|crumbling nail
1165485|NCT01302119|discolored nail
1165486|NCT01302119|weak nail
1165487|NCT01302106|Myelodysplastic Syndromes
1165488|NCT01302106|Clofarabine
1165489|NCT01302106|Low Dose Cytarabine
1165490|NCT01302106|Poor risk MDS
1165498|NCT01302054|Bladder Overactive
1165499|NCT01302054|Overactive urinary bladder
1165500|NCT01302054|Overactive Bladder
1165501|NCT01302041|bone turnover
1165502|NCT01302041|hormone-naïve
1165503|NCT01302041|prostate specific antigen
1165504|NCT01302041|Prostate Cancer
1165505|NCT01302028|Renal Impairment
1165506|NCT01302028|ASP1941
1165507|NCT01302028|Pharmacokinetics
1165508|NCT01302002|Breast Cancer
1165509|NCT01302002|Metformin
1165510|NCT01302002|Pre-Surgery
1165511|NCT01301989|Sleep
1165512|NCT01301989|Children
1165513|NCT01301989|Disparities
1165514|NCT01301989|Minority
1165515|NCT01301989|Urban
1165516|NCT01301976|nutritional state
1165517|NCT01301976|nutrients intake
1165518|NCT01301976|ulcerative colitis
1165519|NCT01301950|Arthroplasties, Knee Replacement
1165520|NCT01301950|Arthroplasties, Replacement, Knee
1165521|NCT01301950|Arthroplasty, Knee Replacement
1165522|NCT01301950|Knee Replacement Arthroplasties
1165523|NCT01301950|Knee Replacement Arthroplasty
1165524|NCT01301950|Knee Replacement, Total
1165525|NCT01301950|Replacement Arthroplasties, Knee
1165526|NCT01301950|Replacement Arthroplasty, Knee
1165527|NCT01301950|Replacement, Total Knee
1165528|NCT01301950|Total Knee Replacement
1165529|NCT01301937|Mucosal Leishmaniasis
1165530|NCT01301937|Leishmania braziliensis
1165531|NCT01301937|Meglumine Antimoniate
1165532|NCT01301937|Treatment Effectiveness
1165533|NCT01301937|Controlled Clinical Trials, Randomized
1165534|NCT01301924|Leishmaniasis Cutaneous
1165535|NCT01301924|Leishmania braziliensis
1165536|NCT01301924|Meglumine Antimoniate
1165537|NCT01301924|Treatment Effectiveness
1165538|NCT01301924|Controlled Clinical Trials, Randomized
1165539|NCT01301911|Breast cancer, Advanced
1165540|NCT01301911|Cipatinib
1165541|NCT01301911|phase I
1165542|NCT01301911|HER2 positive or uncertain advanced breast cancer
1165543|NCT01301898|Hunter syndrome
1165544|NCT01301898|MPS II
1165545|NCT01301898|Idursulfase
1165546|NCT01301885|endometriosis
1165547|NCT01301885|dysmenorrhea
1165548|NCT01301885|infertility
1165549|NCT01301885|biomarker
1165550|NCT01301885|drug target
1165551|NCT01301859|older adults
1165552|NCT01301859|adherence
1165553|NCT01301859|antidepressant
1165554|NCT01301859|depression
1165555|NCT01301833|insulin resistance
1165556|NCT01301820|maintenance treatment
1165557|NCT01301820|Disease free survival
1165558|NCT01301807|Relapsed/refractory multiple myeloma
1165559|NCT01301807|RRMM
1165560|NCT01301807|Carfilzomib
1165561|NCT01301807|Panobinostat
1165562|NCT01301807|LBH589B
1165563|NCT01301794|Hypertriglyceridemia
1165564|NCT01301794|Fish oil
1165565|NCT01301794|Omega 3 fatty acids
1165566|NCT01301768|Dietary Intervention
1165567|NCT01301768|Pregnancy Jail
1165568|NCT01301768|Iodine Deficiency
1165569|NCT01301768|Iodine Nutrition
1165570|NCT01301768|Dietary Habits
1165571|NCT01301768|Urinary Iodine
1165572|NCT01301768|Pregnancy
1165573|NCT01301768|Group Education
1165574|NCT01301768|Cluster Randomized Trial
1165575|NCT01301768|Primary Health Care
1165576|NCT01301703|rheumatoid pertussis tetanus
1165577|NCT01301690|neck mass
1165578|NCT01301690|ultrasound
1165579|NCT01301690|FNA
1165580|NCT01301690|BMVC
1165581|NCT01301664|The bone marrow-derived mesenchymal stem cells (BMMSCs) were obtained from redundant bone marrow from drilling during the joint replacement surgery.
1165582|NCT01301664|The synovial-derived mesenchymal stem cells (SMSCs) were isolated from synovial membranes in the joint replacement surgery.
1165583|NCT01301664|Cartilage slices were obtained from discard cartilage in the joint replacement surgery.
1165584|NCT01301651|Virtual Reality
1165585|NCT01301651|Balance
1165586|NCT01301651|Parkinson's disease
1165587|NCT01301651|Dual Task
1165588|NCT01301625|MitraClip
1165589|NCT01301625|mitral regurgitation (MR)
1165590|NCT01301625|mitral valve insufficiency
1165591|NCT01301625|percutaneous mitral valve repair
1165592|NCT01301625|congestive heart failure
1165593|NCT01301612|carcinoma or adenocarcinoma or uterine cervix adenosquamous carcinoma
1165594|NCT01301599|Benign Prostatic Hyperplasia
1165595|NCT01301599|alpha blocker
1165596|NCT01301599|5-alpha reductase inhibitor
1165597|NCT01301599|combination therapy
1165598|NCT01301560|Asymptomatic brain metastasis
1165599|NCT01301560|NSCLC
1165600|NCT01301560|GKS
1165601|NCT01301534|abdominal aortic aneurysm
1165602|NCT01301521|Pre-Diabetes
1165603|NCT01301521|cinnamon
1165604|NCT01301508|atopic dermatitis
1165605|NCT01301495|Esophageal Cancer, Malignant, Dysphagia, Esophagus, Cancer
1165606|NCT01301482|Acute Sore Throat
1165607|NCT01301482|Ear Acupuncture
1165608|NCT01301456|Phase 1
1165609|NCT01301456|Type 2 Diabetes
1165610|NCT01301456|CVX-096
1165611|NCT01301443|Age Related Macular Degeneration
1165612|NCT01301430|Progressive glioblastoma multiforme
1165613|NCT01301430|Recurrent glioblastoma multiforme
1165614|NCT01301430|Oncolytic virus
1165615|NCT01301417|Compression Anastomosis
1165616|NCT01301404|Postoperative nausea and vomiting (PONV)
1165617|NCT01301404|Spinal morphine
1165618|NCT01301404|Total knee replacement (TKR)
1165619|NCT01301404|blood sugar
1165620|NCT01301404|carbohydrate drink
1165621|NCT01301391|B3 and C malignant thymoma
1165622|NCT01301365|autonomic response
1165623|NCT01301352|Critical Care
1165624|NCT01301352|Intubation, gastrointestinal
1165625|NCT01301352|Child
1165626|NCT01301352|Infant
1165627|NCT01301352|Adolescent
1165628|NCT01301352|Continuous positive airway pressure
1165629|NCT01301352|Enteral Nutrition
1165630|NCT01301339|Pre-Diabetes
1165631|NCT01301339|Diabetes
1165632|NCT01301339|cardiovascular risks
1165633|NCT01301326|retinal arterial macroaneurysm
1165634|NCT01301326|laser treatment
1165635|NCT01301313|Acute heart failure
1165636|NCT01301313|Children
1165637|NCT01301313|Levosimendan
1165638|NCT01301313|Inotropic treatment
1165639|NCT01301274|hyponatremia
1165640|NCT01301274|maintenance solutions
1165641|NCT01301274|pediatrics
1165642|NCT01301261|Sugammadex
1165643|NCT01301261|entropy
1165644|NCT01301261|bispectral index
1165645|NCT01301261|blood pressure
1165646|NCT01301261|heart rate
1165647|NCT01301261|oxygenation
1165648|NCT01301261|end-tidal CO2
1165649|NCT01301261|hemodynamics
1165650|NCT01301261|general anesthesia
1165651|NCT01301248|locally advanced,
1165652|NCT01301248|unresectable,
1165653|NCT01301248|head and neck squamous cell carcinoma,
1165654|NCT01301248|stage III/IV
1165655|NCT01301235|Mitochondria
1165656|NCT01301222|octreotide
1165657|NCT01301222|pancreatic fistula
1165658|NCT01301222|soft pancreas
1165659|NCT01301222|pancreatoduodenectomy
1165660|NCT01301196|sedentary behaviour
1165661|NCT01301196|diabetes
1165662|NCT01301196|structured education
1165663|NCT01301196|18-30 years olds
1165664|NCT01301196|family history of T2DM or CVD
1165665|NCT01301196|BMI ≥ 25 (≥23 for south Asians)
1165666|NCT01301183|Anorexia Nervosa
1165667|NCT01301183|Estrogen
1165668|NCT01301183|Teenagers
1165669|NCT01301183|IGF-1
1165670|NCT01301170|Neck pain
1165671|NCT01301170|Dry Needling
1165672|NCT01301170|Manual Therapy
1165673|NCT01301170|Manipulation
1165674|NCT01301144|Tuberculosis
1165675|NCT01301144|Urea Breath Test
1165676|NCT01301118|Transplantation Infection
1165677|NCT01301118|Wound of skin
1165678|NCT01301118|Burns
1165679|NCT01301118|Graft Loss
1165680|NCT01301118|Infection
1165681|NCT01301105|pain regulation
1165682|NCT01301105|social stress
1165683|NCT01301105|affect
1165684|NCT01301105|attention
1165685|NCT01301105|brain
1165686|NCT01301105|immune
1165687|NCT01301105|endocrine
1165688|NCT01301079|Remifentanil
1165689|NCT01301079|Hyperalgesia
1165690|NCT01301079|Ketamine
1165691|NCT01301079|Von Frey's filament
1165692|NCT01301079|Algometer
1165693|NCT01301079|Interleukines
1165694|NCT01301079|Opioid-induced hyperalgesia
1165695|NCT01301053|hyperglycemia and increased mortality in the ICU
1165696|NCT01301053|hypoglycemia and increased mortality in the ICU
1165697|NCT01301053|glucose variability and increased mortality in the ICU
1165698|NCT01301053|Continuous Glucose Monitoring (CGM) and hypoglycemia
1165699|NCT01301053|hypoglycemia
1165700|NCT01301053|reducing ICU mortality
1165701|NCT01301040|breast cancer, elderly, early cardiac toxicity
1165702|NCT01301027|End stage renal disease
1165703|NCT01301027|Hemodialysis
1165704|NCT01301027|Pioglitazone
1165705|NCT01301027|Adipokines
1165706|NCT01301014|accuracy, anterior cruciate ligament, diagnostic value, examination, knee, Lachman test, sensitivity, specificity
1165707|NCT01301001|Vulvodynia
1165708|NCT01300988|HIV infection
1165709|NCT01300988|Neurokinin-1 receptor antagonist
1165710|NCT01300988|CCR5 expression
1165711|NCT01300988|Treatment Naive
1165712|NCT01300975|Leishmaniasis
1165713|NCT01300975|intralesional antimony
1165714|NCT01300975|cryotherapy
1165715|NCT01300962|Xeloda
1165716|NCT01300962|Capecitabine
1165717|NCT01300962|BKM120
1165718|NCT01300962|Lineberger Comprehensive Cancer Center
1165719|NCT01300962|Metastatic
1165720|NCT01300962|BYL719 Breast Cancer
1165721|NCT01300949|Contrast Sensitivity
1165722|NCT01300949|Pelli-Robson Test
1165723|NCT01300923|Fragile X Syndrome
1165724|NCT01300923|Acamprosate
1165725|NCT01300910|Adult Males
1165726|NCT01300910|Circumcision
1165727|NCT01300910|HIV prevention
1165728|NCT01300910|Device
1165729|NCT01300910|Shang Ring
1165730|NCT01300897|cortical function, motor evoked potential responses
1165731|NCT01300845|Oxygen mask
1165732|NCT01300845|Oxygen cannula
1165733|NCT01300845|Humidification
1165734|NCT01300845|Oxygen therapy
1165735|NCT01300845|Intensive Care Unit
1165736|NCT01300832|Surgery
1165737|NCT01300832|Deep Vein Thrombosis
1165738|NCT01300832|Preoperative
1165739|NCT01300819|Rotigotine
1165740|NCT01300819|Neupro®
1165741|NCT01300819|Non-motor symptoms
1165742|NCT01300806|HIV
1165743|NCT01300806|harmful substance use
1165744|NCT01300793|V-RICE
1165745|NCT01300793|Relapsed NHL
1165746|NCT01300793|Primary Refractory NHL
1165747|NCT01300780|bleaching agent
1165748|NCT01300780|tooth bleaching
1165749|NCT01300780|sensibility
1165750|NCT01300754|Osgood-Schlatter
1165751|NCT01300754|Tendinosis
1165752|NCT01300754|Apophysitis
1165753|NCT01300754|Enthesopathy
1165754|NCT01300754|Dextrose.
1165755|NCT01300728|Intravenous immunotherapy
1165756|NCT01300728|Conversion to Alzheimer Disease
1165757|NCT01300715|zygapophysial joint
1165758|NCT01300715|facet joint
1165759|NCT01300715|low back pain
1165760|NCT01300715|radiofrequency
1165761|NCT01300715|neurotomy
1165762|NCT01300689|HPV
1165763|NCT01300689|MSM
1165764|NCT01300689|Vaccine
1165765|NCT01300689|China
1165766|NCT01300676|Tualang honey
1165767|NCT01300676|HRT
1165768|NCT01300676|safety profiles
1165769|NCT01300676|cardiovascular parameters
1165770|NCT01300676|hormonal levels
1165771|NCT01300676|bone changes
1165772|NCT01300676|postmenopausal women
1165773|NCT01300650|Heart failure
1165774|NCT01300650|Inflammation
1165775|NCT01300650|Interleukin-1
1165776|NCT01300650|Cardiopulmonary exercise
1165777|NCT01300637|schizophrenia
1165778|NCT01300637|clozapine
1165779|NCT01300637|metabolic dysregulation
1165780|NCT01300637|metformin
1165781|NCT01300624|Aphasia
1165782|NCT01300624|therapy
1165783|NCT01300624|treatment
1165784|NCT01300624|verbs
1165785|NCT01300624|sentences
1165786|NCT01300611|Double Cord Blood Transplantation
1165787|NCT01300611|Neutrophil Engraftment
1165788|NCT01300611|Platelet Engraftment
1165789|NCT01300611|Immune Reconstitution
1165790|NCT01300611|Mucositis
1165791|NCT01300585|Breast
1165792|NCT01300585|Cancer
1165793|NCT01300559|efficacy
1165794|NCT01300559|hemoglobin
1165795|NCT01300559|spine
1165796|NCT01300546|Frequent migraine
1165797|NCT01300546|Migraine transformation
1165798|NCT01300546|Migraine
1165799|NCT01300546|Treximet
1165800|NCT01300546|Naproxen
1165801|NCT01300546|Sumatriptan
1165802|NCT01300533|Cancer
1165803|NCT01300533|Neoplasms
1165804|NCT01300533|Solid Tumor
1165805|NCT01300533|Ovarian Cancer
1165806|NCT01300533|Lung Cancer
1165807|NCT01300533|Non-Small Cell Lung Cancer
1165808|NCT01300533|Pancreatic Cancer
1165809|NCT01300533|Breast Cancer
1165810|NCT01300533|Endometrial Cancer
1165811|NCT01300533|Melanoma
1165812|NCT01300533|Prostate Cancer
1165813|NCT01300533|Skin Cancer
1165814|NCT01300533|Head and Neck Cancer
1165815|NCT01300533|Solid Malignancies
1165816|NCT01300520|Fluoroscopy
1165817|NCT01300520|Femoral fracture
1165818|NCT01300520|Tibial fracture
1165819|NCT01300520|Spinal Fusion
1165820|NCT01300507|stent thrombosis
1165821|NCT01300507|intra coronary imaging
1165822|NCT01300507|blood platelet function testing
1165823|NCT01300494|bifurcation lesion
1165824|NCT01300494|optimal viewing angle
1165825|NCT01300494|automated software
1165826|NCT01300468|advanced/metastatic solid tumors
1165827|NCT01300455|Insomnia
1165828|NCT01300455|obstructive sleep apnea
1165829|NCT01300455|orexin receptor antagonist
1165830|NCT01300442|chronic obstructive pulmonary disease
1165831|NCT01300442|diaphragm
1165832|NCT01300442|electrical stimulation
1165833|NCT01300442|pulmonary rehabilitation
1165834|NCT01300429|core biopsy
1165835|NCT01300429|Resistance to Crizotinib
1165836|NCT01300429|Non-small Cell Lung Cancer
1165837|NCT01300429|11-014
1165838|NCT01300416|Kidney transplantation
1165839|NCT01300416|mycophenolate sodium
1165840|NCT01300416|EC-MPS
1165841|NCT01300416|Health Related Quality of Life
1165842|NCT01300416|GI symptoms
1165843|NCT01300416|Immunosuppressants
1165844|NCT01300416|HRQL
1165845|NCT01300416|PGWB
1165846|NCT01300416|GIQLI
1165847|NCT01300390|liver transplant
1165848|NCT01300390|end-stage liver disease
1165849|NCT01300390|cirrhosis
1165850|NCT01300377|Post-operative pain
1165851|NCT01300377|pain
1165852|NCT01300377|pacemaker
1165853|NCT01300377|defibrillator
1165854|NCT01300377|post-operative narcotic use
1165855|NCT01300377|local anesthesia
1165856|NCT01300351|Advanced breast cancer
1165857|NCT01300351|metastatic breast cancer
1165858|NCT01300338|Diabetes
1165859|NCT01300325|Bronchiolitis, 3% Hypertonic Saline Solution
1165860|NCT01300312|eperisone
1165861|NCT01300312|diclofenac
1165862|NCT01300312|low back pain
1165863|NCT01300299|lung cancer
1165864|NCT01300299|radiation
1165865|NCT01300299|stereotactic
1165866|NCT01300273|Diabetic nephropathy
1165867|NCT01300273|Podocyte
1165868|NCT01300273|Low Protein Diet
1165869|NCT01300273|Ketoanalogs
1165870|NCT01300234|tenofovir disoproxil fumarate
1165871|NCT01300234|chronic hepatitis B
1165872|NCT01300234|adefovir dipivoxil
1165873|NCT01300221|Three dimension echocardiography
1165874|NCT01300221|Congenital heart disease
1165875|NCT01300221|Z-score
1165876|NCT01300208|cutaneous lupus erythematosus
1165877|NCT01300208|subacute lupus erythematosus
1165878|NCT01300208|discoid lupus erythematosus
1165879|NCT01300208|lupus
1165880|NCT01300195|VATS
1165881|NCT01300195|standardized surgery
1165882|NCT01300195|persistent pain
1165883|NCT01300182|ACLR
1165884|NCT01300169|Suicide
1165885|NCT01300169|Assessment
1165886|NCT01300169|Intervention
1165887|NCT01300169|CAMS
1165888|NCT01300156|Hodgkin's disease
1165889|NCT01300156|lymphoma
1165890|NCT01300156|Relapsed
1165891|NCT01300156|refractory
1165892|NCT01300130|neurological development
1165893|NCT01300130|preterm infants
1165894|NCT01300130|fatty acid status
1165895|NCT01300117|cardiac surgery
1165896|NCT01300117|adamts13
1165897|NCT01300117|TTP
1165898|NCT01300117|extracorporeal circulation
1165899|NCT01300117|Heart-Lung Machine
1165900|NCT01300104|prostate cancer progression
1165901|NCT01300104|active surveillance
1165902|NCT01300104|whole grain rye
1165903|NCT01300104|exercise
1165904|NCT01300104|insulin sensitivity
1165905|NCT01300104|quality of life
1165906|NCT01300091|Shoulder
1165907|NCT01300091|Pain
1165908|NCT01300091|Range of Motion
1165909|NCT01300091|Disability Evaluation
1165910|NCT01300091|Function
1165911|NCT01300091|Sick Leave
1165912|NCT01300091|Primary Health Care
1165913|NCT01300091|Visual Analog Scale
1165914|NCT01300091|Visual Analog Pain Scale
1165915|NCT01300091|The American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form
1165916|NCT01300078|Hot Flashes
1165917|NCT01300078|Hot Flushes
1165918|NCT01300078|Vasomotor Symptoms
1165919|NCT01300078|Menopausal Symptoms
1165920|NCT01300052|psoriasis
1165921|NCT01300039|nephrolithiasis
1165922|NCT01300039|urolithiasis
1165923|NCT01300039|hyperoxaluria
1165924|NCT01300039|Helicobacter pylori
1165925|NCT01300026|Low intermediate grade B cell Lymphoma
1165926|NCT01300026|Non-cutaneous T-cell NHL
1165927|NCT01300026|Mantle Cell Lymphoma
1165928|NCT01300026|PI3K delta
1165929|NCT01300026|Lymphoid
1165930|NCT01300026|NHL
1165931|NCT01300026|MCL
1165932|NCT01300026|Hematologic
1165933|NCT01300026|CLL
1165934|NCT01300026|Chronic Lymphocytic Leukemia
1165935|NCT01300013|Intravenous
1165936|NCT01300013|IV
1165937|NCT01300013|Left Ventricular Systolic Dysfunction
1165938|NCT01300013|Hospitalized
1165939|NCT01300013|Acute heart failure
1165940|NCT01300013|Heart failure
1165941|NCT01300013|Left ventricular ejection fraction
1165942|NCT01300013|pharmacokinetics
1165943|NCT01300013|Pharmacodynamics
1165944|NCT01300013|Dyspnea
1165945|NCT01300013|hospitalization
1165946|NCT01300013|In-patient
1165947|NCT01300013|Omecamtiv mecarbil
1165948|NCT01300013|Double-blind
1165949|NCT01300013|Randomized
1165950|NCT01300013|Placebo-controlled
1165951|NCT01299987|Keywords provided by University Hospital Mannheim:
1165952|NCT01299987|Intraoperative Radiotherapy
1165953|NCT01299987|Early Breast Cancer
1165954|NCT01299987|Elderly Patients
1165955|NCT01299974|Family-centered
1165956|NCT01299974|teaching
1165957|NCT01299974|residents
1165958|NCT01299974|family faculty
1165959|NCT01299961|Rheumatoid Arthritis
1165960|NCT01299961|Subcutaneous Abatacept
1165961|NCT01299961|Ultrasound
1165962|NCT01299948|HIV
1165963|NCT01299948|AIDS
1165964|NCT01299948|CD4
1165965|NCT01299948|progression
1165966|NCT01299948|immune activation
1165967|NCT01299935|stress reduction
1165968|NCT01299935|Transcendental Meditation technique
1165969|NCT01299935|secondary prevention of coronary heart disease
1165970|NCT01299922|Lupus nephritis
1165971|NCT01299922|Therapy
1165972|NCT01299922|Cyclosporin
1165973|NCT01299922|Mycophenolic acid
1165974|NCT01299909|Mindfulness Training for Smokers
1165975|NCT01299909|Smoking
1165976|NCT01299909|Smoking cessation
1165977|NCT01299909|Addiction
1165978|NCT01299909|behavioral intervention
1165979|NCT01299909|Nicotine
1165980|NCT01299909|Tobacco
1165981|NCT01299909|Mindfulness
1165982|NCT01299909|Meditation
1165983|NCT01299909|MBSR
1165984|NCT01299909|Mindfulness Based Stress Reduction
1165985|NCT01299909|Mindfulness Based Cognitive Therapy
1165986|NCT01299909|MBCT
1165987|NCT01299909|Mindfulness Based Relapse Prevention
1165988|NCT01299909|MBRP
1165989|NCT01299909|Mindfulness Training
1165990|NCT01299909|Nicotine Patch
1165991|NCT01299909|Quit Line
1165992|NCT01299909|Phone counseling
1165993|NCT01299909|Freedom from Smoking
1165994|NCT01299896|Cigarette Smoking
1165995|NCT01299896|Smoking, Tobacco
1165996|NCT01299896|Tobacco Smoking
1165997|NCT01299896|Smoking Cessation
1165998|NCT01299896|Tobacco Dependence
1165999|NCT01299883|Cancer
1166000|NCT01299883|CVD
1166001|NCT01299883|African American
1166002|NCT01299883|Health Education Intervention
1166003|NCT01299883|Intervention RCT
1166004|NCT01299883|Study focus is to examine the influence of health education regarding either CVD or CVD and cancer on health behaviors.
1166005|NCT01299857|pemphigus
1166006|NCT01299857|Mabthéra (R)
1166007|NCT01299857|B lymphocytes
1166008|NCT01299857|desmogleines
1166009|NCT01299844|Type 2 Diabetes
1166010|NCT01299818|central pain
1166011|NCT01299818|spine surgey
1166012|NCT01299818|outcome
1166013|NCT01299818|patients undergo spinal surgery
1166014|NCT01299805|Drug Therapy
1166015|NCT01299805|pharmacodynamic
1166016|NCT01299792|spinal cord injury
1166017|NCT01299792|urodynamics
1166018|NCT01299792|ultrasound
1166019|NCT01299792|neurogenic bladder dysfunction
1166020|NCT01299779|hyponatremia
1166021|NCT01299779|PEG-SD
1166022|NCT01299779|PEG-ELS
1166023|NCT01299766|Mild Cognitive Impairment
1166024|NCT01299766|Memory
1166025|NCT01299727|Recombinant Human Heparan N-Sulfatase (rhHNS)
1166026|NCT01299727|Sanfilippo Syndrome Type A (MPS IIIA)
1166027|NCT01299727|Lysosomal storage disease (LSD)
1166028|NCT01299727|Mucopolysaccharidosis (MPS) III
1166029|NCT01299714|Human Papilloma Virus
1166030|NCT01299714|vaccine
1166031|NCT01299714|stress
1166032|NCT01299714|cervical cancer
1166033|NCT01299714|GARDASIL
1166034|NCT01299701|Advanced or metastatic cancer
1166035|NCT01299701|refractory
1166036|NCT01299701|core phase
1166037|NCT01299701|extension phase
1166038|NCT01299701|dose escalation
1166039|NCT01299701|standard chemotherapy
1166040|NCT01299701|docetaxel
1166041|NCT01299701|paclitaxel
1166042|NCT01299701|carboplatin
1166043|NCT01299701|safety
1166044|NCT01299701|tolerability
1166045|NCT01299675|MR conditional
1166046|NCT01299649|CAD
1166047|NCT01299636|PM060184
1166048|NCT01299636|Phase I
1166049|NCT01299636|Pharma Mar
1166050|NCT01299623|breast cancer
1166051|NCT01299623|breast cancer prevention
1166052|NCT01299623|African American women
1166053|NCT01299610|Atopic Dermatitis
1166054|NCT01299610|GW870086X
1166055|NCT01299610|TIS
1166056|NCT01299610|IGA
1166057|NCT01299597|repeat dose
1166058|NCT01299597|statins
1166059|NCT01299597|safety and tolerability
1166060|NCT01299597|drug interaction
1166061|NCT01299597|sb649868
1166062|NCT01299597|healthy male subjects
1166063|NCT01299597|pharmacokinetics
1166064|NCT01299558|pharmacokinetics
1166065|NCT01299558|GW642444
1166066|NCT01299558|absolute bioavailability
1166067|NCT01299558|healthy subjects
1166068|NCT01299558|fluticasone furoate
1166069|NCT01299558|GW685698
1166070|NCT01299545|Rheumatoid Arthritis
1166071|NCT01299545|Anti TNF
1166072|NCT01299545|Infliximab
1166073|NCT01299545|Methotrexate
1166074|NCT01299545|DMARDs
1166075|NCT01299545|Gene expression biomarkers
1166076|NCT01299519|obesity
1166077|NCT01299519|weight loss
1166078|NCT01299519|insulin resistance
1166079|NCT01299506|soft tissue sarcoma
1166080|NCT01299506|trabectedin
1166081|NCT01299506|Netherlands
1166082|NCT01299493|carcinoma
1166083|NCT01299493|colorectal cancer
1166084|NCT01299493|community health centers
1166085|NCT01299493|cluster-randomized
1166086|NCT01299493|health behavior
1166087|NCT01299480|Healthy adolescents
1166088|NCT01299467|Asthma
1166089|NCT01299467|duration of action
1166090|NCT01299467|allergen challenge
1166091|NCT01299428|CEREBRAL OXYGENATION
1166092|NCT01299428|HYPERNATREMİA
1166093|NCT01299428|NEWBORN
1166094|NCT01299428|NA VALUES
1166095|NCT01299415|ASA404,
1166096|NCT01299415|Phase I,
1166097|NCT01299415|Oncology,
1166098|NCT01299415|CYP1A2,
1166099|NCT01299415|fluvoxamine,
1166100|NCT01299415|drug drug interaction,
1166101|NCT01299415|Novartis,
1166102|NCT01299415|Antisoma
1166103|NCT01299389|Paliperidone palmitate
1166104|NCT01299389|Schizophrenia
1166105|NCT01299376|Essential hypertension
1166106|NCT01299376|Antihypertensive agents
1166107|NCT01299376|Blood pressure
1166108|NCT01299376|Uncontrolled hypertension
1166109|NCT01299363|Prolapse
1166110|NCT01299363|Pain with intercourse
1166111|NCT01299363|Dyspareunia
1166112|NCT01299363|Post operative pain
1166113|NCT01299350|Heart failure
1166114|NCT01299350|Nt-proBNP
1166115|NCT01299324|CHF
1166116|NCT01299311|insulin sensitivity
1166117|NCT01299285|Absorption
1166118|NCT01299285|Distribution
1166119|NCT01299285|Metabolism
1166120|NCT01299285|Excretion
1166121|NCT01299285|Mass balance
1166122|NCT01299285|Metabolic profile
1166123|NCT01299285|Radiolabeled study
1166124|NCT01299285|14C
1166125|NCT01299259|Text message reminders
1166126|NCT01299259|Pelvic inflammatory disease
1166127|NCT01299259|PID
1166128|NCT01299259|Primary care follow-up
1166129|NCT01299259|Emergency department care
1166130|NCT01299259|Discharge instructions
1166131|NCT01299246|Diabetic Foot
1166132|NCT01299246|non-invasive DFP assessment tools
1166133|NCT01299246|early detection of DFP
1166134|NCT01299220|Erlotinib
1166135|NCT01299220|Acitretin
1166136|NCT01299220|Rash
1166137|NCT01299220|Dermatology
1166138|NCT01299220|Oncology
1166139|NCT01299207|Stents
1166140|NCT01299207|Drug-Eluting Stents
1166141|NCT01299207|Stent Thrombosis
1166142|NCT01299207|Bleeding
1166143|NCT01299207|Dual-Antiplatelet Therapy
1166144|NCT01299194|BRONCHIECTASIS
1166145|NCT01299194|PSEUDOMONAS AERUGINOSA
1166146|NCT01299194|STATIN
1166147|NCT01299194|OUTCOME
1166148|NCT01299181|Bronchiectasis
1166149|NCT01299181|Outcome
1166150|NCT01299181|Statin therapy
1166153|NCT01299155|Intraocular Lens
1166154|NCT01299155|Presbyopia Correcting IOL
1166155|NCT01299142|Influenza
1166156|NCT01299142|antibodies
1166157|NCT01299142|monoclonal
1166158|NCT01299142|virus
1166159|NCT01299129|Uveitis
1166160|NCT01299129|Cystoid macular edema
1166161|NCT01299129|microperimetry
1166162|NCT01299129|functional visual acuity
1166163|NCT01299129|intravitreal triamcinolone
1166164|NCT01299116|AE adverse event
1166165|NCT01299116|FDA (U.S.) Food and Drug Administration
1166166|NCT01299116|GCP Good Clinical Practice guidelines
1166167|NCT01299116|ICH International Conference of Harmonisation
1166168|NCT01299116|IRB Institutional Review Board
1166169|NCT01299116|IU International units
1166170|NCT01299116|mg milligram(s)
1166171|NCT01299116|mm3 cubic millimeter(s)
1166172|NCT01299116|LARC Long-Acting reversible contraception
1166173|NCT01299116|PPCNC Planned Parenthood of North Carolina
1166174|NCT01299116|SAE serious adverse event
1166175|NCT01299116|SARC Short-Acting reversible contraception
1166176|NCT01299116|µg microgram
1166177|NCT01299116|ULN upper limit of the normal range
1166178|NCT01299103|wrinkle
1166179|NCT01299103|rhytide
1166180|NCT01299090|wrinkles
1166181|NCT01299090|rhytides
1166182|NCT01299077|Lumbar disc degenerative disease
1166183|NCT01299077|Methycobal
1166184|NCT01299064|mindfulness-based intervention
1166185|NCT01299064|symptoms reduction
1166186|NCT01299064|mental health
1166187|NCT01299051|Weight Management
1166188|NCT01299051|Employee Health
1166189|NCT01299038|Crestor
1166190|NCT01299038|TFBP
1166191|NCT01299038|rosuvastatin
1166192|NCT01299025|balance
1166193|NCT01299025|walking
1166194|NCT01298999|Barrett's Esophagus
1166195|NCT01298999|Esophageal Adenocarcinoma
1166196|NCT01298999|GERD
1166197|NCT01298999|Acid Reflux
1166198|NCT01298986|atrial fibrillation ablation procedures
1166199|NCT01298960|Poor Ovarian response in IVF
1166200|NCT01298960|Metaphase II oocytes
1166201|NCT01298960|Pregnancy Rate
1166202|NCT01298960|Growth Hormone
1166203|NCT01298947|Photoablative Atherectomy
1166204|NCT01298947|Paclitaxel-Coated Balloon
1166205|NCT01298947|Instent Femoro-popliteal Obstructions
1166206|NCT01298921|Headache
1166207|NCT01298921|Cluster Headache
1166208|NCT01298921|Oxygen Therapy
1166209|NCT01298908|varicose veins, oedema
1166210|NCT01298895|optical components
1166211|NCT01298895|pseudoexfoliation
1166212|NCT01298895|cataract
1166213|NCT01298895|LENSTAR® LS 900®
1166214|NCT01298882|Type 2 diabetes mellitus
1166215|NCT01298882|Overweight
1166216|NCT01298882|Obesity
1166217|NCT01298869|CKD
1166218|NCT01298869|HPV infection
1166219|NCT01298869|HPV vaccine
1166220|NCT01298869|antibodies titer
1166221|NCT01298856|hydrotherapy
1166222|NCT01298856|chronic ankle instability
1166223|NCT01298856|ankle taping
1166224|NCT01298843|Confirmed or Suspected Infections
1166225|NCT01298817|Obesity
1166226|NCT01298817|Aging
1166227|NCT01298817|Soy
1166228|NCT01298817|Weight Loss
1166229|NCT01298817|Ectopic Fat
1166230|NCT01298778|chronic pain post delivery
1166231|NCT01298778|postpartum depression
1166232|NCT01298778|tailored pain management
1166233|NCT01298765|buccal soluble film
1166234|NCT01298739|asthma control level , ACQ
1166235|NCT01298726|PHARMACEUTICAL SERVICES
1166236|NCT01298726|DIABETES MELLITUS
1166237|NCT01298713|Hormonoresistance
1166238|NCT01298713|tamoxifen
1166356|NCT01298115|transplantation
1166239|NCT01298713|Previously received anti-aromatase treatment
1166240|NCT01298713|mTor inhibitor
1166241|NCT01298687|open-angle glaucoma
1166242|NCT01298687|ocular hypertension
1166243|NCT01298687|divided dose
1166244|NCT01298661|Exercise Test
1166245|NCT01298661|Reproducibility of Results
1166246|NCT01298661|Mortality
1166247|NCT01298648|Crohn's Disease
1166248|NCT01298635|Primary angle-closure glaucoma
1166249|NCT01298635|cataract
1166250|NCT01298635|trabeculectomy
1166251|NCT01298635|phacotrabeculectomy
1166252|NCT01298609|Fibromyalgia
1166253|NCT01298609|Occipital Nerve Stimulation
1166254|NCT01298570|Metastatic Colorectal Cancer
1166255|NCT01298570|K-RAS mutation
1166256|NCT01298570|BRAF mutation
1166257|NCT01298570|Regorafenib
1166258|NCT01298570|BAY 73-4506
1166259|NCT01298570|FOLFIRI
1166260|NCT01298570|Irinotecan
1166261|NCT01298570|5-FU
1166262|NCT01298570|Leucovorin
1166263|NCT01298570|Placebo
1166264|NCT01298570|Phase II
1166265|NCT01298570|Multi-Center
1166266|NCT01298570|Randomized
1166267|NCT01298570|Lineberger
1166268|NCT01298570|North Carolina Cancer Hospital
1166269|NCT01298570|UNC
1166270|NCT01298557|Traumatic brain injury
1166271|NCT01298557|Post-concussive symptoms
1166272|NCT01298557|Brain imaging
1166273|NCT01298557|Neurocognitive testing
1166274|NCT01298544|Vaccine
1166275|NCT01298544|Prevenar
1166276|NCT01298544|Pneumococcal disease
1166277|NCT01298531|Etanercept
1166278|NCT01298531|Axial Spondyloarthritis
1166279|NCT01298531|NSAIDs sparing effect
1166280|NCT01298518|multiple dose study in type 2 diabetes patients
1166281|NCT01298505|Phase 1 multiple dose safety toleration fexofenadine
1166282|NCT01298492|Anti-TNF Refractory
1166283|NCT01298492|Immunosuppressant Refractory
1166284|NCT01298492|Active Crohn's disease
1166285|NCT01298479|volume delivery
1166286|NCT01298466|identification
1166287|NCT01298466|chronic
1166288|NCT01298466|neuropathic
1166289|NCT01298466|low back pain
1166290|NCT01298466|primary care
1166291|NCT01298466|pregabalin
1166292|NCT01298414|childhood acute myeloid leukemia/other myeloid malignancies
1166293|NCT01298401|adenocarcinoma of the pancreas
1166294|NCT01298401|stage IIB pancreatic cancer
1166295|NCT01298401|stage III pancreatic cancer
1166296|NCT01298388|long-term effects secondary to cancer therapy in children
1166297|NCT01298388|cancer survivor
1166298|NCT01298388|recurrent childhood acute lymphoblastic leukemia
1166299|NCT01298388|untreated childhood acute lymphoblastic leukemia
1166300|NCT01298388|T-cell childhood acute lymphoblastic leukemia
1166301|NCT01298388|non-T, non-B childhood acute lymphoblastic leukemia
1166302|NCT01298388|non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
1166303|NCT01298388|non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
1166304|NCT01298388|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
1166305|NCT01298388|childhood acute lymphoblastic leukemia in remission
1166306|NCT01298375|Metabolic flexibility
1166307|NCT01298375|Mitochondrial function
1166308|NCT01298375|Human primary myoblasts
1166309|NCT01298375|Lipid metabolism
1166310|NCT01298336|Mycobacterium Xenopi Pulmonary Infection
1166311|NCT01298336|Clarithromycin
1166312|NCT01298336|Moxifloxacin
1166313|NCT01298323|Medullary Thyroid Cancer
1166314|NCT01298323|Locally advanced
1166315|NCT01298323|Metastatic
1166316|NCT01298323|Vandetanib
1166317|NCT01298323|Patient Outreach
1166318|NCT01298310|Morton's neuroma, QST measurements
1166319|NCT01298297|Buprenorphine, acute pain, analgesia
1166320|NCT01298284|Variceal bleeding
1166321|NCT01298284|portal hypertension
1166322|NCT01298284|hepatocelluar carcinoma
1166323|NCT01298284|endoscopic variceal ligation
1166324|NCT01298284|non-selective beta-blocker
1166325|NCT01298284|rebleeding
1166326|NCT01298271|gastric variceal bleeding
1166327|NCT01298271|primaryprevention
1166328|NCT01298271|cyanoacrylate injection
1166329|NCT01298271|non-selective beta-blocker
1166330|NCT01298245|diabetes
1166331|NCT01298245|diabetic retinopathy
1166332|NCT01298245|Chinese
1166333|NCT01298245|gene
1166334|NCT01298245|associations
1166335|NCT01298206|A/H1N1 Influenza
1166336|NCT01298206|swine flu
1166337|NCT01298206|virus disease
1166338|NCT01298206|Avian flu
1166339|NCT01298193|Early-stage breast cancer patients
1166340|NCT01298180|Prader-Willi Syndrome
1166341|NCT01298180|Growth Hormone Deficiency
1166342|NCT01298167|Cyanoacrylate
1166343|NCT01298167|Fast Absorbing Gut
1166344|NCT01298167|Mohs Surgery
1166345|NCT01298167|Epidermal closure method
1166346|NCT01298154|Food intake
1166347|NCT01298154|Blood glucose
1166348|NCT01298154|Pulses
1166349|NCT01298154|Protein
1166350|NCT01298141|Replagal
1166351|NCT01298141|Enzyme Replacement Therapy
1166352|NCT01298141|agalsidase alfa
1166353|NCT01298115|chronic kidney disease
1166354|NCT01298115|dialysis
1166355|NCT01298115|pre dialysis education
1166357|NCT01298115|conservative care
1166358|NCT01298102|kidney
1166359|NCT01298102|transplantation
1166360|NCT01298102|haemodialysis
1166361|NCT01298102|vaccination
1166362|NCT01298102|influenza H1N1 2009
1166363|NCT01298089|Flap
1166364|NCT01298089|LASIK
1166365|NCT01298089|Corneal
1166366|NCT01298076|Diabetes
1166367|NCT01298076|Retinopathy
1166368|NCT01298076|Macular oedema
1166369|NCT01298076|Laser
1166370|NCT01298076|Photocoagulation
1166371|NCT01298076|Fovea
1166372|NCT01298076|Steroid
1166373|NCT01298076|Bevacizumab
1166374|NCT01298076|Intravitreal
1166375|NCT01298037|Immunology, Hepatitis B, HBV
1166376|NCT01298024|Achilles tendon rupture
1166377|NCT01298024|Non-surgical treatment
1166378|NCT01298024|Exercise
1166379|NCT01298024|Neuromuscular training
1166380|NCT01298011|operable
1166381|NCT01298011|pancreas
1166382|NCT01298011|Abraxane
1166383|NCT01298011|Gemcitabine
1166384|NCT01298011|Preoperative
1166385|NCT01298011|potentially
1166386|NCT01298011|Pancreatic Cancer
1166387|NCT01297985|Serious mental illness
1166388|NCT01297985|Psychiatric disability
1166389|NCT01297985|Mental health peer-led
1166390|NCT01297985|Mental illness education
1166391|NCT01297985|Illness self-management
1166392|NCT01297972|Aplastic Anemia
1166393|NCT01297972|Mesenchymal Stem Cells
1166394|NCT01297959|Surgical Wound Infection
1166395|NCT01297959|Therapeutic Enzyme System
1166396|NCT01297959|Singlet Oxygen
1166397|NCT01297959|Peroxidase
1166398|NCT01297959|Glucose Oxidase
1166399|NCT01297959|Colorectal surgery
1166400|NCT01297959|Incisional Surgical Site Infections (SSI)
1166401|NCT01297959|Anti-infective Agents, Local
1166402|NCT01297959|Clinical Trial, Phase III
1166403|NCT01297933|parenteral nutrition associated liver disease
1166404|NCT01297933|cholestasis
1166405|NCT01297933|short bowel syndrome
1166406|NCT01297933|Omegaven
1166407|NCT01297920|Open-Angle Glaucoma
1166408|NCT01297920|Ocular Hypertension
1166409|NCT01297920|Brinzolamide
1166410|NCT01297920|Brimonidine
1166411|NCT01297920|Intraocular pressure
1166412|NCT01297907|Crohn's Disease
1166413|NCT01297907|Bronchial hyper reactivity
1166414|NCT01297907|Fractional exhaled NO
1166415|NCT01297907|Methacholine Challenge Test
1166416|NCT01297907|Pediatric Crohn's Disease Activity Index
1166417|NCT01297907|To determine the frequency of bronchial hyperreactivity in pediatric patients followed and treated for Crohn disease
1166418|NCT01297894|A. baumannii
1166419|NCT01297894|colistin
1166420|NCT01297894|fosfomycin
1166421|NCT01297881|Caucasian outpatients
1166422|NCT01297881|undiagnosed respiratory symptoms
1166423|NCT01297881|dyspnea
1166424|NCT01297881|cough
1166425|NCT01297881|sputum
1166426|NCT01297829|ibuprofen
1166427|NCT01297829|postoperative narcotics
1166428|NCT01297829|visual analog pain scale
1166429|NCT01297829|inguinal hernia repair
1166430|NCT01297829|umbilical hernia repair
1166431|NCT01297790|Cough
1166432|NCT01297790|Inhalational cough challenges
1166433|NCT01297790|Cough reflex sensitivity
1166434|NCT01297790|Chronic cough.
1166435|NCT01297777|Mast cell
1166436|NCT01297777|Mastocytosis
1166437|NCT01297777|Mast cell disease
1166438|NCT01297738|diet manipulation
1166439|NCT01297738|serotonin
1166440|NCT01297738|dopamine
1166441|NCT01297738|insulin sensitivity
1166442|NCT01297725|Cesarean section
1166443|NCT01297725|Cesarean section[*methods]
1166444|NCT01297725|Fascia [*surgery]
1166445|NCT01297725|Randomized Controlled Trial
1166446|NCT01297725|Abdominal Wall [*surgery]
1166447|NCT01297725|Pain, postoperative
1166448|NCT01297725|Surgical wound infection
1166449|NCT01297712|screening colonoscopy
1166450|NCT01297712|adenoma
1166451|NCT01297712|hyperplastic polyp
1166452|NCT01297712|differential diagnosis
1166453|NCT01297699|Graves´ orbitopathy
1166454|NCT01297699|Graves´ ophthalmopathy
1166455|NCT01297699|Thyroid eye disease
1166456|NCT01297699|Thyroid-associated ophthalmopathy
1166457|NCT01297699|Tocilizumab
1166458|NCT01297699|EUGOGO
1166459|NCT01297699|CAS
1166460|NCT01297686|Chronic plantar fasciitis
1166461|NCT01297686|Workplace injury
1166462|NCT01297686|Foot and Ankle Disability Index
1166463|NCT01297686|Ultrasound measure of disease severity
1166464|NCT01297673|vesico-ureteral reflux
1166465|NCT01297673|neurogenic bladder dysfunction
1166466|NCT01297673|spinal cord injury
1166467|NCT01297660|neurogenic detrusor overactivity
1166468|NCT01297660|detrusor sphincter dyssynergia
1166469|NCT01297660|compliance
1166470|NCT01297660|video urodynamic
1166471|NCT01297660|spinal cord injury
1166472|NCT01297647|urinary tract infection
1166473|NCT01297647|urodynamics
1166474|NCT01297647|spinal cord injury
1166475|NCT01297634|Botulinum toxin type A
1166476|NCT01297634|Hyperfunctional forehead lines
1166477|NCT01297634|Randomized controlled trial
1166478|NCT01297634|Double-blinded trial
1166479|NCT01297634|Electromyogram (EMG)
1166480|NCT01297634|Electromyographic activity
1166481|NCT01297634|Frontal Area
1166482|NCT01297621|breast hypertrophy
1166483|NCT01297621|physical activity
1166484|NCT01297621|sexuality
1166485|NCT01297621|patient satisfaction
1166486|NCT01297595|relative bioavailability
1166487|NCT01297595|pharmacokinetics
1166488|NCT01297595|crizotinib
1166489|NCT01297595|oral liquid formulation
1166490|NCT01297595|formulated capsule
1166491|NCT01297582|ONO-6950
1166492|NCT01297582|Healthy Adult Subjects
1166493|NCT01297569|Diabetic macular edema
1166494|NCT01297569|Macular edema
1166495|NCT01297569|DME
1166496|NCT01297569|Diabetic retinopathy
1166497|NCT01297569|Diabetic eye disease
1166498|NCT01297569|anti-VEGF
1166499|NCT01297569|ranibizumab
1166500|NCT01297569|Lucentis
1166501|NCT01297556|Irritable Bowel Syndrome
1166502|NCT01297543|Induction chemotherapy
1166503|NCT01297543|Re-induction chemotherapy
1166504|NCT01297543|Consolidation chemotherapy
1166505|NCT01297543|Leukemia
1166506|NCT01297543|Myelodysplasia
1166507|NCT01297530|Phase I
1166508|NCT01297530|Dose Escalation
1166509|NCT01297530|Hypoxia inducible factor 1 alpha
1166510|NCT01297530|Neoplasms
1166511|NCT01297517|AOG
1166512|NCT01297517|OHT
1166513|NCT01297517|Open-Angle Glaucoma
1166514|NCT01297517|Ocular Hypertension
1166515|NCT01297504|palivizumab
1166516|NCT01297504|lower respiratory tract infection
1166517|NCT01297504|Respiratory syncytial virus
1166518|NCT01297504|usage patterns
1166519|NCT01297491|NSCLC
1166520|NCT01297491|PI3K
1166521|NCT01297465|Ovulation Induction
1166522|NCT01297465|Ovarian Stimulation
1166523|NCT01297465|Reproductive Technique, Assisted
1166524|NCT01297465|Assisted Reproductive Technics
1166525|NCT01297465|Assisted Reproductive Technique
1166526|NCT01297465|Reproductive Technology, Assisted
1166527|NCT01297452|BKM120
1166528|NCT01297452|CARBOPLATIN
1166529|NCT01297452|TAXOL (PACLITAXEL)
1166530|NCT01297452|Chemotherapy
1166531|NCT01297452|10-192
1166532|NCT01297439|shoulder dystocia,
1166533|NCT01297439|Mac Roberts' maneuver,
1166534|NCT01297439|pushing maneuver
1166535|NCT01297413|allogeneic
1166536|NCT01297413|adult
1166537|NCT01297413|stem
1166538|NCT01297413|cells
1166539|NCT01297413|stroke
1166540|NCT01297413|ischemic
1166541|NCT01297400|Burns, Partial Thickness Burns
1166542|NCT01297387|Diabetic Patients
1166543|NCT01297387|Critical Limb Ischemia
1166544|NCT01297387|Revascularization
1166545|NCT01297374|Obesity
1166546|NCT01297348|Lybrel
1166547|NCT01297348|levonorgestrel
1166548|NCT01297348|ethinyl estradiol
1166549|NCT01297348|venus thromboembolism (VTE)
1166550|NCT01297348|oral contraceptives (OC)
1166551|NCT01297348|safety
1166552|NCT01297348|database study
1166553|NCT01297348|case-control study
1166554|NCT01297335|intrathecal
1166555|NCT01297335|clonidine
1166556|NCT01297335|poorly
1166557|NCT01297335|controlled
1166558|NCT01297335|hypertension
1166559|NCT01297322|vascular closure system
1166560|NCT01297322|manual compression
1166561|NCT01297322|femoral arteriotomy
1166562|NCT01297322|percutaneous endovascular procedures
1166563|NCT01297309|PTH 1-84
1166564|NCT01297309|Hypoparathyroidism
1166565|NCT01297309|Parathyroid Hormone 1-84
1166566|NCT01297309|NPSP558
1166575|NCT01297283|Heart failure
1166576|NCT01297283|Cardiac resynchronization
1166577|NCT01297283|Leadless ECG
1166578|NCT01297283|Follow-up
1166579|NCT01297244|AV-951
1166580|NCT01297244|Tivozanib
1166581|NCT01297244|Advanced Renal Cell Carcinoma
1166582|NCT01297244|RCC
1166583|NCT01297244|Biomarkers
1166584|NCT01297231|fibroglandular tissue
1166585|NCT01297231|tamoxifen
1166586|NCT01297231|MRI
1166587|NCT01297231|Background Parenchymal Enhancement
1166588|NCT01297231|10-217
1166589|NCT01297218|Alzheimer, Mesenchymal Stem Cells, Umbilical Cord Blood
1166590|NCT01297205|Human Umbilical Cord Blood Derived Mesenchymal Stem Cells
1166591|NCT01297205|Bronchopulmonary dysplasia
1166592|NCT01297205|Premature infants
1166593|NCT01297192|YM178
1166594|NCT01297192|Mirabegron
1166595|NCT01297192|DDI
1166596|NCT01297192|Phase I
1166597|NCT01297192|Solifenacin
1166598|NCT01297192|Pharmacokinetics
1166599|NCT01297192|Pharmacokinetics of mirabegron
1166600|NCT01297179|Pharmacokinetics
1166601|NCT01297179|Oral contraceptives
1166602|NCT01297179|Drug interactions
1166603|NCT01297179|Pharmacokinetics of mirabegron
1166604|NCT01297153|Congenital Cataract
1166605|NCT01297153|Children younger than 2 years
1166606|NCT01297153|Aphakia
1166607|NCT01297153|Primary IOL Implantation
1166608|NCT01297140|Psychiatry
1166609|NCT01297140|Behaviour
1166610|NCT01297140|Alzheimer's
1166611|NCT01297140|Personality
1166612|NCT01297088|Proof of Mechanism
1166613|NCT01297088|Phase I
1166614|NCT01297088|Neoplasm
1166615|NCT01297088|Inflammation
1166616|NCT01297075|Health Services Research
1166617|NCT01297075|Chronic Care
1166618|NCT01297075|Outreach Visits
1166619|NCT01297075|Primary care
1166620|NCT01297075|chronic disease management
1166621|NCT01297062|Diabetes
1166622|NCT01297062|exenatide
1166623|NCT01297062|Amylin
1166624|NCT01297062|Lilly
1166625|NCT01297062|QT interval
1166626|NCT01297049|Diabetes
1166627|NCT01297049|obesity
1166628|NCT01297049|behavior therapy
1166629|NCT01297049|self management
1166630|NCT01297036|Pharmacokinetics
1166631|NCT01297036|Bioequivalence
1166632|NCT01297036|Donepezil
1166633|NCT01297023|calcium phosphate
1166634|NCT01297023|vitamin d3
1166635|NCT01297023|bone metabolism
1166636|NCT01297023|human study
1166637|NCT01297010|Nausea and Vomiting
1166638|NCT01297010|Vomiting
1166639|NCT01297010|Postoperative
1166640|NCT01297010|Anesthesia
1166641|NCT01296997|calcium phosphate
1166642|NCT01296997|incretins
1166643|NCT01296997|human study
1166644|NCT01296984|Rectal cancer
1166645|NCT01296984|APR
1166646|NCT01296958|Taenia solium
1166647|NCT01296958|cysticercosis
1166648|NCT01296958|neurocysticercosis
1166649|NCT01296919|Chronic rhinosinusitis
1166650|NCT01296919|Histopathology
1166651|NCT01296919|Infundibulum
1166652|NCT01296919|Lamina propria
1166653|NCT01296919|Uncinate process
1166654|NCT01296906|Reminder/recall messages
1166655|NCT01296906|reminders
1166656|NCT01296906|recall
1166657|NCT01296906|immunizations
1166658|NCT01296906|immunization information systems
1166659|NCT01296906|effectiveness of reminder/recall
1166660|NCT01296906|population-based reminder/recall
1166661|NCT01296867|Laser ablation algorithms
1166662|NCT01296867|Excimer laser
1166663|NCT01296867|Refractive correction
1166664|NCT01296867|Corneal Asphericity Adjustment
1166665|NCT01296854|spa therapy
1166666|NCT01296841|telemedicine
1166667|NCT01296841|remote consultation
1166668|NCT01296841|telehealth
1166669|NCT01296841|ehealth
1166670|NCT01296841|image archiving
1166671|NCT01296841|inflammatory bowel disease
1166672|NCT01296815|Kaposi sarcoma
1166673|NCT01296815|HIV
1166674|NCT01296815|Bevacizumab
1166675|NCT01296802|Ecstasy
1166676|NCT01296802|MDMA
1166677|NCT01296802|Serotonin
1166678|NCT01296802|Neurotoxicity
1166679|NCT01296802|dexfenfluramine
1166680|NCT01296802|Positron emission tomography
1166681|NCT01296802|altanserin
1166682|NCT01296802|5-HT2A receptor
1166683|NCT01296776|exercise
1166684|NCT01296776|whole-body electromyostimulation
1166685|NCT01296776|bone mineral density
1166686|NCT01296776|falls
1166687|NCT01296776|physical fitness
1166688|NCT01296776|pain
1166689|NCT01296763|Irinotecan
1166690|NCT01296763|Cisplatin
1166691|NCT01296763|Carboplatin
1166692|NCT01296763|Mitomycin-C
1166693|NCT01296763|Olaparib
1166694|NCT01296763|AZD2281
1166695|NCT01296711|Rheumatoid arthritis
1166696|NCT01296711|CDP6038
1166697|NCT01296711|Interleukin-6
1166698|NCT01296698|Smoking Cessation
1166699|NCT01296698|Tobacco Use Disorder
1166700|NCT01296685|cardiovascular surgical procedure
1166701|NCT01296672|Finasteride
1166702|NCT01296672|Placebo
1166703|NCT01296672|Prostate cancer
1166704|NCT01296672|Prostate Specific Antigen (PSA)
1166705|NCT01296672|Men at intermediate risk of prostate cancer
1166706|NCT01296672|Men scheduled for prostate biopsy
1166707|NCT01296659|sarcoma
1166708|NCT01296659|Ridaforolimus
1166709|NCT01296659|soft tissue sarcoma
1166710|NCT01296659|unresectable sarcoma
1166711|NCT01296646|Alcohol
1166712|NCT01296646|Alcoholics
1166713|NCT01296646|Substance Abuse
1166714|NCT01296646|Alcohol Abuse
1166715|NCT01296646|Alcohol Addiction
1166716|NCT01296633|health literacy
1166717|NCT01296633|patient education
1166718|NCT01296633|medication adherence
1166719|NCT01296633|patient/provider communication
1166720|NCT01296633|Diabetes Mellitus
1166721|NCT01296607|Pharmacodynamics
1166722|NCT01296607|Pharmacokinetics
1166723|NCT01296607|Urocortin 2
1166724|NCT01296607|Urocortin 3
1166725|NCT01296607|Reproducibility
1166726|NCT01296607|Onset/ Offset
1166727|NCT01296607|Forearm blood flow
1166728|NCT01296607|Plethysmography
1166729|NCT01296607|Heart Failure
1166730|NCT01296581|Cancer
1166731|NCT01296581|Tumors
1166732|NCT01296581|VEGFR
1166733|NCT01296581|PDGFR
1166734|NCT01296568|metastatic solid tumors
1166735|NCT01296568|Malignant/M-Neoplasm
1166736|NCT01296568|Pancreas NOS
1166737|NCT01296568|Absorption
1166738|NCT01296568|Distribution
1166739|NCT01296568|Metabolism
1166740|NCT01296568|Excretion
1166741|NCT01296568|Mass balance
1166742|NCT01296568|Metabolic profile
1166743|NCT01296568|Radiolabeled study
1166744|NCT01296516|Women
1166745|NCT01296516|Postpartum
1166746|NCT01296516|GDM
1166747|NCT01296503|Multiple Myeloma
1166748|NCT01296503|Treatment
1166749|NCT01296503|Maintenance
1166750|NCT01296503|Thalidomide
1166751|NCT01296490|oxidative stress, physical exercise, fitness level
1166752|NCT01296477|Asthma
1166753|NCT01296477|ASTHMA IQ tool
1166754|NCT01296477|Asthma Control Test (ACT)
1166755|NCT01296477|EPR-3 Guidelines, Exacerbations
1166756|NCT01296464|Parkinson's Disease
1166757|NCT01296464|Motor response
1166758|NCT01296464|Wearing-off
1166759|NCT01296451|Hepatitis C
1166760|NCT01296451|vaccine
1166761|NCT01296451|Adenovirus
1166762|NCT01296451|MVA
1166763|NCT01296451|chronic infection
1166764|NCT01296451|interferon
1166765|NCT01296451|ribavirin
1166766|NCT01296425|Growth disorders
1166767|NCT01296425|Saizen
1166768|NCT01296425|Easypod
1166769|NCT01296425|Growth hormone
1166770|NCT01296425|Pediatric subject
1166771|NCT01296399|in stent restenosis
1166772|NCT01296399|bare metal stent
1166773|NCT01296399|drug eluting stent
1166774|NCT01296399|de novo lesion
1166775|NCT01296373|HIV-1
1166776|NCT01296373|immune
1166777|NCT01296373|restoration
1166778|NCT01296373|observational
1166779|NCT01296360|immune response
1166780|NCT01296360|IC51-325
1166781|NCT01296360|Japanese Encephalitis
1166782|NCT01296360|Intercell AG
1166783|NCT01296347|Ketamine
1166784|NCT01296347|Thoracotomy
1166785|NCT01296347|VATS
1166786|NCT01296347|Pain
1166787|NCT01296334|opioids
1166788|NCT01296334|analgesia
1166789|NCT01296334|secondary hyperalgesia
1166790|NCT01296334|quantitative sensory testing
1166791|NCT01296334|inflammatory injury
1166792|NCT01296308|Diabetes Mellitus, Type 2
1166793|NCT01296308|Diabetic Neuropathy
1166794|NCT01296308|Complementary Medicine
1166795|NCT01296308|Alternative Medicine
1166796|NCT01296308|Integrative Medicine
1166797|NCT01296308|Quality of Life
1166798|NCT01296308|Quantitative Sensory Testing
1166799|NCT01296295|smoking cessation advice
1166800|NCT01296295|spirometry
1166801|NCT01296295|primary health care
1166802|NCT01296269|social cognition
1166803|NCT01296269|oxytocin
1166804|NCT01296269|vasopressin
1166805|NCT01296269|decision making
1166806|NCT01296269|social decision making
1166807|NCT01296256|Bendamustine
1166808|NCT01296256|Conditioning Therapy
1166809|NCT01296256|Autologous Stem Cell Transplant
1166810|NCT01296256|Aggressive Non Hodgkin's Lymphoma
1166811|NCT01296243|Castration-resistant prostate cancer
1166812|NCT01296243|Tesetaxel
1166813|NCT01296243|Taxanes
1166814|NCT01296243|Chemotherapy-naive
1166815|NCT01296243|Chemotherapy-exposed
1166816|NCT01296243|Progressive, metastatic castration-resistant prostate cancer
1166817|NCT01296217|Patients with infiltrant prostatic carcinoma
1166818|NCT01296165|Travel
1166819|NCT01296165|Spread
1166820|NCT01296165|Antibiotic resistance
1166821|NCT01296139|Non-Cutaneous Malignancy
1166822|NCT01296139|Prostatectomy
1166823|NCT01296139|Metastatic Prostate Cancer
1166824|NCT01296139|Imaging Study
1166825|NCT01296139|Magnetic Resonance Imaging
1166826|NCT01296139|Prostate Cancer
1166827|NCT01296126|Post Traumatic Stress Disorder (PTSD)
1166828|NCT01296126|MRI
1166829|NCT01296126|TBI
1166830|NCT01296126|Traumatic Brain Injury
1166831|NCT01296126|Post Traumatic Stress Disorder
1166832|NCT01296126|PTSD
1166833|NCT01296100|impaired glucose tolerance
1166834|NCT01296100|nutrition
1166835|NCT01296100|physical activity
1166836|NCT01296087|Asthma
1166837|NCT01296087|Mild to Moderate Asthma
1166838|NCT01296074|monocyte
1166839|NCT01296074|cardiopulmonary bypass
1166840|NCT01296074|cardiac surgery
1166841|NCT01296061|Dialysis
1166842|NCT01296061|Renal Transplantation
1166843|NCT01296061|Failure of allograft
1166844|NCT01296048|weight
1166845|NCT01296048|body fat
1166846|NCT01296048|total body water
1166847|NCT01296048|bone mass
1166848|NCT01296048|muscle mass
1166849|NCT01296035|recurrent ovarian cancer
1166850|NCT01296035|platinum-refractory ovarian cancer
1166851|NCT01296022|Heart rhythm disturbances
1166852|NCT01296022|Implantable cardiac defibrillator
1166853|NCT01296009|embryonic implantation
1166854|NCT01296009|endometrial receptivity
1166855|NCT01296009|traditional Chinese medicines
1166856|NCT01296009|in vitro fertilization-embryo transfer
1166857|NCT01296009|pregnant rate
1166858|NCT01295970|Surgery of the brain
1166859|NCT01295970|Radiosurgery
1166860|NCT01295970|Brain Metastasis
1166861|NCT01295944|Chemotherapy
1166862|NCT01295944|Brain Tumor
1166863|NCT01295944|Spinal Cord Tumor
1166864|NCT01295944|Malignancy
1166865|NCT01295944|Neurologic
1166866|NCT01295931|Near-infrared
1166867|NCT01295931|NIR
1166868|NCT01295931|Indocyanine green
1166869|NCT01295931|ICG
1166870|NCT01295931|Melanoma
1166871|NCT01295931|Fluorescent dyes
1166872|NCT01295931|Lymph nodes
1166873|NCT01295931|Experimental camera
1166874|NCT01295918|probiotic
1166875|NCT01295918|AAD
1166876|NCT01295918|Lactobacillus reuteri
1166877|NCT01295918|diarrhea
1166878|NCT01295892|menopause
1166879|NCT01295892|obesity
1166880|NCT01295892|capillary
1166881|NCT01295892|microcirculation
1166882|NCT01295892|estrogen
1166883|NCT01295892|Microvascular Function
1166884|NCT01295879|Vitamin D insufficiency
1166885|NCT01295866|chronic nasal inflammation
1166886|NCT01295866|nasal nitric oxide
1166887|NCT01295866|atopy
1166888|NCT01295827|Melanoma
1166889|NCT01295827|Carcinoma
1166890|NCT01295827|Cancer
1166891|NCT01295827|Advanced cancer
1166892|NCT01295827|Metastatic cancer
1166893|NCT01295827|Metastatic melanoma
1166894|NCT01295827|PD-1
1166895|NCT01295827|PD1
1166896|NCT01295814|Interstitial cystitis
1166897|NCT01295814|Humira
1166898|NCT01295814|Adalimumab
1166899|NCT01295801|Linezolid
1166900|NCT01295801|Vitamin B6
1166901|NCT01295801|Linezolid-associated cytopenias
1166902|NCT01295775|diabetic retinopathy
1166903|NCT01295775|sulodexide
1166904|NCT01295775|hard exudates
1166905|NCT01295775|microaneurysms
1166906|NCT01295775|hemorrhages
1166907|NCT01295775|intraretinal microvascular abnormalities
1166908|NCT01295762|Children
1166909|NCT01295762|Cancer
1166910|NCT01295762|Immunomonitoring
1166911|NCT01295762|Prognostic/Predictive Factors
1166912|NCT01295762|Immunotherapy
1166913|NCT01295749|cardiac arrest
1166914|NCT01295749|No Flow
1166915|NCT01295749|Emergency
1166916|NCT01295749|Nurse
1166917|NCT01295749|laryngeal Tube
1166918|NCT01295736|scleroderma
1166919|NCT01295736|digital
1166920|NCT01295736|ulcer
1166921|NCT01295723|Breast cancer
1166922|NCT01295723|Radiation therapy
1166923|NCT01295723|Mobetron
1166924|NCT01295723|IOERT
1166925|NCT01295723|IORT
1166926|NCT01295723|Hypofractionated radiation therapy
1166927|NCT01295723|Partial breast radiation
1166928|NCT01295710|adult acute myeloid leukemia
1166929|NCT01295710|adult acute lymphoid leukemia
1166930|NCT01295710|adult myelodysplastic syndrome
1166931|NCT01295710|allogenic stem cell transplantation
1166932|NCT01295710|unrelated donor
1166933|NCT01295710|GVHD
1166934|NCT01295710|US-ATG-F (Anti-human-T-lymphocyte Immune Globulin, Rabbit)
1166935|NCT01295697|Patients with non-CNS or CNS tumors
1166936|NCT01295697|Pediatric patients with Relapsed/Refractory Solid Tumors
1166937|NCT01295684|cranberry
1166938|NCT01295684|cardiovascular
1166939|NCT01295684|adhesion
1166940|NCT01295684|polyphenol
1166941|NCT01295658|cancer
1166942|NCT01295658|cancer survivor ship
1166943|NCT01295658|psychosocial needs
1166944|NCT01295658|cancer experience
1166945|NCT01295658|metastatic breast cancer
1166946|NCT01295658|multiple myeloma
1166947|NCT01295658|chronic myeloid leukemia
1166948|NCT01295658|breast cancer
1166949|NCT01295658|Prostate
1166950|NCT01295658|Colon
1166951|NCT01295658|Kidney
1166952|NCT01295658|Lung
1166953|NCT01295645|Stem Cell Transplant
1166954|NCT01295645|Hemorrhagic Cystitis
1166955|NCT01295645|Bladder inflammation
1166956|NCT01295645|Frequent urination
1166957|NCT01295645|Pain
1166958|NCT01295645|Polyomavirus hominis type I
1166959|NCT01295645|BK virus
1166960|NCT01295645|BKV
1166961|NCT01295645|Cidofovir
1166962|NCT01295645|Vistide
1166963|NCT01295632|Recurrent glioblastoma multiforme
1166964|NCT01295632|Hormone resistant prostate cancer
1166965|NCT01295632|Relapsed ovarian carcinoma
1166966|NCT01295632|Refractory ovarian carcinoma
1166967|NCT01295632|Refractory breast cancer
1166968|NCT01295632|Relapsed breast cancer
1166969|NCT01295619|Dura
1166970|NCT01295619|Sealant
1166971|NCT01295619|Cranial
1166972|NCT01295619|Craniotomy
1166973|NCT01295619|CSF leakage
1166974|NCT01295619|CSF leakage following cranial surgery
1166975|NCT01295606|cefazolin
1166976|NCT01295606|prophylaxis
1166977|NCT01295606|pharmacokinetics
1166978|NCT01295606|newborn
1166979|NCT01295593|CLL previously treated
1166980|NCT01295567|ischemia reperfusion injury
1166981|NCT01295567|CABG
1166982|NCT01295567|dipyridamole
1166983|NCT01295567|HS-troponin-I
1166984|NCT01295554|Peripheral arterial disease, MRA
1166985|NCT01295541|ICU LOS
1166986|NCT01295541|Progressive Mobility
1166987|NCT01295541|Deconditioning
1166988|NCT01295528|blood pressure
1166989|NCT01295528|heart rate
1166990|NCT01295515|HIV
1166991|NCT01295515|Replication
1166992|NCT01295515|Antiretroviral
1166993|NCT01295515|Interferon
1166994|NCT01295515|Reservoirs
1166995|NCT01295476|adult acute lymphoblastic leukemia in remission
1166996|NCT01295476|childhood acute lymphoblastic leukemia in remission
1166997|NCT01295476|recurrent adult acute lymphoblastic leukemia
1166998|NCT01295476|recurrent childhood acute lymphoblastic leukemia
1166999|NCT01295476|T-cell adult acute lymphoblastic leukemia
1167000|NCT01295476|T-cell childhood acute lymphoblastic leukemia
1167001|NCT01295463|sexual dysfunction
1167002|NCT01295463|psychosocial effects of cancer and its treatment
1167003|NCT01295463|infertility
1167004|NCT01295463|colon cancer
1167005|NCT01295463|male breast cancer
1167006|NCT01295463|breast cancer
1167007|NCT01295463|germ cell tumor
1167008|NCT01295463|ovarian sarcoma
1167009|NCT01295463|uterine sarcoma
1167010|NCT01295463|chronic lymphocytic leukemia
1167011|NCT01295463|osteosarcoma
1167012|NCT01295463|chronic myelogenous leukemia
1167013|NCT01295463|non-Hodgkin lymphoma
1167014|NCT01295463|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1167015|NCT01295463|adult acute myeloid leukemia with inv(16)(p13;q22)
1167016|NCT01295463|adult acute myeloid leukemia with t(15;17)(q22;q12)
1167017|NCT01295463|adult acute myeloid leukemia with t(16;16)(p13;q22)
1167018|NCT01295463|adult acute myeloid leukemia with t(8;21)(q22;q22)
1167019|NCT01295463|mast cell leukemia
1167020|NCT01295463|hairy cell leukemia
1167021|NCT01295463|prolymphocytic leukemia
1167022|NCT01295463|adult acute lymphoblastic leukemia
1167023|NCT01295463|adult acute myeloid leukemia
1167024|NCT01295463|adult Hodgkin lymphoma
1167025|NCT01295463|adult T-cell leukemia/lymphoma
1167026|NCT01295463|small intestine lymphoma
1167027|NCT01295463|anaplastic large cell lymphoma
1167028|NCT01295463|angioimmunoblastic T-cell lymphoma
1167029|NCT01295463|mycosis fungoides/Sezary syndrome
1167030|NCT01295463|intraocular lymphoma
1167031|NCT01295463|primary central nervous system non-Hodgkin lymphoma
1167032|NCT01295463|primary central nervous system Hodgkin lymphoma
1167033|NCT01295463|noncutaneous extranodal lymphoma
1167034|NCT01295463|secondary acute myeloid leukemia
1167035|NCT01295463|acute undifferentiated leukemia
1167036|NCT01295463|central nervous system leukemia
1167037|NCT01295463|T-cell large granular lymphocyte leukemia
1167038|NCT01295463|atypical chronic myeloid leukemia, BCR-ABL1 negative
1167039|NCT01295463|clear cell sarcoma of the kidney
1167040|NCT01295463|Kaposi sarcoma
1167041|NCT01295463|adult soft tissue sarcoma
1167042|NCT01295463|chronic myelomonocytic leukemia
1167043|NCT01295463|secondary central nervous system Hodgkin lymphoma
1167044|NCT01295463|cutaneous lymphoma
1167045|NCT01295463|adult non-Hodgkin lymphoma
1167046|NCT01295450|Phase III
1167047|NCT01295450|Apevinat BC
1167048|NCT01295450|Lack of appetite
1167049|NCT01295437|inguinal hernia, Lichtenstein hernioplasty, chronic pain
1167050|NCT01295424|Cardiac Arrest
1167051|NCT01295424|Intensive Care Unit
1167052|NCT01295424|Emergency Medical Service
1167053|NCT01295385|type 2 diabetes
1167054|NCT01295385|Cardiovascular diseases
1167055|NCT01295385|coronary syndrome have abnormalities of glucidic metabolism
1167056|NCT01295372|Schizophrenia
1167057|NCT01295372|Antipsychotic
1167058|NCT01295372|Risperidone
1167059|NCT01295372|Lu 31-130
1167060|NCT01295359|Chronic Obstructive Pulmonary Disease
1167061|NCT01295359|Walking
1167062|NCT01295359|Hospital
1167063|NCT01295359|Exercise Tolerance
1167064|NCT01295359|Physical Therapy
1167065|NCT01295320|Herpes Zoster
1167066|NCT01295320|vaccine
1167067|NCT01295320|safety
1167068|NCT01295320|immunogenicity
1167069|NCT01295307|acute myeloid leukemia
1167070|NCT01295307|relapsed
1167071|NCT01295307|refractory
1167072|NCT01295307|Relapsed or refractory AML
1167073|NCT01295294|Uterine Hemorrhage
1167074|NCT01295294|Contraception
1167075|NCT01295294|Contraceptive Methods
1167076|NCT01295294|Intrauterine devices
1167077|NCT01295294|Mirena
1167078|NCT01295268|Vulvar pain
1167079|NCT01295268|Vulvodynia
1167080|NCT01295268|Vestibulodynia
1167081|NCT01295268|Vulvar vestibulitis
1167082|NCT01295255|Allergic rhinitis
1167083|NCT01295255|Psychological status
1167084|NCT01295255|Asthma
1167085|NCT01295255|Aeroallergen
1167086|NCT01295242|HPV
1167087|NCT01295242|Cervical Cancer
1167088|NCT01295216|prehypertension
1167089|NCT01295216|blood pressure
1167090|NCT01295216|mobile technology
1167091|NCT01295216|Latin America
1167092|NCT01295216|behavioral change
1167093|NCT01295216|healthy lifestyles
1167094|NCT01295216|mHealth
1167095|NCT01295177|wound healing
1167096|NCT01295177|diabetes mellitus
1167097|NCT01295164|keratoconus, wave-front sensing technology, aberrometer
1167098|NCT01295138|Constipation
1167099|NCT01295138|Caesarean section
1167100|NCT01295138|Abdominal Pain
1167101|NCT01295138|Nausea
1167102|NCT01295138|Vomiting
1167103|NCT01295125|Infected ventral hernia
1167104|NCT01295125|Contaminated incisional hernia
1167105|NCT01295099|scar formation
1167106|NCT01295099|5-FU
1167107|NCT01295099|genetic link
1167108|NCT01295099|psychological impact
1167109|NCT01295099|social impact
1167110|NCT01295086|Adenocarcinoma of the gastro-esophageal
1167111|NCT01295086|Her2
1167112|NCT01295086|Dose finding
1167113|NCT01295086|Taxotere (Docetaxel)
1167114|NCT01295086|Eloxatin (Oxaliplatin)
1167115|NCT01295086|Xeloda (Capecitabine)
1167116|NCT01295086|Herceptin (Trastuzumab)
1167117|NCT01295073|Trientine
1167118|NCT01295073|Cataract surgery
1167119|NCT01295073|Macular Edema
1167120|NCT01295060|Acromegaly
1167121|NCT01295060|Octreotide
1167122|NCT01295060|IGF-1
1167123|NCT01295060|Growth Hormone
1167124|NCT01295060|Implant
1167125|NCT01295060|Hydrogel
1167126|NCT01295047|Marfan Syndrome
1167127|NCT01295047|Large arterial function
1167128|NCT01295047|LV function
1167129|NCT01295047|atenolol
1167130|NCT01295047|perindopril
1167131|NCT01295047|verapamil
1167132|NCT01295047|central arterial pressure
1167133|NCT01295034|HIV
1167134|NCT01295034|combination antiretroviral therapy
1167135|NCT01295034|vitamin D
1167136|NCT01295034|low bone density
1167137|NCT01295021|The prevalence of sympathetic overactivity in hypertensive patients.
1167138|NCT01295008|Fabry disease
1167139|NCT01295008|Male pattern baldness
1167140|NCT01295008|Alopecia
1167141|NCT01295008|GLA gene mutation
1167142|NCT01295008|Alpha-galactosidase A
1167143|NCT01294995|short term consumption
1167144|NCT01294995|Chinese liquor
1167145|NCT01294995|serum lipids
1167146|NCT01294995|uric acid
1167147|NCT01294995|inflammation biomarkers
1167148|NCT01294982|OAB
1167149|NCT01294982|Over Active Bladder
1167150|NCT01294982|overactive bladder
1167151|NCT01294982|Urinary Urge Incontinence
1167152|NCT01294982|Urinary Incontinence
1167153|NCT01294969|Allergic conjunctivitis
1167154|NCT01294956|Dry eye
1167155|NCT01294956|artificial tears
1167156|NCT01294956|corneal staining
1167157|NCT01294943|Intensive Care Units
1167158|NCT01294943|Biofilms
1167159|NCT01294943|Tongue
1167160|NCT01294943|Infection
1167161|NCT01294943|Pneumonia/Aspiration
1167162|NCT01294930|hip fracture
1167163|NCT01294930|mortality
1167164|NCT01294930|complications
1167165|NCT01294904|Hormone
1167166|NCT01294904|Sperm
1167167|NCT01294904|Chronic kidney disease
1167168|NCT01294891|Rheology
1167169|NCT01294891|Sickle cell
1167170|NCT01294891|Paroxysmal nocturnal hemoglobinuria
1167171|NCT01294891|contrast ultrasound
1167172|NCT01294878|anti-IgE treatment
1167173|NCT01294878|interstitial cystitis/bladder pain syndrome
1167174|NCT01294878|omalizumab
1167175|NCT01294865|Sepsis
1167176|NCT01294865|late-onset
1167177|NCT01294865|suPAR
1167178|NCT01294852|prophylactic
1167179|NCT01294852|surfactant
1167180|NCT01294852|premature
1167181|NCT01294852|mechanical ventilation
1167182|NCT01294852|mortality
1167183|NCT01294852|morbidities
1167184|NCT01294839|sinus-node dysfunction
1167185|NCT01294839|RVOTs pacing
1167186|NCT01294839|RVA pacing
1167187|NCT01294826|Colorectal Neoplasms
1167188|NCT01294826|Intestinal Neoplasms
1167189|NCT01294826|Gastrointestinal Neoplasms
1167190|NCT01294826|Digestive System Neoplasms
1167191|NCT01294826|Neoplasms by Site
1167192|NCT01294826|Neoplasms
1167193|NCT01294826|Digestive System Diseases
1167194|NCT01294826|Gastrointestinal Diseases
1167195|NCT01294826|Colonic Diseases
1167196|NCT01294826|Intestinal Diseases
1167197|NCT01294826|Rectal Diseases
1167198|NCT01294826|Cetuximab
1167199|NCT01294826|HSP90 Heat-Shock Proteins
1167200|NCT01294826|EGFR protein, human
1167201|NCT01294813|Electric Impedance Tomography (EIT)
1167202|NCT01294813|Ventilation
1167203|NCT01294813|Bronchoscopy
1167204|NCT01294813|Lung Impedance
1167205|NCT01294813|Recruitment
1167206|NCT01294800|Parkinson's disease
1167207|NCT01294787|COPD
1167208|NCT01294787|QVA149
1167209|NCT01294787|tiotropium
1167210|NCT01294787|exercise
1167211|NCT01294787|exercise tolerance
1167212|NCT01294787|combination bronchodilator
1167213|NCT01294787|moderate to severe COPD
1167214|NCT01294774|Lupus erythematosus
1167215|NCT01294774|skin lupus
1167216|NCT01294761|HIV-1
1167217|NCT01294761|AIDS
1167218|NCT01294761|Clinical Trials, Randomized
1167219|NCT01294748|Coronary Artery Disease
1167220|NCT01294748|Drug-eluting Stent
1167221|NCT01294748|Sirolimus
1167222|NCT01294735|Temozolomide
1167223|NCT01294735|glioblastoma multiforme
1167224|NCT01294735|melanoma
1167225|NCT01294735|advanced neoplasm
1167226|NCT01294722|Rheumatoid Arthritis
1167227|NCT01294722|anti-TNF α
1167228|NCT01294709|angina pectoris
1167229|NCT01294709|coronary artery disease
1167230|NCT01294709|calcitonin gene-related peptide
1167231|NCT01294709|exercise tolerance,
1167232|NCT01294696|Osteoarthritis
1167233|NCT01294696|Standard of care
1167234|NCT01294683|Low-density lipoprotein
1167235|NCT01294683|LDL
1167236|NCT01294683|High-density lipoprotein
1167237|NCT01294683|HDL
1167238|NCT01294683|Niacin
1167239|NCT01294683|Lipid modifying therapy
1167240|NCT01294683|Cholesterol
1167241|NCT01294683|High cholesterol
1167242|NCT01294683|Triglycerides
1167243|NCT01294683|Mixed Dyslipidemia
1167244|NCT01294670|ETOPOSIDE (VP-16)
1167245|NCT01294670|SAHA (SUBEROYLANILIDE HYDROXAMIC ACID) (Vorinostat)
1167246|NCT01294670|Pediatric
1167247|NCT01294670|10-096
1167248|NCT01294670|POETIC
1167249|NCT01294670|phase II component: the population will be restricted to relapsed/refractory sarcomas.
1167250|NCT01294657|Obesity
1167251|NCT01294657|Cancer Risk
1167252|NCT01294657|African Americans
1167253|NCT01294657|Diet
1167254|NCT01294657|Physical Activity
1167255|NCT01294631|Canagliflozin
1167256|NCT01294631|JNJ-28431754
1167257|NCT01294631|Hydrochlorothiazide
1167258|NCT01294631|Pharmacokinetic
1167259|NCT01294631|Pharmacodynamic
1167260|NCT01294618|Chronic Myelogenous Leukemia
1167261|NCT01294618|nilotinib
1167262|NCT01294618|pegylated interferon
1167263|NCT01294618|BCR-ABL Philadelphia chromosome
1167264|NCT01294618|Hematologic, cytogenetic and molecular response rates and kinetics will be studied in addition to the safety of the combination
1167265|NCT01294605|DTPa
1167266|NCT01294605|Td
1167267|NCT01294605|IPV
1167268|NCT01294579|Non-Hodgkin's Lymphoma
1167269|NCT01294579|Ofatumumab
1167270|NCT01294579|Relapsed
1167271|NCT01294579|Rituximab
1167272|NCT01294579|Bendamustine
1167282|NCT01294527|Cardiac Resynchronization Therapy
1167283|NCT01294527|cardiac pacing
1167284|NCT01294527|electrical stimulation
1167285|NCT01294527|bi-ventricular pacing
1167286|NCT01294514|Respiratory Rate
1167287|NCT01294501|Medication administration
1167288|NCT01294501|Medication errors
1167289|NCT01294501|Health Literacy
1167290|NCT01294501|Pediatric Emergency Department
1167291|NCT01294501|Web-based education
1167292|NCT01294488|PCIT
1167293|NCT01294488|Child Maltreatment Prevention
1167294|NCT01294488|Practitioner Fidelity
1167295|NCT01294462|acute coronary syndrome
1167296|NCT01294462|coronary disease
1167297|NCT01294462|coronary artery disease
1167298|NCT01294436|Phase3
1167299|NCT01294436|Clinical trial
1167300|NCT01294436|Type 2 Diabetes Mellitus
1167301|NCT01294423|Phase3
1167302|NCT01294423|Clinical trial
1167303|NCT01294423|Type2 Diabetes Mellitus
1167304|NCT01294397|Amgen
1167305|NCT01294397|Phase 1
1167306|NCT01294397|Postmenopausal
1167307|NCT01294397|Osteopenia
1167308|NCT01294397|Rheumatoid
1167309|NCT01294397|Bone Mineral Density
1167310|NCT01294397|Arthritis
1167311|NCT01294397|Pharmacokinetics
1167312|NCT01294397|Osteoporosis
1167313|NCT01294371|Lucrin Depot
1167314|NCT01294371|genital endometriosis
1167315|NCT01294371|6 months therapy
1167316|NCT01294358|Pancreatic Cancer
1167317|NCT01294358|Regional Therapy
1167318|NCT01294358|Selective Arterial Infusion
1167319|NCT01294358|Locally Advanced Disease
1167320|NCT01294345|Birth Defects
1167321|NCT01294345|Genomics
1167322|NCT01294345|Congenital Malformations
1167323|NCT01294332|Cognition
1167324|NCT01294332|TBI
1167325|NCT01294332|Mood
1167326|NCT01294332|Aerobic Exercise Training
1167327|NCT01294332|Cardiorespiratory Fitness
1167328|NCT01294332|Traumatic Brain Injury
1167329|NCT01294319|Cortical Resistance
1167330|NCT01294319|ACTH
1167331|NCT01294319|Glucocorticoid
1167332|NCT01294319|Mifepristone
1167333|NCT01294319|SPIRONOLACTONE
1167334|NCT01294319|Exercise
1167335|NCT01294319|Hypothalamic-Pituitary-Adrenal Axis
1167336|NCT01294319|Healthy Volunteer
1167337|NCT01294319|HV
1167338|NCT01294280|Stage I Non-Small Cell Lung Cancer
1167339|NCT01294280|Stage II Non-Small Cell Lung Cancer
1167340|NCT01294267|Ventricular Tachycardia
1167341|NCT01294267|Radio Frequency Ablation
1167342|NCT01294267|Percutaneous Left Ventricular Assist Device
1167343|NCT01294267|Hemodynamic Management
1167344|NCT01294267|Interventional Cardiac Procedure
1167345|NCT01294267|Mechanical Cardiac Assistance
1167346|NCT01294267|Intra-Aortic Balloon Pump
1167347|NCT01294267|Coronary Intervention
1167348|NCT01294267|Impella 2.5
1167349|NCT01294267|Circulation Support system
1167350|NCT01294254|wound reepithelialization
1167351|NCT01294241|Epidermolysis bullosa
1167352|NCT01294241|Wound healing
1167353|NCT01294241|Epithelialization
1167354|NCT01294215|BAYA1040
1167355|NCT01294215|Nifedipine
1167356|NCT01294215|Essential hypertension
1167357|NCT01294215|Japanese Patients
1167358|NCT01294215|Phase III
1167359|NCT01294215|combination study
1167360|NCT01294215|14024
1167361|NCT01294202|GIST
1167362|NCT01294202|Gastrointestinal Stromal Tumor
1167363|NCT01294202|unresectable
1167364|NCT01294202|metastatic
1167365|NCT01294202|AT13387
1167366|NCT01294202|Astex
1167367|NCT01294202|Gleevec
1167368|NCT01294202|Imatinib
1167369|NCT01294189|end-of-life decisions, critical care, advance directive
1167370|NCT01294176|Optic Neuritis
1167371|NCT01294176|Lipoic Acid
1167372|NCT01294176|Multiple Sclerosis
1167373|NCT01294176|Antioxidant
1167374|NCT01294176|OCT
1167375|NCT01294176|Acute
1167376|NCT01294163|Xenon
1167377|NCT01294163|Sevoflurane
1167378|NCT01294163|Propofol
1167379|NCT01294163|Total intravenous anaesthesia
1167380|NCT01294163|Anaesthesia
1167381|NCT01294163|Coronary artery disease
1167382|NCT01294163|Coronary artery bypass graft
1167383|NCT01294137|frail
1167384|NCT01294137|elderly
1167385|NCT01294137|hospitalized
1167386|NCT01294137|sleep apnea
1167387|NCT01294137|oximetry
1167388|NCT01294111|Fatigue
1167389|NCT01294111|Quality of life
1167390|NCT01294111|Elderly
1167391|NCT01294098|Femoral Fractures
1167392|NCT01294098|Pediatrics
1167393|NCT01294098|Pain, Postoperative
1167394|NCT01294072|curcumin
1167395|NCT01294072|plant exosomes
1167396|NCT01294072|malignant colon tissue
1167397|NCT01294059|Fibromyalgia
1167398|NCT01294059|Hyperalgesia
1167399|NCT01294059|Pain
1167400|NCT01294059|Central Sensitization
1167401|NCT01294046|Episodic migraine headache
1167402|NCT01294020|Transplant
1167403|NCT01294020|Liver
1167404|NCT01294020|Kidney
1167405|NCT01294020|Heart
1167406|NCT01294020|Lung
1167407|NCT01294020|Immunosuppression
1167408|NCT01294020|Advagraf
1167409|NCT01294020|Pharmacokinetics
1167410|NCT01293994|Chronic Pain, Genetic Variation, Opioid Medications, Pain
1167411|NCT01293968|Aphthous Stomatitis
1167412|NCT01293968|Ibuprofen
1167413|NCT01293968|treatment efficacy
1167414|NCT01293955|cartilage
1167415|NCT01293955|knee osteoarthritis
1167416|NCT01293955|protective effect
1167417|NCT01293942|unresectable liver-only metastases in colorectal cancer
1167418|NCT01293916|pediatric
1167419|NCT01293916|femur
1167420|NCT01293916|femoral
1167421|NCT01293916|fracture
1167422|NCT01293916|spica
1167423|NCT01293916|cast
1167424|NCT01293916|diaphyseal
1167425|NCT01293916|single
1167426|NCT01293916|double
1167427|NCT01293916|patient age 2 to 6 years old
1167428|NCT01293903|Immunomodulation
1167429|NCT01293890|adherence
1167430|NCT01293890|medication
1167431|NCT01293890|exacerbations
1167432|NCT01293890|hospital admission
1167433|NCT01293877|Laparoscopy
1167434|NCT01293877|obesity
1167435|NCT01293877|gastric
1167436|NCT01293877|restrictive
1167437|NCT01293864|structural analysis, diffusible proteins, glycosaminoglycans
1167438|NCT01293851|Biomarkers
1167439|NCT01293851|Gene Expression
1167440|NCT01293851|Neuropathic Pain
1167441|NCT01293851|Neurotoxicity
1167442|NCT01293851|Chemotherapy
1167443|NCT01293851|Peripheral Neuropathic Pain
1167444|NCT01293851|Cancer
1167445|NCT01293838|Adolescents
1167446|NCT01293838|Anxiety Disorder
1167447|NCT01293838|Cipralex
1167448|NCT01293838|Social Phobia
1167449|NCT01293838|Separation Anxiety Disorder
1167450|NCT01293838|Panic Disorder
1167451|NCT01293838|Generalized Anxiety Disorder
1167452|NCT01293838|physiological arousal
1167453|NCT01293838|stress response
1167454|NCT01293838|salivary cortisol
1167455|NCT01293838|salivary alpha-amylase
1167456|NCT01293838|heart rate variability
1167457|NCT01293799|Randomized
1167458|NCT01293799|Peritoneal dialysis
1167459|NCT01293799|Peritonitis
1167460|NCT01293799|Primary prevention
1167461|NCT01293799|Quality control
1167462|NCT01293799|Self care
1167463|NCT01293799|Kidney failure, chronic
1167464|NCT01293786|magnesium
1167465|NCT01293786|kidney transplantation
1167466|NCT01293786|hypomagnesemia
1167467|NCT01293773|Randomized controlled trial
1167468|NCT01293773|Drug-eluting Stent
1167469|NCT01293773|Multicenter study
1167470|NCT01293760|intrauterine device
1167471|NCT01293760|contraception
1167472|NCT01293747|Estrogen
1167473|NCT01293747|Progesterone
1167474|NCT01293747|Microspheres
1167475|NCT01293747|Menopause
1167476|NCT01293747|Pharmacokinetics
1167477|NCT01293734|bronchial asthma
1167478|NCT01293734|cold type
1167479|NCT01293734|heat type
1167480|NCT01293734|Asthenia type
1167481|NCT01293734|TCM syndrome
1167482|NCT01293734|symptoms
1167483|NCT01293734|physical signs
1167484|NCT01293721|Bone Mineral Density
1167485|NCT01293721|Vibration
1167486|NCT01293721|Rehabilitation
1167487|NCT01293721|Fracture healing rate
1167488|NCT01293708|Octogenarians
1167489|NCT01293708|HRQOL
1167490|NCT01293708|mortality
1167491|NCT01293708|prospective observational
1167492|NCT01293708|Elderly
1167493|NCT01293695|hot flashes
1167494|NCT01293695|post menopausal women
1167495|NCT01293695|skin conductance monitors
1167496|NCT01293695|hypnosis
1167497|NCT01293695|hypnotizability
1167498|NCT01293669|Type 2 Diabetes
1167499|NCT01293669|Type 2 Diabetes Mellitus
1167500|NCT01293604|Barley
1167501|NCT01293604|Oats
1167502|NCT01293604|Whole grains
1167503|NCT01293604|Cardiovascular disease
1167504|NCT01293604|adults not taking lipid-lowering or glucoregulatory medications.
1167505|NCT01293591|Garlic
1167506|NCT01293591|Cancer biomarkers
1167507|NCT01293591|Gene expression
1167508|NCT01293591|Oxidative stress
1167509|NCT01293591|DNA damage
1167510|NCT01293578|Decision Aids
1167511|NCT01293578|Shared Medical Decision Making
1167512|NCT01293578|Patient Education
1167513|NCT01293578|Endocrine System Diseases
1167514|NCT01293578|Glucose Metabolism Disorders
1167515|NCT01293578|Metabolic Diseases
1167516|NCT01293565|X-Linked Hypohidrotic Ectodermal Dysplasia
1167517|NCT01293565|Hypohidrotic Ectodermal Dysplasia
1167518|NCT01293565|XLHED
1167519|NCT01293565|HED
1167520|NCT01293539|Retinoblastoma
1167521|NCT01293539|intra-arterial chemotherapy
1167522|NCT01293539|angiography
1167523|NCT01293526|Heart failure
1167524|NCT01293526|echocardiography
1167525|NCT01293513|Only patients with Acute or Primary HIV infection will be studied
1167526|NCT01293500|SIRS
1167527|NCT01293500|shock
1167528|NCT01293500|sepsis
1167529|NCT01293500|pediatric
1167530|NCT01293500|inter-facility transport
1167531|NCT01293500|specialized transport
1167532|NCT01293500|NIRS monitoring
1167533|NCT01293487|Phase 1
1167534|NCT01293487|Osteopenia
1167535|NCT01293487|RN564
1167536|NCT01293448|Esophagectomy
1167537|NCT01293448|Barrett's Esophagus
1167538|NCT01293435|Community Acquired Pneumonia (CAP)
1167539|NCT01293435|Complicated Skin and Skin Structures Infections (cSSSI)
1167540|NCT01293435|Complicated Skin and Soft Tissues Infections (cSSTI)
1167541|NCT01293435|Antibiotics
1167542|NCT01293435|Infection management
1167543|NCT01293435|Use of Resources
1167544|NCT01293435|MRSA
1167545|NCT01293435|PRSP
1167546|NCT01293422|PXR, glucose, cholesterol
1167547|NCT01293396|insulin aspart 30
1167548|NCT01293396|insulin aspart 70
1167549|NCT01293396|insulin aspart
1167550|NCT01293396|postprandial glucose and lipid metabolism
1167551|NCT01293396|consecutive mixed meals
1167552|NCT01293344|Cardiovascular diseases
1167553|NCT01293344|Controlled nutritional intervention
1167554|NCT01293344|Sex differences
1167555|NCT01293344|Women
1167556|NCT01293344|Men
1167557|NCT01293344|Cardiovascular risk
1167558|NCT01293344|Lipid profile
1167559|NCT01293344|Blood pressure
1167560|NCT01293344|Insulin sensitivity
1167561|NCT01293344|Inflammatory markers
1167562|NCT01293344|Endothelial function
1167563|NCT01293344|Oxidative stress
1167564|NCT01293331|Dengue Fever Fever Seroprevalence
1167565|NCT01293318|Copeptin
1167566|NCT01293318|Vasopressin
1167567|NCT01293318|antidiuretic hormone (ADH)
1167568|NCT01293305|osteoarthritis
1167569|NCT01293292|Osteoporosis
1167570|NCT01293292|Forsteo
1167571|NCT01293292|Teriparatide
1167572|NCT01293279|HCV viral genotypes
1167573|NCT01293279|host genotypes
1167574|NCT01293279|IL28B
1167575|NCT01293279|ITPA
1167576|NCT01293279|RNA
1167577|NCT01293279|China
1167578|NCT01293266|Propofol
1167579|NCT01293266|Metabolic Acidosis
1167580|NCT01293266|Pediatric Cardiology
1167581|NCT01293266|Anesthesia
1167582|NCT01293227|Wrist Fracture
1167583|NCT01293214|limb transplantation
1167584|NCT01293214|limb allotransplantation
1167585|NCT01293214|hand transplantation
1167586|NCT01293214|hand allotransplantation
1167587|NCT01293214|hand amputation
1167588|NCT01293214|leg transplantation
1167589|NCT01293201|SAR
1167590|NCT01293201|Seasonal Allergic Rhinitis
1167591|NCT01293188|Aortic Valve Replacement
1167592|NCT01293188|Bioprosthetic
1167593|NCT01293175|whole grains
1167594|NCT01293175|polyphenols
1167595|NCT01293175|overweight
1167596|NCT01293175|bioavailability
1167597|NCT01293175|antioxidant status
1167598|NCT01293175|inflammation
1167599|NCT01293162|Metabolic syndrome
1167600|NCT01293162|Cardiovascular risk
1167601|NCT01293149|knee, reconstructive surgery
1167602|NCT01293149|femoral nerve block
1167603|NCT01293136|knee
1167604|NCT01293136|reconstructive surgery
1167605|NCT01293136|femoral nerve block
1167606|NCT01293123|HIV
1167607|NCT01293123|raltegravir
1167608|NCT01293123|cerebrospinal fluid
1167609|NCT01293110|urodynamics
1167610|NCT01293110|neurogenic lower urinary tract dysfunction
1167611|NCT01293110|neurological disease/injury
1167612|NCT01293084|mucociliary clearance
1167613|NCT01293084|children
1167614|NCT01293084|cystic fibrosis
1167615|NCT01293084|hypertonic saline
1167616|NCT01293071|Antibiotic rotation
1167617|NCT01293071|Cycling
1167618|NCT01293071|Mixing
1167619|NCT01293071|Gram-negative
1167620|NCT01293071|EU
1167621|NCT01293071|Multi center
1167622|NCT01293071|Multi Centre
1167623|NCT01293071|Cluster randomized trial
1167624|NCT01293071|Cross over
1167625|NCT01293058|opioid
1167626|NCT01293058|overdose
1167627|NCT01293058|naloxone
1167628|NCT01293058|intranasal
1167629|NCT01293045|Osteoporosis
1167630|NCT01293045|Postmenopausal women
1167631|NCT01293045|Functional food
1167632|NCT01293045|Hydrolysed collagen
1167633|NCT01293045|Bone metabolism
1167634|NCT01293045|Bone marker of resorption
1167635|NCT01293045|Bone marker of formation
1167636|NCT01293032|Estrogen Receptor Positive
1167637|NCT01293032|Progesterone Receptor Positive
1167638|NCT01293032|HER2/Neu Negative
1167639|NCT01293032|Breast Cancer
1167640|NCT01293019|Complementary and alternative medicine
1167641|NCT01293019|Osteopathic treatment
1167642|NCT01293006|Pulmonary Disease, Chronic Obstructive
1167643|NCT01292980|sDTI
1167644|NCT01292980|Pressure ulcers
1167645|NCT01292980|Therapy surfaces
1167646|NCT01292980|Mattresses
1167647|NCT01292980|Deep Tissue Injury
1167648|NCT01292980|pressure ulcer treatment
1167649|NCT01292967|Flavanol
1167650|NCT01292967|cocoa
1167651|NCT01292967|maltitol
1167652|NCT01292967|absorption
1167653|NCT01292967|metabolism
1167654|NCT01292967|chocolate
1167655|NCT01292967|food matrix
1167656|NCT01292967|bioavailability
1167657|NCT01292954|blueberries
1167658|NCT01292954|vascular function
1167659|NCT01292954|FMD
1167660|NCT01292954|Blood pressure
1167661|NCT01292954|Laser Doppler
1167662|NCT01292954|pharmacokinetics
1167663|NCT01292954|absorption
1167664|NCT01292954|metabolism
1167665|NCT01292954|polyphenols
1167666|NCT01292954|flavonoids
1167667|NCT01292928|Atherosclerosis, Superficial Femoral Artery (SFA), Proximal Popliteal Artery (PPA), lower extremities, Stenting
1167668|NCT01292915|Re-bleeding, NVUGIB
1167669|NCT01292889|Seasonal Affective Disorder
1167670|NCT01292889|Major Depressive Disorder
1167671|NCT01292889|Depression
1167672|NCT01292889|Winter Blues
1167673|NCT01292876|MTURR
1167674|NCT01292876|ECM
1167675|NCT01292876|Muscle Loss
1167676|NCT01292876|Tendon
1167677|NCT01292876|Tendon Repair
1167678|NCT01292876|Muscle Repair
1167679|NCT01292876|Soft Tissue Repair
1167680|NCT01292876|Scaffold
1167681|NCT01292876|Extracellular Matrix
1167682|NCT01292863|Peritoneal dialysis
1167683|NCT01292863|Biocompatible dialysis fluid
1167684|NCT01292850|Topical
1167685|NCT01292850|Skin
1167686|NCT01292850|sterility
1167687|NCT01292850|ethylchloride
1167688|NCT01292850|ethyl
1167689|NCT01292850|chloride
1167690|NCT01292850|spray
1167691|NCT01292837|Levetiracetam
1167692|NCT01292837|Epilepsy
1167693|NCT01292837|Generalized tonic-clonic seizures
1167694|NCT01292824|Hepatitis C virus
1167695|NCT01292824|Entry
1167696|NCT01292824|Scavenger receptor-BI
1167697|NCT01292824|High density lipoprotein
1167698|NCT01292824|Liver transplantation
1167699|NCT01292811|Spinal Cord Injury
1167700|NCT01292811|Functional Electrical Stimulation
1167701|NCT01292811|Hand function
1167702|NCT01292811|Tetraplegia
1167703|NCT01292798|Diabetes
1167704|NCT01292798|Macula
1167705|NCT01292798|Edema
1167706|NCT01292798|Retina
1167707|NCT01292772|breast cancer
1167708|NCT01292772|bilateral mastectomy
1167709|NCT01292772|immediate breast reconstruction
1167710|NCT01292772|locally advanced unilateral breast cancer
1167711|NCT01292772|bilateral mastectomy for prophylaxis
1167712|NCT01292759|stroke volume
1167713|NCT01292759|cardiac output
1167714|NCT01292759|validation
1167715|NCT01292733|Women with increased risk for developing ovarian cancer
1167716|NCT01292733|Women diagnosed with reproductive cancer
1167717|NCT01292733|Women with relatives who have had ovarian or breast cancer
1167718|NCT01292720|vitamin D deficiency, vitamin D insufficiency, heart failure
1167719|NCT01292707|malaria
1167720|NCT01292707|rdt
1167721|NCT01292707|fever
1167722|NCT01292707|treatment
1167723|NCT01292694|supine hypertension
1167724|NCT01292694|autonomic failure
1167725|NCT01292694|angiotensin
1167726|NCT01292694|losartan
1167727|NCT01292694|captopril
1167728|NCT01292681|colorectal cancer
1167729|NCT01292681|FDG-PET-CT
1167730|NCT01292681|MRS,
1167731|NCT01292681|DCE-MRI
1167732|NCT01292681|DWI
1167733|NCT01292681|colorectal cancer with histologically proven distant metastases
1167734|NCT01292642|cognitive behavioral therapy
1167735|NCT01292642|nicotine dependence
1167736|NCT01292642|cannabis dependence
1167737|NCT01292642|smoking cessation
1167738|NCT01292642|nicotine replacement therapy
1167739|NCT01292629|intraocular lens
1167740|NCT01292629|IOL
1167741|NCT01292629|cataract
1167742|NCT01292629|Hoya
1167743|NCT01292629|surgical
1167744|NCT01292629|optics
1167745|NCT01292629|ocular
1167746|NCT01292629|visual acuity
1167747|NCT01292577|Schizophrenia
1167748|NCT01292577|Schizoaffective Disorder
1167749|NCT01292577|Cannabis
1167750|NCT01292577|Alcohol
1167751|NCT01292577|Substance Misuse
1167752|NCT01292577|Cognition
1167753|NCT01292577|Psychosocial Treatment
1167754|NCT01292577|Cognitive Enhancement Therapy
1167755|NCT01292577|Personal Therapy
1167756|NCT01292577|Treatment as Usual
1167757|NCT01292551|single ventricle physiology
1167758|NCT01292551|Fontan procedure
1167759|NCT01292525|Withdrawal of Tacrolimus and renal graft
1167760|NCT01292525|renal allograft
1167761|NCT01292525|stable renal function
1167762|NCT01292512|Bereavement management
1167763|NCT01292512|Complicated grief
1167764|NCT01292499|psychotherapy
1167765|NCT01292499|psychoeducation
1167766|NCT01292499|depression
1167767|NCT01292447|Pain measurement
1167768|NCT01292447|Intrauterine devices
1167769|NCT01292447|Lidocaine
1167770|NCT01292434|Diet
1167771|NCT01292434|Obesity
1167772|NCT01292434|Child Preschool
1167773|NCT01292434|Treatment Outcome
1167774|NCT01292434|Body Mass Index
1167775|NCT01292434|Intervention Studies
1167776|NCT01292434|Randomized Controlled Trial
1167777|NCT01292434|Child Day Care Centers
1167778|NCT01292434|Schools Nursery
1167779|NCT01292434|Child Care
1167780|NCT01292408|autophagy
1167781|NCT01292408|hydroxychloroquine
1167782|NCT01292408|hypoxia
1167783|NCT01292408|proven invasive adenocarcinoma of the breast: tumors are found to be ER negative (<10% ER pos cells)
1167784|NCT01292395|dietary supplement
1167785|NCT01292395|protein metabolism
1167786|NCT01292395|bone turnover
1167787|NCT01292382|Elderly
1167788|NCT01292382|Memory
1167789|NCT01292382|Cognition
1167790|NCT01292382|Repetitive transcranial magnetic stimulation
1167791|NCT01292369|breath test
1167792|NCT01292369|colon cancer
1167793|NCT01292369|breast cancer
1167794|NCT01292343|third molars
1167795|NCT01292343|triclosan
1167796|NCT01292343|toothpaste
1167797|NCT01292343|dry socket
1167798|NCT01292343|wound infection
1167799|NCT01292330|liver Tumor
1167800|NCT01292317|NGAL
1167801|NCT01292317|neutrophil gelatinase-associated Lipocalin
1167802|NCT01292317|contrast media nephropathy
1167803|NCT01292317|CIN
1167804|NCT01292317|volume expansion
1167805|NCT01292317|acute kidney injury
1167806|NCT01292317|contrast media
1167807|NCT01292304|Cirrhotic
1167808|NCT01292304|Tolvaptan
1167809|NCT01292304|v2 receptor antagonist
1167810|NCT01292291|stage I prostate cancer
1167811|NCT01292291|stage IIA prostate cancer
1167812|NCT01292291|stage IIB prostate cancer
1167813|NCT01292278|subarachnoid hemorrhage
1167814|NCT01292278|cerebral vasospasm
1167815|NCT01292278|neuropeptide Y
1167816|NCT01292278|spontaneous
1167817|NCT01292278|aneurysmal
1167818|NCT01292265|Arthritis
1167819|NCT01292265|Joint pain
1167820|NCT01292265|Inflammation
1167821|NCT01292265|Rheumatoid Arthritis
1167822|NCT01292239|Hepatitis C, Chronic
1167823|NCT01292239|Hepatitis C
1167824|NCT01292239|Hepatitis C virus
1167825|NCT01292239|Interferon Alfa-2a
1167826|NCT01292239|Ribavirin
1167827|NCT01292239|Viral RNA
1167828|NCT01292213|Chronic cough
1167829|NCT01292213|Haemophilus influenzae
1167830|NCT01292200|Chinese women
1167831|NCT01292200|Mammography
1167832|NCT01292200|Breast Cancer
1167833|NCT01292187|Osteoporosis
1167834|NCT01292187|Osteopenia
1167835|NCT01292187|Osteoporosis, Postmenopausal
1167836|NCT01292187|Bone Diseases, Metabolic
1167837|NCT01292187|Bone Diseases
1167838|NCT01292187|Musculoskeletal Diseases
1167839|NCT01292187|Salmon calcitonin
1167840|NCT01292187|Calcitonin
1167841|NCT01292174|HIV prevention
1167842|NCT01292161|Hepatitis C
1167843|NCT01292161|Silymarin
1167844|NCT01292161|Quality of life
1167845|NCT01292148|resuscitation, hypothermia
1167846|NCT01292135|Lymphoma, B-Cell
1167847|NCT01292135|Leukemia, Lymphoid
1167848|NCT01292135|Leukemia, B-Cell
1167849|NCT01292135|Bruton's Tyrosine Kinase
1167850|NCT01292122|Wounds
1167851|NCT01292122|Grafts
1167852|NCT01292122|Wound Healing
1167853|NCT01292122|Cell Therapy
1167854|NCT01292122|Split-thickness skin graft donor site wound
1167855|NCT01292109|endoscopy
1167856|NCT01292109|colonoscopy
1167857|NCT01292109|preparation for surgery
1167858|NCT01292096|homelessness
1167859|NCT01292096|substance use
1167860|NCT01292096|frequent hospitalization
1167861|NCT01292096|frequent users of health services
1167862|NCT01292096|enhanced care management
1167863|NCT01292096|coordination services p
1167864|NCT01292096|high risk for frequent hospitalization
1167865|NCT01292070|Fel d 1 protein, Felis domesticus
1167866|NCT01292070|Injections, Intradermal
1167867|NCT01292057|Alcohol
1167868|NCT01292057|Aripiprazole
1167869|NCT01292057|Impulsivity
1167870|NCT01292057|Alcoholism
1167871|NCT01292057|drinking
1167872|NCT01292057|treatment
1167873|NCT01292057|craving
1167874|NCT01292057|brain imaging
1167875|NCT01292057|genetics
1167876|NCT01292044|elastography
1167877|NCT01292044|cytology
1167878|NCT01292031|VAP
1167879|NCT01292031|MDR-GNB
1167880|NCT01292031|colistin
1167881|NCT01292031|meropenem
1167882|NCT01292018|Management of dyslipidemia in Type 2 Diabetes Mellitus adult patients in India
1167883|NCT01292018|Dyslipidemia control rates in Type 2 diabetic Mellitus patients
1167884|NCT01292005|pancreatitis
1167885|NCT01292005|pancreatic necrosis
1167886|NCT01292005|severe acute pancreatitis (SAP)
1167887|NCT01292005|Alcoholic pancreatitis
1167888|NCT01292005|gallstone pancreatitis
1167889|NCT01291992|Non-convulsive seizures
1167890|NCT01291992|Cardiac Surgery
1167891|NCT01291992|Postop
1167892|NCT01291992|24 hour EEG Monitoring
1167893|NCT01291979|Pain
1167894|NCT01291979|Preemptive
1167895|NCT01291979|Lidocaine
1167896|NCT01291979|Intravenous
1167897|NCT01291979|Tonsillectomy
1167898|NCT01291966|medication errors
1167899|NCT01291966|Patient Compliance
1167900|NCT01291966|patient safety
1167901|NCT01291966|polypharmacy
1167902|NCT01291953|atrial fibrillation
1167903|NCT01291953|screening
1167904|NCT01291953|prevention
1167905|NCT01291953|case finding
1167906|NCT01291953|primary care
1167907|NCT01291927|Periampullary carcinoma
1167908|NCT01291927|Pancreas-sparing Duodenectomy
1167909|NCT01291927|pancreaticoduodenectomy
1167910|NCT01291927|lymphadenectomy
1167911|NCT01291914|Osteoarthritis
1167912|NCT01291914|knee
1167913|NCT01291914|intra-articular
1167914|NCT01291914|safety
1167915|NCT01291914|efficacy
1167916|NCT01291914|pharmacokinetics
1167917|NCT01291914|pain
1167918|NCT01291901|pain
1167919|NCT01291901|cancer
1167920|NCT01291901|malignancy
1167921|NCT01291901|intractable
1167922|NCT01291901|gene therapy
1167923|NCT01291901|enkephalin
1167924|NCT01291901|opioid
1167925|NCT01291875|Type 2 Diabetes mellitus
1167926|NCT01291875|Periodontal Disease
1167927|NCT01291875|metabolic control
1167928|NCT01291875|periodontal treatment
1167929|NCT01291875|inflammatory markers
1167930|NCT01291849|nasal surgery
1167931|NCT01291849|endoscopic sinus surgery
1167932|NCT01291849|septoplasty
1167933|NCT01291849|Cough
1167934|NCT01291836|Acute Kidney Injury (AKI)
1167935|NCT01291836|Acute Decompensated Heart Failure (ADHF)
1167936|NCT01291836|Neutrophil Gelatinase Associated Lipocalin (NGAL)
1167937|NCT01291836|biomarker
1167938|NCT01291823|gefitinib
1167939|NCT01291823|radiation
1167940|NCT01291823|esophageal cancer
1167941|NCT01291797|congenital heart disease
1167942|NCT01291797|neurodevelopmental outcome
1167943|NCT01291797|AEEG
1167944|NCT01291797|sleep wake cycles
1167945|NCT01291784|monoclonal antibody
1167946|NCT01291771|End stage renal disease
1167947|NCT01291771|myocardial microvascular disease
1167948|NCT01291771|cardiorenal syndrome
1167949|NCT01291771|coronary flow reserve
1167950|NCT01291771|index of microvascular resistance
1167951|NCT01291771|Patients with end stage renal disease scheduled or not for kidney or kidney + pancreatic transplantation
1167952|NCT01291758|Persian Gulf War
1167953|NCT01291758|Gulf War Syndrome
1167954|NCT01291758|GWI
1167955|NCT01291758|Gulf War Illness
1167956|NCT01291758|Exercise
1167957|NCT01291758|Chronic Fatigue
1167958|NCT01291758|Fibromyalgia
1167959|NCT01291758|Veterans
1167960|NCT01291758|Irritable Bowel Syndrome
1167961|NCT01291758|Migraine headaches
1167962|NCT01291758|Neuropathy
1167963|NCT01291719|closed loop glucose control
1167964|NCT01291719|intensive care glucose control
1167965|NCT01291706|Transcranial Doppler
1167966|NCT01291706|Mild and moderate Traumatic Brain Injury
1167967|NCT01291706|Neurological deterioration
1167968|NCT01291706|Brain CT scan
1167969|NCT01291693|Hazardous drinking
1167970|NCT01291693|general hospital
1167971|NCT01291693|brief intervention
1167972|NCT01291693|Motivational Interviewing
1167973|NCT01291693|computer-generated feedback
1167974|NCT01291693|stage-tailored
1167975|NCT01291693|delivery channel
1167976|NCT01291680|Pregnancy
1167977|NCT01291680|Chronic pain
1167978|NCT01291680|Fibromyalgia
1167979|NCT01291654|PDA
1167980|NCT01291654|Paracetamol
1167981|NCT01291654|Indomethacin
1167982|NCT01291654|Ibuprofen
1167983|NCT01291641|Hyperlipidemias
1167984|NCT01291641|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1167985|NCT01291641|Probucol
1167986|NCT01291641|Cilostazol
1167987|NCT01291628|Capecitabine
1167988|NCT01291628|Hand and foot syndrome
1167989|NCT01291628|Socks
1167990|NCT01291628|Copper
1167991|NCT01291628|Toxicity
1167992|NCT01291602|NXL104
1167993|NCT01291602|ceftazidime
1167994|NCT01291602|CAZ104
1167995|NCT01291602|Healthy Japanese volunteers
1167996|NCT01291602|Phase 1
1167997|NCT01291602|Single and Multiple Dose Study
1167998|NCT01291589|HIV-infected
1167999|NCT01291589|MSM
1168000|NCT01291589|HIV prevention
1168001|NCT01291576|Deep infiltrating endometriosis
1168002|NCT01291576|Rectal endometriosis
1168003|NCT01291576|Colorectal resection
1168004|NCT01291576|Nodule excision
1168005|NCT01291576|Rectal shaving
1168006|NCT01291576|Functional outcomes
1168007|NCT01291576|Constipation
1168008|NCT01291563|TMC207TBC1003
1168009|NCT01291563|TMC207
1168010|NCT01291563|M.Tuberculosis
1168011|NCT01291563|TBC
1168012|NCT01291563|Moxifloxacin
1168013|NCT01291563|ECG
1168014|NCT01291563|QT/QTc
1168015|NCT01291563|Healthy volunteers
1168016|NCT01291550|Detecting volatile biomarkers using breath sample
1168017|NCT01291537|Advanced
1168018|NCT01291537|Severe form
1168019|NCT01291524|pregabalin
1168020|NCT01291524|pharmacokinetics
1168021|NCT01291524|bioavailability
1168022|NCT01291524|bioequivalence
1168023|NCT01291511|Schizophrenia
1168024|NCT01291511|Mental Disorders
1168025|NCT01291511|Antipsychotic Agents
1168026|NCT01291511|Iloperdione
1168027|NCT01291511|Relapse Prevention
1168028|NCT01291498|Primary Parathyroid Adenomas
1168029|NCT01291485|HIV
1168030|NCT01291485|Medication adherence
1168031|NCT01291485|computer-based intervention
1168032|NCT01291472|ketorolac
1168033|NCT01291472|pain
1168034|NCT01291472|pregnancy
1168035|NCT01291472|non-pregnant state
1168036|NCT01291459|HIV
1168037|NCT01291459|naive patients
1168038|NCT01291459|maraviroc
1168039|NCT01291459|raltegravir
1168040|NCT01291446|Intestinal gas production
1168041|NCT01291446|Intestinal microbiota
1168042|NCT01291407|Combined Modality
1168043|NCT01291407|Gastric Cancer
1168044|NCT01291407|Radiation Therapy
1168045|NCT01291407|S-1
1168046|NCT01291394|Growth disorders
1168047|NCT01291394|Saizen
1168048|NCT01291394|Easypod
1168049|NCT01291394|Growth hormone
1168050|NCT01291394|Pediatric subject
1168051|NCT01291381|allergic rhinitis
1168052|NCT01291381|peripheral tolerance
1168053|NCT01291381|regulatory T cells
1168054|NCT01291381|specific immunotherapy
1168055|NCT01291381|Tr1 cells
1168056|NCT01291368|Sedation
1168057|NCT01291368|Delirium
1168058|NCT01291368|PTSD
1168059|NCT01291368|Depression
1168060|NCT01291368|Anxiety
1168061|NCT01291368|HRQoL
1168062|NCT01291368|CAM-ICU
1168063|NCT01291368|RASS
1168064|NCT01291368|SF-36
1168065|NCT01291368|ICU-memory tool
1168066|NCT01291368|Antipsychotic Agents
1168067|NCT01291368|Mobilization
1168068|NCT01291368|ICU-nursing
1168069|NCT01291368|ICU
1168070|NCT01291368|intensive care
1168071|NCT01291368|critical care
1168072|NCT01291368|critical care nursing
1168073|NCT01291355|Maternal position
1168074|NCT01291355|Occipitoposterior position
1168075|NCT01291355|Labor
1168076|NCT01291355|Dystocia
1168077|NCT01291355|Fetal presentation Abnormalities
1168078|NCT01291342|Pregnancy
1168079|NCT01291342|Preeclampsia
1168080|NCT01291342|Volatile biomarkers
1168081|NCT01291342|Chemical sensors
1168082|NCT01291342|Nanomaterials
1168083|NCT01291342|Nanosensors
1168084|NCT01291342|NA-NOSE
1168085|NCT01291329|stem cell
1168086|NCT01291329|acute ST-Elevation Myocardial Infarction
1168087|NCT01291303|Non invasive ventilation
1168088|NCT01291303|acute exacerbation of COPD
1168089|NCT01291303|optimized ventilation
1168090|NCT01291290|rAAA
1168091|NCT01291290|Platelets
1168092|NCT01291290|TEG
1168093|NCT01291290|Massive bleeding
1168094|NCT01291290|Coagulopathy
1168095|NCT01291277|gastrointestinal hemorrhage
1168096|NCT01291277|esophageal varices
1168097|NCT01291277|gastrointestinal endoscopy
1168098|NCT01291277|ligation
1168099|NCT01291264|Chlamydia trachomatis
1168100|NCT01291264|Neisseria gonorrhoeae
1168101|NCT01291264|Sexually Transmitted Diseases
1168102|NCT01291238|learning disability
1168103|NCT01291238|blood lipids
1168104|NCT01291238|cardio metabolic risk factors
1168105|NCT01291238|upper secondary school for learning disability students
1168106|NCT01291238|adolescents
1168107|NCT01291238|cardio respiratory fitness
1168108|NCT01291238|absorptiometry photos
1168109|NCT01291225|playgrounds
1168110|NCT01291225|farms
1168111|NCT01291225|injury prevention
1168112|NCT01291225|safety knowledge, attitudes and practices
1168113|NCT01291225|safe play
1168114|NCT01291225|rural
1168115|NCT01291212|In Vitro Fertilization
1168116|NCT01291212|Testosterone
1168117|NCT01291212|Ovarian Stimulation
1168118|NCT01291212|Luteinizing Hormone
1168119|NCT01291199|double-blind placebo controlled cross-over study
1168120|NCT01291186|spinal anesthesia
1168121|NCT01291186|intrathecal bupivacaine
1168122|NCT01291186|median effective dose
1168123|NCT01291186|height
1168124|NCT01291147|pain
1168125|NCT01291147|anaesthetic
1168126|NCT01291121|Age related macular degeneration
1168127|NCT01291121|Intravitreal ranibizumab
1168128|NCT01291121|Intravitreal expansile gas injection
1168129|NCT01291082|Breast cancer
1168130|NCT01291082|metastasis
1168131|NCT01291082|bone
1168132|NCT01291082|diffusion MRI
1168133|NCT01291069|Fontan
1168134|NCT01291069|Tadalafil
1168135|NCT01291069|Exercise performance
1168136|NCT01291056|Clomiphene citrate
1168137|NCT01291056|Mood symptoms
1168138|NCT01291056|Infertility
1168139|NCT01291056|Superovulation
1168140|NCT01291056|Effects of clomiphene on mood
1168141|NCT01291043|Shiatsu
1168142|NCT01291043|Fibromyalgia
1168143|NCT01291043|Pain
1168144|NCT01291043|Quality of sleep
1168145|NCT01291043|Balance
1168146|NCT01291043|Quality of life
1168147|NCT01291017|Advanced stage
1168148|NCT01290952|off-pump
1168149|NCT01290952|bypass
1168150|NCT01290952|coronary artery surgery
1168151|NCT01290939|adult glioblastoma
1168152|NCT01290939|recurrent adult brain tumor
1168153|NCT01290939|Cognition Disorders
1168154|NCT01290939|functional defects
1168155|NCT01290926|advanced chemorefractory colorectal cancer
1168156|NCT01290926|sorafenib
1168157|NCT01290926|capecitabine
1168158|NCT01290926|FDG-PET
1168159|NCT01290926|early metabolic response
1168160|NCT01290913|peanut allergy
1168161|NCT01290913|Xolair
1168162|NCT01290900|NXL104
1168163|NCT01290900|CAZ104
1168164|NCT01290900|Ceftazidime
1168165|NCT01290900|CXL104
1168166|NCT01290900|Ceftaroline
1168167|NCT01290900|Healthy Male Volunteers
1168168|NCT01290900|Phase 1
1168169|NCT01290900|OT
1168170|NCT01290900|Single Dose Study
1168171|NCT01290874|Asthma
1168172|NCT01290874|Blacks
1168173|NCT01290874|LABA
1168174|NCT01290874|Tiotropium
1168175|NCT01290874|Spiriva
1168176|NCT01290874|African American
1168177|NCT01290874|Serevent
1168178|NCT01290874|salmeterol
1168179|NCT01290874|Foradil
1168180|NCT01290874|formoterol
1168181|NCT01290874|Advair
1168182|NCT01290874|Symbicort
1168183|NCT01290874|Dulera
1168184|NCT01290861|Huntington's Disease
1168185|NCT01290861|Cognitive Battery
1168186|NCT01290861|Cognitive Testing
1168187|NCT01290861|Cognition
1168188|NCT01290861|pre-manifest Huntington's Disease
1168189|NCT01290848|pediatrics
1168190|NCT01290848|Health Promotion Campaign
1168191|NCT01290848|Community events
1168192|NCT01290835|Stereotactic radiotherapy
1168193|NCT01290835|CyberKnife following lumpectomy
1168194|NCT01290835|Breast cancer
1168195|NCT01290822|Biventricular pacing
1168196|NCT01290822|Dilated Cardiomyopathy
1168197|NCT01290822|Ischemic Cardiomyopathy
1168198|NCT01290822|Congestive heart failure
1168199|NCT01290822|Cardiac allograft
1168200|NCT01290822|Cardiac surgery
1168201|NCT01290822|AVD
1168202|NCT01290822|VVD
1168203|NCT01290822|LV pacing site
1168204|NCT01290822|pacing optimization
1168205|NCT01290809|Prophylactic Cranial Irradiation
1168206|NCT01290809|lung cancer
1168207|NCT01290783|mCRC
1168208|NCT01290783|CRC
1168209|NCT01290783|colorectal
1168210|NCT01290783|irinotecan
1168211|NCT01290783|Hyaluronic acid
1168212|NCT01290783|Hyaluronan
1168213|NCT01290770|obesity
1168214|NCT01290770|men
1168215|NCT01290770|TFPI
1168216|NCT01290770|Lipoprotein(a)
1168217|NCT01290770|Lp(a)
1168218|NCT01290770|Tissue Factor pathway inhibitor
1168219|NCT01290770|aspirin
1168220|NCT01290744|leprosy
1168221|NCT01290744|ENL
1168222|NCT01290744|clofazimine
1168223|NCT01290731|Hepatitis C, Chronic
1168224|NCT01290731|Hepatitis C virus
1168225|NCT01290731|Interferon Alfa-2a
1168226|NCT01290731|Ribavirin
1168227|NCT01290731|Viral RNA
1168228|NCT01290705|Knee
1168229|NCT01290705|Anterior Cruciate Ligament
1168230|NCT01290705|Pain
1168231|NCT01290705|Patella
1168232|NCT01290705|Exercise Therapy
1168233|NCT01290692|Brain Neoplasms
1168362|NCT01290172|Liver transplant
1168234|NCT01290692|Central Nervous System Neoplasms
1168235|NCT01290692|Brain Diseases
1168236|NCT01290692|Neoplasms
1168237|NCT01290692|Nervous System Neoplasms
1168238|NCT01290692|Glioblastoma
1168239|NCT01290692|Astrocytoma
1168240|NCT01290692|Nervous System Diseases
1168241|NCT01290692|Central Nervous System Diseases
1168242|NCT01290692|Glioma
1168243|NCT01290692|Recurrent astrocytoma
1168244|NCT01290692|Recurrent glioma
1168245|NCT01290692|Cancer vaccine
1168246|NCT01290692|Immunotherapy
1168247|NCT01290692|Killer T cells
1168248|NCT01290692|Activated T cells
1168249|NCT01290692|GM-CSF
1168250|NCT01290692|Activated lymphocytes
1168251|NCT01290679|Hepatitis C
1168252|NCT01290679|TMC435
1168253|NCT01290679|HCV
1168254|NCT01290679|Hep C
1168255|NCT01290679|genotype 1
1168256|NCT01290601|malaria
1168257|NCT01290601|Plasmodium vivax
1168258|NCT01290601|adults
1168259|NCT01290601|treatment
1168260|NCT01290601|tafenoquine
1168261|NCT01290562|SBRT
1168262|NCT01290562|spinal Metastases
1168263|NCT01290562|Paraspinal Metastases
1168264|NCT01290562|spinal Metastases and SBRT
1168265|NCT01290562|Paraspinal Metastases and SBRT
1168266|NCT01290536|Liver metastases
1168267|NCT01290510|tendinopathy
1168268|NCT01290510|hyaluronan
1168269|NCT01290510|tendon
1168270|NCT01290510|hyaluronic acid
1168271|NCT01290484|Lymphatic malformation, vascular malformation
1168272|NCT01290458|Eccentric training
1168273|NCT01290458|Free radicals
1168274|NCT01290458|Antioxidant supplements
1168275|NCT01290458|Training adaptations
1168276|NCT01290458|Lipid profile
1168277|NCT01290445|varenicline
1168278|NCT01290445|smoking
1168279|NCT01290445|smoking cessation
1168280|NCT01290445|cohort study
1168281|NCT01290445|drug safety
1168282|NCT01290445|prospective study
1168283|NCT01290432|female fertility
1168284|NCT01290432|ovarian reserve
1168285|NCT01290432|oocyte quality
1168286|NCT01290432|oocyte quantity
1168287|NCT01290432|antimullerian hormone
1168288|NCT01290432|AMH
1168289|NCT01290432|dietary supplements
1168290|NCT01290432|inofolic plus
1168291|NCT01290432|myoinositol
1168292|NCT01290432|folic acid
1168293|NCT01290419|RSV
1168294|NCT01290406|Endometrial cancer,
1168295|NCT01290406|uterine cancer,
1168296|NCT01290406|PI3K,
1168297|NCT01290406|mTOR,
1168298|NCT01290406|targeted therapy
1168299|NCT01290393|vaccine
1168300|NCT01290393|Spontaneous abortions
1168301|NCT01290393|Human papillomavirus
1168302|NCT01290393|HPV
1168303|NCT01290393|Cervarix
1168304|NCT01290393|pregnancy
1168305|NCT01290380|Solid tumor malignancies,
1168306|NCT01290380|simvastatin,
1168307|NCT01290380|caffeine,
1168308|NCT01290380|omeprazole and diclofenac,
1168309|NCT01290380|ASA404,
1168310|NCT01290380|PK data
1168311|NCT01290367|Chronic Lumbar Back Pain
1168312|NCT01290367|Low back pain
1168313|NCT01290367|Back pain
1168314|NCT01290367|Degenerative Disc Disease
1168315|NCT01290367|Injection of Degenerated Lumbar Disc
1168316|NCT01290367|Stem Cells
1168317|NCT01290367|Adult Stem Cells
1168318|NCT01290367|Allogeneic Mesenchymal Precursor cells (MPCs)
1168319|NCT01290367|Mesoblast
1168320|NCT01290354|Brain penetration
1168321|NCT01290354|positron emission tomography
1168322|NCT01290354|Lapatinib
1168323|NCT01290341|fungal infection
1168324|NCT01290341|athlete foot
1168325|NCT01290328|anemia
1168326|NCT01290328|kidney transplant
1168327|NCT01290328|alloimmunity
1168328|NCT01290289|Labor
1168329|NCT01290289|Epidural
1168330|NCT01290289|Combined spinal epidural
1168331|NCT01290289|pethidine
1168332|NCT01290276|Ondansetron
1168333|NCT01290276|Methylphenidate
1168334|NCT01290263|Glioblastoma
1168335|NCT01290263|GBM
1168336|NCT01290263|Brain Tumor
1168337|NCT01290263|Glioma
1168338|NCT01290237|vancomycin
1168339|NCT01290237|loading dose
1168340|NCT01290237|pharmacokinetic
1168341|NCT01290237|pediatric
1168342|NCT01290237|Methicillin-Resistant Staphylococcus aureus (MRSA)
1168343|NCT01290237|Serious infection with Gram positive bacteria
1168344|NCT01290211|maraviroc
1168345|NCT01290211|fosamprenavir
1168346|NCT01290211|drug interaction
1168347|NCT01290211|pharmacokinetics
1168348|NCT01290211|HIV
1168349|NCT01290211|AIDS
1168350|NCT01290211|CCR5
1168351|NCT01290211|protease inhibitor
1168352|NCT01290198|epoxy-eicosatrienoic acid
1168353|NCT01290198|Laser Doppler
1168354|NCT01290198|Endothelium derived hyperpolarizing factor
1168355|NCT01290198|cutaneous microcirculation
1168356|NCT01290198|post-occlusive hyperaemia
1168357|NCT01290198|thermal hyperemia
1168358|NCT01290198|intradermal microdialysis
1168359|NCT01290198|fluconazole
1168360|NCT01290185|Arthroplasty
1168361|NCT01290185|Pharmacol Nerve Block
1168363|NCT01290172|portal hypertension
1168364|NCT01290159|tolerance to heat
1168365|NCT01290146|Heart Failure
1168366|NCT01290146|Levosimendan
1168367|NCT01290146|Inotropic agents
1168368|NCT01290146|Phosphodiesterase Inhibitors
1168369|NCT01290146|Vasodilators
1168370|NCT01290146|Diuretics
1168371|NCT01290120|Burkitt Lymphoma
1168372|NCT01290120|B-ALL
1168373|NCT01290120|Adult patients
1168374|NCT01290107|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1168375|NCT01290107|childhood acute myeloid leukemia/other myeloid malignancies
1168376|NCT01290081|Tuberculosis
1168377|NCT01290081|Injecting drug users
1168378|NCT01290081|Case management
1168379|NCT01290068|Intraocular Lens
1168380|NCT01290055|yellow fever
1168381|NCT01290055|vaccine
1168382|NCT01290055|memory T cells
1168383|NCT01290029|pediatric
1168384|NCT01290029|CKD
1168385|NCT01290029|dialysis
1168386|NCT01290029|paediatric
1168387|NCT01290016|randomized controlled trial
1168388|NCT01290016|children
1168389|NCT01290016|obesity
1168390|NCT01290016|nutrition
1168391|NCT01290016|exercise
1168392|NCT01290003|Antibacterial agents
1168393|NCT01290003|Neonate
1168394|NCT01290003|Meconium stained amniotic fluid
1168395|NCT01290003|Neonatal sepsis
1168396|NCT01289977|Sandfly
1168397|NCT01289977|leishmaniasis
1168398|NCT01289977|immune response
1168399|NCT01289977|individuals age 18-50
1168400|NCT01289951|HIV
1168401|NCT01289951|VHC
1168402|NCT01289951|Advanced hepatic cirrhosis
1168403|NCT01289951|Pharmacokinetic
1168404|NCT01289951|Raltegravir
1168405|NCT01289938|pharmacokinetic
1168406|NCT01289938|pharmacogenetic
1168407|NCT01289938|Metoclopramide
1168408|NCT01289938|Diphenhydramine
1168409|NCT01289938|CYP2D6 polymorphisms
1168410|NCT01289925|dietary supplement
1168411|NCT01289925|selenium
1168412|NCT01289925|healthy volunteer
1168413|NCT01289925|Johns Hopkins
1168414|NCT01289925|older
1168415|NCT01289925|aging
1168416|NCT01289925|geriatrics
1168417|NCT01289925|baltimore
1168418|NCT01289925|mineral
1168419|NCT01289925|over 70
1168420|NCT01289912|Tuberous Sclerosis Complex
1168421|NCT01289912|Autism
1168422|NCT01289912|Neurocognition
1168423|NCT01289912|RAD001
1168424|NCT01289912|Everolimus
1168425|NCT01289912|Afinitor
1168426|NCT01289912|TSC
1168427|NCT01289899|BR-A-657
1168428|NCT01289899|Fimasartan
1168429|NCT01289899|multiple-dose
1168430|NCT01289899|pharmacokinetic
1168431|NCT01289899|pharmacodynamic
1168432|NCT01289899|safety
1168433|NCT01289886|single-dose
1168434|NCT01289886|pharmacokinetic
1168435|NCT01289886|pharmacodynamic
1168436|NCT01289886|safety
1168437|NCT01289847|Primary Immune Deficiency Disorders
1168438|NCT01289847|Common Variable Immunodeficiency
1168439|NCT01289847|X-linked agammaglobulinemia
1168440|NCT01289847|Hyper-IgM syndrome
1168441|NCT01289847|Wiskott-Aldrich Syndrome
1168442|NCT01289847|Immunoglobulins
1168443|NCT01289847|Bacterial Infections
1168444|NCT01289834|RSA
1168445|NCT01289834|Bone Cement
1168446|NCT01289808|Glucose
1168447|NCT01289808|analgesic
1168448|NCT01289808|newborns
1168449|NCT01289795|Stroke
1168450|NCT01289795|Cerebral Infarction
1168451|NCT01289795|Cerebrovascular Disorders
1168452|NCT01289795|Brain Diseases
1168453|NCT01289795|Central Nervous System Diseases
1168454|NCT01289782|Hepatitis C
1168455|NCT01289782|TMC435
1168456|NCT01289782|HCV
1168457|NCT01289782|Hep C
1168458|NCT01289782|Genotype 1
1168459|NCT01289756|pharmacokinetic
1168460|NCT01289756|clomiphene
1168461|NCT01289756|CYP2D6 polymorphisms
1168462|NCT01289756|inhibition of CYP2D6 and CYP3A4
1168463|NCT01289743|ankylosing spondylitis
1168464|NCT01289743|atanercept
1168465|NCT01289743|therapy
1168466|NCT01289743|magnetic resonance imaging
1168467|NCT01289730|undifferentiated spondyloarthritis
1168468|NCT01289730|etanercept
1168469|NCT01289730|therapy
1168470|NCT01289730|magnetic resonance imaging
1168471|NCT01289717|biomarkers
1168472|NCT01289717|proteogenomic profiling
1168473|NCT01289717|acute rejection
1168474|NCT01289717|chronic allograft nephropathy/interstitial fibrosis and tubular atrophy
1168475|NCT01289704|Charcot−Marie−Tooth disease,
1168476|NCT01289704|CMT1A,
1168477|NCT01289704|rehabilitation,
1168478|NCT01289704|treadmill,
1168479|NCT01289704|stretching,
1168480|NCT01289704|proprioception,
1168481|NCT01289704|Randomised Controlled Trial.
1168482|NCT01289691|One Lung Ventilation
1168483|NCT01289691|Atelectasis
1168484|NCT01289691|Oxygenation
1168485|NCT01289678|acute myelogenous leukemia
1168486|NCT01289678|interleukin-2
1168487|NCT01289665|lubricating
1168488|NCT01289665|gel
1168489|NCT01289665|speculum
1168490|NCT01289665|Pain, Pelvic
1168491|NCT01289665|Examination, Gynecological
1168492|NCT01289652|Acute hepatitis C (HCV)
1168493|NCT01289652|Human immunodeficiency virus (HIV)
1168494|NCT01289639|non-alcoholic fatty liver disease
1168495|NCT01289639|non-alcoholic steatohepatitis
1168496|NCT01289639|insulin resistance
1168497|NCT01289639|pioglitazone
1168498|NCT01289639|fenofibrate
1168499|NCT01289626|Calciphylaxis, dialysis
1168500|NCT01289613|Bispectral Index
1168501|NCT01289613|Anesthesia
1168502|NCT01289613|Asymmetry
1168503|NCT01289587|Diabetes
1168504|NCT01289587|Physical activity
1168505|NCT01289587|Body composition
1168506|NCT01289587|Aerobic fitness
1168507|NCT01289587|Metabolic control
1168508|NCT01289574|androgen receptor degradation enhancer
1168509|NCT01289548|remote ischaemic preconditioning
1168510|NCT01289548|kidney transplantation
1168511|NCT01289535|Influenza vaccine
1168512|NCT01289535|immune response
1168513|NCT01289535|elderly
1168514|NCT01289522|Squamous cell carcinoma of the head and neck
1168515|NCT01289522|recurrent or metastatic
1168516|NCT01289522|first line chemotherapy
1168517|NCT01289522|cetuximab
1168518|NCT01289522|docetaxel
1168519|NCT01289522|cisplatin
1168520|NCT01289522|antineoplastic agents
1168521|NCT01289522|First Line Palliative Treatment
1168522|NCT01289496|Ribavirin
1168523|NCT01289496|Pegasys
1168524|NCT01289496|Hepatitis
1168525|NCT01289483|awake fiberoptic intubation (AFI)
1168526|NCT01289483|difficult airway
1168527|NCT01289483|fospropofol
1168528|NCT01289470|NIRS Technology
1168529|NCT01289470|Cardiovascular surgery
1168530|NCT01289470|valvular surgery with cardiopulmonary bypass
1168531|NCT01289457|Acute Myelogenous Leukemia
1168532|NCT01289457|AML
1168533|NCT01289457|High-Risk Myelodysplastic Syndrome
1168534|NCT01289457|MDS
1168535|NCT01289457|Relapsed
1168536|NCT01289457|Refractory
1168537|NCT01289457|Clofarabine
1168538|NCT01289457|Clofarex
1168539|NCT01289457|Clolar
1168540|NCT01289457|Idarubicin
1168541|NCT01289457|Idamycin
1168542|NCT01289457|Cytarabine
1168543|NCT01289457|Ara-C
1168544|NCT01289457|Cytosar
1168545|NCT01289457|DepoCyt
1168546|NCT01289457|Cytosine Arabinosine Hydrochloride
1168547|NCT01289444|palliative care
1168548|NCT01289444|AIDS
1168549|NCT01289444|adolescents
1168550|NCT01289444|quality of life
1168551|NCT01289444|adherence
1168552|NCT01289444|spiritual
1168553|NCT01289444|threat appraisal
1168554|NCT01289444|treatment congruence
1168555|NCT01289444|treatment preferences
1168556|NCT01289444|dialysis
1168557|NCT01289444|hospitalization
1168558|NCT01289444|communication
1168559|NCT01289444|family intervention
1168560|NCT01289444|Family Centered Advance Care Planning
1168561|NCT01289444|decision making
1168562|NCT01289444|advance care planning
1168563|NCT01289444|end of life
1168564|NCT01289418|H1N1
1168565|NCT01289418|vaccine safety
1168566|NCT01289418|adverse events
1168567|NCT01289418|health care workers
1168568|NCT01289405|obstructive sleep apnea
1168569|NCT01289405|oropharyngeal exercises
1168570|NCT01289405|speech therapy
1168571|NCT01289392|Obstructive Sleep Apnea
1168572|NCT01289392|CPAP
1168573|NCT01289392|Oral appliance
1168574|NCT01289392|Aerobic exercise
1168575|NCT01289392|Resistance training
1168576|NCT01289379|pneumoperitoneum
1168577|NCT01289379|laparoscopy
1168578|NCT01289379|HFJV
1168579|NCT01289379|cardiovascular
1168580|NCT01289379|Symptomatic
1168581|NCT01289353|triple negative
1168582|NCT01289353|breast cancer
1168583|NCT01289353|adjuvant therapy
1168584|NCT01289353|Carboplatin
1168585|NCT01289353|chemotherapy
1168586|NCT01289353|radiation therapy
1168587|NCT01289353|chemo-radiotherapy
1168588|NCT01289353|accelerated radiotherapy
1168589|NCT01289340|wound healing
1168590|NCT01289340|pain
1168591|NCT01289340|burn
1168592|NCT01289314|total laparoscopic hysterectomy
1168593|NCT01289314|laparoscopic supracervical hysterectomy
1168594|NCT01289301|renal transplantation
1168595|NCT01289301|polyoma BK virus infection
1168596|NCT01289301|everolimus
1168597|NCT01289301|calcineurin inhibitor
1168598|NCT01289301|mTOR inhibitor
1168599|NCT01289288|colorectal cancer screening
1168600|NCT01289288|Chinese Americans
1168601|NCT01289288|patients nonadherent with CRC Screening
1168602|NCT01289275|tobacco cessation
1168603|NCT01289275|smoking cessation
1168604|NCT01289275|telephone
1168605|NCT01289275|self-help
1168606|NCT01289275|smoking abstinence
1168607|NCT01289275|tobacco use disorder
1168608|NCT01289275|hospital
1168609|NCT01289275|cardiopulmonary diseases
1168610|NCT01289275|disparity
1168611|NCT01289262|Cesarean section
1168612|NCT01289262|Kerr incision
1168613|NCT01289262|Purse string suturing in CS
1168614|NCT01289262|Continuous locked suturing in CS
1168615|NCT01289249|meropenem
1168616|NCT01289249|child
1168617|NCT01289249|bacterial infection
1168618|NCT01289249|treatment evaluation
1168619|NCT01289236|Shoulder Pain
1168620|NCT01289223|Indolent B-cell NHL, bendamustine, rituximab, progression-free survival
1168621|NCT01289210|B cell
1168622|NCT01289210|lymphoma
1168623|NCT01289184|Occupational Health Hazards
1168624|NCT01289184|Air Pollution
1168625|NCT01289184|Photocopiers
1168626|NCT01289184|Other Specified Personal Exposures
1168627|NCT01289184|History Presenting Hazards to Health
1168628|NCT01289171|The efficacy, tolerability and safety of 15% glycolic acid lotion for treatment of diffuse flat warts among HIV+ children were investigated
1168629|NCT01289158|malonic and methylmalonic aciduria
1168630|NCT01289158|malonyl-coenzyme A decarboxylase
1168631|NCT01289158|MLYCD
1168632|NCT01289145|Action Planning
1168633|NCT01289145|Positive Outcome Expectancies
1168634|NCT01289145|Randomized Controlled Trial
1168635|NCT01289145|Stages of change
1168636|NCT01289145|Health behavior
1168637|NCT01289145|Motivation
1168638|NCT01289132|Drug Therapy
1168639|NCT01289119|Type 2 Diabetes Mellitus
1168640|NCT01289119|Drug Therapy
1168641|NCT01289106|Hepatitis B vaccine
1168642|NCT01289106|HIV infection
1168643|NCT01289106|Modified HBV vaccine dose
1168644|NCT01289106|Modified HBV vaccine schedule
1168645|NCT01289093|inguinal hernia
1168646|NCT01289093|incisional hernia
1168647|NCT01289093|quality of life
1168648|NCT01289093|disease-specific
1168649|NCT01289080|Schizophrenia
1168650|NCT01289080|psychiatric disorders
1168651|NCT01289080|renal failure
1168652|NCT01289067|Metastatic
1168653|NCT01289067|Castration Resistant
1168654|NCT01289067|Prostate Cancer
1168655|NCT01289054|Female
1168656|NCT01289054|Pregnancy
1168657|NCT01289054|Hematologic Pregnancy
1168658|NCT01289054|Complications
1168659|NCT01289054|Registry
1168660|NCT01289054|Pregnant Registry
1168661|NCT01289054|CML
1168662|NCT01289054|GIST
1168663|NCT01289054|Gleevec
1168664|NCT01289054|Tasigna
1168665|NCT01289054|Glivec
1168666|NCT01289054|Pregnancy Exposure
1168667|NCT01289041|Advanced endometrial cancer
1168668|NCT01289041|PI3K pathway
1168669|NCT01289041|second-line treatment
1168670|NCT01289028|GIST
1168671|NCT01289028|Imatinib
1168672|NCT01289028|Sunitinib
1168673|NCT01289028|Gastrointestinal
1168674|NCT01289028|Stromal
1168675|NCT01289028|Tumors
1168676|NCT01289015|fungal infection
1168677|NCT01289015|athlete foot
1168678|NCT01288989|Advanced Solid Tumors
1168679|NCT01288976|Mitral Valve
1168680|NCT01288976|Mitral Regurgitation
1168681|NCT01288976|MitraClip
1168682|NCT01288976|Mitral Valve Surgery
1168683|NCT01288976|Mitral Valve Insufficiency or Mitral Regurgitation
1168684|NCT01288963|melanoma
1168685|NCT01288963|IL-2
1168686|NCT01288963|Aldesleukin
1168687|NCT01288950|BCG vaccine
1168688|NCT01288950|Vitamin D
1168689|NCT01288950|Cholecalciferol
1168690|NCT01288950|Tuberculosis
1168691|NCT01288937|Milnacipran
1168692|NCT01288937|Idiopathic Peripheral Neuropathy
1168693|NCT01288937|Diabetic neuropathy
1168694|NCT01288937|Neuropathic pain
1168695|NCT01288911|Metastatic
1168696|NCT01288911|MDV3100
1168697|NCT01288911|Prostate
1168698|NCT01288911|progressive
1168699|NCT01288911|Cancer
1168700|NCT01288911|enzalutamide
1168701|NCT01288898|ASP1941
1168702|NCT01288898|Diabetes Mellitus
1168703|NCT01288898|Multiple ascending doses
1168704|NCT01288898|Healthy subjects
1168705|NCT01288885|ASP1941
1168706|NCT01288885|Diabetes Mellitus
1168707|NCT01288885|First in Men
1168708|NCT01288872|Praziquantal, Schistosomiasis, pregnant women, Philippines
1168709|NCT01288859|polyphenols
1168710|NCT01288859|curcumin
1168711|NCT01288859|bioavailability
1168712|NCT01288859|cocoa
1168713|NCT01288846|medication list
1168714|NCT01288846|changes in medication
1168715|NCT01288846|prescription medication
1168716|NCT01288833|Colonoscopy
1168717|NCT01288833|Diagnostic Imaging
1168718|NCT01288833|Colorectal Neoplasm
1168719|NCT01288833|Primary Prevention
1168720|NCT01288833|Cost and Cost Analysis
1168721|NCT01288833|Endoscopy
1168722|NCT01288807|Fibromyalgia
1168723|NCT01288807|pain
1168724|NCT01288794|Cirrhosis
1168725|NCT01288794|Uncomplicated ascites
1168726|NCT01288794|Refractory ascites
1168727|NCT01288794|Chronic albumin treatment
1168728|NCT01288781|High Altitude Headache; intra-cranial pressure; hypoxia
1168729|NCT01288768|Meniscal injury
1168730|NCT01288768|Knee arthroscopy
1168731|NCT01288768|Middleaged
1168732|NCT01288768|Functional outcome
1168733|NCT01288755|TMC278-TiDP6-C153
1168734|NCT01288755|TMC278-C153
1168735|NCT01288755|TMC278
1168736|NCT01288755|HIV
1168737|NCT01288742|TMC435-TiDP16-C108
1168738|NCT01288742|TMC435-C108
1168739|NCT01288742|TMC435
1168740|NCT01288742|HPC
1168741|NCT01288742|HCV
1168742|NCT01288742|Hepatitis C
1168743|NCT01288716|ASD
1168744|NCT01288716|Autism
1168745|NCT01288716|Asperger Syndrome
1168746|NCT01288703|urinary incontinence
1168747|NCT01288690|Refugees
1168748|NCT01288690|Trauma
1168749|NCT01288690|Narrative
1168750|NCT01288690|Exposure
1168751|NCT01288690|Middle East
1168752|NCT01288690|Therapy
1168753|NCT01288677|Healthy volunteer
1168754|NCT01288677|TMC649128HPC1001
1168755|NCT01288677|TMC649128
1168756|NCT01288677|HCV
1168757|NCT01288677|Hepatitis C
1168758|NCT01288677|healthy volunteers
1168759|NCT01288677|Phase I trial
1168760|NCT01288664|Lupus Nephritis
1168761|NCT01288664|Tacrolimus
1168762|NCT01288664|Induction Phase
1168763|NCT01288651|Pulmonary arterial hypertension
1168764|NCT01288651|Iron deficiency
1168765|NCT01288651|Exercise
1168766|NCT01288638|Polycystic Ovary Syndrome
1168767|NCT01288638|Metabolic Syndrome
1168768|NCT01288638|Pulse
1168769|NCT01288638|Lifestyle Intervention
1168770|NCT01288638|Aerobic Exercise
1168771|NCT01288638|Diet
1168772|NCT01288625|Identify whether Cytofos can reduce the incidence and duration of HNC patients' oral mucositis caused by radiotherapy.
1168773|NCT01288612|Barrett's Esophagus
1168774|NCT01288599|Laparoscopy
1168775|NCT01288599|Randomized
1168776|NCT01288599|Single port access
1168777|NCT01288599|Adnexal disease
1168778|NCT01288599|LESS
1168779|NCT01288586|Post Traumatic Arthritis
1168780|NCT01288586|Rheumatoid Arthritis
1168781|NCT01288586|Osteoarthritis
1168782|NCT01288560|medical imaging
1168783|NCT01288560|heart failure
1168784|NCT01288560|morbidity and mortality
1168785|NCT01288560|PET/CT,CMR,SPECT, echo, coronary angiography
1168786|NCT01288560|knowledge translation
1168787|NCT01288560|cost effectiveness
1168788|NCT01288560|quality of life
1168789|NCT01288560|prospective comparative effectiveness randomized clinical trial
1168790|NCT01288547|cognition
1168791|NCT01288547|attention
1168792|NCT01288547|methylxanthine
1168793|NCT01288521|kidney transplantation
1168794|NCT01288521|tacrolimus
1168795|NCT01288521|P-glycoprotein
1168796|NCT01288521|ABCB1
1168797|NCT01288521|genotyping
1168798|NCT01288482|Methacholine challenge
1168799|NCT01288482|nebulizer
1168800|NCT01288482|English-Wright
1168801|NCT01288482|AeroEclipse II
1168802|NCT01288469|10020603
1168803|NCT01288456|medical device, space-occupying device
1168804|NCT01288430|Heat shock protein 90
1168805|NCT01288430|Advanced solid tumors
1168806|NCT01288430|Non-small cell lung carcinoma
1168807|NCT01288430|Epidermal growth factor receptor
1168808|NCT01288430|Tyrosine kinase inhibitor acquired resistance
1168809|NCT01288430|Non-small cell lung carcinoma with acquired resistance to erlotinib, gefitinib, afatinib or others.
1168810|NCT01288417|HIV infections
1168811|NCT01288417|HCV infections
1168812|NCT01288417|interaction
1168813|NCT01288417|pharmacokinetics
1168814|NCT01288417|raltegravir
1168815|NCT01288417|boceprevir
1168816|NCT01288404|Bevacizumab, impending recurrent pterygium
1168817|NCT01288378|fungal infection
1168818|NCT01288378|de novo myelodysplastic syndromes
1168819|NCT01288378|previously treated myelodysplastic syndromes
1168820|NCT01288378|secondary myelodysplastic syndromes
1168821|NCT01288378|recurrent adult acute myeloid leukemia
1168822|NCT01288378|untreated adult acute myeloid leukemia
1168823|NCT01288378|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1168824|NCT01288378|adult acute myeloid leukemia with del(5q)
1168825|NCT01288378|adult acute myeloid leukemia with inv(16)(p13;q22)
1168826|NCT01288378|adult acute myeloid leukemia with t(15;17)(q22;q12)
1168827|NCT01288378|adult acute myeloid leukemia with t(16;16)(p13;q22)
1168828|NCT01288378|adult acute myeloid leukemia with t(8;21)(q22;q22)
1168829|NCT01288378|secondary acute myeloid leukemia
1168830|NCT01288365|heart failure
1168831|NCT01288365|preserved ejection fraction
1168832|NCT01288352|early treatment
1168833|NCT01288352|rhythm control
1168834|NCT01288352|atrial fibrillation
1168835|NCT01288352|cardiovascular complications
1168836|NCT01288313|human milk
1168837|NCT01288313|polyunsaturated fatty acids
1168838|NCT01288313|linolenic acid
1168839|NCT01288313|rapeseed oil
1168840|NCT01288287|Certolizumab pegol
1168841|NCT01288287|Cimzia®
1168842|NCT01288274|Contraception
1168843|NCT01288274|Family planning
1168844|NCT01288274|Task Shifting
1168845|NCT01288274|Community based distribution
1168846|NCT01288274|Ethiopia
1168847|NCT01288274|DMPA
1168848|NCT01288248|Airway
1168849|NCT01288248|Airway laryngeal mask
1168850|NCT01288248|Endotracheal tube
1168851|NCT01288248|Respiration artificial
1168852|NCT01288248|Laryngospasm
1168853|NCT01288248|Safety of airway laryngeal mask
1168854|NCT01288235|proton radiotherapy
1168855|NCT01288222|acute myelogenous leukemia
1168856|NCT01288222|hematopoietic cell transplantation
1168857|NCT01288222|unrelated donor
1168858|NCT01288209|Hepatitis C, Chronic
1168859|NCT01288209|Hepatitis C
1168860|NCT01288209|Hepatitis C virus
1168861|NCT01288209|Interferon Alfa-2a
1168862|NCT01288209|Ribavirin
1168863|NCT01288209|Viral RNA
1168864|NCT01288196|CNTO 6785
1168865|NCT01288196|Intravenous
1168866|NCT01288196|Subcutaneous
1168867|NCT01288196|Pharmacokinetics
1168868|NCT01288196|Immunogenicity
1168869|NCT01288196|Safety
1168870|NCT01288196|Tolerability
1168871|NCT01288183|tobacco
1168872|NCT01288183|smoking
1168873|NCT01288183|tDCS
1168874|NCT01288183|DLPFC
1168875|NCT01288170|cystic fibrosis, bioequivalence, pharmacokinetic, sputum, plasma
1168876|NCT01288157|healthy
1168877|NCT01288157|adult
1168878|NCT01288157|Chinese
1168879|NCT01288157|male
1168880|NCT01288157|Simponi
1168881|NCT01288157|CNTO 148
1168882|NCT01288144|Screening
1168883|NCT01288144|Gestational diabetes mellitus
1168884|NCT01288131|Anti-r-HuEpo antibody
1168885|NCT01288131|Anti-r-HuEpo associated PRCA
1168886|NCT01288131|Treatment
1168887|NCT01288131|Absolute reticulocyte count
1168888|NCT01288105|drug-eluting stents
1168889|NCT01288105|noncardiac surgery
1168890|NCT01288092|Metastatic breast cancer
1168891|NCT01288092|HER2 negative
1168892|NCT01288092|HR positive
1168893|NCT01288092|PI3K pathway
1168894|NCT01288092|no more than 2 prior lines of chemotherapy
1168895|NCT01288092|Metastatic Breast Cancer(MBC)
1168896|NCT01288079|Major Depressive Disorder
1168897|NCT01288079|MDD
1168898|NCT01288079|Monotherapy
1168899|NCT01288079|Inadequate Response to Antidepressant Therapy
1168900|NCT01288066|Shoulder
1168901|NCT01288066|Total arthroplasty
1168902|NCT01288066|Hemiarthroplasty
1168903|NCT01288066|Resurfacing
1168904|NCT01288066|Glenoid
1168905|NCT01288066|Constant score
1168906|NCT01288040|stroke
1168907|NCT01288040|treadmill
1168908|NCT01288040|walking
1168909|NCT01288040|hemiparesis
1168910|NCT01288040|training
1168911|NCT01288014|immune response
1168912|NCT01288014|varicella zoster virus (VZV)
1168913|NCT01288014|cytokine levels
1168914|NCT01288014|immunization
1168915|NCT01287975|Stroke Rehabilitation
1168916|NCT01287975|Brain Computer Interface
1168917|NCT01287975|Upper Limb Rehabilitation
1168918|NCT01287975|EEG-based Motor Imagery
1168919|NCT01287975|Robotic Rehabilitation
1168920|NCT01287975|Haptic Knob
1168921|NCT01287962|Apatinib
1168922|NCT01287962|Non-small Cell Lung Cancer
1168923|NCT01287962|VEGFR TKIs
1168924|NCT01287949|Diphtheria
1168925|NCT01287949|Tetanus
1168926|NCT01287949|Poliomyelitis
1168927|NCT01287949|Pertussis (acellular)
1168928|NCT01287949|Biological/vaccine
1168929|NCT01287936|Chronic Stroke
1168930|NCT01287936|Stable Stroke
1168931|NCT01287923|Hematology
1168932|NCT01287923|Secondary lymphoid organs
1168933|NCT01287910|Cardiac
1168934|NCT01287910|Angina
1168935|NCT01287910|Chest pain
1168936|NCT01287897|Crohn's Disease
1168937|NCT01287897|safety
1168938|NCT01287897|efficacy
1168939|NCT01287897|pharmacokinetics
1168940|NCT01287897|pharmacodynamics
1168941|NCT01287897|Crohn's Disease Activity Index (CDAI)
1168942|NCT01287884|ABG
1168943|NCT01287884|VBG
1168944|NCT01287884|pH
1168945|NCT01287884|pCO2
1168946|NCT01287871|Cervical Cancer Screening
1168947|NCT01287845|Prostate cancer
1168948|NCT01287845|Neoplasm
1168949|NCT01287845|Diagnostic Imaging
1168950|NCT01287845|PET (Positron Emission Tomography) -tracer
1168951|NCT01287845|PET-diagnosis
1168952|NCT01287832|Methicillin-resistant
1168953|NCT01287832|Staphylococcus aureus
1168954|NCT01287806|ulinastatin
1168955|NCT01287806|inhalation injury
1168956|NCT01287780|Humans
1168957|NCT01287780|Prostheses and Implants
1168958|NCT01287780|Gentamicin administration and dosage
1168959|NCT01287780|Surgical sponges
1168960|NCT01287780|Treatment outcomes
1168961|NCT01287767|Dementia
1168962|NCT01287767|Depression
1168963|NCT01287767|Burden of care
1168964|NCT01287767|Psychosocial intervention
1168965|NCT01287767|Family home care
1168966|NCT01287702|early feeding
1168967|NCT01287702|varices bleeding
1168968|NCT01287702|to evaluate impact of early feeding on early rebleeding after ligation of varices
1168969|NCT01287689|Non-interventional trial
1168970|NCT01287689|immunodeficiency
1168971|NCT01287689|outcome study, registry
1168972|NCT01287689|long-term outcomes, drug utilization
1168973|NCT01287689|effectiveness, treatment patterns
1168974|NCT01287689|patient characteristics under real life conditions
1168975|NCT01287689|factors for treatment success
1168976|NCT01287689|long-term tolerability
1168977|NCT01287689|quality of life
1168978|NCT01287637|Rectal cancer
1168979|NCT01287637|Temporary ileostomy
1168980|NCT01287637|Ealy reversal
1168981|NCT01287637|Morbidity
1168982|NCT01287637|Mortality
1168983|NCT01287637|Quality of life
1168984|NCT01287637|Economic effect
1168985|NCT01287624|triple negative breast cancer
1168986|NCT01287624|fine line chemotherapy
1168987|NCT01287611|Cesarean section
1168988|NCT01287611|Kerr incision
1168989|NCT01287611|Purse string suturing in C/S
1168990|NCT01287611|Continuous locked suturing in C/S
1168991|NCT01287598|Phase I
1168992|NCT01287598|Probe substrate
1168993|NCT01287598|target therapy
1168994|NCT01287598|small molecule
1168995|NCT01287598|pharmacokinetics
1168996|NCT01287585|Hepatocellular carcinoma
1168997|NCT01287585|Arginine
1168998|NCT01287585|Arginine deiminase
1168999|NCT01287585|ADI-PEG 20
1169000|NCT01287572|TcCO2
1169001|NCT01287572|sedation
1169002|NCT01287572|procedure
1169003|NCT01287572|PICU
1169004|NCT01287559|NEC
1169005|NCT01287559|Premature Infant
1169006|NCT01287533|Rheumatoid arthritis
1169007|NCT01287533|Glucocorticoid induced osteoporosis
1169008|NCT01287533|Vertebral fracture
1169009|NCT01287507|VLBW, NEC, Late onset sepsis
1169010|NCT01287494|elderly
1169011|NCT01287494|care management
1169012|NCT01287494|primary care
1169013|NCT01287481|Fibromyalgia
1169014|NCT01287481|Behavioral interventions
1169015|NCT01287481|Psychological interventions
1169016|NCT01287468|phytomedicines
1169017|NCT01287468|breast cancer
1169018|NCT01287468|stromal fibroblasts
1169019|NCT01287468|MDSCs
1169020|NCT01287468|functional mechanism
1169021|NCT01287455|Asthma
1169022|NCT01287455|Vitamin D
1169023|NCT01287455|airway reactivity
1169024|NCT01287455|metacholine challenge test
1169025|NCT01287429|Ultrasonography
1169026|NCT01287416|Suicide Intervention
1169027|NCT01287416|Applied Suicide Intervention Skills Training (ASIST)
1169028|NCT01287416|Resilience Retreat
1169029|NCT01287416|First Nations
1169030|NCT01287416|Suicide Intervention and Response Inventory (SIRI)
1169031|NCT01287403|Cereals
1169032|NCT01287403|Alkylresorcinols
1169033|NCT01287403|Betaine
1169034|NCT01287403|Phenolics
1169035|NCT01287403|Plasma and urine cereal phytochemicals
1169036|NCT01287390|squamous cell carcinoma
1169037|NCT01287390|oral cavity
1169038|NCT01287390|oropharynx
1169039|NCT01287390|hypopharynx
1169040|NCT01287390|larynx
1169041|NCT01287377|tobacco cessation
1169042|NCT01287377|smoking cessation
1169043|NCT01287377|nicotine
1169044|NCT01287377|counseling
1169045|NCT01287377|telephone
1169046|NCT01287377|self-help
1169047|NCT01287377|smoking abstinence
1169048|NCT01287377|tobacco use disorder
1169049|NCT01287377|nicotine replacement therapy
1169050|NCT01287364|perennial allergic rhinitis
1169051|NCT01287364|PAR
1169052|NCT01287351|Real-world
1169053|NCT01287351|observational
1169054|NCT01287351|Fluticasone propionate
1169055|NCT01287351|Metred dose inhaler
1169056|NCT01287351|Extra-fine hydrofluoroalkane
1169057|NCT01287351|Asthma management
1169058|NCT01287351|Inhaled corticosteroids
1169059|NCT01287351|Beclomethasone dipropionate
1169060|NCT01287351|USA
1169061|NCT01287325|Chronic obstructive pulmonary disease
1169062|NCT01287325|Cough
1169063|NCT01287325|DNK333
1169064|NCT01287312|We will treat children age 1 month to 20 years with recurrent TEF after surgical failure
1169065|NCT01287299|pregnancy
1169066|NCT01287299|obesity
1169067|NCT01287299|diet glycemic load
1169068|NCT01287299|body composition
1169069|NCT01287299|body fat
1169070|NCT01287299|gestational weight gain
1169071|NCT01287299|insulin resistance
1169072|NCT01287286|Cancers
1169073|NCT01287286|Antrodia cinnamomea
1169074|NCT01287286|Chemotherapy
1169075|NCT01287286|Gastrointestinal Disorder
1169076|NCT01287273|frozen-thawed
1169077|NCT01287273|IVF
1169078|NCT01287273|incubation
1169079|NCT01287273|pregnancy rate
1169080|NCT01287273|Pregnancy rate of frozen-thawed embryos of IVF treatments
1169081|NCT01287260|BAYA1040_Nifedipine
1169082|NCT01287260|Nifedipine
1169083|NCT01287260|Essential hypertension
1169084|NCT01287260|Japanese Patients
1169085|NCT01287260|Phase III
1169086|NCT01287260|13176
1169087|NCT01287247|Cervical dystonia
1169088|NCT01287247|Blepharospasm
1169089|NCT01287208|Physical activity
1169090|NCT01287208|Accelerometer
1169091|NCT01287208|Steps
1169092|NCT01287208|Medical residents
1169093|NCT01287195|Ulcerative Colitis
1169094|NCT01287195|Inflammatory Bowel Disease
1169095|NCT01287182|Asymptomatic Myocardial Ischemic patients
1169096|NCT01287169|Bisphenol A
1169097|NCT01287156|Recruitment
1169098|NCT01287156|TBI
1169099|NCT01287156|Screening
1169100|NCT01287156|Traumatic Brain Injury
1169104|NCT01287130|Antibodies
1169105|NCT01287130|Pharmacokinetics
1169106|NCT01287130|Kinase Inhibitors
1169107|NCT01287130|Colon Cancer
1169108|NCT01287130|K-Ras
1169109|NCT01287130|Colorectal Cancer
1169110|NCT01287130|Solid Tumor
1169111|NCT01287104|Leukemia/Lymphoma
1169112|NCT01287104|Hematologic Malignacies
1169113|NCT01287104|Leukemia
1169114|NCT01287104|Lymphoma
1169115|NCT01287104|Ewing Sarcoma
1169116|NCT01287104|Rhabdomyosarcoma
1169117|NCT01287104|Neuroblastoma
1169118|NCT01287104|Healthy Donor
1169119|NCT01287078|Chronic GVHD of the Lung
1169120|NCT01287078|Peripheral Blood Stem Cell Transplant
1169121|NCT01287078|Inhaled Cyclosporine
1169122|NCT01287078|Graft-Versus-Host Disease
1169123|NCT01287078|GVHD
1169124|NCT01287078|Bronchiolitis Obliterans
1169125|NCT01287078|Lung
1169126|NCT01287065|Fluticasone furoate
1169127|NCT01287065|Vilanterol
1169128|NCT01287065|Efficacy
1169129|NCT01287065|FEV1
1169130|NCT01287065|FF/VI Inhalation powder
1169131|NCT01287052|Migraine
1169132|NCT01287052|Pediatric
1169133|NCT01287052|Adolescent
1169134|NCT01287052|Nitrous Oxide
1169135|NCT01287026|MRI Catheterization
1169136|NCT01287026|Right Heart Catheterization
1169137|NCT01287026|Pulmonary Artery Catheterization
1169138|NCT01287026|MRI Safety
1169139|NCT01287026|Jugular Vein Catheterization
1169140|NCT01287026|Heart Catheterization
1169141|NCT01287026|Heart Disease
1169142|NCT01287026|Cardiovascular Disease
1169143|NCT01287013|Image Guided Procedures
1169144|NCT01287013|Xperguide CT
1169145|NCT01287013|Electromagnetic Tracking
1169146|NCT01287013|Navigation
1169147|NCT01287013|Image Guided Procedure
1169148|NCT01287013|Cancer
1169149|NCT01287013|Granuloma
1169150|NCT01287000|Respiratory Health Outcomes
1169151|NCT01287000|Petroleum
1169152|NCT01287000|Dispersant(s)
1169153|NCT01287000|Oil Spill
1169154|NCT01287000|Longitudinal Study
1169155|NCT01286987|BRCA1 Protein
1169156|NCT01286987|BRCA2 Protein
1169157|NCT01286961|Bowel preparation
1169158|NCT01286961|Polyethylene glycols
1169159|NCT01286961|Colonoscopy
1169160|NCT01286961|Outpatient
1169161|NCT01286948|LNG gel
1169162|NCT01286948|oral LNG
1169163|NCT01286948|follicle rupture
1169164|NCT01286948|intra-vaginal administration
1169165|NCT01286948|growth of the leading follicle
1169166|NCT01286948|preovulatory peak of serum luteinizing hormone
1169167|NCT01286948|characteristics of the cervical mucus
1169168|NCT01286948|serum levels of estradiol (E2) and progesterone (P)
1169169|NCT01286935|Parkinson's Disease
1169170|NCT01286935|PD
1169171|NCT01286935|Levodopa
1169172|NCT01286935|Patients with idiopathic Parkinson's Disease with motor fluctuations,
1169173|NCT01286922|diabetes
1169174|NCT01286922|exercise
1169175|NCT01286922|insulin resistance
1169176|NCT01286922|interval training
1169177|NCT01286922|physical activity
1169178|NCT01286909|Metabolic
1169179|NCT01286896|advanced solid tumors
1169180|NCT01286883|stem cell markers
1169181|NCT01286883|prognostic markers
1169182|NCT01286883|metastatic colorectal cancer
1169183|NCT01286883|circulating tumor cells
1169184|NCT01286883|tumor microenvironment
1169185|NCT01286883|colorectal cancer
1169186|NCT01286883|advanced colorectal cancer
1169187|NCT01286870|Primary Breast Reconstruction
1169188|NCT01286831|Accelerator Mass Spectrometry (AMS)
1169189|NCT01286831|Beta-2 agonist
1169190|NCT01286831|Absorption, Distribution, Metabolism and Excretion (ADME)
1169191|NCT01286831|Radiolabel
1169192|NCT01286818|Colon Cancer
1169193|NCT01286818|Rectal Cancer
1169194|NCT01286766|unresectable
1169195|NCT01286766|locally advanced
1169196|NCT01286740|HIV-1
1169197|NCT01286740|HIV
1169198|NCT01286740|Treatment Experienced
1169199|NCT01286701|Bioequivalence
1169200|NCT01286701|crossover
1169201|NCT01286701|Terbinafine hydrochloride
1169202|NCT01286701|fed
1169203|NCT01286688|Bioequivalence
1169204|NCT01286688|crossover
1169205|NCT01286688|Terbinafine hydrochloride
1169206|NCT01286688|Fasting
1169207|NCT01286675|ASCT
1169208|NCT01286675|G-CSF
1169209|NCT01286662|gardner syndrome
1169210|NCT01286662|colorectal carcinoma
1169211|NCT01286662|desmoid tumor
1169212|NCT01286662|resection
1169213|NCT01286662|colon
1169214|NCT01286649|Alopecia
1169215|NCT01286649|Alopecia, Androgenetic
1169216|NCT01286649|Androgenetic Alopecia
1169217|NCT01286636|artificial neural network
1169218|NCT01286610|vibration
1169219|NCT01286610|ICU
1169220|NCT01286610|blood pressure
1169221|NCT01286610|intracranial pressure
1169222|NCT01286610|infection
1169223|NCT01286610|indirect calorimetry
1169224|NCT01286597|lactose intolerance
1169225|NCT01286597|DNA sequencing
1169226|NCT01286597|psychosocial factors
1169227|NCT01286597|irritable bowel syndrome
1169228|NCT01286597|visceral hypersensitivity
1169229|NCT01286584|varenicline
1169230|NCT01286584|alcohol
1169231|NCT01286584|placebo
1169232|NCT01286584|smoking cessation
1169233|NCT01286545|Ankylosing spondylitis
1169234|NCT01286545|Infliximab
1169235|NCT01286545|Radiographic progression
1169236|NCT01286532|Asthma, Asthma in Children
1169237|NCT01286519|pharmacokinetics
1169238|NCT01286506|Pulse pressure variation
1169239|NCT01286506|Continuous venovenous hemodialysis
1169240|NCT01286506|Volume status
1169241|NCT01286506|Critical care
1169242|NCT01286493|HIV
1169243|NCT01286493|booster
1169244|NCT01286493|rabies
1169245|NCT01286493|immune response
1169246|NCT01286480|Health Care Transition
1169247|NCT01286480|Adolescent
1169248|NCT01286467|PF-04449913
1169249|NCT01286467|Hedgehog Inhibitor
1169250|NCT01286467|Solid tumor
1169251|NCT01286467|Pharmacokinetics
1169252|NCT01286467|Safety
1169253|NCT01286467|Pharmacodynamics
1169254|NCT01286454|BIOAVAILABILITY
1169255|NCT01286454|FOOD EFFECT
1169256|NCT01286441|Verruca vulgaris
1169257|NCT01286428|liver
1169258|NCT01286428|cancer
1169259|NCT01286428|tumor
1169260|NCT01286428|ablation
1169261|NCT01286428|Pathfinder
1169262|NCT01286415|Posttraumatic Stress Disorder
1169263|NCT01286415|Cognitive Processing Therapy
1169264|NCT01286415|combat
1169265|NCT01286415|military
1169266|NCT01286415|CPT
1169267|NCT01286415|group therapy
1169268|NCT01286402|Smoking cessation during pregnancy
1169269|NCT01286402|bupropion
1169270|NCT01286389|Mild cognitive impairment
1169271|NCT01286389|Dementia
1169272|NCT01286389|Obesity
1169273|NCT01286389|Overweight
1169274|NCT01286389|diet
1169275|NCT01286389|caloric restriction
1169276|NCT01286389|body composition
1169277|NCT01286389|weight loss
1169278|NCT01286376|Symbiotics
1169279|NCT01286376|Fiber
1169280|NCT01286376|Constipation
1169281|NCT01286363|Bite force
1169282|NCT01286363|Dental occlusion
1169283|NCT01286363|Face
1169284|NCT01286363|Mastication
1169285|NCT01286363|Morphology
1169286|NCT01286350|motivational interviewing
1169287|NCT01286350|problem solving skills training
1169288|NCT01286350|family communication
1169289|NCT01286350|social support
1169290|NCT01286350|adolescents
1169291|NCT01286337|axilla
1169292|NCT01286337|surgery
1169293|NCT01286337|technique
1169294|NCT01286337|bipolar vessel sealing
1169295|NCT01286324|Matricaria
1169296|NCT01286324|Chamomile
1169297|NCT01286324|Herb
1169298|NCT01286324|Insomnia
1169299|NCT01286311|Health Education
1169300|NCT01286311|Health Knowledge, Attitudes, Practice
1169301|NCT01286311|Hypolipidemic Agents/therapeutic use
1169302|NCT01286311|Patient Education as Topic
1169303|NCT01286298|diode laser
1169304|NCT01286298|gingival enlargement
1169305|NCT01286298|gingival overgrowth
1169306|NCT01286298|gingival hyperplasia
1169307|NCT01286298|orthodontics
1169308|NCT01286285|influenza
1169309|NCT01286285|acute respiratory infections
1169310|NCT01286285|paediatric
1169311|NCT01286285|intensive care units
1169312|NCT01286285|epidemiology
1169313|NCT01286259|HIV
1169314|NCT01286259|HAART suppressed
1169315|NCT01286259|Disulfiram
1169316|NCT01286259|Antabuse
1169317|NCT01286259|Latent reservoir
1169318|NCT01286259|Eradication
1169319|NCT01286259|Cure
1169320|NCT01286246|Progesterone
1169321|NCT01286246|Randomized controlled trial
1169322|NCT01286233|fatigue
1169323|NCT01286233|sleep disorders
1169324|NCT01286233|depression
1169325|NCT01286233|stage IA breast cancer
1169326|NCT01286233|stage IB breast cancer
1169327|NCT01286233|stage II breast cancer
1169328|NCT01286233|stage IIIA breast cancer
1169329|NCT01286207|Migraine headache
1169330|NCT01286181|COPD
1169331|NCT01286181|Biofeedback
1169332|NCT01286181|Dyspnea
1169333|NCT01286181|Quality of life
1169334|NCT01286181|Stress
1169335|NCT01286168|Bilateral breast mastectomy
1169336|NCT01286168|Immediate tissue expanders reconstruction
1169337|NCT01286155|Barrett's esophagus
1169338|NCT01286155|gastroesophageal reflux disease
1169339|NCT01286155|GERD
1169340|NCT01286142|Prospective, Observational Safety Study
1169349|NCT01286103|Canagliflozin
1169350|NCT01286103|Pharmacokinetics
1169351|NCT01286103|Pharmacodynamics
1169352|NCT01286090|Cisapride (PREPULSID)
1169353|NCT01286090|Placebo
1169354|NCT01286090|Diabetes mellitus
1169355|NCT01286090|Diabetic gastroparesis
1169356|NCT01286077|Multiple Myeloma
1169357|NCT01286077|bortezomib
1169358|NCT01286077|hematology
1169359|NCT01286077|bone marrow cancer
1169360|NCT01286077|Myeloma-related bone disease
1169361|NCT01286077|bone mineral density
1169362|NCT01286077|bone markers
1169363|NCT01286064|adenocarcinoma,
1169364|NCT01286064|colorectal tumors,
1169365|NCT01286064|endogenous porphyrins,
1169366|NCT01286064|fluorescence,
1169367|NCT01286064|tumor markers.
1169368|NCT01286051|ovulation induction, GnRH
1169369|NCT01286038|platelets
1169370|NCT01286025|medical education
1169371|NCT01286025|problem-based learning
1169372|NCT01286025|interactive tutorial
1169373|NCT01286012|End Stage Renal Disease, Hemodialysis, SFP
1169374|NCT01285986|Graft patency
1169375|NCT01285986|Limb salvage
1169376|NCT01285960|Uterine fibroids
1169377|NCT01285960|MRgFUS
1169378|NCT01285960|ExAblate
1169379|NCT01285960|Focused Ultrasound
1169380|NCT01285960|Symptomatic uterine fibroids
1169381|NCT01285947|pain experience
1169382|NCT01285947|energy devices
1169383|NCT01285947|Ulthera
1169384|NCT01285947|Thermage
1169385|NCT01285947|VBeam
1169386|NCT01285921|hippocampal
1169387|NCT01285921|vestibular test
1169388|NCT01285908|Baroreceptor
1169389|NCT01285908|Norepinephrine
1169390|NCT01285908|Orthostatic Hypotension
1169391|NCT01285908|Sympathetic Nervous System
1169392|NCT01285908|Blood Pressure
1169393|NCT01285895|Lung and heart transplantations
1169394|NCT01285895|Mucoviscidosis
1169395|NCT01285895|Educational needs
1169396|NCT01285882|Lung transplantations
1169397|NCT01285882|Representations
1169398|NCT01285882|Mucoviscidosis
1169399|NCT01285869|Pneumonia
1169400|NCT01285869|Intervention Studies
1169401|NCT01285869|Aged
1169402|NCT01285869|Aged, 80 and over
1169403|NCT01285869|Geriatric Assessment
1169404|NCT01285856|patients
1169405|NCT01285856|illicit consumption of psychotropic agents and alcohol
1169406|NCT01285856|buprenorphine
1169407|NCT01285856|methadone
1169408|NCT01285830|Infants
1169409|NCT01285830|Probiotics
1169410|NCT01285830|Prevention
1169411|NCT01285830|Lactobacillus reuteri
1169412|NCT01285830|Eczema
1169413|NCT01285830|IgE
1169414|NCT01285830|Sensitization
1169415|NCT01285830|Microbiota
1169416|NCT01285830|Chemokines
1169417|NCT01285791|morbid obesity
1169418|NCT01285791|intra-abdominal visceral fat
1169419|NCT01285791|gastric bypass
1169420|NCT01285791|sleeve gastrectomy
1169421|NCT01285791|gastric banding
1169422|NCT01285791|visceral fat
1169423|NCT01285778|Anal squamous cell carcinoma
1169424|NCT01285778|panitumumab
1169425|NCT01285778|chemoradiation
1169426|NCT01285778|anal cancer
1169427|NCT01285778|GEMCAD-09-02
1169428|NCT01285739|Pulmonary Disease, Chronic Obstructive.
1169429|NCT01285739|Tracheostomy.
1169430|NCT01285739|Invasive Mechanical Ventilation.
1169431|NCT01285739|Non-Invasive Mechanical Ventilation.
1169432|NCT01285726|Peritoneal dialysis
1169433|NCT01285726|Hydration status
1169434|NCT01285726|Residual renal function
1169435|NCT01285726|Bioimpedance spectroscopy
1169436|NCT01285726|Body composition monitor
1169437|NCT01285713|Dehydration
1169438|NCT01285713|Gastroenteritis
1169439|NCT01285713|Dehydration in Gastroenteritis
1169440|NCT01285687|Tonsillectomy
1169441|NCT01285687|Post-Operative Pain
1169442|NCT01285687|Acupuncture
1169443|NCT01285674|cisplatin
1169444|NCT01285674|ototoxicity
1169445|NCT01285674|intratympanic steroids
1169446|NCT01285661|Deep venous thrombosis
1169447|NCT01285661|Pulmonary embolism
1169448|NCT01285661|Ultrasonography
1169449|NCT01285661|D-dimer
1169450|NCT01285661|Venous thromboembolism
1169451|NCT01285661|Bleeding
1169452|NCT01285648|chest tubes,
1169453|NCT01285648|Continuous Positive Airway Pressure,
1169454|NCT01285648|lung resection, thoracic surgery,
1169455|NCT01285648|noninvasive ventilation,
1169456|NCT01285648|postoperative
1169459|NCT01285596|Pharmacokinetics
1169460|NCT01285596|Cardiography
1169461|NCT01285596|Impedance
1169462|NCT01285596|Age groups
1169463|NCT01285596|Gender Identity
1169464|NCT01285583|Amyotrophoc Lateral Sclerosis
1169465|NCT01285583|TRO19622
1169466|NCT01285583|Olesoxime
1169467|NCT01285583|Trophos
1169468|NCT01285557|Gastric Cancer , S-1, Phase 3
1169469|NCT01285544|statins
1169470|NCT01285544|cholesterol
1169471|NCT01285544|hypercholesterolemia
1169472|NCT01285544|atorvastatin
1169473|NCT01285544|Dyslipidemia in cardiovascular disease (KoLipinon)
1169474|NCT01285531|lumbar puncture
1169475|NCT01285531|Compass
1169476|NCT01285531|pressure transducer
1169477|NCT01285531|manometry
1169478|NCT01285531|The focus of the study is to improve lumbar puncture(LP)success, reduce the number of LP attempts, reduce the number of traumatic attempts.
1169479|NCT01285518|Type 2 diabetes
1169480|NCT01285518|intravenous
1169481|NCT01285518|single dose
1169482|NCT01285505|alprazolam
1169483|NCT01285505|sublingual
1169484|NCT01285505|bioequivalence
1169485|NCT01285492|COPD
1169486|NCT01285492|QVA149
1169487|NCT01285492|NVA237
1169488|NCT01285492|indacaterol
1169489|NCT01285492|combination bronchodilator
1169490|NCT01285479|Fingolimod
1169491|NCT01285479|FTY720
1169492|NCT01285479|Gilenya
1169493|NCT01285479|Multiple sclerosis
1169494|NCT01285479|MS
1169495|NCT01285479|Safety
1169496|NCT01285479|Pregnancy
1169497|NCT01285479|Pregnancy outcomes
1169498|NCT01285466|Cancer
1169499|NCT01285466|BEZ235
1169500|NCT01285466|BKM120
1169501|NCT01285466|paclitaxel
1169502|NCT01285466|trastuzumab
1169503|NCT01285453|ASA404,
1169504|NCT01285453|vadimezan,
1169505|NCT01285453|docetaxel
1169506|NCT01285440|breast
1169507|NCT01285440|biopsy
1169508|NCT01285440|suspicious lesion
1169509|NCT01285440|molecular breast imaging
1169510|NCT01285427|DNA, sequencing
1169511|NCT01285427|Identification and definition of Class I and II Human Leukocyte Antigens (HLA)
1169512|NCT01285414|Glioblastoma
1169513|NCT01285414|Brain Neoplasms
1169514|NCT01285414|Brain Cancer
1169515|NCT01285414|Verubulin
1169516|NCT01285401|Multiple Sclerosis
1169517|NCT01285401|Rebif
1169518|NCT01285401|VigantOL® oil
1169519|NCT01285401|Vitamin D
1169520|NCT01285401|Add-on treatment
1169521|NCT01285388|Safety
1169522|NCT01285388|Tolerability
1169523|NCT01285388|Pharmacokinetic
1169524|NCT01285362|Fatty Liver Disease
1169525|NCT01285362|Hepatic Steatosis
1169526|NCT01285362|Docosahexaenoic Acid
1169527|NCT01285362|Eicosapentanoic Acid
1169528|NCT01285362|Omega-3 Fatty Acids
1169529|NCT01285362|Elevated Transaminases
1169530|NCT01285362|Fish oil supplements
1169531|NCT01285349|HIV, STI, condom use, drug use,
1169532|NCT01285336|Rheumatoid arthritis (RA)
1169533|NCT01285336|DNA repair system
1169534|NCT01285336|polymorphism
1169535|NCT01285336|susceptibility
1169536|NCT01285336|copy number variation (CNV)
1169537|NCT01285310|Rheumatoid, Arthritis
1169538|NCT01285297|Transmyocardial revascularization (TMR)
1169539|NCT01285297|Bone marrow aspirate concentrate (BMAC)
1169540|NCT01285297|Angina
1169541|NCT01285284|Colonoscopy
1169542|NCT01285284|Music
1169543|NCT01285284|Tolerance
1169544|NCT01285284|Pain
1169545|NCT01285284|Anxiety
1169546|NCT01285284|Dose of sedative drugs administered during the procedure
1169547|NCT01285271|xenon
1169548|NCT01285271|sevoflurane
1169549|NCT01285271|cardiac anesthesia
1169550|NCT01285271|CABG
1169551|NCT01285271|Bypass surgery
1169552|NCT01285258|Peripartum
1169553|NCT01285258|hysterectomy
1169554|NCT01285258|placenta accreta
1169555|NCT01285258|mortality
1169556|NCT01285245|insulin sensitivity
1169557|NCT01285245|interleukin-1 receptor antagonist
1169558|NCT01285245|inflammation
1169559|NCT01285245|hyperglycemia-induced insulin resistance
1169560|NCT01285219|Granulocyte colony-stimulating factor , recombinant
1169561|NCT01285219|Polyethylene glycols
1169562|NCT01285219|Neutropenia
1169563|NCT01285219|Drug therapy, combination
1169564|NCT01285193|hypertension
1169565|NCT01285193|high blood pressure
1169566|NCT01285193|treatment
1169567|NCT01285193|breath control
1169568|NCT01285193|breathing exercise
1169569|NCT01285193|audio CD
1169570|NCT01285180|COPD
1169571|NCT01285180|Quality of life
1169572|NCT01285180|sociodemographic data
1169573|NCT01285180|cost-of-illness data
1169574|NCT01285180|roflumilast
1169575|NCT01285180|Daxas
1169576|NCT01285167|COPD
1169577|NCT01285167|Quality of life
1169578|NCT01285167|lung function
1169579|NCT01285167|spirometry
1169580|NCT01285167|roflumilast
1169581|NCT01285167|Daxas
1169582|NCT01285167|severe COPD
1169583|NCT01285154|Hip dysplasia
1169584|NCT01285154|Triple Osteotomy
1169585|NCT01285154|Femoral Head Coverage
1169586|NCT01285154|Femoral Head Medialization
1169587|NCT01285141|HIV Infections
1169588|NCT01285141|Acquired Immune Deficiency Syndrome
1169589|NCT01285115|Generalized anxiety disorder
1169590|NCT01285115|Jingji-zhengchong
1169591|NCT01285115|Gamisoyosan
1169592|NCT01285115|anxiety
1169593|NCT01285063|overweight
1169594|NCT01285063|obesity
1169595|NCT01285063|physical fitness
1169596|NCT01285063|kinder garden
1169597|NCT01285063|preschool
1169598|NCT01285050|HIV
1169599|NCT01285050|Human immunodeficiency virus
1169600|NCT01285050|Acquired Immune Deficiency Syndrome Virus
1169601|NCT01285050|AIDS Virus
1169602|NCT01285050|Immunodeficiency Virus, Human
1169603|NCT01285050|Virus, Human Immunodeficiency
1169604|NCT01285050|Hepatitis C
1169605|NCT01285050|Hepatitis C, chronic
1169606|NCT01285050|Hepatitis C virus
1169607|NCT01285050|Hepatitis C antibodies
1169608|NCT01285050|Hepatitis C antigens
1169609|NCT01285024|total hip arthroplasty
1169610|NCT01285024|transfusion
1169611|NCT01285024|hemostat
1169612|NCT01285011|arthrodesis
1169613|NCT01285011|PIP joint
1169614|NCT01284998|forefoot deformities
1169615|NCT01284998|basal osteotomy
1169616|NCT01284959|cognitive function
1169617|NCT01284959|subjective experiences
1169618|NCT01284959|neuroleptic-induced deficit syndrome
1169619|NCT01284959|paliperidone extended-release
1169620|NCT01284959|risperidone
1169621|NCT01284946|PCT sporadic or familial
1169622|NCT01284946|Skin fragility and bullae lesions
1169623|NCT01284946|non-transfusion iron overload
1169624|NCT01284933|Stroke
1169625|NCT01284933|Ischemic Attack, Transient
1169626|NCT01284933|Magnetic Resonance Imaging
1169627|NCT01284933|Carotid Arteries
1169628|NCT01284933|Carotid Artery Plaque
1169629|NCT01284933|Atherosclerosis
1169630|NCT01284920|MDV3100
1169631|NCT01284920|Response Evaluation Criteria in Solid Tumor (RECIST)
1169632|NCT01284920|docetaxel
1169633|NCT01284920|PSA level
1169634|NCT01284907|Asthma
1169635|NCT01284907|Asthma therapy
1169636|NCT01284907|Randomized controlled trial
1169637|NCT01284907|children
1169638|NCT01284894|Dysphagia
1169639|NCT01284894|Conventional manometry
1169640|NCT01284894|High resolution manometry
1169641|NCT01284881|MRA
1169642|NCT01284881|compliance
1169643|NCT01284881|OSAHS
1169644|NCT01284868|Mechanisms of Pharmacological Action
1169645|NCT01284868|Pharmacodynamics
1169646|NCT01284868|Pharmacokinetics
1169647|NCT01284855|neurotoxic envenoming (WHO ICD-10 T63.0)
1169648|NCT01284842|sleep-deprivation
1169649|NCT01284842|virtual reality
1169650|NCT01284842|residency
1169651|NCT01284842|performance
1169652|NCT01284816|severely obese patients
1169653|NCT01284803|patients
1169654|NCT01284803|moderate depression
1169655|NCT01284777|cancerology
1169656|NCT01284777|genetic
1169657|NCT01284764|Endoscopy
1169658|NCT01284764|Gastrectomy
1169659|NCT01284764|Stomach neoplasms
1169660|NCT01284738|TM
1169661|NCT01284738|TI
1169662|NCT01284738|MP
1169663|NCT01284712|treatment by bleedings
1169664|NCT01284699|Parkinson
1169665|NCT01284699|contraindication to Intracerebral electrode implantation
1169666|NCT01284699|Gamma Knife radiosurgery
1169667|NCT01284686|Pathophysiology
1169668|NCT01284686|Parkinson
1169669|NCT01284686|neuronal oscillations
1169670|NCT01284673|Cord blood stem
1169671|NCT01284673|neonatal asphyxia
1169672|NCT01284647|Chronic Erosive Gastritis
1169673|NCT01284647|Teprenone
1169674|NCT01284647|Sucralfate
1169675|NCT01284634|Cannabidiol
1169676|NCT01284634|Fatty liver
1169677|NCT01284634|Diabetes
1169678|NCT01284634|Body fat
1169679|NCT01284608|Observational
1169680|NCT01284608|prospective
1169681|NCT01284608|metabolic changes
1169682|NCT01284608|metabolic syndrome
1169683|NCT01284608|diabetes
1169684|NCT01284608|prostatic cancer
1169685|NCT01284608|risk fracture
1169686|NCT01284595|Radioactive carbon
1169687|NCT01284595|Absorption
1169688|NCT01284595|Distribution
1169689|NCT01284595|Metabolism
1169690|NCT01284595|Excretion
1169691|NCT01284595|Healthy Volunteers
1169692|NCT01284582|CETP
1169693|NCT01284582|Vaccine
1169694|NCT01284582|Cholesterol
1169695|NCT01284582|Inhibition
1169696|NCT01284556|partial onset seizures
1169697|NCT01284530|Epilepsy
1169698|NCT01284530|Pediatrics
1169699|NCT01284530|Young Adults
1169700|NCT01284517|Bipolar I Depression
1169701|NCT01284517|Lurasidone
1169702|NCT01284517|Latuda
1169703|NCT01284491|Breast reduction
1169704|NCT01284491|PlasmaBlade
1169705|NCT01284491|Electrosurgery
1169706|NCT01284491|PEAK Surgical
1169707|NCT01284491|Medtronic Advanced Energy
1169708|NCT01284491|Medtronic
1169709|NCT01284478|pseudophakic cystoid macular edema, diabetic macular edema, Irvine Gass Syndrome, cataract surgery, ozurdex, dexamethasone
1169710|NCT01284465|Type 2 diabetes self-management
1169711|NCT01284465|Minority women
1169712|NCT01284465|Barriers to diabetes self-management
1169713|NCT01284452|Septic shock
1169714|NCT01284452|Severe sepsis
1169715|NCT01284452|Acute lung injury
1169716|NCT01284452|Acute respiratory distress syndrome
1169717|NCT01284452|ARDS
1169718|NCT01284426|Chronic urticaria
1169719|NCT01284426|Natural course
1169720|NCT01284426|Remission
1169721|NCT01284400|heart failure
1169722|NCT01284400|disease management
1169723|NCT01284387|Mild to moderate Alzheimer's disease
1169724|NCT01284387|immunization
1169725|NCT01284387|amyloid imaging
1169726|NCT01284387|injection
1169727|NCT01284387|vaccine
1169728|NCT01284374|HPV Vaccines
1169729|NCT01284374|Attitude to Health
1169730|NCT01284374|Decision Making
1169731|NCT01284374|Qualitative Research
1169732|NCT01284361|intermittent catheter
1169733|NCT01284361|preference
1169734|NCT01284348|Chemotherapy induced anemia
1169735|NCT01284348|Non-small cell lung cancer
1169736|NCT01284335|Advanced solid tumors
1169737|NCT01284335|Unresectable
1169738|NCT01284335|Metastatic
1169739|NCT01284335|Limited treatment options
1169740|NCT01284335|Measurable or nonmeasurable disease
1169741|NCT01284309|Intraocular Pressure (IOP)
1169742|NCT01284309|YM178
1169743|NCT01284283|Arthrosis
1169744|NCT01284283|Rheumatoid Arthrosis
1169745|NCT01284283|Arthritic joint
1169746|NCT01284283|Rheumatoid Arthritis
1169747|NCT01284283|Osteoarthritis
1169748|NCT01284270|Cardiac MRI
1169749|NCT01284270|Plaque
1169750|NCT01284257|EC-MPS
1169751|NCT01284257|MMF
1169752|NCT01284257|kidney transplant
1169753|NCT01284257|outcomes
1169754|NCT01284257|mycophenolate sodium
1169755|NCT01284257|mycophenolic acid (MPA)
1169756|NCT01284244|Urinary Incontinence, Stress
1169757|NCT01284244|pessary
1169758|NCT01284244|conservative management
1169759|NCT01284231|MEDI-565, gastrointestinal adenocarcinomas, carcinoembryonic antigen, bispecific T-cell engager
1169760|NCT01284205|non-muscle invasive bladder cancer
1169761|NCT01284205|superficial bladder cancer
1169762|NCT01284192|B-cell Lymphoma
1169763|NCT01284192|Advanced Malignancies
1169764|NCT01284192|Anaplastic Lymphoma Kinase (ALK)
1169765|NCT01284192|ASP3026
1169766|NCT01284192|Solid Tumor
1169767|NCT01284179|Functional Chest Pain
1169768|NCT01284179|Functional GI Disorders
1169769|NCT01284179|Home Hypnotherapy
1169770|NCT01284153|respiratory gating
1169771|NCT01284153|prone radiotherapy
1169772|NCT01284153|breast cancer
1169773|NCT01284140|Critical illness
1169774|NCT01284140|Sleep
1169775|NCT01284140|Polysomnography
1169776|NCT01284140|Respiratory failure
1169777|NCT01284140|Circadian rhythm
1169778|NCT01284140|Sedation
1169779|NCT01284127|superficial siderosis
1169780|NCT01284114|Elderly chronic kidney disease
1169781|NCT01284114|Hypertension
1169782|NCT01284114|Aliskiren
1169783|NCT01284088|Male Circumcision
1169784|NCT01284088|HIV Prevention
1169785|NCT01284088|Medical Device
1169786|NCT01284062|Active Ulcerative Colitis
1169787|NCT01284062|Phase 2A
1169788|NCT01284062|Double-blind
1169789|NCT01284062|Randomized
1169790|NCT01284062|PK/PD Biomarker Study
1169791|NCT01284049|Home Parenteral Nutrition
1169792|NCT01284049|Intralipid 20%®
1169793|NCT01284049|OMEGAVEN 10%®
1169794|NCT01284049|Liver diseases
1169795|NCT01284036|Healthy subject
1169796|NCT01284036|safety
1169797|NCT01284036|PK study
1169798|NCT01284036|healthy volunteers
1169799|NCT01284023|near infrared spectroscopy
1169800|NCT01284023|acute compartment syndrome
1169801|NCT01284010|adult acute lymphoblastic leukemia
1169802|NCT01283997|Multiple Myeloma
1169803|NCT01283997|Neuropathy
1169804|NCT01283997|Peripheral Nerve Function
1169805|NCT01283997|Touch Detection Threshold
1169806|NCT01283997|Nerve Damage
1169807|NCT01283997|Thalidomide
1169808|NCT01283997|Bortezomib
1169809|NCT01283997|Velcade
1169810|NCT01283997|Minocycline
1169811|NCT01283997|Dynacin
1169812|NCT01283997|Minocin
1169813|NCT01283997|Minocin PAC
1169814|NCT01283997|Myrac
1169815|NCT01283997|Solodyn
1169816|NCT01283984|Safety
1169817|NCT01283984|tolerability
1169818|NCT01283984|healthy
1169819|NCT01283984|inhaled
1169820|NCT01283984|respiratory disease
1169821|NCT01282983|fiber
1169822|NCT01282983|orange juice
1169823|NCT01282983|digestive symptom
1169824|NCT01282944|physical activity in adults 65 or older
1169825|NCT01282931|Women
1169826|NCT01282931|Stage IV
1169827|NCT01282931|Metastatic
1169828|NCT01282931|Breast Cancer
1169829|NCT01282931|Progressed
1169830|NCT01282931|Progression
1169831|NCT01282918|ICD
1169832|NCT01282918|DF Test
1169833|NCT01282918|intra-operative DF testing
1169834|NCT01282918|VT
1169835|NCT01282892|Visceral fat
1169836|NCT01282892|fatty liver
1169837|NCT01282892|atherosclerosis
1169838|NCT01282892|coronary computed tomography angiography
1169839|NCT01282879|Itraconazole oral solution
1169840|NCT01282879|invasive fungal infections
1169841|NCT01282879|prophylaxis
1169842|NCT01282879|Graft vs Host Disease
1169843|NCT01282879|transplantation
1169844|NCT01282853|peptic ulcer
1169845|NCT01282853|hemorrhage
1169846|NCT01282853|rapid urease test
1169847|NCT01282853|urea breath test
1169848|NCT01282840|LUTS
1169849|NCT01283958|Iloprost, Eisenmenger's syndrome
1169850|NCT01283945|VEGFRs
1169851|NCT01283945|FGFR1
1169852|NCT01283945|angiogenesis
1169853|NCT01283906|Mucositis
1169854|NCT01283906|Head and Neck Cancer
1169855|NCT01283906|Squamous Cell Cancer
1169856|NCT01283906|Chemotherapy
1169857|NCT01283906|Radiation Therapy
1169858|NCT01283906|Oral Rinse
1169859|NCT01283880|kidney
1169860|NCT01283880|transplantation
1169861|NCT01283880|metabolic acidosis
1169862|NCT01283880|renal tubular acidosis
1169863|NCT01283880|nephrocalcinosis
1169864|NCT01283815|Laparoscopy
1169865|NCT01283815|Drainage
1169866|NCT01283815|Appendectomy
1169867|NCT01283789|breast
1169868|NCT01283789|cancer
1169869|NCT01283789|metastatic
1169870|NCT01283789|metastasis
1169871|NCT01283763|Cervical Intraepithelial Neoplasia, Imiquimod, conization
1169872|NCT01283750|care coordination
1169873|NCT01283750|dementia care
1169874|NCT01283750|intervention
1169875|NCT01283750|unmet needs
1169876|NCT01283750|community
1169877|NCT01283750|older adults
1169878|NCT01283750|caregiver
1169879|NCT01283737|Osteochondritis Dissecans
1169880|NCT01283737|OCD
1169881|NCT01283737|Mosaicplasty
1169882|NCT01283737|Demineralised Bone Matrix
1169883|NCT01283737|DBX
1169884|NCT01283737|DBX Putty
1169885|NCT01283724|Endometriosis
1169886|NCT01283724|DEXA
1169887|NCT01283724|Adolescent
1169888|NCT01283724|Safety
1169889|NCT01283724|Efficacy
1169890|NCT01283724|Post-menarche
1169891|NCT01283711|wrinkles reduction
1169892|NCT01283711|rhytides reduction
1169893|NCT01283711|RF treatment
1169894|NCT01283698|psoriasis
1169895|NCT01283698|topical
1169896|NCT01283698|PPT
1169897|NCT01283685|Exercise, Physical
1169898|NCT01283672|Whole grains
1169899|NCT01283672|Barley
1169900|NCT01283672|Oats
1169901|NCT01283672|Cardiovascular disease
1169902|NCT01283672|Postprandial lipid metabolism
1169903|NCT01283672|Endothelial function
1169904|NCT01283672|Risk of cardiovascular disease in healthy men and women
1169905|NCT01283659|computed tomographic angiography
1169906|NCT01283659|coronary angiogram
1169907|NCT01283659|cost effectiveness
1169908|NCT01283659|QoL
1169909|NCT01283659|Heart failure
1169910|NCT01283659|diagnostic accuracy
1169911|NCT01283659|prospective comparative effectiveness randomized clinical trial
1169912|NCT01283633|neuromodulation
1169913|NCT01283633|remote presence robotics
1169914|NCT01283620|stroke
1169915|NCT01283620|extremity, upper
1169916|NCT01283607|in vitro fertilization
1169917|NCT01283607|e-health
1169918|NCT01283607|cognitive behavioral therapy
1169919|NCT01283607|psychosocial risk profile
1169920|NCT01283607|emotional maladjustment
1169921|NCT01283568|PMS, climacteric, depression
1169922|NCT01283555|Microbicide, Applicator, Safety
1169923|NCT01283542|Non-functioning pituitary adenoma,
1169924|NCT01283542|pasireotide LAR,
1169925|NCT01283542|tumor volume
1169926|NCT01283529|Intrathoracal blood volume
1169927|NCT01283529|Cardiac output
1169928|NCT01283529|Children
1169929|NCT01283516|ALK inhibitor,
1169930|NCT01283516|NSCLC,
1169931|NCT01283516|LDK378,
1169932|NCT01283516|ceritinib,
1169933|NCT01283516|genetic abnormalities
1169934|NCT01283503|PI3K,
1169935|NCT01283503|Advanced solid tumor
1169936|NCT01283490|topical anesthetic, sonophoresis
1169937|NCT01283477|Caesarean Delivery
1169938|NCT01283477|Pruritis
1169939|NCT01283477|Intrathecal Morphine
1169940|NCT01283477|Acupuncture At LI11
1169941|NCT01283464|Retinol
1169942|NCT01283464|Tretinoin
1169943|NCT01283451|near-infrared spectroscopy
1169944|NCT01283425|MiniMed Paradigm insulin pump
1169945|NCT01283425|insulin Lispro
1169946|NCT01283425|Insulin Aspart
1169947|NCT01283425|Quick-set infusion set
1169948|NCT01283412|Delirium
1169949|NCT01283412|Dexmedetomidine
1169950|NCT01283412|Adult Patients
1169951|NCT01283412|Elective Major Surgery
1169952|NCT01283412|General Anesthesia
1169953|NCT01283360|MSM
1169954|NCT01283360|HIV negative
1169955|NCT01283360|microbicide
1169956|NCT01283360|prevention
1169957|NCT01283347|Parkinson's disease
1169958|NCT01283334|Head and Neck Cancer
1169959|NCT01283334|Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
1169960|NCT01283321|Hemostasis
1169961|NCT01283321|Cardiopulmonary bypass (heart-lung machine)
1169962|NCT01283321|Fibrinogen
1169963|NCT01283321|platelet
1169964|NCT01283308|Diabetes Mellitus, Type 2
1169965|NCT01283308|India
1169966|NCT01283308|Prevention & Control
1169967|NCT01283308|Lifestyle Intervention
1169968|NCT01283308|Translational Research
1169969|NCT01283269|Rehabilitation
1169970|NCT01283269|Cognitive Intervention
1169971|NCT01283269|Prevention
1169972|NCT01283243|ARFI Imaging
1169973|NCT01283243|Normal values
1169974|NCT01283243|HIV infection
1169975|NCT01283230|ARFI imaging
1169976|NCT01283230|normal values
1169977|NCT01283230|chronic liver disease
1169978|NCT01283230|liver donors
1169979|NCT01283230|kidney donors
1169980|NCT01283191|substance use
1169981|NCT01283191|drug use
1169982|NCT01283191|drug abuse
1169983|NCT01283191|exercise
1169984|NCT01283191|physical activity
1169985|NCT01283178|squamous cell carcinoma of the paranasal sinus and nasal cavity
1169986|NCT01283165|health education
1169987|NCT01283165|Polyparasitism
1169988|NCT01283165|school based deworming program
1169989|NCT01283165|integrated control of parasites
1169990|NCT01283152|Hepatic Encephalopathy
1169991|NCT01283152|HE
1169992|NCT01283152|Cirrhosis
1169993|NCT01283152|PSE
1169994|NCT01283152|Portosystemic Encephalopathy
1169995|NCT01283152|Hepatic coma
1169996|NCT01283152|AMS
1169997|NCT01283152|Altered mental status
1169998|NCT01283152|Complications of cirrhosis
1169999|NCT01283152|Chronic liver disease
1170000|NCT01283139|SLE
1170001|NCT01283139|Systemic Lupus Erythematosus
1170002|NCT01283139|Sifalimumab
1170003|NCT01283139|MEDI-545
1170004|NCT01283126|Hypoglycemia, cognitive function
1170005|NCT01283113|Visceral Fat
1170006|NCT01283113|Waist Circumference
1170007|NCT01283113|Bioelectrical Impedance
1170008|NCT01283113|Metabolic Syndrome
1170009|NCT01283113|Obesity
1170010|NCT01283113|Type 2 Diabetes
1170011|NCT01283100|HIV, GSK2248761, GSK1349572, drug interaction, pharmacokinetics
1170012|NCT01283087|TNS
1170013|NCT01283087|Spinal anesthesia
1170014|NCT01283087|Lidocaine
1170015|NCT01283048|Kidney Cancer
1170016|NCT01283048|Avastin
1170017|NCT01283022|Pharmacokinetics
1170018|NCT01283022|Misoprostol Vaginal Insert
1170019|NCT01283022|Induction of labor
1170020|NCT01283022|Cervical Ripening
1170021|NCT01283022|Rate of Cesarean section
1170022|NCT01283009|pneumoniae
1170023|NCT01282996|Mechanical ventilation
1170024|NCT01282996|Postoperative pulmonary complications
1170025|NCT01282996|Positive end-expiratory pressure
1170026|NCT01282996|Protective lung ventilation
1170027|NCT01282996|Alveolar recruitment maneuver
1170028|NCT01282996|General anesthesia
1170029|NCT01282996|Abdominal surgery
1170030|NCT01282814|Bioequivalence
1170031|NCT01282814|Healthy Subjects
1170032|NCT01282801|Bioequivalence
1170033|NCT01282801|Healthy Subjects
1170034|NCT01282788|infant nutrition
1170035|NCT01282788|complementary feeding
1170036|NCT01282788|malnutrition
1170037|NCT01282788|stunting of growth
1170038|NCT01282775|overweight
1170039|NCT01282775|obesity
1170040|NCT01282775|worksite
1170041|NCT01282762|Prevention of Hepatitis B infection.
1170042|NCT01282762|End Stage Renal Disease
1170043|NCT01282762|Hepatitis B vaccination
1170044|NCT01282762|Hepatitis B virus (HBV)
1170045|NCT01282749|Overweight
1170046|NCT01282749|Obesity
1170047|NCT01282749|African American
1170048|NCT01282749|Women
1170049|NCT01282749|Translational
1170050|NCT01282749|Faith based
1170051|NCT01282749|Community based participatory research
1170052|NCT01282736|eating disorder
1170053|NCT01282736|binge eating
1170054|NCT01282684|Safety
1170055|NCT01282684|Tolerability
1170056|NCT01282684|Pharmacokinetics
1170057|NCT01282684|PLX5622
1170058|NCT01282671|breathing exercises
1170059|NCT01282671|cardiac surgery
1170060|NCT01282671|lung function
1170061|NCT01282671|postoperative complication
1170062|NCT01282671|positive expiratory pressure
1170063|NCT01282658|CPT-11,pharmacogenomics,colorectal cancer
1170064|NCT01282645|Cranial defect
1170065|NCT01282645|PSI
1170066|NCT01282645|patient specific implant
1170067|NCT01282645|PEEK
1170068|NCT01282645|polyether ether ketone
1170069|NCT01282645|craniectomy
1170070|NCT01282645|craniotomy
1170071|NCT01282632|depression
1170072|NCT01282632|treatment resistant depression
1170073|NCT01282632|unipolar
1170074|NCT01282632|non- psychotic major depression
1170075|NCT01282632|add-on to a serotonin type antidepressants
1170076|NCT01282632|risperidone
1170077|NCT01282632|olanzapine
1170078|NCT01282632|double blind comparison
1170079|NCT01282632|randomized
1170080|NCT01282606|Chemonucleolysis
1170081|NCT01282606|Lumbar Vertebrae
1170082|NCT01282606|Hernia
1170083|NCT01282593|TEL/ALM1_positive ALL relapses
1170084|NCT01282580|Women at high risk of developing breast cancer
1170085|NCT01282541|Tearing, Epiphora, Botulinum Toxin A
1170089|NCT01282476|DLBCL (Diffuse Large B Cell Lymphoma)
1170090|NCT01282476|Panobinostat
1170091|NCT01282476|LBH589 (Panobinostat)
1170092|NCT01282476|LBH-589 (Panobinostat)
1170093|NCT01282476|HDAC inhibitor (Histone deacetylase inhibitor)
1170094|NCT01282476|DAC inhibitor (deacetylase inhibitor)
1170095|NCT01282476|deacetylase inhibitor
1170096|NCT01282476|lymphoma
1170097|NCT01282463|Carcinoma, Renal Cell
1170098|NCT01282450|Radiotherapy
1170099|NCT01282450|NSCLC
1170100|NCT01282424|indolent Non-Hodgkin Lymphoma
1170101|NCT01282424|Non-Hodgkin Lymphoma
1170102|NCT01282424|iNHL
1170103|NCT01282424|NHL
1170104|NCT01282424|GS-1101
1170105|NCT01282424|CAL-101
1170106|NCT01282424|PI3K
1170107|NCT01282424|Phosphatidylinositol 3-kinase
1170108|NCT01282424|Follicular Lymphoma (FL)
1170109|NCT01282424|Small lymphocytic lymphoma (SLL)
1170232|NCT01281839|TMC435
1170110|NCT01282424|Lymphoplasmacytoid lymphoma (LPL)
1170111|NCT01282424|Marginal zone lymphoma (MZL)
1170112|NCT01282372|Ankylosing spondylitis
1170113|NCT01282372|Sleep
1170114|NCT01282372|Psoriatic arthritis
1170115|NCT01282372|Work Productivity
1170116|NCT01282372|Rheumatoid Arthritis
1170117|NCT01282359|Educational asthma program
1170118|NCT01282359|Clusters analysis study
1170119|NCT01282359|Asthma Control Test
1170120|NCT01282346|Glaucoma shunt
1170121|NCT01282346|Ocular implant
1170122|NCT01282346|Gold
1170123|NCT01282346|Trabeculectomy
1170124|NCT01282320|Randomized Controlled Trial
1170125|NCT01282320|Clinical Tria
1170126|NCT01282320|Postmenopause
1170127|NCT01282320|Hot-flashes
1170128|NCT01282320|Quality of life
1170129|NCT01282320|Physical Fitness
1170130|NCT01282307|Guided Self-Determination
1170131|NCT01282307|Improving insight
1170132|NCT01282307|Autonomy-supportive problem solving intervention
1170133|NCT01282307|Evaluate the effects of the method Guided Self-Determination
1170134|NCT01282307|Improving insight in patients diagnosed with schizophrenia
1170135|NCT01282281|Bipolar Disorder
1170136|NCT01282281|Youth
1170137|NCT01282281|Adults
1170138|NCT01282281|Endocrine-metabolic changes
1170139|NCT01282268|fragile X syndrome
1170140|NCT01282268|autism spectrum disorder
1170141|NCT01282242|acute stroke, IV rt-PA, Activase, Alteplase
1170142|NCT01282229|LANAP, Laser dentistry
1170143|NCT01282203|General surgery
1170144|NCT01282203|General anesthesia
1170145|NCT01282203|Inhalation anesthesia
1170146|NCT01282203|Sevorane
1170147|NCT01282203|Sevoflurane
1170148|NCT01282190|dyslipidemia, motivational interview, prevention
1170149|NCT01282177|surveillance, safety , tolerability , vaccine
1170150|NCT01282164|glucagon stimulation test
1170151|NCT01282164|insulin tolerance test
1170152|NCT01282164|growth hormone deficiency
1170153|NCT01282164|hypothalamic-pituitary disorders
1170154|NCT01282151|NSCLC
1170155|NCT01282151|Non Squamous cell
1170156|NCT01282151|Docetaxel
1170157|NCT01282151|Pemetrexed
1170158|NCT01282138|Allergic conjunctivitis
1170159|NCT01282125|general population
1170160|NCT01282125|prevalence
1170161|NCT01282125|Norway
1170162|NCT01282099|all children entering the PICU eligible for enrollment
1170163|NCT01282099|age range: neonate to 16 years
1170164|NCT01282086|Sevorane
1170165|NCT01282086|Sevoflurane
1170166|NCT01282086|General anesthesia
1170167|NCT01282086|Inhalation anesthesia
1170168|NCT01282086|General surgery
1170169|NCT01282073|Idiopathic membranous nephropathy
1170170|NCT01282073|Mycophenolate mofetil
1170171|NCT01282073|Proteinuria
1170172|NCT01282073|Renal function
1170173|NCT01282060|HBA1C
1170174|NCT01282060|DIABETES-RELATED COMPLICATIONS
1170175|NCT01282060|GLYCAEMIC BALANCE
1170176|NCT01282047|Lenalidomide
1170177|NCT01282047|Kaposi
1170178|NCT01282047|HIV
1170179|NCT01282047|efficacy
1170180|NCT01282047|safety
1170181|NCT01282034|CHONDRAL
1170182|NCT01282034|OSTEOCHONDRAL
1170183|NCT01282021|RBC Antigens
1170184|NCT01282021|Molecular Typing
1170185|NCT01282021|Ethiopian Sub-Populations
1170186|NCT01282021|Immunohematology
1170187|NCT01282021|Immune Response
1170188|NCT01282008|Online Surveys
1170189|NCT01282008|Tobacco Corrective Statements
1170190|NCT01282008|Message Testing
1170191|NCT01282008|Focus Groups
1170192|NCT01281995|Biologic Samples
1170193|NCT01281995|Hydrocortisone
1170194|NCT01281995|Laboratory Research Specimens
1170195|NCT01281995|Glucocorticoids
1170196|NCT01281995|Immune Modulation
1170197|NCT01281995|Healthy Volunteer
1170198|NCT01281995|HV
1170199|NCT01281982|Imaging
1170200|NCT01281982|Gliomas
1170201|NCT01281982|Pet Scan
1170202|NCT01281982|Blood Brain Barrier
1170203|NCT01281982|P-Glycoprotein
1170204|NCT01281982|Brain Tumor
1170205|NCT01281982|Glioma
1170206|NCT01281982|Glioblastoma Multiforme
1170207|NCT01281982|Astrocytoma
1170208|NCT01281969|Placebo Controlled
1170209|NCT01281969|Obsessive-Compulsive Disorder
1170210|NCT01281969|Children and Adolescents
1170211|NCT01281969|Intravenous Immunoglobulin
1170212|NCT01281969|PANDAS
1170213|NCT01281956|Epilepsy
1170214|NCT01281956|Drug Trial
1170215|NCT01281956|Serotonin
1170216|NCT01281956|Serotonin 1A Receptor
1170217|NCT01281956|Temporal Lobe Epilepsy
1170218|NCT01281956|Partial Epilepsy
1170219|NCT01281930|Superficial abscess
1170220|NCT01281930|packing material
1170221|NCT01281930|wick
1170222|NCT01281930|incision and drainage
1170223|NCT01281917|velcade
1170224|NCT01281917|temsirolimus
1170225|NCT01281917|non-hodgkins lymphoma
1170226|NCT01281891|Drug: Morphine intrathecal
1170227|NCT01281891|Pain: Postoperative
1170228|NCT01281891|Surgery: Total hip arthroplasty
1170229|NCT01281878|primary hyperoxaluria
1170230|NCT01281878|Pyridoxal-phosphate
1170231|NCT01281839|Hepatitis C
1170233|NCT01281839|HCV
1170234|NCT01281839|Hep C
1170235|NCT01281839|Genotype 1
1170236|NCT01281813|TMC114IFD3001
1170237|NCT01281813|TMC114
1170238|NCT01281813|HIV
1170239|NCT01281813|Darunavir
1170240|NCT01281813|PREZISTA
1170241|NCT01281787|FAP= post-surgery atrial fibrillation
1170242|NCT01281787|ACEI= angiotensin converting enzyme-inhibitors
1170243|NCT01281787|ARBs= angiotensin II receptor blockers
1170244|NCT01281787|NT-proBNP= brain natriuretic peptide
1170245|NCT01281748|acute exacerbation of COPD
1170246|NCT01281735|treatment outcome
1170247|NCT01281735|side effects
1170248|NCT01281735|Protein Kinase Inhibitors
1170249|NCT01281735|pediatrics
1170250|NCT01281722|healthy adults
1170251|NCT01281722|melanoma
1170252|NCT01281696|Breast cancer
1170253|NCT01281696|CNS metastasis
1170254|NCT01281696|Brain metastasis
1170255|NCT01281696|Leptomeningeal metastasis
1170256|NCT01281696|Bevacizumab
1170257|NCT01281696|Etoposide
1170258|NCT01281696|Cisplatin
1170259|NCT01281670|H reflex; muscle activation; rate of force development; whole body vibration
1170260|NCT01281657|Fingolimod
1170261|NCT01281657|FTY720
1170262|NCT01281657|Relapsing forms of multiple sclerosis
1170263|NCT01281657|Multiple sclerosis
1170264|NCT01281657|MS
1170265|NCT01281657|Safety
1170266|NCT01281657|Efficacy
1170267|NCT01281644|Keratosis pilaris (KP)
1170268|NCT01281631|ALS
1170269|NCT01281618|Barrett's esophagus
1170270|NCT01281605|Type 2 diabetes
1170271|NCT01281605|Basal insulin
1170272|NCT01281605|Insulin detemir
1170273|NCT01281605|Insulin titration algorithm
1170274|NCT01281579|Pharmacokinetics
1170275|NCT01281579|Pharmacodynamics
1170276|NCT01281579|Canagliflozin
1170277|NCT01281566|Cisapride (Prepulsid)
1170278|NCT01281566|Feeding intolerance
1170279|NCT01281566|Enteral feeding
1170280|NCT01281566|Nasogastric tube
1170281|NCT01281566|Neonate
1170282|NCT01281553|Cisapride (PREPULSID)
1170283|NCT01281553|Placebo
1170284|NCT01281553|Gastroesophageal Reflux Disease (GERD)
1170285|NCT01281553|Gastro-oesophageal Reflux Disease (GORD)
1170286|NCT01281540|Cisapride ( PREPULSID )
1170287|NCT01281540|Placebo
1170288|NCT01281540|Idiopathic
1170289|NCT01281540|Stomach Diseases
1170290|NCT01281540|Stomach
1170291|NCT01281527|Paliperidone palmitate
1170292|NCT01281527|Schizophrenia
1170293|NCT01281527|Intramuscular injection
1170294|NCT01281501|Dyspepsia
1170295|NCT01281501|Emergency treatment
1170296|NCT01281501|Pantoprazole
1170297|NCT01281501|Antacid
1170298|NCT01281501|Pain measurement
1170299|NCT01281475|Angelman syndrome
1170300|NCT01281475|Levodopa
1170301|NCT01281475|Carbidopa
1170302|NCT01281475|L-dopa
1170303|NCT01281462|complicated Urinary Tract Infection
1170304|NCT01281462|Acute Pyelonephritis
1170305|NCT01281436|childhood
1170306|NCT01281436|overweight
1170307|NCT01281436|obesity
1170308|NCT01281436|Health information technology
1170309|NCT01281436|HeartSmartKids
1170310|NCT01281436|Motivational Interviewing
1170311|NCT01281410|respiratory muscles
1170312|NCT01281410|hematopoetic stem cell transplantation
1170313|NCT01281410|inspiratory muscle training
1170314|NCT01281397|cardiac surgery
1170315|NCT01281397|aggregometry
1170316|NCT01281397|thromboelastometry
1170317|NCT01281397|platelet function
1170318|NCT01281397|bleeding
1170319|NCT01281397|antiplatelet therapy
1170320|NCT01281384|cardiac magnetic resonance imaging
1170321|NCT01281384|echocardiography
1170322|NCT01281384|heart failure
1170323|NCT01281384|imaging
1170324|NCT01281384|cost effectiveness
1170325|NCT01281384|quality of life
1170326|NCT01281384|definitive diagnosis
1170327|NCT01281384|prospective comparative effectiveness randomized clinical trial
1170328|NCT01281358|Premature infants
1170329|NCT01281358|Motor Development
1170330|NCT01281345|icu
1170331|NCT01281345|candida
1170332|NCT01281345|epidemiology
1170333|NCT01281345|blood stream infection
1170334|NCT01281345|candidemia
1170335|NCT01281332|menopause
1170336|NCT01281332|hot flash
1170337|NCT01281332|quality of life
1170338|NCT01281319|preterm labor
1170339|NCT01281319|PROM
1170340|NCT01281319|mycoplasma
1170341|NCT01281319|ureaplasma
1170342|NCT01281319|high risk pregnancy
1170343|NCT01281306|hypertension
1170344|NCT01281306|blood pressure
1170345|NCT01281306|LCZ696
1170346|NCT01281306|dual-acting
1170347|NCT01281306|neprilysin
1170348|NCT01281306|nep inhibitor
1170349|NCT01281306|vasopeptidase
1170350|NCT01281306|angiotensin receptor
1170351|NCT01281306|angiotensin receptor neprilysin inhibitor (ARNi)
1170352|NCT01281293|V-COMPAS; Vagus Nerve Stimulation Clinical Outcomes;
1170353|NCT01281280|PuLsE 2, Drug-resistant Epilepsy Partial-onset Seizures
1170354|NCT01281267|facial transplantation
1170355|NCT01281267|face transplantation
1170356|NCT01281267|composite tissue allotransplantation
1170357|NCT01281267|VCA
1170358|NCT01281267|composite tissue allograft
1170359|NCT01281267|facial allograft
1170360|NCT01281254|Fallopian tube cancer
1170361|NCT01281254|Primary peritoneal cancer
1170362|NCT01281254|AMG386
1170363|NCT01281254|Pegylated Liposomal Doxorubicin
1170364|NCT01281254|Recurrent epithelial ovarian cancer
1170365|NCT01281241|MTWA
1170366|NCT01281241|mechanical alternans
1170367|NCT01281228|Exenatide
1170368|NCT01281228|Type 2 diabetes mellitus
1170369|NCT01281228|Incretin hormones
1170370|NCT01281228|GLP-1 agonist
1170371|NCT01281228|Satiety
1170372|NCT01281228|Reward
1170373|NCT01281215|Pharmaceutical Education
1170374|NCT01281215|Rational Drug Use
1170375|NCT01281215|Asthma
1170376|NCT01281202|Cocaine
1170377|NCT01281202|Cocaine Addiction Treatment
1170378|NCT01281202|Cocaine Treatment
1170379|NCT01281202|Vigabatrin
1170380|NCT01281202|CPP-109
1170381|NCT01281202|Catalyst
1170382|NCT01281202|National Institute on Drug Abuse
1170383|NCT01281189|Amyotrophic Lateral Sclerosis
1170384|NCT01281189|ALS
1170385|NCT01281189|Motor Neurone Disease
1170386|NCT01281137|stage IA breast cancer
1170387|NCT01281137|stage IB breast cancer
1170388|NCT01281137|stage II breast cancer
1170389|NCT01281137|stage IIIA breast cancer
1170390|NCT01281098|High Risk Proliferative Diabetic Retinopathy
1170391|NCT01281098|Diabetes Mellitus Type I, Type II
1170392|NCT01281098|Pegaptanib
1170393|NCT01281098|Panretinal Photocoagulation
1170394|NCT01281085|Shoulder
1170395|NCT01281085|Outcome treatment
1170396|NCT01281085|Validation Studies
1170397|NCT01281085|Biomechanics
1170398|NCT01281033|primary PCI
1170399|NCT01281033|ST-segment elevation myocardial infarction
1170400|NCT01281033|thrombus aspiration
1170401|NCT01281020|Glaucoma
1170402|NCT01281020|Adherence
1170403|NCT01281020|Fixed combination therapy
1170404|NCT01281007|Herpes Simplex Virus
1170405|NCT01280994|Lung Disease
1170406|NCT01280994|Pulmonary Disease
1170407|NCT01280994|Diagnostic Imaging
1170408|NCT01280994|MRI
1170409|NCT01280981|Menorrhagia
1170410|NCT01280981|Heavy Menstrual Bleeding
1170411|NCT01280981|Lysteda
1170412|NCT01280955|Plerixafor and Allogeneic Myeloablative Stem Cell Transplant
1170413|NCT01280942|clinical deterioration
1170414|NCT01280942|detection algorithms
1170415|NCT01280942|automated warning systems
1170416|NCT01280929|High Risk Proliferative Diabetic Retinopathy
1170417|NCT01280929|Ranibizumab
1170418|NCT01280929|Panretinal Photocoagulation
1170419|NCT01280903|Osteoarthritis, Knee
1170420|NCT01280903|Hypertension
1170421|NCT01280903|Exercise
1170422|NCT01280903|Physical activity
1170423|NCT01280903|Self Efficacy
1170424|NCT01280903|Patient Compliance
1170425|NCT01280903|Aged
1170426|NCT01280890|Dementia
1170427|NCT01280890|Nursing home
1170428|NCT01280890|Person-centred Care
1170429|NCT01280890|Staff training
1170430|NCT01280877|optic neuropathy
1170431|NCT01280877|visual field
1170432|NCT01280877|electric stimulation
1170433|NCT01280877|alternating current
1170434|NCT01280877|perimetry
1170435|NCT01280851|Living renal donor
1170436|NCT01280851|Magnetic Resonance Imaging
1170437|NCT01280851|Renal vascular anatomy
1170438|NCT01280851|Renal function
1170439|NCT01280812|mobile phone
1170440|NCT01280812|physical activity
1170441|NCT01280812|women
1170442|NCT01280812|maintenance
1170443|NCT01280812|health promotion
1170444|NCT01280812|prevention
1170445|NCT01280799|Anorexia Nervosa
1170446|NCT01280799|Adolescents
1170447|NCT01280799|Family Treatment
1170448|NCT01280799|Eating Disorder
1170449|NCT01280799|Acceptance and Commitment Therapy
1170450|NCT01280786|AML
1170451|NCT01280786|leukemia
1170452|NCT01280786|relapsed or refractory AML
1170453|NCT01280773|weaning, mechanical ventilation
1170454|NCT01280747|Prior authorization
1170455|NCT01280747|Fibromyalgia
1170456|NCT01280747|Painful Diabetic Peripheral Neuropathy
1170457|NCT01280747|Policy
1170458|NCT01280747|Real World Data
1170459|NCT01280734|melatonin
1170460|NCT01280734|circadin
1170461|NCT01280734|zolpidem
1170462|NCT01280734|body sway
1170463|NCT01280734|postural instability
1170464|NCT01280708|Urology
1170465|NCT01280708|Nephrology
1170466|NCT01280708|Renal and pancreas transplantation
1170467|NCT01280708|Data base
1170468|NCT01280708|Epidemiology
1170469|NCT01280695|Type 2
1170470|NCT01280695|Diabetes Mellitus
1170471|NCT01280695|Diabetes
1170472|NCT01280695|High blood sugar
1170473|NCT01280695|Blood sugar
1170474|NCT01280695|Blood glucose
1170475|NCT01280695|Glucose
1170476|NCT01280682|type 1 diabetes
1170477|NCT01280682|age
1170478|NCT01280682|course of disease
1170479|NCT01280682|autoantibodies
1170480|NCT01280682|C-peptide levels
1170481|NCT01280669|Non-infectious
1170482|NCT01280669|Uveitis
1170483|NCT01280669|Panuveitis
1170484|NCT01280643|stage IVA colon cancer
1170485|NCT01280643|stage IVA rectal cancer
1170486|NCT01280643|stage IVB colon cancer
1170487|NCT01280643|stage IVB rectal cancer
1170488|NCT01280630|ACS: Acute coronary syndrome Retrospective Registry
1170489|NCT01280617|Renal Transplant
1170490|NCT01280617|Thymoglubulin
1170491|NCT01280591|Naproxen sodium
1170492|NCT01280591|Diphenhydramine
1170494|NCT01280565|non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit
1170495|NCT01280552|Glioblastoma Multiforme
1170496|NCT01280539|Multiple Sclerosis
1170497|NCT01280539|Transcutaneous electrical nerve stimulation
1170498|NCT01280539|Cortical Excitability
1170499|NCT01280487|ZSTK474
1170500|NCT01280487|PI3K inhibitor
1170501|NCT01280474|depression during pregnancy
1170502|NCT01280474|postpartum depression
1170503|NCT01280474|pregnancy outcomes
1170504|NCT01280474|newborn development
1170505|NCT01280474|paternal psychopathology
1170506|NCT01280461|Pneumonia
1170507|NCT01280448|Lung Cancer
1170508|NCT01280448|Tobacco Smoking
1170509|NCT01280448|gene polymorphism
1170510|NCT01280435|Online Discourse
1170511|NCT01280435|e-Learning
1170512|NCT01280435|Biopsy
1170513|NCT01280435|Virtual Pathologic Section
1170514|NCT01280422|ROCDR
1170515|NCT01280396|metabolic
1170516|NCT01280396|SGAs
1170517|NCT01280396|clozapine
1170518|NCT01280383|non-invasive ventilation
1170519|NCT01280383|diaphragm
1170520|NCT01280383|electrical activity
1170521|NCT01280383|neurally adjusted ventilatory assist
1170522|NCT01280383|critically ill patients
1170523|NCT01280370|Incisional hernia repair
1170524|NCT01280357|Fetal Heart Rate (FHR)
1170525|NCT01280357|Uterine Activity (UA)
1170526|NCT01280357|Labor & Delivery
1170527|NCT01280331|Bunionectomy
1170528|NCT01280305|schizophrenia
1170529|NCT01280305|schizoaffective disorder
1170530|NCT01280292|central hypothyroidism, hypopituitarism, eltroxin
1170531|NCT01280279|Behavior modification, Behavior therapy, Nocturia, Polyuria, Quality of life
1170532|NCT01280266|Pathological Conditions
1170533|NCT01280266|Signs and Symptoms
1170534|NCT01280266|Blood circulation
1170535|NCT01280253|Predictor
1170536|NCT01280253|outcome
1170537|NCT01280253|biochemical
1170538|NCT01280240|anemia
1170539|NCT01280240|cancer
1170540|NCT01280240|CIA
1170541|NCT01280227|Symptom management
1170542|NCT01280227|Symptom assessment
1170543|NCT01280227|Patient satisfaction
1170544|NCT01280227|Patient-provider communication
1170545|NCT01280201|Neuroendocrine Tumors
1170546|NCT01280201|Pazopanib
1170547|NCT01280201|GETNE
1170548|NCT01280201|Biomarkers
1170549|NCT01280188|Diabetes
1170550|NCT01280175|BDP
1170551|NCT01280175|Formoterol
1170552|NCT01280175|pMDI
1170553|NCT01280175|Aerochamber Plus
1170554|NCT01280175|Charcoal
1170555|NCT01280162|Plasmodium falciparum, Plasmodium vivax
1170556|NCT01280149|substance P
1170557|NCT01280149|allergic rhinitis
1170558|NCT01280149|allergen immunotherapy
1170559|NCT01280136|HIV
1170560|NCT01280136|Sexually Transmitted Diseases
1170561|NCT01280136|Pregnancy Prevention
1170562|NCT01280136|Abstinence Education
1170563|NCT01280136|Adolescents
1170564|NCT01280136|Sexual Health
1170565|NCT01280123|Parkinson's Disease
1170566|NCT01280123|Biomarkers
1170567|NCT01280110|dry eye
1170568|NCT01280110|pseudophakia
1170569|NCT01280110|cornea
1170570|NCT01280110|lubricating drop
1170571|NCT01280110|BAK
1170572|NCT01280110|blood aqueous barrier
1170573|NCT01280110|blood-retina barrier
1170574|NCT01280097|Intensive care unit delirium
1170575|NCT01280097|Sleep disruption
1170576|NCT01280097|Sleep hygiene
1170577|NCT01280097|Early mobilization in the Intensive care unit
1170578|NCT01280097|Sedative agents and sleep
1170579|NCT01280097|Circadian rhythm
1170580|NCT01280097|Cognitive disorder
1170581|NCT01280097|Electroencephalography (EEG) to measure sleep
1170582|NCT01280097|Confusion Assessment Method in the Intensive Care Unit
1170583|NCT01280097|Immune function
1170584|NCT01280097|REM sleep
1170585|NCT01280084|neonate activity
1170586|NCT01280084|labour analgesia
1170587|NCT01280032|intraoperative radiotherapy
1170588|NCT01280032|kyphoplasty
1170589|NCT01280032|spinal metastases
1170590|NCT01280019|functional residual capacity
1170591|NCT01280019|electrical impedance tomography
1170592|NCT01280019|inflammatory parameters
1170593|NCT01280006|Obstructive Sleep Apnea
1170594|NCT01280006|Hypoxia
1170595|NCT01280006|Sleep
1170596|NCT01280006|Blood Pressure
1170597|NCT01280006|Hypertension
1170598|NCT01280006|Myocardial Infarction
1170599|NCT01280006|Stroke
1170600|NCT01280006|Ventilation
1170601|NCT01280006|Brain
1170602|NCT01280006|Cerebral Blood Flow
1170603|NCT01280006|Renal Blood Flow
1170604|NCT01279980|ERAS
1170605|NCT01279980|Local anaesthetic wound catheter
1170606|NCT01279980|Painbuster
1170607|NCT01279980|Epidural
1170608|NCT01279980|colorectal surgery
1170609|NCT01279980|enhanced recovery program
1170610|NCT01279967|Pleural Mesothelioma
1170611|NCT01279967|ADI-PEG 20
1170612|NCT01279928|paediatric and adolescent population
1170613|NCT01279928|nailfold capillaroscopy
1170614|NCT01279928|laser Doppler flowmetry
1170615|NCT01279928|retinal vessel calibre
1170616|NCT01279928|retinal vessel fractal analysis
1170617|NCT01279928|24 hour Ambulatory Blood Pressure Monitoring
1170618|NCT01279915|ASP0456
1170619|NCT01279915|Pharmacokinetics
1170620|NCT01279915|safety
1170621|NCT01279915|tolerability
1170622|NCT01279902|diffuse large B-cell lymphoma
1170623|NCT01279902|rituximab
1170624|NCT01279902|CHOP
1170625|NCT01279902|abbreviated therapy
1170626|NCT01279889|hypotension
1170627|NCT01279889|cesarean delivery
1170628|NCT01279889|cardiac output
1170629|NCT01279889|blood pressure
1170630|NCT01279889|plethysmography variability index
1170631|NCT01279863|Pneumonia
1170632|NCT01279863|Cough
1170633|NCT01279863|Shortness of breath
1170634|NCT01279863|VRI
1170640|NCT01279837|swallowing disorders
1170641|NCT01279837|swallowing therapy
1170642|NCT01279837|head neck cancer
1170643|NCT01279837|oropharyngeal dysphagia
1170644|NCT01279824|swallowing, treatment, stroke,rehabilitation
1170645|NCT01279811|spinal cord injury, CSF, biomarkers, CSF pressure
1170646|NCT01279798|Lung Cancer
1170647|NCT01279798|NSCLC
1170648|NCT01279798|stage III or IV NSCLC
1170649|NCT01279785|Molecular Imaging
1170650|NCT01279785|PSMA
1170651|NCT01279785|adenocarcinoma
1170652|NCT01279785|prostatectomy
1170653|NCT01279759|Anterior Cruciate Ligament Reconstruction Predictive Factors
1170654|NCT01279759|Function Downstairs walking Step time Symmetry
1170655|NCT01279746|DVT Ultrasound compression Hypoxia Pulmonary Emboli
1170656|NCT01279746|Occult DVT in hypoxic patients
1170657|NCT01279733|microarray
1170658|NCT01279720|Adenosine deaminase deficiency
1170659|NCT01279720|Gene therapy
1170660|NCT01279694|newly-diagnosed multiple myeloma.
1170661|NCT01279681|neurotoxicity
1170662|NCT01279681|cognitive/functional effects
1170663|NCT01279681|stage IVA colon cancer
1170664|NCT01279681|stage IVA rectal cancer
1170665|NCT01279681|stage IVB colon cancer
1170666|NCT01279681|stage IVB rectal cancer
1170667|NCT01279681|recurrent colon cancer
1170668|NCT01279681|recurrent rectal cancer
1170669|NCT01279668|Montelukast
1170670|NCT01279668|Persistent cough
1170671|NCT01279668|Adults
1170672|NCT01279668|Double-blind randomised placebo controlled trial
1170673|NCT01279642|Catheterization, Peripheral
1170674|NCT01279642|Ultrasonography, Interventional
1170675|NCT01279642|Nursing
1170676|NCT01279642|Pediatric
1170677|NCT01279629|chronic plaque psoriasis
1170678|NCT01279629|To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis
1170679|NCT01279616|sickle cell
1170680|NCT01279616|stem cell transplant
1170681|NCT01279603|Cancer
1170682|NCT01279590|Hyperlipidemia
1170683|NCT01279590|Dyslipidemia
1170684|NCT01279590|Metabolic diseases
1170685|NCT01279590|Lipid metabolism disorders
1170686|NCT01279590|Hyperlipoproteinemia Type IIa
1170687|NCT01279590|Hyperlipoproteinemia Type IIb
1170688|NCT01279590|Hypercholesterolemia, Autosomal Dominant
1170689|NCT01279590|Hypercholesterolemia, Autosomal Dominant, Type B
1170690|NCT01279590|Frederickson Type IIa
1170691|NCT01279590|Frederickson Type IIb Hyperlipidemia
1170692|NCT01279577|Crohn´s disease
1170693|NCT01279577|Trichuris suis
1170694|NCT01279577|randomized
1170695|NCT01279577|placebo
1170696|NCT01279577|induction of remission
1170697|NCT01279577|porcine whipworm
1170698|NCT01279564|Endotracheal intubation and its outcomes
1170699|NCT01279538|Kidney Transplantation
1170700|NCT01279538|Pharmacokinetics
1170701|NCT01279538|Pharmacology
1170702|NCT01279538|ASKP1240
1170703|NCT01279525|Falls
1170704|NCT01279525|Prevention
1170705|NCT01279525|Elderly
1170706|NCT01279512|Metformin Acarbose pco infertility overweight
1170707|NCT01279499|Morbid obesity
1170708|NCT01279499|Sevoflurane
1170709|NCT01279499|Propofol
1170710|NCT01279499|Remifentanyl
1170711|NCT01279499|BIS
1170712|NCT01279499|Cardiovascular stability
1170713|NCT01279499|Recovery scores
1170714|NCT01279499|Drug consumption
1170715|NCT01279486|Pregnancy,
1170716|NCT01279473|Chronic Myelogenous Leukemia
1170717|NCT01279473|CML
1170718|NCT01279473|Acute Lymphoblastic Leukemia
1170719|NCT01279473|Philadelphia Chromosome Positive, ph+ ALL
1170720|NCT01279473|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
1170721|NCT01279460|chronic kidney disease
1170722|NCT01279460|CKD
1170723|NCT01279460|pulse wave velocity
1170724|NCT01279460|PWV
1170725|NCT01279447|infrapatellar nerve
1170726|NCT01279447|saphenous nerve
1170727|NCT01279447|knee arthroscopy
1170728|NCT01279447|nerve block
1170729|NCT01279408|Palliative treatment
1170730|NCT01279408|advanced non-small cell lung cancer
1170731|NCT01279408|Patients with Asymptomatic Centrally Located Advance NSCLC who are palliative
1170732|NCT01279395|atherosclerosis
1170733|NCT01279395|cholesterol
1170734|NCT01279395|cyclooxygenase
1170735|NCT01279395|gene expression
1170736|NCT01279395|lipid metabolism
1170737|NCT01279382|Symptoms
1170738|NCT01279382|Psychological status
1170739|NCT01279382|Hypnotherapy
1170740|NCT01279382|Relaxation training
1170741|NCT01279369|Pregnancy
1170742|NCT01279369|Trauma
1170743|NCT01279369|Placental Abruption
1170744|NCT01279369|Fetal fibronectin
1170745|NCT01279356|Liver diseases
1170746|NCT01279356|Volatile organic compounds
1170747|NCT01279356|Inflammation
1170748|NCT01279356|Oxidative stress
1170749|NCT01279356|non-invasive tests
1170750|NCT01279343|labor induction
1170751|NCT01279343|foley bulb
1170752|NCT01279343|misoprostol
1170753|NCT01279330|Colorectal Cancer
1170754|NCT01279330|Screening
1170755|NCT01279330|General Practitioner
1170756|NCT01279330|Fecal Occult Blood Tests
1170757|NCT01279304|breast cancer
1170758|NCT01279304|locoregional recurrence rate
1170759|NCT01279304|neoadjuvant chemotherapy and surgery
1170760|NCT01279304|radiotherapy
1170761|NCT01279304|risk model
1170762|NCT01279304|overall survival
1170763|NCT01279304|relapse free survival
1170764|NCT01279304|cT1-2cN0-1 breast cancer
1170765|NCT01279291|advanced solid tumor
1170766|NCT01279291|Ovarian cancer
1170767|NCT01279291|Primary peritoneal cancer
1170768|NCT01279291|Fallopian tube cancer
1170769|NCT01279278|Colorectal Cancer
1170770|NCT01279278|Screening
1170771|NCT01279278|General Practitioner
1170772|NCT01279278|Fecal Occult Blood Tests
1170773|NCT01279265|Lactobacillus
1170774|NCT01279265|Probiotic
1170775|NCT01279265|Crying time
1170776|NCT01279265|Fecal microbiota
1170777|NCT01279265|Calprotectin
1170778|NCT01279265|Colic
1170779|NCT01279265|Infant Crying
1170780|NCT01279265|Barr Diary
1170781|NCT01279265|Breath Hydrogen
1170782|NCT01279265|Clinical Design
1170783|NCT01279239|Poly Trauma
1170784|NCT01279239|Metabonomics
1170785|NCT01279239|NMR
1170786|NCT01279239|MOF
1170787|NCT01279200|letrozole
1170788|NCT01279200|ovulation monitoring
1170789|NCT01279200|pregnancy rate
1170790|NCT01279187|dental
1170791|NCT01279187|implant
1170792|NCT01279174|Hip, arthrosis
1170793|NCT01279161|overweight, obesity, children, insulin, pump therapy, FTO
1170794|NCT01279148|biopsy guidance
1170795|NCT01279148|tracking device
1170796|NCT01279135|IGRT,Postoperative, Cervix, Late toxicity, Bowel
1170797|NCT01279109|gestational weight gain
1170798|NCT01279096|Acute lymphoblastic leukemia
1170799|NCT01279096|relapse
1170800|NCT01279096|childhood
1170801|NCT01279096|clofarabine
1170802|NCT01279070|Schizophrenia
1170803|NCT01279070|Cognitive remediation
1170804|NCT01279070|Group training
1170805|NCT01279070|Executive function
1170806|NCT01279070|Social functioning
1170807|NCT01279057|Rhinitis, allergic, seasonal, fluticasone furoate, equivalence
1170808|NCT01279044|HIV
1170809|NCT01279044|MSM
1170810|NCT01279044|SUMSM
1170811|NCT01279018|Persistent postsurgical pain
1170812|NCT01279018|breast cancer
1170813|NCT01279018|postmastectomy pain syndrome
1170814|NCT01279018|neuropathic pain
1170815|NCT01279005|MSM
1170816|NCT01279005|focus group
1170817|NCT01279005|HIV
1170818|NCT01279005|risk-taking
1170819|NCT01279005|risk-denial
1170820|NCT01279005|signature on inform consent, willing to participate, MSM either HIV positive or negative, age 20-50 years old
1170821|NCT01278992|fatigue
1170822|NCT01278992|adaptogen
1170823|NCT01278992|Rhodiola rosea
1170824|NCT01278979|obstetric
1170825|NCT01278979|perineal tear
1170826|NCT01278979|perineal injury
1170827|NCT01278979|diagnosis
1170828|NCT01278966|Epilepsy
1170829|NCT01278966|Diet
1170830|NCT01278966|the Modified Atkins Diet
1170831|NCT01278966|Ketogenic diet
1170832|NCT01278953|paroxysmal atrial fibrillation
1170833|NCT01278953|atrial fibrillation
1170834|NCT01278953|radiofrequency ablation
1170835|NCT01278953|pulmonary vein isolation
1170836|NCT01278953|ablation catheter
1170837|NCT01278953|RF
1170838|NCT01278953|contact force sensing
1170839|NCT01278953|contact force
1170840|NCT01278953|contact force assisted ablation
1170841|NCT01278927|exercise
1170842|NCT01278927|stress management
1170843|NCT01278927|post transplant
1170844|NCT01278927|physical and emotional relaxation
1170845|NCT01278901|helicobacter pylori
1170846|NCT01278901|urease test
1170847|NCT01278901|13C-UBT
1170848|NCT01278901|the focus of the study is to evaluate a possible effect of PPI therapy on Helicobacter pylori diagnostic tests
1170849|NCT01278888|Lung cancer
1170850|NCT01278888|Pain
1170851|NCT01278888|Quality of life
1170852|NCT01278888|Economy
1170853|NCT01278875|High density lipoproteins
1170854|NCT01278875|Acute coronary syndromes
1170855|NCT01278875|Cellular cholesterol efflux
1170856|NCT01278875|HDL: proteomics
1170857|NCT01278875|Nitric Acid production
1170858|NCT01278862|Crowns
1170859|NCT01278862|posterior teeth
1170860|NCT01278862|CAD CAM crowns
1170861|NCT01278862|digital veneer system
1170862|NCT01278862|Lava
1170863|NCT01278862|clinical
1170864|NCT01278849|Advanced or metastatic cancer,
1170865|NCT01278849|refractory,
1170866|NCT01278849|core phase,
1170867|NCT01278849|extension phase,
1170868|NCT01278849|dose escalation,
1170869|NCT01278849|standard chemotherapy,
1170870|NCT01278849|pharmacokinetics,
1170871|NCT01278849|doctaxel,
1170872|NCT01278849|paclitaxel,
1170873|NCT01278849|carboplatin,
1170874|NCT01278849|safety,
1170875|NCT01278849|tolerability,
1170876|NCT01278849|hepatic impairment
1170877|NCT01278836|Flap
1170878|NCT01278836|leg defect
1170879|NCT01278836|reconstruction
1170880|NCT01278836|tissue
1170881|NCT01278823|obesity
1170882|NCT01278823|type 2 diabetes
1170883|NCT01278810|Icaritin,
1170884|NCT01278810|ERa36
1170885|NCT01278784|Dry eye syndromes
1170886|NCT01278784|Chitosan-N-Acetylcysteine
1170887|NCT01278771|CHD
1170888|NCT01278758|Advanced or metastatic cancer,
1170889|NCT01278758|refractory,
1170890|NCT01278758|core phase,
1170891|NCT01278758|extension phase,
1170892|NCT01278758|dose escalation,
1170893|NCT01278758|standard chemotherapy,
1170894|NCT01278758|doctaxel,
1170895|NCT01278758|paclitaxel,
1170896|NCT01278758|carboplatin,
1170897|NCT01278758|safety,
1170898|NCT01278758|tolerability
1170899|NCT01278745|cardiac allograft vasculopathy (CAV)
1170900|NCT01278745|prevention
1170901|NCT01278745|cardiac transplantation
1170902|NCT01278745|rituximab
1170903|NCT01278732|arterial hypertension
1170904|NCT01278719|Antrochoanal polyp
1170905|NCT01278719|Ethmoidal polyp
1170906|NCT01278719|Recurrence
1170907|NCT01278719|Risk factors
1170908|NCT01278719|Environmental factors
1170909|NCT01278719|Gene expression
1170910|NCT01278719|Micro array
1170911|NCT01278719|Mutation
1170912|NCT01278693|Renal failure, hemodialysis, dyslipidemia, L-carnitine.
1170913|NCT01278680|Behavioral economics
1170914|NCT01278680|Incentives
1170915|NCT01278680|Health
1170916|NCT01278667|ADHD
1170917|NCT01278667|Memory
1170918|NCT01278667|Social
1170919|NCT01278667|Emotion
1170920|NCT01278667|Methylphenidate
1170921|NCT01278641|Fibromyalgia
1170922|NCT01278641|Widespread pain
1170923|NCT01278641|Fatigue
1170924|NCT01278641|Physical exercise
1170925|NCT01278602|Diffuse large B-cell lymphoma
1170926|NCT01278602|Chemotherapy
1170927|NCT01278602|R-ESHAP
1170928|NCT01278602|Autologous stem cell transplantation
1170929|NCT01278576|Muscle spasticity
1170930|NCT01278576|Stroke
1170931|NCT01278576|Botulinum Toxins
1170932|NCT01278576|Lower extremity
1170933|NCT01278576|Ankle
1170934|NCT01278563|Low Glycemic Index Diet
1170935|NCT01278537|elderly
1170936|NCT01278537|cancer surgery
1170937|NCT01278537|quality of life
1170938|NCT01278537|empowerment
1170939|NCT01278537|shared-decision
1170940|NCT01278524|Delirium
1170941|NCT01278524|Analgosedation
1170942|NCT01278524|ICU
1170943|NCT01278524|Pain
1170944|NCT01278524|Implementation
1170945|NCT01278511|Canadian C-Spine Rule
1170946|NCT01278511|Prehospital Emergency Care
1170947|NCT01278511|Cervical Spine Injuries
1170948|NCT01278511|Cervical Spine Fractures
1170949|NCT01278511|Emergency Medicine Undergraduates
1170950|NCT01278498|Escitalopram
1170951|NCT01278498|Depression
1170952|NCT01278498|Stroke
1170953|NCT01278485|Diabetes complications
1170954|NCT01278472|cholecystectomy
1170955|NCT01278472|laparoscopic
1170956|NCT01278472|single-port
1170957|NCT01278472|gallstones
1170958|NCT01278459|endothelial function
1170959|NCT01278459|cardiovascular
1170960|NCT01278446|Cow's Milk Allergy
1170961|NCT01278446|CMA
1170962|NCT01278433|Polio
1170963|NCT01278433|Poliovirus
1170964|NCT01278433|IMOVAX Polio™
1170965|NCT01278420|Visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs Six months post cataract surgery
1170966|NCT01278407|DLB
1170967|NCT01278407|Dementia with Lewy bodies
1170968|NCT01278407|Lewy Body Disease
1170969|NCT01278407|Dementia
1170970|NCT01278407|E2020
1170971|NCT01278407|Donepezil
1170972|NCT01278407|Aricept
1170973|NCT01278394|Onychomycosis
1170974|NCT01278394|Fungal Nail
1170975|NCT01278381|pancreas, pancreaticoduodenectomy, major complications
1170976|NCT01278368|pancreatic cancer, neoadjuvant chemotherapy
1170977|NCT01278355|pain
1170978|NCT01278355|acupuncture
1170979|NCT01278342|Sandostatin LAR
1170980|NCT01278342|High Dose
1170981|NCT01278342|GH-receptor antagonist
1170982|NCT01278342|combination with dopamine-agonist
1170983|NCT01278342|acromegalic patients
1170984|NCT01278342|octreotide acetate
1170985|NCT01278342|Somavert
1170986|NCT01278342|Dostinex
1170987|NCT01278342|pegvisomant
1170988|NCT01278342|cabergoline
1170989|NCT01278342|not adequately controlled
1170990|NCT01278342|active acromegaly
1170991|NCT01278329|Music
1170992|NCT01278329|Foetal learning
1170993|NCT01278329|Brazelton Neonatal Behavioral Assessment Scale
1170994|NCT01278316|PTSD
1170995|NCT01278316|TBI
1170996|NCT01278316|Cognition
1170997|NCT01278316|Cognitive Training
1170998|NCT01278303|Coarctation
1170999|NCT01278303|Aorta
1171000|NCT01278290|Triptorelin acetate
1171001|NCT01278290|precocious puberty
1171002|NCT01278290|premature thelarche
1171003|NCT01278290|GnRH analog
1171004|NCT01278290|Diagnostic validation study
1171005|NCT01278277|Stargardt disease
1171006|NCT01278277|macula
1171007|NCT01278277|electroretinogram
1171008|NCT01278277|saffron
1171009|NCT01278264|Transversus abdominis plane block
1171010|NCT01278264|Ultrasound guided
1171011|NCT01278264|Abdominoplasty
1171012|NCT01277276|Medical tool
1171013|NCT01277263|Breast Cancer
1171014|NCT01277250|Hospitalized adults
1171015|NCT01277250|Tobacco users
1171016|NCT01277250|Smokers
1171017|NCT01277250|Smoking cessation
1171018|NCT01277250|Web-based
1171019|NCT01277250|Transition coach
1171020|NCT01277237|Non alcoholic fatty liver disease
1171021|NCT01277224|physical activity
1171022|NCT01277224|obesity
1171023|NCT01277224|adiposity
1171024|NCT01277224|children
1171025|NCT01277224|blood lipids
1171026|NCT01277224|blood pressure
1171027|NCT01277224|randomized controlled trials
1171028|NCT01277211|Contraception
1171029|NCT01277211|NuvaRing
1171030|NCT01277198|kidney calculi
1171031|NCT01277198|ureteral calculi
1171032|NCT01277198|cystoscopes
1171033|NCT01277198|laparoscopes
1171034|NCT01277185|calcium
1171035|NCT01277185|healthy
1171036|NCT01277185|Mexican-American adolescents
1171037|NCT01277185|camp
1171038|NCT01277185|girls
1171039|NCT01277185|boys
1171040|NCT01277185|bone
1171041|NCT01277172|DLBCL
1171042|NCT01277172|pharmacokinetics
1171043|NCT01277172|pharmacodynamics
1171044|NCT01277172|Rituximab
1171045|NCT01277172|LymphomaLymphoma
1171046|NCT01277172|Non-HodgkinLymphoma
1171047|NCT01277172|B-CellLymphoma
1171048|NCT01277172|Large B-Cell
1171049|NCT01277172|Disorders Lymphatic Diseases
1171050|NCT01277172|Immunoproliferative Disorders
1171051|NCT01277172|Antineoplastic Agents
1171052|NCT01277172|Adverse Effects
1171053|NCT01277159|Analgesia
1171054|NCT01277159|Duration
1171055|NCT01277159|Popliteal Fossa Nerve Block
1171056|NCT01277159|Dexamethasone
1171057|NCT01277159|Buprenorphine
1171058|NCT01277159|Additives
1171059|NCT01277159|Ankle surgery
1171060|NCT01277146|Phase 1
1171061|NCT01277146|dose escalation
1171062|NCT01277146|histologically confirmed
1171063|NCT01277146|malignancy metastatic
1171064|NCT01277107|PSG
1171065|NCT01277107|LPS
1171066|NCT01277107|TST
1171067|NCT01277107|WASO
1171068|NCT01277107|Subjects With Insomnia characterized by both Difficulty in Falling Asleep and Staying Asleep
1171069|NCT01277081|Paracetamol
1171070|NCT01277081|Common cold
1171071|NCT01277068|obese patients
1171072|NCT01277068|TRL
1171073|NCT01277068|the bariatric surgery
1171074|NCT01277042|Safety
1171075|NCT01277042|HPV vaccine
1171076|NCT01277042|Immune response
1171077|NCT01277042|Human papillomavirus
1171078|NCT01277042|China
1171079|NCT01277016|Amyloidosis
1171080|NCT01277016|Bortezomib
1171081|NCT01278238|Hypotension
1171082|NCT01278238|Caesarean section
1171083|NCT01278238|Spinal anaesthesia
1171084|NCT01278238|Lower limb compression / wrapping
1171085|NCT01278238|Phenylephrine
1171086|NCT01278225|Neurofeedback
1171087|NCT01278225|Neural Function
1171088|NCT01278225|Neuromodulation
1171089|NCT01278225|Chemotherapy-Induced Neuropathic Pain
1171090|NCT01278225|Electroencephalogram
1171091|NCT01278225|EEG
1171092|NCT01278225|Biofeedback
1171093|NCT01278225|BF
1171094|NCT01278225|Quality of Life
1171095|NCT01278225|QOL
1171096|NCT01278225|Pain Quality Assessment Scale
1171097|NCT01278225|PQAS
1171098|NCT01278225|Brief Symptom Inventory
1171099|NCT01278225|BSI
1171100|NCT01278225|Sleep Disturbances
1171101|NCT01278225|Fatigue
1171102|NCT01278225|Questionnaires
1171103|NCT01278212|breast cancer
1171104|NCT01278212|breast neoplasm
1171105|NCT01278212|breast tumor
1171106|NCT01278212|radiotherapy
1171107|NCT01278212|radiation
1171108|NCT01278212|accelerated
1171109|NCT01278212|lumpectomy
1171110|NCT01278199|Bronchial Artery Embolization
1171111|NCT01278199|Non-severe Hemoptysis
1171112|NCT01278199|Bleeding mild-to-moderate abundance
1171113|NCT01278199|Volume ranging from 100 ml to 200 ml
1171114|NCT01278186|Coronary stenosis
1171115|NCT01278186|Bifurcation
1171116|NCT01278186|Drug-eluting balloon
1171117|NCT01278186|Drug-eluting stent
1171118|NCT01278186|Angiographic follow-up
1171119|NCT01278186|Late Lumen Loss
1171120|NCT01278186|Restenosis
1171121|NCT01278173|Vigabatrin-associated vision change
1171122|NCT01278173|Adult refractory complex partial seizures
1171123|NCT01278173|CPS
1171124|NCT01278173|Epilepsy
1171125|NCT01278173|Seizures
1171126|NCT01278173|Brain diseases
1171127|NCT01278173|Central Nervous System Diseases
1171128|NCT01278173|Nervous System Diseases
1171129|NCT01278173|Neurologic Manifestations
1171130|NCT01278173|Enzyme Inhibitors
1171131|NCT01278173|GABA Agents
1171132|NCT01278147|cancer
1171133|NCT01278147|fatigue program education
1171134|NCT01278121|Obesity
1171135|NCT01278121|Diabetes Mellitus, Type 2
1171136|NCT01278121|Cardiovascular diseases
1171137|NCT01278108|Safety
1171138|NCT01278108|Tolerability
1171139|NCT01278108|Pharmacokinetics
1171140|NCT01278095|Safety
1171141|NCT01278095|Tolerability
1171142|NCT01278095|Pharmacokinetics
1171143|NCT01278082|Randomized
1171144|NCT01278082|double-blind
1171145|NCT01278082|Placebo-controlled
1171146|NCT01278082|budesonide
1171147|NCT01278082|collagenous colitis
1171148|NCT01278082|acute treatment
1171149|NCT01278082|maintaining remission
1171150|NCT01278069|Acute myeloid Leukemia
1171151|NCT01278069|Myeloid Sarcoma
1171152|NCT01278069|Extramedullary Acute myeloid Leukemia
1171153|NCT01278069|18FDG-PET-CT
1171154|NCT01278056|Non-alcoholic steatohepatitis (NASH) and increased iron storage / disturbed distribution
1171155|NCT01278043|Antiplatelet
1171156|NCT01278043|Percutaneous Coronary Intervention
1171157|NCT01278043|Coronary artery disease
1171158|NCT01278043|Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention
1171159|NCT01278017|nontyphoidal salmonellae
1171160|NCT01278017|enterocolitis
1171161|NCT01278017|ceftriaxone
1171162|NCT01278004|Adult cancer patients with chemotherapy-induced painful peripheral neuropathy
1171163|NCT01277991|Bioequivalence
1171164|NCT01277991|healthy volunteer study
1171165|NCT01277991|Rheumatoid Arthritis
1171166|NCT01277978|Caesarean section
1171167|NCT01277978|Cardiovascular effects
1171168|NCT01277978|Postpartum hemorrhage
1171169|NCT01277978|Carbetocin
1171170|NCT01277978|Oxytocin
1171171|NCT01277965|Algorithm basal insulin
1171172|NCT01277965|physical activity
1171173|NCT01277965|Type 1 diabetes
1171174|NCT01277965|Insulin pump treatment
1171175|NCT01277952|Traumatic Brain Injury
1171176|NCT01277952|DBS
1171177|NCT01277926|Breast Cancer
1171178|NCT01277926|Hormone Receptor Positive, Advanced Breast Cancer
1171179|NCT01277913|diabetes
1171180|NCT01277913|vitamin D
1171181|NCT01277913|bone density
1171182|NCT01277913|children
1171183|NCT01277887|Smoking
1171184|NCT01277887|Nicotine
1171185|NCT01277887|Nicotine polacrilex
1171186|NCT01277887|Nicotine replacement
1171187|NCT01277861|Desflurane, Fentanyl, Airway responses
1171188|NCT01277848|PLAC1
1171189|NCT01277848|pregnant
1171190|NCT01277848|first prenatal visit
1171191|NCT01277848|pre-eclampsia
1171192|NCT01277835|video-assisted
1171193|NCT01277835|thoracic surgery
1171194|NCT01277835|VATS
1171195|NCT01277835|lidocaine infusion
1171196|NCT01277835|VATS procedures
1171197|NCT01277822|Hypertension
1171198|NCT01277822|Uncontrolled hypertension
1171199|NCT01277822|High blood pressure
1171200|NCT01277822|Uncontrolled high blood pressure
1171201|NCT01277822|Untreated high blood pressure
1171202|NCT01277822|Untreated hypertension
1171203|NCT01277822|Essential hypertension
1171218|NCT01277770|Thymoglobulin
1171219|NCT01277770|Kidney Transplant Recipients
1171220|NCT01277770|Steroid-Free
1171221|NCT01277770|Immunosuppression
1171222|NCT01277744|Desmoplastic small round cell tumor
1171223|NCT01277744|DSRCT
1171224|NCT01277744|Hyperthermic peritoneal perfusion
1171225|NCT01277744|HIPEC
1171226|NCT01277744|Complete abdominal tumor excision
1171227|NCT01277744|Extensive abdominal disease
1171228|NCT01277744|Non-carcinoma tumors
1171229|NCT01277744|Abdominal cavity
1171230|NCT01277744|Cisplatin
1171231|NCT01277744|Platinol-AQ
1171232|NCT01277744|Platinol
1171233|NCT01277744|CDDP
1171234|NCT01277744|Diffuse peritoneal tumor
1171235|NCT01277744|Retroperitoneal tumor
1171236|NCT01277744|Ovarian germ cell
1171237|NCT01277744|Wilms' tumor
1171238|NCT01277705|Booster vaccination
1171240|NCT01277679|lung water measures
1171241|NCT01277679|pulmonary edema
1171242|NCT01277679|MRI
1171243|NCT01277679|heart failure
1171244|NCT01277666|Crohn's disease
1171245|NCT01277666|capsule
1171246|NCT01277666|GSK1605786A
1171247|NCT01277666|quality of life
1171248|NCT01277666|inflammatory bowel disease
1171249|NCT01277666|oral therapy
1171250|NCT01277653|Hepatocellular carcinoma
1171251|NCT01277640|male tolerance
1171252|NCT01277640|HIV-1
1171253|NCT01277640|microbicide
1171254|NCT01277640|The study will assess the safety and tolerability of dapivirine when applied topically to the penis of healthy, HIV-uninfected, adult males, both circumcised
1171255|NCT01277640|and uncircumcised
1171256|NCT01277627|HCV
1171257|NCT01277627|HIV
1171258|NCT01277627|Nevirapine
1171259|NCT01277627|HCV viral load
1171260|NCT01277627|Efavirenz
1171261|NCT01277627|Protease inhibitors
1171262|NCT01277614|lifestyle
1171263|NCT01277614|diet
1171264|NCT01277614|exercise
1171265|NCT01277601|Chronic Hepatitis B
1171266|NCT01277601|Hep B
1171267|NCT01277601|Non cirrhotic
1171268|NCT01277601|Tenofovir disoproxil fumarate (TDF)
1171269|NCT01277601|Peginterferon α-2a (Peg-IFN)
1171270|NCT01277588|fetal scalp sampling
1171271|NCT01277588|experience questionnaire
1171272|NCT01277575|stroke
1171273|NCT01277575|aphasia
1171274|NCT01277575|language
1171275|NCT01277562|Breast Cancer
1171276|NCT01277562|Prostate Cancer
1171277|NCT01277562|Osteopenia
1171278|NCT01277562|Osteoporosis
1171279|NCT01277562|Secondary causes of bone loss
1171280|NCT01277549|Leukapheresis
1171281|NCT01277549|Hematopoetic Stem Cell Mobilization
1171282|NCT01277510|dialysis
1171283|NCT01277510|sensipar
1171284|NCT01277510|mimpara
1171285|NCT01277510|hemodialysis
1171286|NCT01277510|peritoneal dialysis
1171287|NCT01277510|renal
1171288|NCT01277510|parathyroid hormone
1171289|NCT01277510|pediatric
1171290|NCT01277497|Chronic kidney disease
1171291|NCT01277497|Phosphate binder
1171292|NCT01277497|Sevelamer carbonate
1171293|NCT01277497|Calcium acetate
1171294|NCT01277497|Vascular calcification
1171295|NCT01277497|Endothelial Dysfunction
1171296|NCT01277484|decitabine
1171297|NCT01277484|dose
1171298|NCT01277484|schedule
1171299|NCT01277484|safety
1171300|NCT01277484|allogeneic stem cell transplantation
1171301|NCT01277471|meal frequency
1171302|NCT01277471|type two diabetes
1171303|NCT01277458|HIV
1171304|NCT01277458|MSM
1171305|NCT01277458|Ethnicity
1171306|NCT01277445|gut microbiome
1171307|NCT01277445|prebiotics
1171308|NCT01277445|immunological status
1171309|NCT01277445|fructans
1171310|NCT01277432|Diabetes
1171311|NCT01277432|Depression
1171312|NCT01277406|Colorectal Carcinoma
1171313|NCT01277406|Resminostat
1171314|NCT01277406|HDAC
1171315|NCT01277406|4SC-201
1171316|NCT01277406|Phase I
1171317|NCT01277406|Phase II
1171318|NCT01277393|Enteral nutrition feeding
1171319|NCT01277380|H1N1 Influenza virus
1171320|NCT01277380|swine flu
1171321|NCT01277380|Real Time RT-PCR
1171322|NCT01277367|Obesity
1171323|NCT01277367|Sedentary
1171324|NCT01277367|Physical activity
1171325|NCT01277367|exercise
1171326|NCT01277367|incentives
1171327|NCT01277354|Cognitive Processing Therapy (CPT)
1171328|NCT01277315|ALS
1171329|NCT01277315|Anakinra
1171330|NCT01277315|Kineret
1171331|NCT01277315|Progressive Muscular Atrophy
1171332|NCT01277315|PMA
1171333|NCT01277315|Safety Trial
1171334|NCT01277315|Tolerability Trial
1171335|NCT01277289|dexamethasone
1171336|NCT01277289|ery-dex
1171337|NCT01277289|Chron's disease
1171338|NCT01277289|CD
1171339|NCT01276977|Migraine
1171340|NCT01276977|Acute Migraine
1171341|NCT01276977|Headache
1171342|NCT01276964|menses
1171343|NCT01276964|quantitative determination of menstrual losses
1171344|NCT01276964|kinetic definition of menses
1171345|NCT01276951|Cocoa
1171346|NCT01276951|Chocolate
1171347|NCT01276951|Endothelial disfunction
1171348|NCT01276951|Cardiovascular disease
1171349|NCT01276951|Blood Pressure
1171350|NCT01276951|Hypertension
1171351|NCT01276938|Breast cancer
1171352|NCT01276938|Intra Operative Radiation Therapy
1171353|NCT01276938|Toxicity
1171354|NCT01276925|Hip arthroplasty
1171355|NCT01276925|Peripheral nervous blockade
1171356|NCT01276925|Postoperative
1171357|NCT01276925|Pain
1171358|NCT01276925|Ropivacaine
1171359|NCT01276899|Breast Cancer
1171360|NCT01276899|Triple negative breast cancer
1171361|NCT01276899|ERnegative, PRnegative and Her2negative
1171362|NCT01276899|Taxanes
1171363|NCT01276899|Metastases
1171364|NCT01276899|Biomarkers
1171365|NCT01276899|Resistance
1171366|NCT01276899|Biobanking
1171367|NCT01276899|Breast cancer with unresectable metastases to the liver
1171368|NCT01276899|Breast cancer with unresectable metastases to the skin
1171369|NCT01276899|Breast cancer with unresectable metastases to the lymph node
1171370|NCT01276899|Neoadjuvant chemotherapy
1171371|NCT01276886|Left sided acute diverticulitis diagnosed clinically by the presence of abdominal pain, leukocytosis (>11x109) and/or fever >38°C, confirmed by imaging.
1171372|NCT01276886|CT criteria: localized thickening (≥4 mm) of the colonic wall and signs of inflammation of the pericolic fat, abscess and/or extraluminal air and/or contrast.
1171373|NCT01276886|US criteria: bowel wall thickening (>4 mm), diverticular inflammation, pericolic fat edema, intramural or pericolic inflammatory mass, intramural fistula.
1171374|NCT01276886|WSCE criteria: segmental luminal narrowing and a tethered mucosa with or without a mass effect or extravasation of contrast and/or extraluminal air.
1171375|NCT01276873|Artificial Respiration
1171376|NCT01276873|Suction
1171377|NCT01276873|Pain
1171378|NCT01276873|Nursing
1171379|NCT01276873|Neonatology
1171380|NCT01276860|Obstructive Sleep Apnea
1171381|NCT01276860|Pediatric Obstructive Sleep Apnea
1171382|NCT01276860|OSA
1171383|NCT01276860|PVT
1171384|NCT01276860|Psychomotor Vigilance Testing
1171385|NCT01276860|Psychomotor Vigilance Task
1171386|NCT01276847|psoriasis
1171387|NCT01276847|Ustekinumab
1171388|NCT01276847|Stelara
1171389|NCT01276847|Etanercept
1171390|NCT01276847|Enbrel
1171391|NCT01276821|Bronchiolitis
1171392|NCT01276821|L-Epinephrine
1171393|NCT01276821|3% Hypertonic Saline
1171394|NCT01276821|Clinical Severity Score
1171395|NCT01276808|Magnetic navigation, percutaneous coronary intervention
1171396|NCT01276769|Triple Negative Breast Cancer
1171397|NCT01276769|Neoadjuvant chemotherapy
1171398|NCT01276769|Platinum
1171399|NCT01276730|Advanced cervical cancer
1171400|NCT01276730|India
1171401|NCT01276691|Vascular function
1171402|NCT01276691|Inflammation
1171403|NCT01276691|Oxidative stress
1171404|NCT01276691|Hemostatic balance
1171405|NCT01276691|Aspirin
1171406|NCT01276691|Firefighting
1171407|NCT01276678|CAD
1171408|NCT01276665|Bladder cancer
1171409|NCT01276665|urinary diversion
1171410|NCT01276665|Postoperative Complications
1171411|NCT01276665|Fluid Therapy
1171412|NCT01276665|Norepinephrine
1171413|NCT01276652|Polysomnography
1171414|NCT01276652|Circadian rhythmicity
1171415|NCT01276639|Xeljanz
1171416|NCT01276639|tofacitinib
1171417|NCT01276639|chronic
1171418|NCT01276639|Pruritus
1171419|NCT01276639|Itch
1171420|NCT01276639|DLQI
1171421|NCT01276639|severe
1171422|NCT01276639|moderate
1171423|NCT01276639|treatment
1171424|NCT01276639|safety
1171425|NCT01276639|efficacy
1171426|NCT01276639|CP-690,550
1171427|NCT01276639|Plaque Psoriasis
1171428|NCT01276639|Psoriasis Vulgaris
1171429|NCT01276639|Jax-inhibitor
1171430|NCT01276639|Oral Treatment
1171431|NCT01276613|Resectable Adenocarcinoma of the Pancreas
1171432|NCT01276613|Gemcitabine
1171433|NCT01276613|Gemcitabine Hydrochloride
1171434|NCT01276613|Gemzar
1171439|NCT01276574|PET/CT
1171440|NCT01276574|Ovarian cancer
1171441|NCT01276574|HE4
1171442|NCT01276561|laparoscopy
1171443|NCT01276561|splenectomy
1171444|NCT01276561|single site
1171445|NCT01276561|trial
1171446|NCT01276522|Schnitzler syndrome
1171447|NCT01276522|IL-1 beta
1171448|NCT01276522|Canakinumab
1171449|NCT01276522|Ilaris
1171450|NCT01276522|Treatment
1171451|NCT01276522|Efficacy
1171452|NCT01276522|Safety
1171453|NCT01276509|Crohn's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn's Disease Activity Index (CDAI)
1171459|NCT01276470|Adult and Pediatric Autoimmune Disease
1171460|NCT01276470|Antibody
1171461|NCT01276470|Autoimmune Diseases
1171462|NCT01276470|Autoimmunity Pathogenesis
1171463|NCT01276470|Environmental Risk Factors
1171464|NCT01276470|Myositis
1171465|NCT01276457|immunosuppression
1171466|NCT01276457|kidney transplantation
1171467|NCT01276457|everolimus
1171468|NCT01276457|safety
1171469|NCT01276444|valve repair
1171470|NCT01276444|postoperative period
1171471|NCT01276444|goal-directed therapy
1171472|NCT01276444|pulmonary artery catheter
1171473|NCT01276444|transpulmonary thermodilution
1171474|NCT01276444|central venous oxygen saturation
1171475|NCT01276392|regional and systemical anticoagulation
1171476|NCT01276392|continuous renal replacement therapy
1171477|NCT01276392|multiplate
1171478|NCT01276392|rotational thrombelastometry
1171479|NCT01276379|colorectal cancer
1171480|NCT01276379|advanced
1171481|NCT01276379|metastatic
1171482|NCT01276379|KRAS
1171483|NCT01276379|biomarkers (BRAF, IGF1P/MMp7,PI3K-PTEN)
1171484|NCT01276379|cetuximab
1171485|NCT01276366|Heel lance
1171486|NCT01276366|Premature
1171487|NCT01276366|Breast milk
1171488|NCT01276353|Alzheimer Disease
1171489|NCT01276353|Dementia
1171490|NCT01276353|Delirium
1171491|NCT01276353|Amnestic
1171492|NCT01276353|Cognitive Disorders
1171493|NCT01276353|Donepezil
1171494|NCT01276353|Brain Diseases
1171495|NCT01276353|Central Nervous System Diseases
1171496|NCT01276353|Nervous System Diseases
1171497|NCT01276353|Tauopathies
1171498|NCT01276353|Neurodegenerative Diseases
1171499|NCT01276353|Mental Disorders
1171500|NCT01276353|Cholinesterase Inhibitors
1171501|NCT01276353|Enzy
1171502|NCT01276340|Urinary Incontinence
1171503|NCT01276340|Urinary stress incontinence
1171504|NCT01276340|Urinary urge incontinence
1171505|NCT01276340|Women
1171506|NCT01276340|electrical stimulation
1171507|NCT01276340|KEAT stimulator
1171508|NCT01276340|quality of life
1171509|NCT01276314|SCAR
1171510|NCT01276314|anti-TNF-a
1171511|NCT01276275|Acute coronary syndrome, thienopyridine, epidemiology
1171512|NCT01276262|Phase 1, healthy female volunteers, oral contraceptive, pharmacokinetics, Rheumatoid arthritis, RA, fostamatinib
1171513|NCT01276249|Aptus Endosystem
1171514|NCT01276249|EndoStaple
1171515|NCT01276249|Endograft
1171516|NCT01276249|Stent Graft
1171517|NCT01276249|Abdominal Aortic Aneurysm
1171518|NCT01276249|Heli-FX
1171519|NCT01276249|EndoAnchor
1171520|NCT01276236|Kaposi's Sarcoma
1171521|NCT01276236|Maraviroc
1171522|NCT01276236|CCR5
1171523|NCT01276236|HIV
1171524|NCT01276223|Dry eye
1171525|NCT01276223|ocular discomfort
1171526|NCT01276197|hypertension
1171527|NCT01276197|healthcare disparities
1171528|NCT01276197|minority health
1171529|NCT01276197|health behavior
1171530|NCT01276184|HPV Vaccine
1171531|NCT01276184|HPV vaccination
1171532|NCT01276184|SMS
1171533|NCT01276184|Text Message
1171534|NCT01276184|Gardasil
1171535|NCT01276145|pudendal artery disease
1171536|NCT01276145|erectile dysfunction
1171537|NCT01276145|coronary angiography
1171538|NCT01276145|coronary disease
1171539|NCT01276145|cardiac
1171540|NCT01276132|percutaneous coronary artery intervention
1171541|NCT01276132|coronary disease
1171542|NCT01276119|CDP6038
1171543|NCT01276119|single-dose
1171544|NCT01276119|pharmacokinetics
1171545|NCT01276119|healthy subjects
1171546|NCT01276106|AC-201
1171547|NCT01276106|Interleukin 1 inhibitor
1171548|NCT01276093|Atrial fibrillation
1171549|NCT01276093|PVI ablation
1171550|NCT01276093|Elderly patients
1171551|NCT01276093|Efficacy
1171552|NCT01276041|MAB 2C4 (PERTUZUMAB)
1171553|NCT01276041|MAB HER 2 (HERCEPTIN) (TRASTUZUMAB)
1171554|NCT01276041|TAXOL (PACLITAXEL)
1171555|NCT01276041|10-142
1171556|NCT01276041|Stage IV HER2 (+) breast cancer
1171557|NCT01276028|Acupuncture
1171558|NCT01276028|Hot Flashes
1171559|NCT01276028|Menopause
1171560|NCT01276028|Vasomotor Symptoms
1171561|NCT01276015|BoNT-A-botulinum neurotoxin type A
1171562|NCT01276015|CMAP-compound muscle action potential
1171563|NCT01276015|CP-cerebral palsy
1171564|NCT01276015|LG-lateral gastrocnemius
1171565|NCT01276015|MG-medial gastrocnemius
1171566|NCT01276015|TA-tibialis anterior
1171567|NCT01276015|PROMS-passive range of movement
1171568|NCT01276015|MAS-modified Ashworth scale
1171569|NCT01276015|EVGS-Edinburgh visual gait scale
1171570|NCT01276015|GMF-CS-gross motor function classification system
1171571|NCT01276002|disrupted duct
1171572|NCT01276002|pancreatic pseudocysts
1171573|NCT01275976|C1-esterase inhibitor
1171574|NCT01275976|Systemic inflammation
1171575|NCT01275976|Sepsis
1171576|NCT01275976|Trauma
1171577|NCT01275976|Multiple Organ Dysfunction Syndrome
1171578|NCT01275976|Cytokines
1171579|NCT01275963|Echocardiography
1171580|NCT01275963|Strain imaging
1171581|NCT01275963|Ventricular Dysfunction
1171582|NCT01275963|Cardiomyopathy
1171583|NCT01275963|Longitudinal left ventricular function
1171584|NCT01275950|Tobacco vendor
1171585|NCT01275950|students
1171586|NCT01275950|knowledge
1171587|NCT01275950|attitude
1171588|NCT01275950|practice
1171589|NCT01275950|direct advertisements
1171590|NCT01275950|surrogate advertisements
1171591|NCT01275924|Syndesmosis
1171592|NCT01275924|Injury
1171593|NCT01275924|Ankle
1171594|NCT01275924|Fracture
1171595|NCT01275898|NIRS
1171596|NCT01275898|cerebral oxygenation
1171597|NCT01275885|cholecalciferol
1171598|NCT01275885|infant
1171599|NCT01275885|bone mineral density
1171600|NCT01275872|guided imagery
1171601|NCT01275872|progressive muscle relaxation
1171602|NCT01275872|complimentary and alternative medicine
1171603|NCT01275872|quality of life
1171604|NCT01275872|stress
1171605|NCT01275872|pain
1171606|NCT01275872|anxiety
1171607|NCT01275859|Neoadjuvant
1171608|NCT01275859|Letrozole
1171609|NCT01275859|Lapatinib
1171610|NCT01275859|Postmenopausal
1171611|NCT01275846|heart failure
1171612|NCT01275846|congestive heart failure
1171613|NCT01275846|telemedicine
1171614|NCT01275833|Implantable cardioverter-defibrillator (ICD) indicated patients
1171615|NCT01275833|First Degree AV block.
1171616|NCT01275820|diabetes, insulin, blood sugar
1171617|NCT01275807|climacteric, climacteric syndrome
1171618|NCT01275794|Type 2 Diabetes
1171619|NCT01275781|Phase 1
1171620|NCT01275781|healthy male volunteers
1171621|NCT01275781|radioactivity
1171622|NCT01275781|excretion
1171623|NCT01275781|metabolism
1171624|NCT01275781|AZD9742
1171625|NCT01275781|amount of radioactive AZD9742 in urine, feces, and vomitus (if appropriate)
1171626|NCT01275768|radio-frequency ablation
1171627|NCT01275768|Malignant jaundice
1171628|NCT01275755|opioid therapy
1171629|NCT01275755|constipation
1171630|NCT01275755|chronic noncancer pain
1171631|NCT01275755|mu opioid receptor antagonist
1171632|NCT01275755|ADL5945
1171633|NCT01275755|Opioid Induced Constipation
1171634|NCT01275742|Heart failure
1171635|NCT01275742|Depression
1171636|NCT01275742|Depressive symptoms
1171637|NCT01275742|Cognitive therapy
1171638|NCT01275742|Hospitalization
1171639|NCT01275742|Quality of life
1171640|NCT01275729|Renal Replacement Therapy
1171641|NCT01275729|Diuretics
1171642|NCT01275729|Biomarkers
1171643|NCT01275729|Renal Insufficiency
1171644|NCT01275729|Furosemide
1171645|NCT01275729|Therapeutic Uses
1171646|NCT01275729|Physiological Effects of Drugs
1171647|NCT01275729|Biological Markers
1171648|NCT01275716|Patient Education
1171649|NCT01275716|coronary artery disease
1171650|NCT01275716|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications.
1171651|NCT01275703|To determine the utility of a noninvasive method of measuring cardiac output during exercise testing in patients with PH
1171652|NCT01275690|cardiac
1171653|NCT01275690|pulmonary hypertension
1171654|NCT01275690|To determine the accuracy of a noninvasive method of measuring cardiac output as compared to the standard invasive approach in patients with PH
1171655|NCT01275651|adenocarcinoma of the prostate
1171656|NCT01275651|recurrent prostate cancer
1171657|NCT01275638|cortisol, prednisolone, adrenal insufficiency, sepsis
1171658|NCT01275625|maraviroc
1171659|NCT01275625|naive
1171660|NCT01275625|hiv
1171661|NCT01275625|zidovudine
1171662|NCT01275625|lamivudine
1171663|NCT01275625|combivir
1171664|NCT01275625|Clade A
1171665|NCT01275612|Mesenchymal Stromal Cells
1171666|NCT01275612|Solid tumors
1171667|NCT01275612|Cisplatin therapy
1171668|NCT01275612|Acute kidney injury
1171669|NCT01275586|NF1
1171670|NCT01275586|plexiform neurofibromas
1171671|NCT01275586|nilotinib
1171672|NCT01275586|Tasigna
1171673|NCT01275573|Repetitive Transcranial Magnetic Stimulation
1171674|NCT01275573|pain threshold
1171675|NCT01275573|Parkinson's disease
1171676|NCT01275573|Pain threshold in Parkinson's disease
1171677|NCT01275547|Patient controlled analgesia
1171678|NCT01275547|Morphine
1171679|NCT01275547|S-Ketamine intranasal
1171680|NCT01275547|Midazolam intranasal
1171681|NCT01275534|Stem cell transplantation
1171682|NCT01275534|Symptom experience
1171683|NCT01275534|Late effects
1171684|NCT01275534|Self-management
1171685|NCT01275508|Subjects with active Crohn's disease
1171686|NCT01275508|Safety and tolerability of FITC-Adalimumab
1171687|NCT01275508|Intestinal topical application
1171688|NCT01275495|Stroke
1171689|NCT01275495|Family Caregivers
1171690|NCT01275495|Cerebrovascular Accident
1171691|NCT01275495|Carers
1171692|NCT01275495|Care Givers
1171693|NCT01275495|Depression
1171694|NCT01275495|Life change events
1171695|NCT01275495|Family health
1171696|NCT01275495|Quality of life
1171697|NCT01275495|Cost
1171698|NCT01275495|Intervention studies
1171699|NCT01275495|Clinical trial
1171700|NCT01275482|Latent Myofascial trigger point.
1171701|NCT01275482|Transverse friction massage
1171702|NCT01275482|Local twitch response
1171703|NCT01275482|Effectiveness
1171704|NCT01275469|Impaired Glucose tolerance
1171705|NCT01275469|OGTT
1171706|NCT01275469|PPARs
1171707|NCT01275456|allergen provocation
1171708|NCT01275456|environmental challenge
1171709|NCT01275456|allergen chamber
1171710|NCT01275456|house dust mite
1171711|NCT01275456|immunotherapy
1171712|NCT01275443|HIV
1171713|NCT01275430|central venous catheters
1171714|NCT01275430|peripherally inserted central catheters (PICC_
1171715|NCT01275430|Electrocardiography (ECG)
1171716|NCT01275430|intravascular ECG
1171717|NCT01275430|Tip Positioning System
1171718|NCT01275417|Acupuncture
1171719|NCT01275404|Erectile Dysfunction
1171720|NCT01275404|focus group
1171721|NCT01275404|Quality of Life
1171722|NCT01275404|10-204
1171723|NCT01275391|Tobacco use
1171724|NCT01275391|Alcohol abuse
1171725|NCT01275391|Drug abuse
1171726|NCT01275391|Substance use
1171727|NCT01275391|Prevention
1171728|NCT01275391|Brief intervention
1171729|NCT01275391|Screening
1171730|NCT01275391|Adolescents
1171731|NCT01275365|Mobility Limitation
1171732|NCT01275365|Low Protein Intake
1171733|NCT01275365|Older Men
1171734|NCT01275365|Testosterone
1171735|NCT01275352|left ventricular hypertrophy
1171736|NCT01275352|heart failure
1171737|NCT01275339|Aortic valve stenosis
1171738|NCT01275339|Tadalafil
1171739|NCT01275339|Phosphodiesterase inhibitors
1171740|NCT01275339|Hypertension, pulmonary
1171741|NCT01275339|Hypertrophy, left ventricular
1171742|NCT01275326|Indoor Air Quality
1171743|NCT01275326|Infectious Aerosols
1171744|NCT01275313|Pressure ulcers
1171745|NCT01275313|wheelchairs
1171746|NCT01275313|wheelchair functional capacity
1171747|NCT01275313|custom-fitted wheelchair
1171748|NCT01275287|Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
1171749|NCT01275287|Complement Activation
1171750|NCT01275274|ANCA
1171751|NCT01275274|Vasculitis
1171752|NCT01275274|Pauci-immune vasculitis
1171753|NCT01275261|Stroke
1171754|NCT01275261|Urinary Tract Infection
1171755|NCT01275248|OCD
1171756|NCT01275248|Obsessive Compulsive Disorder
1171757|NCT01275222|GIST
1171758|NCT01275222|everolimus
1171759|NCT01275222|mTOR
1171760|NCT01275222|Imatinib resistant
1171761|NCT01275222|Imatinib-refractory/resistant gastrointestinal stromal tumors
1171762|NCT01275209|HCD122
1171763|NCT01275209|Lucatumumab
1171764|NCT01275209|CD40
1171765|NCT01275209|Follicular Lymphoma
1171766|NCT01275209|Non-Hodgkin's Lymphoma
1171767|NCT01275209|Antibody
1171768|NCT01275196|Newly diagnosed,
1171769|NCT01275196|Ph+ chronic myeloid leukemia,
1171770|NCT01275196|CML-CP
1171771|NCT01275183|HNSCC
1171772|NCT01275183|SCC
1171773|NCT01275183|head and neck
1171774|NCT01275183|squamous cell
1171775|NCT01275183|nasopharyngeal
1171776|NCT01275157|Absorption
1171777|NCT01275157|Distribution
1171778|NCT01275157|Metabolism
1171779|NCT01275157|Excretion
1171780|NCT01275157|Mass balance
1171781|NCT01275157|Metabolic profile
1171782|NCT01275157|Radiolabeled study
1171783|NCT01275157|14C
1171784|NCT01275131|Insulin analog
1171785|NCT01275131|Type 1 diabetes mellitus
1171786|NCT01275131|Pharmacokinetic
1171787|NCT01275131|Glucodynamic
1171788|NCT01275131|Phase 1
1171789|NCT01275092|robotic-assisted PCI
1171790|NCT01275092|coronary intervention
1171791|NCT01275092|CorPath PRECISE
1171792|NCT01275092|PCI
1171793|NCT01275079|tonsillectomy
1171794|NCT01275079|nasalance
1171795|NCT01275079|tonsil volume
1171796|NCT01275079|Thai
1171797|NCT01275079|adult
1171798|NCT01275066|Mucopolysaccharidosis IV type A
1171799|NCT01275066|MPS IV Type A
1171800|NCT01275066|Mucopolysaccharidosis IVA
1171801|NCT01275066|MPS IVA
1171802|NCT01275066|Morquio A Syndrome
1171803|NCT01275066|Lysosomal Storage Disorder
1171804|NCT01275066|LSD
1171805|NCT01275066|N-acetylgalactosamine-6-sulfatase
1171806|NCT01275066|N-acetylgalactosamine-6-sulfate sulfatase
1171807|NCT01275066|galactose-6-sulfatase
1171808|NCT01275066|GALNS
1171809|NCT01275066|enzyme replacement therapy
1171810|NCT01275066|ERT
1171811|NCT01275053|Leptin
1171812|NCT01275053|In Vivo
1171813|NCT01275053|Diabetic
1171814|NCT01275053|Obese
1171815|NCT01275053|Lean
1171816|NCT01275040|diabetes
1171817|NCT01275040|mobile screening
1171818|NCT01275040|complications
1171819|NCT01275040|primary care
1171820|NCT01275040|specialised care
1171821|NCT01275040|quality of care
1171822|NCT01275027|diabetes
1171823|NCT01275027|blood sugar
1171824|NCT01275027|insulin
1171825|NCT01275027|nutritional supplement
1171826|NCT01275027|nutraceutical
1171827|NCT01275014|TMJ
1171828|NCT01275014|corticosteroids
1171829|NCT01275014|osteoarthritis
1171830|NCT01275014|arthrocentesis
1171831|NCT01275014|pain
1171832|NCT01275001|brain
1171833|NCT01275001|brain development
1171834|NCT01275001|MRI
1171835|NCT01275001|preschool children
1171836|NCT01275001|cortical mantle thickness
1171837|NCT01275001|hippocampal volume
1171838|NCT01274988|Opiate dependence
1171839|NCT01274988|Deep brain stimulation
1171840|NCT01274988|Nucleus accumbens
1171841|NCT01274949|LI-ESWT
1171842|NCT01274949|Erectile Dysfunction
1171843|NCT01274949|Radical Prostatectomy
1171844|NCT01274949|Non PDE5 inhibitor responders
1171845|NCT01274949|Shock wave
1171846|NCT01274923|Erectile dysfunction
1171847|NCT01274923|Low Intensity Shock Wave
1171848|NCT01274910|Fish Oil
1171849|NCT01274910|Knee
1171850|NCT01274910|Analgetics
1171851|NCT01274897|Meningococcal
1171852|NCT01274897|ACWY-CRM
1171853|NCT01274897|Conjugate Vaccine
1171854|NCT01274897|Meningitis
1171855|NCT01274897|Adolescents
1171856|NCT01274897|Persistence
1171857|NCT01274897|Adults
1171858|NCT01274884|Acromioclavicular
1171859|NCT01274884|Injury
1171860|NCT01274884|Dislocation
1171861|NCT01274884|Surgery
1171862|NCT01274871|Thoracotomy
1171863|NCT01274871|Chronic Pain
1171864|NCT01274871|persistent post-surgical pain
1171865|NCT01274858|persistent pain
1171866|NCT01274858|neuropathic pain
1171867|NCT01274858|Thoracotomy
1171868|NCT01274858|Chronic Pain
1171869|NCT01274845|Meconium aspiration syndrome
1171870|NCT01274845|Heliox
1171871|NCT01274845|Mechanical ventilation
1171872|NCT01274845|Newborn
1171873|NCT01274832|Parkinson
1171874|NCT01274832|DBS of STN
1171875|NCT01274832|PD
1171876|NCT01274832|Deep Brain stimulation of STN
1171877|NCT01274832|Early treatment
1171878|NCT01274819|delirium
1171879|NCT01274819|confusion
1171880|NCT01274806|breast cancer
1171881|NCT01274806|physical therapy
1171882|NCT01274806|massage
1171883|NCT01274806|core stability
1171884|NCT01274793|functional constipation
1171885|NCT01274793|functional diarrhea
1171886|NCT01274793|acupuncture
1171887|NCT01274754|neuroprotection
1171888|NCT01274754|erythromycin
1171889|NCT01274754|neurocognitive assessment
1171890|NCT01274741|Posttraumatic stress disorder
1171891|NCT01274741|Substance use disorder
1171892|NCT01274741|Treatment efficacy
1171893|NCT01274741|Randomized trial
1171894|NCT01274728|Acute myocardial infarction
1171895|NCT01274728|Primary percutaneous coronary intervention
1171896|NCT01274728|Drug-eluting balloon
1171897|NCT01274728|Bivalirudin
1171898|NCT01274715|Behavioral health coaching
1171899|NCT01274715|Diabetes
1171900|NCT01274715|Emotional health
1171901|NCT01274702|History of
1171902|NCT01274702|Patients
1171903|NCT01274702|acute
1171904|NCT01274689|lagophthalmos
1171905|NCT01274689|parotis tumor
1171906|NCT01274689|m. orbicularis oculi paresis
1171907|NCT01274676|stenting
1171908|NCT01274676|carotid plaque
1171909|NCT01274676|stenosis
1171910|NCT01274676|angioplasty
1171911|NCT01274663|Single Ascending Dose
1171912|NCT01274663|Phase 1
1171913|NCT01274663|Safety and Tolerability
1171914|NCT01274663|PK
1171915|NCT01274663|Healthy Subjects
1171916|NCT01274637|postpartum
1171917|NCT01274637|low molecular weight heparin
1171918|NCT01274637|venous thromboembolism
1171919|NCT01274637|prophylaxis
1171920|NCT01274637|Dalteparin Sodium
1171921|NCT01274624|Colorectal
1171922|NCT01274624|Cancer
1171923|NCT01274624|REOLYSIN®
1171924|NCT01274624|Chemotherapy
1171925|NCT01274624|FOLFIRI
1171926|NCT01274624|Reovirus
1171927|NCT01274624|Oncolytic virus
1171928|NCT01274624|Fluorouracil
1171929|NCT01274624|Irinotecan
1171930|NCT01274624|Leucovorin
1171931|NCT01274624|Bevacizumab
1171932|NCT01274611|sweating
1171933|NCT01274611|sweat
1171934|NCT01274611|underarm
1171935|NCT01274611|axillary
1171936|NCT01274611|hyperhidrosis
1171937|NCT01274611|botox
1171938|NCT01274611|liposuction
1171939|NCT01274611|suction-curettage
1171940|NCT01274611|suction
1171941|NCT01274611|curettage
1171942|NCT01274598|Probiotics
1171943|NCT01274598|Safety
1171944|NCT01274598|Elderly
1171945|NCT01274598|Lactobacillus
1171946|NCT01274598|LGG
1171947|NCT01274559|MK-0524A/ER
1171948|NCT01274559|Hypercholesterolemia
1171949|NCT01274559|Dyslipidemia
1171950|NCT01274559|Niacin
1171951|NCT01274559|Laropiprant
1171952|NCT01274533|ATLL
1171953|NCT01274520|ECD liver transplant allografts
1171954|NCT01274520|Hypothermic machine perfusion
1171955|NCT01274520|Cold storage preservation
1171956|NCT01274520|liver transplant
1171957|NCT01274520|portable bypass system
1171958|NCT01274520|machine perfusion preservation
1171959|NCT01274520|extended criteria liver
1171960|NCT01274507|Asthma
1171961|NCT01274507|Pulmonary Disease, Chronic Obstructive
1171962|NCT01274507|Healthy
1171963|NCT01274507|Longitudinal Study
1171964|NCT01274507|Bronchoscopy
1171965|NCT01274494|Hypertension
1171966|NCT01274481|Acute Respiratory Distress Syndrome
1171967|NCT01274481|Acute Lung Injury
1171968|NCT01274481|pulmonary hypertension
1171969|NCT01274481|oxygenation
1171970|NCT01274481|lung mechanics
1171971|NCT01274481|gas exchange
1171972|NCT01274455|Gene therapy
1171973|NCT01274455|pancreatic carcinoma
1171974|NCT01274455|gemcitabine
1171975|NCT01274455|endoscopic ultrasound
1171976|NCT01274442|dental implant
1171977|NCT01274429|Peanut allergy
1171978|NCT01274429|Immunotherapy
1171979|NCT01274429|OIT
1171980|NCT01274416|Anorexia Nervosa
1171981|NCT01274416|Eating Disorder
1171982|NCT01274416|Treatment
1171983|NCT01274416|Acceptance and Commitment Therapy
1171984|NCT01274416|Separated Family Treatment
1171985|NCT01274403|Multiple Myeloma
1171986|NCT01274403|Elderly patients
1171987|NCT01274390|Cardiac Surgery
1171988|NCT01274390|Red Blood Cell
1171989|NCT01274390|Transfusion
1171990|NCT01274390|Oxygen Saturation
1171991|NCT01274390|Microvascular Flow
1171992|NCT01274377|nonmyeloablative allogeneic stem cell transplantation
1171993|NCT01274377|cytomegalovirus
1171994|NCT01274377|donor lymphocyte infusions
1171995|NCT01274377|cytotoxic T lymphocyte
1171996|NCT01274364|Diabetes
1171997|NCT01274364|Structured Care
1171998|NCT01274351|First line treatment
1171999|NCT01274351|newly diagnosed
1172000|NCT01274351|Philadelphia chromosome positive
1172001|NCT01274351|Chronic Myelogenous Leukemia
1172002|NCT01274351|Ph+
1172003|NCT01274351|CML-CP
1172004|NCT01274351|major molecular response
1172005|NCT01274351|Social risk
1172006|NCT01274325|asthma
1172007|NCT01274312|Somato-sensory reflex arch
1172008|NCT01274312|Spinal cord injury
1172009|NCT01274312|Xiao Procedure
1172010|NCT01274299|Infants
1172011|NCT01274299|morphometry
1172012|NCT01274299|face
1172013|NCT01274299|3D
1172014|NCT01274286|hospital accreditation
1172015|NCT01274286|patient-centered
1172016|NCT01274286|healthcare quality index
1172017|NCT01274286|documentary analysis
1172018|NCT01274286|meta analysis
1172019|NCT01274273|Bevacizumab
1172020|NCT01274273|interleukin-2
1172021|NCT01274273|interferon-alpha
1172022|NCT01274260|child
1172023|NCT01274260|infant
1172024|NCT01274260|lung injury
1172025|NCT01274260|inflammation
1172026|NCT01274260|pneumonia
1172027|NCT01274260|ventilator
1172028|NCT01274247|Tongue-tie
1172029|NCT01274247|Ankyloglossia
1172030|NCT01274234|EPC capturing sirolimus eluting COMBO stent
1172031|NCT01274234|Optical coherence tomography (OCT)
1172032|NCT01274234|Early neointimal healing and stent coverage
1172033|NCT01274234|Late neointimal thickness, neointimal area, and lumen loss
1172034|NCT01274208|Gaucher disease, Hepatitis C , Glucocerebroside immunity
1172035|NCT01274195|Hematopoietic stem cell transplantation
1172036|NCT01274156|Erectile dysfunction
1172037|NCT01274156|Low Intensity Shock Wave
1172038|NCT01274143|Colorectal
1172039|NCT01274143|Cancer
1172040|NCT01274143|Colon
1172041|NCT01274143|Rectal
1172042|NCT01274143|Behavioral Intervention
1172043|NCT01274143|Screening
1172044|NCT01274143|Motivational Interviewing
1172045|NCT01274143|Extended Parallel Process Model
1172046|NCT01274143|Implementation Intentions
1172047|NCT01274143|Family CARE
1172048|NCT01274117|Chronic renal failure
1172049|NCT01274117|Basilic vein transposition fistula
1172050|NCT01274104|statin-related myalgia
1172051|NCT01274104|high cholesterol
1172052|NCT01274091|Gene-diet interaction
1172053|NCT01274091|PPARgamma gene
1172054|NCT01274091|Pro12Ala
1172055|NCT01274091|Fatty acids
1172056|NCT01274091|Dietary modification
1172057|NCT01274091|Insulin sensitivity
1172058|NCT01274091|Glucose metabolism
1172059|NCT01274078|inflammation
1172060|NCT01274078|lipids
1172061|NCT01274078|CRP
1172062|NCT01274065|psychiatry
1172063|NCT01274065|psychiatric illness
1172064|NCT01274065|developmental disability
1172065|NCT01274065|mental health
1172066|NCT01274065|medication burden
1172067|NCT01274052|Gestational diabetes mellitus
1172068|NCT01274052|Meal test
1172069|NCT01274052|Incretin hormones
1172070|NCT01274052|Glucagon-like peptide-1 (GLP-1)
1172071|NCT01274052|Glucose-dependent insulinotropic polypeptide
1172072|NCT01274052|Insulin
1172073|NCT01274052|C-peptide
1172074|NCT01274052|Glucagon
1172075|NCT01274026|phenylketonuria
1172076|NCT01274026|PKU
1172077|NCT01274026|phenylalanine
1172078|NCT01274026|neurotransmitters
1172079|NCT01274026|gene
1172080|NCT01274026|Kuvan
1172081|NCT01274026|sapropterin
1172086|NCT01274000|diarrhea
1172087|NCT01274000|IBS
1172088|NCT01274000|Colonic disease
1172089|NCT01274000|YM060
1172090|NCT01274000|Ramosetron
1172091|NCT01273974|intradermal influenza vaccine
1172092|NCT01273974|hemodialysis patients
1172093|NCT01273935|Aspirin, Acute Cerebrovascular Ischemia, Platelet Function
1172094|NCT01273922|NDV-3
1172095|NCT01273922|vaccine
1172096|NCT01273922|Staphylococcus aureus
1172097|NCT01273922|MRSA
1172098|NCT01273922|Candida
1172099|NCT01273909|Breast Cancer
1172100|NCT01273909|BRACA1/2 Genotype
1172101|NCT01273909|Acquired Lymphedema
1172102|NCT01273909|Congenital Lymphedema
1172103|NCT01273896|STA-9090
1172104|NCT01273896|advanced breast cancer
1172105|NCT01273896|10-145
1172106|NCT01273883|hearing
1172107|NCT01273883|magnesium
1172108|NCT01273870|hemodialysis
1172109|NCT01273870|high-flux-dialyzer
1172110|NCT01273870|performance
1172111|NCT01273870|blood compatibility
1172112|NCT01273857|Cardiac progenitor cells
1172113|NCT01273857|Cell therapy
1172114|NCT01273857|Hypoplastic Left Heart Syndrome
1172115|NCT01273857|Single Ventricle
1172116|NCT01273857|Norwood
1172117|NCT01273857|Sano modification
1172118|NCT01273857|Glenn
1172119|NCT01273857|Fontan
1172120|NCT01273844|hematopoietic stem cell transplantation
1172121|NCT01273844|amyloidosis
1172122|NCT01273844|Bortezomib
1172123|NCT01273831|intraocular pressure, anesthesia,cisatracurium,atracurium.
1172124|NCT01273818|inguinal hernia
1172125|NCT01273818|infection prophylaxis
1172126|NCT01273818|topical gentamicin
1172127|NCT01273805|metastatic pancreatic cancer
1172128|NCT01273805|hydroxychloroquine
1172129|NCT01273779|sepsis
1172130|NCT01273779|talactoferrin
1172131|NCT01273779|lactoferrin
1172132|NCT01273779|recombinant human lactoferrin
1172133|NCT01273753|End-stage renal disease
1172134|NCT01273753|Hemodialysis
1172135|NCT01273753|Bioimpedance analysis
1172136|NCT01273753|Blood volume monitoring
1172137|NCT01273740|PTFE bypass
1172138|NCT01273740|femoro-popliteal
1172139|NCT01273740|femoro-crural
1172140|NCT01273740|popliteal arteries
1172141|NCT01273740|crural arteries
1172142|NCT01273740|external support
1172143|NCT01273740|crtical limb ischemia
1172144|NCT01273727|epiretinal membrane
1172145|NCT01273727|macular pucker
1172146|NCT01273727|cellophane maculopathy
1172147|NCT01273727|macular edema
1172148|NCT01273727|retinal edema
1172149|NCT01273727|ozurdex
1172150|NCT01273727|dexamethasone
1172151|NCT01273727|intravitreal implant
1172152|NCT01273714|benign thyroid disease
1172153|NCT01273714|incidental thyroid cancer
1172154|NCT01273714|recurrent goiter
1172155|NCT01273714|revision thyroid surgery
1172156|NCT01273701|amphetamine
1172157|NCT01273701|methamphetamine
1172158|NCT01273701|psychosocial intervention
1172159|NCT01273701|contingency management
1172160|NCT01273701|slow prosecution
1172161|NCT01273701|substance use disorder
1172162|NCT01273688|pain
1172163|NCT01273688|elbow
1172164|NCT01273688|tendinopathy
1172165|NCT01273675|Hypertension
1172166|NCT01273675|Primary disease
1172167|NCT01273662|HCC
1172168|NCT01273649|muscle activation
1172169|NCT01273649|ACL reconstruction
1172170|NCT01273649|cryotherapy
1172171|NCT01273649|TENS
1172172|NCT01273636|Endometrial hyperplasia
1172173|NCT01273636|Hysterectomy
1172174|NCT01273636|Endometrial carcinoma
1172175|NCT01273623|PAD, Peripheral Arterial Disease, Calcium, Atherectomy, Jetstream
1172176|NCT01273610|Breast Neoplasms
1172177|NCT01273610|HER2 protein, human
1172178|NCT01273610|Geriatric Health Services
1172179|NCT01273610|Antineoplastic Agents, Combined
1172180|NCT01273610|Geriatric Assessment
1172181|NCT01273610|Pharmacokinetics
1172182|NCT01273610|Toxicity
1172183|NCT01273610|Patient Adherence
1172184|NCT01273597|Parathyroid hormone,Kidney failure, chronic,Hyperparathyroidism, secondary
1172185|NCT01273584|Metformin, obese, pregnancy, gestational diabetes
1172186|NCT01273571|Canagliflozin
1172187|NCT01273571|Metformin (GLUCOPHAGE IR)
1172188|NCT01273571|Pharmacokinetics
1172189|NCT01273571|Pharmacodynamics
1172190|NCT01273558|Canagliflozin
1172191|NCT01273558|Renal threshold for glucose
1172192|NCT01273558|Pharmacodynamics
1172193|NCT01273545|Dapoxetine hydrochloride (PRILIGY)
1172194|NCT01273545|Premature ejaculation
1172195|NCT01273532|tapentadol
1172196|NCT01273532|NUCYNTA
1172197|NCT01273532|CG5503
1172198|NCT01273532|R331333
1172199|NCT01273532|pharmacokinetics
1172200|NCT01273532|healthy volunteer
1172201|NCT01273519|Ankylosing
1172202|NCT01273519|Rheumatoid
1172203|NCT01273519|Antibodies
1172204|NCT01273519|Arthritis
1172205|NCT01273519|Pain
1172206|NCT01273519|Antirheumatic Agents
1172207|NCT01273519|Psoriatic
1172208|NCT01273519|Spondylitis
1172209|NCT01273519|Monoclonals
1172210|NCT01273506|tapentadol
1172211|NCT01273506|NUCYNTA
1172212|NCT01273506|CG5503
1172213|NCT01273506|R331333
1172214|NCT01273506|pharmacokinetics
1172215|NCT01273506|healthy volunteer
1172216|NCT01273493|Trabectedin, YONDELIS
1172217|NCT01273493|Antineoplastic Agents
1172218|NCT01273493|Solid tumors
1172219|NCT01273493|Locally advanced or metastatic disease
1172220|NCT01273493|Chemotherapy
1172221|NCT01273493|Pharmacokinetics
1172222|NCT01273493|Hepatic Dysfunction
1172223|NCT01273480|Trabectedin, YONDELIS
1172224|NCT01273480|Rifampin (RIFADIN)
1172225|NCT01273480|Antineoplastic Agents
1172226|NCT01273480|Solid tumors
1172227|NCT01273480|Locally advanced or metastatic disease
1172228|NCT01273480|Chemotherapy
1172229|NCT01273480|Pharmacokinetics
1172230|NCT01273467|Ischemic Cerebral Infarction
1172231|NCT01273467|Stroke
1172232|NCT01273467|CNTO0007
1172233|NCT01273467|42037788
1172234|NCT01273454|Open-label
1172235|NCT01273454|Non-interventional
1172236|NCT01273454|OROS hydromorphone
1172237|NCT01273454|Korean cancer patients
1172238|NCT01273415|hormone receptor-positive breast cancer
1172239|NCT01273415|nomogram
1172240|NCT01273415|Ki67
1172241|NCT01273415|Effects of Chemotherapy
1172242|NCT01273402|colorectal cancer
1172243|NCT01273402|TF2 (Recombinant, humanized Tri-Fab bsMAb composed of 2 humanized MN-14 anti-CEA Fab x and one 679 anti-HSG Fab)
1172244|NCT01273402|IMP288 (DOTA-di-HSG hapten-peptide for 111In/90Y labeling)
1172245|NCT01273389|Lupus nephritis
1172246|NCT01273389|CNTO 136
1172247|NCT01273389|Sirukumab
1172248|NCT01273389|Kidney diseases
1172249|NCT01273389|Proteinuria
1172250|NCT01273389|Glomerulonephritis
1172251|NCT01273376|MDD
1172252|NCT01273376|Depression
1172253|NCT01273376|Major Depression
1172254|NCT01273363|Asthma
1172255|NCT01273363|Asthma in Children
1172256|NCT01273350|internal carotid artery
1172257|NCT01273350|common carotid artery
1172258|NCT01273350|bruit
1172259|NCT01273350|tia
1172260|NCT01273337|Stroke
1172261|NCT01273337|Ischemia
1172262|NCT01273337|Ischemic Stroke
1172263|NCT01273337|Middle Cerebral Artery
1172264|NCT01273337|MCA
1172265|NCT01273337|Stem Cells
1172266|NCT01273337|Stem Cell
1172267|NCT01273337|Autologous Bone Marrow
1172268|NCT01273337|Ipsilateral MCA
1172269|NCT01273324|Osteoarthritis
1172270|NCT01273311|Brain Aging
1172271|NCT01273311|Diabetes
1172272|NCT01273311|Aging
1172273|NCT01273311|Obesity
1172274|NCT01273311|CARDIA
1172275|NCT01273298|chronic obstructive pulmonary disease
1172276|NCT01273298|exercise
1172277|NCT01273298|dynamic hyperinflation
1172278|NCT01273298|cardioselective beta blockers
1172279|NCT01273272|Cognitive Behavior Therapy
1172280|NCT01273272|Early dementia, Alzheimer type
1172281|NCT01273259|Hypertension, pulmonary
1172282|NCT01273259|DHEA
1172283|NCT01273259|six-minute walk test
1172284|NCT01273259|pulmonary arterial pressure
1172285|NCT01273220|Epidemiology
1172286|NCT01273220|Epidemiologic Survey
1172287|NCT01273220|Alcohol
1172288|NCT01273207|Peripheral Blood Stem Cell Transplant
1172289|NCT01273207|Inhaled Cyclosporine
1172290|NCT01273207|Graft-Versus-Host Disease
1172291|NCT01273207|Bone Marrow Transplant
1172292|NCT01273207|Lung Transplantation
1172293|NCT01273207|Bronchiolitis Obliterans
1172294|NCT01273207|Graft Versus Host Disease
1172295|NCT01273194|Palliative Care
1172296|NCT01273194|Survey
1172297|NCT01273194|Quality of Life
1172298|NCT01273194|Attitudes
1172299|NCT01273194|Pediatric Cancer
1172300|NCT01273181|Immunotherapy
1172301|NCT01273181|Gene Therapy
1172302|NCT01273181|Metastatic Cancer
1172303|NCT01273181|Clinical Response
1172304|NCT01273181|Metastatic Melanoma
1172408|NCT01272999|Acute otitis media
1172305|NCT01273181|Metastatic Renal Cell Cancer
1172306|NCT01273168|Pharmacokinetics
1172307|NCT01273168|Advanced Cancer
1172308|NCT01273168|Cytochrome P 450
1172309|NCT01273168|Selective Estrogen Receptor Modulator
1172310|NCT01273168|Tamoxifen Metabolite
1172311|NCT01273168|Gynecologic Cancer
1172312|NCT01273168|Breast Cancer
1172313|NCT01273168|Desmoid Tumor
1172314|NCT01273168|Endometrial Cancer
1172315|NCT01273168|Ovarian Cancer
1172316|NCT01273168|Uterine Cancer
1172317|NCT01273168|Fallopian Tube Cancer
1172318|NCT01273168|Peritoneal Cancer
1172319|NCT01273155|Histone Deacetylase Inhibitor
1172320|NCT01273155|Liver Dysfunction
1172321|NCT01273155|Pharmacokinetics
1172322|NCT01273155|UGT1A1 Polymorphisms
1172323|NCT01273155|Solid Tumor
1172324|NCT01273155|Cancer
1172325|NCT01273155|Lymphoma
1172326|NCT01273142|Human Immunodeficiency Virus, liver toxicity, hapatitis co-infection
1172327|NCT01273129|Neurosurgery
1172328|NCT01273129|Childhood Epilepsy
1172329|NCT01273129|Epilepsy
1172330|NCT01273129|Frontal Lobe Epilepsy
1172331|NCT01273129|Temporal Lobe Epilepsy
1172332|NCT01273116|frailty
1172333|NCT01273116|integrated care
1172334|NCT01273116|hospital
1172335|NCT01273116|geriatrics
1172336|NCT01273116|hospital-wide intervention
1172337|NCT01273090|unspecified childhood solid tumor, protocol specific
1172338|NCT01273090|recurrent childhood anaplastic large cell lymphoma
1172339|NCT01273090|recurrent childhood grade III lymphomatoid granulomatosis
1172340|NCT01273090|recurrent childhood large cell lymphoma
1172341|NCT01273090|recurrent childhood lymphoblastic lymphoma
1172342|NCT01273090|recurrent childhood small noncleaved cell lymphoma
1172343|NCT01273090|recurrent/refractory childhood Hodgkin lymphoma
1172344|NCT01273090|recurrent childhood brain stem glioma
1172345|NCT01273090|recurrent childhood anaplastic astrocytoma
1172346|NCT01273090|recurrent childhood anaplastic oligoastrocytoma
1172347|NCT01273090|recurrent childhood anaplastic oligodendroglioma
1172348|NCT01273090|recurrent childhood cerebellar astrocytoma
1172349|NCT01273090|recurrent childhood cerebral astrocytoma
1172350|NCT01273090|recurrent childhood diffuse astrocytoma
1172351|NCT01273090|recurrent childhood fibrillary astrocytoma
1172352|NCT01273090|recurrent childhood gemistocytic astrocytoma
1172353|NCT01273090|recurrent childhood giant cell glioblastoma
1172354|NCT01273090|recurrent childhood glioblastoma
1172355|NCT01273090|recurrent childhood gliomatosis cerebri
1172356|NCT01273090|recurrent childhood gliosarcoma
1172357|NCT01273090|recurrent childhood oligoastrocytoma
1172358|NCT01273090|recurrent childhood oligodendroglioma
1172359|NCT01273090|recurrent childhood pilocytic astrocytoma
1172360|NCT01273090|recurrent childhood pilomyxoid astrocytoma
1172361|NCT01273090|recurrent childhood pleomorphic xanthoastrocytoma
1172362|NCT01273090|recurrent childhood protoplasmic astrocytoma
1172363|NCT01273090|recurrent childhood subependymal giant cell astrocytoma
1172364|NCT01273090|recurrent childhood visual pathway and hypothalamic glioma
1172365|NCT01273090|recurrent childhood visual pathway glioma
1172366|NCT01273090|childhood pineal parenchymal tumor
1172367|NCT01273090|recurrent childhood central nervous system embryonal tumor
1172368|NCT01273090|childhood central nervous system choriocarcinoma
1172369|NCT01273090|childhood central nervous system germ cell tumor
1172370|NCT01273090|childhood central nervous system germinoma
1172371|NCT01273090|childhood central nervous system mixed germ cell tumor
1172372|NCT01273090|childhood central nervous system teratoma
1172373|NCT01273090|childhood central nervous system yolk sac tumor
1172374|NCT01273090|recurrent childhood pineoblastoma
1172375|NCT01273090|childhood diffuse large cell lymphoma
1172376|NCT01273090|childhood nasal type extranodal NK/T-cell lymphoma
1172377|NCT01273090|childhood nodular lymphocyte predominant Hodgkin lymphoma
1172378|NCT01273090|angioimmunoblastic T-cell lymphoma
1172379|NCT01273090|childhood Burkitt lymphoma
1172380|NCT01273090|childhood grade III lymphomatoid granulomatosis
1172381|NCT01273090|childhood immunoblastic large cell lymphoma
1172382|NCT01273090|cutaneous B-cell non-Hodgkin lymphoma
1172383|NCT01273090|hepatosplenic T-cell lymphoma
1172384|NCT01273090|intraocular lymphoma
1172385|NCT01273090|noncutaneous extranodal lymphoma
1172386|NCT01273090|peripheral T-cell lymphoma
1172387|NCT01273090|post-transplant lymphoproliferative disorder
1172388|NCT01273090|recurrent cutaneous T-cell non-Hodgkin lymphoma
1172389|NCT01273090|recurrent mycosis fungoides/Sezary syndrome
1172390|NCT01273090|small intestine lymphoma
1172391|NCT01273077|Rotavirus
1172392|NCT01273077|Rotarix
1172393|NCT01273064|HCV
1172394|NCT01273064|Null Responders
1172395|NCT01273051|Rectal Cancer
1172396|NCT01273051|Radiochemotherapy
1172397|NCT01273051|TEM
1172398|NCT01273051|Organ preservation
1172399|NCT01273025|pharmacokinetic
1172400|NCT01273025|lime powder regimen
1172401|NCT01273025|kidney stone
1172402|NCT01273025|Oxidative stress
1172403|NCT01273012|probiotic
1172404|NCT01273012|cost-effectiveness
1172405|NCT01273012|diarrhea
1172406|NCT01273012|children
1172407|NCT01273012|Sum of the monetary cost of the hospitalization
1172409|NCT01272999|Prevnar 13
1172410|NCT01272999|Streptococcus pneumoniae
1172411|NCT01272986|Determination of the level of oxidised LDL by measuring the level of IgG in Blood
1172412|NCT01272960|Contraception
1172413|NCT01272960|Postnatal care
1172414|NCT01272947|Blunt soft tissue injury/contusion
1172415|NCT01272934|Ankle Sprain, soft tissue injury
1172416|NCT01272895|OCT images
1172417|NCT01272895|Stent strut coverage
1172418|NCT01272895|Endothelialization
1172419|NCT01272895|Neointimal thickness, area and hyperplasia
1172420|NCT01272895|Stent malapposition
1172421|NCT01272830|total joint arthroplasty
1172422|NCT01272830|synovitis
1172423|NCT01272830|ALVAL
1172424|NCT01272830|osteolysis
1172425|NCT01272830|periprosthetic metallosis
1172426|NCT01272817|Nonmyeloablative transplant
1172427|NCT01272817|Allogeneic transplant
1172428|NCT01272817|Transplant
1172429|NCT01272804|Pharmacokinetics PK Pharmacodynamics PD T2DM Phase 1 Type 2 diabetes mellitus safety and tolerability
1172430|NCT01272791|metastatic stage IV pancreatic cancer
1172431|NCT01272765|obesity
1172432|NCT01272765|weight loss
1172433|NCT01272765|weight management
1172434|NCT01272765|anti-psychotic medication
1172435|NCT01272765|Zyprexa
1172436|NCT01272765|Seroquel
1172437|NCT01272765|Risperdal
1172438|NCT01272752|obesity
1172439|NCT01272752|weight loss
1172440|NCT01272752|weight management
1172441|NCT01272752|anti-psychotic medication
1172442|NCT01272752|nutriceutical
1172443|NCT01272739|obesity
1172444|NCT01272739|weight loss
1172445|NCT01272739|weight management
1172446|NCT01272739|overweight
1172447|NCT01272739|nutriceutical
1172448|NCT01272687|Parkinson Disease
1172449|NCT01272687|Parkinsonian Disorders
1172450|NCT01272687|Brain Diseases
1172451|NCT01272687|Central Nervous System Diseases
1172452|NCT01272687|Nervous System Diseases
1172453|NCT01272687|Neurodegenerative Diseases
1172454|NCT01272661|breastfeeding
1172455|NCT01272661|low-income
1172456|NCT01272661|high-risk
1172457|NCT01272661|African-American
1172458|NCT01272661|health disparity
1172459|NCT01272648|Rehabilitation
1172460|NCT01272648|Coping
1172461|NCT01272648|Prostate cancer
1172462|NCT01272648|Nursing
1172463|NCT01272648|Physiotherapy
1172464|NCT01272648|Pelvic floor exercises
1172465|NCT01272648|Motivational Interviewing
1172466|NCT01272635|Asthma
1172467|NCT01272635|Wheezing
1172468|NCT01272635|Respiratory Tract Illness
1172469|NCT01272635|Azythromycin
1172470|NCT01272635|Prednisolone
1172471|NCT01272635|Preschool-age
1172472|NCT01272622|Quality of life
1172473|NCT01272622|Endocrinology
1172474|NCT01272622|Oncology
1172475|NCT01272622|Hypothalamus
1172476|NCT01272622|Irradiation
1172477|NCT01272622|Neurosurgery
1172478|NCT01272622|Pediatric Brain tumors
1172479|NCT01272622|Randomized trial
1172480|NCT01272596|Multiple Sclerosis
1172481|NCT01272596|Visual Contrast Acuity
1172482|NCT01272596|Visual Contrast Sensitivity
1172483|NCT01272596|Sloan Charts
1172484|NCT01272583|Type 1 diabetes
1172485|NCT01272583|DPP-4 inhibitor
1172486|NCT01272583|Glucagon
1172487|NCT01272570|breast
1172488|NCT01272570|oral
1172489|NCT01272570|cancer
1172490|NCT01272557|HCC
1172491|NCT01272544|Dental caries
1172492|NCT01272544|Epidemiology
1172493|NCT01272544|Gingivitis
1172494|NCT01272544|Oral health
1172495|NCT01272531|pharmacogenetics
1172496|NCT01272531|bipolar disorders
1172497|NCT01272531|affective disorders
1172498|NCT01272531|mood disorders
1172499|NCT01272531|pharmacologic actions
1172500|NCT01272531|psychotropic drugs
1172501|NCT01272531|antimanic agents
1172502|NCT01272531|antidepressant agents
1172503|NCT01272531|lithium
1172504|NCT01272531|lithium carbonate
1172505|NCT01272531|Lithobid
1172506|NCT01272531|Eskalith
1172507|NCT01272531|divalproex
1172508|NCT01272531|divalproex sodium
1172509|NCT01272531|Depakote
1172510|NCT01272531|valproate
1172511|NCT01272518|mood disorder chaos theory heart rate variability mania bipolar disorder
1172512|NCT01272479|hemodialysis
1172513|NCT01272479|hepatitis C
1172514|NCT01272479|inflammation
1172515|NCT01272479|iron stores
1172516|NCT01272479|prohepcidin
1172517|NCT01272466|multiple myeloma
1172518|NCT01272466|vaccination
1172519|NCT01272466|antiapoptotic proteins
1172520|NCT01272466|proteasome inhibition
1172521|NCT01272453|coronary artery disease
1172522|NCT01272453|CT scan
1172523|NCT01272453|coronary angiography
1172524|NCT01272453|chest pain
1172525|NCT01272453|aortic aneurysm
1172526|NCT01272453|pulmonary embolism
1172527|NCT01272440|PEG-asparaginase
1172528|NCT01272440|children
1172529|NCT01272440|pharmacokinetics
1172530|NCT01272440|antibodies
1172531|NCT01272440|acute lymphoblastic leukaemia
1172532|NCT01272440|adverse effects
1172533|NCT01272414|Eyelid retraction
1172534|NCT01272414|Botulinum Toxins
1172535|NCT01272388|Aortic valve stenosis
1172536|NCT01272388|Tadalafil
1172537|NCT01272388|Phosphodiesterase inhibitors
1172538|NCT01272388|Hypertension, pulmonary
1172539|NCT01272388|Hypertrophy, left ventricular
1172540|NCT01272362|Indacaterol
1172541|NCT01272362|COPD
1172542|NCT01272362|LABA
1172543|NCT01272362|Reversibility
1172544|NCT01272349|spinal cord injury
1172545|NCT01272349|walking
1172546|NCT01272349|low oxygen
1172547|NCT01272349|air
1172548|NCT01272349|strength
1172549|NCT01272336|spinal cord injury, low oxygen, strength, motor control
1172550|NCT01272323|Cat allergy
1172551|NCT01272323|Rhinoconjunctivitis
1172552|NCT01272310|Chronic Hepatitis C
1172553|NCT01272310|Combination Therapy
1172554|NCT01272310|Hydroxychloroquine
1172555|NCT01272310|Pegylated Interferon Alpha-2a
1172556|NCT01272310|Ribavirin
1172557|NCT01272310|Chronic Hepatitis C Genotype 1 infected adult subjects
1172558|NCT01272297|LI-ESWT
1172559|NCT01272297|Erectile Dysfunction
1172560|NCT01272297|Non PDE5 inhibitor responders
1172561|NCT01272297|Shock wave
1172562|NCT01272284|Female
1172563|NCT01272284|Stress urinary incontinence
1172564|NCT01272284|Mini sling
1172565|NCT01272284|Single incision sling
1172566|NCT01272284|Urinary incontinence
1172567|NCT01272284|Mixed urinary incontinence
1172568|NCT01272284|Additional relevant MeSH terms:
1172569|NCT01272284|Stress
1172570|NCT01272284|Urinary Incontinence, Stress
1172571|NCT01272284|Pathological Processes
1172572|NCT01272284|Urination Disorders
1172573|NCT01272284|Urological Disorders
1172574|NCT01272284|Urological Manifestations
1172575|NCT01272284|Signs and Symptoms
1172576|NCT01272271|Contact lens
1172577|NCT01272271|Infection
1172578|NCT01272271|Cornea
1172579|NCT01272245|Acute Myelogenous Leukemia
1172580|NCT01272245|AML
1172581|NCT01272245|High-Risk Myelodysplastic Syndrome
1172582|NCT01272245|MDS
1172583|NCT01272245|Omacetaxine
1172584|NCT01272245|Cytarabine
1172585|NCT01272245|ARA-C
1172586|NCT01272245|Cytosar
1172587|NCT01272245|DepoCyt
1172588|NCT01272245|Cytosine Arabinosine Hydrochloride
1172589|NCT01272180|Safety
1172590|NCT01272180|Immunogenicity
1172591|NCT01272180|Vaccine
1172592|NCT01272180|Meningococcal
1172593|NCT01272180|Seroresponse
1172594|NCT01272167|Post-menopausal women
1172595|NCT01272167|Grapefruit juice
1172596|NCT01272167|Naringin
1172597|NCT01272167|Vascular protection
1172598|NCT01272167|Bone metabolism
1172599|NCT01272154|Cerebellum
1172600|NCT01272154|Cortical plasticity
1172601|NCT01272154|Sensorimotor adaptation
1172602|NCT01272154|Dystonia
1172603|NCT01272154|Cerebral Palsy
1172604|NCT01272154|Transcranial Magnetic Stimulation
1172605|NCT01272154|and
1172606|NCT01272141|Metastatic breast cancer
1172607|NCT01272141|Triple negative breast cancer
1172608|NCT01272141|Estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer
1172609|NCT01272115|Climacteric stage
1172610|NCT01272115|Integrative health care model
1172611|NCT01272115|Empowerment approach
1172612|NCT01272115|Primary care services
1172613|NCT01272076|Age Related Macular Degeneration
1172614|NCT01272076|Geographic Atrophy
1172615|NCT01272076|Imaging
1172616|NCT01272076|OCT
1172617|NCT01272063|Drusen
1172618|NCT01272063|Dry AMD
1172619|NCT01272063|OCT
1172620|NCT01272063|Imaging
1172621|NCT01272050|adenocarcinoma of the prostate
1172622|NCT01272050|recurrent prostate cancer
1172623|NCT01272050|stage IIA prostate cancer
1172624|NCT01272050|stage IIB prostate cancer
1172625|NCT01272050|stage III prostate cancer
1172626|NCT01272024|clinical trial
1172627|NCT01272024|symptom education
1172628|NCT01272024|advanced cancer
1172629|NCT01272011|Respiration
1172630|NCT01272011|Spinal cord injuries
1172631|NCT01272011|Walking recovery
1172632|NCT01271998|antibiotic
1172633|NCT01271998|healthy subjects
1172634|NCT01271998|pharmacokinetics
1172635|NCT01271985|Cardiovascular Diseases
1172636|NCT01271985|Drug Combinations
1172637|NCT01271985|prevention and control
1172638|NCT01271985|Aspirin
1172639|NCT01271985|Antihypertensive Agents
1172640|NCT01271985|Antilipemic Agents
1172641|NCT01271959|Ovarian
1172642|NCT01271959|Fallopian Tube
1172643|NCT01271959|Peritoneal
1172644|NCT01271959|Uterine Neoplasms
1172645|NCT01271959|Vulva
1172646|NCT01271959|Endometrial
1172647|NCT01271959|Cervical
1172648|NCT01271959|Lung
1172649|NCT01271959|Carcinoid
1172650|NCT01271959|Sarcoma
1172651|NCT01271959|Mesothelioma
1172652|NCT01271959|Adenocarcinoma
1172653|NCT01271959|Colorectal
1172654|NCT01271959|Breast
1172655|NCT01271959|Assay
1172656|NCT01271959|Chemotherapy
1172657|NCT01271959|Recurrent
1172658|NCT01271959|Refractory
1172659|NCT01271959|Persistent
1172660|NCT01271959|Chemoresponse
1172661|NCT01271933|fibromyalgia
1172662|NCT01271933|pain
1172663|NCT01271933|pregabalin
1172664|NCT01271933|Lyrica
1172665|NCT01271920|Trastuzumab-refractory
1172666|NCT01271920|advanced HER2-positive breast cancer,
1172667|NCT01271920|Hsp90,
1172668|NCT01271920|2nd or 3rd line treatment
1172669|NCT01271907|Skin Cancer
1172670|NCT01271907|Malignancy
1172671|NCT01271907|Immunotherapy
1172672|NCT01271907|Melanoma Peptides
1172673|NCT01271907|Melanoma
1172674|NCT01271907|Metastatic Melanoma
1172675|NCT01271894|HIV
1172676|NCT01271894|efavirenz
1172677|NCT01271894|pharmacokinetic
1172678|NCT01271881|Hemodialysis
1172679|NCT01271881|Fistula
1172680|NCT01271881|Angiograph
1172681|NCT01271881|Angiogram
1172682|NCT01271881|Adult patients who are currently receiving hemodialysis treatment via an AV vascular graft or fistula located in the upper extremity
1172684|NCT01271829|Avocados
1172685|NCT01271829|Satiety
1172686|NCT01271829|Feeding study
1172687|NCT01271816|genetics
1172688|NCT01271816|sudden death
1172689|NCT01271816|monitoring
1172690|NCT01271816|loop recorder
1172691|NCT01271816|cardiomyopathy
1172692|NCT01271790|Hepatitis C
1172693|NCT01271790|HCV
1172694|NCT01271790|Rapid Virologic Response
1172695|NCT01271790|Sustained Virologic Response
1172696|NCT01271790|Direct Acting Antiviral
1172697|NCT01271790|Combination Therapy
1172698|NCT01271790|HCV RNA
1172699|NCT01271790|Polymerase inhibitor
1172700|NCT01271790|Protease inhibitor
1172701|NCT01271790|Treatment naïve
1172702|NCT01271790|GS-9190
1172703|NCT01271790|GS-9451
1172704|NCT01271777|Pre-diabetes
1172705|NCT01271777|Clamp technique
1172706|NCT01271777|PPARs
1172707|NCT01271777|Insulin resistance
1172708|NCT01271751|Atherogenic-dyslipidaemia
1172709|NCT01271751|PPARs
1172710|NCT01271738|Breast Cancer
1172711|NCT01271738|Tumors or cancer of the human breast
1172712|NCT01271738|Breast Tumors
1172713|NCT01271738|Cancer of Breast
1172714|NCT01271738|Cancer of the Breast
1172715|NCT01271738|Human Mammary Carcinoma
1172716|NCT01271738|Neoplasms, Breast
1172717|NCT01271712|Gastrointestinal stromal cancer
1172718|NCT01271712|GIST
1172719|NCT01271712|multikinase inhibitor
1172720|NCT01271699|Fabry Disease
1172721|NCT01271699|Fabry´s Disease
1172722|NCT01271699|Anderson-Fabry Disease
1172723|NCT01271699|Multiple Sclerosis
1172724|NCT01271660|muscle cramp
1172725|NCT01271660|liver cirrhosis
1172726|NCT01271660|pregabalin
1172727|NCT01271647|osteopenia,chinese herb
1172728|NCT01271634|cross-transmission
1172729|NCT01271634|offending vessel
1172730|NCT01271621|Airtraq, Intraocular pressure
1172731|NCT01271608|Accident prevention
1172732|NCT01271608|Blood-borne pathogens
1172733|NCT01271608|Protective devices.
1172734|NCT01271608|Needlestick injuries
1172735|NCT01271608|Injections subcutaneous
1172736|NCT01271608|Injections intradermal
1172737|NCT01271595|acupuncture
1172738|NCT01271595|autonomic nervous system
1172739|NCT01271595|seasonal allergic rhinitis
1172740|NCT01271582|Colorecatal cancer
1172741|NCT01271582|Gastric cancer
1172742|NCT01271582|Irinotecan
1172743|NCT01271582|UGT1A1
1172744|NCT01271582|Neutropenia
1172745|NCT01271556|COPD
1172746|NCT01271556|LABA
1172747|NCT01271556|salmeterol
1172748|NCT01271543|Comparison of hemodynamic
1172749|NCT01271543|endotracheal intubation
1172750|NCT01271543|changes induced by
1172751|NCT01271543|performed
1172752|NCT01271543|the aid of the SOS
1172753|NCT01271543|as compared to the Macintosh Laryngoscope
1172754|NCT01271530|Late Effects of Polio
1172755|NCT01271530|Cardiovascular Fitness
1172756|NCT01271530|Fatigue
1172757|NCT01271530|Energy cost of Walking
1172758|NCT01271530|Pain
1172759|NCT01271517|Basal insulin
1172760|NCT01271517|long acting insulin analogs
1172761|NCT01271517|metabolic control
1172762|NCT01271517|HbA1c
1172763|NCT01271517|C-peptide
1172764|NCT01271517|IGF-I
1172765|NCT01271517|GH
1172766|NCT01271517|IGFBP
1172767|NCT01271504|Cancer
1172768|NCT01271504|liver
1172769|NCT01271504|hepatocellular carcinoma
1172770|NCT01271504|phase I
1172771|NCT01271504|phase II
1172772|NCT01271491|Pediatric
1172773|NCT01271478|inflammation
1172774|NCT01271478|telmisartan
1172775|NCT01271478|captopril
1172776|NCT01271478|hemodialysis
1172777|NCT01271426|Polypoidal Choroidal Vasculopathy
1172778|NCT01271426|Ranibizumab
1172779|NCT01271400|Infertility treatments
1172780|NCT01271400|Frozen embryo transfers (FET).
1172781|NCT01271400|IVF.
1172782|NCT01271400|ART.
1172783|NCT01271400|Cryopreservation
1172784|NCT01271400|Slow-Freeze
1172785|NCT01271400|Freeze / thaw survival rates
1172786|NCT01271400|Blastocyst formation
1172787|NCT01271400|Pregnancy
1172788|NCT01271387|Liver disease
1172789|NCT01271387|pharmacokinetics
1172790|NCT01271374|African American
1172791|NCT01271374|Hypertension
1172792|NCT01271374|Cardiometabolic Syndrome
1172793|NCT01271361|thrombus aspiration
1172794|NCT01271361|Drug-Eluting Stent
1172795|NCT01271361|optical frequency domain imaging (OFDI)
1172796|NCT01271335|CTO
1172797|NCT01271335|Angioplasty
1172798|NCT01271335|PCI
1172799|NCT01271322|PET
1172800|NCT01271322|response evaluation
1172801|NCT01271322|neoadjuvant
1172802|NCT01271322|radiochemotherapy
1172803|NCT01271322|adenocarcinoma of the esophagogastric junction
1172804|NCT01271322|esophageal carcinoma
1172805|NCT01271322|evaluation of preoperative (radio)-chemotherapy in patients with adenocarcinomas of the oesophagogastric junction
1172806|NCT01271296|Addison Disease
1172807|NCT01271296|Pharmacokinetics
1172808|NCT01271296|Hormone Replacement Therapy
1172809|NCT01271296|cortisone acetate
1172810|NCT01271296|Quality of Life
1172811|NCT01271270|Age-Related Macular Degeneration (AMD)
1172812|NCT01271270|Palomid 529
1172813|NCT01271270|Age Related Macular Degeneration
1172814|NCT01271270|AMD
1172942|NCT01270698|colorectal cancer
1172815|NCT01271257|misoprostol, pharmacokinetics
1172816|NCT01271231|periodontal treatment, diabetes, glycemia, glycated hemoglobin
1172817|NCT01271205|pneumonia
1172818|NCT01271205|RDW
1172819|NCT01271205|mortality
1172820|NCT01271205|prognostic factor
1172821|NCT01271192|local recurrent rectal cancer
1172822|NCT01271192|surgical resection
1172823|NCT01271192|adjuvant therapy
1172824|NCT01271179|orthotopic liver transplantation
1172825|NCT01271179|preservation solution
1172826|NCT01271179|peribiliary plexus
1172827|NCT01271179|nonanastomotic biliary strictures
1172828|NCT01271179|primary non-function
1172829|NCT01271166|Colorectal,
1172830|NCT01271166|Cancer
1172831|NCT01271153|Septic shock
1172832|NCT01271127|radiation therapy
1172833|NCT01271127|coronary artery disease
1172834|NCT01271127|Hodgkin Lymphoma
1172835|NCT01271101|Non-ST-elevated acute coronary syndromes (NSTE-ACS)
1172836|NCT01271101|anticoagulation
1172837|NCT01271088|ototoxicity
1172838|NCT01271088|aminoglycoside
1172839|NCT01271088|vancomycine
1172840|NCT01271088|peritoneal dialysis
1172841|NCT01271088|peritonitis
1172842|NCT01271075|urticaria
1172843|NCT01271075|bilastine
1172844|NCT01271062|Resolvment of Diabetes Mellitus, Type 2
1172845|NCT01271062|gastric bypass
1172846|NCT01271036|Lubricating Agents
1172847|NCT01271036|Personal Lubricant
1172848|NCT01270984|Imatinib mesylate
1172849|NCT01270984|Pharmacokinetics
1172850|NCT01270984|Healthy volunteers
1172851|NCT01270971|Onychomycosis
1172852|NCT01270971|nail fungus
1172853|NCT01270971|toenail fungus
1172854|NCT01270971|fungal nail
1172855|NCT01270971|hyperkeratosis
1172856|NCT01270971|nail infection
1172857|NCT01270971|nail treatment
1172858|NCT01270971|toenail infection
1172859|NCT01270971|toenail treatment
1172860|NCT01270971|foot dermatoses
1172861|NCT01270971|fungal culture
1172862|NCT01270971|onycholysis
1172863|NCT01270971|podiatrist
1172864|NCT01270971|podiatry
1172865|NCT01270971|subungual
1172866|NCT01270971|tinea unguium
1172867|NCT01270971|antifungal
1172868|NCT01270971|anti-fungal
1172869|NCT01270971|dermatologist
1172870|NCT01270971|dermatology
1172871|NCT01270971|dermatophyte
1172872|NCT01270971|distal subungual onychomycosis
1172873|NCT01270971|yellow nail
1172874|NCT01270971|thick nail
1172875|NCT01270971|brittle nail
1172876|NCT01270971|crumbling nail
1172877|NCT01270971|discolored nail
1172878|NCT01270971|weak nail
1172879|NCT01270958|AVY-REG00108VN
1172880|NCT01270906|Neoplasms
1172881|NCT01270906|Cancer
1172882|NCT01270906|Tumors
1172883|NCT01270906|Administration
1172884|NCT01270906|oral
1172885|NCT01270906|CHIR258
1172886|NCT01270906|CHIR-258
1172887|NCT01270906|CHIR 258
1172888|NCT01270906|TKI258
1172889|NCT01270906|TKI-258
1172890|NCT01270906|TKI 258
1172891|NCT01270906|dose finding
1172892|NCT01270893|Gastrointestinal stromal tumor
1172893|NCT01270893|GIST
1172894|NCT01270893|Nilotinib
1172895|NCT01270893|AMN107
1172896|NCT01270893|Tasigna
1172897|NCT01270867|Ischemia
1172898|NCT01270867|Stroke
1172899|NCT01270867|Ischemic Stroke
1172900|NCT01270867|Mechanical Thrombectomy
1172901|NCT01270867|Brain
1172902|NCT01270867|Brain clot
1172903|NCT01270867|Cerebrovascular disease
1172904|NCT01270867|Recanalization
1172905|NCT01270867|Revascularization
1172906|NCT01270854|Normal saline
1172907|NCT01270854|Plasmalyte
1172908|NCT01270854|Intravenous fluid
1172909|NCT01270854|Traumatic injury
1172910|NCT01270854|Fluid resuscitation
1172911|NCT01270828|Control Release Pregabalin in Post Herpetic Neuralgia
1172912|NCT01270815|pregabalin
1172913|NCT01270815|pharmacokinetics
1172914|NCT01270815|bioavailability
1172915|NCT01270815|bioequivalence
1172916|NCT01270802|Endothelial function
1172917|NCT01270802|Vitamin D
1172918|NCT01270802|Efavirenz
1172919|NCT01270802|Raltegravir
1172920|NCT01270789|beta-cell function
1172921|NCT01270789|GLP-1 analogue
1172922|NCT01270789|diabetes
1172923|NCT01270776|Randomized Controlled Trial
1172924|NCT01270776|Chlorhexidine
1172925|NCT01270776|Infant, Premature
1172926|NCT01270763|Obesity
1172927|NCT01270763|physical fitness
1172928|NCT01270763|cholesterol levels
1172929|NCT01270763|genetics
1172930|NCT01270763|weight loss
1172931|NCT01270750|ENDOTHELIN RECEPTOR ANTAGONIST
1172932|NCT01270750|BOSENTAN
1172933|NCT01270750|SECONDARY PULMONARY HYPERTENSION
1172934|NCT01270750|RHEUMATOID FEVER
1172935|NCT01270750|CONGESTIVE HEART FAILURE
1172936|NCT01270750|SECONDARY PULMONARY HYPERTENSION DUE TO MITRAL STENOSIS
1172937|NCT01270711|compliance study
1172938|NCT01270711|effectiveness study
1172939|NCT01270711|hyperprolactinemia
1172940|NCT01270711|Parkinson's disease
1172941|NCT01270711|retrospective cohort study
1172943|NCT01270672|MDMA
1172944|NCT01270672|carvedilol
1172945|NCT01270672|norepinephrine
1172946|NCT01270672|alpha - beta receptor
1172947|NCT01270672|Ecstasy
1172948|NCT01270672|stimulant
1172949|NCT01270659|Fentanyl buccal tablet
1172950|NCT01270646|Cardiac insufficiency
1172951|NCT01270646|Invasive procedure
1172952|NCT01270646|Heart Failure
1172953|NCT01270646|Noninvasive procedure
1172954|NCT01270646|Congestive Heart Failure
1172955|NCT01270646|Mapping
1172956|NCT01270646|Cardiac resynchronisation therapy
1172957|NCT01270646|Open study
1172958|NCT01270646|Cardiac Pacings, Artificial
1172959|NCT01270646|Hemodynamics
1172960|NCT01270620|elderly obese
1172961|NCT01270581|transient tachypnea of the newborn
1172962|NCT01270581|high flow nasal cannula
1172963|NCT01270581|bubble nasal
1172964|NCT01270581|continuous positive airway pressure
1172965|NCT01270568|positive psychology
1172966|NCT01270568|cardiovascular disease
1172967|NCT01270542|Traction Retinal Detachment (PDR)
1172968|NCT01270542|Proliferative Diabetic Retinopathy (PDR)
1172969|NCT01270529|Physical Activity
1172970|NCT01270529|Physical Performance
1172971|NCT01270529|Physical Functioning
1172972|NCT01270529|CKD
1172973|NCT01270529|ESRD
1172974|NCT01270529|Transplant Recipients
1172975|NCT01270516|diaphragm
1172976|NCT01270516|limb muscle
1172977|NCT01270516|EPA
1172978|NCT01270516|HMB
1172979|NCT01270516|ICU patients
1172980|NCT01270503|Meningitis
1172981|NCT01270503|Meningococcal disease
1172982|NCT01270503|Menactra®
1172983|NCT01270490|candidemia
1172984|NCT01270490|candida sepsis
1172985|NCT01270490|invasive fungal disease
1172986|NCT01270477|Frost injury
1172987|NCT01270451|Weight maintenance
1172988|NCT01270451|Group counseling
1172989|NCT01270451|Prevention of diseases
1172990|NCT01270425|systemic sclerosis
1172991|NCT01270425|hashimoto thyroiditis
1172992|NCT01270425|thyroid nodules
1172993|NCT01270412|Osteoarthritis
1172994|NCT01270412|PRP
1172995|NCT01270412|PRGF
1172996|NCT01270412|Hyaluronic acid
1172997|NCT01270386|NSCLC
1172998|NCT01270386|apatinib
1172999|NCT01270386|phase II
1173000|NCT01270386|lung
1173001|NCT01270386|cancer
1173002|NCT01270373|neoadjuvant therapy
1173003|NCT01270373|drug therapy
1173004|NCT01270321|Thyroid Cancer
1173005|NCT01270308|Bioequivalence
1173006|NCT01270308|two way crossover
1173007|NCT01270295|Receptor for advanced glycation end products (RAGE)
1173008|NCT01270295|Soluble RAGE (sRAGE)
1173009|NCT01270295|Endogenous secretory RAGE (esRAGE)
1173010|NCT01270295|High-mobility group box-1 protein (HMGB-1)
1173011|NCT01270295|Extracellular newly-identified RAGE-binding protein (EN-RAGE or S100A12)
1173012|NCT01270295|Advanced glycation endproducts (AGEs)
1173013|NCT01270295|Pentosidine
1173014|NCT01270295|N--carboxymethyllysine
1173015|NCT01270295|Acute lung injury (ALI)
1173016|NCT01270295|Acute respiratory distress syndrome (ARDS)
1173017|NCT01270295|Alveolar epithelium
1173018|NCT01270295|Mechanical ventilation
1173019|NCT01270295|Intensive Care Unit (ICU)
1173020|NCT01270269|Asthenia
1173021|NCT01270269|Muscle Weakness
1173022|NCT01270269|Brain Injuries
1173023|NCT01270269|Critical Illness
1173024|NCT01270269|Critical Illness Myoneuropathy
1173025|NCT01270269|Rehabilitation
1173026|NCT01270269|Sepsis
1173027|NCT01270269|Respiratory Failure
1173028|NCT01270269|Delirium
1173029|NCT01270269|Over-sedation
1173030|NCT01270269|Immobility
1173031|NCT01270269|Aging
1173032|NCT01270269|Signs and Symptoms
1173033|NCT01270269|Muscular Diseases
1173034|NCT01270269|Musculoskeletal Diseases
1173035|NCT01270269|Neuromuscular Manifestations
1173036|NCT01270269|Neurologic Manifestations
1173037|NCT01270269|Pathologic Processes
1173038|NCT01270269|Brain Diseases
1173039|NCT01270269|Central Nervous System Diseases
1173040|NCT01270269|Craniocerebral Trauma
1173041|NCT01270269|Trauma, Nervous System
1173042|NCT01270269|Wounds and Injuries
1173043|NCT01270269|Disorders of Environmental Origin
1173044|NCT01270256|allergy
1173045|NCT01270230|HIV Prevention Intervention
1173046|NCT01270230|African American Men who have Sex with Men
1173047|NCT01270217|Automobile driving
1173048|NCT01270217|Driving under the influence
1173049|NCT01270217|Interview, psychological
1173050|NCT01270217|Brief intervention
1173051|NCT01270217|Brief motivational interview
1173052|NCT01270204|Dysphagia
1173053|NCT01270204|Swallowing Problems
1173054|NCT01270204|Dynamic Fluoroscopic Swallow Study
1173055|NCT01270204|Aspiration
1173056|NCT01270204|Regurgitation
1173057|NCT01270204|Acid Reflux
1173058|NCT01270191|Exenatide, Beta-Cell Function, Glycemic Control
1173059|NCT01270191|in Newly Diagnosed Type 2 Diabetic Patients
1173060|NCT01270165|lamivudine
1173061|NCT01270165|telbivudine
1173062|NCT01270165|adefovir
1173063|NCT01270165|lamivudine resistance
1173064|NCT01270152|ascorbic acid
1173065|NCT01270152|catheterization central venous
1173066|NCT01270152|nursing care
1173067|NCT01270139|nanoparticles
1173068|NCT01270139|mesenchymal stem cell
1173069|NCT01270139|plasmonics
1173070|NCT01270139|atherosclerosis
1173071|NCT01270139|IVUS
1173072|NCT01270139|stenting
1173073|NCT01270126|optic neuropathy
1173074|NCT01270126|alternating current stimulation
1173075|NCT01270126|vision recovery
1173076|NCT01270126|restoration
1173077|NCT01270126|plasticity
1173078|NCT01270087|Rheumatoid arthritis, cardiovascular disease, adalimumab
1173079|NCT01270074|double blind placebo controlled randomised clinical trial
1173080|NCT01270074|azithromycin
1173081|NCT01270074|infant
1173082|NCT01270074|pediatric
1173083|NCT01270074|cystic fibrosis
1173084|NCT01270074|bronchiectasis
1173085|NCT01270061|HIV testing
1173086|NCT01270061|black Africans
1173087|NCT01270061|immigrants
1173088|NCT01270061|health screening
1173089|NCT01270048|Hwa-byung, Bunsimgi-eum(Fenxinqiyin)
1173090|NCT01269996|type 2 diabetes mellitus
1173091|NCT01269996|JUBILEE Study
1173092|NCT01269996|Janumet
1173093|NCT01269996|Lantus
1173094|NCT01269983|low back pain
1173095|NCT01269983|fascial manipulation
1173096|NCT01269983|physioterapy
1173097|NCT01269983|physical activity
1173098|NCT01269957|halitosis
1173099|NCT01269957|pediatric dentistry
1173100|NCT01269957|mouth breathing
1173101|NCT01269944|osteoarthritis
1173102|NCT01269944|knee
1173103|NCT01269944|high wedge tibial osteotomy
1173104|NCT01269944|dGEMRIC
1173105|NCT01269931|endobronchial ultrasound
1173106|NCT01269931|bronchoscopy
1173107|NCT01269931|education
1173108|NCT01269931|interventional bronchoscopy
1173109|NCT01269931|simulation
1173110|NCT01269918|Craniotomy, pain relief
1173111|NCT01269918|Adult solid neoplasm
1173112|NCT01269892|diarrhea, lactose, milk, weight, acute.
1173113|NCT01269879|epicondylitis
1173114|NCT01269879|pain
1173115|NCT01269879|tendon
1173116|NCT01269866|Lupus Pain
1173117|NCT01269866|Lupus
1173118|NCT01269866|Pain
1173119|NCT01269866|Systemic Lupus Erythematosus
1173120|NCT01269866|Duloxetine
1173121|NCT01269866|Cymbalta
1173122|NCT01269853|GBM
1173123|NCT01269853|AA
1173124|NCT01269853|AO
1173125|NCT01269853|Brain
1173126|NCT01269853|Tumors
1173127|NCT01269853|Malignant
1173128|NCT01269853|Glioblastoma
1173129|NCT01269853|Multiforme
1173130|NCT01269853|Anaplastic
1173131|NCT01269853|Astrocytoma
1173132|NCT01269827|inflammation
1173133|NCT01269827|pentoxifylline
1173134|NCT01269827|hemodialysis
1173135|NCT01269814|Gastrointestinal bleeding
1173136|NCT01269814|Emergency endoscopy
1173137|NCT01269814|Rockall Risk Scoring System
1173138|NCT01269801|BOTOX
1173139|NCT01269801|JUVEDERM
1173140|NCT01269801|Prospective
1173141|NCT01269801|Open Label
1173142|NCT01269801|Randomized
1173143|NCT01269801|Crossover Study
1173144|NCT01269788|non-erosive reflux disease
1173145|NCT01269788|heartburn
1173146|NCT01269788|functional
1173147|NCT01269788|Antidepressive Agents, Second-Generation
1173148|NCT01269788|Proton Pump Inhibitors
1173149|NCT01269762|Red yeast rice
1173150|NCT01269762|Lovastatin
1173151|NCT01269762|Drug-drug interaction
1173152|NCT01269762|Pharmacokinetics
1173153|NCT01269749|Hyperthyroidism
1173154|NCT01269749|Antithyroid drugs
1173155|NCT01269749|Cancer
1173156|NCT01269749|Dosimetry
1173157|NCT01269749|Children
1173158|NCT01269736|electrocardiographic monitoring
1173159|NCT01269736|arrhythmia
1173160|NCT01269736|myocardial ischemia
1173161|NCT01269723|Smoking
1173162|NCT01269723|influenza
1173163|NCT01269723|influenza vaccine
1173164|NCT01269710|Second Generation Antipsychotics
1173165|NCT01269710|Schizophrenia
1173166|NCT01269710|Schizoaffective
1173167|NCT01269710|Schizophreniform
1173168|NCT01269710|Psychosis NOS
1173169|NCT01269710|Mood Disorders
1173170|NCT01269710|Weight
1173171|NCT01269710|Autism
1173172|NCT01269697|AMD
1173173|NCT01269697|food supplementation
1173174|NCT01269697|macular pigments
1173175|NCT01269697|luthéine
1173176|NCT01269697|zéaxanthine
1173177|NCT01269697|visual acuity
1173178|NCT01269697|prevention
1173179|NCT01269697|genetique risk
1173180|NCT01269684|Kidney
1173181|NCT01269684|renal
1173182|NCT01269684|transplantation
1173183|NCT01269684|tacrolimus
1173184|NCT01269684|everolimus
1173185|NCT01269684|stable allograft recipients
1173186|NCT01269671|Functional Abdominal Pain
1173187|NCT01269671|Irritable Bowel Syndrome
1173188|NCT01269671|IBS
1173189|NCT01269671|Functional Dyspepsia
1173190|NCT01269671|Melatonin
1173191|NCT01269671|Simethicone
1173192|NCT01269671|Peppermint Oil
1173193|NCT01269671|mentharil
1173194|NCT01269671|functional bowel disorders
1173195|NCT01269671|quality of life
1173196|NCT01269645|Cancer
1173197|NCT01269645|Clinical trials
1173198|NCT01269632|teenagers to adult transition
1173199|NCT01269632|comparison
1173200|NCT01269619|back pain
1173201|NCT01269619|posture
1173202|NCT01269619|lumbar support
1173203|NCT01269619|dynamic support
1173204|NCT01269593|PET Scan
1173205|NCT01269593|124I-PUH71
1173206|NCT01269593|10-139
1173207|NCT01269567|RectalNeoplasms
1173208|NCT01269567|Colorectal Neoplasms
1173209|NCT01269567|Intestinal Neoplasms
1173210|NCT01269567|Gastrointestinal Neoplasms
1173211|NCT01269567|Digestive System Neoplasms
1173212|NCT01269567|Neoplasms by Site
1173213|NCT01269567|Digestive System Diseases
1173214|NCT01269567|Gastrointestinal Diseases
1173215|NCT01269567|Intestinal Diseases
1173216|NCT01269567|Rectal Diseases
1173217|NCT01269554|diarrhea
1173218|NCT01269554|Guinea-Bissau
1173219|NCT01269554|Finland
1173220|NCT01269554|Children
1173221|NCT01269554|Adults
1173222|NCT01269554|Intestinal pathogens
1173223|NCT01269554|Bacteria
1173224|NCT01269554|Virus
1173225|NCT01269554|Parasites
1173226|NCT01269528|Palivizumab
1173227|NCT01269528|Airway Hyperreactivity
1173228|NCT01269528|EBC
1173229|NCT01269528|MCT
1173230|NCT01269515|Cox-2 inhibitor
1173231|NCT01269515|HIV
1173232|NCT01269515|immune activation
1173233|NCT01269515|immune modulating
1173234|NCT01269515|progression markers
1173235|NCT01269515|vaccine
1173236|NCT01269489|quality of life
1173237|NCT01269489|general Slovenian population
1173238|NCT01269489|EORTC QLQ C30
1173239|NCT01269463|Attention deficit
1173240|NCT01269463|Hyperactivity
1173241|NCT01269463|Impulsivity
1173242|NCT01269463|Inattention
1173243|NCT01269450|second trimester vaginal bleeding
1173244|NCT01269450|late abortion
1173245|NCT01269450|preterm birth
1173246|NCT01269450|progesterone
1173247|NCT01269437|mild to moderate asthma
1173248|NCT01269424|adult giant cell glioblastoma
1173249|NCT01269424|adult glioblastoma
1173250|NCT01269424|adult gliosarcoma
1173251|NCT01269385|Imprime PGG
1173252|NCT01269372|polyps
1173253|NCT01269372|capsule endoscopy
1173254|NCT01269372|colonoscopy
1173255|NCT01269346|Locally recurrent
1173256|NCT01269346|metastatic HER2Positive breast cancer
1173257|NCT01269307|Anesthesia
1173258|NCT01269307|Pain
1173259|NCT01269307|Procedural sedation
1173260|NCT01269307|Airway/Anesthesia/Analgesia
1173261|NCT01269294|Hepatitis C
1173262|NCT01269294|TMC435-TiDP16-C117
1173263|NCT01269294|TMC435-C117
1173264|NCT01269294|TMC435
1173265|NCT01269294|HCV
1173266|NCT01269294|Moxifloxacin
1173267|NCT01269294|ECG
1173268|NCT01269294|QT
1173269|NCT01269294|QTc
1173270|NCT01269281|Bioequivalence
1173271|NCT01269281|two way crossover
1173272|NCT01269242|coronary restenosis
1173273|NCT01269242|angioplasty
1173274|NCT01269242|stent
1173275|NCT01269242|MCP-1/CCL2
1173276|NCT01269242|MCP-3/CCL7
1173277|NCT01269203|multiple myeloma
1173278|NCT01269203|MM
1173279|NCT01269203|maintenance therapy
1173280|NCT01269203|lenalidomide
1173281|NCT01269203|bone marrow transplantation
1173282|NCT01269203|auto-HSCT
1173283|NCT01269203|Autologous Hematopoietic Stem Cell Transplantation
1173284|NCT01269203|NF-kB inhibition
1173285|NCT01269203|reducing symptoms
1173286|NCT01269203|maintenance chemotherapy
1173287|NCT01269203|inflammatory cytokines
1173288|NCT01269203|nuclear factor kappa B
1173289|NCT01269203|NF-kB
1173290|NCT01269203|interleukin
1173291|NCT01269203|IL-6
1173292|NCT01269203|tumor necrosis factor
1173293|NCT01269203|TNF-a
1173294|NCT01269203|NF-kB activation levels
1173295|NCT01269190|oral mucosa in vivo
1173296|NCT01269190|Wide-Field In Vivo Imaging
1173297|NCT01269190|High Resolution In Vivo Imaging
1173298|NCT01269190|Oral Neoplasia
1173299|NCT01269190|Topical Fluorescent Dyes
1173300|NCT01269190|contrast dye
1173301|NCT01269190|oral dysplasia
1173302|NCT01269190|Proflavine
1173303|NCT01269190|oral lesions
1173304|NCT01269190|surgical resection
1173305|NCT01269190|High Resolution Microendoscope
1173306|NCT01269190|HRME
1173307|NCT01269190|Identafi 3000
1173308|NCT01269190|Multispectral Digital Microscope
1173309|NCT01269190|MDM
1173310|NCT01269190|Portable Screening System
1173311|NCT01269190|PS2
1173312|NCT01269177|ACPE
1173313|NCT01269177|Acute respiratory failure
1173314|NCT01269177|Non invasive ventilation
1173315|NCT01269177|acute cardiogenic pulmonary edema
1173316|NCT01269164|Face Transplant
1173317|NCT01269164|Facial Transplantation
1173318|NCT01269164|Composite Facial Allograft Transplantation
1173319|NCT01269151|Age-Related Macular Degeneration
1173320|NCT01269151|Retinal Function
1173321|NCT01269151|multifocal-ERG
1173322|NCT01269151|Electroretinography
1173323|NCT01269151|microperimetry
1173324|NCT01269151|Lucentis
1173325|NCT01269151|Ranibizumab
1173326|NCT01269151|longterm effects
1173327|NCT01269151|best corrected visual acuity
1173328|NCT01269151|BCVA
1173329|NCT01269138|Inherited Factor VII deficiency
1173330|NCT01269138|Inhibitor development in Factor VII deficiency
1173331|NCT01269138|Bleeding in Factor VII Deficiency
1173332|NCT01269138|Surgery in Factor VII deficiency
1173333|NCT01269138|Prophylaxis in Factor VII Deficiency
1173334|NCT01269125|cytokines
1173335|NCT01269125|endometriosis
1173336|NCT01269125|fertilization rate
1173337|NCT01269125|follicular fluid
1173338|NCT01269125|pregnancy rate
1173339|NCT01269099|hypokalemia
1173340|NCT01269099|intravenous patient controlled analgesia
1173341|NCT01269086|Primary Heath Care
1173342|NCT01269086|Preventive Medicine
1173343|NCT01269086|Adolescent Health Services
1173344|NCT01269086|Spouses
1173345|NCT01269086|Family
1173346|NCT01269086|Family Practice
1173347|NCT01269073|Obstructive Sleep Apnea
1173348|NCT01269060|Colorectal Cancer, laparoscopic surgery
1173349|NCT01269047|type 1 diabetes
1173350|NCT01269047|Symlin
1173351|NCT01269047|Byetta
1173352|NCT01269047|CGMS iPro
1173353|NCT01269034|Type 1 diabetes Milletus
1173354|NCT01269034|diabetes
1173355|NCT01269034|healthy controls
1173356|NCT01269034|exenatide
1173357|NCT01269034|byetta
1173358|NCT01269021|MMF treatment IgA Nephropathy (IgAN)
1173359|NCT01269008|Closed loop
1173360|NCT01269008|type 1 diabetes
1173361|NCT01269008|Symlin
1173362|NCT01269008|Byetta
1173363|NCT01269008|diabetes
1173364|NCT01269008|insulin
1173365|NCT01269008|insulin pump
1173366|NCT01268995|NODAT
1173367|NCT01268995|kidney transplantation
1173368|NCT01268995|beta cell function
1173369|NCT01268995|insulin
1173370|NCT01268995|Tacrolimus
1173371|NCT01268995|Cyclosporine A
1173372|NCT01268982|socket preservation
1173373|NCT01268982|alveolar ridge augmentation
1173374|NCT01268969|pilonidal disease PND
1173375|NCT01268943|rectal neoplasms
1173376|NCT01268943|aged
1173377|NCT01268943|radiotherapy
1173378|NCT01268943|drug therapy
1173379|NCT01268943|dose-escalation
1173380|NCT01268943|capecitabine
1173381|NCT01268930|ovarian reserve
1173382|NCT01268930|endometrioma excision
1173383|NCT01268930|hemostatic matrix
1173384|NCT01268930|bipolar electrocoagulation
1173385|NCT01268930|thermal injury
1173386|NCT01268917|coronary artery disease
1173387|NCT01268917|off-pump coronary artery bypass
1173388|NCT01268917|aspirin
1173389|NCT01268891|Azilect
1173390|NCT01268891|Motor fluctuations
1173391|NCT01268891|Parkinson´s Disease
1173392|NCT01268891|Rasagiline
1173393|NCT01268878|effect of febrile neutropenia resulting chemotherapy by TPF
1173394|NCT01268865|Acoustic Radiation Force Impulse (ARFI)
1173395|NCT01268865|Virtual Touch Quantification (VTQ)
1173396|NCT01268865|liver stiffness measurement (LSM)
1173397|NCT01268865|liver fibrosis
1173398|NCT01268865|cirrhosis
1173399|NCT01268865|hepatitis B
1173400|NCT01268865|hepatitis C
1173401|NCT01268839|TMC278, rilpivirine, efavirenz, healthy volunteer
1173402|NCT01268800|AML
1173403|NCT01268800|Induction
1173404|NCT01268761|Ovarian hyperstimulation syndrome (OHSS)
1173405|NCT01268761|GnRH antagonist
1173406|NCT01268761|Ascitis.
1173407|NCT01268748|single site surgery
1173408|NCT01268748|laparoscopic surgery
1173409|NCT01268748|pain
1173410|NCT01268748|nausea
1173411|NCT01268735|Dysfunctional Tear Syndrome
1173412|NCT01268735|Dry Eye
1173413|NCT01268735|LIPCOF
1173414|NCT01268735|Hydroxypropyl-guar
1173415|NCT01268722|Nitinol Stent
1173416|NCT01268722|Balloon angioplasty
1173417|NCT01268722|Chronic total occlusions
1173418|NCT01268722|Femoropopliteal
1173419|NCT01268696|diabetes
1173420|NCT01268696|obesity
1173421|NCT01268696|hypertension
1173422|NCT01268696|dyslipidemia
1173423|NCT01268683|Ischemic stroke
1173424|NCT01268657|PTSD
1173425|NCT01268657|Fear of Falling
1173426|NCT01268657|Older Adults
1173427|NCT01268657|Injurious Falls
1173428|NCT01268657|Exposure Therapy
1173429|NCT01268644|Type 1 Diabetes Mellitus
1173430|NCT01268631|Fibromyalgia
1173431|NCT01268631|Pain modulation
1173432|NCT01268618|IBS
1173433|NCT01268618|Diarrhea
1173434|NCT01268618|Dyspepsia
1173435|NCT01268605|Dental caries
1173436|NCT01268605|Resin based composite
1173437|NCT01268605|Hypersensitivity
1173438|NCT01268605|Teeth
1173439|NCT01268605|Dentistry
1173440|NCT01268605|Practice-based research network
1173441|NCT01268592|fertility preservation
1173442|NCT01268592|oocyte cryopreservation
1173443|NCT01268592|vitrification
1173444|NCT01268592|egg freezing
1173570|NCT01267981|video-capsule endoscopy
1173445|NCT01268592|fertility preservation in female cancer patients
1173446|NCT01268579|ribavirin
1173447|NCT01268579|VIRAZOLE
1173448|NCT01268579|tonsil
1173449|NCT01268579|base of tongue
1173450|NCT01268579|squamous cell carcinoma
1173451|NCT01268579|10-218
1173452|NCT01268566|Glioblastoma
1173453|NCT01268553|pulmonary arterial hypertension
1173454|NCT01268553|inhaled prostacyclin
1173455|NCT01268540|intraocular lens
1173456|NCT01268540|IOL
1173457|NCT01268540|cataract
1173458|NCT01268540|refractive astigmatism
1173459|NCT01268540|Aspheric
1173460|NCT01268540|Toric
1173461|NCT01268540|Hoya
1173462|NCT01268540|Surgical
1173463|NCT01268540|Optics
1173464|NCT01268540|visual acuity
1173465|NCT01268527|Psoriasis vulgaris
1173466|NCT01268514|Complex
1173467|NCT01268514|Abdominal Wall Reconstruction
1173468|NCT01268514|AWR
1173469|NCT01268514|Hernia
1173470|NCT01268475|Bronchiectasis
1173471|NCT01268475|Quality of Life
1173472|NCT01268475|Respiratory Function Tests
1173473|NCT01268475|Exercise Test
1173474|NCT01268449|Tinnitus
1173475|NCT01268449|Low power laser
1173476|NCT01268423|Percutaneous tracheostomy
1173477|NCT01268423|Swallowing dysfunction
1173478|NCT01268423|Mechanical ventilation
1173479|NCT01268423|Intensive Care
1173480|NCT01268410|Acute respiratory failure
1173481|NCT01268410|Acute lung injury
1173482|NCT01268410|Acute respiratory distress syndrome
1173483|NCT01268410|Mechanical Ventilation
1173484|NCT01268410|Non-Invasive Ventilation
1173485|NCT01268397|elderly
1173486|NCT01268397|wrist fracture
1173487|NCT01268397|fracture of the distal radius
1173488|NCT01268397|volar plate
1173489|NCT01268397|plaster cast
1173490|NCT01268384|pancreatic cancer
1173491|NCT01268384|neoadjuvant chemotherapy
1173492|NCT01268384|gemcitabine
1173493|NCT01268384|capecitabine
1173494|NCT01268371|Coronary artery disease
1173495|NCT01268371|Stent
1173496|NCT01268345|blood glucose
1173497|NCT01268332|Placebo IVR as a delivery method
1173498|NCT01268319|Myocardial Infarction
1173499|NCT01268319|percutaneous coronary intervention
1173500|NCT01268319|embolization
1173501|NCT01268319|necrotic core
1173502|NCT01268319|vulnerable plaque
1173503|NCT01268319|coronary plaque rupture
1173504|NCT01268306|contact lens
1173505|NCT01268306|corneal staining
1173506|NCT01268306|fluorescein staining
1173507|NCT01268306|preservatives
1173508|NCT01268306|keratitis
1173509|NCT01268306|punctate keratopathy
1173510|NCT01268306|superficial punctate keratopathy
1173511|NCT01268306|SPK
1173512|NCT01268293|Cancer
1173513|NCT01268254|wine
1173514|NCT01268254|aging
1173515|NCT01268254|atherosclerosis
1173516|NCT01268254|telomere
1173517|NCT01268254|tomography
1173518|NCT01268254|coronary vessels
1173519|NCT01268241|Fabry Disease
1173520|NCT01268241|Fabry´s Disease
1173521|NCT01268241|Anderson-Fabry Disease
1173522|NCT01268228|intracoronary ECG
1173523|NCT01268228|coronary bifurcation stenosis
1173524|NCT01268228|side branch compromise
1173525|NCT01268228|Periprocedural myonecrosis during coronary bifurcation lesion stenting assessed with ic ECG
1173526|NCT01268215|Bronchopulmonary Dysplasia
1173527|NCT01268215|Budesonide
1173528|NCT01268215|Infasurf
1173529|NCT01268202|cutaneous radioinduced fibrosis
1173530|NCT01268189|burn wound
1173531|NCT01268189|management with oxygen
1173532|NCT01268176|Vitamin D
1173533|NCT01268176|vitamin D deficiency
1173534|NCT01268176|vitamin D absorption
1173535|NCT01268163|Docetaxel
1173536|NCT01268163|Phase I
1173537|NCT01268163|Pharmacokinetic
1173538|NCT01268163|Bioequivalence
1173539|NCT01268137|MDD
1173540|NCT01268137|DBS
1173541|NCT01268124|Japanese
1173542|NCT01268111|vitamin D deficiency, insulin sensitivity
1173543|NCT01268098|Hypoparathyroidism, rhPTH[1-84], NPSP558
1173544|NCT01268085|Radiation Safety
1173545|NCT01268085|Computerized Physician Order Entry
1173546|NCT01268085|Decision Support
1173547|NCT01268085|Cat Scans
1173548|NCT01268072|COPD
1173549|NCT01268059|Non-small cell lung cancer
1173550|NCT01268059|NSCLC
1173551|NCT01268046|aging
1173552|NCT01268046|postmenopausal women
1173553|NCT01268046|estrogen
1173554|NCT01268046|memory
1173555|NCT01268033|rituximab
1173556|NCT01268033|idiopathic nephrotic syndrome
1173557|NCT01268033|minimal change disease
1173558|NCT01268033|focal and segmental glomerulosclerosis
1173559|NCT01268020|Alzheimer
1173560|NCT01268020|AD
1173561|NCT01267994|Steroid
1173562|NCT01267994|Steroid-Resistant
1173563|NCT01267994|Autoimmune Inner Ear Disease
1173564|NCT01267994|Immune Mediated Hearing Loss
1173565|NCT01267994|Sudden Sensorineural Hearing Loss
1173566|NCT01267994|Meniere's Disease
1173567|NCT01267994|Autoimmune
1173568|NCT01267994|Hearing
1173569|NCT01267981|Small bowel
1173571|NCT01267981|gastrointestinal bleeding
1173572|NCT01267981|polyethylene glycol
1173573|NCT01267968|pharmacokinetics
1173574|NCT01267968|bronchoalveolar lavage
1173575|NCT01267968|GSK2251052
1173576|NCT01267968|pulmonary
1173577|NCT01267968|healthy volunteer
1173578|NCT01267968|antimicrobial
1173579|NCT01267942|Adenotonsillectomy.
1173580|NCT01267929|Children with cerebral palsy
1173581|NCT01267929|Gross Motor Function Measure
1173582|NCT01267929|Imitative learning
1173583|NCT01267929|Mirror neuron
1173584|NCT01267929|Action observation
1173585|NCT01267929|Conventional physical therapy
1173586|NCT01267916|intrinsic positive end-expiratory pressure
1173587|NCT01267916|obesity
1173588|NCT01267916|ventilator setting
1173589|NCT01267916|respiratory rate
1173590|NCT01267903|Vaccines Adverse Reaction
1173591|NCT01267890|ethics
1173592|NCT01267890|law
1173593|NCT01267890|surrogate
1173594|NCT01267890|conflict
1173595|NCT01267877|U.S. Preventive Services Task Force
1173596|NCT01267877|Patient attitude
1173597|NCT01267877|Mammogram
1173598|NCT01267877|Guideline
1173599|NCT01267864|migraine
1173600|NCT01267864|emergency
1173601|NCT01267864|metoclopramide
1173602|NCT01267864|ketorolac
1173603|NCT01267864|valproate
1173604|NCT01267851|gynecologic disease
1173605|NCT01267838|Coronary artery disease
1173606|NCT01267838|Restenosis
1173607|NCT01267838|Stent thrombosis
1173608|NCT01267825|Disc herniation
1173609|NCT01267825|Lumbosacral radiculopathy
1173610|NCT01267825|Corticosteroids
1173611|NCT01267786|Oxidotic stress
1173612|NCT01267773|depression
1173613|NCT01267773|conduct problems
1173614|NCT01267760|dialysis
1173615|NCT01267760|hemodialysis
1173616|NCT01267760|Effect of recycled low-volume dialysate on dialysis efficacy
1173617|NCT01267747|Atrial fibrillation
1173618|NCT01267747|Atrial Flutter
1173619|NCT01267747|Primary Aldosteronism
1173620|NCT01267747|Aldosterone Producing Adenoma
1173621|NCT01267734|Everolimus
1173622|NCT01267734|Zotarolimus
1173623|NCT01267734|Cilostazol
1173624|NCT01267734|Clopidogrel
1173625|NCT01267721|heart surgery
1173626|NCT01267695|Gastrointestinal Stromal Tumor
1173627|NCT01267695|Imatinib mesylate
1173628|NCT01267695|Perioperative therapy
1173629|NCT01267682|Delirium
1173630|NCT01267682|Dementia
1173631|NCT01267682|Non-pharmacological Intervention
1173632|NCT01267682|Post-acute care
1173633|NCT01267669|Variceal bleeding
1173634|NCT01267669|Endoscopic therapy
1173635|NCT01267669|Band ligation
1173636|NCT01267669|Somatostatin
1173637|NCT01267669|Vasoactive drugs
1173638|NCT01267669|Octreotide
1173639|NCT01267643|Alefacept
1173640|NCT01267643|Amevive
1173641|NCT01267643|Aplastic Anemia
1173642|NCT01267643|Moderate to Severe Aplastic Anemia
1173643|NCT01267630|Delirium of Mixed Origin
1173644|NCT01267630|Subacute Delirium
1173645|NCT01267630|Mental Disorders, Organic
1173646|NCT01267630|Organic Brain Syndrome, Nonpsychotic
1173647|NCT01267630|Organic Mental Disorders
1173648|NCT01267630|Organic Mental Disorders, Psychotic
1173649|NCT01267630|Psychoses, Traumatic
1173650|NCT01267630|Cognition Disorder
1173651|NCT01267630|Confusion state
1173652|NCT01267630|Disorientation
1173653|NCT01267617|hemodialysis
1173654|NCT01267617|hypotension
1173655|NCT01267617|circulatory stress
1173656|NCT01267617|photo-plethysmography
1173657|NCT01267578|Epitope peptide, CTL, Esophageal cancer, Vaccination
1173658|NCT01267565|ventilator-acquired pneumonia
1173659|NCT01267565|prevention
1173660|NCT01267565|amylase
1173661|NCT01267565|tracheal aspiration
1173662|NCT01267565|microaspiration
1173663|NCT01267552|Breast cancer
1173664|NCT01267552|Surgery
1173665|NCT01267552|Complications
1173666|NCT01267552|Drainage
1173667|NCT01267552|Seroma
1173668|NCT01267539|Suan Zao Ren Tang, climacteric, PSQI, WHOQOL-BREF
1173669|NCT01267526|Growth disorders
1173670|NCT01267526|Saizen
1173671|NCT01267526|Easypod
1173672|NCT01267526|Growth hormone
1173673|NCT01267526|Pediatric subject
1173674|NCT01267513|oxygen saturation
1173675|NCT01267513|pulse rate
1173676|NCT01267513|tachycardia
1173677|NCT01267513|bradycardia
1173678|NCT01267513|hypoxia
1173679|NCT01267487|Heparin
1173680|NCT01267487|Protamine
1173681|NCT01267487|Cardiopulmonary Bypass
1173682|NCT01267487|Titration
1173683|NCT01267474|School children
1173684|NCT01267474|Sugar intake
1173685|NCT01267474|Nutritional education program
1173686|NCT01267461|To asses the biological actions of insulin analogs in primary tumor cells
1173687|NCT01267448|Diabetes Mellitus Type2.
1173688|NCT01267448|Severe Hyperglycemia - blood glucose levels >300mg/dl.
1173689|NCT01267435|Arthroscopy, Anterior Cruciate Ligament, Tibial Tunnel.
1173690|NCT01267422|Leber's Hereditary Optic Neuropathy,11778 LHON mutation,
1173691|NCT01267422|rAAV2-ND4,triamcinolone acetonide
1173692|NCT01267409|Mapping the emotional territories of the STN
1173693|NCT01267409|Identifying the emotional spectral signature of the STN single unit activity
1173694|NCT01267409|Manipulating emotional processing of PD patients by high and low frequency stimulation
1173695|NCT01267409|Affecting long-term emotional states of the PD patients
1173696|NCT01267396|Bioequivalence
1173697|NCT01267396|Sertraline
1173698|NCT01267396|crossover
1173699|NCT01267383|Bioequivalence
1173700|NCT01267383|Sertraline
1173701|NCT01267383|crossover
1173702|NCT01267370|clinical trial
1173703|NCT01267370|dietary fiber
1173704|NCT01267370|constipation
1173705|NCT01267370|children
1173706|NCT01267357|Serous Papillary Endometrial Cancer
1173707|NCT01267357|Endometrioid endometrial cancer
1173708|NCT01267357|biomarkers
1173709|NCT01267357|P16
1173710|NCT01267357|P53
1173711|NCT01267357|Prognosis
1173712|NCT01267344|biliary tract cancer
1173713|NCT01267344|BTC
1173714|NCT01267344|cetuximaba
1173715|NCT01267331|Old Myocardial Infarction
1173716|NCT01267331|Stem Cell Therapy
1173717|NCT01267331|Coronary Artery Bypass Grafting
1173718|NCT01267331|Coronary Artery Disease
1173719|NCT01267318|Gastric juice
1173720|NCT01267318|Stomach
1173721|NCT01267318|GI
1173722|NCT01267318|Gastric juice samples with presence of blood.
1173723|NCT01267305|esophagectomy
1173724|NCT01267305|lung resection
1173725|NCT01267305|venous thromboembolism
1173726|NCT01267305|low molecular weight heparin
1173727|NCT01267305|chest drainage
1173728|NCT01267305|TEG
1173729|NCT01267292|cocaine dependence
1173730|NCT01267292|psychopharmacology
1173731|NCT01267292|attentional bias
1173732|NCT01267292|risky decision making
1173733|NCT01267292|buspirone
1173734|NCT01267292|methylphenidate
1173735|NCT01267227|Hyperlipidemia
1173736|NCT01267227|Cholesterol
1173737|NCT01267227|Blood Pressure
1173738|NCT01267227|Oxidative Stress
1173739|NCT01267227|Pterostilbene
1173740|NCT01267227|Blueberry
1173741|NCT01267227|Grape Extract
1173742|NCT01267201|Single dose bioavailability study of methylprednisolone powder for oral suspension (4mg/mL) versus methylprednisolone tablet (32 mg)
1173743|NCT01267162|CHB
1173744|NCT01267149|superficial vertical perioral lines
1173745|NCT01267149|superficial horizontal and lateral canthal lines
1173746|NCT01267149|correct moderate to severe facial wrinkles and folds
1173747|NCT01267136|Tonsillectomy
1173748|NCT01267136|Pain
1173749|NCT01267136|Pediatric
1173750|NCT01267136|Opioids
1173751|NCT01267136|Tramadol
1173752|NCT01267136|Codeine
1173753|NCT01267097|Pediatric Obesity
1173754|NCT01267097|Treatment
1173755|NCT01267097|Cognitive Behavioural Therapy
1173756|NCT01267097|Psychoeducation
1173757|NCT01267097|Canada
1173758|NCT01267084|Trabectedin (YONDELIS)
1173759|NCT01267084|Ketoconazole
1173760|NCT01267084|Antineoplastic Agents
1173761|NCT01267084|Solid tumors
1173762|NCT01267084|Locally advanced or metastatic disease
1173763|NCT01267084|Chemotherapy
1173764|NCT01267084|Pharmacokinetics
1173765|NCT01267071|Entero-test
1173766|NCT01267071|Phase I
1173767|NCT01267071|GSK962040
1173768|NCT01267071|i.v. microtracer
1173769|NCT01267071|radioactivity
1173770|NCT01267071|pharmacokinetics
1173771|NCT01267071|healthy volunteer
1173772|NCT01267058|Booster vaccination
1173773|NCT01267045|Persian Gulf Syndrome
1173774|NCT01267045|Pain
1173775|NCT01267045|Fatigue
1173776|NCT01267045|Attention
1173777|NCT01267045|Meditation
1173778|NCT01267019|social cognition
1173779|NCT01267019|training intervention
1173780|NCT01266993|Persistence
1173781|NCT01266993|Conjugate vaccine
1173782|NCT01266993|Safety
1173783|NCT01266993|Immunogenicity
1173784|NCT01266993|Meningococcal vaccine
1173785|NCT01266980|cortisol
1173786|NCT01266980|renal impairment
1173787|NCT01266980|serum potassium
1173788|NCT01266980|pharmacokinetics
1173789|NCT01266980|Fluticasone furoate
1173790|NCT01266980|heart rate
1173791|NCT01266967|GSK2118436
1173792|NCT01266967|Metastatic melanoma to the brain
1173793|NCT01266967|Brain metastases
1173794|NCT01266967|Braf mutation
1173795|NCT01266967|Brain neoplasm
1173796|NCT01266967|BRAF inhibitor
1173797|NCT01266954|Cancer
1173798|NCT01266954|18F FDG
1173799|NCT01266954|PK
1173800|NCT01266954|PET
1173801|NCT01266954|Positron Emission Tomography
1173802|NCT01266954|PD
1173803|NCT01266954|AKT Inhibitor
1173804|NCT01266954|GSK2141795
1173805|NCT01266941|pharmacokinetics
1173806|NCT01266941|hepatic impairment
1173807|NCT01266941|heart rate
1173808|NCT01266941|serum potassium
1173809|NCT01266941|serum cortisol
1173810|NCT01266941|GW642444M
1173811|NCT01266941|Fluticasone furoate (GW685698)
1173812|NCT01266915|SCLE
1173813|NCT01266915|CLE
1173814|NCT01266915|DLE
1173822|NCT01266889|preterm infant,cerebral oxygenation, intracranial haemorrhagia
1173823|NCT01266863|Hospital-acquired pneumonia
1173824|NCT01266863|E test
1173825|NCT01266863|Antibiogram
1173826|NCT01266863|Bronchoalveolar lavage
1173827|NCT01266850|vaccine, rotavirus, gastroenteritis, infants
1173828|NCT01266837|metastatic renal cell carcinoma
1173829|NCT01266837|biomarker
1173830|NCT01266837|Everolimus
1173831|NCT01266824|Pain
1173832|NCT01266824|Retinopathy of Prematurity
1173833|NCT01266824|Neonates
1173834|NCT01266811|dexamethasone
1173835|NCT01266811|Siltuximab
1173836|NCT01266811|CNTO 328
1173837|NCT01266811|IL-6
1173838|NCT01266811|Monoclonal Antibody
1173839|NCT01266811|Multiple Myeloma
1173840|NCT01266811|Relapsed or Refractory
1173841|NCT01266811|Velcade
1173842|NCT01266811|bortezomib
1173843|NCT01266798|Health literacy, participation
1173844|NCT01266785|crohn's
1173845|NCT01266785|Infliximab
1173846|NCT01266785|Inflammatory bowel disease
1173847|NCT01266785|digestive tract
1173848|NCT01266785|Interleukin
1173849|NCT01266772|asthma; children; montelukast; treatment; exacerbation
1173850|NCT01266759|Menorrhagia
1173851|NCT01266759|Vaginal ring
1173852|NCT01266759|Norethisterone Acetate
1173853|NCT01266746|gas tamponade,
1173854|NCT01266746|macular hole,
1173855|NCT01266746|macular hole retinal detachment,
1173856|NCT01266746|optical coherence tomography
1173857|NCT01266733|fibromyalgia, non pharmacological intervention
1173858|NCT01266720|pancreatic cancer
1173859|NCT01266720|peptide vaccine
1173860|NCT01266720|VEGFR
1173861|NCT01266720|gemcitabine
1173862|NCT01266707|Hepatocellular carcinoma
1173863|NCT01266707|peptide vaccine
1173864|NCT01266707|VEGFR
1173865|NCT01266694|Pericardial effusion
1173866|NCT01266694|Cardiac surgery
1173867|NCT01266694|Tamponade
1173868|NCT01266694|colchicine
1173869|NCT01266668|Diffuse large B cell lymphoma
1173870|NCT01266668|Breast
1173871|NCT01266668|Rituximab
1173872|NCT01266642|Breast cancer
1173873|NCT01266642|Early invasive breast cancer
1173874|NCT01266642|Ductal carcinoma in situ of the breast
1173875|NCT01266642|Tis
1173876|NCT01266642|T1
1173877|NCT01266642|T2
1173878|NCT01266642|N0
1173879|NCT01266642|N1mic
1173880|NCT01266642|N1a
1173881|NCT01266642|Lumpectomy
1173882|NCT01266642|Hypofractionated whole breast irradiation
1173883|NCT01266642|HF-WBI
1173884|NCT01266642|Conventionally fractionated whole breast irradiation
1173885|NCT01266642|CF-WBI
1173886|NCT01266642|Radiation therapy
1173887|NCT01266642|Radiotherapy
1173888|NCT01266629|small bowel
1173889|NCT01266616|Interleukin-12
1173890|NCT01266616|Electroporation
1173891|NCT01266616|HIV Therapeutic Vaccine
1173892|NCT01266603|Metastatic Melanoma
1173893|NCT01266603|Unresectable Melanoma
1173894|NCT01266603|HDIL-2
1173895|NCT01266603|Interleukin-2
1173896|NCT01266603|IL-2
1173897|NCT01266603|Aldesleukin
1173898|NCT01266603|Proleukin
1173899|NCT01266603|recMAGE-A3 + AS15
1173900|NCT01266603|ASCI
1173901|NCT01266603|recMAGE-A3
1173902|NCT01266603|Recombinant MAGE-A3 protein
1173903|NCT01266603|recMAGE-A3 + AS15 ASCI
1173904|NCT01266603|MAGE-A3
1173905|NCT01266603|MAGE-A3 ASCI
1173906|NCT01266577|Brain Metabolism
1173907|NCT01266577|Neurochemistry
1173908|NCT01266577|Magnetic Resonance Imaging
1173909|NCT01266577|Mental Illness
1173910|NCT01266577|Magnetic Resonance Spectroscopy
1173911|NCT01266577|Healthy Volunteer
1173912|NCT01266577|HV
1173913|NCT01266551|Antireflux procedure
1173914|NCT01266551|Gastroesophageal reflux
1173915|NCT01266551|Infant sleep position
1173916|NCT01266551|pH monitoring
1173917|NCT01266499|Klebsiella , pneumonia, carbapenem-hydrolyzing lactamase, carbapenem-resistant Klebsiella (KPC), eradication,
1173918|NCT01266486|Breast cancer
1173919|NCT01266486|Pharmacodynamics
1173920|NCT01266486|AMPK
1173921|NCT01266486|PET Scan
1173922|NCT01266473|Adults
1173923|NCT01266434|moderate persistent asthma
1173924|NCT01266434|Inhaled corticosteroids
1173925|NCT01266421|DNG
1173926|NCT01266421|Anemia
1173927|NCT01266421|Depression
1173928|NCT01266408|Drospirenone
1173929|NCT01266408|Dienogest
1173930|NCT01266408|Metafolin
1173931|NCT01266408|Folic acid
1173932|NCT01266408|Safety
1173933|NCT01266395|morning symptoms COPD
1173934|NCT01266369|mastocytosis
1173935|NCT01266369|D816V
1173936|NCT01266369|handicaps
1173937|NCT01266356|Minor Traumatic Brain Injury
1173938|NCT01266356|Translation
1173939|NCT01266343|Glaucoma
1173940|NCT01266343|anterior chamber paracentesis
1173941|NCT01266343|conventional Mannitol infusion
1173942|NCT01266330|dairy
1173943|NCT01266330|inflammation
1173944|NCT01266330|reactive oxygen species
1173945|NCT01266330|oxidative stress
1173946|NCT01266330|body composition
1173947|NCT01266291|Tuberous sclerosis
1173948|NCT01266291|TS
1173949|NCT01266291|Seizures
1173950|NCT01266278|shoulder injuries
1173951|NCT01266265|pulmonary arterial hypertension
1173952|NCT01266265|PAH
1173953|NCT01266265|treprostinil sodium
1173954|NCT01266265|Tyvaso
1173955|NCT01266265|inhalation
1173956|NCT01266265|Ventavis
1173957|NCT01266265|iloprost
1173958|NCT01266265|prostacyclin
1173959|NCT01266265|epoprostenol sodium
1173960|NCT01266265|Flolan
1173961|NCT01266265|Veletri
1173962|NCT01266265|subcutaneous and intravenous prostacyclin analogue
1173963|NCT01266265|Remodulin
1173964|NCT01266265|oral ERA
1173965|NCT01266265|bosentan
1173966|NCT01266265|Tracleer
1173967|NCT01266265|ambrisentan
1173968|NCT01266265|Letairis
1173969|NCT01266265|oral PDE5 inhibitors
1173970|NCT01266265|sildenafil
1173971|NCT01266265|Revatio
1173972|NCT01266265|tadalafil
1173973|NCT01266265|Adcirca
1173974|NCT01266265|Opsumit
1173975|NCT01266265|macitentan
1173976|NCT01266265|Adempas
1173977|NCT01266265|riociguat
1173978|NCT01266265|Orenitram
1173979|NCT01266265|oral treprostinil
1173980|NCT01266252|neonates
1173981|NCT01266252|single organ respiratory failure
1173982|NCT01266239|Bifurcation lesion, drug-eluting stent, symmetric expansion
1173983|NCT01266226|Rotator cuff tears
1173984|NCT01266226|ACP
1173985|NCT01266213|fulvestrant
1173986|NCT01266213|anastrozole
1173987|NCT01266213|goserelin
1173988|NCT01266213|tamoxifen
1173989|NCT01266213|premenopausal
1173990|NCT01266213|hormone receptor positive
1173991|NCT01266200|microcirculation
1173992|NCT01266200|vertebral fracture
1173993|NCT01266200|inflammation
1173994|NCT01266200|minimal-invasive surgery
1173995|NCT01266187|FOLFOX
1173996|NCT01266187|liver metastasis
1173997|NCT01266187|cetuximab
1173998|NCT01266174|CIAS
1173999|NCT01266174|Cognition
1174000|NCT01266174|Schizophrenia
1174001|NCT01266174|Eltoprazine
1174002|NCT01266161|dental pain
1174003|NCT01266161|multiple dose
1174004|NCT01266161|ibuprofen
1174005|NCT01266161|third molar extraction
1174006|NCT01266135|Interstitial Lung Disease
1174007|NCT01266135|Usual Interstitial Pneumonia
1174008|NCT01266135|Fibrosis,
1174009|NCT01266135|Pulmonary Fibrosis,
1174010|NCT01266135|Respiratory Disease,
1174011|NCT01266135|Interstitial Lung Disease,
1174012|NCT01266135|Biological Therapy,
1174013|NCT01266135|Therapeutic Uses,
1174014|NCT01266122|HIV
1174015|NCT01266122|Psychosocial problems
1174016|NCT01266122|MSM
1174017|NCT01266122|India
1174018|NCT01266109|Substance Use
1174019|NCT01266109|Delinquency
1174020|NCT01266109|Juvenile Drug Court
1174021|NCT01266109|Contingency Management
1174022|NCT01266109|Family Engagement
1174023|NCT01266096|124I-cRGDY-PEG-dots
1174024|NCT01266096|Pet scan
1174025|NCT01266096|10-155
1174026|NCT01266096|melanoma
1174027|NCT01266096|brain
1174028|NCT01266083|MONTANIDE ISA 51
1174029|NCT01266083|WT1 PEPTIDE SPECIFIC T CELLS
1174030|NCT01266083|vaccine
1174031|NCT01266083|10-143
1174032|NCT01266070|VHL
1174033|NCT01266070|Hemangioblastoma
1174034|NCT01266070|Tumor of the central nervous system
1174035|NCT01266070|TKI258
1174036|NCT01266057|Advanced Malignancies
1174037|NCT01266057|Metastatic cancers
1174038|NCT01266057|Sirolimus
1174039|NCT01266057|Hydroxychloroquine
1174040|NCT01266057|Vorinostat
1174041|NCT01266057|Plaquenil
1174042|NCT01266057|Rapamune
1174043|NCT01266057|Saha
1174044|NCT01266057|Suberoylanilide Hydroxamic Acid
1174045|NCT01266057|MSK-390
1174046|NCT01266057|Zolinza
1174047|NCT01266044|Radiation-induced xerostomia
1174048|NCT01266044|Acupuncture
1174049|NCT01266044|Oropharyngeal cancer
1174050|NCT01266044|Radiation Therapy
1174051|NCT01266044|IMRT
1174052|NCT01266044|Dry mouth
1174053|NCT01266031|Glioblastoma Multiforme
1174054|NCT01266018|small cell lung cancer
1174055|NCT01266018|SCLC
1174056|NCT01266018|ADI-PEG 20
1174057|NCT01266018|arginine deiminase pegylated
1174058|NCT01266005|HBe Ag(-) Chronic Hepatitis B
1174059|NCT01265992|Secondary hyperparathyroidism
1174060|NCT01265992|Mineral and Bone Disorder (CKD-MBD)
1174061|NCT01265992|Chronic Kidney Disease
1174062|NCT01265979|advanced
1174063|NCT01265979|metastatic
1174064|NCT01265979|gastro-intestinal
1174065|NCT01265979|stromal
1174066|NCT01265979|GIST
1174067|NCT01265979|regorafenib
1174068|NCT01265966|Moderate Sedation
1174069|NCT01265966|Sedation, Deep
1174070|NCT01265953|cancer prevention
1174071|NCT01265953|isothiocyanate
1174072|NCT01265953|sulforaphane
1174073|NCT01265940|bladder cancer
1174074|NCT01265940|urothelial cancer
1174075|NCT01265940|metastatic urothelial cancer
1174076|NCT01265940|advanced urothelial cancer
1174077|NCT01265927|Breast Cancer
1174078|NCT01265927|Breast Tumors
1174079|NCT01265927|Cancer of Breast
1174080|NCT01265927|Cancer of the Breast
1174081|NCT01265927|Genes, HER-2
1174082|NCT01265927|Genes, HER2
1174086|NCT01265888|PAH
1174087|NCT01265888|PH IPF
1174088|NCT01265875|Chronic Pancreatitis
1174089|NCT01265862|Tracheal intubation
1174090|NCT01265862|Supraglottic airway devices
1174091|NCT01265862|Patients undergoing general anesthesia
1174092|NCT01265836|Dyslipidemia Treatment and Cardiovascular Outcomes
1174093|NCT01265823|Humira
1174094|NCT01265823|Adalimumab
1174095|NCT01265823|Plaque Psoriasis
1174096|NCT01265810|oral mucositis
1174097|NCT01265810|targeted therapy
1174098|NCT01265810|Caphosol
1174099|NCT01265810|management
1174100|NCT01265771|Arrhythmia
1174101|NCT01265771|Children
1174102|NCT01265758|Atrial fibrillation
1174103|NCT01265758|Cardiac arrhythmia
1174104|NCT01265758|ECG
1174105|NCT01265758|Telemonitoring
1174106|NCT01265758|Telemetry
1174107|NCT01265758|Holter
1174108|NCT01265745|Phase I
1174109|NCT01265732|Phase 1
1174110|NCT01265732|relative bioavailability
1174111|NCT01265732|healthy volunteers
1174112|NCT01265732|pharmacokinetics
1174113|NCT01265732|suspension
1174114|NCT01265732|dispersion
1174115|NCT01265719|Prospective
1174116|NCT01265719|non-interventional
1174117|NCT01265719|longitudinal
1174118|NCT01265719|cohort study
1174119|NCT01265706|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1174120|NCT01265680|Blood Transfusion
1174121|NCT01265680|Heart surgery
1174122|NCT01265680|Erythropoietin
1174123|NCT01265680|HRE
1174124|NCT01265667|Psoriasis
1174125|NCT01265667|Plaque psoriasis
1174126|NCT01265654|Advanced Breast Cancer
1174127|NCT01265654|Hormonal Treatment
1174128|NCT01265615|chronic allograft nephropathy
1174129|NCT01265615|stem-progenitor cells
1174130|NCT01265615|cardiorenal syndrome
1174131|NCT01265615|calcitriol
1174132|NCT01265615|paricalcitol
1174133|NCT01265615|cholecalciferol
1174134|NCT01265615|cardiac repair
1174135|NCT01265615|renal repair
1174136|NCT01265602|Actinic Keratosis
1174137|NCT01265602|AK
1174138|NCT01265602|NMSC
1174139|NCT01265589|RDS
1174140|NCT01265589|Infant, newborn
1174141|NCT01265589|Vitamin A
1174142|NCT01265589|Surfactant
1174143|NCT01265563|silymarin
1174144|NCT01265563|glutathione
1174145|NCT01265563|diabetic nephropathies
1174146|NCT01265563|oxidative stress
1174147|NCT01265563|N-acetylcysteine
1174148|NCT01265563|protein tholation
1174149|NCT01265537|Transplant
1174150|NCT01265537|Tacrolimus
1174151|NCT01265537|Diabetes after transplant
1174152|NCT01265537|Acute rejection prevention
1174153|NCT01265537|New onset diabetes after transplant
1174154|NCT01265511|Hepatitis C
1174155|NCT01265511|SCY-635
1174156|NCT01265511|Ribavirin
1174157|NCT01265511|Interferon
1174158|NCT01265498|Farnesoid X Receptor
1174159|NCT01265498|FXR
1174160|NCT01265498|Nonalcoholic fatty liver disease
1174161|NCT01265498|Nonalcoholic steatohepatitis
1174162|NCT01265498|NAFLD
1174163|NCT01265498|NASH
1174164|NCT01265498|obeticholic acid
1174165|NCT01265472|Translocator Protein
1174166|NCT01265472|Basal Cell Carcinoma
1174167|NCT01265472|Squamous Cell Carcinoma
1174168|NCT01265472|Malignancy
1174169|NCT01265446|Sore throat, upper respiratory tract infection, lozenge with lidocaine and cetylpyridinium chloride.
1174170|NCT01265433|GM-CSF
1174171|NCT01265433|MONTANIDE ISA 51
1174172|NCT01265433|WT1 PEPTIDE SPECIFIC T CELLS
1174173|NCT01265433|Vaccine
1174174|NCT01265433|10-134
1174175|NCT01265420|Dupuytren
1174176|NCT01265420|Dupuytren's Disease
1174177|NCT01265407|Children
1174178|NCT01265407|Hemoglobinopathies
1174179|NCT01265407|Epidemiology
1174180|NCT01265407|Malaria
1174181|NCT01265394|Amyloid
1174182|NCT01265394|Magnetic resonance imaging
1174183|NCT01265394|Positron Emission Tomography
1174184|NCT01265394|Standard uptake value ratios
1174185|NCT01265394|Healthy Subjects
1174186|NCT01265381|Cohort
1174187|NCT01265381|Radiation
1174188|NCT01265381|Thyroid Cancer
1174189|NCT01265368|Advanced Renal Cell Carcinoma
1174190|NCT01265368|Tumor Vaccine
1174191|NCT01265368|Cell-based Therapy
1174192|NCT01265342|Bronchial Spasm
1174193|NCT01265342|Respiratory Tract Infections
1174194|NCT01265342|Viral wheezing
1174195|NCT01265342|Child, Preschool
1174196|NCT01265342|Beclomethasone
1174197|NCT01265342|Italy
1174198|NCT01265342|Physicians, Primary Care
1174199|NCT01265342|Pediatrics
1174200|NCT01265316|Cardiac arrest, CPR, pediatric
1174201|NCT01265303|ablation, cardiac arrhythmia, atrial fibrillation, telemonitoring, telemetry
1174202|NCT01265290|Cardiac arrhythmia
1174203|NCT01265290|Cardiogenic syncope
1174204|NCT01265290|Pediatrics
1174205|NCT01265290|Children
1174212|NCT01265264|Gout
1174213|NCT01265264|hyperuricemia
1174214|NCT01265264|arthritis
1174215|NCT01265264|joint diseases
1174216|NCT01265264|allopurinol
1174217|NCT01265251|Normal Pressure Hydrocephalus
1174218|NCT01265251|Neuropsychological Test
1174219|NCT01265251|Assessment of cognitive disorders/dementia
1174220|NCT01265251|Neuropsychological assessment
1174221|NCT01265238|Spastic equinovarus foot
1174222|NCT01265238|Stroke
1174223|NCT01265238|Neurotomy
1174224|NCT01265238|Tendon surgery
1174225|NCT01265225|breast cancer stages 0-II
1174226|NCT01265199|AML
1174227|NCT01265186|Sedation
1174228|NCT01265186|BIS
1174229|NCT01265186|aEEG
1174230|NCT01265186|Neonatal Pain and Sedation Scale
1174231|NCT01265186|neonate
1174232|NCT01265186|newborn
1174233|NCT01265173|SBP
1174234|NCT01265173|liver cirrhosis
1174235|NCT01265173|antibiotics
1174236|NCT01265134|the elders
1174237|NCT01265134|falling
1174238|NCT01265134|loss balance
1174239|NCT01265121|Acromegaly
1174240|NCT01265121|Insulin resistance
1174241|NCT01265121|Euglycemic Clamp
1174242|NCT01265121|Somatostatin analogues
1174243|NCT01265095|VRE
1174244|NCT01265069|Helicobacter pylori
1174245|NCT01265069|concomitant therapy
1174246|NCT01265069|high dose dual therapy
1174247|NCT01265069|antibiotic resistance
1174248|NCT01265043|oral health
1174249|NCT01265043|oral hygiene
1174250|NCT01265043|bacteria
1174251|NCT01265043|quality of life
1174252|NCT01265043|Clinical oral health in patients following acute stroke
1174253|NCT01265043|Oral opportunistic pathogens in patients following acute stroke
1174254|NCT01265043|Oral health-related quality of life in patients following acute stroke
1174255|NCT01265030|Desmoid Tumor
1174256|NCT01265030|Sirolimus
1174257|NCT01265030|Surgically-Resectable Desmoid Tumor
1174258|NCT01265017|type 1 diabetes
1174259|NCT01265017|pregnancy
1174260|NCT01265017|insulin requirement
1174261|NCT01265004|Functional outcome
1174262|NCT01264991|Sham
1174263|NCT01264991|Meniscus tear
1174264|NCT01264991|Meniscectomy
1174265|NCT01264978|COPD
1174266|NCT01264978|Rehabilitation
1174267|NCT01264978|Neuromuscular stimulation
1174268|NCT01264978|Quadriceps muscle
1174269|NCT01264978|Magnetic stimulation
1174270|NCT01264965|Pain
1174271|NCT01264965|Analgesia
1174272|NCT01264965|Cognitive impairment
1174273|NCT01264965|Randomized controlled trial
1174274|NCT01264965|Physical function
1174275|NCT01264952|Liver metastases of colorectal cancer
1174276|NCT01264952|Bleomycin
1174277|NCT01264952|Electrochemotherapy
1174278|NCT01264900|Psychotherapy
1174279|NCT01264900|Cognitive Behavioral Therapy
1174280|NCT01264900|Aggression
1174281|NCT01264900|fMRI
1174282|NCT01264900|Behavioral Intervention
1174283|NCT01264887|analgesia
1174284|NCT01264887|analgesics
1174285|NCT01264887|chronic pain
1174286|NCT01264887|tumour related pain
1174287|NCT01264887|chronic malignant tumor-related pain
1174288|NCT01264861|Evaluate dopamine and serotonin activity in the brain at 3 doses of Safinamide
1174289|NCT01264848|multiple sclerosis
1174290|NCT01264848|venous insufficiency
1174291|NCT01264822|Rabeprazole Sodium
1174292|NCT01264822|Helicobacter pylori
1174293|NCT01264822|stomach neoplasms
1174294|NCT01264809|diabetes
1174295|NCT01264796|Korean American, type 2 diabetes, culturally tailored
1174296|NCT01264770|Rheumatoid Arthritis
1174297|NCT01264770|OSKIRA
1174298|NCT01264770|fostamatinib
1174299|NCT01264757|pedometer
1174300|NCT01264757|accelerometer
1174301|NCT01264757|moderate-to-vigorous physical activity
1174302|NCT01264757|adult
1174303|NCT01264757|randomized trial
1174304|NCT01264744|Bladder cancer
1174305|NCT01264744|Chromosomal aberrations
1174306|NCT01264744|FISH
1174307|NCT01264744|Urine sample
1174308|NCT01264731|melanoma
1174309|NCT01264731|peptide vaccine
1174310|NCT01264731|aldara
1174311|NCT01264731|imiquimod
1174312|NCT01264731|immunotherapy
1174313|NCT01264718|minority health
1174314|NCT01264718|child
1174315|NCT01264718|Medicaid
1174316|NCT01264705|Cirrhosis
1174317|NCT01264705|GI Cancer
1174318|NCT01264705|Hepatitis
1174319|NCT01264705|Oncology
1174320|NCT01264679|Iron deficiency anemia, Feraheme, ferumoxytol, CKD, pediatric, dialysis-dependent, pediatric nondialysis-dependent
1174321|NCT01264666|Chinese tea flavor liquor
1174322|NCT01264666|postprandial
1174323|NCT01264666|uric acid
1174324|NCT01264666|high-sensitive C-reactive protein
1174325|NCT01264653|cataract
1174326|NCT01264640|Brain-derived neurotrophic factor (BDNF)
1174327|NCT01264640|Platelets
1174328|NCT01264640|Aspirin
1174329|NCT01264640|Clopidogrel
1174330|NCT01264627|Hypertension
1174331|NCT01264627|Blood pressure
1174332|NCT01264627|Breathing
1174333|NCT01264627|PetCO2
1174334|NCT01264627|Stress
1174335|NCT01264614|exercise
1174336|NCT01264614|neuropsychological
1174337|NCT01264614|dementia
1174338|NCT01264614|Alzheimer's Disease
1174339|NCT01264614|mild cognitive impairment
1174340|NCT01264614|strength
1174341|NCT01264614|MCI
1174342|NCT01264614|AD
1174343|NCT01264614|EEG
1174344|NCT01264614|neurophysiological
1174345|NCT01264614|growth factor
1174346|NCT01264614|cognitive decline
1174347|NCT01264614|executive function
1174348|NCT01264601|Anaphylaxis to Egg
1174349|NCT01264601|Severe Egg Allergy
1174350|NCT01264575|spinal anesthesia
1174351|NCT01264575|intrathecal bupivacaine
1174352|NCT01264575|epinephrine
1174353|NCT01264575|ED50
1174354|NCT01264575|ED95
1174355|NCT01264562|chemotherapy, adjuvant
1174356|NCT01264562|adverse effects
1174357|NCT01264562|breast neoplasms
1174358|NCT01264562|cognition disorders
1174359|NCT01264562|Stress Disorders, post-traumatic
1174360|NCT01264562|cortisol
1174361|NCT01264549|ischemic stroke
1174362|NCT01264549|stroke-associated infections
1174363|NCT01264549|biomarkers
1174364|NCT01264549|PCT
1174365|NCT01264549|immune and infection parameters
1174366|NCT01264536|lactoferrin
1174367|NCT01264536|sepsis
1174368|NCT01264536|neonates
1174369|NCT01264536|prevention
1174370|NCT01264536|infections
1174371|NCT01264523|chrononutrition
1174372|NCT01264523|moderately high protein
1174373|NCT01264523|glycemic index
1174374|NCT01264523|type-2 diabetes
1174375|NCT01264523|overweight
1174376|NCT01264523|obesity
1174377|NCT01264523|weight management
1174378|NCT01264510|conductive hearing loss
1174379|NCT01264510|mixed hearing loss
1174380|NCT01264510|unilateral deafness
1174381|NCT01264510|implanted with Baha
1174382|NCT01264510|conductive or mixed hearing loss implanted with a Baha or
1174383|NCT01264510|unilateral deafness implanted with a Baha
1174384|NCT01264484|Advantage
1174385|NCT01264484|Non-interventional
1174386|NCT01264484|Post market release study
1174387|NCT01264484|Germany
1174388|NCT01264484|Treated with Advantage prosthetic heart valve
1174389|NCT01264471|Gulf War Syndrome
1174390|NCT01264471|Gulf War Illness
1174391|NCT01264471|Mitochondrial defects
1174392|NCT01264471|Mitochondrial disorders
1174393|NCT01264471|Persian Gulf Syndrome
1174394|NCT01264445|HIV
1174395|NCT01264328|Head and neck cancer, panitumumab, TTCC-2009-03
1174396|NCT01264315|Lenalidomide
1174397|NCT01264315|Tandem Autologous-Allogeneic Transplant
1174398|NCT01264302|Bioequivalence
1174399|NCT01264302|Finasteride
1174400|NCT01264302|crossover
1174401|NCT01264289|Bioequivalence
1174402|NCT01264289|Finasteride
1174403|NCT01264289|crossover
1174404|NCT01264276|ROP
1174405|NCT01264276|Retinopathy of Prematurity
1174406|NCT01264276|Telemedicine
1174407|NCT01264263|cIMT
1174408|NCT01264263|hs CRP (C-reactive protein)
1174409|NCT01264263|DM (Diabetic Mellitus)
1174410|NCT01264263|Korea
1174411|NCT01264263|Corelation between cIMT (carotid intima media thickness)
1174412|NCT01264263|Cardio Vascular risk in Diabetic Mellitus
1174413|NCT01264250|Safety
1174414|NCT01264250|Tolerability
1174415|NCT01264250|pharmacokinetics
1174416|NCT01264250|drug metabolism
1174417|NCT01264237|Postherpetic neuralgia
1174418|NCT01264237|Neuropathic pain
1174419|NCT01264237|Etoricoxib
1174420|NCT01264211|Efficacy of Diacerein
1174421|NCT01264211|Safety of Diacerein
1174422|NCT01264211|Carry-over effect of Diacerein
1174423|NCT01264172|Functional outcome
1174424|NCT01264172|Microcirculation
1174425|NCT01264172|Inflammatory response
1174426|NCT01264159|Developing acute heart failure
1174427|NCT01264146|hyperbaric oxygen therapy
1174428|NCT01264146|calcaneal fracture
1174429|NCT01264146|calcaneal plating
1174430|NCT01264146|wound infection
1174431|NCT01264146|microcirculation
1174432|NCT01264120|Obesity
1174433|NCT01264120|Bariatric surgery
1174434|NCT01264120|Health Psychology
1174435|NCT01264081|Lapatinib
1174436|NCT01264081|Melanoma
1174437|NCT01264081|ERBB4 Mutation
1174438|NCT01264081|Malignant Melanoma
1174439|NCT01264081|Skin Cancer
1174440|NCT01264068|Suan-Tsao-Jen-Tang ,Jia-Wey-Shiau-Yau-San,metabolomics,menopause
1174446|NCT01264042|Iron Supplementation,
1174447|NCT01264042|week 24 to 28 at study day
1174448|NCT01264029|Well-Being
1174449|NCT01264029|Tai Chi
1174450|NCT01264029|Obesity
1174451|NCT01264029|Mindfulness
1174452|NCT01264029|Meditation
1174453|NCT01264029|Overweight
1174454|NCT01264003|inguinal hernia, antibiotic, prophylaxis
1174455|NCT01263990|hemodynamic monitoring systems
1174456|NCT01263990|stroke volume
1174457|NCT01263977|septic shock
1174458|NCT01263977|goal directed volume therapy
1174459|NCT01263977|outcome
1174460|NCT01263964|ischemic stroke
1174461|NCT01263964|troponin elevation
1174462|NCT01263964|transient apical ballooning
1174463|NCT01263964|acute coronary syndrome
1174464|NCT01263964|troponin elevation,
1174465|NCT01263964|culprit lesion on coronary angiogram,
1174466|NCT01263964|troponin elevation and stroke localisation (temporal lobe?)
1174467|NCT01263951|Differentiated metastatic thyroid cancer
1174468|NCT01263938|HIV
1174469|NCT01263938|monocytes
1174470|NCT01263938|CD16+
1174471|NCT01263938|statins
1174472|NCT01263938|mcp1
1174473|NCT01263938|inflammation
1174474|NCT01263925|Alprostadil
1174475|NCT01263925|Prostaglandin E1
1174476|NCT01263925|Prostavasin®
1174477|NCT01263925|PAOD
1174478|NCT01263912|Polyunsaturated fatty acids
1174479|NCT01263912|Cognitive development
1174480|NCT01263912|Growth
1174481|NCT01263912|Infection
1174482|NCT01263899|Lymphoid malignancies
1174483|NCT01263899|Hodgkin lymphoma
1174484|NCT01263899|Mantle Cell Lymphoma
1174485|NCT01263899|Indolent Lymphoma
1174486|NCT01263899|SB1518
1174487|NCT01263847|Dietary Supplement: Galactooligosaccharide
1174488|NCT01263834|Trabeculectomy
1174489|NCT01263834|bevacizumab
1174490|NCT01263834|intraocular pressure
1174491|NCT01263821|glioma
1174492|NCT01263821|biologic imaging
1174493|NCT01263821|magnetic resonance spectroscopy
1174494|NCT01263821|magnetic resonance imaging
1174495|NCT01263821|perfusion imaging
1174496|NCT01263821|diffusion imaging
1174497|NCT01263821|functional magnetic resonance imaging
1174498|NCT01263821|radiation therapy
1174499|NCT01263821|intensity modulated radiation therapy
1174500|NCT01263808|Indacaterol
1174501|NCT01263808|Moxifloxacin
1174502|NCT01263782|Non-Small Cell Lung Cancer
1174503|NCT01263782|NSCLL
1174504|NCT01263782|Nonsquamous cell
1174505|NCT01263782|Metastatic disease
1174506|NCT01263782|Cixutumumab
1174507|NCT01263782|IMC-A12
1174508|NCT01263782|Carboplatin
1174509|NCT01263782|Paraplatin
1174510|NCT01263782|Pemetrexed
1174511|NCT01263782|LY231514
1174512|NCT01263782|Alimta
1174513|NCT01263782|MTA
1174514|NCT01263782|Multitargeted Antifolate
1174515|NCT01263782|NSC-698037
1174516|NCT01263782|Bevacizumab
1174517|NCT01263782|Avastin
1174518|NCT01263782|Anti-VEGF monoclonal antibody
1174519|NCT01263782|rhuMAb-VEGF
1174520|NCT01263769|Locally advanced clear cell renal cell carcinoma
1174521|NCT01263769|AG-013736
1174522|NCT01263769|Axitinib
1174523|NCT01263769|Radical nephrectomy
1174524|NCT01263756|Driving
1174525|NCT01263756|Autism Spectrum Disorders
1174526|NCT01263756|ASD
1174527|NCT01263756|Attention Deficits
1174528|NCT01263756|Adults
1174529|NCT01263756|Adolescents
1174530|NCT01263756|Pervasive Developmental Disorders
1174531|NCT01263743|Stage 1 hypertension
1174532|NCT01263717|HIV
1174533|NCT01263717|lipodystrophy
1174534|NCT01263717|tesamorelin
1174535|NCT01263717|Egrifta
1174536|NCT01263717|growth hormone releasing hormone
1174537|NCT01263691|AVA
1174538|NCT01263691|AV7909
1174539|NCT01263691|Anthrax vaccine
1174540|NCT01263678|Decisional Conflict
1174541|NCT01263678|Coaching
1174542|NCT01263678|Decisional Regret
1174543|NCT01263665|stent-graft
1174544|NCT01263665|superficial femoral artery
1174545|NCT01263665|SFA
1174546|NCT01263665|peripheral artery disease
1174547|NCT01263665|PAD
1174548|NCT01263652|Pain
1174549|NCT01263652|intramuscular
1174550|NCT01263652|oral
1174551|NCT01263652|spine
1174552|NCT01263652|preference
1174553|NCT01263639|patient satisfaction
1174554|NCT01263639|patient-physician relationship
1174555|NCT01263639|orthopaedic trauma
1174556|NCT01263626|Cough
1174557|NCT01263626|Chronic Cough
1174558|NCT01263626|Reflux
1174559|NCT01263600|Hepatitis B
1174560|NCT01263600|HBV
1174561|NCT01263600|Pediatric
1174562|NCT01263587|Hepatitis B
1174563|NCT01263587|HBV
1174564|NCT01263587|Cohort Study
1174568|NCT01263561|glaucoma
1174569|NCT01263561|filtration surgery
1174570|NCT01263561|trabeculectomy
1174571|NCT01263561|ExPRESS shunt
1174572|NCT01263522|primary prevention
1174573|NCT01263522|endurance
1174574|NCT01263522|cardiovascular risk factors
1174575|NCT01263522|training
1174576|NCT01263522|exercise
1174577|NCT01263522|non-responder
1174578|NCT01263509|Diabetes Mellitus - Type 2
1174579|NCT01263509|Diabetes Mellitus
1174580|NCT01263509|Drug Therapy
1174581|NCT01263496|Diabetes Mellitus - Type 2
1174582|NCT01263496|Diabetes Mellitus
1174583|NCT01263496|Drug Therapy
1174584|NCT01263483|Diabetes Mellitus - Type 2
1174585|NCT01263483|Diabetes Mellitus
1174586|NCT01263483|Drug Therapy
1174587|NCT01263470|Diabetes Mellitus - Type 2
1174588|NCT01263470|Diabetes Mellitus
1174589|NCT01263470|Drug Therapy
1174590|NCT01263457|Growth disorders
1174591|NCT01263457|Saizen
1174592|NCT01263457|EasypodTM
1174593|NCT01263457|Growth hormone
1174594|NCT01263457|Pediatric subject
1174595|NCT01263444|AZARGA®
1174596|NCT01263444|Open angle glaucoma
1174597|NCT01263444|Prostaglandin Therapy
1174598|NCT01263431|Hemorrhoidectomy, haemorrhoidal dearterialisation, anopexy
1174599|NCT01263418|Follicular Lymphoma
1174600|NCT01263418|Marginal Zone Lymphoma
1174601|NCT01263418|Non-Hodgkins Lymphoma
1174602|NCT01263418|Elderly
1174603|NCT01263418|Newly Diagnosed
1174604|NCT01263418|Lineberger Comprehensive Cancer Center
1174605|NCT01263418|University of North Carolina
1174606|NCT01263418|Ofatumumab
1174607|NCT01263418|Arzerra
1174608|NCT01263418|Phase 2
1174609|NCT01263418|Geriatric
1174610|NCT01263418|Lymphoma
1174611|NCT01263405|Sarcoma
1174612|NCT01263392|Neurogenic bladder
1174613|NCT01263392|Spina bifida
1174614|NCT01263392|Intermittent catheterization
1174615|NCT01263392|Urinary tract infections
1174616|NCT01263379|gene transfer
1174617|NCT01263366|Radiodermatitis
1174618|NCT01263366|Prevention
1174619|NCT01263366|Radiotherapy
1174620|NCT01263366|Breast
1174621|NCT01263366|Radiation Dermatitis
1174622|NCT01263353|Carcinoid tumor,
1174623|NCT01263353|Gastroenteropancreatic Neuroendocrine Tumors,
1174624|NCT01263353|Pulmonary Neuroendocrine Tumors,
1174625|NCT01263353|pasireotide LAR,
1174626|NCT01263353|SOM230 LAR,
1174627|NCT01263353|everolimus,
1174628|NCT01263353|RAD001,
1174629|NCT01263353|Advanced Neuroendocrine Tumor,
1174630|NCT01263353|Gastroenteropancreatic System
1174631|NCT01263340|COPD
1174632|NCT01263340|observational study
1174633|NCT01263340|prevalence
1174634|NCT01263340|characterisation
1174635|NCT01263327|human papillomavirus vaccine
1174636|NCT01263314|Hypertension
1174637|NCT01263301|subclavian steal
1174638|NCT01263301|carotid duplex
1174639|NCT01263301|subclavian stenosis
1174640|NCT01263301|hemodialysis with vascular access in the upper limbs
1174641|NCT01263301|the focus of this study is to see if duplex can be used as an tool to differentiate the different causes of subclavian steal syndromes
1174642|NCT01263275|depression
1174643|NCT01263275|direct current stimulation
1174644|NCT01263275|alternative electrode montage
1174645|NCT01263262|Surgical site infection
1174646|NCT01263262|Corneal toxicity
1174647|NCT01263262|Ototoxicity
1174648|NCT01263262|Povidone-iodine
1174649|NCT01263262|Chlorhexidine-alcohol
1174650|NCT01263249|Femoral
1174651|NCT01263249|Nerve Block
1174652|NCT01263249|Anterior
1174653|NCT01263249|Posterior
1174654|NCT01263249|Continuous Infusion
1174655|NCT01263249|Perineural Catheter
1174656|NCT01263249|Volunteer
1174657|NCT01263249|Lower Extremity Nerve Blocks
1174658|NCT01263236|Depression
1174659|NCT01263210|Recurrent acute otitis media
1174660|NCT01263210|Conjugate pneumococcal vaccine
1174661|NCT01263210|Ventilation tube treatment
1174662|NCT01263210|Nasopharyngeal flora
1174663|NCT01263184|shoulder
1174664|NCT01263184|strength
1174665|NCT01263184|quality of life
1174666|NCT01263171|adenocarcinoma of the rectum
1174667|NCT01263171|stage IIIB rectal cancer
1174668|NCT01263171|stage IIIC rectal cancer
1174669|NCT01263158|randomised controlled trial
1174670|NCT01263158|nulliparous women
1174671|NCT01263158|slow labour progress
1174672|NCT01263158|prolonged labour
1174673|NCT01263158|oxytocin augmentation
1174674|NCT01263158|operative delivery
1174675|NCT01263158|childbirth experience
1174676|NCT01263132|Polyneuropathy
1174677|NCT01263132|Diabetes Mellitus
1174678|NCT01263132|Diabetic peripheral neuropathy
1174679|NCT01263080|mirtazapine
1174680|NCT01263080|folic acid
1174681|NCT01263080|schizophrenia
1174682|NCT01263067|Posttraumatic Stress Disorder
1174683|NCT01263067|PTSD
1174684|NCT01263067|Car Accident
1174685|NCT01263067|Auto Accident
1174686|NCT01263067|Lifespan Integration
1174687|NCT01263054|Back Pain
1174688|NCT01263054|Low Back Pain
1174689|NCT01263054|Discogenic Back Pain
1174690|NCT01263041|Glutamine, NEC, L-arginine,Preterm,Sepsis
1174691|NCT01263015|GSK1349572
1174692|NCT01263015|Abacavir/Lamivudine
1174693|NCT01263015|Treatment-naive
1174694|NCT01263015|HIV Infection
1174695|NCT01263015|Dolutegravir
1174696|NCT01263015|integrase inhibitor
1174697|NCT01263015|Atripla
1174698|NCT01262989|Bioequivalence
1174699|NCT01262989|Tamsulosin
1174700|NCT01262989|Healthy volunteers
1174701|NCT01262989|Fast conditions
1174702|NCT01262976|Tuberculosis vaccine
1174703|NCT01262963|GSK2118436
1174704|NCT01262963|BRAF inhibitor
1174705|NCT01262963|BRAF positive tumor
1174706|NCT01262963|ADME
1174707|NCT01262963|Oncology
1174708|NCT01262937|confocal, biliary, esophagus
1174709|NCT01262924|Booster vaccination
1174710|NCT01262898|13 C oral breath test
1174711|NCT01262898|pharmacokinetics
1174712|NCT01262898|symptoms
1174713|NCT01262898|tolerability
1174714|NCT01262898|gut motility
1174715|NCT01262898|repeat dose
1174716|NCT01262898|pharmacodynamics
1174717|NCT01262898|GSK962040
1174718|NCT01262898|phase II
1174719|NCT01262898|Type I and II Diabetes mellitus
1174720|NCT01262898|gastric emptying
1174721|NCT01262898|gastroparesis
1174729|NCT01262872|Haemophilus influenzae
1174730|NCT01262872|Streptococcus pneumoniae
1174731|NCT01262872|The Gambia
1174732|NCT01262872|immunogenicity
1174733|NCT01262872|nasopharyngeal carriage
1174734|NCT01262872|infants
1174735|NCT01262872|safety
1174736|NCT01262872|Pneumococcal vaccine
1174737|NCT01262872|children
1174738|NCT01262846|HIV
1174739|NCT01262846|Flu vaccination
1174740|NCT01262846|HIV infected individuals
1174741|NCT01262846|Fluzone SD
1174742|NCT01262846|Fluzone HD
1174743|NCT01262820|Pazopanib
1174744|NCT01262820|Non Squamous Non Small Cell Lung Cancer
1174745|NCT01262820|After Progress on first line therapy
1174746|NCT01262820|Using Bevacizumab
1174747|NCT01262807|fracture
1174748|NCT01262807|radius
1174749|NCT01262807|adult
1174750|NCT01262807|range of motion
1174751|NCT01262794|Healthy volunteers
1174752|NCT01262794|Japanese
1174753|NCT01262781|neonatal adiposity
1174754|NCT01262781|metabolic syndrome
1174755|NCT01262781|fructose
1174756|NCT01262781|maternal diet
1174757|NCT01262768|Nutrition
1174758|NCT01262768|Obesity
1174759|NCT01262768|Parent
1174760|NCT01262768|Portion Size Estimation
1174761|NCT01262768|Accuracy
1174762|NCT01262755|GERD
1174763|NCT01262755|IBS
1174764|NCT01262755|Minority
1174765|NCT01262742|pregnancy
1174766|NCT01262742|postpartum hemorrhage
1174767|NCT01262742|Cesarean delivery
1174768|NCT01262742|carbetocin
1174769|NCT01262729|xenon inhalation
1174770|NCT01262729|therapeutical hypothermia
1174771|NCT01262729|patients after cardiopulmonary resuscitation
1174772|NCT01262729|efficacy
1174773|NCT01262729|safety
1174774|NCT01262716|Chest wall progression breast cancer
1174775|NCT01262716|PDT
1174776|NCT01262716|Photofrin
1174777|NCT01262716|Photosensitizer
1174778|NCT01262690|First-in-human (FIH)
1174779|NCT01262690|Single Ascending Dose (SAD) Study
1174780|NCT01262690|TAM-163
1174781|NCT01262690|PF-05230901
1174782|NCT01262690|Cachexia
1174783|NCT01262677|Partial epilepsy
1174784|NCT01262677|partial seizures
1174785|NCT01262677|epilepsy
1174786|NCT01262677|seizures
1174787|NCT01262677|adjunctive therapy
1174788|NCT01262677|intervention
1174789|NCT01262677|controlled-release
1174790|NCT01262677|placebo-controlled
1174791|NCT01262677|seizure
1174792|NCT01262664|Advanced prostate cancer
1174793|NCT01262664|Castrate-Resistant Prostate Cancer
1174794|NCT01262664|Prohibitin-TP01
1174795|NCT01262651|Cancer pain
1174796|NCT01262651|Opioid therapy
1174797|NCT01262651|Inadequate analgesia
1174798|NCT01262651|Optimized chronic opioid therapy
1174799|NCT01262625|stable angina
1174800|NCT01262625|recurrent chest pain
1174801|NCT01262625|chest pain
1174802|NCT01262625|angina equivalent
1174803|NCT01262625|diagnosis
1174804|NCT01262625|coronary artery disease
1174805|NCT01262612|cediranib
1174806|NCT01262612|malignant ascites
1174807|NCT01262612|malignant pleural effusion
1174808|NCT01262599|Breast and abdomen morbidities after TRAM flap surgery
1174809|NCT01262599|TRAM flap surgery
1174810|NCT01262599|Post-mastectomy breast reconstructive surgery
1174811|NCT01262586|Type II Diabetes Mellitus
1174812|NCT01262586|Vildagliptin
1174813|NCT01262586|Glimepiride
1174814|NCT01262586|Continuous glucose monitoring
1174815|NCT01262560|pain
1174816|NCT01262560|dysphagia
1174817|NCT01262560|recurrent non-small cell lung cancer
1174818|NCT01262560|stage IA non-small cell lung cancer
1174819|NCT01262560|stage IB non-small cell lung cancer
1174820|NCT01262560|stage IIA non-small cell lung cancer
1174821|NCT01262560|stage IIB non-small cell lung cancer
1174822|NCT01262560|stage IIIA non-small cell lung cancer
1174823|NCT01262560|stage IIIB non-small cell lung cancer
1174824|NCT01262560|extensive stage small cell lung cancer
1174825|NCT01262560|limited stage small cell lung cancer
1174826|NCT01262560|recurrent small cell lung cancer
1174827|NCT01262560|esophagitis
1174828|NCT01262534|Psoriasis
1174829|NCT01262534|comorbidities, associated treatment, quality of life
1174830|NCT01262521|Dietary nitrate
1174831|NCT01262508|autonomic nervous system
1174832|NCT01262482|adenocarcinoma
1174833|NCT01262482|gastric
1174834|NCT01262482|gastroesophageal junction
1174835|NCT01262482|Relapsed
1174836|NCT01262482|sorafenib
1174837|NCT01262482|oxaliplatin
1174838|NCT01262443|Atrial flutter
1174839|NCT01262430|Osteoarthritis
1174840|NCT01262417|colorectal cancer
1174841|NCT01262417|two stage surgery for the resection of hepatic metastases
1174842|NCT01262417|resorbable barrier membrane
1174843|NCT01262417|abdominal and peri-hepatic adhesion
1174844|NCT01262391|Overactive bladder
1174845|NCT01262391|Pediatric
1174846|NCT01262391|Pharmacokinetics
1174847|NCT01262391|Single-dose
1174848|NCT01262391|Solifenacin suspension
1174849|NCT01262365|Lupus
1174850|NCT01262365|Monoclonal antibody
1174851|NCT01262365|B-Cell immunotherapy
1174852|NCT01262365|Epratuzumab
1174853|NCT01262339|Primary focal hyperhidrosis
1174854|NCT01262339|interdermal injections
1174855|NCT01262339|iontophoresis
1174856|NCT01262339|BTX-A
1174857|NCT01262300|Immunosenescence
1174858|NCT01262300|Shingles
1174859|NCT01262300|Vitamin D
1174860|NCT01262300|Varicella Zoster Virus
1174861|NCT01262300|Vaccine
1174862|NCT01262300|Immune Response
1174863|NCT01262300|Geriatrics
1174864|NCT01262287|Randomized Trial
1174865|NCT01262287|Medication for Heavy Drinking
1174866|NCT01262287|Dutasteride Treatment
1174867|NCT01262261|opioid dependence
1174868|NCT01262261|opioid addiction
1174869|NCT01262261|buprenorphine
1174870|NCT01262261|implant
1174871|NCT01262261|methadone
1174872|NCT01262261|heroin
1174873|NCT01262261|suboxone
1174874|NCT01262261|opioid pain medication
1174875|NCT01262261|opioid withdrawal
1174876|NCT01262248|small colorectal polyps
1174877|NCT01262248|narrow band imaging
1174878|NCT01262248|vascularization
1174879|NCT01262248|computer-based classification
1174880|NCT01262235|Solid tumor
1174881|NCT01262235|Non-Hodgkin's Lymphoma
1174882|NCT01262235|Hodgkin's Disease
1174883|NCT01262235|Neuroendocrine tumors (NET)
1174884|NCT01262235|Adrenocortical carcinoma (ACC)
1174885|NCT01262235|Carcinoid
1174886|NCT01262222|Predictive Value For Postoperative Cardiac Events
1174887|NCT01262222|Endothelial Dysfunction
1174888|NCT01262222|10-206
1174889|NCT01262209|Vision loss
1174890|NCT01262209|Chronic glaucoma
1174891|NCT01262209|Low vision rehabilitation
1174892|NCT01262196|Trauma
1174893|NCT01262196|Hemorrhage
1174894|NCT01262196|Hemorrhagic shock
1174895|NCT01262196|Lactic acidosis
1174896|NCT01262196|Oxygen carriers
1174897|NCT01262196|Oxygen therapeutics
1174898|NCT01262196|Hemoglobin solutions
1174899|NCT01262196|Red cell substitutes
1174900|NCT01262196|PEG-hemoglobin
1174901|NCT01262183|oesophagus cancer
1174902|NCT01262183|chemoradiotherapy
1174903|NCT01262183|panitumumab
1174904|NCT01262183|irresectable
1174905|NCT01262170|dietary supplement
1174906|NCT01262170|nutraceutical
1174907|NCT01262157|Erectile dysfunction
1174908|NCT01262157|PDE5 Inhibitor
1174909|NCT01262157|Low intensity shock wave therapy.
1174910|NCT01262144|Cervical Cancer
1174911|NCT01262144|PET CT
1174912|NCT01262144|SUV Max
1174913|NCT01262131|Fibromyalgia
1174914|NCT01262131|Pain associated with Fibromyalgia
1174915|NCT01262118|Cholesterol metabolism
1174916|NCT01262118|Cholesterol flux
1174917|NCT01262118|Rheumatoid Arthritis
1174918|NCT01262118|Tasocitinib
1174919|NCT01262118|CP-690
1174920|NCT01262118|550
1174921|NCT01262105|CFU
1174922|NCT01262105|surgery site
1174923|NCT01262092|opioid dependent
1174924|NCT01262092|detoxification
1174925|NCT01262092|buprenorphine
1174926|NCT01262092|suboxone
1174927|NCT01262092|opiate
1174928|NCT01262079|influenza
1174929|NCT01262079|healthy volunteer
1174930|NCT01262079|immunity
1174931|NCT01262079|antibody
1174932|NCT01262079|blood sample
1174933|NCT01262066|hypertension
1174934|NCT01262066|stress reduction
1174935|NCT01262053|Computerized Physician Order Entry
1174936|NCT01262053|CPOE
1174937|NCT01262053|Wrong Patient
1174938|NCT01262053|Juxtaposition
1174939|NCT01262053|Patient Safety
1174940|NCT01262053|Medical Errors
1174941|NCT01262040|NBI
1174942|NCT01262040|ENDOMETRIUM
1174943|NCT01262040|FALLOPIAN TUBE
1174944|NCT01262040|OVARY
1174945|NCT01262040|PERITONEUM
1174946|NCT01262040|Surgery
1174947|NCT01262040|Lung
1174948|NCT01262040|Pancreatic
1174949|NCT01262040|Esophageal
1174950|NCT01262040|thorascopic
1174951|NCT01262040|laparoscopic
1174952|NCT01262040|robotic
1174953|NCT01262040|10-180
1174954|NCT01262027|Metastatic inflammatory breast cancer
1174955|NCT01262027|Stage IV disease
1174956|NCT01262027|HER2-negative
1174957|NCT01262027|Dovitinib
1174958|NCT01262027|TKI258
1174959|NCT01262014|platinum
1174960|NCT01262014|resistant
1174961|NCT01262014|advanced
1174962|NCT01262014|ovarian
1174963|NCT01262014|cancer
1174964|NCT01261975|Ocular Surgery
1174965|NCT01261975|Intraocular Lens
1174966|NCT01261962|Humoral immunity
1174967|NCT01261962|Neutrophil function
1174968|NCT01261962|Gene expression
1174969|NCT01261949|Tinnitus
1174970|NCT01261949|chronic subjective tinnitus
1174971|NCT01261949|transcranial magnetic stimulation
1174972|NCT01261949|sensation disorders
1174973|NCT01261949|hearing disorders
1174974|NCT01261936|Menorrhagia
1174975|NCT01261936|Congenital Bleeding Disorders(CBDs)
1174976|NCT01261936|Diagnosis and treatment of menorrhagia in CBDs
1174977|NCT01261897|Adductor-Canal-Blockade
1174978|NCT01261897|postoperative pain
1174979|NCT01261897|US-guided nerve block
1174980|NCT01261897|total knee arthroplasty
1174981|NCT01261884|Pregnancy
1174982|NCT01261884|Exercise
1174983|NCT01261884|Hypertension
1174984|NCT01261884|Preeclampsia
1174985|NCT01261884|Resistance exercise
1174986|NCT01261858|Sternal closure
1174987|NCT01261858|Coronary artery bypass grafting
1174988|NCT01261858|Biologic bone cement
1174989|NCT01261845|Delivery of Health Care
1174990|NCT01261845|Equity in Health Services
1174991|NCT01261845|Ethnic Groups
1174992|NCT01261845|Health Services Research
1174993|NCT01261845|Health Surveys
1174994|NCT01261845|Immigration
1174995|NCT01261845|Referral and Consultation
1174996|NCT01261845|Resource Allocation
1174997|NCT01261845|Social Justice
1174998|NCT01261845|Vulnerable Populations
1174999|NCT01261832|Acute Myocardial Infarction
1175000|NCT01261832|Percutaneous coronary intervention
1175001|NCT01261819|cystoscopy, minimally invasive hysterectomy
1175002|NCT01261793|Lupus
1175003|NCT01261793|Monoclonal antibody
1175004|NCT01261793|B-Cell immunotherapy
1175005|NCT01261793|Epratuzumab
1175006|NCT01261780|neuropathy,paraneoplastic
1175007|NCT01261780|paraneoplastic peripheral neuropathy
1175008|NCT01261780|pain
1175009|NCT01261780|hyperalgesia
1175010|NCT01261754|Metastatic Prostate Adenocarcinoma
1175011|NCT01261728|Gemcitabine
1175012|NCT01261728|Cisplatin
1175013|NCT01261728|Bladder
1175014|NCT01261728|radical nephroureterectomy
1175015|NCT01261728|ureterectomy
1175016|NCT01261728|10-208
1175017|NCT01261702|Magnesium sulphate
1175018|NCT01261702|Post Pulmonary Resection
1175019|NCT01261702|Pain
1175020|NCT01261689|Epidural analgesia
1175021|NCT01261689|Instrumental delivery
1175022|NCT01261689|Maternal outcome
1175023|NCT01261689|Neonatal outcome
1175024|NCT01261676|caesarean section
1175025|NCT01261676|labour, obstetric
1175026|NCT01261676|implementation guidelines
1175027|NCT01261676|quality indicators
1175028|NCT01261650|widespread chronic pain, transcranial direct current stimulation, fibromyalgia
1175029|NCT01261637|cesarean, pain, transversus abdominus plane block
1175030|NCT01261624|poly JIA
1175031|NCT01261598|Positron-Emission Tomography
1175032|NCT01261598|PET Scan
1175033|NCT01261598|Non-Small-Cell Lung Carcinoma
1175034|NCT01261598|Radiation Oncology
1175035|NCT01261598|SUV
1175036|NCT01261585|Positron-Emission Tomography
1175037|NCT01261585|PET Scan
1175038|NCT01261585|FDG
1175039|NCT01261585|FLT
1175040|NCT01261585|FMISO
1175041|NCT01261585|Non-Small-Cell Lung Carcinoma
1175042|NCT01261585|chemo-Radiation Oncology
1175043|NCT01261585|SUV
1175044|NCT01261572|ASP3550
1175045|NCT01261572|Degarelix
1175046|NCT01261572|Prostate cancer
1175047|NCT01261572|Prostatic neoplasms
1175048|NCT01261559|Computed tomography
1175049|NCT01261559|Radiation dose
1175050|NCT01261559|Dose reduction
1175051|NCT01261559|Breast displacement
1175052|NCT01261559|Chrysalis device
1175053|NCT01261559|Image quality
1175054|NCT01261546|pleural effusion, empyema, corticoids, dexamethasone
1175055|NCT01261533|vitreous body substitute
1175056|NCT01261533|foldable capsular vitreous body
1175057|NCT01261507|lung neoplasm nodule image processing computer-assisted
1175058|NCT01261494|Diabetes Mellitus, Type 2
1175059|NCT01261494|Glucose Metabolism Disorders
1175060|NCT01261494|Metabolic Diseases
1175061|NCT01261494|Cardiovascular Diseases
1175062|NCT01261494|PPARs
1175063|NCT01261494|OGTT
1175064|NCT01261481|Bioavailability
1175065|NCT01261468|Chronic pain
1175066|NCT01261468|Electric Stimulation Therapy
1175067|NCT01261468|Neurologic Examination
1175068|NCT01261442|distal symmetric polyneuropathy
1175069|NCT01261442|diabetic peripheral neuropathy
1175070|NCT01261442|posterior tibial nerve
1175071|NCT01261442|regional anesthesia
1175072|NCT01261442|nerve conduction study
1175073|NCT01261429|Pigmented villonodular synovitis
1175074|NCT01261429|tenosynovial giant cell tumour
1175075|NCT01261429|nilotinib
1175076|NCT01261416|seizures
1175077|NCT01261416|epilepsy
1175078|NCT01261416|neonatal
1175079|NCT01261416|levetiracetam
1175080|NCT01261403|Human Placenta-Derived Cells
1175081|NCT01261390|Sleep Apnea
1175082|NCT01261390|Heart Disease
1175083|NCT01261390|Risk factors for heart disease
1175084|NCT01261377|COPD, obstructive sleep apnea, OSA, BPAP, CPAP
1175085|NCT01261364|GeneSight
1175086|NCT01261364|Assurex
1175087|NCT01261364|AssureRx
1175088|NCT01261351|Pre eclampsia
1175089|NCT01261351|Endogenous thrombin potential
1175090|NCT01261338|PCBs
1175091|NCT01261338|Olestra
1175096|NCT01261312|SGI-110
1175097|NCT01261312|DNA Hypomethylating Agent
1175098|NCT01261312|Intermediate 1, Intermediate 2, CMML or High Risk MDS
1175099|NCT01261312|AML
1175100|NCT01261299|Phase 0 Clinical trial
1175101|NCT01261299|Human microdosing trial
1175102|NCT01261299|Drug resistance, neoplasm
1175103|NCT01261299|Carcinoma, Non-small cell lung
1175104|NCT01261299|Urinary Bladder Neoplasm
1175105|NCT01261299|Individualized Medicine
1175106|NCT01261299|Carboplatin
1175107|NCT01261299|Carboplatin-DNA adducts
1175108|NCT01261286|inflammation
1175109|NCT01261286|receptor downregulation
1175110|NCT01261286|reduced response
1175111|NCT01261286|calcium channels
1175112|NCT01261286|PK-PD relationship
1175113|NCT01261273|PCI
1175114|NCT01261273|observational registry
1175115|NCT01261260|uridine
1175116|NCT01261260|gamma-amino butyric acid
1175117|NCT01261260|Magnetic Resonance Imaging
1175118|NCT01261260|Magnetic Resonance Spectroscopy
1175119|NCT01261260|Proton Echo-Planar Spectroscopic Imaging
1175120|NCT01261234|Carotid Artery Disease
1175121|NCT01261234|Carotid Artery Stenting
1175122|NCT01261234|In stent restenosis
1175123|NCT01261234|Cardiovascular event
1175124|NCT01261234|Intima Media Thickness
1175125|NCT01261208|HIV, AIDS, Helicobacter pylori
1175126|NCT01261182|Malnutrition
1175127|NCT01261182|School feeding
1175128|NCT01261182|Infant nutrition
1175129|NCT01261182|Mother's nutrition
1175130|NCT01261182|Fortified food
1175131|NCT01261182|Anemia
1175132|NCT01261182|Cluster randomized controlled trials
1175133|NCT01261182|Effectiveness
1175134|NCT01261182|Impact evaluation studies
1175135|NCT01261182|Uganda
1175136|NCT01261169|Mycophenolate sodium (Myfortic®)
1175137|NCT01261169|Corticosteroid-refractory autoimmune Uveitis
1175138|NCT01261130|Human Hookworm Vaccine Initiative
1175139|NCT01261130|HHVI
1175140|NCT01261130|Human Hookworm
1175141|NCT01261130|Hookworm
1175142|NCT01261130|Hookworm Disease
1175143|NCT01261130|N. americanus
1175144|NCT01261130|Soil-transmitted helminth infection
1175145|NCT01261130|Intestinal blood loss
1175146|NCT01261130|Iron deficiency anemia
1175147|NCT01261117|Patent ductus arteriosis
1175148|NCT01261117|İbuprofen
1175149|NCT01261117|Extremely Low Birth Weigh infant
1175150|NCT01261104|hearing loss
1175151|NCT01261104|handicap
1175152|NCT01261104|counseling
1175153|NCT01261091|Neurocritical Care
1175154|NCT01261091|Ischemic Stroke
1175155|NCT01261091|Intracerebral Hemorrhage
1175156|NCT01261091|Subarachnoid Hemorrhage
1175157|NCT01261091|Tracheostomy
1175158|NCT01261091|Tracheotomy
1175159|NCT01261091|Percutaneous Dilatative Tracheostomy
1175160|NCT01261091|Weaning
1175161|NCT01261091|Ventilation
1175162|NCT01261078|intrathecal epinephrine
1175163|NCT01261078|duration of anesthesia
1175164|NCT01261078|quality of anesthesia
1175165|NCT01261078|intrathecal fentanyl
1175166|NCT01261065|beta blockers
1175167|NCT01261065|heart failure
1175168|NCT01261065|contractility
1175169|NCT01261065|remodeling
1175170|NCT01261052|glucose sensors
1175171|NCT01261052|artificial pancreas
1175172|NCT01261052|Diabetes Mellitus
1175173|NCT01261013|Keratoconus
1175174|NCT01261013|intrastromal corneal ring segment
1175175|NCT01261013|To evaluate the visual and refractive outcomes of intrastromal corneal ring segment in keratoconic eyes at different stages
1175176|NCT01261000|Acromegaly
1175177|NCT01260987|Moderate to severe actinic keratoses
1175178|NCT01260987|Difficult to treat nodular basal cell carcinomas
1175179|NCT01260974|Invasive fungal infections
1175180|NCT01260974|Liver Transplantation
1175181|NCT01260974|Organ Transplantation
1175182|NCT01260974|Mycoses
1175183|NCT01260974|Fungus Diseases
1175184|NCT01260974|Antifungal Agents
1175185|NCT01260974|Invasive Mycosis
1175186|NCT01260948|Bioequivalence
1175187|NCT01260948|Healthy Subjects
1175188|NCT01260935|GERD
1175189|NCT01260935|laparoscopic surgery
1175190|NCT01260935|gastroesophageal
1175191|NCT01260935|reflux
1175192|NCT01260922|Bioequivalence
1175193|NCT01260922|Healthy Subjects
1175194|NCT01260896|Bioequivalence
1175195|NCT01260896|Healthy Subjects
1175196|NCT01260883|ketorolac pharmacokinetics
1175197|NCT01260883|ketorolac stereo-isomers
1175198|NCT01260883|infants
1175199|NCT01260883|postoperative analgesia
1175200|NCT01260883|safety
1175201|NCT01260857|Spirinolactone
1175202|NCT01260857|Hydroflumethiazide
1175203|NCT01260857|Hypertension
1175204|NCT01260857|Filipinos
1175205|NCT01260857|Diabetes mellitus
1175206|NCT01260857|Proteinuria
1175209|NCT01260818|Tranexamic Acid
1175210|NCT01260805|bioequivalence
1175211|NCT01260805|study
1175212|NCT01260805|ethinylestradiol
1175213|NCT01260805|gestodene
1175214|NCT01260740|Traumatic Brain Injury
1175215|NCT01260740|Explicit Learning
1175216|NCT01260740|Primary Motor Cortex
1175217|NCT01260740|Dorsolateral Prefrontal Cortex
1175218|NCT01260740|Implicit Learning
1175219|NCT01260740|Healthy Volunteer
1175220|NCT01260740|HV
1175221|NCT01260727|HIV Preventive Vaccine
1175224|NCT01260662|Deep Procedural Sedation
1175225|NCT01260662|Propofol
1175226|NCT01260662|Ketamine
1175227|NCT01260662|Emergency Department
1175228|NCT01260662|Monitoring
1175229|NCT01260662|Capnography
1175230|NCT01260662|Procedural Sedation in the Emergency Department
1175231|NCT01260649|Electroconvulsive treatment
1175232|NCT01260649|ketamine
1175233|NCT01260649|Major Depression
1175234|NCT01260649|Treatment-resistant Major Depressive Disorder
1175235|NCT01260623|asthma
1175236|NCT01260623|pharmacokinetics
1175237|NCT01260623|prednisone
1175238|NCT01260623|prednisolone
1175239|NCT01260623|asthma exacerbation
1175240|NCT01260623|pharmacokinetic profile
1175241|NCT01260610|Hepatitis B, Tenofovir, Telbivudine
1175242|NCT01260597|smoking
1175243|NCT01260597|quit line re-enrollment and IVR systems
1175244|NCT01260584|thienopyridine
1175245|NCT01260584|antiplatelet
1175246|NCT01260584|prasugrel
1175247|NCT01260584|clopidogrel
1175248|NCT01260571|blackheads and pimples
1175249|NCT01260571|Acne vulgaris grade II
1175250|NCT01260532|Autoimmune thyroid disease
1175251|NCT01260506|Relapsed Glioblastoma Multiforme, GBM
1175252|NCT01260493|very frail
1175253|NCT01260493|case manager
1175254|NCT01260493|integrated care
1175255|NCT01260493|multiprofessional
1175256|NCT01260493|intervention
1175257|NCT01260480|Carcinoma, non-small-cell lung
1175258|NCT01260480|Head and neck neoplasms
1175259|NCT01260480|Diagnostic imaging
1175260|NCT01260467|recurrent
1175261|NCT01260454|Qutenza
1175262|NCT01260454|Capsaicin
1175263|NCT01260454|Remodulin
1175264|NCT01260454|Treprostinil
1175265|NCT01260428|hypoxia
1175266|NCT01260428|O2 diffusion and convection
1175267|NCT01260428|cardiac output
1175268|NCT01260428|PEEP
1175269|NCT01260428|Effects of hypoxia
1175270|NCT01260415|colorectal cancer
1175271|NCT01260415|liver metastases
1175272|NCT01260415|panitumumab
1175273|NCT01260415|FOLFOX
1175274|NCT01260415|Colorectal cancer with liver metastases
1175275|NCT01260402|heart failure
1175276|NCT01260402|Cardiomyopathy, dilated
1175277|NCT01260402|Coronary disease
1175278|NCT01260402|Cardiac Pacing, Artificial
1175279|NCT01260402|cardiac resynchronization therapy
1175280|NCT01260402|Hemodynamics
1175281|NCT01260402|Randomized Controlled Trials
1175282|NCT01260402|Open Study
1175283|NCT01260389|Chronic Obstructive Pulmonary Disease
1175284|NCT01260389|COPD
1175285|NCT01260376|VLDL-TG
1175286|NCT01260376|Metabolism
1175287|NCT01260376|Exercise
1175288|NCT01260376|Free Fatty Acids
1175289|NCT01260350|PSI-7977
1175290|NCT01260350|Sofosbuvir
1175291|NCT01260350|GS-7977
1175292|NCT01260350|GS-5885
1175293|NCT01260350|GS-9669
1175294|NCT01260350|FDC
1175295|NCT01260350|ribavirin
1175296|NCT01260350|RBV
1175297|NCT01260350|Pegylated Interferon
1175298|NCT01260350|PEG-IFN
1175299|NCT01260350|Chronic Hepatitis C Infection
1175300|NCT01260350|HCV
1175301|NCT01260350|Hepatitis
1175302|NCT01260350|Genotype 1
1175303|NCT01260350|Genotype 2
1175304|NCT01260350|Genotype 3
1175305|NCT01260350|GT 1
1175306|NCT01260350|GT 2
1175307|NCT01260350|GT 3
1175308|NCT01260350|Hemophilia
1175309|NCT01260337|Weight loss
1175310|NCT01260337|Type 2 Diabetes
1175311|NCT01260337|Behavior Modification
1175312|NCT01260337|portion control
1175313|NCT01260324|Phosphodiesterase type 5 inhibitors
1175314|NCT01260324|non-arteritic anterior ischemic optic neuropathy
1175315|NCT01260324|descriptive epidemiology study
1175316|NCT01260311|Observational
1175317|NCT01260298|MC1 VASER VASERShape
1175318|NCT01260272|Cardiovascular
1175319|NCT01260272|Risk Factors
1175320|NCT01260272|Cardiovascular Disease
1175321|NCT01260272|Glucose
1175322|NCT01260272|Blood Pressure
1175323|NCT01260272|BMI
1175324|NCT01260272|Weight
1175325|NCT01260272|Waist Circumference
1175326|NCT01260259|Pediatric
1175327|NCT01260259|Cardiac
1175328|NCT01260259|Surgery
1175329|NCT01260259|Cardiopulmonary
1175330|NCT01260259|Bypass
1175331|NCT01260259|Myocardial
1175332|NCT01260259|Kidney
1175333|NCT01260259|Lung
1175334|NCT01260259|Injury
1175335|NCT01260233|smoking cessation
1175336|NCT01260233|complications
1175337|NCT01260233|cigarettes
1175338|NCT01260233|preoperative
1175339|NCT01260233|perioperative
1175340|NCT01260233|surgery
1175341|NCT01260233|education
1175342|NCT01260233|nicotine replacement therapy
1175343|NCT01260207|Acute Coronary Syndrome
1175344|NCT01260207|Interactive Voice Response Technology
1175345|NCT01260207|Best Practice Guidelines
1175346|NCT01260207|Compliance
1175347|NCT01260207|Health Care Utilization
1175348|NCT01260168|Cancer
1175349|NCT01260168|Colorectal Cancer
1175350|NCT01260168|Neoplasm
1175351|NCT01260168|Colorectal Neoplasm
1175352|NCT01260168|Intestinal Neoplasms
1175353|NCT01260168|Gastrointestinal Neoplasms
1175354|NCT01260168|Digestive System Neoplasms
1175355|NCT01260168|Neoplasms by Site
1175356|NCT01260168|Neoplasms
1175357|NCT01260168|Digestive System Diseases
1175358|NCT01260168|Gastrointestinal Diseases
1175359|NCT01260168|Colonic Diseases
1175360|NCT01260168|Intestinal Diseases
1175361|NCT01260168|Rectal Diseases
1175362|NCT01260129|BPH
1175363|NCT01260129|silodosin
1175364|NCT01260116|Efficacy,safety,ziprasidone,depressive symptoms ,schizophrenia
1175365|NCT01260103|Optic pathway glioma, recurrent
1175366|NCT01260103|Optic pathway glioma, progressive
1175367|NCT01260103|Temozolomide
1175368|NCT01260103|Temodar
1175369|NCT01260103|TMZ
1175370|NCT01260103|Antineoplastons
1175371|NCT01260103|ANP therapy
1175372|NCT01260103|Atengenal (A10)
1175373|NCT01260103|Astugenal (AS2-1)
1175374|NCT01260090|Minimally conscious states
1175375|NCT01260090|Persistently vegetative states
1175376|NCT01260090|Traumatic brain injury
1175377|NCT01260064|Appendicitis
1175378|NCT01260064|Open appendectomy
1175379|NCT01260064|Laparoscopic appendectomy
1175380|NCT01260064|Endoclip
1175381|NCT01260064|Intracorporeal suture
1175382|NCT01260064|Quality-of-life
1175383|NCT01260038|Non Small Cell Lung Cancer
1175384|NCT01260038|observational study
1175385|NCT01260038|EGFR mutation analysis
1175386|NCT01260038|EGFR mutation status
1175387|NCT01260038|testing turn around time
1175388|NCT01260025|Tolerability
1175389|NCT01260025|Pharmacokinetics
1175390|NCT01260025|Endostatin
1175391|NCT01260025|antiangiogenesis
1175392|NCT01260025|cancer
1175393|NCT01260012|Schistosoma mansoni
1175394|NCT01260012|Schistosomiasis
1175395|NCT01260012|periportal fibrosis
1175396|NCT01260012|antioxidant
1175397|NCT01260012|fibrosis reversal
1175398|NCT01259999|malnutrition
1175399|NCT01259999|oleic-acid
1175400|NCT01259999|micronutrient supplement
1175401|NCT01259999|old peoples home
1175402|NCT01259986|Vitiligo
1175403|NCT01259986|Laser
1175404|NCT01259986|Segmental vitiligo
1175405|NCT01259986|Acral vitiligo
1175406|NCT01259973|Pharmacogenetics
1175407|NCT01259973|Antipsychotics
1175408|NCT01259973|Extrapyramidal Symptoms
1175409|NCT01259947|headache
1175410|NCT01259947|migraine
1175411|NCT01259947|medicinal plant
1175412|NCT01259947|essential oil
1175413|NCT01259947|phytotherapy
1175414|NCT01259934|Randomized Phase III trial
1175415|NCT01259934|Adjuvant therapy
1175416|NCT01259934|Interferon
1175417|NCT01259934|Melanoma
1175418|NCT01259921|EEG biofeedback
1175419|NCT01259921|neurofeedback
1175420|NCT01259921|PTSD
1175421|NCT01259921|Affect Regulation
1175422|NCT01259921|Chronic Trauma
1175423|NCT01259908|laparoscopic aortic surgery
1175424|NCT01259908|aorto-iliac occlusive disease
1175425|NCT01259882|Pharmacokinetics Safety Tolerability Pharmacodynamics
1175426|NCT01259856|Polycythemia vera
1175427|NCT01259856|Essential thrombocythemia
1175428|NCT01259856|Hydroxyurea
1175429|NCT01259856|PEGASYS
1175430|NCT01259856|Pegylated Interferon Alfa-2a
1175431|NCT01259843|Acute aortic syndrome
1175432|NCT01259830|fast-track
1175433|NCT01259830|colon or rectal surgery
1175434|NCT01259830|pain relief
1175435|NCT01259817|Polycythemia Vera
1175436|NCT01259817|Essential Thrombocythemia
1175437|NCT01259817|Hydroxyurea Resistant
1175438|NCT01259817|Abdominal Vein Thrombosis
1175439|NCT01259817|PEGASYS
1175440|NCT01259804|peanut
1175441|NCT01259804|food allergy
1175442|NCT01259804|anaphylaxis
1175443|NCT01259804|immunotherapy
1175444|NCT01259778|Growth disorders
1175445|NCT01259778|Saizen
1175446|NCT01259778|easypod™
1175447|NCT01259778|Growth hormone
1175448|NCT01259778|Pediatric subject
1175449|NCT01259765|llama antibody
1175450|NCT01259765|rotavirus diarrhoea
1175451|NCT01259765|children
1175452|NCT01259752|Trauma
1175453|NCT01259752|ankle sprain
1175454|NCT01259752|emergency
1175455|NCT01259752|compression stocking
1175456|NCT01259739|trained cyclists
1175457|NCT01259739|no medications
1175458|NCT01259739|no diseases
1175459|NCT01259739|non-smokers
1175460|NCT01259726|Diarrhea
1175461|NCT01259726|Clostridium difficile
1175462|NCT01259726|Clostridium infections
1175463|NCT01259726|Signs and Symptoms Digestive
1175464|NCT01259726|Bacterial Infections
1175465|NCT01259726|Pharmacologic Actions
1175466|NCT01259713|Ambisome
1175467|NCT01259713|ALL
1175468|NCT01259713|invasive fungal infection
1175469|NCT01259713|prophylaxis
1175470|NCT01259713|liposomal amphotericin B
1175471|NCT01259713|Invasive fungal infection prophylaxis
1175472|NCT01259700|High blood pressure
1175473|NCT01259700|Primary care
1175474|NCT01259700|Cardiovascular disease prevention
1175475|NCT01259700|Salt reduction
1175476|NCT01259687|Electrocardiogram
1175477|NCT01259687|Arterial line waveform
1175478|NCT01259687|Cardiac output
1175479|NCT01259674|Pediatric
1175480|NCT01259674|children
1175481|NCT01259674|acute cough
1175482|NCT01259674|treatment
1175483|NCT01259674|syrup
1175484|NCT01259674|protective natural extracts
1175485|NCT01259661|physical activity
1175486|NCT01259661|metabolic syndrome
1175487|NCT01259661|postmenopausal women
1175488|NCT01259661|exercise training
1175489|NCT01259648|remifentanil
1175490|NCT01259648|anesthesia induction
1175491|NCT01259648|reactional tachycardia
1175492|NCT01259635|Parkinson's disease
1175493|NCT01259635|freezing of gait
1175494|NCT01259609|Diabetic Macular Edema
1175495|NCT01259609|Ciliary Body
1175496|NCT01259609|Ultrasound Biomicroscopy
1175497|NCT01259609|Vitrectomy
1175498|NCT01259596|anxiety
1175499|NCT01259596|rural
1175500|NCT01259596|elderly
1175501|NCT01259544|CP-Chronic Pancreatitis
1175502|NCT01259544|DPT-Di peptide breath test
1175503|NCT01259544|ePFT- Endoscopic pancreatic function test
1175504|NCT01259531|strong
1175505|NCT01259531|silodosin
1175506|NCT01259531|benign prostatic hyperplasia
1175507|NCT01259531|BPH
1175508|NCT01259531|lower urinary tract symptoms associated with severe BPH
1175509|NCT01259505|no number
1175510|NCT01259492|Attention Deficit /Hyperactivity Disorder, hyperactivity
1175511|NCT01259479|Solid Tumors
1175512|NCT01259479|Maximum Tolerated Dose
1175513|NCT01259479|Parmacokinetics
1175514|NCT01259479|Pharmacogenomics
1175515|NCT01259479|Satraplatin
1175516|NCT01259479|Cancer
1175517|NCT01259479|Solid Tumor
1175518|NCT01259479|Brain Tumor
1175519|NCT01259466|Smoking cessation
1175520|NCT01259466|Overweight
1175521|NCT01259466|Obesity
1175522|NCT01259466|Internet treatment
1175523|NCT01259453|Hepatitis B vaccination
1175524|NCT01259453|Syringe exchange programs
1175525|NCT01259453|Injection drug users
1175526|NCT01259453|Hepatitis B prevention through vaccination
1175527|NCT01259440|Telemedicine
1175528|NCT01259440|continuous positive airway pressure
1175529|NCT01259440|treatment adherence
1175530|NCT01259427|Mental Disorders
1175531|NCT01259427|Psychotic Disorders
1175532|NCT01259427|Schizophrenia
1175533|NCT01259427|Stigmatization
1175534|NCT01259427|Mood Disorders
1175535|NCT01259427|Schizophrenia and Disorders with Psychotic Feature
1175536|NCT01259414|Carcinoma,Hepatocellular
1175537|NCT01259414|Liver Neoplasms
1175538|NCT01259414|Survival analysis
1175539|NCT01259414|treatment outcome
1175540|NCT01259414|administration drugs
1175541|NCT01259414|Chemoembolization,
1175542|NCT01259414|TACE
1175543|NCT01259414|polyvinyl alcohol
1175544|NCT01259414|water-soluble contrast mesium
1175545|NCT01259414|iopamidol
1175546|NCT01259414|lipiodol
1175547|NCT01259414|distilled water
1175548|NCT01259401|Sleep
1175549|NCT01259401|Rehabilitation
1175550|NCT01259401|Behavior therapy
1175551|NCT01259401|Insomnia
1175552|NCT01259388|Multiple sclerosis
1175553|NCT01259388|Lithium
1175554|NCT01259349|cataract,
1175555|NCT01259349|phacoemulsification,
1175556|NCT01259349|one percent ultrasound
1175557|NCT01259349|endothelial cell density
1175558|NCT01259336|Itraconazole
1175559|NCT01259336|chronic cavitary pulmonary aspergillosis
1175560|NCT01259336|Aspergillosis
1175561|NCT01259336|fungal ball
1175562|NCT01259336|mycetoma
1175563|NCT01259336|efficacy
1175564|NCT01259336|safety
1175565|NCT01259310|fertility
1175566|NCT01259310|women
1175567|NCT01259310|epilepsy
1175568|NCT01259310|pregnancy
1175569|NCT01259310|seizures
1175570|NCT01259310|seizure frequency
1175571|NCT01259310|ovulation
1175572|NCT01259310|menstruation
1175573|NCT01259310|hormones
1175574|NCT01259310|progesterone
1175575|NCT01259297|Aliskiren
1175576|NCT01259297|Elderly
1175577|NCT01259297|Major Cardiovascular Events
1175578|NCT01259297|Effect of aliskiren-based regimen on major CV events (composite of CV death, non-fatal MI, non-fatal stroke and significant heart failure) in the elderly
1175579|NCT01259284|Breast cancer
1175580|NCT01259284|Colorectal cancer
1175581|NCT01259284|Genitourinary cancer
1175582|NCT01259284|Head and neck cancers
1175583|NCT01259284|Lung cancer
1175584|NCT01259284|Melanoma
1175585|NCT01259284|Sarcoma
1175586|NCT01259284|Atorvastatin
1175587|NCT01259284|Lipitor
1175588|NCT01259284|Fish Oil supplement
1175589|NCT01259284|Placebo
1175590|NCT01259258|varicocele, methylene blue, varicocelectomy, hydrocele,
1175591|NCT01259245|Chronic obstructive pulmonary disease COPD
1175592|NCT01259245|pulmonary rehabilitation program PRP
1175593|NCT01259245|Tai chi
1175594|NCT01259219|HIV
1175595|NCT01259219|Completion of TB treamtment
1175596|NCT01259206|Calcaneal Spur, Diabetic Obese Patients
1175597|NCT01259193|Hepatocellular Carcinoma
1175598|NCT01259193|Sorafenib
1175599|NCT01259193|Zoledronic Acid
1175600|NCT01259193|toxic reaction
1175601|NCT01259180|acupuncture
1175602|NCT01259167|JOBA, Low Back Pain, Physical Exercise
1175603|NCT01256983|Sleep quality
1175604|NCT01256983|Daytime Sleepiness
1175605|NCT01256944|PCOS
1175606|NCT01256944|DM
1175607|NCT01256944|Hypertension
1175608|NCT01256944|CVD
1175609|NCT01256931|2009 H1N1 influenza vaccine, organ transplant patients,
1175610|NCT01256931|booster with Fluarix
1175611|NCT01256918|cataract
1175612|NCT01256918|phacoemulsification
1175613|NCT01256918|phacochop
1175614|NCT01256918|phacotip
1175615|NCT01256827|age-related macular degeneration
1175616|NCT01256827|ranibizumab
1175617|NCT01256827|geographic atrophy
1175618|NCT01256827|ANCHOR Study
1175619|NCT01256827|MARINA Study
1175620|NCT01256814|HIV/AIDS
1175621|NCT01256814|Adult
1175622|NCT01256814|Behavioral Intervention
1175623|NCT01256814|Sleep
1175624|NCT01256814|Physical Activity
1175625|NCT01256801|Metastatic Breast Neoplasms
1175626|NCT01256801|Gene Expression Profiling
1175627|NCT01256801|immunotherapy
1175628|NCT01256788|viscosupplementation
1175629|NCT01256788|meniscus tear
1175630|NCT01256788|degenerative joint disease
1175631|NCT01256775|atherosclerosis
1175632|NCT01256775|carotid intima-media thickness
1175633|NCT01256775|intermittent claudication
1175634|NCT01256775|Nitric Oxide / NO
1175635|NCT01256762|imetelstat
1175636|NCT01256762|imetelstat sodium
1175637|NCT01256762|GRN163L
1175638|NCT01256762|telomerase inhibitor
1175639|NCT01256762|telomerase inhibition
1175640|NCT01256762|metastatic breast cancer
1175641|NCT01256762|locally recurrent breast cancer
1175642|NCT01256762|Bevacizumab
1175643|NCT01256762|Paclitaxel
1175644|NCT01256762|Avastin
1175645|NCT01256762|Taxol
1175646|NCT01256762|HER-2-negative
1175647|NCT01256762|First-Line Chemotherapy
1175648|NCT01256762|Second-Line Chemotherapy
1175649|NCT01256723|drug eluting stent (DES)
1175650|NCT01256723|unprotected left main coronary artery (ULMCA)
1175651|NCT01259141|macrolide- resistant Mycoplasma pneumoniae,
1175652|NCT01259141|Mycoplasm pneumonia antibiotic therapy
1175653|NCT01259115|Healthy subjects
1175654|NCT01259115|Opioid
1175655|NCT01259115|Transdermal
1175656|NCT01259102|Healthy subjects
1175657|NCT01259102|Opioid
1175658|NCT01259102|Transdermal
1175659|NCT01259089|Adenocarcinoma of the Lung
1175660|NCT01259089|Non-small Cell Lung Cancer
1175661|NCT01259063|GEMCITABINE
1175662|NCT01259063|RAD001(EVEROLIMUS)
1175663|NCT01259063|urinary
1175664|NCT01259063|BCG-Refractory
1175665|NCT01259063|Intravesical
1175666|NCT01259063|10-165
1175667|NCT01259050|ALS treatment
1175668|NCT01259050|Zinc
1175669|NCT01259050|Copper
1175670|NCT01259050|BMAA
1175671|NCT01259050|ALS
1175672|NCT01259037|Elastography
1175673|NCT01259037|Cutaneous
1175674|NCT01259037|Imaging
1175675|NCT01259024|hepatocellular carcinoma
1175676|NCT01259024|chemoembolization
1175677|NCT01259024|transarterial chemoembolization
1175678|NCT01259024|liver cancer
1175679|NCT01259024|doxorubicin
1175680|NCT01259024|drug-eluting beads
1175681|NCT01259024|LC Bead
1175682|NCT01259011|end stage renal disease
1175683|NCT01259011|dialysis
1175684|NCT01259011|end of life decision making
1175685|NCT01259011|surrogate psychological morbidities
1175686|NCT01258985|Knee
1175687|NCT01258985|Knee osteoarthritis
1175688|NCT01258985|osteoarthritis
1175689|NCT01258985|Knee pain
1175690|NCT01258985|Tai Chi
1175691|NCT01258985|Physical Therapy
1175692|NCT01258985|mind-body exercise
1175693|NCT01258972|Bifurcation lesions
1175694|NCT01258959|Ultrasound, retrobulbar, parabulbar, ophthalmic surgery.
1175695|NCT01258946|epicardial adipose pcos
1175696|NCT01258933|Leukemia
1175697|NCT01258933|Chronic Lymphocytic Leukemia
1175698|NCT01258933|CLL
1175699|NCT01258933|Lymphoma
1175700|NCT01258933|Small Lymphocytic Lymphoma
1175701|NCT01258933|SLL
1175702|NCT01258933|Ofatumumab
1175703|NCT01258920|Schizophrenia
1175704|NCT01258920|Paliperidone palmitate
1175705|NCT01258920|Intramascular Injection
1175706|NCT01258907|BI-204
1175707|NCT01258868|Mesothelioma
1175708|NCT01258868|Esophageal Cancer
1175709|NCT01258868|Lung Cancer
1175710|NCT01258868|Thoracic Malignancies
1175711|NCT01258868|Tumor Cell Vaccine
1175712|NCT01258842|Influenza
1175713|NCT01258842|Prevention
1175714|NCT01258842|Probiotic
1175715|NCT01258829|Heart Failure Cardiac Resynchronisation Therapy
1175716|NCT01258816|Acute Myeloid Leukaemia (AML)
1175717|NCT01258816|Pharmacokinetics
1175718|NCT01258816|Elacytarabine
1175719|NCT01258816|CP-4055
1175720|NCT01258803|asthma
1175721|NCT01258803|children
1175722|NCT01258803|persistent
1175723|NCT01258790|TS
1175724|NCT01258790|tics
1175725|NCT01258790|tourette
1175726|NCT01258777|Healthy volunteers
1175727|NCT01258777|Japanese male
1175728|NCT01258777|Caucasian male
1175729|NCT01258777|Simponi
1175730|NCT01258764|hypertension
1175731|NCT01258764|Blood Pressure control
1175732|NCT01258764|hypertension treatment
1175733|NCT01258764|antihypertensive
1175734|NCT01258764|N of 1 study
1175735|NCT01258751|Healthy Volunteers
1175736|NCT01258738|Early ankylosing spondylitis (SpA) study; efficacy and safety and health out comes
1175737|NCT01258725|amnioinfusion, severe idiopahic oligohydramnios
1175738|NCT01258673|Fimasartan
1175739|NCT01258673|Fimasartan/Hydrochlorothiazide combination
1175740|NCT01258647|infant nutrition
1175741|NCT01258647|complementary feeding
1175742|NCT01258647|malnutrition
1175743|NCT01258647|stunting of growth
1175744|NCT01258634|Osteosarcoma
1175745|NCT01258634|Surgically Resectable High Grade Osteosarcoma
1175746|NCT01258634|Lung Metastases Only
1175747|NCT01258621|distal pancreatectomy, laparoscopy, learning curve
1175748|NCT01258608|advanced hepatocellular carcinoma
1175749|NCT01258608|Mapatumumab
1175750|NCT01258608|HGS1012
1175751|NCT01258608|sorafenib
1175752|NCT01258595|Influenza
1175753|NCT01258595|Trivalent Inactivated Influenza Vaccine
1175754|NCT01258595|High-Dose Trivalent Inactivated Influenza Vaccine
1175755|NCT01258595|Influenza vaccines
1175756|NCT01258582|HIV
1175757|NCT01258582|Testing
1175758|NCT01258582|HIV Seronegativity
1175759|NCT01258569|laparoscopic
1175760|NCT01258569|colon
1175761|NCT01258569|resection
1175762|NCT01258569|Entereg
1175763|NCT01258543|Global osteopathic evaluation
1175764|NCT01258543|Non-specific back pain
1175765|NCT01258543|Inter-examiner reliability
1175766|NCT01258530|influenza, bioequivalence, oseltamivir, Tamiflu, over-encapsulation
1175767|NCT01258517|RDS
1175768|NCT01258517|surfactant
1175769|NCT01258517|cerebral oxygenation
1175770|NCT01258517|near infrared spectroscopy
1175771|NCT01258504|Steady-state
1175772|NCT01258504|Bosentan
1175773|NCT01258504|St. Johns Wort
1175774|NCT01258478|NSCLC, rehabilitation, CPET, lung resection
1175775|NCT01258465|Communication
1175776|NCT01258465|Pivotal Response Training
1175777|NCT01258465|Picture Exchange Communication System
1175778|NCT01258439|HIV
1175779|NCT01258439|cardiovascular disease
1175780|NCT01258439|post prandial lipids
1175781|NCT01258439|ritonavir
1175782|NCT01258439|darunavir
1175783|NCT01258439|raltegravir
1175784|NCT01258439|arterial stiffness
1175785|NCT01258439|tonometry
1175786|NCT01256684|Vulvar/vaginal atrophy
1175787|NCT01256684|Atrophic Vaginitis
1175788|NCT01256684|Dehydroepiandrosterone
1175789|NCT01256684|DHEA
1175790|NCT01256684|Prasterone
1175791|NCT01256684|Vaginorm
1175792|NCT01256684|Menopause
1175793|NCT01256684|Intrarosa
1175794|NCT01256671|Vulvar/Vaginal Atrophy
1175795|NCT01256671|Atrophic Vaginitis
1175796|NCT01256671|Dehydroepiandrosterone
1175797|NCT01256671|DHEA
1175798|NCT01256671|Prasterone
1175799|NCT01256671|Vaginorm
1175800|NCT01256671|Menopause
1175801|NCT01256658|P. falciparum
1175802|NCT01256658|malaria
1175803|NCT01256658|asymptomatic carriers
1175804|NCT01256658|bed-nets
1175805|NCT01256658|ITN-insecticide-treated net
1175806|NCT01256658|idiopathic trigeminal neuralgia
1175807|NCT01256658|RDT-Rapid diagnostic test
1175808|NCT01256645|weaning
1175809|NCT01256645|mechanical ventilation
1175810|NCT01256645|blood transfusion
1175811|NCT01256645|spontaneous breathing trials
1175812|NCT01256619|Marvelon
1175813|NCT01256619|PMS
1175814|NCT01256619|serum Lipids
1175820|NCT01256554|Stereotactic Radiosurgery
1175821|NCT01256554|SSRS
1175822|NCT01256554|Radiation
1175823|NCT01256554|Radiotherapy
1175824|NCT01256554|Metastatic Epidural Spinal Cord Compression
1175825|NCT01256554|MESCC
1175826|NCT01256528|Invasive breast carcinoma
1175827|NCT01256528|Breast reconstruction
1175828|NCT01256528|Mastectomy
1175829|NCT01256528|Breast cancer
1175830|NCT01256528|Delayed-delayed breast reconstruction
1175831|NCT01256528|Post-mastectomy radiation therapy
1175832|NCT01256515|Healthy adults aged 50 or older
1175833|NCT01256489|KPro
1175834|NCT01256489|Keratoprosthesis
1175835|NCT01256489|Stevens-Johnson Syndrome
1175836|NCT01256489|Infliximab
1175837|NCT01256489|Corneal Blindness
1175838|NCT01258413|Cervical Cancer
1175839|NCT01258413|Radical hysterectomy, Laparoscopic
1175840|NCT01258413|Overall survival
1175841|NCT01258413|Disease-free five-years survival
1175842|NCT01258374|Pharmacokinetics, raltegravir, darunavir, NRTI sparing regimen
1175843|NCT01258361|preoperative fasting
1175844|NCT01258296|Postoperative pain
1175845|NCT01258296|Breast reconstruction
1175846|NCT01258296|Abdominal flap breast reconstruction
1175847|NCT01258257|Aneurysm
1175848|NCT01258257|Subarachnoid hemorrhage
1175849|NCT01258257|Lumbar drain
1175850|NCT01258257|Cerebral vasospasm
1175851|NCT01258257|Cerebral Ventricles
1175852|NCT01258257|Cerebrospinal Fluid
1175853|NCT01258257|Prospective Studies
1175854|NCT01258257|Drainage/methods*
1175855|NCT01258257|Humans
1175856|NCT01258257|Subarachnoid Hemorrhage/cerebrospinal fluid*
1175857|NCT01258257|Subarachnoid Hemorrhage/complications*
1175858|NCT01258257|Subarachnoid Space/surgery*
1175859|NCT01258257|Vasospasm, Intracranial/etiology
1175860|NCT01258257|Vasospasm, Intracranial/surgery*
1175861|NCT01258244|Out-of-Hospital Cardiac Arrest, OHCA
1175862|NCT01258205|Amgen
1175863|NCT01258205|AMG 139
1175864|NCT01258205|Crohn's Disease
1175865|NCT01258192|esophageal squamous cell carcinoma
1175866|NCT01258192|neoadjuvant chemotherapy
1175867|NCT01258192|albumin-bound paclitaxel
1175868|NCT01258192|cisplatin
1175869|NCT01258153|Infantile Colic
1175870|NCT01258153|tachykinin antagonist
1175871|NCT01258153|Nepadutant
1175872|NCT01258140|CT angiography
1175873|NCT01258140|radiation dose
1175874|NCT01258140|contrast medium
1175875|NCT01258127|Pemetrexed
1175876|NCT01258127|Vinorelbine
1175877|NCT01258127|Carboplatin
1175878|NCT01258114|Overweight
1175879|NCT01258114|Obesity
1175880|NCT01258114|Balneotherapy
1175881|NCT01258114|Spa Therapy
1175882|NCT01258114|balneology
1175883|NCT01258114|hydrotherapy
1175884|NCT01258114|SF 12
1175885|NCT01258114|Nutritional counselling
1175886|NCT01258114|Zelen double consent
1175887|NCT01258114|Lifestyle modification program
1175888|NCT01258114|IMC
1175889|NCT01258088|psoriasis
1175890|NCT01258075|type 2 diabetes mellitus
1175891|NCT01258075|blood glucose
1175892|NCT01258075|anti-diabetic
1175893|NCT01258075|bile acid sequestrant
1175894|NCT01258075|colesevelam HCl
1175895|NCT01258075|oral suspension
1175896|NCT01258075|pediatric
1175897|NCT01258075|add-on therapy
1175898|NCT01258075|add-on to metformin
1175899|NCT01258075|metformin
1175900|NCT01258075|adolescent
1175901|NCT01258075|lipid
1175902|NCT01258049|Plasmodium infections
1175903|NCT01258049|Remittent fever
1175904|NCT01258049|Artemether
1175905|NCT01258049|Artemesinins
1175906|NCT01258049|Quinine
1175907|NCT01258049|Malaria
1175908|NCT01258049|Protozoan infections
1175909|NCT01258049|sublingual drug delivery
1175910|NCT01258049|Parasitic disease
1175911|NCT01258049|Antiprotozoan agents
1175912|NCT01258036|Bone microarchitecture
1175913|NCT01258036|Bone mineral density
1175914|NCT01258036|Bone markers
1175915|NCT01258036|hereditary determinism
1175916|NCT01258010|Red blood cell transfusion
1175917|NCT01258010|Neurosurgery
1175918|NCT01258010|Orthopedic surgery
1175919|NCT01258010|Tranexamic acid
1175920|NCT01258010|Surgical blood loss
1175921|NCT01257997|No specific experimental conditions
1175922|NCT01257971|Cholesterol
1175923|NCT01257971|HMG-CoA reductase inhibitor
1175924|NCT01257971|cardiovascular risk
1175925|NCT01257971|LDLl
1175926|NCT01256879|cimetidine
1175927|NCT01256879|pharmacokinetics
1175928|NCT01256879|formulation
1175929|NCT01256866|Dexmedetomidine
1175930|NCT01256866|Midazolam
1175931|NCT01256866|Sedation
1175932|NCT01256866|Mechanical ventilation
1175933|NCT01256866|Critically ill patients
1175934|NCT01256853|histologically confirmed EBV+ NPC patients
1175935|NCT01257958|Vitamin D, 19 nor Vitamin D, Multiple Sclerosis
1175936|NCT01257932|Breast Cancer
1175937|NCT01257906|acne
1175938|NCT01257906|Ziana
1175939|NCT01257906|clindamycin
1175940|NCT01257906|tretinoin
1175941|NCT01257893|migraine
1175942|NCT01257893|chronic migraine
1175943|NCT01257893|migraine with aura
1175944|NCT01257893|migraine without aura
1175945|NCT01257893|aspirin
1175946|NCT01257893|platelets
1175947|NCT01257880|Migraine
1175948|NCT01257880|Migraine with Aura
1175949|NCT01257880|Aura
1175950|NCT01257880|Patent Foramen Ovale
1175951|NCT01257880|Platelets
1175952|NCT01257880|Sleep Apnea
1175953|NCT01257880|Cognitive Function
1175954|NCT01257867|Brain-derived neurotrophic factor
1175955|NCT01257867|Oxidative stress
1175956|NCT01257867|Neurogenesis
1175957|NCT01257867|Lithium
1175958|NCT01257867|Lithia water
1175959|NCT01257854|busulfan
1175960|NCT01257854|pharmacogenetic
1175961|NCT01257854|pharmacokinetic
1175962|NCT01257854|toxicity
1175963|NCT01257854|survival
1175964|NCT01257841|Fasting
1175965|NCT01257841|Gut hormones
1175966|NCT01257841|Inflammatory Cytokines
1175967|NCT01257815|Diabetes mellitus
1175968|NCT01257815|Diabetic retinopathy
1175969|NCT01257815|Macular oedema
1175970|NCT01257815|Visual acuity
1175971|NCT01257789|laparoscopic gastric bypass
1175972|NCT01257789|learning curve
1175973|NCT01257789|complications
1175974|NCT01257789|operative time
1175975|NCT01257776|Critical Limb Ischemia (CLI)
1175976|NCT01257776|Diabetes
1175977|NCT01257776|Mesenchymal Stem Cells
1175978|NCT01257776|Regenerative Therapy
1175979|NCT01257763|needles/adverse effects
1175980|NCT01257763|administration, cutaneous
1175981|NCT01257763|erythema
1175982|NCT01257763|pain measurement
1175983|NCT01257763|Safety
1175984|NCT01257763|Microstructure Transdermal System
1175985|NCT01257750|corneal neovascularization
1175986|NCT01257750|pazopanib
1175987|NCT01257750|votrient
1175988|NCT01257750|rosacea
1175989|NCT01257737|Urea Cycle Disorders
1175990|NCT01257737|GT4P
1175991|NCT01257737|HPN-100
1175992|NCT01257737|Sodium Phenylbutyrate
1175993|NCT01257737|Glyceryl tri-(4-phenylbutyrate)
1175994|NCT01257737|Phenylbutyrate
1175995|NCT01257737|Hyperion
1175996|NCT01257737|Buphenyl
1175997|NCT01257737|hyperammonemia
1175998|NCT01257724|Knowledge translation
1175999|NCT01257724|Community based organizations
1176000|NCT01257724|HIV/AIDS
1176001|NCT01257711|Gastric Cancer
1176002|NCT01257711|Gastrectomy
1176003|NCT01257711|Billroth 2
1176004|NCT01257711|Roux-en-Y
1176005|NCT01257698|Vitrectomy
1176006|NCT01257698|Gas bubble
1176007|NCT01257698|Retinal detachment
1176008|NCT01257698|Macular hole
1176009|NCT01257698|Aqueous suppressant
1176010|NCT01257672|acute gastroenteritis
1176011|NCT01257672|vomiting
1176012|NCT01257672|ondansetron
1176013|NCT01257672|domperidon
1176014|NCT01257672|symptomatic treatment
1176015|NCT01257659|Rectocele
1176016|NCT01257659|Trans anal STARR resection
1176017|NCT01257659|Transvaginal repair
1176018|NCT01257633|da Vinci surgical robot
1176019|NCT01257633|laryngeal cancer
1176020|NCT01257620|Inflammatory Bowel Disease
1176021|NCT01257620|Coeliac Disease
1176022|NCT01257594|Gliomas
1176023|NCT01257594|Erlotinib
1176024|NCT01257594|Glioblastoma
1176025|NCT01257594|GBM
1176026|NCT01257594|Gliosarcoma
1176027|NCT01257594|Glioma
1176028|NCT01257581|ALS
1176029|NCT01257581|Lou Gehrig's Disease
1176030|NCT01257581|Amyotrophic Lateral Sclerosis
1176031|NCT01257581|Creatine
1176032|NCT01257581|Tamoxifen
1176033|NCT01257581|Selection Design
1176034|NCT01257542|randomized
1176035|NCT01257542|parallel
1176036|NCT01257542|double-blind
1176037|NCT01257542|placebo-controlled
1176038|NCT01257542|cough
1176039|NCT01257542|efficacy
1176040|NCT01257542|safety
1176041|NCT01257542|dextromethorphan
1176042|NCT01257529|pregabalin
1176043|NCT01257529|pharmacokinetics
1176044|NCT01257529|bioavailability
1176045|NCT01257529|bioequivalence
1176046|NCT01257516|pregabalin
1176047|NCT01257516|pharmacokinetics
1176048|NCT01257516|bioavailability
1176049|NCT01257516|bioequivalence
1176050|NCT01257503|children
1176051|NCT01257503|upper respiratory tract infections
1176052|NCT01257503|homeopathy
1176053|NCT01257477|Diarrhea
1176054|NCT01257477|IBS
1176055|NCT01257477|Irritable Bowel Syndrome
1176056|NCT01257464|CFRD
1176057|NCT01257464|sitagliptin
1176058|NCT01257464|cystic fibrosis-related diabetes
1176059|NCT01257464|incretins
1176060|NCT01257464|hyperglycemia
1176061|NCT01257464|GIP
1176062|NCT01257464|GLP-1
1176063|NCT01257451|Type 2 Diabetes Mellitus, Vildagliptin, Elderly Patients
1176064|NCT01257412|Phase III
1176065|NCT01257412|Type 2 Diabetes Mellitus
1176066|NCT01257412|inadequate glycaemic control
1176067|NCT01257360|RAS-Wildtype
1176068|NCT01257360|Radiotherapy
1176069|NCT01257360|Neoadjuvant treatment
1176070|NCT01257347|Medication adherence
1176071|NCT01257347|clinical inertia
1176072|NCT01257347|treatment intensification
1176073|NCT01257347|quality of care
1176074|NCT01257334|type 2 diabetes
1176075|NCT01257308|lung cancer
1176076|NCT01257295|dietary fiber
1176077|NCT01257295|energy intake
1176078|NCT01257295|appetite
1176079|NCT01257295|satiety hormones
1176080|NCT01257295|glucose
1176081|NCT01257295|gastric emptying
1176088|NCT01257256|infertile patients
1176089|NCT01257243|cough
1176090|NCT01257243|symptoms
1176091|NCT01257243|cold
1176092|NCT01257243|flu
1176093|NCT01257217|Intraocular Lens
1176094|NCT01257217|Presbyopia
1176095|NCT01257217|multifocal
1176096|NCT01257191|Vehicle Emissions
1176097|NCT01257191|Diesel Exhaust
1176098|NCT01257165|Automobile driving
1176099|NCT01257165|Zopiclone
1176100|NCT01257165|Drug safety
1176101|NCT01257165|Traffic accidents
1176102|NCT01257139|To evaluate a geriatric scale designed to help with treatment
1176103|NCT01257139|allocation to dual-agent therapy based on platinum or to
1176104|NCT01257139|single-agent chemotherapy in elderly subjects with advancedstage
1176105|NCT01257139|NSCLC, based on the time to failure in the two arms
1176106|NCT01257126|Upper respiratory tract infections
1176107|NCT01257126|diclofenac potassium
1176108|NCT01257126|nimesulide
1176109|NCT01257126|fever
1176110|NCT01257126|pain
1176111|NCT01257113|shoulder pain
1176112|NCT01257113|shoulder impingement
1176113|NCT01257113|rotatorcuff pathology
1176114|NCT01257113|supervised exercise
1176115|NCT01257113|homebased exercise
1176116|NCT01257100|Nasopharyngeal Carcinoma
1176117|NCT01257100|Epstein-Barr Virus
1176118|NCT01257100|NPC
1176119|NCT01257087|Type 2 Diabetes Mellitus
1176120|NCT01257087|Obesity
1176121|NCT01257087|Bariatric Surgery
1176122|NCT01257087|Glycaemic control
1176123|NCT01257087|Microvascular complications
1176124|NCT01257087|Intensive
1176125|NCT01257087|Conservative
1176126|NCT01257074|Herpes Simplex
1176127|NCT01257061|Dermatitis
1176128|NCT01257061|Dermatitis, Atopic
1176129|NCT01257048|Oxygen enhanced magnetic resonance imaging
1176130|NCT01257048|chronic obstructive pulmonary disease
1176131|NCT01257048|method evaluation
1176132|NCT01257035|Rectum cancer
1176133|NCT01257035|FAZA
1176134|NCT01257035|18F-FAZA-PET/CT
1176135|NCT01257035|Radiotherapy
1176136|NCT01257035|Chemoradiotherapy
1176137|NCT01257022|Prevention
1176138|NCT01257022|HIV
1176139|NCT01257022|Substance use
1176140|NCT01257022|Hispanic
1176141|NCT01257022|Adolescents
1176142|NCT01257022|Unsafe sexual behavior
1176143|NCT01257022|Behavioral intervention
1176144|NCT01257009|sympathetic activity
1176145|NCT01257009|chronic kidney disease
1176146|NCT01257009|atorvastatin
1176147|NCT01257009|lipitor
1176148|NCT01256450|buccal soluble film
1176149|NCT01256450|enriched enrollment
1176150|NCT01256450|randomized withdrawal
1176151|NCT01256437|Acneiform eruption
1176152|NCT01256437|papulopustular
1176153|NCT01256437|EGFR
1176154|NCT01256437|cetuximab
1176155|NCT01256437|erlotinib
1176156|NCT01256437|gefitinib
1176157|NCT01256437|panitumumab
1176158|NCT01256437|eruption secondary to treatment with either cetuximab
1176159|NCT01256424|CIN
1176160|NCT01256411|hypertension
1176161|NCT01256411|blood pressure
1176162|NCT01256411|LCZ696
1176163|NCT01256411|dual-acting
1176164|NCT01256411|neprilysin
1176165|NCT01256411|nep inhibitor
1176166|NCT01256411|vasopeptidase
1176167|NCT01256411|angiotensin receptor
1176168|NCT01256411|angiotensin receptor neprilysin inhibitor (ARNi)
1176169|NCT01256372|Cardiac surgery
1176170|NCT01256372|Acute kidney injury
1176171|NCT01256346|Premature
1176172|NCT01256346|baby
1176173|NCT01256346|heart rate
1176174|NCT01256346|resuscitation
1176175|NCT01256307|Obstructive Sleep Apnea/Hypopnea Syndrome
1176176|NCT01256307|Exercise training program
1176177|NCT01256307|Inflammation
1176178|NCT01256307|Oxidative Stress
1176179|NCT01256307|Insulin resistance
1176180|NCT01256294|Renal transplant
1176181|NCT01256294|kidney transplant
1176182|NCT01256294|immunosuppressive therapy
1176183|NCT01256294|anti-rejection medication
1176184|NCT01256294|pharmacokinetics
1176185|NCT01256294|tacrolimus
1176186|NCT01256281|Sickle Cell Disease
1176187|NCT01256281|Pain
1176188|NCT01256281|Vasoocclusion
1176189|NCT01256281|Nerve Block
1176190|NCT01256281|Regional Anesthesia
1176191|NCT01256268|metastatic
1176192|NCT01256268|recurrent
1176193|NCT01256268|Solid Cancer
1176194|NCT01256255|transplant
1176195|NCT01256255|influenza infection
1176196|NCT01256242|tendon
1176197|NCT01256242|shoulder
1176198|NCT01256242|rotator cuff
1176199|NCT01256242|Glenohumeral
1176200|NCT01256229|deafness
1176201|NCT01256229|hearing loss
1176202|NCT01256229|developmental delay
1176203|NCT01256229|mental retardation
1176204|NCT01256216|Arthritis
1176205|NCT01256216|Osteoarthritis
1176206|NCT01256216|Arthroplasty
1176207|NCT01256203|PDT
1176208|NCT01256203|Porfimer sodium
1176209|NCT01256203|Phototoxicity
1176210|NCT01256203|Sunscreen
1176211|NCT01256177|Bipolar Depression
1176212|NCT01256177|Mental disease,
1176213|NCT01256164|fibrin sealants
1176214|NCT01256164|hemostatics
1176215|NCT01256164|time to hemostasis
1176216|NCT01256151|Bioequivalence
1176217|NCT01256151|sublingual
1176218|NCT01256151|alprazolam
1176219|NCT01256151|pharmacokinetics
1176220|NCT01256138|Allogene MSCs
1176221|NCT01256138|transplantation
1176222|NCT01256138|chronic liver diseases
1176223|NCT01256138|portal vein
1176224|NCT01256125|allogene MSCs
1176225|NCT01256125|transplantation
1176226|NCT01256125|chronic liver diseases
1176227|NCT01256125|peripheral vein
1176228|NCT01256112|obesity
1176229|NCT01256112|behavioral intervention
1176230|NCT01256112|family based
1176231|NCT01256112|weight loss
1176232|NCT01256099|Self-help treatment
1176233|NCT01256099|Internet treatment
1176234|NCT01256099|CBT
1176235|NCT01256099|Prevention
1176236|NCT01256099|Comorbidity
1176237|NCT01256060|Autism Spectrum disorder
1176238|NCT01256060|Oxytocin
1176239|NCT01256060|Clinical Trial
1176240|NCT01256060|Children
1176241|NCT01256060|Pharmacology
1176242|NCT01256047|immunonutrition
1176243|NCT01256047|hepatectomy
1176244|NCT01256047|Th1
1176245|NCT01256047|Th2
1176246|NCT01256034|immunonutrition
1176247|NCT01256034|pancreaticoduodenectomy
1176248|NCT01256034|Th1
1176249|NCT01256034|Th2
1176250|NCT01256008|Breast Cancer
1176251|NCT01256008|Depression
1176252|NCT01256008|Anxiety
1176253|NCT01256008|Cognitive-Behavioral Therapy
1176254|NCT01255995|PXF
1176255|NCT01255982|Bipolar depression
1176256|NCT01255982|subsyndromal symptoms
1176257|NCT01255982|functioning
1176258|NCT01255982|cognitive function
1176259|NCT01255969|Dialysis
1176260|NCT01255969|Physical exercise
1176261|NCT01255969|Clinical Trial
1176262|NCT01255969|Quality of Life
1176263|NCT01255969|Performance
1176264|NCT01255969|Fitness
1176265|NCT01255969|Cardiovascular Mortality
1176266|NCT01255969|Vascular access
1176267|NCT01255956|restenosis
1176268|NCT01255956|ISR
1176269|NCT01255956|in-stent restenosis
1176270|NCT01255956|drug eluting stent
1176271|NCT01255956|rapamycin eluting stent
1176272|NCT01255956|paclitaxel eluting balloon catheter
1176273|NCT01255943|MRSA
1176274|NCT01255943|bloodstream infections
1176275|NCT01255943|hemodialysis
1176276|NCT01255930|Pregnant Women
1176277|NCT01255930|Sonographic Textures
1176278|NCT01255917|Tio identify role of NGF in pain in CP
1176279|NCT01255917|Identify biomarkers related to progression of CP
1176280|NCT01255891|high risk localized adenocarcinoma of the prostate
1176281|NCT01255878|Sleep bruxism
1176282|NCT01255878|Gabapentine
1176283|NCT01255878|Occlusal splint
1176284|NCT01255878|Polysomnography
1176285|NCT01255865|Thermometry
1176286|NCT01255865|Deep Tissue Temperature
1176287|NCT01255865|Core Temperature
1176288|NCT01255865|Body Temperature
1176289|NCT01255865|Rectal Temperature
1176290|NCT01255865|Oral Temperature
1176291|NCT01255852|atorvastatin
1176292|NCT01255852|intracranial artery stenting
1176293|NCT01255852|restenosis
1176294|NCT01255839|double-balloon
1176295|NCT01255839|balloon catheter
1176296|NCT01255839|prostaglandin
1176297|NCT01255839|minprostin
1176298|NCT01255839|induction of labour
1176299|NCT01255839|fetal outcome
1176300|NCT01255826|Preterm
1176301|NCT01255826|Neonates
1176302|NCT01255826|Delivery room
1176303|NCT01255826|Resuscitation
1176304|NCT01255826|Ventilation
1176305|NCT01255826|Neopuff
1176306|NCT01255826|CPAP
1176307|NCT01255813|Chronic Cluster Headache
1176308|NCT01255787|Major Depressive Disorder
1176309|NCT01255787|Depression
1176310|NCT01255787|Melancholia
1176311|NCT01255787|Drug Therapy
1176312|NCT01255774|subfoveal CNV
1176313|NCT01255774|Wet (Exudative) AMD
1176314|NCT01255774|macular degeneration
1176315|NCT01255761|Certolizumab Pegol
1176316|NCT01255761|Cimzia
1176317|NCT01255761|Rheumatoid Arthritis
1176318|NCT01255761|CDAI
1176319|NCT01255761|RAPID3
1176321|NCT01255735|pediatrics
1176322|NCT01255735|voice
1176323|NCT01255735|voice therapy
1176324|NCT01255735|vocal therapy
1176325|NCT01255735|hoarseness
1176326|NCT01255722|iodinated contrast media, coronary artery disease
1176327|NCT01255709|Asthma
1176328|NCT01255709|shortness of breath
1176329|NCT01255709|wheezing
1176330|NCT01255696|Celiac Disease
1176331|NCT01255696|Coeliac Disease
1176332|NCT01255696|Celiac Sprue
1176333|NCT01255696|Keliakia Disease
1176334|NCT01255683|Chronic
1176335|NCT01255683|Sinusitis
1176336|NCT01255683|Steroid
1176337|NCT01255683|treatment
1176338|NCT01255670|Peritonsillar Abscess
1176339|NCT01255670|Quinsy
1176340|NCT01255670|Penicillin
1176341|NCT01255670|Metronidazole
1176342|NCT01255670|Recurrence
1176343|NCT01255605|Intermittent preventive treatment with sulfadoxin-pyrimethamine
1176344|NCT01255605|in Bobo-Dioulasso peri-urban areas, 5 years after its implementation
1176345|NCT01255605|Burkina Faso.
1176346|NCT01255592|Bronchiectasis
1176347|NCT01255592|Neutrophil
1176348|NCT01255592|Respiratory disease
1176349|NCT01255592|Sputum
1176350|NCT01255579|asthma
1176351|NCT01255579|small airways
1176352|NCT01255579|inhaled corticosteroids
1176353|NCT01255540|Coronary heart disease in patients over
1176354|NCT01255540|80 years of age.
1176355|NCT01255488|Search engine
1176356|NCT01255488|Clinical decision-making
1176357|NCT01255488|Research abstracts
1176358|NCT01255488|Full-text manuscripts
1176359|NCT01255488|Family Nurse Practitioners
1176360|NCT01255462|AMD,
1176361|NCT01255462|ARMD,
1176362|NCT01255462|Age-related Macular Degeneration,
1176363|NCT01255462|Eye Disease,
1176364|NCT01255462|Wet AMD,
1176365|NCT01255462|Neovascular AMD,
1176366|NCT01255462|Choroidal Neovascular Membrane,
1176367|NCT01255462|Choroidal Neovascularization,
1176368|NCT01255462|Drusen,
1176369|NCT01255462|Geographic Atrophy,
1176370|NCT01255462|Complement,
1176371|NCT01255462|C5,
1176372|NCT01255462|Antibody
1176373|NCT01255449|Forced oscillation technique
1176374|NCT01255449|Respiratory input impedance
1176375|NCT01255449|Allogeneic hematopoietic stem cell transplantation
1176376|NCT01255449|Obliterative bronchiolitis
1176377|NCT01255423|Ankle sprain, soft tissue injury
1176378|NCT01255397|male infertility
1176379|NCT01255397|natural cycle IVF
1176380|NCT01255397|in-vitro fertilization
1176381|NCT01255397|intrauterine inseminatio
1176382|NCT01255371|HIV
1176383|NCT01255371|Second line antiretroviral treatment
1176384|NCT01255371|Sub saharian Africa
1176385|NCT01255371|Generic
1176386|NCT01255358|Ataxia Teleangiectasia
1176387|NCT01255358|AT
1176388|NCT01255358|Ery-Dex
1176389|NCT01255358|Dexamethasone
1176390|NCT01255358|Dexamethasone sodium phosphate
1176391|NCT01255345|Physiotherapy
1176392|NCT01255345|Multidisciplinary Pain Centers
1176393|NCT01255345|Pain measurements
1176394|NCT01255345|Physical activity
1176395|NCT01255345|Quality of life
1176396|NCT01255332|ITP
1176397|NCT01255319|MDS
1176398|NCT01255306|Rhegmatogenous retinal detachment
1176399|NCT01255306|Pars plana vitrectomy
1176400|NCT01255306|Silicone oil
1176401|NCT01255306|Retinal nerve fibre layer
1176402|NCT01255293|Retinal detachment
1176403|NCT01255293|Proliferative vitreoretinopathy
1176404|NCT01255293|Diabetic retinopathy
1176405|NCT01255293|Vitrectomy
1176406|NCT01255293|Silicone oil
1176407|NCT01255280|Crystal methamphetamine abuse
1176408|NCT01255280|Crystal methamphetamine dependence
1176409|NCT01255280|Sexual risk behavior
1176410|NCT01255280|Men who have sex with men (MSM)
1176411|NCT01255280|Behavioral activation
1176412|NCT01255267|Acute coronary syndrome and chronic coronary artery disease patients
1176413|NCT01255254|he effect of gingival scaling on Metabolic control
1176414|NCT01255241|Lower Limbs Deformities
1176415|NCT01255241|kinetics
1176416|NCT01255241|kinematics
1176417|NCT01255241|gait
1176418|NCT01255241|energy expenditure
1176419|NCT01255228|obesity
1176420|NCT01255228|body composition
1176421|NCT01255228|adipocyte-derived cytokine
1176422|NCT01255228|low glycemic index
1176423|NCT01255215|malaria
1176424|NCT01255215|children
1176425|NCT01255202|preeclampsia
1176426|NCT01255202|toxemia
1176427|NCT01255202|twin
1176428|NCT01255202|pregnancy
1176429|NCT01255202|pp13
1176430|NCT01255202|prediction
1176431|NCT01255202|kongo red
1176432|NCT01255189|NIRS
1176433|NCT01255176|Infant
1176434|NCT01255176|Physical Therapy
1176435|NCT01255163|Alzheimer's
1176436|NCT01255163|Memory
1176437|NCT01255163|Diabetes
1176438|NCT01255163|Placebo
1176439|NCT01255163|Alzheimer Disease
1176440|NCT01255150|Genetic Ancestry Analysis
1176441|NCT01255150|Molecular Profiling
1176442|NCT01255150|Smoking Status
1176443|NCT01255150|Wood Smoke Exposure
1176444|NCT01255150|EGFR Mutation Analysis
1176445|NCT01255150|Non Small Cell Lung Cancer
1176446|NCT01255137|Selective VEGF Inhibitor
1176447|NCT01255137|Clinical Activity
1176448|NCT01255137|Response Rate
1176449|NCT01255137|Measurable Disease
1176450|NCT01255137|Biological Markers
1176451|NCT01255137|Adrenocortical Cancer
1176452|NCT01255111|Chronic respiratory failure
1176453|NCT01255111|Noninvasive ventilation
1176454|NCT01255111|Patient-ventilator interactions
1176455|NCT01255111|Sleep
1176456|NCT01255111|Sleep fragmentation
1176457|NCT01255085|Obesity
1176458|NCT01255085|Food intake regulation
1176459|NCT01255085|blood glucose regulation
1176460|NCT01255085|protein
1176461|NCT01255085|fiber
1176462|NCT01255085|pulses
1176463|NCT01255085|yellow peas
1176464|NCT01255072|TMS
1176465|NCT01255072|elderly
1176466|NCT01255072|depression
1176467|NCT01255072|neuronavegation
1176468|NCT01255072|neurocognition
1176469|NCT01255059|Genome-wide association studies(GWAS)
1176470|NCT01255059|Single nucleotide polymorphism(SNP)
1176471|NCT01255059|Lung cancer
1176472|NCT01255033|perioperative surgery
1176473|NCT01255033|regional oxygenation
1176474|NCT01255033|hypoxemia
1176475|NCT01255033|brain hypoxemia
1176476|NCT01255033|spectroscopy, near-infrared
1176477|NCT01255020|α-Keto Acid
1176478|NCT01255020|Restricted Protein Diet
1176479|NCT01255020|Residual Renal Function
1176480|NCT01255007|Colorectal
1176481|NCT01255007|liver
1176482|NCT01255007|metastases
1176483|NCT01255007|Primovist
1176484|NCT01255007|MRI
1176485|NCT01255007|CT
1176486|NCT01255007|cancer
1176487|NCT01255007|resection
1176488|NCT01255007|MDCT
1176489|NCT01255007|Diffusion
1176490|NCT01255007|Weighted
1176491|NCT01255007|3T
1176492|NCT01254994|hepatitis B
1176493|NCT01254994|acute on chronic liver failure (ACHBLF)
1176494|NCT01254994|entecavir
1176495|NCT01254994|treatment
1176496|NCT01254994|predicting
1176497|NCT01254981|Percutaneous coronary intervention
1176498|NCT01254981|DES
1176499|NCT01254981|Angina pectoris
1176500|NCT01254981|Stent
1176501|NCT01254968|blood flow in the middle cerebral artery of brain
1176502|NCT01254955|2009 H1N1 influenza vaccine, organ transplant patients
1176503|NCT01254942|exercise
1176504|NCT01254942|hip fractures
1176505|NCT01254942|rehabilitation
1176506|NCT01254942|aged
1176507|NCT01254942|aged 80 and over
1176508|NCT01254929|Cancer
1176509|NCT01254929|Bone metastases
1176510|NCT01254916|Chronic Rhinosinusitis
1176511|NCT01254916|Sinonasal Outcome test 22
1176512|NCT01254903|Stereotactic Radiosurgery
1176513|NCT01254903|Radiation
1176514|NCT01254903|Radiotherapy
1176515|NCT01254903|Metastatic Epidural Spinal Cord Compression
1176516|NCT01254903|MESCC
1176517|NCT01254890|Relapsed Acute Leukemia
1176518|NCT01254890|Chronic Myelomonocytic Leukemia
1176519|NCT01254890|CMML
1176520|NCT01254890|Myelodysplastic Syndrome
1176521|NCT01254890|MDS
1176522|NCT01254890|Acute myeloid leukemia
1176523|NCT01254890|AML
1176524|NCT01254890|5-azacitidine
1176525|NCT01254890|Azacitidine
1176526|NCT01254890|5-aza
1176527|NCT01254890|Vidaza
1176528|NCT01254890|5-AZC
1176529|NCT01254890|AZA-CR
1176530|NCT01254890|Ladakamycin
1176531|NCT01254890|NSC-102816
1176532|NCT01254890|Sorafenib
1176533|NCT01254890|Nexavar
1176534|NCT01254890|BAY43-9006
1176535|NCT01254877|HIV
1176536|NCT01254864|Castrate resistant prostate cancer
1176537|NCT01254864|Adenocarcinoma of the prostate
1176538|NCT01254864|Sunitinib Malate
1176539|NCT01254864|SUO11248
1176540|NCT01254864|Sutent
1176541|NCT01254864|BMS-354825
1176542|NCT01254864|Sprycel
1176543|NCT01254851|discharge criteria, gynecologic surgery, post-op ambulation
1176544|NCT01254825|Adductor Canal Block (ACB)
1176545|NCT01254825|Diagnostic Knee Arthroscopy
1176546|NCT01254825|Saphenous nerve
1176547|NCT01254825|Pain
1176548|NCT01254825|Ultrasound block
1176549|NCT01254812|pulmonary function
1176550|NCT01254812|BD-TAP-block
1176551|NCT01254786|VATS
1176552|NCT01254786|one lung ventilation
1176553|NCT01254786|continuous positive pressure ventilation
1176554|NCT01254786|high frequency positive pressure ventilation
1176555|NCT01254721|Acute bipolar mania
1176556|NCT01254721|Seroquel XR
1176557|NCT01254721|Seroquel XR plus lithium
1176558|NCT01254721|Quetiapine fumarate
1176559|NCT01254695|Idiopathic Fecal Incontinence
1176560|NCT01254695|Fecal Incontinence
1176561|NCT01254695|Sacral Nerve Stimulation
1176562|NCT01254695|Sacral Nerve Neuromodulation
1176563|NCT01254682|wrist
1176564|NCT01254682|joint
1176565|NCT01254682|arthroscopy
1176566|NCT01254682|hyaluronan
1176567|NCT01254682|hyaluronic acid
1176568|NCT01254682|Necessity of Arthroscopic surgery
1176569|NCT01254669|Haitian girls, African American girls
1176570|NCT01254669|Brief Negotiated Interview
1176571|NCT01254669|cognitive behavioral intervention
1176572|NCT01254669|HPV vaccine
1176573|NCT01254669|cervical cancer
1176574|NCT01254643|Papillomavirus vaccines
1176575|NCT01254643|Uterine cervical cancer
1176576|NCT01254643|Human Papilloma Virus infections
1176577|NCT01254630|Herpes zoster
1176578|NCT01254630|vaccine
1176579|NCT01254630|solid tumor malignancy
1176580|NCT01254630|hematologic malignancy
1176581|NCT01254630|immunocompromised
1176582|NCT01254630|herpes-zoster-related complications
1176583|NCT01254604|Tafluprost
1176584|NCT01254604|Glaucoma
1176585|NCT01254604|Ocular Hypertension
1176586|NCT01254604|Timolol
1176587|NCT01254604|Eye Disorder
1176588|NCT01254604|Preservative-Free
1176589|NCT01254604|Prostaglandin Analogue
1176590|NCT01254591|stage IA non-small cell lung cancer
1176591|NCT01254591|stage IB non-small cell lung cancer
1176592|NCT01254591|stage IIA non-small cell lung cancer
1176593|NCT01254591|stage IIB non-small cell lung cancer
1176594|NCT01254591|stage IIIA non-small cell lung cancer
1176595|NCT01254591|stage I colon cancer
1176596|NCT01254591|stage IIA colon cancer
1176597|NCT01254591|stage IIB colon cancer
1176598|NCT01254591|stage IIC colon cancer
1176599|NCT01254591|stage IIIA colon cancer
1176600|NCT01254591|stage I rectal cancer
1176601|NCT01254591|stage IIA rectal cancer
1176602|NCT01254591|stage IIB rectal cancer
1176603|NCT01254591|stage IIC rectal cancer
1176604|NCT01254591|stage IIIA rectal cancer
1176605|NCT01254591|stage IA breast cancer
1176606|NCT01254591|stage IB breast cancer
1176607|NCT01254591|stage II breast cancer
1176608|NCT01254591|stage IIIA breast cancer
1176609|NCT01254591|stage IIIB breast cancer
1176610|NCT01254591|stage I esophageal cancer
1176611|NCT01254591|stage II esophageal cancer
1176612|NCT01254591|stage III esophageal cancer
1176613|NCT01254591|stage I hypopharyngeal cancer
1176614|NCT01254591|stage II hypopharyngeal cancer
1176615|NCT01254591|stage III hypopharyngeal cancer
1176616|NCT01254591|stage I laryngeal cancer
1176617|NCT01254591|stage II laryngeal cancer
1176618|NCT01254591|stage III laryngeal cancer
1176619|NCT01254591|stage I lip and oral cavity cancer
1176620|NCT01254591|stage II lip and oral cavity cancer
1176621|NCT01254591|stage III lip and oral cavity cancer
1176622|NCT01254591|stage I nasopharyngeal cancer
1176623|NCT01254591|stage II nasopharyngeal cancer
1176624|NCT01254591|stage III nasopharyngeal cancer
1176625|NCT01254591|stage I oropharyngeal cancer
1176626|NCT01254591|stage II oropharyngeal cancer
1176627|NCT01254591|stage III oropharyngeal cancer
1176628|NCT01254591|stage I paranasal sinus and nasal cavity cancer
1176629|NCT01254591|stage II paranasal sinus and nasal cavity cancer
1176630|NCT01254591|stage III paranasal sinus and nasal cavity cancer
1176631|NCT01254591|stage I salivary gland cancer
1176632|NCT01254591|stage II salivary gland cancer
1176633|NCT01254591|stage III salivary gland cancer
1176634|NCT01254591|tongue cancer
1176635|NCT01254565|Clinical Trial, Phase 2
1176636|NCT01254565|Renal Dialysis
1176637|NCT01254565|Secondary Hyperparathyroidism
1176638|NCT01254565|Parathyroid hormone
1176639|NCT01254539|Amyotrophic Lateral Sclerosis
1176640|NCT01254539|Bone marrow
1176641|NCT01254539|Stem cells
1176642|NCT01254539|Autologous
1176643|NCT01254539|Safety
1176644|NCT01254513|Metastatic Prostate cancer
1176645|NCT01254513|Elderly patients
1176646|NCT01254513|Vulnerable and Frail (SIOG classification)
1176647|NCT01254513|castration-resistant
1176648|NCT01254500|patients with brain lesions
1176649|NCT01254474|Depolarization, tissue
1176650|NCT01254474|Repolarization, tissue
1176651|NCT01254474|Cardiac Arrhythmias
1176652|NCT01254474|Action potentials, monophasic
1176653|NCT01254474|Mapping, Catheter
1176654|NCT01254474|Cardiac activation
1176655|NCT01254461|Phase 1
1176656|NCT01254461|Drug-Drug interaction
1176657|NCT01254461|pravastatin
1176658|NCT01254461|AZD1981
1176659|NCT01254461|The pharmacokinetics resulting from AZD1981 and pravastatin interaction
1176660|NCT01254461|The effects of taking a combination of AZD1981 and pravastatin
1176661|NCT01254448|Alzheimer's Disease
1176662|NCT01254435|Colonoscopy
1176663|NCT01254435|Positioning in colonoscopy
1176664|NCT01254435|Quality control
1176665|NCT01254422|Dengue fever
1176666|NCT01254422|Dengue hemorrhagic fever
1176667|NCT01254422|CYD dengue vaccine
1176668|NCT01254409|pulmonary, fibrosis
1176669|NCT01254396|Bioavailability Food Effect Oral Dissolving Tablet (ODT)
1176670|NCT01254383|Bioequivalence Oral Dissolving Tablet
1176671|NCT01254357|Burns
1176672|NCT01254357|Trauma
1176673|NCT01254357|Outcomes
1176674|NCT01254357|Quality of Life
1176675|NCT01254344|Colorectal surgery
1176676|NCT01254318|hematological malignancy
1176677|NCT01254318|fungal infection
1176678|NCT01254318|leukemia
1176679|NCT01254305|Depression
1176680|NCT01254305|Fatigue
1176681|NCT01254305|Major Depressive Disorder
1176682|NCT01254266|morbid obesity
1176683|NCT01254266|adolescents
1176684|NCT01254266|inpatient treatment
1176685|NCT01254253|percutaneous coronary intervention
1176686|NCT01254253|chronic total occlusion
1176687|NCT01254253|coronary angiography
1176688|NCT01254253|single photon emission CT
1176689|NCT01254253|Multislice coronary CT angiography
1176690|NCT01254227|Cardiac iron overload,
1176691|NCT01254227|deferasirox,
1176692|NCT01254227|deferoxamine
1176693|NCT01254214|Mindfulness
1176694|NCT01254214|Quality of life
1176695|NCT01254214|Transplantation
1176696|NCT01254214|Renal disease
1176697|NCT01254188|Chronic myeloid leukemia,
1176698|NCT01254188|CML,
1176699|NCT01254188|nilotinib,
1176700|NCT01254188|myelogenous,
1176701|NCT01254188|Philadelphia chromosome
1176702|NCT01254162|Oily Skin
1176703|NCT01254162|Sebum
1176704|NCT01254123|Glucagon Like Peptide-1
1176705|NCT01254123|Exenatide
1176706|NCT01254123|myocardial infarction
1176707|NCT01254123|MRI
1176708|NCT01254123|PCI
1176709|NCT01254084|Herbal medicine; Type 2 diabetes; Gynostemma pentaphyllum Tea; Insulin sensitivity;
1176710|NCT01254071|GI198745
1176711|NCT01254071|Tamsulosin hydrochloride
1176712|NCT01254071|Dutasteride
1176713|NCT01254071|food effect
1176714|NCT01254071|healthy male subjects
1176715|NCT01254071|north-east Asian ancestry
1176716|NCT01254071|Bioequivalence
1176717|NCT01254071|cross-over design
1176718|NCT01254071|Pilot bioequivalence
1176719|NCT01254032|CAT
1176720|NCT01254032|COPD
1176721|NCT01254019|Duchenne Muscular Dystrophy
1176722|NCT01254019|DMD
1176723|NCT01254019|968
1176724|NCT01254019|GSK
1176725|NCT01254019|Duchenne
1176726|NCT01253993|Disruptive Behavior Disorders, Substance abuse,
1176727|NCT01253993|Iowa Gambling Task, Decision Making.
1176728|NCT01253980|pneumonitis
1176729|NCT01253980|paraffin
1176730|NCT01253980|kerosene
1176731|NCT01253967|Gastroenteritis
1176732|NCT01253967|Hospital surveillance
1176733|NCT01253967|Rotavirus gastroenteritis
1176734|NCT01253954|invasive candida infection
1176735|NCT01253941|COPD, Intensive Resistive Breathing, Cytokine IL6,
1176736|NCT01253928|body composition
1176737|NCT01253928|insulin sensitivity
1176738|NCT01253928|protein metabolism
1176739|NCT01253928|pioglitazone
1176740|NCT01253889|Functional echocardiography
1176741|NCT01253889|oral glucose
1176742|NCT01253889|neonatal stress
1176743|NCT01253863|Clinical Examination, Accuracy, Hand, Tendon, Injury.
1176744|NCT01253850|hiv
1176745|NCT01253850|antiretroviral
1176746|NCT01253850|adherence
1176747|NCT01253850|adolescent
1176748|NCT01253837|L19
1176749|NCT01253837|antibody
1176750|NCT01253837|monoclonal
1176751|NCT01253837|tumor targeting
1176752|NCT01253837|TNFa
1176753|NCT01253837|colorectal cancer
1176754|NCT01253837|Phase I: Patients with relapsed or refractory locally advanced or metastatic solid tumors not amenable to standard systemic therapy.
1176755|NCT01253837|Phase II: Patients with relapsed or refractory locally advanced or metastatic colorectal cancer not amenable to standard systemic therapy.
1176756|NCT01253824|NPC-01
1176757|NCT01253824|IKH-01
1176758|NCT01253824|Pharmacodynamics
1176759|NCT01253824|Norethisterone
1176760|NCT01253824|Ethinyl Estradiol
1176761|NCT01253824|Estradiol
1176762|NCT01253824|Progesterone
1176763|NCT01253824|FSH
1176764|NCT01253824|LH
1176765|NCT01253798|exercise
1176766|NCT01253798|hydrotherapy
1176767|NCT01253759|Transpupillary thermotherapy
1176768|NCT01253759|Choroidal melanoma
1176769|NCT01253759|ICG-Photodynamic therapy
1176770|NCT01253746|NTD
1176771|NCT01253746|open NTD
1176772|NCT01253746|spina bifida
1176773|NCT01253746|anencephaly
1176774|NCT01253746|closed NTD
1176775|NCT01253746|lipomeningocele
1176776|NCT01253746|tethered cord.
1176777|NCT01253733|Cystic Fibrosis
1176778|NCT01253733|Inflammatory Bowel Disease
1176779|NCT01253733|Type 1 Diabetes
1176780|NCT01253733|Chronic Disease Management
1176781|NCT01253733|SMS
1176782|NCT01253733|Text messages
1176783|NCT01253733|Internet
1176784|NCT01253733|Healthcare Interactions
1176785|NCT01253720|obesity
1176786|NCT01253720|text messages
1176787|NCT01253720|internet
1176788|NCT01253720|cancer
1176789|NCT01253720|overweight
1176790|NCT01253707|Solid Tumors
1176791|NCT01253707|C-met inhibitor
1176792|NCT01253694|Diabetes
1176793|NCT01253694|edema
1176794|NCT01253694|ranibizumab
1176795|NCT01253694|bevacizumab
1176796|NCT01253694|refractory
1176797|NCT01253681|AMG 386
1176798|NCT01253681|Ovarian Cancer
1176799|NCT01253655|Healthy Volunteers
1176800|NCT01253629|Fragile X Syndrome
1176801|NCT01253629|Martin-Bell Syndrome
1176802|NCT01253629|Genetic Diseases
1176803|NCT01253629|X-Linked
1176804|NCT01253603|Asthma
1176805|NCT01253590|atrial fibrillation
1176806|NCT01253590|ECG monitor
1176807|NCT01253590|Blood pressure device
1176808|NCT01253590|Remote Cardiac Monitoring
1176809|NCT01253551|VX-950HEP1001
1176810|NCT01253551|hepatitis
1176811|NCT01253551|telaprevir
1176812|NCT01253551|raltegravir
1176813|NCT01253551|crossover
1176814|NCT01253551|healthy volunteers
1176815|NCT01253551|VX-950.
1176816|NCT01253538|Mother-to-Child Transmission of HIV
1176817|NCT01253538|HAART
1176818|NCT01253525|Adenocarcinoma
1176819|NCT01253525|Gastroesophageal Junction
1176820|NCT01253512|Ischemic Stroke
1176821|NCT01253512|Thrombolysis
1176822|NCT01253486|expressive writing
1176823|NCT01253486|cardiac rehabilitation
1176824|NCT01253473|COPD
1176825|NCT01253460|Chronic Lymphocytic Leukemia
1176826|NCT01253460|CLL
1176827|NCT01253460|Small Lymphocytic Lymphoma
1176828|NCT01253460|SLL
1176829|NCT01253460|Cyclophosphamide
1176830|NCT01253460|Rituximab
1176831|NCT01253460|Sapacitabine
1176832|NCT01253460|Cytoxan
1176833|NCT01253460|Neosar
1176834|NCT01253460|Rituxan
1176835|NCT01253434|Transdermal Administration
1176836|NCT01253421|MDD
1176837|NCT01253421|Major Depressive Disorder
1176838|NCT01253421|Amisulpride
1176839|NCT01253408|anandamide
1176840|NCT01253408|cannabinoid
1176841|NCT01253408|fatty acid amide hydrolase
1176842|NCT01253408|gastric
1176843|NCT01253408|motility
1176844|NCT01253408|small bowel
1176845|NCT01253395|Exercise
1176846|NCT01253395|Pain
1176847|NCT01253369|pazopanib
1176855|NCT01253252|Abdominal Aortic Aneurysm
1176856|NCT01253252|Prosthesis
1176857|NCT01253252|Fluorodeoxyglucose F18
1176858|NCT01253252|Positron-emission Tomography
1176859|NCT01253252|Spiral computed tomography
1176860|NCT01253252|Biological markers
1176861|NCT01253239|Visual outcomes
1176862|NCT01253239|Patient satisfaction
1176863|NCT01253213|Prostate cancer
1176864|NCT01253213|Ultrasound molecular imaging
1176865|NCT01253213|Contrast agent
1176866|NCT01253213|BR55
1176867|NCT01253213|VEGFR2
1176868|NCT01253200|Type 1 Atrial Flutter
1176869|NCT01253200|Typical Atrial Flutter
1176870|NCT01253200|Arrhythmias, Cardiac
1176871|NCT01253200|Heart Diseases
1176872|NCT01253200|Cardiovascular Diseases
1176873|NCT01253161|advanced
1176874|NCT01253161|metastatic
1176875|NCT01253161|unresectable
1176876|NCT01253161|carcinoma
1176877|NCT01253161|gastrointestinal tract
1176878|NCT01253161|lungs
1176879|NCT01253161|colon
1176880|NCT01253161|liver
1176881|NCT01253161|rectum
1176882|NCT01253161|small intestine
1176883|NCT01253161|stomach
1176884|NCT01253161|pancreatic
1176885|NCT01253148|Liver
1176886|NCT01253148|Bile Duct
1176887|NCT01253135|Fibrin, white petrolatum, wound healing
1176888|NCT01253096|Interleukin
1176889|NCT01253096|IL2
1176890|NCT01253096|monoclonal
1176891|NCT01253096|antibody
1176892|NCT01253096|cytokine
1176893|NCT01253096|metastatic
1176894|NCT01253096|melanoma
1176895|NCT01253096|tumor targeting
1176896|NCT01253096|intratumoral
1176897|NCT01253096|Malignant melanoma with presence of injectable soft-tissue metastases either in clinical stage III or stage IV without visceral metastases.
1176898|NCT01253083|Mobility
1176899|NCT01253083|Developmental Delay
1176900|NCT01253083|Cerebral Palsy
1176901|NCT01253083|Early Walking
1176902|NCT01253083|Postural Control
1176903|NCT01253057|cleaning staff
1176904|NCT01253057|antineoplastic agents
1176905|NCT01253044|OEF/OIF
1176906|NCT01253044|Veterans
1176907|NCT01253044|Psychotherapy
1176908|NCT01253031|hearing loss
1176909|NCT01253031|aging
1176910|NCT01253031|short term memory
1176911|NCT01253031|attentional blink
1176912|NCT01253018|stroke
1176913|NCT01253018|robotics
1176914|NCT01253018|upper extremity rehabilitation
1176915|NCT01252992|Extrapulmonary
1176916|NCT01252992|Tuberculosis
1176917|NCT01252992|Paradoxical reaction
1176918|NCT01252992|Risk factors
1176919|NCT01252992|Incidence
1176920|NCT01252992|CT scan
1176921|NCT01252992|Natural history
1176922|NCT01252992|Immune system phenomena
1176923|NCT01252992|Immune markers
1176924|NCT01252992|Gene Expression Profiling
1176925|NCT01252979|MELAS
1176926|NCT01252979|Ketones
1176927|NCT01252979|Medium Chain Triglycerides
1176928|NCT01252979|MCT oil
1176929|NCT01252979|Mitochondrial Disorder
1176930|NCT01252979|Heteroplasmy
1176931|NCT01252979|3243AG
1176932|NCT01252979|Subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent.
1176933|NCT01252979|Subject is willing and able to comply with all trial requirements.
1176934|NCT01252979|Subject harbors the 3243 A>G mtDNA mutation at a level detectable in blood.
1176935|NCT01252979|Female subjects of child-bearing potential must not be pregnant.
1176936|NCT01252979|Subjects must not have Diabetes Mellitus.
1176937|NCT01252966|Tobacco
1176938|NCT01252966|Smoking
1176939|NCT01252966|Cognition
1176940|NCT01252966|Behavioral Training
1176941|NCT01252966|Relapse
1176942|NCT01252953|vascular disease
1176943|NCT01252953|lipids
1176944|NCT01252953|cholesteryl ester transfer protein (CETP) inhibition
1176945|NCT01252953|anacetrapib
1176946|NCT01252940|HIV-1
1176947|NCT01252940|HIV
1176948|NCT01252940|Treatment Experienced
1176949|NCT01252914|Open angle
1176950|NCT01252914|Glaucoma
1176951|NCT01252914|Surgery
1176952|NCT01252914|Ocular Hypertension
1176953|NCT01252914|Eye Diseases
1176954|NCT01252901|WT1
1176955|NCT01252901|Wilms Tumor
1176956|NCT01252901|Denys-Drash Syndrome
1176957|NCT01252901|Nephrotic Syndrome
1176958|NCT01252901|Proteinuria
1176959|NCT01252888|Open angle
1176960|NCT01252888|Glaucoma
1176961|NCT01252888|Surgery
1176962|NCT01252888|Glaucoma Open-Angle
1176963|NCT01252888|Ocular Hypertension
1176964|NCT01252888|Eye Diseases
1176965|NCT01252875|LDL-C
1176966|NCT01252875|Cholesterol
1176967|NCT01252875|Stroke
1176968|NCT01252875|Transient ischemic attack
1176969|NCT01252875|Statin
1176970|NCT01252875|Lipid lowering therapy
1176971|NCT01252862|Open angle
1176972|NCT01252862|Glaucoma
1176973|NCT01252862|Surgery
1176974|NCT01252862|Ocular Hypertension
1176975|NCT01252862|eye diseases
1176976|NCT01252849|Open angle
1176977|NCT01252849|Glaucoma
1176978|NCT01252849|surgery
1176979|NCT01252849|Glaucoma, Open-Angle
1176980|NCT01252849|Ocular Hypertension
1176981|NCT01252849|Eye Diseases
1176982|NCT01252823|Hemodialysis
1176983|NCT01252823|Cardiac Arrhythmia
1176984|NCT01252823|Cardiac Death
1176985|NCT01252823|Implantable Loop Recorder
1176986|NCT01252810|CATH Catheterization
1176987|NCT01252810|CI-AKI Contrast-induced acute kidney injury
1176988|NCT01252810|DM Diabetes mellitus
1176989|NCT01252810|eGFR Estimated glomerular filtration rate
1176990|NCT01252810|MDRD Modification of Diet in Renal Disease
1176991|NCT01252810|NYHA New York Heart Association
1176992|NCT01252810|PCI Percutaneous coronary intervention
1176993|NCT01252810|SCr Serum creatinine
1176994|NCT01252797|brain metastases
1176995|NCT01252784|higher risk MDS
1176996|NCT01252771|phosphorus
1176997|NCT01252771|dialysis
1176998|NCT01252771|PhosLo
1176999|NCT01252732|ABSSSI
1177000|NCT01252732|Skin Infection
1177001|NCT01252732|Abscess
1177002|NCT01252719|ABSSSI
1177003|NCT01252719|Skin Infection
1177004|NCT01252719|Abscess
1177005|NCT01252706|brief intervention
1177006|NCT01252706|alcohol
1177007|NCT01252706|nicotine
1177008|NCT01252706|drug abuse
1177009|NCT01252654|Lasik
1177010|NCT01252654|Femtosecond Laser
1177011|NCT01252654|Visumax
1177012|NCT01252654|IntraLase
1177013|NCT01252654|Myopia
1177014|NCT01252654|Myopic Patients undergoing LASIK
1177015|NCT01252641|HIV
1177016|NCT01252628|CRC
1177017|NCT01252628|SCCHN
1177018|NCT01252628|PX-866
1177019|NCT01252628|Cetuximab
1177020|NCT01252628|ERBITUX
1177021|NCT01252628|Colon
1177022|NCT01252628|Head and Neck
1177023|NCT01252628|Colorectal cancer
1177024|NCT01252628|Squamous cell carcinoma
1177025|NCT01252628|PI-3K
1177026|NCT01252628|PI3 kinase
1177027|NCT01252628|PI3K
1177028|NCT01252615|ICD
1177029|NCT01252615|HF
1177030|NCT01252615|cardiac arrest
1177031|NCT01252615|VF
1177032|NCT01252615|cardiac arrhythmias
1177033|NCT01252602|breastfeeding, EPDS, prenatal depression
1177034|NCT01252589|Chronic Myeloid Leukemia
1177035|NCT01252589|Quality of Life
1177036|NCT01252589|Symptoms
1177037|NCT01252589|Patient-Reported outcomes
1177038|NCT01252589|Questionnaire
1177039|NCT01252576|FSFI
1177040|NCT01252576|female sexual function
1177041|NCT01252576|italian validation
1177042|NCT01252563|ENTER10
1177043|NCT01252563|Hypertension
1177044|NCT01252563|Japanese
1177045|NCT01252563|Norvasc 10mg
1177046|NCT01252563|Post Marketing surveillance
1177047|NCT01252550|IBS
1177048|NCT01252550|GI
1177049|NCT01252550|QOL
1177050|NCT01252550|Pathophysiology
1177051|NCT01252550|Gut microbiota
1177052|NCT01252550|Danone
1177053|NCT01252550|Activia
1177054|NCT01252550|Probiotics
1177055|NCT01252537|HIV
1177056|NCT01252537|Tuberculosis
1177057|NCT01252537|Immunosuppression
1177058|NCT01252537|ART
1177059|NCT01252537|Ethiopia
1177060|NCT01252537|Primary health care
1177061|NCT01252524|diabetes mellitus
1177062|NCT01252524|fiber
1177063|NCT01252524|glycemic control
1177064|NCT01252524|calcium polycarbophil
1177065|NCT01252511|Malabsorption after RYGB
1177066|NCT01252511|Fat Malabsorption and maldigestion
1177067|NCT01252511|Obesity surgery
1177068|NCT01252511|Bariatric surgery
1177069|NCT01252498|Cancer of the head and neck
1177070|NCT01252498|Radiotherapy
1177071|NCT01252498|Prostaglandins
1177072|NCT01252485|AML
1177073|NCT01252485|Registry study
1177074|NCT01252485|Biology and Outcome
1177075|NCT01252485|Higher Risk MDS
1177076|NCT01252472|Flomax
1177077|NCT01252472|Floppy iris Syndrome
1177078|NCT01252472|Tamsulosin
1177079|NCT01252459|AA-PET
1177080|NCT01252459|T1-Gd-MRI
1177081|NCT01252459|re-irradiation
1177082|NCT01252459|recurrent glioma
1177083|NCT01252446|ICD 10
1177084|NCT01252446|Attention-Deficit-Hyperactivity-Disorder (ADHD)
1177085|NCT01252446|Comorbidity
1177086|NCT01252446|Social-demographic profile
1177087|NCT01252420|Distal Vein Thrombosis
1177088|NCT01252420|Proximal Vein Thrombosis
1177089|NCT01252420|Pulmonary Embolism
1177090|NCT01252420|Post-thrombotic syndrome
1177091|NCT01252420|Limited duration treatment
1177092|NCT01252407|Transcutaneous electrical nerve stimulation
1177093|NCT01252407|Sympathetic nervous system
1177094|NCT01252407|Parasympathetic nervous system
1177095|NCT01252407|heart rate
1177096|NCT01252342|Oxytocin
1177097|NCT01252342|Intramyometrial
1177098|NCT01252329|high risk cutaneous squamous cell carcinoma
1177099|NCT01252329|selective neck dissection
1177100|NCT01252329|elective lymph node management
1177101|NCT01252329|clinical nodal observation
1177102|NCT01252303|Obesity, weight loss, meal replacements
1177103|NCT01252264|biorepository
1177104|NCT01252264|genetics
1177105|NCT01252264|craniofacial
1177106|NCT01252264|cleft lip
1177107|NCT01252264|cleft palate
1177108|NCT01252251|PASIREOTIDE (SOM230)
1177109|NCT01252251|RAD001 (EVEROLIMUS)
1177110|NCT01252251|eye
1177111|NCT01252251|10-123
1177112|NCT01252225|Chronic Cough
1177113|NCT01252225|Lidocaine
1177114|NCT01252212|HIV, antiretroviral, adherence, SMS, cell phone
1177115|NCT01252199|Shigamabs
1177116|NCT01252199|Monoclonal
1177117|NCT01252199|Antibodies
1177118|NCT01252199|Shiga
1177119|NCT01252199|Toxin
1177120|NCT01252199|E.coli
1177121|NCT01252199|HUS
1177122|NCT01252199|Bloody
1177123|NCT01252199|Diarrhea
1177124|NCT01252186|Contraception
1177125|NCT01252186|Hemostasis
1177126|NCT01252186|Blood Coagulation
1177127|NCT01252173|endotracheal
1177128|NCT01252173|intubation
1177129|NCT01252173|tracheal
1177130|NCT01252173|pressure
1177131|NCT01252173|cufflator
1177132|NCT01252160|Neuralgia, Postherpetic
1177133|NCT01252160|QUTENZA
1177134|NCT01252134|Soft Contact lens
1177135|NCT01252134|Multi-purpose solution
1177136|NCT01252134|Wettability
1177137|NCT01252121|Dry Eye
1177138|NCT01252121|Ocular Retention Time
1177139|NCT01252108|Helicobacter pylori
1177140|NCT01252108|peptic ulcer disease
1177141|NCT01252108|stomach ulcers
1177142|NCT01252108|gastric cancer
1177143|NCT01252095|PG545
1177144|NCT01252095|Phase I
1177145|NCT01252095|Progen
1177146|NCT01252095|antimetastatic
1177147|NCT01252095|antiangiogenic
1177148|NCT01252095|advanced cancer patients
1177149|NCT01252095|solid tumors
1177150|NCT01252095|solid tumours
1177151|NCT01252082|metabolic control
1177152|NCT01252082|fasting plasma glucose
1177153|NCT01252082|glycated hemoglobin
1177154|NCT01252043|cholestasis
1177155|NCT01252043|children
1177156|NCT01252030|CAD, physical activity, rehabilitation, prevention
1177157|NCT01252004|Left ventricular ballooning
1177158|NCT01251978|Choroidal melanoma
1177159|NCT01251978|Ranibizumab
1177160|NCT01251978|Transpupillary Thermotherapy
1177161|NCT01251978|CSTIP
1177162|NCT01251978|Indocyanine Green
1177163|NCT01251965|Relapsed Acute Leukemia
1177164|NCT01251965|Acute myeloid leukemia
1177165|NCT01251965|AML
1177166|NCT01251965|Acute lymphocytic leukemia
1177167|NCT01251965|ALL
1177168|NCT01251965|Ruxolitinib
1177169|NCT01251965|Jakafi
1177170|NCT01251965|INC424
1177171|NCT01251965|INCB018424
1177172|NCT01251926|Bevacizumab
1177173|NCT01251926|Camptothecin
1177174|NCT01251926|EZN-2208
1177175|NCT01251926|Anti-Angiogenesis
1177176|NCT01251926|Advanced Cancer
1177177|NCT01251926|Cancer
1177178|NCT01251926|Solid Tumor
1177179|NCT01251913|Tissue Harvest
1177180|NCT01251913|Hospice
1177181|NCT01251913|Autopsy
1177182|NCT01251913|Crainiotomy
1177183|NCT01251913|Brain Tumor
1177184|NCT01251913|Glioma
1177185|NCT01251913|Astrocytoma
1177186|NCT01251900|Triple Negative Disease
1177187|NCT01251900|BRCA1
1177188|NCT01251900|BRCA2
1177189|NCT01251900|Hispanic/Latino
1177190|NCT01251900|Breast Cancer
1177191|NCT01251887|Lipids
1177192|NCT01251887|Obesity
1177193|NCT01251887|Omega-3 Fatty Acids
1177194|NCT01251887|Overweight
1177195|NCT01251848|Sitaxentan
1177196|NCT01251848|ritonavir
1177197|NCT01251848|drug interaction
1177198|NCT01251848|pharmacokinetics
1177199|NCT01251835|Sitaxsentan
1177200|NCT01251835|Rifampin
1177201|NCT01251835|Drug Interaction
1177202|NCT01251835|Pharmacokinetics
1177203|NCT01251809|Asparaginase
1177204|NCT01251809|ALL
1177205|NCT01251783|term babies
1177206|NCT01251770|Hyponatremia
1177207|NCT01251770|Water-Electrolyte Imbalance
1177208|NCT01251757|diabetes
1177209|NCT01251757|cardiovascular disease
1177210|NCT01251757|randomized clinical trial
1177211|NCT01251757|medication adherence
1177212|NCT01251757|health information technology
1177213|NCT01251757|adult
1177214|NCT01251757|telephone calls
1177215|NCT01251757|IVR
1177216|NCT01251744|Pregnancy
1177217|NCT01251744|Congenital
1177218|NCT01251744|Cytomegalovirus infection
1177219|NCT01251718|Donepezil hydrochloride
1177220|NCT01251718|Alzheimer's Disease
1177221|NCT01251705|Cornea
1177222|NCT01251705|SL OCT
1177223|NCT01251705|Spectral OCT Cornea modul
1177224|NCT01251705|ultrasound pachymetry
1177225|NCT01251705|Pentacam
1177226|NCT01251692|Corneal erosions
1177227|NCT01251692|PTK
1177228|NCT01251679|handwashing
1177229|NCT01251679|masks
1177230|NCT01251679|infectious disease transmission
1177231|NCT01251666|Colorectal cancer
1177232|NCT01251666|Screening
1177233|NCT01251666|Average-risk population
1177234|NCT01251666|faecal occult blood tests
1177235|NCT01251640|pancreatic cancer,
1177236|NCT01251640|MEK-inhibitor
1177237|NCT01251627|Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Decitabine
1177238|NCT01251614|Randomized
1177239|NCT01251614|Double-blind
1177240|NCT01251614|Chronic plaque psoriasis
1177241|NCT01251614|Pediatric
1177242|NCT01251588|Cartilage legions
1177243|NCT01251588|Symptomatic focal cartilage defects
1177244|NCT01251588|Microfracture
1177245|NCT01251588|MACI
1177246|NCT01251588|Autologous chondrocyte
1177247|NCT01251549|ReWalk
1177248|NCT01251549|Paraplegia
1177249|NCT01251549|Spinal Cord Injuries (SCI)
1177250|NCT01251536|colorectal cancer
1177251|NCT01251536|K-Ras wildtype
1177252|NCT01251536|first line metastatic
1177253|NCT01251536|standard cetuximab + FOLFIRI
1177254|NCT01251536|dose escalation cetuximab
1177255|NCT01251523|Asthma
1177256|NCT01251471|major depressive disorder
1177257|NCT01251471|MDD
1177258|NCT01251471|imaging genetics
1177259|NCT01251471|pharmacoMRI
1177260|NCT01251432|otitis media
1177261|NCT01251432|Eustachian tube
1177262|NCT01251432|allergy
1177263|NCT01251432|gastroesophageal reflux
1177264|NCT01251432|tympanostomy tube
1177265|NCT01251419|Generic Medication
1177266|NCT01251419|Brand Name Medication
1177267|NCT01251419|Conversion Rates
1177268|NCT01251419|Social Proximity
1177269|NCT01251419|Behavioral Economics
1177270|NCT01251406|Stable
1177271|NCT01251406|Chronic Heart Failure
1177272|NCT01251406|Systolic
1177273|NCT01251393|Cocaine
1177274|NCT01251393|crack
1177275|NCT01251393|treatment
1177276|NCT01251393|dependence
1177277|NCT01251393|biperiden
1177278|NCT01251341|inflammation
1177279|NCT01251341|immune system
1177280|NCT01251341|cytokines
1177281|NCT01251341|meditation
1177282|NCT01251341|compassion
1177283|NCT01251341|attention
1177284|NCT01251315|Glutathione
1177285|NCT01251315|Antioxidant
1177286|NCT01251315|Free radical
1177287|NCT01251315|Oxidative stress
1177288|NCT01251315|N-Acetyl Cysteine
1177289|NCT01251315|Glutathione precursor
1177290|NCT01251302|Coronary Artery Disease
1177291|NCT01251302|Angina
1177292|NCT01251302|Molecular Genetics
1177293|NCT01251302|Atherosclerosis
1177294|NCT01251263|headaches
1177295|NCT01251263|migraines
1177296|NCT01251263|breakthrough bleeding
1177297|NCT01251263|breakthrough spotting
1177298|NCT01251263|menstrually associated migraines
1177299|NCT01251263|breakthrough bleeding or breakthrough spotting
1177300|NCT01251224|asthma
1177301|NCT01251224|mouse allergen
1177302|NCT01251224|environmental intervention
1177303|NCT01251211|BOTULINUM TOXIN
1177304|NCT01251211|NEUROPATHIC PAIN
1177305|NCT01251211|RANDOMIZED CONTROLLED TRIAL
1177306|NCT01251185|Extracorporeal Shockwave Therapy
1177307|NCT01251185|Heart Failure
1177308|NCT01251185|Congestive Heart Failure
1177309|NCT01251185|Non-invasive
1177310|NCT01251185|Device Trial
1177311|NCT01251185|NYHA (New York Heart Association)
1177312|NCT01251185|Ischemic cardiomyopathy
1177313|NCT01251185|Ischemia
1177314|NCT01251185|Myocardial contractility
1177315|NCT01251159|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1177316|NCT01251159|adult acute myeloid leukemia with del(5q)
1177317|NCT01251159|adult acute myeloid leukemia with inv(16)(p13;q22)
1177318|NCT01251159|adult acute myeloid leukemia with t(16;16)(p13;q22)
1177319|NCT01251159|adult acute myeloid leukemia with t(8;21)(q22;q22)
1177320|NCT01251159|untreated adult acute myeloid leukemia
1177321|NCT01251159|adult acute minimally differentiated myeloid leukemia (M0)
1177322|NCT01251159|adult acute myeloblastic leukemia with maturation (M2)
1177323|NCT01251159|adult acute myeloblastic leukemia without maturation (M1)
1177324|NCT01251159|adult acute myelomonocytic leukemia (M4)
1177325|NCT01251159|adult acute monoblastic leukemia (M5a)
1177326|NCT01251159|adult acute monocytic leukemia (M5b)
1177327|NCT01251159|adult erythroleukemia (M6a)
1177328|NCT01251159|adult pure erythroid leukemia (M6b)
1177329|NCT01251159|adult acute megakaryoblastic leukemia (M7)
1177330|NCT01251146|Hypertension
1177331|NCT01251146|Bisoprolol
1177332|NCT01251146|Atenolol
1177333|NCT01251133|Communicable Diseases
1177334|NCT01251133|Infection
1177335|NCT01251133|Influenza
1177336|NCT01251133|Orthomyxoviridae Infections
1177337|NCT01251133|RNA Virus Infections
1177338|NCT01251133|Virus Diseases
1177339|NCT01251133|Respiratory Tract Infections
1177340|NCT01251133|Respiratory Tract Diseases
1177341|NCT01251107|Hodgkin lymphoma
1177342|NCT01251107|ABVD
1177343|NCT01251107|BEACOPP
1177344|NCT01251107|Salvage high dose chemotherapy
1177345|NCT01251094|Dementia
1177346|NCT01251094|Parkinson's
1177347|NCT01251094|impairment
1177348|NCT01251094|Dementia Registry for Parkinson's Disease
1177349|NCT01251081|high volume hemofiltration
1177350|NCT01251081|sepsis
1177351|NCT01251081|acute kidney injury
1177352|NCT01251081|survival
1177353|NCT01251068|anemic preterms, cerebral oxygenation,somatic oxygenation, blood transfusion
1177354|NCT01251055|N-methyl-D-aspartate receptor
1177355|NCT01251055|glycine transporter
1177356|NCT01251055|schizophrenia
1177357|NCT01251016|Type 2 diabetes mellitus
1177358|NCT01251016|Y-Roux gastric bypass
1177359|NCT01251016|Gut hormones
1177360|NCT01251016|Gene expression
1177361|NCT01251016|Surgery
1177362|NCT01251003|Traumatic Brain Injury
1177363|NCT01251003|TBI
1177364|NCT01251003|Pediatric
1177365|NCT01251003|Chronic
1177366|NCT01250990|Niacin
1177367|NCT01250990|HDL
1177368|NCT01250990|Reverse cholesterol transport
1177369|NCT01250977|Non-treatment seeking smokers, reporting consumption of at least
1177370|NCT01250977|10 cigarettes per day for at least the past 6 months
1177371|NCT01250951|Iron Overload
1177372|NCT01250951|hemotranfusion
1177373|NCT01250951|deferasirox
1177374|NCT01250951|ferritin
1177375|NCT01250951|Rare anemia
1177376|NCT01250951|Transfusional Iron Overload
1177377|NCT01250938|autism
1177378|NCT01250938|autism spectrum disorders
1177379|NCT01250938|pervasive developmental disorders
1177380|NCT01250938|intervention
1177381|NCT01250938|low-income
1177382|NCT01250938|underserved populations
1177383|NCT01250938|underrepresented populations
1177384|NCT01250925|Contact lens
1177385|NCT01250925|Lens care
1177386|NCT01250912|Ablation
1177387|NCT01250912|Arrythmia
1177388|NCT01250912|Imaging
1177389|NCT01250899|HIV
1177390|NCT01250899|Vitamin D
1177391|NCT01250899|HAART
1177392|NCT01250860|Manual therapy
1177393|NCT01250860|DoboMed exercise
1177394|NCT01250860|Spirometric test
1177395|NCT01250847|ARMS
1177396|NCT01250847|Ultra High Risk
1177397|NCT01250847|Quetiapine
1177398|NCT01250847|Verbal memory
1177399|NCT01250821|Infertility
1177400|NCT01250821|Anovulation
1177401|NCT01250821|Ovulation induction
1177402|NCT01250795|Prevention
1177403|NCT01250782|Glutamine, trauma patients, infections, mortality
1177404|NCT01250769|dental
1177405|NCT01250769|dentist
1177406|NCT01250769|plaque
1177407|NCT01250769|IP Cleaning
1177408|NCT01250756|vaccine
1177409|NCT01250756|pneumococcal conjugate
1177410|NCT01250743|genotype 1
1177411|NCT01250730|PK profile in Japanese healthy male volunteers
1177412|NCT01250717|prostatectomy
1177413|NCT01250717|docetaxel
1177414|NCT01250704|Neuromyotonia, Isaac's syndrome; Peripheral nerve hyperexcitability; Myokymia; Potassium channelopathy
1177415|NCT01250691|pneumonia
1177416|NCT01250691|ICU
1177417|NCT01250691|isolation room
1177418|NCT01250691|clinical epidemiology
1177419|NCT01250691|infection control
1177420|NCT01250678|multiple sclerosis
1177421|NCT01250678|cognitive impairment
1177422|NCT01250678|natalizumab
1177423|NCT01250678|SDMT
1177424|NCT01250665|multiple sclerosis
1177425|NCT01250665|cognitive impairment
1177426|NCT01250665|interferon-beta 1b
1177427|NCT01250665|corpus callosum index
1177428|NCT01250652|Chronic urticaria
1177429|NCT01250652|Urticaria
1177430|NCT01250652|Antihistamine
1177431|NCT01250639|Type 2 Diabetes Mellitus
1177432|NCT01250639|non-aboriginal Taiwanese
1177433|NCT01250639|Genome-wide association study
1177434|NCT01250626|Inulin
1177435|NCT01250626|childhood GFR formula
1177436|NCT01250587|Open label
1177437|NCT01250587|dose-finding Phase 1 study
1177438|NCT01250574|CD64
1177439|NCT01250574|Procalcitonin
1177440|NCT01250561|gabapentin
1177441|NCT01250561|valacyclovir
1177442|NCT01250561|phn
1177443|NCT01250561|shingles
1177444|NCT01250548|Rheumatoid arthritis
1177445|NCT01250548|RA
1177446|NCT01250548|Active rheumatoid arthritis
1177447|NCT01250535|Drug drug interactions
1177448|NCT01250535|Warfarin
1177449|NCT01250535|Anticoagulants
1177450|NCT01250535|Lovastatin
1177451|NCT01250535|Statins
1177452|NCT01250535|CYP4F2
1177453|NCT01250535|Vitamin K
1177454|NCT01250509|Obesity
1177455|NCT01250509|Mindfulness based stress reduction
1177456|NCT01250509|Mindful eating
1177457|NCT01250509|Stress
1177458|NCT01250509|Overnutrition
1177459|NCT01250509|Nutrition Disorders
1177460|NCT01250509|Overweight
1177461|NCT01250509|Body Weight
1177462|NCT01250509|Signs and Symptoms
1177463|NCT01250496|regadenoson
1177464|NCT01250496|lexiscan
1177465|NCT01250496|aminophylline
1177466|NCT01250496|SPECT
1177467|NCT01250496|Myocardial Perfusion Imaging
1177468|NCT01250496|pharmacologic stress test
1177469|NCT01250483|prostate
1177470|NCT01250483|prostate-specific antigen
1177471|NCT01250483|benign prostatic hyperplasia
1177472|NCT01250483|adrenergic alpha-Antagonists
1177473|NCT01250444|Inspiratory Muscle Training
1177474|NCT01250444|Hypertension
1177475|NCT01250444|Breathing Exercises
1177476|NCT01250444|Cardiac Rehabilitation
1177477|NCT01250418|Bispectral Index
1177478|NCT01250418|Ketamine
1177479|NCT01250392|Active choice
1177480|NCT01250392|Nurse visits
1177481|NCT01250392|Behavioral economics
1177482|NCT01250366|Safety and Pharmacokinetics
1177483|NCT01250353|ocular surface reconstruction
1177484|NCT01250353|conjunctival healing
1177485|NCT01250353|pterygium
1177486|NCT01250353|latex biomembrane
1177487|NCT01250353|pterygium surgery
1177488|NCT01250340|Diabetes
1177489|NCT01250340|Isoprostanes
1177490|NCT01250340|Thromboxane
1177491|NCT01250340|Aspirin
1177492|NCT01250327|right ventricular outflow tract
1177493|NCT01250327|endovascular valve insertion
1177494|NCT01250327|economic evaluation
1177495|NCT01250327|valved stent
1177496|NCT01250314|osteoporosis
1177497|NCT01250314|men
1177498|NCT01250314|bone micro-architecture
1177499|NCT01250314|bone markers
1177500|NCT01250301|Smoking Cessation
1177501|NCT01250301|Tobacco Dependence
1177502|NCT01250301|De-nicotinised cigarettes
1177503|NCT01250288|Health Information Technology
1177504|NCT01250288|Health Records, Personal
1177505|NCT01250288|Hospital Information Systems
1177506|NCT01250288|Patient Access to Records
1177507|NCT01250288|Medical Records
1177508|NCT01250288|Medical Record Systems, Computerized
1177509|NCT01250275|Canola Oil
1177510|NCT01250275|Peripheral Arterial Disease
1177511|NCT01250275|Peripheral Vascular Disease
1177512|NCT01250275|PAD
1177513|NCT01250262|low back pain
1177514|NCT01250262|obese
1177515|NCT01250262|fear avoidance
1177516|NCT01250262|disability and low back pain
1177517|NCT01250262|chronic low back pain in obese older adults
1177518|NCT01250249|To compare Safety and Reactogenecity of BCG vaccine of Green Signal Biopharma Private Limited with BCG vaccine of serum institute of India limited
1177519|NCT01250236|brimonidine
1177520|NCT01250236|alpha-2 adrenoceptor
1177521|NCT01250236|cornea
1177522|NCT01250236|corneal thickness
1177523|NCT01250223|Lymphoma, Follicular
1177524|NCT01250223|Prognosis
1177525|NCT01250223|Progression-Free Survival
1177526|NCT01250223|Outcome
1177527|NCT01250223|International Cooperation
1177528|NCT01250223|Data Collection
1177529|NCT01250223|Prospective studies
1177530|NCT01250223|Rare Diseases
1177531|NCT01250210|contraception
1177532|NCT01250210|pregnancy prevention
1177533|NCT01250197|Normal Volunteers
1177534|NCT01250184|Myofascial pain
1177535|NCT01250184|Trigger points.
1177536|NCT01250184|Lidocaine injection.
1177537|NCT01250184|Physical therapy
1177538|NCT01250171|Dry eye
1177539|NCT01250171|IL17/ IL-1β
1177540|NCT01250171|Biologic
1177541|NCT01250158|Liver Percutaneous Isolated Localized Perfusion
1177542|NCT01250158|PILP
1177543|NCT01250158|Isolated Hepatic Perfusion
1177544|NCT01250158|IHP
1177545|NCT01250158|Liver metastases
1177669|NCT01249612|Knee joint icing
1177546|NCT01250158|Unresectable liver metastases of different etiologies
1177547|NCT01250132|Traumatic brain injury
1177548|NCT01250132|Paediatrics
1177549|NCT01250132|Hypopituitarism
1177550|NCT01250106|probiotics
1177551|NCT01250106|prevention
1177552|NCT01250106|dietary intervention
1177553|NCT01250106|insulin resistance
1177554|NCT01250106|obesity
1177555|NCT01250106|type 2 diabetes
1177556|NCT01250015|colorectal cancer
1177557|NCT01250015|consent
1177558|NCT01250015|screening
1177559|NCT01250002|Pain
1177560|NCT01250002|MQOR 40
1177561|NCT01250002|Lidocaine
1177562|NCT01250002|Gynecologic
1177563|NCT01250002|Surgery
1177564|NCT01250002|Laparoscopic
1177565|NCT01249989|Physical Activity
1177566|NCT01249989|Sedentary Lifestyle
1177567|NCT01249989|Diet
1177568|NCT01249989|Health Behavior
1177569|NCT01249976|blood culture
1177570|NCT01249976|central venous catheter
1177571|NCT01249976|acridine orange leucocyte cytospin test
1177572|NCT01249976|semi-quantitative skin culture
1177573|NCT01249963|acute pancreatitis
1177574|NCT01249963|enteral nutrition
1177575|NCT01249963|nutritional status
1177576|NCT01249963|pancreas
1177577|NCT01249963|T-Diet plus Atémpero
1177578|NCT01249950|Morbid obesity
1177579|NCT01249950|teenagers
1177580|NCT01249950|co-morbidities
1177581|NCT01249950|bariatric surgery
1177582|NCT01249950|epidemiology
1177583|NCT01249937|Macular Degeneration
1177584|NCT01249937|Age-related macular degeneration
1177585|NCT01249937|Anti-inflammatory
1177586|NCT01249937|Anti-vascular endothelial growth factor (Anti-VEGF)
1177587|NCT01249937|Lucentis
1177588|NCT01249937|Ranibizumab
1177589|NCT01249937|Kenalog
1177590|NCT01249937|Triamcinolone Acetonide
1177591|NCT01249937|Vision loss
1177592|NCT01249924|Obstructive sleep apnea (OSA), continuous positive airway pressure(CPAP), surgery, anesthesia
1177593|NCT01249911|Infants
1177594|NCT01249898|Fracture in the Scaphoid fractures
1177595|NCT01249885|pacifier sucking
1177596|NCT01249885|children
1177597|NCT01249885|occlusion
1177598|NCT01249885|drooling
1177599|NCT01249872|open gastric by-pass
1177600|NCT01249872|super morbidly obese patients
1177601|NCT01249872|postoperative thoracic epidural analgesia
1177602|NCT01249872|different drug regimens (morphine and levobupivacaine)
1177603|NCT01249872|Lung function tests
1177604|NCT01249872|Postoperative Bowel recovery
1177605|NCT01249872|Postoperative Ambulation
1177606|NCT01249859|stomach disease
1177607|NCT01249859|signet ring cell carcinoma
1177608|NCT01249859|chemotherapy
1177609|NCT01249859|Prognostic
1177610|NCT01249833|Influenza
1177611|NCT01249833|Cognition
1177612|NCT01249833|Attention
1177613|NCT01249833|Simple Reaction Time
1177614|NCT01249833|Alertness
1177615|NCT01249833|Calmness
1177616|NCT01249833|Contentment
1177617|NCT01249833|Mood
1177618|NCT01249820|anidulafungin
1177619|NCT01249820|antifungal prophylaxis
1177620|NCT01249820|allogeneic haematopoietic stem cell transplant
1177621|NCT01249820|myeloablative chemotherapy
1177622|NCT01249820|AML-MDS
1177623|NCT01249820|pharmacokinetics
1177624|NCT01249807|Cancer Screening
1177625|NCT01249807|health service utilization model
1177626|NCT01249807|quality of health life
1177627|NCT01249794|NIV
1177628|NCT01249794|non invasive ventilation
1177629|NCT01249794|cardiac surgery
1177630|NCT01249794|continuous positive airway pressure
1177631|NCT01249768|Prospective study
1177632|NCT01249768|diagnostic accuracy
1177633|NCT01249768|CSF
1177634|NCT01249768|MRI
1177635|NCT01249742|diabetes mellitus
1177636|NCT01249742|adolescent
1177637|NCT01249742|online intervention
1177638|NCT01249742|psychosocial
1177639|NCT01249742|quality of life
1177640|NCT01249729|Magnetic Resonance Imaging, 3D reconstructed image
1177641|NCT01249716|follow-up home visit
1177642|NCT01249716|Geriatric Disorder
1177643|NCT01249716|rehabilitation
1177644|NCT01249690|Bortezomib,Thalidomide,bone metabolites
1177645|NCT01249677|type 2 diabetes
1177646|NCT01249677|first phase insulin secretion
1177647|NCT01249677|beta-cell rest
1177648|NCT01249677|basal insulin
1177649|NCT01249664|sham-controlled
1177650|NCT01249664|pathologic myopia
1177651|NCT01249664|mCNV
1177652|NCT01249664|choroidal neovascularization
1177653|NCT01249664|intravitreal injection
1177654|NCT01249664|vision loss
1177655|NCT01249664|macular damage
1177656|NCT01249651|Patients, Single
1177657|NCT01249638|Bevacizumab
1177658|NCT01249638|Capecitabine
1177659|NCT01249638|Irinotecan
1177660|NCT01249638|mCRC
1177661|NCT01249625|Influenza
1177662|NCT01249625|H1N1
1177663|NCT01249625|Respiratory protection
1177664|NCT01249625|N95 respirator
1177665|NCT01249625|Medical mask
1177666|NCT01249625|Personal protective equipment
1177667|NCT01249625|Facial protective equipment
1177668|NCT01249625|Pandemic planning
1177670|NCT01249612|knee-extension strength
1177671|NCT01249599|Takotsubo Syndrome
1177672|NCT01249599|apical balooning syndrome
1177673|NCT01249599|stress-cardiomyopathy
1177674|NCT01249599|endothelial function
1177675|NCT01249599|sympathetic nervous activity
1177676|NCT01249599|platelet adhesion
1177677|NCT01249599|arterial compliance
1177678|NCT01249573|fascia therapy
1177679|NCT01249573|transcutaneous fibrolysis
1177680|NCT01249573|acute ankle distortion
1177681|NCT01249495|leg ulcer
1177682|NCT01249495|wound therapy
1177683|NCT01249495|Pro-inflammatory interleukins
1177684|NCT01249482|Helicobacter pylori
1177685|NCT01249482|reflux
1177686|NCT01249482|acid rebound
1177687|NCT01249391|Hand
1177688|NCT01249391|osteoarthritis
1177689|NCT01249391|splint
1177690|NCT01249391|pain
1177691|NCT01249391|deformity
1177692|NCT01249391|function
1177693|NCT01249378|Nutrition
1177694|NCT01249378|Lipid
1177695|NCT01249378|Digestion
1177696|NCT01249378|Endotoxemia
1177697|NCT01249378|Inflammation
1177698|NCT01249378|Metabolism
1177699|NCT01249378|Stable Isotope
1177700|NCT01249378|Obesity
1177701|NCT01249365|medically significant conditions
1177702|NCT01249365|cervical neoplasia
1177703|NCT01249365|serious adverse events (SAEs)
1177704|NCT01249365|HPV vaccine
1177705|NCT01249352|Esophageal Cancer
1177706|NCT01249352|Nimotuzumab
1177707|NCT01249352|EF024
1177708|NCT01249352|EF024-201
1177709|NCT01249339|smokeless tobacco
1177710|NCT01249339|Nicotine
1177711|NCT01249339|Cadmium
1177712|NCT01249339|lead
1177713|NCT01249339|Tobacco Specific Nitrosamines
1177714|NCT01249326|Morbid obesity,
1177715|NCT01249326|Bariatric surgery, by-pass, sleeve gastrectomy,
1177716|NCT01249326|Nitrogen balance,
1177717|NCT01249326|Protein requirement,
1177718|NCT01249326|Weight loss
1177719|NCT01249326|Muscle wasting, muscle disability
1177720|NCT01249313|Risk
1177721|NCT01249313|outcome
1177722|NCT01249300|Dysphagia caused by cerebral vascular accidents
1177723|NCT01249287|stroke
1177724|NCT01249287|stem cell
1177725|NCT01249274|cocaine abuse
1177726|NCT01249274|cocaine dependence
1177727|NCT01249274|postpartum period
1177728|NCT01249261|Postmenopausal Women
1177729|NCT01249261|Osteoporosis
1177730|NCT01249248|Heart rate variability
1177731|NCT01249248|Autonomic dysfunction
1177732|NCT01249248|Exercise
1177733|NCT01249248|Sports
1177734|NCT01249248|Competition
1177735|NCT01249248|Athletes
1177736|NCT01249209|obesity
1177737|NCT01249209|adults
1177738|NCT01249209|lifestyle intervention
1177739|NCT01249209|effect after two years treatment for lifestyle change - morbid obesity adults
1177740|NCT01249183|Diphtheria
1177741|NCT01249183|Tetanus
1177742|NCT01249183|Pertussis (acellular, component)
1177743|NCT01249183|Diphteria
1177744|NCT01249183|Biological / vaccine
1177745|NCT01249170|Communication skills
1177746|NCT01249157|MRI
1177747|NCT01249157|PEM
1177748|NCT01249157|10-189
1177749|NCT01249144|Intraocular Lens (IOL)
1177750|NCT01249144|Quarter Diopter
1177751|NCT01249144|Biaspheric
1177752|NCT01249105|MK-2206
1177753|NCT01249105|GBM
1177754|NCT01249092|biliary cirrhosis
1177755|NCT01249066|AMP-activated protein kinase
1177756|NCT01249066|lung adenocarcinomas
1177757|NCT01249066|Prognosis
1177758|NCT01249066|Observation study
1177759|NCT01249053|OPA1
1177760|NCT01249053|lung adenocarcinomas
1177761|NCT01249053|Prognosis
1177762|NCT01249053|Expression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma
1177763|NCT01249040|Frozen shoulder
1177764|NCT01249040|pain scale
1177765|NCT01249040|range of motion(ROM)
1177766|NCT01249040|muscle strength
1177767|NCT01249040|shoulder arthrography
1177768|NCT01249027|Drug eluting stents
1177769|NCT01249027|Stents
1177770|NCT01249027|China
1177771|NCT01249027|DES
1177772|NCT01249027|XIENCE V EECSS
1177773|NCT01249001|pediatrics
1177774|NCT01249001|nausea
1177775|NCT01249001|vomiting
1177776|NCT01249001|chemotherapy
1177777|NCT01249001|antiemetic
1177778|NCT01248988|Pneumococcal vaccine
1177779|NCT01248988|Safety
1177780|NCT01248988|Synflorix
1177781|NCT01248988|Pneumococcal diseases
1177782|NCT01248975|asthma
1177783|NCT01248975|GSK2190915
1177784|NCT01248962|BEVACIZUMAB (AVASTIN)
1177785|NCT01248962|CARBOPLATIN
1177786|NCT01248962|DEXAMETHASONE
1177787|NCT01248962|GEMCITABINE
1177788|NCT01248962|LIPODOX(LIPOSOMAL DOXORUBICIN)
1177789|NCT01248962|MONTELUKAST (SINGULAR)
1177790|NCT01248962|TAXOL (PACLITAXEL
1177791|NCT01248962|Fallopian Tubes
1177792|NCT01248962|10-184
1177793|NCT01248949|Advanced solid tumors
1177794|NCT01248949|Advanced recurrent ovarian tumors
1177795|NCT01248949|MEDI3617
1177796|NCT01248949|Ang2
1177797|NCT01248949|Ovarian cancer
1177798|NCT01248949|Malignant glioma
1177799|NCT01248923|relapsed multiple myeloma
1177800|NCT01248923|plasma cell dyscrasia
1177801|NCT01248923|plasmacytoma
1177802|NCT01248923|kinesin spindle protein
1177803|NCT01248923|anti-mitotic
1177804|NCT01248884|combination vaccine
1177805|NCT01248884|Primary vaccination
1177806|NCT01248871|renal
1177807|NCT01248871|transplantation
1177808|NCT01248871|Volatile
1177809|NCT01248871|anesthetic
1177810|NCT01248845|Mechanical ventilation
1177811|NCT01248845|Electrical diaphragmatic activity
1177812|NCT01248832|tobacco cessation
1177813|NCT01248832|smoking cessation
1177814|NCT01248832|telephone
1177815|NCT01248832|self-help
1177816|NCT01248832|smoking abstinence
1177817|NCT01248832|tobacco use disorder
1177818|NCT01248832|disparity
1177819|NCT01248819|Laparoscopic Cholecystectomy
1177820|NCT01248819|Nebulization
1177821|NCT01248819|Ropivacaine
1177822|NCT01248806|Lung nodule
1177823|NCT01248806|Screening
1177824|NCT01248806|Spiral low - dose computed tomography
1177825|NCT01248806|Lung cancer
1177826|NCT01248793|Ankylosing Sponylitis, injection, golimumab, simponi
1177827|NCT01248780|Rheumatoid Arthritis
1177828|NCT01248780|injection
1177829|NCT01248780|golimumab
1177830|NCT01248780|simponi
1177831|NCT01248767|Pathological gambling
1177832|NCT01248767|"at risk gambling"
1177833|NCT01248767|cohort
1177834|NCT01248767|cognitive distortions
1177835|NCT01248767|impulsivity
1177836|NCT01248767|psychiatric comorbidities
1177837|NCT01248767|gambling trajectory
1177838|NCT01248767|gambling practice evolution
1177839|NCT01248767|addiction
1177840|NCT01248754|Neurosurgery
1177841|NCT01248754|Neuronavigation
1177842|NCT01248754|Positron emission tomography
1177843|NCT01248754|FDOPA
1177844|NCT01248741|prostate cancer
1177845|NCT01248741|interstitial radiation,
1177846|NCT01248741|brachytherapy
1177847|NCT01248728|Autism Spectrum Disorder
1177848|NCT01248728|Clinical Trial
1177849|NCT01248728|Omega-3 Fatty Acids
1177850|NCT01248728|Toddlers
1177851|NCT01248715|pneumonia, bacterial
1177852|NCT01248715|pneumonia, viral
1177853|NCT01248715|respiratory tract infections
1177854|NCT01248715|oseltamivir, therapeutic use
1177855|NCT01248702|Myocardial Infarction
1177856|NCT01248702|Heart Failure
1177857|NCT01248702|Sudden Cardiac Death
1177858|NCT01248702|Critical Pathways
1177859|NCT01248676|cancer radiation patient education
1177860|NCT01248663|pancreatic cancer
1177861|NCT01248663|pylorus-preserving pancreaticoduodenectomy
1177862|NCT01248663|delayed gastric emptying
1177863|NCT01248663|reconstruction
1177864|NCT01248650|Safety evaluation
1177865|NCT01248650|Pharmacokinetic analysis
1177866|NCT01248637|pancreas
1177867|NCT01248637|pancreatic cancer
1177868|NCT01248637|pancreatic tumor
1177869|NCT01248637|pimonidazole
1177870|NCT01248637|hypoxia
1177871|NCT01248637|whipple's resection
1177872|NCT01248624|Palliative Care
1177873|NCT01248624|Quality of Life
1177874|NCT01248624|Satisfaction with Care
1177875|NCT01248611|pain
1177876|NCT01248611|adverse effects
1177877|NCT01248611|safety
1177878|NCT01248611|feasibility
1177879|NCT01248585|Symptom Control
1177880|NCT01248572|Cataract
1177881|NCT01248572|Biaspheric intraocular lens
1177882|NCT01248572|Uniplanar intraocular lens
1177883|NCT01248572|Effective lens position
1177884|NCT01248546|Breast cancer
1177885|NCT01248546|Computer-aided detection
1177886|NCT01248546|Mammography screening
1177887|NCT01248546|Digital breast tomosynthesis
1177888|NCT01248533|Abdominal aortic aneurysm, atherosclerosis
1177889|NCT01248520|Pregnancy
1177890|NCT01248520|Influenza Vaccination
1177891|NCT01248507|COPD
1177892|NCT01248481|Acarbose/Glucobay®
1177893|NCT01248481|Basal insulin
1177894|NCT01248481|PPG (Postprandial Glycaemia)
1177895|NCT01248468|Pain, Migraine
1177896|NCT01248455|Monoclonal Antibody
1177897|NCT01248455|NK Cell Mediated Killing
1177898|NCT01248455|Response Rate
1177899|NCT01248455|Pharmacokinetics
1177900|NCT01248455|Biological Activity
1177901|NCT01248455|Smoldering Multiple Myeloma
1177902|NCT01248455|SMM
1177903|NCT01248442|Vitamin D Deficiency
1177904|NCT01248442|Autoimmune disease
1177905|NCT01248442|Diabetes
1177906|NCT01248429|thyrosine kinase inhibitor
1177907|NCT01248429|phosphokinase creatinin
1177908|NCT01248429|myalgia
1177909|NCT01248416|Aromatase
1177910|NCT01248416|Growth
1177911|NCT01248416|Letrozole
1177912|NCT01248416|Anastrozole
1177913|NCT01248416|GH
1177914|NCT01248416|Children
1177915|NCT01248416|Puberty
1177916|NCT01248403|RAD001
1177917|NCT01248403|Paclitaxel
1177918|NCT01248403|gastric cancer
1177919|NCT01248403|advanced gastric or esophagogastric junction cancer
1177922|NCT01248377|Cephalosporins
1177923|NCT01248377|Drug hypersensitivity
1177924|NCT01248351|aspirin, clopidogrel, pharmacodynamics, platelet transfusion
1177925|NCT01248299|Chemotherapy
1177926|NCT01248299|Best Supportive Care
1177927|NCT01248286|Diabetes
1177928|NCT01248286|Prediabetes
1177929|NCT01248286|Prevention
1177930|NCT01248286|Whole grain
1177931|NCT01248286|Advanced glycation end products
1177932|NCT01248286|Insulin sensitivity
1177933|NCT01248273|GLOBO H-KLH CONJUGATE
1177934|NCT01248273|MUC-1 KLH
1177935|NCT01248273|QS-21
1177936|NCT01248273|TF(C)-KLH
1177937|NCT01248273|TN(C)-KLH
1177938|NCT01248273|Immunization
1177939|NCT01248273|Vaccine
1177940|NCT01248273|09-184
1177941|NCT01248260|Fetal body size
1177942|NCT01248260|Fetal brain size
1177943|NCT01248260|Folic acid
1177944|NCT01248247|Non small cell lung cancer
1177945|NCT01248247|Biopsy accessible tumor
1177946|NCT01248247|Stage IIIB non small cell lung cancer
1177947|NCT01248247|Stage IV non small cell lung cancer
1177948|NCT01248234|elderly
1177949|NCT01248234|hypertensive
1177950|NCT01248234|anesthesia
1177951|NCT01248221|Breath test
1177952|NCT01248221|Dyspepsia
1177953|NCT01248221|Gastric Emptying
1177954|NCT01248221|Gastroparesis
1177955|NCT01248208|egg allergy
1177956|NCT01248208|influenza vaccine
1177957|NCT01248195|Schizophrenia
1177958|NCT01248195|Schizophreniform disorder
1177959|NCT01248195|Schizoaffective disorder
1177960|NCT01248195|Imaging
1177961|NCT01248195|Prognosis
1177962|NCT01248195|Treatment guidelines
1177963|NCT01248195|Pharmacogenetics
1177964|NCT01248182|acetabular fracture
1177965|NCT01248182|pelvic ring injury
1177966|NCT01248143|Green Tea
1177967|NCT01248143|Fermented papaya preparation
1177968|NCT01248143|Diabetes
1177969|NCT01248143|Cardiovascular diseases
1177970|NCT01248143|Atherosclerotic plaques
1177971|NCT01248143|Glucose
1177972|NCT01248143|Dietary supplements and functional foods
1177973|NCT01248130|Omega-3 Fatty Acid
1177974|NCT01248130|Autism Spectrum Disorders
1177975|NCT01248130|Pervasive Developmental Disorders
1177976|NCT01248130|Children
1177977|NCT01248130|Cognitive Functioning
1177978|NCT01248117|PCV
1177979|NCT01248117|polypoidal
1177980|NCT01248117|choroidal
1177981|NCT01248117|vasculopathy
1177982|NCT01248104|Cardiac Surgery
1177983|NCT01248104|Antifibrinolytic agents
1177984|NCT01248104|Blood transfusion
1177985|NCT01248104|epsilon aminocaproic acid
1177986|NCT01248104|tranexamic acid
1177987|NCT01248091|IUD, Insertion, Decrease, Pain
1177988|NCT01248078|elective cesarean section
1177989|NCT01248078|antibiotic prophylaxis
1177990|NCT01248078|cefazoline
1177991|NCT01248078|wound infection
1177992|NCT01248065|Asthma
1177993|NCT01248065|Vitamin D
1177994|NCT01248065|Corticosteroids
1177995|NCT01248065|Treatment failure
1177996|NCT01248039|Muscle strength, functional performance, joint replacement
1177997|NCT01248026|Cardiovascular disease
1177998|NCT01248026|Buttermilk
1177999|NCT01248026|Blood lipids
1178000|NCT01248026|Cholesterol absorption
1178001|NCT01248026|Cholesterol synthesis
1178002|NCT01248000|Hodgkin lymphoma
1178003|NCT01248000|FDG-PET
1178004|NCT01248000|prognostic factor
1178005|NCT01248000|clinical trial
1178006|NCT01247987|IVF, assisted reproduction, embryo transfer
1178007|NCT01247974|Coronary Artery Bypass Grafting
1178008|NCT01247974|New Onset Postoperative Atrial Fibrillation
1178009|NCT01247948|pedicle screw of fixation operation
1178010|NCT01247948|spine surgery
1178011|NCT01247948|navigation assisted
1178012|NCT01247935|Pain
1178013|NCT01247935|Acupuncture
1178014|NCT01247935|Transcutaneous electrical nerve stimulation
1178015|NCT01247935|Colonoscopy
1178016|NCT01247922|Pediatric Ependymoma
1178017|NCT01247922|Ependymoma
1178018|NCT01247922|Erlotinib
1178019|NCT01247922|Tarceva
1178020|NCT01247883|Phase 1
1178021|NCT01247883|relative bioavailability
1178022|NCT01247883|healthy volunteers
1178023|NCT01247883|pharmacokinetics
1178024|NCT01247883|solution
1178025|NCT01247883|tablet
1178026|NCT01247870|Chronic obstructive pulmonary disease, COPD, metformin
1178027|NCT01247857|Laparoscopic Cholecystectomy
1178028|NCT01247857|Nebulization
1178029|NCT01247857|Ropivacaine
1178030|NCT01247844|adult Males
1178031|NCT01247844|circumcision
1178032|NCT01247844|HIV prevention
1178033|NCT01247844|device
1178034|NCT01247831|glaucoma, selective laser trabeculoplasty, ocular rigidity
1178035|NCT01247805|Bioequivalence
1178036|NCT01247805|Powder for oral suspention
1178037|NCT01247792|sepsis
1178038|NCT01247792|organ failure
1178039|NCT01247792|end-of-life decisions
1178040|NCT01247792|patient-centered communication
1178041|NCT01247779|gynecology
1178042|NCT01247779|oncology
1178043|NCT01247779|coelioscopy
1178044|NCT01247779|robot
1178045|NCT01247779|morbidity
1178046|NCT01247727|Heart rate variability
1178047|NCT01247727|extracorporeal membrane oxygenation
1178048|NCT01247714|T-Diet plus Diabet NP
1178049|NCT01247714|Diabetic
1178050|NCT01247714|Enteral Nutrition
1178051|NCT01247714|Glycaemic response
1178052|NCT01247714|Metabolic Syndrome
1178053|NCT01247714|Insulin resistance
1178054|NCT01247714|Lipidic profile
1178055|NCT01247701|UCB
1178056|NCT01247701|Umbilical Cord Blood
1178057|NCT01247701|Transplant
1178058|NCT01247701|Umbilical Cord Blood Transplant
1178059|NCT01247701|Cord Blood Stem Cell Transplantation
1178060|NCT01247701|Pediatric
1178061|NCT01247701|Myeloid Hematological Malignancies
1178062|NCT01247701|Busulfan
1178063|NCT01247701|Cytoxan
1178064|NCT01247701|Cyclophosphamide
1178065|NCT01247701|Fludarabine
1178066|NCT01247688|Lymphoid
1178067|NCT01247688|hematologic malignancy
1178068|NCT01247688|UCB
1178069|NCT01247688|Umbilical Cord Blood Transplant
1178070|NCT01247688|Total Body Irradiation
1178071|NCT01247688|Cytoxan
1178072|NCT01247688|Cyclophosphamide
1178073|NCT01247688|Fludarabine
1178074|NCT01247662|Autism spectrum disorder
1178075|NCT01247662|Social Responsiveness Scale
1178076|NCT01247662|Childhood Asperger's Syndrome Test
1178077|NCT01247662|Adult Autism Spectrum Quotient
1178078|NCT01247662|psychometric
1178079|NCT01247649|Continuous glucose monitoring system
1178080|NCT01247649|Non invasive
1178081|NCT01247649|Type 1 diabetes
1178082|NCT01247649|Dielectric spectroscopy
1178083|NCT01247636|HLRQ
1178084|NCT01247636|Elderly
1178085|NCT01247636|Balance
1178086|NCT01247636|Mobility
1178087|NCT01247636|Fear of falling
1178088|NCT01247623|Non-resectable, advanced malignant melanoma.
1178089|NCT01247597|Thyroid Cancer
1178090|NCT01247597|Germline DICER1 Mutation
1178091|NCT01247597|MicroRNA Biogenesis
1178092|NCT01247597|Pleuropulmonary Blastoma
1178093|NCT01247597|PPB
1178094|NCT01247584|childhood acute myeloid leukemia/other myeloid malignancies
1178095|NCT01247584|childhood acute erythroleukemia (M6)
1178096|NCT01247584|childhood acute megakaryocytic leukemia (M7)
1178097|NCT01247584|childhood acute monoblastic leukemia (M5a)
1178098|NCT01247584|childhood acute monocytic leukemia (M5b)
1178099|NCT01247584|childhood acute myeloblastic leukemia without maturation (M1)
1178100|NCT01247584|childhood acute myelomonocytic leukemia (M4)
1178101|NCT01247584|childhood acute myeloblastic leukemia with maturation (M2)
1178102|NCT01247558|Metanx®
1178103|NCT01247558|diabetes
1178104|NCT01247558|neuropathy
1178105|NCT01247558|peripheral neurological disorder
1178106|NCT01247558|peripheral circulation disorder
1178107|NCT01247558|folic acid
1178108|NCT01247558|folate
1178109|NCT01247558|L-methylfolate
1178110|NCT01247558|vitamin B6
1178111|NCT01247558|Pyridoxal 5'-phosphate
1178112|NCT01247558|vitamin B12
1178113|NCT01247558|methylcobalamin
1178114|NCT01247545|Remote ischemic preconditioning
1178115|NCT01247545|Coronary artery bypass graft surgery
1178116|NCT01247545|Cardioprotection
1178117|NCT01247545|Clinical Outcomes
1178118|NCT01247532|Cancer
1178119|NCT01247532|Fatigue
1178120|NCT01247532|Mindfulness
1178121|NCT01247532|Meditation
1178122|NCT01247532|Neoplasms
1178123|NCT01247506|microRNA
1178124|NCT01247493|fludarabine
1178125|NCT01247493|AML
1178126|NCT01247493|Efficacy
1178127|NCT01247493|tolerability
1178128|NCT01247454|CVD
1178129|NCT01247454|primary prevention
1178130|NCT01247454|ASA
1178131|NCT01247454|physician behavioral change
1178132|NCT01247454|Patient behavioral change
1178133|NCT01247441|All breast cancer patients who were diagnosed or managed in NUH will be included into this registry
1178134|NCT01247428|Coronary Artery Disease
1178135|NCT01247428|Drug-eluting Stent
1178136|NCT01247428|Sirolimus
1178137|NCT01247415|anaphylaxis
1178138|NCT01247415|allergy
1178139|NCT01247415|IgE mediated
1178140|NCT01247415|ORS
1178141|NCT01247415|oculorespiratory syndrome
1178142|NCT01247415|Allergic-like reactions
1178143|NCT01247415|H1N1
1178144|NCT01247415|Arepanrix
1178145|NCT01247402|peripheral arterial disease
1178146|NCT01247402|in-stent restenosis
1178147|NCT01247402|drug eluting balloon
1178148|NCT01247389|laparoscopy
1178149|NCT01247389|colon resection
1178150|NCT01247389|incisional hernia
1178151|NCT01247376|inflammation
1178152|NCT01247376|arthroscopy
1178153|NCT01247376|knee
1178154|NCT01247376|microdialysis
1178155|NCT01247363|Diabetes glucokinase safety
1178156|NCT01247311|Vitamin D
1178157|NCT01247311|pulse wave velocity
1178158|NCT01247298|Hepatocellular Carcinoma, HCC, TACE, Radiation Induced Liver Disease (RILD), SBRT
1178159|NCT01247285|Bioequivalence
1178160|NCT01247285|Healthy Subjects
1178161|NCT01247272|Bioequivalence
1178162|NCT01247272|Healthy Subjects
1178163|NCT01247259|allergic rhinitis
1178164|NCT01247259|immunotherapy
1178165|NCT01247259|sublingual
1178166|NCT01247246|Oral Mucositis
1178167|NCT01247246|Head and Neck
1178168|NCT01247246|Head and Neck Neoplasms
1178169|NCT01247246|Mucositis
1178170|NCT01247246|Stomatitis
1178171|NCT01247246|Neoplasms by Site
1178172|NCT01247246|Neoplasms
1178173|NCT01247246|Gastroenteritis
1178174|NCT01247246|Gastrointestinal Diseases
1178175|NCT01247246|Digestive System Diseases
1178176|NCT01247246|Mouth Diseases
1178177|NCT01247246|Stomatognathic Diseases
1178178|NCT01247246|SCV-07
1178179|NCT01247233|breast cancer
1178180|NCT01247233|Accelerated Partial Breast Irradiation
1178181|NCT01247233|invasive cancer
1178182|NCT01247233|Hypofractionated Irradiation
1178183|NCT01247233|Lumpectomy
1178184|NCT01247220|Macular Edema
1178185|NCT01247220|Branch retinal vein occlusion
1178186|NCT01247220|Ranibizumab
1178187|NCT01247207|Duchenne muscular dystrophy
1178188|NCT01247207|Becker muscular dystrophy
1178189|NCT01247207|Nonsense mutation
1178190|NCT01247207|Premature stop codon
1178191|NCT01247207|DMD
1178192|NCT01247207|BMD
1178193|NCT01247207|nmDBMD
1178194|NCT01247207|DBMD
1178195|NCT01247207|Ataluren
1178196|NCT01247207|PTC124
1178197|NCT01247194|hepatitis C
1178198|NCT01247194|NS5A
1178199|NCT01247194|HCV RNA
1178200|NCT01247181|compliance
1178201|NCT01247181|observance
1178202|NCT01247181|mobile phone
1178203|NCT01247181|SMS
1178204|NCT01247181|text message
1178205|NCT01247181|ARV
1178206|NCT01247181|HAART
1178207|NCT01247181|AIDS
1178208|NCT01247168|Refractory
1178209|NCT01247168|Solid tumors
1178210|NCT01247168|Cancer
1178211|NCT01247142|invasive pulmonary aspergillosis
1178212|NCT01247142|exhaled breath condensate
1178213|NCT01247129|Superficial inferior epigastric artery flap, delay phenomenon
1178214|NCT01247103|healthy volunteers
1178215|NCT01247103|safety
1178216|NCT01247103|tolerability
1178217|NCT01247090|hypertension
1178218|NCT01247090|end stage renal disease
1178219|NCT01247090|vasopressin
1178220|NCT01247090|Arginine Vasopressin
1178221|NCT01247090|AVP
1178222|NCT01247090|Pitressin®
1178223|NCT01247077|selenium
1178224|NCT01247077|neuropsychological testing
1178225|NCT01247077|autoantibodies
1178226|NCT01247064|Bronchiolitis
1178227|NCT01247064|Hypertonic Saline
1178228|NCT01247051|priming
1178229|NCT01247051|cardiac surgery
1178230|NCT01247051|cardio pulmonary bypass
1178231|NCT01247051|precoating
1178232|NCT01246999|Influenza
1178233|NCT01246999|A/California/7/2009-like (2009 H1N1)
1178234|NCT01246999|A/Perth/16/2009-like (H3N2)
1178235|NCT01246999|B/Brisbane/60/2008-like (B/Victoria lineage)
1178236|NCT01246973|Oral Curcumin
1178237|NCT01246973|Radiation Dermatitis
1178238|NCT01246973|Breast Cancer Patients
1178239|NCT01246960|cancer
1178240|NCT01246960|stomach
1178241|NCT01246960|esophagus
1178242|NCT01246960|gastroesophageal
1178243|NCT01246947|Moderate Tricuspid Valve Regurgitation
1178244|NCT01246947|Tricuspid Valve Repair
1178245|NCT01246947|Mitral Value Surgery
1178246|NCT01246921|Vitiligo, repigmentation, satisfaction
1178247|NCT01246908|TRD
1178248|NCT01246895|Cartilage repair
1178249|NCT01246895|Cartilage
1178250|NCT01246895|Knee
1178251|NCT01246895|Knee Injuries
1178252|NCT01246895|Knee Pain
1178253|NCT01246895|Microfracture
1178254|NCT01246895|Bone Marrow Stimulation
1178255|NCT01246895|Arthroscopy
1178256|NCT01246882|Stroke, gait, walking, disability
1178257|NCT01246882|wireless inertial sensing
1178258|NCT01246882|mobile health
1178259|NCT01246869|brain, cancer,glioblastoma multiforme, meningioma, glioma
1178260|NCT01246856|Cardiotoxicity
1178261|NCT01246856|Breast cancer treatment
1178262|NCT01246856|MIBG scintigraphy
1178263|NCT01246856|Strain Echocardiography
1178264|NCT01246856|patients who have been treated with TAC one year previously
1178265|NCT01246843|sunitinib
1178266|NCT01246843|sorafenib
1178267|NCT01246843|cognitive functioning
1178268|NCT01246817|Carcinoma, Renal Cell
1178269|NCT01246817|temsirolimus
1178270|NCT01246817|FLT-PET
1178271|NCT01246817|FDG-PET
1178272|NCT01246817|Adult patients with metastatic RCC (any histology and any MSKCC prognostic score), with documented
1178273|NCT01246817|progressive disease after more than two prior systemic treatments with any of the following: cytokines (±
1178274|NCT01246817|chemotherapy), sunitinib, sorafenib, or bevacizumab (± IFN).
1178275|NCT01246804|HIV infections
1178276|NCT01246804|interaction
1178277|NCT01246804|pharmacokinetics
1178278|NCT01246791|NPC-01
1178279|NCT01246791|Pharmacokinetics
1178280|NCT01246791|Healthy female volunteer
1178281|NCT01246791|Norethisterone
1178282|NCT01246791|Ethinyl Estradiol
1178283|NCT01246765|Atypical Antipsychotics and pregnancy
1178284|NCT01246765|Pregnancy
1178285|NCT01246765|Medication use during pregnancy
1178286|NCT01246752|AML, Leukemia
1178287|NCT01246752|Acute Myeloid Leukemia
1178288|NCT01246752|HSCT
1178289|NCT01246752|Stem Cell Transplantation
1178290|NCT01246752|Tx
1178291|NCT01246752|Chemotherapy
1178292|NCT01246739|mild hypercortisolism
1178293|NCT01246739|adrenal tumour
1178294|NCT01246739|surgical procedures, elective
1178295|NCT01246739|indication
1178296|NCT01246726|cancer, breast, radiotherapy, boost
1178297|NCT01246713|acetaminophen
1178298|NCT01246713|excipients
1178299|NCT01246700|Parkinson's disease
1178300|NCT01246700|Randomized single-blind crossover trial
1178301|NCT01246700|Sensory Attention Focused Exercise
1178302|NCT01246674|function, hip muscle strength, hip replacement, hip pain,
1178303|NCT01246609|acid base balance
1178304|NCT01246609|Percutaneous Lithotripsy
1178305|NCT01246583|Multi Site
1178306|NCT01246583|Randomized
1178307|NCT01246583|Placebo Controlled
1178308|NCT01246583|Double Blind
1178309|NCT01246583|Parallel Group
1178310|NCT01246583|chronic plaque psoriasis
1178311|NCT01246583|topical treatment
1178312|NCT01246583|skin diseases
1178313|NCT01246583|papulosquamous
1178314|NCT01246570|exercise
1178315|NCT01246570|heart
1178316|NCT01246570|coronary disease
1178317|NCT01246570|rehabilitation
1178318|NCT01246557|Patients with Chronic Lymphatic Leukemia relapsing or resistant to treatment
1178319|NCT01246544|Patient Safety
1178320|NCT01246544|The Helsinki Declaration on Patient Safety in Anaesthesiology
1178321|NCT01246544|Helsinki Declaration on Patient Safety
1178322|NCT01246544|European Board of Anaesthesiology (EBA)
1178323|NCT01246544|European Society of Anaesthesiology (ESA)
1178324|NCT01246531|Urolithiasis
1178325|NCT01246531|Renal calculi
1178326|NCT01246531|Aging
1178327|NCT01246531|Osteoporosis
1178328|NCT01246518|distal subungual onychomycosis
1178329|NCT01246466|Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation, Ablation, catheter ablation
1178330|NCT01246427|Adjuvant hormonal therapy
1178331|NCT01246427|Homeopathic treatment
1178332|NCT01246427|Hot flashes
1178333|NCT01246427|Quality of life
1178334|NCT01246427|Hot flash score
1178335|NCT01246414|Asthma
1178336|NCT01246414|Exhaled breath condensates
1178337|NCT01246414|Cytokines
1178338|NCT01246388|Fibrosis
1178339|NCT01246388|Steatosis
1178340|NCT01246388|Liver biopsy
1178341|NCT01246388|Elastography
1178342|NCT01246388|MRI
1178343|NCT01246349|Motivational Interviewing
1178344|NCT01246349|Child and Adolescent Self-Efficacy
1178345|NCT01246349|Health Behaviours
1178346|NCT01246336|Parkinson's disease, Parkinsonism
1178347|NCT01246336|Biomarkers
1178348|NCT01246336|Exhaled breath
1178349|NCT01246336|Nanothechnology
1178350|NCT01246323|Visual analogue scale
1178351|NCT01246323|pain level
1178352|NCT01246323|analgesia
1178353|NCT01246323|combined anesthesia
1178354|NCT01246284|Alopecia areata
1178355|NCT01246284|Intralesional
1178356|NCT01246284|Triamcinolone acetonide
1178357|NCT01246284|Concentration
1178358|NCT01246258|primary ciliary dyskinesia
1178359|NCT01246258|otolith
1178360|NCT01246258|vestibular tests
1178361|NCT01246245|PIN SITE INFECTION AFTER EXTERNAL FIXATION
1178362|NCT01246219|Idiopathic Short stature
1178363|NCT01246219|Self Image
1178364|NCT01246219|GH therapy
1178365|NCT01246219|Psychological distress
1178366|NCT01246206|● Non-Hodgkin lymphoma,
1178367|NCT01246206|● Hodgkin disease,
1178368|NCT01246206|● Acute Myelogenous or Acute Lymphocytic Leukemia
1178369|NCT01246206|● Myelodysplastic Syndromes,
1178370|NCT01246206|● Chronic Myelogenous Leukemia
1178371|NCT01246206|● Multiple Myeloma
1178372|NCT01246206|● Chronic Lymphocytic Leukemia
1178373|NCT01246206|● Myelofibrosis and other myeloproliferative disorders;
1178374|NCT01246193|CKD-828
1178375|NCT01246193|Hypertension
1178376|NCT01246193|Primary Hypertension
1178377|NCT01246193|Healthy Volunteer
1178378|NCT01246193|S-Amlodipine
1178379|NCT01246193|Telmisartan
1178380|NCT01246193|Amlodipine
1178381|NCT01246193|Pharmacokinetic
1178382|NCT01246193|Phase 1
1178383|NCT01246180|Skin, microcirculation; ASIC, pressure ulcer
1178384|NCT01246167|Proximal humerus fracture
1178385|NCT01246167|conservative
1178386|NCT01246167|locking plate
1178387|NCT01246167|Philos
1178388|NCT01246167|Hemiprosthesis
1178389|NCT01246154|ASTHMA
1178390|NCT01246141|tricuspid valve regurgitation
1178391|NCT01246141|replacement
1178392|NCT01246141|repair
1178393|NCT01246141|outcomes
1178394|NCT01246128|Nicotinic Acetylcholine Receptors
1178395|NCT01246128|Schizophrenia Smokers
1178396|NCT01246128|PET Imaging
1178397|NCT01246102|Targeted Therapy
1178398|NCT01246102|HER2 Positive Cancer
1178399|NCT01246102|Cancer
1178400|NCT01246102|Solid Tumor
1178401|NCT01246102|Breast Cancer
1178402|NCT01246089|Ranibizumab
1178403|NCT01246089|Myopia
1178404|NCT01246089|Complications
1178405|NCT01246089|Neovascularization
1178406|NCT01246089|OCT
1178407|NCT01246050|Heart Failure
1178408|NCT01246050|Outcome Assessment
1178409|NCT01246050|Congestive Heart Failure
1178410|NCT01246037|Pulmonary Arterial Hypertension
1178411|NCT01246037|Beta-blocker
1178412|NCT01246037|Adrenergic Receptor Antagonist
1178413|NCT01245998|Thrombophlebitis
1178414|NCT01245998|Venous thrombosis
1178415|NCT01245998|Pulmonary embolism
1178416|NCT01245998|Anticoagulants
1178417|NCT01245998|Low-Molecular-Weight Heparin
1178418|NCT01245985|SCCHN
1178419|NCT01245985|squamous cell carcinoma of the head and neck
1178420|NCT01245985|oropharyngeal carcinoma
1178421|NCT01245985|hypopharyngeal carcinoma
1178422|NCT01245985|laryngeal carcinoma
1178423|NCT01245972|pulsed dye laser
1178424|NCT01245972|PDL
1178425|NCT01245972|basal cell carcinoma
1178426|NCT01245972|squamous cell carcinoma
1178427|NCT01245972|BCC
1178428|NCT01245972|SCC
1178429|NCT01245972|594nM laser
1178430|NCT01245959|Nasopharyngeal carcinoma
1178431|NCT01245959|Concurrent chemoradiotherapy
1178432|NCT01245959|Induction chemotherapy
1178433|NCT01245959|Clinical trial
1178434|NCT01245946|Acne moderate
1178435|NCT01245946|Photodynamic Therapy
1178436|NCT01245946|Topical retinoids
1178437|NCT01245946|Antimicrobial agents
1178438|NCT01245933|COPD
1178439|NCT01245933|register
1178440|NCT01245933|comorbidities
1178441|NCT01245933|systemic inflammation
1178442|NCT01245920|Dental implant
1178443|NCT01245920|Alveolar bone
1178444|NCT01245920|Clinical attachment Level
1178445|NCT01245907|Hot flashes
1178446|NCT01245907|Menopause
1178447|NCT01245907|HRQoL
1178448|NCT01245907|Applied relaxation
1178449|NCT01245907|Insomnia
1178450|NCT01245907|Women's knowledge
1178451|NCT01245894|Index of microcirculatory resistance
1178452|NCT01245894|Fractional Flow Reserve
1178453|NCT01245881|controlled trial
1178454|NCT01245881|fractional photothermolysis
1178455|NCT01245881|laser surgery
1178456|NCT01245881|melasma
1178457|NCT01245881|pigment disorder
1178458|NCT01245868|Spinal anaesthesia
1178459|NCT01245868|Bupivacaine
1178460|NCT01245868|Lidocaine
1178461|NCT01245868|Duration of blockade
1178462|NCT01245855|Prostaglandin E1
1178463|NCT01245855|percutaneous coronary intervention
1178464|NCT01245855|Cardiac troponin T
1178465|NCT01245855|Creatine kinase-MB
1178466|NCT01245829|Cross Infection
1178467|NCT01245829|Nosocomial Infection
1178468|NCT01245829|Healthcare Acquired Infection
1178469|NCT01245829|Hospital Paperwork
1178470|NCT01245829|Observation Charts
1178471|NCT01245829|Critical Care
1178472|NCT01245829|Contamination
1178473|NCT01245816|colon polyps
1178474|NCT01245803|rosuvastatin
1178475|NCT01245803|angioplasty
1178476|NCT01245803|acute coronary syndrome
1178477|NCT01245790|Phase 1
1178478|NCT01245790|healthy volunteers
1178479|NCT01245790|volunteers with renal impairment
1178480|NCT01245790|pharmacokinetics
1178481|NCT01245790|Rheumatoid arthritis
1178482|NCT01245790|RA
1178483|NCT01245790|fostamatinib
1178484|NCT01245790|Patients
1178485|NCT01245777|RLS
1178486|NCT01245777|Pregnancy
1178487|NCT01245777|Iron Deficiency
1178488|NCT01245777|Anaemia
1178489|NCT01245764|Cervical cancer
1178490|NCT01245764|vulvar cancer
1178491|NCT01245764|vaginal cancer
1178492|NCT01245764|genital warts
1178493|NCT01245764|human papillomavirus
1178494|NCT01245751|Shingles
1178495|NCT01245751|Vaccine
1178496|NCT01245712|Adenocarcinoma of the breast
1178497|NCT01245712|Lumpectomy
1178498|NCT01245712|Stage 0 breast cancer
1178499|NCT01245712|Stage I breast cancer
1178500|NCT01245712|Stage II breast cancer
1178501|NCT01245712|Accelerated partial breast irradiation
1178502|NCT01245712|APBI
1178503|NCT01245699|Cardiac arrest, CPR, quality improvement
1178504|NCT01245686|Diet interventions
1178505|NCT01245686|Physical activity interventions
1178506|NCT01245686|Medication adherence
1178507|NCT01245686|Tailored interventions
1178508|NCT01245673|Advanced Disease
1178509|NCT01245673|MAGE-A3 Immunizations with Hiltonol
1178510|NCT01245673|Vaccine-Primed Autologous T-Cells
1178511|NCT01245673|Lenalidomide Maintenance
1178512|NCT01245660|Phase 0
1178513|NCT01245660|Bladder carcinoma
1178514|NCT01245660|egf pathway
1178515|NCT01245660|infiltrative bladder carcinoma
1178516|NCT01245660|cystectomy
1178517|NCT01245660|LAPATINIB
1178518|NCT01245647|women
1178519|NCT01245647|HIV
1178520|NCT01245647|alcohol
1178521|NCT01245647|medication
1178522|NCT01245647|adherence
1178523|NCT01245647|acceptability
1178524|NCT01245621|palliative care
1178525|NCT01245621|end of life care
1178526|NCT01245621|quality of life
1178527|NCT01245621|caregivers
1178528|NCT01245608|Atorvastatin
1178529|NCT01245608|Aspirin
1178530|NCT01245608|nonalcoholic steatohepatitis
1178531|NCT01245608|nonalcoholic fatty liver disease
1178532|NCT01245608|antihypertensive agents
1178533|NCT01245595|Acute Kidney Injury (AKI)
1178534|NCT01245595|Cardiopulmonary bypass (CPB)
1178535|NCT01245530|Alzheimer disease
1178536|NCT01245517|hyperphosphatemia or malnutrition
1178537|NCT01245478|Surgical Procedures, Elective
1178538|NCT01245452|Rheumatoid arthritis
1178539|NCT01245452|Tocilizumab
1178540|NCT01245452|Cardiorespiratory endurance
1178541|NCT01245426|Asthma
1178542|NCT01245426|GW870086
1178543|NCT01245426|Efficacy
1178544|NCT01245426|FEV1
1178545|NCT01245413|Stoma
1178546|NCT01245413|adhesive
1178547|NCT01245413|warm
1178548|NCT01245413|moist
1178549|NCT01245413|cycling
1178550|NCT01245413|men
1178551|NCT01245413|peel-value
1178552|NCT01245413|healthy men 50-70 years old
1178553|NCT01245413|men with colostoma, above 18 years
1178554|NCT01245400|Z-Lig
1178555|NCT01245400|allograft
1178556|NCT01245400|ACL
1178557|NCT01245400|Anterior Cruciate Ligament
1178558|NCT01245400|ACLR
1178559|NCT01245400|Anterior Cruciate Ligament Reconstruction
1178560|NCT01245400|EU
1178561|NCT01245400|European Union
1178562|NCT01245400|S. Africa
1178563|NCT01245400|Reconstruction of ruptured anterior cruciate ligaments
1178564|NCT01245387|prospective
1178565|NCT01245387|observational
1178566|NCT01245387|Phase 4
1178567|NCT01245387|non-interventional
1178568|NCT01245387|open-label
1178569|NCT01245361|Undifferentiated Arthritis
1178570|NCT01245361|Rheumatoid Arthritis
1178571|NCT01245361|Infliximab
1178572|NCT01245348|Schizophrenia
1178573|NCT01245348|Bipolar Disorder
1178574|NCT01245348|atypical antipsychotic
1178575|NCT01245348|adherence
1178576|NCT01245348|cost effectiveness
1178577|NCT01245348|pharmacogenetics
1178578|NCT01245348|mental illness
1178579|NCT01245348|SULT4A1
1178580|NCT01245335|CLI
1178581|NCT01245335|Critical Limb Ischemia
1178582|NCT01245335|PAOD
1178583|NCT01245335|Peripheral Arterial Disease
1178584|NCT01245335|Stem Cells
1178585|NCT01245335|Limb amputation
1178586|NCT01245335|Leg ulcers
1178587|NCT01245322|treatment, lactobacilli
1178588|NCT01245296|Umbilical cord
1178589|NCT01245296|cord clamping
1178590|NCT01245296|iron
1178591|NCT01245296|Ferritin
1178592|NCT01245296|newborn
1178593|NCT01245296|jaundice
1178594|NCT01245296|infant
1178595|NCT01245296|development
1178596|NCT01245296|infections
1178597|NCT01245283|knee
1178598|NCT01245283|osteoarthritis
1178599|NCT01245283|pain
1178600|NCT01245283|function
1178601|NCT01245283|impairment
1178602|NCT01245270|anthocyanin
1178603|NCT01245270|blaeberries
1178604|NCT01245270|bilberries
1178605|NCT01245270|blueberries
1178606|NCT01245270|mirtoselect
1178607|NCT01245270|glucose AUC
1178608|NCT01245257|Inflammation
1178609|NCT01245257|Urea Synthesis
1178610|NCT01245257|Catabolism
1178611|NCT01245257|Nitrogen balance
1178612|NCT01245231|childhood acute myeloid leukemia/other myeloid malignancies
1178613|NCT01245179|sickle cell anemia
1178614|NCT01245179|sickle cell thalassemia
1178615|NCT01245179|HDAC inhibitor
1178616|NCT01245179|hemoglobin F
1178617|NCT01245179|sickle beta thalassemia
1178618|NCT01245179|Fetal Hemoglobin
1178619|NCT01245153|Urinary incontinence, Pelvic floor muscle training
1178620|NCT01245140|Palmo-Plantar Pustolosis
1178621|NCT01245127|Schnitzler syndrome
1178622|NCT01245101|HIV raltegravir intensification replication activation
1178623|NCT01245088|Crohn's disease
1178624|NCT01245088|chondroitin sulfate
1178625|NCT01245062|MEK inhibitor
1178626|NCT01245062|Cancer
1178627|NCT01245062|Metastatic Melanoma
1178628|NCT01245062|BRAF mutant metastatic melanoma
1178629|NCT01245062|GSK1120212
1178630|NCT01245049|MMR
1178631|NCT01245049|dTpa-IPV
1178632|NCT01245049|Boostrix Polio
1178633|NCT01245049|Repevax
1178634|NCT01245049|Priorix
1178635|NCT01245036|Sarcoidosis
1178636|NCT01245036|Tuberculosis
1178637|NCT01245010|Metabolic Syndrome
1178638|NCT01245010|Water
1178639|NCT01245010|Obesity
1178640|NCT01245010|Clinical trial
1178641|NCT01245010|Prevention
1178642|NCT01244997|Partial edentulism
1178643|NCT01244997|Bone atrophy
1178644|NCT01244997|Bone healing
1178645|NCT01244984|asthma
1178646|NCT01244984|Fluticasone furoate
1178647|NCT01244984|GW642444
1178648|NCT01244958|Active rheumatoid arthritis
1178649|NCT01244958|leflunomide
1178650|NCT01244958|rituximab
1178651|NCT01244958|inadequate clinical response to leflunomide
1178652|NCT01244945|Functional Constipation
1178653|NCT01244945|Functional Foods
1178654|NCT01244945|Probiotics
1178655|NCT01244945|Lactobacillus reuteri
1178656|NCT01244906|Chronic Myelogenous Leukemia
1178657|NCT01244906|Acute Myelogenous Leukemia
1178658|NCT01244906|Myelodysplastic Syndrome
1178659|NCT01244906|Myelofibrosis
1178660|NCT01244906|Acute Lymphocytic Leukemia
1178661|NCT01244906|Acute Lymphoblastic Lymphoma
1178662|NCT01244906|Chronic Lymphocytic Leukemia
1178663|NCT01244906|Prolymphocytic Leukemia
1178664|NCT01244906|Low-grade non-Hodgkin's Lymphoma
1178665|NCT01244906|Mantle Cell Lymphoma
1178666|NCT01244906|Hodgkin Lymphoma
1178667|NCT01244906|Myeloma
1178668|NCT01244880|PF-02545920
1178669|NCT01244880|ketamine
1178670|NCT01244880|fMRI
1178671|NCT01244880|associative Learning
1178672|NCT01244854|chronic mental disorders
1178673|NCT01244854|cardiovascular disease
1178674|NCT01244854|behavior change
1178675|NCT01244841|ST elevation acute myocardial infarction
1178676|NCT01244841|Primary percutaneous coronary intervention
1178677|NCT01244841|Discharge
1178678|NCT01244841|Health status
1178679|NCT01244841|Quality of care
1178680|NCT01244815|Bi-polar I disorder
1178681|NCT01244815|antipsychotic
1178682|NCT01244815|serotonin
1178683|NCT01244815|dopamine
1178684|NCT01244815|noradrenalin
1178685|NCT01244815|histamine
1178686|NCT01244815|pediatric
1178687|NCT01244802|yellow fever vaccine
1178688|NCT01244789|endometrial cancer
1178689|NCT01244789|chemotherapy
1178690|NCT01244789|carboplatin
1178691|NCT01244789|paclitaxel
1178692|NCT01244789|Stage 1 & 2
1178693|NCT01244789|node-negative
1178694|NCT01244789|intermediate risk
1178695|NCT01244789|high risk
1178696|NCT01244763|Kidney
1178697|NCT01244763|Chronic Kidney Disease
1178698|NCT01244763|CKD
1178699|NCT01244763|Renal
1178700|NCT01244763|Anemia
1178701|NCT01244763|Oral anemia treatment
1178702|NCT01244763|Hemoglobin levels
1178703|NCT01244763|Erythropoietin
1178704|NCT01244763|Blood count
1178705|NCT01244763|Predialysis
1178706|NCT01244763|Pre-dialysis
1178707|NCT01244763|Hb
1178708|NCT01244763|Non-dialysis
1178709|NCT01244750|Chronic Phase - Chronic Myeloid Leukemia
1178710|NCT01244737|Brain neoplasms
1178711|NCT01244737|Children
1178712|NCT01244737|Positron-Emission Tomography
1178713|NCT01244737|18F-FLT
1178714|NCT01244711|Major Depression
1178715|NCT01244711|Generalized Anxiety Disorder
1178716|NCT01244711|Benzodiazepine
1178717|NCT01244711|Quetiapine
1178718|NCT01244698|Surgical Site Infection, Breast Reconstruction, Antibiotics
1178719|NCT01244685|bowel resection
1178720|NCT01244685|Deltex CardioQ Probe
1178721|NCT01244685|fluid management
1178722|NCT01244672|Hemorrhoids
1178723|NCT01244672|THD
1178724|NCT01244672|Ferguson
1178725|NCT01244659|Tacrolimus
1178726|NCT01244659|Immunosuppressive Agents
1178727|NCT01244659|Kidney transplantation
1178728|NCT01244646|Diabetes Mellitus
1178729|NCT01244646|Type 2
1178730|NCT01244646|DMT2
1178731|NCT01244646|T2DM
1178732|NCT01244646|metformin
1178733|NCT01244646|sulfonylurea
1178734|NCT01244646|hypoglycemia
1178735|NCT01244646|weight
1178736|NCT01244646|quality of life
1178737|NCT01244646|compliance
1178738|NCT01244633|Tourette's
1178739|NCT01244633|Ecopipam
1178740|NCT01244633|Dopamine receptors
1178741|NCT01244633|Efficacy
1178742|NCT01244633|Safety
1178743|NCT01244633|Adults
1178744|NCT01244620|A pharmacokinetic drug-drug interaction study between sitaxsentan and tadalafil and between sitaxsentan and sildenafil at the steady-state
1178745|NCT01244594|Spinal Cord Injury
1178746|NCT01244594|Cycling
1178747|NCT01244594|Functional Electrical Stimulation
1178748|NCT01244581|middle ear effusion
1178749|NCT01244581|amoxicillin-clavulanate
1178750|NCT01244581|tympanometry
1178751|NCT01244568|Prostate Cancer
1178752|NCT01244568|Decision support interventions (DESI)
1178753|NCT01244568|Comparative Effectiveness Research (CER)
1178754|NCT01244542|Schizophrenia
1178755|NCT01244542|DSM IV criteria
1178756|NCT01244542|Pain insensitivity
1178757|NCT01244542|Painful perception
1178758|NCT01244542|Opioid receptors
1178759|NCT01244490|ADHD
1178760|NCT01244477|Stress Disorders, Post Traumatic
1178761|NCT01244477|Trust
1178762|NCT01244477|functional Magnetic Resonance Imaging (fMRI)
1178763|NCT01244464|Poliomyelitis
1178764|NCT01244464|IMOVAX POLIO™
1178765|NCT01244464|Polio
1178766|NCT01244451|CLL
1178767|NCT01244451|relapsed
1178768|NCT01244451|refractory
1178769|NCT01244451|Bendamustine
1178770|NCT01244451|Ofatumumab
1178771|NCT01244438|endometrial cancer
1178772|NCT01244438|FGFR2 mutations
1178773|NCT01244412|Fundus photography
1178774|NCT01244399|inositol
1178775|NCT01244399|caffeine
1178776|NCT01244399|NTDs
1178777|NCT01244386|Computed tomography
1178778|NCT01244386|Iterative reconstruction
1178779|NCT01244386|Automatic tube current modulation
1178780|NCT01244386|Crohn's disease
1178781|NCT01244386|Inflammatory bowel disease
1178782|NCT01244386|Radiation dose optimization
1178783|NCT01244386|C reactive protein
1178784|NCT01244373|Best-corrected visual acuity
1178785|NCT01244373|posterior capsule opacification
1178786|NCT01244373|QUATRIX® Aspheric Evolutive pre-loaded
1178787|NCT01244360|resveratrol
1178788|NCT01244360|insulin
1178789|NCT01244360|inflammation
1178790|NCT01244360|cognition
1178791|NCT01244360|metabolism
1178792|NCT01244347|folic acid
1178793|NCT01244347|malformations
1178794|NCT01244347|prevention
1178795|NCT01244334|cataract surgery, vision, corneal edema, retinal thickness
1178796|NCT01244321|End stage heart failure
1178797|NCT01244321|heart transplantation
1178798|NCT01244321|Ventricular assist device
1178799|NCT01244321|Patients with end stage heart failure
1178800|NCT01244321|awaiting heart transplantation
1178801|NCT01244308|Phrenic nerve stimulation
1178802|NCT01244308|LV pacing configuration
1178803|NCT01244308|CRT
1178804|NCT01244308|Cardiac resynchronisation therapy
1178805|NCT01244308|Heart failure
1178806|NCT01244295|Grief
1178807|NCT01244295|Bereavement
1178808|NCT01244295|Psychotherapy
1178809|NCT01244295|Randomized controlled trial
1178810|NCT01244295|Treatment study
1178811|NCT01244282|brain imaging
1178812|NCT01244269|Parkinson's disease
1178813|NCT01244269|Methylphenidate
1178814|NCT01244269|Non motor symptoms
1178815|NCT01244269|Postural control
1178816|NCT01244243|stroke
1178817|NCT01244243|rehabilitation
1178818|NCT01244204|vitamin D deficiency
1178819|NCT01244204|tuberculin sin test
1178820|NCT01244204|immunity
1178821|NCT01244204|tuberculosis
1178822|NCT01244191|Non squamous, non-small-cell lung cancer
1178823|NCT01244191|Epidermal growth factor receptor, wild type
1178824|NCT01244191|c-Met inhibitor
1178825|NCT01244178|Sepsis
1178826|NCT01244178|Insulin
1178827|NCT01244139|BIIB033
1178828|NCT01244139|Multiple Sclerosis
1178829|NCT01244139|anti-LINGO-1 antibody
1178830|NCT01244139|Relapsing Remitting MS
1178831|NCT01244139|remyelination
1178832|NCT01244139|myelin repair
1178833|NCT01244139|Multiple ascending dose
1178834|NCT01244139|Secondary progessive MS
1178835|NCT01244126|otitis media
1178836|NCT01244126|recurrent ear infections (otitis media)
1178837|NCT01244100|Food-effects PK study in healthy subjects.
1178838|NCT01244087|Inquiry-based stress reduction
1178839|NCT01244087|Quality of life
1178840|NCT01244087|breast cancer
1178841|NCT01244048|n3 LC-PUFA, yoghurt, inflammatory markers
1178842|NCT01244035|High blood pressure
1178843|NCT01244022|Colorectal cancer
1178844|NCT01244022|Surgical stress response
1178845|NCT01244022|interleukins
1178846|NCT01244009|Poly (ADP-ribose) polymerase (PARP) inhibitor
1178847|NCT01243996|Patent ductus arteriosus, ibuprofen, preterm infants
1178848|NCT01243970|Spinal anaesthesia
1178849|NCT01243970|phenylephrine
1178850|NCT01243970|ephedrine
1178851|NCT01243970|ECG changes
1178852|NCT01243970|Caesarean delivery
1178853|NCT01243970|Myocardial ischaemia
1178854|NCT01243970|Cardiac output
1178855|NCT01243970|hypotension
1178856|NCT01243944|INCB018424
1178857|NCT01243931|Phototherapeutic keratectomy
1178858|NCT01243931|Optical coherence tomography
1178859|NCT01243931|Corneal opacity
1178860|NCT01243918|Acute respiratory failure
1178861|NCT01243918|Oxygen therapy delivery systems
1178862|NCT01243918|Non invasive ventilation
1178863|NCT01243918|High concentration mask
1178864|NCT01243918|Hypoxemic pneumonia
1178865|NCT01243879|fasting
1178866|NCT01243879|starvation
1178867|NCT01243879|calorie restriction
1178868|NCT01243879|fMRI
1178869|NCT01243840|Central aortic pressure
1178870|NCT01243840|Aortic pulse wave velocity
1178871|NCT01243840|Aortic PWV using a single pressure recording
1178872|NCT01243840|Vascular aging
1178873|NCT01243840|Left ventricular hypertrophy
1178874|NCT01243840|Left ventricular diastolic function
1178875|NCT01243827|Hypertension, carvedilol, bisoprolol, central pulse pressure, pulse pressure amplification, reflection magnitude, LV mass index, LV diastolic function
1178876|NCT01243814|hyaluronate
1178877|NCT01243814|hyaluronic acid
1178878|NCT01243814|viscosupplementation
1178879|NCT01243801|chronic pain
1178880|NCT01243801|persistent postsurgical pain
1178881|NCT01243801|hyperalgesia
1178882|NCT01243801|ketamine
1178883|NCT01243801|quantitative sensory testing
1178884|NCT01243788|COPD
1178885|NCT01243788|Seretide
1178886|NCT01243788|Combivent
1178887|NCT01243788|effect and safety
1178888|NCT01243788|Twelve weeks
1178889|NCT01243775|NSCLC
1178890|NCT01243762|Colorectal cancer
1178891|NCT01243762|Solid tumors
1178892|NCT01243762|Ovarian cancer
1178893|NCT01243762|Fallopian tube cancer
1178894|NCT01243762|Primary peritoneal cancer
1178895|NCT01243749|Target Vessel Revascularization (TVR)
1178896|NCT01243749|Target Lesion Revascularization (TLR)
1178897|NCT01243749|Myocardial Infarction (MI)
1178898|NCT01243749|Target Vessel Failure (TVF)
1178899|NCT01243749|Target Lesion Failure (TLF)
1178900|NCT01243749|Stent Thrombosis
1178901|NCT01243749|Restenotic Lesion
1178902|NCT01243749|Percutaneous Coronary Intervention (PCI)
1178903|NCT01243749|Real-world
1178904|NCT01243736|anemic
1178905|NCT01243736|bleeding
1178906|NCT01243736|blood in stool
1178907|NCT01243736|abdomen pain
1178908|NCT01243736|Gastrointestinal bleeding
1178909|NCT01243736|capsule endoscopy (CE)
1178910|NCT01243723|Dyschesia treatment
1178911|NCT01243723|Inconfort related to dyschesia
1178912|NCT01243723|Quality of life
1178913|NCT01243723|Bowel function index
1178914|NCT01243697|Desogestrel
1178915|NCT01243697|Chemosensitivity
1178916|NCT01243684|Spinal cord
1178917|NCT01243684|cervical spondylosis
1178918|NCT01243684|myelopathy
1178919|NCT01243671|Behçet's, intestinal
1178920|NCT01243658|Oxytocin
1178921|NCT01243658|BPD
1178922|NCT01243658|Borderline
1178923|NCT01243632|malignant pleural mesothelioma
1178924|NCT01243632|chemotherapy
1178925|NCT01243632|gemcitabine
1178926|NCT01243632|cisplatin
1178927|NCT01243632|long infusion
1178928|NCT01243619|PET
1178929|NCT01243619|CT
1178930|NCT01243619|radiotherapy
1178931|NCT01243606|Anxiety
1178932|NCT01243606|Depression
1178933|NCT01243606|Obsessive Compulsive Disorder
1178934|NCT01243606|Panic Disorder
1178935|NCT01243606|Generalized Anxiety Disorder
1178936|NCT01243606|Social Anxiety Disorder
1178937|NCT01243606|Transdiagnostic Treatment
1178938|NCT01243606|CBT
1178939|NCT01243593|pediatrics
1178940|NCT01243593|anesthesia
1178941|NCT01243593|pyeloplasty
1178942|NCT01243593|Transversus Abdominis Plane Block
1178943|NCT01243593|Regional Anesthesia
1178944|NCT01243580|PK and safety
1178945|NCT01243580|Pharmacokinetic profile (PK) and safety
1178946|NCT01243554|Exercise training
1178947|NCT01243554|Pregnancy
1178948|NCT01243554|Obesity
1178949|NCT01243528|Malnutrition
1178950|NCT01243528|Infection
1178951|NCT01243528|Neurological
1178952|NCT01243515|Central Venous Pressure
1178953|NCT01243515|Kidney Diseases
1178954|NCT01243515|Chronic Kidney Disease
1178955|NCT01243515|Healthy Subjects
1178956|NCT01243515|Non-Invasive Monitor
1178957|NCT01243489|CML
1178958|NCT01243489|compliance
1178959|NCT01243489|compliance supporting measures
1178960|NCT01243489|complete cytogenetic response
1178961|NCT01243489|mayor molecular remission
1178962|NCT01243489|Philadelphia chromosome
1178963|NCT01243489|BCR-ABL
1178964|NCT01243489|Imatinib
1178965|NCT01243489|tyrosine kinase inhibitor
1178966|NCT01243489|smart blister
1178967|NCT01243476|myelodysplastic syndrome
1178968|NCT01243476|5q deletion
1178969|NCT01243476|anemia
1178970|NCT01243476|lenalidomide
1178971|NCT01243476|red blood cells transfusion
1178972|NCT01243437|plague, ciprofloxacin
1178973|NCT01243411|Peyronie's Disease, penile plaque, penile curvature
1178974|NCT01243398|adenocarcinoma of the gastroesophageal junction
1178975|NCT01243398|adenocarcinoma of the esophagus
1178976|NCT01243398|squamous cell carcinoma of the esophagus
1178977|NCT01243398|recurrent esophageal cancer
1178978|NCT01243398|stage IA esophageal cancer
1178979|NCT01243398|stage IB esophageal cancer
1178980|NCT01243398|stage IIA esophageal cancer
1178981|NCT01243398|stage IIB esophageal cancer
1178982|NCT01243398|stage IIIA esophageal cancer
1178983|NCT01243398|stage IIIB esophageal cancer
1178984|NCT01243398|stage IIIC esophageal cancer
1178985|NCT01243398|stage IV esophageal cancer
1178986|NCT01243385|adenocarcinoma of the prostate
1178987|NCT01243385|hormone-resistant prostate cancer
1178988|NCT01243385|stage III prostate cancer
1178989|NCT01243385|stage IV prostate cancer
1178990|NCT01243385|recurrent prostate cancer
1178991|NCT01243372|recurrent colon cancer
1178992|NCT01243372|stage IIIA colon cancer
1178993|NCT01243372|stage IIIB colon cancer
1178994|NCT01243372|stage IIIC colon cancer
1178995|NCT01243372|stage IVA colon cancer
1178996|NCT01243372|stage IVB colon cancer
1178997|NCT01243372|recurrent rectal cancer
1178998|NCT01243372|stage III rectal cancer
1178999|NCT01243372|stage IV rectal cancer
1179000|NCT01243346|Gastrointestinal Stromal Tumor
1179001|NCT01243346|PDGFR Inhibitor
1179002|NCT01243346|Crenolanib (CP-868,596)
1179003|NCT01243333|cancer, imaging
1179004|NCT01243281|hepatitis B
1179005|NCT01243281|HBeAg
1179006|NCT01243281|pegylated interferon
1179007|NCT01243281|entecavir
1179008|NCT01243255|hypercholesterolemia
1179009|NCT01243255|low density lipoprotein
1179010|NCT01243255|undertreatment of hypercholesterolemia
1179011|NCT01243242|ADHD,Adults,MG01CI,METADOXINE
1179012|NCT01243216|Pregnancy
1179013|NCT01243216|Labor
1179014|NCT01243216|Epidural Analgesia
1179015|NCT01243216|Epidural Anesthesia
1179016|NCT01243216|Spinal Anesthesia
1179017|NCT01243216|Ultrasound
1179018|NCT01243216|Neuraxial Analgesia
1179019|NCT01243216|Neuraxial Anesthesia
1179020|NCT01243216|Cesarean delivery
1179021|NCT01243203|Smoking, surgery, Anesthesia, quit
1179022|NCT01243190|leukemia
1179023|NCT01243190|small lymphocytic leukemia
1179024|NCT01243190|SLL
1179025|NCT01243190|CLL
1179026|NCT01243190|ofatumumab
1179027|NCT01243190|untreated
1179028|NCT01243190|early stage
1179029|NCT01243190|high-risk
1179030|NCT01243177|Lacosamide
1179031|NCT01243177|Vimpat®
1179032|NCT01243177|Epilepsy
1179033|NCT01243177|Monotherapy
1179034|NCT01243177|Velocity
1179035|NCT01243164|confidence
1179036|NCT01243164|wheelchair performance
1179037|NCT01243151|Hypercholesterolemia
1179038|NCT01243151|Dyslipidemia
1179039|NCT01243151|LDL
1179040|NCT01243151|High Cholesterol
1179041|NCT01243151|Japanese Volunteers
1179042|NCT01243151|PF-04950615
1179043|NCT01243151|RN316
1179044|NCT01243138|Cross-sectional
1179045|NCT01243138|epidemiological study
1179046|NCT01243138|to evaluate the prevalence of CV risk factors in patients attending general practice in AfME region
1179047|NCT01243125|Blockage
1179048|NCT01243125|Encrustation
1179049|NCT01243125|Catheter
1179050|NCT01243125|Spinal Cord Injury
1179051|NCT01243125|SCI
1179052|NCT01243086|Macular Degeneration
1179053|NCT01243086|Age-related macular degeneration
1179054|NCT01243086|Anti-inflammatory
1179055|NCT01243086|Anti-vascular endothelial growth factor (Anti-VEGF)
1179056|NCT01243086|Lucentis
1179057|NCT01243086|Ranibizumab
1179058|NCT01243086|OZURDEX
1179059|NCT01243086|Dexamethasone
1179060|NCT01243086|Vision loss
1179061|NCT01243073|imetelstat
1179062|NCT01243073|imetelstat sodium
1179063|NCT01243073|GRN163L
1179064|NCT01243073|telomerase inhibitor
1179065|NCT01243073|telomerase
1179066|NCT01243073|essential thrombocytosis
1179067|NCT01243073|essential thrombocythemia
1179068|NCT01243073|ET
1179069|NCT01243073|polycythemia vera
1179070|NCT01243073|PV
1179071|NCT01243060|Sleep Aid
1179072|NCT01243047|Second line treatment for metastatic colorectal cancer
1179073|NCT01243008|Lyme disease
1179074|NCT01243008|Borreliosis
1179075|NCT01243008|Azithromycin
1179076|NCT01242982|5. metacarpal fracture/fractures
1179077|NCT01242982|subcapital
1179078|NCT01242982|shaft
1179079|NCT01242982|closed
1179080|NCT01242956|stroke
1179081|NCT01242956|video-based training
1179082|NCT01242956|rehabilitation
1179083|NCT01242943|I131
1179084|NCT01242943|L19
1179085|NCT01242943|antibody
1179086|NCT01242943|monoclonal
1179087|NCT01242943|tumour targeting
1179088|NCT01242943|radioimmunotherapy
1179089|NCT01242943|cancer
1179090|NCT01242930|imetelstat
1179091|NCT01242930|imetelstat sodium
1179092|NCT01242930|GRN163L
1179093|NCT01242930|telomerase inhibitor
1179094|NCT01242930|telomerase inhibition
1179095|NCT01242930|multiple myeloma
1179096|NCT01242930|myeloma
1179097|NCT01242930|myeloma progenitor cells
1179098|NCT01242904|dialysis solutions
1179099|NCT01242904|renal replacement therapy
1179100|NCT01242904|peritoneal dialysis
1179101|NCT01242904|bimodal solution
1179102|NCT01242904|glucose sparing therapy
1179103|NCT01242891|Ventricular Assist Device
1179104|NCT01242891|Pediatric Ventricular Assist Device
1179105|NCT01242878|HbSS
1179106|NCT01242878|Sickle cell anemia
1179107|NCT01242878|HbSC
1179108|NCT01242878|HbSbetathalassemia
1179109|NCT01242878|Hemoglobinopathy
1179110|NCT01242878|Hemoglobinopathies
1179111|NCT01242865|Stress
1179112|NCT01242865|Anxiety
1179113|NCT01242865|Resilience
1179114|NCT01242865|Mindfulness
1179115|NCT01242865|Quality of Life
1179116|NCT01242865|Stress Management
1179117|NCT01242852|Hysteroscopy
1179118|NCT01242852|infertility
1179119|NCT01242852|subfertility
1179120|NCT01242852|intrauterine abnormalities
1179121|NCT01242852|intracavitary pathology
1179122|NCT01242852|IVF
1179123|NCT01242852|ICSI
1179124|NCT01242852|in vitro fertilization
1179125|NCT01242852|intracytoplasmic sperm injection
1179126|NCT01242839|CACICOL20
1179127|NCT01242813|TNF-receptor associated periodic syndrome
1179128|NCT01242813|fevers
1179129|NCT01242813|rashes
1179130|NCT01242813|musculoskeletal and abdominal pain
1179131|NCT01242813|periorbital edema
1179132|NCT01242813|TNFR1
1179133|NCT01242800|male breast cancer
1179134|NCT01242800|stage IV breast cancer
1179135|NCT01242787|Chronic hepatitis B
1179136|NCT01242787|LB80380
1179137|NCT01242787|treatment-naive
1179138|NCT01242787|entecavir
1179139|NCT01242787|Extension
1179140|NCT01242774|AML
1179141|NCT01242774|bone marrow
1179142|NCT01242774|abnormal blast cells of myeloid
1179143|NCT01242774|acute leukemia
1179144|NCT01242774|cytogenetic abnormalities
1179145|NCT01242774|HDACi
1179146|NCT01242761|Accuracy of diagnostic ultrasound based in community or as part of a specialist hospital-based service
1179147|NCT01242735|Obsessive Compulsive Disorder
1179148|NCT01242735|OCD
1179149|NCT01242735|Exercise
1179150|NCT01242735|Aerobic Exercise
1179151|NCT01242722|Heart failure
1179152|NCT01242722|auto threshold
1179153|NCT01242722|pacing
1179154|NCT01242722|CRT-D recipients
1179155|NCT01242722|Left Ventricular (LV) evoked response signals
1179156|NCT01242696|Drug Eluting Stents
1179157|NCT01242696|Observational
1179158|NCT01242696|All-Comers
1179159|NCT01242657|Tobacco Use Cessation
1179160|NCT01242657|Youth Tobacco Use
1179161|NCT01242657|Physical Activity
1179162|NCT01242657|Smoking Cessation Intervention
1179163|NCT01242618|nasal cartilage diseases
1179164|NCT01242605|unresectable
1179165|NCT01242605|advanced
1179166|NCT01242566|Temozolomide
1179167|NCT01242566|Elderly
1179168|NCT01242566|Glioblastoma
1179169|NCT01242566|Karnofsky performance score (KPS)
1179170|NCT01242540|Pain
1179171|NCT01242540|Functional Magnetic Resonance Imaging
1179172|NCT01242527|dyslipidemia
1179173|NCT01242527|hyperlipidemia
1179174|NCT01242527|omega-3 carboxylic acid
1179175|NCT01242514|Rheumatoid Arthritis
1179176|NCT01242514|OSKIRA
1179177|NCT01242514|Fostamatinib
1179178|NCT01242501|Prevention
1179179|NCT01242501|Counseling
1179180|NCT01242501|Behavioral interventions
1179181|NCT01242501|HIV risk reduction
1179182|NCT01242488|Rheumatoid Arthritis
1179183|NCT01242488|CDP6038
1179184|NCT01242488|Interleukin-6
1179185|NCT01242488|Tocilizumab
1179186|NCT01242475|tuberculosis
1179187|NCT01242475|rdESAT-6
1179188|NCT01242475|CFP-10
1179189|NCT01242475|skin test
1179190|NCT01242475|diagnostic test
1179191|NCT01242462|Conventional mechanical ventilation
1179192|NCT01242462|Mid-frequency ventilation
1179193|NCT01242462|Respiratory Distress Syndrome
1179194|NCT01242462|Preterm Newborn Infant
1179195|NCT01242462|Mean Airway Pressure
1179196|NCT01242462|Mean Arterial Pressure
1179197|NCT01242462|Mean Peak Inspiratory Pressure
1179198|NCT01242449|Breast cancer
1179199|NCT01242449|Metastatic
1179200|NCT01242449|HER2 positive
1179201|NCT01242449|vinorelbine
1179202|NCT01242436|Ovarian Cancer
1179203|NCT01242436|Peritoneal Metastasis
1179204|NCT01242436|Whole body diffusion MRI
1179205|NCT01242436|therapy
1179206|NCT01242423|musculoskeletal shockwave therapy
1179207|NCT01242410|Short cervix
1179208|NCT01242410|Preterm birth
1179209|NCT01242410|Cervical pessary
1179210|NCT01242410|Twins
1179211|NCT01242371|Schizophrenia
1179212|NCT01242371|Schizoaffective
1179213|NCT01242371|Probiotic supplements
1179214|NCT01242371|Gliadin
1179215|NCT01242371|Casein
1179216|NCT01242358|hypoxaemia - capnography - integrated pulmonary index - PEG
1179217|NCT01242345|Hypoxemia
1179218|NCT01242345|Capnography
1179219|NCT01242345|Integrated pulmonary index
1179220|NCT01242345|Sedation
1179221|NCT01242345|Propofol
1179222|NCT01242345|Safety
1179223|NCT01242332|perioperative
1179224|NCT01242332|pregabalin
1179225|NCT01242332|arthroscopic anterior cruciate ligament reconstruction
1179226|NCT01242332|postoperative pain management
1179227|NCT01242319|quality improvement
1179228|NCT01242319|implementation trials
1179229|NCT01242319|cholesterol guidelines
1179230|NCT01242319|patient activation
1179231|NCT01242306|endothelial dysfunction acetylcholine bms ses
1179232|NCT01242280|Acute variceal bleeding
1179233|NCT01242280|Massive bleeding
1179234|NCT01242280|Liver Cirrhosis
1179235|NCT01242280|Esophageal tamponade
1179236|NCT01242280|Esophageal stent
1179237|NCT01242267|multiple myeloma
1179238|NCT01242267|transplant
1179239|NCT01242267|Multiple myeloma patients undergoing transplant
1179240|NCT01242254|KH902
1179241|NCT01242254|age-related macular degeneration
1179242|NCT01242254|choroidal neovascularization
1179243|NCT01242254|intravitreal injection
1179244|NCT01242254|multiple injections
1179245|NCT01242241|Propofol
1179246|NCT01242241|Childhood obesity
1179247|NCT01242241|Pharmacodynamics
1179248|NCT01242228|ASP1941
1179249|NCT01242228|Diabetes mellitus
1179250|NCT01242228|Dipeptidyl peptidase-4 inhibitor
1179251|NCT01242228|DPP-4 inhibitor
1179252|NCT01242228|long-term safety
1179253|NCT01242215|ASP1941
1179254|NCT01242215|Diabetes mellitus
1179255|NCT01242215|sulfonylurea
1179256|NCT01242202|ASP1941
1179257|NCT01242202|Diabetes mellitus
1179258|NCT01242202|alpha glucosidase inhibitor
1179259|NCT01242202|long-term safety
1179260|NCT01242150|Acute Respiratory Failure
1179261|NCT01242150|Continuous Positive Airway Pressure
1179262|NCT01242150|Infants
1179263|NCT01242150|Helmet
1179264|NCT01242111|Mucopolysaccharidosis IV type A
1179265|NCT01242111|MPS IV Type A
1179266|NCT01242111|Mucopolysaccharidosis IVA
1179267|NCT01242111|MPS IVA
1179268|NCT01242111|Morquio A Syndrome
1179269|NCT01242111|Lysosomal Storage Disorder
1179270|NCT01242111|LSD
1179271|NCT01242111|N-acetylgalactosamine-6-sulfatase
1179272|NCT01242111|N-acetylgalactosamine-6-sulfate sulfatase
1179273|NCT01242111|galactose-6-sulfatase
1179274|NCT01242111|GALNS
1179275|NCT01242111|enzyme replacement therapy
1179276|NCT01242111|ERT
1179277|NCT01242098|Asthma
1179278|NCT01242098|Combination therapy
1179279|NCT01242098|Primary care management
1179280|NCT01242098|Switch
1179281|NCT01242098|ICS/LABA
1179282|NCT01242098|Fostair
1179283|NCT01242098|Seretide
1179284|NCT01242085|alignment
1179285|NCT01242072|malignancy
1179286|NCT01242072|etoposide and carboplatin
1179287|NCT01242072|non small cell lung cancer
1179288|NCT01242072|small cell lung cancer
1179289|NCT01242072|testicular cancer
1179290|NCT01242072|thymoma
1179291|NCT01242072|ovarian cancer
1179292|NCT01242072|osteosarcoma
1179293|NCT01242059|Obesity
1179294|NCT01242059|Food intake regulation
1179295|NCT01242059|blood glucose regulation
1179296|NCT01242059|protein
1179297|NCT01242059|fiber
1179298|NCT01242059|pulses
1179299|NCT01242059|yellow peas
1179300|NCT01242046|female sexual arousal
1179301|NCT01242033|red raspberries
1179302|NCT01242033|post-prandial
1179303|NCT01242033|oxidative stress
1179304|NCT01242033|antioxidants
1179305|NCT01242033|polyphenols
1179306|NCT01242033|vitamin C
1179307|NCT01242033|acute dietary intervention
1179308|NCT01242007|Myotonic dystrophy
1179309|NCT01242007|Steinert's disease
1179310|NCT01241981|Breast
1179311|NCT01241981|Cancer
1179312|NCT01241981|Digital
1179313|NCT01241981|Mammography
1179314|NCT01241981|Tomosynthesis
1179315|NCT01241968|Extracorporeal Shockwave Therapy
1179316|NCT01241968|Myocardial Ischemia
1179317|NCT01241968|Refractory Angina
1179318|NCT01241955|CPR
1179319|NCT01241942|Lung Transplant
1179320|NCT01241942|Emphysema
1179321|NCT01241942|Chronic Obstructive Pulmonary Disease (COPD)
1179322|NCT01241942|Cystic Fibrosis
1179323|NCT01241942|Pulmonary Fibrosis
1179324|NCT01241942|Bronchiectasis
1179325|NCT01241942|Sarcoidosis
1179326|NCT01241942|Pulmonary Hypertension
1179327|NCT01241942|Alpha-1 Antitrypsin Deficiency
1179328|NCT01241929|advanced cancer
1179329|NCT01241916|elbow, splint
1179330|NCT01241903|Platelet activation
1179331|NCT01241903|platelet leukocyte aggregates
1179332|NCT01241890|Cystic Fibrosis
1179333|NCT01241890|Children
1179334|NCT01241890|Exhaled Breath Condensate
1179335|NCT01241890|Non-invasive Inflammatory Markers
1179336|NCT01241890|Volatile Organic Compounds
1179337|NCT01241890|Home monitoring
1179338|NCT01241890|Quality of life
1179339|NCT01241838|Heart failure
1179340|NCT01241838|Left ventricular hypertrophy
1179341|NCT01241838|Diastolic dysfunction
1179342|NCT01241825|capsule endoscopy
1179343|NCT01241825|chewing gum
1179344|NCT01241825|small bowel transit time
1179345|NCT01241812|knee
1179346|NCT01241812|osteoarthritis
1179347|NCT01241799|endoscopic ultrasound guided fine needle aspiration (EUS-FNA)
1179348|NCT01241799|pancreatic biopsy
1179349|NCT01241799|randomized
1179350|NCT01241799|single blind
1179351|NCT01241799|fine needle aspiration (FNA) adequacy
1179352|NCT01241799|fine needle aspiration (FNA) accuracy
1179353|NCT01241786|chronic lymphocytic leukemia (CLL)
1179354|NCT01241786|small lymphocytic lymphoma (SLL)
1179355|NCT01241773|TMC435-TiDP16-C123
1179356|NCT01241773|TMC435-C123
1179357|NCT01241773|TMC435
1179358|NCT01241773|HCV
1179359|NCT01241773|Hepatitis C
1179360|NCT01241760|Genotype 1 chronic hepatitis C
1179361|NCT01241760|VX-950-C211
1179362|NCT01241760|VX-950
1179363|NCT01241760|IL28B
1179364|NCT01241760|Telaprevir
1179365|NCT01241760|Hepatitis C
1179366|NCT01241760|BID
1179367|NCT01241760|Q8h
1179368|NCT01241760|SOC
1179369|NCT01241734|Diffuse Large B cell Lymphoma
1179370|NCT01241721|Breast Diseases
1179371|NCT01241721|Breast Neoplasms
1179372|NCT01241721|Neoplasms
1179373|NCT01241695|Oral nutritional supplement, diabetes mellitus type 2, glycaemic control
1179374|NCT01241695|Oral nutritional supplement (Food for special medical purposes)
1179375|NCT01241682|Mesothelioma
1179376|NCT01241682|Dendritic cells
1179377|NCT01241682|Cyclophosphamide
1179378|NCT01241682|Tumor lysate-loaded
1179379|NCT01241682|Immunotherapy
1179380|NCT01241656|Prostate cancer
1179381|NCT01241656|Decision support intervention (DESI)
1179382|NCT01241656|Shared medical appointments (SMA)
1179383|NCT01241656|Comparative effectiveness research (CER)
1179384|NCT01241643|interleukin-7
1179385|NCT01241643|immune-based therapies
1179386|NCT01241643|HIV
1179387|NCT01241643|infectious disease
1179388|NCT01241643|immune non-responders
1179389|NCT01241630|Somato-sensory reflex arch
1179390|NCT01241630|Spinal cord injury
1179391|NCT01241630|Xiao Procedure
1179392|NCT01241617|Lung disease
1179393|NCT01241617|Lobectomy
1179394|NCT01241617|Pulmonary resection
1179395|NCT01241591|CP-690,550
1179396|NCT01241591|Etanercept
1179397|NCT01241591|Moderate
1179398|NCT01241591|Severe
1179399|NCT01241591|Chronic
1179400|NCT01241591|Plaque
1179401|NCT01241591|Psoriasis
1179402|NCT01241591|Efficacy
1179403|NCT01241591|Safety
1179404|NCT01241591|Tofacitinib
1179405|NCT01241591|Xeljanz
1179406|NCT01241591|OPT Compare
1179407|NCT01241591|OPT
1179408|NCT01241591|head-to-head
1179409|NCT01241591|non-inferiority
1179410|NCT01241591|Psoriasis vulgaris
1179411|NCT01241591|short-term
1179412|NCT01241591|Itch
1179413|NCT01241591|Pruritus
1179414|NCT01241591|Plaque psoriasis
1179415|NCT01241591|DLQI
1179416|NCT01241578|Obesity
1179417|NCT01241578|Behavior Therapy
1179418|NCT01241578|Lifestyle
1179419|NCT01241578|Technology
1179420|NCT01241578|Cellular Phone
1179421|NCT01241565|lung cancer
1179422|NCT01241565|lobectomy
1179423|NCT01241565|wedge resection
1179424|NCT01241552|Clostridium difficile
1179425|NCT01241552|recurrent Clostridium difficile
1179426|NCT01241552|vancomycin
1179427|NCT01241552|metronidazole
1179428|NCT01241552|monoclonal antibody
1179429|NCT01241552|Clostridium difficile infection (CDI)
1179430|NCT01241526|COPD
1179431|NCT01241526|COMET
1179432|NCT01241526|Disease management
1179433|NCT01241513|glutathione
1179434|NCT01241513|redox status
1179435|NCT01241513|carotid body chemosensitivity
1179436|NCT01241513|ventilation
1179437|NCT01241500|Myelodysplastic syndromes
1179438|NCT01241500|MDS
1179439|NCT01241487|Hypertension, Valsartan/Amlodipine,
1179440|NCT01241461|Advanced Cancer
1179441|NCT01241461|Metastatic Cancer
1179442|NCT01241461|p70s6 inhibitor
1179443|NCT01241448|Type 2 Diabetes Mellitus
1179444|NCT01241422|Asthma
1179445|NCT01241422|Mild asthma
1179446|NCT01241422|Singulair
1179447|NCT01241422|JNJ 40929837
1179448|NCT01241422|Montelukast
1179449|NCT01241409|Healthy
1179450|NCT01241409|Sprinkle Capsule Formulation
1179451|NCT01241409|Rabeprazole sodium
1179452|NCT01241409|Pharmacokinetics
1179453|NCT01241409|Bioequivalence
1179454|NCT01241409|Safety
1179455|NCT01241396|Multiple Myeloma
1179456|NCT01241396|observational
1179457|NCT01241396|survey
1179458|NCT01241396|non-interventional
1179459|NCT01241396|international
1179460|NCT01241396|epidemiology
1179461|NCT01241396|treatment
1179462|NCT01241396|routine clinical practice
1179463|NCT01241396|retrospective
1179464|NCT01241396|prospective
1179465|NCT01241383|Scleroderma renal crisis
1179466|NCT01241383|angiotensin converting enzyme inhibitors
1179467|NCT01241383|bosentan
1179468|NCT01241383|endothelin receptor antagonist
1179469|NCT01241370|Retinal endothelia dysfunction
1179470|NCT01241370|Type 2 diabetes mellitus
1179471|NCT01241370|Insulin-resistance
1179472|NCT01241370|micro-lightguide spectrophotometry
1179473|NCT01241370|laserdopplerfluxmetry
1179474|NCT01241357|Iron
1179475|NCT01241357|Iron overload
1179476|NCT01241357|Hepatic iron concentration
1179477|NCT01241357|High-temperature superconductivity
1179478|NCT01241357|Magnetic susceptibility
1179479|NCT01241357|Susceptometer
1179480|NCT01241344|Adv
1179481|NCT01241344|Hematopoeitic Stem cell Transplant
1179482|NCT01241344|HSCT
1179483|NCT01241331|moderate to severe facial acne vulgaris
1179484|NCT01241318|neonate
1179485|NCT01241318|omphalitis
1179486|NCT01241318|neonatal mortality
1179487|NCT01241318|maternal health
1179488|NCT01241318|umbilical cord infection
1179489|NCT01241305|Vasculitis
1179490|NCT01241305|CSS
1179491|NCT01241305|EGPA
1179492|NCT01241305|GCA
1179493|NCT01241305|GPA
1179494|NCT01241305|WG
1179495|NCT01241305|MPA
1179496|NCT01241305|PAN
1179497|NCT01241305|TAK
1179498|NCT01241279|cataract surgery
1179499|NCT01241279|intraocular lens
1179500|NCT01241266|Peptic Ulcer Bleeding
1179501|NCT01241266|high risk
1179502|NCT01241266|None-Interventional Study
1179503|NCT01241266|he proportion of peptic ulcer bleeding patients who are at high risk (Forrest Ia-IIb)
1179504|NCT01241253|legumes
1179505|NCT01241253|glycemic response
1179506|NCT01241253|glucose
1179507|NCT01241253|type 2 diabetes mellitus
1179508|NCT01241227|liver fibrosis
1179509|NCT01241227|survival
1179510|NCT01241227|transient elastography
1179511|NCT01241214|Seasonal allergic rhinitis
1179512|NCT01241214|SAR
1179513|NCT01241214|Allergic rhinitis
1179514|NCT01241214|Allergies
1179515|NCT01241201|intestinal health
1179516|NCT01241201|probiotics
1179517|NCT01241201|inflammation
1179518|NCT01241201|biomarkers
1179519|NCT01241188|tuberculosis
1179520|NCT01241188|rdESAT-6
1179521|NCT01241188|CFP-10
1179522|NCT01241188|skin test
1179523|NCT01241188|diagnostic test
1179524|NCT01241175|IOP
1179525|NCT01241175|ophthalmic anesthesia
1179526|NCT01241175|magnesium sulfate
1179527|NCT01241162|Neuroblastoma
1179528|NCT01241162|Ewings sarcoma
1179529|NCT01241162|osteogenic sarcoma
1179530|NCT01241162|rhabdomyosarcoma
1179531|NCT01241162|synovial sarcoma
1179532|NCT01241162|high-risk
1179533|NCT01241162|relapsed
1179534|NCT01241162|children
1179535|NCT01241149|Nissen fundoplication
1179536|NCT01241149|non-acid reflux disease
1179537|NCT01241149|anti-reflux surgery
1179538|NCT01241136|pilonidal disease, cystectomy, recurrence
1179539|NCT01241123|return of bowel function, post-operative, colon surgery
1179540|NCT01241110|PID, Ofloxacin, Azitromicine, Metronidazole
1179541|NCT01241097|endothelial function
1179542|NCT01241097|statins
1179543|NCT01241097|ezetimibe
1179544|NCT01241097|pleiotropism
1179545|NCT01241084|asthmatic children
1179546|NCT01241071|Lumbar region
1179547|NCT01241071|Pain
1179548|NCT01241071|Fascia
1179549|NCT01241071|Electromyography
1179550|NCT01241071|Goniometry
1179551|NCT01241058|pediatrics, crohn's disease, disease course, therapy
1179552|NCT01241032|DA-8159
1179553|NCT01241032|Udenafil
1179554|NCT01241032|Alcohol
1179555|NCT01241019|asphyxia neonatorum, hypothermia, neuroprotection
1179556|NCT01241006|Relapse
1179557|NCT01241006|Corticosteroids
1179558|NCT01240993|parenting intervention
1179559|NCT01240993|mother-child relations
1179560|NCT01240993|substance abuse
1179561|NCT01240993|attachment
1179562|NCT01240993|child development
1179563|NCT01240967|Phase 1
1179564|NCT01240967|healthy volunteers
1179565|NCT01240967|volunteers with renal impairment
1179566|NCT01240967|pharmacokinetics
1179567|NCT01240967|TC-5214
1179568|NCT01240954|Rhinitis
1179569|NCT01240954|Allergic
1179570|NCT01240954|Immunotherapy
1179571|NCT01240915|safety efficacy MultiStem(r) moderate to severe Ulcerative Colitis
1179572|NCT01240902|Valvular Heart Disease
1179573|NCT01240902|Critical Aortic Stenosis
1179574|NCT01240902|Severe Aortic Stenosis
1179575|NCT01240902|High Risk
1179576|NCT01240902|Aortic Valve Replacement
1179577|NCT01240889|Ragweed allergies
1179578|NCT01240889|acoustic rhinometry
1179579|NCT01240889|nasal allergen challenge
1179580|NCT01240876|Sciatica
1179581|NCT01240876|Pain
1179582|NCT01240863|osteoarthritis
1179583|NCT01240863|low back pain
1179584|NCT01240863|Moderate to Severe Pain
1179585|NCT01240850|Retroperitoneal fibrosis
1179586|NCT01240850|Inflammatory aneurysms
1179587|NCT01240850|Methotrexate
1179588|NCT01240850|Prednisone
1179589|NCT01240850|Aorta
1179590|NCT01240837|glycaemic index
1179591|NCT01240837|arenga pinnata sugar
1179592|NCT01240837|palm sugar
1179593|NCT01240837|diabetes
1179594|NCT01240824|bladder cancer
1179595|NCT01240824|urothelial carcinoma
1179596|NCT01240824|transitional cell carcinoma bladder
1179597|NCT01240824|ureter
1179598|NCT01240811|intrauterine device
1179599|NCT01240811|IUD
1179600|NCT01240811|levonorgestrel
1179601|NCT01240811|copper
1179602|NCT01240811|CD4
1179603|NCT01240811|CCR5
1179604|NCT01240811|microflora
1179605|NCT01240798|Depression
1179606|NCT01240798|Anxiety
1179607|NCT01240798|Coronary disease
1179608|NCT01240785|gestational diabetes
1179609|NCT01240785|metformin
1179610|NCT01240785|insulin
1179611|NCT01240772|Haemorrhoids, Surgery, Cost-effectiveness, Morbidity, Risk assessment,RCT, Stapled haemorrhoidopexy, Doppler-guided, Haemorrhoidal artery ligation, Outcome
1179612|NCT01240759|Type 2 Diabetes Mellitus
1179613|NCT01240759|Metformin
1179614|NCT01240746|Influenza
1179615|NCT01240746|Quadrivalent Influenza Vaccine
1179616|NCT01240746|Trivalent Influenza Vaccine
1179617|NCT01240746|Influenza viruses
1179618|NCT01240746|Fluzone®
1179619|NCT01240720|I131
1179620|NCT01240720|F16
1179621|NCT01240720|antibody
1179622|NCT01240720|monoclonal
1179623|NCT01240720|tumor targeting
1179624|NCT01240720|radioimmunotherapy
1179625|NCT01240720|lymphoma, breast and lung cancer
1179626|NCT01240720|Patients with different cancer types
1179627|NCT01240694|Lupus
1179628|NCT01240694|SLE
1179629|NCT01240681|Locally Advanced Breast Cancer (LABC)
1179630|NCT01240681|neoadjuvant chemotherapy
1179631|NCT01240681|Fluorothymidine Positron Emission Tomography (FLT PET)
1179632|NCT01240681|Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI)
1179633|NCT01240681|tumor response
1179634|NCT01240681|mastectomy
1179635|NCT01240668|Hyponatremia
1179636|NCT01240668|Euvolemia
1179637|NCT01240668|Hypervolemia
1179638|NCT01240668|Euvolemic
1179639|NCT01240668|Hypervolemic
1179640|NCT01240655|LCL161
1179641|NCT01240655|solid tumors
1179642|NCT01240655|paclitaxel
1179643|NCT01240642|Advanced or metastatic cancer
1179644|NCT01240642|refractory
1179645|NCT01240642|core phase
1179646|NCT01240642|extension phase
1179647|NCT01240642|dose escalation
1179648|NCT01240642|standard chemotherapy
1179649|NCT01240642|doctaxel
1179650|NCT01240642|paclitaxel
1179651|NCT01240642|carboplatin
1179652|NCT01240642|safety
1179653|NCT01240642|tolerability
1179654|NCT01240616|Nicotine
1179655|NCT01240616|Mecamylamine
1179656|NCT01240616|Attention
1179657|NCT01240616|fMRI
1179658|NCT01240616|Default Network
1179659|NCT01240616|Healthy Volunteer
1179660|NCT01240616|HV
1179661|NCT01240603|Artemisinin
1179662|NCT01240603|Malaria
1179663|NCT01240603|Drug Resistance
1179664|NCT01240603|Hemoglobin E
1179665|NCT01240590|Anaplastic Thyroid Cancer
1179666|NCT01240590|Crolibulin
1179667|NCT01240590|Solid Tumors
1179668|NCT01240590|ATC
1179669|NCT01240577|IPdR
1179670|NCT01240577|Pharmacokinetics
1179671|NCT01240577|Early Phase I
1179672|NCT01240577|Cancer
1179673|NCT01240577|Solid Tumor
1179674|NCT01240577|Lymphoma
1179675|NCT01240551|Imaging
1179676|NCT01240551|Bone Metastasis
1179677|NCT01240551|Bone Scan
1179678|NCT01240551|Radiopharmaceutical
1179679|NCT01240551|Pet Scan
1179680|NCT01240551|Prostate Cancer
1179681|NCT01240525|graft versus host disease
1179682|NCT01240525|recurrent grade 1 follicular lymphoma
1179683|NCT01240525|recurrent grade 2 follicular lymphoma
1179684|NCT01240525|recurrent small lymphocytic lymphoma
1179685|NCT01240525|stage III small lymphocytic lymphoma
1179686|NCT01240525|stage IV small lymphocytic lymphoma
1179687|NCT01240525|Waldenstrom macroglobulinemia
1179688|NCT01240525|stage III grade 1 follicular lymphoma
1179689|NCT01240525|stage III grade 2 follicular lymphoma
1179690|NCT01240525|stage IV grade 1 follicular lymphoma
1179691|NCT01240525|stage IV grade 2 follicular lymphoma
1179692|NCT01240525|stage III chronic lymphocytic leukemia
1179693|NCT01240525|stage IV chronic lymphocytic leukemia
1179694|NCT01240525|refractory chronic lymphocytic leukemia
1179695|NCT01240525|Non-Hodgkin's lymphoma
1179696|NCT01240525|Hodgkin's lymphoma
1179697|NCT01240525|Chronic (Pro-)lymphocytic leukaemia
1179698|NCT01240525|Plasma cell myeloma
1179699|NCT01240525|Acute myeloid leukaemia
1179700|NCT01240525|Acute lymphoblastic leukaemia
1179701|NCT01240525|Myelodysplastic syndrome
1179702|NCT01240525|Chronic myelomonocytic leukaemia
1179703|NCT01240499|Weight management
1179704|NCT01240499|New weight paradigm
1179705|NCT01240499|Overweight women
1179706|NCT01240499|Eating behaviors
1179707|NCT01240499|Appetite ratings
1179708|NCT01240499|Blood lipids
1179709|NCT01240486|IRIS
1179710|NCT01240486|HIV
1179711|NCT01240486|Immune
1179712|NCT01240486|Reconstitution
1179713|NCT01240486|Inflammatory
1179714|NCT01240486|Syndrome
1179715|NCT01240473|kala azar
1179716|NCT01240473|visceral leishmaniasis
1179717|NCT01240473|diagnosis
1179718|NCT01240473|drug resistance
1179719|NCT01240473|Therapeutics
1179720|NCT01240473|Capacity Building
1179721|NCT01240447|NSCLC
1179722|NCT01240447|lung cancer, small-cell
1179723|NCT01240447|advanced lung cancer
1179724|NCT01240434|trocar hernia closure laparoscopy
1179725|NCT01240421|Metastatic breast cancer with no other treatment options
1179726|NCT01240395|Multiple chemical sensitivities
1179727|NCT01240395|MCS
1179728|NCT01240395|Mindfulness-based cognitive therapy
1179729|NCT01240395|MBCT
1179730|NCT01240369|VEGFC
1179731|NCT01240369|CTTN
1179732|NCT01240369|miR326
1179733|NCT01240369|ESCC
1179734|NCT01240369|NSCLC
1179735|NCT01240356|transcranial doppler
1179736|NCT01240356|sonothrombolysis
1179737|NCT01240356|ultrasound
1179738|NCT01240356|stroke
1179739|NCT01240343|Biobank
1179740|NCT01240343|Genetics
1179741|NCT01240330|Deep Vein Thrombosis
1179742|NCT01240330|Effects of compression therapy
1179743|NCT01240330|Peak Flow Velocity
1179744|NCT01240317|expert system
1179745|NCT01240317|decision support system
1179746|NCT01240317|human patient simulator
1179747|NCT01240317|anesthesia
1179748|NCT01240291|glutamine
1179749|NCT01240291|trauma
1179750|NCT01240291|alanyl-glutamine
1179751|NCT01240265|Vitamin D deficiency
1179752|NCT01240265|Rickets
1179753|NCT01240265|Infant
1179754|NCT01240265|Nutrition
1179755|NCT01240252|diabetes
1179756|NCT01240252|insulin resistance
1179757|NCT01240239|Pre anesthesia consultation
1179758|NCT01240239|telemedicine
1179759|NCT01240213|Vitamin D
1179760|NCT01240213|lifestyle intervention
1179761|NCT01240213|postmenopausal women
1179762|NCT01240200|diabetes
1179763|NCT01240200|elderly
1179764|NCT01240200|insulin injections
1179765|NCT01240187|epilepsy
1179766|NCT01240174|Antibiotic
1179767|NCT01240174|Antimicrobial
1179768|NCT01240174|Prescribing
1179769|NCT01240174|Cough
1179770|NCT01240174|Acute Bronchitis
1179771|NCT01240161|Glioblastoma multiforme
1179772|NCT01240161|FLT
1179773|NCT01240161|PET
1179774|NCT01240148|Allodynia
1179775|NCT01240148|hyperalgesia
1179776|NCT01240148|paresthesia
1179777|NCT01240135|Contact Lens Wear
1179778|NCT01240135|Contact Lens Solution
1179779|NCT01240135|Multi-purpose disinfecting solution
1179780|NCT01240135|Myopia
1179781|NCT01240122|Corneal staining and comfort evaluation in normal, habitual contact lens wearers.
1179782|NCT01240096|Functional dyspepsia
1179783|NCT01240096|Weight loss
1179784|NCT01240096|Mirtazapine
1179785|NCT01240083|Depression
1179786|NCT01240083|Transcranial magnetic stimulation
1179787|NCT01240083|Thetaburst Stimulation
1179788|NCT01240083|Alternative treatment methods
1179789|NCT01240070|diabetes,
1179790|NCT01240070|cardiovascular
1179791|NCT01240070|risk factor
1179792|NCT01240070|cardiovascular event
1179793|NCT01240070|intervention
1179794|NCT01240057|Isolated Congenital Diaphragmatic Hernia
1179795|NCT01240057|Fetal Surgery
1179796|NCT01240057|Pulmonary Hypoplasia
1179797|NCT01240044|Newborn Pain
1179798|NCT01240044|Respiratory Physiotherapy
1179799|NCT01240044|Neonatal intensive care unit
1179800|NCT01240031|Malnutrition
1179801|NCT01240031|Nutritional Risk
1179802|NCT01240031|Intake
1179803|NCT01240031|Food sensory
1179804|NCT01240031|Nutritional therapy
1179805|NCT01240031|Energy
1179806|NCT01240031|Protein
1179807|NCT01240031|Handgrip strength
1179808|NCT01240031|Reaction time
1179809|NCT01240031|Quality of Life
1179810|NCT01239979|coronary artery disease
1179811|NCT01239966|Acute Respiratory Distress syndrome
1179812|NCT01239966|Acute renal Failure
1179813|NCT01239953|In-stent restenosis
1179814|NCT01239953|Drug-eluting balloon
1179815|NCT01239953|Drug-eluting stent
1179816|NCT01239953|Angiography
1179817|NCT01239953|Minimal lumen diameter
1179818|NCT01239940|In-stent restenosis
1179819|NCT01239940|Drug-eluting balloon
1179820|NCT01239940|Drug-eluting stent
1179821|NCT01239940|Angiography
1179822|NCT01239940|Minimal lumen diameter
1179823|NCT01239927|diverticulitis
1179824|NCT01239927|hartmann
1179825|NCT01239927|anastomosis
1179826|NCT01239914|drug eluting stent
1179827|NCT01239914|coronary artery disease
1179828|NCT01239914|Korean registry
1179829|NCT01239901|sickle cell disease
1179830|NCT01239901|sickle cell anemia
1179831|NCT01239901|sickled cells
1179832|NCT01239901|blood vessel
1179833|NCT01239901|iron overload
1179834|NCT01239888|Depression
1179835|NCT01239888|Treatment resistant depression
1179836|NCT01239888|Oxytocin
1179837|NCT01239888|Estrogen Modulators
1179838|NCT01239888|HPA axis
1179839|NCT01239888|Mental Disorders
1179840|NCT01239888|Estrogens
1179841|NCT01239888|Tibolone
1179842|NCT01239888|Estrogen Receptor Modulators
1179843|NCT01239888|Androgens
1179844|NCT01239888|Hormones
1179845|NCT01239888|Hormone Substitutes
1179846|NCT01239888|Physiological Effects of Drugs
1179847|NCT01239888|Pharmacologic Actions
1179848|NCT01239888|Hormone Antagonists
1179849|NCT01239888|Bone Density Conservation Agents
1179850|NCT01239888|Estrogen Antagonists
1179851|NCT01239862|pulmonary, silicosis, chronic and accelerated silicosis, autologous transplantation
1179852|NCT01239862|bone marrow cells, stem cells, cell therapy
1179853|NCT01239849|Diabetes Mellitus, Hypercholesterolemia
1179854|NCT01239836|urinary incontinence, self-management, cost, self-efficacy, continence promotion
1179855|NCT01239823|osteoarthritis
1179856|NCT01239823|whole body vibration
1179857|NCT01239823|mobility
1179858|NCT01239823|rehabilitation
1179859|NCT01239810|hyaluronic acid
1179860|NCT01239810|cartilage
1179861|NCT01239810|T2 mapping
1179862|NCT01239810|quantitative
1179863|NCT01239810|MRI
1179864|NCT01239810|volume
1179865|NCT01239784|pediatrics
1179866|NCT01239784|Heart Defects
1179867|NCT01239784|Neurodevelopmental deficit
1179868|NCT01239784|Neurodevelopmental Rehabilitation
1179869|NCT01239771|Safety
1179870|NCT01239771|tolerability
1179871|NCT01239771|healthy
1179872|NCT01239771|stable disease
1179873|NCT01239771|oral
1179874|NCT01239771|tablet
1179875|NCT01239745|Hormone adjuvant treatment of early breast cancer with aromatase inhibitors following 2-3 years of tamoxifen
1179876|NCT01239719|Allergic dermatitis
1179877|NCT01239693|Stunting
1179878|NCT01239693|Growth failure
1179879|NCT01239693|Malnutrition
1179880|NCT01239693|Lipid based nutrient supplement
1179881|NCT01239693|LNS
1179882|NCT01239693|Prevention
1179883|NCT01239693|Malawi
1179884|NCT01239693|Sub-Saharan Africa
1179885|NCT01239693|Dietary supplementation
1179886|NCT01239693|Efficacy
1179887|NCT01239693|Pregnancy
1179888|NCT01239693|Infancy
1179889|NCT01239693|Newborn
1179890|NCT01239680|hemorrhagic shock
1179891|NCT01239680|glutamine
1179892|NCT01239680|trauma resuscitation
1179893|NCT01239680|department of defense
1179894|NCT01239680|trauma
1179895|NCT01239667|Health related quality of Life, Self Care behavior, activities of daily living
1179896|NCT01239654|acute
1179897|NCT01239654|coronary
1179898|NCT01239654|syndrome
1179899|NCT01239654|everolimus
1179900|NCT01239654|zotarolimus
1179901|NCT01239654|optical
1179902|NCT01239654|coherence
1179903|NCT01239654|tomography
1179904|NCT01239641|Uterine Fibroids
1179905|NCT01239641|Myoectomy
1179906|NCT01239641|High Intensity Focused Ultrasound
1179907|NCT01239641|ablation
1179908|NCT01239602|changes in cortical excitability in subjects with chronic stroke after stem cell therapy
1179909|NCT01239589|Patients admitted as for an acute bipolar manic episode
1179910|NCT01239589|Description of management patterns and hospital stay in patients admitted for acute bipolar manic episode and treated with either quetiapine IR or quetiapine XR
1179911|NCT01239563|kidney transplantation
1179912|NCT01239563|donation after cardiac death
1179913|NCT01239563|ischemia-reperfusion injury
1179914|NCT01239563|thymoglobulin
1179915|NCT01239563|steroid avoidance
1179916|NCT01239563|lymphocyte
1179917|NCT01239550|Insulin
1179918|NCT01239550|Detemir
1180044|NCT01238796|VIBATIV®
1179919|NCT01239550|Dopamine, brain,neurotransmitter
1179920|NCT01239550|Diabetes
1179921|NCT01239550|Obesity
1179922|NCT01239550|Neurotransmitters
1179923|NCT01239524|breast reconstruction, latissimus dorsi flap, thoracodorsal nerve, skeletal muscle disuse, breast MRI
1179924|NCT01239485|Pediatric refractory or relapsed acute leukemia
1179925|NCT01239472|chronic allograft nephropathy
1179926|NCT01239472|cytokines
1179927|NCT01239472|kidney transplant
1179928|NCT01239472|calcineurin inhibitors withdrawn
1179929|NCT01239446|Hodgkin lymphoma
1179930|NCT01239446|mediastinal irradiation
1179931|NCT01239446|Coronary Artery Disease
1179932|NCT01239394|NHL
1179933|NCT01239394|ofatumumab
1179934|NCT01239381|proton radiation
1179935|NCT01239381|stereotactic body radiotherapy
1179936|NCT01239381|SBRT
1179937|NCT01239368|Multiple Myeloma
1179938|NCT01239368|High Risk
1179939|NCT01239368|Newly Diagnosed
1179940|NCT01239368|Adoptive Immunotherapy
1179941|NCT01239368|Autologous
1179942|NCT01239329|Complex multiple disabilities
1179943|NCT01239329|Malnutrition
1179944|NCT01239277|muscle
1179945|NCT01239277|FSR
1179946|NCT01239277|protein
1179947|NCT01239277|carbohydrate
1179948|NCT01239277|leucine
1179949|NCT01239251|GlowCap
1179950|NCT01239251|adjuvant endocrine therapy
1179951|NCT01239238|asthma
1179952|NCT01239238|children
1179953|NCT01239238|home monitoring
1179954|NCT01239238|exhaled breath condensate
1179955|NCT01239238|non-invasive inflammatory markers
1179956|NCT01239238|volatile organic compounds
1179957|NCT01239225|Patients undergoing coronary angiography
1179958|NCT01239212|seizures
1179959|NCT01239212|neonate
1179960|NCT01239212|levetiracetam
1179961|NCT01239212|Epilepsy
1179962|NCT01239212|central nervous system diseases
1179963|NCT01239212|anticonvulsants
1179964|NCT01239199|Infants
1179965|NCT01239199|Exhaled Nitric Oxide
1179966|NCT01239199|Asthma
1179967|NCT01239199|Tobacco smoke exposure
1179968|NCT01239199|environment
1179969|NCT01239186|methylation
1179970|NCT01239186|micro array
1179971|NCT01239186|locus H19
1179972|NCT01239186|male infertility
1179973|NCT01239173|Posttraumatic stress disorder
1179974|NCT01239173|functional Magnetic Resonance Imaging
1179975|NCT01239173|Amygdala
1179976|NCT01239173|emotion regulation
1179977|NCT01239173|memory
1179978|NCT01239160|lymphedema
1179979|NCT01239160|pneumatic compression device
1179980|NCT01239160|randomised clinical trial
1179981|NCT01239160|volume reduction
1179982|NCT01239147|weight maintenance
1179983|NCT01239134|Malignant melanoma
1179984|NCT01239134|Metastatic
1179985|NCT01239134|Unresectable
1179986|NCT01239134|Stage III or Stage IV
1179987|NCT01239134|Solid tumor
1179988|NCT01239121|drug toxicity
1179989|NCT01239121|drug interactions
1179990|NCT01239121|electronic health records
1179991|NCT01239121|medical errors
1179992|NCT01239043|Meningitis
1179993|NCT01239043|Meningococcal Meningitis
1179994|NCT01239043|Meningococcal Infections
1179995|NCT01239043|Menactra®
1179996|NCT01239043|Menomune®
1179997|NCT01239043|Meningococcal vaccine
1179998|NCT01239030|inattention
1179999|NCT01239030|impulsivity
1180000|NCT01239030|hyperactivity
1180001|NCT01239030|ADHD
1180002|NCT01239004|dyslipidemia
1180003|NCT01239004|hyperlipidemia
1180004|NCT01239004|hyperglycemia
1180005|NCT01239004|impaired fasting glucose
1180006|NCT01238978|Diabetes mellitus, vildagliptin, hypoglycemia, elderly
1180007|NCT01238952|solid tumors
1180008|NCT01238952|breast cancer
1180009|NCT01238952|triple negative breast cancer
1180010|NCT01238952|HER2 negative
1180011|NCT01238952|ER negative
1180012|NCT01238952|PR negative
1180013|NCT01238939|solid tumors
1180014|NCT01238939|colorectal cancer
1180015|NCT01238926|Oxidative stress
1180016|NCT01238926|Parkinson's disease
1180017|NCT01238926|Homocysteine
1180018|NCT01238926|Glutathione
1180019|NCT01238926|B vitamins
1180020|NCT01238887|Satiety
1180021|NCT01238887|Food Intake
1180022|NCT01238887|Weight Loss
1180023|NCT01238887|Oxidative Stress
1180024|NCT01238887|botanicals
1180025|NCT01238887|Garcinia Cambogia-derived hydroxycitric acid
1180026|NCT01238861|Asthma
1180027|NCT01238861|Benralizumab
1180028|NCT01238861|MEDI-563
1180029|NCT01238848|Hypertonic
1180030|NCT01238848|Saline
1180031|NCT01238848|Bronchiolitis
1180032|NCT01238848|Efficacy
1180033|NCT01238835|Sapien XT Valve
1180034|NCT01238835|Valvular Heart Disease
1180035|NCT01238835|Aortic Stenosis
1180036|NCT01238835|Heart Valve Therapy
1180037|NCT01238835|Transapical
1180038|NCT01238835|Transcatheter
1180039|NCT01238809|Compliance
1180040|NCT01238809|France
1180041|NCT01238796|telavancin
1180042|NCT01238796|Pharmacokinetics
1180043|NCT01238796|Severe renal disease
1180045|NCT01238796|ASP9809
1180046|NCT01238770|Ovarian cancer
1180047|NCT01238757|Prospective Studies
1180048|NCT01238757|Humans, pediatric
1180049|NCT01238757|Positive-Pressure Respiration/methods*
1180050|NCT01238757|Respiration, Artificial/methods*
1180051|NCT01238757|Intensive Care
1180052|NCT01238757|Intensive Care Units/statistics & numerical data*
1180053|NCT01238757|Respiration, Artificial/statistics & numerical data*
1180054|NCT01238757|Patients/statistics & numerical data*
1180055|NCT01238757|Prevalence
1180056|NCT01238757|Respiratory Muscles/innervation
1180057|NCT01238757|Child
1180058|NCT01238757|Child, Preschool
1180059|NCT01238757|Infant
1180060|NCT01238757|Infant, Newborn
1180061|NCT01238757|Intensive Care Units, Pediatric
1180062|NCT01238757|Respiratory Rate*
1180063|NCT01238731|Valve replacement
1180064|NCT01238731|pulmonary hypertension
1180065|NCT01238731|long term follow up
1180066|NCT01238718|lidocaine
1180067|NCT01238718|anesthetic depth
1180068|NCT01238718|hemodynamics
1180069|NCT01238718|rapid sequence induction
1180070|NCT01238718|BIS
1180071|NCT01238705|Hypertension
1180072|NCT01238705|Antihypertensive Agents
1180073|NCT01238705|Combination
1180074|NCT01238705|Sexual Dysfunction
1180075|NCT01238705|Oxidative Stress
1180076|NCT01238692|Diffuse large B cell lymphoma
1180077|NCT01238692|DLBCL
1180078|NCT01238692|Relapsed B-cell lymphoma
1180079|NCT01238692|Refractory B-cell lymphoma
1180080|NCT01238692|B-cell Lymphoma
1180081|NCT01238692|Panobinostat
1180082|NCT01238692|LBH589
1180083|NCT01238692|Rituximab
1180084|NCT01238692|Histone Deacetylase Inhibitors
1180085|NCT01238679|safety
1180086|NCT01238679|tolerability
1180087|NCT01238679|pharmacokinetics
1180088|NCT01238679|healthy volunteers
1180089|NCT01238666|liver
1180090|NCT01238666|cancer
1180091|NCT01238666|tumor
1180092|NCT01238666|ablation
1180093|NCT01238666|Pathfinder
1180094|NCT01238653|liver
1180095|NCT01238653|cancer
1180096|NCT01238653|tumor
1180097|NCT01238653|Pathfinder
1180098|NCT01238640|Smoking Cessation
1180099|NCT01238640|Nicotine
1180100|NCT01238627|Smoking Cessation
1180101|NCT01238627|Nicotine pharmacokinetics
1180102|NCT01238614|maternal depression
1180103|NCT01238614|clinical decision support
1180104|NCT01238601|Breast augmentation
1180105|NCT01238575|Pervasive Developmental Disorders
1180106|NCT01238575|PDD
1180107|NCT01238575|PDD-NOS
1180108|NCT01238575|Autistic Disorder
1180109|NCT01238575|Autism
1180110|NCT01238575|Asperger's Disorder
1180111|NCT01238575|Hyperactivity
1180112|NCT01238575|Attention Deficit Hyperactivity Disorder
1180113|NCT01238575|ADHD
1180114|NCT01238575|Medication
1180115|NCT01238575|Drug
1180116|NCT01238575|Guanfacine
1180117|NCT01238575|Intuniv
1180118|NCT01238575|Placebo
1180119|NCT01238575|Methylphenidate
1180120|NCT01238562|cancer patient
1180121|NCT01238562|chemotherapy
1180122|NCT01238562|carboplatin
1180123|NCT01238562|taxol
1180124|NCT01238562|cyclophosphamide
1180125|NCT01238562|pharmorubicin
1180126|NCT01238549|Spinal Cord Injuries
1180127|NCT01238549|Quality of Life
1180128|NCT01238536|Epidural Steroid Injection
1180129|NCT01238536|Low Back Pain
1180130|NCT01238536|Spinal Stenosis
1180131|NCT01238536|Elderly
1180132|NCT01238523|tibia
1180133|NCT01238523|shaft
1180134|NCT01238523|fracture
1180135|NCT01238523|children
1180136|NCT01238497|SAPIEN XT™
1180137|NCT01238497|Transfemoral
1180138|NCT01238497|NovaFlex
1180139|NCT01238497|NovaFlex+
1180140|NCT01238497|NF
1180141|NCT01238497|NF+
1180142|NCT01238497|Transapical
1180143|NCT01238497|Transaortic
1180144|NCT01238497|Ascendra2
1180145|NCT01238497|Ascendra+
1180146|NCT01238497|Asc+
1180147|NCT01238497|aortic stenosis
1180148|NCT01238497|aortic valve
1180149|NCT01238497|Transcatheter Heart Valve
1180150|NCT01238497|THV
1180151|NCT01238484|Ankle Equinus
1180152|NCT01238484|Ankle contracture
1180153|NCT01238484|Diabetes Mellitus
1180154|NCT01238484|Dynasplint
1180155|NCT01238484|AFD
1180156|NCT01238471|retinopathy of prematurity
1180157|NCT01238471|Propranolol
1180158|NCT01238471|Vascular endothelial growth factor
1180159|NCT01238471|premature infant
1180160|NCT01238458|[18F]AV-45 PET amyloid binding imaging
1180161|NCT01238458|Alzheimer's disease
1180162|NCT01238458|mild cognitive impartment,
1180163|NCT01238445|Pediatric
1180164|NCT01238432|Pediatric
1180165|NCT01238432|Polymorphism, Genetic
1180166|NCT01238432|Adrenergic beta-Agonists
1180167|NCT01238406|Type 1 diabetes
1180168|NCT01238406|Closed loop
1180169|NCT01238406|Artificial Pancreas
1180170|NCT01238380|Monogenic diabetes
1180171|NCT01238380|HNF1A
1180172|NCT01238380|HNF4A
1180173|NCT01238380|GCK
1180174|NCT01238380|genetic testing
1180175|NCT01238380|health economic model
1180176|NCT01238354|Weight Loss
1180177|NCT01238354|Social support
1180178|NCT01238341|Pancreatobiliary disease in patients with altered gastric anatomy.
1180179|NCT01238328|Mucopolysaccharidosis
1180180|NCT01238328|HSCT
1180181|NCT01238315|Batten's disease
1180182|NCT01238315|INCL
1180183|NCT01238315|LINCL
1180184|NCT01238315|Neuronal Ceroid Lipofuscinosis
1180185|NCT01238315|NCL
1180186|NCT01238289|peer education
1180187|NCT01238289|diabetes
1180188|NCT01238289|randomized
1180189|NCT01238289|trial
1180190|NCT01238276|soft tissue infection
1180191|NCT01238276|wound infection
1180192|NCT01238276|cellulitis
1180193|NCT01238276|foot ulcer
1180194|NCT01238276|Diabetes
1180195|NCT01238276|antibiotics
1180196|NCT01238276|cefazolin
1180197|NCT01238276|cephazolin
1180198|NCT01238276|Ancef
1180199|NCT01238276|Kefzol
1180200|NCT01238276|subcutaneous fluid administration
1180201|NCT01238276|ultrasound
1180202|NCT01238276|MRSA
1180203|NCT01238276|Methicillin-resistant Staphylococcus aureus
1180204|NCT01238263|Atopic dermatitis, autologous serum skin testing, IgE autoantibodies
1180205|NCT01238250|16p11.2
1180206|NCT01238250|16p11.2 del
1180207|NCT01238250|16p11.2 deletion
1180208|NCT01238250|16p11.2 dup
1180209|NCT01238250|16p11.2 duplication
1180210|NCT01238250|chromosome 16
1180211|NCT01238250|chromosome 16p
1180212|NCT01238250|chromosome 16p11
1180213|NCT01238250|chromosome 16p11.2
1180214|NCT01238250|1q21.1
1180215|NCT01238250|1q21.1 del
1180216|NCT01238250|1q21.1 deletion
1180217|NCT01238250|1q21.1 dup
1180218|NCT01238250|1q21.1 duplication
1180219|NCT01238250|chromosome 1
1180220|NCT01238250|chromosome 1q
1180221|NCT01238250|chromosome 1q21
1180222|NCT01238250|chromosome 1q21.1
1180223|NCT01238250|genetic mutation
1180224|NCT01238250|genetic variant
1180225|NCT01238250|gene variant
1180226|NCT01238250|autism
1180227|NCT01238250|ADNP
1180228|NCT01238250|ANKRD1
1180229|NCT01238250|ARID1B
1180230|NCT01238250|ASXL3
1180231|NCT01238250|BAF105
1180232|NCT01238250|BAF180
1180233|NCT01238250|BAF190
1180234|NCT01238250|BAF35
1180235|NCT01238250|BAF35b
1180236|NCT01238250|BCL11A
1180237|NCT01238250|CHD2
1180238|NCT01238250|CHD8
1180239|NCT01238250|CTNNB1
1180240|NCT01238250|CUL3
1180241|NCT01238250|DST
1180242|NCT01238250|DYRK1A
1180243|NCT01238250|FOXP1
1180244|NCT01238250|GRIN2B
1180245|NCT01238250|KDM6B
1180246|NCT01238250|KMT2E
1180247|NCT01238250|MBD5
1180248|NCT01238250|MED13L
1180249|NCT01238250|PTEN
1180250|NCT01238250|REST
1180251|NCT01238250|SCN2A
1180252|NCT01238250|SMARCC1
1180253|NCT01238250|SMARCC2
1180254|NCT01238250|SYNGAP1
1180255|NCT01238250|HIVEP2
1180256|NCT01238250|HNRNPH2
1180257|NCT01238250|PPP2R5D
1180258|NCT01238237|Glioblastoma Multiforme
1180259|NCT01238237|Anaplastic Astrocytoma
1180260|NCT01238237|High Grade Glial Neoplasms
1180261|NCT01238237|Brain Tumor
1180262|NCT01238237|EGFR
1180263|NCT01238237|Epidermal Growth Factor Receptor
1180264|NCT01238237|EGFRvIII
1180265|NCT01238224|Insulin resistance
1180266|NCT01238224|Phosphodiesterase-5 inhibition
1180267|NCT01238224|Microdialysis
1180268|NCT01238224|Type 2 diabetes
1180269|NCT01238224|Endothelial dysfunction
1180270|NCT01238224|Oral hypoglycaemic agents
1180271|NCT01238185|oral leukoplakia
1180272|NCT01238172|stage I prostate cancer
1180273|NCT01238172|stage IIB prostate cancer
1180274|NCT01238172|stage IIA prostate cancer
1180275|NCT01238172|adenocarcinoma of the prostate
1180276|NCT01238159|Natural killer cell
1180277|NCT01238159|T cell
1180278|NCT01238159|Lymphoma
1180279|NCT01238159|Radiation
1180280|NCT01238159|Chemotherapy
1180281|NCT01238120|Cancer
1180282|NCT01238120|Cognitive difficulties
1180283|NCT01238107|Cachexia
1180284|NCT01238107|Cancer
1180285|NCT01238094|colorectal cancer
1180286|NCT01238094|simvastatin
1180287|NCT01238094|second-line chemotherapy
1180288|NCT01238081|Cystic fibrosis
1180289|NCT01238055|advanced gastric cancer
1180290|NCT01238055|sunitinib
1180291|NCT01238055|docetaxel
1180292|NCT01238055|fluoropyrimidine platinum based chemotherapy
1180293|NCT01238029|Dose finding study
1180294|NCT01238029|Combination
1180295|NCT01237990|liver
1180296|NCT01237990|cancer
1180297|NCT01237990|tumor
1180298|NCT01237951|Autologous Hematopoietic-Cell Support
1180299|NCT01237951|Stem Cell Transplant
1180300|NCT01237951|Busulfan
1180301|NCT01237951|Myleran
1180302|NCT01237951|Busulfex
1180303|NCT01237951|Gemcitabine
1180304|NCT01237951|Gemzar
1180305|NCT01237951|Melphalan
1180306|NCT01237951|Alkeran
1180307|NCT01237951|Decadron
1180308|NCT01237951|Dexamethasone
1180309|NCT01237951|G-CSF
1180310|NCT01237951|Filgrastim
1180311|NCT01237951|Neupogen
1180312|NCT01237925|Sunburn
1180313|NCT01237925|Dexchlorpheniramine
1180314|NCT01237925|Gel
1180315|NCT01237925|Cream
1180316|NCT01237899|Kidney
1180317|NCT01237899|Renal
1180318|NCT01237886|spontaneous breathing trial
1180319|NCT01237886|heart rate variability
1180320|NCT01237886|respiratory rate variability
1180321|NCT01237873|Aliskiren
1180322|NCT01237873|Amlodipine
1180323|NCT01237873|Essential hypertension
1180324|NCT01237873|Long term
1180325|NCT01237860|Foot drop
1180326|NCT01237860|Thigh muscle weakness
1180327|NCT01237860|Upper Motor Neuron injury or disease
1180328|NCT01237847|inflammatory bowel disease
1180329|NCT01237847|IBD
1180330|NCT01237847|Crohn's disease
1180331|NCT01237847|ulcerative colitis
1180332|NCT01237847|adolescent
1180333|NCT01237808|AML
1180334|NCT01237808|NPM1 Mutation
1180335|NCT01237808|elderly patients (>60 years)
1180336|NCT01237808|unfit for intensive chemotherapy
1180337|NCT01237795|Chloramine T
1180338|NCT01237795|Complete Denture
1180339|NCT01237795|Dental Plaque Index
1180340|NCT01237795|Dentifrice
1180341|NCT01237795|Denture Bases
1180342|NCT01237795|Denture Cleansers
1180343|NCT01237795|Edentulous Mouth
1180344|NCT01237795|Fluorosurfactant
1180345|NCT01237795|Oral Health
1180346|NCT01237795|Toothpaste
1180347|NCT01237782|Candida
1180348|NCT01237782|Complete Denture
1180349|NCT01237782|Dental Plaque Index
1180350|NCT01237782|Denture Bases
1180351|NCT01237782|Denture Cleansers
1180352|NCT01237782|Edentulous Mouth
1180353|NCT01237782|Mutans Streptococci
1180354|NCT01237782|Oral Health
1180355|NCT01237782|Propolis
1180356|NCT01237782|Streptococcus mutans
1180357|NCT01237769|vitamin D
1180358|NCT01237769|Metabolic syndrome
1180359|NCT01237769|Hypertension
1180360|NCT01237769|Dyslipidemia
1180361|NCT01237769|Dysglycemia
1180362|NCT01237769|Inflammation
1180363|NCT01237756|pediatric anesthesia
1180364|NCT01237756|endotracheal tube
1180365|NCT01237756|electrical impedance tomography
1180366|NCT01237756|misplacement
1180367|NCT01237756|endobronchial
1180368|NCT01237743|Embolism
1180369|NCT01237743|Nervous system
1180370|NCT01237743|Aorta
1180371|NCT01237743|Valves
1180372|NCT01237743|Ultrasonics
1180373|NCT01237730|percutaneous endoscopic gastrostomy
1180374|NCT01237730|peristomal wound infection
1180375|NCT01237730|prophylactic antibiotics
1180376|NCT01237717|hypertension
1180377|NCT01237691|drug use
1180378|NCT01237691|drug arrests
1180379|NCT01237691|incarceration
1180380|NCT01237678|Immunogen
1180381|NCT01237678|Lung
1180382|NCT01237678|Small Cell Lung Cancer
1180383|NCT01237678|Carboplatin
1180384|NCT01237678|ADC
1180385|NCT01237665|locally resectable advanced adenocarcinoma of the rectum
1180386|NCT01237652|Isolated Systolic Hypertension
1180387|NCT01237652|Perioperative Myocardial Ischemia
1180388|NCT01237652|Perioperative Cardiovascular adverse events
1180389|NCT01237639|Red Cells
1180390|NCT01237639|Transfusion
1180391|NCT01237639|Trigger
1180392|NCT01237639|Threshold
1180393|NCT01237639|Hematopoietic Stem cell Transplantation
1180394|NCT01237626|Driving
1180395|NCT01237626|Aging
1180396|NCT01237626|Older drivers
1180397|NCT01237626|Medical Fitness to drive
1180398|NCT01237626|Health Status
1180399|NCT01237626|At-fault collisions
1180400|NCT01237613|Achilles
1180401|NCT01237613|Rupture
1180402|NCT01237613|Tendon
1180403|NCT01237613|Artelon
1180404|NCT01237600|Ocular surface damage
1180405|NCT01237600|Limbal deficiency
1180406|NCT01237600|Cultivated corneal epithelial stem cell transplantation
1180407|NCT01237587|Adolescents
1180408|NCT01237587|Juvenile Primary Fibromyalgia Syndrome
1180409|NCT01237574|Liver Diseases
1180410|NCT01237574|Alcoholic
1180411|NCT01237574|Metabolic Diseases
1180412|NCT01237574|cohort
1180413|NCT01237574|liver disease
1180414|NCT01237561|Chronic Obstructive Pulmonary Disease
1180415|NCT01237561|COPD Guidelines
1180416|NCT01237561|Patient Activation
1180417|NCT01237561|Lung Age
1180418|NCT01237548|water pipe smoking
1180419|NCT01237548|acute effect
1180420|NCT01237548|Endothelial
1180421|NCT01237548|healthy adults who smoke narghile
1180422|NCT01237535|Unexplained infertility
1180423|NCT01237535|Insemination
1180424|NCT01237535|Luteal phase support
1180425|NCT01237535|Ovarian stimulation
1180426|NCT01237522|Diabetes Mellitus, Type 2
1180427|NCT01237522|Metabolic Clearance Rate
1180428|NCT01237522|Pharmacokinetics
1180429|NCT01237522|Pharmacogenetics
1180430|NCT01237509|EEG
1180431|NCT01237509|Sleep
1180432|NCT01237509|device
1180433|NCT01237509|diabetes
1180434|NCT01237509|hypoglycemia
1180435|NCT01237483|reirradiation with Erbitux
1180436|NCT01237483|HNSCC
1180437|NCT01237483|local recurrent inoperable Squamous Cell Cancer of the Head and Neck
1180438|NCT01237470|inguinal hernia
1180439|NCT01237470|hernia recurrence
1180440|NCT01237470|no mesh techniques
1180441|NCT01237470|Desarda technique
1180442|NCT01237444|Lopinavir/ritonavir plus 3TC as a dual therapy regimen.
1180443|NCT01237431|Water drinking
1180444|NCT01237431|osmoreceptors
1180445|NCT01237431|autonomic failure
1180446|NCT01237431|syncope
1180447|NCT01237431|blood pressure
1180448|NCT01237431|liver transplant
1180449|NCT01237405|osteoarthritis
1180450|NCT01237405|nuclear medicine
1180451|NCT01237405|macrophages
1180452|NCT01237392|wound debridement
1180453|NCT01237392|requiring debridement
1180454|NCT01237366|HIV/AIDS
1180455|NCT01237366|Methamphetamine
1180456|NCT01237366|Trauma
1180457|NCT01237340|Adult Growth Hormone Deficiency (AGHD)
1180458|NCT01237340|immunogenicity
1180459|NCT01237340|growth hormone
1180460|NCT01237340|antibodies
1180461|NCT01237340|GH biomarkers
1180462|NCT01237340|IGF-I
1180463|NCT01237327|Metastatic Breast Cancer
1180464|NCT01237327|Advanced
1180465|NCT01237327|Postmenopausal
1180466|NCT01237327|Exemestane vs Megestrol
1180467|NCT01237314|type 2 diabetes
1180468|NCT01237314|metformin
1180469|NCT01237314|glargine
1180470|NCT01237314|exenatide
1180471|NCT01237314|glycemic impact of food
1180472|NCT01237314|continuous glucose monitoring
1180473|NCT01237301|Type 2 Diabetes
1180474|NCT01237301|Continuous Glucose Monitoring
1180475|NCT01237275|Pharmacogenomics
1180476|NCT01237275|Prediction of Antidepressant Response
1180477|NCT01237275|Depressed Patients
1180478|NCT01237262|psoriasis
1180479|NCT01237262|immune infiltrate
1180480|NCT01237262|dendritic cells
1180481|NCT01237262|cytokine expression
1180482|NCT01237249|Multiple Myeloma
1180483|NCT01237249|Velcade
1180484|NCT01237249|Revlimid
1180485|NCT01237236|Advanced solid tumor
1180486|NCT01237236|lymphoma
1180487|NCT01237223|Aliskiren
1180488|NCT01237223|Amlodipine
1180489|NCT01237223|Essential hypertension
1180490|NCT01237210|Parkinson's Disease
1180491|NCT01237210|PD
1180492|NCT01237210|magnetic resonance spectroscopy
1180493|NCT01237184|initial dental implant stability
1180494|NCT01237184|maxillary sinus proximity
1180495|NCT01237184|bicortical fixation
1180496|NCT01237171|Brachytherapy
1180497|NCT01237171|Lung Brachytherapy
1180498|NCT01237171|NSCLC
1180499|NCT01237171|Sub-lobar resection
1180500|NCT01237158|GAD1,
1180501|NCT01237158|GAD67,
1180502|NCT01237158|bipolar,
1180503|NCT01237158|GABA,
1180504|NCT01237158|Glutamate,
1180505|NCT01237158|Reelin,
1180506|NCT01237158|Rln,
1180507|NCT01237158|Spectroscopy
1180508|NCT01237158|euthymic bipolar I patients
1180509|NCT01237145|pigeon
1180510|NCT01237145|bird fancier
1180511|NCT01237145|extrinsic allergic alveolitis
1180512|NCT01237145|BAL
1180513|NCT01237145|broncho-alveolar lavage
1180514|NCT01237145|elispot
1180515|NCT01237145|antigen
1180516|NCT01237106|PCOS
1180517|NCT01237106|IVM
1180518|NCT01237106|Polycystic ovarian syndrome
1180519|NCT01237106|In Vitro Maturation
1180520|NCT01237106|IVF
1180521|NCT01237093|Fish Diet
1180522|NCT01237093|Meat Diet
1180523|NCT01237093|Biomarkers
1180524|NCT01237093|Stable Isotopes
1180525|NCT01237093|Dietary Intake
1180526|NCT01237067|PARP inhibitor, womens's cancers, relapsed, recurrent
1180527|NCT01237067|Ovarian, breast, endometrial, cervical
1180528|NCT01237067|Carboplatin
1180529|NCT01237067|BRCA 1 and BRCA 2
1180530|NCT01237067|Breast Cancer
1180531|NCT01237067|Ovarian Cancer
1180532|NCT01237067|Uterine Cancer
1180533|NCT01237067|Cervical Cancer
1180534|NCT01237067|Peritoneal Cancer
1180535|NCT01237067|Endometrial Cancer
1180536|NCT01237067|Fallopian Tube Cancer
1180537|NCT01237054|18-FDG PET/CT
1180538|NCT01237054|Abnormal Plasma Cells
1180539|NCT01237054|Serum Free Light-Chain Abnormality
1180540|NCT01237054|Serum M-Protein
1180541|NCT01237054|DCE-MRI
1180542|NCT01237054|Multiple Myeloma
1180543|NCT01237054|Smoldering Multiple Myeloma
1180544|NCT01237054|SMM
1180545|NCT01237054|MM
1180546|NCT01237041|Child
1180547|NCT01237041|Body Fat
1180548|NCT01237041|Niacin
1180549|NCT01237041|Growth Hormone
1180550|NCT01237041|Obesity
1180551|NCT01237041|Growth Hormones
1180552|NCT01237041|Short Stature
1180553|NCT01237041|Children
1180554|NCT01237015|Neonate
1180555|NCT01237015|Oral feeding
1180556|NCT01237015|Nasal CPAP
1180557|NCT01237015|Sucking
1180558|NCT01237015|Swallowing
1180559|NCT01237015|Breathing
1180560|NCT01237002|Liver ischemia; Pringle time
1180561|NCT01236989|anatomical resection
1180562|NCT01236989|non-anatomical resection
1180563|NCT01236989|IOUS-guided finger compression
1180564|NCT01236963|Clinical trial
1180565|NCT01236963|Prevention mouthrinse
1180566|NCT01236963|Dental Floss
1180567|NCT01236950|Clinical Trial
1180568|NCT01236950|Prevention Mouthrinse
1180569|NCT01236937|CT, lung nodule biopsy, Respiration Gated, Lung Cancer
1180570|NCT01236911|Calcium , TBI,complications, days in hospital
1180571|NCT01236898|N-acetylneuraminic acid,
1180572|NCT01236898|pharmacokinetics
1180573|NCT01236898|hIBM
1180574|NCT01236872|Nitrate
1180575|NCT01236872|Nitrite
1180576|NCT01236872|Vegetable
1180577|NCT01236872|Aortic stiffness
1180578|NCT01236859|Gabapentin
1180579|NCT01236859|prophylaxis
1180580|NCT01236859|incidence of pruritus
1180581|NCT01236859|intrathecal morphine
1180582|NCT01236846|Vitamin D fortification
1180583|NCT01236846|Yogurt Drink
1180584|NCT01236846|Efficacy
1180585|NCT01236833|Lactated Ringer's Solution
1180586|NCT01236833|Isotonic Solution
1180587|NCT01236833|Intestinal Disease
1180588|NCT01236833|Feeding Intolerance
1180589|NCT01236833|Necrotizing Enterocolitis
1180590|NCT01236833|Newborn
1180591|NCT01236833|Premature Infant
1180592|NCT01236820|L5
1180593|NCT01236820|LDL
1180594|NCT01236820|Cardiovascular disease
1180595|NCT01236820|Chronic kidney disease
1180596|NCT01236820|Hemodialysis
1180597|NCT01236807|Adenosine
1180598|NCT01236807|Magnetic Resonance Imaging
1180599|NCT01236807|MR perfusion
1180600|NCT01236807|Fractional Flow Reserve, Myocardial
1180601|NCT01236807|FFR
1180602|NCT01236807|Pressure wire
1180603|NCT01236807|Coronary Disease
1180604|NCT01236807|Heart Diseases
1180605|NCT01236807|Cardiovascular Diseases
1180606|NCT01236807|Arteriosclerosis
1180607|NCT01236781|breast cancer
1180608|NCT01236781|screening
1180609|NCT01236781|diagnostics
1180610|NCT01236781|diagnosis
1180611|NCT01236781|high-risk
1180612|NCT01236781|breast neoplasms
1180613|NCT01236781|digital mammography
1180614|NCT01236781|mammography
1180615|NCT01236781|tomosynthesis
1180616|NCT01236781|dense breasts
1180617|NCT01236781|radiation dose
1180618|NCT01236781|comparison
1180619|NCT01236781|Hologic
1180620|NCT01236781|Pennsylvania
1180621|NCT01236781|Philadelphia
1180622|NCT01236781|breast study
1180623|NCT01236781|mammo
1180624|NCT01236781|tomo
1180625|NCT01236781|mammary
1180626|NCT01236768|Contraceptive
1180627|NCT01236755|children
1180628|NCT01236755|corneal reshaping
1180629|NCT01236755|myopia
1180630|NCT01236755|myopia progression
1180631|NCT01236755|orthokeratology
1180632|NCT01236742|children
1180633|NCT01236742|corneal reshaping
1180634|NCT01236742|myopia
1180635|NCT01236742|myopia progression
1180636|NCT01236742|orthokeratology
1180637|NCT01236729|knee replacement
1180638|NCT01236729|disability
1180639|NCT01236729|older people
1180640|NCT01236716|squamous cell carcinoma of lung
1180641|NCT01236716|Albumin bound paclitaxel
1180642|NCT01236716|chemotherapy
1180643|NCT01236703|SIRS
1180644|NCT01236703|Sepsis
1180645|NCT01236703|hematological infection score
1180646|NCT01236690|Transcatheter arterial embolization
1180647|NCT01236690|Cinobufacin injection
1180648|NCT01236690|hepatoma
1180649|NCT01236677|Pathogen
1180650|NCT01236664|memory training
1180651|NCT01236664|mnemonics
1180652|NCT01236664|cognition
1180653|NCT01236664|work
1180654|NCT01236638|Primary Myelofibrosis
1180655|NCT01236638|Post-Polycythemia Vera
1180656|NCT01236638|Post-Essential Thrombocythemia
1180657|NCT01236638|CYT387
1180658|NCT01236625|Tissue Adhesions
1180659|NCT01236625|Adhesiolysis
1180660|NCT01236625|Inadvertent enterotomy
1180661|NCT01236625|Prospective cohort study
1180662|NCT01236625|Quality of life
1180663|NCT01236612|Plasmodium
1180664|NCT01236612|falciparum
1180665|NCT01236612|malaria
1180666|NCT01236612|chloroquine
1180667|NCT01236612|immunity
1180668|NCT01236599|preterm infant, thermoregulation, polyethylene bag
1180669|NCT01236586|Maximum Tolerated Dose
1180670|NCT01236586|Toxicity
1180671|NCT01236586|Pharmacokinetics
1180672|NCT01236586|NOTCH Signaling Pathway
1180673|NCT01236586|Expression of JAGGED 1 and 2
1180674|NCT01236586|Cancer
1180675|NCT01236586|Solid Tumor
1180676|NCT01236586|Brain Tumor
1180677|NCT01236586|Wilms Tumor
1180678|NCT01236586|Osteosarcoma
1180679|NCT01236586|Lymphoma
1180680|NCT01236573|Gene Therapy
1180681|NCT01236573|Immunotherapy
1180682|NCT01236573|Adoptive Cell Therapy
1180683|NCT01236573|Metastatic Melanoma
1180684|NCT01236534|Multiple Sclerosis
1180685|NCT01236534|Constipation
1180686|NCT01236534|Multiple Sclerosis Associated Constipation
1180687|NCT01236521|Back pain
1180688|NCT01236521|Care Management
1180689|NCT01236521|Pain
1180690|NCT01236521|Patient outcomes
1180691|NCT01236521|Patient-center Care
1180692|NCT01236521|Primary care
1180693|NCT01236508|White Matter Hyperintensity
1180694|NCT01236508|Stroke
1180695|NCT01236508|Carotid Artery Plaque Inflammation
1180696|NCT01236508|FDG PET
1180697|NCT01236508|MRI
1180698|NCT01236508|TIA
1180699|NCT01236495|thoracotomy
1180700|NCT01236495|postoperative pain
1180701|NCT01236495|spinal morphine
1180702|NCT01236482|Pregnancy
1180703|NCT01236482|Postpartum hemorrhage
1180704|NCT01236482|Uterine tone
1180705|NCT01236482|Oxytocin
1180706|NCT01236482|Ergometrine
1180707|NCT01236482|Pharmacokinetic-pharmacodynamic analysis
1180708|NCT01236469|Aortic Valve
1180709|NCT01236456|chronic inflammatory demyelinating polyneuropathy
1180710|NCT01236456|cyclophosphamide
1180711|NCT01236456|autoimmune
1180712|NCT01236430|Hyperlipidemia
1180713|NCT01236430|statin
1180714|NCT01236430|Ezetimibe
1180715|NCT01236430|Zetia
1180716|NCT01236430|Atorvastatin
1180717|NCT01236430|Lipitor
1180718|NCT01236391|Pharmacyclics
1180719|NCT01236391|Mantle
1180720|NCT01236391|Mantle Cell
1180721|NCT01236391|Lymphoma
1180722|NCT01236391|Non-Hodgkins
1180723|NCT01236391|Bortezomib
1180724|NCT01236391|Velcade
1180725|NCT01236391|Naive
1180726|NCT01236391|PCYC
1180727|NCT01236378|Organ Transplants
1180728|NCT01236378|Anti-Rejection Therapy
1180729|NCT01236378|Pharmacokinetics
1180730|NCT01236365|Type 1 diabetes
1180731|NCT01236365|Children
1180732|NCT01236365|Statins
1180733|NCT01236365|Hypercholesterolemia
1180734|NCT01236365|Lipoproteins
1180735|NCT01236365|C reactive protein
1180736|NCT01236365|Continuous glucose monitors
1180737|NCT01236365|Adolescence
1180738|NCT01236365|Abdominal magnetic resonance imaging
1180739|NCT01236365|Toll like receptors
1180740|NCT01236365|Receptors of advanced glycation end products
1180741|NCT01236365|Nutrition
1180742|NCT01236352|Advanced Cancer, Various, NOS
1180743|NCT01236313|TEE
1180744|NCT01236313|Cardiac Surgery
1180745|NCT01236313|Pulse Pressure
1180746|NCT01236300|Pancreatic cysts
1180747|NCT01236274|Myocardial Infarction
1180748|NCT01236274|Antipsychotic agents
1180749|NCT01236274|Self-controlled case series method
1180750|NCT01236274|General Practice Research Database
1180751|NCT01236274|Myocardial Ischaemia National Audit Project
1180752|NCT01236274|CALIBER
1180753|NCT01236261|Fungemia, fungal infection, susceptibility, antifungal
1180754|NCT01236248|drugs
1180755|NCT01236248|youth
1180756|NCT01236248|parent
1180757|NCT01236248|computer
1180758|NCT01236248|prevention
1180759|NCT01236222|commuter cycling
1180760|NCT01236222|fitness
1180761|NCT01236222|metabolic syndrome
1180762|NCT01236222|children
1180763|NCT01236196|pain
1180764|NCT01236196|chronic pain
1180765|NCT01236196|cognitive therapy
1180766|NCT01236196|telehealth
1180767|NCT01236183|manual skill
1180768|NCT01236183|anesthesia residents
1180769|NCT01236170|Amputees
1180770|NCT01236170|spinal cord injuries
1180771|NCT01236170|quality of life
1180772|NCT01236170|satisfaction
1180773|NCT01236170|healthcare disparities
1180774|NCT01236170|wheelchairs
1180775|NCT01236157|Cardiology
1180776|NCT01236144|Myeloid
1180777|NCT01236144|Leukaemia
1180778|NCT01236144|Acute
1180779|NCT01236144|Myelodysplastic
1180780|NCT01236144|Pilot
1180781|NCT01236144|Cardiff
1180782|NCT01236144|Haematology
1180783|NCT01236144|Burnett
1180784|NCT01236144|AC220
1180785|NCT01236144|Plerixafor
1180786|NCT01236144|Ganetespib
1180787|NCT01236092|resolution of low back pain
1180788|NCT01236092|show measurable improvement in disc measurement
1180789|NCT01236092|conservative therapy vs. surgery in resolving low back pain
1180790|NCT01236066|Rotavirus Gastroenteritis
1180791|NCT01236066|Rotarix
1180792|NCT01236066|RotaTeq
1180793|NCT01236066|Gastroenteritis
1180794|NCT01236053|renal cancer
1180795|NCT01236053|pancreatic cancer
1180796|NCT01236053|epidemiology
1180797|NCT01236053|renal cell carcinoma
1180798|NCT01236053|nervous system cancer
1180799|NCT01236053|lung cancer
1180800|NCT01236053|breast cancer
1180801|NCT01236053|case-control
1180802|NCT01236053|GPRD
1180803|NCT01236053|Gapabentin
1180804|NCT01236053|cancer
1180805|NCT01236053|anal cancer
1180806|NCT01236053|bone and joint cancer
1180807|NCT01236053|renal pelvis cancer
1180808|NCT01236053|penis cancer
1180809|NCT01236053|stomach cancer
1180810|NCT01236053|bladder cancer
1180811|NCT01236040|H5N1
1180812|NCT01236040|Influenza
1180813|NCT01236040|Pandemic
1180814|NCT01236001|Lacosamide
1180815|NCT01236001|Vimpat®
1180816|NCT01235975|Neisseria meningitidis
1180817|NCT01235975|Meningococcal Vaccines
1180818|NCT01235975|serogroups A,C, W-135 or Y
1180819|NCT01235975|meningococcal diseases
1180820|NCT01235975|meningococcal conjugate vaccine
1180821|NCT01235975|Immunogenicity
1180822|NCT01235962|anti-angiogenic agent
1180823|NCT01235962|renal cell carcinoma
1180824|NCT01235962|pazopanib
1180825|NCT01235962|adjuvant therapy
1180826|NCT01235962|VEGFR inhibitor
1180827|NCT01235949|Pneumococcal vaccine
1180828|NCT01235949|Immunogenicity
1180829|NCT01235949|Safety
1180830|NCT01235949|Fever
1180831|NCT01235949|Primary vaccination
1180832|NCT01235949|Booster vaccination
1180833|NCT01235949|Pneumococcal disease
1180834|NCT01235949|Prophylactic antipyretic
1180835|NCT01235936|anemia
1180836|NCT01235936|chronic kidney disease
1180837|NCT01235936|CKD
1180838|NCT01235936|chronic renal insufficiency
1180839|NCT01235936|renal impairment
1180840|NCT01235936|erythropoietin
1180841|NCT01235936|safety
1180842|NCT01235936|efficacy
1180843|NCT01235936|tolerability
1180844|NCT01235936|pharmacokinetics
1180845|NCT01235923|anemia
1180846|NCT01235923|transfusions
1180847|NCT01235923|erythropoiesis
1180848|NCT01235923|neonate
1180849|NCT01235923|preterm
1180850|NCT01235910|Hypertension
1180851|NCT01235910|Cardiac transplantation
1180852|NCT01235910|Aliskiren
1180853|NCT01235910|Cyclosporine
1180854|NCT01235897|Neoplasms
1180855|NCT01235897|Paclitaxel
1180856|NCT01235897|Trastuzumab
1180857|NCT01235884|gaseous colic, regurgitation and of constipation
1180858|NCT01235871|Safety
1180859|NCT01235871|Tolerability
1180860|NCT01235871|SB1578
1180861|NCT01235858|Epidural analgesia
1180862|NCT01235858|Epidural anesthesia labor
1180863|NCT01235858|Aseptic technique
1180864|NCT01235858|gown
1180865|NCT01235858|no gown
1180866|NCT01235832|cholesterol
1180867|NCT01235832|triglycerides
1180868|NCT01235832|low-density lipoprotein
1180869|NCT01235832|high-density lipoprotein
1180870|NCT01235832|reverse cholesterol transport
1180871|NCT01235819|type 1 diabetes
1180872|NCT01235819|exenatide
1180873|NCT01235819|sitagliptin
1180874|NCT01235806|scaphoid
1180875|NCT01235806|MRI
1180876|NCT01235806|ESAOTE
1180877|NCT01235793|Relapsed
1180878|NCT01235793|Refractory
1180879|NCT01235793|Primary Central Nervous System B-cell Lymphoma
1180880|NCT01235793|Autologous Stem Cell Transplant
1180881|NCT01235793|Temozolomide
1180882|NCT01235793|B-Cell Lymphoma
1180883|NCT01235793|RBEAM
1180884|NCT01235793|Conditioning Regimen
1180885|NCT01235780|corneal hysteresis, ocular response analyzer
1180886|NCT01235767|birth weight
1180887|NCT01235767|prematurity
1180888|NCT01235767|gestational age
1180889|NCT01235767|low birth weight
1180890|NCT01235767|pregnancy
1180891|NCT01235767|nutrition
1180892|NCT01235767|Vietnam
1180893|NCT01235754|testosterone
1180894|NCT01235754|hypoactive sexual desire disorder
1180895|NCT01235754|menopause
1180896|NCT01235741|Pramlintide
1180897|NCT01235741|Metreleptin
1180898|NCT01235741|Obesity
1180899|NCT01235741|Amylin
1180900|NCT01235741|Takeda
1180901|NCT01235715|osteoarthritis
1180902|NCT01235715|total knee replacement
1180903|NCT01235702|high blood pressure, hypertension, African Americans, perceived stress
1180904|NCT01235689|Efficacy and Safety of two treatment algorithms in Subjects with Moderate to Severe Crohn's Disease
1180905|NCT01235676|obesity
1180906|NCT01235676|lifestyle
1180907|NCT01235676|pregnancy
1180908|NCT01235676|newborn infant
1180909|NCT01235663|obesity, insulin resistance
1180910|NCT01235637|COMFORT B score
1180911|NCT01235637|Bis score
1180912|NCT01235624|Autosomal dominant retinitis pigmentosa
1180913|NCT01235624|Rare disease
1180914|NCT01235624|Genetics
1180915|NCT01235598|Cimzia®
1180916|NCT01235598|CDP870
1180917|NCT01235598|CZP
1180918|NCT01235598|Certolizumab Pegol
1180919|NCT01235598|Rheumatoid Arthritis
1180920|NCT01235598|MRI
1180921|NCT01235572|Acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
1180922|NCT01235572|Adult acute eosinophilic leukemia
1180923|NCT01235572|Adult acute basophilic leukemia
1180924|NCT01235572|De
1180925|NCT01235572|novo myelodysplastic syndromes
1180926|NCT01235572|Secondary myelodysplastic syndromes
1180927|NCT01235572|Untreated adult acute myeloid leukemia
1180928|NCT01235546|Pregnancy
1180929|NCT01235546|Cesarean section
1180930|NCT01235546|Antibiotic
1180931|NCT01235546|Infections
1180932|NCT01235533|late-life depression
1180933|NCT01235533|recurrence of depression
1180934|NCT01235533|cognition
1180935|NCT01235533|N-3 polyunsaturated fatty acids
1180936|NCT01235481|pulmonary rehabilitation
1180937|NCT01235481|exercise therapy
1180938|NCT01235481|chronic lung disease
1180939|NCT01235481|self-efficacy
1180940|NCT01235468|umbilical cord blood
1180941|NCT01235468|ex vivo expansion
1180942|NCT01235468|engraftment
1180943|NCT01235468|GVHD
1180944|NCT01235455|Multiple Sclerosis
1180945|NCT01235455|Adherence
1180946|NCT01235455|Interferon beta-1b
1180947|NCT01235455|Coping styles
1180948|NCT01235442|Psoriasis
1180949|NCT01235442|Topical
1180950|NCT01235442|etanercept
1180951|NCT01235442|clobetasol propionate
1180952|NCT01235429|Diabetes
1180953|NCT01235429|Behavioral intervention
1180954|NCT01235429|diabetes self-management
1180955|NCT01235429|Native Hawaiians
1180956|NCT01235429|health disparities
1180957|NCT01235403|Epilepsy treatment.
1180958|NCT01235403|Anti-epileptic drugs
1180959|NCT01235403|Seizures
1180960|NCT01235390|Postmenopausal women
1180961|NCT01235390|walnuts
1180962|NCT01235377|prescribing patterns
1180963|NCT01235377|thiazide
1180964|NCT01235377|chlorthalidone
1180965|NCT01235377|hydrochlorothiazide
1180966|NCT01235377|target dose
1180967|NCT01235377|cluster randomized trial
1180968|NCT01235364|Foley catheter
1180969|NCT01235364|induction
1180970|NCT01235364|labour
1180971|NCT01235364|skin conductance
1180972|NCT01235364|visual analogue scale
1180973|NCT01235364|mechanical method
1180974|NCT01235351|Myocardial infarction
1180975|NCT01235351|Percutaneous coronary intervention
1180976|NCT01235351|Clopidogrel
1180977|NCT01235351|Genetics
1180978|NCT01235351|Platelet Function
1180979|NCT01235325|vitamin K
1180980|NCT01235325|supplementation
1180981|NCT01235325|bone health indices
1180982|NCT01235325|adult
1180983|NCT01235325|Crohn's disease
1180984|NCT01235286|remote ischemic preconditioning, free flap, microcirculation
1180985|NCT01235260|REGRANEX (becaplermin)
1180986|NCT01235260|Platelet-derived growth factor BB
1180987|NCT01235260|Cancer
1180988|NCT01235260|Cancer incidence
1180989|NCT01235260|Cancer mortality
1180990|NCT01235260|Lower Extremity Diabetic Neuropathic Ulcer
1180991|NCT01235234|Dry eye disease
1180992|NCT01235234|KCS
1180993|NCT01235234|Aqueous Deficient Dry Eye
1180994|NCT01235208|Overweight
1180995|NCT01235208|Obesity
1180996|NCT01235208|Metabolic syndrome
1180997|NCT01235208|Diet
1180998|NCT01235208|Carbohydrate
1180999|NCT01235208|Low glycemic index
1181000|NCT01235208|Eurodiet
1181001|NCT01235195|bioequivalence study
1181002|NCT01235195|sertraline 50 mg
1181003|NCT01235195|capsules vs tablets
1181004|NCT01235182|acute dyspnea
1181005|NCT01235182|prehospital emergency setting
1181006|NCT01235182|differential diagnosis
1181007|NCT01235182|ultrasound
1181008|NCT01235182|NT-proBNP
1181009|NCT01235156|Premature ventricular contraction
1181010|NCT01235156|Frequent premature ventricular contraction, with or without a short array of non-sustained ventricular tachycardia
1181011|NCT01235143|incidence
1181012|NCT01235143|emergence agitation
1181013|NCT01235143|sevoflurane
1181014|NCT01235143|desflurane
1181015|NCT01235143|ambulatory pediatric surgery
1181016|NCT01235117|chronic myelomonocytic leukemia
1181017|NCT01235091|HIV prevention
1181018|NCT01235091|substance abuse
1181019|NCT01235091|high risk behaviors
1181020|NCT01235091|peer intervention
1181021|NCT01235065|airway management
1181022|NCT01235065|trauma
1181023|NCT01235065|intubation
1181024|NCT01235052|Head and neck neoplasms
1181025|NCT01235052|Positron Emission Tomography
1181026|NCT01235052|F18 fluoromisonidazole
1181027|NCT01235026|Obesity
1181028|NCT01235026|Type-2 Diabetes
1181029|NCT01235026|Metabolic syndrome
1181030|NCT01235026|Low grade inflammation
1181031|NCT01235026|Metabolic endotoxinemia
1181032|NCT01235026|Insulin resistance
1181033|NCT01235026|Lipopolysaccharide
1181034|NCT01235026|LPS-binding protein
1181035|NCT01235026|sCD14
1181036|NCT01235026|Synbiotic
1181037|NCT01235026|Oligofructose
1181038|NCT01235026|Bifidobacterium animalis subsp. lactis Bb12
1181039|NCT01235026|probiotic
1181040|NCT01235026|Prebiotic
1181041|NCT01235013|HIV-1 infection
1181042|NCT01235013|Maraviroc
1181043|NCT01235013|CD4 lymphocyte count
1181044|NCT01235000|Influenza vaccines
1181045|NCT01235000|Infant
1181046|NCT01235000|Dose-Response relationship, immunologic
1181047|NCT01235000|Prime-boost response
1181048|NCT01234987|Cancer
1181049|NCT01234987|Breast Cancer
1181050|NCT01234987|Colon cancer
1181051|NCT01234987|Lung Cancer
1181052|NCT01234974|multiple myeloma
1181053|NCT01234948|Halitosis
1181054|NCT01234948|VSC
1181055|NCT01234948|Periodontitis
1181056|NCT01234948|Gingivitis
1181057|NCT01234948|Putative periodontal pathogens
1181058|NCT01234948|Real-time PCR
1181059|NCT01234909|Missed immunizations
1181060|NCT01234896|Smoking Cessation, Nicotine pharmacokinetics
1181061|NCT01234883|dehydration
1181062|NCT01234883|gastroenteritis
1181063|NCT01234870|Myocardial Perfusion Imaging
1181310|NCT01233752|pharmacogenetics
1181064|NCT01234870|Magnetic Resonance Imaging
1181065|NCT01234857|mTOR
1181066|NCT01234857|breast cancer
1181067|NCT01234857|estrogen receptor positive
1181068|NCT01234844|pet-therapy
1181069|NCT01234844|guinea-pigs
1181070|NCT01234844|rehabilitation
1181071|NCT01234844|elderly
1181072|NCT01234831|MRSA
1181073|NCT01234831|colonization
1181074|NCT01234831|nucleic acid amplification
1181075|NCT01234831|chromogenic agar
1181076|NCT01234818|Endometrial hyperplasia
1181077|NCT01234818|LNG-IUS
1181078|NCT01234792|Smoking Cessation, Nicotine pharmacokinetics
1181079|NCT01234753|Adults with CHD
1181080|NCT01234753|GUCH
1181081|NCT01234753|Congenital heart disease
1181082|NCT01234753|Computer-based education
1181083|NCT01234753|Nursing
1181084|NCT01234740|Los Angeles
1181085|NCT01234727|diabetes, SMBG, glucose testing systems, accuracy
1181086|NCT01234714|Fatty Liver
1181087|NCT01234714|Liver
1181088|NCT01234714|Magnetic Resonance Imaging
1181089|NCT01234714|Surgery
1181090|NCT01234701|Liver
1181091|NCT01234701|Neoplasms
1181092|NCT01234701|Magnetic Resonance Imaging
1181093|NCT01234701|Surgery
1181094|NCT01234701|Pathology
1181095|NCT01234688|Exercise Tolerance
1181096|NCT01234688|Physical Endurance
1181097|NCT01234675|Fibromyalgia
1181098|NCT01234675|Sleep disorders
1181099|NCT01234675|Forest Laboratories
1181100|NCT01234675|Milnacipran
1181101|NCT01234662|Elective cesarean sections
1181102|NCT01234662|Postoperative pain level
1181103|NCT01234662|Spinal anesthesia
1181104|NCT01234662|Combined spinal epidural anesthesia
1181105|NCT01234662|Epidural catheter
1181106|NCT01234649|gestational diabetes mellitus
1181107|NCT01234649|type 2 diabetes mellitus
1181108|NCT01234649|metabolic dysfunction
1181109|NCT01234649|impaired fasting glucose
1181110|NCT01234649|impaired glucose tolerance
1181111|NCT01234649|incretin mimetic
1181112|NCT01234636|Platelets
1181113|NCT01234636|Platelet aggregation
1181114|NCT01234636|Platelet activation
1181115|NCT01234636|Platelet function
1181116|NCT01234636|Light transmission aggregometry
1181117|NCT01234636|Flow cytometry
1181118|NCT01234636|Platelet function analyzer-100 (PFA-100)
1181119|NCT01234636|Linoleic acid, conjugated
1181120|NCT01234636|cis9, trans11 conjugated linoleic acid
1181121|NCT01234636|dietary supplement
1181122|NCT01234636|short-term intervention
1181123|NCT01234623|Umbilical cord serum, eyedrops, GVHD, SS-I, corneal healing
1181124|NCT01234610|Exercise
1181125|NCT01234610|Aortic aneurysm
1181126|NCT01234610|Feasibility
1181127|NCT01234610|Vascular disease
1181128|NCT01234571|Pulmonary hypertension
1181129|NCT01234571|Remodulin (Treprostenil sodium)
1181130|NCT01234571|End-stage renal disease
1181131|NCT01234571|Hemo-dialysis
1181132|NCT01234558|depression
1181133|NCT01234558|NMDA antagonist
1181134|NCT01234558|treatment resistant
1181135|NCT01234519|ureter cancer
1181136|NCT01234519|renal pelvis cancer
1181137|NCT01234519|bladder cancer
1181138|NCT01234519|urethra
1181139|NCT01234506|long term care
1181140|NCT01234506|lignans
1181141|NCT01234506|oxidative stress
1181142|NCT01234506|inflammation
1181143|NCT01234506|aging
1181144|NCT01234506|dementia
1181145|NCT01234506|postural balance
1181146|NCT01234506|depression
1181147|NCT01234506|muscle weakness
1181148|NCT01234506|quality of life
1181149|NCT01234506|pain
1181150|NCT01234493|ankle; fracture; syndesmosis;
1181151|NCT01232972|vitrification
1181152|NCT01232972|egg freezing
1181153|NCT01232972|oocyte cryopreservation
1181154|NCT01232972|female fertility potential
1181155|NCT01232972|fertility preservation
1181156|NCT01232972|Fertility preservation, female
1181157|NCT01232959|Gallbladder removal
1181158|NCT01234467|Diffuse Large B-Cell Lymphoma
1181159|NCT01234467|Elderly
1181160|NCT01234467|Newly Diagnosed
1181161|NCT01234467|Lineberger Comprehensive Cancer Center
1181162|NCT01234467|University of North Carolina
1181163|NCT01234467|Bendamustine
1181164|NCT01234467|Rituximab
1181165|NCT01234467|Rituxan
1181166|NCT01234467|Treanda
1181167|NCT01234467|Phase 2
1181168|NCT01234467|Geriatric
1181169|NCT01234467|Lymphoma
1181170|NCT01234428|laparoscopy
1181171|NCT01234428|adjustable gastric banding
1181172|NCT01234428|morbid obesity
1181173|NCT01234428|esophageal motility
1181174|NCT01234428|esophageal dilatation
1181175|NCT01234415|nasal
1181176|NCT01234415|septum
1181177|NCT01234415|reconstruction
1181178|NCT01234402|Breast Cancer
1181179|NCT01234363|Renal allograft
1181180|NCT01234363|kidney
1181181|NCT01234363|fibrosis
1181182|NCT01234363|elastography
1181183|NCT01234363|elasticity
1181184|NCT01234337|Breast Cancer
1181185|NCT01234337|HER2-neu
1181186|NCT01234324|Stomach Neoplasms
1181187|NCT01234324|Gastroesophageal Junction Neoplasms
1181188|NCT01234324|gastric cancer
1181189|NCT01234324|cancer of the gastroesophageal junction
1181190|NCT01234285|sepsis
1181191|NCT01234285|septic shock
1181192|NCT01234285|anticoagulation
1181193|NCT01234285|intensive care unit
1181194|NCT01234272|patients with
1181195|NCT01234272|undergoing
1181196|NCT01234272|gastrectomy
1181197|NCT01234259|Wrinkles
1181198|NCT01234259|rhytides
1181199|NCT01234259|Cellulite
1181200|NCT01234259|circumference reduction
1181201|NCT01234246|Colorectal cancer
1181202|NCT01234246|Sexual function
1181203|NCT01234246|Sexual dysfunction
1181204|NCT01234246|Quality of (sexual) life
1181205|NCT01234246|Partners
1181206|NCT01234246|Body image
1181207|NCT01234246|Anxiety (state and trait)
1181208|NCT01234246|Depressive symptoms
1181209|NCT01234246|Personality
1181210|NCT01234233|hypothermia, accidental
1181211|NCT01234233|prewarming
1181212|NCT01234233|body temperature monitoring
1181213|NCT01234233|preoperative warming
1181214|NCT01234233|sublingual temperature assessment
1181215|NCT01234233|tympanic temperature assessment
1181216|NCT01234220|Aldosterone
1181217|NCT01234220|Primary Aldosteronism
1181218|NCT01234220|Aldosterone Producing Adenoma (APA)
1181219|NCT01234220|Idiopathic Adrenal Hyperplasia (IHA)
1181220|NCT01234220|Adrenal Venous Sampling
1181221|NCT01234207|Progressive addition lenses
1181222|NCT01234207|Customized free-form
1181223|NCT01234207|Presbyopia
1181224|NCT01234207|Bifocals
1181225|NCT01234207|Subjective assessment
1181226|NCT01234207|Visual performance
1181227|NCT01234207|Visual acuity
1181228|NCT01234207|Amsler grid
1181229|NCT01234194|Composite Variability Index
1181230|NCT01234194|Bispectral Index
1181231|NCT01234194|Electromyography
1181232|NCT01234194|Nociception
1181233|NCT01234194|Pain
1181234|NCT01234155|Exercise
1181235|NCT01234155|Diabetes
1181236|NCT01234155|Obesity
1181237|NCT01234155|Insulin Sensitivity
1181238|NCT01234155|Insulin Secretion
1181239|NCT01234155|Beta-cell Function
1181240|NCT01234155|Glycemic Control
1181241|NCT01234155|GIP
1181242|NCT01234155|GLP-1
1181243|NCT01234142|varenicline transdermal percutaneous transcutaneous transdermal delivery system patch
1181244|NCT01234129|multiple myeloma
1181245|NCT01234129|stem cell transplant
1181246|NCT01234129|zoledronic acid
1181247|NCT01234116|Post exposure prophylaxis
1181248|NCT01234116|Health Care Workers
1181249|NCT01234103|sexually transmitted infection
1181250|NCT01234103|sexual risk
1181251|NCT01234103|HIV
1181252|NCT01234103|young adults
1181253|NCT01234103|cognitive-behavioral intervention
1181254|NCT01234090|Aphasia
1181255|NCT01234090|Quality of Life
1181256|NCT01234077|scheduled for a polysomnogram (overnight sleep study)
1181257|NCT01234064|Symptomatic Venous Thromboembolism
1181258|NCT01234064|Graduated Compression Stockings
1181259|NCT01234064|Randomized Controlled Trial
1181260|NCT01234064|Noncardiac Surgery
1181261|NCT01234038|Non-small cell lung cancer
1181262|NCT01234025|Castrate-Resistant Prostate Cancer
1181263|NCT01234012|melanoma
1181264|NCT01234012|breast cancer
1181265|NCT01234012|ovarian cancer
1181266|NCT01234012|prostate cancer
1181267|NCT01234012|esophageal cancer
1181268|NCT01234012|uterine cancer
1181269|NCT01234012|sarcoma
1181270|NCT01234012|NY-ESO-1
1181271|NCT01233999|Scleroderma
1181272|NCT01233999|Raynaud's Syndrome
1181273|NCT01233986|Acute Ischemic Stroke
1181274|NCT01233986|Atherosclerosis
1181275|NCT01233986|Apolipoprotein B48
1181276|NCT01233973|nursing home
1181277|NCT01233973|advance care planning
1181278|NCT01233960|Crohn's Disease
1181279|NCT01233960|Adult Stem Cell Therapy
1181280|NCT01233960|inflammation of the gastrointestinal tract
1181281|NCT01233934|Insect bites
1181282|NCT01233934|Dexchlorpheniramine
1181283|NCT01233934|Gel
1181284|NCT01233934|Cream
1181285|NCT01233882|Renal impairment
1181286|NCT01233882|healthy volunteers
1181287|NCT01233869|Bosutinib
1181288|NCT01233869|Autosomal Dominant Polycystic Kidney Disease
1181289|NCT01233856|ADHD
1181290|NCT01233843|induction chemotherapy
1181291|NCT01233843|followed by irradiation and concurrent Erbitux, or radiochemotherapy
1181292|NCT01233830|safety, tolerability, pharmacokinetics, AZD2423, Japanese
1181293|NCT01233817|Spinal muscular atrophy
1181294|NCT01233817|Neuromuscular disorder
1181295|NCT01233817|Progressive strength training
1181296|NCT01233817|Children
1181297|NCT01233804|influenza vaccination rates
1181298|NCT01233791|high tone pelvic floor dysfunction
1181299|NCT01233791|levator pain
1181300|NCT01233791|dyspareunia
1181301|NCT01233778|Cardiovascular disease
1181302|NCT01233778|Omega-3 fatty acids
1181303|NCT01233778|Inflammation
1181304|NCT01233778|Endothelial function
1181305|NCT01233778|Canola oil
1181306|NCT01233765|Periodontitis
1181307|NCT01233765|Neutrophil
1181308|NCT01233765|Inflammation
1181309|NCT01233752|systemic morphine analgesia
1181311|NCT01233752|pharmacokinetics
1181312|NCT01233739|rhizarthrosis
1181313|NCT01233739|Chondroitin sulfate
1181314|NCT01233739|Placebo
1181315|NCT01233726|Critical illness
1181316|NCT01233726|Hyperglycemia
1181317|NCT01233726|Mechanical Ventilation
1181318|NCT01233726|Enteral nutrition
1181319|NCT01233726|T-Diet plus Diabet IR
1181320|NCT01233726|Malnutrition
1181321|NCT01233726|Insulin resistance
1181322|NCT01233726|Metabolic stress
1181323|NCT01233713|Emergency Surgery
1181324|NCT01233713|Bowel perforation
1181325|NCT01233713|Diverticulitis
1181326|NCT01233713|Neoplasms
1181327|NCT01233713|Postoperative Complications
1181328|NCT01233713|Randomized Controlled Trial
1181329|NCT01233700|living donation
1181330|NCT01233700|organ donation
1181331|NCT01233700|psychological adaptation
1181332|NCT01233700|mental health
1181333|NCT01233700|physical well-being
1181334|NCT01233700|interpersonal relations
1181335|NCT01233700|quality of life
1181336|NCT01233700|psychosocial factors
1181340|NCT01232946|Diabetes
1181341|NCT01232946|Myocardial metabolism
1181342|NCT01232933|PICC
1181343|NCT01232920|uveitis
1181344|NCT01232920|antimetabolite
1181345|NCT01232920|immunosuppressive
1181346|NCT01232920|clinical trial
1181347|NCT01232907|Spinal Cord Injury (SCI)
1181348|NCT01232894|indacaterol
1181349|NCT01232894|COPD
1181350|NCT01232894|Long-acting beta2-agonist (LABA)
1181351|NCT01232868|Innate immunity
1181352|NCT01232868|Adaptive immunity
1181353|NCT01232868|Slu shot
1181354|NCT01232868|Elderly
1181355|NCT01232855|adult acute myeloid leukemia with t(15;17)(q22;q12)
1181356|NCT01232855|adult acute promyelocytic leukemia (M3)
1181357|NCT01232855|childhood acute promyelocytic leukemia (M3)
1181358|NCT01232855|adult acute myeloid leukemia in remission
1181359|NCT01232855|untreated adult acute myeloid leukemia
1181360|NCT01232855|childhood acute myeloid leukemia in remission
1181361|NCT01232855|untreated childhood acute myeloid leukemia and other myeloid malignancies
1181362|NCT01232842|adult acute myeloid leukemia
1181363|NCT01232842|childhood acute myeloid leukemia/other myeloid malignancies
1181364|NCT01232803|Rectal Microbicides
1181365|NCT01232803|Tenofovir
1181366|NCT01232803|Rectal use
1181367|NCT01232803|Rectal mucosal damage
1181368|NCT01232790|Schizophrenia
1181369|NCT01232790|working memory
1181370|NCT01232790|N-Acetylcysteine
1181371|NCT01232777|Retinopathy of Prematurity
1181372|NCT01232777|Bevacizumab
1181373|NCT01232777|Avastin
1181374|NCT01232777|Vascular Endothelial Growth Factor
1181375|NCT01232751|health
1181376|NCT01232751|women
1181377|NCT01232725|BSID III
1181378|NCT01232725|Human Milk
1181379|NCT01232725|Donor Human Milk
1181380|NCT01232725|Preterm infant
1181381|NCT01232725|Breastfeeding
1181382|NCT01233648|heart failure
1181383|NCT01233648|CRT-D
1181384|NCT01233609|retinitis pigmentosa
1181385|NCT01233609|valproic acid
1181386|NCT01233609|visual field
1181387|NCT01233596|congenital nasolacrimal duct obstruction
1181388|NCT01233596|monocanalicular intubation
1181389|NCT01233596|bicanalicular intubation
1181390|NCT01233596|complications
1181391|NCT01233583|Regulatory T-cells, psoriasis, IL-10.
1181392|NCT01233570|Cutaneous Crohns Disease
1181393|NCT01233570|Topical Tacrolimus
1181394|NCT01233570|Protopic
1181395|NCT01233570|Metastatic Crohns Disease
1181396|NCT01233570|Pyoderma Gangrenosum
1181397|NCT01233570|Granulomatous chelitis
1181398|NCT01233570|Oral crohns disease
1181399|NCT01233570|Perianal crohns disease
1181400|NCT01233544|Colorectal carcinoma
1181401|NCT01233544|Liver metastases
1181402|NCT01233544|Stereotactic body radiation therapy
1181403|NCT01233544|Radiofrequency ablation
1181404|NCT01233518|CCTA Coronary Artery Disease CAD
1181405|NCT01233492|adult glioblastoma
1181406|NCT01233492|adult giant cell glioblastoma
1181407|NCT01233492|adult gliosarcoma
1181408|NCT01233479|untreated childhood medulloblastoma
1181409|NCT01233479|untreated childhood cerebellar astrocytoma
1181410|NCT01233479|untreated childhood cerebral astrocytoma
1181411|NCT01233479|untreated childhood brain stem glioma
1181412|NCT01233479|childhood medulloepithelioma
1181413|NCT01233479|childhood infratentorial ependymoma
1181414|NCT01233479|newly diagnosed childhood ependymoma
1181415|NCT01233479|childhood atypical teratoid/rhabdoid tumor
1181416|NCT01233414|Pervasive Developmental Disorder
1181417|NCT01233414|Autism
1181418|NCT01233414|Children
1181419|NCT01233414|Behavior Therapy
1181420|NCT01233414|Aggression
1181421|NCT01233414|Tantrums
1181422|NCT01233414|Noncompliance
1181423|NCT01233401|Pertussis, Vaccination, Adult
1181424|NCT01233375|cancer
1181425|NCT01233375|metastatic
1181426|NCT01233375|pancreatic
1181427|NCT01233375|pancreas
1181428|NCT01233375|adenocarcinoma
1181429|NCT01233375|gemcitabine
1181430|NCT01233375|human equilibrative nucleoside transporter-1 (hENT1)
1181431|NCT01233375|CO-1.01
1181432|NCT01233375|CO-101
1181433|NCT01233375|CO101
1181434|NCT01233375|Stage 4
1181435|NCT01233375|Stage IV
1181436|NCT01233375|Gemcitabine-Refractory
1181437|NCT01233375|Second-Line Therapy
1181438|NCT01233362|Cholera
1181439|NCT01233362|Vaccine
1181440|NCT01233362|Kolkata
1181441|NCT01233362|West Bengal
1181442|NCT01233362|India
1181443|NCT01233362|Immunogenicity
1181444|NCT01233362|Vaccination Schedules
1181445|NCT01233349|overweight
1181446|NCT01233349|obesity
1181447|NCT01233349|weight loss
1181448|NCT01233349|body fat
1181449|NCT01233349|waist circumference
1181450|NCT01233349|satiety
1181451|NCT01233336|ACS,
1181452|NCT01233336|HGF,
1181453|NCT01233336|myocardial infarction
1181454|NCT01233336|markers of myocardial injury
1181455|NCT01233336|acute coronary syndrome (ACS)
1181456|NCT01233336|prognostic factors in patients with ACS
1181457|NCT01233323|Phrenic nerve stimulation
1181458|NCT01233323|Cardiac Resynchronization Therapy
1181459|NCT01233323|Heart Failure
1181460|NCT01233323|Heart Diseases
1181461|NCT01233310|Crohn's Disease
1181462|NCT01233297|wheeze
1181463|NCT01233297|infections
1181464|NCT01233271|algorithm
1181465|NCT01233271|tight glycemic control
1181466|NCT01233271|glucose control
1181467|NCT01233271|intensive care
1181468|NCT01233271|insulin
1181469|NCT01233271|ICU
1181470|NCT01233258|Haemophilia treatment
1181471|NCT01233258|rFVIII
1181472|NCT01233245|Multiple Sclerosis
1181473|NCT01233245|Adherence
1181474|NCT01233245|Interferon beta-1b
1181475|NCT01233245|Coping Styles
1181476|NCT01233232|Chronic Obstructive Pulmonary Disease, Neutrophil, Respiratory Disease
1181477|NCT01233219|systemic morphine analgesia
1181478|NCT01233219|pharmacogenetics
1181479|NCT01233219|pharmacokinetics
1181480|NCT01233206|PCOS
1181481|NCT01233206|Polycystic ovary syndrome
1181482|NCT01233206|Cancelled cycles
1181483|NCT01233206|OHSS
1181484|NCT01233206|Infertility
1181485|NCT01233193|Home blood pressure measurement
1181486|NCT01233193|Pharmaceutical Services
1181487|NCT01233193|Medication adherence
1181488|NCT01233193|hypertension management
1181489|NCT01233193|Blood Pressure
1181490|NCT01233180|neck pain
1181491|NCT01233180|massage
1181492|NCT01233180|hyperthermia, induced
1181493|NCT01233180|touch perception
1181494|NCT01233180|randomized controlled trial
1181495|NCT01233167|dual antiplatelet therapy
1181496|NCT01233167|sirolimus drug-eluting stent
1181497|NCT01233167|major adverse cardiac events
1181498|NCT01233167|bleeding
1181499|NCT01233141|peripheral artery disease stage IV (Fontaine's classification) or stage 5 and 6 (Rutherford's classification
1181500|NCT01233102|liver Cirrhosis
1181501|NCT01233102|Mesenchymal stem cells
1181502|NCT01233102|Hepatic artery infusion
1181503|NCT01233102|Intravenous infusion
1181504|NCT01233089|Myopia
1181505|NCT01233089|contact lenses
1181506|NCT01233089|children
1181507|NCT01233063|behavior change
1181508|NCT01233063|physical activity
1181509|NCT01233063|nutrition
1181510|NCT01233063|fruits and vegetables
1181511|NCT01233063|saturated fat
1181512|NCT01233063|trans fat
1181513|NCT01233063|added sugars
1181514|NCT01233063|email
1181515|NCT01233063|web
1181516|NCT01233063|obesity
1181517|NCT01233063|aging
1181518|NCT01233050|undergoing elective colon and /or rectal surgical procedures involving an abdominal incision
1181519|NCT01233024|Adult
1181520|NCT01233024|Women
1181521|NCT01233024|Dietary Fiber
1181522|NCT01233024|Satiety Response
1181523|NCT01233024|Food Intake
1181524|NCT01233011|Intubating laryngeal airway
1181525|NCT01233011|Pediatric
1181526|NCT01233011|Observational study
1181527|NCT01232998|Patient Satisfaction
1181528|NCT01232985|Atopic Dermatitis
1181529|NCT01232985|Pruritus
1181530|NCT01232712|MUC1
1181531|NCT01232712|ImMucin
1181532|NCT01232712|Vaccine
1181533|NCT01232712|Multiple Myeloma
1181534|NCT01232699|obesity
1181535|NCT01232699|weight loss
1181536|NCT01232699|internet treatment
1181537|NCT01232699|motivational interviewing
1181538|NCT01232686|Communicable Diseases
1181539|NCT01232686|Epidemiology
1181540|NCT01232686|Population surveillance
1181541|NCT01232686|Computerized Medical Record
1181542|NCT01232686|Data collection
1181543|NCT01232673|Critical Limb Ischemia
1181544|NCT01232673|Bone-Marrow Aspiration Concentrate
1181545|NCT01232673|Diabetes Mellitus
1181546|NCT01232673|Major Amputation
1181547|NCT01232647|osteoporosis
1181548|NCT01232647|vitamin K
1181549|NCT01232647|BONE MINERAL DENSITY
1181550|NCT01232647|BIOCHEMICAL MARKERS OF BONE TURNOVER
1181551|NCT01232634|pediatrics
1181552|NCT01232634|haemophilia
1181553|NCT01232634|ultrasound
1181554|NCT01232634|MRI
1181555|NCT01232634|arthropathy
1181556|NCT01232608|Coronary Artery Disease
1181557|NCT01232608|Atherosclerosis.
1181558|NCT01232608|Diabetes Mellitus, type 2
1181559|NCT01232608|Exercise
1181560|NCT01232608|HbA1c
1181561|NCT01232608|Carotid Atherosclerotic Disease
1181562|NCT01232608|Inflammation
1181563|NCT01232595|Clostridium difficile,
1181564|NCT01232595|C. difficile,
1181565|NCT01232595|CDI,
1181566|NCT01232595|Clostridium difficile-associated disease,
1181567|NCT01232595|CDAD,
1181568|NCT01232595|pseudomembranous colitis,
1181569|NCT01232595|PMC,
1181570|NCT01232595|antibiotic-associated diarrhea
1181571|NCT01232582|Lower back pain, Facets joints Osteoarthritis
1181572|NCT01232556|inotuzumab ozogamicin
1181573|NCT01232556|aggressive Non-Hodgkin lymphoma
1181574|NCT01232556|diffuse large b-cell lymphoma
1181575|NCT01232556|relapsed/refractory lymphoma
1181576|NCT01232543|Atopic Dermatitis
1181577|NCT01232530|Malria, ACT, Safety, Efficacy, pregarnancy
1181578|NCT01232504|Allo-HSCT
1181579|NCT01232504|rhGM-CSF
1181580|NCT01232504|Systemic fungal infection (SFI)
1181581|NCT01232478|Cystic Fibrosis
1181582|NCT01232478|Adherence
1181583|NCT01232478|Problem-Solving
1181584|NCT01232478|Adolescents
1181585|NCT01232478|Education
1181586|NCT01232478|Skills Remediation
1181587|NCT01232465|sperm DNA integrity
1181588|NCT01232465|Toluidine blue assay (TBA)
1181589|NCT01232465|IVF outcome
1181590|NCT01232452|lung cancer
1181591|NCT01232452|advanced
1181592|NCT01232452|non-small cell
1181593|NCT01232413|Thorough QT (TQT)
1181594|NCT01232413|ASP1941
1181595|NCT01232400|subarachnoid hemorrhage
1181596|NCT01232400|esmolol
1181597|NCT01232400|cardiac function
1181598|NCT01232400|cardiac electrophysiology
1181599|NCT01232387|Fetomaternal hemorrhage
1181600|NCT01232387|neonatal anemia
1181601|NCT01232387|perinatal epidemiology
1181602|NCT01232387|Kleihauer-Betke
1181603|NCT01232387|flow cytometry
1181604|NCT01232374|Nimotuzumab
1181605|NCT01232374|local advanced esophageal squamous cell carcinoma
1181606|NCT01232374|chemo-irradiation
1181607|NCT01232361|ADHD
1181608|NCT01232361|HIV
1181609|NCT01232361|Pharmacokinetics
1181610|NCT01232348|bronchial asthma
1181611|NCT01232348|Symbicort
1181612|NCT01232335|bronchial asthma
1181613|NCT01232335|Symbicort
1181614|NCT01232335|long term use,
1181615|NCT01232322|bronchial asthma
1181616|NCT01232322|Pulmicort Respules
1181617|NCT01232322|long term use
1181618|NCT01232322|pediatrics
1181619|NCT01232309|Arterial Health
1181620|NCT01232309|Fiber
1181621|NCT01232309|Chitin-glucan
1181622|NCT01232309|oxidized LDL
1181623|NCT01232296|Hepatocellular Carcinoma
1181624|NCT01232296|HCC
1181625|NCT01232296|Liver cancer
1181626|NCT01232296|Child Pugh A
1181627|NCT01232296|HCC Stage C
1181628|NCT01232257|Chronic kidney disease
1181629|NCT01232257|Chronic kidney failure
1181630|NCT01232257|End stage kidney disease
1181631|NCT01232257|End stage renal disease
1181632|NCT01232257|Hydrogen sulfide
1181633|NCT01232257|N-acetylcysteine
1181634|NCT01232257|Acetylcysteine
1181635|NCT01232244|Incretin hormones
1181636|NCT01232244|Glucagon
1181637|NCT01232244|Satiety
1181638|NCT01232244|Hunger
1181639|NCT01232244|Energy expenditure
1181640|NCT01232231|methicillin-resistant Staphylococcus aureus
1181641|NCT01232231|decolonization
1181642|NCT01232231|random allocation
1181643|NCT01232231|outpatient
1181644|NCT01232218|Cerebral Vascular Accident
1181645|NCT01232218|Stroke
1181646|NCT01232218|Hemiplegic
1181647|NCT01232218|Shoulder pain
1181648|NCT01232218|range of motion
1181649|NCT01232218|scapula
1181650|NCT01232218|mobilization
1181651|NCT01232205|antioxidant supplementation
1181652|NCT01232205|preeclampsia
1181653|NCT01232153|chest tube
1181654|NCT01232153|preoxygenation
1181655|NCT01232153|NIV
1181656|NCT01232153|out-of-hospital
1181657|NCT01232153|patients needing tracheal chest tube managed by Medical Mobile Emergency rescue services
1181658|NCT01232140|COPD
1181659|NCT01232140|exacerbation
1181660|NCT01232140|antibiotic treatment
1181661|NCT01232140|CRP
1181662|NCT01232140|sputum
1181663|NCT01232140|inflammation
1181664|NCT01232101|covered, uncovered, palliative treatment, stent
1181665|NCT01232088|drug labelling
1181666|NCT01232088|standardized drug syringe labelling
1181667|NCT01232088|European ICU
1181668|NCT01232075|Letrozole ,Clomiphene citrate , IUI,unexplained infertility
1181669|NCT01232062|breast neoplasm
1181670|NCT01232062|Neoplasm Metastasis
1181671|NCT01232062|Drug Therapy
1181672|NCT01232049|healthy volunteers
1181673|NCT01232036|healthy volunteers
1181674|NCT01232023|Indobufen
1181675|NCT01232023|healthy volunteers
1181676|NCT01232010|SK-3530
1181677|NCT01232010|renal impairment
1181678|NCT01232010|healthy volunteers
1181679|NCT01231997|Udenafil
1181680|NCT01231997|DA-8159
1181681|NCT01231997|renal impairment
1181682|NCT01231997|healthy volunteers
1181683|NCT01231984|diabetes
1181684|NCT01231984|obesity
1181685|NCT01231984|hypoglycemia
1181686|NCT01231984|hyperglycemia
1181687|NCT01231984|pen needle
1181688|NCT01231971|amyloid
1181689|NCT01231971|plaques
1181690|NCT01231971|neuroimaging
1181691|NCT01231971|biomarkers
1181692|NCT01231971|cognition disorder
1181693|NCT01231971|early detection
1181694|NCT01231971|Amnestic MCI
1181695|NCT01231971|pre-dementia
1181696|NCT01231971|dementia
1181697|NCT01231971|Alzheimer's disease
1181698|NCT01231971|tau
1181699|NCT01231958|Puerto Rican; CVD; Hispanic; health disparities; allostatic load; diet
1181700|NCT01231945|Cervical Cancer
1181701|NCT01231945|Human Papilloma Virus (HPV)
1181702|NCT01231945|Cervical Intraepithelial Neoplasia (CIN)
1181703|NCT01231932|Fatigue
1181704|NCT01231932|Cancer
1181705|NCT01231932|Cancer Therapy
1181706|NCT01231932|Cancer Treatment
1181707|NCT01231932|Gene Expression Patterns
1181708|NCT01231893|human, spinal cord injury, olfactory ensheathing cells, transplantation
1181709|NCT01231880|Malaria
1181710|NCT01231867|Coronary Heart Disease
1181711|NCT01231867|Acute Coronary Syndrome
1181712|NCT01231867|Drug interactions
1181713|NCT01231867|Clopidogrel
1181714|NCT01231867|Proton Pump Inhibitors
1181715|NCT01231867|Gastrointestinal Hemorrhage
1181716|NCT01231854|atopic hand dermatitis
1181717|NCT01231854|Chronic hand dermatitis
1181718|NCT01231828|sleep
1181719|NCT01231828|cirrhosis
1181720|NCT01231828|encephalopathy
1181721|NCT01231828|simulated driving
1181722|NCT01231828|sleep disorders
1181723|NCT01231815|Heart transplantation
1181724|NCT01231789|cardiac surgery
1181725|NCT01231789|RIPC
1181726|NCT01231789|brain injury
1181727|NCT01231776|cardiopulmonary bypass
1181728|NCT01231776|sleep
1181729|NCT01231776|acupuncture
1181730|NCT01231763|HIV prevention
1181731|NCT01231763|Vaginal film
1181732|NCT01231763|Microbicide
1181733|NCT01231763|Administration, intravaginal
1181734|NCT01231737|Prophylasy
1181735|NCT01231737|recurrent urinary tract infection
1181736|NCT01231737|prulifloxacin
1181737|NCT01231737|phosphomycin
1181738|NCT01231711|depression
1181739|NCT01231711|post traumatic stress syndrome
1181740|NCT01231711|functional status
1181741|NCT01231711|veteran
1181742|NCT01231711|military
1181743|NCT01231711|stigma
1181744|NCT01231711|mental health self-efficacy
1181745|NCT01231698|septic shock
1181746|NCT01231698|esmolol
1181747|NCT01231698|tachycardia
1181748|NCT01231698|betablockers
1181749|NCT01231685|Liver fibrosis
1181750|NCT01231685|HIV
1181751|NCT01231685|Hepatitis C Virus
1181752|NCT01231685|Coinfection
1181753|NCT01231659|RAD001 (Everolimus)
1181754|NCT01231659|Letrozole
1181755|NCT01231659|Breast cancer
1181756|NCT01231659|Metastatic Breast cancer
1181757|NCT01231659|Estrogen receptor positive
1181758|NCT01231659|Failure of Tamoxifen
1181759|NCT01231659|Anastrozole or Examestane
1181760|NCT01231646|Folate Receptor Autoantibodies
1181761|NCT01231646|Epilepsy
1181762|NCT01231646|Psychiatric conditions
1181763|NCT01231633|Macular Edema
1181764|NCT01231633|Central Retinal Vein Occlusion
1181765|NCT01231620|Seasonal Influenza
1181766|NCT01231620|Pandemic
1181767|NCT01231620|Orthomyxoviridae Infections
1181768|NCT01231620|Influenza
1181769|NCT01231620|Influenza A Virus, H1N1 Subtype
1181770|NCT01231620|Enzyme Inhibitors
1181771|NCT01231620|Influenza, seasonal
1181772|NCT01231620|Respiratory Tract Diseases
1181773|NCT01231620|Zanamivir
1181774|NCT01231620|Pharmacologic Actions
1181775|NCT01231620|Antiviral Agents
1181776|NCT01231620|Anti-Infective Agents
1181777|NCT01231620|H1N1
1181778|NCT01231620|Neuraminidase inhibitor
1181779|NCT01231620|Influenza B virus
1181780|NCT01231594|BRAF Inhibitor
1181781|NCT01231594|Cancer
1181782|NCT01231594|Safety
1181783|NCT01231594|GSK2118436
1181784|NCT01231594|BRAF mutation positive tumors
1181785|NCT01231568|particle size
1181786|NCT01231568|food effect; high fat meal
1181787|NCT01231568|GSK2118436
1181788|NCT01231568|pharmacokinetic
1181789|NCT01231568|BRAF inhibitor
1181790|NCT01231568|BRAF positive tumor
1181791|NCT01231555|antiretroviral
1181792|NCT01231555|HAART
1181793|NCT01231555|NNRTI
1181794|NCT01231555|emtricitabine
1181795|NCT01231555|Sexually Transmitted Disease
1181796|NCT01231555|antiretroviral therapy (ART)-naive adults
1181797|NCT01231555|Immunologic Deficiency Syndrome
1181798|NCT01231555|tenofovir
1181799|NCT01231555|abacavir
1181800|NCT01231555|Retroviridae Infections
1181801|NCT01231555|GSK2248761
1181802|NCT01231555|lamivudine
1181803|NCT01231555|Acquired ImmunoDeficiency Syndrome (AIDS)
1181804|NCT01231555|HIV infection
1181805|NCT01231555|efavirenz
1181806|NCT01231542|GSK1349572
1181807|NCT01231542|pharmacokinetics
1181808|NCT01231542|dolutegravir
1181809|NCT01231542|integrase
1181810|NCT01231542|rifabutin
1181811|NCT01231542|rifampin
1181812|NCT01231516|ART-experienced
1181813|NCT01231516|Integrase inhibitor
1181814|NCT01231516|Raltegravir
1181815|NCT01231516|GSK1349572
1181816|NCT01231516|Integrase inhibitor naive
1181817|NCT01231503|Africa
1181818|NCT01231503|malaria vaccine
1181819|NCT01231503|schedule
1181820|NCT01231503|EPI
1181821|NCT01231503|Plasmodium falciparum
1181822|NCT01231477|anaesthetic techniques, inhalation
1181823|NCT01231477|sevoflurane
1181824|NCT01231477|Cytokines
1181825|NCT01231477|Immune response
1181826|NCT01231464|safety
1181827|NCT01231464|efficacy
1181828|NCT01231464|placebo
1181829|NCT01231464|allergic rhinitis
1181830|NCT01231464|fluticasone furoate
1181831|NCT01231451|HIV Infection
1181832|NCT01231438|Renal failure stage 3B
1181833|NCT01231425|Back pain
1181834|NCT01231425|cervicalgia
1181835|NCT01231425|dorsalgia
1181836|NCT01231425|lumbalgia
1181837|NCT01231425|acupuncture
1181838|NCT01231386|Female Breast Cancer
1181839|NCT01231386|miRNA expression
1181840|NCT01231386|Neoadjuvant/Adjuvant Treatment
1181841|NCT01231386|Locally and Inflammatory Breast Cancer
1181842|NCT01231373|varicose veins
1181843|NCT01231360|claudication
1181844|NCT01231360|peripheral artery disease
1181845|NCT01231360|PAD
1181846|NCT01231347|pancreas
1181847|NCT01231347|gemcitabine
1181848|NCT01231347|metastatic
1181849|NCT01231347|jaundice
1181850|NCT01231321|Adalimumab added to inadequate standard anti-rheumatic therapy in patients with active Rheumatoid Arthritis
1181851|NCT01231256|Quality of life
1181852|NCT01231256|preventive health consultation
1181853|NCT01231256|General practice
1181854|NCT01231256|resources
1181855|NCT01231256|life style
1181856|NCT01231243|tooth bleaching, bleaching agent, hydrogen peroxide
1181857|NCT01231230|asthma, corticosteroids, bronchodilator, airway blood flow
1181858|NCT01231204|Breast Cancer
1181859|NCT01231204|Mastectomy
1181860|NCT01231204|UCSD
1181861|NCT01231204|Surgery
1181862|NCT01231204|PVB Catheter
1181863|NCT01231204|Paravertebral Catheter
1181864|NCT01231204|Breast Pain
1181865|NCT01231204|Mastectomy Pain
1181866|NCT01231204|Postoperative Pain
1181867|NCT01231139|Brain Injury
1181868|NCT01231139|Temperature
1181869|NCT01231139|Paracetamol
1181870|NCT01231139|Phase 2
1181871|NCT01231139|TBI
1181872|NCT01231126|Induced labor
1181873|NCT01231126|Misoprostol
1181874|NCT01231126|Postpartum blood
1181875|NCT01231126|Erythrocyte indices
1181876|NCT01231126|Vaginal delivery
1181877|NCT01231113|malaria,
1181878|NCT01231113|pregnancy,
1181879|NCT01231113|dihydroartemisinin-piperaquine,
1181880|NCT01231113|efficacy,
1181881|NCT01231113|safety,
1181882|NCT01231113|Ghana
1181883|NCT01231087|energy expenditure
1181884|NCT01231087|morbid obesity
1181885|NCT01231087|bariatric surgery
1181886|NCT01231087|nutritional follow-up
1181887|NCT01231074|obesity
1181888|NCT01231074|weight gain
1181889|NCT01231074|metformin
1181890|NCT01231074|psychotropic drugs
1181891|NCT01231061|spine metastasis
1181892|NCT01231061|SBRT
1181893|NCT01231061|Radiosurgery
1181894|NCT01231035|acute cardiac syndrome
1181895|NCT01231035|stent thrombosis
1181896|NCT01231035|platelet function
1181897|NCT01231035|antiplatelet therapy
1181898|NCT01231022|breast neoplasm
1181899|NCT01231022|Neoplasm Metastasis
1181900|NCT01231022|Stem Cells
1181901|NCT01231022|Drug-Induced Liver Injury
1181902|NCT01230996|cervical adenocarcinoma
1181903|NCT01230996|cervical adenosquamous cell carcinoma
1181904|NCT01230996|cervical squamous cell carcinoma
1181905|NCT01230996|stage IB cervical cancer
1181906|NCT01230996|stage IIA cervical cancer
1181907|NCT01230996|stage IIB cervical cancer
1181908|NCT01230996|stage III cervical cancer
1181909|NCT01230996|stage IVA cervical cancer
1181910|NCT01230983|stage III childhood lymphoblastic lymphoma
1181911|NCT01230983|stage IV childhood lymphoblastic lymphoma
1181912|NCT01230983|untreated childhood acute lymphoblastic leukemia
1181913|NCT01230983|T-cell childhood acute lymphoblastic leukemia
1181914|NCT01230983|cardiac toxicity
1181915|NCT01230957|Clostridium difficile infection
1181916|NCT01230957|Diarrhea
1181917|NCT01230957|Pseudomembranous colitis
1181918|NCT01230957|Clostridium Difficile Toxoid Vaccine
1181919|NCT01230957|ACAM-CDIFF™ vaccine
1181920|NCT01230944|GERD
1181921|NCT01230944|LNF
1181922|NCT01230944|CNF
1181923|NCT01230944|Laparoscopic Nissen fundoplication
1181924|NCT01230944|Open Nissen fundoplication
1181925|NCT01230944|Antireflux surgery
1181926|NCT01230931|Acetabulum
1181927|NCT01230931|Fracture
1181928|NCT01230931|Hemostatis
1181929|NCT01230931|Vitagel
1181930|NCT01230931|Fibrin sealant
1181931|NCT01230918|Hypertrophic Cardiomyopathy
1181932|NCT01230918|Acute Coronary Syndrome
1181933|NCT01230918|Myocardial Fibrosis
1181934|NCT01230918|Fibrogenesis
1181935|NCT01230918|Intimal Hyperplasia
1181936|NCT01230918|Sudden Death
1181937|NCT01230918|avB3 Integrin Expression
1181938|NCT01230905|Androgen Suppression Therapy
1181939|NCT01230905|Hormonal Toxicity
1181940|NCT01230905|Quantitative PET
1181941|NCT01230905|Myocardial blood flow
1181942|NCT01230905|Coronary blood flow reserve
1181943|NCT01230905|Endothelial dysfunction
1181944|NCT01230905|Coronary Artery Disease
1181945|NCT01230879|Aging lung
1181946|NCT01230879|Airway remodeling
1181947|NCT01230879|Airway segmentation
1181948|NCT01230879|Chest CT
1181950|NCT01230840|fiber
1181951|NCT01230840|calcium
1181952|NCT01230840|magnesium
1181953|NCT01230827|Juvenile Idiopathic Arthritis
1181954|NCT01230827|golimumab
1181955|NCT01230827|juvenile arthritis
1181956|NCT01230827|GO KIDS
1181957|NCT01230827|anti TNF alpha medications
1181958|NCT01230827|juvenile psoriatic arthritis
1181959|NCT01230814|Bacterial vaginosis, metronidazole, miconazole, vulvovaginal candidiasis, trichomonas vaginalis, women, Kenya
1181960|NCT01230788|ALL
1181961|NCT01230788|Leukemia
1181962|NCT01230788|Rituximab
1181963|NCT01230788|Pediatrics
1181964|NCT01230762|Dapoxetine, Orgasmic disorder
1181965|NCT01230762|Premature ejaculation
1181966|NCT01230762|Sexual dysfunction
1181967|NCT01230762|Sexual intercourse
1181968|NCT01230762|Ejaculation
1181969|NCT01230762|Erectile Dysfunction
1181970|NCT01230749|Diabetes Mellitus, Type 2
1181971|NCT01230749|Diabetes Mellitus
1181972|NCT01230749|Hyperglycemia
1181973|NCT01230749|JNJ-41443532
1181974|NCT01230749|Pioglitazone
1181975|NCT01230749|Placebo
1181976|NCT01230697|Advanced
1181977|NCT01230697|hepatocarcinoma
1181978|NCT01230684|CEUS, Abdominal Aortic Aneurysm, Endoleaks
1181979|NCT01230658|prophylactic enoxaparin
1181980|NCT01230658|Roux en Y gastric bypass surgery
1181981|NCT01230632|assisted reproduction technology
1181982|NCT01230632|Metabolic risk factors
1181983|NCT01230632|In Vitro Fertilisation
1181984|NCT01230606|Percutaneous Intervention
1181985|NCT01230606|Percutaneous Coronary Intervention
1181986|NCT01230606|Catheterization
1181987|NCT01230606|Coronary Catheterization
1181988|NCT01230606|Same day Discharge
1181989|NCT01230606|Next Day Discharge
1181990|NCT01230606|Patient Satisfaction
1181991|NCT01230606|Multi-Center
1181992|NCT01230606|Randomized
1181993|NCT01230606|Low-risk PCI
1181994|NCT01230606|BlindedClosure device
1181995|NCT01230606|Vascular closure device
1181996|NCT01230580|Protease Inhibitors
1181997|NCT01230580|RNA virus infections
1181998|NCT01230580|Virus diseases
1181999|NCT01230580|Sexually Transmitted Diseases viral
1182000|NCT01230580|Immune system diseases
1182001|NCT01230580|Anti-infective Agents
1182002|NCT01230580|Drug resistance
1182003|NCT01230567|Problem wounds
1182004|NCT01230567|Non healing wounds
1182005|NCT01230567|BCC
1182006|NCT01230567|SCC
1182007|NCT01230567|Vasculitis
1182008|NCT01230554|contact lens
1182009|NCT01230541|Semen characteristics
1182010|NCT01230541|Erectile Dysfunction
1182011|NCT01230515|Oncology Pain Management in outpatient hospice setting
1182012|NCT01230502|immunosuppression
1182013|NCT01230502|anti-rejection
1182014|NCT01230502|immune tolerance
1182015|NCT01230476|Locally advanced nasopharyngeal carcinoma
1182016|NCT01230476|Neoadjuvant chemotherapy
1182017|NCT01230476|Chemoradiation
1182018|NCT01230476|Cetuximab
1182019|NCT01230463|Pain, Postoperative
1182020|NCT01230463|Ketorolac
1182021|NCT01230463|Anti-Inflammatory Agents, Non-Steroidal
1182022|NCT01230463|Intraoperative Care
1182023|NCT01230450|urodynamic urinary incontinence, sub-urethral tape
1182024|NCT01230437|montelukast
1182025|NCT01230437|asthma
1182026|NCT01230437|allergic rhinitis
1182027|NCT01230437|nasal epithelial cells
1182028|NCT01230437|inflammatory mediators
1182029|NCT01230424|OA
1182030|NCT01230424|Knee arthritis
1182031|NCT01230424|MRI
1182032|NCT01230424|Steroid
1182033|NCT01230411|Episodic migraine
1182034|NCT01230385|lersivirine
1182035|NCT01230385|UK-453
1182036|NCT01230385|061
1182037|NCT01230385|safety
1182038|NCT01230385|tolerability
1182039|NCT01230385|pharmacokinetics
1182040|NCT01230385|HIV
1182041|NCT01230385|non-nucleoside reverse transcriptase inhibitor
1182042|NCT01230385|NNRTI
1182043|NCT01230359|Autism
1182044|NCT01230359|Children
1182045|NCT01230359|ASD
1182046|NCT01230359|Vitamin B6
1182047|NCT01230359|Magnesium
1182048|NCT01230320|Cost estimates
1182049|NCT01230320|Complete Denture
1182050|NCT01230320|Dental Economics
1182051|NCT01230320|Dental Impression Technique
1182052|NCT01230320|Denture Retention
1182053|NCT01230320|Edentulous
1182054|NCT01230320|Edentulism
1182055|NCT01230320|Oral Health-Related Quality of Life
1182056|NCT01230320|Patient Acceptance of Health Care
1182057|NCT01230320|Patient Satisfaction
1182058|NCT01230320|Quality of Health Care
1182059|NCT01230320|Quality of Life
1182060|NCT01230307|Vitamin D
1182061|NCT01230307|Systolic failure
1182062|NCT01230307|Genomics
1182063|NCT01230307|Biomarkers
1182064|NCT01230307|Exercise
1182065|NCT01230307|Quality of Life
1182066|NCT01230294|echocardiography of the right heart
1182067|NCT01230294|3D 4D echocardiography
1182068|NCT01230294|strain measurement
1182069|NCT01230294|chronic heart failure
1182070|NCT01230294|pulmonary hypertension
1182071|NCT01230281|C3G
1182072|NCT01230281|Oxidative stress
1182073|NCT01230281|Antioxidant
1182074|NCT01230281|Black bean
1182075|NCT01230268|C3G
1182076|NCT01230268|Oxidative stress
1182077|NCT01230268|Antioxidant
1182078|NCT01230268|Mulberry
1182079|NCT01230255|intra-abdominal pressure
1182080|NCT01230255|intra-abdominal hypertension
1182081|NCT01230255|abdominal compartment syndrome
1182082|NCT01230255|open abdomen
1182083|NCT01230255|percutaneous
1182084|NCT01230242|Mirena
1182085|NCT01230242|postplacental intrauterine device
1182086|NCT01230242|postpartum insertion
1182087|NCT01230229|Intermittent claudication
1182088|NCT01230229|Superficial femoral artery
1182089|NCT01230229|Stenting
1182090|NCT01230229|Medical treatment
1182091|NCT01230229|Quality of life
1182092|NCT01230216|coronary artery disease
1182093|NCT01230216|hypertension
1182094|NCT01230190|infants
1182095|NCT01230190|adaptive immunology
1182096|NCT01230190|atopic dermatitis
1182097|NCT01230190|probiotics
1182098|NCT01230151|Deep Brain Stimulation
1182099|NCT01230151|DBS
1182100|NCT01230151|Parkinson's disease
1182101|NCT01230151|PD
1182102|NCT01230151|Patients who have a preexisting Deep Brain Stimulation (DBS) system for the treatment of Parkinson's disease (PD)
1182103|NCT01230125|Inflammation
1182104|NCT01230125|Pain
1182105|NCT01230125|Ocular surgery
1182106|NCT01230099|Critical Illness
1182107|NCT01230099|Mechanical Ventilation
1182108|NCT01230099|Palliative Care
1182109|NCT01230099|Caregivers
1182110|NCT01230086|ICD
1182111|NCT01230086|DFT-testing
1182112|NCT01230073|ICD
1182113|NCT01230073|Home-Monitoring
1182114|NCT01230073|Quality of life
1182115|NCT01230060|ocular surgery
1182116|NCT01230060|phacoemulsification
1182117|NCT01230047|depression
1182118|NCT01230047|anxiety
1182119|NCT01230047|psychoeducation
1182120|NCT01230047|self-help
1182121|NCT01230047|psychosocial
1182122|NCT01230034|Imidapril, Ramipril, Hypertension, Type 2 diabetes mellitus, Microalbuminuria
1182123|NCT01230008|primary mediastinal lymphoma
1182124|NCT01230008|radiotherapy
1182125|NCT01230008|chemotherapy
1182126|NCT01230008|rituximab
1182127|NCT01229969|falls, balance problems, gaming systems, balance assessments
1182128|NCT01229956|childhood acute myeloid leukemia in remission
1182129|NCT01229956|recurrent childhood acute myeloid leukemia
1182130|NCT01229956|untreated childhood acute myeloid leukemia and other myeloid malignancies
1182131|NCT01229930|cervical adenocarcinoma
1182132|NCT01229930|cervical adenosquamous cell carcinoma
1182133|NCT01229930|cervical squamous cell carcinoma
1182134|NCT01229930|recurrent cervical cancer
1182135|NCT01229930|stage IVB cervical cancer
1182136|NCT01229930|stage IVA cervical cancer
1182137|NCT01229891|vitamin D fortification
1182138|NCT01229891|yogurt drink
1182139|NCT01229891|type 2 diabetes
1182140|NCT01229891|efficacy
1182141|NCT01229852|Fibromyalgia
1182142|NCT01229852|Transcranial Magnetic Stimulation
1182143|NCT01229852|Pain
1182144|NCT01229839|Carcinoma,Hepatocellular
1182145|NCT01229839|Liver Neoplasms
1182146|NCT01229839|Therapeutic
1182147|NCT01229839|Chemoembolization,
1182148|NCT01229839|TACE
1182149|NCT01229839|pharmacokinetics
1182150|NCT01229839|Iodized Oil/administration & dosage
1182151|NCT01229839|polyvinyl alcohol
1182152|NCT01229839|Humans
1182153|NCT01229826|Uterine fibroids
1182154|NCT01229826|Uterine leiomyomas
1182155|NCT01229826|MR Elastography
1182156|NCT01229826|MRI (Magnetic Resonance Imaging)
1182157|NCT01229826|Symptomatic Uterine Fibroids
1182158|NCT01229813|Untreated
1182159|NCT01229813|First line
1182160|NCT01229813|Chemotherapy
1182161|NCT01229813|Maintenance treatment
1182162|NCT01229813|KRAS wt
1182163|NCT01229813|KRAS mutated
1182164|NCT01229813|Anti-angiogenetic treatment
1182165|NCT01229813|Metronomic capecitabine
1182166|NCT01229813|bevacizumab
1182167|NCT01229813|erlotinib
1182168|NCT01229813|Translational research
1182169|NCT01229800|Polyethylene Glycol, Sodium Phosphate, Bowel preparation, Efficacy
1182170|NCT01229787|asthma
1182171|NCT01229787|allergies
1182172|NCT01229787|obesity
1182173|NCT01229761|HIV
1182174|NCT01229761|Trimethoprim-Sulfamethoxazole Combination
1182175|NCT01229761|Breast Feeding
1182176|NCT01229761|Infant Mortality
1182177|NCT01229761|Morbidity
1182178|NCT01229761|Botswana
1182179|NCT01229761|Africa
1182180|NCT01229761|Infectious disease transmission, vertical
1182181|NCT01229761|adverse drug event
1182182|NCT01229735|levetiracetam
1182183|NCT01229735|topiramate
1182184|NCT01229735|epilepsy
1182185|NCT01229735|partial seizures
1182186|NCT01229722|adherence
1182187|NCT01229722|reminders
1182188|NCT01229722|text messages
1182189|NCT01229722|SMS
1182190|NCT01229722|mHealth
1182191|NCT01229709|Tinnitus
1182192|NCT01229709|Mindfulness
1182193|NCT01229709|MBSR
1182194|NCT01229709|Mindfulness Based Stress Reduction
1182195|NCT01229709|MBTR
1182196|NCT01229696|Popliteal
1182197|NCT01229696|UCSD
1182198|NCT01229696|Postoperative pain
1182199|NCT01229696|Foot surgery
1182200|NCT01229696|Ankle surgery
1182201|NCT01229696|Popliteal Catheter
1182202|NCT01229696|Popliteal Nerve Block
1182203|NCT01229696|Lower extremity surgery
1182204|NCT01229696|Bifurcation
1182205|NCT01229696|Catheter Insertion Site
1182206|NCT01229683|UCSD
1182207|NCT01229683|Perineural Nerve Block
1182208|NCT01229683|Shoulder Surgery
1182209|NCT01229683|Pain
1182210|NCT01229683|Grip Strength
1182211|NCT01229683|Sensation
1182212|NCT01229683|Interscalene Nerve Block
1182213|NCT01229670|Heart failure
1182214|NCT01229670|Hemorheology
1182215|NCT01229670|Atherothrombosis
1182216|NCT01229670|Angiogenesis
1182217|NCT01229657|Reopening of macular hole;
1182218|NCT01229657|Visual acuity;
1182219|NCT01229657|Phacoemulsification cataract surgery;
1182220|NCT01229657|Vitrectomy
1182221|NCT01229644|Glioma
1182222|NCT01229644|Brain Cancer
1182223|NCT01229644|Recurrent glioma
1182224|NCT01229644|Low grade glioma
1182225|NCT01229644|PDGFR Inhibitor
1182226|NCT01229644|Crenolanib (CP-868,596)
1182227|NCT01229644|Neo-adjuvant Therapy
1182228|NCT01229631|Periodontitis
1182229|NCT01229631|Dietary supplementation
1182230|NCT01229618|Prostate Cancer
1182231|NCT01229592|infection
1182232|NCT01229592|catheter
1182233|NCT01229592|bacteriaemia
1182234|NCT01229592|ethanol
1182235|NCT01229579|poliomyelitis
1182236|NCT01229579|OPV
1182237|NCT01229579|zinc supplement
1182238|NCT01229579|diarrhea
1182239|NCT01229579|placebo
1182240|NCT01229579|double blind randomized control trial
1182241|NCT01229579|elemental zinc
1182242|NCT01229579|seroconversion
1182243|NCT01229579|bOPV
1182244|NCT01229579|infants
1182245|NCT01229579|immunity
1182246|NCT01229527|Colonoscopy
1182247|NCT01229527|Remifentanil
1182248|NCT01229527|Sedation
1182249|NCT01229514|Children
1182250|NCT01229514|before
1182251|NCT01229514|the age of 2 years
1182252|NCT01229475|Atrial fibrillation
1182253|NCT01229475|recurrence
1182254|NCT01229475|repeat procedure
1182255|NCT01229475|linear ablation
1182256|NCT01229475|stepwise approach
1182257|NCT01229449|Dental pain
1182258|NCT01229449|Ibuprofen
1182259|NCT01229449|Acetaminophen
1182260|NCT01229449|Nurofen Plus®
1182261|NCT01229449|Panadeine® Extra
1182262|NCT01229436|Dupuytren's
1182263|NCT01229436|treatment
1182264|NCT01229436|injection
1182265|NCT01229436|recovery
1182266|NCT01229436|health care resources
1182267|NCT01229397|Influenza
1182268|NCT01229397|Virus
1182269|NCT01229397|Vaccination
1182270|NCT01229397|Immunisation
1182271|NCT01229371|Influenza
1182272|NCT01229371|Virus
1182273|NCT01229371|Vaccination
1182274|NCT01229371|Immunisation
1182275|NCT01229358|vascular surgery
1182276|NCT01229358|wound infection
1182277|NCT01229358|wound complication
1182278|NCT01229332|Motor fluctuations levodopa pharmacokinetics carbidopa solution continuous
1182279|NCT01229319|actinic keratosis, keratocytic lesion, keratoses, cryotherapy, imiquimod
1182280|NCT01229293|Mechanical muscle function
1182281|NCT01229293|Muscle strength
1182282|NCT01229293|Hip replacement
1182283|NCT01229293|Osteoarthritis
1182284|NCT01229293|Hip arthroplasty
1182285|NCT01229280|Bioequivalence
1182286|NCT01229280|Darifenacin
1182287|NCT01229280|Healthy volunteers
1182288|NCT01229280|Postprandial
1182289|NCT01229267|Herpes zoster
1182290|NCT01229267|vaccine
1182291|NCT01229267|herpes zoster-related complications
1182292|NCT01229267|immunocompromised
1182293|NCT01229267|autologous hematopoietic cell transplants
1182294|NCT01229254|Betrixaban
1182295|NCT01229254|MK-4448
1182296|NCT01229254|nonvalvular atrial fibrillation
1182297|NCT01229241|local anesthetic
1182298|NCT01229241|epidural
1182299|NCT01229241|pharmacokinetics
1182300|NCT01229241|plasmatic concentration
1182301|NCT01229241|epidural continuous infusion
1182302|NCT01229202|trabeculectomy
1182303|NCT01229202|glaucoma surgery
1182304|NCT01229202|bevacizumab
1182305|NCT01229202|Vascular Endothelial Growth Inhibitor
1182306|NCT01229202|glaucoma
1182307|NCT01229189|Vitamin D
1182308|NCT01229189|Effectiveness
1182309|NCT01229189|Pregnant women and their neonates
1182310|NCT01229163|Motivational Incentive
1182311|NCT01229163|Automation
1182312|NCT01229163|Contingency Management
1182313|NCT01229163|Counseling Adherance
1182314|NCT01229150|Kinase Signal Transduction Pathway
1182315|NCT01229150|Tumor Mutational Analysis
1182316|NCT01229150|Tissue Immunohistochemistry
1182317|NCT01229150|MIB-1 (Ki-67) Rate
1182318|NCT01229150|PERK Level
1182319|NCT01229150|Lung Cancer
1182320|NCT01229150|Non-Small Cell Lung Cancer
1182321|NCT01229124|childhood acute myeloid leukemia/other myeloid malignancies
1182322|NCT01229085|Psoriasis, mometasone, salicylic acid.
1182323|NCT01229072|Safety
1182324|NCT01229072|Non-inferiority
1182325|NCT01229059|FFA
1182326|NCT01229059|insulin resistance
1182327|NCT01229059|mitochondria
1182328|NCT01229046|presumed sepsis
1182329|NCT01229033|Atrial fibrillation
1182330|NCT01229033|ablation
1182331|NCT01229033|atrial flutter
1182332|NCT01229020|Emphysema
1182333|NCT01229020|COPD
1182334|NCT01229020|lung sounds
1182335|NCT01229020|vibration response imaging
1182336|NCT01229007|Hemophilia A
1182337|NCT01229007|Children
1182338|NCT01228994|smoking cessation treatment
1182339|NCT01228994|baclofen
1182340|NCT01228994|Smoking cessation counselling
1182341|NCT01228968|obesity
1182342|NCT01228942|ovarian cancer
1182343|NCT01228942|fallopian tube cancer
1182344|NCT01228942|primary peritoneal cancer
1182345|NCT01228929|Dry Eye
1182346|NCT01228929|Non-invasive instruments
1182347|NCT01228929|MGD
1182348|NCT01228929|Environment
1182349|NCT01228929|Thermal Imaging
1182350|NCT01228916|tobacco
1182351|NCT01228916|smoking
1182352|NCT01228916|secondhand smoke
1182353|NCT01228903|uric acid kidney disease endothelial dysfunction
1182354|NCT01228851|Parkinson's Disease
1182355|NCT01228851|Rehabilitation
1182356|NCT01228851|Balance
1182357|NCT01228851|Exercise
1182358|NCT01228851|Parkinson's disease with balance deficits
1182359|NCT01228851|H&Y 2.5-3
1182360|NCT01228838|postherpetic neuralgia
1182361|NCT01228838|PHN
1182362|NCT01228838|capsaicin
1182363|NCT01228838|herpes zoster
1182364|NCT01228838|shingles
1182365|NCT01228838|analgesics
1182366|NCT01228838|neuropathy
1182367|NCT01228825|Cardiac surgery
1182368|NCT01228825|Cardiopulmonary bypass
1182369|NCT01228825|Antibiotic prophylaxis
1182370|NCT01228825|Cefuroxime
1182371|NCT01228812|Rheumatoid arthritis, physical activity
1182372|NCT01228799|trabeculectomy,
1182373|NCT01228799|canaloplasty,
1182374|NCT01228799|glaucoma surgery
1182375|NCT01228799|non-penetrating surgery
1182376|NCT01228786|VDR, CaSR, PTH, Cyclin D1, Ki67, PCNA
1182377|NCT01228773|Cancer Survivors, Fatigue, web-based, tailored program
1182378|NCT01228760|Castration-Resistant Prostate Cancer
1182379|NCT01228760|ASG-5ME
1182380|NCT01228760|Pharmacokinetics of ASG-5ME
1182381|NCT01228747|Levetiracetam
1182382|NCT01228747|epilepsy
1182383|NCT01228747|generalized tonic-clonic
1182384|NCT01228734|Metastatic colorectal cancer
1182385|NCT01228734|RAS wild type
1182386|NCT01228734|Cetuximab
1182387|NCT01228734|First line treatment
1182388|NCT01228734|First occurrence of metastatic colorectal cancer in Chinese subjects with RAS wildtype
1182389|NCT01228734|status
1182390|NCT01228708|Implementation strategy
1182391|NCT01228708|Chronic disease management programme
1182392|NCT01228708|COPD
1182393|NCT01228695|steroids
1182394|NCT01228695|patients treated with systemic steroids
1182395|NCT01228682|Sodium
1182396|NCT01228682|SIADH
1182397|NCT01228682|Hyponatremia
1182398|NCT01228682|Vasopressin
1182399|NCT01228682|Salt
1182400|NCT01228682|Water
1182401|NCT01228656|Psoriasis
1182402|NCT01228643|Pancreatic enzymes.
1182403|NCT01228643|To evaluate the efficacy of drugs in chronic renal failure
1182404|NCT01228630|rhinitis, loratadine, coated pill
1182405|NCT01228617|Smoking Cessation
1182406|NCT01228617|Nicotine pharmacokinetics
1182407|NCT01228604|open label
1182408|NCT01228604|Ritalin®
1182409|NCT01228604|ADHD
1182410|NCT01228578|Multivitamins
1182411|NCT01228578|HIV/AIDS
1182412|NCT01228578|Immune reconstitution
1182413|NCT01228578|Weight Gain
1182414|NCT01228578|Quality of Life
1182415|NCT01228565|Head and neck carcinoma treated by radiotherapy plus erbitux
1182416|NCT01228552|Acute Migraine Treatment
1182417|NCT01228552|Migraine Treatment
1182418|NCT01228552|Migraine
1182419|NCT01228552|Headache
1182420|NCT01228552|Treatment
1182421|NCT01228539|PTSD
1182422|NCT01228539|Anger
1182423|NCT01228539|Aggression
1182424|NCT01228539|Military
1182425|NCT01228487|Oxidative Dysbalance
1182426|NCT01228487|Oxidative Stress
1182427|NCT01228487|Biomarker
1182428|NCT01228461|Hodgkin Lymphoma Survivors
1182429|NCT01228461|Adolescent and Young Adults
1182430|NCT01228448|external beam proton radiotherapy
1182431|NCT01228448|PET
1182432|NCT01228435|NSCLC
1182433|NCT01228435|IPI-504
1182434|NCT01228435|ALK translocation
1182435|NCT01228435|Hsp90 inhibitor
1182436|NCT01228422|Will be studied 24 subjects divided Research and 2 parallel groups
1182437|NCT01228422|The treatment is a dose of 3MUI of alpha interferon 2nd
1182438|NCT01228422|There will be collection of blood at times: 0, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours.
1182439|NCT01228422|The volunteers will be hospitalized 24 hours.
1182440|NCT01228422|Will be measured labels the AUC, Tmax, Cmax, neopterin and beta2-microglobulin
1182441|NCT01228409|Psoriasis
1182442|NCT01228409|phototherapy
1182443|NCT01228409|soriatane
1182444|NCT01228409|acitretin
1182445|NCT01228409|retinoid-related adverse events
1182446|NCT01228396|bladder
1182447|NCT01228396|optic neuritis
1182448|NCT01228396|secondary progressive multiple sclerosis
1182449|NCT01228396|AIMSPRO
1182450|NCT01228396|hyperimmune caprine serum
1182451|NCT01228396|hyperimmune goat serum
1182452|NCT01228383|Monoclonal antibody
1182453|NCT01228383|Rabies
1182454|NCT01228383|Post-exposure prophylaxis
1182455|NCT01228370|sildosin
1182456|NCT01228370|neurogenic bladder
1182457|NCT01228370|voiding dysfunction
1182458|NCT01228357|Pharmacogenomics
1182459|NCT01228357|Depressed Patients
1182460|NCT01228344|Artemether-lumefantrine
1182461|NCT01228344|demographics
1182462|NCT01228344|malaria
1182463|NCT01228331|childhood acute lymphoblastic leukemia
1182464|NCT01228331|untreated childhood acute lymphoblastic leukemia
1182465|NCT01228318|HAART
1182466|NCT01228318|Antiresorptive drugs
1182467|NCT01228318|HIV/AIDS
1182468|NCT01228318|Bone loss
1182469|NCT01228305|ventricular septal defect
1182470|NCT01228305|atrioventricular septal defect
1182471|NCT01228305|oxidative stress
1182472|NCT01228305|cardiopulmonary bypass
1182473|NCT01228305|acetaminophen
1182474|NCT01228305|hemolysis
1182475|NCT01228305|acute kidney injury
1182476|NCT01228305|Congenital heart disease undergoing cardiopulmonary bypass
1182477|NCT01228292|Anticoagulation
1182478|NCT01228292|Intensive Care Medicine
1182479|NCT01228292|Hemodialysis
1182480|NCT01228292|Critical Ill Patients
1182481|NCT01228279|Peritoneal Dialysis
1182482|NCT01228279|Dialysis Solutions
1182483|NCT01228279|Artificial Kidney
1182484|NCT01228279|Renal Replacement Therapy
1182485|NCT01228279|Renal Dialysis
1182486|NCT01228279|Sympathetic Nervous System
1182487|NCT01228279|Leptin
1182488|NCT01228279|Icodextrin
1182489|NCT01228266|Multiple Sclerosis
1182490|NCT01228240|Diabetes mellitus, type 2, Metformin, Generic, Efficacy
1182491|NCT01228227|Myonecrosis
1182492|NCT01228227|Percutaneous Angioplasty
1182493|NCT01228227|Myocardial Infarction
1182494|NCT01228188|FTMH
1182495|NCT01228188|PPV
1182496|NCT01228188|inverted ILM repositioning
1182497|NCT01228149|glaucoma
1182498|NCT01228149|trabeculectomy
1182499|NCT01228149|intraocular pressure
1182500|NCT01228136|Adenotonsillectomy
1182501|NCT01228136|Tranexamic acid
1182502|NCT01228136|Blood loss
1182503|NCT01228136|Postoperative hemorrhage
1182504|NCT01228084|sulforaphane
1182505|NCT01228084|broccoli sprout extract (BSE)
1182506|NCT01228084|prostate cancer
1182507|NCT01228084|recurrent prostate cancer
1182508|NCT01228084|phase II
1182509|NCT01228071|testosterone deficiency
1182510|NCT01228071|hypogonadism
1182511|NCT01228058|Trauma
1182512|NCT01228058|Coagulopathy
1182513|NCT01228058|Coagulopathy in adult trauma patients
1182514|NCT01228045|Patients with histologically proved adenocarcinoma of advanced gastric cancer
1182515|NCT01228019|Usual practice re-examination
1182516|NCT01228006|Reduction of stress and fatigue
1182517|NCT01227993|Central Serous Chorioretinopathy
1182518|NCT01227993|Finasteride
1182519|NCT01227993|Proscar
1182520|NCT01227993|Retinal Eye Disease
1182521|NCT01227980|Addiction
1182522|NCT01227980|Alcohol
1182523|NCT01227980|Alcohol Treatment
1182524|NCT01227980|Alcoholics
1182525|NCT01227980|Alcohol Dependence
1182526|NCT01227980|Anxiety Disorder
1182527|NCT01227980|Alcoholism
1182528|NCT01227967|Adaptive Design
1182529|NCT01227967|At Risk
1182530|NCT01227967|H1N1
1182531|NCT01227967|Synergy
1182532|NCT01227967|TCAD
1182533|NCT01227954|cognitive/functional effects
1182534|NCT01227954|tumors metastatic to brain
1182535|NCT01227954|unspecified adult solid tumor, protocol specific
1182536|NCT01227941|advanced solid tumors
1182537|NCT01227941|ovarian cancer
1182538|NCT01227941|pegylated liposomal doxorubicin
1182539|NCT01227941|Doxil
1182540|NCT01227941|Caelyx
1182541|NCT01227928|tyrosine kinase inhibitors
1182542|NCT01227928|Primary Peritoneal Carcinoma
1182543|NCT01227928|primary peritoneal cancer
1182544|NCT01227928|ovarian cancer
1182545|NCT01227928|Fallopian Tube Cancer
1182546|NCT01227928|gynecologic cancer
1182547|NCT01227928|anti-angiogenesis
1182548|NCT01227928|pazopanib
1182549|NCT01227915|SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS
1182550|NCT01227902|Seizures
1182551|NCT01227902|retigabine IR
1182552|NCT01227902|GW582892
1182553|NCT01227902|Epilepsy
1182554|NCT01227902|Open label, flexible dose
1182555|NCT01227902|Partial-onset seizures
1182556|NCT01227889|Metastatic melanoma
1182557|NCT01227889|melanoma
1182558|NCT01227889|BRAF mutant
1182559|NCT01227889|Advanced melanoma
1182560|NCT01227876|Control of postoperative inflammation in cataract surgery by phacoemulsification
1182561|NCT01227863|SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS
1182562|NCT01227850|Leptin
1182563|NCT01227850|IGF1
1182564|NCT01227850|Refeeding Index
1182565|NCT01227850|Hypophosphataemia
1182566|NCT01227850|Primary focus of the study was to detemine whether the 'Refeeding Index', could reliably predict,that the refeeding syndrome would occur
1182567|NCT01227837|omega 3
1182568|NCT01227837|CRT_AICD
1182569|NCT01227837|congestive heart failure
1182570|NCT01227837|CHF
1182571|NCT01227824|integrase inhibitor
1182572|NCT01227824|HIV Infection
1182573|NCT01227824|raltegravir
1182574|NCT01227824|GSK1349572
1182575|NCT01227811|Darifenacin
1182576|NCT01227811|Bioequivalence
1182577|NCT01227811|Healthy volunteers
1182578|NCT01227811|Postprandial
1182579|NCT01227798|influenza A, H1N1
1182580|NCT01227772|gastric cancer vaccine
1182581|NCT01227772|OTSGC-A24
1182582|NCT01227772|A Phase I/IIa study
1182583|NCT01227772|HLA-A24-positive
1182584|NCT01227746|Advanced gastro-intestinal stromal tumors
1182585|NCT01227720|Smoking Cessation, Nicotine pharmacokinetics
1182586|NCT01227694|Cell therapy
1182587|NCT01227694|Regenerative therapy
1182588|NCT01227694|Advance therapy
1182589|NCT01227694|Bone marrow
1182590|NCT01227694|Mesenchymal stem cell
1182591|NCT01227694|Autologous
1182592|NCT01227694|Interventional clinical trial
1182593|NCT01227694|Osteoarthrosis
1182594|NCT01227694|Osteoarthritis
1182595|NCT01227694|Knee
1182596|NCT01227655|Parkinson
1182597|NCT01227655|PD
1182598|NCT01227655|Wearing-off
1182599|NCT01227655|Levodopa/DDCI
1182600|NCT01227642|Prostate Cancer
1182601|NCT01227642|Prostate brachytherapy
1182602|NCT01227642|Ultrasound treatment planning
1182603|NCT01227616|Iron deficiency anemia (IDA), Feraheme, ferumoxytol, chronic kidney disease (CKD), hemodialysis, magnetic resonance imaging (MRI)
1182604|NCT01227603|Bioequivalence
1182605|NCT01227603|Nifedipine
1182606|NCT01227603|Candesartan
1182607|NCT01227603|FDC
1182608|NCT01227590|Herbal medicine
1182609|NCT01227590|African Potato
1182610|NCT01227590|Hypoxis obtusa
1182611|NCT01227590|Drug interaction
1182612|NCT01227590|HIV Infections
1182613|NCT01227590|Acquired Immunodeficiency Syndrome
1182614|NCT01227590|Healthy Subjects
1182615|NCT01227590|Anti-retroviral Agents
1182616|NCT01227590|Lopinavir
1182617|NCT01227590|Ritonavir
1182618|NCT01227577|CML
1182619|NCT01227577|Chronic Myelogenous Leukemia
1182620|NCT01227577|Leukemia
1182621|NCT01227577|CML-CP
1182622|NCT01227577|Nilotinib
1182623|NCT01227564|Early Alzheimer's disease
1182624|NCT01227564|active immunization
1182625|NCT01227564|amyloid imaging
1182626|NCT01227551|Melanoma
1182627|NCT01227551|CALM
1182628|NCT01227538|Beta cell reserve, urinary C peptide
1182629|NCT01227512|Hyponatremia
1182630|NCT01227512|Dilutional Hyponatremia
1182631|NCT01227512|Euvolemic Hyponatremia
1182753|NCT01226758|Safety
1182632|NCT01227512|Hypervolemic Hyponatremia
1182633|NCT01227512|Fluid Restriction
1182634|NCT01227512|Tolvaptan
1182635|NCT01227486|Intubation, intratracheal
1182636|NCT01227486|Ultrasonography
1182637|NCT01227486|Auscultation
1182638|NCT01227486|Capnography
1182639|NCT01227486|Obesity
1182640|NCT01227473|prediabetes
1182641|NCT01227473|African Americans
1182642|NCT01227473|mindfulness
1182643|NCT01227473|behavioral
1182644|NCT01227473|diabetes
1182645|NCT01227460|Type 1 diabetes, Sitagliptin
1182646|NCT01227434|Glioblastoma
1182647|NCT01227434|Gliosarcoma
1182648|NCT01227434|Anaplastic astrocytoma
1182649|NCT01227434|Malignant astrocytoma NOS
1182650|NCT01227434|Malignant glioma
1182651|NCT01227434|GBM
1182652|NCT01227421|influenza
1182653|NCT01227408|Patients with confirmed breast cancer for neoadjuvant chemotherapy
1182654|NCT01227395|HIV
1182655|NCT01227395|Post Marketing Surveillance
1182656|NCT01227369|Bisphosphonates
1182657|NCT01227369|OPSAT-Q
1182658|NCT01227356|Chronic myeloid leukemia, imatinib, interferon
1182659|NCT01227343|Gender differences
1182660|NCT01227343|nicotine
1182661|NCT01227343|cigarette smoking habits
1182662|NCT01227343|behavior changes
1182663|NCT01227317|Dyspnea
1182664|NCT01227317|Mortality
1182665|NCT01227291|Glaucoma
1182666|NCT01227291|IOP
1182667|NCT01227291|siRNAs
1182668|NCT01227291|RNAi
1182669|NCT01227291|beta inhibitor
1182670|NCT01227278|Benralizumab
1182671|NCT01227278|MEDI-563
1182672|NCT01227278|Pulmonary Disease, Chronic Obstructive
1182673|NCT01227226|Dry eye
1182674|NCT01227187|Hemodialysis
1182675|NCT01227187|Anticoagulation
1182676|NCT01227187|Xigris
1182677|NCT01227187|PTT
1182678|NCT01227174|propofol only
1182679|NCT01227174|safety and efficacy
1182680|NCT01227161|ASA I-II children between the age 0-7
1182681|NCT01227161|general anesthesia
1182682|NCT01227148|critical care, glycemic control, insulin, nitrogen balance
1182683|NCT01227135|chronic phase chronic myelogenous leukemia
1182684|NCT01227135|chronic myelogenous leukemia, BCR-ABL1 positive
1182685|NCT01227122|NGAL plasmatic level
1182686|NCT01227122|Preoperative KIDNEY FAILURE, CHRONIC
1182687|NCT01227122|Postoperative KIDNEY FAILURE, ACUTE
1182688|NCT01227122|Cardiac Surgery Procedures
1182689|NCT01227109|Infections
1182690|NCT01227109|Cancer
1182691|NCT01227109|Procalcitonin
1182692|NCT01227109|C reactive protein
1182693|NCT01227096|electroacupuncture pediatric cardioprotection
1182694|NCT01227083|AQLQ and cAQOL
1182695|NCT01227070|Asthma, hospitalization, children, exhaled nitric oxide, lung function, breath condensate, cysteinyl leukotrienes
1182696|NCT01227057|exposure therapy
1182697|NCT01227057|case management
1182698|NCT01227057|older adults
1182699|NCT01227057|cognitive rehabilitation
1182700|NCT01227044|Substance Abuse Counseling
1182701|NCT01227044|Adherence (medication)
1182702|NCT01227044|Alcohol Abuse
1182703|NCT01227044|Highly Active Antiretroviral Therapy (HAART)
1182704|NCT01227044|Naltrexone
1182705|NCT01227044|Vivitrol
1182706|NCT01227044|HIV
1182707|NCT01227031|Genetic susceptibility of androgenetic alopecia
1182708|NCT01227031|Genetic difference in Finasteride response
1182709|NCT01227005|Transfusion
1182710|NCT01227005|Whole Blood
1182711|NCT01227005|Trauma
1182712|NCT01227005|Coagulopathy
1182713|NCT01227005|Component Therapy
1182714|NCT01227005|Civilian
1182715|NCT01227005|Military
1182716|NCT01226992|Clostridium difficile
1182717|NCT01226992|Fecal Transplant
1182718|NCT01226992|Recurrent Diarrhea
1182719|NCT01226992|Abdominal distension/bloating
1182720|NCT01226992|Fever
1182721|NCT01226979|rectal cancer
1182722|NCT01226979|high dose endorectal brachytherapy
1182723|NCT01226953|Haemophilus influenzae type b (Hib)
1182724|NCT01226953|Vaccine
1182725|NCT01226953|Anti-PRP antibody
1182726|NCT01226914|EVICEL, Fibrin Sealant, Thyroidectomy
1182727|NCT01226901|Poly (ADP-ribose) polymerase (PARP) inhibitor
1182728|NCT01226901|tumor
1182729|NCT01226901|cancer
1182730|NCT01226888|brown adipose tissue
1182731|NCT01226888|androgen deprivation therapy
1182732|NCT01226875|SWL
1182733|NCT01226875|kidney stones
1182734|NCT01226875|renal calculi
1182735|NCT01226862|Stroke
1182736|NCT01226862|Telemedicine
1182737|NCT01226862|Telestroke
1182738|NCT01226849|diffuse large B-cell lymphoma relapse refractory
1182739|NCT01226836|Pulmonary Rehabilitation
1182740|NCT01226823|cholestasis
1182741|NCT01226823|pregnancy
1182742|NCT01226823|ursodeoxycholic acid
1182743|NCT01226823|ICP
1182744|NCT01226797|Chronic HCV infection
1182745|NCT01226797|raised ALT
1182746|NCT01226797|transaminitis
1182747|NCT01226797|HCV infection
1182748|NCT01226771|hepatitis V virus
1182749|NCT01226771|genotype 1
1182750|NCT01226771|ribavirin
1182751|NCT01226771|interferon
1182752|NCT01226771|Alternative ribavirin dosing
1182754|NCT01226758|Tolerability
1182755|NCT01226758|Efficacy
1182756|NCT01226758|Influenza
1182757|NCT01226758|Flu
1182758|NCT01226758|Virus
1182759|NCT01226758|Vaccine
1182760|NCT01226745|Multiple sclerosis
1182761|NCT01226745|ONO-4641
1182762|NCT01226745|MSC2430913A
1182763|NCT01226745|Efficacy
1182764|NCT01226732|Solid tumor
1182765|NCT01226732|Capecitabine
1182766|NCT01226732|Hsp90 inhibitor AUY922
1182767|NCT01226719|liver-only metastatic KRAS wild-type colorectal cancer
1182768|NCT01226719|Panitumumab
1182769|NCT01226719|Oxaliplatin
1182770|NCT01226719|Irinotecan
1182771|NCT01226719|Leucovorin
1182772|NCT01226719|5-Fluorouracil
1182773|NCT01226706|Urinary incontinence, urge
1182774|NCT01226706|detrusor hyperreflexia
1182775|NCT01226706|detrusor instability
1182776|NCT01226706|non-neurogenic
1182777|NCT01226706|Female Urogenital Diseases and Pregnancy Complications
1182778|NCT01226706|Female Urogenital Diseases
1182779|NCT01226706|Urologic Diseases
1182780|NCT01226706|Urination Disorders
1182781|NCT01226706|Urinary Incontinence
1182782|NCT01226693|pharmacokinetic
1182783|NCT01226693|single dose bioequivalence study
1182784|NCT01226693|balanced incomplete block design
1182785|NCT01226693|PH-797804
1182786|NCT01226693|P38 kinase inhibitor
1182787|NCT01226680|Dry Eye
1182788|NCT01226680|Schirmer test
1182789|NCT01226680|corneal staining
1182790|NCT01226680|OSDI
1182791|NCT01226680|OCI
1182792|NCT01226667|fibromyalgia
1182793|NCT01226667|lyrica
1182794|NCT01226667|pregabalin
1182795|NCT01226654|Quantitative Imaging of Multiple Sclerosis
1182796|NCT01226641|Obstructive Sleep Apnea Syndrome
1182797|NCT01226641|SCORE
1182798|NCT01226641|Telemedicine
1182799|NCT01226641|Arterial blood pressure
1182800|NCT01226641|Daily physical activity
1182801|NCT01226628|Macular degeneration
1182802|NCT01226628|Age-related macular degeneration
1182803|NCT01226628|Cell therapy
1182804|NCT01226628|CNTO 2476
1182805|NCT01226628|Human umbilical tissue-derived cells
1182806|NCT01226628|hUTC
1182807|NCT01226628|Geographic Atrophy
1182808|NCT01226628|Subretinal
1182809|NCT01226628|Visual Acuity
1182810|NCT01226615|Chondroitin sulphate
1182811|NCT01226615|Knee osteoarthritis
1182812|NCT01226615|Functional Magnetic Resonance Imaging
1182813|NCT01226602|Ticagrelor
1182814|NCT01226602|Healthy
1182815|NCT01226602|Coronary flow velocity
1182816|NCT01226602|Adenosine
1182817|NCT01226589|Cancer cancer
1182818|NCT01226589|MRS
1182819|NCT01226589|Treatment response
1182820|NCT01226589|Histologically confirmed diagnosed Breast cancer.
1182821|NCT01226589|Patient is 18 years or older.
1182822|NCT01226589|Karnofsky performance score is equal to or greater than 70.
1182823|NCT01226589|No previously irradiated or recurrent breast.
1182824|NCT01226589|No contraindication to MRS/MRI.
1182825|NCT01226576|MRgFUS
1182826|NCT01226576|Prostate Cancer
1182827|NCT01226576|Low-Intermediate Risk Prostate Cancer
1182828|NCT01226576|Localized Prostate Cancer
1182829|NCT01226576|InSightec
1182830|NCT01226576|ExAblate
1182831|NCT01226563|STEMI
1182832|NCT01226563|Acute Myocardial Infarction
1182833|NCT01226563|Congestive Heart Failure
1182834|NCT01226563|Left Ventricular Remodeling
1182835|NCT01226563|Devices, Medical
1182836|NCT01226550|hyperthermic intraoperative peritoneal chemotherapy (HIPEC)
1182837|NCT01226550|Irinotecan
1182838|NCT01226550|Pharmacokinetics
1182839|NCT01226550|peritoneal carcinomatosis (PC)
1182840|NCT01226537|Taurine,Diabetes mellitus,oxidative stress,glycemic control
1182841|NCT01226498|Blood Transfusion, Autologous
1182842|NCT01226498|Blood Preservation/adverse effects
1182843|NCT01226498|Blood Transfusion/adverse effects
1182844|NCT01226498|Endothelium, Vascular/physiopathology
1182845|NCT01226498|Inflammation Mediators
1182846|NCT01226485|Cancer
1182847|NCT01226485|Terminal
1182848|NCT01226485|Solid Tumor
1182849|NCT01226485|End Stage
1182850|NCT01226485|Metastatic
1182851|NCT01226472|PTCL
1182852|NCT01226472|CTCL
1182853|NCT01226472|MF
1182854|NCT01226472|SS
1182855|NCT01226459|Female Pattern Baldness
1182856|NCT01226433|AE adverse event
1182857|NCT01226433|AIDS acquired immunodeficiency syndrome
1182858|NCT01226433|ALT (SGPT) alanine aminotransferase
1182859|NCT01226433|ART antiretroviral therapy
1182860|NCT01226433|AST (SGOT) aspartate aminotransferase
1182861|NCT01226433|DCF data collection forms
1182862|NCT01226433|DMC Data Monitoring Committee
1182863|NCT01226433|FDA (U.S.) Food and Drug Administration
1182864|NCT01226433|GCP Good Clinical Practice guidelines
1182865|NCT01226433|HB sAg Hepatitis B surface antigen
1182866|NCT01226433|ICH International Conference of Harmonisation
1182867|NCT01226433|IND Investigational New Drug Application
1182868|NCT01226433|IRB Institutional Review Board
1182869|NCT01226433|IU International units
1182870|NCT01226433|mg milligram(s)
1182871|NCT01226433|mm3 cubic millimeter(s)
1182872|NCT01226433|PCR polymerase chain reaction
1182873|NCT01226433|SAE serious adverse event
1182874|NCT01226433|µg microgram
1182875|NCT01226433|ULN upper limit of the normal range
1182876|NCT01226433|WB Western Blot
1182877|NCT01226420|GVHD
1182878|NCT01226420|Alefacept
1182879|NCT01226420|Amevive
1182880|NCT01226407|Solid Tumour
1182881|NCT01226394|peritoneal carcinomatosis
1182882|NCT01226394|HIPEC
1182883|NCT01226394|controlled clinical trial
1182884|NCT01226381|Paracetamol and setrons
1182885|NCT01226381|No disease, healthy volunteers
1182886|NCT01226368|HIV, HPV, cervical-vaginal smear
1182887|NCT01226342|Chronic obstructive pulmonary disease
1182888|NCT01226329|Minority Groups
1182889|NCT01226329|Decision Making
1182890|NCT01226329|Patient Participation
1182891|NCT01226329|Mental Health Services
1182892|NCT01226329|retention
1182893|NCT01226329|attendance
1182894|NCT01226329|patient activation
1182895|NCT01226329|Hispanic Americans
1182896|NCT01226329|patient-provider communication
1182897|NCT01226316|Advanced solid malignancy,PIK3CA mutated,AKT1 mutated, PTEN mutation, PTEN alteration, metastatic,ER+,breast,ovarian,endometrial,AZD5363,AKT inhibitor,
1182898|NCT01226290|uterine fibroid RF ablation
1182899|NCT01226290|intrauterine ultrasound
1182900|NCT01226290|VizAblate
1182901|NCT01226264|Uterine cervical cancer
1182902|NCT01226264|diffusion-weighted MRI
1182903|NCT01226264|recurrence
1182904|NCT01226251|oral malodour
1182905|NCT01226251|halitosis
1182906|NCT01226251|Subjects consulting a bad breath clinic
1182907|NCT01226225|Patients with recent coronary event
1182908|NCT01226212|Older people
1182909|NCT01226212|Synbiotic
1182910|NCT01226212|Prebiotic
1182911|NCT01226212|Probiotic
1182912|NCT01226212|Bacteria
1182913|NCT01226212|Immune
1182914|NCT01226186|Knee replacement
1182915|NCT01226186|Pain control
1182916|NCT01226186|Self medication
1182917|NCT01226173|Prospective screening of blood donors.
1182918|NCT01226147|Lupus Nephritis
1182919|NCT01226147|SLE
1182920|NCT01226147|retinoid
1182921|NCT01226147|tamibarotene
1182922|NCT01226134|Functional Dyspepsia
1182923|NCT01226134|Itopride
1182924|NCT01226134|Gastric Emptying
1182925|NCT01226134|Gastric Accommodation
1182926|NCT01226134|Dyspeptic Symptoms
1182927|NCT01226121|dupuytren
1182928|NCT01226121|dupuytren's
1182929|NCT01226095|Osteoarthritis
1182930|NCT01226095|Pain
1182931|NCT01226095|Morning stiffness
1182932|NCT01226069|superficial phlebitis
1182933|NCT01226069|cannula-related vein inflammation
1182934|NCT01226069|Glycerine magnesium sulphate
1182935|NCT01226069|Hirudoid cream
1182936|NCT01226069|Nursing
1182937|NCT01226056|advanced solid tumors
1182938|NCT01226056|Sorafenib (Nexavar®)
1182939|NCT01226056|RAD001 (everolimus)
1182940|NCT01226056|tumor molecular targets
1182941|NCT01226030|Advanced Solid Tumors
1182942|NCT01226017|Oxytocin
1182943|NCT01226017|Animal Assisted therapy
1182944|NCT01226017|Farm animals
1182945|NCT01226017|Healthy nursing students
1182946|NCT01226004|radiosurgery
1182947|NCT01226004|prostate
1182948|NCT01226004|cancer
1182949|NCT01226004|early
1182950|NCT01226004|intermediate
1182951|NCT01226004|CyberKnife
1182952|NCT01225991|Pain, Fatigue, Geriatric, Rheumatoid Arthritis, Milnacipran
1182953|NCT01225978|Genetic Information
1182954|NCT01225978|Variant Updates
1182955|NCT01225978|Information Technology
1182956|NCT01225978|Hypertrophic Cardiomyopathy
1182957|NCT01225978|Hearing Loss
1182958|NCT01225978|Oncology
1182959|NCT01225965|Particulate Matter induced inflammation of the lung
1182960|NCT01225952|phacoemulsification
1182961|NCT01225952|intraocular lens
1182962|NCT01225939|Type 2 diabetes mellitus
1182963|NCT01225939|Healthy
1182964|NCT01225926|Intraocular Lens
1182965|NCT01225926|Toric
1182966|NCT01225913|asthma
1182967|NCT01225913|lung function
1182968|NCT01225913|inflammation
1182969|NCT01225874|untreated childhood acute lymphoblastic leukemia
1182970|NCT01225874|B-cell childhood acute lymphoblastic leukemia
1182971|NCT01225874|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
1182972|NCT01225809|AD01 follow-up extension
1182973|NCT01225796|Bicarbonate
1182974|NCT01225796|Chronic allograft nephropathy
1182975|NCT01225796|Urinary TGF-beta
1182976|NCT01225796|Urinary acid excretion
1182977|NCT01225770|green tea
1182978|NCT01225770|gargling
1182979|NCT01225770|prophylaxis
1182980|NCT01225770|influenza
1182981|NCT01225770|Respiratory Tract Infections
1182982|NCT01225770|high school students
1182983|NCT01225757|Echocardiography
1182984|NCT01225757|HIPEC
1182985|NCT01225692|Brain Injury
1182986|NCT01225692|Head Trauma
1182987|NCT01225692|Trauma Systems
1182988|NCT01225692|Head Injury Guideline
1182989|NCT01225692|Time to Tertiary Care
1182990|NCT01225679|Congenital Central Hypoventilation Syndrome
1182991|NCT01225679|Phox2B gene
1182992|NCT01225679|invasive ventilation
1182993|NCT01225679|genetics
1182994|NCT01225679|late-onset
1182995|NCT01225679|sleep
1182996|NCT01225679|central sleep apnea
1182997|NCT01225666|MOD-4023
1182998|NCT01225666|Growth Hormone Deficient Adults
1182999|NCT01225666|Phase II
1183000|NCT01225653|Latanoprost
1183001|NCT01225653|vasodilation
1183002|NCT01225653|diabetic retinopathy
1183003|NCT01225640|Tuberculosis
1183004|NCT01225640|EBA
1183005|NCT01225640|WBA
1183006|NCT01225627|Chronic disease management
1183007|NCT01225627|Chronic obstructive pulmonary disease
1183008|NCT01225627|Discharge planning
1183009|NCT01225627|Discharge coordinator
1183010|NCT01225614|Home ventilation
1183011|NCT01225614|Myotonic dystrophy type 1 (DM1)
1183012|NCT01225575|large cartilage defects
1183013|NCT01225575|knee joint
1183014|NCT01225575|femoral condyle, tibia, trochlear, retropatellar
1183015|NCT01225562|Heart attack
1183016|NCT01225562|Heart Disease
1183017|NCT01225562|Acute coronary syndrome
1183018|NCT01225562|ACS
1183019|NCT01225562|Cardiovascular Disease
1183020|NCT01225549|Allergen Challenge
1183021|NCT01225549|Asthma
1183022|NCT01225549|Inhaled selective glucocorticoid receptor agonist (iSEGRA)
1183023|NCT01225536|BRAF mutations
1183024|NCT01225510|recurrent glioblastoma multiforme (GBM)
1183025|NCT01225510|CVX-060
1183026|NCT01225510|PF-04856884
1183027|NCT01225510|phase 2
1183028|NCT01225510|open-label
1183029|NCT01225510|bevacizumab
1183030|NCT01225510|anti-angiogenic
1183031|NCT01225497|Randomized
1183032|NCT01225497|Pilot study
1183033|NCT01225497|VISA-A
1183034|NCT01225497|VAS
1183035|NCT01225484|Knee arthroplasty, perioperative analgesia
1183036|NCT01225471|novel epitope peptide
1183037|NCT01225471|CTL
1183038|NCT01225471|advanced prostate cancer
1183039|NCT01225458|Elderly patients
1183040|NCT01225458|renal insufficiency
1183041|NCT01225458|systematized gerontologic evaluation
1183042|NCT01225419|Plerixafor
1183043|NCT01225419|Hematopoietic Stem Cell Transplant mobilization
1183044|NCT01225419|children
1183045|NCT01225406|Third line ARV therapy
1183046|NCT01225406|HIV RNA
1183047|NCT01225406|Absolute CD4+ T cell count
1183048|NCT01225406|serious adverse events (SAEs)
1183049|NCT01225406|Drug resistance
1183050|NCT01225380|Hepatitis C
1183051|NCT01225380|HCV
1183052|NCT01225380|Rapid Virologic Response
1183053|NCT01225380|Sustained Virologic Response
1183054|NCT01225380|Direct Acting Antiviral
1183055|NCT01225380|Combination Therapy
1183056|NCT01225380|HCV RNA
1183057|NCT01225380|Polymerase inhibitor
1183058|NCT01225380|Protease inhibitor
1183059|NCT01225380|Treatment naïve
1183060|NCT01225380|GS-9190
1183061|NCT01225380|GS-9256
1183062|NCT01225354|Cheek
1183063|NCT01225354|Cheek flattening
1183064|NCT01225354|Malar deficiency
1183065|NCT01225354|Filler
1183066|NCT01225341|HSV-1
1183067|NCT01225341|Herpes labialis
1183068|NCT01225341|Cold sores
1183069|NCT01225341|Fever blisters
1183070|NCT01225289|Multiple Sclerosis
1183071|NCT01225289|Vitamin A
1183072|NCT01225289|CD4-Positive T-Lymphocytes
1183073|NCT01225289|Th1 Cells
1183074|NCT01225289|Th2 Cells
1183075|NCT01225276|CIDP
1183076|NCT01225276|IVIG
1183077|NCT01225263|Migraine disorders
1183078|NCT01225263|Headache
1183079|NCT01225263|Simvastatin
1183080|NCT01225263|Vitamin D
1183081|NCT01225250|Caudal septal extension graft
1183082|NCT01225250|Primary rhinoplasty
1183083|NCT01225250|Secondary rhinoplasty
1183084|NCT01225237|diarrhea
1183085|NCT01225237|IBS
1183086|NCT01225237|Colonic disease
1183087|NCT01225237|YM060
1183088|NCT01225224|ASP015K
1183089|NCT01225224|Ethnic difference
1183090|NCT01225198|Vitamins
1183091|NCT01225198|Minerals
1183092|NCT01225185|neurological complications
1183093|NCT01225185|brain blood flow autoregulation
1183094|NCT01225159|tight glycemic control
1183095|NCT01225159|cardiac surgery
1183096|NCT01225146|Ischemic
1183097|NCT01225146|Central
1183098|NCT01225146|Retinal
1183099|NCT01225146|Vein
1183100|NCT01225146|Occlusion
1183101|NCT01225146|Ranibizumab
1183102|NCT01225146|Lucentis
1183103|NCT01225146|CRVO
1183104|NCT01225146|ISCRVO
1183105|NCT01225133|Osteoarthritis, Osteoarthrosis, Arthritis, Arthrosis
1183106|NCT01225107|Burns
1183107|NCT01225107|Infections
1183108|NCT01225107|Cranberry
1183109|NCT01225094|AAA
1183110|NCT01225094|abdominal aortic aneurysm
1183111|NCT01225094|acute kidney injury
1183112|NCT01225094|ischemia-reperfusion
1183113|NCT01225081|ASP1941
1183114|NCT01225081|Diabetes mellitus
1183115|NCT01225081|pioglitazone
1183116|NCT01225042|infectious diarrhea
1183117|NCT01225042|probiotics
1183118|NCT01225042|prevention
1183119|NCT01225042|dietary intervention
1183120|NCT01225042|E. coli infection
1183121|NCT01225042|intestinal infection
1183122|NCT01225042|intestinal resistance
1183123|NCT01225029|premature birth
1183124|NCT01225029|late preterm birth
1183125|NCT01225029|respiratory distress of the newborn
1183126|NCT01225029|Transient tachypnea of the newborn
1183127|NCT01225003|gliomas
1183128|NCT01225003|magnetic resonance
1183129|NCT01225003|diffusion kurtosis imaging
1183130|NCT01225003|MR spectroscopy
1183131|NCT01225003|grading
1183132|NCT01224990|gastro-intestinal tumor
1183133|NCT01224990|accurate staging
1183134|NCT01224990|whole-body diffusion weighted MRI
1183135|NCT01224990|non-invasive
1183136|NCT01224925|carious exposure
1183137|NCT01224925|pulp capping
1183138|NCT01224925|MTA
1183139|NCT01224925|Dycal
1183140|NCT01224912|Insomnia
1183141|NCT01224912|Intervention
1183142|NCT01224912|Self-help
1183143|NCT01224912|Internet
1183144|NCT01224899|Heart Failure
1183145|NCT01224899|Sympathetic Nervous System
1183146|NCT01224899|Sympathectomy
1183147|NCT01224899|Adrenergic beta-Antagonists
1183148|NCT01224899|Ventricular Dysfunction, Left
1183149|NCT01224886|Aging
1183150|NCT01224886|Insulin resistance
1183151|NCT01224886|Ectopic lipids
1183152|NCT01224886|Obesity
1183153|NCT01224886|Exercise
1183154|NCT01224886|Physical activity
1183155|NCT01224886|Oxidative capacity
1183156|NCT01224886|Diabetes
1183157|NCT01224886|Metabolic syndrome
1183158|NCT01224873|breast cancer
1183159|NCT01224873|bone metastasis
1183160|NCT01224873|comparison of diagnostic methods
1183161|NCT01224873|bone scintigraphy
1183162|NCT01224873|fluoride PET/CT
1183163|NCT01224873|FDG-PET/CT
1183164|NCT01224860|Telmisartan
1183165|NCT01224860|Losartan
1183166|NCT01224860|Renal transplant
1183167|NCT01224847|AMD
1183168|NCT01224847|Intravitreal Injection
1183169|NCT01224847|Anesthesia
1183170|NCT01224834|Ragweed, allergy, sublingual immunotherapy
1183171|NCT01224821|iodine I 131 tositumomab
1183172|NCT01224821|anti-B1 Antibody
1183173|NCT01224821|Bexxar
1183174|NCT01224821|radioimmunotherapy
1183175|NCT01224821|tositumomab
1183176|NCT01224808|von Willebrand Disease
1183177|NCT01224795|uncomplicated influenza
1183178|NCT01224782|Zemplar capsules
1183179|NCT01224782|Chronic kidney disease (CKD) stage 3 or 4
1183180|NCT01224782|Secondary hyperparathyroidism (SHPT)
1183181|NCT01224782|Postmarketing observational study (PMOS)
1183182|NCT01224756|Tonsillitis
1183183|NCT01224756|Pharyngitis
1183184|NCT01224756|Sore Throat
1183185|NCT01224756|Drug Therapy
1183186|NCT01224717|Osteoporosis
1183187|NCT01224704|Hypertonic Saline Infusion
1183188|NCT01224704|Water Deprivation
1183189|NCT01224704|Thirst
1183190|NCT01224704|Water/Electrolytes Homeostasis
1183191|NCT01224704|Obesity
1183192|NCT01224691|Respiratory Syncytial Virus
1183193|NCT01224691|TGF Beta
1183194|NCT01224691|RSV
1183195|NCT01224691|Asthma
1183196|NCT01224691|Healthy Volunteer
1183197|NCT01224678|breast cancer
1183198|NCT01224665|stage II bladder cancer
1183199|NCT01224665|stage III bladder cancer
1183200|NCT01224665|transitional cell carcinoma of the bladder
1183201|NCT01224652|gastric cancer
1183202|NCT01224652|paclitaxel
1183203|NCT01224652|irinotecan
1183204|NCT01224639|dengue fever
1183205|NCT01224639|live attenuated tetravalent dengue vaccine
1183206|NCT01224639|TDV
1183207|NCT01224639|Drug therapy
1183208|NCT01224626|VRE
1183209|NCT01224626|Japanese
1183210|NCT01224626|Post Marketing Surveillance
1183211|NCT01224600|lower limbs
1183212|NCT01224600|Arterial Diseases
1183213|NCT01224587|Imaging technique
1183214|NCT01224587|gastric transport through the gut
1183215|NCT01224574|atrial fribrillation, cardiovascular events, aging, D-dimer
1183216|NCT01224561|Thinness
1183217|NCT01224561|Leanness
1183218|NCT01224561|healthy volunteers
1183219|NCT01224561|Lipid metabolism disorder
1183220|NCT01224548|vegan
1183221|NCT01224548|diet
1183222|NCT01224548|diabetes
1183223|NCT01224548|overweight
1183224|NCT01224548|workplace
1183225|NCT01224548|nutrition
1183226|NCT01224548|diabetes and/or overweight
1183227|NCT01224535|Complementary foods
1183228|NCT01224535|Amaranth
1183229|NCT01224535|Food Based approaches
1183230|NCT01224535|Iron Deficiency anemia
1183231|NCT01224535|Arid Areas
1183232|NCT01224535|Africa
1183233|NCT01224522|Randomized Controlled Trial
1183234|NCT01224522|Total Knee Arthroplasty
1183235|NCT01224522|Patient Matched Cutting Blocks
1183236|NCT01224509|Cervix
1183237|NCT01224509|EP3 receptors
1183238|NCT01224509|Mifepristone
1183239|NCT01224509|Prostaglandin
1183240|NCT01224509|Receptors
1183241|NCT01224509|Steroids
1183242|NCT01224496|Chronic cytopenic haematological diseases
1183243|NCT01224496|Chinese herbal concoction
1183244|NCT01224496|Supportive management
1183245|NCT01224444|colon polyps
1183246|NCT01224444|adenoma resection
1183247|NCT01224444|colon cancer screening
1183248|NCT01224444|colonoscopy
1183249|NCT01224431|pain
1183250|NCT01224431|lidocaine
1183251|NCT01224431|lumbar puncture
1183252|NCT01224431|j-tip
1183253|NCT01224418|Tacrolimus
1183254|NCT01224418|Prograf
1183255|NCT01224418|Calcinurin inhibitor
1183256|NCT01224418|Rheumatoid arthritis(RA)
1183257|NCT01224392|colorectal cancer
1183258|NCT01224392|colorectal neoplasms
1183259|NCT01224392|radiotherapy
1183260|NCT01224392|chemoradiotherapy
1183261|NCT01224392|T3-4 rectal cancer
1183262|NCT01224379|Lumbar spine
1183263|NCT01224379|fusion
1183264|NCT01224379|adjacent instability
1183265|NCT01224379|topping-off.
1183266|NCT01224366|Add-on to insulin
1183267|NCT01224327|Liver cirrhosis
1183268|NCT01224327|Radiology
1183269|NCT01224327|Mesenchymal Stem Cells
1183270|NCT01224327|Umbilical Cord
1183271|NCT01224314|Haemodynamics
1183272|NCT01224314|Hypotension
1183273|NCT01224314|Potassium
1183274|NCT01224314|Haemodialysis
1183275|NCT01224314|Dialysis fluids
1183276|NCT01224301|seasonal influenza vaccine
1183277|NCT01224301|school-based clinics
1183278|NCT01224301|economic analysis of school based influenza vaccine delivery
1183279|NCT01224301|pediatric influenza vaccine rates
1183280|NCT01224301|Influenza vaccine information for parents
1183281|NCT01224288|RCC
1183282|NCT01224288|Kidney cancer
1183283|NCT01224288|Metastatic renal cell carcinoma
1183284|NCT01224288|mRCC
1183285|NCT01224288|Dynamic contrast enhanced CT
1183286|NCT01224288|DCE-CT
1183287|NCT01224288|Tumor perfusion
1183288|NCT01224275|group based care
1183289|NCT01224275|antenatal care
1183290|NCT01224275|parents satisfaction
1183291|NCT01224275|Antenatal care´s organization and patient satisfaction
1183292|NCT01224262|influenza vaccine
1183293|NCT01224262|seasonal influenza
1183294|NCT01224262|novel vaccine
1183295|NCT01224262|flu
1183296|NCT01224249|Selenium
1183297|NCT01224249|Selenoprotein P
1183298|NCT01224249|Fish
1183299|NCT01224249|Shellfish
1183300|NCT01224249|Bioavailability
1183301|NCT01224223|asthma
1183302|NCT01224210|portopulmonary hypertension
1183303|NCT01224210|portal hypertension
1183304|NCT01224210|esophageal or gastric varices
1183305|NCT01224210|right heart catheterization
1183306|NCT01224210|transpulmonary gradient
1183307|NCT01224210|Endothelin Receptor Antagonist
1183308|NCT01224210|Ambrisentan
1183309|NCT01224210|Letairis
1183310|NCT01224210|pulmonary hemodynamics
1183311|NCT01224197|TMC435HPC1004
1183312|NCT01224197|TMC435
1183313|NCT01224197|HCV
1183314|NCT01224197|Hepatitis C
1183315|NCT01224197|Healthy Chinese volunteer
1183316|NCT01224184|HIV
1183317|NCT01224184|Sexually Transmitted Diseases
1183318|NCT01224184|Substance Abuse Detection
1183319|NCT01224184|Randomized Controlled Trial
1183320|NCT01224132|Atopic dermatitis, probiotic, SCORAD index, prick tests, cytokines
1183321|NCT01224119|foot ankle arthritis bone graft
1183322|NCT01224054|Tolerance alimentary
1183323|NCT01224054|Morbid obesity
1183324|NCT01224054|Type 2 Diabetes Mellitus
1183325|NCT01224041|Tacrolimus
1183326|NCT01224041|Prograf
1183327|NCT01224041|Calcinurin inhibitor
1183328|NCT01224041|Rheumatoid arthritis (RA)
1183329|NCT01224028|Tacrolimus
1183330|NCT01224028|Prograf
1183331|NCT01224028|Calcinurin inhibitor
1183332|NCT01224028|Albuminurea
1183333|NCT01224028|Proteinurea
1183334|NCT01224028|FK506
1183335|NCT01224002|Cross-Sectional
1183336|NCT01224002|Observational
1183337|NCT01224002|Comparative
1183338|NCT01224002|Retrospective
1183339|NCT01224002|Feasibility
1183340|NCT01224002|Dental Decay
1183341|NCT01224002|Drug Abuse
1183342|NCT01224002|Survey
1183343|NCT01223989|overweight
1183344|NCT01223989|obesity
1183345|NCT01223989|bread
1183346|NCT01223989|hypocaloric diet
1183347|NCT01223976|latent tuberculosis psoriasis arthritis TST QTF
1183348|NCT01223976|Screening of latent tuberculosis in psoriasis
1183349|NCT01223963|Macrolane
1183350|NCT01223963|Retrospective
1183351|NCT01223924|cancer
1183352|NCT01223898|CML,
1183353|NCT01223898|nilotinib,
1183354|NCT01223898|midazolam
1183355|NCT01223859|Radiofrequency, ablation, RFA, RFTA, RFITT, soft palate.
1183356|NCT01223833|breast cancer
1183357|NCT01223833|postmenopausal
1183358|NCT01223833|aromatase inhibitors
1183359|NCT01223833|tamoxifen
1183360|NCT01223833|arthralgia
1183361|NCT01223833|IGF-I
1183362|NCT01223833|BMI
1183363|NCT01223833|grip strength
1183364|NCT01223807|COPD, diaphragm, rehabilitation
1183365|NCT01223794|Fall
1183366|NCT01223794|all in surgical & Medical in-patient
1183367|NCT01223781|Freezing
1183368|NCT01223781|biofeedback
1183369|NCT01223781|motor learning
1183370|NCT01223781|freezing of gait in PD
1183371|NCT01223755|Autosomal dominant polycystic kidney disease
1183372|NCT01223755|Sirolimus
1183373|NCT01223755|Renal insufficiency
1183374|NCT01223729|Acetyl-L-carnitine;
1183375|NCT01223729|Minimal hepatic encephalopathy;
1183376|NCT01223729|Quality of life;
1183377|NCT01223729|Depression.
1183378|NCT01223716|amblyopia treatment
1183379|NCT01223716|neural plasticity
1183380|NCT01223716|perceptual learning
1183381|NCT01223716|vision therapy
1183382|NCT01223716|spatial vision
1183383|NCT01223716|video games
1183384|NCT01223716|occlusion therapy
1183385|NCT01223703|n-3 PUFAs
1183386|NCT01223703|Heart Failure
1183387|NCT01223703|Dilated cardiomyopathy
1183388|NCT01223703|Ejection Fraction
1183389|NCT01223703|Exercise Capacity
1183390|NCT01223690|sepsis
1183391|NCT01223690|infection
1183392|NCT01223690|bacteremia
1183393|NCT01223690|clarithromycin
1183394|NCT01223664|ABMSC
1183395|NCT01223664|Allogenic bone marrow mesenchymal stem cells
1183396|NCT01223664|Liver cirrhosis
1183397|NCT01223664|Transplantation
1183398|NCT01223651|Diabetes Mellitus, Type 1
1183399|NCT01223651|Continuous Glucose Monitoring System
1183400|NCT01223651|Accuracy
1183401|NCT01223651|Altitude
1183402|NCT01223638|Congenital hypothyroidism(CH)
1183403|NCT01223638|Hearing loss among children with CH
1183404|NCT01223612|Diabetes Mellitus
1183405|NCT01223612|Diabetes Complications
1183406|NCT01223612|Retinal Diseases
1183407|NCT01223612|Edema
1183408|NCT01223612|Endothelial Growth Factors
1183409|NCT01223612|Monoclonal Antibodies
1183410|NCT01223612|Ranibizumab
1183411|NCT01223612|Laser therapy
1183412|NCT01223599|pilonidal disease
1183413|NCT01223599|natal cleft
1183414|NCT01223599|limberg flap
1183415|NCT01223560|Artificial pancreas
1183416|NCT01223560|Model predictive control
1183417|NCT01223560|Virtual patient
1183418|NCT01223547|Carbohydrate counting
1183419|NCT01223547|Insulin bolus calculation
1183420|NCT01223534|Tuberculosis
1183421|NCT01223534|Latent tuberculosis infection
1183422|NCT01223534|Tuberculin skin test
1183423|NCT01223534|Interferon-gamma release assays
1183424|NCT01223534|Contact-tracing study
1183425|NCT01223521|Contraception
1183426|NCT01223521|Abortion
1183427|NCT01223521|First trimester
1183428|NCT01223521|Intrauterine device
1183429|NCT01223482|Miscarriage
1183430|NCT01223482|Karyotyping
1183431|NCT01223482|Genetic testing
1183432|NCT01223469|Atrial Fibrillation
1183433|NCT01223469|Supraventricular Tachycardia
1183434|NCT01223469|Contact Force
1183435|NCT01223469|RF Ablation
1183436|NCT01223469|Radiofrequency
1183437|NCT01223469|Pulmonary Vein Isolation
1183438|NCT01223469|Paroxysmal Atrial Fibrillation
1183439|NCT01223456|Saxagliptin
1183440|NCT01223456|type 2 diabetes
1183441|NCT01223456|clinical practice
1183442|NCT01223443|Coronary Artery Bypass Grafting
1183443|NCT01223443|Drug Eluting Stent
1183444|NCT01223443|Saphenous Vein Graft
1183445|NCT01223430|septic shock
1183446|NCT01223430|shock reversal
1183447|NCT01223430|ICU
1183448|NCT01223430|traditional Chinese medicine
1183449|NCT01223404|nicotine
1183450|NCT01223404|mecamylamine
1183451|NCT01223404|attention
1183452|NCT01223404|default network
1183453|NCT01223404|fMRI
1183454|NCT01223391|orthostatic
1183455|NCT01223391|abdominal compression
1183456|NCT01223365|moderate to severe pain
1183457|NCT01223365|diabetic peripheral neuropathy
1183458|NCT01223365|postherpetic neuralgia
1183459|NCT01223365|traumatic injury
1183460|NCT01223365|complex regional pain syndrome
1183461|NCT01223365|back pain
1183462|NCT01223365|neck pain
1183463|NCT01223365|osteoarthritis
1183464|NCT01223365|rheumatoid arthritis
1183465|NCT01223352|pulmonary arterial hypertension
1183466|NCT01223352|children
1183467|NCT01223352|pediatric
1183468|NCT01223352|bosentan
1183469|NCT01223339|Ertugliflozin
1183470|NCT01223339|Japanese and Western population
1183471|NCT01223339|pharmacokinetics
1183472|NCT01223339|pharmacodynamics
1183473|NCT01223326|Acetylcysteine
1183474|NCT01223313|Contraception
1183475|NCT01223313|Woman's Condom
1183476|NCT01223313|Female Condom
1183477|NCT01223313|Condom
1183478|NCT01223287|NICHD Neonatal Research Network
1183479|NCT01223287|Extremely Low Birth Weight (ELBW)
1183480|NCT01223287|Very Low Birth Weight (VLBW)
1183481|NCT01223287|Prematurity
1183482|NCT01223287|Mechanical ventilation
1183483|NCT01223287|Chronic Lung Disease (CLD)
1183484|NCT01223274|NICHD Neonatal Research Network
1183485|NCT01223274|Extremely Low Birth Weight (ELBW)
1183486|NCT01223274|Very Low Birth Weight (VLBW)
1183487|NCT01223274|Prematurity
1183488|NCT01223274|Mechanical ventilation
1183489|NCT01223274|Positive-Pressure Ventilation
1183490|NCT01223274|Surfactant
1183491|NCT01223274|Intubation
1183492|NCT01223274|Pulse oximetry
1183493|NCT01223274|Oxygen saturation
1183494|NCT01223261|NICHD Neonatal Research Network
1183495|NCT01223261|Very Low Birth Weight (VLBW)
1183496|NCT01223261|Extremely Low Birth Weight (ELBW)
1183497|NCT01223261|Prematurity
1183498|NCT01223261|Laparotomy
1183499|NCT01223261|Drainage
1183500|NCT01223261|Isolated intestinal perforation
1183501|NCT01223261|Focal intestinal performation
1183502|NCT01223248|radiation
1183503|NCT01223248|Hypofractionated Image- Guided
1183504|NCT01223248|IGIMRT
1183505|NCT01223248|RT
1183506|NCT01223248|10-154
1183507|NCT01223235|FALLOPIAN TUBE
1183508|NCT01223235|OVARY
1183509|NCT01223235|PERITONEUM
1183510|NCT01223235|BEVACIZUMAB (AVASTIN)
1183511|NCT01223235|GLOBO H-KLH CONJUGATE
1183512|NCT01223235|MUC-1 KLH
1183513|NCT01223235|OPT-821
1183514|NCT01223235|TF (C) - KLH
1183515|NCT01223235|TN(C)-KLH
1183516|NCT01223235|10-099
1183517|NCT01223222|Uncomplicated skin infections
1183518|NCT01223222|Impetigo
1183519|NCT01223222|Gram-negative
1183520|NCT01223222|Diagnosis of uncomplicated, Gram-positive, skin infection. This may include patients with mild eczema/dermatoses such as atopic dermatitis.
1183521|NCT01223222|Gram-positive organisms which in the opinion of the investigator are causative for infection of the lesion(s),
1183522|NCT01223209|Cancer
1183523|NCT01223209|Carcinoma
1183524|NCT01223209|Curative surgery
1183525|NCT01223209|Curative surgery for carcinoma at least three months and not more than 5 years prior to treatment start
1183526|NCT01223196|Type 2 Diabetes, Thiazolidinediones, TIMP-3, TACE, TNF-a,
1183527|NCT01223196|insulin resistance
1183528|NCT01223183|cystic fibrosis
1183529|NCT01223183|nuclear medicine
1183530|NCT01223183|aerosol
1183531|NCT01223183|nebulizer
1183532|NCT01223170|Tailoring
1183533|NCT01223170|Cardiac rehabilitation
1183534|NCT01223170|Internet based intervention
1183535|NCT01223170|Exercise
1183536|NCT01223170|Cardiovascular Disease rehabilitation
1183537|NCT01223157|obesity
1183538|NCT01223157|endocannabinoids
1183539|NCT01223144|Cognition
1183540|NCT01223144|orbitofrontal cortex
1183541|NCT01223144|Iowa Gambling Task
1183542|NCT01223144|facial emotion recognition
1183543|NCT01223118|Oocyte
1183544|NCT01223118|vitrification
1183545|NCT01223118|IVF
1183546|NCT01223118|PGD
1183547|NCT01223118|embryo biopsy
1183548|NCT01223105|slow freeze
1183549|NCT01223105|cryopreservation
1183550|NCT01223105|vitrification
1183551|NCT01223105|oocyte preservation
1183552|NCT01223092|IVF
1183553|NCT01223092|infertility
1183554|NCT01223092|DNA
1183555|NCT01223079|r-hFSH
1183556|NCT01223079|r-hLH
1183557|NCT01223066|Macrolane
1183558|NCT01223053|Sprain
1183559|NCT01223053|Strain
1183560|NCT01223053|Pain
1183561|NCT01223053|Ankle Pain
1183562|NCT01223053|Knee Pain
1183563|NCT01223053|Wrist Pain
1183564|NCT01223053|Hand Pain
1183565|NCT01223027|Dovitinib
1183566|NCT01223027|TKI
1183567|NCT01223027|Renal cell cancer
1183568|NCT01223027|RCC
1183569|NCT01223027|mRCC
1183570|NCT01223014|Radioactive
1183571|NCT01223014|ADME
1183572|NCT01223014|Neuropathic pain
1183573|NCT01223001|Depression
1183574|NCT01223001|Traumatic brain injury
1183575|NCT01223001|Duloxetine
1183576|NCT01223001|Cymbalta
1183577|NCT01223001|impaired cognitive function
1183578|NCT01222975|risperidone fasting study
1183579|NCT01222936|LBH581
1183580|NCT01222936|Panobinostat
1183581|NCT01222936|Small Cell Lung Carcinoma
1183582|NCT01222923|Risperidone fed study
1183583|NCT01222910|Valacyclovir hydrochloride fasting study
1183584|NCT01222897|Valacyclovir hydrochloride fed study
1183585|NCT01222871|Treatment
1183586|NCT01222858|Obesity
1183587|NCT01222858|Primary Care
1183588|NCT01222858|Internet
1183589|NCT01222858|Technology
1183590|NCT01222858|Behavior Modification
1183591|NCT01222819|Febrile neutropenia
1183592|NCT01222819|growth factors
1183593|NCT01222819|leukemia
1183594|NCT01222806|Functional Magnetic Resonance Imaging (fMRI)
1183595|NCT01222806|Cocaine
1183596|NCT01222806|Cue-Induced Craving
1183597|NCT01222806|Repetitive TMS (rTMS)
1183598|NCT01222806|Cocaine Craving
1183599|NCT01222793|High Weight Gain Liability (HWLA)
1183600|NCT01222793|Antipsychotic
1183601|NCT01222793|Obesity
1183602|NCT01222793|Low Weight Gain
1183603|NCT01222793|Schizophrenia
1183604|NCT01222793|Food Craving
1183605|NCT01222780|Hematologic Malignancies
1183606|NCT01222780|Vincristine Sulfate
1183607|NCT01222780|Maximum Tolerated Dose
1183608|NCT01222780|Pharmacokinetics
1183609|NCT01222780|Solid Tumors
1183610|NCT01222780|Cancer
1183611|NCT01222780|Pediatrics
1183612|NCT01222780|Sarcoma
1183613|NCT01222780|Wilms Tumor
1183614|NCT01222780|Leukemia
1183615|NCT01222780|Lymphoma
1183616|NCT01222780|Brain Tumor
1183617|NCT01222767|EFT
1183618|NCT01222767|PNET
1183619|NCT01222767|EOE
1183620|NCT01222754|Newly Diagnosed
1183621|NCT01222754|DIPG
1183622|NCT01222754|CC 5013
1183623|NCT01222754|Radiation Therapy
1183624|NCT01222754|Lenalidomide
1183625|NCT01222754|XRT
1183626|NCT01222754|Brain Tumor
1183627|NCT01222754|Glioma
1183628|NCT01222754|Pediatrics
1183629|NCT01222741|AIRE- Autoimmune Regulator Gene
1183630|NCT01222741|APECED- Autoimmune Polyendocrinopathy-Candidiasis Ectodermal Dystrophy
1183631|NCT01222741|CGD- Chronic Granulomatous Disease
1183632|NCT01222741|CMC- Chronic Mucocutaneous Candidiasis
1183633|NCT01222728|PET Imaging
1183634|NCT01222728|Vestibular Schwannoma
1183635|NCT01222728|Neurofibromatosis
1183636|NCT01222728|Neurofibromatosis Type 2
1183637|NCT01222728|NF2
1183638|NCT01222702|CDIFF
1183639|NCT01222702|CDAD
1183640|NCT01222702|CDI
1183641|NCT01222702|Clostridium difficile infection
1183642|NCT01222676|transitional cell carcinoma of the bladder
1183643|NCT01222676|stage II bladder cancer
1183644|NCT01222676|stage III bladder cancer
1183645|NCT01222676|stage IV bladder cancer
1183646|NCT01222663|peritonitis
1183647|NCT01222663|septic shock
1183648|NCT01222663|hemoperfusion
1183649|NCT01222663|Polymyxin B
1183650|NCT01222663|endotoxin
1183651|NCT01222650|Benign Prostatic Hyperplasia
1183652|NCT01222650|I-PSS
1183653|NCT01222650|α1A-AR antagonist
1183654|NCT01222637|advanced solid cancers
1183655|NCT01222637|metastatic solid cancers
1183656|NCT01222624|advanced solid malignancies
1183657|NCT01222611|HIV
1183658|NCT01222611|HCV
1183659|NCT01222611|HIV/HCV
1183660|NCT01222611|Coinfection
1183661|NCT01222611|Fosamprenavir
1183662|NCT01222585|Metronidazole
1183663|NCT01222585|Neonate
1183664|NCT01222585|Premature
1183665|NCT01222585|Sepsis
1183666|NCT01222585|Necrotizing enterocolitis
1183667|NCT01222572|radiation therapy
1183668|NCT01222572|stereotactic radiotherapy
1183669|NCT01222572|stereotactic boost
1183670|NCT01222559|Cartilage defects
1183671|NCT01222559|Knee joint
1183672|NCT01222559|Femoral Condyle
1183673|NCT01222507|tinnitus
1183674|NCT01222507|cognition
1183675|NCT01222507|brain processing speed
1183676|NCT01222507|Brain Fitness Program
1183677|NCT01222507|Posit Science
1183678|NCT01222494|Child Psychiatry
1183679|NCT01222494|Obesity
1183680|NCT01222494|Antipsychotic
1183681|NCT01222481|Head and Neck Cancer
1183682|NCT01222481|Functional Status
1183683|NCT01222481|Cognitive Status
1183684|NCT01222481|Neurocognitive Assessments
1183685|NCT01222481|Performance-based Assessments
1183686|NCT01222481|Cancer
1183687|NCT01222481|Function
1183688|NCT01222481|Cognition
1183689|NCT01222481|Quality of Life
1183690|NCT01222468|Spasticity, Spinal Cord Injury
1183691|NCT01222455|Phase 1
1183692|NCT01222455|Healthy volunteers
1183693|NCT01222455|Volunteers with hepatic impairment
1183694|NCT01222455|Pharmacokinetics
1183695|NCT01222455|Fostamatinib
1183696|NCT01222442|Respiratory disease
1183697|NCT01222442|Bronchiolitis
1183698|NCT01222442|Emphysema
1183699|NCT01222442|Lung disease causing persistent narrowing of the airways
1183700|NCT01222390|Breast Cancer Reconstruction
1183701|NCT01222390|Tissue Expander
1183702|NCT01222390|3-D Camera
1183703|NCT01222390|Breast Reconstruction
1183704|NCT01222390|Crescentric
1183705|NCT01222390|Expander Profile
1183706|NCT01222390|Fill-Volume
1183707|NCT01222390|Lower Pole
1183708|NCT01222390|Upper Pole
1183709|NCT01222390|Acellular Dermis
1183710|NCT01222390|3-D Imaging
1183711|NCT01222364|NICHD Neonatal Research Network
1183712|NCT01222364|Extremely Low Birth Weight (ELBW)
1183713|NCT01222364|Very Low Birth Weight (VLBW)
1183714|NCT01222364|Prematurity
1183715|NCT01222351|Alzheimer's disease
1183716|NCT01222351|Positron emission tomography
1183717|NCT01222351|Biomarker
1183718|NCT01222351|Plasma Aβ
1183719|NCT01222351|Brain amyloid plaque load
1183720|NCT01222338|Mycobacterium
1183721|NCT01222338|MDR-TB
1183722|NCT01222338|XDR-TB
1183723|NCT01222338|HIV
1183724|NCT01222338|HCV
1183725|NCT01222325|kidney calculi
1183726|NCT01222325|urolithiasis
1183727|NCT01222325|urologic surgical procedures
1183728|NCT01222325|extracorporeal shockwave lithotripsy
1183729|NCT01222312|advanced NSCLC
1183730|NCT01222312|oxaliplatin
1183731|NCT01222312|cisplatin
1183732|NCT01222312|docetaxel
1183733|NCT01222312|locally advanced or metastatic non small cell lung cancer (stage IIIB-IV)
1183734|NCT01222286|Smoldering Multiple Myeloma
1183735|NCT01222273|cystic fibrosis
1183736|NCT01222273|Allergic bronchopulmonary aspergillosis
1183737|NCT01222273|A. fumigatus
1183738|NCT01222273|Immune response
1183739|NCT01222260|Amyloidosis
1183740|NCT01222260|Dexamethasone
1183741|NCT01222260|Bendamustine
1183742|NCT01222260|Relapsed AL Amyloidosis
1183743|NCT01222247|Betamethasone
1183744|NCT01222247|Celestone
1183745|NCT01222247|Steroids
1183746|NCT01222247|Perinatology
1183747|NCT01222221|adult gliosarcoma
1183748|NCT01222221|adult giant cell glioblastoma
1183749|NCT01222221|adult glioblastoma
1183750|NCT01222208|Bowel resection
1183751|NCT01222195|Myelodysplastic Syndrome
1183752|NCT01222195|Red cell transfusion independence
1183753|NCT01222195|Darbepoetin alfa
1183754|NCT01222195|Lenalidomide
1183755|NCT01222195|CC-5013
1183756|NCT01222195|Revlimid
1183757|NCT01222195|Aranesp
1183758|NCT01222195|Erythropoietin
1183759|NCT01222195|Erythropoiesis Stimulating Protein
1183760|NCT01222182|low density lipoprotein (LDL) cholesterol
1183761|NCT01222182|statin
1183762|NCT01222182|dose equivalent
1183763|NCT01222182|Hypercholesterolemia (defined by LDL guidelines)
1183764|NCT01222169|Anesthesia
1183765|NCT01222169|Children
1183766|NCT01222169|Larynx
1183767|NCT01222156|Cardiac arrhythmias
1183768|NCT01222156|Catheter ablation
1183769|NCT01222156|Electrophysiology
1183770|NCT01222156|Magnetic
1183771|NCT01222156|Mapping
1183772|NCT01222156|Remote navigation
1183773|NCT01222143|AML
1183774|NCT01222143|NOVE-HiDAC
1183775|NCT01222143|Nilotinib
1183776|NCT01222130|HIV
1183777|NCT01222130|Infant infection
1183778|NCT01222130|Diagnosis
1183779|NCT01222130|Non-virological algorithm
1183780|NCT01222117|Acute Limb Ischemia
1183781|NCT01222104|vascular closure
1183782|NCT01222104|Angio-Seal
1183783|NCT01222104|Interventional radiology
1183784|NCT01222104|femoral artery
1183785|NCT01222078|newly diagnosed type 1 diabetes mellitus
1183786|NCT01222078|re-treatment
1183787|NCT01222078|intravenous otelixizumab
1183788|NCT01222078|beta-cell preservation
1183789|NCT01222065|Glaucoma
1183790|NCT01222065|Neurotubules
1183791|NCT01222065|Birefringence
1183792|NCT01222065|Retinal Nerve Fiber Layer (RNFL)
1183793|NCT01222052|high risk breast cancer
1183794|NCT01222052|low risk breast cancer
1183795|NCT01222052|uPA
1183796|NCT01222052|urokinase-type plasminogen activator
1183797|NCT01222052|PAI
1183798|NCT01222052|plasminogen activator inhibitor-type
1183799|NCT01222039|Graft versus host disease
1183800|NCT01222039|Mesenchymal stem cell
1183801|NCT01222039|Allogeneic mesenchymal stem cell
1183802|NCT01222039|Adipose tissue
1183803|NCT01222039|Allotransplant
1183804|NCT01222039|Allogenic
1183805|NCT01222039|Mesenchymal Stem Cells
1183806|NCT01222039|Immune System Diseases
1183807|NCT01222039|Chronic
1183808|NCT01222039|Expanded
1183809|NCT01222026|Primary Hyperparathyroidism
1183810|NCT01222026|Osteopenia
1183811|NCT01222026|Osteoporosis
1183812|NCT01221987|Human papillomavirus
1183813|NCT01221987|neoplasia
1183814|NCT01221974|Hydrosalpinx or infertility
1183815|NCT01221961|Major spine surgery
1183816|NCT01221961|Hemoglobin
1183817|NCT01221961|Blood transfusion
1183818|NCT01221948|Deep Brain Stimulation
1183819|NCT01221948|Parkinson's Disease
1183820|NCT01221935|retrospective chart review study
1183821|NCT01221935|desvenlafaxine utilization
1183822|NCT01221935|psychiatrists and primary care physicians
1183823|NCT01221935|treatment of major depressive disorder
1183824|NCT01221909|bleeding
1183825|NCT01221909|dacryocystorhinostomy
1183826|NCT01221909|operative duration
1183827|NCT01221896|Localization of a parathyroid adenoma in patients with primary hyperparathyroidism.
1183828|NCT01221883|Posttraumatic Stress
1183829|NCT01221883|Prevention
1183830|NCT01221883|Diazepam
1183831|NCT01221870|Metastatic breast cancer
1183832|NCT01221870|First-line therapy
1183833|NCT01221870|Tesetaxel
1183834|NCT01221870|Oral taxane
1183835|NCT01221857|Double Umbilical Cord Blood Stem Cell Transplantation
1183836|NCT01221857|Hematological Malignancies
1183837|NCT01221857|HLA Mismatched Donors
1183838|NCT01221857|Cord Blood Transplantation
1183839|NCT01221844|Lactoferrin
1183840|NCT01221844|Pregnancy
1183841|NCT01221844|Hereditary Thrombophilia
1183842|NCT01221844|Iron deficiency
1183843|NCT01221844|Iron deficiency anemia
1183844|NCT01221818|Inflammatory Bowel Disease
1183845|NCT01221805|deep venous thrombosis
1183846|NCT01221805|pulmonary embolism
1183847|NCT01221805|venous thromboembolism
1183848|NCT01221805|D-dimer
1183849|NCT01221805|Wells score
1183850|NCT01221805|Wells clinical pretest probability
1183851|NCT01221792|PTSD
1183852|NCT01221792|Anxiety
1183853|NCT01221792|Trauma
1183854|NCT01221792|Assault
1183855|NCT01221792|Victim
1183856|NCT01221792|Witness
1183857|NCT01221792|Post Traumatic Stress Disorder
1183858|NCT01221792|Combat veteran
1183859|NCT01221792|Flashbacks
1183860|NCT01221792|Nightmares
1183861|NCT01221792|Sleep Disturbance
1183862|NCT01221792|Hyperarousal
1183863|NCT01221792|Numbness
1183864|NCT01221792|Avoidance
1183865|NCT01221779|Intensive language therapy
1183866|NCT01221779|Anomia
1183867|NCT01221779|Magnetic Resonance Imaging
1183868|NCT01221766|adnexal
1183869|NCT01221766|hair and nail
1183870|NCT01221766|chronic graft vs host disease
1183871|NCT01221766|children
1183872|NCT01221753|SSCHN
1183873|NCT01221753|HPV
1183874|NCT01221753|IMRT
1183875|NCT01221740|To show that patients with greater pain sensitivity
1183876|NCT01221740|will show greater improvement in their symptoms
1183877|NCT01221740|(self-reported pain intensity, mood, sleep, and
1183878|NCT01221740|quality of life) than those with lower pain
1183879|NCT01221740|sensitivity, based on QST, after taking milnacipran.
1183880|NCT01221740|To compare outcome differences
1183881|NCT01221740|(pain intensity, mood, activity interference,
1183882|NCT01221740|sleep, and side effects) with those patients
1183883|NCT01221740|who are either taking or not taking opioids for
1183884|NCT01221740|their pain 10 weeks after being prescribed milnacipran.
1183885|NCT01221740|To show that patients who are older, male,
1183886|NCT01221740|with more medical comorbidities, greater disability,
1183887|NCT01221740|and longer pain duration will report less improvement
1183888|NCT01221740|(pain, mood, sleep, health-related quality of life)
1183889|NCT01221740|and treatment satisfaction while taking milnacipran
1183890|NCT01221740|compared with others without such characteristics.
1183891|NCT01221740|identify patients back or neck pain
1183892|NCT01221740|greater 6 months
1183893|NCT01221740|QST
1183894|NCT01221740|10 weeks
1183895|NCT01221740|milnacipran
1183896|NCT01221740|pain intensity
1183897|NCT01221740|mood
1183898|NCT01221740|activity
1183899|NCT01221740|interference
1183900|NCT01221740|sleep
1183901|NCT01221740|side effects
1183902|NCT01221740|age
1183903|NCT01221740|gender
1183904|NCT01221740|medical comorbidities
1183905|NCT01221740|pain diagnosis
1183906|NCT01221740|pain duration
1183907|NCT01221740|disability status
1183908|NCT01221727|Amgen
1183909|NCT01221727|Phase 1
1183910|NCT01221727|Postmenopausal
1183911|NCT01221727|Osteoporosis
1183912|NCT01221714|nutritional supplements
1183913|NCT01221714|supplements
1183914|NCT01221714|vitamins
1183915|NCT01221714|omega-3
1183916|NCT01221714|Amerisciences
1183917|NCT01221714|Carlos Montesinos
1183918|NCT01221701|depression
1183919|NCT01221701|psychological treatments
1183920|NCT01221701|Cognitive Behavioral Therapy
1183921|NCT01221701|child social/emotional functioning
1183922|NCT01221701|parenting
1183923|NCT01221701|home visitation
1183924|NCT01221688|Sentinel lymph node biopsy (SLNB)
1183925|NCT01221688|large operable breast cancer
1183926|NCT01221688|neoadjuvant chemotherapy
1183927|NCT01221688|patients with large operable breast cancer after neoadjuvant chemotherapy (NAC)
1183928|NCT01221675|Small Cell Lung Cancer or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
1183929|NCT01221675|Radio Immunotherapy
1183930|NCT01221675|Lutetium
1183931|NCT01221675|patient ≥ 18 years of age with CEA-positive SCLC in partial response
1183932|NCT01221675|or who failed at least two lines of standard radiation and/or chemotherapy
1183933|NCT01221675|or Patients with histologic diagnosis of NSCLC
1183934|NCT01221662|Siwu tang
1183935|NCT01221662|brain hypoperfusion
1183936|NCT01221662|cognition function
1183937|NCT01221623|Peyronie's Disease
1183938|NCT01221623|penile plaque
1183939|NCT01221623|penile curvature
1183940|NCT01221610|Stenosis
1183941|NCT01221610|Occlusions
1183942|NCT01221610|SFA
1183943|NCT01221610|PTA
1183944|NCT01221610|POBA
1183945|NCT01221610|DRB
1183946|NCT01221597|Peyronie's Disease
1183947|NCT01221597|penile plaque
1183948|NCT01221597|penile curvature
1183949|NCT01221584|Dyslipidaemia
1183950|NCT01221584|LDL-C goals
1183951|NCT01221584|guidelines
1183952|NCT01221571|Phase I
1183953|NCT01221571|Dose escalation
1183954|NCT01221571|AFM 13
1183955|NCT01221571|Natural killer cell
1183956|NCT01221545|Diabetes Mellitus
1183957|NCT01221519|Phase I
1183958|NCT01221519|Bioavailability
1183959|NCT01221519|Type 2 Diabetes Mellitus
1183960|NCT01221519|Diabetic treatment
1183961|NCT01221519|Metformin
1183962|NCT01221519|High blood sugar
1183963|NCT01221506|unresectable
1183964|NCT01221506|metastatic
1183965|NCT01221506|clear cell renal carcinoma
1183966|NCT01221493|solitary pulmonary nodules
1183967|NCT01221493|transbronchial lung biopsy
1183968|NCT01221493|endobronchial ultrasound
1183969|NCT01221454|ABMSC
1183970|NCT01221454|Allogenic bone marrow mesenchymal stem cells
1183971|NCT01221454|Liver Failure
1183972|NCT01221454|Transplantation
1183973|NCT01221441|Cartilage
1183974|NCT01221441|Knee
1183975|NCT01221441|Osteoarthritis
1183976|NCT01221428|Ulcerative colitis
1183977|NCT01221428|Mesenchymal Stem Cells
1183978|NCT01221428|Umbilical Cord
1183979|NCT01221389|hemorrhage
1183980|NCT01221389|plasma
1183981|NCT01221389|coagulopathy
1183982|NCT01221389|trauma
1183983|NCT01221363|Life style disease
1183984|NCT01221363|Obesity
1183985|NCT01221363|Sedentary behaviour
1183986|NCT01221363|Cardiovascular biomarkers
1183987|NCT01221350|Asthma
1183988|NCT01221350|Allergic rhinitis
1183989|NCT01221350|Respiratory disease
1183990|NCT01221350|Allergy
1183991|NCT01221350|Lipoic acid
1183992|NCT01221350|Thioctic acid
1183993|NCT01221350|Antioxidant
1183994|NCT01221350|Oxidative stress
1183995|NCT01221311|stenosis
1183996|NCT01221311|bile duct
1183997|NCT01221311|chronic pancreatitis
1183998|NCT01221311|postoperative
1183999|NCT01221311|post-liver transplant
1184000|NCT01221285|Cockroach
1184001|NCT01221285|Immunotherapy
1184002|NCT01221285|Subcutaneous immunotherapy
1184003|NCT01221285|Inner city asthma
1184004|NCT01221272|SPECT MPI
1184005|NCT01221246|Acute Middle Cerebral Artery Ischemic Stroke within 18 hours
1184006|NCT01221207|diabetic foot ulcers
1184007|NCT01221207|casting
1184008|NCT01221207|wound care
1184009|NCT01221194|diabetes
1184010|NCT01221194|foot ulcer prevention
1184011|NCT01221194|therapeutic stockings
1184012|NCT01221181|Dense deposit disease
1184013|NCT01221181|C3 nephropathy
1184014|NCT01221181|Eculizumab
1184015|NCT01221168|prostate
1184016|NCT01221168|cancer
1184017|NCT01221168|genetic
1184018|NCT01221168|epidemiology
1184019|NCT01221168|susceptibility
1184020|NCT01221155|Musculoskeletal
1184021|NCT01221142|Hypothermia, ICH
1184022|NCT01221129|zinc
1184023|NCT01221129|reticulocyte
1184024|NCT01221129|PBMC
1184025|NCT01221129|whole blood
1184026|NCT01221129|transcriptome
1184027|NCT01221129|microarray
1184028|NCT01221116|coronary artery disease,
1184029|NCT01221116|aortic stenosis,
1184030|NCT01221116|heart failure
1184031|NCT01221103|Dexamethasone
1184032|NCT01221103|Ofatumumab
1184033|NCT01221103|Bendamustine
1184034|NCT01221103|Lymphoma, Mantle-Cell
1184035|NCT01221103|Non-Hodgkin lymphoma
1184036|NCT01221090|Type 2 diabetes
1184037|NCT01221090|Health disparities
1184038|NCT01221090|Central Texas
1184039|NCT01221090|PDA
1184040|NCT01221090|CDSMP
1184041|NCT01221077|NSCLC
1184042|NCT01221077|Non-small cell lung cancer
1184043|NCT01221077|OSI-906
1184044|NCT01221077|IGF-IR
1184045|NCT01221077|Tarceva
1184046|NCT01221077|Erlotinib
1184047|NCT01221077|Epidermal Growth Factor Receptor
1184048|NCT01221077|EGFR
1184049|NCT01221077|Chemonaive
1184050|NCT01221077|Activating mutations
1184051|NCT01221064|Breast cancer
1184052|NCT01221064|Axillary clearance
1184053|NCT01221064|lymphorrhoea
1184054|NCT01221051|third stage of labor,oxytocics, postpartum hemorrhage,
1184055|NCT01221025|Parecoxib;
1184056|NCT01221025|emergence delirium;
1184057|NCT01221025|postoperative pain;
1184058|NCT01221025|elderly patients;
1184059|NCT01221025|abdominal surgery
1184060|NCT01221025|Parecoxib on emergence agitation and postoperative pain
1184061|NCT01220999|Clinical trial
1184062|NCT01220999|CS-1008 mAb
1184063|NCT01220999|monoclonal antibody CS-1008
1184064|NCT01220999|Positron-Emission Tomography
1184065|NCT01220999|Pharmacokinetics
1184066|NCT01220999|Pharmacodynamics
1184067|NCT01220999|apoptosis
1184068|NCT01220999|caspases
1184069|NCT01220986|Liver regeneration
1184070|NCT01220986|Innate immune response
1184071|NCT01220973|stage IV prostate cancer
1184072|NCT01220973|stage III prostate cancer
1184073|NCT01220973|recurrent prostate cancer
1184074|NCT01220973|stage IIB prostate cancer
1184075|NCT01220973|stage IIA prostate cancer
1184076|NCT01220960|art therapy
1184077|NCT01220960|breast cancer
1184078|NCT01220960|women
1184079|NCT01220960|young women
1184080|NCT01220960|older women
1184081|NCT01220960|quality of life
1184082|NCT01220960|meaning making
1184083|NCT01220960|support group
1184084|NCT01220960|art making
1184085|NCT01220960|art symbols
1184086|NCT01220908|LVRS (Lung Volume Reduction Surgery)
1184087|NCT01220908|LVRC (Lung Volume Reduction Coil)
1184088|NCT01220908|Emphysema
1184089|NCT01220908|coil
1184090|NCT01220908|RePneu
1184091|NCT01220895|Adoptive cellular therapy
1184092|NCT01220895|Hematopoietic Stem Cell Transplantation
1184093|NCT01220882|Slipped capital femoral epiphysis
1184094|NCT01220856|Islet transplantation
1184095|NCT01220856|Type 1 diabetes mellitus
1184096|NCT01220843|chronic renal failure
1184097|NCT01220843|FGF23
1184098|NCT01220843|Sevelamer carbonate
1184099|NCT01220830|Multiple sclerosis
1184100|NCT01220830|RFQMR
1184101|NCT01220830|Cytotron
1184102|NCT01220830|EDSS
1184103|NCT01220830|QOL assessment with FAMS
1184104|NCT01220817|prostate
1184105|NCT01220817|cancer
1184106|NCT01220817|psa
1184107|NCT01220817|psadt
1184108|NCT01220817|pomegranate
1184109|NCT01220817|POMx
1184110|NCT01220791|methylprednisolone
1184111|NCT01220791|IVF
1184112|NCT01220791|progesterone
1184113|NCT01220791|corticosteroid
1184114|NCT01220791|late follicular phase
1184115|NCT01220791|pregnancy rates
1184116|NCT01220765|hypoxemia
1184117|NCT01220765|capnography
1184118|NCT01220765|sedation
1184119|NCT01220752|IMRT
1184120|NCT01220752|carbon ion therapy
1184121|NCT01220752|paranasal sinus
1184122|NCT01220752|nasal cavity
1184123|NCT01220752|adenocarcinoma
1184124|NCT01220752|squamous cell carcinoma
1184125|NCT01220739|ischemic stroke
1184126|NCT01220739|transcranial laser
1184127|NCT01220739|tissue plasminogen activator
1184128|NCT01220739|therapy
1184129|NCT01220726|OAB
1184130|NCT01220713|Traumatic Brain Injury
1184131|NCT01220713|Veterans
1184132|NCT01220713|Hyperbaric Oxygen Treatment
1184133|NCT01220713|OEF/OIF
1184134|NCT01220713|Post-Concussive Symptoms
1184135|NCT01220713|Blast Exposure
1184136|NCT01220687|Prematurity
1184137|NCT01220687|Oxygen exposure
1184138|NCT01220687|Nitric Oxide
1184139|NCT01220674|neuropsychological assessment
1184140|NCT01220674|cognitive impairment
1184141|NCT01220674|computer-aided diagnostic tool
1184142|NCT01220661|Colorectal Surgery
1184143|NCT01220661|Surgical Wound Infection
1184144|NCT01220661|Laparoscopy
1184145|NCT01220661|Anti-Bacterial Agents
1184146|NCT01220648|Chronic myeloid leukemia
1184147|NCT01220648|interferon alfa
1184148|NCT01220648|nilotinib
1184149|NCT01220648|combination
1184150|NCT01220648|CML
1184151|NCT01220648|Philadelphia chromosome positive (Ph+) chronic myeloid leukemia patients in chronic phase (CML-CP) after switch from previous CML treatment
1184152|NCT01220635|Depressive Symptoms
1184153|NCT01220635|Depression prevention
1184154|NCT01220635|Adolescents
1184155|NCT01220635|School-Based Services
1184156|NCT01220635|Health Behavior
1184157|NCT01220622|Stroke
1184158|NCT01220622|Mild cognitive impairment
1184159|NCT01220622|Nimodipine
1184160|NCT01220583|stage I salivary gland cancer
1184161|NCT01220583|stage II salivary gland cancer
1184162|NCT01220583|stage III salivary gland cancer
1184163|NCT01220583|high-grade salivary gland mucoepidermoid carcinoma
1184164|NCT01220583|salivary gland adenocarcinoma
1184165|NCT01220583|stage IVA salivary gland cancer
1184166|NCT01220583|stage IVB salivary gland cancer
1184167|NCT01220583|stage IVC salivary gland cancer
1184168|NCT01220570|breast cancer
1184169|NCT01220570|ridaforolimus
1184170|NCT01220570|ridaforolimus/dalotuzumab combination therapy
1184171|NCT01220557|Diabetes mellitus, education, self management
1184172|NCT01220531|DiGeorge Anomaly
1184173|NCT01220531|Thymus Transplantation
1184174|NCT01220531|DiGeorge Syndrome
1184175|NCT01220531|Athymia
1184176|NCT01220531|Low T cell numbers
1184177|NCT01220531|Immunoreconstitution
1184178|NCT01220531|Immunodeficiency
1184179|NCT01220531|Complete DiGeorge
1184180|NCT01220531|Typical DiGeorge
1184181|NCT01220531|Atypical DiGeorge
1184182|NCT01220531|Complete DiGeorge Anomaly
1184183|NCT01220505|scoliosis
1184184|NCT01220505|kyphosis
1184185|NCT01220505|spinal deformity
1184186|NCT01220505|curvature
1184187|NCT01220505|lordosis
1184188|NCT01220492|liver cirrhosis
1184189|NCT01220492|mesenchymal stem cells
1184190|NCT01220492|ascites
1184191|NCT01220492|serum albumin
1184192|NCT01220479|Type 1 Diabetes, Bone mineral density, Growth
1184193|NCT01220479|Cardiovascular diseases, Exercise, Training,
1184194|NCT01220479|Child, Adolescent
1184195|NCT01220440|ADHD
1184196|NCT01220440|Children
1184197|NCT01220440|Methylphenidate
1184198|NCT01220440|Dextroamphetamine
1184199|NCT01220440|Placebo
1184200|NCT01220440|Crossover
1184201|NCT01220440|Double Blind
1184202|NCT01220440|Neuropsychological tests
1184203|NCT01220440|Behavioural Questionnaires
1184204|NCT01220427|high-risk prostate cancer
1184205|NCT01220427|radical prostatectomy
1184206|NCT01220427|micro-RNA
1184207|NCT01220401|Nightmare
1184208|NCT01220401|PTSD
1184209|NCT01220401|Posttraumatic stress disorder
1184210|NCT01220401|Suicide
1184211|NCT01220401|Exposure Relaxation Rescription Therapy
1184212|NCT01220401|Sleep
1184213|NCT01220388|Aldosterone
1184214|NCT01220388|L-lysine
1184215|NCT01220388|Cortisol
1184216|NCT01220388|Adrenal glands
1184217|NCT01220375|Mobilization of autologous peripheral blood progenitor cells PBPC
1184218|NCT01220375|Autologous stem cell mobilization
1184219|NCT01220375|Multiple Myeloma
1184220|NCT01220375|Plerixafor
1184221|NCT01220362|Analgesia, Epidural
1184222|NCT01220362|Urodynamics
1184223|NCT01220362|Urinary Retention
1184224|NCT01220284|solid tumors
1184225|NCT01220284|oral treatment
1184226|NCT01220284|platinum compound
1184227|NCT01220284|vinca alkaloid
1184228|NCT01220284|drug combination
1184229|NCT01220271|Glioma
1184230|NCT01220271|Glioblastoma
1184231|NCT01220245|endoluminal
1184232|NCT01220245|surgical
1184233|NCT01220245|bypass
1184234|NCT01220245|patency
1184235|NCT01220245|quality of life
1184236|NCT01220245|multicentre
1184237|NCT01220245|RCT
1184238|NCT01220245|superficial femoral artery
1184239|NCT01220245|vascular patency
1184240|NCT01220232|Lersivirine
1184241|NCT01220232|UK-453
1184242|NCT01220232|061
1184243|NCT01220232|NNRTI
1184244|NCT01220232|Abacavir
1184245|NCT01220232|Lamivudine
1184246|NCT01220232|Combivir
1184247|NCT01220232|Pharmacokinetics
1184248|NCT01220232|Drug Interaction
1184249|NCT01220232|HIV
1184250|NCT01220232|AIDS
1184251|NCT01220219|pregabalin
1184252|NCT01220219|pharmacokinetics
1184253|NCT01220219|bioavailability
1184254|NCT01220219|bioequivalence
1184255|NCT01220206|ED
1184256|NCT01220206|POMx
1184257|NCT01220206|Pomegranate
1184258|NCT01220206|Erectile dysfunction
1184259|NCT01220180|epilepsy
1184260|NCT01220180|neuropathic pain
1184261|NCT01220180|fibromyalgia
1184262|NCT01220180|post-market surveillance
1184263|NCT01220180|prospective observational
1184264|NCT01220154|ovarian
1184265|NCT01220154|cancer
1184266|NCT01220154|fallopian tube
1184267|NCT01220154|peritoneal
1184268|NCT01220154|intraperitoneal
1184269|NCT01220154|bevacizumab
1184270|NCT01220154|carboplatin
1184271|NCT01220154|paclitaxel
1184272|NCT01220154|chemo-naive
1184273|NCT01220128|WT1
1184274|NCT01220128|neoadjuvant
1184275|NCT01220128|tumor antigen
1184276|NCT01220128|immunotherapy
1184277|NCT01220128|breast cancer
1184278|NCT01220128|adult
1184279|NCT01220115|sickle cell disease
1184280|NCT01220115|iron over load
1184281|NCT01220102|acne
1184282|NCT01220102|Epiduo
1184283|NCT01220102|adapalene/ benzoyl peroxide
1184284|NCT01220089|obesity
1184285|NCT01220089|weight loss
1184286|NCT01220076|Tamoxifen,
1184287|NCT01220076|Breat Cancer
1184288|NCT01220076|Pharmacogenetic
1184289|NCT01220076|non metastatic breast cancer, HR +
1184290|NCT01220063|RSHF
1184291|NCT01220063|Irinotecan
1184292|NCT01220063|Colorectal Cancer
1184293|NCT01220063|metastases
1184294|NCT01220050|Paricalcitol
1184295|NCT01220050|Renal transplant
1184296|NCT01220050|Secondary Hyperparathyroidism
1184297|NCT01220011|Fetoscopic Laser surgery
1184298|NCT01220011|Stage 1 Twin - twin transfusion syndrome
1184299|NCT01219998|Postoperative Complications
1184300|NCT01219998|Acute Kidney Failure
1184301|NCT01219998|Peritoneal Dialysis
1184302|NCT01219998|NGAL
1184303|NCT01219985|positron emission tomography / computed tomography
1184304|NCT01219985|18F-fluoro-2-deoxyglucose
1184305|NCT01219985|liver neoplasm
1184306|NCT01219985|respiratory motion
1184307|NCT01219972|Bone marrow transplant
1184308|NCT01219972|Pulmonary complications
1184309|NCT01219959|ESRD
1184310|NCT01219959|Diabetes
1184311|NCT01219959|CAPD
1184312|NCT01219946|Chronic Obstructive Pulmonary Disease, symptoms
1184313|NCT01219920|Metastatic colorectal cancer
1184314|NCT01219920|Phase III
1184315|NCT01219920|FOLFOXIRI
1184316|NCT01219920|FOLFIRI
1184317|NCT01219894|Coronary Disease
1184318|NCT01219894|Stent
1184319|NCT01219894|Healing
1184320|NCT01219894|Anti-platelet therapy
1184321|NCT01219881|desflurane
1184322|NCT01219881|sevoflurane
1184323|NCT01219855|Parathyroid Diseases
1184324|NCT01219855|Renal Insufficiency
1184325|NCT01219855|Kidney Failure, Chronic
1184326|NCT01219855|Hyperparathyroidism, Secondary
1184327|NCT01219855|Vitamin D
1184328|NCT01219855|Hyperparathyroidism
1184329|NCT01219855|Kidney Diseases
1184330|NCT01219855|Kidney Failure
1184331|NCT01219855|Renal Insufficiency, Chronic
1184332|NCT01219842|Intermittent claudication
1184333|NCT01219842|Health Related Quality of Life
1184334|NCT01219842|Walking performance
1184335|NCT01219842|Daily walking capacity
1184336|NCT01219829|Pancreatic intraepithelial neoplasia (PanIN)
1184337|NCT01219829|Pancreatic Cancer
1184338|NCT01219829|Recurrence of pancreatic cancer
1184339|NCT01219829|Field Effect
1184340|NCT01219829|Genetic mutations in pancreatic cancer
1184341|NCT01219816|efficacy of Chemo-immunotherapy
1184342|NCT01219803|Dose-Response Relationship, type 2 diabetes,TCM
1184343|NCT01219790|Patients with painful vertebral metastases with a prostate cancer with an indication of analgesic treatment.
1184344|NCT01219777|bevacizumab
1184345|NCT01219777|paclitaxel
1184346|NCT01219777|carboplatin
1184347|NCT01219777|ovarian
1184348|NCT01219777|cancer
1184349|NCT01219777|fallopian tube
1184350|NCT01219777|primary peritoneal
1184351|NCT01219764|Helicobacter pylori infection
1184352|NCT01219764|quadruple therapy
1184353|NCT01219764|Amoxicillin
1184354|NCT01219764|Metronidazole
1184355|NCT01219764|Clarithromycin
1184356|NCT01219764|Rabeprazole
1184357|NCT01219738|Asthma, airway blood flow, budesonide, glucocorticosteroid.
1184358|NCT01219725|Body composition
1184359|NCT01219725|Endothelial function
1184360|NCT01219725|Lipoprotein profile
1184361|NCT01219725|Inflammatory markers
1184362|NCT01219725|Aerobic capacity
1184363|NCT01219725|Thrombotic markers
1184364|NCT01219725|Arterial stiffness
1184365|NCT01219725|Cardiac function
1184366|NCT01219725|Traditional and emerging cardiovascular disease risk factors
1184367|NCT01219712|NT-proBNP
1184368|NCT01219712|non-cardiac surgery
1184369|NCT01219712|left ventricular dysfunction
1184370|NCT01219712|cardiac complications
1184371|NCT01219699|advanced solid tumors
1184372|NCT01219699|mutation
1184373|NCT01219699|amplification
1184374|NCT01219699|wild type
1184375|NCT01219699|PIK3CA gene
1184376|NCT01219699|dose-escalation
1184377|NCT01219699|estrogen receptor positive breast cancer
1184378|NCT01219686|unipolar depression, escitalopram, pindolol
1184379|NCT01219673|Epithelial carcinoma
1184380|NCT01219673|Oropharynx
1184381|NCT01219673|Larynx
1184382|NCT01219673|Symptom-management
1184383|NCT01219673|Chemoradiation
1184384|NCT01219673|Placebo
1184385|NCT01219673|Armodafinil
1184386|NCT01219673|Nuvigil
1184387|NCT01219673|Bupropion
1184388|NCT01219673|Wellbutrin
1184389|NCT01219673|Wellbutrin SR
1184390|NCT01219673|Zyban
1184391|NCT01219673|Minocycline
1184392|NCT01219673|Dynacin
1184393|NCT01219673|Minocin
1184394|NCT01219673|Minocin PAC
1184395|NCT01219673|Myrac
1184396|NCT01219673|Solodyn
1184397|NCT01219660|sleep
1184398|NCT01219660|apnea
1184399|NCT01219647|Multiple Sclerosis
1184400|NCT01219647|Exercise
1184401|NCT01219647|Cognition
1184402|NCT01219621|Symphony DR 2550,
1184403|NCT01219621|Dual Chamber Pacemaker,
1184404|NCT01219621|Sorin,
1184405|NCT01219621|Ela Medical,
1184406|NCT01219621|DDD Mode,
1184407|NCT01219621|AAIsafeR2 mode,
1184408|NCT01219621|AV-Conduction,
1184409|NCT01219621|Reducing Ventricular Pacing,
1184410|NCT01219621|Congestive Heart Failure,
1184411|NCT01219621|Cardiac Function,
1184412|NCT01219621|Atrial Arrhythmia,
1184413|NCT01219621|Atrial Fibrillation,
1184414|NCT01219621|Atrial and Ventricular Hemodynamics,
1184415|NCT01219621|Long AV-delays.
1184416|NCT01219621|Ventricular Function,
1184417|NCT01219621|Implantation,
1184418|NCT01219595|Urinary Tract Infection
1184419|NCT01219595|UTI
1184420|NCT01219582|Diabetes Mellitus Type-2
1184421|NCT01219582|Acarbose
1184422|NCT01219582|Metformin
1184423|NCT01219582|Drug Therapy, Combination
1184424|NCT01219569|blindness
1184425|NCT01219569|ischemic optic neuropathy
1184426|NCT01219556|Hypertension
1184427|NCT01219556|Antihypertensive Agents
1184428|NCT01219556|Drug Therapy, Combination
1184429|NCT01219556|Olmesartan Medoxomil
1184430|NCT01219556|Hydrochlorothiazide
1184431|NCT01219543|Advanced solid malignancies
1184432|NCT01219543|Child-Pugh A to B7 advanced hepatocellular carcinoma
1184433|NCT01219543|EGFR and/or ROS mutant NSCLC
1184434|NCT01219543|Non-smokers with lung metastasis
1184435|NCT01219543|Gastric cancer
1184436|NCT01219543|Solid tumour
1184437|NCT01219543|AZD1480
1184438|NCT01219543|JAK1/JAK2 kinase inhibitor
1184439|NCT01219530|gestational carrier
1184440|NCT01219530|intended parent
1184441|NCT01219517|IVF
1184442|NCT01219517|embryo biopsy
1184443|NCT01219517|DNA fingerprinting
1184444|NCT01219517|SNP
1184445|NCT01219504|PGD
1184446|NCT01219504|IVF
1184447|NCT01219491|egg donor
1184448|NCT01219491|recipients
1184449|NCT01219491|donor characteristics
1184450|NCT01219478|To investigate the relationship between retinal thickness (RT) and metabolic risks (MRs) in patients without retinal lesion
1184451|NCT01219465|Diabetes Mellitus
1184452|NCT01219465|Diabetes Mellitus, Type 1
1184453|NCT01219465|mesenchymal stem cells
1184454|NCT01219465|Umbilical cord
1184455|NCT01219452|Dilated Cardiomyopathy
1184456|NCT01219452|Umbilical cord
1184457|NCT01219452|Mesenchymal stem cells
1184458|NCT01219452|Children
1184459|NCT01219439|discarded pathological specimens
1184460|NCT01219439|discarded media
1184461|NCT01219439|IVF
1184462|NCT01219426|Gambling
1184463|NCT01219426|cognitive distortions
1184464|NCT01219426|assessment tool
1184465|NCT01219426|validation
1184466|NCT01219426|French
1184467|NCT01219413|aliskiren
1184468|NCT01219413|renin inhibitor
1184469|NCT01219413|proteinuria
1184470|NCT01219413|chronic kidney diseases
1184471|NCT01219413|ACE inhibitor
1184472|NCT01219400|DPP-4
1184473|NCT01219400|GLP-1
1184474|NCT01219400|Glucagon
1184475|NCT01219400|Catecholamines
1184476|NCT01219400|Counterregulation
1184477|NCT01219400|Insulin-treatment
1184478|NCT01219400|Type 2 diabetes
1184479|NCT01219387|AMH
1184480|NCT01219387|inhibin B
1184481|NCT01219387|infertility
1184482|NCT01219374|egg donor
1184483|NCT01219361|Donated embryos
1184484|NCT01219348|IDO enzyme
1184485|NCT01219348|Vaccination trial
1184486|NCT01219348|Immunotherapy
1184487|NCT01219348|NSCLC, stage III_IV
1184488|NCT01219348|Indeolamine 2,3 dioxygenase = IDO
1184489|NCT01219335|IVF
1184490|NCT01219322|general endotracheal anesthesia
1184491|NCT01219322|ASA I or II
1184492|NCT01219309|Attention-deficit/hyperactivity disorder
1184493|NCT01219309|Omega 3/6 fatty acids
1184494|NCT01219309|Developmental coordination disorder
1184495|NCT01219309|Reading/writing difficulties.
1184496|NCT01219296|infertility
1184497|NCT01219296|IVF
1184498|NCT01219283|PGD
1184499|NCT01219283|IVF
1184500|NCT01219270|Radiocontrast media,
1184501|NCT01219270|hyponatremia
1184502|NCT01219257|SpA
1184503|NCT01219257|Anti-TNF alpha treatment
1184504|NCT01219257|Ultrasonography
1184505|NCT01219257|Synovitis
1184506|NCT01219257|Enthesitis
1184507|NCT01219244|memory
1184508|NCT01219244|diet
1184509|NCT01219244|elderly
1184510|NCT01219244|cognition
1184511|NCT01219244|prevention
1184512|NCT01219244|lifestyle
1184513|NCT01219231|Exercise
1184514|NCT01219231|elderly
1184515|NCT01219231|cognition
1184516|NCT01219231|prevention
1184517|NCT01219231|cognitive decline
1184518|NCT01219231|Lifestyle
1184519|NCT01219218|Extracorporeal Shockwave Therapy
1184520|NCT01219218|Myocardial Ischemia
1184521|NCT01219218|Refractory Angina
1184522|NCT01219205|macular edema secondary to retinal benous occlusion
1184523|NCT01219179|Extremely Low Birth Weight Infants
1184524|NCT01219179|Hypernatremia
1184525|NCT01219179|Enteral Sterile Water Feeds
1184526|NCT01219153|Letrozole ,IVF, poor responders , GnRH antagonist
1184527|NCT01219140|POMx
1184528|NCT01219140|Osteopenia
1184529|NCT01219140|postmenopausal women
1184530|NCT01219140|Pomegranate
1184531|NCT01219127|Hyperbaric oxygen therapy
1184532|NCT01219114|Daptomycin
1184533|NCT01219114|endocarditis
1184534|NCT01219114|complicated skin and skin structure infection
1184535|NCT01219101|Ethinyl estradiol
1184536|NCT01219101|Polycystic ovary syndrome
1184537|NCT01219101|Intrauterine insemination
1184538|NCT01219049|Diet
1184539|NCT01219049|Fibromyalgia
1184540|NCT01219049|Pain
1184541|NCT01219049|Drug
1184542|NCT01219049|Amino-acid
1184543|NCT01219049|Fatigue
1184544|NCT01219036|Asthma
1184545|NCT01219036|Non-adherence
1184546|NCT01219036|Fractional exhaled nitric oxide
1184547|NCT01219023|Hand foot syndrome
1184548|NCT01219023|Palmar Plantar Erythrodysesthesia
1184549|NCT01219023|chemotherapy
1184550|NCT01219023|Sunitinib
1184551|NCT01219023|Capecitebine
1184552|NCT01219023|Sildenafil
1184553|NCT01219010|Monoclonal Gammopathy of Undetermined Significance
1184554|NCT01219010|Smoldering Multiple Myeloma
1184555|NCT01219010|Indolent Multiple Myeloma
1184556|NCT01219010|QT
1184557|NCT01219010|Siltuximab
1184558|NCT01219010|CNTO 328
1184559|NCT01219010|IL-6
1184560|NCT01219010|Monoclonal Antibody
1184561|NCT01218997|Alcoholism
1184562|NCT01218997|Alcohol dependence
1184563|NCT01218984|Opiate Dependence
1184564|NCT01218971|Alcohol Dependence
1184565|NCT01218958|Alcoholism
1184566|NCT01218932|primaquine
1184567|NCT01218932|chloroquine
1184568|NCT01218932|pharmacokinetic
1184569|NCT01218932|interactions
1184570|NCT01218906|Dengue Fever Fever Dengue Infection
1184571|NCT01218867|Clinical Response
1184572|NCT01218867|Metastatic Cancer
1184573|NCT01218867|Immunotherapy
1184574|NCT01218867|Adoptive Cell Therapy
1184575|NCT01218867|Metastatic Melanoma
1184576|NCT01218854|Biopsy
1184577|NCT01218854|Surgical Navigation
1184578|NCT01218854|Image-guided Therapy
1184579|NCT01218854|CT- Guided Biopsy
1184580|NCT01218854|Cancer
1184581|NCT01218841|Fish oil
1184582|NCT01218841|Omega-3 fatty acids
1184583|NCT01218841|Parenteral lipid emulsions
1184584|NCT01218841|Immune response
1184585|NCT01218841|Surgery
1184586|NCT01218828|Contrast
1184587|NCT01218828|nephropathy
1184588|NCT01218828|cardiac catheterization
1184589|NCT01218828|angiography
1184590|NCT01218828|percutaneous coronary intervention is
1184591|NCT01218802|HIV
1184592|NCT01218802|Heart Disease
1184593|NCT01218802|Bone Density
1184594|NCT01218789|Blindness
1184595|NCT01218789|Eye Diseases
1184596|NCT01218789|Nap Disorders
1184597|NCT01218789|Circadian Rhythm Disorders
1184598|NCT01218789|Sleep disorders
1184599|NCT01218789|Circadian Rhythm Sleep Disorders
1184600|NCT01218789|Dyssomnias
1184601|NCT01218789|Nervous System Diseases
1184602|NCT01218776|Acute Coronary Syndrome, Eastern Europe, Therapies
1184603|NCT01218763|Cardiac Event recorder
1184604|NCT01218763|Sensitivity
1184605|NCT01218763|Efficacy
1184606|NCT01218750|DDME, ppV, ILM peeling, bevacizumab injection
1184607|NCT01218685|Immunocompromised patients
1184608|NCT01218685|Safety of pandemic influenza A (H1N1)vaccine
1184609|NCT01218685|Immunogenicity of pandemic influenza A (H1N1)vaccine
1184610|NCT01218672|BPH
1184611|NCT01218672|Benign Prostatic Hyperplasia
1184612|NCT01218659|Fabry Disease
1184613|NCT01218646|Influenza
1184614|NCT01218646|Quadrivalent Inactivated Influenza Vaccine
1184615|NCT01218646|Trivalent Inactivated Influenza Vaccine
1184616|NCT01218646|Influenza viruses
1184617|NCT01218607|Heart Septal Defects, Atrial
1184618|NCT01218607|Pulmonary Circulation
1184619|NCT01218607|Ventricular Function, Right
1184620|NCT01218607|Echocardiography, Stress
1184621|NCT01218607|Ergometry
1184622|NCT01218607|Tissue Doppler Imaging
1184623|NCT01218594|Stage III
1184624|NCT01218594|Unresectable
1184625|NCT01218594|Non-small cell lung cancer
1184626|NCT01218581|Adenomyosis, letrozole, GnRH-a
1184627|NCT01218555|kidney cancer
1184628|NCT01218555|adenoidcystic cancer
1184629|NCT01218542|Secondary brain malignancies
1184630|NCT01218542|RapidArc
1184631|NCT01218542|Volumetric modulated arc therapy
1184760|NCT01217970|speed
1184632|NCT01218529|Brain metastases from lung and breast tumors
1184633|NCT01218490|surgery
1184634|NCT01218490|ovarian cancer
1184635|NCT01218490|lymphadectomy
1184636|NCT01218477|Leukemia
1184637|NCT01218477|(Chronic Myeloid Leukemia-Chronic Phase and Advanced)
1184638|NCT01218464|Liver Failure
1184639|NCT01218464|Mesenchymal Stem Cells
1184640|NCT01218464|Model for End-Stage Liver Disease
1184641|NCT01218464|Ascite
1184642|NCT01218464|Serum Albumin
1184643|NCT01218425|dopamine
1184644|NCT01218425|EEG
1184645|NCT01218425|episodic memory
1184646|NCT01218425|contingent negative variation
1184647|NCT01218425|response preparation
1184648|NCT01218425|levodopa
1184649|NCT01218425|methylphenidate
1184650|NCT01218412|Physical Activity
1184651|NCT01218412|Motivational Interviewing
1184652|NCT01218412|Web-based
1184653|NCT01218412|Physician Referral
1184654|NCT01218399|Asthma
1184655|NCT01218386|ICSI
1184656|NCT01218386|GnRH antagonists
1184657|NCT01218386|planning
1184658|NCT01218373|older people
1184659|NCT01218373|living independently at home
1184660|NCT01218360|Crohn's disease
1184661|NCT01218360|standard-of-care
1184662|NCT01218360|Crohn Disease
1184663|NCT01218360|Active Crohn's Disease
1184664|NCT01218347|OATP1B1
1184665|NCT01218347|rosuvastatin
1184666|NCT01218321|antiepileptic drugs
1184667|NCT01218321|mitochondria
1184668|NCT01218308|Influenza
1184669|NCT01218295|COPD
1184670|NCT01218295|inspiratory muscles training
1184671|NCT01218282|COPD
1184672|NCT01218282|home exercise training
1184673|NCT01218269|anastomoses
1184674|NCT01218256|diabetes mellitus
1184675|NCT01218256|type 2 diabetes
1184676|NCT01218256|T2DM
1184677|NCT01218256|resistance training
1184678|NCT01218256|hypertrophy training
1184679|NCT01218256|endurance training
1184680|NCT01218243|Acupuncture
1184681|NCT01218243|Mild and moderate BPH
1184682|NCT01218230|Pegaptanib, myopic CNVM, intravitreal anti-VEGF
1184683|NCT01218217|TB
1184684|NCT01218217|Tuberculosis
1184685|NCT01218217|EBA
1184686|NCT01218217|Pulmonary
1184687|NCT01218217|Early Bactericidal Activity
1184688|NCT01218204|Dyslipidemia
1184689|NCT01218204|Tolerability
1184690|NCT01218204|Safety
1184691|NCT01218204|Ezetimibe
1184692|NCT01218204|Pharmacokinetics
1184693|NCT01218204|Lipids
1184694|NCT01218204|Statin
1184695|NCT01218204|Atorvastatin
1184696|NCT01218204|Pharmacodynamics
1184697|NCT01218204|GSK1292263
1184698|NCT01218191|subarachnoid hemorrhage
1184699|NCT01218191|scintigraphy
1184700|NCT01218191|neurocardiogenic injury
1184701|NCT01218178|acute myocardial infarction
1184702|NCT01218178|acute kidney injury
1184703|NCT01218178|contrast induced nephropathy
1184704|NCT01218178|primary PCI
1184705|NCT01218178|sodium-bicarbonate
1184706|NCT01218178|N-acetylcysteine
1184707|NCT01218165|Healthy Eldery People
1184708|NCT01218152|NF1
1184709|NCT01218152|MPNST
1184710|NCT01218152|plasma
1184711|NCT01218152|microarray CGH
1184712|NCT01218139|neurofibroma
1184713|NCT01218139|MPNST
1184714|NCT01218139|array CGH
1184715|NCT01218139|sequencing
1184716|NCT01218113|Human Immunodeficiency Virus (HIV)-1
1184717|NCT01218113|safety
1184718|NCT01218113|vaccine
1184719|NCT01218113|immunogenicity
1184720|NCT01218113|reactogenicity
1184721|NCT01218113|HIV infection
1184722|NCT01218087|Positional Head Shape Deformity
1184723|NCT01218074|bleeding
1184724|NCT01218074|blood sparing procedure
1184725|NCT01218074|desmopressin
1184726|NCT01218074|aggregometry
1184727|NCT01218074|thromboelastography
1184728|NCT01218061|Pre-diabetes
1184729|NCT01218061|Type 2 diabetes
1184730|NCT01218061|Biomarkers
1184731|NCT01218061|Cohort
1184732|NCT01218061|Diabetes Risk Score
1184733|NCT01218048|Carcinoma
1184734|NCT01218048|Head and Neck
1184735|NCT01218048|Cetuximab
1184736|NCT01218048|Locally Advanced Head and Neck Squamous Cell Carcinoma
1184737|NCT01218035|Hip osteoarthritis
1184738|NCT01218035|Bisphophonate therapy
1184739|NCT01218035|Zoledronic acid
1184740|NCT01218035|Radiostereometric analysis
1184741|NCT01218035|Osteoporosis
1184742|NCT01218009|asthma
1184743|NCT01218009|dry powder inhaler
1184744|NCT01218009|short-acting beta2-agonist
1184745|NCT01218009|SABA
1184746|NCT01218009|bronchoconstriction
1184747|NCT01218009|bronchodilation
1184748|NCT01218009|bronchodilator
1184749|NCT01218009|metered dose inhaler
1184750|NCT01217996|working memory intervention
1184751|NCT01217996|memory impairment
1184752|NCT01217996|cognitive late effects
1184753|NCT01217996|Childhood Cancer Survivors
1184754|NCT01217970|methamphetamine
1184755|NCT01217970|dependence
1184756|NCT01217970|stimulant
1184757|NCT01217970|amphetamine
1184758|NCT01217970|los angeles
1184759|NCT01217970|meth
1184761|NCT01217970|crank
1184762|NCT01217970|abuse
1184763|NCT01217957|Drug therapy
1184764|NCT01217944|Pathologic myopia
1184765|NCT01217944|PM
1184766|NCT01217944|choroidal neovascularization
1184767|NCT01217944|CNV
1184768|NCT01217944|ranibizumab
1184769|NCT01217944|verteporfin PDT
1184770|NCT01217931|Renal Cell Carcinoma
1184771|NCT01217931|Metastatic Renal Cell Carcinoma
1184772|NCT01217931|Clear cell component
1184773|NCT01217931|RCC
1184774|NCT01217931|Bevacizumab
1184775|NCT01217931|Everolimus
1184776|NCT01217931|Pazopanib
1184777|NCT01217931|GW786034
1184778|NCT01217931|Avastin
1184779|NCT01217931|Anti-VEGF monoclonal antibody
1184780|NCT01217931|rhuMAb-VEGF
1184781|NCT01217931|Afinitor
1184782|NCT01217931|RAD001
1184783|NCT01217918|PH-797804
1184784|NCT01217918|Japanese
1184785|NCT01217918|Phase 1
1184786|NCT01217918|multiple dose study
1184787|NCT01217905|Phase 1
1184788|NCT01217905|Type 2 diabetes
1184789|NCT01217905|obesity
1184790|NCT01217905|Japanese healthy volunteer
1184791|NCT01217905|AZD7687
1184792|NCT01217892|Type 2 diabetes
1184793|NCT01217892|metformin treated
1184794|NCT01217892|inadequate control
1184795|NCT01217892|metformin treatment alone
1184796|NCT01217879|Cough
1184797|NCT01217879|Telmisartan
1184798|NCT01217879|Bradykinin
1184799|NCT01217879|Tolerability
1184800|NCT01217866|laparoscopic
1184801|NCT01217866|vaginal
1184802|NCT01217866|hysterectomy
1184803|NCT01217840|Adolescents, Vitamin D
1184804|NCT01217788|Generalized Social Phobia
1184805|NCT01217788|Social Anxiety Disorder
1184806|NCT01217788|Social Phobia
1184807|NCT01217788|Phobic Disorders
1184808|NCT01217788|Phobias
1184809|NCT01217775|PMDD, Premenstrual, Dysphoria, Mood Swings, Bloating.
1184810|NCT01217762|Oraya
1184811|NCT01217762|Oraya Therapeutics, Inc.
1184812|NCT01217762|low voltage stereotactic radiosurgery
1184813|NCT01217762|radiosurgery
1184814|NCT01217762|radiotherapy
1184815|NCT01217762|IRay
1184816|NCT01217762|AMD
1184817|NCT01217762|Macular Degeneration
1184818|NCT01217762|Wet AMD
1184819|NCT01217762|xray
1184820|NCT01217762|radiation
1184821|NCT01217762|x ray
1184822|NCT01217762|external beam radiation
1184823|NCT01217762|Ranibizumab
1184824|NCT01217762|Lucentis
1184825|NCT01217723|Acute leukemia (myeloid,lymphoid,or biphenotypic)
1184826|NCT01217723|Chronic myeloid leukemia
1184827|NCT01217723|Chronic lymphocytic leukemia
1184828|NCT01217723|Lymphoma
1184829|NCT01217723|Myelodysplastic syndrome
1184830|NCT01217723|Myeloproliferative disorder
1184831|NCT01217710|Chronic Obstructive Pulmonary Disease
1184832|NCT01217710|Physical Activity
1184833|NCT01217710|Self Management
1184834|NCT01217710|Exercise
1184835|NCT01217710|Technology
1184836|NCT01217710|Motivational Interviewing
1184837|NCT01217697|Metastatic Castration-Resistant Prostate Cancer (CRPC)
1184838|NCT01217697|Abiraterone Acetate
1184839|NCT01217671|Pulmonary, Emphysema
1184840|NCT01217671|Alpha-1 Antitrypsin Deficiency
1184841|NCT01217658|Randomized Trial
1184842|NCT01217658|Infant Colic
1184843|NCT01217658|Abusive Head Trauma
1184844|NCT01217658|Shaken Baby Syndrome
1184845|NCT01217645|Major depression disorder
1184846|NCT01217632|Connective tissue growth factor (CTGF)
1184847|NCT01217632|human IgG1 monoclonal antibody
1184848|NCT01217619|neoadjuvant treatment
1184849|NCT01217593|mastectomy
1184850|NCT01217593|breast cancer
1184851|NCT01217593|breast surgery
1184852|NCT01217580|c-section
1184853|NCT01217580|cesarean section
1184854|NCT01217580|TAP block
1184855|NCT01217580|pain
1184856|NCT01217580|pain after delivery
1184857|NCT01217580|pain after C-section
1184858|NCT01217580|pain after C-section delivery
1184859|NCT01217580|pain after cesarean delivery
1184860|NCT01217580|pain after cesarean
1184861|NCT01217567|cicatrix
1184862|NCT01217567|cesarean section
1184863|NCT01217567|sutures
1184864|NCT01217567|surgical staples
1184865|NCT01217567|postoperative pain
1184866|NCT01217567|Infection
1184867|NCT01217554|Low Back Pain
1184868|NCT01217554|Disability
1184869|NCT01217554|Kinematic measures
1184870|NCT01217541|Dementia
1184871|NCT01217541|BPSD
1184872|NCT01217541|Quality of Life
1184873|NCT01217541|Person-centred care
1184874|NCT01217541|Job satisfaction
1184875|NCT01217541|Nursing home
1184876|NCT01217541|Primary care
1184877|NCT01217528|ICD
1184878|NCT01217528|CRTD
1184879|NCT01217528|Sudden cardiac death
1184880|NCT01217528|Device settings
1184881|NCT01217528|Patients who received ICD/CRTD for primary prevention of sudden cardiac death
1184882|NCT01217502|Aged
1184883|NCT01217502|Homes for the aged
1184884|NCT01217502|Self management
1184885|NCT01217502|Personal autonomy
1184886|NCT01217502|Disease management
1184887|NCT01217502|Self efficacy
1184888|NCT01217502|Participation
1184889|NCT01217489|breast
1184890|NCT01217489|cancer
1184891|NCT01217489|diagnosis
1184892|NCT01217489|electrical
1184893|NCT01217489|non-invasive
1184894|NCT01217489|mammography
1184895|NCT01217476|Diabetic foot
1184896|NCT01217476|Neuropathic
1184897|NCT01217476|Wound
1184898|NCT01217476|Growth factor
1184899|NCT01217463|Diabetic foot
1184900|NCT01217463|Neuropathic
1184901|NCT01217463|Wound
1184902|NCT01217463|Growth factor
1184903|NCT01217424|psychosocial effects of cancer and its treatment
1184904|NCT01217424|pain
1184905|NCT01217424|unspecified adult solid tumor, protocol specific
1184906|NCT01217398|ciliary body and choroid melanoma, medium/large size
1184907|NCT01217398|ciliary body and choroid melanoma, small size
1184908|NCT01217398|iris melanoma
1184909|NCT01217398|metastatic intraocular melanoma
1184910|NCT01217398|stage IV intraocular melanoma
1184911|NCT01217385|stage IIIA breast cancer
1184912|NCT01217385|stage IIIB breast cancer
1184913|NCT01217385|stage IIIC breast cancer
1184914|NCT01217372|Recurrent idiopathic calcium oxalate nephrolithiasis.
1184915|NCT01217333|Telephones
1184916|NCT01217333|Community-Based Participatory Research
1184917|NCT01217333|Participation, Patient
1184918|NCT01217333|Rural health services
1184919|NCT01217320|rheumatology
1184920|NCT01217320|creatine supplementation
1184921|NCT01217320|quality of life
1184922|NCT01217320|strength
1184923|NCT01217320|juvenile systemic lupus erythematosus
1184924|NCT01217320|juvenile dermatomyositis
1184925|NCT01217307|Metformin
1184926|NCT01217307|ST elevation myocardial infarction (STEMI)
1184927|NCT01217307|Coronary artery disease
1184928|NCT01217307|Heart failure
1184929|NCT01217307|Diabetes
1184930|NCT01217294|anaesthetic techniques, regional
1184931|NCT01217294|analgesia, post-operative
1184932|NCT01217294|fascia iliaca compartment block
1184933|NCT01217294|ultrasound guided
1184934|NCT01217294|surgery, orthopaedic
1184935|NCT01217281|CKD, Renal, Chronic Kidney Disease, Periodontitis, Perio
1184936|NCT01217255|Hemophilia
1184937|NCT01217255|Burden of Illness
1184938|NCT01217255|Pediatric
1184939|NCT01217255|Quality of Life
1184940|NCT01217255|Disability
1184941|NCT01217255|Participation
1184942|NCT01217242|cerebral palsy
1184943|NCT01217242|walking activity
1184944|NCT01217242|physical activity
1184945|NCT01217242|participation
1184946|NCT01217242|activity performance
1184947|NCT01217242|activity capacity
1184948|NCT01217229|Hodgkin Lymphoma
1184949|NCT01217216|Breast Cancer
1184950|NCT01217216|Weight loss
1184951|NCT01217216|Group Intervention
1184952|NCT01217216|Telephone Intervention
1184953|NCT01217177|Cervical cancer,
1184954|NCT01217177|radiotherapy,
1184955|NCT01217177|chemotherapy,
1184956|NCT01217177|rad001,
1184957|NCT01217177|everolimus
1184958|NCT01217164|nutrition
1184959|NCT01217164|very low birth weight
1184960|NCT01217164|premature
1184961|NCT01217151|Hemodynamic Monitoring
1184962|NCT01217151|Goal-Directed Therapy
1184963|NCT01217138|Anaphylaxis, autoinjector, design, epinephrine
1184964|NCT01217125|tuberousclerosis, angiomyolipoma, rapamycin
1184965|NCT01217112|Dyslipidemias
1184966|NCT01217112|Diabetes
1184967|NCT01217112|Liver Fat
1184968|NCT01217112|Body Fat
1184969|NCT01217099|refractory mycoplasma pneumoniae pneumonia
1184970|NCT01217060|Adenocarcinoma
1184971|NCT01217060|Squamous cell carcinoma
1184972|NCT01217060|Thoracic esophagus
1184973|NCT01217060|Gastroesophageal junction
1184974|NCT01217060|Chemoradiotherapy
1184975|NCT01217060|Esophagectomy
1184976|NCT01217060|5-Fluorouracil
1184977|NCT01217060|Docetaxel
1184978|NCT01217060|Radiation
1184979|NCT01217060|Radiotherapy
1184980|NCT01217060|XRT
1184981|NCT01217060|IMRT
1184982|NCT01217060|Taxotere
1184983|NCT01217060|Adrucil
1184984|NCT01217060|Efudex
1184985|NCT01217060|Dexamethasone
1184986|NCT01217060|Decadron
1184987|NCT01217047|Spinal cord injury
1184988|NCT01217047|Functional electrical stimulation
1184989|NCT01217047|Rehabilitation
1184990|NCT01217047|Growth factors
1184991|NCT01217047|Cytokines
1184992|NCT01217034|Transcatheter arterial chemoembolization
1184993|NCT01217034|TACE
1184994|NCT01217034|sorafenib
1184995|NCT01217034|Time to untreatable progression
1184996|NCT01217034|TTUP
1184997|NCT01217008|Spinal Cord Injury
1184998|NCT01217008|GRNOPC1
1184999|NCT01216995|Heart Attack
1185000|NCT01216995|Regenerative Cells
1185001|NCT01216995|Stem Cells
1185002|NCT01216982|Mood Disorders
1185003|NCT01216982|Depression
1185004|NCT01216982|Combat Disorders
1185005|NCT01216982|Stress Disorders
1185006|NCT01216982|Fatty Acids, Omega-3
1185007|NCT01216982|Military Personnel
1185008|NCT01216982|Docosahexaenoic Acids/*therapeutic use
1185009|NCT01216982|Eicosapentaenoic Acid/*therapeutic use
1185010|NCT01216956|extended release nicotinic acid
1185011|NCT01216956|non esterified fatty acid (NEFA)
1185012|NCT01216956|insulin resistance
1185013|NCT01216956|Cholesteryl ester transfer protein (CETP)
1185014|NCT01216956|High density lipoprotein cholesterol
1185015|NCT01216891|Schizophrenia
1185016|NCT01216891|Schizoaffective Disorder
1185017|NCT01216891|Schizophreniform Disorder
1185018|NCT01216891|Delusional Disorder
1185019|NCT01216891|Psychosis
1185020|NCT01216891|First episode
1185021|NCT01216865|Diabetic foot
1185022|NCT01216865|critical limb ischemia
1185023|NCT01216865|mesenchymal stem cells
1185024|NCT01216865|umbilical cord
1185025|NCT01216813|esophageal cancer
1185026|NCT01216813|gastric cancer
1185027|NCT01216813|cervical cancer
1185028|NCT01216813|fallopian tube cancer
1185029|NCT01216813|ovarian epithelial cancer
1185030|NCT01216813|ovarian germ cell tumor
1185031|NCT01216813|ovarian sarcoma
1185032|NCT01216813|ovarian stromal cancer
1185033|NCT01216813|endometrial cancer
1185034|NCT01216813|uterine sarcoma
1185035|NCT01216813|vaginal cancer
1185036|NCT01216813|vulvar cancer
1185037|NCT01216813|adenocarcinoma of the gastroesophageal junction
1185038|NCT01216800|ototoxicity
1185039|NCT01216800|radiation toxicity
1185040|NCT01216800|stage I salivary gland cancer
1185041|NCT01216800|stage II salivary gland cancer
1185042|NCT01216800|stage III salivary gland cancer
1185043|NCT01216761|Bacteremia
1185044|NCT01216761|Blood culture
1185045|NCT01216761|Contamination
1185046|NCT01216761|Antiseptic agents
1185047|NCT01216748|airway blood flow
1185048|NCT01216748|albuterol
1185049|NCT01216748|acidosis
1185050|NCT01216748|alkalosis
1185051|NCT01216735|smokers
1185052|NCT01216735|inhaled corticosteroids
1185053|NCT01216735|brachial flow
1185054|NCT01216735|airway blood flow
1185055|NCT01216735|albuterol
1185056|NCT01216735|spirometry
1185057|NCT01216735|endothelial dysfunction
1185058|NCT01216722|Muscle Wasting
1185059|NCT01216722|Strengthening
1185060|NCT01216722|Liver Disease
1185061|NCT01216722|Transplant
1185062|NCT01216709|Infant
1185063|NCT01216709|Dietary Supplements
1185064|NCT01216709|Food, Fortified
1185065|NCT01216709|Iron Absorption
1185066|NCT01216696|ipilimumab
1185067|NCT01216696|melanoma
1185068|NCT01216696|NY-ESO-1
1185069|NCT01216683|contiguous stage II grade 1 follicular lymphoma
1185070|NCT01216683|contiguous stage II grade 2 follicular lymphoma
1185071|NCT01216683|contiguous stage II grade 3 follicular lymphoma
1185072|NCT01216683|noncontiguous stage II grade 1 follicular lymphoma
1185073|NCT01216683|noncontiguous stage II grade 2 follicular lymphoma
1185074|NCT01216683|noncontiguous stage II grade 3 follicular lymphoma
1185075|NCT01216683|stage III grade 1 follicular lymphoma
1185076|NCT01216683|stage III grade 2 follicular lymphoma
1185077|NCT01216683|stage III grade 3 follicular lymphoma
1185078|NCT01216683|stage IV grade 1 follicular lymphoma
1185079|NCT01216683|stage IV grade 2 follicular lymphoma
1185080|NCT01216683|stage IV grade 3 follicular lymphoma
1185081|NCT01216670|Reveal® XT
1185082|NCT01216670|Acute Heart Failure
1185083|NCT01216670|Low Ejection Fraction
1185084|NCT01216670|Reveal® XT implanted
1185085|NCT01216657|melanoma
1185086|NCT01216657|sunitinib
1185087|NCT01216644|gastric cancer
1185088|NCT01216644|perioperative
1185089|NCT01216644|FLOT
1185090|NCT01216644|ECF
1185091|NCT01216644|pathological complete remission
1185092|NCT01216644|locally advanced resectable adenocarcinoma of the esophagogastric juction or the stomach
1185093|NCT01216631|seronegative
1185094|NCT01216631|oligoarthritis
1185095|NCT01216631|infliximab
1185096|NCT01216631|intraarticular
1185097|NCT01216618|MiniMed paradigm insulin pumps
1185098|NCT01216618|insulin Lispro
1185099|NCT01216618|Insulin Asprt.
1185100|NCT01216592|COPD
1185101|NCT01216592|Airway inflammation
1185102|NCT01216592|Symptoms
1185103|NCT01216592|Lung function
1185104|NCT01216592|Correlation
1185105|NCT01216553|Bronchiolitis
1185106|NCT01216553|Infants
1185107|NCT01216553|Nebulized Inhalation
1185108|NCT01216553|RSV
1185109|NCT01216553|Oxygen
1185110|NCT01216540|vancomycin
1185111|NCT01216540|nephrotoxicity
1185112|NCT01216540|length of stay
1185113|NCT01216540|costs
1185114|NCT01216527|Stage IIB or III squamous cell esophageal carcinoma.
1185115|NCT01216514|chronic inflammatory bowel diseases
1185116|NCT01216514|crohn disease
1185117|NCT01216514|hemorrhagic rectocolitis
1185118|NCT01216514|immunological markers
1185119|NCT01216514|serological markers
1185120|NCT01216514|ANCA
1185121|NCT01216514|ASCA
1185122|NCT01216488|Forearm surgery
1185123|NCT01216488|Hand surgery
1185124|NCT01216488|Anesthesia
1185125|NCT01216462|Acute Coronary Syndrome
1185126|NCT01216449|Citalopram
1185127|NCT01216449|Functional Magnetic Resonance Imaging
1185128|NCT01216449|fMRI
1185129|NCT01216449|Pharmacokinetics
1185130|NCT01216449|Pharmacodynamics
1185131|NCT01216449|Amygdala
1185132|NCT01216449|Elderly
1185133|NCT01216436|melanoma
1185134|NCT01216436|immunotherapy
1185135|NCT01216436|dendritic cell
1185136|NCT01216436|GITR-ligand
1185137|NCT01216436|CTLA-4
1185138|NCT01216423|Patent Foramen Ovale
1185139|NCT01216423|Pulmonary embolism
1185140|NCT01216423|Stroke
1185141|NCT01216410|Nausea
1185142|NCT01216410|Vomiting
1185143|NCT01216371|carcinoma
1185144|NCT01216371|metastases
1185145|NCT01216371|renal
1185146|NCT01216371|lung
1185147|NCT01216358|Headache
1185148|NCT01216358|Contraception
1185149|NCT01216319|Biodesign
1185150|NCT01216319|Nipple Reconstruction
1185151|NCT01216319|Breast Cancer
1185152|NCT01216319|Mastectomy
1185153|NCT01216306|Obesity
1185154|NCT01216306|Physical Activity
1185155|NCT01216306|Sedentary Activity
1185156|NCT01216306|Television viewing
1185157|NCT01216306|Latino
1185158|NCT01216306|Hispanic
1185159|NCT01216306|Preschool
1185160|NCT01216306|School
1185161|NCT01216306|Head Start
1185162|NCT01216293|Drug Therapy
1185163|NCT01216280|Natura-alpha
1185164|NCT01216280|ulcerative colitis
1185165|NCT01216280|cytokines
1185166|NCT01216280|Th1
1185167|NCT01216280|Th17
1185168|NCT01216267|chromogranin A
1185169|NCT01216267|neuroendocrine
1185170|NCT01216267|carcinoid
1185171|NCT01216267|Proton Pump Inhibitor
1185172|NCT01216254|breast cancer
1185173|NCT01216254|stage 2
1185174|NCT01216254|breast conserving therapy
1185175|NCT01216254|sentinel lymph node dissection
1185176|NCT01216254|high frequency electrocoagulation
1185177|NCT01216202|Rectal cancer
1185178|NCT01216202|Preoperative radiotherapy
1185179|NCT01216202|Pelvic surgery
1185180|NCT01216202|Sexual function
1185181|NCT01216202|Wellbeing
1185182|NCT01216202|Hormone levels
1185183|NCT01216202|Spermatogenesis
1185184|NCT01216189|Rectal cancer
1185185|NCT01216189|Preoperative radiotherapy
1185186|NCT01216189|Pelvic surgery
1185187|NCT01216189|Sexual function
1185188|NCT01216189|Wellbeing
1185189|NCT01216189|Hormone levels
1185190|NCT01216176|Breast Cancer
1185191|NCT01216176|Postmenopausal
1185192|NCT01216176|Metastatic Phase I ONLY
1185193|NCT01216176|AZD0530
1185194|NCT01216176|Anastrozole
1185195|NCT01216176|Phase I for metastatic disease
1185196|NCT01216176|Phase II for newly diagnosed breast cancer
1185197|NCT01216176|Pharmacokinetic
1185198|NCT01216176|PK
1185199|NCT01216176|Hormone Receptor
1185200|NCT01216176|Estrogen Receptor
1185201|NCT01216176|Progesterone Receptor
1185202|NCT01216176|ER+
1185203|NCT01216176|PR+
1185204|NCT01216176|HER negative
1185205|NCT01216176|Aromatase Inhibitors
1185206|NCT01216163|Pain following third molar extraction (wisdom tooth)
1185207|NCT01216150|antifibrinolytic drug
1185208|NCT01216150|coronary surgery
1185209|NCT01216150|hemorrhage
1185210|NCT01216150|aspirin
1185211|NCT01216150|clopidogrel
1185212|NCT01216137|Multiple Sclerosis
1185213|NCT01216137|Fatigue
1185214|NCT01216137|Balance
1185215|NCT01216137|Upright Postural Control
1185216|NCT01216137|Dizziness
1185217|NCT01216124|triple negative local advanced breast cancer(TNLABC),neoadjuvant chemotherapy
1185218|NCT01216111|triple negative breast cancer，local recurrence,distant metastasis
1185219|NCT01216098|Intrapartum
1185220|NCT01216098|Clinical trial
1185221|NCT01216098|Perinatal
1185222|NCT01216098|Doula
1185223|NCT01216098|VBAC
1185224|NCT01216098|Perinatal Outcomes
1185225|NCT01216072|Relapsing Forms of Multiple Sclerosis
1185226|NCT01216072|Disease Modifying Therapy
1185227|NCT01216072|fingolimod
1185228|NCT01216072|Patient Reported Outcomes
1185229|NCT01216059|adherence
1185230|NCT01216059|text message
1185231|NCT01216059|reminder
1185232|NCT01216059|adolescents
1185233|NCT01216033|Breast cancer
1185234|NCT01216033|Diagnostics
1185235|NCT01216033|HER2
1185236|NCT01216033|Imaging
1185237|NCT01216033|Metastases
1185238|NCT01216033|SPECT
1185239|NCT01216033|Imaging of metastases
1185240|NCT01216020|Head and Neck Cancer
1185241|NCT01216020|Radiotherapy
1185242|NCT01216020|Cetuximab
1185243|NCT01216020|Cisplatin
1185244|NCT01216007|Plasma
1185245|NCT01216007|bupivacaine
1185246|NCT01216007|concentration
1185247|NCT01216007|caudal
1185248|NCT01216007|epidural
1185249|NCT01216007|TIVA
1185250|NCT01216007|Inhalational
1185251|NCT01216007|anesthesia
1185252|NCT01216007|Caudal epidural
1185253|NCT01215981|influenza vaccine
1185254|NCT01215955|Type 2 Diabetes
1185255|NCT01215955|Insulin
1185256|NCT01215955|Algorithms
1185257|NCT01215955|Blood glucose levels
1185258|NCT01215942|Rheumatoid Arthritis
1185259|NCT01215929|methamphetamine withdrawal
1185260|NCT01215929|mood
1185261|NCT01215929|retention
1185262|NCT01215929|sleep
1185263|NCT01215916|Solid tumors
1185264|NCT01215890|Crohn's disease
1185265|NCT01215890|Low bone mineral density
1185266|NCT01215890|inflammatory bowel disease
1185267|NCT01215890|bisphosphonate
1185268|NCT01215877|Bladder cancer
1185269|NCT01215877|Previously treated patients
1185270|NCT01215877|Tesetaxel
1185271|NCT01215877|Oral taxane
1185272|NCT01215864|metastatic tumors
1185273|NCT01215864|refractory tumors
1185274|NCT01215864|recurrent tumors
1185275|NCT01215851|Tuberculosis
1185276|NCT01215851|EBA
1185277|NCT01215851|TMC207
1185278|NCT01215851|pretomanid
1185279|NCT01215851|Early Bactericidal Activity
1185280|NCT01215851|Pulmonary Tuberculosis
1185281|NCT01215851|PA-824
1185282|NCT01215851|bedaquiline
1185283|NCT01215851|pyrazinamide
1185284|NCT01215851|moxifloxacin
1185285|NCT01215851|ethambutol
1185286|NCT01215851|rifafour
1185287|NCT01215838|HCC
1185288|NCT01215838|hepatocellular carcinoma
1185289|NCT01215838|Eovist
1185290|NCT01215838|MR
1185291|NCT01215838|MRI
1185292|NCT01215838|magnetic resonance
1185293|NCT01215825|Chronic obstructive pulmonary disease
1185294|NCT01215825|systemic steroid
1185295|NCT01215799|Hormone Refractory Prostate Cancer
1185296|NCT01215799|HRPC
1185297|NCT01215760|peripheral nerve injury
1185298|NCT01215760|sensory reeducation
1185299|NCT01215760|brain plasticity
1185300|NCT01215760|training with a mirror
1185301|NCT01215760|rehabilitation
1185302|NCT01215747|Kiacta for AA amyloidosis
1185303|NCT01215721|Incontinence
1185304|NCT01215721|Robotic Prostatectomy
1185305|NCT01215721|Prostate Cancer
1185306|NCT01215708|Kidney calculi
1185307|NCT01215708|Lithotripsy
1185308|NCT01215708|Calcium channel blockers
1185309|NCT01215708|Adrenergic alpha-antagonists.
1185310|NCT01215695|Intubation, Endotracheal
1185311|NCT01215695|Endotracheal Intubation, adverse events
1185312|NCT01215682|infections
1185313|NCT01215682|immune system
1185314|NCT01215682|vitamin D
1185315|NCT01215682|sport
1185316|NCT01215682|children
1185317|NCT01215669|Influenza
1185318|NCT01215669|Influenza Virus Vaccines
1185319|NCT01215669|Intradermal Injections
1185320|NCT01215643|Chronic hepatitis C genotype 2
1185321|NCT01215643|Chronic hepatitis C genotype 3
1185322|NCT01215643|Cyclophilin inhibitor
1185323|NCT01215630|Veins
1185324|NCT01215630|Exercise tests
1185325|NCT01215630|maximal oxygen uptake
1185326|NCT01215630|VO2max
1185327|NCT01215617|Randomized controlled study
1185328|NCT01215617|Exercise training
1185329|NCT01215617|Lung function
1185330|NCT01215617|Heart function
1185331|NCT01215604|elderly patients
1185332|NCT01215604|acute infection
1185333|NCT01215604|translation initiation factors
1185334|NCT01215604|eIF4E
1185335|NCT01215604|eIF4G
1185336|NCT01215591|Neonatal
1185337|NCT01215591|Nasal CPAP
1185338|NCT01215591|Randomized controlled trial
1185339|NCT01215591|Weaning
1185340|NCT01215578|Neuroendocrine Tumors
1185341|NCT01215578|Neuroectodermal Tumors
1185342|NCT01215578|Neoplasms, Germ Cell and Embryonal
1185343|NCT01215578|Neoplasms by Histologic Type
1185344|NCT01215578|Neoplasms
1185345|NCT01215578|Neoplasms, Glandular and Epithelial
1185346|NCT01215578|Neoplasms, Nerve Tissue
1185347|NCT01215578|Pancreatic Neoplasms
1185348|NCT01215578|Digestive System Neoplasms
1185349|NCT01215578|Neoplasms by Site
1185350|NCT01215578|Endocrine Gland Neoplasms
1185351|NCT01215578|Adenoma, Islet Cell
1185352|NCT01215578|Adenocarcinoma
1185353|NCT01215578|Carcinoma
1185354|NCT01215578|Adenoma
1185355|NCT01215578|Digestive System Diseases
1185356|NCT01215578|Pancreatic Diseases
1185357|NCT01215578|Endocrine System Diseases
1185358|NCT01215578|Sunitinib
1185359|NCT01215578|Antineoplastic Agents
1185360|NCT01215578|Therapeutic Uses
1185361|NCT01215578|Pharmacologic Actions
1185362|NCT01215578|Angiogenesis Inhibitors
1185363|NCT01215578|Angiogenesis Modulating Agents
1185364|NCT01215578|Growth Substances
1185365|NCT01215578|Physiological Effects of Drugs
1185366|NCT01215578|Growth Inhibitors
1185367|NCT01215565|Carcinoma, Hepatocellular
1185368|NCT01215565|Carcinoma
1185369|NCT01215565|Fibrosis
1185370|NCT01215565|Liver Neoplasms
1185371|NCT01215565|Pathologic Processes
1185372|NCT01215565|Digestive System Neoplasms
1185373|NCT01215565|Neoplasms by Site
1185374|NCT01215565|Neoplasms
1185375|NCT01215565|Liver Diseases
1185376|NCT01215565|Adenocarcinoma
1185377|NCT01215565|Neoplasms, Glandular and Epithelial
1185378|NCT01215565|Neoplasms by Histologic Type
1185379|NCT01215565|Sunitinib
1185380|NCT01215565|Antineoplastic Agents
1185381|NCT01215565|Therapeutic Uses
1185382|NCT01215565|Pharmacologic Actions
1185383|NCT01215565|Angiogenesis Inhibitors
1185384|NCT01215565|Angiogenesis Modulating Agents
1185385|NCT01215565|Growth Substances
1185386|NCT01215565|Physiological Effects of Drugs
1185387|NCT01215565|Growth Inhibitors
1185388|NCT01215500|solid tumor cancer
1185389|NCT01215500|epithelial carcinoma
1185390|NCT01215487|CML Predictive Study
1185391|NCT01215461|Neonatal mortality
1185392|NCT01215461|Preterm birth
1185393|NCT01215461|Low gestational age
1185394|NCT01215461|VLBW
1185395|NCT01215448|Fatigue
1185396|NCT01215448|Quality of life
1185397|NCT01215448|Lifestyle
1185398|NCT01215448|Complementary medicine
1185399|NCT01215422|Surgical procedures
1185400|NCT01215422|Intubation
1185401|NCT01215422|Anesthesiologist
1185402|NCT01215422|Laryngoscope
1185403|NCT01215422|Videolaryngoscope
1185404|NCT01215409|Levitra
1185405|NCT01215409|Erectile dysfunction
1185406|NCT01215409|Taiwan
1185407|NCT01215396|Branched Chain Amino Acids
1185408|NCT01215396|Mental Performance
1185409|NCT01215396|Muscular Performance
1185410|NCT01215396|Central Fatigue Theory
1185411|NCT01215383|HDL
1185412|NCT01215383|psychiatric patients
1185413|NCT01215383|psychiatric patients before and during antipsychotic therapy
1185414|NCT01215357|Pathological Gambling
1185415|NCT01215357|ecopipam
1185416|NCT01215357|Dopamine
1185417|NCT01215331|Gestational Diabetes Mellitus
1185418|NCT01215331|Treatment
1185419|NCT01215331|Insulin
1185420|NCT01215331|Metformin
1185421|NCT01215331|Glyburide
1185422|NCT01215305|Gastroesophageal Reflux Disease, extraesophageal symptoms
1185423|NCT01215292|testosterone
1185424|NCT01215292|acyline
1185425|NCT01215292|ketoconazole
1185426|NCT01215292|dutasteride
1185427|NCT01215292|anastrazole
1185428|NCT01215292|Intratesticular hormone concentration
1185429|NCT01215279|Respiratory disease
1185430|NCT01215279|Chronic Obstructive Pulmonary Disease
1185431|NCT01215266|Bladder cancer
1185432|NCT01215266|Chemotherapy
1185433|NCT01215266|Urothelium cancer
1185434|NCT01215253|Sudden Death
1185435|NCT01215253|Ranolazine
1185436|NCT01215253|Heart failure
1185437|NCT01215253|Ventricular tachycardia
1185438|NCT01215253|Ventricular fibrillation
1185439|NCT01215253|Implantable cardioverter-defibrillator
1185440|NCT01215214|metabolite profiles
1185441|NCT01215214|pharmacokinetics
1185442|NCT01215214|CYP3A
1185443|NCT01215214|metabolomics
1185444|NCT01215201|Periodontal maintenance
1185445|NCT01215201|≥5mm probing depth
1185446|NCT01215201|bleeding on probing and/or suppuration
1185447|NCT01215188|Invasive pneumococcal disease
1185448|NCT01215188|Pneumonia
1185449|NCT01215188|Pneumococcal conjugate vaccine
1185450|NCT01215175|Pneumococcal disease
1185451|NCT01215149|HIV
1185452|NCT01215110|Bedaquiline
1185453|NCT01215110|Sirturo
1185454|NCT01215110|Early Bactericidal Activity
1185455|NCT01215110|EBA
1185456|NCT01215110|Pulmonary Tuberculosis
1185457|NCT01215110|TMC207
1185458|NCT01215084|Human Volunteers
1185459|NCT01215071|Lymphadenectomy
1185460|NCT01215071|Extension
1185461|NCT01215071|Bladder cancer
1185462|NCT01215058|Compliance, France
1185463|NCT01215058|Gastrointestinal bleeding ulcer or symptomatic ulcer with NSAID
1185464|NCT01215045|AcrySof ReSTOR Aspheric +4
1185465|NCT01215032|castration-resistant prostate cancer
1185466|NCT01215032|insulin levels
1185467|NCT01215032|metformin
1185468|NCT01215019|traumatic brain injury
1185469|NCT01214993|GSK1349572
1185470|NCT01214993|para-aminohippurate
1185471|NCT01214993|iohexol
1185472|NCT01214980|Low-frequency ultrasound
1185473|NCT01214980|Wound healing
1185474|NCT01214980|Split thickness wound healing
1185475|NCT01214980|Skin graft donor site healing
1185476|NCT01214967|risk factors for maternal depression
1185477|NCT01214954|Total Hip Replacement
1185478|NCT01214954|Rehabilitation
1185479|NCT01214954|Resistance training
1185480|NCT01214928|vitamin D
1185481|NCT01214928|cholecalciferol
1185482|NCT01214928|hemodialysis
1185483|NCT01214928|randomized controlled trial
1185484|NCT01214928|pilot
1185485|NCT01214889|Diphtheria
1185486|NCT01214889|Tetanus
1185487|NCT01214889|Pertussis
1185488|NCT01214889|Haemophilus influenzae type B
1185489|NCT01214889|Poliomyelitis
1185490|NCT01214889|PENTAXIM™
1185491|NCT01214889|TETRAXIM™
1185492|NCT01214863|Toric Intraocular Lens (IOL)
1185493|NCT01214850|Meningococcal vaccines
1185494|NCT01214850|Meningococcal B
1185495|NCT01214850|Meningococcal ACWY serogroups
1185496|NCT01214837|Meningococcal
1185497|NCT01214837|ACWY
1185498|NCT01214837|Conjugate Vaccine
1185499|NCT01214837|Meningitis
1185500|NCT01214837|Infants
1185501|NCT01214837|Persistence
1185502|NCT01214824|Diabetes
1185503|NCT01214824|Continuous Glucose Monitoring
1185504|NCT01214811|The change in signs of inflammation/local infection
1185505|NCT01214811|To evaluate the comfort, conformability,
1185506|NCT01214811|Pain during wear
1185507|NCT01214798|sesamoid displacement,
1185508|NCT01214798|metacarpophalangeal joint,
1185509|NCT01214798|radial condylar ridge of the metacarpal head.
1185510|NCT01214772|pregnancy
1185511|NCT01214772|heparin
1185512|NCT01214772|fertilization
1185513|NCT01214759|HIV
1185514|NCT01214759|prevention
1185515|NCT01214759|prophylaxis
1185516|NCT01214759|Raltegravir
1185517|NCT01214759|Truvada
1185518|NCT01214746|Statin
1185519|NCT01214746|L-NMMA
1185520|NCT01214746|Healthy subjects
1185521|NCT01214746|Nephrology
1185522|NCT01214707|Exercise/No active Treatment
1185523|NCT01214694|TBI
1185524|NCT01214694|intracranial edema
1185525|NCT01214694|brain edema
1185526|NCT01214694|craniocerebral trauma
1185527|NCT01214694|head injury
1185528|NCT01214694|brain hemorrhage, traumatic
1185529|NCT01214694|subdural hematoma
1185530|NCT01214694|brain concussion
1185531|NCT01214694|head injuries, closed
1185532|NCT01214694|epidural hematoma
1185533|NCT01214694|extra-axial hemorrhage
1185534|NCT01214694|cortical contusion
1185535|NCT01214694|Additional relevant MeSH terms:
1185536|NCT01214694|Nervous System Diseases
1185537|NCT01214694|Wounds and Injuries
1185538|NCT01214694|Disorders of Environmental Origin
1185539|NCT01214694|Central Nervous System Diseases
1185540|NCT01214694|Trauma, Nervous System
1185541|NCT01214694|Brain Diseases
1185542|NCT01214694|Brain Injuries
1185543|NCT01214681|Biomarkers
1185544|NCT01214681|Colorectal cancer
1185545|NCT01214681|Resistant starch
1185546|NCT01214681|Polydextrose
1185547|NCT01214681|Non-digestible carbohydrate
1185548|NCT01214655|Acute Myelogenous Leukemia
1185549|NCT01214655|Acute Lymphoblastic Leukemia
1185550|NCT01214655|Chronic Myelogenous Leukemia,Blast Crisis
1185551|NCT01214642|Advanced Cancer
1185552|NCT01214642|Cancer
1185553|NCT01214629|Advanced Cancer
1185554|NCT01214629|Metastatic Cancer
1185555|NCT01214629|Cancer
1185556|NCT01214603|Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute
1185557|NCT01214603|Leukemia, Leukemia
1185558|NCT01214577|PEP005
1185559|NCT01214577|Peplin
1185560|NCT01214577|Photo-damage
1185561|NCT01214564|PEP005
1185562|NCT01214564|Peplin
1185563|NCT01214564|Seborrhoeic Keratosis
1185564|NCT01214538|Vaccine pneumococcal natural history Acute otitis media
1185565|NCT01214525|Meatal stenosis
1185566|NCT01214525|Meatotomy
1185567|NCT01214525|Uroflow
1185568|NCT01214525|Postvoid residual
1185569|NCT01214499|Refractory angina
1185570|NCT01214499|Transmyocardial revascularization
1185571|NCT01214499|Stem cells
1185572|NCT01214499|Diffuse coronary disease not amenable to percutaneous coronary intervention, and angina, despite proper medical treatment
1185573|NCT01214486|HIV
1185574|NCT01214486|RAL
1185575|NCT01214486|Raltegravir
1185576|NCT01214486|Isentress
1185577|NCT01214486|Pharmacokinetics
1185578|NCT01214473|Clinical sepsis
1185579|NCT01214473|Pneumonia
1185580|NCT01214473|Diarrhea
1185581|NCT01214473|Probiotics
1185582|NCT01214473|Synbiotics
1185583|NCT01214460|MET
1185584|NCT01214447|Hemodialysis
1185585|NCT01214447|Inflammation
1185586|NCT01214447|Malnutrition
1185587|NCT01214447|Phase Angle
1185588|NCT01214434|Cradle Cap
1185589|NCT01214434|Infantile seborrheic Dermatitis
1185590|NCT01214421|Kidney Disease
1185591|NCT01214421|ADPKD
1185592|NCT01214421|Autosomal Dominant Polycystic Kidney Disease
1185593|NCT01214421|Adult Polycystic Kidney Disease
1185594|NCT01214395|haemodialysis
1185595|NCT01214395|peritoneal dialysis
1185596|NCT01214382|Gastric Bypass
1185597|NCT01214382|Bariatric Surgery
1185598|NCT01214382|Sertraline
1185599|NCT01214382|Zoloft
1185600|NCT01214382|Pharmacokinetic
1185601|NCT01214369|intraosseous injection
1185602|NCT01214369|X-tip
1185603|NCT01214369|PDL injection
1185604|NCT01214369|Supplementary Injection
1185605|NCT01214356|diabetes
1185606|NCT01214356|kidney disease
1185607|NCT01214356|vitamin D
1185608|NCT01214343|sorafenib
1185609|NCT01214343|Hepatic intraarterial infusion chemotherapy
1185610|NCT01214343|HAIC
1185611|NCT01214343|Low dose FP
1185612|NCT01214343|cisplatin
1185613|NCT01214343|fluorouracil
1185614|NCT01214330|cervical cancer
1185615|NCT01214317|multiple sclerosis
1185616|NCT01214317|mitoxantrone
1185617|NCT01214317|plasmapheresis
1185618|NCT01214317|induction therapy
1185619|NCT01214304|Colposcopy
1185620|NCT01214291|fractures
1185621|NCT01214291|prostate cancer
1185622|NCT01214291|androgen deprivation therapy
1185623|NCT01214278|bioavailability
1185624|NCT01214278|marine n-3 fatty acids
1185625|NCT01214278|EPA
1185626|NCT01214278|DHA
1185627|NCT01214252|Repair of patients' abdominal wall defects
1185628|NCT01214187|idiopathic pulmonary fibrosis
1185629|NCT01214187|IPF
1185630|NCT01214187|pulmonary fibrosis
1185631|NCT01214187|carbon monoxide
1185632|NCT01214174|cataract
1185633|NCT01214174|inflammation
1185634|NCT01214161|IUD
1185635|NCT01214161|Lidocaine gel
1185636|NCT01214135|Mental disorder
1185637|NCT01214135|antipsychotic treatment
1185638|NCT01214122|Phase 1
1185639|NCT01214122|Drug-Drug interaction
1185640|NCT01214122|warfarin
1185641|NCT01214122|AZD9668
1185642|NCT01214122|resulting from AZD9668 and Warfarin interaction
1185643|NCT01214122|pharmacokinetics
1185644|NCT01214122|pharmacodynamics
1185645|NCT01214096|Chronic Heart failure
1185646|NCT01214096|rhNRG-1
1185647|NCT01214096|MRI
1185648|NCT01214083|N-acetylcysteine
1185649|NCT01214083|naltrexone
1185650|NCT01214070|Visual Perception
1185651|NCT01214070|Vision, Ocular
1185652|NCT01214070|Neuronal Plasticity
1185653|NCT01214057|chronic rhinosinusitis
1185654|NCT01214057|endoscopic sinus surgery
1185655|NCT01214057|TIVA
1185656|NCT01214057|surgical field visualization
1185657|NCT01214031|Confocal laser endomicroscope
1185658|NCT01214031|Adenomatous polyps
1185659|NCT01214031|Colonoscopy
1185660|NCT01214005|nicotine
1185661|NCT01214005|reinforcement
1185662|NCT01214005|craving
1185663|NCT01214005|relapse
1185664|NCT01213966|Acute uncomplicated Plasmodium Falciparum malaria
1185665|NCT01213966|Blood stage Plasmodium Vivax malaria
1185666|NCT01213953|Vertebral disc, mesenchymal stem cell.
1185667|NCT01213914|Burns
1185668|NCT01213914|Hemofiltration
1185669|NCT01213914|Vasopressins
1185670|NCT01213914|Kidney Failure Acute
1185671|NCT01213914|Shock, Septic
1185672|NCT01213901|Insulin absorption
1185673|NCT01213901|Insulin injection technique
1185674|NCT01213888|Diabetic retinopathy
1185675|NCT01213888|pan-retinal photocoagulation
1185676|NCT01213888|macular edema
1185677|NCT01213875|heart failure
1185678|NCT01213875|nursing
1185679|NCT01213875|home based intervention
1185680|NCT01213875|cost
1185681|NCT01213875|efficacy
1185682|NCT01213862|Home Based education
1185683|NCT01213862|Knowledge of Disease
1185684|NCT01213862|Self-Care Skills
1185685|NCT01213862|Quality of Life
1185686|NCT01213862|Heart Failure
1185687|NCT01213862|Randomized Clinical Trial
1185688|NCT01213836|Stable schizophrenia
1185689|NCT01213836|cognitive functioning
1185690|NCT01213823|invasive candidiasis
1185691|NCT01213823|candidemia
1185692|NCT01213823|severe hepatic injury
1185693|NCT01213823|echinocandins
1185694|NCT01213823|anidulafungin
1185695|NCT01213823|caspofungin
1185696|NCT01213823|micafungin
1185697|NCT01213810|HIV
1185698|NCT01213810|VZV (Varicella zoster Virus)
1185699|NCT01213810|vaccine
1185700|NCT01213810|T cell
1185701|NCT01213810|immunogenicity
1185702|NCT01213810|safety
1185703|NCT01213797|Suicide
1185704|NCT01213771|Preoperative
1185705|NCT01213771|Intervention
1185706|NCT01213771|Support
1185707|NCT01213771|Care
1185708|NCT01213758|liver function
1185709|NCT01213758|galactose
1185710|NCT01213758|18-F-deoxy-galactose
1185711|NCT01213758|PET/CT
1185712|NCT01213758|stereotactic body radiation therapy
1185713|NCT01213758|SBRT
1185714|NCT01213745|lung
1185715|NCT01213745|cancer
1185716|NCT01213745|quality of life
1185717|NCT01213732|L19, antibody, monoclonal, tumor targeting, TNFa, ILP, melanoma
1185718|NCT01213719|betaine, creatine, strength
1185719|NCT01213706|airway blood flow
1185720|NCT01213706|albuterol
1185721|NCT01213706|Whole Body Periodic Acceleration (WBPA)
1185722|NCT01213706|Nitric Oxide
1185723|NCT01213706|Endothelial Dysfunction
1185724|NCT01213693|COPD
1185725|NCT01213693|Bacteria
1185726|NCT01213693|Virus
1185727|NCT01213693|Inhaled Corticosteroids
1185728|NCT01213680|Inflammatory Bowel Disease, IBD
1185729|NCT01213654|Lung cancer
1185730|NCT01213654|VATS Lobectomy
1185731|NCT01213641|Cryopyrin-associated periodic syndromes(CAPS)
1185732|NCT01213641|CIAS1 protein
1185733|NCT01213641|NLRP3 protein
1185734|NCT01213641|human cryopyrin protein
1185735|NCT01213641|Familial Cold Autoinflammatory Syndrome(FCAS)
1185736|NCT01213641|Muckle-Wells Syndrome(MWS)
1185737|NCT01213641|Neonatal Onset Multisystem Inflammatory disease(NOMID)
1185738|NCT01213641|NALP3
1185739|NCT01213641|canakinumab
1185740|NCT01213641|Interleukin-1(IL-1)
1185741|NCT01213628|abdominal surgery
1185742|NCT01213628|hypothermia
1185743|NCT01213628|wound desiccation
1185744|NCT01213628|warming
1185745|NCT01213602|Trauma patients
1185746|NCT01213589|descending
1185747|NCT01213589|thoracic
1185748|NCT01213589|aortic
1185749|NCT01213589|dissection
1185750|NCT01213589|Valiant
1185751|NCT01213589|Medtronic
1185752|NCT01213589|Type B
1185753|NCT01213589|VIRTUE
1185754|NCT01213589|stent
1185755|NCT01213576|Lymphatic filariasis
1185756|NCT01213576|microfilaria
1185757|NCT01213576|Albendazole
1185758|NCT01213576|ivermectin
1185759|NCT01213576|human immunodeficiency
1185760|NCT01213563|Diabetes Mellitus, Type 2
1185761|NCT01213537|Heart failure
1185762|NCT01213524|nicotine
1185763|NCT01213524|craving
1185764|NCT01213524|dual-diagnosis
1185765|NCT01213524|comorbidity
1185766|NCT01213511|coronary artery disease; coronary artery bypass grafting; cardiopulmonary bypass; minimal extracorporeal circulation
1185767|NCT01213498|Nephrology
1185768|NCT01213498|Atorvastatin
1185769|NCT01213498|L-NMMA
1185770|NCT01213498|NO
1185771|NCT01213472|ASCI
1185772|NCT01213472|melanoma
1185773|NCT01213472|tumor antigen
1185774|NCT01213472|unresectable
1185775|NCT01213472|progressive
1185776|NCT01213472|NY-ESO-1
1185777|NCT01213472|adult
1185778|NCT01213472|cancer-testis antigen
1185779|NCT01213472|Immunotherapy
1185780|NCT01213459|Human papillomavirus
1185781|NCT01213446|Von Willebrand Disease
1185782|NCT01213420|Donor sites after wound closure
1185783|NCT01213407|Dendritic cell
1185784|NCT01213407|Cancer vaccine
1185785|NCT01213407|Anti-tumor immune therapy
1185786|NCT01213407|Interleukine-12
1185787|NCT01213407|Individualised autologous therapy
1185788|NCT01213407|Brain cancer
1185789|NCT01213407|Temozolomide
1185790|NCT01213407|Radiotherapy
1185791|NCT01213407|Irradiation
1185792|NCT01213407|High-grade glioma
1185793|NCT01213407|Advanced therapy medicinal product ATMP
1185794|NCT01213407|Somatic cell therapy
1185795|NCT01213407|Leukocyte apheresis
1185796|NCT01213407|Neurosurgery
1185797|NCT01213407|Neurooncology
1185798|NCT01213407|Neurology
1185799|NCT01213407|Immunology
1185800|NCT01213407|Tumor immunology
1185801|NCT01213407|Transfusion medicine
1185802|NCT01213407|Monocyte
1185803|NCT01213407|Killer cell
1185804|NCT01213407|Cytotoxic T-cell
1185805|NCT01213407|Cytotoxic T-lymphocyte
1185806|NCT01213394|Framingham score
1185807|NCT01213394|kidney transplant
1185808|NCT01213394|immunosuppression
1185809|NCT01213394|cardiovascular disease
1185810|NCT01213394|CellCept
1185811|NCT01213394|mycophenolate mofetil
1185812|NCT01213355|Randomized
1185813|NCT01213355|double-blind
1185814|NCT01213355|placebo-controlled
1185815|NCT01213355|5-way crossover
1185816|NCT01213355|single oral administrations of PF 05212377
1185817|NCT01213355|scopolamine induced deficits in healthy subjects
1185818|NCT01213342|dry eye disease
1185819|NCT01213316|HIV
1185820|NCT01213316|antiretroviral
1185821|NCT01213316|human immunodeficiency virus
1185822|NCT01213316|Raltegravir
1185823|NCT01213316|Adults with HIV-1 infection
1185824|NCT01213303|cardiovascular risk
1185825|NCT01213303|metabolic syndrome
1185826|NCT01213303|fatty acids
1185827|NCT01213303|oxysterols
1185828|NCT01213303|antioxidants
1185829|NCT01213303|oxidative stress
1185830|NCT01213290|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
1185831|NCT01213290|Stylet
1185832|NCT01213277|Diabetes Mellitus
1185833|NCT01213277|HbA1c
1185834|NCT01213277|Glycation Rate
1185835|NCT01213277|Fructosamine
1185836|NCT01213264|neuromuscular blockade, NMBA, sugammadex, Bridion, TOF,
1185837|NCT01213238|Liver metastasis
1185838|NCT01213238|hepatic arterial infusion
1185839|NCT01213238|HAI
1185840|NCT01213238|Eloxatin
1185841|NCT01213238|Xeloda
1185842|NCT01213238|Avastin
1185843|NCT01213238|Anti-VEGF monoclonal antibody
1185844|NCT01213238|rhuMAb-VEGF
1185845|NCT01213238|Oxaliplatin
1185846|NCT01213238|Capecitabine
1185847|NCT01213238|Bevacizumab
1185848|NCT01213225|Elderly
1185849|NCT01213225|Hospitalization
1185850|NCT01213225|Geriatrics
1185851|NCT01213225|Mortality
1185852|NCT01213225|Readmission
1185853|NCT01213225|Length of Stay
1185854|NCT01213212|Caloric restriction
1185855|NCT01213212|type 2 diabetes
1185856|NCT01213212|abdominal obesity
1185857|NCT01213212|renal disease
1185858|NCT01213186|stem cell
1185859|NCT01213186|hiv
1185860|NCT01213186|CD4
1185861|NCT01213186|immune activation
1185862|NCT01213173|angina pectoris
1185863|NCT01213173|chest pain
1185864|NCT01213173|heart rate
1185865|NCT01213160|Phase I
1185866|NCT01213160|cancer
1185867|NCT01213160|solid tumours
1185868|NCT01213160|advanced solid malignancies
1185869|NCT01213160|dose escalation
1185870|NCT01213160|FGFR TKI
1185871|NCT01213160|Japanese
1185872|NCT01213147|Pregnancy
1185873|NCT01213147|Clomiphene Citrate
1185874|NCT01213147|Fertilization
1185875|NCT01213147|Buserelin
1185876|NCT01213134|Medical Education
1185877|NCT01213134|Resident Training
1185878|NCT01213134|Portfolio
1185879|NCT01213121|bipolar depression
1185880|NCT01213121|heart rate variability
1185881|NCT01213121|cardio-respiratory coupling
1185882|NCT01213121|electroencephalography
1185883|NCT01213108|Örebro prevention program
1185884|NCT01213108|Youth drinking
1185885|NCT01213095|Lymphoma
1185886|NCT01213095|B-Cell
1185887|NCT01213095|Marginal Zone
1185888|NCT01213095|Rituximab
1185889|NCT01213082|Exudative Age-related Macular Degeneration
1185890|NCT01213082|Proton beam irradiation
1185891|NCT01213082|ranibizumab
1185892|NCT01213082|bevacizumab
1185893|NCT01213082|anti-VEGF therapy
1185894|NCT01213056|Mindfulness Based Cognitive Therapy
1185895|NCT01213056|Chronic Headache Pain
1185896|NCT01213056|Randomized Controlled Trial.
1185897|NCT01213043|emphysema
1185898|NCT01213043|alpha 1-antitrypsin
1185899|NCT01213043|alpha 1-antitrypsin deficiency (AATD)
1185900|NCT01213043|alpha 1-proteinase inhibitor (Alpha-1 PI)
1185901|NCT01213030|HX4
1185902|NCT01213030|[F-18]HX4
1185903|NCT01213030|FMISO
1185904|NCT01213030|[F-18]FMISO
1185905|NCT01213030|Solitary Tumor
1185906|NCT01213030|Hypoxia
1185907|NCT01213017|Certolizumab pegol
1185908|NCT01213017|Magnetic Resonance Imaging
1185909|NCT01213017|Rheumatoid Arthritis
1185910|NCT01213017|RAPID 3
1185911|NCT01213004|gastro-esophageal junction
1185912|NCT01213004|lung
1185913|NCT01213004|abdominal
1185914|NCT01213004|cone-beam CT (CBCT)
1185915|NCT01213004|10-146
1185916|NCT01212991|Progressive Metastatic Prostate Cancer
1185917|NCT01212978|Aging
1185918|NCT01212978|Endothelium,Vascular
1185919|NCT01212978|Arterial Remodeling
1185920|NCT01212978|Ventricular Vascular Coupling
1185921|NCT01212978|Nitric Oxide
1185922|NCT01212978|Walking
1185923|NCT01212978|Software
1185924|NCT01212965|Selenium
1185925|NCT01212965|Lymphatic Malformations
1185926|NCT01212965|Adolescents
1185927|NCT01212939|Dead pulps and open root ends
1185928|NCT01212939|Patients who have teeth with dead pulp and open root ends
1185929|NCT01212900|Atherosclerosis
1185930|NCT01212900|Cardiovascular Disease
1185931|NCT01212900|Cardiac MRI
1185932|NCT01212900|Cardiac CT
1185933|NCT01212900|Cholesterol
1185934|NCT01212887|unspecified adult solid tumor, protocol specific
1185935|NCT01212887|recurrent colon cancer
1185936|NCT01212887|stage IIIA colon cancer
1185937|NCT01212887|stage IIIB colon cancer
1185938|NCT01212887|stage IIIC colon cancer
1185939|NCT01212887|stage IV colon cancer
1185940|NCT01212887|stage IVB colon cancer
1185941|NCT01212887|recurrent rectal cancer
1185942|NCT01212887|stage IIIA rectal cancer
1185943|NCT01212887|stage IIIB rectal cancer
1185944|NCT01212887|stage IIIC rectal cancer
1185945|NCT01212887|stage IVA rectal cancer
1185946|NCT01212887|stage IVB rectal cancer
1185947|NCT01212887|recurrent gastric cancer
1185948|NCT01212887|stage IV gastric cancer
1185949|NCT01212887|recurrent pancreatic cancer
1185950|NCT01212887|stage III pancreatic cancer
1185951|NCT01212887|stage IV pancreatic cancer
1185952|NCT01212887|recurrent breast cancer
1185953|NCT01212887|stage IIIC breast cancer
1185954|NCT01212887|stage IV breast cancer
1185955|NCT01212887|extensive stage small cell lung cancer
1185956|NCT01212887|recurrent non-small cell lung cancer
1185957|NCT01212887|recurrent small cell lung cancer
1185958|NCT01212887|stage IIIA non-small cell lung cancer
1185959|NCT01212887|stage IIIB non-small cell lung cancer
1185960|NCT01212887|stage IV non-small cell lung cancer
1185961|NCT01212887|recurrent ovarian epithelial cancer
1185962|NCT01212887|recurrent ovarian germ cell tumor
1185963|NCT01212887|stage IIIA ovarian epithelial cancer
1185964|NCT01212887|stage IIIA ovarian germ cell tumor
1185965|NCT01212887|stage IIIB ovarian epithelial cancer
1185966|NCT01212887|stage IIIB ovarian germ cell tumor
1185967|NCT01212887|stage IIIC ovarian epithelial cancer
1185968|NCT01212887|stage IIIC ovarian germ cell tumor
1185969|NCT01212887|stage IV ovarian epithelial cancer
1185970|NCT01212887|stage IV ovarian germ cell tumor
1185971|NCT01212848|Transcranial Magnetic Stimulation
1185972|NCT01212848|Suicidal ideation
1185973|NCT01212835|Obesity
1185974|NCT01212835|gastroesophageal reflux disease
1185975|NCT01212835|Morbid obesity
1185976|NCT01212835|esophagitis
1185977|NCT01212835|GERD
1185978|NCT01212835|silastic ring
1185979|NCT01212835|Gastric bypass
1185980|NCT01212796|allogeneic stem cell transplantation
1185981|NCT01212783|depression
1185982|NCT01212783|psychological treatments
1185983|NCT01212783|Cognitive Behavioral Therapy
1185984|NCT01212783|child development
1185985|NCT01212783|parenting
1185986|NCT01212783|home visitation
1185987|NCT01212770|Psoriatic Arthritis
1185988|NCT01212770|Psoriasis
1185989|NCT01212770|Arthritis
1185990|NCT01212770|inflammation
1185991|NCT01212770|skin condition
1185992|NCT01212770|inflammatory cells
1185993|NCT01212770|apremilast
1185994|NCT01212770|CC-10004
1185995|NCT01212770|phosphodiesterase type 4
1185996|NCT01212757|Psoriasis
1185997|NCT01212757|Arthritis
1185998|NCT01212757|Psoriatic Arthritis
1185999|NCT01212757|inflammation
1186000|NCT01212757|skin condition
1186001|NCT01212757|inflammatory cells
1186002|NCT01212757|apremilast
1186003|NCT01212757|CC-10004
1186004|NCT01212757|phosphodiesterase type 4
1186005|NCT01212744|PEG PAL; PKU; injection;
1186006|NCT01212731|Patients with malignancies of the skull base or patients with low grade glioma who require radiotherapy.
1186007|NCT01212718|Colorectal Cancer
1186008|NCT01212718|non resectable metastasis
1186009|NCT01212718|reference lesion
1186010|NCT01212718|biopsy
1186011|NCT01212718|thymidylate synthase quantitation
1186012|NCT01212679|nerve growth factor
1186013|NCT01212679|traumatic brain injury
1186014|NCT01212679|intranasal
1186015|NCT01212679|prognosis
1186016|NCT01212679|neurological function
1186017|NCT01212666|Adductor Canal Block (ACB)
1186018|NCT01212666|Anterior Cruciate Ligament (ACL) Reconstruction
1186019|NCT01212666|Saphenous nerve
1186020|NCT01212666|Pain
1186021|NCT01212666|Ultrasound block
1186022|NCT01212653|Ankylosing Spondylitis
1186023|NCT01212653|Golimumab
1186024|NCT01212653|Simponi
1186025|NCT01212653|Anti-TNF alpha
1186026|NCT01212653|EPCs
1186027|NCT01212653|Vascular stiffness
1186028|NCT01212640|Transfusion, distress
1186029|NCT01212627|Non-Small Cell Lung Cancer
1186030|NCT01212601|safety
1186031|NCT01212601|efficacy
1186032|NCT01212601|Chinese patients
1186033|NCT01212601|practice
1186034|NCT01212588|BPD
1186035|NCT01212588|Borderline
1186036|NCT01212588|personality disorder
1186037|NCT01212588|mifepristone
1186038|NCT01212575|Mental disorder
1186039|NCT01212575|Antipsychotic treatment
1186040|NCT01212562|basal cell carcinoma
1186041|NCT01212562|cryosurgery
1186042|NCT01212562|imiquimod
1186043|NCT01212562|immunocryosurgery
1186044|NCT01212549|basal cell carcinoma
1186045|NCT01212549|cryosurgery
1186046|NCT01212549|imiquimod
1186047|NCT01212549|immunocryosurgery
1186048|NCT01212536|children
1186049|NCT01212536|intubation
1186050|NCT01212536|laryngoscope
1186051|NCT01212523|propofol
1186052|NCT01212523|isoflurane
1186053|NCT01212523|pulmonary hypertension
1186054|NCT01212523|congenital heart disease
1186055|NCT01212510|metastatic colorectal cancer
1186056|NCT01212510|circulating tumor markers
1186057|NCT01212510|circulating tumor cell
1186058|NCT01212510|circulating tumor DNA
1186059|NCT01212510|marker's kinetic
1186060|NCT01212497|mindfulness
1186061|NCT01212497|meditation
1186062|NCT01212497|training
1186063|NCT01212497|coaching
1186064|NCT01212497|virtual coach
1186065|NCT01212471|Sign and symptoms of dry eye disease
1186066|NCT01212458|gesunde Probanden
1186067|NCT01212432|Gram positive infection and CRRT
1186068|NCT01212406|Organ rejection
1186069|NCT01212406|Lung transplantation
1186070|NCT01212406|Bronchiolitis Obliterans
1186071|NCT01212406|Vitamin D
1186072|NCT01212406|Prevention
1186073|NCT01212393|venous thromboembolism disease
1186074|NCT01212393|emergency
1186075|NCT01212393|prevention
1186076|NCT01212393|thromboprophylaxis
1186077|NCT01212393|medical
1186078|NCT01212393|hosptitalization
1186079|NCT01212393|health care risks
1186080|NCT01212380|Chronic Lymphocytic Leukemia
1186081|NCT01212380|Small Lymphocytic Lymphoma
1186082|NCT01212380|Prolymphocytic Leukemia
1186083|NCT01212367|Gene transfer
1186084|NCT01212367|Immunology
1186085|NCT01212367|Cancer
1186086|NCT01212354|intensity modulated radiotherapy
1186087|NCT01212354|selective dose escalation
1186088|NCT01212354|hypoxia
1186089|NCT01212354|head cancer
1186090|NCT01212354|neck cancer
1186091|NCT01212341|Allogenetic NK cells
1186092|NCT01212341|Lymphomas
1186093|NCT01212341|Solid tumors
1186094|NCT01212328|T2DM
1186095|NCT01212328|Decision support software
1186096|NCT01212328|care coordinator
1186097|NCT01212315|Wound infection
1186098|NCT01212315|SSI
1186099|NCT01212315|Suture
1186100|NCT01212302|Clopidogrel
1186101|NCT01212302|ASA
1186102|NCT01212302|Low Response
1186103|NCT01212302|Resistance
1186104|NCT01212263|PCOS
1186105|NCT01212263|Clomiphene resistance
1186106|NCT01212263|ovulation induction
1186107|NCT01212263|low dose uFSH
1186108|NCT01212263|uFSH step-up protocol
1186109|NCT01212237|glioma
1186110|NCT01212237|meningioma
1186111|NCT01212237|anaplastic astrocytoma
1186112|NCT01212211|Hyponatremia; Sodium level
1186113|NCT01212211|Falls
1186114|NCT01212211|Gait
1186115|NCT01212211|elderly
1186116|NCT01212185|oxytocin
1186117|NCT01212185|alcohol withdrawal
1186118|NCT01212185|lorazepam
1186119|NCT01212185|alcoholism
1186120|NCT01212185|intranasal administration
1186121|NCT01212185|CIWA-Ar
1186122|NCT01212172|Hair removal
1186123|NCT01212172|Laser
1186124|NCT01212172|Diode laser
1186125|NCT01212159|Internet based monitoring system
1186126|NCT01212146|Artichokes
1186127|NCT01212146|Constipation
1186128|NCT01212146|Functional Foods
1186129|NCT01212146|Prebiotics
1186130|NCT01212146|Probiotics
1186131|NCT01212120|Diabetic foot
1186132|NCT01212107|Advanced cancer
1186133|NCT01212107|Metastatic cancer
1186134|NCT01212107|Oncology
1186135|NCT01212094|Rituximab
1186136|NCT01212094|Multiple Sclerosis
1186137|NCT01212094|Intrathecal
1186138|NCT01212094|MS
1186139|NCT01212094|Secondary-Progressive Multiple Sclerosis
1186140|NCT01212094|SP-MS
1186141|NCT01212081|Virtual Reality
1186142|NCT01212081|Schizophrenia
1186143|NCT01212081|Cannabis
1186144|NCT01212081|Assessment
1186145|NCT01212081|Craving
1186146|NCT01212068|MEG
1186147|NCT01212068|Epilepsy
1186148|NCT01212068|Brain Imaging
1186149|NCT01212068|Brain Scan
1186150|NCT01212068|Auditory Processing
1186151|NCT01212068|Auditory Perceptual Disorder
1186152|NCT01212055|PBSC Collection
1186153|NCT01212055|Immunodeficiency
1186154|NCT01212055|Spectra Apheresis System
1186155|NCT01212055|Stem Cell Mobilization
1186156|NCT01212055|Leukapheresis
1186157|NCT01212042|Pneumonia
1186158|NCT01212042|Pulmonary Pathogens
1186159|NCT01212042|HIV
1186160|NCT01212042|Immunocompromised Host
1186161|NCT01212042|Respiratory Infection
1186162|NCT01212042|Mycobacteria
1186163|NCT01212029|Near Infrared
1186164|NCT01212029|Optical Imaging
1186165|NCT01212029|Brain Imaging
1186166|NCT01212029|Healthy Volunteer
1186167|NCT01212029|HV
1186168|NCT01212016|Eosinophilic Esophagitis
1186169|NCT01212016|Eosinophilic Gastroenteritis
1186170|NCT01212016|Peanut Allergy
1186171|NCT01212016|T Cell
1186172|NCT01212016|IgE
1186173|NCT01212016|Food Allergy
1186174|NCT01212003|Mycobacterium Tuberculosis
1186175|NCT01212003|Active Tuberculosis
1186176|NCT01212003|Latent Tuberculosis
1186177|NCT01212003|Tuberculosis
1186178|NCT01212003|TB
1186179|NCT01211990|Pediatric
1186180|NCT01211990|Children
1186181|NCT01211990|Cancer
1186182|NCT01211990|Bone Marrow Transplant
1186183|NCT01211977|Muckle Wells Syndrome
1186184|NCT01211977|Autoinflammatory
1186185|NCT01211977|Interleukin-1
1186186|NCT01211951|Dry eye syndromes
1186187|NCT01211951|Corneal diseases
1186188|NCT01211951|Conjunctival diseases
1186189|NCT01211938|phase II/III
1186190|NCT01211938|upper aerodigestive tract carcinoma
1186191|NCT01211938|re irradiation
1186192|NCT01211938|Recurrent or second upper aerodigestive tract carcinoma
1186193|NCT01211925|unreconstructable peripheral arterial disease
1186194|NCT01211912|Fetal movement
1186195|NCT01211912|Fetal breathing
1186196|NCT01211912|Acetaminophen
1186197|NCT01211899|polymorphism,
1186198|NCT01211899|plasminogen activator inhibitor,
1186199|NCT01211899|disseminated intravascular coagulation,
1186200|NCT01211886|Brain natriuretic peptide
1186201|NCT01211886|Cardio-renal syndrome
1186202|NCT01211873|CNS
1186203|NCT01211873|Contrast Agent
1186204|NCT01211873|MRI
1186205|NCT01211873|Dotarem
1186206|NCT01211873|Magnevist
1186207|NCT01211860|DCCR
1186208|NCT01211860|Diazoxide Chonline Controlled-Release Tablet = DCCR
1186209|NCT01211860|Hypertriglyceridemia
1186210|NCT01211860|Triglycerides
1186211|NCT01211860|Pharmacokinetics
1186212|NCT01211847|triglycerides
1186213|NCT01211847|Apo B
1186214|NCT01211847|non-HDL
1186215|NCT01211847|statin
1186216|NCT01211847|fenofibrate
1186217|NCT01211795|Migraine
1186218|NCT01211795|Prevention
1186219|NCT01211795|Treatment
1186220|NCT01211795|Ketoprofen
1186221|NCT01211795|Trigeminal nerve
1186222|NCT01211782|Alzheimer's disease
1186223|NCT01211782|AD
1186224|NCT01211782|AC-1204
1186225|NCT01211782|ketogenic
1186226|NCT01211782|ketosis
1186227|NCT01211769|PUFAs
1186228|NCT01211769|Alcoholism
1186229|NCT01211769|Treatment
1186230|NCT01211769|Effectiveness
1186231|NCT01211743|SILS
1186232|NCT01211743|Oxidative Stress
1186233|NCT01211743|8-epiPGF2a
1186234|NCT01211743|SILS vs standard laparoscopic cholecystectomy
1186235|NCT01211730|Liver
1186236|NCT01211730|transplantation
1186237|NCT01211730|Glucose
1186238|NCT01211730|Hyperglycemia
1186239|NCT01211730|Insulin
1186240|NCT01211730|Rejection
1186241|NCT01211730|Hypoglycemia
1186242|NCT01211717|Branched Chained Amino Acids
1186243|NCT01211717|Delayed Onset Muscle Soreness
1186244|NCT01211717|Diabetes
1186245|NCT01211717|Muscle Damage
1186246|NCT01211704|Bipolar, Alcoholism
1186247|NCT01211691|Hematologic
1186248|NCT01211691|Leukemia
1186249|NCT01211691|Malignancies
1186250|NCT01211691|Myeloproliferative Neoplasms
1186251|NCT01211665|IVMP
1186252|NCT01211665|corticosteroids
1186253|NCT01211665|IRIS
1186254|NCT01211665|Progressive Multifocal Leukoencephalopathy
1186255|NCT01211665|Immune reconstitution inflammatory syndrome
1186256|NCT01211665|PML
1186257|NCT01211652|Compliance
1186258|NCT01211652|France
1186259|NCT01211652|Self-administered questionnaire to patients
1186260|NCT01211613|Manipulation
1186261|NCT01211613|Chiropractic
1186262|NCT01211613|Low Back Pain
1186263|NCT01211600|Staples
1186264|NCT01211600|Sutures
1186265|NCT01211600|Wound infections
1186266|NCT01211600|Cosmesis
1186267|NCT01211600|Aesthetic appearance of skin incision
1186268|NCT01211587|Parkinson's Disease
1186269|NCT01211587|Cognition
1186270|NCT01211587|Safinamide
1186271|NCT01211587|Phase 2
1186272|NCT01211587|Non-demented patients
1186273|NCT01211587|Levodopa
1186274|NCT01211587|Dopamine agonist
1186275|NCT01211535|Soft contact lenses
1186276|NCT01211535|Multi-purpose Solution
1186277|NCT01211522|Delirium
1186278|NCT01211522|Intensive care
1186279|NCT01211522|Mechanical ventilation
1186280|NCT01211522|Antipsychotic
1186281|NCT01211522|Haloperidol
1186282|NCT01211522|Ziprasidone
1186283|NCT01211522|Randomized
1186284|NCT01211522|Placebo
1186285|NCT01211522|Sepsis
1186286|NCT01211522|Sedation
1186287|NCT01211522|Long-term cognitive impairment
1186288|NCT01211509|montelukast
1186289|NCT01211509|cysteinyl leukotriene
1186290|NCT01211509|lung transplantation
1186291|NCT01211509|bronchiolitis obliterans syndrome
1186292|NCT01211496|functional testing
1186293|NCT01211496|resistance training
1186294|NCT01211496|velocity training
1186295|NCT01211496|elderly
1186296|NCT01211496|geriatric
1186297|NCT01211496|knee
1186298|NCT01211496|leg
1186299|NCT01211496|leg strength
1186300|NCT01211483|Lung cancer
1186301|NCT01211470|MRSA
1186302|NCT01211470|ABSSSI
1186303|NCT01211470|Staphylococcus aureus
1186304|NCT01211444|Obstructive Sleep Apnea
1186305|NCT01211444|OSA
1186306|NCT01211444|Hypoglossal nerve stimulation
1186307|NCT01211444|Sleep apnea
1186308|NCT01211431|cesarean section
1186309|NCT01211431|pain
1186310|NCT01211431|ropivacain
1186311|NCT01211431|diclofena
1186312|NCT01211431|morphine
1186313|NCT01211405|MDMA
1186314|NCT01211405|Psychotherapy
1186315|NCT01211405|Veterans
1186316|NCT01211405|Posttraumatic Stress Disorder
1186317|NCT01210417|Trauma
1186318|NCT01210417|Hypovolemia
1186319|NCT01210417|Hemorrhage
1186320|NCT01210417|Out of hospital trauma
1186321|NCT01210404|Drug interaction with methadone.
1186322|NCT01210378|NSCLC
1186323|NCT01210378|Nitroglycerin
1186324|NCT01210378|Tumour perfusion
1186325|NCT01210378|Hypoxia
1186326|NCT01210378|Toxicity
1186327|NCT01210378|Phase II
1186328|NCT01210378|HX4
1186329|NCT01210365|CHF functional class II
1186330|NCT01210365|Patients with CHF
1186331|NCT01210365|Patients with CHF functional class II (NYHA) of any etiology
1186332|NCT01211379|colorectal cancer screening
1186333|NCT01211379|primary care
1186334|NCT01211379|health disparities
1186335|NCT01211366|cell saver
1186336|NCT01211366|allogeneic RBCs
1186337|NCT01211366|washed cells
1186338|NCT01211366|PRBC transfusion
1186339|NCT01211353|Alcohol
1186340|NCT01211353|Brief Intervention
1186341|NCT01211353|Personalized Feedback
1186342|NCT01211353|Veterans
1186343|NCT01211340|Hospice
1186344|NCT01211340|Caregivers
1186345|NCT01211340|Interdisciplinary Team
1186346|NCT01211340|Pain management
1186347|NCT01211314|hypertension
1186348|NCT01211314|Fixed combination
1186349|NCT01211314|lercanidipine
1186350|NCT01211314|enalapril
1186351|NCT01211314|Blood Pressure Monitoring, Ambulatory
1186352|NCT01211301|obesity
1186353|NCT01211301|overweight
1186354|NCT01211301|weight loss
1186355|NCT01211301|randomized controlled trial
1186356|NCT01211301|Medifast
1186357|NCT01211288|HIV
1186358|NCT01211288|Implant
1186359|NCT01211288|Crown
1186360|NCT01211275|mesothelioma
1186361|NCT01211275|chemotherapy
1186362|NCT01211275|translational research
1186363|NCT01211275|axitinib
1186364|NCT01211262|Melanoma
1186365|NCT01211262|Phase I
1186366|NCT01211262|Biologic
1186367|NCT01211249|Methotrexate-refractory
1186368|NCT01211223|Chronic periodontitis
1186369|NCT01211223|Metronidazole plus Amoxicillin
1186370|NCT01211223|Mechanical periodontal therapy
1186371|NCT01211223|Scaling and Root Planning
1186372|NCT01211223|Periodontal treatment
1186373|NCT01211210|rectal cancer
1186374|NCT01211210|neoadjuvant therapy
1186375|NCT01211210|oxaliplatin
1186376|NCT01211210|radiation
1186377|NCT01211184|Hip surgery
1186378|NCT01211184|Metabolism
1186379|NCT01211184|Glucose
1186380|NCT01211184|Body fluids
1186381|NCT01211184|Complications
1186382|NCT01211171|Cough
1186383|NCT01211171|Telmisartan
1186384|NCT01211171|Bradykinin
1186385|NCT01211171|Tolerability
1186386|NCT01211158|emergency department
1186387|NCT01211158|procedural sedation
1186388|NCT01211158|ketofol
1186389|NCT01211158|ketamine
1186390|NCT01211158|propofol
1186391|NCT01211158|conscious sedation
1186392|NCT01211145|Migraine
1186393|NCT01211145|Headache
1186394|NCT01211145|Pain
1186395|NCT01211145|Efficacy
1186396|NCT01211145|Adolescents
1186397|NCT01211132|Colon polyps
1186398|NCT01211132|Adenoma detection
1186399|NCT01211132|Cap
1186400|NCT01211132|Standard
1186401|NCT01211132|Colon Cancer
1186402|NCT01211106|Treatment
1186403|NCT01211106|PTSD
1186404|NCT01211106|Addiction
1186405|NCT01211093|vibration
1186406|NCT01211093|muscle
1186407|NCT01211093|cerebrovascular accident
1186408|NCT01211093|exercise
1186409|NCT01211093|rehabilitation
1186410|NCT01211080|infancy hemangioma
1186411|NCT01211080|propranolol
1186412|NCT01211080|study design
1186413|NCT01211080|side effects
1186414|NCT01211080|safety
1186415|NCT01211067|Inguinal hernia
1186416|NCT01211067|Inguinal ring
1186417|NCT01211067|Histology
1186418|NCT01211067|Hernioplasty
1186419|NCT01211067|Lichtenstein
1186420|NCT01211041|Candida albicans, fungemia , prognostic factor
1186421|NCT01211028|Critical leg ischemia
1186422|NCT01211028|Adipose derived Stroma/Stem Cells
1186423|NCT01211028|Autologous
1186424|NCT01211028|Angiogenesis
1186425|NCT01211002|Radiotherapy
1186426|NCT01211002|rh-endostatin
1186427|NCT01211002|chemotherapy
1186428|NCT01211002|NSCLC
1186429|NCT01210976|levosimendan
1186430|NCT01210976|CABG
1186431|NCT01210976|AVR
1186432|NCT01210950|distraction
1186433|NCT01210950|osteogenesis
1186434|NCT01210950|limb length discrepancy
1186435|NCT01210950|callus
1186436|NCT01210937|Internal Carotid Artery Stenosis
1186437|NCT01210937|Carotid Endarterectomy
1186438|NCT01210937|Stroke
1186439|NCT01210937|Cerebrovascular
1186440|NCT01210937|Atherosclerosis
1186441|NCT01210924|children
1186442|NCT01210924|Acquired Immunodeficiency Syndrome
1186443|NCT01210924|antiretroviral therapy
1186444|NCT01210924|China
1186445|NCT01210924|Mortality
1186446|NCT01210911|pancreatic cancer
1186447|NCT01210911|metformin
1186448|NCT01210911|MAPK pathway
1186449|NCT01210911|PI3K/Akt pathway
1186450|NCT01210911|gemcitabine
1186451|NCT01210898|Influenza
1186452|NCT01210898|Trivalent
1186453|NCT01210898|Adjuvanted
1186454|NCT01210898|Vaccine
1186455|NCT01210898|Children
1186456|NCT01210885|Meningococcal Disease
1186457|NCT01210885|Vaccines
1186458|NCT01210885|Adolescents
1186459|NCT01210872|stage I squamous cell carcinoma of the lip and oral cavity
1186460|NCT01210872|stage II squamous cell carcinoma of the lip and oral cavity
1186461|NCT01210872|stage III squamous cell carcinoma of the lip and oral cavity
1186462|NCT01210872|stage I lymphoepithelioma of the oropharynx
1186463|NCT01210872|stage II lymphoepithelioma of the oropharynx
1186464|NCT01210872|stage III lymphoepithelioma of the oropharynx
1186465|NCT01210872|stage I squamous cell carcinoma of the oropharynx
1186466|NCT01210872|stage II squamous cell carcinoma of the oropharynx
1186467|NCT01210872|stage III squamous cell carcinoma of the oropharynx
1186468|NCT01210872|stage I lymphoepithelioma of the nasopharynx
1186469|NCT01210872|stage II lymphoepithelioma of the nasopharynx
1186470|NCT01210872|stage III lymphoepithelioma of the nasopharynx
1186471|NCT01210872|stage I squamous cell carcinoma of the nasopharynx
1186472|NCT01210872|stage II squamous cell carcinoma of the nasopharynx
1186473|NCT01210872|stage III squamous cell carcinoma of the nasopharynx
1186474|NCT01210872|stage I squamous cell carcinoma of the hypopharynx
1186475|NCT01210872|stage II squamous cell carcinoma of the hypopharynx
1186476|NCT01210872|stage III squamous cell carcinoma of the hypopharynx
1186477|NCT01210872|stage I squamous cell carcinoma of the larynx
1186478|NCT01210872|stage II squamous cell carcinoma of the larynx
1186479|NCT01210872|stage III squamous cell carcinoma of the larynx
1186480|NCT01210872|stage I verrucous carcinoma of the larynx
1186481|NCT01210872|stage II verrucous carcinoma of the larynx
1186482|NCT01210872|stage III verrucous carcinoma of the larynx
1186483|NCT01210872|tongue cancer
1186484|NCT01210859|detrusitol
1186485|NCT01210859|overactive
1186486|NCT01210859|bladder
1186487|NCT01210859|ureteral
1186488|NCT01210859|stents
1186489|NCT01210846|AV-951
1186490|NCT01210846|tivozanib
1186491|NCT01210846|QTc
1186492|NCT01210846|advanced solid tumors
1186493|NCT01210846|pharmacokinetics
1186494|NCT01210833|Finger Fractures
1186495|NCT01210833|Tendon Injuries
1186496|NCT01210833|Soft Tissue Injuries
1186497|NCT01210781|All indication for deep brain stimulation (DBS)
1186498|NCT01210768|Phase II
1186499|NCT01210768|Pegylated Liposomal Doxorubicin
1186500|NCT01210768|Adjuvant Chemotherapy
1186501|NCT01210768|Breast Cancer
1186502|NCT01210755|Antithrombotics
1186503|NCT01210755|Haemostatics
1186504|NCT01210755|Antidote
1186505|NCT01210729|stroke
1186506|NCT01210729|mechanical recanalization
1186507|NCT01210729|self-expanding stent
1186508|NCT01210729|Solitaire
1186509|NCT01210716|Therapeutic plasma exchange
1186510|NCT01210716|Autoimmune diseases
1186511|NCT01210716|Kidney transplant
1186512|NCT01210716|Hematologic disorders
1186513|NCT01210716|Monoclonal gammopathy
1186514|NCT01210716|Neurologic disorders
1186515|NCT01210703|Acoustic Pharyngometry
1186516|NCT01210703|CPAP
1186517|NCT01210703|Obstructive Sleep Apnea Syndrome
1186518|NCT01210690|Levetiracetam
1186519|NCT01210690|Keppra® Oral Solution
1186520|NCT01210690|Keppra® in Children
1186521|NCT01210677|Cardiac Sarcoidosis
1186522|NCT01210677|Sarcoidosis
1186523|NCT01210664|Diabetes
1186524|NCT01210664|Treg
1186525|NCT01210651|Yoga
1186526|NCT01210651|Major Depression
1186527|NCT01210651|Self-Efficacy
1186528|NCT01210651|Self-Esteem
1186529|NCT01210651|Hatha yoga
1186530|NCT01210651|mind-body therapies
1186531|NCT01210651|depression
1186532|NCT01210625|Constipation
1186533|NCT01210599|Back Pain
1186534|NCT01210599|Bisphosphonate
1186535|NCT01210599|Pamidronate
1186536|NCT01210599|Bone Pain
1186537|NCT01210573|Heart Failure
1186538|NCT01210573|Heart-Assist Devices
1186539|NCT01210573|Left Ventricular Assist Device
1186540|NCT01210560|Kidney Disease
1186541|NCT01210560|Polycystic Kidney Disease
1186542|NCT01210521|Asthmatic Patients
1186543|NCT01210521|Vitamin D
1186544|NCT01210521|Steroid Resistant Asthmatic Patients
1186545|NCT01210521|cholecalciferol
1186546|NCT01210508|Cancer patients with metastases to the spinal column
1186547|NCT01210495|Hepatocellular Carcinoma
1186548|NCT01210482|Torisel
1186549|NCT01210482|Regulatory Post Marketing Commitment Plan
1186550|NCT01210469|elderly
1186551|NCT01210469|postural balance
1186552|NCT01210469|musculoskeletal equilibrium
1186553|NCT01210469|posture
1186554|NCT01210469|muscle strength
1186555|NCT01210469|muscle stretching exercises
1186556|NCT01210456|Chronic Kidney Disease
1186557|NCT01210456|Contrast Media
1186558|NCT01210456|Acute Kidney Injury
1186559|NCT01210456|N-Acetylcysteine
1186560|NCT01210456|Bicarbonate
1186561|NCT01210443|sitaxentan sodium pulmonary hypertension
1186562|NCT01210430|Postural Tachycardia Syndrome
1186563|NCT01210430|Orthostatic Intolerance
1186564|NCT01210430|Reactive Oxygen Species
1186565|NCT01210430|Oxidative Stress
1186566|NCT01210430|Angiotensin II
1186567|NCT01210430|Nitric Oxide
1186568|NCT01210430|Blood Flow
1186569|NCT01210430|POTS
1186570|NCT01210430|Ascorbic Acid
1186571|NCT01210430|Vitamin C
1186572|NCT01210430|Losartan
1186573|NCT01210352|surgical pain
1186574|NCT01210352|acute pain
1186575|NCT01210352|Acute Post Surgical Pain
1186576|NCT01210339|phase 1
1186577|NCT01210339|cross-over
1186578|NCT01210339|drug-drug Interaction
1186579|NCT01210339|esomeprazole
1186580|NCT01210339|acetylsalicylic acid
1186581|NCT01210339|clopidogrel
1186582|NCT01210339|healthy volunteers
1186583|NCT01210339|cardiovascular disease
1186584|NCT01210339|patients with acid associated gastrointestinal symptoms
1186585|NCT01210326|TESE
1186586|NCT01210326|TESA
1186587|NCT01210326|non obstructive
1186588|NCT01210326|azoospermi
1186589|NCT01210313|physical activity
1186590|NCT01210300|caesarean section
1186591|NCT01210300|vaginal birth after caesarean section
1186592|NCT01210300|repeat caesarean section
1186593|NCT01210300|childbirth expectation
1186594|NCT01210300|childbirth experience
1186595|NCT01210287|hepatitis B virus reactivation
1186596|NCT01210287|HBsAg negative
1186597|NCT01210287|HBcAb positive
1186598|NCT01210287|lymphoma
1186599|NCT01210287|rituximab
1186600|NCT01210261|OSA
1186601|NCT01210261|CPAP
1186602|NCT01210261|APAP
1186603|NCT01210261|SPAP
1186604|NCT01210261|Obstructive Sleep Apnea
1186605|NCT01210261|Sleep Apnea
1186606|NCT01210235|colorectal cancer screening
1186607|NCT01210235|preventive health
1186608|NCT01210235|primary care
1186609|NCT01210209|Ewing sarcoma
1186610|NCT01210209|Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
1186611|NCT01210196|Fabry
1186612|NCT01210183|Dextrose
1186613|NCT01210183|Cartilage
1186614|NCT01210183|Regeneration
1186615|NCT01210170|asthma,
1186616|NCT01210170|inhaled corticosteroids,
1186617|NCT01210170|airway blood flow,
1186618|NCT01210170|mometasone,
1186619|NCT01210170|albuterol
1186620|NCT01210170|spirometry
1186621|NCT01210144|Infertility
1186622|NCT01210144|Gonal-f
1186623|NCT01210144|gene expression
1186624|NCT01210144|Assisted Reproductive Technologies
1186625|NCT01210144|Follitropin alfa
1186626|NCT01210144|endometrium
1186627|NCT01210131|Toxicity
1186628|NCT01210131|Progression
1186629|NCT01210131|Survival
1186630|NCT01210131|SCLC
1186631|NCT01210118|Pregnancy
1186632|NCT01210118|Smoking cessation
1186633|NCT01210118|Cognitive-Behavioural interventions
1186634|NCT01210105|intubation
1186635|NCT01210105|video laryngoscopes
1186636|NCT01210079|opioid-induced hyperalgesia
1186637|NCT01210079|methadone
1186638|NCT01210079|gabapentin
1186639|NCT01210079|opioid addiction
1186640|NCT01210066|inflammation
1186641|NCT01210066|opioid-induced hyperalgesia
1186642|NCT01210066|bupenorphine
1186643|NCT01210066|prescription opioid abuse
1186644|NCT01210053|Non-Small Cell Lung Cancer
1186645|NCT01210040|Pregnancy
1186646|NCT01210040|Iron deficiency
1186647|NCT01210040|Iron supplementation
1186648|NCT01210040|Burkina Faso
1186649|NCT01210014|Recurrent aphthous stomatitis
1186650|NCT01210014|treatment
1186651|NCT01210014|zinc sulphate
1186652|NCT01209975|blood flow
1186653|NCT01209975|glaucoma
1186654|NCT01209975|SLT
1186655|NCT01209936|Body Fat
1186656|NCT01209936|Total body water
1186657|NCT01209923|Percent body fat
1186658|NCT01209923|Body Composition
1186659|NCT01209923|Stayhealthy
1186660|NCT01209897|Smoking
1186661|NCT01209871|Lymphoplasmacytic Lymphoma
1186662|NCT01209871|Recombinant DNA
1186663|NCT01209871|Fusion DNA Vaccine
1186664|NCT01209871|Waldenström macroglobulinemia
1186665|NCT01209858|epilepsy
1186666|NCT01209845|depression
1186667|NCT01209845|suicide ideation
1186668|NCT01209845|emergency department
1186669|NCT01209845|ketamine
1186670|NCT01209832|Metastatic Tumors
1186671|NCT01209832|Lymphoma
1186672|NCT01209819|Bone Mineral Density
1186673|NCT01209819|Adults
1186674|NCT01209780|seasonal influenza, vaccine
1186675|NCT01209767|Cellulite
1186676|NCT01209767|Cryolipolysis
1186677|NCT01209767|Zeltiq
1186678|NCT01209767|Subcision
1186679|NCT01209754|Pregnancy
1186680|NCT01209754|Chemoprophylactic Exposure
1186681|NCT01209754|Mother
1186682|NCT01209754|Infant
1186683|NCT01209754|malformations
1186684|NCT01209754|HIV
1186685|NCT01209728|insomnia
1186686|NCT01209728|insomniacs
1186687|NCT01209728|simulated driving
1186688|NCT01209728|alcohol
1186689|NCT01209728|ethanol
1186690|NCT01209715|airway blood flow,
1186691|NCT01209715|COPD,
1186692|NCT01209715|endothelial dysfunction
1186693|NCT01209715|inhaled corticosteroids
1186694|NCT01209676|melanoma, with advanced unresectable
1186695|NCT01209663|General Surgery
1186696|NCT01209663|Emergency treatment
1186697|NCT01209663|Postoperative care
1186698|NCT01209663|Intermediate care unit
1186699|NCT01209663|High dependency unit
1186700|NCT01209663|Mortality
1186701|NCT01209637|stable coronary artery disease
1186702|NCT01209637|significant coronary stenosis
1186703|NCT01209624|prospective
1186704|NCT01209624|non-interventional
1186705|NCT01209624|observational
1186706|NCT01209624|multi-center
1186707|NCT01209624|long-term
1186708|NCT01209598|soft tissue
1186709|NCT01209598|Palbociclib (PD0332991)
1186710|NCT01209598|10-094
1186711|NCT01209572|energy expenditure
1186712|NCT01209572|heart rate
1186713|NCT01209572|accelerometry
1186714|NCT01209572|body temperature
1186715|NCT01209572|heat flow galvanic response of skin
1186716|NCT01209546|Bronchiectasis
1186717|NCT01209546|Pulmonary function
1186718|NCT01209546|Respiratory muscle strength
1186719|NCT01209546|Respiratory secretions
1186720|NCT01209533|Asthma
1186721|NCT01209520|Lung Cancer
1186722|NCT01209520|Non-Small Cell Lung Carcinoma
1186723|NCT01209520|NSCLC
1186724|NCT01209520|Methylation Analysis
1186725|NCT01209520|Hypermethylation
1186726|NCT01209520|Targeted Genes
1186727|NCT01209520|Tumorigenesis
1186728|NCT01209520|Tumor Supressor Genes
1186729|NCT01209507|Adrenal suppression
1186730|NCT01209507|Chemotherapy fatigue
1186731|NCT01209507|Quality of life
1186732|NCT01209494|sudden cardiac death
1186733|NCT01209494|implantable cardioverter defibrillator
1186734|NCT01209494|ventricular arrhythmias
1186735|NCT01209494|genetic syndromes
1186736|NCT01209494|calcium metabolism
1186737|NCT01209494|ventricular repolarization
1186738|NCT01209494|ECG
1186739|NCT01209494|T wave
1186740|NCT01209494|programmed electrical stimulation
1186741|NCT01209494|alternans
1186742|NCT01209494|late potentials
1186743|NCT01209494|risk stratification
1186744|NCT01209481|fruits
1186745|NCT01209481|vegetables
1186746|NCT01209481|primary health care
1186747|NCT01209481|nutritional education
1186748|NCT01209455|Acetylcysteine
1186749|NCT01209455|Adverse effects
1186750|NCT01209455|Acetaminophen
1186751|NCT01209455|Anaphylactoid reactions
1186752|NCT01209442|Glioblastoma
1186753|NCT01209442|Multiforme
1186754|NCT01209429|Calorie restriction
1186755|NCT01209429|GH/IGF-I axis
1186756|NCT01209429|STATb5
1186757|NCT01209429|SIRT1
1186758|NCT01209429|Intracellular signaling peptides and proteins
1186759|NCT01209429|Fasting
1186760|NCT01209429|Growth hormone
1186761|NCT01209429|IGF-1
1186762|NCT01209416|ghrelin
1186763|NCT01209416|metabolism
1186764|NCT01209416|type 2 diabetes
1186765|NCT01209416|insulin resistance
1186766|NCT01209403|Dialysis
1186767|NCT01209403|Malnutrition
1186768|NCT01209403|Insulin-Like Growth Factor I
1186769|NCT01209403|Insulin-Like Growth Factor Binding Protein 1
1186770|NCT01209403|Inflammation
1186771|NCT01209390|osteochondral
1186772|NCT01209390|regenerative
1186773|NCT01209390|repair
1186774|NCT01209390|cartilage lesion
1186775|NCT01209377|standard
1186776|NCT01209377|fixed
1186777|NCT01209377|no focus
1186778|NCT01209377|EMDR treatment with bilateral stimulation via eye movement
1186779|NCT01209377|EMDR treatment with fixed eyes
1186780|NCT01209377|Trauma exposition without external stimulus
1186781|NCT01209364|comparative
1186782|NCT01209364|randomized
1186783|NCT01209364|double-blind
1186784|NCT01209364|non-inferior
1186785|NCT01209364|knee OA
1186786|NCT01209351|Pharmacokinetics
1186787|NCT01209351|Pharmacodynamics
1186788|NCT01209351|teduglutide
1186789|NCT01209325|human papilloma virus infection
1186790|NCT01209325|anal cancer
1186791|NCT01209325|penile cancer
1186792|NCT01209325|HIV infection
1186793|NCT01209299|recurrent melanoma
1186794|NCT01209299|stage IIIC melanoma
1186795|NCT01209299|stage IV melanoma
1186796|NCT01209286|Blinatumomab
1186797|NCT01209286|B-ALL
1186798|NCT01209286|adult ALL
1186799|NCT01209286|relapsed ALL
1186800|NCT01209286|refractory ALL
1186801|NCT01209286|Leukemia
1186802|NCT01209286|ALL
1186803|NCT01209286|Lymphatic diseases
1186804|NCT01209286|Lymphoproliferative disorders
1186805|NCT01209286|bispecific antibody
1186806|NCT01209286|anti-CD19
1186807|NCT01209286|Immunotherapeutic treatment
1186808|NCT01209273|Quality of Life
1186809|NCT01209273|Automated Peritoneal Dialysis
1186810|NCT01209273|Continuous Ambulatory Peritoneal Dialysis
1186811|NCT01209273|End Stage Renal Disease
1186812|NCT01209260|Transseptal Puncture
1186813|NCT01209260|Radiofrequency Energy
1186814|NCT01209260|Left Atrium Access
1186815|NCT01209260|Left Atrial Catheterization
1186816|NCT01209260|Ablation
1186817|NCT01209260|Transseptal Catheterization
1186818|NCT01209260|Electrocautery
1186819|NCT01209260|Catheter Ablation
1186820|NCT01209260|Atrial Fibrillation
1186821|NCT01209247|Fluoroquinolone -resistance
1186822|NCT01209247|Commensal flora
1186823|NCT01209247|Emergence of resistance
1186824|NCT01209234|Methicillin-resistant Staphylococcus aureus
1186825|NCT01209234|MRSA
1186826|NCT01209195|Ovarian cancer
1186827|NCT01209195|HER-2 negative breast cancer
1186828|NCT01209195|Breast cancer
1186829|NCT01209195|Fallopian tube cancer
1186830|NCT01208415|Zenith aortoiliac aneurysm
1186831|NCT01208415|iliac aneurysm
1186832|NCT01208415|branch
1186833|NCT01208415|connections
1186834|NCT01208415|endovascular graft
1186835|NCT01208415|graft-iliac bifurcation
1186836|NCT01208415|Aneurysm
1186837|NCT01208415|Vascular Diseases
1186838|NCT01208415|Cardiovascular Diseases
1186839|NCT01208363|Iron fortification
1186840|NCT01208363|polyphenols
1186841|NCT01208363|NaFeEDTA
1186842|NCT01208363|cowpea
1186843|NCT01208363|school feeding program
1186844|NCT01208350|Weight Loss
1186845|NCT01208350|Motivation
1186846|NCT01208350|Workplace
1186847|NCT01208350|Web platform
1186848|NCT01208337|Rejection
1186849|NCT01209169|Kidney Renal
1186850|NCT01209117|formulation
1186851|NCT01209117|bioavailability
1186852|NCT01209117|pharmacokinetics
1186853|NCT01209117|GSK2248761
1186854|NCT01209104|omeprazole
1186855|NCT01209104|proton pump inhibitor
1186856|NCT01209104|COPD
1186857|NCT01209104|CXCR2 inhibitor
1186858|NCT01209104|bioavailability
1186859|NCT01209104|food-effect
1186860|NCT01209078|methicillin-resistant Staphylococcus aureus
1186861|NCT01209078|linezolid
1186862|NCT01209078|repeat dose
1186863|NCT01209078|GSK1322322
1186864|NCT01209065|integrase
1186865|NCT01209065|fosamprenavir
1186866|NCT01209065|ritonavir
1186867|NCT01209065|GSK1349572
1186868|NCT01209052|COPD
1186869|NCT01209052|CXCR2 inhibitor
1186872|NCT01209026|Fluticasone furoate (GW685698)
1186873|NCT01209026|moxifloxacin
1186874|NCT01209026|QTc
1186875|NCT01209026|GW642444
1186876|NCT01209026|pharmacokinetics
1186877|NCT01209013|PDT
1186878|NCT01209013|porfimer sodium
1186879|NCT01209013|BE
1186880|NCT01209000|Focal and Segmental Glomerulosclerosis
1186881|NCT01209000|Focal & Segmental Glomerulosclerosis
1186882|NCT01209000|Focal Segmental Glomerulosclerosis
1186883|NCT01209000|FSGS
1186884|NCT01209000|Minimal change disease
1186885|NCT01209000|MCD
1186886|NCT01209000|Membranous Nephropathy
1186887|NCT01209000|MN
1186888|NCT01209000|Nephrotic Syndrome
1186889|NCT01209000|Neph Syndrome
1186890|NCT01209000|NEPTUNE
1186891|NCT01209000|NephCure
1186892|NCT01209000|Halpin
1186893|NCT01208974|Breast Cancer
1186894|NCT01208974|Nipple Area Complex
1186895|NCT01208974|Mastectomy
1186896|NCT01208974|Radiation Therapy
1186897|NCT01208974|Nipple-Sparing
1186898|NCT01208974|Breast Reconstruction
1186899|NCT01208961|Eicosapentaenoic Acid
1186900|NCT01208961|Docosahexaenoic Acid
1186901|NCT01208961|Hypertriglyceridemia
1186902|NCT01208961|Omega-3 acid ethyl esters
1186903|NCT01208961|Omega-3 carboxylic acids
1186904|NCT01208961|Epanova
1186905|NCT01208961|Lovaza
1186906|NCT01208961|bioavailability
1186907|NCT01208961|pharmacokinetics
1186908|NCT01208961|low-fat meal
1186909|NCT01208961|high-fat meal
1186910|NCT01208948|macular edema
1186911|NCT01208948|diabetes mellitus
1186912|NCT01208948|prevention alpha lipoic acid
1186913|NCT01208935|Randomized
1186914|NCT01208935|Double blind
1186915|NCT01208935|double-dummy
1186916|NCT01208935|placebo-controlled
1186917|NCT01208896|Allogeneic hematopoietic stem cell transplantation
1186918|NCT01208896|Reduced-intensity conditioning
1186919|NCT01208896|Chemosensitive relapsed follicular lymphoma
1186920|NCT01208883|Primary non-operated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx.
1186921|NCT01208831|Advanced tumors
1186922|NCT01208831|hedgehog
1186923|NCT01208831|smoothened inhibitor
1186924|NCT01208792|Auto antibodies
1186925|NCT01208792|Target antigens
1186926|NCT01208792|2D-immunoblot
1186927|NCT01208792|Reactive oxygen species
1186928|NCT01208792|Pulmonary arterial hypertension
1186929|NCT01208792|Systemic sclerosis
1186930|NCT01208792|Human immunodeficiency virus infection
1186931|NCT01208792|Porto pulmonary hypertension
1186932|NCT01208792|Congenital heart defect
1186933|NCT01208792|Systemic lupus erythematosus
1186934|NCT01208792|Mixed connective tissue disease
1186935|NCT01208792|Sjögren's syndrome
1186936|NCT01208779|Compliance
1186937|NCT01208779|HR+ breast cancer
1186938|NCT01208779|epidemiology
1186939|NCT01208766|Multiple Myeloma (Kahler's disease)
1186940|NCT01208753|Safety
1186941|NCT01208753|Tolerability
1186942|NCT01208753|Pharmacokinetics
1186943|NCT01208740|Gonadotropins
1186944|NCT01208740|infertility
1186945|NCT01208740|IVF
1186946|NCT01208740|metformin
1186947|NCT01208740|PCOS
1186948|NCT01208740|poor prognosis
1186949|NCT01208740|poor responder
1186950|NCT01208727|Myocardial infarction
1186951|NCT01208727|Postconditioning
1186952|NCT01208727|Microvascular obstruction
1186953|NCT01208727|No reflow
1186954|NCT01208727|MRI
1186955|NCT01208714|Renal artery stenosis
1186956|NCT01208714|Atherosclerosis
1186957|NCT01208714|Arterial hypertension
1186958|NCT01208714|Percutaneous renal angioplasty
1186959|NCT01208714|Stenting
1186960|NCT01208701|Atorvastatin
1186961|NCT01208701|L-NMMA
1186962|NCT01208701|NO
1186963|NCT01208701|Nephrology
1186964|NCT01208701|Diabetes Mellitus
1186965|NCT01208688|Spinal Cord Injuries
1186966|NCT01208662|Lenalidomide
1186967|NCT01208662|Bortezomib
1186968|NCT01208662|Dexamethasone
1186969|NCT01208662|Stem Cell Transplant
1186970|NCT01208662|Myeloma
1186971|NCT01208662|Multiple Myeloma
1186972|NCT01208649|exenatide
1186973|NCT01208649|hepatic steatosis
1186974|NCT01208649|insulin resistance
1186975|NCT01208649|insulin sensitizers
1186976|NCT01208649|nonalcoholic fatty liver disease
1186977|NCT01208649|- GLP1-Analog
1186978|NCT01208636|Vitamin D deficiency
1186979|NCT01208636|Sun
1186980|NCT01208636|Genetics
1186981|NCT01208584|functional MRI,primary motor cortex,spinal cord injury
1186982|NCT01208571|Harmful use
1186983|NCT01208571|Hazardous use
1186984|NCT01208571|Dependence
1186999|NCT01208545|taxol
1187000|NCT01208545|vincristine
1187001|NCT01208545|oxaliplatin
1187002|NCT01208545|chemotherapy
1187003|NCT01208545|nerve degeneration
1187004|NCT01208545|nerve conduction
1187005|NCT01208545|cancer
1187006|NCT01208545|nerve conduction studies
1187007|NCT01208519|Drug resistance, Microbial
1187008|NCT01208519|Methicillin-Resistant Staphylococcus aureus
1187009|NCT01208519|ESBL
1187010|NCT01208519|Colonisation
1187011|NCT01208519|Screening
1187012|NCT01208519|Gram-negative
1187013|NCT01208493|prematurity
1187014|NCT01208493|enteral feeding
1187015|NCT01208493|proteins
1187016|NCT01208493|formula
1187017|NCT01208480|stage II breast cancer
1187018|NCT01208480|stage IIIA breast cancer
1187019|NCT01208480|stage IIIB breast cancer
1187020|NCT01208480|stage IIIC breast cancer
1187021|NCT01208480|triple-negative breast cancer
1187022|NCT01208428|Depression
1187023|NCT01208324|Cognitive difficulties
1187024|NCT01208324|memory impairment
1187025|NCT01208324|mood changes
1187026|NCT01208324|brain activation
1187027|NCT01208311|Alcoholic cirrhosis
1187028|NCT01208311|hepatitis c cirrhosis
1187029|NCT01208311|cirrhosis
1187030|NCT01208298|Cold Sore Patch
1187031|NCT01208272|Body Mass Index
1187032|NCT01208272|Bulimia/therapy
1187033|NCT01208272|Comorbidity
1187034|NCT01208272|Interpersonal Relations
1187035|NCT01208272|Psychotherapy/methods
1187036|NCT01208259|Body Mass Index
1187037|NCT01208259|Bulimia/therapy
1187038|NCT01208259|Comorbidity
1187039|NCT01208259|Interpersonal Relations
1187040|NCT01208259|Psychotherapy/methods
1187041|NCT01208233|Phase 2 Ischemic stroke Safety and efficacy
1187042|NCT01208220|Collagenase Santyl
1187043|NCT01208220|Enzymatic debridement
1187044|NCT01208220|maintenance debridement
1187045|NCT01208220|VAC
1187046|NCT01208220|NPWT
1187047|NCT01208194|Advanced colorectal carcinoma
1187048|NCT01208194|Maintenance therapy
1187049|NCT01208194|Immunomodulator
1187050|NCT01208168|toenail fungus
1187051|NCT01208168|onychomycosis
1187052|NCT01208168|nail infection
1187053|NCT01208155|Phase 1
1187054|NCT01208155|Healthy
1187055|NCT01208155|pharmacokinetics
1187056|NCT01208155|Fostamatinib
1187057|NCT01208142|toe walker
1187058|NCT01208142|Pediatric toe walking
1187059|NCT01208142|ankle flexion
1187060|NCT01208129|toenail fungus
1187061|NCT01208129|onychomycosis
1187062|NCT01208129|nail infection
1187063|NCT01208116|Atherosclerosis
1187064|NCT01208116|Prognosis
1187065|NCT01208116|Flow-mediated dilatation
1187066|NCT01208116|Brachial-ankle pulse wave velocity
1187067|NCT01208116|Carotid Intimal-Medial Thickness
1187068|NCT01208116|coronary artery calcification score
1187069|NCT01208116|Ankle-brachial index
1187070|NCT01208103|Cancer
1187071|NCT01208103|Small bowel
1187072|NCT01208103|Ampulla of Vater
1187073|NCT01208103|CAPOX Chemotherapy
1187074|NCT01208103|Bevacizumab
1187075|NCT01208103|Capecitabine
1187076|NCT01208103|Oxaliplatin
1187077|NCT01208103|Xeloda
1187078|NCT01208103|Eloxatin
1187079|NCT01208103|Avastin
1187080|NCT01208103|Anti-VEGF monoclonal antibody
1187081|NCT01208103|rhuMab-VEGF
1187082|NCT01208090|psoriasis
1187083|NCT01208090|chronic plaque psoriasis
1187084|NCT01208090|Moderate to severe chronic plaque psoriasis
1187085|NCT01208077|ED hemodynamic profiles
1187086|NCT01208077|patients treated under current clinical standards
1187087|NCT01208077|Acute CHF
1187088|NCT01208077|Stroke syndromes
1187089|NCT01208077|Systemic infection
1187090|NCT01208064|adenocarcinoma of the lung
1187091|NCT01208064|adenosquamous cell lung cancer
1187092|NCT01208064|bronchoalveolar cell lung cancer
1187093|NCT01208064|large cell lung cancer
1187094|NCT01208064|recurrent non-small cell lung cancer
1187095|NCT01208064|stage IIIB non-small cell lung cancer
1187096|NCT01208064|stage IV non-small cell lung cancer
1187097|NCT01208025|Plaque
1187098|NCT01208025|Imaging
1187099|NCT01208012|Diabetes Mellitus treatment Metformin
1187100|NCT01207999|Human papillomavirus
1187101|NCT01207960|dental phobia
1187102|NCT01207960|psychotherapy
1187103|NCT01207960|eye movement desensitization and reprocessing - EMDR
1187104|NCT01207960|efficacy
1187105|NCT01207960|wait-list control
1187106|NCT01207947|Vardenafil
1187107|NCT01207947|Erectile dysfunction
1187108|NCT01207947|Phosphodiesterase Inhibitors
1187109|NCT01207947|Combination use with alpha-blockers
1187110|NCT01207934|diabetes
1187111|NCT01207934|obesity
1187112|NCT01207908|DMD
1187113|NCT01207908|Duchenne Muscular Dystrophy
1187114|NCT01207908|Insulin like growth factor
1187115|NCT01207908|6 minute walk test
1187116|NCT01207869|Bronchopulmonary dysplasia (BPD)
1187117|NCT01207869|Extremely premature infant
1187118|NCT01207869|Mesenchymal stem cells (MSCs)
1187119|NCT01207869|umbilical cord
1187120|NCT01207856|Multiple sclerosis
1187121|NCT01207856|functional MRI
1187122|NCT01207856|cognitive rehabilitation
1187123|NCT01207856|ecological evaluation
1187124|NCT01207856|neuroplasticity
1187125|NCT01207843|Computed tomography
1187126|NCT01207830|Obesity
1187127|NCT01207817|a light flash in each eye for a total of 48 measurements
1187128|NCT01207804|Obesity
1187129|NCT01207791|drug abuse
1187130|NCT01207791|emergency department
1187131|NCT01207791|brief intervention
1187132|NCT01207791|motivational interviewing
1187133|NCT01207791|SBIRT
1187134|NCT01207778|brain
1187135|NCT01207778|development
1187136|NCT01207778|erythropoietin
1187137|NCT01207778|neuroprotection
1187138|NCT01207778|MRI
1187139|NCT01207765|Multiple Myeloma
1187140|NCT01207765|Zevalin
1187141|NCT01207752|dry eye, meibomian gland dysfunction, tear film break up time
1187142|NCT01207739|Prolonged antibiotic treatment in Lyme disease
1187143|NCT01207739|Doxycycline
1187144|NCT01207739|Clarithromycin
1187145|NCT01207739|Hydroxychloroquine
1187146|NCT01207700|post discharge intervention
1187147|NCT01207700|adherence
1187148|NCT01207700|compliance
1187149|NCT01207700|community health worker
1187150|NCT01207674|Pathological gambling
1187151|NCT01207674|"at risk gambling"
1187152|NCT01207674|gambling practice evolution
1187153|NCT01207674|psychiatric comorbidities
1187154|NCT01207674|gambling trajectory
1187155|NCT01207674|cognitive distortions
1187156|NCT01207674|ADHD
1187157|NCT01207674|addiction
1187158|NCT01207674|recourse to care
1187159|NCT01207661|Mesenchymal cells
1187160|NCT01207661|osteoarthritis
1187161|NCT01207661|intra articular injection
1187162|NCT01207648|Interferon beta 1a
1187163|NCT01207648|Autoimmune Diseases
1187164|NCT01207648|Demyelinating Diseases
1187165|NCT01207648|Immune System Diseases
1187166|NCT01207648|Immunologic Factors
1187167|NCT01207648|Nervous System Diseases
1187168|NCT01207648|Physiological Effects of Drugs
1187169|NCT01207648|Demyelinating Autoimmune Diseases, CNS
1187170|NCT01207648|Autoimmune Diseases of the Nervous System
1187171|NCT01207648|Retrospective Cohort Study
1187172|NCT01207635|Cancer
1187173|NCT01207635|Arimidex
1187174|NCT01207609|Obesity
1187175|NCT01207609|Morbid Obesity
1187176|NCT01207609|Bariatric Surgery
1187177|NCT01207609|Laparoscopic Gastric Plication
1187178|NCT01207596|Pain
1187179|NCT01207596|Neuropathy
1187180|NCT01207596|Neuropathic Pain
1187181|NCT01207596|Hydromorphone
1187182|NCT01207583|vaccine
1187183|NCT01207583|infant
1187184|NCT01207583|healthy subjects
1187185|NCT01207570|flexibility
1187186|NCT01207570|muscle
1187187|NCT01207570|stretching
1187188|NCT01207570|cerebral palsy
1187189|NCT01207570|developmental
1187190|NCT01207557|Healthcare personnel
1187191|NCT01207557|influenza
1187192|NCT01207557|immunization
1187193|NCT01207557|flu
1187194|NCT01207557|vaccine
1187195|NCT01207544|motor
1187196|NCT01207544|balance
1187197|NCT01207544|developmental
1187198|NCT01207544|physiotherapy
1187199|NCT01207531|sepsis
1187200|NCT01207531|miRNA
1187201|NCT01207518|influenza
1187202|NCT01207518|immunization
1187203|NCT01207518|healthcare personnel
1187204|NCT01207505|bipolar disorder
1187205|NCT01207505|depression
1187206|NCT01207505|mania
1187207|NCT01207505|emotion regulation
1187208|NCT01207505|dialectical behavior therapy
1187209|NCT01207505|group therapy
1187210|NCT01207505|mindfulness
1187211|NCT01207492|nilotinib
1187212|NCT01207453|Arthritis, Rheumatoid
1187213|NCT01207453|Milnacipran
1187214|NCT01207453|Pain
1187215|NCT01207440|CML
1187216|NCT01207440|ALL
1187217|NCT01207440|PH
1187218|NCT01207440|ponatinib
1187219|NCT01207440|Ph+ALL
1187220|NCT01207440|T315I mutation
1187221|NCT01207440|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
1187222|NCT01207427|opioid therapy
1187223|NCT01207427|constipation
1187224|NCT01207427|chronic noncancer pain
1187225|NCT01207427|mu opioid receptor antagonist
1187226|NCT01207427|ADL5945
1187227|NCT01207414|Schizophrenia
1187228|NCT01207414|iloperidone
1187229|NCT01207414|switch
1187230|NCT01207414|gradual switch
1187231|NCT01207414|immediate switch
1187232|NCT01207401|intrauterine device
1187233|NCT01207401|local anesthetic
1187234|NCT01207388|Blinatumomab
1187235|NCT01207388|MRD
1187236|NCT01207388|B-ALL
1187237|NCT01207388|Minimal residual disease
1187238|NCT01207388|adult ALL
1187239|NCT01207388|Leukemia
1187240|NCT01207388|ALL
1187241|NCT01207388|Lymphatic diseases
1187242|NCT01207388|Lymphoproliferative disorders
1187243|NCT01207388|bispecific antibody
1187244|NCT01207388|anti-CD19
1187245|NCT01207388|Immunotherapeutic treatment
1187246|NCT01207375|memory
1187247|NCT01207375|learning
1187248|NCT01207375|Traumatic Brain Injury
1187249|NCT01207375|cognition
1187250|NCT01207375|treatment
1187251|NCT01207375|therapy
1187252|NCT01207349|Type 2 diabetes
1187253|NCT01207349|Secondary prevention
1187254|NCT01207349|Physical activity
1187255|NCT01207349|Nutritional education
1187256|NCT01207349|HbA1c
1187257|NCT01207349|Reunion island
1187258|NCT01207349|diabetic patients, both female and male, age >=18 years, able to practise a physical activity, in Saint Pierre (GHSR) and Saint Denis (CHD)
1187259|NCT01207336|stroke
1187260|NCT01207336|rehabilitation
1187261|NCT01207336|transcranial direct current stimulation
1187262|NCT01207336|nerve stimulation
1187263|NCT01207310|smoking
1187264|NCT01207310|smoking of 10 cigarettes per day
1187265|NCT01207297|Lupus nephritis
1187266|NCT01207297|tacrolimus
1187267|NCT01207297|cyclophosphamide
1187268|NCT01207271|depression
1187269|NCT01207271|community mental health
1187270|NCT01207271|treatment
1187271|NCT01207271|psychotherapy
1187272|NCT01207271|mediators
1187273|NCT01207258|Motivational Interviewing
1187274|NCT01207258|Brief Intervention
1187275|NCT01207258|Intimate Partner Violence
1187276|NCT01207258|Domestic Violence
1187277|NCT01207258|Alcohol Abuse
1187278|NCT01207245|Cystic fibrosis
1187279|NCT01207245|Tobramycin
1187280|NCT01207245|Pharmacokinetics
1187281|NCT01207245|Toxicity
1187282|NCT01207232|seasonal influenza
1187283|NCT01207232|behavioral economics
1187284|NCT01207232|implementation intentions
1187285|NCT01207232|planning prompt
1187286|NCT01207232|nudge
1187287|NCT01207219|psychosis
1187288|NCT01207219|yoga
1187289|NCT01207219|aerobic exercise
1187290|NCT01207219|memory
1187291|NCT01207219|attention
1187292|NCT01207219|neuro cognition
1187293|NCT01207206|Patient suffering from severe cancer pain despite the opioid treatment
1187294|NCT01207206|Opiate tolerance suspected on the basis of rapid escalation in opiate dose
1187295|NCT01207206|Severe opiate side effects
1187296|NCT01207193|bone cyst bone defect mesenchymal cell
1187297|NCT01207180|emergency medicine
1187298|NCT01207180|primary care physicians
1187299|NCT01207141|Liver Transplantation
1187300|NCT01207141|Thymoglobulin
1187301|NCT01207141|Rejection
1187302|NCT01207102|Breast cancer
1187303|NCT01207102|Triple negative
1187304|NCT01207089|Safety
1187305|NCT01207089|tolerability
1187306|NCT01207089|PK
1187307|NCT01207089|healthy
1187308|NCT01207089|overweight
1187309|NCT01207089|obese
1187310|NCT01207076|CD45+ disease
1187311|NCT01207063|Radiotherapy
1187312|NCT01207063|NSCLC
1187313|NCT01207063|Stage II-III non-small cell lung cancer
1187314|NCT01207050|sleep disorders
1187315|NCT01207050|traumatic brain injury
1187316|NCT01207024|knee arthrosis
1187317|NCT01207024|obesity
1187318|NCT01207024|MRI
1187319|NCT01207024|bariatric surgery
1187320|NCT01206998|preterm labor
1187321|NCT01206998|progesterone
1187322|NCT01206998|tocolysis
1187323|NCT01206998|cervical length
1187324|NCT01206985|Paracetamol
1187325|NCT01206985|per-oral mucosa PMB
1187326|NCT01206985|No disease, healthy volunteers
1187327|NCT01206972|venous thromboembolism
1187328|NCT01206972|prevention
1187329|NCT01206972|orthopaedic surgery
1187330|NCT01206959|BP
1187331|NCT01206946|Respiratory distress
1187332|NCT01206946|Antenatal steroids
1187333|NCT01206946|late preterm
1187334|NCT01206933|HIV/HCV Coinfection
1187335|NCT01206933|Tat Protein
1187336|NCT01206933|HCV
1187337|NCT01206920|HIV
1187338|NCT01206920|AIDS
1187339|NCT01206920|Co-morbidities
1187340|NCT01206907|sickle cell anemia
1187341|NCT01206907|juvenile rheumatoid arthritis
1187342|NCT01206907|burn victim
1187343|NCT01206907|cancer
1187344|NCT01206907|Chronic pain of malignant or non-malignant etiology
1187345|NCT01206894|lung cancer
1187346|NCT01206894|chest wall invasion
1187347|NCT01206894|transthoracic ultrasound
1187348|NCT01206881|breast cancer
1187349|NCT01206881|neoadjuvant
1187350|NCT01206881|liposomal doxorubicin
1187351|NCT01206881|PET scan
1187352|NCT01206868|kidney, transplantation, surgery, complications, lymphocele, fluid collections.
1187353|NCT01206855|MIST Therapy
1187354|NCT01206842|functional capacity
1187355|NCT01206842|training
1187356|NCT01206842|neurocognition
1187357|NCT01206829|Hearing Impaired Persons
1187358|NCT01206829|Tinnitus
1187359|NCT01206829|Life Change Events
1187360|NCT01206829|Adaptation, Psychological
1187361|NCT01206829|Rehabilitation, Vocational
1187362|NCT01206829|Cognitive Therapy
1187363|NCT01206829|Avoidance Learning
1187364|NCT01206829|Escape Reaction
1187365|NCT01206803|ovarian stimulation
1187366|NCT01206803|recombinant FSH
1187367|NCT01206803|GnRH-antagonist
1187368|NCT01206803|corifollitropin alfa
1187369|NCT01206790|PTSD
1187370|NCT01206790|Narrative Exposure Therapy
1187371|NCT01206790|torture victims
1187372|NCT01206790|immune system
1187373|NCT01206777|Hypersensitivity Reactions
1187374|NCT01206777|B-cell malignancies
1187375|NCT01206764|RCC,
1187376|NCT01206764|mTOR pathway,
1187377|NCT01206764|angiogenesis,
1187378|NCT01206764|PFS,
1187379|NCT01206764|partial response [PR] + complete response [CR])
1187380|NCT01206764|metastatic recurrent renal cell carcinoma
1187381|NCT01206764|metastatic unresectable renal cell carcinoma
1187382|NCT01206725|Diabetes type 2
1187383|NCT01206725|exercise
1187384|NCT01206725|tissue Doppler velocity
1187385|NCT01206712|Diabetes Mellitus Type 2
1187386|NCT01206712|insulin glargine
1187387|NCT01206712|Metformin
1187388|NCT01206686|seasonal influenza
1187389|NCT01206686|behavioral economics
1187390|NCT01206686|nudge
1187391|NCT01206686|implementations intentions
1187392|NCT01206686|vaccination
1187393|NCT01206621|dyspnea
1187394|NCT01206621|COPD
1187395|NCT01206621|CHF
1187396|NCT01206621|asthma
1187397|NCT01206608|Breast augmentation
1187398|NCT01206608|Pain
1187399|NCT01206608|Analgesia
1187400|NCT01206595|Postoperative Pain
1187401|NCT01206595|Bunionectomy
1187402|NCT01206595|Analgesia
1187403|NCT01206569|glomerulonephritis
1187404|NCT01206569|systemic lupus erythematosus
1187405|NCT01206556|HUMAN PAPILLOMA VIRUS
1187406|NCT01206556|HPV
1187407|NCT01206543|Craniopharyngioma
1187408|NCT01206543|Surgery
1187409|NCT01206543|Intraoperative imaging
1187410|NCT01206543|Rate of total removal
1187411|NCT01206530|histologically documented
1187412|NCT01206530|advanced
1187413|NCT01206530|metastatic
1187414|NCT01206530|adenocarcinoma
1187415|NCT01206530|colon
1187416|NCT01206530|rectum
1187417|NCT01206517|asenapine
1187418|NCT01206517|pediatric schizophrenia
1187419|NCT01206517|bipolar I disorder
1187420|NCT01206504|West Nile virus
1187421|NCT01206504|WNV
1187422|NCT01206504|Encephalitis
1187423|NCT01206504|Meningitis
1187424|NCT01206504|Acute Flaccid Paralysis
1187425|NCT01206504|Monoclonal Antibody
1187426|NCT01206504|WNND
1187427|NCT01206504|West Nile Neuroinvasive Disease
1187428|NCT01206504|Accidental Exposure to West Nile Virus
1187429|NCT01206452|Atrial Fibrillation; Ablation
1187430|NCT01206426|Urothelial, cancer, cisplatin, neoadjuvant, chemotherapy, germline
1187431|NCT01206413|overweight; treatment; women
1187432|NCT01206400|eugonadal, testosterone
1187433|NCT01206374|Vitiligo Vulgaris
1187434|NCT01206361|Real world
1187435|NCT01206361|observational
1187436|NCT01206361|retrospective
1187437|NCT01206361|database analysis
1187438|NCT01206348|Acne
1187439|NCT01206335|Cancer Cachexia
1187440|NCT01206335|Anorexia
1187441|NCT01206335|Advanced Malignancies
1187442|NCT01206335|Weight Loss
1187443|NCT01206335|Fatigue
1187444|NCT01206335|Karnofsky
1187445|NCT01206335|C-Reactive Protein
1187446|NCT01206335|Simmonds Functional Assessment
1187447|NCT01206322|diabetes, blood flow, brain perfusion, cognitive function
1187448|NCT01206309|Graft vs Host Disease
1187449|NCT01206309|Allogeneic Hematopoietic Cell Transplantation
1187450|NCT01206309|Bone Marrow Transplantation
1187451|NCT01206309|Peripheral Blood Stem Cell Transplantation
1187452|NCT01206309|Umbilical Cord Blood Stem Cell Transplantation
1187453|NCT01206296|Adjuvant
1187454|NCT01206296|Intraperitoneal
1187455|NCT01206296|Gemcitabine
1187456|NCT01206296|Pancreas
1187457|NCT01206296|Adenocarcinoma
1187458|NCT01206283|traumatic brain injury
1187459|NCT01206283|subarachnoid hemorrhage
1187460|NCT01206283|secondary brain ischemia
1187461|NCT01206283|microdialysis
1187462|NCT01206283|modified Lund concept
1187463|NCT01206283|cerebral perfusion pressure
1187464|NCT01206283|intracranial pressure
1187465|NCT01206270|Klinefelter
1187466|NCT01206270|Leydig
1187467|NCT01206270|Testicular Tumor
1187468|NCT01206270|LH
1187469|NCT01206270|Infertility
1187470|NCT01206257|Survey
1187471|NCT01206257|Angiography
1187472|NCT01206257|ADR
1187473|NCT01206257|Image quality
1187474|NCT01206244|dry eye
1187475|NCT01206244|tear meniscus
1187476|NCT01206244|tear osmolarity
1187477|NCT01206231|Standard daily practice in managing patients with hypercholesterolemia
1187478|NCT01206218|Gastric Cancer, BRCA1
1187479|NCT01206205|De novo Multiple Myeloma
1187480|NCT01206205|Bortezomib
1187481|NCT01206205|Lenalidomide
1187482|NCT01206205|induction therapy
1187483|NCT01206205|consolidation therapy
1187484|NCT01206205|maintenance therapy
1187485|NCT01206205|High dose therapy
1187486|NCT01206205|frontline therapy including new drugs and high dose therapy
1187487|NCT01206192|Intimate Terrorism
1187488|NCT01206192|Situational couple violence
1187489|NCT01206192|Mental health
1187490|NCT01206192|Chinese
1187491|NCT01206192|Women
1187492|NCT01206179|nonunion fracture bone formation pain relief
1187493|NCT01206166|Randomized trial
1187494|NCT01206166|Parental nutrition
1187495|NCT01206166|Enteral nutrition
1187496|NCT01206166|Intensive care unit
1187497|NCT01206166|BMI < 25 or ≥ 35
1187498|NCT01206114|2009 H1N1 influenza
1187499|NCT01206114|vaccination
1187500|NCT01206114|pandemic
1187501|NCT01206114|effectiveness
1187502|NCT01206075|Beta Thalassemia Major
1187503|NCT01206075|Hematopoietic Stem Cell Mobilization
1187504|NCT01206075|Gene Transfer Techniques
1187505|NCT01206062|blood pressure
1187506|NCT01206062|antihypertensive
1187507|NCT01206062|systolic
1187508|NCT01206062|diastolic
1187509|NCT01206062|heart failure
1187510|NCT01206062|myocardial infarction
1187511|NCT01206062|stroke
1187512|NCT01206062|chronic kidney disease
1187513|NCT01206062|dementia
1187514|NCT01206062|cognitive decline
1187515|NCT01206049|Cholangiocarcinoma
1187516|NCT01206049|Inoperable
1187517|NCT01206049|KRAS mutation
1187518|NCT01206049|Biological treatment
1187519|NCT01206049|Combination chemotherapy
1187520|NCT01206049|Monoclonal antibody
1187521|NCT01206036|castration
1187522|NCT01206036|prostate cancer
1187523|NCT01206036|castration resistant prostate cancer
1187524|NCT01206036|PSA
1187525|NCT01206036|Docetaxel
1187526|NCT01206036|Temsirolimus
1187527|NCT01206036|disease progression free survival
1187528|NCT01206036|DPFS
1187529|NCT01206036|dose escalation
1187530|NCT01206023|Multiple Sclerosis
1187531|NCT01206023|Breath
1187532|NCT01206023|Diagnosis
1187533|NCT01206023|Discrimination MS/healthy subj. via exhaled breath samples
1187534|NCT01206010|Tobacco Dependence
1187535|NCT01206010|Smoking cessation
1187536|NCT01206010|Varenicline
1187537|NCT01206010|Tailored dosing
1187538|NCT01205997|magnesium
1187539|NCT01205997|fentanyl
1187540|NCT01205997|intrathecal
1187541|NCT01205997|pain
1187542|NCT01205984|Chronic rhinosinusitis
1187543|NCT01205984|Computed tomography scan
1187544|NCT01205984|Methylprednisolone
1187545|NCT01205958|Cervical pain
1187546|NCT01205958|Neck pain
1187547|NCT01205958|western medicine
1187548|NCT01205958|oriental medicine
1187549|NCT01205958|acupuncture
1187550|NCT01205958|needle
1187551|NCT01205945|Aortic aneurysm, abdominal
1187552|NCT01205945|Screening
1187553|NCT01205945|Mortality
1187554|NCT01205932|venous thromboembolism
1187555|NCT01205932|prevention
1187556|NCT01205932|othopaedic surgery
1187557|NCT01205919|Tinnitus
1187558|NCT01205919|Internet Training
1187559|NCT01205919|Cognitive-Behavior Therapy
1187560|NCT01205919|CBT
1187561|NCT01205906|Tinnitus
1187562|NCT01205906|Internet Training
1187563|NCT01205906|Cognitive-Behavior Therapy
1187564|NCT01205906|CBT
1187565|NCT01205880|combination treatment
1187566|NCT01205880|topical corticosteroid
1187567|NCT01205880|vitamin D analogue
1187568|NCT01205880|clobex
1187569|NCT01205880|vectical
1187570|NCT01205880|clobetasol
1187571|NCT01205880|calcitriol
1187572|NCT01205867|Butyrylcholinesterase deficiency
1187573|NCT01205867|tolerability
1187574|NCT01205867|safety
1187575|NCT01205867|AZD8848
1187576|NCT01205867|pharmacokinetics
1187577|NCT01205867|pharmacodynamics
1187578|NCT01205867|BChE deficient subjects and matched control subject
1187579|NCT01205854|rheumatoid arthritis
1187580|NCT01205854|ultrasonography
1187581|NCT01205854|remission
1187582|NCT01205854|imaging remission
1187583|NCT01205854|tight control
1187584|NCT01205854|treat to target
1187585|NCT01205841|Ottawa Ankle and Foot Rules
1187586|NCT01205841|Buffalo Rule
1187587|NCT01205841|Bernese Ankle Rules
1187588|NCT01205841|Low Risk Exam
1187589|NCT01205841|Malleolar Zone Algorithm
1187590|NCT01205841|Clinical decision rule
1187591|NCT01205841|Ankle injury
1187592|NCT01205841|Ankle sprain
1187593|NCT01205841|Inversion trauma
1187594|NCT01205828|liver cancer
1187595|NCT01205828|hepatocellular
1187596|NCT01205828|temozolomide
1187597|NCT01205828|veliparib
1187598|NCT01205802|patency, hepatic venous congestion, liver transplantation
1187599|NCT01205789|Drug eluting stents
1187600|NCT01205789|Stents
1187601|NCT01205789|Angioplasty
1187602|NCT01205789|Left Main Coronary Artery Disease
1187603|NCT01205776|Drug eluting stents
1187604|NCT01205776|Stents
1187605|NCT01205776|Unprotected Left Main Coronary Artery Disease
1187606|NCT01205776|Coronary artery bypass graft surgery
1187607|NCT01205737|DLBCL
1187608|NCT01205737|pharmacokinetics
1187609|NCT01205737|pharmacodynamics
1187610|NCT01205711|recurrent colon cancer
1187611|NCT01205711|stage IV colon cancer
1187612|NCT01205711|recurrent rectal cancer
1187613|NCT01205711|stage IV rectal cancer
1187614|NCT01205672|Endometrium
1187615|NCT01205672|Gynecologic malignancy
1187616|NCT01205672|Endometrial adenocarcinoma
1187617|NCT01205672|Insulin/glucose metabolism
1187618|NCT01205672|Metformin
1187619|NCT01205646|prostate cancer
1187620|NCT01205646|metastatic
1187621|NCT01205646|zoledronate
1187622|NCT01205646|zometa
1187623|NCT01205633|neurodegenerative disease
1187624|NCT01205633|neurovascular disease
1187625|NCT01205633|fatigue
1187626|NCT01205633|Hubbard Foundation
1187627|NCT01205633|angioplasty
1187628|NCT01205620|CABG
1187629|NCT01205607|traumatic brain injury
1187630|NCT01205594|CABG surgery
1187631|NCT01205581|Fluzone
1187632|NCT01205581|Trivalent Influenza Vaccine
1187633|NCT01205555|intra uterine insemination
1187634|NCT01205529|Atrial Fibrillation
1187635|NCT01205529|ST elevation
1187636|NCT01205529|Genotype
1187637|NCT01205503|chemobrain
1187638|NCT01205503|Oxidative Stress
1187639|NCT01205503|Mesna
1187640|NCT01205477|Anserine bursitis
1187641|NCT01205464|Persistent symptoms
1187642|NCT01205464|Doxycycline
1187643|NCT01205464|Placebo
1187644|NCT01205464|Neuroborreliosis
1187645|NCT01205451|GSK1358820
1187646|NCT01205451|upper limb
1187647|NCT01205451|spasticity
1187648|NCT01205451|post-stroke
1187649|NCT01205438|SLE
1187650|NCT01205438|Systemic Lupus Erythematosis
1187651|NCT01205438|Lupus
1187652|NCT01205438|autoimmune disease
1187653|NCT01205438|LY2127399
1187654|NCT01205438|Immune System Disease
1187655|NCT01205425|Computed coronary angiography
1187656|NCT01205425|Stent implantation
1187657|NCT01205425|IVUS
1187658|NCT01205386|CTO
1187659|NCT01205386|peripheral artery occlusive disease
1187660|NCT01205386|PAOD
1187661|NCT01205386|SFA
1187662|NCT01205386|superficial femoral artery
1187663|NCT01205360|Analgesia, labour;
1187664|NCT01205360|Analgesic techniques, epidural;
1187665|NCT01205360|Drug delivery, intermittent bolus;
1187666|NCT01205360|Anesthetics local, Bupivacaine;
1187667|NCT01205360|Analgesics opioid, Fentanyl;
1187668|NCT01205347|Statin
1187669|NCT01205347|Myocardial infarction
1187670|NCT01205347|Insulin sensitivity
1187671|NCT01205334|Glioblastoma multiforme
1187672|NCT01205334|GBM
1187673|NCT01205334|Brain Cancer
1187674|NCT01205334|CTL
1187675|NCT01205321|Neoplasm
1187676|NCT01205321|PET/CT diagnosis
1187677|NCT01205321|PET tracer
1187678|NCT01205308|Plant stanols
1187679|NCT01205308|type 1 diabetes
1187680|NCT01205308|sterol metabolism
1187681|NCT01205308|cholesterol
1187682|NCT01205295|hip
1187683|NCT01205295|shoulder
1187684|NCT01205295|mental disorders
1187685|NCT01205295|anxiety
1187686|NCT01205295|concern
1187687|NCT01205295|efficacy of treatment
1187688|NCT01205282|ASD
1187689|NCT01205269|Chronic Obstructive Pulmonary Disease (COPD)
1187690|NCT01205269|safety
1187691|NCT01205269|inhalation
1187692|NCT01205269|long-acting muscarinic receptor antagonist (LAMA)
1187693|NCT01205256|Methadone pharmacokinetics in adolescents
1187694|NCT01205243|Abacavir
1187695|NCT01205243|post-marketing surveillance
1187696|NCT01205230|Esomeprazole
1187697|NCT01205230|Pharmacogenetics
1187698|NCT01205230|Pharmacokinetics
1187699|NCT01205230|Ketoconazole
1187700|NCT01205230|Pazopanib
1187701|NCT01205230|Drug Interaction
1187702|NCT01205230|Safety
1187703|NCT01205230|Solid Tumors
1187704|NCT01205217|lapatinib
1187705|NCT01205217|epirubicin
1187706|NCT01205217|cyclophosphamide
1187707|NCT01205217|trastuzumab
1187708|NCT01205217|paclitaxel
1187709|NCT01205217|neoadjuvant therapy
1187710|NCT01205217|Breast Cancer
1187711|NCT01205204|Clonidine
1187712|NCT01205204|Fentanyl
1187713|NCT01205204|Bupivacaine
1187714|NCT01205204|Spinal Anesthesia
1187715|NCT01205204|Lower Segment Caesarian Section
1187716|NCT01205191|Cognitive behavioural therapy
1187717|NCT01205191|Anxiety
1187718|NCT01205191|Primary care
1187719|NCT01205191|Effectiveness trial
1187720|NCT01205191|Cell-phone supported therapy
1187721|NCT01205152|Hypophosphatasia
1187722|NCT01205152|HPP
1187723|NCT01205152|Bone Disease
1187724|NCT01205152|Soft Bones
1187725|NCT01205152|Low Alkaline Phosphatase
1187726|NCT01205152|genetic metabolic disorder
1187727|NCT01205152|alkaline phosphatase
1187728|NCT01205152|tissue non-specific alkaline phosphatase
1187729|NCT01205152|rickets
1187730|NCT01205152|osteomalacia
1187731|NCT01205139|TMC435-TiDP16-C114
1187732|NCT01205139|TMC435-C114
1187733|NCT01205139|TMC435
1187734|NCT01205139|HCV
1187735|NCT01205139|Hepatitis C
1187736|NCT01205126|Pain
1187737|NCT01205126|Hydromorphone hydrochloride
1187738|NCT01205126|Oxycodone hydrochloride
1187739|NCT01205100|Gastrointestinal Diseases
1187740|NCT01205100|Irritable Bowel Syndrome
1187741|NCT01205100|Behavioral Research
1187742|NCT01205100|Biofeedback
1187743|NCT01205074|Patients with chronic liver disease and cirrhosis
1187744|NCT01205035|Idiopathic Parafoveal Telangiectasia
1187745|NCT01205035|Macular Telangiectasia
1187746|NCT01205035|Macula Lutea/pathology
1187747|NCT01205035|Retinal Diseases/pathology
1187748|NCT01205035|Retinal Pigments/metabolism
1187749|NCT01205035|Telangiectasis/metabolism
1187750|NCT01205035|Telangiectasis/pathology
1187751|NCT01205009|in-vitro fertilization
1187752|NCT01205009|poor responders
1187753|NCT01205009|human chorionic gonadotropin
1187754|NCT01205009|Fertility Agents, Female
1187755|NCT01204996|monoclonal antibody
1187756|NCT01204996|solid tumor
1187757|NCT01204996|chemotherapy
1187758|NCT01204996|standard of care
1187759|NCT01204983|very low birth weight infant
1187760|NCT01204983|donor human milk
1187761|NCT01204970|Confocal Laser Scanning Microendoscopy
1187762|NCT01204970|Small airways
1187763|NCT01204970|COPD
1187764|NCT01204970|Lung transplantation
1187765|NCT01204957|Homocysteine
1187766|NCT01204957|Insulin-like growth factor
1187886|NCT01204723|Narcotic Antagonists
1187767|NCT01204957|Insulin-like growth factor binding protein
1187768|NCT01204957|Serum estrogen
1187769|NCT01204957|Urinary phytoestrogens
1187770|NCT01204957|Thyroid hormones
1187771|NCT01204931|reflux
1187772|NCT01204931|gastroesophageal reflux disease
1187773|NCT01204931|GERD
1187774|NCT01204918|MDD
1187775|NCT01204918|Depression
1187776|NCT01204918|Treatment refractory
1187777|NCT01204918|Glutamate
1187778|NCT01204918|Riluzole
1187779|NCT01204918|Major depressive disorder
1187780|NCT01204918|psychopharmacology
1187781|NCT01204918|rilutek
1187782|NCT01204905|HIV-1
1187783|NCT01204905|CD4
1187784|NCT01204905|Viral Load
1187785|NCT01204905|Human Immunodeficiency Virus (HIV)
1187786|NCT01204866|Allergic-Like Reaction
1187787|NCT01204866|Selected Formulation Components
1187788|NCT01204853|sitaxentan sodium hypertension
1187789|NCT01204840|in vitro fertilization
1187790|NCT01204840|IVF
1187791|NCT01204840|poor responder
1187792|NCT01204840|growth hormone
1187793|NCT01204840|Poor responders to in vitro fertilization treatments
1187794|NCT01204827|Patients with chronic HBeAg negative hepatitis B virus infection treated with Sebivo (Telbivudine)
1187795|NCT01204814|HIV
1187796|NCT01204814|Drug resistance
1187797|NCT01204814|mutations
1187798|NCT01204814|ARV's
1187799|NCT01204801|Cancer
1187800|NCT01204801|Breast Cancer
1187801|NCT01204801|Breast Tumor
1187802|NCT01204801|Breast Neoplasm
1187803|NCT01204801|Neoplasms by Site
1187804|NCT01204801|Neoplasms
1187805|NCT01204801|Breast Diseases
1187806|NCT01204801|Breast Conserving Surgery
1187807|NCT01204801|Breast Conservation
1187808|NCT01204801|Partial Mastectomy
1187809|NCT01204801|Lumpectomy
1187810|NCT01204801|Mastectomy
1187811|NCT01204801|Surgery
1187812|NCT01204801|Neoadjuvant Therapy
1187813|NCT01204801|Primary Therapy
1187814|NCT01204801|Neoadjuvant Systemic Therapy
1187815|NCT01204801|Thermotherapy
1187816|NCT01204801|Fever Therapy
1187817|NCT01204801|Hot Temperature
1187818|NCT01204801|Hyperthermia
1187819|NCT01204801|Hyperthermia, Therapeutic
1187820|NCT01204801|Hyperthermia, Local
1187821|NCT01204801|Hyperthermia, Induced
1187822|NCT01204801|Therapeutic Hyperthermia
1187823|NCT01204801|Microwave
1187824|NCT01204801|Focused Microwave
1187825|NCT01204801|Focused Microwave Thermotherapy
1187826|NCT01204801|Minimally Invasive
1187827|NCT01204801|Doxorubicin
1187828|NCT01204801|Epirubicin
1187829|NCT01204801|Epidoxirubicin
1187830|NCT01204801|Immunosuppresive Agent
1187831|NCT01204801|Immunologic Factors
1187832|NCT01204801|Physiological Effects of Drugs
1187833|NCT01204801|Chemotherapy
1187834|NCT01204801|Drug Therapy
1187835|NCT01204801|Pharmalogic Actions
1187836|NCT01204801|Antirheumatic Agents
1187837|NCT01204801|Therapeutic Uses
1187838|NCT01204801|Antineoplastic Agents, Alkylating
1187839|NCT01204801|Alkylating Agents
1187840|NCT01204801|Molecular Mechanisms of Pharmacological Action
1187841|NCT01204801|Antineoplastic Agents
1187842|NCT01204801|Myeloblative Agonists
1187843|NCT01204801|Antibiotics, Antineoplastic
1187844|NCT01204801|Anthracycline Agents
1187845|NCT01204788|Acute myelogenous leukemia
1187846|NCT01204788|AML
1187847|NCT01204788|Undifferentiated and bi-phenotypic leukemia
1187967|NCT01204320|Stenting
1187848|NCT01204788|High-risk myelodysplastic syndrome
1187849|NCT01204788|Chronic myelogenous leukemia
1187850|NCT01204788|Infection
1187851|NCT01204788|Radiated Prophylactic White Cell Transfusions
1187852|NCT01204788|Therapeutic Radiated White Cell Transfusion
1187853|NCT01204788|prophylactic antibiotics
1187854|NCT01204749|AMGEN
1187855|NCT01204749|AMG 386
1187856|NCT01204749|Angiogenesis Inhibitors
1187857|NCT01204749|Fallopian Tube Cancer
1187858|NCT01204749|Primary Peritoneal Cancer
1187859|NCT01204749|Paclitaxel
1187860|NCT01204749|Ovarian Cancer
1187861|NCT01204749|TRINOVA-1
1187862|NCT01204736|tendon transfer
1187863|NCT01204736|elbow
1187864|NCT01204723|Marijuana Abuse
1187865|NCT01204723|Nicotine Dependence
1187866|NCT01204723|Nicotine Withdrawal
1187867|NCT01204723|neurokinin Receptor
1187868|NCT01204723|NK1 Receptor antagonist
1187869|NCT01204723|Substance P
1187870|NCT01204723|Recurrence
1187871|NCT01204723|Substance Withdrawal Syndrome
1187872|NCT01204723|Substance-Related Disorders
1187873|NCT01204723|Disorders of Environmental Origin
1187874|NCT01204723|Mental Disorders
1187875|NCT01204723|Disease Attributes
1187876|NCT01204723|Pathologic Processes
1187877|NCT01204723|Tetrahydrocannabinol
1187878|NCT01204723|Therapeutic Uses
1187879|NCT01204723|Psychotropic Drugs
1187880|NCT01204723|Analgesics, Non-Narcotic
1187881|NCT01204723|Analgesics
1187882|NCT01204723|Sensory System Agents
1187883|NCT01204723|Peripheral Nervous System Agents
1187884|NCT01204723|Neurotransmitter Agents
1187885|NCT01204723|Molecular Mechanisms of Pharmacological Action
1187887|NCT01204723|cannabis
1187888|NCT01204710|Prostate Cancer
1187889|NCT01204684|dendritic cells
1187890|NCT01204684|glioma
1187891|NCT01204684|vaccine
1187892|NCT01204684|glioma of WHO Grade III or IV
1187893|NCT01204671|influenza infection
1187894|NCT01204671|GSK Biologicals influenza vaccine GSK2321138A
1187895|NCT01204658|Haemophilus influenzae
1187896|NCT01204658|Streptococcus pneumoniae
1187897|NCT01204658|immunogenicity
1187898|NCT01204658|Pneumococcal vaccine
1187899|NCT01204658|infants
1187900|NCT01204658|safety
1187901|NCT01204619|peritoneal dialysis
1187902|NCT01204567|HLRQ
1187903|NCT01204567|elderly
1187904|NCT01204567|aerobic fitness
1187905|NCT01204567|cognitive capacity
1187906|NCT01204554|perforator flaps
1187907|NCT01204541|Non-exudative age-related macular degeneration
1187908|NCT01204528|Dysfunction in CKD
1187909|NCT01204515|IBS
1187910|NCT01204515|irritable bowel syndrome
1187911|NCT01204515|abdominal pain
1187912|NCT01204515|urgency
1187913|NCT01204515|bloating
1187914|NCT01204515|diarrhea
1187915|NCT01204515|constipation
1187916|NCT01204502|Gene therapy
1187917|NCT01204502|Haploidentical
1187918|NCT01204502|Bone marrow transplant
1187919|NCT01204502|Graft versus host disease
1187920|NCT01204502|haploidentical stem cell transplantation
1187921|NCT01204502|T-cell suicide gene therapy
1187922|NCT01204450|recurrent childhood brain tumor
1187923|NCT01204450|recurrent childhood rhabdomyosarcoma
1187924|NCT01204450|recurrent childhood soft tissue sarcoma
1187925|NCT01204450|recurrent childhood supratentorial primitive neuroectodermal tumor
1187926|NCT01204450|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1187927|NCT01204450|recurrent neuroblastoma
1187928|NCT01204450|recurrent osteosarcoma
1187929|NCT01204450|unspecified childhood solid tumor, protocol specific
1187930|NCT01204437|adjuvant chemotherapy
1187931|NCT01204437|primary carcinoma
1187932|NCT01204437|elderly non frail patients
1187933|NCT01204437|EC
1187934|NCT01204437|CMF
1187935|NCT01204437|Capecitabine
1187936|NCT01204437|Nab-Paclitaxel
1187937|NCT01204424|minimal invasive
1187938|NCT01204424|sinus floor augmentation
1187939|NCT01204424|sinuslift
1187940|NCT01204424|dental implants
1187941|NCT01204411|Efficacy
1187942|NCT01204411|Safety
1187943|NCT01204411|Artesunate-amodiaquine
1187944|NCT01204411|Malaria
1187945|NCT01204411|Plasmodium falciparum
1187946|NCT01204411|Malnutrition
1187947|NCT01204385|Non-typeable Haemophilus Influenzae
1187948|NCT01204385|Acute Otitis Media
1187949|NCT01204385|Streptococcus Pneumoniae
1187950|NCT01204385|etiology
1187951|NCT01204372|Metastatic pancreatic adenocarcinoma
1187952|NCT01204372|First-line chemotherapy
1187953|NCT01204372|Combination chemotherapy
1187954|NCT01204372|Targeted agents
1187955|NCT01204346|adolescents
1187956|NCT01204346|MBT
1187957|NCT01204346|depression
1187958|NCT01204346|emerging personality disorder
1187959|NCT01204333|Cerebral venous and sinus thrombosis
1187960|NCT01204333|Cerebral venous thrombosis
1187961|NCT01204333|Sinus Thrombosis, Intracranial
1187962|NCT01204333|Endovascular thrombolysis
1187963|NCT01204333|Thrombolysis
1187964|NCT01204333|Thrombectomy
1187965|NCT01204320|Restenosis
1187966|NCT01204320|POBA
1187968|NCT01204320|Paclitaxel
1187969|NCT01204281|Proportional Assist Ventilation plus
1187970|NCT01204281|Acute respiratory failure
1187971|NCT01204281|Mechanical ventilation
1187972|NCT01204268|cerebral ischemia
1187973|NCT01204268|sevoflurane preconditioning
1187974|NCT01204268|intracranial aneurysm surgery
1187975|NCT01204255|healthy, no evidence of disease
1187976|NCT01204242|Breast Cancer
1187977|NCT01204229|Alcohol Consumption
1187978|NCT01204229|Social Anxiety
1187979|NCT01204229|Depression
1187980|NCT01204229|Brief Intervention
1187981|NCT01204229|Motivational Interviewing
1187982|NCT01204229|Cognitive Behavioral Therapy
1187983|NCT01204229|Sub-Clinical Social Anxiety
1187984|NCT01204229|Sub-Clinical Depression
1187985|NCT01204216|Hemoglobin A1c
1187986|NCT01204216|HbA1c
1187987|NCT01204216|glycated serum proteins
1187988|NCT01204216|fructosamine
1187989|NCT01204216|glycated albumin
1187990|NCT01204216|glycation gap
1187991|NCT01204203|mesothelioma
1187992|NCT01204203|zoledronic acid
1187993|NCT01204203|zometa
1187994|NCT01204203|bisphosphonate therapy
1187995|NCT01204203|CT scan
1187996|NCT01204203|PET scan
1187997|NCT01204190|Administration
1187998|NCT01204190|Cutaneous
1187999|NCT01204177|Hepatocellular carcinoma (HCC)
1188000|NCT01204177|MEK inhibitor
1188001|NCT01204177|Sorafenib
1188002|NCT01204177|Disease control rate (DCR)
1188003|NCT01204177|Safety
1188004|NCT01204164|AML
1188005|NCT01204164|ALL
1188006|NCT01204164|MDS
1188007|NCT01204164|CML in blast crisis
1188008|NCT01204164|Multiple Myeloma
1188009|NCT01204164|Carfilzomib refractory
1188010|NCT01204138|RA, treatment, TNF, cytokines
1188011|NCT01204112|Drug-Drug Interaction
1188012|NCT01204112|Tasocitinib (CP-690
1188013|NCT01204112|550)
1188014|NCT01204112|Rifampin
1188015|NCT01204112|Healthy Volunteers
1188016|NCT01204099|PX-866
1188017|NCT01204099|Non small cell lung cancer
1188018|NCT01204099|solid tumors
1188019|NCT01204099|Squamous cell cancer of the head and neck
1188020|NCT01204099|docetaxel
1188021|NCT01204099|NSCLC
1188022|NCT01204099|taxotere
1188023|NCT01204099|SCCHN
1188024|NCT01204099|PI-3K
1188025|NCT01204099|PI3 kinase
1188026|NCT01204099|PI3K
1188027|NCT01204086|Major Depressive Disorder
1188028|NCT01204086|Antidepressants
1188029|NCT01204086|Pharmacogenetics
1188030|NCT01204086|venlafaxine
1188031|NCT01204086|fluoxetine
1188032|NCT01204060|Nasal Allergen Lipopolysaccharide Inflammation Asthma
1188033|NCT01204034|COPD
1188034|NCT01204034|Formoterol
1188035|NCT01204034|Beclomethasone Dipropionate
1188036|NCT01204034|Computational Fluid Dynamics
1188037|NCT01204034|Functional Imaging
1188038|NCT01204034|Central and Peripheral Airways
1188039|NCT01204034|BODE index
1188040|NCT01204034|COPD Assessment Test (CAT)
1188041|NCT01204034|Borg CR10 scale
1188042|NCT01204021|Stress
1188043|NCT01204021|loneliness
1188044|NCT01204021|social isolation
1188045|NCT01204021|autonomic activity
1188046|NCT01204021|inflammation
1188047|NCT01204021|Perceived social isolation
1188048|NCT01204021|Chronic stress
1188049|NCT01203982|CIMT
1188050|NCT01203982|IVUS-VH
1188051|NCT01203982|Coronary artery disease
1188052|NCT01203956|AutoAdjust
1188053|NCT01203956|SmartFlex
1188054|NCT01203956|Apnea Hypopnea Index
1188055|NCT01203956|Patient reported outcomes
1188056|NCT01203943|Idiopathic Pulmonary Fibrosis
1188057|NCT01203943|Pulmonary Fibrosis
1188058|NCT01203943|Fibrosis
1188059|NCT01203943|Interstitial Lung Disease
1188060|NCT01203943|Lung Diseases, Interstitial
1188061|NCT01203943|CC-930
1188062|NCT01203930|CLL
1188063|NCT01203930|SLL
1188064|NCT01203930|GS-1101
1188065|NCT01203930|CAL-101
1188066|NCT01203930|Phosphatidylinositol 3-kinase (PI3K)
1188067|NCT01203930|Rituximab
1188068|NCT01203930|Rituxan
1188069|NCT01203917|Gefitinib
1188070|NCT01203917|EGFR TKI
1188071|NCT01203917|efficacy
1188072|NCT01203917|Caucasian patients
1188073|NCT01203917|EGFR mutation positive advanced NSCLC
1188074|NCT01203917|safety
1188075|NCT01203904|bronchial asthma, Pulmicort, long term use, pediatrics
1188076|NCT01203891|SPECT
1188077|NCT01203891|Imaging
1188078|NCT01203891|Healthy brain
1188079|NCT01203891|regional cerebral blood flow
1188080|NCT01203878|Imiquimod
1188081|NCT01203878|Photodynamic therapy
1188082|NCT01203878|Actinic keratoses
1188083|NCT01203878|Sequential therapy
1188084|NCT01203878|Therapeutic uses
1188085|NCT01203865|Fibromyalgia
1188086|NCT01203865|Fatigue
1188087|NCT01203852|hypertension
1188088|NCT01203852|antihypertensive drug
1188089|NCT01203852|pharmacogenetics
1188090|NCT01203852|genetics
1188091|NCT01203852|blood pressure
1188092|NCT01203852|glucose
1188093|NCT01203839|stage 1 breast cancer
1188094|NCT01203839|invasive ductal breast
1188095|NCT01203839|Partial Breast Irradiation (PBI)
1188096|NCT01203839|radiation
1188097|NCT01203839|10-114
1188098|NCT01203826|Hypophosphatasia
1188099|NCT01203826|HPP
1188100|NCT01203826|Bone Disease
1188101|NCT01203826|Soft Bones
1188102|NCT01203826|Low Alkaline Phosphatase
1188103|NCT01203826|genetic metabolic disorder
1188104|NCT01203826|alkaline phosphatase
1188105|NCT01203826|tissue non-specific alkaline phosphatase
1188106|NCT01203826|rickets
1188107|NCT01203826|osteomalacia
1188108|NCT01203813|Chronic kidney disease
1188109|NCT01203813|Quality improvement
1188110|NCT01203813|Self management support
1188111|NCT01203813|Electronic health records
1188112|NCT01203813|Clinical decision support
1188113|NCT01203813|Electronic reminders
1188114|NCT01203813|Patient outreach
1188115|NCT01203787|Hepatocellular Carcinoma
1188116|NCT01203787|HCC
1188117|NCT01203787|Liver Cancer
1188118|NCT01203774|Diabetes
1188119|NCT01203761|loneliness
1188120|NCT01203735|Non-small-cell lung cancer
1188121|NCT01203735|Valproic acid
1188122|NCT01203735|Chemotherapy
1188123|NCT01203735|Radiotherapy
1188124|NCT01203722|Reduced intensity
1188125|NCT01203722|partially HLA mismatched allogeneic BMT
1188126|NCT01203722|Acute leukemias
1188127|NCT01203722|Chronic leukemias
1188128|NCT01203722|Myelodysplasia
1188129|NCT01203722|Lymphomas
1188130|NCT01203722|Unrelated or non-first-degree related donors
1188131|NCT01203709|lupus
1188132|NCT01203709|nephritis
1188133|NCT01203709|glomerulonephritis
1188134|NCT01203709|nephropathy
1188135|NCT01203709|refractory
1188136|NCT01203696|Clopidogrel
1188137|NCT01203696|Platelet reactivity
1188138|NCT01203696|Amlodipine
1188139|NCT01203683|depression
1188140|NCT01203670|Glomerular filtration rate (GFR)
1188141|NCT01203670|Aspartate Amino Transferase (ASAT)
1188142|NCT01203670|Alanine Amino transferase (ALAT)
1188143|NCT01203670|gamma Glutamyl transpeptidase (gamma GT)
1188144|NCT01203670|Lipase
1188145|NCT01203670|Amylase
1188146|NCT01203657|exercise
1188147|NCT01203657|physical activity
1188148|NCT01203657|tai chi
1188149|NCT01203644|Postoperative pain
1188150|NCT01203644|Analgesia
1188151|NCT01203618|Resectable, non-functioning pituitary adenoma
1188152|NCT01203618|Pituitary tumor
1188153|NCT01203618|Pituitary adenoma
1188154|NCT01203618|Pituitary macroadenoma
1188155|NCT01203605|Operative surgical procedures
1188156|NCT01203605|mortality
1188157|NCT01203605|adverse effects
1188158|NCT01203605|Postoperative complications
1188159|NCT01203605|Epidemiological Study
1188160|NCT01203592|Congenital myasthenic syndrome
1188161|NCT01203592|Albuterol
1188162|NCT01203592|Neuromuscular transmission
1188163|NCT01203579|CDT-Lung,CT scan,lung cancer detection
1188164|NCT01203566|Single incision laparoscopic surgery
1188165|NCT01203566|Single site access laparoscopic surgery
1188166|NCT01203566|SILS
1188167|NCT01203566|Single-port access
1188168|NCT01203566|Laparoendoscopic single site surgery
1188169|NCT01203566|Appendectomy
1188170|NCT01203553|Incisional hernias
1188171|NCT01203553|Prophylaxis
1188172|NCT01203553|Preperitoneal mesh
1188173|NCT01203527|H1N1 influenza
1188174|NCT01203527|Swine flu
1188175|NCT01203527|Oseltamivir
1188176|NCT01203527|Tamiflu
1188177|NCT01203527|Pregnancy
1188178|NCT01203514|NICHD Neonatal Research Network
1188179|NCT01203514|Extremely Low Birth Weight (ELBW)
1188180|NCT01203514|Prematurity
1188181|NCT01203514|Erythrocyte transfusions
1188182|NCT01203514|Erythropoietin (Epo)
1188183|NCT01203514|Blood loss
1188184|NCT01203514|Phlebotomy
1188185|NCT01203501|NICHD Neonatal Research Network
1188186|NCT01203501|Extremely Low Birth Weight (ELBW)
1188187|NCT01203501|Prematurity
1188188|NCT01203501|Antenatal Magnesium sulfate
1188189|NCT01203488|NICHD Neonatal Research Network
1188190|NCT01203488|Extremely Low Birth Weight (ELBW)
1188191|NCT01203488|Prematurity
1188192|NCT01203488|Vitamin A
1188193|NCT01203488|Chronic Lung Disease
1188194|NCT01203475|NICHD Neonatal Research Network
1188195|NCT01203475|Extremely Low Birth Weight (ELBW)
1188196|NCT01203475|Prematurity
1188197|NCT01203475|Growth Curve
1188198|NCT01203475|Head Circumference
1188199|NCT01203475|Length
1188200|NCT01203449|NICHD Neonatal Research Network
1188201|NCT01203449|Extremely Low Birth Weight (ELBW)
1188202|NCT01203449|Prematurity
1188203|NCT01203449|Gestational Age
1188204|NCT01203436|NICHD Neonatal Research Network
1188205|NCT01203436|Very Low Birth Weight (VLBW)
1188206|NCT01203436|Extremely Low Birth Weight (ELBW)
1188207|NCT01203436|Prematurity
1188208|NCT01203423|NICHD Neonatal Research Network
1188209|NCT01203423|Extremely Low Birth Weight (ELBW)
1188210|NCT01203423|Prematurity
1188211|NCT01203423|Persistent Pulmonary Hypertension of Newborn (PPHN)
1188212|NCT01203410|NICHD Neonatal Research Network
1188213|NCT01203410|Term infant
1188214|NCT01203410|Hyperbilirubinemia
1188215|NCT01203397|SUPERFICIAL VARICOSE VEINS
1188216|NCT01203371|naftopidil
1188217|NCT01203371|symptoms of lower urinary tract
1188218|NCT01203371|benign prostate hyperplasia
1188219|NCT01203371|LUTS
1188220|NCT01203358|NICHD Neonatal Research Network
1188221|NCT01203358|Extremely Low Birth Weight (ELBW)
1188222|NCT01203358|Prematurity
1188223|NCT01203358|Respiratory distress syndrome
1188224|NCT01203358|Surfactant
1188225|NCT01203345|NICHD Neonatal Research Network
1188226|NCT01203345|Extremely Low Birth Weight (ELBW)
1188227|NCT01203345|Prematurity
1188228|NCT01203345|Septicemia
1188229|NCT01203345|Meningitis
1188230|NCT01203345|Urinary tract infection
1188231|NCT01203345|Immune globulin
1188232|NCT01203332|HIV testing
1188233|NCT01203332|Latino
1188234|NCT01203332|Latina
1188235|NCT01203332|Men who have sex with men
1188236|NCT01203319|immunogenicity
1188237|NCT01203319|safety
1188238|NCT01203319|recombinant hepatitis B vaccine
1188239|NCT01203319|nonresponders
1188240|NCT01203306|bevacizumab
1188241|NCT01203306|somatostatin analogue
1188242|NCT01203306|metronomic capecitabine
1188243|NCT01203306|neuroendocrine tumors
1188244|NCT01203280|icing
1188245|NCT01203280|boxer
1188246|NCT01203280|balance
1188247|NCT01203280|neck range of motion
1188248|NCT01203280|neck isometric strength
1188249|NCT01203280|balance performance
1188250|NCT01203267|Breast Neoplasms
1188251|NCT01203267|Neoadjuvant
1188252|NCT01203267|Chemotherapy
1188253|NCT01203267|Paclitaxel
1188254|NCT01203267|Carboplatin
1188255|NCT01203267|Pathological Complete Remission
1188256|NCT01203254|Colesevelam
1188257|NCT01203254|IBD
1188258|NCT01203254|Bile Acid Malabsorption
1188259|NCT01203254|Crohns disease
1188260|NCT01203228|Reduced Intensity conditioning
1188261|NCT01203228|Myeloablative conditionig
1188262|NCT01203228|Allogeneic stem cell transplantation
1188263|NCT01203228|MUD
1188264|NCT01203215|exercise
1188265|NCT01203215|physical activity
1188266|NCT01203215|women
1188267|NCT01203215|community
1188268|NCT01203202|PE
1188269|NCT01203202|IELT
1188270|NCT01203202|DCIT
1188271|NCT01203189|dandruff, flaky scalp
1188272|NCT01203176|Endometrial polyp
1188273|NCT01203176|Endometrial carcinoma
1188274|NCT01203176|Endometrial hyperplasia
1188275|NCT01203176|Postmenopausal symptomatic women
1188276|NCT01203176|Postmenopausal asymptomatic women
1188277|NCT01203163|PDT
1188278|NCT01203163|porfimer sodium
1188279|NCT01203163|esophageal cancer
1188280|NCT01203163|NSCLC
1188281|NCT01203163|HGD in BE
1188282|NCT01203137|tricuspid regurgitation, severe
1188283|NCT01203124|Intranasal
1188284|NCT01203124|Biomarker
1188285|NCT01203124|Healthy
1188286|NCT01203124|Effect of different doses and dosing regimens of AZD8848 on biomarkers
1188287|NCT01203124|Effect different doses and dosing frequency of AZD8848 on biomarkers
1188288|NCT01203098|prevention
1188289|NCT01203098|venous thromboembolism
1188290|NCT01203098|edoxaban
1188291|NCT01203098|anticoagulants
1188292|NCT01203072|prevention
1188293|NCT01203072|venous thromboembolism
1188294|NCT01203072|edoxaban
1188295|NCT01203072|factor Xa
1188296|NCT01203046|DURATION OF THERAPY
1188297|NCT01203046|PENETRATING ABDOMINAL TRAUMA
1188298|NCT01203033|acute myeloid leukemia
1188299|NCT01203033|single cell network profiling
1188300|NCT01203033|AML
1188301|NCT01203033|SCNP
1188302|NCT01203020|Hodgkin's
1188303|NCT01203020|non-Hodgkin's
1188304|NCT01203020|lymphomas
1188305|NCT01203020|allogeneic hematopoietic progenitor cell transplant
1188306|NCT01203020|HPCT
1188307|NCT01203020|busulfex
1188308|NCT01203020|fludarabine
1188309|NCT01203020|reduced-toxicity conditioning
1188310|NCT01203020|reduced-intensity conditioning
1188311|NCT01202994|Alzheimer's disease
1188312|NCT01202994|Mild cognitive impairment
1188313|NCT01202994|PET
1188314|NCT01202994|Practice effects
1188315|NCT01202981|glistenings
1188316|NCT01202981|contrast sensitivity
1188317|NCT01202981|visual quality
1188318|NCT01202981|straylight
1188319|NCT01202981|AcrySof IOL
1188320|NCT01202968|intubation electric stimulation deglutition disorder
1188321|NCT01202955|Smoking, Abstinence
1188322|NCT01202929|High Resolution Manometry
1188323|NCT01202929|achalasia
1188324|NCT01202929|dysphagia
1188325|NCT01202929|GERD
1188326|NCT01202929|chest pain
1188327|NCT01202929|Post fundoplication
1188328|NCT01202916|children with congenital heart disease
1188329|NCT01202903|omalizumab
1188330|NCT01202903|asthma
1188331|NCT01202903|immunoglobulin E
1188332|NCT01202903|IgE
1188333|NCT01202890|lenalidomide
1188334|NCT01202890|revlimid
1188335|NCT01202890|liposomal doxorubicin
1188336|NCT01202890|doxil
1188337|NCT01202890|bevacizumab
1188338|NCT01202890|avastin
1188339|NCT01202890|platinum resistant ovarian cancer
1188340|NCT01202890|ovarian cancer
1188341|NCT01202877|Myelodysplastic Syndrome
1188342|NCT01202877|MDS
1188343|NCT01202877|Refractory acute leukemias
1188344|NCT01202877|Relapsed acute leukemia
1188345|NCT01202877|Acute myeloid leukemia
1188346|NCT01202877|AML
1188347|NCT01202877|5-Azacytidine
1188348|NCT01202877|Azacitidine
1188349|NCT01202877|5-aza
1188350|NCT01202877|Vidaza
1188351|NCT01202877|5-AZC
1188352|NCT01202877|AZA-CR
1188353|NCT01202877|Ladakamycin
1188354|NCT01202877|NSC-102816
1188355|NCT01202877|PKC412
1188356|NCT01202864|Intracerebral Hemorrhage
1188357|NCT01202864|ICH
1188358|NCT01202864|Stroke
1188359|NCT01202864|Cerebrovascular accident
1188360|NCT01202851|radiotherapy
1188361|NCT01202851|radiation therapy
1188362|NCT01202851|stretching
1188363|NCT01202851|relaxation
1188364|NCT01202851|quality of life
1188365|NCT01202851|QOL
1188366|NCT01202851|fatigue
1188367|NCT01202851|sleep disturbances
1188368|NCT01202851|mental health
1188369|NCT01202851|cost-effectiveness analysis
1188370|NCT01202851|work productivity
1188371|NCT01202851|home productivity
1188372|NCT01202851|cortisol rhythmicity
1188373|NCT01202838|Cranial bone reconstruction, composite
1188374|NCT01202825|HCV genotype 1 infected patients
1188375|NCT01202825|TMC647055HPC1001
1188376|NCT01202825|TMC647055
1188377|NCT01202825|HPC
1188378|NCT01202825|Hepatitis C
1188379|NCT01202825|Healthy volunteers
1188380|NCT01202825|TMC435
1188381|NCT01202812|Sickle Cell Anemia
1188382|NCT01202812|Sickle Cell Disease
1188383|NCT01202812|Hemoglobin SS Disease
1188384|NCT01202812|Hemoglobin S beta-0 Thalassemia
1188385|NCT01202812|Inflammation
1188386|NCT01202812|Quality of Life
1188387|NCT01202812|Sickle Thalassemia
1188388|NCT01202812|C-Reative Protein
1188389|NCT01202812|Hemolytic Anemia
1188390|NCT01202812|Hemostasis
1188391|NCT01202812|Biomarkers
1188392|NCT01202812|Coagulation
1188393|NCT01202812|Omega-3 Fatty Acids
1188394|NCT01202812|Eicosapentaenoic Acid
1188395|NCT01202812|Docosahexaenoic Acid
1188396|NCT01202812|Fish Oils
1188397|NCT01202812|Drug: Placebo
1188398|NCT01202812|Drug: LOVAZA
1188399|NCT01202799|Pharmacokinetics
1188400|NCT01202799|Healthy volunteers
1188401|NCT01202799|PENNSAID
1188402|NCT01202799|Topical NSAID
1188403|NCT01202799|Diclofenac
1188404|NCT01202786|Cancer of Unknown Primary Site (CUP)
1188405|NCT01202773|Rheumatoid Arthritis
1188406|NCT01202760|Rheumatoid Arthritis
1188407|NCT01202734|CONCERTA
1188408|NCT01202734|Methylphenidate HCl
1188409|NCT01202734|Pharmacokinetic
1188410|NCT01202734|Safety
1188411|NCT01202734|Adult
1188412|NCT01202734|Men
1188413|NCT01202734|Male
1188414|NCT01202721|Congenital
1188415|NCT01202721|Aortic Valve
1188416|NCT01202721|Bicuspid
1188417|NCT01202721|Aortopathy
1188418|NCT01202721|bicuspid aortic valve aortopathy
1188419|NCT01202682|Healthy subject exercise study
1188420|NCT01202656|Fertility Agents, Female
1188421|NCT01202656|In vitro fertilization
1188422|NCT01202643|Thin Endometrium
1188423|NCT01202643|Asherman's Syndrome
1188424|NCT01202643|Endometrial Scarring
1188425|NCT01202630|Clostridium difficile
1188426|NCT01202630|diarrhea
1188427|NCT01202617|Seroquel XR
1188428|NCT01202617|schizophrenia
1188429|NCT01202617|relapse prevention
1188430|NCT01202604|Bipolar disorder I and II
1188431|NCT01202604|mood event
1188432|NCT01202604|manic or depressive
1188433|NCT01202604|Greece
1188434|NCT01202591|Breast Cancer
1188435|NCT01202591|ER+
1188436|NCT01202591|FGFR1
1188437|NCT01202591|Exemestane
1188438|NCT01202591|AZD4547
1188439|NCT01202591|Fulvestrant
1188440|NCT01202565|Post-marketing observational study (PMOS) Protocol
1188441|NCT01202565|Moderate to Severe Plaque Psoriasis
1188442|NCT01202565|Treatment of Scalp and Nail Affection
1188443|NCT01202565|Effectiveness of Adalimumab (HUMIRA®)
1188444|NCT01202552|influenza
1188445|NCT01202552|aged
1188446|NCT01202552|intradermal injection
1188447|NCT01202526|Insulin resistance
1188448|NCT01202526|Gastric bypass
1188449|NCT01202513|Vitiligo
1188450|NCT01202513|Repigmentation
1188451|NCT01202487|Laceration
1188452|NCT01202487|Lacerations
1188453|NCT01202487|LET
1188454|NCT01202487|Lidocaine Epinephrine Tetracaine
1188455|NCT01202487|LAT
1188456|NCT01202487|Lidocaine Adrenaline Tetracaine
1188457|NCT01202487|Tissue Adhesive
1188458|NCT01202487|Skin Glue
1188459|NCT01202487|Pre-Treatment with LET
1188460|NCT01202487|Pre-Treatment with LAT
1188461|NCT01202487|Pre-Treatment with Lidocaine Epinephrine Tetracaine
1188462|NCT01202487|Pre-Treatment with Lidocaine Adrenaline Tetracaine
1188463|NCT01202487|Use of LET with Skin Glue
1188464|NCT01202487|Use of LET with Tissue Adhesive
1188465|NCT01202487|Histoacryl
1188466|NCT01202461|Diabetic macular edema
1188467|NCT01202461|Combination therapy for DME
1188468|NCT01202461|DME
1188469|NCT01202448|Diffuse large B cell lymphoma
1188470|NCT01202448|central nervous system
1188471|NCT01202448|prognosis
1188472|NCT01202435|pregabalin
1188473|NCT01202435|pharmacokinetics
1188474|NCT01202435|bioavailability
1188475|NCT01202435|bioequivalence
1188476|NCT01202422|pregabalin
1188477|NCT01202422|pharmacokinetics
1188478|NCT01202422|bioavailability
1188479|NCT01202422|bioequivalence
1188480|NCT01202409|Ampulla of Vater
1188481|NCT01202409|Adenocarcinoma of the small bowel
1188482|NCT01202409|Metastatic
1188483|NCT01202409|Kirsten rat sarcoma
1188484|NCT01202409|KRAS
1188485|NCT01202409|Capecitabine
1188486|NCT01202409|Xeloda
1188487|NCT01202409|Oxaliplatin
1188488|NCT01202409|Eloxatin
1188489|NCT01202409|CAPOX
1188490|NCT01202409|Panitumumab
1188491|NCT01202409|Vectibix
1188492|NCT01202396|pouch
1188493|NCT01202396|pouchitis
1188494|NCT01202396|ulcerative colitis
1188495|NCT01202396|microbiota
1188496|NCT01202396|defensins
1188497|NCT01202396|epithelial integrity
1188498|NCT01202370|Cancer
1188499|NCT01202370|Tumors
1188500|NCT01202357|Psychotic Disorders
1188501|NCT01202357|Psychosis
1188502|NCT01202344|Angioplasty
1188503|NCT01202344|Stenosis
1188504|NCT01202344|Restenosis
1188505|NCT01202344|Elastic Recoil
1188506|NCT01202344|cheduled for percutaneous dilation of a peripheral artery
1188632|NCT01201811|Vidaza
1188507|NCT01202344|Target lesion in native artery
1188508|NCT01202344|Baseline lumen diameter greater than 4 mm
1188509|NCT01202331|Bacterial Infections
1188510|NCT01202331|Chlamydia Infections
1188511|NCT01202331|Eye Diseases
1188512|NCT01202318|Cerebrovascular Accident
1188513|NCT01202318|Stroke,Acute
1188514|NCT01202305|HIV
1188515|NCT01202305|HIV persistence
1188516|NCT01202305|Lymph node fibrosis
1188517|NCT01202292|overweight
1188518|NCT01202292|obesity
1188519|NCT01202292|motivational intervention
1188520|NCT01202279|Acute Upper Respiratory Track Infection Who Seek Treatment
1188521|NCT01202266|Multiple Ascending Dose
1188522|NCT01202266|Phase 1
1188523|NCT01202266|Safety and Tolerability
1188524|NCT01202266|PK
1188525|NCT01202266|Healthy Subjects
1188526|NCT01202253|Ecalta
1188527|NCT01202253|Eraxis
1188528|NCT01202253|Candida
1188529|NCT01202253|Candidemia
1188530|NCT01202253|Systemic Candidiasis
1188531|NCT01202253|ICU
1188532|NCT01202253|Intensive Care Unit
1188533|NCT01202253|Critical Care Unit
1188534|NCT01202240|Drug-Drug Interaction
1188535|NCT01202240|Healthy Volunteers
1188536|NCT01202240|Tasocitinib (CP-690
1188537|NCT01202240|550)
1188538|NCT01202240|Ketoconazole
1188539|NCT01202227|Central Nervous System Diseases
1188540|NCT01202227|Therapeutic Uses
1188541|NCT01202227|Wounds and Injuries
1188542|NCT01202227|Trauma
1188543|NCT01202227|Nervous System
1188544|NCT01202227|pregabalin
1188545|NCT01202188|QVA149, COPD, combination bronchodilator, indacaterol, glycopyrronium bromide
1188546|NCT01202175|Genetic risk of hypertension
1188547|NCT01202162|Induction
1188548|NCT01202162|Coughing
1188549|NCT01202162|Anesthesia
1188550|NCT01202149|eczema
1188551|NCT01202149|elidel
1188552|NCT01202149|non-medicated device
1188553|NCT01202149|hylatopic plus
1188554|NCT01202149|pimecrolimus
1188555|NCT01202149|bilateral comparison study
1188556|NCT01202149|topical therapy
1188557|NCT01202136|pancreatic cyst
1188558|NCT01202136|IPMN
1188559|NCT01202136|PAN INs
1188560|NCT01202136|Pancreatic cancer
1188561|NCT01202136|pancreatic neoplasia
1188562|NCT01202071|Rabeprazole
1188563|NCT01202071|proton pump inhibitor
1188564|NCT01202071|pharmacokinetics
1188565|NCT01202071|pharmacodynamics
1188566|NCT01202071|healthy adult male Japanese subjects
1188567|NCT01202058|Coronary artery disease
1188568|NCT01202058|Drug-eluting stents
1188569|NCT01202058|Reservoir technology
1188570|NCT01202045|Echocardiography, Stress
1188571|NCT01202045|right heart catheterization
1188572|NCT01202032|Metastatic renal cell carcinoma
1188573|NCT01202032|Advanced solid tumors
1188574|NCT01202032|Dose escalation
1188575|NCT01202032|Association Pazopanib-Bevacizumab
1188576|NCT01202019|cardiovascular risk
1188577|NCT01202019|exercise
1188578|NCT01202019|post-exercise diet supplementation
1188579|NCT01202006|Heart failure
1188580|NCT01202006|Diagnosis
1188581|NCT01202006|Treatment
1188582|NCT01202006|Primary care
1188583|NCT01201993|syncope
1188584|NCT01201993|evaluation
1188585|NCT01201993|recurrence
1188586|NCT01201993|morbidity
1188587|NCT01201980|essential arterial hypertension
1188588|NCT01201980|calcium antagonist
1188589|NCT01201967|Collaborative care
1188590|NCT01201967|Cardiovascular disease
1188591|NCT01201967|Depression
1188592|NCT01201967|Anxiety
1188593|NCT01201954|pain
1188594|NCT01201954|sucrose
1188595|NCT01201954|newborn
1188596|NCT01201954|mechanical ventilation
1188597|NCT01200836|Statins
1188598|NCT01200836|Immune Modulation
1188599|NCT01200836|Healthy Volunteer
1188600|NCT01200823|Laboratory Research
1188601|NCT01200823|Biologic Samples
1188602|NCT01200823|Tissue Collection
1188603|NCT01200823|Tissue Procurement
1188604|NCT01200771|FDG-PET/CT
1188605|NCT01200771|FUO
1188606|NCT01200771|Chronic Inflammatory syndrome
1188607|NCT01200771|Fever of unknown origin
1188608|NCT01200745|neck pain
1188609|NCT01200745|capsaicin
1188610|NCT01200745|dermal patch
1188611|NCT01201876|Dental Caries
1188612|NCT01201876|Assessments
1188613|NCT01201876|dental materials
1188614|NCT01201863|Testosterone
1188615|NCT01201863|Traumatic Brain Injury
1188616|NCT01201863|Hypogonadism
1188617|NCT01201863|Endocrine Dysfunction
1188618|NCT01201863|Low Testosterone in men with new Traumatic Brain Injury
1188619|NCT01201850|radiation necrosis
1188620|NCT01201850|Bevacizumab (Avastin®)
1188621|NCT01201850|Central Nervous System Tumors
1188622|NCT01201837|Acute coronary syndrome
1188623|NCT01201837|HDL mimetic
1188624|NCT01201837|ApoA-I
1188625|NCT01201824|lung cancer
1188626|NCT01201824|intracavitary ultrasound
1188627|NCT01201824|pulmonary nodules
1188628|NCT01201824|VATS procedures
1188629|NCT01201811|Myelodysplastic Syndromes
1188630|NCT01201811|Taiwan
1188631|NCT01201811|Azacitidine
1188633|NCT01201811|Celgene
1188634|NCT01201811|Pathologic Processes
1188635|NCT01201811|Neoplasms
1188636|NCT01201811|Bone Marrow Diseases
1188637|NCT01201811|Hematologic Diseases
1188638|NCT01201811|Antineoplastic Agents
1188639|NCT01201811|Antimetabolites, Antineoplastic
1188640|NCT01201811|Antimetabolites
1188641|NCT01201811|Molecular Mechanisms of Pharmacological Action
1188642|NCT01201811|Pharmacologic Actions
1188643|NCT01201811|Therapeutic Uses
1188644|NCT01201811|Enzyme inhibitors
1188645|NCT01201785|diabetes mellitus, coronary artery disease, aspirin therapy
1188646|NCT01201772|coronary artery disease
1188647|NCT01201772|percutaneous coronary revascularization
1188648|NCT01201772|prasugrel therapy
1188649|NCT01201759|cardiovascular risk
1188650|NCT01201746|Non-surgical periodontal therapy
1188651|NCT01201746|Coronary heart disease (CHD)
1188652|NCT01201746|periodontal Disease
1188653|NCT01201746|hsCRP
1188654|NCT01201746|Fibrinogen
1188655|NCT01201746|WBCs
1188656|NCT01201720|cirrhosis
1188657|NCT01201720|cirrhotic patients with acute on chronic liver failure
1188658|NCT01201707|Multiple Sclerosis
1188659|NCT01201707|Angioplasty
1188660|NCT01201707|Vein
1188661|NCT01201694|Advanced malignancies
1188662|NCT01201694|Surface-controlled water soluble curcumin
1188663|NCT01201694|Turmeric
1188664|NCT01201694|Dietary supplements
1188665|NCT01201681|Post-operative pain
1188666|NCT01201681|intra-operative pain
1188667|NCT01201681|root canal therapy
1188668|NCT01201681|feasibility
1188669|NCT01201681|post-surgical persistent pain
1188670|NCT01201668|post-operative pain
1188671|NCT01201668|root canal therapy
1188672|NCT01201668|feasibility
1188673|NCT01201668|post-surgical persistent pain
1188674|NCT01201655|Posthepatitic cirrhosis;
1188675|NCT01201655|Hepatocarcinogenesis;
1188676|NCT01201655|Splenectomy;
1188677|NCT01201642|Bell's palsy
1188678|NCT01201642|Prednisolone
1188679|NCT01201642|acupuncture
1188680|NCT01201629|Ischemic Strokes
1188681|NCT01201629|t DC stimulation
1188682|NCT01201629|Functional recovery
1188683|NCT01201616|Cognitive function
1188684|NCT01201616|mood
1188685|NCT01201616|women
1188686|NCT01201616|high fat diet
1188687|NCT01201616|high carbohydrate diet
1188688|NCT01201603|Women
1188689|NCT01201603|Orange Juice
1188690|NCT01201603|Insulin Resistance
1188691|NCT01201603|Obesity
1188692|NCT01201590|Insulin resistance
1188693|NCT01201590|obesity
1188694|NCT01201590|cocoa
1188695|NCT01201590|women
1188696|NCT01201577|Quorum sensing
1188697|NCT01201577|Prebiotics
1188698|NCT01201577|Probiotics
1188699|NCT01201577|Sepsis
1188700|NCT01201564|umbilical hernia,
1188701|NCT01201564|wound complications,
1188702|NCT01201564|mesh repair, IPOM,
1188703|NCT01201564|quality of life,
1188704|NCT01201564|sublay mesh repair,
1188705|NCT01201564|recurrence rate
1188706|NCT01201551|Alphagan
1188707|NCT01201551|Xalatan
1188708|NCT01201551|corneal temperature
1188709|NCT01201551|primary vascular dysregulation
1188710|NCT01201512|TMJD pain
1188711|NCT01201512|feasibility
1188712|NCT01201486|Ultrasound
1188713|NCT01201486|Pregnancy
1188714|NCT01201486|Fetal heart defects
1188715|NCT01201486|Color doppler
1188716|NCT01201473|effect of participation
1188717|NCT01201473|effect of association
1188718|NCT01201460|glucose testing
1188719|NCT01201447|Assessment
1188720|NCT01201447|Questionable Caries
1188721|NCT01201434|cystic fibrosis
1188722|NCT01201434|probiotics
1188723|NCT01201434|pulmonary
1188724|NCT01201434|infections
1188725|NCT01201421|patient satisfaction
1188726|NCT01201421|assessments
1188727|NCT01201421|dental caries
1188728|NCT01201421|dental materials
1188729|NCT01201408|Dental Caries
1188730|NCT01201408|Assessments
1188731|NCT01201408|dental materials
1188732|NCT01201395|Dental Caries
1188733|NCT01201395|Assessment
1188734|NCT01201395|dental materials
1188735|NCT01201382|Depression
1188736|NCT01201382|Prevention
1188737|NCT01201382|Adolescents
1188738|NCT01201369|Percutaneous Coronary Intervention
1188739|NCT01201369|Coronary Artery Stenosis
1188740|NCT01201369|Acute Myocardial Infarction
1188741|NCT01201369|Coronary Artery Stent
1188742|NCT01201369|Optical Coherence Tomography
1188743|NCT01201356|Fingolimod
1188744|NCT01201356|FTY720
1188745|NCT01201356|Relapsing forms of MS
1188746|NCT01201356|Multiple Sclerosis
1188747|NCT01201356|Efficacy
1188748|NCT01201343|Multiple sclerosis, relapsing, remitting
1188749|NCT01201343|Interferon-beta
1188750|NCT01201330|ONJ
1188751|NCT01201317|Analgesic effect
1188752|NCT01201304|Anxiety sensitivity
1188753|NCT01201304|Panic
1188754|NCT01201291|TBI
1188755|NCT01201291|Normobaric hyperoxia
1188756|NCT01201291|Outcome
1188757|NCT01201291|GOS
1188758|NCT01201291|GOSE
1188759|NCT01201278|intranasal insulin
1188760|NCT01201252|children
1188761|NCT01201252|gastroenteritis
1188762|NCT01201252|Rotavirus
1188763|NCT01201239|raltegravir
1188764|NCT01201239|HIV-1
1188765|NCT01201239|drug resistance
1188766|NCT01201226|Primordial ovarian follicles
1188767|NCT01201226|PTEN
1188768|NCT01201226|PI3K activating peptide
1188769|NCT01201226|Low ovarian reserve
1188770|NCT01201226|Gonadotrophins
1188771|NCT01201213|Bupivacaine
1188772|NCT01201213|levobupivacaine
1188773|NCT01201213|ropivacaine
1188774|NCT01201200|Obstructive Sleep Apnea
1188775|NCT01201200|Right Ventricular Function
1188776|NCT01201200|Pulmonary Hypertension
1188777|NCT01201187|ADHD(Attention Deficit Hyperactivity Disorder)
1188778|NCT01201174|Hemolysis in Patients with Hereditary Spherocytosis
1188779|NCT01201174|with documented family history of HS.
1188780|NCT01201174|spherocyte morphology,
1188781|NCT01201174|splenomegaly and non-immune mediated hemolysis.
1188782|NCT01201161|Diabetic Retinopathy
1188783|NCT01201161|Retinal detachment
1188784|NCT01201161|Vitreous Hemorrhage
1188785|NCT01201161|Preoperative Ranibizumab
1188786|NCT01201161|pars plana vitrectomy
1188787|NCT01201148|depression
1188788|NCT01201148|transcranial direct current stimulation (tDCS)
1188789|NCT01201148|random noise stimulation
1188790|NCT01201148|oscillatory tDCS
1188791|NCT01201148|intermittent tDCS
1188792|NCT01201122|Pediatric
1188793|NCT01201122|Ulcerative colitis
1188794|NCT01201122|5-ASA
1188795|NCT01201122|Mesalamine
1188796|NCT01201122|Dosing
1188797|NCT01201109|Carpal tunnel syndrome
1188798|NCT01201109|Entrapment neuropathies
1188799|NCT01201109|Diabetes
1188800|NCT01201096|neuroendocrine tumor
1188801|NCT01201096|liver metastasis
1188802|NCT01201096|peptide receptor therapy
1188803|NCT01201096|gastro-entero-pancreatic system
1188804|NCT01201057|SPL7013
1188805|NCT01201057|VivaGel
1188806|NCT01201057|bacterial vaginosis
1188807|NCT01201057|BV
1188808|NCT01201044|BAI
1188809|NCT01201044|3DCRT
1188810|NCT01201031|for the active surveillance of VRE colinization and infection
1188811|NCT01201018|Tumor
1188812|NCT01201018|cancer
1188813|NCT01201018|metastasis
1188814|NCT01200992|Urinary Bladder Neoplasms
1188815|NCT01200992|Neoplasms
1188816|NCT01200992|Urologic Neoplasms
1188817|NCT01200992|Urogenital Neoplasms
1188818|NCT01200992|Neoplasms by Site
1188819|NCT01200992|Urinary Bladder Diseases
1188820|NCT01200992|Urologic Diseases
1188821|NCT01200992|Mycobacterial cell wall DNA complex
1188822|NCT01200992|Intravesical drug administration
1188823|NCT01200979|Cytokine
1188824|NCT01200979|Lymphocyte
1188825|NCT01200979|Toll-Like Receptor
1188826|NCT01200979|NK Cell
1188827|NCT01200979|Innate Immunity
1188828|NCT01200979|Pregnancy
1188829|NCT01200979|Immune Function
1188830|NCT01200966|Essential Tremor
1188831|NCT01200966|Transcranial Magnetic Stimulation (TMS)
1188832|NCT01200966|Ethanol
1188833|NCT01200966|Alcohol
1188834|NCT01200966|Alcohol Clamp
1188835|NCT01200966|ET
1188836|NCT01200953|Select Agents
1188837|NCT01200953|Biosafety
1188838|NCT01200953|Bioterrorism
1188839|NCT01200953|SCSU (Special Clinical Studies Unit)
1188840|NCT01200953|Infectious Disease
1188841|NCT01200953|Bioterrorism-Related Illness
1188842|NCT01200940|GLP-1
1188843|NCT01200940|Glucose Tolerance
1188844|NCT01200940|Gut Hormones
1188845|NCT01200940|Gastric Bypass
1188846|NCT01200940|Roux-en-Y
1188847|NCT01200940|Bariatric Surgery
1188848|NCT01200927|infant
1188849|NCT01200927|sitting
1188850|NCT01200927|postural control
1188851|NCT01200914|Hemodialysis
1188852|NCT01200914|Fistula
1188853|NCT01200914|Angiograph
1188854|NCT01200914|Angiogram
1188855|NCT01200901|depression
1188856|NCT01200901|healthy
1188857|NCT01200875|PRP
1188858|NCT01200875|platelet rich plasma
1188859|NCT01200875|platelet
1188860|NCT01200875|growth hormone
1188861|NCT01200875|tendonitis
1188862|NCT01200875|tendinosis
1188863|NCT01200875|tendinopathy
1188864|NCT01200875|enthesopathy
1188865|NCT01200875|muscle
1188866|NCT01200875|sport
1188867|NCT01200875|tendon
1188868|NCT01200862|Obese
1188869|NCT01200862|obesity
1188870|NCT01200862|hypogonadism
1188871|NCT01200862|hypogonadotropic
1188872|NCT01200862|hyperestrogenemic
1188873|NCT01200862|testosterone
1188874|NCT01200862|hypogonadal
1188875|NCT01200732|Tadalafil
1188876|NCT01200732|phosphodiesterase-5 inhibitor
1188877|NCT01200732|Eisenmenger syndrome
1188878|NCT01200719|brain electrical stimulation
1188879|NCT01200719|sub-acute post-stroke
1188880|NCT01200719|rehabilitation
1188881|NCT01200706|children aged under 5 years
1188882|NCT01200706|Non-severe
1188883|NCT01200693|Angioplasty, Transluminal, Percutaneous Coronary
1188884|NCT01200693|Drug-Eluting Stents
1188885|NCT01200680|Sporadic Chordoma
1188886|NCT01200680|Pediatric and Adult
1188887|NCT01200680|Gene Identification
1188888|NCT01200680|Rare Bone Cancer
1188889|NCT01200680|All Chordoma Sites
1188890|NCT01200680|Bone Cancer
1188891|NCT01200654|Population pharmacokinetics
1188892|NCT01200654|Linezolid
1188893|NCT01200654|Monolix
1188894|NCT01200654|nonlinear mixed effects models
1188895|NCT01200641|melatonin
1188896|NCT01200641|gabapentin
1188897|NCT01200641|anxiety
1188898|NCT01200641|pain
1188899|NCT01200641|retrobulbar block
1188900|NCT01200628|posttraumatic stress disorder
1188901|NCT01200628|acute PTSD
1188902|NCT01200628|PTSD
1188903|NCT01200628|motor vehicle accident
1188904|NCT01200615|nocebo side-effects SSRI informed consent
1188905|NCT01200589|Randomized trial
1188906|NCT01200589|Ofatumumab
1188907|NCT01200589|Rituximab
1188908|NCT01200589|Indolent B-Cell Non Hodgkin Lymphoma
1188909|NCT01200576|CRF: Case Report Form
1188910|NCT01200576|DM: Data Management
1188911|NCT01200576|FHI: FHI (formerly known as Family Health International)
1188912|NCT01200576|IRB: Institutional Review Board
1188913|NCT01200576|IUD: Intra-uterine Device
1188914|NCT01200576|LTPM: Long-term and Permanent Contraceptive Methods
1188915|NCT01200576|MSI: Marie Stopes International
1188916|NCT01200576|MSM: Marie Stopes Madagascar
1188917|NCT01200576|PHSC: Protection of Human Subjects Committee
1188918|NCT01200576|PI: Principal Investigator
1188919|NCT01200576|SAE: Serious Adverse Event
1188920|NCT01200576|Sino-Implant (II)
1188921|NCT01200576|SOP: Standard Operating Procedure
1188922|NCT01200576|Zarin
1188923|NCT01200563|MIST Therapy
1188924|NCT01200563|Negative Pressure Wound Therapy
1188925|NCT01200563|Wound care in long-term acute care hospital
1188926|NCT01200563|Wound care in skilled nursing facility setting
1188927|NCT01200550|Gastroesophageal reflux disease
1188928|NCT01200550|GERD Impact Scale
1188929|NCT01200537|IVF
1188930|NCT01200537|poor responders
1188931|NCT01200537|follicle synchrony
1188932|NCT01200537|IVF response
1188933|NCT01200537|estrogen
1188934|NCT01200537|estradiol (E2)
1188935|NCT01200537|oral contraceptive pill (OCP)
1188936|NCT01200537|birth control pill (BCP)
1188937|NCT01200524|Analgesic effect
1188938|NCT01200511|intraocular lens
1188939|NCT01200511|multifocal
1188940|NCT01200511|toric
1188941|NCT01200498|Primary Polycythemia Vera
1188942|NCT01200498|Post Polycythemia Vera
1188943|NCT01200498|Post Essential Thrombocythemia Myelofibrosis
1188944|NCT01200498|SB939
1188945|NCT01200498|PMF
1188946|NCT01200498|post-PV MF
1188947|NCT01200498|post-ET MF
1188948|NCT01200485|Supportive Care
1188949|NCT01200485|Recombinant urate oxidase
1188950|NCT01200485|Chemotherapy
1188951|NCT01200485|Tumor Lysis Syndrome (TLS)
1188952|NCT01200485|Hematologic malignancies
1188953|NCT01200485|Acute myeloid leukemia
1188954|NCT01200472|EHOA
1188955|NCT01200459|Obesity
1188956|NCT01200459|Weight Loss
1188957|NCT01200459|Healthy Lifestyle
1188958|NCT01200459|Social
1188959|NCT01200459|Mobile
1188960|NCT01200459|Facebook
1188961|NCT01200459|Text Messages
1188962|NCT01200446|Asthma
1188963|NCT01200446|Exercise-Induced Bronchoconstriction
1188964|NCT01200446|Inflammation
1188965|NCT01200446|Airway
1188966|NCT01200446|Fish Oil
1188967|NCT01200446|Docosahexaenoic Acid
1188968|NCT01200446|DHA
1188969|NCT01200433|dexmedetomidine
1188970|NCT01200433|propofol
1188971|NCT01200433|cerebral blood flow
1188972|NCT01200433|brain oxygenation
1188973|NCT01200420|Antisense
1188974|NCT01200420|miR-122 antagonist
1188975|NCT01200420|host factor
1188976|NCT01200420|CHC
1188977|NCT01200407|Hypertension
1188978|NCT01200407|fixed drug combination
1188979|NCT01200407|Filipinos
1188980|NCT01200407|Amlodipine
1188981|NCT01200407|Olmesartan medoxomil
1188982|NCT01200407|uncontrolled hypertension
1188983|NCT01200407|difficult to treat hypertension
1188984|NCT01200394|Diabetic nephropathy
1188985|NCT01200394|chronic kidney disease
1188986|NCT01200394|PF-00489791
1188987|NCT01200394|phosphodiesterase
1188988|NCT01200394|PDE5
1188989|NCT01200381|ICD
1188990|NCT01200381|CRTD
1188991|NCT01200381|Remote care
1188992|NCT01200381|Remote monitoring
1188993|NCT01200381|Heart failure
1188994|NCT01200368|vaccine
1188995|NCT01200368|pneumococcal conjugate
1188996|NCT01200355|MICAFUNGIN
1188997|NCT01200355|POSACONAZOLE
1188998|NCT01200355|antifungal
1188999|NCT01200355|prolonged neutropenia
1189000|NCT01200355|10-038
1189001|NCT01200342|Uveal melanoma
1189002|NCT01200342|Carboplatin
1189003|NCT01200342|Genasense
1189004|NCT01200342|Paclitaxel
1189005|NCT01200342|oblimersen
1189006|NCT01200342|GCP
1189007|NCT01200329|Hodgkin's disease
1189008|NCT01200329|Relapsed
1189009|NCT01200329|Refractory
1189010|NCT01200329|High-dose chemotherapy
1189011|NCT01200329|Busulfan
1189012|NCT01200329|Gemcitabine
1189013|NCT01200329|Melphalan
1189014|NCT01200316|Colon Cancer
1189015|NCT01200316|Abdominal Surgery
1189016|NCT01200316|Stress
1189017|NCT01200316|Rocking Motion
1189018|NCT01200316|Salivary Cortisol
1189019|NCT01200316|Postoperative Ileus
1189020|NCT01200303|colon cancer
1189021|NCT01200303|adenomatous colonic polyps
1189022|NCT01200303|colon screening
1189023|NCT01200303|CT Colonography (Virtual Colonoscopy)
1189024|NCT01200303|Computer Aided Detection
1189025|NCT01200303|Electronic Cleansing
1189026|NCT01200290|end stage renal disease
1189027|NCT01200290|end stage kidney disease
1189028|NCT01200290|ESRD
1189029|NCT01200290|Uremia
1189030|NCT01200290|Renal Dialysis
1189031|NCT01200277|osteoporosis
1189032|NCT01200277|vertebral fracture
1189033|NCT01200277|vertebroplasty
1189034|NCT01200277|percutaneous
1189035|NCT01200238|STA9090
1189036|NCT01200238|STA-9090
1189037|NCT01200238|HSP90
1189038|NCT01200212|Palliative Therapy
1189039|NCT01200212|bevacizimab
1189040|NCT01200212|Avastin
1189041|NCT01200212|Xeloda
1189042|NCT01200212|metastatic breast cancer
1189043|NCT01200212|Progression Free Survival
1189044|NCT01200212|Time to Progression
1189045|NCT01200212|Overall survival
1189046|NCT01200173|Probiotic - Lactobacillus casei DN-114 001 - dairy
1189047|NCT01200173|product - infections - children
1189048|NCT01200160|Low-Density Lipoprotein Cholesterol
1189049|NCT01200160|Hypertriglyceridemia
1189050|NCT01200160|Latin America
1189051|NCT01200160|Cardiovascular Diseases
1189052|NCT01200160|Cholesterol
1189053|NCT01200160|Sedentary Lifestyle
1189054|NCT01200160|High-Density Lipoprotein Cholesterol
1189055|NCT01200134|glioma patients : anaplasic glioma (grade III) and GBM (grade IV)
1189056|NCT01200121|Symptomatic malignant ascites due to advanced-stage gastrointestinal cancers
1189057|NCT01200108|Severe Asthma, requiring chronic oral steroid use
1189058|NCT01200082|chronic hepatitis C/B
1189059|NCT01200082|alcoholic liver disease
1189060|NCT01200082|primary biliary cirrhosis
1189061|NCT01200082|primary sclerosing cholangitis
1189062|NCT01200082|progressive familial intrahepatic cholestasis
1189063|NCT01200069|depression,myalgia
1189064|NCT01200056|Volumetric virtual histology intravascular ultrasound.
1189065|NCT01200056|Statin-naive patient.
1189066|NCT01200056|Varying doses atorvastatin.
1189067|NCT01200056|Clinical outcomes.
1189068|NCT01200043|Childhood obesity
1189069|NCT01200043|metabolic syndrome
1189070|NCT01200043|insulin resistance
1189071|NCT01200043|intrahepatic fat
1189072|NCT01200043|hypertension
1189073|NCT01200030|Sitting balance
1189074|NCT01200030|Stroke
1189075|NCT01200017|T cell depleted
1189076|NCT01200017|Matched unrelated donors
1189077|NCT01200017|Haplocompatible donors
1189078|NCT01200017|Graft vs Host Disease
1189079|NCT01200017|Hemoglobinopathies
1189080|NCT01200017|Leukemia
1189081|NCT01200017|Leukemia, Lymphoid
1189082|NCT01200017|Precursor Cell Lymphoblastic Leukemia-Lymphoma
1189083|NCT01200017|Leukemia, Myeloid, Acute
1189084|NCT01200017|Leukemia, Myeloid
1189085|NCT01200017|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1189086|NCT01200017|Lymphoma
1189087|NCT01200017|Myelodysplastic Syndromes
1189088|NCT01200017|Preleukemia
1189089|NCT01200017|Osteopetrosis
1189090|NCT01200017|Pancytopenia
1189091|NCT01200017|Immune System Diseases
1189092|NCT01200017|Hematologic Diseases
1189093|NCT01200017|Genetic Diseases, Inborn
1189094|NCT01200017|Neoplasms by Histologic Type
1189095|NCT01200017|Neoplasms
1189096|NCT01200017|Lymphoproliferative Disorders
1189097|NCT01200017|Lymphatic Diseases
1189098|NCT01200017|Immunoproliferative Disorders
1189099|NCT01200017|Myeloproliferative Disorders
1189100|NCT01200017|Bone Marrow Diseases
1189101|NCT01200017|Precancerous Conditions
1189102|NCT01200017|Osteosclerosis
1189103|NCT01200017|Osteochondrodysplasias
1189104|NCT01200017|Bone Diseases, Developmental
1189105|NCT01200017|Bone Diseases
1189106|NCT01200017|Musculoskeletal Diseases
1189107|NCT01200017|Severe acquired and congenital cytopenias
1189108|NCT01200017|White and red blood cell abnormalities
1189109|NCT01200004|Advanced solid tumor
1189110|NCT01200004|Azacitidine
1189111|NCT01200004|Grifola frondosa
1189112|NCT01200004|Basidiomycete fungus
1189113|NCT01200004|Lenalidomide
1189114|NCT01199978|radiation
1189115|NCT01199978|fractionated proton radiation
1189116|NCT01199952|contraception
1189117|NCT01199939|Human Immunodeficiency Virus
1189118|NCT01199939|HIV
1189119|NCT01199939|Etravirine
1189120|NCT01199939|Darunavir
1189121|NCT01199939|Prezista
1189122|NCT01199939|Intelence
1189123|NCT01199939|Ritonavir
1189124|NCT01199939|INROADS
1189125|NCT01199926|25-hydroxyvitamin D
1189126|NCT01199926|Parathyroid hormone
1189127|NCT01199926|Lean mass
1189128|NCT01199926|Muscular strength
1189129|NCT01199926|Glucose tolerance
1189130|NCT01199913|problems with thinking after surgery;
1189131|NCT01199900|Healthy People
1189132|NCT01199900|Glucocorticoids
1189133|NCT01199900|Prednisone
1189134|NCT01199887|safety, biologic effects, IPF, autoimmune
1189135|NCT01199874|Rotavirus
1189136|NCT01199874|Rotavirus vaccine
1189137|NCT01199874|Dosing schedule
1189138|NCT01199874|Immunogenicity
1189139|NCT01199874|Breast feeding
1189140|NCT01199874|Pakistan
1189141|NCT01199861|Relapsing multiple sclerosis
1189142|NCT01199861|MS
1189143|NCT01199861|Immune response
1189144|NCT01199848|nutrition
1189145|NCT01199848|polyphenolic
1189146|NCT01199848|strawberry
1189147|NCT01199848|insulin resistance
1189148|NCT01199848|metabolic syndrome
1189149|NCT01199835|obesity
1189150|NCT01199835|metabolic syndrome
1189151|NCT01199835|fecal fat excretion
1189152|NCT01199835|fecal calcium
1189153|NCT01199835|weight loss
1189154|NCT01199835|appetite regulation
1189155|NCT01199835|intestinal micro flora
1189156|NCT01199835|lipid profile
1189157|NCT01199835|energy balance
1189158|NCT01199783|Diabetic Foot,MRSA,
1189159|NCT01199783|Complicated skin and skin structure infections
1189160|NCT01199783|Antimicrobial therapy
1189161|NCT01199783|Daptomycin
1189162|NCT01199770|pasta
1189163|NCT01199770|appetite
1189164|NCT01199770|hunger
1189165|NCT01199770|satiety
1189166|NCT01199770|nutrition
1189167|NCT01199770|metabolic
1189168|NCT01199770|gut peptide hormones
1189169|NCT01199770|psychological phenomena and processes
1189170|NCT01199757|ocular symptoms
1189171|NCT01199757|nasal symptoms
1189172|NCT01199757|Allergic Rhinitis
1189173|NCT01199757|Symptom Free Days
1189174|NCT01199757|Quality of Life
1189175|NCT01199744|Influenza
1189176|NCT01199744|Relenza®
1189177|NCT01199744|SSMP
1189178|NCT01199731|raltegravir
1189179|NCT01199731|NNRTI
1189180|NCT01199731|ritonavir
1189181|NCT01199731|darunavir
1189182|NCT01199731|HIV
1189183|NCT01199731|GSK2248761
1189184|NCT01199731|antiretroviral
1189185|NCT01199731|HIV Infection
1189186|NCT01199731|HAART
1189187|NCT01199718|Multiple myeloma
1189188|NCT01199718|Plasmacytoma
1189189|NCT01199705|Immune globulin subcutaneous
1189190|NCT01199705|SCIG
1189191|NCT01199705|Primary immunodeficiency
1189192|NCT01199705|PID
1189193|NCT01199679|Gastroesophageal Reflux Disease
1189194|NCT01199679|Heartburn
1189195|NCT01199679|Regurgitation
1189196|NCT01199679|Dyspepsia
1189197|NCT01199666|Underimmunization, text message, vaccination
1189198|NCT01199666|Underimmunization
1189199|NCT01199653|clavicle fractures
1189200|NCT01199653|midshaft
1189201|NCT01199653|dislocated
1189202|NCT01199653|operative treatment
1189203|NCT01199653|conservative treatment
1189204|NCT01199653|non-operative treatment
1189205|NCT01199653|randomized controlled trial
1189206|NCT01199653|bone plates
1189207|NCT01199627|total hip replacement
1189208|NCT01199627|tranexamic acid
1189209|NCT01199614|Hypoparathyroidism
1189210|NCT01199614|Hypopara
1189211|NCT01199614|HPTH
1189212|NCT01199614|Hypocalcemia
1189213|NCT01199614|Hypercalciuria
1189214|NCT01199614|PTH
1189215|NCT01199614|PTH(1-84)
1189216|NCT01199588|VLU
1189217|NCT01199588|Venous Leg Ulcers
1189218|NCT01199588|Ulcers
1189219|NCT01199588|chronic wounds
1189220|NCT01199588|wounds
1189221|NCT01199588|Nexagon
1189222|NCT01199588|CoDa
1189223|NCT01199575|Chronic Lymphocytic Leukemia
1189224|NCT01199575|CLL
1189225|NCT01199575|Relapsed or Refractory
1189226|NCT01199575|previously treated
1189227|NCT01199536|Helicobacter-positive duodenal ulcer
1189228|NCT01199523|YM178
1189229|NCT01199523|Mirabegron
1189230|NCT01199523|QT
1189231|NCT01199497|cough, acute rhinitis, nasal congestion, common cold, nasal symptoms, children.
1189232|NCT01199497|Nasal congestion and non-productive cough, with or without associate other nasal and extranasal symptoms.
1189233|NCT01199484|Cow's milk allergy
1189234|NCT01199484|food allergy
1189235|NCT01199484|oral desensitization
1189236|NCT01199484|randomized trial
1189237|NCT01199484|specific oral tolerance induction.
1189238|NCT01199471|Sevoflurane
1189239|NCT01199471|Physician's Practice Patterns
1189240|NCT01199471|Economics, Pharmaceutical
1189241|NCT01199471|Chinese
1189242|NCT01199458|Lower Esophageal Sphincter
1189243|NCT01199458|Barrier pressure
1189244|NCT01199445|vitamin A deficiency
1189245|NCT01199432|Primary Breast Cancer
1189246|NCT01199419|multivessel coronary artery disease
1189247|NCT01199419|drug-eluting stent
1189248|NCT01199419|CABG
1189249|NCT01199419|cost-effectiveness
1189250|NCT01199406|gallstone
1189251|NCT01199406|gallbladder
1189252|NCT01199406|cholecystectomy
1189253|NCT01199406|laparoscopic
1189254|NCT01199406|pain
1189255|NCT01199393|breast neoplasm
1189256|NCT01199393|drug therapy
1189257|NCT01199393|polymorphism
1189258|NCT01199393|gene
1189259|NCT01199380|Smoking, Smoking Cessation
1189260|NCT01199367|advanced or metastatic breast cancer
1189261|NCT01199354|Invasive breast carcinoma
1189262|NCT01199341|Phase 1
1189263|NCT01199341|Drug-Drug interaction
1189264|NCT01199341|warfarin
1189265|NCT01199341|AZD1981
1189266|NCT01199328|Nexium
1189267|NCT01199328|aspirin
1189268|NCT01199328|peptic ulcers
1189269|NCT01199328|pharmacodynamic (PD)
1189270|NCT01199328|Esomoeprazole
1189271|NCT01199315|safety
1189272|NCT01199315|tolerability
1189273|NCT01199315|AZD1446
1189274|NCT01199315|AD
1189275|NCT01199315|ADHD
1189276|NCT01199315|Japanese
1189277|NCT01199302|Amgen
1189278|NCT01199302|Crohn's
1189279|NCT01199302|Inflammatory Bowel Disease
1189280|NCT01199302|IBD
1189281|NCT01199302|Irritable Bowel Syndrome
1189282|NCT01199302|IBS
1189283|NCT01199302|Inflammation
1189284|NCT01199302|bowel
1189285|NCT01199302|colon
1189286|NCT01199302|gastrointestinal
1189287|NCT01199289|Amgen
1189288|NCT01199289|chronic inflammatory disease
1189289|NCT01199289|wheezing
1189290|NCT01199276|Delirium
1189291|NCT01199276|Hip Fracture
1189292|NCT01199276|Elderly
1189293|NCT01199237|Reflex, Pharyngeal
1189294|NCT01199237|Anesthetics, Inhalation
1189295|NCT01199224|Solid Tumors
1189296|NCT01199224|veliparib
1189297|NCT01199224|refractory
1189298|NCT01199224|relapsed
1189299|NCT01199211|hypertrophy, exercise, HDL, lipids, cholesterol
1189300|NCT01199198|Hyponatremia
1189301|NCT01199198|Serum sodium
1189302|NCT01199198|Tolvaptan
1189303|NCT01199198|Placebo
1189304|NCT01199172|Student teachers with normal or mildly disordered voices
1189305|NCT01199159|misoprostol
1189306|NCT01199159|hysterectomy
1189307|NCT01199159|operative blood loss
1189308|NCT01199159|total abdominal hysterectomy
1189309|NCT01199146|Abiraterone acetate
1189310|NCT01199120|Omega-3
1189311|NCT01199120|Cognition
1189312|NCT01199120|Malnourishment
1189313|NCT01199107|PTSD
1189314|NCT01199107|Anxiety
1189315|NCT01199107|Behavior Therapy
1189316|NCT01199107|Prolonged Exposure
1189317|NCT01199107|Exercise
1189318|NCT01199107|Wellness
1189319|NCT01199107|Posttraumatic
1189320|NCT01199107|Stress
1189321|NCT01199094|low density lipoprotein receptor 5
1189322|NCT01199094|high bone mass
1189323|NCT01199094|autosomal dominant osteopetrosis type I
1189324|NCT01199094|bone turnover markers
1189325|NCT01199068|PPAR gamma agonist
1189326|NCT01199068|Tumor
1189327|NCT01199068|Cancer
1189328|NCT01199068|Antineoplastic Agent
1189329|NCT01199068|Respiratory Tract Neoplasms
1189330|NCT01199068|Erlotinib
1189331|NCT01199068|Protein Kinase Inhibitors
1189332|NCT01199068|Neoplasms
1189333|NCT01199055|PPAR gamma agonist
1189334|NCT01199055|Tumor
1189335|NCT01199055|Cancer
1189336|NCT01199055|Antineoplastic Agent
1189337|NCT01199055|Respiratory Tract Neoplasms
1189338|NCT01199055|Carboplatin
1189339|NCT01199055|Paclitaxel
1189340|NCT01199055|Neoplasms
1189341|NCT01199029|Healthy People
1189342|NCT01199029|Glucocorticoids
1189343|NCT01199029|Prednisone
1189344|NCT01199016|Acute otitis media
1189345|NCT01199016|Prevnar 13
1189346|NCT01199016|Streptococcus pneumoniae
1189347|NCT01199016|nasopharyngeal colonization.
1189348|NCT01198977|multiple sclerosis
1189349|NCT01198977|Fatigue
1189350|NCT01198977|exercise
1189351|NCT01198977|telemedicine
1189352|NCT01198977|motivational interviewing
1189353|NCT01198977|counseling
1189354|NCT01198977|depression
1189355|NCT01198977|physical activity
1189356|NCT01198964|ECoG
1189357|NCT01198964|Epilepsy
1189358|NCT01198964|cortical
1189359|NCT01198964|stimulation
1189360|NCT01198964|Electrocorticography
1189361|NCT01198964|electrodes
1189362|NCT01198964|mapping
1189363|NCT01198938|Cardiac surgery, delirium, melatonin
1189364|NCT01198925|Infectious disease
1189365|NCT01198925|piperacillin
1189366|NCT01198925|continuous infusion
1189367|NCT01198925|extended infusion
1189368|NCT01198912|rhinosinusitis
1189369|NCT01198912|doxycycline
1189370|NCT01198912|Chronic rhinosinusitis with or without nasal polyps
1189371|NCT01198899|Fabry-Anderson disease
1189372|NCT01198899|gen mutation
1189373|NCT01198899|left ventricular hypertrophy
1189374|NCT01198886|Mobility disability
1189375|NCT01198886|Older adults
1189376|NCT01198886|Physical activity
1189377|NCT01198886|Nutritional status
1189378|NCT01198860|HBsAg
1189379|NCT01198847|child overweight
1189380|NCT01198847|child obesity
1189381|NCT01198847|prevention
1189382|NCT01198847|targeted intervention
1189383|NCT01198847|development of overweight
1189384|NCT01198834|ankle sprains
1189385|NCT01198821|pancreas
1189386|NCT01198821|adenocarcinoma
1189387|NCT01198821|metastatic
1189388|NCT01198821|unresectable
1189389|NCT01198808|Bladder cancer
1189390|NCT01198808|chemotherapy
1189391|NCT01198808|T cells
1189392|NCT01198808|Immunotherapy
1189393|NCT01198808|Tumor-specific immunity in bladder cancer
1189394|NCT01198795|depression
1189395|NCT01198795|major depressive disorder
1189396|NCT01198795|escitalopram
1189397|NCT01198795|Lexapro
1189398|NCT01198795|pediatric
1189399|NCT01198769|Human rotavirus vaccine
1189400|NCT01198756|Influenza
1189401|NCT01198743|Genetics modifications
1189402|NCT01198743|colorectal cancer
1189403|NCT01198743|prognosis aim
1189404|NCT01198743|DNA
1189405|NCT01198743|Plasma
1189406|NCT01198730|DM
1189407|NCT01198730|CAD
1189408|NCT01198730|Meal tolerance test
1189409|NCT01198730|Acarbose
1189410|NCT01198704|Hepatocellular carcinoma
1189411|NCT01198704|Cirrhosis
1189412|NCT01198704|Transplantation
1189413|NCT01198691|metallic staples
1189414|NCT01198691|absorbable staples
1189415|NCT01198691|Cesarean Delivery
1189416|NCT01198665|RAD001
1189417|NCT01198665|chemotherpy
1189418|NCT01198665|T cell lymphoma
1189419|NCT01198626|community-acquired bacterial pneumonia
1189420|NCT01198626|CABP
1189421|NCT01198626|CAP
1189422|NCT01198626|pneumonia
1189423|NCT01198626|pneumonia, bacterial
1189424|NCT01198626|bacterial infections
1189425|NCT01198626|anti-bacterial agents
1189426|NCT01198626|anti-infective agents
1189427|NCT01198626|lung disease, interstitial
1189428|NCT01198626|respiratory tract diseases
1189429|NCT01198626|respiratory tract infections
1189430|NCT01198626|community-acquired infections
1189431|NCT01198613|Ragweed allergy
1189432|NCT01198613|Rhinoconjunctivitis
1189433|NCT01198613|Exposure chamber
1189434|NCT01198613|Immunotherapy
1189435|NCT01198613|ToleroMune Ragweed
1189436|NCT01198587|Diarrhea
1189437|NCT01198587|Gastroenteritis
1189438|NCT01198587|Zinc Supplementation
1189439|NCT01198574|anemia
1189440|NCT01198574|iron supplementation
1189441|NCT01198574|sub-clinical inflammation
1189442|NCT01198574|adolescents
1189443|NCT01198561|repetitive Transcranial Magnetic Stimulation
1189444|NCT01198561|Major Depressive Disorder
1189445|NCT01198522|Interleukin, IL2, Gemcitabine, monoclonal, antibody, cytokine, tumour targeting, dose finding, fusion protein, Pancreatic cancer,
1189446|NCT01198522|L19
1189447|NCT01198509|rheumatoid arthritis
1189448|NCT01198509|psoriatic arthritis
1189449|NCT01198509|periodontitis
1189450|NCT01198509|microbiota
1189451|NCT01198509|microbiome
1189452|NCT01198509|vancomycin
1189453|NCT01198509|doxycycline
1189454|NCT01198509|T cell
1189455|NCT01198509|Th17
1189456|NCT01198496|hypertension
1189457|NCT01198496|stroke
1189458|NCT01198496|blood pressure
1189459|NCT01198483|refraction
1189460|NCT01198483|refractive error
1189461|NCT01198483|combined surgery
1189462|NCT01198483|microincision
1189463|NCT01198483|smallincision
1189464|NCT01198483|cataract surgery
1189465|NCT01198483|vitrectomy
1189466|NCT01198470|Low back pain
1189467|NCT01198470|Leg pain
1189468|NCT01198470|Discogenic pain
1189469|NCT01198470|Degenerative Disc Disease (DDD)
1189470|NCT01198470|Herniated disc
1189471|NCT01198470|Radiculopathy
1189472|NCT01198457|Clodronate
1189473|NCT01198457|Compliance
1189474|NCT01198444|Contraception
1189475|NCT01198444|Compliance
1189476|NCT01198431|Appetite regulation
1189477|NCT01198431|Physical activity
1189478|NCT01198431|Energy balance
1189479|NCT01198418|STI
1189480|NCT01198418|MSM
1189481|NCT01198418|HIV
1189482|NCT01198418|Prevention
1189483|NCT01198418|Men having sex with men
1189484|NCT01198405|coronary artery disease
1189485|NCT01198405|enhanced external counterpulsation
1189486|NCT01198392|gastric cancer
1189487|NCT01198379|aspirin
1189488|NCT01198379|aspirin resistance
1189489|NCT01198379|hemodialysis
1189490|NCT01198379|cardiovascular
1189491|NCT01198379|Prevalence of aspirin resistance, cardiovascular events, and safety profile
1189492|NCT01198366|Tuberculosis
1189493|NCT01198366|Vaccine
1189494|NCT01198366|Immunogenicity
1189495|NCT01198366|Prevention of Tuberculosis
1189496|NCT01198353|Schizophrenia
1189497|NCT01198353|Schizoaffective Disorder
1189498|NCT01198353|Ziprasidone
1189499|NCT01198353|Switch
1189500|NCT01198353|Metabolic syndrome
1189501|NCT01198327|RVO
1189502|NCT01198327|CRVO
1189503|NCT01198327|BRVO
1189504|NCT01198327|Horizon
1189505|NCT01198327|Bravo
1189506|NCT01198327|Cruise
1189507|NCT01198314|long term
1189508|NCT01198314|stable
1189509|NCT01198314|recipients
1189510|NCT01198301|Metastatic Breast Neoplasms
1189511|NCT01198301|Gene Expression Profiling
1189512|NCT01198301|Drug Therapy
1189513|NCT01198288|COPD
1189514|NCT01198288|Respiratory Physiotherapy
1189515|NCT01198275|PUFA atrial fibrillation
1189516|NCT01198262|polymerase chain reaction
1189517|NCT01198236|hematological malignancy
1189518|NCT01198236|previous proven or probable invasive fungal infection
1189519|NCT01198223|denture stomatitis
1189520|NCT01198223|nystatin
1189521|NCT01198223|garlic
1189522|NCT01198210|pain
1189523|NCT01198210|tonsillectomy
1189524|NCT01198210|peritonsillar infiltration
1189525|NCT01198210|postoperative pain
1189526|NCT01198197|Nociceptin/Orphanin FQ Peptide (NOP)
1189527|NCT01198197|PET Imaging
1189528|NCT01198197|Brain Imaging
1189529|NCT01198197|Healthy Volunteer
1189530|NCT01198197|HV
1189531|NCT01198145|diarrhea
1189532|NCT01198145|gastrointestinal complications
1189533|NCT01198145|unspecified adult solid tumor, protocol specific
1189534|NCT01198132|Multiple Sclerosis Relapsing-Remitting
1189535|NCT01198132|Relapsing Multiple Sclerosis (RMS)
1189536|NCT01198132|Rebif
1189537|NCT01198132|Vitamin D3
1189538|NCT01198132|Cholecalciferol
1189539|NCT01198119|oral cavity tumor
1189540|NCT01198119|narrow band imaging
1189541|NCT01198119|subclinical cancer lesion
1189542|NCT01198106|simulator sickness
1189543|NCT01198106|scopolamine
1189544|NCT01198106|cinnarizine
1189545|NCT01198093|Alzheimer's disease
1189546|NCT01198093|Mild Cognitive Impairment
1189547|NCT01198093|cohort study
1189548|NCT01198080|Avascular osteonecrosis,CD133+,core decompression
1189549|NCT01198067|Waldenstrom Macroglobulinemia
1189550|NCT01198067|B-cell lymphoproliferative disorder
1189551|NCT01198067|Bone marrow
1189552|NCT01198067|Lymphoplasmacytic cells
1189553|NCT01198067|Monoclonal gammopathy
1189554|NCT01198067|Pomalidomide
1189555|NCT01198067|Actimid
1189556|NCT01198067|CC-4047
1189557|NCT01198054|AML
1189558|NCT01198054|Lenalidomide
1189559|NCT01198028|Squamous cell carcinoma of the skin
1189560|NCT01198028|Cutaneous squamous cell carcinoma
1189561|NCT01198028|CSCC
1189562|NCT01198028|epidermal growth factor receptor
1189563|NCT01198028|EGFR
1189564|NCT01198028|tyrosine kinase inhibitor
1189565|NCT01198028|recurrent
1189566|NCT01198028|Erlotinib
1189567|NCT01198028|Erlotinib hydrochloride
1189568|NCT01198028|OSI-774
1189569|NCT01198028|Tarceva
1189570|NCT01198015|Rett syndrome
1189571|NCT01198015|Nutritional status
1189572|NCT01198015|Creatine metabolism
1189573|NCT01198002|Rheumatoid Arthritis
1189574|NCT01197989|pustulosis
1189575|NCT01197989|soles
1189576|NCT01197989|teflon
1189577|NCT01197976|psoriasis
1189578|NCT01197976|soles
1189579|NCT01197976|teflon
1189580|NCT01197963|Type 2 diabetes mellitus
1189581|NCT01197950|acupuncture
1189582|NCT01197950|labour
1189583|NCT01197950|pain
1189584|NCT01197950|pain relief
1189585|NCT01197950|complementary
1189586|NCT01197924|child cancer brain
1189587|NCT01197898|Diabetic
1189588|NCT01197898|Foot
1189589|NCT01197898|Ulcers
1189590|NCT01197898|Wounds
1189591|NCT01197833|varicose veins
1189592|NCT01197833|Great saphenous vein
1189593|NCT01197833|varicosities
1189594|NCT01197820|HIFU
1189595|NCT01197820|mobile organs
1189596|NCT01197820|thermometry
1189597|NCT01197820|MR
1189598|NCT01197820|liver
1189599|NCT01197820|kidney
1189600|NCT01197820|cancer
1189601|NCT01197820|Liver tumors, kidney carcinoma
1189602|NCT01197807|Suctioning
1189603|NCT01197807|Wiping
1189604|NCT01197807|Neonate
1189605|NCT01197807|Resuscitation
1189606|NCT01197794|Efficacy
1189607|NCT01197794|safety
1189608|NCT01197794|tolerability
1189609|NCT01197794|dose finding
1189610|NCT01197794|asthma patients
1189611|NCT01197781|Phase I
1189612|NCT01197781|FosD
1189613|NCT01197781|fostamatinib disodium
1189614|NCT01197781|verapamil
1189615|NCT01197781|healthy volunteers
1189616|NCT01197755|Rheumatoid Arthritis
1189617|NCT01197742|Diabetes
1189618|NCT01197742|STEMI
1189619|NCT01197742|NSTEMI
1189620|NCT01197742|Myocardial infarction
1189621|NCT01197729|Myocardial infarction
1189622|NCT01197729|ST-Elevation myocardial infarction
1189623|NCT01197729|Non-ST-Elevation myocardial infarction
1189624|NCT01197729|Register
1189625|NCT01197729|CARDS
1189626|NCT01197716|Chest Pain Unit
1189627|NCT01197716|Myocardial infarction
1189628|NCT01197716|Register
1189629|NCT01197716|Admission to a Chest Pain Unit for any reason
1189630|NCT01197703|Clinical Practice Cardiac CT
1189631|NCT01197703|Clinical Implications Coronary CT Angiography
1189632|NCT01197703|Radiation Exposure of Coronary CT Angiography
1189633|NCT01197703|Registry
1189634|NCT01197690|Bronchial asthma
1189635|NCT01197690|level of control of asthma
1189636|NCT01197690|fractional exhaled nitric oxide (FeNO)
1189637|NCT01197690|asthma control test (ACT)
1189638|NCT01197677|CMR
1189639|NCT01197677|Register
1189640|NCT01197677|CAD
1189641|NCT01197677|myocard scarring
1189642|NCT01197651|Aorta
1189643|NCT01197651|Aorta-Stent-Graft
1189644|NCT01197651|Surgical operation
1189645|NCT01197651|Aortic dissection
1189646|NCT01197638|Cardiac arrhythmia
1189647|NCT01197638|Catheter ablation
1189648|NCT01197638|Register
1189649|NCT01197625|Vaccination treatment, dendritic cells
1189650|NCT01197599|Healthy Control
1189651|NCT01197586|surfactant protein B
1189652|NCT01197586|differential diagnostics
1189653|NCT01197560|Diffuse Large B-Cell Lymphoma
1189654|NCT01197560|Non Hodgkin's Lymphoma
1189655|NCT01197560|relapsed
1189656|NCT01197560|refractory
1189657|NCT01197560|relapsed/refractory
1189658|NCT01197560|DLBCL
1189659|NCT01197560|Diffuse Large B Cell Lymphoma
1189660|NCT01197547|Menorrhagia
1189661|NCT01197534|Rheumatoid Arthritis
1189662|NCT01197521|Rheumatoid Arthritis
1189663|NCT01197508|Major Depressive Disorder, MDD, Depression
1189664|NCT01197482|asthma
1189665|NCT01197482|inhalation
1189666|NCT01197469|Secondary Pulmonary Hypertension
1189667|NCT01197456|Breast cancer
1189668|NCT01197456|Ovarian insufficiency
1189669|NCT01197456|Ovarian failure
1189670|NCT01197456|Reproduction
1189671|NCT01197443|obesity
1189672|NCT01197443|overweight
1189673|NCT01197443|overweight children
1189674|NCT01197443|overweight parents
1189675|NCT01197443|families with overweight child
1189676|NCT01197443|body mass index
1189677|NCT01197443|BMI
1189678|NCT01197443|weight
1189679|NCT01197443|childhood obesity
1189680|NCT01197443|diet
1189681|NCT01197443|treatment
1189682|NCT01197443|parent modeling
1189683|NCT01197443|traffic light diet
1189684|NCT01197443|stop light diet
1189685|NCT01197430|volleyball
1189686|NCT01197430|neck vertical stability training
1189687|NCT01197430|eye-hand coordination
1189688|NCT01197417|Sickle Cell Disease
1189689|NCT01197417|Magnesium Sulfate
1189690|NCT01197417|Pediatric
1189691|NCT01197404|HIV Prevention
1189692|NCT01197378|cystinosis
1189693|NCT01197378|cysteamine
1189694|NCT01197378|inheritable disease
1189695|NCT01197378|orphan disease
1189696|NCT01197378|CTNS protein, human
1189697|NCT01197378|metabolic disease
1189698|NCT01197378|nephropathic cystinosis
1189699|NCT01197365|Acidified milk
1189700|NCT01197365|Beta-palmitate
1189701|NCT01197365|Bifidobacteria
1189702|NCT01197365|Infant formula
1189703|NCT01197365|Galacto-oligosaccharides
1189704|NCT01197365|Growth
1189705|NCT01197365|Infants
1189706|NCT01197365|Prebiotics
1189707|NCT01197352|Alcohol
1189708|NCT01197352|Abuse
1189709|NCT01197352|Drinking
1189710|NCT01197352|Behavior
1189711|NCT01197352|Text
1189712|NCT01197352|Computer
1189713|NCT01197339|acute phonotrauma
1189714|NCT01197339|computer modeling
1189715|NCT01197339|resonant voice
1189716|NCT01197339|breathy voice
1189717|NCT01197339|voice rest
1189718|NCT01197339|relaxation
1189719|NCT01197326|patient deterioration
1189720|NCT01197326|unplanned ICU admissions
1189721|NCT01197326|rapid response teams
1189722|NCT01197313|chronic heart failure (CHF); anxiety and depression; quality of life (QOL); exercise
1189723|NCT01197300|Osteoporosis, children and adolescents, zoledronic acid, chronic inflammation, Duchenne muscular dystrophy, glucocorticoids
1189724|NCT01197287|Chronic obstructive pulmonary disease
1189725|NCT01197274|allergy
1189726|NCT01197274|skin prick test
1189727|NCT01197274|mite sensitivity
1189728|NCT01197261|Severe pain
1189729|NCT01197261|Bladder Pain Syndrome
1189730|NCT01197261|Interstitial Cystitis
1189731|NCT01197261|Painful Bladder Syndrome
1189732|NCT01197261|Severe pain due to Bladder Pain Syndrome/Interstitial Cystitis/Painful Bladder Syndrome
1189733|NCT01197248|cystocele
1189734|NCT01197248|voiding
1189735|NCT01197248|dysfunction
1189736|NCT01197235|darbepoetin, chronic kidney disease, coronary angiography
1189737|NCT01197222|Laparoscopic
1189738|NCT01197222|EndoClear
1189739|NCT01197222|Lens Cleaning Device
1189740|NCT01197209|Prostate Cancer
1189741|NCT01197209|Prostatectomy
1189742|NCT01197209|Postectomy
1189743|NCT01197209|Oncology
1189744|NCT01197209|REIC
1189745|NCT01197209|Dikkoff
1189746|NCT01197209|Apoptosis
1189747|NCT01197196|Migraine
1189748|NCT01197196|Obesity
1189749|NCT01197196|Weight loss
1189750|NCT01197196|Lifestyle
1189751|NCT01197196|Behavior
1189752|NCT01197183|Hypothyroidism
1189753|NCT01197183|Thyroid hormones
1189754|NCT01197170|Hormonal therapies
1189755|NCT01197170|Estrogen receptor
1189756|NCT01197170|Progesterone receptor
1189757|NCT01197170|Hormone blockade
1189758|NCT01197170|Hormone-positive tumors
1189759|NCT01197170|Advanced cancer
1189760|NCT01197170|Metastatic cancer
1189761|NCT01197170|Avastin
1189762|NCT01197170|Anti-VEGF monoclonal antibody
1189763|NCT01197170|rhuMAB-VEGF
1189764|NCT01197170|Afinitor
1189765|NCT01197170|RAD001
1189766|NCT01197170|Nexavar
1189767|NCT01197170|BAY43-9006
1189768|NCT01197170|OSI-774
1189769|NCT01197170|Tarceva
1189770|NCT01197157|chronic hepatitis C
1189771|NCT01197157|genotype 4
1189772|NCT01197157|treatment naive patients
1189773|NCT01197157|Egypt
1189774|NCT01197144|TNF
1189775|NCT01197144|functional Magnetic Resonance Imaging
1189776|NCT01197144|Autonomic
1189777|NCT01197144|Vagus
1189778|NCT01197144|adalimumab
1189779|NCT01197131|autism
1189780|NCT01197131|autism spectrum disorder
1189781|NCT01197131|steroids
1189782|NCT01197131|steroid metabolites
1189783|NCT01197131|urinary steroid metabolites
1189784|NCT01197131|hormone formation
1189785|NCT01197131|androgen precursor
1189786|NCT01197118|gastric cancer
1189787|NCT01197118|sequence chemoradiotherapy
1189788|NCT01197118|OLF regimen
1189789|NCT01197118|survival rate
1189790|NCT01197105|gingivitis
1189791|NCT01197105|schinus terebinthifolius
1189792|NCT01197105|natural products
1189793|NCT01197092|Diabetes
1189794|NCT01197079|HPV
1189795|NCT01197079|Vaccine
1189796|NCT01197079|Vaccine utilization
1189797|NCT01197079|Disease awareness
1189798|NCT01197053|Peanut Allergy
1189799|NCT01197053|Food Allergy
1189800|NCT01197053|Epicutaneous Immunotherapy (EPIT)
1189801|NCT01197053|Food Challenge
1189806|NCT01197014|Amlodipine, Losartan
1189807|NCT01197001|Amlodipine, Losartan
1189808|NCT01196988|GSK Biologicals influenza vaccine GSK2321138A
1189809|NCT01196988|influenza infection
1189810|NCT01196975|Influenza
1189811|NCT01196962|central venous catheter
1189812|NCT01196962|complications
1189813|NCT01196962|internal jugular vein
1189814|NCT01196962|randomized trial
1189815|NCT01196962|subclavian vein
1189816|NCT01196949|Ankle
1189817|NCT01196949|Chronic
1189818|NCT01196949|Instability
1189819|NCT01196949|Manipulative
1189820|NCT01196949|Rehabilitative
1189821|NCT01196949|Manipulation
1189822|NCT01196949|Rehabilitation
1189823|NCT01196936|Cancer survivors
1189824|NCT01196936|Low Dose Tamoxifen
1189825|NCT01196936|Breast Cancer Risk Reduction
1189826|NCT01196897|Atrial fibrillation
1189827|NCT01196897|Stroke
1189828|NCT01196897|Warfarin
1189829|NCT01196897|Coumadin
1189830|NCT01196897|TIA
1189831|NCT01196897|Trans Ischemic Attack
1189832|NCT01196884|Patients with primary Immune Thrombocytopenia (ITP)
1189833|NCT01196871|Fabry disease
1189834|NCT01196871|drug drug interaction
1189835|NCT01196845|adipose tissue
1189836|NCT01196845|obese patients
1189837|NCT01196845|inflammation
1189838|NCT01196845|oxidative stress
1189839|NCT01196845|sleep apnea syndrome
1189840|NCT01196806|Non-Invasive Blood Pressure(NIBP)
1189841|NCT01196793|Feverish illness in children
1189842|NCT01196767|Sternotomy
1189843|NCT01196767|Pain
1189844|NCT01196767|Respiratory function
1189845|NCT01196767|Opiates
1189846|NCT01196767|Patient-controlled
1189847|NCT01196767|Scheduled cardiac surgery under general anaesthesia without any locoregional anaesthesia protocol other than this presently studied
1189848|NCT01196754|Pharmacokinetics
1189849|NCT01196754|Sevoflurane
1189850|NCT01196754|Fluorides
1189851|NCT01196754|Sedation
1189852|NCT01196754|Adult patients with a predicted sedation more than 48 h
1189853|NCT01196754|Stable respiratory and hemodynamic conditions for SBT
1189854|NCT01196754|Consent of patients
1189855|NCT01196754|Arterial line
1189856|NCT01196715|Quality of Life
1189857|NCT01196715|Erythroid response
1189858|NCT01196715|disease progression
1189859|NCT01196715|survival
1189860|NCT01196715|Overall erythroid response at 24 weeks
1189861|NCT01196715|Quality of life at 24 weeks
1189862|NCT01196715|Quality of life at 12, 36 and 52 weeks
1189863|NCT01196715|Overall erythroid response at 12 and 52 weeks
1189864|NCT01196715|Incidence of disease progression
1189865|NCT01196715|Overall Survival
1189866|NCT01196702|common variable immunodeficiency
1189867|NCT01196702|granulomatous disease
1189868|NCT01196702|crohns disease
1189869|NCT01196702|bronchiectasis
1189870|NCT01196702|immunoglobulin replacement or treatment
1189871|NCT01196702|B-cell immunophenotyping
1189872|NCT01196689|Pharmacokinetics AZD1981
1189873|NCT01196689|Asthma
1189874|NCT01196676|AZD4451
1189875|NCT01196676|Bipolar
1189876|NCT01196676|depression
1189877|NCT01196663|TMS
1189878|NCT01196637|thoracic outlet syndrome
1189879|NCT01196637|brachial plexopathy
1189880|NCT01196637|ultrasonography
1189881|NCT01196624|PTSD
1189882|NCT01196624|FLASHBACKS
1189883|NCT01196624|TMS
1189884|NCT01196624|EXPOSURE
1189885|NCT01196611|Voice disorders
1189886|NCT01196611|Voice
1189887|NCT01196598|pelvic floor
1189888|NCT01196598|pelvic organ prolapse
1189889|NCT01196585|Pleura
1189890|NCT01196585|biopsy
1189891|NCT01196585|diagnosis
1189892|NCT01196585|CT
1189893|NCT01196585|ultrasonography
1189894|NCT01196572|stricture
1189895|NCT01196572|urethra
1189896|NCT01196572|laser
1189897|NCT01196572|urethrotomy
1189898|NCT01196572|holmium
1189899|NCT01196572|bladder outlet obstruction
1189900|NCT01196559|ovarian cancer
1189901|NCT01196546|Type 2 Diabetes Mellitus
1189902|NCT01196546|vildagliptin
1189903|NCT01196546|metformin
1189904|NCT01196533|Non Invasive, Invasive, optical, light source, color image sensor,
1189905|NCT01196533|, Hemodynamic, Arterial Systolic, Arterial Diastolic, MAP, PA Systolic,
1189906|NCT01196533|PA Diastolic, Heart rate, Stroke volume, CBC, WBC, RBC, Hgb, HCT ,Iron.
1189907|NCT01196533|PLT, PH, PCO2, PO2, HCO3, SaO2 , Na, K, Cl, CO2, Bun, Cr, Gluc, HGB (A1C),
1189908|NCT01196533|TBiLi, LDL, HDL.
1189909|NCT01196520|Burkitt Lymphoma
1189910|NCT01196520|Epstein-Barr Virus
1189911|NCT01196520|Malaria
1189912|NCT01196494|Obstructive left-sided colonic cancer
1189913|NCT01196494|Colorectal stent
1189914|NCT01196494|Intraoperative colon lavage
1189915|NCT01196494|Lavage
1189916|NCT01196494|Stent
1189917|NCT01196468|HIV
1189918|NCT01196468|Testing
1189919|NCT01196468|Targeted
1189920|NCT01196468|Indicator
1189921|NCT01196468|Diseases
1189922|NCT01196468|Anal dysplasia
1189923|NCT01196468|Cervical dysplasia
1189924|NCT01196468|STI
1189925|NCT01196468|Lymphoma
1189926|NCT01196468|Seborrhoeic dermatitis
1189927|NCT01196468|Exanthema
1189928|NCT01196468|Thrombocytpaenia
1189929|NCT01196468|Lymphopaenia
1189930|NCT01196468|Hypergammaglobulinaemia
1189931|NCT01196455|Metastatic breast cancer patients
1189932|NCT01196403|transitional cell carcinoma of the bladder
1189933|NCT01196403|squamous cell carcinoma of the bladder
1189934|NCT01196403|adenocarcinoma of the bladder
1189935|NCT01196403|stage I bladder cancer
1189936|NCT01196403|stage II bladder cancer
1189937|NCT01196403|stage III bladder cancer
1189938|NCT01196377|Asthma
1189939|NCT01196377|Acute asthma
1189940|NCT01196377|Pediatrics
1189941|NCT01196364|Girls
1189942|NCT01196351|boys
1189943|NCT01196351|obesity
1189944|NCT01196351|physical activity
1189945|NCT01196351|exercise
1189946|NCT01196338|Ankle fracture
1189947|NCT01196338|Return to work
1189948|NCT01196338|Return to function
1189949|NCT01196338|Rehabilitation
1189950|NCT01196338|Weight-bearing
1189951|NCT01196325|Diabetes
1189952|NCT01196325|Diabetic Macular Edema
1189953|NCT01196325|Laser
1189954|NCT01196325|Anti-VEGF
1189955|NCT01196325|Morphology
1189956|NCT01196325|Blood Flow
1189957|NCT01196325|Vision
1189958|NCT01196312|anxiety sensitivity
1189959|NCT01196312|heroin
1189960|NCT01196299|diffusion tensor imaging
1189961|NCT01196299|magnetic resonance spectroscopy
1189962|NCT01196299|traumatic brain injury
1189963|NCT01196299|Metabolite changes
1189964|NCT01196299|Cerebral perfusion
1189965|NCT01196299|Hemorrhagic burden
1189966|NCT01196286|First-episode psychosis
1189967|NCT01196286|cognitive remediation
1189968|NCT01196286|family psychoeducation
1189969|NCT01196273|Cardiac Diseases,
1189970|NCT01196273|HIV-Infection,
1189971|NCT01196273|AIDS,
1189972|NCT01196273|Antiretroviral Therapy,
1189973|NCT01196273|Cardiovascular Medication,
1189974|NCT01196273|Risk Factors,
1189975|NCT01196273|coronary heart disease,
1189976|NCT01196273|heart failure,
1189977|NCT01196273|metabolic syndrome
1189978|NCT01196260|efficiency
1189979|NCT01196260|capecitabine
1189980|NCT01196260|oxaliplatin
1189981|NCT01196260|colorectal cancer
1189982|NCT01196247|pancreatic cancer
1189983|NCT01196247|molecular profiling
1189984|NCT01196247|SU2C
1189985|NCT01196247|Second line therapy
1189986|NCT01196247|Stage 4
1189987|NCT01196208|Disease, Hodgkin
1189988|NCT01196208|Lymphoma
1189989|NCT01196208|Monomethylauristatin E
1189990|NCT01196208|Lymphoma, Large-Cell, Anaplastic
1189991|NCT01196208|Lymphoma, T-Cell, Cutaneous
1189992|NCT01196208|Lymphoma, Non-Hodgkin
1189993|NCT01196208|Antibodies, Monoclonal
1189994|NCT01196208|Antibody-Drug Conjugate
1189995|NCT01196208|Antigens, CD30
1189996|NCT01196208|Hematologic Diseases
1189997|NCT01196208|Immunotherapy
1189998|NCT01196195|antiretroviral therapy
1189999|NCT01196195|child
1190000|NCT01196195|HIV-1
1190001|NCT01196169|daptomycin
1190002|NCT01196169|vancomycin
1190003|NCT01196169|perioperative
1190004|NCT01196169|prophylaxis
1190005|NCT01196169|arthroplasty
1190006|NCT01196169|prosthesis
1190007|NCT01196169|preoperative
1190008|NCT01196156|Infant, Small for Gestational Age
1190009|NCT01196156|Dwarfism Pituitary
1190010|NCT01196156|Saizen
1190011|NCT01196156|Somatropin; Growth Hormone
1190012|NCT01196156|Insulin resistance
1190013|NCT01196143|Ovulation induction
1190014|NCT01196143|Intrauterine insemination
1190015|NCT01196143|Gonal-f
1190016|NCT01196143|Controlled ovarian stimulation
1190017|NCT01196143|Female infertility
1190018|NCT01196130|Metastatic colorectal cancer
1190019|NCT01196130|CRC
1190020|NCT01196130|Colorectal adenocarcinoma
1190021|NCT01196130|Biomarker determination
1190022|NCT01196130|Tumor tissue
1190023|NCT01196130|Treatment protocols
1190024|NCT01196117|automatic positive airway pressure (APAP)
1190025|NCT01196117|continuous positive airway pressure (CPAP)
1190026|NCT01196117|Salivary Cortisol
1190027|NCT01196117|Apnea
1190028|NCT01196117|Sleep Apnea and/or any Sleep Disordered Breathing
1190029|NCT01196091|Lupus
1190030|NCT01196091|SLE
1190031|NCT01196091|Systemic Lupus Erythematosis
1190032|NCT01196091|autoimmune disease
1190033|NCT01196091|LY2127399
1190034|NCT01196091|Immune system disease
1190035|NCT01196026|Influenza
1190036|NCT01196026|H1N1
1190037|NCT01196026|Fluarix
1190038|NCT01196026|Pandemrix
1190039|NCT01195987|Hepatitis C
1190040|NCT01195987|Arthritis
1190041|NCT01195974|oral contraceptive, drug interaction, pharmacokinetics
1190042|NCT01195961|Direct Current Stimulation
1190043|NCT01195961|Learning
1190044|NCT01195961|Cognitive Enhancement
1190045|NCT01195961|Cognitive Tasks
1190046|NCT01195961|Cognitive Training
1190047|NCT01195961|Developmental Dyscalculia
1190048|NCT01195961|Learning Disability
1190049|NCT01195961|Cognition Disorder
1190050|NCT01195948|Uveitis
1190051|NCT01195948|Oral Tolerance
1190052|NCT01195922|Head and Neck Squamous Cell Carcinoma
1190053|NCT01195922|Oral Cancer
1190054|NCT01195922|mTOR Inhibitors
1190055|NCT01195922|Targeted Therapies
1190056|NCT01195922|Signal Transduction Inhibitors
1190057|NCT01195922|Head and Neck Cancer
1190058|NCT01195922|Squamous Cell Carcinoma
1190059|NCT01195922|Tongue Cancer
1190060|NCT01195883|IV fluid
1190061|NCT01195883|recovery
1190062|NCT01195883|goal directed fluid replacement
1190063|NCT01195883|improved patient recovery
1190064|NCT01195870|Multiple sclerosis
1190065|NCT01195870|Rebif
1190066|NCT01195870|Interferon beta-1a
1190067|NCT01195857|Multiple sclerosis
1190068|NCT01195857|Rebif
1190069|NCT01195857|Interferon beta-1a
1190070|NCT01195844|Pediatric gastroenteritis, rotavirus infection
1190071|NCT01195818|Albuminuria, hyperfiltration, RAS inhibitors, ADMA
1190072|NCT01195805|Blood pressure, PWV, HRV, PWV, potassium
1190073|NCT01195792|Opioid receptors
1190074|NCT01195792|Body weight
1190075|NCT01195792|Over-eating behaviour
1190076|NCT01195792|Obesity
1190077|NCT01195792|Fat mass
1190078|NCT01195779|immunogenicity
1190079|NCT01195779|safety
1190080|NCT01195779|Influenza
1190081|NCT01195779|children
1190082|NCT01195779|vaccine
1190083|NCT01195766|Hodgkin
1190084|NCT01195766|Ofatumumab
1190085|NCT01195766|Lymphoma
1190086|NCT01195753|Urea cycle Disorders
1190087|NCT01195740|Suicide Ideation
1190088|NCT01195740|Depression
1190089|NCT01195740|Family Conflict
1190090|NCT01195701|female sexual dysfunction
1190091|NCT01195701|anorgasmia
1190092|NCT01195701|clitoral complex
1190093|NCT01195701|pelvic MRI
1190094|NCT01195701|testosterone
1190095|NCT01195662|Diabetes Mellitus, Type 2
1190096|NCT01195662|Diabetes Mellitus
1190097|NCT01195662|Endocrine System Diseases
1190098|NCT01195662|Glucose Metabolism Disorders
1190099|NCT01195662|Metabolic Diseases
1190100|NCT01195662|Angiotensin Receptor Inhibitors
1190101|NCT01195662|Angiotensin-Converting Enzyme Inhibitors
1190102|NCT01195662|Antihypertensive Agents
1190103|NCT01195662|Cardiovascular Agents
1190104|NCT01195662|Pharmacological Actions
1190105|NCT01195636|Pain from Shingles, PHN, Postherpetic Neuralgia
1190106|NCT01195623|varicose veins
1190107|NCT01195623|venous insufficiency
1190108|NCT01195623|surgery
1190109|NCT01195623|duplex
1190110|NCT01195623|recurrence
1190111|NCT01195597|electronic cigarette
1190112|NCT01195597|ENDD
1190113|NCT01195597|nicotine
1190114|NCT01195597|smoking cessation
1190115|NCT01195597|smoking reduction
1190116|NCT01195584|complication rate in 3 cohorts (BMI < 25, > 25 and > 30)
1190117|NCT01195558|Non-24
1190118|NCT01195558|N24HSWD
1190119|NCT01195558|Blindness
1190120|NCT01195558|Sleep
1190121|NCT01195558|Wake
1190122|NCT01195558|Circadian Rhythm
1190123|NCT01195558|Nap
1190124|NCT01195545|Veritas® Collagen Matrix, Hiatal hernia
1190125|NCT01195532|hypoglycemic drug
1190126|NCT01195519|peritoneal dialysis
1190127|NCT01195519|hemodialysis patients
1190128|NCT01195506|We Will Collect the Bone Marrow Specimens From AML Patients
1190129|NCT01195493|Chronic periodontitis
1190130|NCT01195480|Immunotherapy
1190131|NCT01195480|Gene Therapy
1190132|NCT01195480|Paediatric
1190133|NCT01195480|B cell Acute Lymphoblastic Leukaemia
1190134|NCT01195441|Preeclampsia
1190135|NCT01195441|Doppler ultrasound
1190136|NCT01195441|First trimester
1190137|NCT01195441|Acetylsalicylic acid
1190138|NCT01195402|COPD
1190139|NCT01195402|pulmonary rehabilitation
1190140|NCT01195389|dementia
1190141|NCT01195389|memory loss
1190142|NCT01195389|cognitive decline
1190143|NCT01195376|PI3K
1190144|NCT01195376|mTOR
1190145|NCT01195376|Advanced solid tumor
1190146|NCT01195363|bipolar disorder, mania, depression
1190147|NCT01195350|Ischemic Stroke
1190148|NCT01195350|Hemorrhagic Stroke
1190149|NCT01195350|Blood pressure
1190150|NCT01195350|Intensive care
1190151|NCT01195337|Sedentary minority adult
1190152|NCT01195337|Psychosocial factors
1190153|NCT01195337|Environmental factors
1190154|NCT01195337|Obesity
1190155|NCT01195337|Physical Activity
1190156|NCT01195337|PA
1190157|NCT01195337|Cancer Risk
1190158|NCT01195337|African Americans
1190159|NCT01195337|Latino
1190160|NCT01195324|Canagliflozin (JNJ-28431754)
1190161|NCT01195324|Warfarin
1190162|NCT01195324|Pharmacokinetic
1190163|NCT01195324|Pharmacodynamic
1190164|NCT01195324|Prothrombin time (PT)
1190165|NCT01195324|International normalized ratio (INR)
1190166|NCT01195311|Refractory, Advanced malignancies
1190167|NCT01195298|metastatic breast cancer
1190168|NCT01195298|elderly patients
1190169|NCT01195298|chemoimmunotherapy
1190170|NCT01195298|Triple negative metastatic breast cancer
1190171|NCT01195285|Laparoscopic cholecystectomy
1190172|NCT01195285|Quality of life
1190173|NCT01195285|Biliary Cholic
1190174|NCT01195285|Chronic Cholecystitis
1190175|NCT01195285|Symptomatic Cholelithiasis
1190176|NCT01195259|rosiglitazone
1190177|NCT01195259|ADOPT
1190178|NCT01195259|metformin
1190179|NCT01195259|malignancy
1190180|NCT01195259|RECORD
1190181|NCT01195246|end stage renal failure
1190182|NCT01195246|renal failure
1190183|NCT01195246|kidney failure
1190184|NCT01195246|kidney failure, chronic
1190185|NCT01195246|chronic kidney failure
1190186|NCT01195246|hepatitis B virus (HBV) vaccine
1190187|NCT01195246|hepatitis B vaccine
1190188|NCT01195246|hepatitis B
1190189|NCT01195246|hepatitis
1190190|NCT01195246|HBV
1190191|NCT01195246|prevention and control
1190192|NCT01195246|dialysis
1190193|NCT01195233|Xerostomia
1190194|NCT01195233|Radiotherapy of head and neck
1190195|NCT01195233|BioXtra
1190196|NCT01195220|STI screening
1190197|NCT01195220|Emergency Department
1190198|NCT01195220|Chlamydia
1190199|NCT01195220|Gonorrhea
1190200|NCT01195220|HIV
1190201|NCT01195220|behavior
1190202|NCT01195220|teenagers
1190203|NCT01195220|intervention
1190204|NCT01195207|CNTO 3157
1190205|NCT01195207|healthy volunteers
1190206|NCT01195207|asthma
1190207|NCT01195194|T-cell lymphocyte allo-recognition
1190208|NCT01195194|CNI-free immunosuppressive regimen
1190209|NCT01195194|Enzyme-linked immunospot (ELISPOT)
1190210|NCT01195181|peginterferon alfa 2a and 2b type
1190211|NCT01195181|ribavirin
1190212|NCT01195181|chronic hepatitis C
1190213|NCT01195181|antiviral therapy cost/efficacy
1190214|NCT01195181|viral kinetics
1190215|NCT01195168|PCOS
1190216|NCT01195155|PCOS
1190217|NCT01195142|PCOS
1190218|NCT01195129|Stent
1190219|NCT01195129|cerebral aneursym
1190220|NCT01195129|neurology
1190221|NCT01195129|radiology
1190222|NCT01195116|Post-operative pain management
1190223|NCT01195116|Pain Management
1190224|NCT01195116|Painful bladder syndrome
1190225|NCT01195116|frequency and urgency
1190226|NCT01195116|Dexmedetomidine
1190227|NCT01195116|hydrodistension
1190228|NCT01195103|Procedural sedation
1190229|NCT01195103|Regional Anesthesia block
1190230|NCT01195103|Orthopedic surgery
1190231|NCT01195103|Lusedra
1190232|NCT01195103|Fospropofol disodium
1190233|NCT01195103|Midazolam
1190234|NCT01195090|sitagliptin
1190235|NCT01195090|pioglitazone
1190236|NCT01195090|type 2 diabetes
1190237|NCT01195077|HIV
1190238|NCT01195077|Dietary intervention
1190239|NCT01195077|Algae
1190240|NCT01195077|HIV progression
1190241|NCT01195077|Algae specific kind
1190242|NCT01195064|COPD patients
1190243|NCT01195064|OSAS patients
1190244|NCT01195064|cardiovascular surgery
1190245|NCT01195064|Endothelial function
1190246|NCT01195051|Medication Reconciliation
1190247|NCT01195051|Inpatient
1190248|NCT01195051|Electronic Medical Records
1190249|NCT01195038|Avian influenza, H5N1, pandemic, recombinant HA vaccine
1190250|NCT01195025|Blood volume
1190251|NCT01195025|blood coagulation
1190252|NCT01195025|volume kinetics
1190253|NCT01195012|child
1190254|NCT01195012|primary care
1190255|NCT01195012|treatment
1190256|NCT01195012|parenting
1190257|NCT01195012|lifestyle behaviors
1190258|NCT01194999|OAB
1190259|NCT01194999|Urinary Bladder, Overactive
1190260|NCT01194999|Overactive Bladder Syndrome
1190261|NCT01194999|VESIcare
1190262|NCT01194999|Urgency
1190263|NCT01194999|Nocturia
1190264|NCT01194999|Frequency
1190265|NCT01194999|Urge Urinary Incontinence
1190266|NCT01194999|UUI
1190267|NCT01194999|Pubovaginal Sling
1190268|NCT01194999|PVS
1190269|NCT01194999|Incontinence
1190270|NCT01194986|Receptor binding
1190271|NCT01194986|Histamine H3 receptor
1190272|NCT01194986|binding
1190273|NCT01194986|radioligand
1190274|NCT01194973|Atypical Hemolytic-Uremic Syndrome
1190275|NCT01194960|cancer of prostate
1190276|NCT01194960|cancer of the prostate
1190277|NCT01194960|neoplasms prostate
1190278|NCT01194960|neoplasms prostatic
1190279|NCT01194960|prostate cancer
1190280|NCT01194960|prostate neoplasms
1190281|NCT01194960|prostatic cancer
1190282|NCT01194960|prostate specific antigen
1190283|NCT01194960|prostatic hyperplasia
1190284|NCT01194947|banal-appearing nevi
1190285|NCT01194947|NEVUS
1190286|NCT01194934|Stem Cell Transplantation
1190287|NCT01194934|SDF-1
1190288|NCT01194934|L-oligonucleotide Aptamer
1190289|NCT01194934|Spiegelmer
1190290|NCT01194934|Hematopoietic Stem Cells
1190291|NCT01194908|Breast Cancer
1190292|NCT01194908|Breast Tumors
1190293|NCT01194908|Breast Neoplasms
1190294|NCT01194895|esophagectomy
1190295|NCT01194895|acute lung injury
1190296|NCT01194895|protective ventilation
1190297|NCT01194869|Breast Cancer
1190298|NCT01194856|HIV
1190299|NCT01194856|Lipoatrophy
1190300|NCT01194856|mitochondrial dysfunction
1190301|NCT01194817|total knee arthroplasty
1190302|NCT01194817|total knee replacement
1190303|NCT01194817|cementless TKA
1190304|NCT01194817|high flexion
1190305|NCT01194817|trabecular metal
1190306|NCT01194804|Hemolytic Paroxysmal Nocturnal Hemoglobinuria
1190307|NCT01194804|Eculizumab
1190308|NCT01194804|PNH
1190309|NCT01194791|Amyloidosis
1190310|NCT01194791|Lenalidomide
1190311|NCT01194713|Alzheimer Disease
1190312|NCT01194713|Cerebrospinal fluid
1190313|NCT01194713|Sleep
1190314|NCT01194713|Abeta
1190315|NCT01194700|lung bioavailability
1190316|NCT01194700|asthma
1190317|NCT01194700|seretide
1190318|NCT01194700|Spacer
1190319|NCT01194687|Estrogens
1190320|NCT01194687|Fecal Microbiome
1190321|NCT01194687|Fecal Occult Blood
1190322|NCT01194674|Microplasmin
1190323|NCT01194674|Macular Edema
1190324|NCT01194674|Uveitis
1190325|NCT01194661|Inhibitory Control
1190326|NCT01194661|Executive Function
1190327|NCT01194661|fMRI
1190328|NCT01194661|TMS
1190329|NCT01194661|TBI
1190330|NCT01194661|Traumatic Brain Injury
1190331|NCT01194661|Healthy Volunteer
1190332|NCT01194661|HV
1190333|NCT01194648|urinary incontinence
1190334|NCT01194648|male erectile disorder
1190335|NCT01194648|therapy-related toxicity
1190336|NCT01194648|stage I prostate cancer
1190337|NCT01194648|stage IIB prostate cancer
1190338|NCT01194648|stage IIA prostate cancer
1190339|NCT01194635|stage IV squamous cell carcinoma of the lip and oral cavity
1190340|NCT01194635|stage IV verrucous carcinoma of the oral cavity
1190341|NCT01194635|stage IV squamous cell carcinoma of the nasopharynx
1190342|NCT01194635|stage IV squamous cell carcinoma of the oropharynx
1190343|NCT01194635|stage IV squamous cell carcinoma of the hypopharynx
1190344|NCT01194635|stage IV squamous cell carcinoma of the larynx
1190345|NCT01194635|stage IV verrucous carcinoma of the larynx
1190346|NCT01194609|Low dose radiation
1190347|NCT01194609|Adoptive immune cell therapy
1190348|NCT01194609|Cervical cancer
1190349|NCT01194609|Pilot study
1190350|NCT01194596|smoking cessation advice
1190351|NCT01194596|spirometry
1190352|NCT01194596|primary health care
1190353|NCT01194583|electronic cigarette
1190354|NCT01194583|nicotine
1190355|NCT01194583|smoking cessation
1190356|NCT01194583|smoking reduction
1190357|NCT01194557|history of fever
1190358|NCT01194557|measured fever
1190359|NCT01194557|appropriate treatment
1190360|NCT01194557|appropriate referral
1190361|NCT01194531|Preimplantation Gentic Screening
1190362|NCT01194531|PGS
1190363|NCT01194531|In Vitro Fertilization
1190364|NCT01194531|IVF
1190365|NCT01194531|Preimplantation Genetic Diagnosis
1190366|NCT01194531|PGD
1190367|NCT01194518|Life experience
1190368|NCT01194518|Life style
1190369|NCT01194518|Health behavior
1190370|NCT01194518|Mixed method
1190371|NCT01194505|anterior cruciate ligament reconstruction
1190372|NCT01194505|obturator nerve block
1190373|NCT01194505|sciatic nerve block
1190374|NCT01194505|femoral nerve block
1190375|NCT01194505|posterior lumbar plexus block
1190376|NCT01194505|ultrasound guided nerve block
1190377|NCT01194492|plasma albumin
1190378|NCT01194492|inflammatory reaction
1190379|NCT01194492|systemic inflammatory response syndrome
1190380|NCT01194479|type 1 diabetes
1190381|NCT01194479|hypoglycemia
1190382|NCT01194479|formoterol
1190383|NCT01194466|Head and Neck Cancer
1190384|NCT01194466|Oral Cancer
1190385|NCT01194466|Laryngeal Cancer
1190386|NCT01194466|Oropharyngeal Cancer
1190387|NCT01194466|Transcutaneous Electrical Nerve Stimulation (TENS)
1190388|NCT01194466|Oral Mucositis
1190389|NCT01194466|Pain
1190390|NCT01194466|Function
1190391|NCT01194466|TENS
1190392|NCT01194466|Functional Pain
1190393|NCT01194466|Non-pharamcologic
1190394|NCT01194466|Quality of Life
1190395|NCT01194427|Preoperative
1190396|NCT01194427|Neoadjuvant
1190397|NCT01194388|Patients presenting with an intracranial aneurysm
1190398|NCT01194362|aortic valve disease
1190399|NCT01194362|gene expression
1190400|NCT01194349|S. pneumoniae
1190401|NCT01194349|thrombocytosis
1190402|NCT01194349|pediatric patients
1190403|NCT01194349|The study aimed to understand the diagnostic value of thrombocytosis in children with S. pneumoniae infection
1190404|NCT01194336|Central nervous system
1190405|NCT01194336|Cholinesterase
1190406|NCT01194336|Neurocognitive performance testing
1190407|NCT01194323|esophageal erosion
1190408|NCT01194323|abnormal pH monitoring
1190409|NCT01194310|glaucoma
1190410|NCT01194310|cataract
1190411|NCT01194297|influenza
1190412|NCT01194297|premature infant
1190413|NCT01194297|very low birth weight infant
1190414|NCT01194297|immunization
1190415|NCT01194297|vaccine
1190416|NCT01194271|Hormone Ablation
1190417|NCT01194271|Prostate adenocarcinoma
1190418|NCT01194271|Radical prostatectomy
1190419|NCT01194271|Leuprolide Acetate
1190420|NCT01194271|Lupron Depot
1190421|NCT01194271|Ipilimumab
1190422|NCT01194271|BMS-734016
1190423|NCT01194271|MDX010
1190424|NCT01194258|Type 2 diabetes
1190425|NCT01194245|Type 1 diabetes
1190426|NCT01194232|Cystic Fibrosis
1190427|NCT01194232|CF
1190428|NCT01194232|CMRI
1190429|NCT01194232|vascularization
1190430|NCT01194232|perfusion
1190431|NCT01194219|Plaque Psoriasis
1190432|NCT01194193|Cancer
1190433|NCT01194193|Advanced solid tumours
1190434|NCT01194193|lymphomas
1190435|NCT01194193|dose escalation
1190436|NCT01194193|preliminary anti-tumour activity
1190437|NCT01194193|Tor kinase inhibitor
1190438|NCT01194193|oral administration
1190439|NCT01194193|intermittent dosing
1190440|NCT01194180|Mycobacterium tuberculosis
1190441|NCT01194180|BCG
1190442|NCT01194180|MVA85A
1190443|NCT01194167|Platelet refractory thrombocytopenia
1190444|NCT01194141|Barth syndrome
1190445|NCT01194141|cardiomyopathy
1190446|NCT01194141|mitochondria
1190447|NCT01194141|cardiolipin
1190448|NCT01194128|caregivers,
1190449|NCT01194128|institutionalization,
1190450|NCT01194128|dementia patients,
1190451|NCT01194128|bereavement,
1190452|NCT01194128|grief
1190453|NCT01194128|complicated grief
1190454|NCT01194115|surgical site infection
1190455|NCT01194115|obesity
1190456|NCT01194115|pregnancy
1190457|NCT01194115|cesarean section
1190458|NCT01194115|cesarean delivery
1190459|NCT01194102|Stroke
1190460|NCT01194102|Exercise
1190461|NCT01194102|Physical function
1190462|NCT01194102|Community program
1190463|NCT01194102|Patient education
1190464|NCT01194102|Self-management
1190465|NCT01194089|Nicotine
1190466|NCT01194089|Postoperative pain
1190467|NCT01194089|Bariatric surgery
1190468|NCT01194076|cognitive behavior therapy
1190469|NCT01194076|exposure and response prevention
1190470|NCT01194076|pediatric
1190471|NCT01194076|obsessive compulsive disorder
1190472|NCT01194076|child
1190473|NCT01194076|anxiety
1190474|NCT01194076|intensive
1190475|NCT01194076|OCD
1190476|NCT01194076|CBT
1190477|NCT01194063|short bowel syndrome
1190478|NCT01194063|parenteral nutrition associated liver disease
1190479|NCT01194063|pediatric
1190480|NCT01194037|Hepatitis C
1190481|NCT01194037|HCV
1190482|NCT01194037|Interferon
1190483|NCT01194037|Hanferon
1190484|NCT01194024|Inhalation Injury, Smoke
1190485|NCT01194024|Inhalation Injury, Acute
1190486|NCT01194011|Health care quality, information openness, health care information website
1190487|NCT01193972|Smoking cessation
1190488|NCT01193972|Smoking
1190489|NCT01193972|Tobacco
1190490|NCT01193946|Protein requirement
1190491|NCT01193946|Elderly women
1190492|NCT01193946|Indicator amino acid oxidation
1190493|NCT01193933|adult ALL
1190494|NCT01193933|Ph-negative
1190495|NCT01193933|dexamethasone
1190496|NCT01193933|L-asparaginase
1190497|NCT01193920|Group B streptococcus
1190498|NCT01193920|GBS
1190499|NCT01193920|Vaccine
1190500|NCT01193920|Prevention of group B streptococcus infection
1190501|NCT01193907|Typhoid fever
1190502|NCT01193907|Glycoconjugate vaccine
1190503|NCT01193907|Vi polysaccharide
1190504|NCT01193907|Immunogenicity
1190505|NCT01193894|IBD
1190506|NCT01193894|UC
1190507|NCT01193894|Profermin
1190508|NCT01193894|Fresubin
1190509|NCT01193894|Probiotics
1190510|NCT01193894|Dietetic
1190511|NCT01193855|stage IIB prostate cancer
1190512|NCT01193855|stage IIA prostate cancer
1190513|NCT01193816|restlessness during mechanical ventilation weaning
1190514|NCT01193803|Prosthetic Joint Infections
1190515|NCT01193803|Vertebral Osteomyelitis
1190516|NCT01193803|Septic arthritis
1190517|NCT01193803|Molecular methods
1190518|NCT01193790|chronic tonsillitis
1190519|NCT01193790|radio-frequency coblation
1190520|NCT01193790|radio-frequency coblation in chronic tonsillitis treatment
1190521|NCT01193777|Carnitine
1190522|NCT01193777|Shock
1190523|NCT01193777|Sepsis
1190524|NCT01193764|acne
1190525|NCT01193764|cocoa
1190526|NCT01193764|chocolate
1190527|NCT01193764|gelatin
1190528|NCT01193764|pustule
1190529|NCT01193764|comedones
1190530|NCT01193764|papules
1190531|NCT01193764|pustules
1190532|NCT01193751|Birth Asphyxia
1190533|NCT01193751|Newborn's Resuscitation
1190534|NCT01193751|Death
1190535|NCT01193751|Neurodevelopmental Impairment
1190536|NCT01193738|osteopathy
1190537|NCT01193725|Combat Disorders
1190538|NCT01193725|Exposure Therapy
1190539|NCT01193725|Army Personnel
1190540|NCT01193712|Electrophysiologic Techniques, Cardiac
1190541|NCT01193660|umbilical cord blood
1190542|NCT01193660|stem cell
1190543|NCT01193660|cerebral palsy
1190544|NCT01193634|ICD VR 9250, DR 9550 and CRT 9750 - PARADYM RF ICD
1190545|NCT01193621|early evaluation
1190546|NCT01193621|pharmacokinetics
1190547|NCT01193621|pharmacodynamics
1190548|NCT01193621|Biodistribution
1190549|NCT01193621|D2-receptor occupancy
1190550|NCT01193608|Randomized
1190551|NCT01193608|Safety Study
1190552|NCT01193608|Adaptive
1190553|NCT01193608|Double Blind
1190554|NCT01193582|Prevenar
1190555|NCT01193582|catch-up
1190556|NCT01193582|pneumococcal
1190557|NCT01193582|pneumonia
1190558|NCT01193556|Tonsillectomy
1190559|NCT01193556|PlasmaBlade
1190560|NCT01193556|Electrosurgery
1190561|NCT01193556|PEAK Surgical
1190562|NCT01193556|Medtronic Advanced Energy
1190563|NCT01193556|Medtronic
1190564|NCT01193530|Sleep Disturbances
1190565|NCT01193530|Depression
1190566|NCT01193530|Anxiety
1190567|NCT01193530|Fatigue
1190568|NCT01193530|Quality of life
1190569|NCT01193517|Refractory metastatic colorectal cancer
1190570|NCT01193517|CRC
1190571|NCT01193517|colorectal adenocarcinoma with metastatic disease
1190572|NCT01193517|Azacitidine
1190573|NCT01193517|5-Azacytidine
1190574|NCT01193517|5-aza
1190575|NCT01193517|Vidaza
1190576|NCT01193517|5-AZC
1190577|NCT01193517|AZA-CR
1190578|NCT01193517|Ladakamycin
1190579|NCT01193517|NSC-102816
1190580|NCT01193517|Capecitabine
1190581|NCT01193517|Oxaliplatin
1190582|NCT01193517|CAPOX
1190583|NCT01193517|Xeloda
1190584|NCT01193517|Eloxatin
1190585|NCT01193517|Hypermethylation
1190586|NCT01193517|CpG island methylator phenotype
1190587|NCT01193504|Prevention of Retinal Thickening and CME Following Phacoemulsification
1190588|NCT01193504|Pseudophakia following cataract surgery
1190589|NCT01193491|Phase 1
1190590|NCT01193491|AML
1190591|NCT01193491|CML
1190592|NCT01193491|MPD
1190593|NCT01193491|Client Proteins
1190594|NCT01193491|Hsp90
1190595|NCT01193478|Hepatitis C
1190596|NCT01193478|HCV RNA
1190597|NCT01193478|multiple ascending dose
1190598|NCT01193478|NS5A
1190599|NCT01193478|GS-5885
1190600|NCT01193478|chronic genotype 1 HCV infection
1190601|NCT01193465|Humidity
1190602|NCT01193465|Temperature
1190603|NCT01193465|Low Flow Anesthesia
1190604|NCT01193452|elderly patients
1190605|NCT01193452|advanced colorectal cancer
1190606|NCT01193452|chemotherapy
1190607|NCT01193452|S-1
1190608|NCT01193452|5-fluorouracil
1190609|NCT01193452|leucovorin
1190610|NCT01193439|thoracoscopy
1190611|NCT01193439|pleural diseases
1190612|NCT01193439|complications
1190613|NCT01193439|safety
1190614|NCT01193426|Hepatic
1190615|NCT01193426|cirrhosis
1190616|NCT01193426|IL-6
1190617|NCT01193426|IL-8
1190618|NCT01193426|Leptine
1190619|NCT01193413|acute pancreatitis
1190620|NCT01193413|Drainage
1190621|NCT01193413|Pancreatic surgery
1190622|NCT01193413|Biological Markers/analysis
1190623|NCT01193413|Infection diagnosis
1190624|NCT01193413|ROC Curve
1190625|NCT01193413|Sensitivity and Specificity
1190626|NCT01193413|Endoscopic ultrasonography
1190627|NCT01193400|Acute myelogenous leukemia
1190628|NCT01193400|Clofarabine
1190629|NCT01193400|Cytarabine
1190630|NCT01193374|Childhood Obesity
1190631|NCT01193374|Primary Care
1190632|NCT01193374|Counseling
1190633|NCT01193374|Screening
1190634|NCT01193348|Atypical Hemolytic-Uremic Syndrome
1190635|NCT01193335|13-valent pneumococcal conjugate vaccine
1190636|NCT01193335|premature
1190637|NCT01193335|immunization
1190638|NCT01193335|safety.
1190639|NCT01193296|Diabetes mellitus, vildagliptin, continuous glucose monitoring
1190640|NCT01193283|Aplastic Anemia
1190641|NCT01193283|Immunosuppression
1190642|NCT01193283|T-Cells
1190643|NCT01193283|Hematopoiesis
1190644|NCT01193283|Autoimmunity
1190645|NCT01193283|Severe Aplastic Anemia
1190646|NCT01193270|NICHD Neonatal Research Network
1190647|NCT01193270|Intraventricular Hemorrhage (IVH)
1190648|NCT01193270|Very Low Birth Weight (VLBW)
1190649|NCT01193270|Extremely Low Birth Weight (ELBW)
1190650|NCT01193270|Prematurity
1190651|NCT01193231|Laser Vision Correction
1190652|NCT01193231|Photorefractive Keratectomy
1190653|NCT01193231|PRK
1190654|NCT01193231|Nearsighted
1190655|NCT01193231|Myopia
1190656|NCT01193205|Borderline Personality Disorder
1190657|NCT01193205|Skills Training
1190658|NCT01193205|Dialectical Behavior Therapy
1190659|NCT01193205|Suicidal and parasuicidal behavior
1190660|NCT01193192|Neevo
1190661|NCT01193192|Neevo DHA
1190662|NCT01193192|L-methylfolate
1190663|NCT01193192|anemia during pregnancy
1190664|NCT01193192|folic acid
1190665|NCT01193192|vitamin B12
1190666|NCT01193192|prenatal vitamins
1190667|NCT01193192|hemoglobin
1190668|NCT01193192|iron deficiency
1190669|NCT01193192|Pregnancy
1190670|NCT01193166|Schizophrenia
1190671|NCT01193166|Risperidone
1190672|NCT01193166|Risperdal
1190673|NCT01193166|Paliperidone palmitate
1190674|NCT01193166|Aripiprazole
1190675|NCT01193166|Haloperidol
1190676|NCT01193166|Olanzapine
1190677|NCT01193166|Paliperidone
1190678|NCT01193166|Perphenazine
1190679|NCT01193166|Quetiapine
1190680|NCT01193153|schizoaffective disorder
1190681|NCT01193153|paliperidone palmitate
1190682|NCT01193153|INVEGA SUSTENNA
1190683|NCT01193153|schizoaffective disorder relapse prevention
1190684|NCT01193140|veliparib
1190685|NCT01193140|relapsed and refractory tumors
1190686|NCT01193140|Temodar
1190687|NCT01193140|temozolomide
1190688|NCT01193140|ABT-888
1190689|NCT01193140|Solid Tumors
1190690|NCT01193114|substance abuse
1190691|NCT01193114|homeless mothers
1190692|NCT01193101|hypertension
1190693|NCT01193101|blood pressure
1190694|NCT01193101|LCZ696
1190695|NCT01193101|dual-acting
1190696|NCT01193101|neprilysin
1190697|NCT01193101|nep inhibitor
1190698|NCT01193101|vasopeptidase
1190699|NCT01193101|angiotensin receptor
1190700|NCT01193101|ARNi
1190701|NCT01193101|Essential hypertension
1190702|NCT01193088|CMT
1190703|NCT01193088|CMT1A
1190704|NCT01193075|Charcot Marie Tooth disease
1190705|NCT01193075|CMT
1190706|NCT01193075|HMSN
1190707|NCT01193075|HMN
1190708|NCT01193075|HSN
1190709|NCT01193075|CMT1
1190710|NCT01193075|CMT2
1190711|NCT01193062|healthy volunteers
1190712|NCT01193062|pharmacokinetics-pharmacodynamics
1190713|NCT01193062|cerebrospinal fluid
1190714|NCT01193062|serial sampling
1190715|NCT01193049|Nasal Allergen Challenge, Inhaled Allergen Challenge, Asthma
1190716|NCT01193036|Psychosocial
1190717|NCT01193036|Skin Problems
1190718|NCT01193036|Supportive Care
1190719|NCT01193036|Melanoma
1190720|NCT01193036|Questionnaire
1190721|NCT01193023|Prospective Studies
1190722|NCT01193023|Humans, pediatric
1190723|NCT01193023|Positive-Pressure Respiration/methods*
1190724|NCT01193023|Respiration, Artificial/methods*
1190725|NCT01193023|Intensive Care
1190726|NCT01193023|Intensive Care Units/statistics & numerical data*
1190727|NCT01193023|Respiration, Artificial/statistics & numerical data*
1190728|NCT01193023|Patients/statistics & numerical data*
1190729|NCT01193023|Prevalence
1190730|NCT01193023|Respiratory Muscles/innervation
1190731|NCT01192997|Meningitis
1190732|NCT01192997|Meningococci
1190733|NCT01192997|Meningitis C
1190734|NCT01192997|Meningitis A
1190735|NCT01192997|Meningitis W135
1190736|NCT01192997|Meningitis Y
1190737|NCT01192997|Antibody
1190738|NCT01192971|hcc, apatinib, phase II, cancer
1190739|NCT01192958|swine flu
1190740|NCT01192958|novel h1n1v
1190741|NCT01192958|novel h1n1
1190742|NCT01192958|h1n1
1190743|NCT01192945|Azacitidin
1190744|NCT01192945|Vidaza
1190745|NCT01192945|Piaza
1190746|NCT01192945|myelodysplastic syndrome
1190747|NCT01192945|MDS
1190748|NCT01192945|chronic myelomonocytic leukemia
1190749|NCT01192945|CMML
1190750|NCT01192945|acute myeloid leukemia
1190751|NCT01192945|AML
1190752|NCT01192945|daily routine
1190753|NCT01192945|concomitant antiemetic therapy
1190754|NCT01192945|germany
1190755|NCT01192945|non-interventional study
1190756|NCT01192919|bronchial carcinoma
1190757|NCT01192919|registry
1190758|NCT01192919|real life treatment
1190759|NCT01192919|cohort study
1190760|NCT01192919|NSCLC
1190761|NCT01192919|SCLC
1190762|NCT01192919|Germany
1190763|NCT01192854|Clevudine
1190764|NCT01192854|efficacy
1190765|NCT01192854|safety
1190766|NCT01192854|chronic hepatitis B
1190767|NCT01192841|physician uniform
1190768|NCT01192841|MRSA
1190769|NCT01192841|bacterial contamination
1190770|NCT01192828|cystathionine beta-synthase (CBS)
1190771|NCT01192802|albendazole
1190772|NCT01192802|ascaris
1190773|NCT01192802|trichiurus
1190774|NCT01192802|hookworms
1190775|NCT01192789|Severe pneumonia
1190776|NCT01192789|Pneumonia
1190777|NCT01192789|Lady health workers
1190778|NCT01192789|Amoxicillin
1190779|NCT01192789|Treatment failure
1190780|NCT01192789|Injectable Antibiotics
1190781|NCT01192789|Referral treatment
1190782|NCT01192789|Health Facility
1190783|NCT01192789|Under five children
1190784|NCT01192789|home based management
1190785|NCT01192789|community case management
1190786|NCT01192776|NICHD Neonatal Research Network
1190787|NCT01192776|Hypoxic-ischemic encephalopathy (HIE)
1190788|NCT01192776|Hypothermia
1190789|NCT01192776|Neonatal depression
1190790|NCT01192776|Perinatal asphyxia
1190791|NCT01192776|Fetal acidosis
1190792|NCT01192750|recurrent metastatic squamous neck cancer with occult primary
1190793|NCT01192750|recurrent squamous cell carcinoma of the hypopharynx
1190794|NCT01192750|recurrent squamous cell carcinoma of the larynx
1190795|NCT01192750|recurrent squamous cell carcinoma of the lip and oral cavity
1190796|NCT01192750|recurrent squamous cell carcinoma of the nasopharynx
1190797|NCT01192750|recurrent squamous cell carcinoma of the oropharynx
1190798|NCT01192750|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1190799|NCT01192750|stage IV squamous cell carcinoma of the hypopharynx
1190800|NCT01192750|stage IV squamous cell carcinoma of the larynx
1190801|NCT01192750|stage IV squamous cell carcinoma of the lip and oral cavity
1190802|NCT01192750|stage IV squamous cell carcinoma of the nasopharynx
1190803|NCT01192750|stage IV squamous cell carcinoma of the oropharynx
1190804|NCT01192750|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1190805|NCT01192750|recurrent verrucous carcinoma of the larynx
1190806|NCT01192750|recurrent verrucous carcinoma of the oral cavity
1190807|NCT01192750|stage IV verrucous carcinoma of the larynx
1190808|NCT01192750|stage IV verrucous carcinoma of the oral cavity
1190809|NCT01192750|recurrent salivary gland cancer
1190810|NCT01192750|salivary gland squamous cell carcinoma
1190811|NCT01192737|pandemic
1190812|NCT01192737|A/H1N1
1190813|NCT01192737|pregnancy
1190814|NCT01192737|cohort
1190815|NCT01192737|vaccine
1190816|NCT01192737|Influenza and Pregnancy
1190817|NCT01192724|Antiplatelet
1190818|NCT01192724|Coronary artery diseae
1190819|NCT01192724|Percutaneous coronary intervention
1190820|NCT01192711|diabetes
1190821|NCT01192711|telemedicine
1190822|NCT01192711|self monitoring blood glucose
1190823|NCT01192698|hepatitis c
1190824|NCT01192698|liver transplant
1190825|NCT01192698|hepatitis C after liver transplant
1190826|NCT01192685|Depression
1190827|NCT01192685|Depressed
1190828|NCT01192685|TMS
1190829|NCT01192685|Transcranial Magnetic Stimulation
1190830|NCT01192646|maternal health
1190831|NCT01192646|birth preparedness
1190832|NCT01192646|cost effectiveness
1190833|NCT01192646|male involvement
1190834|NCT01192646|delivery at hospital
1190835|NCT01192646|complication readiness
1190836|NCT01192646|Health seeking behavior in pregnancy, labour and pregnancy complication
1190837|NCT01192633|Sarcoma
1190838|NCT01192633|gemcitabine
1190839|NCT01192633|vincristine
1190840|NCT01192633|cisplatin
1190841|NCT01192633|chemotherapy
1190842|NCT01192620|Pediatric Appendicitis
1190843|NCT01192620|Pathway
1190844|NCT01192594|symptom management
1190845|NCT01192594|empowerment
1190846|NCT01192594|medication adherence
1190847|NCT01192594|recovery
1190848|NCT01192594|schizophrenia
1190849|NCT01192594|post-psychotic adjustment process
1190850|NCT01192594|psychological adjustment
1190851|NCT01192594|psychiatric case managers
1190852|NCT01192594|psychosis
1190853|NCT01192594|insight
1190854|NCT01192594|cognitive function
1190855|NCT01192581|brain hypoperfusion
1190856|NCT01192581|Vuloven
1190857|NCT01192581|computed tomography perfusion
1190858|NCT01192555|Neuroblastoma
1190859|NCT01192555|Chemotherapy
1190860|NCT01192555|Pediatrics
1190861|NCT01192555|Cytoxan
1190862|NCT01192555|immunotherapy
1190863|NCT01192555|vaccine
1190864|NCT01192529|Senile
1190865|NCT01192529|Dementia
1190866|NCT01192529|Neurodegenerative
1190867|NCT01192529|Supressi
1190868|NCT01192529|Specific diet
1190869|NCT01192529|Cognitive Status
1190870|NCT01192529|Memory
1190871|NCT01192529|Malnutrition
1190872|NCT01192529|Parkinson
1190873|NCT01192529|Alzheimer
1190874|NCT01192516|Osteoarthritis
1190875|NCT01192516|Activity Pacing
1190876|NCT01192503|Restless Legs Syndrome
1190877|NCT01192503|rasagiline
1190878|NCT01192503|futility
1190879|NCT01192477|Air pollution
1190880|NCT01192477|Ozone
1190881|NCT01192477|Health effects of ozone exposure
1190882|NCT01192464|Hodgkin's Lymphoma
1190883|NCT01192464|Non-Hodgkin's Lymphoma
1190884|NCT01192438|prostate
1190885|NCT01192438|cancer
1190886|NCT01192438|ablation
1190887|NCT01192438|laser-induced
1190888|NCT01192438|focal therapy
1190889|NCT01192425|PNH clone cells
1190890|NCT01192425|Aplastic Anemia
1190891|NCT01192425|AA
1190892|NCT01192425|Myelodysplastic Syndromes
1190893|NCT01192425|MDS
1190894|NCT01192425|bone marrow failure syndromes
1190895|NCT01192425|FLAER
1190896|NCT01192425|Paroxysmal Nocturnal Hemoglobinuria
1190897|NCT01192412|hypertension
1190898|NCT01192412|pregnancy
1190899|NCT01192412|antihypertensive therapy
1190900|NCT01192412|perinatal outcome
1190901|NCT01192412|maternal outcome
1190902|NCT01192412|Non-severe, non-proteinuric pre-existing or gestational hypertension in pregnancy
1190903|NCT01192399|Hemolytic Paroxysmal Nocturnal Hemoglobinuria
1190904|NCT01192399|Eculizumab
1190905|NCT01192399|PNH
1190906|NCT01192399|Japan
1190907|NCT01192360|pediatrics
1190908|NCT01192360|Heart Disease
1190909|NCT01192360|Cystic Fibrosis
1190910|NCT01192360|Severe Asthma
1190911|NCT01192360|Magnetic Resonance Imaging
1190912|NCT01192334|knee osteoarthritis arthroplasty postural balance
1190913|NCT01192321|intraocular lens
1190914|NCT01192321|Toric
1190915|NCT01192308|Breast cancer
1190916|NCT01192308|Tamoxifen
1190917|NCT01192308|Pharmacokinetics
1190918|NCT01192308|Pharmacogenetics
1190919|NCT01192308|CYP2D6
1190920|NCT01192295|Malignant pain
1190921|NCT01192295|Nonmalignant pain
1190922|NCT01192295|Pediatric
1190923|NCT01192295|Opioid
1190924|NCT01192295|Moderate to severe malignant or nonmalignant pain
1190925|NCT01192282|Female Genital Warts
1190926|NCT01192282|HPV Typing
1190927|NCT01192282|HIV Status
1190928|NCT01192282|Treatment Modalities and Recurrence
1190929|NCT01192282|Socio-economic Burdens
1190930|NCT01192269|cheek cells
1190931|NCT01192269|phospholipids
1190932|NCT01192269|fatty acids
1190933|NCT01192269|docosahexaenoic acid
1190934|NCT01192269|Buccal Cheek cells
1190935|NCT01192269|non invasive fatty acid status marker
1190936|NCT01192256|smoking
1190937|NCT01192256|cessation
1190938|NCT01192256|mortality
1190939|NCT01192256|quality of life
1190940|NCT01192243|Objective response rate
1190941|NCT01192243|Time to Progression
1190942|NCT01192243|Quality of Live
1190943|NCT01192230|Objective response rate
1190944|NCT01192230|Disease control rate
1190945|NCT01192230|Disease free survival
1190946|NCT01192230|Overall survival
1190947|NCT01192230|Quality of Live
1190948|NCT01192230|Nonsmall cell lung cancer
1190949|NCT01192230|toxicity
1190950|NCT01192217|video-assisted thoracic surgery
1190951|NCT01192217|axillary mini-thoracotomy
1190952|NCT01192217|bullectomy
1190953|NCT01192204|FBR, OSCC, chemoprevention
1190954|NCT01192191|GW642444
1190955|NCT01192191|COPD
1190956|NCT01192191|Fluticasone Furoate
1190957|NCT01192178|pediatric
1190958|NCT01192178|exacerbation
1190959|NCT01192178|viral induced exacerbation
1190960|NCT01192178|asthma
1190961|NCT01192165|Taxotere
1190962|NCT01192165|Cisplatin
1190963|NCT01192165|Carboplatin
1190964|NCT01192165|Trametinib
1190965|NCT01192165|GSK1120212
1190966|NCT01192165|Tarceva
1190967|NCT01192165|KRAS
1190968|NCT01192165|Pemetrexed
1190969|NCT01192165|MEK inhibitor
1190970|NCT01192165|nab-Paclitaxel
1190971|NCT01192165|Docetaxel
1190972|NCT01192165|Alimta
1190973|NCT01192165|Abraxane
1190974|NCT01192165|Erlotinib
1190975|NCT01192113|Mecobalamin
1190976|NCT01192113|peripheral neuropathy
1190977|NCT01192113|diabetic neuropathy
1190978|NCT01192100|Protein-rich breakfast
1190979|NCT01192100|Breakfast Skipping
1190980|NCT01192100|Adolescents
1190981|NCT01192100|Obesity
1190982|NCT01192100|Increased dietary protein
1190983|NCT01192100|Breakfast
1190984|NCT01192100|fMRI
1190985|NCT01192100|Ghrelin
1190986|NCT01192100|PYY
1190987|NCT01192087|adenoid cystic carcinoma
1190988|NCT01192087|carbon ion therapy
1190989|NCT01192087|IMRT (intensity-modulated therapy)
1190990|NCT01192087|radioimmunotherapy
1190991|NCT01192087|Cetuximab
1190992|NCT01192074|Obstetric
1190993|NCT01192074|Analgesia
1190994|NCT01192074|Anesthesia
1190995|NCT01192074|Obstetric Anesthesia
1190996|NCT01192074|Obstetric Analgesia
1190997|NCT01192074|ultrasound
1190998|NCT01192074|ultrasonography
1190999|NCT01192074|epidural analgesia
1191000|NCT01192074|epidural anesthesia
1191001|NCT01192074|spinal anesthesia
1191002|NCT01192074|neuraxial anesthesia
1191003|NCT01192074|neuraxial analgesia
1191004|NCT01192074|pregnancy
1191005|NCT01192074|labor
1191006|NCT01192074|cesarean delivery
1191007|NCT01192074|cesarean section
1191008|NCT01192061|autonomic nervous system
1191009|NCT01192061|heart rate variability
1191010|NCT01192061|blood pressure variability
1191011|NCT01192061|retrobulbar hemodynamics
1191012|NCT01192061|vascular dysregulation
1191013|NCT01192048|Congenital Heart Disease
1191014|NCT01192048|birth defect
1191015|NCT01192048|genetics
1191016|NCT01192048|gene
1191017|NCT01192048|DNA
1191018|NCT01192048|direct sequencing
1191019|NCT01192048|microarray
1191020|NCT01192048|single nucleotide polymorphism
1191021|NCT01192048|whole genome array comparative genomic hybridization
1191022|NCT01192048|chromosomal copy number change
1191023|NCT01192048|nucleotide sequence variation
1191024|NCT01192048|exome sequencing
1191025|NCT01192048|whole exome sequencing
1191026|NCT01192035|Africa, Western
1191027|NCT01192035|Antiretroviral Therapy, Highly Active
1191028|NCT01192022|Liver resection
1191029|NCT01192022|Liver transplantation
1191030|NCT01192022|Liver surgery
1191031|NCT01192022|Secondary hemostasis
1191032|NCT01192009|Leucine
1191033|NCT01192009|Skeletal Muscle Disuse
1191034|NCT01192009|Atrophy
1191035|NCT01192009|Proteolysis
1191036|NCT01191996|SPMS
1191037|NCT01191996|PPMS
1191038|NCT01191996|MS
1191039|NCT01191996|Multiple Sclerosis
1191040|NCT01191970|epidural
1191041|NCT01191970|beta-endorphins
1191042|NCT01191970|breast-feeding
1191043|NCT01191970|colostrum
1191044|NCT01191970|feeding
1191045|NCT01191957|Acute Myeloid Leukemia
1191046|NCT01191957|Allogeneic hematopoietic stem cell transplantation
1191047|NCT01191918|acetylcholinesterase inhibitor
1191048|NCT01191918|donepezil
1191049|NCT01191918|bipolar disorder
1191050|NCT01191918|mania
1191051|NCT01191918|lithium
1191052|NCT01191892|metastatic transitional cell cancer of the renal pelvis and ureter
1191053|NCT01191892|regional transitional cell cancer of the renal pelvis and ureter
1191054|NCT01191892|transitional cell carcinoma of the bladder
1191055|NCT01191892|stage III bladder cancer
1191056|NCT01191892|stage IV bladder cancer
1191057|NCT01191892|anterior urethral cancer
1191058|NCT01191892|posterior urethral cancer
1191059|NCT01191892|urethral cancer associated with invasive bladder cancer
1191060|NCT01191892|ureter cancer
1191061|NCT01191866|diabetes mellitus
1191062|NCT01191866|psychosocial
1191063|NCT01191866|metabolic control
1191064|NCT01191866|quality of life questionnaires
1191065|NCT01191866|children
1191066|NCT01191866|adolescents
1191067|NCT01191853|Post Swine Flu Blood Samples
1191068|NCT01191853|Biologic Samples
1191069|NCT01191853|Laboratory Research Samples
1191070|NCT01191853|Swine Flu
1191071|NCT01191853|Immunization
1191072|NCT01191853|Healthy Volunteer
1191073|NCT01191853|HV
1191074|NCT01191840|staphylococci
1191075|NCT01191814|pancreatic cancer
1191076|NCT01191814|obstructive jaundice
1191077|NCT01191814|Obstructive jaundice secondary to pancreatic cancer
1191078|NCT01191801|Leukemia
1191079|NCT01191801|Acute Myeloid Leukemia
1191080|NCT01191801|Hematologic
1191081|NCT01191801|Hematologic diseases
1191082|NCT01191801|Blood
1191083|NCT01191801|Cancer
1191084|NCT01191801|Malignancy
1191085|NCT01191801|Vosaroxin
1191086|NCT01191801|Cytarabine
1191087|NCT01191801|First Relapsed AML
1191088|NCT01191801|Refractory AML
1191089|NCT01191801|VALOR
1191090|NCT01191801|Sunesis
1191091|NCT01191801|Voreloxin
1191092|NCT01191801|SNS-595
1191093|NCT01191788|Depression
1191094|NCT01191788|Substance Use
1191095|NCT01191788|Group Cognitive Behavioral Therapy
1191096|NCT01191775|Oligonucleotide
1191097|NCT01191775|DNAi
1191098|NCT01191775|Oncology
1191099|NCT01191775|Antineoplastic agent
1191100|NCT01191775|Lymphoma
1191101|NCT01191775|PNT2258
1191102|NCT01191762|secondary hyperparathyroidism
1191103|NCT01191762|phosphate
1191104|NCT01191762|calcium
1191105|NCT01191762|chronic kidney disease
1191106|NCT01191749|Hematologic Disorder
1191107|NCT01191749|Aplastic Anemia
1191108|NCT01191749|T - Cell Large Granular Lymphocytic Leukemia
1191109|NCT01191749|T-LGL
1191110|NCT01191749|Myelodysplastic Syndrome
1191111|NCT01191749|Chronic Lymphocytic Leukemia
1191112|NCT01191749|CLL
1191113|NCT01191749|Chemotherapy
1191114|NCT01191749|Alemtuzumab
1191115|NCT01191736|hands only
1191116|NCT01191736|CPR
1191117|NCT01191736|resuscitation
1191118|NCT01191736|cardiac arrest
1191119|NCT01191736|Education of general public regarding resuscitation methods
1191120|NCT01191723|Healthy Volunteers
1191121|NCT01191710|progesterone
1191122|NCT01191697|HER2 positive
1191123|NCT01191671|Child Development
1191124|NCT01191671|Child
1191125|NCT01191671|Daycare centers
1191126|NCT01191671|Language
1191127|NCT01191645|Lower esophageal sphincter pressure
1191128|NCT01191645|Esophageal motility
1191129|NCT01191645|Remifentanil
1191130|NCT01191645|Metoclopramide
1191131|NCT01191645|Naloxone
1191132|NCT01191645|High resolution solid state manometry
1191133|NCT01191632|T cell
1191134|NCT01191632|surgery
1191135|NCT01191632|radiation
1191136|NCT01191619|McIvor retractor
1191137|NCT01191619|Proseal laryngeal mask airway
1191138|NCT01191606|pressure controlled
1191139|NCT01191606|volume controlled
1191140|NCT01191606|arterial oxygenation
1191141|NCT01191606|one lung ventilation
1191142|NCT01191593|Adductor-Canal-Blockade
1191143|NCT01191593|postoperative pain
1191144|NCT01191593|US-guided nerve block
1191145|NCT01191593|revision knee arthroplasty
1191146|NCT01191567|acute wounds
1191147|NCT01191567|postoperative wounds
1191148|NCT01191541|ara-c
1191149|NCT01191541|As2O3
1191150|NCT01191541|pediatric
1191151|NCT01191541|acute
1191152|NCT01191528|Adult
1191153|NCT01191528|Post
1191154|NCT01191528|operative
1191155|NCT01191528|oximetry
1191156|NCT01191528|capnometry
1191157|NCT01191528|Integrated
1191158|NCT01191528|Pulmonary
1191159|NCT01191528|Index
1191160|NCT01191528|End-tidal
1191161|NCT01191528|Monitoring Respiratory status
1191162|NCT01191528|post-operative
1191163|NCT01191515|Previous Cataract patients
1191164|NCT01191515|Monofocal IOL implant
1191165|NCT01191515|Evaluation
1191166|NCT01191502|Patients who have had binocular implantation of the Tecnis Multifocal IOL or the Crystalens™ HD Accommodating IOL.
1191167|NCT01191476|Sevoflurane
1191168|NCT01191476|Propofol
1191169|NCT01191476|Economics
1191170|NCT01191476|Pharmaceutical
1191171|NCT01191476|Chinese
1191172|NCT01191450|chlortalidone
1191173|NCT01191450|amiloride
1191174|NCT01191450|arterial hypertension
1191175|NCT01191424|Asthma
1191176|NCT01191424|PK
1191177|NCT01191424|Adolescents
1191178|NCT01191424|Adults
1191179|NCT01191411|colorectal neoplasms
1191180|NCT01191411|screening
1191181|NCT01191398|Hypersalivation
1191182|NCT01191398|Conscious Sedation
1191183|NCT01191398|Procedural Sedation
1191184|NCT01191398|Ketamine
1191185|NCT01191398|Atropine
1191186|NCT01191398|Glycopyrrolate
1191187|NCT01191385|HCC
1191188|NCT01191385|Liver cancer
1191189|NCT01191385|Cancer of liver
1191190|NCT01191385|Cancer, liver
1191191|NCT01191385|Hepatic cancer
1191192|NCT01191385|Cancer, hepatic
1191193|NCT01191385|Carcinoma, hepatocellular
1191194|NCT01191372|Hemophilia A
1191195|NCT01191372|Hemophilia B
1191196|NCT01191372|pharmacokinetics
1191197|NCT01191372|pharmacodynamics
1191198|NCT01191372|Tissue Factor Pathway Inhibitor
1191199|NCT01191333|Mood Disorder
1191200|NCT01191333|Depression
1191201|NCT01191333|stress disorder, post-traumatic
1191202|NCT01191333|Depressive Disorder
1191203|NCT01191333|Stress Disorders, Traumatic
1191204|NCT01191333|substance related disorders
1191205|NCT01191333|Transcranial Magnetic Stimulation, repetitive
1191206|NCT01191333|transcranial magnetic stimulation
1191207|NCT01191333|Veterans
1191208|NCT01191333|mental health
1191209|NCT01191320|Adult onset hypogonadotropic hypogonadism
1191210|NCT01191307|Primary dystonia
1191211|NCT01191307|Epilepsy
1191212|NCT01191307|Hydrocephalus
1191213|NCT01191307|Bladder Control
1191214|NCT01191307|Deaf or Hearing Impaired
1191215|NCT01191294|Melanoma
1191216|NCT01191294|Simulation Training
1191217|NCT01191294|Medical Students
1191218|NCT01191281|food habits
1191219|NCT01191281|nutrition requirements
1191220|NCT01191281|antiretroviral therapy
1191221|NCT01191255|ESRD
1191222|NCT01191255|end-stage renal disease
1191223|NCT01191255|dialysis
1191224|NCT01191255|hemodialysis
1191225|NCT01191255|peritoneal dialysis
1191226|NCT01191255|hemodialysis (HD)
1191227|NCT01191255|peritoneal dialysis (PD)
1191228|NCT01191255|chronic renal insufficiency
1191229|NCT01191255|phosphate binder
1191230|NCT01191255|kidney failure
1191231|NCT01191255|renal failure
1191232|NCT01191242|methadone
1191233|NCT01191242|genetic
1191234|NCT01191203|Acceptability and Adherence to methods
1191235|NCT01191190|Leukemia
1191236|NCT01191190|Chronic leukemia
1191237|NCT01191190|Chronic Lymphocytic Leukemia
1191238|NCT01191190|Relapsed
1191239|NCT01191190|Refractory
1191246|NCT01191164|Brachytherapy, Partial Breast Irradiation, Breast Seed Implant, Palladium Seeds
1191247|NCT01191151|Orthopedic surgery
1191248|NCT01191151|sports medicine
1191249|NCT01191138|Delayed Gastric emptying
1191250|NCT01191138|Gastric emptying scintigraphy
1191251|NCT01191138|Pancreatic fistula
1191252|NCT01191138|Pancreatic Neoplasms
1191253|NCT01191138|Whipple Operation
1191254|NCT01191086|Epilepsy
1191255|NCT01191086|partial onset seizure
1191256|NCT01191086|adjunctive therapy
1191257|NCT01191073|edentulous
1191258|NCT01191060|Progression free survival prolongation
1191259|NCT01191060|Disease Progression
1191260|NCT01191060|Overall survival
1191261|NCT01191021|breath
1191262|NCT01191021|propofol
1191263|NCT01191021|general anesthesia
1191264|NCT01191008|Xalacom Regulatory post marketing commitment plan safety
1191265|NCT01190995|Pain
1191266|NCT01190995|Neonate
1191267|NCT01190995|Procedure
1191268|NCT01190995|Neurobehavioural outcome
1191269|NCT01190969|Elderly
1191270|NCT01190969|malnutrition
1191271|NCT01190969|nutritional supplement
1191272|NCT01190943|localized osteosarcoma
1191273|NCT01190943|metastatic osteosarcoma
1191274|NCT01190943|recurrent osteosarcoma
1191275|NCT01190917|Autism
1191276|NCT01190917|Autism Spectrum Disorder
1191277|NCT01190917|Disorder
1191278|NCT01190917|Autistic
1191279|NCT01190917|Asperger Syndrome
1191280|NCT01190917|social skills group
1191281|NCT01190917|behavioral intervention
1191282|NCT01190917|Imaging, Magnetic Resonance
1191283|NCT01190917|fMRI
1191284|NCT01190917|Functional MRI
1191285|NCT01190917|MRI, Functional
1191286|NCT01190917|Magnetic Resonance Imaging
1191287|NCT01190917|Functional
1191288|NCT01190904|Androgen deficiency
1191289|NCT01190904|Erectile dysfunction
1191290|NCT01190904|Coronary Artery Disease
1191291|NCT01190904|Coronary Revascularization
1191292|NCT01190904|Diabetes mellitus
1191293|NCT01190904|MI
1191294|NCT01190904|Stroke
1191295|NCT01190904|MACCE
1191296|NCT01190904|DM
1191297|NCT01190904|ED
1191298|NCT01190904|CAD
1191299|NCT01190904|Development of predictive cardiovascular/cerebrovascular AE
1191300|NCT01190891|Rotator cuff tendonitis
1191301|NCT01190891|Shoulder pain
1191302|NCT01190891|Shoulder impingement
1191303|NCT01190839|Crohn's Disease
1191304|NCT01190839|Inflammatory Bowel Disease
1191305|NCT01190839|infliximab
1191306|NCT01190839|TNF-alpha
1191307|NCT01190826|Stable moderate asthma
1191308|NCT01190813|amblyopia, levodopa
1191309|NCT01190800|Alzheimer's Disease
1191310|NCT01190800|Capacity assessment
1191311|NCT01190800|Decision-making assessment
1191312|NCT01190800|Capacity to consent to treatment
1191313|NCT01190800|Capacity to vote
1191314|NCT01190800|Capacity to appoint a proxy
1191315|NCT01190787|Multiple Myeloma
1191316|NCT01190787|Elderly Patients
1191317|NCT01190787|Diagnosis
1191318|NCT01190787|Velcade subcutaneous
1191319|NCT01190787|Prednisone
1191320|NCT01190787|Melphalan
1191321|NCT01190787|Cyclophosphamide
1191322|NCT01190774|dental anxiety
1191323|NCT01190774|state anxiety
1191324|NCT01190774|randomised control trial
1191325|NCT01190774|psychological intervention
1191326|NCT01190761|Bioequivalence
1191327|NCT01190761|Galantamine
1191328|NCT01190761|Reminyl
1191329|NCT01190761|Galantamine hydrobromide
1191330|NCT01190761|Healthy subjects
1191331|NCT01190748|Bioequivalence
1191332|NCT01190748|Galantamine
1191333|NCT01190748|Reminyl
1191334|NCT01190748|Galantamine hydrobromide
1191335|NCT01190748|Healthy subjects
1191336|NCT01190735|Caffeine
1191337|NCT01190735|Parkinson's Disease
1191338|NCT01190735|Parkinson Disease
1191339|NCT01190735|Parkinsonian Disorders
1191340|NCT01190735|Basal Ganglia Diseases
1191341|NCT01190735|Brain Diseases
1191342|NCT01190735|Central Nervous System Diseases
1191343|NCT01190735|Nervous System Diseases
1191344|NCT01190735|Movement Disorders
1191345|NCT01190735|Neurodegenerative Diseases
1191346|NCT01190735|Caffeine citrate
1191347|NCT01190735|Molecular Mechanisms of Pharmacological Action
1191348|NCT01190735|Pharmacologic Actions
1191349|NCT01190735|Central Nervous System Stimulants
1191350|NCT01190735|Physiological Effects of Drugs
1191351|NCT01190735|Central Nervous System Agents
1191352|NCT01190735|Therapeutic Uses
1191353|NCT01190722|Day case surgery
1191354|NCT01190722|postoperative pain
1191355|NCT01190722|NSAIDs
1191356|NCT01190722|Coxibs
1191357|NCT01190709|Close Fracture
1191358|NCT01190709|Tibia
1191359|NCT01190709|Unreamed Intramedullary Nailing
1191360|NCT01190709|Dynamic Compression Plate
1191361|NCT01190696|Spica Cast
1191362|NCT01190696|TEN
1191363|NCT01190696|Femoral Shaft Fracture
1191364|NCT01190696|Children
1191365|NCT01190670|ASP015K
1191366|NCT01190670|tacrolimus
1191367|NCT01190670|healthy volunteers
1191368|NCT01190657|Teprenone
1191369|NCT01190657|safety
1191370|NCT01190657|efficacy
1191371|NCT01190657|acute gastric lesion
1191372|NCT01190657|chronic gastritis
1191373|NCT01190644|Red Blood Cell Mass
1191374|NCT01190644|Plasma Volume
1191375|NCT01190644|Solid Tumors
1191376|NCT01190631|intraocular lens
1191377|NCT01190631|cataracts
1191378|NCT01190631|total residual spherical aberration
1191379|NCT01190631|high order aberrations
1191380|NCT01190605|HIV
1191381|NCT01190605|postpartum
1191382|NCT01190605|postpartum entry into HIV care
1191383|NCT01190592|Resistance training
1191384|NCT01190592|Body Composition
1191385|NCT01190592|Cardiovascular Risk factors
1191386|NCT01190592|Dairy
1191387|NCT01190579|Coronary Artery Disease
1191388|NCT01190579|Chest Pain
1191389|NCT01190579|Computed Tomography
1191390|NCT01190566|Magnetic Resonance Imaging, Functional
1191391|NCT01190566|Tomography, Positron-Emission
1191392|NCT01190566|chemotherapy
1191393|NCT01190553|amantadine
1191394|NCT01190553|parkinson disease
1191395|NCT01190553|dyskinesia
1191396|NCT01190540|On site support services.
1191397|NCT01190540|mid level health professionals.
1191398|NCT01190540|cost effectiveness.
1191399|NCT01190540|infectious disease.
1191400|NCT01190540|capacity building.
1191401|NCT01190514|DVS SR
1191402|NCT01190514|healthy
1191403|NCT01190514|Bioequivalence study
1191404|NCT01190501|blood pressure
1191405|NCT01190501|antihypertensive treatments
1191406|NCT01190488|End of life decision making
1191407|NCT01190488|End of life decision aid
1191408|NCT01190488|Palliative care decision making
1191409|NCT01190488|Palliative care decision aid
1191410|NCT01190488|Advanced care planning
1191411|NCT01190488|Decision Aid
1191412|NCT01190475|Endometriosis
1191413|NCT01190475|Infertility
1191414|NCT01190475|Pain
1191415|NCT01190475|Vaginal Diseases
1191416|NCT01190475|Uterine Diseases
1191417|NCT01190462|recurrent colon cancer
1191418|NCT01190462|stage III colon cancer
1191419|NCT01190462|stage IV colon cancer
1191420|NCT01190462|recurrent rectal cancer
1191421|NCT01190462|stage III rectal cancer
1191422|NCT01190462|stage IV rectal cancer
1191423|NCT01190449|stage III grade 1 follicular lymphoma
1191424|NCT01190449|stage III grade 2 follicular lymphoma
1191425|NCT01190449|stage III grade 3 follicular lymphoma
1191426|NCT01190449|stage IV grade 1 follicular lymphoma
1191427|NCT01190449|stage IV grade 2 follicular lymphoma
1191428|NCT01190449|stage IV grade 3 follicular lymphoma
1191429|NCT01190449|contiguous stage II grade 1 follicular lymphoma
1191430|NCT01190449|contiguous stage II grade 2 follicular lymphoma
1191431|NCT01190449|contiguous stage II grade 3 follicular lymphoma
1191432|NCT01190449|noncontiguous stage II grade 1 follicular lymphoma
1191433|NCT01190449|noncontiguous stage II grade 2 follicular lymphoma
1191434|NCT01190449|noncontiguous stage II grade 3 follicular lymphoma
1191435|NCT01190436|Hypertension
1191436|NCT01190436|Diabetes Mellitus
1191437|NCT01190436|Bisoprolol
1191438|NCT01190423|AN
1191439|NCT01190410|Certolizumab Pegol
1191440|NCT01190410|Cimzia®
1191441|NCT01190410|Crohn's Disease
1191442|NCT01190410|Children and Adolescents with Crohn's Disease
1191443|NCT01190397|Warming goggles
1191444|NCT01190384|Metabolic Syndrome
1191445|NCT01190384|Inflammation
1191446|NCT01190384|Antioxidants
1191447|NCT01190384|Satiety
1191448|NCT01190384|Fiber
1191449|NCT01190371|Artemisinin tolerance
1191450|NCT01190345|breast cancer
1191451|NCT01190332|common bile duct stones
1191452|NCT01190319|blood pressure
1191453|NCT01190319|strawberry
1191454|NCT01190319|fruit phenolics
1191455|NCT01190319|LDL oxidation
1191456|NCT01190319|Flow mediated dilation (FMD)
1191457|NCT01190254|Asenapine
1191458|NCT01190254|adolescents
1191459|NCT01190254|schizophrenia
1191460|NCT01190254|phase IIIb
1191461|NCT01190254|placebo-controlled
1191462|NCT01190241|targeted therapy
1191463|NCT01190241|individualized medicine
1191464|NCT01190241|tyrosine kinase inhibitor
1191465|NCT01190241|kinome profiling
1191466|NCT01190241|Metastasized
1191467|NCT01190228|Japanese Encephalitis
1191468|NCT01190228|Japanese encephalitis chimeric virus vaccine
1191469|NCT01190228|Varicella
1191470|NCT01190228|Varicella vaccine
1191471|NCT01190215|Influenza
1191472|NCT01190215|Pandemrix
1191473|NCT01190215|H1N1
1191474|NCT01190215|Fluarix
1191475|NCT01190202|Malaria
1191476|NCT01190202|Plasmodium falciparum
1191477|NCT01190189|Serious adverse events (SAEs)
1191478|NCT01190189|HPV vaccine
1191479|NCT01190189|Medically significant conditions
1191480|NCT01190189|Cervical neoplasia
1191481|NCT01190176|HPV
1191482|NCT01190176|HPV vaccine
1191483|NCT01190176|Cervical neoplasia
1191484|NCT01190176|Human papillomavirus
1191485|NCT01190176|Papillomavirus
1191486|NCT01190176|Cervical cancer
1191487|NCT01190176|Human papillomavirus (HPV) type 16/18 infections
1191488|NCT01190163|Vaginal Birth delivery within 24 hours and C-section rate
1191489|NCT01190150|Cyclic Heavy Menstrual Bleed
1191490|NCT01190150|Menorraghia
1191491|NCT01190137|Optimal vitamin D status
1191492|NCT01190137|25-hydroxy vitamin D
1191493|NCT01190137|Rickets and bone mineralization
1191494|NCT01190137|Breast fed infants
1191495|NCT01190137|Cholecalciferol and ergocalciferol
1191496|NCT01190124|HIV infections
1191497|NCT01190124|HIV-1
1191498|NCT01190124|HIV-2
1191499|NCT01190124|Acquired Immunodeficiency Syndrome
1191500|NCT01190124|AIDS
1191501|NCT01190124|Anti-Retroviral Agents
1191502|NCT01190124|Raltegravir
1191503|NCT01190124|Integrase Inhibitors
1191504|NCT01190124|multiple-experienced HIV infected patients
1191505|NCT01190111|interleukin-7
1191506|NCT01190111|immune-based therapy
1191507|NCT01190111|HIV
1191508|NCT01190111|viral disease
1191509|NCT01190098|Partial epilepsy
1191510|NCT01190098|Excessive daytime sleepiness
1191511|NCT01190098|Epworth Sleepiness Scale
1191512|NCT01190098|Maintenance of Wakefulness Test
1191513|NCT01190085|alcoholism
1191514|NCT01190085|ghrelin
1191515|NCT01190085|craving
1191516|NCT01190072|Blood lipids
1191517|NCT01190072|percutaneous coronary intervention
1191518|NCT01190072|lipid lowering treatment
1191519|NCT01190059|Lung
1191520|NCT01190059|Transplantation
1191521|NCT01190059|Lung Transplantation
1191522|NCT01190059|Transplantation Lung
1191523|NCT01190046|elderly
1191524|NCT01190046|muscle
1191525|NCT01190046|disuse
1191526|NCT01190046|osteoarthritis
1191527|NCT01190046|exercise
1191528|NCT01189994|Fibromyalgia
1191529|NCT01189994|Acupuncture
1191530|NCT01189994|Randomized Controlled Trial
1191531|NCT01189994|Pain
1191532|NCT01189994|Quality of Life
1191533|NCT01189968|Phase 1,
1191534|NCT01189968|dose escalation,
1191535|NCT01189968|histologically
1191536|NCT01189968|confirmed
1191537|NCT01189968|malignancy
1191538|NCT01189968|metastatic
1191539|NCT01189955|thyroidectomy
1191540|NCT01189955|harmonic
1191541|NCT01189955|RLN
1191542|NCT01189942|Phase 1
1191543|NCT01189942|dose escalation
1191544|NCT01189942|histologically
1191545|NCT01189942|confirmed
1191546|NCT01189942|malignancy
1191547|NCT01189942|metastatic
1191548|NCT01189929|Phase 1,
1191549|NCT01189929|dose escalation,
1191550|NCT01189929|histologically
1191551|NCT01189929|cytologically
1191552|NCT01189929|confirmed
1191553|NCT01189929|malignancy
1191554|NCT01189929|metastatic
1191555|NCT01189890|Type 2 Diabetes Mellitus, Hemoglobin A1C, glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), dipeptidyl peptidase 4 inhibitor (DPP-4)
1191556|NCT01189877|Direct pO2 Measurements
1191557|NCT01189877|10-121
1191558|NCT01189851|breast
1191559|NCT01189851|IORT
1191560|NCT01189851|electronic brachytherapy
1191561|NCT01189838|Cancer
1191562|NCT01189838|cysteine-rich 61
1191563|NCT01189838|prognosis
1191564|NCT01189838|transitional cell carcinoma
1191565|NCT01189825|Physiological
1191566|NCT01189825|Antidepressive Agents
1191567|NCT01189812|hopelessness
1191568|NCT01189812|alone
1191569|NCT01189812|sad
1191570|NCT01189812|troubled
1191571|NCT01189812|depression
1191572|NCT01189799|Co-occurring Disorders
1191573|NCT01189799|Depression
1191574|NCT01189799|Substance Dependence
1191575|NCT01189799|Motivational Therapy
1191576|NCT01189799|Aftercare
1191577|NCT01189799|Cognitive Behavioral Therapy
1191578|NCT01189786|Haploidentical Stem Cell Transplant
1191579|NCT01189786|CD34+ Selection
1191580|NCT01189786|CliniMACS CD34 Reagent system
1191581|NCT01189773|pain control
1191582|NCT01189773|limb trauma
1191583|NCT01189734|common bile duct stones
1191584|NCT01189734|laparoscopic common bile duct exploration
1191585|NCT01189734|intraoperative ercp
1191586|NCT01189734|Preoperatively diagnosed common bile duct stones
1191587|NCT01189721|remifentanil
1191588|NCT01189721|hyperalgesia
1191589|NCT01189708|Abdominal aortic aneurysm
1191590|NCT01189708|Abdominal hernia
1191591|NCT01189695|HIV or AIDS
1191592|NCT01189695|Lopinavir
1191593|NCT01189695|Ritonavir
1191594|NCT01189695|Anti-Retroviral Agents
1191595|NCT01189695|treatment failure
1191596|NCT01189695|treatment experienced
1191597|NCT01189695|NNRTI failure
1191598|NCT01189695|monotherapy
1191599|NCT01189682|catheter
1191600|NCT01189682|dressing
1191601|NCT01189682|chlorhexidine
1191602|NCT01189682|Patient admitted in ICU with a CVC or art. catheter
1191603|NCT01189669|PCOS
1191604|NCT01189656|Chronic hepatitis B patients
1191605|NCT01189643|BEVACIZUMAB (AVASTIN)
1191606|NCT01189643|IRINOTECAN (CPT-11) CAMPTOSAR
1191607|NCT01189643|TEMOZOLOMIDE
1191608|NCT01189643|DSRCT
1191609|NCT01189643|10-091
1191610|NCT01189630|"Real World Electronic Database with clinical information"
1191611|NCT01189630|related to Implantable Cardiac devices.
1191612|NCT01189617|Personal Lubricant
1191613|NCT01189604|propofol endoscopy sedation
1191614|NCT01189578|Recreational
1191615|NCT01189578|cocaine
1191616|NCT01189578|fMRI
1191617|NCT01189578|neuroimaging
1191618|NCT01189578|craving
1191619|NCT01189578|impulsivity
1191620|NCT01189565|Total Hip Replacement/Revision
1191621|NCT01189526|Branch retinal vein occlusion
1191622|NCT01189526|macular edema
1191623|NCT01189526|intravitreal injection
1191624|NCT01189526|ranibizumab
1191625|NCT01189513|Recurrent Glioblastoma
1191626|NCT01189513|Gliosarcoma
1191627|NCT01189513|SCH 900105
1191628|NCT01189500|Pharmacokinetic
1191629|NCT01189500|safety and tolerability
1191630|NCT01189500|genetic testing
1191631|NCT01189500|CYP 2D6
1191632|NCT01189487|ampicillin sodium/sulbactam sodium
1191633|NCT01189487|Unasyn-S
1191634|NCT01189487|community acquired pneumonia
1191635|NCT01189487|bacterial pneumonia
1191636|NCT01189474|Meibomian Gland Dysfunction
1191637|NCT01189461|pegaptanib sodium
1191638|NCT01189461|diabetic macular edema
1191639|NCT01189448|Congenital Toxoplasmosis,
1191640|NCT01189448|Pregnancy,
1191641|NCT01189448|prenatal diagnosis,
1191642|NCT01189448|mother-to-child transmission,
1191643|NCT01189448|prevention,
1191644|NCT01189448|spiramycine,
1191645|NCT01189448|pyrimethamine-sulfadiazine
1191646|NCT01189435|OSI-774, TARCEVA (ERLOTINIB)
1191647|NCT01189435|Lung
1191648|NCT01189435|recurrent
1191649|NCT01189435|10-097
1191650|NCT01189435|Gefitinib
1191651|NCT01189422|Type 1 Diabetes Mellitus
1191652|NCT01189422|T1DM
1191653|NCT01189409|Constipation
1191654|NCT01189409|Opioids
1191655|NCT01189409|Cancer
1191656|NCT01189409|Polyethylene glycol
1191657|NCT01189409|Sennosides
1191658|NCT01189409|Opioid Therapy
1191659|NCT01189396|asthma
1191660|NCT01189396|bronchospasm
1191661|NCT01189396|COPD
1191662|NCT01189396|reversibility
1191663|NCT01189396|efficacy
1191664|NCT01189383|Melanoma
1191665|NCT01189383|Vaccine
1191666|NCT01189383|Dendritic Cell
1191667|NCT01189383|Immune response
1191668|NCT01189383|Safety
1191669|NCT01189383|Efficacy
1191670|NCT01189370|carcinoma, renal cell
1191671|NCT01189370|kidney
1191672|NCT01189370|cancer
1191673|NCT01189357|meniscal transplant
1191674|NCT01189344|Obesity
1191675|NCT01189344|LT4
1191676|NCT01189344|Absorption
1191677|NCT01189344|Thyroid function
1191678|NCT01189331|Coronary artery disease
1191679|NCT01189331|CT
1191680|NCT01189331|Computational flow dynamics
1191681|NCT01189305|Drug Abuse
1191682|NCT01189305|Female Patients
1191683|NCT01189292|postoperative nausea and vomitus
1191684|NCT01189292|PONV
1191685|NCT01189292|thyroid surgery
1191686|NCT01189253|stage III adult soft tissue sarcoma
1191687|NCT01189253|stage IV adult soft tissue sarcoma
1191688|NCT01189253|adult alveolar soft-part sarcoma
1191689|NCT01189253|adult angiosarcoma
1191690|NCT01189253|adult desmoplastic small round cell tumor
1191691|NCT01189253|adult epithelioid sarcoma
1191692|NCT01189253|adult extraskeletal chondrosarcoma
1191693|NCT01189253|adult extraskeletal osteosarcoma
1191694|NCT01189253|adult fibrosarcoma
1191695|NCT01189253|adult leiomyosarcoma
1191696|NCT01189253|adult malignant fibrous histiocytoma
1191697|NCT01189253|adult malignant hemangiopericytoma
1191698|NCT01189253|adult malignant mesenchymoma
1191699|NCT01189253|adult neurofibrosarcoma
1191700|NCT01189253|adult synovial sarcoma
1191701|NCT01189227|stage IV colon cancer
1191702|NCT01189227|adenocarcinoma of the colon
1191703|NCT01189227|stage IV rectal cancer
1191704|NCT01189227|adenocarcinoma of the rectum
1191705|NCT01189227|liver metastases
1191706|NCT01189162|Primary treatment of RDS and treatment of RDS post extubation
1191707|NCT01189136|Voiding dysfunction
1191708|NCT01189123|influenza
1191709|NCT01189123|vaccine
1191710|NCT01189123|cell mediated immunity
1191711|NCT01189123|elderly
1191712|NCT01189123|high dose influenza vaccine
1191713|NCT01189110|smoking cessation
1191714|NCT01189110|veterans
1191715|NCT01189110|auriculotherapy
1191716|NCT01189084|Alzheimer's disease
1191717|NCT01189084|amyloid beta
1191718|NCT01189084|vaccine
1191719|NCT01189071|Stents [E07.695.750]
1191720|NCT01189071|Darifenacin (C101207)
1191721|NCT01189071|Kidney calculi
1191722|NCT01189058|Perinatal stroke
1191723|NCT01189058|Periventricular venous infarction
1191724|NCT01189058|Presumed perinatal stroke
1191725|NCT01189058|Neonatal stroke
1191726|NCT01189058|Arterial ischemic stroke
1191727|NCT01189058|Fetal stroke
1191728|NCT01189058|Transcranial magnetic stimulation
1191729|NCT01189058|Constraint-induced movement therapy
1191730|NCT01189058|CIMT
1191731|NCT01189058|Cerebral palsy
1191732|NCT01189058|Congenital hemiplegia
1191733|NCT01189058|Hemiplegic cerebral palsy
1191734|NCT01189058|Neuroplasticity
1191735|NCT01189058|Developmental plasticity
1191736|NCT01189045|Stroke
1191737|NCT01189045|Exercise
1191738|NCT01189045|Rehabilitation
1191739|NCT01189045|Risk factors
1191740|NCT01189019|ranibizumab
1191741|NCT01189019|Wet macular degeneration
1191742|NCT01189019|macular degeneration
1191743|NCT01189019|PED
1191744|NCT01189019|Retinal Pigment Epithelial Detachment
1191745|NCT01188967|Drugs, Investigational
1191746|NCT01188967|Nicotine Dependence
1191747|NCT01188967|Therapies for Relapse to Nicotine
1191748|NCT01188967|Relapse Prevention
1191749|NCT01188967|Smoking Cessation
1191750|NCT01188967|Nicotine Cessation Therapies
1191751|NCT01188954|Seroma
1191752|NCT01188954|Doxycycline
1191753|NCT01188954|Cardiopulmonary By-Pass
1191754|NCT01188954|Femoral Artery/Vein Cannulation
1191755|NCT01188954|Prevent Seroma Formation
1191756|NCT01188915|Hodgkin disease
1191757|NCT01188915|Breast cancer
1191758|NCT01188889|Chronic Myeloid Leukemia
1191759|NCT01188876|carboplatin
1191760|NCT01188876|recurrent
1191761|NCT01188876|platinum sensitive
1191762|NCT01188876|pralatrexate
1191763|NCT01188850|CIN 2 or 3
1191764|NCT01188850|cervical cancer
1191765|NCT01188850|Human Papillomavirus (HPV)
1191766|NCT01188837|Osteoarthritis, Knee
1191767|NCT01188837|Manipulation Therapy
1191768|NCT01188811|Multiple Sclerosis
1191769|NCT01188811|Multiple sclerosis, chronic progressive
1191770|NCT01188811|Neuroprotective agents
1191771|NCT01188811|Magnetic resonance imaging
1191772|NCT01188811|Optical coherence tomography
1191773|NCT01188811|Gait
1191774|NCT01188811|Thioctic acid
1191775|NCT01188811|Alpha-lipoic acid
1191776|NCT01188798|Allogeneic Bone Marrow Transplantation
1191777|NCT01188798|Graft versus host disease
1191778|NCT01188798|Tacrolimus
1191779|NCT01188798|Sirolimus
1191780|NCT01188798|Methotrexate
1191781|NCT01188798|Pentostatin
1191782|NCT01188785|siRNA
1191783|NCT01188785|RNA interference (RNAi)
1191784|NCT01188785|Cancer
1191785|NCT01188785|Pancreatic ductal adenocarcinoma
1191786|NCT01188785|Pancreatic cancer
1191787|NCT01188785|Solid tumor
1191788|NCT01188785|Operable pancreatic ductal adenocarcinoma
1191789|NCT01188785|Non operable pancreatic ductal adenocarcinoma
1191790|NCT01188772|Hepatitis C Virus
1191791|NCT01188772|HCV
1191792|NCT01188772|hepatitis
1191793|NCT01188772|Genotype 1
1191794|NCT01188772|Genotype 2
1191795|NCT01188772|Genotype 3
1191796|NCT01188759|Aspergillosis
1191797|NCT01188759|Combination Therapy
1191798|NCT01188759|Voriconazole
1191799|NCT01188759|Anidulafungin
1191800|NCT01188746|catheter
1191801|NCT01188746|palliative
1191802|NCT01188746|quality of life
1191803|NCT01188746|10-059
1191804|NCT01188733|portal hypertension
1191805|NCT01188733|varices
1191806|NCT01188733|cirrhosis
1191807|NCT01188733|octreotide
1191808|NCT01188733|somatostatin analog
1191809|NCT01188733|Child Pugh Class A,B
1191810|NCT01188707|Non small cell lung cancer
1191811|NCT01188707|Belinostat
1191812|NCT01188707|Erlotinib
1191813|NCT01188707|HDAC inhibitor
1191814|NCT01188707|Phase I/II
1191820|NCT01188668|Pharmacokinetic
1191821|NCT01188668|safety and tolerability
1191822|NCT01188668|genetic testing
1191823|NCT01188668|CYP 2D6 and CYP 3A4
1191824|NCT01188655|Ankylosing Spondylitis
1191825|NCT01188642|childhood obesity
1191826|NCT01188642|adipocytokines
1191827|NCT01188642|physical exercise
1191828|NCT01188642|nutrition education
1191829|NCT01188629|Preventive Care
1191830|NCT01188629|Medication Management
1191831|NCT01188629|Electronic Medical Records
1191832|NCT01188629|Automated Telephone System
1191833|NCT01188616|Childhood Obesity
1191834|NCT01188616|Obesity Intervention
1191835|NCT01188590|Post operative Respiratory insufficiency
1191836|NCT01188577|asthma
1191837|NCT01188577|bronchospasm
1191838|NCT01188577|wheezing
1191839|NCT01188577|shortness of breath
1191840|NCT01188564|Hereditary Angioedema
1191841|NCT01188564|HAE
1191842|NCT01188564|Angioedema
1191843|NCT01188564|Recombinant C1 Inhibitor
1191844|NCT01188564|rhC1INH
1191845|NCT01188551|myringotomy
1191846|NCT01188551|pressure equalization tubes
1191847|NCT01188538|P. acnes, Acne vulgaris
1191848|NCT01188525|pharmacokinetics
1191849|NCT01188525|enzymes
1191850|NCT01188525|metabolism prediction
1191851|NCT01188512|Live nasal vaccine for prevention of pertussis
1191852|NCT01188473|Status Asthmaticus
1191853|NCT01188473|Noninvasive Positive Pressure Ventilation
1191854|NCT01188473|Asthma in Children
1191855|NCT01188460|Insomnia
1191856|NCT01188460|Chronic pain
1191857|NCT01188447|cervical-spine injuries
1191858|NCT01188447|cervical-spine fractures
1191859|NCT01188447|spinal cord injury
1191860|NCT01188447|neck injury
1191861|NCT01188447|Canadian C-Spine Rule
1191862|NCT01188447|paramedics
1191863|NCT01188447|emergency medical services
1191864|NCT01188434|Methamphetamine
1191865|NCT01188434|Substance Abuse
1191866|NCT01188434|Child Neglect
1191867|NCT01188434|Child Welfare
1191868|NCT01188434|Evidence Based Practice
1191869|NCT01188382|Intracranial pressure
1191870|NCT01188382|resistance
1191871|NCT01188382|CSF outflow
1191872|NCT01188382|elderly
1191873|NCT01188382|reference value
1191874|NCT01188369|levosimendan
1191875|NCT01188369|heart failure
1191876|NCT01188369|inotropics
1191877|NCT01188369|diastolic dysfunction
1191878|NCT01188369|left ventricular hypertrophy
1191879|NCT01188369|aortic valve stenosis
1191880|NCT01188356|Reply
1191881|NCT01188356|Symphony
1191882|NCT01188356|Atrial arrhythmias
1191883|NCT01188356|V pacing
1191884|NCT01188356|Evaluate the incidence and evolution over-time of co-morbidities
1191885|NCT01188343|Japanese Encephalitis
1191886|NCT01188343|Japanese encephalitis chimeric virus vaccine
1191887|NCT01188343|Measles
1191888|NCT01188343|Mumps
1191889|NCT01188343|Rubella
1191890|NCT01188330|acute myeloid leukemia
1191891|NCT01188291|Optical Coherence Tomography
1191892|NCT01188291|Retinal Nerve Fiber Layer Thickness
1191893|NCT01188291|Obstructive Sleep Apnea
1191894|NCT01188291|Hypopnea syndrome
1191895|NCT01188291|Glaucoma
1191896|NCT01188252|Phase I
1191897|NCT01188252|Dose escalation
1191898|NCT01188252|Kinase inhibitor
1191899|NCT01188252|Cyclin-dependent kinases
1191900|NCT01188239|electronic cigarette
1191901|NCT01188239|nicotine
1191902|NCT01188239|smoking cessation
1191903|NCT01188239|smoking reduction
1191904|NCT01188187|custirsen sodium
1191905|NCT01188187|prostate cancer
1191906|NCT01188187|overall survival
1191907|NCT01188187|Metastatic Castrate Resistant Prostate Cancer
1191908|NCT01188174|AML
1191909|NCT01188174|primary induction failure
1191910|NCT01188161|Posturography
1191911|NCT01188161|Balance
1191912|NCT01188161|Falls
1191913|NCT01188161|Gyroscope
1191914|NCT01188161|Rotational Chair
1191915|NCT01188161|Vestibular
1191916|NCT01188161|Movement Disorders
1191917|NCT01188135|depression
1191918|NCT01188135|interactive voice messaging
1191919|NCT01188135|patient persistence with antidepressant medication treatment
1191920|NCT01188122|VAP
1191921|NCT01188109|Pancreatic Neoplasms
1191922|NCT01188109|Pancreatic cancer
1191923|NCT01188096|glioma
1191924|NCT01188096|pediatrics
1191925|NCT01188096|cancer
1191926|NCT01188096|brain tumor
1191927|NCT01188083|NASH
1191928|NCT01188083|non-alcoholic fatty-liver disease
1191929|NCT01188083|Hispanic
1191930|NCT01188083|overweight
1191931|NCT01188070|Behavioral/Social
1191932|NCT01188070|Cardiology
1191933|NCT01188070|Clinical Laboratory Methods
1191934|NCT01188070|Congestive Heart Failure
1191935|NCT01188070|Heart Disease
1191936|NCT01188070|Knowledge Dissemination
1191937|NCT01188070|Lipids
1191938|NCT01188070|Nursing
1191939|NCT01188070|Health Promotion
1191940|NCT01188070|Alzheimer's Disease/Dementia
1191941|NCT01188057|Bioequivalence
1191942|NCT01188057|ALPRAZOLAM
1191943|NCT01188057|Healthy subjects
1191944|NCT01188044|Motor activity
1191945|NCT01188044|Infant
1191946|NCT01188044|Validation studies
1191947|NCT01188044|Malawi
1191948|NCT01188044|Sub-Saharan Africa
1191949|NCT01188031|Bioequivalence
1191950|NCT01188031|ALPRAZOLAM
1191951|NCT01188031|Healthy subjects
1191952|NCT01188018|Smoking
1191953|NCT01188018|Smoking Cessation
1191954|NCT01188018|Nicotine Dependence
1191955|NCT01188018|Tobacco Use Cessation
1191956|NCT01188018|Health Education
1191957|NCT01188018|Patient Education
1191958|NCT01188005|OSAS
1191959|NCT01188005|Sleep Apnoea
1191960|NCT01188005|IL6
1191961|NCT01188005|TNFα
1191962|NCT01188005|Oxidative Stress
1191963|NCT01188005|Antioxidants
1191964|NCT01187992|Atorvastatin
1191965|NCT01187992|Acute coronary syndrome
1191966|NCT01187992|Advanced coronary artery disease
1191967|NCT01187979|Cash incentive
1191968|NCT01187979|HIV prevention
1191969|NCT01187979|Adolescents
1191970|NCT01187979|South Africa
1191971|NCT01187979|HIV
1191972|NCT01187966|Parkinson's Disease
1191973|NCT01187966|PD
1191974|NCT01187966|Levodopa
1191975|NCT01187966|Patients with idiopathic Parkinson's disease with motor fluctuations
1191976|NCT01187953|Tacrolimus
1191977|NCT01187953|Acute Rejection
1191978|NCT01187953|Kidney
1191979|NCT01187940|Autism Spectrum Disorder;
1191980|NCT01187940|Psychoeducation
1191981|NCT01187914|Paroxysmal Atrial Fibrillation
1191982|NCT01187914|Radio-frequency Ablation
1191983|NCT01187914|Ablation
1191984|NCT01187914|Open irrigation cooled-tip
1191985|NCT01187901|Familial Adenomatous Polyposis
1191986|NCT01187901|Attenuated Familial Polyposis
1191987|NCT01187888|PSP
1191988|NCT01187888|Progressive Supranuclear Palsy
1191989|NCT01187888|Rasagiline
1191990|NCT01187888|Azilect
1191991|NCT01187888|PROSPERA
1191992|NCT01187875|satiety, dietary fiber
1191993|NCT01187823|Chronic heart failure
1191994|NCT01187823|Central sleep apnea
1191995|NCT01187823|Obstructive sleep apnea
1191996|NCT01187823|Adaptive servo ventilation
1191997|NCT01187810|leukemia,lymphoma
1191998|NCT01187758|antibiotic use
1191999|NCT01187758|antibiotic prescription
1192000|NCT01187758|antibiotic resistant S. pneumoniae
1192001|NCT01187758|MRSA
1192002|NCT01187745|renal calculi
1192003|NCT01187732|skin damage
1192004|NCT01187732|intertrigo
1192005|NCT01187732|dermatitis
1192006|NCT01187732|erythema
1192007|NCT01187732|aggression
1192008|NCT01187732|body Wipes
1192009|NCT01187732|soaps
1192010|NCT01187732|no rinse
1192011|NCT01187732|cost effectiveness
1192012|NCT01187732|nursing home residents
1192013|NCT01187732|nurse
1192014|NCT01187719|HIV
1192015|NCT01187719|pregnancy
1192016|NCT01187719|phenytoin
1192017|NCT01187719|ARV prophylaxis
1192018|NCT01187719|nevirapine
1192019|NCT01187706|gynecological cancer survivors
1192020|NCT01187706|quality of life
1192021|NCT01187680|Tissue adhesions
1192022|NCT01187680|Laparoscopy
1192023|NCT01187667|delirium
1192024|NCT01187667|prevention
1192025|NCT01187667|critical care
1192026|NCT01187667|haloperidol
1192027|NCT01187654|myocardial infarction
1192028|NCT01187654|bone marrow stem cell
1192029|NCT01187654|AC133
1192030|NCT01187654|mono nuclear cell
1192032|NCT01187628|Long-term study in Chronic Kidney Disease
1192033|NCT01187628|Lanthanum Carbonate
1192034|NCT01187615|Nonsquamous Non-small cell lung cancer
1192035|NCT01187615|Phase I
1192036|NCT01187576|Physical activity
1192037|NCT01187576|Hypertension
1192038|NCT01187576|Diabetes mellitus
1192039|NCT01187576|Motivational interviewing
1192040|NCT01187563|Rheumatoid arthritis, tocilizumab
1192041|NCT01187550|Dwarfism, pituitary
1192042|NCT01187550|Growth hormone
1192043|NCT01187537|Knee Replacement
1192044|NCT01187537|Analgesia
1192045|NCT01187537|Analgesics
1192046|NCT01187537|Nerve blocks
1192047|NCT01187537|Recovery of functions
1192048|NCT01187537|Post operative analgesia
1192049|NCT01187524|Patient Registry
1192050|NCT01187524|FMR1 Gene
1192051|NCT01187524|Fragile X Syndrome
1192052|NCT01187524|Primary Ovarian Insufficiency
1192053|NCT01187524|Premature Ovarian Failure
1192054|NCT01187524|Premature Ovarian Insufficiency
1192055|NCT01187511|Addiction
1192056|NCT01187511|Alcohol Dependence
1192057|NCT01187511|Anxiety
1192058|NCT01187511|CRH Antagonist
1192059|NCT01187511|Stress Induced Craving
1192060|NCT01187498|Overactive bladder
1192061|NCT01187498|Behavioral treatment
1192062|NCT01187498|Drug therapy
1192063|NCT01187498|Lower urinary tract symptoms
1192064|NCT01187498|Urinary incontinence
1192065|NCT01187498|Clinical trial
1192066|NCT01187485|Androderm®
1192067|NCT01187485|Testosterone
1192068|NCT01187485|refractory
1192069|NCT01187485|prostate
1192070|NCT01187485|cancer
1192071|NCT01187485|"Patients with hormone refractory prostate cancer will be treated with a daily testosterone patch Androderm® applied every 24 hours to the skin"
1192072|NCT01187472|Head
1192073|NCT01187472|neck
1192074|NCT01187472|cancer
1192075|NCT01187472|advanced
1192076|NCT01187472|oral cavity
1192077|NCT01187472|lip
1192078|NCT01187472|larynx
1192079|NCT01187459|Vitamin D
1192080|NCT01187459|Crohn's Disease
1192081|NCT01187459|Dose Response
1192082|NCT01187446|Cutaneous T-cell Lymphoma
1192083|NCT01187433|Dengue
1192084|NCT01187433|Dengue hemorrhagic fever
1192085|NCT01187433|CYD Dengue Vaccines
1192086|NCT01187420|Cerebral vasospasm
1192087|NCT01187420|delayed cerebral ischemia (DCI)
1192088|NCT01187420|subarachnoid hemorrhage (SAH) patients
1192089|NCT01187394|Frozen Plasma
1192090|NCT01187394|Fresh Frozen Plasma
1192091|NCT01187394|Cardiac Surgery
1192092|NCT01187394|Bleeding
1192093|NCT01187394|Knowledge Translation
1192094|NCT01187368|heart failure
1192095|NCT01187368|LVAS
1192096|NCT01187368|LVAD
1192097|NCT01187368|bridge-to-transplant
1192098|NCT01187368|rotary pump
1192099|NCT01187355|Symptomatic, Contact lens care
1192100|NCT01187355|Multi-purpose solution
1192101|NCT01187342|Stroke
1192102|NCT01187329|Hyperglycemia
1192103|NCT01187329|open heart surgery
1192104|NCT01187329|bypass
1192105|NCT01187316|Facial Pain
1192106|NCT01187316|Temporomandibular Joint Disorders
1192107|NCT01187316|Transcutaneous Electric Nerve Stimulation
1192108|NCT01187316|Adolescent
1192109|NCT01187290|Preoperative chemoradiotherapy
1192110|NCT01187290|stage IIIA, N2
1192111|NCT01187277|stroke
1192112|NCT01187277|rehabilitation
1192113|NCT01187277|gait training
1192114|NCT01187277|robot-assisted therapy
1192115|NCT01187251|tinnitus
1192116|NCT01187251|mp3 players
1192117|NCT01187251|noise induced hearing loss
1192118|NCT01187251|high frequencies audiometry
1192119|NCT01187251|acoustic otoemissions
1192120|NCT01187238|Nasopharyngeal carcinoma
1192121|NCT01187238|Stage II
1192122|NCT01187238|Intensity-modulated radiotherapy
1192123|NCT01187238|Concurrent chemoradiotherapy
1192124|NCT01187238|Cisplatin
1192125|NCT01187225|Cardiac surgical procedures
1192126|NCT01187225|Fibrinogen
1192127|NCT01187225|Bleeding
1192128|NCT01187225|Cryoprecipitate
1192129|NCT01187212|First line chemotherapy in advanced gastric cancer
1192130|NCT01187199|Metastatic cancer
1192131|NCT01187199|Chemotherapy
1192132|NCT01187199|Avastin
1192133|NCT01187199|Carboplatin
1192134|NCT01187199|Paclitaxel
1192135|NCT01187199|Sorafenib
1192136|NCT01187199|Temsirolimus
1192137|NCT01187186|Liver disease
1192138|NCT01187186|ASP1941
1192139|NCT01187160|Obstructive sleep apnea
1192140|NCT01187147|Asthma, green tea, antioxidants
1192141|NCT01187134|sepsis
1192142|NCT01187134|shock, septic
1192143|NCT01187134|quality assurance, health care
1192144|NCT01187134|quality control
1192145|NCT01187134|Survival Rate
1192146|NCT01187134|Follow-Up Studies
1192147|NCT01187134|Anti-Infective Agents/*therapeutic use
1192148|NCT01187121|Graduated Sanctions
1192149|NCT01187121|Probationary failure
1192150|NCT01187121|recidivism
1192151|NCT01187121|drug relapse
1192152|NCT01187121|criminal justice
1192153|NCT01187108|Cobalt
1192154|NCT01187108|Excessive Erythrocytosis
1192155|NCT01187108|Monge's Disease
1192156|NCT01187108|Acetazolamide
1192157|NCT01187108|N-acetylcysteine
1192158|NCT01187108|Altitude Sickness
1192159|NCT01187108|Chronic Mountain Sickness
1192160|NCT01187095|Involuntary childlessness
1192161|NCT01187095|Infertility
1192162|NCT01187095|IVF
1192163|NCT01187095|EWI
1192164|NCT01187095|Couples in IVF treatment
1192165|NCT01187095|Psychosocial intervention
1192166|NCT01187082|overactive bladder
1192167|NCT01187082|women
1192168|NCT01187082|bladder training
1192169|NCT01187082|groups
1192170|NCT01187069|Motivation
1192171|NCT01187069|patients with type 2 diabetes
1192172|NCT01187069|practice nurses
1192173|NCT01187069|general practice
1192174|NCT01187069|Self-determination Theory
1192175|NCT01187056|Shared decision-making
1192176|NCT01187056|Risk information
1192177|NCT01187056|Decision aids
1192178|NCT01187043|Liver Function
1192179|NCT01187043|Steady State Exposure
1192180|NCT01187030|Frozen Plasma
1192181|NCT01187030|Fresh Frozen Plasma
1192182|NCT01187030|Prothrombin Complex Concentrates
1192183|NCT01187030|RAND UCLA
1192184|NCT01187030|Modified Delphi Methodology
1192185|NCT01187030|Expert Panel
1192186|NCT01187030|Appropriateness Rating
1192187|NCT01187017|Severe Aplastic Anemia
1192188|NCT01187017|Aplastic Anemia
1192189|NCT01187017|Immunosuppression
1192190|NCT01187017|Immunosuppressive Therapy
1192191|NCT01187017|T-Cells
1192192|NCT01186965|Diabetes
1192193|NCT01186965|Second Life
1192194|NCT01186965|virtual community
1192195|NCT01186965|diabetes education
1192196|NCT01186965|diabetes support group
1192197|NCT01186952|overweight
1192198|NCT01186952|obesity
1192199|NCT01186952|type 2 diabetes
1192200|NCT01186952|caloric restriction
1192201|NCT01186952|exercise program
1192202|NCT01186952|epicardial fat
1192203|NCT01186939|Myelodysplastic Syndromes
1192204|NCT01186939|MDS
1192205|NCT01186926|Obstructive sleep apnea
1192206|NCT01186926|OSA
1192207|NCT01186926|hypoglossal nerve stimulation
1192208|NCT01186926|sleep apnea
1192209|NCT01186900|skin abscess
1192210|NCT01186900|needle aspiration
1192211|NCT01186900|incision and drainage
1192212|NCT01186887|primary ACL reconstruction with a hamstring graft
1192213|NCT01186861|NSCLC
1192214|NCT01186861|Erlotinib
1192215|NCT01186861|OSI-906
1192216|NCT01186861|Placebo
1192217|NCT01186861|Platinum-based chemotherapy
1192218|NCT01186848|Stretch marks
1192219|NCT01186848|Striae distensae
1192220|NCT01186809|hematologic malignancies (excluding Chronic Myeloid Leukemia)
1192221|NCT01186796|Women
1192222|NCT01186796|Fulvestrant Study
1192223|NCT01186796|Post Menopausal Women
1192224|NCT01186796|Hormones
1192225|NCT01186796|Healthy Adult Women
1192226|NCT01186783|heart rate
1192227|NCT01186783|multiple organ dysfunction syndrome
1192228|NCT01186783|ivabradine
1192229|NCT01186783|sepsis
1192230|NCT01186783|cardiogenic shock
1192231|NCT01186770|Treatment of Opioid-Induced Constipation in Subjects with Chronic, Non-Malignant Pain
1192232|NCT01186744|OPT Retreatment
1192233|NCT01186744|OPT
1192234|NCT01186744|chronic
1192235|NCT01186744|moderate
1192236|NCT01186744|severe
1192237|NCT01186744|treatment
1192238|NCT01186744|safety
1192239|NCT01186744|treatment withdrawal
1192240|NCT01186744|retreatment
1192241|NCT01186744|retreatment withdrawal
1192242|NCT01186744|CP-690,550
1192243|NCT01186744|Psoriasis Vulgaris
1192244|NCT01186744|Plaque Psoriasis
1192245|NCT01186744|tofacitinib
1192246|NCT01186744|Xeljanz
1192247|NCT01186744|nail psoriasis
1192248|NCT01186744|Jak-inhibitor
1192249|NCT01186744|oral treatment
1192250|NCT01186744|Pruritus
1192251|NCT01186744|Itch
1192252|NCT01186744|DLQI
1192253|NCT01186744|rebound
1192254|NCT01186744|intermittent
1192255|NCT01186744|retreat
1192256|NCT01186731|SPARC (secreted protein acid rich in cysteine)
1192257|NCT01186731|serum Carbohydrate Antigen CA 19-9
1192258|NCT01186718|Cervical, motions, kinematics
1192259|NCT01186705|MK-2206
1192260|NCT01186705|colon
1192261|NCT01186705|rectal
1192262|NCT01186705|10-068
1192263|NCT01186666|Atherosclerosis
1192264|NCT01186666|Vulnerable plaque
1192265|NCT01186666|Intravascular ultrasound
1192266|NCT01186666|Virtual histology
1192267|NCT01186666|Fluorodeoxyglucose
1192268|NCT01186666|Positron emission tomography
1192269|NCT01186666|Multidetector computed tomography
1192270|NCT01186640|T-PLL
1192271|NCT01186640|Polychemotherapy
1192272|NCT01186640|Alemtuzumab
1192273|NCT01186640|Efficacy
1192274|NCT01186627|Neurodevelopmental Impairment
1192275|NCT01186627|Intraventricular hemorrhage
1192276|NCT01186627|Retinopathy of prematurity
1192277|NCT01186627|Mortality
1192278|NCT01186627|Apgar Score
1192279|NCT01186614|cardiac arrest
1192280|NCT01186614|ECMO
1192281|NCT01186614|hypothermia
1192282|NCT01186614|automated CPR
1192283|NCT01186614|coronary intervention
1192284|NCT01186601|Prostatic Neoplasms
1192285|NCT01186601|Colorectal Neoplasms
1192286|NCT01186601|Head and Neck Neoplasms
1192287|NCT01186601|Melanoma
1192288|NCT01186601|Neoplasm Metastasis
1192289|NCT01186588|Canagliflozin
1192290|NCT01186588|JNJ-28431754
1192291|NCT01186588|Liver diseases
1192292|NCT01186588|Hepatic impairment
1192293|NCT01186588|Pharmacokinetic
1192294|NCT01186588|Normal hepatic function
1192295|NCT01186575|HIV Infections
1192296|NCT01186575|Acquired Immunodeficiency Syndrome
1192297|NCT01186575|Circumcision, Male
1192298|NCT01186575|Coitus
1192299|NCT01186575|Patient Compliance
1192300|NCT01186575|Cellular Phone
1192301|NCT01186562|Pancreatitis
1192302|NCT01186562|Pancreatectomy
1192303|NCT01186562|Islet autotransplant
1192304|NCT01186562|Sitagliptin
1192305|NCT01186562|Diabetes
1192306|NCT01186549|propofol
1192307|NCT01186549|ephedrine
1192308|NCT01186549|pain
1192309|NCT01186536|Whey Protein
1192310|NCT01186536|Soy Protein
1192311|NCT01186536|Resistance training
1192312|NCT01186536|Weight Management
1192313|NCT01186523|Obesity
1192314|NCT01186523|Weight Management
1192315|NCT01186523|Physical Activity
1192316|NCT01186497|Healthy
1192317|NCT01186497|Rabeprazole sodium
1192318|NCT01186497|Rabeprazole sprinkle capsule granule formulation
1192319|NCT01186497|Pharmacokinetics
1192320|NCT01186497|Bioavailability
1192321|NCT01186497|Safety
1192322|NCT01186497|Adult
1192323|NCT01186484|Castration-resistant prostate cancer
1192324|NCT01186484|Abiraterone acetate
1192325|NCT01186484|JNJ-212082
1192326|NCT01186471|Symptomatic treatment
1192327|NCT01186471|Cognition
1192328|NCT01186471|Cognitive deficits
1192329|NCT01186471|Schizophrenia
1192330|NCT01186445|Acute Myocardial Infarction
1192331|NCT01186445|Cardioprotective effect
1192332|NCT01186445|Pharmacological postconditioning
1192333|NCT01186445|Morphine Chlorhydrate
1192334|NCT01186445|Cardiac MRI
1192335|NCT01186419|Beta-thalassemia
1192336|NCT01186419|Sickle cell anemia
1192337|NCT01186419|Transfusional iron overload
1192338|NCT01186419|Iron overload
1192339|NCT01186419|Iron chelation
1192340|NCT01186406|glioblastoma multiforme
1192341|NCT01186406|gliosarcoma
1192342|NCT01186406|malignant glioma
1192343|NCT01186406|glioma
1192344|NCT01186406|Gliadel
1192345|NCT01186406|carmustine wafers
1192346|NCT01186406|Avastin
1192347|NCT01186406|bevacizumab
1192348|NCT01186406|Temodar
1192349|NCT01186406|temozolomide
1192350|NCT01186406|Pro00025180
1192351|NCT01186406|Desjardins
1192352|NCT01186406|Duke
1192353|NCT01186406|Preston Robert Tisch Brain Tumor Center
1192354|NCT01186393|Weight Loss
1192355|NCT01186393|Potatoes
1192356|NCT01186393|Dietary Meetings
1192357|NCT01186393|Glycemic Control
1192358|NCT01186380|TEE
1192359|NCT01186380|Transesophageal
1192360|NCT01186380|Transducer
1192361|NCT01186380|Esophagus
1192362|NCT01186380|Ease of passage and during transitioning into and down the esophagus to complete a normal TEE study
1192363|NCT01186367|breast cancer
1192364|NCT01186367|Linear Versus Nonlinear Aerobic Training
1192365|NCT01186367|15-147
1192366|NCT01186354|Type 2 diabetes
1192367|NCT01186354|health literacy
1192368|NCT01186354|genetic literacy
1192369|NCT01186354|genetic risk
1192370|NCT01186341|Chronic Pain
1192371|NCT01186328|Relapse
1192372|NCT01186328|T cell
1192373|NCT01186328|Lymphoblastic
1192374|NCT01186328|Leukemia
1192375|NCT01186328|EZN3042
1192376|NCT01186328|Refractory
1192377|NCT01186328|Precursor B
1192378|NCT01186328|Pre B cell
1192379|NCT01186328|Survivan
1192380|NCT01186328|Acute
1192381|NCT01186328|Childhood
1192382|NCT01186328|Pediatric
1192383|NCT01186315|Addiction
1192384|NCT01186315|Posttraumatic Stress
1192385|NCT01186315|substance abuse and posttraumatic stress
1192386|NCT01186302|medical abortion
1192387|NCT01186302|Nepal
1192388|NCT01186302|midlevel providers
1192389|NCT01186289|Neurocognitive Dysfunction
1192390|NCT01186263|liver metastases
1192391|NCT01186263|MAA
1192392|NCT01186263|B20
1192393|NCT01186263|SIR spheres
1192394|NCT01186263|SPECT
1192395|NCT01186263|intra-hepatic distribution
1192396|NCT01186250|cardiac allograft vasculopathy
1192397|NCT01186250|pioglitazone
1192398|NCT01186250|insulin resistance
1192399|NCT01186250|heart transplant
1192400|NCT01186237|Colon/Rectal Cancer Rectal Cancer
1192401|NCT01186237|Quality of Life
1192402|NCT01186211|knee, joint
1192403|NCT01186198|Coronary Dilatation Catheter
1192404|NCT01186198|Balloon Dilatation Catheter
1192405|NCT01186198|Predilatation Balloon
1192406|NCT01186198|Angioplasty
1192407|NCT01186198|Myocardial Ischemia
1192408|NCT01186198|Coronary Stenosis
1192409|NCT01186198|PCI
1192410|NCT01186198|PTCA
1192411|NCT01186198|CTO
1192412|NCT01186185|sudden
1192413|NCT01186185|sensorineural
1192414|NCT01186185|hearing loss
1192415|NCT01186185|fludrocortisone
1192416|NCT01186185|mineralocorticoid
1192417|NCT01186185|steroid
1192418|NCT01186172|ethanol
1192419|NCT01186172|lock therapy
1192420|NCT01186172|vascular access
1192421|NCT01186172|central venous catheter
1192422|NCT01186172|sepsis
1192423|NCT01186159|COX-2
1192424|NCT01186159|PMNL
1192425|NCT01186159|pain
1192426|NCT01186159|macrophages
1192427|NCT01186159|NSAIDs
1192428|NCT01186146|coronary disease
1192429|NCT01186146|stents
1192430|NCT01186146|antiplatelet drugs
1192431|NCT01186146|drug-eluting stents
1192432|NCT01186133|coronary disease
1192433|NCT01186133|drug eluting stent
1192434|NCT01186120|coronary disease
1192435|NCT01186120|stent
1192436|NCT01186107|coronary disease
1192437|NCT01186107|stent
1192438|NCT01186094|Coronary Artery Disease
1192439|NCT01186094|Stent
1192440|NCT01186081|Rectal cancer
1192441|NCT01186081|Preoperative CCRT
1192442|NCT01186081|Postoperative CCRT
1192443|NCT01186081|Capecitabine
1192444|NCT01186068|Rosacea, erythema
1192445|NCT01186055|Smoking Relapse
1192446|NCT01186055|Nicotine Abstinence
1192447|NCT01186042|HIV
1192448|NCT01186042|Aging
1192449|NCT01186042|Neuropsychological function
1192450|NCT01186042|Activity
1192451|NCT01186042|Sleep patterns
1192452|NCT01186042|Frailty
1192453|NCT01186042|Emotional well-being
1192454|NCT01186042|Sexual health
1192455|NCT01186029|Looking at adding drug to already established treatment regimen for
1192456|NCT01186029|Nausea and Vomiting
1192457|NCT01186016|Genetic Education
1192458|NCT01186016|Smoking Cessation
1192459|NCT01186016|Quitting Smoking
1192460|NCT01186016|Standard Smoking Cessation Program
1192461|NCT01186016|Genetic Education for Smoking Cessation
1192462|NCT01186003|Diabetes
1192463|NCT01185977|Major Depressive Disorder
1192464|NCT01185977|Fluoxetine
1192465|NCT01185977|QEEG
1192466|NCT01185977|cordance
1192467|NCT01185977|ATR
1192468|NCT01185964|Sarcoma, Soft Tissue
1192469|NCT01185964|Advanced Soft Tissue Sarcoma
1192470|NCT01185951|Achilles Tendon
1192471|NCT01185951|Patella
1192472|NCT01185951|Allergy
1192473|NCT01185951|Necrosis
1192474|NCT01185951|Infection
1192475|NCT01185938|statin
1192476|NCT01185938|CIN
1192477|NCT01185938|periprocedural damage
1192478|NCT01185925|PDE5-inhibition
1192479|NCT01185925|exercise ventilation
1192480|NCT01185925|heart failure
1192481|NCT01185925|sildenafil
1192482|NCT01185925|pulmonary hemodynamics
1192483|NCT01185912|Cardiac MRI
1192484|NCT01185912|Cardiac ultrasound
1192485|NCT01185912|Cardiac surgery
1192486|NCT01185899|heart attack
1192487|NCT01185899|acute myocardial infarction
1192488|NCT01185899|STEMI
1192489|NCT01185899|NSTEMI
1192490|NCT01185899|Unstable Angina
1192491|NCT01185899|suspected acute coronary syndrome
1192492|NCT01185899|Non-ischemic chest pain
1192493|NCT01185886|untreated childhood acute lymphoblastic leukemia
1192494|NCT01185886|L1 childhood acute lymphoblastic leukemia
1192495|NCT01185886|L2 childhood acute lymphoblastic leukemia
1192496|NCT01185886|B-cell childhood acute lymphoblastic leukemia
1192497|NCT01185886|T-cell childhood acute lymphoblastic leukemia
1192498|NCT01185886|stage I childhood lymphoblastic lymphoma
1192499|NCT01185886|stage II childhood lymphoblastic lymphoma
1192500|NCT01185886|stage III childhood lymphoblastic lymphoma
1192501|NCT01185886|stage IV childhood lymphoblastic lymphoma
1192502|NCT01185886|Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia
1192503|NCT01185821|Multiple Sclerosis
1192504|NCT01185821|Relapsing remitting Multiple Sclerosis
1192505|NCT01185821|Demyelinating Autoimmune Diseases
1192506|NCT01185808|sinusitis
1192507|NCT01185808|chronic sinusitis with polyps
1192508|NCT01185795|yogurt
1192509|NCT01185795|probiotic
1192510|NCT01185795|cholesterol
1192511|NCT01185782|Infertility
1192512|NCT01185782|Ovulation induction
1192513|NCT01185782|Gonalef® (Follitropin alfa)
1192514|NCT01185782|Purified pituitary gonadotropin (Fertinorm-P®)
1192515|NCT01185782|gonadotropin
1192516|NCT01185782|Reproductive technologies, assisted
1192517|NCT01185782|Polycystic ovary syndrome
1192518|NCT01185769|Vitamin E
1192519|NCT01185769|Absorption
1192520|NCT01185756|Heart failure
1192521|NCT01185756|Sudden death
1192522|NCT01185756|Implantable Cardioverter Defibrillator
1192523|NCT01185756|MIBG scintigraphy
1192524|NCT01185743|healthy volunteers
1192525|NCT01185743|antipsychotics
1192526|NCT01185743|gene expression
1192527|NCT01185730|Pulmonary hypertension
1192528|NCT01185730|Prognostic factors
1192529|NCT01185730|Idiopathic pulmonary hypertension
1192530|NCT01185730|Family pulmonary hypertension
1192531|NCT01185730|use anorectics
1192532|NCT01185704|Cetrorelix acetate; follitropin alfa; human chorionic-gonadotropin alfa; follicular maturation; pregnancy; ovarian stimulation
1192533|NCT01185678|Contraception
1192534|NCT01185678|Compliance
1192535|NCT01185665|FBSS
1192536|NCT01185652|Smoking
1192537|NCT01185652|airflow obstruction
1192538|NCT01185652|pulmonary function tests
1192539|NCT01185639|lung cancer
1192540|NCT01185639|metastatic
1192541|NCT01185639|SBRT
1192542|NCT01185639|Stereotactic body radiation therapy
1192543|NCT01185639|liver
1192544|NCT01185639|spine
1192545|NCT01185639|adrenal
1192546|NCT01185639|bone cancer
1192547|NCT01185639|Spinal Column
1192548|NCT01185626|patients
1192549|NCT01185600|transfusion complications
1192550|NCT01185600|washed RBC
1192551|NCT01185600|microparticles
1192552|NCT01185600|storage lesion
1192553|NCT01185587|SCN5A protein
1192554|NCT01185587|voltage-gated Na+ channel
1192555|NCT01185561|Diabetes
1192556|NCT01185561|SWEEP
1192557|NCT01185561|Dysphoria
1192558|NCT01185548|Advanced or Metastatic Solid Tumors or Lymphoma
1192559|NCT01185535|topical anesthesia
1192560|NCT01185535|tracheal intubation
1192561|NCT01185535|difficult airway
1192562|NCT01185509|HER2 negative
1192563|NCT01185509|HER2 positive
1192564|NCT01185496|diabetes mellitus
1192565|NCT01185483|Endoscopic submucosal dissection
1192566|NCT01185483|Submucosal tumor
1192567|NCT01185483|Minimal invasive
1192568|NCT01185483|Gastroscopy
1192569|NCT01185470|Chronic pain
1192570|NCT01185470|Morphine Sufate
1192571|NCT01185470|Intrathecal
1192572|NCT01185470|Implantable drug delivery pumps
1192573|NCT01185457|Shoulder surgery
1192574|NCT01185457|Beach chair position
1192575|NCT01185457|Interscalene block
1192576|NCT01185457|HRV
1192577|NCT01185457|Autonomic nervous system
1192578|NCT01185444|Knee Balance
1192579|NCT01185444|Hyaluronate
1192580|NCT01185444|Osteoarthritis
1192581|NCT01185444|Viscosupplementation
1192582|NCT01185431|Ficus Carica
1192583|NCT01185431|Functional Constipation
1192584|NCT01185431|Dietary Supplement
1192585|NCT01185431|Fig Paste
1192586|NCT01185405|Voriconazole
1192587|NCT01185405|Therapeutic drug monitoring
1192588|NCT01185405|Intensive care unit
1192589|NCT01185392|Cardiac Resynchronisation Therapy in Heart Failure
1192590|NCT01185379|Docosahexaenoic acid
1192591|NCT01185379|omega 3
1192592|NCT01185379|cerebral blood flow
1192593|NCT01185379|Near Infrared spectroscopy
1192594|NCT01185379|cognitive function
1192595|NCT01185379|mood
1192596|NCT01185366|Advanced non-clear cell renal cell cancer (RCC)
1192597|NCT01185366|Clear-cell renal cell carcinoma
1192598|NCT01185366|Collecting duct carcinoma
1192599|NCT01185366|Translocation carcinoma
1192600|NCT01185366|Chromophobe
1192601|NCT01185366|Everolimus
1192602|NCT01185366|Sunitinib
1192603|NCT01185366|Afinitor
1192604|NCT01185366|RAD001
1192605|NCT01185366|Sunitinib Malate
1192606|NCT01185366|SUO11248
1192607|NCT01185366|Sutent
1192608|NCT01185366|ESPN
1192609|NCT01185353|Rheumatoid Arthritis
1192610|NCT01185353|RA
1192611|NCT01185340|Depression
1192612|NCT01185340|MDD
1192613|NCT01185327|Regurgitation
1192614|NCT01185327|Infants to Israeli Ethiopian-origin mothers
1192615|NCT01185314|NSCLC, EGFR mutation
1192616|NCT01185301|Arthritis
1192617|NCT01185301|Erosion
1192618|NCT01185301|Humira
1192619|NCT01185301|Adalimumab
1192620|NCT01185301|Injection
1192621|NCT01185301|Rheumatoid
1192622|NCT01185301|Methotrexate
1192623|NCT01185288|Rheumatoid Arthritis
1192624|NCT01185262|Recurrent and refractory chronic lymphocytic leukemia
1192625|NCT01185249|CHF
1192626|NCT01185249|congestive heart failure
1192627|NCT01185236|Diabetes mellitus
1192628|NCT01185223|Valganciclovir
1192629|NCT01185223|Ganciclovir
1192630|NCT01185223|Antiviral Drug
1192631|NCT01185223|CMV disease
1192632|NCT01185197|Minimal Change Nephrotic Syndrome
1192633|NCT01185197|Corticosteroid
1192634|NCT01185197|Mycophenolate
1192635|NCT01185197|Remission
1192636|NCT01185197|Safety
1192637|NCT01185184|Relative bioavailability
1192638|NCT01185184|controlled release
1192639|NCT01185184|Phase 1
1192640|NCT01185184|CP-690
1192641|NCT01185184|550
1192642|NCT01185171|Larynx
1192643|NCT01185171|Lip
1192644|NCT01185171|Oral Cavity and Pharynx
1192645|NCT01185158|Larynx
1192646|NCT01185158|Lip
1192647|NCT01185158|Oral Cavity and Pharynx
1192648|NCT01185145|breast-conservation
1192649|NCT01185145|accelerated partial breast irradiation
1192650|NCT01185145|APBI
1192651|NCT01185145|IMRT
1192652|NCT01185145|Intensity modulated radiotherapy
1192653|NCT01185145|breast brachytherapy
1192654|NCT01185145|lumpectomy
1192655|NCT01185145|early stage breast cancer
1192656|NCT01185145|DCIS
1192657|NCT01185145|Mammosite
1192658|NCT01185132|breast-conservation
1192659|NCT01185132|adjuvant radiotherapy
1192660|NCT01185132|breast cancer
1192661|NCT01185132|early-stage breast cancer
1192662|NCT01185132|DCIS
1192663|NCT01185132|lumpectomy
1192664|NCT01185132|accelerated partial breast irradiation
1192665|NCT01185132|APBI
1192666|NCT01185132|three dimensional conformal external radiotherapy
1192667|NCT01185132|intensity modulated radiotherapy
1192668|NCT01185132|3D CRT
1192669|NCT01185132|IMRT
1192670|NCT01185119|glucose uptake and metabolism in brain
1192671|NCT01185093|Cells
1192672|NCT01185093|Prevention
1192673|NCT01185093|Cancer education
1192674|NCT01185093|Nutrition
1192675|NCT01185093|Healthy living
1192676|NCT01185093|Physical activity
1192677|NCT01185093|Dangers of tobacco
1192678|NCT01185093|Sun protection
1192679|NCT01185080|AZD8848
1192680|NCT01185080|allergic rhinitis
1192681|NCT01185080|efficacy
1192682|NCT01185080|tolerability
1192683|NCT01185080|safety
1192684|NCT01185080|nasal symptoms
1192685|NCT01185067|Hypertension
1192686|NCT01185067|Endothelial function
1192687|NCT01185067|Antioxidants
1192688|NCT01185067|Oxidative stress
1192689|NCT01185067|Grapes
1192690|NCT01185067|Polyphenols
1192691|NCT01185067|Resveratrol
1192692|NCT01185067|Quercetin
1192693|NCT01185067|Anthocyanins
1192694|NCT01185067|Flavanols
1192695|NCT01185067|Flavonols
1192696|NCT01185067|Congestive heart failure
1192697|NCT01185067|Heart failure with normal ejection fraction
1192698|NCT01185067|Heart failure with preserved systolic function
1192699|NCT01185067|HFNEF
1192700|NCT01185067|HFPSF
1192701|NCT01185067|HFPEF
1192702|NCT01185067|DHF
1192703|NCT01185054|Pediatrics
1192704|NCT01185054|Gastroenteritis
1192705|NCT01185054|Oral Rehydration
1192706|NCT01185054|Electrolyte Maintenance Solution
1192707|NCT01185041|Arterial Stiffness
1192708|NCT01185041|Wave Reflection
1192709|NCT01185041|Watermelon Supplementation
1192710|NCT01185041|Aortic Blood Pressure
1192711|NCT01185041|Obesity
1192712|NCT01185028|Chronic HCV
1192713|NCT01185028|HCV Treatment Nonresponders
1192714|NCT01185028|HCV Treatment Relapsers
1192715|NCT01185028|HIV-HCV Co-Infection
1192716|NCT01185028|Nitazoxanide
1192717|NCT01185028|Hepatitis C
1192718|NCT01185015|Angina Pectoris, Coronary disease
1192719|NCT01185002|CE
1192720|NCT01185002|colonoscopy
1192721|NCT01185002|colon
1192722|NCT01185002|Eligable for colon evaluation
1192723|NCT01184976|H5N1
1192724|NCT01184976|Avian Influenza
1192725|NCT01184976|DNA Vaccine
1192726|NCT01184976|Electroporation
1192727|NCT01184976|Intramuscular (IM) Injection
1192728|NCT01184963|PCOS
1192729|NCT01184963|High protein diet
1192730|NCT01184924|Arthritis
1192731|NCT01184924|Tai Chi
1192732|NCT01184911|Malaria
1192733|NCT01184911|Pregnancy
1192734|NCT01184898|AML
1192735|NCT01184898|mTOR
1192736|NCT01184898|rapamycin
1192737|NCT01184885|hyperCVAD
1192738|NCT01184885|rapamycin
1192739|NCT01184885|lymphoid malignancies
1192740|NCT01184885|lymphoblastic leukemia
1192741|NCT01184885|B and T cell
1192742|NCT01184885|philadelphia chromosome negative
1192743|NCT01184885|burkitt lymphoma
1192744|NCT01184885|burkitt-type lymphoma
1192745|NCT01184885|lymphoblastic lymphoma
1192746|NCT01184885|mantle cell lymphoma
1192747|NCT01184885|adult t cell leukemia
1192748|NCT01184885|adult t cell lymphoma
1192749|NCT01184872|Skin infection
1192750|NCT01184872|Daptomycin
1192751|NCT01184872|Elderly
1192752|NCT01184872|Gram positive
1192753|NCT01184872|Complicated skin and soft tissue infections
1192754|NCT01184859|nocturia
1192755|NCT01184859|bladder function
1192756|NCT01184846|Chronic inflammatory demyelinating polyneuropathy
1192757|NCT01184846|CIDP
1192758|NCT01184833|Multiple sclerosis
1192759|NCT01184833|Interferon beta-1b
1192760|NCT01184833|Compliance to treatment
1192761|NCT01184833|Premature treatment discontinuation
1192762|NCT01184820|Pharmacokinetics
1192763|NCT01184820|Safety
1192764|NCT01184807|Advanced solid tumor
1192765|NCT01184794|Analgesia laparoscopy
1192766|NCT01184768|type 2 diabetes
1192767|NCT01184768|HbA1c
1192768|NCT01184768|vitamin D
1192769|NCT01184768|diagnosis
1192770|NCT01184755|Device-guided breathing
1192771|NCT01184755|hypertension
1192772|NCT01184755|behavioral intervention
1192773|NCT01184755|stress reduction
1192774|NCT01184755|Heart Rate Variability (HRV) biofeedback
1192775|NCT01184729|aerobic capacity
1192776|NCT01184716|Vitamin D status (serum 25-hydroxyvitamin D)
1192777|NCT01184703|Diabetes Mellitus, Type 1
1192778|NCT01184703|Glycemic Index Diet
1192779|NCT01184703|HbA1c
1192780|NCT01184703|Lipids
1192781|NCT01184690|double-balloon endoscopy
1192782|NCT01184690|diagnostic yield
1192783|NCT01184664|Smoking cessation
1192784|NCT01184664|Tobacco dependence
1192785|NCT01184664|Varenicline
1192786|NCT01184664|Nicotine Replacement Therapy
1192787|NCT01184664|Combination therapy
1192788|NCT01184651|Congenital Adrenal Hyperplasia
1192789|NCT01184651|CAH
1192790|NCT01184651|sex differences
1192791|NCT01184651|adolescence
1192792|NCT01184651|androgen
1192793|NCT01184651|behavior
1192794|NCT01184651|gender development
1192795|NCT01184638|Cognitive Disorders
1192796|NCT01184638|General anesthesia
1192797|NCT01184638|Sevoflurane
1192798|NCT01184638|Propofol
1192799|NCT01184638|Memory
1192800|NCT01184625|Myositis
1192801|NCT01184625|Physical exercise
1192802|NCT01184625|Disability
1192803|NCT01184612|Inmates with heavy use of alcohol or drugs
1192804|NCT01184599|Aliskiren
1192805|NCT01184599|Albuminuria
1192806|NCT01184599|Angiotensinogen
1192807|NCT01184599|collagen type IV
1192808|NCT01184599|Transforming Growth Factor beta
1192809|NCT01184599|aldosterone
1192810|NCT01184599|renin
1192811|NCT01184599|prorenin receptor
1192812|NCT01184599|des-angiotensin I renin substrate
1192813|NCT01184599|oxidative stress
1192814|NCT01184599|advanced glycosylation end-product receptor
1192815|NCT01184599|N,N-dimethylarginine
1192816|NCT01184586|function
1192817|NCT01184586|DASH
1192818|NCT01184586|MHQ
1192819|NCT01184586|pain
1192820|NCT01184586|strength
1192821|NCT01184573|chronic pancreatitis
1192822|NCT01184573|breath test
1192823|NCT01184573|bicarbonate
1192824|NCT01184560|obesity
1192825|NCT01184534|Lung Biopsy
1192826|NCT01184534|Multimedia patient education tool
1192827|NCT01184534|Multimedia Education Tool
1192828|NCT01184534|Computed tomography guided lung biopsy
1192829|NCT01184534|Computerized Tomography
1192830|NCT01184534|CT
1192831|NCT01184534|Questionnaire
1192832|NCT01184534|Lung nodules
1192833|NCT01184508|classic with aura
1192834|NCT01184508|common without aura
1192835|NCT01184508|migraine
1192836|NCT01184508|headache
1192837|NCT01184495|Erythropoietin
1192838|NCT01184495|Chronic renal failure
1192839|NCT01184495|Hemodialysis
1192840|NCT01184495|Anemia
1192841|NCT01184482|recurrent colorectal cancer
1192842|NCT01184482|recurrent head and neck cancer
1192843|NCT01184482|recurrent lung cancer
1192844|NCT01184482|cetuximab
1192845|NCT01184482|lapatinib
1192846|NCT01184456|AIDS
1192847|NCT01184456|Acquired Immunodeficiency Syndrome
1192848|NCT01184456|HIV
1192849|NCT01184456|Human Immunodeficiency Virus
1192850|NCT01184443|Anorexia Nervosa
1192851|NCT01184443|Eating Disorder Not Otherwise Specified
1192852|NCT01184443|Olanzapine
1192853|NCT01184443|Pediatric
1192854|NCT01184430|advanced hemodynamic monitoring
1192855|NCT01184430|goal-directed therapy
1192856|NCT01184430|cardiac surgery
1192857|NCT01184430|hemodynamic monitoring
1192858|NCT01184404|Congenital heart disease
1192859|NCT01184404|Cardiac surgery
1192860|NCT01184404|Bosentan
1192861|NCT01184378|infant formula
1192862|NCT01184378|dairy fat
1192863|NCT01184378|soluble milk protein
1192864|NCT01184365|fatigue
1192865|NCT01184365|energy management
1192866|NCT01184365|spinal cord injury
1192867|NCT01184365|self-efficacy
1192868|NCT01184365|environment
1192869|NCT01184339|Staphylococcus
1192870|NCT01184339|aureus
1192871|NCT01184339|methicillin
1192872|NCT01184339|resistant
1192873|NCT01184339|MRSA
1192874|NCT01184339|MSSA
1192875|NCT01184339|Blood Culture
1192876|NCT01184339|diagnostic
1192877|NCT01184326|RAD001
1192878|NCT01184326|pazopanib
1192879|NCT01184326|everolimus
1192880|NCT01184326|advanced cancer
1192881|NCT01184313|aortic valve surgery
1192882|NCT01184313|CPB
1192883|NCT01184313|lung injury
1192884|NCT01184300|CYP2C19*2
1192885|NCT01184300|Pharmacogenomics
1192886|NCT01184300|Clopidogrel
1192887|NCT01184300|Prasugrel
1192888|NCT01184300|Percutaneous Coronary Intervention
1192889|NCT01184287|Non Small Cell Lung Cancer, NSCLC, Lung Cancer
1192890|NCT01184287|Previously untreated Non-Squamous, Non-Small Cell Lung Cancer
1192891|NCT01184235|Circadian Disorders
1192892|NCT01184235|Autism Spectrum Disorders
1192893|NCT01184235|Mood Disorders
1192894|NCT01184235|Executive Functioning
1192895|NCT01184235|Pediatric Mood Disorders
1192896|NCT01184196|knee replacement
1192897|NCT01184196|knee arthroplasty
1192898|NCT01184196|total knee replacement
1192899|NCT01184196|arthroplasty, knee replacement
1192900|NCT01184183|Patch for Carotid Endarterectomy
1192901|NCT01184170|obesity
1192902|NCT01184170|metabolism
1192903|NCT01184170|cardiovascular metabolic syndrome
1192904|NCT01184144|Endometriosis
1192905|NCT01184144|Peritoneal fluid
1192906|NCT01184144|Cytokines
1192907|NCT01184144|Peroxisome Proliferator-Activated Receptors
1192908|NCT01184131|Mentor Training
1192909|NCT01184131|Randomized trial of mentoring effectiveness
1192910|NCT01184131|Mentoring clinical researchers
1192911|NCT01184118|asthma
1192912|NCT01184118|sleep apnea
1192913|NCT01184092|Bioequivalence
1192914|NCT01184092|healthy volunteer study
1192915|NCT01184092|Rheumatoid Arthritis
1192916|NCT01184079|human papillomavirus vaccine L1, type 6,11,16,18
1192917|NCT01184079|HPV Vaccines
1192918|NCT01184079|HPV L1 vaccine, quadrivalent 6,11,16,18
1192919|NCT01184066|Chemotherapy
1192920|NCT01184066|Patient Adherence
1192921|NCT01184066|African Americans
1192922|NCT01184066|Cancer Survivor
1192923|NCT01184066|Decision Making
1192924|NCT01184066|Communication
1192925|NCT01184066|Quality of Life
1192926|NCT01184066|Social Support
1192927|NCT01184066|Patient Education
1192928|NCT01184053|endometrial
1192929|NCT01184053|carcinoma
1192930|NCT01184053|recurrent
1192931|NCT01184053|metastatic
1192932|NCT01184053|Trisenox
1192933|NCT01184053|arsenic trioxide
1192934|NCT01184053|Phase II
1192935|NCT01184053|VEGF
1192936|NCT01184053|gynecology
1192937|NCT01184053|Lineberger
1192938|NCT01184053|UNC
1192939|NCT01184053|vascular endothelial growth factor
1192940|NCT01184053|University of North Carolina at Chapel Hill
1192941|NCT01184027|head and neck cancer
1192942|NCT01184027|surgery
1192943|NCT01184027|nutrition
1192944|NCT01184014|corticosteroid
1192945|NCT01184014|hyperglycemia
1192946|NCT01184014|hospital
1192947|NCT01184014|corticosteroid induced hyperglycemia in the hospital
1192948|NCT01184001|Healthy subjects
1192949|NCT01184001|Food Effect Study
1192950|NCT01183962|CAD
1192951|NCT01183962|Vitamin D
1192952|NCT01183962|CVD
1192953|NCT01183949|Neoplasms
1192954|NCT01183949|Neoplasms, Plasma Cell
1192955|NCT01183949|Neoplasms by Histologic Type
1192956|NCT01183949|Hemostatic Disorders
1192957|NCT01183949|Paraproteinemias
1192958|NCT01183949|Blood Protein Disorders
1192959|NCT01183949|Hematologic Diseases
1192960|NCT01183949|Hemorrhagic Disorders
1192961|NCT01183949|Lymphoproliferative Disorders
1192962|NCT01183949|Immunoproliferative Disorders
1192963|NCT01183949|Immune System Diseases
1192964|NCT01183949|Bortezomib
1192965|NCT01183949|Antineoplastic Agents
1192966|NCT01183936|Melanoma/mortality/pathology/*surgery
1192967|NCT01183936|Randomized Controlled Trials as Topic
1192968|NCT01183936|Survival
1192969|NCT01183936|Disease-Free Survival
1192970|NCT01183923|asthma
1192971|NCT01183923|dietary interventions
1192972|NCT01183923|mouse allergy
1192973|NCT01183910|PURPURA
1192974|NCT01183910|SENILE PURPURA
1192975|NCT01183910|BATEMAN'S PURPURA
1192976|NCT01183897|GM-CSF
1192977|NCT01183897|MAB 3F8
1192978|NCT01183897|RETINOIC ACID (CIS-9 & 13)
1192979|NCT01183897|09-161
1192980|NCT01183884|GM-CSF
1192981|NCT01183884|MAB 3F8
1192982|NCT01183884|RETINOIC ACID (CIS-9 & 13)
1192983|NCT01183884|09-160
1192984|NCT01183871|Cerebral oxygenation
1192985|NCT01183871|thoracotomy
1192986|NCT01183871|lung resection
1192987|NCT01183871|pulmonary dysfunction
1192988|NCT01183845|Crohn Disease
1192989|NCT01183845|Crohn's Disease Endoscopy Index of Severity
1192990|NCT01183845|Colon Capsule Endoscopy
1192991|NCT01183845|Crohn's Disease located in colon and/or ileum
1192992|NCT01183832|Breast cancer
1192993|NCT01183832|radiotherapy
1192994|NCT01183832|hormonotherapy
1192995|NCT01183819|cognitive function
1192996|NCT01183819|fMRI
1192997|NCT01183819|apoE
1192998|NCT01183819|inflammatory markers
1192999|NCT01183819|exercise
1193000|NCT01183819|cognitive intervention
1193001|NCT01183819|Space Fortress
1193002|NCT01183806|Alzheimer's disease
1193003|NCT01183806|Exercise
1193004|NCT01183806|Rivastigmine
1193005|NCT01183806|Quality of life
1193006|NCT01183793|Gastrointestinal Tract [A03.556]
1193007|NCT01183780|second line
1193008|NCT01183780|metastatic colorectal cancer
1193009|NCT01183780|FOLFIRI
1193010|NCT01183780|ramucirumab
1193011|NCT01183780|CRC
1193012|NCT01183780|mCRC
1193013|NCT01183767|Duchenne Muscular Dystrophy
1193014|NCT01183767|Epigallocatechin-Gallate
1193015|NCT01183767|Green tea extract
1193016|NCT01183754|coronary disease
1193017|NCT01183754|platelet reactivity
1193018|NCT01183754|drug-eluting stent
1193019|NCT01183741|Hypertension
1193020|NCT01183741|Hypotension
1193021|NCT01183741|Blood pressure
1193022|NCT01183728|Knee degenerative disease
1193023|NCT01183728|osteoarthritis
1193024|NCT01183728|gonarthrosis
1193025|NCT01183728|stem cell
1193026|NCT01183728|cellular therapy
1193027|NCT01183728|regenerative therapy
1193028|NCT01183728|Mesenchymal stem cells
1193029|NCT01183728|Bone marrow
1193030|NCT01183728|musculoskeletal Diseases
1193031|NCT01183715|Single Ascending Dose
1193032|NCT01183715|Phase 1
1193033|NCT01183715|Safety and Tolerability
1193034|NCT01183715|PK
1193035|NCT01183715|Healthy Subjects
1193036|NCT01183702|LASIK vs. non-LASIK
1193037|NCT01183663|Lenalidomide
1193038|NCT01183663|Bevacizumab
1193039|NCT01183663|Sorafenib
1193040|NCT01183663|Temsirolimus
1193041|NCT01183663|5-Fluorouracil
1193042|NCT01183663|Leucovorin
1193043|NCT01183663|Oxaliplatin
1193044|NCT01183663|Avastin
1193045|NCT01183663|Anti-VEGF monoclonal antibody
1193046|NCT01183663|rhuMAB-VEGF
1193047|NCT01183663|CC-5013
1193048|NCT01183663|Revlimid
1193049|NCT01183663|Nexavar
1193050|NCT01183663|BAY 43-90006
1193051|NCT01183663|Metastatic cancer
1193052|NCT01183663|Metastatic colorectal cancer
1193053|NCT01183663|Advanced solid tumors
1193054|NCT01183663|Hematologic malignancies
1193055|NCT01183663|Colon cancer
1193056|NCT01183663|Advanced colorectal cancer
1193057|NCT01183663|Breast cancer
1193058|NCT01183663|Pancreatic cancer
1193059|NCT01183663|Gastric cancer
1193060|NCT01183663|Advanced renal cell carcinoma
1193061|NCT01183663|Prostate cancer
1193062|NCT01183663|Melanoma
1193063|NCT01183663|Unresectable hepatocellular carcinoma
1193064|NCT01183663|Renal cell carcinoma
1193065|NCT01183663|Metastatic breast cancer
1193066|NCT01183663|Glioblastoma
1193067|NCT01183663|Multiple myeloma
1193068|NCT01183637|Cartilage
1193069|NCT01183637|Knee
1193070|NCT01183637|Osteochondral
1193071|NCT01183624|Osteoarthritis
1193072|NCT01183624|Pain
1193073|NCT01183624|Herbal medicine
1193074|NCT01183624|Topical administration
1193075|NCT01183611|safety
1193076|NCT01183611|immunogenicity
1193077|NCT01183611|HBV vaccine
1193078|NCT01183611|perinatal transmission
1193079|NCT01183572|multivitamins
1193080|NCT01183572|folate
1193081|NCT01183572|iron
1193082|NCT01183572|periconception
1193083|NCT01183546|rehabilitation
1193084|NCT01183546|spinal cord injury
1193085|NCT01183546|wheelchairs
1193086|NCT01183533|Wake-Up Stroke
1193087|NCT01183533|Ischemic stroke
1193088|NCT01183533|ischemic stroke patients who wake-up with their symptoms
1193089|NCT01183481|nausea
1193090|NCT01183481|vomiting
1193091|NCT01183481|antiemetics
1193092|NCT01183481|radiotherapy
1193093|NCT01183481|Radiation-induced nausea and vomiting
1193094|NCT01183468|Diabetes Mellitus, Type 1 (new-onset)
1193095|NCT01183468|Diabetes Mellitus, Insulin-Dependent (new-onset)
1193096|NCT01183468|new-onset T1DM
1193097|NCT01183468|new-onset T1D
1193098|NCT01183468|Diabetes Mellitus, Juvenile-Onset
1193099|NCT01183468|Diabetes, Autoimmune
1193100|NCT01183468|Aralast NP
1193101|NCT01183468|Alpha-1 Antitrypsin
1193102|NCT01183468|AAT
1193103|NCT01183455|Diabetes Mellitus, Type 1 (new-onset)
1193104|NCT01183455|T1DM (new-onset)
1193105|NCT01183455|T1D (new-onset)
1193106|NCT01183455|Diabetes, Autoimmune
1193107|NCT01183455|Alpha1-Proteinase Inhibitor
1193108|NCT01183455|Alpha-1 Antitrypsin
1193109|NCT01183455|AAT
1193110|NCT01183442|endothelial function
1193111|NCT01183442|insulin sensitivity
1193112|NCT01183429|MAB 3F8
1193113|NCT01183429|RETINOIC ACID (CIS-9 & 13)
1193114|NCT01183429|Bone Marrow
1193115|NCT01183429|09-159
1193116|NCT01183416|GM-CSF
1193117|NCT01183416|MAB 3F8
1193118|NCT01183416|RETINOIC ACID (CIS-9 & 13)
1193119|NCT01183416|09-158
1193120|NCT01183403|stricture
1193121|NCT01183403|anti-TNF
1193122|NCT01183403|ileal Crohn'Disease
1193123|NCT01183403|patients with ileal Crohn's disease complicated by
1193124|NCT01183403|symptomatic stricture after failure of corticosteroids
1193249|NCT01182818|Fabry´s Disease
1193125|NCT01183403|and/or immunosuppressives
1193126|NCT01183390|Bioequivalence
1193127|NCT01183390|Healthy Subjects
1193128|NCT01183377|Female Athlete Triad syndrom
1193129|NCT01183377|Eating disorder
1193130|NCT01183377|osteoprosis
1193131|NCT01183364|solid tumor malignancies
1193132|NCT01183364|tumor
1193133|NCT01183364|cancer
1193134|NCT01183364|STA-9090
1193135|NCT01183364|ganetespib
1193136|NCT01183364|HSP90 inhibitor
1193137|NCT01183351|Dementia
1193138|NCT01183351|Agitation
1193139|NCT01183351|Challenging behaviour
1193140|NCT01183351|Behavioural and psychological symptoms in dementia (BPSD)
1193141|NCT01183338|SpO2
1193142|NCT01183338|Oxygen saturation
1193143|NCT01183325|Umbilical and small ventral hernias less than 3cm diameter
1193144|NCT01183312|Hypersomnia
1193145|NCT01183312|Primary Hypersomnia
1193146|NCT01183312|Idiopathic Hypersomnia
1193147|NCT01183312|Narcolepsy without Cataplexy
1193148|NCT01183312|Flumazenil
1193149|NCT01183299|bone metabolism
1193150|NCT01183299|salt intake
1193151|NCT01183299|acid base balance
1193152|NCT01183299|bed rest
1193153|NCT01183260|revision total hip arthroplasty
1193154|NCT01183260|bone mineral density
1193155|NCT01183260|trabecular metal
1193156|NCT01183260|DEXA
1193157|NCT01183247|Everolimus,
1193158|NCT01183247|rapamycin,
1193159|NCT01183247|prednisone,
1193160|NCT01183247|tacrolimus,
1193161|NCT01183247|MMF,
1193162|NCT01183247|steroid-free,
1193163|NCT01183247|protocol biopsy
1193164|NCT01183182|Lung nodule
1193165|NCT01183182|Lung lesion
1193166|NCT01183169|Chronic hepatitis C
1193167|NCT01183169|Cyclophilin inhibitor
1193168|NCT01183156|Colorectal Cancer
1193169|NCT01183156|Screening
1193170|NCT01183156|Colonoscopy
1193171|NCT01183156|Attendance
1193172|NCT01183156|Participation
1193173|NCT01183143|Infertility
1193174|NCT01183143|Ovulation induction
1193175|NCT01183143|Gonal-F
1193176|NCT01183143|Follitropin alpha
1193177|NCT01183143|Controlled ovarian stimulation.
1193178|NCT01183130|opiate dependence
1193179|NCT01183130|compliance monitoring
1193180|NCT01183130|substitution treatment
1193181|NCT01183104|Type 2 Diabetes
1193182|NCT01183104|Sitagliptin
1193183|NCT01183104|Glimepiride
1193184|NCT01183104|Elderly patients
1193185|NCT01183104|Japanese
1193186|NCT01183091|Atrial fibrillation
1193187|NCT01183091|Ablation
1193188|NCT01183078|efficacy
1193189|NCT01183078|drill placement
1193190|NCT01183078|nail placement
1193191|NCT01183078|radiation
1193192|NCT01183078|Operative time
1193193|NCT01183078|Reduction in exposure to radiation
1193194|NCT01183078|Accuracy for nail placement
1193195|NCT01183065|Pralatrexate
1193196|NCT01183065|Vitamin B12
1193197|NCT01183065|Folic Acid
1193198|NCT01183065|10-112
1193199|NCT01183052|COPD
1193200|NCT01183052|exercise tolerance
1193201|NCT01183052|oxidative stress
1193202|NCT01183039|Sedentary
1193203|NCT01183000|Formation of adhesions assessed at subsequent cs
1193204|NCT01182987|Quality improvement
1193205|NCT01182987|Quality of care
1193206|NCT01182987|Health care utilization
1193207|NCT01182987|Behavioral change
1193208|NCT01182974|fever in severe sepsis
1193209|NCT01182961|Gait
1193210|NCT01182961|Falls
1193211|NCT01182961|Virtual reality
1193212|NCT01182948|aerobic training
1193213|NCT01182948|resistance training
1193214|NCT01182948|type 2 diabetes
1193215|NCT01182948|therapy
1193216|NCT01182935|vitamin D
1193217|NCT01182935|triglycerides
1193218|NCT01182935|type 2 diabetes
1193219|NCT01182922|Attendance
1193220|NCT01182922|Colorectal cancer
1193221|NCT01182922|Screening
1193222|NCT01182922|Invitation letter
1193223|NCT01182909|NPC
1193224|NCT01182909|Environmental and Genetic
1193225|NCT01182909|evaluate putative environmental exposures and NPC
1193226|NCT01182909|assess the effect of genetic factors
1193227|NCT01182909|investigate gene-environment interactions
1193228|NCT01182909|examine the natural history of EBV infection
1193229|NCT01182883|Maximum Tolerated Dose
1193230|NCT01182883|Dose Escalation
1193231|NCT01182883|Pharmacokinetics
1193232|NCT01182883|Antitumor Activity
1193233|NCT01182883|Biologic Activity
1193234|NCT01182870|vitamin D
1193235|NCT01182870|influenza
1193236|NCT01182870|prevention
1193237|NCT01182857|Quality of Life
1193238|NCT01182857|Gene Therapy
1193239|NCT01182857|ADA-SCID
1193240|NCT01182857|SCID-ADA
1193241|NCT01182857|Severe Combined Immunodeficiency
1193242|NCT01182844|metabolic syndrome, probiotic
1193243|NCT01182831|carcinoma pancreas
1193244|NCT01182831|percutaneous celiac plexus neurolysis
1193245|NCT01182831|endosonography guided celiac plexus neurolysis
1193246|NCT01182818|Cerebrovascular Accident
1193247|NCT01182818|Cerebrovascular Accident, Acute
1193248|NCT01182818|Fabry Disease
1193250|NCT01182818|Anderson-Fabry Disease
1193251|NCT01182818|CVA (Cerebrovascular Accident)
1193252|NCT01182818|Stroke, Acute
1193253|NCT01182818|Cerebral Stroke
1193254|NCT01182792|Endothelial Function
1193255|NCT01182792|Chronic Hypoxia
1193256|NCT01182792|Oxidative Stress
1193257|NCT01182779|base of skull chordoma
1193258|NCT01182779|radiation
1193259|NCT01182779|carbon ions
1193260|NCT01182779|protons
1193261|NCT01182766|alcohol
1193262|NCT01182766|alcoholism
1193263|NCT01182766|nicotine
1193264|NCT01182766|cigarette
1193265|NCT01182753|Chondrosarcoma
1193266|NCT01182753|Radiation
1193267|NCT01182753|carbon ion
1193268|NCT01182727|schizophrenia
1193269|NCT01182727|salsalate
1193270|NCT01182727|obesity
1193271|NCT01182714|Hysterectomy
1193272|NCT01182714|Catheterisation
1193273|NCT01182701|Type 2 Diabetes
1193274|NCT01182701|Asian Pacific Islanders
1193275|NCT01182701|Cognitive behavioral intervention
1193276|NCT01182688|utilization of Procalcitonin in the cardiac setting
1193277|NCT01182675|SCID
1193278|NCT01182675|Transplant
1193279|NCT01182675|Alemtuzumab
1193280|NCT01182675|Plerixafor
1193281|NCT01182662|Bone Marrow Disease
1193282|NCT01182662|Aplastic Anemia
1193283|NCT01182662|Umbilical Cord/placenta-Derived MSC
1193284|NCT01182662|Transplantation
1193285|NCT01182649|Drug Eluting Stents
1193286|NCT01182649|Everolimus Eluting Stent
1193287|NCT01182649|Coronary Angioplasty
1193288|NCT01182636|Bioequivalence
1193289|NCT01182636|Acne Vulgaris
1193290|NCT01182623|FICE
1193291|NCT01182623|Chromoendoscopy
1193292|NCT01182623|Colonic polyps
1193293|NCT01182623|Adenomas
1193294|NCT01182623|Hyperplastic polyps
1193295|NCT01182597|Oral PPI treatment has similar benefit as proton pump inhibitor infusion in patient with bleeding ulcers after combined endoscopic hemostasis
1193296|NCT01182571|Heart Transplantation
1193297|NCT01182571|Symptom Distress
1193298|NCT01182571|Fatigue
1193299|NCT01182571|Depression
1193300|NCT01182571|Quality Of Life.
1193301|NCT01182558|Muscle
1193302|NCT01182558|Activation
1193303|NCT01182558|Effect
1193304|NCT01182558|Compound muscle action potential
1193305|NCT01182545|Anaesthesia
1193306|NCT01182545|laparoscopic cholecystectomy
1193307|NCT01182545|CO2 insufflation
1193308|NCT01182545|hemodynamic
1193309|NCT01182545|hyperventilation
1193310|NCT01182532|Mild type of hand, foot and mouth disease
1193311|NCT01182532|Traditional Chinese Medicine
1193312|NCT01182532|Effectiveness
1193313|NCT01182532|Safety
1193314|NCT01182519|lung inflammation
1193315|NCT01182519|lung metastases
1193316|NCT01182519|10-115
1193317|NCT01182506|Cogmed Working Memory Training (CWMT)
1193318|NCT01182506|cognitive
1193319|NCT01182506|10-105
1193320|NCT01182506|Breast cancer survivor
1193321|NCT01182493|Diabetes Mellitus
1193322|NCT01182493|MDI
1193323|NCT01182493|pump therapy
1193324|NCT01182467|Inflammatory bowel disease, PET scan, Crohn's disease
1193325|NCT01182454|blood pressure
1193326|NCT01182441|atrial fibrillation
1193327|NCT01182441|stroke
1193328|NCT01182441|TIA
1193329|NCT01182441|trans ischemic attack
1193330|NCT01182441|warfarin
1193331|NCT01182441|Coumadin
1193332|NCT01182428|Stents
1193333|NCT01182428|Angioplasty
1193334|NCT01182428|Total coronary occlusions
1193335|NCT01182428|Coronary restenosis
1193336|NCT01182428|Stent thrombosis
1193337|NCT01182428|Everolimus
1193338|NCT01182415|CNS involvement
1193339|NCT01182402|opiate dependence
1193340|NCT01182402|substitution treatment
1193341|NCT01182402|unsupervised dosing
1193342|NCT01182402|monitoring
1193343|NCT01182389|Ventricular Tachycardia
1193344|NCT01182389|Implantable Cardioverter Defibrillator
1193345|NCT01182389|Catheter Ablation
1193346|NCT01182389|Robotic
1193347|NCT01182376|Multaq
1193348|NCT01182376|dronedarone
1193349|NCT01182376|Atrial Fibrillation
1193350|NCT01182363|maternal depression
1193351|NCT01182363|prematurity
1193352|NCT01182363|early intervention
1193353|NCT01182363|developmental delay
1193354|NCT01182350|Molecularly Determined Treatment
1193355|NCT01182324|Expectations
1193356|NCT01182324|Duchenne Muscular Dystrophy
1193357|NCT01182324|Clinical Trial
1193358|NCT01182324|Motivations
1193359|NCT01182311|Hepatitis B Virus
1193360|NCT01182311|Hepatitis B Vaccine
1193361|NCT01182311|Immunity
1193362|NCT01182311|B-Cell Response
1193363|NCT01182311|T-Cell Response
1193364|NCT01182311|Hepatitis B Immunity
1193365|NCT01182311|Hepatitis B Virus Vaccine
1193366|NCT01182298|Latino
1193367|NCT01182298|HCV
1193368|NCT01182298|pegIFN
1193369|NCT01182298|Viral Kinetics
1193370|NCT01182298|IL-28 Haplotype
1193371|NCT01182285|Depakote
1193372|NCT01182285|Poorly Differentiated Thyroid Cancer
1193373|NCT01182285|RAI Uptake
1193374|NCT01182285|Thyrogen
1193375|NCT01182272|adult primary hepatocellular carcinoma
1193376|NCT01182272|localized resectable adult primary liver cancer
1193377|NCT01182246|adenocarcinoma
1193378|NCT01182246|Pancreatic cancer
1193379|NCT01182233|Multiple Myeloma
1193380|NCT01182233|Autologous Hematopoietic Stem Cell Transplant
1193381|NCT01182233|Total Skeletal Irradiation
1193382|NCT01182233|High dose chemotherapy
1193383|NCT01182220|epidural
1193384|NCT01182220|labor pain
1193385|NCT01182220|ultrasound
1193386|NCT01182207|Bioequivalence
1193387|NCT01182207|Healthy Subjects
1193388|NCT01182194|Bioequivalence
1193389|NCT01182194|Healthy Subjects
1193390|NCT01182181|Healthy Subjects
1193391|NCT01182181|Bioequivalence
1193392|NCT01182168|CISPLATIN
1193393|NCT01182168|GEMCITABINE
1193394|NCT01182168|RAD001 (EVEROLIMUS)
1193395|NCT01182168|10-106
1193396|NCT01182155|Lung Cancer Non-Small Cell Cancer (NSCLC)
1193397|NCT01182155|Lung Cancer Small Cell Lung Cancer (SCLC)
1193398|NCT01182129|Nicotine Polacrilex chewing gum versus Swedish Snus
1193399|NCT01182116|J pouch
1193400|NCT01182116|colorectal
1193401|NCT01182116|rectal cancer
1193402|NCT01182116|coloplasty
1193403|NCT01182103|Major depression
1193404|NCT01182103|BDNF
1193405|NCT01182103|DNA methylation
1193406|NCT01182103|Histone modification
1193407|NCT01182090|pelvic organ prolapse
1193408|NCT01182090|colposacropexy
1193409|NCT01182090|surgery
1193410|NCT01182077|ASP015K
1193411|NCT01182077|midazolam
1193412|NCT01182077|healthy volunteers
1193413|NCT01182064|Heart injuries
1193414|NCT01182064|Posttraumatic myocardial infarction
1193415|NCT01182064|Echocardiography
1193416|NCT01182064|Coronary angiography
1193417|NCT01182051|headache
1193418|NCT01182051|anxiety
1193419|NCT01182051|pediatric headache and anxiety
1193420|NCT01182038|birth seat
1193421|NCT01182038|childbirth
1193422|NCT01182038|instrumental delivery
1193423|NCT01182038|upright position
1193424|NCT01182025|Mild type of hand, foot and mouth disease
1193425|NCT01182025|Xiyanping Injection
1193426|NCT01182025|Effectiveness
1193427|NCT01182025|Safety
1193428|NCT01182012|Cardiovascular risk factor
1193429|NCT01182012|Severe mental illness
1193430|NCT01182012|Drug appropriateness
1193431|NCT01182012|Drug compliance
1193432|NCT01182012|Lifestyle counseling
1193433|NCT01181999|diffuse large B-cell lymphoma
1193434|NCT01181999|elderly patients
1193435|NCT01181999|rituximab augmentation
1193436|NCT01181986|Type 2 diabetes mellitus, Impaired glucose tolerance
1193437|NCT01181973|Relative bioavailability
1193438|NCT01181973|pegvisomant
1193567|NCT01181492|CYP3A4
1193439|NCT01181960|Risperidone long acting injectable
1193440|NCT01181960|Risperdal Consta
1193441|NCT01181960|Paliperidone Palmitate
1193442|NCT01181960|Invega Sustenna
1193443|NCT01181947|Stent graft
1193444|NCT01181947|thoracic aorta
1193445|NCT01181947|dissection
1193446|NCT01181947|aneurysm
1193447|NCT01181947|TEVAR
1193448|NCT01181947|VALIANT
1193449|NCT01181947|CAPTIVIA
1193450|NCT01181947|endovascular
1193451|NCT01181934|symptomatic treatment
1193452|NCT01181934|cognition
1193453|NCT01181934|cognitive deficits
1193454|NCT01181934|Schizophrenia
1193455|NCT01181921|Alzheimer Disease
1193456|NCT01181921|Dementia
1193457|NCT01181921|Sleep Disorders
1193458|NCT01181921|Galantamine
1193459|NCT01181921|Reminyl
1193463|NCT01181895|asthma
1193464|NCT01181882|Cardiovascular Disease
1193465|NCT01181882|Aspirin Resistance
1193466|NCT01181882|Diabetes Mellitus, Type 2
1193467|NCT01181882|Platelet Function
1193468|NCT01181882|Omega-3 Fatty Acids
1193469|NCT01181882|Aspirin
1193470|NCT01181882|Lysophospholipids
1193471|NCT01181882|Lysophosphatidic Acid
1193472|NCT01181882|Lysophosphatidylcholine
1193473|NCT01181869|respiratory failure
1193474|NCT01181869|oxygen
1193475|NCT01181869|sleep apnoea
1193476|NCT01181869|ventilation
1193477|NCT01181856|Vaccine
1193478|NCT01181856|MVA 85A
1193479|NCT01181843|postoperative pain management
1193480|NCT01181843|respiratory depression
1193481|NCT01181843|capnography
1193482|NCT01181843|duramorph
1193483|NCT01181830|magnesium
1193484|NCT01181830|metabolic syndrome
1193485|NCT01181830|diabetes
1193486|NCT01181830|family history
1193487|NCT01181817|FBSS
1193488|NCT01181817|at least one prior spinal surgery
1193489|NCT01181804|boceprevir
1193490|NCT01181804|hepatitis C
1193491|NCT01181804|bioequivalence
1193492|NCT01181804|SCH 503034
1193493|NCT01181791|probiotics
1193494|NCT01181791|premature infants
1193495|NCT01181791|feeding tolerance
1193496|NCT01181778|hormonal contraceptive methods
1193497|NCT01181778|combined hormonal contraceptive methods
1193498|NCT01181778|physician counseling
1193499|NCT01181765|Crohn's Disease
1193500|NCT01181765|infliximab
1193501|NCT01181765|capsule endoscopy
1193502|NCT01181752|proficiency
1193503|NCT01181752|eye drop instillation
1193504|NCT01181752|postoperative cataract surgery
1193505|NCT01181752|Ghana
1193506|NCT01181739|Colonoscopy
1193507|NCT01181739|Virtual Colonoscopy
1193508|NCT01181739|Colonography
1193509|NCT01181739|Colorectal Cancer
1193510|NCT01181739|Colonic Polyps
1193511|NCT01181739|Screening
1193512|NCT01181726|Bioequivalence
1193513|NCT01181726|Healthy Subjects
1193514|NCT01181687|COMFORT behavioral scale
1193515|NCT01181687|pain assessment scale
1193516|NCT01181687|child
1193517|NCT01181687|validity
1193518|NCT01181687|reliability
1193519|NCT01181674|Diabetes
1193520|NCT01181674|Insulin
1193521|NCT01181674|Glargine
1193522|NCT01181674|Metformin
1193523|NCT01181674|Acarbose
1193524|NCT01181674|Diet
1193525|NCT01181674|Exercise
1193526|NCT01181674|Lifestyle
1193527|NCT01181661|Cigarette
1193528|NCT01181661|Smoking
1193529|NCT01181661|Nicotine
1193530|NCT01181661|Contingency Management
1193531|NCT01181661|Voucher Reinforcement
1193532|NCT01181661|Smoking Abstinence
1193533|NCT01181661|Internet
1193534|NCT01181661|Internet-based Treatment
1193535|NCT01181661|Group Contingencies
1193536|NCT01181648|Survivor
1193537|NCT01181648|Human Papillomavirus (HPV)
1193538|NCT01181648|Quality of Life
1193539|NCT01181648|Surviving Oropharynx Cancer
1193540|NCT01181648|10-111
1193541|NCT01181596|neonates and infants, from the 23-week gestational (0.5 kg)
1193542|NCT01181596|up to a 6 month old born at term (7 kg), for whom the PIV,
1193543|NCT01181596|PAC, UAC, UVC or PICC catheter insertion is medically
1193544|NCT01181596|indicated.
1193545|NCT01181570|psoriasis
1193546|NCT01181570|adalimumab
1193547|NCT01181570|obstructive sleep apnea
1193548|NCT01181570|obesity
1193549|NCT01181557|quality of life
1193550|NCT01181544|Anticoagulation
1193551|NCT01181544|Heparin
1193552|NCT01181544|Hemodialysis
1193553|NCT01181544|Dialysis
1193554|NCT01181544|Renal Dialysis
1193555|NCT01181531|Secondary Hyperthyroidism
1193556|NCT01181531|Hemodialysis
1193557|NCT01181531|Parathyroid
1193558|NCT01181531|PARADIGM
1193559|NCT01181518|Tamoxifen
1193560|NCT01181518|Pharmacogenomics
1193561|NCT01181518|Breast cancer
1193562|NCT01181505|HNF4a
1193563|NCT01181505|CYP2D6
1193564|NCT01181505|Toterodine
1193565|NCT01181505|Genetic polymorphism
1193566|NCT01181492|gene polymorphism
1193568|NCT01181492|fentanyl
1193569|NCT01181492|HPLC
1193570|NCT01181492|Analgesics
1193571|NCT01181479|Contraceptive
1193572|NCT01181466|PLVR
1193573|NCT01181466|BLVR
1193574|NCT01181466|AeriSeal
1193575|NCT01181466|treatment
1193576|NCT01181466|device
1193577|NCT01181466|breathing
1193578|NCT01181466|COPD
1193579|NCT01181466|emphysema
1193580|NCT01181466|polymeric lung volume reduction
1193581|NCT01181466|biologic lung volume reduction
1193582|NCT01181466|heterogeneous
1193583|NCT01181466|homogeneous
1193584|NCT01181466|Pathologic Processes
1193585|NCT01181466|Respiratory Tract Diseases
1193586|NCT01181466|Lung Diseases
1193587|NCT01181466|Pulmonary Disease, Chronic Obstructive
1193588|NCT01181453|Diabetic foot ulcer
1193589|NCT01181453|Randomized trial
1193590|NCT01181453|Clinical trial
1193591|NCT01181453|Dermagraft
1193592|NCT01181453|Standard care
1193593|NCT01181440|Diabetic foot ulcer
1193594|NCT01181440|Randomized trial
1193595|NCT01181440|Clinical trial
1193596|NCT01181440|Dermagraft
1193597|NCT01181440|Conventional care
1193598|NCT01181414|Permanent Atrial Fibrillation
1193599|NCT01181414|Resynchronization therapy
1193600|NCT01181414|Ablation
1193601|NCT01181401|induction chemotherapy
1193602|NCT01181401|radiotherapy
1193603|NCT01181401|locally advanced head neck tumor
1193604|NCT01181401|toxicity
1193605|NCT01181401|LA SCCHN
1193606|NCT01181401|Unresectable squamous cell cancer of the head and neck,
1193607|NCT01181401|Stage IV (UICC)
1193608|NCT01181375|cervical cancer
1193609|NCT01181375|assay
1193610|NCT01181375|hypoxia
1193611|NCT01181362|Endoscopy
1193612|NCT01181362|Head and Neck region
1193613|NCT01181362|Scope
1193614|NCT01181349|neuromuscular blockade; general anesthesia
1193615|NCT01181336|Safety
1193616|NCT01181336|Tolerability
1193617|NCT01181336|Immunogenicity
1193618|NCT01181336|Influenza
1193619|NCT01181336|Virus
1193620|NCT01181336|Vaccine
1193621|NCT01181323|influenza, vaccine, breastfeeding, post-partum women, infant, LAIV, TIV, parent protocol
1193622|NCT01181310|dementia, cognitive impairment, neurodegeneration, Alzheimer's, acetylcholine, AchE
1193623|NCT01181297|Confirmed milk allergy
1193624|NCT01181284|Pulmonary Arterial Hypertension (PAH)
1193625|NCT01181271|Lymphoma
1193626|NCT01181271|non-hodgkins lymphoma
1193627|NCT01181271|Hodgkin's lymphoma
1193628|NCT01181271|Hodgkin's disease
1193629|NCT01181271|stem cell transplant
1193630|NCT01181271|High-risk diffuse large B cell
1193631|NCT01181271|Transformed low grade lymphoma
1193632|NCT01181271|T-cell non-Hodgkin's lymphoma
1193633|NCT01181271|Mantle cell lymphoma at any time in therapy
1193634|NCT01181271|"Double-hit lymphoma"
1193635|NCT01181258|related HLA-haploidentical donor
1193636|NCT01181245|Pancreatic Cancer
1193637|NCT01181232|insomnia
1193638|NCT01181232|zolpidem
1193639|NCT01181206|Surgical site infections
1193640|NCT01181206|Covering the abdominal wound edge in laparotomies
1193641|NCT01181193|glioblastoma multiforme
1193642|NCT01181193|chemoradiotherapy
1193643|NCT01181193|vitamin D
1193644|NCT01181180|Ageing
1193645|NCT01181180|Balance control
1193646|NCT01181180|Falls
1193647|NCT01181180|dehydration
1193648|NCT01181167|Anticoagulants
1193649|NCT01181167|Venous thromboembolism
1193650|NCT01181167|Thromboembolism
1193651|NCT01181167|Thrombosis
1193652|NCT01181167|enoxaparin sodium
1193653|NCT01181167|Embolism
1193654|NCT01181167|Deep vein thrombosis
1193655|NCT01181167|DU-176b
1193656|NCT01181167|edoxaban
1193657|NCT01181167|factor Xa
1193658|NCT01181167|total hip arthroplasty
1193659|NCT01181154|Auto-Immune
1193660|NCT01181154|Hemolytic
1193661|NCT01181154|Anemia
1193662|NCT01181154|AHA
1193663|NCT01181154|AIHA
1193664|NCT01181154|Rituximab
1193665|NCT01181141|Anticoagulants
1193666|NCT01181141|Enoxaparin sodium
1193667|NCT01181141|venous thromboembolism.
1193668|NCT01181141|thromboembolism
1193669|NCT01181141|Thrombosis
1193670|NCT01181141|deep vein thrombosis
1193671|NCT01181141|DU-176b
1193672|NCT01181141|Edoxaban
1193673|NCT01181141|factor Xa
1193674|NCT01181141|hip fracture surgery
1193675|NCT01181141|embolism
1193676|NCT01181115|Chinese Patients
1193677|NCT01181115|Relapsing MS
1193678|NCT01181115|Safety
1193679|NCT01181115|Avonex
1193680|NCT01181115|Tolerability
1193681|NCT01181115|Gadolinium
1193682|NCT01181115|Interferon Beta 1a
1193683|NCT01181102|anticoagulant
1193684|NCT01181102|venus thromboembolism
1193685|NCT01181102|thrombosis
1193686|NCT01181102|thromboembolism
1193687|NCT01181102|embolism and thrombosis
1193688|NCT01181102|deep vein thrombosis
1193689|NCT01181102|DU-176b
1193690|NCT01181102|Edoxaban
1193691|NCT01181102|factor Xa
1193692|NCT01181102|total knee arthroplasty
1193693|NCT01181102|Enoxaparin sodium
1193694|NCT01181076|Stem cell transplantation
1193695|NCT01181076|Individualized Nutrition
1193696|NCT01181076|Quality of life
1193697|NCT01181076|Oral Mucositis
1193698|NCT01181076|Adult
1193699|NCT01181063|Asthma
1193700|NCT01181063|Easyhaler
1193701|NCT01181037|Displaced subcapital femoral fracture
1193702|NCT01181037|Bbipolar H.A.
1193703|NCT01181037|CRIF with Ttrochanteric Antegrade Nail
1193704|NCT01180972|Obesity, diabetes, hispanic, physical activity, nutrition
1193705|NCT01180959|Advanced Liver Cancer
1193706|NCT01180959|primary neoplasm of the liver
1193707|NCT01180959|Erlotinib
1193708|NCT01180959|Bevacizumab
1193709|NCT01180959|Hepatocellular Carcinoma
1193710|NCT01180959|HCC
1193711|NCT01180959|Avastin
1193712|NCT01180959|Anti-VEGF monoclonal antibody
1193713|NCT01180959|rhuMAb-VEGF
1193714|NCT01180959|OSI-774
1193715|NCT01180959|Tarceva
1193716|NCT01180946|FGF23
1193717|NCT01180946|FGF-23
1193718|NCT01180946|vitamin D
1193719|NCT01180946|vitamin D deficiency
1193720|NCT01180946|insulin resistance
1193721|NCT01180946|Healthy volunteers
1193722|NCT01180933|docosahexaenoic acid
1193723|NCT01180933|folate
1193724|NCT01180933|neurological development
1193725|NCT01180933|allergies
1193726|NCT01180933|long term consequences for the offspring
1193727|NCT01180933|allergy risk
1193728|NCT01180920|Dental
1193729|NCT01180920|Periodontal
1193730|NCT01180920|Surgery
1193731|NCT01180920|Gums
1193732|NCT01180907|18F-FAC
1193733|NCT01180907|imaging
1193734|NCT01180907|cancer
1193735|NCT01180907|inflammation
1193736|NCT01180907|PET
1193737|NCT01180894|Trauma
1193738|NCT01180894|Anemia
1193739|NCT01180894|Iron
1193740|NCT01180894|Erythropoeisis
1193741|NCT01180881|Proton Radiation
1193742|NCT01180881|CNS tumors
1193743|NCT01180881|Brain Tumors
1193744|NCT01180881|Neurobehavioral functioning
1193745|NCT01180868|imaging probe
1193746|NCT01180868|cancer
1193747|NCT01180868|inflammatory tissue
1193748|NCT01180868|inflammatory diseases
1193749|NCT01180855|Melatonin
1193750|NCT01180855|Cognitive Behavior Therapy
1193751|NCT01180842|CF
1193752|NCT01180816|GBM
1193753|NCT01180816|AA
1193754|NCT01180816|AO
1193755|NCT01180816|Brain
1193756|NCT01180816|Tumors
1193757|NCT01180816|Malignant
1193758|NCT01180816|Glioblastoma
1193759|NCT01180816|Multiforme
1193760|NCT01180816|Anaplastic
1193761|NCT01180816|Astrocytoma
1193762|NCT01180803|COPD - long term oxygenotherapy
1193763|NCT01180803|COPD patients with respiratory failure
1193764|NCT01180790|HCV
1193765|NCT01180790|Hepatitis C Genotype 1
1193766|NCT01180764|hypertriglyceridemia
1193767|NCT01180764|omega-3 acid ethyl esters
1193768|NCT01180764|high-density lipoproteins
1193769|NCT01180764|fish oil
1193770|NCT01180751|Positron Emission Tomography
1193771|NCT01180751|Fluorodeoxyglucose
1193772|NCT01180751|FDG (18F-Fluorodeoxyglucose)
1193773|NCT01180751|Oncology
1193774|NCT01180751|Neurology
1193775|NCT01180738|chronic stroke
1193776|NCT01180738|walking training
1193777|NCT01180738|rehabilitation
1193778|NCT01180738|body weight supported treadmill training
1193779|NCT01180738|physical therapy
1193780|NCT01180738|balance
1193781|NCT01180725|To investigate and compare the effects of dried plums and psyllium on the overall relief of constipation symptoms
1193782|NCT01180725|To investigate and compare the taste of dried plums and psyllium
1193783|NCT01180725|To investigate and compare the quality of life of dried plums and psyllium
1193784|NCT01180712|anthocyanin
1193785|NCT01180712|blaeberries
1193786|NCT01180712|bilberries
1193787|NCT01180712|blueberries
1193788|NCT01180712|mirtoselect
1193789|NCT01180712|type 2 diabetes
1193790|NCT01180712|insulin resistance
1193791|NCT01180712|Adipose tissue
1193792|NCT01180712|inflammation
1193793|NCT01180699|adult solid organ transplant patients
1193794|NCT01180686|low back pain
1193795|NCT01180686|chiropractic
1193796|NCT01180686|manipulation
1193797|NCT01180673|Hypertension
1193798|NCT01180673|Older Adults
1193799|NCT01180673|Motivational Interviewing
1193800|NCT01180673|Lifestyle Counseling
1193801|NCT01180673|Senior Centers
1193802|NCT01180660|Gastric Surgery
1193803|NCT01180660|Pain
1193804|NCT01180660|Recovery
1193805|NCT01180660|Laparoscopic Surgery
1193806|NCT01180647|Extended-release naltrexone
1193807|NCT01180647|Prisoners
1193808|NCT01180647|Opioid addiction prevention
1193809|NCT01180647|Medication Treatment Alternatives
1193810|NCT01180647|Prevention of Relapse to Opioid Addiction
1193811|NCT01180621|vaccine
1193812|NCT01180621|Seasonal Influenza Vaccine
1193813|NCT01180621|Influenza Vaccine
1193814|NCT01180621|Vaccine Safety
1193815|NCT01180621|Vaccine Immunogenicity
1193816|NCT01180621|Fluviral 2010-2011
1193817|NCT01180608|neuropathic pain
1193818|NCT01180608|Diabetic Polyneuropathy
1193819|NCT01180595|osteoarthritis
1193820|NCT01180595|arthroplasty
1193821|NCT01180595|knee joint
1193822|NCT01180595|radiography
1193823|NCT01180595|surgery
1193824|NCT01180595|Bone Density
1193825|NCT01180595|Outcome Assessment (Health Care)
1193826|NCT01180582|knee
1193827|NCT01180582|arthroplasty
1193828|NCT01180582|RSA
1193829|NCT01180582|migration
1193830|NCT01180582|micromotion
1193831|NCT01180582|osteoarthritis
1193832|NCT01180569|Lenalidomide
1193833|NCT01180569|10-022
1193834|NCT01180556|childhood
1193835|NCT01180556|abdominal pain
1193836|NCT01180556|probiotics
1193837|NCT01180517|Angioplasty Balloon
1193838|NCT01180504|ovarian cancer
1193839|NCT01180504|whole-abdominal radiotherapy
1193840|NCT01180504|consolidation treatment
1193841|NCT01180504|helical tomotherapy
1193842|NCT01180491|Discoloured and deformed nails resulting from onychomycosis
1193843|NCT01180478|Bladder Cancer
1193844|NCT01180478|Urothelial carcinoma
1193845|NCT01180478|Stage pTa or pT1
1193846|NCT01180478|NMIBC Ta/T1
1193847|NCT01180478|Narrow Band Imaging
1193848|NCT01180478|White Light Cystoscopy
1193849|NCT01180478|Transurethral resection
1193850|NCT01180478|Superficial bladder tumor
1193851|NCT01180478|Positive urine cytology
1193852|NCT01180465|Treatment of abdominal adiposity
1193853|NCT01180452|Crohn disease
1193854|NCT01180452|dysplasia
1193855|NCT01180452|adenocarcinoma
1193856|NCT01180452|endoscopy
1193857|NCT01180452|jejunum
1193858|NCT01180452|ileum
1193859|NCT01180439|Non-invasive ventilation
1193860|NCT01180439|Chronic Obstructive Pulmonary Disease
1193861|NCT01180439|Patient-ventilator synchronisation
1193862|NCT01180439|Sleep study
1193863|NCT01180439|Polysomnography
1193864|NCT01180426|Relapse Refractory Acute Myeloid Leukemia
1193865|NCT01180413|Inward eutrophic remodelling
1193866|NCT01180400|Major Depressive Disorder
1193867|NCT01180400|MDD
1193868|NCT01180400|Depression
1193869|NCT01180400|Safety
1193870|NCT01180400|add-on therapy
1193871|NCT01180374|Cannabis
1193872|NCT01180374|Marijuana
1193873|NCT01180374|Cannabidiol
1193874|NCT01180374|CBD
1193875|NCT01180374|THC
1193876|NCT01180374|Psychotic Disorders
1193877|NCT01180361|rheumatoid arthritis
1194001|NCT01179815|Monogenetic diabetes
1193878|NCT01180361|systemic lupus erythematosus
1193879|NCT01180361|atherosclerosis
1193880|NCT01180361|adenosine
1193881|NCT01180348|Wrinkles, glabellar, facial.
1193882|NCT01180335|Genomic driven chemotherapy
1193883|NCT01180322|azacitidine
1193884|NCT01180322|Acute myeloid Leukemia (AML)
1193885|NCT01180309|Tongue frenum
1193886|NCT01180309|Lingual frenum
1193887|NCT01180309|Audio Phonology
1193888|NCT01180309|Speech disorders
1193889|NCT01180296|Preterm birth, prevention, progesterone, oral
1193890|NCT01180283|Erectile dysfunction
1193891|NCT01180283|Lodenafil carbonate
1193892|NCT01180283|Diabetes
1193893|NCT01180270|Cervical dystonia
1193894|NCT01180270|torticollis spasmodicus
1193895|NCT01180270|botulinum toxin
1193896|NCT01180270|Subjective visual vertical (SVV)
1193897|NCT01180270|SVV
1193898|NCT01180270|static graviceptive function
1193899|NCT01180244|fibromyalgia
1193900|NCT01180244|noninvasive
1193901|NCT01180244|electrical
1193902|NCT01180244|cortical
1193903|NCT01180244|stimulation
1193904|NCT01180244|pain
1193905|NCT01180244|brain
1193906|NCT01180244|tender point
1193907|NCT01180231|Overweight or obese young adults (18 to 30 years old) with no previous history of cardiovascular disease/psychiatric illness, and not on medications
1193908|NCT01180218|myocardial revascularization
1193909|NCT01180218|myocardial infarction
1193910|NCT01180205|FMD
1193911|NCT01180205|hypertension
1193912|NCT01180205|Telmisartan
1193913|NCT01180205|Amlodipine
1193914|NCT01180192|blood loss
1193915|NCT01180192|oxygen inhalation
1193916|NCT01180179|H. pylori-negative idiopathic peptic ulcers
1193917|NCT01180179|Recurrent ulcer bleeding
1193918|NCT01180166|Gastric cancer
1193919|NCT01180166|concurrent chemoradiotherapy
1193920|NCT01180166|target therapy
1193921|NCT01180153|40 S-1/L-OHP
1193922|NCT01180153|biliary tract
1193923|NCT01180153|ampullary carcinoma
1193924|NCT01180140|Seamguard
1193925|NCT01180140|staple-line reinforcement
1193926|NCT01180140|leak
1193927|NCT01180140|bleeding
1193928|NCT01180127|flavonol
1193929|NCT01180127|exercise
1193930|NCT01180127|dentate gyrus
1193931|NCT01180127|cerebral blood volume
1193932|NCT01180127|dentate gyrus CBV
1193933|NCT01180114|economic empowerment model,
1193934|NCT01180114|orphaned children and youth,
1193935|NCT01180114|Uganda,
1193936|NCT01180114|sub-Saharan Africa
1193937|NCT01180101|Obesity
1193938|NCT01180101|Chronic Kidney Disease
1193939|NCT01180088|LIVER TUMOURS
1194061|NCT01179425|cognition
1193940|NCT01180062|Latanoprost subconjunctival insert
1193941|NCT01180049|Mantle Cell Lymphoma
1193942|NCT01180049|non-Hodgkin lymphoma (NHL)
1193943|NCT01180049|temsirolimus
1193944|NCT01180036|Membranous Nephropathy
1193945|NCT01180023|GBS
1193946|NCT01180023|Membrane sweeping
1193947|NCT01180010|Hodgkin's Lymphoma
1193948|NCT01180010|Lung Cancer
1193949|NCT01180010|Lung Nodule
1193950|NCT01180010|CT scan
1193951|NCT01179971|n-3 fatty acids
1193952|NCT01179971|n-6 fatty acids
1193953|NCT01179971|anti-inflammatory action
1193954|NCT01179971|clinical trial
1193955|NCT01179971|randomized double-blinded
1193956|NCT01179971|incorporation of fatty acids
1193957|NCT01179958|cognitive function
1193958|NCT01179958|fMRI
1193959|NCT01179958|apoE
1193960|NCT01179958|inflammatory markers
1193961|NCT01179958|exercise
1193962|NCT01179945|diabetes
1193963|NCT01179945|benzoic acid
1193964|NCT01179945|benzoate
1193965|NCT01179945|soda
1193966|NCT01179945|soft drink
1193967|NCT01179945|preservative
1193968|NCT01179945|blood sugar
1193969|NCT01179932|Pilot
1193970|NCT01179932|Charting
1193971|NCT01179932|Anesthesia Record
1193972|NCT01179932|Cardiac surgical operating room
1193973|NCT01179932|Cardiac surgical intensive care unit
1193974|NCT01179932|Electrophysiology lab
1193975|NCT01179919|Oseltamivir
1193976|NCT01179919|Obesity
1193977|NCT01179919|Influenza
1193978|NCT01179919|Pharmacokinetics in Obesity
1193979|NCT01179906|CKD
1193980|NCT01179893|Myasthenia Gravis
1193981|NCT01179893|IVIG
1193982|NCT01179893|PLEX
1193983|NCT01179880|Dermatitis
1193984|NCT01179880|Atopic
1193985|NCT01179867|Medication reconciliation
1193986|NCT01179867|Adverse drug events
1193987|NCT01179867|Hospital readmission
1193988|NCT01179867|Medication management
1193989|NCT01179841|Autism Spectrum Disorder
1193990|NCT01179841|language
1193991|NCT01179841|social
1193992|NCT01179841|toddlers
1193993|NCT01179828|Quantitative sensory testing
1193994|NCT01179828|Drug efficacy
1193995|NCT01179828|Low back pain syndrome
1193996|NCT01179828|Imipramine
1193997|NCT01179828|Oxycodone
1193998|NCT01179828|Clobazam
1193999|NCT01179828|Tolterodine
1194000|NCT01179815|Patients with type 1 or type 2 diabetes mellitus
1194002|NCT01179815|Pancreatogenic diabetes,
1194003|NCT01179815|Drug-induced diabetes, other forms
1194004|NCT01179815|Cohort Studies
1194005|NCT01179789|Healthy Elderly People
1194006|NCT01179776|ST-eleveation
1194007|NCT01179776|Myocardial infarct
1194008|NCT01179776|Percutaneous coronary intervention
1194009|NCT01179776|Myocardial infarct STEMI patients
1194010|NCT01179763|Amblyopia
1194011|NCT01179763|Retinal layer thickness
1194012|NCT01179750|Ultrasonic coagulating shears in gastrectomy
1194013|NCT01179737|Pulmonary Arterial Hypertension
1194014|NCT01179737|Nilotinib
1194015|NCT01179737|6MWD
1194016|NCT01179737|Pulmonary Hypertension
1194017|NCT01179711|accommodative esotropia
1194018|NCT01179698|computer-assisted surgery
1194019|NCT01179698|bone tumor
1194020|NCT01179698|We will evaluate whether computer-assisted surgery
1194021|NCT01179698|will be feasible and safe for bone tumor resection
1194022|NCT01179672|Diabetic Peripheral Neuropathic Pain
1194023|NCT01179659|Single dose crossover BE study
1194024|NCT01179646|Bioequivalency
1194025|NCT01179620|Hemodialysis, Certoparin
1194026|NCT01179581|Safety
1194027|NCT01179581|Tolerability
1194028|NCT01179581|Pharmacokinetics
1194029|NCT01179568|Grief
1194030|NCT01179568|Bereavement
1194031|NCT01179568|Psychotherapy
1194032|NCT01179568|Medication
1194033|NCT01179568|Treatment study
1194034|NCT01179555|Diabetic Complications
1194035|NCT01179555|Intervention Studies
1194036|NCT01179555|African Americans
1194037|NCT01179555|Vision Screening
1194038|NCT01179555|Vision, Low
1194039|NCT01179555|Geriatric Assessment
1194040|NCT01179555|Outcomes Assessment
1194041|NCT01179555|Cultural Characteristics
1194042|NCT01179555|Cultural Competency
1194043|NCT01179555|Appointment Adherence
1194044|NCT01179555|Cost-effectiveness
1194045|NCT01179555|Personalization of care
1194046|NCT01179555|Follow-up Care
1194047|NCT01179542|iugr pet eIF4E Translation Initiation Factor
1194048|NCT01179542|4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
1194049|NCT01179529|Atopic dermatitis (atopic eczema)
1194050|NCT01179516|Major Depressive Disorder
1194051|NCT01179516|Depression
1194052|NCT01179516|Drug Therapy
1194053|NCT01179503|vitamin D
1194054|NCT01179503|physical performance
1194055|NCT01179490|Multiple Myeloma
1194056|NCT01179477|Left heart pacing lead
1194057|NCT01179477|Cardiac resynchronization therapy (CRT)
1194058|NCT01179477|Heart failure
1194059|NCT01179425|marijuana
1194060|NCT01179425|dependence
1194062|NCT01179425|stress
1194063|NCT01179386|methylphenidate
1194064|NCT01179386|ADHD
1194065|NCT01179386|driving
1194066|NCT01179386|simulator
1194067|NCT01179386|pressure
1194068|NCT01179386|adolescent
1194069|NCT01179360|Locally advanced
1194070|NCT01179360|HNSCC
1194071|NCT01179334|Pulmonary Hypertension
1194072|NCT01179334|Riociguat
1194073|NCT01179334|Blood Pressure
1194074|NCT01179308|regional analgesia
1194075|NCT01179308|routine general anesthesia
1194076|NCT01179308|immune system response
1194077|NCT01179308|lung cancer (stage 1-3)
1194082|NCT01179282|DUST MITE ALLERGIES
1194083|NCT01179269|Non-small cell lung cancer
1194084|NCT01179269|Pazopanib
1194085|NCT01179269|Stage IIIB/IV non small cell lung cancer
1194086|NCT01179256|ASTHMA
1194087|NCT01179243|microcirculatory alterations
1194088|NCT01179243|SDF imaging
1194089|NCT01179230|CAD
1194090|NCT01179230|chest pain
1194091|NCT01179230|acute coronary syndrome
1194092|NCT01179230|Myocardial perfusion imaging
1194093|NCT01179217|Sickle Cell Anemia
1194094|NCT01179217|Sickle Cell Pain Crises
1194095|NCT01179217|Painful Crises
1194096|NCT01179217|Sickle Cell Pain
1194097|NCT01179217|Vaso-occlusive Crises
1194098|NCT01179191|chronic pain
1194099|NCT01179191|Embeda
1194100|NCT01179191|opioid
1194101|NCT01179191|moderate pain
1194102|NCT01179191|severe pain
1194103|NCT01179191|conversion
1194104|NCT01179191|converting
1194105|NCT01179191|switching
1194106|NCT01179191|morphine
1194107|NCT01179191|aberrant behavior
1194108|NCT01179191|Pain (DT) + Chronic Disease (DT)
1194109|NCT01179152|asthma, september epidemic, children, preventive
1194110|NCT01179139|CRS
1194111|NCT01179126|myocardial infarction
1194112|NCT01179126|primary angioplasty
1194113|NCT01179126|multivessel disease
1194114|NCT01179126|stress echocardiography
1194115|NCT01179113|Laminectomy
1194116|NCT01179113|Esmolol Infusion
1194117|NCT01179113|Quality of recovery
1194118|NCT01179113|beta-blockers
1194119|NCT01179113|Pain management
1194120|NCT01179113|Postoperative pain
1194121|NCT01179113|Opioid requirements
1194122|NCT01179113|Intraoperative esmolol infusion
1194123|NCT01179113|Return to normal activities of daily living
1194124|NCT01179100|elderly
1194125|NCT01179100|general anesthesia
1194126|NCT01179100|lidocaine infusion
1194127|NCT01179100|lidocaine
1194128|NCT01179100|local anesthetic
1194129|NCT01179100|pain management
1194130|NCT01179100|cognitive function
1194131|NCT01179087|sleep disordered breathing
1194132|NCT01179087|lung transplantation
1194133|NCT01179074|palliation inoperable oesophageal cancer
1194134|NCT01179061|Apelin
1194135|NCT01179061|Heart failure
1194136|NCT01179061|Pulmonary artery pressure
1194137|NCT01179061|Inotropic
1194138|NCT01179061|Diuretic
1194139|NCT01179035|Post-release, community health
1194140|NCT01179022|Bacteremia
1194141|NCT01179022|Argon Plasma Coagulation
1194142|NCT01179022|Endobronchial Lesions
1194143|NCT01179009|depression
1194144|NCT01178983|work related musculoskeletal disorders (WRMSD) among computer operators
1194145|NCT01178957|Type 1 diabetes
1194146|NCT01178957|Very-Low-Density-Lipoprotein(VLDL)
1194147|NCT01178957|Hyperglycemia
1194148|NCT01178931|IVF
1194149|NCT01178931|luteal phase support
1194150|NCT01178931|oral progesterone
1194151|NCT01178931|vaginal progesterone
1194152|NCT01178931|pregnancy rate
1194153|NCT01178931|safety
1194154|NCT01178931|tolerability
1194155|NCT01178918|Influenza H1N1
1194156|NCT01178918|Vaccine
1194157|NCT01178918|Adjuvant
1194158|NCT01178918|T Lymphocytes
1194159|NCT01178918|Non-specific response
1194160|NCT01178918|Interleukin-2
1194161|NCT01178918|Non-specific T cell responce
1194162|NCT01178905|Postnatal CMV infection of preterm infants
1194163|NCT01178905|breast milk
1194164|NCT01178892|Hot Flashes
1194165|NCT01178892|Menopause
1194166|NCT01178892|Vasomotor symptoms
1194167|NCT01178892|Yoga
1194168|NCT01178892|Exercise
1194169|NCT01178892|Omega-3
1194170|NCT01178892|Fish oil
1194171|NCT01178879|Telehealth
1194172|NCT01178879|nurse consultation
1194173|NCT01178879|outpatient clinic
1194174|NCT01178866|thoracic surgery
1194175|NCT01178866|myocardial revascularization
1194176|NCT01178866|left ventricular dysfunction
1194177|NCT01178866|tissue perfusion
1194178|NCT01178866|prognosis
1194179|NCT01178853|Healthy Volunteers
1194180|NCT01178840|female condom
1194181|NCT01178840|condom
1194182|NCT01178840|clinical failure
1194183|NCT01178840|prostate-specific antigen
1194184|NCT01178840|semen exposure
1194185|NCT01178840|acceptability
1194186|NCT01178840|Prevention of semen exposure
1194187|NCT01178801|liver cancer
1194188|NCT01178801|data mining
1194189|NCT01178801|knowledge discovering
1194190|NCT01178801|The clinical data of the patients with liver cancer.
1194191|NCT01178788|Progestagens
1194192|NCT01178788|Tertiary Prophylaxis
1194193|NCT01178788|Micronized Progesterone
1194194|NCT01178788|17 alpha hydroxy P
1194195|NCT01178788|Preterm Delivery
1194196|NCT01178788|Cervical shortening
1194197|NCT01178775|fatigue
1194198|NCT01178775|meaning
1194199|NCT01178775|education
1194200|NCT01178775|walking program
1194201|NCT01178762|Oral Azithromycin
1194202|NCT01178762|Chlamydial Conjunctivitis
1194203|NCT01178749|Hepatitis C
1194204|NCT01178749|Interferon
1194205|NCT01178749|Symptom Distress
1194206|NCT01178749|Quality of Life
1194207|NCT01178736|neoplasms
1194208|NCT01178723|breakfast size
1194209|NCT01178723|blood glucose balance
1194210|NCT01178723|hormonal profile
1194211|NCT01178723|appetite hormones
1194212|NCT01178723|adipokines
1194213|NCT01178723|pro-inflammatory cytokines
1194214|NCT01178684|ENFD
1194215|NCT01178684|epidermal nerve fiber density
1194216|NCT01178684|HIV
1194217|NCT01178684|HIV-infection
1194218|NCT01178671|PTSD
1194219|NCT01178671|trauma
1194220|NCT01178671|anxiety disorder
1194221|NCT01178671|medication
1194222|NCT01178671|sertraline
1194223|NCT01178671|mirtazapine
1194224|NCT01178671|pharmacotherapy
1194225|NCT01178632|Herbal
1194226|NCT01178632|Phytotherapy
1194227|NCT01178632|Passiflora
1194228|NCT01178632|Valeriana
1194229|NCT01178632|Anxiety
1194230|NCT01178619|IUGR fetuses
1194231|NCT01178619|symmetrical IUGR
1194232|NCT01178619|asymmetrical IUGR
1194233|NCT01178606|echogenic halo around lateral fetal ventricles
1194234|NCT01178593|IBS
1194235|NCT01178593|RCT
1194236|NCT01178593|psychology
1194237|NCT01178593|hypnosis
1194238|NCT01178593|psychotherapy
1194239|NCT01178593|group therapy
1194240|NCT01178580|fibrinolytic activity
1194241|NCT01178580|Community acquired pneumonia (CAP)
1194242|NCT01178580|Pleural effusion
1194243|NCT01178567|laparoscopic sleeve gastrectomy
1194244|NCT01178567|Gastrectomy
1194245|NCT01178567|Pulmonary Complications
1194246|NCT01178554|anxiety disorders
1194247|NCT01178554|depression
1194248|NCT01178554|depressive disorders
1194249|NCT01178554|disruptive behavioral problems
1194250|NCT01178554|conduct problems
1194251|NCT01178541|ventricles
1194252|NCT01178541|fetal
1194253|NCT01178541|brain
1194254|NCT01178541|asymmetry
1194255|NCT01178528|heart failure
1194256|NCT01178528|heart rate
1194257|NCT01178528|ivabradine
1194258|NCT01178528|carvedilol
1194259|NCT01178515|epidemiological risk
1194260|NCT01178515|diet
1194261|NCT01178515|fat intake
1194262|NCT01178450|Renal transplant
1194263|NCT01178450|Hypercalcemia
1194264|NCT01178437|seizure disorder,
1194265|NCT01178437|seizures,
1194266|NCT01178437|convulsions,
1194267|NCT01178437|grand mal,
1194268|NCT01178437|petit mal,
1194269|NCT01178437|absence seizures,
1194270|NCT01178437|repeated seizures,
1194271|NCT01178437|children's seizures,
1194272|NCT01178437|secondary epilepsy,
1194273|NCT01178437|symptomatic epilepsy,
1194274|NCT01178437|generalized seizures,
1194275|NCT01178437|partial seizure,
1194276|NCT01178437|focal seizure,
1194277|NCT01178437|partial complex seizure,
1194278|NCT01178437|anticonvulsant medication
1194279|NCT01178424|Unipolar depression
1194280|NCT01178424|Mindfulness based cognitive therapy
1194281|NCT01178424|Cognitive behavioural Therapy
1194282|NCT01178424|Functional magnetic resonance imaging
1194283|NCT01178424|Relapse
1194284|NCT01178424|Depressive relapse
1194285|NCT01178424|Dysphoric
1194286|NCT01178424|Cognitive reactivity
1194287|NCT01178424|Serotonin transporter gene
1194288|NCT01178411|hepatocellular carcinoma
1194289|NCT01178411|renal cell carcinoma
1194290|NCT01178411|melanoma
1194291|NCT01178411|non-small cell lung cancer
1194292|NCT01178411|breast cancer
1194293|NCT01178411|ovarian cancer
1194294|NCT01178411|MiT tumors
1194295|NCT01178398|fish
1194296|NCT01178398|pregnancy
1194297|NCT01178398|nutrition
1194298|NCT01178398|mercury
1194299|NCT01178398|focus group
1194300|NCT01178398|omega-3 fatty acid
1194301|NCT01178398|docosahexaenoic acid (DHA)
1194302|NCT01178385|Autism
1194303|NCT01178385|Asperger's Syndrome
1194304|NCT01178385|Treatment
1194305|NCT01178385|Cognitive-behavioral therapy
1194306|NCT01178385|Anxiety
1194307|NCT01178385|Children
1194308|NCT01178385|Therapy
1194309|NCT01178372|hepatic encephalopathy
1194310|NCT01178372|lactulose
1194311|NCT01178372|probiotics
1194312|NCT01178359|cardiac arrest
1194313|NCT01178359|ventricular fibrillation
1194314|NCT01178359|nitrite
1194315|NCT01178346|Pharmacoeconomic
1194316|NCT01178346|Quality of Life
1194317|NCT01178346|Health Outcomes
1194318|NCT01178346|Smoking
1194319|NCT01178346|NicVAX
1194320|NCT01178346|Smoking vaccine
1194321|NCT01178346|Smoking cessation
1194322|NCT01178333|Thrombocytopenia
1194323|NCT01178333|Heparin
1194324|NCT01178320|Magnetic Resonance Imaging
1194325|NCT01178320|Atherosclerotic Plaque
1194326|NCT01178320|Lipid Lowering Therapy
1194327|NCT01178307|GI cancers
1194328|NCT01178307|GIST
1194329|NCT01178307|Symptom Severity
1194330|NCT01178307|Quality of Life
1194331|NCT01178307|Questionnaire
1194332|NCT01178307|M.D. Anderson Symptom Inventory
1194333|NCT01178307|MDASI-GIST
1194334|NCT01178307|patient-reported outcomes
1194335|NCT01178294|hemophilia A
1194336|NCT01178294|haemophilia A
1194337|NCT01178294|blood coagulation disorders
1194338|NCT01178294|hemorrhagic disorders
1194339|NCT01178294|coagulation protein disorder
1194340|NCT01178294|hematologic diseases
1194341|NCT01178294|Acquired Hemophilia A
1194342|NCT01178281|Myelofibrosis
1194343|NCT01178281|Post-polycythemia vera myelofibrosis
1194344|NCT01178281|Post-essential thrombocythemia myelofibrosis
1194345|NCT01178281|RBC-transfusion-dependence
1194346|NCT01178281|Primary Myelofibrosis
1194347|NCT01178268|Drug eluting stents
1194348|NCT01178268|Stents
1194349|NCT01178268|Angioplasty
1194350|NCT01178255|depression
1194351|NCT01178255|homoeopathy
1194352|NCT01178242|Labial mucous membrane
1194353|NCT01178242|symblepharon
1194354|NCT01178242|dry eye
1194355|NCT01178242|Stevens -Johnson syndrome
1194356|NCT01178242|salivary gland
1194357|NCT01178242|ocular surface disease
1194358|NCT01178242|transplantation
1194359|NCT01178229|Sleep bruxism
1194360|NCT01178229|Airway remodeling
1194361|NCT01178229|Physical therapy modalities
1194362|NCT01178229|Child preschool.
1194363|NCT01178216|Kidney transplant
1194364|NCT01178216|highly sensitized
1194365|NCT01178203|Endodontics
1194366|NCT01178203|pain
1194367|NCT01178203|visual analogue scale
1194368|NCT01178203|NSAIDs
1194369|NCT01178190|narrow band imaging
1194370|NCT01178190|malignant lesion
1194371|NCT01178190|lung cancer
1194372|NCT01178190|NBI
1194373|NCT01178177|Invasive pulmonary aspergillosis
1194374|NCT01178177|Solid organ transplantation
1194375|NCT01178177|Hematologic disease
1194376|NCT01178164|chronic pains
1194377|NCT01178164|unknown aetiology
1194378|NCT01178151|Peutz-Jeghers syndrome
1194379|NCT01178151|mTOR inhibition
1194380|NCT01178151|cancer
1194381|NCT01178138|substance abuse
1194382|NCT01178125|Pregnancy Prevention
1194383|NCT01178125|Oral Contraceptives
1194384|NCT01178112|Metastasis
1194385|NCT01178112|Carboplatin
1194386|NCT01178112|Trientine
1194387|NCT01178112|Chemotherapy
1194388|NCT01178073|Pulmonary Arterial Hypertension
1194389|NCT01178073|Ambrisentan
1194390|NCT01178073|Sponsor Rest of World: GSK
1194391|NCT01178073|Tadalafil
1194392|NCT01178073|PAH
1194393|NCT01178073|Sponsor US: Gilead
1194394|NCT01178060|Stroke
1194395|NCT01178060|Risk
1194396|NCT01178060|Communication
1194397|NCT01178060|Cardiovascular Disease Knowledge
1194398|NCT01178060|Improve Risk Communication
1194399|NCT01178034|Warfarin
1194400|NCT01178034|Dose
1194401|NCT01178034|Pharmacogenetic
1194402|NCT01178034|INR
1194403|NCT01178021|malaria
1194404|NCT01178021|vivax
1194405|NCT01178021|relapse
1194406|NCT01178008|Insomnia
1194407|NCT01178008|Post-partum Depression
1194408|NCT01178008|Electroacupuncture
1194409|NCT01178008|Acupuncture
1194410|NCT01178008|Randomized Clinical Trial
1194411|NCT01178008|Traditional Chinese Medicine
1194412|NCT01177982|pregnancy, opioid, cocaine, alcohol, benzodiazepines, neonate
1194413|NCT01177969|Autism
1194414|NCT01177969|Anxiety
1194415|NCT01177969|Asperger's Syndrome
1194416|NCT01177969|Cognitive-behavioral therapy
1194417|NCT01177969|Treatment
1194418|NCT01177969|Obsessive-compulsive disorder
1194419|NCT01177969|Fears
1194420|NCT01177956|Recurrent and/or metastatic squamous cell carcinoma of the head and neck
1194421|NCT01177956|1st-line
1194422|NCT01177956|Cetuximab
1194423|NCT01177956|Chemotherapy
1194424|NCT01177956|EMR 62241 -055
1194425|NCT01177956|Merck KGaA
1194426|NCT01177956|Recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
1194427|NCT01177865|adenocarcinoma of the prostate
1194428|NCT01177865|stage I prostate cancer
1194429|NCT01177865|stage IIB prostate cancer
1194430|NCT01177865|stage IIA prostate cancer
1194431|NCT01177865|stage III prostate cancer
1194432|NCT01177852|cough, acute rhinitis, common cold, nasal symptoms, children.
1194433|NCT01177852|Acute inflammation upper airway
1194434|NCT01177826|Hospitalized
1194435|NCT01177826|Rotavirus
1194436|NCT01177826|Children
1194437|NCT01177826|effectiveness
1194438|NCT01177826|Gastroenteritis
1194439|NCT01177800|Psoriasis
1194440|NCT01177800|Infliximab
1194441|NCT01177800|Remicade
1194442|NCT01177787|cryolipolysis fat zeltiq thigh Korean women
1194443|NCT01177774|functional connectivity MRI
1194444|NCT01177774|brain volumetry
1194445|NCT01177774|negative reinforcement
1194446|NCT01177774|OCD
1194447|NCT01177774|ADHD
1194448|NCT01177761|Osteoporosis
1194449|NCT01177761|exercise
1194450|NCT01177761|fractures
1194451|NCT01177761|Bone Mineral Density
1194452|NCT01177761|CHD-risk
1194453|NCT01177748|Stroke
1194454|NCT01177748|Cardiac Monitoring
1194455|NCT01177735|Pomalidomide
1194456|NCT01177735|multiple myeloma
1194457|NCT01177735|relapsed
1194458|NCT01177722|Diphtheria
1194459|NCT01177722|Tetanus
1194460|NCT01177722|Whooping cough
1194461|NCT01177722|Hepatitis B
1194462|NCT01177722|Poliomyelitis
1194463|NCT01177722|Diphtheria-Tetanus-acellular Pertussis Vaccines
1194464|NCT01177709|schizophrenia
1194465|NCT01177709|antipsychotics
1194466|NCT01177709|obesity
1194467|NCT01177709|diabetes
1194468|NCT01177696|caregivers
1194469|NCT01177696|Family Health
1194470|NCT01177696|Psychotherapeutic
1194471|NCT01177696|Primary Health Care
1194472|NCT01177670|Adiana Permanent Contraception System
1194473|NCT01177670|women seeking permanent sterilization.
1194474|NCT01177631|Carcinoma, hepatocellular
1194475|NCT01177631|Portal vein
1194476|NCT01177631|Proteomics
1194477|NCT01177618|Chronic Obstructive Pulmonary Disease
1194478|NCT01177618|COPD
1194479|NCT01177618|Emphysema
1194480|NCT01177618|Chronic Bronchitis
1194481|NCT01177618|Genetics
1194482|NCT01177618|Association Studies
1194483|NCT01177579|Bariatric surgery, copper deficiency, biomarkers
1194484|NCT01177566|Atopic dermatitis
1194485|NCT01177566|Elidel
1194486|NCT01177566|pimecrolimus cream 1%
1194487|NCT01177566|Eletone
1194488|NCT01177566|medical device cream
1194489|NCT01177566|topical calcineurin inhibitor
1194490|NCT01177553|Intrauterine Growth Retardation in Monochorionic Twins
1194491|NCT01177527|Waldenstrom
1194492|NCT01177527|myeloma
1194493|NCT01177527|smoldering
1194494|NCT01177527|lymphoma
1194495|NCT01177527|MGUS
1194496|NCT01177527|distinct B-cell lymphoproliferative disorder
1194497|NCT01177514|Refractive surgery
1194498|NCT01177514|PRK
1194499|NCT01177514|PAIN
1194500|NCT01177514|Gabapentin
1194501|NCT01177501|Ovarian cancer
1194502|NCT01177501|Topotecan
1194503|NCT01177501|Carboplatine
1194504|NCT01177501|Higt dose chemotherapy
1194505|NCT01177488|Military
1194506|NCT01177488|Health Service Delivery
1194507|NCT01177488|Behavioral Symptoms
1194508|NCT01177488|Telepsychology
1194509|NCT01177488|Behavioral Activation
1194510|NCT01177488|Exposure Therapy
1194511|NCT01177488|Veterans
1194512|NCT01177488|Telemedicine
1194513|NCT01177475|kidney-transplant recipients
1194514|NCT01177462|coordinate system
1194515|NCT01177462|normal
1194516|NCT01177449|prolotherapy
1194517|NCT01177436|prostate cancer
1194518|NCT01177436|benign prostatic hypertrophy
1194519|NCT01177423|restorative odontology
1194520|NCT01177423|Patients cared in restorative odontology department
1194521|NCT01177410|IBS
1194522|NCT01177410|Diarrhea
1194523|NCT01177410|IBS-D
1194524|NCT01177410|Irritable Bowel Syndrome
1194525|NCT01177410|Abdominal pain
1194526|NCT01177410|Bloating
1194527|NCT01177397|Advanced solid malignant neoplasms,Non-Hodgkin Lymphoma,
1194528|NCT01177397|Multiple Myeloma
1194529|NCT01177384|Type 2 diabetes mellitus
1194530|NCT01177384|T2DM
1194531|NCT01177358|Scar
1194532|NCT01177358|Botox
1194533|NCT01177332|FFA
1194534|NCT01177332|Liver
1194535|NCT01177332|steatosis
1194536|NCT01177332|exercise
1194537|NCT01177319|Parkinson's Disease
1194538|NCT01177319|Glutathione
1194539|NCT01177306|ADHD, working memory
1194540|NCT01177293|biological availability
1194541|NCT01177293|bioavailability
1194542|NCT01177293|amlodipine
1194543|NCT01177293|orally disintegrating tablet
1194544|NCT01177293|ODT
1194545|NCT01177293|tablets
1194546|NCT01177280|retrospective chronic low back pain
1194547|NCT01177267|retrospective database analysis in osteoarthritis patients
1194548|NCT01177254|retrospective chronic low back pain
1194549|NCT01177241|retrospective chronic low back pain
1194550|NCT01177215|Algorithm
1194551|NCT01177215|Treatment Protocol
1194552|NCT01177215|Thoracic Drainage Device
1194553|NCT01177202|HAC1, H1N1
1194554|NCT01177189|Oxidative Stress
1194555|NCT01177189|Free radicals
1194556|NCT01177189|Aging
1194557|NCT01177176|Cigarette smoking
1194558|NCT01177176|Tobacco smoking
1194559|NCT01177163|Type 2 diabetes mellitus
1194560|NCT01177163|Canagliflozin
1194561|NCT01177163|JNJ-28431754
1194562|NCT01177163|Insulin
1194563|NCT01177163|Pharmacokinetic
1194564|NCT01177163|Pharmacodynamic
1194565|NCT01177163|SGLT-1
1194566|NCT01177150|Sodium-Glucose Transporter 2
1194567|NCT01177150|Canagliflozin
1194568|NCT01177150|Pharmacodynamic
1194569|NCT01177150|Pharmacokinetic
1194570|NCT01177150|Safety
1194571|NCT01177150|Tolerability
1194572|NCT01177137|tinnitus
1194573|NCT01177137|tinnitus retraining therapy
1194574|NCT01177137|standard of care
1194575|NCT01177137|directive counseling
1194576|NCT01177137|sound therapy
1194577|NCT01177137|tinnitus questionnaire
1194578|NCT01177137|tinnitus handicap inventory
1194579|NCT01177124|Breast cancer
1194580|NCT01177124|Survivors
1194581|NCT01177124|Mindfulness-Based Stress Reduction (MBSR)
1194582|NCT01177124|Symptoms
1194583|NCT01177124|Immune markers
1194584|NCT01177085|obesity
1194585|NCT01177085|weight
1194586|NCT01177085|weight-loss
1194587|NCT01177085|mushroom
1194588|NCT01177085|oxidative
1194589|NCT01177085|stress
1194590|NCT01177085|immune
1194591|NCT01177085|function
1194592|NCT01177085|inflammation
1194593|NCT01177072|PTSD
1194594|NCT01177059|Gene Therapy
1194595|NCT01177059|Anti-HIV-1 Ribozyme
1194596|NCT01177059|OZ1
1194597|NCT01177059|HIV-1 Infections
1194598|NCT01177046|Women receiving labour epidural for most recent delivery
1194599|NCT01177007|Gastrointestinal Diseases
1194600|NCT01177007|Colonic Diseases
1194601|NCT01177007|Intestinal Diseases
1194602|NCT01177007|Rectal Diseases
1194603|NCT01177007|Neoplastic Processes
1194604|NCT01177007|Pathologic Processes
1194605|NCT01177007|Neuroendocrine Tumors
1194606|NCT01177007|Neuroectodermal Tumors
1194607|NCT01177007|Neoplasms, Germ Cell and Embryonal
1194608|NCT01177007|Adenocarcinoma
1194609|NCT01177007|Neoplasms, Nerve Tissue
1194610|NCT01177007|Liver Diseases
1194611|NCT01177007|Neoplasms
1194612|NCT01177007|Carcinoma
1194613|NCT01177007|Colorectal Neoplasms
1194614|NCT01177007|Neoplasm Metastasis
1194615|NCT01177007|Carcinoma, Neuroendocrine
1194616|NCT01177007|Liver Neoplasms
1194617|NCT01177007|Neoplasms, Glandular and Epithelial
1194618|NCT01177007|Neoplasms by Histologic Type
1194619|NCT01177007|Intestinal Neoplasms
1194620|NCT01177007|Gastrointestinal Neoplasms
1194621|NCT01177007|Digestive System Neoplasms
1194622|NCT01177007|Neoplasms by Site
1194623|NCT01177007|Digestive System Diseases
1194624|NCT01176994|Patients with skin lesions that are treated by dermatologists with destructive modalities without histological evaluation.
1194625|NCT01176981|pediatrics
1194626|NCT01176981|Osteosarcoma
1194627|NCT01176981|Methotrexate
1194628|NCT01176981|Outpatient
1194629|NCT01176968|Eplerenone
1194630|NCT01176968|myocardial infarction
1194631|NCT01176968|mortality
1194632|NCT01176968|morbidity
1194633|NCT01176955|Acne
1194634|NCT01176955|Acne vulgaris
1194635|NCT01176955|Adherence
1194636|NCT01176955|Compliance
1194637|NCT01176955|MEMS
1194638|NCT01176955|Benzoyl peroxide
1194639|NCT01176929|Suicide, Attempted
1194640|NCT01176929|prevention suicidal act
1194641|NCT01176929|telephone contact
1194642|NCT01176929|professional coordination
1194643|NCT01176916|breast cancer
1194644|NCT01176916|Aromasin
1194645|NCT01176916|adjuvant chemotherapy
1194646|NCT01176916|endocrine therapy
1194647|NCT01176890|truncal vagotomy
1194648|NCT01176890|GLP-1
1194649|NCT01176890|gastric emptying
1194650|NCT01176890|appetite
1194651|NCT01176890|food intake
1194652|NCT01176864|Small-Bowel Disorders
1194653|NCT01176864|Double-balloon enteroscopy
1194654|NCT01176864|Single-balloon enteroscopy
1194655|NCT01176851|None (study in healthy volunteers)
1194656|NCT01176838|Breast Cancer Quality of Life Survey
1194657|NCT01176825|bipolar disorder
1194658|NCT01176825|cognitive behavior therapy
1194659|NCT01176825|alcohol abuse
1194660|NCT01176825|drug abuse
1194661|NCT01176825|high risk behaviors
1194662|NCT01176825|medication adherence
1194663|NCT01176825|psychosocial functioning
1194664|NCT01176812|Facialwasting
1194665|NCT01176812|Juvederm
1194666|NCT01176812|Restylane
1194667|NCT01176799|Breast cancer patients with measurable primary breast cancer tumor.
1194668|NCT01176786|infection
1194669|NCT01176786|tissue expander
1194670|NCT01176786|breast implant
1194671|NCT01176786|breast reconstruction
1194672|NCT01176786|Infections rates
1194673|NCT01176760|vagotomy
1194674|NCT01176760|vagus
1194675|NCT01176760|GLP-1
1194676|NCT01176760|Insulin secretion
1194677|NCT01176734|Pulsatile Tinnitus
1194678|NCT01176734|Ringing-Buzzing-Tinnitus
1194679|NCT01176734|Spontaneous Oto-Acoustic Emission Tinnitus
1194680|NCT01176734|Tensor Palatini Induced Tinnitus
1194681|NCT01176734|Tensor Tympani Induced Tinnitus
1194682|NCT01176734|Tinnitus of Vascular Origin
1194683|NCT01176734|Tinnitus, Clicking
1194684|NCT01176734|Tinnitus, Leudet
1194685|NCT01176734|Tinnitus, Leudet's
1194686|NCT01176734|Tinnitus, Noise Induced
1194687|NCT01176734|Tinnitus, Objective
1194688|NCT01176734|Tinnitus, Spontaneous Oto-Acoustic Emission
1194689|NCT01176734|Tinnitus, Subjective
1194690|NCT01176734|Tinnitus, Tensor Palatini Induced
1194691|NCT01176734|Tinnitus, Tensor Tympani Induced
1194692|NCT01176734|Vascular Origin Tinnitus
1194693|NCT01176721|schizophrenic disorders
1194694|NCT01176721|psychosis
1194695|NCT01176721|psychotic
1194696|NCT01176721|dementia
1194697|NCT01176721|delusional
1194698|NCT01176721|delusions
1194699|NCT01176721|hallucinations
1194700|NCT01176721|residual-type schizophrenia
1194701|NCT01176721|illusions
1194702|NCT01176721|split mind
1194703|NCT01176721|mental health disorder
1194704|NCT01176721|schizoid
1194705|NCT01176721|paranoid-type schizophrenia
1194706|NCT01176721|disorganized-type schizophrenia
1194707|NCT01176721|undifferentiated-type schizophrenia
1194708|NCT01176721|catatonic-type schizophrenia
1194709|NCT01176721|mental illness
1194710|NCT01176721|tardive dyskinesia
1194711|NCT01176721|neuroleptic malignant syndrome
1194712|NCT01176721|NMS
1194713|NCT01176721|antipsychotics
1194714|NCT01176721|atypical antipsychotics
1194715|NCT01176721|psychosocial treatments
1194716|NCT01176721|rehabilitation
1194717|NCT01176708|liver transplantation
1194718|NCT01176708|kidney transplanted
1194719|NCT01176708|glucagon-like peptide-1
1194720|NCT01176708|insulin secretion
1194721|NCT01176708|vagotomy
1194722|NCT01176682|NSAID-treated patients
1194723|NCT01176682|gastrointestinal events
1194724|NCT01176682|Non-steroid anti-inflammatory drug (NSAID)
1194725|NCT01176682|Gastrointestinal events (GI events)
1194726|NCT01176682|Proton Pump Inhibitors (PPI)
1194727|NCT01176669|Apatinib
1194728|NCT01176669|Triple-Negative Breast Cancer
1194729|NCT01176669|Metastatic Breast Cancer
1194730|NCT01176669|ER/PR Negative
1194731|NCT01176669|Her2/Neu Negative
1194732|NCT01176656|Type 2 Diabetes Mellitus
1194733|NCT01176656|Hypoglycemia
1194734|NCT01176643|SLE
1194735|NCT01176643|Yoga
1194736|NCT01176630|metabolic syndrome, ESRD patient
1194737|NCT01176617|Atrial Fibrillation
1194738|NCT01176617|A-Fib
1194739|NCT01176617|AF
1194740|NCT01176617|Persistent
1194741|NCT01176617|Permanent
1194742|NCT01176617|Pulmonary Vein isolation
1194743|NCT01176617|Ablation
1194744|NCT01176604|Hepatocellular carcinoma (HCC) of the liver
1194745|NCT01176604|Hepatocellular cancer
1194999|NCT01175720|gingival recession
1194746|NCT01176604|Hepatocellular carcinoma
1194747|NCT01176604|Liver cancer
1194748|NCT01176604|HCC
1194749|NCT01176604|Humanitarian Device Exemption
1194750|NCT01176604|Liver Diseases
1194751|NCT01176604|(HDE)
1194752|NCT01176604|Radioactive
1194753|NCT01176604|TheraSphere
1194754|NCT01176591|Cocaine and alcohol dependence (CAD)
1194755|NCT01176565|Acute hypertensive response
1194756|NCT01176565|intracerebral hemorrhage
1194757|NCT01176565|blood pressure
1194758|NCT01176565|outcome
1194759|NCT01176565|nicardipine
1194760|NCT01176552|Kidney Cancer
1194761|NCT01176552|Renal cell carcinoma
1194762|NCT01176552|High risk
1194763|NCT01176552|Adjuvant therapy
1194764|NCT01176526|Coping
1194765|NCT01176526|Quality of Life
1194766|NCT01176526|Prostate Cancer
1194767|NCT01176513|Prostate Cancer
1194768|NCT01176513|MRI
1194769|NCT01176513|PET
1194770|NCT01176513|GE-148 (18F)
1194771|NCT01176500|PET Imaging
1194772|NCT01176500|(18F)Fluciclatide
1194773|NCT01176500|Anti-Angiogenic Therapies
1194774|NCT01176500|Solid Tumors
1194775|NCT01176487|recurrent non-small cell lung cancer
1194776|NCT01176487|recurrent small cell lung cancer
1194777|NCT01176487|extensive stage small cell lung cancer
1194778|NCT01176487|stage IIIA non-small cell lung cancer
1194779|NCT01176487|stage IIIB non-small cell lung cancer
1194780|NCT01176487|stage IV non-small cell lung cancer
1194781|NCT01176474|stage IV melanoma
1194782|NCT01176474|stage IIIC melanoma
1194783|NCT01176461|recurrent melanoma
1194784|NCT01176461|stage IIIA melanoma
1194785|NCT01176461|stage IIIB melanoma
1194786|NCT01176461|stage IIIC melanoma
1194787|NCT01176461|stage IV melanoma
1194788|NCT01176448|Cicatrix
1194789|NCT01176448|Dermabrasion
1194790|NCT01176448|Coagulation, Laser
1194791|NCT01176435|Levodopa
1194792|NCT01176435|Albinism
1194793|NCT01176435|Vision
1194794|NCT01176422|AML
1194795|NCT01176422|MDS
1194796|NCT01176396|Dental Caries
1194797|NCT01176396|Preventive Dentistry
1194798|NCT01176396|Dental Prophylaxis
1194799|NCT01176396|Dental Care
1194800|NCT01176383|Nicotine addiction
1194801|NCT01176383|Behaviour
1194802|NCT01176383|Gene test
1194803|NCT01176383|Lung cancer
1194804|NCT01176383|Lifetime risk of lung cancer in smokers
1194805|NCT01176370|Heart Failure
1194806|NCT01176370|Device
1194807|NCT01176370|Implantable
1194808|NCT01176370|Active
1194809|NCT01176370|Class III and Class IV
1194810|NCT01176370|Counterpulsation
1194811|NCT01176357|Coronary artery disease (CAD)
1194812|NCT01176357|atherosclerosis
1194813|NCT01176357|mediastinal adipose tissue
1194814|NCT01176357|adiponectin, inflammatory mediators
1194815|NCT01176344|Vitamin D supplementation
1194816|NCT01176344|Osteoarthritis
1194817|NCT01176344|Knee
1194818|NCT01176344|Randomised clinical trial (RCT)
1194819|NCT01176344|Cartilage
1194820|NCT01176344|MRI
1194821|NCT01176318|cough
1194822|NCT01176318|exacerbation
1194823|NCT01176318|quality of life
1194824|NCT01176305|Thromboembolic event
1194825|NCT01176292|total knee replacement
1194826|NCT01176292|high flexion
1194827|NCT01176292|range of motion
1194828|NCT01176292|rotating platform
1194829|NCT01176292|TKA
1194830|NCT01176279|Critical illness
1194831|NCT01176279|Hyperglycemia
1194832|NCT01176279|Catheters, Indwelling
1194833|NCT01176279|Intensive care unit
1194834|NCT01176266|Hypophosphatasia
1194835|NCT01176266|HPP
1194836|NCT01176266|Bone Disease
1194837|NCT01176266|Soft Bones
1194838|NCT01176266|Low Alkaline Phosphatase
1194839|NCT01176266|genetic metabolic disorder
1194840|NCT01176266|alkaline phosphatase
1194841|NCT01176266|tissue-specific alkaline phosphatase (TNSALP)
1194842|NCT01176266|rickets
1194843|NCT01176266|osteomalacia
1194844|NCT01176253|Type I DM
1194845|NCT01176240|lightheadedness
1194846|NCT01176240|unsteadiness
1194847|NCT01176240|dizziness
1194848|NCT01176240|weak
1194849|NCT01176240|fatigue
1194850|NCT01176240|concentration
1194851|NCT01176240|head & neck pain
1194852|NCT01176240|standing/walking for a short time
1194853|NCT01176240|standing/walking for a long time
1194854|NCT01176240|Neurogenic Orthostatic Hypotension
1194855|NCT01176240|falls
1194856|NCT01176240|NOH
1194857|NCT01176240|Parkinson's disease
1194858|NCT01176240|weakness
1194859|NCT01176227|bloating
1194860|NCT01176227|constipation
1194861|NCT01176227|diarrhea
1194862|NCT01176227|gas
1194863|NCT01176227|mucous
1194864|NCT01176227|cramping
1194865|NCT01176214|supratentorial intracerebral hemorrhage
1194866|NCT01176214|tracheostomy
1194867|NCT01176214|sedation
1194868|NCT01176214|weaning
1194869|NCT01176201|SLV337
1194870|NCT01176201|Diabetes
1194871|NCT01176201|Relative bioavailability
1194872|NCT01176201|ADME
1194873|NCT01176188|Pediatric Intensive Care Unit
1194874|NCT01176188|Environmental Stressors
1194875|NCT01176188|Sleep
1194876|NCT01176188|Psychological Outcomes
1194877|NCT01176188|Pediatrics
1194878|NCT01176175|Progesterone
1194879|NCT01176175|Microspheres
1194880|NCT01176175|postmenopausal
1194881|NCT01176175|Luteal phase support
1194882|NCT01176162|Non Invasive measurement
1194883|NCT01176162|Preterm infants
1194884|NCT01176162|Aldosterone resistance
1194885|NCT01176149|Diabetes
1194886|NCT01176149|Self monitoring blood glucose
1194887|NCT01176136|ADHD
1194888|NCT01176136|School-Based
1194889|NCT01176136|Organizational Skills
1194890|NCT01176136|Homework
1194891|NCT01176136|Time Management
1194892|NCT01176123|Cognitive behavioral therapy
1194893|NCT01176123|Insomnia
1194894|NCT01176123|Traumatic Stress
1194895|NCT01176110|hypothermia
1194896|NCT01176110|minimal invasive valve replacement
1194897|NCT01176097|First in man study evaluating AZD5658 in Type 2 Diabetics.
1194898|NCT01176097|Effect of fasting
1194899|NCT01176097|Safety
1194900|NCT01176097|Tolerability
1194901|NCT01176084|low carbohydrate diet
1194902|NCT01176084|obesity
1194903|NCT01176084|moderate exercise
1194904|NCT01176084|men
1194905|NCT01176071|galactomannan
1194906|NCT01176071|beta-D-glucan
1194907|NCT01176071|aspergillosis
1194908|NCT01176071|outcome
1194909|NCT01176058|Phase 3b
1194910|NCT01176058|Efficacy and Safety evaluation of Anidulafungin
1194911|NCT01176058|ICC
1194912|NCT01176045|Dry Eye Disease
1194913|NCT01176045|Osmolarity
1194914|NCT01176045|Refractive Surgery
1194915|NCT01176045|Lasik
1194916|NCT01176045|TearLab
1194917|NCT01176032|Aliskiren
1194918|NCT01176032|hypertension
1194919|NCT01176032|concentric LVH
1194920|NCT01176032|LV remodeling
1194921|NCT01176032|LVMI
1194922|NCT01176032|biomarkers
1194923|NCT01176032|PICP
1194924|NCT01176032|CT-1
1194925|NCT01176032|MMP-1
1194926|NCT01176032|TIMP-1
1194927|NCT01176032|AnxA5
1194928|NCT01176032|Aldosterone
1194929|NCT01176032|Essential hypertension with concentric left ventricle hypertrophy
1194930|NCT01176019|Amniocentesis
1194931|NCT01176019|Chorionic Villus Sampling
1194932|NCT01176019|First trimester screening
1194933|NCT01176019|Down syndrome
1194934|NCT01176006|DOCK8
1194935|NCT01176006|Molluscum
1194936|NCT01176006|Transplant
1194937|NCT01176006|Immunodeficiency
1194938|NCT01175993|Motor Training
1194939|NCT01175993|Post-Traumatic Stress Disorder (PTSD)
1194940|NCT01175993|Balance
1194941|NCT01175967|psychosocial effects of cancer and its treatment
1194942|NCT01175967|perioperative/postoperative complications
1194943|NCT01175967|stage III ovarian epithelial cancer
1194944|NCT01175967|stage IV ovarian epithelial cancer
1194945|NCT01175954|Partial Epilepsy
1194946|NCT01175928|Diabetic polyneuropathy
1194947|NCT01175928|Pneumatic Compression Device
1194948|NCT01175915|Mild type of hand, foot and mouth disease
1194949|NCT01175915|Reduning Injection
1194950|NCT01175915|Effectiveness
1194951|NCT01175915|Safety
1194952|NCT01175902|Normal tension glaucoma
1194953|NCT01175876|MMSE
1194954|NCT01175876|NSE
1194955|NCT01175876|S100B
1194956|NCT01175876|hsCRP
1194957|NCT01175876|DWI-MRI
1194958|NCT01175863|intravascular ultrasound
1194959|NCT01175863|fractional flow reserve
1194960|NCT01175824|Metabolic Diseases
1194961|NCT01175824|Diabetes Mellitus, Type 2
1194962|NCT01175824|Glargine
1194963|NCT01175824|Diabetes Mellitus
1194964|NCT01175824|Insulin LISPRO
1194965|NCT01175824|Insulin
1194966|NCT01175811|Metabolic Diseases
1194967|NCT01175811|Diabetes Mellitus, Type 2
1194968|NCT01175811|Glargine
1194969|NCT01175811|Diabetes Mellitus
1194970|NCT01175811|Insulin LISPRO
1194971|NCT01175811|Insulin
1194972|NCT01175798|Vitamin D deficiency
1194973|NCT01175798|End-stage renal disease
1194974|NCT01175798|Immunity
1194975|NCT01175772|Ovary
1194976|NCT01175772|Carcinoma
1194977|NCT01175772|Maintenance
1194978|NCT01175772|Metronomic
1194979|NCT01175772|Chemotherapy
1194980|NCT01175772|Time to Progression
1194981|NCT01175772|overall survival
1194982|NCT01175759|Unexplained Recurrent Pregnancy Loss
1194983|NCT01175759|Recurrent Abortions
1194984|NCT01175759|Recurrent Miscarriages
1194985|NCT01175759|Hormones
1194986|NCT01175759|Skin tests
1194987|NCT01175759|Allergen
1194988|NCT01175759|Immunotherapy
1194989|NCT01175759|Hypersensitivity
1194990|NCT01175759|Skin reaction
1194991|NCT01175746|healthy adult patients
1194992|NCT01175746|ASA class I
1194993|NCT01175746|hypotensive anesthesia
1194994|NCT01175733|Panitumumab
1194995|NCT01175733|Chemoradiation
1194996|NCT01175733|Pancreatic cancer
1194997|NCT01175733|Locally advanced
1194998|NCT01175733|Inoperable
1195000|NCT01175720|acellular dermal matrix graft
1195001|NCT01175720|root coverage
1195002|NCT01175694|Brachytherapy
1195003|NCT01175694|APBI
1195004|NCT01175694|dose modification
1195005|NCT01175694|local recurrences
1195006|NCT01175694|side effects
1195007|NCT01175694|cosmetic result
1195008|NCT01175681|rheumatic heart disease
1195009|NCT01175681|degenerated heart valve disease
1195010|NCT01175681|heart valve prolapse
1195011|NCT01175655|Mesenchymal stromal cells
1195012|NCT01175655|Bronchiolitis obliterans
1195013|NCT01175655|Lung transplant
1195014|NCT01175642|Schizophrenia
1195015|NCT01175642|Psychosis
1195016|NCT01175642|Schizoaffective Disorder
1195017|NCT01175629|Stress Disorders, Post-Traumatic
1195018|NCT01175629|Depression
1195019|NCT01175629|Diabetes
1195020|NCT01175629|Cardiovascular Disease
1195021|NCT01175629|Depressive Disorder
1195022|NCT01175629|Behavioral Symptoms
1195023|NCT01175629|Metabolic Diseases
1195024|NCT01175629|Mental Disorders
1195025|NCT01175629|Anxiety Disorders
1195026|NCT01175616|Depression
1195027|NCT01175616|Adults
1195028|NCT01175603|depression, African American, home visiting, prevention
1195029|NCT01175577|mixed carotenes
1195030|NCT01175564|TC-5214
1195031|NCT01175564|safety
1195032|NCT01175564|pharmacokinetics
1195033|NCT01175564|single dose
1195034|NCT01175564|repeated dose
1195035|NCT01175564|Japanese
1195036|NCT01175564|healthy subjects
1195037|NCT01175551|Preterm Birth
1195038|NCT01175551|Cervix
1195039|NCT01175551|Cervical Shortening
1195040|NCT01175551|Cervical remodeling
1195041|NCT01175551|PTB
1195042|NCT01175538|Hepatic encephalopathy
1195043|NCT01175538|Lactulose
1195044|NCT01175499|laryngoscopy
1195045|NCT01175499|Laryngoscopic Surgery
1195046|NCT01175499|laryngoscopes
1195047|NCT01175499|upper aerodigestive tract lesions
1195048|NCT01175499|endoscopy
1195049|NCT01175499|biopsy
1195050|NCT01175486|thiazolidinediones
1195051|NCT01175486|diabetes
1195052|NCT01175486|retinopathy
1195053|NCT01175486|nephropathy
1195054|NCT01175460|esophageal Cancer
1195055|NCT01175460|radiation
1195056|NCT01175460|s-1
1195057|NCT01175460|nedaplatin
1195058|NCT01175447|S-1
1195059|NCT01175447|radiation
1195060|NCT01175447|esophageal Cancer
1195061|NCT01175434|Asthma
1195062|NCT01175421|snoring
1195063|NCT01175421|sleep apnea
1195064|NCT01175421|sleep study
1195065|NCT01175421|cardiovascular outcomes
1195066|NCT01175408|Remote Blood Glucose Monitoring System,
1195067|NCT01175408|Continuous Glucose Monitoring System,
1195068|NCT01175408|Self Monitoring Blood Glucose,
1195069|NCT01175408|Strip Counting,
1195070|NCT01175408|Type 2 Diabetes
1195071|NCT01175395|Choroidal neovascular membranes
1195072|NCT01175395|CNV
1195073|NCT01175395|AMD
1195074|NCT01175395|Age-relate Macular Degeneration
1195075|NCT01175395|CNVM
1195076|NCT01175395|subfoveal
1195077|NCT01175382|Male Urogenital Diseases
1195078|NCT01175382|Urinary Bladder, overactive
1195079|NCT01175382|Behavioral Medicine
1195080|NCT01175382|Drug Therapy
1195081|NCT01175369|Asthma
1195082|NCT01175330|Omega-3 fatty acid
1195083|NCT01175330|Ischemic Heart Disease
1195084|NCT01175330|Atrial Fibrillation
1195085|NCT01175330|Subcutaneous cardiac monitoring
1195086|NCT01175317|Hemodynamic optimization
1195087|NCT01175317|Enhanced recovery after surgery
1195088|NCT01175317|Goal-directed fluid
1195089|NCT01175304|sleep
1195090|NCT01175304|sleep apnea
1195091|NCT01175304|work
1195092|NCT01175304|sleep habits
1195093|NCT01175304|sleepiness
1195094|NCT01175291|colon
1195095|NCT01175291|rectum
1195096|NCT01175291|colorectal
1195097|NCT01175291|metastatic
1195098|NCT01175291|adenocarcinoma
1195099|NCT01175278|vertebral
1195100|NCT01175278|compression
1195101|NCT01175278|fracture
1195102|NCT01175278|VCF
1195103|NCT01175278|kyphoplasty
1195104|NCT01175278|spine
1195105|NCT01175265|clinically stable
1195106|NCT01175265|COPD (GOLD-classification I-IV)
1195107|NCT01175265|COPD
1195108|NCT01175265|breathing retraining
1195109|NCT01175265|pulmonary rehabilitation
1195110|NCT01175265|cardiac autonomic function
1195111|NCT01175265|quality of life
1195112|NCT01175265|exercise capacity
1195113|NCT01175265|pulmonary function
1195114|NCT01175252|Gastroenteritis
1195115|NCT01175239|X-linked severe combined immunodeficiency, gene therapy
1195116|NCT01175239|Patients will be enrolled following diagnosis and referral to Great Ormond Street Immunology Service.
1195117|NCT01175226|Human rhinovirus
1195118|NCT01175226|Aviragen Therapeutics, Inc.
1195119|NCT01175226|Aviragen Therapeutics
1195120|NCT01175226|Aviragen
1195121|NCT01175187|evron
1195122|NCT01175174|asthma
1195123|NCT01175174|preschool children
1195124|NCT01175174|adenosine provocation test
1195125|NCT01175174|metacholine provocation test
1195126|NCT01175174|pediatric emergency department
1195127|NCT01175161|Postpartum Contraception
1195128|NCT01175161|Intrauterine device
1195129|NCT01175161|feasibility
1195130|NCT01175161|IUD
1195131|NCT01175161|Immediate postpartum IUD
1195132|NCT01175148|HSCT
1195133|NCT01175148|HPC
1195134|NCT01175148|HCT
1195135|NCT01175148|BMT
1195136|NCT01175148|lipitor
1195137|NCT01175148|atorvastatin
1195138|NCT01175148|HMG-CoA Reductase Inhibitor
1195139|NCT01175148|Hematopoietic stem cell transplant
1195140|NCT01175148|allogeneic transplant
1195141|NCT01175148|GVHD
1195142|NCT01175148|graft-versus-host-disease
1195143|NCT01175148|Graft vs Host Disease
1195144|NCT01175135|schizophrenia
1195145|NCT01175135|acute exacerbation
1195146|NCT01175135|inpatient
1195147|NCT01175109|Chordoma
1195148|NCT01175096|neuroendocrine tumors
1195149|NCT01175096|carcinoid tumor
1195150|NCT01175096|RAD001 (everolimus, Afinitor®)
1195151|NCT01175083|Catch-up vaccination
1195152|NCT01175083|Pneumococcal vaccine
1195153|NCT01175083|Sickle cell disease
1195154|NCT01175083|Booster vaccination
1195155|NCT01175083|Safety
1195156|NCT01175083|Immunogenicity
1195157|NCT01175083|Pneumococcal disease
1195158|NCT01175070|diabetic macular oedema
1195159|NCT01175070|ischaemia
1195160|NCT01175070|anti VEGF
1195161|NCT01175070|pegaptanib
1195162|NCT01175070|Ischaemic diabetic macular oedema
1195163|NCT01175057|feasibility
1195164|NCT01175057|compliance
1195165|NCT01175057|telemedical home monitoring
1195166|NCT01175057|post stationary rehabilitation
1195167|NCT01175057|patients with myocardial infarction
1195168|NCT01175044|Revision
1195169|NCT01175044|Knee
1195170|NCT01175044|Arthroplasty
1195171|NCT01175044|Betadine
1195172|NCT01175044|Lavage
1195173|NCT01175044|Infection
1195174|NCT01175018|Acute myocardial infarction
1195175|NCT01175018|Heart Failure
1195176|NCT01175018|Cardiac Remodeling
1195177|NCT01175005|Fever
1195178|NCT01175005|Central venous catheter
1195179|NCT01175005|Procalcitonin
1195180|NCT01175005|Fever with a central venous catheter
1195181|NCT01174992|Fibrin sealant
1195182|NCT01174992|CSF leak
1195183|NCT01174979|Morbus Meniere
1195184|NCT01174979|Sudden hearing loss
1195185|NCT01174979|Blast injury
1195186|NCT01174979|Presbyacusis
1195187|NCT01174979|Chron. Otitis Media
1195188|NCT01174966|oxygen challenge test
1195189|NCT01174966|shock
1195190|NCT01174966|mortality
1195191|NCT01174966|Oxygen Delivery Index
1195192|NCT01174966|cardiac output index
1195193|NCT01174953|prostate cancer
1195194|NCT01174940|myelogenous leukemia
1195195|NCT01174940|lymphocytic leukemia
1195196|NCT01174940|lymphoblastic leukemia
1195197|NCT01174940|myelodysplastic syndrome
1195198|NCT01174940|non-Hodgkin's lymphoma
1195199|NCT01174940|Hodgkin's disease
1195200|NCT01174927|Substance use disorder
1195201|NCT01174927|Stress
1195202|NCT01174901|cephalalgia
1195203|NCT01174901|copeptins
1195204|NCT01174901|biomarkers
1195205|NCT01174901|headache
1195206|NCT01174901|C-terminal provasopression
1195207|NCT01174901|physiological stress response
1195208|NCT01174888|Acute Myeloid Leukemia
1195209|NCT01174888|AML
1195210|NCT01174875|Epigenetics
1195211|NCT01174875|Development
1195212|NCT01174875|Metabolic
1195213|NCT01174875|Neurodevelopment
1195214|NCT01174862|aspirin
1195215|NCT01174862|aspirin responsiveness
1195216|NCT01174862|long-term outcome
1195217|NCT01174862|CABG
1195218|NCT01174849|otitis media
1195219|NCT01174849|pneumococcal vaccines
1195220|NCT01174849|randomised controlled trial
1195221|NCT01174849|high-risk children
1195222|NCT01174849|indigenous
1195223|NCT01174849|Australia
1195224|NCT01174836|CT utilization
1195225|NCT01174836|physician attitudes
1195226|NCT01174810|Parkinson's Disease
1195227|NCT01174810|PD
1195228|NCT01174810|Moderate Parkinson's Disease
1195229|NCT01174784|Chronic Total Occlusions
1195230|NCT01174784|Superficial Femoral Artery
1195231|NCT01174784|Popliteal Artery
1195232|NCT01174771|Transcranial magnetic stimulation
1195233|NCT01174771|Cortical excitability
1195234|NCT01174771|parkinsonism
1195235|NCT01174771|Progressive Supranuclear Palsy
1195236|NCT01174771|Corticobasal Degeneration
1195237|NCT01174771|PSP
1195238|NCT01174771|CBD
1195239|NCT01174771|CBGD
1195240|NCT01174758|balance
1195241|NCT01174758|mobility
1195242|NCT01174758|ON/OFF Levodopa
1195243|NCT01174732|asthma
1195244|NCT01174732|bronchospasm
1195245|NCT01174732|COPD
1195246|NCT01174732|chronic respiratory disease
1195247|NCT01174719|Hydroxyethylstarch
1195248|NCT01174719|Humanalbumin
1195249|NCT01174719|Ringer Lactate
1195250|NCT01174719|patients undergoing cardiac surgery
1195251|NCT01174706|infections
1195252|NCT01174706|flu
1195253|NCT01174706|abdominal pain
1195254|NCT01174706|chest pain
1195255|NCT01174706|cold
1195256|NCT01174706|fever
1195257|NCT01174706|different acute care conditions
1195258|NCT01174693|prospective
1195259|NCT01174693|randomized
1195260|NCT01174693|open label
1195261|NCT01174693|multi-center
1195262|NCT01174693|double-blind for CYP2C19 genotypes
1195263|NCT01174680|cardiogoniometry
1195264|NCT01174680|stable angina pectoris patients
1195265|NCT01174667|Myofascial pain
1195266|NCT01174667|Trigger points
1195267|NCT01174641|unilateral neglect
1195268|NCT01174641|TMS intervention
1195269|NCT01174628|Exercise Tolerance
1195270|NCT01174628|Venous Thrombosis
1195271|NCT01174628|Pulmonary Embolism
1195272|NCT01174628|Quality of Life (QOL)
1195273|NCT01174615|Blood/bone marrow collection, hematologic diseases, leukemia
1195274|NCT01174589|Lower limb strength training
1195275|NCT01174589|Randomized clinical trial
1195276|NCT01174589|Patients with Hip fracture
1195277|NCT01174589|6 vs. 12 weeks physical strength training
1195278|NCT01174576|coffee
1195279|NCT01174576|appetite
1195280|NCT01174576|energy intake
1195281|NCT01174576|inflammation
1195282|NCT01174576|cortisol
1195283|NCT01174576|glucose
1195284|NCT01174576|randomized controlled trial
1195285|NCT01174550|chest pain
1195286|NCT01174550|coronary artery disease
1195287|NCT01174550|CAD
1195288|NCT01174537|NDV
1195289|NCT01174537|Metastatic
1195290|NCT01174537|Refractory
1195291|NCT01174537|Cancer
1195292|NCT01174537|Progression-free
1195293|NCT01174537|survival
1195294|NCT01174537|recurrent
1195295|NCT01174524|Quality of life
1195296|NCT01174524|Menopause
1195297|NCT01174524|Contraception
1195298|NCT01174511|ATOPIC DERMATITIS
1195299|NCT01174511|A-1 COOL CREAM
1195300|NCT01174498|discomfort
1195301|NCT01174498|distress
1195302|NCT01174498|hurt
1195303|NCT01174498|sting
1195304|NCT01174485|Liposuction
1195305|NCT01174485|exercise
1195306|NCT01174485|metabolism
1195307|NCT01174485|adiposity
1195308|NCT01174472|Dialysis access
1195309|NCT01174472|angioplasty
1195310|NCT01174472|drug eluting balloon
1195311|NCT01174433|Bifurcation coronary artery disease
1195312|NCT01174433|Percutaneous coronary intervention
1195313|NCT01174433|Tryton Stent
1195314|NCT01174420|ologen
1195315|NCT01174420|Mitomycin-C
1195316|NCT01174420|Collagen Matrix
1195317|NCT01174420|trabeculectomy
1195318|NCT01174420|glaucoma
1195319|NCT01174420|filtering surgery
1195320|NCT01174394|Acupuncture
1195321|NCT01174394|Post Stroke Depression
1195322|NCT01174394|Depressive Disorder
1195323|NCT01174394|Cardiovascular Accident
1195324|NCT01174394|Stroke
1195325|NCT01174394|Apoplexy
1195326|NCT01174394|CVA
1195327|NCT01174381|Non communicable disease
1195328|NCT01174381|Lifestyle Modification
1195329|NCT01174381|Community Based organization
1195330|NCT01174381|community based study
1195331|NCT01174342|Intraocular pressure
1195332|NCT01174342|Ocular tonometry
1195333|NCT01174342|Obstetric delivery
1195334|NCT01174316|Acute exacerbation
1195335|NCT01174316|Respiratory insufficiency
1195336|NCT01174316|Respiratory failure
1195337|NCT01174316|Hypercapnia
1195338|NCT01174316|Hypoventilation
1195339|NCT01174316|Sleep
1195340|NCT01174316|Hypoxia
1195341|NCT01174316|Titration
1195342|NCT01174316|Non Invasive Ventilation
1195343|NCT01174290|subsyndromal delirium
1195344|NCT01174290|delirium
1195345|NCT01174290|haloperidol
1195346|NCT01174290|antipsychotic
1195347|NCT01174290|randomized controlled trial
1195348|NCT01174290|placebo-controlled
1195349|NCT01174290|intensive care unit
1195350|NCT01174290|critical care
1195351|NCT01174290|subsyndromal delirium in the intensive care unit
1195352|NCT01174277|chronic graft versus host disease
1195353|NCT01174277|transplant
1195354|NCT01174277|stem cell
1195355|NCT01174251|general anesthesia
1195356|NCT01174251|electrocardiography
1195357|NCT01174251|long QT syndrome, acquired
1195358|NCT01174238|Melanoma
1195359|NCT01174238|Axitinib
1195360|NCT01174238|Carboplatin
1195361|NCT01174238|Paclitaxel
1195362|NCT01174225|Copper IUD
1195363|NCT01174225|Nova T 200
1195364|NCT01174225|Flexi T 380
1195365|NCT01174225|expulsion
1195366|NCT01174225|contraception satisfaction
1195367|NCT01174225|post-abortion contraception
1195368|NCT01174212|revision
1195369|NCT01174212|infection
1195370|NCT01174212|knee
1195371|NCT01174212|hip
1195372|NCT01174212|replacement
1195373|NCT01174212|antibiotics
1195374|NCT01174173|Angina
1195375|NCT01174173|Right Ventricular Ischemia
1195376|NCT01174173|Pulmonary Arterial Hypertension
1195377|NCT01174173|Pulmonary Hypertension
1195378|NCT01174160|Atrial Fibrillation
1195379|NCT01174121|Digestive Tract Cancers
1195380|NCT01174121|Breast Cancer
1195381|NCT01174121|Cell Therapy
1195382|NCT01174121|Ovarian/Endometrial Cancer
1195383|NCT01174121|Urothelial Cancers
1195384|NCT01174108|Myelodysplastic Syndrome (MDS)
1195385|NCT01174108|Severe Aplastic Anemia
1195386|NCT01174108|Pure Red Cell Aplasia
1195387|NCT01174108|Paroxysmal Nocturnal Hemoglobinuria (PNH)
1195388|NCT01174108|Miltenyi CD34 Reagent System
1195389|NCT01174108|Allogeneic Stem Cell Transplant
1195390|NCT01174095|Diffuse Coronary Artery Disease
1195391|NCT01174095|Ischemic Myocardium
1195392|NCT01174095|Ischemia
1195393|NCT01174082|Multiple Myeloma
1195394|NCT01174082|Vaccine
1195395|NCT01174082|Lymphocyte Infusion
1195396|NCT01174069|NOTES
1195397|NCT01174069|cholecystectomy
1195398|NCT01174069|endoscopic
1195399|NCT01174056|Lung inflammation
1195400|NCT01174056|positron emission tomography
1195401|NCT01174056|fluorodeoxyglucose
1195402|NCT01174056|rosiglitazone
1195403|NCT01174056|zileuton
1195404|NCT01174056|lung anti-inflammatory therapy
1195405|NCT01174043|Leukemia, Myelomonocytic, Acute
1195406|NCT01174043|Erlotinib
1195407|NCT01174017|prostate cancer
1195408|NCT01174017|Iodine 125 brachytherapy
1195409|NCT01174017|seed migration
1195410|NCT01174017|seed migration in the first month after brachytherapy
1195411|NCT01173991|carbohydrate counting
1195412|NCT01173991|continuous subcutaneous insulin infusion
1195413|NCT01173991|type 1 diabetes mellitus
1195414|NCT01173978|Incretin hormones
1195415|NCT01173978|Glucagon
1195416|NCT01173978|Insulin/c-peptide
1195417|NCT01173978|Plasma glucose
1195418|NCT01173978|Insulin resistance
1195419|NCT01173978|Deteriorated glucose homeostasis
1195420|NCT01173978|Inactivity
1195421|NCT01173939|Hypercholesterolemia with concomitant type 2 diabetes and hypertension
1195422|NCT01173913|oral docetaxel
1195423|NCT01173913|ModraDoc
1195424|NCT01173913|pharmacokinetics
1195425|NCT01173913|safety
1195426|NCT01173913|MTD
1195427|NCT01173913|DLT
1195428|NCT01173900|human papillomavirus
1195429|NCT01173900|vaccine
1195430|NCT01173900|school girls
1195431|NCT01173900|Tanzania
1195432|NCT01173900|acceptability
1195433|NCT01173900|vaccine coverage
1195434|NCT01173900|Cervical cancer prevention
1195435|NCT01173874|Cognition
1195436|NCT01173874|Function
1195437|NCT01173874|Attention
1195438|NCT01173874|Vigilance
1195439|NCT01173874|Verbal Memory
1195440|NCT01173874|Visual Memory
1195441|NCT01173874|Processing Speed
1195442|NCT01173874|Problem Solving
1195443|NCT01173874|Social Cognition
1195444|NCT01173848|CKD
1195445|NCT01173848|Vitamin D
1195446|NCT01173835|Adolescent tobacco use
1195447|NCT01173835|Tobacco Free and Win
1195448|NCT01173835|Incentive-based intervention
1195449|NCT01173835|Contingency Management
1195450|NCT01173835|Smoking Prevention
1195451|NCT01173835|Smoking cessation
1195452|NCT01173822|cardiopulmonary bypass
1195453|NCT01173822|hemorrhage
1195454|NCT01173822|trials
1195455|NCT01173822|surgery
1195456|NCT01173809|AF
1195457|NCT01173809|Catheter Ablation
1195458|NCT01173809|Recurrence of AF
1195459|NCT01173809|Amiodarone
1195460|NCT01173783|Heart failure
1195461|NCT01173783|Cardiac insufficiency
1195462|NCT01173783|Implantable Cardioverter/Defibrillator
1195463|NCT01173783|Cardiac Resynchronization therapy
1195464|NCT01173783|ICD
1195465|NCT01173783|CRT
1195466|NCT01173783|Register
1195467|NCT01173757|Healthy Volunteers
1195468|NCT01173744|Intertrochanteric femoral fractures - unstable
1195469|NCT01173731|Parkinson Disease
1195470|NCT01173731|L-dopa
1195471|NCT01173731|Levodopa
1195472|NCT01173731|Dyskinesia
1195473|NCT01173731|involuntary movement
1195474|NCT01173731|motor complication
1195475|NCT01173718|Hemodialysis
1195476|NCT01173718|Vascular Graft
1195477|NCT01173705|Obesity
1195478|NCT01173705|Insulin Resistance
1195479|NCT01173705|Inflammation
1195480|NCT01173692|Oropharynx Cancer
1195481|NCT01173692|Radiation Therapy
1195482|NCT01173692|XRT
1195483|NCT01173692|Radiotherapy
1195484|NCT01173692|Minocycline
1195485|NCT01173692|Symptoms
1195486|NCT01173692|Head and Neck
1195487|NCT01173679|CLL
1195488|NCT01173679|fludarabine
1195489|NCT01173679|rituximab
1195490|NCT01173679|dasatinib
1195491|NCT01173679|refractory
1195492|NCT01173679|relapsed
1195493|NCT01173666|RAS
1195494|NCT01173666|LVMI
1195495|NCT01173666|Renal revascularization
1195496|NCT01173653|smoking
1195497|NCT01173653|smoking cessation
1195498|NCT01173653|health behavior
1195499|NCT01173640|drug interactions
1195500|NCT01173640|midazolam
1195501|NCT01173640|cytochrome P450
1195502|NCT01173640|resveratrol
1195503|NCT01173640|pharmacokinetics
1195504|NCT01173627|Bioequivalence
1195505|NCT01173627|Fentanyl
1195506|NCT01173588|bowel function
1195507|NCT01173588|functional foods
1195508|NCT01173562|Healthy volunteers
1195509|NCT01173562|Parasitic Diseases
1195510|NCT01173562|Mebendazole (VERMOX)
1195511|NCT01173562|Anthelmintics
1195512|NCT01173562|Antiparasitic Agents
1195513|NCT01173562|Soil-transmitted helminth (STH) infections
1195514|NCT01173562|Pediatric
1195515|NCT01173549|Canagliflozin
1195516|NCT01173549|Pharmacodynamic
1195517|NCT01173549|Glucose absorption
1195518|NCT01173549|Glucose metabolism
1195519|NCT01173523|Hsp90 Inhibitor
1195520|NCT01173523|relapsed
1195521|NCT01173523|refractory
1195522|NCT01173510|HIV
1195523|NCT01173510|AIDS
1195524|NCT01173510|Atripla
1195525|NCT01173510|Truvada
1195526|NCT01173510|Raltegravir
1195527|NCT01173510|Human Immunodeficiency Virus
1195528|NCT01173510|Acquired Immune Deficiency Syndrome Virus
1195529|NCT01173497|Triple negative breast cancer
1195530|NCT01173497|Brain metastasis
1195531|NCT01173497|BSI-201
1195532|NCT01173497|iniparib
1195533|NCT01173484|Idiopathic gastroparesis
1195534|NCT01173484|Vomiting
1195535|NCT01173484|Dyspepsia
1195536|NCT01173484|GERD
1195537|NCT01173471|Raised intraocular pressure
1195538|NCT01173458|cancer
1195539|NCT01173458|lung
1195540|NCT01173458|small cell
1195541|NCT01173445|cancer
1195542|NCT01173445|kidney
1195543|NCT01173445|renal cell
1195544|NCT01173445|tumor cells
1195545|NCT01173445|circulating tumor cells
1195546|NCT01173445|circulating endothelial cells
1195547|NCT01173432|obstructive sleep apnea
1195548|NCT01173432|metabolic dysfunction
1195549|NCT01173432|metabolic syndrome
1195550|NCT01173432|adipocyte fatty acid binding protein
1195551|NCT01173419|Great Saphenous Vein
1195552|NCT01173406|Continuous Positive Airway Pressure treatment
1195553|NCT01173406|Adherence
1195554|NCT01173406|Education
1195555|NCT01173393|out of hospital cardiac arrest
1195556|NCT01173393|OHCA
1195557|NCT01173393|EMS
1195558|NCT01173393|Emergency medical System
1195559|NCT01173393|non-VF
1195560|NCT01173393|non-ventricular fibrillation
1195561|NCT01173380|Soy
1195562|NCT01173380|Equol
1195563|NCT01173380|Metabolic syndrome
1195564|NCT01173380|Endothelial function
1195565|NCT01173367|Fever
1195566|NCT01173367|ICU
1195567|NCT01173367|Acetaminophen
1195568|NCT01173367|Inflammatory mediators
1195569|NCT01173367|Safety
1195570|NCT01173354|COPD
1195571|NCT01173354|Protein metabolism
1195572|NCT01173354|Essential amino acid intake
1195573|NCT01173328|exercise tolerance
1195574|NCT01173328|dynamic hyperinflation
1195575|NCT01173328|respiratory mechanics
1195576|NCT01173315|Type 2 diabetes
1195577|NCT01173315|micronutrients
1195578|NCT01173315|nephropathy
1195579|NCT01173315|neuropathy
1195580|NCT01173302|Rabies
1195581|NCT01173302|Anti-rabies antibody
1195582|NCT01173302|Persistence
1195583|NCT01173289|Thyroid Carcinoma
1195584|NCT01173289|External Beam Radiotherapy
1195585|NCT01173276|Acquired Immune Deficiency Syndrome
1195586|NCT01173276|Assisted Reproductive Technology
1195587|NCT01173276|Fertility
1195588|NCT01173276|HIV
1195589|NCT01173276|HIV Discordant
1195590|NCT01173276|Infertility
1195591|NCT01173276|Intrauterine Insemination
1195592|NCT01173276|Sexually Transmitted Diseases
1195593|NCT01173276|Sperm Washing
1195594|NCT01173263|breathing machine
1195595|NCT01173263|mechanical ventilator
1195596|NCT01173250|total proctocolectomy with ileal pouch anal anastomosis with and without ileostomy
1195597|NCT01173237|tracheal intubation
1195598|NCT01173237|proseal laryngeal mask airway
1195599|NCT01173237|neonate
1195600|NCT01173237|surfactant
1195601|NCT01173237|respiratory distress syndrome
1195602|NCT01173224|influenza, DAS181, antiviral
1195603|NCT01173211|pregnant, women, influenza, vaccine
1195604|NCT01173198|LOW TO MODERATE MYOPIC PATIENTS
1195605|NCT01173172|Boron neutron capture therapy (BNCT)
1195606|NCT01173172|Head and neck cancer
1195607|NCT01173172|toxicities
1195608|NCT01173172|response rate
1195609|NCT01173159|Parenteral Nutrition
1195610|NCT01173159|Cholestasis
1195611|NCT01173146|Primary prostate cancer undergoing prostatectomy
1195612|NCT01173133|Free Flap
1195613|NCT01173133|Surgery
1195614|NCT01173133|Ischemia
1195615|NCT01173133|Outcome
1195616|NCT01173133|Reconstructive Plastic Surgery
1195617|NCT01173133|Monitoring
1195618|NCT01173094|Critical limb ischemia
1195619|NCT01173094|Diabetes Mellitus
1195620|NCT01173094|Diabetes foot
1195621|NCT01173081|Jones fracture
1195622|NCT01173081|fifth metatarsal fracture
1195623|NCT01173081|teriparatide
1195624|NCT01173081|fracture healing
1195625|NCT01173068|Ertapenem
1195626|NCT01173068|Clinical outcome
1195627|NCT01173068|Complicated Urinary Tract Infections
1195628|NCT01173042|Overweight
1195629|NCT01173042|Obese
1195630|NCT01173029|Systemic arterial hypertension
1195631|NCT01173029|Hypertension Resistant to Conventional Therapy
1195632|NCT01173029|Genetic polymorphisms
1195633|NCT01173029|Renin-angiotensin-aldosterone system genetic polymorphism
1195634|NCT01173029|Risk markers
1195635|NCT01173029|Adverse events
1195636|NCT01173029|Acute myocardial infarction
1195637|NCT01173029|Stroke
1195638|NCT01173016|mucopolysaccharide IH (MPS IH)
1195639|NCT01173003|Medical abortion
1195640|NCT01173003|mifepristone
1195641|NCT01173003|misoprostol
1195642|NCT01173003|Tunisia
1195643|NCT01172990|ST Depression
1195644|NCT01172977|Diabetes mellitus
1195645|NCT01172977|Stroke
1195646|NCT01172964|Los Angeles
1195647|NCT01172951|Post-prandial
1195648|NCT01172951|Nutrigenomic
1195649|NCT01172951|Test meal
1195650|NCT01172951|Oral glucose tolerance test
1195651|NCT01172951|Oral lipid tolerance test
1195652|NCT01172938|Psoriatic Arthritis
1195653|NCT01172938|Psoriasis
1195654|NCT01172938|Arthritis
1195655|NCT01172938|inflammation
1195656|NCT01172938|skin condition
1195657|NCT01172938|inflammatory cells
1195658|NCT01172938|apremilast
1195659|NCT01172938|CC-10004
1195660|NCT01172938|phosphodiesterase type 4
1195661|NCT01172925|NSCLC
1195662|NCT01172925|dyspnea
1195663|NCT01172925|phase II
1195664|NCT01172925|crossover
1195665|NCT01172925|tiotropium
1195666|NCT01172912|recurrent extragonadal germ cell tumor
1195667|NCT01172912|recurrent extragonadal non-seminomatous germ cell tumor
1195668|NCT01172912|recurrent malignant testicular germ cell tumor
1195669|NCT01172912|stage IV extragonadal non-seminomatous germ cell tumor
1195670|NCT01172912|stage III malignant testicular germ cell tumor
1195671|NCT01172912|recurrent extragonadal seminoma
1195672|NCT01172912|stage IV extragonadal seminoma
1195673|NCT01172912|testicular mature teratoma
1195674|NCT01172912|adult central nervous system germ cell tumor
1195675|NCT01172912|testicular immature teratoma
1195676|NCT01172899|Bariatric Surgery
1195677|NCT01172899|Adolescent
1195678|NCT01172886|Metabolic Syndrome obesity visceral adiposity breast cancer
1195679|NCT01172873|OCD
1195680|NCT01172873|DCS
1195681|NCT01172873|D-cycloserine
1195682|NCT01172873|CBT
1195683|NCT01172873|E/RP
1195684|NCT01172873|exposure response prevention
1195685|NCT01172860|Inoperable
1195686|NCT01172860|Colorectal
1195687|NCT01172860|Endoscopic
1195688|NCT01172860|Electroporation
1195689|NCT01172860|Outpatient
1195690|NCT01172834|Nurses
1195691|NCT01172795|Whiplash associated disorder
1195692|NCT01172795|chronic pain
1195693|NCT01172795|neural inhibition
1195694|NCT01172795|neuropsychological tests
1195695|NCT01172769|HNSCC
1195696|NCT01172756|Pulmonary Hypertension
1195697|NCT01172756|Left ventricular dysfunction
1195698|NCT01172743|Diabetes Mellitus
1195699|NCT01172743|Diabetes
1195700|NCT01172743|Type-2
1195701|NCT01172743|Adult Onset
1195702|NCT01172730|Post operative pain
1195703|NCT01172730|thoracic epidural
1195704|NCT01172730|acute pain
1195705|NCT01172730|Ultrasound scanning of the thoracic spine
1195706|NCT01172717|Carcinoid
1195707|NCT01172717|Carcinoid syndrome
1195708|NCT01172704|Motivational Interviewing
1195709|NCT01172704|Serious Mental Illness
1195710|NCT01172704|HIV/AIDS
1195711|NCT01172704|HIV Testing
1195712|NCT01172691|Liver transplant
1195713|NCT01172665|Celiac Disease
1195714|NCT01172652|Bipolar disorder
1195715|NCT01172652|Anxiety
1195716|NCT01172652|Panic
1195717|NCT01172652|GAD
1195718|NCT01172652|Generalized Anxiety Disorder
1195719|NCT01172639|CoBRA
1195720|NCT01172626|epilepsy
1195721|NCT01172626|valproate sodium
1195722|NCT01172626|metabolic enzymes
1195723|NCT01172626|adverse effects
1195724|NCT01172626|systemic adverse effects
1195725|NCT01172613|allergic rhinitis
1195726|NCT01172613|concentration of diagnostic reagent
1195727|NCT01172613|allergen extract, house dust mites (Dp)
1195728|NCT01172613|skin prick test
1195729|NCT01172613|nasal allergen provocation test
1195730|NCT01172600|radiating back pain
1195731|NCT01172600|epidural block
1195732|NCT01172600|steroid
1195733|NCT01172600|recurrent low back pain
1195734|NCT01172600|Lumbar Epidural Steroid Block with 3 injections
1195735|NCT01172587|Cognitive Behavioral Therapy
1195736|NCT01172587|Couples Treatment
1195737|NCT01172587|Alcohol Use
1195738|NCT01172587|Effects on Youth
1195739|NCT01172574|Osteoporosis
1195740|NCT01172574|Pain
1195741|NCT01172574|Kyphosis
1195742|NCT01172574|Posture
1195743|NCT01172574|Exercise therapy
1195744|NCT01172548|Resected GIST
1195745|NCT01172548|primary GIST
1195746|NCT01172548|tumor recurrence
1195747|NCT01172548|KIT receptor
1195748|NCT01172548|KIT positive
1195749|NCT01172548|advanced GIST
1195750|NCT01172548|minimal toxicity
1195751|NCT01172548|GIST
1195752|NCT01172535|Lopinavir/ritonavir
1195753|NCT01172535|Pediatric dosing
1195754|NCT01172535|World Health Organization
1195755|NCT01172522|Under eye dark circles
1195756|NCT01172522|Under eye puffiness
1195757|NCT01172509|plasticity
1195758|NCT01172509|excitatory
1195759|NCT01172509|inhibitory
1195760|NCT01172509|synaptic plasticity
1195761|NCT01172509|R-Baclofen
1195762|NCT01172509|TMS
1195763|NCT01172509|transcranial magnetic stimulation
1195764|NCT01172509|biomarker
1195765|NCT01172509|autism
1195766|NCT01172483|primary care
1195767|NCT01172483|physical and aquatic exercises
1195768|NCT01172483|promotion physical activity
1195769|NCT01172483|chronic disorders
1195770|NCT01172470|Recurrent head and neck cancer
1195771|NCT01172470|larynx, lip, oral cavity and pharynx
1195772|NCT01172457|low back pain
1195773|NCT01172457|failed back surgery syndrome (FBSS)
1195774|NCT01172457|epidural fibrosis
1195775|NCT01172457|ozone therapy
1195776|NCT01172457|oxygen therapy
1195777|NCT01172457|epiduroscopy
1195778|NCT01172457|spinal endoscopy
1195779|NCT01172444|Mild to Moderate Ulcerative Proctitis
1195780|NCT01172431|hypertension
1195781|NCT01172431|renal insufficiency
1195782|NCT01172431|indapamide
1195783|NCT01172431|hydrochlorothiazide
1195784|NCT01172418|adult
1195785|NCT01172418|primary kidney transplant recipient
1195786|NCT01172405|Headache
1195787|NCT01172405|Migraine
1195788|NCT01172405|Ibuprofen
1195789|NCT01172405|Caffeine
1195790|NCT01172366|Open label, single dose, pharmacokinetic study
1195791|NCT01172353|contras-induced nephropathy
1195792|NCT01172340|behavioral
1195793|NCT01172340|diet
1195794|NCT01172340|exercise
1195795|NCT01172314|NSCLC
1195796|NCT01172314|Weight loss
1195797|NCT01172314|protein metabolism
1195798|NCT01172314|essential amino acid intake
1195799|NCT01172301|CF
1195800|NCT01172301|protein metabolism
1195801|NCT01172301|essential amino acid intake
1195802|NCT01172288|Tic disorders,
1195803|NCT01172288|Tourette syndrome
1195804|NCT01172288|Chronic Tic Disorders
1195805|NCT01172275|Obsessive-Compulsive Disorder
1195806|NCT01172275|OCD
1195807|NCT01172262|Tinnitus
1195808|NCT01172262|MRI
1195809|NCT01172262|fMRI
1195810|NCT01172262|task based MRI
1195811|NCT01172262|Otolaryngology
1195812|NCT01172249|Osteoarthritis
1195813|NCT01172249|Knee
1195814|NCT01172249|Glucosamine
1195815|NCT01172249|Chondroitin
1195816|NCT01172223|HER2-positive
1195817|NCT01172223|early breast cancer
1195818|NCT01172197|local anesthetic
1195819|NCT01172197|levobupivacaine
1195820|NCT01172197|ropivacaine
1195821|NCT01172197|femoral perineural block
1195822|NCT01172184|Left atrial distensibility
1195823|NCT01172184|Left ventricular filling pressure
1195824|NCT01172184|Severe mitral regurgitation
1195825|NCT01172184|Prognosis
1195826|NCT01172184|Post-operation (mitral valve replacement or valvuloplasty) atrial fibrillation
1195827|NCT01172171|Ischemia-reperfusion injury
1195828|NCT01172171|Acute Myocardial Infarction
1195829|NCT01172171|Intracoronary melatonin
1195830|NCT01172158|forgotten ureteral stents, SMS Reminder
1195831|NCT01172145|apathy
1195832|NCT01172145|Alzheimer's disease
1195833|NCT01172145|activities of daily living performance
1195834|NCT01172145|caregiver burden
1195835|NCT01172132|Leukemia
1195836|NCT01172132|Lymphoma
1195837|NCT01172132|Bone-Marrow Transplant
1195838|NCT01172132|Neutropenia
1195839|NCT01172132|Acute respiratory failure
1195840|NCT01172132|Mechanical ventilation
1195841|NCT01172132|Post ICU burden
1195842|NCT01172132|ICU triage
1195843|NCT01172132|Dialysis
1195844|NCT01172132|Septic shock
1195845|NCT01172119|Coronary Disease, Coronary Stenosis, Angioplasty, Coronary restenosis, Drug Eluting Stent
1195846|NCT01172106|Postpartum psychosis
1195847|NCT01172106|Perceived social support
1195848|NCT01172106|Family psychoeducation
1195849|NCT01172093|obstructive sleep apnea
1195850|NCT01172093|prevalence
1195851|NCT01172093|diabetes mellitus
1195852|NCT01172093|Chinese
1195853|NCT01172080|colonoscopy
1195854|NCT01172080|adherence
1195855|NCT01172080|reminders
1195856|NCT01172080|quality
1195857|NCT01172067|CRT
1195858|NCT01172067|heart failure
1195859|NCT01172067|optimization
1195860|NCT01172067|Timing cycle optimization methods
1195861|NCT01172054|influenza vaccine recombinant
1195862|NCT01172028|stage IIIA non-small cell lung cancer
1195863|NCT01172028|stage IIIB non-small cell lung cancer
1195864|NCT01172028|stage IV non-small cell lung cancer
1195865|NCT01172028|recurrent non-small cell lung cancer
1195866|NCT01172028|male breast cancer
1195867|NCT01172028|stage IIIA breast cancer
1195868|NCT01172028|stage IIIB breast cancer
1195869|NCT01172028|stage IIIC breast cancer
1195870|NCT01172028|stage IV breast cancer
1195871|NCT01172028|recurrent breast cancer
1195872|NCT01172028|stage III prostate cancer
1195873|NCT01172028|stage IV prostate cancer
1195874|NCT01172028|recurrent prostate cancer
1195875|NCT01172028|stage III esophageal cancer
1195876|NCT01172028|stage IV esophageal cancer
1195877|NCT01172028|recurrent esophageal cancer
1195878|NCT01172028|recurrent adenoid cystic carcinoma of the oral cavity
1195879|NCT01172028|recurrent mucoepidermoid carcinoma of the oral cavity
1195880|NCT01172028|stage III adenoid cystic carcinoma of the oral cavity
1195881|NCT01172028|stage III mucoepidermoid carcinoma of the oral cavity
1195882|NCT01172028|stage IV adenoid cystic carcinoma of the oral cavity
1195883|NCT01172028|stage IV mucoepidermoid carcinoma of the oral cavity
1195884|NCT01172028|recurrent basal cell carcinoma of the lip
1195885|NCT01172028|stage III basal cell carcinoma of the lip
1195886|NCT01172028|stage IV basal cell carcinoma of the lip
1195887|NCT01172028|recurrent lymphoepithelioma of the nasopharynx
1195888|NCT01172028|stage III lymphoepithelioma of the nasopharynx
1195889|NCT01172028|stage IV lymphoepithelioma of the nasopharynx
1195890|NCT01172028|recurrent lymphoepithelioma of the oropharynx
1195891|NCT01172028|stage III lymphoepithelioma of the oropharynx
1195892|NCT01172028|stage IV lymphoepithelioma of the oropharynx
1195893|NCT01172028|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1195894|NCT01172028|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1195895|NCT01172028|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1195896|NCT01172028|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1195897|NCT01172028|stage III inverted papilloma of the paranasal sinus and nasal cavity
1195898|NCT01172028|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1195899|NCT01172028|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1195900|NCT01172028|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1195901|NCT01172028|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1195902|NCT01172028|recurrent salivary gland cancer
1195903|NCT01172028|stage III salivary gland cancer
1195904|NCT01172028|stage IV salivary gland cancer
1195905|NCT01172028|stage III ovarian epithelial cancer
1195906|NCT01172028|stage IV ovarian epithelial cancer
1195907|NCT01172028|recurrent ovarian epithelial cancer
1195908|NCT01172028|stage III ovarian germ cell tumor
1195909|NCT01172028|stage IV ovarian germ cell tumor
1195910|NCT01172028|recurrent ovarian germ cell tumor
1195911|NCT01172028|stage III gastric cancer
1195912|NCT01172028|stage IV gastric cancer
1195913|NCT01172028|recurrent gastric cancer
1195914|NCT01172028|recurrent hypopharyngeal cancer
1195915|NCT01172028|stage III hypopharyngeal cancer
1195916|NCT01172028|stage IV hypopharyngeal cancer
1195917|NCT01172028|recurrent laryngeal cancer
1195918|NCT01172028|stage III laryngeal cancer
1195919|NCT01172028|stage IV laryngeal cancer
1195920|NCT01172002|Lupus Nephritis
1195921|NCT01172002|Leflunomide
1195922|NCT01172002|Azathioprine
1195923|NCT01171989|booster vaccination
1195924|NCT01171989|combined vaccine
1195925|NCT01171976|DME
1195926|NCT01171976|Diabetic macula edema
1195927|NCT01171976|RETAIN
1195928|NCT01171976|ranibizumab
1195929|NCT01171963|Liquid human retrovirus vaccine
1195930|NCT01171950|Thoratec Corporation
1195931|NCT01171937|ages 8-16
1195932|NCT01171937|Repetitive Behaviors
1195933|NCT01171924|Head and Neck Cancer
1195934|NCT01171924|Liver Cancer
1195935|NCT01171924|Breast Cancer
1195936|NCT01171924|Gastric Cancer
1195937|NCT01171924|Non-Small Cell Lung Cancer
1195938|NCT01171924|EGFR
1195939|NCT01171924|HDAC
1195940|NCT01171924|Her2
1195941|NCT01171924|CUDC-101
1195942|NCT01171911|Endothelial shear stress
1195943|NCT01171911|Calcium channel blocker
1195944|NCT01171898|Non-Metastatic
1195945|NCT01171898|Rising PSA
1195946|NCT01171898|Castration-Resistant
1195947|NCT01171898|Treatment-Naive
1195948|NCT01171898|Post-abiraterone
1195949|NCT01171885|Superficial cervical block
1195950|NCT01171885|Thyroidectomy
1195951|NCT01171885|Pain
1195952|NCT01171872|Inflammatory Bowel Disease
1195953|NCT01171872|Inflammatory Bowel Disease (IBD)
1195954|NCT01171872|Crohn's Disease
1195955|NCT01171872|Ulcerative Colitis
1195956|NCT01171872|Indeterminate Colitis
1195957|NCT01171872|IBD
1195958|NCT01171872|CD
1195959|NCT01171872|UC
1195960|NCT01171872|IC
1195961|NCT01171859|amyloidosis
1195962|NCT01171859|transthyretin
1195963|NCT01171859|doxycycline
1195964|NCT01171859|Tauroursodeoxycholic acid
1195965|NCT01171846|prevention
1195966|NCT01171846|pelvic floor muscle training
1195967|NCT01171846|prolapse symptoms
1195968|NCT01171846|urinary symptoms
1195969|NCT01171846|sexual function
1195970|NCT01171846|randomised controlled trial
1195971|NCT01171833|Anesthetic induction
1195972|NCT01171833|Desflurane
1195973|NCT01171833|Isoflurane
1195974|NCT01171833|Sevoflurane
1195975|NCT01171833|Ventilation
1195976|NCT01171820|drug eluting stents
1195977|NCT01171820|stents
1195978|NCT01171820|Angioplasty
1195979|NCT01171820|coronary artery disease
1195980|NCT01171820|total coronary occlusion
1195981|NCT01171820|coronary artery restenosis
1195982|NCT01171820|stent thrombosis
1195983|NCT01171820|vascular disease
1195984|NCT01171820|myocardial ischemia
1195985|NCT01171820|coronary artery stenosis
1195986|NCT01171807|Ulcerative colitis
1195987|NCT01171807|Steroid-dependency
1195988|NCT01171807|Steroid adverse events
1195989|NCT01171807|Erythrocytes
1195990|NCT01171768|Vascular endothelial growth factor
1195991|NCT01171768|angiopoietin-2
1195992|NCT01171729|Prostate cancer
1195993|NCT01171729|PSA
1195994|NCT01171729|Hormone refractory prostatic cancer
1195995|NCT01171716|overweight, protein intake, satiety, eating, meal patterns
1195996|NCT01171703|Critical limb ischemia
1195997|NCT01171703|Diabetes
1195998|NCT01171703|Femoropopliteal artery bypass
1195999|NCT01171703|Stent
1196000|NCT01171690|Hypoparathyroidism
1196001|NCT01171677|addiction
1196002|NCT01171677|exercise
1196003|NCT01171677|cognitive function
1196004|NCT01171677|mood
1196005|NCT01171677|self efficacy
1196006|NCT01171664|Phase 2
1196007|NCT01171664|SAR
1196008|NCT01171664|STAHIST
1196009|NCT01171651|Vaccinia
1196010|NCT01171651|Vaccinia Virus
1196011|NCT01171651|JX-594
1196012|NCT01171651|Jennerex
1196013|NCT01171651|Primary Hepatocellular Carcinoma
1196014|NCT01171651|Primary Liver Cancer
1196015|NCT01171651|Liver Cancer
1196016|NCT01171651|Sorafenib
1196017|NCT01171651|Nexavar
1196018|NCT01171651|Pexa-Vec
1196019|NCT01171638|near infrared spectroscopy
1196020|NCT01171638|compartment syndrome
1196021|NCT01171638|fasciotomy
1196022|NCT01171638|INVOS
1196023|NCT01171625|PERIMOUNT, Aortic valve replacement/regurgitation
1196024|NCT01171612|Coronary Stent
1196025|NCT01171612|BMS stent
1196026|NCT01171612|DES stent
1196027|NCT01171612|Date of stent implantation
1196028|NCT01171612|cardiac event
1196029|NCT01171612|neurovascular event
1196030|NCT01171612|Bleeding
1196031|NCT01171612|transfusion
1196032|NCT01171599|Weight Loss
1196033|NCT01171599|Obesity
1196034|NCT01171599|Overweight
1196035|NCT01171599|Physical Activity
1196036|NCT01171599|Nutrition
1196037|NCT01171599|Youth
1196038|NCT01171599|Adolescent
1196039|NCT01171599|Technology
1196040|NCT01171586|Obesity
1196041|NCT01171586|overweight
1196042|NCT01171586|weight loss
1196043|NCT01171586|weight maintenance
1196044|NCT01171586|SMS
1196045|NCT01171586|technology
1196046|NCT01171586|cell phone
1196047|NCT01171586|physical activity
1196048|NCT01171586|nutrition
1196049|NCT01171573|Polymyositis
1196050|NCT01171573|Dermatomyositis
1196051|NCT01171573|Inclusion Body Myositis
1196052|NCT01171560|EZ Blocker
1196053|NCT01171560|Double-lumen Tube
1196054|NCT01171560|Airway
1196055|NCT01171560|thoracic surgery
1196056|NCT01171560|time for intubation
1196057|NCT01171560|blind insertion
1196058|NCT01171560|conditions of surgery
1196059|NCT01171560|postoperative sore throat
1196060|NCT01171560|postoperative hoarseness
1196061|NCT01171547|pharmacokinetics
1196062|NCT01171508|Circadian Rhythm Disorders
1196063|NCT01171508|Breast Neoplasms Surgery
1196064|NCT01171508|Sleep
1196065|NCT01171508|Heart Rate
1196066|NCT01171495|HIV/AIDS
1196067|NCT01171495|Nutrition Therapy
1196068|NCT01171495|Dietary Supplement
1196069|NCT01171495|Antioxidant
1196070|NCT01171495|Immunity
1196071|NCT01171495|CD4 count
1196072|NCT01171495|Anthropometry
1196073|NCT01171495|Body Mass Index
1196074|NCT01171469|Brain tumor
1196075|NCT01171469|Immunotherapy
1196076|NCT01171469|Glioma
1196077|NCT01171456|GDM
1196078|NCT01171456|Gestational Diabetes
1196079|NCT01171456|Diabetes
1196080|NCT01171456|Pregnancy
1196081|NCT01171430|multiple myeloma
1196082|NCT01171430|Autologous Stem Cell Transplantation
1196083|NCT01171417|Fulvestrant
1196084|NCT01171417|Exemestane
1196085|NCT01171417|postmenopausal patients
1196086|NCT01171417|advanced HR+ breast cancer
1196087|NCT01171417|Hormone Receptor positive
1196088|NCT01171417|advanced breast cancer
1196089|NCT01171404|Acute coronary syndrome
1196090|NCT01171404|heart attack
1196091|NCT01171404|myocardial infarction
1196092|NCT01171404|ACS long-tem follow up
1196093|NCT01171404|antithrombotic management
1196094|NCT01171404|quality of life
1196095|NCT01171404|Antithrombotic
1196096|NCT01171391|Nocturia
1196097|NCT01171391|Pharmacokinetics
1196098|NCT01171391|Pharmacodynamics
1196099|NCT01171391|Water-loading
1196100|NCT01171391|Females
1196101|NCT01171378|Richter's Syndrome
1196354|NCT01170312|Pilot
1196102|NCT01171378|High-grade transformation in patients with B cell chronic lymphocytic leukemia
1196103|NCT01171378|Feasibility
1196104|NCT01171378|Ofatumumab Induction and maintenance
1196105|NCT01171378|CHOP
1196106|NCT01171378|CHOP-0
1196107|NCT01171378|CHOP-OR
1196108|NCT01171378|Non Hodgkin's lymphoma
1196109|NCT01171365|Ciclesonide
1196110|NCT01171365|Asthma
1196111|NCT01171365|Therapeutic Uses
1196112|NCT01171365|Pulmonary Eosinophilia
1196113|NCT01171365|Nitric Oxide
1196114|NCT01171365|Lung Diseases
1196115|NCT01171365|Respiratory Tract Diseases
1196116|NCT01171352|hemodialysis
1196117|NCT01171352|dialysis
1196118|NCT01171352|hypotension
1196119|NCT01171352|CritLine
1196120|NCT01171352|PiCCO
1196121|NCT01171352|Thermodilution
1196122|NCT01171352|CVVHDF
1196123|NCT01171352|IHD
1196124|NCT01171339|elderly
1196125|NCT01171339|multimorbidity
1196126|NCT01171339|polypharmacy
1196127|NCT01171339|multimedication
1196128|NCT01171339|medication appropriateness
1196129|NCT01171339|medication appropriateness index
1196130|NCT01171339|cluster-randomised controlled trial
1196131|NCT01171339|pragmatic trial
1196132|NCT01171326|topical
1196133|NCT01171326|minocycline
1196134|NCT01171326|foam
1196135|NCT01171326|phase II
1196136|NCT01171326|impetigo
1196137|NCT01171300|staged T3-4 N0 and T1-4N1-2
1196138|NCT01171300|adenocarcinoma of the rectum
1196139|NCT01171300|rectum
1196140|NCT01171287|Automobile Driving
1196141|NCT01171287|Fracture Fixation/instrumentation
1196142|NCT01171287|Lower Extremity
1196143|NCT01171287|Orthopedic Fixation Devices
1196144|NCT01171287|Orthopedic Procedures
1196145|NCT01171287|Reaction Time
1196146|NCT01171287|Task Performance and Analysis
1196147|NCT01171287|Time Factors
1196148|NCT01171274|neck pain
1196149|NCT01171274|yoga
1196150|NCT01171274|proprioception
1196151|NCT01171274|sensory thresholds
1196152|NCT01171274|randomized controlled trial
1196153|NCT01171261|Physical Activity
1196154|NCT01171261|Sedentary Behavior
1196155|NCT01171261|Video Games
1196156|NCT01171261|Exergames
1196157|NCT01171248|nocturnal blood pressure dip
1196158|NCT01171248|complications
1196159|NCT01171248|ambulatory blood pressure
1196160|NCT01171235|Laryngeal Neoplasms
1196161|NCT01171235|Pharyngeal Neoplasms
1196162|NCT01171222|soccer
1196163|NCT01171222|prevention
1196164|NCT01171222|veteran athletes
1196165|NCT01171222|exercise
1196166|NCT01171222|Cardiovascular
1196167|NCT01171209|MS
1196168|NCT01171196|Sleep Apnea
1196169|NCT01171196|Questionnaire
1196170|NCT01171183|cocaine dependence
1196171|NCT01171183|cocaine withdrawal
1196172|NCT01171170|non small cell lung cancer
1196173|NCT01171170|stage IV
1196174|NCT01171170|nitroglycerin
1196175|NCT01171170|carboplatin
1196176|NCT01171170|paclitaxel
1196177|NCT01171170|bevacizumab
1196178|NCT01171157|vaccine effectiveness
1196179|NCT01171157|Influenza-like illness
1196180|NCT01171157|elderly
1196181|NCT01171157|Influenza
1196182|NCT01171131|TBI
1196183|NCT01171131|Brain Injury
1196184|NCT01171118|Breathing
1196185|NCT01171118|Sedation
1196186|NCT01171105|AZD5213 Phase 1
1196187|NCT01171105|Safety
1196188|NCT01171105|tolerability
1196189|NCT01171092|stem cell
1196190|NCT01171092|transplant
1196191|NCT01171092|myeloma
1196192|NCT01171092|lymphoma
1196193|NCT01171092|BMT
1196194|NCT01171092|autologous
1196195|NCT01171079|postoperative adhesion after thyroidectomy
1196196|NCT01171053|Cognitive behavior therapy
1196197|NCT01171053|Internet
1196198|NCT01171053|Cost-effectiveness
1196199|NCT01171053|Irritable bowel syndrome
1196200|NCT01171040|left atrial distensibility
1196201|NCT01171040|mortality
1196202|NCT01171040|heart failure
1196203|NCT01171040|atrial fibrillation
1196204|NCT01171040|stroke
1196205|NCT01171040|prognosis
1196206|NCT01171027|Cholecystectomy
1196207|NCT01171027|NOTES
1196208|NCT01171027|Transvaginal
1196209|NCT01171027|Transgastric
1196210|NCT01171027|Natural orifice
1196211|NCT01171027|Gallbladder removal
1196212|NCT01170988|patients scheduled for bypass grafting
1196213|NCT01170975|Advanced solid tumors
1196214|NCT01170949|urticaria
1196215|NCT01170936|Urticarial vasculitis
1196216|NCT01170936|anti-IL1ß therapy
1196217|NCT01170923|non small cell lung cancer
1196218|NCT01170923|FDG PET
1196219|NCT01170910|Chronic renal failure
1196220|NCT01170910|Transplantation
1196221|NCT01170910|Marginal kidney graft
1196222|NCT01170910|Pulsatile perfusion machine
1196223|NCT01170897|PEGPH20
1196224|NCT01170897|PEGylated Recombinant Human Hyaluronidase
1196225|NCT01170897|Metastatic or Locally Advanced Solid Tumors
1196226|NCT01170845|Esophagectomy
1196227|NCT01170845|Postoperative respiratory complications
1196228|NCT01170845|neutrophil elastase inhibitor
1196229|NCT01170819|Cervical ripening
1196230|NCT01170819|Induction of labor
1196231|NCT01170819|Prostaglandins
1196232|NCT01170819|Mechanical methods
1196233|NCT01170819|Balloon catheter
1196234|NCT01170806|Intestinal lipase
1196235|NCT01170806|Orlistat
1196236|NCT01170806|fecal fat
1196237|NCT01170806|obesity
1196238|NCT01170793|education, quality of life
1196239|NCT01170780|Inguinal hernia
1196240|NCT01170780|Transabdominal preperitoneal hernia repair
1196241|NCT01170780|TAPP
1196242|NCT01170780|Dexamethasone
1196243|NCT01170780|Pain
1196244|NCT01170767|Age-related Macular Degeneration
1196245|NCT01170767|Bevacizumab
1196246|NCT01170767|Ranibizumab
1196247|NCT01170754|PEG-3350, polyethylene glycol, colonoscopy
1196248|NCT01170728|Male Sling
1196249|NCT01170728|Fixation
1196250|NCT01170728|Stress Urinary Incontinence
1196251|NCT01170728|Urinary incontinence
1196252|NCT01170715|Psoriasis
1196253|NCT01170715|Co morbidities
1196254|NCT01170715|Inflammation
1196255|NCT01170702|Cesarean Delivery
1196256|NCT01170702|Ropivicaine
1196257|NCT01170702|TAP block
1196258|NCT01170689|Schizophrenia
1196259|NCT01170689|inpatient
1196260|NCT01170689|obesity
1196261|NCT01170689|prevalence
1196262|NCT01170676|asthma
1196263|NCT01170676|smoking
1196264|NCT01170676|teens
1196265|NCT01170663|Metastatic Adenocarcinoma
1196266|NCT01170663|Gastric Adenocarcinoma
1196267|NCT01170663|Gastroesophageal Junction Adenocarcinoma
1196268|NCT01170650|cancer
1196269|NCT01170650|ovarian
1196270|NCT01170650|platinum-resistant
1196271|NCT01170650|Phase III
1196272|NCT01170650|EC145
1196273|NCT01170650|EC20
1196274|NCT01170624|PhD
1196275|NCT01170624|EGM
1196276|NCT01170624|CRT-D
1196277|NCT01170624|The study will particularly focus on a new-based diagnostic feature, called PhD-Clinical Status (PhD)
1196278|NCT01170598|acute myeloid leukemia
1196279|NCT01170598|AML
1196280|NCT01170598|chemotherapy
1196281|NCT01170598|exercise
1196282|NCT01170598|quality of life
1196283|NCT01170598|cancer-related fatigue
1196284|NCT01170598|elderly
1196285|NCT01170598|physical fitness
1196286|NCT01170598|muscular strength
1196287|NCT01170598|Feasibility
1196288|NCT01170598|Efficacy
1196289|NCT01170598|Safety
1196290|NCT01170546|anterior cruciate ligament
1196291|NCT01170546|agility
1196292|NCT01170546|knee stability
1196293|NCT01170546|hamstring
1196294|NCT01170546|knee internal rotator
1196295|NCT01170533|proton pump inhibitor
1196296|NCT01170533|clopidogrel
1196297|NCT01170533|platelet function
1196298|NCT01170520|adolescent resistant depression
1196299|NCT01170520|repetitive transcranial magnetic stimulation
1196300|NCT01170520|treatment of resistant adolescent depression
1196301|NCT01170507|vitamin D3, 25 OH vitamin D3 level
1196302|NCT01170494|vitamin D2, vitamin D3, 25 Oh vitamin D2, 25 Oh vitamin D3
1196303|NCT01170481|anterior and intermediate uveitis
1196304|NCT01170481|papilloedema
1196305|NCT01170468|Prediabetics
1196306|NCT01170468|DM
1196307|NCT01170468|vitamin D
1196308|NCT01170455|nasal
1196309|NCT01170455|intubation
1196310|NCT01170455|direct laryngoscope
1196311|NCT01170455|blind
1196312|NCT01170455|normal airway
1196313|NCT01170429|Cough Variant Asthma
1196314|NCT01170429|Procaterol Hydrochloride
1196315|NCT01170416|Ventricular Tachycardia
1196316|NCT01170416|Body Surface Mapping
1196317|NCT01170403|coronary heart disease
1196318|NCT01170403|Multidetector row cardiac computed tomography
1196319|NCT01170403|type 2 diabetes
1196320|NCT01170403|metabolic syndrome
1196321|NCT01170390|Obesity
1196322|NCT01170390|Body weight
1196323|NCT01170390|Oral contraception
1196324|NCT01170390|Efficacy
1196325|NCT01170377|Intravenous sedation
1196326|NCT01170377|Dental treatment
1196327|NCT01170377|Mental retardation
1196328|NCT01170377|Antiepileptic drug
1196329|NCT01170377|Valproate
1196330|NCT01170377|Propofol
1196331|NCT01170364|Obesity
1196332|NCT01170364|sibutramine
1196333|NCT01170364|eating behavior
1196334|NCT01170351|autoimmune hepatitis
1196335|NCT01170351|corticosteroids
1196336|NCT01170351|cysclosporine-A
1196337|NCT01170351|treatment
1196338|NCT01170351|treatment-naive
1196339|NCT01170351|induction of remossion
1196340|NCT01170351|efficacy
1196341|NCT01170351|tolerability
1196342|NCT01170338|smoking
1196343|NCT01170338|tobacco abuse
1196344|NCT01170325|Valproic Acid
1196345|NCT01170325|Divalproex
1196346|NCT01170325|Autism
1196347|NCT01170325|EEG
1196348|NCT01170325|Electroencephalogram (EEG)
1196349|NCT01170325|Depakote
1196350|NCT01170312|Arthroscopic repair
1196351|NCT01170312|Rotator cuff
1196352|NCT01170312|Platelet rich plasma
1196353|NCT01170312|Randomized
1196355|NCT01170299|radiation toxicity
1196356|NCT01170299|gastrointestinal complications
1196357|NCT01170299|cervical cancer
1196358|NCT01170299|fallopian tube cancer
1196359|NCT01170299|ovarian epithelial cancer
1196360|NCT01170299|ovarian germ cell tumor
1196361|NCT01170299|ovarian sarcoma
1196362|NCT01170299|ovarian stromal cancer
1196363|NCT01170299|uterine sarcoma
1196364|NCT01170299|bladder cancer
1196365|NCT01170299|colon cancer
1196366|NCT01170299|rectal cancer
1196367|NCT01170299|anal cancer
1196368|NCT01170286|Food allergy
1196369|NCT01170286|Immediate hypersensitivity
1196370|NCT01170286|Whole peanut extract
1196371|NCT01170286|Allergenic product
1196372|NCT01170286|Specific Immunotherapy
1196373|NCT01170286|Epicutaneous Immunotherapy (EPIT)
1196374|NCT01170286|Safety
1196375|NCT01170273|aged
1196376|NCT01170273|vitamin d deficiency
1196377|NCT01170247|Procedural Sedation
1196378|NCT01170234|Exhaled nitric oxide
1196379|NCT01170234|Eosinophilic esophagitis
1196380|NCT01170221|ABSSSI
1196381|NCT01170221|Tedizolid Phosphate
1196382|NCT01170221|TR-701
1196383|NCT01170221|Acute Bacterial Skin and Skin Structure Infections
1196384|NCT01170208|insulin
1196385|NCT01170208|dosage software
1196386|NCT01170195|Postmenopausal
1196387|NCT01170195|licorice
1196388|NCT01170195|vaginal complaints
1196389|NCT01170156|deep sedation
1196390|NCT01170156|respiratory resuscitation
1196391|NCT01170156|Hi-Lo Evac tube
1196392|NCT01170156|suctioning manoeuvre
1196393|NCT01170143|IIB-IIIB Breast Cancer
1196394|NCT01170143|Her2 positive
1196395|NCT01170130|Cataract
1196396|NCT01170130|Mydriasis
1196397|NCT01170130|Lidocaine
1196398|NCT01170117|Eating Disorders
1196399|NCT01170117|Anorexia Nervosa
1196400|NCT01170104|Hepatocellular Carcinoma
1196401|NCT01170104|Sorafenib
1196402|NCT01170104|TACE
1196403|NCT01170104|locally, advanced Hepatocellular Carcinoma
1196404|NCT01170078|chronic renal failure requiring hemodialysis
1196405|NCT01170052|Relapsed Mantle Cell Lymphoma
1196406|NCT01170052|Refractory Mantle Cell Lymphoma
1196407|NCT01170052|Non-Hodgkins Lymphoma
1196408|NCT01170052|Temsirolimus
1196409|NCT01170052|Bendamustine
1196410|NCT01170052|Phase 1/2
1196411|NCT01170039|Constipation
1196412|NCT01170039|Diabetes
1196413|NCT01170039|Lubiprostone
1196414|NCT01170039|Amitiza
1196415|NCT01170039|African Americans
1196416|NCT01170026|substance use
1196417|NCT01170026|adolescents
1196418|NCT01170026|intervention
1196419|NCT01170026|truancy
1196420|NCT01170026|sexual risk behavior
1196421|NCT01170013|substance use
1196422|NCT01170013|adolescents
1196423|NCT01170013|initiation
1196424|NCT01169987|Multicenter study
1196425|NCT01169974|Microcirculation
1196426|NCT01169974|laser flowmetry
1196427|NCT01169974|Skin
1196428|NCT01169974|Physiology
1196429|NCT01169961|IRON OVERLOAD IN HEMODIALYSIS PATIENTS
1196430|NCT01169948|Coronary disease
1196431|NCT01169948|Coronary artery bypass
1196432|NCT01169948|Cardiac surgery
1196433|NCT01169948|Computed tomography
1196434|NCT01169948|Coronary angiography
1196435|NCT01169935|MRI
1196436|NCT01169935|SPIO
1196437|NCT01169935|Healthy Volunteer
1196438|NCT01169909|Pterygium
1196439|NCT01169896|Impact of ventricular pacing on the incidence of VT/VF episodes for each models
1196440|NCT01169883|adherence
1196441|NCT01169883|asthma
1196442|NCT01169883|pediatrics
1196443|NCT01169883|behavioral intervention
1196444|NCT01169883|inner city
1196445|NCT01169870|metastatic
1196446|NCT01169857|Proliferative lupus nephritis
1196447|NCT01169857|WHO class III/IV/V lupus nephritis
1196448|NCT01169857|Proteinuria
1196449|NCT01169857|Hematuria
1196450|NCT01169857|Velcade
1196451|NCT01169857|SLE
1196452|NCT01169857|Bortezomib
1196453|NCT01169857|Proteasome inhibitor
1196454|NCT01169844|Psoriatic arthritis
1196455|NCT01169844|IgG1K monoclonal antibody
1196456|NCT01169844|Interleukin -17A neutralizing
1196457|NCT01169792|Tamoxifen
1196458|NCT01169792|Cytochrome P-450 CYP2D6
1196459|NCT01169792|Polymorphism
1196460|NCT01169792|Single nucleotide
1196461|NCT01169792|Antineoplastic Agents, Hormonal
1196462|NCT01169753|Chronic Myeloid Leukemia
1196463|NCT01169753|CML
1196464|NCT01169753|Nuvigil
1196465|NCT01169753|Armodafinil
1196466|NCT01169753|Fatigue
1196467|NCT01169740|Hyperbilirubinemia
1196468|NCT01169740|Neonatal
1196469|NCT01169740|Serum bilirubin
1196470|NCT01169740|Transcutaneous bilirubin
1196471|NCT01169740|Skin color
1196472|NCT01169727|COPD and CCQ score
1196473|NCT01169727|Changes in PEF,overall CCQ score
1196474|NCT01169714|multiple dose
1196475|NCT01169714|healthy volunteer
1196476|NCT01169714|healthy elderly volunteer
1196477|NCT01169714|safety
1196478|NCT01169714|pharmacokinetic
1196594|NCT01169311|Hemorrhoid
1196479|NCT01169701|Renal transplant, everolimus, cardiovascular profile, CNI-free immunosuppression, left ventricular hypertrophy, biopsy proved acute rejection (BPAR)
1196480|NCT01169688|Cataract Surgery
1196481|NCT01169688|Pupillary Dilation
1196482|NCT01169649|MK-2206
1196483|NCT01169649|Neuroendocrine Tumors
1196484|NCT01169649|10-067
1196485|NCT01169636|Chemotherapy
1196486|NCT01169636|Panobinostat
1196487|NCT01169636|Ifosfamide
1196488|NCT01169636|Mesna
1196489|NCT01169636|Etoposide
1196490|NCT01169636|Carboplatin
1196491|NCT01169636|Pegfilgrastim
1196492|NCT01169636|ICE
1196493|NCT01169623|Supportive leadership behaviour
1196494|NCT01169623|Nurse Performance
1196495|NCT01169623|Educational Intervention
1196496|NCT01169610|Alcohol
1196497|NCT01169610|Smoking
1196498|NCT01169597|polymyalgia rheumatica
1196499|NCT01169597|prednisone
1196500|NCT01169597|clinical examination
1196501|NCT01169597|remission
1196502|NCT01169597|ultrasonography
1196503|NCT01169584|Phase I
1196504|NCT01169584|advanced metastatic pediatric solid tumors
1196505|NCT01169584|pediatric
1196506|NCT01169584|vaccinia virus
1196507|NCT01169584|oncolytic virus
1196508|NCT01169584|neuroblastoma
1196509|NCT01169584|rhabdomyosarcoma
1196510|NCT01169584|lymphoma
1196511|NCT01169584|Wilm's tumor
1196512|NCT01169584|Ewing's sarcoma
1196513|NCT01169584|osteosarcoma
1196514|NCT01169584|non-rhabdomyosarcoma soft tissue sarcomas
1196515|NCT01169584|malignant peripheral nerve sheath tumors
1196516|NCT01169584|Pexa-Vec
1196517|NCT01169571|Initially intubated
1196518|NCT01169571|Mechanically ventilated
1196519|NCT01169571|Post-surgical
1196520|NCT01169545|any type of cancer
1196521|NCT01169519|Hypoplastic left heart syndrome
1196522|NCT01169519|Hypoplastic right heart syndrome
1196523|NCT01169519|Superior cavopulmonary anastomosis
1196524|NCT01169519|Total cavopulmonary anastomosis
1196525|NCT01169519|Children with single ventricle anatomy
1196526|NCT01169506|blood gas analysis
1196527|NCT01169506|ventilatory insufficiency
1196528|NCT01169493|Heart Failure
1196529|NCT01169493|Right Bundle-Branch Block
1196530|NCT01169493|Cardiac Resynchronization Therapy
1196531|NCT01169480|Massage
1196532|NCT01169480|Therapist, Massage
1196533|NCT01169480|DASS
1196534|NCT01169480|Depression
1196535|NCT01169480|Anxiety, State
1196536|NCT01169480|Anxiety, Trait
1196537|NCT01169480|Stress
1196538|NCT01169480|Touch
1196539|NCT01169480|Therapeutic Relationship
1196540|NCT01169454|Cerebral Spinal Fluid
1196541|NCT01169454|Ventriculostomy
1196542|NCT01169454|Subarachnoid hemorrhage
1196543|NCT01169454|Vasospasm
1196544|NCT01169454|Human Subjects
1196545|NCT01169441|ICD leads
1196546|NCT01169441|Removal
1196547|NCT01169441|Extraction
1196548|NCT01169441|Ventricular leads
1196549|NCT01169441|Extract
1196550|NCT01169441|laser
1196551|NCT01169441|Observe the lead with x-ray during movement and collect information on current ways of removing an ICD lead.
1196552|NCT01169428|Mindfulness-Based Weight Loss Maintenance
1196553|NCT01169428|prevention of weight regain
1196554|NCT01169428|Obesity
1196555|NCT01169415|Randomized
1196556|NCT01169415|Dexamethasone
1196557|NCT01169415|Abbreviated
1196558|NCT01169415|Protracted
1196559|NCT01169415|Post-operatively
1196560|NCT01169402|extracorporeal membrane oxygenation
1196561|NCT01169402|ECMO
1196562|NCT01169402|extracorporeal life support
1196563|NCT01169402|fluconazole
1196564|NCT01169402|diflucan
1196565|NCT01169402|pharmacokinetics
1196566|NCT01169402|pharmacodynamics
1196567|NCT01169376|disseminated neuroblastoma
1196568|NCT01169376|localized resectable neuroblastoma
1196569|NCT01169376|localized unresectable neuroblastoma
1196570|NCT01169376|regional neuroblastoma
1196571|NCT01169376|stage 4S neuroblastoma
1196572|NCT01169363|adult acute myeloid leukemia in remission
1196573|NCT01169363|recurrent adult acute myeloid leukemia
1196574|NCT01169363|adult erythroleukemia (M6a)
1196575|NCT01169363|adult pure erythroid leukemia (M6b)
1196576|NCT01169363|adult acute megakaryoblastic leukemia (M7)
1196577|NCT01169363|adult acute minimally differentiated myeloid leukemia (M0)
1196578|NCT01169363|adult acute monoblastic leukemia (M5a)
1196579|NCT01169363|adult acute monocytic leukemia (M5b)
1196580|NCT01169363|adult acute myeloblastic leukemia with maturation (M2)
1196581|NCT01169363|adult acute myeloblastic leukemia without maturation (M1)
1196582|NCT01169363|adult acute myelomonocytic leukemia (M4)
1196583|NCT01169363|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1196584|NCT01169363|adult acute myeloid leukemia with del(5q)
1196585|NCT01169363|adult acute myeloid leukemia with inv(16)(p13;q22)
1196586|NCT01169363|adult acute myeloid leukemia with t(16;16)(p13;q22)
1196587|NCT01169363|adult acute myeloid leukemia with t(8;21)(q22;q22)
1196588|NCT01169324|Parkinson's disease
1196589|NCT01169324|Tremor
1196590|NCT01169324|Dystonia
1196591|NCT01169324|DBS
1196592|NCT01169324|Sleep
1196593|NCT01169311|Hemorrhoids
1196595|NCT01169311|grade II, III, IV
1196596|NCT01169298|Adult T-cell Leukemia-Lymphoma
1196597|NCT01169298|Peripheral T-cell Lymphoma
1196598|NCT01169298|PTCL
1196599|NCT01169298|HTLV-1
1196600|NCT01169285|Burn Department Nursing Staff
1196601|NCT01169272|ICD CRT 9770 - PARADYM RF ICD - SonR atrial lead
1196602|NCT01169259|vitamin D3
1196603|NCT01169259|omega-3 fatty acids
1196604|NCT01169259|fish oil
1196605|NCT01169259|cardiovascular disease
1196606|NCT01169259|cancer
1196607|NCT01169259|primary prevention
1196608|NCT01169246|ATP,CRT, ICD PARADYM
1196609|NCT01169233|Sleep
1196610|NCT01169233|Alertness
1196611|NCT01169233|fatigue
1196612|NCT01169233|performance
1196613|NCT01169233|spaceflight
1196614|NCT01169233|isolation
1196615|NCT01169233|light
1196616|NCT01169233|Sleep , alertness and performance during a simulated spaceflight mission
1196617|NCT01169220|Colonoscopy
1196618|NCT01169220|Bowel preparation
1196619|NCT01169207|Inflammatory Bowel Disease
1196620|NCT01169207|Crohn's Disease
1196621|NCT01169207|Ulcerative Colitis
1196622|NCT01169207|Indeterminate Colitis
1196623|NCT01169207|IBD
1196624|NCT01169207|CD
1196625|NCT01169207|UC
1196626|NCT01169207|IC
1196627|NCT01169194|Inflammatory Bowel Disease
1196628|NCT01169194|Crohn's Disease
1196629|NCT01169194|Ulcerative Colitis
1196630|NCT01169194|Indeterminate Colitis
1196631|NCT01169194|IBD
1196632|NCT01169194|African American IBD
1196633|NCT01169194|African American CD
1196634|NCT01169194|African American UC
1196635|NCT01169194|Black IBD
1196636|NCT01169194|Black CD
1196637|NCT01169194|Black UC
1196638|NCT01169194|African American Inflammatory Bowel Disease
1196639|NCT01169194|African American Crohn's Disease
1196640|NCT01169194|African American Ulcerative Colitis
1196641|NCT01169194|Black Inflammatory Bowel Disease
1196642|NCT01169194|Black Crohn's Disease
1196643|NCT01169194|Black Ulcerative Colitis
1196644|NCT01169181|Stroke
1196645|NCT01169181|Cerebrovascular Accident
1196646|NCT01169181|Plegia
1196647|NCT01169181|Upper Extremity
1196648|NCT01169181|rTMS
1196649|NCT01169181|tDCS
1196650|NCT01169168|fibrinogen
1196651|NCT01169168|SIRS
1196652|NCT01169168|sepsis
1196653|NCT01169168|liver disease
1196654|NCT01169168|chronic liver disease
1196655|NCT01169168|septic shock
1196656|NCT01169155|Smoke inhalation injury
1196657|NCT01169155|Burns
1196658|NCT01169155|Injuries
1196659|NCT01169142|Vitamin D
1196660|NCT01169142|Schizophrenia
1196661|NCT01169142|Severely Mentally Ill
1196662|NCT01169129|brain metastases
1196663|NCT01169129|radiosurgery
1196664|NCT01169129|neurosurgery
1196665|NCT01169129|surgery
1196666|NCT01169129|radiotherapy
1196667|NCT01169129|resectable brain metastases
1196668|NCT01169116|radiotherapy
1196669|NCT01169116|radiation oncology
1196670|NCT01169116|brain metastasis
1196671|NCT01169116|metastases
1196672|NCT01169116|radiosurgery
1196673|NCT01169116|neurosurgery
1196674|NCT01169116|hypofractionation
1196675|NCT01169116|stereotaxy
1196676|NCT01169103|Obesity
1196677|NCT01169103|Adolescent
1196678|NCT01169103|Insulin resistance
1196679|NCT01169103|Growth hormone
1196680|NCT01169103|Visceral fat
1196681|NCT01169103|Adolescent obesity
1196682|NCT01169077|malaria, plasmodium falciparum, electroporation
1196683|NCT01169064|Wound infection prevention
1196684|NCT01169064|Silver-containing surgical dressing
1196685|NCT01169064|Cesarean delivery infection prevention
1196686|NCT01169051|Esophagectomy
1196687|NCT01169051|Pulmonary wedge resection
1196688|NCT01169051|Pulmonary lobectomy
1196689|NCT01169051|Pulmonary pneumonectomy
1196690|NCT01169051|Thoracic Surgery
1196691|NCT01169051|Lung Cancer
1196692|NCT01169051|Esophageal Cancer
1196693|NCT01169038|sarcoidosis
1196694|NCT01169038|mycobacteria
1196695|NCT01169038|lung
1196696|NCT01169038|pulmonary
1196697|NCT01169038|radiographic improvement
1196698|NCT01169025|Analgesia
1196699|NCT01169025|Pain
1196700|NCT01169012|Myelodysplastic syndrome
1196701|NCT01169012|Acute Myeloid Leukemia
1196702|NCT01169012|Acute Lymphoblastic Leukemia
1196703|NCT01169012|Chronic myelomonocytic leukemia
1196704|NCT01169012|Clofarabine
1196705|NCT01169012|Clolar
1196706|NCT01169012|University of North Carolina at Chapel Hill
1196707|NCT01169012|Lineberger Comprehensive Cancer Center
1196708|NCT01168999|low back pain
1196709|NCT01168999|spinal manipulation
1196710|NCT01168999|manual therapy
1196711|NCT01168999|placebo
1196712|NCT01168986|neck pain
1196713|NCT01168986|manual therapy
1196714|NCT01168986|exercise
1196715|NCT01168973|second line
1196716|NCT01168973|non small cell lung cancer
1196717|NCT01168973|NSCLC
1196718|NCT01168973|phase 3
1196719|NCT01168973|ramucirumab
1196720|NCT01168973|lung cancer
1196721|NCT01168973|docetaxel
1196722|NCT01168973|taxotere
1196723|NCT01168947|sodium
1196724|NCT01168947|hypertension
1196725|NCT01168947|fluid overload
1196726|NCT01168947|hemodialysis
1196727|NCT01168947|dialysate
1196728|NCT01168947|interdialytic weight gain
1196729|NCT01168947|intradialytic hypotension
1196730|NCT01168934|healthy volunteers
1196731|NCT01168934|crizotinib
1196732|NCT01168934|absolute bioavailability
1196733|NCT01168934|pharmacokinetics
1196734|NCT01168921|Chronic Lymphocytic Leukemia
1196735|NCT01168921|CLL
1196736|NCT01168921|Thrombocytopenia
1196737|NCT01168921|Small lymphocytic lymphoma
1196738|NCT01168921|SLL
1196739|NCT01168921|Eltrombopag
1196740|NCT01168921|Promacta
1196741|NCT01168921|thrombopoietin (TPO)-receptor agonist
1196742|NCT01168921|platelets
1196743|NCT01168908|Clinical trial
1196744|NCT01168908|Revatio
1196745|NCT01168908|Sildenafil
1196746|NCT01168908|Muscular Dystrophy
1196747|NCT01168908|Duchenne
1196748|NCT01168908|Becker
1196749|NCT01168908|Adult
1196750|NCT01168908|Adolescent
1196751|NCT01168895|75 mg dose strength
1196752|NCT01168895|Safety
1196753|NCT01168895|Pharmacokinetics
1196754|NCT01168882|RGB-286638
1196755|NCT01168882|Hematological Malignancies
1196756|NCT01168869|Manifestation
1196757|NCT01168869|Coronary Heart Disease
1196758|NCT01168869|Myocardial infarction
1196759|NCT01168869|Angina pectoris
1196760|NCT01168869|Unheralded
1196761|NCT01168869|General Practice Research Database
1196762|NCT01168869|Myocardial Ischaemia National Audit Project
1196763|NCT01168869|CALIBER
1196764|NCT01168817|Combination Drug Therapy
1196765|NCT01168817|Phosphodiesterase inhibitors
1196766|NCT01168804|multiple myeloma
1196767|NCT01168804|bendamustine
1196768|NCT01168804|bortezomib
1196769|NCT01168804|dexamethasone
1196770|NCT01168791|Metastatic
1196771|NCT01168791|Front line
1196772|NCT01168765|Physical Activity, Mexican-American, Obesity, Diabetes, Nutrition, Border Health
1196773|NCT01168752|Cancer
1196774|NCT01168752|solid tumour
1196775|NCT01168752|lymphoma
1196776|NCT01168752|dose-escalation
1196777|NCT01168752|Hsp90 inhibitor
1196778|NCT01168739|thermotolerance
1196779|NCT01168739|heat acclimation
1196780|NCT01168739|quercetin
1196781|NCT01168739|exertional heat illness
1196904|NCT01168154|Diverticula
1196782|NCT01168739|gastrointestinal barrier permeability
1196783|NCT01168713|Adults with Community-Acquired Bacterial Pneumonia
1196784|NCT01168700|Metabolic syndrome, Aged Garlic Extract, Insulin, inflammation, endothelium.
1196785|NCT01168687|keppra
1196786|NCT01168687|levetiracetam
1196787|NCT01168687|alcoholism
1196788|NCT01168687|genetics
1196789|NCT01168687|subjective report
1196790|NCT01168674|Major Depressive Disorder
1196791|NCT01168674|MDD
1196792|NCT01168674|Bipolar Disorder
1196793|NCT01168674|BD
1196794|NCT01168674|Depression
1196795|NCT01168674|Major Depressive Disorder with Bipolar features
1196796|NCT01168661|Stress
1196797|NCT01168661|Burnout
1196798|NCT01168661|Anxiety
1196799|NCT01168661|Depression
1196800|NCT01168648|Yoga
1196801|NCT01168648|Stress
1196802|NCT01168648|Stress management
1196803|NCT01168648|Hypothalamus-pituitary-adrenal axis
1196804|NCT01168635|Asthma
1196805|NCT01168635|Spirometry
1196806|NCT01168635|Pediatric
1196807|NCT01168635|Primary Health Care
1196808|NCT01168635|Education, Distance
1196809|NCT01168609|Left atrial distensibility
1196810|NCT01168609|left ventricular filling pressure
1196811|NCT01168609|tissue Doppler
1196812|NCT01168609|prognosis
1196813|NCT01168609|acute myocardial infarction
1196814|NCT01168596|Parkinson's Disease
1196815|NCT01168596|Fatigue
1196816|NCT01168570|familial Mediterranean fever
1196817|NCT01168570|amyloidosis AA
1196818|NCT01168570|serum amyloid A
1196819|NCT01168570|renal failure
1196820|NCT01168570|nephrotic syndrome
1196821|NCT01168557|electric impedance tomography
1196822|NCT01168557|stress-echocardiography
1196823|NCT01168557|ventilation
1196824|NCT01168557|perfusion
1196825|NCT01168544|Vitamin D
1196826|NCT01168544|Colecalciferol
1196827|NCT01168544|Nursing home
1196828|NCT01168544|Loading dose
1196829|NCT01168531|patients undergoing lumbar spinal surgery
1196830|NCT01168518|Evaluate the Sorin Group new passive- and active- fixation pacing leads
1196831|NCT01168492|pediatric
1196832|NCT01168492|gastroscopy
1196833|NCT01168492|colonoscopy
1196834|NCT01168492|sedation
1196835|NCT01168492|ketamine
1196836|NCT01168479|prostate cancer
1196837|NCT01168479|external beam radiotherapy
1196838|NCT01168479|dose escalation
1196839|NCT01168479|dose painting
1196840|NCT01168479|95Gy in 35 fractions
1196841|NCT01168479|MRI
1196842|NCT01168479|FLAME
1196843|NCT01168466|Frontotemporal Lobar Degeneration
1196844|NCT01168466|EEG Biofeedback
1196845|NCT01168466|Cerebral oxygenation biofeedback
1196846|NCT01168466|Peak Alpha Rhythm Biofeedback
1196847|NCT01168466|Frontotemporal Dementia
1196848|NCT01168453|jugular vein
1196849|NCT01168453|anatomy
1196850|NCT01168453|ultrasonography
1196851|NCT01168440|von Hippel-Lindau
1196852|NCT01168440|VHL
1196853|NCT01168440|sunitinib
1196854|NCT01168401|Prevention of acute gastroenteritis due to infection with noroviruses
1196855|NCT01168388|Dystonia
1196856|NCT01168388|Hemifacial spasm
1196857|NCT01168388|Cervical dystonia
1196858|NCT01168388|Blepharospasm
1196859|NCT01168362|coronary artery disease
1196860|NCT01168362|cardiovascular risk
1196861|NCT01168362|pericardial fat
1196862|NCT01168336|betahistine olanzapine weight sleepiness
1196863|NCT01168336|olanzapine induced weight gain and sleepiness
1196864|NCT01168323|Medical Education
1196865|NCT01168323|Educational Technology
1196866|NCT01168323|Clinical Practice Guideline
1196867|NCT01168323|Prostate specific antigen
1196868|NCT01168310|Pulmonary, Obstructive, lungs, COPD
1196869|NCT01168297|Obesity
1196870|NCT01168297|Type 2 Diabetes Mellitus
1196871|NCT01168297|Genetics
1196872|NCT01168297|Energy Expenditure
1196873|NCT01168297|Physical Activity
1196874|NCT01168284|Autism Spectrum Disorders
1196880|NCT01168258|Diabetic Retinopathy
1196881|NCT01168258|Diabetes
1196882|NCT01168258|Single Nucleotide Polymorphism (SNP)
1196883|NCT01168258|Diabetic Macular Edema
1196884|NCT01168245|Alzheimer Disease
1196885|NCT01168245|Dementia
1196886|NCT01168245|Brain Diseases
1196887|NCT01168245|Central Nervous System Diseases
1196888|NCT01168245|Nervous System Disease
1196889|NCT01168245|Cognitive Training
1196890|NCT01168245|Cortical Reorganization
1196891|NCT01168245|Brain Plasticity
1196892|NCT01168193|surgery
1196893|NCT01168193|post operative
1196894|NCT01168193|complications
1196895|NCT01168193|length of stay
1196896|NCT01168180|Traditional Thai Massage
1196897|NCT01168180|Scapulocostal Syndrome
1196898|NCT01168167|Antiretroviral Therapy, Highly Active
1196899|NCT01168167|MK 0518
1196900|NCT01168167|HIV-1 DNA species
1196901|NCT01168167|viral slope
1196902|NCT01168167|Ribonucleic Acid
1196903|NCT01168167|DNA, Complementary
1196905|NCT01168154|Diverticular disease
1196906|NCT01168154|Diverticulitis
1196907|NCT01168154|Probiotics
1196908|NCT01168141|Castrate-resistant prostate cancer with bone metastasis
1196909|NCT01168128|Enteral Nutrition
1196910|NCT01168128|Parenteral Nutrition
1196911|NCT01168128|Critically ill
1196912|NCT01168128|Nutrition Therapy
1196913|NCT01168128|Nutrition Support
1196914|NCT01168128|Practice Guidelines as Topic
1196915|NCT01168128|Guideline Adherence
1196916|NCT01168128|Quality Assurance, Health Care
1196917|NCT01168128|Nutrition Surveys
1196918|NCT01168128|Questionnaires
1196919|NCT01168063|Helicobacter pylori
1196920|NCT01168063|Diagnostic molecular testing
1196921|NCT01168063|Antibiotic resistance
1196922|NCT01168063|Treatment protocols
1196923|NCT01168050|Malignant Skin Melanoma T0
1196924|NCT01168050|stage III unresectable melanomas,
1196925|NCT01168050|or stage IV melanomas with c-KIT mutation
1196926|NCT01168050|or amplification.
1196927|NCT01168037|Aorta
1196928|NCT01168037|Aneurysm
1196929|NCT01168037|endovascular
1196930|NCT01168037|stent-graft
1196931|NCT01168024|Acute Kidney Injury
1196932|NCT01168024|Iodinated Contrast Agent Retrieval
1196933|NCT01168024|Coronary Sinus Cannulation
1196934|NCT01167985|antibacterial polyethyleneimine nanoparticles
1196935|NCT01167985|quaternary ammonium
1196936|NCT01167985|dental
1196937|NCT01167985|Endodotnic
1196938|NCT01167985|pulp
1196939|NCT01167985|bacteria
1196940|NCT01167985|Root canal sealer
1196941|NCT01167985|temporary filling
1196942|NCT01167985|provisional restoration
1196943|NCT01167972|M + mutation
1196944|NCT01167972|Non Small Cell Lung Cancer adenocarcinoma
1196945|NCT01167972|To determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma
1196946|NCT01167959|Obesity
1196947|NCT01167959|Diabetes
1196948|NCT01167959|Bariatric surgery
1196949|NCT01167946|Alopecia Areata
1196950|NCT01167946|Alopecia totalis
1196951|NCT01167946|Alopecia Universalis
1196952|NCT01167946|Ophiasic alopecia
1196953|NCT01167946|Oral Pulse steroid
1196954|NCT01167946|Methylprednisolone
1196955|NCT01167933|Bioequivalence
1196956|NCT01167933|Crossover
1196957|NCT01167933|Simvastatin
1196958|NCT01167920|High Blood Pressure
1196959|NCT01167920|Hypertension
1196960|NCT01167920|Home Blood Pressure Measurements
1196961|NCT01167920|Wireless communication of measurements
1196962|NCT01167920|Wireless communication of blood pressure measurements
1196963|NCT01167907|ankle
1196964|NCT01167907|arthrodesis
1196965|NCT01167907|internal fixation
1196966|NCT01167907|bi/tri malleolar fracture
1196967|NCT01167894|Bioequivalence
1196968|NCT01167894|Crossover
1196969|NCT01167894|Simvastatin
1196970|NCT01167868|fostamatinib disodium
1196971|NCT01167868|FosD
1196972|NCT01167868|Japanese
1196973|NCT01167868|Healthy volunteers
1196974|NCT01167868|Phase 1
1196975|NCT01167868|Single and Multiple Ascending Dose Study
1196976|NCT01167868|Healthy Japanese volunteers
1196977|NCT01167868|Healthy White volunteers
1196978|NCT01167855|Pediatric Asthma
1196979|NCT01167855|Low-income
1196980|NCT01167855|Arkansas Delta Region
1196981|NCT01167829|Experimental
1196982|NCT01167829|Acyline plus 27 oral testosterone pills
1196983|NCT01167829|taken 3x/day
1196984|NCT01167803|Bariatric surgery
1196985|NCT01167803|Anesthesia
1196986|NCT01167790|Precancerous lesions of the oral mucosa
1196987|NCT01167790|Fluorescence visualization
1196988|NCT01167777|CT
1196989|NCT01167777|GC
1196990|NCT01167777|NG
1196991|NCT01167777|chlamydia
1196992|NCT01167777|gonorrhoeae
1196993|NCT01167764|hemoptysis
1196994|NCT01167764|recurrence
1196995|NCT01167751|Myocardial infarction
1196996|NCT01167751|Bone marrow stem cells
1196997|NCT01167751|AC133
1196998|NCT01167738|adenocarcinoma of the pancreas
1196999|NCT01167738|stage IV pancreatic cancer
1197000|NCT01167725|mucinous adenocarcinoma of the colon
1197001|NCT01167725|stage III colon cancer
1197002|NCT01167725|stage IV colon cancer
1197003|NCT01167699|Oxycodone/naloxone
1197004|NCT01167699|patient preference
1197005|NCT01167699|WHO step I/II
1197006|NCT01167699|Moderate to severe non-malignant pain
1197007|NCT01167686|Respiratory infection
1197008|NCT01167686|Viral infection
1197009|NCT01167686|Food supplement
1197010|NCT01167686|Goldtrain Plus (GT+)
1197011|NCT01167673|irritable bowel syndrome
1197012|NCT01167673|selenium
1197013|NCT01167673|curcumin
1197014|NCT01167673|green tea
1197015|NCT01167660|Coagulation tests
1197016|NCT01167660|Neonates
1197017|NCT01167660|Non invasive
1197018|NCT01167647|Tuberculosis, culture, bronchoscopy
1197019|NCT01167634|Weight Loss
1197020|NCT01167634|Motivation
1197021|NCT01167634|Contracts
1197022|NCT01167621|Refractory Acute Respiratory Distress Syndrome
1197023|NCT01167621|Indexed Extra-vascular Lung Water
1197024|NCT01167621|HFO-ventilation
1197025|NCT01167608|Parkinson's disease
1197026|NCT01167608|Depression
1197027|NCT01167608|Anxiety
1197028|NCT01167608|Treatment
1197029|NCT01167595|Critically ill
1197030|NCT01167595|Nutrition therapy
1197031|NCT01167595|Enteral nutrition
1197032|NCT01167582|blood transfusion
1197033|NCT01167582|red blood cell transfusion
1197034|NCT01167582|myocardial infarction
1197035|NCT01167582|acute coronary syndrome
1197036|NCT01167582|anemia
1197037|NCT01167569|Free Radicals
1197038|NCT01167569|Ascorbic Acid
1197039|NCT01167569|Cardiac Surgery
1197040|NCT01167569|Prevention of Reperfusion Injury
1197041|NCT01167556|Family intervention
1197042|NCT01167556|Recent-onset schizophrenia
1197043|NCT01167556|Motivational Interviewing
1197044|NCT01167556|Cannabis use
1197045|NCT01167530|Everolimus
1197046|NCT01167530|Radiotherapy
1197047|NCT01167530|Chemotherapy
1197048|NCT01167517|Breast milk
1197049|NCT01167517|Feeding
1197050|NCT01167517|Prematurity
1197051|NCT01167517|Low birth weight infant
1197052|NCT01167517|Low maternal breast milk feeding
1197053|NCT01167504|saliva
1197054|NCT01167504|food
1197055|NCT01167504|sensory
1197056|NCT01167504|oral health
1197057|NCT01167504|film
1197058|NCT01167504|pellicle
1197059|NCT01167491|Wegener
1197060|NCT01167491|CD4+ T cells
1197061|NCT01167491|DAP12
1197062|NCT01167491|NKG2D
1197063|NCT01167478|Exercise
1197064|NCT01167478|Caffeine
1197065|NCT01167478|Reserve
1197066|NCT01167465|Diaper Dermatitis
1197067|NCT01167465|Diaper Rash
1197068|NCT01167465|Erythema
1197069|NCT01167452|Obesity
1197070|NCT01167452|Pharmacokinetics
1197071|NCT01167452|MRSA
1197072|NCT01167452|Tuberculosis
1197073|NCT01167452|PCP
1197074|NCT01167439|OPMD, dysphagia
1197075|NCT01167439|Dysphagia severity
1197076|NCT01167439|Nutritional state
1197077|NCT01167439|Speech quality
1197078|NCT01167439|Upper esophageal sphincter myotomy
1197079|NCT01167426|Relapsing Remitting Multiple Sclerosis
1197080|NCT01167426|RRMS
1197081|NCT01167426|Clinically Isolated Syndrome
1197082|NCT01167426|CIS
1197083|NCT01167426|Copaxone
1197084|NCT01167426|glatiramer acetate
1197085|NCT01167426|Autoject 2
1197086|NCT01167400|exercise
1197087|NCT01167400|executive function
1197088|NCT01167400|older adults
1197089|NCT01167387|carbohydrate
1197090|NCT01167387|glucose metabolism
1197091|NCT01167387|surgery, outcome
1197092|NCT01167387|major elective surgery
1197093|NCT01167387|urology
1197094|NCT01167387|hyperglicemia
1197095|NCT01167374|HCC
1197096|NCT01167361|upper respiratory tract infection
1197097|NCT01167361|lower respiratory tract infection
1197098|NCT01167348|auricular acupressure
1197099|NCT01167348|obesity
1197100|NCT01167348|schizophrenia
1197101|NCT01167348|body weight
1197102|NCT01167335|partial onset seizure
1197103|NCT01167335|seizure frequency
1197104|NCT01167335|nervous system diseases
1197105|NCT01167335|central nervous system diseases
1197106|NCT01167335|CNS
1197107|NCT01167335|brain diseases
1197108|NCT01167335|neurologic manifestations
1197109|NCT01167335|adjunctive treatment
1197110|NCT01167335|AEDs
1197111|NCT01167335|antiepileptic drug
1197112|NCT01167322|NPC-07, 5-ALA, photodynamic diagnosis, pharmacokinetics
1197113|NCT01167309|Safety and tolerability of LEO 27847
1197114|NCT01167296|Intrauterine adhesion
1197115|NCT01167296|Cook balloon uterine stent
1197116|NCT01167283|COPD
1197117|NCT01167270|Infant Diet
1197118|NCT01167270|Toddler Diet
1197119|NCT01167270|Responsive Feeding
1197120|NCT01167270|Infant Temperament
1197121|NCT01167270|Parent competency
1197122|NCT01167270|Childhood Obesity prevention
1197123|NCT01167270|Rapid infant weight gain
1197124|NCT01167257|Overactive bladder
1197125|NCT01167257|Detrusor overactivity
1197126|NCT01167257|Liposome
1197127|NCT01167257|Botulinum toxin A
1197128|NCT01167231|Diabetes
1197129|NCT01167231|Acarbose
1197130|NCT01167218|verify now assay for hematological disorders
1197131|NCT01167205|Healthy adults with BMI over 25.0 kg/m2
1197132|NCT01167179|head and neck cancer
1197133|NCT01167179|nurse-led care
1197134|NCT01167179|follow-up care
1197135|NCT01167179|professional-patient relations
1197136|NCT01167179|psychosocial adjustment
1197137|NCT01167179|quasi-experimental
1197138|NCT01167179|prospective
1197139|NCT01167179|quality of life
1197140|NCT01167166|Acute Myelocytic Leukemia
1197141|NCT01167166|Acute Lymphocytic Leukemia
1197142|NCT01167166|Myeloproliferative Disease
1197143|NCT01167166|Myelofibrosis
1197144|NCT01167166|Essential thrombocythemia
1197145|NCT01167166|Polycythemia vera
1197146|NCT01167166|Chronic Myeloid Leukemia
1197147|NCT01167153|Hypertension
1197148|NCT01167153|Valsartan Amlodipine single pill combination
1197149|NCT01167153|BP control
1197150|NCT01167153|ABPM
1197151|NCT01167153|Hypertensive patients not adequately controlled by mono antihypertensive drugs
1197152|NCT01167127|Oxycodone/naloxone
1197153|NCT01167127|pain relief
1197154|NCT01167127|bowel function
1197155|NCT01167127|moderate to severe non-malignant pain
1197156|NCT01167114|STA-9090
1197157|NCT01167101|Rebamipide
1197158|NCT01167101|gastric ulcer
1197159|NCT01167101|healing rate
1197160|NCT01167101|iatrogenic gastric ulcer after endoscopic submucosal dissection
1197161|NCT01167088|Double-blind
1197162|NCT01167088|Placebo-controlled
1197163|NCT01167088|Non-alcoholic fatty liver disease
1197164|NCT01167088|NAFLD
1197165|NCT01167075|critically ill
1197166|NCT01167075|sepsis
1197167|NCT01167075|antioxidants
1197168|NCT01167075|enteral nutrition
1197169|NCT01167075|SIRS (APACHE score 10-30)
1197170|NCT01167075|enteral feeding within 48 h of admission
1197171|NCT01167049|gastric cancer with liver metastasis
1197172|NCT01167036|Myofascial pain syndrome
1197173|NCT01167036|Trigger points, Myofascial
1197174|NCT01167036|Chiropractic
1197175|NCT01167036|Massage
1197176|NCT01167036|Musculoskeletal manipulation
1197177|NCT01167023|Sickle Cell Disease
1197178|NCT01167023|Sickle Cell Anemia
1197179|NCT01167023|Adult
1197180|NCT01166997|Pulmonary embolism
1197181|NCT01166997|Pulmonary thromboembolism
1197182|NCT01166997|anticoagulation
1197183|NCT01166997|thrombolysis
1197184|NCT01166997|ultrasound accelerated thrombolysis
1197185|NCT01166984|sepsis
1197186|NCT01166984|septic shock
1197187|NCT01166971|presbyopia
1197188|NCT01166971|intraocular lens
1197189|NCT01166945|Child
1197190|NCT01166945|Child, preschool
1197191|NCT01166945|Sinusitis
1197192|NCT01166945|Antimicrobial agents
1197193|NCT01166932|pneumonia
1197194|NCT01166932|children
1197195|NCT01166932|antibiotics
1197196|NCT01166906|pain blocking
1197197|NCT01166893|burn wound
1197198|NCT01166880|assessment
1197199|NCT01166867|assessment
1197200|NCT01166854|muscle and bone disease
1197201|NCT01166841|minimally invasive cardiac surgery
1197202|NCT01166841|cardiac surgery
1197203|NCT01166841|near infrared spectroscopy
1197204|NCT01166841|mitral valve repair
1197205|NCT01166841|mitral valve replacement
1197206|NCT01166828|Spinal cord injury
1197207|NCT01166828|telehealth
1197208|NCT01166828|pressure ulcers
1197209|NCT01166828|quality of life
1197210|NCT01166815|diarrhea morbidity
1197211|NCT01166815|malaria incidence
1197212|NCT01166815|zinc supplementation
1197213|NCT01166802|questionnaire development
1197214|NCT01166802|hypervigilance
1197215|NCT01166802|pain sensitivity
1197216|NCT01166789|IBS
1197217|NCT01166789|pain threshold
1197218|NCT01166789|constipation
1197219|NCT01166776|Wharton's jelly
1197220|NCT01166776|umbilical cord
1197221|NCT01166776|decellularization
1197222|NCT01166763|breast atypia
1197223|NCT01166763|high risk for breast cancer
1197224|NCT01166763|random periareolar fine needle aspiration
1197225|NCT01166763|RPFNA
1197226|NCT01166763|breast epithelial hyperplasia
1197227|NCT01166763|ki-67
1197228|NCT01166763|chemoprevention
1197229|NCT01166763|vitamin D3
1197230|NCT01166763|Additional relevant MeSH terms:
1197231|NCT01166763|Molecular Mechanisms of Pharmacological Action
1197232|NCT01166763|Physiological Effects of Drugs
1197233|NCT01166763|Breast Neoplasms
1197234|NCT01166763|Pharmacologic Actions
1197235|NCT01166763|Hyperplasia
1197236|NCT01166763|high risk for development of breast cancer
1197237|NCT01166763|Neoplasms
1197238|NCT01166763|Neoplasms by Site
1197239|NCT01166763|Pathologic Processes
1197240|NCT01166763|Antirheumatic Agents
1197241|NCT01166763|Breast Diseases
1197242|NCT01166737|Ovarian Cancer
1197243|NCT01166737|Cancer of the fallopian tube
1197244|NCT01166737|Primary peritoneal cancer
1197245|NCT01166737|Recurrent disease
1197246|NCT01166737|Platinum-sensitive
1197247|NCT01166737|Surgery
1197248|NCT01166737|Chemotherapy
1197249|NCT01166737|Quality of Life
1197250|NCT01166737|First recurrence of platinum sensitive:
1197251|NCT01166737|Fallopian Tube Cancer
1197252|NCT01166737|or Ovarian Cancer
1197253|NCT01166737|or Peritoneal Cavity Cancer
1197254|NCT01166724|Kidney transplant
1197255|NCT01166698|Safety
1197256|NCT01166698|tolerability
1197257|NCT01166698|healthy
1197258|NCT01166698|inhalation
1197259|NCT01166685|coronary artery disease
1197260|NCT01166685|drug-eluting stent
1197261|NCT01166685|anti-thrombotic therapy
1197262|NCT01166685|bare-metal stent
1197263|NCT01166685|long-term outcome
1197264|NCT01166672|obese women (BMI greater than or equal to 30), do not already have a diagnosis of lymphedema, who are done
1197265|NCT01166672|with surgery, chemotherapy, and radiation therapy, and who were diagnosed with breast cancer within the
1197266|NCT01166672|past 2 years will be invited to participate.
1197267|NCT01166659|Glaucoma
1197268|NCT01166659|Glaucoma device
1197269|NCT01166659|Glaucoma surgery
1197270|NCT01166659|Intraocular pressure
1197271|NCT01166633|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1197272|NCT01166633|hyperlipidemia
1197273|NCT01166594|Glaucoma
1197274|NCT01166594|Elevated Intraocular Pressure (IOP)
1197275|NCT01166594|Optic Neuropathy
1197276|NCT01166594|Bleb Failure
1197277|NCT01166594|Avastin (Bevacizumab)
1197278|NCT01166581|early stage breast cancer
1197279|NCT01166581|preoperative breast MRI
1197280|NCT01166581|mastectomy
1197281|NCT01166568|Presbyopia
1197282|NCT01166568|Reading Vision
1197283|NCT01166568|Near Vision
1197284|NCT01166555|Safety and tolerability
1197285|NCT01166555|Pharmacokinetics
1197286|NCT01166555|PF-04236921
1197287|NCT01166555|Rheumatoid Arthritis
1197288|NCT01166542|carcinoma
1197289|NCT01166542|squamous cell
1197290|NCT01166542|head
1197291|NCT01166542|neck
1197292|NCT01166542|REOLYSIN (Reovirus Type 3 Dearing)
1197293|NCT01166542|chemotherapy
1197294|NCT01166542|Carboplatin
1197295|NCT01166542|Paclitaxel
1197296|NCT01166542|metastatic
1197297|NCT01166542|recurrent
1197298|NCT01166516|Prolonged air leak
1197299|NCT01166516|lobectomy
1197300|NCT01166516|segmentectomy
1197301|NCT01166516|lung volume reduction surgery (LVRS)
1197302|NCT01166503|pediatrics
1197303|NCT01166503|Esotropia
1197304|NCT01166503|Surgery
1197305|NCT01166490|Monomethyl auristatin E (MMAE)
1197306|NCT01166490|Immunotherapy
1197307|NCT01166490|AGS-5 Antigen
1197308|NCT01166490|SLC44A4 Antigen
1197309|NCT01166490|Gastric Neoplasms
1197310|NCT01166490|Pancreatic Neoplasms
1197311|NCT01166490|Antibody-Drug Conjugate
1197312|NCT01166490|Antibodies, Monoclonal
1197313|NCT01166490|Drug Therapy
1197314|NCT01166464|tobacco
1197315|NCT01166464|smoking
1197316|NCT01166464|text message
1197317|NCT01166464|therapy
1197318|NCT01166451|iron deficiency anemia
1197319|NCT01166451|cognitive development
1197320|NCT01166451|motor development
1197321|NCT01166438|incontinence
1197322|NCT01166438|overactive bladder
1197323|NCT01166438|botox
1197324|NCT01166438|anticholinergic
1197325|NCT01166399|Fecal Incontinence,
1197326|NCT01166399|bowel incontinence,
1197327|NCT01166399|pelvic floor disorder
1197328|NCT01166386|rehabilitation
1197329|NCT01166386|brain injury
1197330|NCT01166373|prolapse
1197331|NCT01166373|urinary incontinence
1197332|NCT01166373|uterosacral vaginal vault ligament suspension
1197333|NCT01166373|sacrospinous ligament fixation
1197334|NCT01166373|behavioral therapy
1197335|NCT01166373|pelvic muscle training
1197336|NCT01166360|Risk prediction
1197337|NCT01166360|Euroscore
1197338|NCT01166360|GDF-15
1197339|NCT01166360|hsTnT
1197340|NCT01166360|cardiac surgery
1197341|NCT01166334|Smoking
1197342|NCT01166334|Smoke
1197343|NCT01166334|Cigarette
1197344|NCT01166334|Cessation
1197345|NCT01166334|Quit
1197346|NCT01166334|Online
1197347|NCT01166334|Web
1197348|NCT01166334|Stop
1197349|NCT01166321|Atypical Meningioma
1197350|NCT01166308|Recurrent Glioma
1197351|NCT01166282|inflammatory back pain
1197352|NCT01166282|ankylosing spondylitis
1197353|NCT01166282|sacroiliitis
1197354|NCT01166282|Juvenile Idiopathic Arthritis
1197355|NCT01166282|enthesitis
1197356|NCT01166282|arthritis
1197357|NCT01166269|grass-pollen allergy
1197358|NCT01166256|respiratory failure
1197359|NCT01166243|Hemostasis
1197360|NCT01166217|Single Dose Study in Healthy Subjects
1197361|NCT01166204|Radiotherapy
1197362|NCT01166204|NSCLC
1197363|NCT01166191|Radiotherapy
1197364|NCT01166191|SCLC
1197365|NCT01166178|Multiple Sclerosis
1197366|NCT01166178|Osteoporosis
1197367|NCT01166178|Zoledronic Acid
1197368|NCT01166165|Hypertension
1197369|NCT01166165|blood pressure
1197370|NCT01166165|vitamin d
1197371|NCT01166165|winter
1197372|NCT01166165|cholecalciferol
1197373|NCT01166165|arterial stiffness
1197374|NCT01166165|renin
1197375|NCT01166165|angiotensin
1197376|NCT01166165|aldosterone
1197377|NCT01166165|calcium
1197378|NCT01166152|autistic spectrum disorders
1197379|NCT01166152|developmental disorders
1197380|NCT01166139|Systemic Sclerosis
1197381|NCT01166113|Pomalidomide
1197382|NCT01166113|Relapsed/Refractory to Lenalidomide
1197383|NCT01166100|Bioequivalence
1197384|NCT01166100|Crossover
1197385|NCT01166100|Fluoxetine Hydrochloride
1197386|NCT01166087|Bioequivalence
1197387|NCT01166087|Crossover
1197388|NCT01166087|Fluoxetine Hydrochloride
1197389|NCT01166061|Grass Allergy
1197390|NCT01166061|Immunotherapy
1197391|NCT01166061|Rhinoconjunctivitis
1197392|NCT01166061|ToleroMune Grass
1197393|NCT01166048|Chronic Low Back Pain
1197394|NCT01166048|Radicular component
1197395|NCT01166048|neuropathic pain
1197396|NCT01166048|duloxetine
1197397|NCT01166048|CLBP
1197398|NCT01166035|Solid tumors
1197399|NCT01166035|Lenalidomide
1197400|NCT01166035|Cetuximab
1197401|NCT01166035|Colorectal Cancer
1197402|NCT01166035|Non-Small Cell Lung Cancer
1197403|NCT01166035|Head and Neck Cancer
1197404|NCT01166022|Spinal Muscular Atrophy
1197405|NCT01166022|Exercise
1197406|NCT01166022|Conditioning
1197407|NCT01166022|Strengthening
1197408|NCT01166009|Data Collection
1197409|NCT01166009|CIBMTR
1197410|NCT01166009|NMDP
1197411|NCT01166009|Stem Cell Transplantation
1197412|NCT01165996|previously treated myelodysplastic syndromes
1197413|NCT01165996|secondary myelodysplastic syndromes
1197414|NCT01165970|enamel
1197415|NCT01165970|dentin
1197416|NCT01165970|saliva substitute
1197417|NCT01165970|demineralization
1197418|NCT01165970|remineralization
1197419|NCT01165957|Knee replacement
1197420|NCT01165957|Mobile and fixed bearings
1197421|NCT01165957|Volumetric wear
1197422|NCT01165957|Micro-CT analysis
1197423|NCT01165957|Articular and backside wear
1197424|NCT01165944|Post transplant diabetes mellitus
1197425|NCT01165931|Coronary artery disease
1197431|NCT01165892|Pulmonary embolism
1197432|NCT01165892|contrast agent
1197433|NCT01165879|Pregnancy
1197434|NCT01165879|Term
1197435|NCT01165879|Preterm
1197436|NCT01165879|Uterine Contractions
1197437|NCT01165866|Ondansetron
1197438|NCT01165866|Metoclopramide
1197439|NCT01165866|Gastroenteritis
1197440|NCT01165840|Obesity
1197441|NCT01165840|Pharmacokinetics
1197442|NCT01165840|Dapsone
1197443|NCT01165840|Leprosy
1197444|NCT01165840|Tuberculosis
1197445|NCT01165827|Aortic Valve Insufficiency
1197446|NCT01165827|Aortic Valve Stenosis
1197447|NCT01165827|Aortic Valve Valvuloplasty
1197448|NCT01165827|Aortic valve Replacement
1197449|NCT01165827|Aortic valve Intervention
1197450|NCT01165814|Pain control after cesarean section
1197451|NCT01165801|AMD
1197452|NCT01165801|Cataract surgery
1197453|NCT01165801|Size of AMD
1197454|NCT01165801|Influence of cataract surgery on AMD Size
1197455|NCT01165788|Blood and Marrow Transplant (BMT)
1197456|NCT01165736|pharmacokinetics
1197457|NCT01165736|safety
1197458|NCT01165736|tolerability
1197459|NCT01165736|Chronic Pain
1197460|NCT01165723|safety
1197461|NCT01165723|tolerability
1197462|NCT01165723|pharmacokinetics
1197463|NCT01165723|pharmacodynamics
1197464|NCT01165723|chronic pain
1197465|NCT01165710|Irregular heart beat
1197466|NCT01165697|Fabry Disease
1197467|NCT01165697|vascular disease
1197468|NCT01165697|storage endotheliopathy
1197469|NCT01165671|Primary Glioblastoma
1197470|NCT01165658|non-small cell lung cancer
1197471|NCT01165658|NSCLC
1197472|NCT01165658|small cell lung cancer
1197473|NCT01165658|SCLC
1197474|NCT01165658|carcinoid
1197475|NCT01165658|thymic cancer
1197476|NCT01165658|lung cancer
1197477|NCT01165658|radiation therapy
1197478|NCT01165658|radiotherapy
1197479|NCT01165658|proton therapy
1197480|NCT01165645|recurrent adult Hodgkin lymphoma
1197481|NCT01165554|Amyloid
1197482|NCT01165554|PET-Positron Emission Tomography
1197483|NCT01165554|SUVR-Standard uptake value ratios
1197484|NCT01165502|MAD study CM3.1-AC100
1197485|NCT01165502|Healthy men, age 18 - 50
1197486|NCT01165489|Laryngomalacia
1197487|NCT01165489|Congenital Anomalies
1197488|NCT01165489|Associated Health Problems
1197489|NCT01165476|treprostinil
1197490|NCT01165476|bioavailability
1197491|NCT01165476|bioequivalence
1197492|NCT01165463|Aging
1197493|NCT01165463|Healthy
1197494|NCT01165450|persistent epithelial defect
1197495|NCT01165450|cornea
1197496|NCT01165437|Peripheral
1197497|NCT01165437|Arterial
1197498|NCT01165437|Vascular
1197499|NCT01165411|Central Catheterization
1197500|NCT01165411|Central Line
1197501|NCT01165411|Database
1197502|NCT01165411|Registry
1197503|NCT01165411|Registries
1197504|NCT01165398|Education
1197505|NCT01165398|central lines
1197506|NCT01165398|infections
1197507|NCT01165398|complications
1197508|NCT01165398|Bundles
1197509|NCT01165385|Relapsed or refractory solid tumors
1197510|NCT01165385|Pazopanib
1197511|NCT01165385|Cisplatin
1197512|NCT01165372|Malaria
1197513|NCT01165372|Drug resistance
1197514|NCT01165346|liver cancer
1197515|NCT01165346|hepatocellular carcinoma
1197516|NCT01165333|Paediatric oncology
1197517|NCT01165333|Cilengitide
1197518|NCT01165333|Glioma
1197519|NCT01165307|Menorrhagia
1197520|NCT01165307|Endometrial ablation
1197521|NCT01165307|Heavy menstrual bleeding
1197522|NCT01165294|Ketamine
1197523|NCT01165281|Pain
1197524|NCT01165281|R331333 (JNS024ER, CG5503), tapentadol (NUCYNTA)
1197525|NCT01165281|Opioid analgesic
1197526|NCT01165281|Oxycodone CR (OXYCONTIN CR)
1197527|NCT01165281|Chronic malignant tumor related cancer pain
1197528|NCT01165255|congenital malformation
1197529|NCT01165255|cardiovascular malformation
1197530|NCT01165255|cardiovascular defect
1197531|NCT01165255|antidepressants
1197532|NCT01165255|pregnancy
1197533|NCT01165255|first trimester
1197534|NCT01165255|Bupropion
1197535|NCT01165255|prevalence
1197536|NCT01165242|Neisseria meningitidis
1197537|NCT01165242|Adult
1197538|NCT01165242|Adolescent
1197539|NCT01165242|Safety
1197540|NCT01165242|Vaccines, conjugate
1197541|NCT01165242|Meningococcal vaccines
1197542|NCT01165242|Immunogenicity
1197543|NCT01165229|Immunogenicity
1197544|NCT01165229|Subjects 70 years and older
1197545|NCT01165229|Efficacy
1197546|NCT01165229|Herpes Zoster
1197547|NCT01165229|Safety
1197548|NCT01165229|Adults
1197549|NCT01165229|Vaccine
1197550|NCT01165203|immunogenicity
1197551|NCT01165203|vaccine
1197552|NCT01165203|safety
1197553|NCT01165203|HIV
1197554|NCT01165203|Herpes Zoster
1197555|NCT01165177|subjects 50 years and older
1197556|NCT01165177|vaccine
1197557|NCT01165177|immunogenicity
1197558|NCT01165177|efficacy
1197559|NCT01165177|Herpes Zoster
1197560|NCT01165177|safety
1197561|NCT01165164|Dry eye
1197562|NCT01165164|artificial tears
1197563|NCT01165151|obesity
1197564|NCT01165151|weight loss
1197565|NCT01165151|group size
1197566|NCT01165138|GW642444
1197567|NCT01165138|Vilanterol
1197568|NCT01165138|Asthma
1197569|NCT01165138|Fluticasone Furoate
1197570|NCT01165125|pharmacodynamics
1197571|NCT01165125|drug interaction
1197572|NCT01165125|ketoconazole
1197573|NCT01165125|pharmacokinetics
1197574|NCT01165125|Fluticasone furoate
1197575|NCT01165125|GW642444
1197576|NCT01165099|acupuncture
1197577|NCT01165099|induced labour
1197578|NCT01165099|labour outcome
1197579|NCT01165099|nulliparae
1197580|NCT01165099|pain-relief
1197581|NCT01165099|epidural during labour
1197582|NCT01165073|Cirrhosis
1197583|NCT01165073|Malnutrition
1197584|NCT01165073|Enteral nutrition
1197585|NCT01165060|X-ALD
1197586|NCT01165060|AMN
1197587|NCT01165060|adrenomyeloneuropathy phenotype
1197588|NCT01164995|MK-1775
1197589|NCT01164995|Carboplatin
1197590|NCT01164995|epithelial ovarian cancer
1197591|NCT01164995|p53
1197592|NCT01164956|methylphenidate
1197593|NCT01164956|fatigue
1197594|NCT01164917|Lupus
1197595|NCT01164917|Discoid Lupus
1197596|NCT01164917|Cutaneous Lupus
1197597|NCT01164904|Inflammatory Bowel Disease
1197598|NCT01164904|Amgen
1197599|NCT01164878|Cholestasis
1197600|NCT01164878|Liver damage
1197601|NCT01164878|Parenteral Nutrition
1197602|NCT01164878|Aggressive Nutrition
1197603|NCT01164878|Preterm
1197604|NCT01164878|Extreme low birth weight infant
1197605|NCT01164878|Parenteral Nutrition Associated Cholestasis
1197606|NCT01164865|Soft Contact lens
1197607|NCT01164865|Multi-Purpose Solution
1197608|NCT01164865|Hydrogen Peroxide
1197609|NCT01164839|coronary artery
1197610|NCT01164839|CT angiography
1197611|NCT01164839|image quality
1197612|NCT01164839|multicenter trial
1197613|NCT01164826|Bioequivalence
1197614|NCT01164826|Crossover
1197615|NCT01164826|Nabumetone
1197616|NCT01164813|Bioequivalence
1197617|NCT01164813|Crossover
1197618|NCT01164813|Nabumetone
1197619|NCT01164800|Bioequivalence
1197620|NCT01164800|Crossover
1197621|NCT01164800|Trandolapril
1197622|NCT01164787|Bioequivalence
1197623|NCT01164787|Crossover
1197624|NCT01164787|Trandolapril
1197625|NCT01164774|Bioavailability
1197626|NCT01164774|Crossover
1197627|NCT01164774|Ramipril
1197628|NCT01164761|Bioavailability
1197629|NCT01164761|Crossover
1197630|NCT01164761|Ramipril
1197631|NCT01164722|anal cancer
1197632|NCT01164722|HIV infection
1197633|NCT01164722|human papilloma virus infection
1197634|NCT01164722|neoplasm of uncertain malignant potential
1197635|NCT01164722|high-grade squamous intraepithelial lesion
1197636|NCT01164709|refractory multiple myeloma
1197637|NCT01164709|recurrent adult acute myeloid leukemia
1197638|NCT01164709|recurrent adult acute lymphoblastic leukemia
1197639|NCT01164709|recurrent adult diffuse large cell lymphoma
1197640|NCT01164709|recurrent adult Hodgkin lymphoma
1197641|NCT01164709|recurrent mantle cell lymphoma
1197642|NCT01164709|recurrent adult T-cell leukemia/lymphoma
1197643|NCT01164709|adult nasal type extranodal NK/T-cell lymphoma
1197644|NCT01164709|angioimmunoblastic T-cell lymphoma
1197645|NCT01164709|peripheral T-cell lymphoma
1197646|NCT01164709|T-cell large granular lymphocyte leukemia
1197647|NCT01164709|anaplastic large cell lymphoma
1197648|NCT01164709|recurrent grade 3 follicular lymphoma
1197649|NCT01164709|recurrent cutaneous T-cell non-Hodgkin lymphoma
1197650|NCT01164709|recurrent mycosis fungoides/Sezary syndrome
1197651|NCT01164709|aggressive NK-cell leukemia
1197652|NCT01164709|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1197653|NCT01164709|adult acute myeloid leukemia with inv(16)(p13;q22)
1197654|NCT01164709|adult acute myeloid leukemia with t(15;17)(q22;q12)
1197655|NCT01164709|adult acute myeloid leukemia with t(16;16)(p13;q22)
1197656|NCT01164709|adult acute myeloid leukemia with t(8;21)(q22;q22)
1197657|NCT01164709|secondary acute myeloid leukemia
1197658|NCT01164709|stage III adult diffuse large cell lymphoma
1197659|NCT01164709|stage IV adult diffuse large cell lymphoma
1197660|NCT01164709|stage III adult Hodgkin lymphoma
1197661|NCT01164709|stage IV adult Hodgkin lymphoma
1197662|NCT01164709|stage III mantle cell lymphoma
1197663|NCT01164709|stage IV mantle cell lymphoma
1197664|NCT01164709|stage III adult T-cell leukemia/lymphoma
1197665|NCT01164709|stage IV adult T-cell leukemia/lymphoma
1197666|NCT01164709|stage III grade 3 follicular lymphoma
1197667|NCT01164709|stage IV grade 3 follicular lymphoma
1197668|NCT01164709|stage III mycosis fungoides/Sezary syndrome
1197669|NCT01164709|stage IV mycosis fungoides/Sezary syndrome
1197670|NCT01164709|stage III cutaneous T-cell non-Hodgkin lymphoma
1197671|NCT01164709|stage IV cutaneous T-cell non-Hodgkin lymphoma
1197672|NCT01164709|prolymphocytic leukemia
1197673|NCT01164696|Quality of Life, Health Care Costs
1197674|NCT01164683|sleep apnea
1197675|NCT01164683|adherence
1197676|NCT01164657|upright position
1197677|NCT01164657|birth position
1197678|NCT01164657|childbirth
1197679|NCT01164657|instrumental deliveries
1197680|NCT01164657|primiparous
1197681|NCT01164644|ecchymosis
1197682|NCT01164644|bruising
1197683|NCT01164644|rhinoplasty
1197684|NCT01164644|nose job
1197685|NCT01164644|arnica
1197686|NCT01164644|arnica montana
1197687|NCT01164631|Sleep Apnea Syndrome
1197688|NCT01164631|Orthodontics
1197689|NCT01164631|Tonsillectomy
1197690|NCT01164631|Child
1197691|NCT01164618|pediatrics
1197692|NCT01164618|Remote ischemic preconditioning
1197693|NCT01164605|NRTI-regimen
1197694|NCT01164605|Raltegravir
1197695|NCT01164605|Elvitegravir
1197696|NCT01164605|HIV-1 integrase inhibitor
1197697|NCT01164605|Fat Waste
1197698|NCT01164592|Heart failure (HF)
1197699|NCT01164592|Sleep disordered breathing (SDB)
1197700|NCT01164592|Cheyne Stokes Respiration (CSR)
1197701|NCT01164592|Adaptive Servoventilation (ASV)
1197702|NCT01164579|Early Rheumatoid Arthritis
1197703|NCT01164579|Joint Structure
1197704|NCT01164579|Magnetic Resonance Imaging
1197705|NCT01164579|Janus Kinase (JAK) Inhibitor
1197706|NCT01164579|Tasocitinib
1197707|NCT01164579|Tofacitinib
1197708|NCT01164553|influenza, pediatric, vaccine
1197709|NCT01164540|Deep venous thrombosis
1197710|NCT01164540|Pulmonary embolism
1197711|NCT01164540|rosuvastatin treatment
1197712|NCT01164514|bacterial sepsis, septicemia, vaccine
1197713|NCT01164449|algorithm
1197714|NCT01164449|tight glycemic control
1197715|NCT01164449|glucose control
1197716|NCT01164449|intensive care
1197717|NCT01164449|insulin
1197718|NCT01164449|ICU
1197719|NCT01164423|algorithm
1197720|NCT01164423|tight glycemic control
1197721|NCT01164423|glucose control
1197722|NCT01164423|intensive care
1197723|NCT01164423|insulin
1197724|NCT01164423|ICU
1197725|NCT01164397|Hypercholesterolemia
1197726|NCT01164397|Statins
1197727|NCT01164371|coronary disease
1197728|NCT01164371|cardiovascular disease
1197729|NCT01164371|cardiovascular risk
1197730|NCT01164371|cardiovascular risk management
1197731|NCT01164371|primary care
1197732|NCT01164371|angina
1197733|NCT01164371|stable angina
1197734|NCT01164371|angina pectoris
1197735|NCT01164371|acute coronary syndrome
1197736|NCT01164371|coronary death
1197737|NCT01164371|unheralded acute coronary syndrome
1197738|NCT01164371|unheralded coronary death
1197739|NCT01164371|gender differences
1197740|NCT01164371|sex differences
1197741|NCT01164371|myocardial infarction
1197742|NCT01164371|ST elevation myocardial infarction
1197743|NCT01164371|non ST elevation myocardial infarction
1197744|NCT01164371|STEMI
1197745|NCT01164371|nSTEMI
1197746|NCT01164371|unstable angina
1197747|NCT01164358|Presbyopia
1197748|NCT01164358|INTRACOR
1197749|NCT01164358|patient satisfaction
1197750|NCT01164358|long term
1197751|NCT01164345|non-Hodgkin's lymphoma
1197752|NCT01164345|Hodgkin's lymphoma
1197753|NCT01164345|stem cell mobilization
1197754|NCT01164345|autologous stem cell transplantation
1197755|NCT01164319|Atrial fibrillation
1197756|NCT01164319|Percutaneous continous monitoring
1197757|NCT01164319|ablation
1197758|NCT01164306|LifeSkills Training
1197759|NCT01164306|Tobacco prevention
1197760|NCT01164306|Tobacco cessation
1197761|NCT01164306|Healthy lifestyles
1197762|NCT01164306|Tobacco control
1197763|NCT01164293|Atopy patch test
1197764|NCT01164254|Exposure Assessment
1197765|NCT01164254|Web-Based Dietary Assessment
1197766|NCT01164254|Web-Based Physical Activity Assessment
1197767|NCT01164241|Eczema
1197768|NCT01164241|Allergy
1197769|NCT01164241|Immunodeficiency
1197770|NCT01164241|Netherton's Syndrome
1197771|NCT01164241|Piebaldism
1197772|NCT01164228|recurrent renal cell cancer
1197773|NCT01164228|stage IV renal cell cancer
1197774|NCT01164228|clear cell renal cell carcinoma
1197775|NCT01164228|papillary renal cell carcinoma
1197776|NCT01164228|clear cell sarcoma of the kidney
1197777|NCT01164215|neutropenia
1197778|NCT01164215|diarrhea
1197779|NCT01164215|stage I colon cancer
1197780|NCT01164215|stage II colon cancer
1197781|NCT01164215|stage III colon cancer
1197782|NCT01164215|stage IV colon cancer
1197783|NCT01164215|recurrent colon cancer
1197784|NCT01164215|stage I rectal cancer
1197785|NCT01164215|stage II rectal cancer
1197786|NCT01164215|stage III rectal cancer
1197787|NCT01164215|stage IV rectal cancer
1197788|NCT01164215|recurrent rectal cancer
1197789|NCT01164202|adult primary hepatocellular carcinoma
1197790|NCT01164202|localized unresectable adult primary liver cancer
1197791|NCT01164202|advanced adult primary liver cancer
1197792|NCT01164189|adult anaplastic astrocytoma
1197793|NCT01164189|adult diffuse astrocytoma
1197794|NCT01164189|adult pilocytic astrocytoma
1197795|NCT01164189|adult pineal gland astrocytoma
1197796|NCT01164189|adult subependymal giant cell astrocytoma
1197797|NCT01164189|adult oligodendroglioma
1197798|NCT01164189|adult anaplastic oligodendroglioma
1197799|NCT01164189|recurrent adult brain tumor
1197800|NCT01164189|adult giant cell glioblastoma
1197801|NCT01164189|adult glioblastoma
1197802|NCT01164189|adult gliosarcoma
1197803|NCT01164189|adult mixed glioma
1197804|NCT01164176|anaplastic thyroid cancer
1197805|NCT01164176|insular thyroid cancer
1197806|NCT01164176|recurrent thyroid cancer
1197807|NCT01164176|stage III follicular thyroid cancer
1197808|NCT01164176|stage III papillary thyroid cancer
1197809|NCT01164176|stage IV follicular thyroid cancer
1197810|NCT01164176|stage IV papillary thyroid cancer
1197811|NCT01164176|thyroid gland medullary carcinoma
1197812|NCT01164163|unspecified childhood solid tumor, protocol specific
1197813|NCT01164163|recurrent childhood acute lymphoblastic leukemia
1197814|NCT01164163|recurrent childhood acute myeloid leukemia
1197815|NCT01164163|refractory chronic lymphocytic leukemia
1197816|NCT01164163|relapsing chronic myelogenous leukemia
1197817|NCT01164163|childhood myelodysplastic syndromes
1197818|NCT01164163|previously treated myelodysplastic syndromes
1197819|NCT01164163|atypical chronic myeloid leukemia, BCR-ABL1 negative
1197820|NCT01164163|chronic myelomonocytic leukemia
1197821|NCT01164163|juvenile myelomonocytic leukemia
1197822|NCT01164163|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1197823|NCT01164163|polycythemia vera
1197824|NCT01164163|essential thrombocythemia
1197825|NCT01164163|childhood acute promyelocytic leukemia (M3)
1197948|NCT01163812|D2 lymph node dissection
1197826|NCT01164163|acute myeloid leukemia/transient myeloproliferative disorder
1197827|NCT01164163|primary myelofibrosis
1197828|NCT01164150|gastrointestinal complications
1197829|NCT01164150|urinary complications
1197830|NCT01164150|radiation toxicity
1197831|NCT01164150|recurrent endometrial carcinoma
1197832|NCT01164150|endometrial adenocarcinoma
1197833|NCT01164150|stage IA endometrial carcinoma
1197834|NCT01164150|stage IB endometrial carcinoma
1197835|NCT01164150|stage II endometrial carcinoma
1197836|NCT01164150|stage IIIA endometrial carcinoma
1197837|NCT01164150|stage IIIB endometrial carcinoma
1197838|NCT01164150|stage IIIC endometrial carcinoma
1197839|NCT01164137|Adverse Drug Events
1197840|NCT01164137|Medication Reconciliation
1197841|NCT01164137|Pharmacist-led Intervention
1197842|NCT01164124|extremely low birth weight
1197843|NCT01164124|probiotics
1197844|NCT01164124|growth
1197845|NCT01164124|nutrition
1197846|NCT01164124|premature infants
1197847|NCT01164124|growth in extremely low birth weight infants
1197848|NCT01164111|osteoarthritis
1197849|NCT01164111|hip arthroplasty
1197850|NCT01164111|resistance training
1197851|NCT01164111|preoperative training
1197852|NCT01164085|Inflammation
1197853|NCT01164085|Macular Edema
1197854|NCT01164072|electronic cigarette
1197855|NCT01164072|nicotine
1197856|NCT01164072|smoking cessation
1197857|NCT01164072|smoking reduction
1197858|NCT01164059|Schizophrenia
1197859|NCT01164059|atypical antipsychotic drugs
1197860|NCT01164059|conventional antipsychotic drugs
1197861|NCT01164059|olanzapine
1197862|NCT01164059|quetiapine
1197863|NCT01164059|aripiprazole
1197864|NCT01164059|haloperidol
1197865|NCT01164059|flupentixol
1197866|NCT01164046|anticoagulants
1197867|NCT01164046|Heparin, Low-Molecular-Weight
1197868|NCT01164046|4-Hydroxycoumarins
1197869|NCT01164046|recurrent venous thrombosis
1197870|NCT01164020|cognition
1197871|NCT01164020|supplementation creatine
1197872|NCT01164020|resistance training
1197873|NCT01164020|aging
1197874|NCT01163994|erythema migrans
1197875|NCT01163994|Lyme borreliosis
1197876|NCT01163994|ceftriaxone treatment
1197877|NCT01163994|doxycycline treatment
1197878|NCT01163994|outcome
1197879|NCT01163994|subjective symptoms
1197880|NCT01163981|duplex Ultrasound
1197881|NCT01163981|Haemodialysis
1197882|NCT01163981|Vascular Access
1197883|NCT01163968|Weight reduction
1197884|NCT01163968|Cardiac revascularization
1197885|NCT01163968|Percutaneous Coronary Intervention
1197886|NCT01163968|Cardiac Rehabilitation
1197887|NCT01163968|Rural
1197888|NCT01163955|Posture analysis
1197889|NCT01163955|Video gaming
1197890|NCT01163955|Forward Head Position
1197891|NCT01163955|Rounded Shoulder Position
1197892|NCT01163955|Spine Posture
1197893|NCT01163929|breast cancer
1197894|NCT01163929|HER2 positive
1197895|NCT01163929|Phase II
1197896|NCT01163929|RAD001
1197897|NCT01163929|paclitaxel
1197898|NCT01163929|trastuzumab
1197899|NCT01163929|everolimus
1197900|NCT01163916|Rheumatoid Arthritis
1197901|NCT01163916|Psoriatic Arthritis
1197902|NCT01163916|Ankylosing Spondylitis
1197903|NCT01163903|Advanced solid tumours
1197904|NCT01163903|Pantoprazole
1197905|NCT01163903|Doxorubicin
1197906|NCT01163903|PANTO IV
1197907|NCT01163903|Adriamycin
1197908|NCT01163903|no standard treatment options
1197909|NCT01163903|dose-escalation schedule
1197910|NCT01163903|Phase I
1197911|NCT01163903|single-centre
1197912|NCT01163903|open label
1197913|NCT01163903|dose finding
1197914|NCT01163903|recommended phase II dose
1197915|NCT01163903|proton pump inhibitor
1197916|NCT01163903|advanced cancer
1197917|NCT01163903|anthracycline
1197918|NCT01163903|gastric acid secretion
1197919|NCT01163890|Depression
1197920|NCT01163890|Work Performance and Productivity
1197921|NCT01163890|Worksite Intervention
1197922|NCT01163877|iron absorption
1197923|NCT01163877|iron utilization
1197924|NCT01163877|malaria
1197925|NCT01163877|helminth
1197926|NCT01163877|Ivory Coast
1197927|NCT01163877|Acute symptomatic uncomplicated falciparum malaria
1197928|NCT01163877|Asymptomatic falciparum malaria
1197929|NCT01163877|Moderate to heavy hookworm infection
1197930|NCT01163877|Heavy Schistosoma haematobium infection
1197931|NCT01163864|smoking
1197932|NCT01163864|smoking relapse
1197933|NCT01163864|smoking cessation
1197934|NCT01163864|pregnancy
1197935|NCT01163864|smoking cessation in pregnant women
1197936|NCT01163851|Hypercholesterolemia
1197937|NCT01163851|Dyslipidemia
1197938|NCT01163851|LDL
1197939|NCT01163851|Cholesterol
1197940|NCT01163851|High Cholesterol
1197941|NCT01163851|PF-04950615
1197942|NCT01163851|RN316
1197943|NCT01163838|Hypercholesterolemia
1197944|NCT01163838|Dyslipidemia
1197945|NCT01163838|LDL
1197946|NCT01163838|Cholesterol
1197947|NCT01163838|High Cholesterol
1197949|NCT01163799|Kidney
1197950|NCT01163799|Transplant
1197951|NCT01163799|Northwestern
1197952|NCT01163799|Calcineurin Inhibitor
1197953|NCT01163799|Corticosteroids
1197954|NCT01163799|Steroid avoidance
1197955|NCT01163786|Bortezomib GVHD Bronchiolitis Obliterans
1197956|NCT01163773|Cardiovascular disease
1197957|NCT01163773|Milk
1197958|NCT01163773|Metabolic syndrome
1197959|NCT01163773|Blood lipids
1197960|NCT01163773|Menopausal women
1197961|NCT01163734|Heart Failure with Preserved Ejection Fraction (HFpEF)
1197962|NCT01163734|Coronary Artery Disease (CAD)
1197963|NCT01163721|Type 2 diabetes mellitus
1197964|NCT01163721|T2DM
1197965|NCT01163721|Ranolazine
1197966|NCT01163721|Ranexa
1197967|NCT01163721|HbA1c
1197968|NCT01163695|economic empowerment model, orphans, sub-Saharan Africa
1197969|NCT01163682|Taxane induced neuropathy
1197970|NCT01163669|hyperparathyroidism
1197971|NCT01163656|Neonate
1197972|NCT01163656|Laryngoscopes
1197973|NCT01163630|open label, randomized
1197974|NCT01163630|single-center
1197975|NCT01163630|2-way crossover
1197976|NCT01163630|food interaction study
1197977|NCT01163617|Rheumatoid
1197978|NCT01163617|Arthritis
1197979|NCT01163604|Argatroban
1197980|NCT01163604|intracranial artery stenting
1197981|NCT01163604|extracranial artery stenting
1197982|NCT01163604|occlusion
1197983|NCT01163604|restenosis
1197984|NCT01163591|Diabetes
1197985|NCT01163591|Nephropathy
1197986|NCT01163591|Screening
1197987|NCT01163578|Transplantation
1197988|NCT01163578|Rejection
1197989|NCT01163565|Thyroidectomy
1197990|NCT01163552|pleural metastases
1197991|NCT01163513|ethnicity
1197992|NCT01163513|prognosis
1197993|NCT01163474|Telemedicine
1197994|NCT01163474|Surgery, Cardiac
1197995|NCT01163448|Prostate
1197996|NCT01163448|Radiation
1197997|NCT01163448|Radical prostatectomy
1197998|NCT01163448|09-013
1197999|NCT01163435|Helicobacter pylori
1198000|NCT01163435|antibiotic resistance
1198001|NCT01163435|high dose dual therapy
1198002|NCT01163435|sequential therapy
1198003|NCT01163435|clarithromycin-based triple therapy
1198004|NCT01163435|levofloxacin-based triple therapy
1198005|NCT01163422|Right ventricular failure
1198006|NCT01163422|Pacemaker
1198007|NCT01163422|Cardiac resynchronization therapy
1198008|NCT01163422|Pulmonary hypertension
1198009|NCT01163409|juvenile fibromyalgia
1198010|NCT01163409|acupuncture
1198011|NCT01163409|exercise training
1198012|NCT01163383|Refractory Neuroblastoma
1198013|NCT01163383|Recurrent Neuroblastoma
1198014|NCT01163383|Neuroblastoma
1198015|NCT01163383|stage IV neuroblastoma
1198016|NCT01163383|metastatic pheochromocytoma
1198017|NCT01163383|paraganglioma
1198018|NCT01163370|creatine supplementation
1198019|NCT01163370|resistance training
1198020|NCT01163370|osteopenia
1198021|NCT01163370|osteoporosis
1198022|NCT01163370|bone mineral density
1198023|NCT01163344|Gait, balance, Parkinson's Disease
1198024|NCT01163331|Parkinson's Disease, voice quality, vocal strength, voice loudness
1198025|NCT01163318|Rheumatoid Arthritis
1198026|NCT01163305|Identifying an early indicator of drug efficacy
1198027|NCT01163292|Rheumatoid Arthritis
1198028|NCT01163279|Age-related changes
1198029|NCT01163266|Major Depressive Disorder
1198030|NCT01163266|Depression
1198031|NCT01163266|Melancholia
1198032|NCT01163266|Drug Therapy
1198033|NCT01163253|chronic
1198034|NCT01163253|severe
1198035|NCT01163253|treatment
1198036|NCT01163253|safety
1198037|NCT01163253|CP-690
1198038|NCT01163253|550
1198039|NCT01163253|Plaque Psoriasis
1198040|NCT01163253|Psoriasis Vulgaris
1198041|NCT01163253|Xeljanz
1198042|NCT01163253|Tofacitinib
1198043|NCT01163240|hepatitis B
1198044|NCT01163240|HBV
1198045|NCT01163240|chronic hepatitis B
1198046|NCT01163240|pediatric
1198047|NCT01163227|Hallucinations,
1198048|NCT01163227|psychotic,
1198049|NCT01163227|delusions,
1198050|NCT01163227|cognitive deficits
1198051|NCT01163188|very low birthweight/ very preterm children
1198052|NCT01163188|Bavarian Longitudinal Study (BLS)
1198053|NCT01163188|Quality of life and social adjustment in adulthood
1198054|NCT01163175|Cardiovascular disease
1198055|NCT01163175|Trans fatty acids
1198056|NCT01163175|Ruminant
1198057|NCT01163175|Blood lipids
1198058|NCT01163162|Chronic Kidney Disease
1198059|NCT01163162|Vitamin D
1198060|NCT01163149|Hypophosphatasia
1198061|NCT01163149|HPP
1198062|NCT01163149|Bone Disease
1198063|NCT01163149|Soft Bones
1198064|NCT01163149|Low Alkaline Phosphatase
1198065|NCT01163149|genetic metabolic disorder
1198066|NCT01163149|alkaline phosphatase
1198067|NCT01163149|tissue-specific alkaline phosphatase (TNSALP)
1198068|NCT01163149|rickets
1198069|NCT01163149|osteomalacia
1198070|NCT01163136|Parental decision making
1198193|NCT01162486|Rifapentine
1198071|NCT01163136|Decision Making in Serious Pediatric Illness (DSPI)
1198072|NCT01163136|palliative care decision making
1198073|NCT01163123|Subclinical infection of Japanese encephalitis virus
1198074|NCT01163045|neurostimulation
1198075|NCT01163045|intraoperative neuromonitoring
1198076|NCT01163045|recurrent laryngeal nerve
1198077|NCT01163045|palsy of recurrent laryngeal nerve
1198078|NCT01163045|RCT
1198079|NCT01163032|Blindness
1198080|NCT01163032|Eye Diseases
1198081|NCT01163032|Nap Disorders
1198082|NCT01163032|Circadian Rhythm Disorders
1198083|NCT01163032|Sleep disorders
1198084|NCT01163032|Circadian Rhythm Sleep Disorders
1198085|NCT01163032|Dyssomnias
1198086|NCT01163032|Nervous System Diseases
1198087|NCT01163019|Chest pain
1198088|NCT01163019|acute coronary syndrome
1198089|NCT01163019|Emergency department
1198090|NCT01163019|speckle tracking imaging
1198091|NCT01163019|2D strain
1198092|NCT01163019|Echocardiography
1198093|NCT01162993|Electric stimulation therapy
1198094|NCT01162993|Diabetic Neuropathies
1198095|NCT01162980|ACE inhibitors
1198096|NCT01162980|ARBs
1198097|NCT01162954|Eye drop, Dry eye
1198098|NCT01162941|ITP
1198099|NCT01162928|critically ill, mechanically ventilated patients requiring enteral and parenteral nutritional support
1198100|NCT01162915|Spinal Cord Injury
1198101|NCT01162889|pharmacokinetics
1198102|NCT01162889|Crohn's disease
1198103|NCT01162876|Diabetes, Type 2
1198104|NCT01162863|IBSC
1198105|NCT01162863|irritable bowel syndrome
1198106|NCT01162863|constipation
1198107|NCT01162850|Melasma
1198108|NCT01162837|Acne
1198109|NCT01162824|Endothelial Dysfunction
1198110|NCT01162824|Microvascular dysfunction
1198111|NCT01162824|Coronary artery spasm
1198112|NCT01162824|Inflammation
1198113|NCT01162824|CD4+CD28null T cells
1198114|NCT01162824|Myocardial ischemia
1198115|NCT01162824|Early atherosclerosis
1198116|NCT01162811|Visualization
1198117|NCT01162811|relaxation
1198118|NCT01162811|self hypnotic relaxation
1198119|NCT01162811|hypnosis
1198120|NCT01162811|invasive medical procedures
1198121|NCT01162811|atrial fibrillation
1198122|NCT01162811|ablation
1198123|NCT01162811|catheter ablation
1198124|NCT01162811|pain
1198125|NCT01162811|anxiety
1198126|NCT01162798|infant formula
1198127|NCT01162798|premature infants
1198128|NCT01162798|Growth and Development
1198129|NCT01162785|BCG Refractory Superficial Bladder Cancer
1198130|NCT01162785|SCH 721015
1198131|NCT01162785|Syn3
1198132|NCT01162785|novel excipient
1198133|NCT01162785|interferon -alpha-2b
1198134|NCT01162785|Intravesical
1198135|NCT01162785|urine IFNa
1198136|NCT01162785|transitional cell carcinoma of the bladder
1198137|NCT01162785|superficial non-muscle invasive tumor
1198138|NCT01162759|hypertension, intervention
1198139|NCT01162733|Vancomycin
1198140|NCT01162733|Therapeutic Levels
1198141|NCT01162733|Infectious Disease
1198142|NCT01162733|Recommendations
1198143|NCT01162720|Primary knee replacement
1198144|NCT01162720|Unilateral knee replacement
1198145|NCT01162694|Remote Blood Glucose Monitoring System,
1198146|NCT01162694|Continuous Glucose Monitoring System,
1198147|NCT01162694|Type 2 Diabetes
1198148|NCT01162681|SLE
1198149|NCT01162681|Lupus
1198150|NCT01162681|Lupus Erythematosus, Systemic
1198151|NCT01162681|Autoimmune Diseases
1198152|NCT01162681|A-623
1198153|NCT01162681|Blisibimod
1198154|NCT01162668|bariatric surgery
1198155|NCT01162668|obesity
1198156|NCT01162668|outcomes
1198157|NCT01162655|Insomnia
1198158|NCT01162655|Cognitive-Behavioral Therapy
1198159|NCT01162655|Internet
1198160|NCT01162655|Telehealth
1198161|NCT01162642|Healthy moderately heavy smokers
1198162|NCT01162629|bounded saddles
1198163|NCT01162629|missing teeth
1198164|NCT01162629|dental implants
1198165|NCT01162629|Tooth, Nonvital
1198166|NCT01162616|iron absorption
1198167|NCT01162616|polyphenols
1198168|NCT01162616|sodium iron EDTA
1198169|NCT01162616|sorghum
1198170|NCT01162590|Human Rotavirus vaccine
1198171|NCT01162577|Weight
1198172|NCT01162577|Smoking
1198173|NCT01162577|Quitline
1198174|NCT01162551|Leukemia
1198175|NCT01162551|Non-Hodgkin's Lymphoma
1198176|NCT01162538|Raltegravir, non B subtype, naive patients
1198177|NCT01162525|Fecal Incontinence
1198178|NCT01162525|Fecal Urge Incontinence
1198179|NCT01162525|Percutaneous tibial nerve stimulation
1198180|NCT01162512|physical activity
1198181|NCT01162512|obesity
1198182|NCT01162512|adolescents
1198183|NCT01162512|telephone
1198184|NCT01162512|BMI
1198185|NCT01162512|body mass index
1198186|NCT01162499|Post prandial hypoglycemia
1198187|NCT01162499|hypoglycemia
1198188|NCT01162499|Nissen fundoplication
1198189|NCT01162499|Dumping
1198190|NCT01162486|Anti-infective agents
1198191|NCT01162486|Anti-bacterial agents
1198192|NCT01162486|Rifampin
1198194|NCT01162486|Midazolam
1198195|NCT01162486|Molecular mechanisms of pharmacological action
1198196|NCT01162486|Antitubercular agents
1198197|NCT01162486|Pharmacologic actions
1198198|NCT01162473|Food hypersensitivity
1198199|NCT01162473|Milk hypersensitivity
1198200|NCT01162473|Milk allergy
1198201|NCT01162473|Food allergy
1198202|NCT01162447|BMP- 4 and 7, polycystic ovarian syndrome
1198203|NCT01162434|Treatment resistant depression
1198204|NCT01162434|Deep brain stimulation
1198205|NCT01162434|Brain volumetric analysis
1198206|NCT01162421|Rheumatoid Arthritis
1198207|NCT01162421|Anti-Inflammatory
1198208|NCT01162421|Biological Therapy
1198209|NCT01162421|adalimumab
1198210|NCT01162421|Disease-Modifying Antirheumatic Drugs
1198211|NCT01162421|Antirheumatic Agents
1198212|NCT01162421|Agents
1198213|NCT01162408|ICU
1198214|NCT01162395|Prostate Cancer
1198215|NCT01162395|Tumour
1198216|NCT01162395|Castration Resistant
1198217|NCT01162395|Prostate Androgen Receptor Down Regulator
1198218|NCT01162395|Metastatic
1198219|NCT01162382|transcranial magnetic stimulation
1198220|NCT01162382|TMS
1198221|NCT01162382|rTMS
1198222|NCT01162382|depression
1198223|NCT01162382|fcMRI
1198224|NCT01162382|EEG
1198225|NCT01162369|Delirium, diagnosis, elderly, hospitalization
1198226|NCT01162356|Vitrectomy
1198227|NCT01162356|Glaucoma
1198228|NCT01162356|Macula
1198229|NCT01162356|Optic nerve
1198230|NCT01162356|Ocular Coherence Tomography
1198231|NCT01162343|Delirium, diagnosis, elderly, hospitalization
1198232|NCT01162330|Screening
1198233|NCT01162330|Congenital Cytomegalovirus
1198234|NCT01162330|CMV
1198235|NCT01162330|Hearing loss
1198236|NCT01162317|Acupuncture
1198237|NCT01162317|Sleep
1198238|NCT01162317|Traumatic brain injury
1198239|NCT01162304|Chronic Pain
1198240|NCT01162304|This clinical trial will compare immediate-release (IR)
1198369|NCT01161719|Parent training
1198241|NCT01162304|oxycodone and extended-release (ER) oxycodone in the
1198242|NCT01162304|management of chronic pain
1198243|NCT01162291|intramuscular
1198244|NCT01162291|distribution
1198245|NCT01162291|NaCl
1198246|NCT01162291|botulinum toxin
1198247|NCT01162291|muscle
1198248|NCT01162291|volume
1198249|NCT01162291|movement
1198250|NCT01162291|biceps brachii
1198251|NCT01162291|primary distribution of intramuscular NaCl representative for primary distribution of intramuscular botulinum toxin
1198252|NCT01162291|shift from extracellular to intracellular viewed by DTI technology
1198253|NCT01162291|effect of volume
1198254|NCT01162291|effect of muscle movement
1198255|NCT01162278|liver metastases
1198256|NCT01162278|Stereotactic Body Radiation Therapy
1198257|NCT01162265|Tuberculosis
1198258|NCT01162265|IGRA
1198259|NCT01162265|latent
1198260|NCT01162252|psoriasis
1198261|NCT01162252|mindfulness
1198262|NCT01162252|MBSR
1198263|NCT01162252|stress
1198264|NCT01162252|living well
1198265|NCT01162239|smoking
1198266|NCT01162239|tobacco
1198267|NCT01162239|nicotine
1198268|NCT01162239|smoking cessation
1198269|NCT01162226|gait
1198270|NCT01162226|movement disorders
1198271|NCT01162226|balance
1198272|NCT01162226|function
1198273|NCT01162213|Postmenopausal Women
1198274|NCT01162213|Healthy Males
1198275|NCT01162213|Cardiovascular
1198276|NCT01162213|Flavanols
1198277|NCT01162187|secondary prevention
1198278|NCT01162187|aspirin
1198279|NCT01162187|beta blocker
1198280|NCT01162187|ACE inhibitor
1198281|NCT01162187|statin
1198282|NCT01162187|acute coronary syndrome
1198283|NCT01162187|myocardial infarction
1198284|NCT01162187|unstable angina
1198285|NCT01162187|trends
1198286|NCT01162174|Flavanols
1198287|NCT01162174|cardiovascular
1198288|NCT01162161|sphingolipid
1198289|NCT01162161|ceramide
1198290|NCT01162161|sphingomyelinase
1198291|NCT01162148|inspiratory muscle training
1198292|NCT01162148|pulmonary rehabilitation
1198293|NCT01162135|Digoxin
1198294|NCT01162135|Recurrent Prostate Cancer
1198295|NCT01162135|Prostate Specific Antigen
1198296|NCT01162122|Elderly
1198297|NCT01162122|Influenza
1198298|NCT01162122|Immunogenicity
1198299|NCT01162122|Safety
1198300|NCT01162122|Adjuvant
1198301|NCT01162122|Adjuvanted
1198302|NCT01162122|Adjuvants
1198303|NCT01162122|Vaccines
1198304|NCT01162109|Zinc
1198305|NCT01162109|sepsis
1198306|NCT01162109|critical illness
1198307|NCT01162109|mechanical ventilation
1198308|NCT01162109|ICU
1198309|NCT01162096|Reduced Intensity Haploidentical Transplant
1198310|NCT01162083|Exercise Physiology
1198311|NCT01162083|Cardiopulmonary Interaction
1198312|NCT01162083|Heart Failure
1198313|NCT01162070|Uveitis
1198314|NCT01162070|etiological diagnosis
1198315|NCT01162070|standardized strategy
1198316|NCT01162057|Hemodialysis
1198317|NCT01162057|Hearing
1198318|NCT01162057|Hemodialysis patients
1198319|NCT01162044|PTSD
1198320|NCT01162044|prevention
1198321|NCT01162005|Primary Nephrotic syndrome
1198322|NCT01161992|Primary Sclerosing Cholangitis
1198323|NCT01161992|PSC
1198324|NCT01161992|Cholestatic Liver Disease
1198325|NCT01161953|Primary Biliary Cirrhosis
1198326|NCT01161953|PBC
1198327|NCT01161953|Cholestatic Liver Disease
1198328|NCT01161940|Bioavailability
1198329|NCT01161940|Nizatidine
1198330|NCT01161940|Crossover
1198331|NCT01161927|Bioavailability
1198332|NCT01161927|Nizatidine
1198333|NCT01161927|Crossover
1198334|NCT01161914|Type I Gaucher
1198335|NCT01161901|ARDS
1198336|NCT01161901|Plasmatic biomarkers
1198337|NCT01161901|Lung Morphology
1198338|NCT01161901|Mechanical ventilation
1198339|NCT01161901|CT scan
1198340|NCT01161862|Closed-loop
1198341|NCT01161862|Artificial pancreas
1198342|NCT01161862|Bi-hormonal
1198343|NCT01161862|Insulin
1198344|NCT01161862|Glucagon
1198345|NCT01161862|Diabetes mellitus type 1
1198346|NCT01161849|lactate
1198347|NCT01161849|urgent surgery
1198348|NCT01161849|major surgery
1198349|NCT01161849|surgical complications
1198350|NCT01161849|possum
1198351|NCT01161849|sapsII
1198352|NCT01161849|relaparotomy
1198353|NCT01161810|Burn
1198354|NCT01161810|Rehabilitation
1198355|NCT01161797|1,5-Anhydroglucitol
1198356|NCT01161784|Functional constipation
1198357|NCT01161784|Probiotic
1198358|NCT01161784|Probiotic microorganism
1198359|NCT01161784|Lactobacillus casei Shirota (LcS)
1198360|NCT01161758|physical therapy
1198361|NCT01161758|pain threshold
1198362|NCT01161758|electromyography
1198363|NCT01161758|musculoskeletal manipulation
1198364|NCT01161758|neck muscles
1198365|NCT01161745|sepsis
1198366|NCT01161732|aortic stenosis
1198367|NCT01161732|surgery, survival
1198368|NCT01161719|ADHD
1198370|NCT01161719|Videoconference
1198371|NCT01161706|vegetable juice
1198372|NCT01161706|cardiovascular
1198373|NCT01161706|blood pressure
1198374|NCT01161693|Cesarean section
1198375|NCT01161693|spinal anesthesia
1198376|NCT01161693|CSE
1198377|NCT01161693|ramped up position
1198378|NCT01161693|TROOP pillow
1198379|NCT01161693|elevation pillow
1198380|NCT01161693|maternal comfort
1198381|NCT01161693|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
1198382|NCT01161680|Cross sectional and Longitudinal Observational study
1198383|NCT01161641|Protein Losing Enteropathy
1198384|NCT01161628|Chronic Graft versus Host Disease
1198385|NCT01161628|allogeneic stem cell transplant
1198386|NCT01161615|tendonitis and/or bursitis of the shoulder
1198387|NCT01161615|acute tendonitis and/or bursitis of the shoulder
1198388|NCT01161602|Symptoms of Gastroesophageal Reflux Disease (GERD)
1198389|NCT01161589|sensing
1198390|NCT01161589|S-ICD
1198391|NCT01161589|ICD
1198392|NCT01161589|CRT D
1198393|NCT01161576|Batten Disease
1198394|NCT01161576|Late Infantile Neuronal Lipofuscinosis
1198395|NCT01161576|gene transfer
1198396|NCT01161563|palliative treatment
1198397|NCT01161563|prostate cancer
1198398|NCT01161511|CLL
1198399|NCT01161511|SLL
1198400|NCT01161511|CD19
1198401|NCT01161498|squamous cell
1198402|NCT01161498|OncoVEX^GM-CSF
1198403|NCT01161498|Oncovex
1198404|NCT01161498|chemoradiation
1198405|NCT01161498|Cisplatin
1198406|NCT01161485|HIV Infections
1198407|NCT01161485|Treatment
1198408|NCT01161485|Methamphetamine
1198409|NCT01161459|Idiopathic Membranous Nephropathy
1198410|NCT01161459|Treatment
1198411|NCT01161459|FK506
1198412|NCT01161459|Tripterygium wilfordii
1198413|NCT01161446|HIV
1198414|NCT01161446|Home testing
1198415|NCT01161446|Self-testing
1198416|NCT01161446|HIV Infections/diagnosis
1198417|NCT01161446|HIV Infections/prevention and control
1198418|NCT01161446|AIDS Serodiagnosis
1198419|NCT01161446|Oral fluids
1198420|NCT01161446|Homosexuality, Male
1198421|NCT01161446|Sexually transmitted diseases
1198422|NCT01161446|Sexual behavior
1198423|NCT01161433|Asthma
1198424|NCT01161433|Spirometry
1198425|NCT01161433|Pediatric
1198426|NCT01161433|Primary Health Care
1198427|NCT01161433|Education, Distance
1198428|NCT01161420|tongue
1198429|NCT01161420|surgery
1198430|NCT01161420|neurostimulation
1198431|NCT01161420|hypoglossal nerve
1198432|NCT01161420|upper airway stimulation
1198433|NCT01161381|OSAHS
1198434|NCT01161381|nonlinear analysis
1198435|NCT01161381|polysomnography
1198436|NCT01161381|biosignal analysis
1198437|NCT01161381|DFA
1198438|NCT01161381|APEN
1198439|NCT01161381|LLE
1198440|NCT01161368|Metastatic Breast Cancer
1198441|NCT01161355|Safety
1198442|NCT01161355|tolerability
1198443|NCT01161355|healthy
1198444|NCT01161355|microdose
1198445|NCT01161342|Malnutrition
1198446|NCT01161342|Aged
1198447|NCT01161342|Aged 80 and over
1198448|NCT01161342|Prevalence
1198449|NCT01161342|Mortality
1198450|NCT01161329|stroke
1198451|NCT01161329|physical activity
1198452|NCT01161329|balance
1198453|NCT01161329|muscle-strength
1198454|NCT01161316|metastatic colorectal cancer
1198455|NCT01161316|wild-type KRAS tumours
1198456|NCT01161316|cetuximab
1198457|NCT01161316|mFOLFOX-6
1198458|NCT01161303|Asthma
1198459|NCT01161303|TNF alpha
1198460|NCT01161303|epithelial cell culture
1198461|NCT01161290|Telemedicine
1198462|NCT01161290|Internet
1198463|NCT01161290|Dyspnea
1198464|NCT01161290|Self care
1198465|NCT01161290|Breathing Exercises
1198466|NCT01161290|Real-Time Systems
1198467|NCT01161277|Aripiprazole
1198468|NCT01161277|Haloperidol
1198469|NCT01161277|Ventral striatum
1198470|NCT01161277|Reward
1198471|NCT01161277|fMRI
1198472|NCT01161264|Elderly
1198473|NCT01161264|Influenza
1198474|NCT01161264|Immunogenicity
1198475|NCT01161264|Safety
1198476|NCT01161264|Influenza vaccine
1198477|NCT01161251|Atrial Fibrillation
1198478|NCT01161251|ABI
1198479|NCT01161251|PAD
1198480|NCT01161251|Registry
1198481|NCT01161251|Italian
1198482|NCT01161225|Adolescents
1198483|NCT01161225|Peer leader program
1198484|NCT01161225|asthma camp
1198485|NCT01161225|asthma control
1198486|NCT01161225|quality of life
1198487|NCT01161225|self-efficacy
1198488|NCT01161225|knowledge
1198489|NCT01161225|attitudes
1198490|NCT01161225|barrier perceptions
1198491|NCT01161212|body mass index
1198492|NCT01161212|health-related quality of life
1198493|NCT01161212|physical education
1198494|NCT01161212|children
1198495|NCT01161212|cluster randomized controlled trial
1198496|NCT01161212|prevention
1198497|NCT01161212|Child
1198498|NCT01161212|French
1198499|NCT01161212|Schoolchildren
1198500|NCT01161199|HIV
1198501|NCT01161199|latent reservoir
1198502|NCT01161199|functional cure
1198503|NCT01161199|leukapheresis
1198504|NCT01161186|pancreas
1198505|NCT01161186|cancer
1198506|NCT01161186|abraxane
1198507|NCT01161186|metastatic
1198508|NCT01161186|gemcitabine
1198509|NCT01161186|capecitabine
1198510|NCT01161186|adenocarcinoma
1198511|NCT01161160|H1N1
1198512|NCT01161160|Influenza
1198513|NCT01161160|Pandemic
1198514|NCT01161160|GSK Bio's influenza vaccines GSK2340274A and GSK234072A
1198518|NCT01161108|Pediatrics
1198519|NCT01161108|Epilepsy
1198520|NCT01161108|Insomnia
1198521|NCT01161108|Melatonin
1198522|NCT01161095|Intrauterine Device
1198523|NCT01161095|Postpartum contraception
1198524|NCT01161095|Long-acting reversible contraception
1198525|NCT01161069|phase 1
1198526|NCT01161069|healthy young adult volunteers
1198527|NCT01161069|healthy elderly adult volunteers
1198528|NCT01161043|diabetes
1198529|NCT01161043|glucose
1198530|NCT01161043|sensor
1198531|NCT01161017|migraine patients
1198532|NCT01160991|schizophrenia
1198533|NCT01160991|olanzapine
1198534|NCT01160991|atypical antipsychotic drugs
1198535|NCT01160991|amisulpride
1198536|NCT01160991|diabetes
1198537|NCT01160991|insulin resistance
1198538|NCT01160991|insulin secretion
1198539|NCT01160991|glucose
1198540|NCT01160991|euglycemic hyperinsulinemic clamp
1198541|NCT01160991|hyperglycemic clamp
1198542|NCT01160978|Transplantation
1198543|NCT01160978|Simvastatin treatment
1198544|NCT01160978|Ischemia-reperfusion injury
1198545|NCT01160978|Lung failure
1198546|NCT01160965|epidural top-up
1198547|NCT01160965|emergency Caesarean section
1198548|NCT01160952|primary prophylaxis
1198549|NCT01160952|itraconazole
1198550|NCT01160952|stem cell transplantation
1198551|NCT01160939|Exercise
1198552|NCT01160939|heart failure
1198553|NCT01160939|rehabilitation
1198554|NCT01160926|rectal cancer
1198555|NCT01160926|capecitabine
1198556|NCT01160926|radiotherapy
1198557|NCT01160926|AZD6244
1198558|NCT01160926|MEK inhibitor
1198559|NCT01160926|AZD2171
1198560|NCT01160926|Cediranib
1198561|NCT01160926|VEGFR inhibitor
1198562|NCT01160926|FLT-PET (fluoro-l-pyrimidine positron emission tomography)
1198563|NCT01160926|DCE-MRI (dynamic contrast enhanced magnetic resonance imaging)
1198564|NCT01160900|cardiovascular diseases
1198565|NCT01160900|heart disease
1198566|NCT01160900|hemorrhage
1198567|NCT01160900|coronary angioplasty
1198568|NCT01160900|drug eluting stents
1198569|NCT01160874|Attention Deficit Disorder / Hyperactivity (ADHD)
1198570|NCT01160874|Cognition
1198571|NCT01160874|Sleepiness
1198572|NCT01160874|Driving
1198573|NCT01160848|Moderate to severe Acne Vulgaris
1198574|NCT01160835|total knee arthroplasty
1198575|NCT01160835|minimally invasive
1198576|NCT01160835|quadriceps-sparing
1198577|NCT01160835|Quadriceps-sparing total knee arthroplasty
1198578|NCT01160822|Osteo arthritis
1198579|NCT01160822|pain control
1198580|NCT01160822|intra- articular injections
1198581|NCT01160822|Knee OA
1198582|NCT01160809|Malaria
1198583|NCT01160809|Mosquito repellent
1198584|NCT01160809|LLINs
1198585|NCT01160783|Autism
1198586|NCT01160783|Asperger's Syndrome
1198587|NCT01160783|Asperger Syndrome
1198588|NCT01160783|Autistic Disorder
1198589|NCT01160783|Autism Spectrum Disorder
1198590|NCT01160783|Pervasive Developmental Disorders
1198591|NCT01160783|PDD-NOS
1198592|NCT01160783|Child Development Disorders, Pervasive
1198593|NCT01160783|Pervasive Developmental Disorder-Not Otherwise Specified
1198594|NCT01160770|Lennox-Gastaut Syndrome (LGS)
1198595|NCT01160770|Epilepsy
1198596|NCT01160770|Drop Seizures
1198597|NCT01160770|Clobazam
1198598|NCT01160744|Lung neoplasms
1198599|NCT01160744|Lung cancer
1198600|NCT01160744|Non-small Cell Lung Cancer
1198601|NCT01160744|pemetrexed
1198602|NCT01160744|ALIMTA®
1198603|NCT01160744|squamous
1198604|NCT01160744|nonsquamous
1198605|NCT01160731|extensive stage small cell lung cancer
1198606|NCT01160718|estrogen receptor-positive breast cancer
1198607|NCT01160718|HER2-positive breast cancer
1198608|NCT01160718|HER2-negative breast cancer
1198609|NCT01160718|progesterone receptor-positive breast cancer
1198610|NCT01160718|recurrent breast cancer
1198611|NCT01160718|stage IIIA breast cancer
1198612|NCT01160718|stage IIIB breast cancer
1198613|NCT01160718|stage IIIC breast cancer
1198614|NCT01160718|stage IV breast cancer
1198615|NCT01160705|adenocarcinoma of the prostate
1198616|NCT01160705|recurrent prostate cancer
1198617|NCT01160705|stage III prostate cancer
1198618|NCT01160705|stage IV prostate cancer
1198619|NCT01160705|bone metastases
1198620|NCT01160705|liver metastases
1198621|NCT01160705|lung metastases
1198622|NCT01160705|hormone-resistant prostate cancer
1198623|NCT01160692|Memory
1198624|NCT01160692|Cognitive Function
1198625|NCT01160692|Elderly
1198626|NCT01160692|Gingko
1198627|NCT01160692|Age Associated Memory Impairment (AAMI)
1198628|NCT01160679|anhedonic features in patients with schizophrenia
1198629|NCT01160666|Belimumab
1198630|NCT01160666|Sjögren's syndrome
1198631|NCT01160666|Sjögren disease
1198632|NCT01160653|stroke
1198633|NCT01160653|Gait training
1198634|NCT01160653|Cognitive Training
1198635|NCT01160640|PID
1198636|NCT01160640|Pelvic Inflammatory Disease
1198637|NCT01160627|CIN STEMI
1198638|NCT01160614|Pediatric
1198639|NCT01160614|Post-operative
1198640|NCT01160614|Nonsurgical
1198641|NCT01160614|patients
1198642|NCT01160614|Opioid
1198643|NCT01160601|NSCLC
1198644|NCT01160601|lung cancer
1198645|NCT01160601|non small cell lung cancer
1198646|NCT01160601|bavituximab
1198647|NCT01160601|monoclonal antibody
1198648|NCT01160588|Anxiety
1198649|NCT01160588|Social Phobia
1198650|NCT01160588|Social Anxiety
1198651|NCT01160588|Generalized Anxiety
1198652|NCT01160588|Separation Anxiety
1198653|NCT01160575|Counseling
1198654|NCT01160575|Epidemiology
1198655|NCT01160575|HIV
1198656|NCT01160575|AIDS
1198657|NCT01160575|Prevention
1198658|NCT01160562|Prevalence
1198659|NCT01160562|Incidence
1198660|NCT01160562|Children
1198661|NCT01160562|Adults
1198662|NCT01160562|Global Positioning system
1198663|NCT01160549|Pregnancy
1198664|NCT01160549|Hormones
1198665|NCT01160549|Mongolia
1198666|NCT01160549|Asian
1198667|NCT01160549|Breast Cancer
1198668|NCT01160536|Hypertrophic Cardiomyopathy (HCM)
1198669|NCT01160536|Genetic Testing
1198670|NCT01160523|Podoconiosis
1198671|NCT01160523|Genetic Education
1198672|NCT01160523|Primary Prevention
1198673|NCT01160523|Ethiopa
1198674|NCT01160523|Youth
1198675|NCT01160510|Breast
1198676|NCT01160510|Mammographic Density
1198677|NCT01160484|multiple myeloma
1198678|NCT01160484|refractory
1198679|NCT01160484|relapsed
1198680|NCT01160484|bortezomib
1198681|NCT01160484|doxil
1198682|NCT01160471|Heart Failure
1198683|NCT01160471|Computed Tomography
1198684|NCT01160471|Ultrasound
1198685|NCT01160471|Fibrosis
1198686|NCT01160471|Biomarker
1198687|NCT01160458|Monoclonal Antibody
1198688|NCT01160458|Pleural Mesothelioma
1198689|NCT01160458|Peritoneal Mesothelioma
1198690|NCT01160445|Metastatic Melanoma
1198691|NCT01160445|Metastatic Kidney Cancer
1198692|NCT01160445|Clinical Performance
1198693|NCT01160445|Tumor Regression
1198694|NCT01160445|Toxicity
1198695|NCT01160432|opiate dependence
1198696|NCT01160432|methadone
1198697|NCT01160432|naloxone
1198698|NCT01160432|withdrawal symptom
1198699|NCT01160432|substitution treatment
1198700|NCT01160406|silent paroxysmal atrial fibrillation
1198701|NCT01160406|stroke
1198702|NCT01160406|tele ECG
1198703|NCT01160393|Atrial fibrillation
1198704|NCT01160393|Cardiac surgery
1198705|NCT01160393|Prevention
1198706|NCT01160393|Conventional bypass system
1198707|NCT01160393|Miniaturized bypass system
1198708|NCT01160393|Arrhythmia
1198709|NCT01160393|The Incidence of atrial fibrillation after cardiac surgery
1198710|NCT01160380|cancer related fatigue
1198711|NCT01160380|fatigue
1198712|NCT01160380|multiple myeloma
1198713|NCT01160380|cancer
1198714|NCT01160380|quality of life
1198715|NCT01160354|Leukemia
1198716|NCT01160354|AML
1198717|NCT01160354|Clofarabine
1198718|NCT01160354|Plerixafor
1198719|NCT01160354|elderly patients
1198720|NCT01160354|previously untreated
1198721|NCT01160354|unfavorable prognostic factors
1198722|NCT01160341|Metabolic syndrome
1198723|NCT01160341|Hypogonadism
1198724|NCT01160341|Testosterone
1198725|NCT01160328|Regional Fat Storage
1198726|NCT01160328|Fat Oxidation
1198727|NCT01160328|Testosterone
1198728|NCT01160328|Male
1198729|NCT01160315|ovarian failure, chemotherapy, lymphoma, GnRH agonist
1198730|NCT01160302|cancer
1198731|NCT01160276|renal graft
1198732|NCT01160276|colchicine
1198733|NCT01160276|drug interaction
1198734|NCT01160276|cyclosporine
1198735|NCT01160276|tacrolimus
1198736|NCT01160276|renal transplantation
1198737|NCT01160276|renal transplant
1198738|NCT01160276|ABCB1
1198739|NCT01160276|CYP3A5
1198740|NCT01160276|SLCO1B1
1198741|NCT01160263|ALS
1198742|NCT01160263|serotonin
1198743|NCT01160263|dopamine
1198744|NCT01160237|H1N1
1198745|NCT01160237|Pandemrix
1198746|NCT01160237|Fluarix
1198747|NCT01160237|Influenza
1198748|NCT01160224|Asthma
1198875|NCT01159639|aspirin resistance
1198749|NCT01160224|CCR3 receptor antagonists
1198750|NCT01160224|GW766944
1198751|NCT01160211|1st line MBC
1198752|NCT01160211|MBC
1198753|NCT01160211|hormone receptor positive
1198754|NCT01160211|lapatinib
1198755|NCT01160211|trastuzumab
1198756|NCT01160211|HER2 positive
1198757|NCT01160211|aromatase inhibitor
1198758|NCT01160172|vaccine
1198759|NCT01160172|young adults
1198760|NCT01160172|Staphylococcus aureus
1198761|NCT01160159|Venous thrombosis
1198762|NCT01160159|Women
1198763|NCT01160159|Vasodilatation endothelium-dependent
1198764|NCT01160159|IMT
1198765|NCT01160159|Arterial stiffness
1198766|NCT01160159|Arterial compliance
1198767|NCT01160159|Capillary density
1198768|NCT01160146|Obestiy
1198769|NCT01160146|Over weight
1198770|NCT01160146|referral patterns
1198771|NCT01160146|Continuing Medical Education
1198772|NCT01160133|Systane
1198773|NCT01160133|Refresh Tears
1198774|NCT01160133|Dry Eye
1198775|NCT01160133|Moderate to Severe Dry Eye
1198776|NCT01160120|fixed dose combinations
1198777|NCT01160120|tenofovir
1198778|NCT01160120|lamivudine
1198779|NCT01160120|efavirenz
1198780|NCT01160120|therapeutic drug levels
1198781|NCT01160120|safety and efficacy
1198782|NCT01160120|HIV
1198783|NCT01160120|To evaluation new formulations of FDC of TDF/3TC/EFV
1198784|NCT01160107|Diagnosis
1198785|NCT01160107|Elderly Patients
1198786|NCT01160107|Imids
1198787|NCT01160107|Chemotherapy
1198788|NCT01160094|Trastuzumab
1198789|NCT01160094|Metastatic Breast Cancer
1198790|NCT01160094|Breast Cancer
1198791|NCT01160094|Observational Study
1198792|NCT01160094|Lapatinib
1198793|NCT01160003|ACTH stimulation test
1198794|NCT01160003|Pharmacokinetics
1198795|NCT01160003|Nebules
1198796|NCT01160003|Cortisol
1198797|NCT01159990|HIV Preventive Vaccine
1198798|NCT01159990|HIV Seronegativity
1198799|NCT01159964|Antigen-Specific Cancer Immunotherapeutic (ASCI)
1198800|NCT01159964|PRAME
1198801|NCT01159964|PRAME-positive stage IB, II or IIIA Non-Small Cell Lung Cancer patients after complete surgical resection
1198802|NCT01159964|Non-Small Cell Lung Cancer
1198803|NCT01159912|fluticasone propionate
1198804|NCT01159912|Fluticasone furoate
1198805|NCT01159899|Osteoarthritis
1198806|NCT01159899|knee arthritis
1198807|NCT01159899|Knee arthrosis
1198808|NCT01159899|articular cartilage defects
1198809|NCT01159899|osteochondral defects
1198810|NCT01159899|mesenchymal stem cells
1198811|NCT01159899|stem cells
1198812|NCT01159899|cellules souches,
1198813|NCT01159899|genou
1198814|NCT01159899|arthrose genou
1198815|NCT01159899|PRP platelet rich plasma
1198816|NCT01159899|thérapie cellulaire
1198817|NCT01159899|implantation cellules souches mésenchymateuses
1198818|NCT01159899|régénération cartilage
1198819|NCT01159899|cicatrisation ménisque
1198820|NCT01159899|ligament
1198821|NCT01159899|plasma riche plaquettaire
1198822|NCT01159899|platelet rich plasma
1198823|NCT01159899|stem cell
1198824|NCT01159899|regrowt cartilage
1198825|NCT01159899|cellules souches
1198826|NCT01159899|PRP
1198827|NCT01159886|Tuberculosis
1198828|NCT01159886|IBD
1198829|NCT01159886|endoscopy
1198830|NCT01159860|seborrheic keratoses
1198831|NCT01159860|cryosurgery
1198832|NCT01159860|curettage
1198833|NCT01159847|sitagliptin
1198834|NCT01159847|LADA
1198835|NCT01159847|C-Peptide
1198836|NCT01159847|Flow Cytometry
1198837|NCT01159847|ELISPOT
1198838|NCT01159834|HPV infection
1198839|NCT01159834|Cervical cancer
1198840|NCT01159834|HPV vaccine
1198841|NCT01159821|31001074
1198842|NCT01159821|Paroxetine
1198843|NCT01159821|CYP2D6 inhibitor
1198844|NCT01159808|Safety and Pharmacokinetics
1198845|NCT01159795|Respiratory Syncytial Virus
1198846|NCT01159795|Infant
1198847|NCT01159795|Interferon
1198848|NCT01159769|Allergic conjunctivitis
1198849|NCT01159756|Travacom
1198850|NCT01159756|Glaucoma
1198851|NCT01159756|Travoprost
1198852|NCT01159756|Timolol
1198853|NCT01159743|lipodystrophy
1198854|NCT01159743|Lipoatrophy
1198855|NCT01159743|antiretroviral treatment
1198856|NCT01159704|HIV infection
1198857|NCT01159704|Intervention
1198858|NCT01159704|Risk-reduction
1198859|NCT01159704|Injection drug users
1198860|NCT01159691|Rotigotine
1198861|NCT01159691|Neupro®
1198862|NCT01159691|Parkinson's disease
1198863|NCT01159691|Gastrointestinal
1198864|NCT01159691|Switch from oral therapy to patch
1198865|NCT01159652|sleep
1198866|NCT01159652|memory
1198867|NCT01159652|hypnotics
1198868|NCT01159652|zaleplon
1198869|NCT01159652|zolpidem
1198870|NCT01159652|Sonata
1198871|NCT01159652|Ambien
1198872|NCT01159652|Hypnotics and Sedatives
1198873|NCT01159652|Polysomnography
1198874|NCT01159652|Monitoring, sleep
1198876|NCT01159639|coronary artery bypass grafting
1198877|NCT01159639|multiple electrode aggregometry
1198878|NCT01159639|multiplate
1198879|NCT01159626|Phase1
1198880|NCT01159626|Pharmacokinetics
1198881|NCT01159626|Healthy Male
1198882|NCT01159626|Japanese
1198883|NCT01159626|Schizophrenia
1198884|NCT01159613|SVR
1198885|NCT01159613|Cholesterol level
1198886|NCT01159613|fibrosis score
1198887|NCT01159613|HDL
1198888|NCT01159535|substance use
1198889|NCT01159535|addiction
1198890|NCT01159535|meditation
1198891|NCT01159535|mindfulness
1198892|NCT01159535|relapse prevention
1198893|NCT01159522|Advanced Solid Tumors Who Have Failed Standard Therapy
1198894|NCT01159509|hypertrophic pyloric stenosis
1198895|NCT01159509|sodium intake
1198896|NCT01159509|Healthy children with no chronic diseases
1198897|NCT01159509|Status post HPS
1198898|NCT01159483|safety
1198899|NCT01159483|tolerability
1198900|NCT01159483|pharmacokinetics
1198901|NCT01159470|CRP velocity
1198902|NCT01159457|Celiac Disease
1198903|NCT01159457|Hepatitis B vaccination
1198904|NCT01159444|noninvasive ventilation
1198905|NCT01159444|ventilator software
1198906|NCT01159444|ventilator settings
1198907|NCT01159444|domiciliary ventilation
1198908|NCT01159431|partial seizures
1198909|NCT01159431|poorly controlled epilepsy
1198910|NCT01159431|intractable epilepsy
1198911|NCT01159431|treatment resistant epilepsy
1198912|NCT01159431|Trigeminal Nerve
1198913|NCT01159431|Trigeminal Nerve Stimulation
1198914|NCT01159418|solid tumors
1198915|NCT01159418|Panobinostat
1198916|NCT01159418|histone deacetylase inhibitors
1198917|NCT01159392|brain injury
1198918|NCT01159392|mechanical ventilation
1198919|NCT01159392|acute lung injury
1198920|NCT01159392|lung recruitment
1198921|NCT01159379|IgE-mediated allergy
1198922|NCT01159379|Beta-lactams
1198923|NCT01159379|Ertapenem
1198924|NCT01159379|Cross-reactivity
1198925|NCT01159379|Immediate-type skin tests
1198926|NCT01159379|Intravenous tolerance tests
1198927|NCT01159366|myocardial infarction
1198928|NCT01159366|coronary occlusion
1198929|NCT01159366|myocardial revascularization
1198930|NCT01159366|collaterals
1198931|NCT01159366|prognosis
1198932|NCT01159327|Sorafenib (nexavar)
1198933|NCT01159327|ED-SCLC
1198934|NCT01159327|Maintenance
1198935|NCT01159327|Extensive Disease Small cell lung cancer
1198936|NCT01159314|glaucoma
1198937|NCT01159314|Baerveldt Implants
1198938|NCT01159288|Advanced unresectable non small cell lung cancer
1198939|NCT01159288|Responding or stabilized after induction chemotherapy
1198940|NCT01159275|lopinavir/ritonavir
1198941|NCT01159275|pharmacokinetics
1198942|NCT01159275|HIV-1 infected adults
1198943|NCT01159275|aim to investigate the lower dose of boosted lopinavir in Thais and to compare the levels of lopinavir/ritonavir from Abbot and GPO
1198944|NCT01159262|Initially intubated and mechanically ventilated neonates
1198945|NCT01159249|Vildagliptin, Type 2 Diabetes, HbA1c, Fasting Plasma Glucose, Long-Term Safety
1198946|NCT01159236|Gene signatures
1198947|NCT01159236|HER-2 normal stage I-III breast cancer
1198948|NCT01159236|Estrogen Receptor
1198949|NCT01159236|ER-positive
1198950|NCT01159236|ER-negative
1198951|NCT01159236|RCB categories II-III
1198952|NCT01159236|Neoadjuvant Chemotherapy
1198953|NCT01159236|adjuvant systemic therapy
1198954|NCT01159236|molecular testing
1198955|NCT01159236|Fluorouracil
1198956|NCT01159236|5-fluorouracil
1198957|NCT01159236|5-FU
1198958|NCT01159236|Doxorubicin
1198959|NCT01159236|Adriamycin
1198960|NCT01159236|Rubex
1198961|NCT01159236|Epirubicin
1198962|NCT01159236|Ellence
1198963|NCT01159236|Cyclophosphamide
1198964|NCT01159236|Cytoxan
1198965|NCT01159236|Neosar
1198966|NCT01159236|Bevacizumab
1198967|NCT01159236|Avastin
1198968|NCT01159236|Anti-VEGF monoclonal
1198969|NCT01159236|rhu-MAb-VEGF
1198970|NCT01159223|atazanavir / ritonavir
1198971|NCT01159223|low dose
1198972|NCT01159223|noninferiority
1198973|NCT01159223|safety and efficacy
1198974|NCT01159223|efficacy and safety of lower dose atazanavir/ritonavir in suppressed HIV-infected adults
1198975|NCT01159197|sleep disturbance
1198976|NCT01159197|cognitive behavioral therapy
1198977|NCT01159197|inflammation
1198978|NCT01159197|oxidative stress
1198979|NCT01159197|hemodialysis
1198980|NCT01159184|stress
1198981|NCT01159184|coping methods
1198982|NCT01159184|social support
1198983|NCT01159184|diabetes mellitus
1198984|NCT01159145|Healthy volunteer
1198985|NCT01159145|Japanese males
1198986|NCT01159145|homo-EM/hetero-EM/PM
1198987|NCT01159132|pharmacokinetics
1198988|NCT01159132|low dose raltegravir
1198989|NCT01159132|HIV
1198990|NCT01159132|To study the pharmacokinetics profile of low dose raltegravir (RAL) (400mg OD and 800mg OD) and standard dose of 400mg BID in Thai HIV-infected patients.
1198991|NCT01159119|Chronic Abdominal Pain
1198992|NCT01159119|Exocrine Pancreatic Insufficiency
1198993|NCT01159106|Positive Pressure Ventilation
1198994|NCT01159106|Neurally Adjusted Ventilatory Assist
1198995|NCT01159106|Patient/ventilator Asynchrony
1198996|NCT01159106|Pediatric patient
1198997|NCT01159106|Infant
1198998|NCT01159093|Clinical Decision Support Systems
1198999|NCT01159080|immunosuppression control in kidney transplantation
1199000|NCT01159067|hematopoietic stem cell transplant, iron overload, deferasirox, labile plasma iron
1199001|NCT01159041|Depression, children, adolescent, family
1199002|NCT01159028|Liposomal Grb-2 treatment of CML, AML, CLL, MDS
1199003|NCT01159028|Liposomal Grb-2 with LDAC for AML
1199004|NCT01159002|Endoscopy, Video Capsule
1199005|NCT01159002|Motility, Gastrointestinal
1199006|NCT01158989|Critical care
1199007|NCT01158989|Endoscopy, Video Capsule
1199008|NCT01158989|Nutrition, Enteral
1199009|NCT01157897|Malaria
1199010|NCT01157897|Plasmodium Vivax
1199011|NCT01157897|Vaccine
1199012|NCT01157884|body composition
1199013|NCT01157884|obesity
1199014|NCT01157884|kidney transplantation
1199015|NCT01157858|liver cyst
1199016|NCT01157832|water pipe smoking acute effect
1199017|NCT01157819|swimmer's ear
1199018|NCT01157819|ear drops
1199019|NCT01157819|ear foam
1199020|NCT01157819|otic foam
1199021|NCT01157819|ear infection
1199022|NCT01157819|ear pain
1199023|NCT01157819|ear inflammation
1199024|NCT01157806|rectal cancer
1199025|NCT01157806|unresectable synchronous metastases
1199026|NCT01157806|pelvic radiochemotherapy
1199027|NCT01158937|meropenem
1199028|NCT01158937|cystic fibrosis
1199029|NCT01158937|extended infusion
1199030|NCT01158937|pharmacokinetic
1199031|NCT01158911|kidney disease
1199032|NCT01158911|uric acid
1199033|NCT01158911|outcomes
1199034|NCT01158911|cardiovascular
1199035|NCT01158911|mortality
1199036|NCT01158911|kidney failure
1199037|NCT01158911|Uric Acid levels in patients with Chronic Kidney Disease
1199038|NCT01158898|Mild to moderate asthma
1199039|NCT01158898|Allergen inhalation challenge
1199040|NCT01158885|relapsed
1199041|NCT01158885|relapse
1199042|NCT01158885|refractory
1199043|NCT01158885|Minimal Residual disease
1199044|NCT01158885|MRD
1199045|NCT01158885|MRD positive
1199046|NCT01158885|MRD+
1199047|NCT01158885|ALL
1199048|NCT01158885|Acute lymphoblastic leukemia
1199049|NCT01158885|AML
1199050|NCT01158885|Acute myelogenous leukemia
1199051|NCT01158885|Relapsed AML
1199052|NCT01158859|Anesthesia, General
1199053|NCT01158859|Propofol
1199054|NCT01158859|Pregabalin
1199055|NCT01158859|Preoperative care
1199056|NCT01158859|Laparoscopic surgery
1199057|NCT01158846|STEMI
1199058|NCT01158846|Primary PCI
1199059|NCT01158846|anticoagulants
1199060|NCT01158846|antiplatelets
1199061|NCT01158833|Cerebral palsy
1199062|NCT01158833|diplegia
1199063|NCT01158833|gait
1199064|NCT01158833|classification
1199065|NCT01158820|bronchoscopy
1199066|NCT01158807|Hereditary Hemorrhagic Telangiectasia
1199067|NCT01158807|Cerebral arteriovenous malformations
1199068|NCT01158794|Iron overload
1199069|NCT01158794|Blood Transfusion
1199070|NCT01158781|TBI
1199071|NCT01158781|motor learning
1199072|NCT01158781|robotics
1199073|NCT01158781|Functional electrical stimulation
1199074|NCT01158768|domestic violence in childhood/adolescence
1199075|NCT01158768|comorbidities
1199076|NCT01158768|climactery
1199077|NCT01158768|domestic violence against women
1199078|NCT01158768|trauma questionnaire
1199079|NCT01158768|Violence
1199080|NCT01158755|Meningitis, tuberculous
1199081|NCT01158755|Intensified Regimen
1199082|NCT01158755|PK/PD and tolerability
1199083|NCT01158755|Outcome
1199084|NCT01158742|Glomerular Filtration Rate
1199085|NCT01158729|Antithrombin III
1199086|NCT01158729|Postoperative Hemorrhage
1199087|NCT01158729|Cardiopulmonary Bypass
1199088|NCT01158729|Pediatrics
1199089|NCT01158729|Blood Transfusion
1199090|NCT01158716|percutaneous coronary intervention
1199091|NCT01158716|remote ischemic preconditioning
1199092|NCT01158703|aspirin
1199093|NCT01158703|clopidogrel
1199094|NCT01158703|coronary artery bypass graft
1199095|NCT01158703|Plavix
1199096|NCT01158690|Intimate partner violence
1199097|NCT01158677|meniscectomy
1199098|NCT01158664|dental implants
1199099|NCT01158664|different tread pitch design
1199100|NCT01158651|NF1
1199101|NCT01158651|low-grade glioma
1199102|NCT01158651|progressive
1199103|NCT01158651|children
1199104|NCT01158651|Participants studied have NF Type 1 and a low grade glioma that has either not responded to one or more standard treatments.
1199105|NCT01158638|Physical Activity Enhancement
1199106|NCT01158599|Japanese Encephalitis
1199107|NCT01158599|Vaccination
1199108|NCT01158599|Ixiaro
1199109|NCT01158599|elderly population
1199110|NCT01158586|post total knee replacement
1199111|NCT01158586|patient control
1199112|NCT01158586|epidural analgesia
1199113|NCT01158573|Asthma
1199114|NCT01158573|Obesity
1199115|NCT01158560|upper respiratory tract infections
1199116|NCT01158560|rhinovirus infections
1199117|NCT01158560|vitamin D
1199118|NCT01158534|recurrent renal cell cancer
1199119|NCT01158508|cerebral aneurysm
1199120|NCT01158508|cerebral vasospasm
1199121|NCT01158508|subarachnoid hemorrhage
1199122|NCT01158508|remote ischemic preconditioning
1199123|NCT01158456|smoking
1199124|NCT01158456|lung cancer
1199125|NCT01158456|ethnic racial differences
1199126|NCT01158456|tobacco specific nitrosamines
1199127|NCT01158456|metabolism of carcinogens
1199128|NCT01158443|HIV+
1199129|NCT01158443|fatigue
1199130|NCT01158443|return to work
1199131|NCT01158430|Hypochondriasis
1199132|NCT01158430|Acceptance and Commitment Therapy
1199133|NCT01158430|ACT
1199134|NCT01158417|Type 2 Diabetes
1199135|NCT01158417|Obesity
1199136|NCT01158417|Insulin Resistance
1199137|NCT01158417|Resveratrol
1199138|NCT01158417|Inflammation
1199139|NCT01158404|Metastatic Cancer
1199140|NCT01158404|Solid Tumors
1199141|NCT01158391|Premature Birth
1199142|NCT01158378|Adherus Dural Sealant
1199143|NCT01158378|Adherus AutoSpray Dural Sealant
1199144|NCT01158352|Growth
1199145|NCT01158352|Low weight
1199146|NCT01158352|Low height
1199147|NCT01158352|Nutritional Formula
1199148|NCT01158339|Low back pain
1199149|NCT01158339|Cognitive behavioural therapy
1199150|NCT01158339|Group therapy
1199151|NCT01158339|Exposure in session
1199152|NCT01158326|reducing symptoms
1199153|NCT01158326|events
1199154|NCT01158326|Common Cold
1199155|NCT01158326|flu syndrome
1199156|NCT01158326|Symptomatic treatment of the Common Cold and Flu syndrome
1199157|NCT01158300|recurrent childhood malignant germ cell tumor
1199158|NCT01158300|recurrent childhood brain stem glioma
1199159|NCT01158300|recurrent childhood brain tumor
1199160|NCT01158300|recurrent childhood central nervous system embryonal tumor
1199161|NCT01158300|recurrent childhood cerebellar astrocytoma
1199162|NCT01158300|recurrent childhood cerebral astrocytoma
1199163|NCT01158300|recurrent childhood ependymoma
1199164|NCT01158300|recurrent childhood medulloblastoma
1199165|NCT01158300|recurrent childhood pineoblastoma
1199166|NCT01158300|recurrent childhood rhabdomyosarcoma
1199167|NCT01158300|recurrent childhood spinal cord neoplasm
1199168|NCT01158300|recurrent childhood subependymal giant cell astrocytoma
1199169|NCT01158300|recurrent childhood visual pathway and hypothalamic glioma
1199170|NCT01158300|recurrent childhood visual pathway glioma
1199171|NCT01158300|childhood central nervous system choriocarcinoma
1199172|NCT01158300|childhood central nervous system germ cell tumor
1199173|NCT01158300|childhood central nervous system germinoma
1199174|NCT01158300|childhood central nervous system mixed germ cell tumor
1199175|NCT01158300|childhood central nervous system teratoma
1199176|NCT01158300|childhood central nervous system yolk sac tumor
1199177|NCT01158300|childhood astrocytoma
1199178|NCT01158300|childhood medulloepithelioma
1199179|NCT01158300|childhood meningioma
1199180|NCT01158300|childhood mixed glioma
1199181|NCT01158300|childhood oligodendroglioma
1199182|NCT01158300|childhood pineal parenchymal tumor
1199183|NCT01158287|adenocarcinoma of the esophagus
1199184|NCT01158287|recurrent esophageal cancer
1199185|NCT01158287|recurrent gastric cancer
1199186|NCT01158287|adenocarcinoma of the stomach
1199187|NCT01158261|hemostasis
1199188|NCT01158248|cervical adenocarcinoma
1199189|NCT01158248|cervical adenosquamous cell carcinoma
1199190|NCT01158248|cervical small cell carcinoma
1199191|NCT01158248|stage IB cervical cancer
1199192|NCT01158248|stage IIA cervical cancer
1199193|NCT01158248|stage IIB cervical cancer
1199194|NCT01158248|stage III cervical cancer
1199195|NCT01158248|cervical squamous cell carcinoma
1199196|NCT01158235|MRSA
1199197|NCT01158235|nose
1199198|NCT01158196|laser
1199199|NCT01158196|keloid
1199200|NCT01158196|scar
1199201|NCT01158183|Outcomes
1199202|NCT01158183|real world and web tool
1199203|NCT01158183|electronic data capture
1199204|NCT01158170|nonsmall cell lung cancer
1199205|NCT01158170|brain metastasis
1199206|NCT01158170|prophylactic cranial irradiation
1199207|NCT01158144|Non-small cell lung cancer
1199208|NCT01158144|Locally advanced
1199209|NCT01158144|Radiotherapy
1199210|NCT01158144|Concomitant Chemotherapy
1199211|NCT01158144|Endostar
1199212|NCT01158131|Gestational diabetes mellitus (GDM) in the most recent pregnancy
1199213|NCT01158118|Precursor Cell Lymphoblastic Leukemia-Lymphoma
1199214|NCT01158118|Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1199215|NCT01158105|Steroid refractory chronic graft vs host disease (cGVHD)
1199216|NCT01158105|Bortezomib
1199217|NCT01158105|Velcade
1199218|NCT01158079|Liver
1199219|NCT01158079|Solid Tumors
1199220|NCT01158079|Advanced Solid Tumors with Liver Involvement
1199221|NCT01158066|NAFLD
1199222|NCT01158066|Calcium score
1199223|NCT01158066|Liver Fat
1199224|NCT01158066|Visceral fat
1199225|NCT01158066|excessive visceral fat
1199226|NCT01158066|excessive liver fat accumulation
1199227|NCT01158066|Biomarkers of insulin resistance (HOMA), inflammation (CRP) and (MDA-Paraoxonase)
1199228|NCT01158040|Maternal intrapartum glycemic control
1199229|NCT01158040|Pregestational diabetes
1199230|NCT01158014|pterygium
1199231|NCT01158014|conjunctival graft
1199232|NCT01158014|recurrence
1199233|NCT01158014|primary pterygium
1199234|NCT01158001|Posttraumatic stress disorders
1199235|NCT01158001|Telemedicine
1199236|NCT01158001|Psychotherapy
1199237|NCT01158001|Neuropsychological test
1199238|NCT01158001|Depression
1199239|NCT01157988|bulky diffuse large B cell lymphoma
1199240|NCT01157988|90Y-ibritumomab tiuxetan
1199241|NCT01157988|clinical response
1199242|NCT01157988|Safety and toxicity
1199243|NCT01157962|Sentinel Concept
1199244|NCT01157962|Lymphadenectomy
1199245|NCT01157962|Early Stage Cervical Cancer
1199246|NCT01157962|Overall Survive
1199247|NCT01157962|Improvement Therapy
1199248|NCT01157936|hypertension
1199249|NCT01157936|hyperuricemia
1199250|NCT01157936|metabolic syndrome
1199251|NCT01157923|Type 1 diabetes
1199252|NCT01157923|Insulin Pump Therapy
1199253|NCT01157910|Ear infection
1199254|NCT01157910|Chronic
1199255|NCT01157793|Dwarfism
1199256|NCT01157793|Growth hormone deficiency
1199257|NCT01157793|Growth hormone
1199258|NCT01157780|Fish oil
1199259|NCT01157767|exercise
1199260|NCT01157767|lymphedema
1199261|NCT01157767|post-operative chemotherapy
1199262|NCT01157767|post-operative radiation
1199263|NCT01157767|10-062
1199264|NCT01157754|Infertility patients requiring IVF
1199265|NCT01157754|good prognosis
1199266|NCT01157741|Community based follow up, severely underweight children
1199267|NCT01157728|Multiple sclerosis
1199268|NCT01157728|Cognitive impairment
1199269|NCT01157715|KH902
1199270|NCT01157715|age-related macular degeneration (AMD)
1199271|NCT01157715|choroidal neovascularization (CNV)
1199272|NCT01157715|intravitreal injection
1199273|NCT01157715|best corrected visual acuity (BCVA)
1199274|NCT01157715|central retinal thickness
1199275|NCT01157689|malaria
1199276|NCT01157689|children
1199277|NCT01157689|Guinea-Bissau
1199278|NCT01157689|artemether
1199279|NCT01157689|lumefantrine
1199280|NCT01157689|effectiveness
1199281|NCT01157676|open cystectomy
1199282|NCT01157676|robotic assisted radical cystectomy
1199283|NCT01157676|bladder cancer
1199284|NCT01157663|Functional ankle instability
1199285|NCT01157650|Fistulizing Crohn's disease
1199286|NCT01157650|stem cells implant
1199287|NCT01157624|hypoxia or hypercarbia during surgery under the drape
1199288|NCT01157611|online based mentoring program,
1199289|NCT01157611|type 1 diabetes,
1199290|NCT01157611|blood glucose,
1199291|NCT01157611|satisfaction score
1199292|NCT01157598|gastric adenoma
1199293|NCT01157598|early gastric cancer
1199294|NCT01157572|Aortic valve insufficiency
1199295|NCT01157572|Beta-blocker
1199296|NCT01157533|Vancomycin
1199297|NCT01157533|Pharmacokinetic testing
1199298|NCT01157533|PK
1199299|NCT01157507|Botulinum A toxin
1199300|NCT01157507|Painful Bladder Syndrome (PBS)
1199301|NCT01157507|Bladder overdistention
1199302|NCT01157494|cerebral palsy
1199303|NCT01157494|hemiplegia
1199304|NCT01157494|upper limb
1199305|NCT01157494|assessment
1199306|NCT01157494|classification system
1199307|NCT01157481|Diastolic Heart Failure
1199308|NCT01157481|Heart failure with preserved ejection fraction
1199309|NCT01157481|nifedipine
1199310|NCT01157468|Systemic Lupus Erythematosus in Martinique
1199311|NCT01157468|Hydrolase and DNase activities
1199312|NCT01157455|Stent
1199313|NCT01157455|Coronary artery diseases
1199314|NCT01157442|prevention of maternal to child transmission of HIV
1199315|NCT01157442|mhealth
1199316|NCT01157442|access to antenatal care
1199317|NCT01157442|pregnancy
1199318|NCT01157429|Cognitive Behavior Therapy
1199319|NCT01157429|Children
1199320|NCT01157429|Adolescents
1199321|NCT01157429|Pharmacotherapy
1199322|NCT01157416|Cognitive Behavior Therapy
1199323|NCT01157416|Children
1199324|NCT01157416|Pharmacotherapy
1199325|NCT01157403|mesenchymal stem cells
1199326|NCT01157390|Term-infant
1199327|NCT01157390|sn-2 palmitic acid
1199328|NCT01157390|infant formula
1199329|NCT01157351|Schizophrenia
1199330|NCT01157351|Risperidone
1199331|NCT01157351|Risperdal
1199332|NCT01157351|Paliperidone palmitate
1199333|NCT01157351|Aripiprazole
1199334|NCT01157351|Haloperidol
1199335|NCT01157351|Olanzapine
1199336|NCT01157351|Paliperidone
1199337|NCT01157351|Perphenazine
1199338|NCT01157351|Quetiapine
1199339|NCT01157338|Catheter
1199340|NCT01157338|coronary artery disease
1199341|NCT01157338|embolus
1199342|NCT01157338|stroke
1199343|NCT01157338|retinal emboli
1199344|NCT01157325|Epidural analgesia
1199345|NCT01157325|Latent analgesia
1199346|NCT01157325|Active analgesia
1199347|NCT01157325|Cesarean section
1199348|NCT01157312|Polycystic ovary syndrome
1199349|NCT01157312|clomiphene citrate
1199350|NCT01157312|minimal stimulation
1199351|NCT01157312|infertility treatment
1199352|NCT01157299|Hemodynamics
1199353|NCT01157299|Pediatric Intensive Care Unit
1199354|NCT01157299|Low cardiac output
1199355|NCT01157299|Thermodilution
1199356|NCT01157299|Stroke volume
1199357|NCT01157299|Global end-diastolic volume
1199358|NCT01157299|Fluid responsiveness
1199359|NCT01157299|Passive leg raising
1199360|NCT01157299|Infant
1199361|NCT01157286|OBSTRUCTIVE SLEEP APNEA LARINGECTOMY CPAP
1199362|NCT01157273|Behavior
1199363|NCT01157273|Anxiety
1199364|NCT01157273|Communication
1199365|NCT01157273|Voice
1199366|NCT01157260|Indoxyl sulfate
1199367|NCT01157260|AST-120
1199368|NCT01157247|Anesthetic techniques
1199369|NCT01157247|regional, spinal
1199370|NCT01157247|Pain
1199371|NCT01157247|lumbar puncture
1199372|NCT01157247|Analgesia, local
1199373|NCT01157247|Analgesia, intravenous
1199374|NCT01157234|Hypertension
1199375|NCT01157234|Kidney transplantation
1199376|NCT01157234|Renal function
1199377|NCT01157234|Nitric Oxide
1199378|NCT01157234|Nebivolol
1199379|NCT01157208|chronic pain
1199380|NCT01157208|headache
1199381|NCT01157208|nutrition
1199382|NCT01157208|inflammation
1199383|NCT01157208|complementary medicine
1199384|NCT01157195|stroke
1199385|NCT01157195|chronic
1199386|NCT01157195|arm
1199387|NCT01157195|rehabilitation
1199388|NCT01157195|tele-health
1199389|NCT01157182|Healthy
1199390|NCT01157182|Bioequivalence
1199391|NCT01157182|Post-Menopausal
1199392|NCT01157169|Bioequivalence
1199393|NCT01157169|Healthy
1199394|NCT01157130|Breast Cancer
1199395|NCT01157130|Exercise
1199396|NCT01157130|CRP
1199397|NCT01157130|C-reactive protein
1199398|NCT01157130|BMI
1199399|NCT01157130|Nevada Cancer Institute
1199400|NCT01157130|Rehabilitation
1199401|NCT01157130|Prescriptive exercise
1199402|NCT01157130|Physical Activity
1199403|NCT01157130|DEXA
1199404|NCT01157130|Obesity
1199405|NCT01157130|lifestyle intervention
1199406|NCT01157130|Early Stage Breast Cancer Patients (stage 0-III)
1199407|NCT01157117|food allergy
1199408|NCT01157104|HCV
1199409|NCT01157104|Hepatitis C
1199410|NCT01157078|Major Depressive Disorder
1199411|NCT01157078|MDD
1199412|NCT01157078|Depression
1199413|NCT01157078|Safety
1199414|NCT01157078|add-on therapy
1199415|NCT01157065|Wet AMD
1199416|NCT01157065|Intravitreal Injection
1199417|NCT01157065|Macular Degeneration
1199418|NCT01157065|VEGF treatment
1199419|NCT01157052|magnesium
1199420|NCT01157052|calcium
1199421|NCT01157052|adverse effects
1199422|NCT01157052|kinetics, drug
1199423|NCT01157039|glutamine
1199424|NCT01157039|oxaliplatin
1199425|NCT01157039|adverse effects
1199426|NCT01157026|Breast cancer
1199427|NCT01157026|Tocotrienol-rich fraction with tamoxifen
1199428|NCT01157013|Positron Emission Tomography
1199429|NCT01157013|Hepatocellular carcinoma
1199430|NCT01157013|Liver Cancer
1199431|NCT01157013|Sorafenib
1199432|NCT01157013|Response Evaluation
1199433|NCT01157000|Canagliflozin
1199434|NCT01157000|Pharmacokinetic
1199435|NCT01157000|Bioavailability
1199436|NCT01156974|care management
1199437|NCT01156974|chronic disease
1199438|NCT01156974|outpatient
1199439|NCT01156948|misoprostol
1199440|NCT01156948|nulliparous
1199441|NCT01156948|hysteroscopy
1199442|NCT01156935|Neoplasm
1199443|NCT01156935|Laugh-Yoga
1199444|NCT01156935|Mood
1199445|NCT01156935|Quality of life
1199446|NCT01156922|Chronic fatigue syndrome
1199447|NCT01156922|CFS
1199448|NCT01156922|Myalgic encephalomyelitis
1199449|NCT01156922|Rituximab
1199450|NCT01156922|B-cell depletion
1199451|NCT01156909|Chronic fatigue syndrome
1199452|NCT01156909|CFS
1199453|NCT01156909|Myalgic encephalomyelitis
1199454|NCT01156909|Rituximab
1199455|NCT01156909|B-cell depletion
1199456|NCT01156896|Non-transferrin-bound iron
1199457|NCT01156896|Iron stable isotopes
1199458|NCT01156896|Iron deficiency
1199459|NCT01156896|Malaria
1199460|NCT01156896|Iron supplementation
1199461|NCT01156896|Iron fortification
1199462|NCT01156883|B-cell adult acute lymphoblastic leukemia
1199463|NCT01156883|recurrent adult acute lymphoblastic leukemia
1199464|NCT01156883|T-cell adult acute lymphoblastic leukemia
1199465|NCT01156883|untreated adult acute lymphoblastic leukemia
1199466|NCT01156844|Indacaterol
1199467|NCT01156844|Asthma
1199468|NCT01156844|Bronchodilation
1199469|NCT01156844|Beta-agonist
1199470|NCT01156831|Esophageal cancer
1199471|NCT01156831|PET-CT planning
1199472|NCT01156818|Wheeze measurements
1199473|NCT01156805|Children
1199474|NCT01156805|School-based program
1199475|NCT01156805|Obesity
1199476|NCT01156792|asthma
1199477|NCT01156792|GSK2190915
1199478|NCT01156779|SR-Exenatide
1199479|NCT01156766|Fracture
1199480|NCT01156766|Radius
1199481|NCT01156766|Osteosynthesis
1199482|NCT01156766|Metaphyseal
1199483|NCT01156766|Pinning
1199484|NCT01156766|Locking anterior plate
1199485|NCT01156753|CR011-vcMMAE
1199486|NCT01156753|locally advanced breast cancer
1199487|NCT01156753|metastatic breast cancer
1199488|NCT01156753|breast cancer
1199489|NCT01156753|CDX-011
1199490|NCT01156753|GPNMB
1199491|NCT01156753|Targeted treatment for breast cancer
1199492|NCT01156753|Locally advanced or metastatic breast cancer
1199493|NCT01156740|streptococcal pharyngitis
1199494|NCT01156740|randomized clinical trial
1199495|NCT01156740|amoxicillin
1199496|NCT01156740|intramuscular benzathine penicillin G.
1199497|NCT01156727|OEF/OIF
1199498|NCT01156727|Mental Health
1199499|NCT01156727|Veterans
1199500|NCT01156714|Parkinson's Disease
1199501|NCT01156714|Treadmill Training
1199502|NCT01156714|Exercise
1199503|NCT01156714|Cognitive Training
1199504|NCT01156714|Executive Function
1199505|NCT01156714|Dual Task
1199506|NCT01156701|Influenza
1199507|NCT01156701|Zanamivir
1199508|NCT01156701|Influenza prophylaxis
1199509|NCT01156701|Relenza
1199510|NCT01156688|medical abortion for pregnancy of less than 9 weeks gestation
1199511|NCT01156675|Back pain
1199512|NCT01156675|Pain
1199513|NCT01156675|Spinal Diseases
1199514|NCT01156675|Spinal Stenosis
1199515|NCT01156675|Lumbar Vertebrae
1199516|NCT01156675|Spinal Canal
1199517|NCT01156662|Thrombus aspiration
1199518|NCT01156662|Percutaneous coronary intervention
1199519|NCT01156649|Obstructive sleep apnea
1199520|NCT01156649|neurocognitive function
1199521|NCT01156649|cognition
1199522|NCT01156649|pediatrics
1199523|NCT01156649|children
1199524|NCT01156649|continuous positive airway pressure therapy
1199525|NCT01156649|sham treatment
1199526|NCT01156649|randomized clinical trial
1199527|NCT01156649|behavior
1199528|NCT01156649|treatment
1199529|NCT01156636|Diastolic Heart Failure
1199530|NCT01156636|Pulmonary Hypertension
1199531|NCT01156623|EBUS-TBNA
1199532|NCT01156623|NSCLC
1199533|NCT01156623|Mediastinal lymph node
1199534|NCT01156623|tuberculosis
1199535|NCT01156610|Smoking
1199536|NCT01156610|Smoking Cessation
1199537|NCT01156610|Electronic Health Record
1199538|NCT01156610|Telephone
1199539|NCT01156597|diabetes
1199540|NCT01156597|dyslipidemia
1199541|NCT01156597|pioglitazone
1199542|NCT01156597|HDL-Cholesterol
1199543|NCT01156597|Reverse cholesterol transport
1199544|NCT01156584|glioma
1199545|NCT01156584|glioblastoma
1199546|NCT01156584|glioblastoma multiforme
1199547|NCT01156584|Grade IV astrocytoma
1199548|NCT01156584|brain cancer
1199549|NCT01156584|recurrent glioblastoma
1199550|NCT01156584|GBM
1199551|NCT01156584|AA
1199552|NCT01156584|AOD
1199553|NCT01156584|anaplastic astrocytoma
1199554|NCT01156584|anaplastic oligodendroglioma
1199555|NCT01156584|anaplastic oligoastrocytoma
1199556|NCT01156584|malignant glioma
1199557|NCT01156584|high grade glioma
1199558|NCT01156545|BIBW 2992
1199559|NCT01156545|Simvastatin
1199560|NCT01156545|NSCLC
1199561|NCT01156545|advanced stage
1199562|NCT01156545|previously treated patients
1199563|NCT01156545|non-adenocarcinoma
1199564|NCT01156532|adalimumab therapy
1199565|NCT01156532|Psoriasis
1199566|NCT01156532|observational study
1199567|NCT01156519|Infra-clinic cortisol adenoma
1199568|NCT01156519|Salivary cortisol
1199569|NCT01156519|Obesity
1199570|NCT01156506|quality of life
1199571|NCT01156506|patient education
1199572|NCT01156506|rehabilitation
1199573|NCT01156506|focus group interview
1199574|NCT01156493|feeding intolerance
1199575|NCT01156493|prematurity
1199576|NCT01156480|necrotizing enterocolitis
1199577|NCT01156480|NEC
1199578|NCT01156480|premature
1199579|NCT01156480|hydrocortisone
1199580|NCT01156480|steroids
1199581|NCT01156480|anti-inflammatory
1199582|NCT01156467|Neurally adjusted ventilatory assist NAVA
1199583|NCT01156467|Premature infant
1199584|NCT01156467|Edi-signal
1199585|NCT01156454|sentinel lymph node dissection
1199586|NCT01156454|radiology
1199587|NCT01156454|X-ray identification of nodes in a surgical specimen
1199588|NCT01156441|Myocardial Infarction
1199589|NCT01156441|Mitral Regurgitation
1199590|NCT01156441|Percutaneous Coronary Intervention
1199591|NCT01156428|Nephritic syndrome
1199592|NCT01156428|Nephrotic syndrome
1199593|NCT01156428|Proteinuria
1199594|NCT01156428|Acute kidney injury
1199595|NCT01156428|Chronic kidney disease
1199596|NCT01156428|Lupus nephritis
1199597|NCT01156415|agomelatine
1199598|NCT01156415|Major Depressive Disorder
1199599|NCT01156415|MDD
1199600|NCT01156415|depression
1199601|NCT01156402|Obesity
1199602|NCT01156402|Pediatric Obesity
1199603|NCT01156389|malaria
1199604|NCT01156389|artemisinin-based combination therapy
1199605|NCT01156350|Neuroblastoma - Haplo HSCT - Reduced Intensity Conditioning - immunotherapy NK
1199606|NCT01156337|Heart failure III NYHA class
1199607|NCT01156337|Furosemide
1199608|NCT01156337|Sodium
1199609|NCT01156337|water restriction
1199610|NCT01156337|decompensated heart failure
1199611|NCT01156337|Hypertonic saline solution
1199612|NCT01156337|Moderate sodium restriction
1199613|NCT01156324|IVF
1199614|NCT01156324|Stress management
1199615|NCT01156311|BG00012
1199616|NCT01156311|MS
1199617|NCT01156311|RRMS
1199618|NCT01156272|Isolated aortic valve replacement
1199619|NCT01156272|heart valve
1199620|NCT01156259|B cell cll/lymphoma, human
1199621|NCT01156246|Healthy volunteers
1199622|NCT01156246|Dapagliflozin
1199623|NCT01156246|Diabetes Type 2
1199624|NCT01156246|Food interaction
1199625|NCT01156233|evaluating precision of tube tip position with two methods
1199626|NCT01156220|gender, diuretics, furosemide, aminohippuric acid
1199627|NCT01156207|To establish the coupling between components of arterial load ( and components of LV myocardial deformations at baseline and 6 months after randomization.
1199628|NCT01156207|To establish the role of EPCs on modulation of the components of arterial load and LV myocardial deformations and their coupling.
1199629|NCT01156194|third stage, labor, postpartum hemorrhage, homeopathy, arnica, bellis perennis
1199630|NCT01156181|Cervical mucus, Embryo transfer, ICSI cycle, Pregnancy rate
1199631|NCT01156168|male breast cancer
1199632|NCT01156168|stage IV breast cancer
1199633|NCT01156168|recurrent breast cancer
1199634|NCT01156155|rheumatoid arthritis
1199635|NCT01156155|osteoarthritis
1199636|NCT01156155|periodontal disease
1199637|NCT01156142|oral complications of radiation therapy
1199638|NCT01156142|mucositis
1199639|NCT01156142|pain
1199640|NCT01156142|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1199641|NCT01156142|recurrent squamous cell carcinoma of the hypopharynx
1199642|NCT01156142|squamous cell carcinoma of the hypopharynx
1199643|NCT01156142|recurrent squamous cell carcinoma of the larynx
1199644|NCT01156142|recurrent verrucous carcinoma of the larynx
1199645|NCT01156142|squamous cell carcinoma of the larynx
1199646|NCT01156142|verrucous carcinoma of the larynx
1199647|NCT01156142|recurrent adenoid cystic carcinoma of the oral cavity
1199648|NCT01156142|recurrent mucoepidermoid carcinoma of the oral cavity
1199649|NCT01156142|recurrent verrucous carcinoma of the oral cavity
1199650|NCT01156142|adenoid cystic carcinoma of the oral cavity
1199651|NCT01156142|mucoepidermoid carcinoma of the oral cavity
1199652|NCT01156142|verrucous carcinoma of the oral cavity
1199653|NCT01156142|squamous cell carcinoma of the lip and oral cavity
1199654|NCT01156142|recurrent basal cell carcinoma of the lip
1199655|NCT01156142|recurrent squamous cell carcinoma of the lip and oral cavity
1199656|NCT01156142|basal cell carcinoma of the lip
1199657|NCT01156142|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1199658|NCT01156142|recurrent metastatic squamous neck cancer with occult primary
1199659|NCT01156142|untreated metastatic squamous neck cancer with occult primary
1199660|NCT01156142|recurrent lymphoepithelioma of the nasopharynx
1199661|NCT01156142|recurrent squamous cell carcinoma of the nasopharynx
1199662|NCT01156142|lymphoepithelioma of the nasopharynx
1199663|NCT01156142|squamous cell carcinoma of the nasopharynx
1199664|NCT01156142|recurrent lymphoepithelioma of the oropharynx
1199665|NCT01156142|recurrent squamous cell carcinoma of the oropharynx
1199666|NCT01156142|lymphoepithelioma of the oropharynx
1199667|NCT01156142|squamous cell carcinoma of the oropharynx
1199668|NCT01156142|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1199669|NCT01156142|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1199670|NCT01156142|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1199671|NCT01156142|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1199672|NCT01156142|esthesioneuroblastoma of the paranasal sinus and nasal cavity
1199673|NCT01156142|inverted papilloma of the paranasal sinus and nasal cavity
1199674|NCT01156142|midline lethal granuloma of the paranasal sinus and nasal cavity
1199675|NCT01156142|squamous cell carcinoma of the paranasal sinus and nasal cavity
1199676|NCT01156142|high-grade salivary gland mucoepidermoid carcinoma
1199677|NCT01156142|low-grade salivary gland mucoepidermoid carcinoma
1199678|NCT01156142|recurrent salivary gland cancer
1199679|NCT01156142|salivary gland acinic cell tumor
1199680|NCT01156142|salivary gland adenocarcinoma
1199681|NCT01156142|salivary gland adenoid cystic carcinoma
1199682|NCT01156142|salivary gland anaplastic carcinoma
1199683|NCT01156142|salivary gland malignant mixed cell type tumor
1199684|NCT01156142|salivary gland poorly differentiated carcinoma
1199685|NCT01156142|salivary gland squamous cell carcinoma
1199686|NCT01156142|salivary gland cancer
1199687|NCT01156142|tongue cancer
1199688|NCT01156129|liver transplant
1199689|NCT01156129|liver resection
1199690|NCT01156116|CPAP
1199691|NCT01156116|diabetes
1199692|NCT01156116|sleep apnea
1199693|NCT01156103|obesity
1199694|NCT01156103|minority
1199695|NCT01156103|child
1199696|NCT01156103|physical fitness
1199697|NCT01156103|school
1199698|NCT01156103|physical activity
1199699|NCT01156090|vectibix
1199700|NCT01156077|antibiotic
1199701|NCT01156077|Adolescents receiving antibiotics
1199702|NCT01156064|Endoscopy
1199703|NCT01156064|Confocal laser endomicroscopy
1199704|NCT01156064|Digestive Diseases
1199705|NCT01156051|ADHD
1199706|NCT01156051|ADD
1199707|NCT01156051|sleep disturbance
1199708|NCT01156038|Atopy patch test
1199709|NCT01156025|GV550
1199710|NCT01156025|Acute adenoviral keratoconjunctivitis
1199711|NCT01155986|analgesic
1199712|NCT01155986|analgesics
1199713|NCT01155986|pain
1199714|NCT01155986|chronic pain
1199715|NCT01155986|localized pain
1199716|NCT01155986|focal pain
1199717|NCT01155986|neuropathic pain
1199718|NCT01155986|postoperative pain
1199719|NCT01155986|topical analgesia
1199720|NCT01155973|Hypertension.
1199721|NCT01155973|Cardiovascular risk.
1199722|NCT01155973|Monitoring.
1199723|NCT01155973|Primary health care.
1199724|NCT01155973|Randomised controlled trial.
1199725|NCT01155973|Cluster analysis
1199726|NCT01155960|Bioavailability
1199727|NCT01155960|Anastrozole
1199728|NCT01155960|Crossover
1199729|NCT01155947|Bioavailability
1199730|NCT01155947|Anastrozole
1199731|NCT01155947|Crossover
1199732|NCT01155934|Bioavailability
1199733|NCT01155934|Crossover
1199734|NCT01155934|Risperidone
1199735|NCT01155921|Bioavailability
1199736|NCT01155921|Crossover
1199737|NCT01155921|Risperidone
1199738|NCT01155908|Bioavailability
1199739|NCT01155908|10 mg Amlodipine besylate/20 mg benazepril hydrochloride capsules
1199740|NCT01155908|Crossover
1199741|NCT01155895|Bioavailability
1199742|NCT01155895|10 mg Amlopdipine besylate /20 mg Benazepril Hydrochloride
1199743|NCT01155895|Crossover
1199744|NCT01155869|alcohol dependence
1199745|NCT01155869|homelessness
1199746|NCT01155869|naltrexone
1199747|NCT01155856|telemedicine
1199748|NCT01155856|COPD
1199749|NCT01155830|inflammatory cytokines
1199750|NCT01155830|extracorporeal membrane oxygenation
1199751|NCT01155830|ECMO
1199752|NCT01155804|preparation of the delivery
1199753|NCT01155804|lumbago
1199754|NCT01155804|anxiety
1199755|NCT01155804|urinary incontinence
1199756|NCT01155778|Sanfilippo Syndrome Type A (MPS IIIA)
1199757|NCT01155778|Recombinant Human Heparan N-Sulfatase (rhHNS)
1199758|NCT01155778|Lysosomal Storage Disease (LSD)
1199759|NCT01155778|Intrathecal Drug Delivery Device (IDDD)
1199760|NCT01155765|Clopidogrel Resistance
1199761|NCT01155765|prasugrel
1199762|NCT01155765|Hemodialysis
1199763|NCT01155752|sinusitis
1199764|NCT01155752|cystic fibrosis
1199765|NCT01155752|therapy
1199766|NCT01155713|Neoplasms
1199767|NCT01155713|Cancer
1199768|NCT01155713|Tumors
1199769|NCT01155713|Administration, oral
1199770|NCT01155713|Capsules
1199771|NCT01155713|CHIR258, CHIR-258, CHIR 258, TKI258, TKI-258, TKI 258,
1199772|NCT01155713|Bioavailability,
1199773|NCT01155713|Food
1199774|NCT01155700|omalizumab
1199775|NCT01155700|allergic asthma
1199776|NCT01155700|pediatric patients
1199777|NCT01155687|afghanistan
1199778|NCT01155687|depression
1199779|NCT01155687|anxiety
1199780|NCT01155687|social stress
1199781|NCT01155687|counseling
1199782|NCT01155687|medication
1199783|NCT01155687|psychotherapy
1199784|NCT01155687|mental health
1199785|NCT01155674|Innate immunity
1199786|NCT01155674|Neutrophils
1199787|NCT01155674|Band forms
1199788|NCT01155648|Mechanical ventilation
1199789|NCT01155648|Chest physiotherapy
1199790|NCT01155648|Chest wall compression
1199794|NCT01155622|Hypothermia, induced
1199795|NCT01155622|Cardiac arrest
1199796|NCT01155622|Disability evaluation
1199797|NCT01155622|Cardiac arrhythmia
1199798|NCT01155622|Ventricular function
1199799|NCT01155622|Internal cooling
1199800|NCT01155622|Out-of-hospital cardiac arrest
1199801|NCT01155622|Post-cardiac arrest syndrome
1199802|NCT01155596|Acute respiratory failure patients in medical ICUs.
1199803|NCT01155570|Psoriasis
1199804|NCT01155557|Tension-Type Headache
1199805|NCT01155557|Strength Capacity
1199806|NCT01155557|Neck and Shoulder
1199807|NCT01155544|Aripiprazole
1199808|NCT01155544|Psychotic experiences
1199809|NCT01155544|Substance abuse
1199810|NCT01155544|Substance dependence
1199811|NCT01155544|Craving
1199812|NCT01155544|Mood
1199813|NCT01155544|Substance use
1199814|NCT01155531|Obesity
1199815|NCT01155531|Overweight
1199816|NCT01155531|Sertraline
1199817|NCT01155531|Telenzepine
1199818|NCT01155531|Decrease appetite
1199819|NCT01155531|Reduce appetite
1199820|NCT01155531|Lose weight
1199821|NCT01155518|hypogonadism
1199822|NCT01155518|diabetes
1199823|NCT01155518|spermatogenesis
1199824|NCT01155518|insulin resistance
1199825|NCT01155492|lipopolysaccharides
1199826|NCT01155492|etiology
1199827|NCT01155492|inflammation
1199828|NCT01155492|colonic bacteria
1199829|NCT01155492|intestinal permeability
1199830|NCT01155466|Idiopathic Parkinson Disease
1199831|NCT01155466|Idiopathic Parkinson's Disease
1199832|NCT01155453|BKM120
1199833|NCT01155453|RAS RAF mutations,
1199834|NCT01155453|triple negative breast cancer,
1199835|NCT01155453|pancreatic cancer,
1199836|NCT01155453|PI3K inhibitor,
1199837|NCT01155453|MEK inhibitor
1199838|NCT01155440|60 patients scheduled to have a colorectal surgery
1199839|NCT01155440|recruit at Montreal General Hospital
1199840|NCT01155401|acute upper gastrointestinal bleeding
1199841|NCT01155401|patients with drug-induced upper gastrointestinal bleeding
1199842|NCT01155401|routine management
1199843|NCT01155388|Iron deficiency anemia
1199844|NCT01155388|Feraheme
1199845|NCT01155388|ferumoxytol
1199846|NCT01155388|CKD
1199847|NCT01155388|pediatric
1199848|NCT01155388|nondialysis-dependent
1199849|NCT01155388|The treatment of iron deficiency anemia in pediatric subjects with nondialysis dependent chronic kidney disease
1199850|NCT01155375|Iron deficiency anemia
1199851|NCT01155375|Feraheme
1199852|NCT01155375|ferumoxytol
1199853|NCT01155375|CKD
1199854|NCT01155375|pediatric
1199855|NCT01155375|dialysis-dependent
1199856|NCT01155375|non-dialysis dependent
1199857|NCT01155375|The treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease.
1199858|NCT01155362|Human Placenta-Derived Cells for the Treatment of Moderate-to-Severe Crohn's Disease
1199859|NCT01155349|brain fitness
1199860|NCT01155349|cognitive training
1199861|NCT01155349|cognitive intervention
1199862|NCT01155349|speed of processing training
1199863|NCT01155349|Parkinson's disease
1199864|NCT01155336|Acute Coronary Syndrome
1199865|NCT01155336|Fish Oils
1199866|NCT01155336|Platelet Function Tests
1199867|NCT01155336|Cardiac Electrophysiology
1199868|NCT01155310|Exacerbation of COPD
1199869|NCT01155310|Helium/Oxygen
1199870|NCT01155310|ICU
1199871|NCT01155310|Non-Invasive Ventilation
1199872|NCT01155310|Patient with known or suspected COPD
1199873|NCT01155310|patient Admitted in an ICU
1199874|NCT01155310|Patient presenting current exacerbation of COPD
1199875|NCT01155297|Quality of Life
1199876|NCT01155297|Biological Markers
1199877|NCT01155297|Renal Insufficiency
1199878|NCT01155297|Resistance Training
1199879|NCT01155297|Exercise
1199880|NCT01155297|Chronic Kidney Failure
1199881|NCT01155284|diabetes
1199882|NCT01155284|HGB A1C
1199883|NCT01155284|Beta Cell Regeneration
1199884|NCT01155245|osteoporosis
1199885|NCT01155245|HR-pQCT
1199886|NCT01155245|PTH
1199887|NCT01155232|osteoporosis
1199888|NCT01155232|Forteo
1199889|NCT01155232|Parathyroid hormone
1199890|NCT01155232|HR-pQCT
1199891|NCT01155219|Bilateral Glaucoma
1199892|NCT01155219|Bilateral ocular hypertension
1199893|NCT01155219|Bilateral primary open angle glaucoma
1199894|NCT01155219|Bilateral ocular hypertension already treated and controlled by mono-therapy of Xalatan® (1drop per day)
1199895|NCT01155219|With local intolerance signs in at least one eye
1199896|NCT01155206|glucagon,
1199897|NCT01155206|high physiological dose and basal dose of glucagon
1199898|NCT01155206|hepatic lipoprotein production,
1199899|NCT01155206|free fatty acid
1199900|NCT01155206|intestinal lipoprotein production
1199901|NCT01155206|particle
1199902|NCT01155206|glucagon affects production of fat in intestine and liver.
1199903|NCT01155193|Children
1199904|NCT01155193|Pre-term infants
1199905|NCT01155193|Congenital heart disease
1199906|NCT01155193|Infection
1199907|NCT01155193|Respiratory syncytial virus
1199908|NCT01155167|radial artery spasm
1199909|NCT01155154|wounds and lacerations
1199910|NCT01155154|hand
1199911|NCT01155154|infection
1199912|NCT01155154|Antibiotics
1199913|NCT01155154|antibacterial agents
1199914|NCT01155128|physical activity
1199915|NCT01155128|exercise
1199916|NCT01155128|sedentarism
1199917|NCT01155128|chronic renal disease
1199918|NCT01155128|failure renal chronic
1199919|NCT01155128|proteinuria
1199920|NCT01155128|progression
1199921|NCT01155128|Renal Protective Effects of Exercise
1199922|NCT01155128|quality of life changes with exercise in CKD
1199923|NCT01155128|Endothelial progenitor cells in CKD
1199924|NCT01155128|Chronic Kidney Disease and Ankle Brachial Index
1199925|NCT01155115|pediatrics
1199926|NCT01155115|CF
1199927|NCT01155115|PCD
1199928|NCT01155115|exacerbation
1199929|NCT01155115|inflammatory markers
1199930|NCT01155115|induced sputum
1199931|NCT01155063|Exemestane
1199932|NCT01155063|Adjuvant Treatment In Postmenopausal Women
1199933|NCT01155063|Estrogen Receptor Positive Early Breast Cancer
1199934|NCT01155063|Tamoxifen
1199935|NCT01155050|overweight
1199936|NCT01155050|obese
1199937|NCT01155050|type II diabetes
1199938|NCT01155050|hypertension
1199939|NCT01155037|HIV, influenza A H1N1, vaccine
1199940|NCT01155024|Lower extremity amputation
1199941|NCT01155024|Prosthetic Sockets
1199942|NCT01155024|Direct Manufactured (DM)
1199943|NCT01155011|Older adults
1199944|NCT01155011|physical activity
1199945|NCT01155011|sedentary
1199946|NCT01155011|retirement communities
1199947|NCT01155011|advocacy
1199948|NCT01155011|built environment
1199949|NCT01155011|peer mentoring
1199950|NCT01155011|walkability
1199951|NCT01154998|non-specific interstitial pneumonia
1199952|NCT01154985|omega-3 fatty acids
1199953|NCT01154985|alanine transaminase
1199954|NCT01154985|triglycerides
1199955|NCT01154985|lipids
1199956|NCT01154985|EPA
1199957|NCT01154985|ethyl-EPA
1199958|NCT01154985|ethyl icosapentate
1199959|NCT01154985|Non Alcoholic steatohepatitis
1199960|NCT01154985|Non Alcoholic fatty liver disease
1199961|NCT01154985|fatty acids
1199962|NCT01154972|breast
1199963|NCT01154972|cancer
1199964|NCT01154972|sentinel lymph node
1199965|NCT01154959|Pulmonary TB
1199966|NCT01154959|Immune response
1199967|NCT01154959|ATT
1199968|NCT01154959|Immune responses in pulmonary tuberculosis
1199969|NCT01154959|Predictors for relapse
1199970|NCT01154946|detrusor after-contraction
1199971|NCT01154946|urodynamic
1199972|NCT01154946|LUTS
1199973|NCT01154946|urinary bladder, overactive
1199974|NCT01154946|bladder dysfunction
1199975|NCT01154933|type 2 diabetes
1199976|NCT01154933|obesity
1199977|NCT01154920|Head and Neck Cancer
1199978|NCT01154920|HNSCC
1199979|NCT01154920|Paclitaxel
1199980|NCT01154920|Carboplatin
1199981|NCT01154920|Cetuximab
1199982|NCT01154920|Docetaxel
1199983|NCT01154920|Taxotere
1199984|NCT01154920|Cisplatin
1199985|NCT01154920|Platinol-AQ
1199986|NCT01154920|Platinol
1199987|NCT01154920|CDDP
1199988|NCT01154920|Fluorouracil
1199989|NCT01154920|5-FU
1199990|NCT01154920|Adrucil
1199991|NCT01154920|Efudex
1199992|NCT01154920|chemotherapy
1199993|NCT01154920|radiation
1199994|NCT01154920|Chemoradiotherapy
1199995|NCT01154907|Uro-genital schistosomiasis
1199996|NCT01154907|Female
1199997|NCT01154907|South Africa
1199998|NCT01154907|Rural
1199999|NCT01154907|Sexually transmitted diseases
1200000|NCT01154894|arachidonic acid
1200001|NCT01154894|autism spectrum disorders
1200002|NCT01154894|social interaction
1200003|NCT01154894|randomized controlled trial
1200004|NCT01154894|DHA
1200005|NCT01154855|Periodontal disease
1200006|NCT01154855|Gum disease
1200007|NCT01154855|Dental
1200008|NCT01154855|Inflammation
1200009|NCT01154855|Microorganisms
1200010|NCT01154855|Bacteria
1200011|NCT01154842|FGF-23
1200012|NCT01154842|Dialysis
1200013|NCT01154842|plasma FGF-23 levels
1200014|NCT01154842|echocardiography
1200015|NCT01154829|dopamine
1200016|NCT01154829|first episode
1200017|NCT01154829|reward
1200018|NCT01154829|cognition
1200019|NCT01154829|MRI
1200020|NCT01154829|fMRI
1200021|NCT01154829|PPI
1200022|NCT01154829|P300
1200023|NCT01154829|P50 gating
1200024|NCT01154829|endophenotypes
1200025|NCT01154803|Supplementation
1200026|NCT01154803|RUTF
1200027|NCT01154803|Micronutrients
1200028|NCT01154803|Plumpynut
1200029|NCT01154803|Mixme
1200030|NCT01154803|sprinkles
1200031|NCT01154803|convalescence
1200032|NCT01154803|weight
1200033|NCT01154803|morbidity
1200034|NCT01154790|healthy volunteers
1200035|NCT01154777|Neurofeedback
1200036|NCT01154777|Braintraining
1200037|NCT01154777|Autism
1200038|NCT01154777|Mild
1200039|NCT01154777|Moderate
1200040|NCT01154777|Mild to Moderate Autism
1200041|NCT01154764|healthy male volunteers
1200042|NCT01154751|Femoral artery stenosis
1200043|NCT01154751|Peripheral vascular Disease
1200044|NCT01154725|Patient education
1200045|NCT01154725|Health-Related Quality of Life
1200046|NCT01154725|patients with stomas
1200047|NCT01154725|stomatherapy
1200048|NCT01154725|health economics
1200049|NCT01154712|Gambling
1200050|NCT01154712|Deep TMS
1200051|NCT01154712|addiction
1200052|NCT01154712|Brain stimulation
1200053|NCT01154699|Asthma
1200054|NCT01154699|Nocturnal Asthma
1200055|NCT01154699|Lung volumes
1200056|NCT01154699|Deep inspiration
1200057|NCT01154699|Obstructive sleep apnea
1200058|NCT01154660|any operation that required for general anesthesia
1200059|NCT01154634|Pharmacodynamic effect
1200060|NCT01154634|Reflux inhibition
1200061|NCT01154621|Phase I
1200062|NCT01154621|Double-blind
1200063|NCT01154621|Randomized
1200064|NCT01154621|Placebo-controlled study
1200306|NCT01153568|osteoporosis
1200065|NCT01154621|Safety and tolerability of single intravenous dose of AZD9742 in healthy elderly volunteers
1200066|NCT01154608|Protein absorption in pancreatitis
1200067|NCT01154608|Protein metabolism in pancreatitis
1200068|NCT01154595|moderate acute malnutrition, prevention, Lipid-based supplement
1200069|NCT01154582|ingestive behavior
1200070|NCT01154569|drug absorption
1200071|NCT01154569|azithromycin
1200072|NCT01154569|obesity
1200073|NCT01154569|bariatric surgery
1200074|NCT01154556|Antiretroviral therapy experienced
1200075|NCT01154556|failed NNRTI regime
1200076|NCT01154543|Recurrent genital Herpes Simplex Virus
1200077|NCT01154530|Gastroscopy
1200078|NCT01154530|Bacteria
1200079|NCT01154530|Chlorhexidine
1200080|NCT01154530|General surgery
1200081|NCT01154504|adrenomedullin
1200082|NCT01154504|heart failure
1200083|NCT01154504|ultrafiltration
1200084|NCT01154504|hemofiltration
1200085|NCT01154491|hip fractures
1200086|NCT01154491|blood substitutes
1200087|NCT01154491|blood transfusion
1200088|NCT01154491|intravenous infusion
1200089|NCT01154491|erythropoietin, recombinant
1200090|NCT01154491|frail elderly
1200091|NCT01154478|polyphenols omega-3 postprandial lipemia adipose tissue
1200092|NCT01154465|Central venous catheterization
1200093|NCT01154465|Obese
1200094|NCT01154465|Ultrasound guidance
1200095|NCT01154465|Jugular
1200096|NCT01154465|Randomized
1200097|NCT01154465|Intensive Care Unit
1200098|NCT01154439|secondary acute myeloid leukemia
1200099|NCT01154439|untreated adult acute myeloid leukemia
1200100|NCT01154439|adult acute basophilic leukemia
1200101|NCT01154439|adult acute eosinophilic leukemia
1200102|NCT01154439|adult erythroleukemia (M6a)
1200103|NCT01154439|adult pure erythroid leukemia (M6b)
1200104|NCT01154439|adult acute megakaryoblastic leukemia (M7)
1200105|NCT01154439|adult acute minimally differentiated myeloid leukemia (M0)
1200106|NCT01154439|adult acute monoblastic leukemia (M5a)
1200107|NCT01154439|adult acute monocytic leukemia (M5b)
1200108|NCT01154439|adult acute myeloblastic leukemia with maturation (M2)
1200109|NCT01154439|adult acute myeloblastic leukemia without maturation (M1)
1200110|NCT01154439|adult acute myelomonocytic leukemia (M4)
1200111|NCT01154439|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1200112|NCT01154439|adult acute myeloid leukemia with inv(16)(p13;q22)
1200113|NCT01154439|adult acute myeloid leukemia with t(16;16)(p13;q22)
1200114|NCT01154439|adult acute myeloid leukemia with t(8;21)(q22;q22)
1200115|NCT01154400|casein protein
1200116|NCT01154400|whey protein
1200117|NCT01154400|hydrolysates
1200118|NCT01154400|leucine
1200119|NCT01154400|protein metabolism
1200120|NCT01154400|COPD
1200121|NCT01154387|Kidney
1200122|NCT01154387|Renal
1200123|NCT01154387|Transplant
1200124|NCT01154387|Kidney Transplant
1200125|NCT01154387|Kidney Failure
1200126|NCT01154387|Induction
1200127|NCT01154387|Monoclonal
1200128|NCT01154387|Antibody
1200129|NCT01154387|T cell
1200130|NCT01154387|Anti-rejection
1200131|NCT01154387|Immunosuppression
1200132|NCT01154374|Diabetic Foot Ulcers (DFUs)
1200133|NCT01154361|ACE inhibitor induced angioedema
1200134|NCT01154361|Bradykinin
1200135|NCT01154361|Non-itching edema
1200136|NCT01154361|Non-allergic angioedema
1200137|NCT01154361|Quincke edema
1200138|NCT01154361|Drug induced angioedema
1200139|NCT01154361|Bradykinin B2 receptor antagonist
1200140|NCT01154361|Icatibant
1200141|NCT01154361|HOE 140
1200142|NCT01154348|Metformin
1200143|NCT01154335|refractory metastatic colorectal cancer
1200144|NCT01154309|Depression
1200145|NCT01154309|Substance Use
1200146|NCT01154309|Group Cognitive Behavioral Therapy
1200147|NCT01154296|HIV
1200148|NCT01154296|Rapid Testing
1200149|NCT01154296|Counseling
1200150|NCT01154296|STD
1200151|NCT01154296|U.S.
1200152|NCT01154270|cancer of the salivary glands
1200153|NCT01154270|radiation
1200154|NCT01154270|carbon ion therapy
1200155|NCT01154257|Dental plaque
1200156|NCT01154257|Gingivitis
1200157|NCT01154244|Insulin resistance
1200158|NCT01154244|Insulin deficiency
1200159|NCT01154244|HOMA-IR
1200160|NCT01154244|Drug naive
1200161|NCT01154244|Diabetes mellitus, type II
1200162|NCT01154231|BeneFIX Regulatory Post Marketing Commitment Plan
1200163|NCT01154218|bioequivalence
1200164|NCT01154218|food effect
1200165|NCT01154218|pharmacokinetics
1200166|NCT01154218|crizotinib
1200167|NCT01154192|PCOS
1200168|NCT01154192|oligomenorrhea
1200169|NCT01154192|irregular menses
1200170|NCT01154192|hyperandrogenemia
1200171|NCT01154192|elevated testosterone
1200172|NCT01154192|adolescents
1200173|NCT01154192|androgens
1200174|NCT01154192|ovary
1200175|NCT01154192|LH
1200176|NCT01154179|permissive underfeeding
1200177|NCT01154179|hypocaloric feeding
1200178|NCT01154179|artificial nutrition
1200179|NCT01154140|open label
1200180|NCT01154140|randomized Phase 3
1200181|NCT01154140|first line treatment
1200182|NCT01154140|non squamous lung cancer
1200183|NCT01154140|ALK translocation event positive
1200184|NCT01154127|NVA237
1200185|NCT01154127|COPD
1200186|NCT01154127|bronchodilator
1200187|NCT01154127|exercise endurance
1200188|NCT01154114|healthy volunteer
1200189|NCT01154114|hepatic impairment
1200190|NCT01154114|darapladib
1200191|NCT01154114|atherosclerosis
1200192|NCT01154088|Adolescent
1200193|NCT01154088|Vaccine, conjugate
1200194|NCT01154088|Adult
1200195|NCT01154088|Neisseria meningitidis
1200196|NCT01154088|Immunogenicity
1200197|NCT01154088|Meningococcal vaccine
1200198|NCT01154088|Safety
1200199|NCT01154075|Liver transplant
1200200|NCT01154075|Adherence
1200201|NCT01154075|Compliance
1200202|NCT01154075|Tacrolimus
1200203|NCT01154062|age-related macular degeneration
1200204|NCT01154062|pazopanib
1200205|NCT01154062|choroidal neovascularization
1200206|NCT01154062|GW786034
1200207|NCT01154049|Schistosomiasis
1200208|NCT01154049|Vaccine
1200209|NCT01154049|sm14
1200210|NCT01154023|Sleep Initiation and Maintenance Disorders
1200211|NCT01154023|Behavior Therapy
1200212|NCT01154010|PEMF
1200213|NCT01154010|iritis
1200214|NCT01154010|anterior uveitis
1200215|NCT01153958|Vaginosis, Bacterial
1200216|NCT01153958|Colposeptine
1200217|NCT01153958|Metronidazole
1200218|NCT01153945|Hypothyroid and non hypothyroid
1200219|NCT01153932|968
1200220|NCT01153932|muscular dystrophy
1200221|NCT01153932|duchenne
1200222|NCT01153932|DMD
1200223|NCT01153906|autoimmune diseases
1200224|NCT01153906|HPV vaccine
1200225|NCT01153906|papillomavirus
1200226|NCT01153906|human papillomavirus
1200227|NCT01153906|HPV
1200228|NCT01153893|Pneumococcal disease
1200229|NCT01153893|Pneumococcal vaccine
1200230|NCT01153893|Catch-up vaccination
1200231|NCT01153893|Immunogenicity
1200232|NCT01153893|Booster vaccination
1200233|NCT01153893|Safety
1200234|NCT01153880|Altabax
1200235|NCT01153880|United States
1200236|NCT01153880|topical
1200237|NCT01153880|Mupirocin
1200238|NCT01153880|Retapamulin
1200239|NCT01153880|Bactroban
1200240|NCT01153867|Schema Focused Therapy
1200241|NCT01153867|Chronic Depression
1200242|NCT01153867|Mechanisms of Change
1200243|NCT01153854|acute diarrhea
1200244|NCT01153854|Acute diarrhea (three or more watery or semi-watery bowel movements for at least one day lasting no more than 5 days before being admitted)
1200245|NCT01153841|Pneumococcal vaccine
1200246|NCT01153828|Altargo
1200247|NCT01153828|Bactroban
1200248|NCT01153828|Fucidin
1200249|NCT01153828|Fusidic acid
1200250|NCT01153828|Mupirocin
1200251|NCT01153828|topical
1200252|NCT01153828|Retapamulin
1200253|NCT01153828|United Kingdom
1200266|NCT01153789|Vergence-accommodation evaluation
1200267|NCT01153789|Vergence and postural control
1200268|NCT01153789|Dynamic visual acuity
1200273|NCT01153763|Metastatic melanoma
1200274|NCT01153763|BRAF mutant
1200275|NCT01153763|Melanoma
1200276|NCT01153763|BRAF mutant metastatic melanoma
1200277|NCT01153750|cholangiocellular carcinoma
1200278|NCT01153750|bile duct cancer
1200279|NCT01153737|Neck pain
1200280|NCT01153737|Primary Health Care
1200281|NCT01153737|Manual Therapy
1200282|NCT01153737|TENS
1200283|NCT01153685|Fluviral®Influenza
1200284|NCT01153659|rabeprazole
1200285|NCT01153659|esomeprazole
1200286|NCT01153659|h. pylori-negative
1200287|NCT01153659|nocturnal acid breakthrough
1200288|NCT01153659|intragastric pH, PK/PD
1200289|NCT01153659|effect on gastric pH in healthy, H. pylori-Negative subjects
1200290|NCT01153646|HIV
1200291|NCT01153646|Gene Transfer
1200292|NCT01153646|T-Cell Immunotherapy
1200293|NCT01153646|HIV-1 infected patients who have failed anti-retroviral therapy
1200294|NCT01153620|Acute traumatic wounds
1200295|NCT01153607|Alzheimer's disease
1200296|NCT01153607|Diagnostic imaging
1200297|NCT01153607|PET diagnosis
1200298|NCT01153607|PET tracer
1200299|NCT01153594|Substance Use Disorders
1200300|NCT01153594|Relapse
1200301|NCT01153594|Recovery
1200302|NCT01153594|Disease Management
1200303|NCT01153594|Long term outcomes
1200304|NCT01153594|Addiction Treatment
1200305|NCT01153568|Vitamin D
1200307|NCT01153568|african american women
1200308|NCT01153529|PTSD
1200309|NCT01153516|Type 2 diabetes
1200310|NCT01153516|Bariatric surgery
1200311|NCT01153516|Obesity
1200312|NCT01153516|Weight loss
1200313|NCT01153503|Postoperative pain, TAP block, Hysterectomy
1200314|NCT01153490|Quetiapine
1200315|NCT01153490|Psychotic experiences
1200316|NCT01153490|Cannabis dependence
1200317|NCT01153490|Craving
1200318|NCT01153490|Mood
1200319|NCT01153490|Substance use
1200320|NCT01153451|Pending tests
1200321|NCT01153451|Discharge
1200322|NCT01153451|Awareness
1200323|NCT01153451|Care transitions
1200324|NCT01153438|Diabetes
1200325|NCT01153438|Obesity
1200326|NCT01153438|Bariatric surgery
1200327|NCT01153438|Gut hormones
1200328|NCT01153438|Glucagon like peptide 1
1200329|NCT01153438|Insulin
1200330|NCT01153425|Osteoporosis
1200331|NCT01153425|Osteopenia
1200332|NCT01153425|Fracture Risk
1200333|NCT01153425|teriparatide or Forteo
1200334|NCT01153425|zoledronic acid or Reclast
1200335|NCT01153399|Non Small Cell Lung Cancer
1200336|NCT01153399|EGFR mutations
1200337|NCT01153386|Pulmonary arterial hypertension
1200338|NCT01153386|Treprostinil
1200339|NCT01153386|Pharmacokinetics
1200340|NCT01153373|Detection of tobacco, alcohol, and drug use.
1200341|NCT01153347|Major Depressive Disorder
1200342|NCT01153347|MDD
1200343|NCT01153347|Depression
1200344|NCT01153347|Safety
1200345|NCT01153347|add-on therapy
1200346|NCT01153321|Respiratory disease
1200347|NCT01153321|chronic obstructive pulmonary disease
1200348|NCT01153308|Morbid Obesity
1200349|NCT01153308|Obesity
1200350|NCT01153308|Weight Loss
1200351|NCT01153308|Bariatric Surgery
1200352|NCT01153295|IBS
1200353|NCT01153295|Irritable bowel syndrome
1200354|NCT01153295|diagnosis
1200355|NCT01153295|safety
1200356|NCT01153295|Health related quality of life
1200357|NCT01153282|Breast Cancer patients
1200358|NCT01153269|Human Immunodeficiency Virus
1200359|NCT01153269|Co-infection with Hepatitis B or Hepatitis C
1200360|NCT01153269|Tolerability
1200361|NCT01153269|Effectiveness
1200362|NCT01153243|inflammatory markers
1200363|NCT01153230|PQ
1200364|NCT01153217|Tenofovir
1200365|NCT01153217|HIV-infection
1200366|NCT01153217|BMD
1200367|NCT01153217|Osteoporosis
1200368|NCT01153217|Osteopenia
1200369|NCT01153204|Erectile Dysfunction
1200370|NCT01153204|Group Psychotherapy
1200371|NCT01153204|Sildenafil [Substance Name]
1200372|NCT01153204|Patient Satisfaction
1200373|NCT01153204|Efficacy
1200374|NCT01153204|Randomized Controlled Trial [Publication Type]
1200375|NCT01153191|colorectal surgery
1200376|NCT01153165|Refractory
1200377|NCT01153165|Asthma
1200378|NCT01153165|Depression
1200379|NCT01153152|wisdom teeth
1200380|NCT01153152|acute pulpitis
1200381|NCT01153152|extraction
1200382|NCT01153152|pain
1200383|NCT01153152|Pain Following Removal of Wisdom Teeth with Acute Pulpitis
1200384|NCT01153139|Transcranial Magnetic Stimulation
1200385|NCT01153139|Depression
1200386|NCT01153139|Theta Burst Stimulation
1200387|NCT01153126|Diagnostic Imaging
1200388|NCT01153126|Breast Screening
1200389|NCT01153126|Breast Cancer
1200390|NCT01153126|To be eligible for the study, subjects must:
1200391|NCT01153126|Be females at least 18 years of age,
1200392|NCT01153126|Have had their screening mammogram performed at the UW Breast Center,
1200393|NCT01153126|Be able to read and write English at the 6th grade level (as shown by their, ability to understand the informed consent),
1200394|NCT01153126|Have access to a computer with internet capability.
1200395|NCT01153113|adenocarcinoma of the prostate
1200396|NCT01153113|metastatic prostate adenocarcinoma, Stage (T1-4, N+, M0) or (T1-4, N0-3, M+)
1200397|NCT01153113|rising PSA levels while maintained on LHRH analogues
1200398|NCT01153100|Diabetes
1200399|NCT01153074|Bronchopleural fistula
1200400|NCT01153074|Bronchoscopy
1200401|NCT01153048|Intensification of Education
1200402|NCT01153048|learning nest methodology
1200403|NCT01153048|peer educators
1200404|NCT01153048|type 2 diabetes
1200405|NCT01153048|Mali
1200406|NCT01153048|the focus of this study is on the intensification of education on the treatment of type 2 diabetes
1200407|NCT01153035|Breast Conservation Therapy
1200408|NCT01153035|Lumpectomy
1200409|NCT01153035|Radiofrequency Ablation
1200410|NCT01153035|Radiation
1200411|NCT01153022|Musculoskeletal manipulations
1200412|NCT01153022|Muscle spasticity
1200413|NCT01153009|Major Depressive Disorder
1200414|NCT01153009|Depression
1200415|NCT01153009|Melancholia
1200416|NCT01153009|Drug Therapy
1200417|NCT01152996|Depression
1200418|NCT01152996|Melancholia
1200419|NCT01152996|Paraphrenia
1200420|NCT01152996|Drug Therapy
1200421|NCT01152983|Finger sticks
1200422|NCT01152983|Rapid Ring
1200423|NCT01152983|Finger sticks method of obtaining blood for diagnostic testing
1200424|NCT01152957|diabetes
1200425|NCT01152957|cardiovascular
1200426|NCT01152957|chronic
1200427|NCT01152957|Community Health Workers
1200428|NCT01152957|behavioral
1200429|NCT01152957|social
1200430|NCT01152957|diet
1200431|NCT01152957|exercise
1200432|NCT01152957|patient
1200433|NCT01152957|cholesterol
1200434|NCT01152957|A1C
1200435|NCT01152957|glucose
1200436|NCT01152944|Symptomatic intracranial atherosclerotic disease enrolled in the medical arm of SAMMPRIS
1200437|NCT01152931|Antioxidants
1200438|NCT01152931|Micronutrients
1200439|NCT01152931|Malaria
1200440|NCT01152931|focus is to determine the effect of antioxidant micronutrients in malaria
1200441|NCT01152918|HIV Prevention
1200442|NCT01152918|HIV Treatment
1200443|NCT01152918|HIV Test and Treat Model of Prevention
1200444|NCT01152918|ART for Prevention
1200445|NCT01152918|Prevention for HIV Positives
1200446|NCT01152918|Financial Incentives
1200447|NCT01152918|Computer-delivered risk-reduction counseling
1200448|NCT01152905|Neuromuscular blockade
1200449|NCT01152905|Neuromuscular blocking agents
1200450|NCT01152905|Atracurium
1200451|NCT01152905|Nitrous oxide
1200452|NCT01152892|end stage renal disease
1200453|NCT01152892|chronic kidney disease
1200454|NCT01152892|cardiovascular event
1200455|NCT01152892|sudden cardiac death
1200456|NCT01152892|autonomic function
1200457|NCT01152879|Parenteral Nutrition
1200458|NCT01152879|Quality of Life
1200459|NCT01152866|Multifollicular stimulation
1200460|NCT01152866|Pregnancy
1200461|NCT01152866|Reproductive Techniques, Assisted
1200462|NCT01152866|Fertilization in Vitro
1200463|NCT01152866|Infertility
1200464|NCT01152853|advanced gastric cancer
1200465|NCT01152853|HER2
1200466|NCT01152853|PF00299804
1200467|NCT01152840|Adenoid cystic carcinoma
1200468|NCT01152840|RAD001
1200469|NCT01152827|Pheochromocytoma
1200470|NCT01152827|extra-adrenal paraganglioma
1200471|NCT01152827|non-functioning carcinoid
1200472|NCT01152827|RAD001
1200473|NCT01152814|Seasonal influenza
1200474|NCT01152814|Vaccine
1200475|NCT01152801|mRCC,
1200476|NCT01152801|everolimus,
1200477|NCT01152801|mTOR,
1200478|NCT01152801|intolerant of VEGF-therapies
1200479|NCT01152775|partnered surgical decision-making
1200480|NCT01152775|impact of multimedia-based teaching
1200481|NCT01152775|patient education
1200482|NCT01152775|understanding and retention by patients
1200483|NCT01152762|Physiotherapy, COPD, effectiveness, primary care
1200484|NCT01152749|Smoking Cessation
1200485|NCT01152749|Nicotine pharmacokinetics
1200486|NCT01152736|Smoking Cessation, Nicotine pharmacokinetics
1200487|NCT01152723|Smoking Cessation, Nicotine pharmacokinetics
1200488|NCT01152710|capecitabine
1200489|NCT01152710|chemoradiation
1200490|NCT01152710|rectal cancer
1200491|NCT01152710|phase II study
1200492|NCT01152697|nonadherence
1200493|NCT01152697|noncompliance
1200494|NCT01152697|homeless
1200495|NCT01152697|schizophrenia
1200496|NCT01152697|schizoaffective
1200497|NCT01152684|CAM
1200498|NCT01152684|HIV-Positive
1200499|NCT01152684|Latinos
1200500|NCT01152684|US-Mexico Border region
1200501|NCT01152684|San Diego-Tijuana
1200502|NCT01152684|Identify the nature and extent of complementary and alternative medicine use among HIV-positive Latinos in the US-Mexico border region
1200503|NCT01152658|Partial supraspinatus tear
1200504|NCT01152658|partial tear ssp per echo
1200505|NCT01152645|Advanced/recurrent gastric cancer
1200506|NCT01152632|acupuncture
1200507|NCT01152632|migraine
1200508|NCT01152632|specific acupoints
1200509|NCT01152632|brain network
1200510|NCT01152580|melatonin
1200511|NCT01152580|menopause
1200512|NCT01152580|perimenopause
1200513|NCT01152580|sleep
1200514|NCT01152580|osteoporosis
1200515|NCT01152580|osteopenia
1200516|NCT01152580|anxiety
1200517|NCT01152580|depression
1200518|NCT01152580|hypertension
1200519|NCT01152567|Hypertension
1200520|NCT01152567|ACE
1200521|NCT01152567|ARB
1200522|NCT01152567|real life data
1200523|NCT01152567|CVD
1200524|NCT01152567|cost effectiveness
1200525|NCT01152554|Major Depressive Disorder
1200526|NCT01152554|MDD
1200527|NCT01152554|Depression
1200528|NCT01152554|Safety
1200529|NCT01152554|add-on therapy
1200530|NCT01152541|Keratoconus
1200531|NCT01152541|Corneal Ectasia
1200532|NCT01152541|Collagen Crosslinking
1200533|NCT01152541|Riboflavin
1200534|NCT01152528|bacterial vaginosis
1200535|NCT01152528|screening
1200536|NCT01152528|abortion
1200537|NCT01152528|preterm delivery
1200538|NCT01152515|safety and efficacy of maintaining a remifentanil infusion during extubation in propofol-remifentanil sedated patients after surgery
1200539|NCT01152502|Post operative conditions, paracetamol metabolites
1200540|NCT01152489|Pain
1200541|NCT01152476|healthy pediatric patients undergoing tonsillectomy and adenoidectomy
1200542|NCT01152463|thoracic ultrasound (US)
1200543|NCT01152463|post-op care
1200544|NCT01152463|pneumothorax
1200545|NCT01152463|pleural effusion
1200546|NCT01152424|Acute eosinophilic pneumonia
1200547|NCT01152424|Exhaled nitric oxide
1200548|NCT01152411|Renal Failure
1200549|NCT01152411|Chronic Kidney Disease
1200550|NCT01152411|Chronic Renal Failure
1200551|NCT01152398|Breast cancer
1200552|NCT01152398|Vaccine
1200553|NCT01152398|Metastatic
1200554|NCT01152398|HER-2-positive
1200555|NCT01152398|Phase I
1200556|NCT01152398|HER-2 Positive Breast Cancer
1200557|NCT01152385|Type 2 diabetes mellitus
1200558|NCT01152385|Japanese
1200559|NCT01152385|phase 2
1200560|NCT01152385|AZD1656
1200561|NCT01152385|efficacy
1200562|NCT01152385|dose regimen
1200563|NCT01152385|pharmacokinetics
1200564|NCT01152359|obesity
1200565|NCT01152359|diet, low carbohydrate
1200566|NCT01152359|diet, fat-restricted
1200567|NCT01152359|food preferences
1200568|NCT01152359|quality of life
1200569|NCT01152359|patient compliance
1200570|NCT01152346|Bioequivalence
1200571|NCT01152346|Myelodysplastic Syndrome
1200572|NCT01152346|MDS
1200573|NCT01152346|Azacitidine
1200574|NCT01152320|Asthma
1200575|NCT01152320|Spirometry
1200576|NCT01152320|Pediatric
1200577|NCT01152320|Primary Health Care
1200578|NCT01152320|Education, Distance
1200579|NCT01152307|Depression
1200580|NCT01152307|Depressive disorder
1200581|NCT01152307|Decision Making
1200582|NCT01152307|Decision Aids
1200583|NCT01152307|Decision Quality Instrument
1200584|NCT01152294|Menopause
1200585|NCT01152294|Decision making
1200586|NCT01152294|Decision aids
1200587|NCT01152294|Decision quality instrument
1200588|NCT01152281|retention
1200589|NCT01152281|attrition
1200590|NCT01152281|empowering
1200591|NCT01152281|reactance
1200592|NCT01152281|motivational
1200593|NCT01152281|goals
1200594|NCT01152281|Basic control
1200595|NCT01152281|Control with stories of people with AIDS
1200596|NCT01152281|Instrumental
1200597|NCT01152281|Instrumental and Empowering
1200598|NCT01152268|sperm banking
1200599|NCT01152268|Adolescent males
1200600|NCT01152268|Infertility
1200601|NCT01152268|Adolescents diagnosed with cancer
1200602|NCT01152255|Treatment of HIV-1 Infection
1200603|NCT01152242|Insulin
1200604|NCT01152203|Bendamustine
1200605|NCT01152203|Bevacizumab
1200606|NCT01152177|Heading Health Plan Implementation
1200607|NCT01152177|General Practice
1200608|NCT01152177|Point of care testing
1200609|NCT01152177|education
1200610|NCT01152164|quality of life
1200611|NCT01152164|rectal cancer
1200612|NCT01152151|Heading Health Plan Implementation
1200613|NCT01152151|General Practice
1200614|NCT01152151|Point of care testing
1200615|NCT01152151|education
1200616|NCT01152138|Acute myocardial infarction
1200617|NCT01152138|Closed cell stent
1200618|NCT01152138|Open cell stent
1200619|NCT01152138|primary percutaneous coronary intervention
1200620|NCT01152125|Osteoarthritis
1200621|NCT01152125|stem cell implantation
1200622|NCT01152125|bone marrow
1200623|NCT01152125|autologous
1200624|NCT01152112|morcellator
1200625|NCT01152112|hysteroscope
1200626|NCT01152112|myomectomy
1200627|NCT01152112|polypectomy
1200628|NCT01152112|uterine fibroids
1200629|NCT01152112|uterine polyps
1200630|NCT01152112|office
1200631|NCT01152112|cost
1200632|NCT01152112|local anesthetic
1200633|NCT01152112|cervical block
1200634|NCT01152112|pain management
1200635|NCT01152099|Postmastectomy
1200636|NCT01152086|Physical activity
1200637|NCT01152086|mountain hiking
1200638|NCT01152086|exercise
1200639|NCT01152086|training program
1200640|NCT01152086|hopelessness
1200641|NCT01152086|chronic suicidality
1200642|NCT01152086|depression
1200643|NCT01152086|suicide attempt
1200644|NCT01152086|suicide
1200645|NCT01152073|Cholesterol
1200646|NCT01152073|Statin
1200647|NCT01152073|Nutraceuticals
1200648|NCT01152073|Niacin
1200649|NCT01152073|Hyperlipidemia
1200650|NCT01152073|Liquid
1200651|NCT01152060|remission of proteinuria
1200652|NCT01152060|HBVe-antigen
1200653|NCT01152047|oxytocin
1200654|NCT01152047|satiety
1200655|NCT01152047|dyspepsia
1200656|NCT01152034|Bipolar disorder
1200657|NCT01152034|psychosocial intervention
1200658|NCT01152034|group therapy
1200659|NCT01152034|relapse prevention
1200660|NCT01152034|parasuicide
1200661|NCT01152034|Recurrence
1200662|NCT01152034|hospitalization
1200663|NCT01152034|Medication adherence
1200664|NCT01152034|Self-Injurious Behavior
1200665|NCT01152034|Quality of Life
1200666|NCT01152021|dexmedetomidine
1200667|NCT01152021|propofol
1200668|NCT01152021|sedation
1200669|NCT01152021|MRI
1200670|NCT01152021|scanning
1200671|NCT01152021|pediatric
1200672|NCT01152021|children
1200673|NCT01152021|Magnetic Resonance Imaging
1200674|NCT01152008|Microcirculation
1200675|NCT01152008|laser flowmetry
1200676|NCT01152008|Skin
1200677|NCT01152008|Physiology
1200678|NCT01151995|Clinical Trial Monitoring
1200679|NCT01151995|Effectiveness of remote monitoring
1200680|NCT01151995|Efficiency of remote monitoring
1200681|NCT01151995|Costs of remote monitoring
1200682|NCT01151982|Depression
1200683|NCT01151982|Primary prevention.
1200684|NCT01151982|Primary health care.
1200685|NCT01151982|Randomised controlled trial.
1200686|NCT01151969|Health Service Misuse
1200687|NCT01151969|Overutilization of Health Services
1200688|NCT01151969|Primary Health Care
1200689|NCT01151969|Cost Effectiveness
1200690|NCT01151969|Quality of life
1200691|NCT01151969|Randomised Controlled Trial
1200692|NCT01151969|Multilevel analysis
1200693|NCT01151956|observational study
1200694|NCT01151956|actinic keratosis
1200695|NCT01151956|imiquimod
1200696|NCT01151943|cesarean section
1200697|NCT01151943|continuous wound infiltration
1200698|NCT01151943|transversus abdominis plane block
1200699|NCT01151930|Advanced solid tumor failed with standard therapy
1200700|NCT01151917|Bilio-pancreatic diversion
1200701|NCT01151917|morbid obesity
1200702|NCT01151917|insulin resistance
1200703|NCT01151917|proteomics
1200704|NCT01151891|Pedal puncture wounds
1200705|NCT01151891|Infection in pedal puncture wounds
1200706|NCT01151891|Diabetes education and pedal puncture wounds
1200707|NCT01151878|constipation
1200708|NCT01151878|children
1200709|NCT01151865|Delirium
1200710|NCT01151865|Intensive Care Unit
1200711|NCT01151865|Dexmedetomidine
1200712|NCT01151852|Imatinib
1200713|NCT01151852|Re-challenge
1200714|NCT01151839|Esophagus
1200715|NCT01151839|squamous cell carcinoma
1200716|NCT01151839|neoadjuvant chemoradiation
1200717|NCT01151826|Lung transplantation
1200718|NCT01151826|Primary Graft Dysfunction
1200719|NCT01151826|Extravascular Lung Water
1200720|NCT01151826|Receptor for Advanced Glycation Endproducts (RAGE)
1200721|NCT01151826|Intercellular Adhesion Molecule-1 (ICAM-1)
1200722|NCT01151800|ACS
1200723|NCT01151800|Interactive Voice Response Technology
1200724|NCT01151800|Best Practice Guidelines
1200725|NCT01151800|Health Care Utilization
1200726|NCT01151800|Outcome Assessment
1200727|NCT01151787|migraine
1200728|NCT01151735|Angioedema
1200729|NCT01151735|Hereditary Diseases
1200730|NCT01151735|Orphan Disease
1200731|NCT01151735|HAE
1200732|NCT01151709|Gout
1200733|NCT01151709|Chronic condition management
1200734|NCT01151709|Gout management
1200735|NCT01151696|Pain
1200736|NCT01151696|morphine
1200737|NCT01151696|hydroxyzine
1200738|NCT01151696|acute pain
1200739|NCT01151696|traumatic pain
1200740|NCT01151696|anxiety
1200741|NCT01151696|post trauma stress
1200742|NCT01151696|post trauma anxiety
1200743|NCT01151696|post trauma disorders
1200744|NCT01151683|hypertension
1200745|NCT01151683|endothelial dysfunction
1200746|NCT01151670|radiation therapy
1200747|NCT01151670|cognitive dysfunction
1200748|NCT01151670|brain tumor
1200749|NCT01151670|memory problems
1200750|NCT01151670|short term memory loss
1200751|NCT01151657|IBS
1200752|NCT01151657|Irritable bowel syndrome
1200753|NCT01151657|Probiotics
1200754|NCT01151657|Treatment
1200755|NCT01151657|Adequate relief
1200756|NCT01151644|H1N1 VACCINE
1200757|NCT01151644|INFLUENZA
1200758|NCT01151644|RHEUMATIC DISEASES
1200759|NCT01151644|ANTI-H1N1 IMMUNIZATION
1200760|NCT01151592|Iron deficiency anemia in Chronic Kidney Disease Patients
1200761|NCT01151579|Tachycardia
1200762|NCT01151579|tachyarrhythmias
1200763|NCT01151579|bronchodilator therapy
1200764|NCT01151579|Critically ill patients
1200765|NCT01151566|Ultrasound
1200766|NCT01151566|Contrast enhanced Ultrasound (CEUS)
1200767|NCT01151566|Nephrotoxicity
1200768|NCT01151566|CT contrast agents
1200769|NCT01151553|Cardiology
1200770|NCT01151553|Cardiomyopathy
1200771|NCT01151553|Cardiovascular Disease
1200772|NCT01151553|Cardiac Resynchronization Therapy (CRT)
1200773|NCT01151540|Epilepsy
1200774|NCT01151540|Seizures
1200775|NCT01151514|No referral
1200776|NCT01151514|Late referral
1200777|NCT01151514|Acute kidney injury
1200778|NCT01151514|Intensive care unit
1200779|NCT01151514|In-hospital mortality
1200780|NCT01151514|Renal outcome
1200781|NCT01151514|Requirement for renal replacement therapy
1200782|NCT01151514|Length of hospital stay
1200783|NCT01151514|Impact
1200784|NCT01151514|Incidence
1200785|NCT01151501|acute hypoxemic respiratory failure
1200786|NCT01151501|intermittent positive-pressure ventilation
1200787|NCT01151501|noninvasive positive pressure ventilation
1200788|NCT01151501|ventilator weaning
1200789|NCT01151475|liver cirrhosis
1200790|NCT01151475|hepatic encephalopathy
1200791|NCT01151475|ammonia
1200792|NCT01151475|cerebral blood flow
1200793|NCT01151462|Postnatal HCMV infection in very preterm infants
1200794|NCT01151462|Neurodevelopmental disabilities
1200795|NCT01151462|Hearing loss
1200796|NCT01151462|Mental retardation
1200797|NCT01151462|Microcephaly
1200798|NCT01151462|Chorioretinitis
1200799|NCT01151462|Growth
1200800|NCT01151436|Facial wrinkle correction
1200801|NCT01151410|Pediatric hypertension
1200802|NCT01151410|primary hypertension
1200803|NCT01151410|secondary
1200804|NCT01151410|hypertension
1200805|NCT01151397|SVR
1200806|NCT01151397|VITAMIN D
1200807|NCT01151397|Hepatitis C
1200808|NCT01151397|Genotype 2,3
1200809|NCT01151397|Naive
1200810|NCT01151397|RVR
1200811|NCT01151384|Cancer Patients
1200812|NCT01151358|radioimmunotherapy
1200813|NCT01151358|follicular non-Hodgkin´s lymphoma
1200814|NCT01151358|FDG-PET
1200815|NCT01151358|prognostic factors
1200816|NCT01151358|multicenter study
1200817|NCT01151345|diltiazem
1200818|NCT01151345|angiotrofin
1200819|NCT01151345|bioequivalence
1200820|NCT01151293|Type D personality
1200821|NCT01151293|diabetes
1200822|NCT01151293|medical compliance
1200823|NCT01151293|HbA1c
1200824|NCT01151293|complication
1200825|NCT01151293|mortality
1200826|NCT01151293|T2DM
1200827|NCT01151267|Isocapnic hyperpnoea (IH)
1200828|NCT01151267|Anesthesia
1200829|NCT01151267|Accelerate elimination of inhalation agents
1200830|NCT01151267|Recovery from anesthesia
1200831|NCT01151254|Cardiac Surgery
1200832|NCT01151254|Sedation
1200833|NCT01151254|Intensive care
1200834|NCT01151254|Volatile anesthesia
1200835|NCT01151254|Intravenous anesthesia
1200836|NCT01151254|Pre and post conditioning after cardiac surgery
1200837|NCT01151241|elbow surgery
1200838|NCT01151241|infraclavicular nerve block
1200839|NCT01151241|continuous passive motion
1200840|NCT01151241|ultrasound guided regional anesthesia
1200841|NCT01151241|early discharge
1200842|NCT01151228|gastroscopy
1200843|NCT01151228|ultrasound
1200844|NCT01151228|stomach volume
1200845|NCT01151228|patients having gastroscopy
1200846|NCT01151215|Cancer
1200847|NCT01151215|tumour
1200848|NCT01151215|breast cancer
1200849|NCT01151215|metastatic
1200850|NCT01151215|secondary
1200851|NCT01151215|locally advanced
1200852|NCT01151202|acute upper respiratory tract infection, chronic inflamatory bronchitis
1200853|NCT01151189|HIV
1200854|NCT01151189|Tuberculosis
1200855|NCT01151189|Vaccine
1200856|NCT01151176|Intensive Insulin Therapy
1200857|NCT01151176|Glucose control
1200858|NCT01151176|Acute Coronary Syndrome
1200859|NCT01151176|Intensive Care
1200860|NCT01151163|Fibromyalgia, Peripheral arterial tonometry, sleep
1200861|NCT01151111|Parkinson's disease
1200862|NCT01151111|Relaxation
1200863|NCT01151111|Visual imagery
1200864|NCT01151111|Motor fluctuations
1200865|NCT01151111|Treatment
1200866|NCT01151098|Chronic nonmalignant pain
1200867|NCT01151098|Opioid
1200868|NCT01151098|Transdermal
1200869|NCT01151098|Butrans (BTDS)
1200870|NCT01151085|Systemic Mycosis
1200871|NCT01151085|Aspergillus infection
1200872|NCT01151085|Candidiasis
1200873|NCT01151085|Cryptococcal infections
1200874|NCT01151085|Japanese
1200875|NCT01151085|voriconazole
1200876|NCT01151085|VFEND
1200877|NCT01151085|Regulatory Post Marketing Commitment Plan.
1200878|NCT01151059|seasonal influenza
1200879|NCT01151059|vaccine
1200880|NCT01151046|Breast Cancer
1200881|NCT01151046|Her2 negative
1200882|NCT01151046|Estrogen Receptor Positive
1200883|NCT01151046|Progesterone Receptor Positive
1200884|NCT01151046|MM-121
1200885|NCT01151046|Exemestane
1200886|NCT01151046|Postmenopausal Women
1200887|NCT01151033|ProNOVA XR Polymer Free Drug Eluting Coronary Stent System
1200888|NCT01151033|DES
1200889|NCT01151033|stent
1200890|NCT01151033|coronary artery lesions
1200891|NCT01151033|ProNOVA
1200892|NCT01151033|stent implantation
1200893|NCT01151020|Aortic Aneurysm
1200894|NCT01151020|Aneurysm
1200895|NCT01151020|Vascular Prosthesis
1200896|NCT01151020|Vascular Disease
1200897|NCT01151020|Blood Vessel Prosthesis Implantation
1200898|NCT01151007|Kras mutation
1200899|NCT01151007|colorectal carcinoma
1200900|NCT01151007|Martinique
1200901|NCT01150994|Suicide screening among ED patients
1200902|NCT01150955|Resveratrol
1200903|NCT01150955|Diabetes
1200904|NCT01150955|SIRT1
1200905|NCT01150955|STAT5
1200906|NCT01150955|IGF-I
1200907|NCT01150955|Growth hormone
1200908|NCT01150955|NAFLD
1200909|NCT01150955|Longevity
1200910|NCT01150955|Substrate metabolism
1200911|NCT01150955|Calorie restriction
1200912|NCT01150942|JEV
1200913|NCT01150942|vero cell
1200914|NCT01150929|Knee arthroplasty
1200915|NCT01150929|RSA
1200916|NCT01150929|DXA
1200917|NCT01150929|Gait analysis
1200918|NCT01150929|Motion analysis
1200919|NCT01150916|natriuretic peptide
1200920|NCT01150916|heart failure
1200921|NCT01150916|ascites
1200922|NCT01150916|liver cirrhosis
1200923|NCT01150903|erectile dysfunction
1200924|NCT01150903|phosphodiesterase inhibitor
1200925|NCT01150903|cardiovascular diseases
1200926|NCT01150890|Ileal Crohn's Disease
1200927|NCT01150890|Ileo-colonic Crohn's Disease
1200928|NCT01150890|Colonic Chron's Disease
1200929|NCT01150877|Vitamin D
1200930|NCT01150877|Vitamin D3
1200931|NCT01150877|colon cancer
1200932|NCT01150877|rectal cancer
1200933|NCT01150877|Cholecalciferol
1200934|NCT01150864|Hot water humidifier, Passive heat and moisture exchangers
1200935|NCT01150838|intubation of children without neuromuscular blockade
1200936|NCT01150825|STEMI
1200937|NCT01150825|NSTEMI
1200938|NCT01150825|acute ischemia
1200939|NCT01150825|non-invasive diagnosis
1200940|NCT01150825|elevated troponin
1200941|NCT01150812|First time in man
1200942|NCT01150812|healthy
1200943|NCT01150812|thrombin inhibitor
1200944|NCT01150786|inflammation
1200945|NCT01150786|oxidative stress
1200946|NCT01150786|selenium
1200947|NCT01150786|hemodialysis
1200948|NCT01150760|GI recovery after bowel resection
1200949|NCT01150760|morbidity after bowel resection
1200950|NCT01150760|mortality
1200951|NCT01150760|readmission
1200952|NCT01150760|length of stay
1200953|NCT01150734|differences of Muscle evoked potentials (MEP) in psychiatric illnesses
1200954|NCT01150734|differences in neuromodulation
1200955|NCT01150734|normalization of neuromodulation after pharmacological treatment
1200956|NCT01150721|Atypical Mycobacterium Infection
1200957|NCT01150721|Microbial Tests
1200958|NCT01150721|Molecular Tests
1200959|NCT01150721|Inflammation
1200960|NCT01150721|Respiratory Secretions
1200961|NCT01150708|Syringomyelia
1200962|NCT01150708|Magnetic Resonance Imaging
1200963|NCT01150708|Natural History Study
1200964|NCT01150708|Neurological Examination
1200965|NCT01150695|vaccine, Francisella tularensis, Tularemia, rabbit fever, parent protocol
1200966|NCT01150682|endometrial adenocarcinoma
1200967|NCT01150682|stage II endometrial carcinoma
1200968|NCT01150682|stage III endometrial carcinoma
1200969|NCT01150682|stage IV endometrial carcinoma
1200970|NCT01150682|endometrial adenosquamous cell carcinoma
1200971|NCT01150682|endometrial clear cell carcinoma
1200972|NCT01150682|endometrial papillary serous carcinoma
1200973|NCT01150656|childhood acute myeloid leukemia/other myeloid malignancies
1200974|NCT01150643|stage III grade 1 follicular lymphoma
1200975|NCT01150643|stage III grade 2 follicular lymphoma
1200976|NCT01150643|stage IV grade 1 follicular lymphoma
1200977|NCT01150643|stage IV grade 2 follicular lymphoma
1200978|NCT01150630|adenocarcinoma of the pancreas
1200979|NCT01150630|stage I pancreatic cancer
1200980|NCT01150630|stage II pancreatic cancer
1200981|NCT01150617|Type 2 diabetes mellitus
1200982|NCT01150617|Normoglycemia
1200983|NCT01150617|Peripheral angioplasty
1200984|NCT01150604|Cognitive Behavioral Therapy
1200985|NCT01150604|Mood Management
1200986|NCT01150604|Self-help
1200987|NCT01150604|Internet
1200988|NCT01150578|Echocardiography, 2D
1200989|NCT01150578|speckle tracking
1200990|NCT01150578|Lexiscan
1200991|NCT01150578|regadenoson
1200992|NCT01150578|Myocardial ischemia
1200993|NCT01150578|Myocardial perfusion imaging
1200994|NCT01150578|cost and cost analysis
1200995|NCT01150578|Cardiac-Gated SPECT Imaging
1200996|NCT01150578|Echocardiography
1200997|NCT01150552|Serology
1200998|NCT01150552|Poultry
1200999|NCT01150552|H5N1 virus
1201000|NCT01150552|HPAI virus
1201001|NCT01150526|Acute Exercise
1201002|NCT01150526|Muscle Inflammation
1201003|NCT01150526|CaHMB
1201004|NCT01150526|HMB Free Acid Gel
1201005|NCT01150526|Healthy Subjects
1201006|NCT01150513|TRIPLE-NEGATIVE
1201007|NCT01150513|BREAST CANCER
1201008|NCT01150500|Medtronic
1201009|NCT01150500|Japan
1201010|NCT01150500|Arterial Occlusive Diseases
1201011|NCT01150500|Myocardial Ischemia
1201012|NCT01150500|Cardiovascular Diseases
1201013|NCT01150500|Coronary Artery Disease
1201014|NCT01150500|Small Vessel Stent
1201015|NCT01150487|kidney transplant
1201016|NCT01150474|Belladonna
1201017|NCT01150474|Morphine
1201018|NCT01150474|Suppositories
1201019|NCT01150474|Vaginal
1201020|NCT01150474|Surgery
1201021|NCT01150474|Postoperative
1201022|NCT01150474|Pain
1201023|NCT01150461|Hypertrophic nonobstructive cardiomyopathy
1201024|NCT01150448|Paliperidone palmitate
1201025|NCT01150448|paliperidone ER (INVEGA)
1201026|NCT01150448|R092670PSY1008
1201027|NCT01150448|Risperidone
1201028|NCT01150448|Risperdal (RISPERDAL CONSTA)
1201029|NCT01150448|Pharmacokinetics
1201030|NCT01150422|medical abortion
1201031|NCT01150409|Sepsis
1201032|NCT01150409|hydrocortisone
1201033|NCT01150396|extremely premature infant
1201034|NCT01150396|outcome
1201035|NCT01150396|follow-up
1201036|NCT01150383|Lung Diseases, Obstructive
1201037|NCT01150383|Respiratory Tract Diseases
1201038|NCT01150383|Lung Diseases
1201039|NCT01150383|Respiration Disorders
1201040|NCT01150383|Pulmonary Disease, Chronic Obstructive
1201041|NCT01150383|COPD
1201042|NCT01150383|Chronic Obstructive Lung Disease
1201043|NCT01150383|Chronic Obstructive Airway Disease
1201044|NCT01150383|Chronic Airflow Obstruction
1201045|NCT01150383|oxygen
1201046|NCT01150383|oxygen supplementation
1201047|NCT01150370|male circumcision
1201048|NCT01150370|HIV
1201049|NCT01150370|Rwanda
1201050|NCT01150370|HIV Seronegativity
1201051|NCT01150357|Pediatric hypertension
1201052|NCT01150357|primary hypertension
1201053|NCT01150357|secondary hypertension
1201054|NCT01150344|Multicentric study
1201055|NCT01150344|Antimalarial
1201056|NCT01150344|P. falciparum
1201057|NCT01150344|Efficacy
1201058|NCT01150344|Failures
1201059|NCT01150344|Malarone
1201060|NCT01150344|RIAMET
1201061|NCT01150331|status epilepticus
1201062|NCT01150331|generalised convulsive status epilepticus
1201063|NCT01150331|first line treatments
1201064|NCT01150331|double-blind randomized controlled trial
1201065|NCT01150331|prehospital treatment
1201066|NCT01150318|Male
1201067|NCT01150318|Infertility
1201068|NCT01150318|Radioisotopes Therapy
1201069|NCT01150318|Follicular thyroid cancer
1201070|NCT01150305|Autosomal dominant inheritance
1201071|NCT01150305|Mutation
1201072|NCT01150305|Prevalence
1201073|NCT01150292|DHA supplementation
1201074|NCT01150292|Type 2 diabetic patient
1201075|NCT01150292|Platelet function
1201076|NCT01150279|medical abortion
1201077|NCT01150279|Medical Abortion Follow Up Care
1201078|NCT01150266|stroke
1201079|NCT01150266|ischemia
1201080|NCT01150266|thrombolysis
1201081|NCT01150266|thrombolytics
1201082|NCT01150266|tPA
1201083|NCT01150266|rt-PA
1201084|NCT01150266|t-PA
1201085|NCT01150266|Activase®
1201086|NCT01150266|Alteplase
1201087|NCT01150266|wake-up stroke
1201088|NCT01150266|waking onset stroke
1201089|NCT01150266|sleep
1201090|NCT01150240|Primary Immunodeficiency Disease
1201091|NCT01150214|atrial fibrillation
1201092|NCT01150214|af
1201093|NCT01150214|magnetic resonance imaging
1201094|NCT01150214|mri
1201095|NCT01150214|left atrium
1201096|NCT01150214|fibrosis
1201097|NCT01150214|structural remodeling
1201098|NCT01150201|CKD
1201099|NCT01150201|proteinuria
1201100|NCT01150201|eGFR
1201101|NCT01150201|Progression of chronic kidney disease
1201102|NCT01150188|aging
1201103|NCT01150188|lipid metabolism
1201104|NCT01150188|very low density lipoproteins
1201105|NCT01150188|amino acids
1201106|NCT01150188|dietary supplements
1201107|NCT01150175|END-HF
1201108|NCT01150149|Influenza
1201109|NCT01150149|Humans
1201110|NCT01150149|Experimental
1201111|NCT01150149|Challenge
1201112|NCT01150136|choline
1201113|NCT01150136|cystic fibrosis
1201114|NCT01150136|methyl metabolism
1201115|NCT01150136|oxidative stress
1201116|NCT01150123|Group B streptococcus
1201117|NCT01150123|GBS
1201118|NCT01150123|Vaccine
1201119|NCT01150123|Group B streptococcus (GBS) disease
1201120|NCT01150110|Temporomandibular disorders
1201121|NCT01150110|occlusal splints
1201122|NCT01150110|electromyography
1201123|NCT01150110|TMD (muscle and joint dysfunction)
1201124|NCT01150110|masseteres e anterior temporalis muscles.
1201125|NCT01150097|Liver transplantation
1201126|NCT01150097|Everolimus
1201127|NCT01150097|Calcineurin inhibitors
1201128|NCT01150097|Tacrolimus
1201129|NCT01150097|Renal function
1201130|NCT01150097|Progression of HCV related allograft fibrosis
1201131|NCT01150084|increasing physical activity in sedentary employees
1201132|NCT01150071|extremely premature infant
1201133|NCT01150071|follow-up
1201134|NCT01150071|behavior
1201135|NCT01150071|growth
1201136|NCT01150071|mental health
1201137|NCT01150071|lung function
1201138|NCT01150071|spirometry
1201139|NCT01150071|muscle mass
1201140|NCT01150071|bone density
1201141|NCT01150071|magnetic Resonance imaging
1201142|NCT01150058|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1201143|NCT01150058|adult acute myeloid leukemia with del(5q)
1201144|NCT01150058|adult acute myeloid leukemia with inv(16)(p13;q22)
1201145|NCT01150058|adult acute myeloid leukemia with t(15;17)(q22;q12)
1201146|NCT01150058|adult acute myeloid leukemia with t(16;16)(p13;q22)
1201147|NCT01150058|adult acute myeloid leukemia with t(8;21)(q22;q22)
1201148|NCT01150058|childhood acute myeloid leukemia/other myeloid malignancies
1201149|NCT01150058|adult acute myeloid leukemia
1201152|NCT01150032|Osteoporosis
1201153|NCT01150032|Fracture
1201154|NCT01150032|Bone microarchitecture
1201155|NCT01150019|atherosclerosis
1201156|NCT01150019|vascular inflammation
1201157|NCT01150019|resistin
1201158|NCT01150019|adiponectin
1201159|NCT01150019|18FDG-PET
1201160|NCT01150006|atherosclerosis
1201161|NCT01150006|vascular inflammation
1201162|NCT01150006|adipocyte fatty acid binding protein
1201163|NCT01150006|adiponectin
1201164|NCT01150006|leptin
1201165|NCT01150006|18FDG-PET
1201166|NCT01149993|living donation
1201167|NCT01149993|kidney transplantation
1201168|NCT01149993|delayed graft function
1201169|NCT01149993|ischemia reperfusion injury
1201170|NCT01149980|Bioequivalence
1201171|NCT01149980|Crossover
1201172|NCT01149980|Citalopram
1201173|NCT01149967|Bioequivalence
1201174|NCT01149967|Citalopram
1201175|NCT01149967|Crossover
1201176|NCT01149954|Bioequivalence
1201177|NCT01149954|Crossover
1201178|NCT01149954|Ibuprofen
1201179|NCT01149941|Bioequivalence
1201180|NCT01149941|Crossover
1201181|NCT01149941|Ibuprofen
1201182|NCT01149928|Fetal lung fluid
1201183|NCT01149928|Pulmonary adaptation
1201184|NCT01149928|Transient tachypnea of the newborn
1201185|NCT01149928|Epinephrine
1201186|NCT01149928|Stress hormones
1201187|NCT01149915|Advanced Leukemias
1201188|NCT01149915|Relapsed/Refractory Leukemias
1201189|NCT01149915|AML
1201190|NCT01149915|ALL
1201191|NCT01149915|CML
1201192|NCT01149915|MDS
1201193|NCT01149915|CLL
1201194|NCT01149915|MF
1201195|NCT01149915|Evofosfamide
1201196|NCT01149863|Autologous Transplantation
1201197|NCT01149850|adult giant cell glioblastoma
1201198|NCT01149850|adult glioblastoma
1201199|NCT01149850|adult gliosarcoma
1201200|NCT01149837|HTLV
1201201|NCT01149837|HTLV I
1201202|NCT01149837|HTLV II
1201203|NCT01149837|HTLV Type I and/or HTLV Type II antibody
1201204|NCT01149824|Salvia divinorum
1201205|NCT01149824|Salvinorin A
1201206|NCT01149811|Dyskinesia
1201207|NCT01149798|metastatic breast cancer
1201208|NCT01149798|combined chemotherapy
1201209|NCT01149785|crizotinib
1201210|NCT01149785|healthy volunteers
1201211|NCT01149785|ketoconazole
1201212|NCT01149785|pharmacokinetics
1201213|NCT01149785|single dose
1201214|NCT01149772|Chronic Obstructive Pulmonary Disease
1201215|NCT01149772|Heart Failure
1201216|NCT01149772|Anxiety
1201217|NCT01149772|Depression
1201218|NCT01149759|Atopic Dermatitis
1201219|NCT01149759|Eczema
1201220|NCT01149720|Relative bioavailability
1201221|NCT01149720|ARQ 197
1201222|NCT01149707|PUR 0110
1201223|NCT01149707|PUR 0110 Rectal Enema
1201224|NCT01149707|Distal Ulcerative Colitis
1201225|NCT01149707|Left-Sided Ulcerative Colitis
1201226|NCT01149707|Mild
1201227|NCT01149707|Moderate
1201228|NCT01149694|PurGenesis Technologies Inc.
1201229|NCT01149694|PUR 0110 rectal enema
1201230|NCT01149694|Ulcerative colitis
1201231|NCT01149694|Distal
1201232|NCT01149694|Normal healthy volunteers
1201233|NCT01149681|Aplidin
1201234|NCT01149681|Plitidepsin
1201235|NCT01149681|Myelofibrosis
1201236|NCT01149681|Pharma Mar
1201237|NCT01149668|PCI-24781
1201238|NCT01149668|Lymphoma
1201239|NCT01149668|Non-Hodgkin's
1201240|NCT01149668|Hodgkin Disease
1201241|NCT01149668|Multiple Myeloma
1201242|NCT01149668|Leukemia
1201243|NCT01149668|Lymphocytic
1201244|NCT01149668|Chronic
1201245|NCT01149655|Adolescent
1201246|NCT01149655|Schizophrenia
1201247|NCT01149629|Droxidopa
1201248|NCT01149629|Randomized
1201249|NCT01149629|Crossover
1201250|NCT01149629|Open Label
1201251|NCT01149629|Bioequivalence
1201252|NCT01149629|Fed Fast
1201253|NCT01149629|TID
1201254|NCT01149603|failing Fontan
1201255|NCT01149603|single-ventricle
1201256|NCT01149603|destination therapy
1201257|NCT01149603|HeartMate II
1201258|NCT01149603|HMII
1201259|NCT01149603|cardiac congenital anomaly
1201260|NCT01149603|ventricular assist device
1201261|NCT01149603|VAD
1201262|NCT01149590|Angina
1201263|NCT01149590|Coronary Heart Disease
1201264|NCT01149590|Computed Tomography
1201265|NCT01149590|Angiogram
1201266|NCT01149590|Coronary Artery Calcium Score
1201267|NCT01149590|Chest Pain
1201268|NCT01149590|Angina Pectoris due to Coronary Heart Disease
1201269|NCT01149577|Olanzapine
1201270|NCT01149577|Schizophrenia
1201271|NCT01149577|Polysomnography
1201272|NCT01149577|Slow wave sleep
1201273|NCT01149551|Schizophrenia
1201274|NCT01149551|Bipolar disorder
1201275|NCT01149551|Genetic research
1201276|NCT01149538|FASD
1201277|NCT01149538|FAS
1201278|NCT01149538|Alcohol
1201279|NCT01149538|Prenatal Alcohol
1201280|NCT01149525|Multiple Sclerosis/complications
1201281|NCT01149525|Fatigue Syndrome
1201282|NCT01149525|Chronic/drug therapy
1201283|NCT01149486|Bioequivalence
1201284|NCT01149486|Healthy Subjects
1201285|NCT01149473|Bioequivalence
1201286|NCT01149473|Healthy Subjects
1201287|NCT01149447|cryptogenic stroke
1201288|NCT01149447|percutaneous closure of PFO
1201289|NCT01149447|follow-up exams
1201290|NCT01149434|Low grade endocrine tumors
1201291|NCT01149434|ovarian cancers
1201292|NCT01149434|K-RAS mutant colon cancers
1201293|NCT01149421|Type 2 Diabetes
1201294|NCT01149421|Diabetes
1201295|NCT01149421|Ambulatory Blood Pressure Monitoring
1201296|NCT01149421|ABPM
1201297|NCT01149421|Blood Pressure
1201298|NCT01149421|Heart Rate
1201299|NCT01149408|AML
1201300|NCT01149408|Decitabine
1201301|NCT01149408|Acute Myeloid Leukemia
1201302|NCT01149408|Elderly Patients
1201303|NCT01149408|Cancer
1201304|NCT01149395|Heartburn
1201305|NCT01149395|Gastroesophageal Reflux Disease
1201306|NCT01149382|flu shot
1201307|NCT01149382|islet cell transplant recipients
1201308|NCT01149369|gastroparesis
1201309|NCT01149369|nausea
1201310|NCT01149369|vomiting
1201311|NCT01149343|PRAME
1201312|NCT01149343|Cancer immunotherapeutic
1201313|NCT01149343|Malignant melanoma
1201314|NCT01149343|ASCI (Antigen-Specific Cancer Immunotherapeutic)
1201315|NCT01149330|Adapalene
1201316|NCT01149330|Benzoyl Peroxide
1201317|NCT01149330|Acne Vulgaris
1201318|NCT01149317|acupuncture
1201319|NCT01149317|health services research
1201320|NCT01149317|chronic pain
1201321|NCT01149317|health disparities
1201322|NCT01149304|brachytherapy
1201323|NCT01149304|liver metastases
1201324|NCT01149304|irradiation
1201325|NCT01149304|radiation induced liver disease
1201326|NCT01149304|dosimetry
1201327|NCT01149291|high sensitivity C-reactive protein (hsCRP)
1201328|NCT01149291|cardiorenal
1201329|NCT01149291|end stage renal disease (ESRD)
1201330|NCT01149291|Secondary hyperparathyroidism (SHPT)
1201331|NCT01149291|dialysis
1201332|NCT01149291|paricalcitol
1201333|NCT01149291|osteodystrophy
1201334|NCT01149291|selective Vitamin D receptor activators (sVDRA)
1201335|NCT01149291|chronic kidney disease
1201336|NCT01149252|Psoriasis
1201337|NCT01149226|pediatric patients
1201338|NCT01149226|ASA physical status I or II
1201339|NCT01149226|aged between 1-5 yrs
1201340|NCT01149213|Major depressive disorder
1201341|NCT01149213|follow-up
1201342|NCT01149213|relapse
1201343|NCT01149213|remission
1201344|NCT01149213|transcranial direct current stimulation
1201345|NCT01149200|Irritable Bowel Syndrome
1201346|NCT01149200|IBS-C
1201347|NCT01149174|intravesical chemotherapy
1201348|NCT01149174|early single instillation
1201349|NCT01149174|mitomycin-C
1201350|NCT01149174|electromotive drug administration
1201351|NCT01149161|neck dissection
1201352|NCT01149161|sentinel lymph node
1201353|NCT01149161|Carcinoma
1201354|NCT01149161|Papillary
1201355|NCT01149161|thyroid
1201356|NCT01149161|dissection
1201357|NCT01149148|Aortic Surgeries
1201358|NCT01149148|Deep Hypothermic Circulatory Arrest
1201359|NCT01149135|Seasonal Affective Disorder
1201360|NCT01149135|phototherapy
1201361|NCT01149135|circadian rhythms
1201362|NCT01149135|blue enriched light
1201363|NCT01149135|melanopsin
1201364|NCT01149135|low intensity
1201365|NCT01149122|unresectable, metastatic biliary tract carcinoma
1201366|NCT01149122|Gemcitabine/Oxaliplatin (GEMOX)
1201367|NCT01149122|Erlotinib
1201368|NCT01149109|MGMT promotor status
1201369|NCT01149109|overall survival
1201370|NCT01149070|Infertility
1201371|NCT01149070|Controlled ovarian stimulation
1201372|NCT01149070|Reproductive techniques, assisted
1201373|NCT01149070|Sperm injections, intracytoplasmic
1201374|NCT01149070|Gonal-f
1201375|NCT01149070|Ovitrelle
1201376|NCT01149044|Acute Coronary Syndrome
1201377|NCT01149044|PCI
1201378|NCT01149044|Percutaneous Coronary Intervention
1201379|NCT01149044|STEMI
1201380|NCT01149044|Thrombectomy
1201381|NCT01149031|Provoked Vestibulodynia
1201382|NCT01149031|Low Level Laser Therapy
1201383|NCT01149018|Fibromyalgia
1201384|NCT01149018|Tetrahydrocannabinol
1201385|NCT01149018|Chronic Widespread Pain
1201386|NCT01149005|Normal Glucose Tolerance Test
1201387|NCT01149005|Mixed Meal Tolerance Test
1201388|NCT01149005|Cystic Fibrosis
1201389|NCT01149005|Pulmonary Exacerbation
1201390|NCT01149005|Impaired Glucose Tolerance Test
1201391|NCT01149005|Insulin Therapy
1201392|NCT01148979|Major Depressive Disorder
1201393|NCT01148979|Cognitive Impairment
1201394|NCT01148979|Partial Response
1201395|NCT01148979|Residual Symptoms
1201396|NCT01148940|sickle cell trait
1201397|NCT01148940|thrombosis
1201398|NCT01148940|D-Dimer
1201399|NCT01148914|Inflammatory biomarkers
1201400|NCT01148914|Atrial fibrillation
1201401|NCT01148914|Catheter ablation
1201402|NCT01148914|To assess if pre-ablation levels of inflammatory biomarkers serve as independent predictors of procedure outcome
1201403|NCT01148914|To evaluate the inflammatory activation following catheter ablation and examine its predictive role in procedure success
1201404|NCT01148914|To determine if a change in the baseline level of biomarkers at 3-months follow-up has any correlation with long-term outcome
1201530|NCT01148368|renal impairment
1201405|NCT01148914|To study the association of certain biomarkers with specific types of AF (paroxysmal or persistent or long standing persistent)
1201406|NCT01148901|Ankylosing spondylitis
1201407|NCT01148901|Hip arthritis
1201408|NCT01148901|Infliximab
1201409|NCT01148888|pediatrics
1201410|NCT01148888|Anaesthesia
1201411|NCT01148888|Scoliosis
1201412|NCT01148888|Magnesium
1201413|NCT01148875|breast cancer screening
1201414|NCT01148875|mammography adherence
1201415|NCT01148875|non-adherent
1201416|NCT01148862|ASPIRE (Automation to Simulate Pancreatic Insulin Response)
1201417|NCT01148862|X54
1201418|NCT01148862|Medtronic Diabetes
1201419|NCT01148862|Diabetes Mellitus
1201420|NCT01148862|Type 1
1201421|NCT01148849|HER2 positive
1201422|NCT01148849|breast cancer
1201423|NCT01148849|gastric cancer
1201424|NCT01148836|Coenzyme Q-10
1201425|NCT01148836|Pulmonary Arterial Hypertension
1201426|NCT01148836|Pulmonary Arterial Hypertension Class I (Venice 2003)
1201427|NCT01148823|breast
1201428|NCT01148823|plastic surgery
1201429|NCT01148823|bandages
1201430|NCT01148823|surgical site infection
1201431|NCT01148823|skin colonization
1201432|NCT01148810|Inflammatory muscle disease
1201433|NCT01148810|Muscle weakness
1201434|NCT01148810|Myositis
1201435|NCT01148797|FMF, Colchicine resistant
1201436|NCT01148797|Colchicine intolerant
1201437|NCT01148797|Flare rate
1201438|NCT01148797|Canakinumab
1201439|NCT01148784|anterior cruciate ligament tear
1201440|NCT01148784|ACL
1201441|NCT01148784|ligament
1201442|NCT01148784|knee
1201443|NCT01148784|allograft
1201444|NCT01148771|Pharmacokinetics
1201445|NCT01148771|Safety
1201446|NCT01148732|Endotracheal tube
1201447|NCT01148732|ultrasonography
1201448|NCT01148719|Heart Failure
1201449|NCT01148719|Chronic Obstructive Pulmonary Disease
1201450|NCT01148719|Dyspnea
1201451|NCT01148719|Elderly
1201452|NCT01148719|Diagnosis
1201453|NCT01148719|Primary health care
1201454|NCT01148706|thorax
1201455|NCT01148706|abdomen
1201456|NCT01148693|Cholangitis; Cholangiopancreatography, Endoscopic Retrograde; stents; cholestasis
1201457|NCT01148680|Islet Cell Transplantation
1201458|NCT01148680|Metabolic Diseases
1201459|NCT01148680|Endocrine System Diseases
1201460|NCT01148667|atopic dermatitis
1201461|NCT01148667|barrier function
1201462|NCT01148667|gut
1201463|NCT01148667|probiotics
1201464|NCT01148667|skin
1201465|NCT01148654|preterm birth
1201466|NCT01148654|preterm labor
1201467|NCT01148654|PTB
1201468|NCT01148654|PTL
1201469|NCT01148641|Lipid-based supplements
1201470|NCT01148641|LNS
1201471|NCT01148641|Acceptability
1201472|NCT01148641|Infant nutrition
1201473|NCT01148641|Guatemala
1201474|NCT01148641|Malnutrition
1201475|NCT01148602|Acute stroke
1201476|NCT01148602|Emergency departments
1201477|NCT01148602|Quality Improvement
1201478|NCT01148602|Improved Processes
1201479|NCT01148602|tPA
1201480|NCT01148602|door-to-needle
1201481|NCT01148602|door-to-treatment
1201482|NCT01148576|hepatic steatosis, chronic hepatitis B, entecavir
1201483|NCT01148563|congestive heart failure
1201484|NCT01148563|systolic
1201485|NCT01148563|chronic disease
1201486|NCT01148563|heart failure
1201487|NCT01148550|neonatal acute liver failure
1201488|NCT01148550|late-onset liver failure
1201489|NCT01148550|cholestasis,
1201490|NCT01148550|fatty liver,
1201491|NCT01148550|liver dysfunction,
1201492|NCT01148550|cirrhosis
1201493|NCT01148537|Healthy subjects
1201494|NCT01148537|Opioid
1201495|NCT01148537|Transdermal
1201496|NCT01148524|Meningococcal disease
1201497|NCT01148524|Vaccines
1201498|NCT01148524|Adolescents
1201499|NCT01148511|Macula degeneration
1201500|NCT01148511|Ranibizumab
1201501|NCT01148511|Choroidal neovascularisation
1201502|NCT01148511|Treat and extend
1201503|NCT01148511|Treat and observe
1201504|NCT01148485|- Staphylococcus aureus Carriage among Athletes
1201505|NCT01148472|Depressive disorder, major
1201506|NCT01148472|Randomized controlled trials
1201507|NCT01148472|Antidepressive agents
1201508|NCT01148459|Plasmodium falciparum
1201509|NCT01148459|schedule
1201510|NCT01148459|HIV
1201511|NCT01148459|malaria vaccine
1201512|NCT01148459|EPI
1201513|NCT01148459|Africa
1201514|NCT01148446|DLBCL
1201515|NCT01148446|R-CHOP
1201516|NCT01148446|R-CEOP
1201517|NCT01148446|Elderly patients
1201518|NCT01148407|breast cancer
1201519|NCT01148407|platelets
1201520|NCT01148407|metastatic cancer
1201521|NCT01148407|malignancy
1201522|NCT01148394|Colorectal surgery
1201523|NCT01148394|multimodal rehabilitation
1201524|NCT01148394|fast track
1201525|NCT01148394|early feeding
1201526|NCT01148381|Genotype
1201527|NCT01148381|Phenotype
1201528|NCT01148381|Characterization
1201529|NCT01148368|fimasartan
1201531|NCT01148368|hypertension
1201532|NCT01148355|Craving
1201533|NCT01148355|Moods
1201534|NCT01148355|Adolescents
1201535|NCT01148355|Nicotine
1201536|NCT01148355|Reinforcement
1201537|NCT01148342|Ecstacy
1201538|NCT01148342|fMRI
1201539|NCT01148342|Alternative Matrices
1201540|NCT01148342|Cognitive Training
1201541|NCT01148342|Brain Imaging
1201542|NCT01148329|Coronary stenting
1201543|NCT01148329|Drug-eluting stent
1201544|NCT01148329|Post-market surveillance study
1201545|NCT01148329|Promus Element stent
1201546|NCT01148316|Developmental Psychiatry
1201547|NCT01148316|Sequential Randomized Clinical Trial
1201548|NCT01148316|Obsessive-Compulsive Disorder D009771
1201549|NCT01148303|Headache
1201550|NCT01148303|Fasting
1201551|NCT01148303|Fasting Headache
1201552|NCT01148303|Ramadan
1201553|NCT01148303|Ramadan Headache
1201554|NCT01148303|Yom Kippur
1201555|NCT01148303|Yom Kippur Headache
1201556|NCT01148290|bulking agent
1201557|NCT01148290|emivulvectomy
1201558|NCT01148290|radical vulvectomy
1201559|NCT01148290|TVT
1201560|NCT01148290|urinary incontinence
1201561|NCT01148290|vulvar cancer
1201562|NCT01148277|Endoscopies
1201563|NCT01148277|Liver diseases
1201564|NCT01148277|Propofol
1201565|NCT01148277|Midazolam and remifentanyl
1201566|NCT01148264|break-through
1201567|NCT01148264|emesis
1201568|NCT01148264|break through emesis after prophylaxis with dexamethasone, 5-HT 3RA and aprepitant
1201569|NCT01148238|Autoimmune diabetes
1201570|NCT01148238|LADA
1201571|NCT01148238|T-reg
1201572|NCT01148238|cytokine
1201573|NCT01148225|Non-infectious Uveitis
1201574|NCT01148225|Active Uveitis
1201575|NCT01148225|Posterior-Uveitis
1201576|NCT01148225|Uveitis
1201577|NCT01148225|Pan-uveitis
1201578|NCT01148225|Intermediate-Uveitis
1201579|NCT01148199|biliary anastomotic stricture
1201580|NCT01148199|orthotopic liver transplantation
1201581|NCT01148199|ERCP
1201582|NCT01148186|Polypharmacy
1201583|NCT01148186|Benzodiazepine use
1201584|NCT01148186|Oxybutynin use
1201585|NCT01148186|cognition disorders/drug therapy
1201586|NCT01148186|incontinence
1201587|NCT01148173|CNS relapse
1201588|NCT01148173|aggressive lymphoma
1201589|NCT01148173|HD-ASCT
1201590|NCT01148160|voriconazole
1201591|NCT01148160|invasive pulmonary aspergillosis
1201592|NCT01148160|hematologic malignancy
1201593|NCT01148160|therapeutic drug monitoring
1201594|NCT01148160|genetic polymorphism
1201595|NCT01148160|efficacy
1201596|NCT01148160|safety
1201597|NCT01148147|Adenosine
1201598|NCT01148147|randomized trial
1201599|NCT01148147|periprocedural myocardial necrosis
1201600|NCT01148147|elective coronary angioplasty
1201601|NCT01148108|NHL
1201602|NCT01148108|Non-Hodgkins Lymphoma
1201603|NCT01148108|Lymphoma
1201604|NCT01148108|Mantle Cell
1201605|NCT01148108|Diffuse Large B Cell
1201606|NCT01148108|Multiple Myeloma
1201607|NCT01148108|Telcyta
1201608|NCT01148108|canfosfamide
1201609|NCT01148108|TLK286
1201610|NCT01148108|Prodrug
1201611|NCT01148108|Enzyme activated drug
1201612|NCT01148108|Glutathione Transferase P1-1 activated drug
1201613|NCT01148108|GSTp1-1 activated drug
1201614|NCT01148108|Glutathione Transferase activated drug
1201615|NCT01148108|Glutathione
1201616|NCT01148108|Glutathione analong
1201617|NCT01148095|AZD2516
1201618|NCT01148095|Phase 1
1201619|NCT01148095|Healthy volunteer
1201620|NCT01148095|pharmacokinetics
1201621|NCT01148095|safety
1201622|NCT01148095|tolerability
1201623|NCT01148095|Multiple ascending doses
1201624|NCT01148082|Carcinomas (including Squamous Cell and Adenocarcinoma)
1201625|NCT01148069|IMRT-IGRT
1201626|NCT01148069|radiotherapy toxicity
1201627|NCT01148069|seminal vesicles
1201628|NCT01148056|IMRT
1201629|NCT01148056|radiation therapy
1201630|NCT01148017|Meningococcal
1201631|NCT01148017|ACWY
1201632|NCT01148017|Conjugate Vaccine
1201633|NCT01148017|Meningitis
1201634|NCT01148017|Children
1201635|NCT01148017|Persistence
1201636|NCT01148017|Booster dose
1201637|NCT01148004|HIV
1201638|NCT01148004|Hypertriglyceridemia
1201639|NCT01148004|Protease Inhibitors
1201640|NCT01148004|Healthy Volunteer
1201641|NCT01148004|HV
1201642|NCT01147991|Epstein-Barr virus infection
1201643|NCT01147991|stage I nasopharyngeal cancer
1201644|NCT01147991|stage II nasopharyngeal cancer
1201645|NCT01147991|stage I adult Hodgkin lymphoma
1201646|NCT01147991|stage II adult Hodgkin lymphoma
1201647|NCT01147991|post-transplant lymphoproliferative disorder
1201648|NCT01147991|stage I gastric cancer
1201649|NCT01147991|stage II gastric cancer
1201650|NCT01147991|adult nasal type extranodal NK/T-cell lymphoma
1201651|NCT01147991|angioimmunoblastic T-cell lymphoma
1201652|NCT01147991|stage I adult Burkitt lymphoma
1201653|NCT01147991|contiguous stage II adult Burkitt lymphoma
1201654|NCT01147991|contiguous stage II adult immunoblastic large cell lymphoma
1201655|NCT01147991|stage I adult immunoblastic large cell lymphoma
1201656|NCT01147978|ICU
1201657|NCT01147978|Anxiety
1201658|NCT01147978|Depression
1201659|NCT01147978|PTSD
1201660|NCT01147965|Colon Cancer
1201661|NCT01147965|Lung Cancer
1201662|NCT01147965|Breast Cancer
1201663|NCT01147965|CEA
1201664|NCT01147952|angina
1201665|NCT01147952|gene expression
1201666|NCT01147952|depression
1201667|NCT01147952|anxiety
1201668|NCT01147939|Acute Myeloid Leukaemia
1201669|NCT01147939|AML
1201670|NCT01147939|Haematology
1201671|NCT01147939|Investigator's Choice
1201672|NCT01147939|Elacytarabine
1201673|NCT01147939|Refractory or relapsed AML
1201674|NCT01147939|Phase III
1201675|NCT01147939|Randomized
1201676|NCT01147939|CLAVELA
1201677|NCT01147939|CP4055-306
1201678|NCT01147939|Elacyt
1201679|NCT01147926|Constipation
1201680|NCT01147926|Male
1201681|NCT01147913|Major Depression
1201682|NCT01147913|Depression
1201683|NCT01147913|Anxiety
1201684|NCT01147913|Dysthymia
1201685|NCT01147900|Immune persistence
1201686|NCT01147900|Boostrix
1201687|NCT01147900|dTpa booster study
1201688|NCT01147887|26489112
1201689|NCT01147887|Omeprazole
1201690|NCT01147887|Tolbutamide
1201691|NCT01147874|non-therapeutic
1201692|NCT01147874|interventional
1201693|NCT01147861|T2DM
1201694|NCT01147861|Pharmacodynamics
1201695|NCT01147861|GSK256073
1201696|NCT01147848|Salmeterol
1201697|NCT01147848|fluticasone furoate
1201698|NCT01147848|Vilanterol
1201699|NCT01147848|fluticasone propionate
1201700|NCT01147848|GW642444
1201701|NCT01147835|Herbal lollipops
1201702|NCT01147835|Asthma
1201703|NCT01147835|Dental Caries
1201704|NCT01147835|Streptococcus mutans levels
1201705|NCT01147835|DMFT/dmft scores
1201706|NCT01147822|SUTENT
1201707|NCT01147822|GW76034
1201708|NCT01147822|Sunitinib
1201709|NCT01147822|Renal cell carcinoma
1201710|NCT01147822|Pazopanib
1201711|NCT01147809|Solid Tumor
1201712|NCT01147809|Eltrombopag
1201713|NCT01147809|chemotherapy-induced thrombocytopenia
1201714|NCT01147809|Thrombocytopenia
1201715|NCT01147796|Thrombus
1201716|NCT01147796|computed tomography
1201717|NCT01147796|Transoesophageal echocardiography
1201718|NCT01147770|progesterone
1201719|NCT01147770|antagonist
1201720|NCT01147770|rec FSH
1201721|NCT01147770|IVF
1201722|NCT01147770|pregnancy
1201723|NCT01147757|pediatric patients (ASA physical status I or II) aged between
1201724|NCT01147744|Efficacy
1201725|NCT01147744|Asthma
1201726|NCT01147744|Safety
1201727|NCT01147744|Fluticasone Propionate
1201728|NCT01147744|FLAP
1201729|NCT01147744|Beta-agonists
1201730|NCT01147744|GSK2190915
1201731|NCT01147744|Montelukast
1201732|NCT01147744|Placebo
1201733|NCT01147744|FLAIR
1201738|NCT01147718|pharmacokinetics
1201739|NCT01147718|albiglutide
1201740|NCT01147718|Healthy volunteer
1201741|NCT01147718|digoxin
1201742|NCT01147705|Peripheral arterial disease
1201743|NCT01147705|Allopurinol
1201744|NCT01147692|albiglutide
1201745|NCT01147692|simvastatin
1201746|NCT01147692|healthy volunteers
1201747|NCT01147692|pharmacokinetics
1201748|NCT01147679|Frontotemporal dementia
1201749|NCT01147679|Alzheimer's disease
1201750|NCT01147679|Young-Onset
1201751|NCT01147679|Frontotemporal degeneration
1201752|NCT01147679|control
1201753|NCT01147679|social
1201754|NCT01147679|behavior
1201755|NCT01147679|observation
1201756|NCT01147679|emotion
1201757|NCT01147679|morality
1201758|NCT01147679|dementia
1201759|NCT01147679|brain
1201760|NCT01147679|relationships
1201761|NCT01147679|caregiver
1201762|NCT01147679|MRI
1201763|NCT01147679|neurology
1201764|NCT01147666|Kidney
1201765|NCT01147666|End Stage Renal Disease
1201766|NCT01147666|ESRD
1201767|NCT01147666|Chronic Kidney Disease
1201768|NCT01147666|CKD
1201769|NCT01147666|Renal
1201770|NCT01147666|Anemia
1201771|NCT01147666|Oral anemia treatment
1201772|NCT01147666|Hemoglobin levels
1201773|NCT01147666|Blood count
1201774|NCT01147666|Erythropoietin
1201775|NCT01147666|Hemodialysis
1201776|NCT01147666|Normoresponder
1201777|NCT01147666|Hyporesponder
1201778|NCT01147653|Cerebral Palsy
1201779|NCT01147653|CP
1201780|NCT01147653|Spastic Cerebral Palsy
1201781|NCT01147653|Cord Blood
1201782|NCT01147653|Umbilical Cord Blood
1201783|NCT01147653|Autologous Cord Blood
1201784|NCT01147627|diabetes mellitus, type 2
1201785|NCT01147627|newly diagnosed
1201786|NCT01147627|exenatide
1201787|NCT01147627|premixed insulin analog
1201788|NCT01147627|thiazolidinedione
1201789|NCT01147627|β-cell function
1201790|NCT01147627|glycemic control
1201791|NCT01147614|Child
1201792|NCT01147614|adolescent
1201793|NCT01147614|anxiety
1201794|NCT01147614|depression
1201795|NCT01147614|internalizing
1201796|NCT01147614|cognitive behavioral therapy
1201797|NCT01147614|pediatric primary care
1201798|NCT01147601|topical 0.5% Timolol
1201799|NCT01147601|infantile hemangioma (IH)
1201800|NCT01147588|open label
1201801|NCT01147588|randomized
1201802|NCT01147588|4-treatment
1201803|NCT01147588|3-period
1201804|NCT01147588|crossover
1201805|NCT01147588|interaction study
1201806|NCT01147588|Safety
1201807|NCT01147588|tolerability
1201808|NCT01147588|pharmacokinetics
1201809|NCT01147588|pharmacodynamics
1201810|NCT01147575|Rett Syndrome, Randomized, Methylation
1201811|NCT01147562|Lung cancer
1201812|NCT01147562|Biopsy
1201813|NCT01147562|Biomarker
1201814|NCT01147562|Tissue Collection
1201815|NCT01147549|ADME
1201816|NCT01147523|nonalcoholic fatty liver disease
1201817|NCT01147523|nonalcoholic steatohepatitis
1201818|NCT01147523|adipokines
1201819|NCT01147523|spironolactone
1201820|NCT01147523|vitamin E
1201821|NCT01147523|adiponectin
1201822|NCT01147523|visfatin
1201823|NCT01147523|leptin
1201824|NCT01147523|resistin
1201825|NCT01147523|TNF-alpha
1201826|NCT01147523|IL-6
1201827|NCT01147523|IL-1
1201828|NCT01147510|asthma control in elderly patients
1201829|NCT01147510|age 60-75
1201830|NCT01147497|IUD insertion
1201831|NCT01147497|nulliparous women
1201832|NCT01147497|contraception
1201833|NCT01147497|family planning
1201834|NCT01147497|IUD insertion in nulliparous women
1201835|NCT01147484|Breast Cancer
1201836|NCT01147471|flail chest
1201837|NCT01147471|rib fixation
1201838|NCT01147458|Cross-over
1201839|NCT01147458|safety
1201840|NCT01147458|efficacy
1201841|NCT01147458|tolerability
1201842|NCT01147458|osteoarthritis
1201843|NCT01147458|knee
1201844|NCT01147458|pain
1201845|NCT01147445|Enterotoxigenic Escherichia coli, vaccine
1201846|NCT01147432|Healthy male volunteers
1201847|NCT01147432|capsaicin challenge
1201848|NCT01147432|safety
1201849|NCT01147432|toleration
1201850|NCT01147419|critical limb ischemia
1201851|NCT01147419|peripheral artery occlusive disease
1201852|NCT01147419|femoropopliteal artery bypass
1201853|NCT01147419|Stent
1201854|NCT01147367|exercise
1201855|NCT01147367|breast cancer
1201856|NCT01147367|physical activity
1201857|NCT01147367|fatigue
1201858|NCT01147367|sleep dysfunction
1201859|NCT01147367|cytokines
1201860|NCT01147367|muscle strength
1201861|NCT01147367|inflammation
1201862|NCT01147354|Hemodialysis
1201863|NCT01147354|oxidative stress
1201864|NCT01147354|selenium
1201865|NCT01147354|inflammation
1201866|NCT01147341|rheumatoid arthritis
1201867|NCT01147341|anti-TNF therapy
1201868|NCT01147328|Health information technology
1201869|NCT01147328|Health information exchange
1201870|NCT01147328|Virtual health record
1201871|NCT01147328|Health care utilization
1201872|NCT01147315|mandibular osteoradionecrosis
1201873|NCT01147315|hybrid bone substitution
1201874|NCT01147315|calcium-phosphate ceramic biomaterial
1201875|NCT01147315|autologous bone marrow
1201876|NCT01147289|lumbar sciatic pain
1201877|NCT01147289|moderate to severe lumbar sciatic pain within the last three days
1201878|NCT01147276|DPP-4
1201879|NCT01147276|GLP-1
1201880|NCT01147276|Glucagon
1201881|NCT01147276|Catecholamines
1201882|NCT01147276|Counterregulation
1201883|NCT01147276|Type 1 diabetes
1201884|NCT01147263|Fibromyalgia
1201885|NCT01147263|Autonomic dysfunction
1201886|NCT01147263|Tachycardia
1201887|NCT01147263|Palpitations
1201888|NCT01147224|Asthma
1201889|NCT01147224|Allergy
1201890|NCT01147224|Ciclesonide
1201891|NCT01147224|Alvesco
1201892|NCT01147224|Inhaled steroids
1201893|NCT01147211|dose defining
1201894|NCT01147211|MK-2206
1201895|NCT01147211|NSCLC With EGFR Mutation
1201896|NCT01147211|NSCLC
1201897|NCT01147198|Moderate
1201898|NCT01147198|Wasting
1201899|NCT01147198|Malnutrition
1201900|NCT01147198|Ready to Use Food
1201901|NCT01147198|Fortified Blended Flour
1201902|NCT01147185|Spinal Cord Injuries, Locomotor training, Dose-Response
1201903|NCT01147172|Nasolabial Folds
1201904|NCT01147172|Cosmetic
1201905|NCT01147172|Injectable Dermal Filler
1201906|NCT01147172|Hyaluronic Acid with Lidocaine
1201907|NCT01147146|transurethral surgery
1201908|NCT01147133|Platelet aggregation
1201909|NCT01147133|Generic
1201910|NCT01147133|Clopidogrel
1201911|NCT01147133|Comparison
1201912|NCT01147133|VASP-PRI
1201913|NCT01147107|HIV/HCV co-infection
1201914|NCT01147107|Antiretroviral therapy
1201915|NCT01147081|Influenza vaccine
1201916|NCT01147081|Vaccine
1201917|NCT01147068|Influenza
1201918|NCT01147055|crizotinib
1201919|NCT01147055|healthy volunteers
1201920|NCT01147055|rifampin
1201921|NCT01147055|pharmacokinetics
1201922|NCT01147055|single dose
1201923|NCT01147042|NADPH Oxidase
1201924|NCT01147042|CGD
1201925|NCT01147042|Gene Mutation
1201926|NCT01147042|Superoxide by Phagocytes
1201927|NCT01147042|IFN-Gamma
1201928|NCT01147042|Chronic Granulomatous Disease
1201929|NCT01147029|unspecified adult solid tumor, protocol specific
1201930|NCT01147016|estrogen receptor-negative breast cancer
1201931|NCT01147016|HER2-negative breast cancer
1201932|NCT01147016|male breast cancer
1201933|NCT01147016|progesterone receptor-negative breast cancer
1201934|NCT01147016|recurrent breast cancer
1201935|NCT01147016|stage IIA breast cancer
1201936|NCT01147016|stage IIB breast cancer
1201937|NCT01147016|stage IIIA breast cancer
1201938|NCT01147016|stage IIIB breast cancer
1201939|NCT01147016|triple-negative breast cancer
1201940|NCT01147003|Seizure frequency
1201941|NCT01147003|nervous system diseases
1201942|NCT01147003|brain diseases
1201943|NCT01147003|neurologic manifestations
1201944|NCT01147003|adjunctive treatment
1201945|NCT01147003|AEDs
1201946|NCT01147003|antiepileptic drug
1201947|NCT01146990|17P Efficacy Trial Follow up
1201948|NCT01146977|CBF(+)
1201949|NCT01146964|Age related cataract
1201950|NCT01146964|Phacoemulsification
1201951|NCT01146964|Manual super small incision cataract surgery
1201952|NCT01146951|Epilepsy
1201953|NCT01146951|Seizures
1201954|NCT01146938|fimasartan
1201955|NCT01146938|hepatic impairment
1201956|NCT01146925|Acute Kidney Injury
1201957|NCT01146925|Contrast-Induced Nephropathy
1201958|NCT01146925|Labile Iron
1201959|NCT01146925|Iron Chelation
1201960|NCT01146925|Deferiprone
1201961|NCT01146912|Influenza, text message, vaccination
1201962|NCT01146899|influenza, vaccine, clinical decision support
1201963|NCT01146860|BNO 1016, acute rhinosinusitis
1201964|NCT01146847|algorithm
1201965|NCT01146847|tight glycemic control
1201966|NCT01146847|glucose control
1201967|NCT01146847|intensive care
1201968|NCT01146847|insulin
1201969|NCT01146847|ICU
1201970|NCT01146808|Vaccination
1201971|NCT01146808|Immunocompromised Host
1201972|NCT01146808|Antiviral Agents
1201973|NCT01146808|Drug Resistance, Viral
1201974|NCT01146808|Resource Allocation
1201975|NCT01146769|Cancer of rectum
1201976|NCT01146769|Physiotherapy
1201977|NCT01146756|MEK inhibitor
1201978|NCT01146756|thoracic radiotherapy
1201979|NCT01146756|lung cancer
1201980|NCT01146743|EUS-guided transmural cholecystostomy
1201981|NCT01146730|Anxiety
1201982|NCT01146730|Depression
1201983|NCT01146730|Vocational Rehabilitation
1201984|NCT01146730|Common Mental Disorders
1201985|NCT01146730|Mental Health Problems
1201986|NCT01146730|Work Related Therapy
1201987|NCT01146717|Mild Cognitive Impairment
1201988|NCT01146717|Exercise
1201989|NCT01146704|Obesity
1201990|NCT01146691|Organizational models
1201991|NCT01146691|Intensive care units
1201992|NCT01146691|Physicians
1201993|NCT01146691|Staffing and scheduling
1201994|NCT01146691|Burnout, professional
1201995|NCT01146691|Job satisfaction
1201996|NCT01146691|Education, medical
1201997|NCT01146691|Patient satisfaction
1201998|NCT01146665|alcohol consumption
1201999|NCT01146665|personalized assessment feedback
1202000|NCT01146665|youth
1202001|NCT01146665|emergency department
1202002|NCT01146639|EVAR DynaCT
1202003|NCT01146626|Vitamin D
1202004|NCT01146626|Hepatitis C
1202005|NCT01146626|Genotype2,3
1202006|NCT01146626|SVR
1202007|NCT01146626|Naive
1202008|NCT01146626|RVR rate
1202009|NCT01146626|EVR rate
1202010|NCT01146626|SVR rate
1202011|NCT01146613|Alcohol
1202012|NCT01146613|Alcohol abuse
1202013|NCT01146613|Alcoholism
1202014|NCT01146613|Alcohol Dependence
1202015|NCT01146613|Varenicline
1202016|NCT01146613|Drinking
1202017|NCT01146600|Primary hypersomnia
1202018|NCT01146600|CNS hypersomnia
1202019|NCT01146600|hypersomnia
1202020|NCT01146600|idiopathic hypersomnia
1202021|NCT01146600|narcolepsy without cataplexy
1202022|NCT01146600|clarithromycin
1202023|NCT01146587|Stroke
1202024|NCT01146587|Robotics
1202025|NCT01146587|Gait
1202026|NCT01146587|Rehabilitation
1202027|NCT01146574|End-Stage Renal Disease
1202028|NCT01146574|Anemia
1202029|NCT01146574|Hemodialysis
1202030|NCT01146574|Renal Anemia
1202031|NCT01146574|ESRD
1202032|NCT01146548|Fluoxetine effect
1202033|NCT01146548|Multiple System Atrophy
1202034|NCT01146548|MSA
1202035|NCT01146535|interferon-alpha
1202036|NCT01146535|oseltamivir
1202158|NCT01145937|Corneal grafting
1202037|NCT01146535|drug therapy, combination
1202038|NCT01146535|influenza
1202039|NCT01146535|therapies, investigational
1202040|NCT01146522|Familial hyperchylomicronemia
1202041|NCT01146522|Lipoprotein lipase deficiency
1202042|NCT01146522|Hyperlipoproteinemia
1202043|NCT01146522|Triglycerides
1202044|NCT01146522|Hypertriglyceridemia
1202045|NCT01146522|LCQ908
1202046|NCT01146522|Hyperlipoproteinemia associated with lipoprotein lipase deficiency
1202047|NCT01146509|migraine
1202048|NCT01146509|headache
1202049|NCT01146496|Pesticide poisoning
1202050|NCT01146496|Suicide
1202051|NCT01146496|Unintentional poisoning
1202052|NCT01146496|Prevention
1202053|NCT01146496|Cluster randomised controlled trial
1202054|NCT01146457|Obstetric anesthesia
1202055|NCT01146457|labor analgesia
1202056|NCT01146457|morphine
1202057|NCT01146457|epidural analgesia
1202058|NCT01146444|Sunscreening Agents
1202059|NCT01146418|Reproductive Techniques, Assisted
1202060|NCT01146418|Follicle Stimulating Hormone, Human
1202061|NCT01146418|Fertilization In Vitro
1202062|NCT01146405|Laparoscopic
1202063|NCT01146392|Epidemiological
1202064|NCT01146392|COPD health care
1202065|NCT01146392|treatment in primary care
1202066|NCT01146379|stroke
1202067|NCT01146379|upper extremity
1202068|NCT01146379|paresis
1202069|NCT01146379|function
1202070|NCT01146379|translational research
1202071|NCT01146366|Early stage lung cancer
1202072|NCT01146366|Cervical mediastinoscopy
1202073|NCT01146366|Observational study
1202074|NCT01146366|clinical stage T2N0M0 and select T1N0M0 (suvMAX on FDG-PET of >/=10)
1202075|NCT01146353|peramivir
1202076|NCT01146353|CVVH
1202077|NCT01146353|CRRT
1202078|NCT01146353|CVVHD
1202079|NCT01146353|influenza
1202080|NCT01146353|sieving coefficient
1202081|NCT01146353|clearance
1202082|NCT01146340|Prostatic Neoplasms
1202083|NCT01146340|Radiotherapy
1202084|NCT01146340|Hypofractionation
1202085|NCT01146340|Low and Intermediate Risk Prostate Cancer
1202086|NCT01146327|Multiple Dose Study in Overweight Healthy Subjects
1202087|NCT01146327|body weight
1202088|NCT01146314|family-focused intervention
1202089|NCT01146314|pediatric obesity
1202090|NCT01146314|diabetes prevention
1202091|NCT01146301|Platelet Aggregation Inhibitors
1202092|NCT01146301|Coronary Artery Bypass Grafting
1202093|NCT01146288|obesity
1202094|NCT01146288|acetazolamide
1202095|NCT01146288|furosemide
1202096|NCT01146275|Patients who participated in pilot study (31GB0601) and performed breast augmentation with previous formulation of Macrolane
1202097|NCT01146262|Antitumoral immune response after autologous dendritic cells vaccination
1202098|NCT01146249|Multisensorial integration
1202099|NCT01146249|Postural control
1202100|NCT01146249|Visual reliance
1202101|NCT01146236|Surgical
1202102|NCT01146236|Infection
1202103|NCT01146236|Post-operative
1202104|NCT01146236|Sutures
1202105|NCT01146236|Staples
1202106|NCT01146197|Hypokalemia
1202107|NCT01146197|Hypomagnesemia
1202108|NCT01146197|Salt loosing nephropathy
1202109|NCT01146184|Cholelithiasis
1202110|NCT01146184|Single Incision
1202111|NCT01146184|Flexible Endoscope
1202112|NCT01146184|Ethicon Manually Articulating Device
1202113|NCT01146184|Pain
1202114|NCT01146158|Axillary dissection
1202115|NCT01146145|postoperative
1202116|NCT01146145|pain
1202117|NCT01146145|analgesia
1202118|NCT01146145|morphine
1202119|NCT01146145|titration
1202120|NCT01146145|ketamine
1202121|NCT01146132|Nutrition
1202122|NCT01146132|Physical activity
1202123|NCT01146132|Cerebrovascular disease
1202124|NCT01146132|wine consumption
1202125|NCT01146132|BMI
1202126|NCT01146132|Pulse transit time
1202127|NCT01146132|transcranial Doppler sonography
1202128|NCT01146119|HAI
1202129|NCT01146119|Influenza
1202130|NCT01146119|prime
1202131|NCT01146119|boost
1202132|NCT01146119|immune response
1202133|NCT01146119|seroconversion
1202134|NCT01146119|universal
1202135|NCT01146119|vaccine
1202136|NCT01146080|drug eluting stent
1202137|NCT01146080|everolimus eluting stent
1202138|NCT01146080|optical coherence tomography
1202139|NCT01146080|intravascular ultrasound
1202140|NCT01146067|Bioequivalence
1202141|NCT01146041|Bioequivalence
1202142|NCT01146015|Influenza
1202143|NCT01146015|Vaccine
1202144|NCT01146015|CHMP criteria
1202145|NCT01146002|Attention-deficit/hyperactivity disorder, primarily inattentive or combined type.
1202146|NCT01145989|Relapsed or Refractory Multiple Myeloma
1202147|NCT01145976|aplastic anemia, fludarabine, cyclophosphamide, thymoglobulin
1202148|NCT01145963|pasta
1202149|NCT01145963|appetite
1202150|NCT01145963|hunger
1202151|NCT01145963|satiation
1202152|NCT01145963|nutrition
1202153|NCT01145963|Psychological Phenomena and Processes
1202154|NCT01145950|Etanercept
1202155|NCT01145950|Enbrel
1202156|NCT01145950|healthy volunteers
1202157|NCT01145937|Keratoconus
1202159|NCT01145937|Corneal transplantation
1202160|NCT01145937|Anterior Lamellar Keratoplasty
1202161|NCT01145924|bronchoscopy
1202162|NCT01145924|endobronchial ultrasound
1202163|NCT01145924|transbronchial needle aspiration
1202164|NCT01145924|lung cancer
1202165|NCT01145924|staging
1202166|NCT01145911|Glaucoma
1202167|NCT01145911|Blood Flow
1202168|NCT01145911|Progression
1202169|NCT01145898|Glaucoma
1202170|NCT01145898|Cosopt
1202171|NCT01145898|blood flow
1202172|NCT01145898|progression
1202173|NCT01145872|Mindfulness
1202174|NCT01145872|clinical trial
1202175|NCT01145872|intervention
1202176|NCT01145872|prevention
1202177|NCT01145859|Venous Thrombosis
1202178|NCT01145859|Pediatrics
1202179|NCT01145833|obesity
1202180|NCT01145833|guided self help treatment
1202181|NCT01145833|treatment method
1202182|NCT01145833|overweight
1202183|NCT01145833|overweight children and parents
1202184|NCT01145833|families with overweight child
1202185|NCT01145833|efficacy
1202186|NCT01145833|body mass index
1202187|NCT01145833|weight
1202188|NCT01145820|third molar
1202189|NCT01145820|trauma
1202190|NCT01145820|pain
1202191|NCT01145820|wound healing
1202192|NCT01145820|post operative morbidity
1202193|NCT01145820|acute trauma
1202194|NCT01145820|short-term wound healing
1202195|NCT01145807|Distal Subungual Toenail Onychomycosis
1202196|NCT01145794|SHS
1202197|NCT01145781|ectocervical CIN lesions
1202198|NCT01145768|Double-blind
1202199|NCT01145768|randomized
1202200|NCT01145768|placebo-controlled
1202201|NCT01145768|parallel-group study
1202202|NCT01145768|Safety
1202203|NCT01145768|pharmacokinetics
1202204|NCT01145755|Depression
1202205|NCT01145742|Type 2 diabetes
1202206|NCT01145742|Hypertension
1202207|NCT01145742|Health services research
1202208|NCT01145742|Health disparities
1202209|NCT01145742|Behavior change
1202210|NCT01145729|Biomarker feedback
1202211|NCT01145729|Smoking cessation
1202212|NCT01145729|Childhood secondhand smoke exposure
1202213|NCT01145716|TFCC injuries
1202214|NCT01145716|Distal radius fractures
1202215|NCT01145703|Body Composition
1202216|NCT01145703|Cardiovascular Risk
1202217|NCT01145703|Cognitive Function
1202218|NCT01145690|cognitive behaviour therapy
1202219|NCT01145677|Alcohol dependence
1202220|NCT01145677|Alcoholism
1202221|NCT01145677|Topiramate
1202222|NCT01145664|Chinese medicines
1202223|NCT01145664|Severe hand-foot-mouth diseases
1202224|NCT01145664|effectiveness
1202225|NCT01145664|safety
1202226|NCT01145638|cancer
1202227|NCT01145638|chemotherapy induced anaemia
1202228|NCT01145638|iron
1202229|NCT01145638|Patients with non-myeloid malignancies and Chemotherapy Induced Anaemia (CIA)
1202230|NCT01145638|CIA
1202231|NCT01145625|Female Pattern Baldness
1202232|NCT01145612|Aortic dilation
1202233|NCT01145612|Marfan syndrome
1202234|NCT01145612|Losartan
1202235|NCT01145612|Atenolol
1202236|NCT01145573|calcium
1202237|NCT01145573|vitamin D
1202238|NCT01145573|bone
1202239|NCT01145573|pregnancy
1202240|NCT01145560|severe sepsis
1202241|NCT01145560|TNF neutralisation
1202242|NCT01145560|septic shock patients
1202243|NCT01145547|glycemic index
1202244|NCT01145547|Diabetes Mellitus
1202245|NCT01145547|continuous glucose monitoring
1202246|NCT01145534|diabetes,
1202247|NCT01145534|medicinal plants,
1202248|NCT01145534|glucose
1202249|NCT01145482|Memory Disorders
1202250|NCT01145482|Alzheimer's Disease
1202251|NCT01145469|stage I chronic lymphocytic leukemia
1202252|NCT01145469|stage II chronic lymphocytic leukemia
1202253|NCT01145469|stage III chronic lymphocytic leukemia
1202254|NCT01145469|stage IV chronic lymphocytic leukemia
1202255|NCT01145469|B-cell chronic lymphocytic leukemia
1202256|NCT01145443|Organizational models
1202257|NCT01145443|Intensive care units
1202258|NCT01145443|Physicians
1202259|NCT01145443|Staffing and scheduling
1202260|NCT01145443|Burnout, professional
1202261|NCT01145443|Job satisfaction
1202262|NCT01145417|peripheral neuropathic pain
1202263|NCT01145417|pregabalin
1202264|NCT01145417|safety
1202265|NCT01145404|Her2 Gastro Gastric Esophageal Cancer
1202266|NCT01145391|hypertension
1202267|NCT01145391|blood pressure
1202268|NCT01145391|primary care
1202269|NCT01145391|patient centered medical home
1202270|NCT01145391|health information technology
1202271|NCT01145391|clinical inertia
1202272|NCT01144624|TNF neutralisation
1202273|NCT01144611|valve replacement
1202274|NCT01144611|CABG
1202275|NCT01144611|SIRTS
1202276|NCT01144611|Combined aortic valve replacement and CABG surgery
1202277|NCT01144598|Rheumatoid Arthritis
1202278|NCT01144598|Disease-Modifying Anti-Rheumatic Drug
1202279|NCT01144598|Work Limitation
1202280|NCT01144585|RIPC
1202281|NCT01144585|lung protection
1202282|NCT01144585|ischemic reperfusion injury
1202283|NCT01144585|cardiopulmonary bypass
1202284|NCT01144572|Quality of Life
1202285|NCT01144572|postmenopausal HR(+)
1202286|NCT01144572|Early Breast Cancer
1202287|NCT01144572|adjuvant AI treatment
1202288|NCT01144572|Quality of Life in Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
1202289|NCT01144559|Femoral
1202290|NCT01144559|Nerve Block
1202291|NCT01144559|Bolus
1202292|NCT01144559|Continuous Infusion
1202293|NCT01144559|UCSD
1202294|NCT01144559|Perineural Catheter
1202295|NCT01144559|Volunteer
1202296|NCT01144559|lower extremity nerve blocks
1202297|NCT01144546|Passive leg raising
1202298|NCT01144546|FloTrac/Vigileo
1202299|NCT01144546|Anesthesia hypotension
1202300|NCT01144507|Cystic Fibrosis
1202301|NCT01144507|Pancreatic insufficiency
1202302|NCT01144494|Aqueous Humor Dynamics
1202303|NCT01144494|Aqueous Humor Dynamics and Circadian Rhythms
1202304|NCT01145365|Crohns
1202305|NCT01145365|Fistula
1202306|NCT01145365|Perianal Abscess
1202307|NCT01145365|Perianal
1202308|NCT01145352|Enbrel-JIA
1202309|NCT01145326|venipuncture
1202310|NCT01145326|phlebotomy
1202311|NCT01145326|pain perception
1202312|NCT01145300|COPD
1202313|NCT01145300|Inflammation
1202314|NCT01145300|Small airways
1202315|NCT01145287|Celiac disease
1202316|NCT01145287|Gluten-free diet
1202317|NCT01145287|Screen-detected
1202318|NCT01145287|Asymptomatic
1202319|NCT01145287|Quality of life
1202320|NCT01145287|Self-perceived health
1202321|NCT01145287|Healthcare resource utilization
1202322|NCT01145274|allopurinol
1202323|NCT01145274|chronic kidney diseae
1202324|NCT01145261|Anxiety,
1202325|NCT01145261|Emotional Regulation
1202326|NCT01145248|Cholangiocellular Carcinoma
1202327|NCT01145235|Breast augmentation with Macrolane
1202328|NCT01145222|CNS 7056
1202329|NCT01145222|Procedural Sedation
1202330|NCT01145222|Colonoscopy
1202336|NCT01145196|Retinal Disease
1202337|NCT01145196|Plaquenil-Induced
1202338|NCT01145183|Cocaine Dependence
1202339|NCT01145183|Substance Related Disorders
1202340|NCT01145183|genotype
1202341|NCT01145170|brainstem gliomas
1202342|NCT01145170|pediatric patients
1202343|NCT01145157|knee
1202344|NCT01145157|arthroplasty
1202345|NCT01145144|Dehydroepiandrosterone
1202346|NCT01145144|DHEA
1202347|NCT01145144|IVF outcome
1202348|NCT01145144|long protocol IVF
1202349|NCT01145144|poor-responder
1202350|NCT01145144|recombinant LH
1202351|NCT01145144|embryo quality
1202352|NCT01145144|pregnancy rate
1202353|NCT01145144|live birth rate
1202354|NCT01145144|poor response to ovarian stimulation
1202355|NCT01145131|muscle
1202356|NCT01145131|FSR
1202357|NCT01145131|protein
1202358|NCT01145131|meat
1202359|NCT01145118|Plantar Fasciitis
1202360|NCT01145118|Physiotherapy
1202361|NCT01145105|Low back pain
1202362|NCT01145105|Sciatica
1202363|NCT01145105|Pain
1202364|NCT01145105|Physiotherapy
1202365|NCT01145092|type 2 diabetes
1202366|NCT01145092|exercise training
1202367|NCT01145092|ATP-synthesis
1202368|NCT01145092|intramyocellular lipids
1202369|NCT01145092|hepatocellular lipids
1202370|NCT01145092|first degree relatives of T2DM patients
1202371|NCT01145066|diabetes
1202372|NCT01145066|metabolic syndrome
1202373|NCT01145066|inflammation
1202374|NCT01145066|botanical oils
1202375|NCT01145040|Overt primary hypothyroidism
1202376|NCT01145040|Overt primary hyperthyroidism
1202377|NCT01145040|Thyrotropic feedback control
1202378|NCT01145040|Mathematical modelling
1202379|NCT01145040|Nonlinear modelling
1202380|NCT01145040|Thyroid
1202381|NCT01145040|Pituitary
1202382|NCT01145040|Physiological cybernetics
1202383|NCT01145040|Full-dose levothyroxine substitution therapy
1202384|NCT01145040|Syndrome T
1202385|NCT01145027|Capillary recruitment
1202386|NCT01145027|Cephalic Phase of Insulin Secretion
1202387|NCT01145027|Dietary Intake
1202388|NCT01145001|smoking
1202389|NCT01145001|adolescents
1202390|NCT01145001|contingency management
1202391|NCT01145001|nicotine replacement therapy
1202392|NCT01144988|Recurrent Malignant Glioma
1202393|NCT01144988|Bevacizumab / Irinotecan
1202394|NCT01144988|Functional MR Imaging
1202395|NCT01144988|Metabolic Imaging (FET/FLT-PET)
1202396|NCT01144975|Diabetes
1202397|NCT01144975|Type 2
1202398|NCT01144975|Mellitus
1202399|NCT01144962|Crohn's Disease
1202400|NCT01144962|Fistula
1202401|NCT01144962|Mesenchymal Stem Cell
1202402|NCT01144962|Mesenchymal Stromal Cell
1202403|NCT01144962|MSC
1202404|NCT01144962|IBD
1202405|NCT01144949|ureteral calculi
1202406|NCT01144949|renal colic
1202407|NCT01144949|ureteral stones
1202408|NCT01144949|kidney stones
1202409|NCT01144949|medical expulsive therapy
1202410|NCT01144923|epidural steroid injection
1202411|NCT01144923|neck pain
1202412|NCT01144923|pharmacotherapy
1202413|NCT01144923|radiculopathy
1202414|NCT01144910|asthma
1202415|NCT01144910|preschool child
1202416|NCT01144910|bronchial hyperresponsiveness
1202417|NCT01144910|methacholine challenge test
1202418|NCT01144910|atopy
1202419|NCT01144897|Castrate resistant
1202420|NCT01144897|Prostate cancer
1202421|NCT01144897|Docetaxel
1202422|NCT01144897|Taxotere
1202423|NCT01144897|PET Acetate
1202424|NCT01144884|Neck pain
1202425|NCT01144884|education
1202426|NCT01144884|exercise
1202427|NCT01144884|clinical prediction rule
1202428|NCT01144871|adolescent
1202429|NCT01144871|reproductive health
1202430|NCT01144871|parents
1202431|NCT01144871|STIs
1202432|NCT01144871|confidentiality
1202433|NCT01144871|Examine parental knowledge/attitudes of confidential health services/STI care for adolescents.
1202434|NCT01144871|Examine how parental knowledge/attitudes affects parent's behavioral intentions to support adolescent's access to confidential care.
1202435|NCT01144871|Identify key mechanisms to form an intervention to parents knowledge/skills to facilitate teen's access to confidential STI services.
1202436|NCT01144858|atrial fibrillation
1202437|NCT01144858|ablation catheter
1202438|NCT01144858|left atrial appendage peak emptying velocity
1202439|NCT01144858|tool for predicting successful catheter ablation
1202440|NCT01144845|Thoracotomy
1202441|NCT01144845|Thoracic Surgery
1202442|NCT01144845|Thoracic Surgical Procedures
1202443|NCT01144845|Thoracic Surgery, Video-Assisted
1202444|NCT01144845|Lung Neoplasms
1202445|NCT01144845|Thoracic Nerves
1202446|NCT01144832|visceral hypersensitivity
1202447|NCT01144832|mast cells
1202448|NCT01144819|STEMI
1202449|NCT01144819|Acute myocardial infarction
1202450|NCT01144819|Antiplatelet therapy
1202451|NCT01144819|aspirin
1202452|NCT01144819|clopidogrel
1202453|NCT01144819|VerifyNow aggregometry
1202454|NCT01144819|Multiplate aggregometry
1202455|NCT01144806|SAM
1202456|NCT01144806|RUTF
1202457|NCT01144806|BIA
1202458|NCT01144806|D2O
1202459|NCT01144806|Children with severe malnutrition
1202460|NCT01144741|rehabilitation
1202461|NCT01144741|surgery
1202462|NCT01144741|therapy
1202463|NCT01144741|Quality Of Life
1202464|NCT01144741|Health-Related Quality Of Life
1202465|NCT01144741|Health Status
1202466|NCT01144741|Depressive Symptoms
1202467|NCT01144741|Situational Depression
1202468|NCT01144715|Stroke Rehabilitation
1202469|NCT01144715|Home rehabilitation
1202470|NCT01144715|robotic therapy
1202471|NCT01144702|malaria
1202472|NCT01144702|Plasmodium falciparum
1202473|NCT01144702|artesunate and mefloquine combination (ASMQ)
1202474|NCT01144702|treatment
1202475|NCT01144702|Juruá Valley
1202476|NCT01144702|Brazil
1202477|NCT01144702|multidrug resistance 1 gene of Plasmodium falciparum -Pfmdr1
1202478|NCT01144689|mindfulness
1202479|NCT01144689|smoking
1202480|NCT01144689|stress
1202481|NCT01144663|Infants
1202482|NCT01144663|conjugate vaccine
1202483|NCT01144663|immunogenicity
1202484|NCT01144663|meningococcal vaccine
1202485|NCT01144663|non-inferiority
1202486|NCT01144663|co-administration
1202487|NCT01144650|Dapsone
1202488|NCT01144650|Cerebrovascular Accident, Acute
1202489|NCT01144650|Neuroprotection
1202490|NCT01144481|bone metastasis
1202491|NCT01144481|breast cancer
1202492|NCT01144481|skeletal related event
1202493|NCT01144481|HR-pQCT
1202494|NCT01144481|VFA
1202495|NCT01144468|breast cancer prevention
1202496|NCT01144468|osteoporosis
1202497|NCT01144455|Locally Advanced Unresectable Pancreatic Adenocarcinoma
1202498|NCT01144455|Metastatic Pancreatic Adenocarcinoma
1202499|NCT01144455|Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
1202500|NCT01144442|recurrent ovarian cancer
1202501|NCT01144442|recurrent fallopian tube cancer
1202502|NCT01144442|recurrent peritoneal carcinoma
1202503|NCT01144429|Allergic Rhinitis +- intermittent asthma
1202504|NCT01144429|Allergic Rhinoconjunctivitis +- intermittent asthma
1202505|NCT01144429|Specific Immunotherapy
1202506|NCT01144416|Reproductive Techniques, Assisted
1202507|NCT01144416|Follicle Stimulating Hormone, Human
1202508|NCT01144416|Fertilization In Vitro
1202509|NCT01144390|heroin dependence
1202510|NCT01144390|community-based
1202511|NCT01144390|MMT
1202512|NCT01144377|osteoporosis
1202513|NCT01144351|MS
1202514|NCT01144351|SPMS
1202515|NCT01144351|RRMS
1202516|NCT01144351|Relapsing Forms of Secondary Progressive Multiple Sclerosis (SPMS)
1202517|NCT01144351|or Relapsing-Remitting Multiple Sclerosis (RRMS)
1202518|NCT01144338|exenatide once weekly
1202519|NCT01144338|cardiovascular
1202520|NCT01144338|Bydureon
1202521|NCT01144338|Amylin
1202522|NCT01144325|Minimally Invasive Esophagectomy
1202523|NCT01144312|LDLT
1202524|NCT01144299|Influenza
1202525|NCT01144286|VVC
1202526|NCT01144286|candidiasis
1202527|NCT01144286|vaginal candidiasis
1202528|NCT01144260|CLL
1202529|NCT01144260|leukemia
1202530|NCT01144260|chronic lymphocytic leukemia
1202531|NCT01144247|Recurrent Grade III or Grade IV Gliomas
1202532|NCT01144247|anaplastic astrocytoma
1202533|NCT01144247|anaplastic oligodendroglioma
1202534|NCT01144247|anaplastic mixed glioma
1202535|NCT01144247|glioblastoma multiforme
1202536|NCT01144247|biotherapy
1202537|NCT01144247|malignant meningioma
1202538|NCT01144234|Prevention of mother-to-child transmission of HIV-1
1202539|NCT01144221|Chronic Ischemic Heart Disease
1202540|NCT01144208|Radius fracture
1202541|NCT01144208|Adverse effects
1202542|NCT01144208|Wrist
1202543|NCT01144208|Postoperative complications
1202544|NCT01144208|Colles' fracture
1202545|NCT01144208|Intraoperative complications
1202546|NCT01144208|Osteoporosis
1202547|NCT01144208|Dual-energy x-ray absorptiometry (DXA)
1202548|NCT01144208|Bone Density
1202549|NCT01144182|heart failure
1202550|NCT01144182|quality of life
1202551|NCT01144182|readmissions
1202552|NCT01144169|Renal cell carcinoma
1202553|NCT01144169|Hydroxychloroquine
1202554|NCT01144169|Nephrectomy
1202555|NCT01144169|Autophagy
1202556|NCT01144156|Crohn's disease
1202557|NCT01144156|Small bowel
1202558|NCT01144156|Mucosal healing
1202559|NCT01144156|Capsule endoscopy
1202560|NCT01144156|Adalimumab
1202561|NCT01144156|Small bowel Crohn's disease
1202562|NCT01144143|Mild to moderate osteoarthritis of the knee
1202563|NCT01144117|Progressive Multiple Sclerosis
1202564|NCT01144091|diabetes mellitus
1202565|NCT01144091|creatinin level
1202566|NCT01144091|contrast induced nephropathy
1202567|NCT01144091|prevention contrast induced nephropathy in high risk patients
1202568|NCT01144078|Adiposity
1202569|NCT01144078|Exercise training
1202570|NCT01144078|Older adults
1202571|NCT01144065|Myocardial infarction
1202572|NCT01144065|Cortisol
1202573|NCT01144065|Testosterone
1202574|NCT01144052|Natalizumab
1202575|NCT01144052|Interferon-beta 1b
1202576|NCT01144052|De-escalation
1202577|NCT01144052|Ticino
1202578|NCT01144026|HIV
1202579|NCT01144026|vaccine
1202580|NCT01144026|lipopeptide
1202581|NCT01144026|Tat
1202582|NCT01144026|TUTI-16
1202583|NCT01144026|THYMON
1202584|NCT01144000|Prosthetic joint infection
1202585|NCT01144000|daptomycin
1202586|NCT01144000|staphylococcus
1202587|NCT01143987|hyperparathyroidism
1202588|NCT01143987|pulse wave velocity
1202589|NCT01143987|end-stage renal disease
1202590|NCT01143987|arterial stiffness
1202591|NCT01143974|progress free survival
1202592|NCT01143974|response rate
1202593|NCT01143974|safety
1202594|NCT01143961|Positive pressure ventilation
1202595|NCT01143961|Electrical impedance tomography
1202596|NCT01143948|Diabetes
1202597|NCT01143948|Cirrhosis
1202598|NCT01143948|Insulin
1202599|NCT01143948|Inpatient
1202600|NCT01143935|Liver volume estimation
1202601|NCT01143935|Indian population
1202602|NCT01143922|Intraoperative ultrasound
1202603|NCT01143922|GI tract malignancies
1202604|NCT01143922|modality
1202605|NCT01143922|ultrasound
1202606|NCT01143922|staging modality
1202607|NCT01143909|Fresh frozen plasma
1202608|NCT01143909|Coagulopathy
1202609|NCT01143909|Intensive care
1202610|NCT01143909|Adverse effects
1202611|NCT01143909|Lung injury
1202612|NCT01143896|Hepatitis C
1202613|NCT01143896|Depression
1202614|NCT01143896|Collaborative care
1202615|NCT01143896|Antiviral treatment
1202616|NCT01143883|All patients undergoing a colorectal resection
1202617|NCT01143883|surgical site infections
1202618|NCT01143844|Oncofertility
1202619|NCT01143844|Fertility
1202620|NCT01143844|Late effects
1202621|NCT01143844|cancer
1202622|NCT01143844|chemotherapy
1202623|NCT01143844|radiation therapy
1202624|NCT01143844|survivor
1202625|NCT01143844|ovarian reserve
1202626|NCT01143844|premature ovarian failure
1202627|NCT01143844|early menopause
1202628|NCT01143844|healthy volunteers
1202629|NCT01143844|perimenopause
1202630|NCT01143844|middle age
1202631|NCT01143844|pediatric survivors
1202632|NCT01143844|healthy women
1202633|NCT01143831|Vitamin K
1202634|NCT01143831|Thrombosis
1202635|NCT01143818|Male hypogonadism
1202636|NCT01143805|Absolute Bioavailability
1202637|NCT01143805|Rheumatoid Arthritis
1202638|NCT01143792|Substance abuse
1202639|NCT01143792|Homelessness
1202640|NCT01143792|HIV risk behavior
1202641|NCT01143779|Advanced Malignancy
1202642|NCT01143779|FLT-PET Scan
1202643|NCT01143779|[F-18]-fluoro-L-thymidine
1202644|NCT01143779|FLT
1202645|NCT01143779|Positron emission tomography
1202646|NCT01143779|PET
1202647|NCT01143779|Imaging Biomarker
1202648|NCT01143779|Temsirolimus
1202649|NCT01143779|Topotecan
1202650|NCT01143779|Bortezomib
1202651|NCT01143766|Sedation
1202652|NCT01143766|Gabapentin
1202653|NCT01143766|ERCP
1202654|NCT01143766|Endoscopy
1202655|NCT01143675|Humerus fractures
1202656|NCT01143675|Tomography, x-ray computed
1202657|NCT01143675|Bone and bones
1202658|NCT01143675|Orthopedic fixation devices
1202659|NCT01143675|Surgery
1202660|NCT01143675|Postoperative complications
1202661|NCT01143675|Osteoporosis
1202662|NCT01143675|Intraoperative complications
1202663|NCT01143675|Bone density
1202664|NCT01143675|Radiography, dual-energy scanned projection
1202665|NCT01143662|peginterferon
1202666|NCT01143662|interferon
1202667|NCT01143662|Pegasys
1202668|NCT01143662|HBV
1202669|NCT01143662|Hepatitis B
1202670|NCT01143662|HBeAg positive
1202671|NCT01143649|Stroke
1202672|NCT01143649|Transcranial direct current stimulation
1202673|NCT01143649|Motor function
1202674|NCT01143636|Transcranial direct current stimulation
1202675|NCT01143636|Chronic Pelvic Pain
1202676|NCT01143623|antibiotic
1202677|NCT01143623|diarrhea
1202678|NCT01143623|probiotic
1202679|NCT01143610|Root coverage
1202680|NCT01143610|Graft
1202681|NCT01143610|Soft tissue
1202682|NCT01143610|Periodontal regeneration
1202683|NCT01143597|task-specific training
1202684|NCT01143597|arm and hand function
1202685|NCT01143597|corticomotor plasticity
1202686|NCT01143597|individuals with motor-incomplete spinal cord injury
1202687|NCT01143584|Prolactin
1202688|NCT01143584|Cabergoline
1202689|NCT01143584|Macroadenomas
1202690|NCT01143584|escalation
1202691|NCT01143571|Microbiome
1202692|NCT01143571|Samples
1202693|NCT01143558|Borrelia Burgdorferi
1202694|NCT01143558|Xenodiagnosis
1202695|NCT01143558|Ticks
1202696|NCT01143558|Skin Biopsy
1202697|NCT01143558|Lyme Disease
1202698|NCT01143545|Cancer Vaccine
1202699|NCT01143545|Immunotherapy
1202700|NCT01143545|Adjuvant Therapy
1202701|NCT01143545|Surgical Intervention
1202702|NCT01143545|Lung Cancer
1202703|NCT01143545|Esophageal Cancer
1202704|NCT01143545|Thymic Carcinoma
1202705|NCT01143545|Malignant Pleural Mesothelioma
1202706|NCT01143532|African-Americans
1202707|NCT01143532|MYH9
1202708|NCT01143532|Chronic Kidney Disease
1202709|NCT01143532|Focal Segmental Glomerulosclerosis
1202710|NCT01143532|Proteinuria
1202711|NCT01143532|Kidney Disease
1202712|NCT01143532|Kidney Transplant
1202713|NCT01143532|African-American
1202714|NCT01143519|p53
1202715|NCT01143519|Inflammatory Response
1202716|NCT01143519|Gene Association
1202717|NCT01143519|Nutlin
1202718|NCT01143519|Doxorubicin
1202719|NCT01143519|Healthy Volunteer
1202720|NCT01143519|HV
1202721|NCT01143506|Sense of Agency
1202722|NCT01143506|Ulnar Nerve Block
1202723|NCT01143506|Healthy Volunteer
1202724|NCT01143506|fMRI
1202725|NCT01143506|EEG
1202726|NCT01143493|Genetic Polymorphism
1202727|NCT01143493|Glucocorticoid
1202728|NCT01143493|Health Volunteer
1202729|NCT01143493|HV
1202730|NCT01143480|Endotoxin
1202731|NCT01143480|Cytokines
1202732|NCT01143480|Gene Association
1202733|NCT01143480|Inflammatory Response
1202734|NCT01143480|Healthy Volunteer
1202735|NCT01143480|HV
1202736|NCT01143467|Fatigue
1202737|NCT01143467|Mitochondria
1202738|NCT01143467|Mitochondrial Abnormality
1202739|NCT01143467|Oxidative Stress
1202740|NCT01143467|Gene Expression
1202741|NCT01143467|Prostate Cancer
1202742|NCT01143454|Cardiac Disease
1202743|NCT01143454|iPS Cells
1202744|NCT01143454|Cardiac Risk Factors
1202745|NCT01143454|Cardiac Disease Discovery
1202746|NCT01143454|Heart Disease
1202747|NCT01143454|Heart Disease Risk
1202748|NCT01143441|Multiple Sclerosis
1202749|NCT01143441|Daclizumab
1202750|NCT01143428|Motor Neuron Disease
1202751|NCT01143428|Primary Lateral Sclerosis
1202752|NCT01143428|Oxidative Stress
1202753|NCT01143428|Physiology
1202754|NCT01143428|PLS
1202755|NCT01143389|Keratoconus
1202756|NCT01143389|Ectasia
1202757|NCT01143389|cross linking
1202758|NCT01143389|collagen cross linking
1202759|NCT01143376|Obesity
1202760|NCT01143376|exercise
1202761|NCT01143376|body composition
1202762|NCT01143376|insulin sensitivity
1202763|NCT01143376|appetite
1202764|NCT01143376|food intake
1202765|NCT01143363|Obesity
1202766|NCT01143363|exercise
1202767|NCT01143363|appetite
1202768|NCT01143363|hunger
1202769|NCT01143363|satiety
1202770|NCT01143363|food intake
1202771|NCT01143337|Rheumatoid Arthritis
1202772|NCT01143324|Single or double level instrumented fusion
1202773|NCT01143324|Degenerative lumbar spine
1202774|NCT01143324|PLIF
1202775|NCT01143324|TLIF
1202776|NCT01143324|MAST procedure
1202777|NCT01143285|Active nutritional and dietary management
1202778|NCT01143285|Metastatic colorectal cancer
1202779|NCT01143285|Non surgical metastatic colorectal cancer
1202780|NCT01143272|antibiotic
1202781|NCT01143272|associated
1202782|NCT01143272|diarrhoea
1202783|NCT01143272|saccharomyces boulardii
1202784|NCT01143272|Antibiotic-associated diarrhoea (AAD)
1202785|NCT01143272|Clostridium difficile-associated-diarrhoea (CDAD)
1202786|NCT01143259|Ileus
1202787|NCT01143259|Post operative ileus
1202788|NCT01143246|Hepatorenal syndrome
1202789|NCT01143246|Renal failure
1202790|NCT01143246|Cirrhosis
1202791|NCT01143246|Alcoholic hepatitis
1202792|NCT01143246|Ascites
1202793|NCT01143220|Cardiac Resynchronization Therapy
1202794|NCT01143220|Heart Failure
1202795|NCT01143220|Pathologic Processes
1202796|NCT01143220|Heart Diseases
1202797|NCT01143220|Tachycardia
1202798|NCT01143220|Cardiovascular Diseases
1202799|NCT01143220|Ventricular Flutter
1202800|NCT01143220|Tachycardia, Ventricular
1202801|NCT01143220|Ventricular Fibrillation
1202802|NCT01143220|Arrhythmias, Cardiac
1202803|NCT01143220|Ease of Use
1202804|NCT01143207|AE adverse event
1202805|NCT01143207|DCF data collection forms
1202806|NCT01143207|DMC Data Monitoring Committee
1202807|NCT01143207|FDA U.S.) Food and Drug Administration
1202808|NCT01143207|GCP Good Clinical Practice guidelines
1202809|NCT01143207|ICH International Conference of Harmonisation
1202810|NCT01143207|IND Investigational New Drug Application
1202811|NCT01143207|IRB Institutional Review Board
1202812|NCT01143207|IU International units
1202813|NCT01143207|mg milligram(s)
1202814|NCT01143207|SAE serious adverse event
1202815|NCT01143207|µg microgram
1202816|NCT01143207|ULN upper limit of the normal range
1202817|NCT01143194|Attention
1202818|NCT01143194|Vigilance
1202819|NCT01143194|Concentration
1202820|NCT01143194|Memory
1202821|NCT01143194|Healthy Volunteer
1202822|NCT01143181|CMV, ADV, HSV, VAVC, VARV
1202823|NCT01143181|life threatening
1202824|NCT01143168|stem cells;
1202825|NCT01143168|diabetes mellitus;
1202826|NCT01143168|treatment.
1202827|NCT01143155|Pneumonia
1202828|NCT01143155|Community-acquired pneumonia
1202829|NCT01143155|Healthcare-associated pneumonia
1202830|NCT01143155|Failure
1202831|NCT01143155|Cardiovascular events
1202832|NCT01143155|Outcome
1202833|NCT01143142|Human papillomavirus
1202834|NCT01143142|HPV
1202835|NCT01143142|Prevention
1202836|NCT01143142|Tailoring
1202837|NCT01143142|Persuasive communication
1202838|NCT01143142|Adolescent
1202839|NCT01143129|Atrial fibrillation
1202840|NCT01143129|Cardiac surgery
1202841|NCT01143129|Cardiopulmonary bypass
1202842|NCT01143129|New-onset
1202843|NCT01143103|Respiratory therapy in neurologic disorder
1202844|NCT01143090|Schizophrenia
1202845|NCT01143090|Lurasidone
1202846|NCT01143090|Latuda
1202847|NCT01143077|Lurasidone
1202848|NCT01143077|Schizophrenia
1202849|NCT01143077|Latuda
1202850|NCT01143064|Brain Injury
1202851|NCT01143064|Trauma
1202852|NCT01143051|Asthma
1202853|NCT01143051|Pharmacokinetics
1202854|NCT01143051|Epinephrine
1202855|NCT01143051|Bronchodilator
1202856|NCT01143051|metered dose inhaler
1202857|NCT01143038|ITP
1202858|NCT01143025|Laparoscopic Cholecystectomy
1202859|NCT01143025|Nebulization
1202860|NCT01143025|Ropivacaine
1202861|NCT01143012|Group eczema education
1202862|NCT01142986|Methadone
1202863|NCT01142986|Syringe exchange
1202864|NCT01142986|Treatment retention
1202865|NCT01142986|Voucher incentives
1202866|NCT01142947|Inhaled corticosteroids
1202867|NCT01142947|Asthma
1202868|NCT01142947|Pharmacogenomics
1202869|NCT01142947|Genome wide association study
1202870|NCT01142947|Admixture mapping
1202871|NCT01142947|Continental population groups
1202872|NCT01142934|Catheter-related bloodstream infections
1202873|NCT01142934|Chlorhexidine
1202874|NCT01142934|Transparent dressings
1202875|NCT01142921|Stent Occlusion
1202876|NCT01142921|Biliary Bleeding
1202877|NCT01142921|Biliary Perforation
1202878|NCT01142908|Cardiovascular Disease
1202879|NCT01142908|Hypertension
1202880|NCT01142908|Diabetes
1202881|NCT01142908|Hyperlipidemia
1202882|NCT01142908|Adherence
1202883|NCT01142882|adolescent HIV prevention
1202884|NCT01142882|web-based interventions
1202885|NCT01142882|adolescent substance abuse treatment
1202886|NCT01142882|comparative effectiveness research
1202887|NCT01142882|HIV prevention
1202888|NCT01142882|hepatitis prevention
1202889|NCT01142882|STI prevention
1202890|NCT01142869|Carcinoma, Squamous Cell
1202891|NCT01142869|Erbitux
1202892|NCT01142869|Neoplasms, Squamous Cell
1202893|NCT01142843|clinical trial
1202894|NCT01142843|mouthwash
1202895|NCT01142843|green propolis
1202896|NCT01142843|dental plaque
1202897|NCT01142843|gingivitis
1202898|NCT01142830|Craniotomy
1202899|NCT01142830|Pain
1202900|NCT01142830|Children
1202901|NCT01142817|HIV
1202902|NCT01142817|Women
1202903|NCT01142817|Menopause
1202904|NCT01142817|Dyslipidemia
1202905|NCT01142817|Bone Mineral Density
1202906|NCT01142804|Walking programs
1202907|NCT01142804|Physical Activity
1202908|NCT01142804|Behavior Modification
1202909|NCT01142804|Social Support
1202910|NCT01142791|Uterine fibroids
1202911|NCT01142791|MRgFUS
1202912|NCT01142791|ExAblate
1202913|NCT01142791|Focused Ultrasound
1202914|NCT01142791|Symptomatic uterine fibroids
1202915|NCT01142765|Vaccine
1202916|NCT01142765|Safety
1202917|NCT01142765|Immunogenicity
1202918|NCT01142765|Protection
1202919|NCT01142765|Sporozoite challenge
1202920|NCT01142713|Small Bowel Radiotherapy Dose
1202921|NCT01142713|This is a prospective non-randomized open study to evaluate the impact of patient's positioning and use of belly board in rectal radiotherapy
1202922|NCT01142687|Resting energy expenditure (REE)
1202923|NCT01142687|metabolic rate
1202924|NCT01142674|Lymphoma, T-Cell, Peripheral
1202925|NCT01142674|Prognosis
1202926|NCT01142674|Outcome
1202927|NCT01142674|International Cooperation
1202928|NCT01142674|Biological Characteristics
1202929|NCT01142674|Heterogeneity
1202930|NCT01142674|Rare Diseases
1202931|NCT01142661|Advanced breast cancer refractory to all commercially available therapies
1202932|NCT01142648|Electroencephalogram
1202933|NCT01142648|Electromyogram
1202934|NCT01142648|Entropy Index
1202935|NCT01142648|Bispectral Index
1202936|NCT01142648|Reversal of neuromuscular blockade
1202937|NCT01142635|Electroencephalogram
1202938|NCT01142635|Electromyogram
1202939|NCT01142635|Entropy Index
1202940|NCT01142635|Bispectral Index
1202941|NCT01142635|Neuromuscular blockade; rocuronium
1202942|NCT01142635|Propofol
1202943|NCT01142635|Intubation
1202944|NCT01142622|Ovarian Cysts
1202945|NCT01142622|Nebulization
1202946|NCT01142622|Ropivacaine
1202947|NCT01142609|Web based videoconferencing
1202948|NCT01142609|methadone
1202949|NCT01142609|substance abuse counseling
1202950|NCT01142583|Multiple sclerosis
1202951|NCT01142583|Expanded Disability Status Scale
1202952|NCT01142583|Multiple Sclerosis, Relapsing-Remitting
1202953|NCT01142570|Mechanical Ventilation
1202954|NCT01142557|Multiple sclerosis
1202955|NCT01142557|Rebif
1202956|NCT01142557|Interferon-beta
1202957|NCT01142544|acute lung injury
1202958|NCT01142544|incidence
1202959|NCT01142544|lung damage
1202960|NCT01142544|PaO2/FiO2 ratio
1202961|NCT01142518|Interferon beta-1a
1202962|NCT01142518|Multiple Sclerosis
1202963|NCT01142505|wheeze
1202964|NCT01142505|preschool
1202965|NCT01142505|leukotriene
1202966|NCT01142505|montelukast
1202967|NCT01142505|5-lipoxygenase
1202968|NCT01142492|Interferon beta
1202969|NCT01142492|Multiple Sclerosis
1202970|NCT01142479|Breast Cancer
1202971|NCT01142479|Radiotherapy
1202972|NCT01142479|Chinese herbal medicine
1202973|NCT01142479|TPE-1
1202974|NCT01142479|Leukopenia
1202975|NCT01142466|Multiple sclerosis
1202976|NCT01142466|Expanded Disability Status Scale
1202977|NCT01142466|Multiple Sclerosis, Relapsing-Remitting
1202978|NCT01142466|Rebif
1202979|NCT01142466|Beta-1, interferon
1202980|NCT01142453|Multiple sclerosis
1202981|NCT01142453|Rebif
1202982|NCT01142453|Interferon
1202983|NCT01142414|stage III squamous cell carcinoma of the hypopharynx
1202984|NCT01142414|stage IV squamous cell carcinoma of the hypopharynx
1202985|NCT01142414|stage III squamous cell carcinoma of the larynx
1202986|NCT01142414|stage IV squamous cell carcinoma of the larynx
1202987|NCT01142414|stage III squamous cell carcinoma of the lip and oral cavity
1202988|NCT01142414|stage IV squamous cell carcinoma of the lip and oral cavity
1202989|NCT01142414|stage III squamous cell carcinoma of the oropharynx
1202990|NCT01142414|stage IV squamous cell carcinoma of the oropharynx
1202991|NCT01142414|tongue cancer
1202992|NCT01142375|AML
1202993|NCT01142362|H5N1
1202994|NCT01142362|Avian Influenza
1202995|NCT01142362|DNA Vaccine
1202996|NCT01142362|Intramuscular (IM) Injection
1202997|NCT01142362|Electroporation
1202998|NCT01142362|Healthy Adults
1202999|NCT01142349|Arthritis
1203000|NCT01142349|Group Program
1203001|NCT01142349|Pain
1203002|NCT01142349|Insomnia
1203373|NCT01140932|Physiology
1203003|NCT01142349|Pain dysfunction and sleep disturbance among older adults with osteoarthritis.
1203004|NCT01142336|Alzheimer's Disease
1203005|NCT01142336|Prevention
1203006|NCT01142336|Spinal Fluid
1203007|NCT01142336|Biomarkers
1203008|NCT01142336|Simvastatin
1203009|NCT01142297|dental implant
1203010|NCT01142297|implant stabilization
1203011|NCT01142297|type 2 diabetes
1203012|NCT01142297|glycated hemoglobin 8.0-12.0%
1203013|NCT01142284|Biomarker
1203014|NCT01142284|Endothelial Function
1203015|NCT01142284|Peripheral Artery Disease
1203016|NCT01142284|Coronary Artery Disease
1203017|NCT01142284|Flow Mediated Dilation
1203018|NCT01142284|Cilostazol
1203019|NCT01142284|Probucol
1203020|NCT01142271|Distal gastrectomy
1203021|NCT01142271|Reconstruction
1203022|NCT01142271|Reflux
1203023|NCT01142271|subtotal gastrectomy
1203024|NCT01142258|Sleep Disturbances
1203025|NCT01142258|Alzheimer disease
1203026|NCT01142258|Insomnia
1203027|NCT01142258|Trazodone
1203028|NCT01142258|Treatment
1203029|NCT01142245|ulcer bleeding
1203030|NCT01142245|endoscopic therapy
1203031|NCT01142232|autologous stem cell transplantation
1203032|NCT01142219|sickle cell disease
1203033|NCT01142219|L-arginine
1203034|NCT01142219|hemolysis
1203035|NCT01142219|nitric oxide
1203036|NCT01142219|pulmonary arterial hypertension
1203037|NCT01142206|Obesity
1203038|NCT01142206|Weight Loss
1203039|NCT01142206|Leisure-time activities
1203040|NCT01142206|Physical Activity
1203041|NCT01142206|Television watching
1203042|NCT01142206|Dietary Intake
1203043|NCT01142206|Energy
1203044|NCT01142206|Behavioral
1203045|NCT01142206|Healthy Eating
1203046|NCT01142193|Epilepsy
1203047|NCT01142193|partial onset seizure
1203048|NCT01142193|adjunctive therapy
1203049|NCT01142180|Bleeding peptic ulcer
1203050|NCT01142180|Active bleeding
1203051|NCT01142180|Trans-arterial angiographic embolization
1203052|NCT01142167|Ultra-thin colonoscope
1203053|NCT01142154|Cockayne Syndrome
1203054|NCT01142154|Ageing
1203055|NCT01142154|pediatrics
1203056|NCT01142154|Pharmacokinetics
1203057|NCT01142154|Prodarsan
1203058|NCT01142154|Dwarfism
1203059|NCT01142154|Genetic disease, inborn
1203060|NCT01142154|DNA Repair-Deficiency Disorders
1203061|NCT01142154|Tolerability
1203062|NCT01142154|Safety
1203063|NCT01142102|Bladder
1203064|NCT01142102|Radiotherapy
1203065|NCT01142102|Online
1203066|NCT01142102|Adaptive
1203067|NCT01142089|traveler's
1203068|NCT01142089|diarrhea
1203069|NCT01142076|adiposity
1203070|NCT01142063|Neratinib
1203071|NCT01142050|stem cells;
1203072|NCT01142050|diabetes mellitus;
1203073|NCT01142050|treatment.
1203074|NCT01142037|Healthy volunteer
1203075|NCT01142024|contrast medium induced nephropathy
1203076|NCT01142024|polymorphism of oxidative stress genes
1203077|NCT01142024|antioxidant prevention
1203078|NCT01142011|Waldenstroms
1203079|NCT01142011|Belimumab
1203080|NCT01142011|anti Blys
1203081|NCT01142011|monoclonal antibody
1203082|NCT01141985|cataract
1203083|NCT01141985|cornea
1203084|NCT01141985|keratoplasty
1203085|NCT01141972|Vitamin D
1203086|NCT01141972|Obesity
1203087|NCT01141972|Menopause
1203088|NCT01141972|Hot Flashes
1203089|NCT01141959|hematopoietic stem cell transplantation
1203090|NCT01141959|cyclophosphamide
1203091|NCT01141959|fludarabine
1203092|NCT01141959|mycophenolate mofetil
1203093|NCT01141959|mycophenolic acid
1203094|NCT01141959|biomarkers
1203095|NCT01141946|lung cancer
1203096|NCT01141946|pleural effusion
1203097|NCT01141946|post-op care
1203098|NCT01141946|diaphragmatic ultrasound
1203099|NCT01141933|Creating meaning
1203100|NCT01141933|Therapy
1203101|NCT01141933|Cancer
1203102|NCT01141933|Oncology
1203103|NCT01141933|Existential
1203104|NCT01141933|Spirituality
1203105|NCT01141933|Quality of life
1203106|NCT01141933|QOL
1203107|NCT01141933|Psycho-oncology
1203108|NCT01141933|French-canadian
1203109|NCT01141933|Cognitive therapy
1203110|NCT01141933|Existentialism
1203111|NCT01141920|treatment retention
1203112|NCT01141920|methadone maintenance
1203113|NCT01141920|treatment induction
1203114|NCT01141920|Retention in methadone maintenance treatment
1203115|NCT01141907|heart failure
1203116|NCT01141907|self care
1203117|NCT01141907|decision support
1203118|NCT01141907|telemonitoring
1203119|NCT01141907|navigator
1203120|NCT01141894|Proximal Femoral Fracture
1203121|NCT01141881|Tissue Plasminogen activator,
1203122|NCT01141881|Clinically significant macular edema,
1203123|NCT01141881|Refractory Diabetic macular edema ,
1203124|NCT01141881|posterior vitreous detachment
1203125|NCT01141868|insomnia
1203126|NCT01141868|breast cancer survivor
1203127|NCT01141868|Internet intervention
1203128|NCT01141855|Cardiovascular Diseases
1203129|NCT01141855|Peripheral Vascular Diseases
1203130|NCT01141855|Cerebrovascular Stroke
1203131|NCT01141855|Lung Diseases, Obstructive
1203132|NCT01141855|Asthma
1203133|NCT01141855|Tobacco Use Disorder
1203134|NCT01141855|Smoking
1203135|NCT01141855|Smoking Cessation
1203136|NCT01141842|lung cancer
1203137|NCT01141842|exhalation analysis
1203138|NCT01141842|chronic obstructive pulmonary disease
1203139|NCT01141842|cancer screening test
1203140|NCT01141829|NADPH oxidase
1203141|NCT01141816|renal cell carcinoma
1203142|NCT01141816|radiofrequency ablation
1203143|NCT01141816|contrast enhanced ultrasound
1203144|NCT01141816|monitoring
1203145|NCT01141816|follow up
1203146|NCT01141803|Apple
1203147|NCT01141803|Apple pomace
1203148|NCT01141803|Metabolomics
1203149|NCT01141803|Gene expression
1203150|NCT01141803|Lipid metabolism
1203151|NCT01141803|Prevention
1203152|NCT01141803|Antiinflammatory effect
1203153|NCT01141790|Glasgow Coma Scale
1203154|NCT01141790|Glasgow Outcome Scale
1203155|NCT01141790|Ethics
1203156|NCT01141777|Spirulina platensis
1203157|NCT01141777|Insulin resistance
1203158|NCT01141777|HIV/AIDS
1203159|NCT01141777|HAART
1203160|NCT01141777|Soya beans
1203161|NCT01141764|pediatrics
1203162|NCT01141764|Epilepsy
1203163|NCT01141764|Deep Brain Stimulation
1203164|NCT01141764|Positron Emission Tomography
1203165|NCT01141751|Multiple sclerosis
1203166|NCT01141751|Expanded Disability Status Scale
1203167|NCT01141751|Multiple Sclerosis, Relapsing-Remitting; Rebif
1203168|NCT01141751|Beta-1, interferon
1203169|NCT01141738|stroke
1203170|NCT01141738|caregiver
1203171|NCT01141738|depression
1203172|NCT01141738|mediators
1203173|NCT01141738|problem-solving
1203174|NCT01141712|HIV
1203175|NCT01141712|B-cell Lymphoma
1203176|NCT01141712|Burkitt's Lymphoma
1203177|NCT01141712|Follicular Lymphoma
1203178|NCT01141712|Hodgkin's Lymphoma
1203179|NCT01141699|women health behaviors
1203180|NCT01141686|lung cancer
1203181|NCT01141673|FLT3-ITD
1203182|NCT01141673|acute myeloid leukemia
1203183|NCT01141673|FLT3
1203184|NCT01141673|D835
1203185|NCT01141647|Adult
1203186|NCT01141647|Depression
1203187|NCT01141647|Supported Employment
1203188|NCT01141647|Health Service
1203189|NCT01141647|Humans
1203190|NCT01141647|Outcomes
1203191|NCT01141647|Quality of Life
1203192|NCT01141647|Veterans/rh (rehabilitation)
1203193|NCT01141647|Workplace
1203194|NCT01141647|Spinal Cord Injuries
1203195|NCT01141634|Attention Deficit Hyperactivity Disorder
1203196|NCT01141634|Attention Deficit Disorder
1203197|NCT01141634|ADHD
1203198|NCT01141634|ADD
1203199|NCT01141634|Homeopathy
1203200|NCT01141621|HS
1203201|NCT01141621|congenital hemolytic anemia
1203202|NCT01141621|splenectomy
1203203|NCT01141621|quality of life
1203204|NCT01141556|selenium
1203205|NCT01141556|clinical outcome
1203206|NCT01141556|heart surgery
1203207|NCT01141543|Plerixafor injection
1203208|NCT01141530|Identify novel genes and predict putative proteins in breast cancer.
1203209|NCT01141530|Find biomarkers that can be used for early detection, diagnosis, and prognosis.
1203210|NCT01141517|adolescent quit-smoking program.
1203211|NCT01141504|Supplemental ATP
1203212|NCT01141504|Muscle Work Performed
1203213|NCT01141504|Muscle Fatigue
1203214|NCT01141491|Sarcoma
1203215|NCT01141491|Metastatic
1203216|NCT01141491|Vaccine
1203217|NCT01141491|Adjuvant
1203218|NCT01141478|Carcinoma, Hepatocellular
1203219|NCT01141478|Proton Beam Radiotherapy
1203220|NCT01141478|Sorafenib
1203221|NCT01141465|Primary care
1203222|NCT01141465|Asthma management
1203223|NCT01141465|Combined therapy
1203224|NCT01141465|Real-world
1203225|NCT01141465|Effectiveness
1203226|NCT01141465|Control
1203227|NCT01141465|Exacerbations
1203228|NCT01141452|chronic obstructive pulmonary disease
1203229|NCT01141452|inhaled corticosteroid
1203230|NCT01141452|increase
1203231|NCT01141452|initiate
1203232|NCT01141452|exacerbations
1203233|NCT01141452|treatment success
1203234|NCT01141439|Primary care
1203235|NCT01141439|Asthma management
1203236|NCT01141439|Inhaled corticosteroids
1203237|NCT01141439|Beclomethasone dipropionate
1203238|NCT01141439|Fluticasone propionate
1203239|NCT01141439|Metred dose inhaler
1203240|NCT01141439|Extra-fine hydrofluoroalkane
1203241|NCT01141439|Chlorofluorocarbon
1203242|NCT01141426|depression
1203243|NCT01141426|treatment-resistance
1203244|NCT01141426|psychodynamic psychotherapy
1203245|NCT01141426|Treatment refractory depression
1203246|NCT01141374|Stress
1203247|NCT01141361|Claudication
1203248|NCT01141361|Artery
1203249|NCT01141361|Ambulatory technique
1203250|NCT01141361|GPS
1203251|NCT01141335|shrinkage
1203252|NCT01141335|postoperative pain and discomfort
1203863|NCT01138878|acceptability
1203253|NCT01141322|drug-induced liver injury
1203254|NCT01141322|hepatitis, toxic
1203255|NCT01141322|ursodeoxycholic acid
1203256|NCT01141309|Everolimus
1203257|NCT01141309|Sorafenib
1203258|NCT01141309|Thyroid
1203259|NCT01141309|10-060
1203260|NCT01141283|Osteoarthritis
1203261|NCT01141283|Opioid
1203262|NCT01141283|Transdermal
1203263|NCT01141270|recombinant human follicle stimulating hormone
1203264|NCT01141270|pharmacokinetics
1203265|NCT01141270|bioequivalence
1203266|NCT01141257|Angiocal®; PRS-050-PEG40; Solid tumor; Phase I
1203267|NCT01141231|hypopharyngeal cancer
1203268|NCT01141231|laryngeal cancer
1203269|NCT01141231|lip and oral cavity cancer
1203270|NCT01141231|nasopharyngeal cancer
1203271|NCT01141231|oropharyngeal cancer
1203272|NCT01141231|paranasal sinus and nasal cavity cancer
1203273|NCT01141231|salivary gland cancer
1203274|NCT01141231|radiation toxicity
1203275|NCT01141231|xerostomia
1203276|NCT01141231|long-term effects of cancer treatment
1203277|NCT01141231|oral complications of radiation therapy
1203278|NCT01141218|non-small cell lung cancer
1203279|NCT01141205|AIDS vaccines
1203280|NCT01141205|HIV-1 vaccine
1203281|NCT01141205|Therapeutic vaccine
1203282|NCT01141205|Cellular immunity
1203283|NCT01141192|vitamin D status
1203284|NCT01141192|25-OH D
1203285|NCT01141192|ionized calcium
1203286|NCT01141192|fasting glucose
1203287|NCT01141192|hemoglobin A1c
1203288|NCT01141192|fasting insulin
1203289|NCT01141192|glucose metabolism
1203290|NCT01141192|HOMA index
1203291|NCT01141192|blood lipids
1203292|NCT01141192|type 2 diabetes
1203293|NCT01141192|PTH
1203294|NCT01141192|adiposity
1203295|NCT01141192|body fat percentage
1203296|NCT01141192|dual energy x-ray absorptiometry
1203297|NCT01141192|pulse wave velocity
1203298|NCT01141192|arterial stiffness
1203299|NCT01141192|flow-mediated dilation
1203300|NCT01141192|African American
1203301|NCT01141192|inflammatory markers
1203302|NCT01141166|ELDERLY
1203303|NCT01141166|NUTRITION
1203304|NCT01141153|atrial fibrillation
1203305|NCT01141153|Coronary Stent implantation
1203306|NCT01141153|Low-moderate risk of stroke
1203307|NCT01141153|dual antiplatelet therapy
1203308|NCT01141153|anticoagulation
1203309|NCT01141127|tranexamic acid in pediatric surgery
1203310|NCT01141127|fibrinolysis and paediatric cardiac surgery
1203311|NCT01141114|community health centers
1203312|NCT01141114|colorectal cancer screening
1203313|NCT01141114|urban health
1203314|NCT01141101|Methicillin-resistant Staphylococcus aureus
1203315|NCT01141101|Neonatal
1203316|NCT01141101|Vertical transmission
1203317|NCT01141101|Horizontal transmission
1203318|NCT01141101|MRSA colonization in enrolled infants
1203319|NCT01141101|MRSA colonization obtained from maternal source
1203320|NCT01141101|MRSA colonization obtained from source other that mother
1203321|NCT01141062|Uterine Fibroids
1203322|NCT01141049|Alcohol Withdrawal
1203323|NCT01141049|Reducing Alcohol Consumption
1203324|NCT01141049|Promoting abstinence in alcohol-dependent patients
1203325|NCT01141049|Gabapentin
1203326|NCT01141036|Propofol
1203327|NCT01141036|Midazolam
1203328|NCT01141036|sedation
1203329|NCT01141036|cirrhosis
1203330|NCT01141036|endoscopy
1203331|NCT01141036|recovery time
1203332|NCT01141036|efficacy and safety of sedation
1203333|NCT01141036|patient satisfaction
1203334|NCT01141036|return to baseline function
1203335|NCT01141036|saturation of oxygen
1203336|NCT01141023|Parkinson
1203337|NCT01141023|Bio-markers
1203338|NCT01141023|Neurodegenerative disorder
1203339|NCT01141023|Imaging
1203340|NCT01141023|Prodromal
1203341|NCT01141010|Linguistic
1203342|NCT01141010|Stress response
1203343|NCT01141010|Corticosteroid
1203344|NCT01141010|Cesarean section
1203345|NCT01141010|Anxiety
1203346|NCT01141010|Depression
1203347|NCT01141010|Maternal psychosis
1203348|NCT01140997|HCV
1203349|NCT01140997|CHC
1203350|NCT01140997|Hepatitis C, Chronic
1203351|NCT01140997|Liver Diseases
1203352|NCT01140997|Hepatitis, Chronic
1203353|NCT01140997|Hepatitis, Viral, Human
1203354|NCT01140997|Hepadnaviridae Infections
1203355|NCT01140997|Antiviral Agents
1203356|NCT01140997|Virus Diseases
1203357|NCT01140997|Peginterferon alfa
1203358|NCT01140984|acute graft versus host disease
1203359|NCT01140984|intra arterial steroid infusion
1203360|NCT01140984|steroid resistant acute hepatic graft versus host disease
1203361|NCT01140971|Balloon dilatation,
1203362|NCT01140971|misoprostol,
1203363|NCT01140971|cervical ripening,
1203364|NCT01140971|obstetric labor,
1203365|NCT01140971|labor induced.
1203366|NCT01140958|lung cancer
1203367|NCT01140958|pharmacoeconomics
1203368|NCT01140958|new agents
1203369|NCT01140932|Retina
1203370|NCT01140932|Electroretinography
1203371|NCT01140932|Diabetes Mellitus
1203372|NCT01140932|Glucose Intolerance
1203374|NCT01139879|Pressure Ulcer treatment Mattresses
1203375|NCT01139879|Home Care
1203376|NCT01139879|Extended Care
1203377|NCT01139879|Wound measurements
1203378|NCT01139866|Long-term Safety
1203379|NCT01139866|Shoulder Surgery
1203380|NCT01139866|bupivacaine
1203381|NCT01139853|pyloric stenosis
1203382|NCT01139853|nasogastric tube
1203383|NCT01139853|pyloromyotomy
1203384|NCT01140906|Major depressive disorder
1203385|NCT01140906|Placebo-controlled
1203386|NCT01140906|Active reference
1203387|NCT01140906|Multicenter study
1203388|NCT01140906|Randomised study
1203389|NCT01140906|Acute treatment
1203390|NCT01140893|Type 2 diabetes
1203391|NCT01140893|CSII
1203392|NCT01140893|Exenatide
1203393|NCT01140893|Double Blind Placebo Controlled Study
1203394|NCT01140880|Methamphetamine
1203395|NCT01140880|Amphetamine
1203396|NCT01140880|Cocaine
1203397|NCT01140880|HIV
1203398|NCT01140880|Post-exposure prophylaxis
1203399|NCT01140880|HIV seronegativity
1203400|NCT01140854|hypertension
1203401|NCT01140854|hypotension
1203402|NCT01140854|cognitive
1203403|NCT01140854|neurocognitive
1203404|NCT01140854|cognitive dysfunction
1203405|NCT01140854|postoperative cognitive dysfunction (POCD)
1203406|NCT01140854|neuropsychometric
1203407|NCT01140841|Dyskinesia
1203408|NCT01140828|Arthritis
1203409|NCT01140828|Bone pain
1203410|NCT01140828|dyspepsia
1203411|NCT01140815|Total Knee Arthroplasty
1203412|NCT01140815|Bicompartmental Knee Arthroplasty
1203413|NCT01140802|First degree relatives
1203414|NCT01140802|Crohn's disease
1203415|NCT01140802|Ulcerative colitis
1203416|NCT01140802|Healthy control
1203417|NCT01140776|metastasis
1203418|NCT01140776|molecular pathology
1203419|NCT01140763|metastasis
1203420|NCT01140750|Heart Rate Variability
1203421|NCT01140750|Temperature Curve Complexity
1203422|NCT01140750|Autonomic Dysfunction
1203423|NCT01140750|Prolonged Mechanical Ventilation
1203424|NCT01140750|Failure to Wean
1203425|NCT01140737|advanced soft tissue sarcoma
1203426|NCT01140724|pain
1203427|NCT01140724|genes
1203428|NCT01140724|morphine
1203429|NCT01140724|respiratory depression
1203430|NCT01140724|tonsillectomy
1203431|NCT01140724|children
1203432|NCT01140724|Opioid adverse effects
1203433|NCT01140724|Pharmacogenetics of morphine
1203434|NCT01140724|Pharmacokinetics of morphine
1203435|NCT01140724|Personalizing analgesia
1203436|NCT01140685|mucus-stimulated (induced sputum)
1203437|NCT01140685|lung disease (asthma, COPD, ILD and OLD)
1203438|NCT01140685|HO-1 (heme oxigenase-1)
1203439|NCT01140685|oxidative stress
1203440|NCT01140685|CO (carbon monoxide)
1203441|NCT01140685|The oxidative stress in lung diseases
1203442|NCT01140672|Healthy volunteers
1203443|NCT01140672|pharmacokinetics
1203444|NCT01140672|safety
1203445|NCT01140672|tolerability
1203446|NCT01140672|multiple dosing
1203447|NCT01140672|Diabetic Nephropathies
1203448|NCT01140659|Hyperhidrosis
1203449|NCT01140659|Thoracic sympathectomy
1203450|NCT01140659|Objective measurement of sweat
1203451|NCT01140646|Hot flashes, dietary supplements, symptom management
1203452|NCT01140633|HIV/AIDS
1203453|NCT01140633|pediatric
1203454|NCT01140633|wireless adherence monitoring
1203455|NCT01140633|HIV Infections
1203456|NCT01140620|NMDA receptor antagonism
1203457|NCT01140620|cognitive processes
1203458|NCT01140620|healthy volunteers
1203459|NCT01140620|dopamine antagonist
1203460|NCT01140620|schizophrenia
1203461|NCT01140568|glioma
1203462|NCT01140568|PDGFR
1203463|NCT01140568|kinase
1203464|NCT01140568|inhibitor
1203465|NCT01140568|malignant
1203466|NCT01140568|nilotinib
1203467|NCT01140542|Diabetes Mellitus Type 2
1203468|NCT01140542|Roflumilast
1203469|NCT01140529|Dexmedetomidine
1203470|NCT01140516|Antenatal
1203471|NCT01140490|Hemodialysis
1203472|NCT01140490|Sub-total Parathyroidectomy
1203473|NCT01140464|Adolescents
1203474|NCT01140438|Latent autoimmune diabetes
1203475|NCT01140438|adults
1203476|NCT01140438|Beta cell rest
1203477|NCT01140438|Insulin secretion
1203478|NCT01140425|PF-00232798
1203479|NCT01140425|CCR5
1203480|NCT01140425|QT
1203481|NCT01140425|QTc
1203482|NCT01140425|pharmacokinetics
1203483|NCT01140412|maraviroc
1203484|NCT01140412|fosamprenavir
1203485|NCT01140412|drug interaction
1203486|NCT01140412|pharmacokinetics
1203487|NCT01140412|HIV
1203488|NCT01140412|AIDS
1203489|NCT01140412|CCR5
1203490|NCT01140412|protease inhibitor
1203491|NCT01140399|1 Acute Decompensated Heart Failure
1203492|NCT01140399|2 Cardiorenal Syndrome
1203493|NCT01140399|3 Ultrafiltration
1203494|NCT01140399|4 Dopamine
1203495|NCT01140386|venous thromboembolism
1203496|NCT01140386|duplex ultrasound
1203497|NCT01140386|pediatric population
1203498|NCT01140386|Vascular lab duplex ultrasound database
1203499|NCT01140386|Inpatient hospital admission/discharge ICD-9 database
1203500|NCT01140386|PTSF pediatric trauma database
1203501|NCT01140373|Prostate
1203502|NCT01140373|Autologous T Cells
1203503|NCT01140373|Castrate Metastatic Prostate Cancer
1203504|NCT01140373|cyclophosphamide
1203505|NCT01140373|09-036
1203506|NCT01140360|Neurofibromas
1203507|NCT01140347|Hepatocellular carcinoma (HCC)
1203508|NCT01140347|recombinant human immunoglobulin G
1203509|NCT01140347|subclass 1 (IgG1) monoclonal antibody (MAb)
1203510|NCT01140347|Hepatocellular Carcinoma (HCC) following First-Line Therapy With Sorafenib
1203511|NCT01140334|Psychiatric adherence
1203512|NCT01140334|Voucher incentives
1203513|NCT01140334|Methadone treatment
1203514|NCT01140321|Thalassemia
1203515|NCT01140321|Neridronate
1203516|NCT01140321|Osteopenia
1203517|NCT01140321|Osteoporosis
1203518|NCT01140308|Statin Myopathy
1203519|NCT01140308|CoEnzyme Q10
1203520|NCT01140308|CoQ10
1203521|NCT01140308|Statin Myalgia
1203522|NCT01140295|Preparation
1203523|NCT01140295|Pediatric
1203524|NCT01140295|Colonoscopy
1203525|NCT01140282|cancer survivor
1203526|NCT01140269|Burn
1203527|NCT01140269|Sepsis
1203528|NCT01140269|Infection
1203529|NCT01140256|Zinc
1203530|NCT01140256|SGA
1203531|NCT01140256|AGA
1203532|NCT01140256|stable isotope
1203533|NCT01140243|fat formulation
1203534|NCT01140230|rotator cuff tear
1203535|NCT01140230|rotator cuff repair
1203536|NCT01140230|age
1203537|NCT01140230|timing to surgery
1203538|NCT01140217|contraception
1203539|NCT01140217|pregnancy
1203540|NCT01140204|stent
1203541|NCT01140204|contrast media
1203542|NCT01140204|paclitaxel
1203543|NCT01140204|stent implantation
1203544|NCT01140191|leishmaniasis
1203545|NCT01140191|cutaneous
1203546|NCT01140191|WR 279,396
1203547|NCT01140191|paromomycin
1203548|NCT01140191|gentamicin
1203549|NCT01140191|pharmacokinetics
1203550|NCT01140191|safety
1203551|NCT01140191|efficacy
1203552|NCT01140191|military
1203553|NCT01140178|Photodynamic Therapy
1203554|NCT01140178|Oral dysplasia
1203555|NCT01140178|oral cavity carcinoma
1203556|NCT01140178|oropharynx carcinoma.
1203557|NCT01140152|intestinal transplantation
1203558|NCT01140152|rejection
1203559|NCT01140152|proteomics
1203560|NCT01140152|innate immunity
1203561|NCT01140126|HIV-1, CD4, antibody, immunotherapy
1203562|NCT01140113|hemoconcentration
1203563|NCT01140113|ultrafiltration
1203564|NCT01140113|coronary artery disease
1203565|NCT01140087|Face Transplant
1203566|NCT01140087|Composite Tissue Allograft
1203567|NCT01140087|Facial Allotransplantation
1203568|NCT01140074|acute diarrhoea, children
1203569|NCT01140048|Asthma
1203570|NCT01140035|Insulin
1203571|NCT01140035|Deceased donors
1203572|NCT01140035|Renal Allograft Function
1203573|NCT01140035|Transplanted Allograft Outcomes
1203574|NCT01140022|Chlamydia, Screening, young women, kiosk, computer module
1203575|NCT01140009|Vaccine
1203576|NCT01140009|Seasonal Influenza vaccine
1203577|NCT01140009|Influenza vaccine
1203578|NCT01140009|Vaccine safety
1203579|NCT01140009|Vaccine immunogenicity
1203580|NCT01140009|Fluviral 2010/11
1203581|NCT01139983|osteosarcoma
1203582|NCT01139944|recurrent non-small cell lung cancer
1203583|NCT01139944|stage I non-small cell lung cancer
1203584|NCT01139944|stage II non-small cell lung cancer
1203585|NCT01139944|squamous cell lung cancer
1203586|NCT01139931|childhood acute myeloid leukemia/other myeloid malignancies
1203587|NCT01139918|psoriatic arthritis
1203588|NCT01139918|psoriasis
1203589|NCT01139918|Quality of life
1203590|NCT01139905|Lopinavir/ritonavir
1203591|NCT01139905|pharmacokinetic
1203592|NCT01139905|low dose
1203593|NCT01139905|HIV-infected children
1203594|NCT01139905|pharmacokinetics of low-dose lopinavir/ritonavir in HIV-1 infected Thai children.
1203595|NCT01139892|Unruptured aneurysm
1203596|NCT01139892|endovascular treatment
1203597|NCT01139892|surgical treatment
1203598|NCT01139892|randomized
1203599|NCT01139892|intracranial aneurysm
1203600|NCT01139840|vitamin D2
1203601|NCT01139840|vitamin D3
1203602|NCT01139840|ergocalciferol
1203603|NCT01139840|cholecalciferol
1203604|NCT01139840|vitamin D status
1203605|NCT01139840|To determine relative potency of vitamins D2 and D3 under conditions of continuous administration
1203606|NCT01139840|To determine change in vitamin D content of subcutaneous fat after 12 weeks' administration
1203607|NCT01139827|atherosclerosis
1203608|NCT01139827|inflammation
1203609|NCT01139827|hsCRP
1203610|NCT01139827|Framingham risk score
1203611|NCT01139827|positron emission tomography
1203612|NCT01139827|inflammation in FDG-PET
1203613|NCT01139814|atrial flutter
1203614|NCT01139814|AVNRT
1203615|NCT01139814|right sided accessory pathway
1203616|NCT01139814|ventricular tachycardia
1203864|NCT01138878|feasibility
1203617|NCT01139814|Patients who have one or more standard indications for a right-sided diagnostic electrophysiology procedure.
1203618|NCT01139801|Cervical Ripening
1203619|NCT01139801|Rate of Cesearean Section
1203620|NCT01139788|Cancer
1203621|NCT01139775|solid tumors
1203622|NCT01139775|Mesothelioma
1203623|NCT01139775|Carcinoma
1203624|NCT01139762|Benign Prostatic Hyperplasia (BPH)
1203625|NCT01139762|Enlarged Prostate
1203626|NCT01139749|oral isotretinoin
1203627|NCT01139749|sebaceous secretion
1203628|NCT01139749|seborrhea
1203629|NCT01139749|seborrheic dermatitis
1203630|NCT01139749|quality of life
1203631|NCT01139749|Malassezia
1203632|NCT01139736|Irritable bowel syndrome
1203633|NCT01139736|IBS
1203634|NCT01139736|probiotics
1203635|NCT01139736|rectal sensitivity
1203636|NCT01139736|gut flora
1203637|NCT01139736|gut bacteria
1203638|NCT01139710|SARCOIDOSIS
1203639|NCT01139710|PULMONARY HYPERTENSION
1203640|NCT01139710|outpatients clinic at Meir medical center
1203641|NCT01139697|Heart failure
1203642|NCT01139697|Cortisol
1203643|NCT01139697|Testosterone
1203644|NCT01139684|Exercise test
1203645|NCT01139671|Remifentanil
1203646|NCT01139671|Sufentanil
1203647|NCT01139671|Surgical removal of three to four wisdom teeth
1203648|NCT01139671|General anaesthesia
1203649|NCT01139671|Ambulatory oral surgery
1203650|NCT01139671|Target Controlled Infusion (TCI)
1203651|NCT01139671|Opioid induced hyperalgesia
1203652|NCT01139671|Postoperative nausea and vomiting
1203653|NCT01139671|Postoperative Morphine consumption
1203654|NCT01139671|Under General anaesthesia
1203655|NCT01139671|In Ambulatory surgery
1203656|NCT01139645|Calcium
1203657|NCT01139645|bone
1203658|NCT01139645|metabolism
1203659|NCT01139645|Proton Pump Inhibitors
1203660|NCT01139645|Rabeprazole
1203661|NCT01139645|Esomeprazole
1203662|NCT01139645|Lanzoprazole
1203663|NCT01139645|Vitamin D
1203664|NCT01139645|bone and bones
1203665|NCT01139632|NAFLD
1203666|NCT01139632|lP-pla2
1203667|NCT01139632|Coronary Arthery Disease
1203668|NCT01139619|Biopsy Mapping
1203669|NCT01139619|Non small cell lung cancer
1203670|NCT01139619|NSCLC
1203671|NCT01139619|Lung cancer diagnosis
1203672|NCT01139619|Retrospective
1203673|NCT01139619|Inoperable Non Small Cell Lung Cancer
1203674|NCT01139593|IVF
1203675|NCT01139593|ICSI
1203676|NCT01139593|gonadotropin
1203677|NCT01139593|am dose
1203678|NCT01139593|pm dose
1203679|NCT01139593|pregnancy
1203680|NCT01139593|implantation
1203681|NCT01139593|live birth
1203682|NCT01139580|Plaque Psoriasis
1203683|NCT01139580|Psoriasis
1203684|NCT01139567|Diabetic Wounds
1203685|NCT01139567|Hyperbaric Oxygen
1203686|NCT01139567|Laser Speckle Imaging
1203687|NCT01139567|Hyperbaric Oxygenation
1203688|NCT01139528|Fracture
1203689|NCT01139528|5th metacarpal bone
1203690|NCT01139528|Bouquet pinning
1203691|NCT01139528|Fractures of the neck of the 5th metacarpal bone
1203692|NCT01139515|pharmacokinetic
1203693|NCT01139515|eletriptan
1203694|NCT01139515|Korean
1203695|NCT01139515|crossover
1203696|NCT01139502|schizophrenia spectrum disorders
1203697|NCT01139502|work rehabilitation
1203698|NCT01139502|cognitive therapy
1203699|NCT01139502|cognitive training
1203700|NCT01139502|Adaptation to work
1203701|NCT01139502|Work as a treatment factor
1203702|NCT01139489|Procalcitonin
1203703|NCT01139489|antibiotic therapy
1203704|NCT01139489|antibiotics
1203705|NCT01139489|sepsis
1203706|NCT01139489|infections
1203707|NCT01139489|biomarker
1203708|NCT01139476|Multiple Myeloma
1203709|NCT01139476|MGUS
1203710|NCT01139476|Leukemia
1203711|NCT01139476|Biorepository
1203712|NCT01139463|antipsychotics
1203713|NCT01139463|lactates
1203714|NCT01139463|side effects
1203715|NCT01139450|Atopic Dermatitis
1203716|NCT01139437|Vaccine
1203717|NCT01139437|HPIV2
1203718|NCT01139437|Infants
1203719|NCT01139424|surgical leak
1203720|NCT01139424|endoscopic suturing
1203721|NCT01139424|Anastomotic leakage
1203722|NCT01139424|esophageal or gastric resection
1203723|NCT01139398|Cholesterol
1203724|NCT01139398|LDL-cholesterol
1203725|NCT01139398|Coronary artery disease
1203726|NCT01139398|Red yeast rice
1203727|NCT01139398|Plants extract
1203728|NCT01139398|Cholesterol excess.
1203729|NCT01139372|Dry eye, artificial tears
1203730|NCT01139359|Lymphoma
1203731|NCT01139359|Darinaparsin
1203732|NCT01139359|CHOP
1203733|NCT01139359|Frontline
1203734|NCT01139359|PTCL
1203735|NCT01139359|B-cell
1203736|NCT01139346|carcinoma
1203737|NCT01139346|sarcoma
1203738|NCT01139346|metastatic
1203739|NCT01139346|solid tumor
1203740|NCT01139333|childhood acute myeloid leukemia/other myeloid malignancies
1203741|NCT01139320|untreated childhood acute myeloid leukemia and other myeloid malignancies
1203742|NCT01139307|adult acute megakaryoblastic leukemia (M7)
1203743|NCT01139307|childhood acute megakaryocytic leukemia (M7)
1203744|NCT01139307|recurrent adult acute myeloid leukemia
1203745|NCT01139307|recurrent childhood acute myeloid leukemia
1203746|NCT01139307|untreated adult acute myeloid leukemia
1203747|NCT01139307|untreated childhood acute myeloid leukemia and other myeloid malignancies
1203748|NCT01139294|cardiac output
1203749|NCT01139294|dehydration
1203750|NCT01139294|pediatrics
1203751|NCT01139281|Ear protection
1203752|NCT01139281|Ginkgo Biloba Extract
1203753|NCT01139281|Distortion-product otoacoustic emission
1203754|NCT01139281|Ototoxicity
1203755|NCT01139281|Cisplatin
1203756|NCT01139268|embryo viability
1203757|NCT01139242|CRC screening status
1203758|NCT01139242|physical activity level
1203759|NCT01139242|fruit and vegetable consumption
1203760|NCT01139242|Early Detection of Cancer
1203761|NCT01139242|Colorectal Cancer (CRC) screening status
1203762|NCT01139229|Esophagogastrostomy
1203763|NCT01139229|Circular everted anastomosis
1203764|NCT01139229|Side-side anastomosis
1203765|NCT01139229|Randomized clinical trial
1203766|NCT01139216|Digestive system diseases
1203767|NCT01139216|Gastrointestinal diseases
1203768|NCT01139216|Intestinal diseases
1203769|NCT01139216|Colonic inertia
1203770|NCT01139203|HBV recurrence
1203771|NCT01139203|entecavir
1203772|NCT01139190|NSAID-induced gastroduodenal ulcerations or erosion
1203773|NCT01139177|Peripheral vascular disease - SFA and popliteal arteries.
1203774|NCT01139164|high-risk hematological malignancies
1203775|NCT01139151|Advanced Hematologic Malignancies
1203776|NCT01139151|4'-Thio-araC
1203777|NCT01139151|Thiarabine
1203778|NCT01139151|4'-thio-â-D-arabinofuranosylcytosine
1203779|NCT01139151|deoxycytidine nucleoside analog
1203780|NCT01139151|poor-risk myelodysplasia
1203781|NCT01139151|MDS
1203782|NCT01139151|refractory anemia
1203783|NCT01139151|Excess blasts
1203784|NCT01139151|RAEB-1
1203785|NCT01139151|RAEB-2
1203786|NCT01139151|Chronic myelomonocytic leukemia
1203787|NCT01139151|CMML
1203788|NCT01139151|Relapsed/refractory leukemia
1203789|NCT01139151|Acute non-lymphocytic leukemia
1203790|NCT01139151|AML
1203791|NCT01139151|Acute lymphocytic leukemia
1203792|NCT01139151|ALL
1203793|NCT01139151|Chronic lymphocytic leukemia
1203794|NCT01139151|CLL
1203795|NCT01139151|Chronic myelogenous leukemia
1203796|NCT01139151|CML
1203797|NCT01139151|blast crisis
1203798|NCT01139138|Colorectal Cancer
1203799|NCT01139138|Colorectal Carcinoma
1203800|NCT01139138|Colorectal Tumors
1203801|NCT01139138|Neoplasms, Colorectal
1203802|NCT01139112|Necrotizing Fasciitis, Klebsiella Pneumoniae
1203803|NCT01139086|chronic heart failure
1203804|NCT01139086|isokinetic test
1203805|NCT01139086|near-infrared spectroscopy
1203806|NCT01139086|laser Doppler flowmetry
1203807|NCT01139086|endothelial function
1203808|NCT01139073|Halitosis
1203809|NCT01139060|chronic or recurrent depression
1203810|NCT01139021|Children
1203811|NCT01139021|Meningococcal disease
1203812|NCT01139021|Prevention
1203813|NCT01139021|Vaccination
1203814|NCT01138995|Poststroke/CVA hemiparesis
1203815|NCT01138995|Drop Foot
1203816|NCT01138995|Gait Disorders, Neurological
1203817|NCT01138995|Gait, Drop foot
1203818|NCT01138982|Youth mentoring
1203819|NCT01138982|Effectiveness
1203820|NCT01138982|Sweden
1203821|NCT01138982|low-risk youth
1203822|NCT01138969|proton pump inhibitor
1203823|NCT01138969|peptic ulcer
1203824|NCT01138969|clopidogrel
1203825|NCT01138969|prevention
1203826|NCT01138956|Visceral leishmaniasis
1203827|NCT01138956|N-acetylcysteine
1203828|NCT01138956|Antimony
1203829|NCT01138956|Immune response
1203830|NCT01138943|Chlorhexidine mouthrinse
1203831|NCT01138943|Plaque control
1203832|NCT01138930|Polycystic Ovary Syndrome
1203833|NCT01138930|Obesity
1203834|NCT01137903|Diabetic foot
1203835|NCT01137903|Osteomyelitis
1203836|NCT01137903|Diabetic foot ulcers
1203837|NCT01137903|Foot infections
1203838|NCT01137890|cocaine
1203839|NCT01137890|addiction
1203840|NCT01137890|drug dependence
1203841|NCT01137890|anticonvulsant
1203842|NCT01137890|zonisamide
1203843|NCT01137890|drug self-administration
1203844|NCT01137890|nicotine withdrawal
1203845|NCT01137890|neurocognition
1203846|NCT01137864|Emergency wards
1203847|NCT01137864|Hospitalization
1203848|NCT01137864|Adults
1203849|NCT01137864|Antimicrobial therapy
1203850|NCT01138904|gastric cancer
1203851|NCT01138904|oxaliplatin
1203852|NCT01138904|irinotecan
1203853|NCT01138904|sequential treatment
1203854|NCT01138891|Breast implants
1203855|NCT01138891|capsular contraction
1203856|NCT01138891|sonication
1203857|NCT01138891|biofilm
1203858|NCT01138891|Complications
1203859|NCT01138891|surgery
1203860|NCT01138878|HIV
1203861|NCT01138878|testing
1203862|NCT01138878|non traditional settings
1203865|NCT01138865|Obstructive sleep apnea
1203866|NCT01138865|Cytokine levels
1203867|NCT01138865|Insulin resistance
1203868|NCT01138865|Hypertension
1203869|NCT01138865|Dyslipidemia
1203870|NCT01138865|Albumin-creatinine ratio
1203871|NCT01138865|Continuous positive airway pressure (CPAP)
1203872|NCT01138852|post-cesarean infections
1203873|NCT01138852|ampicillin-sulbactam
1203874|NCT01138852|cefuroxime
1203875|NCT01138852|cesarean
1203876|NCT01138839|HELLP 1
1203877|NCT01138839|Dexamethasone
1203878|NCT01138839|Clinical trial
1203879|NCT01138826|biological availability
1203880|NCT01138826|bioavailability
1203881|NCT01138826|amlodipine
1203882|NCT01138826|orally disintegrating tablet
1203883|NCT01138826|ODT
1203884|NCT01138826|tablets
1203885|NCT01138813|magnetic resonance spectroscopy (MRS)
1203886|NCT01138813|lactate editing
1203887|NCT01138813|metabolite content
1203888|NCT01138813|glioma
1203889|NCT01138774|Obesity
1203890|NCT01138774|Calorie restriction
1203891|NCT01138774|Eicosapentaenoic acid (EPA)
1203892|NCT01138774|Lipoic acid
1203893|NCT01138774|Weight loss
1203894|NCT01138774|Insulin sensitivity
1203895|NCT01138774|Lipid metabolism
1203896|NCT01138774|Adipokines
1203897|NCT01138774|Inflammation
1203898|NCT01138774|Oxidative stress
1203899|NCT01138774|Adipose tissue gene profile
1203900|NCT01138774|Metabolomic profile
1203901|NCT01138761|pediatric atopic dermatitis
1203902|NCT01138761|EASI
1203903|NCT01138761|REALM-SF
1203904|NCT01138761|nurse instruction
1203905|NCT01138761|health literacy
1203906|NCT01138748|inoperable early stage non-small cell lung cancer
1203907|NCT01138748|radiation therapy
1203908|NCT01138722|early stage non-small cell lung cancer
1203909|NCT01138722|hypofractionated radiation therapy
1203910|NCT01138696|ACL
1203911|NCT01138683|Acute decompensated heart failure
1203912|NCT01138683|ultrafiltration
1203913|NCT01138683|diuretics
1203914|NCT01138683|AKI
1203915|NCT01138657|inflammation of uvea
1203916|NCT01138644|Atrial Fibrillation
1203917|NCT01138644|Atrial Flutter
1203918|NCT01138631|IVF, Infertility, embryo selection, embryoscope, time-lapse
1203919|NCT01138618|Clozapine
1203920|NCT01138618|hematological monitoring
1203921|NCT01138618|CHEMPAQ
1203922|NCT01138618|Granulocytes
1203923|NCT01138618|WBC
1203924|NCT01138605|TMC114
1203925|NCT01138605|TMC114-TiDP29-C232
1203926|NCT01138605|TMC114-C232
1203927|NCT01138605|Darunavir
1203928|NCT01138605|PREZISTA
1203929|NCT01138579|FBTA05
1203930|NCT01138579|CD20
1203931|NCT01138579|CLL
1203932|NCT01138579|NHL
1203933|NCT01138579|DLI
1203934|NCT01138579|allogeneic transplantation
1203935|NCT01138579|CD20 positive chronic lymphocytic leukemia (CLL)
1203936|NCT01138579|low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantation with active disease
1203937|NCT01138566|community-onset urinary tract infections caused by Enterobacteriaceae
1203938|NCT01138553|biomarker
1203939|NCT01138553|breast cancer
1203940|NCT01138553|antiprogesterone
1203941|NCT01138540|VAP
1203942|NCT01138527|multi-parametric MRI approach
1203943|NCT01138475|PTH
1203944|NCT01138475|Gastric bypass surgery
1203945|NCT01138475|vitamin D
1203946|NCT01138475|paricalcitol
1203947|NCT01138462|Methicillin-Resistant Staphylococcus aureus
1203948|NCT01138462|Decolonisation
1203949|NCT01138462|Nursing homes
1203950|NCT01138462|Infection Control
1203951|NCT01138449|Vitamin A
1203952|NCT01138449|Neonatal mortality
1203953|NCT01138449|Infant mortality
1203954|NCT01138436|Venous Leg Ulcers, VLU
1203955|NCT01138423|Hypertension
1203956|NCT01138423|Metabolic Syndrome X
1203957|NCT01138423|Obesity
1203958|NCT01138423|Adiposity
1203959|NCT01138423|Clinical trial
1203960|NCT01138410|Immunotherapy
1203961|NCT01138410|Melanoma
1203962|NCT01138410|Gene therapy
1203963|NCT01138410|DNA plasmid
1203964|NCT01138410|Cancer vaccine
1203965|NCT01138410|Electroporation
1203966|NCT01138410|CTL response
1203967|NCT01138397|Influenza
1203968|NCT01138397|Influenza vaccine
1203969|NCT01138397|Influenza virus
1203970|NCT01138397|Intradermal
1203971|NCT01138384|Breast Cancer
1203972|NCT01138371|LDL apheresis
1203973|NCT01138371|Familial hypercholesterolemia
1203974|NCT01138371|Inflammatory markers
1203975|NCT01138371|Hyperlipidemia
1203976|NCT01138371|Cardiovascular disease
1203977|NCT01138358|dyspnea
1203978|NCT01138358|lung metastases
1203979|NCT01138358|recurrent non-small cell lung cancer
1203980|NCT01138358|recurrent small cell lung cancer
1203981|NCT01138358|extensive stage small cell lung cancer
1203982|NCT01138358|stage IIIA non-small cell lung cancer
1203983|NCT01138358|stage IIIB non-small cell lung cancer
1203984|NCT01138358|stage IV non-small cell lung cancer
1203985|NCT01138345|cancer survivor
1203986|NCT01138345|stage I breast cancer
1203987|NCT01138345|stage II breast cancer
1203988|NCT01138345|stage IIIA breast cancer
1203989|NCT01138345|stage IIIB breast cancer
1203990|NCT01138345|stage IIIC breast cancer
1203991|NCT01138332|childhood acute myeloid leukemia/other myeloid malignancies
1203992|NCT01138319|adult acute myeloid leukemia
1203993|NCT01138319|childhood acute myeloid leukemia/other myeloid malignancies
1203994|NCT01138306|childhood acute myeloid leukemia/other myeloid malignancies
1203995|NCT01138293|differences between patients´ self-assessment and objective perception of physical activity and eating habits
1203996|NCT01138280|biofilm formation
1203997|NCT01138280|proinflammatory cytokines
1203998|NCT01138280|high sensitive c reactive protein
1203999|NCT01138280|cardiovascular events
1204000|NCT01138280|overall mortality
1204001|NCT01138280|hemodialysis
1204002|NCT01138267|pharmacogenomics
1204003|NCT01138267|ATV
1204004|NCT01138267|EFV
1204005|NCT01138267|pharmacogenomics of ATV and EFV
1204006|NCT01138254|flow,echocardiography,far infrared therapy,nitric oxide
1204007|NCT01138241|HIV
1204008|NCT01138241|Chronic kidney disease
1204009|NCT01138241|Glomerular Filtration Rate (GFR)
1204010|NCT01138241|Tenofovir
1204011|NCT01138241|Serum creatinine (sCr)
1204012|NCT01138241|24 hr urine creatinine clearance
1204013|NCT01138241|Serum Cystatin C[40]
1204014|NCT01138241|Modification of Diet in Renal Disease (MDRD)
1204015|NCT01138241|Cockcroft Gault Equation
1204016|NCT01138241|Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
1204017|NCT01138241|99mTc-diethylenetriaminepentaacetic acid (Tc-99m DTPA) scan
1204018|NCT01138241|Validate which renal function assessments can accurately detect GFR and assess the effect of TDF concentration on renal function
1204019|NCT01138228|intravenous cannulation
1204020|NCT01138228|vein identification
1204021|NCT01138228|vascular identification
1204022|NCT01138228|vein cannulation
1204023|NCT01138215|varicella-zoster virus vaccine
1204024|NCT01138215|varicella-zoster virus antibody
1204025|NCT01138215|immunogenicity
1204026|NCT01138215|safety and efficacy
1204027|NCT01138215|HIV-infected children
1204028|NCT01138215|Assess protective VZV Antibody
1204029|NCT01138215|Adverse events from VZV vaccine
1204030|NCT01138202|pharmacokinetics
1204031|NCT01138202|safety
1204032|NCT01138202|efficacy
1204033|NCT01138202|Lopinavir/ritonavir
1204034|NCT01138202|HIV/TB
1204035|NCT01138202|rifampicin containing anti-tuberculosis therapy
1204036|NCT01138202|Pharmacokinetics and safety of Lopinavir/ritonavir with rifampicin containing anti-tuberculosis therapy
1204037|NCT01138189|Wavefront-guided LASIK.
1204038|NCT01138189|Wavefront-optimized LASIK.
1204039|NCT01138189|Custom LASIK
1204040|NCT01138176|Neonatal encephalopathy
1204041|NCT01138176|Therapeutic hypothermia
1204042|NCT01138176|Phase changing material
1204043|NCT01138176|MR imaging
1204044|NCT01138163|NSCLC
1204045|NCT01138163|second-line
1204046|NCT01138163|lung cancer
1204047|NCT01138163|non small cell lung cancer
1204048|NCT01138163|bavituximab
1204049|NCT01138163|monoclonal antibody
1204050|NCT01138150|migraine, headache, sumatriptan, naproxen sodium
1204051|NCT01138137|ovarian cancer
1204052|NCT01138137|epithelial ovarian cancer
1204053|NCT01138137|peritoneal cancer
1204054|NCT01138124|renal cell carcinoma
1204055|NCT01138124|epidemiology
1204056|NCT01138124|pancreatic cancer
1204057|NCT01138124|renal cancer
1204058|NCT01138124|renal pelvis cancer
1204059|NCT01138124|GPRD
1204060|NCT01138124|case-control
1204061|NCT01138124|Gapabentin
1204062|NCT01138111|Florbetaben
1204063|NCT01138111|Amyloid beta-protein
1204064|NCT01138111|MCI
1204065|NCT01138111|Alzheimer's disease
1204066|NCT01138098|Persistence
1204067|NCT01138098|challenge dose
1204068|NCT01138098|Engerix-B
1204069|NCT01138098|immune response
1204070|NCT01138085|Triple negative breast cancer
1204071|NCT01138085|BRAF wild-type melanoma
1204072|NCT01138085|Solid tumors
1204073|NCT01138085|Endometrial Cancer
1204074|NCT01138085|Oncology
1204075|NCT01138085|GSK2141795
1204076|NCT01138085|AKT Inhibitor
1204077|NCT01138085|GSK1120212
1204078|NCT01138072|GSK2248761, atorvastatin, rosuvastatin, simvastatin, drug interaction, pharmacokinetics
1204079|NCT01138059|Acute ischemic stroke with unclear onset time
1204080|NCT01138046|advanced/metastatic breast cancer
1204081|NCT01138046|lapatinib
1204082|NCT01138046|ErbB2
1204083|NCT01138046|ErbB2-overexpressing
1204084|NCT01138046|pharmacokinetics
1204085|NCT01138046|dual kinase inhibitor
1204086|NCT01138046|HER-2/neu
1204087|NCT01138046|EGFR
1204088|NCT01138046|ErbB1
1204089|NCT01138033|pharmacodynamics
1204090|NCT01138033|cancer
1204091|NCT01138033|focal adhesion kinase inhibitor
1204092|NCT01138033|pharmacokinetics
1204093|NCT01138033|solid tumors
1204094|NCT01138033|Phase 1
1204095|NCT01138020|Rehabilitation Outcome
1204096|NCT01138020|Cognitive treatment
1204097|NCT01138020|TBI
1204098|NCT01138007|Bupropion
1204099|NCT01138007|323U66 Sustained Release (SR)
1204100|NCT01138007|MDD (Major Depressive Disorder)
1204101|NCT01138007|IVRS HAM-D
1204102|NCT01138007|IDS-SR
1204103|NCT01138007|MADRS
1204104|NCT01137994|ErbB2
1204105|NCT01137994|Trastuzumab
1204106|NCT01137994|p95HER2
1204107|NCT01137994|Metastatic Breast Cancer
1204108|NCT01137994|HER2
1204109|NCT01137994|Lapatinib
1204110|NCT01137981|Combivir (Zidovudine+Lamivudine)
1204111|NCT01137981|Antiretrovirals
1204112|NCT01137981|ARV
1204113|NCT01137981|HAART
1204114|NCT01137981|Maraviroc
1204115|NCT01137981|Delavirdine
1204116|NCT01137981|Lamivudine
1204117|NCT01137981|Antiretroviral Pregnancy Registry
1204118|NCT01137981|Fosamprenavir
1204119|NCT01137981|APR
1204120|NCT01137981|Zidovudine
1204121|NCT01137981|pregnancy registry
1204122|NCT01137981|Amprenavir
1204123|NCT01137981|HIV
1204124|NCT01137981|Trizivir (Abacavir+Lamivudine+Zidovudine)
1204125|NCT01137981|Epzicom (Abacavir+Lamivudine)
1204126|NCT01137968|imetelstat
1204127|NCT01137968|imetelstat sodium
1204128|NCT01137968|GRN163L
1204129|NCT01137968|telomerase inhibitor
1204130|NCT01137968|telomerase inhibition
1204131|NCT01137968|maintenance therapy
1204132|NCT01137968|non-small cell lung cancer
1204133|NCT01137968|relapsed non-small cell lung cancer
1204134|NCT01137968|advanced non-small cell lung cancer
1204135|NCT01137968|NSCLC, cancer stem cells
1204136|NCT01137968|Bevacizumab
1204137|NCT01137968|post induction chemotherapy
1204138|NCT01137955|Gastrointestinal Symptom Rating Scale (GSRS)
1204139|NCT01137955|Poorly responsive
1204140|NCT01137955|Refractory
1204141|NCT01137955|Small intestine bacterial overgrowth
1204142|NCT01137955|Breath test
1204143|NCT01137942|helicobacter pylori
1204144|NCT01137942|eradication failure
1204145|NCT01137929|Vesicoureteral reflux
1204146|NCT01137929|Kidney
1204147|NCT01137929|Renal Scar
1204148|NCT01137929|Urinary tract infection
1204149|NCT01137825|cognitive/functional effects
1204150|NCT01137825|unspecified adult solid tumor, protocol specific
1204151|NCT01137825|accelerated phase chronic myelogenous leukemia
1204152|NCT01137825|acute undifferentiated leukemia
1204153|NCT01137825|adult acute lymphoblastic leukemia in remission
1204154|NCT01137825|adult acute myeloid leukemia in remission
1204155|NCT01137825|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1204156|NCT01137825|adult acute myeloid leukemia with inv(16)(p13;q22)
1204157|NCT01137825|adult acute myeloid leukemia with t(15;17)(q22;q12)
1204158|NCT01137825|adult acute myeloid leukemia with t(16;16)(p13;q22)
1204159|NCT01137825|adult acute myeloid leukemia with t(8;21)(q22;q22)
1204160|NCT01137825|atypical chronic myeloid leukemia, BCR-ABL negative
1204161|NCT01137825|blastic phase chronic myelogenous leukemia
1204162|NCT01137825|chronic myelomonocytic leukemia
1204163|NCT01137825|chronic phase chronic myelogenous leukemia
1204164|NCT01137825|mast cell leukemia
1204165|NCT01137825|meningeal chronic myelogenous leukemia
1204166|NCT01137825|progressive hairy cell leukemia, initial treatment
1204167|NCT01137825|prolymphocytic leukemia
1204168|NCT01137825|recurrent adult acute lymphoblastic leukemia
1204169|NCT01137825|recurrent adult acute myeloid leukemia
1204170|NCT01137825|recurrent adult T-cell leukemia/lymphoma
1204171|NCT01137825|refractory chronic lymphocytic leukemia
1204172|NCT01137825|refractory hairy cell leukemia
1204173|NCT01137825|relapsing chronic myelogenous leukemia
1204174|NCT01137825|secondary acute myeloid leukemia
1204175|NCT01137825|stage 0 chronic lymphocytic leukemia
1204176|NCT01137825|stage I adult T-cell leukemia/lymphoma
1204177|NCT01137825|stage I chronic lymphocytic leukemia
1204178|NCT01137825|stage II adult T-cell leukemia/lymphoma
1204179|NCT01137825|stage II chronic lymphocytic leukemia
1204180|NCT01137825|stage III adult T-cell leukemia/lymphoma
1204181|NCT01137825|stage III chronic lymphocytic leukemia
1204182|NCT01137825|stage IV adult T-cell leukemia/lymphoma
1204183|NCT01137825|stage IV chronic lymphocytic leukemia
1204184|NCT01137825|T-cell large granular lymphocyte leukemia
1204185|NCT01137825|untreated adult acute lymphoblastic leukemia
1204186|NCT01137825|untreated adult acute myeloid leukemia
1204187|NCT01137825|untreated hairy cell leukemia
1204188|NCT01137825|recurrent adult Hodgkin lymphoma
1204189|NCT01137825|stage I adult Hodgkin lymphoma
1204190|NCT01137825|stage II adult Hodgkin lymphoma
1204191|NCT01137825|stage III adult Hodgkin lymphoma
1204192|NCT01137825|stage IV adult Hodgkin lymphoma
1204193|NCT01137825|anaplastic large cell lymphoma
1204194|NCT01137825|angioimmunoblastic T-cell lymphoma
1204195|NCT01137825|cutaneous B-cell non-Hodgkin lymphoma
1204196|NCT01137825|recurrent cutaneous T-cell non-Hodgkin lymphoma
1204197|NCT01137825|stage I cutaneous T-cell non-Hodgkin lymphoma
1204198|NCT01137825|stage II cutaneous T-cell non-Hodgkin lymphoma
1204199|NCT01137825|stage III cutaneous T-cell non-Hodgkin lymphoma
1204200|NCT01137825|stage IV cutaneous T-cell non-Hodgkin lymphoma
1204201|NCT01137825|recurrent mycosis fungoides/Sezary syndrome
1204202|NCT01137825|stage I mycosis fungoides/Sezary syndrome
1204203|NCT01137825|stage II mycosis fungoides/Sezary syndrome
1204204|NCT01137825|stage III mycosis fungoides/Sezary syndrome
1204615|NCT01137006|Melanoma
1204205|NCT01137825|stage IV mycosis fungoides/Sezary syndrome
1204206|NCT01137825|adult grade III lymphomatoid granulomatosis
1204207|NCT01137825|adult nasal type extranodal NK/T-cell lymphoma
1204208|NCT01137825|Waldenstrom macroglobulinemia
1204209|NCT01137825|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1204210|NCT01137825|nodal marginal zone B-cell lymphoma
1204211|NCT01137825|splenic marginal zone lymphoma
1204212|NCT01137825|contiguous stage II adult Burkitt lymphoma
1204213|NCT01137825|contiguous stage II adult diffuse large cell lymphoma
1204214|NCT01137825|contiguous stage II adult diffuse mixed cell lymphoma
1204215|NCT01137825|contiguous stage II adult diffuse small cleaved cell lymphoma
1204216|NCT01137825|contiguous stage II adult immunoblastic large cell lymphoma
1204312|NCT01137799|schizophrenia
1204217|NCT01137825|contiguous stage II adult lymphoblastic lymphoma
1204218|NCT01137825|contiguous stage II grade 1 follicular lymphoma
1204219|NCT01137825|contiguous stage II grade 2 follicular lymphoma
1204220|NCT01137825|contiguous stage II grade 3 follicular lymphoma
1204221|NCT01137825|contiguous stage II mantle cell lymphoma
1204222|NCT01137825|contiguous stage II marginal zone lymphoma
1204223|NCT01137825|contiguous stage II small lymphocytic lymphoma
1204224|NCT01137825|stage I adult Burkitt lymphoma
1204225|NCT01137825|stage I adult diffuse large cell lymphoma
1204226|NCT01137825|stage I adult diffuse mixed cell lymphoma
1204227|NCT01137825|stage I adult diffuse small cleaved cell lymphoma
1204228|NCT01137825|stage I adult immunoblastic large cell lymphoma
1204229|NCT01137825|stage I adult lymphoblastic lymphoma
1204230|NCT01137825|stage I grade 1 follicular lymphoma
1204231|NCT01137825|stage I grade 2 follicular lymphoma
1204232|NCT01137825|stage I grade 3 follicular lymphoma
1204233|NCT01137825|stage I mantle cell lymphoma
1204234|NCT01137825|stage I marginal zone lymphoma
1204235|NCT01137825|stage I small lymphocytic lymphoma
1204236|NCT01137825|noncontiguous stage II adult Burkitt lymphoma
1204237|NCT01137825|noncontiguous stage II adult diffuse large cell lymphoma
1204238|NCT01137825|noncontiguous stage II adult diffuse mixed cell lymphoma
1204239|NCT01137825|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1204240|NCT01137825|noncontiguous stage II adult immunoblastic large cell lymphoma
1204241|NCT01137825|noncontiguous stage II adult lymphoblastic lymphoma
1204242|NCT01137825|noncontiguous stage II grade 1 follicular lymphoma
1204243|NCT01137825|noncontiguous stage II grade 2 follicular lymphoma
1204244|NCT01137825|noncontiguous stage II grade 3 follicular lymphoma
1204245|NCT01137825|noncontiguous stage II mantle cell lymphoma
1204246|NCT01137825|noncontiguous stage II marginal zone lymphoma
1204247|NCT01137825|noncontiguous stage II small lymphocytic lymphoma
1204248|NCT01137825|stage III adult Burkitt lymphoma
1204249|NCT01137825|stage III adult diffuse large cell lymphoma
1204250|NCT01137825|stage III adult diffuse mixed cell lymphoma
1204251|NCT01137825|stage III adult diffuse small cleaved cell lymphoma
1204252|NCT01137825|stage III adult immunoblastic large cell lymphoma
1204253|NCT01137825|stage III adult lymphoblastic lymphoma
1204254|NCT01137825|stage III grade 1 follicular lymphoma
1204255|NCT01137825|stage III grade 2 follicular lymphoma
1204256|NCT01137825|stage III grade 3 follicular lymphoma
1204257|NCT01137825|stage III mantle cell lymphoma
1204258|NCT01137825|stage III marginal zone lymphoma
1204259|NCT01137825|stage III small lymphocytic lymphoma
1204260|NCT01137825|stage IV adult Burkitt lymphoma
1204261|NCT01137825|stage IV adult diffuse large cell lymphoma
1204262|NCT01137825|stage IV adult diffuse mixed cell lymphoma
1204263|NCT01137825|stage IV adult diffuse small cleaved cell lymphoma
1204264|NCT01137825|stage IV adult immunoblastic large cell lymphoma
1204265|NCT01137825|stage IV adult lymphoblastic lymphoma
1204266|NCT01137825|stage IV grade 1 follicular lymphoma
1204267|NCT01137825|stage IV grade 2 follicular lymphoma
1204268|NCT01137825|stage IV grade 3 follicular lymphoma
1204269|NCT01137825|stage IV mantle cell lymphoma
1204270|NCT01137825|stage IV marginal zone lymphoma
1204271|NCT01137825|stage IV small lymphocytic lymphoma
1204272|NCT01137825|recurrent adult Burkitt lymphoma
1204273|NCT01137825|recurrent adult diffuse large cell lymphoma
1204274|NCT01137825|recurrent adult diffuse mixed cell lymphoma
1204275|NCT01137825|recurrent adult diffuse small cleaved cell lymphoma
1204276|NCT01137825|recurrent adult grade III lymphomatoid granulomatosis
1204277|NCT01137825|recurrent adult immunoblastic large cell lymphoma
1204278|NCT01137825|recurrent adult lymphoblastic lymphoma
1204279|NCT01137825|recurrent grade 1 follicular lymphoma
1204280|NCT01137825|recurrent grade 2 follicular lymphoma
1204281|NCT01137825|recurrent grade 3 follicular lymphoma
1204282|NCT01137825|recurrent mantle cell lymphoma
1204283|NCT01137825|recurrent marginal zone lymphoma
1204284|NCT01137825|recurrent small lymphocytic lymphoma
1204285|NCT01137825|intraocular lymphoma
1204286|NCT01137825|post-transplant lymphoproliferative disorder
1204287|NCT01137825|chronic eosinophilic leukemia
1204288|NCT01137825|chronic neutrophilic leukemia
1204289|NCT01137825|primary myelofibrosis
1204290|NCT01137825|essential thrombocythemia
1204291|NCT01137825|polycythemia vera
1204292|NCT01137825|extramedullary plasmacytoma
1204293|NCT01137825|isolated plasmacytoma of bone
1204294|NCT01137825|stage I multiple myeloma
1204295|NCT01137825|stage II multiple myeloma
1204296|NCT01137825|stage III multiple myeloma
1204297|NCT01137825|primary systemic amyloidosis
1204298|NCT01137825|refractory multiple myeloma
1204299|NCT01137825|de novo myelodysplastic syndromes
1204300|NCT01137825|previously treated myelodysplastic syndromes
1204301|NCT01137825|secondary myelodysplastic syndromes
1204302|NCT01137825|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1204303|NCT01137812|Canagliflozin
1204304|NCT01137812|Sitagliptin (Januvia)
1204305|NCT01137812|Metformin
1204306|NCT01137812|Sulphonylurea
1204307|NCT01137812|Hemoglobin A1c
1204308|NCT01137812|Type 2 diabetes mellitus
1204309|NCT01137799|symptomatic treatment
1204310|NCT01137799|cognition
1204311|NCT01137799|cognitive deficits
1204313|NCT01137799|Alzheimer's Disease
1204314|NCT01137773|SAH (Subarachnoid Hemorrhage)
1204315|NCT01137773|Brain Hemorrhage
1204316|NCT01137773|Traumatic Brain Injury
1204317|NCT01137773|SAH
1204318|NCT01137773|ICH
1204319|NCT01137760|adults
1204320|NCT01137760|fiber
1204321|NCT01137760|cold
1204322|NCT01137760|flu
1204323|NCT01137760|stress
1204324|NCT01137760|microbiota
1204325|NCT01137747|carfilzomib
1204326|NCT01137747|acute myeloid leukemia
1204327|NCT01137747|acute lymphoblastic leukemia
1204328|NCT01137747|phase I
1204329|NCT01137734|Heart Diseases
1204330|NCT01137734|Heart Valve Diseases
1204331|NCT01137734|Cardiovascular Diseases
1204332|NCT01137721|magnetic resonance imaging
1204333|NCT01137721|sickle cell disease
1204334|NCT01137721|hydroxyurea therapy
1204335|NCT01137708|drug interactions
1204336|NCT01137708|CYP3A
1204337|NCT01137708|oral contraceptive
1204338|NCT01137708|anti-rheumatic agents
1204339|NCT01137695|pramlintide
1204340|NCT01137695|glucose
1204341|NCT01137695|type 2 diabetes mellitus
1204342|NCT01137695|amylin
1204343|NCT01137682|Acromegaly
1204344|NCT01137682|hormone disorder
1204345|NCT01137682|growth hormone
1204346|NCT01137682|insulin like growth factor-1
1204347|NCT01137682|pituitary tumor
1204348|NCT01137669|immunocompromised,parent protocol,shingles,varicella-zoster virus,ZOSTAVAX®
1204349|NCT01137656|Blood storage
1204350|NCT01137656|Blood transfusion
1204351|NCT01137656|Aged blood
1204352|NCT01137656|Blood Forearm
1204353|NCT01137656|Storage lesion in blood
1204354|NCT01137643|accelerated phase chronic myelogenous leukemia
1204355|NCT01137643|acute undifferentiated leukemia
1204356|NCT01137643|adult acute lymphoblastic leukemia in remission
1204357|NCT01137643|adult acute myeloid leukemia in remission
1204358|NCT01137643|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1204359|NCT01137643|adult acute myeloid leukemia with inv(16)(p13;q22)
1204360|NCT01137643|adult acute myeloid leukemia with t(15;17)(q22;q12)
1204361|NCT01137643|adult acute myeloid leukemia with t(16;16)(p13;q22)
1204362|NCT01137643|adult acute myeloid leukemia with t(8;21)(q22;q22)
1204363|NCT01137643|atypical chronic myeloid leukemia, BCR-ABL negative
1204364|NCT01137643|blastic phase chronic myelogenous leukemia
1204365|NCT01137643|mast cell leukemia
1204366|NCT01137643|meningeal chronic myelogenous leukemia
1204367|NCT01137643|progressive hairy cell leukemia, initial treatment
1204368|NCT01137643|prolymphocytic leukemia
1204369|NCT01137643|recurrent adult acute lymphoblastic leukemia
1204370|NCT01137643|recurrent adult acute myeloid leukemia
1204371|NCT01137643|recurrent adult T-cell leukemia/lymphoma
1204372|NCT01137643|refractory chronic lymphocytic leukemia
1204373|NCT01137643|refractory hairy cell leukemia
1204374|NCT01137643|relapsing chronic myelogenous leukemia
1204375|NCT01137643|secondary acute myeloid leukemia
1204376|NCT01137643|stage 0 chronic lymphocytic leukemia
1204377|NCT01137643|stage I adult T-cell leukemia/lymphoma
1204378|NCT01137643|stage I chronic lymphocytic leukemia
1204379|NCT01137643|stage II adult T-cell leukemia/lymphoma
1204380|NCT01137643|stage II chronic lymphocytic leukemia
1204381|NCT01137643|stage III adult T-cell leukemia/lymphoma
1204382|NCT01137643|stage III chronic lymphocytic leukemia
1204383|NCT01137643|stage IV adult T-cell leukemia/lymphoma
1204384|NCT01137643|stage IV chronic lymphocytic leukemia
1204385|NCT01137643|T-cell large granular lymphocyte leukemia
1204386|NCT01137643|untreated adult acute lymphoblastic leukemia
1204387|NCT01137643|untreated adult acute myeloid leukemia
1204388|NCT01137643|untreated hairy cell leukemia
1204389|NCT01137643|recurrent adult Hodgkin lymphoma
1204390|NCT01137643|stage I adult Hodgkin lymphoma
1204391|NCT01137643|stage II adult Hodgkin lymphoma
1204392|NCT01137643|stage III adult Hodgkin lymphoma
1204393|NCT01137643|stage IV adult Hodgkin lymphoma
1204394|NCT01137643|anaplastic large cell lymphoma
1204395|NCT01137643|angioimmunoblastic T-cell lymphoma
1204396|NCT01137643|cutaneous B-cell non-Hodgkin lymphoma
1204397|NCT01137643|recurrent cutaneous T-cell non-Hodgkin lymphoma
1204398|NCT01137643|stage I cutaneous T-cell non-Hodgkin lymphoma
1204399|NCT01137643|stage II cutaneous T-cell non-Hodgkin lymphoma
1204400|NCT01137643|stage III cutaneous T-cell non-Hodgkin lymphoma
1204401|NCT01137643|stage IV cutaneous T-cell non-Hodgkin lymphoma
1204402|NCT01137643|recurrent mycosis fungoides/Sezary syndrome
1204403|NCT01137643|stage I mycosis fungoides/Sezary syndrome
1204404|NCT01137643|stage II mycosis fungoides/Sezary syndrome
1204405|NCT01137643|stage III mycosis fungoides/Sezary syndrome
1204406|NCT01137643|stage IV mycosis fungoides/Sezary syndrome
1204407|NCT01137643|adult grade III lymphomatoid granulomatosis
1204408|NCT01137643|adult nasal type extranodal NK/T-cell lymphoma
1204409|NCT01137643|Waldenstrom macroglobulinemia
1204410|NCT01137643|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1204411|NCT01137643|nodal marginal zone B-cell lymphoma
1204412|NCT01137643|splenic marginal zone lymphoma
1204413|NCT01137643|contiguous stage II adult Burkitt lymphoma
1204414|NCT01137643|contiguous stage II adult diffuse large cell lymphoma
1204415|NCT01137643|contiguous stage II adult diffuse mixed cell lymphoma
1204511|NCT01137591|Antidotes
1204416|NCT01137643|contiguous stage II adult diffuse small cleaved cell lymphoma
1204417|NCT01137643|contiguous stage II adult immunoblastic large cell lymphoma
1204418|NCT01137643|contiguous stage II adult lymphoblastic lymphoma
1204419|NCT01137643|contiguous stage II grade 1 follicular lymphoma
1204420|NCT01137643|contiguous stage II grade 2 follicular lymphoma
1204421|NCT01137643|contiguous stage II grade 3 follicular lymphoma
1204422|NCT01137643|contiguous stage II mantle cell lymphoma
1204423|NCT01137643|contiguous stage II marginal zone lymphoma
1204424|NCT01137643|contiguous stage II small lymphocytic lymphoma
1204425|NCT01137643|stage I adult Burkitt lymphoma
1204426|NCT01137643|stage I adult diffuse large cell lymphoma
1204427|NCT01137643|stage I adult diffuse mixed cell lymphoma
1204428|NCT01137643|stage I adult diffuse small cleaved cell lymphoma
1204429|NCT01137643|stage I adult immunoblastic large cell lymphoma
1204430|NCT01137643|stage I adult lymphoblastic lymphoma
1204431|NCT01137643|stage I grade 1 follicular lymphoma
1204432|NCT01137643|stage I grade 2 follicular lymphoma
1204433|NCT01137643|stage I grade 3 follicular lymphoma
1204434|NCT01137643|stage I mantle cell lymphoma
1204435|NCT01137643|stage I marginal zone lymphoma
1204436|NCT01137643|stage I small lymphocytic lymphoma
1204437|NCT01137643|noncontiguous stage II adult Burkitt lymphoma
1204438|NCT01137643|noncontiguous stage II adult diffuse large cell lymphoma
1204439|NCT01137643|noncontiguous stage II adult diffuse mixed cell lymphoma
1204440|NCT01137643|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1204441|NCT01137643|noncontiguous stage II adult immunoblastic large cell lymphoma
1204442|NCT01137643|noncontiguous stage II adult lymphoblastic lymphoma
1204443|NCT01137643|noncontiguous stage II grade 1 follicular lymphoma
1204444|NCT01137643|noncontiguous stage II grade 2 follicular lymphoma
1204445|NCT01137643|noncontiguous stage II grade 3 follicular lymphoma
1204446|NCT01137643|noncontiguous stage II mantle cell lymphoma
1204447|NCT01137643|noncontiguous stage II marginal zone lymphoma
1204448|NCT01137643|noncontiguous stage II small lymphocytic lymphoma
1204449|NCT01137643|stage III adult Burkitt lymphoma
1204450|NCT01137643|stage III adult diffuse large cell lymphoma
1204451|NCT01137643|stage III adult diffuse mixed cell lymphoma
1204452|NCT01137643|stage III adult diffuse small cleaved cell lymphoma
1204453|NCT01137643|stage III adult immunoblastic large cell lymphoma
1204454|NCT01137643|stage III adult lymphoblastic lymphoma
1204455|NCT01137643|stage III grade 1 follicular lymphoma
1204456|NCT01137643|stage III grade 2 follicular lymphoma
1204457|NCT01137643|stage III grade 3 follicular lymphoma
1204458|NCT01137643|stage III mantle cell lymphoma
1204459|NCT01137643|stage III marginal zone lymphoma
1204460|NCT01137643|stage III small lymphocytic lymphoma
1204461|NCT01137643|stage IV adult Burkitt lymphoma
1204462|NCT01137643|stage IV adult diffuse large cell lymphoma
1204463|NCT01137643|stage IV adult diffuse mixed cell lymphoma
1204464|NCT01137643|stage IV adult diffuse small cleaved cell lymphoma
1204465|NCT01137643|stage IV adult immunoblastic large cell lymphoma
1204466|NCT01137643|stage IV adult lymphoblastic lymphoma
1204467|NCT01137643|stage IV grade 1 follicular lymphoma
1204468|NCT01137643|stage IV grade 2 follicular lymphoma
1204469|NCT01137643|stage IV grade 3 follicular lymphoma
1204470|NCT01137643|stage IV mantle cell lymphoma
1204471|NCT01137643|stage IV marginal zone lymphoma
1204472|NCT01137643|stage IV small lymphocytic lymphoma
1204473|NCT01137643|recurrent adult Burkitt lymphoma
1204474|NCT01137643|recurrent adult diffuse large cell lymphoma
1204475|NCT01137643|recurrent adult diffuse mixed cell lymphoma
1204476|NCT01137643|recurrent adult diffuse small cleaved cell lymphoma
1204477|NCT01137643|recurrent adult grade III lymphomatoid granulomatosis
1204478|NCT01137643|recurrent adult immunoblastic large cell lymphoma
1204479|NCT01137643|recurrent adult lymphoblastic lymphoma
1204480|NCT01137643|recurrent grade 1 follicular lymphoma
1204481|NCT01137643|recurrent grade 2 follicular lymphoma
1204482|NCT01137643|recurrent grade 3 follicular lymphoma
1204483|NCT01137643|recurrent mantle cell lymphoma
1204484|NCT01137643|recurrent marginal zone lymphoma
1204485|NCT01137643|recurrent small lymphocytic lymphoma
1204486|NCT01137643|intraocular lymphoma
1204487|NCT01137643|post-transplant lymphoproliferative disorder
1204488|NCT01137643|chronic eosinophilic leukemia
1204489|NCT01137643|chronic neutrophilic leukemia
1204490|NCT01137643|primary myelofibrosis
1204491|NCT01137643|essential thrombocythemia
1204492|NCT01137643|polycythemia vera
1204493|NCT01137643|extramedullary plasmacytoma
1204494|NCT01137643|isolated plasmacytoma of bone
1204495|NCT01137643|stage I multiple myeloma
1204496|NCT01137643|stage II multiple myeloma
1204497|NCT01137643|stage III multiple myeloma
1204498|NCT01137643|primary systemic amyloidosis
1204499|NCT01137643|refractory multiple myeloma
1204500|NCT01137643|de novo myelodysplastic syndromes
1204501|NCT01137643|previously treated myelodysplastic syndromes
1204502|NCT01137643|secondary myelodysplastic syndromes
1204503|NCT01137643|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1204504|NCT01137643|aplastic anemia
1204505|NCT01137630|seborrhoeic dermatitis
1204506|NCT01137630|scalp
1204507|NCT01137630|K40a
1204508|NCT01137630|K40b
1204509|NCT01137591|Acetaminophen
1204510|NCT01137591|Acetylcysteine
1204512|NCT01137565|Amgen
1204513|NCT01137565|Adolescent
1204514|NCT01137565|Safety
1204515|NCT01137552|First-In-Human
1204516|NCT01137552|Dose Escalation
1204517|NCT01137552|Dose Expansion
1204518|NCT01137552|Advance Solid Tumors
1204519|NCT01137552|Anti-Angiopoietin
1204520|NCT01137552|Advance Malignancy
1204521|NCT01137552|Cancer
1204522|NCT01137552|Oncology
1204523|NCT01137552|Oncology Patients
1204524|NCT01137552|Phase 1
1204525|NCT01137552|Clinical Trial
1204526|NCT01137552|Tumors
1204527|NCT01137552|Solid Tumors
1204528|NCT01137552|Angiogenesis Inhibitors
1204529|NCT01137539|urinary incontinence
1204530|NCT01137539|stress urinary incontinence
1204531|NCT01137539|mid-urethral slings
1204532|NCT01137539|Tension-free vaginal taping
1204533|NCT01137539|TVT
1204534|NCT01137513|Chest Pain
1204535|NCT01137513|Acute coronary syndrome
1204536|NCT01137513|AMI
1204537|NCT01137487|mechanical ventilation
1204538|NCT01137487|enteral nutrition
1204539|NCT01137487|Ventilation-Associated Pneumonia
1204540|NCT01137487|residual gastric volume measurement
1204541|NCT01137487|vomiting
1204542|NCT01137487|gastro-oesophageal reflux
1204543|NCT01137487|early enteral nutrition
1204544|NCT01137487|Intensive care unit
1204545|NCT01137487|Enteral Feeding
1204546|NCT01137474|Diabetes Mellitus, Type 2
1204547|NCT01137474|Diabetes Mellitus
1204548|NCT01137474|Endocrine System Diseases
1204549|NCT01137474|Glucose Metabolism Disorders
1204550|NCT01137474|Metabolic Diseases
1204551|NCT01137474|Angiotensin Receptor Antagonists
1204552|NCT01137474|Angiotensin-Converting Enzyme Inhibitors
1204553|NCT01137474|Hypoglycemic Agents
1204554|NCT01137474|Pharmacologic Actions
1204555|NCT01137474|Physiological Effects of Drugs
1204556|NCT01137461|Female infertility with indication of oocyte reception
1204557|NCT01137448|Psoriasis
1204558|NCT01137448|Obesity
1204559|NCT01137435|Adacel
1204560|NCT01137435|Diphtheria
1204561|NCT01137435|Tetanus
1204562|NCT01137435|Pertussis
1204563|NCT01137383|Hepatitis C
1204564|NCT01137331|seborrhoeic eczema
1204565|NCT01137331|scalp
1204566|NCT01137331|dandruff
1204567|NCT01137331|K301
1204568|NCT01137331|K40
1204569|NCT01137318|ADHD
1204570|NCT01137318|Impairment
1204571|NCT01137318|Treatment
1204572|NCT01137318|Cognitive Remediation
1204573|NCT01137318|Behavioral Parent Training
1204574|NCT01137305|Virtual reality
1204575|NCT01137305|surgical training
1204576|NCT01137305|Health Care [N]
1204577|NCT01137292|observational study
1204578|NCT01137292|voriconazole
1204579|NCT01137292|high-risk patients
1204580|NCT01137266|chronic pain osteo-arthritis in one or both knees, adults
1204581|NCT01137253|Nitric Oxide
1204582|NCT01137253|Autonomic Nervous System
1204583|NCT01137240|subjects suffering from mitochondrial disorders with one or more gastrointestinal symptoms would be the focus of the study
1204584|NCT01137227|Physical activity
1204585|NCT01137227|Epidemiology
1204586|NCT01137227|Questionnaire
1204587|NCT01137227|Cross-sectional study
1204588|NCT01137214|complex sleep apnea
1204589|NCT01137201|Small bowel obstruction
1204590|NCT01137201|Laparoscopic gastric bypass
1204591|NCT01137201|Internal Hernia
1204592|NCT01137201|Mesenteric defect
1204593|NCT01137201|Morbid obesity
1204594|NCT01137175|Rickettsioses
1204595|NCT01137175|Scrub Typhus
1204596|NCT01137175|Q fever
1204597|NCT01137175|Typhus fever
1204598|NCT01137175|Spotted fever
1204599|NCT01137175|Rickettsioses reported cases
1204600|NCT01137149|Adolescent Depression
1204601|NCT01137149|Treatment of depression in adolescents
1204602|NCT01137149|Behavioral activation treatment for depressed adolescents
1204603|NCT01137123|esophageal squamous cell carcinoma
1204604|NCT01137110|Subarachnoid Hemorrhage
1204605|NCT01137110|Seizure Prophylaxis
1204606|NCT01137110|Levetiracetam
1204607|NCT01137045|rabies vaccine
1204608|NCT01137045|vero cells
1204609|NCT01137045|serology
1204610|NCT01137045|safety
1204611|NCT01137032|Psoriasis
1204612|NCT01137032|Atopic Dermatitis
1204613|NCT01137019|Drug-eluting stents
1204614|NCT01137019|Tomography, Optical Coherence
1204616|NCT01137006|Phase I
1204617|NCT01137006|antibody
1204618|NCT01137006|melanin
1204619|NCT01137006|tyrosinase related protein 1
1204620|NCT01137006|glycoprotein
1204621|NCT01137006|20D7S
1204622|NCT01136993|Stroke
1204623|NCT01136993|Thrombolysis
1204624|NCT01136993|Telestroke
1204625|NCT01136980|GERD
1204626|NCT01136980|Esophagitis
1204627|NCT01136980|Fundoplication
1204628|NCT01136980|Anti-reflux surgery
1204629|NCT01136980|PPI dependent
1204630|NCT01136928|Antiretroviral therapy
1204631|NCT01136928|American ginseng
1204632|NCT01136928|Efavirenz
1204633|NCT01136928|Cytochrome P450 enzymes
1204634|NCT01136928|Complementary and Alternative Medicine
1204635|NCT01136928|Herbal
1204636|NCT01136928|Pharmacikinetics
1204637|NCT01136928|Healthy volunteers
1204638|NCT01136902|Diabetes Mellitus
1204639|NCT01136902|Retinal Vessels
1204640|NCT01136902|Physiology
1204641|NCT01136889|PFMT
1204642|NCT01136889|Vaginal pessary
1204643|NCT01136889|Pelvic Organ Prolapse
1204644|NCT01136863|hypertension
1204645|NCT01136863|felodipine
1204646|NCT01136863|moderate to high risk patients
1204647|NCT01136850|Plasmodium falciparum
1204648|NCT01136850|Plasmodium vivax
1204649|NCT01136850|azithromycin
1204650|NCT01136850|sulphadoxine pyrimethamine
1204651|NCT01136850|low birth weight
1204652|NCT01136850|haemoglobin
1204653|NCT01136850|Chlamydia trachomatis
1204654|NCT01136850|Neisseria gonorrhoeae
1204655|NCT01136850|Treponema pallidum
1204656|NCT01136824|Sarcoma
1204657|NCT01136824|questionnaire
1204658|NCT01136824|doxorubicin plus ifosfamide (AI)
1204659|NCT01136798|slow wave sleep
1204660|NCT01136798|exenatide and sleep
1204661|NCT01136759|Prevention
1204662|NCT01136759|Microbicide
1204663|NCT01136759|Mother-to-Child-Transmission
1204664|NCT01136759|Pregnancy
1204665|NCT01136746|Hyperglycemia
1204666|NCT01136746|Diabetes
1204667|NCT01136746|Hospital
1204668|NCT01136746|Diabetic
1204669|NCT01136733|Unresectable advanced or metastatic renal cell carcinoma
1204670|NCT01136681|Anonymised Electronic Cohort
1204671|NCT01136681|Record Linkage
1204672|NCT01136681|Routine Data
1204673|NCT01136681|Environment
1204674|NCT01136681|Childhood Obesity
1204675|NCT01136681|Low birth weight
1204676|NCT01136681|Premature birth
1204677|NCT01136668|pediatrics
1204678|NCT01136668|Transversus Abdominis Plane Block
1204679|NCT01136668|Ostomy Surgery
1204680|NCT01136668|Anesthesia
1204681|NCT01136668|Regional Anesthetic
1204682|NCT01136655|asthmatic children
1204683|NCT01136655|Symbicort
1204684|NCT01136655|Foradil
1204685|NCT01136642|Nicotine
1204686|NCT01136642|Nicotine Nasal Spray
1204687|NCT01136642|Attention
1204688|NCT01136642|Smoking
1204689|NCT01136629|Hyper-pigmented spots
1204690|NCT01136629|Lentigines
1204691|NCT01136629|Mealsma
1204692|NCT01136629|RNA extraction
1204693|NCT01136629|Isolation of Keratinocytes
1204694|NCT01136629|Isolation of Melanocytes
1204695|NCT01136616|Nasal fracture
1204696|NCT01136616|Nasal buttresses
1204697|NCT01136616|Septal deviation
1204698|NCT01136616|Nasal morphology
1204699|NCT01136616|CT Scan
1204700|NCT01136603|Abdominal wall defects
1204701|NCT01136603|Inflammation reactions
1204702|NCT01136603|Amount of tissue ingrowth
1204703|NCT01136603|Adhesion formation
1204704|NCT01136603|Shrinkage profiles of the implant
1204705|NCT01136590|Spinal deformity correction
1204706|NCT01136590|Surgical bleeding
1204707|NCT01136590|Transfusion practice
1204708|NCT01136590|Spinal Fusion
1204709|NCT01136590|Antifibrinolytic Agents
1204710|NCT01136590|Hemorrhage
1204711|NCT01136590|Blood Transfusion
1204712|NCT01136577|Jaundice
1204713|NCT01136577|Hyperbilirubinemia
1204714|NCT01136577|Phototherapy
1204715|NCT01136577|term newborn
1204716|NCT01136577|LED
1204717|NCT01136577|Fluorescent lamps
1204718|NCT01136564|paricalcitol
1204719|NCT01136564|vitamin d
1204720|NCT01136564|kidney disease
1204721|NCT01136564|renin
1204722|NCT01136564|proteinuria
1204723|NCT01136551|Pharmacokinetic profile of controlled release formulation of Huperzine A
1204724|NCT01136551|Bioequivalence of Huperzine A IR formulation and CR formulation
1204725|NCT01136538|Bioequivalence
1204726|NCT01136538|Crossover
1204727|NCT01136538|Valacyclovir Hydrochloride
1204728|NCT01136525|Bioequivalence
1204729|NCT01136525|Crossover
1204730|NCT01136525|Valacyclovir Hydrochloride
1204731|NCT01136512|metformin
1204732|NCT01136512|vitamin B12
1204733|NCT01136512|type 2 diabetes
1204734|NCT01136512|methylmalonic acid
1204735|NCT01136512|deficiency
1204736|NCT01136499|Sarcoma
1204737|NCT01136499|Safety
1204738|NCT01136499|Efficacy
1204739|NCT01136499|PANOBINOSTAT
1204740|NCT01136486|head trauma; traumatic brain injury
1204741|NCT01136473|congenital cataract
1204742|NCT01136473|aphakic
1204743|NCT01136473|pseudophakic glaucoma
1204744|NCT01136473|pediatric patients
1204745|NCT01136460|Primary congenital glaucoma
1204746|NCT01136460|neonatal
1204747|NCT01136460|Genotype correlation
1204748|NCT01136460|Phenotype correlation
1204749|NCT01136447|Brachial plexus
1204750|NCT01136447|Ultrasound
1204751|NCT01136421|COPD exacerbation
1204752|NCT01136421|Magnesium sulfate
1204753|NCT01136421|Ipratropium bromide
1204754|NCT01136421|Emergency departement
1204755|NCT01136395|Kidney Transplantation
1204756|NCT01136395|Rituximab
1204757|NCT01136395|Living Donor
1204758|NCT01136395|ABO Incompatible Transplantation
1204759|NCT01136395|Immunology
1204760|NCT01136395|CMV
1204761|NCT01136395|EBV
1204762|NCT01136395|Polyomavirus
1204763|NCT01136382|asthma, children, budesonide pMDI
1204764|NCT01136369|metastasis
1204765|NCT01136369|molecular pathology
1204766|NCT01136356|opioid pharmacology
1204767|NCT01136356|buprenorphine
1204768|NCT01136356|morphine
1204769|NCT01136356|withdrawal
1204770|NCT01136356|human research
1204771|NCT01136343|women
1204772|NCT01136343|middle age
1204773|NCT01136343|risk factor
1204774|NCT01136330|Myotonic dystrophy
1204775|NCT01136330|Prognosis
1204776|NCT01136330|Sudden death
1204777|NCT01136330|Respiratory failure
1204778|NCT01136304|Gaucher disease
1204779|NCT01136304|Imiglucerase
1204780|NCT01136304|Cerezyme
1204781|NCT01136304|Severity score
1204782|NCT01136291|pregnancy
1204783|NCT01136291|obesity
1204784|NCT01136291|physical exercise
1204785|NCT01136291|quality of life
1204786|NCT01136278|MDMA
1204787|NCT01136278|norepinephrine
1204788|NCT01136278|alpha2 receptor
1204789|NCT01136278|Ecstasy
1204790|NCT01136278|stimulant
1204791|NCT01136265|dual-time PET/CT
1204792|NCT01136265|sentinel node
1204793|NCT01136239|COPD
1204794|NCT01136239|N-acetylcysteine
1204795|NCT01136239|airtrapping
1204796|NCT01136239|airway resistance
1204797|NCT01136239|antioxidant
1204798|NCT01136226|Prostate Cancer
1204799|NCT01136200|Surgical and medical wards
1204800|NCT01136200|Adults
1204801|NCT01136200|Antimicrobial therapy
1204802|NCT01136187|Myocardial infarction
1204803|NCT01136187|Primary percutaneous coronary intervention
1204804|NCT01136187|Radial
1204805|NCT01136187|Bleeding
1204806|NCT01136161|LTBI (Latent Tuberculosis Infection)
1204807|NCT01136161|TB (Tuberculosis)
1204808|NCT01136161|Vaccine
1204809|NCT01136148|Mental Health
1204810|NCT01136148|Aged
1204811|NCT01136148|Hospitals, general
1204812|NCT01136148|Dementia
1204813|NCT01136148|Delirium
1204814|NCT01136148|Dementia and confusion
1204815|NCT01136135|Heart transplant rejection
1204816|NCT01136135|cardiac MRI
1204817|NCT01136135|diagnosis
1204818|NCT01136096|diabetes
1204819|NCT01136096|physical activity
1204820|NCT01136096|adiponectin
1204821|NCT01136096|metabolic risks
1204822|NCT01136096|exercise
1204823|NCT01136096|primary prevention
1204824|NCT01136083|Tumor
1204825|NCT01136083|Angiogenesis
1204826|NCT01136083|Exercise training
1204827|NCT01136083|VEGF
1204828|NCT01136083|Myostatin
1204829|NCT01136070|Psychological Functioning in Burn Patients
1204830|NCT01136044|tensor fasciae latae
1204831|NCT01136044|septocutaneous perforators
1204832|NCT01136031|advanced gastric cancer
1204833|NCT01136031|1st-line failure
1204834|NCT01136005|receptor, epidermal growth factor
1204835|NCT01136005|skin toxicity
1204836|NCT01136005|quality of life
1204837|NCT01136005|adherence
1204838|NCT01135966|COPD
1204839|NCT01135966|Whole Body Vibration training
1204840|NCT01135966|Conventional resistance training
1204841|NCT01135953|Brain excitation
1204842|NCT01135953|transcranial Direct Stimulation
1204843|NCT01135953|administration pattern
1204844|NCT01135940|neuromuscular scoliosis
1204845|NCT01135940|dermabond
1204846|NCT01135940|infection
1204847|NCT01135940|wound closure
1204848|NCT01135914|DME
1204849|NCT01135914|visual impairment
1204850|NCT01135914|diabetes
1204851|NCT01135914|macular edema
1204852|NCT01135914|diabetic macular edema
1204853|NCT01135914|ranibizumab
1204854|NCT01135914|laser
1204855|NCT01135914|photocoagulation
1204856|NCT01135914|retinopathy
1204857|NCT01135914|retina
1204858|NCT01135901|prevention
1204859|NCT01135901|public health
1204860|NCT01135901|community health services
1204861|NCT01135901|Norway
1204862|NCT01135888|hypohidrotic ectodermal dysplasia
1204863|NCT01135888|exertional hyperthermia
1204864|NCT01135888|cooling device
1204865|NCT01135875|GBM
1204866|NCT01135875|Brain Tumor
1204867|NCT01135875|Brain Neoplasm
1204868|NCT01135875|Control
1204869|NCT01135875|Normal Control
1204870|NCT01135875|Volunteer
1204871|NCT01135836|Shoulder pain
1204872|NCT01135836|Gynecologic laparoscopic surgery
1204873|NCT01135836|Nausea
1204874|NCT01135836|Vomiting
1204875|NCT01135836|Abdominal fullness
1204876|NCT01135810|healthy subjects
1204877|NCT01135771|glucose monitoring
1204878|NCT01135771|diabetes
1204879|NCT01135771|glucose monitoring in patients with diabetes
1204880|NCT01135758|depression, ketamine, fMRI
1204881|NCT01135732|late development cholangiocarcinoma
1204882|NCT01135719|Myopia
1204883|NCT01135719|Hyperopia
1204884|NCT01135719|Astigmatism
1204885|NCT01135719|PRK
1204886|NCT01135719|LASIK
1204887|NCT01135706|Pulmonary Hypertension
1204888|NCT01135706|Fractal dimension
1204889|NCT01135693|Section 136
1204890|NCT01135693|Mental Health Act 1983
1204891|NCT01135693|Police
1204892|NCT01135693|Detention
1204893|NCT01135693|Failure of community care
1204894|NCT01135667|clopidogrel
1204895|NCT01135667|prasugrel
1204896|NCT01135667|low responder
1204897|NCT01135667|multiplate
1204898|NCT01135667|verify now
1204899|NCT01135654|alcohol dependence
1204900|NCT01135654|unhealthy drinking
1204901|NCT01135654|SBIRT
1204902|NCT01135641|Adult patients (≥18 years)
1204903|NCT01135641|first allogeneic stem cell transplantation
1204904|NCT01135641|first episode of chronic GVHD requiring systemic immunosuppressive therapy
1204905|NCT01135628|Hepatic cirrhosis
1204906|NCT01135628|Minimal hepatic encephalopathy
1204907|NCT01135628|Hyperproteic and fiber-rich diet
1204908|NCT01135628|Lactobacillus reuteri
1204909|NCT01135628|Psychometric Hepatic Encephalopathy Score (PHES)
1204910|NCT01135628|Critical Flicker Frequency (CFF)
1204911|NCT01135615|FGF-23, endothelial dysfunction, sevelamer
1204912|NCT01135602|Alcohol dependence
1204913|NCT01135602|Alcoholism
1204914|NCT01135602|Topiramate
1204915|NCT01135589|pediatric
1204916|NCT01135589|adolescent
1204917|NCT01135589|micafungin
1204918|NCT01135576|Ferric pyrophosphate
1204919|NCT01135576|Fortification
1204920|NCT01135576|Fruit juice
1204921|NCT01135576|Functional food
1204922|NCT01135576|Bioavailability
1204923|NCT01135576|iron status
1204924|NCT01135576|Women
1204925|NCT01135576|iron-deficiency anemia
1204926|NCT01135563|pediatrics
1204927|NCT01135563|Solid Tumors
1204928|NCT01135563|CNS Tumors
1204929|NCT01135563|Vinblastine
1204930|NCT01135563|Sirolimus
1204931|NCT01135563|Recurrent
1204932|NCT01135563|Refractory
1204933|NCT01135550|Pediatrics
1204934|NCT01135550|Vomiting
1204935|NCT01135550|Headache
1204936|NCT01135550|Radiation Therapy
1204937|NCT01135537|allogeneic hematopoietic stem cell transplantation
1204938|NCT01135537|pharmacokinetics
1204939|NCT01135537|pediatrics
1204940|NCT01135524|Osteoarthritis
1204941|NCT01135524|Opioid
1204942|NCT01135524|Transdermal
1204943|NCT01135511|Dry eye
1204944|NCT01135472|NEXIUM
1204945|NCT01135472|HEALTHY VOLUNTEERS
1204946|NCT01135472|BLOOD DRAW
1204947|NCT01135472|to measure gastrin levels in healthy volunteers while taking nexium
1204948|NCT01135459|Lupus
1204949|NCT01135433|ASP1941
1204950|NCT01135433|Diabetes mellitus
1204951|NCT01135433|Metformin
1204952|NCT01135407|Parkinson's disease
1204953|NCT01135407|Deep brain stimulation
1204954|NCT01135407|Subthalamic nucleus
1204955|NCT01135407|Levodopa
1204956|NCT01135407|Selective visual attention
1204957|NCT01135407|Basal ganglia diseases
1204958|NCT01135394|Pioglitazone
1204959|NCT01135394|Type 2 diabetes
1204960|NCT01135394|Insulin sensitivity
1204961|NCT01135394|Healthy adults
1204962|NCT01135394|Thiazolidinediones
1204963|NCT01135394|Pharmacogenetics
1204964|NCT01135381|care transitions
1204965|NCT01135381|information technology
1204966|NCT01135368|GERD
1204967|NCT01135368|Gastroesophageal Reflux Disease
1204968|NCT01135368|Drug Therapy
1204969|NCT01135342|Insomnia
1204970|NCT01135342|Weight loss
1204971|NCT01135342|Adults
1204972|NCT01135329|Lymphoma
1204973|NCT01135329|Hodgkin's lymphoma
1204974|NCT01135329|Non hodgkin's lymphoma
1204975|NCT01135329|Leukemia
1204976|NCT01135329|Acute myeloid leukemia (AML)
1204977|NCT01135329|Acute lymphoblastic leukemia(ALL)
1204978|NCT01135329|Chronic myeloid leukemia (CML)
1204979|NCT01135329|Chronic Myelomonocytic (CMML)
1204980|NCT01135329|Myelodysplastic syndrome (MDS)
1204981|NCT01135329|High-risk acute leukemia in first remission
1204982|NCT01135329|Relapsed leukemia in remission
1204983|NCT01135329|Cyclophosphamide
1204984|NCT01135329|High-dose cyclophosphamide
1204985|NCT01135329|Fludarabine
1204986|NCT01135329|Busulfan
1204987|NCT01135329|Allogeneic
1204988|NCT01135329|Nonmyeloablative
1204989|NCT01135329|Reduced intensity
1204990|NCT01135329|Haploidentical
1204991|NCT01135329|Bone marrow transplant (BMT)
1204992|NCT01135316|NSF, Ablavar, Kidney Disease, Magnetic Resonance Imaging (MRI),
1204993|NCT01135303|Sleep Apnea Syndromes
1204994|NCT01135303|Polysomnography
1204995|NCT01135303|Holter ECG
1204996|NCT01135303|Thoracic impedance
1204997|NCT01135303|Heart rate variability
1204998|NCT01135290|The management of post-treatment symptoms for subjects that had either a medium grade chemical peel or fractional resurfacing
1204999|NCT01135251|Neuropathic pain
1205000|NCT01135251|AIDS
1205001|NCT01135251|Dimiracetam
1205002|NCT01135251|Treatment related painful neuropathy in AIDS patients
1205003|NCT01135238|adrenalectomy
1205004|NCT01135238|metastasis
1205005|NCT01135238|morbidity
1205006|NCT01135238|mortality
1205007|NCT01135238|survival
1205008|NCT01135225|Drug-eluting stent
1205009|NCT01135225|Percutaneous coronary intervention
1205010|NCT01135225|Stent implantation
1205011|NCT01135225|Evolution Stent System
1205012|NCT01135225|Biodegradable polymer coating
1205013|NCT01135225|Feasibility study
1205014|NCT01135212|Hypertension
1205015|NCT01135212|ARB
1205016|NCT01135212|Fimasartan
1205017|NCT01135173|Smoking Cessation, Waterpipe
1205018|NCT01135160|weight bearing
1205019|NCT01135160|pain
1205020|NCT01135160|total hip arthroplasty
1205021|NCT01135160|total knee arthroplasty
1205022|NCT01135160|weight bearing after TKA or THA
1205023|NCT01135108|Analgesics. Non-narcotic / therapeutic use
1205024|NCT01135108|Spinal Cord Injuries
1205025|NCT01135108|Pain
1205026|NCT01135108|Pain measurement / drug effect
1205027|NCT01135108|Pain postoperative / drug therapy
1205028|NCT01135095|Myocardial perfusion
1205029|NCT01135095|Low radiation dose
1205030|NCT01135095|Single photon emission computed tomography
1205031|NCT01135082|immunogenicity
1205032|NCT01135082|safety
1205033|NCT01135082|Pneumococcal conjugate vaccine
1205034|NCT01135082|HIV infected children
1205035|NCT01135082|objective of this study is to assess the safety and immunogenicity of a 7 - valent PCV vaccine among HIV - infected compared with HIV - exposed children
1205036|NCT01135056|Hepatocellular Carcinoma
1205037|NCT01135056|Randomized
1205038|NCT01135056|Open-label
1205039|NCT01135056|Multi-Centre
1205040|NCT01135056|Phase III
1205041|NCT01135056|Sorafenib
1205042|NCT01135056|SIR-Spheres
1205043|NCT01135043|acceptable sputum
1205044|NCT01135043|AFB culture
1205045|NCT01135043|pulmonary tuberculosis
1205046|NCT01135030|total knee arthroplasty
1205047|NCT01135004|pneumothorax
1205048|NCT01135004|thoracoscopy
1205049|NCT01135004|pathogenesis
1205050|NCT01135004|blebs
1205051|NCT01135004|surgery
1205052|NCT01134991|rosacea
1205053|NCT01134991|topical
1205054|NCT01134991|minocycline
1205055|NCT01134991|foam
1205056|NCT01134991|phase II
1205057|NCT01134978|repeated measures design
1205058|NCT01134978|random assignment to groups
1205059|NCT01134952|sirolimus
1205060|NCT01134952|everolimus
1205061|NCT01134952|mycophenolic acid
1205062|NCT01134952|hepatitis C virus
1205063|NCT01134952|tacrolimus
1205064|NCT01134952|viral load
1205065|NCT01134926|Retained products of conception
1205066|NCT01134926|residua
1205067|NCT01134926|misoprostol
1205068|NCT01134926|expectant management
1205069|NCT01134913|ACS
1205070|NCT01134913|Acute Coronary Syndrome
1205071|NCT01134913|Emergency Department
1205072|NCT01134900|Medication Errors
1205073|NCT01134900|Adverse Drug Events
1205074|NCT01134900|Decision Support Systems, Clinical
1205075|NCT01134887|hypertension
1205076|NCT01134887|physician-patient relations
1205077|NCT01134887|communication
1205078|NCT01134861|stage II non-small cell lung cancer
1205079|NCT01134861|stage IIIA non-small cell lung cancer
1205080|NCT01134861|stage IIIB non-small cell lung cancer
1205081|NCT01134848|Bile ducts
1205082|NCT01134848|Sphincter of Oddi
1205083|NCT01134848|Pancreatic ducts
1205084|NCT01134822|Idiopathic Pulmonary Fibrosis
1205085|NCT01134822|IPF
1205086|NCT01134822|Lung Fibrosis
1205087|NCT01134822|Biomarkers
1205088|NCT01134809|Major abdominal surgery
1205089|NCT01134770|Prenatal Substance Use
1205090|NCT01134770|Cocaine
1205091|NCT01134770|Cigarette Smoking
1205092|NCT01134770|Mothers
1205093|NCT01134770|Pregnant women
1205094|NCT01134770|Smoking Mothers
1205095|NCT01134757|EAR
1205096|NCT01134757|LAR
1205097|NCT01134757|BHR
1205098|NCT01134757|house dust mite
1205099|NCT01134757|alternaria
1205100|NCT01134744|CXray
1205101|NCT01134731|depression
1205102|NCT01134731|suicidality
1205103|NCT01134731|Major Depressive Disorder, current episode, with suicidality
1205104|NCT01134718|TMC435-TiDP16-C119
1205105|NCT01134718|TMC435-C119
1205106|NCT01134718|TMC435
1205107|NCT01134718|Protease inhibitor
1205108|NCT01134718|HCV
1205109|NCT01134718|Hepatitis C
1205110|NCT01134718|Bioavailability
1205111|NCT01134692|Patients with cirrhosis who have large esophageal varices with No history of upper GI bleeding in the past
1205112|NCT01134679|Drug Eluting Stent
1205113|NCT01134679|Clopidogrel
1205114|NCT01134679|Aspirin
1205115|NCT01134666|Colorectal neoplasms
1205116|NCT01134666|Intestinal neoplasms
1205117|NCT01134666|Neoplasms
1205118|NCT01134666|cetuximab
1205119|NCT01134666|Erbitux
1205120|NCT01134653|Acute ankle sprain in children and young adults
1205121|NCT01134640|metastatic colorectal cancer
1205122|NCT01134640|mCRC
1205123|NCT01134640|post marketing surveillance
1205124|NCT01134640|Erbitux
1205125|NCT01134640|Cetuximab
1205126|NCT01134640|KRAS
1205127|NCT01134627|Multiple Sclerosis, Relapsing-Remitting
1205128|NCT01134627|Interferon-β
1205129|NCT01134627|Rebif®
1205130|NCT01134627|Minocycline
1205135|NCT01134575|Relapsed
1205136|NCT01134575|Refractory
1205137|NCT01134575|Acute Lymphoblastic Leukemia
1205138|NCT01134575|ALL
1205139|NCT01134575|Burkitt's lymphoma
1205140|NCT01134575|Lymphoblastic lymphoma
1205141|NCT01134575|CMC-544
1205142|NCT01134575|Inotuzumab Ozogamycin
1205143|NCT01134575|Rituxan
1205144|NCT01134575|Rituximab
1205145|NCT01134562|Clinical Trial, Phase 1
1205146|NCT01134562|Renal Dialysis
1205147|NCT01134562|Secondary Hyperparathyroidism
1205148|NCT01134562|Parathyroid hormone
1205149|NCT01134536|Pain, Postoperative
1205150|NCT01134536|Postoperative Pain
1205151|NCT01134536|Tapentadol
1205152|NCT01134536|NUCYNTA
1205153|NCT01134536|CG5503
1205154|NCT01134536|R331333
1205155|NCT01134536|Pharmacokinetics
1205156|NCT01134536|Postsurgical pain
1205157|NCT01134536|Children
1205158|NCT01134536|Adolescents
1205159|NCT01134523|positive lymph node
1205160|NCT01134510|Kidney transplantation
1205161|NCT01134484|autologous stem cell transplantation
1205162|NCT01134484|complete remission
1205163|NCT01134484|bortezomib
1205164|NCT01134484|thalidomide
1205165|NCT01134484|progression free survival
1205166|NCT01134484|induction and consolidation therapy
1205167|NCT01134458|cardiovascular disease
1205168|NCT01134445|Arthroplasty
1205169|NCT01134445|Replacement
1205170|NCT01134445|Hip
1205171|NCT01134445|Conservative
1205172|NCT01134445|Anatomic
1205173|NCT01134445|Cementless
1205174|NCT01134432|autoimmune hemolytic anemia
1205175|NCT01134432|hemolytic anemia
1205176|NCT01134432|Rituximab
1205177|NCT01134432|Treatment of autoimmune hemolytic anemia
1205178|NCT01134432|warm antibody dependant autoimmune hemolytic anemia
1205179|NCT01134419|Patient Safety
1205180|NCT01134419|Medical Errors
1205181|NCT01134419|Handoff
1205182|NCT01134419|Sign-out
1205183|NCT01134419|Resident
1205184|NCT01134419|Intern
1205185|NCT01134419|Graduate Medical Education
1205186|NCT01134406|Osteoarthritis
1205187|NCT01134406|knee
1205188|NCT01134380|Percutaneous coronary intervention
1205189|NCT01134380|Acute coronary syndrome
1205190|NCT01134380|Dual antiplatelet therapy
1205191|NCT01134380|clopidogrel/prasugrel
1205192|NCT01134380|genotyping
1205193|NCT01134380|stent
1205194|NCT01134380|compliance
1205195|NCT01134367|gastroesophageal reflux disease (GERD)
1205196|NCT01134354|Validation study
1205197|NCT01134354|Outcome Measures
1205198|NCT01134354|Patient Outcomes Assessment
1205199|NCT01134354|Patient expectations
1205200|NCT01134354|Physician patient relationship
1205201|NCT01134341|Relapsed
1205202|NCT01134341|Refractory
1205203|NCT01134315|Evaluating incidence of hypercalcemia in pediatric patients
1205204|NCT01134302|Hybrid
1205205|NCT01134302|Norwood
1205206|NCT01134302|congenital heart disease
1205207|NCT01134302|single ventricle
1205208|NCT01134289|complex regional pain syndrome
1205209|NCT01134289|lumbar sympathetic blockade
1205210|NCT01134289|photoplethysmography
1205211|NCT01134289|diagnostic lumbar sympathetic blockade
1205212|NCT01134263|Dengue Fever
1205213|NCT01134263|Dengue Hemorrhagic Fever
1205214|NCT01134263|CYD Dengue Vaccine
1205215|NCT01134263|Lot Consistency
1205216|NCT01134250|Interleukin, IL2, F16, monoclonal, antibody, cytokine Paclitaxel, breast cancer,solid tumour
1205217|NCT01134250|metastatic melanoma, non-small cell lung cancer (NSCLC)
1205218|NCT01134237|non-surgical rate
1205219|NCT01134198|Cocaine Dependence
1205220|NCT01134185|Two groups of 8 hepatically impaired subjects, one group of 8 matched healthy subjects
1205221|NCT01134172|Sociodemographic
1205222|NCT01134172|Ethnicity
1205223|NCT01134172|Work-related
1205224|NCT01134172|Health system
1205225|NCT01134172|QOL
1205226|NCT01134172|Questionnaires
1205227|NCT01134172|10-071
1205228|NCT01134146|Intensity Modulated Radiotherapy
1205229|NCT01134146|IMRT
1205230|NCT01134146|Malignant Pleural Mesothelioma
1205231|NCT01134146|Radical Pleurectomy
1205232|NCT01134146|Decortication
1205233|NCT01134146|PD
1205234|NCT01134146|pleurectomy
1205235|NCT01134146|lung surgery
1205236|NCT01134146|pleura
1205237|NCT01134094|Undisplaced
1205238|NCT01134094|Ankle Fracture
1205239|NCT01134094|Weber B
1205240|NCT01134081|gum
1205241|NCT01134081|recession
1205242|NCT01134068|D-dimer
1205243|NCT01134068|Pulmonary embolism
1205244|NCT01134068|Diagnostic strategy
1205245|NCT01134068|Safety of ruling PE with and age-adjusted DD cut-off
1205246|NCT01134055|ranibizumab
1205247|NCT01134055|wet AMD
1205248|NCT01134055|MD7110852
1205249|NCT01134055|age related macular degeneration
1205250|NCT01134055|age-related macular degeneration
1205251|NCT01134055|macular degeneration
1205252|NCT01134055|pazopanib
1205253|NCT01134042|Fluticasone propionate
1205254|NCT01134042|asthma
1205255|NCT01134042|vilanterol
1205256|NCT01134042|GW642444
1205257|NCT01134042|Fluticasone furoate
1205258|NCT01134029|obesity
1205259|NCT01134029|weight management and cardiovascular risk factors
1205260|NCT01134016|Lung cancer
1205261|NCT01134016|NSCLC
1205262|NCT01134003|Gynecare Prolift
1205263|NCT01134003|Pelvic organ prolapse
1205264|NCT01134003|forming a large database of women who have recieve Gynecare prolift system
1205265|NCT01133964|Dairy proteins
1205266|NCT01133964|Appetite regulation
1205267|NCT01133964|Energy expenditure
1205268|NCT01133951|Helicobacter Infections
1205269|NCT01133951|Helicobacter pylori
1205270|NCT01133951|Drug Therapy
1205271|NCT01133951|Precancerous Conditions
1205272|NCT01133951|Stomach Neoplasms
1205273|NCT01133951|Incidence
1205274|NCT01133925|Coronary Artery Disease
1205275|NCT01133925|Percutaneous Coronary Intervention
1205276|NCT01133925|Drug Eluting Stent
1205277|NCT01133925|Optical Coherence Tomography
1205278|NCT01133925|Thrombosi
1205279|NCT01133925|Long lesions in native vessels requiring overlap
1205280|NCT01133912|Patients with HER2 Positive Operable Breast Cancer
1205281|NCT01133899|strength, anaerobic performance, recovery, ergogenic
1205282|NCT01133860|inherited thrombocytopenia
1205283|NCT01133860|MYH9 mutations
1205284|NCT01133860|eltrombopag
1205285|NCT01133834|meningococcal disease
1205286|NCT01133834|cytokines
1205287|NCT01133821|Bipolar II Disorder
1205288|NCT01133821|Bipolar II Depression
1205289|NCT01133821|Psychotherapy
1205290|NCT01133821|IPSRT
1205291|NCT01133821|Seroquel
1205292|NCT01133821|Quetiapine
1205293|NCT01133821|Placebo
1205294|NCT01133821|Sugar Pill
1205295|NCT01133808|diarrhea
1205296|NCT01133808|childhood
1205297|NCT01133808|rotavirus
1205298|NCT01133808|vaccine
1205299|NCT01133808|Nicaragua
1205300|NCT01133795|cirrhosis
1205301|NCT01133795|renal failure
1205302|NCT01133795|hepatorenal syndrome
1205303|NCT01133795|albumine
1205304|NCT01133795|midodrine
1205305|NCT01133769|Clavicle fracture
1205306|NCT01133769|fixation
1205307|NCT01133769|polytrauma
1205308|NCT01133769|Clavicle fracture patients with chest injury
1205309|NCT01133743|Lenalidomide
1205310|NCT01133743|Dexamethasone
1205311|NCT01133743|Immunomodulatory Drugs(IMiD™)
1205312|NCT01133743|Thalidomide analogues
1205313|NCT01133730|supraclavicular nerve block
1205314|NCT01133730|regional anesthesia
1205315|NCT01133730|transversalis fascia plane block
1205316|NCT01133730|ultrasound guided
1205317|NCT01133730|opioid consumption
1205318|NCT01133730|iliac crest bone harvest
1205319|NCT01133730|hand surgery
1205320|NCT01133730|wrist surgery
1205321|NCT01133730|Upper limb surgery combined with iliac crest bone harvest.
1205322|NCT01133717|Sleep Apnea
1205323|NCT01133717|Cerebrovascular Reactivity
1205324|NCT01133704|asymptomatic metastatic hormone-refractory prostate cancer
1205325|NCT01133691|gastric emptying
1205326|NCT01133691|children
1205327|NCT01133691|gastric fluid volume
1205328|NCT01133691|preoperative fasting
1205329|NCT01133678|Squamous Cell Carcinoma
1205330|NCT01133665|Head and Neck, Squamous Cell
1205331|NCT01133665|Recurrent or metastatic squamous cell or undifferentiated carcinoma of the head and neck that is not amenable to curative therapy
1205332|NCT01133652|Venipuncture
1205333|NCT01133652|Randomized Controlled Trial
1205334|NCT01133652|Intravenous access
1205335|NCT01133652|Children
1205336|NCT01133652|Pediatric Emergency Department
1205337|NCT01133652|Peripheral intravenous catheterization
1205338|NCT01133652|Catheterization, Peripheral Phlebotomy
1205339|NCT01133587|Schizophrenia
1205340|NCT01133587|bipolar disorder
1205341|NCT01133587|Long term care
1205342|NCT01133587|patient admission
1205343|NCT01133574|Healthy volunteers
1205344|NCT01133574|SLV354
1205345|NCT01133574|Phase I
1205346|NCT01133574|SRDT
1205347|NCT01133561|psoriasis
1205348|NCT01133561|insulin resistance
1205349|NCT01133561|metabolic syndrome
1205350|NCT01133561|pioglitazone
1205351|NCT01133561|randomized control trial
1205352|NCT01133548|testosterone, hypogonadal, males
1205353|NCT01133522|AMG145
1205354|NCT01133522|Multiple Dose
1205355|NCT01133522|Statin
1205356|NCT01133522|Ascending
1205357|NCT01133496|Bioequivalence
1205358|NCT01133496|Alendronate Sodium
1205359|NCT01133496|crossover
1205360|NCT01133483|Bioequivalence
1205361|NCT01133483|Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride
1205362|NCT01133470|Bioequivalence
1205363|NCT01133470|Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride
1205364|NCT01133457|Bioequivalence,Finasteride,Crossover
1205365|NCT01133444|Bioequivalence,Finasteride,Crossover
1205366|NCT01133431|CKD-501
1205367|NCT01133431|Glimepiride
1205368|NCT01133431|Placebo
1205369|NCT01133431|Healthy male volunteer
1205370|NCT01133431|Pharmacokinetic
1205371|NCT01133431|Metabolite
1205372|NCT01133392|insulin
1205373|NCT01133392|lispro
1205374|NCT01133366|ISIS301012
1205375|NCT01133366|antisense
1205376|NCT01133366|ApoB (Apolipoprotein B)
1205377|NCT01133366|LDL (low density lipoprotein)
1205378|NCT01133366|mipomersen
1205379|NCT01133340|RADIOTHERAPY
1205380|NCT01133340|CT simulation
1205381|NCT01133340|MRI simulation
1205382|NCT01133340|Endoscopic clip placement
1205383|NCT01133340|Rectal cancer
1205384|NCT01133340|Accuracy of MRI Simulation for target delineation and planning
1205385|NCT01133327|Carotid Artery Stenting
1205386|NCT01133327|High Risk patient
1205387|NCT01133327|Carotid artery stenosis
1205388|NCT01133327|stroke
1205389|NCT01133327|Carotid artery disease
1205390|NCT01133327|ASTI study
1205391|NCT01133327|Adapt Carotid Stent system
1205392|NCT01133327|FilterWire EZ Embolic Protection System
1205393|NCT01133301|Borderline Personality Disorder
1205394|NCT01133301|Dissociation
1205395|NCT01133301|Naltrexone
1205396|NCT01133249|total hip
1205397|NCT01133236|Salt restriction
1205398|NCT01133236|Fluid restriction
1205399|NCT01133236|Congestion
1205400|NCT01133236|Heart Failure
1205401|NCT01133223|Stroke, mecanical thrombectomy
1205402|NCT01133210|hypertriglyceridemia
1205403|NCT01133210|triglyceride
1205404|NCT01133210|cholesterol
1205405|NCT01133210|Maraviroc
1205406|NCT01133197|thumb
1205407|NCT01133197|arthritis
1205408|NCT01133197|Impact of thumb arthritis on health
1205409|NCT01133184|HBV transmission PreS1/PreS2/S HBV vaccine
1205410|NCT01133171|Cardiovascular Disease
1205411|NCT01133171|Stroke
1205412|NCT01133158|Follicular non-Hodgkin's lymphoma in relapse or refractory to standard first-line immunochemotherapy
1205413|NCT01133145|composite tissue allotransplantation
1205414|NCT01133145|hand transplantation
1205415|NCT01133145|knee transplantation
1205416|NCT01133145|face transplantation
1205417|NCT01133132|Colon cancer patients who have completed treatment
1205418|NCT01133119|cardiac catheterization
1205419|NCT01133119|local anesthetic
1205420|NCT01133119|pain experienced post-operatively
1205421|NCT01133119|pediatric patients
1205422|NCT01133106|stroke recovery
1205423|NCT01133106|quality of life
1205424|NCT01133093|Cardiovascular risk factors
1205425|NCT01133093|Nutritional assessment
1205426|NCT01133093|Epidemiology
1205427|NCT01133067|lung cancer
1205428|NCT01133067|followup
1205429|NCT01133067|physical follow up
1205430|NCT01133067|telephonic followup
1205431|NCT01133054|Coronary Vessel Anomalies
1205432|NCT01133028|Attention Deficit Hyperactivity Disorder (ADHD)
1205433|NCT01133015|FFR
1205434|NCT01133015|IVUS
1205435|NCT01133015|MLA
1205436|NCT01132989|Patients with cutaneous T cell lymphoma
1205437|NCT01132976|Personality disorders
1205438|NCT01132976|Personal Concerns Inventory
1205439|NCT01132976|Non completion
1205440|NCT01132937|Diffusion/Perfusion-MRI
1205441|NCT01132937|Magnetic Resonance Imaging (MRI)
1205442|NCT01132937|Traumatic Brain Injury
1205443|NCT01132937|Brain Imaging
1205444|NCT01132937|Brain Injuries
1205445|NCT01132937|TBI
1205446|NCT01132924|Early Pregnancy
1205447|NCT01132924|Gestational Age
1205448|NCT01132924|Fecundability
1205449|NCT01132924|Ovulation
1205450|NCT01132924|Recall
1205451|NCT01132911|Solid Tumors
1205452|NCT01132911|Maximum Tolerated Dose
1205453|NCT01132911|Lymphoma
1205454|NCT01132911|Dose Escalation
1205455|NCT01132911|Pharmacokinetics
1205456|NCT01132911|Pediatric Cancer
1205457|NCT01132911|Solid Tumor
1205458|NCT01132911|Sarcoma
1205459|NCT01132911|Wilms Tumor
1205460|NCT01132911|Neuroblastoma
1205461|NCT01132898|Traumatic Brain Injury
1205462|NCT01132898|Biomarkers
1205463|NCT01132898|Magnetic Resonance Imaging (MRI)
1205464|NCT01132898|DTI
1205465|NCT01132898|Functional Capacity
1205466|NCT01132898|TBI
1205467|NCT01132885|MRI
1205468|NCT01132885|Children
1205469|NCT01132885|Williams Syndrome
1205470|NCT01132885|Phenotype
1205471|NCT01132885|Brain
1205472|NCT01132885|Healthy Volunteer
1205473|NCT01132885|HV
1205474|NCT01132872|Serotonin 1A Receptor
1205475|NCT01132872|Positron Emission Tomograhy (PET)
1205476|NCT01132872|Dosimetry
1205477|NCT01132872|Healthy Volunteer
1205478|NCT01132872|HV
1205479|NCT01132859|Specimen Collection
1205480|NCT01132859|Mucosal Immunity
1205481|NCT01132859|Immune Responses
1205482|NCT01132859|Immunity
1205483|NCT01132859|Vaccines
1205484|NCT01132859|Healthy Volunteer
1205485|NCT01132859|HV
1205486|NCT01132833|thromboembolism
1205487|NCT01132833|stage I multiple myeloma
1205488|NCT01132833|stage II multiple myeloma
1205489|NCT01132833|stage III multiple myeloma
1205490|NCT01132807|stage I adult Hodgkin lymphoma
1205491|NCT01132807|stage II adult Hodgkin lymphoma
1205608|NCT01132547|recurrent Wilms tumor
1205492|NCT01132794|Pain relief and sedation condition
1205493|NCT01132781|rhinosinusitis
1205494|NCT01132781|asthma
1205495|NCT01132781|allergic rhinitis
1205496|NCT01132781|theophylline
1205497|NCT01132755|gastric
1205498|NCT01132755|pancreas
1205499|NCT01132755|laparoscopy
1205500|NCT01132755|peritoneal lavage
1205501|NCT01132755|10-011
1205502|NCT01132755|gastric and pancreatic cancer
1205503|NCT01132742|Malnutrition
1205504|NCT01132742|children
1205505|NCT01132742|Hospital Stay
1205506|NCT01132742|Screening Tools
1205507|NCT01132742|Anthropometry
1205508|NCT01132690|gaucher disease
1205509|NCT01132690|pediatric
1205510|NCT01132677|OA of Knee
1205511|NCT01132677|Osteoarthritis of Knee
1205512|NCT01132677|Viscosupplementation and Osteoarthritis
1205513|NCT01132677|Viscosupplementation and OA
1205514|NCT01132677|Hyaluronic Acid
1205515|NCT01132677|Corticosteroid injection versus hyaluronic acid
1205516|NCT01132677|Synvisc One and Knee OA
1205517|NCT01132677|viscosupplementation and knee pain
1205518|NCT01132677|knee Pain from OA
1205519|NCT01132664|HER2
1205520|NCT01132664|BKM120
1205521|NCT01132664|PIK3
1205522|NCT01132664|metastatic breast cancer
1205523|NCT01132664|brain metastases
1205524|NCT01132664|Herceptin
1205525|NCT01132664|trastuzumab
1205526|NCT01132664|capecitabine
1205527|NCT01132664|open-label
1205528|NCT01132664|maximum tolerated dose
1205529|NCT01132664|Phase I/Phase ll
1205530|NCT01132651|eczema
1205531|NCT01132651|itch
1205532|NCT01132651|pruritus
1205533|NCT01132651|head
1205534|NCT01132651|neck
1205535|NCT01132638|Gastroesophageal
1205536|NCT01132638|Pantoprazole
1205537|NCT01132638|erosive
1205538|NCT01132638|Erosive GERD grades A-D, acc. to Los Angeles classification
1205539|NCT01132625|HSP90
1205540|NCT01132625|molecular chaperone
1205541|NCT01132625|advanced solid tumors
1205542|NCT01132625|Japan
1205543|NCT01132612|Chronic plaque-type psoriasis
1205544|NCT01132612|AIN457
1205545|NCT01132612|dermatology
1205546|NCT01132612|Moderate to severe chronic plaque-type psoriasis
1205547|NCT01132599|stage IV prostate cancer
1205548|NCT01132560|ductal breast carcinoma in situ
1205549|NCT01132547|cachexia
1205550|NCT01132547|weight changes
1205551|NCT01132547|nausea and vomiting
1205552|NCT01132547|alveolar childhood rhabdomyosarcoma
1205553|NCT01132547|anaplastic osteosarcoma
1205554|NCT01132547|childhood alveolar soft-part sarcoma
1205555|NCT01132547|childhood angiosarcoma
1205556|NCT01132547|childhood epithelioid sarcoma
1205557|NCT01132547|childhood fibrosarcoma
1205558|NCT01132547|childhood gliosarcoma
1205559|NCT01132547|childhood leiomyosarcoma
1205560|NCT01132547|childhood liposarcoma
1205561|NCT01132547|childhood neurofibrosarcoma
1205562|NCT01132547|childhood synovial sarcoma
1205563|NCT01132547|chondrosarcoma
1205564|NCT01132547|chondrosarcomatous osteosarcoma
1205565|NCT01132547|clear cell sarcoma of the kidney
1205566|NCT01132547|embryonal childhood rhabdomyosarcoma
1205567|NCT01132547|embryonal-botryoid childhood rhabdomyosarcoma
1205568|NCT01132547|endometrial stromal sarcoma
1205569|NCT01132547|extraosseous Ewing sarcoma
1205570|NCT01132547|peripheral primitive neuroectodermal tumor
1205571|NCT01132547|fibrosarcomatous osteosarcoma
1205572|NCT01132547|localized Ewing sarcoma
1205573|NCT01132547|localized osteosarcoma
1205574|NCT01132547|mast cell sarcoma
1205575|NCT01132547|metastatic childhood soft tissue sarcoma
1205576|NCT01132547|metastatic Ewing sarcoma
1205577|NCT01132547|metastatic osteosarcoma
1205578|NCT01132547|mixed childhood rhabdomyosarcoma
1205579|NCT01132547|mixed osteosarcoma
1205580|NCT01132547|nonmetastatic childhood soft tissue sarcoma
1205581|NCT01132547|osteoblastic osteosarcoma
1205582|NCT01132547|ovarian carcinosarcoma
1205583|NCT01132547|ovarian sarcoma
1205584|NCT01132547|pleomorphic childhood rhabdomyosarcoma
1205585|NCT01132547|previously treated childhood rhabdomyosarcoma
1205586|NCT01132547|previously untreated childhood rhabdomyosarcoma
1205587|NCT01132547|recurrent adult soft tissue sarcoma
1205588|NCT01132547|recurrent childhood gliosarcoma
1205589|NCT01132547|recurrent childhood rhabdomyosarcoma
1205590|NCT01132547|recurrent childhood soft tissue sarcoma
1205591|NCT01132547|recurrent Ewing sarcoma
1205592|NCT01132547|recurrent osteosarcoma
1205593|NCT01132547|recurrent uterine sarcoma
1205594|NCT01132547|small intestine leiomyosarcoma
1205595|NCT01132547|stage I uterine sarcoma
1205596|NCT01132547|stage II uterine sarcoma
1205597|NCT01132547|stage III uterine sarcoma
1205598|NCT01132547|stage IV uterine sarcoma
1205599|NCT01132547|telangiectatic osteosarcoma
1205600|NCT01132547|untreated childhood gliosarcoma
1205601|NCT01132547|uterine carcinosarcoma
1205602|NCT01132547|uterine leiomyosarcoma
1205603|NCT01132547|localized resectable neuroblastoma
1205604|NCT01132547|localized unresectable neuroblastoma
1205605|NCT01132547|recurrent neuroblastoma
1205606|NCT01132547|regional neuroblastoma
1205607|NCT01132547|stage 4S neuroblastoma
1205609|NCT01132547|childhood kidney tumors
1205610|NCT01132547|stage III Wilms tumor
1205611|NCT01132547|stage IV Wilms tumor
1205612|NCT01132547|childhood hepatoblastoma
1205613|NCT01132547|childhood extracranial germ cell tumor
1205614|NCT01132547|childhood extragonadal germ cell tumor
1205615|NCT01132547|childhood gonadal germ cell tumor
1205616|NCT01132547|childhood malignant ovarian germ cell tumor
1205617|NCT01132547|childhood malignant testicular germ cell tumor
1205618|NCT01132547|recurrent childhood malignant germ cell tumor
1205619|NCT01132547|recurrent extragonadal germ cell tumor
1205620|NCT01132547|recurrent extragonadal non-seminomatous germ cell tumor
1205621|NCT01132547|recurrent malignant testicular germ cell tumor
1205622|NCT01132547|recurrent ovarian germ cell tumor
1205623|NCT01132547|stage III extragonadal non-seminomatous germ cell tumor
1205624|NCT01132547|stage III malignant testicular germ cell tumor
1205625|NCT01132547|stage IIIA ovarian germ cell tumor
1205626|NCT01132547|stage IIIB ovarian germ cell tumor
1205627|NCT01132547|stage IIIC ovarian germ cell tumor
1205628|NCT01132547|stage IV extragonadal non-seminomatous germ cell tumor
1205629|NCT01132547|stage IV ovarian germ cell tumor
1205630|NCT01132547|recurrent childhood medulloblastoma
1205631|NCT01132547|untreated childhood medulloblastoma
1205632|NCT01132547|childhood ependymoblastoma
1205633|NCT01132547|childhood infratentorial ependymoma
1205634|NCT01132547|newly diagnosed childhood ependymoma
1205635|NCT01132547|recurrent childhood ependymoma
1205636|NCT01132547|recurrent childhood subependymal giant cell astrocytoma
1205637|NCT01132547|untreated childhood subependymal giant cell astrocytoma
1205638|NCT01132547|peripheral primitive neuroectodermal tumor of the kidney
1205639|NCT01132547|childhood supratentorial primitive neuroectodermal tumor
1205640|NCT01132547|recurrent childhood brain stem glioma
1205641|NCT01132547|recurrent childhood brain tumor
1205642|NCT01132547|untreated childhood brain stem glioma
1205643|NCT01132547|recurrent childhood anaplastic astrocytoma
1205644|NCT01132547|recurrent childhood anaplastic oligoastrocytoma
1205645|NCT01132547|recurrent childhood anaplastic oligodendroglioma
1205646|NCT01132547|stage I childhood anaplastic large cell lymphoma
1205647|NCT01132547|stage II childhood anaplastic large cell lymphoma
1205648|NCT01132547|stage III childhood anaplastic large cell lymphoma
1205649|NCT01132547|stage IV childhood anaplastic large cell lymphoma
1205650|NCT01132547|untreated childhood anaplastic astrocytoma
1205651|NCT01132547|untreated childhood anaplastic oligoastrocytoma
1205652|NCT01132547|untreated childhood anaplastic oligodendroglioma
1205653|NCT01132547|childhood high-grade cerebellar astrocytoma
1205654|NCT01132547|childhood low-grade cerebellar astrocytoma
1205655|NCT01132547|recurrent childhood astrocytoma
1205656|NCT01132547|other tumor of glial origin
1205657|NCT01132547|recurrent childhood cerebellar astrocytoma
1205658|NCT01132547|recurrent childhood cerebral astrocytoma
1205659|NCT01132547|recurrent childhood diffuse astrocytoma
1205660|NCT01132547|recurrent childhood fibrillary astrocytoma
1205661|NCT01132547|recurrent childhood gemistocytic astrocytoma
1205662|NCT01132547|recurrent childhood oligoastrocytoma
1205663|NCT01132547|recurrent childhood pilocytic astrocytoma
1205664|NCT01132547|recurrent childhood pilomyxoid astrocytoma
1205665|NCT01132547|recurrent childhood pleomorphic xanthoastrocytoma
1205666|NCT01132547|recurrent childhood protoplasmic astrocytoma
1205667|NCT01132547|untreated childhood cerebellar astrocytoma
1205668|NCT01132547|untreated childhood cerebral astrocytoma
1205669|NCT01132547|untreated childhood diffuse astrocytoma
1205670|NCT01132547|untreated childhood fibrillary astrocytoma
1205671|NCT01132547|untreated childhood gemistocytic astrocytoma
1205672|NCT01132547|untreated childhood oligoastrocytoma
1205673|NCT01132547|untreated childhood pilocytic astrocytoma
1205674|NCT01132547|untreated childhood pilomyxoid astrocytoma
1205675|NCT01132547|untreated childhood pleomorphic xanthoastrocytoma
1205676|NCT01132547|untreated childhood protoplasmic astrocytoma
1205677|NCT01132547|recurrent childhood gliomatosis cerebri
1205678|NCT01132547|recurrent childhood oligodendroglioma
1205679|NCT01132547|recurrent childhood visual pathway
1205680|NCT01132547|hypothalamic glioma
1205681|NCT01132547|recurrent childhood visual pathway glioma
1205682|NCT01132547|untreated childhood gliomatosis cerebri
1205683|NCT01132547|untreated childhood oligodendroglioma
1205684|NCT01132547|untreated childhood visual pathway
1205685|NCT01132547|untreated childhood visual pathway glioma
1205686|NCT01132547|recurrent childhood giant cell glioblastoma
1205687|NCT01132547|recurrent childhood glioblastoma
1205688|NCT01132547|untreated childhood giant cell glioblastoma
1205689|NCT01132547|untreated childhood glioblastoma
1205690|NCT01132547|childhood choroid plexus tumor
1205691|NCT01132547|childhood grade I meningioma
1205692|NCT01132547|childhood grade II meningioma
1205693|NCT01132547|childhood grade III meningioma
1205694|NCT01132547|minimally differentiated myeloid leukemia (M0)
1205695|NCT01132547|myeloblastic leukemia with maturation (M2)
1205696|NCT01132547|myeloblastic leukemia without maturation (M1)
1205697|NCT01132547|childhood acute myelomonocytic leukemia (M4)
1205698|NCT01132547|childhood acute promyelocytic leukemia (M3)
1205699|NCT01132547|recurrent childhood acute myeloid leukemia
1205700|NCT01132547|untreated childhood acute myeloid leukemia
1205701|NCT01132547|other myeloid malignancies
1205702|NCT01132547|childhood acute monoblastic leukemia (M5a)
1205703|NCT01132547|childhood acute monocytic leukemia (M5b)
1205704|NCT01132547|childhood acute erythroleukemia (M6)
1205705|NCT01132547|childhood acute megakaryocytic leukemia (M7)
1205706|NCT01132547|unspecified childhood solid tumor
1205707|NCT01132534|OGD
1205708|NCT01132534|NBI
1205709|NCT01132534|AFI
1205710|NCT01132534|Videoendoscopy
1205711|NCT01132534|Narrow Band Imaging
1205712|NCT01132534|Autofluorescence Imaging
1205713|NCT01132521|ulinastatin
1205714|NCT01132521|severe acute pancreatitis
1205715|NCT01132508|Tibial plateau fracture
1205716|NCT01132508|Orthopaedic Trauma Association (OTA) B2 B3 C3
1205717|NCT01132508|Bone Void
1205718|NCT01132495|Stable angina
1205719|NCT01132495|angina pectoris
1205720|NCT01132495|PCI
1205721|NCT01132495|FAME
1205722|NCT01132495|FAME II
1205723|NCT01132495|FFR
1205724|NCT01132495|Fractional Flow Reserve
1205725|NCT01132495|Pressure wire
1205726|NCT01132482|Cystic fibrosis
1205727|NCT01132482|CFTR
1205728|NCT01132482|Phosphodiesterase inhibitor
1205729|NCT01132482|Nasal potential difference
1205730|NCT01132482|Sweat test
1205731|NCT01132456|TARGET VESSEL REVASCULARIZATION (TVR)
1205732|NCT01132456|MYOCARDIAL INFARCTION (MI)
1205733|NCT01132456|TARGET VESSEL FAILURE (TVF)
1205734|NCT01132456|TARGET LESION REVASCULARIZATION (TLR)
1205735|NCT01132456|TARGET LESION FAILURE (TLF)
1205736|NCT01132456|STENT THROMBOSIS
1205737|NCT01132456|RESTENOTIC LESION
1205738|NCT01132456|PERCUTANEOUS CORONARY INTERVENTION (PCI)
1205739|NCT01132456|LONG LESION
1205740|NCT01132456|DUAL VESSEL
1205741|NCT01132430|ADHERENCE
1205742|NCT01132430|ASTHMA CONTROL
1205743|NCT01132430|ASTHMA QUALITY OF LIFE
1205744|NCT01132430|MOTIVATIONAL INTERVIEWING
1205745|NCT01132417|Tigecycline, MDR
1205746|NCT01132417|Patient infected with multidrug resistance bacteria
1205747|NCT01132391|anal fissure
1205748|NCT01132391|nitroglycerin
1205749|NCT01132391|medical treatment
1205750|NCT01132378|Total knee arthroplasty
1205751|NCT01132365|knee arthroplasty
1205752|NCT01132352|Bioavailability
1205753|NCT01132352|Crossover
1205754|NCT01132352|Levetiracetam
1205755|NCT01132339|Adverse reactions to Gadolinium-based contrast agents.
1205756|NCT01132339|Adverse reactions to Iodine-basedcontrast agents.
1205757|NCT01132326|Symptomatic NOH
1205758|NCT01132287|Contact lens wear
1205759|NCT01132287|lubricant eye drops
1205760|NCT01132274|Supraventricular arrhythmia catheter ablation
1205761|NCT01132248|schistosomiasis, schistosoma haematobium
1205762|NCT01132222|Bioequivalence
1205763|NCT01132222|Crossover
1205764|NCT01132222|Ibuprofen and Pseudoephedrine
1205765|NCT01132209|surgery
1205766|NCT01132209|incisional hernia
1205767|NCT01132209|woundinfection
1205768|NCT01132209|burst abdomen
1205769|NCT01132209|pain
1205770|NCT01132196|Bioequivalence
1205771|NCT01132196|Crossover
1205772|NCT01132196|Divalproex Sodium
1205773|NCT01132170|Bioequivalence
1205774|NCT01132170|Crossover
1205775|NCT01132170|Divalproex Sodium
1205776|NCT01132157|Healthy Kidney Donors and Their Recipients with End Stage Renal Disease
1205777|NCT01132144|Reproductive Techniques
1205778|NCT01132144|Embryo Implantation
1205779|NCT01132144|Endometrium
1205780|NCT01132144|Ultrasonography
1205781|NCT01132131|Urinary tract infection
1205782|NCT01132131|Cystitis
1205783|NCT01132131|Bacteruria
1205784|NCT01132118|rheumatoid arthritis
1205785|NCT01132118|insulin resistance
1205786|NCT01132118|hydroxychloroquine
1205787|NCT01132118|cholesterol
1205788|NCT01132092|Evoked Potentials, Adult, Hearing Loss
1205789|NCT01132079|atopic dermatitis
1205790|NCT01132079|barrier function
1205791|NCT01132079|pimecrolimus
1205792|NCT01132066|swallowing
1205793|NCT01132066|stroke
1205794|NCT01132053|JC Virus
1205795|NCT01132040|Bioequivalence
1205796|NCT01132040|Crossover
1205797|NCT01132040|Primidone
1205798|NCT01132027|Bioavailability, crossover, tacrolimus
1205799|NCT01132014|Subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer,
1205800|NCT01132014|from whom solid tumor or ascites have been harvested and are available and
1205801|NCT01132014|sufficient for tumorlysate preparation;and whose largest tumor nodule is 4.5
1205802|NCT01132014|cm. Subjects may have undergone chemotherapy or other therapy following
1205803|NCT01132014|tumor harvesting and prior to enrollment.
1205804|NCT01131988|Bioavailability, crossover, tacrolimus
1205805|NCT01131975|Bioequivalence
1205806|NCT01131975|Crossover
1205807|NCT01131975|Lamotrigine (chewable, dispersible)
1205808|NCT01131962|esophageal varices
1205809|NCT01131962|hematemesis
1205810|NCT01131962|endoscopy
1205811|NCT01131949|Bioequivalence
1205812|NCT01131949|Crossover
1205813|NCT01131949|Lamotrigine (chewable, dispersible)
1205814|NCT01131936|Bioequivalence
1205815|NCT01131936|Amlodipine Besylate
1205816|NCT01131923|Bioequivalence
1205817|NCT01131923|Amlodipine Besylate
1205818|NCT01131910|Rheumatoid arthritis
1205819|NCT01131910|TBE-vaccine
1205820|NCT01131910|Immunosuppression
1205821|NCT01131897|Bioavailability
1205822|NCT01131897|Crossover
1205823|NCT01131897|Levetiracetam
1205824|NCT01131884|ASIA A or ASIA B Spinal Cord Injury
1205825|NCT01131871|obesity
1205826|NCT01131871|overweight
1205827|NCT01131832|Cholesterol, Plant sterols, Non-response, SNPs,
1205828|NCT01131819|Trans-tibial Amputation
1205829|NCT01131806|chronic obstructive pulmonary disease
1205830|NCT01131806|lung function change FEV1 FVC
1205831|NCT01131806|acute exacerbation
1205832|NCT01131806|life quality questionnaire
1205833|NCT01131793|Coronary Artery Chronic Total Occlusion In-Stent
1205834|NCT01131780|Bioequivalence
1205835|NCT01131780|Crossover
1205836|NCT01131780|Ibuprofen and Pseudoephedrine
1205837|NCT01131767|Bioequivalence
1205838|NCT01131767|Crossover
1205839|NCT01131767|Naproxen Sodium and Pseudoephedrine Hydrochloride
1205840|NCT01131754|Peripheral venous catheter complications
1205841|NCT01131754|PVC occlusion
1205842|NCT01131754|PVC phlebitis
1205843|NCT01131741|anesthesia, general
1205844|NCT01131741|blood pressure
1205845|NCT01131741|epinephrine
1205846|NCT01131741|heart rate
1205847|NCT01131741|injections, intravenous
1205848|NCT01131728|Bioequivalence
1205849|NCT01131728|Crossover
1205850|NCT01131728|Naproxen Sodium and Pseudoephedrine Hydrochloride
1205851|NCT01131715|Qualitetive interview
1205852|NCT01131715|Coronary heart disease (CHD)
1205853|NCT01131715|Patient experience
1205854|NCT01131715|Patient perception
1205855|NCT01131702|Bioequivalence
1205856|NCT01131702|Crossover
1205857|NCT01131702|Ranitidine
1205858|NCT01131689|metastatic HCC
1205859|NCT01131663|Infants, aerosol, acceptance, face mask, drug delivery
1205860|NCT01131650|Prevalence of diabetic retinopathy
1205861|NCT01131650|Diabetes
1205862|NCT01131650|Retinopathy
1205863|NCT01131650|Prevalence
1205864|NCT01131650|Population
1205865|NCT01131637|chronic heart failure
1205866|NCT01131637|rhNRG-1
1205867|NCT01131637|mortality
1205868|NCT01131624|Iron deficiency
1205869|NCT01131611|Spinal Stenosis
1205870|NCT01131611|Rehabilitation
1205871|NCT01131611|Physical Therapy (specialty)
1205872|NCT01131611|Cognitive Behavior Therapy
1205873|NCT01131611|Behavioral Research
1205874|NCT01131598|ALI
1205875|NCT01131598|SDRA
1205876|NCT01131585|Diabetic macular edema
1205877|NCT01131585|DME
1205878|NCT01131585|Proliferative diabetic retinopathy
1205879|NCT01131585|PDR
1205880|NCT01131585|ranibizumab
1205881|NCT01131585|laser
1205882|NCT01131559|bipolar disorder
1205883|NCT01131559|manic depression
1205884|NCT01131559|depression
1205885|NCT01131559|Bipolar I or II
1205886|NCT01131546|Essential Hypertension
1205887|NCT01131546|Levamlodipine Besylate
1205888|NCT01131546|Amlodipine Maleate
1205889|NCT01131520|SBIRT
1205890|NCT01131520|Drug abuse
1205891|NCT01131507|Exocrine Pancreatic Insufficiency
1205892|NCT01131507|Infants with CF
1205893|NCT01131494|Parkinson's disease
1205894|NCT01131494|Dysphagia
1205895|NCT01131494|Treatment
1205896|NCT01131481|cataracts,glistenings,intraocular lenses.
1205897|NCT01131468|ototoxicity
1205898|NCT01131468|aminoglycoside
1205899|NCT01131468|vancomycine
1205900|NCT01131468|peritoneal dialysis
1205901|NCT01131468|peritonitis
1205902|NCT01131442|immune
1205903|NCT01131429|mutation analysis
1205904|NCT01131429|first-line
1205905|NCT01131429|second-line
1205906|NCT01131429|targeted therapy
1205907|NCT01131403|IL-1α, skin care; baby wet wipes; full-term newborn; skin barrier function
1205908|NCT01131377|mechanical ventilation weaning phase patients with metabolic alkalosis
1205909|NCT01131364|Interleukin
1205910|NCT01131364|IL2
1205911|NCT01131364|F16
1205912|NCT01131364|monoclonal
1205913|NCT01131364|antibody
1205914|NCT01131364|cytokine
1205915|NCT01131364|doxorubicin
1205916|NCT01131364|breast cancer
1205917|NCT01131364|solid tumour
1205918|NCT01131364|Phase I: Advanced Solid Tumour Patients
1205919|NCT01131364|Phase II: Breast Cancer Patients Amenable to anthracyclin Therapy
1205920|NCT01131351|MDR-TB
1205921|NCT01131351|Dose Escalation
1205922|NCT01131351|Phase II
1205923|NCT01131351|Open Label
1205924|NCT01131351|Non Controlled
1205925|NCT01131351|Pulmonary Multidrug-Resistant Tuberculosis (MDR TB)
1205926|NCT01131325|Philadelphia chromosome positive
1205927|NCT01131325|Ph+
1205928|NCT01131325|chronic myelogenous leukemia chronic phase
1205929|NCT01131325|CML-CP
1205930|NCT01131325|low imatinib trough levels
1205931|NCT01131312|Cervix
1205932|NCT01131312|CIN
1205933|NCT01131312|HPV
1205934|NCT01131312|Triage
1205935|NCT01131312|ASCUS/LSIL
1205936|NCT01131312|Pap Smear
1205937|NCT01131312|HPV Test
1205938|NCT01131299|HDL
1205939|NCT01131299|Cholesterol
1205940|NCT01131299|Lipoproteins
1205941|NCT01131299|Serum Lipids
1205942|NCT01131299|Alpha-Cyclodextrin
1205943|NCT01131299|Atherosclerosis
1205944|NCT01131299|Heart Disease
1205945|NCT01131273|buprenorphine injecting
1205946|NCT01131273|opiate dependence
1205947|NCT01131273|HIV risk
1205948|NCT01131273|treatment outcome
1205949|NCT01131273|opiate dependence with buprenorphine injecting
1205950|NCT01131260|STAN
1205951|NCT01131260|Fetal monitoring
1205952|NCT01131260|Fetal acidosis
1205953|NCT01131260|Fetal heart rate monitoring
1205954|NCT01131260|Perinatology
1205955|NCT01131247|CLL
1205956|NCT01131247|bendamustine
1205957|NCT01131247|ofatumumab
1205958|NCT01131247|blood cancer
1205959|NCT01131247|leukemia
1205960|NCT01131247|lymphoma
1205961|NCT01131247|lymphocyte
1205962|NCT01131247|refractory
1205963|NCT01131247|Advanced
1205964|NCT01131247|relapsed
1205965|NCT01131247|hematologic
1205966|NCT01131247|hematology
1205967|NCT01131247|antibody
1205968|NCT01131247|non-Hodgkin lymphoma
1205969|NCT01131247|small lymphocytic lymphoma
1205970|NCT01131247|nevada cancer institute
1205971|NCT01131247|cephalon
1205972|NCT01131247|Glaxosmithkline
1205973|NCT01131221|contiguous stage II grade 1 follicular lymphoma
1205974|NCT01131221|contiguous stage II grade 2 follicular lymphoma
1205975|NCT01131221|contiguous stage II grade 3 follicular lymphoma
1205976|NCT01131221|noncontiguous stage II grade 1 follicular lymphoma
1205977|NCT01131221|noncontiguous stage II grade 2 follicular lymphoma
1205978|NCT01131221|noncontiguous stage II grade 3 follicular lymphoma
1205979|NCT01131221|stage III grade 1 follicular lymphoma
1205980|NCT01131221|stage III grade 2 follicular lymphoma
1205981|NCT01131221|stage III grade 3 follicular lymphoma
1205982|NCT01131221|stage IV grade 1 follicular lymphoma
1205983|NCT01131221|stage IV grade 2 follicular lymphoma
1205984|NCT01131221|stage IV grade 3 follicular lymphoma
1205985|NCT01131208|contiguous stage II adult diffuse large cell lymphoma
1205986|NCT01131208|noncontiguous stage II adult diffuse large cell lymphoma
1205987|NCT01131208|recurrent adult diffuse large cell lymphoma
1205988|NCT01131208|stage I adult diffuse large cell lymphoma
1205989|NCT01131208|stage III adult diffuse large cell lymphoma
1205990|NCT01131208|stage IV adult diffuse large cell lymphoma
1205991|NCT01131195|HER2-negative breast cancer
1205992|NCT01131195|recurrent breast cancer
1205993|NCT01131195|stage IIIB breast cancer
1205994|NCT01131195|stage IIIC breast cancer
1205995|NCT01131195|stage IV breast cancer
1205996|NCT01131169|Myeloma
1205997|NCT01131169|Busulfan
1205998|NCT01131169|Melphalan
1205999|NCT01131169|Fludarabine
1206000|NCT01131169|T-Cell
1206001|NCT01131169|Stem Cell Transplantation
1206002|NCT01131169|10-051
1206003|NCT01131156|postpartum
1206004|NCT01131156|smoking
1206005|NCT01131156|relapse
1206006|NCT01131156|breastfeeding
1206007|NCT01131143|Urban community centers
1206008|NCT01131143|Obesity
1206009|NCT01131143|Obesity counseling
1206010|NCT01131143|Low-cost intervention
1206011|NCT01131130|Contact lens
1206015|NCT01131104|NAION
1206016|NCT01131065|Hepatitis B
1206017|NCT01131065|HBV
1206018|NCT01131065|Orthotopic liver transplantation
1206019|NCT01131065|Liver transplantation
1206020|NCT01131065|Recurrence
1206021|NCT01131065|Reinfection
1206022|NCT01131065|Protective titers
1206023|NCT01131065|HBsAb
1206024|NCT01131065|Hepatitis B virus immune globulin
1206025|NCT01131065|Niuliva
1206026|NCT01131052|elderly populations
1206027|NCT01131052|diabetes
1206028|NCT01131039|Ovarian Cancer
1206029|NCT01131026|Helicobacter pylori
1206030|NCT01131026|levofloxacin
1206031|NCT01131026|amoxicillin
1206032|NCT01131026|lansoprazole
1206033|NCT01131026|efficacy
1206034|NCT01131026|safety
1206035|NCT01131026|triple therapy
1206036|NCT01130987|resident
1206037|NCT01130987|intern
1206038|NCT01130987|patient safety
1206039|NCT01130987|medical error
1206040|NCT01130987|time motion
1206041|NCT01130987|handoff
1206042|NCT01130987|sign-out
1206043|NCT01130987|Resident Workflow
1206044|NCT01130987|Resident Communications
1206045|NCT01130961|Advanced NSCLC
1206046|NCT01130961|Gefitinib
1206047|NCT01130961|Thai patient
1206048|NCT01130948|hypoxia
1206049|NCT01130948|altitude
1206050|NCT01130948|sleep
1206051|NCT01130948|sleep apnea
1206052|NCT01130948|periodic breathing
1206053|NCT01130948|vigilance
1206054|NCT01130948|psychomotor
1206055|NCT01130948|endothelial function
1206056|NCT01130935|GERD
1206057|NCT01130935|gastric and duodenal ulcers
1206058|NCT01130935|NSAID therapy
1206059|NCT01130922|Roux-and-Y gastric bypass surgery
1206060|NCT01130922|stable body weight
1206061|NCT01130909|Healthy
1206062|NCT01130909|Effect of a single dose on gamma-band qEEG
1206063|NCT01130896|MRI, pacemakers, Defibrillator
1206064|NCT01130883|acute tracheitis
1206065|NCT01130883|acute tracheobronchitis or acute bronchitis
1206066|NCT01130883|acute exacerbation of chronic bronchitis
1206067|NCT01130883|mild community-acquired pneumonia
1206068|NCT01130870|Fecal incontinence
1206069|NCT01130870|Sacral nerve stimulation
1206070|NCT01130870|Quality of life
1206071|NCT01130870|DR15.9 Incontinentia alva
1206072|NCT01130818|Safety
1206073|NCT01130818|Tolerability
1206074|NCT01130818|Pharmacokinetics
1206075|NCT01130818|Bioavailability (solid vs solution, fasting vs fed)
1206076|NCT01130818|Young healthy subjects
1206077|NCT01130818|Elderly healthy subjects
1206078|NCT01130805|gastric cancer pazopanib capecitabine, oxaliplatin
1206079|NCT01130805|Metastatic or recurrent gastric cancer
1206080|NCT01130792|rotavirus
1206081|NCT01130792|cryptosporidium
1206082|NCT01130792|probiotics
1206083|NCT01130792|intestinal function
1206084|NCT01130792|immune response
1206085|NCT01130779|Non-small Cell Lung Cancer
1206086|NCT01130779|Erlotinib
1206087|NCT01130779|brain metastasis
1206088|NCT01130766|Non-small Cell Lung Cancer
1206089|NCT01130766|Asymptomatic brain metastasis
1206090|NCT01130766|Stereotactic radiosurgery (SRS)
1206091|NCT01130740|Osteoarthritis
1206092|NCT01130740|Exercise
1206093|NCT01130740|Diet
1206094|NCT01130740|Coping Skills
1206095|NCT01130740|Education, Medical
1206096|NCT01130727|diabetes mellitus
1206097|NCT01130727|diabetic nephropathy
1206098|NCT01130727|hypertension
1206099|NCT01130727|green tea
1206100|NCT01130727|cocoa
1206101|NCT01130727|polyphenol
1206102|NCT01130727|nitric oxide
1206103|NCT01130714|inflammation
1206104|NCT01130714|chemotherapy
1206105|NCT01130714|lung cancer
1206106|NCT01130701|Pancreatic Cancer
1206107|NCT01130701|Neoadjuvant
1206108|NCT01130701|Panitumumab
1206109|NCT01130701|Capecitabine
1206110|NCT01130688|Leukemia
1206111|NCT01130688|Zileuton
1206112|NCT01130688|myeloproliferative neoplasm
1206113|NCT01130662|acute myeloid leukemia
1206114|NCT01130662|AML
1206115|NCT01130662|Relapsed AML
1206116|NCT01130662|Refractory AML
1206117|NCT01130649|Epilepsy
1206118|NCT01130649|Tracking
1206119|NCT01130649|Electronic diary
1206120|NCT01130636|oseltamivir carboxylate
1206121|NCT01130636|oseltamivir phosphate
1206122|NCT01130636|Tamiflu pharmacokinetics in lactating women with influenza
1206123|NCT01130623|VEGF Inhibitor
1206124|NCT01130623|Maximum Tolerated Dose
1206125|NCT01130623|Dose Escalation
1206126|NCT01130623|Pharmacokinetics
1206127|NCT01130623|Antitumor Activity
1206128|NCT01130623|Pediatric Cancer
1206129|NCT01130623|Solid Tumor
1206130|NCT01130623|Sarcoma
1206131|NCT01130623|Neuroblastoma
1206132|NCT01130623|Wilms Tumor
1206133|NCT01130623|Osteosarcoma
1206134|NCT01130623|Brain Tumor
1206135|NCT01130610|preoperative period
1206136|NCT01130610|preoperative care
1206137|NCT01130610|anesthesia
1206138|NCT01130610|program evaluation
1206139|NCT01130597|HF
1206140|NCT01130597|Heart failure
1206141|NCT01130597|hyperkalemia
1206142|NCT01130597|chronic kidney disease
1206143|NCT01130597|prevention of hyperkalemia in heart failure participants
1206144|NCT01130584|Cancer Patients
1206145|NCT01130558|type 2 diabetes mellitus
1206146|NCT01130558|basal-bolus insulin
1206147|NCT01130558|insulin ordering
1206148|NCT01130545|Magnetic Resonance Imaging
1206149|NCT01130545|Gadolinium
1206150|NCT01130545|Healthy Volunteer
1206151|NCT01130545|HV
1206152|NCT01130532|Erectile Dysfunction
1206153|NCT01130532|ED
1206154|NCT01130532|Impotence
1206164|NCT01130467|Attention Deficit Disorders with Hyperactivity
1206165|NCT01130467|Attention Deficit Disorder
1206166|NCT01130467|Event related potential
1206167|NCT01130454|Unfavorable effect of environmental factors, stressors
1206168|NCT01130441|adolescent behavior
1206169|NCT01130441|harm reduction
1206170|NCT01130428|Mechanical stimulation
1206171|NCT01130428|Vibration platform
1206172|NCT01130428|Bone metabolism
1206173|NCT01130428|ATP release
1206174|NCT01130415|Sacral neuromodulation
1206175|NCT01130415|Screening
1206176|NCT01130415|Percutaneous nerve evaluation
1206177|NCT01130415|Tined lead
1206178|NCT01130402|age
1206179|NCT01130402|lymphadenopathy
1206180|NCT01130402|fine needle aspiration
1206181|NCT01130402|sonography
1206182|NCT01130389|ONJ
1206183|NCT01130376|Immune based therapy
1206184|NCT01130376|Therapeutic vaccination
1206185|NCT01130376|cytokine therapy
1206186|NCT01130376|HIV therapeutic vaccine
1206187|NCT01130363|Proton Pump Inhibitor
1206188|NCT01130363|Gastric carcinoid tumors
1206189|NCT01130363|Gastric cancer
1206190|NCT01130363|Fundic Gland Polyps
1206191|NCT01130324|VIBATIV
1206192|NCT01130324|telavancin
1206193|NCT01130324|Pregnancy
1206194|NCT01130324|Registry
1206195|NCT01130298|testosterone, replacement, therapy
1206196|NCT01130285|Lung Cancer
1206197|NCT01130272|Irritable bowel syndrome with diarrhea
1206198|NCT01130272|Irritable bowel syndrome
1206199|NCT01130272|Diarrhea predominant irritable bowel syndrome
1206200|NCT01130272|Colonic diseases
1206201|NCT01130272|Colonic diseases, functional
1206202|NCT01130272|Digestive system disease
1206203|NCT01130272|Gastrointestinal disease
1206204|NCT01130272|Intestinal disease
1206205|NCT01130272|Colonic pseudo-obstruction
1206206|NCT01130272|Diarrhea
1206207|NCT01130272|Signs and Symptoms, Digestive
1206208|NCT01130259|mTNBC
1206209|NCT01130259|triple negative breast cancer
1206210|NCT01130259|metastatic triple negative breast cancer
1206211|NCT01130259|metastatic breast cancer that is ER-, PR-, and HER2-negative
1206212|NCT01130233|rectal cancer
1206213|NCT01130220|Brain Tumor
1206214|NCT01130220|Brain Neoplasm
1206215|NCT01130207|Obesity
1206216|NCT01130207|Diabetes
1206217|NCT01130207|Periodontal disease
1206218|NCT01130194|follicular lymphoma
1206219|NCT01130194|radioimmunotherapy
1206220|NCT01130194|rituximab
1206221|NCT01130194|C-MOPP-R
1206222|NCT01130194|autologous transplant
1206223|NCT01130155|Antimalarials
1206224|NCT01130155|Diagnosis
1206225|NCT01130155|Access to treatment
1206226|NCT01130155|Quality of care
1206227|NCT01130129|Flavonoids
1206228|NCT01130129|Platelets
1206229|NCT01130103|PTSD
1206230|NCT01130103|anxiety disorders
1206231|NCT01130103|trauma
1206232|NCT01130077|Pediatric glioma
1206233|NCT01130077|Vaccine therapy
1206234|NCT01130064|Asthma
1206235|NCT01130064|QAX576
1206236|NCT01130051|bioavailability
1206237|NCT01130038|Characteristic of play
1206238|NCT01130038|DCD
1206239|NCT01130038|children
1206240|NCT01130038|Typical Development
1206241|NCT01130038|Whether there are any differences in the issue of Characteristic of play between Children with DCD and Children with Typical Development
1206242|NCT01130012|Gestational diabetes mellitus
1206243|NCT01130012|Lifestyle intervention
1206244|NCT01130012|Oral glucose tolerance test
1206245|NCT01130012|Insulin treatment
1206246|NCT01130012|Pregnancy outcomes
1206247|NCT01129999|smoking cessation, CBT, hypnotherapy
1206248|NCT01129986|venous ulcer Dermastream
1206249|NCT01129973|speech and language
1206250|NCT01129973|phonoaudiology
1206251|NCT01129973|marketing
1206252|NCT01129960|Diabetic Neuropathic Pain
1206253|NCT01129934|Low Back Pain,
1206254|NCT01129934|Emergency medicine,
1206255|NCT01129934|Promethazine,
1206256|NCT01129934|Morphine,
1206257|NCT01129934|Pain relief
1206258|NCT01129921|Lumbar Spine Stenosis
1206259|NCT01129921|Decompression
1206260|NCT01129908|oral health in children with celiac disease
1206261|NCT01129882|Schizophrenia
1206262|NCT01129869|Survey
1206263|NCT01129869|Perception
1206264|NCT01129869|Perception of Clinical Research Participation
1206265|NCT01129869|Research Participant Perception
1206266|NCT01129856|Dry eye
1206267|NCT01129856|Keratoconjunctivitis sicca
1206268|NCT01129856|Iontophoresis
1206269|NCT01129856|Ophthalmic drug delivery
1206270|NCT01129856|EGP-437
1206271|NCT01129856|Dexamethasone phosphate
1206272|NCT01129843|anemia
1206273|NCT01129843|iron deficiency
1206274|NCT01129843|nutritional
1206275|NCT01129843|iron supplementation
1206276|NCT01129843|cluster randomized control trial
1206277|NCT01129830|ovarian reserve
1206278|NCT01129830|FSH
1206279|NCT01129830|anti-mullerian hormone
1206280|NCT01129830|estradiol
1206281|NCT01129830|oocyte
1206282|NCT01129830|IVF
1206283|NCT01129830|embryo transfer
1206284|NCT01129817|Cognitive Functional Therapy
1206285|NCT01129817|Manual Therapy and Exercise
1206286|NCT01129817|Chronic Low Back Pain
1206287|NCT01129817|Randomized Controlled Trial
1206288|NCT01129817|Subclassification
1206289|NCT01129804|Alcohol dependence
1206290|NCT01129804|Network Support
1206291|NCT01129804|Cognitive-behavioral treatment
1206292|NCT01129804|Relapse prevention
1206293|NCT01129804|Consequences of drinking
1206294|NCT01129804|Social network development
1206295|NCT01129791|Lactose intolerance
1206296|NCT01129791|Dairy products
1206297|NCT01129791|Raw milk
1206298|NCT01129791|Adults
1206299|NCT01129765|Nasal suction
1206300|NCT01129765|Nasal aspiration
1206301|NCT01129765|Nasal saline irrigation
1206302|NCT01129765|Nasal lavage
1206303|NCT01129739|Bone Marrow Disease
1206304|NCT01129739|MDS-RA
1206305|NCT01129739|MDS-RARS
1206306|NCT01129739|Umbilical Cord/placenta-Derived MSC
1206307|NCT01129739|Transplant
1206308|NCT01129726|Transillumination-guided
1206309|NCT01129726|Fiberoptic Intubation
1206310|NCT01129726|time
1206311|NCT01129726|success rate
1206312|NCT01129726|intubation
1206313|NCT01129713|GERD
1206314|NCT01129713|Acid Reflux
1206315|NCT01129713|Heartburn
1206316|NCT01129713|Regurgitation
1206317|NCT01129713|Indigestion
1206318|NCT01129700|rectal cancer, short-course, chemoradiotherapy
1206319|NCT01129648|Hyperuricemia, gout
1206320|NCT01129635|Heart failure
1206321|NCT01129635|Cardiac resynchronization therapy
1206322|NCT01129635|Regional left ventricular dyssynchrony
1206323|NCT01129635|CRT
1206324|NCT01129622|Letrozole
1206325|NCT01129622|Breast MRI
1206326|NCT01129622|Postmenopausal women
1206327|NCT01129609|Post-approval observation of patients being treated according to the indications for use for the Talent Converter Stent Graft
1206328|NCT01129583|Botulinum Toxin
1206329|NCT01129583|Elbow Stiffness
1206330|NCT01129544|Severe combined immunodeficiency
1206331|NCT01129544|SCID
1206332|NCT01129544|XSCID
1206333|NCT01129544|SCID-X1
1206334|NCT01129518|meningococcal serogroup C
1206335|NCT01129518|vaccine
1206336|NCT01129518|conjugate
1206337|NCT01129505|pregnancy
1206338|NCT01129505|intervention
1206339|NCT01129505|exercise
1206340|NCT01129505|nutrition
1206341|NCT01129505|infants
1206342|NCT01129492|Autoimmune Thyroiditis, Laser, Therapy, Thyroid, Ultrasound
1206343|NCT01129479|Aphasia
1206344|NCT01129479|treatment
1206345|NCT01129479|cholinesterase inhibitor
1206346|NCT01129479|stroke
1206347|NCT01129453|Salmonella
1206348|NCT01129453|Vaccine
1206349|NCT01129440|Children
1206350|NCT01129440|Fluoride varnish
1206351|NCT01129440|Glass ionomer sealant
1206352|NCT01129440|Prevention
1206353|NCT01129401|methamphetamine
1206354|NCT01129401|men who have sex with men
1206355|NCT01129401|HIV/AIDS
1206359|NCT01129349|Solid Tumors
1206360|NCT01129336|HER2-negative
1206361|NCT01129336|HER2
1206362|NCT01129336|Metastatic breast cancer
1206363|NCT01129336|First Line breast cancer
1206364|NCT01129336|Second Line breast cancer
1206365|NCT01129336|Breast cancer
1206366|NCT01129336|Metastatic
1206367|NCT01129336|Stage IV breast cancer
1206368|NCT01129336|Progression free survival
1206369|NCT01129336|PFS
1206370|NCT01129336|Circulating Tumor Cells
1206371|NCT01129336|CTCs
1206372|NCT01129336|Zoledronic acid
1206373|NCT01129336|HER2-negative metastatic breast cancer patients without bone metastasis
1206374|NCT01129323|Anemia, Severe, Aplastic, Reduced-Intensity, Allogeneic, Stem, Cell, Transplantation
1206375|NCT01129310|irinotecan
1206376|NCT01129310|capecitabine
1206377|NCT01129310|oxaliplatin
1206378|NCT01129310|health-related quality of life
1206379|NCT01129310|gastroesophageal(GE) junction adenocarcinoma
1206380|NCT01129297|Obesity
1206381|NCT01129297|surgery
1206382|NCT01129297|genetic expression
1206383|NCT01129297|collection of samples
1206384|NCT01129284|Treatment Resistance
1206385|NCT01129284|Nephrotic Syndrome
1206386|NCT01129284|Focal Segmental Glomerulosclerosis
1206387|NCT01129284|lipoid nephrosis
1206388|NCT01129284|Membranous nephropathy
1206389|NCT01129284|IgA nephropathy
1206390|NCT01129284|proteinuria
1206391|NCT01129258|phase 1
1206392|NCT01129258|safety and tolerability
1206393|NCT01129258|pharmacokinetics
1206394|NCT01129258|PK
1206395|NCT01129258|pharmacodynamics
1206396|NCT01129258|PD
1206397|NCT01129258|type 2 diabetes mellitus
1206398|NCT01129245|Celebrex
1206399|NCT01129245|prostoglandin inhibitor
1206400|NCT01129245|ovulation
1206401|NCT01129245|emergency contraception
1206402|NCT01129232|insulin
1206403|NCT01129219|Strength
1206404|NCT01129219|Function
1206405|NCT01129219|Mobility
1206406|NCT01129206|Gastroesophageal Cancer
1206407|NCT01129206|Gastroesophageal Carcinoma
1206408|NCT01129206|Adenocarcinoma
1206409|NCT01129180|T-Cell Lymphoma
1206410|NCT01129167|Pancreatic adenocarcinoma
1206411|NCT01129167|Local invasion by pancreatic adenocarcinoma
1206412|NCT01129167|Recurrence of pancreatic cancer
1206413|NCT01129167|Surgical resection of pancreatic cancer
1206414|NCT01129154|Squamous cell carcinoma
1206415|NCT01129141|Tinnitus
1206416|NCT01129141|Traumatic Brain Injury Counseling
1206417|NCT01129141|Counseling
1206418|NCT01129141|Education
1206419|NCT01129141|Evaluation studies
1206420|NCT01129141|Quality of health care
1206421|NCT01129128|Echinacea
1206422|NCT01129128|immune modulation
1206423|NCT01129128|prevention
1206424|NCT01129089|Acceptability
1206425|NCT01129089|Lipid-based nutrient supplements
1206426|NCT01129089|Micronutrient powder
1206427|NCT01129089|Malnutrition
1206428|NCT01129076|Thalassemia Major
1206429|NCT01129076|Stigma
1206430|NCT01129076|Singapore
1206431|NCT01129076|Qualitative
1206432|NCT01129050|Fish oil
1206433|NCT01129050|Omega-3 fatty acids
1206434|NCT01129050|Metabolic syndrome
1206435|NCT01129050|Adults
1206436|NCT01129037|Oncology
1206437|NCT01129024|Splenectomy
1206438|NCT01129024|Low Platelet Count
1206439|NCT01129024|Thrombopoiesis
1206440|NCT01129024|Thrombocytopaenia
1206441|NCT01129024|Idiopathic Thrombocytopenic Purpura
1206442|NCT01129024|Immune Thrombocytopenia (ITP)
1206443|NCT01129024|Thrombotic Thrombocytopenic Purpura (ITP)
1206444|NCT01129024|Hematologic Disease
1206445|NCT01129024|Auto-immune Thrombocytopenic Purpura
1206446|NCT01129024|S-888711
1206447|NCT01129024|Blood Platelet Disorders
1206448|NCT01129024|Relapsed Persistent or Chronic ITP
1206449|NCT01129024|ITP
1206450|NCT01129011|NSAID
1206451|NCT01129011|gastric ulcers
1206452|NCT01129011|Vimovo
1206453|NCT01129011|Esomeprazole
1206454|NCT01129011|Naproxen
1206455|NCT01128998|Sorafenib
1206456|NCT01128998|S1
1206457|NCT01128998|Advanced Solid Tumors
1206458|NCT01128998|RD
1206459|NCT01128998|MTD
1206460|NCT01128998|DLT
1206461|NCT01128998|PK
1206462|NCT01128998|PG
1206463|NCT01128998|Biomarker
1206464|NCT01128985|Canagliflozin
1206465|NCT01128985|Placebo
1206466|NCT01128985|Type 2 diabetes mellitus
1206467|NCT01128985|Pharmacokinetic
1206468|NCT01128985|Pharmacodynamic
1206469|NCT01128972|enamel erosion
1206470|NCT01128972|tooth remineralization
1206471|NCT01128972|tooth erosion
1206472|NCT01128959|Epilepsy
1206473|NCT01128959|Intravenous Carbamazepine
1206474|NCT01128959|Oral Carbamazepine
1206475|NCT01128946|Enamel remineralization
1206476|NCT01128946|Fluoride
1206477|NCT01128946|caries
1206478|NCT01128933|Fractional flow reserve
1206479|NCT01128933|Revascularization
1206480|NCT01128933|Prognosis
1206481|NCT01128933|Hemodynamics
1206482|NCT01128933|Hypertension
1206483|NCT01128920|bacterial infections
1206484|NCT01128920|skin infections
1206485|NCT01128920|HIV
1206486|NCT01128920|Hepatitis C
1206487|NCT01128920|risk reduction intervention
1206488|NCT01128907|Invasive Aspergillosis in neutropenic patients
1206489|NCT01128894|GSK716155
1206490|NCT01128894|liraglutide
1206491|NCT01128894|albiglutide
1206492|NCT01128894|open-label
1206493|NCT01128868|Reverse oblique intertrochanteric fractures
1206494|NCT01128868|Reverse oblique subtrochanteric fractures
1206495|NCT01128855|Duchenne
1206496|NCT01128855|Duchenne Muscular Dystrophy
1206497|NCT01128855|DMD
1206498|NCT01128855|968
1206499|NCT01128842|Neratinib
1206500|NCT01128842|Capecitabine
1206501|NCT01128842|Combination
1206502|NCT01128842|Solid Tumor
1206503|NCT01128829|obesity
1206504|NCT01128829|diabetes
1206505|NCT01128829|artificial sweeteners
1206506|NCT01128816|obstructive sleep apnea
1206507|NCT01128816|central sleep apnea
1206508|NCT01128816|heart failure
1206509|NCT01128816|congestive heart failure
1206510|NCT01128816|adaptive servo ventilation
1206511|NCT01128816|ASV
1206512|NCT01128803|Hepatocellular carcinoma
1206513|NCT01128803|immunotherapy
1206514|NCT01128803|alpha foetoprotein
1206515|NCT01128803|dendritic cells
1206516|NCT01128790|exercise
1206517|NCT01128790|remote ischemic preconditioning
1206518|NCT01128790|heart failure
1206519|NCT01128790|left ventricular dysfunction
1206520|NCT01128777|depression
1206521|NCT01128777|anxiety
1206522|NCT01128777|family conflict
1206523|NCT01128777|behavior problems
1206524|NCT01128751|Cognition
1206525|NCT01128751|Neuroprotection
1206526|NCT01128751|Cardiopulmonary bypass
1206527|NCT01128751|Aortic valve replacement
1206528|NCT01128751|Micro-emboli
1206529|NCT01128738|Neuromuscular Agents
1206530|NCT01128738|Botulinum Toxin Type A
1206531|NCT01128738|Sweating
1206532|NCT01128738|Sweat Gland Disease
1206533|NCT01128738|Axillary Hyperhidrosis
1206534|NCT01128738|Skin Disease
1206535|NCT01128699|Ahmed valve
1206536|NCT01128699|Neovascular Glaucoma
1206537|NCT01128699|Uveitic glaucoma
1206538|NCT01128699|Failed glaucoma
1206539|NCT01128699|VEGF-A
1206540|NCT01128699|Intraocular pressure
1206541|NCT01128699|Subconjunctival Avastin
1206542|NCT01128686|retrospective
1206543|NCT01128686|naïve Chronic Hepatitis B (CHB) patients
1206544|NCT01128686|cohort study
1206545|NCT01128686|lamivudine
1206546|NCT01128673|Hypoxic Ischemic encephalopathy
1206547|NCT01128673|Magnet resonance imaging
1206548|NCT01128673|Selective Head cooling
1206549|NCT01128673|Therapeutic hypothermia
1206550|NCT01128660|Prescription, General practitioner, Pharmacy
1206551|NCT01128634|Verapamil
1206552|NCT01128634|Anticholinergic, β2 agonist
1206553|NCT01128634|P-GP
1206554|NCT01128634|LABA
1206555|NCT01128634|Muscarinic Receptor Antagonist
1206556|NCT01128634|LAMA
1206557|NCT01128621|Pharmacokinetics
1206558|NCT01128621|Glucose
1206559|NCT01128621|Safety
1206560|NCT01128621|Male
1206561|NCT01128621|Female
1206562|NCT01128621|Metformin
1206563|NCT01128621|Pharmacodynamics
1206564|NCT01128621|Tolerability
1206565|NCT01128621|Type II Diabetes
1206566|NCT01128608|GERD
1206567|NCT01128608|Heartburn
1206568|NCT01128608|Acid Reflux
1206569|NCT01128595|allergen challenge
1206570|NCT01128595|early asthmatic response
1206571|NCT01128595|mild asthma
1206572|NCT01128595|late asthmatic response
1206573|NCT01128582|GERD
1206574|NCT01128582|Insomnia
1206575|NCT01128582|Acid Reflux
1206576|NCT01128582|Heartburn
1206577|NCT01128569|mild asthma
1206578|NCT01128569|allergen challenge
1206579|NCT01128569|early asthmatic response
1206580|NCT01128556|allergic conjunctivitis
1206581|NCT01128556|histamine skin testing
1206582|NCT01128543|lapatinib
1206583|NCT01128543|breast cancer
1206584|NCT01128530|cSSSI
1206585|NCT01128530|complicated skin and skin structure infections
1206586|NCT01128530|acute bacterial skin and skin structure infections
1206587|NCT01128530|abscess
1206588|NCT01128530|cellulitis
1206589|NCT01128530|bacterial infections
1206590|NCT01128530|anti-bacterial agents
1206591|NCT01128530|anti-infective agents
1206592|NCT01128530|skin diseases, infectious
1206593|NCT01128530|skin diseases
1206594|NCT01128530|wound infection
1206595|NCT01128517|Maternal education
1206596|NCT01128517|Complementary food
1206597|NCT01128517|Infant growth
1206598|NCT01128478|Acute pancreatitis
1206599|NCT01128478|Enteral nutrition
1206600|NCT01128478|Pancreas rest
1206601|NCT01128465|propofol
1206602|NCT01128465|awake craniotomy
1206603|NCT01128465|patients requiring an awake craniotomy for brain tumor/lesion resection
1206604|NCT01128452|Treatment-Resistant Depression
1206605|NCT01128439|Pneumococcal conjugate vaccine
1206606|NCT01128426|Pneumococcal conjugate vaccine
1206607|NCT01128413|Shock
1206608|NCT01128413|Resuscitation
1206609|NCT01128413|Hemodynamics
1206610|NCT01128413|Emergencies
1206611|NCT01128413|Critical Care
1206612|NCT01128413|Lactic Acid
1206613|NCT01128413|Plasma volume
1206614|NCT01128400|obesity
1206615|NCT01128400|orlistat
1206616|NCT01128400|taste perception
1206617|NCT01128387|esophageal cancer
1206618|NCT01128387|Locally advanced esophageal cancer
1206619|NCT01128374|Periodontal disease
1206620|NCT01128374|Nonsurgical therapy
1206621|NCT01128374|Type 2 Diabetes Mellitus
1206622|NCT01128374|Bacterial burden
1206623|NCT01128374|Gene polymorphisms
1206624|NCT01128348|asthma
1206625|NCT01128348|adherence
1206626|NCT01128348|quality of life
1206627|NCT01128348|health literacy
1206628|NCT01128348|health disparities
1206629|NCT01128335|Liver transplantation
1206630|NCT01128335|HCV-negative recipient
1206631|NCT01128335|deceased donor
1206632|NCT01128335|sotrastaurin
1206633|NCT01128335|oran transplantation
1206634|NCT01128335|tacrolimus
1206635|NCT01128322|CKD-828
1206636|NCT01128322|Hypertension
1206637|NCT01128322|Primary Hypertension
1206638|NCT01128322|S-Amlodipine
1206639|NCT01128322|Telmisartan
1206640|NCT01128322|Amlodipine
1206641|NCT01128322|Factorial
1206642|NCT01128322|Phase 2
1206643|NCT01128296|high risk stage IIb or III adenocarcinoma of the pancreas
1206644|NCT01128283|Sepsis
1206645|NCT01128283|organ failure
1206646|NCT01128283|cytokines
1206647|NCT01128283|clotting factors
1206648|NCT01128270|Dichloroacetate
1206649|NCT01128270|Chloral Hydrate
1206650|NCT01128270|Metabolism
1206651|NCT01128244|oral contraceptives
1206652|NCT01128244|Vitamin B6
1206653|NCT01128244|birth control pills
1206654|NCT01128244|amino acids
1206655|NCT01128244|Vitamin B6 deficiency
1206656|NCT01128244|Vitamin B6 deficiency in women on oral contraceptives
1206657|NCT01128218|Brain Neoplasms
1206658|NCT01128218|5-ALA
1206659|NCT01128218|Aminolevulinic acid
1206660|NCT01128218|Fluorescence
1206661|NCT01128218|Gliomas
1206662|NCT01128218|Glioblastoma
1206663|NCT01128218|Surgery
1206664|NCT01128205|diabetes
1206665|NCT01128205|cardiovascular risk factors
1206666|NCT01128205|blood pressure
1206667|NCT01128205|blood lipid
1206668|NCT01128205|blood glucose
1206669|NCT01128166|Heart Failure
1206670|NCT01128166|Decompensation
1206671|NCT01128166|Cardiac Resynchronization Therapy
1206672|NCT01128153|Type 2 Diabetes
1206673|NCT01128153|Inadequate Glycaemic Control
1206674|NCT01128153|Saxagliptin
1206675|NCT01128153|Metformin
1206676|NCT01128153|Sulfonylurea
1206677|NCT01128153|Triple Oral Therapy
1206678|NCT01128140|motivational enhancement therapy
1206679|NCT01128127|knowledge translation
1206680|NCT01128127|prescription
1206681|NCT01128127|primary care
1206682|NCT01128127|NSAID
1206683|NCT01128127|PPI
1206684|NCT01128127|Gastrointestinal damage
1206685|NCT01128127|Inappropriate prescription
1206686|NCT01128114|Acute bipolar mania
1206687|NCT01128114|Seroquel XR
1206688|NCT01128114|Quetiapine fumarate
1206689|NCT01128114|Add-on therapy
1206690|NCT01128101|spironolactone
1206691|NCT01128101|chronic kidney disease
1206692|NCT01128101|dialysis
1206693|NCT01128101|LHV
1206694|NCT01128088|Enhanced recovery program in laparoscopic surgery
1206695|NCT01128075|RebiSmart
1206696|NCT01128075|Rebif
1206697|NCT01128075|Adherence
1206698|NCT01128075|Multidose
1206699|NCT01128075|Relapsing Multiple Sclerosis
1206700|NCT01128075|RMS
1206701|NCT01128062|Canthaxanthin retinopathy
1206702|NCT01128049|Aqueous deficient dry eye (ADDE)
1206703|NCT01128049|Meibomium Gland Dysfunction (MGD)
1206704|NCT01128049|Normal/Control (Non Dry Eye)
1206705|NCT01128036|Congestive Heart failure
1206706|NCT01128036|Cardiomyopathy
1206707|NCT01128023|myocardial perfusion imaging
1206708|NCT01128023|rubidium-82
1206709|NCT01128023|medical isotope production
1206710|NCT01128023|Positron emission tomography
1206711|NCT01128023|clinically useful
1206712|NCT01127984|pacemaker
1206713|NCT01127984|pocket haematoma
1206714|NCT01127984|antiplatelet therapy
1206715|NCT01127984|fibrin glue
1206716|NCT01127971|patients
1206717|NCT01127971|receiving
1206718|NCT01127971|irradiation
1206719|NCT01127971|device
1206720|NCT01127971|External Beam
1206721|NCT01127958|In-stent restenosis
1206722|NCT01127958|Minimal lumen diameter
1206723|NCT01127958|Drug eluting balloon
1206724|NCT01127958|Drug eluting stent
1206725|NCT01127932|Cognitive Behavioral Therapy
1206726|NCT01127919|Exercise
1206727|NCT01127919|Activity
1206728|NCT01127919|Adherence
1206729|NCT01127919|Genetics
1206730|NCT01127906|Healthy Volunteers
1206731|NCT01127906|cross-over
1206732|NCT01127906|randomized
1206733|NCT01127906|placebo and active controlled
1206734|NCT01127906|heat pain
1206735|NCT01127906|UVB-Induced pain model
1206736|NCT01127893|Musculoskeletal Diseases
1206737|NCT01127893|Joint Diseases
1206738|NCT01127893|Arthritis
1206739|NCT01127893|Rheumatic Diseases
1206740|NCT01127880|Traumatic Hemopneumothorax
1206741|NCT01127880|Thoracotomy
1206742|NCT01127880|Antibiotics
1206743|NCT01127854|kidney stone
1206744|NCT01127854|urolithiasis
1206745|NCT01127854|calcium oxalate kidney stone
1206746|NCT01127854|calcium oxalate stone
1206747|NCT01127854|calcium oxalate
1206748|NCT01127828|IBS (Irritable Bowel Syndrome)
1206749|NCT01127828|Probiotic yoghurt
1206750|NCT01127828|Symptom severity
1206751|NCT01127815|Peritoneal washing cytology
1206752|NCT01127815|pancreatic cancer
1206753|NCT01127815|peritoneal metastasis
1206754|NCT01127815|anoikis
1206755|NCT01127815|to determine the relationship between PWC results and clinicopathologic parameters of pancreatic cancers
1206756|NCT01127815|to identify the predictive value of PWC and postoperative drainage cytology on the peritoneal recurrence or outcomes
1206757|NCT01127815|to dissect the molecular mechanism of peritoneal recurrence, especially on the PWC-inducing peritoneal seeding process.
1206758|NCT01127802|CABG
1206759|NCT01127802|functional status
1206760|NCT01127802|symptoms distress
1206761|NCT01127802|quality of life
1206762|NCT01127802|the trajectory of functional status
1206763|NCT01127802|the changes of symptoms distress
1206764|NCT01127802|the changes of quality of life
1206765|NCT01127776|patient after bi-trimalleolar fracture of ankle
1206766|NCT01127763|metastatic
1206767|NCT01127763|breast
1206768|NCT01127763|cancer
1206769|NCT01127750|Relapsing multiple sclerosis
1206770|NCT01127750|MS
1206771|NCT01127750|safety
1206772|NCT01127750|tolerability
1206773|NCT01127750|health outcomes
1206774|NCT01127737|SCCs
1206775|NCT01127737|Squamous Cell Carcinoma
1206776|NCT01127737|Skin Self Exam
1206777|NCT01127737|SSE
1206778|NCT01127737|Organ Transplant
1206779|NCT01127737|Performance of SSE with our written educational intervention
1206780|NCT01127737|Time after organ transplantation to deliver intervention
1206781|NCT01127737|Evaluate internation information
1206782|NCT01127724|Vitamin B12
1206783|NCT01127724|Aphthous stomatitis
1206784|NCT01127724|Cobalamin
1206785|NCT01127724|Doses
1206786|NCT01127685|weight bearing
1206787|NCT01127685|acl
1206788|NCT01127672|plantar fasciitis
1206789|NCT01127672|PRP
1206790|NCT01127672|platelet rich plasma
1206791|NCT01127659|diabetes
1206792|NCT01127659|hypogonadism
1206793|NCT01127659|obesity
1206794|NCT01127659|testosterone
1206795|NCT01127659|insulin sensitivity
1206796|NCT01127659|inflammation
1206797|NCT01127620|Allergic Rhinoconjunctivitis
1206798|NCT01127620|Persistent allergic rhinitis
1206799|NCT01127620|Hay fever
1206800|NCT01127620|Allergic Rhinitis
1206801|NCT01127620|Sneezing
1206802|NCT01127620|Nasal congestion
1206803|NCT01127620|Rhinorrhea
1206804|NCT01127620|Nasal itching
1206805|NCT01127620|Ocular itching
1206806|NCT01127620|Ocular tearing
1206807|NCT01127620|Antihistamine
1206808|NCT01127607|parenting
1206809|NCT01127594|Melanoma
1206810|NCT01127581|Misoprostol vaginal insert
1206811|NCT01127581|Dinoprostone vaginal insert
1206812|NCT01127581|Cervidil
1206813|NCT01127581|Cervical ripening
1206814|NCT01127581|Induction of labor
1206815|NCT01127581|Rate of cesarean section
1206816|NCT01127568|Post-Traumatic Stress Disorders
1206817|NCT01127568|Posttraumatic Stress Disorders
1206818|NCT01127568|PTSD
1206819|NCT01127568|Stress Disorder, Post Traumatic
1206820|NCT01127568|Stress Disorders, Posttraumatic
1206821|NCT01127568|Chronic Post Traumatic Stress Disorder
1206822|NCT01127555|Biliary Tract Cancer
1206823|NCT01127555|Salvage therapy
1206824|NCT01127555|FOLFOX
1206825|NCT01127516|Susceptibility testing
1206826|NCT01127516|Antimicrobial stewardship
1206827|NCT01127503|Patients with velocardiofacial syndrome and psychosis
1206828|NCT01127477|Hypovolemia, surgical blood loss
1206829|NCT01127464|HIV-1
1206830|NCT01127464|HIV preventative vaccine
1206831|NCT01127464|Healthy Volunteers
1206832|NCT01127451|Neoplasms
1206833|NCT01127438|Monitored anesthesia care sedation
1206834|NCT01127425|nursing hours
1206835|NCT01127425|length of hospital stay
1206836|NCT01127425|reconvalescence
1206837|NCT01127425|colorectal surgery
1206838|NCT01127425|laparoscopic
1206839|NCT01127425|sigmoid neoplasms
1206840|NCT01127412|overweight
1206841|NCT01127412|physical activity
1206842|NCT01127412|infancy
1206843|NCT01127412|body composition
1206844|NCT01127412|motor development
1206845|NCT01127412|motor activity
1206846|NCT01127373|Breast
1206847|NCT01127373|Radiation
1206848|NCT01127373|Multi-Beam Intensity-Modulated Radiation
1206849|NCT01127373|post mastectomy
1206850|NCT01127373|post partial mastectomy
1206851|NCT01127373|node-positive breast cancer
1206852|NCT01127373|10-025
1206853|NCT01127360|Anti-VEGF
1206854|NCT01127360|Ranibizumab
1206855|NCT01127360|Bevacizumab
1206856|NCT01127360|exudative
1206857|NCT01127360|macular degeneration
1206858|NCT01127334|Dyssynchrony
1206859|NCT01127334|Cardiac resynchronization therapy
1206860|NCT01127321|Systemic lupus erythematosus
1206861|NCT01127321|SLE
1206862|NCT01127321|MEDI-570
1206863|NCT01127308|Absorption
1206864|NCT01127308|Distribution
1206865|NCT01127308|Metabolism
1206866|NCT01127308|and Excretion
1206867|NCT01127308|Mass Balance
1206868|NCT01127308|Metabolic Profile
1206869|NCT01127308|Radiolabel Study
1206870|NCT01127295|Pharmacokinetics
1206871|NCT01127295|Pharmacogenetic
1206872|NCT01127295|tamoxifen
1206873|NCT01127295|anti-aromatases
1206874|NCT01127295|breast cancer
1206875|NCT01127295|pharmacodynamy
1206876|NCT01127295|Observance
1206877|NCT01127282|influenza
1206878|NCT01127282|vitamin
1206879|NCT01127282|improvement of symptom
1206880|NCT01127243|Hysterectomy
1206881|NCT01127243|laparoscopy
1206882|NCT01127243|day-case surgery
1206883|NCT01127243|quality of life
1206884|NCT01127243|Ambulatory Surgical Procedures
1206885|NCT01127230|ADRC
1206886|NCT01127230|adipocyte derived regenerative cells
1206887|NCT01127230|stem cells
1206888|NCT01127230|liposuction
1206889|NCT01127230|Cytori
1206890|NCT01127230|Celution
1206891|NCT01127230|Lipoaspirate is obtained from patients who have opted for liposuction and consent to donate the lipoasirate for this study, which would otherwise be discarded.
1206892|NCT01127217|amlodipine
1206893|NCT01127217|losartan
1206894|NCT01127217|hypertension
1206895|NCT01127217|stage 2
1206896|NCT01127204|HIV
1206897|NCT01127204|Antiretroviral therapy
1206898|NCT01127204|Infant
1206899|NCT01127204|Sub Saharian Africa
1206900|NCT01127191|military exercises
1206901|NCT01127191|neuromuscular fatigue
1206902|NCT01127191|physiological responses
1206903|NCT01127191|biomechanical responses
1206904|NCT01127191|simulated military effort
1206905|NCT01127191|high load carriage
1206906|NCT01127191|Healthy voluntary
1206907|NCT01127152|Noradrenalin relays
1206908|NCT01127152|Automatic relays
1206909|NCT01127152|Manual relays
1206910|NCT01127152|Hypotension
1206911|NCT01127152|Intensive care unit
1206912|NCT01127139|Essential hypertension
1206913|NCT01127113|Myocardial infarction
1206914|NCT01127113|Magnetic resonance imaging
1206915|NCT01127113|Nanoparticles
1206916|NCT01127113|Mononuclear cells
1206917|NCT01127113|Cell tracking
1206918|NCT01127100|neuropathic pain
1206919|NCT01127100|gabapentin
1206920|NCT01127100|transdermal fentanyl matrix
1206921|NCT01127100|multicenter
1206922|NCT01127100|non-inferiority trial
1206923|NCT01127087|Hyperoxaluria
1206924|NCT01127087|Oxazyme
1206925|NCT01127087|oxalate
1206926|NCT01127087|enteric hyperoxaluria
1206927|NCT01127074|metastatic breast cancer
1206928|NCT01127074|breast cancer stage IV
1206929|NCT01127074|vaccination
1206930|NCT01127074|CD80
1206931|NCT01127074|immunotherapy
1206932|NCT01127061|Hypertrophic Cardiomyopathy
1206933|NCT01127061|Exercise
1206934|NCT01127061|Oxygen consumption
1206935|NCT01127048|bronchitis
1206936|NCT01127048|coughing
1206937|NCT01127048|children
1206938|NCT01127048|Ivy
1206939|NCT01127048|Hedera helix L.
1206940|NCT01127035|allergic rhinitis
1206941|NCT01127035|alternaria alternata
1206942|NCT01127035|symptom score
1206943|NCT01127022|Pregnancy
1206944|NCT01127022|Lactation
1206945|NCT01127022|Choline
1206946|NCT01127022|Cognition
1206947|NCT01127022|Biomarkers
1206948|NCT01126996|MenC conjugate vaccine
1206949|NCT01126996|Healthy children previously vaccinated against MenC
1206950|NCT01126970|reduced calorie diet
1206951|NCT01126970|orlistat
1206952|NCT01126970|velneperit
1206953|NCT01126944|heart failure
1206954|NCT01126944|resynchronization
1206955|NCT01126944|left ventricular assist device
1206956|NCT01126931|Crohn disease
1206957|NCT01126931|Involuntary weight loss in cancer
1206958|NCT01126931|IgA nephropathy
1206959|NCT01126931|Depression with reduced appetite
1206960|NCT01126918|Eating Disorders
1206961|NCT01126918|Obesity
1206962|NCT01126918|Body Dissatisfaction
1206963|NCT01126918|Female
1206964|NCT01126905|Reticulated Haemoglobin Equivalent
1206965|NCT01126905|Functional Iron Deficiency
1206966|NCT01126905|Response to therapy
1206967|NCT01126905|Iron deficiency
1206968|NCT01126892|Advanced Disease,
1206969|NCT01126892|Resistance,
1206970|NCT01126892|Intolerance
1206971|NCT01126866|advanced colorectal carcinoma
1206972|NCT01126866|CRC
1206973|NCT01126866|UICC Stages IV
1206974|NCT01126866|liver and/or lung only metastases
1206975|NCT01126853|Immunization
1206976|NCT01126853|Immunity
1206977|NCT01126853|Prevention
1206978|NCT01126840|Lynch Syndrome
1206979|NCT01126840|Families
1206980|NCT01126840|Quality of life
1206981|NCT01126840|QOL
1206982|NCT01126840|First-degree relatives
1206983|NCT01126840|Questionnaire
1206984|NCT01126840|Interview
1206985|NCT01126827|Bipolar Disorder
1206986|NCT01126827|Mood Disorders
1206987|NCT01126827|Residual Symptoms
1206988|NCT01126827|Depression
1206989|NCT01126827|Mania
1206990|NCT01126827|Hypomania
1206991|NCT01126827|Bipolar
1206992|NCT01126827|Bipolar I
1206993|NCT01126827|Bipolar II
1206994|NCT01126814|Gleevec
1206995|NCT01126814|c-kit
1206996|NCT01126814|aml
1206997|NCT01126775|Systematic prevention, stroke, vascular dementia, silent strokes, cerebral microangiopathy.
1206998|NCT01126762|Docosahexaenoic acid
1206999|NCT01126762|fish
1207000|NCT01126762|pregnancy
1207001|NCT01126762|methylmercury
1207002|NCT01126762|n-3 polyunsaturated fatty acid
1207003|NCT01126749|Locally Advanced or Metastatic Bladder Cancer, including other transitional cell cancers of the urothelium (prostate, urethra, ureter, and renal pelvis)
1207004|NCT01126736|neoplams
1207005|NCT01126736|lung neoplasms
1207006|NCT01126736|Stage IIIB
1207007|NCT01126736|IV Nonsquamous Non Small Cell Lung Cancer
1207008|NCT01126710|infiltration
1207009|NCT01126710|extravasation
1207010|NCT01126710|optical monitoring
1207011|NCT01126697|Cardiac
1207012|NCT01126697|Muscular Dystrophy
1207013|NCT01126697|Randomized
1207014|NCT01126684|essential hypertension
1207015|NCT01126671|vitamin D
1207016|NCT01126658|pressure-volume curve
1207017|NCT01126658|intracranial pressure
1207018|NCT01126658|volume pressure response
1207019|NCT01126658|pressure-volume relationship
1207020|NCT01126658|mathematical model
1207021|NCT01126645|Liver
1207022|NCT01126645|HCC
1207023|NCT01126632|Colonoscopy
1207024|NCT01126619|Psoriasis
1207025|NCT01126567|Phase 1 Clinical Trials, Cerebrospinal Fluid, Biomarker
1207026|NCT01126554|Prognostic value
1207027|NCT01126528|Vitamin D
1207028|NCT01126528|cholecalciferol
1207029|NCT01126528|Micronutrients
1207030|NCT01126528|Developing countries
1207031|NCT01126528|Bangladesh
1207032|NCT01126528|Infant, Newborn
1207033|NCT01126528|Reproductive Health
1207034|NCT01126528|Infant, Newborn, Diseases
1207035|NCT01126528|Perinatology
1207036|NCT01126528|Immunology
1207037|NCT01126528|cathelicidin
1207038|NCT01126528|Maternal Nutrition Physiology
1207039|NCT01126515|brain injury
1207040|NCT01126515|sequelae
1207041|NCT01126515|stroke
1207042|NCT01126515|anoxia
1207043|NCT01126515|trauma
1207295|NCT01125371|Binge drinking
1207044|NCT01126476|Adults with non-CNS recurrent tumors who have been previously irradiated
1207045|NCT01126476|and have a tumor recurrence in or near prior radiation fields
1207046|NCT01126463|Hepatocellular carcinomas
1207047|NCT01126463|lipiodol
1207048|NCT01126463|rhenium
1207049|NCT01126463|Non operable Hepatocellular carcinomas
1207050|NCT01126450|recurrent colon cancer
1207051|NCT01126450|recurrent rectal cancer
1207052|NCT01126424|Anti-muscarinics
1207053|NCT01126424|Anti-cholinergics
1207054|NCT01126424|Cognition
1207055|NCT01126424|Solifenacin
1207056|NCT01126411|pulmonary hypertension
1207057|NCT01126411|autoantibodies
1207058|NCT01126411|immunoadsorption
1207059|NCT01126411|immunoglobulin substitution
1207060|NCT01126411|right ventricular function
1207061|NCT01126385|Spinal Diseases
1207062|NCT01126385|Bone strength
1207063|NCT01126385|Transpedicular fixation
1207064|NCT01126385|Dorsal instrumentation
1207065|NCT01126385|DensiProbe
1207066|NCT01126372|Prostaglandin-dependent Congenital Heart Disease
1207067|NCT01126372|Prematurity
1207068|NCT01126372|Feeding intolerances
1207069|NCT01126372|Necrotizing Enterocolitis
1207070|NCT01126372|Regional Oxygen Saturation
1207071|NCT01126372|Near Infrared Spectroscopy
1207072|NCT01126372|Somanetics INVOS Oxyalert
1207073|NCT01126359|Wound Vacuum Assisted Dressings
1207074|NCT01126359|Lidocaine
1207075|NCT01126359|Dressing change
1207076|NCT01126359|Pain management
1207077|NCT01126359|palliative care
1207078|NCT01126333|Nephrotoxicity, Kidney Transplantation, Graft Survival
1207079|NCT01126333|Kidney transplant survival.
1207080|NCT01126320|VAP
1207081|NCT01126307|refractory epilepsy- greater than 4 seizures in 2 month baseline period
1207082|NCT01126294|lumbar laminectomy, melatonin, perioperative, pain, anxiety, analgesia, VAS score
1207083|NCT01126268|Eczema
1207084|NCT01126268|Atopic dermatitis
1207085|NCT01126268|Infection
1207086|NCT01126268|Impetigo
1207087|NCT01126268|Folliculitis
1207088|NCT01126255|vulvar lichen sclerosus
1207089|NCT01126255|progesterone
1207090|NCT01126255|clobetasol
1207091|NCT01126255|randomized controlled trial
1207092|NCT01126242|Ankle
1207093|NCT01126242|ligament injuries
1207094|NCT01126242|non-surgical treatment
1207095|NCT01126242|tape
1207096|NCT01126242|brace
1207097|NCT01126242|orthotic device
1207098|NCT01126242|bandage
1207099|NCT01126242|cost-effectiveness
1207100|NCT01126242|randomized trial
1207101|NCT01126229|Resveratrol
1207102|NCT01126229|Grape
1207103|NCT01126229|Aging
1207104|NCT01126229|functional MRI (fMRI)
1207105|NCT01126229|Anti-Aging therapeutic
1207106|NCT01126229|Oxidative Stress
1207107|NCT01126229|Functional Performance
1207108|NCT01126216|Radiochemotherapy
1207109|NCT01126216|head and neck cancer
1207110|NCT01126216|Paclitaxel
1207111|NCT01126216|Cisplatin
1207112|NCT01126216|5-FU
1207113|NCT01126203|Pseudoexfoliation
1207114|NCT01126203|Glaucoma
1207115|NCT01126203|Ocular Hypertension
1207116|NCT01126203|SLT
1207117|NCT01126203|Selective Laser Trabeculoplasy (SLT)
1207118|NCT01126203|Argon Laser Trabeculoplasty (ALT)
1207119|NCT01126177|asthma
1207120|NCT01126164|parents
1207121|NCT01126164|peer
1207122|NCT01126164|basics
1207123|NCT01126164|college student drinking
1207124|NCT01126151|drinking
1207125|NCT01126151|alcohol consequences
1207126|NCT01126138|unresectable
1207127|NCT01126138|locally advanced
1207128|NCT01126138|metastatic
1207129|NCT01126138|breast cancer
1207130|NCT01126125|iodine
1207131|NCT01126125|infant
1207132|NCT01126125|breastfeeding
1207133|NCT01126125|deficiency
1207134|NCT01126112|advanced colorectal cancer; K-RAS; panitumumab
1207135|NCT01126112|advanced Wild Type K-RAS colorectal cancer
1207136|NCT01126099|double-blind
1207137|NCT01126099|treatment
1207138|NCT01126099|prazosin
1207139|NCT01126099|Disruptive behaviors in Alzheimer's Disease
1207140|NCT01126073|niacin/laropiprant
1207141|NCT01126073|endothelial function
1207142|NCT01126060|Neck dissection
1207143|NCT01126047|Lung Diseases
1207144|NCT01126034|Metoclopramide
1207145|NCT01126034|Randomized Controlled Trial
1207146|NCT01126021|Senior citizens
1207147|NCT01126021|mental acuity
1207148|NCT01126021|memory
1207149|NCT01126008|locally advanced Squamous cell carcinoma
1207150|NCT01125995|limited disease
1207151|NCT01125969|diabetes
1207152|NCT01125969|glucose
1207153|NCT01125969|peer mentor
1207154|NCT01125969|incentives
1207155|NCT01125969|behavioral economics
1207156|NCT01125969|cost-effectiveness
1207157|NCT01125956|Diabetes
1207158|NCT01125956|Diabetes mellitus
1207159|NCT01125956|HbA1c
1207160|NCT01125930|rosacea
1207161|NCT01125930|tretinoin
1207162|NCT01125930|atralin
1207163|NCT01125917|Low back pain
1207164|NCT01125917|Opioid
1207165|NCT01125917|Transdermal
1207166|NCT01125904|Crizotinib
1207170|NCT01125878|satiety
1207171|NCT01125878|appetite
1207172|NCT01125878|fiber
1207173|NCT01125878|starch
1207174|NCT01125878|nutrition
1207175|NCT01125865|Malignant hilar stricture
1207176|NCT01125852|Peptic ulcer hemorrhage
1207177|NCT01125852|Peptic ulcer bleeding
1207178|NCT01125852|Angiographic embolization
1207179|NCT01125852|Arterial embolization
1207180|NCT01125852|Angiography
1207181|NCT01125839|osteomyelitis
1207182|NCT01125839|16S rRNA
1207183|NCT01125839|spine
1207184|NCT01125839|Magnetic resonance imaging
1207185|NCT01125800|Recurrent,
1207186|NCT01125800|refractory,
1207187|NCT01125800|medulloblastoma,
1207188|NCT01125800|rhabdomyosarcoma,
1207189|NCT01125800|neuroblastoma,
1207190|NCT01125800|hepatoblastoma,
1207191|NCT01125800|astrocytoma,
1207192|NCT01125800|children,
1207193|NCT01125800|pediatric,
1207194|NCT01125800|hedgehog pathway inhibitor, adult
1207195|NCT01125787|CLL
1207196|NCT01125787|bendamustine
1207197|NCT01125787|ofatumumab
1207198|NCT01125787|blood cancer
1207199|NCT01125787|leukemia
1207200|NCT01125787|lymphocyte
1207201|NCT01125787|hematology
1207202|NCT01125787|non-Hodgkin lymphoma
1207203|NCT01125787|small lymphocytic lymphoma
1207204|NCT01125787|nevada cancer institute
1207205|NCT01125787|cephalon
1207206|NCT01125787|Glaxosmithkline
1207207|NCT01125774|Menstrually related migraine
1207208|NCT01125774|migraine
1207209|NCT01125774|Premenstrual migraine
1207210|NCT01125761|Allergic dermatitis
1207211|NCT01125722|Urinary Incontinence
1207212|NCT01125722|Overactive Bladder
1207213|NCT01125722|Frequency
1207214|NCT01125722|Urgency
1207215|NCT01125709|Neuromuscular disease
1207216|NCT01125709|Duchenne
1207217|NCT01125709|Muscular Dystrophy
1207218|NCT01125709|DMD
1207219|NCT01125709|Strength assessment
1207220|NCT01125709|CINRG Quantitative Measurement System
1207221|NCT01125709|CQMS
1207222|NCT01125709|Hand Held Myometry
1207223|NCT01125709|HHM
1207224|NCT01125696|mother-to-child transmission
1207225|NCT01125696|HIV
1207226|NCT01125696|Hepatitis B
1207227|NCT01125696|Pregnant women
1207228|NCT01125696|Tenofovir
1207229|NCT01125696|Infants
1207230|NCT01125683|Phase II
1207231|NCT01125683|Alzheimer's disease
1207232|NCT01125683|EEG
1207233|NCT01125683|cognition
1207234|NCT01125683|pharmacodynamic
1207235|NCT01125670|YM150
1207236|NCT01125670|Food effect
1207237|NCT01125657|YM150
1207238|NCT01125657|bioequivalence study
1207239|NCT01125644|necrotic pulmonary infections
1207240|NCT01125631|Alzheimer's disease
1207241|NCT01125631|amyloid
1207242|NCT01125631|antibody
1207243|NCT01125631|Japanese
1207244|NCT01125618|child mortality
1207245|NCT01125618|intervention
1207246|NCT01125618|Poverty
1207247|NCT01125618|Africa
1207248|NCT01125618|Millennium Development Goal
1207249|NCT01125618|Millennium Development Goals
1207250|NCT01125605|PASCONAL
1207251|NCT01125605|nervousness
1207252|NCT01125605|nervosity
1207253|NCT01125605|sleep disorder
1207254|NCT01125592|assess the ability of the IonCleanse machine to remove heavy metals through the feet
1207255|NCT01125579|nervousness
1207256|NCT01125579|restlessness
1207257|NCT01125579|depression
1207258|NCT01125579|affective disorder
1207259|NCT01125540|Allergic conjunctivitis
1207260|NCT01125527|Haemophilus influenzae type b (Hib)
1207261|NCT01125527|Vaccine
1207262|NCT01125527|Anti PRP antibody
1207263|NCT01125514|Heart failure,
1207264|NCT01125514|aliskiren,
1207265|NCT01125514|furosemide,
1207266|NCT01125514|diuretic efficacy,
1207267|NCT01125514|interaction
1207268|NCT01125488|Maintenance therapy
1207269|NCT01125488|LNG-IUS
1207270|NCT01125488|recurrence,endometriosis
1207271|NCT01125488|Recurrence
1207272|NCT01125475|Relapsing Remitting Multiple Sclerosis
1207273|NCT01125475|RebiSmart
1207274|NCT01125475|Rebif
1207275|NCT01125475|Adherence
1207276|NCT01125462|Ovulation Induction
1207277|NCT01125462|Infertility
1207278|NCT01125462|Gonal-f
1207279|NCT01125462|FertiQoL
1207280|NCT01125462|Quality of Life
1207281|NCT01125449|ascorbic acid
1207282|NCT01125449|vitamin C
1207283|NCT01125449|antioxidants
1207284|NCT01125449|vitamins
1207285|NCT01125423|Female
1207286|NCT01125423|age 18 to 70
1207287|NCT01125410|Fluomizin
1207288|NCT01125410|Dequalinium chloride
1207289|NCT01125410|Bacterial vaginosis
1207290|NCT01125410|vaginal therapy
1207291|NCT01125397|bariatric surgery
1207292|NCT01125397|behavioral weight management
1207293|NCT01125397|psychosocial outcomes following bariatric surgery
1207294|NCT01125371|Hazardous alcohol use
1207296|NCT01125371|High risk sexual behaviors
1207297|NCT01125371|HIV risk reduction
1207298|NCT01125345|hydrophobic acrylic
1207299|NCT01125345|PCO
1207300|NCT01125345|posterior capsule opacification
1207301|NCT01125345|hydrophilic acrylic IO
1207302|NCT01125306|Drug consumption
1207303|NCT01125306|The Xal-Ease device
1207304|NCT01125306|Patient's compliance
1207305|NCT01125306|Using a novel Pfizer-Pharmacia device to facilitate the Xalatan/Xalacom instillation and to avoid loss of eye drops
1207306|NCT01125293|everolimus
1207307|NCT01125293|rituximab
1207308|NCT01125293|bortezomib
1207309|NCT01125293|RAD001
1207310|NCT01125293|Rituxan
1207311|NCT01125293|Velcade
1207312|NCT01125280|Small bowel occlusion
1207313|NCT01125280|Conservative treatment for small bowel occlusion
1207314|NCT01125280|Surgical treatment for small bowel occlusion
1207315|NCT01125280|Small bowel resection
1207316|NCT01125280|Score of severity of small bowel occlusion
1207317|NCT01125267|medication adherence
1207318|NCT01125267|schizophrenia
1207319|NCT01125267|Mexican American
1207320|NCT01125267|multifamily groups
1207321|NCT01125254|thalassemia major
1207322|NCT01125254|calcium channel blockade
1207323|NCT01125254|magnetic resonance imaging
1207324|NCT01125241|wuling capsule
1207325|NCT01125241|epilepsy
1207326|NCT01125241|depression
1207327|NCT01125241|superiority clinical research
1207328|NCT01125228|AIDS
1207329|NCT01125228|Antiretroviral
1207330|NCT01125228|Kaposi's Sarcoma
1207331|NCT01125215|Painful diabetic neuropathy
1207332|NCT01125215|Capsaicin
1207333|NCT01125215|Nanoparticle
1207334|NCT01125215|Quantitative Sensory Testing
1207335|NCT01125202|Intervention studies
1207336|NCT01125202|Computers, handheld
1207337|NCT01125202|Randomized controlled trial
1207338|NCT01125202|Sodium, dietary
1207339|NCT01125176|CLL
1207340|NCT01125163|very low birth weight infants
1207341|NCT01125163|anemia
1207342|NCT01125163|iron supplementation
1207343|NCT01125150|diffuse reflectance spectroscopy
1207344|NCT01125137|Keloid
1207345|NCT01125137|MMP
1207346|NCT01125137|Matrix metalloproteinase
1207347|NCT01125137|dermatology
1207348|NCT01125124|Pleurodesis
1207349|NCT01125124|Malignant pleural effusion
1207350|NCT01125124|Silver Nitrate
1207351|NCT01125124|Pain
1207352|NCT01125098|COPD
1207353|NCT01125098|PRO-CT
1207354|NCT01125098|antibiotics
1207355|NCT01125085|I131
1207356|NCT01125085|L19
1207357|NCT01125085|antibody
1207358|NCT01125085|monoclonal
1207359|NCT01125085|multiple brain metastasis
1207360|NCT01125085|tumor targeting
1207361|NCT01125085|radioimmunotherapy
1207362|NCT01125085|Patients with brain metastases of solid tumors (>1), who are not amenable for surgical excision or stereotactic radiosurgery.
1207363|NCT01125072|chest pain
1207364|NCT01125072|echocardiography
1207365|NCT01125072|strain imaging
1207366|NCT01125059|hydromorphone
1207367|NCT01125059|lumbar posterior spinal fusion
1207368|NCT01125059|lumbosacral spondylosis
1207369|NCT01125059|Spinal Fusion
1207370|NCT01125033|Dialysis, Restless legs syndrome, Ascorbic acid, Vitamin E
1207371|NCT01125007|Dental plaque
1207372|NCT01125007|Gingival abrasion
1207373|NCT01125007|toothbrushing
1207374|NCT01124994|Barrett's oesophagus
1207375|NCT01124994|High grade intraepithelial neoplasia (HGIEN)
1207376|NCT01124981|Fibrinogen concentrate
1207377|NCT01124981|Coagulopathy
1207378|NCT01124968|User-Computer Interface
1207379|NCT01124968|Office Visits
1207380|NCT01124968|Primary Health Care
1207381|NCT01124968|Patient Satisfaction
1207382|NCT01124968|Job Satisfaction
1207383|NCT01124968|Health Services Research
1207384|NCT01124955|treatment
1207385|NCT01124955|acupuncture
1207386|NCT01124955|spine
1207387|NCT01124929|Intestinal tuberculosis
1207388|NCT01124929|Tuberculous peritonitis
1207389|NCT01124929|Abdominal tuberculosis
1207390|NCT01124916|incontinence
1207391|NCT01124916|prolapse
1207392|NCT01124916|Abdominal sacrocolpopexy
1207393|NCT01124903|dehydration
1207394|NCT01124903|hypohydration
1207395|NCT01124903|diagnostic accuracy
1207396|NCT01124903|biological variation
1207397|NCT01124903|hydration assessment
1207398|NCT01124903|body mass
1207399|NCT01124903|osmolality
1207400|NCT01124903|plasma
1207401|NCT01124903|saliva
1207402|NCT01124903|urine
1207403|NCT01124890|acute myocardial infarction
1207404|NCT01124890|thrombolysis
1207405|NCT01124890|percutaneous coronary interention
1207406|NCT01124877|Children and Adolescents with Bipolar I Disorder (manic or mixed)
1207407|NCT01124864|Non-small-cell lung cancer
1207408|NCT01124864|HSP90
1207409|NCT01124864|2nd to 3rd line treatment
1207410|NCT01124851|Sleep disorder
1207411|NCT01124838|Uveitis
1207412|NCT01124825|Anesthesia induction and maintenance
1207413|NCT01124825|Surgery
1207414|NCT01124812|I131
1207415|NCT01124812|L19
1207416|NCT01124812|antibody
1207417|NCT01124812|monoclonal
1207418|NCT01124812|NSCLC
1207419|NCT01124812|lung
1207420|NCT01124812|tumor targeting
1207421|NCT01124812|radioimmunotherapy
1207422|NCT01124812|Patients with newly diagnosed inoperable, locally-advanced (stage III) NSCLC
1207423|NCT01124799|Hepatitis C virus
1207424|NCT01124799|TMC435-TiDP16-C125
1207425|NCT01124799|TMC435-C125
1207426|NCT01124799|TMC435
1207427|NCT01124799|TMC435350
1207428|NCT01124799|protease inhibitor
1207429|NCT01124799|HCV
1207430|NCT01124799|Hepatitis C
1207431|NCT01124799|photosensitivity
1207432|NCT01124799|phototoxicity
1207433|NCT01124786|cancer
1207434|NCT01124786|metastatic
1207435|NCT01124786|pancreatic
1207436|NCT01124786|pancreas
1207437|NCT01124786|adenocarcinoma
1207438|NCT01124786|gemcitabine
1207439|NCT01124786|human equilibrative nucleoside transporter-1 (hENT1)
1207440|NCT01124786|CO-1.01
1207441|NCT01124786|CO-101
1207442|NCT01124786|CO101
1207443|NCT01124786|Stage 4
1207444|NCT01124786|Stage IV
1207445|NCT01124773|cognition
1207446|NCT01124773|memory
1207447|NCT01124773|hormone therapy
1207448|NCT01124760|open label
1207449|NCT01124760|2-consecutive-group
1207450|NCT01124760|2-period
1207451|NCT01124760|1-sequence crossover study
1207452|NCT01124747|ASP1585
1207453|NCT01124747|Healthy Volunteers
1207454|NCT01124734|metastatic melanoma
1207455|NCT01124721|Cognitive training
1207456|NCT01124708|ADHD
1207457|NCT01124708|Attention Deficit Hyperactive Disorder
1207458|NCT01124695|estrogen receptor-positive breast cancer
1207459|NCT01124695|male breast cancer
1207460|NCT01124695|progesterone receptor-positive breast cancer
1207461|NCT01124695|recurrent breast cancer
1207462|NCT01124695|stage IV breast cancer
1207463|NCT01124682|adenocarcinoma of the bladder
1207464|NCT01124682|squamous cell carcinoma of the bladder
1207465|NCT01124682|transitional cell carcinoma of the bladder
1207466|NCT01124682|recurrent bladder cancer
1207467|NCT01124682|stage II bladder cancer
1207468|NCT01124682|stage III bladder cancer
1207469|NCT01124682|stage IV bladder cancer
1207470|NCT01124669|recurrent non-small cell lung cancer
1207471|NCT01124669|stage IIIB non-small cell lung cancer
1207472|NCT01124669|stage IV non-small cell lung cancer
1207473|NCT01124656|angiotensin II receptor blocker
1207474|NCT01124656|thiazolidinediones
1207475|NCT01124656|combination
1207476|NCT01124656|Actos
1207477|NCT01124656|HbA1c
1207478|NCT01124656|Type 2 diabetes
1207479|NCT01124656|Drug Therapy
1207480|NCT01124656|Hypertension
1207481|NCT01124643|Replagal
1207482|NCT01124643|Agalsidase alfa
1207483|NCT01124643|Alpha-Galactosidase
1207484|NCT01124643|Enzyme Replacement Therapy
1207485|NCT01124617|Chronic pain
1207486|NCT01124617|Diabetic Neuropathic Pain
1207487|NCT01124617|Neuralgia, Postherpetic
1207488|NCT01124617|Tapentadol hydrochloride extended-release
1207489|NCT01124617|JNS024ER
1207490|NCT01124617|Placebo
1207491|NCT01124604|Pain
1207492|NCT01124604|Low Back Pain
1207493|NCT01124604|Back Pain
1207494|NCT01124604|Osteoarthritis, Knee
1207495|NCT01124604|Tapentadol
1207496|NCT01124604|Tapentadol Hydrochloride Extended Release
1207497|NCT01124578|Ventilators, Mechanical
1207498|NCT01124565|Lateral Canthal Lines
1207499|NCT01124565|Crow's Feet
1207500|NCT01124565|Facial Wrinkles
1207501|NCT01124552|Lateral Canthal Lines
1207502|NCT01124552|Crow's Feet Wrinkles
1207503|NCT01124552|Facial Wrinkles
1207504|NCT01124539|Adult Patients
1207505|NCT01124539|Recurrence of Glioblastoma Multiforme
1207506|NCT01124539|Recurrence of GBM
1207507|NCT01124539|Gliosarcoma
1207508|NCT01124526|R F C treatment in patients with Non Hodgkin Lymphoma
1207509|NCT01124513|Melanin Index
1207510|NCT01124513|Fitzpatrick Skin Phototype
1207511|NCT01124513|Videodermoscopy
1207512|NCT01124513|Spectrophotometry
1207513|NCT01124500|methylphenidate
1207514|NCT01124500|transdermal patch
1207515|NCT01124500|placebo
1207516|NCT01124500|fatigue
1207517|NCT01124500|10-020
1207518|NCT01124487|fat
1207519|NCT01124487|inflammation
1207520|NCT01124487|lipids
1207521|NCT01124487|total cholesterol
1207522|NCT01124487|Triglycerides
1207523|NCT01124487|insulin sensitivity
1207524|NCT01124461|Malignant Brain Tumors
1207525|NCT01124461|Cancer of the Brain
1207526|NCT01124435|Carboplatin plus Celecoxib
1207527|NCT01124435|Pre-treated Recurrent Ovarian Cancer Patients
1207528|NCT01124435|The antitumor activity and potential adverse effects
1207529|NCT01124435|tumor response rate
1207530|NCT01124435|toxicity
1207531|NCT01124435|progression free survival
1207532|NCT01124435|duration of response
1207533|NCT01124435|quality of life
1207534|NCT01124422|endurance shuttle walk test
1207535|NCT01124422|chronic obstructive pulmonary disease
1207536|NCT01124422|fluticasone propionate
1207537|NCT01124422|dyspnea
1207538|NCT01124422|exercise endurance time
1207539|NCT01124422|tiotropium
1207540|NCT01124422|salmeterol
1207541|NCT01124422|exercise inspiratory capacity
1207542|NCT01124422|quality of life
1207543|NCT01124409|IGRT
1207544|NCT01124409|3DCRT
1207545|NCT01124409|EPID
1207546|NCT01124409|CBCT
1207547|NCT01124409|HNSCC
1207548|NCT01124383|Glycine absorption
1207549|NCT01124383|Operative hysteroscopy
1207550|NCT01124383|Endometrial resection
1207551|NCT01124383|General anesthesia
1207552|NCT01124383|Local anesthesia
1207553|NCT01124370|Sleep Disordered Breathing
1207554|NCT01124370|Cheyne Stokes Respiration
1207555|NCT01124370|Periodic Breathing
1207556|NCT01124370|Sleep Apnea
1207557|NCT01124370|Central Sleep Apnea
1207558|NCT01124357|Heavy menstrual bleeding
1207559|NCT01124357|menorrhagia
1207560|NCT01124357|ThermachoiceTM
1207561|NCT01124357|NovaSureTM
1207562|NCT01124357|Endometrail Ablation
1207563|NCT01124331|prospective meta-analysis
1207564|NCT01124331|preterm infant
1207565|NCT01124331|pulse oximetry
1207566|NCT01124331|oxygen saturation
1207567|NCT01124318|Lactofiltrum
1207568|NCT01124318|atopic dermatitis
1207569|NCT01124318|itching
1207570|NCT01124318|Dermatological Index of Life Quality
1207571|NCT01124318|SCORAD
1207572|NCT01124318|Behavioral Rating Scores
1207573|NCT01124305|Total Knee Arthroplasty
1207574|NCT01124305|Instrumentation
1207575|NCT01124292|Disability
1207576|NCT01124292|Quadriplegia
1207577|NCT01124292|Paralysis
1207578|NCT01124292|Assistive technology
1207579|NCT01124292|Quality of life
1207580|NCT01124292|Computer access
1207581|NCT01124292|Wheeled mobility
1207582|NCT01124279|Amgen
1207583|NCT01124279|Healthy
1207584|NCT01124279|Adult
1207585|NCT01124266|polyp
1207586|NCT01124266|adenoma
1207587|NCT01124266|screening
1207588|NCT01124266|colonoscopy
1207589|NCT01124266|diagnosis
1207590|NCT01124253|adjuvant therapy
1207591|NCT01124253|non-small cell lung cancer
1207592|NCT01124253|vinorelbine
1207593|NCT01124253|cisplatin
1207594|NCT01124253|recombinant human endostatin
1207595|NCT01124253|endostar
1207596|NCT01124240|Glioblastoma Multiforme
1207597|NCT01124227|Congestive Heart Failure
1207598|NCT01124227|Peritoneal Dialysis
1207599|NCT01124227|Symptomatic improvement
1207600|NCT01124227|Renal function
1207601|NCT01124214|Barrett's
1207602|NCT01124214|BE
1207603|NCT01124214|esophageal cancer
1207604|NCT01124214|esophageal dysplasia
1207605|NCT01124201|low back pain
1207606|NCT01124201|clinical trial
1207607|NCT01124201|stabilization
1207608|NCT01124201|muscle stretching exercises
1207609|NCT01124201|exercise therapy
1207610|NCT01124188|Geriatric psychiatry
1207611|NCT01124188|Aged
1207612|NCT01124188|Elderly
1207613|NCT01124188|Venlafaxine
1207614|NCT01124188|Self efficacy
1207615|NCT01124188|Pain
1207616|NCT01124188|Psychotherapy
1207617|NCT01124188|Effexor
1207618|NCT01124175|Bioequivalence
1207619|NCT01124175|Healthy Subjects
1207620|NCT01124162|Bioequivalence
1207621|NCT01124162|Healthy Subjects
1207622|NCT01124136|Chronic Heart Failure
1207623|NCT01124136|Neurostimulation
1207624|NCT01124123|Pharmacokinetics
1207625|NCT01124123|Oral bioavailability
1207626|NCT01124123|absorption
1207627|NCT01124123|AUC
1207628|NCT01124123|Bioequivalence
1207629|NCT01124123|Bioavailability study
1207630|NCT01124110|Operating Engineers
1207631|NCT01124110|Smoking Cessation
1207632|NCT01124097|post herpetic neuralgia
1207633|NCT01124071|Korean Diet
1207634|NCT01124058|restarting warfarin
1207635|NCT01124058|time to therapeutic INR
1207636|NCT01124045|Pediatric
1207637|NCT01124045|Cataracts
1207638|NCT01124045|Inflammation
1207639|NCT01124045|Durezol
1207640|NCT01124045|Pred Forte
1207641|NCT01124045|Difluprednate
1207642|NCT01124045|Prednisolone
1207643|NCT01124019|Women undergoing screening mammography will be chosen if they are between the ages of 40 and 65.
1207644|NCT01123993|Thai traditional music
1207645|NCT01123993|dementia
1207646|NCT01123993|Cognitive function
1207647|NCT01123993|behavioural problem
1207648|NCT01123993|sleep quality
1207649|NCT01123993|psychological health
1207650|NCT01123993|quality of sleep
1207651|NCT01123967|nicotine replacement therapy
1207652|NCT01123967|smoking cessation
1207653|NCT01123967|tobacco dependent
1207654|NCT01123954|Seasonal influenza
1207655|NCT01123954|Vaccine
1207656|NCT01123941|Typhoid fever
1207657|NCT01123941|Glycoconjugate vaccine
1207658|NCT01123941|Carrier protein
1207659|NCT01123941|Immunogenicity
1207660|NCT01123928|cataract
1207661|NCT01123928|counseling
1207662|NCT01123928|surgical uptake
1207663|NCT01123928|follow-up
1207664|NCT01123915|HIV
1207665|NCT01123915|Therapeutic
1207666|NCT01123915|Immunotherapy
1207667|NCT01123915|Acquired Immunodeficiency Syndrome
1207668|NCT01123915|Virus Diseases
1207669|NCT01123915|Lentivirus Infections
1207670|NCT01123915|Human Immunodeficiency Virus
1207671|NCT01123902|Breathlessness
1207672|NCT01123902|Dyspnea
1207673|NCT01123902|Hand-held fan
1207674|NCT01123902|Palliative Care
1207675|NCT01123889|subacromial impingement
1207676|NCT01123889|partial thickness rotator cuff
1207677|NCT01123889|PRP
1207678|NCT01123889|platelet rich plasma
1207679|NCT01123876|Gastric Cancer
1207680|NCT01123863|Neuro cognitive deficits;
1207681|NCT01123863|Brigance pre-school screen;
1207682|NCT01123850|CopiOs
1207683|NCT01123850|Degenerative spondylolisthesis,
1207684|NCT01123850|stenosis with instability, or
1207685|NCT01123850|degenerative disc disease as diagnosed by radicular signs and/or imaging studies
1207686|NCT01123824|healthy subjects
1207687|NCT01123811|adenocarcinoma
1207688|NCT01123811|gastric cancer
1207689|NCT01123811|esophagogastric junction cancer
1207690|NCT01123798|near infrared spectroscopy
1207691|NCT01123798|lower extremity injury
1207692|NCT01123785|glaucoma
1207693|NCT01123785|ocular hypertension
1207694|NCT01123785|adenosine agonist
1207695|NCT01123785|eye drop
1207696|NCT01123785|primary open angle glaucoma
1207697|NCT01123772|adenosine agonist
1207698|NCT01123772|eye drop
1207699|NCT01123772|elderly volunteer
1207700|NCT01123772|older healthy volunteer
1207701|NCT01123759|Fish
1207702|NCT01123759|mercury
1207703|NCT01123759|omega-3 fatty acids
1207704|NCT01123759|infant
1207705|NCT01123759|brain development
1207706|NCT01123759|pregnancy
1207707|NCT01123759|nursing mother
1207708|NCT01123759|dietary recommendations
1207709|NCT01123759|Hair mercury
1207710|NCT01123759|Blood mercury
1207711|NCT01123759|Recommendations for pregnant or nursing women
1207712|NCT01123759|Infant brain health
1207713|NCT01123746|Seizure
1207714|NCT01123746|electrolyte
1207715|NCT01123746|risk factor
1207716|NCT01123733|Baby-friendly hospitals
1207717|NCT01123733|Non baby-friendly hospitals
1207718|NCT01123733|Breastfeeding
1207719|NCT01123733|Ten steps for successful breastfeeding
1207720|NCT01123707|Major Depressive Disorder
1207721|NCT01123707|MDD
1207722|NCT01123707|Depression
1207723|NCT01123694|xeroderma pigmentosum
1207724|NCT01123694|quality of life
1207725|NCT01123694|DLQI
1207726|NCT01123694|CDLQI
1207727|NCT01123681|Respiration, Artificial
1207728|NCT01123681|Pneumonia, Ventilator-Associated
1207729|NCT01123681|Critical Illness
1207730|NCT01123668|Smoking
1207731|NCT01123668|ADHD
1207732|NCT01123668|Nicotine
1207733|NCT01123668|Methylphenidate
1207734|NCT01123668|function Magnetic Resonance Imaging
1207735|NCT01123668|Neurobiological basis of abstinence-induced deficits in response inhibition
1207736|NCT01123642|post-traumatic stress disorder
1207737|NCT01123642|depressive disorder
1207738|NCT01123642|alcoholism
1207739|NCT01123642|Longitudinal studies
1207740|NCT01123642|readjustment
1207741|NCT01123616|surgical site infection
1207742|NCT01123616|elective colorectal surgery
1207743|NCT01123616|level of surgical site infection
1207744|NCT01123616|complication of surgical site infection
1207745|NCT01123616|type of changed bandage
1207746|NCT01123616|frequency of bandage changing
1207747|NCT01123603|frequency
1207748|NCT01123603|women
1207749|NCT01123603|fibroids
1207750|NCT01123603|uterine artery embolization
1207751|NCT01123603|myomectomy
1207752|NCT01123603|hysterectomy
1207753|NCT01123590|Thymoma
1207754|NCT01123590|Autoimmune diseases
1207755|NCT01123590|Immunodeficiency
1207756|NCT01123577|Self Blood Pressure Monitoring
1207757|NCT01123577|SBPM
1207758|NCT01123577|Randomized Control Trial
1207759|NCT01123577|Hypertension (HTN)
1207760|NCT01123577|Cardiovascular Disease (CVD)
1207761|NCT01123577|HTN
1207762|NCT01123577|CVD
1207763|NCT01123564|macular edema secondary to retinal vein occlusion
1207764|NCT01123551|Nebulized morphine
1207765|NCT01123551|Intravenous morphine
1207766|NCT01123551|Post traumatic
1207767|NCT01123551|Pain
1207768|NCT01123551|Emergency department
1207769|NCT01123512|Vertebral Compression Fracture
1207770|NCT01123512|Kyphoplasty
1207771|NCT01123512|Spine
1207772|NCT01123512|Vertebral Body Compression Fracture
1207773|NCT01123512|Back Pain
1207774|NCT01123499|G-CSF
1207775|NCT01123499|Plerixafor
1207776|NCT01123499|Normal Volunteer
1207777|NCT01123499|Apheresis
1207778|NCT01123499|Healthy Volunteer
1207779|NCT01123499|HV
1207780|NCT01123486|Intravenous opioids
1207781|NCT01123486|Patient Controlled Analgesia
1207782|NCT01123486|volunteer pharmacokinetic-pharmacodynamic study
1207783|NCT01123473|adenocarcinoma of the gastroesophageal junction
1207784|NCT01123473|adenocarcinoma of the stomach
1207785|NCT01123473|stage IIIA gastric cancer
1207786|NCT01123473|stage IIIB gastric cancer
1207787|NCT01123473|stage IIIC gastric cancer
1207788|NCT01123473|stage IV gastric cancer
1207789|NCT01123460|non-small cell lung cancer
1207790|NCT01123434|prostate cancer
1207791|NCT01123434|adjuvant
1207792|NCT01123434|hormonal
1207793|NCT01123421|osteoporosis
1207794|NCT01123421|fracture risk
1207795|NCT01123421|aging
1207796|NCT01123421|tibia
1207797|NCT01123421|sonometer
1207798|NCT01123421|ultrasound
1207799|NCT01123421|BMD
1207800|NCT01123421|bone mineral density
1207801|NCT01123421|DXA
1207802|NCT01123421|3D-HRpQT
1207803|NCT01123421|waveform profiles
1207804|NCT01123408|schizophrenia
1207805|NCT01123408|aggression
1207806|NCT01123408|clozapine
1207807|NCT01123408|olanzapine
1207808|NCT01123395|bioavailability
1207809|NCT01123382|Stroke
1207810|NCT01123382|Shoulder pain
1207811|NCT01123382|Electrical stimulation
1207812|NCT01123382|Neuromuscular stimulation
1207813|NCT01123382|Intramuscular stimulation
1207814|NCT01123369|Sickle Cell Disease
1207815|NCT01123356|Relapsed chronic lymphocytic leukemia
1207816|NCT01123343|limbal relaxing incision
1207817|NCT01123343|LRI
1207818|NCT01123343|capsulorhexis
1207819|NCT01123343|surgical guidance
1207820|NCT01123343|3d visualization
1207821|NCT01123317|Schizophrenia
1207822|NCT01123317|PET
1207823|NCT01123317|Oxytocin
1207824|NCT01123304|melanoma
1207825|NCT01123291|follow-up coronary angiography
1207826|NCT01123278|Adiponectin
1207827|NCT01123278|Resistin
1207828|NCT01123278|Adipocytes
1207829|NCT01123278|Testosterone
1207830|NCT01123278|Aging
1207831|NCT01123278|HOMA-IR
1207832|NCT01123278|Insulin
1207833|NCT01123278|Hypogonadism
1207834|NCT01123278|Metabolic Syndrome
1207835|NCT01123278|Obesity
1207836|NCT01123278|Erectile Dysfunction
1207837|NCT01123265|PsA
1207838|NCT01123265|methotrexate
1207839|NCT01123265|Anti-TNF
1207840|NCT01123265|TNF
1207841|NCT01123265|DC-Stamp
1207842|NCT01123252|Lactobacillus casei
1207843|NCT01123239|Healthcare Disparities
1207844|NCT01123213|pelvic organ prolapse
1207845|NCT01123213|pessary fitting
1207846|NCT01123187|diabetes type 1
1207847|NCT01123187|kidney transplantation
1207848|NCT01123187|islet
1207849|NCT01123187|hypoglycemia
1207850|NCT01123174|Suicide
1207851|NCT01123174|case management algorithm
1207852|NCT01123174|suicidal behaviors
1207853|NCT01123174|prevention of suicide
1207854|NCT01123161|Hypothermia
1207855|NCT01123161|Molecular Mechanisms of Pharmacological Action
1207856|NCT01123161|Cerebral Infarction
1207857|NCT01123161|Hematologic Agents
1207858|NCT01123161|Stroke
1207859|NCT01123161|Nervous System Diseases
1207860|NCT01123161|Vascular Diseases
1207861|NCT01123161|Tissue Plasminogen Activator
1207862|NCT01123161|Central Nervous System Diseases
1207863|NCT01123161|Fibrinolytic Agents
1207864|NCT01123161|Cardiovascular Agents
1207865|NCT01123161|Body Temperature Changes
1207866|NCT01123161|Brain Diseases
1207867|NCT01123161|Cerebrovascular Disorders
1207868|NCT01123161|Pharmacologic Actions
1207869|NCT01123161|Signs and Symptoms
1207870|NCT01123161|Fibrin Modulating Agents
1207871|NCT01123161|Therapeutic Uses
1207872|NCT01123161|Brain Ischemia
1207873|NCT01123161|Cardiovascular Diseases
1207874|NCT01123161|Brain Infarction
1207875|NCT01123161|Plasminogen
1207876|NCT01123161|cooling
1207877|NCT01123161|tPA
1207878|NCT01123161|thrombolysis
1207879|NCT01123148|Brain computer interface
1207880|NCT01123148|wheelchair control
1207881|NCT01123135|urodynamic stress incontinence
1207882|NCT01123135|postmenopausal women
1207883|NCT01123109|nulliparous women
1207884|NCT01123096|Stress urinary incontinence
1207885|NCT01123083|new onset type 1 diabetes
1207886|NCT01123083|juvenile diabetes
1207887|NCT01123083|T1DM
1207888|NCT01123083|Type 1 diabetes
1207889|NCT01123057|keratoconus
1207890|NCT01123057|collagen cross-linking
1207891|NCT01123057|LASIK ectasia
1207892|NCT01123057|keratoconus,lasik ectasia
1207893|NCT01123018|Memory Loss
1207894|NCT01122992|Limbal relaxing incision
1207895|NCT01122992|Astigmatic correction
1207896|NCT01122992|Phacoemulsification surgery
1207897|NCT01122992|Chinese eyes
1207898|NCT01122966|trabeculectomy
1207899|NCT01122953|Bioequivalence
1207900|NCT01122953|EPAMIN
1207901|NCT01122953|PHENYTOIN
1207902|NCT01122940|Bioequivalence
1207903|NCT01122940|Phenytoin
1207904|NCT01122940|Epamin
1207905|NCT01122927|schizophrenia
1207906|NCT01122927|adolescent
1207907|NCT01122927|bipolar
1207908|NCT01122914|Kineret
1207909|NCT01122914|Anakinra
1207910|NCT01122914|Atopic Dermatitis
1207911|NCT01122914|Eczema
1207912|NCT01122914|Allergic Disease
1207913|NCT01122862|tooth plaque
1207914|NCT01122849|trouble with sleep
1207915|NCT01122849|night time nasal congestion
1207916|NCT01122836|Massage
1207917|NCT01122836|Chronic Neck Pain
1207918|NCT01122836|Dosing Study
1207919|NCT01122823|Chronic Disease Self-Management Program (CDSMP)
1207920|NCT01122810|Diagnostic accuracy of coronary angiography
1207921|NCT01122810|Transplant heart patients
1207922|NCT01122810|X-Ray and contrast agent exposure
1207923|NCT01122810|Coronary stenosis
1207924|NCT01122797|PNPLA3
1207925|NCT01122797|fibrosis
1207926|NCT01122797|cirrhosis
1207927|NCT01122797|alcoholic liver disease
1207928|NCT01122784|Plague
1207929|NCT01122784|Vaccine
1207930|NCT01122771|visceral leishmaniasis
1207931|NCT01122771|phase III
1207932|NCT01122771|randomised ccontrolled trial
1207933|NCT01122771|Bangladesh
1207934|NCT01122771|Combination treatment
1207935|NCT01122771|Ambisome
1207936|NCT01122771|miltefosine
1207937|NCT01122771|paromomycin
1207938|NCT01122758|Cohort
1207939|NCT01122758|COPD
1207940|NCT01122758|Natural history
1207941|NCT01122758|Phenotyping
1207942|NCT01122758|Smoking
1207943|NCT01122745|continuous block
1207944|NCT01122745|single shot
1207945|NCT01122745|interscalene
1207946|NCT01122745|rotator cuff surgery
1207947|NCT01122732|nerve block
1207948|NCT01122732|continuous catheter
1207949|NCT01122732|shoulder surgery
1207950|NCT01122732|pain control after total shoulder arthroplasty
1207951|NCT01122719|Optima
1207952|NCT01122719|Tacrolimus
1207953|NCT01122719|Drug eluting stent
1207954|NCT01122706|tai ji
1207955|NCT01122706|psychosocial stress
1207956|NCT01122706|primary prevention
1207957|NCT01122706|Trier Social Stress Test
1207958|NCT01122706|salivary cortisol
1207959|NCT01122706|salivary alpha amylase
1207960|NCT01122706|heart rate variability
1207961|NCT01122706|stress management
1207962|NCT01122693|Regional Anesthesia
1207963|NCT01122693|Pain Medicine
1207964|NCT01122693|Ultrasound
1207965|NCT01122693|Nerve Blocks
1207966|NCT01122667|Renal Insufficiency
1207967|NCT01122641|Insulin resistance
1207968|NCT01122641|incretins
1207969|NCT01122641|DPP4 inhibitors
1207970|NCT01122641|vildagliptin
1207971|NCT01122641|microcirculation
1207972|NCT01122628|Distal Radial Fracture
1207973|NCT01122628|Volar Locking Plate
1207974|NCT01122615|Kidney
1207975|NCT01122615|metastatic renal cell carcinoma
1207976|NCT01122615|RCC
1207977|NCT01122615|Sunitinib
1207978|NCT01122615|Sunitinib Malate
1207979|NCT01122615|Sutent
1207980|NCT01122615|Temsirolimus
1207981|NCT01122615|Torisel
1207982|NCT01122602|Aspirin
1207983|NCT01122589|Smoking Abstinence
1207984|NCT01122589|Smoking Cessation
1207985|NCT01122576|Intra Ocular Lens
1207986|NCT01122576|Ocular surgery
1207987|NCT01122576|Phacoemulsification
1207988|NCT01122563|OABSS
1207989|NCT01122563|IPSS
1207990|NCT01122563|PPBC
1207991|NCT01122563|3-day micturition diary
1207992|NCT01122563|Solifenacin
1207993|NCT01122550|OABSS
1207994|NCT01122550|IPSS
1207995|NCT01122550|PPBC
1207996|NCT01122550|3-day micturition diary
1207997|NCT01122537|Meningitis
1207998|NCT01122537|infection
1207999|NCT01122537|cerebrospinal fluid
1208000|NCT01122537|procalcitonin
1208001|NCT01122537|adenosine deaminase
1208002|NCT01122524|Trisomy 21
1208003|NCT01122472|lenalidomide (Revlimid)
1208004|NCT01122472|diffuse large B-cell lymphoma
1208005|NCT01122472|phase III study
1208006|NCT01122472|after R-CHOP
1208007|NCT01122472|Maintenance treatment
1208008|NCT01122472|Maintenance
1208009|NCT01122459|Perioperative intravenous fluids
1208010|NCT01122446|Alum-GAD
1208011|NCT01122446|Type 1 diabetes
1208012|NCT01122446|prevention
1208013|NCT01122446|immune tolerance
1208014|NCT01122446|glucose tolerance
1208015|NCT01122446|glutamate decarboxylase autoantibodies
1208016|NCT01122433|difficult airway
1208017|NCT01122433|indirect laryngoscopy
1208018|NCT01122433|C-MAC video laryngoscope
1208019|NCT01122420|Obesity
1208020|NCT01122394|stroke
1208021|NCT01122394|recurrence
1208022|NCT01122394|blood pressure
1208023|NCT01122394|prevention
1208024|NCT01122381|headache, migraine
1208025|NCT01122381|depression
1208026|NCT01122381|disability evaluation
1208027|NCT01122381|weight gain
1208028|NCT01122368|Micafungin
1208029|NCT01122368|mycoses
1208030|NCT01122368|invasive fungal infection
1208031|NCT01122368|intra-abdominal surgery
1208032|NCT01122368|intra-abdominal infection
1208033|NCT01122342|Testosterone
1208034|NCT01122342|Vaginal administration
1208035|NCT01122342|Aromatase inhibitors
1208036|NCT01122329|dementia
1208037|NCT01122316|Heart Failure
1208038|NCT01122316|Diabetes
1208039|NCT01122316|Metformin
1208040|NCT01122303|Autologous serum eye drops
1208041|NCT01122303|EGF
1208042|NCT01122303|TGF-β1
1208043|NCT01122303|TGF-β2
1208044|NCT01122303|Fibronectin
1208045|NCT01122303|Stevens-Johnson syndrome
1208046|NCT01122303|Dry eye
1208047|NCT01122290|Emotional eating
1208048|NCT01122290|Eating in the absence of hunger
1208049|NCT01122290|emotion induction
1208050|NCT01122277|Volume therapy
1208051|NCT01122277|Fluid therapy
1208052|NCT01122277|Patients in ICU
1208053|NCT01122264|Erectile Dysfunction
1208054|NCT01122251|hypertension
1208055|NCT01122251|lercanidipine
1208056|NCT01122251|valsartan
1208057|NCT01122238|Smoking
1208058|NCT01122238|Smoking Cessation
1208059|NCT01122238|Motivation
1208060|NCT01122238|Nicotine Dependence
1208061|NCT01122225|septic shock
1208062|NCT01122225|medical intensive care
1208063|NCT01122212|intracerebral hemorrhage
1208064|NCT01122212|ct scans
1208065|NCT01122212|protein s100
1208066|NCT01122212|inpatient treatment
1208067|NCT01122186|Medication Adherence
1208068|NCT01122186|Methamphetamine Use
1208069|NCT01122186|Sexual Risk
1208070|NCT01122186|Poly-substance Use
1208071|NCT01122186|HIV
1208072|NCT01122186|Treatment
1208073|NCT01122186|Motivational Interviewing
1208074|NCT01122186|Cognitive Behavioral Skills Training
1208075|NCT01122186|Men Who Have Sex With Men
1208076|NCT01122173|Atrial Fibrillation
1208077|NCT01122173|Robotic Control
1208078|NCT01122173|Remote Control
1208079|NCT01122160|anthocyanin
1208080|NCT01122160|omeprazole
1208081|NCT01122160|Prilosec
1208082|NCT01122160|gastric pH
1208083|NCT01122160|proton pump inhibitor
1208084|NCT01122160|PPI
1208085|NCT01122160|nutrition
1208086|NCT01122147|Aphthous stomatitis; Herbal medicines; Matricaria Chamomilla
1208087|NCT01122134|severe
1208088|NCT01122134|malaria
1208089|NCT01122134|artesunate
1208090|NCT01122134|intravenous
1208091|NCT01122121|Drug Therapy
1208092|NCT01122121|Radiotherapy
1208093|NCT01122108|Bile Acid Sequestrant
1208094|NCT01122108|Resin
1208095|NCT01122108|Lipids
1208096|NCT01122108|Glucose
1208097|NCT01122108|Cholesterol
1208098|NCT01122108|Diabetes Mellitus
1208099|NCT01122108|Bile Acid Sequestrant Acceptability Scale
1208100|NCT01122095|Psoriasis
1208101|NCT01122095|Cardiovascular risk
1208102|NCT01122082|energy intake
1208103|NCT01122082|energy expenditure
1208104|NCT01122082|macronutrient selection
1208105|NCT01122056|Multiple Sclerosis
1208106|NCT01122056|b1b-interferon
1208107|NCT01122056|Fatigue
1208108|NCT01122056|Exercise
1208109|NCT01122043|Endoglide
1208110|NCT01122043|Endothelial Keratoplasty
1208111|NCT01122043|Donor Insertion
1208112|NCT01122043|DSAEK
1208113|NCT01122043|Corneal Transplant
1208114|NCT01122043|Patients with Bullous Keratopathy
1208115|NCT01122030|Chronic pain
1208116|NCT01122030|Opioid physical dependence
1208117|NCT01121991|Infertility
1208118|NCT01121991|Ovarian Stimulation
1208119|NCT01121991|Luveris
1208120|NCT01121991|Lutropin alpha
1208121|NCT01121991|Controlled ovarian stimulation
1208122|NCT01121991|Reproductive techniques, assisted
1208123|NCT01121978|macular tractional maculopathy
1208124|NCT01121978|pathologic myopia
1208125|NCT01121965|macular hole
1208126|NCT01121965|impending macular hole
1208127|NCT01121965|stage 1 macular hole
1208128|NCT01121952|Ankle joint
1208129|NCT01121952|Talo-crural joint
1208130|NCT01121952|Vertical jump
1208131|NCT01121952|Chiropractic manipulation (HVLA)
1208132|NCT01121952|ROM
1208133|NCT01121952|Proprioception
1208134|NCT01121952|Pain
1208135|NCT01121939|advanced neuroendocrine
1208136|NCT01121939|Gastrointestinal
1208137|NCT01121939|Bevacizumab
1208138|NCT01121939|Avastin
1208139|NCT01121939|Pertuzumab
1208140|NCT01121939|Omnitarg
1208141|NCT01121939|2C4
1208142|NCT01121939|Sandostatin
1208143|NCT01121939|Octreotide
1208144|NCT01121926|Healthy subjects
1208145|NCT01121926|Bioavailability
1208146|NCT01121926|Pharmacokinetics
1208147|NCT01121926|Trazodone
1208148|NCT01121926|Steady-state
1208149|NCT01121913|Healthy subjects
1208150|NCT01121900|Healthy subjects
1208151|NCT01121887|smoking cessation
1208152|NCT01121887|telephone counselling
1208153|NCT01121887|motivational interviewing
1208154|NCT01121887|treatment integrity
1208155|NCT01121887|Tobacco Smoking
1208156|NCT01121874|CMC arthritis
1208157|NCT01121874|thumb carpometacarpal arthritis
1208158|NCT01121874|basal joint arthritis
1208159|NCT01121874|thumb CMC arthritis
1208160|NCT01121861|efficacy
1208161|NCT01121861|safety
1208162|NCT01121861|predictability
1208163|NCT01121861|stability
1208164|NCT01121861|toric IOL
1208165|NCT01121861|refractive astigmatism
1208166|NCT01121861|phacoemulsification
1208167|NCT01121822|Influenza
1208168|NCT01121822|Influenza vaccine
1208169|NCT01121822|Influenza virus
1208170|NCT01121822|Intramuscular
1208171|NCT01121809|Raltegravir
1208172|NCT01121809|etravirine
1208173|NCT01121809|pharmacokinetics
1208174|NCT01121809|intracellular
1208175|NCT01121757|relapsed
1208176|NCT01121757|refractory
1208177|NCT01121757|lymphoma
1208178|NCT01121757|follicular
1208179|NCT01121757|marginal zone
1208180|NCT01121744|Coronary Artery Disease
1208181|NCT01121744|Drug Eluting Stents (DES)
1208182|NCT01121744|Pharmacokinetic (PK)
1208183|NCT01121731|Chronic Hepatitis C Viral Infection
1208184|NCT01121731|Interferon alfa-5
1208185|NCT01121731|Interferon
1208186|NCT01121718|lymph node
1208187|NCT01121705|genotype 3
1208188|NCT01121705|Combination treatment
1208189|NCT01121705|Short treatment
1208190|NCT01121692|Couples
1208191|NCT01121692|Alcohol use
1208192|NCT01121692|HIV risk
1208193|NCT01121692|Outreach
1208194|NCT01121679|Older patients
1208195|NCT01121679|Aged, 80 and Over
1208196|NCT01121679|Cardiology
1208197|NCT01121666|Assisted reproductive treatment
1208198|NCT01121666|Superovulation
1208199|NCT01121666|Follitropin alfa
1208200|NCT01121666|r-hFSH
1208201|NCT01121666|AFOLIA
1208202|NCT01121653|Neuropathic pain, magnesium
1208203|NCT01121640|Ovarian Cancer
1208204|NCT01121640|Screening
1208205|NCT01121640|Biomarkers
1208206|NCT01121627|Computerized Cognitive training
1208207|NCT01121627|Quality of life
1208208|NCT01121627|Gait Function
1208209|NCT01121627|Executive Function
1208210|NCT01121614|Harmonic scalpel
1208211|NCT01121614|ultrasonic scalpel
1208212|NCT01121614|LOTUS
1208213|NCT01121614|LigaSure
1208214|NCT01121614|vessel sealing
1208215|NCT01121614|burst pressure
1208216|NCT01121614|collateral damage
1208217|NCT01121588|neoplasm malignant
1208218|NCT01121588|lymphoma
1208219|NCT01121588|neuroblastoma
1208220|NCT01121588|Crizotinib
1208221|NCT01121588|anaplastic lymphoma kinase
1208222|NCT01121588|ALK
1208223|NCT01121575|Phase 1 acquired resistance to erlotinib or gefitinib cMET inhibitor EGFR inhibitor panHER inhibitor combination trial Crizotinib
1208224|NCT01121562|Neuroendocrine tumors
1208225|NCT01121549|Prospective
1208226|NCT01121549|non-comparative
1208227|NCT01121549|NIS
1208228|NCT01121549|600
1208229|NCT01121549|postmenopausal
1208230|NCT01121549|hormone-receptor
1208231|NCT01121549|positive
1208232|NCT01121549|EBC
1208233|NCT01121549|tamoxifen
1208234|NCT01121549|current medical practice.
1208235|NCT01121536|Bipolar I Disorder
1208236|NCT01121523|Prematurity
1208237|NCT01121523|massage
1208238|NCT01121523|stress
1208239|NCT01121523|parenting
1208240|NCT01121523|infancy
1208241|NCT01121523|sleep
1208242|NCT01121523|intervention
1208243|NCT01121510|vascular closure device
1208244|NCT01121497|Sedation
1208245|NCT01121497|Cognitive decline
1208246|NCT01121497|Physostigmine
1208247|NCT01121497|Colonoscopy
1208248|NCT01121471|diabetes
1208249|NCT01121471|conjugated linoleic acid
1208250|NCT01121458|pulmonary artery
1208251|NCT01121458|vascular resistance
1208252|NCT01121445|Sleep apnea
1208253|NCT01121445|CPAP
1208254|NCT01121445|Saline irrigation
1208255|NCT01121419|Neuroblastoma
1208256|NCT01121419|IMP3
1208257|NCT01121419|Prognosis
1208258|NCT01121380|Healthy
1208259|NCT01121380|Volunteers
1208260|NCT01121367|emphysema; pulmonary fibrosis;chemokine;sputum
1208261|NCT01121354|Cefazolin
1208262|NCT01121354|Caphalosporin
1208263|NCT01121354|antibiotic
1208264|NCT01121354|gram positive
1208265|NCT01121354|Infection control
1208266|NCT01121341|Endoscopic vein harvesting
1208267|NCT01121341|Saphenous vein
1208268|NCT01121341|Conventional vein harvesting
1208269|NCT01121328|Preterm neonates.
1208270|NCT01121328|Autologous cord blood transfusion.
1208271|NCT01121315|Epidemiological
1208272|NCT01121315|Diabetes
1208273|NCT01121315|Glucose Lowering Drug Treatment in Primary care
1208274|NCT01121315|CVD
1208275|NCT01121302|AZD5213
1208276|NCT01121302|Phase 1
1208277|NCT01121302|Safety
1208278|NCT01121263|coronary arteriosclerosis
1208279|NCT01121263|coronary heart disease
1208280|NCT01121263|coronary artery bypass
1208281|NCT01121263|coronary artery bypass, off-pump
1208282|NCT01121263|coronary angiography
1208283|NCT01121263|drug-eluting stents
1208284|NCT01121250|Combat disorders
1208285|NCT01121250|Spouses
1208286|NCT01121250|Support
1208287|NCT01121250|Military personnel
1208288|NCT01121237|chronic kidney disease
1208289|NCT01121237|end-stage renal disease
1208290|NCT01121237|renal anaemia
1208291|NCT01121237|epoetin alfa
1208292|NCT01121224|Saphenous vein graft
1208293|NCT01121224|Percutaneous coronary intervention
1208294|NCT01121224|Stents
1208295|NCT01121211|Testosterone
1208296|NCT01121211|Hormones
1208297|NCT01121211|Mental Health
1208298|NCT01121198|Food effect
1208299|NCT01121185|Hepatitis C virus (HCV)
1208300|NCT01121185|Liver transplantation
1208301|NCT01121185|Human Monoclonal Antibody
1208302|NCT01121146|Osteolysis
1208303|NCT01121146|Polyethylene
1208304|NCT01121146|Crosslinked Polyethylene
1208305|NCT01121146|Total Hip Replacement
1208306|NCT01121146|CT
1208307|NCT01121120|Lymphoma, Non-Hodgkin
1208308|NCT01121120|Hodgkin Disease
1208309|NCT01121120|Multiple myeloma
1208310|NCT01121120|Peripheral Blood Stem Cell Transplant
1208311|NCT01121120|Autologous Peripheral Blood Stem Cell Transplant
1208312|NCT01121120|Limited re-infusion of CD34+ cells
1208313|NCT01121107|Heart Failure
1208314|NCT01121107|Decompensated Heart Failure
1208315|NCT01121107|Acute Decompensated Heart Failure
1208316|NCT01121107|Hemodynamic Monitoring
1208317|NCT01121107|Implantable Pressure Monitor
1208318|NCT01121107|Left Atrial Pressure Monitoring
1208319|NCT01121094|Liver, spleen , T2* , MRI, fetus
1208320|NCT01121081|Male or female subjects
1208321|NCT01121081|≥18 to ≤75 years of age
1208322|NCT01121081|who have a diagnosis of plaque or guttate psoriasis
1208323|NCT01121068|IGRA
1208324|NCT01121068|variability
1208325|NCT01121068|Long-term variability of IGRA
1208326|NCT01121055|Fiberoptic Bronchoscopy
1208327|NCT01121055|Patient
1208328|NCT01121055|Satisfaction
1208329|NCT01121055|Lorazepam
1208330|NCT01121016|NAEB, chronic cough, montelukast, induced sputum
1208331|NCT01121003|Fructose
1208332|NCT01121003|VLDL-triglycerides
1208333|NCT01121003|de novo lipogenesis
1208334|NCT01121003|Human metabolism
1208335|NCT01120990|Blood pressure measuring devices
1208336|NCT01120990|Essential Hypertension
1208337|NCT01120990|Automated blood pressure measurement
1208338|NCT01120951|Respiratory rate R8 Anaxsys
1208339|NCT01120938|AIrways, Patency, Infant death
1208340|NCT01120925|Cirrhotic
1208341|NCT01120925|Stem Cells
1208342|NCT01120925|Bone marrow stem cells
1208343|NCT01120925|Decompensate Cirrhotic Patients
1208344|NCT01120912|oral insulin
1208345|NCT01120899|Diabetic Macular Edema
1208346|NCT01120899|Microglia
1208347|NCT01120899|Minocycline
1208348|NCT01120899|Diabetes
1208349|NCT01120886|Ion channelopathy,
1208350|NCT01120886|Still birth
1208351|NCT01120886|Sudden death
1208352|NCT01120873|Hyperglycemia
1208353|NCT01120873|dyslipidemia
1208354|NCT01120873|Hypertension
1208355|NCT01120873|Obesity
1208356|NCT01120860|Cognitive Aging
1208357|NCT01120860|Apolipoproteins E
1208358|NCT01120860|Magnetic Resonance Imaging
1208359|NCT01120834|diffuse large b cell lymphoma
1208360|NCT01120821|PV
1208361|NCT01120769|Myocardial Infarction
1208362|NCT01120769|Percutaneous Coronary Intervention
1208363|NCT01120769|Acetaminophen
1208364|NCT01120769|Lipid Peroxidation
1208365|NCT01120756|executive dysfunction
1208366|NCT01120756|brain injury
1208367|NCT01120756|attention
1208368|NCT01120756|rehabilitation
1208369|NCT01120756|fMRI
1208370|NCT01120743|liver failure
1208371|NCT01120743|cytokines
1208372|NCT01120743|hemodynamic instability
1208373|NCT01120717|QVA149
1208374|NCT01120717|COPD
1208375|NCT01120717|combination bronchodilator
1208376|NCT01120704|Smoking
1208377|NCT01120704|Smoking Cessation
1208378|NCT01120704|Adherence
1208379|NCT01120704|Nicotine
1208380|NCT01120704|Motivation
1208381|NCT01120691|QVA149
1208382|NCT01120691|NVA237
1208383|NCT01120691|COPD
1208384|NCT01120691|exacerbation
1208385|NCT01120691|combination bronchodilator
1208386|NCT01120678|cytokines
1208387|NCT01120678|late-onset neonatal sepsis
1208388|NCT01120678|neonatal sepsis
1208389|NCT01120678|diagnosis of sepsis
1208390|NCT01120678|bacteremia
1208391|NCT01120678|blood culture
1208392|NCT01120678|clinical sepsis
1208393|NCT01120665|women's health
1208394|NCT01120665|hormone replacement therapy
1208395|NCT01120665|exercise
1208396|NCT01120613|Nocturnal Hypertension
1208397|NCT01120613|Nondipping
1208398|NCT01120613|Renal Transplant
1208399|NCT01120613|Chronotherapy
1208400|NCT01120587|Deglutition
1208401|NCT01120587|Fluoroscopy
1208402|NCT01120574|Nocturnal hypercapnic response to oxygen
1208403|NCT01120574|Home mechanical ventilation
1208404|NCT01120574|COPD
1208405|NCT01120561|TDM-1 EAP
1208406|NCT01120561|T-DM1 EAP
1208407|NCT01120561|TDM1 EAP
1208408|NCT01120561|Trastuzumab-MCC-DM1 EAP
1208409|NCT01120561|Trastuzumab emtansine
1208410|NCT01120561|EAP
1208411|NCT01120561|T-PAS
1208412|NCT01120548|CARDIAC REHABILITATION
1208413|NCT01120548|Nocturnal Ventilation
1208414|NCT01120548|Apnea hypopnea index is > 15/h
1208415|NCT01120535|Vena Cava
1208416|NCT01120535|Vena Cava Filter
1208417|NCT01120535|Pulmonary Embolism
1208418|NCT01120535|Venous Thromboembolism
1208419|NCT01120535|Risk of Pulmonary Embolism
1208420|NCT01120522|Vena Cava
1208421|NCT01120522|Vena Cava Filter
1208422|NCT01120522|Pulmonary Embolism
1208423|NCT01120522|Venous Thromboembolism
1208424|NCT01120522|Risk of Pulmonary Embolism
1208425|NCT01120509|Vena Cava
1208426|NCT01120509|Vena Cava Filter
1208427|NCT01120509|Pulmonary Embolism
1208428|NCT01120509|Venous Thromboembolism
1208429|NCT01120509|Risk of Pulmonary Embolism
1208430|NCT01120496|Hypertonic saline solution, bronchiolitis, RSV
1208431|NCT01120483|mortality
1208432|NCT01120483|functional status
1208433|NCT01120470|Castration Resistant
1208434|NCT01120470|Prostate Cancer
1208435|NCT01120470|OGX-427
1208436|NCT01120444|Diabetes
1208437|NCT01120444|Insulin
1208438|NCT01120444|Blood Glucose
1208439|NCT01120431|dehydration
1208440|NCT01120431|fluid therapy
1208441|NCT01120431|hyaluronoglucosaminidase
1208442|NCT01120431|hyaluronidase
1208443|NCT01120431|hypodermoclysis
1208444|NCT01120431|clysis
1208445|NCT01120431|subcutaneous hydration
1208446|NCT01120431|subcutaneous rehydration
1208447|NCT01120431|hyaluronan
1208448|NCT01120431|rHuPH20
1208449|NCT01120431|pediatric
1208450|NCT01120431|ORT
1208451|NCT01120418|Endothelial cell density
1208452|NCT01120418|screening
1208453|NCT01120405|Xenon
1208454|NCT01120405|Cardiac safety
1208455|NCT01120405|Cardiovascular risk
1208456|NCT01120405|Non cardiac surgery
1208457|NCT01120405|Atherosclerotic vascular surgery
1208458|NCT01120392|Parkinson's disease
1208459|NCT01120392|Physical therapy
1208460|NCT01120392|Virtual Reality
1208461|NCT01120392|Quality of life
1208462|NCT01120392|Motor performance
1208463|NCT01120379|drug eluting stents
1208464|NCT01120379|Stents
1208465|NCT01120379|Angioplasty
1208466|NCT01120379|Stent thrombosis
1208467|NCT01120353|Childhood cancer
1208468|NCT01120353|Young Children
1208469|NCT01120353|Adults
1208470|NCT01120301|stroke
1208471|NCT01120288|Anti-Angiogenesis
1208472|NCT01120288|Targeted Therapy
1208473|NCT01120288|HIF
1208474|NCT01120288|Antisense
1208475|NCT01120288|VEGF
1208476|NCT01120288|Cancer
1208477|NCT01120288|Solid Tumor
1208478|NCT01120288|Liver Metastasis
1208479|NCT01120262|recurrent prostate cancer
1208480|NCT01120262|stage IV prostate cancer
1208481|NCT01120249|stage I renal cell cancer
1208482|NCT01120249|stage II renal cell cancer
1208483|NCT01120249|stage III renal cell cancer
1208484|NCT01120249|clear cell renal cell carcinoma
1208485|NCT01120249|papillary renal cell carcinoma
1208486|NCT01120210|Heart Failure
1208487|NCT01120210|Cardiac Failure
1208488|NCT01120197|randomized controlled trial
1208489|NCT01120197|osteoporosis
1208490|NCT01120197|moderate-intensity circuit exercises
1208491|NCT01120197|balance
1208492|NCT01120197|health-related quality of life
1208493|NCT01120171|Breast cancer
1208494|NCT01120171|Elderly
1208495|NCT01120171|Chemotherapy
1208496|NCT01120171|Cardiotoxicity
1208497|NCT01120158|Breast cancer
1208498|NCT01120158|Elderly
1208499|NCT01120158|Chemotherapy
1208500|NCT01120158|Anti-angiogenesis therapy
1208501|NCT01120145|Malaria
1208502|NCT01120145|Pregnancy
1208503|NCT01120145|Sulphadoxine-pyrimethamine
1208504|NCT01120106|levosimendan
1208505|NCT01120106|pediatric cardiac surgery
1208506|NCT01120106|low cardiac output syndrome
1208507|NCT01120106|transposition of the great arteries
1208508|NCT01120093|COPD
1208509|NCT01120080|Smoking
1208510|NCT01120080|Tobacco
1208511|NCT01120080|Drinking
1208512|NCT01120067|Psychology
1208513|NCT01120067|Pain
1208514|NCT01120067|Veterans
1208515|NCT01120067|Stress Disorders, Post-Traumatic
1208516|NCT01120054|Traumatic Brain Injury
1208517|NCT01120054|Homelessness
1208518|NCT01120015|OA
1208519|NCT01120015|knee
1208520|NCT01120002|mild to moderate Alzheimer's Disease
1208521|NCT01119989|hepatic fat content
1208522|NCT01119989|hepatic de novo lipogenesis
1208523|NCT01119963|Preterm delivery
1208524|NCT01119950|COPD
1208525|NCT01119937|COPD
1208526|NCT01119937|NVA237
1208527|NCT01119924|Mirtazapine
1208528|NCT01119924|Smilon
1208529|NCT01119924|Depression
1208530|NCT01119924|Pain
1208531|NCT01119911|Blood sampling
1208532|NCT01119911|Venipuncture
1208533|NCT01119911|Peripheral venous catheter
1208534|NCT01119911|Complete blood count
1208535|NCT01119911|Basic chemistry
1208536|NCT01119911|Hemolysis
1208537|NCT01119911|Peripheral venous catheter replaces venipuncture.
1208538|NCT01119911|Peripheral venous catheter blood sampling reduces pain.
1208539|NCT01119898|Osteoarthritis
1208540|NCT01119898|Arthritis
1208541|NCT01119898|NSAIDs
1208542|NCT01119898|Topical NSAID
1208543|NCT01119898|Diclofenac
1208544|NCT01119898|PENNSAID
1208545|NCT01119885|chronic pain
1208546|NCT01119885|fentanyl matrix
1208547|NCT01119885|arthritis
1208548|NCT01119885|osteoarthritis
1208549|NCT01119872|Positive-Pressure Respiration
1208550|NCT01119872|Respiration, Artificial
1208551|NCT01119846|Tolerability
1208552|NCT01119846|Pharmacokinetics
1208553|NCT01119846|Safety
1208554|NCT01119846|Pharmacodynamics
1208555|NCT01119846|Glucose
1208556|NCT01119833|Sickle Cell Disease
1208557|NCT01119820|elective obstetric or gynecologic surgery
1208558|NCT01119807|Intraosseous infusion
1208559|NCT01119807|Emergency Medical Services
1208560|NCT01119794|B-cell small lymphocytic lymphoma
1208561|NCT01119794|marginal zone lymphoma
1208562|NCT01119794|follicular lymphoma
1208563|NCT01119794|mantle cell lymphoma
1208564|NCT01119794|Waldenström macroglobulinemia.
1208565|NCT01119794|Low Grade B cell Non-Hodgkins Lymphoma
1208566|NCT01119768|GI
1208567|NCT01119768|Nexium
1208568|NCT01119768|Phase IV
1208569|NCT01119768|Co-diagnosed NERD
1208570|NCT01119755|TREATMENT OF HYPERTENSION
1208571|NCT01119742|Tinea Pedis
1208572|NCT01119742|Interdigital
1208573|NCT01119729|Cardiac Diseases • HIV-Infection • AIDS • Antiretroviral Therapy
1208574|NCT01119716|Atrial Fibrillation
1208575|NCT01119716|Afib
1208576|NCT01119716|cardioversion
1208577|NCT01119716|normal sinus rhythm
1208578|NCT01119716|arrhythmia
1208579|NCT01119716|AF
1208580|NCT01119703|Vaccine Hyporesponse
1208581|NCT01119690|Dietary
1208582|NCT01119690|Cross-Over Study
1208583|NCT01119690|Lipids
1208584|NCT01119690|Rapeseed oil
1208585|NCT01119690|Butter
1208586|NCT01119690|Milk Fat
1208587|NCT01119690|Unsaturated Fat
1208588|NCT01119690|Saturated Fat
1208589|NCT01119690|Oxidized LDL
1208590|NCT01119690|Platelet Function
1208591|NCT01119690|Arterial Elasticity
1208592|NCT01119664|Adult subjects with malignant pleural mesothelioma who present for first (front) line or second line chemotherapy,
1208593|NCT01119651|Healthy Volunteer Subjects
1208594|NCT01119638|Alzheimer's disease
1208595|NCT01119638|BPSD
1208596|NCT01119638|escitalopram
1208597|NCT01119638|Risperidone
1208598|NCT01119638|Agitation
1208599|NCT01119638|Psychosis
1208600|NCT01119638|Dementia
1208601|NCT01119638|Elderly
1208602|NCT01119625|safety
1208603|NCT01119625|Streptococcus pneumoniae
1208604|NCT01119625|immunogenicity
1208605|NCT01119625|Pneumococcal conjugate vaccine
1208606|NCT01119625|Haemophilus influenzae
1208607|NCT01119612|Malaria
1208608|NCT01119612|Iron
1208609|NCT01119612|Pregnancy
1208610|NCT01119612|Anemia
1208611|NCT01119612|Birth Weight
1208612|NCT01119586|B-cell adult acute lymphoblastic leukemia
1208613|NCT01119586|B-cell childhood acute lymphoblastic leukemia
1208614|NCT01119586|untreated adult acute lymphoblastic leukemia
1208615|NCT01119586|untreated childhood acute lymphoblastic leukemia
1208616|NCT01119573|stage I endometrial carcinoma
1208617|NCT01119573|stage III endometrial carcinoma
1208618|NCT01119547|Musculoskeletal Diseases
1208619|NCT01119547|Osteoarthritis
1208620|NCT01119547|Joint Diseases
1208621|NCT01119547|Arthritis
1208622|NCT01119547|Rheumatic Diseases
1208623|NCT01119534|Cough treatment
1208624|NCT01119521|South Africa,tuberculosis,vaccine
1208625|NCT01119508|Advanced
1208626|NCT01119508|Inoperable
1208627|NCT01119508|Melanoma
1208628|NCT01119508|Ipilimumab
1208629|NCT01119508|MDX010
1208630|NCT01119508|BMS-734016
1208631|NCT01119508|Temozolomide
1208632|NCT01119508|Temodar
1208633|NCT01119508|TMZ
1208634|NCT01119508|skin
1208635|NCT01119508|mucosal
1208636|NCT01119482|Serogroup A meningococcal vaccine
1208637|NCT01119482|meningococcal carriage
1208638|NCT01119482|incidence
1208639|NCT01119482|prevalence
1208640|NCT01119469|Hypochondriasis
1208641|NCT01119469|Health Anxiety
1208642|NCT01119469|randomized controlled trial
1208643|NCT01119469|Cognitive Therapy
1208644|NCT01119469|Exposure Therapy
1208645|NCT01119456|Tumors
1208646|NCT01119456|Macrophage stimulating 1 receptor, human
1208647|NCT01119456|RON protein
1208648|NCT01119456|RON receptor protein tyrosine kinase
1208649|NCT01119430|major depression
1208650|NCT01119430|DU 125530
1208651|NCT01119430|Treatment depression
1208652|NCT01119430|Latency antidepressant
1208653|NCT01119417|supine Hypertension
1208654|NCT01119417|autonomic failure
1208655|NCT01119417|BQ123
1208656|NCT01119417|BQ-123
1208657|NCT01119417|endothelin
1208658|NCT01119404|Metabolic Syndrome
1208659|NCT01119404|Coronary Heart Disease
1208660|NCT01119404|Erectile Dysfunction
1208661|NCT01119404|Arterial Elasticity
1208662|NCT01119404|Oxidized Low Density Lipoprotein
1208663|NCT01119404|Cardiovascular Diseases
1208664|NCT01119404|Risk Assessment
1208665|NCT01119404|Endothelial Dysfunction
1208666|NCT01119404|Diabetes Mellitus
1208667|NCT01119404|Surrogate Markers
1208668|NCT01119404|Risk Factors
1208669|NCT01119391|IVF
1208670|NCT01119391|Lifestyle habits
1208671|NCT01119378|Post menopausal
1208672|NCT01119378|Vitamin D sufficiency
1208673|NCT01119378|Calcium absorption efficiency
1208674|NCT01119378|Dual isotope technique
1208675|NCT01119365|Healthy controls
1208676|NCT01119352|Safety
1208677|NCT01119352|tolerability
1208678|NCT01119352|PK
1208679|NCT01119352|healthy
1208680|NCT01119352|overweight
1208681|NCT01119352|obese
1208682|NCT01119339|psoriasis
1208683|NCT01119339|topical
1208684|NCT01119339|psoriasis plaques test
1208685|NCT01119326|scar prevention
1208686|NCT01119326|healing
1208687|NCT01119326|tissue
1208688|NCT01119326|AFT
1208689|NCT01119326|scar analysis
1208690|NCT01119300|Venous Thromboembolism (VTE)
1208691|NCT01119300|Atrial Fibrillation (AF)
1208692|NCT01119287|Conjunctivitis
1208693|NCT01119287|ocular allergy
1208694|NCT01119261|Venous thromboembolism (VTE)
1208695|NCT01119261|Atrial fibrillation (AF)
1208696|NCT01119248|Children MRI General Anesthesia
1208697|NCT01119235|Pharmacokinetics
1208698|NCT01119235|tablet performance
1208699|NCT01119235|healthy volunteers
1208700|NCT01119235|open label
1208701|NCT01119222|Cold pain methodology
1208702|NCT01119222|Healthy male volunteers
1208703|NCT01119222|gabapentin
1208704|NCT01119222|Diphenhydramine
1208705|NCT01119222|morphine
1208706|NCT01119209|Hip fracture
1208707|NCT01119209|intertrochanteric
1208708|NCT01119196|Peritoneal Dialysis
1208709|NCT01119196|Insulin resistance
1208710|NCT01119183|Patient understanding and counseling
1208711|NCT01119170|nutrition
1208712|NCT01119170|infant formula
1208713|NCT01119170|probiotics
1208714|NCT01119157|influenza vaccine
1208715|NCT01119157|cellular immune response
1208716|NCT01119157|humoral immune response
1208717|NCT01119144|Orbital
1208718|NCT01119144|fractures
1208719|NCT01119144|enophthalmos
1208720|NCT01119144|diplopia
1208721|NCT01119144|eye
1208722|NCT01119131|Vitamin D
1208723|NCT01119131|Parkinson disease
1208724|NCT01119131|accidental falls
1208725|NCT01119118|Metastatic
1208726|NCT01119118|castrate-resistant prostate cancer
1208727|NCT01119118|bone metastasis
1208728|NCT01119105|acute bacterial skin and skin structure infection
1208729|NCT01119105|bacteria
1208730|NCT01119092|Ankle Sprain
1208731|NCT01119092|Joint Mobilization
1208732|NCT01119092|Manual Therapy
1208733|NCT01119092|Range of Motion
1208734|NCT01119079|labor pain
1208735|NCT01119079|epidural
1208736|NCT01119066|Leukemia
1208737|NCT01119066|Multiple Myeloma
1208738|NCT01119066|radiation
1208739|NCT01119066|Thiotepa
1208740|NCT01119066|cyclophosphamide
1208741|NCT01119066|fludarabine
1208742|NCT01119066|Clofarabine
1208743|NCT01119066|CliniMACS device
1208744|NCT01119066|GCSF
1208745|NCT01119066|10-050
1208746|NCT01119053|VNS
1208747|NCT01119053|Depression
1208748|NCT01119053|Personality-Disorder
1208749|NCT01119053|Stimulation
1208750|NCT01119040|Dislodged PEG tube
1208751|NCT01119040|NOTES
1208752|NCT01119027|Laparoscopic Colectomy
1208753|NCT01119027|Colorectal Skills Training
1208754|NCT01119014|Aripiprazole
1208755|NCT01119014|Quetiapine
1208756|NCT01119014|Psychosis
1208757|NCT01119014|Child
1208758|NCT01119014|Adolescent
1208759|NCT01118988|Peer Support
1208760|NCT01118988|Social Support
1208761|NCT01118988|Chronic Pain
1208762|NCT01118988|Behavioral Interventions for Pain
1208763|NCT01118988|Adolescents
1208764|NCT01118988|Children
1208765|NCT01118988|Pediatric
1208766|NCT01118988|Mentorship
1208767|NCT01118988|Complementary and Alternative Medicine
1208768|NCT01118988|CAM
1208769|NCT01118988|Pain
1208770|NCT01118988|Pain Management
1208771|NCT01118988|Behavioral
1208772|NCT01118975|lapatinib ditosylate
1208773|NCT01118975|Zolinza (vorinostat)
1208774|NCT01118975|Cancer Stem Cells
1208775|NCT01118962|Primary Generalized Tonic-Clonic (PGTC) Seizures
1208776|NCT01118962|Absence Seizures
1208777|NCT01118962|Myoclonic Seizures
1208778|NCT01118962|Idiopathic Generalized Epilepsy (IGE)
1208779|NCT01118949|Primary Generalized Tonic-Clonic (PGTC) Seizures
1208780|NCT01118949|Absence Seizures
1208781|NCT01118949|Myoclonic Seizures
1208782|NCT01118949|Idiopathic Generalized Epilepsy (IGE)
1208783|NCT01118936|Chronic Obstructive Pulmonary Disease
1208784|NCT01118936|Daily magnesium supplement
1208785|NCT01118936|EQ-5D
1208786|NCT01118923|Bronchial challenge test
1208787|NCT01118923|Hyperreactivity
1208788|NCT01118923|PD20 for metacholine
1208789|NCT01118923|Daily magnesium supplement
1208790|NCT01118910|Intertrigo
1208791|NCT01118910|Vusion
1208792|NCT01118897|Gall bladder
1208793|NCT01118897|Pancreatic cancers
1208794|NCT01118897|Tomotherapy
1208795|NCT01118884|Midazolam
1208796|NCT01118884|Nitrous oxide
1208797|NCT01118884|Behaviour management
1208798|NCT01118871|Treatment experienced
1208799|NCT01118858|CYP2D6
1208800|NCT01118858|CYP3A4
1208801|NCT01118858|cytochrome P450
1208802|NCT01118858|children
1208803|NCT01118858|pediatrics
1208804|NCT01118858|dextromethorphan
1208805|NCT01118858|phenotype
1208806|NCT01118858|genotype
1208807|NCT01118845|Non-Hodgkin's lymphoma
1208808|NCT01118845|Lymphoma, Large B-Cell
1208809|NCT01118845|Diffuse, Mantle cell lymphoma, Lymphoma
1208810|NCT01118845|Follicular, Lymphoma
1208811|NCT01118845|Large B-Cell, Diffuse
1208812|NCT01118832|Thermography
1208813|NCT01118819|Phase I
1208814|NCT01118819|Metastatic Disease
1208815|NCT01118819|Solid Tumor
1208816|NCT01118819|Malignancy
1208817|NCT01118819|Metastases
1208818|NCT01118819|Clinical trial
1208819|NCT01118819|Hypoxia
1208820|NCT01118819|Necrosis
1208821|NCT01118780|GAD
1208822|NCT01118780|Generalized Anxiety Disorder
1208823|NCT01118780|Anxiety
1208824|NCT01118767|Adherence
1208825|NCT01118767|Appointment
1208826|NCT01118767|Cell Phone
1208827|NCT01118767|Cellular Phone
1208828|NCT01118767|Clinic
1208829|NCT01118767|Computers
1208830|NCT01118767|Controlled Clinical Trials, Randomized
1208831|NCT01118767|HIV/AIDS
1208832|NCT01118767|Health Informatics
1208833|NCT01118767|Health behavior
1208834|NCT01118767|Information Technology
1208835|NCT01118767|Internet
1208836|NCT01118767|Intervention
1208837|NCT01118767|Medication
1208838|NCT01118767|Patient Satisfaction
1208839|NCT01118767|Patient Self-Report
1208840|NCT01118767|Patients
1208841|NCT01118767|Peru
1208842|NCT01118767|Phone
1208843|NCT01118767|Public Health
1208844|NCT01118767|Public Health Informatics
1208845|NCT01118767|Randomized
1208846|NCT01118767|Randomized Controlled Clinical Trials
1208847|NCT01118767|Randomized Controlled Trials
1208848|NCT01118767|Research
1208849|NCT01118767|Secondary Prevention
1208850|NCT01118767|Self-Report
1208851|NCT01118767|Sex Behavior
1208852|NCT01118767|Sexual Behavior
1208853|NCT01118767|Sexually Transmitted Diseases
1208854|NCT01118767|Sexually Transmitted Infection
1208855|NCT01118767|Survey Instrument
1208856|NCT01118767|Surveys
1208857|NCT01118767|Telephone
1208858|NCT01118767|Telephone, Cellular
1208859|NCT01118767|Text
1208860|NCT01118767|Unprotected Sex
1208861|NCT01118767|Viral Load result
1208862|NCT01118767|Vulnerable Populations
1208863|NCT01118767|WWW
1208864|NCT01118767|anti-retroviral therapy
1208865|NCT01118767|consumer informatics
1208866|NCT01118767|evidence base
1208867|NCT01118767|follow-up
1208868|NCT01118767|medication adherence
1208869|NCT01118767|medication compliance
1208870|NCT01118767|randomization
1208871|NCT01118767|randomized controlled study
1208872|NCT01118767|randomized trial
1208873|NCT01118767|randomly assigned
1208874|NCT01118767|safer sex
1208875|NCT01118767|treatment adherence
1208876|NCT01118767|user centered design
1208877|NCT01118767|web
1208878|NCT01118767|world wide web
1208879|NCT01118754|Santen
1208880|NCT01118754|Dry
1208881|NCT01118754|Eye
1208882|NCT01118741|Rising PSA
1208883|NCT01118741|Recurrent Non Metastatic Prostate Cancer
1208884|NCT01118715|distal radius fracture
1208885|NCT01118715|post-traumatic carpal tunnel syndrome
1208886|NCT01118715|complex regional pain syndrome
1208887|NCT01118715|compression glove
1208888|NCT01118715|edema glove
1208889|NCT01118702|Pharmacokinetic
1208890|NCT01118702|Methylphenidate
1208891|NCT01118702|Novo-methylphenidate ER-C
1208892|NCT01118702|Ritalin-SR
1208893|NCT01118702|CONCERTA
1208894|NCT01118702|Plasma profile
1208895|NCT01118676|locally advanced non small cell lung cancer (NSCLC), locally advanced, Phase I, Cilengitide, concomitant radiochemotherapy
1208896|NCT01118663|Acetaminophen overdose; induced hepatotoxicity, liver injury
1208897|NCT01118650|Inattention
1208898|NCT01118650|Hyperactivity
1208899|NCT01118650|Impulsivity
1208900|NCT01118637|trichotillomania
1208901|NCT01118637|self-help
1208902|NCT01118637|web-based
1208903|NCT01118637|habit reversal
1208904|NCT01118637|behavior therapy
1208905|NCT01118624|Female
1208906|NCT01118624|Advanced
1208907|NCT01118624|Metastatic
1208908|NCT01118611|unspecified adult solid tumor, protocol specific
1208909|NCT01118598|PCOS
1208910|NCT01118585|GERD
1208911|NCT01118585|Esophagitis
1208912|NCT01118585|Fundoplication
1208913|NCT01118585|Anti-reflux surgery
1208914|NCT01118585|PPI dependent
1208915|NCT01118572|Celecoxib
1208916|NCT01118572|Celecox
1208917|NCT01118572|Pain
1208918|NCT01118572|Surgery
1208919|NCT01118572|NSAIDs
1208920|NCT01118559|YM150
1208921|NCT01118559|Food effect
1208922|NCT01118559|Healthy volunteer
1208923|NCT01118546|aspirin
1208924|NCT01118546|coronary artery disease
1208925|NCT01118546|hypersensitivity
1208926|NCT01118546|Platelet aggregation
1208927|NCT01118533|Intubation
1208928|NCT01118533|Sore throat
1208929|NCT01118533|Blades
1208930|NCT01118533|Laryngoscopy
1208931|NCT01118533|Morbidity
1208932|NCT01118520|abdominal aortic aneurysm
1208933|NCT01118520|ACE Inhibition
1208934|NCT01118507|Trisomy of chromosome 21 diagnosis
1208935|NCT01118507|first trimester of pregnancy
1208936|NCT01118507|maternal blood
1208937|NCT01118507|High output shotgun sequencing
1208938|NCT01118494|CKD
1208939|NCT01118494|RAS
1208940|NCT01118494|AGT
1208941|NCT01118481|Coronary stenosis
1208942|NCT01118481|Wave intensity analysis
1208943|NCT01118481|Instantaneous Flow Reserve
1208944|NCT01118481|iFR
1208945|NCT01118481|Fractional Flow Reserve
1208946|NCT01118468|Competitive Flow
1208947|NCT01118468|Coronary artery bypass
1208948|NCT01118468|Wave Intensity Analysis
1208949|NCT01118442|Aortic Stenosis
1208950|NCT01118442|Coronary Flow
1208951|NCT01118442|Wave Intensity Analysis
1208952|NCT01118429|hyperhidrosis
1208953|NCT01118429|axillary
1208954|NCT01118429|osmidrosis
1208955|NCT01118429|oxybutynin
1208956|NCT01118416|sexual risk
1208957|NCT01118416|substance use
1208958|NCT01118416|HIV
1208959|NCT01118416|prevention
1208960|NCT01118416|intervention
1208961|NCT01118416|Motivational Enhancement Therapy
1208962|NCT01118416|young men who have sex with men
1208963|NCT01118403|Ventilator associated pneumonia
1208964|NCT01118403|Coma
1208965|NCT01118403|Brain Injuries
1208966|NCT01118403|Intensive care units
1208967|NCT01118403|antibiotic prophylaxis
1208968|NCT01118390|telangiectasias
1208969|NCT01118390|leg
1208970|NCT01118390|sclerotherapy
1208971|NCT01118390|laser
1208972|NCT01118390|glycose
1208973|NCT01118364|Social circumstances
1208974|NCT01118325|Stable Coronary Artery Disease
1208975|NCT01118325|Platelet Aggregation
1208976|NCT01118312|Asthma
1208977|NCT01118312|Rhinitis
1208978|NCT01118312|Sinusitis
1208979|NCT01118312|Chronic
1208980|NCT01118312|ACRC
1208981|NCT01118312|STAN
1208982|NCT01118312|Nasal steroid
1208983|NCT01118312|Mometasone
1208984|NCT01118312|Nasal spray
1208985|NCT01117272|PCOS
1208986|NCT01117272|hyperprolactinemia
1208987|NCT01117272|obesity
1208988|NCT01117272|hyperandrogenic
1208989|NCT01117246|bone metastasis
1208990|NCT01117246|pain palliation
1208991|NCT01117233|Healthy volunteers
1208992|NCT01117233|PK
1208993|NCT01117233|PD
1208994|NCT01117233|safety and toleration
1208995|NCT01117220|pediatric
1208996|NCT01117220|bipolar
1208997|NCT01118286|Hypertension
1208998|NCT01118286|Drug therapy, combination
1208999|NCT01118273|Naproxen sodium
1209000|NCT01118273|Diphenhydramine
1209001|NCT01118273|Drugs, Investigational
1209002|NCT01118260|prostata hyperplasia
1209003|NCT01118260|transurethral resection
1209004|NCT01118260|TIVA
1209005|NCT01118260|spinal anaesthesia
1209006|NCT01118247|Uncemented THA
1209007|NCT01118247|alumina-on-alumina
1209008|NCT01118247|survival
1209009|NCT01118247|HHS
1209010|NCT01118247|Patient satisfaction
1209011|NCT01118234|CLL
1209012|NCT01118234|Rituximab
1209013|NCT01118234|Maintenance
1209014|NCT01118221|oxidant stress
1209015|NCT01118221|exercise
1209016|NCT01118208|Medication adherence
1209017|NCT01118208|Accidental overdose
1209018|NCT01118208|Deliberate overdose
1209019|NCT01118208|Suicide, attempted
1209020|NCT01118182|Traumatic Brain Injury
1209021|NCT01118182|Veterans
1209022|NCT01118182|Psychiatric Disorders
1209023|NCT01118182|Suicide
1209024|NCT01118169|Personal values
1209025|NCT01118169|Suicidal thoughts
1209026|NCT01118156|Suicide Nomenclature
1209027|NCT01118130|Genetics
1209028|NCT01118130|genomics
1209029|NCT01118130|Multiple Sclerosis
1209030|NCT01118130|beta-interferons
1209031|NCT01118117|atherosclerotic stenosis
1209032|NCT01118117|occlusions
1209033|NCT01118117|Superficial Femoral Artery
1209034|NCT01118117|SFA
1209035|NCT01118091|Immunotherapy
1209036|NCT01118091|Metastatic Melanoma
1209037|NCT01118091|Randomized
1209038|NCT01118091|Cell Therapy
1209039|NCT01118091|Skin Cancer
1209040|NCT01118091|Melanoma
1209041|NCT01118065|anaplastic thyroid cancer
1209042|NCT01118065|recurrent thyroid cancer
1209043|NCT01118065|stage III follicular thyroid cancer
1209044|NCT01118065|stage III papillary thyroid cancer
1209045|NCT01118065|stage IV follicular thyroid cancer
1209046|NCT01118065|stage IV papillary thyroid cancer
1209047|NCT01118065|thyroid gland medullary carcinoma
1209048|NCT01118039|localized transitional cell cancer of the renal pelvis and ureter
1209049|NCT01118039|metastatic transitional cell cancer of the renal pelvis and ureter
1209050|NCT01118039|recurrent transitional cell cancer of the renal pelvis and ureter
1209051|NCT01118039|transitional cell carcinoma of the bladder
1209052|NCT01118039|distal urethral cancer
1209053|NCT01118039|proximal urethral cancer
1209054|NCT01118039|recurrent urethral cancer
1209055|NCT01118039|recurrent bladder cancer
1209056|NCT01118039|stage IV bladder cancer
1209057|NCT01118039|stage III bladder cancer
1209058|NCT01118039|urethral cancer associated with invasive bladder cancer
1209059|NCT01118039|stage III urethral cancer
1209060|NCT01118039|stage IV urethral cancer
1209069|NCT01118013|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1209070|NCT01118013|adult acute myeloid leukemia with inv(16)(p13;q22)
1209071|NCT01118013|adult acute myeloid leukemia with t(15;17)(q22;q12)
1209072|NCT01118013|adult acute myeloid leukemia with t(16;16)(p13;q22)
1209073|NCT01118013|adult acute myeloid leukemia with t(8;21)(q22;q22)
1209074|NCT01118013|juvenile myelomonocytic leukemia
1209075|NCT01118013|prolymphocytic leukemia
1209076|NCT01118013|recurrent adult acute myeloid leukemia
1209077|NCT01118013|recurrent adult T-cell leukemia/lymphoma
1209078|NCT01118013|recurrent childhood acute myeloid leukemia
1209079|NCT01118013|refractory chronic lymphocytic leukemia
1209080|NCT01118013|recurrent adult Hodgkin lymphoma
1209081|NCT01118013|recurrent adult Burkitt lymphoma
1209082|NCT01118013|recurrent adult diffuse large cell lymphoma
1209083|NCT01118013|recurrent adult diffuse mixed cell lymphoma
1209084|NCT01118013|recurrent adult diffuse small cleaved cell lymphoma
1209085|NCT01118013|recurrent adult grade III lymphomatoid granulomatosis
1209086|NCT01118013|recurrent adult immunoblastic large cell lymphoma
1209087|NCT01118013|recurrent adult lymphoblastic lymphoma
1209088|NCT01118013|recurrent childhood grade III lymphomatoid granulomatosis
1209089|NCT01118013|recurrent childhood large cell lymphoma
1209090|NCT01118013|recurrent childhood lymphoblastic lymphoma
1209091|NCT01118013|recurrent childhood small noncleaved cell lymphoma
1209092|NCT01118013|recurrent cutaneous T-cell non-Hodgkin lymphoma
1209093|NCT01118013|recurrent mycosis fungoides/Sezary syndrome
1209094|NCT01118013|recurrent grade 1 follicular lymphoma
1209095|NCT01118013|recurrent grade 2 follicular lymphoma
1209096|NCT01118013|recurrent grade 3 follicular lymphoma
1209097|NCT01118013|recurrent mantle cell lymphoma
1209098|NCT01118013|recurrent marginal zone lymphoma
1209099|NCT01118013|recurrent small lymphocytic lymphoma
1209100|NCT01118013|recurrent/refractory childhood Hodgkin lymphoma
1209101|NCT01118013|childhood diffuse large cell lymphoma
1209102|NCT01118013|childhood grade III lymphomatoid granulomatosis
1209103|NCT01118013|childhood immunoblastic large cell lymphoma
1209104|NCT01118013|childhood nasal type extranodal NK/T-cell lymphoma
1209105|NCT01118013|post-transplant lymphoproliferative disorder
1209106|NCT01118013|stage I multiple myeloma
1209107|NCT01118013|stage II multiple myeloma
1209108|NCT01118013|stage III multiple myeloma
1209109|NCT01118013|refractory multiple myeloma
1209110|NCT01118013|de novo myelodysplastic syndromes
1209111|NCT01118013|previously treated myelodysplastic syndromes
1209112|NCT01118013|secondary myelodysplastic syndromes
1209113|NCT01118013|childhood myelodysplastic syndromes
1209114|NCT01118013|recurrent childhood anaplastic large cell lymphoma
1209115|NCT01118013|adult acute myelomonocytic leukemia (M4)
1209116|NCT01118013|childhood acute myelomonocytic leukemia (M4)
1209117|NCT01118013|adult acute minimally differentiated myeloid leukemia (M0)
1209118|NCT01118013|childhood acute minimally differentiated myeloid leukemia (M0)
1209119|NCT01118013|adult acute myeloblastic leukemia without maturation (M1)
1209120|NCT01118013|childhood acute myeloblastic leukemia without maturation (M1)
1209121|NCT01118013|adult acute myeloblastic leukemia with maturation (M2)
1209122|NCT01118013|childhood acute myeloblastic leukemia with maturation (M2)
1209123|NCT01118013|adult acute promyelocytic leukemia (M3)
1209124|NCT01118013|childhood acute promyelocytic leukemia (M3)
1209125|NCT01118013|adult acute monoblastic leukemia (M5a)
1209126|NCT01118013|adult acute monocytic leukemia (M5b)
1209127|NCT01118013|childhood acute monoblastic leukemia (M5a)
1209128|NCT01118013|childhood acute monocytic leukemia (M5b)
1209129|NCT01118013|adult erythroleukemia (M6a)
1209130|NCT01118013|adult pure erythroid leukemia (M6b)
1209131|NCT01118013|childhood acute erythroleukemia (M6)
1209132|NCT01118013|adult acute megakaryoblastic leukemia (M7)
1209133|NCT01118013|childhood acute megakaryocytic leukemia (M7)
1209134|NCT01118013|childhood Burkitt lymphoma
1209135|NCT01118013|atypical chronic myeloid leukemia, BCR-ABL1 negative
1209136|NCT01118013|chronic myelomonocytic leukemia
1209137|NCT01118013|cutaneous B-cell non-Hodgkin lymphoma
1209138|NCT01118013|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1209139|NCT01118013|nodal marginal zone B-cell lymphoma
1209140|NCT01118013|splenic marginal zone lymphoma
1209141|NCT01118013|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1209142|NCT01118000|ischemic preconditioning,serum proteins,human
1209143|NCT01117987|Pulmonary arterial hypertension, imatinib, 6MWD, pulmonary hypertension
1209144|NCT01117961|Excessive gestational weight gain
1209145|NCT01117935|IMRT
1209146|NCT01117935|prostate cancer
1209147|NCT01117935|radiation therapy
1209148|NCT01117935|external beam
1209149|NCT01117935|recurrent prostate cancer
1209150|NCT01117922|preterm birth
1209151|NCT01117922|interconceptional intervention
1209152|NCT01117922|pregnancy outcomes
1209153|NCT01117909|ankle sprain
1209154|NCT01117909|athletic injury
1209155|NCT01117909|arthritis
1209156|NCT01117896|CPR
1209157|NCT01117896|Rescuer fatigue
1209158|NCT01117896|Chest Compression effectiveness
1209159|NCT01117883|Perfusion pressures
1209160|NCT01117883|central venous pressure
1209161|NCT01117883|cardiac output
1209162|NCT01117883|CPR
1209163|NCT01117883|cardiac arrest
1209164|NCT01117883|Leaning
1209165|NCT01117883|incomplete release
1209166|NCT01117870|chronic
1209167|NCT01117870|pain
1209168|NCT01117870|lumbar
1209169|NCT01117870|Radicular
1209170|NCT01117831|Diabetes mellitus
1209171|NCT01117805|Asthma
1209172|NCT01117779|kidney tumors
1209173|NCT01117779|renal tumors
1209174|NCT01117779|renal cell carcinoma
1209175|NCT01117779|kidney lesions
1209176|NCT01117779|renal lesions
1209177|NCT01117779|cryoablation
1209178|NCT01117779|cryotherapy
1209179|NCT01117779|cryosurgery
1209180|NCT01117766|Methodology
1209181|NCT01117766|Quantitative Sensory Testing
1209182|NCT01117766|Neuropathies Pain
1209183|NCT01117766|Pregabalin
1209184|NCT01117740|Malignant Pleural Effusions
1209185|NCT01117740|MPE
1209186|NCT01117740|Lungs
1209187|NCT01117740|Quality of Life
1209188|NCT01117740|M. D. Anderson Symptom Inventory
1209189|NCT01117740|MDASI
1209190|NCT01117740|Indwelling Pleural Catheters
1209191|NCT01117740|Thoracoscopic Pleurodesis
1209192|NCT01117740|Symptom burden
1209193|NCT01117740|Pleurodesis efficacy
1209194|NCT01117740|Complications
1209195|NCT01117740|Health care resource utilization
1209196|NCT01117714|Lung cancer
1209197|NCT01117714|Lung neoplasm
1209198|NCT01117714|Pulmonary cancer
1209199|NCT01117714|Pulmonary neoplasm
1209200|NCT01117714|Lung cancer staging
1209201|NCT01117688|Ureteroscopy
1209202|NCT01117675|Telemedicine
1209203|NCT01117675|Home care
1209204|NCT01117675|Chronic HIV infection
1209205|NCT01117675|HIV-infected patients
1209206|NCT01117662|transplantation
1209207|NCT01117662|acute rejection
1209208|NCT01117662|kidney
1209209|NCT01117649|PVR
1209210|NCT01117649|HES 130
1209211|NCT01117649|pancreatic head
1209212|NCT01117649|goal-directed
1209213|NCT01117649|intraoperative PVR in elective surgery of the pancreatic head
1209214|NCT01117636|Aspirin
1209215|NCT01117623|Oncology patients with advanced disease
1209216|NCT01117623|BAY73-4506
1209217|NCT01117610|pain
1209218|NCT01117610|preemptive
1209219|NCT01117610|postoperative
1209220|NCT01117610|epidural injection
1209221|NCT01117610|laminectomy
1209222|NCT01117597|Healthy subjects
1209223|NCT01117584|Type 2 diabetes
1209224|NCT01117584|diabetes
1209225|NCT01117584|ASP1941
1209226|NCT01117584|metformin
1209227|NCT01117571|knee
1209228|NCT01117571|osteoarthritis
1209229|NCT01117571|unicompartmental
1209230|NCT01117571|arthroplasty
1209231|NCT01117558|PCOS,
1209232|NCT01117558|DM,
1209233|NCT01117558|Hypertension,
1209234|NCT01117558|CVD
1209235|NCT01117545|veterans,
1209236|NCT01117545|PTSD,
1209237|NCT01117545|EFT (Emotional Freedom Techniques),
1209238|NCT01117545|depression,
1209239|NCT01117545|anxiety
1209240|NCT01117532|students,
1209241|NCT01117532|depression,
1209242|NCT01117532|group therapy,
1209243|NCT01117532|EFT (Emotional Freedom Techniques),
1209244|NCT01117532|energy psychology
1209245|NCT01117519|fluid and volume management
1209246|NCT01117519|acid-base balance
1209247|NCT01117519|goal-directed therapy
1209248|NCT01117519|transoesophageal doppler
1209249|NCT01117506|Angina
1209250|NCT01117506|Myocardial Ischemia
1209251|NCT01117506|Molecular Genetics
1209252|NCT01117506|Atherosclerosis
1209253|NCT01117480|Moderate Rheumatoid Arthritis
1209254|NCT01117480|Rheumatoid Arthritis
1209255|NCT01117480|Severe Rheumatoid Arthritis
1209256|NCT01117480|Adalimumab
1209257|NCT01117480|Clinical Effectiveness
1209258|NCT01117467|Simulation
1209259|NCT01117467|Learning
1209260|NCT01117467|Medical Students
1209261|NCT01117467|Empathy
1209262|NCT01117467|Anxiety
1209263|NCT01117454|Catecholaminergic Polymorphic Ventricular Tachycardia
1209264|NCT01117454|implantable cardioverter-defibrillator
1209265|NCT01117454|flecainide
1209266|NCT01117428|Advanced solid tumors
1209267|NCT01117428|Metastatic colorectal Cancer
1209268|NCT01117415|Gall Bladder
1209269|NCT01117415|Cholecystectomy
1209270|NCT01117402|recurrent carcinoma cervix
1209271|NCT01117402|Vault carcinoma
1209272|NCT01117402|Tomotherapy
1209273|NCT01117402|Brachytherapy
1209274|NCT01117389|Human Papillomavirus Vaccination
1209275|NCT01117389|Childhood cancer survivors
1209276|NCT01117389|cervical cancer
1209277|NCT01117389|sexually transmitted infection
1209278|NCT01117376|Gastroparesis
1209279|NCT01117376|Erythromycin
1209280|NCT01117376|Methylnaltrexone
1209281|NCT01117376|ICU
1209282|NCT01117363|Appetite whole grain
1209408|NCT01116856|Lipidic profile
1209283|NCT01117337|Hernia, laparoscopic, recurrence, pain, inguinal
1209284|NCT01117324|Bone density
1209285|NCT01117324|infant of diabetic mother
1209286|NCT01117324|large birth weight
1209287|NCT01117311|Vagus
1209288|NCT01117311|Diabetes
1209289|NCT01117311|Obesity
1209290|NCT01117298|Raynaud's phenomenon
1209291|NCT01117298|ischemic ulcers
1209292|NCT01117298|digital ulcers
1209293|NCT01117298|digital infarcts
1209294|NCT01117298|gangrene
1209295|NCT01117298|vasodilators
1209296|NCT01117298|endothelial dysfunction
1209297|NCT01117298|scleroderma
1209298|NCT01117285|Occupational Therapy
1209299|NCT01117285|Evidence-Based Practice
1209300|NCT01117285|Continuing Education
1209301|NCT01117285|utilization
1209302|NCT01117285|Guideline
1209303|NCT01117285|Dementia
1209304|NCT01117285|Guideline implementation
1209305|NCT01117181|Alzheimer's disease
1209306|NCT01117181|Apathy
1209307|NCT01117181|Methylphenidate
1209308|NCT01117181|Dopaminergic agents
1209309|NCT01117181|Apathy Evaluation Scale
1209310|NCT01117181|Dementia
1209311|NCT01117168|Children's Oncology Group
1209312|NCT01117168|Pediatric Oncology
1209313|NCT01117168|Pediatric Cancer
1209314|NCT01117168|Registration
1209315|NCT01117168|Leukemia
1209316|NCT01117168|Brain Tumor
1209317|NCT01117168|Sarcoma
1209318|NCT01117155|Brain Tumor
1209319|NCT01117155|Imaging
1209320|NCT01117155|FLT
1209321|NCT01117155|FDG
1209322|NCT01117155|Spectroscopy
1209323|NCT01117155|Glioma
1209324|NCT01117155|Glioblastoma Multiforme
1209325|NCT01117155|Astrocytoma
1209326|NCT01117142|CLL
1209327|NCT01117142|MBL
1209328|NCT01117142|SLL
1209329|NCT01117142|MCL
1209330|NCT01117142|Growth
1209331|NCT01117142|Development
1209332|NCT01117142|Aging
1209333|NCT01117142|Chronic Lymphocytic Leukemia
1209334|NCT01117142|Monoclonal B-Cell Lymphocytosis
1209335|NCT01117142|Small Lymphocytic Lymphoma
1209336|NCT01117142|Mantle Cell Lymphoma
1209337|NCT01117142|Healthy Volunteer
1209338|NCT01117142|HV
1209339|NCT01117103|Type 2 diabetes
1209340|NCT01117103|Diabetes Mellitus
1209341|NCT01117103|Glucophage
1209342|NCT01117103|Metformin
1209343|NCT01117090|Feasibility
1209344|NCT01117090|SynchroMed II
1209345|NCT01117090|Intrathecal catheter
1209346|NCT01117090|Baclofen
1209347|NCT01117077|liver transplantation
1209348|NCT01117077|aspergillus infection
1209349|NCT01117077|interleukin-17
1209350|NCT01117077|Treg cell
1209351|NCT01117077|immune tolerance
1209352|NCT01117064|Sleep Apnea
1209353|NCT01117064|OSA
1209354|NCT01117064|CPAP
1209355|NCT01117051|Opioid induced constipation/prucalopride chronic non-cancer pain
1209356|NCT01117051|Subjects with chronic non-cancer pain suffering from OIC
1209357|NCT01117038|ED
1209358|NCT01117038|Erectile Dysfunction
1209359|NCT01117025|Resistant hypertension
1209360|NCT01117025|Atrial Fibrillation
1209361|NCT01117025|Percutaneous renal denervation
1209362|NCT01116986|Smoking
1209363|NCT01116986|Smoking Cessation
1209364|NCT01116986|Nicotine
1209365|NCT01116973|CVP monitoring compared with peripheral monitoring
1209366|NCT01116960|P4P
1209367|NCT01116947|Hypoalbuminemia
1209368|NCT01116947|Hyperphosphatemia
1209369|NCT01116947|Phosphorus
1209370|NCT01116947|Protein
1209371|NCT01116947|CKD
1209372|NCT01116947|Dialysis
1209373|NCT01116947|Meals
1209374|NCT01116947|Lanthanum
1209375|NCT01116947|End-Stage Renal Disease (ESRD)
1209376|NCT01116947|Dietary Protein Intake (DPI)
1209377|NCT01116947|Dietary Phosphorus Binding (DPB)
1209378|NCT01116947|Protein-Energy Wasting (PEW)
1209379|NCT01116947|Sources of Dietary Phosphorus
1209380|NCT01116934|blood culture, IL-1β, IL-6, IL-8, IP-10, interferon-gamma
1209381|NCT01116921|laryngeal mask airway
1209382|NCT01116921|surfactant
1209383|NCT01116921|respiratory distress syndrome
1209384|NCT01116921|neonate
1209385|NCT01116908|Diarrhea
1209386|NCT01116908|Water
1209387|NCT01116908|Household Water Treatment
1209388|NCT01116908|HIV
1209389|NCT01116908|Infant Health
1209390|NCT01116895|Psoriasis Vulgaris
1209391|NCT01116895|Systemic
1209392|NCT01116895|Anti-psoriatic
1209393|NCT01116882|PCI
1209394|NCT01116882|heart disease
1209395|NCT01116882|ischemic heart disease
1209396|NCT01116869|MBC
1209397|NCT01116869|Healthy
1209398|NCT01116869|Benign disease
1209399|NCT01116869|Confirmed metastatic breast cancer patient with at least one measurable solid tumor according to the RECIST guideline
1209400|NCT01116869|Medical examinations detect no breast benign and malignant tumors
1209401|NCT01116869|Benign Breast Disease
1209402|NCT01116869|Pathology diagnosed breast benign tumor disease
1209403|NCT01116856|Exercise
1209404|NCT01116856|Training
1209405|NCT01116856|Obesity
1209406|NCT01116856|Overweight
1209407|NCT01116856|Body composition
1209409|NCT01116856|Nutrition
1209410|NCT01116856|Polymorphisms
1209411|NCT01116843|Oral cavity cancer
1209412|NCT01116843|No prior treatment
1209413|NCT01116817|Long-term Lopinavir/ritonavir monotherapy
1209414|NCT01116817|neurocognitive performance
1209415|NCT01116817|ultrasensitive CSF-viraemia
1209416|NCT01116804|Primary liver cancer
1209417|NCT01116791|cytoreductive surgery
1209418|NCT01116791|peritoneal chemotherapy
1209419|NCT01116791|cisplatin
1209420|NCT01116791|cancer
1209421|NCT01116791|gastric
1209422|NCT01116791|biliary
1209423|NCT01116791|pancreas
1209424|NCT01116791|peritoneal metastases
1209425|NCT01116791|liver metastases
1209426|NCT01116791|peritoneal carcinomatosis from upper gastrointestinal cancer
1209427|NCT01116778|perennial allergic rhinitis
1209428|NCT01116778|probiotics
1209429|NCT01116778|Lactobacillus paracasei GMNL-32 (eN-Lac®)
1209430|NCT01116778|efficacy and safety
1209431|NCT01116765|preterm infants born between 26 to 29 weeks of gestation age.
1209432|NCT01116752|Intensive Care
1209433|NCT01116752|Critical care
1209434|NCT01116752|Glycemic Control
1209435|NCT01116752|Hypoglycemia
1209436|NCT01116752|Hyperglycemia
1209437|NCT01116752|Insulin treatment
1209438|NCT01116752|Organ Function
1209439|NCT01116752|PELOD
1209440|NCT01116752|Outcomes
1209441|NCT01116752|Pediatrics
1209442|NCT01116713|Mastectomy
1209443|NCT01116713|Breast cancer
1209444|NCT01116713|Postoperative pain
1209445|NCT01116713|Postoperative nausea and vomiting
1209446|NCT01116700|Epilepsy
1209447|NCT01116700|Dexmedetomidine
1209448|NCT01116700|Seizure
1209449|NCT01116674|Intensive critical care, glycemic control, hypoglycemia, hyperglycemia , insulin treatment, intensive care outcomes, pediatrics
1209450|NCT01116661|glioma
1209451|NCT01116661|high grade glioma, low grade glioma
1209452|NCT01116635|chemoembolization
1209453|NCT01116635|drug eluting microsphere
1209454|NCT01116635|hepato
1209455|NCT01116635|embolotherapy
1209456|NCT01116635|downstage
1209457|NCT01116622|Aerodigestive
1209458|NCT01116622|Targretin
1209459|NCT01116622|Tarceva
1209460|NCT01116609|Phenylalanine
1209461|NCT01116609|Palmitate
1209462|NCT01116609|hyperinsulinemic-euglycemic-clamp
1209463|NCT01116609|Effects of epinephrine in healthy volunteers
1209464|NCT01116596|Glutathione
1209465|NCT01116596|Paracetamol
1209466|NCT01116596|elderly people
1209467|NCT01116583|Gabapentin
1209468|NCT01116583|Thoracotomy
1209469|NCT01116583|Pain, Postoperative
1209470|NCT01116583|Analgesia
1209471|NCT01116583|Recovery of Function
1209472|NCT01116583|Quality of Life
1209473|NCT01116570|Muscular Dystrophy
1209474|NCT01116570|Facioscapulohumeral
1209475|NCT01116570|Physical training
1209476|NCT01116570|Exercise
1209477|NCT01116557|radiofrequency
1209478|NCT01116557|ablation
1209479|NCT01116557|atrial fibrillation
1209480|NCT01116557|CARTO
1209481|NCT01116557|THERMOCOOL
1209482|NCT01116557|LASSO
1209483|NCT01116557|PVAC
1209484|NCT01116544|AMES device
1209485|NCT01116544|Cerebrovascular Accident
1209486|NCT01116544|Chronic Stroke
1209487|NCT01116544|Rehabilitation
1209488|NCT01116544|Upper Extremity
1209489|NCT01116544|Biofeedback
1209490|NCT01116531|Pharmacokinetics
1209491|NCT01116531|Pharmacodynamics
1209492|NCT01116531|Interaction
1209493|NCT01116531|tramadol
1209494|NCT01116531|duloxetine
1209495|NCT01116531|pregabalin
1209496|NCT01116505|Celiac disease
1209497|NCT01116505|Endomysial antibodies
1209498|NCT01116505|Gluten-free diet
1209499|NCT01116505|Screen-detected
1209500|NCT01116505|Asymptomatic
1209501|NCT01116505|Bone mineral density
1209502|NCT01116492|SILS
1209503|NCT01116492|Inflammatory reaction
1209504|NCT01116492|a-defensins
1209505|NCT01116492|SILS vs standard laparoscopic cholecystectomy
1209506|NCT01116479|Anaemia, transfusion, cancer, chemotherapy, Quality of life
1209507|NCT01116453|dysmenorrhea
1209508|NCT01116453|acupuncture
1209509|NCT01116453|randomized controlled trial
1209510|NCT01116440|Menstrual pain
1209511|NCT01116440|Refractory endometriosis
1209512|NCT01116440|Pelvic pain
1209513|NCT01116427|MS
1209514|NCT01116427|multiple sclerosis
1209515|NCT01116427|relapsing-remitting multiple sclerosis
1209516|NCT01116427|RRMS
1209517|NCT01116401|Hot Flashes
1209518|NCT01116401|Sleep disturbance
1209519|NCT01116401|Lupron
1209520|NCT01116401|Menopause
1209521|NCT01116388|Autism
1209522|NCT01116388|Gastrointestinal Disorders
1209523|NCT01116388|Food Allergy
1209524|NCT01116388|Gluten free, casein free diet
1209525|NCT01116388|Diarrhea
1209526|NCT01116388|Constipation
1209527|NCT01116388|Reflux
1209528|NCT01116388|Abdominal pain
1209529|NCT01116388|Pain after eating
1209530|NCT01116388|Self injurious behavior
1209531|NCT01116375|Obesity
1209532|NCT01116375|OSA
1209533|NCT01116375|PAP therapy
1209534|NCT01116362|ulna
1209535|NCT01116362|median
1209536|NCT01116362|repair
1209537|NCT01116362|primary
1209538|NCT01116349|humeral diaphysis fracture
1209539|NCT01116349|plate and screws for humeral diaphysis fracture
1209540|NCT01116349|nailing for humerus diaphysis fracture
1209541|NCT01116349|Hanging Support System
1209542|NCT01116336|Pre-cancerous conditions
1209543|NCT01116336|Head and neck tumors
1209544|NCT01116336|Cancer of head and neck
1209545|NCT01116323|Adverse events
1209546|NCT01116323|Adverse effects
1209547|NCT01116323|Emergency Service, Hospital
1209548|NCT01116323|Emergency department
1209549|NCT01116323|Crowding
1209550|NCT01116310|Hot flushes
1209551|NCT01116310|Hot flashes
1209552|NCT01116310|menopause
1209553|NCT01116310|postmenopause
1209554|NCT01116310|Soy isoflavones
1209555|NCT01116310|Red clover
1209556|NCT01116310|Equol
1209557|NCT01116297|breast reconstruction
1209558|NCT01116297|breast cancer
1209559|NCT01116297|near infrared imaging
1209560|NCT01116284|Weight Loss
1209561|NCT01116284|Obesity
1209562|NCT01116284|Gastric Bypass
1209563|NCT01116271|colorectal
1209564|NCT01116271|second line therapy
1209565|NCT01116271|K-ras or B-raf mutations
1209566|NCT01116271|response rate
1209567|NCT01116271|Progression Free Survival
1209568|NCT01116258|Safety
1209569|NCT01116245|Cervical Intraepithelial Neoplasia Stage 2/3
1209570|NCT01116232|graft versus host disease
1209571|NCT01116232|accelerated phase chronic myelogenous leukemia
1209572|NCT01116232|adult acute lymphoblastic leukemia in remission
1209573|NCT01116232|adult acute myeloid leukemia in remission
1209574|NCT01116232|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1209575|NCT01116232|adult acute myeloid leukemia with inv(16)(p13;q22)
1209576|NCT01116232|adult acute myeloid leukemia with t(15;17)(q22;q12)
1209577|NCT01116232|adult acute myeloid leukemia with t(16;16)(p13;q22)
1209578|NCT01116232|adult acute myeloid leukemia with t(8;21)(q22;q22)
1209579|NCT01116232|atypical chronic myeloid leukemia, BCR-ABL negative
1209580|NCT01116232|blastic phase chronic myelogenous leukemia
1209581|NCT01116232|chronic myelomonocytic leukemia
1209582|NCT01116232|chronic phase chronic myelogenous leukemia
1209583|NCT01116232|meningeal chronic myelogenous leukemia
1209584|NCT01116232|progressive hairy cell leukemia, initial treatment
1209585|NCT01116232|prolymphocytic leukemia
1209586|NCT01116232|recurrent adult acute lymphoblastic leukemia
1209587|NCT01116232|recurrent adult acute myeloid leukemia
1209588|NCT01116232|recurrent adult T-cell leukemia/lymphoma
1209589|NCT01116232|refractory chronic lymphocytic leukemia
1209590|NCT01116232|refractory hairy cell leukemia
1209591|NCT01116232|relapsing chronic myelogenous leukemia
1209592|NCT01116232|stage I adult T-cell leukemia/lymphoma
1209593|NCT01116232|stage I chronic lymphocytic leukemia
1209594|NCT01116232|stage II adult T-cell leukemia/lymphoma
1209595|NCT01116232|stage II chronic lymphocytic leukemia
1209596|NCT01116232|stage III adult T-cell leukemia/lymphoma
1209597|NCT01116232|stage III chronic lymphocytic leukemia
1209598|NCT01116232|stage IV adult T-cell leukemia/lymphoma
1209599|NCT01116232|stage IV chronic lymphocytic leukemia
1209600|NCT01116232|T-cell large granular lymphocyte leukemia
1209601|NCT01116232|untreated adult acute lymphoblastic leukemia
1209602|NCT01116232|untreated adult acute myeloid leukemia
1209603|NCT01116232|untreated hairy cell leukemia
1209604|NCT01116232|recurrent adult Hodgkin lymphoma
1209605|NCT01116232|stage I adult Hodgkin lymphoma
1209606|NCT01116232|stage II adult Hodgkin lymphoma
1209607|NCT01116232|stage III adult Hodgkin lymphoma
1209608|NCT01116232|stage IV adult Hodgkin lymphoma
1209609|NCT01116232|anaplastic large cell lymphoma
1209610|NCT01116232|angioimmunoblastic T-cell lymphoma
1209611|NCT01116232|cutaneous B-cell non-Hodgkin lymphoma
1209612|NCT01116232|recurrent cutaneous T-cell non-Hodgkin lymphoma
1209613|NCT01116232|stage I cutaneous T-cell non-Hodgkin lymphoma
1209614|NCT01116232|stage II cutaneous T-cell non-Hodgkin lymphoma
1209615|NCT01116232|stage III cutaneous T-cell non-Hodgkin lymphoma
1209616|NCT01116232|stage IV cutaneous T-cell non-Hodgkin lymphoma
1209617|NCT01116232|recurrent mycosis fungoides/Sezary syndrome
1209618|NCT01116232|stage I mycosis fungoides/Sezary syndrome
1209619|NCT01116232|stage II mycosis fungoides/Sezary syndrome
1209620|NCT01116232|stage III mycosis fungoides/Sezary syndrome
1209621|NCT01116232|stage IV mycosis fungoides/Sezary syndrome
1209622|NCT01116232|adult grade III lymphomatoid granulomatosis
1209623|NCT01116232|adult nasal type extranodal NK/T-cell lymphoma
1209624|NCT01116232|Waldenstrom macroglobulinemia
1209625|NCT01116232|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1209626|NCT01116232|nodal marginal zone B-cell lymphoma
1209627|NCT01116232|splenic marginal zone lymphoma
1209628|NCT01116232|contiguous stage II adult Burkitt lymphoma
1209629|NCT01116232|contiguous stage II adult diffuse large cell lymphoma
1209630|NCT01116232|contiguous stage II adult diffuse mixed cell lymphoma
1209631|NCT01116232|contiguous stage II adult diffuse small cleaved cell lymphoma
1209632|NCT01116232|contiguous stage II adult immunoblastic large cell lymphoma
1209633|NCT01116232|contiguous stage II adult lymphoblastic lymphoma
1209634|NCT01116232|contiguous stage II grade 1 follicular lymphoma
1209635|NCT01116232|contiguous stage II grade 2 follicular lymphoma
1209636|NCT01116232|contiguous stage II grade 3 follicular lymphoma
1209637|NCT01116232|contiguous stage II mantle cell lymphoma
1209638|NCT01116232|contiguous stage II marginal zone lymphoma
1209639|NCT01116232|contiguous stage II small lymphocytic lymphoma
1209640|NCT01116232|stage I adult Burkitt lymphoma
1209641|NCT01116232|stage I adult diffuse large cell lymphoma
1209642|NCT01116232|stage I adult diffuse mixed cell lymphoma
1209643|NCT01116232|stage I adult diffuse small cleaved cell lymphoma
1209644|NCT01116232|stage I adult immunoblastic large cell lymphoma
1209645|NCT01116232|stage I adult lymphoblastic lymphoma
1209646|NCT01116232|stage I grade 1 follicular lymphoma
1209647|NCT01116232|stage I grade 2 follicular lymphoma
1209648|NCT01116232|stage I grade 3 follicular lymphoma
1209649|NCT01116232|stage I mantle cell lymphoma
1209650|NCT01116232|stage I marginal zone lymphoma
1209651|NCT01116232|stage I small lymphocytic lymphoma
1209652|NCT01116232|noncontiguous stage II adult Burkitt lymphoma
1209653|NCT01116232|noncontiguous stage II adult diffuse large cell lymphoma
1209654|NCT01116232|noncontiguous stage II adult diffuse mixed cell lymphoma
1209655|NCT01116232|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1209656|NCT01116232|noncontiguous stage II adult immunoblastic large cell lymphoma
1209657|NCT01116232|noncontiguous stage II adult lymphoblastic lymphoma
1209658|NCT01116232|noncontiguous stage II grade 1 follicular lymphoma
1209659|NCT01116232|noncontiguous stage II grade 2 follicular lymphoma
1209660|NCT01116232|noncontiguous stage II grade 3 follicular lymphoma
1209661|NCT01116232|noncontiguous stage II mantle cell lymphoma
1209662|NCT01116232|noncontiguous stage II marginal zone lymphoma
1209663|NCT01116232|noncontiguous stage II small lymphocytic lymphoma
1209664|NCT01116232|stage III adult Burkitt lymphoma
1209665|NCT01116232|stage III adult diffuse large cell lymphoma
1209666|NCT01116232|stage III adult diffuse mixed cell lymphoma
1209667|NCT01116232|stage III adult diffuse small cleaved cell lymphoma
1209668|NCT01116232|stage III adult immunoblastic large cell lymphoma
1209669|NCT01116232|stage III adult lymphoblastic lymphoma
1209670|NCT01116232|stage III grade 1 follicular lymphoma
1209671|NCT01116232|stage III grade 2 follicular lymphoma
1209672|NCT01116232|stage III grade 3 follicular lymphoma
1209673|NCT01116232|stage III mantle cell lymphoma
1209674|NCT01116232|stage III marginal zone lymphoma
1209675|NCT01116232|stage III small lymphocytic lymphoma
1209676|NCT01116232|stage IV adult Burkitt lymphoma
1209677|NCT01116232|stage IV adult diffuse large cell lymphoma
1209678|NCT01116232|stage IV adult diffuse mixed cell lymphoma
1209679|NCT01116232|stage IV adult diffuse small cleaved cell lymphoma
1209680|NCT01116232|stage IV adult immunoblastic large cell lymphoma
1209681|NCT01116232|stage IV adult lymphoblastic lymphoma
1209682|NCT01116232|stage IV grade 1 follicular lymphoma
1209683|NCT01116232|stage IV grade 2 follicular lymphoma
1209684|NCT01116232|stage IV grade 3 follicular lymphoma
1209685|NCT01116232|stage IV mantle cell lymphoma
1209686|NCT01116232|stage IV marginal zone lymphoma
1209687|NCT01116232|stage IV small lymphocytic lymphoma
1209688|NCT01116232|recurrent adult Burkitt lymphoma
1209689|NCT01116232|recurrent adult diffuse large cell lymphoma
1209690|NCT01116232|recurrent adult diffuse mixed cell lymphoma
1209691|NCT01116232|recurrent adult diffuse small cleaved cell lymphoma
1209692|NCT01116232|recurrent adult grade III lymphomatoid granulomatosis
1209693|NCT01116232|recurrent adult immunoblastic large cell lymphoma
1209694|NCT01116232|recurrent adult lymphoblastic lymphoma
1209695|NCT01116232|recurrent grade 1 follicular lymphoma
1209696|NCT01116232|recurrent grade 2 follicular lymphoma
1209697|NCT01116232|recurrent grade 3 follicular lymphoma
1209698|NCT01116232|recurrent mantle cell lymphoma
1209699|NCT01116232|recurrent marginal zone lymphoma
1209700|NCT01116232|recurrent small lymphocytic lymphoma
1209701|NCT01116232|intraocular lymphoma
1209702|NCT01116232|post-transplant lymphoproliferative disorder
1209703|NCT01116232|chronic eosinophilic leukemia
1209704|NCT01116232|chronic neutrophilic leukemia
1209705|NCT01116232|primary myelofibrosis
1209706|NCT01116232|stage I multiple myeloma
1209707|NCT01116232|stage II multiple myeloma
1209708|NCT01116232|stage III multiple myeloma
1209709|NCT01116232|refractory multiple myeloma
1209710|NCT01116232|de novo myelodysplastic syndromes
1209711|NCT01116232|previously treated myelodysplastic syndromes
1209712|NCT01116232|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1209713|NCT01116219|adenocarcinoma of the lung
1209714|NCT01116219|bronchoalveolar cell lung cancer
1209715|NCT01116219|large cell lung cancer
1209716|NCT01116219|stage IV non-small cell lung cancer
1209717|NCT01116219|recurrent non-small cell lung cancer
1209718|NCT01116206|Constipation
1209719|NCT01116206|Prucalopride
1209720|NCT01116206|Resolor
1209721|NCT01116193|antileukemic therapy
1209722|NCT01116193|lymphoblastic leukemia
1209723|NCT01116193|lenalidomide
1209724|NCT01116193|dexamethasone
1209725|NCT01116180|Type 1 diabetes
1209726|NCT01116180|Hypoglycaemia
1209727|NCT01116180|genetic susceptibility
1209728|NCT01116180|Renin angiotensin system activity
1209729|NCT01116167|Polycystic Ovary Syndrome
1209730|NCT01116141|rheumatoid arthritis
1209731|NCT01116141|MTX
1209732|NCT01116141|CH-405
1209733|NCT01116141|antifolates
1209734|NCT01116128|relapsed/refractory myeloma patients
1209735|NCT01116128|Progression free survival
1209736|NCT01116128|Overall survival
1209737|NCT01116128|dasatinib
1209738|NCT01116115|Term Infants
1209739|NCT01116115|Intestine flora
1209740|NCT01116115|Stool characteristics
1209741|NCT01116102|dehydration
1209742|NCT01116102|fluid therapy
1209743|NCT01116102|hyaluronoglucosaminidase
1209744|NCT01116102|hyaluronidase
1209745|NCT01116102|hypodermoclysis
1209746|NCT01116102|clysis
1209747|NCT01116102|subcutaneous hydration
1209748|NCT01116102|subcutaneous rehydration
1209749|NCT01116102|hyaluronan
1209750|NCT01116102|rHuPH20
1209751|NCT01116089|Cystic fibrosis, tobramycin,nebulizer, PK
1209752|NCT01116063|COPD, Pulmonary hypertension
1209753|NCT01116037|Diseased Heart Valve, Replacement, Aortic, Stentless
1209754|NCT01116024|Diseased Heart Valve, Replacement, Aortic
1209755|NCT01116011|Phase I
1209756|NCT01116011|Japanese Healthy volunteer
1209757|NCT01115998|cerebral palsy
1209758|NCT01115998|wheelchair
1209759|NCT01115998|disabled children
1209760|NCT01115985|ASP1585
1209761|NCT01115985|Drug-drug interaction
1209762|NCT01115985|Atorvastatin
1209763|NCT01115985|Healthy volunteer
1209764|NCT01115972|ASP1585
1209765|NCT01115972|Drug-drug interaction
1209766|NCT01115972|valsartan
1209767|NCT01115972|Healthy volunteer
1209768|NCT01115946|ASP1585
1209769|NCT01115946|Drug-drug interaction
1209770|NCT01115946|enalapril
1209771|NCT01115946|Healthy volunteer
1209772|NCT01115933|drug eluting stents
1209773|NCT01115933|small vessel
1209774|NCT01115933|Stents
1209775|NCT01115933|Everolimus
1209776|NCT01115933|Angioplasty
1209777|NCT01115920|Drug Safety
1209778|NCT01115920|Clinical Trial, Phase I
1209779|NCT01115920|Nontherapeutic Human Experimentation
1209780|NCT01115920|Heading Pharmacokinetics
1209781|NCT01115920|Phase I Safety and Tolerability
1209782|NCT01115907|Aortic
1209783|NCT01115907|Valve replacement
1209784|NCT01115894|problem drinking
1209785|NCT01115894|alcohol
1209786|NCT01115881|To examine the relationship between signal strength and macular thickness measured by stratus OCT
1209787|NCT01115855|Double-blind
1209788|NCT01115855|eplerenone
1209789|NCT01115855|Japanese
1209790|NCT01115842|Vitamin D
1209791|NCT01115842|Acute coronary syndrome
1209792|NCT01115842|inflammatory cytokines
1209793|NCT01115803|Advanced Cancer
1209794|NCT01115803|Metastatic Cancer
1209795|NCT01115803|Non-Small Cell Lung Cancer
1209796|NCT01115803|Renal Cell Carcinoma
1209797|NCT01115803|Neuroendocrine Tumors
1209798|NCT01115777|Pediatric patients
1209799|NCT01115777|treated with
1209800|NCT01115777|radiation therapy
1209801|NCT01115777|for brain tumors
1209802|NCT01115777|and non-CNS malignancies
1209803|NCT01115764|diastolic dysfunction
1209804|NCT01115751|Advanced Cancer
1209805|NCT01115751|Metastatic Cancer
1209806|NCT01115751|Solid Tumors
1209807|NCT01115738|Plavix, Effient
1209808|NCT01115725|Follitropin alfa
1209809|NCT01115725|Fertilization in vitro
1209810|NCT01115725|Intracytoplasmic sperm injection
1209811|NCT01115725|Reproductive techniques, assisted
1209812|NCT01115712|Healthy Volunteers
1209813|NCT01115699|Depression
1209814|NCT01115699|rTMS
1209815|NCT01115660|stroke
1209816|NCT01115660|patient education
1209817|NCT01115660|medication adherence
1209818|NCT01115647|Malnutrition
1209819|NCT01115647|Nutritional intervention
1209820|NCT01115647|Behavioural intervention
1209821|NCT01115647|Burkina Faso
1209822|NCT01115647|Cluster randomize trial
1209823|NCT01115634|Fibroblast
1209824|NCT01115634|Cell transplantation
1209825|NCT01115634|Facial deformities
1209826|NCT01115608|Preventive Health Services
1209827|NCT01115595|Allergic rhinitis
1209828|NCT01115595|Allergen injection immunotherapy
1209829|NCT01115595|Efficacy
1209830|NCT01115582|Inborn Errors
1209831|NCT01115582|Bile Acid
1209832|NCT01115582|Pediatrics
1209833|NCT01115582|Liver Disease
1209834|NCT01115569|chronic pain
1209835|NCT01115504|Thiamine
1209836|NCT01115504|heart failure
1209837|NCT01115478|Malaria
1209838|NCT01115478|Low birth weight
1209839|NCT01115478|Anemia
1209840|NCT01115478|Perinatal mortality
1209841|NCT01115478|Vitamin A
1209842|NCT01115478|Zinc
1209843|NCT01115465|Stress Urinary Incontinence
1209844|NCT01115465|silicone elastomer
1209845|NCT01115452|potassium nitrate
1209846|NCT01115452|tooth sensitivity
1209847|NCT01115452|dentin sensitivity
1209848|NCT01115439|falciparum malaria
1209849|NCT01115439|artemisinin combination treatments
1209850|NCT01115413|teenage
1209851|NCT01115413|pregnancy
1209852|NCT01115413|obstetrical risk
1209853|NCT01115400|Abdominal Wall Hernia
1209854|NCT01115400|quality of life
1209855|NCT01115387|Age-related macular degeneration
1209856|NCT01115387|AMD
1209857|NCT01115387|Genetic risk
1209858|NCT01115387|Environmental risk factors
1209859|NCT01115387|Complex genetic disorder
1209860|NCT01115387|Age-related maculopathy
1209861|NCT01115387|Risk modeling
1209862|NCT01115387|Smoking
1209863|NCT01115387|Light exposure
1209864|NCT01115387|Sleep apnea
1209865|NCT01115387|Fundus Photography
1209866|NCT01115387|Macula
1209867|NCT01115387|Drusen
1209868|NCT01115387|Wet AMD
1209869|NCT01115387|Dry AMD
1209870|NCT01115387|Geographic atrophy
1209871|NCT01115387|Vitamins & supplements
1209872|NCT01115361|family planning
1209873|NCT01115361|postpartum
1209874|NCT01115361|immunization
1209875|NCT01115361|integration
1209876|NCT01115361|Contraceptive behavior
1209877|NCT01115335|neonatal male circumcision
1209878|NCT01115335|Gomco
1209879|NCT01115335|Plastibell
1209880|NCT01115335|Mogen
1209881|NCT01115335|Safety
1209882|NCT01115335|Uptake
1209883|NCT01115335|Acceptability
1209884|NCT01115335|Feasibility
1209885|NCT01115335|Zambia
1209888|NCT01115309|Sinusitis
1209889|NCT01115296|Helicobacter Pylori
1209890|NCT01115296|gastritis
1209891|NCT01115296|Probiotics
1209892|NCT01115296|Lactobacillus Reuteri
1209893|NCT01115283|amblyopia treatment
1209894|NCT01115283|neural plasticity
1209895|NCT01115283|perceptual learning
1209896|NCT01115283|vision therapy
1209897|NCT01115283|spatial vision
1209898|NCT01115283|video games
1209899|NCT01115283|occlusion therapy
1209900|NCT01115270|Normal Pressure Hydrocephalus
1209901|NCT01115257|severe proliferative diabetic retinopathy
1209902|NCT01115257|vitrectomy
1209903|NCT01115257|panretinalphotocoagulation
1209904|NCT01115244|Dermatitis herpetiformis
1209905|NCT01115244|Dapsone
1209906|NCT01115231|Age-Related Macular Degeneration
1209907|NCT01115231|Age-Related Maculopathies
1209908|NCT01115231|Age-Related Maculopathy
1209909|NCT01115231|Macular Dystrophy
1209910|NCT01115231|Maculopathies, Age-Related
1209911|NCT01115231|Maculopathy, Age-Related
1209912|NCT01115218|Glaucoma
1209913|NCT01115205|Exercise, Walking, Type 2 diabetes, Therapy
1209914|NCT01115179|propofol
1209915|NCT01115179|inflammation
1209916|NCT01115179|perioperative
1209917|NCT01115179|lipids
1209918|NCT01115179|Apolipoprotein A-I
1209919|NCT01115166|blood volume
1209920|NCT01115153|Acute appendicitis
1209921|NCT01115153|Antibiotic prophylaxis
1209922|NCT01115153|Wound infection
1209923|NCT01115153|Nosocomial infection
1209924|NCT01115140|Folate
1209925|NCT01115140|Metformin
1209926|NCT01115140|PCOS
1209927|NCT01115140|Pregnancy
1209928|NCT01115140|Trophoblastic invasion
1209929|NCT01115140|Uterine artery velocimetry
1209930|NCT01115127|pre-menopause
1209931|NCT01115127|melatonin
1209932|NCT01115127|myo-inositol
1209933|NCT01115101|pain after cesarean
1209934|NCT01115101|visual analog scale
1209935|NCT01115101|oxycodon
1209936|NCT01115101|piritramid
1209937|NCT01115075|Leptin
1209938|NCT01115075|Changes in leptin may precede the
1209939|NCT01115075|phasing of oscillations of dietary fat intake
1209940|NCT01115062|Pain
1209941|NCT01115062|Children
1209942|NCT01115062|Local anesthetics
1209943|NCT01115036|glioblastoma
1209944|NCT01115036|recurrent
1209945|NCT01115036|surgical resection
1209946|NCT01115023|iron deficiency anemia
1209947|NCT01115023|dietary intervention
1209948|NCT01115023|To evaluate a cheap and sustainable dietary intervention to improve the iron status of the entire family of the index case of non-severe iron deficiency anemia.
1209949|NCT01115010|intubation rate
1209950|NCT01115010|intubation time
1209951|NCT01115010|stiffening device
1209952|NCT01115010|stiffening wire
1209953|NCT01114997|Lidocaine Infusion
1209954|NCT01114997|Esmolol Infusion
1209955|NCT01114997|Anesthetic adjuvant
1209956|NCT01114997|Abdominal surgery
1209957|NCT01114997|Pain management
1209958|NCT01114997|Hemodynamic stability
1209959|NCT01114997|Perioperative outcomes
1209960|NCT01114984|Pain management
1209961|NCT01114984|Radical mastectomy
1209962|NCT01114984|Breast surgery
1209963|NCT01114984|post-operative pain
1209964|NCT01114971|Labetalol
1209965|NCT01114971|Esmolol
1209966|NCT01114971|Fentanyl
1209967|NCT01114971|Anesthetic adjuvant
1209968|NCT01114971|Ambulatory surgery
1209969|NCT01114971|Outpatient surgery
1209970|NCT01114971|Pain management
1209971|NCT01114971|Hemodynamic stability
1209972|NCT01114971|Perioperative outcomes
1209973|NCT01114958|Lung cancer
1209974|NCT01114958|Non-small cell lung cancer
1209975|NCT01114958|Small-cell lung cancer
1209976|NCT01114958|Lung metastases
1209977|NCT01114958|Metastatic cancer
1209978|NCT01114958|Stage IIIA
1209979|NCT01114958|Stage IIIB
1209980|NCT01114958|Stage III
1209981|NCT01114958|Stage 3
1209982|NCT01114945|Direct Laryngoscopy
1209983|NCT01114945|Video-Mac
1209984|NCT01114945|GlideScope
1209985|NCT01114945|McGrath
1209986|NCT01114945|Laryngoscopy
1209987|NCT01114945|Bariatrics
1209988|NCT01114945|Glottic view
1209989|NCT01114945|Airway intubating devices
1209990|NCT01114945|Tracheal intubation
1209991|NCT01114932|pre-oxygenation
1209992|NCT01114932|body mass index
1209993|NCT01114932|end-tidal O2
1209994|NCT01114932|anesthesia induction
1209995|NCT01114919|Problem drinking
1209996|NCT01114919|Alcohol dependence
1209997|NCT01114919|Alcohol abuse
1209998|NCT01114919|Internet based intervention
1209999|NCT01114919|Treatment
1210000|NCT01114919|Alcohol Use Disorders Identification Test
1210001|NCT01114906|Asthma
1210002|NCT01114906|Resource use
1210003|NCT01114880|ankylosing spondylitis
1210004|NCT01114880|China
1210005|NCT01114867|ultrasound
1210006|NCT01114867|penis length
1210007|NCT01114867|corpus cavernosum
1210008|NCT01114867|length of fetal penis and fetal corpus cavernosum
1210009|NCT01114841|Healthy Volunteer Subjects
1210010|NCT01114828|Cirrhosis
1210011|NCT01114828|ascites
1210012|NCT01114828|Tolvaptan
1210013|NCT01114828|OPC-41061
1210014|NCT01114815|CADASIL
1210015|NCT01114815|cerebral
1210016|NCT01114815|autosomal dominant
1210017|NCT01114815|arteriopathy
1210018|NCT01114815|subcortical infarcts
1210019|NCT01114815|leukoencephalopathy
1210020|NCT01114802|Cancer survivors
1210021|NCT01114802|Anxiety
1210022|NCT01114802|Depression
1210023|NCT01114802|Technology Assisted
1210024|NCT01114802|Internet
1210025|NCT01114789|chronic renal failure
1210026|NCT01114789|hemodialysis
1210027|NCT01114789|obesity
1210028|NCT01114789|proteolysis
1210029|NCT01114763|Metabolic Syndrome
1210030|NCT01114763|Oxidized Low Density Lipoprotein
1210031|NCT01114763|Arterial Elasticity
1210032|NCT01114763|Diabetes Mellitus
1210033|NCT01114763|Cardiovascular Diseases
1210034|NCT01114750|blood glucose
1210035|NCT01114750|blood insulin
1210036|NCT01114750|dextran
1210037|NCT01114750|diabetes
1210038|NCT01114750|hyperglycemia
1210039|NCT01114750|hypoglycemia
1210040|NCT01114750|oral delivery
1210041|NCT01114750|portal delivery
1210042|NCT01114737|Phenylketonuria
1210043|NCT01114737|PKU
1210044|NCT01114737|Kuvan
1210045|NCT01114737|Sapropterin dihydrochloride
1210046|NCT01114737|Neuropsychiatric disorder
1210047|NCT01114737|ADHD
1210048|NCT01114724|Thoracic dissection
1210049|NCT01114724|Endovascular aortic repair
1210050|NCT01114711|Menstrual Migraine
1210051|NCT01114711|Frova
1210052|NCT01114711|Imaging
1210053|NCT01114711|fMRI
1210054|NCT01114711|Pain
1210055|NCT01114698|Depression
1210056|NCT01114698|Major Depressive Disorder
1210057|NCT01114698|Venlafaxine XR (EFFEXOR XR)
1210058|NCT01114698|26489112
1210059|NCT01114698|JNJ26489112
1210060|NCT01114672|Pruritis in hemodialysis patients
1210061|NCT01114672|25-Vitamin D in chronic kidney disease
1210062|NCT01114646|Hemiarthroplasty
1210063|NCT01114646|Cemented
1210064|NCT01114646|Press Fit
1210065|NCT01114646|Mortality
1210066|NCT01114646|Morbidity
1210067|NCT01114646|Functional Status
1210068|NCT01114646|Displaced femoral neck fracture
1210069|NCT01114633|PCOS
1210070|NCT01114633|Acne
1210071|NCT01114633|Hirsutism
1210072|NCT01114620|elderly
1210073|NCT01114620|post-marketing
1210074|NCT01114620|H1N1
1210075|NCT01114620|Clinical trial
1210076|NCT01114620|pandemic influenza
1210077|NCT01114607|relative bioavailability
1210078|NCT01114607|GSK1605786
1210079|NCT01114607|CCR9 receptor antagonist
1210080|NCT01114594|Chronic Kidney Disease (CKD)
1210081|NCT01114594|Autosomal Dominant Polycystic Kidney Disease (ADPKD)
1210082|NCT01114581|Acute Respiratory Infection
1210083|NCT01114581|Mucociliary
1210084|NCT01114581|Cough Clearance
1210085|NCT01114581|Guaifenesin
1210086|NCT01114568|Relative Bioavailability
1210087|NCT01114568|Pharmacokinetics
1210088|NCT01114568|Pharmacodynamics
1210089|NCT01114555|Bevacizumab
1210090|NCT01114555|Irinotecan
1210091|NCT01114555|Temozolomide
1210092|NCT01114555|10-015
1210093|NCT01114529|de novo renal allograft recipients
1210094|NCT01114529|renal allograft function
1210095|NCT01114529|CNI-free regimen
1210096|NCT01114516|cervical insufficiency
1210097|NCT01114503|GSK2136525
1210098|NCT01114503|Pharmacodynamics
1210099|NCT01114503|Safety
1210100|NCT01114503|Otelixizumab
1210101|NCT01114503|Thyroid eye disease
1210102|NCT01114503|Graves' ophthalmopathy
1210103|NCT01114503|Repeat dose
1210104|NCT01114503|Intravenous infusion
1210105|NCT01114503|Tolerability
1210106|NCT01114503|EUGOGO
1210107|NCT01114490|Hepatic Insufficiency
1210108|NCT01114477|Transcranial magnetic stimulation
1210109|NCT01114477|TMS
1210110|NCT01114477|Observational study
1210111|NCT01114477|Major Depression
1210112|NCT01114464|Breast cancer
1210113|NCT01114464|Ovarian reserve
1210114|NCT01114464|Anti-Mullerian Hormone (AMH)
1210115|NCT01114464|Chemotherapy
1210116|NCT01114451|Cesarean delivery
1210117|NCT01114451|Obesity
1210118|NCT01114451|Skin staples
1210119|NCT01114451|Wound complications
1210120|NCT01114425|tolerability of post exposure to HIV infection prophylaxis
1210121|NCT01114412|focus groups
1210122|NCT01114412|overactive bladder
1210123|NCT01114412|bladder sensations
1210124|NCT01114399|Cardiovascular Disease
1210125|NCT01114399|Cardiovascular Disease risk (mild to moderate)
1210126|NCT01114399|Cholesterol
1210127|NCT01114399|Ambulatory blood pressure
1210128|NCT01114399|Arterial Stiffness
1210129|NCT01114386|Smoking
1210130|NCT01114386|Dyspnea
1210131|NCT01114386|Cough
1210132|NCT01114386|Exercise
1210133|NCT01114373|Melatonin
1210134|NCT01114373|Hypertension
1210135|NCT01114373|Blood Pressure
1210136|NCT01114373|Cardiovascular
1210137|NCT01114373|Sleep
1210138|NCT01114373|Nighttime
1210139|NCT01114373|Nocturnal
1210140|NCT01114373|Catecholamines
1210141|NCT01114373|Sympathetic Nervous System
1210142|NCT01114373|Endothelial Function
1210143|NCT01114373|African American
1210144|NCT01114360|Melatonin
1210145|NCT01114360|Hypertension
1210146|NCT01114360|Blood Pressure
1210147|NCT01114360|Cardiovascular
1210148|NCT01114360|Sleep
1210149|NCT01114360|Nighttime
1210150|NCT01114360|Nocturnal
1210151|NCT01114360|Catecholamines
1210152|NCT01114360|Sympathetic Nervous System
1210153|NCT01114360|Endothelial function
1210154|NCT01114360|African American
1210155|NCT01114321|Idiopathic Parkinson's disease
1210156|NCT01114321|Glucose intolerance
1210157|NCT01114321|Diabetes
1210158|NCT01114321|OGTT
1210159|NCT01114321|Patient with an Idiopathic Parkinson's disease
1210160|NCT01114308|opioid dependence
1210161|NCT01114308|opioid addiction
1210162|NCT01114308|buprenorphine
1210163|NCT01114308|implant
1210164|NCT01114308|methadone
1210165|NCT01114308|heroin
1210166|NCT01114308|suboxone
1210167|NCT01114308|opioid pain medication
1210168|NCT01114308|opioid withdrawal
1210169|NCT01114295|overt
1210170|NCT01114295|obscure
1210171|NCT01114295|gastrointestinal
1210172|NCT01114295|bleeding
1210173|NCT01114295|hemorrhage
1210174|NCT01114269|Coronary Artery Disease
1210175|NCT01114269|Sudden Cardiac Death
1210176|NCT01114269|Myocardial Infarction
1210177|NCT01114269|Percutaneous Coronary Intervention
1210178|NCT01114269|Implantable Cardiac Defibrillator
1210179|NCT01114230|Advanced Renal Cell Carcinoma
1210180|NCT01114230|Advanced Kidney Cancer
1210181|NCT01114230|AGS-16M8F
1210182|NCT01114217|Iron deficiency anemia
1210183|NCT01114217|Feraheme
1210184|NCT01114217|ferumoxytol
1210185|NCT01114217|AUB
1210186|NCT01114217|cancer
1210187|NCT01114217|GI disorders
1210188|NCT01114217|postpartum anemia
1210189|NCT01114217|The treatment of iron deficiency anemia (IDA)
1210190|NCT01114204|Iron deficiency anemia
1210191|NCT01114204|Feraheme
1210192|NCT01114204|ferumoxytol
1210193|NCT01114204|iron sucrose
1210194|NCT01114204|Venofer
1210195|NCT01114204|AUB
1210196|NCT01114204|cancer
1210197|NCT01114204|GI disorders
1210198|NCT01114204|postpartum anemia
1210199|NCT01114204|The treatment of iron deficiency anemia (IDA)
1210200|NCT01114178|questionnaire
1210201|NCT01114178|peripheral artery disease
1210202|NCT01114178|exercise
1210203|NCT01114165|Neutropenia
1210204|NCT01114165|Febrile Neutropenia
1210205|NCT01114165|Sepsis
1210206|NCT01114165|Polymerase Chain Reaction
1210207|NCT01114152|AZD9742
1210208|NCT01114152|Japanese Healthy Volunteers
1210209|NCT01114152|Phase I
1210210|NCT01114152|Single and Multiple Ascending Dose
1210211|NCT01114139|Iron deficiency anemia
1210212|NCT01114139|Feraheme
1210213|NCT01114139|ferumoxytol
1210214|NCT01114139|AUB
1210215|NCT01114139|cancer
1210216|NCT01114139|GI disorders
1210217|NCT01114139|postpartum anemia
1210218|NCT01114139|The treatment of iron deficiency anemia (IDA)
1210219|NCT01114126|Neu-P11
1210220|NCT01114126|Insomnia
1210221|NCT01114126|PSG
1210222|NCT01114126|safety
1210223|NCT01114113|IBS-D
1210224|NCT01114113|Post meal Diarrhea
1210225|NCT01114113|Trigger meals
1210226|NCT01114100|chest pain
1210227|NCT01114100|panic attacks
1210228|NCT01114100|palpitations
1210229|NCT01114100|depression
1210230|NCT01114100|panic disorder
1210231|NCT01114100|depressive disorder
1210232|NCT01114100|non cardiac chest pain
1210233|NCT01114087|Spermatogenesis
1210234|NCT01114087|Inhibitors of tyrosine kinase
1210235|NCT01114087|Fragmentation of the spermatic DNA
1210236|NCT01114074|Thrombosis
1210237|NCT01114074|Blood coagulation
1210238|NCT01114074|Perfusion flow experiments
1210239|NCT01114074|Factor XII
1210240|NCT01114074|Factor XI
1210241|NCT01114074|Prekallikrein
1210242|NCT01114074|High molecular weight kininogen
1210243|NCT01114061|diabetes
1210244|NCT01114061|postprandial glucose level
1210245|NCT01114061|insulin pharmacodynamics
1210246|NCT01114061|Insulin Pharmacokinetics
1210247|NCT01114048|age under 65
1210248|NCT01114048|Previous untreated
1210249|NCT01114035|intestinal epithelial dysplasia
1210250|NCT01114035|characterization phenotypic
1210251|NCT01114035|genetic study
1210252|NCT01114035|"or  tufting enteropathy "
1210253|NCT01114022|Acute respiratory failure
1210254|NCT01114009|recruitment maneuvers
1210255|NCT01114009|ARDS
1210256|NCT01114009|lung protective strategy
1210257|NCT01114009|ARDS, Human
1210258|NCT01113996|Obesity
1210259|NCT01113996|Gastric by-pass
1210260|NCT01113996|Body composition
1210261|NCT01113996|Nutrition
1210262|NCT01113996|Physical activity
1210263|NCT01113983|SAPIEN XT Valve, Cardiovascular Disease, Valvular Heart Disease, Aortic Stenosis, Heart Valve Therapy, Transapical, Transcatheter, Transfemoral
1210264|NCT01113970|breast cancer
1210265|NCT01113970|Indibulin
1210266|NCT01113970|unresectable, locally advanced breast cancer
1210267|NCT01113957|Ovarian Cancer
1210268|NCT01113931|Chlamydia
1210269|NCT01113918|Obesity,
1210270|NCT01113918|PCOS,
1210271|NCT01113918|HA,
1210272|NCT01113918|CVD
1210273|NCT01113905|Fatigue
1210274|NCT01113905|Breast Cancer
1210275|NCT01113879|rehabilitation
1210276|NCT01113879|aphasia
1210277|NCT01113879|exercise
1210278|NCT01113879|fMRI
1210279|NCT01113879|BDNF
1210280|NCT01113853|asthma
1210281|NCT01113853|exhaled nitric oxide
1210282|NCT01113853|lung function
1210283|NCT01113840|elderly
1210284|NCT01113840|heart failure
1210285|NCT01113840|exercise
1210286|NCT01113840|diastolic dysfunction
1210287|NCT01113827|Olive
1210288|NCT01113827|antioxidant
1210289|NCT01113827|exercise
1210290|NCT01113827|inflammation
1210291|NCT01113827|recovery
1210292|NCT01113827|Healthy men
1210293|NCT01113801|Chronic Kidney Disease
1210294|NCT01113801|Diabetic Kidney Disease
1210295|NCT01113801|End-Stage Renal Disease
1210296|NCT01113801|Transforming Growth Factor beta 1 Monoclonal Antibody
1210297|NCT01113801|Type 1 Diabetes
1210298|NCT01113801|Type 2 Diabetes
1210299|NCT01113788|atrial flutter, tricuspid isthmus, ablation
1210300|NCT01113775|pulmonary embolism
1210301|NCT01113775|computed tomography
1210302|NCT01113762|Arthroplasty, Replacement, Hip
1210303|NCT01113762|Bone Density
1210304|NCT01113762|Rehabilitation
1210305|NCT01113762|T-Lymphocytes
1210306|NCT01113762|Chromium Alloys
1210307|NCT01113749|Dementia
1210308|NCT01113749|Nutrition
1210309|NCT01113749|Feeding
1210310|NCT01113736|Ileostomy
1210311|NCT01113736|Stenosis
1210312|NCT01113736|Surgical Wound Dehiscence
1210313|NCT01113736|Peritoneal
1210314|NCT01113736|Colorectal Surgery
1210315|NCT01113723|C-MAC
1210316|NCT01113723|Fiberoptic bronchoscope
1210317|NCT01113723|Laryngoscopy
1210318|NCT01113723|Cervical spine injury
1210319|NCT01113723|Glottic view
1210320|NCT01113723|Tracheal intubation
1210321|NCT01113710|Rotigotine
1210322|NCT01113710|Neupro®
1210323|NCT01113710|Restless Legs Syndrome
1210324|NCT01113697|allergen challenge
1210325|NCT01113697|blood draw
1210326|NCT01113697|gene expression analysis
1210327|NCT01113697|protein analysis
1210328|NCT01113697|genetics
1210329|NCT01113671|Diabetes Mellitus type 2
1210330|NCT01113671|Haptoglobin phenotype
1210331|NCT01113671|Vitamin E
1210332|NCT01113658|negative pressure wound therapy
1210333|NCT01113658|NPWT
1210334|NCT01113658|Spiracur
1210335|NCT01113658|SNaP Wound Care System
1210336|NCT01113645|Decompressive craniectomy
1210337|NCT01113645|Cranioplasty
1210338|NCT01113645|Cerebral blood flow
1210339|NCT01113645|Cerebral hemodynamic
1210340|NCT01113645|Neurological-cognitive test GOS, FAB, MMSE,
1210341|NCT01113645|Transcranial Doppler
1210342|NCT01113632|Chronic Lymphocytic Leukemia
1210343|NCT01113632|Small Lymphocytic Lymphoma
1210344|NCT01113632|Ofatumumab
1210345|NCT01113619|lactose maldigestion
1210346|NCT01113619|dairy intolerance
1210347|NCT01113619|intolerance to milk
1210348|NCT01113619|intolerance to dairy
1210349|NCT01113619|milk intolerance
1210350|NCT01113619|GI disorder
1210351|NCT01113619|lactose metabolism
1210352|NCT01113619|GI symptoms after dairy ingestion
1210353|NCT01113606|Moderate to severe facial photo damage
1210354|NCT01113606|Periocular or perioral fine wrinkles
1210355|NCT01113593|COPD
1210356|NCT01113567|Hepatic Encephalopathy
1210357|NCT01113567|Liver Cirrhosis
1210358|NCT01113567|Disaccharides
1210359|NCT01113567|Lactose
1210360|NCT01113567|Quality of Life
1210361|NCT01113541|Ziprasidone
1210362|NCT01113541|Bipolar Disorder
1210363|NCT01113541|Metabolic Syndrome
1210364|NCT01113528|Bone allograft
1210365|NCT01113528|IL-1
1210366|NCT01113528|IL-10
1210367|NCT01113528|periodontal regeneration
1210368|NCT01113528|omega-3
1210369|NCT01113528|aspirin
1210370|NCT01113515|Diabetic foot ulcer
1210371|NCT01113515|Diabetic wound
1210372|NCT01113515|chronic non healing ulcer
1210377|NCT01113463|Brain Tumor
1210378|NCT01113463|Central Nervous System
1210379|NCT01113463|CNS
1210380|NCT01113463|Glioblastoma Multiforme
1210381|NCT01113463|GBM
1210382|NCT01113463|TPI 287
1210383|NCT01113463|Radiation Therapy
1210384|NCT01113463|Temozolomide
1210385|NCT01113463|Chemotherapy
1210386|NCT01113463|taxanes
1210387|NCT01113450|hearing, newborn, screening
1210388|NCT01113437|Bronchial Asthma
1210389|NCT01113437|Allergy
1210390|NCT01113424|Smoking Cessation
1210391|NCT01113424|Nicotine pharmacokinetics
1210392|NCT01113411|humerus fracture
1210393|NCT01113411|locked plate
1210394|NCT01113398|glioblastoma multiforme
1210395|NCT01113398|gliosarcoma
1210396|NCT01113398|malignant glioma
1210397|NCT01113398|glioma
1210398|NCT01113398|Avastin
1210399|NCT01113398|bevacizumab
1210400|NCT01113398|AMG 102
1210401|NCT01113398|rilotumumab
1210402|NCT01113398|recurrent
1210403|NCT01113398|Duke
1210404|NCT01113398|Pro00022491
1210405|NCT01113385|Nephrotic syndrome
1210406|NCT01113385|Focal Segmental glomerulosclerosis
1210407|NCT01113385|FSGS
1210408|NCT01113385|Minimal change
1210409|NCT01113385|Steroid resistant
1210410|NCT01113385|Pediatric
1210411|NCT01113385|Proteinuria
1210412|NCT01113385|Galactose
1210413|NCT01113385|FSPF
1210414|NCT01113372|Coronary, Disease
1210415|NCT01113359|HCMV infection
1210416|NCT01113359|Hypertension
1210417|NCT01113359|The Potential Link Between HCMV Infection and Essential Hypertension
1210418|NCT01113346|enterosorbent
1210419|NCT01113346|sorbent
1210420|NCT01113346|gastrointestinal decontamination
1210421|NCT01113346|viral diarrhea
1210422|NCT01113346|rotavirus
1210423|NCT01113346|Filtrum
1210424|NCT01113346|Filtrum-STI
1210425|NCT01113346|lignin
1210426|NCT01113320|Safinamide - Parkinson's disease - Levodopa induced dyskinesia
1210427|NCT01113320|Advanced idiopathic PD patients treated with L-dopa and suffering from temporally predictable L-dopa induced peak-dose dyskinesia.
1210428|NCT01113307|Chronic ulcers
1210429|NCT01113307|pressure ulcers
1210430|NCT01113307|venous ulcers
1210431|NCT01113307|diabetic foot ulcers
1210432|NCT01113307|post operative ulcers
1210433|NCT01113307|hard to heal ulcers
1210434|NCT01113281|Tuberculosis
1210435|NCT01113281|Vaccine
1210436|NCT01113281|Live Vaccine
1210437|NCT01113281|rBCG
1210438|NCT01113268|Patient collection
1210439|NCT01113268|Cardiac remodelling
1210440|NCT01113268|Echography
1210441|NCT01113268|Magnetic Resonance Imaging
1210442|NCT01113268|Gene polymorphisms
1210443|NCT01113268|Biomarkers
1210444|NCT01113255|VENTILATORS
1210445|NCT01113255|BENCH EVALUATION
1210446|NCT01113255|MECHANICAL VENTILATION
1210447|NCT01113242|Parkinson Disease Dementia
1210448|NCT01113242|Observational
1210449|NCT01113242|Case control
1210450|NCT01113242|Neuropsychological assessment
1210451|NCT01113229|Post Partum Haemorrhage,
1210452|NCT01113229|oxytocin,
1210453|NCT01113229|misoprostol,
1210454|NCT01113229|prevention,
1210455|NCT01113229|delivery.
1210456|NCT01113216|CF
1210457|NCT01113216|CFRD
1210458|NCT01113216|Diabetes
1210459|NCT01113216|Genetic Modifiers
1210460|NCT01113203|resistance training
1210461|NCT01113203|blood pressure
1210462|NCT01113203|hemodynamics
1210463|NCT01113203|autonomic
1210464|NCT01113203|Elderly Subjects
1210465|NCT01113177|Mandibular growth temporomandibular arthritis
1210466|NCT01113164|ondansetron
1210467|NCT01113164|sertraline
1210468|NCT01113164|lab studies
1210469|NCT01113164|alcoholism
1210470|NCT01113164|alcohol dependence
1210471|NCT01113151|Steroid-resistant
1210472|NCT01113151|Severe asthmatics
1210473|NCT01113151|Annual symptoms
1210474|NCT01113151|Daily magnesium supplement
1210475|NCT01113151|ACT (asthma control test)
1210476|NCT01113138|Clearance
1210477|NCT01113138|Half-life
1210478|NCT01113138|Absorption fraction
1210479|NCT01113138|Pharmacokinetics
1210480|NCT01113125|hypertrophic scar
1210481|NCT01113125|keloid
1210482|NCT01113125|central venous catheter
1210483|NCT01113125|children
1210484|NCT01113125|cancer
1210485|NCT01113112|Ovarian Neoplasms
1210486|NCT01113086|Parkinson
1210487|NCT01113086|Transcranial direct current stimulation
1210488|NCT01113086|Motor function
1210489|NCT01113086|Cognitive function
1210490|NCT01113086|Affective function
1210491|NCT01113073|pulse pressure variation
1210492|NCT01113073|hemodynamic monitoring
1210493|NCT01113073|fluid responsiveness
1210494|NCT01113073|mechanical ventilation
1210495|NCT01113073|fluid therapy
1210496|NCT01113060|Coronary Artery Disease
1210497|NCT01113060|Aspirin
1210498|NCT01113060|Secondary Prevention
1210499|NCT01113047|Hypertension
1210500|NCT01113047|Aliskiren
1210501|NCT01113047|Amlodipine
1210502|NCT01113034|Asthma
1210503|NCT01113034|Bronchiectasis
1210504|NCT01113008|Myocardial Reperfusion Injury/mortality
1210505|NCT01113008|Coronary angioplasty
1210506|NCT01113008|Reperfusion
1210507|NCT01113008|Myocardial Reperfusion Injury/prevention & control
1210508|NCT01112995|Probiotic
1210509|NCT01112995|Lactobacillus
1210510|NCT01112995|Antibiotic resistance
1210511|NCT01112982|Gout
1210512|NCT01112982|Synovial pannus
1210513|NCT01112982|Magnetic resonance imaging
1210514|NCT01112969|Internet-based supportive coaching
1210515|NCT01112969|guided self-help
1210516|NCT01112969|Caregivers
1210517|NCT01112969|Brain Injury
1210518|NCT01112969|Caregiver Burden
1210519|NCT01112969|Coping
1210520|NCT01112969|Stress
1210521|NCT01112969|Depression
1210522|NCT01112956|HSV-2
1210523|NCT01112956|HSV-1
1210524|NCT01112956|Sensitivity
1210525|NCT01112956|Specificity
1210526|NCT01112956|Testing algorithm
1210527|NCT01112956|Test evaluation
1210528|NCT01112943|Acupuncture, Pulmonary Rehabilitation, Inflammation, COPD
1210529|NCT01112930|essential fatty acids
1210530|NCT01112930|DHA
1210531|NCT01112930|preschool children
1210532|NCT01112930|docosahexanoic acid (DHA)
1210533|NCT01112904|essential fatty acids
1210534|NCT01112904|DHA status
1210535|NCT01112904|preschool children
1210536|NCT01112904|gestation
1210537|NCT01112891|Vitamin D
1210538|NCT01112891|Infant
1210539|NCT01112891|Lactation
1210540|NCT01112891|Dose-Response
1210541|NCT01112878|Shoulder arthroscopy
1210542|NCT01112878|Knee arthroscopy
1210543|NCT01112878|Clonidine
1210544|NCT01112878|Gabapentin
1210545|NCT01112878|Pain management
1210546|NCT01112878|Ambulatory surgery
1210547|NCT01112878|Perioperative outcome
1210548|NCT01112878|Analgesia
1210549|NCT01112865|Growth Hormone Deficiency
1210550|NCT01112865|Somatropin
1210551|NCT01112865|Injection Pen
1210552|NCT01112865|Medical Device
1210553|NCT01112865|Cross Over Study
1210554|NCT01112865|Preference
1210555|NCT01112865|Convenience
1210556|NCT01112865|Children
1210557|NCT01112865|Dyads
1210558|NCT01112865|Adults
1210559|NCT01112852|control of bleed
1210560|NCT01112839|Overweight
1210561|NCT01112839|Obese
1210562|NCT01112839|Breast cancer survivors
1210563|NCT01112839|Weight loss
1210564|NCT01112839|Exercise
1210565|NCT01112839|Physical activity
1210566|NCT01112826|triple-negative breast cancer
1210567|NCT01112826|metronomic chemotherapy
1210568|NCT01112826|capecitabine (xeloda)
1210569|NCT01112813|Stroke
1210570|NCT01112813|lithium
1210571|NCT01112813|MRI
1210572|NCT01112813|gray matter
1210573|NCT01112800|Anthracycline
1210574|NCT01112800|Cardiac Muscle Injury
1210575|NCT01112800|Doxorubicin
1210576|NCT01112800|Doppler Imaging
1210577|NCT01112800|Intermediate non-rhabdomyosarcoma soft tissue sarcomas
1210578|NCT01112800|High-risk non-rhabdomyosarcoma soft tissue sarcomas
1210580|NCT01112774|Transcranial direct current stimulation
1210581|NCT01112774|Spinal cord injury
1210582|NCT01112774|Chronic pain
1210583|NCT01112774|Brain excitability
1210584|NCT01112761|Athletes
1210585|NCT01112761|Multiple Concussions
1210586|NCT01112761|Transcranial Stimulation
1210587|NCT01112748|Focal neuropathic pain
1210588|NCT01112735|Abdominoplasty
1210589|NCT01112735|Flap adherence in subjects undergoing abdominoplasty to eliminate dead space and reduce seroma/hematoma formation
1210590|NCT01112722|honeybee toxin
1210591|NCT01112722|Apitox
1210592|NCT01112722|pain
1210593|NCT01112722|inflammation
1210594|NCT01112722|osteoarthritis
1210595|NCT01112722|Apitoxin
1210596|NCT01112709|Diabetes
1210597|NCT01112709|Prediabetes
1210598|NCT01112709|Resistance training
1210599|NCT01112709|behavior
1210600|NCT01112709|behavioral change theory
1210601|NCT01112696|diabetes
1210602|NCT01112696|glucose sensor
1210603|NCT01112696|CGM
1210604|NCT01112683|Down syndrome
1210605|NCT01112683|Trisomy 21
1210606|NCT01112683|Pattern Recognition Memory (PRM)
1210607|NCT01112683|Paired Associates Learning (PAL)
1210608|NCT01112683|California Verbal Learning Test (CVLT)
1210609|NCT01112683|Test of Reception of Grammar (TROG-II)
1210610|NCT01112683|Peabody Picture Vocabulary Test (PPVT-III)
1210735|NCT01112020|parachloroaniline (PCA)
1210611|NCT01112683|Scales of Independent Behavior revised (SIB-R)
1210612|NCT01112670|Healthy volunteers
1210613|NCT01112657|Multiple Sclerosis
1210614|NCT01112657|Clinical isolated syndrome
1210615|NCT01112657|Demyelination
1210616|NCT01112631|NSCLC,
1210617|NCT01112631|PORT,
1210618|NCT01112631|Quality of Life,
1210619|NCT01112631|Pulmonary function after RT
1210620|NCT01112618|Infertility
1210621|NCT01112618|Reproductive technologies, Assisted
1210622|NCT01112618|r-hFSH
1210623|NCT01112618|r-hLH
1210624|NCT01112618|Pergoveris
1210625|NCT01112605|achilles tendon
1210626|NCT01112605|sural nerve
1210627|NCT01112605|distance
1210628|NCT01112605|US
1210629|NCT01112605|ultrasound
1210630|NCT01112605|Distance between Sural nerve and the Achilles tendon
1210631|NCT01112592|NETs
1210632|NCT01112592|Infections
1210633|NCT01112592|Neutrophil function
1210634|NCT01112553|Acute Migraine
1210635|NCT01112553|Treximet
1210636|NCT01112553|Imaging
1210637|NCT01112553|fMRI
1210638|NCT01112553|Pain
1210639|NCT01112553|Heat Stimulus
1210640|NCT01112540|to evaluate the anal. efficacy of IV morph. vs. place. for elderly presenting to the ED with UAP and determine if it has an impact on diag. accu. and phy. exam
1210641|NCT01112527|PF-00299804
1210642|NCT01112514|ICG
1210643|NCT01112514|indocyanine green
1210644|NCT01112501|Diagnosis
1210645|NCT01112501|Dementia
1210646|NCT01112501|Imaging
1210647|NCT01112488|stroke
1210648|NCT01112488|patient engagement programme
1210649|NCT01112488|community rehabilitation
1210650|NCT01112488|new carer
1210651|NCT01112462|Nasal congestion, Headache
1210652|NCT01112449|selenium
1210653|NCT01112449|oxidative stress
1210654|NCT01112449|prostate cancer
1210655|NCT01112449|PSA
1210656|NCT01112449|glucose
1210657|NCT01112436|Pain
1210658|NCT01112436|preemptive
1210659|NCT01112436|Postoperative
1210660|NCT01112436|delirium
1210661|NCT01112410|Bronchiectasis
1210662|NCT01112410|Hypertonic saline
1210663|NCT01112397|Jak2
1210664|NCT01112397|cancer
1210665|NCT01112397|jak 1
1210666|NCT01112397|stat 3
1210667|NCT01112397|Phase 1
1210668|NCT01112371|scars after abdominal Caesarean section
1210669|NCT01112358|Lutropin alfa
1210670|NCT01112358|Fertilization in vitro
1210671|NCT01112358|Intracytoplasmic sperm injection
1210672|NCT01112358|Reproductive techniques, assisted
1210673|NCT01112345|Multiple Sclerosis, Relapsing-Remitting
1210674|NCT01112345|Interferon-beta
1210675|NCT01112319|COLD HOT or Electrotherapy treatment
1210676|NCT01112306|Open-label
1210677|NCT01112306|PAH
1210678|NCT01112306|Pulmonary Arterial Hypertension
1210679|NCT01112293|Subjects who have pleural malignant mesothelioma
1210680|NCT01112280|Colorectal neoplasm
1210681|NCT01112280|Colonoscopy
1210682|NCT01112280|chromoendoscopy
1210683|NCT01112280|cap-assisted colonoscopy
1210684|NCT01112267|Chronic low back pain
1210685|NCT01112267|Tramadol Hydrochloride (HCl)
1210686|NCT01112267|acetaminophen
1210687|NCT01112254|Ductal Carcinoma In Situ (DCIS) breast cancer
1210688|NCT01112241|Obliterative bronchiolitis
1210689|NCT01112241|Bronchodilator responsiveness
1210690|NCT01112241|Partial forced expiratory flow
1210691|NCT01112241|Lung volumes
1210692|NCT01112215|SLE
1210693|NCT01112215|non-renal manifestations
1210694|NCT01112202|direct thrombin inhibitors
1210695|NCT01112202|Dabigatran
1210696|NCT01112202|Coagulation parameters
1210697|NCT01112189|Lymphedema
1210698|NCT01112189|Stem cells
1210699|NCT01112189|Mastectomy
1210700|NCT01112189|Breast Cancer
1210701|NCT01112176|Strain
1210702|NCT01112176|Ejection fraction
1210703|NCT01112176|Diastolic function
1210704|NCT01112163|ischemic heart disease
1210705|NCT01112150|Edema
1210706|NCT01112150|Heart failure
1210707|NCT01112150|Pulmonary hypertension
1210708|NCT01112150|Edema in legs
1210709|NCT01112124|Typical
1210710|NCT01112124|Development
1210711|NCT01112124|Microwave
1210712|NCT01112124|Children
1210713|NCT01112124|Behavior
1210714|NCT01112085|Diabetic macular edema
1210715|NCT01112085|Ranibizumab
1210716|NCT01112072|keratoconus
1210717|NCT01112072|corneal ectasia
1210718|NCT01112072|collagen crosslinking
1210719|NCT01112072|riboflavin
1210720|NCT01112072|cornea
1210721|NCT01112072|ultraviolet
1210722|NCT01112059|cystic fibrosis
1210723|NCT01112046|Early colorectal neoplasms
1210724|NCT01112033|biliverdin reductase
1210725|NCT01112033|BLVRA
1210726|NCT01112033|hepatitis C
1210727|NCT01112033|HCV
1210728|NCT01112033|peripheral blood mononuclear cells
1210729|NCT01112033|PBMC
1210730|NCT01112033|liver
1210731|NCT01112033|genetic polymorphisms
1210732|NCT01112020|Chlorhexidine digluconate (CHG)
1210733|NCT01112020|Biopatch Protective Disk
1210734|NCT01112020|Tegaderm CHG IV (intravenous) Securement Dressing
1210736|NCT01112020|No condition being studied.
1210737|NCT01112020|Assessing components of CHG-containing dressings after use.
1210738|NCT01112007|Insulin Resistance
1210739|NCT01112007|Hypertension
1210740|NCT01112007|Blood pressure
1210741|NCT01112007|Aldosterone
1210742|NCT01112007|Renin
1210743|NCT01111994|hyperpigmentation
1210744|NCT01111981|alopecia
1210745|NCT01111981|CCCA - Central Centrifugal Cicatricial Alopecia
1210746|NCT01111968|vaccine
1210747|NCT01111968|pandemic influenza A
1210748|NCT01111968|adjuvant
1210749|NCT01111968|safety
1210750|NCT01111942|head and neck cancer
1210751|NCT01111942|chemotherapy
1210752|NCT01111942|radiation
1210753|NCT01111929|Emergency contraception
1210754|NCT01111929|pregnancy during breastfeeding
1210755|NCT01111929|Lactational amenorrhea Method
1210756|NCT01111929|unplanned pregnancy
1210757|NCT01111877|ear tubes
1210758|NCT01111877|ear drainage
1210759|NCT01111877|ear infection
1210760|NCT01111877|ear drops
1210761|NCT01111877|tympanostomy tubes
1210762|NCT01111877|Pediatric patients
1210763|NCT01111851|NK1-receptor occupancy
1210764|NCT01111838|STA-9090
1210765|NCT01111838|colon
1210766|NCT01111838|rectal
1210767|NCT01111838|10-029
1210768|NCT01111825|HKI-272 (NERATINIB)
1210769|NCT01111825|TEMSIROLIMUS (CCI-779)
1210770|NCT01111825|HER2-Amplified
1210771|NCT01111825|Triple-negative
1210772|NCT01111825|invasive adenocarcinoma
1210773|NCT01111825|10-005
1210774|NCT01111812|overweight
1210775|NCT01111812|obese
1210776|NCT01111812|children
1210777|NCT01111812|weighing
1210778|NCT01111812|weight
1210779|NCT01111799|endometrial biopsy
1210780|NCT01111799|implantation
1210781|NCT01111799|uterine receptivity
1210782|NCT01111799|infertility
1210783|NCT01111799|controled ovarian hyperstimulation
1210784|NCT01111799|intra uterine insemination
1210785|NCT01111786|scleroderma
1210786|NCT01111786|skin
1210787|NCT01111786|tightness
1210788|NCT01111786|durometer
1210789|NCT01111773|Patellar tendonitis
1210790|NCT01111760|cardiovascular disease
1210791|NCT01111760|heart CT scan
1210792|NCT01111760|CT scan
1210793|NCT01111760|pulmonary embolisms
1210794|NCT01111760|aortography
1210795|NCT01111747|platelet-rich plasma
1210796|NCT01111747|patellar ligament
1210797|NCT01111747|regeneration
1210798|NCT01111747|growth substances
1210799|NCT01111734|self harm
1210800|NCT01111734|self injury
1210801|NCT01111734|self mutilation
1210802|NCT01111734|N-Acetylcysteine
1210803|NCT01111734|adolescents
1210804|NCT01111734|impulse control disorder
1210805|NCT01111734|borderline personality disorder
1210806|NCT01111734|fMRI
1210807|NCT01111721|Sexually Transmitted Diseases
1210808|NCT01111721|HIV Infections
1210809|NCT01111721|Genital Diseases, Female
1210810|NCT01111721|Acquired Immunodeficiency Syndrome
1210811|NCT01111721|Risk Reduction Behavior
1210812|NCT01111721|HIV prevention
1210813|NCT01111695|wound healing
1210814|NCT01111695|granulation tissue
1210815|NCT01111695|Varicose Ulcer
1210816|NCT01111682|traumatic brain injury
1210817|NCT01111682|hypertonic saline therapy
1210818|NCT01111682|intracranial pressure
1210819|NCT01111669|Functional Endoscopic Sinus Surgery
1210820|NCT01111669|Tranexamic Acid
1210821|NCT01111656|Multi-center
1210822|NCT01111656|randomized
1210823|NCT01111656|prospective
1210824|NCT01111656|parallel-group
1210825|NCT01111656|rater-blinded
1210826|NCT01111656|RR-MS
1210827|NCT01111630|chronic renal failure
1210828|NCT01111630|Anaemia
1210829|NCT01111604|Colonic Neoplasms
1210830|NCT01111604|Rectal Neoplasms
1210831|NCT01111604|Adenocarcinoma
1210832|NCT01111604|Antibodies, Monoclonal
1210833|NCT01111591|Cyclooxygenase-2 inhibitor (Celecoxib)
1210834|NCT01111591|Extrahepatic bile duct cancer
1210835|NCT01111591|Pancreas cancer
1210836|NCT01111565|Major Depressive Disorder
1210837|NCT01111565|MDD
1210838|NCT01111565|Depression
1210839|NCT01111552|Major Depressive Disorder
1210840|NCT01111552|MDD
1210841|NCT01111552|Depression
1210842|NCT01111539|Major Depressive Disorder
1210843|NCT01111539|MDD
1210844|NCT01111539|Depression
1210845|NCT01111526|Graft versus host disease
1210846|NCT01111526|GVHD
1210847|NCT01111526|allogeneic transplant
1210848|NCT01111526|acute GVHD
1210849|NCT01111526|chronic GVHD
1210850|NCT01111513|knee surgery
1210851|NCT01111513|total knee arthroplasty
1210852|NCT01111513|total knee replacement
1210853|NCT01111513|ropivacaine
1210854|NCT01111513|femoral nerve block
1210855|NCT01111487|COPD
1210856|NCT01111487|Electromyography
1210857|NCT01111487|Inspiratory muscles
1210858|NCT01111474|dentin hypersensitivity
1210859|NCT01111474|cyanoacrylate
1210860|NCT01111474|laser
1210861|NCT01111461|Advanced Endometrial Cancer
1210862|NCT01111448|Myelodysplastic Syndromes of all IPSS subgroups
1210863|NCT01111422|Antioxidant
1210864|NCT01111422|Epithelial to Mesenchymal Transition
1210865|NCT01111422|peritoneal fibrosis
1210866|NCT01111422|Peritoneal Dialysis, Continuous Ambulatory
1210867|NCT01111396|ALL
1210868|NCT01111396|GMALL 2003
1210869|NCT01111396|Chemotherapy
1210870|NCT01111396|Hippocampus
1210871|NCT01111383|cystic fibrosis
1210872|NCT01111383|P. aeruginosa
1210873|NCT01111383|tobramycin
1210874|NCT01111370|diabetes mellitus requiring insulin
1210875|NCT01111357|Rheumatoid Arthritis
1210876|NCT01111357|Rheumatoid Arthritis according to ACR criteria of diagnosis
1210877|NCT01111344|Dietary supplement
1210878|NCT01111344|Anogenital warts
1210879|NCT01111344|Viusid
1210880|NCT01111344|Glizigen
1210881|NCT01111305|Filariasis
1210882|NCT01111305|Post-Treatment Reactions
1210883|NCT01111305|Monoclonal Antibody
1210884|NCT01111305|Loa Loa
1210885|NCT01111305|Loiasis
1210886|NCT01111266|in vivo KUF
1210887|NCT01111266|ß2M
1210888|NCT01111266|leptin
1210889|NCT01111253|multicenter randomized, open label, clinical trial
1210890|NCT01111253|acute uncomplicated (mild) diverticulitis
1210891|NCT01111253|treatment strategies
1210892|NCT01111253|management of diverticulitis
1210893|NCT01111253|antibiotics
1210894|NCT01111253|observation and supportive care
1210895|NCT01111253|cost analysis
1210896|NCT01111253|economic evaluation
1210897|NCT01111240|Humira
1210898|NCT01111240|Long-term safety and effectiveness
1210899|NCT01111240|Psoriatic Arthritis
1210900|NCT01111227|cytokines
1210901|NCT01111227|propofol
1210902|NCT01111227|isoflurane
1210903|NCT01111227|flow cytometry
1210904|NCT01111227|Types of General Anesthesia
1210905|NCT01111214|Invasive Pneumococcal Disease (IPD)
1210906|NCT01111214|pneumococcal serotypes
1210907|NCT01111201|Autologous Bone Marrow Transplant
1210908|NCT01111201|Breast
1210909|NCT01111201|Lymphoma
1210910|NCT01111201|International travel
1210911|NCT01111201|questionnaire
1210912|NCT01111201|Hematopoietic Stem Cell Transplant (HSCT) recipients
1210913|NCT01111175|Locally recurrent breast cancer
1210914|NCT01111162|HIV
1210915|NCT01111162|H1N1 vaccination
1210916|NCT01111162|HIV infected individuals
1210917|NCT01111149|Schizophrenia
1210918|NCT01111149|Smoking cessation
1210919|NCT01111149|Varenicline
1210920|NCT01111149|Bupropion
1210921|NCT01111136|Urticaria
1210922|NCT01111136|Hives
1210923|NCT01111136|Stress
1210924|NCT01111123|plaque psoriasis
1210925|NCT01111123|lac-hydrin
1210926|NCT01111123|ammonium lactate
1210927|NCT01111123|Ultravate
1210928|NCT01111123|halobetasol propionate
1210929|NCT01111123|weekend only application
1210930|NCT01111123|topical therapy
1210931|NCT01111123|topical corticosteroid
1210932|NCT01111123|class I steroid
1210933|NCT01111097|Brain tumors, Glioblastoma and DCA
1210934|NCT01111097|Brain tumor,Glioblastoma recurrent
1210935|NCT01111084|Ovulation induction
1210936|NCT01111084|Ovarian Hyperstimulation Syndrome
1210937|NCT01111084|Pregnancy
1210938|NCT01111084|Fertility
1210939|NCT01111071|hospital variation
1210940|NCT01111071|30 day mortality
1210941|NCT01111071|in hospital mortality
1210942|NCT01111071|acute coronary syndrome
1210943|NCT01111071|myocardial infarction
1210944|NCT01111071|unstable angina
1210945|NCT01111071|hospital performance
1210946|NCT01111071|trends
1210947|NCT01111058|Squamous Cell Cancer
1210948|NCT01111032|Treadmill
1210949|NCT01111032|Exercise
1210950|NCT01111032|Cancer
1210951|NCT01111032|Validity
1210952|NCT01111032|Reliability
1210958|NCT01111006|Electronic toilet
1210959|NCT01111006|Bidet
1210960|NCT01111006|Anorectal resting pressure
1210961|NCT01110993|Multiple Sclerosis, Interferon-beta 1-a
1210962|NCT01110980|Head and Neck neoplasms
1210963|NCT01110980|Radiotherapy
1210964|NCT01110980|Diet counselling
1210965|NCT01110980|Swallow therapy
1210966|NCT01110980|Food intake
1210967|NCT01110941|S-1
1210968|NCT01110941|leucovorin
1210969|NCT01110941|oxaliplatin
1210970|NCT01110941|colorectal cancer
1210971|NCT01110941|SOL
1210972|NCT01110941|unresectable or recurrent colorectal cancer
1210973|NCT01110902|Agomelatine
1210974|NCT01110902|Major Depressive Disorder
1210975|NCT01110902|MDD
1210976|NCT01110902|depression
1210977|NCT01110889|Agomelatine
1210978|NCT01110889|Major Depressive Disorder
1210979|NCT01110889|MDD
1210980|NCT01110889|depression
1210981|NCT01110876|Recurrent Glioblastoma Multiforme
1210982|NCT01110876|GBM
1210983|NCT01110876|Brain
1210984|NCT01110876|Central Nervous Center
1210985|NCT01110876|Malignant glioma
1210986|NCT01110876|Glioblastoma multiforme
1210987|NCT01110876|Gliosarcoma
1210988|NCT01110876|Anaplastic astrocytoma
1210989|NCT01110876|Anaplastic oligodendroglioma
1210990|NCT01110876|Anaplastic oligoastrocytoma
1210991|NCT01110876|Vorinostat
1210992|NCT01110876|SAHA
1210993|NCT01110876|Suberoylanilide Hydroxamic Acid
1210994|NCT01110876|MSK-390
1210995|NCT01110876|Zolinza
1210996|NCT01110876|Erlotinib
1210997|NCT01110876|Erlotinib Hydrochloride
1210998|NCT01110876|OSI-774
1210999|NCT01110876|Tarceva
1211000|NCT01110876|Temozolomide
1211001|NCT01110876|Temodar
1211002|NCT01110863|Chronic Lymphocytic Leukemia
1211003|NCT01110850|Chronic Lymphocytic Leukemia
1211004|NCT01110837|Allergic rhinitis
1211005|NCT01110837|Allergen
1211006|NCT01110824|Prevention
1211007|NCT01110824|ventricular dysfunction
1211008|NCT01110824|chemotherapy
1211009|NCT01110824|acute myeloid leukemia
1211010|NCT01110824|precursor-cell lymphoblastic leukemia
1211011|NCT01110824|multiple myeloma
1211012|NCT01110824|lymphoma
1211013|NCT01110824|ejection fraction
1211014|NCT01110824|Autologous hematopoietic stem cell transplantation
1211015|NCT01110811|GERD
1211016|NCT01110811|Esophagitis
1211017|NCT01110811|Fundoplication
1211018|NCT01110811|Anti-reflux surgery
1211019|NCT01110811|PPI dependent
1211020|NCT01110798|perioperative/postoperative complications
1211021|NCT01110798|gastrointestinal complications
1211022|NCT01110798|adenocarcinoma of the rectum
1211023|NCT01110798|stage I rectal cancer
1211024|NCT01110798|stage II rectal cancer
1211025|NCT01110798|stage III rectal cancer
1211026|NCT01110785|recurrent colon cancer
1211027|NCT01110785|stage III colon cancer
1211028|NCT01110785|stage IV colon cancer
1211029|NCT01110785|recurrent rectal cancer
1211030|NCT01110785|stage III rectal cancer
1211031|NCT01110785|stage IV rectal cancer
1211032|NCT01110772|Surgical site infection
1211033|NCT01110772|Skin preparation
1211034|NCT01110772|Cost analysis
1211035|NCT01110759|pain management
1211036|NCT01110759|ambulatory surgery
1211037|NCT01110759|opioid
1211038|NCT01110759|local anesthesia
1211039|NCT01110759|hand surgery
1211040|NCT01110759|postoperative pain
1211041|NCT01110733|Non-Hodgkins Lymphoma
1211042|NCT01110733|Non-Hodgkin's Lymphoma
1211043|NCT01110733|Lymphoma
1211044|NCT01110707|Reproductive technology, Assisted
1211045|NCT01110707|Recombinant human follicle stimulating hormone (r-hFSH)
1211046|NCT01110707|Recombinant leutinizing hormone (r-hLH)
1211047|NCT01110707|Ovulation induction
1211048|NCT01110707|Infertility
1211055|NCT01110668|Unresectable
1211056|NCT01110668|metastatic gastrointestinal stromal tumor
1211057|NCT01110668|disease progression
1211058|NCT01110668|progression-free survival
1211059|NCT01110655|Exercise-associated hyponatremia
1211060|NCT01110655|Randomized treatment trial
1211061|NCT01110655|Endurance runners
1211062|NCT01110629|Chronic kidney disease not on dialysis
1211063|NCT01110629|Lanthanum carbonate
1211064|NCT01110616|EEG Standardization
1211065|NCT01110603|Cancer
1211066|NCT01110603|Advanced Solid Tumors
1211067|NCT01110590|Erectile Dysfunction
1211068|NCT01110577|MRI
1211069|NCT01110577|Hepatic Steatosis Study
1211070|NCT01110564|Chronic Obstructive Pulmonary Disease
1211071|NCT01110564|daily symptom variability
1211072|NCT01110564|effects of symptom on morning activities
1211073|NCT01110551|Dengue, vaccine, flavivirus
1211074|NCT01110525|Phase I
1211075|NCT01110525|Drug-drug interaction
1211076|NCT01110525|Oral contraceptives
1211077|NCT01110525|AZD 1981
1211078|NCT01110512|Improvement of CVI parameters
1211079|NCT01110447|Hepatic Encephalopathy, probiotics
1211080|NCT01110421|Doripenem
1211081|NCT01110421|Child, Hospitalized
1211082|NCT01110421|Cefepime
1211083|NCT01110421|Infusions, Intravenous
1211084|NCT01110421|Severe community acquired pneumonia
1211085|NCT01110421|Nosocomial pneumonia
1211086|NCT01110421|Ventilator associated pneumonia
1211087|NCT01110408|Antibiotic
1211088|NCT01110408|Child, Hospitalized
1211089|NCT01110408|Complicated Urinary Tract Infection
1211090|NCT01110408|Pyelonephritis
1211091|NCT01110408|Doripenem
1211092|NCT01110408|Cefepime
1211093|NCT01110382|Anti-Infective Agents
1211094|NCT01110382|Doripenem
1211095|NCT01110382|Meropenem
1211096|NCT01110382|Child, Hospitalized
1211097|NCT01110382|Complicated Intra-Abdominal Infections
1211098|NCT01110369|sarcopenia
1211099|NCT01110369|frail elderly
1211100|NCT01110369|protein drink
1211101|NCT01110369|resistance exercise
1211102|NCT01110369|Skeletal muscle mass
1211103|NCT01110369|muscle mass in elderly
1211104|NCT01110343|parent stress
1211105|NCT01110343|parent coping
1211106|NCT01110343|parent anxiety
1211107|NCT01110343|parent health
1211108|NCT01110343|parent depression
1211109|NCT01110330|Tinea Pedis
1211110|NCT01110330|Ketoconazole (NIZORAL)
1211111|NCT01110330|Antifungal Agents
1211112|NCT01110330|Miconazole (DAKTARIN)
1211113|NCT01110317|Paliperidone palmitate
1211114|NCT01110317|R092670PSY1001
1211115|NCT01110317|Pharmacokinetics
1211116|NCT01110317|Risperdal (CONSTA)
1211117|NCT01110317|Risperidone, Paliperidone
1211118|NCT01110304|acromio-clavicular joint dislocation
1211119|NCT01110304|type III acromio-clavicular joint dislocation
1211120|NCT01110304|joint dislocation
1211121|NCT01110304|clavicle hook plate
1211122|NCT01110291|docetaxel toxicity
1211123|NCT01110291|CYP3A activity
1211124|NCT01110291|CYP3A5
1211125|NCT01110291|MDR1
1211126|NCT01110291|peroral midazolam
1211127|NCT01110278|Urge Urinary Incontinence
1211128|NCT01110278|Magnetic Resonance Imaging
1211129|NCT01110278|Diffusion Tensor Imaging
1211130|NCT01110278|Brain Connectivity
1211131|NCT01110278|Bladder Control
1211132|NCT01110278|fMRI
1211133|NCT01110252|Chronic Obstructive Pulmonary Disease
1211134|NCT01110252|Emphysema
1211135|NCT01110252|Cell therapy
1211136|NCT01110252|Bone marrow mononuclear cells
1211137|NCT01110252|stem cells
1211138|NCT01110239|limb preconditioning
1211139|NCT01110239|remote preconditioning
1211140|NCT01110239|ischemic preconditioning
1211141|NCT01110226|non small cell lung cancer
1211142|NCT01110226|small cell lung cancer
1211143|NCT01110226|Platinum Responsive
1211144|NCT01110226|solid tumor malignancies
1211145|NCT01110213|Aging
1211146|NCT01110213|physical activity
1211147|NCT01110213|diet
1211148|NCT01110213|goal setting
1211149|NCT01110200|Hospitalization
1211150|NCT01110200|Exacerbations of COPD
1211151|NCT01110200|Chronic Obstructive Pulmonary Disease (COPD)
1211152|NCT01110187|Lacosamide
1211153|NCT01110187|Fosphenytoin
1211154|NCT01110187|traumatic brain injury
1211155|NCT01110187|Glasgow coma scale
1211156|NCT01110187|Disability Rating Scale
1211157|NCT01110187|Resource Utilization Questionnaire
1211158|NCT01110187|Continuous EEG
1211159|NCT01110187|seizures
1211160|NCT01110161|Abdominal Fat
1211161|NCT01110161|Visceral Fat
1211162|NCT01110161|Subcutaneous Fat
1211163|NCT01110161|Dual-energy x-ray absorptiometry
1211164|NCT01110161|DXA
1211165|NCT01110161|Computed Tomography
1211166|NCT01110161|CT
1211167|NCT01110161|Body Mass Index
1211168|NCT01110161|Body composition
1211169|NCT01110161|Percent fat
1211170|NCT01110161|Waist circumference
1211171|NCT01110161|Hip circumference
1211172|NCT01110148|skin biopsy
1211173|NCT01110148|informed consent
1211174|NCT01110148|patient education
1211175|NCT01110148|video education
1211176|NCT01110148|patients requiring skin biopsies
1211177|NCT01110122|Muscle recovery
1211178|NCT01110122|Intermittent exercise
1211179|NCT01110122|Whey protein
1211180|NCT01110122|Soccer
1211181|NCT01110109|Adult
1211182|NCT01110109|Surgery
1211183|NCT01110109|Endotracheal Tube
1211184|NCT01110109|Ventilator
1211185|NCT01110109|Pneumonia
1211186|NCT01110109|Suctioning
1211187|NCT01110096|Obesity
1211188|NCT01110096|Child
1211189|NCT01110096|Parent
1211190|NCT01110096|Family
1211191|NCT01110083|Phase 1
1211192|NCT01110083|advanced solid tumors
1211193|NCT01110083|refractory to standard therapy
1211194|NCT01110083|Patients with solid tumors, either refractory to standard therapy or for which no effective standard therapy is available
1211195|NCT01110070|articular
1211196|NCT01110070|cartilage
1211197|NCT01110070|microfracture
1211198|NCT01110070|knee pain
1211199|NCT01110070|cartilage repair
1211200|NCT01110070|Subjects with an articular cartilage defect in the knee.
1211201|NCT01110057|p38 kinase inhibitor
1211202|NCT01110057|male and female
1211203|NCT01110057|patients
1211204|NCT01110044|Neonatal vaccination
1211205|NCT01110031|Chronic lymphocytic leukemia
1211206|NCT01110031|Cardiac Repolarization (QTc)
1211215|NCT01110005|D5LR
1211216|NCT01110005|glucose containing IV solution
1211217|NCT01110005|LR
1211218|NCT01110005|non glucose IV solution
1211219|NCT01109992|coronary artery disease
1211220|NCT01109992|exercise
1211221|NCT01109992|regadenoson
1211222|NCT01109992|positron emission tomography
1211223|NCT01109979|Cardiovascular, vascular
1211224|NCT01109966|Allergy
1211225|NCT01109966|Cow's Milk
1211226|NCT01109966|Infants
1211227|NCT01109966|Food Allergy
1211228|NCT01109953|Lung
1211229|NCT01109953|PET/CT scan
1211230|NCT01109953|10-054
1211231|NCT01109940|Ankylosing spondylitis
1211232|NCT01109940|IgG1K monoclonal antibody
1211233|NCT01109940|Interleukin -17A neutralizing
1211234|NCT01109914|Renal transplantation
1211235|NCT01109914|Immunosuppression
1211236|NCT01109914|ETEC
1211237|NCT01109914|Dukoral
1211238|NCT01109914|Vaccination
1211239|NCT01109914|Immunity, Humoral
1211240|NCT01109901|Cubital tunnel,subcutaneous transposition,submuscular
1211241|NCT01109862|Femoral neck fractures
1211242|NCT01109862|Hip fractures
1211243|NCT01109862|Elderly
1211244|NCT01109862|Total hip arthroplasty
1211245|NCT01109862|Bipolar hemiarthroplasty
1211246|NCT01109849|ADHD
1211247|NCT01109849|growth
1211248|NCT01109849|BMI
1211249|NCT01109849|stimulant medication
1211250|NCT01109836|prevention
1211251|NCT01109836|cognitive decline
1211252|NCT01109836|post-stroke dementia
1211253|NCT01109836|life-style intervention
1211254|NCT01109836|vascular risk factors
1211255|NCT01109836|polyintervention
1211256|NCT01109836|multifactorial treatment
1211257|NCT01109823|Patients hospitalized at Intensive Care Unit treated with levofloxacin IV
1211258|NCT01109784|coronary angioplasty
1211259|NCT01109784|clopidogrel resistance
1211260|NCT01109784|prasugrel
1211261|NCT01109771|Ventral hernia
1211262|NCT01109758|Fenofibrate
1211263|NCT01109758|Gene Expression
1211264|NCT01109758|DNA methylation
1211265|NCT01109745|Asthma
1211266|NCT01109745|health-related quality of life
1211267|NCT01109745|patient-centred care
1211268|NCT01109719|Protocol
1211269|NCT01109719|Critical pathway
1211270|NCT01109719|Intensive care units
1211271|NCT01109706|Acute coronary syndrome
1211272|NCT01109706|PCSK9
1211273|NCT01109706|cardiovascular safety
1211274|NCT01109667|Thromboplastin, Prothrombin, Diagnostic Reagent Kits, International Normalized Ratio, Laboratory Tests.
1211275|NCT01109654|Fertilization in Vitro
1211276|NCT01109654|Reproductive Techniques, Assisted
1211277|NCT01109654|Follicle Stimulating Hormone
1211278|NCT01109654|Cetrotide
1211279|NCT01109654|Gonal-f
1211280|NCT01109628|sarcopenia
1211281|NCT01109628|frail elderly
1211282|NCT01109628|protein drink
1211283|NCT01109628|skeletal muscle mass
1211284|NCT01109628|muscle mass in elderly
1211285|NCT01109615|Colorectal cancer
1211286|NCT01109615|Metastatic colorectal cancer
1211287|NCT01109615|Treatment resistant
1211288|NCT01109615|Chemotherapy refractory
1211289|NCT01109615|KRAS mutation
1211290|NCT01109602|Stroke
1211291|NCT01109602|accidental falls
1211292|NCT01109602|Yoga
1211293|NCT01109602|Blood pressure
1211294|NCT01109602|Range of Motion
1211295|NCT01109602|Rehabilitation
1211296|NCT01109602|Exercise
1211297|NCT01109602|balance
1211298|NCT01109602|quality of life
1211299|NCT01109602|mobility
1211300|NCT01109589|antibiotics
1211301|NCT01109589|prescriptions
1211302|NCT01109589|pregnancy
1211303|NCT01109589|children
1211304|NCT01109576|deafness-blindness
1211305|NCT01109576|pilot study
1211306|NCT01109576|self management education
1211307|NCT01109576|dual sensory loss
1211308|NCT01109576|rehabilitation
1211309|NCT01109576|peer support groups
1211310|NCT01109576|age related
1211311|NCT01109563|cannabis use disorder
1211312|NCT01109563|marijuana
1211313|NCT01109563|motivational enhancement treatment
1211314|NCT01109563|cognitive behavioral treatment
1211315|NCT01109563|continuing care
1211316|NCT01109537|Restless Legs Syndrome (RLS)
1211317|NCT01109537|GABA
1211318|NCT01109537|Glutamate
1211319|NCT01109537|Magnetic Resonance Spectroscopy
1211320|NCT01109498|LPLD
1211321|NCT01109498|Lipoprotein Lipase Deficiency
1211322|NCT01109498|Chylomicronaemia
1211323|NCT01109498|Genetherapy
1211324|NCT01109498|AAV
1211325|NCT01109498|Alipogene Tiparvovec
1211326|NCT01109498|AMT-011
1211327|NCT01109498|Lipoprotein Lipase
1211328|NCT01109485|Allergic conjunctivitis
1211329|NCT01109459|preschool
1211330|NCT01109459|screening
1211331|NCT01109459|cluster randomized
1211332|NCT01109459|physician practice patterns
1211333|NCT01109459|behavior
1211334|NCT01109459|knowledge
1211335|NCT01109459|attitudes
1211336|NCT01109459|guideline adherence
1211337|NCT01109446|Lateral Epicondylitis
1211338|NCT01109446|Tennis Elbow
1211339|NCT01109446|Epicondylitis Lateralis
1211340|NCT01109433|Behcet's Disease
1211341|NCT01109433|Intermediate Uveitis
1211342|NCT01109433|Uveitis
1211343|NCT01109433|Immunogenetics
1211344|NCT01109420|Thyroid Malignancy
1211345|NCT01109420|Hereditary Thyroid Cancer
1211346|NCT01109420|Inherited Thyroid Cancer
1211347|NCT01109420|Thyroid Cancer
1211348|NCT01109407|Plasma Cell Neoplasm
1211349|NCT01109407|Natural History
1211350|NCT01109407|Translational Studies
1211351|NCT01109407|Gene Expression Profiling
1211352|NCT01109407|Protein Markers
1211353|NCT01109407|Smoldering Myeloma
1211354|NCT01109407|SMM
1211355|NCT01109407|Monoclonal Gammopathy of Undetermined Significance
1211356|NCT01109407|MGUS
1211367|NCT01109381|bacterial infections
1211368|NCT01109381|anti-infective agents
1211369|NCT01109381|gastrointestinal agents
1211370|NCT01109381|antibacterial agents
1211371|NCT01109381|omeprazole
1211372|NCT01109381|lauric acid
1211373|NCT01109381|n-acetylcysteine
1211374|NCT01109381|helicobacter infections
1211375|NCT01109381|helicobacter pylori
1211376|NCT01109381|non-antibiotic treatment
1211377|NCT01109368|Autosomal Dominant Familial Hypercholesterolemia
1211378|NCT01109355|PEEP
1211379|NCT01109355|Patients with hemorrhage stroke under mechanical ventilation
1211380|NCT01109342|HIV Prevention
1211381|NCT01109342|Vaccine
1211382|NCT01109342|Recombinant Adenovirus-5
1211383|NCT01109342|HIV Preventative Vaccine
1211384|NCT01109329|Vaccine
1211385|NCT01109303|ankle fracture with syndesmotic ligament rupture
1211386|NCT01109303|ankle syndesmosis rupture
1211387|NCT01109264|Chronic Lymphocytic Leukemia
1211388|NCT01109264|Bendamustine Hydrochloride
1211389|NCT01109264|Chlorambucil
1211390|NCT01109238|Refractory Neuroblastoma
1211391|NCT01109238|Relapsed Neuroblastoma
1211392|NCT01109225|aldosterone
1211393|NCT01109225|myocardial infarction
1211394|NCT01109225|cardiac remodeling
1211395|NCT01109212|Type 2-Diabetic Nephrophaty
1211396|NCT01109212|bindarit
1211397|NCT01109212|albuminuria
1211398|NCT01109212|MCP-1
1211399|NCT01109199|viscous
1211400|NCT01109199|fibre
1211401|NCT01109199|polysaccharide
1211402|NCT01109199|appetite
1211403|NCT01109199|hunger
1211404|NCT01109199|satiety
1211405|NCT01109199|weight management
1211406|NCT01109186|patient with a kidney transplantation since less than 30 days
1211407|NCT01109160|azithromycin
1211408|NCT01109160|lymphocytic bronchitis or bronchiolitis
1211409|NCT01109160|lung transplantation
1211410|NCT01109160|acute allograft rejection
1211411|NCT01109160|chronic allograft rejection
1211412|NCT01109160|bronchiolitis obliterans syndrome
1211413|NCT01109147|Schizophrenic Disorders
1211414|NCT01109147|Schizophrenia
1211415|NCT01109147|Affect
1211416|NCT01109147|Emotional Blunting
1211417|NCT01109134|primary angioplasty
1211418|NCT01109134|tirofiban
1211419|NCT01109134|microcirculation
1211420|NCT01109121|Moderate to severe gout
1211421|NCT01109121|Hyperuricemia
1211422|NCT01109108|pneumococcal vaccine
1211423|NCT01109108|nasopharyngeal carriage
1211424|NCT01109095|Glioblastoma Multiforme (GBM)
1211425|NCT01109095|HER2
1211426|NCT01109095|CMV
1211427|NCT01109095|Brain Cancer
1211428|NCT01109095|Autologous HER2.CAR CMV-specific cytotoxic CTL
1211429|NCT01109095|CMV-specific cytotoxic CTL
1211430|NCT01109082|Scoliosis
1211431|NCT01109082|gait
1211432|NCT01109082|posture
1211433|NCT01109082|balance
1211434|NCT01109069|PCI-32765
1211435|NCT01109069|Lymphoma, B-Cell
1211436|NCT01109069|Leukemia, Lymphoid
1211437|NCT01109069|Leukemia, B-Cell
1211438|NCT01109069|Bruton's Tyrosine Kinase
1211439|NCT01109043|Hypertension
1211440|NCT01109043|Bisoprolol
1211441|NCT01109043|Antihypertensive drugs
1211442|NCT01109043|Blood pressure
1211443|NCT01109043|Quality of life
1211444|NCT01109043|Diabetes
1211445|NCT01109043|Ketohexokinase
1211446|NCT01109030|Major depressive disorder
1211447|NCT01109030|pioglitazone
1211448|NCT01109030|double blind
1211449|NCT01109030|placebo controlled
1211450|NCT01109004|Symptomatic Multiple Myeloma
1211451|NCT01109004|Lenalidomide
1211452|NCT01109004|Anti-Myeloma Agents
1211453|NCT01109004|Hematologic Disorders
1211454|NCT01109004|Maintenance Therapy
1211455|NCT01109004|Progression
1211456|NCT01109004|Autologous Transplant
1211457|NCT01109004|RVD Consolidation
1211458|NCT01108991|Chronic obstructive pulmonary disease
1211459|NCT01108991|Randomized controlled trial
1211460|NCT01108991|Self-management support
1211461|NCT01108991|Physical activity
1211462|NCT01108978|Type 2 Diabetes Mellitus
1211463|NCT01108978|Cardiovascular Disease
1211464|NCT01108978|hypercholesterolemia
1211465|NCT01108965|Hydrocephalus
1211466|NCT01108965|Shunt Dysfunction
1211467|NCT01108965|Shunt Flow
1211468|NCT01108952|Chemotherapy
1211469|NCT01108952|Memory
1211470|NCT01108952|Methotrexate
1211471|NCT01108952|Glucocorticoids
1211472|NCT01108952|Trauma
1211473|NCT01108952|pediatric oncology
1211474|NCT01108952|traumatization
1211475|NCT01108939|Malaria, Iron absorption, Iron utilization, Benin
1211476|NCT01108913|COPD
1211477|NCT01108900|Erectile Dysfunction udenafil sildenafil treatment satisfaction
1211478|NCT01108887|Multiple Sclerosis, Relapsing-Remitting
1211479|NCT01108887|RebiSmart
1211480|NCT01108887|Rebif
1211481|NCT01108887|Interferon beta-1a
1211482|NCT01108874|Cesarean section
1211483|NCT01108874|Hypotension
1211484|NCT01108874|Metaraminol
1211485|NCT01108874|Vasoconstrictor Agents
1211486|NCT01108874|Adult
1211487|NCT01108874|Female
1211488|NCT01108874|Pregnancy
1211489|NCT01108874|Anesthesia, Obstetrical/adverse effects
1211490|NCT01108874|Anesthesia,Spinal
1211491|NCT01108874|Blood Pressure/drug effects
1211492|NCT01108874|Nausea
1211493|NCT01108874|Vomiting
1211494|NCT01108861|Peripheral Vascular Disease
1211495|NCT01108861|In-stent restenosis
1211496|NCT01108861|Endoprosthesis
1211497|NCT01108861|Plain old balloon angioplasty
1211498|NCT01108848|C1-esterase Inhibitor
1211499|NCT01108848|Hereditary angioedema
1211500|NCT01108848|Acute HAE attack
1211501|NCT01108835|COPD
1211502|NCT01108835|Comprehensive care
1211503|NCT01108783|Rhinitis
1211504|NCT01108783|Allergic
1211505|NCT01108783|Seasonal
1211506|NCT01108783|Hay Fever
1211507|NCT01108783|Pollen Allergy
1211508|NCT01108783|Pollinosis
1211509|NCT01108783|Rhinoconjunctivitis
1211510|NCT01108783|Sneezing
1211511|NCT01108783|Nasal itching
1211512|NCT01108783|Nasal Congestion
1211513|NCT01108783|Rhinorrhea
1211514|NCT01108783|Ocular itching
1211515|NCT01108783|Ocular redness
1211516|NCT01108783|Tearing
1211517|NCT01108770|HED
1211518|NCT01108770|XLHED
1211519|NCT01108770|Hypohidrotic Ectodermal Dysplasia
1211520|NCT01108757|catheter
1211521|NCT01108757|urinary tract infection
1211522|NCT01108744|clinical trial
1211523|NCT01108744|mannitol
1211524|NCT01108744|intracranial pressure (ICP)
1211525|NCT01108744|hypertonic saline
1211526|NCT01108744|cerebral edema
1211527|NCT01108744|traumatic brain injury (TBI)
1211528|NCT01108718|Mattress
1211529|NCT01108718|Tempur-Pedic
1211530|NCT01108718|Fibromyalgia
1211531|NCT01108718|Sleep patterns
1211532|NCT01108692|atrial fibrillation
1211533|NCT01108692|supraventricular arrhythmia
1211534|NCT01108692|antithrombotic treatment
1211535|NCT01108692|antiarrhythmic drugs
1211536|NCT01108692|medical reaction time
1211537|NCT01108692|telecardiology
1211538|NCT01108692|early detection
1211539|NCT01108692|holters memories
1211540|NCT01108692|Pacemaker
1211541|NCT01108666|Adult subjects with a confirmed diagnosis of Stage IIIA or IIIB NSCLC, with adequate bone marrow, liver and renal function.
1211542|NCT01108653|Cardiovascular diseases
1211543|NCT01108653|Heart diseases
1211544|NCT01108653|Myocardial infarction
1211545|NCT01108653|Rehabilitation
1211546|NCT01108653|Health Economy
1211547|NCT01108653|Randomized controlled trials
1211548|NCT01108653|Non ST Elevation Myocardial Infarction (NSTEMI)
1211549|NCT01108653|Cost analysis
1211550|NCT01108653|Sick-leave
1211551|NCT01108653|Quality of Life
1211552|NCT01108614|Methadone maintenance treatment
1211553|NCT01108614|drug users
1211554|NCT01108614|heroin
1211555|NCT01108614|HIV
1211556|NCT01108614|HCV
1211557|NCT01108614|Syphilis
1211558|NCT01108614|HSV-2
1211559|NCT01108601|Ringer's
1211560|NCT01108601|lactate
1211561|NCT01108601|cisplatin
1211562|NCT01108601|ototoxicity
1211563|NCT01108601|hearing loss
1211564|NCT01108575|Mechanical ventilation
1211565|NCT01108575|mechanical ventilation weaning
1211566|NCT01108575|inspiratory muscle strength training
1211567|NCT01108575|Patients admitted to a surgical intensive care unit who are expected to receive mechanical ventilation for more than three days.
1211568|NCT01108562|postoperative pain management
1211569|NCT01108549|Fibromyalgia
1211570|NCT01108549|Chronic Fatigue Syndrome
1211571|NCT01108549|D-ribose
1211572|NCT01108549|fatigue
1211573|NCT01108536|prosthetics
1211574|NCT01108536|socket comfort
1211575|NCT01108536|amputation stump
1211576|NCT01108536|amputee rehabilitation
1211577|NCT01108523|Moisture Associated Skin Damage
1211578|NCT01108510|Treatment Naive
1211579|NCT01108510|HIV 1 Infected
1211580|NCT01108484|Cancer survivors, exercise, diet, emotional support
1211581|NCT01108471|cesarean section; hemoglobin; postpartum hemorrhage;
1211582|NCT01108445|cancer
1211583|NCT01108445|kidney cancer
1211584|NCT01108445|sutent
1211585|NCT01108445|everolimus
1211586|NCT01108445|renal cancer
1211587|NCT01108445|papillary renal cell
1211588|NCT01108445|chromophobe renal cell
1211589|NCT01108445|papillary
1211590|NCT01108445|chromophobe
1211591|NCT01108432|Tobacco cessation counseling
1211592|NCT01108419|healthy adults
1211593|NCT01108406|Hearing Loss
1211594|NCT01108406|Unilateral Hearing Loss
1211595|NCT01108406|Single Sided Deafness
1211596|NCT01108393|Obsessive Compulsive Disorder
1211597|NCT01108393|Agomelatine
1211598|NCT01108380|Liver cirrhosis
1211599|NCT01108380|liver regeneration
1211600|NCT01108380|liver volume
1211601|NCT01108380|liver function
1211602|NCT01108380|hepatocellular carcinoma, extensive
1211603|NCT01108380|hepatectomy
1211604|NCT01108328|viscous
1211605|NCT01108328|fibre
1211606|NCT01108328|polysaccharide
1211607|NCT01108328|blood glucose
1211608|NCT01108328|postprandial
1211609|NCT01108328|appetite
1211610|NCT01108328|hunger
1211611|NCT01108328|satiety
1211612|NCT01108315|Patient Reported Outcomes (PRO)
1211613|NCT01108315|Web-based
1211614|NCT01108315|Phone-based
1211615|NCT01108315|Breast Cancer
1211616|NCT01108302|uterotonic
1211617|NCT01108302|oxytocin
1211618|NCT01108302|randomized trial
1211619|NCT01108302|India
1211620|NCT01108302|community
1211621|NCT01108302|hemorrhage
1211622|NCT01108289|hemorrhage
1211623|NCT01108289|uterotonic
1211624|NCT01108289|oxytocin
1211625|NCT01108289|blood loss
1211626|NCT01108289|community
1211627|NCT01108289|Ghana
1211628|NCT01108289|randomized trial
1211629|NCT01108237|Arthroplasties, Knee Replacement
1211630|NCT01108237|Arthroplasties, Replacement, Knee
1211631|NCT01108237|Arthroplasty, Knee Replacement
1211632|NCT01108237|Knee Replacement Arthroplasties
1211633|NCT01108237|Knee Replacement Arthroplasty
1211634|NCT01108237|Knee Replacement, Total
1211635|NCT01108237|Replacement Arthroplasties, Knee
1211636|NCT01108237|Replacement Arthroplasty, Knee
1211637|NCT01108237|Replacement, Total Knee
1211638|NCT01108237|Total Knee Replacement
1211639|NCT01108224|Quality of life
1211640|NCT01108224|Coping
1211641|NCT01108224|Social relations
1211642|NCT01108224|Survival
1211643|NCT01108224|Psychotherapy
1211644|NCT01108211|Adolescent Idiopathic Scoliosis
1211645|NCT01108211|AIS
1211646|NCT01108211|Vibration Therapy
1211647|NCT01108211|Low bone mass
1211648|NCT01108211|osteopenia
1211649|NCT01108198|phimosis,
1211650|NCT01108198|non-retractable foreskin
1211651|NCT01108198|topical steroids
1211652|NCT01108198|children
1211653|NCT01108185|treatment with Klacid®SR
1211654|NCT01108185|tracheitis
1211655|NCT01108185|tracheobronchitis
1211656|NCT01108185|bronchitis
1211657|NCT01108185|chronic bronchitis
1211658|NCT01108185|community-acquired pneumonia
1211659|NCT01108133|Posttraumatic Stress Disorder
1211660|NCT01108133|Traumatic Memories
1211661|NCT01108133|fMRI
1211662|NCT01108120|diabetic foot ulcer
1211663|NCT01108120|artery mini-pump
1211664|NCT01108120|continuous infusion of urokinase
1211665|NCT01108120|femoral artery
1211666|NCT01108107|Colon cancer
1211667|NCT01108107|Neoadjuvant treatment
1211668|NCT01108107|KRAS mutation
1211669|NCT01108107|BRAF mutation
1211670|NCT01108107|PIK3CA mutation
1211671|NCT01108107|Possibly avoid chemotherapy after operation
1211672|NCT01108081|Sleep apnea
1211673|NCT01108081|Sleep symptoms
1211674|NCT01108081|Quality of Life
1211675|NCT01108068|Osteoporosis-pseudoglioma syndrome, OPPG, LRP5 mutation
1211676|NCT01108029|Parkinson's disease
1211677|NCT01108029|Freezing of Gait
1211678|NCT01108029|Memantine
1211679|NCT01108029|NMDA receptor
1211680|NCT01108029|glutamate
1211681|NCT01108029|No Dementia
1211682|NCT01107964|Dry Eye Syndrome
1211683|NCT01107964|Recent Diagnosis of Dry Eye Syndrome
1211684|NCT01107951|Rituximab
1211685|NCT01107951|Dexamethasone
1211686|NCT01107951|Low-dose
1211687|NCT01107951|ITP
1211688|NCT01107938|GERD
1211689|NCT01107925|Platelet function
1211690|NCT01107912|Platelet function
1211691|NCT01107899|Acute Coronary Syndromes
1211692|NCT01107899|Angina
1211693|NCT01107899|Platelet Function
1211694|NCT01107899|Coronary Angiography
1211695|NCT01107899|Clinical Symptoms of Angina
1211696|NCT01107899|Positive Stress Test
1211697|NCT01107886|Risk of cardiovascular disease and death in patients with type 2 diabetes mellitus
1211698|NCT01107873|Twenty (ASA status I) unpremedicated children, ages 1 to 5 yr old
1211699|NCT01107847|electrical impedance tomography
1211700|NCT01107847|EIT
1211701|NCT01107847|acute lung injury
1211702|NCT01107847|regional lung opening pressure
1211703|NCT01107847|regional lung closing pressure
1211704|NCT01107834|HIV
1211705|NCT01107834|heart function
1211706|NCT01107834|HAART
1211707|NCT01107834|in utero
1211708|NCT01107834|children
1211709|NCT01107821|Pressure sores grade III and IV
1211710|NCT01107821|Traumatic wounds with considerable soft tissue loss
1211711|NCT01107821|Wounds after necrotizing fasciitis
1211712|NCT01107821|Abdominal wounds
1211713|NCT01107808|Adolescents
1211714|NCT01107808|African American
1211715|NCT01107808|Female
1211716|NCT01107782|sildenafil
1211717|NCT01107782|FGR
1211718|NCT01107743|Hypertension
1211719|NCT01107743|Angina pectoris
1211720|NCT01107743|Hypercholesterolemia
1211721|NCT01107743|Familial hypercholesterolemia
1211722|NCT01107743|Japanese
1211723|NCT01107743|caduet
1211724|NCT01107743|Regulatory Post Marketing Commitment Plan
1211725|NCT01107730|Atrial fibrillation
1211726|NCT01107730|Cardiac valve repair
1211727|NCT01107730|Aneurysm repair
1211728|NCT01107730|CABG
1211729|NCT01107730|On-pump
1211730|NCT01107730|Cardiac surgery
1211731|NCT01107730|Vitamin C
1211732|NCT01107717|type 2 diabetes
1211733|NCT01107717|new onset
1211734|NCT01107717|combination therapy
1211735|NCT01107717|new onset type 2 diabetes
1211736|NCT01107704|Intensive Care Units
1211737|NCT01107704|Surrogates
1211738|NCT01107704|Family Members
1211739|NCT01107704|Physicians
1211740|NCT01107704|Critically Ill
1211741|NCT01107704|Depression
1211742|NCT01107704|Anxiety
1211743|NCT01107704|Emotional
1211744|NCT01107704|Support
1211745|NCT01107704|Multi-faceted communication
1211746|NCT01107704|Grief
1211747|NCT01107704|Prognosis
1211748|NCT01107704|Family Support Counselor
1211749|NCT01107691|resistance and weight loss training
1211750|NCT01107678|YMCA; Preventative child obesity
1211751|NCT01107665|pazopanib
1211752|NCT01107665|paclitaxel
1211753|NCT01107665|melanoma
1211754|NCT01107639|stage IIB esophageal cancer
1211755|NCT01107639|adenocarcinoma of the esophagus
1211756|NCT01107639|adenocarcinoma of the gastroesophageal junction
1211757|NCT01107639|squamous cell carcinoma of the esophagus
1211758|NCT01107639|stage IIIA esophageal cancer
1211759|NCT01107639|stage IIIB esophageal cancer
1211760|NCT01107639|stage IIIC esophageal cancer
1211761|NCT01107626|recurrent non-small cell lung cancer
1211762|NCT01107626|stage IIIB non-small cell lung cancer
1211763|NCT01107626|stage IV non-small cell lung cancer
1211764|NCT01107626|adenocarcinoma of the lung
1211765|NCT01107626|bronchoalveolar cell lung cancer
1211766|NCT01107626|large cell lung cancer
1211767|NCT01107613|opinion leader
1211768|NCT01107613|COPD
1211769|NCT01107613|Emergency Department
1211770|NCT01107613|relapse
1211771|NCT01107613|follow-up
1211772|NCT01107613|evidence-based guidelines
1211773|NCT01107613|Exacerbation of COPD
1211774|NCT01107600|Dental Implants, Single-Tooth
1211775|NCT01107600|Bone Regeneration
1211776|NCT01107600|Dental Restoration
1211777|NCT01107600|Socket preservation
1211778|NCT01107587|Human rotavirus vaccine
1211779|NCT01107574|Chronic Pain, tenderpoints, insomnia, mood disorder, fatigue
1211780|NCT01107561|cricothyroidotomy
1211781|NCT01107561|intubation
1211782|NCT01107561|airway
1211783|NCT01107561|emergency medicine
1211784|NCT01107561|education
1211785|NCT01107535|Synagis (palivizumab) immunoprophylaxis
1211786|NCT01107535|Respiratory syncytial virus infection
1211787|NCT01107535|Preterm infants
1211788|NCT01107509|Renal cell carcinoma
1211789|NCT01107509|Metastatic
1211790|NCT01107509|everolimus
1211791|NCT01107509|neo-adjuvant
1211792|NCT01107509|biomarkers
1211793|NCT01107509|nephrectomy
1211794|NCT01107509|Locally advanced clear cell renal carcinoma
1211795|NCT01107509|Metastatic clear cell renal carcinoma
1211796|NCT01107509|Clear Cell Renal Carcinoma
1211797|NCT01107483|endotoxaemia
1211798|NCT01107470|Infertility IVF ART
1211799|NCT01107457|Moderate
1211800|NCT01107457|Severe
1211801|NCT01107457|Plaque
1211802|NCT01107457|Chronic
1211803|NCT01107431|glucose
1211804|NCT01107431|insulin
1211805|NCT01107431|L-arabinose
1211806|NCT01107431|Chromium
1211807|NCT01107366|lupiae techinque
1211808|NCT01107366|aortic aneurism
1211809|NCT01107366|aortic dissection
1211810|NCT01107327|cancer
1211811|NCT01107301|ADHD
1211812|NCT01107288|Aged
1211813|NCT01107288|Balance
1211814|NCT01107288|Dual-task
1211815|NCT01107288|Exercise
1211816|NCT01107288|Falls
1211817|NCT01107288|Gait
1211818|NCT01107288|Music
1211819|NCT01107275|Rabies
1211820|NCT01107275|PCECV
1211821|NCT01107275|pre-exposure immunization
1211822|NCT01107275|intradermal
1211823|NCT01107275|children
1211824|NCT01107262|H5N1 Subtype
1211825|NCT01107262|Avian viruses
1211826|NCT01107262|Highly pathogenic avian influenza (HPAI)
1211827|NCT01107249|esophageal
1211828|NCT01107249|stenting
1211829|NCT01107249|perforations
1211830|NCT01107249|gastric
1211831|NCT01107249|esophageal stenting
1211832|NCT01107236|Healthy subjects
1211833|NCT01107223|Antibiotic
1211834|NCT01107223|Prescribing behaviour
1211835|NCT01107223|Guidelines
1211836|NCT01107223|Respiratory tract infections
1211837|NCT01107223|Non-antibiotic prescription
1211838|NCT01107210|stroke
1211839|NCT01107210|physical fitness
1211840|NCT01107210|evolution
1211841|NCT01107210|determinants
1211842|NCT01107197|Pressure ulcers
1211843|NCT01107197|Healing
1211844|NCT01107197|Malnutrition
1211845|NCT01107197|Nutritional support
1211846|NCT01107197|Micronutrients
1211847|NCT01107184|Remote ischemic conditioning
1211848|NCT01107184|CABG surgery
1211849|NCT01107184|Atrial fibrillation
1211850|NCT01107184|Coronary Artery Bypass
1211851|NCT01107184|Ischemic Preconditioning
1211852|NCT01107171|Tang-min-ling pills;
1211853|NCT01107171|overweight type 2 diabetes mellitus;
1211854|NCT01107171|blood glucose
1211855|NCT01107171|Traditional Chinese Medicine
1211856|NCT01107171|Clinical Trial
1211857|NCT01107171|Intervention Studies
1211858|NCT01107145|Plasmodium
1211859|NCT01107145|Vivax
1211860|NCT01107145|Malaria
1211861|NCT01107145|Pregnancy
1211862|NCT01107145|Brazil
1211863|NCT01107145|Treatment
1211864|NCT01107119|Frail elderly
1211865|NCT01107119|Chronic illness
1211866|NCT01107119|Integrated care model
1211867|NCT01107119|Clinical pathways
1211868|NCT01107119|Home care services
1211869|NCT01107106|Contraceptive Methods
1211870|NCT01107106|Female Contraception
1211871|NCT01107080|breast cancer
1211872|NCT01107080|breast carcinoma in situ
1211873|NCT01107080|ductal breast carcinoma in situ
1211874|NCT01107080|invasive carcinoma
1211875|NCT01107080|invasive ductal carcinoma
1211876|NCT01107080|invasive lobular carcinoma
1211877|NCT01107067|hypogonadism
1211878|NCT01107067|paraoxonase
1211879|NCT01107067|Hipogonadism
1211880|NCT01107054|QTC
1211881|NCT01107041|Depression
1211882|NCT01107041|Technology Assisted
1211883|NCT01107041|Mobile Phone
1211884|NCT01107028|Idiopathic pulmonary fibrosis
1211885|NCT01107028|Dyspnea
1211886|NCT01107028|Functional capacity
1211887|NCT01107028|Quality of life
1211888|NCT01107015|Diabetes
1211889|NCT01107015|Glucose control
1211890|NCT01107015|Diabetes monitoring
1211891|NCT01107015|Care management
1211892|NCT01107015|Electronic communication
1211893|NCT01107015|Mobile phone technology
1211894|NCT01107015|Self care
1211895|NCT01107002|infertility
1211896|NCT01107002|Embryo transfer
1211897|NCT01106976|PET
1211898|NCT01106976|acetylcholine
1211899|NCT01106963|knee
1211900|NCT01106963|tibial fractures
1211901|NCT01106963|pain
1211902|NCT01106963|osteosynthesis
1211903|NCT01106963|intramedullary nailing
1211904|NCT01106950|acute myelogenous leukemia
1211905|NCT01106950|primary acute myelogenous leukemia
1211906|NCT01106950|secondary acute myelogenous leukemia
1211907|NCT01106950|relapsed acute myelogenous leukemia
1211908|NCT01106924|Probiotics, Weight control, Body composition
1211909|NCT01106911|digital breast tomosynthesis
1211910|NCT01106911|baseline screening mammography
1211911|NCT01106911|recall rates
1211912|NCT01106885|Diabetes
1211913|NCT01106885|Depression
1211914|NCT01106885|Telephone Care Management
1211915|NCT01106885|Medication Care Management (MCM)
1211916|NCT01106885|Cognitive Behavioral Therapy (CBT)
1211917|NCT01106872|Sarcoma
1211918|NCT01106872|Soft Tissue Sarcoma
1211919|NCT01106872|Locally Advanced Sarcoma
1211920|NCT01106872|Unresectable Sarcoma
1211921|NCT01106872|Metastatic Sarcoma
1211922|NCT01106872|Valproic Acid
1211923|NCT01106872|Bevacizumab
1211924|NCT01106872|Histone Deacetylase Inhibitor
1211925|NCT01106859|insomnia
1211926|NCT01106846|Ketamine
1211927|NCT01106846|Anesthesia
1211928|NCT01106846|Pain
1211929|NCT01106846|Outpatient surgery
1211930|NCT01106833|Chronic Graft-versus-Host Disease (cGVHD)
1211931|NCT01106794|diffuse intrinsic pontine glioma
1211932|NCT01106794|DIPG
1211933|NCT01106794|childhood brainstem glioma
1211934|NCT01106794|pediatric brainstem glioma
1211935|NCT01106794|brainstem glioma
1211936|NCT01106794|BSG
1211937|NCT01106781|EGFR mutation test
1211938|NCT01106781|NSCLC
1211939|NCT01106781|Non-Interventional Study
1211940|NCT01106781|EGFR mutation status
1211941|NCT01106768|oral health needs
1211942|NCT01106768|children
1211943|NCT01106768|attention deficit disorder with or without hyperactivity
1211944|NCT01106755|kinematic
1211945|NCT01106755|hemiparesis
1211946|NCT01106755|gait
1211947|NCT01106755|Body weight support
1211948|NCT01106755|Functional electrical stimulation
1211949|NCT01106742|Inflammatory
1211950|NCT01106742|AbM
1211951|NCT01106742|IBD
1211952|NCT01106729|Flavonoids
1211953|NCT01106729|Anthocyanin
1211954|NCT01106729|Cyanidin 3 glucoside
1211955|NCT01106729|Acute feeding trial
1211956|NCT01106729|Stable isotope
1211957|NCT01106729|Metabolism
1211958|NCT01106729|Clearance
1211959|NCT01106729|Bioavailability
1211960|NCT01106729|Pharmacokinetics
1211961|NCT01106716|Lidocaine
1211962|NCT01106716|Lignocaine
1211963|NCT01106716|Analgesics. Non-narcotic / therapeutic use
1211964|NCT01106716|Neuralgia, Postherpetic
1211965|NCT01106716|Pain
1211966|NCT01106716|Pain measurement / drug effect
1211967|NCT01106716|Pain postoperative / drug therapy
1211968|NCT01106716|PHN
1211969|NCT01106703|atopy, IgE
1211970|NCT01106690|Canagliflozin
1211971|NCT01106690|Placebo
1211972|NCT01106690|Sitagliptin (Januvia)
1211973|NCT01106690|Metformin
1211974|NCT01106690|Pioglitazone (Actos)
1211975|NCT01106690|Hemoglobin A1c
1211976|NCT01106690|Type 2 diabetes mellitus
1211977|NCT01106677|Type 2 diabetes mellitus
1211978|NCT01106677|Canagliflozin
1211979|NCT01106677|Placebo
1211980|NCT01106677|Sitagliptin
1211981|NCT01106677|Januvia
1211982|NCT01106677|Metformin Immediate Release (IR)
1211983|NCT01106677|Hemoglobin A1c
1211984|NCT01106664|ONO-7746
1211985|NCT01106664|Healthy adult subjects
1211986|NCT01106651|Canagliflozin
1211987|NCT01106651|Placebo
1211988|NCT01106651|Hemoglobin A1c
1211989|NCT01106651|Bone
1211990|NCT01106651|Type 2 diabetes mellitus
1211991|NCT01106638|HIV
1211992|NCT01106638|AIDS
1211993|NCT01106638|Smoking
1211994|NCT01106638|Tobacco
1211995|NCT01106638|Cessation
1211996|NCT01106638|Tobacco use in persons living with HIV/AIDS
1211997|NCT01106625|Canagliflozin
1211998|NCT01106625|Placebo
1211999|NCT01106625|Metformin
1212000|NCT01106625|Sulphonylurea
1212001|NCT01106625|Hemoglobin A1c
1212002|NCT01106625|Type 2 diabetes mellitus
1212003|NCT01106612|randomized controlled trial
1212004|NCT01106612|controlled clinical trial
1212005|NCT01106612|comparative effectiveness research
1212006|NCT01106612|chest pain
1212007|NCT01106612|angina pectoris
1212008|NCT01106612|non-invasive cardiac imaging
1212009|NCT01106612|nuclear stress testing
1212010|NCT01106612|coronary CT angiography
1212011|NCT01106612|coronary catheterization
1212012|NCT01106612|coronary revascularization
1212013|NCT01106586|HIV 1 Infection
1212014|NCT01106586|Treatment Naive
1212015|NCT01106573|Diabetes Mellitus
1212016|NCT01106573|Arteriosclerosis
1212017|NCT01106573|Intima media thickness
1212018|NCT01106573|arterial stiffness
1212019|NCT01106573|pulsewave velocity
1212020|NCT01106573|fibulin-1
1212021|NCT01106547|abdominal hysterectomy
1212022|NCT01106547|glucocorticoids
1212023|NCT01106547|rehabilitation
1212024|NCT01106547|postoperative pain
1212025|NCT01106547|analgetics
1212026|NCT01106534|drug eluting stents
1212027|NCT01106534|Stents
1212028|NCT01106534|Angioplasty
1212029|NCT01106534|Stent thrombosis
1212030|NCT01106534|antiplatelet treatment
1212031|NCT01106521|Infiltrating ductal carcinoma
1212032|NCT01106521|Brachytherapy
1212033|NCT01106508|Advanced solid tumors
1212034|NCT01106508|recurrent or refractory medulloblastoma
1212035|NCT01106508|locally advanced or metastatic basal cell carcinoma
1212036|NCT01106508|hedgehog pathway inhibitor
1212037|NCT01106495|Atherosclerosis
1212038|NCT01106495|Vascular Endothelium
1212039|NCT01106495|Counterpulsation, External
1212040|NCT01106482|TBE
1212041|NCT01106482|Tick Borne Encephalitis
1212042|NCT01106469|Healthy Volunteers
1212043|NCT01106469|Healthy
1212044|NCT01106469|JNJ-41443532
1212045|NCT01106469|Pharmacokinetics
1212046|NCT01106443|Indeterminate thyroid nodule
1212047|NCT01106443|fine needle aspirate biopsy
1212048|NCT01106443|thyroidectomy
1212049|NCT01106443|central lymph node dissection
1212050|NCT01106430|ADHD
1212051|NCT01106417|Cervical Degenerative Disc Disease
1212052|NCT01106417|Degenerative Spondylolisthesis
1212053|NCT01106417|Spinal Stenosis
1212054|NCT01106417|Stem cells
1212055|NCT01106417|Adult Stem Cells
1212056|NCT01106417|Anterior cervical discectomy and Fusion (ACDF)
1212057|NCT01106417|Anterior Cervical Plate Fixation
1212058|NCT01106391|Abdominal aortic aneurysm
1212059|NCT01106391|AAA
1212060|NCT01106391|Safety
1212061|NCT01106391|Performance
1212062|NCT01106391|Stent graft system
1212063|NCT01106391|First in Human
1212064|NCT01106391|Endovascular repair
1212065|NCT01106378|Coronary artery disease
1212066|NCT01106378|drug-eluting stents
1212067|NCT01106378|sirolimus-eluting coronary stents
1212068|NCT01106365|multiple sclerosis
1212069|NCT01106365|fatigue
1212070|NCT01106365|depressivity
1212071|NCT01106365|repetitive deep transcranial magnetic stimulation
1212072|NCT01106352|The target population is patients with bone metastasis from castration-resistant prostate cancer intended for treatment with docetaxel
1212073|NCT01106339|humans
1212074|NCT01106339|patients
1212075|NCT01106339|somatoform disorders
1212076|NCT01106339|fibromyalgia
1212077|NCT01106339|myofascial pain syndrome diffuse
1212078|NCT01106339|depression
1212079|NCT01106339|chronic fatigue syndrome
1212080|NCT01106339|inflammation
1212081|NCT01106339|inflammatory response
1212082|NCT01106339|biomarkers
1212083|NCT01106339|cytokines
1212084|NCT01106339|cell surface markers
1212085|NCT01106339|functional polymorphisms
1212086|NCT01106326|Asthma
1212087|NCT01105793|cyclic mastalgia
1212088|NCT01105793|cyclic breast pain
1212089|NCT01105793|fibrocystic breast disease
1212090|NCT01105780|Healthy Volunteers
1212091|NCT01105780|Healthy
1212092|NCT01105780|Japanese
1212093|NCT01105780|Pharmacokinetics
1212094|NCT01105780|JNJ-41443532
1212095|NCT01105767|Staphylococcus aureus
1212096|NCT01105767|MRSA Skin Infection
1212097|NCT01105767|Staphylococcal Skin Infections
1212098|NCT01105767|Chlorhexidine gluconate
1212099|NCT01106248|tumor
1212100|NCT01106209|premature infants
1212101|NCT01106209|polymorphonuclear leukocytes
1212102|NCT01106209|PMNs
1212103|NCT01106209|neutrophil extracellular traps
1212104|NCT01106209|NET formation
1212105|NCT01106209|necrotizing enterocolitis
1212106|NCT01106196|Influenza, Human
1212107|NCT01106196|Influenza, Human/complications
1212108|NCT01106196|Myocardial infarction/etiology
1212109|NCT01106196|Cardiovascular Diseases/mortality
1212110|NCT01106157|Autoimmune, Diabetes Mellitus, Glucose Metabolism
1212111|NCT01106079|Early psoriatic arthritis
1212112|NCT01106079|Tight control
1212113|NCT01106079|Intensive management
1212114|NCT01106053|Binge eating disorder
1212115|NCT01106053|Food craving
1212116|NCT01106053|Obesity
1212117|NCT01106053|Pramipexole
1212118|NCT01106053|Mirapex
1212119|NCT01106053|Binge
1212120|NCT01106040|Lymphoseek
1212121|NCT01106040|Breast Cancer
1212122|NCT01106040|Melanoma
1212123|NCT01106040|Experimental
1212124|NCT01106014|pulmonary arterial hypertension
1212125|NCT01106014|PAH
1212126|NCT01106001|total hip arthroplasty
1212127|NCT01106001|periarticular injection
1212128|NCT01106001|pain
1212129|NCT01105988|GBM
1212130|NCT01105988|PET scans
1212131|NCT01105988|MRI scans
1212132|NCT01105975|Dyslipidemias
1212133|NCT01105975|Mixed dyslipidemia
1212134|NCT01105975|Hypercholesterolemia
1212135|NCT01105975|Atherosclerosis
1212136|NCT01105975|Atorvastatin
1212137|NCT01105975|Simvastatin
1212138|NCT01105975|Rosuvastatin
1212139|NCT01105975|Metabolic Diseases
1212140|NCT01105975|Antilipemic Agents
1212141|NCT01105975|Enzyme Inhibitors
1212142|NCT01105975|Anticholesteremic Agents
1212143|NCT01105975|Cholesteryl Ester Transfer Protein Inhibitors
1212144|NCT01105975|Cholesteryl Ester
1212145|NCT01105975|Lipid Metabolism Disorders
1212146|NCT01105962|traumatic
1212147|NCT01105962|brain
1212148|NCT01105962|injury
1212149|NCT01105962|post-traumatic
1212150|NCT01105962|stress
1212151|NCT01105962|hyperbaric
1212152|NCT01105962|oxygen
1212153|NCT01105962|HBOT
1212154|NCT01105962|TBI
1212155|NCT01105962|PTSD
1212156|NCT01105949|nasal patency
1212157|NCT01105949|acoustic rhinometry
1212158|NCT01105949|nasal strip
1212159|NCT01105936|pain
1212160|NCT01105936|paracetamol
1212161|NCT01105936|Blood-Oxygen-Level-Dependent functional magnetic resonance imaging
1212162|NCT01105936|osteoarthritis
1212163|NCT01105910|Dry Eye, Post Menopausal dry eye
1212164|NCT01105897|endometriosis
1212165|NCT01105897|deep endometriosis
1212166|NCT01105897|surgery
1212167|NCT01105897|laparoscopy
1212168|NCT01105897|chronic pain
1212169|NCT01105897|quality of life
1212170|NCT01105897|sexual function
1212171|NCT01105897|complications
1212172|NCT01105897|recurrence
1212173|NCT01105884|Wound healing, type 2 diabetes, diabetic foot ulcers, different dressings
1212174|NCT01105871|Pain relief
1212175|NCT01105858|Diabetes Mellitus
1212176|NCT01105858|Obesity
1212177|NCT01105858|Diabetic Complications
1212178|NCT01105858|Genetics
1212179|NCT01105858|Molecular Profiling
1212180|NCT01105845|Motor Learning
1212181|NCT01105845|Genetic Analysis
1212182|NCT01105845|BDNF
1212183|NCT01105845|Parkinson Disease
1212184|NCT01105845|Movement Disorders
1212185|NCT01105845|Dystonia
1212186|NCT01105845|Healthy Volunteer
1212187|NCT01105845|HV
1212188|NCT01105832|Teriparatide
1212189|NCT01105832|fracture healing
1212190|NCT01105832|proximal humeral fractures
1212191|NCT01105819|Probiotics
1212192|NCT01105819|Lactobacillus plantarum 299
1212193|NCT01105819|Ventilator-associated pneumonia VAP
1212194|NCT01105819|Chlorhexidine
1212195|NCT01105819|Tracheal secretions
1212196|NCT01105819|Oropharyngeal secretions
1212197|NCT01105806|advance directive
1212198|NCT01105806|CPR Intervention
1212199|NCT01105806|Video
1212200|NCT01105806|Narrative
1212201|NCT01105806|10-043
1212202|NCT01105741|Crohn's disease
1212203|NCT01105741|Adalimumab
1212204|NCT01105741|Metabolome
1212205|NCT01105728|Gastric subepitelial mass
1212206|NCT01105728|Endoscopic full thickness resection
1212207|NCT01105715|Rheumatoid Arthritis
1212208|NCT01105715|cLDL
1212209|NCT01105715|Cardiovascular disease
1212210|NCT01105702|brain tumor
1212211|NCT01105702|brain cancer
1212212|NCT01105702|glioma
1212213|NCT01105689|Urine Calcium to Creatinine Ratio
1212214|NCT01105689|Hypocalciuria
1212215|NCT01105689|Infants
1212216|NCT01105689|Toddlers
1212217|NCT01105676|vascular malformation
1212218|NCT01105676|vascular anomalies
1212219|NCT01105676|abnormalities of growth
1212220|NCT01105676|overgrowth
1212221|NCT01105676|subjects with vascular malformations abnormalities of growth.
1212222|NCT01105663|sedated
1212223|NCT01105663|intubated
1212224|NCT01105663|mechanically ventilated
1212225|NCT01105663|pediatric
1212226|NCT01105663|lung injury
1212227|NCT01105650|recurrent ovarian cancer
1212228|NCT01105650|recurrent fallopian tube cancer
1212229|NCT01105650|recurrent primary peritoneal cancer
1212230|NCT01105650|refractory ovarian cancer
1212231|NCT01105650|refractory fallopian tube cancer
1212232|NCT01105650|refractory peritoneal cancer
1212233|NCT01105650|metastatic breast cancer
1212234|NCT01105637|burn injuries
1212235|NCT01105637|exercise
1212236|NCT01105611|HIV
1212237|NCT01105611|Hepatitis C
1212238|NCT01105611|Co-infection
1212239|NCT01105611|Intravenous drug users
1212240|NCT01105611|Treatment-naïve
1212241|NCT01105611|Methadone
1212242|NCT01105585|Cataracts
1212243|NCT01105585|aspheric
1212244|NCT01105585|IOL
1212245|NCT01105585|ocular aberrations
1212246|NCT01105572|Congestive Heart Failure
1212247|NCT01105559|Diphtheria
1212248|NCT01105559|Tetanus
1212249|NCT01105559|Whooping cough
1212250|NCT01105559|Hepatitis B
1212251|NCT01105559|Poliomyelitis
1212252|NCT01105559|Diphtheria-Tetanus-acellular Pertussis Vaccines
1212253|NCT01105546|hemophilia A
1212254|NCT01105546|inhibitors
1212255|NCT01105546|prophylaxis
1212256|NCT01105546|immune tolerance induction
1212257|NCT01105533|VGEF inhibitor
1212258|NCT01105533|Anti angiogenesis
1212259|NCT01105533|Advanced Solid Tumors
1212260|NCT01105520|Intraspinal processes (tumor or vascular malformation AVM)
1212261|NCT01105507|Canakinumab
1212262|NCT01105507|Cryopyrin-associated periodic syndromes
1212263|NCT01105507|Familial Cold Autoinflammatory Syndrome (FCAS)
1212264|NCT01105507|Familial Cold Urticaria (FCU)
1212265|NCT01105507|Muckle-Wells Syndrome (MWS)
1212266|NCT01105507|Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
1212267|NCT01105507|Chronic Infantile Neurological
1212268|NCT01105507|Cutaneous
1212269|NCT01105507|Articular Syndrome (CINCA)
1212270|NCT01105507|Treatment of patients diagnosed with CAPS (Cryopyrin associated periodic syndrome)
1212271|NCT01105481|treatment-resistant schizophrenia
1212272|NCT01105481|clozapine
1212273|NCT01105481|amisulpride
1212274|NCT01105468|Breath gas analysis
1212275|NCT01105468|Volatile components in exhaled breath
1212276|NCT01105455|Randomized clinical trial
1212277|NCT01105455|Gestational diabetes
1212278|NCT01105455|Carbohydrates
1212279|NCT01105455|Glycemic index
1212280|NCT01105442|Post-operative pain treatment
1212281|NCT01105442|Fast-track colonic surgery patients
1212282|NCT01105442|Surgery
1212283|NCT01105416|Pediatric Emergency Department
1212284|NCT01105416|Parental monitoring
1212285|NCT01105416|Adolescent
1212286|NCT01105416|Parents
1212287|NCT01105416|Communication
1212288|NCT01105416|Alcohol Drinking
1212289|NCT01105403|Hematopoietic stem cells
1212290|NCT01105403|Mobilisation
1212291|NCT01105403|Autologous transplantation
1212292|NCT01105364|recurrent renal cell cancer
1212293|NCT01105364|stage IV renal cell cancer
1212294|NCT01105364|liver metastases
1212295|NCT01105351|Folate
1212296|NCT01105351|MTHFR
1212297|NCT01105351|Homocysteine
1212298|NCT01105338|prostate cancer
1212299|NCT01105325|acute coronary syndrome
1212300|NCT01105325|treatment compliance
1212301|NCT01105325|cardiac intensive care unit
1212302|NCT01105325|secondary prevention
1212303|NCT01105325|cardiac intensive care unit (CIC)
1212304|NCT01105325|compliance
1212305|NCT01105325|intensive care
1212306|NCT01105312|male breast cancer
1212307|NCT01105312|estrogen receptor-negative breast cancer
1212308|NCT01105312|estrogen receptor-positive breast cancer
1212309|NCT01105312|HER2-negative breast cancer
1212310|NCT01105312|HER2-positive breast cancer
1212311|NCT01105312|progesterone receptor-negative breast cancer
1212312|NCT01105312|progesterone receptor-positive breast cancer
1212313|NCT01105312|triple-negative breast cancer
1212314|NCT01105312|recurrent breast cancer
1212315|NCT01105312|stage IV breast cancer
1212316|NCT01105299|bioequivalence
1212317|NCT01105299|anastrozole
1212318|NCT01105299|Healthy subjects
1212319|NCT01105299|Antineoplastic Agents
1212320|NCT01105299|Therapeutic Uses
1212321|NCT01105299|Enzyme Inhibitors
1212322|NCT01105273|Aplastic anemia
1212323|NCT01105273|Fludarabine
1212324|NCT01105273|CD3±CD19 depletion
1212325|NCT01105273|Haploidentical hematopoietic stem cell transplantation
1212326|NCT01105260|early reconditioning program
1212327|NCT01105260|spinal cord injury
1212328|NCT01105260|early rehabilitation
1212329|NCT01105260|wheelchair
1212330|NCT01105247|PCI-32765
1212331|NCT01105247|Lymphoma, B-Cell
1212332|NCT01105247|Leukemia, Lymphoid
1212333|NCT01105247|Leukemia, B-Cell
1212334|NCT01105247|Bruton's Tyrosine Kinase
1212335|NCT01105234|Healthy volunteers
1212336|NCT01105221|Acupuncture
1212337|NCT01105221|Dry eye
1212338|NCT01105221|Artificial tear drop
1212339|NCT01105221|Mixed method approach
1212340|NCT01105221|Qualitative study
1212341|NCT01105221|Cost effectiveness analysis
1212342|NCT01105221|Tear cytokine analysis
1212343|NCT01105195|DuraPrep
1212344|NCT01105195|ChloraPrep
1212345|NCT01105195|Lumbar Spine
1212346|NCT01105182|Radiofrequency Ablation
1212347|NCT01105169|Personalized prevention
1212348|NCT01105169|Colorectal cancer
1212349|NCT01105169|Investigational Nutrigenetic Studies
1212350|NCT01105169|Magnesium
1212351|NCT01105169|Gene polymorphism
1212352|NCT01105156|Gastric band
1212353|NCT01105156|Questionnaire
1212354|NCT01105156|Post operative management
1212355|NCT01105156|Adjustment
1212356|NCT01105143|weight loss
1212357|NCT01105143|muscle mass
1212358|NCT01105130|radiation toxicity
1212359|NCT01105130|male erectile disorder
1212360|NCT01105130|prostate cancer
1212361|NCT01105117|Pulmonary Arterial Hypertension
1212362|NCT01105117|PAH
1212363|NCT01105117|EPITOME-1
1212364|NCT01105091|Pulmonary Arterial Hypertension
1212365|NCT01105091|PAH
1212366|NCT01105091|EPITOME-1
1212367|NCT01105078|cardiopulmonary bypass flow rate outcome tissue perfusion oxygenation l/min/m2
1212368|NCT01105065|Normal Pressure Glaucoma
1212369|NCT01105052|Insomnia
1212370|NCT01105052|Co-morbid
1212371|NCT01105052|CBT
1212372|NCT01105052|Self-help
1212373|NCT01105052|Bibliotherapy
1212374|NCT01105039|Pain pattern
1212375|NCT01105039|overall pain
1212376|NCT01105039|incisional pain
1212377|NCT01105039|shoulder pain
1212378|NCT01105039|visceral pain
1212379|NCT01105026|alveolar ridge preservation, bioactive glass, tooth extraction, graft material
1212380|NCT01105013|fungal infections
1212381|NCT01105013|tinea
1212382|NCT01105013|tonaftato
1212383|NCT01105000|HPV
1212384|NCT01105000|HPV vaccine
1212385|NCT01104987|Ankylosing spondylitis
1212386|NCT01104987|spondarthritis
1212387|NCT01104987|Osteoporosis
1212388|NCT01104987|Bone mineral density
1212389|NCT01104987|Dual energy x-ray absorptiometry
1212390|NCT01104987|Quantitative computed tomography
1212391|NCT01103973|IVF, Mind/Body
1212392|NCT01103947|Anesthesia induction
1212393|NCT01103947|Facemask
1212394|NCT01103947|surgery
1212395|NCT01103921|sugar
1212396|NCT01103921|fructose
1212397|NCT01103921|glucose
1212398|NCT01103921|HFCS
1212399|NCT01103921|metabolism
1212400|NCT01103908|cardiac output
1212401|NCT01103908|cardiopulmonary bypass
1212402|NCT01103908|ultrasound dilution
1212403|NCT01103895|cardiac output
1212404|NCT01103895|cardiopulmonary bypass
1212405|NCT01103895|ultrasound dilution
1212406|NCT01102829|Knee Joint
1212407|NCT01102829|Arthroplasty
1212408|NCT01102829|Replacement
1212409|NCT01102829|Knee
1212410|NCT01102816|hemodialysis
1212411|NCT01102816|end-stage renal disease
1212412|NCT01102816|pain
1212413|NCT01102816|acupuncture
1212414|NCT01102803|Phobias
1212415|NCT01102803|Anxiety Disorders
1212416|NCT01102803|D-Cycloserine
1212417|NCT01102803|Phobic Disorders
1212418|NCT01102803|Mental Disorders
1212419|NCT01102803|Heights
1212420|NCT01102803|Acrophobia
1212421|NCT01102790|HIT
1212422|NCT01102777|internet
1212423|NCT01102777|walking
1212424|NCT01102764|Anxiety Disorders: PTSD
1212425|NCT01102764|Prolong Exposure (PE)
1212426|NCT01102764|Telemedicine
1212427|NCT01102764|cost effectiveness
1212428|NCT01102764|deployment related problems
1212429|NCT01102764|mental health care delivery
1212430|NCT01102751|fibroblast growth factor 23
1212431|NCT01102751|Osteomalacia
1212432|NCT01102751|vitamin D
1212433|NCT01102725|Colon Surgery
1212434|NCT01102725|Rectal Surgery
1212435|NCT01102725|Colorectal Surgery
1212436|NCT01104974|HIV
1212437|NCT01104974|HIV providers
1212438|NCT01104974|Infectious Disease
1212439|NCT01104974|HIV and pregnancy
1212440|NCT01104961|Bacterial infection
1212441|NCT01104961|Loss of epithelial cells
1212442|NCT01104922|Re-irradiation with Fractionated Stereotactic Radiosurgery for Head and Neck
1212443|NCT01104909|Dry weight
1212444|NCT01104909|Blood Pressure
1212445|NCT01104909|Chronic Kidney disease
1212446|NCT01104896|Cigarette
1212447|NCT01104896|tobacco
1212448|NCT01104896|mechanical ventilation
1212449|NCT01104896|nicotine
1212450|NCT01104883|Adductor-Canal-Blockade
1212451|NCT01104883|postoperative pain
1212452|NCT01104883|US-guided nerve block
1212453|NCT01104883|total knee arthroplasty
1212454|NCT01104857|Respiratory muscle
1212455|NCT01104857|Myosin
1212456|NCT01104857|Mechanical ventilation
1212457|NCT01104844|dental pain
1212458|NCT01104844|Analgesia
1212459|NCT01104831|Tibial Plateau Fracture
1212460|NCT01104831|AO/OTA 41
1212461|NCT01104818|Sibling relationship quality
1212462|NCT01104818|Foster Care
1212463|NCT01104818|Parent Management Training
1212464|NCT01104818|Mental health outcomes
1212465|NCT01104805|Drug Abuse
1212466|NCT01104805|Substance Abuse
1212467|NCT01104805|Substance Use Disorder
1212468|NCT01104805|Addiction
1212469|NCT01104805|Behavioral Treatment
1212470|NCT01104792|Schizophrenia
1212471|NCT01104792|Acute Schizophrenia
1212472|NCT01104792|Psychotropic Drugs
1212473|NCT01104792|Antipsychotic Agents
1212474|NCT01104792|Mental Disorders
1212475|NCT01104792|Dopamine Agents
1212476|NCT01104792|Central Nervous System Agents
1212477|NCT01104779|Schizophrenia
1212478|NCT01104779|Acute Schizophrenia
1212479|NCT01104779|Psychotropic Drugs
1212480|NCT01104779|Antipsychotic Agents
1212481|NCT01104779|Mental Disorders
1212482|NCT01104779|Dopamine Agents
1212483|NCT01104779|Central Nervous System Agents
1212484|NCT01104766|Schizophrenia
1212485|NCT01104766|Acute Schizophrenia
1212486|NCT01104766|Psychotropic Drugs
1212487|NCT01104766|Aripiprazole
1212488|NCT01104766|Antipsychotic Agents
1212489|NCT01104766|Mental Disorders
1212490|NCT01104766|Dopamine Agents
1212491|NCT01104766|Central Nervous System Agents
1212492|NCT01104727|SINGLE PORT SURGERY
1212493|NCT01104727|LAPAROSCOPY, CHOLECYSTECTOMY
1212494|NCT01104701|Exenatide
1212495|NCT01104701|Amylin
1212496|NCT01104701|Lilly
1212497|NCT01104701|Byetta
1212498|NCT01104701|Exenatide Once Weekly
1212499|NCT01104688|Abdominal Aortic Aneurysm
1212500|NCT01104688|Wall Stress
1212501|NCT01104688|Shear Stress
1212502|NCT01104688|Inflammation
1212503|NCT01104688|Magnetic Resonance Imaging
1212504|NCT01104675|ovarian
1212505|NCT01104675|platinum resistant ovarian cancer
1212506|NCT01104649|Spinocerebellar ataxia
1212507|NCT01104649|Friedreich ataxia
1212508|NCT01104623|ADHD
1212509|NCT01104597|Healthy Asian Indians and Caucasians
1212510|NCT01104584|Breast Cancer
1212511|NCT01104584|Gadobutrol-enhanced MRI
1212512|NCT01104584|Mammography
1212513|NCT01104584|Diagnostic Imaging
1212514|NCT01104571|HER2-positive breast cancer
1212515|NCT01104571|stage IA breast cancer
1212516|NCT01104571|stage IB breast cancer
1212517|NCT01104571|stage II breast cancer
1212518|NCT01104571|stage IIIA breast cancer
1212519|NCT01104571|estrogen receptor-negative breast cancer
1212520|NCT01104571|estrogen receptor-positive breast cancer
1212521|NCT01104558|Bisoprolol
1212522|NCT01104558|Chronic Heart failure
1212523|NCT01104532|ASP1941
1212524|NCT01104532|Januvia
1212525|NCT01104532|sitagliptin
1212526|NCT01104480|Relapsing Polychondritis
1212527|NCT01104480|Unremitting
1212528|NCT01104480|Inflammation
1212529|NCT01104480|IL6
1212530|NCT01104467|Acute Ischemic Stroke
1212531|NCT01104467|Desmoteplase
1212532|NCT01104467|Japan
1212533|NCT01104467|Safety
1212534|NCT01104467|Stroke
1212535|NCT01104467|Tolerability
1212537|NCT01104441|critical limb ischaemia
1212538|NCT01104441|Aspirin resistance
1212539|NCT01104428|Hench-schonlein purpura
1212540|NCT01104428|Renal damage
1212541|NCT01104428|Relapse
1212542|NCT01104428|End event
1212543|NCT01104428|TCM syndrome
1212544|NCT01104415|Carcinoid syndrome
1212545|NCT01104402|telemedicine
1212546|NCT01104402|spirometer
1212547|NCT01104402|CF
1212548|NCT01104402|pulmonary
1212549|NCT01104402|home monitoring
1212550|NCT01104376|Cytochrome P450
1212551|NCT01104376|CYP2B6
1212552|NCT01104376|Voriconazole
1212553|NCT01104376|Efavirenz
1212554|NCT01104376|Pharmacokinetics
1212555|NCT01104376|Drug-Interactions
1212556|NCT01104376|Pharmacogenetics
1212557|NCT01104376|Healthy volunteers
1212558|NCT01104363|Dental implants
1212559|NCT01104350|Bladder
1212560|NCT01104350|Radiotherapy
1212561|NCT01104350|Gemcitabine
1212562|NCT01104350|Chemotherapy
1212563|NCT01104350|10-031
1212564|NCT01104337|paracetamol
1212565|NCT01104337|warfarin
1212566|NCT01104337|drug interaction
1212567|NCT01104337|pathogenic mechanism
1212568|NCT01104324|bone health
1212569|NCT01104324|Osteonecrosis
1212570|NCT01104324|acute lymphoblastic leukemia
1212571|NCT01104311|Blood Pressure
1212572|NCT01104311|Atherosclerosis
1212573|NCT01104311|Brain Ischemia
1212574|NCT01104298|metastatic STS
1212575|NCT01104298|Trabectedin
1212576|NCT01104298|doxorrubicin
1212577|NCT01104298|soft tissue sarcoma
1212578|NCT01104298|non operable sarcoma
1212579|NCT01104272|Ultrasound Treatment of Subcutaneous Adipose Tissue
1212580|NCT01104246|Hypogonadism
1212581|NCT01104246|Testosterone
1212582|NCT01104246|Hormone replacement therapy
1212583|NCT01104233|Video-assisted Thoracoscopic Surgery
1212584|NCT01104233|Soft spreading
1212585|NCT01104233|LAP Protector
1212586|NCT01104220|NAFLD
1212587|NCT01104220|Obesity
1212588|NCT01104220|Metabolic syndrome
1212589|NCT01104207|tinnitus
1212590|NCT01104207|TMS
1212591|NCT01104207|transcranial magnetic stimulation
1212592|NCT01104194|depression
1212593|NCT01104194|cognition
1212594|NCT01104194|heart rate variability
1212595|NCT01104194|omega-3 fatty acids
1212596|NCT01104194|Depression (in remission) (vulnerability to depression)
1212597|NCT01104181|Anal HPV
1212598|NCT01104181|Anal Dysplasia
1212599|NCT01104181|Ana Cancer
1212600|NCT01104168|diabetes
1212601|NCT01104168|elderly
1212602|NCT01104168|nursing home resident
1212603|NCT01104155|NSCLC
1212604|NCT01104129|Pancreatic Cancer
1212605|NCT01104129|Intraductal Papillary Mucinous Neoplasm (IPMN)
1212606|NCT01104129|Stool-based digital melt curve (DMC) assay
1212607|NCT01104129|Surgical resection for pancreatic cancer
1212608|NCT01104129|Hereditary Pancreatic Cancer Syndrome
1212609|NCT01104129|Genetic mutations linked to pancreatic cancer
1212610|NCT01104116|Pancreatic Cancer
1212611|NCT01104116|Intraductal Papillary Mucinous Neoplasm
1212612|NCT01104116|Pre-cancerous pancreatic lesion
1212613|NCT01104116|PET Scan
1212614|NCT01104116|Pancreatic Cancer Screening
1212615|NCT01104103|Catheterization, Peripheral
1212616|NCT01104103|Disposable Equipment
1212617|NCT01104103|Emergency Medical Technicians
1212618|NCT01104103|Emergency Nursing
1212619|NCT01104090|C-MAC
1212620|NCT01104090|direct laryngoscopy
1212621|NCT01104090|indirect laryngoscopy
1212622|NCT01104090|to determine the safety and efficacy of the C-MAC
1212623|NCT01104077|Pancreatic Cancer
1212624|NCT01104077|Family History
1212625|NCT01104077|Pre-cancerous lesion
1212626|NCT01104077|Intraductal Papillary Mucinous Neoplasm (IPMN)
1212627|NCT01104077|Intraductal Papillary Mucinous Neoplasm
1212628|NCT01104064|Stroke
1212629|NCT01104038|physical activity
1212630|NCT01104038|cardiometabolic risk
1212631|NCT01104038|children
1212632|NCT01104025|hemophagocytic lymphohistiocytosis
1212633|NCT01104025|hybrid immunotherapy
1212634|NCT01104025|dexamethasone
1212635|NCT01104025|Etoposide
1212636|NCT01104025|ATG,rabbit
1212637|NCT01103999|spleen
1212638|NCT01103986|health literacy
1212639|NCT01103986|consumer health information
1212640|NCT01103986|patient education as topics/methods
1212641|NCT01103986|patient participation
1212642|NCT01103856|HIV
1212643|NCT01103856|adherence to care
1212644|NCT01103856|retention in care
1212645|NCT01103856|patient navigation
1212646|NCT01103843|Coronary artery disease
1212647|NCT01103843|clopidogrel
1212648|NCT01103843|prasugrel
1212649|NCT01103843|Verify Now
1212650|NCT01103843|PRU measurements
1212651|NCT01103843|Drug eluting stents (EDS)
1212652|NCT01103843|P2Y12
1212653|NCT01103843|Platelet reactivity
1212654|NCT01103830|P. falciparum Malaria, Eurartesim, ACT
1212655|NCT01103817|Type 1 Diabetes
1212656|NCT01103817|Adolescents and Young Adults
1212657|NCT01103817|Vitamin D
1212658|NCT01103817|Cardiovascular Disease
1212659|NCT01103804|GerdQ questionnaire
1212660|NCT01103778|Chronic kidney disease
1212661|NCT01103778|IgA nephropathy
1212662|NCT01103778|Velcade®
1212663|NCT01103778|Proteinuria
1212664|NCT01103778|Bortezomib
1212665|NCT01103778|Proteasome inhibitor
1212666|NCT01103765|Post-dilatation
1212667|NCT01103765|noncompliant balloon
1212668|NCT01103765|optimal stent deployment of drug-eluting stent
1212669|NCT01103765|Intravascular ultrasound (IVUS)
1212670|NCT01103765|Optimal stent deployment defined by intravascular ultrasound analysis
1212671|NCT01103739|pharmacokinetics
1212672|NCT01103739|drug-drug interaction
1212673|NCT01103726|FDG-PET
1212674|NCT01103726|regional cerebral glucose metabolism
1212675|NCT01103726|striatum
1212676|NCT01103726|PDE10 inhibitor
1212677|NCT01103713|P. falciparum malaria
1212678|NCT01103713|asymptomatic parasitemia
1212679|NCT01103713|parasitological clearance
1212680|NCT01103713|Intermittent Preventive Treatment of Falciparum Malaria in Pregnant Women (IPTp)
1212681|NCT01103700|Quality of dying and death of terminal cancer patients
1212682|NCT01103687|HIV Preventive Vaccine
1212683|NCT01103674|Paroxysmal Atrial Fibrillation
1212684|NCT01103674|AF
1212685|NCT01103674|Atrial Fibrillation
1212686|NCT01103674|RF ablation
1212687|NCT01103661|Longstanding Persistent Atrial Fibrillation
1212688|NCT01103661|AF
1212689|NCT01103661|Chronic AF
1212690|NCT01103661|RF Ablation
1212691|NCT01103661|nContact Surgical
1212692|NCT01103661|Therapy Cool Path Ablation Catheter
1212693|NCT01103661|St. Jude Medical
1212694|NCT01103648|Prediabetes
1212695|NCT01103648|Statin
1212696|NCT01103648|Ezetimibe
1212697|NCT01103648|Pleiotropic effects
1212698|NCT01103648|Cardiometabolic risk
1212699|NCT01103622|Diabetes
1212700|NCT01103622|Type 2
1212701|NCT01103622|Digoxin
1212702|NCT01103622|drug-drug interaction
1212703|NCT01103609|Diabetes
1212704|NCT01103609|Type 2
1212705|NCT01103609|Warfarin
1212706|NCT01103609|drug-drug interaction
1212707|NCT01103596|Evaluation of the impact of Kaletra on antiretroviral resistance
1212708|NCT01103570|Laparoscopic cholecystectomy
1212709|NCT01103570|Intra-operative cholangiography
1212710|NCT01103557|Papillary thyroid carcinoma with neck metastasis
1212711|NCT01103557|neck dissection
1212712|NCT01103544|TCCU
1212713|NCT01103544|advanced TCCU
1212714|NCT01103544|metastatic TCCU
1212715|NCT01103544|transitional cell carcinoma of the urothelium
1212716|NCT01103544|advanced transitional cell carcinoma of the urothelium
1212717|NCT01103544|metastatic transitional cell carcinoma of the urothelium
1212718|NCT01103544|Cisplatinum failure
1212719|NCT01103544|Vinflunine
1212720|NCT01103544|Javlor
1212721|NCT01103544|daily routine
1212722|NCT01103544|concomitant antiemetic treatment
1212723|NCT01103544|concomitant antiobstipative treatment
1212724|NCT01103544|concomitant antiobstipative diet
1212725|NCT01103544|patient compliance
1212726|NCT01103544|quality of life
1212727|NCT01103544|non-interventional study
1212728|NCT01103544|Germany
1212729|NCT01103544|Advanced / metastatic TCCU after Cisplatinum-failure
1212730|NCT01103531|Methamphetamine
1212731|NCT01103531|Methamphetamine Dependence
1212732|NCT01103531|Methamphetamine Treatment
1212733|NCT01103531|Aerobic Exercise
1212734|NCT01103531|Resistance Exercise
1212735|NCT01103531|Brain Imaging
1212736|NCT01103531|D2 and D3 receptor availability
1212737|NCT01103518|Menstrual irregularity
1212738|NCT01103518|Menstruation disturbances
1212739|NCT01103518|Hyperandrogenism
1212740|NCT01103505|AMD
1212741|NCT01103505|CNV
1212742|NCT01103492|prostate cancer
1212743|NCT01103492|endometrial cancer
1212744|NCT01103492|radiation proctitis
1212745|NCT01103492|pelvic radiotherapy
1212746|NCT01103492|rectal bleeding
1212747|NCT01103479|Early Detection of Cancer
1212748|NCT01103479|Colorectal Cancer Screening
1212749|NCT01103466|Ileostomy base plate
1212750|NCT01103453|MCI
1212751|NCT01103453|Executive Function
1212752|NCT01103453|ADL
1212753|NCT01103453|Virtual Supermarket
1212754|NCT01103440|Major Adverse Cardiovascular Event
1212755|NCT01103440|MACE
1212756|NCT01103440|Death
1212757|NCT01103440|MI
1212758|NCT01103440|CK MB greater 3x Normal
1212759|NCT01103440|Urgent Revascularization
1212760|NCT01103440|Stent Thrombosis
1212761|NCT01103440|Bleeding
1212762|NCT01103427|smoking cessation
1212763|NCT01103427|telemedicine
1212764|NCT01103427|smoking
1212765|NCT01103427|prevention intervention
1212766|NCT01103427|internet-based
1212767|NCT01103427|text messages
1212768|NCT01103427|behavioral
1212769|NCT01103414|Diabetes
1212770|NCT01103388|Rituximab
1212771|NCT01103388|Rituxan
1212772|NCT01103388|Lymphoma
1212773|NCT01103388|High dose chemotherapy
1212774|NCT01103388|Autologous transplantation
1212775|NCT01103388|Autologous stem cell transplant
1212776|NCT01103388|ASCT
1212777|NCT01103336|Patients with chronic renal failure undergoing coronary angiography
1212778|NCT01103323|Metastatic Colorectal Cancer
1212779|NCT01103310|Neoplasm
1212780|NCT01103310|PET/CT diagnosis
1212781|NCT01103310|PET tracer
1212782|NCT01103297|Distal radius fracture
1212783|NCT01103297|Double row plate
1212784|NCT01103297|Volar approach
1212785|NCT01103297|DVR plate
1212786|NCT01103297|Postoperative complications [MeSH]
1212787|NCT01103284|beta-cells
1212788|NCT01103284|autoimmune
1212789|NCT01103284|Diabetes
1212790|NCT01103284|immunomodulation
1212791|NCT01103271|depression
1212792|NCT01103271|placebo effect
1212793|NCT01103271|complementary therapies
1212794|NCT01103271|alternative therapies
1212795|NCT01103258|Incompetence of the great saphenous vein.
1212796|NCT01103245|Glucose
1212797|NCT01103245|Insulin
1212798|NCT01103232|Cross education
1212799|NCT01103232|Muscle training
1212800|NCT01103219|VLBW
1212801|NCT01103219|nutrition
1212802|NCT01103219|vitamin A
1212803|NCT01103219|long-chain unsaturated fatty acids
1212804|NCT01103219|growth
1212805|NCT01103219|cognitive functions
1212806|NCT01103219|Very low birth weight infants (birth weight below 1,500 grams).
1212807|NCT01103206|Parathyroid hormone
1212808|NCT01103206|Cinacalcet
1212809|NCT01103206|Primary hyperparathyroidism
1212810|NCT01103206|Diagnosis
1212811|NCT01103193|ASA class I/II patients, with surgery under general anesthesia
1212812|NCT01103180|Selective Serotonin Reuptake Inhibitor
1212813|NCT01103180|Escitalopram
1212814|NCT01103180|Borderline Personality Disorder
1212815|NCT01103180|Major Depressive Disorder
1212816|NCT01103180|Self-harm
1212817|NCT01103167|body composition
1212818|NCT01103167|blood pressure
1212819|NCT01103167|hemodialysis
1212820|NCT01103154|beta blocker
1212821|NCT01103154|variceal rebleeding
1212822|NCT01103154|efficacy and safety in reducing variceal rebleeding
1212823|NCT01103141|Vascular Surgical Procedures
1212824|NCT01103141|Angioplasty
1212825|NCT01103141|Radiology, Interventional
1212826|NCT01103128|Pancreatic Cancer
1212827|NCT01103128|Pre-neoplastic lesions
1212828|NCT01103128|Breast and Ovarian Cancer Syndrome
1212829|NCT01103128|BRCA1/2
1212830|NCT01103128|Mouse model for pancreatic cancer
1212831|NCT01103115|Adolescent Idiopathic Scoliosis
1212832|NCT01103115|AIS
1212833|NCT01103115|low bone mass
1212834|NCT01103115|osteopenia
1212835|NCT01103115|bone health
1212836|NCT01103115|bone density
1212837|NCT01103102|Gingivitis
1212838|NCT01103102|Biological Markers
1212839|NCT01103089|NSCLC
1212840|NCT01103089|EGFR
1212841|NCT01103089|gefitinib
1212842|NCT01103089|observational
1212843|NCT01103076|Immune dysfunction
1212844|NCT01103076|Hemodialysis
1212845|NCT01103076|HBV
1212846|NCT01103076|Vaccination
1212847|NCT01103076|Immune response
1212848|NCT01103063|P. falciparum malaria
1212849|NCT01103063|IPTp
1212850|NCT01103050|Allergic inflammation
1212851|NCT01103050|Seasonal rhinitis
1212852|NCT01103037|Mild
1212853|NCT01103037|Moderate
1212854|NCT01103037|Asthma
1212855|NCT01103024|Active uveitis
1212856|NCT01103024|intermediate uveitis
1212857|NCT01103024|panuveitis
1212858|NCT01103024|posterior uveitis
1212859|NCT01103024|uveitis
1212860|NCT01102998|Sleep complaints
1212861|NCT01102998|Brain Tumor Survivors
1212862|NCT01102985|exercise
1212863|NCT01102985|physical activity
1212864|NCT01102985|intervention
1212865|NCT01102985|cancer survivor
1212866|NCT01102972|HIV-1
1212867|NCT01102972|HIV
1212868|NCT01102959|EDUCATION
1212869|NCT01102959|DIABETES MELLITUS
1212870|NCT01102959|ADOLESCENT
1212871|NCT01102959|DIABETIC DIET
1212872|NCT01102946|proliferative diabetic retinopathy
1212873|NCT01102946|retinal neovascularization
1212874|NCT01102946|Angiogenesis Inhibitors
1212875|NCT01102946|ranibizumab
1212876|NCT01102946|laser
1212877|NCT01102920|Obstructive sleep apnea
1212878|NCT01102920|Obesity
1212879|NCT01102920|Behavioural medicine
1212880|NCT01102920|Physical therapy
1212881|NCT01102920|Health behaviour change
1212882|NCT01102920|Physical activity
1212883|NCT01102920|Eating habits
1212884|NCT01102907|Appetite
1212885|NCT01102907|Satiety
1212886|NCT01102907|Gastric Emptying Time
1212887|NCT01102907|Food Intake
1212888|NCT01102907|Food Form
1212889|NCT01102881|Healthy adults
1212890|NCT01102712|Emphysema
1212891|NCT01102712|COPD
1212892|NCT01102712|Lung Volume Reduction
1212893|NCT01102712|BTVA
1212894|NCT01102699|Diabetes
1212895|NCT01102699|stem cells
1212896|NCT01102699|bone marrow
1212897|NCT01102699|mobilization
1212898|NCT01102686|Late-onset GM2-gangliosidosis
1212899|NCT01102686|pyrimethamine
1212900|NCT01102673|phase 1
1212901|NCT01102673|safety and tolerability
1212902|NCT01102673|PK
1212903|NCT01102673|T2DM
1212904|NCT01102673|type 2 diabetes mellitus
1212905|NCT01102660|Knee osteoarthritis
1212906|NCT01102660|clinical trial
1212907|NCT01102660|cross-over
1212908|NCT01102621|hearing loss
1212909|NCT01102621|head and neck cancer
1212910|NCT01102621|radiotherapy
1212911|NCT01102621|hearing complaint
1212912|NCT01102621|Hearing loss due to the exposure of radiotherapy
1212913|NCT01102608|sarcoma
1212914|NCT01102608|ifosfamide
1212915|NCT01102595|Unresectable/inoperable glioblastomas
1212916|NCT01102582|Parkinson's disease dementia, neuropsychiatric symptoms
1212917|NCT01102569|Hereditary pancreatic cancer
1212918|NCT01102569|Breast and Ovarian Cancer Syndrome
1212919|NCT01102569|BRCA1/2
1212920|NCT01102569|Ashkenazi Jewish patients
1212921|NCT01102556|Pancreatic Cancer
1212922|NCT01102556|Pre-Neoplastic Lesions
1212923|NCT01102556|Pancreatic Cancer Surgery
1212924|NCT01102556|High-Risk for Pancreatic Cancer
1212925|NCT01102556|Tissue and Blood Bank for Pancreatic Cancer
1212926|NCT01102556|Pancreatic Cancer Questionnaire
1212927|NCT01102543|pulmonary surfactant
1212928|NCT01102543|Respiratory distress syndrome
1212929|NCT01102543|Newborn
1212930|NCT01102543|prophylaxis
1212931|NCT01102517|NSCLC
1212932|NCT01102517|Clinical
1212933|NCT01102517|Early-stage
1212934|NCT01102504|carotid atheroma
1212935|NCT01102504|plaque vulnerability
1212936|NCT01102504|stroke risk
1212937|NCT01102491|postoperative nausea and vomiting
1212938|NCT01102439|Clopidogrel
1212939|NCT01102439|Aspirin
1212940|NCT01102439|Interaction
1212941|NCT01102426|Multiple Myeloma
1212942|NCT01102426|Aplidin
1212943|NCT01102426|plitidepsin
1212944|NCT01102426|dexamethasone
1212945|NCT01102400|cancer
1212946|NCT01102400|tumor
1212947|NCT01102400|hepatocellular carcinoma
1212948|NCT01102387|Candida infections in intertriginous areas
1212949|NCT01102374|Vitamin D Deficiency
1212950|NCT01102374|Respiratory Infection
1212951|NCT01102374|Nursing Home Residents
1212952|NCT01102374|Geriatrics
1212953|NCT01102374|Immunosenescence
1212954|NCT01102374|Prevention
1212955|NCT01102348|Critically Ill
1212956|NCT01102348|Nutrition Therapy
1212957|NCT01102348|Enteral Nutrition
1212958|NCT01102335|hepatitis B virus
1212959|NCT01102335|Antiviral Agents
1212960|NCT01102335|Liver Neoplasms
1212961|NCT01102335|Drug Toxicity
1212962|NCT01102335|Survival
1212963|NCT01102322|Acute respiratory distress syndrome
1212964|NCT01102309|cerebrovascular accident
1212965|NCT01102309|hemiparesis
1212966|NCT01102309|recovery of function
1212967|NCT01102309|rehabilitation
1212968|NCT01102309|robotics
1212969|NCT01102309|subacute therapy
1212970|NCT01102309|training
1212971|NCT01102296|hepatitis A vaccine
1212972|NCT01102296|male homosexual
1212973|NCT01102296|HIV infection
1212974|NCT01102296|male homosexuals who are seronegative for hepatitis A virus
1212975|NCT01102283|Colonic obstruction
1212976|NCT01102270|Obstructive sleep apnea
1212977|NCT01102270|Arousal threshold
1212978|NCT01102270|Sedative medication
1212979|NCT01102270|upper airway
1212980|NCT01102257|Dry Eye Disease
1212981|NCT01102257|DED
1212982|NCT01102257|Keratoconjunctivitis Sicca
1212983|NCT01102257|Omega-3
1212984|NCT01102244|blepharitis
1212985|NCT01102244|moderate to severe chronic blepharitis
1212986|NCT01102218|Anemia, ESRD
1212987|NCT01102192|Myasthenia gravis
1212988|NCT01102192|Thymoma
1212989|NCT01102192|T-cells
1212990|NCT01102192|Thymectomy
1212991|NCT01102166|This study was conducted in healthy subjects
1212992|NCT01102153|sudden cardiac arrest
1212993|NCT01102153|Hypothermia
1212994|NCT01102153|Coolgard
1212995|NCT01102153|arctic sun
1212996|NCT01102153|neurological outcome
1212997|NCT01102153|neuron specific enolase
1212998|NCT01102140|Cardiomyopathy
1212999|NCT01102140|Heart Failure
1213000|NCT01102127|elastography
1213001|NCT01102127|thyroid nodule
1213002|NCT01102127|fine-needle aspiration
1213003|NCT01102114|Smoking Cessation
1213004|NCT01102114|NicVAX
1213005|NCT01102114|Smoking Vaccine
1213006|NCT01102114|Smoking Abstinence
1213007|NCT01102114|Smoking
1213008|NCT01102114|Tobacco Cessation
1213009|NCT01102101|Remifentanil
1213010|NCT01102101|Hyperalgesia
1213011|NCT01102101|Zoster
1213012|NCT01102101|Postherpetic neuralgia
1213025|NCT01102075|Obesity
1213026|NCT01102075|Electroacupuncture
1213027|NCT01102075|Sham electroacupuncture
1213028|NCT01102075|Waist circumference
1213029|NCT01102075|Thickness of subcutaneous fat
1213030|NCT01102036|Transit time
1213031|NCT01102036|constipation
1213032|NCT01102036|gut regularity
1213033|NCT01102036|defecation frequency
1213034|NCT01102036|Colonic transit time
1213035|NCT01102010|Blood transfusion
1213036|NCT01102010|Hip fracture
1213037|NCT01102010|Elderly
1213038|NCT01102010|Geriatrics
1213039|NCT01102010|Hospitalization
1213040|NCT01102010|Frail elderly
1213041|NCT01101997|Lipolysis
1213042|NCT01101997|Cryolipolysis
1213043|NCT01101997|Fat Reduction
1213044|NCT01101971|Education, Medical
1213045|NCT01101971|Students, Medical
1213046|NCT01101971|Gynecology
1213047|NCT01101971|Physical Examination
1213048|NCT01101971|Computer-Assisted Instruction
1213049|NCT01101945|diabetes
1213050|NCT01101945|DPP4 inhibitor
1213051|NCT01101945|dutogliptin
1213052|NCT01101945|PHX1149
1213053|NCT01101932|Safety
1213054|NCT01101932|Tolerability
1213055|NCT01101932|Pharmacokinetics/Pharmacodynamics
1213056|NCT01101932|Rheumatoid Arthritis
1213057|NCT01101932|healthy volunteers
1213058|NCT01101919|Rheumatoid Arthritis
1213059|NCT01101906|OSI-906
1213060|NCT01101906|HCC
1213061|NCT01101906|Hepatocellular Carcinoma
1213062|NCT01101893|GSK2248761, raltegravir, drug interaction, pharmacokinetics
1213063|NCT01101867|diabetes
1213064|NCT01101867|glucose
1213065|NCT01101867|hospital
1213066|NCT01101854|gene expression in wounds
1213067|NCT01101854|healing wounds
1213068|NCT01101854|non-healing wounds
1213069|NCT01101854|punch biopsy
1213070|NCT01101854|debridement
1213071|NCT01101841|Vasomotor Symptoms
1213072|NCT01101841|Menopause
1213073|NCT01101841|Hot Flashes
1213074|NCT01101841|Perimenopause
1213075|NCT01101841|Nonhormonal therapies
1213076|NCT01101841|Climacteric symptoms
1213077|NCT01101841|Mesafem
1213078|NCT01101841|Low-Dose Mesylate salt of Paroxetine (LDMP)
1213079|NCT01101815|Viral Loads
1213080|NCT01101815|Naltrexone
1213081|NCT01101815|HIV Risk
1213082|NCT01101815|Substance Abuse
1213083|NCT01101802|SLE
1213084|NCT01101802|Atherosclerosis
1213085|NCT01101802|Endothelial function
1213086|NCT01101802|Mycophenolate mofetil
1213087|NCT01101789|surgical wound infection
1213088|NCT01101789|triclosan-coated suture
1213089|NCT01101776|Multiple Sclerosis, relapsing
1213090|NCT01101776|Rebif New Formulation
1213091|NCT01101776|Interferon beta-1a
1213092|NCT01101750|Gardasil
1213093|NCT01101750|HPV
1213094|NCT01101750|transplant
1213095|NCT01101750|adolescent
1213096|NCT01101750|prevention
1213097|NCT01101750|vaccine
1213098|NCT01101750|immunogenicity
1213099|NCT01101750|vaccination
1213100|NCT01101737|Hypertension, clinical trial, nurse-led clinic, primary care
1213101|NCT01101724|mild traumatic brain injury
1213102|NCT01101724|Concussion
1213103|NCT01101724|postconcussive syndrome
1213104|NCT01101698|Vitamin K
1213105|NCT01101698|chronic kidney disease
1213106|NCT01101698|coronary artery calcification
1213107|NCT01101698|intima media thickness
1213108|NCT01101685|non-dysphoric
1213109|NCT01101685|Dysphoric
1213110|NCT01101672|Single port laparoscopic colectomy
1213111|NCT01101659|Activity of JNJ-40411813
1213112|NCT01101659|Challenge study
1213113|NCT01101646|Rabeprazole sodium
1213114|NCT01101646|Pharmacokinetics
1213115|NCT01101646|Biological Availability
1213116|NCT01101646|Safety
1213117|NCT01101646|Adult
1213118|NCT01101633|Appetite
1213119|NCT01101633|Energy intake
1213120|NCT01101633|gastric emptying
1213121|NCT01101633|well being
1213122|NCT01101633|Body weight
1213123|NCT01101607|Pediatrics
1213124|NCT01101607|Distal Forearm fractures
1213125|NCT01101607|Pediatric Emergency Medicine
1213126|NCT01101607|Pediatric Orthopedics
1213127|NCT01101594|Treatment
1213128|NCT01101594|Multiple Myeloma
1213129|NCT01101594|Relapsed, refractory multiple myeloma
1213130|NCT01101581|Diffuse Large cell NHL
1213131|NCT01101581|Mantle cell NHL
1213132|NCT01101581|Lymphoblastic lymphoma
1213133|NCT01101581|Diffuse mixed cell lymphoma
1213134|NCT01101581|Diffuse large cell lymphoma
1213135|NCT01101581|large noncleaved cell lymphoma
1213136|NCT01101568|GSK1292263, rosuvastatin, simvastatin, pharmacokinetics, drug interaction
1213137|NCT01101555|Rheumatoid arthritis
1213138|NCT01101555|repeat dose
1213139|NCT01101555|pharmacodynamics
1213140|NCT01101555|pharmacokinetics
1213141|NCT01101555|subcutaneous
1213142|NCT01101555|safety
1213143|NCT01101555|Otelixizumab
1213144|NCT01101555|long term follow up
1213145|NCT01101555|tolerability
1213146|NCT01101542|Post-marketing surveillance
1213147|NCT01101542|Human papillomavirus
1213148|NCT01101542|Korea
1213149|NCT01101542|Safety
1213150|NCT01101542|Prescribing Information
1213151|NCT01101529|Chemotherapy-induced nausea and vomiting CINV
1213152|NCT01101503|Newly diagnosed type 2 diabetes
1213153|NCT01101503|Endothelial dysfunction
1213154|NCT01101503|Intensive therapy
1213155|NCT01101503|Metabolic Memorial Effect
1213156|NCT01101490|To compare the change of cerebral oxygen saturation and blood flow between right and left side in lateral decubitus position during nephrectomy
1213157|NCT01101477|Target-controlled infusion,
1213158|NCT01101477|bronchoscopy,
1213159|NCT01101477|sedation,
1213160|NCT01101477|propofol
1213161|NCT01101438|stage I breast cancer
1213162|NCT01101438|stage II breast cancer
1213163|NCT01101438|stage IIIA breast cancer
1213164|NCT01101438|stage IIIC breast cancer
1213165|NCT01101438|male breast cancer
1213166|NCT01101438|HER2-negative breast cancer
1213167|NCT01101438|estrogen receptor-positive breast cancer
1213168|NCT01101438|HER2-positive breast cancer
1213366|NCT01101243|Dose-Response
1213169|NCT01101438|progesterone receptor-positive breast cancer
1213170|NCT01101425|male
1213171|NCT01101425|breast cancer
1213172|NCT01101412|infection
1213173|NCT01101412|unspecified adult solid tumor, protocol specific
1213174|NCT01101412|accelerated phase chronic myelogenous leukemia
1213175|NCT01101412|acute undifferentiated leukemia
1213176|NCT01101412|adult acute lymphoblastic leukemia in remission
1213177|NCT01101412|adult acute myeloid leukemia in remission
1213178|NCT01101412|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1213179|NCT01101412|adult acute myeloid leukemia with inv(16)(p13;q22)
1213180|NCT01101412|adult acute myeloid leukemia with t(15;17)(q22;q12)
1213181|NCT01101412|adult acute myeloid leukemia with t(16;16)(p13;q22)
1213182|NCT01101412|adult acute myeloid leukemia with t(8;21)(q22;q22)
1213183|NCT01101412|atypical chronic myeloid leukemia, BCR-ABL negative
1213184|NCT01101412|blastic phase chronic myelogenous leukemia
1213185|NCT01101412|chronic myelomonocytic leukemia
1213186|NCT01101412|chronic phase chronic myelogenous leukemia
1213187|NCT01101412|mast cell leukemia
1213188|NCT01101412|meningeal chronic myelogenous leukemia
1213189|NCT01101412|progressive hairy cell leukemia, initial treatment
1213190|NCT01101412|prolymphocytic leukemia
1213191|NCT01101412|recurrent adult acute lymphoblastic leukemia
1213192|NCT01101412|recurrent adult acute myeloid leukemia
1213193|NCT01101412|recurrent adult T-cell leukemia/lymphoma
1213194|NCT01101412|refractory chronic lymphocytic leukemia
1213195|NCT01101412|refractory hairy cell leukemia
1213196|NCT01101412|relapsing chronic myelogenous leukemia
1213197|NCT01101412|secondary acute myeloid leukemia
1213198|NCT01101412|stage 0 chronic lymphocytic leukemia
1213199|NCT01101412|stage I adult T-cell leukemia/lymphoma
1213200|NCT01101412|stage I chronic lymphocytic leukemia
1213201|NCT01101412|stage II adult T-cell leukemia/lymphoma
1213202|NCT01101412|stage II chronic lymphocytic leukemia
1213203|NCT01101412|stage III adult T-cell leukemia/lymphoma
1213204|NCT01101412|stage III chronic lymphocytic leukemia
1213205|NCT01101412|stage IV adult T-cell leukemia/lymphoma
1213206|NCT01101412|stage IV chronic lymphocytic leukemia
1213207|NCT01101412|T-cell large granular lymphocyte leukemia
1213208|NCT01101412|untreated adult acute lymphoblastic leukemia
1213209|NCT01101412|untreated adult acute myeloid leukemia
1213210|NCT01101412|untreated hairy cell leukemia
1213211|NCT01101412|recurrent adult Hodgkin lymphoma
1213212|NCT01101412|stage I adult Hodgkin lymphoma
1213213|NCT01101412|stage II adult Hodgkin lymphoma
1213214|NCT01101412|stage III adult Hodgkin lymphoma
1213215|NCT01101412|stage IV adult Hodgkin lymphoma
1213216|NCT01101412|anaplastic large cell lymphoma
1213217|NCT01101412|angioimmunoblastic T-cell lymphoma
1213218|NCT01101412|cutaneous B-cell non-Hodgkin lymphoma
1213219|NCT01101412|recurrent cutaneous T-cell non-Hodgkin lymphoma
1213220|NCT01101412|stage I cutaneous T-cell non-Hodgkin lymphoma
1213221|NCT01101412|stage II cutaneous T-cell non-Hodgkin lymphoma
1213222|NCT01101412|stage III cutaneous T-cell non-Hodgkin lymphoma
1213223|NCT01101412|stage IV cutaneous T-cell non-Hodgkin lymphoma
1213224|NCT01101412|recurrent mycosis fungoides/Sezary syndrome
1213225|NCT01101412|stage I mycosis fungoides/Sezary syndrome
1213226|NCT01101412|stage II mycosis fungoides/Sezary syndrome
1213227|NCT01101412|stage III mycosis fungoides/Sezary syndrome
1213228|NCT01101412|stage IV mycosis fungoides/Sezary syndrome
1213229|NCT01101412|adult grade III lymphomatoid granulomatosis
1213230|NCT01101412|adult nasal type extranodal NK/T-cell lymphoma
1213231|NCT01101412|Waldenstrom macroglobulinemia
1213232|NCT01101412|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1213233|NCT01101412|nodal marginal zone B-cell lymphoma
1213234|NCT01101412|splenic marginal zone lymphoma
1213235|NCT01101412|contiguous stage II adult Burkitt lymphoma
1213236|NCT01101412|contiguous stage II adult diffuse large cell lymphoma
1213237|NCT01101412|contiguous stage II adult diffuse mixed cell lymphoma
1213238|NCT01101412|contiguous stage II adult diffuse small cleaved cell lymphoma
1213239|NCT01101412|contiguous stage II adult immunoblastic large cell lymphoma
1213240|NCT01101412|contiguous stage II adult lymphoblastic lymphoma
1213241|NCT01101412|contiguous stage II grade 1 follicular lymphoma
1213242|NCT01101412|contiguous stage II grade 2 follicular lymphoma
1213243|NCT01101412|contiguous stage II grade 3 follicular lymphoma
1213244|NCT01101412|contiguous stage II mantle cell lymphoma
1213245|NCT01101412|contiguous stage II marginal zone lymphoma
1213246|NCT01101412|contiguous stage II small lymphocytic lymphoma
1213247|NCT01101412|stage I adult Burkitt lymphoma
1213248|NCT01101412|stage I adult diffuse large cell lymphoma
1213249|NCT01101412|stage I adult diffuse mixed cell lymphoma
1213250|NCT01101412|stage I adult diffuse small cleaved cell lymphoma
1213251|NCT01101412|stage I adult immunoblastic large cell lymphoma
1213252|NCT01101412|stage I adult lymphoblastic lymphoma
1213253|NCT01101412|stage I grade 1 follicular lymphoma
1213254|NCT01101412|stage I grade 2 follicular lymphoma
1213255|NCT01101412|stage I grade 3 follicular lymphoma
1213256|NCT01101412|stage I mantle cell lymphoma
1213257|NCT01101412|stage I marginal zone lymphoma
1213258|NCT01101412|stage I small lymphocytic lymphoma
1213259|NCT01101412|noncontiguous stage II adult Burkitt lymphoma
1213260|NCT01101412|noncontiguous stage II adult diffuse large cell lymphoma
1213367|NCT01101230|Cardiovascular disease
1213261|NCT01101412|noncontiguous stage II adult diffuse mixed cell lymphoma
1213262|NCT01101412|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1213263|NCT01101412|noncontiguous stage II adult immunoblastic large cell lymphoma
1213264|NCT01101412|noncontiguous stage II adult lymphoblastic lymphoma
1213265|NCT01101412|noncontiguous stage II grade 1 follicular lymphoma
1213266|NCT01101412|noncontiguous stage II grade 2 follicular lymphoma
1213267|NCT01101412|noncontiguous stage II grade 3 follicular lymphoma
1213268|NCT01101412|noncontiguous stage II mantle cell lymphoma
1213269|NCT01101412|noncontiguous stage II marginal zone lymphoma
1213270|NCT01101412|noncontiguous stage II small lymphocytic lymphoma
1213271|NCT01101412|stage III adult Burkitt lymphoma
1213272|NCT01101412|stage III adult diffuse large cell lymphoma
1213273|NCT01101412|stage III adult diffuse mixed cell lymphoma
1213274|NCT01101412|stage III adult diffuse small cleaved cell lymphoma
1213275|NCT01101412|stage III adult immunoblastic large cell lymphoma
1213276|NCT01101412|stage III adult lymphoblastic lymphoma
1213277|NCT01101412|stage III grade 1 follicular lymphoma
1213278|NCT01101412|stage III grade 2 follicular lymphoma
1213279|NCT01101412|stage III grade 3 follicular lymphoma
1213280|NCT01101412|stage III mantle cell lymphoma
1213281|NCT01101412|stage III marginal zone lymphoma
1213282|NCT01101412|stage III small lymphocytic lymphoma
1213283|NCT01101412|stage IV adult Burkitt lymphoma
1213284|NCT01101412|stage IV adult diffuse large cell lymphoma
1213285|NCT01101412|stage IV adult diffuse mixed cell lymphoma
1213286|NCT01101412|stage IV adult diffuse small cleaved cell lymphoma
1213287|NCT01101412|stage IV adult immunoblastic large cell lymphoma
1213288|NCT01101412|stage IV adult lymphoblastic lymphoma
1213289|NCT01101412|stage IV grade 1 follicular lymphoma
1213290|NCT01101412|stage IV grade 2 follicular lymphoma
1213291|NCT01101412|stage IV grade 3 follicular lymphoma
1213292|NCT01101412|stage IV mantle cell lymphoma
1213293|NCT01101412|stage IV marginal zone lymphoma
1213294|NCT01101412|stage IV small lymphocytic lymphoma
1213295|NCT01101412|recurrent adult Burkitt lymphoma
1213296|NCT01101412|recurrent adult diffuse large cell lymphoma
1213297|NCT01101412|recurrent adult diffuse mixed cell lymphoma
1213298|NCT01101412|recurrent adult diffuse small cleaved cell lymphoma
1213299|NCT01101412|recurrent adult grade III lymphomatoid granulomatosis
1213300|NCT01101412|recurrent adult immunoblastic large cell lymphoma
1213301|NCT01101412|recurrent adult lymphoblastic lymphoma
1213302|NCT01101412|recurrent grade 1 follicular lymphoma
1213303|NCT01101412|recurrent grade 2 follicular lymphoma
1213304|NCT01101412|recurrent grade 3 follicular lymphoma
1213305|NCT01101412|recurrent mantle cell lymphoma
1213306|NCT01101412|recurrent marginal zone lymphoma
1213307|NCT01101412|recurrent small lymphocytic lymphoma
1213308|NCT01101412|intraocular lymphoma
1213309|NCT01101412|post-transplant lymphoproliferative disorder
1213310|NCT01101412|chronic eosinophilic leukemia
1213311|NCT01101412|chronic neutrophilic leukemia
1213312|NCT01101412|primary myelofibrosis
1213313|NCT01101412|essential thrombocythemia
1213314|NCT01101412|polycythemia vera
1213315|NCT01101412|extramedullary plasmacytoma
1213316|NCT01101412|isolated plasmacytoma of bone
1213317|NCT01101412|stage I multiple myeloma
1213318|NCT01101412|stage II multiple myeloma
1213319|NCT01101412|stage III multiple myeloma
1213320|NCT01101412|primary systemic amyloidosis
1213321|NCT01101412|refractory multiple myeloma
1213322|NCT01101412|de novo myelodysplastic syndromes
1213323|NCT01101412|previously treated myelodysplastic syndromes
1213324|NCT01101412|secondary myelodysplastic syndromes
1213325|NCT01101412|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1213326|NCT01101399|Anemia
1213327|NCT01101399|Lymphoproliferative Disorders
1213328|NCT01101399|Chemotherapy
1213329|NCT01101399|ferric carboxymaltose
1213330|NCT01101399|iron
1213331|NCT01101386|Voriconazole
1213332|NCT01101386|SBECD
1213333|NCT01101386|pharmacokinetics
1213334|NCT01101386|Renal Failure
1213335|NCT01101373|Limbic surgery
1213336|NCT01101373|Stereotactic surgery
1213337|NCT01101373|Major Depressive Disorder: Treatment Refractory
1213338|NCT01101360|port wine stains
1213339|NCT01101360|radiofrequency
1213340|NCT01101360|Pulse Dye Laser
1213341|NCT01101334|NSCLC
1213342|NCT01101321|Healthy subjects
1213343|NCT01101321|Opioid
1213344|NCT01101321|Healthy volunteers
1213345|NCT01101308|Healthy subjects
1213346|NCT01101308|Opioid
1213347|NCT01101308|Healthy volunteers
1213348|NCT01101295|Immune Thrombocytopenia
1213349|NCT01101295|Rituximab
1213350|NCT01101295|side effects
1213351|NCT01101295|tolerance
1213352|NCT01101295|safety
1213353|NCT01101295|splenectomy
1213354|NCT01101295|serum sickness
1213355|NCT01101282|PEP
1213356|NCT01101282|exacerbation
1213357|NCT01101282|physiotherapy
1213358|NCT01101282|airway clearance
1213359|NCT01101282|sputum
1213360|NCT01101282|physical Therapy modalities
1213361|NCT01101269|Diabetic nephropathy
1213362|NCT01101243|Vitamin D
1213363|NCT01101243|UVB
1213364|NCT01101243|Frequency
1213365|NCT01101243|Body surface area
1213368|NCT01101230|cholesterol
1213369|NCT01101230|low-density
1213370|NCT01101230|lipoprotein
1213371|NCT01101230|high-density lipoprotein
1213372|NCT01101230|triglycerides
1213373|NCT01101217|hemocystein zinc renal failure
1213374|NCT01101191|Healthy subjects
1213375|NCT01101191|Opioid
1213376|NCT01101191|Healthy volunteers
1213377|NCT01101178|Healthy subjects
1213378|NCT01101178|Opioid
1213379|NCT01101178|Healthy volunteers
1213380|NCT01101165|Healthy subjects
1213381|NCT01101165|Opioid
1213382|NCT01101165|Healthy volunteers
1213383|NCT01101152|Antidepressant
1213384|NCT01101152|healthy volunteers
1213385|NCT01101152|desvenlafaxine succinate
1213386|NCT01101152|norepinephrine reuptake
1213387|NCT01101152|serotonin reuptake
1213388|NCT01101152|tyramine test
1213389|NCT01101126|Chronic obstructive pulmonary disease (COPD)
1213390|NCT01101126|Asthma
1213391|NCT01101113|peritoneal dialysis
1213392|NCT01101100|Psoriasis
1213393|NCT01101087|Dialysis
1213394|NCT01101074|Swine Flu A (H1N1) vaccine
1213395|NCT01101074|Adjuvanted flu egg derived
1213396|NCT01101074|Novel influenza A (H1N1): a new flu virus of swine origin
1213397|NCT01101061|Amgen
1213398|NCT01101061|Phase 1
1213399|NCT01101061|Postmenopausal
1213400|NCT01101061|Japanese
1213401|NCT01101048|Amgen
1213402|NCT01101048|Phase 1b
1213403|NCT01101048|Postmenopausal
1213404|NCT01101048|Bone Mineral Density
1213405|NCT01101035|cardiovascular outcomes
1213406|NCT01101035|heart attack
1213407|NCT01101035|stroke
1213408|NCT01101035|Drug Therapy
1213409|NCT01101035|physiology
1213410|NCT01101035|Hyperuricemia
1213411|NCT01101035|Uric Acid
1213412|NCT01101009|Sevikar®
1213413|NCT01101009|Central Arterial Blood Pressure
1213414|NCT01100996|enteral nutrition
1213415|NCT01100996|endotoxemia
1213416|NCT01100996|innate immunity
1213417|NCT01100996|nutritional anti-inflammatory pathway
1213418|NCT01100996|intestinal damage
1213419|NCT01100970|Caesarean section
1213420|NCT01100970|cortisol
1213421|NCT01100970|stress
1213422|NCT01100970|unipolar electric needle
1213423|NCT01100970|bipolar electric needle
1213424|NCT01100944|Gene Expression
1213425|NCT01100944|HDAC Class I and II enzymes
1213426|NCT01100944|Thymoma
1213427|NCT01100944|Chemotherapy
1213428|NCT01100944|Hydroxamic Acid Deacetylase Inhibitor
1213429|NCT01100944|Thymic Cancer
1213430|NCT01100931|NSCLC
1213431|NCT01100931|Solid Tumors
1213432|NCT01100931|YM155
1213433|NCT01100931|Survivin
1213434|NCT01100931|Non Small-Cell Lung Cancer
1213435|NCT01100931|Solid Tumor
1213436|NCT01100918|Cardiac resynchronisation therapy
1213437|NCT01100918|Tissue Doppler Imaging
1213438|NCT01100918|Dyssynchrony
1213439|NCT01100905|Iron
1213440|NCT01100905|Iron status
1213441|NCT01100905|Iron deficiency
1213442|NCT01100905|Iron deficiency anemia
1213443|NCT01100892|Pediatrics
1213444|NCT01100892|Pancreas
1213445|NCT01100879|Anemia
1213446|NCT01100879|Lymphoproliferative Disorders
1213447|NCT01100879|Chemotherapy
1213448|NCT01100879|ferric carboxymaltose
1213449|NCT01100879|iron
1213450|NCT01100866|clinically localized Prostate Cancer
1213451|NCT01100866|low and intermediate risk for relapse
1213452|NCT01100866|candidates for radical prostatectomy
1213453|NCT01100853|amphetamine dependence
1213454|NCT01100853|amphetamine injection
1213455|NCT01100853|VIVITROL/VIVITROL placebo
1213456|NCT01100853|amphetamine craving
1213457|NCT01100827|EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC
1213458|NCT01100827|The association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.
1213459|NCT01100801|advanced
1213460|NCT01100801|metastatic
1213461|NCT01100775|Galantamine
1213462|NCT01100775|Schizophrenia
1213463|NCT01100775|working memory
1213464|NCT01100775|cognitive
1213465|NCT01100762|Parkinson's Disease
1213466|NCT01100762|Cranial Electric Stimulation
1213467|NCT01100762|Gait
1213468|NCT01100749|Hepatitis C
1213469|NCT01100749|Genotype 3
1213470|NCT01100749|Demographics
1213471|NCT01100749|Genetics
1213472|NCT01100749|Metabolic status
1213473|NCT01100736|Forearm Blood Flow
1213474|NCT01100736|Vasodilation
1213475|NCT01100736|Vasoconstriction
1213476|NCT01100736|Endothelin System
1213477|NCT01100736|Endothelin-1
1213478|NCT01100736|Endothelin-3
1213479|NCT01100736|Endothelin antagonists
1213480|NCT01100736|Bosentan
1213481|NCT01100736|Sitaxsentan
1213482|NCT01100736|Endothelin
1213483|NCT01100736|Regional Blood Flow
1213484|NCT01100723|secondary hyperparathyroidism
1213485|NCT01100723|calcium
1213486|NCT01100723|phosphorus
1213487|NCT01100723|ESRD
1213488|NCT01100723|CKD
1213489|NCT01100723|mineral disorder
1213490|NCT01100710|Age Gender left ventricular mass high sensitive Troponin T
1213491|NCT01100697|prenatal diagnosis
1213492|NCT01100697|ultrasound
1213493|NCT01100697|outcome
1213494|NCT01100697|spina bifida
1213495|NCT01100697|neural tube defect
1213496|NCT01100684|diarrhea predominant irritable bowel syndrome
1213497|NCT01100671|atherosclerosis
1213498|NCT01100671|vascular inflammation
1213499|NCT01100671|MDCT
1213500|NCT01100671|18FDG-PET
1213501|NCT01100606|Exocrine Pancreatic Insufficiency
1213502|NCT01100606|Infants with CF
1213503|NCT01100593|Ultrasound
1213504|NCT01100593|IV catheters
1213505|NCT01100593|Extravasation
1213506|NCT01100580|Low-salt diet
1213507|NCT01100580|calciuria
1213508|NCT01100580|blood pressure
1213509|NCT01100580|nephrolithiasis
1213510|NCT01100580|hypertension
1213511|NCT01100580|BMI
1213512|NCT01100580|urinary stone risk factors
1213513|NCT01100567|skeletal health
1213514|NCT01100567|bone turnover
1213515|NCT01100567|bone geometry
1213516|NCT01100567|malnutrition
1213517|NCT01100541|Therapeutic Hyperthermia
1213518|NCT01100541|Thermotherapy
1213519|NCT01100541|Polymers
1213520|NCT01100541|Castor Oil
1213521|NCT01100515|intoxication
1213522|NCT01100515|carbon monoxide
1213523|NCT01100515|adults
1213524|NCT01100515|domestic accident
1213525|NCT01100515|acute domestic carbon monoxide poisoning
1213526|NCT01100502|Antigens, CD30
1213527|NCT01100502|Antibody-Drug Conjugate
1213528|NCT01100502|Antibodies, Monoclonal
1213529|NCT01100502|Disease, Hodgkin
1213530|NCT01100502|Drug Therapy
1213531|NCT01100502|Hematologic Diseases
1213532|NCT01100502|Immunotherapy
1213533|NCT01100502|Lymphoma
1213534|NCT01100502|Monomethylauristatin E
1213535|NCT01100476|Closure Device
1213536|NCT01100476|endovascular procedures
1213537|NCT01100476|sealing femoral arterial access
1213538|NCT01100476|Mynx M5
1213539|NCT01100463|HFS, Hand-Foot Syndrome, Capecitabine, Breast Cancer
1213540|NCT01100450|bariatric surgery
1213541|NCT01100450|class III obesity
1213542|NCT01100450|resistance training
1213543|NCT01100450|strength
1213544|NCT01100450|fitness
1213545|NCT01100437|opioid
1213546|NCT01100437|morphine
1213547|NCT01100437|naltrexone
1213548|NCT01100437|withdrawal signs
1213549|NCT01100437|withdrawal symptoms
1213550|NCT01100424|Contact lenses
1213551|NCT01100424|Contact lens solution
1213552|NCT01100424|Corneal staining
1213553|NCT01100411|Contact lenses, myopia, lens geometry
1213554|NCT01100398|Fatty liver disease
1213555|NCT01100385|Healthy adults
1213556|NCT01100372|recurrent ovarian epithelial cancer
1213557|NCT01100372|recurrent fallopian tube cancer
1213805|NCT01099319|elderly
1213558|NCT01100372|recurrent primary peritoneal cavity cancer
1213559|NCT01100359|endometrial clear cell carcinoma
1213560|NCT01100359|recurrent endometrial carcinoma
1213561|NCT01100359|stage IIIA endometrial carcinoma
1213562|NCT01100359|stage IIIB endometrial carcinoma
1213563|NCT01100359|stage IIIC endometrial carcinoma
1213564|NCT01100359|stage IVA endometrial carcinoma
1213565|NCT01100359|stage IVB endometrial carcinoma
1213566|NCT01100346|Ovulation induction
1213567|NCT01100346|Intrauterine insemination
1213568|NCT01100346|Gonal-f
1213569|NCT01100346|Controlled ovarian stimulation
1213570|NCT01100346|Infertility
1213571|NCT01100333|Infertility
1213572|NCT01100333|Reproductive technologies, Assisted
1213573|NCT01100333|r-hFSH
1213574|NCT01100333|Gonal-f
1213575|NCT01100320|Healthy subjects
1213576|NCT01100320|Opioid
1213577|NCT01100307|diabetic macular edema
1213578|NCT01100307|Macugen
1213579|NCT01100307|sham-controlled study
1213580|NCT01100294|Influenza
1213581|NCT01100294|Pandemic vaccine
1213582|NCT01100294|Seasonal vaccine
1213583|NCT01100294|Prevention
1213584|NCT01100294|Influenza vaccine
1213585|NCT01100294|Influenza in humans
1213586|NCT01100294|Pandemic influenza in humans
1213587|NCT01100294|Influenza vaccine for children
1213588|NCT01100281|prefrontal cortex
1213589|NCT01100268|Hoarding
1213590|NCT01100255|OCD
1213591|NCT01100242|Renal Cell Carcinoma
1213592|NCT01100242|metastatic renal cell cancer
1213593|NCT01100242|kidney cancer
1213594|NCT01100216|smokeless tobacco
1213595|NCT01100216|nicotine
1213596|NCT01100216|snus
1213597|NCT01100216|snuff
1213598|NCT01100216|chewing tobacco
1213599|NCT01100216|oral tobacco
1213600|NCT01100203|aldosterone receptor inhibition
1213601|NCT01100203|arterial stiffness
1213602|NCT01100203|ambulatory arterial stiffness index
1213603|NCT01100177|Patients with non resectable Glioblastoma who have only a
1213604|NCT01100177|biopsy as surgical treatment
1213605|NCT01100164|INSOMNIA
1213606|NCT01100164|FOR THE TREATMENT OF INSOMNIA
1213607|NCT01100151|Opioid-induced constipation
1213608|NCT01100151|RDC-1036
1213609|NCT01100151|ALKS 37
1213610|NCT01100125|Diabetes
1213611|NCT01100125|Sitagliptin
1213612|NCT01100125|insulin
1213613|NCT01100125|C-peptide
1213614|NCT01100112|ulcerative colitis
1213615|NCT01100112|Budesonide
1213616|NCT01100099|Celiac disease.
1213617|NCT01100099|Food intolerance.
1213618|NCT01100099|Gluten intolerance without celiac disease.
1213619|NCT01100086|Healthy subjects
1213620|NCT01100086|Opioid
1213621|NCT01100060|Azithromycin
1213622|NCT01100060|chloroquine
1213623|NCT01100060|microsphere
1213624|NCT01100060|pharmacokinetics
1213625|NCT01100060|bioavailability
1213626|NCT01100047|Phase I
1213627|NCT01100047|Japanese healthy volunteer
1213628|NCT01100047|AZD5069
1213629|NCT01100034|pediatric psoriasis
1213630|NCT01100034|etanercept
1213631|NCT01100034|PASS
1213632|NCT01100034|safety
1213633|NCT01100034|effectiveness
1213634|NCT01100008|Pulmonary arterial hypertension
1213635|NCT01100008|cardiac MRI (magnetic resonance imaging)
1213636|NCT01100008|severity
1213637|NCT01100008|prognosis
1213638|NCT01099995|domestic accident
1213639|NCT01099995|coma
1213640|NCT01099995|carbon monoxide
1213641|NCT01099995|intoxication
1213642|NCT01099995|acute domestic carbon monoxide poisoning
1213643|NCT01099982|Congestive Heart Failure
1213644|NCT01099982|Left Ventricular Assist Device
1213645|NCT01099982|LVAD
1213646|NCT01099982|Myocardium
1213647|NCT01099982|Remodeling
1213648|NCT01099982|Microvasculature
1213649|NCT01099982|Fibrosis
1213650|NCT01099982|Cardiac Transplant
1213651|NCT01099969|Endotrol Endotracheal tube
1213652|NCT01099969|Regular endotracheal tube
1213653|NCT01099969|glide rite stylet
1213654|NCT01099969|McGarth video laryngoscope
1213655|NCT01099969|Glidescope
1213656|NCT01099969|comparison of endotrol endotracheal tube to regular endotracheal tube with video laryngoscopes Glidescope and McGrath
1213657|NCT01099956|type 1 diabetes
1213658|NCT01099956|children
1213659|NCT01099956|low grade inflammation
1213660|NCT01099956|cytokine
1213661|NCT01099956|CRP
1213662|NCT01099930|immunoablation
1213663|NCT01099930|stem cell transplantation
1213664|NCT01099917|MDS
1213665|NCT01099917|Maitake
1213666|NCT01099917|mushroom
1213667|NCT01099917|09-094
1213668|NCT01099878|Cycling Exercise
1213669|NCT01099878|Functional Electrical Stimulation
1213670|NCT01099878|Stroke
1213671|NCT01099852|dengue
1213672|NCT01099852|fever
1213673|NCT01099852|dengue hemorrhagic fever
1213674|NCT01099852|dengue virus
1213675|NCT01099852|Chikungunya virus
1213676|NCT01099852|Zika Virus
1213677|NCT01099852|Joint pain
1213678|NCT01099839|ASP1941
1213679|NCT01099839|Miglitol
1213806|NCT01099293|Hepatic Encephalopathy
1213680|NCT01099826|colorectal cancer screening
1213681|NCT01099826|tailored education
1213682|NCT01099826|motivational interview
1213683|NCT01099826|patient education
1213684|NCT01099813|Critical Illness
1213685|NCT01099813|Sepsis
1213686|NCT01099813|Duration
1213687|NCT01099813|Severity of Illness Scores
1213688|NCT01099813|Trajectory
1213689|NCT01099800|asthma
1213690|NCT01099800|health disparities
1213691|NCT01099800|illness representations
1213692|NCT01099800|CAM
1213693|NCT01099800|Latino
1213694|NCT01099748|Drug interaction
1213695|NCT01099748|pharmacokinetics
1213696|NCT01099748|lersivirine
1213697|NCT01099748|methadone
1213698|NCT01099735|Bariatric Surgery
1213699|NCT01099735|Sleep Apnea
1213700|NCT01099735|Gastroesophageal Reflux Disease
1213701|NCT01099735|GERD
1213702|NCT01099722|moderate to severe persistent reversible asthma
1213703|NCT01099709|healthy subjects
1213704|NCT01099709|opioid
1213705|NCT01099696|abdominal discomfort and bloating
1213706|NCT01099644|Peritoneum
1213707|NCT01099644|Desmoplastic Small Round Cell Tumors
1213708|NCT01099644|Intraperitoneal Radioimmunotherapy
1213709|NCT01099644|131 I-8H9
1213710|NCT01099644|09-090
1213711|NCT01099631|Salmonella typhimurium
1213712|NCT01099631|unresectable hepatic cancer
1213713|NCT01099631|attenuated Salmonella typhimurium
1213714|NCT01099631|IL-2
1213715|NCT01099605|hemorrhoidectomy
1213716|NCT01099605|pain management
1213717|NCT01099579|HIV, Pediatric
1213718|NCT01099566|human endotoxemia
1213719|NCT01099566|tissue factor induced coagulation
1213720|NCT01099566|platelet activation
1213721|NCT01099566|thienopyridines
1213722|NCT01099553|Educational video
1213723|NCT01099553|colonoscopy
1213724|NCT01099553|bowel preparation
1213725|NCT01099553|Bowel preparation for colonoscopy
1213726|NCT01099540|neuroendocrine tumor
1213727|NCT01099527|gastric cancer
1213728|NCT01099527|refractory
1213729|NCT01099527|metastatic
1213730|NCT01099501|Mechanical Ventilation
1213732|NCT01099475|liver surgery
1213733|NCT01099475|pringle manoeuvre
1213734|NCT01099475|hepatocellular damage
1213735|NCT01099475|surgical complications
1213736|NCT01099475|patients requiring liver surgery
1213737|NCT01099462|fever
1213738|NCT01099462|Ibuprofen
1213739|NCT01099449|neurotoxicity
1213740|NCT01099449|neuropathy
1213741|NCT01099449|chemotherapeutic agent toxicity
1213742|NCT01099449|stage II colon cancer
1213743|NCT01099449|stage III colon cancer
1213744|NCT01099449|stage IV colon cancer
1213745|NCT01099449|stage II rectal cancer
1213746|NCT01099449|stage III rectal cancer
1213747|NCT01099449|stage IV rectal cancer
1213748|NCT01099449|adenocarcinoma of the colon
1213749|NCT01099449|adenocarcinoma of the rectum
1213750|NCT01099436|HER2-negative breast cancer
1213751|NCT01099436|stage II breast cancer
1213752|NCT01099436|stage IIIA breast cancer
1213753|NCT01099436|stage IIIB breast cancer
1213754|NCT01099436|stage IIIC breast cancer
1213755|NCT01099423|clear cell renal cell carcinoma
1213756|NCT01099423|stage IV renal cell cancer
1213757|NCT01099410|macrophages, alveolar
1213758|NCT01099410|monocytes
1213759|NCT01099410|Receptor Protein-Tyrosine Kinases
1213760|NCT01099410|Humans
1213761|NCT01099410|Phagocytosis
1213762|NCT01099410|Lung
1213763|NCT01099410|in vitro
1213764|NCT01099397|Glucose
1213765|NCT01099397|Glucose Tolerance Test
1213766|NCT01099397|Insulin Resistance
1213767|NCT01099397|Metabolic adverse effects
1213768|NCT01099397|Hypertension
1213769|NCT01099397|Beta-blocker
1213770|NCT01099397|Atenolol
1213771|NCT01099397|Diuretic
1213772|NCT01099397|Hydrochlorothiazide
1213773|NCT01099397|Blood pressure
1213774|NCT01099371|Knee
1213775|NCT01099371|Osteoarthritis
1213776|NCT01099371|Exercise
1213777|NCT01099358|Cancer of Head
1213778|NCT01099358|Cancer of Head and Neck
1213779|NCT01099358|Cancer of Neck
1213780|NCT01099358|Cancer of the Head
1213781|NCT01099358|Cancer of the Head and Neck
1213782|NCT01099358|Cancer of the Neck
1213783|NCT01099358|Head and Neck Cancer
1213784|NCT01099358|Head Cancer
1213785|NCT01099358|Head Neoplasms
1213786|NCT01099358|Head, Neck Neoplasms
1213787|NCT01099358|Neck Cancer
1213788|NCT01099358|Neck Neoplasms
1213789|NCT01099358|Solid Neoplasm
1213790|NCT01099358|Carcinoma
1213791|NCT01099358|Sarcoma
1213792|NCT01099345|OAB
1213793|NCT01099345|Nocturia
1213794|NCT01099345|Bladder function
1213795|NCT01099345|cystometry
1213796|NCT01099345|polysomnography
1213797|NCT01099332|Alzheimer's disease
1213798|NCT01099332|Mild Cognitive Impairment
1213799|NCT01099332|Copper metabolism
1213800|NCT01099332|Zinc metabolism
1213801|NCT01099332|Ceruloplasmin
1213802|NCT01099319|Dietary supplement
1213803|NCT01099319|Renalof
1213804|NCT01099319|gallstones
1213807|NCT01099293|Psychometric Hepatic Encephalopathy Score
1213808|NCT01099293|Critical Flicker Frequency
1213809|NCT01099293|Cerebrovascular Reactivity
1213810|NCT01099293|Endotoxemia
1213811|NCT01099293|Transcranial Doppler
1213812|NCT01099293|Liver Cirrhosis
1213813|NCT01099280|induction of labor in term
1213814|NCT01099280|premature rupture of membranes
1213815|NCT01099280|dinoprostone
1213816|NCT01099280|oxytocin
1213817|NCT01099267|MDS
1213818|NCT01099254|CVP
1213819|NCT01099254|US
1213820|NCT01099254|Trendelenburg position
1213821|NCT01099254|Ultrasound
1213822|NCT01099254|Head Down Tilt
1213823|NCT01099241|CVP
1213824|NCT01099241|US
1213825|NCT01099241|Ultrasonography
1213826|NCT01099228|Neuroendocrine Tumor
1213827|NCT01099228|Imaging
1213828|NCT01099215|peripheral artery disease
1213829|NCT01099215|percutaneous transluminal angioplasty
1213830|NCT01099215|stent
1213831|NCT01099215|balloon/stent
1213832|NCT01099215|superficial femoral artery
1213833|NCT01099202|Procrit
1213834|NCT01099202|Acute Lymphocytic Leukemia
1213835|NCT01099202|Lymphoblastic Lymphoma
1213836|NCT01099202|Burkitt's
1213837|NCT01099202|Chemotherapy
1213838|NCT01099202|Hyper-CVAD
1213839|NCT01099202|augmented BFM
1213840|NCT01099202|Epoetin alfa
1213841|NCT01099202|Epogen
1213842|NCT01099202|Erythropoietin
1213843|NCT01099189|Histology
1213844|NCT01099189|Compliance
1213845|NCT01099189|Dialysis
1213846|NCT01099189|Arteriovenous access fistula
1213847|NCT01099189|vein
1213848|NCT01099176|hyperlipidemia
1213849|NCT01099176|impaired fasting glycemia
1213850|NCT01099176|adipokines
1213851|NCT01099176|atorvastatin
1213852|NCT01099176|fenofibrate
1213853|NCT01099163|Diabetes mellitus
1213854|NCT01099163|CLA
1213855|NCT01099163|Antioxidant
1213856|NCT01099163|Glycemic control
1213857|NCT01099150|Platelets
1213858|NCT01099150|Platelet aggregation
1213859|NCT01099150|Platelet activation
1213860|NCT01099150|Platelet function
1213861|NCT01099150|Light transmission aggregometry
1213862|NCT01099150|Platelet Function Analyzer-100 (PFA-100)
1213863|NCT01099150|P-selectin
1213864|NCT01099150|Fibrinogen receptor
1213865|NCT01099150|Glycoprotein IIb-IIIa
1213866|NCT01099150|Chocolate
1213867|NCT01099150|Cocoa
1213868|NCT01099150|Flavan-3-ols
1213869|NCT01099150|Procyanidins
1213870|NCT01099137|Diabetes
1213871|NCT01099137|Vildagliptin
1213872|NCT01099137|insulin
1213873|NCT01099137|C-peptide
1213874|NCT01099124|M2ES
1213875|NCT01099124|NSCLC
1213876|NCT01099124|Phase I Trial
1213877|NCT01099124|Advanced NSCLC
1213878|NCT01099124|Recurrent NSCLC
1213879|NCT01099111|IBS
1213880|NCT01099111|UC
1213881|NCT01099111|CD
1213882|NCT01099111|CRAP/CRC
1213883|NCT01099098|People who have fibrosis or nodules in their upper lobe of the lung
1213884|NCT01099085|gastric cancer, unresectable/metastatic
1213885|NCT01099072|ADHD
1213886|NCT01099072|carnitine
1213887|NCT01099072|methylphenidate
1213888|NCT01099059|Attention-deficit/hyperactivity disorder
1213889|NCT01099059|Clinical Trial
1213890|NCT01099059|Amantadine
1213891|NCT01099059|Methylphenidate
1213892|NCT01099046|Meniere's disease
1213893|NCT01099046|stress management
1213894|NCT01099046|vasopressin
1213895|NCT01099046|V2 receptor
1213896|NCT01099046|water intake
1213897|NCT01099046|tympanic tubing
1213898|NCT01099046|regular sleep under dark
1213899|NCT01099033|hiatal hernia
1213900|NCT01099033|paraesophageal hernia
1213901|NCT01099033|biologic mesh
1213902|NCT01099033|MMPs
1213903|NCT01099033|Hiatal/Paraesophageal hernia
1213904|NCT01099020|Subjects receiving large volumes of Radiation
1213905|NCT01099007|Women
1213906|NCT01099007|Menopause
1213907|NCT01099007|Cardiovascular Disease
1213908|NCT01099007|Physical Activity
1213909|NCT01099007|Weight Loss
1213910|NCT01098994|Type 1 diabetes
1213911|NCT01098994|Haptoglobin genotype
1213912|NCT01098994|HDL function
1213913|NCT01098994|Heart disease
1213914|NCT01098994|Feasibility of clinical trial
1213915|NCT01098955|Cancer
1213916|NCT01098955|Smoking Cessation Treatment
1213917|NCT01098955|Acceptance and Commitment Therapy
1213918|NCT01098955|ACT Theory
1213919|NCT01098955|Motivational and Behavioral Counseling
1213920|NCT01098955|MBC
1213921|NCT01098955|abstinence
1213922|NCT01098955|Varenicline
1213923|NCT01098955|Chantix
1213924|NCT01098942|bariatric surgery
1213925|NCT01098929|genes
1213926|NCT01098929|genetic
1213927|NCT01098929|chromosome
1213928|NCT01098929|chromosome microarray
1213929|NCT01098916|hospital at home
1213930|NCT01098916|radiology at home
1213931|NCT01098916|frail elderly
1213932|NCT01098903|sunitinib
1213933|NCT01098903|cancer
1213934|NCT01098903|pharmacogenomics
1213935|NCT01098903|pharmacokinetics
1213936|NCT01098903|Patients who have a malignancy and are going to be treated with sunitinib
1213937|NCT01098903|doseindividualism
1213938|NCT01098877|Phase1
1213939|NCT01098877|pharmacokinetics
1213940|NCT01098877|safety
1213941|NCT01098877|toleration
1213942|NCT01098877|pharmacodynamics
1213943|NCT01098864|Behavior
1213944|NCT01098864|Impulsivity
1213945|NCT01098864|Transcranial Magnetic Stimulation
1213946|NCT01098851|Obstructive Sleep Apnea
1213947|NCT01098851|Pulse Oximetry
1213948|NCT01098838|Cancer
1213949|NCT01098838|adults
1213950|NCT01098838|solid tumor
1213951|NCT01098838|apoptosis
1213952|NCT01098838|programmed cell death
1213953|NCT01098838|LCL161
1213954|NCT01098825|vaccine hesitancy
1213955|NCT01098825|vaccine refusal
1213956|NCT01098812|Cataract, Intraocular lens
1213957|NCT01098799|Urotensin II,Chronic renal disease
1213958|NCT01098786|Influenza A
1213959|NCT01098786|H1N1 subtype
1213960|NCT01098786|Vaccine
1213961|NCT01098786|Adjuvant
1213962|NCT01098786|Cell culture
1213963|NCT01098773|Weaning from mechanical ventilation
1213964|NCT01098773|BNP
1213965|NCT01098773|Lung ultrasound
1213966|NCT01098773|Echocardiography
1213967|NCT01098760|Sorafenib
1213968|NCT01098760|Hepatocellular Carcinoma (HCC)
1213969|NCT01098747|Pain following third molar extraction
1213970|NCT01098734|non-steroid
1213971|NCT01098734|anti-inflammatory
1213972|NCT01098734|skin disease
1213973|NCT01098734|topical cream
1213974|NCT01098734|small molecule
1213975|NCT01098734|atopic dermatitis
1213976|NCT01098734|eczema
1213977|NCT01098721|plaque psoriasis
1213978|NCT01098721|skin diseases
1213979|NCT01098721|anti-inflammatory
1213980|NCT01098721|non-steroid
1213981|NCT01098721|topical cream
1213982|NCT01098708|DMD
1213983|NCT01098708|non ambulatory
1213984|NCT01098695|parenting interventions
1213985|NCT01098695|Family Check-Up
1213986|NCT01098695|Early Intervention
1213987|NCT01098695|Self-Regulation
1213988|NCT01098669|cancer survivor
1213989|NCT01098669|lymphedema
1213990|NCT01098669|head and neck cancer
1214111|NCT01098162|Adjunctive therapy
1213991|NCT01098656|stage III mycosis fungoides/Sezary syndrome
1213992|NCT01098656|stage IV mycosis fungoides/Sezary syndrome
1213993|NCT01098656|stage II mycosis fungoides/Sezary syndrome
1213994|NCT01098656|stage II cutaneous T-cell non-Hodgkin lymphoma
1213995|NCT01098656|stage III cutaneous T-cell non-Hodgkin lymphoma
1213996|NCT01098656|stage IV cutaneous T-cell non-Hodgkin lymphoma
1213997|NCT01098643|unspecified adult solid tumor, protocol specific
1213998|NCT01098617|endoscopic sphincterotomy
1213999|NCT01098617|hemorrhage
1214000|NCT01098617|nonsteroidal antiinflammatory agents
1214001|NCT01098617|antiaggregants
1214002|NCT01098617|anticoagulants
1214003|NCT01098617|Endoscopic biliary sphincterotomy induced bleeding
1214004|NCT01098591|meta-analysis
1214005|NCT01098591|stem cell
1214006|NCT01098591|cardiac
1214007|NCT01098591|remodeling
1214008|NCT01098591|MESS
1214009|NCT01098578|Posterior Epistaxis
1214010|NCT01098552|Prostate Cancer
1214011|NCT01098539|sitagliptin
1214012|NCT01098539|albiglutide
1214013|NCT01098539|renal impairment
1214014|NCT01098526|GSK1349572
1214015|NCT01098526|efavirenz
1214016|NCT01098526|integrase
1214017|NCT01098526|pharmacokinetics
1214018|NCT01098513|HIV
1214019|NCT01098513|healthy
1214020|NCT01098513|GSK1349572
1214021|NCT01098500|Liver function
1214022|NCT01098500|Tyrosine Kinase Inhibitor
1214023|NCT01098487|Immune (idiopathic) thrombocytopenic purpura (ITP)
1214024|NCT01098487|bone marrow fibers
1214025|NCT01098487|eltrombopag olamine
1214026|NCT01098487|thrombopoietin receptor agonist
1214027|NCT01098474|Tuberculosis vaccine
1214028|NCT01098461|dose-ranging
1214029|NCT01098461|pharmacokinetics
1214030|NCT01098461|GSK716155
1214031|NCT01098461|Japan
1214032|NCT01098461|albiglutide
1214033|NCT01098448|Amoxicillin
1214034|NCT01098448|antibiotics
1214035|NCT01098448|chronic periodontitis
1214036|NCT01098448|local drug delivery
1214037|NCT01098448|metronidazol
1214038|NCT01098448|randomized controlled trial
1214039|NCT01098448|subgingival scaling
1214040|NCT01098448|surgery
1214041|NCT01098448|tetracycline
1214042|NCT01098448|moderate to advanced chronic periodontitis
1214043|NCT01098435|Binge eating disorder
1214044|NCT01098435|RDC-0313
1214045|NCT01098422|liver
1214046|NCT01098422|colorectal
1214047|NCT01098422|metastasis
1214048|NCT01098422|carcinoma
1214049|NCT01098422|Yttrium-90
1214050|NCT01098422|microspheres
1214051|NCT01098409|sodium nitrite
1214052|NCT01098409|coronary artery bypass surgery
1214053|NCT01098409|cardioprotection
1214054|NCT01098409|myocardial injury
1214055|NCT01098396|parkinson disease
1214056|NCT01098396|gait
1214057|NCT01098383|Autism
1214058|NCT01098357|rhPDGF, diabetic foot ulcer,
1214059|NCT01098344|stage III pancreatic cancer
1214060|NCT01098344|stage IV pancreatic cancer
1214061|NCT01098344|duct cell adenocarcinoma of the pancreas
1214062|NCT01098331|stage I prostate cancer
1214063|NCT01098331|stage IIB prostate cancer
1214064|NCT01098331|stage IIA prostate cancer
1214065|NCT01098318|Depression
1214066|NCT01098318|Antidepressant Therapy
1214067|NCT01098318|Herbal Treatment
1214068|NCT01098318|Rhodiola rosea
1214069|NCT01098318|Alternative Therapy
1214070|NCT01098305|nicotine smokeless tobacco chewing tobacco varenicline
1214071|NCT01098292|Fibromyalgia
1214072|NCT01098292|Irritable Bowel Syndrome
1214073|NCT01098292|Chronic Fatigue Syndrome
1214074|NCT01098292|Interstitial Cystitis
1214075|NCT01098292|Chronic Prostatitis
1214076|NCT01098292|Urological Chronic Pelvic Pain
1214077|NCT01098292|Painful Bladder Syndrome
1214078|NCT01098279|Interstitial Cystitis
1214079|NCT01098279|Chronic Prostatitis
1214080|NCT01098279|Urological Chronic Pelvic Pain
1214081|NCT01098279|Painful Bladder Syndrome
1214082|NCT01098266|MPM
1214083|NCT01098266|NGR-hTNF
1214084|NCT01098266|NGR-hTNF plus BIC
1214085|NCT01098266|Randomized double-blind phase III study
1214086|NCT01098253|adherence
1214087|NCT01098253|diabetes mellitus
1214088|NCT01098253|depression
1214089|NCT01098253|primary health care
1214090|NCT01098240|Antidepressant Augmentation
1214091|NCT01098227|RSV Bronchiolitis
1214092|NCT01098227|Lower Respiratory Viral infection
1214093|NCT01098227|Exhaled Nitric Oxide
1214094|NCT01098214|Normal pregnancy
1214095|NCT01098214|Amniotic fluid
1214096|NCT01098214|Cytokines
1214097|NCT01098214|Biomarkers
1214098|NCT01098201|Certolizumab
1214099|NCT01098201|TNF
1214100|NCT01098201|RA
1214101|NCT01098201|Cizmia
1214102|NCT01098175|laparotomy
1214103|NCT01098175|thoracotomy
1214104|NCT01098175|peritoneal conditioning
1214105|NCT01098175|humidification
1214106|NCT01098175|temperature control
1214107|NCT01098162|Lacosamide
1214108|NCT01098162|Vimpat®
1214109|NCT01098162|Epilepsy
1214110|NCT01098162|Partial-Onset Seizures
1214112|NCT01098149|Haemodialysis treatment tolerance
1214113|NCT01098149|acetate free biofiltration
1214114|NCT01098149|frequency of hypotensive events during dialysis
1214115|NCT01098149|nurse intervention during dialysis
1214116|NCT01098136|Pelvic girdle pain
1214117|NCT01098136|Chiropractic
1214118|NCT01098136|Single-blinded
1214119|NCT01098136|Outcome study
1214120|NCT01098084|Decitabine, chronic myelomonocytic leukemia
1214121|NCT01098058|Adult attention deficit hyperactivity disorder
1214122|NCT01098058|cognitive-behavioural therapy
1214123|NCT01098058|randomised controlled trial
1214124|NCT01098045|HIV
1214125|NCT01098045|fat redistribution
1214126|NCT01098045|brown adipose tissue
1214127|NCT01098045|PET
1214128|NCT01098032|Contrast media
1214129|NCT01098032|Kidney
1214130|NCT01098032|Complication
1214131|NCT01098019|Notalgia paresthetica
1214132|NCT01098019|Xeomin
1214133|NCT01098019|Botulinum Toxin A
1214134|NCT01098019|Pruritus
1214135|NCT01098019|Upper Back
1214136|NCT01098019|Hyperpigmentation
1214137|NCT01098006|Immunological assays
1214138|NCT01098006|Chronic hepatitis B
1214139|NCT01097980|trazodone
1214140|NCT01097980|SSRI
1214141|NCT01097980|sexual dysfunction
1214142|NCT01097980|5-HT2A polymorphism
1214143|NCT01097967|Sleep disordered breathing
1214144|NCT01097967|Continuous Positive Airway Pressure
1214145|NCT01097967|Sleep apnoea
1214146|NCT01097967|Markers of atherosclerosis
1214147|NCT01097954|Exercise induced asthma
1214148|NCT01097954|Exercise induced bronchospasm
1214149|NCT01097954|exhaled Nitric Oxide
1214150|NCT01097941|Influenza
1214151|NCT01097941|H1N1
1214152|NCT01097915|PROP taste sensitivity
1214153|NCT01097915|Gustin (CAVI) polymorphism
1214154|NCT01097915|Salivary zinc
1214155|NCT01097915|BMI
1214156|NCT01097915|Electrophysiological recording from the tongue
1214157|NCT01097889|United Nations World Food Programme
1214158|NCT01097889|blended food (CSB)
1214159|NCT01097889|ready-to-use supplementary foods (RUSF)
1214160|NCT01097889|Plumpy®
1214161|NCT01097876|healthy volunteer
1214162|NCT01097876|pharmacokinetic
1214163|NCT01097876|safety
1214164|NCT01097850|hand foot skin syndrome
1214165|NCT01097850|palmar plantar erythrodysesthesia
1214166|NCT01097850|doxorubicin
1214167|NCT01097850|capecitabine
1214168|NCT01097837|Epilepsy
1214169|NCT01097837|Contraceptive
1214170|NCT01097837|Birth Control
1214171|NCT01097837|Seizure
1214172|NCT01097837|This study is looking at the use of different birth control measures in women with epilepsy.
1214173|NCT01097811|Hepatic Encephalopathy
1214174|NCT01097811|Hypertension, Portal
1214175|NCT01097811|Liver Cirrhosis
1214176|NCT01097811|Bacterial Overgrowth Syndrome
1214177|NCT01097798|muscle injury
1214178|NCT01097772|abdominal
1214179|NCT01097772|aortic
1214180|NCT01097772|aneurysm
1214181|NCT01097759|hemorrhoids
1214182|NCT01097759|prolapsed
1214183|NCT01097759|hemorrhoidectomy
1214184|NCT01097759|Hemorrhoidopexy
1214185|NCT01097759|LigaSure
1214186|NCT01097759|Stapled
1214187|NCT01097746|Cancer
1214188|NCT01097746|Fallopian Tube
1214189|NCT01097746|Ovary
1214190|NCT01097746|Peritoneum
1214191|NCT01097746|Epithelial ovarian
1214192|NCT01097746|Paclitaxel
1214193|NCT01097746|Carboplatin
1214194|NCT01097746|Bevacizumab
1214195|NCT01097746|Taxol
1214196|NCT01097746|Avastin
1214197|NCT01097746|Paraplatin
1214198|NCT01097746|Carcinoma
1214199|NCT01097746|Surgery
1214200|NCT01097720|Valproate
1214201|NCT01097720|Lamotrigine
1214202|NCT01097720|Carbamazepine
1214203|NCT01097720|Anticonvulsant
1214204|NCT01097720|Antiepileptic
1214205|NCT01097720|Teratogen
1214206|NCT01097720|Autism
1214207|NCT01097720|Developmental Delay
1214208|NCT01097694|cKIT inhibition in Asthma
1214209|NCT01097694|Efficacy of Imatinib in severe resistent asthma.
1214210|NCT01097681|ASP1941
1214211|NCT01097681|Diabetes mellitus
1214212|NCT01097681|Urinary glucose excretion
1214213|NCT01097668|Multiple sclerosis
1214214|NCT01097668|Immunomodulation
1214215|NCT01097668|Phase 1
1214216|NCT01097655|Tablets
1214217|NCT01097655|Infection
1214218|NCT01097655|Non Nucleoside Reverse Transcriptase Inhibitor
1214219|NCT01097655|Tolerability
1214220|NCT01097655|Viral load
1214221|NCT01097655|Human immunodeficiency Virus
1214222|NCT01097655|Effectiveness
1214223|NCT01097655|Treatment-naïve
1214224|NCT01096615|Allergic rhinitis-Probiotic Lactobacillus paracasei LP-33-
1214225|NCT01096602|Dendritic Cell/AML vaccine
1214226|NCT01096602|CT-011
1214227|NCT01096589|lymphoedema
1214228|NCT01096589|lymphedema
1214229|NCT01096563|Phase I
1214230|NCT01096563|Japanese healthy volunteer
1214231|NCT01096563|AZD9164
1214232|NCT01096550|opioid dependence
1214233|NCT01096550|outpatient treatment
1214234|NCT01096550|intensive outpatient treatment
1214235|NCT01097603|Non-Invasive Blood Pressure
1214236|NCT01097590|ulcerative colitis
1214237|NCT01097590|leukapheresis treatment
1214238|NCT01097577|photorefractive keratectomy
1214239|NCT01097577|excimer laser
1214240|NCT01097577|PRK
1214241|NCT01097577|pain, postoperative
1214242|NCT01097577|pregabalin
1214243|NCT01097564|Genetic
1214244|NCT01097564|Cerebral angiopathy
1214245|NCT01097564|Retinal angiopathy
1214246|NCT01097564|COL4A1 gene
1214247|NCT01097564|Infantile Cerebral Palsy
1214248|NCT01097564|Congenital porencephaly
1214249|NCT01097564|Congenital cataract
1214250|NCT01097564|Leukoencephalopathy
1214251|NCT01097564|COL4A1 gene related cerebra-retinal angiopathy
1214252|NCT01097551|Type 1 diabetes mellitus
1214253|NCT01097551|Diabetic retinopathy
1214254|NCT01097551|Pathogenesis
1214255|NCT01097551|Dynamic Vessel Analyser
1214256|NCT01097551|Endothelial dysfunction
1214257|NCT01097538|exercise
1214258|NCT01097538|rehabilitation
1214259|NCT01097538|progressive multiple sclerosis
1214260|NCT01097538|functional ability
1214261|NCT01097538|fatigue
1214262|NCT01097538|quality of life
1214263|NCT01097512|AS703569
1214264|NCT01097512|MSC1992371A
1214265|NCT01097512|Aurora kinase inhibitor
1214266|NCT01097512|Cancer treatable with gemcitabine
1214267|NCT01097499|Dental implant initial stability
1214268|NCT01097499|Initial bone resorption post implant placement
1214269|NCT01097499|Analgesia effect of LED intervention
1214270|NCT01097486|Cervical Degenerative Disc Disease
1214271|NCT01097486|Degenerative Spondylolisthesis
1214272|NCT01097486|Spinal Stenosis
1214273|NCT01097486|Stem cells
1214274|NCT01097486|Adult Stem Cells
1214275|NCT01097486|Anterior cervical discectomy and Fusion (ACDF)
1214276|NCT01097486|Cervical Allograft Spacer
1214277|NCT01097486|Anterior Cervical Plate Fixation
1214278|NCT01097460|HER2/HER3
1214279|NCT01097460|Bispecific Antibody
1214280|NCT01097460|Breast Cancer
1214281|NCT01097460|Advanced Breast Cancer
1214282|NCT01097460|Metastatic Breast Cancer
1214283|NCT01097460|HER2 Positive Breast Cancer
1214284|NCT01097460|Trastuzumab
1214285|NCT01097460|Herceptin
1214286|NCT01097447|Diagnosis of keratoconus, post-LASIK ectasia, FFKC, or pellucid marginal degeneration
1214290|NCT01097343|Clopidogrel pharmacogenomics study
1214291|NCT01097343|Performing genetic study looking at clopidogrel resistance
1214292|NCT01097330|Defibrillators, Implantable
1214293|NCT01097330|Tachycardia, Ventricular
1214294|NCT01097330|Catheter Ablation
1214295|NCT01097330|Amiodarone
1214296|NCT01097317|chemotherapeutic agent toxicity
1214297|NCT01097317|musculoskeletal complications
1214298|NCT01097317|fatigue
1214299|NCT01097317|stage I non-small cell lung cancer
1214300|NCT01097317|stage II non-small cell lung cancer
1214646|NCT01096095|Spinocerebellar Ataxia
1214301|NCT01097317|stage IIIA non-small cell lung cancer
1214302|NCT01097317|stage IIIB non-small cell lung cancer
1214303|NCT01097317|stage IV non-small cell lung cancer
1214304|NCT01097317|recurrent non-small cell lung cancer
1214305|NCT01097278|breast cancer
1214306|NCT01097278|ductal breast carcinoma in situ
1214307|NCT01097278|lobular breast carcinoma in situ
1214308|NCT01097278|BRCA1 mutation carrier
1214309|NCT01097278|BRCA2 mutation carrier
1214310|NCT01097265|stage I colon cancer
1214311|NCT01097265|stage II colon cancer
1214312|NCT01097252|Cervical Neoplasm
1214313|NCT01097252|chemoradiation
1214314|NCT01097252|compliance
1214315|NCT01097252|toxicity
1214316|NCT01097239|High Intensity Focused Ultrasound
1214317|NCT01097239|HIFU
1214318|NCT01097239|Rectal Cancer
1214319|NCT01097239|Sonablate 500
1214320|NCT01097239|Transrectal
1214321|NCT01097226|Dietary intervention
1214322|NCT01097226|bioavailability
1214323|NCT01097226|Healthy volunteers
1214324|NCT01097200|sacrocolpopexy
1214325|NCT01097200|meshes
1214326|NCT01097200|sacrospinous ligament
1214327|NCT01097174|Glaucoma
1214328|NCT01097174|Glaucoma device
1214329|NCT01097174|Glaucoma surgery
1214330|NCT01097174|Intraocular pressure
1214331|NCT01097161|Stuttering
1214332|NCT01097161|Apraxia of speech
1214333|NCT01097161|Motor control
1214334|NCT01097161|Prosody
1214335|NCT01097161|Pitch range
1214336|NCT01097161|Speech rate
1214337|NCT01097161|fluency disorders
1214338|NCT01097148|Obese
1214339|NCT01097148|Atracurium
1214340|NCT01097148|Cefazolin
1214341|NCT01097148|Morfine
1214342|NCT01097148|Nadroparin
1214343|NCT01097122|bone
1214344|NCT01097122|motor neuron excitability
1214345|NCT01097122|forearm vibration
1214346|NCT01097122|mechanical loading
1214347|NCT01097122|muscle electrical activity
1214348|NCT01097109|Effect of Somatic Dysfunctions of Pelvis
1214349|NCT01097109|Effect of Somatic Dysfunctions of Sacrum
1214350|NCT01097109|Effect of Somatic Dysfunctions of Lower Lumbar Spine
1214351|NCT01097109|Weight-Bearing
1214352|NCT01097096|Active immunization
1214353|NCT01097096|Alzheimer disease
1214354|NCT01097096|Antibody
1214355|NCT01097096|Central Nervous System Diseases
1214356|NCT01097096|Neurodegenerative diseases
1214357|NCT01097096|Vaccine
1214358|NCT01097083|Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
1214359|NCT01097083|Patients who are unfit for standard therapy
1214360|NCT01097044|Erythropoietic Protoporphyria
1214361|NCT01097044|EPP
1214362|NCT01097044|Afamelanotide
1214363|NCT01097031|blood pressure
1214364|NCT01097031|pediatric
1214365|NCT01097031|nursing
1214366|NCT01097031|maintenance arterial catheter
1214367|NCT01097005|Mycobacterium Infections, Atypical
1214368|NCT01096992|Chronic lymphocytic leukemia
1214369|NCT01096992|CLL
1214370|NCT01096992|Bendamustine
1214371|NCT01096992|Fludarabine
1214372|NCT01096992|Fludara
1214373|NCT01096992|Fludarabine Phosphate
1214374|NCT01096992|Rituximab
1214375|NCT01096992|Rituxan
1214376|NCT01096979|Subcutaneous Adipose Tissue Reduction
1214377|NCT01096966|chronic low back pain
1214378|NCT01096953|Attention Deficit Hyperactivity Disorder
1214379|NCT01096953|ADHD
1214380|NCT01096953|attention deficit
1214381|NCT01096940|Type 2 Diabetes Mellitus
1214382|NCT01096940|Glucose lowering
1214383|NCT01096927|Lower Abdominal Pain
1214384|NCT01096927|Right Iliac Fossa Pain
1214385|NCT01096927|Acute Appendicitis
1214386|NCT01096927|Antibiotic Therapy
1214387|NCT01096927|Conservative Management
1214388|NCT01096927|Appendectomy
1214389|NCT01096927|Recurrence
1214390|NCT01096927|Length of hospital stay
1214391|NCT01096927|Sick leave time
1214392|NCT01096927|Short and Long Term Abdominal pain evaluation
1214393|NCT01096888|WIC
1214394|NCT01096888|Weight loss
1214395|NCT01096888|Overweight
1214396|NCT01096888|Post Partum
1214397|NCT01096888|Internet based weight loss intervention for Mothers in the WIC program.
1214398|NCT01096875|Endothelial progenitor cells
1214399|NCT01096875|Atorvastatin
1214400|NCT01096875|Coronary surgery
1214401|NCT01096862|Psoriasis
1214402|NCT01096862|ASP015K
1214403|NCT01096849|urinary tract infection
1214404|NCT01096849|UTI
1214405|NCT01096849|cUTI
1214406|NCT01096849|pyelonephritis
1214407|NCT01096849|AP
1214408|NCT01096849|ACHN-490
1214409|NCT01096836|resistance exercise
1214410|NCT01096836|body mass index
1214411|NCT01096836|hypertrophy
1214412|NCT01096836|endothelial function
1214413|NCT01096836|blood lipids
1214414|NCT01096823|Rheumatoid Arthritis
1214415|NCT01096823|Yoga
1214416|NCT01096823|Adolescents
1214417|NCT01096823|Young Adults
1214418|NCT01096810|Asymptomatic
1214419|NCT01096784|insulin-like growth factor
1214420|NCT01096784|ROP
1214421|NCT01096784|IGF-I
1214422|NCT01096784|BPD
1214423|NCT01096784|bronchopulmonary dysplasia
1214424|NCT01096784|retinopathy of prematurity
1214425|NCT01096771|ARDS
1214426|NCT01096771|Parenteral
1214427|NCT01096771|Pharmaconutrition
1214428|NCT01096758|PKU
1214429|NCT01096758|phenylketonuria
1214430|NCT01096758|adult
1214431|NCT01096758|patient
1214432|NCT01096758|development
1214433|NCT01096758|nutritional deficiencies
1214434|NCT01096758|neurological outcome
1214435|NCT01096758|psychological and neurological development
1214436|NCT01096758|comparison with healthy adults
1214437|NCT01096758|longitudinal development
1214438|NCT01096758|quality of life
1214439|NCT01096745|Gemcitabine
1214440|NCT01096745|Cisplatin
1214441|NCT01096745|S-1
1214442|NCT01096745|bile duct cancer
1214443|NCT01096732|Pancreatic
1214444|NCT01096732|adenocarcinoma
1214445|NCT01096732|cancer
1214446|NCT01096719|Weight
1214447|NCT01096719|Dietary intake
1214448|NCT01096719|Energy Density
1214449|NCT01096719|Behavioral
1214450|NCT01096719|Satiety
1214451|NCT01096719|Deprivation
1214452|NCT01096719|Hunger
1214453|NCT01096719|Fruit
1214454|NCT01096719|Vegetable
1214455|NCT01096706|Urocortin 2
1214456|NCT01096706|Urocortin 3
1214457|NCT01096706|Nitric Oxide
1214458|NCT01096706|Plethysmography
1214459|NCT01096706|Forearm blood flow
1214460|NCT01096706|Vascular
1214461|NCT01096706|Heart failure
1214462|NCT01096706|endothelium
1214463|NCT01096706|Cyclo-oxygenase pathway
1214464|NCT01096706|EDHF
1214465|NCT01096693|Urocortin 2
1214466|NCT01096693|Urocortin 3
1214467|NCT01096693|Astressin 2B
1214468|NCT01096693|forearm blood flow
1214469|NCT01096693|plethysmography
1214470|NCT01096693|vascular
1214471|NCT01096693|heart failure
1214472|NCT01096667|type 2 diabetes
1214473|NCT01096667|hypertension
1214474|NCT01096667|ambulatory blood pressure monitoring
1214475|NCT01096654|endocrine hypertension
1214476|NCT01096654|primary hyperaldosteronism
1214477|NCT01096654|aldosterone
1214478|NCT01096654|aldosterone-producing adenoma
1214479|NCT01096654|bilateral adrenal hyperplasia
1214480|NCT01096654|computed tomography
1214481|NCT01096654|adrenal vein sampling
1214482|NCT01096641|Fatigued disease-free Cancer Patients
1214483|NCT01096641|cancer treatment finished > one year and < ten years ago
1214484|NCT01096628|adolescent
1214485|NCT01096628|low back pain
1214486|NCT01096628|chiropractic
1214487|NCT01096628|exercise
1214488|NCT01096537|incidence
1214489|NCT01096537|young workers
1214490|NCT01096537|occupations at risk
1214491|NCT01096537|public health
1214492|NCT01096537|epidemiology
1214493|NCT01096537|polymorphisms
1214494|NCT01096537|gentic
1214495|NCT01096524|Kneehab
1214496|NCT01096524|NMES
1214497|NCT01096524|Total Knee Arthroplasty
1214498|NCT01096524|Total Knee Replacement
1214499|NCT01096524|TKA
1214500|NCT01096524|Disuse atrophy
1214501|NCT01096524|muscle hypertrophy
1214502|NCT01096524|TKR
1214503|NCT01096524|Atrophy Prevention
1214504|NCT01096511|Moxifloxacin,
1214505|NCT01096511|cIAI
1214506|NCT01096511|non-interventional
1214507|NCT01096472|Tinea pedis
1214508|NCT01096459|spina
1214509|NCT01096459|bifida
1214510|NCT01096459|restore
1214511|NCT01096459|urinary
1214512|NCT01096459|function
1214513|NCT01096459|nerve
1214514|NCT01096459|reroute
1214515|NCT01096433|Sleep apnea
1214516|NCT01096433|CPAP
1214517|NCT01096433|Prostaglandins
1214518|NCT01096433|Circadian variations
1214519|NCT01096420|chronic migraine
1214520|NCT01096420|acupuncture
1214521|NCT01096420|Topiramate
1214522|NCT01096420|Randomized trial
1214523|NCT01096407|pain
1214524|NCT01096407|arthralgia
1214525|NCT01096407|unspecified adult solid tumor, protocol specific
1214526|NCT01096394|stage III ovarian epithelial cancer
1214527|NCT01096394|stage IV ovarian epithelial cancer
1214528|NCT01096381|cardiovascular complications
1214529|NCT01096381|stage I breast cancer
1214530|NCT01096381|stage II breast cancer
1214531|NCT01096381|stage IIIA breast cancer
1214532|NCT01096381|stage IIIB breast cancer
1214533|NCT01096381|stage IIIC breast cancer
1214534|NCT01096381|stage IV breast cancer
1214535|NCT01096381|stage I colon cancer
1214536|NCT01096381|stage II colon cancer
1214537|NCT01096381|stage III colon cancer
1214538|NCT01096381|stage IV colon cancer
1214539|NCT01096381|stage I rectal cancer
1214540|NCT01096381|stage II rectal cancer
1214541|NCT01096381|stage III rectal cancer
1214542|NCT01096381|stage IV rectal cancer
1214543|NCT01096381|stage I non-small cell lung cancer
1214544|NCT01096381|stage II non-small cell lung cancer
1214545|NCT01096381|stage IIIA non-small cell lung cancer
1214546|NCT01096381|stage IIIB non-small cell lung cancer
1214547|NCT01096381|stage IV non-small cell lung cancer
1214548|NCT01096381|unspecified adult solid tumor, protocol specific
1214647|NCT01096095|Sodium Phenylbutyrate
1214549|NCT01096381|recurrent squamous cell carcinoma of the hypopharynx
1214550|NCT01096381|stage IV squamous cell carcinoma of the hypopharynx
1214551|NCT01096381|recurrent squamous cell carcinoma of the larynx
1214552|NCT01096381|stage IV squamous cell carcinoma of the larynx
1214553|NCT01096381|recurrent verrucous carcinoma of the larynx
1214554|NCT01096381|stage IV verrucous carcinoma of the larynx
1214555|NCT01096381|recurrent adenoid cystic carcinoma of the oral cavity
1214556|NCT01096381|recurrent mucoepidermoid carcinoma of the oral cavity
1214557|NCT01096381|recurrent verrucous carcinoma of the oral cavity
1214558|NCT01096381|stage IV adenoid cystic carcinoma of the oral cavity
1214559|NCT01096381|stage IV mucoepidermoid carcinoma of the oral cavity
1214560|NCT01096381|stage IV verrucous carcinoma of the oral cavity
1214561|NCT01096381|recurrent basal cell carcinoma of the lip
1214562|NCT01096381|recurrent squamous cell carcinoma of the lip and oral cavity
1214563|NCT01096381|stage IV basal cell carcinoma of the lip
1214564|NCT01096381|stage IV squamous cell carcinoma of the lip and oral cavity
1214565|NCT01096381|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1214566|NCT01096381|recurrent metastatic squamous neck cancer with occult primary
1214567|NCT01096381|untreated metastatic squamous neck cancer with occult primary
1214568|NCT01096381|recurrent lymphoepithelioma of the nasopharynx
1214569|NCT01096381|recurrent squamous cell carcinoma of the nasopharynx
1214570|NCT01096381|stage IV lymphoepithelioma of the nasopharynx
1214571|NCT01096381|stage IV squamous cell carcinoma of the nasopharynx
1214572|NCT01096381|recurrent lymphoepithelioma of the oropharynx
1214573|NCT01096381|recurrent squamous cell carcinoma of the oropharynx
1214574|NCT01096381|stage IV lymphoepithelioma of the oropharynx
1214575|NCT01096381|stage IV squamous cell carcinoma of the oropharynx
1214576|NCT01096381|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1214577|NCT01096381|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1214578|NCT01096381|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1214579|NCT01096381|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1214580|NCT01096381|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1214581|NCT01096381|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1214582|NCT01096381|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1214583|NCT01096381|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1214584|NCT01096381|stage II ovarian epithelial cancer
1214585|NCT01096381|stage III ovarian epithelial cancer
1214586|NCT01096381|stage IV ovarian epithelial cancer
1214587|NCT01096381|fallopian tube cancer
1214588|NCT01096381|peritoneal cavity cancer
1214589|NCT01096329|postmenopausal
1214590|NCT01096329|hormone replacement therapy
1214591|NCT01096316|mood disorders
1214592|NCT01096316|depressive disorder
1214593|NCT01096316|women
1214594|NCT01096316|depression
1214595|NCT01096303|COPD
1214596|NCT01096303|pulmonary function
1214597|NCT01096303|tobacco and marihuana smoking
1214598|NCT01096290|constipation
1214599|NCT01096290|lubiprostone
1214600|NCT01096290|healthy volunteers
1214601|NCT01096264|Arterial stiffness
1214602|NCT01096264|Pulse wave velocity
1214603|NCT01096264|Ultrafastecho
1214604|NCT01096264|Supersonic shear imaging
1214605|NCT01096251|Obesity
1214606|NCT01096251|Binge Eating Disorder
1214607|NCT01096251|Cognitive Behavioural Therapy
1214608|NCT01096251|Brief Strategic Therapy
1214609|NCT01096251|Telepsychology
1214610|NCT01096238|The immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in adults after half a year will be analyzed and discussed.
1214611|NCT01096225|the antibody response
1214612|NCT01096225|T-cell response
1214613|NCT01096225|S-OIV
1214614|NCT01096225|vaccine
1214615|NCT01096225|Immunogenicity assessment
1214616|NCT01096212|Efficacy
1214617|NCT01096212|Minimum alveolar concentration
1214618|NCT01096212|Safety
1214619|NCT01096212|Sevoflurane
1214620|NCT01096199|The purpose of the study is to evaluate the safety and feasibility of combining TS-1/CDDP with RAD001. Primary
1214621|NCT01096199|Objectives
1214622|NCT01096199|To determine the MTD/recommended phase II dose of TS-1/CDDP/RAD001 combination —To determine
1214623|NCT01096199|the safety of TS-1/CDDP/RAD001 combination Secondary Objectives —To preliminarily describe any clinical activity in
1214624|NCT01096199|platinum refractory disease
1214625|NCT01096199|To assess to effect of concurrent TS-1/CDDP on RAD001 pharmacokinetics —To explore
1214626|NCT01096199|the relationship of tumour biomarkers and treatment response
1214627|NCT01096186|motor Symptoms
1214628|NCT01096186|efficacy
1214629|NCT01096186|IPX066
1214630|NCT01096186|Parkinson's Disease
1214631|NCT01096173|Sputum
1214632|NCT01096173|chronic obstructive pulmonary disease
1214633|NCT01096160|Hypertension
1214634|NCT01096147|FBSS
1214635|NCT01096147|chronic pain
1214636|NCT01096147|leg pain
1214637|NCT01096147|low back pain
1214638|NCT01096147|spinal cord stimulation
1214639|NCT01096121|Angiotensin-converting enzyme inhibitors (ACE)
1214640|NCT01096121|Renal disease
1214641|NCT01096121|Microalbuminemia
1214642|NCT01096108|Smoking cessation
1214643|NCT01096108|Quit smoking
1214644|NCT01096108|Quit & Win
1214645|NCT01096095|SCA
1214648|NCT01096095|Machado-Joseph Disease
1214649|NCT01096095|Treatment
1214650|NCT01096082|spinocerebellar ataxia
1214651|NCT01096082|Treatment
1214652|NCT01096082|Lithium carbonate
1214653|NCT01096069|Rituximab, rheumatoid arthritis, CD55, CD59
1214654|NCT01096056|Children
1214655|NCT01096056|Influenza
1214656|NCT01096056|Safety
1214657|NCT01096056|Immunogenicity
1214658|NCT01096056|Vaccine
1214659|NCT01096043|Heart Failure
1214660|NCT01096043|ADHF
1214661|NCT01096030|Regorafenib
1214662|NCT01096030|Advanced
1214663|NCT01096030|Refractory solid tumors
1214664|NCT01096017|Terbutaline
1214665|NCT01096017|Turbuhaler
1214666|NCT01096017|Efficacy
1214667|NCT01096017|Asthma
1214668|NCT01096017|Japanese
1214669|NCT01096017|salbutamol
1214670|NCT01096017|Bricanyl
1214671|NCT01096004|Pharmacodynamic method evaluation
1214672|NCT01095991|Type 2 Diabetes Mellitus, Sitagliptin
1214673|NCT01095978|Klacid SR
1214674|NCT01095978|Clarithromycin
1214675|NCT01095978|Respiratory tract infections
1214676|NCT01095978|Bronchitis
1214677|NCT01095978|Pneumonia
1214678|NCT01095965|Nutrition education intervention
1214679|NCT01095965|Type 2 diabetes mellitus
1214680|NCT01095952|atrial fibrillation
1214681|NCT01095952|inappropriate shock
1214682|NCT01095952|AV-node stimulation
1214683|NCT01095952|ventricular arrhythmia
1214684|NCT01095939|Renal function consecutive to pre-eclampsia
1214685|NCT01095926|pharmacokinetic
1214686|NCT01095926|doxorubicin
1214687|NCT01095926|cancer
1214688|NCT01095926|troponin
1214689|NCT01095926|natriuretic peptide
1214690|NCT01095926|cardiotoxicity
1214691|NCT01095926|anthracyclines
1214692|NCT01095926|Ewing
1214693|NCT01095926|ALL
1214694|NCT01095913|Near-Infrared Imaging
1214695|NCT01095913|Fluorescent Dyes
1214696|NCT01095913|Lymph Node Mapping
1214697|NCT01095913|Indocyanine green
1214698|NCT01095913|IC-Green
1214699|NCT01095913|nonradioactive optical imaging
1214700|NCT01095913|fluorescent contrast agent
1214701|NCT01095913|ICG
1214702|NCT01095913|lymph nodes
1214703|NCT01095913|axillary nodal dissection
1214704|NCT01095900|Pain after treatment
1214705|NCT01095900|healing of fissure after treatment
1214706|NCT01095900|continence scores after treatment
1214707|NCT01095887|ABO incompatibility
1214708|NCT01095887|living donor kidney transplant
1214709|NCT01095887|kidney transplant
1214710|NCT01095887|ABO blood type incompatible
1214711|NCT01095874|myelodysplasia
1214712|NCT01095874|allogeneic hematopoietic stem cell transplantation
1214713|NCT01095874|Survival
1214714|NCT01095874|Transplantation
1214715|NCT01095861|endotracheal tube
1214716|NCT01095848|vaccine
1214717|NCT01095848|cancer
1214718|NCT01095848|ovarian
1214719|NCT01095848|breast
1214720|NCT01095848|prostate
1214721|NCT01095848|tumor
1214722|NCT01095848|Immunotherapy
1214723|NCT01095822|Diabetes
1214724|NCT01095822|Hypertension
1214725|NCT01095822|Platelets
1214726|NCT01095822|Hemostasis
1214727|NCT01095822|Aliskiren
1214728|NCT01095822|Valsartan
1214729|NCT01095796|Treatment Naive
1214730|NCT01095796|HIV 1 Infected
1214731|NCT01095783|low back pain
1214732|NCT01095783|physiotherapy
1214733|NCT01095783|hemodialysis
1214734|NCT01095783|end-stage renal disease
1214735|NCT01095770|Atrial Fibrillation
1214736|NCT01095770|Atrial Fibrillation Ablation
1214737|NCT01095770|Atrial Fibrillation monitoring
1214738|NCT01095770|Ablation Frontiers
1214739|NCT01095770|Reveal XT
1214740|NCT01095770|LASSO
1214741|NCT01095757|Myeloma
1214742|NCT01095757|Lymphoma
1214743|NCT01095757|Stem cell transplantation
1214744|NCT01095744|PIB imaging,
1214745|NCT01095744|brain atrophy
1214746|NCT01095744|cognitive impairment
1214747|NCT01095744|Pet imaging
1214748|NCT01095744|Alzheimer's disease
1214749|NCT01095744|amyloid protein
1214750|NCT01095731|aneurysm
1214751|NCT01095731|aneurysmal
1214752|NCT01095731|subarachnoid
1214753|NCT01095731|hemorrhage
1214754|NCT01095731|haemorrhage
1214755|NCT01095731|neuroprotection
1214756|NCT01095731|3-aminopropanal
1214757|NCT01095731|3AP
1214758|NCT01095731|polyamine oxidase
1214759|NCT01095731|spermine
1214760|NCT01095731|spermidine
1214761|NCT01095731|vasospasm
1214762|NCT01095731|cerebral ischemia
1214763|NCT01095731|neurosurgery
1214764|NCT01095731|neurological intensive care unit
1214765|NCT01095731|NICU
1214766|NCT01095731|Tiopronin
1214767|NCT01095731|Thiola
1214768|NCT01095731|FDA
1214769|NCT01095731|Thiopronin
1214770|NCT01095731|Thiosol
1214771|NCT01095731|Tioglis
1214772|NCT01095731|Acadione
1214773|NCT01095731|Capen
1214774|NCT01095731|Captimer
1214775|NCT01095731|Epatiol
1214776|NCT01095731|Vincol
1214777|NCT01095731|Mucolysin
1214778|NCT01095731|Sutilan
1214779|NCT01095731|Meprin
1214780|NCT01095731|Thiolpropionamidoacetic acid
1214781|NCT01095731|Mercaptopropionyl glycine
1214782|NCT01095731|2 MPG
1214783|NCT01095705|Hypnosis
1214784|NCT01095705|Transesophageal Echocardiography
1214785|NCT01095705|Efficiency of Hypnosis
1214786|NCT01095692|Occult stress Incontinence,
1214787|NCT01095692|Pelvic Organ Prolapse,
1214788|NCT01095692|Prevention of stress urinary incontinence,
1214789|NCT01095692|Postoperative incontinence,
1214790|NCT01095692|Sub-urethral tape
1214791|NCT01095679|CHEYNE Stokes respiration
1214792|NCT01095679|Periodic ventilation
1214793|NCT01095679|baclofen
1214794|NCT01095679|hypoxia
1214795|NCT01095679|healthy subject
1214796|NCT01095640|acne
1214797|NCT01095640|adapalene
1214798|NCT01095640|Differin
1214799|NCT01095614|Women
1214800|NCT01095614|Hormonal status
1214801|NCT01095614|Exercise
1214802|NCT01095614|Substrate utilization
1214803|NCT01095614|Women Hormonal Status (with oral contraception or without any contraception)
1214804|NCT01095601|avanafil
1214805|NCT01095601|absoprion
1214806|NCT01095601|bioavailability
1214807|NCT01095601|food effect
1214808|NCT01095601|dose-proportionality
1214809|NCT01095601|TA-1790
1214810|NCT01095601|Pharmacokinetics of avanafil
1214811|NCT01095588|ED
1214812|NCT01095575|Epidural
1214813|NCT01095575|Morphine
1214814|NCT01095575|Preoperative
1214815|NCT01095575|Postoperative
1214816|NCT01095575|Analgesia
1214817|NCT01095575|Tolerance
1214818|NCT01095575|Preoperative, Postoperative Analgesia
1214819|NCT01095549|ankle-brachial index (ABI)
1214820|NCT01095549|brachial-ankle pulse wave velocity (baPWV)
1214821|NCT01095549|far infrared therapy (FIR)
1214822|NCT01095549|hemodialysis (HD)
1214823|NCT01095549|peripheral artery disease (PAD)
1214824|NCT01095549|Peripheral artery disease in hemodialysis
1214825|NCT01095536|laparoscopic cholecystectomy, elective
1214826|NCT01095536|anesthesia, general
1214827|NCT01095536|shoulder pain
1214828|NCT01095536|nausea
1214829|NCT01095536|vomiting
1214830|NCT01095536|laparoscopic cholecystectomy
1214831|NCT01095536|general anesthesia
1214832|NCT01095523|Colon Cancer
1214833|NCT01095523|Rectal Cancer
1214834|NCT01095523|Peritoneal Perfusion
1214835|NCT01095523|Metastatic Cancer
1214836|NCT01095523|Recurrence
1214837|NCT01095523|Colorectal Cancer
1214838|NCT01095510|HAE
1214839|NCT01095510|CINRYZE
1214840|NCT01095510|C1 INH
1214841|NCT01095510|C1 inhibitor
1214842|NCT01095510|Pediatric
1214843|NCT01095510|PK/PD
1214844|NCT01095497|HAE
1214845|NCT01095497|C1 inhibitor (C1INH)
1214846|NCT01095497|Subcutaneous
1214847|NCT01095484|Rotigotine
1214848|NCT01095484|Neupro®
1214849|NCT01095471|7 valent Pneumococcal conjugate vaccine
1214850|NCT01095471|13 valent Pneumococcal conjugate vaccine
1214851|NCT01095471|PCV13
1214852|NCT01095471|PCV7
1214853|NCT01095458|Obesity
1214854|NCT01095458|Phone vs Clinical methods
1214855|NCT01095445|hepatitis C
1214856|NCT01095445|genotype 3
1214857|NCT01095445|end of treatment response
1214858|NCT01095445|relapse rate
1214859|NCT01095445|rapid virologic response
1214860|NCT01095445|complete early virologic response
1214861|NCT01095432|Colonoscopy
1214862|NCT01095432|Flexible Sigmoidoscopy
1214863|NCT01095419|massage therapy
1214864|NCT01095419|sleep quality
1214865|NCT01095419|coronary artery bypass grafting surgery
1214866|NCT01095419|Patients after Coronary Artery Bypass Graft Surgery
1214867|NCT01095406|Weaning
1214868|NCT01095406|closed loop
1214869|NCT01095406|mechanical ventilation
1214870|NCT01095406|children
1214871|NCT01095393|Certolizumab Pegol
1214872|NCT01095393|CZP
1214873|NCT01095393|Cimzia®
1214874|NCT01095393|NDB
1214875|NCT01095393|registry
1214876|NCT01095380|task-specific training
1214877|NCT01095380|walking
1214878|NCT01095380|locomotion
1214879|NCT01095380|function
1214880|NCT01095380|body weight support
1214881|NCT01095380|Individuals with motor-incomplete spinal cord injury
1214882|NCT01095367|Adhesion barrier sheets
1214883|NCT01095367|ovarian cancer
1214884|NCT01095367|Advanced stage epithelial ovarian cancer
1214885|NCT01095354|pediatric
1214886|NCT01095354|lung ventilation inhomogeneity
1214887|NCT01095341|hyperthyroidism
1214888|NCT01095341|tertiary hyperparathyroidism
1214889|NCT01095341|palpation thyroiditis
1214890|NCT01095341|parathyroidectomy
1214891|NCT01095341|thyroglobulin
1214892|NCT01095341|rate of postoperative hyperthyroidism
1214893|NCT01095328|Q fever
1214894|NCT01095328|Pregnancy
1214895|NCT01095328|Screening
1214896|NCT01095328|Cost-effectiveness
1214897|NCT01095289|electromyography
1214898|NCT01095289|laryngeal neoplasms
1214899|NCT01095289|masticatory muscles
1214900|NCT01095276|Mechanical Ventilation
1214901|NCT01095276|Extubation
1214902|NCT01095276|dornase alpha
1214903|NCT01095276|oxygenation
1214904|NCT01095276|chest x ray
1214905|NCT01095250|Active uveitis
1214906|NCT01095250|intermediate uveitis
1214907|NCT01095250|panuveitis
1214908|NCT01095250|posterior uveitis
1214909|NCT01095250|uveitis
1214910|NCT01095237|Peripheral Arterial Disease
1214911|NCT01095237|Peripheral Vascular Disease
1214912|NCT01095237|PAD
1214913|NCT01095237|vascular prosthesis
1214914|NCT01095237|revascularization
1214915|NCT01095237|patency
1214916|NCT01095237|blood vessel
1214917|NCT01095237|Rutherford
1214918|NCT01095237|ABI
1214919|NCT01095237|Ankle Brachial Index
1214920|NCT01095237|Vascular Graft
1214921|NCT01095237|Carbothane
1214922|NCT01095237|ProEndoTecc
1214923|NCT01095237|implantation
1214924|NCT01095224|HIV Preventive Vaccine
1214925|NCT01095211|folic acid
1214926|NCT01095211|homocysteine
1214927|NCT01095211|MMSE scores
1214928|NCT01095211|methyl malonic acid
1214929|NCT01095211|betaine
1214930|NCT01095198|vaginal self collection
1214931|NCT01095198|human papillomavirus (hpv)
1214932|NCT01095198|cervical intraepithelial neoplasia
1214933|NCT01095172|Immunosuppression
1214934|NCT01095172|Rituximab
1214935|NCT01095172|B cell
1214936|NCT01095159|TVTO
1214937|NCT01095159|TVTSecur
1214938|NCT01095159|Mini sling
1214939|NCT01095159|stress urinary incontinence
1214940|NCT01095146|MAS
1214941|NCT01095146|Hemophagocytosis
1214942|NCT01095146|Reactive HLH
1214943|NCT01095146|Macrophage activation syndrome
1214944|NCT01095146|Systemic onset juvenile idiopathic arthritis
1214945|NCT01095146|SoJIA
1214946|NCT01095146|JIA
1214947|NCT01095133|Gastroesophageal reflux disease
1214948|NCT01095133|Heartburn
1214949|NCT01095107|Determining whether adjustments in the amounts of fat grams within the current inpatient protocol meal plans will lead to a change in the hospital stay duration
1214950|NCT01095107|Alter their recovery by affecting vital signs
1214951|NCT01095107|Rate of weight change or need for supplemental feeds/medications
1214952|NCT01095107|Effect gastrointestinal symptoms (bloating, gastroesophageal reflux, constipation, diarrhea, abdominal pain
1214953|NCT01095107|And/or effect their perceived body image or cause any changes in their mood.
1214954|NCT01095094|adult brain tumor
1214955|NCT01095094|adult anaplastic astrocytoma
1214956|NCT01095094|adult anaplastic ependymoma
1214957|NCT01095094|adult anaplastic oligodendroglioma
1214958|NCT01095094|adult brain stem glioma
1214959|NCT01095094|adult giant cell glioblastoma
1214960|NCT01095094|adult glioblastoma
1214961|NCT01095094|adult gliosarcoma
1214962|NCT01095094|adult mixed glioma
1214963|NCT01095094|recurrent adult brain tumor
1214964|NCT01095042|HRV
1214965|NCT01095042|emotion
1214966|NCT01095042|cognition
1214967|NCT01095042|stress
1214968|NCT01095042|cortisol
1214969|NCT01095042|Autonomic nervous system
1214970|NCT01095029|Positron emission tomography (PET)
1214971|NCT01095029|Idiopathic Faecal Incontinence
1214972|NCT01095029|Bilateral Sacral Nerve Stimulation
1214973|NCT01095029|Sacral Nerve Stimulation
1214974|NCT01095029|Sacral Nervemodulation
1214975|NCT01094990|crossover; double blinded; intrathecal chemotherapy; dexamethasone; ketamine;vomiting
1214976|NCT01094977|Blood Loss and Transfusion
1214977|NCT01094977|Craniosynostoses
1214978|NCT01094977|Tranexamic Acid
1214979|NCT01094977|Children
1214980|NCT01094964|recurrent bladder cancer
1214981|NCT01094964|stage 0 bladder cancer
1214982|NCT01094964|stage I bladder cancer
1214983|NCT01094964|adenocarcinoma of the bladder
1214984|NCT01094964|squamous cell carcinoma of the bladder
1214985|NCT01094951|Depression
1214986|NCT01094938|Aortic aneurysm repair
1214987|NCT01094925|Cesarean section
1214988|NCT01094925|Gabapentin
1214989|NCT01094912|Cancer pain
1214990|NCT01094899|diabetes
1214991|NCT01094899|osteopenia
1214992|NCT01094899|neuropathy
1214993|NCT01094899|foot
1214994|NCT01094899|AGE
1214995|NCT01094886|Total Hip Replacement
1214996|NCT01094886|Total Knee Replacement
1214997|NCT01094886|Hip Implant
1214998|NCT01094886|Knee Implant
1214999|NCT01094886|Joint Prosthesis
1215000|NCT01094886|Orthopedic Surgery
1215001|NCT01094886|Rivaroxaban
1215002|NCT01094886|Xarelto
1215003|NCT01094886|Blood Clot
1215004|NCT01094873|Hepatitis C
1215005|NCT01094873|HCV
1215006|NCT01094873|Adenovirus
1215007|NCT01094873|Vaccine
1215008|NCT01094860|Relapsed/Refractory Lymphoid Malignancies
1215009|NCT01094860|Chronic lymphocytic leukemia
1215010|NCT01094860|CLL
1215011|NCT01094860|Small lymphocytic lymphoma
1215012|NCT01094860|SLL
1215013|NCT01094860|B-prolymphocytic leukemia
1215014|NCT01094860|Follicular lymphoma
1215015|NCT01094860|Mantle cell lymphoma
1215016|NCT01094860|Lymphoplasmacytoid lymphoma
1215017|NCT01094860|Marginal zone lymphoma
1215018|NCT01094860|T-cell prolymphocytic leukemia
1215019|NCT01094860|large granular lymphocyte leukemia
1215020|NCT01094860|mycosis fungoides
1215021|NCT01094860|Sezary syndrome
1215022|NCT01094860|peripheral T-cell lymphoma
1215023|NCT01094860|Chemotherapy
1215024|NCT01094860|Monoclonal antibody therapy
1215025|NCT01094860|T-cell or B-cell acute lymphoblastic leukemia (ALL)
1215026|NCT01094860|Continuous Infusion Nelarabine
1215027|NCT01094860|Arranon
1215028|NCT01094821|Healthy volunteers
1215029|NCT01094821|ATI-7505
1215030|NCT01094821|Scintigraphy
1215031|NCT01094821|Gastrointestinal transit
1215032|NCT01094808|pregabalin
1215033|NCT01094808|motor
1215034|NCT01094808|sensation
1215035|NCT01094808|colon
1215036|NCT01094808|pain
1215037|NCT01094808|gas
1215038|NCT01094782|Pain
1215039|NCT01094782|Pain management
1215040|NCT01094756|Obesity
1215041|NCT01094717|psoriasis
1215042|NCT01094717|excimer
1215043|NCT01094717|acitretin
1215044|NCT01094717|tazarotene
1215045|NCT01094704|cystic fibrosis
1215046|NCT01094704|mucociliary clearance
1215047|NCT01094704|hypertonic saline
1215048|NCT01094678|Peripheral Aterial Disease (PAD)
1215049|NCT01094678|Peripheral Vascular Disease
1215050|NCT01094678|Drug-Eluting Stent
1215051|NCT01094678|Drug-Coated Stent
1215052|NCT01094678|Vascular Diseases
1215053|NCT01094678|Cardiovascular Diseases
1215054|NCT01094652|Adolescent
1215055|NCT01094652|Whole grain
1215056|NCT01094652|Digestive health
1215057|NCT01094652|Dietary fiber
1215058|NCT01094652|Grain
1215059|NCT01094652|Microbiota
1215060|NCT01094652|Inflammation
1215061|NCT01094652|Mucosal Immunity
1215062|NCT01094626|Pancreatic adenocarcinoma
1215063|NCT01094626|Intraductal papillary mucinous neoplasm
1215064|NCT01094626|Imaging techniques
1215065|NCT01094626|Pancreatic surgical resection
1215066|NCT01094626|Synthetic human secretin
1215067|NCT01094613|Crohn's Disease
1215068|NCT01094613|Delayed Release
1215069|NCT01094613|Targeted Ileal Delivery
1215070|NCT01094600|Pancreatic cancer
1215071|NCT01094600|Pancreatic resection
1215072|NCT01094600|Synthetic human secretin
1215073|NCT01094600|Secretin-enhanced MRCP
1215074|NCT01094600|Endoscopic pancreatic function test
1215075|NCT01094600|Pancreatic exocrine insufficiency
1215076|NCT01094561|Family history of pancreatic cancer
1215077|NCT01094561|Pancreatic adenocarcinoma
1215078|NCT01094561|Imaging techniques
1215079|NCT01094561|Synthetic human secretin
1215080|NCT01094561|Pancreatic abnormalities
1215081|NCT01094561|Early detection and prevention
1215082|NCT01094548|L-BLP25 liposome
1215083|NCT01094548|Multiple myeloma
1215084|NCT01094535|Pancreatic adenocarcinoma
1215085|NCT01094535|Synthetic human secretin
1215086|NCT01094535|Secretin-enhanced MRCP
1215087|NCT01094535|Pancreatic insufficiency
1215088|NCT01094535|Endoscopic Pancreatic Function Test (ePFT)
1215089|NCT01094535|Endocrine pancreatic function test
1215090|NCT01094535|Exocrine pancreatic function test
1215091|NCT01094496|bladder cancer
1215092|NCT01094496|immunotherapy
1215093|NCT01094496|cystectomy
1215094|NCT01094496|cancer vaccine
1215095|NCT01094496|human chorionic gonadotropin
1215096|NCT01094496|hCG
1215097|NCT01094496|urogenital neoplasms
1215098|NCT01094496|urinary bladder neoplasms
1215099|NCT01094496|muscle invasive
1215100|NCT01094496|non-metastatic
1215101|NCT01094496|transitional cell (urothelial) bladder cancer
1215102|NCT01094483|Thromboxane B2
1215103|NCT01094470|gait
1215104|NCT01094470|ambulation
1215105|NCT01094470|kinematics
1215106|NCT01094457|antiplatelet therapy
1215107|NCT01094457|clopidogrel low responsiveness
1215108|NCT01094457|acute coronary syndromes
1215109|NCT01094457|percutaneous coronary intervention
1215110|NCT01094457|cilostazol
1215111|NCT01094444|Vitamin K3 lotion
1215112|NCT01094444|Cetuximab induced folliculitis
1215113|NCT01094431|Fever
1215114|NCT01094431|Etiology
1215115|NCT01094431|Children under five years of age
1215116|NCT01094431|IMCI
1215117|NCT01094418|polyneuropathy
1215118|NCT01094418|Nerve conduction study
1215119|NCT01094418|Impaired glucose tolerance test
1215120|NCT01094418|Diabetes mellitus
1215121|NCT01094405|NPC with persistent, recurrent or metastatic disease patients
1215122|NCT01094392|ALL
1215123|NCT01094392|PEG-asparaginase
1215124|NCT01094392|prolonged treatment
1215125|NCT01094392|Thrombosis
1215126|NCT01094392|Central venous line
1215127|NCT01094392|Echocardiography
1215128|NCT01094379|cholecystectomy
1215129|NCT01094379|laparoscopic
1215130|NCT01094379|pain
1215131|NCT01094379|single incision
1215132|NCT01094366|Paracervical Block
1215133|NCT01094366|pain control
1215134|NCT01094366|abortion
1215139|NCT01094327|focal segmental glomerulosclerosis
1215140|NCT01093352|Alveolar-decortication
1215141|NCT01093352|Corticotomy assisted orthodontics
1215142|NCT01093352|Palatally impacted canine
1215143|NCT01093352|Surgical exposure of canines
1215144|NCT01093352|Velocity of tooth movement
1215145|NCT01093339|GERD
1215146|NCT01093339|SLEEP DEPRIVATION
1215147|NCT01093339|APPETITE REGULATION
1215148|NCT01093339|GHRELIN
1215149|NCT01093339|LEPTIN
1215150|NCT01093274|colonoscopy
1215151|NCT01093274|Cathartics
1215152|NCT01093274|Sodium picosulfate
1215153|NCT01093274|Polyethylene Glycol
1215154|NCT01093261|trauma
1215155|NCT01093261|trauma brain injury
1215156|NCT01093261|multiple trauma
1215157|NCT01093261|head trauma
1215158|NCT01093261|hydrocortisone
1215159|NCT01093261|fludrocortisone
1215160|NCT01093261|glucocorticoid insufficiency related to ICU
1215161|NCT01093261|adrenal Insufficiency
1215162|NCT01093261|pneumonia
1215163|NCT01093261|intensive care unit
1215164|NCT01093261|shock
1215165|NCT01093261|neurological recovery
1215166|NCT01093235|cardiac toxicity
1215167|NCT01093235|perioperative/postoperative complications
1215168|NCT01093235|HER2-negative breast cancer
1215169|NCT01093235|male breast cancer
1215170|NCT01093235|estrogen receptor-negative breast cancer
1215171|NCT01093235|estrogen receptor-positive breast cancer
1215172|NCT01093235|progesterone receptor-negative breast cancer
1215173|NCT01093235|progesterone receptor-positive breast cancer
1215174|NCT01093235|stage II breast cancer
1215175|NCT01093235|stage IIIA breast cancer
1215176|NCT01093235|stage IIIB breast cancer
1215177|NCT01093235|inflammatory breast cancer
1215178|NCT01093209|Carpal Tunnel Syndrome
1215179|NCT01093209|Interferential laser therapy
1215180|NCT01093209|Low-level laser therapy
1215181|NCT01093209|Neuropathic pain
1215182|NCT01093209|Median nerve compression
1215183|NCT01093196|Multiple Myeloma
1215184|NCT01093196|Elderly Patients
1215185|NCT01093196|Diagnosis
1215186|NCT01093196|Lenalidomide
1215187|NCT01093196|Prednisone
1215188|NCT01093196|Melphalan
1215189|NCT01093196|Dexamethasone
1215190|NCT01093196|Cyclophosphamide
1215191|NCT01093157|Kidney disease, Glomerulonephritis
1215192|NCT01093144|Delivery mode
1215193|NCT01093144|pelvic measurement
1215194|NCT01093131|Contrast induced nephropathy
1215195|NCT01093131|Percutaneous transluminal coronary angioplasty
1215196|NCT01093131|chronic kidney disease
1215197|NCT01093131|Prevention
1215198|NCT01093131|Equivalence
1215199|NCT01093118|Distal subungual onychomycosis
1215200|NCT01093105|Leukodystrophy, Globoid Cell
1215201|NCT01093105|Classic Globoid Cell Leukodystrophy
1215202|NCT01093105|Early-Onset Globoid Cell Leukodystrophy
1215203|NCT01093105|Globoid Cell Leukodystrophy
1215204|NCT01093105|Globoid Cell Leukoencephalopathy
1215205|NCT01093105|Infantile Globoid Cell Leukodystrophy
1215206|NCT01093105|Late-Onset Globoid Cell Leukodystrophy
1215207|NCT01093105|Leukodystrophy, Globoid Cell, Classic
1215208|NCT01093105|Leukodystrophy, Globoid Cell, Early-Onset
1215209|NCT01093105|Leukodystrophy, Globoid Cell, Infantile
1215210|NCT01093105|Leukodystrophy, Globoid Cell, Late-Onset
1215211|NCT01093105|Psychosine
1215212|NCT01093105|galactosylsphingosine (psychosine) beta-galactosidase
1215213|NCT01093105|Psychosine-UDP galactosyltransferase
1215214|NCT01093105|Krabbe Disease
1215215|NCT01093105|Krabbe Leukodystrophy
1215216|NCT01093105|Krabbe's Disease
1215217|NCT01093105|Krabbe's Leukodystrophy
1215218|NCT01093079|Renal tumor, RCC, Partial nephrectomy, Laparoscopy
1215219|NCT01093066|urothelial carcinoma
1215220|NCT01093066|TURB
1215221|NCT01093066|chemotherapy
1215222|NCT01094301|electrical stimulation
1215223|NCT01094301|neurostimulation
1215224|NCT01094301|neuromodulation
1215225|NCT01094301|shoulder pain
1215226|NCT01094301|post-stroke shoulder pain
1215227|NCT01094301|hemiplegic shoulder pain
1215228|NCT01094275|drug resistance
1215229|NCT01094275|gene polymorphism
1215230|NCT01094262|Osteoarthritis pain of the knee
1215231|NCT01094262|Osteoarthritis
1215232|NCT01094262|Osteoarthritis, Knee
1215233|NCT01094262|Pain
1215234|NCT01094262|Arthralgia
1215235|NCT01094262|Joint Pain
1215236|NCT01094262|JNJ-42160443
1215237|NCT01094249|Paliperidone ER
1215238|NCT01094249|INVEGA
1215239|NCT01094249|Divalproex sodium
1215240|NCT01094249|Depakote ER
1215241|NCT01094249|Valproic acid
1215242|NCT01094249|Pharmacokinetics
1215243|NCT01094249|R076477BIM1004
1215244|NCT01094236|behavior management
1215245|NCT01094236|academic performance
1215246|NCT01094236|playground supervision
1215247|NCT01094236|harm reduction
1215248|NCT01094236|Behavioral Research
1215249|NCT01094223|Stimulant
1215250|NCT01094223|Addiction
1215251|NCT01094223|Mindfulness
1215252|NCT01094223|Treatment
1215253|NCT01094210|Anti-erosion dental benefits
1215254|NCT01094197|Transfusion-associated microchimerism
1215255|NCT01094197|Injuries
1215256|NCT01094197|Leukocytes
1215257|NCT01094171|poliomyelitis
1215258|NCT01094171|diphtheria
1215259|NCT01094171|Primary immunization
1215260|NCT01094171|pertussis
1215261|NCT01094171|Children
1215262|NCT01094171|tetanus
1215263|NCT01094158|NAFLD
1215264|NCT01094158|NASH
1215265|NCT01094158|Fatty Liver
1215266|NCT01094158|Metabolic Syndrome
1215267|NCT01094158|Endothelial Dysfunction
1215268|NCT01094158|Insulin Resistance
1215269|NCT01094158|Liver Fat
1215270|NCT01094145|(light to moderate)
1215271|NCT01094132|cervical cancer
1215272|NCT01094132|cervical intraepithelial neoplasia grade 1
1215273|NCT01094132|cervical intraepithelial neoplasia grade 2
1215274|NCT01094132|cervical intraepithelial neoplasia grade 3
1215275|NCT01094132|Nonmalignant Condition
1215276|NCT01094119|heated blanket
1215277|NCT01094119|heated pad
1215278|NCT01094106|postoperative pain
1215279|NCT01094106|infiltration analgesia
1215280|NCT01094106|ropivacaine
1215281|NCT01094106|Caesarean Section
1215282|NCT01094093|Amgen
1215283|NCT01094093|AMG 139
1215284|NCT01094080|fully formula fed
1215285|NCT01094080|fully breast fed
1215286|NCT01094041|Gluten
1215287|NCT01094041|Diarrhea or diarrhea predominant irritable bowel syndrome
1215288|NCT01094041|Colonic permeability
1215289|NCT01094041|Small bowel permeability
1215290|NCT01094041|Colonic inflammatory response
1215291|NCT01094041|Small bowel inflammatory response
1215292|NCT01094028|Blood loss in the third and fourth stage of labor and the duration of third stage of labor
1215293|NCT01094015|hysteroscopy
1215294|NCT01094015|local anaesthetic
1215295|NCT01094015|pain relief
1215296|NCT01094015|gynecological pathology
1215297|NCT01094002|OCCUPATIONAL THERAPY
1215298|NCT01094002|RANDOMISED CLINICAL TRIAL
1215299|NCT01094002|AGED
1215300|NCT01094002|PATIENT CARE
1215301|NCT01093976|Skin Picking
1215302|NCT01093976|OCD
1215303|NCT01093976|Trichotillomania
1215431|NCT01093430|Gynecological surgery
1215304|NCT01093976|Pathological Skin Picking
1215305|NCT01093950|anthropometric
1215306|NCT01093950|white light scanner
1215307|NCT01093950|extraction profiles
1215308|NCT01093950|Body lipodystrophy
1215309|NCT01093937|Bipolar disorder
1215310|NCT01093937|Bipolar-I
1215311|NCT01093937|Varenicline
1215312|NCT01093937|Champix
1215313|NCT01093937|Chantix
1215314|NCT01093937|Nicotine
1215315|NCT01093937|Nicotinic receptor
1215316|NCT01093937|Nicotinic receptor dysregulation
1215317|NCT01093937|Dopamine
1215318|NCT01093937|Acetylcholine
1215319|NCT01093937|Cigarette
1215320|NCT01093937|Smoking
1215321|NCT01093937|Tobacco
1215322|NCT01093937|Dependence
1215323|NCT01093937|Neuropsychological function
1215324|NCT01093924|Behavioral weight loss maintenance intervention
1215325|NCT01093924|Weight loss
1215326|NCT01093924|Weight loss maintenance
1215327|NCT01093911|Lupus
1215328|NCT01093911|SLE
1215329|NCT01093859|acetylcholinesterase
1215330|NCT01093846|uveitis
1215331|NCT01093833|Diabetes
1215332|NCT01093833|Type 1 diabetes
1215333|NCT01093833|Type 2 diabetes
1215334|NCT01093833|Diabetes mellitus
1215335|NCT01093833|Blood glucose
1215336|NCT01093833|Continuous blood glucose monitoring
1215337|NCT01093833|CGM
1215338|NCT01093820|acute myocardial infarction
1215339|NCT01093820|continuous erythropoetin receptor activator
1215340|NCT01093820|Mircera
1215341|NCT01093820|hemoglobin kinetics
1215342|NCT01093807|Hypertension
1215343|NCT01093807|Lercanidipine
1215344|NCT01093807|Calcium antagonist
1215345|NCT01093807|Enalapril
1215346|NCT01093794|Type 2 Diabetes
1215347|NCT01093781|membranous nephropathy aliskiren proteinuria, glomerulonephritis
1215348|NCT01093768|Oxytocin
1215349|NCT01093768|Vasopressin
1215350|NCT01093768|Autism
1215351|NCT01093768|Amygdala
1215352|NCT01093768|Social Cognition
1215353|NCT01093768|Autism Spectrum Disorders
1215354|NCT01093768|ASD
1215355|NCT01093768|Healthy Volunteer
1215356|NCT01093768|HV
1215357|NCT01093755|Barrett's Esophagus
1215358|NCT01093755|Radiofrequency ablation
1215359|NCT01093755|Patients post-radiofrequency ablation for Barrett's Esophagus.
1215360|NCT01093742|Healthy
1215361|NCT01093729|Exendin-4
1215362|NCT01093716|Alcohol dependence
1215363|NCT01093716|Craving
1215364|NCT01093716|rTMS
1215365|NCT01093716|Dorsolateral prefrontal cortex
1215366|NCT01093703|kidney transplantation
1215367|NCT01093703|hypertension
1215368|NCT01093703|chronotherapy
1215369|NCT01093703|graft function
1215370|NCT01093703|circadian pattern
1215371|NCT01093690|chemotherapy induced nausea and vomiting, metoclopramide
1215372|NCT01093612|HER2-positive breast cancer
1215373|NCT01093599|Smoking
1215374|NCT01093599|Smoking cessation
1215375|NCT01093599|Nicotine
1215376|NCT01093599|Tobacco
1215377|NCT01093599|Mindfulness
1215378|NCT01093599|Meditation
1215379|NCT01093599|MBSR
1215380|NCT01093599|Mindfulness Training
1215381|NCT01093599|Behavioral Intervention
1215382|NCT01093599|Nicotine Patch
1215383|NCT01093599|Quit Line
1215384|NCT01093599|Phone counseling
1215385|NCT01093573|Untreated myelodysplastic syndromes
1215386|NCT01093560|metabolic syndrome
1215387|NCT01093560|premenopausal women
1215388|NCT01093560|fat feeding
1215389|NCT01093534|Vesicare
1215390|NCT01093534|Solifenacin
1215391|NCT01093534|Detrusor Overactivity
1215392|NCT01093534|Urinary Nerve Growth Factor
1215393|NCT01093534|Overactive Bladder
1215394|NCT01093534|Bladder wall thickness
1215395|NCT01093521|IV Gallium
1215396|NCT01093521|Gallium
1215397|NCT01093521|Ganite
1215398|NCT01093521|Cystic Fibrosis
1215399|NCT01093521|Gallium Infusion
1215400|NCT01093495|Nasal Continuous positive Airway pressure
1215401|NCT01093495|Nasal Cannula
1215402|NCT01093495|CPAP
1215403|NCT01093495|Premature
1215404|NCT01093495|RDS
1215405|NCT01093495|HMD
1215406|NCT01093495|NICU
1215407|NCT01093482|mechanical ventilation
1215408|NCT01093482|epidemiology
1215409|NCT01093482|outcomes
1215410|NCT01093482|mortality
1215411|NCT01093482|weaning
1215412|NCT01093482|sedation
1215413|NCT01093482|non-invasive positive pressure ventilation
1215414|NCT01093469|Atopic Dermatitis
1215415|NCT01093469|Wake Forest
1215416|NCT01093469|Dermatology
1215417|NCT01093469|Skin
1215418|NCT01093469|Over-the-counter
1215419|NCT01093469|Moisturizer
1215420|NCT01093469|Children
1215421|NCT01093456|diurnal variation
1215422|NCT01093456|peritoneal dialysis
1215423|NCT01093456|uremic retention solutes
1215424|NCT01093456|phosphorous
1215425|NCT01093456|indoxyl sulfate
1215426|NCT01093456|p-cresol sulfate
1215427|NCT01093443|IVF
1215428|NCT01093443|ICSI
1215429|NCT01093443|GnRH antagonist
1215430|NCT01093443|pretreatment
1215432|NCT01093430|laparoscopic ports
1215433|NCT01093430|neuropathy
1215434|NCT01093417|Vitamin D
1215435|NCT01093417|Human Immunodeficiency Virus (HIV)
1215436|NCT01093417|Complementary Therapies
1215437|NCT01093404|Heart disease
1215438|NCT01093404|Myocardial infarction
1215439|NCT01093404|Angioplasty
1215440|NCT01093404|Thrombus aspiration
1215441|NCT01093391|coronary artery
1215442|NCT01093391|thrombosis
1215443|NCT01093391|stent
1215444|NCT01093378|Infertility
1215445|NCT01093378|Obesity
1215446|NCT01093378|Dietary intake
1215447|NCT01093378|Fertility
1215448|NCT01093378|nutrition
1215449|NCT01093378|diet
1215450|NCT01093378|weight
1215451|NCT01093365|Schizophrenia
1215452|NCT01093365|Schizoaffective Disorder
1215453|NCT01093365|Varenicline
1215454|NCT01093365|Champix
1215455|NCT01093365|Chantix
1215456|NCT01093365|Nicotine
1215457|NCT01093365|Nicotinic receptor
1215458|NCT01093365|Dopamine
1215459|NCT01093365|Acetylcholine
1215460|NCT01093365|Cigarette
1215461|NCT01093365|Smoking
1215462|NCT01093365|Tobacco
1215463|NCT01093365|Executive function
1215464|NCT01093365|Working memory
1215465|NCT01093365|Verbal memory
1215466|NCT01093365|Cognitive function
1215467|NCT01093365|Neuropsychological function
1215468|NCT01093053|Mind-Body Therapies
1215469|NCT01093027|Essential Tremor
1215470|NCT01093027|Cooling
1215471|NCT01093027|Temperature
1215472|NCT01093027|Patients with Essential Tremor involving the upper limbs with at least moderate tremor.
1215473|NCT01093014|Quadriceps Muscle
1215474|NCT01093014|RNA, Messenger
1215475|NCT01093014|Hypertrophy
1215476|NCT01093014|Electric Stimulation Therapy
1215477|NCT01093001|Reduce Tricuspid Regurgitation
1215478|NCT01093001|Reduce Right Ventricular pacing
1215479|NCT01093001|Lead position
1215480|NCT01093001|Lead size
1215481|NCT01092988|Uterine Fibroids
1215482|NCT01092988|Bleeding
1215483|NCT01092988|Pain
1215484|NCT01092988|Quality of life
1215485|NCT01092988|MR guided focused ultrasound
1215486|NCT01092975|radiotherapy
1215487|NCT01092962|Children
1215488|NCT01092962|Mycophenolate mofetil
1215489|NCT01092962|Cyclophosphamide
1215490|NCT01092962|Idiopathic nephrotic steroid sensitive syndrome
1215491|NCT01092949|Placenta
1215492|NCT01092949|perfusion
1215493|NCT01092949|MRI
1215494|NCT01092949|spin tagging
1215495|NCT01092949|Gadolinium
1215496|NCT01092949|placental insufficiency
1215497|NCT01092949|urinary tract, sexual organs and pregnancy conditions
1215498|NCT01092936|Comparative fit index
1215499|NCT01092936|Movement Disorders' Society
1215500|NCT01092936|Unified Parkinson's Disease Rating Scale
1215501|NCT01092923|Nitrous Oxide
1215502|NCT01092923|washin
1215503|NCT01092923|washout
1215504|NCT01092923|second gas effect
1215505|NCT01092923|sevoflurane
1215506|NCT01092923|induction
1215507|NCT01092923|emergence
1215508|NCT01092910|Sensorineural
1215509|NCT01092910|Hearing Loss
1215510|NCT01092884|melasma
1215511|NCT01092884|sunscreen
1215512|NCT01092884|polypodium leucotomos
1215513|NCT01092858|Testosterone undecanoate
1215514|NCT01092858|Hypogonadism
1215515|NCT01092845|Double-Blind
1215516|NCT01092845|Randomized
1215517|NCT01092845|Placebo-Controlled
1215518|NCT01092845|2-Way Crossover
1215519|NCT01092845|Polysomnographic Endpoints
1215520|NCT01092832|Invasive Candidiasis Candidemia Esophageal Candidiasis
1215521|NCT01092819|acute ischemic stroke, large vessel occlusion, natural history, functional outcome
1215522|NCT01092806|tacrolimus
1215523|NCT01092806|pharmacokinetics
1215524|NCT01092806|formulations
1215525|NCT01092806|once daily
1215526|NCT01092806|twice daily
1215527|NCT01092806|renal transplant recipients
1215528|NCT01092806|Kidney transplantation
1215529|NCT01092793|Fish oil
1215530|NCT01092793|Krill
1215531|NCT01092793|CAD
1215532|NCT01092767|Thoracic Aneurysm
1215533|NCT01092767|Thoracic Transection
1215534|NCT01092767|Endovascular Aortic Repair
1215535|NCT01092754|brain, spine, liver, MRI, Pediatric
1215536|NCT01092741|Leukemia
1215537|NCT01092741|Gleevec
1215538|NCT01092741|STI571
1215539|NCT01092741|CML
1215540|NCT01092741|Chronic Myelogenous Leukemia
1215541|NCT01092728|Acral lentiginous melanoma
1215542|NCT01092728|Mucosal melanoma
1215543|NCT01092728|Chronic sun-damaged melanoma
1215544|NCT01092728|Surgically removed tumor
1215545|NCT01092728|biopsied
1215546|NCT01092728|Sprycel
1215547|NCT01092728|Dasatinib
1215548|NCT01092715|Neck pain
1215549|NCT01092715|Spinal manipulation
1215550|NCT01092715|Massage
1215551|NCT01092702|Tobacco Dependence
1215552|NCT01092702|Smoking
1215553|NCT01092702|Tobacco Cessation
1215554|NCT01092689|heterocyclic amines
1215555|NCT01092689|PhIP
1215556|NCT01092689|Meat
1215557|NCT01092689|pancreas neoplasms
1215558|NCT01092676|Pediatrics
1215559|NCT01092676|Emergency
1215560|NCT01092663|Colesevelam
1215561|NCT01092663|type 2 diabetes
1215562|NCT01092663|sitagliptin
1215563|NCT01092663|glucose metabolism
1215564|NCT01092650|Tobacco toxicants
1215565|NCT01092650|Polycyclic aromatic hydrocarbons
1215566|NCT01092650|Smoking
1215567|NCT01092624|voiding dysfunction
1215568|NCT01092624|defecatory dysfunction
1215569|NCT01092624|vaginal bulge symptoms
1215570|NCT01092611|long-term follow-up study
1215571|NCT01092611|HIV-infected subjects
1215572|NCT01092611|HIV therapeutic vaccine
1215573|NCT01092572|cystic fibrosis
1215574|NCT01092572|adult cystic fibrosis
1215575|NCT01092559|Diagnostic Techniques and Procedures
1215576|NCT01092546|Amyloid
1215577|NCT01092546|Normal pressure hydrocephalus (NPH)
1215578|NCT01092546|Positron Emission Tomography (PET)
1215579|NCT01092546|Standard uptake value ratios (SUVR)
1215580|NCT01092520|Gabapentin
1215581|NCT01092520|Burn Injuries in Children
1215582|NCT01092520|pruritus
1215583|NCT01092507|Encephalitis
1215584|NCT01092507|Japanese Encephalitis
1215585|NCT01092507|Japanese Encephalitis Vaccines
1215586|NCT01092507|Infant
1215587|NCT01092494|Endometrioma recurrence
1215588|NCT01092494|oral contraceptives
1215589|NCT01092494|gonadotropin-releasing hormone agonist
1215590|NCT01092481|Adjuvant FOLFOX or CAPOX Therapy
1215591|NCT01092481|Stage II/III Colon Cancer
1215592|NCT01092481|Adjuvant Therapy
1215593|NCT01092468|cancer
1215594|NCT01092468|reconstruction
1215595|NCT01092468|free flap
1215596|NCT01092468|surgery
1215597|NCT01092455|End Stage Renal Disease
1215598|NCT01092455|Renal Dialysis
1215599|NCT01092455|Hemodialysis therapy
1215600|NCT01092455|Heparin
1215601|NCT01092455|Citrasate
1215602|NCT01092455|Anticoagulant
1215603|NCT01092442|Pulmonary Valve
1215604|NCT01092442|Right Ventricular Outflow Tract Reconstruction
1215605|NCT01092442|Ross Procedure
1215606|NCT01092429|CAD
1215607|NCT01092416|CAD
1215608|NCT01092416|Severely calcified lesion
1215609|NCT01092390|randomized trial
1215610|NCT01092390|omega three fatty acids
1215611|NCT01092364|Young adults
1215612|NCT01092351|urinary tract infection
1215613|NCT01092351|nitrofurantoin
1215614|NCT01092338|Human Immunodeficiency Virus
1215615|NCT01092338|Acquired Immune Deficiency Syndrome
1215616|NCT01092338|Vitamin D
1215617|NCT01092338|HIV
1215618|NCT01092338|Complementary therapies
1215619|NCT01092325|Heart Failure
1215620|NCT01092312|knee
1215621|NCT01092312|arthroplasty
1215622|NCT01092299|Phase I
1215623|NCT01092299|Relative bioavailability
1215624|NCT01092299|Pharmacokinetic study
1215625|NCT01092299|AZD1446
1215626|NCT01092299|healthy volunteers
1215627|NCT01092286|Knee injury
1215628|NCT01092286|ankle sprain
1215629|NCT01092286|anterior cruciate ligament
1215630|NCT01092286|adolescent
1215631|NCT01092286|soccer
1215632|NCT01092286|basketball
1215633|NCT01092286|prevention
1215634|NCT01092273|Glaucoma and Ocular Hypertension
1215635|NCT01092260|Glomerular Filtration Rate
1215636|NCT01092260|Kidney disease
1215637|NCT01092260|Child
1215638|NCT01092260|Iohexol
1215639|NCT01092260|Cystatin C
1215640|NCT01092260|Measurement of kidney function in children
1215641|NCT01092247|Patients with malignant tumors
1215642|NCT01092234|Observational units
1215643|NCT01092234|Length of stay (LOS)
1215644|NCT01092234|Readmission
1215645|NCT01092221|mania, allopurinol, add-on treatment
1215646|NCT01092208|Autism
1215647|NCT01092208|iPS Cells
1215648|NCT01092208|Fibroblasts
1215649|NCT01092208|Gene Networks
1215650|NCT01092208|Tuberous Sclerosis
1215651|NCT01092208|Healthy Volunteer
1215652|NCT01092208|HV
1215661|NCT01092182|Microarray
1215662|NCT01092182|Toxicity
1215663|NCT01092182|Therapeutic Index
1215664|NCT01092182|HIV Positive
1215665|NCT01092182|HIV Negative
1215666|NCT01092182|Lymphoma
1215667|NCT01092182|Burkitt Lymphoma
1215668|NCT01092182|Diffuse Large B-Cell Lymphoma
1215669|NCT01092182|HIV Infections
1215670|NCT01092156|Nipple pain during lactation
1215671|NCT01092130|Heart failure
1215672|NCT01092130|Vitamin D
1215673|NCT01092130|Plasma renin activity
1215674|NCT01092130|Renin angiotensin system
1215675|NCT01092117|abdominal
1215676|NCT01092117|aortic
1215677|NCT01092117|aneurysm
1215678|NCT01092091|Neoplasm
1215679|NCT01092091|Hepatocellular Carcinoma
1215680|NCT01092078|hypertension
1215681|NCT01092078|colon cancer screening
1215682|NCT01092078|african american
1215683|NCT01092078|men
1215684|NCT01092078|motivational interviewing
1215685|NCT01092078|patient navigation
1215686|NCT01092065|Parkinson's Disease
1215687|NCT01092065|Dyskinesia
1215688|NCT01092065|Drug-induced
1215689|NCT01092065|Levodopa
1215690|NCT01092065|L-dopa
1215691|NCT01092052|Phase I study
1215692|NCT01092052|Advanced/Metastatic Solid Tumors
1215693|NCT01092052|Cdc7 kinase inhibitor
1215694|NCT01092039|Common Cold
1215695|NCT01092039|Cold Virus
1215696|NCT01092039|Feeling sick
1215697|NCT01092039|Influenza
1215698|NCT01092000|Health Promotion, Dietary Guidelines, Physical Activity Guidelines
1215699|NCT01091987|Insomnia
1215700|NCT01091974|Insomnia
1215701|NCT01091974|Fatigue
1215702|NCT01091974|QOL
1215703|NCT01091974|CBT
1215704|NCT01091974|Breast cancer
1215705|NCT01091974|Survivors
1215706|NCT01091974|Chemotherapy
1215707|NCT01091961|ACE inhibitor
1215708|NCT01091961|ARB
1215709|NCT01091961|Non-cardiac surgery
1215710|NCT01091961|Perioperative
1215711|NCT01091961|Preoperative
1215712|NCT01091961|Hypotension
1215713|NCT01091961|Congestive heart failure
1215714|NCT01091961|Hypertension
1215715|NCT01091961|Angiotensin-Converting Enzyme Inhibitors
1215716|NCT01091961|Angiotensin II Type 1 Receptor Blockers
1215717|NCT01091961|Perioperative Care
1215718|NCT01091948|elective general surgery
1215719|NCT01091948|orotracheal intubation
1215720|NCT01091948|Patients would be eligible for inclusion if they were at least 18 years old and scheduled for elective surgery requiring orotracheal intubation.
1215721|NCT01091935|Lidocaine,Intravenous Infusions,Neuropathic Pain,Side Effects
1215722|NCT01091922|flavonoids
1215723|NCT01091922|flavanols
1215724|NCT01091922|bacteria
1215725|NCT01091909|type 2 diabetes
1215726|NCT01091909|wound healing
1215727|NCT01091909|neutrophil count
1215728|NCT01091909|dental extraction
1215729|NCT01091896|bevacizumab
1215730|NCT01091896|vitreous hemorrhage
1215731|NCT01091896|diabetes mellitus
1215732|NCT01091883|Bone cancer
1215733|NCT01091883|Bone Metastases
1215734|NCT01091883|pain palliation
1215735|NCT01091883|metastasis
1215736|NCT01091883|breast cancer
1215737|NCT01091883|lung cancer
1215738|NCT01091883|prostate cancer
1215739|NCT01091883|cancer related pain
1215740|NCT01091883|tumors
1215741|NCT01091870|Aneurysm
1215742|NCT01091870|Vasospasm
1215743|NCT01091870|sildenafil
1215744|NCT01091870|Viagra
1215745|NCT01091857|Exercise
1215746|NCT01091857|Transdisciplinary
1215747|NCT01091857|Physiology
1215748|NCT01091857|Mood
1215749|NCT01091857|Motivation
1215750|NCT01091844|voiding trial, urinary retention, catheterization
1215751|NCT01091844|Urinary retention after gynecologic surgery
1215752|NCT01091831|Multiple Myeloma
1215753|NCT01091831|Lenalidomide
1215754|NCT01091831|High dose melphalan
1215755|NCT01091831|Mobilization
1215756|NCT01091831|CD 34
1215757|NCT01091831|Newly Diagnosed patients
1215758|NCT01091818|To see if sedation with dexmedetomidine results in faster emergence after end of intensive care treatment in children
1215759|NCT01091818|treatment
1215760|NCT01091792|GBM
1215761|NCT01091792|Grade IV
1215762|NCT01091792|glioma
1215763|NCT01091779|Male patients scheduled to have spinal anaesthesia for TURP
1215764|NCT01091766|local anaesthetics toxicity
1215765|NCT01091766|heart arrhythmia
1215766|NCT01091766|heart rate
1215767|NCT01091766|heart conduction
1215768|NCT01091766|regional anaesthesia
1215769|NCT01091766|paediatric anaesthesia
1215770|NCT01091766|cardio-vascular system
1215771|NCT01091766|prevention
1215772|NCT01091753|Non-dipper HTN patient
1215773|NCT01091740|Drug eluting stent
1215774|NCT01091740|Tomography, optical coherence
1215775|NCT01091727|Neurogenic
1215776|NCT01091727|Detrusor
1215777|NCT01091727|Overactive
1215778|NCT01091727|Overactivity
1215779|NCT01091727|Bladder
1215780|NCT01091727|Spinal
1215781|NCT01091727|Cord
1215782|NCT01091727|Injury
1215783|NCT01091701|Ischemic Cerebral Stroke
1215784|NCT01091688|neonatal
1215785|NCT01091688|discharge planning
1215786|NCT01091688|health transition
1215787|NCT01091688|educational needs assessment
1215788|NCT01091688|Intensive care, neonatal
1215789|NCT01091675|ankylosing spondylitis
1215790|NCT01091675|biologic therapies
1215791|NCT01091675|ASAS
1215792|NCT01091675|ASASBIO
1215793|NCT01091675|etoricoxib
1215794|NCT01091675|NSAIDs
1215795|NCT01091675|COX-2 Inhibitor
1215796|NCT01091675|ARCOXIA 90 mg
1215797|NCT01091675|BASDAI Bath Ankylosing Spondylitis Disease Activity Index
1215798|NCT01091662|Seizures
1215799|NCT01091662|Epilepsy
1215800|NCT01091662|Anticonvulsant
1215801|NCT01091662|Monotherapy
1215802|NCT01091662|Historical control
1215803|NCT01091649|Pharmacokinetics, Safety
1215804|NCT01091623|improvement of exercise capacity in patients with COPD
1215805|NCT01091610|retrospective study
1215806|NCT01091610|wounds and injuries/epidemiology
1215807|NCT01091610|emergency medical technicians
1215808|NCT01091610|human
1215809|NCT01091610|emergency medical services
1215810|NCT01091610|ambulance
1215811|NCT01091610|health personnel
1215812|NCT01091610|emergency medicine
1215813|NCT01091610|risk factors
1215814|NCT01091571|Adenosine
1215815|NCT01091571|Endotoxin
1215816|NCT01091571|Innate Immunity
1215817|NCT01091571|Dipyridamole
1215818|NCT01091558|ulcerative colitis
1215819|NCT01091558|colon cancer
1215820|NCT01091558|endoscopy
1215821|NCT01091558|screening
1215822|NCT01091545|breast cancer
1215823|NCT01091545|screening
1215824|NCT01091545|sensitivity
1215825|NCT01091545|tomosynthesis
1215826|NCT01091519|Non-interventional study fesoterodine educational materials
1215827|NCT01091506|L-methylfolate
1215828|NCT01091506|Deplin
1215829|NCT01091506|schizophrenia
1215830|NCT01091506|folate
1215831|NCT01091506|folic acid
1215832|NCT01091506|homocysteine
1215833|NCT01091506|methionine
1215834|NCT01091506|MTHFR genotype
1215835|NCT01091506|C677T mutation
1215836|NCT01091506|vitamin B6
1215837|NCT01091506|vitamin B12
1215838|NCT01091506|psychotic symptoms
1215839|NCT01091506|MTHFR C677T Polymorphism
1215840|NCT01091493|COPD
1215841|NCT01091480|Hypertrophic cardiomyopathy
1215842|NCT01091480|Observatory
1215843|NCT01091480|LVH
1215844|NCT01091467|Heart Failure
1215845|NCT01091467|Ejection Fraction
1215846|NCT01091467|Echocardiography
1215847|NCT01091454|stage IV breast cancer
1215848|NCT01091454|triple-negative breast cancer
1215849|NCT01091454|male breast cancer
1215850|NCT01091441|therapeutic education
1215851|NCT01091428|RECIST: Response Evaluation Criteria in Solid Tumors
1215852|NCT01091428|OC: Ovarian Cancer
1215853|NCT01091428|GCIG: Gynecologic Cancer Intergroup
1215854|NCT01091428|Breast carcinoma (Phase 1)
1215855|NCT01091402|autologous serum skin test, IL-18
1215856|NCT01091389|Atrial Fibrillation
1215857|NCT01091389|Totally Thoracoscopic PV isolation
1215858|NCT01091376|Non-small cell lung cancer
1215859|NCT01091376|EGFR-TKI
1215860|NCT01091376|Erlotinib
1215861|NCT01091376|Radiotherapy
1215862|NCT01091363|smoking cessation
1215863|NCT01091363|tobacco dependence treatment
1215864|NCT01091363|cultural adaptation
1215865|NCT01091363|Asian Americans
1215866|NCT01091324|CKD, proteinuria, dextromethorphan, silymarin
1215867|NCT01091324|patients with 15 ml<eGFR< 60ml and 0.5 g/day<proteinuria<3g/day
1215868|NCT01091311|Meibomian Gland Dysfunction
1215869|NCT01091298|Safety of vaccine
1215870|NCT01091272|healthy volunteer
1215871|NCT01091272|safety
1215872|NCT01091272|pharmacokinetic
1215873|NCT01091259|antibody therapy
1215874|NCT01091259|chemotherapy
1215875|NCT01091259|biologic therapy
1215876|NCT01091259|combination therapy
1215877|NCT01091233|Critically ill patients
1215878|NCT01091233|liver cirrhosis
1215879|NCT01091233|ascites requiring Paracentesis
1215880|NCT01091220|certolizumab pegol
1215881|NCT01091220|Cimzia®
1215882|NCT01091220|healthy male volunteers
1215883|NCT01091220|sperm
1215884|NCT01091207|Sorafenib
1215885|NCT01091207|GIST
1215886|NCT01091207|Refractory
1215887|NCT01091207|advanced GIST failed after both imatinib and sunitinib
1215888|NCT01091194|Heart Transplantation
1215889|NCT01091194|Aerobic Exercise
1215890|NCT01091194|Exercise, Physical
1215891|NCT01091194|Exercise Test
1215892|NCT01091194|Treadmill Test
1215893|NCT01091194|VO2 peak
1215894|NCT01091194|Muscle Strength
1215895|NCT01091194|Quality of Life
1215896|NCT01091194|Reinnervation
1215897|NCT01091194|Heart Rate
1215898|NCT01091194|Myocardial Function
1215899|NCT01091181|Caesarean
1215900|NCT01091155|Colon Anastomosis
1215901|NCT01091155|Rectum Anastomosis
1215902|NCT01091155|Intestine
1215903|NCT01091155|Colorectal Surgery
1215904|NCT01091155|Colorectal Anastomosis
1215905|NCT01091129|hyperhidrosis
1215906|NCT01091116|Injections, Intra-Articular
1215907|NCT01091090|Smoking cessation
1215908|NCT01091090|Nicotine dependence
1215909|NCT01091090|Chronic pain
1215910|NCT01091077|dietary supplement
1215911|NCT01091051|Ustekinumab, Palmo-Plantar, Pustular Psoriasis, Pustulosis
1215912|NCT01091038|Adverse drug events
1215913|NCT01091038|medical errors
1215914|NCT01091038|computerized physician order entry
1215915|NCT01091038|clinical decision support
1215916|NCT01091025|Adults
1215917|NCT01091025|Cystic Fibrosis Related Diabetes
1215918|NCT01091025|Screening
1215919|NCT01091025|Oral glucose tolerance test
1215920|NCT01091025|Royal Brompton & Harefield Foundation Trust
1215921|NCT01090999|COPD
1215922|NCT01090999|Pulmonary Rehabilitation
1215923|NCT01090986|Restrictive pulmonary disease with hypercapnic chronic respiratory failure.
1215924|NCT01090986|COPD patients who need NIV hypercapnic chronic respiratory failure.
1215925|NCT01090973|relapsed
1215926|NCT01090973|refractory
1215927|NCT01090973|CLL
1215928|NCT01090973|chronic lymphocytic leukemia
1215929|NCT01090973|MCL
1215930|NCT01090973|mantle cell lymphoma
1215931|NCT01090934|Diagnosis
1215932|NCT01090934|Partial Epilepsy
1215933|NCT01090921|Multiple Myeloma
1215934|NCT01090921|Bortezomib
1215935|NCT01090921|Newly diagnosed
1215936|NCT01090921|Newly diagnosed Multiple Myeloma
1215937|NCT01090895|Percutaneous Coronary Intervention
1215938|NCT01090895|Vitamin C
1215939|NCT01090895|Biomarkers
1215940|NCT01090895|Magnetic Risonance
1215941|NCT01090882|Local anaesthetic
1215942|NCT01090882|Laparoscopic cholecystectomy
1215943|NCT01090882|Pain scores
1215944|NCT01090882|Bupivocaine
1215945|NCT01090882|Day case surgery
1215946|NCT01090856|Bifurcations
1215947|NCT01090856|Drug eluting-stents
1215948|NCT01090856|Provisional stenting
1215949|NCT01090843|Obscure digestive bleeding (ODB)
1215950|NCT01090843|Chronic anaemia of unknown origin
1215951|NCT01090843|Chronic diarrhoea
1215952|NCT01090830|Non small cell lung cancer
1215953|NCT01090830|Belinostat
1215954|NCT01090830|carboplatin
1215955|NCT01090830|Paclitaxel
1215956|NCT01090830|Bevacizumab
1215957|NCT01090830|chemotherapy
1215958|NCT01090830|Maximum Tolerated Dose
1215959|NCT01090830|Neoplasms, Pulmonary
1215960|NCT01090830|Lung Cancer
1215961|NCT01090830|Event Free Survival
1215962|NCT01090830|Disease free survival
1215963|NCT01090830|Progression Free Survival
1215964|NCT01090830|Histone Deacetylase Inhibitors
1215965|NCT01090830|Treatment Efficacy
1215966|NCT01090817|mesenchymal stromal cells
1215967|NCT01090817|ileitis
1215968|NCT01090817|colitis
1215969|NCT01090804|BreatheMAX breathing device
1215970|NCT01090804|Secretion clearance
1215971|NCT01090804|Ventilatory dependence
1215972|NCT01090804|Intubated patients
1215973|NCT01090791|critically ill patient
1215974|NCT01090778|growth hormone deficiency
1215975|NCT01090778|circadian variation
1215976|NCT01090765|Prostate
1215977|NCT01090765|Tumor
1215978|NCT01090765|Cancer
1215979|NCT01090765|Hormone
1215980|NCT01090765|Androgen
1215981|NCT01090765|Prostate Cancer
1215982|NCT01090752|diabetes
1215983|NCT01090752|blood pressure
1215984|NCT01090752|pioglitazone
1215985|NCT01090752|sodium
1215986|NCT01090752|insulin resistance, renal function, sodium, pioglitazone
1215987|NCT01090739|Fecal incontinence
1215988|NCT01090739|Accidental bowel leakage
1215989|NCT01090739|Failure conservative therapy
1215990|NCT01090739|Women
1215991|NCT01090739|Class III medical device
1215992|NCT01090739|Surgical mesh
1215993|NCT01090700|TMC435-TiDP16-C112
1215994|NCT01090700|TMC435-C112
1215995|NCT01090700|TMC435
1215996|NCT01090700|HCV
1215997|NCT01090700|Hepatitis C
1215998|NCT01090687|breast cancer, CT scans, mammography
1215999|NCT01090674|Diaphragmatic force
1216000|NCT01090674|mobility
1216001|NCT01090661|antisense
1216002|NCT01090661|ApoB (Apolipoprotein B)
1216003|NCT01090661|LDL (low density lipoprotein)
1216004|NCT01090661|thorough QT
1216005|NCT01090648|TMC125HIV1083
1216006|NCT01090648|TMC125
1216007|NCT01090648|HIV
1216008|NCT01090648|Etravirine
1216009|NCT01090648|ETR
1216010|NCT01090648|Intelence
1216011|NCT01090648|HIV Infections
1216012|NCT01090635|Cervical Intraepithelial Neoplasia
1216013|NCT01090609|Coronary Stent
1216014|NCT01090609|Cobalt-Chromium coronary stent
1216015|NCT01090583|Cytokines
1216016|NCT01090583|Pregnancy
1216017|NCT01090583|Cesarean
1216018|NCT01090544|COPD
1216019|NCT01090544|TNI
1216020|NCT01090544|PaCO2
1216021|NCT01090492|Raynaud's phenomenon
1216022|NCT01090492|vasospasm
1216023|NCT01090492|scleroderma
1216024|NCT01090492|systemic sclerosis
1216025|NCT01090492|CREST
1216026|NCT01090492|phosphodiesterase inhibitor
1216027|NCT01090479|Surgical site infections
1216028|NCT01090479|Chlorhexidine
1216029|NCT01090479|Shoulder surgery
1216030|NCT01090466|transitional cell carcinoma of the bladder
1216031|NCT01090466|recurrent bladder cancer
1216032|NCT01090466|recurrent urethral cancer
1216033|NCT01090466|recurrent transitional cell cancer of the renal pelvis and ureter
1216034|NCT01090466|stage IV bladder cancer
1216035|NCT01090466|metastatic transitional cell cancer of the renal pelvis and ureter
1216036|NCT01090466|regional transitional cell cancer of the renal pelvis and ureter
1216037|NCT01090466|distal urethral cancer
1216038|NCT01090466|proximal urethral cancer
1216039|NCT01090466|urethral cancer associated with invasive bladder cancer
1216040|NCT01090466|stage IV urethral cancer
1216047|NCT01090427|Ustekinumab
1216048|NCT01090427|Injection
1216049|NCT01090427|CNTO 1275
1216050|NCT01090427|Stelara
1216051|NCT01090427|Pediatric psoriasis
1216052|NCT01090427|Adolescents
1216053|NCT01090414|Idelalisib
1216054|NCT01090414|Chronic lymphocytic leukemia (CLL)
1216055|NCT01090414|Non-Hodgkin lymphoma (NHL)
1216056|NCT01090414|Phosphatidylinositol 3-kinase (PI3K)
1216057|NCT01090388|Cross-sectional survey
1216058|NCT01090388|Health-related quality of life
1216059|NCT01090388|Symptom management
1216060|NCT01090375|osteoarthritis
1216061|NCT01090375|biochemical markers
1216062|NCT01090375|cartilage
1216063|NCT01090375|inflammation
1216064|NCT01090375|microdialysis
1216065|NCT01090362|Atrial fibrillation
1216066|NCT01090362|Anticoagulation
1216067|NCT01090362|Stroke
1216068|NCT01090362|Stroke prevention
1216069|NCT01090362|Health Economics
1216070|NCT01090349|ICD, CRTD, Remote Care
1216071|NCT01090336|platelet aggregation inhibition
1216072|NCT01090336|prasugrel
1216073|NCT01090336|clopidogrel
1216074|NCT01090336|ACS
1216075|NCT01090323|Deferasirox
1216076|NCT01090323|ICL670A
1216077|NCT01090323|Iron chelators
1216078|NCT01090323|Sickle Cell Disease
1216079|NCT01090323|Transfusional Hemosiderosis
1216080|NCT01090310|Quiescent uveitis
1216081|NCT01090310|intermediate uveitis
1216082|NCT01090310|panuveitis
1216083|NCT01090310|posterior uveitis
1216084|NCT01090310|uveitis
1216085|NCT01090310|NVS Definition: Words or phrases that best describe the protocol. Keywords help users find studies in the database.
1216086|NCT01090310|Avoid acronyms, abbreviations and trade names.
1216087|NCT01090310|Examples: Heart failure, aliskiren, heart attack, cardiovascular diseases
1216088|NCT01090310|Psoriasis, inflammatory skin disease, scaly patches
1216089|NCT01090297|Obstructive Sleep Apnea Syndrome
1216090|NCT01090297|Blood pressure
1216091|NCT01090297|Continuous Positive Airway Pressure
1216092|NCT01090284|Inguinal hernia
1216093|NCT01090284|Immune system
1216094|NCT01090284|Cytokines
1216095|NCT01090284|Prosthetic repair
1216096|NCT01090284|Oxidative Stress
1216097|NCT01090271|Subacromial impingement syndrome
1216098|NCT01090271|Muscle Strength
1216099|NCT01090271|Resistance Training
1216100|NCT01090258|cardiac surgery
1216101|NCT01090258|mechanical ventilation
1216102|NCT01090258|automation
1216103|NCT01090258|weaning
1216104|NCT01090245|contingency management
1216105|NCT01090245|substance abuse treatment
1216106|NCT01090245|criminal justice populations
1216107|NCT01090245|substance abuse treatment retention
1216108|NCT01090245|HIV prevention in criminal justice settings
1216109|NCT01090245|voucher based reinforcement therapy
1216110|NCT01090245|Parole treatment admission for substance abusing parolees
1216111|NCT01090245|Parole treatment retention for substance abusing parolees
1216112|NCT01090245|HIV testing and counseling for substance abusing parolees
1216113|NCT01090219|Inguinal Hernia
1216114|NCT01090219|contraction of two different meshes in the repair of inguinal hernias in men
1216115|NCT01090206|Hemophilia
1216116|NCT01090206|Vitamin D
1216117|NCT01090193|Obstructive jaundice
1216118|NCT01090193|kidney histopathology
1216119|NCT01090193|lactulose
1216120|NCT01090180|PTSD
1216121|NCT01090180|combat
1216122|NCT01090180|stress disorders
1216123|NCT01090180|veteran
1216124|NCT01090154|Ulcerative colitis
1216125|NCT01090154|UC
1216126|NCT01090154|Inflammatory Bowel Disease
1216127|NCT01090141|Micafungin
1216128|NCT01090141|Body Weight
1216129|NCT01090141|Anti-Infective Agents
1216130|NCT01090141|Signs and Symptoms
1216131|NCT01090141|Mycoses
1216132|NCT01090141|Therapeutic Uses
1216133|NCT01090141|Antifungal Agents
1216134|NCT01090141|Overnutrition
1216135|NCT01090141|Pharmacologic Actions
1216136|NCT01090076|Pressure Ulcer Wound
1216137|NCT01090076|Specialized Amino Acid Mixture
1216138|NCT01090063|Palmar Plantar Psoriasis
1216139|NCT01090050|Chronic Migraine
1216140|NCT01090050|Migraine
1216141|NCT01090050|Treximet
1216142|NCT01090050|naproxen
1216143|NCT01090050|sumatriptan
1216144|NCT01090037|ESRD
1216145|NCT01090037|Chronic Renal Failure
1216146|NCT01090037|Prostaglandin
1216147|NCT01090037|Prostacyclin
1216148|NCT01090037|Asian Multinational Study
1216149|NCT01089998|Neoplasm
1216150|NCT01089998|PET/CT diagnosis
1216151|NCT01089998|PET tracer
1216152|NCT01089998|Inflammation
1216153|NCT01089972|radial artery
1216154|NCT01089972|ulnar artery
1216155|NCT01089972|catheterization
1216156|NCT01089972|regional blood flow
1216157|NCT01089959|Acid re-flux,GERD
1216158|NCT01089959|sleep related arousals due to GERD
1216159|NCT01089959|Treatment of acid reflux during sleep in patients with GERD.
1216160|NCT01089946|Mobilization
1216161|NCT01089946|Hip arthroplasty
1216162|NCT01089946|cardiovascular
1216163|NCT01089933|Anesthesia
1216164|NCT01089933|Local Anesthetics
1216165|NCT01089933|Analgesia
1216166|NCT01089933|Quality of life
1216167|NCT01089933|Paravertebral blocks
1216168|NCT01089933|Arm morbidity
1216169|NCT01089907|genomic
1216170|NCT01089907|childhood
1216171|NCT01089907|acute lymphoblastic leukemia
1216172|NCT01089894|18F-FLT
1216173|NCT01089894|PET
1216174|NCT01089894|non-small cell lung cancer
1216175|NCT01089894|cell proliferation
1216176|NCT01089894|therapeutic response
1216177|NCT01089894|18F-3'-fluoro-3'-deoxy-L-thymidine (18F-FLT)
1216178|NCT01089881|prostate cancer
1216179|NCT01089881|18F-fluorocholine
1216180|NCT01089881|PET
1216181|NCT01089881|recurrence
1216182|NCT01089881|metastases
1216183|NCT01089868|Glioblastoma multiforme
1216184|NCT01089868|Microsurgery
1216185|NCT01089868|Stereotactic biopsy
1216186|NCT01089868|Radiochemotherapy
1216187|NCT01089868|Temodar
1216188|NCT01089868|FET PET
1216189|NCT01089868|Molecular imaging
1216190|NCT01089855|Neuropathic Pain
1216191|NCT01089855|Brief Pain Inventory
1216192|NCT01089855|DN4 questionnaire
1216193|NCT01089855|ElectroCardioGram
1216194|NCT01089842|Secondary Prevention
1216195|NCT01089842|Health Promotion
1216196|NCT01089842|Behavioral Medicine
1216197|NCT01089842|Exercise Therapy
1216198|NCT01089829|CKD
1216199|NCT01089829|Foot Ulceration
1216200|NCT01089829|Diabetes
1216201|NCT01089816|Influenza infections
1216202|NCT01089816|Orthomyxoviridae infections
1216203|NCT01089816|Influenza Human
1216204|NCT01089803|laryngectomy
1216205|NCT01089803|larynx
1216206|NCT01089803|hypopharynx
1216207|NCT01089764|breast neoplasm
1216208|NCT01089764|breast cancer
1216209|NCT01089764|behavioral intervention
1216210|NCT01089764|online support
1216211|NCT01089764|relationship distress
1216212|NCT01089764|dyadic coping
1216213|NCT01089738|mulitple dose
1216214|NCT01089738|pharmacokinetics
1216215|NCT01089738|safety
1216216|NCT01089738|healthy elderly volunteers
1216217|NCT01089725|safety
1216218|NCT01089725|efficacy
1216219|NCT01089725|parallel group
1216220|NCT01089725|double-blind
1216221|NCT01089725|multicenter
1216222|NCT01089725|injection
1216223|NCT01089725|infusion
1216224|NCT01089725|osteoarthritis
1216225|NCT01089725|bridging
1216226|NCT01089725|subcutaneous
1216227|NCT01089725|intravenous
1216228|NCT01089725|tanezumab
1216229|NCT01089712|Infection
1216230|NCT01089712|Cardiac Surgery
1216231|NCT01089712|Post Operative Cardiac Surgery Infection
1216232|NCT01089712|Management Practices
1216233|NCT01089699|breast cancer
1216234|NCT01089699|support groups
1216235|NCT01089699|Primary diagnosis of breast cancer within the past three years.
1216236|NCT01089686|Chronic Cerebrospinal Venous Insufficiency
1216237|NCT01089673|retrospective data collection
1216238|NCT01089660|Influenza
1216239|NCT01089660|Pandemic Flu
1216240|NCT01089660|Swine-origin Influenza
1216241|NCT01089660|Inactivated split-virion vaccine
1216242|NCT01089647|OSA
1216243|NCT01089647|Medical treatment
1216244|NCT01089634|LV measurement
1216245|NCT01089634|CRT
1216246|NCT01089634|Concerto
1216247|NCT01089634|LVCM
1216248|NCT01089634|LV threshold
1216249|NCT01089634|new CRT
1216250|NCT01089608|Azyter in patients affected by chronic blepharitis.
1216251|NCT01089595|Imatinib Resistance
1216252|NCT01089595|GIST
1216253|NCT01089595|Advanced Disease
1216254|NCT01089595|Nilotinib
1216255|NCT01089582|non-interventional
1216256|NCT01089582|mild to moderate Alzheimer's
1216257|NCT01089582|ARICEPT.
1216258|NCT01089569|diabetes
1216259|NCT01089569|continuous glucose monitoring
1216260|NCT01089569|exenatide
1216261|NCT01089569|insulin glargine
1216262|NCT01089543|dyspepsia
1216263|NCT01089543|rabeprazole
1216264|NCT01089543|Japan
1216265|NCT01089530|Fibrinogen
1216266|NCT01089530|Cholesterol
1216267|NCT01089530|Cardiovascular risk factors
1216268|NCT01089530|Primary prevention
1216269|NCT01089530|High levels fibrinogen
1216270|NCT01089530|High plasma fibrinogen
1216271|NCT01089504|phenobarbital
1216272|NCT01089504|neonate
1216273|NCT01089504|antiepileptic drugs
1216274|NCT01089504|neurodevelopmental outcome
1216275|NCT01089504|seizure
1216276|NCT01089491|Low back pain
1216277|NCT01089491|Epiduroscopy
1216278|NCT01089491|Cytology
1216279|NCT01089491|Electrical stimulation
1216286|NCT01089465|Bed bugs
1216287|NCT01089465|Cimex
1216288|NCT01089465|insects
1216289|NCT01089465|bites
1216290|NCT01089452|Mild to moderate hypertension
1216291|NCT01089439|Nitric oxide
1216412|NCT01088958|Social marketing
1216292|NCT01089426|Pediatric patients with Parenteral Nutrition (PN) induced Liver Injury
1216293|NCT01089400|influenza
1216294|NCT01089400|H1N1
1216295|NCT01089400|lymphocytes
1216296|NCT01089400|T cell
1216297|NCT01089400|CD4
1216298|NCT01089400|CD8
1216299|NCT01089400|cytokine
1216300|NCT01089400|serology
1216301|NCT01089400|broncho-alveolar lavage
1216302|NCT01089400|acute respiratory distress syndrome
1216303|NCT01089400|ventilation
1216304|NCT01089400|intensive care unit
1216305|NCT01089387|radical prostatectomy
1216306|NCT01089374|Phyllodes
1216307|NCT01089361|systemic inflammatory syndrome
1216308|NCT01089361|sepsis syndrome
1216309|NCT01089361|septic shock
1216310|NCT01089361|Cytokine
1216311|NCT01089361|Ketamine
1216312|NCT01089348|Vaginosis, Bacterial
1216313|NCT01089348|Prebiotics
1216314|NCT01089348|Lactofiltrum
1216315|NCT01089348|Therapy
1216316|NCT01089335|Sentinel node
1216317|NCT01089335|Thyroid cancer
1216318|NCT01089335|Thyroid neoplasia
1216319|NCT01089335|Follicular neoplasia
1216320|NCT01089322|SEVERE ASTHMA
1216321|NCT01089322|RISK FACTORS
1216322|NCT01089322|CHARACTERIZATION
1216323|NCT01089322|CLINICAL CONTROL
1216324|NCT01089322|INFLAMMATORY MARKERS
1216325|NCT01089322|SEVERE
1216326|NCT01089322|CONTROL
1216327|NCT01089309|Aldosterone Blockade
1216328|NCT01089309|Arterial elasticity
1216329|NCT01089309|Glycemic control
1216330|NCT01089296|Infants born preterm
1216331|NCT01089296|Early physiotherapy intervention
1216332|NCT01089296|Motor development
1216333|NCT01089296|Parental participation
1216334|NCT01089296|Parental competency
1216335|NCT01089283|parkinson
1216336|NCT01089283|fdg pet-ct
1216337|NCT01089283|i123 dat scan
1216338|NCT01089283|LRRK2
1216339|NCT01089283|GBA
1216340|NCT01089283|parkinson patients with known genetic characteristic
1216341|NCT01089270|Parkinson
1216342|NCT01089270|fdg pet-ct
1216343|NCT01089270|i123 dat scan
1216344|NCT01089270|first degree relatives of diagnosed Parkinson patients
1216345|NCT01089270|with no clinical evidence of movement disorders
1216346|NCT01089257|Cardiovascular risks
1216347|NCT01089257|Oxidative stress
1216348|NCT01089257|Systemic inflammation
1216349|NCT01089257|Endothelial function
1216350|NCT01089257|Peripheral Arterial Tone
1216351|NCT01089257|Positive Airway Pressure
1216352|NCT01089244|Low grade glioma
1216353|NCT01089244|Astrocytoma
1216354|NCT01089244|Molecular imaging
1216355|NCT01089244|FET PET
1216356|NCT01089244|Therapy monitoring
1216357|NCT01089244|Temodar
1216358|NCT01089231|Hyperlipidemia
1216359|NCT01089231|coronary heart disease
1216360|NCT01089231|gene expression
1216361|NCT01089231|fish oil
1216362|NCT01089231|DHA, EPA
1216363|NCT01089218|bronchoscopy
1216364|NCT01089218|post-bronchoscopy fever
1216365|NCT01089218|pneumonia
1216366|NCT01089218|cytokines
1216367|NCT01089218|amoxicillin/clavulanate
1216368|NCT01089218|prophylaxis
1216369|NCT01089153|human blood, urine and fecal samples
1216370|NCT01089140|pediatrics
1216371|NCT01089140|scoliosis
1216372|NCT01089140|tranexamic acid
1216373|NCT01089140|Investigating non-idiopathic scoliosis
1216374|NCT01089127|Indacaterol
1216375|NCT01089127|COPD
1216376|NCT01089127|salmeterol
1216377|NCT01089114|Cardiac Imaging
1216378|NCT01089114|MR Spectroscopy
1216379|NCT01089114|HIV
1216380|NCT01089114|Lipid Metabolism
1216381|NCT01089114|HIV Infection
1216382|NCT01089114|Cardiovascular Disease
1216383|NCT01089114|HIV Infections
1216384|NCT01089088|recurrent urethral cancer
1216385|NCT01089088|recurrent transitional cell cancer of the renal pelvis and ureter
1216386|NCT01089088|metastatic transitional cell cancer of the renal pelvis and ureter
1216387|NCT01089088|regional transitional cell cancer of the renal pelvis and ureter
1216388|NCT01089088|posterior urethral cancer
1216389|NCT01089088|urethral cancer associated with invasive bladder cancer
1216390|NCT01089088|transitional cell carcinoma of the bladder
1216391|NCT01089088|stage IV bladder cancer
1216392|NCT01089088|recurrent bladder cancer
1216393|NCT01089088|anterior urethral cancer
1216394|NCT01089075|neuropsychological effects of hydrocortisone replacement
1216395|NCT01089062|Healthy volunteers
1216396|NCT01089049|Urinary Estrogen Metabolites
1216397|NCT01089049|2-OH Estrone
1216398|NCT01089049|16-alpha-OH Estrone
1216399|NCT01089049|Urinary 2/16a Estrogen Metabolite Ratio
1216400|NCT01089036|ECMO
1216401|NCT01089036|cardiogenic shock
1216402|NCT01089036|ROS
1216403|NCT01089036|GPx
1216404|NCT01089036|cytokines
1216405|NCT01088997|Persistent pulmonary hypertension of newborn
1216406|NCT01088997|PPHN
1216407|NCT01088997|Persistent pulmonary hypertension
1216408|NCT01088997|Pulmonary hypertension
1216409|NCT01088997|Pulmonary hypertension of newborn
1216410|NCT01088958|Kenya
1216411|NCT01088958|Child Nutrition Disorders
1216413|NCT01088945|Infant, Premature, Diseases
1216414|NCT01088932|Safety in Healthy Volunteers
1216415|NCT01088919|ASP1941
1216416|NCT01088919|Actos
1216417|NCT01088919|pioglitazone hydrochloride
1216418|NCT01088906|Phalcis
1216419|NCT01088906|BRCA1
1216420|NCT01088906|RAP80
1216421|NCT01088906|TS
1216422|NCT01088906|First line
1216423|NCT01088906|Non-squamous
1216424|NCT01088893|everolimus
1216425|NCT01088893|neoadjuvant
1216426|NCT01088893|m-TOR inhibitor
1216427|NCT01088880|Familial Mediterranean Fever
1216428|NCT01088880|canakinumab
1216429|NCT01088880|colchicine resistance
1216430|NCT01088867|Pain
1216431|NCT01088867|Acupuncture
1216432|NCT01088867|DNIC
1216433|NCT01088867|Electroacupuncture
1216434|NCT01088828|MRI, clubfoot, CTEV, Congenital Talipes Equinovarus
1216435|NCT01088815|Adenocarcinoma
1216436|NCT01088815|Hedgehog
1216437|NCT01088815|Neoplasms
1216438|NCT01088815|Digestive System Diseases
1216439|NCT01088815|Neoplasms by Site
1216440|NCT01088815|Digestive System Neoplasms
1216441|NCT01088815|Neoplasms by Histologic Type
1216442|NCT01088815|Pancreatic Neoplasms
1216443|NCT01088815|Pancreatic Diseases
1216444|NCT01088815|Carcinoma
1216445|NCT01088802|Squamous Cell Carcinoma
1216446|NCT01088802|Oropharynx
1216447|NCT01088789|Adenocarcinoma
1216448|NCT01088789|Cyclophosphamide
1216449|NCT01088789|Immunotherapy
1216450|NCT01088789|Neo-Adjuvant
1216451|NCT01088789|Pancreatic tumor vaccine
1216452|NCT01088789|GM-CSF
1216453|NCT01088789|Randomize
1216454|NCT01088776|CKD
1216455|NCT01088776|hypertriglyceridemia
1216456|NCT01088776|Fatty Acid Supplementation
1216457|NCT01088776|Children
1216458|NCT01088776|Omega-3
1216459|NCT01088750|childhood nodular lymphocyte predominant Hodgkin lymphoma
1216460|NCT01088750|stage I childhood Hodgkin lymphoma
1216461|NCT01088750|stage II childhood Hodgkin lymphoma
1216462|NCT01088737|Lentigo maligna
1216463|NCT01088737|melanoma
1216464|NCT01088737|imiquimod
1216465|NCT01088737|prevention
1216466|NCT01088711|Type 2 diabetes (T2D)
1216467|NCT01088698|psoriasis
1216468|NCT01088698|golimumab
1216469|NCT01088698|TNF-alpha inhibition
1216470|NCT01088698|phototherapy
1216471|NCT01088698|311-nm
1216472|NCT01088672|Stroke
1216473|NCT01088672|Ischemic
1216474|NCT01088672|Thrombus
1216475|NCT01088672|Embolectomy
1216476|NCT01088672|Thrombectomy
1216477|NCT01088672|Concentric
1216478|NCT01088672|Embolus
1216479|NCT01088672|Mechanical
1216480|NCT01088672|Trevo
1216481|NCT01088646|capsule endoscopy
1216482|NCT01088646|small bowel disease
1216483|NCT01088646|inflammatory bowel disease
1216484|NCT01088646|Subjects indicated for EGD endoscopy
1216485|NCT01088633|COPD
1216486|NCT01088620|NSCLC
1216487|NCT01088620|Stage IIIb or IV
1216488|NCT01088620|Nonsquamous
1216489|NCT01088620|KRAS-Wildtype
1216490|NCT01088607|Primary sclerosing cholangitis
1216491|NCT01088607|Autoimmune hepatitis
1216492|NCT01088607|Cholestatic liver disease
1216493|NCT01088607|Cirrhosis
1216494|NCT01088607|Children
1216495|NCT01088607|Primary Sclerosing Cholangitis/Autoimmune Hepatitis Overlap
1216496|NCT01088594|urinary sodium excretion
1216497|NCT01088594|Pioglitazone
1216498|NCT01088594|Rosiglitazone
1216499|NCT01088594|Methodological study
1216500|NCT01088581|hepatocellular carcinoma
1216501|NCT01088581|hepatic arterial infusion chemotherapy
1216502|NCT01088581|5-fluorouracil
1216503|NCT01088581|cisplatin
1216504|NCT01088581|adjuvant chemotherapy
1216505|NCT01088581|hepatectomy
1216506|NCT01088568|Keratomileusis, laser in situ
1216507|NCT01088568|Phakic Intraocular Lenses
1216508|NCT01088568|myopia
1216509|NCT01088568|astigmatism
1216510|NCT01088568|Implantable Collamer Lens, Toric
1216511|NCT01088555|nephrolithiasis
1216512|NCT01088555|calcium stones
1216513|NCT01088555|kidney stones
1216514|NCT01088555|hypercalciuria
1216515|NCT01088555|sodium thiosulfate
1216516|NCT01088555|Calcium containing kidney stones
1216517|NCT01088542|substance use
1216518|NCT01088542|delinquency
1216519|NCT01088542|risky sexual behavior
1216520|NCT01088542|risk factors
1216521|NCT01088542|protective factors
1216522|NCT01088542|prevention
1216523|NCT01088542|community coalitions
1216524|NCT01088542|systems transformation
1216525|NCT01088542|violence
1216526|NCT01088529|Neoadjuvant Prostate Cancer
1216527|NCT01088529|Abiraterone Acetate
1216528|NCT01088529|LHRHa
1216529|NCT01088529|high risk prostate cancer
1216530|NCT01088529|Radical prostatectomy
1216531|NCT01088529|Prednisone
1216532|NCT01088529|Luteinizing Hormone-Releasing Hormone
1216533|NCT01088529|LHRH analogue
1216534|NCT01088516|Human Immunodeficiency Virus
1216535|NCT01088516|Vertical Transmission
1216536|NCT01088516|Pregnancy
1216537|NCT01088516|Breastfeeding
1216538|NCT01088516|Prevention of mother to child transmission
1216539|NCT01088516|HAART
1216540|NCT01088516|Aluvia
1216541|NCT01088516|Lopinavir
1216542|NCT01088516|Africa
1216543|NCT01088516|Infectious Disease Transmission, Vertical
1216544|NCT01088490|Hydrogen sulfide
1216545|NCT01088490|critically ill
1216546|NCT01088490|mortality
1216547|NCT01088477|Acquired anti-hormonal resistant breast cancer
1216548|NCT01088464|Human Immunoglobulin Gamma-1 (IgG1)
1216549|NCT01088464|Monoclonal Antibody (MAb)
1216550|NCT01088464|Epidermal Growth Factor Receptor (EGFR)
1216551|NCT01088464|Advanced Solid Tumors
1216552|NCT01088451|Diabetes Mellitus, Type 1
1216553|NCT01088451|Prandial Glycemia
1216554|NCT01088451|Rapid Acting Insulin Analogue
1216555|NCT01088451|Human Insulin
1216556|NCT01088438|medical education
1216557|NCT01088438|decision making
1216558|NCT01088438|diagnostic error
1216559|NCT01088438|contextualization
1216560|NCT01088425|vitrification
1216561|NCT01088425|2PN oocyte
1216562|NCT01088425|maternal and infant health
1216563|NCT01088425|embryo survival, clinical pregnancy rate
1216564|NCT01088425|mode of delivery
1216565|NCT01088425|injury during delivery
1216566|NCT01088425|infant development
1216567|NCT01088425|infant morbidity
1216568|NCT01088425|slow- rate freezing
1216569|NCT01088347|TRAIL
1216570|NCT01088347|TRM1
1216571|NCT01088347|advanced cervical cancer
1216572|NCT01088347|mapatumumab
1216573|NCT01088347|Uterine cervical neoplasm
1216574|NCT01088347|Radiotherapy
1216575|NCT01088347|Cisplatin
1216576|NCT01088334|Idiopathic venous thromboembolism
1216577|NCT01088334|Malignancy
1216578|NCT01088334|screening
1216579|NCT01088295|Metabolic
1216580|NCT01088295|HIV
1216581|NCT01088295|Fat accumulation
1216582|NCT01088295|AIDS
1216583|NCT01088295|Metabolic abnormalities in HIV infection
1216584|NCT01088295|HIV Infections
1216585|NCT01088282|Diffractive multifocal IOL
1216586|NCT01088269|Blood Pressure Measurement
1216587|NCT01088269|Atrial Fibrillation
1216588|NCT01088269|Blood pressure measurement in atrial fibrillation
1216589|NCT01088269|Atrial Fibrillation diagnosis
1216590|NCT01088256|CRPS
1216591|NCT01088256|Morbus Sudeck
1216592|NCT01088256|Causalgia
1216593|NCT01088256|Etoricoxib
1216594|NCT01088256|Polyneuropathy
1216595|NCT01088256|post herpetic neuralgia
1216596|NCT01088256|peripheral nerve injury
1216597|NCT01088256|radiculopathy
1216598|NCT01088256|Nervenverletzung
1216599|NCT01088256|postherpetische Neuralgie
1216600|NCT01088256|COX-2-Inhibitor
1216601|NCT01088243|Berylliosis
1216602|NCT01088243|Beryllium Disease
1216603|NCT01088230|hemiparesis
1216604|NCT01088230|robotics
1216605|NCT01088230|stroke
1216606|NCT01088230|Botox®
1216607|NCT01088230|rehabilitation
1216608|NCT01088230|wrist spasticity
1216609|NCT01088217|Idiopathic Pulmonary Fibrosis
1216610|NCT01088217|Familial Pulmonary Fibrosis
1216611|NCT01088217|Idiopathic Interstitial Pneumonia
1216612|NCT01088217|Familial Interstitial Pneumonia
1216613|NCT01088217|Pulmonary Fibrosis
1216614|NCT01088191|Acute Anterior Cruciate Ligament Injury
1216615|NCT01088191|Anterior Cruciate Ligament Reconstruction
1216616|NCT01088191|Adult Stem Cells
1216617|NCT01088191|Mesenchymal precursor cells
1216618|NCT01088178|Long-Acting Reversible Contraception
1216619|NCT01088178|Contraceptive Agents
1216620|NCT01088178|Therapeutic Uses
1216621|NCT01088178|Contraceptive Agents, Female
1216622|NCT01088178|Reproductive Control Agents
1216623|NCT01088178|Pharmacologic Actions
1216624|NCT01088178|Levonorgestrel
1216625|NCT01088165|Psoriasis
1216626|NCT01088165|Cardiovascular Diseases
1216627|NCT01088165|Diabetes Mellitus, Type 2
1216628|NCT01088165|Adalimumab
1216629|NCT01088165|Fumaric acid esters
1216630|NCT01088152|Celiac disease
1216631|NCT01088152|Education
1216632|NCT01088152|Sweden
1216633|NCT01088152|Gluten-free diet
1216634|NCT01088139|Nutritional support
1216635|NCT01088139|Rehabilitation outcomes
1216636|NCT01088113|Tai Chi
1216637|NCT01088113|Qigong
1216638|NCT01088113|Heart rate variability
1216639|NCT01088113|Near Infrared Spectroscopy
1216640|NCT01088113|blood pressure
1216641|NCT01088100|POCD
1216642|NCT01088100|clock-gene genotypes
1216643|NCT01088100|HPER3
1216644|NCT01088074|Total Knee Replacement
1216645|NCT01088074|Closure Methods
1216646|NCT01088048|CLL
1216647|NCT01088048|non-Hodgkin lymphoma (NHL)
1216648|NCT01088048|mantle cell lymphoma (MCL)
1216649|NCT01088048|phosphatidylinositol 3-kinase
1216650|NCT01088048|bendamustine
1216651|NCT01088048|CD20 mAb
1216652|NCT01088048|rituximab
1216653|NCT01088048|CAL-101
1216654|NCT01088048|Ofatumumab
1216655|NCT01088048|indolent non-Hodgkin lymphoma (iNHL)
1216656|NCT01088048|fludarabine
1216657|NCT01088048|everolimus
1216658|NCT01088048|bortezomib
1216659|NCT01088048|chlorambucil
1216660|NCT01088048|lenalidomide
1216661|NCT01088035|Childhood ependymoma
1216662|NCT01088035|Ependymoma
1216663|NCT01088035|Survivin
1216664|NCT01088022|the complete response (CR) rate defined as the number of patients with no emetic episodes and no rescue medication in the first 120 hours post-chemotherapy
1216665|NCT01088009|chronic hepatitis B
1216666|NCT01087996|Chronic Ischemic Left Ventricular
1216667|NCT01087983|Metastatic cancer
1216668|NCT01087983|Lapatinib
1216669|NCT01087983|Tykerb
1216670|NCT01087983|Metformin
1216671|NCT01087983|Glucophage
1216672|NCT01087983|Sirolimus
1216673|NCT01087983|Rapamune
1216674|NCT01087970|Pharynx
1216675|NCT01087970|Larynx
1216676|NCT01087970|Nose
1216677|NCT01087970|Parathyroid
1216678|NCT01087931|Local anesthetic
1216679|NCT01087931|Iliac crest bone harvest
1216680|NCT01087931|Patients undergoing spine surgery that require use of iliac crest bone autograft
1216681|NCT01087918|ASIA C and D
1216682|NCT01087905|Smoking
1216683|NCT01087905|Smoking cessation
1216684|NCT01087905|Medication adherence
1216685|NCT01087879|oral glucose tolerance test
1216686|NCT01087879|hormonal contraception
1216687|NCT01087879|androgens
1216688|NCT01087879|crp
1216689|NCT01087866|Gestational diabetes mellitus
1216690|NCT01087866|treatment
1216691|NCT01087866|metformin
1216692|NCT01087853|Fluid Therapy
1216693|NCT01087853|Water Electrolyte Imbalance
1216694|NCT01087853|Acid Base Imbalance
1216695|NCT01087853|Renal Circulation
1216696|NCT01087853|Magnetic Resonance Imaging
1216697|NCT01087840|HIV
1216698|NCT01087840|nonoccupational
1216699|NCT01087840|postexposure
1216700|NCT01087840|prophylaxis
1216701|NCT01087840|HIV Seronegativity
1216702|NCT01087827|oscillometric blood pressure
1216703|NCT01087827|cuff site
1216704|NCT01087827|forearm blood pressure
1216705|NCT01087827|upper arm blood pressure
1216706|NCT01087827|anthropometric measurements
1216707|NCT01087827|tonometry
1216708|NCT01087827|site of blood pressure measurement
1216709|NCT01087827|measurement accuracy
1216710|NCT01087814|efavirenz
1216711|NCT01087814|Sustiva
1216712|NCT01087814|pharmacokinetics
1216713|NCT01087801|Genetic End Marker
1216714|NCT01087788|Certolizumab Pegol
1216715|NCT01087788|Cimzia
1216716|NCT01087762|Certolizumab Pegol
1216717|NCT01087762|Cimzia
1216718|NCT01087736|PTSD
1216719|NCT01087736|Alcohol abuse
1216720|NCT01087736|Alcoholism
1216721|NCT01087736|Topiramate
1216722|NCT01087736|Stress Disorder, Post Traumatic
1216723|NCT01087736|Chronic Post-Traumatic Stress Disorder
1216724|NCT01087723|EUROMAX
1216725|NCT01087723|STEMI
1216726|NCT01087723|STE-ACS
1216727|NCT01087723|UFH
1216728|NCT01087723|bivalirudin
1216729|NCT01087723|PCI
1216730|NCT01087723|ambulance study
1216731|NCT01087723|STE-MI participants
1216732|NCT01087697|bladder cancer
1216733|NCT01087697|radical cystectomy
1216734|NCT01087697|incontinent urinary diversion
1216735|NCT01087684|Glaucoma
1216736|NCT01087684|laser trabeculoplasty
1216737|NCT01087684|intraocular pressure
1216738|NCT01087632|Metabolic Syndrome Insulin-resistance Endothelial Function
1216739|NCT01087619|Hyperparathyroidism, primary
1216740|NCT01087619|Aged 66 years or older
1216741|NCT01087619|Mild hypercalcaemia
1216742|NCT01087619|Surgical Procedures, Elective
1216743|NCT01087619|Indication
1216744|NCT01087619|Osteoporosis
1216745|NCT01087619|Cognitive function
1216746|NCT01087619|Atherosclerosis
1216747|NCT01087619|Follow-up
1216748|NCT01087619|Randomized trial
1216749|NCT01087593|estrogen
1216750|NCT01087593|substitution
1216751|NCT01087593|pain
1216752|NCT01087593|hormonal levels
1216753|NCT01087593|quantitative sensory testing
1216754|NCT01087580|Prostate Cancer
1216755|NCT01087580|non metastatic prostate cancer
1216756|NCT01087580|oligometastatic prostate cancer
1216757|NCT01087567|diabetes
1216758|NCT01087567|insulin
1216759|NCT01087567|rescue therapy
1216760|NCT01087554|Advanced Cancer
1216761|NCT01087554|Sirolimus
1216762|NCT01087554|Rapamune
1216763|NCT01087554|mTOR Inhibitor
1216764|NCT01087554|Histone Deacetylase Inhibitor
1216765|NCT01087554|Vorinostat
1216766|NCT01087554|SAHA
1216767|NCT01087554|Suberoylanilide Hydroxamic Acid
1216768|NCT01087554|MSK-390
1216769|NCT01087554|Zolinza
1216770|NCT01087554|Everolimus
1216771|NCT01087554|Afinitor
1216772|NCT01087554|Zortress
1216773|NCT01087554|RAD001
1216774|NCT01087554|Temsirolimus
1216775|NCT01087554|CCI-779
1216776|NCT01087554|Torisel
1216777|NCT01087541|Patient's Safety
1216778|NCT01087541|Diabetes mellitus
1216779|NCT01087541|Public Health for professionals
1216780|NCT01087541|Safety
1216781|NCT01087541|Public health
1216782|NCT01087528|Colonic Diseases
1216783|NCT01087528|bowel diseases
1216784|NCT01087528|large bowel diseases
1216785|NCT01087489|pain
1216786|NCT01087489|discomfort
1216787|NCT01087489|anesthetic drugs
1216788|NCT01087489|topical drug administration
1216789|NCT01087489|injections, intraocular
1216790|NCT01087489|lidocaine
1216791|NCT01087489|intraocular pressure
1216792|NCT01087489|keratopathy
1216793|NCT01087476|oral mucositis
1216794|NCT01087476|chemotherapy
1216795|NCT01087476|acute leukemia
1216796|NCT01087476|salivary flow.
1216797|NCT01087450|Erythropoietin
1216798|NCT01087450|Sepsis
1216799|NCT01087450|Septic shock
1216800|NCT01087450|Orthogonal Polarization Spectroscopy
1216801|NCT01087450|Severe sepsis or Septic shock
1216802|NCT01087437|Distraction osteogenesis
1216803|NCT01087424|Diffuse Large B-Cell Lymphoma
1216804|NCT01087411|accelerometry
1216805|NCT01087411|physical activity
1216806|NCT01087411|obesity
1216807|NCT01087411|children
1216808|NCT01087411|cardiovascular risk markers
1216809|NCT01087411|metabolic risk markers
1216810|NCT01087411|DXA
1216811|NCT01087411|obesity prevention
1216812|NCT01087411|omega 3
1216813|NCT01087411|fish liver oil
1216814|NCT01087411|motivational interviewing
1216815|NCT01087398|Osteopetrosis
1216816|NCT01087398|HSCT
1216817|NCT01087385|peripheral arterial occlusive disease
1216818|NCT01087385|mortality
1216819|NCT01087385|cardiovascular events
1216820|NCT01087385|amputation
1216821|NCT01087385|peripheral arterial revascularization
1216822|NCT01087372|Stress hyperglycemia
1216823|NCT01087372|Incretins
1216824|NCT01087372|GLP-1
1216825|NCT01087372|GIP
1216826|NCT01087372|glucoregulatory hormones
1216832|NCT01087333|Cytotoxicity Assay
1216833|NCT01087333|Neutralizing Antibodies
1216834|NCT01087333|Apheresis
1216835|NCT01087333|Flow Cytometry
1216836|NCT01087333|Hemolytic Uremic Syndrome (HUS)
1216837|NCT01087333|Leukemia
1216838|NCT01087333|Lymphoma
1216839|NCT01087333|Hairy Cell Leukemia
1216840|NCT01087333|Chronic Lymphocytic Leukemia
1216841|NCT01087333|Non-Hodgkin Lymphoma
1216842|NCT01087333|Cutaneous T Cell Lymphoma
1216843|NCT01087333|Adult T Cell Lymphoma
1216844|NCT01087320|Genetic Counseling
1216845|NCT01087320|Genetic Disorders
1216846|NCT01087320|Genetic Testing
1216847|NCT01087320|Genetic/Genomic Researchers
1216848|NCT01087320|Human Genetic Variation
1216849|NCT01087320|Congenital Disorders
1216850|NCT01087320|Inherited Diseases
1216851|NCT01087307|Biospecimen
1216852|NCT01087307|Registry
1216853|NCT01087307|Assay Development
1216854|NCT01087307|Assay Validation
1216855|NCT01087307|Specimen Collection
1216856|NCT01087294|CD19
1216857|NCT01087294|Chimeric-Antigen-Receptor
1216858|NCT01087294|Gene Therapy
1216859|NCT01087294|Adoptive T Cell Therapy
1216860|NCT01087294|Allogeneic Stem Cell Transplantation
1216861|NCT01087294|B Cell Cancer
1216862|NCT01087294|Allogenic Stem Cell Transplant
1216863|NCT01087281|Visual Attention
1216864|NCT01087281|Visual Cortex
1216865|NCT01087281|Focal Lesions
1216866|NCT01087281|Neurological Disorder
1216867|NCT01087281|Functional Magnetic Resonance Imaging (fMRI)
1216868|NCT01087281|Focal Brain Lesion
1216869|NCT01087281|Healthy Volunteer
1216870|NCT01087281|HV
1216871|NCT01087268|gastrointestinal complications
1216872|NCT01087268|radiation toxicity
1216873|NCT01087268|long-term effects secondary to cancer therapy in adults
1216874|NCT01087268|stage I rectal cancer
1216875|NCT01087268|stage II rectal cancer
1216876|NCT01087268|stage III rectal cancer
1216877|NCT01087268|stage I prostate cancer
1216878|NCT01087268|stage IIB prostate cancer
1216879|NCT01087268|stage IIA prostate cancer
1216880|NCT01087268|stage III prostate cancer
1216881|NCT01087268|stage IV prostate cancer
1216882|NCT01087268|stage I bladder cancer
1216883|NCT01087268|stage II bladder cancer
1216884|NCT01087268|stage III bladder cancer
1216885|NCT01087268|stage IV bladder cancer
1216886|NCT01087268|stage IA cervical cancer
1216887|NCT01087268|stage IB cervical cancer
1216888|NCT01087268|stage IIA cervical cancer
1216889|NCT01087268|stage IIB cervical cancer
1216890|NCT01087268|stage III cervical cancer
1216891|NCT01087268|stage I vaginal cancer
1216892|NCT01087268|stage II vaginal cancer
1216893|NCT01087268|stage III vaginal cancer
1216894|NCT01087268|stage I malignant testicular germ cell tumor
1216895|NCT01087268|stage II malignant testicular germ cell tumor
1216896|NCT01087268|stage III malignant testicular germ cell tumor
1216897|NCT01087268|stage I endometrial carcinoma
1216898|NCT01087268|stage II endometrial carcinoma
1216899|NCT01087268|stage III endometrial carcinoma
1216900|NCT01087268|stage I uterine sarcoma
1216901|NCT01087268|stage II uterine sarcoma
1216902|NCT01087268|stage III uterine sarcoma
1216903|NCT01087268|stage IA ovarian epithelial cancer
1216904|NCT01087268|stage IB ovarian epithelial cancer
1216905|NCT01087268|stage IC ovarian epithelial cancer
1216906|NCT01087268|stage IIA ovarian epithelial cancer
1216907|NCT01087268|stage IIB ovarian epithelial cancer
1216908|NCT01087268|stage IIC ovarian epithelial cancer
1216909|NCT01087268|stage IIIA ovarian epithelial cancer
1216910|NCT01087268|stage IIIB ovarian epithelial cancer
1216911|NCT01087268|stage IIIC ovarian epithelial cancer
1216912|NCT01087268|stage IA ovarian germ cell tumor
1216913|NCT01087268|stage IB ovarian germ cell tumor
1216914|NCT01087268|stage IC ovarian germ cell tumor
1216915|NCT01087268|stage IIA ovarian germ cell tumor
1216916|NCT01087268|stage IIB ovarian germ cell tumor
1216917|NCT01087268|stage IIC ovarian germ cell tumor
1216918|NCT01087268|stage IIIA ovarian germ cell tumor
1216919|NCT01087268|stage IIIB ovarian germ cell tumor
1216920|NCT01087268|stage IIIC ovarian germ cell tumor
1216921|NCT01087255|Caregiver-based interventions
1216922|NCT01087255|Chronic Kidney Disease
1216923|NCT01087255|Medication Adherence
1216924|NCT01087242|Tang-min Lin pills
1216925|NCT01087242|type 2 diabetes
1216926|NCT01087242|liver and stomach heat retention
1216927|NCT01087242|Evaluate the safety and efficacy of Tang-min Lin pills
1216928|NCT01087203|diabetic peripheral neuropathy
1216929|NCT01087203|tanezumab
1216930|NCT01087203|diabetic neuropathies
1216931|NCT01087203|diabetic polyneuropathy
1216932|NCT01087203|diabetic neuropathy painful
1216933|NCT01087190|kidney
1216934|NCT01087190|transplantation
1216935|NCT01087190|tuberculosis
1216936|NCT01087190|ELISPOT
1216937|NCT01087190|isoniazid
1216938|NCT01087177|Smoking
1216939|NCT01087177|Tobacco
1216940|NCT01087177|Pediatrics
1216941|NCT01087164|Vaccine acceptance
1216942|NCT01087164|human papillomavirus
1216943|NCT01087164|brief messages
1216944|NCT01087164|social compliance
1216945|NCT01087164|Message sidedness
1216946|NCT01087151|Rituxan
1216947|NCT01087151|Apoptosis
1216948|NCT01087151|BCl-2
1216949|NCT01087138|bone health
1216950|NCT01087138|bone density
1216951|NCT01087138|bone mass
1216952|NCT01087112|MIP
1216953|NCT01087112|RCT
1216954|NCT01087112|postnatal depression
1216955|NCT01087112|Mother-child relationship
1216956|NCT01087086|Metabolic syndrome
1216957|NCT01087086|Oxidative stress
1216958|NCT01087086|Proinflammatory state
1216959|NCT01087086|Insulin resistance
1216960|NCT01087086|Hypertension
1216961|NCT01087086|Dyslipidemia
1216962|NCT01087086|Mediterranean diet
1216963|NCT01087086|Glycemic index
1216964|NCT01087086|Hypocaloric diet
1216965|NCT01087086|Hyperproteic diet
1216966|NCT01087086|Macronutrient distribution
1216967|NCT01087086|Antioxidant capacity of the diet
1216968|NCT01087086|Crononutrition
1216969|NCT01087086|Dietary and psychological support
1216970|NCT01087086|Waist circumference
1216971|NCT01087073|Healthcare Disparities
1216972|NCT01087073|Health Care Quality Improvement
1216973|NCT01087073|Shared Decision-Making
1216974|NCT01087073|Patient Education
1216975|NCT01087073|Patient Activation
1216976|NCT01087073|Community Outreach
1216977|NCT01087073|Provider Training
1216978|NCT01087047|Pregnancy
1216979|NCT01087047|Upper airways
1216980|NCT01087047|Acoustic reflection method
1216981|NCT01087034|Infantile scoliosis
1216982|NCT01087034|bracing
1216983|NCT01087034|acoustic reflection method
1216984|NCT01087034|EOS™
1216985|NCT01087034|noninvasive
1216986|NCT01087034|upper airways
1216987|NCT01087034|thoracic penetration index
1216988|NCT01087034|Idiopathic juvenile evolutive thoracic scoliosis
1216989|NCT01087008|Multiple Myeloma
1216990|NCT01087008|Zoledronic acid
1216991|NCT01086995|extubation
1216992|NCT01086995|weaning
1216993|NCT01086995|mechanical ventilation
1216994|NCT01086969|Meningococcal Infection
1216995|NCT01086969|Meningitis, Bacterial
1216996|NCT01086969|Menactra®
1216997|NCT01086956|patients of prostatic cancer aged more than 65 years
1216998|NCT01086917|Malaria Challenge
1216999|NCT01086917|Plasmodium falciparum
1217000|NCT01086917|Controlled human malaria infection
1217001|NCT01086917|PfSPZ Challenge
1217002|NCT01086904|renal transplantation
1217003|NCT01086904|immunosuppression
1217004|NCT01086904|inflenza A (H1N1)
1217005|NCT01086904|vaccine
1217006|NCT01086878|Antiretroviral Therapy, Highly Active
1217007|NCT01086878|Trimethoprim-Sulfamethoxazole Combination
1217008|NCT01086878|anemia
1217009|NCT01086878|neutropenia
1217010|NCT01086878|safety
1217011|NCT01086878|hematologic toxicity
1217012|NCT01086865|inappetence
1217013|NCT01086865|apetiviton BC
1217014|NCT01086852|Factor X deficiency
1217015|NCT01086852|surgery
1217016|NCT01086852|Factor X deficiency subjects requiring surgery
1217017|NCT01086839|Cystic Fibrosis
1217018|NCT01086839|chronic rhinosinusitis
1217019|NCT01086813|Safety
1217020|NCT01086813|Tolerability
1217021|NCT01086813|Pharmacokinetics
1217022|NCT01086813|Sedation
1217023|NCT01086787|Heart failure
1217024|NCT01086787|Bone marrow
1217025|NCT01086787|Bone marrow mononuclear cells
1217026|NCT01086787|Surgery
1217027|NCT01086787|Orthopedic surgery
1217028|NCT01086787|Cardiac surgery
1217029|NCT01086774|Dry eye
1217030|NCT01086774|Tear Film Stability
1217031|NCT01086735|hematological malignancy
1217032|NCT01086735|allogeneic hematopoietic stem cell transplantation
1217033|NCT01086735|donor lymphocyte infusion
1217034|NCT01086735|antitumor immunotherapy
1217035|NCT01086735|graft-versus-tumor effect
1217036|NCT01086735|gene therapy
1217037|NCT01086735|relapse
1217038|NCT01086735|adult
1217039|NCT01086709|Human Papillomavirus
1217040|NCT01086709|Vaccine
1217041|NCT01086709|Crossover
1217042|NCT01086709|Hepatitis A
1217043|NCT01086709|Hepatitis B
1217044|NCT01086696|PET Imaging
1217045|NCT01086696|F-18 Paclitaxel (FPAC)
1217046|NCT01086696|Breast Cancer
1217047|NCT01086696|Lung Cancer
1217048|NCT01086696|Renal and Adrenal Cancers
1217049|NCT01086696|Kidney Cancer
1217050|NCT01086696|Adrenal Cancer
1217051|NCT01086683|neoplasms
1217052|NCT01086683|rehabilitation
1217053|NCT01086683|intervention
1217054|NCT01086683|quality of life
1217055|NCT01086683|lifestyle
1217056|NCT01086670|Coordination
1217057|NCT01086670|Neuroimaging
1217058|NCT01086670|Motion Analysis
1217059|NCT01086670|Locomotor
1217060|NCT01086670|Cerebral Palsy
1217061|NCT01086670|Pediatrics
1217062|NCT01086657|Bird Flu
1217063|NCT01086657|Avian Influenza
1217064|NCT01086657|Healthy
1217065|NCT01086657|Immunity
1217066|NCT01086657|Prevention
1217067|NCT01086657|Healthy Volunteer
1217068|NCT01086657|HV
1217069|NCT01086631|Autoimmune Retinopathy
1217070|NCT01086631|RITUXAN
1217071|NCT01086631|Rituximab
1217072|NCT01086631|Immunosuppression
1217073|NCT01086618|stage IV colon cancer
1217074|NCT01086618|stage IV rectal cancer
1217075|NCT01086605|HER2-negative breast cancer
1217076|NCT01086605|male breast cancer
1217077|NCT01086605|recurrent breast cancer
1217078|NCT01086605|stage IV breast cancer
1217079|NCT01086605|stage IIIC breast cancer
1217080|NCT01086592|Aged
1217081|NCT01086592|Strength
1217082|NCT01086592|Balance
1217083|NCT01086592|Electrotherapy
1217084|NCT01086592|Quality of life
1217085|NCT01086579|paclitaxel PTCA drug-eluting balloon
1217086|NCT01086579|provisional spot stenting
1217087|NCT01086579|coronary artery disease
1217088|NCT01086579|Late Lumen Loss
1217089|NCT01086579|Minimal lumen diameter
1217090|NCT01086579|coronary artery disease in a small vessel
1217091|NCT01086566|Influenza, H5N1, avian influenza, parent protocol
1217092|NCT01086553|Crohn´s disease
1217093|NCT01086553|budesonide
1217094|NCT01086553|induction of remission
1217095|NCT01086540|Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
1217096|NCT01086540|Autoimmune Disease
1217097|NCT01086540|Systemic Scleroderma
1217098|NCT01086540|Pulmonary Arterial Hypertension
1217099|NCT01086527|Pharmacogenetics
1217100|NCT01086527|Singulair
1217101|NCT01086527|montelukast
1217102|NCT01086527|Leukotriene Antagonists
1217103|NCT01086527|Anti-Asthmatic Agents
1217104|NCT01086527|Intestinal Absorption
1217105|NCT01086527|pharmacokinetics
1217106|NCT01086527|absorption
1217107|NCT01086527|biochemical transport
1217108|NCT01086527|Membrane Transport Proteins
1217109|NCT01086514|Breast
1217110|NCT01086514|mammography
1217111|NCT01086514|MRI
1217112|NCT01086514|Digital Mammography
1217113|NCT01086514|10-024
1217114|NCT01086501|open, non-interventional
1217115|NCT01086488|recurrent or persistent Nasopharyngeal Carcinoma
1217116|NCT01086488|treatment of patients with squamous cell carcinoma of the head and neck
1217117|NCT01086488|Foscan-PDT
1217118|NCT01086488|Brachytherapy
1217119|NCT01086475|Autism Spectrum Disorder
1217120|NCT01086475|D-cycloserine
1217121|NCT01086475|Social Skills Training
1217122|NCT01086462|GSK2239633
1217123|NCT01086462|RADIOLABEL
1217124|NCT01086462|PHARMACOKINETICS
1217125|NCT01086462|INTRAVENOUS
1217126|NCT01086462|MICRODOSE
1217127|NCT01086449|safety
1217128|NCT01086449|Japanese
1217129|NCT01086449|Herpes Zoster
1217130|NCT01086449|immunogenicity
1217131|NCT01086449|Herpes Zoster in healthy ethnic Japanese adults
1217132|NCT01086449|Vaccine
1217133|NCT01086436|Human Rotavirus vaccine
1217134|NCT01086423|Infanrix-IPV+Hib
1217135|NCT01086410|HPA axis
1217136|NCT01086397|pneumococcal pneumonia
1217137|NCT01086397|community-acquired pneumonia
1217138|NCT01086371|Multiple Sclerosis
1217139|NCT01086371|gait
1217140|NCT01086358|productivity
1217141|NCT01086358|migraine
1217142|NCT01086358|Treximet
1217143|NCT01086358|triptan
1217144|NCT01086345|adult giant cell glioblastoma
1217145|NCT01086345|adult gliosarcoma
1217146|NCT01086345|recurrent adult brain tumor
1217147|NCT01086332|radiotherapy
1217148|NCT01086332|gemcitabine
1217149|NCT01086332|nelfinavir
1217150|NCT01086332|neoplasms
1217151|NCT01086241|Tomography
1217152|NCT01086241|Mammography
1217153|NCT01086241|Breast Neoplasms
1217154|NCT01086241|Prevention and Control
1217155|NCT01086228|Drug eluting stents
1217156|NCT01086228|Stents
1217157|NCT01086228|Angioplasty
1217158|NCT01086202|irreparable rotator cuff tears
1217159|NCT01086163|Omacor
1217160|NCT01086163|Simvastatin
1217161|NCT01086163|Aspirin
1217162|NCT01086163|Platelet activity
1217163|NCT01086163|Coronary artery disease
1217164|NCT01086137|salivary biomarker
1217165|NCT01086137|metabolic syndrome
1217166|NCT01086137|prediabetes
1217167|NCT01086137|diabetes hypertension
1217168|NCT01086124|echocardiography
1217169|NCT01086124|ST elevation myocardial infarction
1217170|NCT01086124|Heart failure
1217171|NCT01086124|Coronary artery disease
1217172|NCT01086124|Cardiovascular diseases
1217173|NCT01086111|type 2 diabetes
1217174|NCT01086111|gastric bypass
1217175|NCT01086111|sleeve gastrectomy
1217176|NCT01086111|clamp study
1217177|NCT01086111|weight loss surgery
1217178|NCT01086098|Pacemakers
1217179|NCT01086098|Survival
1217180|NCT01086059|Autoimmune diseases
1217181|NCT01086059|adalimumab
1217182|NCT01086059|pregnancy
1217183|NCT01086059|birth defects
1217184|NCT01086059|TNF
1217185|NCT01086059|Tumor necrosis factor
1217186|NCT01086046|platelet
1217187|NCT01086046|thrombozyme
1217188|NCT01086046|ASD
1217189|NCT01086046|Heparin
1217190|NCT01086046|Enoxaparin
1217191|NCT01086033|Evaluation of safety and efficacy
1217192|NCT01086033|Adalimumab treatment
1217193|NCT01086033|Rheumatoid Arthritis
1217194|NCT01086020|IVUS
1217195|NCT01086020|coronary plaque
1217196|NCT01086020|regression
1217197|NCT01086007|Groin hernia
1217198|NCT01086007|chronic pain
1217199|NCT01086007|Persistent postoperative pain
1217200|NCT01086007|Laparoscopic inguinal herniotomy
1217201|NCT01086007|Sexual dysfunction
1217202|NCT01085994|antibiotics
1217203|NCT01085994|resistance
1217204|NCT01085994|bio-marker
1217205|NCT01085994|procalcitonin
1217206|NCT01085994|algorithm
1217207|NCT01085994|critically ill
1217208|NCT01085981|quantitative assessment of the effects of a topically
1217209|NCT01085981|applied vasodilating cream to the clitoris using doppler
1217210|NCT01085981|flow plethysmography
1217211|NCT01085968|Parkinson's disease
1217212|NCT01085968|Cognitive deficits
1217213|NCT01085968|fMRI
1217214|NCT01085968|neuro rehabilitation
1217215|NCT01085968|Age Matched Controls
1217216|NCT01085955|peripartum
1217217|NCT01085955|cardiomyopathy
1217218|NCT01085955|post pregnancy
1217219|NCT01085955|myocardial recovery
1217220|NCT01085955|pregnant women with peripartum cardiomyopathy
1217221|NCT01085942|rotator cuff tear
1217222|NCT01085942|asymptomatic
1217223|NCT01085942|natural course
1217224|NCT01085942|tear characteristics
1217225|NCT01085942|Asymptomatic rotator cuff tears
1217226|NCT01085942|Natural course of rotator cuff tears
1217227|NCT01085929|abscess
1217228|NCT01085929|infection
1217229|NCT01085929|ultrasound guidance
1217230|NCT01085929|incision and drainage
1217231|NCT01085929|needle aspiration
1217232|NCT01085929|skin
1217233|NCT01085929|ultrasound
1217234|NCT01085916|prevalence of asthma and Rhinitis symptoms among secondary school students in Saudi Arabia
1217235|NCT01085903|Spatial Neglect
1217236|NCT01085903|Dysphagia
1217237|NCT01085903|Arousal
1217238|NCT01085903|Modafinil
1217239|NCT01085903|Stroke
1217240|NCT01085890|Blood Pressure
1217241|NCT01085890|Life Style
1217242|NCT01085890|Body Mass Index
1217243|NCT01085890|Obesity, Abdominal
1217244|NCT01085890|Blood Chemical Analysis
1217245|NCT01085864|Lung Nodules
1217366|NCT01085409|Quality of life
1217367|NCT01085396|Fiber Optic
1217246|NCT01085864|A need exists for non-invasive testing to aid in clinical decision-making for CT scan detected lung nodules of indeterminate etiology.
1217247|NCT01085851|Sunburn
1217248|NCT01085851|Dexchlorpheniramine
1217249|NCT01085851|Lotion
1217250|NCT01085851|Cream
1217251|NCT01085838|Erlotinib
1217252|NCT01085838|myelodysplastic syndrome
1217253|NCT01085825|induced abortion
1217254|NCT01085825|termination of pregnancy
1217255|NCT01085825|manual vacuum aspiration
1217256|NCT01085825|electric vacuum aspiration
1217257|NCT01085799|Educational activities
1217258|NCT01085799|Cluster-randomized controlled trial
1217259|NCT01085799|Albendazole
1217260|NCT01085799|Deworming
1217261|NCT01085799|School-age children
1217262|NCT01085799|Peru
1217263|NCT01085799|Ascaris lumbricoides
1217264|NCT01085799|Trichuris trichiura
1217265|NCT01085799|Hookworm
1217266|NCT01085799|STH infections
1217267|NCT01085799|Intestinal helminth infections
1217268|NCT01085786|Helicobacter pylori infection
1217269|NCT01085773|HbA1c
1217270|NCT01085773|Type 2 Diabetes
1217271|NCT01085773|Lifestyle changes
1217272|NCT01085773|Exercise
1217273|NCT01085747|Chronic pancreatitis
1217274|NCT01085747|Biliary stricture
1217275|NCT01085747|Endoscopic treatment
1217276|NCT01085747|SEMS
1217277|NCT01085721|allergic rhinitis
1217278|NCT01085721|viral infections of the upper respiratory tract
1217279|NCT01085721|dexchlorpheniramine
1217280|NCT01085721|pseudoephedrine
1217281|NCT01085721|guaifenesin
1217282|NCT01085708|Rabeprazole
1217283|NCT01085708|Japan
1217284|NCT01085708|healthy Japanese male
1217285|NCT01085695|Rabeprazole
1217286|NCT01085695|Japan
1217287|NCT01085695|healthy Japanese male
1217288|NCT01085682|Diabetes prevention
1217289|NCT01085682|Lifestyle modification
1217290|NCT01085682|Obesity
1217291|NCT01085682|Impaired glucose tolerance
1217292|NCT01085682|Diet
1217293|NCT01085682|Physical activity
1217294|NCT01085669|Infection rate of VEPTR-Implants
1217295|NCT01085669|VEPTR. Vertical Expandable
1217296|NCT01085669|Prosthetic Titanium Rib
1217297|NCT01085643|IBS
1217298|NCT01085643|Lubiprostone
1217299|NCT01085643|Small Bowel
1217300|NCT01085643|High Resolution Manometry
1217301|NCT01085643|Delayed Intestinal Transit
1217302|NCT01085630|epithelial mesothelioma
1217303|NCT01085630|sarcomatous mesothelioma
1217304|NCT01085630|stage II malignant mesothelioma
1217305|NCT01085630|stage III malignant mesothelioma
1217306|NCT01085630|stage IV malignant mesothelioma
1217307|NCT01085617|oral complications
1217308|NCT01085617|mucositis
1217309|NCT01085617|untreated adult acute lymphoblastic leukemia
1217310|NCT01085617|B-cell adult acute lymphoblastic leukemia
1217311|NCT01085617|T-cell adult acute lymphoblastic leukemia
1217312|NCT01085617|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
1217313|NCT01085604|low back pain
1217314|NCT01085604|clinical instability
1217315|NCT01085604|neuromuscular control
1217316|NCT01085604|core stabilization
1217317|NCT01085604|physical therapy
1217318|NCT01085591|CDI
1217319|NCT01085591|Clostridium difficile Infection
1217320|NCT01085591|Diarrhea
1217321|NCT01085578|healthy male volunteers
1217322|NCT01085578|fasted and fed state
1217323|NCT01085565|Bone cancer
1217324|NCT01085565|Bone Metastases
1217325|NCT01085565|pain palliation
1217326|NCT01085565|metastasis
1217327|NCT01085565|breast cancer
1217328|NCT01085565|lung cancer
1217329|NCT01085565|prostate cancer
1217330|NCT01085565|cancer related pain
1217331|NCT01085565|tumors
1217332|NCT01085552|NeoRecormon®
1217333|NCT01085552|Caucasian
1217334|NCT01085552|Japanese
1217335|NCT01085552|Bioequivalence
1217336|NCT01085552|Ethnic
1217337|NCT01085539|neonatal intensive care
1217338|NCT01085539|infant pulse oximetry
1217339|NCT01085526|basophil activity
1217340|NCT01085526|plasma cells
1217341|NCT01085526|IgE
1217342|NCT01085526|IgG1
1217343|NCT01085526|IgG4
1217344|NCT01085526|mast cells
1217345|NCT01085526|IgE receptor
1217346|NCT01085526|allergic rhinoconjunctivitis
1217347|NCT01085526|grass pollen allergy
1217348|NCT01085513|intestinal abnormalities
1217349|NCT01085500|laparoscopic
1217350|NCT01085500|totally extraperitoneal inguinal hernia repair
1217351|NCT01085487|Menorrhagia
1217352|NCT01085474|Asthma
1217353|NCT01085474|Pharmaceutical intervention
1217354|NCT01085474|Effect of a pharmaceutical intervention on the level of control of the asthmatic patient
1217355|NCT01085448|low back pain
1217356|NCT01085448|core stabilization
1217357|NCT01085448|physical therapy
1217358|NCT01085435|ICD
1217359|NCT01085435|defibrillator
1217360|NCT01085422|Prostate Cancer
1217361|NCT01085409|experienced utility
1217362|NCT01085409|decision utility
1217363|NCT01085409|subjective well-being
1217364|NCT01085409|experience sampling method
1217365|NCT01085409|day reconstruction method
1217368|NCT01085396|Melanoma
1217369|NCT01085396|UV Exposure
1217370|NCT01085383|Antipsychotic
1217371|NCT01085383|hyperprolactinemia
1217372|NCT01085383|hypogonadism
1217373|NCT01085383|aripiprazole
1217374|NCT01085370|posttraumatic stress
1217375|NCT01085370|prevention
1217376|NCT01085370|children
1217377|NCT01085370|acute stress disorder due to burn injury or injuries associated with road traffic accidents
1217378|NCT01085357|Glaucoma
1217379|NCT01085357|Glaucoma device
1217380|NCT01085357|Glaucoma surgery
1217381|NCT01085357|Intraocular pressure
1217382|NCT01085344|hemophilia, prophylaxis, cost effectiveness
1217383|NCT01085331|Mek Inhibitor
1217384|NCT01085331|Metastatic Colorectal Cancer
1217385|NCT01085331|K-Ras Mutation
1217386|NCT01085331|Phase II
1217387|NCT01085331|Second line K-Ras mutated metastatic colorectal cancer
1217388|NCT01085305|Behavior problems
1217389|NCT01085305|Parent-Child Interaction
1217390|NCT01085305|Locus of control
1217391|NCT01085305|Psychiatric symptoms
1217392|NCT01085305|Depressive symptoms
1217393|NCT01085305|Attachment
1217394|NCT01085279|fractional laser
1217395|NCT01085279|melasma
1217396|NCT01085279|topical bleaching
1217397|NCT01085253|Parkinson's
1217398|NCT01085253|supranuclear palsy
1217399|NCT01085253|substantia nigra
1217400|NCT01085253|sub thalamic nucleus
1217401|NCT01085253|MRI
1217402|NCT01085227|Parkinson's disease
1217403|NCT01085227|LRRK2
1217404|NCT01085227|asymptomatic carriers
1217405|NCT01085201|lexiscan
1217406|NCT01085175|Heart Failure,
1217407|NCT01085175|PET Imaging,
1217408|NCT01085175|Implantable Cardioverter-Defibrillator,
1217409|NCT01085175|Sudden Cardiac Death
1217410|NCT01085162|Coronary Artery Disease
1217411|NCT01085162|PET imaging
1217412|NCT01085162|SPECT imaging
1217413|NCT01085149|simvastatin
1217414|NCT01085149|alveolar bone
1217415|NCT01085149|tooth extraction
1217416|NCT01085149|remodeling
1217417|NCT01085149|alveolar bone remodeling
1217418|NCT01085123|Migraine
1217419|NCT01085123|ZOMIG® Rapimelt
1217420|NCT01085110|Groin hernia
1217421|NCT01085110|Chronic pain
1217422|NCT01085110|QST
1217423|NCT01085110|Quantitative sensory testing
1217424|NCT01085110|Persistent postoperative pain
1217425|NCT01085110|Laparoscopic inguinal herniotomy
1217426|NCT01085110|Postherniotomy Pain after laparoscopic inguinal herniotomy
1217427|NCT01085110|laparoscopic inguinal hernia repair
1217428|NCT01085097|Systemic Lupus Erythematosus (SLE)
1217429|NCT01085097|Lupus Nephritis
1217430|NCT01085097|Laquinimod
1217431|NCT01085084|Systemic Lupus Erythematosus (SLE)
1217432|NCT01085084|Lupus Arthritis
1217433|NCT01085084|Laquinimod
1217434|NCT01085071|intensive care unit
1217435|NCT01085071|potassium
1217436|NCT01085071|atrial fibrillation
1217437|NCT01085071|cardiac surgery
1217438|NCT01085071|Critically ill patients post CABG and/or valvular surgery
1217439|NCT01085071|Critically ill patients not post CABG and/or valvular surgery
1217440|NCT01085071|coronary artery bypass graft
1217441|NCT01085058|Lymphoproliferative diseases (Hodgkin's disease, non-Hodgkin's lymphomas, multiple myelomas) and high-dose therapy
1217442|NCT01085045|COPD
1217443|NCT01085032|Smoking Cessation
1217444|NCT01085032|Substance Withdrawal Syndrome
1217445|NCT01085032|Depression
1217446|NCT01085019|Endothelial function
1217447|NCT01085019|Cardiovascular risk factors
1217448|NCT01085019|Spices
1217449|NCT01085019|Herbs
1217450|NCT01085019|Antioxidant
1217451|NCT01085006|cesarean delivery
1217452|NCT01085006|Tranexamic acid
1217453|NCT01085006|hemorrhage
1217454|NCT01085006|Spinal analgesia
1217455|NCT01085006|1-the amount of hemorrhage during cesarean delivery
1217456|NCT01085006|2-the amount of hemorrhage in the first 2 hours of cesarean delivery
1217457|NCT01085006|3-the amount of hemorrhage in the first 24 hour after cesarean delivery
1217458|NCT01084993|Coronary artery stenting, transradial, intracoronary
1217459|NCT01084980|minimal change disease
1217460|NCT01084980|tacrolimus
1217461|NCT01084980|corticosteroid
1217462|NCT01084967|obesity
1217463|NCT01084967|metabolic syndrome
1217464|NCT01084967|genetic risk markers
1217465|NCT01084967|copy number variation
1217466|NCT01084954|HIV validation helicase-dependent amplification
1217467|NCT01084941|pregnancy
1217468|NCT01084941|weight gain
1217469|NCT01084941|obesity
1217470|NCT01084941|pregnancy and weight gain
1217471|NCT01084928|diabetes
1217472|NCT01084928|obesity
1217473|NCT01084928|pre-diabetes
1217474|NCT01084928|South Asian
1217475|NCT01084915|Weight loss after SAGB VC band placement
1217476|NCT01084902|POAG
1217477|NCT01084902|OH
1217478|NCT01084902|Xalatan
1217479|NCT01084902|Azopt
1217480|NCT01084902|Primary Open Angle Study
1217485|NCT01084876|Herceptin
1217486|NCT01084876|metastatic breast cancer
1217487|NCT01084876|CT-P6
1217488|NCT01084863|Herceptin
1217489|NCT01084863|Her 2-positive
1217490|NCT01084863|metastatic breast cancer
1217491|NCT01084863|CT-P6
1217492|NCT01084850|Corneal endothelium
1217493|NCT01084850|diabetes mellitus
1217494|NCT01084850|corneal thickness
1217495|NCT01084837|Multiple myeloma
1217496|NCT01084837|Renal failure
1217497|NCT01084824|Warts
1217498|NCT01084824|Verruca vulgaris
1217499|NCT01084824|Liquid Nitrogen
1217500|NCT01084824|Cantharidin
1217501|NCT01084824|combination treatment
1217502|NCT01084798|Multiple sclerosis
1217503|NCT01084798|Expanded Disability Status Scale
1217504|NCT01084798|Sclerosis
1217505|NCT01084785|Cancer
1217506|NCT01084785|genomics
1217507|NCT01084785|proteomics
1217508|NCT01084746|Colorectal Cancer Screening
1217509|NCT01084746|Computer Interactive Intervention
1217510|NCT01084746|Predictors
1217511|NCT01084746|Cost Effective Analysis
1217512|NCT01084746|Transtheoretical Model
1217513|NCT01084707|Smoking Cessation, Nicotine pharmacokinetics
1217514|NCT01084694|HSCT
1217515|NCT01084694|Caregiver
1217516|NCT01084694|Caregiver Burden
1217517|NCT01084694|Allogeneic Transplant
1217518|NCT01084694|Autologous Transplant
1217519|NCT01084694|Hematopoietic Stem Cell Transplantation
1217520|NCT01084681|SILK flow diverter, intracranial stents, intracranial aneurysms
1217521|NCT01084668|moderate to severe chronic plaque psoriasis
1217522|NCT01084668|adalimumab
1217523|NCT01084668|Psoriasis Area and Severity Index (PASI)
1217524|NCT01084668|Disease Life Quality Index (DLQI)
1217525|NCT01084668|Nail Psoriasis Severity Index (NAPSI)
1217526|NCT01084668|biologic disease modifying anti-rheumatic drug (BDMARD)
1217527|NCT01084668|antibodies
1217528|NCT01084668|monoclonals
1217529|NCT01084642|Survey
1217530|NCT01084642|Sexual Health Issues
1217531|NCT01084642|10-034
1217532|NCT01084629|Barrett's Esophagus
1217533|NCT01084629|Surveillance
1217534|NCT01084603|Smoking Cessation
1217535|NCT01084603|Nicotine pharmacokinetics
1217536|NCT01084590|Prevention
1217537|NCT01084590|Obesity
1217538|NCT01084590|Safety
1217539|NCT01084590|Unhealthy weight gain
1217540|NCT01084590|Injury prevention
1217541|NCT01084564|Cost-effectiveness analysis
1217542|NCT01084564|Colombia
1217543|NCT01084538|paricalcitol iv
1217544|NCT01084538|vitamin D
1217545|NCT01084538|secondary hyperparathyroidism
1217546|NCT01084538|hemodialysis
1217547|NCT01084525|Meniere's Disease
1217548|NCT01084525|Vertigo
1217549|NCT01084525|Definitive vertigo
1217550|NCT01084525|Vertigo episodes
1217551|NCT01084525|Vertigo frequency
1217552|NCT01084525|Tinnitus
1217553|NCT01084525|Hearing loss
1217554|NCT01084525|Aural Fullness
1217555|NCT01084512|kinematic analysis,
1217556|NCT01084512|three-compartment model,
1217557|NCT01084512|chest wall motion,
1217558|NCT01084512|spinal cord injury.
1217559|NCT01084499|Healthy Subjects
1217560|NCT01084486|nonalcoholic fatty liver disease
1217561|NCT01084486|Pulse wave velocity
1217562|NCT01084486|augmentation index
1217563|NCT01084486|metformin
1217564|NCT01084473|Dexmedetomidine
1217565|NCT01084473|gastric emptying
1217566|NCT01084473|oro-cecal transit time
1217567|NCT01084473|Sedation in intensive care
1217568|NCT01084473|Gastrointestinal effects of sedation
1217569|NCT01084460|Gastrointestinal stromal tumor,endoscopic ultrasound,submucosal tumor
1217570|NCT01084447|obesity
1217571|NCT01084447|gastroplasty
1217572|NCT01084447|respiratory muscle training
1217573|NCT01084447|muscle strength
1217574|NCT01084447|physical therapy
1217575|NCT01084421|Adolescents
1217576|NCT01084421|Parents
1217577|NCT01084421|Computer Based
1217578|NCT01084421|Latino
1217579|NCT01084421|Sexual Communication
1217580|NCT01084408|de-novo
1217581|NCT01084408|coronary stenoses
1217582|NCT01084408|PEPCAD
1217583|NCT01084408|DEBonly
1217584|NCT01084408|Paclitaxel
1217585|NCT01084395|Parent
1217586|NCT01084395|Adolescent
1217587|NCT01084395|Mexico
1217588|NCT01084395|Safer Sex Communication
1217589|NCT01084395|Randomized Controlled Trial
1217590|NCT01084395|HIV/AIDS
1217591|NCT01084395|STD
1217592|NCT01084395|Sexual Behavior
1217593|NCT01084382|Arthrospira platensis
1217594|NCT01084382|female HIV patient
1217595|NCT01084382|Yaounde
1217596|NCT01084382|Redox potential
1217597|NCT01084382|Life quality
1217598|NCT01084382|female patient infected by HIV in Yaounde: Cameroon
1217599|NCT01084369|Type 2 diabetes
1217600|NCT01084369|Hypogonadism
1217601|NCT01084369|Testosterone
1217602|NCT01084369|Endothelial dysfunction
1217603|NCT01084356|CZT
1217604|NCT01084356|sentinel node
1217605|NCT01084356|osseous processes
1217606|NCT01084343|vaccination
1217607|NCT01084343|prophylaxis
1217608|NCT01084330|gastric cancer
1217609|NCT01084330|metastatic gastric cancer
1217610|NCT01084330|advanced gastric cancer
1217611|NCT01084317|asthma
1217612|NCT01084317|children
1217613|NCT01084317|delay in asthma diagnosis
1217614|NCT01084304|Pregnancy
1217615|NCT01084304|Ovulation tests
1217616|NCT01084304|stress
1217617|NCT01084304|Wishing to become pregnant
1217618|NCT01084291|Vaccine
1217619|NCT01084291|Dengue Hemorrhagic Fever
1217620|NCT01084265|Hypogonadism
1217621|NCT01084265|Recombinant human follicle stimulating hormone (r-hFSH)
1217622|NCT01084265|Recombinant leutinizing hormone (r-hLH)
1217623|NCT01084239|acute chest pain
1217624|NCT01084239|emergency department
1217625|NCT01084239|cardiac computed tomography
1217626|NCT01084226|Rye fiber
1217627|NCT01084226|Alkylresorcinols
1217628|NCT01084226|Plant sterols
1217629|NCT01084226|Cholesterol
1217630|NCT01084226|Antioxidant
1217631|NCT01084226|Effects of plant sterols in rye bread on serum lipids
1217632|NCT01084226|Effects of alkylresorcinols in rye fiber on LDL particles
1217633|NCT01084213|Low birth weight
1217634|NCT01084213|Placenta malaria
1217635|NCT01084213|Anaemia
1217636|NCT01084213|Intermittent preventive treatment
1217637|NCT01084213|Intermittent screening and treatment
1217638|NCT01084213|Rapid diagnostic test
1217639|NCT01084200|Postoperative pain
1217640|NCT01084200|Sevoflurane
1217641|NCT01084200|Propofol
1217642|NCT01084200|Female
1217643|NCT01084200|Elective gynaecological surgery
1217644|NCT01084200|Laparoscopic and hysteroscopic surgery
1217645|NCT01084200|Female patients
1217646|NCT01084200|Undergoing elective laparoscopic and hysteroscopic surgery
1217647|NCT01084187|erectile dysfunction
1217648|NCT01084187|arterial hypertension
1217649|NCT01084187|flow mediated vasodilation
1217650|NCT01084187|endothelial dysfunction
1217651|NCT01084187|carotid intima media thickness
1217652|NCT01084187|vardenafil
1217653|NCT01084174|Peanut Allergy
1217654|NCT01084135|Clinical trial
1217655|NCT01084135|Down syndrome
1217656|NCT01084135|adolescents
1217657|NCT01084135|cognitive
1217658|NCT01084135|rivastigmine
1217659|NCT01084122|Intravenous iron sucrose
1217660|NCT01084122|Anemia
1217661|NCT01084122|Transfusion
1217662|NCT01084109|Complementary feeding
1217663|NCT01084109|Infant growth
1217664|NCT01084109|Developing countries
1217665|NCT01084096|Antenatal Corticosteroids, Preterm Birth, Diffusion
1217666|NCT01084083|human papilloma virus infection
1217667|NCT01084083|stage III squamous cell carcinoma of the oropharynx
1217668|NCT01084083|stage IV squamous cell carcinoma of the oropharynx
1217669|NCT01084083|tongue cancer
1217670|NCT01084070|early feeding
1217671|NCT01084070|postoperative care
1217672|NCT01084070|emergency surgery
1217673|NCT01084018|acute postoperative pain
1217674|NCT01084018|nursing intervention
1217675|NCT01083992|NAFLD
1217676|NCT01083992|Galvus
1217677|NCT01083992|vitamin D
1217678|NCT01083966|Vestibular
1217679|NCT01083966|Schwannoma
1217680|NCT01083966|earing-loss
1217681|NCT01083966|brain-tumor
1217682|NCT01083966|Acoustic
1217683|NCT01083966|Neuroma
1217684|NCT01083953|end tidal concentration
1217685|NCT01083927|Pterygium
1217686|NCT01083914|extracorporeal circulation, off-pump CABG
1217687|NCT01083888|Pharmacokinetics
1217688|NCT01083888|Safety and tolerability
1217689|NCT01083888|Plasma concentration
1217690|NCT01083888|ASP1517
1217691|NCT01083888|FG-4592
1217692|NCT01083875|Radiation
1217693|NCT01083875|mucositis
1217694|NCT01083875|head and neck carcinoma
1217695|NCT01083875|oral rinse
1217696|NCT01083875|amlexanox
1217697|NCT01083875|MuGard
1217698|NCT01083862|Health literacy
1217699|NCT01083862|patient education
1217700|NCT01083862|health behaviors
1217701|NCT01083862|chronic disease management
1217702|NCT01083862|shared decision-making
1217703|NCT01083862|patient-centered decision making
1217704|NCT01083849|Observational study
1217705|NCT01083849|Paricalcitol
1217706|NCT01083849|Treatment of Hyperparathyroidism
1217707|NCT01083849|Chronic kidney disease stage 3, 4 and 5 (CKD stage 3, 4 and 5)
1217708|NCT01083849|Chronic Kidney Disease
1217709|NCT01083849|Zemplar
1217710|NCT01083849|sHPT
1217711|NCT01083849|Secondary
1217712|NCT01083823|Mental health telemetry
1217713|NCT01083823|Mood telemetry
1217714|NCT01083823|Mood
1217715|NCT01083823|Bipolar disorder
1217716|NCT01083823|Affective instability
1217717|NCT01083823|Cyclothymia
1217718|NCT01083823|Electronic diaries
1217719|NCT01083823|Mood diaries
1217720|NCT01083823|Mood swings
1217721|NCT01083810|Human Immunodeficiency Virus
1217722|NCT01083810|Infection
1217723|NCT01083810|Kaletra
1217724|NCT01083810|Resistance
1217725|NCT01083810|Mutations
1217726|NCT01083810|alternative Therapy regimen
1217727|NCT01083797|Sedation
1217728|NCT01083797|Electroencephalography
1217729|NCT01083797|Dexmedetomidine
1217730|NCT01083797|Chloral hydrate
1217731|NCT01083784|Cardiac arrest
1217732|NCT01083784|Prophylactic anticonvulsant
1217733|NCT01083719|Glioblastoma
1217734|NCT01083719|FDG-PET
1217735|NCT01083719|MRI
1217736|NCT01083693|Monoclonals
1217737|NCT01083693|Antibodies
1217738|NCT01083693|Ankylosing Spondylitis
1217739|NCT01083693|Antirheumatic Agents
1217740|NCT01083693|Quality of Life
1217741|NCT01083693|Adalimumab
1217742|NCT01083693|rheumatoid arthritis
1217743|NCT01083693|psoriatic arthritis
1217744|NCT01083680|Routine clinical setting
1217745|NCT01083680|Long-term efficacy and safety
1217746|NCT01083680|Crohn's Disease
1217747|NCT01083680|Humira®
1217748|NCT01083680|Adalimumab
1217749|NCT01083667|ALS
1217750|NCT01083667|Familial ALS
1217751|NCT01083667|SOD1 Gene Mutation
1217752|NCT01083654|Smoking
1217753|NCT01083654|Smoking cessation
1217754|NCT01083641|Breast Cancer
1217755|NCT01083615|CRPC patients with cancer related pain
1217756|NCT01083615|CRPC
1217757|NCT01083615|HRPC
1217758|NCT01083602|Multiple Myeloma
1217759|NCT01083602|Relapsed Multiple Myeloma
1217760|NCT01083602|Refractory Multiple Myeloma
1217761|NCT01083589|Lung Cancer
1217762|NCT01083589|Metastatic NSCLC
1217763|NCT01083589|Tumor
1217764|NCT01083589|Imatinib Mesylate
1217765|NCT01083589|Gleevec
1217766|NCT01083589|Docetaxel
1217767|NCT01083589|Taxotere
1217768|NCT01083576|leishmaniasis
1217769|NCT01083576|cutaneous
1217770|NCT01083576|WR 279,396
1217771|NCT01083576|paromomycin
1217772|NCT01083576|gentamicin
1217773|NCT01083576|pharmacokinetics
1217774|NCT01083576|safety
1217775|NCT01083576|efficacy
1217776|NCT01083563|TNF
1217777|NCT01083563|CD20
1217778|NCT01083563|RA
1217779|NCT01083550|thyroid carcinoma
1217780|NCT01083550|thyroid cancer
1217781|NCT01083550|therapeutic radioisotopes
1217782|NCT01083550|radioactive iodine
1217783|NCT01083537|malignant bowel obstruction
1217784|NCT01083537|ovarian cancer
1217785|NCT01083537|Peritoneal cancer
1217786|NCT01083537|Fallopian Tube cancer
1217787|NCT01083524|Pulmonary arterial hypertension
1217788|NCT01083524|Pulmonary hypertension
1217789|NCT01083524|Dichloroacetate
1217790|NCT01083524|Dichloroacetate Sodium
1217791|NCT01083524|DCA
1217792|NCT01083511|Influenza
1217793|NCT01083511|Influenza A
1217794|NCT01083511|Influenza B
1217795|NCT01083511|Swine Influenza A/H1N1
1217796|NCT01083511|Respiratory Virus
1217797|NCT01083498|Becker's nevus
1217798|NCT01083498|ablative fractional laser therapy
1217799|NCT01083498|randomized controlled trial
1217800|NCT01083498|split-lesion design
1217801|NCT01083485|Oxycodone
1217802|NCT01083485|Naloxone
1217803|NCT01083485|Postoperative pain
1217804|NCT01083485|Arthroplasty
1217805|NCT01083485|Efficacy
1217806|NCT01083472|dehiscence
1217807|NCT01083472|laparotomy
1217808|NCT01083472|Hernia repair
1217809|NCT01083472|surgical wound
1217810|NCT01083472|surgical mesh
1217811|NCT01083446|Encephalopathy
1217812|NCT01083446|Cirrhotics
1217813|NCT01083433|Continuous Glucose Monitor
1217814|NCT01083433|Adherence
1217815|NCT01083433|Adolescents
1217816|NCT01083433|Diabetes Education
1217817|NCT01083420|Oral lichen planus
1217818|NCT01083420|Minocycline
1217819|NCT01083420|Dexamethasone
1217820|NCT01083407|Oral care.
1217821|NCT01083407|Chlorhexidine.
1217822|NCT01083407|Pediatric Nursing
1217823|NCT01083407|Intensive Care
1217824|NCT01083407|Nosocomial infection
1217825|NCT01083407|Pneumonia
1217826|NCT01083407|Oropharyngeal colonization
1217827|NCT01083407|Tracheal colonization
1217828|NCT01083394|PTA
1217829|NCT01083394|paclitaxel
1217830|NCT01083394|restenosis
1217831|NCT01083381|Schizophrenia treatment MS14 randomized clinical trial
1217832|NCT01083368|adenocarcinoma of the prostate
1217833|NCT01083368|hormone-resistant prostate cancer
1217834|NCT01083368|recurrent prostate cancer
1217835|NCT01083368|stage IV prostate cancer
1217836|NCT01083355|Variable ventilation
1217837|NCT01083355|Pressure regulated volume control ventilation
1217838|NCT01083355|Airway pressure release ventilation
1217839|NCT01083342|primary CNS lymphoma
1217840|NCT01083342|MTX: Methotrexate,Leucovorin
1217841|NCT01083342|MVD: Methotrexate,Vincristine,Dexamethasone
1217842|NCT01083342|VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
1217843|NCT01083342|Newly diagnosed primary CNS lymphoma patients
1217844|NCT01083329|nicotinic acid
1217845|NCT01083329|lipolysis
1217846|NCT01083329|training program
1217847|NCT01083329|adipose tissue inflammation
1217848|NCT01083329|obese
1217849|NCT01083316|Amyloid
1217850|NCT01083316|Amyloidosis
1217851|NCT01083316|AL Amyloidosis
1217852|NCT01083316|Primary Amyloidosis
1217853|NCT01083316|Stem Cell Transplant
1217854|NCT01083303|energy expenditure
1217855|NCT01083303|hypothermia
1217856|NCT01083303|body temperature
1217857|NCT01083303|weaning
1217858|NCT01083303|preterm infants
1217859|NCT01083290|spironolactone
1217860|NCT01083290|linearity of pharmacokinetics
1217861|NCT01083290|Healthy volunteers
1217862|NCT01083277|oxygenation
1217863|NCT01083277|ventilation
1217864|NCT01083277|tidal volume
1217865|NCT01083277|patterns of breathing
1217866|NCT01083277|variable ventilation
1217867|NCT01083277|mechanical ventilation
1217868|NCT01083264|Pharmacokinetics
1217869|NCT01083251|HBV
1217870|NCT01083251|VITAMIN D
1217871|NCT01083251|PEGITERFERON
1217872|NCT01083251|Telbivudine
1217873|NCT01083238|pharmacokinetics
1217874|NCT01083238|fasting or after a high fat meal
1217875|NCT01083238|adult
1217876|NCT01083238|elderly adult
1217877|NCT01083238|COPD
1217878|NCT01083212|Type 2 Diabetes Mellitus
1217879|NCT01083212|Gemfibrozil
1217880|NCT01083199|Prostate Cancer
1217881|NCT01083199|Radical Prostatectomy
1217882|NCT01083199|Vesico-Urethral Anastomosis
1217883|NCT01083186|Secondary Hyperparathyroidism
1217884|NCT01083186|Chronic Kidney Failure
1217885|NCT01083173|Postmarketing Drug Surveillance
1217886|NCT01083173|HIV-1 infection
1217887|NCT01083173|Kaletra
1217888|NCT01083160|Rheumatoid Arthritis
1217889|NCT01083160|Anti-TNF
1217890|NCT01083160|Adalimumab
1217891|NCT01083160|Infliximab
1217892|NCT01083160|Etanercept
1217893|NCT01083147|Intermediate AMD
1217894|NCT01083134|CAD
1217895|NCT01083121|Postmarketing Drug Surveillance
1217896|NCT01083108|Behavioral Weight Loss Treatment
1217897|NCT01083108|Bariatric Surgery
1217898|NCT01083108|Diabetes Type II
1217899|NCT01083108|Obesity
1217900|NCT01083108|Adult
1217901|NCT01083108|Type 2 Diabetes
1217902|NCT01083095|Malaria
1217903|NCT01083095|Sporozoite
1217904|NCT01083095|Challenge Model
1217905|NCT01083095|Plasmodium vivax
1217906|NCT01083095|Human Volunteers
1217907|NCT01083082|lifestyles
1217908|NCT01083082|diet
1217909|NCT01083082|exercise
1217910|NCT01083082|central blood pressure
1217911|NCT01083082|arterial stiffness
1217912|NCT01083082|endothelial dysfunction
1217913|NCT01083082|Healthy people
1217914|NCT01083069|Sudden cardiac arrest
1217915|NCT01083069|hypothermia
1217916|NCT01083069|neurological outcome
1217917|NCT01083056|retina
1217918|NCT01083056|gliosis
1217919|NCT01083056|macula
1217920|NCT01083056|membrane
1217921|NCT01083056|ILM
1217922|NCT01083043|Glycemic Variability
1217923|NCT01083043|Endothelial Dysfunction
1217924|NCT01083030|pAVK
1217925|NCT01083030|PTA
1217926|NCT01083030|drug coated balloon
1217927|NCT01083004|dye
1217928|NCT01083004|internal limiting membrane
1217929|NCT01083004|macular hole
1217930|NCT01083004|macular pucker
1217931|NCT01082978|Quality of Life
1217932|NCT01082978|Health Care Quality and Safety
1217933|NCT01082978|Randomized controlled trial
1217934|NCT01082965|ASL MRI
1217935|NCT01082965|perfusion
1217936|NCT01082965|cognition
1217937|NCT01082965|donepezil
1217938|NCT01082965|alzheimer's disease
1217939|NCT01082965|translational medicine
1217940|NCT01082939|Chronic lymphocytic leukemia
1217941|NCT01082939|Refractory CLL
1217942|NCT01082939|CFAR
1217943|NCT01082939|Alemtuzumab
1217944|NCT01082939|Campath-1H
1217945|NCT01082939|Campath
1217946|NCT01082939|Cyclophosphamide
1217947|NCT01082939|Cytoxan
1217948|NCT01082939|Neosar
1217949|NCT01082939|Fludarabine
1217950|NCT01082939|Fludara
1217951|NCT01082939|Fludarabine Phosphate
1217952|NCT01082939|Rituximab
1217953|NCT01082939|Rituxan
1217954|NCT01082939|CLL
1217955|NCT01082926|adult anaplastic astrocytoma
1217956|NCT01082926|adult anaplastic ependymoma
1217957|NCT01082926|adult anaplastic meningioma
1217958|NCT01082926|adult anaplastic oligodendroglioma
1217959|NCT01082926|adult brain stem glioma
1217960|NCT01082926|adult ependymoblastoma
1217961|NCT01082926|adult giant cell glioblastoma
1217962|NCT01082926|adult glioblastoma
1217963|NCT01082926|adult gliosarcoma
1217964|NCT01082926|adult grade III meningioma
1217965|NCT01082926|adult meningeal hemangiopericytoma
1217966|NCT01082926|adult mixed glioma
1217967|NCT01082926|adult pineal gland astrocytoma
1217968|NCT01082926|recurrent adult brain tumor
1217969|NCT01082926|Los Angeles
1217970|NCT01082900|Transient Tachypnea of the Newborn
1217971|NCT01082900|Elective Cesarean section
1217972|NCT01082900|Late preterm
1217973|NCT01082900|CPAP
1217974|NCT01082900|Delivery Room
1217975|NCT01082887|Immunotherapy TIL (Tumor Infiltrating Lymphocytes)
1217976|NCT01082887|Intra-tumoral injection
1217977|NCT01082887|Interferon gamma-adenovirus(Ad-IFNg)
1217978|NCT01082887|Metastatic melanoma
1217979|NCT01082887|A stage IIIc/IV metastatic melanoma with nodal relapse
1217980|NCT01082887|in transit metastasis
1217981|NCT01082887|cutaneous unresectable metastases
1217982|NCT01082887|visceral metastases
1217983|NCT01082874|Randomized Controlled Trial
1217984|NCT01082874|Blinded
1217985|NCT01082874|Clonidine
1217986|NCT01082874|acetyl-salicylic acid (ASA)
1217987|NCT01082874|Perioperative vascular complications
1217988|NCT01082874|Noncardiac surgery
1217989|NCT01082861|1998 female birth cohort eligible for HPV vaccination in 2011 within the Dutch NIP
1217990|NCT01082835|Chinese herbs
1217991|NCT01082822|cell sheet PDLSC periodontitis
1217992|NCT01082809|advanced biliary tract carcinoma
1217993|NCT01082809|Sunitinib
1217994|NCT01082783|stroke-induced immunodepression
1217995|NCT01082783|acute media infarct
1217996|NCT01082783|acute intracerebral bleeding
1217997|NCT01082783|leucocytes
1217998|NCT01082783|autoaggressive T-cells
1217999|NCT01082783|acute media infarct or acute intracerebral bleeding
1218000|NCT01082757|Colorectal neoplasms
1218001|NCT01082757|metastasis
1218002|NCT01082757|colorectal cancer
1218003|NCT01082744|Paravertebral Block
1218004|NCT01082744|Regional Anesthesia
1218005|NCT01082744|Anesthetics Local
1218006|NCT01082744|Ropivacaine
1218007|NCT01082744|Sufentanil
1218008|NCT01082744|Pain Postoperative
1218009|NCT01082744|Chronic Pain
1218010|NCT01082744|Thoracic Surgery Video-Assisted.
1218011|NCT01082731|Malaria
1218012|NCT01082731|Plasmodium falciparum
1218013|NCT01082731|Treatment
1218014|NCT01082731|Brazil
1218015|NCT01082718|Malaria
1218016|NCT01082718|Pregnancy
1218017|NCT01082718|Pharmacokinetics
1218018|NCT01082718|Brazil
1218019|NCT01082705|malaria
1218020|NCT01082705|treatment
1218021|NCT01082705|artemisinin combination therapy
1218022|NCT01082705|Tanzania
1218023|NCT01082705|P. falciparum malaria in children age 6-59 months
1218024|NCT01082692|HIV Infection
1218025|NCT01082692|DNA vaccine
1218026|NCT01082692|Electroporation
1218027|NCT01082692|HIV therapeutic vaccine
1218028|NCT01082679|opioid dependent
1218029|NCT01082679|methadone
1218030|NCT01082679|Suboxone
1218031|NCT01082679|buprenorphine
1218032|NCT01082666|Cuff pressure
1218033|NCT01082666|microaspiration
1218034|NCT01082666|pepsin
1218035|NCT01082666|VAP
1218036|NCT01082666|Mechanical ventilation
1218037|NCT01082653|ALS
1218038|NCT01082653|Lou Gehrig's Disease
1218039|NCT01082640|Gout
1218040|NCT01082640|physiology
1218041|NCT01082640|Hyperuricemia
1218042|NCT01082640|Uric Acid
1218043|NCT01082640|Drug Therapy
1218044|NCT01082627|Somatostatin small bowel obstruction
1218045|NCT01082601|Catheter Ablation
1218046|NCT01082601|Atrial Fibrillation
1218047|NCT01082601|Congestive heart failure
1218048|NCT01082588|schizophrenia
1218049|NCT01082588|pravastatin
1218050|NCT01082588|inflammation
1218051|NCT01082588|cognition
1218052|NCT01082588|antipsychotics
1218053|NCT01082588|cholesterol
1218054|NCT01082575|Post Op Patients
1218055|NCT01082575|Continuous Pulse Oximetry Monitoring
1218056|NCT01082575|Major Surgery
1218057|NCT01082549|Patients with Previously Untreated Advanced Squamous Cell Lung Cancer
1218058|NCT01082536|Pediatrics
1218059|NCT01082536|Congenital heart disease
1218060|NCT01082536|NIRS
1218061|NCT01082536|Brain oxygenation
1218062|NCT01082510|UFT
1218063|NCT01082510|BCG
1218064|NCT01082497|Mindfulness
1218065|NCT01082497|Stress
1218066|NCT01082497|Burnout
1218067|NCT01082497|Ward atmosphere
1218068|NCT01082497|Stress and burnout among staff, psychosocial atmosphere at the ward
1218069|NCT01082484|Healthy volunteers
1218070|NCT01082484|iontophoresis
1218071|NCT01082471|Morphine 6-glucuronide
1218072|NCT01082471|Morphine
1218073|NCT01082471|Patient Controlled Analgesia
1218074|NCT01082471|Post Operative Nausea and Vomiting
1218075|NCT01082458|Patients scheduled to undergo thyroidectomy
1218076|NCT01082445|stage C
1218077|NCT01082445|grade 0 (Texas University)
1218078|NCT01082432|thumb
1218079|NCT01082432|Ulnar collateral ligament
1218080|NCT01082432|superimposed electrical stimulation
1218081|NCT01082432|stiffness
1218082|NCT01082432|adhesions
1218083|NCT01082419|Liver stiffness measurement
1218084|NCT01082419|ARFI
1218085|NCT01082419|fibrosis
1218086|NCT01082419|hepatopathy
1218087|NCT01082393|vitiligo
1218088|NCT01082380|radiolabeled
1218089|NCT01082380|healthy volunteers
1218090|NCT01082367|Tobramycin Inhalation solution
1218091|NCT01082367|Cystic fibrosis
1218092|NCT01082367|Lung disease
1218093|NCT01082367|anti-bacterial agents
1218094|NCT01082354|Infant, Low birth weight
1218095|NCT01082354|Infant, Low birth height
1218096|NCT01082354|Infant, Small for Gestational Age
1218097|NCT01082341|GCP Good Clinical Practice
1218098|NCT01082341|IFAT Indirect Immunofluorescence antibody test
1218099|NCT01082341|MFA Membrane Feeding Assay
1218100|NCT01082341|N Number (typically refers to subjects)
1218101|NCT01082341|RBC Red Blood Cells
1218102|NCT01082341|SOP Standard Operating Procedure
1218103|NCT01082341|TBS Thick blood smear
1218104|NCT01082341|P. Vivax
1218105|NCT01082341|irradiated sporozoite vaccination.
1218106|NCT01082328|Phenylketonuria (PKU)
1218107|NCT01082328|Hyperphenylalaninemia (HPA)
1218108|NCT01082328|Kuvan®
1218109|NCT01082328|Sapropterin dihydrochloride
1218110|NCT01082328|Kuvan responder
1218111|NCT01082328|Tetrahydrobiopterin (BH4)
1218112|NCT01082315|Colorectal cancer
1218113|NCT01082315|Neoplasm metastasis
1218114|NCT01082315|Cetuximab
1218115|NCT01082315|Erbitux
1218116|NCT01082315|EGFR
1218117|NCT01082302|green tea extract
1218118|NCT01082302|Polyphenon E
1218119|NCT01082302|Pharmacokinetics
1218120|NCT01082289|Lurasidone
1218121|NCT01082289|Schizophrenia
1218122|NCT01082289|Latuda
1218123|NCT01082276|Rifampin DDI with Lurasidone HCl
1218124|NCT01082263|DDI study between Midazolam and Lurasidone HCl
1218125|NCT01082263|Male and Female
1218126|NCT01082250|Bioequivalence
1218127|NCT01082250|Male/Female Patient
1218128|NCT01082250|Reference/Test Formulation
1218129|NCT01082250|Schizophrenia Patients
1218130|NCT01082237|Major Depressive Disorder
1218131|NCT01082237|EEG
1218132|NCT01082237|SSRI
1218133|NCT01082224|adult primary hepatocellular carcinoma
1218134|NCT01082224|localized unresectable adult primary liver cancer
1218135|NCT01082224|recurrent adult primary liver cancer
1218136|NCT01082211|invasive ductal breast carcinoma
1218137|NCT01082211|medullary ductal breast carcinoma with lymphocytic infiltrate
1218138|NCT01082211|invasive lobular breast carcinoma
1218139|NCT01082211|tubular ductal breast carcinoma
1218140|NCT01082211|mucinous ductal breast carcinoma
1218141|NCT01082211|ductal breast carcinoma in situ
1218142|NCT01082211|lobular breast carcinoma in situ
1218143|NCT01082211|recurrent breast cancer
1218144|NCT01082198|stage III melanoma
1218145|NCT01082185|abdominal
1218146|NCT01082185|aortic
1218147|NCT01082185|aneurysm
1218148|NCT01082185|AAA
1218149|NCT01082172|thoracic
1218150|NCT01082172|aortic
1218151|NCT01082172|aneurysm
1218152|NCT01082172|TAA
1218153|NCT01082159|Spinal Stenosis
1218154|NCT01082159|Lumbar Spinal Stenosis
1218155|NCT01082146|pharmacokinetics, lurasidone
1218156|NCT01082133|Fanconi Anemia
1218157|NCT01082120|Type 2 Diabetes Mellitus
1218158|NCT01082120|Pioglitazone
1218159|NCT01082094|Ischemic heart failure
1218160|NCT01082094|Congestive heart failure
1218161|NCT01082094|Stromal cell-derived factor 1
1218162|NCT01082094|SDF-1
1218163|NCT01082094|Gene therapy
1218164|NCT01082081|paracetamol
1218165|NCT01082081|dental pain
1218166|NCT01082081|Post-surgical dental pain
1218167|NCT01082068|HER2 negative
1218168|NCT01082068|Hormone Receptor Positive
1218169|NCT01082068|Breast Neoplasms
1218170|NCT01082055|Cardiac
1218171|NCT01082055|Dysrhythmia
1218172|NCT01082055|Safety
1218173|NCT01082042|Balance, postural
1218174|NCT01082042|Aged, over 70
1218175|NCT01082042|Exercise
1218176|NCT01082042|Accidental falls
1218177|NCT01082016|Sleep
1218178|NCT01082016|Critical Illness
1218179|NCT01082016|Sleep promotion during recovery form illness
1218180|NCT01082003|Capsular contractures in breast cancer patients
1218181|NCT01081977|Delayed cord clamping
1218182|NCT01081977|Ferritin
1218183|NCT01081977|Hemoglobin
1218184|NCT01081977|Neonatal anemia
1218185|NCT01081977|Postpartum haemorrhage
1218186|NCT01081977|Neonatal jaundice
1218187|NCT01081964|pneumonia
1218188|NCT01081964|Community acquired pneumonia of moderate severity
1218189|NCT01081951|Poly(ADP ribose)
1218190|NCT01081951|polymerisation (PARP)
1218191|NCT01081951|Platinum sensitive
1218192|NCT01081951|Advanced Serous Ovarian cancer
1218193|NCT01081951|olaparib
1218194|NCT01081951|PARP inhibitors
1218195|NCT01081951|Platinum Sensitive Advanced Serous Ovarian Cancer
1218196|NCT01081925|Congestive Heart Failure
1218197|NCT01081925|Cardiac Failure
1218198|NCT01081912|chronic pain
1218199|NCT01081912|back pain
1218200|NCT01081899|dying patients
1218201|NCT01081899|cancer
1218202|NCT01081899|hospital
1218203|NCT01081899|Liverpool Care Pathways
1218204|NCT01081886|Total knee arthroplasty
1218205|NCT01081886|PlasmaBlade
1218206|NCT01081886|Electrosurgery
1218207|NCT01081886|PEAK Surgical
1218208|NCT01081886|Medtronic Advanced Energy
1218209|NCT01081886|Medtronic
1218210|NCT01081873|Multicenter study
1218211|NCT01081860|Carpal tunnel syndrome
1218212|NCT01081860|CTS
1218213|NCT01081860|Skinstiffness
1218214|NCT01081860|Jointstiffness
1218215|NCT01081847|Malaria
1218216|NCT01081847|Synthetic peptides
1218217|NCT01081847|Plasmodium vivax
1218218|NCT01081847|Human volunteers
1218219|NCT01081834|Diabetes Mellitus, Type 2
1218220|NCT01081834|Canagliflozin
1218221|NCT01081834|Placebo
1218222|NCT01081834|Hemoglobin A1c
1218223|NCT01081834|Type 2 diabetes mellitus
1218224|NCT01081821|JNJ 39758979
1218225|NCT01081821|Japanese descent
1218226|NCT01081808|PhaseI
1218227|NCT01081808|Solid Tumor
1218228|NCT01081808|biomarkers
1218229|NCT01081808|T cell
1218230|NCT01081808|Cetuximab
1218231|NCT01081808|Epidermal Growth Factor Receptor
1218232|NCT01081808|Aldesleukin
1218233|NCT01081808|Lymphocytes
1218234|NCT01081808|Autologous
1218235|NCT01081808|Recurrent
1218236|NCT01081808|Refractory
1218237|NCT01081808|Metastatic
1218238|NCT01081808|Immunotherapy
1218239|NCT01081808|Antibodies
1218240|NCT01081808|Neoplasms by Site
1218241|NCT01081808|Anti-Retroviral Agents
1218242|NCT01081808|Therapeutic Uses
1218243|NCT01081808|Anti-Infective Agents
1218244|NCT01081808|Neoplasms by Histologic Type
1218245|NCT01081808|Antineoplastic Agents
1218246|NCT01081808|Antiviral Agents
1218247|NCT01081808|Pharmacologic Actions
1218248|NCT01081808|Carcinoma
1218249|NCT01081808|Neoplasms
1218250|NCT01081795|Topiramate
1218251|NCT01081795|Migraine
1218252|NCT01081782|Multiple Sclerosis
1218253|NCT01081782|ONO-4641
1218254|NCT01081769|Schizophrenia
1218255|NCT01081769|paliperidone palmitate
1218256|NCT01081769|Invega
1218257|NCT01081769|Intramuscular injection
1218258|NCT01081769|Oral antipsychotics
1218259|NCT01081769|Relapse
1218260|NCT01081756|Reproductive technology; Assisted
1218261|NCT01081756|recombinant human chorionic hormone (r-hCG)
1218262|NCT01081743|Alzheimer
1218263|NCT01081743|Dementia
1218264|NCT01081743|Mild to moderately severe
1218265|NCT01081743|New diagnosis
1218266|NCT01081743|Prevention of behavioural problems
1218267|NCT01081730|psoriasis
1218268|NCT01081730|ustekinumab
1218269|NCT01081730|anti-TNF biologics
1218270|NCT01081730|non-anti-TNF biologics
1218271|NCT01081730|systemic non-biological treatments
1218272|NCT01081717|Rheumatoid arthritis
1218273|NCT01081717|psoriatic arthritis
1218274|NCT01081717|ankylosing spondylitis
1218275|NCT01081717|golimumab
1218276|NCT01081717|anti-TNF biologics
1218277|NCT01081717|non-anti-TNF biologics
1218278|NCT01081717|non-biological treatments
1218279|NCT01081704|Healthy volunteer
1218280|NCT01081704|Chinese male
1218281|NCT01081704|Stelara
1218282|NCT01081691|CNTO 5825
1218283|NCT01081691|Safety
1218284|NCT01081691|Phase I
1218285|NCT01081691|Healthy adults
1218286|NCT01081691|Healthy Atopic adults
1218287|NCT01081678|AMG 785
1218288|NCT01081678|Proximal Femur
1218289|NCT01081678|Fracture Healing
1218290|NCT01081678|Hip Fracture
1218291|NCT01081665|Chronic Kidney Failure
1218292|NCT01081665|Secondary Hyperparathyroidism
1218293|NCT01081665|Paricalcitol IV treatment
1218294|NCT01081665|Safety and efficacy assessment
1218295|NCT01081652|Fertilisation, In vitro
1218296|NCT01081652|Embryo transfer
1218297|NCT01081652|progesterone
1218298|NCT01081652|Reproductive technologies, Assisted
1218299|NCT01081639|Follitropin alfa
1218300|NCT01081639|Follitropin beta
1218301|NCT01081639|Fertilization, in vitro
1218302|NCT01081639|Intracytoplasmic sperm injection
1218303|NCT01081639|Assisted reproductive techniques
1218304|NCT01081639|Polycystic ovary syndrome
1218305|NCT01081626|Infertility
1218306|NCT01081626|Ovulation induction
1218307|NCT01081626|Gonal-f
1218308|NCT01081626|Follitropin alpha
1218309|NCT01081626|Polycystic ovarian syndrome
1218310|NCT01081626|Anovulatory infertility
1218311|NCT01081613|heat shock protein
1218312|NCT01081613|breast cancer
1218313|NCT01081613|PET imaging
1218314|NCT01081613|bevacizumab
1218315|NCT01081600|Heat shock protein
1218316|NCT01081600|breast cancer
1218317|NCT01081600|PET imaging
1218318|NCT01081600|trastuzumab
1218319|NCT01081587|Non MeSH terms:
1218320|NCT01081587|Children
1218321|NCT01081587|Malnutrition
1218322|NCT01081587|Computer Clinical Decision Support System
1218323|NCT01081587|Cluster randomized trial
1218324|NCT01081587|Healthcare workers
1218325|NCT01081587|Guideline adherence
1218326|NCT01081587|Patient safety
1218327|NCT01081587|MeSH terms:
1218328|NCT01081587|Nutrition Surveys
1218329|NCT01081587|Secondary Prevention
1218330|NCT01081587|Pediatrics
1218331|NCT01081587|Child Care
1218332|NCT01081587|Health Personnel
1218333|NCT01081587|Reminder Systems
1218334|NCT01081587|Intervention Studies
1218335|NCT01081587|Quality of Health Care
1218336|NCT01081574|Allergic Rhinitis
1218337|NCT01081574|Seasonal Allergic Rhinitis
1218338|NCT01081574|Perennial Allergic Rhinitis
1218339|NCT01081574|Urticaria
1218340|NCT01081574|Chronic Idiopathic Urticaria
1218341|NCT01081574|Allergy
1218342|NCT01081574|Sneezing
1218343|NCT01081574|Nasal Itching
1218344|NCT01081574|Rhinorrhea
1218345|NCT01081574|Nasal Congestion
1218346|NCT01081574|Wheals
1218347|NCT01081574|Hives
1218348|NCT01081574|Skin itching
1218349|NCT01081574|Flare
1218350|NCT01081574|Erythema
1218476|NCT01081028|Multiple Myeloma
1218351|NCT01081535|Pediatric patients (6 months-5 years) scheduled elective ureteroneocystostomy
1218352|NCT01081509|adherence
1218353|NCT01081509|early breast cancer
1218354|NCT01081509|Arimidex
1218355|NCT01081509|Therapy adherence
1218356|NCT01081496|EGFR mutation, Non-small cell lung carcinoma, Spain
1218357|NCT01081496|Evaluate the prevalence of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC
1218358|NCT01081483|Healthy Volunteers
1218359|NCT01081483|HCV Infections
1218360|NCT01081457|Parkinson's disease
1218361|NCT01081457|deep brain stimulation
1218362|NCT01081457|GI motility
1218363|NCT01081444|repetitive transcranial stimulation
1218364|NCT01081431|Myelodysplastic Syndromes
1218365|NCT01081431|MDS
1218366|NCT01081431|deletion 5q
1218367|NCT01081431|del 5q
1218368|NCT01081431|IPSS
1218369|NCT01081431|low risk
1218370|NCT01081431|intermediate-1 risk
1218371|NCT01081431|GMIHO
1218372|NCT01081431|ClinAssess
1218373|NCT01081431|Germing
1218374|NCT01081431|Düsseldorf
1218375|NCT01081431|MDS-LE-MON-5
1218376|NCT01081431|Lenalidomide
1218377|NCT01081431|Revlimid
1218378|NCT01081418|Schizophrenia, assertive community treatment, quetiapine
1218379|NCT01081405|ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
1218380|NCT01081405|TOTAL LYMPHOID IRRADIATION
1218381|NCT01081405|ANTI-THYMOCYTE GLOBULIN
1218382|NCT01081392|LPS
1218383|NCT01081392|endotoxin
1218384|NCT01081392|inflammatory markers
1218385|NCT01081392|healthy volunteers
1218386|NCT01081392|neutrophils in sputum
1218387|NCT01081379|Cytomegalovirus Infections
1218388|NCT01081379|Pregnancy
1218389|NCT01081379|T-Lymphocytes
1218390|NCT01081379|Transmission
1218391|NCT01081353|Aspirin
1218392|NCT01081353|Acetylsalicylic Acid
1218393|NCT01081340|gestational weight gain
1218394|NCT01081340|postpartum weight loss
1218395|NCT01081340|breastfeeding
1218396|NCT01081340|overfeeding
1218397|NCT01081327|Atrial Fibrillation
1218398|NCT01081327|Warfarin
1218399|NCT01081327|Safety
1218400|NCT01081301|hope
1218401|NCT01081301|quality of life
1218402|NCT01081301|caregivers
1218403|NCT01081288|Breast cancer
1218404|NCT01081288|Breast screening
1218405|NCT01081288|Mammography
1218406|NCT01081288|Routine screening programme
1218407|NCT01081275|Multiple Sclerosis
1218408|NCT01081275|MS
1218409|NCT01081275|CI Therapy
1218410|NCT01081275|CIMT
1218411|NCT01081275|Constraint-Induced Movement Therapy
1218412|NCT01081275|Complementary and Alternative Medicine
1218413|NCT01081275|CAM
1218414|NCT01081275|Physical Therapy
1218415|NCT01081275|Occupational Therapy
1218416|NCT01081275|Relaxation
1218417|NCT01081275|Exercise
1218418|NCT01081275|Massage
1218419|NCT01081275|Yoga
1218420|NCT01081275|Pool Therapy
1218421|NCT01081275|Aquatherapy
1218422|NCT01081275|Aquatic Therapy
1218423|NCT01081249|psychotherapy
1218424|NCT01081236|liver cirrhosis
1218425|NCT01081236|intestinal permeability
1218426|NCT01081236|microbiota
1218427|NCT01081236|complications
1218428|NCT01081223|Brain Neoplasms
1218429|NCT01081223|Central Nervous System Neoplasms
1218430|NCT01081223|Brain Diseases
1218431|NCT01081223|Neoplasms
1218432|NCT01081223|Nervous System Neoplasms
1218433|NCT01081223|Glioblastoma
1218434|NCT01081223|Astrocytoma
1218435|NCT01081223|Nervous System Diseases
1218436|NCT01081223|Central Nervous System Diseases
1218437|NCT01081223|Glioma
1218438|NCT01081223|Recurrent astrocytoma
1218439|NCT01081223|Recurrent glioma
1218440|NCT01081223|Cancer vaccine
1218441|NCT01081223|Immunotherapy
1218442|NCT01081223|Killer T cells
1218443|NCT01081223|Activated T cells
1218444|NCT01081223|GM-CSF
1218445|NCT01081223|Low dose IL-2
1218446|NCT01081223|Activated lymphocytes
1218447|NCT01081210|Echocardiography
1218448|NCT01081210|Heart failure
1218449|NCT01081210|Kidney
1218450|NCT01081210|Lung
1218451|NCT01081210|Aorta
1218452|NCT01081197|heart failure
1218453|NCT01081197|liver
1218454|NCT01081197|depression
1218455|NCT01081197|neuropathy
1218456|NCT01081184|primary Sjögren syndrome
1218457|NCT01081184|neurotrophins
1218458|NCT01081184|B cell
1218459|NCT01081184|sicca syndrome
1218460|NCT01081184|T cell
1218461|NCT01081119|adolescent
1218462|NCT01081119|middle school
1218463|NCT01081119|prevention
1218464|NCT01081119|alcohol
1218465|NCT01081119|cigarettes
1218466|NCT01081119|marijuana
1218467|NCT01081106|Breast Cancer
1218468|NCT01081093|Hypertrophic Cardiomyopathy Diastolic Ventricular Interaction
1218469|NCT01081093|Biventricular Pacemaker cardiac surgery aortic valve replacement
1218470|NCT01081080|cardiac
1218471|NCT01081080|muscle
1218472|NCT01081080|pediatric
1218473|NCT01081080|dystrophy
1218474|NCT01081054|Diverticulitis
1218475|NCT01081054|Not complicated diverticulitis
1218477|NCT01081028|MM
1218478|NCT01081028|disease registry
1218479|NCT01081028|Connect®
1218480|NCT01081015|Chronic Lymphocytic Leukemia
1218481|NCT01081015|CLL
1218482|NCT01081015|disease registry
1218483|NCT01081015|Connect™
1218484|NCT01081002|Propofol
1218485|NCT01081002|Conscious sedation
1218486|NCT01081002|Topical pharyngeal anesthesia
1218487|NCT01081002|Anesthetics, Local
1218488|NCT01081002|Gastrointestinal Endoscopy
1218489|NCT01080989|solomon islands
1218490|NCT01080989|malaria
1218491|NCT01080989|flavivirus
1218492|NCT01080989|alphavirus
1218493|NCT01080989|parasite
1218494|NCT01080989|leptospirosis
1218495|NCT01080963|Prophylaxis
1218496|NCT01080963|Antibiotic
1218497|NCT01080963|Sternotomy
1218498|NCT01080963|Heart-Lung Machine
1218499|NCT01080950|zinc
1218500|NCT01080950|sepsis
1218501|NCT01080950|fever
1218502|NCT01080950|vitamin d
1218503|NCT01080937|acute heart failure
1218504|NCT01080911|Spinal morphine
1218505|NCT01080911|Vaginal hysterectomy
1218506|NCT01080898|Age - Related Macular Degeneration
1218507|NCT01080898|Optical Coherence Tomography
1218508|NCT01080898|Choroidal neovascularization
1218509|NCT01080898|FLORESCEIN Angiography
1218510|NCT01080898|Fundus photographs
1218511|NCT01080885|Prevention
1218512|NCT01080885|Prevention of unhealthy weight gain
1218513|NCT01080872|acute coronary syndrome
1218514|NCT01080872|coronary flow reserve
1218515|NCT01080872|OCT
1218516|NCT01080872|healing
1218517|NCT01080872|drug eluting stent
1218518|NCT01080859|titanium
1218519|NCT01080859|everolimus
1218520|NCT01080859|oct
1218521|NCT01080859|acute coronary syndrome
1218522|NCT01080859|stent
1218523|NCT01080859|pci
1218524|NCT01080859|stenting
1218525|NCT01080846|Primary postpartum hemorrhage
1218526|NCT01080846|PPH
1218527|NCT01080846|uterine atony
1218528|NCT01080846|high fever
1218529|NCT01080846|hyperpyrexia
1218530|NCT01080833|EMS
1218531|NCT01080833|ERCP
1218532|NCT01080833|Training
1218533|NCT01080833|Trainees
1218534|NCT01080820|Healthy adult volunteers
1218535|NCT01080820|Pharmacokinetics
1218536|NCT01080794|Parkinson's Disease
1218537|NCT01080794|Depression
1218538|NCT01080794|Transcranial Magnetic Stimulation
1218539|NCT01080781|Cardiomyopathy
1218540|NCT01080781|Ephrin-B1 expression
1218541|NCT01080781|cell-cell junctions
1218542|NCT01080781|heart rate variability
1218543|NCT01080781|right appendage
1218544|NCT01080768|Pedal edema
1218545|NCT01080768|hypertension
1218546|NCT01080768|aliskiren
1218547|NCT01080768|amlodipine
1218548|NCT01080755|Adult Growth Hormone Deficiency
1218549|NCT01080755|Pituitary
1218550|NCT01080755|Saizen
1218551|NCT01080755|Somatropin
1218552|NCT01080755|Growth Hormone
1218553|NCT01080742|Hypertension
1218554|NCT01080742|Lodoz
1218555|NCT01080742|Bisoprolol
1218556|NCT01080742|Hydrochlorothiazide
1218557|NCT01080729|Ovulation induction
1218558|NCT01080729|Ovarian Hyperstimulation Syndrome
1218559|NCT01080729|Multifollicular stimulation
1218560|NCT01080729|Pregnancy
1218561|NCT01080729|Sperm injections, intracytoplasmic
1218562|NCT01080729|Fertility
1218563|NCT01080703|Lung Transplant
1218564|NCT01080703|Quadriceps Strength
1218565|NCT01080703|Quality of Life
1218566|NCT01080703|Patients with pulmonary disease awaiting lung transplant.
1218567|NCT01080690|endosonography, right side abdominal pain
1218568|NCT01080690|Endosonography (diagnostic value in right side abdominal pain)
1218569|NCT01080664|AS703569
1218570|NCT01080664|Aurora Kinase Inhibitor
1218571|NCT01080664|Haematological malignancies
1218572|NCT01080638|abciximab
1218573|NCT01080638|Myocardial Infarction
1218574|NCT01080638|angioplasty
1218575|NCT01080638|Platelet
1218576|NCT01080625|postreperfusion syndrome
1218577|NCT01080625|phenylephrine
1218578|NCT01080625|epinephrine
1218579|NCT01080625|liver transplantation
1218580|NCT01080612|pregabalin
1218581|NCT01080612|pharmacokinetics
1218582|NCT01080612|bioavailability
1218583|NCT01080599|obturator nerve block in TURB
1218584|NCT01080586|Bioequivalence study in healthy volunteers
1218585|NCT01080573|Multiple sclerosis
1218586|NCT01080573|Rebif
1218587|NCT01080573|Interferon beta-1a
1218588|NCT01080560|Bioequivalence study in healthy volunteers
1218589|NCT01080534|Bioequivalence study in healthy volunteers
1218590|NCT01080508|pressure pattern
1218591|NCT01080508|esophageal and tracheal ventilation.
1218592|NCT01080508|esophageal intubation.
1218593|NCT01080495|left ventricular function
1218594|NCT01080495|radial strain
1218595|NCT01080495|fractional shortening
1218596|NCT01080495|fractional area change
1218597|NCT01080482|Bioequivalence study in healthy volunteers
1218598|NCT01080469|Bioequivalence study in healthy volunteers
1218599|NCT01080456|Bioequivalence study in healthy volunteers
1218600|NCT01080443|Bioequivalence study in healthy volunteers
1218601|NCT01080430|vestibular
1218602|NCT01080430|vertigo
1218603|NCT01080430|rehabilitation
1218604|NCT01080430|rotation
1218605|NCT01080430|balance
1218606|NCT01080417|Bioequivalence study in healthy volunteers
1218607|NCT01080404|Obstructive sleep apnea
1218608|NCT01080404|Obesity
1218609|NCT01080404|Metabolism
1218610|NCT01080404|Bariatric surgery
1218611|NCT01080404|CPAP
1218612|NCT01080391|Multiple Myeloma
1218613|NCT01080352|Prostate cancer
1218614|NCT01080352|palliative care
1218615|NCT01080352|antioxidants
1218616|NCT01080352|ascorbic acid
1218617|NCT01080352|rna expression
1218618|NCT01080339|insulin resistance
1218619|NCT01080339|cardiovascular risk
1218620|NCT01080339|physical activity
1218621|NCT01080339|child
1218622|NCT01080326|ulcer repair surgery
1218623|NCT01080326|transluminal omental patch
1218624|NCT01080300|Hot Flushes
1218625|NCT01080300|Vasomotor Symptoms
1218626|NCT01080300|Menopausal Hot Flashes
1218627|NCT01080287|autonomic
1218628|NCT01080287|orthostatic
1218629|NCT01080287|syncope
1218630|NCT01080287|biopsy
1218631|NCT01080287|prevalence of autonomic dysfunction in migraineurs with orthostatic intolerance
1218632|NCT01080287|characterize autonomic findings utilizing neurocardiac testing, neurophysiological testing and skin biopsies to analyze autonomic fibers in the dermis
1218633|NCT01080274|ergometry
1218634|NCT01080274|vitamin d
1218635|NCT01080274|zinc
1218636|NCT01080261|Atherosclerosis
1218637|NCT01080261|Coronary Artery Disease
1218638|NCT01080248|Pancreas
1218639|NCT01080235|quality improvement
1218640|NCT01080235|geriatric care
1218641|NCT01080235|residency training
1218642|NCT01080222|VX-950
1218643|NCT01080196|Falling risk
1218644|NCT01080196|muscle conditioning
1218645|NCT01080196|whole muscle volume
1218646|NCT01080196|isometric strength and concentric power
1218647|NCT01080196|Incidence in falls following a 3 month multi-component fall reduction exercise program
1218648|NCT01080183|Health-related quality of life
1218649|NCT01080183|physical activity
1218650|NCT01080170|Aromatase Inhibitor
1218651|NCT01080170|Anastrazole
1218652|NCT01080170|Arimidex
1218653|NCT01080170|Heart disease
1218654|NCT01080170|Lipids
1218655|NCT01080170|Body composition
1218656|NCT01080170|Breast cancer.
1218657|NCT01080157|Diabetes
1218658|NCT01080157|Diabetes Screening
1218659|NCT01080157|Experimental Medical Device
1218660|NCT01080144|Cirrhosis
1218661|NCT01080144|TIPS (Transjugular intrahepatic portosystemic shunt)
1218662|NCT01080144|Encephalopathy
1218663|NCT01080131|Frequent flares
1218664|NCT01080131|Gout
1218665|NCT01080131|Anti-interleukin-1β monoclonal antibody
1218666|NCT01080118|Teaching
1218667|NCT01080118|Video Scope
1218668|NCT01080118|Intubation
1218669|NCT01080105|Depression Prevention
1218670|NCT01080105|Prevention
1218671|NCT01080105|Major Depressive Disorder
1218672|NCT01080105|Internet
1218673|NCT01080105|Technology Assisted
1218674|NCT01080092|smokers
1218675|NCT01080079|Onychomycosis
1218676|NCT01080066|Carcinoma
1218677|NCT01080066|Squamous cell
1218678|NCT01080066|Erbitux
1218679|NCT01080066|cetuximab
1218680|NCT01080066|Head
1218681|NCT01080066|Neck
1218682|NCT01080053|Multiple Sclerosis, Relapsing Remitting
1218683|NCT01080053|Sexual dysfunction
1218684|NCT01080040|Multiple Sclerosis, Relapsing Remitting
1218685|NCT01080040|Quality of life
1218686|NCT01080027|Multiple sclerosis
1218687|NCT01080027|Relapsing remitting
1218688|NCT01080027|Rebif
1218689|NCT01080014|Relapsing-remitting multiple sclerosis (RRMS)
1218690|NCT01080014|primary progressive multiple sclerosis (PPMS)
1218691|NCT01080014|secondary progressive multiple sclerosis (SPMS)
1218692|NCT01080014|Multiple Sclerosis Functional Composite (MSFC)
1218693|NCT01080014|Expanded Disability Status Scale (EDSS)
1218694|NCT01080001|Multiple sclerosis
1218695|NCT01080001|Multiple sclerosis, Relapsing-remitting
1218696|NCT01080001|Expanded Disability Status Scale
1218697|NCT01080001|Fatigue
1218698|NCT01080001|Hamilton Depression Inventory
1218699|NCT01080001|Depression
1218700|NCT01079988|Psoriasis
1218701|NCT01079988|Discontinuation of efalizumab
1218702|NCT01079988|Managing inflammatory recurrence
1218703|NCT01079975|Multiple sclerosis
1218704|NCT01079975|Depression
1218705|NCT01079962|Bisoprolol
1218706|NCT01079962|Atenolol
1218707|NCT01079962|Hypertension
1218708|NCT01079962|Blood pressure
1218709|NCT01079949|Infertility
1218710|NCT01079949|Ovulation induction
1218711|NCT01079949|Luveris
1218712|NCT01079949|Lutropin alfa
1218713|NCT01079949|Controlled ovarian stimulation
1218714|NCT01079949|Reproductive technologies, Assisted
1218715|NCT01079936|Multiple Myeloma
1218716|NCT01079936|Lenalidomide
1218717|NCT01079936|Revlimid
1218718|NCT01079936|Melphalan
1218719|NCT01079936|Alkeran
1218720|NCT01079936|Autologous stem cell transplantation
1218721|NCT01079936|High-dose chemotherapy
1218722|NCT01079923|healthy volunteers
1218723|NCT01079923|healthy subjects
1218724|NCT01079923|vitamin D
1218725|NCT01079923|cholecalciferol
1218726|NCT01079923|vitamin D3
1218727|NCT01079923|total vitamin D
1218728|NCT01079910|Plaque
1218729|NCT01079910|Toothpaste
1218730|NCT01079910|Gingivitis
1218731|NCT01079897|Atopic dermatitis
1218732|NCT01079897|Ectoine
1218733|NCT01079897|Treatment
1218734|NCT01079897|Atopiclair
1218735|NCT01079897|Medical device
1218736|NCT01079871|Sjogren's Syndrome
1218737|NCT01079871|Dry Eye
1218859|NCT01079286|Akt inhibition
1218738|NCT01079858|Meibomian Gland Dysfunction
1218739|NCT01079858|Dry Eye
1218740|NCT01079845|Diet
1218741|NCT01079845|Nutrition
1218742|NCT01079845|Adolescent
1218743|NCT01079845|Young Adult
1218744|NCT01079845|Overweight
1218745|NCT01079845|Obesity
1218746|NCT01079793|adenocarcinoma of the prostate
1218747|NCT01079793|stage III prostate cancer
1218748|NCT01079780|mucinous adenocarcinoma of the colon
1218749|NCT01079780|recurrent colon cancer
1218750|NCT01079780|signet ring adenocarcinoma of the colon
1218751|NCT01079780|stage III colon cancer
1218752|NCT01079780|stage IV colon cancer
1218753|NCT01079780|mucinous adenocarcinoma of the rectum
1218754|NCT01079780|recurrent rectal cancer
1218755|NCT01079780|signet ring adenocarcinoma of the rectum
1218756|NCT01079780|stage III rectal cancer
1218757|NCT01079780|stage IV rectal cancer
1218758|NCT01079767|adult primary hepatocellular carcinoma
1218759|NCT01079767|advanced adult primary liver cancer
1218760|NCT01079767|localized unresectable adult primary liver cancer
1218761|NCT01079767|recurrent adult primary liver cancer
1218762|NCT01079754|Spinal morphine 0.05 mg
1218763|NCT01079754|Spinal morphine
1218764|NCT01079741|Melanoma
1218765|NCT01079741|Skin Cancer
1218766|NCT01079741|Adjuvant Therapy
1218767|NCT01079741|Oncogenesis
1218768|NCT01079741|LAGE
1218769|NCT01079741|Cancer Immunity
1218770|NCT01079741|Neoplasms
1218771|NCT01079741|Immunogenicity
1218772|NCT01079741|Vaccine
1218773|NCT01079741|Immunotherapy
1218774|NCT01079728|ischemic stroke
1218775|NCT01079728|stroke-associated pneumonia
1218776|NCT01079728|prediction
1218777|NCT01079728|immune and infection parameters
1218778|NCT01079715|Newborn
1218779|NCT01079715|Retinal Diseases
1218780|NCT01079715|Angiogenesis Modulating Agents
1218781|NCT01079715|Adrenergic beta-Antagonists
1218782|NCT01079689|basic science
1218783|NCT01079689|healthy volunteers
1218784|NCT01079650|children
1218785|NCT01079637|Sella and Barrete Stage 0 1 or 2
1218786|NCT01079624|Incretin hormones
1218787|NCT01079624|Glucose-insulinotropic peptide
1218788|NCT01079624|Glucagon-like peptide-1
1218789|NCT01079624|Gastric emptying
1218790|NCT01079624|Appetite
1218791|NCT01079624|Glucose disposal
1218792|NCT01079624|Gut hormones
1218793|NCT01079598|IPV
1218794|NCT01079598|RadioFrequency
1218795|NCT01079598|QOL
1218796|NCT01079572|osteoarthritis
1218797|NCT01079572|arthroplasty
1218798|NCT01079572|web-based
1218799|NCT01079572|electronic follow-up
1218800|NCT01079559|total knee arthroplasty
1218801|NCT01079559|infection
1218802|NCT01079559|antibiotic bone cement
1218803|NCT01079546|HPV, Israel, Squamous cell carcinoma of head and neck
1218804|NCT01079533|Colorectal Neoplasms
1218805|NCT01079533|Mass Screening
1218806|NCT01079533|Patient Compliance
1218807|NCT01079533|Intervention Studies
1218808|NCT01079533|Clinical Trial
1218809|NCT01079520|Cancer
1218810|NCT01079520|Lung Cancer
1218811|NCT01079520|Ultrasound
1218812|NCT01079520|Surgery
1218813|NCT01079507|single nucleotide polymorphism
1218814|NCT01079507|adult acute lymphoblastic leukemia
1218815|NCT01079494|Uncontrolled blood pressure
1218816|NCT01079481|Relapsed or Refractory Small Cell Lung Cancer
1218817|NCT01079481|Paclitaxel
1218818|NCT01079481|Everolimus
1218819|NCT01079468|Transient cognitive decline following orthopaedic surgery
1218820|NCT01079455|Coxarthrosis
1218821|NCT01079455|Hip
1218822|NCT01079455|Infiltration
1218823|NCT01079455|Hyaluronic Acid
1218824|NCT01079455|Corticosterone
1218825|NCT01079442|postoperative ileus after colonic resections
1218826|NCT01079429|Monoclonal gammopathy of undetermined significance
1218827|NCT01079429|MGUS
1218828|NCT01079429|Smoldering myeloma
1218829|NCT01079429|SMM
1218830|NCT01079429|Multiple myeloma
1218831|NCT01079416|Esophageal Capsule Endoscopy, Screening
1218832|NCT01079390|acupuncture
1218833|NCT01079390|osteoarthritis
1218834|NCT01079390|fMRI
1218835|NCT01079377|Adolescents
1218836|NCT01079377|Bariatric Surgery
1218837|NCT01079377|Psychological Symptoms
1218838|NCT01079377|Cognitive Behavioral Therapy
1218839|NCT01079377|Telemedicine
1218840|NCT01079377|Longitudinal
1218841|NCT01079351|Epilepsy
1218842|NCT01079351|Intravenous Carbamazepine
1218843|NCT01079351|Oral Carbamazepine
1218844|NCT01079338|sensitivity to caffeine
1218845|NCT01079325|Diabetic neuropathy
1218846|NCT01079325|Diabetes Type 1 or 2
1218847|NCT01079325|Moderately severe sensorimotor diabetic polyneuropathy
1218848|NCT01079312|ERCP
1218849|NCT01079312|patient-controlled sedation
1218850|NCT01079312|propofol
1218851|NCT01079312|remifentanil
1218852|NCT01079312|sedation level
1218853|NCT01079299|venous ulcer
1218854|NCT01079299|secondary lymphedema
1218855|NCT01079299|chronic lower leg ulceration
1218856|NCT01079286|mTOR inhibition
1218857|NCT01079286|advanced malignancies
1218858|NCT01079286|pharmacokinetics
1218860|NCT01079286|Advanced malignancies, including metastatic renal cell cancer
1218861|NCT01079273|Influenza
1218862|NCT01079273|Vaccines
1218863|NCT01079273|A/H1N1
1218864|NCT01079273|Influenza Vaccines
1218865|NCT01079260|Malnourished
1218866|NCT01079260|Elderly
1218867|NCT01079260|Nutrition support
1218868|NCT01079247|Burn
1218869|NCT01079247|Transfusion
1218870|NCT01079247|blood
1218871|NCT01079247|hemoglobin
1218872|NCT01079221|exercise
1218873|NCT01079221|Knee extensor
1218874|NCT01079208|infant formula, synbiotics, probiotics, nutrition
1218875|NCT01079195|Effectiveness and tolerability of Tarka
1218876|NCT01079195|Hypertensive patients
1218877|NCT01079195|Diabetes mellitus
1218878|NCT01079195|Observational study
1218879|NCT01079182|Daily practice
1218880|NCT01079182|Humira
1218881|NCT01079182|Efficacy
1218882|NCT01079182|Safety
1218883|NCT01079182|Ankylosing spondylitis
1218884|NCT01079169|urinary tract infection
1218885|NCT01079169|prevention
1218886|NCT01079169|rehabilitation
1218887|NCT01079169|spinal cord injury
1218888|NCT01079143|De Novo renal transplantation
1218889|NCT01079130|Indacaterol
1218890|NCT01079130|asthma
1218891|NCT01079130|salmeterol
1218892|NCT01079117|Opiate
1218893|NCT01079117|Methadone
1218894|NCT01079117|Slow Release Oral Morphine (SORM)
1218895|NCT01079117|Sevre-Long™
1218896|NCT01079104|Liver failure
1218897|NCT01079104|Hepatic insufficiency
1218898|NCT01079104|Artificial liver
1218899|NCT01079104|Albumin dialysis
1218900|NCT01079091|Liver failure
1218901|NCT01079091|Hepatic insufficiency
1218902|NCT01079091|Liver Cirrhosis
1218903|NCT01079091|Artificial liver
1218904|NCT01079091|Albumin dialysis
1218905|NCT01079078|Acetaminophen fed study
1218906|NCT01079065|Famotidine tablets fasting study
1218907|NCT01079052|Famotidine tablets fed study
1218908|NCT01079026|biomarker
1218909|NCT01079026|epidural steroid
1218910|NCT01079026|radiculopathy
1218911|NCT01079026|hnp
1218912|NCT01079000|asthma
1218913|NCT01079000|exacerbation
1218914|NCT01079000|emergency department
1218915|NCT01079000|relapse
1218916|NCT01078987|Nephrogenic Fibrosing Dermopathy (NFD)
1218917|NCT01078987|Nephrogenic Systemic Fibrosis (NSF)
1218918|NCT01078974|WM
1218919|NCT01078974|pomalidomide
1218920|NCT01078974|dexamethasone
1218921|NCT01078974|rituximab
1218922|NCT01078961|bortezomib
1218923|NCT01078961|sorafenib
1218924|NCT01078961|advanced melanoma
1218925|NCT01078948|tDCS
1218926|NCT01078948|transcranial direct current stimulation
1218927|NCT01078948|major depression
1218928|NCT01078948|double-blind
1218929|NCT01078948|randomized
1218930|NCT01078948|placebo-controlled
1218931|NCT01078948|treatment
1218932|NCT01078935|Crohn's disease activity index
1218933|NCT01078935|CDAI
1218934|NCT01078922|ofatumumab diffuse B cell non hodgkins lymphoma DLBCL
1218935|NCT01078922|refractory DLBCL
1218936|NCT01078922|relapsed DLBCL
1218937|NCT01078909|Cardiovascular disease
1218938|NCT01078909|Inflammation
1218939|NCT01078909|Fish Oil
1218940|NCT01078909|Omega-3 Fatty Acids
1218941|NCT01078909|LPS
1218942|NCT01078909|Endotoxin
1218943|NCT01078883|Lung cancer
1218944|NCT01078883|Respiratory muscle strength
1218945|NCT01078883|Dyspnea
1218946|NCT01078883|Functional capacity
1218947|NCT01078870|Negative symptom
1218948|NCT01078857|Chronic kidney disease
1218949|NCT01078857|Small-fiber neuropathy
1218950|NCT01078857|Skin biopsy
1218951|NCT01078857|Contact heat evoked potential
1218952|NCT01078857|Autonomic neuropathy
1218953|NCT01078857|Neuropathy in late stage chronic kidney disease
1218954|NCT01078844|Autism
1218955|NCT01078844|Asperger's Disorder
1218956|NCT01078844|Pervasive Developmental Disorder NOS
1218957|NCT01078844|Adult
1218958|NCT01078844|Memantine
1218959|NCT01078818|Cardiac surgery
1218960|NCT01078818|Extracorporeal circulation
1218961|NCT01078818|Anaemia
1218962|NCT01078818|Intravenous iron
1218963|NCT01078818|Oral Iron
1218964|NCT01078779|Influenza
1218965|NCT01078779|Prevention
1218966|NCT01078779|Chloroquine
1218967|NCT01078779|Randomised controlled trial
1218968|NCT01078779|Respiratory virus infection
1218969|NCT01078766|cerebral palsy
1218970|NCT01078740|cystic fibrosis
1218971|NCT01078740|cystic fibrosis transmembrane conductance regulator
1218972|NCT01078740|biomarkers
1218973|NCT01078740|Intestinal Current Measurement
1218974|NCT01078727|Thermal Stimulation
1218975|NCT01078727|Upper Extremity
1218976|NCT01078727|Motor Recovery
1218977|NCT01078727|Stroke
1218978|NCT01078714|Autism
1218979|NCT01078714|Bumetanide
1218980|NCT01078714|GABA
1218981|NCT01078714|NKCC1
1218982|NCT01078701|live attenuated flu vaccines
1218983|NCT01078701|Influenza A (H1N1)
1218984|NCT01078701|intranasal application
1218985|NCT01078701|replication-deficient influenza virus
1218986|NCT01078688|Limitations of activities
1218987|NCT01078688|persistent asthma
1218988|NCT01078688|general practitioner
1218989|NCT01078688|frequency of limitations of activities
1218990|NCT01078688|depending on gender and age-group
1218991|NCT01078675|Familial Hypercholesterolaemia
1218992|NCT01078675|pediatric
1218993|NCT01078662|olaparib
1218994|NCT01078662|PARP inhibitors
1218995|NCT01078662|genetic BRCA1 mutation
1218996|NCT01078662|BRCA2 mutation
1218997|NCT01078662|solid tumour refractory
1218998|NCT01078649|cancer
1218999|NCT01078649|solid tumors
1219000|NCT01078649|lymphoma
1219001|NCT01078649|smac mimetic
1219002|NCT01078649|IAP inhibitor
1219003|NCT01078649|Phase I
1219004|NCT01078649|Dose escalation
1219005|NCT01078636|amyloid
1219006|NCT01078636|plaques
1219007|NCT01078636|imaging
1219008|NCT01078636|early detection
1219009|NCT01078636|Amnestic MCI
1219010|NCT01078636|pre-dementia
1219011|NCT01078623|Bronchitis
1219012|NCT01078623|Chronic
1219013|NCT01078623|Emphysema
1219014|NCT01078610|Psoriatic Arthritis
1219015|NCT01078610|Long-term Observation
1219016|NCT01078610|Humira
1219017|NCT01078610|Safety
1219018|NCT01078610|Effectiveness
1219019|NCT01078610|Quality of Life
1219020|NCT01078610|Work Productivity
1219021|NCT01078597|anti-MCV
1219022|NCT01078597|anti-CCP
1219023|NCT01078597|Biomarkers
1219024|NCT01078597|Rheumatoid Arthritis
1219025|NCT01078584|Uncontrolled hypertension
1219026|NCT01078584|trandolapril
1219027|NCT01078571|Rheumatoid Arthritis
1219028|NCT01078571|Biologic
1219029|NCT01078571|Tumor Necrosis Factors blockers agents Monoclonal antibody
1219030|NCT01078558|Multicenter study
1219031|NCT01078545|Prostate cancer
1219032|NCT01078545|Lower urinary tract symptoms
1219033|NCT01078545|Hormonotherapy
1219034|NCT01078545|LHRH analogue
1219035|NCT01078545|Androgen deprivation therapy (ADT)
1219036|NCT01078532|medically complex diseases that increase cardiovascular risk
1219037|NCT01078519|Fever
1219038|NCT01078519|anesthesia
1219039|NCT01078519|Labor
1219040|NCT01078506|Chinese
1219041|NCT01078506|intracranial aneurysm
1219042|NCT01078506|magnetic resonance imaging
1219043|NCT01078493|Platelet rich plasma
1219044|NCT01078493|PRP
1219045|NCT01078493|wrinkles
1219046|NCT01078493|MyCells®
1219047|NCT01078493|CREATE
1219048|NCT01078493|Life Source Medical Centre
1219049|NCT01078493|Dr Tan Kok leong
1219050|NCT01078480|Fracture
1219051|NCT01078480|Collar bone
1219052|NCT01078467|Wound Healing
1219053|NCT01078467|Oral Wounds
1219054|NCT01078467|Cutaneous Wounds
1219055|NCT01078467|Gene Array Analysis
1219056|NCT01078467|Proteomic Analysis
1219057|NCT01078467|Healthy Volunteer
1219058|NCT01078467|HV
1219059|NCT01078454|Melphalan
1219060|NCT01078454|Dexamethasone
1219061|NCT01078454|Bortezomib
1219062|NCT01078454|Systemic Light-chain (AL) Amyloidosis
1219063|NCT01078441|Bortezomib
1219064|NCT01078441|Liposomal Doxorubicin
1219065|NCT01078441|Dexamethasone
1219066|NCT01078441|Cyclophosphamide
1219067|NCT01078441|refractory multiple myeloma
1219068|NCT01078428|Hypertrophic scars
1219069|NCT01078428|Topical silicone gel
1219070|NCT01078428|Scar thickness
1219071|NCT01078428|Scar Color
1219072|NCT01078428|Scar pliability
1219073|NCT01078428|Scar appearance
1219074|NCT01078415|HCC
1219075|NCT01078415|Hepatocellular Carcinoma
1219076|NCT01078415|Early Stage
1219077|NCT01078415|Prospective
1219078|NCT01078415|Multicenter
1219079|NCT01078415|Irreversible Electroporation (IRE)
1219080|NCT01078415|Electroporation
1219081|NCT01078415|Low Energy Direct Current
1219082|NCT01078415|LEDC
1219083|NCT01078415|Nonthermal ablation
1219084|NCT01078415|NTIRE (nonthermal IRE)
1219085|NCT01078415|Ablation
1219086|NCT01078415|Soft Tissue
1219087|NCT01078402|Treatment compliance and tolerability of Humira in patients
1219088|NCT01078402|Eastern European countries
1219089|NCT01078402|Rheumatoid Arthritis
1219090|NCT01078402|Psoriatic Arthritis
1219091|NCT01078402|Adalimumab
1219092|NCT01078402|Ankylosing Spondylitis
1219093|NCT01078402|Evaluation of clinical outcome
1219094|NCT01078389|Gout
1219095|NCT01078389|Hyperuricemia
1219096|NCT01078389|Uric Acid
1219097|NCT01078389|Drug Therapy
1219098|NCT01078376|Pediatrics
1219099|NCT01078376|Blood Pressure, High
1219100|NCT01078376|Drug Therapy
1219101|NCT01078363|Heart Transplantation
1219102|NCT01078350|Lymphoma
1219103|NCT01078350|Hodgkin Disease
1219104|NCT01078311|Patients with advanced hepatocellular cancer
1219105|NCT01078298|smoking
1219106|NCT01078298|smoking cessation
1219107|NCT01078298|smoking cessation in depressed subjects
1219108|NCT01078285|Integrated program on adherence using counseling
1219223|NCT01077635|HIV
1219109|NCT01078285|support services including cost-sharing where appropriate and educational materials mailed monthly.
1219110|NCT01078272|Coronary Atherosclerosis
1219111|NCT01078272|Percutaneous Coronary Intervention
1219112|NCT01078272|Coronary Stenting
1219113|NCT01078272|Coronary Stenosis
1219114|NCT01078272|Remote Ischemic Preconditioning
1219115|NCT01078246|HIV
1219116|NCT01078233|HIV
1219117|NCT01078233|antiretroviral treatment
1219118|NCT01078233|HIV Cohort
1219119|NCT01078233|Treatment
1219120|NCT01078220|Human Papillomavirus (HPV)
1219121|NCT01078194|Weight regain
1219122|NCT01078194|Weight loss failure
1219123|NCT01078194|Gastric bypass
1219124|NCT01078181|gastric bypass
1219125|NCT01078181|banded gastric bypass
1219126|NCT01078181|weight loss
1219127|NCT01078181|weight regain
1219128|NCT01078181|bariatric surgery
1219129|NCT01078168|Alzheimer`s Disease
1219130|NCT01078155|Bone mineral density
1219131|NCT01078155|Bone turnover markers
1219132|NCT01078155|Rheumatoid arthritis
1219133|NCT01078155|Osteoporosis
1219134|NCT01078142|temsirolimus
1219135|NCT01078142|bendamustine
1219136|NCT01078142|rituximab
1219137|NCT01078142|mantle cell lymphoma
1219138|NCT01078142|follicular lymphoma
1219139|NCT01078129|cognitive deficits
1219140|NCT01078116|Rheumatoid Arthritis
1219141|NCT01078116|Adalimumab treatment
1219142|NCT01078116|Evaluation of the patients' Health Related Quality of Life
1219143|NCT01078116|Cost of the disease management
1219144|NCT01078103|Diabetes Mellitus
1219145|NCT01078103|cornea endothelium
1219146|NCT01078103|cell loss
1219147|NCT01078103|cataract surgery
1219148|NCT01078090|Safety
1219149|NCT01078090|Rheumatoid Arthritis
1219150|NCT01078090|Effectiveness
1219151|NCT01078077|healthy females ages twentyfive through sixty
1219152|NCT01078064|Gastroesophageal reflux disease, gastric motility
1219153|NCT01078051|chronic total occlusion
1219154|NCT01078051|stent
1219155|NCT01078051|medical therapy
1219156|NCT01078038|Coronary Artery Disease
1219157|NCT01078038|Stent
1219158|NCT01078025|transvaginal access for cholecystectomy
1219159|NCT01077999|chemoradiation
1219160|NCT01077999|panitumumab
1219161|NCT01077999|esophageal cancer
1219162|NCT01077999|Resectable squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus or gastro esophageal junction
1219163|NCT01077986|mTOR inhibition
1219164|NCT01077986|EGFR inhibition
1219165|NCT01077986|pancreatic cancer
1219166|NCT01077986|pharmacodynamics
1219167|NCT01077973|Headache
1219168|NCT01077960|Serostim
1219169|NCT01077960|HARS
1219170|NCT01077947|low back pain
1219171|NCT01077947|spinal fusion
1219172|NCT01077947|Primarily axial low back pain
1219173|NCT01077934|All Patients admitted to Grady Memorial Hospital with Unilateral Lower leg injury at risk for compartment syndrome
1219174|NCT01077921|sickle
1219175|NCT01077921|adhesion
1219176|NCT01077921|propranolol
1219177|NCT01077908|Adoptive cellular therapy
1219178|NCT01077908|Hematopoietic Stem Cell Transplantation
1219179|NCT01077895|Critically ill patients with positive fluid balance, IAH and AKI requiring RRT
1219180|NCT01077882|Moderate and severe psoriasis and atopic dermatitis
1219181|NCT01077869|oropharynx and lymph node metastases from an unknown primary tumor
1219182|NCT01077856|congenital anomaly
1219183|NCT01077856|pregnancy
1219184|NCT01077856|GARDASIL®
1219185|NCT01077856|Nordic
1219186|NCT01077856|population-based
1219187|NCT01077843|Ankylosing Spondylitis
1219188|NCT01077830|New Incidence of Cancer
1219189|NCT01077791|Schizophrenia
1219190|NCT01077791|social cognition
1219191|NCT01077791|theory of mind
1219192|NCT01077791|cognitive therapy
1219193|NCT01077791|therapeutic trial
1219194|NCT01077791|magnetoencephalography (MEG)
1219195|NCT01077778|Magnetic Resonance Imaging/methods
1219196|NCT01077778|Magnetic Resonance Angiography
1219197|NCT01077778|Perfusion Imaging
1219198|NCT01077778|Pulmonary Embolism/diagnosis
1219199|NCT01077765|HIV-associated Lipodystrophy
1219200|NCT01077765|Polyacrylamide hydrogel
1219201|NCT01077752|Pain, postoperative
1219202|NCT01077752|Local infiltration
1219203|NCT01077752|Hyperalgesia, postoperative
1219204|NCT01077752|Local anesthetic, ropivacaine, lidocaine
1219205|NCT01077752|Colorectal laparoscopic surgery
1219206|NCT01077752|Pain management after colorectal laparoscopic surgery
1219207|NCT01077687|schizophrenia
1219208|NCT01077687|genome-wide association study (GWAS)
1219209|NCT01077687|single-nucleotide polymorphisms (SNPs)
1219210|NCT01077687|Han Chinese population
1219211|NCT01077687|trio families
1219212|NCT01077687|Schizophrenia with trio families
1219213|NCT01077674|Electroencephalogram
1219214|NCT01077674|Entropy
1219215|NCT01077674|BIS
1219216|NCT01077674|Sevoflurane
1219217|NCT01077661|Nebivolol
1219218|NCT01077661|PMS (post-marketing surveillance)
1219219|NCT01077648|Breast Cancer
1219220|NCT01077648|Treatment
1219221|NCT01077648|Brain metastases
1219222|NCT01077648|ErbB2 expression
1219224|NCT01077635|Antiretroviral therapy
1219225|NCT01077635|protease inbitor
1219226|NCT01077635|fosamprenavir
1219227|NCT01077635|paediatrics
1219228|NCT01077609|Intranasal steroids
1219229|NCT01077609|beclometasone diproprionate
1219230|NCT01077609|steroid-related outcomes
1219231|NCT01077596|Carcinogenicity
1219232|NCT01077596|Case control
1219233|NCT01077596|Bupropion
1219234|NCT01077583|Pregnancy test
1219235|NCT01077583|Wishing to become pregnant
1219236|NCT01077557|Combivir (Zidovudine+Lamivudine)
1219237|NCT01077557|Trizivir (Abacavir+Lamivudine+Zidovudine)
1219238|NCT01077557|Zidovudine
1219239|NCT01077557|Epzicom (Abacavir+Lamivudine)
1219240|NCT01077557|Fracture
1219241|NCT01077557|Amprenavir
1219242|NCT01077557|human immunodeficiency virus (HIV) infection
1219243|NCT01077557|antiretroviral (ARV) therapy
1219244|NCT01077557|Lamivudine
1219245|NCT01077557|incidence
1219246|NCT01077557|Abacavir
1219247|NCT01077557|risk
1219248|NCT01077557|Fosamprenavir
1219249|NCT01077544|Chronic Myeloid Leukemia
1219250|NCT01077544|Acute Lymphoblastic Leukemia
1219251|NCT01077544|Ph+ CML
1219252|NCT01077544|Ph+ ALL
1219253|NCT01077544|pediatric
1219254|NCT01077544|nilotinib
1219255|NCT01077544|imatinib
1219256|NCT01077544|chronic phase
1219257|NCT01077544|accelerated phase
1219258|NCT01077544|newly diagnosed Ph+ CML
1219259|NCT01077544|dasatinib
1219260|NCT01077531|Rheumatoid arthritis
1219261|NCT01077531|intravenous infusion
1219262|NCT01077531|long-term followup
1219268|NCT01077505|pharmacokinetics
1219269|NCT01077505|GSK716155
1219270|NCT01077505|Brevicon
1219271|NCT01077505|albiglutide
1219272|NCT01077505|healthy female volunteers
1219273|NCT01077505|oral contraceptive
1219274|NCT01077492|lung cancer
1219275|NCT01077492|mediastinal lymph nodes
1219276|NCT01077492|TBNA
1219277|NCT01077492|staging lung cancer
1219278|NCT01077479|body fat mass gain
1219279|NCT01077479|Insulin resistance
1219280|NCT01077466|Primary Progressive Multiple Sclerosis
1219281|NCT01077466|Secondary Progressive Multiple Sclerosis
1219282|NCT01077466|Natalizumab
1219283|NCT01077466|Treatment
1219284|NCT01077466|Safety
1219285|NCT01077466|Efficacy
1219286|NCT01077466|Cerebrospinal fluid
1219287|NCT01077466|Osteopontin
1219288|NCT01077440|cancer survivor
1219289|NCT01077440|stage III adult Burkitt lymphoma
1219290|NCT01077440|stage III adult diffuse large cell lymphoma
1219291|NCT01077440|stage III adult diffuse mixed cell lymphoma
1219292|NCT01077440|stage III adult diffuse small cleaved cell lymphoma
1219293|NCT01077440|stage III adult Hodgkin lymphoma
1219294|NCT01077440|stage III adult immunoblastic large cell lymphoma
1219295|NCT01077440|stage III adult lymphoblastic lymphoma
1219296|NCT01077440|stage III grade 1 follicular lymphoma
1219297|NCT01077440|stage III grade 2 follicular lymphoma
1219298|NCT01077440|stage III grade 3 follicular lymphoma
1219299|NCT01077440|stage III mantle cell lymphoma
1219300|NCT01077440|stage III marginal zone lymphoma
1219301|NCT01077440|stage III small lymphocytic lymphoma
1219302|NCT01077440|stage IV adult Burkitt lymphoma
1219303|NCT01077440|stage IV adult diffuse large cell lymphoma
1219304|NCT01077440|stage IV adult diffuse mixed cell lymphoma
1219305|NCT01077440|stage IV adult diffuse small cleaved cell lymphoma
1219306|NCT01077440|stage IV adult Hodgkin lymphoma
1219307|NCT01077440|stage IV adult immunoblastic large cell lymphoma
1219308|NCT01077440|stage IV adult lymphoblastic lymphoma
1219309|NCT01077440|stage IV grade 1 follicular lymphoma
1219310|NCT01077440|stage IV grade 2 follicular lymphoma
1219311|NCT01077440|stage IV grade 3 follicular lymphoma
1219312|NCT01077440|stage IV mantle cell lymphoma
1219313|NCT01077440|stage IV marginal zone lymphoma
1219314|NCT01077440|stage IV small lymphocytic lymphoma
1219315|NCT01077440|recurrent adult Burkitt lymphoma
1219316|NCT01077440|recurrent adult diffuse large cell lymphoma
1219317|NCT01077440|recurrent adult diffuse mixed cell lymphoma
1219318|NCT01077440|recurrent adult diffuse small cleaved cell lymphoma
1219319|NCT01077440|recurrent adult Hodgkin lymphoma
1219320|NCT01077440|recurrent adult immunoblastic large cell lymphoma
1219321|NCT01077440|recurrent adult lymphoblastic lymphoma
1219322|NCT01077440|recurrent cutaneous T-cell non-Hodgkin lymphoma
1219553|NCT01076699|diarrhea
1219323|NCT01077440|recurrent grade 1 follicular lymphoma
1219324|NCT01077440|recurrent grade 2 follicular lymphoma
1219325|NCT01077440|recurrent grade 3 follicular lymphoma
1219326|NCT01077440|recurrent mantle cell lymphoma
1219327|NCT01077440|recurrent marginal zone lymphoma
1219328|NCT01077440|recurrent small lymphocytic lymphoma
1219329|NCT01077440|recurrent mycosis fungoides/Sezary syndrome
1219330|NCT01077440|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1219331|NCT01077440|nodal marginal zone B-cell lymphoma
1219332|NCT01077440|splenic marginal zone lymphoma
1219441|NCT01077245|Metronidazole
1219333|NCT01077440|noncontiguous stage II adult Burkitt lymphoma
1219334|NCT01077440|noncontiguous stage II adult diffuse large cell lymphoma
1219335|NCT01077440|noncontiguous stage II adult diffuse mixed cell lymphoma
1219336|NCT01077440|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1219337|NCT01077440|noncontiguous stage II adult immunoblastic large cell lymphoma
1219338|NCT01077440|noncontiguous stage II adult lymphoblastic lymphoma
1219339|NCT01077440|noncontiguous stage II grade 1 follicular lymphoma
1219340|NCT01077440|noncontiguous stage II grade 2 follicular lymphoma
1219341|NCT01077440|noncontiguous stage II grade 3 follicular lymphoma
1219342|NCT01077440|noncontiguous stage II mantle cell lymphoma
1219343|NCT01077440|noncontiguous stage II marginal zone lymphoma
1219344|NCT01077440|noncontiguous stage II small lymphocytic lymphoma
1219345|NCT01077440|accelerated phase chronic myelogenous leukemia
1219346|NCT01077440|adult acute lymphoblastic leukemia in remission
1219347|NCT01077440|adult acute myeloid leukemia in remission
1219348|NCT01077440|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1219349|NCT01077440|adult acute myeloid leukemia with inv(16)(p13;q22)
1219350|NCT01077440|adult acute myeloid leukemia with t(15;17)(q22;q12)
1219351|NCT01077440|adult acute myeloid leukemia with t(16;16)(p13;q22)
1219352|NCT01077440|adult acute myeloid leukemia with t(8;21)(q22;q22)
1219353|NCT01077440|atypical chronic myeloid leukemia, BCR-ABL negative
1219354|NCT01077440|blastic phase chronic myelogenous leukemia
1219355|NCT01077440|chronic myelomonocytic leukemia
1219356|NCT01077440|chronic phase chronic myelogenous leukemia
1219357|NCT01077440|recurrent adult acute lymphoblastic leukemia
1219358|NCT01077440|recurrent adult acute myeloid leukemia
1219359|NCT01077440|refractory chronic lymphocytic leukemia
1219360|NCT01077440|refractory hairy cell leukemia
1219361|NCT01077440|relapsing chronic myelogenous leukemia
1219362|NCT01077440|secondary acute myeloid leukemia
1219363|NCT01077440|stage III chronic lymphocytic leukemia
1219364|NCT01077440|stage IV chronic lymphocytic leukemia
1219365|NCT01077440|chronic eosinophilic leukemia
1219366|NCT01077440|primary myelofibrosis
1219367|NCT01077440|chronic neutrophilic leukemia
1219368|NCT01077440|de novo myelodysplastic syndromes
1219369|NCT01077440|disseminated neuroblastoma
1219370|NCT01077440|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1219371|NCT01077440|previously treated myelodysplastic syndromes
1219372|NCT01077440|recurrent neuroblastoma
1219373|NCT01077440|recurrent malignant testicular germ cell tumor
1219374|NCT01077440|secondary myelodysplastic syndromes
1219375|NCT01077440|stage I multiple myeloma
1219376|NCT01077440|stage II multiple myeloma
1219377|NCT01077440|stage III multiple myeloma
1219378|NCT01077440|stage III malignant testicular germ cell tumor
1219379|NCT01077440|refractory multiple myeloma
1219380|NCT01077427|pancreatic cancer
1219381|NCT01077427|adjuvant treatment
1219382|NCT01077427|hyperthermia
1219383|NCT01077414|Psychosocial Functioning
1219384|NCT01077414|Psychosocial Stress
1219385|NCT01077414|Palliative Care
1219386|NCT01077414|Spirituality
1219387|NCT01077414|Cancer
1219388|NCT01077401|Diabetic
1219389|NCT01077401|edema
1219390|NCT01077401|DME
1219391|NCT01077388|CVD
1219392|NCT01077388|uncontrolled HTN
1219393|NCT01077375|Milnacipran
1219394|NCT01077375|Duloxetine
1219395|NCT01077375|Switch
1219396|NCT01077375|Forest Research Institute
1219397|NCT01077362|Ustekinumab
1219398|NCT01077362|CNTO 1275
1219399|NCT01077362|Stelara
1219400|NCT01077362|Psoriatic Arthritis
1219401|NCT01077362|Psoriasis
1219402|NCT01077362|TNF alpha
1219403|NCT01077349|Cardiac surgery
1219404|NCT01077349|Shock
1219405|NCT01077349|Continuous Veno-Venous Haemofiltration
1219406|NCT01077349|Continuous Renal Replacement Therapy
1219407|NCT01077349|Renal Insufficiency
1219408|NCT01077349|Acute
1219409|NCT01077336|susceptibility testing
1219410|NCT01077323|pancreatitis
1219411|NCT01077323|exenatide
1219412|NCT01077323|Byetta
1219413|NCT01077323|Amylin
1219414|NCT01077323|Lilly
1219415|NCT01077310|HIV
1219416|NCT01077310|Acquired Immunodeficiency Syndrome
1219417|NCT01077310|Alcohol dependence
1219418|NCT01077310|CD4
1219419|NCT01077310|HIV-1 RNA
1219420|NCT01077310|Alcohol treatment outcomes
1219421|NCT01077284|Kidney Calculi
1219422|NCT01077284|Kidney Stones
1219423|NCT01077284|Nephrolithiasis
1219424|NCT01077284|Drug Therapy
1219425|NCT01077284|Uric Acid
1219426|NCT01077271|Premature infants
1219554|NCT01076699|irritable bowel
1219427|NCT01077271|Respiratory Syncytial Virus (RSV)
1219428|NCT01077271|Compliance
1219429|NCT01077271|Palivizumab
1219430|NCT01077258|Safety
1219431|NCT01077258|Long-term observation
1219432|NCT01077258|Routine Clinical Setting
1219433|NCT01077258|Rheumatoid Arthritis
1219434|NCT01077258|Effectiveness
1219435|NCT01077245|Clostridium difficile
1219436|NCT01077245|Clostridium Infections
1219437|NCT01077245|Gram-Positive Bacterial Infections
1219438|NCT01077245|Bacterial Infections
1219439|NCT01077245|Anti-Infective Agents
1219440|NCT01077245|Clostridium butyricum
1219442|NCT01077245|Vancomycin
1219443|NCT01077245|Gastrointestinal Diseases
1219444|NCT01077245|Physiological Effects of Drugs
1219445|NCT01077245|Colonic Diseases
1219446|NCT01077245|Enterocolitis, Pseudomembranous
1219447|NCT01077245|Intestinal Diseases
1219448|NCT01077245|Enterocolitis
1219449|NCT01077245|Pharmacologic Actions
1219450|NCT01077245|Digestive System Diseases
1219451|NCT01077245|Therapeutic Uses
1219452|NCT01077245|Gastroenteritis
1219453|NCT01077245|Colitis
1219454|NCT01077245|Diarrhea
1219455|NCT01077245|Probiotics
1219456|NCT01077245|Gastrointestinal Agents
1219457|NCT01077232|Moderate to Severe Plaque Psoriasis
1219458|NCT01077232|Safety
1219459|NCT01077232|Efficacy
1219460|NCT01077232|Humira
1219461|NCT01077232|Work Productivity
1219462|NCT01077219|healthy female
1219463|NCT01077206|Aneurysm
1219464|NCT01077206|statin
1219465|NCT01077206|subarachnoid hemorrhage
1219466|NCT01077193|Bariatric
1219467|NCT01077193|Obesity
1219468|NCT01077167|Omecamtiv mecarbil
1219469|NCT01077167|pharmacokinetics
1219470|NCT01077154|Early Stage Breast Cancer
1219471|NCT01077154|Bone Metastasis
1219472|NCT01077154|Adjuvant treatment
1219473|NCT01077154|Neoadjuvant treatment
1219474|NCT01077154|Denosumab
1219475|NCT01077154|Stage II breast cancer
1219476|NCT01077154|Stage III breast cancer
1219477|NCT01077154|Stage IIA breast cancer
1219478|NCT01077154|Stage IIB breast cancer
1219479|NCT01077154|Stage IIIA breast cancer
1219480|NCT01077154|Stage IIIB breast cancer
1219481|NCT01077154|Stage IIIC breast cancer
1219482|NCT01077154|Early breast cancer
1219483|NCT01077154|Breast Tumors
1219484|NCT01077154|Breast Neoplasms
1219485|NCT01077128|Psoriasis
1219486|NCT01077128|Quality of life
1219487|NCT01077115|Cholecystectomy
1219488|NCT01077115|Cholecystitis
1219489|NCT01077115|Laparoscopy
1219490|NCT01077115|Cholelithiasis
1219491|NCT01077115|Operative trauma
1219492|NCT01077102|COPD
1219493|NCT01077102|eccentric exercise training
1219494|NCT01077102|cycle ergometer
1219495|NCT01077102|muscle function
1219496|NCT01077089|traumatic brain injury
1219497|NCT01077089|In-hospital transport
1219498|NCT01077076|Gastric Acid
1219499|NCT01077076|Human Experimentation
1219500|NCT01077063|Pleurx catheter
1219501|NCT01077063|malignant ascites
1219502|NCT01077024|Stimulant treatment
1219503|NCT01077024|Smoking Cessation
1219504|NCT01077011|Dry eye
1219505|NCT01077011|artificial tears
1219506|NCT01076998|Dry eye
1219507|NCT01076998|artificial tears
1219508|NCT01076985|Human Immunodeficiency Virus
1219509|NCT01076972|Human Immunodeficiency Virus
1219510|NCT01076959|Rheumatoid Arthritis
1219511|NCT01076946|ballooning
1219512|NCT01076946|TLVBS
1219513|NCT01076933|Borderline Personality Disorder
1219514|NCT01076933|Transcranial Magnetic Stimulation
1219515|NCT01076933|Neuropsychological Test
1219516|NCT01076933|Randomised Control Trial
1219517|NCT01076907|colonoscopy
1219518|NCT01076907|polyps
1219519|NCT01076894|pain
1219520|NCT01076894|thoracotomy
1219521|NCT01076894|pulmonary function
1219522|NCT01076894|epidural anesthesia
1219523|NCT01076894|intercostal nerve block
1219524|NCT01076868|vivax
1219525|NCT01076868|malaria
1219526|NCT01076868|relapse
1219527|NCT01076842|Diabetes
1219528|NCT01076829|MDA
1219529|NCT01076829|Spice
1219530|NCT01076816|Patients with single-organ failure in need of mechanical ventilation
1219531|NCT01076803|Malignant intestinal obstruction in inoperable patients
1219532|NCT01076790|Nociception
1219533|NCT01076790|Dexmedetomidine
1219534|NCT01076790|Electroencephalogram
1219535|NCT01076790|Electromyogram
1219536|NCT01076790|Entropy Index
1219537|NCT01076790|Bispectral Index
1219538|NCT01076790|Electrocardiogram
1219539|NCT01076790|Plethysmogram
1219540|NCT01076790|Heart
1219541|NCT01076790|Heart rate
1219542|NCT01076790|Heart rate variability
1219543|NCT01076790|Surgery
1219544|NCT01076777|Panic disorder
1219545|NCT01076777|Physical exercise
1219546|NCT01076777|Cognitive-behavioral therapy
1219547|NCT01076777|Manualized
1219548|NCT01076725|ProSeal LMA
1219549|NCT01076725|standard insertion
1219550|NCT01076725|rotational insertion
1219551|NCT01076699|abdominal pain
1219552|NCT01076699|bloating
1219555|NCT01076686|Augmentation mammoplasty
1219556|NCT01076686|Breast augmentation
1219557|NCT01076686|Postoperative pain
1219558|NCT01076686|Analgesia
1219559|NCT01076660|Ischemic cardiomyopathy
1219560|NCT01076660|Nonischemic cardiomyopathy
1219561|NCT01076660|Implantable cardioverter defibrillator
1219562|NCT01076660|Sudden Cardiac Death
1219563|NCT01076660|Ventricular tachycardia
1219564|NCT01076660|Ventricular fibrillation
1219565|NCT01076608|primary care patients
1219566|NCT01076595|Multiple sclerosis
1219567|NCT01076595|BetaPlus program
1219568|NCT01076595|Recurrent/remittent multiple sclerosis patients
1219569|NCT01076595|Adherence to treatment regimen
1219570|NCT01076582|hormone withdrawal associated symptoms
1219571|NCT01076504|SCLC
1219572|NCT01076504|Amrubicin
1219573|NCT01076504|Carboplatin
1219574|NCT01076504|Pegfilgrastim
1219575|NCT01076504|Neulasta
1219576|NCT01076478|Symmetric Diabetic Polyneuropathy
1219577|NCT01076465|Heart failure
1219578|NCT01076465|Elderly
1219579|NCT01076465|Disease management
1219580|NCT01076452|Parkinson's Disease
1219581|NCT01076452|levo-dopa
1219582|NCT01076452|tremor
1219583|NCT01076452|dyskinesia
1219584|NCT01076452|subthalamic nucleus
1219585|NCT01076452|globus pallidus
1219586|NCT01076426|probiotic
1219587|NCT01076426|peritoneal dialysis
1219588|NCT01076426|peritonitis
1219589|NCT01076426|nutrition status
1219590|NCT01076413|gait
1219591|NCT01076413|exercise
1219592|NCT01076413|skill-based
1219593|NCT01076413|aerobic
1219594|NCT01076387|Bladder
1219595|NCT01076387|Cystectomy
1219596|NCT01076387|Robotic
1219597|NCT01076387|Open Radical
1219598|NCT01076387|10-016
1219599|NCT01076374|pacemaker
1219600|NCT01076361|Epicardial
1219601|NCT01076361|Pacing Lead
1219602|NCT01076348|Epicardial
1219603|NCT01076348|Pacing Lead
1219604|NCT01076335|Neoadjuvant Hormonal Therapy
1219605|NCT01076335|Docetaxel
1219606|NCT01076335|Taxotere
1219607|NCT01076335|Chemotherapy
1219608|NCT01076335|Radical Prostatectomy
1219609|NCT01076335|Node-positive Prostate Cancer
1219610|NCT01076335|Androgen-dependent prostate cancer
1219611|NCT01076335|Lymph node metastases
1219612|NCT01076309|cataract surgery
1219613|NCT01076309|tamsulosin
1219614|NCT01076309|endothelium cell
1219615|NCT01076283|baclofen
1219616|NCT01076283|alcoholism
1219617|NCT01076283|urge
1219618|NCT01076283|craving
1219619|NCT01076283|alcohol drinking
1219620|NCT01076283|biobehavioral mechanisms of baclofen in alcoholism
1219621|NCT01076257|brain damage
1219622|NCT01076257|constraint induced movement therapy
1219623|NCT01076257|kinematic
1219624|NCT01076257|function
1219625|NCT01076257|outcome
1219626|NCT01076257|Quality of life
1219627|NCT01076218|Continuous Glucose Monitoring
1219628|NCT01076218|Accuracy
1219629|NCT01076218|Continuous Glucose Error-Grid Analysis
1219630|NCT01076205|Work Productivity
1219631|NCT01076205|Long-term Observation
1219632|NCT01076205|Humira
1219633|NCT01076205|Quality of Life
1219634|NCT01076205|Rheumatoid Arthritis
1219635|NCT01076192|Moderate Psoriasis
1219636|NCT01076192|Psoriasis
1219637|NCT01076192|Severe Psoriasis
1219638|NCT01076192|Adalimumab
1219639|NCT01076192|Effectiveness
1219640|NCT01076192|Safety
1219641|NCT01076192|Clinical practice
1219642|NCT01076179|Infection
1219643|NCT01076179|Rilpivirine
1219644|NCT01076179|CCR5 antagonists
1219645|NCT01076179|Etravirine
1219646|NCT01076179|Human Immunodeficiency Virus
1219647|NCT01076179|Maraviroc
1219648|NCT01076179|Safety and efficacy
1219649|NCT01076179|Non nucleoside reverse transcriptase inhibitors (NNRTIs)
1219650|NCT01076179|Integrase inhibitors
1219651|NCT01076179|Raltegravir
1219652|NCT01076179|Kaletra
1219653|NCT01076166|Post-marketing observational study
1219654|NCT01076166|Lower respiratory tract infections
1219655|NCT01076166|Klacid Granules for Oral Suspension
1219656|NCT01076153|Post-marketing observational study
1219657|NCT01076153|Upper or lower respiratory tract infection
1219658|NCT01076153|Klacid MR
1219659|NCT01076140|Hypertension as a result of bevacizumab therapy
1219660|NCT01076101|SLE
1219661|NCT01076101|sister
1219662|NCT01076101|autoimmune disease
1219663|NCT01076075|Type 2 Diabetes Mellitus
1219664|NCT01076062|Pregnancy Maintenance
1219665|NCT01076062|Labor, Induced
1219666|NCT01076062|spontaneous labor
1219667|NCT01076062|cesarean delivery
1219668|NCT01076036|ischemia
1219669|NCT01076036|stent
1219670|NCT01076023|Diabetes
1219671|NCT01076023|Cardiovascular disease
1219672|NCT01076023|Observational study
1219673|NCT01076023|China
1219674|NCT01075997|Diabetes Mellitus
1219675|NCT01075984|Antifungal Agents pharmacokinetics
1219676|NCT01075984|Mycoses prevention and control
1219677|NCT01075971|Buprenorphine tablet
1219678|NCT01075971|Fast dissolving tablet
1219679|NCT01075971|Opioid dependant patients
1219680|NCT01075958|n-3 PUFAs
1219681|NCT01075958|Fish oil
1219682|NCT01075958|Cognitive function
1219683|NCT01075958|Healthy young adults
1219684|NCT01075945|antimalarials
1219685|NCT01075945|ACTs
1219686|NCT01075945|Piperaquine
1219687|NCT01075945|uncomplicated
1219688|NCT01075932|cerebral blood flow
1219689|NCT01075932|NIRS
1219690|NCT01075932|n-3 PUFAs
1219691|NCT01075932|fish oil
1219692|NCT01075932|cognitive function
1219693|NCT01075919|n-3 PUFAs
1219694|NCT01075919|Cognitive function
1219695|NCT01075919|Healthy young adults
1219696|NCT01075919|Fish oil
1219697|NCT01075919|Mood
1219698|NCT01075906|pharmacokinetics
1219699|NCT01075893|Colorectal cancer
1219700|NCT01075893|Stem cells
1219701|NCT01075893|Ulcerative colitis
1219702|NCT01075893|Polyps
1219703|NCT01075880|Multiple Sclerosis, Relapsing-Remitting
1219704|NCT01075880|Rebif
1219705|NCT01075880|Interferon beta-1a
1219706|NCT01075854|Gonal-F
1219707|NCT01075854|Multifollicular stimulation
1219708|NCT01075854|Pregnancy
1219709|NCT01075854|Ovarian hyperstimulation
1219710|NCT01075854|In vitro fertilization
1219711|NCT01075854|Intracytoplasmic sperm injection
1219712|NCT01075854|Infertility
1219713|NCT01075841|Head and neck neoplasms
1219714|NCT01075841|Carcinoma, squamous cell
1219715|NCT01075841|Cetuximab
1219716|NCT01075828|Head and Neck Neoplasms
1219717|NCT01075828|Neoplasms, Squamous Cell
1219718|NCT01075828|Cetuximab
1219719|NCT01075815|Infertility
1219720|NCT01075815|Ovulation induction
1219721|NCT01075815|Luveris
1219722|NCT01075815|Controlled ovarian stimulation
1219723|NCT01075815|Reproductive technologies, assisted
1219724|NCT01075802|Breast cancer
1219725|NCT01075802|Tamoxifen
1219726|NCT01075802|Endoxifen
1219727|NCT01075802|polymorphism of CYP2D6
1219728|NCT01075789|Pain
1219729|NCT01075789|Discomfort
1219730|NCT01075789|Insertion
1219731|NCT01075789|Nasogastric tube
1219732|NCT01075763|Alzheimer's
1219733|NCT01075763|Dementia
1219734|NCT01075763|Interferon beta-1a
1219735|NCT01075763|Rebif
1219736|NCT01075750|hyperkalaemia
1219737|NCT01075750|metabolic acidosis
1219738|NCT01075750|renal transplantation
1219739|NCT01075750|normal saline
1219740|NCT01075750|elomel isoton
1219741|NCT01075750|fluid management in renal transplantation
1219742|NCT01075737|Multiple sclerosis
1219743|NCT01075737|Sclerosis
1219744|NCT01075737|Quality of life
1219745|NCT01075724|Perioperative Hypothermia Prevention
1219746|NCT01075724|Accidental Perioperative Hypothermia
1219747|NCT01075711|Arthritis, Rheumatoid
1219748|NCT01075711|Prednisone
1219749|NCT01075698|Type 2 Diabetes
1219750|NCT01075698|Cerebrovascular disease
1219751|NCT01075698|Coronary Artery Disease
1219752|NCT01075698|Chronic Kidney Disease
1219753|NCT01075698|Peripheral Artery Disease
1219754|NCT01075672|OCD
1219755|NCT01075672|BDD
1219756|NCT01075672|Tourette syndrome
1219757|NCT01075672|trichotillomania
1219758|NCT01075672|Compulsive Skin Picking
1219759|NCT01075672|panic disorder
1219760|NCT01075672|social phobia
1219761|NCT01075672|generalized anxiety disorder
1219762|NCT01075672|depression
1219763|NCT01075672|PTSD
1219764|NCT01075672|ADHD
1219765|NCT01075672|eating disorder
1219766|NCT01075672|Specific Phobia
1219767|NCT01075659|Smoking Cessation
1219768|NCT01075659|VAS
1219769|NCT01075659|Urges to smoke
1219770|NCT01075646|postoperative pain
1219771|NCT01075646|wound infusion
1219772|NCT01075646|local anesthesia
1219773|NCT01075633|FOBT
1219774|NCT01075633|colonoscopy
1219775|NCT01075633|familiar risk
1219776|NCT01075633|colorectal cancer
1219777|NCT01075633|advanced adenoma
1219778|NCT01075620|rotating platform
1219779|NCT01075620|posterior stabilized
1219780|NCT01075620|non-posterior stabilized
1219781|NCT01075607|Lymph fluid collection
1219782|NCT01075594|Dyslipidemia
1219783|NCT01075594|Target cholesterol
1219784|NCT01075594|Undertreatment
1219785|NCT01075581|Hemodynamic instability
1219786|NCT01075581|Hemostasis
1219787|NCT01075555|adult primary hepatocellular carcinoma
1219788|NCT01075555|localized unresectable adult primary liver cancer
1219789|NCT01075555|advanced adult primary liver cancer
1219790|NCT01075555|recurrent adult primary liver cancer
1219791|NCT01075542|Corneal astigmatism
1219792|NCT01075542|Intraocular lens
1219793|NCT01075529|major depressive disorder, fluoxetine, Hamilton Rating Scale for Depression (HAM-D-17)
1219794|NCT01075516|Remote Monitoring
1219795|NCT01075516|ICD patients
1219796|NCT01075516|EQ-5D questionnaire
1219797|NCT01075516|remote follow up
1219798|NCT01075503|Supraclavicular
1219799|NCT01075503|Interscalene
1219800|NCT01075503|Infraclavicular
1219801|NCT01075503|Brachial plexus block
1219802|NCT01075503|Ropivacaine
1219803|NCT01075490|spinal anesthesia
1219804|NCT01075490|neonates
1219805|NCT01075490|clonidine
1219806|NCT01075490|post operative apnea
1219807|NCT01075464|Solid Tumor
1219808|NCT01075451|Staphylococcus aureus
1219809|NCT01075451|Antimicrobial Stewardship
1219810|NCT01075451|Antibacterial resistance
1219811|NCT01075451|Vancomycin
1219812|NCT01075438|ataxia telangiectasia
1219813|NCT01075438|Pneumococcal Vaccines
1219814|NCT01075425|leukemia
1219815|NCT01075425|acute leukemia
1219816|NCT01075425|chronic myelogenous leukemia
1219817|NCT01075425|myelodysplastic syndrome
1219818|NCT01075425|relapsed acute leukemia
1219819|NCT01075425|refractory acute leukemia
1219820|NCT01075425|belinostat
1219821|NCT01075425|bortezomib
1219822|NCT01075425|Velcade
1219823|NCT01075425|PXD-101
1219824|NCT01075412|Positron-Emission Tomography
1219825|NCT01075412|Radiotherapy, Intensity-Modulated
1219826|NCT01075399|[F 18]HX4
1219827|NCT01075399|HX4
1219828|NCT01075399|Hypoxia
1219829|NCT01075399|Head/Neck Cancer
1219830|NCT01075399|Lung Cancer
1219831|NCT01075399|Liver Cancer
1219832|NCT01075399|Rectal Cancer
1219833|NCT01075399|Cervical Cancer
1219834|NCT01075399|HIF1 alpha
1219835|NCT01075399|CAIX
1219836|NCT01075386|Hysterectomy
1219837|NCT01075386|Endometrial cancer
1219838|NCT01075386|Benign
1219839|NCT01075386|Endocrine system
1219840|NCT01075386|Tissue collection
1219841|NCT01075373|early stage schizophrenia
1219842|NCT01075373|drug naïve schizophrenia
1219843|NCT01075373|treatment response
1219844|NCT01075373|Aripiprazole
1219845|NCT01075373|pharmacogenetics
1219846|NCT01075373|Disrupted-in-Schizophrenia 1 gene (DISC1)
1219847|NCT01075373|Neuregulin 1 gene (NRG1)
1219848|NCT01075373|Dopamine receptor type 2 gene (DRD2)
1219849|NCT01075373|Catechol-O-Methyltransferase gene (COMT)
1219850|NCT01075373|neurocognitive function
1219851|NCT01075373|event-related evoked potential (ERP)
1219852|NCT01075373|Niacin skin test
1219853|NCT01075373|plasma neurotransmitter level
1219854|NCT01075373|plasma cytokine level
1219855|NCT01075373|plasma signaling protein level
1219856|NCT01075373|AKT1 protein level in the peripheral lymphocytes
1219857|NCT01075373|16-45 y/o
1219858|NCT01075373|without mental retardation or epilepsy
1219859|NCT01075360|Neuroblastoma, MYCN, AHR
1219860|NCT01075347|autoserum
1219861|NCT01075347|ocular surgery
1219862|NCT01075347|corneal epithelium healing
1219863|NCT01075334|sperm
1219864|NCT01075334|male infertility
1219865|NCT01075334|Carnitine
1219866|NCT01075334|food supplementation
1219867|NCT01075334|insemination
1219868|NCT01075308|hormone-resistant prostate cancer
1219869|NCT01075308|recurrent prostate cancer
1219870|NCT01075308|stage IV prostate cancer
1219871|NCT01075308|stage III prostate cancer
1219872|NCT01075308|adenocarcinoma of the prostate
1219873|NCT01075295|Schizophreniform Disorder
1219874|NCT01075295|Schizophrenia, Schizoaffective disorder
1219875|NCT01075295|Bipolar I Disorder
1219876|NCT01075295|Bipolar II Disorder
1219877|NCT01075295|Major Depressive Disorder with Psychotic Features,
1219878|NCT01075295|Substance-Induced Psychoses
1219879|NCT01075295|Psychosis Not Otherwise Specified
1219880|NCT01075295|antipsychotic
1219881|NCT01075295|weight gain
1219882|NCT01075295|body mass index
1219883|NCT01075295|BMI
1219884|NCT01075295|waist circumference
1219885|NCT01075295|WC
1219886|NCT01075295|coronary heart disease
1219887|NCT01075295|CHD
1219888|NCT01075269|robotic thyroidectomy, comparative study, cosmetic result, postoperative neck discomfort, swallowing symptom
1219889|NCT01075269|Robotic thyroidectomy, cosmetic effect, postoperative distress, surgical outcome
1219890|NCT01075256|sensitivity
1219891|NCT01075256|occlusion
1219892|NCT01075243|dental pain
1219893|NCT01075243|paracetamol
1219894|NCT01075243|Post-surgical dental pain
1219895|NCT01075230|PRP, TKA, pain scale, hemoglobin, hematocrit, narcotics
1219896|NCT01075217|Peripheral arterial occlusive disease (PAOD)
1219897|NCT01075204|Respiratory Tract Infection
1219898|NCT01075204|Clarithromycin
1219899|NCT01075204|Recovery
1219900|NCT01075191|Viral load
1219901|NCT01075191|Resistance
1219902|NCT01075191|Double protease inhibitors
1219903|NCT01075191|Mutations
1219904|NCT01075191|Immune system
1219905|NCT01075191|Infection
1219906|NCT01075191|Nucleoside Reverse Transcriptase Inhibitors-free
1219907|NCT01075191|Human Immunodeficiency Virus
1219908|NCT01075178|Infection
1219909|NCT01075178|Arrhythmia
1219910|NCT01075178|Death
1219911|NCT01075178|Palivizumab
1219912|NCT01075178|Safety
1219913|NCT01075178|Hemodynamically Significant Congenital Heart Disease
1219914|NCT01075178|Pediatric
1219915|NCT01075178|Observational
1219916|NCT01075165|silicone
1219917|NCT01075165|burn scar
1219918|NCT01075165|hypertrophic scar
1219919|NCT01075165|keloid
1219920|NCT01075165|scar assessment
1219921|NCT01075165|abnormal scarring
1219922|NCT01075165|Burn patients
1219923|NCT01075152|cryptococcal meningitis
1219924|NCT01075152|cryptococcus
1219925|NCT01075152|cryptococcosis
1219926|NCT01075152|HIV
1219927|NCT01075152|AIDS
1219928|NCT01075152|strategy
1219929|NCT01075139|Motivational interviewing
1219930|NCT01075139|Physical activity
1219931|NCT01075139|Diet
1219932|NCT01075126|bipolar affective disorder
1219933|NCT01075126|African American
1219934|NCT01075126|antimanic
1219935|NCT01075126|lithium
1219936|NCT01075126|depakote
1219937|NCT01075113|adult primary hepatocellular carcinoma
1219938|NCT01075113|advanced adult primary liver cancer
1219939|NCT01075113|recurrent adult primary liver cancer
1219940|NCT01075100|metastatic
1219941|NCT01075100|breast
1219942|NCT01075100|cancer
1219943|NCT01075087|TAP Block
1219944|NCT01075087|Pain
1219945|NCT01075087|Obesity
1219946|NCT01075087|Surgery
1219947|NCT01075087|Laparoscopic Banding
1219948|NCT01075074|Pain
1219949|NCT01075074|TAP block
1219950|NCT01075074|Laparoscopic
1219951|NCT01075074|Gynecologic
1219952|NCT01075061|Congenital mirror movement, physiopathology, imaging, transcranial magnetic stimulation, candidate gene
1219953|NCT01075048|Colorectal cancer
1219954|NCT01075048|wild-type KRAS
1219955|NCT01075048|irinotecan
1219956|NCT01075048|cetuximab
1219957|NCT01075048|second-line therapy
1219958|NCT01075035|Traumatic Brain Injury
1219959|NCT01075035|TBI
1219960|NCT01075035|Military
1219961|NCT01075035|Imaging
1219962|NCT01075035|MEG
1219963|NCT01075035|PET/CT
1219964|NCT01075035|MRI
1219965|NCT01075035|fMRI
1219966|NCT01075035|DTI
1219967|NCT01075035|SANIC
1219968|NCT01075035|veteran
1219969|NCT01075009|Antibiotics
1219970|NCT01075009|Resistance
1219971|NCT01075009|Epidemiology
1219972|NCT01075009|Gram-negative bacteria
1219973|NCT01075009|Epidemiology of antibiotic use
1219974|NCT01074996|Pancreatic cancer
1219975|NCT01074996|S-1
1219976|NCT01074996|S-1 plus Leucovorin
1219977|NCT01074996|second-line therapy
1219978|NCT01074983|Prehospital, Oxygen, Trauma, Hypoxemia
1219979|NCT01074970|PARP inhibition + breast cancer
1219980|NCT01074970|breast cancer
1219981|NCT01074970|PARP inhibitor
1219982|NCT01074970|Triple negative
1219983|NCT01074944|Gaucher disease
1219984|NCT01074944|Genz-112638
1219985|NCT01074944|beta-glucosidase
1219986|NCT01074944|acid β-glucosidase
1219987|NCT01074944|glucocerebrosidase
1219988|NCT01074944|glucosylceramide
1219989|NCT01074944|D-glucosyl-N-acylsphingosine glucohydrolase
1219990|NCT01074944|substrate reduction therapy
1219991|NCT01074931|Lopinavir/ritonavir
1219992|NCT01074918|Pre-hypertension
1219993|NCT01074918|Hypertension
1219994|NCT01074905|vivax malaria
1219995|NCT01074905|artesunate
1219996|NCT01074905|chloroquine
1219997|NCT01074905|primaquine
1219998|NCT01074905|relapse
1219999|NCT01074892|endometrial hyperplasia treatment MPA per os LNG-IUD
1220000|NCT01074879|Elderly
1220001|NCT01074879|protein consumption
1220002|NCT01074879|resistance exercise
1220003|NCT01074879|muscle mass
1220004|NCT01074866|Mechanical ventilation
1220005|NCT01074866|Non invasive Ventilation
1220006|NCT01074866|Patient-ventilator interaction
1220007|NCT01074866|Pressure support
1220008|NCT01074866|Neurally adjusted ventilatory assist
1220009|NCT01074840|Food Hypersensitivity
1220010|NCT01074840|Hypersensitivity
1220011|NCT01074840|Immune System Diseases
1220012|NCT01074840|Hypersensitivity, Immediate
1220013|NCT01074840|Peanut Hypersensitivity
1220014|NCT01074840|Food Allergy
1220015|NCT01074827|Multiple Sclerosis
1220016|NCT01074827|Walking ability
1220017|NCT01074827|Strength
1220018|NCT01074827|Balance
1220019|NCT01074827|Treadmill walking
1220020|NCT01074814|Metastatic Breast Cancer
1220021|NCT01074814|Molecular profiling
1220022|NCT01074801|Closed-loop systems
1220023|NCT01074801|day-and-night glucose control
1220024|NCT01074788|rehabilitation
1220025|NCT01074788|mind body therapy
1220026|NCT01074788|integrative medicine
1220027|NCT01074775|innate immunity
1220028|NCT01074775|mycobacterium bovis
1220029|NCT01074775|mucosal immunity
1220030|NCT01074775|adaptive immunity
1220031|NCT01074775|genomics
1220032|NCT01074762|Diabetes mellitus
1220033|NCT01074762|Quality of health care
1220034|NCT01074762|Health services research
1220035|NCT01074749|AF
1220036|NCT01074749|Automatic Mode Switch
1220037|NCT01074749|FFRW
1220038|NCT01074749|paroxysmal AF
1220039|NCT01074736|influenza A/H5N1
1220040|NCT01074736|host genetic susceptibility
1220041|NCT01074736|genotyping
1220042|NCT01074723|b-cryptoxanthin
1220043|NCT01074723|cholesterol
1220044|NCT01074723|bone markers
1220045|NCT01074723|Osteoporosis
1220046|NCT01074723|cardiovascular risk
1220047|NCT01074723|post-menopausal women
1220048|NCT01074697|Randomized Controlled Trial
1220049|NCT01074697|Serotonin Agonists
1220050|NCT01074697|Dexamethasone
1220051|NCT01074697|Receptors, Neurokinin-1
1220052|NCT01074697|Radiotherapy
1220053|NCT01074697|Cisplatin
1220054|NCT01074697|Prevention & control
1220055|NCT01074684|diagnosis
1220056|NCT01074684|nodules
1220057|NCT01074684|fine needle aspiration
1220058|NCT01074658|Advance
1220059|NCT01074658|Medtronic CoreValve System
1220060|NCT01074658|International
1220061|NCT01074658|Interventional
1220062|NCT01074658|Post Market Study
1220063|NCT01074645|Acute-on -chronic liver failure
1220064|NCT01074645|Reactivation of hepatitis B
1220065|NCT01074645|Spontaneous reactivation of chronic hepatitis B presenting as to acute-on-chronic liver failure
1220066|NCT01074606|Cataract
1220067|NCT01074593|PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUG INTERFERON BETA-1A
1220068|NCT01074580|Crohn's disease
1220069|NCT01074580|sonography
1220070|NCT01074580|contrast enhanced ultrasound
1220071|NCT01074554|sarcoidosis
1220072|NCT01074554|mycobacteria
1220073|NCT01074554|cutaneous lesions
1220074|NCT01074541|Vitamin D
1220075|NCT01074541|UVB
1220076|NCT01074541|Dose-Response
1220077|NCT01074541|UV intensity
1220078|NCT01074541|Skin cancer
1220079|NCT01074528|cancer patients
1220080|NCT01074528|relatives or partners of cancer patients
1220081|NCT01074515|COPD
1220082|NCT01074515|Depression
1220083|NCT01074515|Inflammation
1220084|NCT01074515|Genetics
1220085|NCT01074515|Functioning
1220086|NCT01074515|Dyspnea
1220087|NCT01074515|Physical activity
1220088|NCT01074502|acne
1220089|NCT01074489|GDM
1220090|NCT01074489|Gestational Diabetes
1220091|NCT01074489|GTT
1220092|NCT01074489|CGMS
1220093|NCT01074476|Knee osteoarthritis
1220094|NCT01074476|glucosamine
1220095|NCT01074476|synovial fluid
1220096|NCT01074476|viscosity
1220097|NCT01074476|viscoelasticity
1220098|NCT01074476|WOMAC
1220099|NCT01074463|Bioequivalence
1220100|NCT01074463|Healthy Subjects
1220101|NCT01074450|Bioequivalence
1220102|NCT01074450|Healthy Subjects
1220103|NCT01074424|stage IIB cervical cancer
1220104|NCT01074424|stage III cervical cancer
1220105|NCT01074424|stage IVA cervical cancer
1220106|NCT01074424|cervical adenocarcinoma
1220107|NCT01074424|cervical adenosquamous cell carcinoma
1220108|NCT01074424|cervical squamous cell carcinoma
1220109|NCT01074398|recurrent ovarian epithelial cancer
1220110|NCT01074398|stage III ovarian epithelial cancer
1220111|NCT01074398|stage IV ovarian epithelial cancer
1220112|NCT01074398|fallopian tube cancer
1220113|NCT01074398|peritoneal cavity cancer
1220114|NCT01074385|Stage IV Colorectal Cancer
1220115|NCT01074359|A3243G Mitochondrial DNA Point Mutation
1220116|NCT01074346|Multiple sclerosis
1220117|NCT01074346|Interferon-beta 1-a
1220118|NCT01074333|Colorectal cancer
1220119|NCT01074333|Metastasis
1220120|NCT01074333|Cetuximab
1220121|NCT01074333|Erbitux
1220122|NCT01074333|Epidermal growth factor receptor
1220123|NCT01074320|breast cancer
1220124|NCT01074320|aromatase inhibitors
1220125|NCT01074320|musculoskeletal symptoms
1220126|NCT01074307|Systolic heart failure
1220127|NCT01074307|Bisoprolol
1220128|NCT01074307|Concor
1220129|NCT01074307|Echocardiogram
1220130|NCT01074294|Inattention
1220131|NCT01074294|Hyperactivity
1220132|NCT01074294|Impulsivity
1220133|NCT01074294|Distractibility
1220134|NCT01074294|Procrastination
1220135|NCT01074294|Disorganized
1220136|NCT01074294|ADHD
1220137|NCT01074281|Hypertension
1220138|NCT01074281|Isolated systolic hypertonia
1220139|NCT01074281|Eneas
1220140|NCT01074255|Nausea
1220141|NCT01074255|Vomiting
1220142|NCT01074255|Chemotherapy
1220143|NCT01074255|Post-chemotherapy
1220144|NCT01074242|Gastroenteritis rotavirus
1220145|NCT01074229|Pain
1220146|NCT01074229|Post Operative
1220147|NCT01074229|Opioids
1220148|NCT01074229|Laparoscopic
1220149|NCT01074229|Surgery
1220150|NCT01074229|Hysterectomy
1220151|NCT01074216|Vitamin D
1220152|NCT01074216|Vitamin D3
1220153|NCT01074216|colon cancer
1220154|NCT01074216|rectum cancer
1220155|NCT01074216|Cholecalciferol
1220156|NCT01074216|09-143
1220157|NCT01074203|nitazoxanide
1220158|NCT01074203|liver transplantation
1220159|NCT01074203|HCV recurrence
1220160|NCT01074190|Epidural Labor Analgesia
1220161|NCT01074190|Pain
1220162|NCT01074190|Infant
1220163|NCT01074190|Breastfeeding
1220164|NCT01074177|BIBW 2992
1220165|NCT01074177|NSCLC
1220166|NCT01074164|eczema
1220167|NCT01074164|atopic dermatitis
1220168|NCT01074164|itch
1220169|NCT01074164|pruritus
1220170|NCT01074164|acupressure
1220171|NCT01074164|acupuncture
1220176|NCT01074138|CPRC
1220177|NCT01074125|Hyperphosphatemia
1220178|NCT01074125|ESRD
1220179|NCT01074125|Dialysis
1220180|NCT01074125|End Stage Renal Disease
1220181|NCT01074125|Phosphorus
1220182|NCT01074125|Renal
1220183|NCT01074125|Kidney
1220184|NCT01074112|Ultrasound
1220185|NCT01074112|Prehospital
1220186|NCT01074112|Trauma
1220187|NCT01074112|EMS
1220188|NCT01074112|Paramedics
1220189|NCT01074112|Sonography
1220190|NCT01074112|Ultrasonography
1220191|NCT01074112|Ambulance
1220192|NCT01074112|FAST
1220193|NCT01074112|EFAST
1220194|NCT01074086|RAD 001 in relapsed AML
1220195|NCT01074073|Lithium DDI with Lurasidone HCl
1220196|NCT01074073|Male/Female, Schizophrenia Patients
1220197|NCT01074047|Acute Myeloid Leukemia
1220198|NCT01074047|Cytarabine
1220199|NCT01074047|Vidaza
1220200|NCT01074047|azacitidine
1220201|NCT01074047|Intensive Chemotherapy
1220202|NCT01074047|Low Dose Cytarabine
1220203|NCT01074047|Celgene
1220204|NCT01074021|Nimotuzumab
1220205|NCT01074021|Nasopharyngeal cancer
1220206|NCT01074021|chemoradiation
1220207|NCT01073995|Radiculopathy
1220208|NCT01073995|Sciatica
1220209|NCT01073995|Lumbar Disc Herniation
1220210|NCT01073995|Surgical Alternative
1220211|NCT01073982|pain
1220212|NCT01073982|inflammation
1220213|NCT01073982|osteoarthritis
1220214|NCT01073969|prebiotic study
1220215|NCT01073969|modulating colonic bacteria
1220216|NCT01073956|Subacromial Impingement Syndrome
1220217|NCT01073956|Shoulder Pain
1220218|NCT01073956|Physical therapy
1220219|NCT01073956|Electrotherapy
1220220|NCT01073956|Ultrasonic therapy
1220221|NCT01073956|Medium-wave 448 kHz therapy
1220222|NCT01073943|Bowel Preparation
1220223|NCT01073943|Colonoscopy
1220224|NCT01073930|Bowel Preparation
1220225|NCT01073930|Colonoscopy
1220226|NCT01073917|Ventilation
1220227|NCT01073917|General Anesthesia
1220228|NCT01073917|electrical impedance tomography
1220229|NCT01073917|pressure support
1220230|NCT01073917|spontaneous breathing
1220231|NCT01073917|laryngeal mask
1220232|NCT01073917|Patients who are scheduled for elective knee or ankle surgery
1220233|NCT01073891|Pharmacokinetics
1220234|NCT01073891|Bioavailability
1220235|NCT01073891|Food effect
1220236|NCT01073891|Oral liquid formulation
1220237|NCT01073878|Urinary Urge Incontinence
1220238|NCT01073878|Urinary Stress Incontinence
1220239|NCT01073878|Urinary Mixed Incontinence
1220240|NCT01073865|ZOLADEX
1220241|NCT01073865|Pre-menopausal
1220242|NCT01073865|Oestrogen Receptor
1220243|NCT01073865|Advanced Breast Cancer
1220244|NCT01073865|Progression Free Survival
1220245|NCT01073852|Chronic Urticaria
1220246|NCT01073852|Hives
1220247|NCT01073852|Hydroxychloroquine
1220248|NCT01073813|Minocycline
1220249|NCT01073813|Retinal nerve fibre layer thickness
1220250|NCT01073813|Macular volume
1220251|NCT01073813|Visual outcomes
1220252|NCT01073800|atorvastatin
1220253|NCT01073800|vascular occlusion
1220254|NCT01073800|myocardial infarction
1220255|NCT01073800|stroke
1220256|NCT01073800|renal failure
1220257|NCT01073800|critically ill
1220258|NCT01073800|Vascular occlusive events among the critically ill
1220259|NCT01073787|migraine
1220260|NCT01073787|headache
1220261|NCT01073787|pediatric
1220262|NCT01073787|children
1220263|NCT01073787|Emergency Department
1220264|NCT01073774|breast cancer couples coping
1220265|NCT01073748|Asthma
1220266|NCT01073748|Acetaminophen
1220267|NCT01073748|paracetamol
1220268|NCT01073748|FeNO
1220269|NCT01073748|Spirometry
1220270|NCT01073748|Lung function
1220271|NCT01073735|Needs assessment
1220272|NCT01073735|Health-related needs
1220273|NCT01073735|Childhood cancer survivors
1220274|NCT01073722|thoracic surgery
1220275|NCT01073722|one-lung ventilation
1220276|NCT01073722|double lumen tube
1220277|NCT01073722|endobronchial blocker
1220278|NCT01073709|Acetaminophen fasting study
1220279|NCT01073696|Sancuso
1220280|NCT01073696|granisetron
1220281|NCT01073696|Pharmacokinetics
1220282|NCT01073683|TPF
1220283|NCT01073683|INDUCTION CHEMOTHERAPY
1220284|NCT01073683|LARYNX PRESERVATION
1220285|NCT01073683|SUPACRICOID LARYNGECTOMY
1220286|NCT01073683|Stage 3 and 4 larynx cancer
1220287|NCT01073670|NSAIDs
1220288|NCT01073670|bleeding
1220289|NCT01073670|thromboelastography
1220290|NCT01073670|cardiac surgery
1220291|NCT01073670|Indomethacin
1220292|NCT01073670|acetaminophen
1220293|NCT01073657|Rehabilitation
1220294|NCT01073644|imatinib resistant or intolerant
1220295|NCT01073631|voriconazole
1220296|NCT01073631|Korea
1220297|NCT01073631|invasive fungal infection
1220298|NCT01073618|voriconazole
1220299|NCT01073618|Korea
1220300|NCT01073618|invasive fungal infection
1220301|NCT01073605|Short height
1220302|NCT01073605|intra-uterine growth retardation
1220303|NCT01073605|Genotonorm
1220304|NCT01073605|continuous treatment
1220305|NCT01073605|intermittent treatment
1220306|NCT01073592|HMP
1220307|NCT01073592|CNV
1220308|NCT01073592|AMD
1220309|NCT01073592|PHP
1220310|NCT01073592|HPHP
1220311|NCT01073592|FORESEE HOME
1220312|NCT01073579|Cryptogenic Infantile Spasms
1220313|NCT01073579|Cryptogenic West Syndrome
1220314|NCT01073579|Hypsarrhythmia
1220315|NCT01073579|Infantile Spasms
1220316|NCT01073579|Symptomatic Infantile Spasms
1220317|NCT01073579|Symptomatic West Syndrome
1220318|NCT01073579|West Syndrome
1220319|NCT01073579|Refractory Complex Partial Seizures
1220320|NCT01073579|Complex Partial Epilepsy
1220321|NCT01073579|Complex Partial Seizure Disorder
1220322|NCT01073579|Cryptogenic Partial Complex Epilepsy
1220323|NCT01073579|Disorder, Complex Partial Seizures
1220324|NCT01073579|Epilepsy, Cryptogenic, Partial Complex
1220325|NCT01073579|Epilepsy, Psychic Equivalent
1220326|NCT01073579|Epilepsy, Psychomotor
1220327|NCT01073579|Epilepsy, Symptomatic, Partial Complex
1220328|NCT01073579|Partial Complex Epilepsy, Cryptogenic
1220329|NCT01073579|Partial Complex Epilepsy, Symptomatic
1220330|NCT01073579|Seizure Disorder, Complex Partial
1220331|NCT01073579|Symptomatic Partial Complex Epilepsy
1220332|NCT01073566|Autoimmune Diseases
1220333|NCT01073566|Diabetes Mellitus
1220334|NCT01073566|Endocrine System Diseases
1220335|NCT01073566|Glucose Metabolism Disorders
1220336|NCT01073566|Immune System Diseases
1220337|NCT01073566|Insulin
1220338|NCT01073566|Metabolic Diseases
1220339|NCT01073527|Child, preschool
1220340|NCT01073527|Pediatric emergency department
1220341|NCT01073514|Malignant biliary obstruction (MBO)
1220342|NCT01073501|UREMIC PRURITUS
1220343|NCT01073501|PREGABALIN
1220344|NCT01073501|UP
1220345|NCT01073488|Pregnancy
1220346|NCT01073488|Maternal child health
1220347|NCT01073488|Developing countries
1220348|NCT01073488|Stillbirth
1220349|NCT01073488|Neonatal mortality
1220350|NCT01073488|Maternal mortality
1220351|NCT01073488|Community intervention
1220352|NCT01073488|Community mobilization
1220353|NCT01073488|Home-based Life Saving Skills
1220354|NCT01073475|Pregnancy
1220355|NCT01073475|Maternal mortality
1220356|NCT01073475|Neonatal mortality
1220357|NCT01073475|Stillbirth
1220358|NCT01073475|Maternal Near Miss
1220359|NCT01073475|Maternal Cause of Death
1220360|NCT01073475|Neonatal Cause of Death
1220361|NCT01073462|Secondary Hyperparathyroidism (sHPT)
1220362|NCT01073462|Paricalcitol
1220363|NCT01073462|Chronic kidney disease stage 5 (CKD stage 5)
1220364|NCT01073449|Cardiac devices
1220365|NCT01073449|In-Hospital Follow-up
1220366|NCT01073449|Analytical
1220367|NCT01073436|diagnosis of Ph+) CML in chronic phase.
1220368|NCT01073436|prior therapy with interferon-alpha for at least 2 years, and achieved at least a partial cytogenetic response
1220369|NCT01073436|receiving a TKI (imatinib mesylate, dasatinib, nilotinib)
1220370|NCT01073436|WBC ≤ 10 x 109/L.
1220371|NCT01073436|Platelet count < 450,000 x 109/L.
1220372|NCT01073436|No blasts or promyelocytes in peripheral blood.
1220373|NCT01073436|No evidence of disease-related symptoms and extramedullary disease
1220374|NCT01073436|complete cytogenetic response (CCyR) on a TKI for a minimum of 1 yr
1220375|NCT01073436|major molecular remission on a TKI for a minimum of 1 yr
1220376|NCT01073436|18 years of age or older
1220377|NCT01073436|ECOG performance status of 0-2 (Appendix 13.1)
1220378|NCT01073436|Informed Consent
1220379|NCT01073423|HIV
1220380|NCT01073423|sleep
1220381|NCT01073423|insomnia
1220382|NCT01073423|yoga
1220383|NCT01073423|music
1220384|NCT01073397|Menopause
1220385|NCT01073397|Hot Flashes
1220386|NCT01073397|Vasomotor symptoms
1220387|NCT01073397|Yoga
1220388|NCT01073371|Liposome
1220389|NCT01073371|Prilocaine
1220390|NCT01073371|Dental anesthesia
1220391|NCT01073358|resectable hepatic metastases of colorectal cancer
1220392|NCT01073345|Patients undergoing elective hepatic resection
1220393|NCT01073319|Methamphetamine
1220394|NCT01073319|Rivastigmine
1220395|NCT01073306|Vaccine
1220396|NCT01073306|Dengue Hemorrhagic Fever
1220397|NCT01073280|Cerebral and subarachnoid biopsy
1220398|NCT01073280|flexible endoscopy
1220399|NCT01073280|Patients with neurological findings without diagnosis.
1220400|NCT01073267|Stage IB-IIIA Mycosis fungoides
1220401|NCT01073267|Total Skin Electron Beam Therapy
1220402|NCT01073267|TSEBT
1220403|NCT01073241|benign prostatic hyperplasia
1220404|NCT01073241|Transurethral Resection of Prostate
1220405|NCT01073241|transurethral enucleation of prostate
1220406|NCT01073228|Alzheimer's disease
1220407|NCT01073228|Central Nervous System diseases
1220408|NCT01073228|Cognition
1220409|NCT01073215|Adolescents
1220410|NCT01073215|Obesity
1220411|NCT01073215|Weight Management
1220412|NCT01073215|Family-based Lifestyle Modification
1220413|NCT01073189|Acute kidney injury
1220414|NCT01073189|Fenoldopam mesylate
1220415|NCT01073189|Benephit catheter
1220416|NCT01073176|ADHD
1220417|NCT01073176|Executive function
1220418|NCT01073176|Preschool children
1220419|NCT01073176|Treatment
1220420|NCT01073176|Memory
1220421|NCT01073176|Attention
1220422|NCT01073176|Training
1220423|NCT01073176|Cognitive enhancement
1220424|NCT01073150|Tea Tree Oil
1220425|NCT01073150|Chronic Blepharitis
1220426|NCT01073137|diabetes
1220427|NCT01073072|bovine pericardium bioprosthesis
1220428|NCT01073072|contamination
1220429|NCT01073072|hernia repair
1220430|NCT01073072|abdominal wall reconstruction
1220431|NCT01073072|Tutomesh
1220432|NCT01073072|Tutopatch
1220433|NCT01073072|Potentially Contaminated Hernia Repair
1220434|NCT01073072|Potentially Contaminated Abdominal Wall Reconstruction
1220435|NCT01073059|valproic acid
1220436|NCT01073059|ertapenem
1220437|NCT01073046|Naso-Gastric/Jejunal Tube
1220438|NCT01073046|Sub-total Gastrectomy
1220439|NCT01073046|Gastric Cancer
1220440|NCT01073046|Decompression
1220441|NCT01073046|Discomfort
1220442|NCT01073046|Complications
1220443|NCT01073033|pregnancy
1220444|NCT01073033|lactation
1220445|NCT01073033|oral supplement
1220446|NCT01073033|probiotics
1220447|NCT01073033|early infections
1220448|NCT01073020|Type 2 Diabetes Mellitus
1220449|NCT01073020|Obesity
1220450|NCT01073020|Lifestyle
1220451|NCT01073020|Bariatric Surgery
1220452|NCT01073020|Laparoscopic Adjustable Gastric Band
1220453|NCT01073020|Laparoscopic Roux-en-Y Gastric Bypass
1220454|NCT01073007|Acute Stroke
1220455|NCT01073007|tissue plasminogen activator
1220456|NCT01073007|simvastatin
1220457|NCT01072994|Myocardium
1220458|NCT01072994|Phospholipid
1220459|NCT01072994|Fish oil
1220460|NCT01072994|Cardiolipin
1220461|NCT01072994|Transplantation
1220462|NCT01072981|Pancreatic Cancer
1220463|NCT01072981|Vaccine Therapy
1220464|NCT01072968|Multicenter
1220465|NCT01072968|Randomized
1220466|NCT01072968|Double-blind
1220467|NCT01072968|Efficacy and safety study
1220468|NCT01072968|BF2.649 versus placebo
1220469|NCT01072968|Patients suffering from Obstructive Sleep Apnea
1220470|NCT01072968|Complaining from Excessive Daytime Sleepiness
1220471|NCT01072968|Refusing nasal Continuous Positive Airway Pressure
1220472|NCT01072942|Chronic Obstructive
1220473|NCT01072942|Phase I
1220474|NCT01072942|Pharmacokinetics
1220475|NCT01072942|Microbiology
1220476|NCT01072929|Bipolar I Disorder
1220477|NCT01072916|Colon, Irritable
1220478|NCT01072916|Microbiota
1220479|NCT01072903|inflammation
1220480|NCT01072903|colon, irritable
1220481|NCT01072903|Colonic Diseases, Functional
1220482|NCT01072903|Irritable Bowel Syndrome
1220483|NCT01072890|Temsirolimus, Pazopanib
1220484|NCT01072877|Varicose Veins
1220485|NCT01072864|Postmenopausal
1220486|NCT01072851|colorectal cancer screening
1220487|NCT01072851|multimedia education
1220488|NCT01072851|print education
1220489|NCT01072851|culturally competent
1220490|NCT01072838|breast cancer
1220491|NCT01072838|APBI
1220492|NCT01072838|brachytherapy
1220493|NCT01072838|Contura
1220494|NCT01072812|Alzheimer's
1220495|NCT01072812|Amnestic Mild Cognitive Impairment
1220496|NCT01072812|Pharmacokinetics
1220497|NCT01072812|Pharmacodynamics
1220498|NCT01072812|Biomarkers
1220499|NCT01072799|A (H1N1)
1220500|NCT01072786|Dengue Virus
1220501|NCT01072786|Dengue Fever
1220502|NCT01072786|Dengue Vaccine
1220503|NCT01072786|Dengue Hemorrhagic Fever
1220504|NCT01072786|Dengue Shock Syndrome
1220505|NCT01072760|Mallet finger
1220506|NCT01072760|extensor tendon
1220507|NCT01072760|Kirschner wire
1220508|NCT01072760|Fracture Fixation
1220509|NCT01072734|Lupus
1220510|NCT01072734|CXCR4 on leucocytes of patients with SLE
1220511|NCT01072734|Influenza vaccine
1220512|NCT01072721|Liver
1220513|NCT01072721|Fibrosis
1220514|NCT01072721|Elastometry
1220515|NCT01072721|FIBROSCANN
1220516|NCT01072721|Children
1220517|NCT01072708|Cystic fibrosis -diabetes - glucose tolerance - reversibility - oral glucose tolerance test - predictive factors
1220518|NCT01072695|Hepatitis C
1220519|NCT01072695|HCV
1220520|NCT01072695|GS-9256
1220521|NCT01072695|GS-9190
1220522|NCT01072695|Genotype 1
1220523|NCT01072682|Acute Renal Failure
1220524|NCT01072682|Acute tubular necrosis
1220525|NCT01072682|Continuous Renal Replacement Therapy
1220526|NCT01072682|Selective cytopheretic device
1220527|NCT01072669|Ambrisentan increases digital micro-vascular flow (measured by LDPI) in patients with Raynaud's phenomenon (RP) and digital ischemia secondary to SSc.
1220528|NCT01072643|Sedation
1220529|NCT01072643|Pulmonary Hypertension
1220530|NCT01072643|Pediatric
1220531|NCT01072643|Cardiac Catheterization
1220532|NCT01072643|Pulmonary Vascular Resistance
1220533|NCT01072630|Bipolar I Disorder
1220534|NCT01072604|Aspirin
1220535|NCT01072604|Acetylsalicylic Acid
1220536|NCT01072591|anti-NGF
1220537|NCT01072591|OA
1220538|NCT01072591|pain
1220539|NCT01072578|Healthy volunteers
1220540|NCT01072578|Inhibition of glucose re-absorption
1220541|NCT01072578|diabetes
1220542|NCT01072578|dapagliflozin
1220543|NCT01072565|Type 2 Diabetes
1220544|NCT01072565|A1c
1220545|NCT01072565|Continuous Glucose Monitoring
1220546|NCT01072565|Blood Glucose
1220547|NCT01072552|recurrent wheezing
1220548|NCT01072552|asthma
1220549|NCT01072552|preterm infants
1220550|NCT01072552|palivizumab
1220551|NCT01072552|atopic diseases
1220552|NCT01072539|infection
1220553|NCT01072539|Tygacil
1220554|NCT01072539|PMS
1220555|NCT01072526|Dry Eye Syndromes
1220556|NCT01072526|Lacrimal Apparatus Diseases
1220557|NCT01072513|Semen Analysis, Prostate Cancer, Proton Radiation
1220558|NCT01072500|Aging
1220559|NCT01072500|Physical Activity
1220560|NCT01072500|Exercise
1220561|NCT01072500|Sedentary Lifestyle
1220562|NCT01072500|Mobility
1220563|NCT01072500|Disability
1220564|NCT01072500|Falls
1220565|NCT01072500|Cost effectiveness
1220566|NCT01072500|Behavioral counseling
1220567|NCT01072487|Safety
1220568|NCT01072487|Sedation
1220569|NCT01072487|Gastrointestinal endoscopy
1220570|NCT01072487|Colonoscopy
1220571|NCT01072474|Safety
1220572|NCT01072474|Sedation
1220573|NCT01072474|Gastrointestinal endoscopy
1220574|NCT01072474|Colonoscopy
1220575|NCT01072461|Cerebrovascular Accident
1220576|NCT01072461|Robotics
1220577|NCT01072461|Virtual Reality
1220578|NCT01072461|Rehabilitation
1220579|NCT01072461|Neuroplasticity
1220580|NCT01072448|COPD
1220581|NCT01072448|indacaterol
1220582|NCT01072435|ERCP
1220583|NCT01072435|patient-controlled sedation
1220584|NCT01072435|target-controlled infusion
1220585|NCT01072435|propofol
1220586|NCT01072435|Sedation with propofol for ERCP
1220587|NCT01072435|Endoscopic Retrograde Cholangiopancreatography
1220588|NCT01072422|Smoking
1220589|NCT01072422|Pulmonary Disease, Chronic Obstructive
1220590|NCT01072422|Questionnaires
1220591|NCT01072422|Nurses
1220592|NCT01072422|Primary Health Care
1220593|NCT01072409|Speech perception ability in the CI alone condition
1220594|NCT01072383|chronic plaque psoriasis
1220595|NCT01072383|psoriasis vulgaris
1220596|NCT01072383|autoimmune disease
1220597|NCT01072370|Umbilical Cord Blood
1220598|NCT01072370|Stem Cells
1220599|NCT01072370|Autologous Blood Transfusion
1220600|NCT01072370|Cerebral Palsy
1220601|NCT01072357|High-Risk Corneal Transplantation
1220602|NCT01072357|Penetrating Keratoplasty
1220603|NCT01072357|Neovascularization
1220604|NCT01072357|Corneal Blood Vessels
1220605|NCT01072357|Avastin
1220606|NCT01072357|Bevacizumab
1220607|NCT01072357|Corneal Graft
1220608|NCT01072344|Anxiety
1220609|NCT01072344|Chamomile
1220610|NCT01072344|Herbal Remedy
1220611|NCT01072344|Complementary and Alternative Medicine
1220612|NCT01072331|insulin resistance
1220613|NCT01072318|Breast cancer
1220614|NCT01072318|extended adjuvant hormonal therapy
1220615|NCT01072318|letrozole
1220616|NCT01072318|Toremifene
1220617|NCT01072305|fluid restriction
1220618|NCT01072305|fluid therapy
1220619|NCT01072305|intraoperative care
1220620|NCT01072279|Malnutrition;
1220621|NCT01072279|Infant nutrition;
1220622|NCT01072279|Fortified food
1220623|NCT01072279|Linear growth
1220624|NCT01072279|Cluster randomized controlled trials
1220625|NCT01072279|Effectiveness
1220626|NCT01072279|Impact evaluation studies
1220627|NCT01072279|Burundi
1220628|NCT01072279|Guatemala
1220629|NCT01072266|Refractory, Advanced malignancies
1220630|NCT01072227|Non-typeable Haemophilus Influenzae
1220631|NCT01072227|Acute Otitis Media
1220632|NCT01072227|Streptococcus Pneumoniae
1220633|NCT01072227|Etiology
1220634|NCT01072214|Pazopanib
1220635|NCT01072214|Tolerability
1220636|NCT01072214|Pharmacokinetics
1220637|NCT01072214|GW786034
1220638|NCT01072214|Safety
1220639|NCT01072175|drug-drug interaction
1220640|NCT01072175|BRAF inhibitor
1220641|NCT01072175|expansion cohorts
1220642|NCT01072175|melanoma
1220643|NCT01072175|dose escalation
1220644|NCT01072175|MEK inhibitor
1220645|NCT01072162|healthy
1220646|NCT01072162|powder for suspension
1220647|NCT01072162|tablets
1220648|NCT01072162|bioavailibility
1220649|NCT01072162|eltrombopag
1220650|NCT01072149|COPD
1220651|NCT01072149|Safety
1220652|NCT01072149|FEV1
1220653|NCT01072149|Efficacy
1220654|NCT01072136|mucopurulent cervicitis, chlamydia, gonorrhea, women
1220655|NCT01072110|Patients with diarrhea
1220656|NCT01072097|PCOS
1220657|NCT01072097|Atorvastatin
1220658|NCT01072097|Androgens
1220659|NCT01072097|Glucose metabolism
1220660|NCT01072097|Inflammatory markers
1220661|NCT01072084|food allergy
1220662|NCT01072084|confocal laser endoscope
1220663|NCT01072084|diagnosis
1220664|NCT01072084|Diagnosis of food allergy
1220665|NCT01072071|abdominal compartment syndrome
1220666|NCT01072071|intra-abdominal pressure
1220667|NCT01072071|furosemide
1220668|NCT01072071|fluid balance
1220669|NCT01072058|Infliximab
1220670|NCT01072058|Adalimumab
1220671|NCT01072058|Etanercept
1220672|NCT01072058|Heart failure
1220673|NCT01072058|Diastolic disfunction
1220674|NCT01072058|TNF blocker
1220675|NCT01072058|Anti-TNF
1220676|NCT01072058|Echocardiography
1220677|NCT01072058|Tissue doppler imaging
1220678|NCT01072058|Brain Natriuretic Peptide
1220679|NCT01072058|NT-proBNP
1220680|NCT01072045|Hemangioma
1220681|NCT01072045|Proliferative hemangioma
1220682|NCT01072045|Treatment
1220683|NCT01072045|Propranolol
1220684|NCT01072045|Corticosteroid
1220685|NCT01072032|EEG
1220686|NCT01072032|Robotics (ankle)
1220687|NCT01072032|Motor-learning
1220688|NCT01072032|Brain Plasticity
1220689|NCT01072006|TBI (Traumatic Brain Injury)
1220690|NCT01072006|PTSD
1220691|NCT01072006|fMRI
1220692|NCT01072006|attention
1220693|NCT01071993|prevention
1220694|NCT01071993|nephropathy
1220695|NCT01071967|Community Health Nursing
1220696|NCT01071967|Nursing Care Management
1220697|NCT01071967|Aged
1220698|NCT01071967|Aged, 80 and over
1220699|NCT01071967|Health Services for the Aged
1220700|NCT01071967|Geriatric Nursing
1220701|NCT01071967|Geriatric Assessment
1220702|NCT01071967|Longevity
1220703|NCT01071967|Mortality
1220704|NCT01071954|Immune thrombocytopenic Purpura
1220705|NCT01071954|Pediatric
1220706|NCT01071954|Thrombocytopenia
1220707|NCT01071941|rRp450
1220708|NCT01071941|Herpes virus
1220709|NCT01071941|Gene therapy
1220710|NCT01071928|Advanced Urothelial Carcinoma
1220711|NCT01071902|ear tubes
1220712|NCT01071902|ear drainage
1220713|NCT01071902|ear infection
1220714|NCT01071902|ear drops
1220715|NCT01071902|acute otitis media
1220716|NCT01071889|Healthy Volunteers
1220717|NCT01071876|Sleep disorder
1220718|NCT01071876|obstructive sleep apnea
1220719|NCT01071876|excessive daytime sleepiness
1220720|NCT01071876|patients with OSA treated by CPAP presenting EDS
1220721|NCT01071850|Type 2 diabetes
1220722|NCT01071850|diabetes
1220723|NCT01071850|ASP1941
1220724|NCT01071850|Metformin
1220725|NCT01071837|Glioblastoma Multiforme
1220726|NCT01071824|size
1220727|NCT01071824|limb
1220728|NCT01071824|transverse coloplasty pouch
1220729|NCT01071824|rectal resection
1220730|NCT01071824|mesorectal excision
1220731|NCT01071824|treatment outcome
1220732|NCT01071811|Randomized controlled trial
1220733|NCT01071811|Pedometer
1220734|NCT01071811|Physical activity
1220735|NCT01071811|Health measurement
1220736|NCT01071811|Self-rated health
1220737|NCT01071811|Stress
1220738|NCT01071811|Sleep quality
1220739|NCT01071785|Metabolic Syndrome
1220740|NCT01071785|diet
1220741|NCT01071785|fiber
1220742|NCT01071785|Serum lipids
1220743|NCT01071785|Albuminuria
1220744|NCT01071759|Pregnancy
1220745|NCT01071759|anemia
1220746|NCT01071759|Helicobacter pylori
1220747|NCT01071759|Hemoglobin
1220748|NCT01071759|Iron
1220749|NCT01071759|Ferritin
1220750|NCT01071720|Healthy subjects
1220751|NCT01071707|IPF
1220752|NCT01071707|Idiopathic Pulmonary Fibrosis
1220753|NCT01071694|Multiple Sclerosis,
1220754|NCT01071694|Relapsing-Remitting,
1220755|NCT01071694|Interferon beta-1b,
1220756|NCT01071694|Quality of life
1220757|NCT01071681|Arterial hypertension
1220758|NCT01071668|onset of labor
1220759|NCT01071668|metabolomics
1220760|NCT01071668|vaginal secretions
1220761|NCT01071668|urine
1220762|NCT01071668|blood
1220763|NCT01071655|colorectal cancer
1220764|NCT01071655|Bevacizumab
1220765|NCT01071655|Oxaliplatin
1220766|NCT01071655|Irinotecan
1220767|NCT01071655|5FU
1220768|NCT01071655|capecitabine
1220773|NCT01071629|interval training
1220774|NCT01071629|strength training
1220775|NCT01071629|exercise capacity
1220776|NCT01071629|chronic heart failure
1220777|NCT01071629|Cardiac rehabilitation
1220778|NCT01071616|Cannabinoids
1220779|NCT01071616|Oral Fluid
1220780|NCT01071616|Pharmacokinetics
1220781|NCT01071616|Stability
1220782|NCT01071616|Smoked Cannabis
1220783|NCT01071603|Biomarkers
1220784|NCT01071603|Extrapulmonary TB
1220785|NCT01071603|NTM
1220786|NCT01071603|HRCT
1220787|NCT01071603|MDRTB
1220788|NCT01071603|Tuberculosis
1220789|NCT01071590|Parkinson's Disease
1220790|NCT01071590|Sensory Input
1220791|NCT01071590|Gait
1220792|NCT01071590|Imagery
1220793|NCT01071590|Parkinson Disease
1220794|NCT01071590|PD
1220795|NCT01071577|Bone Marrow Stromal Cells
1220796|NCT01071577|Mesenchymal Stem Cells
1220797|NCT01071577|Immune Modulation
1220798|NCT01071577|Tissue Regeneration
1220799|NCT01071577|Bone Marrow
1220800|NCT01071577|Healthy Volunteer
1220801|NCT01071577|HV
1220802|NCT01071551|Children
1220803|NCT01071551|Obesity
1220804|NCT01071551|Lifestyle
1220805|NCT01071551|LSES
1220806|NCT01071551|Caries
1220807|NCT01071538|Depressive Disorder, Major
1220808|NCT01071538|Late-Life Depression
1220809|NCT01071538|Geriatrics
1220810|NCT01071538|Buprenorphine
1220811|NCT01071512|MRI
1220812|NCT01071512|OCT
1220813|NCT01071512|Tysabri
1220814|NCT01071512|Multiple Sclerosis
1220815|NCT01071512|cognition
1220816|NCT01071499|pharmacokinetics
1220817|NCT01071499|pharmacogenetics
1220818|NCT01071499|morphine
1220819|NCT01071499|children
1220820|NCT01071486|Busulfan
1220821|NCT01071486|Glutathione S-transferase
1220822|NCT01071486|Genetic polymorphism
1220823|NCT01071486|HVOD
1220824|NCT01071486|GVHD
1220825|NCT01071473|Childhood cancer
1220826|NCT01071473|Anthracyclines
1220827|NCT01071473|Cardiomyopathy
1220828|NCT01071460|PAD
1220829|NCT01071447|Rheumatic diseases
1220830|NCT01071447|Biologic treatment
1220831|NCT01071447|Nurse-led
1220832|NCT01071421|Sleep apnea syndrome
1220833|NCT01071421|community acquired pneumonia
1220834|NCT01071421|prevalence
1220835|NCT01071408|chronic care model
1220836|NCT01071408|stroke prevention
1220837|NCT01071408|health services research
1220838|NCT01071395|Parkinson's disease
1220839|NCT01071395|Dyskinesia
1220840|NCT01071395|Dyskinesia Rating Scales
1220841|NCT01071395|Amantadine
1220842|NCT01071395|Placebo
1220843|NCT01071382|Aeromedical Evacuation
1220844|NCT01071382|Repatriation
1220845|NCT01071356|methamphetamine
1220846|NCT01071356|motivational interviewing
1220847|NCT01071343|muscular atrophy
1220848|NCT01071343|recovery of function
1220849|NCT01071343|rehabilitation
1220850|NCT01071343|Intensive care unit
1220851|NCT01071304|Relapsed or refractory advanced cancer, metastatic cancer, locally advanced cancer
1220852|NCT01071278|Lipid metabolism disorder
1220853|NCT01071252|Moderate to severe chronic plaque-type psoriasis
1220854|NCT01071252|AIN457
1220855|NCT01071252|dermatology
1220856|NCT01071239|Fanconi Anemia
1220857|NCT01071239|Hematopoietic stem cell transplant
1220858|NCT01071226|Malignant and non-malignant diseases
1220859|NCT01071226|Hematopoietic stem cell transplant
1220860|NCT01071226|Peripheral blood progenitor cell transplant
1220861|NCT01071226|CliniMACS device
1220862|NCT01071226|T cell depletion
1220863|NCT01071200|Reproductive Techniques, Assisted
1220864|NCT01071200|Recombinant human follicle stimulating hormone (r-hFSH)
1220865|NCT01071200|Recombinant leutinizing hormone (r-hLH)
1220866|NCT01071187|alcohol dependence
1220867|NCT01071187|addiction
1220868|NCT01071187|alcohol
1220869|NCT01071187|relapse prevention
1220870|NCT01071174|HIV infections
1220871|NCT01071174|Anti-HIV agents
1220872|NCT01071174|HIV-1
1220873|NCT01071161|chronic cough
1220874|NCT01071161|COPD
1220875|NCT01071161|Azithromycin
1220876|NCT01071161|Zithromax
1220877|NCT01071161|LCQ
1220878|NCT01071148|Infertility
1220879|NCT01071148|Gonal-f
1220880|NCT01071148|Pergoveris
1220881|NCT01071148|Luveris
1220882|NCT01071122|Central blood pressure
1220883|NCT01071122|Nifedipine
1220884|NCT01071122|Valsartan
1220885|NCT01071109|Therapeutic massage
1220886|NCT01071109|massage
1220887|NCT01071109|inflammation
1220888|NCT01071109|fatigue
1220889|NCT01071109|insomnia
1220890|NCT01071109|radiation therapy
1220891|NCT01071109|breast cancer
1220892|NCT01071109|Breast Cancer patients receiving radiation therapy
1220893|NCT01071096|Botox
1220894|NCT01071096|OnabotulinumtoxinA
1220895|NCT01071096|Chronic Migraine
1220896|NCT01071096|Calcitonin Gene-Related Peptide
1220897|NCT01071096|Saliva
1220898|NCT01071083|MS
1220899|NCT01071070|Chronic Kidney Disease
1220900|NCT01071070|Secondary hyperparathyroidism
1220901|NCT01071057|opioid-induced pruritus
1220902|NCT01071057|naloxone
1220903|NCT01071044|Chronic Fatigue Syndrome
1220904|NCT01071031|Safety
1220905|NCT01071031|Tolerability
1220906|NCT01071031|Immunogenicity
1220907|NCT01071031|Human Immunodeficiency Virus
1220908|NCT01071031|HIV-1
1220909|NCT01071031|Vaccine
1220910|NCT01071031|CD4
1220911|NCT01071031|Viral Load
1220912|NCT01071031|HIV
1220913|NCT01071018|locally advanced or metastatic solid tumors
1220914|NCT01071005|Decrease serum levels of luteinizing hormone, FSH and Testosterone
1220915|NCT01070966|Atherosclerosis
1220916|NCT01070953|Hypercholesterolemia
1220917|NCT01070940|L-NMMA
1220918|NCT01070940|blood pressure
1220919|NCT01070940|arterial stiffness
1220920|NCT01070940|pulse wave velocity
1220921|NCT01070940|augmentation index
1220922|NCT01070940|dose-response
1220923|NCT01070940|healthy subjects
1220924|NCT01070940|GFR
1220925|NCT01070914|Cilia
1220926|NCT01070914|Phenotyping
1220927|NCT01070914|Diagnosis
1220928|NCT01070914|Nitric Oxide
1220929|NCT01070914|Bronchiectasis
1220930|NCT01070888|Asthma
1220931|NCT01070888|Exercise Induced Asthma
1220932|NCT01070875|Antithrombotic prophylaxis
1220933|NCT01070862|multiple myeloma, treatment, first line
1220934|NCT01070849|exercise
1220935|NCT01070849|physical activity
1220936|NCT01070836|JCV
1220937|NCT01070836|Sample Collection
1220938|NCT01070836|PML
1220939|NCT01070836|Antibody
1220940|NCT01070823|Sample Collection
1220941|NCT01070823|JCV
1220942|NCT01070823|PML
1220943|NCT01070810|Septic Shock
1220944|NCT01070810|Sepsis
1220945|NCT01070797|Epstein-Barr virus
1220946|NCT01070797|CTL
1220947|NCT01070797|cytotoxic T Lymphocytes
1220948|NCT01070797|CMV
1220949|NCT01070797|Adenovirus Infection
1220950|NCT01070797|viral infection
1220951|NCT01070797|hematopoietic stem cell transplantation
1220952|NCT01070784|Symbicort
1220953|NCT01070784|Safety
1220954|NCT01070784|Efficacy
1220955|NCT01070784|COPD
1220956|NCT01070784|Japanese
1220957|NCT01070771|Pressure wire
1220958|NCT01070771|Fractional flow reserve
1220959|NCT01070758|Congenital hyperinsulinism
1220960|NCT01070758|Somatostatin analog
1220961|NCT01070758|Lanreotide autogel
1220962|NCT01070758|Hypoglycemia
1220963|NCT01070745|PDA
1220964|NCT01070745|Indomethacin
1220965|NCT01070745|Ibuprofen
1220966|NCT01070732|Fever
1220967|NCT01070732|Infectious diseases
1220968|NCT01070732|Neoplasia
1220969|NCT01070732|Pain
1220970|NCT01070732|cholecystectomy
1220971|NCT01070732|Colectomy
1220972|NCT01070719|Multiple Sclerosis, relapsing forms
1220973|NCT01070706|Patients with HER2- stage II/III breast cancer
1220974|NCT01070693|Inguinal hernia
1220975|NCT01070693|Open mesh repair
1220976|NCT01070693|Long term outcome
1220977|NCT01070693|Recurrence
1220978|NCT01070693|Discomfort
1220979|NCT01070680|ERCP
1220980|NCT01070680|dexmedetomidine
1220981|NCT01070680|propofol
1220982|NCT01070680|patient-controlled sedation
1220983|NCT01070680|Chronic Alcoholic pancreatitis
1220984|NCT01070667|PAF
1220985|NCT01070667|AF
1220986|NCT01070667|Dronedarone
1220987|NCT01070667|AF Burden
1220988|NCT01070667|AFB
1220989|NCT01070667|PPM
1220990|NCT01070667|Permanent Pacemaker
1220991|NCT01070667|Atrial Fibrillation Burden in Paroxysmal Atrial Fibrillation
1220992|NCT01070654|ARDS
1220993|NCT01070654|Recruitment Manoeuvres
1220994|NCT01070654|PEEP
1220995|NCT01070654|Cytokines
1220996|NCT01070654|Respiratory Insufficiency
1220997|NCT01070641|CARVEDILOL
1220998|NCT01070641|VARICEAL BAND LIGATION
1220999|NCT01070641|PRIMARY PROPHYLAXIS
1221000|NCT01070628|Pharmacokinetic
1221001|NCT01070602|IFIS
1221002|NCT01070589|Obesity
1221003|NCT01070589|Growth hormone secretion
1221004|NCT01070589|Anaerobic exercise
1221005|NCT01070576|non union
1221006|NCT01070576|fracture
1221007|NCT01070576|healing
1221008|NCT01070576|arginine
1221009|NCT01070576|NO
1221010|NCT01070563|Brain death
1221011|NCT01070563|CT angiography
1221012|NCT01070563|Ultrasonography, doppler, transcranial
1221013|NCT01070537|Otolaryngology
1221014|NCT01070537|Equipment and Supplies
1221015|NCT01070537|Intubation
1221016|NCT01070511|Muscular Dystrophy
1221017|NCT01070511|Tadalafil
1221018|NCT01070498|peanut hypersensitivity
1221019|NCT01070498|tree nut hypersensitivity
1221020|NCT01070498|allergy
1221021|NCT01070498|Trichuris suis
1221022|NCT01070498|hygiene hypothesis
1221023|NCT01070498|treatment
1221024|NCT01070498|clinical trial
1221025|NCT01070498|food/adverse effect
1221026|NCT01070498|peanut allergy (mild to moderate)
1221027|NCT01070498|tree nut allergy (mild to moderate)
1221028|NCT01070472|labor induction at term using a titrated oral misoprostol solution
1221029|NCT01070459|Stroke aerobic exercise daily functioning rehabilitation
1221030|NCT01070446|choline
1221031|NCT01070446|cystic fibrosis
1221032|NCT01070446|methyl metabolism
1221033|NCT01070446|fatty acids
1221034|NCT01070446|oxidative stress
1221035|NCT01070446|pulmonary function
1221036|NCT01070433|Diabetic Foot Ulcers (DFUs)
1221037|NCT01070420|Adenosine
1221038|NCT01070420|Fractional flow reserve, Hyperemia
1221039|NCT01070420|Fractional Flow Reserve, Myocardial
1221040|NCT01070407|Hepatitis C virus
1221041|NCT01070407|HCV
1221042|NCT01070407|Adenovirus
1221043|NCT01070407|Vaccine
1221044|NCT01070394|ADHD
1221045|NCT01070394|Lisdexamfetamine Dimesylate
1221046|NCT01070394|Amphetamine
1221047|NCT01070368|skin test
1221048|NCT01070368|open wheat challenge
1221049|NCT01070355|Colorectal Neoplasms
1221050|NCT01070355|Fish Oils
1221051|NCT01070355|Fatty Acids, Omega-3
1221052|NCT01070355|Eicosapentaenoic Acid
1221053|NCT01070355|Liver Metastases
1221054|NCT01070355|Randomised Controlled Trial
1221055|NCT01070316|Epilepsy
1221056|NCT01070316|Tuberous Sclerosis Complex
1221057|NCT01070316|Everolimus
1221058|NCT01070316|RAD001
1221059|NCT01070316|Mammalian Target of Rapamycin (MTOR)
1221060|NCT01070303|HUMIRA
1221061|NCT01070303|adalimumab
1221062|NCT01070303|Inflammatory Bowel Disease
1221063|NCT01070290|gastric carcinoma
1221064|NCT01070290|Locally Advanced or Metastatic Gastric Cancer
1221065|NCT01070277|chronic diarrhea
1221066|NCT01070277|travelers
1221067|NCT01070277|Parasites
1221068|NCT01070277|albendazole
1221069|NCT01070277|tinidazole
1221070|NCT01070264|Osteoarthritis
1221071|NCT01070238|Isomaltulose
1221072|NCT01070238|Slow Released Carbohydrates
1221073|NCT01070238|Postprandial Glucose Metabolism
1221074|NCT01070238|Type 2 diabetes
1221075|NCT01070212|human, chewing, appetite,
1221076|NCT01070199|obese, liquid, solid, fitness, humans, appetite
1221077|NCT01070186|nephrectomy
1221078|NCT01070186|T1b
1221079|NCT01070186|T2
1221080|NCT01070186|T3
1221081|NCT01070186|T4
1221082|NCT01070186|N1
1221083|NCT01070186|Kidney Cancer
1221084|NCT01070173|Ghrelin
1221085|NCT01070173|short stature
1221086|NCT01070173|failure to thrive
1221087|NCT01070160|Polycystic Ovarian Syndrome (PCOS)
1221088|NCT01070160|Metformin
1221089|NCT01070160|Endometrin
1221090|NCT01070147|asthma
1221091|NCT01070147|emergency medicine
1221092|NCT01070147|medical informatics
1221093|NCT01070147|computerized reminder systems
1221094|NCT01070121|Rheumatoid Arthritis
1221095|NCT01070121|RA
1221096|NCT01070121|Autoimmune Disease
1221097|NCT01070121|Muscular Skeletal Disease
1221098|NCT01070108|Preemption, ketamine, escalating, dose, pain, analgesia
1221099|NCT01070082|adult ICU patients
1221100|NCT01070082|procedural pain
1221101|NCT01070082|pain intensity
1221102|NCT01070082|pain distress
1221103|NCT01070082|pain behaviors
1221104|NCT01070082|pain
1221105|NCT01070082|ICU procedures
1221106|NCT01070069|Percutaneous
1221107|NCT01070069|Preclose
1221108|NCT01070069|Endologix
1221109|NCT01070069|Abbott Vascular
1221110|NCT01070069|Endovascular
1221111|NCT01070069|PEVAR
1221112|NCT01070069|Stent graft
1221113|NCT01070069|Suture mediated closure devices
1221114|NCT01070056|Blood Pressure
1221115|NCT01070056|Lifestyle Changes
1221116|NCT01070056|African American
1221117|NCT01070043|Hypertension
1221118|NCT01070043|valsartan
1221119|NCT01070043|amlodipine
1221120|NCT01070043|high blood pressure
1221121|NCT01070030|Stage II Hypertension, Aliskiren, Amlodipine, Hydrochlorothiazide
1221122|NCT01070017|Peru
1221123|NCT01070017|DOT
1221124|NCT01070017|HIV
1221125|NCT01070017|AIDS
1221126|NCT01070017|Community based
1221127|NCT01070017|social capital
1221128|NCT01070004|sleepiness
1221129|NCT01070004|driving
1221130|NCT01070004|countermeasures
1221131|NCT01070004|coffee
1221132|NCT01070004|blue light exposure
1221133|NCT01070004|physical activity
1221134|NCT01069991|Asthma
1221135|NCT01069991|Adolescents
1221136|NCT01069991|Patient Education
1221137|NCT01069991|Schools
1221138|NCT01069965|Type 2
1221139|NCT01069952|Deep Brain Stimulation
1221140|NCT01069952|Treatment Refractory
1221141|NCT01069952|Neurosurgery
1221142|NCT01069952|Implantable Neurostimulator (INS)
1221143|NCT01069952|Internal Capsule
1221144|NCT01069939|Gastric ulcer
1221145|NCT01069939|Duodenal ulcer
1221146|NCT01069939|Low-dose aspirin
1221147|NCT01069926|Diabetes
1221148|NCT01069913|Healthy Volunteer
1221149|NCT01069900|Intra-abdominal infection
1221150|NCT01069900|Pediatric infection
1221151|NCT01069887|febrile events
1221152|NCT01069887|invasive fungal infections
1221153|NCT01069887|hematological patients
1221154|NCT01069874|Bone Density Conservation Agents
1221155|NCT01069874|Cholecalciferol
1221156|NCT01069874|Communicable Diseases
1221157|NCT01069874|Growth Substances
1221158|NCT01069874|Housing for the Elderly
1221159|NCT01069874|Infection
1221160|NCT01069874|Micronutrients
1221161|NCT01069874|Pharmacologic Actions
1221162|NCT01069874|Physiological Effects of Drugs
1221163|NCT01069874|Respiratory Tract Diseases
1221164|NCT01069874|Vitamins
1221165|NCT01069874|Respiratory Tract Infections/prevention & control*
1221166|NCT01069874|Vitamin D
1221167|NCT01069861|PPHN
1221168|NCT01069861|neonates
1221169|NCT01069861|sildanefil IV
1221170|NCT01069835|Non small cell lung cancer
1221171|NCT01069835|EGFR mutation
1221172|NCT01069835|NSCLC
1221173|NCT01069822|Midazolam
1221174|NCT01069822|Pharmacokinetics
1221175|NCT01069796|triple negative
1221176|NCT01069796|metastatic
1221177|NCT01069796|breast cancer
1221178|NCT01069796|First line chemotherapy
1221179|NCT01069783|dyslipidemia
1221180|NCT01069783|cholesterol
1221181|NCT01069783|LDL
1221182|NCT01069770|Neoadjuvant Therapy
1221183|NCT01069770|Sunitinib
1221184|NCT01069770|Clear Cell Renal Cell Carcinoma
1221185|NCT01069770|Metastasis
1221186|NCT01069757|Advanced/recurrent non-small-cell lung cancer
1221187|NCT01069705|Tobramycin Inhalation Powder
1221188|NCT01069705|Cystic fibrosis
1221189|NCT01069705|Lung diseases
1221190|NCT01069705|Anti-Bacterial Agents
1221191|NCT01069705|Treatment of pulmonary infections with P. aeruginosa in cystic fibrosis patients
1221192|NCT01069692|Chronic Kidney Disease
1221193|NCT01069692|Hemodialysis
1221194|NCT01069692|Hyperphosphatemia
1221195|NCT01069692|Hyperphosphatemia patients with chronic kidney disease on 3x/week hemodialysis
1221196|NCT01069666|atopic dermatitis
1221197|NCT01069666|Thai pediatricians
1221198|NCT01069653|CDCA1
1221199|NCT01069653|KIF20A
1221200|NCT01069653|lung cancer
1221201|NCT01069653|vaccine
1221202|NCT01069653|HLA-A*2402
1221203|NCT01069640|URLC10
1221204|NCT01069640|lung cancer
1221205|NCT01069640|vaccine
1221206|NCT01069640|HLA-A*0201
1221207|NCT01069640|HLA-A*0206
1221208|NCT01069614|Equipment and supplies
1221209|NCT01069601|solid organ transplantation
1221210|NCT01069601|bone marrow transplantation
1221211|NCT01069601|adults
1221212|NCT01069601|adults with solid organ transplantation
1221213|NCT01069601|adults with bone marrow transplantation
1221214|NCT01069588|bioabsorbable screw
1221215|NCT01069588|acl reconstruction
1221216|NCT01069575|URLC10
1221217|NCT01069575|CDCA1
1221218|NCT01069575|KIF20A
1221219|NCT01069575|lung cancer
1221220|NCT01069575|vaccine
1221221|NCT01069575|HLA-A*2402
1221222|NCT01069562|closed loop control of anesthesia
1221223|NCT01069562|isoflurane
1221224|NCT01069562|open heart surgery
1221225|NCT01069549|Type 2 Diabetes Mellitus
1221226|NCT01069549|Diabetic Nephropathy
1221227|NCT01069549|Angiotensin II type 1 receptor gene polymorphism
1221228|NCT01069549|Acetyl coA carboxylase beta gene polymorphism.
1221229|NCT01069536|metoclopramide
1221230|NCT01069536|akathisia
1221231|NCT01069536|nausea
1221232|NCT01069536|vomiting
1221233|NCT01069536|antiemetic
1221234|NCT01069536|improvement of nausea
1221235|NCT01069523|Attention Deficit Disorder with Hyperactivity
1221236|NCT01069523|Guanfacine
1221237|NCT01069523|Event Related Potentials
1221238|NCT01069497|Infection control
1221239|NCT01069497|Urinary Tract Infections
1221240|NCT01069497|Respiratory Tract Infections
1221241|NCT01069484|Randomized controlled trial
1221242|NCT01069484|Post partum pelvic floor muscle training
1221243|NCT01069484|Urinary incontinence
1221244|NCT01069484|Pelvic floor dysfunction
1221245|NCT01069484|Pelvic floor muscle injury
1221246|NCT01069484|Pelvic floor muscle strength
1221247|NCT01069484|Pelvic floor muscle morphology
1221248|NCT01069471|S.dysenteriae
1221249|NCT01069471|Healthy volunteers
1221250|NCT01069471|Conjugate vaccine
1221251|NCT01069471|Safety
1221252|NCT01069471|Immunogenicity
1221253|NCT01069471|Dose scaling
1221257|NCT01069445|diet
1221258|NCT01069445|probiotics
1221259|NCT01069445|inflammaging
1221260|NCT01069445|oxidative stress
1221261|NCT01069445|gut microbiota
1221262|NCT01069445|food complements
1221263|NCT01069432|Chronic Lymphocytic Leukemia
1221264|NCT01069432|CLL
1221265|NCT01069432|Normal Volunteers
1221266|NCT01069419|Certolizumab Pegol
1221267|NCT01069419|Cimzia
1221268|NCT01069406|notch
1221269|NCT01069406|uterine
1221270|NCT01069406|first
1221271|NCT01069406|bleeding
1221272|NCT01069380|resting metabolic rate
1221273|NCT01069380|bed ridden, vegetative
1221274|NCT01069380|low conscious
1221275|NCT01069380|minimal conscious state
1221276|NCT01069380|immobilized
1221277|NCT01069380|resting energy expenditure
1221278|NCT01069367|Influenza A
1221279|NCT01069367|H1N1 subtype
1221280|NCT01069367|Children/adolescent
1221281|NCT01069367|Vaccine
1221282|NCT01069367|Adjuvant
1221283|NCT01069367|Cell culture
1221284|NCT01069341|Rubeosis
1221285|NCT01069341|Neovascularization of iris
1221286|NCT01069341|Proliferative diabetic retinopathy
1221287|NCT01069341|PDR
1221288|NCT01069341|Cataract
1221289|NCT01069328|Lung
1221290|NCT01069328|cancer
1221291|NCT01069328|NSCLC
1221292|NCT01069315|open wound
1221293|NCT01069315|solution
1221294|NCT01069315|pressure
1221295|NCT01069315|randomized
1221296|NCT01069302|Coronary artery disease
1221297|NCT01069289|Symbicort
1221298|NCT01069289|Oxis
1221299|NCT01069289|Chronic Obstructive Pulmonary Disease
1221300|NCT01069289|COPD
1221301|NCT01069289|Efficacy
1221302|NCT01069276|Stroke
1221303|NCT01069276|prehospital ultrasound
1221304|NCT01069263|Interstitial cystitis
1221305|NCT01069263|Painful bladder syndrome
1221306|NCT01069263|Chronic pelvic pain
1221307|NCT01069263|DMSO
1221308|NCT01069263|Hyperbaric oxygen therapy
1221309|NCT01069250|dynamic cerebrovascular autoregulation
1221310|NCT01069250|static cerebrovascular autoregulation
1221311|NCT01069250|acute brain injury
1221312|NCT01069250|transcranial Doppler ultrasound
1221313|NCT01069250|critical care
1221314|NCT01069237|contact lens wear
1221315|NCT01069237|multi-purpose solution
1221316|NCT01069237|corneal staining
1221317|NCT01069224|rotator cuff
1221318|NCT01069224|synovial fluid
1221319|NCT01069224|proinflammatory cytokines
1221320|NCT01069211|Breast cancer, Letrozole
1221321|NCT01069211|postmenopause
1221322|NCT01069211|hormone receptor positive breast cancer
1221323|NCT01069198|Visceral leishmaniasis
1221324|NCT01069198|Kala-azar
1221325|NCT01069198|Bangladesh
1221326|NCT01069198|Malnutrition
1221327|NCT01069198|Asymptomatic
1221328|NCT01069198|Albendazole
1221329|NCT01069198|Iron
1221330|NCT01069198|Zinc
1221331|NCT01069198|Vitamin A
1221332|NCT01069185|Unplanned extubation
1221333|NCT01069185|Length of stay in PICU
1221334|NCT01069185|Length of mechanical ventilation
1221335|NCT01069172|Cataract
1221336|NCT01069172|Surgery, cataract extraction
1221337|NCT01069172|Optical devices, laser
1221338|NCT01069159|Traumatic memory
1221339|NCT01069159|Traumatic memories
1221340|NCT01069159|Traumatic memories and associated symptoms
1221341|NCT01069159|Posttraumatic Stress Disorder
1221342|NCT01069159|PTSD
1221343|NCT01069146|sepsis,
1221344|NCT01069146|septic shock,
1221345|NCT01069146|therapeutic hypothermia
1221346|NCT01069133|minimal hepatic encephalopathy
1221347|NCT01069133|cirrhosis
1221348|NCT01069133|complications
1221349|NCT01069120|Uterine Fibroids
1221350|NCT01069107|community hospital
1221351|NCT01069107|alternative acute admissions
1221352|NCT01069094|Uterine fibroids
1221353|NCT01069081|Metastasis Breast Cancer
1221354|NCT01069081|Proton Pump Inhibitor
1221355|NCT01069081|Chemotherapy
1221356|NCT01069081|Phase II study
1221357|NCT01069081|TTP
1221358|NCT01069068|To evaluate the effect of advancing Jaw on airway dimension
1221359|NCT01069055|inguinal hernia
1221360|NCT01069055|surgery
1221361|NCT01069055|general anesthesia
1221362|NCT01069055|analgesia
1221363|NCT01069055|pre-emptive
1221364|NCT01069055|SF36
1221365|NCT01069042|Rho kinase activity
1221366|NCT01069042|Heart failure
1221367|NCT01069042|ACE inhibitor
1221368|NCT01069042|LVEF change
1221369|NCT01069042|Rho kinase activity change
1221370|NCT01069029|Macular Hole
1221371|NCT01069029|Cataract surgery
1221372|NCT01069029|Vitreoretinal surgery
1221373|NCT01069029|Combined surgery
1221374|NCT01069029|Idiopathic
1221375|NCT01069016|Fecal Incontinence
1221376|NCT01069016|Colorectal surgery
1221377|NCT01069016|Sacral nerve stimulation
1221378|NCT01069016|Pudendal nerve stimulation
1221379|NCT01069003|Heart Disease
1221380|NCT01069003|Cardiovascular Disease
1221381|NCT01069003|Platelet Aggregation Inhibitors
1221382|NCT01069003|Dual Antiplatelet Therapy
1221383|NCT01069003|Clopidogrel
1221384|NCT01069003|Prasugrel
1221385|NCT01069003|Vascular Disease
1221386|NCT01069003|Myocardial Ischemia
1221387|NCT01068990|pneumonia
1221388|NCT01068951|type 1 diabetes
1221389|NCT01068951|mesenchymal stem cells
1221390|NCT01068951|intervention
1221391|NCT01068938|visual field
1221392|NCT01068938|perimetry
1221393|NCT01068938|glaucoma progression
1221394|NCT01068938|grid
1221395|NCT01068938|POAG and glaucoma suspects with prostaglandin monotherapy
1221396|NCT01068925|healthy volunteer
1221397|NCT01068925|pharmacokinetics
1221398|NCT01068925|HIV, GSK1349572, tipranavir, ritonavir, drug interaction
1221399|NCT01068912|Influenza
1221400|NCT01068899|healthy adults
1221401|NCT01068899|healthy children
1221402|NCT01068886|Pancreaticoduodenectomy
1221403|NCT01068873|HIV
1221404|NCT01068873|Protease Inhibitor
1221405|NCT01068873|CCR5 Co-receptor Antagonist
1221406|NCT01068873|treatment naive
1221407|NCT01068860|Type 2 Diabetes Mellitus
1221408|NCT01068860|canakinumab
1221409|NCT01068860|Pre diabetic
1221410|NCT01068860|glucose intolerant
1221411|NCT01068860|oral anti diabetic medication
1221412|NCT01068860|insulin treatment
1221413|NCT01068860|metabolic syndrome
1221414|NCT01068847|Opioid dependence
1221415|NCT01068847|methadone
1221416|NCT01068847|opioid
1221417|NCT01068834|Adherence
1221418|NCT01068834|Statins
1221419|NCT01068834|Kinesin-like protein 6
1221420|NCT01068821|Slide
1221421|NCT01068821|Trendelenburg's position
1221422|NCT01068821|Postoperative
1221423|NCT01068821|neurologic complaints
1221424|NCT01068808|Nonallergic rhinitis
1221425|NCT01068808|Allergic rhinitis
1221426|NCT01068808|Development
1221427|NCT01068795|placental syndrome
1221428|NCT01068795|maternal thromboembolic event
1221429|NCT01068795|enoxaparin
1221430|NCT01068795|anti-factor Xa
1221431|NCT01068782|Glioblastoma
1221432|NCT01068782|Glioma
1221433|NCT01068782|Brain Cancer
1221434|NCT01068782|Brain Tumor
1221435|NCT01068782|Astrocytoma
1221436|NCT01068769|regorafenib
1221437|NCT01068769|GIST
1221438|NCT01068691|aortic dissection
1221439|NCT01068691|ambulatory blood pressure
1221440|NCT01068691|obstructive sleep apnea syndrome
1221441|NCT01068691|patients undergoing surgery for a dissection of the thoracic aorta
1221442|NCT01068613|COPD
1221443|NCT01068613|Long acting muscarinic antagonist
1221444|NCT01068600|COPD
1221445|NCT01068600|Indacaterol
1221446|NCT01068587|recurrent non-small cell lung cancer
1221447|NCT01068587|stage IIIA non-small cell lung cancer
1221448|NCT01068587|stage IIIB non-small cell lung cancer
1221449|NCT01068587|stage IV non-small cell lung cancer
1221450|NCT01068574|Acute illnesses in children under five
1221451|NCT01068561|Retinitis pigmentosa
1221452|NCT01068561|stem cell
1221453|NCT01068561|bone marrow
1221454|NCT01068535|metabolic syndrome
1221455|NCT01068535|MetS
1221456|NCT01068535|premenopausal women
1221457|NCT01068535|vascular risk
1221458|NCT01068535|atherosclerosis detection
1221459|NCT01068522|Intracranial pressure
1221460|NCT01068522|Intracranial pressure monitoring
1221461|NCT01068522|Head injury
1221462|NCT01068509|Cvac
1221463|NCT01068483|Advanced solid tumors
1221464|NCT01068483|Breast Cancer
1221465|NCT01068483|Colon Cancer
1221466|NCT01068483|Ovarian Cancer
1221467|NCT01068483|Endometrium cancer
1221468|NCT01068470|Interleukin-2
1221469|NCT01068470|Melanoma
1221470|NCT01068470|Kidney Cancer
1221471|NCT01068470|Lymphokine Activated Killer cells
1221472|NCT01068457|persistent pain
1221473|NCT01068457|neuropathic pain
1221474|NCT01068457|Thoracic Surgery, Video Assisted
1221475|NCT01068457|Chronic Pain
1221476|NCT01068444|NASH
1221477|NCT01068444|Pioglitazone
1221478|NCT01068444|Treatment
1221479|NCT01068431|lymphedema
1221480|NCT01068431|conservative treatment
1221481|NCT01068431|compression therapy
1221482|NCT01068431|interface pressure
1221483|NCT01068418|Obesity
1221484|NCT01068418|Renin Angiotensin System
1221485|NCT01068418|Vitamin D deficiency
1221486|NCT01068418|Hypertension
1221487|NCT01068392|relapsed
1221488|NCT01068392|marginal zone B-cell lymphoma
1221489|NCT01068392|oxaliplatin
1221490|NCT01068392|prednisolone
1221491|NCT01068379|rhegmatogenous retinal detachment
1221492|NCT01068379|cryopexy
1221493|NCT01068379|photocoagulation
1221494|NCT01068366|Nickel Allergic Syndrome
1221495|NCT01068366|Septal Closure Devices
1221496|NCT01068353|Alzheimer's disease
1221497|NCT01068353|Dementia
1221498|NCT01068353|TNF-alpha
1221499|NCT01068353|Etanercept
1221500|NCT01068340|Adhesions
1221501|NCT01068340|Small Bowel Obstruction
1221502|NCT01068340|Ileus
1221503|NCT01068314|Endothelium
1221504|NCT01068314|Vasodilatation
1221505|NCT01068314|Vein
1221506|NCT01068314|Compliance
1221507|NCT01068314|Arteriovenous shunt, surgical
1221508|NCT01068301|Allogeneic Stem Cell transplantation
1221509|NCT01068301|Plerixafor
1221510|NCT01068301|Acute Lymphoblastic leukemia
1221511|NCT01068301|Acute Myeloid leukemia
1221512|NCT01068301|Chronic Myeloid leukemia
1221513|NCT01068301|Myelodysplastic Syndrome
1221514|NCT01068301|Non-Hodgkin's Lymphoma
1221515|NCT01068301|Other Leukemia
1221516|NCT01068288|laparoscopic appendectomy
1221517|NCT01068288|open appendectomy
1221518|NCT01068288|expectant management
1221519|NCT01068288|paediatric
1221520|NCT01068275|anterior cruciate ligament
1221521|NCT01068275|pain, postoperative
1221522|NCT01068275|peripheral nerve catheter
1221523|NCT01068275|nerve block
1221524|NCT01068275|Children undergoing anterior cruciate ligament repair
1221525|NCT01068249|Advanced
1221526|NCT01068249|Recurrent
1221527|NCT01068249|Progressive
1221528|NCT01068249|Endometrial Cancer
1221529|NCT01068249|Letrozole
1221530|NCT01068249|RAD001
1221531|NCT01068249|Afinitor
1221532|NCT01068249|Everolimus
1221533|NCT01068249|Femara
1221534|NCT01068236|Teen girls
1221535|NCT01068236|weightloss
1221536|NCT01068236|healthy lifestyle
1221537|NCT01068236|yoga
1221538|NCT01068236|Weight loss and healthy lifestyle
1221539|NCT01068223|Cetirizine, CR016609
1221540|NCT01068210|Exercise Intervention
1221541|NCT01068210|Lung Cancer
1221542|NCT01068210|15-215
1221543|NCT01068197|Low Glycemic Load diet
1221544|NCT01068197|Low Glycemic Index diet
1221545|NCT01068197|Low Fat diet
1221546|NCT01068197|Obese Hispanic American children and adolescents
1221547|NCT01068197|At risk for type 2 diabetes mellitus
1221548|NCT01068184|AZD6553
1221549|NCT01068184|Chronic
1221550|NCT01068184|obstructive
1221551|NCT01068184|pulmonary
1221552|NCT01068184|lung
1221553|NCT01068184|respiratory disease
1221554|NCT01068184|placebo-controlled
1221555|NCT01068184|COPD
1221556|NCT01068184|Healthy Volunteers
1221557|NCT01068184|COPD Patients
1221558|NCT01068171|diabetes
1221559|NCT01068171|foot ulcers
1221560|NCT01068171|off-loading
1221561|NCT01068171|collagen
1221562|NCT01068171|Wagner 1
1221563|NCT01068158|Head lice infestation
1221564|NCT01068158|Pediculus humanus capitis
1221565|NCT01068145|COPD
1221566|NCT01068132|Colorectal Neoplasms
1221567|NCT01068132|KRAS
1221568|NCT01068132|PTEN
1221569|NCT01068119|Acute coronary syndrome
1221570|NCT01068119|percutaneous coronary angioplasty
1221571|NCT01068119|Troponin negative
1221572|NCT01068119|cardiac
1221573|NCT01068080|fatty acid metabolism
1221574|NCT01068080|insulin resistance
1221575|NCT01068080|cardiac death
1221576|NCT01068080|hemodialysis
1221577|NCT01068080|normal coronary arteries
1221578|NCT01068080|Predictive values of impaired myocardial fatty acid metabolism or insulin resistance for cardiac death of hemodialysis patients with normal coronary arteries
1221579|NCT01068054|vernal keratoconjunctivitis
1221580|NCT01068054|FK-506
1221581|NCT01068054|tacrolimus
1221582|NCT01068054|cyclosporine
1221583|NCT01068054|children
1221584|NCT01068028|Healthy volunteer study
1221585|NCT01068015|MSM
1221586|NCT01068015|Intervention
1221587|NCT01068015|Popular Opinion Leader
1221588|NCT01068015|Male Circumcision
1221589|NCT01068015|HIV
1221590|NCT01068015|Syphilis
1221591|NCT01068015|HSV-2
1221592|NCT01068002|Hypertension Pregnancy
1221593|NCT01067989|metronomic chemotherapy
1221594|NCT01067989|anti-angiogenic effect
1221595|NCT01067989|Breast cancer
1221596|NCT01067976|Breast Cancer
1221597|NCT01067976|Gadobutrol-enhanced MRI
1221598|NCT01067976|Mammography
1221599|NCT01067963|self-care
1221600|NCT01067963|self-management
1221601|NCT01067963|health behavior change
1221602|NCT01067963|motivational interviewing
1221603|NCT01067963|computer assisted learning
1221604|NCT01067950|isolated pancreas transplant
1221605|NCT01067950|intensive insulin therapy
1221606|NCT01067937|Appendicitis
1221607|NCT01067937|children
1221608|NCT01067924|Type 2 diabetes, motivational interviewing, physical activity maintenance, physical activity adherence
1221609|NCT01067911|Postprandial lipids
1221610|NCT01067911|test meal
1221611|NCT01067911|fatty acids
1221612|NCT01067898|vitamin D supplementation
1221613|NCT01067898|cholecalciferol
1221614|NCT01067898|PTH
1221615|NCT01067898|bone turnover markers
1221616|NCT01067898|elderly women
1221617|NCT01067885|Nitinol Stent
1221618|NCT01067885|Superficial femoral artery
1221619|NCT01067885|SFA
1221620|NCT01067885|Angioplasty
1221621|NCT01067885|peripheral artery disease
1221622|NCT01067885|peripheral artery obstructive disease
1221623|NCT01067885|PAOD
1221624|NCT01067885|PAD
1221625|NCT01067885|Peripheral Vascular Disease
1221626|NCT01067859|Heart Failure
1221627|NCT01067846|cocaine dependence
1221628|NCT01067846|relapse prevention
1221629|NCT01067846|computerized cognitive behavioral therapy (CBT)
1221630|NCT01067846|D-cycloserine (DCS)
1221631|NCT01067833|atrial fibrillation
1221632|NCT01067833|AF
1221633|NCT01067820|ApolipoproteinA1
1221634|NCT01067820|HDL-C
1221635|NCT01067820|Atherosclerosis
1221636|NCT01067807|Pharmacokinetics
1221637|NCT01067794|Metastatic
1221638|NCT01067794|Advanced
1221639|NCT01067794|Stage IIIB-IV
1221640|NCT01067794|daily
1221641|NCT01067794|hospital
1221642|NCT01067794|practice
1221643|NCT01067794|setting
1221644|NCT01067781|Prevention of Travelers' Diarrhea
1221645|NCT01067768|Urinary Tract Infections
1221646|NCT01067768|Catheter-associated urinary tract infections
1221647|NCT01067768|Prevention and control
1221648|NCT01067768|Controlled clinical trial
1221649|NCT01067755|navigation
1221650|NCT01067755|bronchoscopy
1221651|NCT01067755|lymphadenopathy
1221652|NCT01067742|Mucolipidosis, retinal dystrophy, mucolipin-1,
1221653|NCT01067742|lysosomal storage disease, gastrin, mental retardation,
1221654|NCT01067742|dysmyelination, dysplastic corpus callosum,corneal clouding
1221655|NCT01067729|Burn
1221656|NCT01067729|Superficial burns
1221657|NCT01067729|Partial thickness burns
1221658|NCT01067729|Rate of healing
1221659|NCT01067729|Infection rate
1221660|NCT01067729|Pain perception
1221661|NCT01067729|Non adherence
1221662|NCT01067729|Scarring
1221663|NCT01067703|remote ischaemic preconditioning, cardiac surgery
1221664|NCT01067690|classical Kaposi's sarcoma
1221665|NCT01067690|chemotherapy
1221666|NCT01067690|indinavir
1221667|NCT01067690|HIV protease inhibitor
1221668|NCT01067690|Advanced classical (non HIV-associated) Kaposi's sarcoma
1221669|NCT01067677|PONV
1221670|NCT01067677|Post operative nausea and vomiting
1221671|NCT01067677|rescue emetic therapy
1221672|NCT01067599|Biomarkers of tobacco exposure
1221673|NCT01067599|Smokeless Tobacco
1221674|NCT01067586|Smokeless Tobacco
1221675|NCT01067586|Biomarkers of tobacco exposure
1221676|NCT01067573|MS
1221677|NCT01067573|Serum Leptin Levels during relapse
1221678|NCT01067573|Multiple sclerosis
1221679|NCT01067573|relapse
1221680|NCT01067560|Glucose
1221681|NCT01067560|CSF
1221682|NCT01067560|Cesarean section, spinal anesthesia
1221683|NCT01067560|Nova Stat Strip
1221684|NCT01067560|Abbott Precision Xtra
1221685|NCT01067560|Roche Accucheck Inform 2
1221686|NCT01067547|Iron deficiency
1221687|NCT01067547|Inflammatory Bowel Disease
1221688|NCT01067547|Crohn's Disease
1221689|NCT01067547|Ulcerative colitis
1221690|NCT01067521|Relapsing Remitting Multiple Sclerosis
1221691|NCT01067521|Glatiramer Acetate
1221692|NCT01067495|stroke
1221693|NCT01067495|rehabilitation
1221694|NCT01067495|exercise
1221695|NCT01067495|walking
1221696|NCT01067495|risk factors
1221697|NCT01067482|OCT
1221698|NCT01067482|spectral domain cirrus
1221699|NCT01067482|glaucoma
1221700|NCT01067482|glaucoma suspect
1221701|NCT01067482|normal population
1221702|NCT01067469|CNS
1221703|NCT01067469|Central Nervous System
1221704|NCT01067469|malignant brain tumor
1221705|NCT01067469|Recurrent Glioblastoma Multiforme
1221706|NCT01067469|GBM
1221707|NCT01067469|Bevacizumab
1221708|NCT01067469|Lomustine
1221709|NCT01067469|CCNU
1221710|NCT01067443|Phase II
1221711|NCT01067443|Randomised clinical trial
1221712|NCT01067443|Visceral Leishmaniasis
1221713|NCT01067430|Rheumatoid Arthritis
1221714|NCT01067430|Etoricoxib
1221715|NCT01067430|Diclofenac
1221716|NCT01067430|Pain
1221717|NCT01067430|Stiffness
1221718|NCT01067417|Hydroxychloroquine
1221719|NCT01067417|Chloroquine
1221720|NCT01067417|HIV Infection
1221721|NCT01067417|Acquired Immunodeficiency Syndrome
1221722|NCT01067417|Immune Activation
1221723|NCT01067417|inflammation
1221724|NCT01067417|treatment naive
1221725|NCT01067417|disease progression
1221726|NCT01067404|Influenza vaccines
1221727|NCT01067404|Infant
1221728|NCT01067404|Dose-Response relationship, immunologic
1221729|NCT01067391|Hypotension in SCI males
1221730|NCT01067391|Erectile Dysfunction
1221731|NCT01067378|Interdisciplinary Health Team
1221732|NCT01067378|Training
1221733|NCT01067365|Secondary Hypogonadism
1221734|NCT01067352|Infant, small for gestational age
1221735|NCT01067352|Growth hormone
1221736|NCT01067352|Saizen
1221737|NCT01067339|coronary endothelial dysfunction
1221738|NCT01067339|coronary vasospasm
1221739|NCT01067326|Endothelial Dysfunction
1221740|NCT01067326|Endothelial Function
1221741|NCT01067326|Tekturna
1221742|NCT01067326|Endothelial Peripheral Arterial Tomography (EndoPAT)
1221743|NCT01067326|Progenitor Cells
1221744|NCT01067326|renin inhibition
1221745|NCT01067326|endothelial progenitor cells
1221746|NCT01067326|early atherosclerosis
1221747|NCT01067313|Intensive Care Unit
1221748|NCT01067313|continuous hemodialysis
1221749|NCT01067313|continuous hemofiltration
1221750|NCT01067313|High Cut-off membrane
1221751|NCT01067313|"Enhanced middle molecule clearance membrane"
1221752|NCT01067313|Septic shock
1221753|NCT01067313|Acute kidney injury
1221754|NCT01067313|Blood purification
1221755|NCT01067313|Renal replacement therapy
1221756|NCT01067300|young
1221757|NCT01067300|acute leukemia in remission
1221758|NCT01067300|Children or young adults (< 35 years) with acute leukemia in remission
1221759|NCT01067287|dendritic cell fusion vaccine
1221760|NCT01067287|CT-011
1221761|NCT01067287|autologous stem cell transplant
1221762|NCT01067274|Acute Myeloid Leukemia
1221763|NCT01067274|Aged of 65 to 79 years
1221764|NCT01067274|Older Patients with Acute Myeloblastic Leukemia
1221765|NCT01067261|Nerve stimulation
1221766|NCT01067261|TMNS
1221767|NCT01067261|Prostatectomy
1221768|NCT01067261|Prevention
1221769|NCT01067261|Restoration
1221770|NCT01067261|Treatment
1221771|NCT01067261|Vibration
1221772|NCT01067261|Non-invasive
1221773|NCT01067248|COPD
1221774|NCT01067248|Osteoporosis
1221775|NCT01067248|Pathophysiology
1221776|NCT01067248|Mechanism
1221777|NCT01067248|Bone markers
1221778|NCT01067248|Bone turnover
1221779|NCT01067248|Protein turnover
1221780|NCT01067248|Ageing
1221781|NCT01067248|Endocrinology
1221782|NCT01067248|Vitamin D
1221783|NCT01067235|Narcolespy
1221784|NCT01067235|Cataplexy
1221785|NCT01067235|Excesssive daytime Sleepiness
1221786|NCT01067235|Sleep Disorders
1221787|NCT01067235|Sleep attacks
1221788|NCT01067235|Orphan Drug
1221789|NCT01067235|Pitolisant
1221790|NCT01067222|Narcolepsy
1221791|NCT01067222|Excessive daytime Sleepiness
1221792|NCT01067222|Cataplexy
1221793|NCT01067222|Sleep Disorders
1221794|NCT01067222|Sleep attacks
1221795|NCT01067222|Orphan Drug
1221796|NCT01067222|Pitolisant
1221797|NCT01067209|Reversal of Obesity-related and Diabetic Cardiomyopathy
1221798|NCT01067196|Proton Radiation
1221799|NCT01067196|Central Nervous System Tumors
1221800|NCT01067196|Brain
1221801|NCT01067196|Spine
1221802|NCT01067196|Cancer
1221803|NCT01067183|stress reduction
1221804|NCT01067183|physician wellness
1221805|NCT01067170|Hemodialysis
1221806|NCT01067170|Intradialytic hypotension
1221807|NCT01067157|Obesity
1221808|NCT01067157|overweight
1221809|NCT01067157|childhood
1221810|NCT01067157|adolescence
1221811|NCT01067157|inpatient therapy
1221812|NCT01067157|lifestyle intervention
1221813|NCT01067157|cardiovascular risk
1221814|NCT01067157|gene-lifestyle-interaction
1221815|NCT01067157|Obesity and associated cardiovascular risk in childhood and adolescence,
1221816|NCT01067157|health behaviour
1221817|NCT01067131|Candida albicans
1221818|NCT01067131|Fungal vaginal infection
1221819|NCT01067131|Vulvovaginal candidiasis
1221820|NCT01067131|Candidose
1221821|NCT01067131|Vaccine
1221822|NCT01067131|Virosome
1221823|NCT01067105|Perennial allergic rhinitis
1221824|NCT01067105|allergic rhinitis
1221825|NCT01067105|ciclesonide
1221826|NCT01067079|Rabies vaccine
1221827|NCT01067079|Long-term Immunogenicity
1221828|NCT01067066|TPI 287
1221829|NCT01067066|microtubule inhibitor
1221830|NCT01067066|Temozolomide
1221831|NCT01067066|Temodar
1221832|NCT01067066|cytotoxic agent
1221833|NCT01067066|unresectable Stage III
1221834|NCT01067066|Stage IV
1221835|NCT01067066|Metastatic Melanoma
1221836|NCT01067053|Bevacizumab
1221837|NCT01067053|Capecitabine
1221838|NCT01067053|Oxaliplatin
1221839|NCT01067053|Metastatic colorectal cancer
1221840|NCT01067027|Colic
1221841|NCT01067027|Colic in Breast-fed Infants
1221842|NCT01067014|Lumbar spinal stenosis
1221843|NCT01067014|Decompression
1221844|NCT01067014|Lumbar spinal decompression
1221845|NCT01067014|Lumbar spinal decompressive surgery
1221846|NCT01066988|lipid layer thickness
1221847|NCT01066975|loaded backpack
1221848|NCT01066975|unloaded backpack
1221849|NCT01066962|HIV-infected antiretroviral naïve subjects
1221850|NCT01066949|hemodialysis
1221851|NCT01066949|behavior change
1221852|NCT01066949|patient adherence
1221853|NCT01066949|self management
1221854|NCT01066923|firefighter
1221855|NCT01066923|heat stress
1221856|NCT01066923|platelet activation
1221857|NCT01066923|aspirin
1221858|NCT01066910|Obesity
1221859|NCT01066910|Childhood Obesity
1221860|NCT01066910|Exercise
1221861|NCT01066910|Nutrition
1221862|NCT01066871|Knee cartilage injury
1221863|NCT01066871|fibroblast growth factor 18
1221864|NCT01066871|FGF18
1221865|NCT01066858|tenofovir
1221866|NCT01066858|renal and bone toxicity
1221867|NCT01066858|pregnancy
1221868|NCT01066858|breastfeeding
1221869|NCT01066858|mother to child transmission
1221870|NCT01066832|Drug-eluting balloon
1221871|NCT01066832|Paclitaxel
1221872|NCT01066832|DIOR
1221873|NCT01066832|short term registry
1221874|NCT01066832|Valentines Trial
1221875|NCT01066832|Drug-eluting balloon treatment of in-stent restenosis
1221876|NCT01066780|cochlear implant
1221877|NCT01066780|adults
1221878|NCT01066780|HiResolution
1221879|NCT01066780|Fidelity 120
1221880|NCT01066780|listening benefits
1221881|NCT01066780|noise
1221882|NCT01066780|cochlear implant benefit
1221883|NCT01066741|Epidermoid carcinoma
1221884|NCT01066741|Hypopharynx
1221885|NCT01066741|Oropharynx
1221886|NCT01066741|Oral cavity
1221887|NCT01066741|Oral mucosa
1221888|NCT01066741|Cavum
1221889|NCT01066741|Severe Oral mucositis
1221890|NCT01066741|Radiotherapy
1221891|NCT01066741|Phytotherapy
1221892|NCT01066728|apnea
1221893|NCT01066728|premature
1221894|NCT01066728|infant
1221895|NCT01066728|prematurity
1221896|NCT01066715|Diabetes
1221897|NCT01066715|Type 2
1221898|NCT01066715|Mellitus
1221899|NCT01066689|kidney transplantation, acute humoral rejection, rituximab
1221900|NCT01066663|CLL
1221901|NCT01066663|SLL
1221902|NCT01066663|relapsed
1221903|NCT01066663|pyrimethamine
1221904|NCT01066650|TWENTE
1221905|NCT01066650|randomized study
1221906|NCT01066650|stent
1221907|NCT01066650|coronary stent
1221908|NCT01066650|drug-eluting stent
1221909|NCT01066650|Zotarolimus
1221910|NCT01066650|Everolimus
1221911|NCT01066650|Xience V
1221912|NCT01066650|Endeavor Resolute
1221913|NCT01066650|head to head comparison
1221914|NCT01066650|real world patients
1221915|NCT01066650|target vessel failure
1221916|NCT01066650|investigator initiated study
1221917|NCT01066650|coronary artery disease
1221918|NCT01066650|coronary arteries
1221919|NCT01066650|atherosclerosis
1221920|NCT01066650|non inferiority
1221921|NCT01066637|Heart transplant patients
1221922|NCT01066624|Mucositis
1221923|NCT01066624|Multiple myeloma
1221924|NCT01066624|Autologous hematopoietic stem cell transplantation
1221925|NCT01066611|Allergic Rhinitis
1221926|NCT01066611|Allergy
1221927|NCT01066611|Phosphatidylinositol 3-kinase
1221928|NCT01066598|graft versus host disease
1221929|NCT01066598|chronic graft versus host disease
1221930|NCT01066598|cGVHD
1221931|NCT01066585|Head lice
1221932|NCT01066585|Pediculus humanus capitis
1221933|NCT01066546|Delirium
1221934|NCT01066546|Dementia
1221935|NCT01066546|Amnestic
1221936|NCT01066546|Cognitive Disorders
1221937|NCT01066546|Mental Disorders
1221938|NCT01066546|Nervous System Diseases
1221939|NCT01066546|Central Nervous System Diseases
1221940|NCT01066533|MTA
1221941|NCT01066533|NEC
1221942|NCT01066533|Immunohistochemistry
1221943|NCT01066533|fibronectin
1221944|NCT01066533|tenascin
1221945|NCT01066520|ankle sprain
1221946|NCT01066520|traumeel
1221947|NCT01066520|diclofenac
1221948|NCT01066520|antiinflammatory
1221949|NCT01066520|time to normal function
1221950|NCT01066507|Her2
1221951|NCT01066507|FISH
1221952|NCT01066507|Breast cancer
1221953|NCT01066507|Amplification
1221954|NCT01066494|AML
1221955|NCT01066494|Pgp
1221956|NCT01066494|MDR
1221957|NCT01066494|sAML
1221958|NCT01066494|AS1413
1221959|NCT01066494|Amonafide
1221960|NCT01066481|Alzheimer's disease
1221961|NCT01066481|clinical trial
1221962|NCT01066481|memory loss
1221963|NCT01066481|investigational drug
1221964|NCT01066481|neurodegenerative disease
1221965|NCT01066481|dementia
1221966|NCT01066468|Chronic myeloid leukemia
1221967|NCT01066468|CML
1221968|NCT01066468|Philadelphia chromosome positive
1221969|NCT01066468|acute lymphoblastic leukemia
1221970|NCT01066468|PhGlivec,
1221971|NCT01066468|Gleevec,
1221972|NCT01066468|hypereosinophilic syndrome,
1221973|NCT01066468|HES,
1221974|NCT01066468|chronic eosinophilic leukemia,
1221975|NCT01066468|CEL,
1221976|NCT01066468|myelodysplastic syndrome,
1221977|NCT01066468|MDS,
1221978|NCT01066468|myeloproliferative disease,
1221979|NCT01066468|MPD+ ALL
1221980|NCT01066455|Cardiac
1221981|NCT01066455|Muscular Dystrophy
1221982|NCT01066455|Prospective
1221983|NCT01066455|Pediatric
1221984|NCT01066455|Echocardiogram
1221985|NCT01066442|Excessive Daytime Sleepiness (EDS)
1221986|NCT01066442|Parkinson's Disease
1221987|NCT01066429|poor-prognosis diffuse large B-cell lymphoma
1221988|NCT01066429|dose-adjusted
1221989|NCT01066429|R-EDOCH-14
1221990|NCT01066429|rituximab
1221991|NCT01066429|age-adjusted IPI
1221992|NCT01066429|toxicity
1221993|NCT01066403|schizophrenia
1221994|NCT01066403|cognitive deficits
1221995|NCT01066403|dopamine
1221996|NCT01066403|dopamine agonists
1221997|NCT01066403|prefrontal cortex
1221998|NCT01066403|D1 specific modulation
1221999|NCT01066403|pergolide
1222000|NCT01066403|executive control
1222001|NCT01066403|working memory
1222002|NCT01066403|Influence of pergolide on cognition in Schizophrenia
1222003|NCT01066403|D1-specific modulation of prefrontal functions
1222004|NCT01066403|Influence of pergolide on psychopathology and depression
1222005|NCT01066403|Influence of pergolide on extrapyramidal symptoms
1222006|NCT01066390|stage IIIC/IV melanoma
1222007|NCT01066377|prebiotic
1222008|NCT01066377|probiotic
1222009|NCT01066377|influenza
1222010|NCT01066377|vaccination
1222011|NCT01066377|ageing
1222012|NCT01066377|immunosenescence
1222013|NCT01066364|NASH
1222014|NCT01066364|NAFLD
1222015|NCT01066364|Steatohepatitis
1222016|NCT01066364|Nonalcoholic
1222017|NCT01066364|Fatty Liver Disease
1222018|NCT01066351|acute kidney injury
1222019|NCT01066351|erythropoietin
1222020|NCT01066351|cardiac surgery
1222021|NCT01066338|SNP array
1222022|NCT01066338|prognosis
1222023|NCT01066338|acute myeloid leukemia
1222024|NCT01066338|normal karyotype
1222025|NCT01066338|acute myeloid leukemia with normal karyotype
1222026|NCT01066325|Sit-n-Reach Test
1222027|NCT01066325|Flexibility
1222028|NCT01066325|Hamstring
1222029|NCT01066325|Mindbody
1222030|NCT01066325|Complementary and Alternative Medicine
1222031|NCT01066325|Neuro Emotional Technique (NET)
1222032|NCT01066312|Muscle testing
1222033|NCT01066312|Kinesiology
1222034|NCT01066312|Muscles
1222035|NCT01066312|Complementary and Alternative Medicine
1222036|NCT01066312|Practitioner Experience
1222037|NCT01066312|This study is actually not a randomised controlled trial,
1222038|NCT01066312|but an assessment of diagnostic test accuracy. We will be
1222160|NCT01065792|HIV Infection
1222039|NCT01066312|looking at the accuracy of MMT to distinguish congruent from
1222040|NCT01066312|incongruent statements under varying levels of blinding.
1222041|NCT01066299|oxytocin
1222042|NCT01066299|psychophysiology
1222043|NCT01066299|startle
1222044|NCT01066299|anxiety
1222045|NCT01066299|emotion
1222046|NCT01066299|physiology
1222047|NCT01066286|genome wide SNP-array
1222048|NCT01066286|micro-cytogenetic lesion
1222049|NCT01066286|KIT mutation
1222050|NCT01066286|core binding factor
1222051|NCT01066286|acute myeloid leukemia
1222052|NCT01066286|The Approval status was changed from Pending to Approved.
1222053|NCT01066260|Probiotics
1222054|NCT01066260|Energy balance
1222055|NCT01066247|spinal anesthesia
1222056|NCT01066247|heart rate variability
1222057|NCT01066247|premedication
1222058|NCT01066247|heart rate
1222059|NCT01066247|blood pressure
1222060|NCT01066234|Microscopic N2 Non-small Cell Lung Cancer
1222061|NCT01066234|Paclitaxel
1222062|NCT01066234|Carboplatin
1222063|NCT01066234|Cisplatin
1222064|NCT01066221|clostridium difficile
1222065|NCT01066208|Classification criteria
1222066|NCT01066208|Diagnostic criteria
1222067|NCT01066195|Non-Small Cell Lung Cancer
1222068|NCT01066195|Never-Smoker and Adenocarcinoma patients
1222069|NCT01066195|Pemetrexed (ALIMTA)
1222070|NCT01066195|Gefitinib (IRESSA®)
1222071|NCT01066182|DHA
1222072|NCT01066182|Learning
1222073|NCT01066182|Reading
1222074|NCT01066182|Memory
1222075|NCT01066182|Children
1222076|NCT01066182|Omega 3
1222077|NCT01066182|Education
1222078|NCT01066182|Learning and behaviour in children
1222079|NCT01066169|Pandemic Influenza A/H1N1
1222080|NCT01066169|HIV
1222081|NCT01066169|Antibodies
1222082|NCT01066169|Replicaton
1222083|NCT01066156|Post-traumatic Stress Disorder
1222084|NCT01066156|PTSD
1222085|NCT01066156|Seroquel
1222086|NCT01066156|fMRI
1222087|NCT01066143|Seroquel
1222088|NCT01066143|Generalized Anxiety Disorder
1222089|NCT01066143|fMRI
1222090|NCT01066130|Diabetes Mellitus
1222091|NCT01066130|Arthritis, Rheumatoid
1222092|NCT01066130|psychosocial aspects
1222093|NCT01066130|Patient Adherence
1222094|NCT01066130|Social Work
1222095|NCT01066130|Coping Behavior
1222096|NCT01066130|Coping Skills
1222097|NCT01066130|Adaptation, Psychological
1222098|NCT01066117|urinary incontinent
1222099|NCT01066091|Inflammatory response
1222100|NCT01066091|High-fat meal
1222101|NCT01066091|cytokines
1222102|NCT01066091|Body composition
1222103|NCT01066078|heart failure - congestive
1222104|NCT01066078|Cardiovascular imaging agents/Techniques]
1222105|NCT01066078|Echocardiography
1222106|NCT01066078|Other diagnostic testing
1222107|NCT01066078|Other Treatment
1222108|NCT01066078|Recipients of cardiac resynchronization therapy systems
1222109|NCT01066065|cardiovascular disease
1222110|NCT01066065|HIV
1222111|NCT01066065|metabolic disorder
1222112|NCT01066065|HIV naive patients initiating HAART with Raltegravir or boosted Darunavir
1222113|NCT01066052|Growth hormone
1222114|NCT01066052|Turner syndrome
1222115|NCT01066052|r-hGH
1222116|NCT01066052|early treatment
1222117|NCT01066039|Bisoprolol
1222118|NCT01066039|Hypertension
1222119|NCT01066039|Diabetes mellitus, Type II
1222120|NCT01066039|Blood pressure
1222121|NCT01066039|Glycemic level
1222122|NCT01066026|metallic cannula
1222123|NCT01066026|Hyaluronic acid
1222124|NCT01066013|Antimicrobial De escalation
1222125|NCT01066013|Meropenem
1222126|NCT01066013|Piperacillin tazobactam
1222127|NCT01066013|Medical patients
1222128|NCT01066013|Appropriate use
1222129|NCT01066013|Cost savings
1222130|NCT01066013|Antimicrobial De-escalation strategy
1222131|NCT01065974|Nutritional Intake
1222132|NCT01065974|Psychosocial Outcome
1222133|NCT01065961|anterior
1222134|NCT01065961|cervical
1222135|NCT01065961|fusion
1222136|NCT01065961|swallowing
1222137|NCT01065961|Swallowing after anterior cervical discectomy and fusion
1222138|NCT01065961|Bony fusion rates post anterior cervical discectomy and fusion
1222139|NCT01065948|subcutaneous glucose monitoring
1222140|NCT01065948|diabetes
1222141|NCT01065948|fluorescence
1222142|NCT01065948|affinity
1222143|NCT01065948|biosensor
1222144|NCT01065948|type I Diabetes
1222145|NCT01065948|type II diabetes
1222146|NCT01065935|ALN-RSV01
1222147|NCT01065935|RSV
1222148|NCT01065935|Respiratory Syncytial Virus
1222149|NCT01065896|spinal cord injury
1222150|NCT01065896|coronary artery disease
1222151|NCT01065857|Colonoscopy, Preparation, Evacuating, Bowel Cleansing.
1222152|NCT01065844|Nelfinavir
1222153|NCT01065831|motivational interviewing, lay health advisers
1222154|NCT01065818|Esophageal cancer
1222155|NCT01065818|FLT-PET
1222156|NCT01065818|Chemoradiotherapy
1222157|NCT01065805|18F-FLT
1222158|NCT01065805|Positive Emission Tomography
1222159|NCT01065805|Cancer
1222161|NCT01065766|Diabetes Mellitus
1222162|NCT01065766|Non-Insulin-Dependent
1222163|NCT01065753|Rho kinase
1222164|NCT01065753|Brain-derived neurotrophic factor
1222165|NCT01065740|Peripheral arterial disease
1222166|NCT01065740|Patient education
1222167|NCT01065740|Physical activity coaching
1222168|NCT01065740|Lifestyle modifications
1222169|NCT01065740|Walking capacity
1222170|NCT01065740|6 minutes walking test
1222171|NCT01065727|Reemitting aggressive multiple sclerosis
1222172|NCT01065714|Transepidermal water loss
1222173|NCT01065714|Epidermal barrier
1222174|NCT01065714|Skin hydration
1222175|NCT01065688|distal gastrectomy
1222176|NCT01065688|Billroth-I reconstruction
1222177|NCT01065688|gastric cancer
1222178|NCT01065688|QOL
1222179|NCT01065675|Medication Reconciliation
1222180|NCT01065675|Emergency Department
1222181|NCT01065675|Nurse
1222182|NCT01065675|Pharmacist
1222183|NCT01065675|Certified Pharmacy Technician
1222184|NCT01065675|Medication reconciliation: inpatients admitted from the ED
1222185|NCT01065662|AZD2171
1222186|NCT01065662|temsirolimus
1222187|NCT01065662|advanced gynecological malignancies
1222188|NCT01065649|reflux disease
1222189|NCT01065649|heartburn
1222190|NCT01065623|Phase I
1222191|NCT01065623|Dose escalation
1222192|NCT01065623|Immunoconjugate
1222193|NCT01065597|electroconvulsive therapy
1222194|NCT01065597|seizure
1222195|NCT01065597|nonconvulsive
1222196|NCT01065597|subconvulsive
1222197|NCT01065597|major depression
1222198|NCT01065597|bipolar disorder
1222199|NCT01065584|liver transplantation
1222200|NCT01065584|Patients undergoing liver transplantation
1222201|NCT01065571|relapse
1222202|NCT01065571|carrageenan
1222203|NCT01065571|inflammation
1222204|NCT01065558|Ecopipam
1222205|NCT01065558|Lesch-Nyhan Disease
1222206|NCT01065558|Safety
1222207|NCT01065558|Self-Injurious Behavior
1222208|NCT01065545|leukemia
1222209|NCT01065532|Restenosis
1222210|NCT01065532|PCI
1222211|NCT01065532|Drug-eluting stent
1222212|NCT01065532|Drug-eluting balloon
1222213|NCT01065532|Optical Coherence Tomography
1222214|NCT01065519|Coronary stent
1222215|NCT01065519|Optical coherence tomography
1222216|NCT01065519|Intravascular ultrasound
1222217|NCT01065480|Training
1222218|NCT01065480|Substance Abuse
1222219|NCT01065480|Counseling
1222220|NCT01065480|Motivational Interviewing
1222221|NCT01065467|LBH589
1222222|NCT01065467|panobinostat
1222223|NCT01065454|Pulmonary Hypertension
1222224|NCT01065454|Left ventricular dysfunction
1222225|NCT01065441|breast cancer
1222226|NCT01065441|colorectal cancer
1222227|NCT01065441|prostate cancer
1222228|NCT01065441|melanoma
1222229|NCT01065441|ovarian cancer
1222230|NCT01065441|GI cancer
1222231|NCT01065441|Sarcoma
1222232|NCT01065441|Renal Cell Carcinoma
1222233|NCT01065428|neuromechanical efficiency
1222234|NCT01065428|neuroventilatory efficiency
1222235|NCT01065428|weaning
1222236|NCT01065428|Respiration, Artificial
1222237|NCT01065415|Magnetic Resonance Imaging/Positron Emission Tomography
1222238|NCT01065415|Whole body imaging
1222239|NCT01065415|Non-small cell lung cancer
1222240|NCT01065415|staging
1222241|NCT01065415|Diagnostic accuracy
1222242|NCT01065402|Diabetes mellitus
1222243|NCT01065402|continuous glucose monitoring system (CGMS)
1222244|NCT01065389|Intradialysis
1222245|NCT01065389|Resistance training
1222246|NCT01065389|Protein Catabolic Rate
1222247|NCT01065389|Urea kinetics
1222248|NCT01065389|Quality of life
1222249|NCT01065389|VO2 max
1222250|NCT01065376|IVF
1222251|NCT01065376|OHSS
1222252|NCT01065376|cabergoline
1222253|NCT01065363|Hepatitis B virus DNA
1222254|NCT01065363|Metabolic factor
1222255|NCT01065363|Body mass index
1222256|NCT01065363|Obesity
1222257|NCT01065363|Insulin resistance
1222258|NCT01065363|Lifestyle factor
1222259|NCT01065363|Preventive Medicine
1222260|NCT01065363|Health Promotion
1222261|NCT01065350|ketofol
1222262|NCT01065350|hemodynamics
1222263|NCT01065350|propofol
1222264|NCT01065350|anesthesia
1222265|NCT01065337|peripheral arterial occlusion disease (PAD)
1222266|NCT01065337|diabetic foot
1222267|NCT01065337|critical limb ischemia (CLI)
1222268|NCT01065337|stem cell therapy
1222269|NCT01065324|balloon
1222270|NCT01065324|enteroscopy
1222271|NCT01065324|bacteremia
1222272|NCT01065311|Depressive Disorder
1222273|NCT01065311|Psychotherapy
1222274|NCT01065285|Influenza
1222275|NCT01065285|autoimmune diseases
1222276|NCT01065285|vaccination
1222277|NCT01065285|H1N1
1222278|NCT01065272|Dexamethasone
1222279|NCT01065272|Bronchiolitis
1222280|NCT01065259|attention deficit hyperactivity disorder
1222281|NCT01065259|executive function
1222282|NCT01065259|OROS MPH
1222283|NCT01065259|atomoxetine
1222284|NCT01065246|malignant ascites
1222285|NCT01065246|second cycle
1222286|NCT01065246|trifunctional
1222287|NCT01065220|Serotonin Transporter
1222288|NCT01065220|Hormone therapy
1222289|NCT01065220|Gender Dysphoria
1222290|NCT01065220|Transsexualism
1222291|NCT01065181|shoulder
1222292|NCT01065181|posterior inferior glenohumeral ligament
1222293|NCT01065181|posterior capsule
1222294|NCT01065181|capsular contracture
1222295|NCT01065181|baseball
1222296|NCT01065181|throwing injury
1222297|NCT01065168|endometriosis
1222298|NCT01065168|endometrioma
1222299|NCT01065168|antimullerian hormone
1222300|NCT01065168|cystectomy
1222301|NCT01065142|Heart Failure
1222302|NCT01065142|Patient Education as Topic
1222303|NCT01065142|Primary Health Care
1222304|NCT01065142|Quality of Life
1222305|NCT01065116|Malaria
1222306|NCT01065103|STEMI
1222307|NCT01065103|Primary angioplasty
1222308|NCT01065103|Non-culprit vessel at STEMI
1222309|NCT01065103|Fractional Flow Reserve
1222310|NCT01065103|ST-elevation myocardial infarction
1222311|NCT01065103|Fractional Flow Reserve in non-culprit vessel at STEMI
1222312|NCT01065090|Capacity for Work Questionnaire
1222313|NCT01065090|exercise
1222314|NCT01065090|AVONEX
1222315|NCT01065090|SDMT: Symbol Digit Modalities Test
1222316|NCT01065090|FSMC: Fatigue Scale for Motor and Cognitive functions
1222317|NCT01065090|effects of exercise
1222318|NCT01065090|EDSS: Expanded Disability Status Scale
1222319|NCT01065077|Heart Failure
1222320|NCT01065064|Multifocal IOL
1222321|NCT01065064|ReSTOR IOL
1222322|NCT01065051|Pulmonary Hypertension
1222323|NCT01065051|Left ventricular dysfunction
1222324|NCT01065025|4SC-205
1222325|NCT01065025|Solid tumors
1222326|NCT01065025|Lymphomas
1222327|NCT01065025|Phase I
1222328|NCT01064999|Neoadjuvant chemotherapy
1222329|NCT01064999|locally advanced rectal cancer
1222330|NCT01064999|intensity-modulated radiation therapy
1222331|NCT01064999|pathological complete response
1222332|NCT01064986|Immune System
1222333|NCT01064973|autism
1222334|NCT01064960|Neoplasms, Connective and Soft Tissue
1222335|NCT01064960|Neoplasms, Muscle Tissue
1222336|NCT01064960|Neoplasms
1222337|NCT01064960|Myofibroma
1222338|NCT01064960|Neoplasms by Histologic Type
1222339|NCT01064960|Connective Tissue Diseases
1222340|NCT01064960|Neoplasms, Connective Tissue
1222341|NCT01064960|Leiomyoma
1222342|NCT01064934|coronary heart disease
1222343|NCT01064934|cerebrovascular disease
1222344|NCT01064934|peripheral arterial disease
1222345|NCT01064934|atherosclerosis
1222346|NCT01064934|hyperlipoproteinemia
1222347|NCT01064921|oropharyngeal cancer
1222348|NCT01064921|recurrent squamous cell carcinoma of the oropharynx
1222349|NCT01064908|Endarterectomy, Carotid
1222350|NCT01064908|Carotid stenosis
1222351|NCT01064908|Oxygen mask
1222352|NCT01064895|Benephit
1222353|NCT01064895|Acute Kidney Injury
1222354|NCT01064895|Acute Renal Failure
1222355|NCT01064895|Contrast Induced Nephropathy
1222356|NCT01064895|Chronic Kidney Disease
1222357|NCT01064869|Adherence
1222358|NCT01064869|Asthma
1222359|NCT01064869|medication
1222360|NCT01064856|peripheral spondyloarthritis
1222361|NCT01064856|adalimumab
1222362|NCT01064856|humira
1222363|NCT01064843|Edentulous
1222364|NCT01064843|Edentulism
1222365|NCT01064843|Lower denture
1222366|NCT01064843|Mini dental implant
1222367|NCT01064843|Imtec MDI
1222368|NCT01064843|Denture stabilization
1222369|NCT01064843|Case success rate of overdentures stabilized by MDI
1222370|NCT01064843|General satisfaction of patients with this treatment
1222371|NCT01064843|Oral health-related quality of life of these patients
1222372|NCT01064843|Cost estimates
1222373|NCT01064830|brittle nail
1222374|NCT01064817|glaucoma, trabeculectomy
1222375|NCT01064791|Renal transplantation
1222376|NCT01064778|Glycemic Index
1222377|NCT01064778|Brain
1222378|NCT01064778|Intake Regulation
1222379|NCT01064778|Weight Loss
1222380|NCT01064778|Hunger
1222381|NCT01064778|Diet
1222382|NCT01064765|Heart failure
1222383|NCT01064765|Self management
1222384|NCT01064765|cognitive dysfunction
1222385|NCT01064765|Self management of heart failure
1222386|NCT01064752|Minocycline
1222387|NCT01064752|HIV-1
1222388|NCT01064752|Immune activation
1222389|NCT01064752|Cerebrospinal fluid
1222390|NCT01064752|Observational
1222391|NCT01064739|Healthy Volunteers
1222392|NCT01064739|Fava bean consumption
1222393|NCT01064739|L-Dopa content in Fava Beans
1222394|NCT01064739|Sodium
1222395|NCT01064739|Potassium
1222396|NCT01064739|Electrolyte Balance
1222397|NCT01064739|Natriuresis
1222398|NCT01064726|Allergic Rhinitis Nasal Allergen Challenge Inflammatory Markers
1222399|NCT01064713|Tesetaxel
1222400|NCT01064713|Second-line therapy
1222401|NCT01064713|Metastatic melanoma
1222402|NCT01064713|Normal serum LDH
1222403|NCT01064700|Anxiety
1222404|NCT01064700|Phototherapy
1222405|NCT01064700|Psychic Anxiety
1222406|NCT01064674|renal transplantation
1222407|NCT01064674|cardiovascular morbidity
1222408|NCT01064674|evaluation before renal transplantation
1222409|NCT01064661|Probiotics
1222410|NCT01064661|abdominal pain
1222411|NCT01064661|abdominal discomfort
1222412|NCT01064661|bloating
1222413|NCT01064661|Functional Bowel Disorders
1222414|NCT01064635|stage IA breast cancer
1222415|NCT01064635|stage IB breast cancer
1222416|NCT01064635|stage II breast cancer
1222417|NCT01064635|stage IIIA breast cancer
1222418|NCT01064635|stage IIIB breast cancer
1222419|NCT01064635|stage IIIC breast cancer
1222420|NCT01064596|obesity
1222421|NCT01064596|fondaparinux
1222422|NCT01064596|surgery
1222423|NCT01064596|anti-Xa activity
1222424|NCT01064570|Acute Promyelocytic Leukemia
1222425|NCT01064570|APL
1222426|NCT01064557|Acute promyelocytic Leukemia
1222427|NCT01064544|Sleep problems
1222428|NCT01064544|melatonin
1222429|NCT01064544|mood
1222430|NCT01064544|Hemodialysis
1222431|NCT01064518|Lateral Canthal Lines
1222432|NCT01064518|Crow's Feet Wrinkles
1222433|NCT01064518|Facial Wrinkles
1222434|NCT01064505|Ocular Neuroprotection
1222435|NCT01064505|ocular neuroprotectant
1222436|NCT01064505|NAION
1222437|NCT01064505|NAAION
1222438|NCT01064505|Non-arteritic ischemic optic neuropathy
1222439|NCT01064505|Non-arteritic anterior ischemic optic neuropathy
1222440|NCT01064505|chronic optic nerve atrophy
1222441|NCT01064505|optic nerve atrophy
1222442|NCT01064505|retinal degeneration
1222443|NCT01064505|optic neuritis
1222444|NCT01064505|end stage glaucoma
1222445|NCT01064505|Leber's hereditary optic neuropathy
1222446|NCT01064479|SCCHN
1222447|NCT01064479|Oral cavity
1222448|NCT01064479|Oropharynx
1222449|NCT01064479|Hypopharynx
1222450|NCT01064479|Larynx
1222451|NCT01064479|Tarceva
1222452|NCT01064479|Erlotinib
1222453|NCT01064479|OSI-774
1222454|NCT01064479|Docetaxel
1222455|NCT01064479|Taxotere
1222456|NCT01064479|Cisplatin
1222457|NCT01064479|Platinol
1222458|NCT01064479|CDDP
1222459|NCT01064479|Placebo
1222460|NCT01064479|Chemotherapy
1222461|NCT01064466|SCLC
1222462|NCT01064466|Etoposide
1222463|NCT01064466|SNP
1222464|NCT01064466|Topo
1222465|NCT01064466|CYP
1222466|NCT01064466|Genotype
1222467|NCT01064466|Oncology
1222468|NCT01064466|Genetics
1222469|NCT01064466|Lung
1222470|NCT01064466|Cancer
1222471|NCT01064453|Menopause
1222472|NCT01064453|Menopausal symptoms
1222473|NCT01064453|Prevention of osteoporosis in menopausal women
1222474|NCT01064453|Estrogen deficiency symptoms
1222475|NCT01064453|Hormone replacement therapy
1222476|NCT01064440|Painful legs
1222477|NCT01064440|Ischemic legs
1222478|NCT01064440|Treatment for Claudication
1222479|NCT01064440|Gene therapy
1222480|NCT01064427|breast cancer
1222481|NCT01064427|fatigue
1222482|NCT01064427|adjuvant chemotherapy
1222483|NCT01064427|quality of life
1222484|NCT01064414|Canagliflozin
1222485|NCT01064414|JNJ 28431754
1222486|NCT01064414|Placebo
1222487|NCT01064414|Sodium-Glucose Transporter 2
1222488|NCT01064414|hemoglobin A1c protein, Blood Glucose
1222489|NCT01064414|reduced kidney function, Type 2 diabetes mellitus
1222490|NCT01064388|Safety
1222491|NCT01064375|DNA vaccine
1222492|NCT01064375|Electroporation
1222493|NCT01064362|Haemorrhage
1222494|NCT01064362|Thromboprophylaxis
1222495|NCT01064349|brain metastases
1222496|NCT01064349|ErbB2 treatment
1222497|NCT01064349|ErbB2+ breast cancer
1222498|NCT01064336|Thrombocytopenia
1222499|NCT01064336|Pregnancy
1222500|NCT01064323|intermittent pneumatic leg compression
1222501|NCT01064323|nitric oxide
1222502|NCT01064323|vascular endothelial cells
1222503|NCT01064323|IPC
1222504|NCT01064323|EECP
1222505|NCT01064323|atherosclerosis
1222506|NCT01064310|renal cell carcinoma
1222507|NCT01064310|Votrient
1222508|NCT01064310|cancer
1222509|NCT01064310|pazopanib
1222510|NCT01064310|patient preference
1222511|NCT01064310|quality of life
1222512|NCT01064297|Pregnancy registry
1222513|NCT01064297|Major congenital malformations
1222514|NCT01064297|Pregnancy outcomes
1222515|NCT01064297|Pregnancy
1222516|NCT01064297|First trimester
1222517|NCT01064297|Lamotrigine
1222518|NCT01064284|Hemophilia A
1222519|NCT01064284|Factor VIII inhibitors
1222520|NCT01064284|vWF/FVIII
1222521|NCT01064284|rFVIII
1222522|NCT01064258|treatment
1222523|NCT01064258|CPAP
1222524|NCT01064258|sleep apnea
1222525|NCT01064245|Asthma
1222526|NCT01064245|Cough Variant Asthma
1222527|NCT01064245|Mannitol
1222528|NCT01064245|Methacholine
1222529|NCT01064245|Cough
1222530|NCT01064245|Hypersensitivity
1222531|NCT01064219|hCG
1222532|NCT01064219|Treg cells
1222533|NCT01064219|implantation
1222534|NCT01064219|pinopodes
1222535|NCT01064219|endometrium
1222536|NCT01064206|thrombangiitis obliterans
1222537|NCT01064206|Buerger's disease
1222538|NCT01064206|atheromatous arteritis
1222539|NCT01064206|psychiatric disorders
1222540|NCT01064206|personality disorders
1222541|NCT01064206|addictive profile
1222542|NCT01064206|addiction
1222543|NCT01064206|tobacco
1222544|NCT01064206|cannabis
1222545|NCT01064193|In Vitro Fertilization
1222546|NCT01064193|biopsy
1222547|NCT01064193|pregnancy
1222548|NCT01064193|Implantation
1222549|NCT01064193|Embryo
1222550|NCT01064193|first or second IVF tentative
1222551|NCT01064167|Tranexamic Acid
1222552|NCT01064167|off-pump coronary Artery Bypass
1222553|NCT01064141|Dengue Fever
1222554|NCT01064141|Dengue Hemorrhagic Fever
1222555|NCT01064141|CYD Dengue Vaccine
1222556|NCT01064141|Toddlers
1222557|NCT01064128|Single-port
1222558|NCT01064128|Laparoscopy
1222559|NCT01064128|Hysterectomy
1222560|NCT01064128|Pain
1222561|NCT01064128|Cosmesis
1222562|NCT01064128|Analgesics
1222563|NCT01064089|HSP990
1222564|NCT01064089|HSP90
1222565|NCT01064089|Japan/Korea
1222566|NCT01064089|Phase I
1222567|NCT01064089|advanced solid tumors
1222568|NCT01064089|dose escalation
1222569|NCT01064089|maximum tolerated dose
1222570|NCT01064089|MTD
1222571|NCT01064089|Japanese paatients
1222572|NCT01064089|Korean patients
1222573|NCT01064076|ICD, defibrillator
1222574|NCT01064050|tumoral obstruction of the main stem bronchus
1222575|NCT01064050|bronchoscopy
1222576|NCT01064050|silicone stent
1222577|NCT01064037|Heart Failure
1222578|NCT01064024|uUTI
1222579|NCT01064024|Pain or burning associated with Uncomplicated Urinary Tract Infections
1222580|NCT01063998|Renal cell
1222581|NCT01063998|Carcinoma
1222582|NCT01063998|Biomarkers
1222583|NCT01063985|Skin testing for mouse allergies
1222584|NCT01063959|Laparoscopic Sleeve Gastrectomy
1222585|NCT01063959|Laparoscopic Gastric Bypass
1222586|NCT01063933|influenza, Peramivir, children, pharmacokinetic, pharmacodynamic
1222587|NCT01063920|LT-NS001
1222588|NCT01063920|Gastric Ulcers
1222589|NCT01063920|NSAID
1222590|NCT01063920|Osteoarthritis
1222591|NCT01063920|Naproxen
1222592|NCT01063907|Leukemia
1222593|NCT01063907|Immunoproliferative Disorder
1222594|NCT01063907|Neoplasma by Histologic Type
1222595|NCT01063907|Immune System Diseases
1222596|NCT01063907|Hematologic Diseases
1222597|NCT01063907|Blood Protein Disorders
1222598|NCT01063907|Paraproteinemias
1222599|NCT01063907|Multiple Myeloma
1222600|NCT01063907|Hematologic Disorders
1222601|NCT01063907|Leukemia, Chronic, B-cell
1222602|NCT01063907|Leukemia, B-cell
1222603|NCT01063907|Leukemia, Chronic
1222604|NCT01063907|Neoplasms, Plasma Cell
1222605|NCT01063907|Monoclonal Gammopathy of unknown significance (MGUS)
1222606|NCT01063881|Sexual Dysfunction, physiological
1222607|NCT01063881|R096769
1222608|NCT01063881|Dapoxetine
1222609|NCT01063881|Phase 3b
1222610|NCT01063881|Premature Ejaculation
1222611|NCT01063868|Diabetic neuropathy
1222612|NCT01063868|Painful
1222613|NCT01063868|Polyneuropathy
1222614|NCT01063868|Peripheral neuropathy
1222615|NCT01063855|Erectile Dysfunction
1222616|NCT01063855|Sexual Dysfunction
1222617|NCT01063855|Dapoxetine hydrochloride
1222618|NCT01063855|PRILIGY
1222619|NCT01063855|Premature ejaculation
1222620|NCT01063855|Serotonin Uptake Inhibitors
1222621|NCT01063855|Sildenafil (Viagra)
1222622|NCT01063855|Vardenafil (Levitra)
1222623|NCT01063855|Tadalafil (Cialis)
1222624|NCT01063842|Drop-out rate
1222625|NCT01063842|Osteoarthritis
1222626|NCT01063842|Tolerability
1222627|NCT01063842|Tramadol
1222628|NCT01063842|Acetaminophen
1222629|NCT01063829|HCMV
1222630|NCT01063816|PARP Inhibitors
1222631|NCT01063803|Open-label
1222632|NCT01063803|Long-term safety study of ATN-103 in RA
1222633|NCT01063790|Post-operative pain
1222634|NCT01063790|inguinal hernia repair surgery
1222635|NCT01063790|Patient education
1222636|NCT01063777|Hip Osteoarthritis, Exercise therapy, Patient Education
1222637|NCT01063764|Keppra
1222638|NCT01063764|Levetiracetam
1222639|NCT01063764|Children
1222640|NCT01063764|Epilepsy
1222641|NCT01063764|Partial Seizures
1222642|NCT01063751|Osteoarthritis
1222643|NCT01063751|Traumatic arthritis
1222644|NCT01063751|Avascular Necrosis
1222645|NCT01063738|Rehabilitation
1222646|NCT01063738|Intensive Care
1222647|NCT01063738|Critical illness
1222648|NCT01063738|Physiotherapy
1222649|NCT01063738|Nutritional supplementation
1222650|NCT01063725|menopause
1222651|NCT01063725|hot flashes
1222652|NCT01063725|vasomotor symptoms
1222653|NCT01063725|femarelle
1222654|NCT01063725|soy extract
1222655|NCT01063725|SERM
1222656|NCT01063712|Ductus
1222657|NCT01063712|Patent ductus Arterious
1222658|NCT01063712|"Nit-Occlud® PDA-R"
1222659|NCT01063712|Interventional closure of PDA
1222660|NCT01063712|Percutaneous closure
1222661|NCT01063699|biliary atresia - laparoscopy - kasai - portoenterostomy
1222662|NCT01063686|Pregnancy
1222663|NCT01063673|Running, overuse injury, limits humans
1222664|NCT01063660|Treosulfan
1222665|NCT01063660|Fludarabine
1222666|NCT01063660|ATG
1222667|NCT01063660|AML
1222668|NCT01063647|Treosulfan
1222669|NCT01063647|Allogeneic stem cell transplantation
1222670|NCT01063647|Conditioning therapy
1222671|NCT01063634|malignant biliary obstruction
1222672|NCT01063634|viaduct
1222673|NCT01063634|self-expandable metal stents
1222674|NCT01063595|Octaplas LG
1222675|NCT01063595|Octaplas SD
1222676|NCT01063582|echocardiogram
1222677|NCT01063582|electrocardiographic
1222678|NCT01063582|risk factors
1222679|NCT01063582|noise
1222680|NCT01063569|Addison's disease
1222681|NCT01063569|Glucocorticoid treatment
1222682|NCT01063569|Continuous subcutaneous hydrocortisone infusion
1222683|NCT01063569|CSHI
1222684|NCT01063569|Quality of Life
1222685|NCT01063569|Sleep
1222686|NCT01063556|end-stage renal disease hemodialysis donepezil hydrochloride pharmacokinetics Cross-Over Study
1222687|NCT01063543|fondaparinux
1222688|NCT01063543|orthopedic surgery
1222689|NCT01063543|patients with major orthopedic surgery
1222690|NCT01063530|FLuoride
1222691|NCT01063530|Dental Sensitivity
1222692|NCT01063530|Abfraction
1222693|NCT01063530|Cervical lesions
1222694|NCT01063517|Poly(ADP ribose)
1222695|NCT01063517|polymerase (PARP)
1222696|NCT01063517|Gastric cancer
1222697|NCT01063517|olaparib
1222698|NCT01063517|PARP inhibitor
1222699|NCT01063517|ATM AZD2281
1222700|NCT01063517|Ku0059436
1222701|NCT01063517|Homologous Recombination deficiency (HRD)
1222702|NCT01063517|Recurrent gastric cancer
1222703|NCT01063517|metastatic gastric cancer
1222704|NCT01063491|coronary artery bypass graft surgery
1222705|NCT01063491|bypass grafts
1222706|NCT01063491|angiography
1222707|NCT01063491|percutaneous coronary intervention
1222708|NCT01063491|coronary imaging
1222709|NCT01063491|coronary artery bypass graft surgery, bypass graft patency
1222710|NCT01063478|Non-Small Cell
1222711|NCT01063478|Lung Cancer
1222712|NCT01063478|Unresectable advanced NSCLC
1222713|NCT01063465|Achilles
1222714|NCT01063465|Tendon
1222715|NCT01063465|weightbearing
1222716|NCT01063452|Urinary Catheterization
1222717|NCT01063452|Urinary Tract Infections
1222718|NCT01063439|DLBCL
1222719|NCT01063439|NHL
1222720|NCT01063426|Statin
1222721|NCT01063426|Vein
1222722|NCT01063413|Behavioral Research
1222723|NCT01063413|Community-Based Participatory Research
1222724|NCT01063387|cervical cancer,semaphorin 4C (Sema4C),
1222725|NCT01063387|Prophylactic Irradiation
1222726|NCT01063348|N-Acetyl Cysteine
1222727|NCT01063348|Picking
1222728|NCT01063348|Impulse Control Disorder
1222729|NCT01063348|Obsessive Compulsive Disorder
1222730|NCT01063335|CB1 Receptor
1222731|NCT01063335|Schizophrenia
1222732|NCT01063335|Positron Emission Tomography (PET)
1222733|NCT01063335|Healthy Volunteers
1222734|NCT01063335|HV
1222735|NCT01063322|Mitral Regurgitation
1222736|NCT01063322|Echocardiography
1222737|NCT01063322|Cardiac Magnetic Resonance
1222738|NCT01063322|Regurgitant Volume
1222739|NCT01063322|Mitral Valve Regurgitation
1222740|NCT01063309|Chronic Granulomatous Disease (CGD)
1222741|NCT01063309|Atherosclerosis
1222742|NCT01063309|Inflammatory Bowel Disease
1222743|NCT01063309|Immune Deficiencies
1222744|NCT01063309|Immune System Deficiences
1222745|NCT01063309|Chronic Granulomatous Disease
1222746|NCT01063309|CGD
1222747|NCT01063296|cervical cancer
1222748|NCT01063283|Non-squamous Non-Small Cell Lung Cancer
1222749|NCT01063283|Bevacizumab
1222750|NCT01063283|Ambulatory Blood Pressure Monitoring
1222751|NCT01063270|Hidradenitis Suppurativa
1222752|NCT01063270|Antibiotics
1222753|NCT01063270|Laser
1222754|NCT01063257|Myelodysplastic Syndrome
1222755|NCT01063244|pregnancy
1222756|NCT01063244|induction of Labor
1222757|NCT01063244|Cervical ripening
1222758|NCT01063244|Foley balloon
1222759|NCT01063231|Colonic Diseases
1222760|NCT01063231|bowel diseases
1222761|NCT01063218|Dermatitis, Atopic
1222762|NCT01063218|Corticoids, topic
1222763|NCT01063218|Corticosteroids
1222764|NCT01063205|Methamphetamine
1222765|NCT01063205|NAC
1222766|NCT01063205|N-acetylcysteine
1222767|NCT01063192|Locally Advanced Pancreatic Cancer
1222768|NCT01063179|Elderly patients
1222769|NCT01063179|Bortezomib
1222770|NCT01063179|Thalidomide
1222771|NCT01063153|ADHD
1222772|NCT01063153|Adults
1222773|NCT01063153|Electroencephalography (EEG)
1222774|NCT01063153|Concerta
1222775|NCT01063140|Rabies Immune Globulin
1222776|NCT01063140|Source Plasma Donors
1222777|NCT01063140|Booster Immunization
1222778|NCT01063127|Morbid obesity
1222779|NCT01063127|Insulin resistance
1222780|NCT01063127|Euglycemic clamp
1222781|NCT01063114|proton beam radiation
1222782|NCT01063088|Prophylaxis of seasonal influenza in adults
1222783|NCT01063075|Cancer of Head
1222784|NCT01063075|Cancer of Head and Neck
1222785|NCT01063075|Cancer of Neck
1222786|NCT01063075|Head and Neck Cancer
1222787|NCT01063075|Head Cancer
1222788|NCT01063075|Head Neoplasms
1222789|NCT01063075|Head, Neck Neoplasms
1222790|NCT01063075|Neck Cancer
1222791|NCT01063075|Neck Neoplasms
1222792|NCT01063075|Solid Neoplasm
1222793|NCT01063075|Carcinoma
1222794|NCT01063075|Sarcoma
1222795|NCT01063010|sepsis
1222796|NCT01063010|septic shock
1222797|NCT01063010|Bevacizumab
1222798|NCT01063010|Avastin
1222799|NCT01062984|Renal Replacement Therapy
1222800|NCT01062971|Open-angle glaucoma
1222801|NCT01062971|Ocular hypertension
1222802|NCT01062971|POAG
1222803|NCT01062958|Neevo
1222804|NCT01062958|Neevo DHA
1222805|NCT01062958|L-methylfolate
1222806|NCT01062958|anemia during pregnancy
1222807|NCT01062958|folic acid
1222808|NCT01062958|vitamin B12
1222809|NCT01062958|prenatal vitamins
1222810|NCT01062958|hemoglobin
1222811|NCT01062958|iron deficiency
1222812|NCT01062958|Pregnancy
1222813|NCT01062945|Cocaine
1222814|NCT01062945|Doxazosin
1222815|NCT01062932|Cycloserine
1222816|NCT01062932|Nicotine
1222817|NCT01062932|Smoking
1222818|NCT01062906|intravenous lidocaine
1222819|NCT01062906|postoperative pain
1222820|NCT01062906|laparoscopic surgery
1222821|NCT01062906|opioids
1222822|NCT01062906|opioids side-effects
1222823|NCT01062893|labor pain treatment
1222824|NCT01062893|duration analgesia
1222825|NCT01062893|Analgesic duration with normal saline injection.
1222826|NCT01062893|Analgesic duration without normal saline injection
1222827|NCT01062867|Anaesthetic
1222828|NCT01062854|snoring, sleep disordered breathing, polysomnography, sleep fragmentation
1222829|NCT01062841|Long-Term Care
1222830|NCT01062841|Nursing Homes
1222831|NCT01062841|Infection Control
1222832|NCT01062841|Multi-drug resistant pathogens
1222833|NCT01062841|Long-term care residents with in-dwelling devices
1222834|NCT01062828|Prematurity
1222835|NCT01062828|Necrotizing Enterocolitis
1222836|NCT01062828|Feeding Intolerance
1222837|NCT01062815|PNALD
1222838|NCT01062815|PNAC
1222839|NCT01062815|Parenteral Nutrition-Associated Cholestasis
1222840|NCT01062815|Congenital Anomalies of Gastrointestinal Tract
1222841|NCT01062789|lung biopsy
1222842|NCT01062789|computed tomograph
1222843|NCT01062789|respiratory motion
1222844|NCT01062789|Controlling respiratory motion in CT guided lung biopsies
1222845|NCT01062789|biopsy
1222846|NCT01062776|dehydration
1222847|NCT01062776|fluid therapy
1222848|NCT01062776|pharmacokinetics
1222849|NCT01062776|hemoglobin
1222850|NCT01062763|hypertension
1222851|NCT01062763|spironolactone
1222852|NCT01062763|antihypertensive treatment
1222853|NCT01062763|Type-2 diabetes
1222854|NCT01062750|Liver Cirrhosis
1222855|NCT01062724|Cholestasis
1222856|NCT01062724|TPN
1222857|NCT01062724|Neonates
1222858|NCT01062724|Primene
1222859|NCT01062724|Trophamine
1222860|NCT01062724|Methionine
1222861|NCT01062724|Cysteine
1222862|NCT01062724|Taurine
1222863|NCT01062724|Total Parenteral Nutrition
1222864|NCT01062711|sarcopenia
1222865|NCT01062711|muscle
1222866|NCT01062711|protein
1222867|NCT01062711|muscle protein synthesis
1222868|NCT01062711|muscle protein breakdown
1222869|NCT01062711|whey
1222870|NCT01062711|soy
1222871|NCT01062711|casein
1222872|NCT01062711|dose response
1222873|NCT01062711|resistance exercise
1222874|NCT01062711|unilateral
1222875|NCT01062711|knee extension
1222876|NCT01062711|whole body protein
1222877|NCT01062698|mechanical Thrombectomy
1222878|NCT01062698|CVA (Cerebrovascular Accident)
1222879|NCT01062698|Cerebrovascular Accident, Acute
1222880|NCT01062685|septic shock
1222881|NCT01062685|sepsis
1222882|NCT01062685|St02
1222883|NCT01062685|Near Infrared Spectroscopy
1222884|NCT01062685|NIRS
1222885|NCT01062672|plasticity
1222886|NCT01062672|reorganization
1222887|NCT01062672|cortical
1222888|NCT01062672|fMRI
1222889|NCT01062672|rehabilitation
1222890|NCT01062659|HCV
1222891|NCT01062659|hepatitis C virus
1222892|NCT01062659|CHC
1222893|NCT01062659|chronic hepatitis c
1222894|NCT01062659|interferon
1222895|NCT01062659|ribavirin
1222896|NCT01062659|Hepatitis, Viral, Human
1222897|NCT01062659|Anti-Infective Agents
1222898|NCT01062659|peginterferon alfa-2a
1222899|NCT01062659|peginterferon alfa-2b
1222900|NCT01062646|music therapy
1222901|NCT01062646|multimodal psychotherapy
1222902|NCT01062646|children
1222903|NCT01062646|anxiety disorders
1222904|NCT01062646|pediatric anxiety
1222905|NCT01062633|dental caries
1222906|NCT01062633|prevention
1222907|NCT01062633|dietary supplements
1222908|NCT01062607|bipolar disorders
1222909|NCT01062607|everyday setting
1222910|NCT01062607|treatment adherence
1222911|NCT01062607|global
1222912|NCT01062581|Recipient
1222913|NCT01062581|Donor
1222914|NCT01062581|Organ Transplant
1222915|NCT01062581|Registry
1222916|NCT01062581|University of Minnesota
1222917|NCT01062568|adolescents
1222918|NCT01062568|puberty
1222919|NCT01062568|androgens
1222920|NCT01062568|hyperandrogenemia
1222921|NCT01062529|GH signalling
1222922|NCT01062529|insulin resistance
1222923|NCT01062529|somatostatin
1222924|NCT01062529|acromegaly
1222925|NCT01062516|acute coronary syndrome
1222926|NCT01062516|acute myocardial infarction
1222927|NCT01062516|percutaneous coronary intervention
1222928|NCT01062516|aspirin
1222929|NCT01062516|clopidogrel
1222930|NCT01062516|esomeprazole
1222931|NCT01062516|famotidine
1222932|NCT01062516|platelet function
1222933|NCT01062503|Cancer
1222934|NCT01062503|Prostate
1222935|NCT01062503|metastatic
1222936|NCT01062490|Treosulfan
1222937|NCT01062490|MDS
1222938|NCT01062490|allogeneic stem cell transplantation
1222939|NCT01062490|leukemia
1222940|NCT01062490|Conditioning
1222941|NCT01062477|Diphtheria Tetanus Pertussis Haemophilus Influenzae Type B
1222942|NCT01062451|Methamphetamine
1222943|NCT01062451|Perindopril
1222944|NCT01062451|Candesartan
1222945|NCT01062451|Angiotensin receptor blocker
1222946|NCT01062451|ACE Inhibitor
1222947|NCT01062438|localized osteosarcoma
1222948|NCT01062438|metastatic osteosarcoma
1222949|NCT01062399|adult glioblastoma
1222950|NCT01062399|adult giant cell glioblastoma
1222951|NCT01062399|adult gliosarcoma
1222952|NCT01062386|prevalence
1222953|NCT01062386|transmission
1222954|NCT01062386|knowledge
1222955|NCT01062386|attitude
1222956|NCT01062386|practice
1222957|NCT01062373|Premature Newborns
1222958|NCT01062373|Human Milk
1222959|NCT01062373|DHA
1222960|NCT01062373|Mother-child
1222961|NCT01062360|Sore Throat
1222962|NCT01062360|Upper Respiratory Tract Infections
1222963|NCT01062360|Nasal Congestion
1222964|NCT01062347|To identify a new bio-marker for zinc status
1222965|NCT01062334|Anastomotic leakage after LAR
1222966|NCT01062321|Hepatitis E Virus
1222967|NCT01062321|Cytokines
1222968|NCT01062321|Pregnancy
1222969|NCT01062308|Stroke
1222970|NCT01062308|Taping
1222971|NCT01062308|Pain
1222972|NCT01062308|Shoulder Injury
1222973|NCT01062295|passenger,
1222974|NCT01062295|sleep,
1222975|NCT01062295|rest,
1222976|NCT01062282|Pulmonary Hypertension
1222977|NCT01062269|Bile acid sequestrant
1222978|NCT01062269|Resin
1222979|NCT01062269|Cholesterol
1222980|NCT01062269|Diabetes mellitus
1222981|NCT01062269|Lipids
1222982|NCT01062269|Glucose
1222983|NCT01062269|Bile Acid Sequestrant Acceptability Scale (BASA)validation study
1222984|NCT01062256|Cough assessment in upper respiratory infection
1222985|NCT01062256|guaifenesin
1222986|NCT01062256|honey
1222987|NCT01062243|brain injury
1222988|NCT01062243|family treatment
1222989|NCT01062230|Cancer
1222990|NCT01062230|Hematologic malignancy
1222991|NCT01062204|Skin Graft donor sites
1222992|NCT01062191|hydrogel
1222993|NCT01062191|dressing
1222994|NCT01062191|burn
1222995|NCT01062191|joint
1222996|NCT01062178|Small renal Mass
1222997|NCT01062178|Contrast Enhanced Ultrasound
1222998|NCT01062178|Renal Cell Carcinoma
1222999|NCT01062178|noninvasive diagnosis of RCC
1223000|NCT01062165|Echinocandin
1223001|NCT01062165|Obesity
1223002|NCT01062165|Pharmacokinetics
1223003|NCT01062165|Pharmacodynamics
1223004|NCT01062165|Fungal infection
1223005|NCT01062152|Hematology
1223006|NCT01062152|MDS
1223007|NCT01062152|Myelodysplastic Syndrome
1223008|NCT01062152|Low risk MDS
1223009|NCT01062152|Patients with non-deletion(5q)
1223010|NCT01062152|Non-deletion 5q
1223011|NCT01062152|Non del(5q)
1223012|NCT01062152|Revlimid
1223013|NCT01062152|lenalidomide
1223014|NCT01062152|Telintra
1223015|NCT01062152|ezatiostat hydrochloride
1223016|NCT01062152|ezatiostat
1223017|NCT01062152|TLK199
1223018|NCT01062152|Glutathione
1223019|NCT01062152|Glutathione analog
1223020|NCT01062152|Glutathione Transferase
1223021|NCT01062152|Glutathione Transferase inhibitor
1223022|NCT01062152|Glutathione Transferase P1-1 inhibitor
1223023|NCT01062152|GSTp1-1 inhibitor
1223024|NCT01062152|Apoptosis
1223025|NCT01062152|Differentiation
1223026|NCT01062152|Enzyme inhibitor
1223027|NCT01062126|Pacemaker
1223028|NCT01062126|Advanced Features
1223029|NCT01062126|Clinical Outcomes
1223156|NCT01061554|Soft gel capsules
1223030|NCT01062113|Acute pain after oral surgery lateral mandibular Impacted third molar tooth extraction
1223031|NCT01062100|breast cancer
1223032|NCT01062100|molecular breast imaging
1223033|NCT01062100|MRI
1223034|NCT01062100|gamma camera
1223035|NCT01062087|postoperative pain
1223036|NCT01062087|tubal ligation
1223037|NCT01062087|local anesthetic
1223038|NCT01062061|Varicella
1223039|NCT01062035|Advanced colon polyp
1223040|NCT01062035|Adenomatous colon polyp
1223041|NCT01062035|Adenoma, villous colon polyp
1223042|NCT01062035|Advanced colorectal adenomas
1223043|NCT01062035|Colonic neoplasms
1223044|NCT01062035|High grade dysplasia
1223045|NCT01062035|Telomere blood testing
1223046|NCT01062022|intervention
1223047|NCT01062022|combat wounded
1223048|NCT01062022|family
1223049|NCT01062022|Focus-CI
1223050|NCT01061996|Ulcerative Colitis
1223051|NCT01061983|Deep brain stimulation
1223052|NCT01061983|Treatment refractory
1223053|NCT01061983|Ventral internal capsule/ventral striatum
1223054|NCT01061983|Neurosurgery
1223055|NCT01061983|Neuroimaging
1223056|NCT01061970|Hypogonadism
1223057|NCT01061970|Chronic Obstructive Pulmonary Disease
1223058|NCT01061970|COPD
1223059|NCT01061957|Treatment outcome
1223060|NCT01061957|HIV treatment
1223061|NCT01061944|biopsy
1223062|NCT01061944|tumor biopsy
1223063|NCT01061944|genetic studies
1223064|NCT01061931|MRI
1223065|NCT01061931|left-sided atrial catheter ablation
1223066|NCT01061931|paroxysmal atrial fibrillation
1223067|NCT01061931|cryoballoon technique
1223068|NCT01061931|mesh ablator catheter
1223069|NCT01061931|stroke
1223070|NCT01061931|silent stroke
1223071|NCT01061931|major complications
1223072|NCT01061918|Compare the visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs 6 months post cataract surgery.
1223073|NCT01061905|health behavior
1223074|NCT01061905|behavioral economics
1223075|NCT01061905|calorie labeling
1223076|NCT01061905|exercise
1223077|NCT01061879|umbilical cord
1223078|NCT01061879|umbilical cord blood collection
1223079|NCT01061879|pregnancy
1223080|NCT01061866|Thalidomide
1223081|NCT01061866|Antiepileptic drugs
1223082|NCT01061866|Refractory epilepsy
1223083|NCT01061866|Sedative drugs
1223084|NCT01061853|Oral lichen planus
1223085|NCT01061853|chronic inflammatory
1223086|NCT01061853|mucous membranes
1223087|NCT01061853|erosive lesions
1223088|NCT01061840|Ewings Sarcoma
1223089|NCT01061840|Non Small Cell Lung Cancer
1223090|NCT01061840|Liver Cancer
1223091|NCT01061827|GMS-package;dementia;depression
1223092|NCT01061814|ApoB (Apolipoprotein B)
1223093|NCT01061814|LDL (low density lipoprotein)
1223094|NCT01061814|mipomersen
1223095|NCT01061814|ISIS301012
1223096|NCT01061814|antisense
1223097|NCT01061801|caregivers
1223098|NCT01061801|cancer
1223099|NCT01061801|emotion
1223100|NCT01061801|protective buffering
1223101|NCT01061788|Phase I
1223102|NCT01061788|Solid Tumor
1223103|NCT01061788|AMG 479
1223104|NCT01061788|Panitumumab
1223105|NCT01061788|Everolimus
1223106|NCT01061788|RAD001
1223107|NCT01061788|Duke
1223108|NCT01061788|Subjects with refractory advanced solid tumors
1223109|NCT01061788|non-small cell lung cancer
1223110|NCT01061775|Hypothalamic Obesity
1223111|NCT01061775|Exenatide
1223112|NCT01061775|Byetta
1223113|NCT01061775|Craniopharyngioma
1223114|NCT01061762|Treatment adherence
1223115|NCT01061762|Low literacy skills
1223116|NCT01061762|HIV treatment
1223117|NCT01061710|Smoking
1223118|NCT01061710|smoking cessation
1223119|NCT01061710|Japanese
1223120|NCT01061710|varenicline
1223121|NCT01061710|retreatment
1223122|NCT01061710|Regulatory Post Marketing Commitment Plan
1223123|NCT01061684|fatty liver disease
1223124|NCT01061684|NASH
1223125|NCT01061684|NAFLD
1223126|NCT01061684|non-alcoholic steatohepatitis
1223127|NCT01061671|Chronic Obstructive Pulmonary Disease
1223128|NCT01061671|COPD
1223129|NCT01061671|Exacerbation
1223130|NCT01061671|Lung function
1223131|NCT01061671|Cardiovascular
1223132|NCT01061671|Smoking
1223133|NCT01061671|Statins
1223134|NCT01061671|Simvastatin
1223135|NCT01061645|MDT and DLT
1223136|NCT01061632|deadlift
1223137|NCT01061632|motor control
1223138|NCT01061632|exercises
1223139|NCT01061632|pain
1223140|NCT01061632|function
1223141|NCT01061632|functional capacity
1223142|NCT01061619|prediagnostic symptoms
1223143|NCT01061619|sentinel events
1223144|NCT01061619|pathway to diagnosis
1223145|NCT01061593|TB
1223146|NCT01061593|MDR-TB
1223147|NCT01061593|XDR-TB
1223148|NCT01061593|TB/HIV
1223149|NCT01061580|Bone Marrow Concentrate
1223150|NCT01061580|CABG
1223151|NCT01061580|Cardiac
1223152|NCT01061580|Stem Cell
1223153|NCT01061554|Bioavailability
1223154|NCT01061554|Eicosapentaenoic acid
1223155|NCT01061554|Docosahexaenoic acid
1223157|NCT01061554|Gastric stable emulsion
1223158|NCT01061554|Omega-3
1223159|NCT01061554|Tri-glycerides
1223160|NCT01061554|Marine phospholipids
1223161|NCT01061541|Pertussis
1223162|NCT01061541|Tetanus
1223163|NCT01061541|Hiberix™
1223164|NCT01061541|Hepatitis B
1223165|NCT01061541|DTPw-HBV vaccine
1223166|NCT01061541|Tritanrix™-HepB
1223167|NCT01061541|Haemophilus influenzae type b
1223168|NCT01061541|Diphtheria
1223169|NCT01061541|Hib vaccine
1223170|NCT01061528|cigarette smoking
1223171|NCT01061528|smoking cessation
1223172|NCT01061528|nicotine dependence
1223173|NCT01061502|Burns
1223174|NCT01061502|Wounds and Injuries
1223175|NCT01061502|Skin Grafts, Bioelectric
1223176|NCT01061502|Grafting, skin
1223177|NCT01061489|neuroplasticity
1223178|NCT01061489|Mild Cognitive Impairment (MCI)
1223179|NCT01061489|Alzheimer
1223180|NCT01061489|sensory-cognitive training
1223181|NCT01061489|physical fitness
1223182|NCT01061476|sleep apnea
1223183|NCT01061476|treatment
1223184|NCT01061476|collapsibility
1223185|NCT01061476|expiratory nasal resistance
1223186|NCT01061463|Radiation cataracts
1223187|NCT01061463|Lens opacities
1223188|NCT01061463|X-rays
1223189|NCT01061463|Interventional Cardiologists
1223190|NCT01061463|Electrophysiologists
1223191|NCT01061450|Diastolic dysfunction
1223192|NCT01061450|hypertension
1223193|NCT01061450|Statins
1223194|NCT01061450|ACE inhibitor
1223195|NCT01061450|Echocardiography
1223196|NCT01061437|H. pylori
1223197|NCT01061424|pediatric asthma
1223198|NCT01061398|cardiac ct
1223199|NCT01061398|stress testing
1223200|NCT01061398|coronary artery disease
1223201|NCT01061372|RLS
1223202|NCT01061359|Breast Cancer
1223203|NCT01061359|Neoadjuvant Treatment
1223204|NCT01061359|Chemotherapy
1223205|NCT01061359|Adjuvant
1223206|NCT01061359|Epirubicin
1223207|NCT01061346|Fructose
1223208|NCT01061346|Glucose
1223209|NCT01061320|Alpha-Tocopherol (Vitamin E)
1223210|NCT01061320|Contrast induced nephropathy
1223211|NCT01061320|Chronic kidney disease
1223212|NCT01061320|Coronary procedures
1223213|NCT01061307|Fe deficiency, Zn deficiency, vitamin A deficiency
1223214|NCT01061294|Assess the efficacy, predictability and safety of the Advanced CustomVue™ iLASIK procedure.
1223215|NCT01061281|Aphakia following refractive lensectomy to treat presbyopia
1223216|NCT01061268|Relief of dry eye symptoms following implantation of TMF IOL
1223217|NCT01061255|Stress
1223218|NCT01061255|Cortisol
1223219|NCT01061255|Clinical reasoning
1223220|NCT01061255|Ambulatory setting
1223221|NCT01061255|Medical students
1223222|NCT01061255|Year 6 medical students
1223223|NCT01061242|Neurocognitive function
1223224|NCT01061242|Sleep quality
1223225|NCT01061242|Critical care
1223226|NCT01061242|Quality Assurance, health care
1223227|NCT01061216|Diabetes
1223228|NCT01061216|Insulin Therapy
1223229|NCT01061216|Blood Glucose
1223230|NCT01061216|Basal insulin
1223231|NCT01061216|Diabetics
1223232|NCT01061203|Rhinitis
1223233|NCT01061203|allergic
1223234|NCT01061203|Seasonal
1223235|NCT01061203|grass
1223236|NCT01061203|Asthma
1223237|NCT01061190|Stroke
1223238|NCT01061177|Leukemia
1223239|NCT01061177|myeloid
1223240|NCT01061177|myelogenous
1223241|NCT01061177|chronic BCR-ABL positive
1223242|NCT01061177|Nilotinib
1223243|NCT01061177|Philadelphia chromosome
1223244|NCT01061177|CML in chronic phase
1223245|NCT01061138|breast cancer
1223246|NCT01061138|screening mammograms
1223247|NCT01061138|breast biopsy
1223248|NCT01061125|atrial fibrillation
1223249|NCT01061125|implantable loop recorder
1223250|NCT01061125|TTM
1223251|NCT01061112|drug interactions
1223252|NCT01061112|genetics
1223253|NCT01061112|healthy volunteers
1223254|NCT01061112|normal controls
1223255|NCT01061112|CYP2C9
1223256|NCT01061099|Type II or Type III Osteogenesis imperfecta
1223257|NCT01061099|OI
1223258|NCT01061099|Mesenchymal Stromal Cells
1223259|NCT01061099|MSC
1223260|NCT01061086|Acute Coronary Syndromes
1223261|NCT01061086|Epidemiology
1223262|NCT01061086|Management of disease
1223263|NCT01061086|Outcomes
1223264|NCT01061086|Greece
1223265|NCT01061060|Prostaglandin I2
1223266|NCT01061060|Beraprost Na
1223267|NCT01061060|Endothelial cell function
1223268|NCT01061047|patients infected with a bacteria sensible to ertapeneme
1223269|NCT01061034|pharmacokinetics
1223270|NCT01061034|aspirin
1223271|NCT01061034|proton pump inhiditor
1223272|NCT01061021|HIV prevention
1223273|NCT01061021|Treatment adherence
1223274|NCT01061021|Treatment for Prevention
1223275|NCT01061008|Exercise; arteriovenous fistula; chronic kidney disease
1223276|NCT01060995|Informed Consent
1223277|NCT01060995|Oral Health
1223278|NCT01060995|Patient Decision-making
1223279|NCT01060982|Primary hyperparathyroidism
1223280|NCT01060982|High Intensity Focused Ultrasound
1223281|NCT01060982|Parathyroid tumor
1223282|NCT01060982|Parathyroid hormone
1223283|NCT01060982|Calcium
1223284|NCT01060969|Acute Mountain Sickness
1223285|NCT01060969|travellers
1223286|NCT01060969|Acetazolamide
1223287|NCT01060969|Tadalafil
1223288|NCT01060969|Acute Mountain Sickness assessed by Lake Louise score
1223289|NCT01060969|High altitude pulmonary edema
1223290|NCT01060969|High altitude cerebral edema
1223291|NCT01060956|Urinary tract infection with two bacteria in culture
1223292|NCT01060943|injectable collagen filler
1223293|NCT01060943|correction of wrinkles and folds
1223294|NCT01060943|enrolled : 73
1223295|NCT01060943|withdrawal : 4
1223296|NCT01060943|ongoing : 0
1223297|NCT01060943|completed : 69
1223298|NCT01060930|Nitric oxide
1223299|NCT01060930|Diesel exhaust
1223300|NCT01060930|Air pollution
1223301|NCT01060930|Cardiac output
1223302|NCT01060930|Healthy volunteers
1223303|NCT01060917|diabetes
1223304|NCT01060904|Antibodies, Monoclonal
1223305|NCT01060904|Antibody-Drug Conjugate
1223306|NCT01060904|Antigens, CD30
1223307|NCT01060904|Disease, Hodgkin
1223308|NCT01060904|Hematologic Diseases
1223309|NCT01060904|Immunotherapy
1223310|NCT01060904|Lymphoma
1223311|NCT01060904|monomethyl auristatin E
1223312|NCT01060891|patients infected with with multiresistant gram-negative bacteria
1223313|NCT01060878|Early-stage
1223314|NCT01060865|hypertension
1223315|NCT01060865|aliskiren
1223316|NCT01060865|Blood Pressure Monitoring, Ambulatory
1223317|NCT01060839|counseling
1223318|NCT01060826|acute pancreatits
1223319|NCT01060813|cirrhosis
1223320|NCT01060813|exercise
1223321|NCT01060813|leucin
1223322|NCT01060813|glutamine synthetase
1223323|NCT01060800|Chiari
1223324|NCT01060800|Chiari Type I
1223325|NCT01060800|Chiari Type I Malformation
1223326|NCT01060800|Familial Chiari
1223327|NCT01060774|Bupivacaine
1223328|NCT01060774|Lidocaine
1223329|NCT01060774|Inflammation
1223330|NCT01060774|Pain
1223331|NCT01060774|Local Anesthetic
1223332|NCT01060761|cancer
1223333|NCT01060761|Rehabilitation program (patient and a relative together)
1223334|NCT01060761|counselling
1223335|NCT01060761|retreat weekend
1223336|NCT01060748|Vaccination
1223337|NCT01060748|Challenge
1223338|NCT01060748|Diarrhea
1223339|NCT01060748|ETEC illness
1223340|NCT01060748|Travelers diarrhea
1223341|NCT01060748|ETEC
1223342|NCT01060748|Enterotoxigenic E.coli
1223343|NCT01060735|Vitamin D
1223344|NCT01060735|pregnancy
1223345|NCT01060735|children
1223346|NCT01060735|bone
1223347|NCT01060735|quantitative ultrasound
1223348|NCT01060735|Healthy pregnant women
1223349|NCT01060722|Healthy Male Volunteers
1223350|NCT01060709|Carbon dioxide
1223351|NCT01060709|TcC02
1223352|NCT01060709|Hypoventilation
1223353|NCT01060709|endoscopic
1223354|NCT01060709|elective colonoscopy and requiring sedation
1223355|NCT01060696|Infertility
1223356|NCT01060696|Saline infusion sonohysterography
1223357|NCT01060696|Pain
1223358|NCT01060696|Hyoscine
1223359|NCT01060696|Mefenamic acid
1223360|NCT01060696|women
1223361|NCT01060683|hemoglobin
1223362|NCT01060683|Coagulation variables
1223363|NCT01060683|blood chemistry
1223364|NCT01060683|Blood gas analysis
1223365|NCT01060670|Foot Ulcer
1223366|NCT01060670|Diabetic
1223367|NCT01060670|Wound Healing
1223368|NCT01060670|Integra Dermal Regeneration Template
1223369|NCT01060670|Full Thickness
1223370|NCT01060670|Neuropathic
1223371|NCT01060670|Omnigraft
1223372|NCT01060657|X-ray Computed Tomography
1223373|NCT01060657|Coronary vessels
1223374|NCT01060657|Radiation dosage
1223375|NCT01060644|Maxillary Sinus
1223376|NCT01060644|Bone Augmentation
1223377|NCT01060644|Dental Implant
1223378|NCT01060644|Sinus Membrane
1223379|NCT01060631|bispectral index
1223380|NCT01060631|lesions
1223381|NCT01060631|consciousness
1223382|NCT01060605|islet transplantation
1223383|NCT01060605|insulin independence
1223384|NCT01060605|C-peptide secretion
1223385|NCT01060592|Gastric Band
1223386|NCT01060592|LapBand
1223387|NCT01060592|Bariatric Surgery
1223388|NCT01060579|Glaucoma
1223389|NCT01060553|Post-traumatic stress disorders
1223390|NCT01060553|Acupuncture
1223391|NCT01060553|Quality of life
1223392|NCT01060553|sleep disorder
1223393|NCT01060540|genetic screening
1223394|NCT01060527|irritable bowel syndrome,protease activity,China
1223395|NCT01060514|Lung cancer
1223396|NCT01060514|Breast cancer
1223397|NCT01060501|rectal cancer
1223398|NCT01060501|adjuvant chemoradiotherapy
1223399|NCT01060501|5-FU, interferon-alpha
1223400|NCT01060501|Locally advanced resectable rectal cancer (UICC stage II and III)
1223401|NCT01060488|GH secretion tests
1223402|NCT01060488|adverse effects
1223403|NCT01060488|adult growth hormone deficiency
1223404|NCT01060488|growth-hormone releasing hormone and arginine test
1223405|NCT01060488|insulin tolerance test
1223406|NCT01060488|GHRH + Arginine test
1223407|NCT01060475|Transplant
1223408|NCT01060462|Defervescence rate
1223409|NCT01060462|Defervescence timing
1223410|NCT01060462|Itraconazole
1223411|NCT01060449|cardiac resynchronization therapy
1223412|NCT01060449|congestive heart failure
1223413|NCT01060436|sleep apnea
1223414|NCT01060436|sleep disordered breathing
1223415|NCT01060436|CPAP
1223416|NCT01060436|BiPAP
1223417|NCT01060436|treatment outcomes
1223418|NCT01060423|colorectal
1223419|NCT01060423|liver metastasis
1223420|NCT01060423|KRAS wildtype
1223421|NCT01060423|chemoembolization
1223422|NCT01060423|irinotecan eluting beads
1223423|NCT01060410|Myelosuppression
1223424|NCT01060410|Infection
1223425|NCT01060410|Nausea
1223426|NCT01060397|Alcohol
1223427|NCT01060397|nurse
1223428|NCT01060397|alcohol dependence
1223429|NCT01060397|acute hospital
1223430|NCT01060397|brief interventions
1223431|NCT01060371|Spinocerebellar Ataxia
1223432|NCT01060371|Natural History
1223433|NCT01060371|Genetic Modifiers
1223434|NCT01060371|DNA testing
1223435|NCT01060358|lumbar spine
1223436|NCT01060358|low back pain
1223437|NCT01060345|DCIS
1223438|NCT01060293|Heart Failure
1223439|NCT01060293|Dopamine
1223440|NCT01060293|Furosemide
1223441|NCT01060293|Worsening Renal Function
1223442|NCT01060293|Hypokalemia
1223443|NCT01060293|Outcomes
1223444|NCT01060293|Prognosis
1223445|NCT01060280|low back pain
1223446|NCT01060280|physiotherapy
1223447|NCT01060280|exercise
1223448|NCT01060280|active management
1223449|NCT01060254|Interstitial cystitis (IC) and/or painful bladder syndrome (PBS)-related pain
1223450|NCT01060254|Moderate to severe chronic bladder pain
1223451|NCT01060254|JNJ-42160443
1223452|NCT01060241|Remote Blood Glucose Monitoring System, Type 2 Diabetes
1223453|NCT01060228|Paliperidone ER
1223454|NCT01060228|INVEGA
1223455|NCT01060228|Divalproex sodium
1223456|NCT01060228|Depakote ER
1223457|NCT01060228|Pharmacokinetics
1223458|NCT01060228|Valproic Acid
1223459|NCT01060228|Human Experimentation
1223460|NCT01060215|effusion
1223461|NCT01060215|osteoarthritis
1223462|NCT01060215|knee
1223463|NCT01060202|Multiple Myeloma
1223464|NCT01060202|Bortezomib
1223465|NCT01060202|Velcade
1223466|NCT01060202|QoL
1223467|NCT01060202|Proteasome inhibitor
1223468|NCT01060202|EORTC QLQ C30
1223469|NCT01060202|EQ 5D
1223470|NCT01060189|ulinastatin
1223471|NCT01060189|tranexamic acid
1223472|NCT01060189|cardiac surgery procedures
1223473|NCT01060189|hemostasis
1223474|NCT01060189|anti-inflammation
1223475|NCT01060176|tranexamic acid
1223476|NCT01060176|cardiac surgery procedures
1223477|NCT01060176|hemostasis
1223478|NCT01060176|anti-inflammation
1223479|NCT01060163|Clopidogrel
1223480|NCT01060163|Tranexamic Acid
1223481|NCT01060163|Cardiac Surgical Procedures
1223482|NCT01060163|Hemostasis
1223483|NCT01060150|Attention Deficit Hyperactivity Disorder
1223484|NCT01060150|Methylphenidate hydrochloride
1223485|NCT01060150|Methylphenidate
1223486|NCT01060150|CONCERTA
1223487|NCT01060137|fentanyl matrix
1223488|NCT01060124|Pain; Cancer
1223489|NCT01060124|TTS-Fentanyl D-trans
1223490|NCT01060124|Durogesic D-trans
1223491|NCT01060111|Migraine
1223492|NCT01060111|Topiramate
1223493|NCT01060111|Propranolol
1223494|NCT01060085|Breast Cancer
1223495|NCT01060059|diabetes; exenatide; Byetta; basal insulin; Amylin; Lilly
1223496|NCT01060046|biologic mesh
1223497|NCT01060046|ventral hernia repair
1223498|NCT01060046|breast reconstruction
1223499|NCT01060046|MMPs
1223500|NCT01060033|Squamous cell cervical cancer
1223501|NCT01060020|Aortic valve stenosis
1223502|NCT01060020|Sildenafil
1223503|NCT01060020|Phosphodiesterase inhibitors
1223504|NCT01060020|Hypertension, Pulmonary
1223505|NCT01059994|fatigue
1223506|NCT01059994|aging
1223507|NCT01059968|bone density
1223508|NCT01059968|energy availability
1223509|NCT01059968|menstrual status
1223510|NCT01059968|female
1223511|NCT01059968|adolescent
1223512|NCT01059955|scleritis
1223513|NCT01059955|anterior scleritis
1223514|NCT01059955|nodular anterior scleritis
1223515|NCT01059955|diffuse anterior scleritis
1223516|NCT01059942|communication barriers
1223517|NCT01059942|clinical competence
1223518|NCT01059942|medical education
1223519|NCT01059942|internship and residency
1223520|NCT01059942|hospitalist
1223521|NCT01059942|Quality Assurance, Healthcare
1223522|NCT01059942|Patient Care
1223523|NCT01059942|Internal Medicine
1223524|NCT01059929|Hypnotics and Sedatives
1223525|NCT01059929|Respiration, Artificial
1223526|NCT01059929|Ventilators, Mechanical
1223527|NCT01059929|Critical care
1223528|NCT01059929|Intensive care
1223529|NCT01059929|Physical therapy
1223530|NCT01059929|Occupational therapy
1223531|NCT01059929|Sedative medications
1223532|NCT01059903|Rotigotine
1223533|NCT01059903|Neupro®
1223534|NCT01059903|Transdermal Patch
1223535|NCT01059877|dementia alzheimers frontotemporal lyme,
1223536|NCT01059877|lewy body cognitive impairment
1223537|NCT01059864|cholesterol
1223538|NCT01059864|lipids
1223539|NCT01059864|rheumatoid arthritis
1223540|NCT01059864|CP-690
1223541|NCT01059864|550
1223542|NCT01059838|pediatrics
1223543|NCT01059838|cochlear implant
1223544|NCT01059825|Phase 2
1223545|NCT01059825|safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)
1223546|NCT01059825|Type 2 diabetes mellitus
1223547|NCT01059786|Monoclonal Antibody
1223548|NCT01059786|Purine Analog
1223549|NCT01059786|Soluble CD25
1223550|NCT01059786|Minimal Residual Disease MRD
1223551|NCT01059786|CD20
1223552|NCT01059786|Hairy Cell Leukemia
1223553|NCT01059773|Psoriasis
1223554|NCT01059773|Ustekinumab
1223555|NCT01059773|Stelara
1223556|NCT01059773|Methotrexate
1223557|NCT01059773|Biologic
1223558|NCT01059760|Fasting
1223559|NCT01059760|Short-term starvation
1223560|NCT01059760|Diet
1223561|NCT01059760|Coronary artery disease
1223562|NCT01059734|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1223563|NCT01059734|adult acute myeloid leukemia with del(5q)
1223564|NCT01059734|adult acute myeloid leukemia with inv(16)(p13;q22)
1223565|NCT01059734|adult acute myeloid leukemia with t(16;16)(p13;q22)
1223566|NCT01059734|adult acute myeloid leukemia with t(8;21)(q22;q22)
1223567|NCT01059734|recurrent adult acute myeloid leukemia
1223568|NCT01059734|untreated adult acute myeloid leukemia
1223569|NCT01059734|adult erythroleukemia (M6a)
1223570|NCT01059734|adult pure erythroid leukemia (M6b)
1223571|NCT01059734|adult acute monoblastic leukemia (M5a)
1223572|NCT01059734|adult acute monocytic leukemia (M5b)
1223573|NCT01059734|adult acute myeloblastic leukemia with maturation (M2)
1223574|NCT01059734|adult acute myeloblastic leukemia without maturation (M1)
1223575|NCT01059734|adult acute myelomonocytic leukemia (M4)
1223576|NCT01059734|secondary acute myeloid leukemia
1223577|NCT01059734|adult acute minimally differentiated myeloid leukemia (M0)
1223578|NCT01059734|adult acute megakaryoblastic leukemia (M7)
1223579|NCT01059721|Centralisation
1223580|NCT01059721|Patella dislocation
1223581|NCT01059721|Open epiphyses
1223582|NCT01059721|Malalignment syndrome
1223583|NCT01059721|Relapse rate
1223584|NCT01059708|outcomes carbon monoxide poisoning children pediatric
1223585|NCT01059695|cervical cancer
1223586|NCT01059695|retrospective
1223587|NCT01059695|quality of life
1223588|NCT01059695|treatment
1223589|NCT01059669|Chronic pancreatitis
1223590|NCT01059669|Pain
1223591|NCT01059669|Exocrine insufficiency
1223592|NCT01059669|Diabetes
1223593|NCT01059669|Nutrition
1223594|NCT01059669|Ultrasound
1223595|NCT01059656|Dermatofibrosarcoma
1223596|NCT01059656|Pazopanib¨
1223597|NCT01059656|Phase II
1223598|NCT01059630|follicular
1223599|NCT01059630|follicular lymphoma
1223600|NCT01059617|Pandemic
1223601|NCT01059617|GSK Bio's influenza vaccine GSK2340274A
1223602|NCT01059617|H1N1
1223603|NCT01059617|Influenza
1223604|NCT01059604|pregnancy outcomes
1223605|NCT01059604|pregnancy
1223606|NCT01059604|first trimester
1223607|NCT01059604|Sumatriptan
1223608|NCT01059604|major congenital malformations
1223609|NCT01059604|naratriptan
1223610|NCT01059604|sumatriptan-naproxen combination
1223611|NCT01059604|pregnancy registry
1223612|NCT01059591|First time in Human
1223613|NCT01059591|Safety
1223614|NCT01059591|Healthy subjects
1223615|NCT01059591|NK1 antagonist and SSRI
1223616|NCT01059578|Nk1 Antagonist and SSRI
1223617|NCT01059578|Safety
1223618|NCT01059578|First Time in Humans
1223619|NCT01059578|Healthy Subjects
1223620|NCT01059565|Cystic Fibrosis
1223621|NCT01059565|Aztreonam Lysine
1223622|NCT01059565|lung infection
1223623|NCT01059565|Burkholderia
1223624|NCT01059565|CFQ-R
1223625|NCT01059565|inhaled antibiotic
1223626|NCT01059552|lung cancer
1223627|NCT01059552|locally advanced lung cancer
1223628|NCT01059539|mania
1223629|NCT01059539|acute mania
1223630|NCT01059539|bipolar I disorder
1223631|NCT01059526|HAE
1223632|NCT01059513|T1c
1223633|NCT01059513|T2a
1223634|NCT01059513|T2b
1223635|NCT01059500|Computer-derived, quantitative pretest probability (PTP)
1223636|NCT01059500|Overtesting
1223637|NCT01059500|Radiation
1223638|NCT01059500|Intravenous Contrast
1223639|NCT01059500|Anticoagulation
1223640|NCT01059487|Traditional Chinese Medicine
1223641|NCT01059487|Acupuncture
1223642|NCT01059474|DMPS
1223643|NCT01059474|mercury
1223644|NCT01059461|Hypoxic Ischemic Encephalopathy (HIE)
1223645|NCT01059461|Perinatal Asphyxia
1223646|NCT01059461|Nerve growth factor
1223647|NCT01059461|Cerebrolysin
1223648|NCT01059461|Cerebral palsy
1223649|NCT01059448|Amgen
1223650|NCT01059448|RA
1223651|NCT01059448|AMG 827
1223652|NCT01059448|20090061
1223653|NCT01059435|Amgen
1223654|NCT01059435|First in Human
1223655|NCT01059435|Postmenopausal
1223656|NCT01059435|Phase 1
1223657|NCT01059409|Meniscal Allografts
1223658|NCT01059409|Osteoarthritis
1223659|NCT01059383|Gastroesophageal Reflux
1223660|NCT01059383|GERD
1223661|NCT01059383|Nocturnal GERD
1223662|NCT01059383|Heartburn
1223663|NCT01059383|Nighttime Heartburn
1223664|NCT01059370|Autonomic dysfunction
1223665|NCT01059370|Spinal cord injured
1223666|NCT01059370|Neurogenic bowel
1223667|NCT01059370|Neurogenic bladder
1223668|NCT01059344|Mesalamine
1223669|NCT01059344|Asacol
1223670|NCT01059344|Ulcerative colitis
1223671|NCT01059344|induction therapy
1223672|NCT01059344|acute disease
1223673|NCT01059344|mild to moderate
1223674|NCT01059344|Active Ulcerative Colitis (mild to moderate)
1223675|NCT01059331|Kidney
1223676|NCT01059318|Lymphangioleiomyomatosis,
1223677|NCT01059318|High Resolution CT scan,
1223678|NCT01059318|chest x-ray,
1223679|NCT01059318|6 minute walk test,
1223680|NCT01059318|pulse oximetry,
1223681|NCT01059318|renal MRI,
1223682|NCT01059318|Pikometer
1223683|NCT01059305|Erlotinib
1223684|NCT01059305|Erlotinib Hydrochloride
1223685|NCT01059305|OSI-774
1223686|NCT01059305|Tarceva
1223687|NCT01059305|Squamous cell carcinoma of the skin
1223688|NCT01059305|Aggressive cutaneous squamous cell carcinoma
1223689|NCT01059305|CSCC
1223690|NCT01059305|Local surgery
1223691|NCT01059305|Radiation therapy
1223692|NCT01059305|Epidermal growth factor receptor
1223693|NCT01059305|EGFR
1223694|NCT01059305|Small Molecule Tyrosine Kinase Inhibitor
1223695|NCT01059292|we have complieted party research
1223696|NCT01059279|Familial Mediterranean fever
1223697|NCT01059279|Cytokines
1223698|NCT01059279|Inflammatory proteins
1223699|NCT01059279|MEFV
1223700|NCT01059279|mutations
1223701|NCT01059279|Heat Intolerance
1223702|NCT01059279|Heat Tolerance Test
1223703|NCT01059266|immunotherapy
1223704|NCT01059266|grass pollen
1223705|NCT01059266|seasonal allergy
1223706|NCT01059266|dose tolerability
1223707|NCT01059253|Falls
1223708|NCT01059253|Balance
1223709|NCT01059253|Elderly
1223710|NCT01059253|Aged
1223711|NCT01059240|Survival Motor Neuron 1 (SMN1)
1223712|NCT01059240|Survival Motor Neuron 2 (SMN2)
1223713|NCT01059240|Spinal Muscular Atrophy (SMA)
1223714|NCT01059240|SMN Copy Number in Mali
1223715|NCT01059240|Spinal Muscular Antrophy
1223716|NCT01059240|SMA
1223717|NCT01059227|Treatment
1223718|NCT01059227|Anxiety
1223719|NCT01059227|Fear
1223720|NCT01059227|Fear Potentiated Startle
1223721|NCT01059227|Healthy Volunteer
1223722|NCT01059227|HV
1223723|NCT01059214|Acute Myocardial Infarction
1223724|NCT01059214|Reperfusion
1223725|NCT01059214|MRI
1223726|NCT01059214|Heart Attack
1223727|NCT01059201|Autism Spectrum Disorder
1223728|NCT01059201|Cholesterol
1223729|NCT01059201|Exome Sequencing
1223730|NCT01059201|Autistic Spectrum Disorder
1223731|NCT01059201|ASD
1223732|NCT01059188|stage IIIB non-small cell lung cancer
1223733|NCT01059188|adenocarcinoma of the lung
1223734|NCT01059188|adenosquamous cell lung cancer
1223735|NCT01059188|large cell lung cancer
1223736|NCT01059188|squamous cell lung cancer
1223737|NCT01059175|Heart failure
1223738|NCT01059175|Cardiac resynchronization therapy
1223739|NCT01059175|Biventricular stimulation
1223740|NCT01059175|Multisite stimulation
1223741|NCT01059175|Non responders
1223742|NCT01059162|Glaucoma Surgery
1223743|NCT01059162|Filtering Surgery
1223744|NCT01059162|Non Penetrating glaucoma surgery
1223745|NCT01059149|Rehabilitation
1223746|NCT01059149|Transcranial magnetic stimulation
1223747|NCT01059149|Brain magnetic stimulation
1223748|NCT01059149|Repetitive
1223749|NCT01059149|Stroke
1223750|NCT01059149|Subacute
1223751|NCT01059136|Myocardial infarction
1223752|NCT01059136|Outcome
1223753|NCT01059136|Aldosterone
1223754|NCT01059136|Spironolactone
1223755|NCT01059123|Amoxicillin
1223756|NCT01059123|Erysipelas
1223757|NCT01059123|Short course
1223758|NCT01059110|Occlusive dressings
1223759|NCT01059110|Salicylate ointment
1223760|NCT01059110|Cryotherapy
1223761|NCT01059110|Topical 5-fluoro-uracil
1223762|NCT01059110|Imiquimod
1223763|NCT01059110|Randomized clinical trial
1223764|NCT01059110|Plantar warts
1223765|NCT01059084|HIV
1223766|NCT01059084|Valacyclovir
1223767|NCT01059084|Valtrex®
1223768|NCT01059071|Refractory Neuroblastoma
1223769|NCT01059071|Relapsed neuroblastoma
1223770|NCT01059058|MI Paste Plus
1223771|NCT01059058|Fluoride Varnish
1223772|NCT01059058|CPP-ACP
1223773|NCT01059058|White Spot Lesions
1223774|NCT01059058|Remineralization
1223775|NCT01059058|Orthodontic Treatment
1223776|NCT01059019|Refractive Surgery
1223777|NCT01059019|PRK
1223778|NCT01059019|Photorefractive Keratectomy
1223779|NCT01059019|Omega 3 Fatty Acids
1223780|NCT01059019|Cornea
1223781|NCT01059006|Reflective Surgery
1223782|NCT01059006|Presbyopia
1223783|NCT01059006|PresbyLASIK
1223784|NCT01058993|neutropenia
1223785|NCT01058993|myelokathexis
1223786|NCT01058993|WHIM syndrome
1223787|NCT01058993|AMD 3100
1223788|NCT01058993|plerixafor
1223789|NCT01058993|Myelokathexis syndrome
1223790|NCT01058993|Neutropenia due to mutations of CXCR-4
1223791|NCT01058980|catheter ablation
1223792|NCT01058980|atrial fibrillation
1223793|NCT01058980|adenosine
1223794|NCT01058967|Code III trauma (highest acuity)
1223795|NCT01058967|Life Flight aeromedical ambulance service
1223796|NCT01058941|Alzheimer's disease
1223797|NCT01058941|fish oil
1223798|NCT01058941|lipoic acid
1223799|NCT01058928|Tracheal tube
1223800|NCT01058928|Size
1223801|NCT01058915|ST-Segment Elevation Myocardial Infarction
1223802|NCT01058902|Non small cell lung cancer
1223803|NCT01058902|survival
1223804|NCT01058902|aspirin
1223805|NCT01058889|Diabetes mellitus Type 2
1223806|NCT01058889|Telemedicine
1223807|NCT01058889|Insulin
1223808|NCT01058876|Smoking
1223809|NCT01058876|nicotine
1223810|NCT01058837|Sudden Cardiac Death
1223811|NCT01058837|Implantable Cardioverter Defibrillator
1223812|NCT01058837|Ventricular Fibrillation
1223813|NCT01058824|Bioequivalence
1223814|NCT01058824|Lincomycin Hydrocloride
1223815|NCT01058811|lung cancer
1223816|NCT01058798|Neuroblastoma
1223817|NCT01058798|B4GALNT3
1223818|NCT01058798|Prognosis
1223819|NCT01058785|Gene therapy
1223820|NCT01058785|Flow cytometry
1223821|NCT01058785|Immunoenzyme technique
1223822|NCT01058785|Laboratory biomarker analysis
1223823|NCT01058785|Tumor cell-derivative vaccine therapy
1223824|NCT01058772|Induced Labour
1223825|NCT01058772|Expectant Management
1223826|NCT01058772|C-section rate
1223827|NCT01058772|Maternal Outcomes
1223828|NCT01058772|Neonatal Outcomes
1223829|NCT01058759|non-small cell lung cancer
1223830|NCT01058759|NSCLC
1223831|NCT01058759|Enoxaparin
1223832|NCT01058759|Locally Advanced or Metastatic Non-small Cell Lung Cancer stadium IIIb/IV
1223833|NCT01058746|pancreas
1223834|NCT01058746|surgery
1223835|NCT01058746|Pancreaticoduodenectomy
1223836|NCT01058746|Central Pancreatectomy
1223837|NCT01058746|Distal Pancreatectomy
1223838|NCT01058746|resection
1223839|NCT01058746|IV fluids
1223840|NCT01058746|09-185
1223841|NCT01058733|semi-automatic response system (SARS)
1223842|NCT01058733|Diabetes Mellitus
1223843|NCT01058733|Internet
1223844|NCT01058733|ubiquitous health care system
1223845|NCT01058720|Vitamin D
1223846|NCT01058720|Supplementation
1223847|NCT01058720|Adolescence
1223848|NCT01058707|Solid tumors, MLN0128, TORC1/2 inhibitors
1223849|NCT01058694|Mobile phones,
1223850|NCT01058694|Medication Adherence
1223851|NCT01058694|Micro-Electrical-Mechanical Systems
1223852|NCT01058694|HIV Infections
1223853|NCT01058681|LH pulsatility
1223854|NCT01058681|GnRH regulation
1223855|NCT01058681|isocaloric nutrition
1223856|NCT01058681|hypercaloric nutrition
1223857|NCT01058681|euglycemic clamps
1223858|NCT01058681|hyperinsulinemic clamps
1223859|NCT01058681|testosterone
1223860|NCT01058681|LH
1223861|NCT01058681|leptine
1223862|NCT01058681|ghrelin
1223863|NCT01058681|PYY
1223864|NCT01058681|CCK
1223865|NCT01058681|GLP-1
1223866|NCT01058681|GIP
1223867|NCT01058681|cortisol
1223868|NCT01058668|Acute Mania
1223869|NCT01058668|Bipolar I Disorder
1223870|NCT01058655|Colorectal Cancer
1223871|NCT01058642|pain
1223872|NCT01058642|delta opioid receptor agonist
1223873|NCT01058629|Hybrid
1223874|NCT01058629|contact lens
1223875|NCT01058629|myopia
1223876|NCT01058629|hyperopia
1223877|NCT01058629|near sighted
1223878|NCT01058629|astigmatism
1223879|NCT01058629|far sighted
1223880|NCT01058603|Infertility
1223881|NCT01058603|Cell Culture
1223882|NCT01058603|AECC
1223883|NCT01058603|Endocell
1223884|NCT01058603|IVF
1223885|NCT01058590|Inflammation
1223886|NCT01058590|Adenotonsillectomy
1223887|NCT01058577|diabetes
1223888|NCT01058564|GERD
1223889|NCT01058551|Sleep Apnea
1223890|NCT01058551|Atrial Fibrillation
1223891|NCT01058538|Interleukin, IL2, monoclonal, antibody, cytokine, tumour targeting, solid tumours, dose finding, renal cell carcinoma, fusion protein, RCC,
1223892|NCT01058538|L19
1223893|NCT01058512|hepatitis C
1223894|NCT01058512|chronic HCV
1223895|NCT01058512|viral HCV
1223896|NCT01058512|genotype 1
1223897|NCT01058512|failed treatment with pegylated interferon plus ribavirin
1224145|NCT01057446|sodium phosphate
1223898|NCT01058499|Chronic Obstructive Pulmonary Disease
1223899|NCT01058499|COPD
1223900|NCT01058486|Chronic Disease Management
1223901|NCT01058486|Physical Activity
1223902|NCT01058486|Self-efficacy
1223903|NCT01058486|Self management
1223904|NCT01058473|Sickle Cell Disease
1223905|NCT01058473|Pain
1223906|NCT01058473|Assessment
1223907|NCT01058460|Cervical Intraepithelial Neoplasia, Grade III
1223908|NCT01058460|Cervical Intraepithelial Neoplasia, Grade II
1223909|NCT01058447|ADME
1223910|NCT01058447|Healthy volunteers
1223911|NCT01058434|Multiple myeloma
1223912|NCT01058434|relapsed
1223913|NCT01058434|refractory
1223914|NCT01058434|t(4;14)
1223915|NCT01058434|FGFR3
1223916|NCT01058421|mechanical ventilation
1223917|NCT01058421|acute respiratory failure
1223918|NCT01058421|physical therapy
1223919|NCT01058421|critical illness neuropathy
1223920|NCT01058421|critical illness myopathy
1223921|NCT01058408|advanced head and neck cancer
1223922|NCT01058408|cisplatin
1223923|NCT01058408|RAD001
1223924|NCT01058408|radiation
1223925|NCT01058408|HNSCC
1223926|NCT01058395|Traumatic Brain Injury
1223927|NCT01058395|Minocycline
1223928|NCT01058395|Outcome
1223929|NCT01058382|FET
1223930|NCT01058382|Progesterone Support
1223931|NCT01058382|Frozen Embryo Transfer
1223932|NCT01058356|antibiotics associated colitis
1223933|NCT01058356|lactobacilli
1223934|NCT01058356|probiotics
1223935|NCT01058356|prevention
1223936|NCT01058356|pulmonary infection
1223937|NCT01058356|Prevention of antibiotics associated colitis
1223938|NCT01058356|the role of probiotics for prevention of antibiotics associated colitis
1223939|NCT01058356|the lactobacilli effect for antibiotics associated colitis
1223940|NCT01058356|antibiotic associated colitis on pulmonary infectious disease
1223941|NCT01058343|SLE
1223942|NCT01058330|Neurofibromatosis type 1
1223943|NCT01058330|NF1
1223944|NCT01058317|respiratory, papilloma, pediatric, juvenile
1223945|NCT01058304|osteoarthritis
1223946|NCT01058304|knee
1223947|NCT01058304|physical therapy (specialty)
1223948|NCT01058304|veterans
1223949|NCT01058278|Glaucoma
1223950|NCT01058278|Ocular Hypertension
1223951|NCT01058278|Intraocular Pressure
1223952|NCT01058278|Trabeculectomy
1223958|NCT01058226|Experimental malaria challenge
1223959|NCT01058213|COPD
1223960|NCT01058213|Pulmonary rehabilitation
1223961|NCT01058213|Resistance Training
1223962|NCT01058213|Aerobic Training
1223963|NCT01058213|Dyspnea
1223964|NCT01058174|Liver transplantation
1223965|NCT01058174|Prophylaxis
1223966|NCT01058174|Prevention
1223967|NCT01058174|Mycoses
1223968|NCT01058174|Invasive Fungal Infection
1223969|NCT01058174|Micafungin
1223970|NCT01058161|wrist and hand cartilage abnormalities in inflammatory and chronic rheumatisms
1223971|NCT01058148|Cervical Cancer Screening
1223972|NCT01058148|Cervical Precancer
1223973|NCT01058148|Self-Collection
1223974|NCT01058148|Cytology
1223975|NCT01058148|Human Papilloma Virus (HPV)
1223976|NCT01058135|insulin resistance
1223977|NCT01058135|dietary fiber
1223978|NCT01058135|resistant starch
1223979|NCT01058122|Adverse drug reactions in patients on the oncology ward
1223980|NCT01058109|bone health, bone density, bone mass
1223981|NCT01058096|Acute Mania
1223982|NCT01058096|Bipolar I Disorder
1223983|NCT01058070|GERD
1223984|NCT01058057|atorvastatin
1223985|NCT01058057|percutaneous coronary intervention
1223986|NCT01058057|periprocedural myocardial infarction
1223987|NCT01058057|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1223988|NCT01058044|Cancer, Sunitinib, capecitabine, anastrozole, letrozole
1223989|NCT01058044|adherence, anticancer treatment
1223990|NCT01058018|Cholesterol
1223991|NCT01058018|High density lipoprotein
1223992|NCT01058018|Atherosclerosis
1223993|NCT01058018|ApolipoproteinA1
1223994|NCT01058018|Stable angina artery disease
1223995|NCT01058005|MS
1223996|NCT01057979|exercise
1223997|NCT01057979|college students
1223998|NCT01057979|Sedentary college students
1223999|NCT01057966|Bioavailability
1224000|NCT01057966|Ocular Vitamins
1224001|NCT01057953|Colo-Rectal Cancer
1224002|NCT01057914|Randomized controlled trial
1224003|NCT01057914|Malnutrition
1224004|NCT01057914|Aged
1224005|NCT01057914|Aged 80 and over
1224006|NCT01057914|Nutrition therapy
1224007|NCT01057888|Immunization status for:
1224008|NCT01057888|Tdap
1224009|NCT01057888|Menactra
1224010|NCT01057888|HPV (if female)
1224011|NCT01057888|Well child care visit
1224012|NCT01057862|Naltrexone
1224013|NCT01057862|Pathological Gambling
1224014|NCT01057862|Opioid Antagonist
1224015|NCT01057849|schizophrenia
1224016|NCT01057849|first episode
1224017|NCT01057849|atypical antipsychotics
1224018|NCT01057849|psychosocial intervention
1224019|NCT01057849|outcome
1224020|NCT01057849|effectiveness
1224021|NCT01057823|aged
1224022|NCT01057823|sleep deprivation
1224023|NCT01057823|actigraphy
1224024|NCT01057823|ambulatory monitoring
1224025|NCT01057797|COPD
1224026|NCT01057797|Pulmonary rehabilitation
1224027|NCT01057797|Self-efficacy
1224028|NCT01057797|Muscle strength
1224029|NCT01057797|Dyspnea
1224030|NCT01057797|Exercise adherence
1224031|NCT01057784|obesity
1224032|NCT01057784|bariatric
1224033|NCT01057784|surgery
1224034|NCT01057784|sleeve
1224035|NCT01057784|gastric bypass
1224036|NCT01057784|vitamin D
1224037|NCT01057784|quality of life
1224038|NCT01057784|body composition
1224039|NCT01057784|bone density
1224040|NCT01057784|adolescent
1224041|NCT01057784|child
1224042|NCT01057784|teenager
1224043|NCT01057784|fertility
1224044|NCT01057784|offspring
1224045|NCT01057784|biomarker
1224046|NCT01057784|epigenome
1224047|NCT01057784|gene expression
1224048|NCT01057771|meditation
1224049|NCT01057771|exercise
1224050|NCT01057771|immunity
1224051|NCT01057771|respiratory infection
1224052|NCT01057771|influenza
1224053|NCT01057771|flu shot
1224054|NCT01057771|immunomodulation
1224055|NCT01057758|Suspicion of ventilator-associated pneumonia
1224061|NCT01057719|cross-over design
1224062|NCT01057719|mixed model
1224063|NCT01057719|multiple sclerosis
1224064|NCT01057719|physical performance measures
1224065|NCT01057719|physical therapy
1224066|NCT01057719|the Bobath concept
1224067|NCT01057719|warm climate
1224068|NCT01057719|6-minute walk test
1224069|NCT01057706|chiropractic
1224070|NCT01057706|exercise
1224071|NCT01057706|seniors
1224072|NCT01057693|Diabetic peripheral neuropathy
1224073|NCT01057693|Lyrica
1224074|NCT01057693|pregabalin
1224075|NCT01057693|pain
1224076|NCT01057680|Bone
1224077|NCT01057680|Muscle
1224078|NCT01057680|Strength
1224079|NCT01057680|Kidney
1224080|NCT01057680|Liver
1224081|NCT01057680|Creatine
1224082|NCT01057654|Cholesterol
1224083|NCT01057641|PIDLSS, Spacer
1224084|NCT01057628|ASP1941
1224085|NCT01057628|Diabetes mellitus
1224086|NCT01057628|Blood glucose
1224087|NCT01057615|Asthma
1224088|NCT01057615|Exercise-Induced Bronchoconstriction
1224089|NCT01057615|Inflammation
1224090|NCT01057615|Airway
1224091|NCT01057615|Fish Oil
1224092|NCT01057615|Ascorbic Acid
1224093|NCT01057602|Dementia
1224094|NCT01057602|Screening Tests
1224095|NCT01057602|Cognition
1224096|NCT01057602|Memory
1224097|NCT01057602|MOST
1224098|NCT01057589|Pharynx
1224099|NCT01057589|Larynx
1224100|NCT01057589|Cervical esophagus
1224101|NCT01057589|Nose
1224102|NCT01057589|Thyroid Gland
1224103|NCT01057589|Parathyroid Gland
1224104|NCT01057576|bioactives
1224105|NCT01057576|insulin
1224106|NCT01057576|botanicals
1224107|NCT01057563|Coronary artery disease
1224108|NCT01057563|Neointimal hyperplasia
1224109|NCT01057563|Drug-eluting balloon
1224110|NCT01057563|Optical coherence tomography
1224111|NCT01057550|Stress urinary Incontinence
1224112|NCT01057550|autologous slings
1224113|NCT01057550|slings
1224114|NCT01057550|tvt
1224115|NCT01057550|grafts
1224116|NCT01057550|surgery
1224117|NCT01057537|Polypill
1224118|NCT01057537|Red Heart Pill
1224119|NCT01057537|Cardiovascular disease
1224120|NCT01057537|Adherence
1224121|NCT01057537|Secondary prevention
1224122|NCT01057524|Airway clearance
1224123|NCT01057524|Cystic fibrosis
1224124|NCT01057524|High frequency chest wall oscillation
1224125|NCT01057511|Crinone
1224126|NCT01057511|progesterone
1224127|NCT01057511|endometrial progesterone concentration
1224128|NCT01057485|Atrial Fibrillation
1224129|NCT01057485|Ablation
1224130|NCT01057472|Repeatability of measurements
1224143|NCT01057446|Colonoscopy preparation
1224144|NCT01057446|sennoside
1224146|NCT01057446|the aim is to assess the bowel cleansing effects of two different agents
1224147|NCT01057433|Healthy Volunteers
1224148|NCT01057407|Hyperphosphatemia
1224149|NCT01057407|hemodialysis
1224150|NCT01057407|CKD
1224151|NCT01057407|ASP1585
1224152|NCT01057394|Atrial Fibrillation
1224153|NCT01057381|Adenotonsillectomy
1224154|NCT01057381|Postoperative analgesia
1224155|NCT01057381|Pediatrics
1224156|NCT01057355|Intraductal papillary mucinous neoplasm
1224157|NCT01057355|Mucinous cystic neoplasm
1224158|NCT01057355|Endoscopic ultrasound
1224159|NCT01057355|Endoscopic retrograde cholangiopancreatography
1224160|NCT01057355|Pancreatic cyst
1224161|NCT01057355|Pancreas cyst
1224162|NCT01057355|Alcohol
1224163|NCT01057342|extensive stage small cell lung cancer
1224164|NCT01057329|TDM
1224165|NCT01057329|Drug
1224166|NCT01057329|Psychopharmacology
1224167|NCT01057329|children
1224168|NCT01057329|adolescents
1224169|NCT01057303|childhood acute myeloid leukemia/other myeloid malignancies
1224170|NCT01057290|childhood acute myeloid leukemia/other myeloid malignancies
1224171|NCT01057277|Head and Neck Cancer
1224172|NCT01057277|Advanced Inoperable Head & Neck Cancer
1224173|NCT01057264|Liver
1224174|NCT01057264|Cancer
1224175|NCT01057264|Hepatic arterial infusion
1224176|NCT01057264|HAI
1224177|NCT01057264|Abraxane
1224178|NCT01057264|Nab-Paclitaxel
1224179|NCT01057264|Paclitaxel
1224180|NCT01057264|ABI-007
1224181|NCT01057264|Gemcitabine
1224182|NCT01057264|Gemcitabine Hydrochloride
1224183|NCT01057264|Gemzar
1224184|NCT01057264|Bevacizumab
1224185|NCT01057264|Avastin
1224186|NCT01057264|Anti-VEGF monoclonal antibody
1224187|NCT01057264|rhuMAb-VEGF
1224188|NCT01057264|Filgrastim
1224189|NCT01057264|G-CSF
1224190|NCT01057264|Neupogen
1224191|NCT01057251|Nebivolol
1224192|NCT01057251|Bystolic TM
1224193|NCT01057251|Hypertension
1224194|NCT01057251|Stage 2 Hypertension
1224195|NCT01057238|mechanical ventilation
1224196|NCT01057238|critical care
1224197|NCT01057212|advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
1224198|NCT01057199|adult acute myeloid leukemia
1224199|NCT01057199|childhood acute myeloid leukemia/other myeloid malignancies
1224200|NCT01057173|Heart Valve Disease
1224201|NCT01057173|Heart Valve Prosthesis
1224202|NCT01057173|Heart Valve Prosthesis Implantation
1224203|NCT01057173|Randomized Controlled Trial
1224204|NCT01057121|HIV Infections
1224205|NCT01057108|Hyperphosphatemia
1224206|NCT01057108|chronic kidney disease
1224207|NCT01057108|salivary phosphorus
1224208|NCT01057095|adult acute myeloid leukemia with inv(16)(p13;q22)
1224209|NCT01057095|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1224210|NCT01057095|adult acute myeloid leukemia with del(5q)
1224211|NCT01057095|adult acute myeloid leukemia with t(16;16)(p13;q22)
1224212|NCT01057095|adult acute myeloid leukemia in remission
1224213|NCT01057095|recurrent adult acute myeloid leukemia
1224214|NCT01057095|untreated adult acute myeloid leukemia
1224215|NCT01057095|childhood acute myeloid leukemia in remission
1224216|NCT01057095|recurrent childhood acute myeloid leukemia
1224217|NCT01057095|untreated childhood acute myeloid leukemia and other myeloid malignancies
1224218|NCT01057082|Sarcopenia
1224219|NCT01057082|Aging
1224220|NCT01057082|Muscle
1224221|NCT01057082|Dietary Supplement
1224222|NCT01057082|HMB
1224223|NCT01057082|Arginine
1224224|NCT01057082|Glutamine
1224225|NCT01057069|Neo adjuvant
1224226|NCT01057069|Triple negative
1224227|NCT01057069|primary tumor over 2 cm and/or positive lymphnodes
1224228|NCT01057056|patients in a sub-acute geriatric rehabilitation department
1224229|NCT01057043|Osteoarthritis
1224230|NCT01057017|colorectal cancer
1224231|NCT01057004|heart failure
1224232|NCT01056978|palliative care unit
1224233|NCT01056978|bleeding
1224234|NCT01056978|thromboembolic
1224235|NCT01056978|hemorrhagic risk
1224236|NCT01056978|antithrombotic prophylaxis
1224237|NCT01056965|Frontotemporal Dementia
1224238|NCT01056965|Corticobasal Degeneration
1224239|NCT01056965|Progressive Nonfluent Aphasia
1224240|NCT01056965|Progressive Supranuclear Palsy
1224241|NCT01056965|FTLD
1224242|NCT01056965|FTD
1224243|NCT01056965|PNFA
1224244|NCT01056965|CBD
1224245|NCT01056965|PSP
1224246|NCT01056965|Predicted tauopathies, including:
1224247|NCT01056965|Progressive Supranuclear Palsy (PSP)
1224248|NCT01056965|(CBS)
1224249|NCT01056965|Progressive Nonfluent Aphasia (PNFA)
1224250|NCT01056939|Ventilatory care, children, intensive care, NAVA
1224251|NCT01056939|Children needing ventilatory care
1224252|NCT01056926|smoking
1224253|NCT01056926|nicotine
1224254|NCT01056926|Effects of nicotine and non-nicotine factors on continuous working memory.
1224255|NCT01056926|Effects of nicotine and non-nicotine factors on cue reactivity.
1224256|NCT01056926|Use of nicotine patches, placebo patches, and denicotinized cigarettes.
1224257|NCT01056926|memory
1224258|NCT01056913|anastomotic leakage
1224259|NCT01056913|bleeding from the anastomotic region
1224260|NCT01056913|anastomotic stenosis
1224261|NCT01056900|articular cartilage defects
1224262|NCT01056900|ACI
1224263|NCT01056900|Autologous Chondrocyte Implantation
1224264|NCT01056900|Knee joint
1224265|NCT01056900|chondron
1224266|NCT01056887|diabetes insipidus
1224267|NCT01056887|primary polydipsia
1224268|NCT01056887|copeptin
1224269|NCT01056887|Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test
1224270|NCT01056874|Maraviroc
1224271|NCT01056874|Digoxin
1224272|NCT01056874|P-glycoprotein
1224273|NCT01056874|Pharmacokinetics
1224274|NCT01056874|Drug Interaction
1224275|NCT01056874|HIV
1224276|NCT01056861|cervical dystonia
1224277|NCT01056861|torticollis
1224278|NCT01056861|Botulinum toxin
1224279|NCT01056861|magnetoencephalography
1224280|NCT01056861|MEG
1224281|NCT01056861|cortical organizational changes detected by MEG after botulinum toxin in patients with torticollis, correlating with improvement in the symptoms
1224282|NCT01056848|Euvolemic Hyponatremia
1224283|NCT01056848|Hypervolemic Hyponatremia
1224284|NCT01056848|SIADH
1224285|NCT01056848|Serum Sodium
1224286|NCT01056809|Colorectal cancer
1224287|NCT01056809|Metastases
1224288|NCT01056809|Treatment strategies
1224289|NCT01056809|Colorectal cancer with synchronous metastases
1224290|NCT01056796|compression anastomosis
1224291|NCT01056796|Colorectal cancer
1224292|NCT01056796|Low anterior resection
1224293|NCT01056796|Radiated to the pelvic area
1224294|NCT01056796|Radiotherapy
1224295|NCT01056783|EoE
1224296|NCT01056770|Smallpox vaccine efficacy
1224297|NCT01056757|metastatic breast cancer
1224298|NCT01056757|ribavirin
1224299|NCT01056757|eIF4E
1224300|NCT01056744|coronary stent
1224301|NCT01056744|optical coherence tomography
1224302|NCT01056744|drug-eluting
1224303|NCT01056744|neointimal proliferation
1224304|NCT01056731|high blood pressure
1224305|NCT01056731|aliskiren
1224306|NCT01056731|hydrochlorothiazide
1224307|NCT01056731|control rate
1224308|NCT01056718|Diastolic Function
1224309|NCT01056718|Nebivolol
1224310|NCT01056705|Inactivated Poliomyelitis Vaccine
1224311|NCT01056705|Sabin Strains
1224312|NCT01056705|poliomyelitis
1224313|NCT01056692|Asthma
1224314|NCT01056692|bronchial allergen challenge
1224315|NCT01056692|sputum eosinophiilia
1224316|NCT01056653|father-child relations
1224317|NCT01056653|paternal behaviour
1224318|NCT01056653|early intervention
1224319|NCT01056653|child-rearing
1224320|NCT01056640|telemonitoring
1224321|NCT01056640|usual care
1224322|NCT01056640|elderly
1224323|NCT01056640|hospitalization
1224324|NCT01056640|Emergency room visits
1224325|NCT01056601|insulinoma
1224326|NCT01056601|cancer of pancreas
1224327|NCT01056601|neoplasms, pancreas
1224328|NCT01056601|alpha-cell tumor
1224329|NCT01056601|glucagonoma
1224330|NCT01056601|beta-cell tumor
1224331|NCT01056601|somatostatinoma
1224332|NCT01056588|adolescent smoking
1224333|NCT01056588|Contingency management
1224334|NCT01056588|Quit smoking
1224335|NCT01056562|Prostate
1224336|NCT01056562|GU
1224337|NCT01056562|Urological Oncology
1224338|NCT01056549|Intestinal lipoprotein
1224339|NCT01056549|Apo B48 and apoB100
1224340|NCT01056549|Pancreatic clamp
1224341|NCT01056549|GLP-1 agonist
1224342|NCT01056536|Travel
1224343|NCT01056536|casual sexual relationships
1224344|NCT01056536|condoms
1224345|NCT01056536|Structured intervention
1224346|NCT01056523|AML
1224347|NCT01056497|diabetes
1224348|NCT01056497|alpha lipoic acid
1224349|NCT01056497|endoplasmic reticulum (ER) stress
1224350|NCT01056497|insulin secretion
1224351|NCT01056497|insulin sensitivity
1224352|NCT01056484|Alcohol Dependence
1224353|NCT01056484|Alcoholism
1224354|NCT01056484|Substance Use Disorders
1224355|NCT01056484|Substance Abuse
1224356|NCT01056471|Multiple Sclerosis
1224357|NCT01056471|Mesenchymal Stem Cells
1224358|NCT01056471|Autologous
1224359|NCT01056458|acupressure
1224360|NCT01056458|perimenopause
1224361|NCT01056458|menopause
1224362|NCT01056458|anxiety
1224363|NCT01056458|life quality
1224364|NCT01056458|insomnia
1224365|NCT01056445|Carotid artery stenting
1224366|NCT01056445|Hemodynamic Instability
1224367|NCT01056445|Valsalva Ratio
1224368|NCT01056432|osteoporosis, bone fracture risk, bone ultrasonometry
1224369|NCT01056419|Graves' ophthalmopathy
1224370|NCT01056419|Total thyroidectomy
1224371|NCT01056419|Anti-thyroid drug treatment
1224372|NCT01056419|Clinical activity score
1224373|NCT01056406|Pregnancy
1224374|NCT01056406|Overweight
1224375|NCT01056406|Obese
1224376|NCT01056406|Nutrition intervention
1224377|NCT01056393|HIV
1224378|NCT01056380|influenza
1224379|NCT01056380|influenza like illness
1224380|NCT01056367|Resistant hypertension
1224381|NCT01056367|Type-II-Diabetes Mellitus
1224382|NCT01056367|Arterial stiffness
1224383|NCT01056367|Ventricular function
1224384|NCT01056354|Influenza
1224385|NCT01056354|respiratory virus
1224386|NCT01056354|pandemic
1224387|NCT01056354|swine flu
1224388|NCT01056354|infection
1224389|NCT01056354|MERS-CoV
1224390|NCT01056354|SARS-CoV
1224391|NCT01056341|Infantile Hemangioma
1224392|NCT01056341|Propranolol
1224393|NCT01056315|Analgesia
1224394|NCT01056315|Diabetic Neuropathy
1224395|NCT01056315|Neuropathic pain
1224396|NCT01056315|Painful
1224397|NCT01056315|Chronic pain
1224398|NCT01056302|Reconstructive surgical procedures
1224399|NCT01056302|visuohaptic
1224400|NCT01056276|Multiple Myeloma
1224401|NCT01056276|Bendamustine
1224402|NCT01056276|Bortezomib
1224403|NCT01056276|Dexamethasone
1224404|NCT01056263|retrospective trial
1224405|NCT01056263|5-year survival
1224406|NCT01056263|metastatic renal cancer cell
1224407|NCT01056250|cholelithiasis
1224408|NCT01056224|skull pin insertion
1224409|NCT01056224|remifentanil
1224410|NCT01056224|short acting opioid
1224411|NCT01056224|craniotomy
1224412|NCT01056224|cervical spine surgery
1224413|NCT01056224|hemodynamic changes
1224414|NCT01056224|dose requirement
1224415|NCT01056224|age related
1224416|NCT01056198|Diabetic Foot Ulcers
1224417|NCT01056198|Diabetic Foot Wounds
1224418|NCT01056185|influenza
1224419|NCT01056185|flu
1224420|NCT01056185|swine flu
1224421|NCT01056185|respiratory virus
1224422|NCT01056185|hospitalization
1224423|NCT01056185|MERS-CoV
1224424|NCT01056185|SARS-CoV
1224425|NCT01056172|Chronic hepatitis C
1224426|NCT01056172|Genotype 2
1224427|NCT01056172|Rapid virologic response
1224428|NCT01056172|Sustained virologic response
1224429|NCT01056172|Peginterferon alfa-2a
1224430|NCT01056172|Ribavirin
1224431|NCT01056159|asthma
1224432|NCT01056159|dry powder inhaler
1224433|NCT01056159|short-acting beta2-agonist
1224434|NCT01056159|SABA
1224435|NCT01056159|bronchoconstriction
1224436|NCT01056159|bronchodilation
1224437|NCT01056159|bronchodilator
1224438|NCT01056159|metered dose inhaler
1224439|NCT01056146|TBI
1224440|NCT01056146|intracranial edema
1224441|NCT01056146|brain edema
1224442|NCT01056146|craniocerebral trauma
1224443|NCT01056146|head injury
1224444|NCT01056146|brain hemorrhage, traumatic
1224445|NCT01056146|subdural hematoma
1224446|NCT01056146|brain concussion
1224447|NCT01056146|head injuries, closed
1224448|NCT01056146|epidural hematoma
1224449|NCT01056146|extra-axial hemorrhage
1224450|NCT01056146|cortical contusion
1224451|NCT01056146|Additional relevant MeSH terms:
1224452|NCT01056146|Nervous System Diseases
1224453|NCT01056146|Wounds and Injuries
1224454|NCT01056146|Disorders of Environmental Origin
1224455|NCT01056146|Central Nervous System Diseases
1224456|NCT01056146|Trauma, Nervous System
1224457|NCT01056146|Brain Diseases
1224458|NCT01056146|Brain Injuries
1224459|NCT01056133|non-alcoholic fatty liver disease
1224460|NCT01056133|non-alcoholic steatohepatitis
1224461|NCT01056107|Constipation, Irritable Bowel Syndrome (IBS), Glucagon Like Peptide analogue
1224462|NCT01056081|COPD
1224463|NCT01056081|inspiratory muscles
1224464|NCT01056081|diaphragm
1224465|NCT01056055|Ankle
1224466|NCT01056055|Chronic lateral instability
1224467|NCT01056055|Modified Brostrom procedure
1224468|NCT01056055|Suture anchor
1224469|NCT01056055|Bone tunnel
1224470|NCT01056042|pelvic pain
1224471|NCT01056042|postoperative
1224472|NCT01056042|medical therapy
1224473|NCT01056029|Solid Tumors
1224474|NCT01056016|ADHD
1224475|NCT01056003|gastric inlet patch
1224476|NCT01056003|prevalence
1224477|NCT01056003|globus sensations
1224478|NCT01055990|pandemic influenza A (H1N1) 2009
1224479|NCT01055990|blood fix treatment
1224480|NCT01055990|influenza A (H1N1) 2009 monovalent vaccine
1224481|NCT01055990|effectiveness
1224482|NCT01055990|immunogenicity
1224483|NCT01055990|safety
1224484|NCT01055977|statin therapy
1224485|NCT01055977|treatment goal
1224486|NCT01055977|dyslipidaemia
1224487|NCT01055951|Insulin pumps
1224488|NCT01055951|Diabetes
1224489|NCT01055912|Congestive Heart Failure
1224490|NCT01055912|Volume Overload
1224491|NCT01055899|RA
1224492|NCT01055886|PTSD
1224493|NCT01055886|smoking cessation
1224494|NCT01055886|nicotine patch
1224495|NCT01055873|immune status
1224496|NCT01055873|adolescents or young adults infected
1224497|NCT01055873|impact of viral replication
1224498|NCT01055860|uterine Prolapse
1224499|NCT01055860|vaginal prolapse
1224500|NCT01055860|mesh erosion
1224501|NCT01055860|urinary incontinence
1224502|NCT01055860|bowel symptoms
1224503|NCT01055847|cystic fibrosis
1224504|NCT01055847|CF
1224505|NCT01055847|aztreonam
1224506|NCT01055847|lung infection
1224507|NCT01055847|Pseudomonas aeruginosa
1224508|NCT01055834|Insomnia
1224509|NCT01055834|primary insomnia
1224510|NCT01055834|insomnia associated with psychiatric or physical disorder(s)
1224511|NCT01055821|Hepatitis C
1224512|NCT01055821|Vaccine
1224513|NCT01055821|HCVac
1224514|NCT01055821|MVA-HCV
1224515|NCT01055808|Insulin
1224516|NCT01055808|ITR-QOL
1224517|NCT01055808|DTSQ
1224518|NCT01055808|Diabetes Mellitus, Type 2
1224519|NCT01055782|Colonoscopy
1224520|NCT01055782|Endoguide
1224521|NCT01055782|Pain perception
1224522|NCT01055782|Colonoscopy to the coecum (success rate)
1224523|NCT01055782|Patient's perception of pain
1224524|NCT01055782|Duration of successful colonoscopies
1224525|NCT01055769|Bio-equivalence
1224526|NCT01055769|Linezolid OS
1224527|NCT01055769|Linezolid tablet
1224528|NCT01055756|Reduction of signs and symptoms and enhanced nasal flow
1224529|NCT01055756|Nasal Flow
1224530|NCT01055743|Fluorouracil Implants
1224531|NCT01055743|Hepatocellular carcinoma
1224532|NCT01055743|Radical resection
1224533|NCT01055730|Pulmonary rehabilitation
1224534|NCT01055730|Exercise therapy
1224535|NCT01055730|Interstitial lung disease
1224536|NCT01055730|Pulmonary fibrosis
1224537|NCT01055730|Mobility limitation
1224538|NCT01055730|Dyspnea
1224539|NCT01055730|Mental health
1224540|NCT01055717|avenanthramide
1224541|NCT01055717|enriched
1224542|NCT01055717|oat
1224543|NCT01055717|phytochemical
1224544|NCT01055717|bioavailability
1224545|NCT01055704|Methylnaltrexone
1224546|NCT01055704|Codeine
1224547|NCT01055704|Gastrointestinal motility
1224548|NCT01055704|Colonic transit
1224549|NCT01055691|healthy volunteers
1224550|NCT01055691|bioequivalence
1224551|NCT01055691|dapagliflozin
1224552|NCT01055691|metformin
1224553|NCT01055678|breast cancer
1224554|NCT01055678|ductal breast carcinoma in situ
1224555|NCT01055678|breast cancer in situ
1224556|NCT01055678|invasive carcinoma
1224557|NCT01055678|invasive ductal carcinoma
1224558|NCT01055678|invasive lobular carcinoma
1224559|NCT01055652|Type 2 diabetes mellitus
1224560|NCT01055652|Japanese
1224561|NCT01055652|phase 1
1224562|NCT01055652|safety
1224563|NCT01055652|dapagliflozin
1224564|NCT01055652|Pharmacokinetics
1224565|NCT01055652|Drug-drug Interaction
1224566|NCT01055652|voglibose
1224567|NCT01055639|Chronic Pain
1224568|NCT01055639|Acceptance and Commitment Therapy (ACT)
1224569|NCT01055626|Body mass index
1224570|NCT01055626|Body fat
1224571|NCT01055626|Obesity
1224572|NCT01055626|Overweight
1224573|NCT01055626|Diabetes Mellitus, Type 2
1224574|NCT01055626|Air displacement plethysmography
1224575|NCT01055600|eltrombopag
1224576|NCT01055600|pharmacokinetics
1224577|NCT01055600|PROMACTA
1224578|NCT01055600|lactation
1224579|NCT01055600|milk-only study
1224580|NCT01055587|major abdominal surgery
1224581|NCT01055587|severe burn injury
1224582|NCT01055587|infection
1224583|NCT01055587|diagnostic
1224584|NCT01055574|lumbar disc arthroplasty
1224585|NCT01055574|total disc replacement
1224586|NCT01055574|ProDisc L
1224587|NCT01055574|anterior lumbar interbody fusion
1224588|NCT01055574|lumbar spine surgery outcomes
1224589|NCT01055561|Acupuncture
1224590|NCT01055561|Behavioral and Psychological Symptoms of Dementia
1224591|NCT01055561|BPSD
1224592|NCT01055561|MMSE
1224593|NCT01055561|BEHAVE-AD
1224594|NCT01055561|The Questionnaire of Acupuncture Events
1224595|NCT01055561|healthy volunteers
1224596|NCT01055548|Preterm
1224597|NCT01055548|Perinatal
1224598|NCT01055548|Ultrasound
1224599|NCT01055548|Cerebral palsy
1224600|NCT01055548|Anxiety
1224601|NCT01055548|Parents
1224602|NCT01055522|Interleukin, IL2, monoclonal, antibody, cytokine, Dacarbazine, metastatic, melanoma, tumor targeting, Dose definition
1224603|NCT01055522|, L19
1224604|NCT01055509|Social Adjustment
1224605|NCT01055509|Quality of life
1224606|NCT01055509|Recurrence
1224607|NCT01055509|Hospitalization
1224608|NCT01055496|Non-Hodgkin's lymphoma
1224609|NCT01055483|Acute myeloid leukemia
1224610|NCT01055483|AML
1224611|NCT01055483|relapsed acute myeloid leukemia
1224612|NCT01055483|refractory acute myeloid leukemia
1224613|NCT01055431|iron
1224614|NCT01055431|bioavailability
1224615|NCT01055431|status
1224616|NCT01055431|deficiency
1224617|NCT01055431|anaemia
1224618|NCT01055431|functional foods
1224619|NCT01055431|child bearing
1224620|NCT01055418|Vitamin C
1224621|NCT01055418|Cognitive performance
1224622|NCT01055418|Cerebral blood flow
1224623|NCT01055418|Trans cranial doppler
1224624|NCT01055418|Near infrared spectroscopy
1224625|NCT01055405|Exercise tolerance
1224626|NCT01055405|COPD
1224627|NCT01055405|Pulmonary hypertension
1224628|NCT01055405|Sildenafil
1224629|NCT01055392|mild cognitive impairment
1224630|NCT01055392|Alzheimer's disease
1224631|NCT01055392|Lithium
1224632|NCT01055392|disease-modification
1224633|NCT01055392|cognition
1224634|NCT01055392|early Alzheimer`s disease
1224635|NCT01055379|Rasagiline
1224636|NCT01055379|Depressive Symptoms
1224637|NCT01055379|Cognition
1224638|NCT01055366|Open angle glaucoma
1224639|NCT01055366|OAG
1224640|NCT01055366|Elazop
1224641|NCT01055366|Azarga
1224642|NCT01055366|Brinzolamide/Timolol combination
1224643|NCT01055353|Target organs damage
1224644|NCT01055353|hypertensive patients
1224645|NCT01055340|Ketogenesis
1224646|NCT01055340|Glucose-Dependent Insulin Secretion
1224647|NCT01055340|Graded Glucose Infusion
1224648|NCT01055340|Oxyntomodulin
1224649|NCT01055327|Isolated oral clefts
1224650|NCT01055327|lamotrigine
1224651|NCT01055327|EUROCAT
1224652|NCT01055327|congenital malformations
1224653|NCT01055327|anti-epileptic drugs
1224654|NCT01055301|stage I multiple myeloma
1224655|NCT01055301|stage II multiple myeloma
1224656|NCT01055301|stage III multiple myeloma
1224657|NCT01055275|iliac aneurysm
1224658|NCT01055275|aortic aneurysm
1224659|NCT01055275|endovascular grafts
1224660|NCT01055262|Safety
1224661|NCT01055262|tolerability
1224662|NCT01055262|heatwrap
1224663|NCT01055262|lower back
1224664|NCT01055262|healthy subjects
1224665|NCT01055249|UVB
1224666|NCT01055249|pain
1224667|NCT01055249|inflammation
1224668|NCT01055249|model
1224669|NCT01055249|healthy volunteers
1224670|NCT01055249|Ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers
1224671|NCT01055236|sedation
1224672|NCT01055223|thiazolidinediones
1224673|NCT01055223|rosiglitazone
1224674|NCT01055223|amiloride
1224675|NCT01055223|pioglitazone
1224676|NCT01055223|fracture
1224677|NCT01055223|Spironolactone
1224678|NCT01055210|Heart Failure
1224679|NCT01055210|Pacemakers
1224680|NCT01055197|extensive stage small cell lung cancer
1224681|NCT01055184|Influenza
1224682|NCT01055184|H1N1
1224683|NCT01055171|alcohol dependence
1224684|NCT01055171|PTSD
1224685|NCT01055171|propanolol
1224686|NCT01055171|craving
1224687|NCT01055171|beta-block
1224688|NCT01055171|cue exposure
1224689|NCT01055171|addiction
1224690|NCT01055171|memory
1224691|NCT01055171|trauma
1224692|NCT01055171|addictive behavior
1224693|NCT01055158|HIV
1224694|NCT01055145|Multidrug-resistant TB, sensitive to levofloxacin and moxifloxacin
1224695|NCT01055106|bacterial vaginosis
1224696|NCT01055106|vaginal infection
1224697|NCT01055106|vaginal discharge
1224698|NCT01055106|vaginal disease
1224699|NCT01055093|diabetes mellitus
1224700|NCT01055093|prospective observational study
1224701|NCT01055093|diabetic complications
1224702|NCT01055080|type 1 diabetes
1224703|NCT01055080|beta-cell autoantibodies
1224704|NCT01055080|cow's milk formula
1224705|NCT01055080|bovine insulin
1224706|NCT01055054|bariatrics
1224707|NCT01055015|total knee arthroplasty
1224708|NCT01055002|Health male volunteers
1224709|NCT01055002|Male volunteers aged 18-45 years
1224710|NCT01055002|Non-smokers and in good health
1224711|NCT01054989|Healthy adults
1224712|NCT01054989|Insulin sensitivity
1224713|NCT01054976|Alzheimer's disease
1224714|NCT01054976|Galantamine
1224715|NCT01054976|Dementia
1224716|NCT01054963|early inflammatory arthritis
1224717|NCT01054963|chronic disease
1224718|NCT01054963|peer support
1224719|NCT01054963|peer mentor
1224720|NCT01054963|peer counselling
1224721|NCT01054937|4SC-203
1224722|NCT01054937|Phase I
1224723|NCT01054937|single dose
1224724|NCT01054937|healthy volunteers
1224725|NCT01054911|GIST
1224726|NCT01054911|gastrointestinal stromal tumor
1224727|NCT01054911|gastrointestinal stomach tumor
1224728|NCT01054911|Sunitinib
1224729|NCT01054898|depression
1224730|NCT01054898|spouse abuse
1224731|NCT01054898|intervention studies
1224732|NCT01054885|COPD
1224733|NCT01054885|Chronic Obstructive Pulmonary Disease
1224734|NCT01054885|Efficacy
1224735|NCT01054885|FEV1
1224736|NCT01054885|Safety
1224737|NCT01054872|HIV Seronegativity
1224738|NCT01054872|HIV Preventive Vaccine
1224739|NCT01054846|Bicycle helmet
1224740|NCT01054820|FLECTORÂ® Patch
1224741|NCT01054820|acute back strain
1224742|NCT01054794|Gastroparesis
1224743|NCT01054794|Gastric Electrical Stimulation
1224744|NCT01054781|Diffuse Large B-Cell Lymphoma (DLBCL)
1224745|NCT01054781|rituximab
1224746|NCT01054781|CHOP
1224747|NCT01054768|Antioxidant
1224748|NCT01054768|Inflammation
1224749|NCT01054768|Sickle Cell Disease
1224750|NCT01054768|Oxidative Stress
1224751|NCT01054768|Cytokines
1224752|NCT01054768|anti-inflammatory
1224753|NCT01054768|Acetylcarnitine
1224754|NCT01054729|Chronic Hepatitis C infection Genotype 1
1224755|NCT01054729|HCV
1224756|NCT01054729|GT1
1224757|NCT01054729|GT 1
1224758|NCT01054716|RhD negative
1224759|NCT01054716|RhD disease
1224760|NCT01054716|fetal nucleic acid
1224761|NCT01054716|fetal DNA
1224762|NCT01054716|cell free fetal DNA
1224763|NCT01054716|Fetal RHD genotype
1224764|NCT01054690|Catheterization
1224765|NCT01054690|Urinary Tract Infection
1224766|NCT01054690|Elective Surgery
1224767|NCT01054677|Infections in nursing homes
1224768|NCT01054677|especially urinary tract infections
1224769|NCT01054664|liver enzymes
1224770|NCT01054664|peripheral mononuclear blood cells
1224771|NCT01054664|hemodialysis
1224772|NCT01054664|hepatitis C
1224773|NCT01054664|RNA
1224774|NCT01054651|Schistosoma mansoni
1224775|NCT01054651|Praziquantel
1224776|NCT01054651|Artesunate + Sulfamethoxypyrazine/pyrimethamine
1224777|NCT01054651|Randomized open-label controlled clinical trial
1224778|NCT01054638|amprenavir
1224779|NCT01054638|fosamprenavir
1224780|NCT01054638|HIV
1224781|NCT01054638|HAART treatment
1224782|NCT01054638|Epzicom
1224783|NCT01054638|Trizivir
1224784|NCT01054638|Combivir
1224785|NCT01054638|zidovudine
1224786|NCT01054638|lamivudine
1224787|NCT01054638|cardiovascular disease
1224788|NCT01054638|HIV Infections
1224789|NCT01054625|Squamous Cell Carcinoma of the Head and Neck
1224790|NCT01054625|Head and Neck Cancer
1224791|NCT01054625|Head and Neck Neoplasms
1224792|NCT01054625|anti-EGFr monoclonal antibody
1224793|NCT01054625|Zalutumumab
1224794|NCT01054612|Histology
1224795|NCT01054612|Immunohistochemical
1224796|NCT01054612|Gene Expression
1224797|NCT01054612|Tissue Sectioning
1224798|NCT01054599|epilepsy
1224799|NCT01054599|memory
1224800|NCT01054599|memantine
1224801|NCT01054599|localization related epilepsy
1224802|NCT01054599|focal epilepsy
1224803|NCT01054586|antiretroviral therapy
1224804|NCT01054586|hepatic impairment
1224805|NCT01054586|HIV
1224806|NCT01054573|Hepatitis C, Chronic
1224807|NCT01054573|Telaprevir
1224808|NCT01054573|Roll-over study
1224809|NCT01054560|Ischemic Stroke
1224810|NCT01054560|SOLITAIRE™ Device
1224811|NCT01054560|SOLITAIRE™
1224812|NCT01054560|MERCI® Device
1224813|NCT01054560|MERCI®
1224814|NCT01054560|Stroke
1224815|NCT01054560|Ischemic
1224816|NCT01054560|Mechanical Thrombectomy
1224817|NCT01054560|Brain
1224818|NCT01054560|Brain Clot
1224819|NCT01054560|Brain Artery Revascularization
1224820|NCT01054560|Recanalization
1224821|NCT01054560|Brain Stroke
1224822|NCT01054560|Clot Retriever
1224823|NCT01054560|Device
1224824|NCT01054560|Neurosurgery
1224825|NCT01054560|Neurovascular Intervention
1224826|NCT01054560|Interventional Neuroradiology
1224827|NCT01054560|Brain study
1224828|NCT01054560|neurovascular clinical trial
1224829|NCT01054547|topical anesthetic
1224830|NCT01054547|liposomal ropivacaine
1224831|NCT01054547|dentistry
1224832|NCT01054534|urinary incontinence
1224833|NCT01054521|radiofrequency turbinate reduction
1224834|NCT01054521|nasal obstruction
1224835|NCT01054521|Temperature-controlled radiofrequency
1224836|NCT01054521|Bipolar radiofrequency
1224837|NCT01054521|chronic rhinitis.
1224838|NCT01054495|Acupuncture
1224839|NCT01054495|Sham acupuncture
1224840|NCT01054495|Laser
1224841|NCT01054495|Methodology
1224842|NCT01054495|Control intervention
1224843|NCT01054495|Pilot
1224844|NCT01054495|Nausea and vomiting in early pregnancy
1224845|NCT01054495|Patient's experience of different acu-stimulation
1224846|NCT01054495|Blinding in acupuncture research
1224847|NCT01054482|Neoadjuvant chemotherapy
1224848|NCT01054482|neoadjuvant chemoradiotherapy
1224849|NCT01054469|nephrectomy
1224850|NCT01054456|LEC
1224851|NCT01054456|Low Emetogenic Chemotherapy
1224852|NCT01054456|Nausea and Vomiting
1224853|NCT01054456|Nausea
1224854|NCT01054456|Vomiting
1224855|NCT01054456|Anti- emetic
1224856|NCT01054443|Blood Platelet Disorders
1224857|NCT01054443|Immune Thrombocytopenia (ITP)
1224858|NCT01054443|Low Platelet Count
1224859|NCT01054443|Thrombocytopaenia
1224860|NCT01054443|S-888711
1224861|NCT01054443|Splenectomy
1224862|NCT01054443|Thrombopoiesis
1224863|NCT01054443|Hematologic Disease
1224864|NCT01054443|Auto-immune thrombocytopenic Purpura
1224865|NCT01054443|Relapsed Persistent or Chronic ITP
1224866|NCT01054443|Idiopathic Thrombocytopenic Purpura
1224867|NCT01054443|Thrombotic Thrombocytopenic Purpura (TTP)
1224868|NCT01054430|Avanafil
1224869|NCT01054430|Hepatic
1224870|NCT01054430|Erectile Dysfunction
1224871|NCT01054430|Impairment
1224872|NCT01054417|Appendicitis
1224873|NCT01054417|Laparoscopy
1224874|NCT01054417|Appendectomy
1224875|NCT01054404|Brain Swelling
1224876|NCT01054404|Brain Edema
1224877|NCT01054404|Dehydration
1224878|NCT01054352|Seasonal allergies
1224879|NCT01054352|Allergic rhinitis
1224880|NCT01054339|Alpha-1 antitrypsin deficiency
1224881|NCT01054339|Adeno-associated virus vector
1224882|NCT01054339|AAV
1224883|NCT01054339|Gene therapy
1224884|NCT01054339|Human gene transfer
1224885|NCT01054326|arthroscopic subacromial decompression
1224886|NCT01054326|exercise
1224887|NCT01054326|physical therapy
1224888|NCT01054326|rotator cuff
1224889|NCT01054326|shoulder impingement syndrome
1224890|NCT01054326|Subacromial impingement after arthroscopic subacromial decompression
1224891|NCT01054313|Advanced Malignancies
1224892|NCT01054313|Taxotere
1224893|NCT01054313|Docetaxel
1224894|NCT01054313|Rapamycin
1224895|NCT01054313|Sirolimus
1224896|NCT01054313|Rapamune
1224897|NCT01054313|Prednisone
1224898|NCT01054313|Resistant to standard therapy
1224899|NCT01054274|esophageal cancer
1224900|NCT01054274|dysphagia
1224901|NCT01054274|stent
1224902|NCT01054274|brachytherapy
1224903|NCT01054261|avanafil, renal, impairment, TA-1790
1224904|NCT01054248|pregnancy, malaria, artemisinin, vivax, falciparum
1224905|NCT01054235|prenatal care
1224906|NCT01054235|community-based randomized controlled trial
1224907|NCT01054235|perinatal mortality
1224908|NCT01054235|China
1224909|NCT01054222|overactive bladder idiopathic
1224910|NCT01054222|elderly fesoterodine SOFIA Portugal extension study
1224911|NCT01054209|Inadvertent Peri-operative Hypothermia
1224912|NCT01054209|Shivering
1224913|NCT01054209|Caesarean Section
1224914|NCT01054209|Elective
1224915|NCT01054209|Warming Mattress
1224916|NCT01054209|Regional Anaesthesia
1224917|NCT01054183|respiratory failure, intubation, GlideScope, pediatric
1224918|NCT01054170|Chronic
1224919|NCT01054170|obstructive
1224920|NCT01054170|pulmonary
1224921|NCT01054170|lung
1224922|NCT01054170|respiratory disease
1224923|NCT01054170|efficacy
1224924|NCT01054170|placebo-controlled
1224925|NCT01054170|COPD
1224926|NCT01054170|FEV1
1224927|NCT01054170|St Georges Respiratory Questionnaire
1224928|NCT01054170|Computed Tomography
1224929|NCT01054170|MSCT
1224930|NCT01054144|Newly Diagnosed Standard Risk Multiple Myeloma
1224931|NCT01054144|Senior Adults
1224932|NCT01054131|peer support
1224933|NCT01054131|peer mentor
1224934|NCT01054131|self-management
1224935|NCT01054131|early inflammatory arthritis
1224936|NCT01054131|chronic disease
1224937|NCT01054118|Type 2 Diabetes Mellitus
1224938|NCT01054105|Pulmonary hypertension
1224939|NCT01054105|genes
1224940|NCT01054105|mutation
1224941|NCT01054105|drug therapy
1224942|NCT01054092|ASP1941
1224943|NCT01054092|Diabetes mellitus
1224944|NCT01054092|Blood glucose
1224945|NCT01054092|Food effect
1224946|NCT01054066|Chronic Kidney Disease
1224947|NCT01054066|Cardiovascular Disease
1224948|NCT01054066|Hypertension
1224949|NCT01054066|Anemia
1224950|NCT01054053|Neisseria meningitidis B:14, P1-7, 16
1224951|NCT01054053|Serum bactericidal activity
1224952|NCT01054053|Menbvac
1224953|NCT01054040|cardiovascular disease, portion plate
1224954|NCT01054027|Retinopathy of Prematurity (ROP)
1224955|NCT01054027|Eye exams
1224956|NCT01054027|Premature infants
1224957|NCT01054027|cyclomydril
1224958|NCT01054014|CR016795
1224959|NCT01054001|prostate cancer
1224960|NCT01054001|prostatectomy
1224961|NCT01054001|erectile dysfunction
1224962|NCT01053988|Safety
1224963|NCT01053988|Chronic Obstructive Pulmonary Disease
1224964|NCT01053988|Efficacy
1224965|NCT01053988|FEV1
1224966|NCT01053988|COPD
1224967|NCT01053975|RSR
1224968|NCT01053975|SECG
1224969|NCT01053975|SPECT
1224970|NCT01053975|QCA
1224971|NCT01053975|SCAD
1224972|NCT01053962|Chronic Idiopathic Constipation
1224973|NCT01053962|Constipation
1224974|NCT01053962|Irritable Bowel Syndrome
1224975|NCT01053949|Multiple myeloma
1224976|NCT01053949|dexamethasone
1224977|NCT01053949|pomalidomide
1224978|NCT01053949|response
1224979|NCT01053949|safety
1224980|NCT01053936|Chronic Kidney Disease
1224981|NCT01053936|Type 2 diabetes
1224982|NCT01053936|Diabetic Nephropathy
1224983|NCT01053923|Perianal Cancer
1224984|NCT01053923|Anal Cancer
1224985|NCT01053923|MRI scan
1224986|NCT01053897|GBT009
1224987|NCT01053897|incisional scar
1224988|NCT01053897|breast reconstruction
1224989|NCT01053884|Invasive Candidiasis
1224990|NCT01053884|invasive fungal disease
1224991|NCT01053884|Anidulafungin
1224992|NCT01053871|normal
1224993|NCT01053858|bevacizumab,triamcinolone, intravitreal injection
1224994|NCT01053845|Neuropathic pain
1224995|NCT01053832|ventricular pace suppression
1224996|NCT01053832|pacemaker
1224997|NCT01053832|efficacy
1224998|NCT01053832|safety
1224999|NCT01053832|support of intrinsic heart rhythm
1225000|NCT01053819|psoriasis
1225001|NCT01053819|melanoma
1225002|NCT01053819|non-melanoma skin cancer
1225003|NCT01053819|etanercept
1225004|NCT01053819|Enbrel
1225005|NCT01053806|MDS
1225006|NCT01053806|Lenalidomide
1225007|NCT01053806|5-Azacytidine.
1225008|NCT01053806|ORR
1225009|NCT01053806|PFS
1225010|NCT01053806|myelodysplastic syndrome.High risk.
1225011|NCT01053793|Glycemic index
1225012|NCT01053793|Anthocyanin
1225013|NCT01053793|Potato
1225014|NCT01053793|Polyphenol
1225015|NCT01053780|Intercessory Prayer, pregnants
1225016|NCT01053767|Group B streptococcus
1225017|NCT01053767|GBS
1225018|NCT01053767|Vaccine
1225019|NCT01053754|adrenocortical insufficiency
1225020|NCT01053754|prolonged corticotherapy
1225021|NCT01053715|Hemophilia
1225022|NCT01053715|Quality of Life
1225023|NCT01053689|Bioequivalence, Glimepiride, Crossover
1225024|NCT01053676|Hyperphosphatemia
1225025|NCT01053676|BE
1225026|NCT01053676|Granule
1225027|NCT01053676|Healthy volunteers
1225028|NCT01053650|Healthy volunteers
1225029|NCT01053650|Open / hidden
1225030|NCT01053650|Placebo effect
1225031|NCT01053637|lacerations
1225032|NCT01053637|sutures
1225033|NCT01053637|pediatrics
1225034|NCT01053637|child
1225035|NCT01053637|pain
1225036|NCT01053637|Anxiety
1225037|NCT01053624|Tracheostomy and thoracic surgery
1225038|NCT01053624|postoperative complications
1225039|NCT01053624|pulmonary surgical procedures
1225040|NCT01053624|respiratory failure
1225041|NCT01053611|composite variability index
1225042|NCT01053611|bispectral index
1225043|NCT01053611|pain
1225044|NCT01053598|Mycobacterium tuberculosis
1225045|NCT01053598|Nitrate Reductase Assay
1225046|NCT01053598|NRA
1225047|NCT01053598|REMA
1225048|NCT01053598|RETA
1225049|NCT01053598|Rezazurine
1225050|NCT01053585|Gastro-esophageal junction, reflux, insertion angle, magnetic resonance imaging, manometry
1225051|NCT01053572|Chronic low back pain
1225052|NCT01053572|Post lumbar laminectomy syndrome
1225053|NCT01053572|Lower extremity pain
1225054|NCT01053572|Local anesthetic
1225055|NCT01053572|Steroid
1225056|NCT01053572|Percutaneous lumbar adhesiolysis
1225057|NCT01053559|Crohn's
1225058|NCT01053559|Inflammatory Bowel Disease
1225059|NCT01053533|Chinese herbal medicines
1225060|NCT01053533|pandemic H1N1 influenza
1225061|NCT01053533|effectiveness
1225062|NCT01053533|safety
1225063|NCT01053507|Headache
1225064|NCT01053507|Post-traumatic headache
1225065|NCT01053507|Brain injury
1225066|NCT01053507|Cognitive impairment
1225067|NCT01053468|breast cancer
1225068|NCT01053468|physical activity
1225069|NCT01053468|quality of life
1225070|NCT01053468|theory of planned behavior
1225071|NCT01053468|behavior change
1225072|NCT01053468|health promotion
1225073|NCT01053455|Non-invasive ventilation
1225074|NCT01053455|SiPAP
1225075|NCT01053455|CPAP
1225076|NCT01053455|low birth weight infants
1225077|NCT01053455|respiratory distress syndrome
1225078|NCT01053442|iron absorption
1225079|NCT01053442|stable isotopes
1225080|NCT01053442|NaFeEDTA
1225081|NCT01053442|Non-transferrin-bound iron (NTBI)
1225082|NCT01053442|Hepcidin
1225083|NCT01053429|Regulatory Post-Marketing Surveillance
1225084|NCT01053429|Regulatory Pharmacovigilance
1225085|NCT01053429|ziprasidone
1225086|NCT01053416|glaucoma
1225087|NCT01053416|pigmentary glaucoma
1225088|NCT01053416|laser iridotomy
1225089|NCT01053403|MDMA
1225090|NCT01053403|Ecstasy
1225091|NCT01053403|MDMA effect on sleep
1225092|NCT01053403|MDMA effect on water homeostasis
1225093|NCT01053403|MDMA effect on neurocognitive function
1225094|NCT01053403|Recreational Drug Use
1225095|NCT01053403|Drug Abuse
1225096|NCT01053390|gallbladder neoplasmas
1225097|NCT01053390|Gallbladder Neoplasms,Advanced Stage,Chemotherapy,Somatostatin
1225098|NCT01053377|Influenza
1225099|NCT01053377|Tamiflu
1225100|NCT01053377|Osteltamivir
1225101|NCT01053377|Transmission
1225102|NCT01053377|Prevention
1225103|NCT01053377|Resistance
1225104|NCT01053377|Post-Exposure Profylaxe
1225105|NCT01053338|Bioequivalence,Ibuprofen Diphenhydramine Citrate,Crossover
1225106|NCT01053325|Malaria
1225107|NCT01053325|Pregnancy
1225108|NCT01053325|Prevention
1225109|NCT01053325|HIV
1225110|NCT01053325|Sub-Sahara Africa
1225111|NCT01053312|Amyloid
1225112|NCT01053312|NPH Normal pressure hydrocephalus
1225113|NCT01053312|PET Positron Emission Tomography
1225114|NCT01053312|SUVR Standard uptake value ratios
1225115|NCT01053299|Developmental dysplasia of the hip (DDH)
1225116|NCT01053299|newborn
1225117|NCT01053299|universal screening
1225118|NCT01053299|Universal ultrasound-screening for DDH in newborns
1225119|NCT01053299|The accuracy of ultrasound-recording of the hip in newborns
1225120|NCT01053286|Dysphagia
1225121|NCT01053286|Globus
1225122|NCT01053286|Gastroesophageal reflux
1225123|NCT01053273|Low back pain
1225124|NCT01053273|Post lumbar laminectomy syndrome
1225125|NCT01053273|Lumbar spinal stenosis
1225126|NCT01053273|Local anesthetic steroid
1225127|NCT01053273|Lumbar transforaminal epidural injection
1225128|NCT01053273|Percutaneous epidural adhesiolysis
1225129|NCT01053273|Caudal epidural injection
1225130|NCT01053260|Contingency Management
1225131|NCT01053260|Weight Loss
1225132|NCT01053247|Atopic Dermatitis
1225133|NCT01053234|Hyperglycaemia
1225134|NCT01053234|Postprandial
1225135|NCT01053234|Type 2 diabetes
1225136|NCT01053234|Cardiovascular risk markers
1225137|NCT01053221|mycophenolate
1225138|NCT01053221|living donor
1225139|NCT01053208|Bioequivalence,Ibuprofen Diphenhydramine Citrate,Crossover
1225140|NCT01053195|Diabetes
1225141|NCT01053195|prevention
1225142|NCT01053195|intervention
1225143|NCT01053182|esophageal cancer
1225144|NCT01053182|postoperative complications
1225145|NCT01053182|diaphragm
1225146|NCT01053182|pulmonary function
1225147|NCT01053169|Coagulopathy
1225148|NCT01053169|Perioperative bleeding
1225149|NCT01053169|Prothrombin complex
1225150|NCT01053169|Liver disease
1225151|NCT01053156|Fragile X syndrome
1225152|NCT01053156|minocycline
1225153|NCT01053156|targeted treatment
1225154|NCT01053143|Influenza
1225155|NCT01053143|Pandemic Influenza
1225156|NCT01053143|Swine-Origin Influenza A/H1N1 Non-adjuvanted Vaccine
1225157|NCT01053143|Influenza A Virus, H1N1 subtype
1225158|NCT01053143|Adults
1225159|NCT01053130|obesity
1225160|NCT01053130|bariatric surgery
1225161|NCT01053130|chronic kidney disease
1225162|NCT01053130|weight loss
1225163|NCT01053130|exercise
1225164|NCT01053117|central venous catheter
1225165|NCT01053117|arteriovenous fistula
1225166|NCT01053117|hemodialysis
1225167|NCT01053117|vascular access
1225168|NCT01053117|dialysis
1225169|NCT01053104|Colorectal cancer
1225170|NCT01053104|Breast cancer
1225171|NCT01053104|Capecitabine
1225172|NCT01053104|Docetaxel
1225173|NCT01053104|Mobile phone
1225174|NCT01053104|Toxicity
1225175|NCT01053104|Metastatic
1225176|NCT01053091|exercise-base rehabilitation
1225177|NCT01053091|diastolic heart failure
1225178|NCT01053091|cardiovascular function
1225179|NCT01053091|aerobic fitness
1225180|NCT01053078|Type 1 diabetes
1225181|NCT01053078|Hypoglycemia unawareness
1225182|NCT01053078|low blood sugar
1225183|NCT01053065|Atherosclerosis
1225184|NCT01053065|Macrophages
1225185|NCT01053065|Carotid arteries
1225186|NCT01053065|Statin
1225187|NCT01053052|Patency Tests, Fallopian Tubes
1225188|NCT01053052|Hysterosalpingography
1225189|NCT01053052|Sonography, Medical
1225190|NCT01053026|Angiotensin receptor II antagonist
1225191|NCT01053013|macrobead
1225192|NCT01053013|biological
1225193|NCT01053013|mouse cells
1225194|NCT01053000|ACTINIC KERATOSES
1225195|NCT01053000|HAND
1225196|NCT01053000|FOREARM
1225197|NCT01052987|Gout
1225198|NCT01052987|Hyperuricemia
1225199|NCT01052974|femoral neck fracture
1225200|NCT01052974|analgesia
1225201|NCT01052961|severe influenza
1225202|NCT01052961|hospitalized adults
1225203|NCT01052961|oseltamivir treatment
1225204|NCT01052948|dopamine agonists
1225205|NCT01052948|cabergoline
1225206|NCT01052948|Parkinson's disease
1225207|NCT01052948|hyperprolactinemia
1225208|NCT01052948|epidemiology
1225209|NCT01052948|cardiac valvulopathy
1225210|NCT01052935|Group B streptococcus
1225211|NCT01052935|GBS
1225212|NCT01052935|Vaccine
1225221|NCT01052909|Bioequivalence, Glimepiride, Crossover
1225222|NCT01052896|Dyspepsia
1225223|NCT01052896|Functional
1225224|NCT01052883|TMC114-TiDP3-C182
1225225|NCT01052883|TMC114-C182
1225226|NCT01052883|TMC114
1225227|NCT01052883|HIV
1225228|NCT01052883|HIV Infections
1225229|NCT01052870|pharmacogenomics, androgen receptor gene, androgen sensitivity, CAG repeats, androgenetic alopecia
1225230|NCT01052870|Pharmacogenomics in treatment for androgenetic alopecia in women
1225231|NCT01052857|to evaluate acupuncture as possible alternative treatment for induction of labor
1225232|NCT01052857|Induction
1225233|NCT01052857|treatment
1225234|NCT01052857|posterm
1225235|NCT01052844|Vomiting
1225236|NCT01052844|Antiemetics
1225237|NCT01052844|Dexamethasone
1225238|NCT01052844|Cisplatin
1225239|NCT01052844|Antineoplastic combined chemotherapy protocols
1225240|NCT01052831|Compulsive Gambling
1225241|NCT01052831|Compulsive Buying
1225242|NCT01052831|Compulsive Shopping
1225243|NCT01052831|Compulsive Eating
1225244|NCT01052831|Hypersexuality
1225245|NCT01052831|Dopamine Agonists
1225246|NCT01052831|Mirapex
1225247|NCT01052831|Pramipexole
1225248|NCT01052831|Requip
1225249|NCT01052831|Ropinirole
1225250|NCT01052831|Impulse Control Disorders
1225251|NCT01052818|Non small-cell lung cancer
1225252|NCT01052818|Circulating tumor cells
1225253|NCT01052818|Carcinoembryonic antigen
1225254|NCT01052818|Cytokeratin
1225255|NCT01052805|nerve
1225256|NCT01052805|myelinated nerve
1225257|NCT01052805|unmyelinated nerve
1225258|NCT01052792|Bioequivalence
1225259|NCT01052792|Naproxen
1225260|NCT01052792|crossover
1225261|NCT01052779|Iron deficiency anemia
1225262|NCT01052779|chronic kidney disease
1225263|NCT01052779|Feraheme
1225264|NCT01052779|ferumoxytol
1225265|NCT01052779|iron sucrose
1225266|NCT01052779|iron deficiency anemia (IDA)
1225267|NCT01052779|chronic kidney disease (CKD)
1225268|NCT01052766|lung cancer
1225269|NCT01052766|PET Scan
1225270|NCT01052766|CT Scan
1225271|NCT01052766|BH-PET scan
1225272|NCT01052766|09-134
1225273|NCT01052753|Attention-deficit/hyperactivity disorder
1225274|NCT01052753|executive function
1225275|NCT01052753|endophenotype
1225276|NCT01052753|dopaminergic system
1225277|NCT01052753|noradrenergic system
1225278|NCT01052753|candidate gene
1225279|NCT01052753|Family-based association study
1225280|NCT01052740|Breast Cancer
1225281|NCT01052740|Mammography
1225282|NCT01052740|Screening
1225283|NCT01052727|Laparoscopic Cholecystectomy
1225284|NCT01052727|quality of life
1225285|NCT01052714|Antipsychotic
1225286|NCT01052714|Bipolar
1225287|NCT01052714|Diabetes
1225288|NCT01052714|Mental Illness
1225289|NCT01052714|Nutrition
1225290|NCT01052714|Obesity
1225291|NCT01052714|Schizoaffective
1225292|NCT01052714|Schizophrenia
1225293|NCT01052714|Weight Gain
1225294|NCT01052714|Weight Loss
1225295|NCT01052688|Down syndrome, aneuploidy, amniocentesis, chorionic villus sampling, Trisomy
1225296|NCT01052675|Drug and substance problematic use, abuse or dependence
1225297|NCT01052662|Drug Abuse
1225298|NCT01052649|MNC subpopulations
1225299|NCT01052649|Gene Expression
1225300|NCT01052649|Metabolomics
1225301|NCT01052649|Immunological Status
1225302|NCT01052636|Hip fracture
1225303|NCT01052636|Intervention program
1225304|NCT01052636|Elderly
1225305|NCT01052623|GH/IGF-1
1225306|NCT01052623|Ataxia telangiectasia (AT)
1225307|NCT01052623|IGF-1 Generation Test
1225308|NCT01052623|Growth hormone
1225309|NCT01052610|SLIT
1225310|NCT01052610|bronchial asthma
1225311|NCT01052610|allergic rhinitis
1225312|NCT01052597|Type 2 diabetes
1225313|NCT01052597|Metabolic syndrome
1225314|NCT01052597|cardiovascular risk
1225315|NCT01052584|malaria
1225316|NCT01052584|therapeutic efficacy
1225317|NCT01052584|in vivo
1225318|NCT01052584|artemether lumefantrine
1225319|NCT01052584|coartem
1225320|NCT01052584|chloroquine
1225321|NCT01052584|Plasmodium falciparum
1225322|NCT01052584|Plasmodium vivax
1225323|NCT01052571|Chronic low back pain
1225324|NCT01052571|Lumbar disc herniation
1225325|NCT01052571|Lower extremity pain
1225326|NCT01052571|Lumbar radiculitis
1225327|NCT01052571|Local anesthetic
1225328|NCT01052571|Steroid
1225329|NCT01052571|Lumbar transforaminal epidural injection
1225330|NCT01052558|Open angle
1225331|NCT01052558|Glaucoma
1225332|NCT01052558|Cataract
1225333|NCT01052558|Surgery
1225334|NCT01052558|Intraocular Pressure
1225335|NCT01052545|urinary tract infection
1225336|NCT01052545|urinary catheter
1225337|NCT01052545|bacteriuria
1225338|NCT01052545|clinical guidelines
1225339|NCT01052545|audit-feedback
1225340|NCT01052545|guidelines implementation
1225341|NCT01052532|Mitral Regurgitation
1225342|NCT01052532|LV remodeling
1225343|NCT01052532|Reactive nitrogen species
1225344|NCT01052532|Cardiac MRI
1225345|NCT01052532|Adrenergic overdrive
1225346|NCT01052519|Obesity
1225347|NCT01052519|Esophageal Doppler monitoring
1225348|NCT01052519|tissue oxygen tension
1225349|NCT01052506|Human volunteers
1225350|NCT01052493|obesity
1225351|NCT01052493|pancreatic polypeptide
1225352|NCT01052493|gut hormones
1225353|NCT01052480|Antiviral
1225354|NCT01052480|Anti-Influenza Immune Plasma
1225355|NCT01052480|Emerging Infectious Disease
1225356|NCT01052480|Swine Flu
1225357|NCT01052454|hot flashes
1225358|NCT01052454|mindfulness
1225359|NCT01052454|stress
1225360|NCT01052441|CCTA
1225361|NCT01052441|Coronary Artery Stenosis
1225362|NCT01052441|Iodinated Contrast
1225363|NCT01052441|Invasive Coronary Angiography
1225364|NCT01052428|Chronic MR
1225365|NCT01052428|Volume Overload
1225366|NCT01052428|Beta-1 receptor blocker
1225367|NCT01052428|LV remodelling, LV dimensions
1225368|NCT01052428|LV systolic function
1225369|NCT01052428|LV diastolic dysfunction
1225370|NCT01052428|Cardiac MRI
1225371|NCT01052415|HIV
1225372|NCT01052415|Stigma
1225373|NCT01052415|POL
1225374|NCT01052415|Service providers
1225375|NCT01052415|China
1225376|NCT01052415|Universal precaution
1225377|NCT01052389|Schizophrenia
1225378|NCT01052389|Pragmatic RCT
1225379|NCT01052389|Aripiprazole
1225380|NCT01052389|Olanzapine
1225381|NCT01052389|Haloperidol
1225382|NCT01052389|Metabolic syndrome
1225383|NCT01052389|Drug discontinuation
1225384|NCT01052376|nflammatory bowel diseases (IBD)
1225385|NCT01052376|Familial adenomatous polyposis (FAP)
1225386|NCT01052363|CNS tumors
1225387|NCT01052350|Parkinson disease
1225388|NCT01052350|PET imaging
1225389|NCT01052350|PIB
1225390|NCT01052350|dementia
1225391|NCT01052311|Coronary artery disease
1225392|NCT01052311|Endothelial function
1225393|NCT01052311|Platelet function
1225394|NCT01052311|Statins
1225395|NCT01052311|Niacin
1225396|NCT01052298|Ciprofloxacin
1225397|NCT01052298|Inhalation
1225398|NCT01052298|Pharmacokinetics
1225399|NCT01052298|Safety
1225400|NCT01052298|Tolerability
1225401|NCT01052298|COPD
1225402|NCT01052285|Transversus abdominis plane block
1225403|NCT01052272|Diabetes
1225404|NCT01052272|Acute MI
1225405|NCT01052272|Ang II type-1 receptor blockade (AT1RB)
1225406|NCT01052272|LV remodeling
1225407|NCT01052272|ACE inhibitor therapy
1225408|NCT01052272|XO inhibitor, Allopurinol
1225409|NCT01052272|Systolic dysfunction
1225410|NCT01052272|Diastolic dysfunction
1225411|NCT01052272|LV dimensions
1225412|NCT01052272|Cardiac MRI
1225413|NCT01052259|Chronic rejection
1225414|NCT01052259|Kidney
1225415|NCT01052259|Transplantation
1225416|NCT01052259|Immunosuppressive
1225417|NCT01052246|acne vulgaris
1225418|NCT01052246|laser surgery
1225419|NCT01052246|pulsed dye lasers
1225420|NCT01052246|benzoyl peroxidase
1225421|NCT01052246|clindamycin
1225422|NCT01052246|randomized controlled trial
1225423|NCT01052233|Sham-surgery
1225424|NCT01052233|Development of osteoarthritis
1225425|NCT01052233|Randomized, double-blinded, placebo-controlled
1225426|NCT01052220|Hypertension
1225427|NCT01052220|Blood Pressure
1225428|NCT01052220|End Stage Renal Disease
1225429|NCT01052220|Hemodialysis
1225430|NCT01052220|Interdialytic Weight Gain
1225431|NCT01052220|Self-Regulation
1225432|NCT01052207|Biological Response Modifiers
1225433|NCT01052207|Endocrinology
1225434|NCT01052207|Hormone Dysfunction
1225435|NCT01052207|Hormones
1225436|NCT01052207|Neuroendocrinology
1225437|NCT01052194|Rheumatoid Arthritis
1225438|NCT01052181|Vitamin D
1225439|NCT01052181|Insulin sensitivity
1225440|NCT01052181|Centrally obese
1225441|NCT01052168|simulation
1225442|NCT01052168|simulators
1225443|NCT01052168|motion metrics
1225444|NCT01052168|performance metrics
1225445|NCT01052168|skills training
1225446|NCT01052168|proficiency
1225447|NCT01052168|laparoscopic
1225448|NCT01052155|Controlled substances
1225449|NCT01052155|Opioids
1225450|NCT01052155|Benzodiazepines
1225451|NCT01052155|Illicit drugs
1225452|NCT01052155|Immunoassay drug testing
1225453|NCT01052155|Point of care (POC) testing
1225454|NCT01052155|Liquid Chromatography Tandem Mass Spectometry
1225455|NCT01052142|Melanoma
1225456|NCT01052142|Cancer vaccines
1225457|NCT01052129|Bioequivalence
1225458|NCT01052129|Naproxen
1225459|NCT01052129|crossover
1225460|NCT01052116|Asthma
1225461|NCT01052116|Soy
1225462|NCT01052116|Supplement
1225463|NCT01052116|ACRC
1225464|NCT01052116|SOYA
1225465|NCT01052090|HCV
1225466|NCT01052077|OPC-34712
1225467|NCT01052077|Major Depressive Disorder
1225468|NCT01052077|Adjunctive Treatment
1225469|NCT01052064|Children
1225470|NCT01052064|ADHD
1225471|NCT01052064|rTMS
1225472|NCT01052064|Safety
1225473|NCT01052038|Sore throat
1225474|NCT01052038|Dexamethasone
1225475|NCT01052038|Pain
1225476|NCT01052012|Postoperative pain
1225477|NCT01052012|Post-operative pain
1225478|NCT01052012|Opioid
1225479|NCT01052012|Laparoscopic surgery
1225480|NCT01052012|Bupivacaine
1225481|NCT01052012|Local anesthetic
1225482|NCT01051999|Glutamine
1225483|NCT01051986|coronary artery bypass
1225484|NCT01051986|off-pump surgery
1225485|NCT01051986|composite graft
1225486|NCT01051986|saphenous vein
1225487|NCT01051986|internal thoracic artery
1225488|NCT01051973|Cognitive behavior therapy
1225489|NCT01051973|exposure
1225490|NCT01051973|stress management
1225491|NCT01051960|Systemic Sclerosis
1225492|NCT01051960|connective tissue disease
1225493|NCT01051960|Shortness of breath
1225494|NCT01051960|Pulmonary Hypertension
1225495|NCT01051947|Nebivolol
1225496|NCT01051947|Metoprolol
1225497|NCT01051947|central aortic pressure
1225498|NCT01051947|hypertension
1225499|NCT01051934|Recombinant Immunotoxin
1225500|NCT01051934|Monoclonal Antibody
1225501|NCT01051934|Pseudomonas Exotoxin
1225502|NCT01051934|Targeted Therapy
1225503|NCT01051934|Lung Cancer
1225504|NCT01051934|Non-Small Cell Lung Cancer
1225505|NCT01051921|HCV
1225506|NCT01051921|Null Responder
1225507|NCT01051895|Cervical intra-epithelial neoplasia
1225508|NCT01051895|Colposcopy
1225509|NCT01051895|HPV DNA testing
1225510|NCT01051895|treatment failure
1225511|NCT01051882|Mesenchymal Stromal Cells (MSC)
1225512|NCT01051882|Amyotrophic Lateral Sclerosis (ALS)
1225513|NCT01051882|Neuroprotection
1225514|NCT01051882|Neurodegeneration
1225515|NCT01051882|Stem cells
1225516|NCT01051882|ALS
1225517|NCT01051869|distal humerus
1225518|NCT01051869|fractures
1225519|NCT01051869|ulnar nerve
1225520|NCT01051869|simple decompression
1225521|NCT01051869|anterior transposition
1225522|NCT01051843|Maternal Breastfeeding
1225523|NCT01051843|Orofacial Difficulties
1225524|NCT01051843|Rooming-in
1225525|NCT01051843|Speech and Language Therapy
1225526|NCT01051817|relapsing-remitting multiple sclerosis
1225527|NCT01051817|RRMS
1225528|NCT01051804|Dry eye
1225529|NCT01051804|Visual Performance
1225530|NCT01051791|RAD001
1225531|NCT01051791|Everolimus
1225532|NCT01051778|Recurrent abortion
1225533|NCT01051778|Antiphospholipid syndrome
1225534|NCT01051778|unfractionated heparin
1225535|NCT01051778|Low Molecular Weight Heparin
1225663|NCT01051258|homogeneous
1225536|NCT01051752|Nontuberculous mycobacterial diseases
1225537|NCT01051752|pharmacokinetics
1225538|NCT01051752|pharmacodynamics
1225539|NCT01051739|vision testing
1225540|NCT01051739|perimetry
1225541|NCT01051739|glaucoma
1225542|NCT01051739|test variability
1225543|NCT01051726|aromatherapy
1225544|NCT01051726|childbirth
1225545|NCT01051726|Obstetrics
1225546|NCT01051726|Labour
1225547|NCT01051726|Complementary Medicine
1225548|NCT01051726|delivery, obstetric
1225549|NCT01051713|obesity
1225550|NCT01051713|behavioraladherence
1225551|NCT01051713|weight loss
1225552|NCT01051713|smartphone
1225553|NCT01051700|GW786034
1225554|NCT01051700|pazopanib
1225555|NCT01051700|age-related macular degeneration
1225556|NCT01051700|choroidal neovascularization
1225557|NCT01051700|vascular endothelial growth factor
1225558|NCT01051700|platelet derived growth factor
1225559|NCT01051700|stem cell growth factor
1225560|NCT01051700|repeat-dose
1225561|NCT01051700|safety
1225562|NCT01051700|tolerability
1225563|NCT01051700|pharmacokinetics
1225564|NCT01051687|vitiligo
1225565|NCT01051674|Obesity
1225566|NCT01051674|Type 2 diabetes
1225567|NCT01051674|Fiber
1225568|NCT01051674|Dietary fiber
1225569|NCT01051674|Low-carbohydrate diet
1225570|NCT01051674|High protein diet
1225571|NCT01051661|Influenza
1225572|NCT01051661|H1N1
1225573|NCT01051661|Pandemic
1225574|NCT01051648|Triamcinolone acetenoide
1225575|NCT01051648|anterior vitrectomy
1225576|NCT01051648|presence of vitreous in the anterior chamber.
1225577|NCT01051648|effect of triamcinolone injection on IOP,intraocular infection
1225583|NCT01051622|PBMC (Peripheral Blood Mononuclear Cells)
1225584|NCT01051622|Crohn's Disease
1225585|NCT01051622|SPECT (Single Photon Emission Computerized Tomography)
1225586|NCT01051609|Post Menopausal
1225587|NCT01051609|Breast Cancer
1225588|NCT01051596|metastatic
1225589|NCT01051596|colorectal cancer
1225590|NCT01051583|Neovascular glaucoma
1225591|NCT01051583|diode laser
1225592|NCT01051583|cyclophotocoagulation
1225593|NCT01051583|Avastin
1225594|NCT01051570|hormone-resistant prostate cancer
1225595|NCT01051570|recurrent prostate cancer
1225596|NCT01051570|stage IV prostate cancer
1225597|NCT01051570|adenocarcinoma of the prostate
1225598|NCT01051544|ITI
1225599|NCT01051544|HAEMOPHILIA A
1225600|NCT01051544|INHIBITORS
1225601|NCT01051544|VWF/FVIII Concentrates
1225602|NCT01051531|Schizophrenia
1225603|NCT01051531|R092670
1225604|NCT01051531|Paliperidone palmitate
1225605|NCT01051531|Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
1225606|NCT01051531|Intramuscular injection
1225607|NCT01051505|Phase I
1225608|NCT01051505|multiple ascending dose
1225609|NCT01051505|Safety
1225610|NCT01051505|Tolerability
1225611|NCT01051505|Healthy Volunteer
1225612|NCT01051479|PET Positron emission tomography
1225613|NCT01051479|CT X-ray computed tomography
1225614|NCT01051479|Patients with Locally Advanced Esophageal Cancer
1225615|NCT01051440|lisdexamfetamine
1225616|NCT01051440|vyvanse
1225617|NCT01051440|bipolar disorder
1225618|NCT01051440|depression
1225619|NCT01051440|stimulant
1225620|NCT01051440|magnetic resonance spectroscopy
1225621|NCT01051440|functional magnetic resonance imaging
1225622|NCT01051440|neuropsychological testing
1225623|NCT01051427|Nasal packing
1225624|NCT01051427|Haemostatic matrix
1225625|NCT01051427|Epistaxis control
1225626|NCT01051388|The efficacy of PPI
1225627|NCT01051388|Patients receiving low-dose aspirin for vascular protection
1225628|NCT01051375|anorexia nervosa
1225629|NCT01051375|bulimia nervosa
1225630|NCT01051375|EDNOS
1225631|NCT01051362|Advanced Non-small Cell Lung Cancer
1225632|NCT01051362|Pegylated liposomal doxorubicin
1225633|NCT01051362|Carboplatin
1225634|NCT01051362|Chemotherapy
1225635|NCT01051349|MS
1225636|NCT01051349|Multiple Sclerosis
1225637|NCT01051336|TARIS Placebo
1225638|NCT01051336|Bladder
1225639|NCT01051336|Interstitial Cystitis
1225640|NCT01051336|Normal Healthy Volunteers
1225641|NCT01051297|Obstructive sleep apnea
1225642|NCT01051297|venous thrombosis
1225643|NCT01051297|pulmonary embolism
1225644|NCT01051297|venous thromboembolism
1225645|NCT01051284|Pancreas
1225646|NCT01051284|Newly diagnosed
1225647|NCT01051284|Cyberknife
1225648|NCT01051284|Gemcitabine
1225649|NCT01051271|metoclopramide
1225650|NCT01051271|akathisia
1225651|NCT01051271|midazolam
1225652|NCT01051271|diphenhydramine
1225653|NCT01051271|metoclopramide induced akathisia
1225654|NCT01051258|Polymeric Lung Volume Reduction (PLVR)
1225655|NCT01051258|Biologic Lung Volume Reduction (BLVR)
1225656|NCT01051258|AeriSeal
1225657|NCT01051258|treatment
1225658|NCT01051258|device
1225659|NCT01051258|breathing
1225660|NCT01051258|COPD
1225661|NCT01051258|emphysema
1225662|NCT01051258|heterogeneous
1225664|NCT01051258|Pathologic Processes
1225665|NCT01051258|Respiratory Tract Diseases
1225666|NCT01051258|Lung Diseases
1225667|NCT01051258|Pulmonary Disease, Chronic Obstructive
1225668|NCT01051245|Diabetes Mellitus, Type 2 [C18.452.394.750.149]
1225669|NCT01051245|Case Management [N04.590.233.624.250]
1225670|NCT01051245|Disease Management [N04.590.607]
1225671|NCT01051245|Diabetes Complications [C19.246.099]
1225672|NCT01051232|filibuvir
1225673|NCT01051232|pharmacokinetics
1225674|NCT01051232|Japanese
1225675|NCT01051232|Asian
1225676|NCT01051219|Losartan
1225677|NCT01051219|Liver fibrosis
1225678|NCT01051219|Nonalcoholic steatohepatitis
1225679|NCT01051193|Seizures
1225680|NCT01051193|oxcarbazepine
1225681|NCT01051193|child
1225682|NCT01051180|HEMORRHOIDS
1225683|NCT01051180|TREATMENT
1225684|NCT01051180|PILES
1225685|NCT01051180|BLEEDING
1225686|NCT01051180|HALO
1225687|NCT01051154|Docosahexaenoic acid
1225688|NCT01051154|Nutritional status
1225689|NCT01051154|Acute lymphoblastic leukemia
1225690|NCT01051154|Long chain polyunsaturated fatty acids
1225691|NCT01051154|n-3 fatty acids
1225692|NCT01051154|Remission-induction phase
1225693|NCT01051141|alcohol use
1225694|NCT01051141|brief intervention
1225695|NCT01051141|risk behaviors
1225696|NCT01051128|neurological disorders
1225697|NCT01051128|multiple sclerosis
1225698|NCT01051128|stroke
1225699|NCT01051128|cerebral palsy
1225700|NCT01051128|spinal cord
1225701|NCT01051128|brain injuries
1225702|NCT01051128|neurodegenerative diseases
1225703|NCT01051115|CLL
1225704|NCT01051115|refractory
1225705|NCT01051115|dasatinib
1225706|NCT01051115|fludarabine
1225707|NCT01051089|type 2 diabetes mellitus
1225708|NCT01051089|lifestyle modification
1225709|NCT01051076|ITI
1225710|NCT01051076|Haemophilia A
1225711|NCT01051076|Inhibitors
1225712|NCT01051076|Failed ITI
1225713|NCT01051076|VWF/FVIII concentrates
1225714|NCT01051063|adult
1225715|NCT01051063|WT1
1225716|NCT01051063|ASCI
1225717|NCT01051063|complete remission with incomplete blood count recovery
1225718|NCT01051063|partial remission
1225719|NCT01051063|post-induction therapy
1225720|NCT01051063|tumor antigen
1225721|NCT01051063|Acute Myeloid Leukemia
1225722|NCT01051063|Immunotherapy
1225723|NCT01051050|Evidence based medicine
1225724|NCT01051050|Improving surgical residents skills and application of EBM in surgical practice
1225725|NCT01051037|lung tumors
1225726|NCT01051037|central airways
1225727|NCT01051024|Dietary supplement
1225728|NCT01051024|Diamel
1225729|NCT01051024|Polycystic Ovary Syndrome
1225730|NCT01051024|Female Infertility
1225731|NCT01050998|Rheumatoid Arthritis
1225732|NCT01050998|Mavrilimumab
1225733|NCT01050998|CAM-3001
1225734|NCT01050985|advanced cancer
1225735|NCT01050985|temsirolimus
1225736|NCT01050985|capecitabine
1225737|NCT01050972|Headache
1225738|NCT01050972|Cervical Pain
1225739|NCT01050972|Cognitive treatment
1225740|NCT01050972|Relaxation
1225741|NCT01050972|Exercise
1225742|NCT01050946|Unrelated Umbilical Cord Blood Transplant(UCB)
1225743|NCT01050946|CD34+ Selected mismatched related donor
1225744|NCT01050946|Haploidentical donor
1225745|NCT01050946|hematopoietic stem cell transplantation(HSCT)
1225746|NCT01050946|ALL
1225747|NCT01050946|Leukemia, Lymphocytic, Acute
1225748|NCT01050946|AML
1225749|NCT01050946|Leukemia, Myelocytic, Acute
1225750|NCT01050946|CML
1225751|NCT01050946|Leukemia, Myeloid, Chronic
1225752|NCT01050946|NHL
1225753|NCT01050946|Lymphoma, Non-Hodgkin
1225754|NCT01050946|HL
1225755|NCT01050946|Lymphoma, Hodgkins
1225756|NCT01050933|Healthy volunteer
1225757|NCT01050907|leishmaniasis
1225758|NCT01050907|cutaneous disease
1225759|NCT01050907|mucosal disease
1225760|NCT01050907|miltefosine
1225761|NCT01050894|osteoarthritis
1225762|NCT01050881|blood donor notification
1225763|NCT01050881|emotional response
1225764|NCT01050881|variant Creutzfeldt-Jacob Disease
1225765|NCT01050855|Non-malignant diseases
1225766|NCT01050855|Immune deficiencies
1225767|NCT01050855|Hemoglobinopathies
1225768|NCT01050855|Reduced Intensity Conditioning(RIC)
1225769|NCT01050829|Magnetic resonance imaging
1225770|NCT01050829|Tumor
1225771|NCT01050829|Contrast media
1225772|NCT01050829|Gadobutrol
1225773|NCT01050816|articular cartilage defects
1225774|NCT01050816|ACI
1225775|NCT01050816|ankle joint
1225776|NCT01050816|chondron
1225777|NCT01050803|Diabetes Mellitus
1225778|NCT01050803|Intervention studies
1225779|NCT01050803|Program effectiveness
1225780|NCT01050790|stage I multiple myeloma
1225781|NCT01050790|stage II multiple myeloma
1225782|NCT01050790|stage III multiple myeloma
1225783|NCT01050777|Cutaneous Leishmaniasis caused by l. tropica
1225784|NCT01050751|Bioavailability
1225785|NCT01050751|Bioequivalence
1225786|NCT01050751|Lersivirine
1225787|NCT01050751|UK-453
1225788|NCT01050751|061
1225789|NCT01050751|Pharmacokinetics
1225790|NCT01050725|proteome
1225791|NCT01050725|biomarkers
1225792|NCT01050725|radiotherapy
1225793|NCT01050725|cancer
1225794|NCT01050699|critical illness
1225795|NCT01050699|sleep
1225796|NCT01050699|polysomnography
1225797|NCT01050699|inflammatory cytokines
1225798|NCT01050699|dexmedetomidine
1225799|NCT01050699|acute lung injury
1225800|NCT01050699|acute respiratory distress syndrome
1225801|NCT01050699|midazolam
1225802|NCT01050699|fentanyl
1225803|NCT01050699|cytokines
1225804|NCT01050686|ileostomy reversal
1225805|NCT01050686|subcutaneous drain
1225806|NCT01050686|hospital stay
1225807|NCT01050686|postoperative wound infection
1225808|NCT01050686|patients with elective ileostomy reversal
1225809|NCT01050673|VERSAJET hydro-surgical debridement
1225810|NCT01050673|traumatic wound
1225811|NCT01050660|Parenteral nutrition associated liver disease
1225812|NCT01050660|Direct bilirubin
1225813|NCT01050660|Intravenous fat emulsion
1225814|NCT01050660|Very low birth weight infants
1225815|NCT01050660|PNAC
1225816|NCT01050634|Aromatase inhibitor
1225817|NCT01050634|Switch after Tamoxifen
1225818|NCT01050634|Quality of Life
1225819|NCT01050634|Safety
1225820|NCT01050621|ascorbic acid
1225821|NCT01050621|vitamin C
1225822|NCT01050621|antioxidants
1225823|NCT01050621|redox therapy
1225824|NCT01050621|cytotoxic chemotherapy
1225825|NCT01050608|Alcohol Rub
1225826|NCT01050608|Hand Hygiene
1225827|NCT01050608|Provider Feedback
1225828|NCT01050608|Health Care Associated Infections
1225829|NCT01050595|Intensive Care Unit
1225830|NCT01050595|Constipation
1225831|NCT01050595|Bowel Management
1225832|NCT01050582|Schizophrenia
1225833|NCT01050582|Bipolar Disorder
1225834|NCT01050582|Autistic Disorder
1225835|NCT01050582|Conduct and Other Disruptive Behavior Disorders
1225836|NCT01050582|Risperidone
1225837|NCT01050582|RISPERDAL
1225838|NCT01050582|Antipsychotic Agents
1225839|NCT01050582|Prolactin
1225840|NCT01050582|Pediatrics
1225841|NCT01050569|Smoking Cessation
1225842|NCT01050569|Nicotine Free Cigarettes
1225843|NCT01050556|arsenic
1225844|NCT01050556|folate
1225845|NCT01050556|folic acid
1225846|NCT01050556|creatine
1225847|NCT01050556|arsenicosis
1225848|NCT01050556|nutrition
1225849|NCT01050530|Cirrhosis
1225850|NCT01050530|ascites
1225851|NCT01050530|Tolvaptan
1225852|NCT01050530|OPC-41061
1225853|NCT01050491|asthma
1225854|NCT01050491|airway remodeling
1225855|NCT01050491|airway obstruction
1225856|NCT01050478|acute agitation
1225857|NCT01050478|aggression
1225858|NCT01050478|psychosis
1225859|NCT01050478|paliperidone extended release
1225860|NCT01050465|HIV
1225861|NCT01050465|Knee pain
1225862|NCT01050465|Colonoscopy
1225863|NCT01050465|Mammography
1225864|NCT01050465|Vaccination
1225865|NCT01050439|Allogeneic Stem Cell Transplant
1225866|NCT01050439|Unrelated donor
1225867|NCT01050439|Cord blood donor
1225868|NCT01050413|Thymidine Kinase 1 activity
1225869|NCT01050413|diagnosis
1225870|NCT01050413|prognosis
1225871|NCT01050413|follow-up
1225872|NCT01050400|CYP2D6
1225873|NCT01050400|Genetic Polymorphism
1225874|NCT01050400|codeine
1225875|NCT01050400|breastfeeding
1225876|NCT01050387|Vitamin D Deficiency
1225877|NCT01050387|VDD
1225878|NCT01050387|Vitamin D Supplementation
1225879|NCT01050387|Vitamin D Binding Protein
1225880|NCT01050387|DBP
1225881|NCT01050387|Nutritional rickets
1225882|NCT01050387|rickets
1225883|NCT01050387|25hydroxyvitamin D
1225884|NCT01050387|25OHD
1225885|NCT01050387|1,25OH2D
1225886|NCT01050387|vitamin D metabolites
1225887|NCT01050387|PTH
1225888|NCT01050387|vitamin D homeostasis
1225889|NCT01050361|To reduce perioperative morbidity and mortality associated with congestive heart failure for non-cardiac surgeries
1225890|NCT01050322|receptor HER two positive
1225891|NCT01050322|lapatinib
1225892|NCT01050322|metastatic breast cancer
1225893|NCT01050296|Neuroblastoma
1225894|NCT01050296|Retinoblastoma
1225895|NCT01050296|Osteosarcoma
1225896|NCT01050296|Rhabdomyosarcoma
1225897|NCT01050296|Ewing sarcoma
1225898|NCT01050296|Non-rhabdomyosarcoma soft tissue sarcoma
1225899|NCT01050296|Adrenocortical tumors
1225900|NCT01050296|Liver malignancies
1225901|NCT01050283|Advanced pancreatic adenocarcinoma
1225902|NCT01050244|Soy protein
1225903|NCT01050244|Milk protein
1225904|NCT01050244|Neuropathic pain
1225905|NCT01050231|stroke
1225906|NCT01050231|cerebrovascular accident
1225907|NCT01050231|robot
1225908|NCT01050218|Diabetic Peripheral Neuropathy
1225909|NCT01050205|Diabetes Prevention
1225910|NCT01050205|Cardiovascular Risk Reduction
1225911|NCT01050205|Lifestyle Intervention
1225912|NCT01050205|Group Lifestyle Balance
1225913|NCT01050192|Prematurity
1225914|NCT01050192|Nutrition
1225915|NCT01050192|Breast Feeding
1225916|NCT01050179|chemosensitivity
1225917|NCT01050166|islet transplantation
1225918|NCT01050166|magnetic resonance
1225919|NCT01050166|Type 1 DM
1225920|NCT01050153|Prevention of venous thromboembolism
1225921|NCT01050140|fructose
1225922|NCT01050140|fatty liver disease
1225923|NCT01050140|diet
1225924|NCT01050127|Pharmacokinetics
1225925|NCT01050127|Pharmacodynamics
1225926|NCT01050127|Drug Safety
1225927|NCT01050127|Phase 1 Clinical Trial
1225928|NCT01050114|Botulinum Toxin
1225929|NCT01050114|Oxybutynin
1225930|NCT01050114|Overactive Bladder
1225931|NCT01050114|Spinal Cord Injury
1225932|NCT01050114|Urinary Incontinence
1225933|NCT01050114|Nerve Growth Factor
1225934|NCT01050114|Urine Biomarkers
1225935|NCT01050101|Satiety
1225936|NCT01050101|Fiber
1225937|NCT01050101|Nutrition
1225938|NCT01050101|Pre- and post-menopausal women
1225939|NCT01050101|overweight
1225940|NCT01050088|clubfoot
1225941|NCT01050088|casting
1225942|NCT01050088|ponseti
1225943|NCT01050088|discomfort
1225944|NCT01050075|male breast cancer
1225945|NCT01050075|neurotoxicity
1225946|NCT01050075|recurrent breast cancer
1225947|NCT01050036|Leukemia, Myeloid
1225948|NCT01050036|Primary complete remission
1225949|NCT01050036|Favorable karyotype
1225950|NCT01050036|Autologous hematopoietic cell transplantation
1225951|NCT01050036|Hematopoietic cell transplantation
1225952|NCT01050023|venous stasis ulcer
1225953|NCT01050023|wound healing
1225954|NCT01050023|Provant Wound Closure System
1225955|NCT01050023|radiofrequency
1225956|NCT01050023|Provant
1225957|NCT01050023|pain relief
1225958|NCT01050010|rheumatoid arthritis
1225959|NCT01050010|clinical remission
1225960|NCT01050010|synovitis
1225961|NCT01050010|dedicated extremity MRI
1225962|NCT01049997|Non ST Elevation Myocardial Infarction (NSTEMI)
1225963|NCT01049997|Elderly
1225964|NCT01049997|Frailty
1225965|NCT01049984|Parkinson's Disease
1225966|NCT01049984|UPDRS
1225967|NCT01049984|Clinical Global Evaluation Illness Severity score
1225968|NCT01049984|Clinical Global Evaluation Improvement
1225969|NCT01049984|B-SIT
1225970|NCT01049984|SCOPA - Sleep Daytime Sleepiness
1225971|NCT01049984|PDQ -39
1225972|NCT01049984|SCOPA - Cognition
1225973|NCT01049984|Levodopa
1225974|NCT01049984|rasagiline
1225975|NCT01049984|Dopamine Agonist Therapy
1225976|NCT01049984|monoamine oxidase type B inhibitor
1225977|NCT01049971|colorectal surgery
1225978|NCT01049971|wound infection
1225979|NCT01049971|wound protector
1225980|NCT01049971|laparoscopy
1225981|NCT01049971|surgical site infection after laparoscopic colorectal surgery with minilaparotomy
1225982|NCT01049958|asynchrony
1225983|NCT01049958|mechanical ventilation
1225984|NCT01049958|blunt trauma
1225985|NCT01049932|HIV
1225986|NCT01049932|Human Immunodeficiency Virus (HIV)
1225987|NCT01049932|HIV Seronegativity
1225988|NCT01049919|Critical Limb Ischemia
1225989|NCT01049919|Peripheral Arterial Disease
1225990|NCT01049919|Peripheral Vascular Disease
1225991|NCT01049919|CLI
1225992|NCT01049919|PAD
1225993|NCT01049919|PVD
1225994|NCT01049919|Angiogenesis
1225995|NCT01049919|Stem Cells
1225996|NCT01049919|Cell Therapy
1225997|NCT01049919|Limb Salvage
1225998|NCT01049919|Amputation
1225999|NCT01049919|Leg Pain
1226000|NCT01049906|foot surgery
1226001|NCT01049906|ankle surgery
1226002|NCT01049906|Patients scheduled for foot and ankle surgery
1226003|NCT01049880|Ascorbic Acid
1226004|NCT01049880|Gemcitabine
1226005|NCT01049854|unrelated donor transplant
1226006|NCT01049854|CD34 selection
1226007|NCT01049841|pediatric
1226008|NCT01049841|children
1226009|NCT01049841|perifosine
1226010|NCT01049841|temsirolimus
1226011|NCT01049841|recurrent
1226012|NCT01049841|progressive
1226013|NCT01049841|09-124
1226014|NCT01049828|Tinnitus
1226015|NCT01049828|fcMRI
1226016|NCT01049828|Neural Connectivity
1226017|NCT01049828|Bother
1226018|NCT01049815|hemodialysis
1226019|NCT01049815|intimal media thickness
1226020|NCT01049802|stroke
1226021|NCT01049802|hemiplegia
1226022|NCT01049802|TMS
1226023|NCT01049789|youth
1226024|NCT01049789|HIV
1226025|NCT01049789|Depression
1226026|NCT01049789|Cognitive Behavioral Therapy
1226027|NCT01049789|Medication management
1226028|NCT01049776|Lung Cancer Non Small Cell
1226029|NCT01049763|obese adult
1226030|NCT01049763|non obese healthy volunteers
1226031|NCT01049763|oseltamivir carboxylate
1226032|NCT01049763|pharmacokinetics
1226033|NCT01049763|healthy volunteers
1226034|NCT01049750|type 2 diabetes mellitus
1226035|NCT01049750|male
1226036|NCT01049750|erectile dysfunction
1226037|NCT01049724|Myopia
1226038|NCT01049724|refractive surgery
1226039|NCT01049724|LASIK
1226040|NCT01049724|PRK
1226041|NCT01049724|Lacritin
1226042|NCT01049724|Heparanase
1226043|NCT01049711|erythropoietin
1226044|NCT01049711|hemodialysis
1226045|NCT01049711|cost utility
1226046|NCT01049711|incremental cost-effectiveness ratio
1226047|NCT01049711|Quality adjusted life year
1226048|NCT01049711|quality of life
1226049|NCT01049698|Obesity
1226050|NCT01049698|Overweight
1226051|NCT01049698|Older adults
1226052|NCT01049698|resistance training
1226053|NCT01049698|exercise
1226054|NCT01049685|HIV
1226055|NCT01049685|Antiretroviral Therapy, Highly Active
1226056|NCT01049685|Efavirenz
1226057|NCT01049685|Lopinavir
1226058|NCT01049685|Comparative Effectiveness Research
1226059|NCT01049685|Treatment Naive
1226060|NCT01049659|pregnancy
1226061|NCT01049659|iodine deficiency
1226062|NCT01049659|neuropsychological development
1226063|NCT01049646|renin-angiotensin system
1226064|NCT01049646|apelin
1226065|NCT01049646|systemic haemodynamics
1226066|NCT01049633|Insulin dependence
1226067|NCT01049633|Hypoglycemia
1226068|NCT01049633|Hypoglycemia unawareness
1226069|NCT01049633|Islet transplantation
1226070|NCT01049620|XELOX
1226071|NCT01049620|RAD001
1226072|NCT01049620|phase 1
1226073|NCT01049607|Patients undergoing hepatic resection
1226074|NCT01049581|Gross motor function performance
1226075|NCT01049581|pediatric aquatic therapy
1226076|NCT01049581|spastic cerebral palsy
1226077|NCT01049568|HIV
1226078|NCT01049568|Cell phone
1226079|NCT01049568|HAART
1226080|NCT01049555|alzheimer
1226081|NCT01049555|apathy
1226082|NCT01049555|actigraphy
1226083|NCT01049542|Astressin 2B
1226084|NCT01049542|Forearm blood flow
1226085|NCT01049542|vascular
1226086|NCT01049542|plethysmography
1226087|NCT01049542|heart failure
1226088|NCT01049529|Docosahexaenoic acid
1226089|NCT01049529|n-3 Long Chain Polyunsaturated Fatty Acids
1226090|NCT01049529|omega 3 fatty acids
1226091|NCT01049529|neonates
1226092|NCT01049529|clinical outcomes
1226093|NCT01049529|critically ill patients
1226094|NCT01049529|Inflammatory and antiinflammatory cytokines
1226095|NCT01049529|Length of intensive care stay
1226096|NCT01049516|Military
1226097|NCT01049516|Combat
1226098|NCT01049516|Psychological Treatment
1226099|NCT01049516|Psychotherapy
1226100|NCT01049516|Trauma
1226101|NCT01049516|Posttraumatic Stress
1226102|NCT01049516|Posttraumatic Stress Disorder
1226103|NCT01049516|PTSD
1226104|NCT01049516|Prolonged Exposure
1226105|NCT01049516|Exposure therapy
1226106|NCT01049516|Behavior Therapy
1226107|NCT01049516|Cognitive Behavior Therapy
1226108|NCT01049516|Post-Traumatic Stress Disorders
1226109|NCT01049516|Stress Disorders, Post-traumatic
1226110|NCT01049503|Dentifrices
1226111|NCT01049503|Fluoride
1226112|NCT01049503|Nails
1226113|NCT01049503|Plaque
1226114|NCT01049490|Intradermal vaccination, H1N1, microneedle
1226115|NCT01049477|Pregnancy
1226116|NCT01049477|Cesarean Section
1226117|NCT01049464|Atrial fibrillation
1226118|NCT01049464|Hemodynamically unstable patients
1226119|NCT01049464|Magnesium sulfate
1226120|NCT01049464|Septic shock
1226121|NCT01049464|Medical intensive care unit
1226122|NCT01049464|New onset atrial fibrillation
1226123|NCT01049464|Critically ill patients
1226124|NCT01049451|Multiple Sclerosis
1226125|NCT01049451|ACTH
1226126|NCT01049451|Steroids
1226127|NCT01049438|MRSA
1226128|NCT01049438|Methicillin Resistant Staphylococcus aureus
1226129|NCT01049438|Staphylococcus aureus
1226130|NCT01049438|Skin Infections
1226131|NCT01049438|Body Decolonization
1226132|NCT01049425|anthracycline-free
1226133|NCT01049425|OncotypDX
1226134|NCT01049425|taxane
1226135|NCT01049425|Her2 negative breast cancer
1226136|NCT01049386|intestinal permeability
1226137|NCT01049386|health
1226138|NCT01049386|sugar absorption
1226139|NCT01049386|intestinal permeability examined in different men (lean vs obese) and different conditions (no breakfast and high-fat breakfast)
1226140|NCT01049373|low-back
1226141|NCT01049373|pain
1226142|NCT01049373|chronic
1226143|NCT01049373|constitution
1226144|NCT01049373|diathesism
1226145|NCT01049373|homoeopathy
1226146|NCT01049373|fixed combination
1226147|NCT01049373|herbal preparation
1226148|NCT01049373|chronic low back pain lasting more than 6 months
1226149|NCT01049360|Chronic Obstructive Pulmonary Disease
1226150|NCT01049360|COPD
1226151|NCT01049360|Chronic Bronchitis
1226152|NCT01049360|Emphysema
1226153|NCT01049360|Airflow Obstruction, Chronic
1226154|NCT01049360|Chronic Airflow Obstruction
1226155|NCT01049360|Chronic Obstructive Airway Disease
1226156|NCT01049360|Chronic Obstructive Lung Disease
1226157|NCT01049347|depression
1226158|NCT01049321|Dietary Approach to Stop Hypertension
1226159|NCT01049321|weight
1226160|NCT01049321|coagulation
1226161|NCT01049321|DASH eating pattern.
1226162|NCT01049308|heart failure
1226163|NCT01049308|cognitive disorders
1226164|NCT01049308|medication adherence
1226165|NCT01049308|patient readmissions
1226166|NCT01049295|taxanes
1226167|NCT01049295|breast cancer
1226168|NCT01049295|n3 fatty acids
1226169|NCT01049295|inflammation
1226170|NCT01049282|safety
1226171|NCT01049282|immunogenicity
1226172|NCT01049282|adjuvanted TB subunit vaccine
1226173|NCT01049269|Body Scanning
1226174|NCT01049269|Body Fat
1226175|NCT01049269|Body Volume
1226176|NCT01049269|Obesity
1226177|NCT01049269|No Conditions
1226178|NCT01049256|Periodic breathing
1226179|NCT01049256|Heart Failure
1226180|NCT01049256|Chemoreflex
1226181|NCT01049256|Chemosensitivity
1226182|NCT01049243|Atopic Dermatitis
1226183|NCT01049243|Open-Label
1226184|NCT01049243|Topical
1226185|NCT01049243|Cream
1226186|NCT01049243|Eczema
1226187|NCT01049243|Vanos
1226188|NCT01049230|proton beam radiation
1226189|NCT01049230|CNS germ cell tumor
1226190|NCT01049217|neuropathy
1226191|NCT01049217|pain
1226192|NCT01049217|HIV-1
1226193|NCT01049217|HIV Infections
1226194|NCT01049204|HIV
1226195|NCT01049204|HIV-1 Infections
1226196|NCT01049191|Osteoporosis
1226197|NCT01049191|Fracture
1226198|NCT01049191|microMRI
1226199|NCT01049191|Bone architecture
1226200|NCT01049191|Bone matrix
1226201|NCT01049191|Bone and Bones
1226202|NCT01049191|Magnetic Resonance Imaging
1226203|NCT01049178|antioxidant enzymes
1226204|NCT01049178|asthma
1226205|NCT01049178|silymarin
1226206|NCT01049178|RCT
1226207|NCT01049152|Diabetes mellitus
1226208|NCT01049152|ESRD
1226209|NCT01049152|CGM
1226210|NCT01049152|Inflammation markers
1226211|NCT01049152|Hemodialysis
1226212|NCT01049152|Diabetic patients
1226213|NCT01049152|Nondiabetic patients
1226214|NCT01049152|All with ESRD
1226215|NCT01049152|All undergone hemodialysis
1226216|NCT01049139|vaccination
1226217|NCT01049139|HIV prevention
1226218|NCT01049139|YMSM
1226219|NCT01049139|youth
1226220|NCT01049139|HIV Preventative Vaccine
1226221|NCT01049126|Late Stage
1226222|NCT01049113|Lymphoma
1226223|NCT01049113|B-cell Acute Lymphocytic Leukemia
1226224|NCT01049113|ALL
1226225|NCT01049100|Surgical Staging
1226226|NCT01049100|Cervical Cancer
1226227|NCT01049100|Chemoradiation
1226228|NCT01049100|Outcome
1226229|NCT01049100|Toxicity
1226230|NCT01049087|plasma volume
1226231|NCT01049087|technetium-labeled albumin
1226232|NCT01049087|radioiodine-labeled albumin
1226233|NCT01049087|Healthy volunteers
1226234|NCT01049074|Low Back Pain
1226235|NCT01049074|Acupuncture
1226236|NCT01049074|RCT
1226237|NCT01049061|Cancer
1226238|NCT01049061|FRα
1226239|NCT01049048|Endothelial Function
1226240|NCT01049048|Arterial stiffness
1226241|NCT01049048|Vitamin D
1226242|NCT01049035|Meningitis
1226243|NCT01049035|Meningococcal Infection
1226244|NCT01049035|Neisseria meningitidis
1226245|NCT01049035|Tetravalent Meningococcal Vaccine
1226246|NCT01049022|Pharmacokinetics
1226247|NCT01049009|Nitric Oxide
1226248|NCT01049009|Adrenergic beta-Antagonists
1226249|NCT01049009|Antihypertensive Agents
1226250|NCT01049009|Vasodilator Agents
1226251|NCT01049009|Anti-Arrhythmia Agents
1226252|NCT01049009|Sympatholytics
1226253|NCT01049009|Vascular Resistance
1226254|NCT01049009|Neurotransmitter Agents
1226255|NCT01049009|Cardiovascular Diseases
1226256|NCT01049009|Metoprolol succinate
1226257|NCT01049009|Therapeutic Uses
1226258|NCT01049009|Metoprolol
1226259|NCT01049009|Vascular Diseases
1226260|NCT01049009|Nebivolol
1226261|NCT01049009|Cardiovascular Agents
1226262|NCT01049009|Endothelium-Dependent Relaxing Factors
1226263|NCT01048996|Acute Lung Injury
1226264|NCT01048996|Acute Respiratory Distress Syndrome
1226265|NCT01048996|Genetic Variability
1226266|NCT01048996|Plasma Biomarkers
1226267|NCT01048996|Pediatrics
1226268|NCT01048983|Lung Cancer
1226269|NCT01048983|NSCLC
1226270|NCT01048983|Concurrent Chemoradiation Therapy
1226271|NCT01048983|Side Effects
1226272|NCT01048983|Armodafinil
1226273|NCT01048983|Nuvigil
1226274|NCT01048983|Bupropion
1226275|NCT01048983|Wellbutrin
1226276|NCT01048983|Wellbutrin SR
1226277|NCT01048983|Zyban
1226278|NCT01048983|Curcumin
1226279|NCT01048983|Minocycline
1226280|NCT01048983|Dynacin
1226281|NCT01048983|Minocin
1226282|NCT01048983|Minocin PAC
1226283|NCT01048983|Myrac
1226284|NCT01048983|Solodyn
1226285|NCT01048970|Lung cancer
1226286|NCT01048970|Eicosapentaenoic acid oral supplementation
1226287|NCT01048970|Weight loss
1226288|NCT01048970|Toxicity
1226289|NCT01048970|Body composition
1226290|NCT01048970|Inflammatory response
1226291|NCT01048957|Nicotine
1226292|NCT01048957|Craving
1226293|NCT01048957|fMRI
1226294|NCT01048957|EEG
1226295|NCT01048957|Real Time fMRI Feedback
1226296|NCT01048944|Electroencephalography
1226297|NCT01048944|nicotine
1226298|NCT01048944|bupropion
1226299|NCT01048944|attention
1226300|NCT01048944|drug withdrawal symptoms
1226301|NCT01048931|Single-port, laparoscopic-assisted, vaginal hysterectomy
1226302|NCT01048918|Circulating tumor cells in breast cancer
1226303|NCT01048905|Pulmonary Hypertension
1226304|NCT01048905|Sickle Cell Disease
1226305|NCT01048905|Thalassemia
1226306|NCT01048892|recurrent neuroblastoma
1226307|NCT01048892|previously treated childhood rhabdomyosarcoma
1226308|NCT01048892|recurrent childhood rhabdomyosarcoma
1226309|NCT01048892|recurrent Wilms tumor and other childhood kidney tumors
1226310|NCT01048892|recurrent retinoblastoma
1226311|NCT01048892|recurrent adrenocortical carcinoma
1226312|NCT01048892|recurrent gastrointestinal carcinoid tumor
1226313|NCT01048879|oseltamivir
1226314|NCT01048879|influenza
1226315|NCT01048879|continuous renal replacement therapy
1226316|NCT01048879|extracorporeal membrane oxygenation
1226317|NCT01048879|pharmacokinetics
1226318|NCT01048853|Cervix
1226319|NCT01048853|Stage IA2 or IB1 Carcinoma
1226320|NCT01048853|Conservative Surgery
1226321|NCT01048853|Cervix Cancer recurrence
1226322|NCT01048853|Quality of Life Factors
1226323|NCT01048853|Pelvic lymph nodes
1226324|NCT01048853|Pelvic Lymphadenectomy
1226325|NCT01048853|parametrium
1226326|NCT01048853|Cervical cone biopsy
1226327|NCT01048853|Endocervical curettage
1226328|NCT01048853|ECC
1226329|NCT01048840|Gastroesophageal Reflux
1226330|NCT01048827|AML
1226331|NCT01048827|autologous transplant
1226332|NCT01048801|History of fever
1226333|NCT01048801|measured fever
1226334|NCT01048788|Cirrhosis
1226335|NCT01048788|ascites
1226336|NCT01048788|Tolvaptan
1226337|NCT01048788|OPC-41061
1226338|NCT01048775|bispectral index
1226339|NCT01048775|cardiac surgery
1226340|NCT01048775|asymmetry
1226341|NCT01048762|pulmonary cancer
1226342|NCT01048762|radically operated
1226343|NCT01048762|exercise training
1226344|NCT01048762|dyspnea counseling
1226345|NCT01048762|quality of life
1226346|NCT01048762|physical therapy
1226347|NCT01048749|Low back pain
1226348|NCT01048749|nerve root compression
1226349|NCT01048749|spinal height
1226350|NCT01048736|obesity
1226351|NCT01048736|exercise
1226352|NCT01048736|intensity
1226353|NCT01048736|weight loss
1226354|NCT01048736|diet
1226355|NCT01048723|Soft Tissue
1226356|NCT01048723|Retroperitoneal
1226357|NCT01048723|resectable
1226358|NCT01048710|Knee osteoarthritis
1226359|NCT01048710|knee osteonecrosis
1226360|NCT01048710|osteotomy
1226361|NCT01048697|Obesity
1226362|NCT01048697|Pharmacokinetics
1226363|NCT01048697|Pharmacodynamics
1226364|NCT01048697|Dose individualization
1226365|NCT01048697|Tuberculosis
1226366|NCT01048684|Brain tumor
1226367|NCT01048684|Intracranial pressure
1226368|NCT01048671|HIV
1226369|NCT01048658|Sevoflurane
1226370|NCT01048658|anesthesia
1226371|NCT01048658|abortion
1226372|NCT01048658|blood loss
1226373|NCT01048645|All-trans retinoic acid
1226374|NCT01048645|non-small cell lung cancer
1226500|NCT01048099|PRO Onc Assay
1226375|NCT01048645|retinoic acid receptor beta
1226376|NCT01048645|chemotherapy
1226377|NCT01048632|Neonates with HLHS or variant with plan to undergo Norwood Procedure
1226380|NCT01048606|Postmenopause
1226381|NCT01048606|Overweight
1226382|NCT01048606|Women
1226383|NCT01048606|Phytoestrogens
1226384|NCT01048606|Exercise
1226385|NCT01048606|Cardiovascular Diseases
1226386|NCT01048606|Risk Factors
1226387|NCT01048606|Aging
1226388|NCT01048593|ocular inflammation cataract surgery
1226389|NCT01048593|post cataract surgery inflammation
1226390|NCT01048580|Perifosine
1226391|NCT01048580|Capecitabine
1226392|NCT01048580|Colon Cancer
1226393|NCT01048567|Antibiotics
1226394|NCT01048567|Diarrhea
1226395|NCT01048567|Clostridium difficile
1226396|NCT01048567|Probiotics
1226397|NCT01048567|Prevention & control
1226398|NCT01048554|Melanoma
1226399|NCT01048554|Brain mets
1226400|NCT01048554|Bevacizumab
1226401|NCT01048554|Temozolomide
1226402|NCT01048554|Avastin
1226403|NCT01048554|Temodar
1226404|NCT01048554|Melanoma with brain mets
1226405|NCT01048528|immune response to vaccines
1226406|NCT01048528|stress management
1226407|NCT01048528|perceived risk for breast cancer
1226408|NCT01048515|Caffeine
1226409|NCT01048515|Physiological Effects of Drugs
1226410|NCT01048515|Central Nervous System Agents
1226411|NCT01048502|healthy volunteer
1226412|NCT01048476|AMD
1226413|NCT01048463|gastric cancer
1226414|NCT01048463|colorectal cancer
1226415|NCT01048463|chemotherapy
1226416|NCT01048463|eicosapentaenoic acid
1226417|NCT01048463|enteral nutrition
1226418|NCT01048450|arthritis
1226419|NCT01048450|degeneration
1226420|NCT01048424|Urinary incontinence
1226421|NCT01048424|Paced respiration
1226422|NCT01048411|stroke rehabilitation
1226423|NCT01048411|outcome
1226424|NCT01048411|barthel-index
1226425|NCT01048411|geriatrics
1226426|NCT01048411|elderly
1226427|NCT01048398|ceophalic version
1226428|NCT01048398|breech presentation
1226429|NCT01048398|pregnancy
1226430|NCT01048398|remifentanil
1226431|NCT01048398|paracetamol
1226432|NCT01048385|Mitochondrial dysfunction
1226433|NCT01048385|Mitochondrial nutrients
1226434|NCT01048385|Aneuploidy
1226435|NCT01048385|Meiotic Spindle
1226436|NCT01048385|Coenzyme Q10
1226437|NCT01048385|Electron transfer chain
1226438|NCT01048372|HIV
1226439|NCT01048372|monoclonal antibody
1226440|NCT01048372|immune therapy
1226441|NCT01048372|pathogenesis
1226442|NCT01048372|cytotoxic T lymphocyte
1226443|NCT01048372|anti-CD4
1226444|NCT01048372|anti-self
1226445|NCT01048372|viral replication
1226446|NCT01048372|Acute Infection
1226447|NCT01048359|Drug abuse, injury, trauma, screening, brief intervention.
1226448|NCT01048346|employment, disabilities
1226449|NCT01048333|Chronic Obstructive Pulmonary Disease
1226450|NCT01048333|Onset of effect
1226451|NCT01048333|COPD
1226452|NCT01048333|Oxis Turbuhaler
1226453|NCT01048320|pancreatic cancer
1226454|NCT01048320|toxicity
1226455|NCT01048320|chemotherapy
1226456|NCT01048320|dose finding
1226457|NCT01048307|prontosan
1226458|NCT01048307|wound cleansing
1226459|NCT01048307|wound irrigation
1226460|NCT01048307|phmb
1226461|NCT01048307|polihexanide
1226462|NCT01048307|betaine
1226463|NCT01048294|Seasonal affective disorder
1226464|NCT01048294|phototherapy
1226465|NCT01048294|circadian rhythms
1226466|NCT01048294|blue enriched light
1226467|NCT01048294|melanopsin
1226468|NCT01048294|Primary disease: Seasonal Affective Disorder, winter type
1226469|NCT01048268|T1DM
1226470|NCT01048268|T2DM
1226471|NCT01048268|GIP
1226472|NCT01048268|Glucose-dependent insulinotropic polypeptide
1226473|NCT01048268|Incretin
1226474|NCT01048216|colorectal liver cancer
1226475|NCT01048216|metastatic
1226476|NCT01048216|radiation therapy
1226477|NCT01048203|14C ABR 215050 Metabolism and Mass Balance Study
1226478|NCT01048203|tasquinimod
1226479|NCT01048203|Metabolic pattern of 14C ABR-215050
1226480|NCT01048190|Inactivated Poliomyelitis Vaccine
1226481|NCT01048190|Sabin Strains
1226482|NCT01048190|poliomyelitis
1226483|NCT01048177|vulvodynia
1226484|NCT01048177|interstitial cystitis
1226485|NCT01048177|pelvic pain
1226486|NCT01048164|Massage
1226487|NCT01048164|Relaxation
1226488|NCT01048151|Prostate
1226489|NCT01048151|TNFerade Biologic
1226490|NCT01048138|Biperiden
1226491|NCT01048138|Post-traumatic Epilepsy
1226492|NCT01048138|Traumatic Brain Injury
1226493|NCT01048125|Stress-induced cardiomyopathy
1226494|NCT01048125|Takotsubo cardiomyopathy
1226495|NCT01048112|campylobacter
1226496|NCT01048112|gastroenteritis
1226497|NCT01048112|challenge models
1226498|NCT01048099|Breast Cancer
1226499|NCT01048099|Metastatic
1226501|NCT01048099|FISH Testing
1226502|NCT01048099|HER Negative
1226503|NCT01048099|HER Overexpression
1226504|NCT01048099|HER Activation
1226505|NCT01048086|neuroblastoma
1226506|NCT01048086|neuroendocrine tumor
1226507|NCT01048086|NET
1226508|NCT01048086|retinoic acid
1226509|NCT01048073|lower respiratory tract infection
1226510|NCT01048073|non influenza
1226511|NCT01048073|PCR assay
1226512|NCT01048047|aliskiren
1226513|NCT01048047|amlodipine
1226514|NCT01048047|hypertension
1226515|NCT01048047|ankle-foot volume
1226516|NCT01048047|mild and moderate hypertension
1226517|NCT01048034|Myelodysplastic syndrome
1226518|NCT01048034|Chronic myelomonocytic leukemia
1226519|NCT01048034|Transfusion therapy
1226520|NCT01048034|Transfusion dependency
1226521|NCT01048034|Hypomethylating therapy
1226522|NCT01048034|Azacitidine
1226523|NCT01048034|DNA-methylation
1226524|NCT01048034|Epigenetic modifications
1226525|NCT01048021|Measurement of lung mechanics (FEV1, FVC and PEF)
1226526|NCT01048008|Glioblastoma multiforme
1226527|NCT01048008|Advanced cancers
1226528|NCT01048008|Brain Neoplasms, Malignant, Primary
1226529|NCT01048008|Brain Tumor, Recurrent
1226530|NCT01048008|Advanced cancer
1226531|NCT01047982|gestational diabetes
1226532|NCT01047982|macrosomia
1226533|NCT01047982|hypertension in pregnancy
1226534|NCT01047982|HOMA-IR
1226535|NCT01047982|obesity
1226536|NCT01047969|locally invasive high-risk rectal adenocarcinoma
1226537|NCT01047956|Methadone
1226538|NCT01047956|NAC
1226539|NCT01047956|opioids
1226540|NCT01047930|Insomnia
1226541|NCT01047930|Smoking
1226542|NCT01047930|Cue reactivity
1226543|NCT01047930|Exercise timing
1226544|NCT01047930|Acute nicotine withdrawal
1226545|NCT01047930|Mood disturbances
1226546|NCT01047930|Smoking abstinence
1226547|NCT01047930|Exercise intensity
1226548|NCT01047930|Altered sleep
1226549|NCT01047930|Exercise duration
1226550|NCT01047930|Nonpharmacologic behavioral treatment
1226551|NCT01047930|Smoking cessation
1226552|NCT01047930|Exercise Test
1226553|NCT01047930|Polysomnography
1226554|NCT01047917|Meditation
1226555|NCT01047917|Relaxation Therapy
1226556|NCT01047917|Quality of Life
1226557|NCT01047865|Type 1 Diabetes (T1D)
1226558|NCT01047865|Autoimmunity
1226559|NCT01047852|chronic respiratory disorders
1226560|NCT01047852|hypercapnic respiratory failure
1226561|NCT01047852|noninvasive ventilation
1226562|NCT01047839|Pediatric
1226563|NCT01047839|Japanese Encephalitis Vaccine
1226564|NCT01047839|non-endemic countries
1226565|NCT01047839|to assess immunogenicity of purified inactivated Japanese Encephalitis (JE) vaccine IC51
1226566|NCT01047826|Fractured Tibia
1226567|NCT01047826|Expert Tibial Nail
1226568|NCT01047826|Minimally Invasive Plate Osteosynthesis (M.I.P.O)
1226569|NCT01047826|Intramedullary Nailing
1226570|NCT01047826|Locked Plate
1226571|NCT01047826|distal third
1226572|NCT01047826|43-A
1226573|NCT01047813|Cognitive performance
1226574|NCT01047813|Type 2 diabetes
1226575|NCT01047813|Blood glucose
1226576|NCT01047800|Functional gastrointestinal disorder
1226577|NCT01047800|GERD
1226578|NCT01047800|reflux
1226579|NCT01047800|irritable bowel syndrome
1226580|NCT01047800|Functional dyspepsia
1226581|NCT01047800|postprandial fullness
1226582|NCT01047800|counseling
1226583|NCT01047800|service
1226584|NCT01047787|Sleep apnea
1226585|NCT01047787|Cheyne-Stokes Respiration
1226586|NCT01047787|Congestive Heart Failure
1226587|NCT01047774|soy protein
1226588|NCT01047774|diet
1226589|NCT01047761|Myasthenia Gravis
1226590|NCT01047761|Exercise
1226591|NCT01047761|Fitness
1226592|NCT01047761|Body Composition
1226593|NCT01047761|Physical Activity
1226594|NCT01047761|Pulmonary Function
1226595|NCT01047761|Balance
1226596|NCT01047748|abortion
1226597|NCT01047735|21+ years old
1226598|NCT01047735|Address
1226599|NCT01047735|Adult
1226600|NCT01047735|Amputation
1226601|NCT01047735|Area
1226602|NCT01047735|Arm
1226603|NCT01047735|Atheroscleroses
1226604|NCT01047735|Atherosclerosis
1226605|NCT01047735|Atherosclerotic
1226606|NCT01047735|Cardiovascular Disease
1226607|NCT01047735|Bariatrics
1226608|NCT01047735|Behavior Conditioning Therapy
1226609|NCT01047735|Behavior Modification
1226610|NCT01047735|Behavior Therapy
1226611|NCT01047735|Behavior Treatment
1226612|NCT01047735|Behavior or Life Style Modifications
1226613|NCT01047735|Behavioral
1226614|NCT01047735|Behavioral Conditioning Therapy
1226615|NCT01047735|Behavioral Modification
1226616|NCT01047735|Behavioral Therapy
1226617|NCT01047735|Behavioral Treatment
1226618|NCT01047735|Beta Cell
1226619|NCT01047735|Blindness
1226620|NCT01047735|Blood Pressure, High
1226621|NCT01047735|Blood Vessels
1226622|NCT01047735|Body Composition
1226623|NCT01047735|Body Weight decreased
1226624|NCT01047735|Cancers
1226625|NCT01047735|Cardiac infarction
1226626|NCT01047735|Cardiovascular Diseases
1226627|NCT01047735|Care, Health
1226628|NCT01047735|Cause of Death
1226629|NCT01047735|Cell Function
1226630|NCT01047735|Cell Process
1226631|NCT01047735|Cell physiology
1226632|NCT01047735|Cellular Function
1226633|NCT01047735|Cellular Physiology
1226634|NCT01047735|Cellular Process
1226635|NCT01047735|Cessation of life
1226636|NCT01047735|Clinical
1226637|NCT01047735|Clinical Trials Design
1226638|NCT01047735|Communities
1226639|NCT01047735|Conditioning Therapy
1226640|NCT01047735|Controlled Clinical Trials, Randomized
1226641|NCT01047735|Controlled Study
1226642|NCT01047735|Country
1226643|NCT01047735|D-Glucose
1226644|NCT01047735|Death
1226645|NCT01047735|Decision Making
1226646|NCT01047735|Dextrose
1226647|NCT01047735|Diabetes Mellitus
1226648|NCT01047735|Diabetes Mellitus, Adult-Onset
1226649|NCT01047735|Diabetes Mellitus, Ketosis-Resistant
1226650|NCT01047735|Diabetes Mellitus, Non-Insulin-Dependent
1226651|NCT01047735|Diabetes Mellitus, Noninsulin Dependent
1226652|NCT01047735|Diabetes Mellitus, Slow-Onset
1226653|NCT01047735|Diabetes Mellitus, Stable
1226654|NCT01047735|Diabetes Mellitus, Type 2
1226655|NCT01047735|Diabetes Mellitus, Type II
1226656|NCT01047735|Diet
1226657|NCT01047735|Disease
1226658|NCT01047735|Disease remission
1226659|NCT01047735|Disorder
1226660|NCT01047735|Drugs
1226661|NCT01047735|Dysfunction
1226662|NCT01047735|Effectiveness
1226663|NCT01047735|Epidemic
1226664|NCT01047735|Functional disorder
1226665|NCT01047735|Future
1226666|NCT01047735|Gastric Bypass
1226667|NCT01047735|Glucose
1226668|NCT01047735|Health
1226669|NCT01047735|Healthcare
1226670|NCT01047735|Hepatic Disorder
1226671|NCT01047735|Human, Adult
1226672|NCT01047735|Hypertension
1226673|NCT01047735|INFLM
1226674|NCT01047735|Incidence
1226675|NCT01047735|Inflammation
1226676|NCT01047735|Insulin Cell
1226677|NCT01047735|Insulin Resistance
1226678|NCT01047735|Insulin Secreting Cell
1226679|NCT01047735|Intestinal
1226680|NCT01047735|Intestines
1226681|NCT01047735|Intravenous Glucose Tolerance
1226682|NCT01047735|Intravenous Glucose Tolerance Test
1226683|NCT01047735|Kidney Failure
1226684|NCT01047735|Kidney Insufficiency
1226685|NCT01047735|Learning
1226686|NCT01047735|Life Style
1226687|NCT01047735|Life Style Modification
1226688|NCT01047735|Lifestyle
1226689|NCT01047735|Link
1226690|NCT01047735|Liver diseases
1226691|NCT01047735|Longitudinal Studies
1226692|NCT01047735|MODY
1226693|NCT01047735|Malignant Neoplasms
1226694|NCT01047735|Malignant Tumor
1226695|NCT01047735|Maturity-Onset Diabetes Mellitus
1226696|NCT01047735|Measures
1226697|NCT01047735|Medical
1226698|NCT01047735|Medication
1226699|NCT01047735|Metabolic
1226700|NCT01047735|Methods
1226701|NCT01047735|Modification
1226702|NCT01047735|Morbid Obesity
1226703|NCT01047735|Morbidity
1226704|NCT01047735|Morbidity - disease rate
1226705|NCT01047735|Mortality
1226706|NCT01047735|Mortality Vital Statistics
1226707|NCT01047735|Myocardial Infarct
1226708|NCT01047735|Myocardial Infarction
1226709|NCT01047735|NAFLD
1226710|NCT01047735|NASH
1226711|NCT01047735|NIDDM
1226712|NCT01047735|Non-Insulin Dependent Diabetes
1226713|NCT01047735|Non-Insulin-Dependent Diabetes Mellitus
1226714|NCT01047735|Non-alcoholic steatohepatitis
1226715|NCT01047735|Obesity
1226716|NCT01047735|Obesity, Morbid
1226717|NCT01047735|Operation
1226718|NCT01047735|Operative Procedures
1226719|NCT01047735|Operative Surgical Procedures
1226720|NCT01047735|Outcome
1226721|NCT01047735|Outcome Measure
1226722|NCT01047735|PROV
1226723|NCT01047735|Participant
1226724|NCT01047735|Patients
1226725|NCT01047735|Pharmaceutic Preparations
1226726|NCT01047735|Pharmaceutical Preparations
1226727|NCT01047735|Physical activity
1226728|NCT01047735|Physiopathology
1226729|NCT01047735|Pilot Projects
1226730|NCT01047735|Population
1226731|NCT01047735|Procedures
1226732|NCT01047735|Programs (PT)
1226733|NCT01047735|Programs [Publication Type]
1226734|NCT01047735|Provider
1226735|NCT01047735|Psychosocial Factor
1226736|NCT01047735|Public Health
1226737|NCT01047735|RMSN
1226738|NCT01047735|Randomized
1226739|NCT01047735|Randomized Controlled Clinical Trials
1226740|NCT01047735|Randomized Controlled Trials
1226741|NCT01047735|Remission
1226742|NCT01047735|Renal Failure
1226743|NCT01047735|Renal Insufficiency
1226744|NCT01047735|Reporting
1226745|NCT01047735|Resolution
1226746|NCT01047735|Science
1226747|NCT01047735|Severe obesity
1226748|NCT01047735|Structure
1226749|NCT01047735|Subcellular Process
1226750|NCT01047735|Surgical
1226751|NCT01047735|Surgical Interventions
1226752|NCT01047735|Surgical Procedure
1226753|NCT01047735|T2D
1226754|NCT01047735|T2DM
1226755|NCT01047735|Testing
1226756|NCT01047735|Type 2 diabetes
1226757|NCT01047735|Type II diabetes
1226758|NCT01047735|United States
1226759|NCT01047735|Upper arm
1226760|NCT01047735|Vascular Hypertensive Disease
1226761|NCT01047735|Vascular Hypertensive Disorder
1226762|NCT01047735|Weight
1226763|NCT01047735|Weight Loss
1226764|NCT01047735|Weight Reduction
1226765|NCT01047735|Work
1226766|NCT01047735|adiposity
1226767|NCT01047735|adult human (21+)
1226768|NCT01047735|adult onset diabetes
1226769|NCT01047735|atheromatosis
1226770|NCT01047735|atherosclerotic vascular disease
1226771|NCT01047735|bariatric surgery
1226772|NCT01047735|behavior intervention
1226773|NCT01047735|behavioral intervention
1226774|NCT01047735|blood glucose regulation
1226775|NCT01047735|body weight loss
1226776|NCT01047735|bowel
1226777|NCT01047735|cardiac infarct
1226778|NCT01047735|cardiovascular disorder
1226779|NCT01047735|cardiovascular risk
1226780|NCT01047735|cardiovascular risk factor
1226781|NCT01047735|clinical practice
1226782|NCT01047735|comparative effectiveness
1226783|NCT01047735|coronary attack
1226784|NCT01047735|coronary infarct
1226785|NCT01047735|coronary infarction
1226786|NCT01047735|corpulence
1226787|NCT01047735|corpulency
1226788|NCT01047735|corpulentia
1226789|NCT01047735|design
1226790|NCT01047735|designing
1226791|NCT01047735|diabetes
1226792|NCT01047735|diabetic patient
1226793|NCT01047735|disease/disorder
1226794|NCT01047735|drug/agent
1226795|NCT01047735|effective therapy
1226796|NCT01047735|effectiveness research
1226797|NCT01047735|fitness
1226798|NCT01047735|gastric banding
1226799|NCT01047735|gastric bypass surgery
1226800|NCT01047735|glucose control
1226801|NCT01047735|glucose homeostasis
1226802|NCT01047735|glucose metabolism
1226803|NCT01047735|glucose regulation
1226804|NCT01047735|heart attack
1226805|NCT01047735|heart infarct
1226806|NCT01047735|heart infarction
1226807|NCT01047735|hepatopathy
1226808|NCT01047735|hyperpiesia
1226809|NCT01047735|hyperpiesis
1226810|NCT01047735|hypertensive disease
1226811|NCT01047735|implantable gastric stimulation banding
1226812|NCT01047735|insulin resistant
1226813|NCT01047735|interest
1226814|NCT01047735|ketosis resistant diabetes
1226815|NCT01047735|life style intervention
1226816|NCT01047735|lifestyle intervention
1226817|NCT01047735|liver disorder
1226818|NCT01047735|long-term study
1226819|NCT01047735|malignancy
1226820|NCT01047735|maturity onset diabetes
1226821|NCT01047735|moderate obesity
1226822|NCT01047735|neoplasm/cancer
1226823|NCT01047735|non-alcohol fatty liver
1226824|NCT01047735|non-alcohol induced steatohepatitis
1226825|NCT01047735|non-alcoholic fatty liver
1226826|NCT01047735|non-alcoholic steato-hepatitis
1226827|NCT01047735|nonalcohol fatty liver
1226828|NCT01047735|nonalcoholic fatty liver
1226829|NCT01047735|nonalcoholic steato-hepatitis
1226830|NCT01047735|nonalcoholic steatohepatitis
1226831|NCT01047735|obese
1226832|NCT01047735|obese people
1226833|NCT01047735|obese person
1226834|NCT01047735|obese population
1226835|NCT01047735|obesity surgery
1226836|NCT01047735|obesity, extreme
1226837|NCT01047735|pathophysiology
1226838|NCT01047735|pilot study
1226839|NCT01047735|programs
1226840|NCT01047735|psychosocial
1226841|NCT01047735|psychosocial variables
1226842|NCT01047735|public health medicine (field)
1226843|NCT01047735|public health relevance
1226844|NCT01047735|randomisation
1226845|NCT01047735|randomization
1226846|NCT01047735|randomized controlled study
1226847|NCT01047735|randomized trial
1226848|NCT01047735|randomly assigned
1226849|NCT01047735|respiratory
1226850|NCT01047735|response
1226851|NCT01047735|stomach bypass
1226852|NCT01047735|stomach stapling
1226853|NCT01047735|surgery
1226854|NCT01047735|trial comparing
1226855|NCT01047735|vascular
1226856|NCT01047735|weight loss intervention
1226857|NCT01047735|weight loss surgery
1226858|NCT01047735|wt-loss
1226859|NCT01047722|platelet function test
1226860|NCT01047722|platelets
1226861|NCT01047722|in vivo test
1226862|NCT01047722|aspirin
1226863|NCT01047722|aspirin resistance
1226864|NCT01047722|aspirin non-responsiveness
1226865|NCT01047722|in-vivo
1226866|NCT01047722|To assess the specificity and sensitivity of a novel in-vivo diagnostic test of platelet function
1226867|NCT01047722|"To use this test to define and assess aspirin resistance"
1226868|NCT01047683|hypertriglyceridemia
1226869|NCT01047683|omega-3 fatty acids
1226870|NCT01047683|statin
1226871|NCT01047683|triglycerides
1226872|NCT01047683|lipids
1226873|NCT01047683|EPA
1226874|NCT01047683|docosahexaenoic acid
1226875|NCT01047683|fish
1226876|NCT01047683|fatty acids
1226877|NCT01047683|fibrates
1226878|NCT01047683|niacin
1226879|NCT01047683|lipid
1226880|NCT01047683|atorvastatin
1226881|NCT01047683|Lovaza
1226882|NCT01047683|simvastatin
1226883|NCT01047683|lovastatin
1226884|NCT01047683|pravastatin
1226885|NCT01047683|fluvastatin
1226886|NCT01047683|rosuvastatin
1226887|NCT01047683|Trilipix
1226888|NCT01047683|Vytorin
1226889|NCT01047683|Simcor
1226890|NCT01047683|Niaspan
1226891|NCT01047683|ezetimibe
1226892|NCT01047683|Zetia
1226893|NCT01047683|ethyl-EPA
1226894|NCT01047683|ethyl icosapentate
1226895|NCT01047683|Crestor
1226896|NCT01047683|Zocor
1226897|NCT01047683|Lipitor
1226898|NCT01047683|LDL
1226899|NCT01047683|HDL
1226900|NCT01047683|cholesterol
1226901|NCT01047683|dyslipidemia
1226902|NCT01047683|VASCEPA
1226903|NCT01047683|icosapent ethyl
1226904|NCT01047670|sepsis, shock, adrenal insufficiency, hydrocortisone, children, paediatric intensive care.
1226905|NCT01047670|number of days free of vasoactive support in 7 days
1226906|NCT01047670|days free of mechanical ventilation
1226907|NCT01047670|PICU mortality
1226908|NCT01047670|mortality among patient with inappropriate response to the ACTH test
1226909|NCT01047670|baseline cortisol/ PIM2 correlation
1226910|NCT01047657|Asthma
1226911|NCT01047657|Obesity
1226912|NCT01047657|weight loss
1226913|NCT01047644|port
1226914|NCT01047644|catheter
1226915|NCT01047644|infusion
1226916|NCT01047644|flush
1226917|NCT01047644|cleanse
1226918|NCT01047644|chemotherapy
1226919|NCT01047618|venous thromboembolism
1226920|NCT01047605|qEEG
1226921|NCT01047605|herbal medicine
1226922|NCT01047605|cognitive function
1226923|NCT01047605|Neurapas balance
1226924|NCT01047605|Pascoflair
1226925|NCT01047605|hypericum
1226926|NCT01047605|passionflower
1226927|NCT01047605|valerian
1226928|NCT01047605|Healthy volunteers
1226929|NCT01047605|Influence on quantitative electro-encephalogram (qEEG).
1226930|NCT01047592|Schizophrenia
1226931|NCT01047592|cognitive function
1226932|NCT01047592|N-methyl-D-aspartate receptor
1226933|NCT01047579|Alzheimer's Disease
1226934|NCT01047579|Rivastigmine transdermal
1226935|NCT01047579|caregiver preference
1226936|NCT01047553|Chronic Obstructive Pulmonary Disease
1226937|NCT01047553|COPD
1226938|NCT01047553|Japanese
1226939|NCT01047553|Phase 3
1226940|NCT01047553|Safety
1226941|NCT01047553|OT
1226942|NCT01047553|Oxis
1226943|NCT01047527|nicotine replacement therapy, smoking cessation, transdermal nicotine
1226944|NCT01047501|hypertriglyceridemia
1226945|NCT01047501|omega-3 fatty acids
1226946|NCT01047501|statin
1226947|NCT01047501|triglycerides
1226948|NCT01047501|lipids
1226949|NCT01047501|EPA
1226950|NCT01047501|docosahexaenoic acid
1226951|NCT01047501|fish
1226952|NCT01047501|fatty acids
1226953|NCT01047501|fibrates
1226954|NCT01047501|niacin
1226955|NCT01047501|lipid
1226956|NCT01047501|atorvastatin
1226957|NCT01047501|Lovaza
1226958|NCT01047501|simvastatin
1226959|NCT01047501|lovastatin
1226960|NCT01047501|pravastatin
1226961|NCT01047501|fluvastatin
1226962|NCT01047501|rosuvastatin
1226963|NCT01047501|Trilipix
1226964|NCT01047501|Vytorin
1226965|NCT01047501|Simcor
1226966|NCT01047501|Niaspan
1226967|NCT01047501|ezetimibe
1226968|NCT01047501|Zetia
1226969|NCT01047501|ethyl-EPA
1226970|NCT01047501|ethyl icosapentate
1226971|NCT01047501|Crestor
1226972|NCT01047501|Zocor
1226973|NCT01047501|Lipitor
1226974|NCT01047501|LDL
1226975|NCT01047501|HDL
1226976|NCT01047501|cholesterol
1226977|NCT01047501|dyslipidemia
1226978|NCT01047501|VASCEPA
1226979|NCT01047501|icosapent ethyl
1226980|NCT01047488|polyneuropathy
1226981|NCT01047488|neuropathic pain
1226982|NCT01047488|treatment
1226983|NCT01047475|MB-6
1226984|NCT01047475|FOLFOX4
1226985|NCT01047475|Metastatic Colorectal Cancer
1226986|NCT01047449|saphenous vein graft patency
1226987|NCT01047449|fish oil supplementation
1226988|NCT01047449|coronary artery bypass surgery
1226989|NCT01047449|coronary artery disease
1226990|NCT01047436|Plasmodium infections
1226991|NCT01047436|Remittent fever
1226992|NCT01047436|Artemether
1226993|NCT01047436|Artemisinins
1226994|NCT01047436|quinine
1226995|NCT01047436|Malaria
1226996|NCT01047436|Protozoan Infections
1226997|NCT01047436|Anti-Infective Agents
1226998|NCT01047436|Antiprotozoal Agents
1226999|NCT01047436|Schistosomicides
1227000|NCT01047436|Pharmacologic Actions
1227001|NCT01047436|Malaria, Falciparum
1227002|NCT01047436|Antimalarials
1227003|NCT01047436|Antiparasitic Agents
1227004|NCT01047436|Parasitic Diseases
1227005|NCT01047436|sublingual
1227006|NCT01047423|Hypertension endothelial dysfunction statin prevention
1227007|NCT01047410|physical exercise training
1227008|NCT01047410|quality of life
1227009|NCT01047410|exercise capacity
1227010|NCT01047410|skeletal muscle strength
1227011|NCT01047410|physical activity level
1227012|NCT01047410|costeffectiveness
1227013|NCT01047410|renal transplantation
1227014|NCT01047410|hemodialysis
1227015|NCT01047410|peritoneal dialysis
1227016|NCT01047410|diet
1227017|NCT01047397|hemodialysis
1227018|NCT01047397|tolerability
1227019|NCT01047397|pharmacokinetics
1227020|NCT01047397|safety
1227021|NCT01047397|anemia
1227022|NCT01047397|renal impairment
1227023|NCT01047397|repeat dose
1227024|NCT01047345|Cervical cancer
1227025|NCT01047345|Genital warts
1227026|NCT01047345|Human papillomavirus vaccine
1227027|NCT01047345|GARDASIL™
1227028|NCT01047319|Relapsing Multiple Sclerosis
1227029|NCT01047293|colorectal cancer
1227030|NCT01047280|Conjugated linoleic acid
1227031|NCT01047280|Body weight
1227032|NCT01047280|Body composition
1227033|NCT01047280|Blood lipid profile
1227034|NCT01047280|Body inflammatory and oxidative status
1227035|NCT01047267|candidiasis
1227036|NCT01047267|invasive fungal disease
1227037|NCT01047267|critically ill
1227038|NCT01047267|anidulafungin
1227039|NCT01047267|pharmacokinetics
1227040|NCT01047241|Painful medical procedures
1227041|NCT01047215|schizophrenia
1227042|NCT01047215|bipolar
1227043|NCT01047215|aripiprazole
1227044|NCT01047215|quetiapine
1227045|NCT01047189|Mild to moderate acne vulgaris
1227046|NCT01047176|Statins
1227047|NCT01047176|Coronary Heart Disease
1227048|NCT01047176|Percutaneous coronary intervention (PCI)
1227049|NCT01047163|Muscle soreness
1227050|NCT01047163|Simvastatin
1227051|NCT01047163|Men
1227052|NCT01047163|Muscle Atrophy
1227053|NCT01047150|Myocardial Perfusion Imaging
1227054|NCT01047150|Repeat studies
1227055|NCT01047150|Tetrofosmin
1227056|NCT01047150|Sestamibi
1227057|NCT01047137|Urticaria
1227058|NCT01047137|Hives
1227059|NCT01047137|Stress
1227060|NCT01047137|Immune dysregulation
1227061|NCT01047124|Depression
1227062|NCT01047124|Collaborative Care
1227063|NCT01047124|Cognitive Behaviour Therapy
1227064|NCT01047124|Mental Health Services
1227065|NCT01047124|Antidepressants
1227066|NCT01047111|Esophageal Neoplasms
1227067|NCT01047111|Esophagectomy
1227068|NCT01047098|Lactation
1227069|NCT01047098|Breastfeeding
1227070|NCT01047098|Iron
1227071|NCT01047098|Oxidative stress
1227072|NCT01047098|Iron status and oxidative stress during lactation
1227073|NCT01047085|cholecystolithiasis
1227074|NCT01047085|cholecystectomy
1227075|NCT01047085|gastroesophageal reflux
1227076|NCT01047085|impedance pH
1227077|NCT01047085|The relationship between cholecystolithiasis, cholecystectomy and gastroesophageal reflux by impedance pH-method.
1227078|NCT01047072|Scleroderma, systemic sclerosis, allogeneic hematopoietic stem cell transplantation
1227079|NCT01047059|NSCLC
1227080|NCT01047059|Lung Cancer
1227081|NCT01047046|SNM device
1227082|NCT01047046|Chart review of patients with surgical placed SNM device
1227083|NCT01047033|Poverty
1227084|NCT01047033|Global health
1227085|NCT01047033|International health
1227086|NCT01047033|Latin America
1227087|NCT01047033|Peru
1227088|NCT01047033|Child health
1227089|NCT01047033|Microcredit
1227090|NCT01047033|Microenterprise
1227091|NCT01047033|Microfinance
1227092|NCT01047020|Impairments of musculoskeletal Health;
1227093|NCT01047020|Physical activity;
1227094|NCT01047020|Motor Proficiency;
1227095|NCT01047007|Head and Neck Cancer
1227096|NCT01047007|Esophageal Cancer
1227097|NCT01047007|Gastric Cancer
1227098|NCT01046981|Surgical site infections
1227099|NCT01046981|Prevention
1227100|NCT01046981|Prophylaxis
1227101|NCT01046981|Tumescent
1227102|NCT01046981|Intravenous
1227103|NCT01046981|Antibiotic
1227104|NCT01046981|Absorption
1227105|NCT01046981|Pharmacokinetics
1227106|NCT01046981|Bioavailability
1227107|NCT01046968|Obesity
1227108|NCT01046968|metabolic syndrome
1227109|NCT01046968|C-reactive protein
1227110|NCT01046968|Leptin
1227111|NCT01046955|ESRD
1227112|NCT01046942|Saphenous vein
1227113|NCT01046942|Antiplatelet therapy
1227114|NCT01046942|Hypercoagulable
1227115|NCT01046942|Clopidogrel resistance
1227116|NCT01046942|Aspirin resistance
1227117|NCT01046942|Clopidogrel
1227118|NCT01046942|Aspirin
1227119|NCT01046942|Saphenous vein graft disease
1227120|NCT01046942|TEG
1227121|NCT01046942|Thrombelastography
1227122|NCT01046942|Multiplate aggregometry
1227123|NCT01046942|Multislice CT
1227124|NCT01046942|Coronary artery bypass graft surgery
1227125|NCT01046942|coagulation status
1227126|NCT01046942|graft patency
1227127|NCT01046942|CABG
1227128|NCT01046929|limonene
1227129|NCT01046929|breast cancer
1227130|NCT01046929|cancer prevention
1227131|NCT01046903|observational prolonged thromboprophylaxis
1227132|NCT01046890|Darunavir
1227133|NCT01046890|Echinacea purpurea
1227134|NCT01046890|Interaction
1227135|NCT01046890|Complementary Therapies
1227136|NCT01046864|Gastro-Intestinal Cancer, NOS
1227137|NCT01046838|Diastolic Heart Failure
1227138|NCT01046825|Lymphoma
1227139|NCT01046825|Leukemia
1227140|NCT01046825|Non-Hodgkin's Lymphoma
1227141|NCT01046812|questionnaire
1227142|NCT01046812|halitosis
1227143|NCT01046812|caphosol
1227144|NCT01046812|Quality of life questionnaire assessing halitosis
1227145|NCT01046799|hepatitis B
1227146|NCT01046799|liver transplantation
1227147|NCT01046799|shortterm HBIg
1227148|NCT01046799|lamivudine resistance
1227149|NCT01046786|spinal cord injury
1227150|NCT01046786|cord blood mononuclear cell
1227151|NCT01046786|Methylprednisolone
1227152|NCT01046786|Lithium Carbonate
1227153|NCT01046773|Children
1227154|NCT01046773|Crohn's disease
1227155|NCT01046773|Vitamin D
1227156|NCT01046760|epilepsy
1227157|NCT01046760|language
1227158|NCT01046760|childhood
1227159|NCT01046760|praxis
1227160|NCT01046747|external fixation
1227161|NCT01046747|pin tract infection
1227162|NCT01046747|self drilling
1227163|NCT01046734|Influenza
1227164|NCT01046734|virus shedding
1227165|NCT01046734|infection control
1227166|NCT01046734|swine flu
1227167|NCT01046721|blood pressure
1227168|NCT01046721|superior mesenteric artery blood flow
1227169|NCT01046721|cardiovascular effects
1227170|NCT01046721|Exenatide
1227171|NCT01046708|IUI
1227172|NCT01046708|clomiphene citrate
1227173|NCT01046708|utrogestan
1227174|NCT01046695|VATS
1227175|NCT01046695|Video-Assisted Thoracotomy
1227176|NCT01046695|Thoracic Surgery, Video-Assisted
1227177|NCT01046682|HIV
1227178|NCT01046682|Endothelial dysfunction
1227179|NCT01046682|Inflammation
1227180|NCT01046682|Insulin resistance
1227181|NCT01046656|nosocomial infection
1227182|NCT01046656|diarrhea
1227183|NCT01046656|Lactobacillus reuteri
1227184|NCT01046656|gastroenteritis
1227185|NCT01046656|rotavirus
1227186|NCT01046643|Women
1227187|NCT01046643|Healthy
1227188|NCT01046643|Menopausal
1227189|NCT01046643|Hormone treatment
1227190|NCT01046630|Phase I
1227191|NCT01046630|BOLD signal
1227192|NCT01046630|fMRI
1227193|NCT01046630|AZD6765
1227194|NCT01046630|BOLD signal measured by fMRI
1227195|NCT01046617|infantile colic
1227196|NCT01046617|Lactobacillus reuteri
1227197|NCT01046617|duration of crying
1227198|NCT01046604|mitral valve regurgitation
1227199|NCT01046604|omega 3 fatty acids
1227200|NCT01046604|fish oil
1227201|NCT01046604|cardiac
1227202|NCT01046604|mitochondria
1227203|NCT01046604|apoptosis
1227204|NCT01046604|human heart
1227205|NCT01046591|Cleft Palate
1227206|NCT01046591|Cleft Lip
1227207|NCT01046591|Obstructive Sleep Apnea
1227208|NCT01046591|Sleep-Disordered Breathing
1227209|NCT01046591|Behavior
1227210|NCT01046591|Learning
1227211|NCT01046578|Folliculogenesis
1227212|NCT01046578|Letrozole
1227213|NCT01046578|Aromatase Inhibitor
1227214|NCT01046578|Estrogen
1227215|NCT01046552|Choledocholithias
1227216|NCT01046552|Common bile duct stones
1227217|NCT01046552|Endoscopic retrograde cholangiopancreatography
1227218|NCT01046552|endoscopic sphincterotomy
1227219|NCT01046552|Preoperative
1227220|NCT01046552|intraoperative
1227221|NCT01046552|Laparoscopic common bile duct exploration
1227222|NCT01046526|Psychopathology
1227223|NCT01046526|Nicotine Patch
1227224|NCT01046526|Eye Tracking
1227225|NCT01046526|Attention
1227226|NCT01046526|Schizophrenic Participants
1227227|NCT01046513|Nicotinic Acetylcholine Receptors
1227228|NCT01046513|Neuroimaging
1227229|NCT01046513|Positron Emission Tomography (PET)
1227230|NCT01046513|Alpha4beta2
1227231|NCT01046513|Nicotine
1227232|NCT01046513|Receptor Upregulation
1227233|NCT01046500|insulin resistance
1227234|NCT01046500|body mass index
1227235|NCT01046500|myo-inositol
1227236|NCT01046500|serum triglycerides and cholesterol
1227237|NCT01046500|blood pressure
1227238|NCT01046500|metformin
1227239|NCT01046487|dermatofibrosarcoma
1227240|NCT01046487|cylindroma
1227241|NCT01046487|choroid melanoma
1227242|NCT01046487|gastrointestinal stroma tumor
1227243|NCT01046487|chordoma
1227244|NCT01046487|ocular melanoma
1227245|NCT01046487|conjunctival melanoma
1227246|NCT01046487|malignant melanoma of the anus
1227247|NCT01046487|gastric melanoma
1227248|NCT01046487|desmoid tumor
1227249|NCT01046474|school children
1227250|NCT01046474|body mass index
1227251|NCT01046474|sugar intake
1227252|NCT01046474|beverage intake
1227253|NCT01046461|Ramosetron
1227254|NCT01046461|aprepitant
1227255|NCT01046461|dexamethasone
1227256|NCT01046461|cancer
1227257|NCT01046461|chemotherapy
1227258|NCT01046461|antiemetics
1227259|NCT01046461|cisplatin
1227260|NCT01046461|nausea
1227261|NCT01046461|vomiting
1227262|NCT01046461|high dose cisplatin
1227263|NCT01046448|Children
1227264|NCT01046448|chronic renal failure
1227265|NCT01046448|chronic kidney disease
1227266|NCT01046448|cardiovascular disease
1227267|NCT01046448|cardiovascular morbidity
1227268|NCT01046448|left ventricular hypertrophy
1227269|NCT01046448|carotid intima media thickness
1227270|NCT01046448|arterial stiffness
1227271|NCT01046448|pulse wave velocity
1227272|NCT01046448|augmentation index
1227273|NCT01046448|left ventricular cardiac function
1227274|NCT01046448|progression
1227275|NCT01046448|genetic risk factors
1227276|NCT01046448|vasculopathy
1227277|NCT01046448|cardiopathy
1227278|NCT01046448|whole genome analysis
1227279|NCT01046448|haplotype analysis
1227280|NCT01046448|SNP-screening
1227281|NCT01046435|periodontitis
1227282|NCT01046435|cardiovascular disease
1227283|NCT01046435|diabetes
1227284|NCT01046409|Coronary artery disease
1227285|NCT01046409|Bifurcation
1227286|NCT01046409|Myocardial infarction
1227287|NCT01046409|Myocardial ischemia
1227288|NCT01046409|Collateral
1227289|NCT01046383|NON-SMALL CELL LUNG CANCER PATIENTS
1227290|NCT01046383|WEIGHT LOSS
1227291|NCT01046383|QUALITY OF LIFE
1227292|NCT01046383|SURVIVAL
1227293|NCT01046383|CHEMOTHERAPY
1227294|NCT01046383|RADIOTHERAPY
1227295|NCT01046383|SURGERY
1227296|NCT01046383|CYSTEINE-RICH WHEY PROTEIN ISOLATE
1227297|NCT01046383|IMN1207
1227298|NCT01046383|CANCER-RELATED WASTING (CACHEXIA)
1227299|NCT01046383|BODY WEIGHT
1227300|NCT01046383|NUTRITIONAL PROTEIN SUPPLEMENT
1227301|NCT01046357|First in human
1227302|NCT01046357|Safety
1227303|NCT01046305|Chronic Myeloid Leukemia
1227304|NCT01046305|CML
1227305|NCT01046305|Symptom Burden
1227306|NCT01046305|M. D. Anderson Symptom Inventory
1227307|NCT01046305|MDASI-CML
1227308|NCT01046305|Severity
1227309|NCT01046305|Interference
1227310|NCT01046305|Questionnaire
1227311|NCT01046305|Interview
1227312|NCT01046292|Gait, Ginkgo biloba, mild cognitive impairment
1227313|NCT01046253|Bioequivalence
1227314|NCT01046253|Healthy Subjects
1227315|NCT01046240|chemotherapy
1227316|NCT01046240|emesis
1227317|NCT01046240|palonosetron
1227318|NCT01046227|Serology
1227319|NCT01046227|Monovalent inactivated H1N1 vaccine
1227320|NCT01046227|Pediatric haemato-oncology patients
1227321|NCT01046188|Education
1227322|NCT01046188|Internet
1227323|NCT01046188|In vitro fertilization
1227324|NCT01046175|Respiratory complications
1227325|NCT01046175|respiratory insufficiency
1227326|NCT01046175|respiratory therapy
1227327|NCT01046162|Alprazolam
1227328|NCT01046162|Tafil
1227329|NCT01046162|Xanax
1227330|NCT01046162|Bioequivalence
1227331|NCT01046162|Drug Kinetics
1227332|NCT01046149|Depression
1227333|NCT01046149|Depressive Symptoms
1227334|NCT01046149|postmenopause
1227335|NCT01046149|RSA biofeedback
1227336|NCT01046136|common cold
1227337|NCT01046097|Pneumococcal vaccine
1227338|NCT01046084|Bioequivalence
1227339|NCT01046084|Healthy Subjects
1227340|NCT01046071|Transversus abdominis plane block, postoperative pain.
1227341|NCT01046058|TMC435-TiDP16-C113
1227342|NCT01046058|TMC435-C113
1227343|NCT01046058|TMC435
1227344|NCT01046058|HCV
1227345|NCT01046058|Protease Inhibitor
1227346|NCT01046058|Hepatitis C
1227347|NCT01046045|mammalian target-of-rapamycin inhibitors
1227348|NCT01046045|chronic allograft dysfunction
1227349|NCT01046045|everolimus
1227350|NCT01046045|calcineurin inhibitors
1227351|NCT01046032|Polycystic ovaries
1227352|NCT01046032|Ovarian stimulation
1227353|NCT01046032|IVF
1227354|NCT01046032|Ovarian hyperstimulation
1227355|NCT01046032|Metformin
1227356|NCT01046019|DXA
1227357|NCT01046019|Hip
1227358|NCT01046019|Arthroplasty
1227359|NCT01046006|lymphoma
1227360|NCT01046006|Bortezomib
1227361|NCT01046006|Rituximab
1227362|NCT01045993|Pilot Study to Assess Methodologies
1227363|NCT01045980|Peritoneal dialysis
1227364|NCT01045980|Impedance, bioelectric
1227365|NCT01045980|Hypertrophy, left ventricular
1227366|NCT01045980|Fluid status
1227367|NCT01045980|Volume overload
1227368|NCT01045980|Congestive heart failure
1227369|NCT01045980|Cardiovascular outcomes
1227370|NCT01045980|Randomized controlled trial
1227371|NCT01045967|Bioequivalence
1227372|NCT01045967|Healthy Subjects
1227373|NCT01045954|diabetes mellitus type 1
1227374|NCT01045954|continuous glucose monitoring
1227375|NCT01045941|Distal Pancreas
1227376|NCT01045941|Adenocarcinoma
1227377|NCT01045941|Laparoscopic
1227378|NCT01045941|Gemcitabine
1227379|NCT01045915|Stage IIIB, stage IIIC or stage IV melanoma
1227380|NCT01045915|Progressive melanoma not responding to previous treatments
1227381|NCT01045902|Pulmonary Abscess
1227382|NCT01045902|Aspiration Pneumonia
1227383|NCT01045889|HIV
1227384|NCT01045889|non hodgkin lymphoma
1227385|NCT01045889|peripheral blood stem cell transplantation
1227386|NCT01045876|Randomized controlled trial
1227387|NCT01045876|Dexamethasone
1227388|NCT01045876|Single dose
1227389|NCT01045876|Preoperative
1227390|NCT01045876|Plasma Cortisol level
1227391|NCT01045863|volunteer
1227392|NCT01045850|coronary stents
1227393|NCT01045850|non cardiac surgery
1227394|NCT01045850|cardiovascular complications
1227395|NCT01045850|hemorrhagic complications
1227396|NCT01045850|antiplatelet agents
1227397|NCT01045850|bare metal stent
1227398|NCT01045850|drug eluting stent
1227399|NCT01045850|surgery
1227400|NCT01045837|Celiac disease, steroids, immunohistochemistry
1227401|NCT01045824|Schizophrenia
1227402|NCT01045824|DNA
1227403|NCT01045824|MRI
1227404|NCT01045811|Depression
1227405|NCT01045811|Depressive Symptoms
1227406|NCT01045811|postmenopause
1227407|NCT01045811|RSA biofeedback
1227408|NCT01045798|Candidiasis
1227409|NCT01045798|Invasive Candidiasis
1227410|NCT01045798|Fungal Infection
1227411|NCT01045798|Empirical Therapy
1227412|NCT01045785|aspirin resistance, platelet function assay, dialysis, end stage renal disease
1227413|NCT01045772|Schnitler syndrome, Muckle-Wells syndrome, anti-IL-1
1227414|NCT01045759|VENOUS THROMBOSIS
1227415|NCT01045759|ultrasonography
1227416|NCT01045759|intensive care unit
1227417|NCT01045746|whole-body vibration
1227418|NCT01045746|stochastic resonance Therapy
1227419|NCT01045746|static balance
1227420|NCT01045746|balance, mobility
1227421|NCT01045746|elderly, reaction time
1227422|NCT01045746|The focus of the study is effect of SRT on postural balance
1227423|NCT01045733|Cataract
1227424|NCT01045733|Toric
1227425|NCT01045733|IOL
1227426|NCT01045733|AcrySof
1227427|NCT01045733|LRI
1227428|NCT01045733|Astigmatism
1227429|NCT01045720|Schizophrenia
1227430|NCT01045720|clozapine
1227431|NCT01045720|hypersalivation
1227432|NCT01045720|Suo Quan Wan
1227433|NCT01045720|Wu Lin San
1227434|NCT01045694|Carpometacarpal Joints
1227435|NCT01045694|Osteoarthritis
1227436|NCT01045694|Basal thumb joint arthritis
1227437|NCT01045694|Trapeziometacarpal arthritis
1227438|NCT01045681|Multiple Myeloma
1227439|NCT01045681|Elderly patients
1227440|NCT01045681|first relapse
1227441|NCT01045681|refractory to first line therapy
1227442|NCT01045681|Bendamustine Velcade Dexamethasone Association
1227443|NCT01045655|Depression
1227444|NCT01045655|Perinatal care
1227445|NCT01045655|Postpartum period
1227446|NCT01045655|Pregnancy
1227447|NCT01045655|Female
1227448|NCT01045655|Low-income population
1227449|NCT01045642|Bioequivalence
1227450|NCT01045642|Omeprazole
1227451|NCT01045642|Crossover
1227452|NCT01045629|schizophrenia
1227453|NCT01045629|PANSS
1227454|NCT01045603|Instanyl
1227455|NCT01045603|non-interventional
1227456|NCT01045603|breakthrough cancer pain
1227457|NCT01045603|BTP
1227458|NCT01045603|BTCP
1227459|NCT01045603|Intranasal fentanyl spray
1227460|NCT01045577|Severe Psoriasis
1227461|NCT01045577|Kinase Inhibitor
1227462|NCT01045577|Masitinib
1227463|NCT01045564|Immunogenicity
1227464|NCT01045564|Vaccines
1227465|NCT01045564|H5N1
1227466|NCT01045564|Influenza
1227467|NCT01045564|Pandemic
1227468|NCT01045564|Human
1227469|NCT01045564|Avian
1227470|NCT01045564|Safety
1227471|NCT01045551|Inflammatory rosacea
1227472|NCT01045551|Papules and pustules
1227473|NCT01045551|Moderate to severe erythema
1227474|NCT01045551|Telangiectasia
1227475|NCT01045538|gastric cancer
1227476|NCT01045538|histone deacetylase inhibitor
1227477|NCT01045538|1st line chemotherapy
1227478|NCT01045525|Phlebotomy
1227479|NCT01045525|Dysmetabolic liversiderosis
1227480|NCT01045525|Hepatic Iron overload
1227481|NCT01045512|immunosenescence
1227482|NCT01045512|heart rate variability
1227483|NCT01045512|autonomic nervous system
1227484|NCT01045512|ageing
1227485|NCT01045512|inflammatory/pathogen burden
1227486|NCT01045512|physical activity
1227487|NCT01045499|adolescent obesity surgery
1227488|NCT01045499|bariatric surgery
1227489|NCT01045499|adjustable gastric banding
1227490|NCT01045486|Atopic dermatitis
1227491|NCT01045486|Food allergy
1227492|NCT01045486|Probiotics
1227493|NCT01045473|MIS
1227494|NCT01045473|Minimally Invasive Spine Surgery
1227495|NCT01045473|Fusion
1227496|NCT01045473|Spine
1227497|NCT01045473|SMISS
1227498|NCT01045460|Patients with active myeloma (Stage II/III) that have completed induction therapy and are eligible for an autologous stem cell transplant
1227499|NCT01045434|Bioequivalence
1227500|NCT01045434|omeprazole
1227501|NCT01045434|crossover
1227502|NCT01045421|NSCLC
1227503|NCT01045421|SCLC
1227504|NCT01045421|HNSCC
1227505|NCT01045408|Helicobacter pylori
1227506|NCT01045408|Berry extract
1227507|NCT01045408|Triple therapy
1227508|NCT01045395|Algae
1227509|NCT01045395|Psoriasis
1227510|NCT01045395|Lipid metabolism
1227511|NCT01045395|Inflammation
1227512|NCT01045395|Oxidative stress
1227513|NCT01045382|HSC transplantation
1227514|NCT01045382|HLA-mismatched
1227515|NCT01045382|Mesenchymal stem cells
1227516|NCT01045382|GVHD
1227517|NCT01045382|co-infusion
1227518|NCT01045369|HIV
1227519|NCT01045369|Treatment Naive
1227520|NCT01045343|heart failure
1227521|NCT01045343|home monitoring
1227522|NCT01045343|integrated diagnostics
1227523|NCT01045343|Cardiac Resynchronization Therapy with Defibrillator (CRT D)
1227524|NCT01045317|micro-dose
1227525|NCT01045317|pharmacokinetics
1227526|NCT01045317|open label
1227527|NCT01045317|PF-04776548
1227528|NCT01045278|Hepatitis C patients
1227529|NCT01045278|Hepacivirus
1227530|NCT01045252|hemodynamics
1227531|NCT01045252|neonatal
1227532|NCT01045239|Diabetic macular edema
1227533|NCT01045239|Diabetic macular oedema
1227534|NCT01045239|micropulse laser
1227535|NCT01045239|laser treatment
1227536|NCT01045239|macular thickness
1227537|NCT01045213|Chronic obstructive pulmonary disease
1227538|NCT01045213|COPD
1227539|NCT01045200|rectal cancer
1227540|NCT01045200|follow-up
1227541|NCT01045200|specialist nurse
1227542|NCT01045187|endometrial cancer
1227543|NCT01045187|Uterine cancer
1227544|NCT01045187|electronic brachytherapy
1227545|NCT01045187|Xoft
1227546|NCT01045174|Asthma
1227547|NCT01045174|Pediatric
1227548|NCT01045174|Emergency department
1227549|NCT01045174|Nebulizer
1227550|NCT01045161|Chronic Obstructive Pulmonary Disease
1227551|NCT01045161|COPD
1227552|NCT01045161|Chronic Bronchitis
1227553|NCT01045161|Emphysema
1227554|NCT01045161|Airflow Obstruction, Chronic
1227555|NCT01045161|Chronic Airflow Obstruction
1227556|NCT01045161|Chronic Obstructive Airway Disease
1227557|NCT01045161|Chronic Obstructive Lung Disease
1227558|NCT01045148|Prostatic Cancer
1227559|NCT01045148|Prostatic Neoplasms
1227560|NCT01045148|Prostate Neoplasms
1227561|NCT01045148|Cancer of the Prostate
1227562|NCT01045135|Pelvic organ prolapse
1227563|NCT01045135|Levator hiatus
1227564|NCT01045135|3 and 4 dimensional ultrasound
1227565|NCT01045122|Obstructive Sleep Apnea
1227566|NCT01045109|prostate
1227567|NCT01045109|cancer
1227568|NCT01045109|vitamin D3
1227569|NCT01045109|early stage
1227570|NCT01045109|active surveillance
1227571|NCT01045096|Gastroesophageal Reflux
1227572|NCT01045096|Erosive Esophagitis
1227573|NCT01045096|Pharmacokinetics
1227574|NCT01045096|Pediatrics
1227575|NCT01045096|Drug Therapy
1227576|NCT01045070|periodontitis and coronary heart disease
1227577|NCT01045057|voice prosthesis, larynx cancer, laryngectomy
1227578|NCT01045044|Breast cancer
1227579|NCT01045044|Magnetic Resonance Imaging
1227580|NCT01045044|Anthracycline based systemic chemotherapy
1227581|NCT01045044|Tumor response
1227582|NCT01045044|Cognitive Impairment
1227583|NCT01045044|Chemo Brain
1227584|NCT01045031|cognitive function, aging, brain-derived neurotrophic factor
1227585|NCT01045018|colitis
1227586|NCT01045018|ulcerative
1227587|NCT01045018|ulcerative colitis
1227588|NCT01045005|Type 1 diabetes
1227589|NCT01045005|Endothelial dysfunction
1227590|NCT01045005|Doppler Ultrasound Velocity Waveforms
1227591|NCT01044992|Multi systemic atrophy
1227592|NCT01044992|Parkinson Disease
1227593|NCT01044992|PET investigation
1227594|NCT01044992|Motor control
1227595|NCT01044992|levodopa
1227596|NCT01044992|MSA
1227597|NCT01044992|Comparison with Parkinson disease and dopaminergic challenge.
1227598|NCT01044979|Colloid osmotic pressure in interstitial fluid
1227599|NCT01044979|Colloid osmotic pressure in plasma
1227600|NCT01044979|Protein fractions in interstitial fluid
1227601|NCT01044966|Glioblastoma
1227602|NCT01044966|Subventricular
1227603|NCT01044966|gliomagenesis
1227604|NCT01044966|temozolomide
1227605|NCT01044966|depocyt
1227606|NCT01044953|injury incidence
1227607|NCT01044953|male professional soccer
1227608|NCT01044953|Change of injury incidence in professional soccer
1227609|NCT01044940|Colloid Osmotic pressure in interstitial fluid
1227610|NCT01044940|Colloid Osmotic pressure in plasma
1227611|NCT01044940|Protein fractions in interstitial fluid
1227612|NCT01044927|Chronic obstructive pulmonary disease
1227613|NCT01044927|telemedicine
1227614|NCT01044927|COPD
1227615|NCT01044901|Sickle Cell Disease
1227616|NCT01044901|Cardiac magnetic resonance imaging
1227617|NCT01044901|Coronary Disease
1227618|NCT01044901|Pulmonary Hypertension
1227619|NCT01044888|Heparin responsiveness
1227620|NCT01044888|Off-pump coronary artery bypass graft surgery
1227621|NCT01044888|Risk factors
1227622|NCT01044888|Myocardial infarction
1227623|NCT01044875|Diabetic retinopathy
1227624|NCT01044875|Laser treatment
1227625|NCT01044875|Complications
1227626|NCT01044875|Laser wavelength
1227627|NCT01044862|Pregnancy
1227628|NCT01044862|Infertility
1227629|NCT01044862|Ovarian stimulation
1227630|NCT01044862|Aromatase inhibitors
1227631|NCT01044862|Follicle Stimulating Hormone
1227632|NCT01044849|Blood Pressure
1227633|NCT01044836|Healthy volunteer
1227634|NCT01044823|RA
1227635|NCT01044823|JRA
1227636|NCT01044810|HIV
1227637|NCT01044810|efavirenz
1227638|NCT01044810|nevirapine
1227639|NCT01044810|allergy
1227640|NCT01044810|rash
1227641|NCT01044810|Cohort Studies, Historical
1227642|NCT01044810|Retrospective Study
1227643|NCT01044810|exanthem
1227644|NCT01044810|Antiretroviral Agents
1227645|NCT01044810|Highly Active Antiretroviral Therapy
1227646|NCT01044810|HAART
1227647|NCT01044810|treatment failure
1227648|NCT01044797|Healthy Volunteer
1227649|NCT01044797|Given Capsule Manipulation
1227650|NCT01044784|CRT
1227651|NCT01044771|HIV
1227652|NCT01044771|Human immunodeficiency virus
1227653|NCT01044771|tenofovir
1227654|NCT01044771|viread
1227655|NCT01044771|truvada
1227656|NCT01044771|proteinuria
1227657|NCT01044758|Mild Cognitive Impairment
1227658|NCT01044758|Amnestic Mild Cognitive Impairment
1227659|NCT01044758|Functional Magnetic Resonance Imaging
1227660|NCT01044758|Levetiracetam
1227661|NCT01044758|Keppra
1227662|NCT01044758|Medial Temporal Lobe
1227663|NCT01044758|Memory Impairment
1227664|NCT01044758|Alzheimer's Disease
1227665|NCT01044758|AD
1227666|NCT01044732|Colorectal
1227667|NCT01044732|Neoplasms
1227668|NCT01044732|Adenomas
1227669|NCT01044732|Polyps
1227670|NCT01044732|Miss rates
1227671|NCT01044732|Detection rates
1227672|NCT01044732|Colonoscope
1227673|NCT01044732|Third Eye Retroscope
1227674|NCT01044706|Bioequivalency
1227675|NCT01044693|supine Hypertension
1227676|NCT01044693|autonomic failure
1227677|NCT01044693|nitric oxide
1227678|NCT01044693|nebivolol
1227679|NCT01044680|fiber
1227680|NCT01044680|metabolic syndrome
1227681|NCT01044680|overweight
1227682|NCT01044680|satiety
1227683|NCT01044654|HIV
1227684|NCT01044654|Treatment Experienced
1227685|NCT01044641|Colloid Osmotic pressure in interstitial fluid
1227686|NCT01044641|Colloid Osmotic pressure in plasma
1227687|NCT01044641|Protein fractions in interstitial fluid
1227688|NCT01044628|COPD
1227689|NCT01044628|CANOX
1227690|NCT01044628|Oxygen therapy
1227691|NCT01044628|Nocturnal
1227692|NCT01044628|Desaturation
1227693|NCT01044615|Mild Traumatic Brain Injury
1227694|NCT01044615|Concussion
1227695|NCT01044615|Magnetic Resonance Imaging (MRI)
1227696|NCT01044615|Positron Emission Tomography(PET)
1227697|NCT01044615|Computed Tomography (CT)
1227698|NCT01044602|Obesity
1227699|NCT01044602|Type 2 Diabetes Mellitus
1227700|NCT01044602|Roux-en-Y Gastric Bypass Surgery
1227701|NCT01044576|Multiple Sclerosis
1227702|NCT01044563|Depression
1227703|NCT01044563|Depressive Symptoms
1227704|NCT01044563|postmenopause
1227705|NCT01044563|RSA biofeedback
1227706|NCT01044550|Diaphragm injury
1227707|NCT01044550|Herniation
1227708|NCT01044537|phase 1
1227709|NCT01044537|safety and tolerability
1227710|NCT01044537|PK
1227711|NCT01044537|PD
1227712|NCT01044537|type 2 diabetes mellitus
1227713|NCT01044537|T2DM
1227714|NCT01044524|14C labeled ADME (Aborption Distribution Metabolism and Elimination) study
1227715|NCT01044524|Phase I
1227716|NCT01044511|Esophageal cancer
1227717|NCT01044511|Cardia cancer
1227718|NCT01044511|Health Related quality of Life
1227719|NCT01044511|SEMS
1227720|NCT01044511|Home visits
1227721|NCT01044485|HER-2 positive advanced or metastatic breast cancer
1227722|NCT01044485|dose escalation study
1227723|NCT01044485|lapatinib
1227724|NCT01044485|docetaxel
1227725|NCT01044472|CRT-D
1227726|NCT01044459|Chronic Obstructive Pulmonary Disease
1227727|NCT01044459|COPD
1227728|NCT01044459|Chronic Bronchitis
1227729|NCT01044459|Emphysema
1227730|NCT01044459|Airflow Obstruction, Chronic
1227731|NCT01044459|Chronic Airflow Obstruction
1227732|NCT01044459|Chronic Obstructive Airway Disease
1227733|NCT01044459|Chronic Obstructive Lung Disease
1227734|NCT01044446|peritoneal dialysis
1227735|NCT01044446|peritonitis
1227736|NCT01044446|CAPD
1227737|NCT01044446|end-stage renal disease
1227738|NCT01044446|peritonitis outcome and ultrafiltration
1227739|NCT01044407|respiration
1227740|NCT01044407|sleep apnea
1227741|NCT01044407|pacemaker
1227742|NCT01044394|colonoscopy
1227743|NCT01044394|bowel preparation
1227744|NCT01044394|polyethylene glycol
1227745|NCT01044394|Quality in endoscopy
1227746|NCT01044394|Bowel Preparation for colonoscopy
1227747|NCT01044381|Toenail
1227748|NCT01044381|Fungal Infections
1227749|NCT01044381|DSO
1227750|NCT01044368|Remote Blood Glucose Monitoring System, Type 2 Diabetes
1227751|NCT01044355|Resistant Hypertension
1227752|NCT01044355|Obstructive Sleep Apnea
1227753|NCT01044355|24 Hour Blood Pressure
1227754|NCT01044355|Arterial Stiffness
1227755|NCT01044355|Insulin Resistance
1227756|NCT01044355|CPAP
1227757|NCT01044355|APAP
1227758|NCT01044342|Healthy Volunteers
1227759|NCT01044342|EEG
1227760|NCT01044316|Haemophilus influenzae type b (Hib)
1227761|NCT01044316|Vaccine
1227762|NCT01044316|Booster
1227763|NCT01044303|Kidney Transplantation
1227764|NCT01044303|Mycophenolic Acid
1227765|NCT01044303|Donor-Specific Antibodies
1227766|NCT01044303|Kidney Rejection
1227767|NCT01044290|quality of life
1227768|NCT01044290|end of life
1227769|NCT01044290|self-disclosure
1227770|NCT01044290|palliative care
1227771|NCT01044277|glutathione
1227772|NCT01044277|gluthathione peroxidases
1227773|NCT01044277|GSH
1227774|NCT01044264|Acne Vulgaris
1227775|NCT01044264|bioequivalency
1227776|NCT01044264|clindamycin
1227777|NCT01044264|benzoyl peroxide
1227778|NCT01044251|Medication overuse headache
1227779|NCT01044251|Rebound headache
1227780|NCT01044251|Analgesic overuse headache
1227781|NCT01044251|Transitional therapy
1227782|NCT01044251|Frovatriptan
1227783|NCT01044251|Migraine
1227784|NCT01044238|methamphetamine
1227785|NCT01044238|methylphenidate
1227786|NCT01044238|clinical trial
1227787|NCT01044238|random assignment
1227788|NCT01044238|double blind
1227789|NCT01044238|abstinence
1227790|NCT01044238|reduction in methamphetamine use
1227791|NCT01044225|newly diagnosed glioblastoma
1227792|NCT01044212|Urogynecology
1227793|NCT01044199|rabies
1227794|NCT01044199|rabies vaccine
1227795|NCT01044199|purified cultured embryo chicken rabies vaccine
1227796|NCT01044186|Deferasirox
1227797|NCT01044186|ICL670A
1227798|NCT01044186|Iron chelators
1227799|NCT01044186|Deferiprone
1227800|NCT01044186|Transfusional hemosiderosis
1227801|NCT01044186|Congenital aplastic anemia (Diamond Blackfan anemia)
1227802|NCT01044186|Red cell aplasia
1227803|NCT01044186|Thalassemia
1227804|NCT01044186|β thalassemia
1227805|NCT01044173|acute abdomen
1227806|NCT01044173|CT
1227807|NCT01044173|MRI
1227808|NCT01044173|fast imaging
1227811|NCT01044147|Obesity
1227812|NCT01044147|Internet
1227813|NCT01044121|mattress
1227814|NCT01044121|pain
1227815|NCT01044121|sleep
1227816|NCT01044121|low back pain
1227817|NCT01044121|back
1227818|NCT01044121|neck
1227819|NCT01044121|arousal
1227820|NCT01044121|pillow
1227821|NCT01044121|kingsdown
1227822|NCT01044121|sleep to live
1227823|NCT01044121|duke university
1227824|NCT01044121|sleep to live institute
1227825|NCT01044121|missouri
1227826|NCT01044121|springfield
1227827|NCT01044121|joplin
1227828|NCT01044121|body diagnostic
1227829|NCT01044121|dormo diagnostic
1227830|NCT01044121|morning pain
1227831|NCT01044095|seasonal influenza vaccine
1227832|NCT01044095|avian influenza H5N1
1227833|NCT01044095|cross reactivity
1227834|NCT01044095|prime boost
1227835|NCT01044082|Postpartum haemorrhage
1227836|NCT01044082|Third stage of labour
1227837|NCT01044082|Controlled cord traction
1227838|NCT01044082|Randomized controlled trial
1227839|NCT01044082|Prevention
1227840|NCT01044069|Cyclophosphamide
1227841|NCT01044069|T cell
1227842|NCT01044069|leukapheresis
1227843|NCT01044069|stem cell transplant
1227844|NCT01044069|bone marrow transplant
1227845|NCT01044069|09-114
1227846|NCT01044030|otitis media
1227847|NCT01044030|ear infection
1227848|NCT01043991|STEMI
1227849|NCT01043991|AMI,
1227850|NCT01043991|acute myocardial infarct
1227851|NCT01043991|Epo
1227852|NCT01043991|Erythropoietin
1227853|NCT01043991|ischemia-reperfusion
1227854|NCT01043991|apoptosis
1227855|NCT01043965|Diabetes Mellitus
1227856|NCT01043965|Myocardial perfusion imaging
1227857|NCT01043965|Heart diseases
1227858|NCT01043965|Echocardiography
1227859|NCT01043965|Endothelium
1227860|NCT01043952|Propofol
1227861|NCT01043952|Remifentanil
1227862|NCT01043952|Bispectral Index Monitor
1227863|NCT01043939|childhood cancers
1227864|NCT01043939|cardiovascular disease
1227865|NCT01043939|childhood cancer survivor
1227866|NCT01043926|Hepatic Insufficiency
1227867|NCT01043913|Fatigue
1227868|NCT01043913|Breast Neoplasms
1227869|NCT01043913|Quality of Life
1227870|NCT01043913|Paullinia
1227871|NCT01043900|Obsessive-Compulsive Disorder
1227872|NCT01043900|rTMS
1227873|NCT01043900|Transcranial Magnetic Stimulation
1227874|NCT01043900|treatment
1227875|NCT01043900|randomized controlled trials
1227876|NCT01043887|Healthy Volunteers
1227877|NCT01043887|Hepatic Insufficiency
1227878|NCT01043874|Chronic phase
1227879|NCT01043874|Chronic myelogenous leukemia
1227880|NCT01043874|CML
1227881|NCT01043874|Philadelphia chromosome positive
1227882|NCT01043874|Ph+
1227883|NCT01043874|Nilotinib
1227884|NCT01043874|CML-CP
1227885|NCT01043874|Suboptimal molecular response
1227886|NCT01043848|neurogenic detrusor overactivity
1227887|NCT01043848|neuromodulation
1227888|NCT01043848|spinal cord injury
1227889|NCT01043848|pudendal nerve stimulation
1227890|NCT01043848|videocystometry
1227891|NCT01043848|neurophysiology
1227892|NCT01043848|neuroplasticity
1227893|NCT01043835|Stomach Neoplasm
1227894|NCT01043835|Laparoscopy
1227895|NCT01043835|gastrectomy
1227896|NCT01043822|Autism
1227897|NCT01043822|mental retardation
1227898|NCT01043822|pain
1227899|NCT01043822|emotion
1227900|NCT01043822|sensory profile
1227901|NCT01043822|children
1227902|NCT01043809|schools
1227903|NCT01043809|handwashing
1227904|NCT01043809|prevention and control
1227905|NCT01043809|communicable diseases
1227906|NCT01043809|absenteeism
1227907|NCT01043796|Insecticide treated wall liners
1227908|NCT01043796|Insecticide treated nets
1227909|NCT01043796|Incidence cohort
1227910|NCT01043783|Obesity
1227911|NCT01043770|Metabolic syndrome
1227912|NCT01043770|Primary prevention
1227913|NCT01043770|Diabetes
1227914|NCT01043770|Cardiovascular disease
1227915|NCT01043770|Patient education
1227916|NCT01043757|Sedentary lifestyle
1227917|NCT01043757|physical exercise
1227918|NCT01043757|behavioral economics
1227919|NCT01043757|financial incentives
1227920|NCT01043757|obesity
1227921|NCT01043744|malaria
1227922|NCT01043744|presumptive treatment
1227923|NCT01043744|Integrated Management of Childhood Illness
1227924|NCT01043744|fever
1227925|NCT01043718|Obesity
1227926|NCT01043718|Internet
1227927|NCT01043705|Pacemaker infection
1227928|NCT01043705|Defibrillator infection
1227929|NCT01043705|ICD infection
1227930|NCT01043705|CRT infection
1227931|NCT01043705|Cardiovascular implantable electronic device infection
1227932|NCT01043705|Infection
1227933|NCT01043705|Pacemaker, Artificial
1227934|NCT01043705|Defibrillators
1227935|NCT01043692|Chronic Pain > 3 months
1227936|NCT01043692|Acupuncture
1227937|NCT01043692|Acceptability
1227938|NCT01043692|Geriatrics
1227939|NCT01043679|Bipolar, Mania
1227940|NCT01043679|Utapine
1227941|NCT01043679|Seroquel
1227942|NCT01043666|Micturition
1227943|NCT01043666|YM178
1227944|NCT01043666|Urinary incontinence
1227945|NCT01043666|Frequency
1227946|NCT01043666|Overactive Bladder
1227947|NCT01043666|Urgency
1227948|NCT01043666|Urinary urge incontinence
1227949|NCT01043653|recovery
1227950|NCT01043653|serious mental illness
1227951|NCT01043640|inherited metabolic disorders
1227952|NCT01043614|Obesity
1227953|NCT01043614|Obesity Prevention
1227954|NCT01043614|Freshman women
1227955|NCT01043614|Freshman 15 weight gain
1227956|NCT01043614|Self efficacy
1227957|NCT01043614|Activity and nutrition intervention
1227958|NCT01043614|Peer education
1227959|NCT01043588|Surgery
1227960|NCT01043588|Prostate
1227961|NCT01043588|Laser 532 nm
1227962|NCT01043588|Photo selective Vaporization of the Prostate (PVP)
1227963|NCT01043588|TransUrethral Resection of the Prostate (TURP)
1227964|NCT01043588|Men health
1227965|NCT01043575|rifapentine, pharmacokinetics, pharmacodynamics, tuberculosis
1227966|NCT01043549|Gilles de la Tourette syndrome
1227967|NCT01043549|Tics
1227968|NCT01043549|Transcranial magnetic stimulation
1227969|NCT01043536|IMRT
1227970|NCT01043536|Radiotherapy escalation dose
1227971|NCT01043536|glioblastoma
1227972|NCT01043536|escalation radiotherapy dose
1227973|NCT01043523|Liver neoplasms
1227974|NCT01043523|Adenoma
1227975|NCT01043523|Liver cell carcinoma
1227976|NCT01043523|Hepatocellular
1227977|NCT01043523|Liver abscess
1227978|NCT01043484|Resectable rectal cancer
1227979|NCT01043484|Radiotherapy
1227980|NCT01043484|Bevacizumab
1227981|NCT01043484|Capecitabine
1227982|NCT01043471|Obesity
1227983|NCT01043458|Pharmacokinetics
1227984|NCT01043445|GPR 119
1227985|NCT01043445|GLP-1 secretion
1227986|NCT01043445|2-oleoyl-glycerol
1227987|NCT01043445|Dietary supplementation
1227988|NCT01043432|Traumatic Brain Injury
1227989|NCT01043432|Suicide
1227990|NCT01043432|Executive Function
1227991|NCT01043419|Xenon Anesthesia
1227992|NCT01043419|LENOXe™ (xénon 100 % v/v) anesthesia
1227993|NCT01043419|Muscle Sympathetic Activity
1227994|NCT01043419|Baroreflex reagibility
1227995|NCT01043406|Epilepsy
1227996|NCT01043406|Seizures
1227997|NCT01043406|Advisory
1227998|NCT01043406|Prediction
1227999|NCT01043393|Plaque psoriasis
1228000|NCT01043380|Heart Diseases
1228001|NCT01043380|Hyperlipidemia
1228002|NCT01043380|Atorvastatin
1228003|NCT01043380|Ezetimibe
1228004|NCT01043380|Cardiovascular Diseases
1228005|NCT01043380|Hypercholesterolemia
1228006|NCT01043380|Coronary Artery Disease
1228007|NCT01043380|Dyslipidemias
1228008|NCT01043380|Intravascular Ultrasound
1228009|NCT01043367|Depression
1228010|NCT01043367|Dietary supplement
1228011|NCT01043367|Deprexil
1228012|NCT01043354|cholesterol
1228013|NCT01043354|diabetes
1228014|NCT01043354|adherence
1228015|NCT01043341|HPV
1228016|NCT01043341|vaccines
1228017|NCT01043341|knowledge
1228018|NCT01043341|attitude
1228019|NCT01043328|human papillomavirus
1228020|NCT01043328|nested PCR
1228021|NCT01043328|saliva
1228022|NCT01043328|serum
1228023|NCT01043328|oral tissues
1228024|NCT01043315|Cognitive Function
1228025|NCT01043315|Cognitive Impairment
1228026|NCT01043315|Hospitalization
1228027|NCT01043315|Cardiac Disease
1228028|NCT01043302|lymphoma, intestine, outcome, quality of life
1228029|NCT01043289|light therapy
1228030|NCT01043289|antepartum depression
1228031|NCT01043289|controlled trial
1228032|NCT01043276|Healthy
1228033|NCT01043250|schizophrenia
1228034|NCT01043250|atypical antipsychotics
1228035|NCT01043250|appetite
1228036|NCT01043250|eating behavior
1228037|NCT01043237|acoustic
1228038|NCT01043237|digital
1228039|NCT01043237|sound
1228040|NCT01043237|vibration
1228041|NCT01043237|coronary
1228042|NCT01043237|auscultation
1228043|NCT01043237|artery
1228044|NCT01043237|diagnosis
1228045|NCT01043211|Back Pain
1228046|NCT01043211|Lidocaine
1228047|NCT01043198|CGH array technology
1228048|NCT01043198|mental retardation
1228049|NCT01043198|chromosomal abnormalities
1228050|NCT01043198|syndromic obesity
1228051|NCT01043198|obesity
1228052|NCT01043185|GERD
1228053|NCT01043185|lesogaberan
1228054|NCT01043185|impedance
1228055|NCT01043185|pH
1228056|NCT01043185|pharmacokinetics
1228057|NCT01043185|safety
1228058|NCT01043185|tolerability
1228059|NCT01043146|anti-beta1 adrenergic receptor
1228060|NCT01043146|autoantibody
1228061|NCT01043146|cyclic peptide
1228062|NCT01043146|heart failure
1228063|NCT01043133|electronic medical records
1228064|NCT01043133|documentation templates
1228065|NCT01043133|clinical encounter notes
1228066|NCT01043081|African American women who have sex with women
1228067|NCT01043081|Sexually transmitted infections
1228068|NCT01043081|Homosexuality
1228069|NCT01043081|Human papillomavirus
1228070|NCT01043081|Cervical intraepithelial neoplasia
1228071|NCT01043081|Herpes simplex virus types 1 and 2
1228072|NCT01043081|Chlamydia
1228073|NCT01043081|Gonorrhea
1228074|NCT01043081|Trichomoniasis
1228075|NCT01043081|Bacterial vaginosis
1228076|NCT01043081|Syphilis
1228077|NCT01043081|Human immunodeficiency virus
1228078|NCT01043068|cancer pain
1228079|NCT01043068|opioid
1228080|NCT01043068|guideline
1228081|NCT01043055|Breast Cancer Screening
1228082|NCT01043042|hypoglycemia among inpatients
1228083|NCT01043042|hyperglycemia among inpatients
1228084|NCT01043016|skin cancer
1228085|NCT01043016|esophageal cancer
1228086|NCT01043016|photodynamic therapy
1228087|NCT01042990|Stroke
1228088|NCT01042990|Exercise
1228089|NCT01042990|Balance
1228090|NCT01042990|Dynamic Gait
1228091|NCT01042990|Cardiovascular Fitness
1228092|NCT01042977|dapagliflozin
1228093|NCT01042977|diabetes
1228094|NCT01042977|cardiovascular disease
1228095|NCT01042964|platelet adhesion and aggregation
1228096|NCT01042964|acute coronary syndrome
1228097|NCT01042964|myocardial infarction
1228098|NCT01042964|stroke
1228099|NCT01042964|inhibition of platelet adhesion to plaques
1228100|NCT01042964|collagen-induced platelet aggregation
1228101|NCT01042951|safety
1228102|NCT01042951|immunogenicity
1228103|NCT01042951|Healthy Participants
1228104|NCT01042938|Radiation dermatitis in breast cancer patients
1228105|NCT01042925|HER2 positive breast cancer
1228106|NCT01042925|breast cancer
1228107|NCT01042925|breast tumors
1228108|NCT01042925|human mammary carcinoma
1228109|NCT01042912|diagnosis
1228110|NCT01042912|carotid
1228111|NCT01042912|artery
1228112|NCT01042912|disease
1228113|NCT01042912|auscultation
1228114|NCT01042912|sound
1228115|NCT01042899|TBI
1228116|NCT01042899|intracranial edema
1228117|NCT01042899|brain edema
1228118|NCT01042899|craniocerebral trauma
1228119|NCT01042899|head injury
1228120|NCT01042899|brain hemorrhage, traumatic
1228121|NCT01042899|subdural hematoma
1228122|NCT01042899|brain concussion
1228123|NCT01042899|head injuries, closed
1228124|NCT01042899|epidural hematoma
1228125|NCT01042899|extra-axial hemorrhage
1228126|NCT01042899|cortical contusion
1228127|NCT01042899|wounds and injuries
1228128|NCT01042899|disorders of environmental origin
1228129|NCT01042899|trauma, nervous system
1228130|NCT01042899|brain injuries
1228131|NCT01042886|Non-blind, randomized controlled trial
1228132|NCT01042886|Pilot study
1228133|NCT01042873|Desensitization
1228134|NCT01042873|beta adrenergic receptors
1228135|NCT01042873|Healthy subjects
1228136|NCT01042860|macular pigment
1228137|NCT01042860|lutein
1228138|NCT01042860|age-related macular degeneration
1228139|NCT01042860|AMD
1228140|NCT01042847|ovarian
1228141|NCT01042834|air pollution
1228142|NCT01042834|autonomic nervous system
1228143|NCT01042834|sleep apnea
1228144|NCT01042834|Heart rate variability
1228145|NCT01042834|Healthy volunteers
1228146|NCT01042821|anal fistula
1228147|NCT01042821|advancement flap
1228148|NCT01042821|incontinence
1228149|NCT01042795|sunitinib
1228150|NCT01042795|bladder neoplasm
1228151|NCT01042795|adjuvant treatment
1228152|NCT01042795|disease free survival
1228153|NCT01042795|Patients with extravesical tumor (pT2-4,Nany, M0 or pTanyN+M0) after cystectomy and platin-based neoadjuvant chemotherapy
1228154|NCT01042782|gastric cancer
1228155|NCT01042782|RAD001
1228156|NCT01042782|Mitomycin C
1228157|NCT01042782|MTD
1228158|NCT01042743|colon cancer
1228159|NCT01042743|robot
1228160|NCT01042743|laparoscopy
1228161|NCT01042743|primary, right-side colon cancer
1228162|NCT01042743|robot-assisted surgery
1228163|NCT01042730|Pitavastatin
1228164|NCT01042730|Coronary Artery Disease
1228165|NCT01042730|Cardiovascular Disease
1228166|NCT01042717|plerixafor
1228167|NCT01042717|autologous transplantation
1228168|NCT01042717|hematopoietic stem cell mobilization
1228169|NCT01042717|multiple myeloma
1228170|NCT01042717|non-Hodgkins lymphoma
1228171|NCT01042704|Relapsed Myeloma
1228172|NCT01042704|Refractory Myeloma
1228173|NCT01042665|Glaucoma
1228174|NCT01042665|intraocular pressure
1228175|NCT01042665|latanoprost
1228176|NCT01042665|retinal ganglion cell
1228177|NCT01042665|pattern electroretinogram
1228178|NCT01042652|Methadone
1228179|NCT01042652|HIV
1228180|NCT01042652|Raltegravir
1228181|NCT01042652|Antiretroviral
1228182|NCT01042652|Intravenous Drug User
1228183|NCT01042652|Methadone Maintenance
1228184|NCT01042652|Treatment Naive
1228185|NCT01042639|osteopenia
1228186|NCT01042639|very low birthweight infants
1228187|NCT01042639|bone speed of sound
1228188|NCT01042639|quantitative ultrasound
1228189|NCT01042626|Receptors, Calcium sensing
1228190|NCT01042626|Parathyroid Hormone
1228191|NCT01042613|AccuVein AV300 device;
1228192|NCT01042613|Intravenous cannulation
1228193|NCT01042600|Respiratory distress syndrome
1228194|NCT01042600|Surfactant
1228195|NCT01042600|Tracheal intubation
1228196|NCT01042600|Laryngeal mask airway
1228197|NCT01042600|Newborn
1228198|NCT01042587|bright light therapy
1228199|NCT01042587|circadian rhythm,
1228200|NCT01042587|entrainment
1228201|NCT01042574|intracranial hemorrhage (ICH)
1228202|NCT01042574|subarachnoid hemorrhage (SAH)
1228203|NCT01042574|intracranial monitoring
1228204|NCT01042574|external ventricular drain (ventriculostomy)
1228205|NCT01042574|hypertension
1228206|NCT01042561|vitamin d
1228207|NCT01042561|prematurity
1228208|NCT01042561|25(OH)D
1228209|NCT01042561|infant
1228210|NCT01042561|CRP
1228211|NCT01042561|PTH
1228212|NCT01042548|Proteomics
1228213|NCT01042548|Breast Cancer Markers
1228214|NCT01042548|Tissue Interstitial Fluid
1228215|NCT01042509|Chronic Graft vs Host Disease
1228216|NCT01042509|Alemtuzumab
1228217|NCT01042509|Rituximab
1228218|NCT01042509|Low-dose
1228219|NCT01042509|Alemtuzumab and rituximab combination
1228220|NCT01042496|Bipolar
1228221|NCT01042496|depression
1228222|NCT01042483|active stage
1228223|NCT01042483|labor
1228224|NCT01042483|progression
1228225|NCT01042483|pregnant women during active phases of labor
1228226|NCT01042470|pelvic organ prolapse
1228227|NCT01042470|pelvic floor dysfunction
1228228|NCT01042470|biomechanics
1228229|NCT01042470|aspiration device
1228230|NCT01042470|connective tissue
1228231|NCT01042457|trough level
1228232|NCT01042457|therapeutic drug monitoring
1228233|NCT01042457|Mycophenolate mofetil
1228234|NCT01042457|Mycophenolic acid
1228235|NCT01042457|lupus nephritis
1228236|NCT01042444|Heart disease
1228237|NCT01042444|Embolic Protection Device
1228238|NCT01042444|PCI
1228239|NCT01042444|SVG
1228240|NCT01042431|Nutritional status of ward patients and hospitalization outcome
1228241|NCT01042418|satiety
1228242|NCT01042418|grain structure
1228243|NCT01042418|rye
1228244|NCT01042392|Moderate systolic hypertension - adults - aliskiren -ramipril
1228245|NCT01042379|I-SPY 2
1228246|NCT01042379|Neoadjuvant
1228247|NCT01042379|Breast
1228248|NCT01042379|Cancer
1228249|NCT01042379|Neoplasm
1228250|NCT01042379|Adaptive
1228251|NCT01042379|pCR
1228617|NCT01041079|GI hemorrhage
1228252|NCT01042379|Pathologic Complete Response
1228253|NCT01042379|Biomarkers signature
1228254|NCT01042379|MRI Volume
1228255|NCT01042366|Melanoma
1228256|NCT01042340|nutrition
1228257|NCT01042340|geriatric
1228258|NCT01042340|supplement
1228259|NCT01042340|energy
1228260|NCT01042327|solute clearances
1228261|NCT01042288|Non-Small-Cell Lung Cancer
1228262|NCT01042288|NSCLC
1228263|NCT01042288|Panitumumab
1228264|NCT01042288|Vectibix
1228265|NCT01042288|Pemetrexed
1228266|NCT01042288|Alimta
1228267|NCT01042288|Carboplatin
1228268|NCT01042275|stress urinary incontinence
1228269|NCT01042275|retropubic sling
1228270|NCT01042275|transobturator sling
1228271|NCT01042275|tension-free vaginal tape
1228272|NCT01042275|transobturator tape
1228273|NCT01042275|TVT
1228274|NCT01042275|TVT-O
1228275|NCT01042275|TOT
1228276|NCT01042275|REMEEX
1228277|NCT01042275|IVS
1228278|NCT01042262|Superoxide dismutase
1228279|NCT01042262|Oxygen
1228280|NCT01042262|Oxygen free radicals
1228281|NCT01042262|Labor and delivery
1228282|NCT01042249|PFMT
1228283|NCT01042249|Stroke
1228284|NCT01042249|LUTS
1228285|NCT01042249|Men
1228286|NCT01042236|Phase 2 stress urinary incontinence Fesoterodine
1228287|NCT01042223|Factors Predisposing or Causing
1228288|NCT01042210|preeclampsia
1228289|NCT01042210|agouti-related peptide
1228290|NCT01042210|intrauterine growth
1228291|NCT01042210|birth weight
1228292|NCT01042210|Intrauterine growth restriction due to preeclampsia
1228293|NCT01042197|Vitamin D
1228294|NCT01042197|UVB
1228295|NCT01042197|Dose-Response
1228296|NCT01042197|Body surface area
1228297|NCT01042184|H. pylori infected patients without prior eradication therapy
1228298|NCT01042158|Tadalafil
1228299|NCT01042158|Ambrisentan
1228300|NCT01042158|Quality of Life
1228301|NCT01042145|Primary Care
1228302|NCT01042145|Treatment
1228303|NCT01042145|Croup
1228304|NCT01042145|Corticosteroids
1228305|NCT01042145|Prednisone
1228306|NCT01042145|Dexamethasone
1228307|NCT01042145|Randomized trial
1228308|NCT01042132|intramedullary reaming
1228309|NCT01042132|inflammatory response
1228310|NCT01042132|human
1228311|NCT01042132|femoral shaft fracture
1228312|NCT01042132|Reamer-irrigator-aspirator
1228313|NCT01042119|botulinum neurotoxin type A
1228314|NCT01042119|BoNT/A
1228315|NCT01042119|Botox
1228316|NCT01042119|overactive bladder syndrome
1228317|NCT01042106|diabetes
1228318|NCT01042093|Analgesia
1228319|NCT01042093|postoperative pain
1228320|NCT01042093|periarticular
1228321|NCT01042093|arthroplasty
1228322|NCT01042093|pain management
1228323|NCT01042080|Mechanical ventilation
1228324|NCT01042080|Neurally adjusted ventilatory assist (NAVA)
1228325|NCT01042080|Acute respiratory failure
1228326|NCT01042080|Chronic obstructive pulmonary disease
1228327|NCT01042080|Weaning
1228328|NCT01042080|Invasive mechanical ventilation
1228329|NCT01042080|Positive Pressure support Ventilation
1228330|NCT01042067|warfarin
1228331|NCT01042067|genotyping
1228332|NCT01042067|vitamin K
1228333|NCT01042067|dosing
1228334|NCT01042067|adverse events
1228335|NCT01042067|initial phase of treatment
1228336|NCT01042067|algorithm
1228337|NCT01042054|Postoperative Care
1228338|NCT01042054|Enhanced
1228339|NCT01042054|Recovery
1228340|NCT01042054|Hepatectomy
1228341|NCT01042054|Analgesia
1228342|NCT01042028|Pancreas cancer
1228343|NCT01042028|Everolimus
1228344|NCT01042028|Irinotecan
1228345|NCT01042028|Cetuximab
1228346|NCT01042028|Capecitabine
1228347|NCT01042028|Oxaliplatin
1228348|NCT01042028|Gemcitabine resistant pancreascancer
1228349|NCT01042015|trauma
1228350|NCT01042015|cardiac arrest
1228351|NCT01042015|hemorrhagic shock
1228352|NCT01042002|High intensity exercise
1228353|NCT01042002|morbid obesity
1228354|NCT01042002|gastric bypass
1228355|NCT01041989|dementia
1228356|NCT01041989|cognitive impairment
1228357|NCT01041989|disability
1228358|NCT01041989|intervention
1228359|NCT01041989|elderly
1228360|NCT01041989|lifestyle counseling
1228361|NCT01041976|Veterans
1228362|NCT01041976|Vocational Rehabilitation
1228363|NCT01041963|ACEI
1228364|NCT01041963|ARB
1228365|NCT01041963|CAPD
1228366|NCT01041963|Peritoneal membrane transport
1228367|NCT01041950|intracerebral hemorrhage
1228368|NCT01041950|intraventricular hemorrhage
1228369|NCT01041950|hydrocephalus
1228370|NCT01041950|Intracerebral hemorrhage with severe ventricular involvement and obstructive hydrocephalus
1228371|NCT01041924|Sleep apnea
1228372|NCT01041924|Periodic breathing
1228373|NCT01041924|Heart Failure
1228374|NCT01041911|Hemorrhoids
1228375|NCT01041898|osteocalcin
1228376|NCT01041898|insulin
1228377|NCT01041898|body composition
1228378|NCT01041898|bone mineral density
1228379|NCT01041898|Evaluate the effect of osteocalcin on bone mineral density
1228380|NCT01041898|Evaluate the effect of osteocalcin on body fat distribution
1228381|NCT01041898|Evaluate the effect of osteocalcin on insulin homeostasis
1228382|NCT01041885|knee cartilage defect repair
1228383|NCT01041885|cartilage lesion
1228384|NCT01041885|autologous chondrocyte
1228385|NCT01041885|scaffold
1228386|NCT01041885|INSTRUCT
1228387|NCT01041859|Diabetic Peripheral Neuropathy
1228388|NCT01041859|Painful
1228389|NCT01041859|Polyneuropathy
1228390|NCT01041859|Peripheral neuropathy
1228391|NCT01041846|Myelodysplastic Syndrome
1228392|NCT01041846|Dacogen
1228393|NCT01041846|Decitabine
1228394|NCT01041846|Epigenetic therapy
1228395|NCT01041846|Hypomethylating agent
1228396|NCT01041833|All-trans retinoic acid
1228397|NCT01041833|non-small cell lung cancer
1228398|NCT01041833|retinoic acid receptor beta
1228399|NCT01041820|exercise
1228400|NCT01041820|bone marrow adipose tissue
1228401|NCT01041820|bone mineral density
1228402|NCT01041820|Children in the intervention condition will complete a supervised physical activity program 3 days/wk for 10 weeks
1228403|NCT01041820|Control treatment will be provided no intervention
1228404|NCT01041820|All participants will be instructed not to change their current dietary habits during the study period.
1228405|NCT01041807|Hypertension
1228406|NCT01041794|body composition
1228407|NCT01041794|fat distribution
1228408|NCT01041794|exercise
1228409|NCT01041794|diet
1228410|NCT01041781|adenocarcinoma of the lung
1228411|NCT01041781|adenosquamous cell lung cancer
1228412|NCT01041781|large cell lung cancer
1228413|NCT01041781|squamous cell lung cancer
1228414|NCT01041781|recurrent non-small cell lung cancer
1228535|NCT01041300|Brainsway
1228415|NCT01041781|stage IIIB non-small cell lung cancer
1228416|NCT01041781|stage IV non-small cell lung cancer
1228417|NCT01041768|Type 2 Diabetes Mellitus
1228418|NCT01041755|Encephalopathy
1228419|NCT01041755|Cirrhosis
1228420|NCT01041716|Carbapenem
1228421|NCT01041716|Klebsiella pneumoniae carbapenemase
1228422|NCT01041716|Acinetobacter baumannii
1228423|NCT01041716|Pseudomonas aeruginosa
1228424|NCT01041690|Proliferative Diabetic Retinopathy
1228425|NCT01041690|Vitrectomy
1228426|NCT01041690|Bevacizumab
1228427|NCT01041677|Obesity
1228428|NCT01041677|Overweight
1228429|NCT01041677|Body Weight
1228430|NCT01041677|Body Size
1228431|NCT01041677|Nutritional and Metabolic Diseases
1228432|NCT01041664|nutrigenomics
1228433|NCT01041664|admixture
1228434|NCT01041664|Hispanic American
1228435|NCT01041664|body composition
1228436|NCT01041664|Association of diet and body composition
1228437|NCT01041664|Association between genes and body composition
1228438|NCT01041664|Association between gen by diet interaction and body composition
1228439|NCT01041625|Lichen Planus
1228440|NCT01041612|CBD
1228441|NCT01041612|HBD
1228442|NCT01041612|cancer of bile duct
1228443|NCT01041612|pancreatic cancer
1228444|NCT01041599|Diabetes Mellitus
1228445|NCT01041599|Hypertension
1228446|NCT01041599|Albuminuria
1228447|NCT01041599|vascular stiffness
1228448|NCT01041586|Emphysema
1228449|NCT01041586|COPD
1228450|NCT01041586|Lung Volume Reduction
1228451|NCT01041586|BTVA
1228452|NCT01041573|Pediatric
1228453|NCT01041573|Japanese Encephalitis Vaccine
1228454|NCT01041573|endemic countries
1228455|NCT01041573|to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51
1228456|NCT01041560|Stroke
1228457|NCT01041560|Tone
1228458|NCT01041560|Strength
1228459|NCT01041547|Insulin sensitivity
1228460|NCT01041547|Vascular function
1228461|NCT01041547|Flow-mediated dilation
1228462|NCT01041547|Arterial stiffness
1228463|NCT01041547|Glucose tolerance
1228464|NCT01041547|Hypertension
1228465|NCT01041534|Adjustable gastric band, morbid obesity, bariatric surgery
1228466|NCT01041521|HIV infection
1228467|NCT01041521|Dyslipidemia
1228468|NCT01041521|Elevated Triglyceride level
1228469|NCT01041521|vascular function (BART)
1228470|NCT01041521|arterial stiffness
1228471|NCT01041521|omega three fatty acids
1228472|NCT01041521|complementary therapies
1228473|NCT01041508|ALL
1228474|NCT01041508|AML
1228475|NCT01041508|Recurrence
1228476|NCT01041508|Relapsed
1228477|NCT01041508|Stem Cell Transplant
1228478|NCT01041508|Non-myeloablastive
1228479|NCT01041495|fibromyalgia
1228480|NCT01041495|Pain
1228481|NCT01041495|Sleep
1228482|NCT01041495|Fatigue
1228483|NCT01041482|sorafenib
1228484|NCT01041482|renal cell carcinoma
1228485|NCT01041482|disease free survival
1228486|NCT01041482|Hand food skin reaction
1228487|NCT01041469|Down syndrome, Humans,Clinical study,Immunity, Autoimmunity,
1228488|NCT01041456|complicated biliopancreatic diversion
1228489|NCT01041456|failed biliopancreatic diversion
1228490|NCT01041456|revision gastric bypass
1228491|NCT01041456|conversion bariatric surgery
1228492|NCT01041456|revision bariatric surgery
1228493|NCT01041456|re-operative bariatric surgery
1228494|NCT01041456|malabsorptive syndrome
1228495|NCT01041456|protein malnutrition
1228496|NCT01041456|metabolic bone disease
1228497|NCT01041430|Ambulatory Surgery
1228498|NCT01041430|Aged
1228499|NCT01041417|claudication
1228500|NCT01041391|Surgical intervention vs Non-Surgical intervention
1228501|NCT01041378|Pediatric patients (6 months-5 years) scheduled elective day-case orchiopexy
1228502|NCT01041365|insulin sensitivity
1228503|NCT01041365|vascular function
1228504|NCT01041365|flow-mediated dilation
1228505|NCT01041365|arterial stiffness
1228506|NCT01041365|ethnicity
1228507|NCT01041365|adolescents
1228508|NCT01041365|females
1228509|NCT01041365|glucose tolerance
1228510|NCT01041365|diabetes
1228511|NCT01041365|hypertension
1228512|NCT01041365|cardiovascular
1228513|NCT01041352|anaesthesia
1228514|NCT01041352|laryngeal mask
1228515|NCT01041352|prone position
1228516|NCT01041339|LpPLA2
1228517|NCT01041339|ST elevation
1228518|NCT01041339|acute pericarditis
1228519|NCT01041326|prostatectomy
1228520|NCT01041326|radiation
1228521|NCT01041326|neoadjuvant
1228522|NCT01041313|Adjuvants, pharmaceuticals
1228523|NCT01041313|Receptors, N-Methyl-D-Aspartate
1228524|NCT01041313|Drug tolerance
1228525|NCT01041313|Pain Measurement
1228526|NCT01041300|Transcranial Magnetic Stimulation
1228527|NCT01041300|TMS
1228528|NCT01041300|Motor Threashold
1228529|NCT01041300|Multiway
1228530|NCT01041300|Magstim Rapid 2
1228531|NCT01041300|Abductor policis brevis
1228532|NCT01041300|Figure 8 coil
1228533|NCT01041300|Double cone coil
1228534|NCT01041300|Circular coil
1228536|NCT01041300|Healthy participants.
1228537|NCT01041274|Schizophrenia
1228538|NCT01041274|Citalopram
1228539|NCT01041274|First episode
1228540|NCT01041274|fMRI
1228541|NCT01041274|Cognitive behavioral therapy
1228542|NCT01041274|Psychoeducation
1228543|NCT01041261|Laparoscopic gastric bypass surgery
1228544|NCT01041261|Medical food
1228545|NCT01041261|Body composition
1228546|NCT01041261|Dietary intervention
1228547|NCT01041248|Relapsing Polychondritis
1228548|NCT01041248|Single Patient Study
1228549|NCT01041248|Tocilizumab
1228550|NCT01041235|Solid Neoplasms
1228551|NCT01041235|Carcinoma
1228552|NCT01041235|Breast
1228553|NCT01041235|Ovarian
1228554|NCT01041235|Ovary
1228555|NCT01041235|Pancreas
1228556|NCT01041235|Pancreatic
1228557|NCT01041235|Lung
1228558|NCT01041235|NSCLC
1228559|NCT01041235|Non Small Cell Lung
1228560|NCT01041235|Prostate
1228561|NCT01041235|Gastric
1228562|NCT01041235|Head and Neck
1228563|NCT01041222|Familial ALS
1228564|NCT01041222|ALS
1228565|NCT01041222|SOD1 Protein
1228566|NCT01041222|ISIS 333611
1228567|NCT01041222|SOD1Rx
1228568|NCT01041209|Pneumonia
1228569|NCT01041209|Children
1228570|NCT01041196|obesity
1228571|NCT01041196|ulcer disease
1228572|NCT01041196|marginal ulcer
1228573|NCT01041196|perforation
1228574|NCT01041196|abdominal pain
1228575|NCT01041196|bariatric surgery
1228576|NCT01041196|weight loss surgery
1228577|NCT01041183|Oral plus IV ramosetron may be more effective than
1228578|NCT01041183|IV ramosetron and oral ramosetron for the prophylaxis of
1228579|NCT01041183|PONV after laparoscopic cholecystectomy
1228580|NCT01041170|Rimonabant
1228581|NCT01041170|fMRI
1228582|NCT01041170|Alternative Matrices
1228583|NCT01041170|Brain Imaging
1228584|NCT01041170|THC
1228585|NCT01041157|Torticollis
1228586|NCT01041157|Botulinum Toxins
1228587|NCT01041144|Diabetes
1228588|NCT01041144|PDA
1228589|NCT01041144|Internet
1228590|NCT01041144|HbA1c
1228591|NCT01041131|Obesity
1228592|NCT01041131|Obesity recidivism
1228593|NCT01041131|Inadequate Initial Weight Loss
1228594|NCT01041131|Technical bariatric complications
1228595|NCT01041131|Complicated gastroplasty
1228596|NCT01041131|Failed gastroplasty
1228597|NCT01041131|Gastroesophageal reflux disease
1228598|NCT01041131|Revisional gastric bypass
1228599|NCT01041131|Conversion bariatric surgery
1228600|NCT01041131|Re-operative bariatric surgery
1228601|NCT01041131|Technical complications of vertical gastroplasty
1228602|NCT01041131|Complicated vertical gastroplasty
1228603|NCT01041105|Obesity
1228604|NCT01041105|Gastroesophageal Reflux Disease
1228605|NCT01041105|Nissen funduplication
1228606|NCT01041105|Antireflux surgery
1228607|NCT01041105|Revisional Gastric Bypass
1228608|NCT01041105|Re-operative bariatric surgery
1228609|NCT01041105|Bariatric surgery
1228610|NCT01041105|Nissen
1228611|NCT01041105|Conversion of Nissen to Gastric Bypass
1228612|NCT01041079|ulcer disease
1228613|NCT01041079|marginal ulcer
1228614|NCT01041079|morbidity of gastric bypass
1228615|NCT01041079|late morbidity of gastric bypass
1228616|NCT01041079|chronic abdominal pain
1228618|NCT01041079|Perforation
1228619|NCT01041079|Penetration
1228620|NCT01041079|Obstruction
1228621|NCT01041066|patients who are intubated for general anesthesia
1228622|NCT01041040|Acute Myeloblastic Leukemia
1228623|NCT01041014|Limited English proficiency
1228624|NCT01041014|Cost-effectiveness
1228625|NCT01041014|Emergency Departments
1228626|NCT01041014|Language Discordance
1228627|NCT01041014|Satisfaction
1228628|NCT01041014|Limited English proficient patients
1228629|NCT01041014|Spanish-speaking patients
1228630|NCT01041001|Umbilical Cord Blood
1228631|NCT01041001|Mesenchymal Stem Cells
1228632|NCT01041001|cartilage injury
1228633|NCT01041001|osteoarthritis
1228634|NCT01040988|Pacemaker
1228635|NCT01040988|Implantable cardioverter-defibrillator
1228636|NCT01040962|neuropathy
1228637|NCT01040962|diabetes
1228638|NCT01040949|smoking cessation
1228639|NCT01040949|pregnant Latinas
1228640|NCT01040949|couples communication
1228641|NCT01040949|Latino community
1228642|NCT01040949|couples communication in Latino couples
1228643|NCT01040936|acute coronary syndrome
1228644|NCT01040936|intervention
1228645|NCT01040936|outcome
1228646|NCT01040936|patients diagnosed ad Non-ST elevation ACS
1228647|NCT01040936|patients received PCI therapy
1228648|NCT01040923|CAD
1228649|NCT01040923|Diagnostic
1228650|NCT01040910|cannabis
1228651|NCT01040910|Crohn's disease
1228652|NCT01040910|Ulcerative colitis
1228653|NCT01040910|IBD
1228654|NCT01040897|Obesity prevention
1228655|NCT01040897|Health Literacy
1228656|NCT01040897|Health Communication
1228657|NCT01040858|cognitive strategy intervention
1228658|NCT01040858|cognitive disorders
1228659|NCT01040845|healthy
1228660|NCT01040845|pharmacokinetics
1228661|NCT01040845|drug-interaction
1228662|NCT01040832|Head and Neck Cancer
1228663|NCT01040832|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer
1228664|NCT01040832|Cetuximab
1228665|NCT01040832|EMD 1201081
1228666|NCT01040819|Diabetes Mellitus
1228667|NCT01040819|6-Ketoprostaglandin F1 alpha
1228668|NCT01040819|15-epi-lipoxin A4
1228669|NCT01040819|Thiazolidinediones
1228670|NCT01040819|Pioglitazone
1228671|NCT01040806|Diabetes
1228672|NCT01040780|Efficacy
1228673|NCT01040780|Safety
1228674|NCT01040780|EGFR-TKI
1228675|NCT01040780|phase III
1228676|NCT01040780|NSCLC
1228677|NCT01040767|Ultrasound education
1228678|NCT01040767|Blended learning
1228679|NCT01040767|Distance education
1228680|NCT01040767|Trauma ultrasound
1228681|NCT01040767|FAST
1228682|NCT01040741|Pandemic influenza A (H1N1) vaccine
1228683|NCT01040741|Adjuvanted
1228684|NCT01040715|Rheumatoid arthritis
1228685|NCT01040715|anti-drug antibodies
1228686|NCT01040715|Rheumatoid arthritis with secondary loss of efficacy to anti-TNFa antagonists and anti-drug antibodies
1228687|NCT01040676|Diabetes Mellitus
1228688|NCT01040676|Telephone
1228689|NCT01040676|Nutrition Support
1228690|NCT01040676|Automated
1228691|NCT01040676|Low English Proficiency
1228692|NCT01040676|Hispanic
1228693|NCT01040676|Latino
1228694|NCT01040637|Healthy subjects
1228695|NCT01040624|Prostate Cancer, Proton Radiation
1228696|NCT01040611|music therapy
1228697|NCT01040611|Tuberculosis
1228698|NCT01040611|anxiety
1228699|NCT01040611|physiological response
1228700|NCT01040598|Eosinophilic Esophagitis
1228701|NCT01040598|Xolair
1228702|NCT01040598|Omalizumab
1228703|NCT01040598|Esophagitis
1228704|NCT01040598|Eosinophils
1228705|NCT01040598|monoclonal antibody
1228706|NCT01040585|cost effectiveness
1228707|NCT01040585|linezolid
1228708|NCT01040585|ventilator acquired pneumonia
1228709|NCT01040585|central america
1228710|NCT01040572|Obesity recidivism
1228711|NCT01040572|Weight Regain
1228712|NCT01040572|Weight recidivism
1228713|NCT01040572|Morbidity
1228714|NCT01040572|Complication
1228715|NCT01040572|Late complications
1228716|NCT01040572|Revisional gastric bypass
1228717|NCT01040572|Re-operative gastric bypass
1228718|NCT01040572|Revisional bariatric surgery
1228719|NCT01040572|Re-operative bariatric surgery
1228720|NCT01040546|Obesity
1228721|NCT01040546|Metabolic syndrome
1228722|NCT01040546|Weight control educational intervention
1228723|NCT01040546|Food intake
1228724|NCT01040533|Failed jejunoileal bypass
1228725|NCT01040533|Complicated jejunoileal bypass
1228726|NCT01040533|Revision gastric bypass
1228727|NCT01040533|Revisional surgery
1228728|NCT01040533|Reoperations
1228729|NCT01040533|Metabolic and nutritional complications
1228730|NCT01040520|CT-based autopsy
1228731|NCT01040520|virtual autopsy
1228732|NCT01040520|medical autopsy
1228733|NCT01040520|quality control
1228734|NCT01040507|severe obesity
1228735|NCT01040507|morbid obesity
1228736|NCT01040507|gastric bypass
1228737|NCT01040507|efficacy of gastric bypass
1228738|NCT01040494|Aliskiren
1228739|NCT01040494|Congestive heart failure
1228740|NCT01040494|Central hemodynamics
1228741|NCT01040481|Failed gastric bypass
1228742|NCT01040481|Malabsorptive distal gastric bypass
1228743|NCT01040481|Distal gastric bypass
1228744|NCT01040481|Malabsorptive gastric bypass
1228745|NCT01040481|Adding malabsorption
1228746|NCT01040481|Increasing malabsorption
1228747|NCT01040481|Re-operative bariatric surgery
1228748|NCT01040481|Revisional bariatric surgery
1228749|NCT01040481|Revisional gastric bypass
1228750|NCT01040481|Reoperations
1228751|NCT01040481|Conversions
1228752|NCT01040468|Type 2 Diabetes
1228753|NCT01040468|Bariatric Surgery
1228754|NCT01040468|Roux-en-Y Gastric Bypass
1228755|NCT01040468|Gastric Banding
1228756|NCT01040468|Obesity
1228757|NCT01040468|Weight loss
1228758|NCT01040468|Insulin sensitivity
1228759|NCT01040468|GLP-1
1228760|NCT01040468|Meal Challenge
1228761|NCT01040468|Euglycemic Clamp
1228762|NCT01040455|functional dyspepsia
1228763|NCT01040455|lansoprazole
1228764|NCT01040455|placebo effect
1228765|NCT01040442|Postural Balance
1228766|NCT01040442|Aging
1228767|NCT01040442|Accidental Falls
1228768|NCT01040442|Vibration
1228769|NCT01040429|Adolescent
1228770|NCT01040429|Clonidine
1228771|NCT01040429|Autonomic nervous system
1228772|NCT01040429|Stress
1228773|NCT01040416|complicated marginal ulcer
1228774|NCT01040416|complex marginal ulcer
1228775|NCT01040416|complication after gastric bypass
1228776|NCT01040416|gastrointestinal hemorrhage
1228777|NCT01040390|Acne Vulgaris
1228778|NCT01040390|Homoeopathy
1228779|NCT01040390|Lappa Arctium
1228780|NCT01040377|Inadequate Initial Weight Loss
1228781|NCT01040377|Inadequate weight loss
1228782|NCT01040377|Poor weight loss
1228783|NCT01040377|Failed gastric bypass
1228784|NCT01040377|Revision gastric bypass
1228785|NCT01040364|Internal hernia
1228786|NCT01040364|Mesocolic hernia
1228787|NCT01040364|Petersen´s hernia
1228788|NCT01040364|Jejunojejunostomy hernia
1228789|NCT01040364|Bowel obstruction
1228790|NCT01040364|Ischemic bowel
1228791|NCT01040364|Complication after gastric bypass
1228792|NCT01040364|Re-operative bariatric surgery
1228793|NCT01040364|Chronic pain after gastric bypass
1228794|NCT01040351|Infertility
1228795|NCT01040351|Hydrosalpinx
1228796|NCT01040351|IVF-ET
1228797|NCT01040338|Smoking
1228798|NCT01040338|Tobacco
1228799|NCT01040338|Nicotine
1228800|NCT01040338|Dependence
1228801|NCT01040338|Genetics
1228802|NCT01040312|UGT1A1, irinotecan
1228803|NCT01040299|GangTrainer
1228804|NCT01040299|Gait Rehabilitation
1228805|NCT01040299|Cerebrovascular Disorders
1228806|NCT01040299|Robot assisted
1228807|NCT01040299|Transcranial direct current stimulation
1228808|NCT01040286|Subjects, age>21, with Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal
1228809|NCT01040286|pockets of 5-9 mm in depth demonstrating bleeding on probing without involving the
1228810|NCT01040286|apex of the tooth and confirmed by dental X-ray.
1228811|NCT01040260|tobacco use disorder
1228812|NCT01040247|Infertility
1228813|NCT01040247|Low Responder
1228814|NCT01040247|IVF
1228815|NCT01040247|Embryo Transfer
1228816|NCT01040234|postoperative pain
1228817|NCT01040234|abdominal surgery
1228818|NCT01040234|bilateral dual TAP block
1228819|NCT01040221|Autism, Autism Spectrum Disorder
1228820|NCT01040221|ASD
1228821|NCT01040221|Trichuris Suis Ova
1228822|NCT01040221|TSO
1228823|NCT01040221|Treatment
1228824|NCT01040221|Clinical Trial
1228825|NCT01040195|ankylosing spondylitis
1228826|NCT01040195|undifferentiated spondyloarthropathy
1228827|NCT01040195|spondyloarthropathy
1228828|NCT01040195|inflammatory back pain
1228829|NCT01040195|methotrexate
1228830|NCT01040195|sulfasalazine
1228831|NCT01040195|hydroxychloroquine
1228832|NCT01040182|ischemic stroke patients
1228833|NCT01040143|Pneumococci
1228834|NCT01040143|Streptococcus pneumoniae
1228835|NCT01040117|Equilibrium
1228836|NCT01040117|Rehabilitation
1228837|NCT01040117|Randomized Controlled Trial
1228838|NCT01040117|Postural instability
1228839|NCT01040117|Sensory-motor integration
1228840|NCT01040104|wound healing
1228841|NCT01040104|hypertrophic scar
1228842|NCT01040104|skin transplantation
1228843|NCT01040104|diabetes mellitus
1228844|NCT01040091|HIV Seronegativity
1228845|NCT01040091|Treatment Experienced
1228846|NCT01040065|Acromioclavicular joint arthritis
1228847|NCT01040065|distal clavicle resection
1228848|NCT01040065|Mumford procedure
1228849|NCT01040052|Diphtheria
1228850|NCT01040052|Tetanus
1228851|NCT01040052|Pertussis
1228852|NCT01040052|Adacel®
1228853|NCT01040039|HCV
1228854|NCT01040039|HIV
1228855|NCT01040013|LAPAROSCOPY,
1228856|NCT01040013|LAPAROTOMY,
1228857|NCT01040013|OXYGENATION,
1228858|NCT01040013|ISCHEMIA-REPERFUSION INJURY
1228859|NCT01040000|NPC-1C
1228860|NCT01040000|Monoclonal antibody
1228861|NCT01040000|Pancreatic Cancer
1228862|NCT01040000|Adenocarcinoma of the pancreas
1228863|NCT01040000|Ductal carcinoma of the pancreas
1228864|NCT01040000|Duct cell carcinomas, pancreas
1228865|NCT01040000|Carcinomas, pancreas duct cell
1228866|NCT01040000|Pancreas duct cell carcinoma
1228867|NCT01040000|Pancreatic duct cell carcinoma
1228868|NCT01040000|Adenocarcinoma of the colon
1228869|NCT01040000|Adenocarcinoma of the rectum
1228870|NCT01040000|Colorectal cancer
1228871|NCT01040000|Colorectal tumor
1228872|NCT01040000|Colorectal neoplasm
1228873|NCT01039987|Autosomal dominant polycystic kidney disease
1228874|NCT01039987|ADPKD
1228875|NCT01039987|kidney
1228876|NCT01039987|Biomarker
1228877|NCT01039987|MRI
1228882|NCT01039961|healthy volunteers
1228883|NCT01039961|IV formulation study
1228884|NCT01039948|Neoplasms
1228885|NCT01039948|Carcinoma
1228886|NCT01039948|Carcinoma, Non-Small-Cell Lung
1228887|NCT01039948|Lung Neoplasms
1228888|NCT01039948|Respiratory Tract Neoplasms
1228889|NCT01039948|Neoplasms, Glandular and Epithelial
1228890|NCT01039948|Neoplasms by Histological Type
1228891|NCT01039948|Thoracic Neoplasms
1228892|NCT01039948|Neoplasms by Site
1228893|NCT01039948|Lung Diseases
1228894|NCT01039948|Respiratory Tract Diseases
1228895|NCT01039948|Gefitinib
1228896|NCT01039948|Antineoplastic Agents
1228897|NCT01039948|Therapeutic Uses
1228898|NCT01039948|Pharmacologic Actions
1228899|NCT01039948|Protein Kinase Inhibitors
1228900|NCT01039948|Enzyme Inhibitors
1228901|NCT01039948|Molecular Mechanisms of Pharmacological Action
1228902|NCT01039935|Odor Discrimination
1228903|NCT01039922|Neuroendocrine Tumors
1228904|NCT01039922|Registries
1228906|NCT01039870|postthoracotomy pain
1228907|NCT01039857|Psychotherapy
1228908|NCT01039857|Depression
1228909|NCT01039857|Adjustment Disorders
1228910|NCT01039857|Neuropsychology
1228911|NCT01039857|Rehabilitation
1228912|NCT01039857|Coping Skills
1228913|NCT01039857|Stroke
1228914|NCT01039857|Caregivers
1228915|NCT01039844|LOC-paclitaxel Injection
1228916|NCT01039844|metastatic Melanoma
1228917|NCT01039831|PIGD
1228918|NCT01039831|tremor
1228919|NCT01039831|falls
1228920|NCT01039831|white matter
1228921|NCT01039818|Graves Disease
1228922|NCT01039818|Hyperthyroidism
1228923|NCT01039818|Radioiodine
1228924|NCT01039818|Clinical trial
1228925|NCT01039805|GSK962040
1228926|NCT01039805|13C octanoic acid breath test
1228927|NCT01039805|pharmacokinetics
1228928|NCT01039805|critically ill patients
1228929|NCT01039805|gut motility
1228930|NCT01039805|pharmacodynamics
1228931|NCT01039805|tolerability
1228932|NCT01039805|single dose
1228933|NCT01039805|gastric emtpying
1228934|NCT01039792|Autism
1228935|NCT01039792|Pervasive Developmental Disorders
1228936|NCT01039779|older fallers
1228937|NCT01039779|tai chi
1228938|NCT01039766|post traumatic stress disorder
1228939|NCT01039766|prevention
1228940|NCT01039766|oxytocin
1228941|NCT01039753|acute kidney injury
1228942|NCT01039753|renal replacement therapy
1228943|NCT01039753|biomarkers
1228944|NCT01039740|Pharmacogenomics
1228945|NCT01039740|Prediction of Mirtazapine response
1228946|NCT01039740|Depressed patients
1228947|NCT01039740|Mirtazapine response
1228948|NCT01039740|Adverse event
1228949|NCT01039727|Pain [C10.597.617]
1228950|NCT01039714|Hypocalcemia
1228951|NCT01039714|Hypoparathyroidism
1228952|NCT01039714|Vitamin D deficiency
1228953|NCT01039714|Total thyroidectomy
1228954|NCT01039714|calcium
1228955|NCT01039714|PTH
1228956|NCT01039701|safety
1228957|NCT01039701|tolerability
1228958|NCT01039701|mild to moderate Alzheimer's disease
1228959|NCT01039701|To determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil in patients with mild to moderate Alzheimer's disease
1228960|NCT01039688|oral JAK inhibitor
1228961|NCT01039688|MTX
1228962|NCT01039688|DMARD
1228963|NCT01039688|clinical trial
1228964|NCT01039688|joint diseases
1228965|NCT01039688|autoimmune diseases
1228966|NCT01039688|anti-Inflammatory agents
1228967|NCT01039688|rheumatic diseases
1228968|NCT01039675|long-acting beta2-receptor agonist
1228969|NCT01039675|Safety and tolerability
1228970|NCT01039675|pharmacodynamics
1228971|NCT01039675|pharmacokinetics
1228972|NCT01039675|long-acting muscarinic receptor antagonist
1228973|NCT01039675|COPD
1228974|NCT01039649|radiation
1228975|NCT01039649|Tomography, Spiral Computed
1228976|NCT01039649|Four-Dimensional Computed Tomography
1228977|NCT01039649|Respiratory Function Tests
1228978|NCT01039636|Beta-thalassemia
1228979|NCT01039636|Sickle cell anemia
1228980|NCT01039636|Transfusional iron overload
1228981|NCT01039636|Iron overload
1228982|NCT01039636|Iron chelation
1228983|NCT01039623|Healthy volunteers
1228984|NCT01039610|single dose
1228985|NCT01039610|pharmacokinetics
1228986|NCT01039610|GSK945237
1228987|NCT01039610|tolerability
1228988|NCT01039610|safety
1228989|NCT01039610|antibiotics
1228990|NCT01039610|linezolid
1228991|NCT01039610|QTc
1228992|NCT01039610|bacterial type II topoisomerase Inhibitors (BTI)
1228993|NCT01039610|moxifloxacin
1228994|NCT01039610|repeat dose
1228995|NCT01039597|IBD
1228996|NCT01039597|Ulcerative colitis
1228997|NCT01039584|bioequivalence
1228998|NCT01039584|butoconazole
1228999|NCT01039584|vulvovaginal
1229000|NCT01039584|candidiasis
1229001|NCT01039571|rotator cuff tear
1229002|NCT01039571|arthroscopic repair
1229003|NCT01039571|single row repair
1229004|NCT01039571|double row repair
1229005|NCT01039571|retear rate
1229006|NCT01039558|gastroesophageal reflux disease
1229007|NCT01039558|lansoprazole
1229008|NCT01039558|ecabet sodium
1229009|NCT01039545|Urinary tract infections
1229010|NCT01039545|Anti-bacterial agents
1229011|NCT01039532|Type 2 diabetes mellitus
1229012|NCT01039532|Biphasic human insulin thrice a day
1229013|NCT01039532|Basal bolus insulin
1229014|NCT01039519|G.I. Stromal Tumor
1229015|NCT01039519|GIST
1229016|NCT01039506|UGT1A1, irinotecan
1229017|NCT01039480|pharmacological biomarker
1229018|NCT01039480|compliance monitoring
1229019|NCT01039480|platelet aggregometry
1229020|NCT01039480|resistance
1229021|NCT01039480|Platelet Aggregation Inhibitors
1229022|NCT01039480|Medication Non-Compliance
1229023|NCT01039467|Managed Ventricular Pacing
1229024|NCT01039454|Food Reward
1229025|NCT01039454|fMRI
1229026|NCT01039454|Obese
1229027|NCT01039454|Cognition
1229028|NCT01039454|Food Addiction
1229029|NCT01039454|Behaviour
1229030|NCT01039454|Overweight
1229031|NCT01039454|Food Reinforcement
1229032|NCT01039454|Metabolic endpoints
1229033|NCT01039428|hyperphosphatemia
1229034|NCT01039428|hemodialysis
1229035|NCT01039428|chitosan
1229036|NCT01039415|marijuana
1229037|NCT01039415|marijuana abuse
1229038|NCT01039415|marijuana dependence
1229039|NCT01039415|cannabis
1229040|NCT01039415|substance-related disorder
1229041|NCT01039415|abstinence
1229042|NCT01039402|cardiovascular risk
1229043|NCT01039402|France
1229044|NCT01039402|Observational, descriptive study
1229045|NCT01039389|Coronary Artery Disease
1229046|NCT01039389|Stable
1229047|NCT01039389|Coronary Collaterals
1229048|NCT01039389|Therapeutic Collateral Promotion
1229049|NCT01039389|Arteriogenesis
1229050|NCT01039389|Bradycardia
1229051|NCT01039376|maintenance therapy
1229052|NCT01039376|anti-CD20 monoclonal antibody
1229053|NCT01039376|ofatumumab
1229054|NCT01039363|Relapse or refractory acute myeloid leukemia
1229055|NCT01039350|Myelodysplastic syndrome
1229056|NCT01039337|osteoarthritis
1229057|NCT01039337|manual therapy
1229058|NCT01039337|manipulation
1229059|NCT01039337|hip school
1229060|NCT01039337|chiropractic
1229061|NCT01039337|patient education
1229062|NCT01039324|Complex patients
1229063|NCT01039324|Care transitions
1229064|NCT01039324|Patient safety
1229065|NCT01039324|Patient care
1229066|NCT01039324|Health Information Technology
1229067|NCT01039324|Health Information Exchange
1229068|NCT01039324|Clinical Decision Support
1229069|NCT01039324|Care coordination
1229070|NCT01039324|Data sharing
1229071|NCT01039311|Lung
1229072|NCT01039311|cancer
1229073|NCT01039311|bronchoscopy
1229074|NCT01039311|optical
1229075|NCT01039311|coherence
1229076|NCT01039311|tomography
1229077|NCT01039298|Oral cancer
1229078|NCT01039298|fluorescence visualization
1229079|NCT01039298|surgical margin
1229080|NCT01039298|recurrence
1229081|NCT01039285|Very premature infant
1229082|NCT01039285|Surfactant
1229083|NCT01039285|Respiratory Distress
1229084|NCT01039285|Bronchopulmonary Dysplasia
1229085|NCT01039272|oral cancer
1229086|NCT01039272|EBV
1229087|NCT01039272|PCR
1229088|NCT01039259|adolescent
1229089|NCT01039259|body piercing/adverse effects
1229090|NCT01039259|tongue piercing
1229091|NCT01039259|tongue/microbiology
1229092|NCT01039181|Vitamin D
1229093|NCT01039181|Calcitriol
1229094|NCT01039181|cholangiocarcinoma
1229095|NCT01039181|Clinical trial
1229096|NCT01039168|Burnout
1229097|NCT01039168|Sick leave
1229098|NCT01039168|Intervention study
1229099|NCT01039168|Prospective study
1229100|NCT01039168|Work
1229101|NCT01039142|Psoriasis
1229102|NCT01039129|Gallstones
1229103|NCT01039129|Appendicitis
1229104|NCT01039129|Pelvic pain
1229105|NCT01039129|Peritoneal mass
1229106|NCT01039116|obesity
1229107|NCT01039116|nutrition
1229108|NCT01039116|type 2 diabetes
1229109|NCT01039116|community-based.
1229110|NCT01039103|PEG-liposomal prednisolone sodium phosphate
1229111|NCT01039090|Not eligible for deep brain stimulation
1229112|NCT01039090|Parkinsons's patients
1229113|NCT01035788|PTSD
1229114|NCT01035788|mindfulness meditation
1229115|NCT01035788|cognitive behavior therapy
1229116|NCT01035788|relationship function
1229117|NCT01035788|couple therapy
1229118|NCT01035775|Colonoscopy
1229119|NCT01035775|Adenoma detection
1229120|NCT01035775|Colorectal polyps
1229121|NCT01035749|pandemic influenza
1229122|NCT01035749|Clinical trial
1229123|NCT01035749|H1N1
1229124|NCT01035749|children
1229125|NCT01035723|Prefrontal Cortex
1229126|NCT01035723|Hippocampus
1229127|NCT01035723|Amygdala
1229128|NCT01035723|MRI
1229129|NCT01035723|Cognitive Tasks
1229130|NCT01035697|NICHD Neonatal Research Network
1229131|NCT01035697|Very Low Birth Weight (VLBW)
1229132|NCT01035697|Extremely Low Birth Weight (ELBW)
1229133|NCT01035697|Prematurity
1229134|NCT01035697|Pro-inflammatory cytokines
1229135|NCT01035697|Anti-inflammatory cytokines
1229136|NCT01035697|Interleukin-1 (IL-1β)
1229137|NCT01035697|Interleukin-2 (IL-2)
1229138|NCT01035697|Interleukin-3 (IL-3)
1229139|NCT01035697|Interleukin-8 (IL-8)
1229140|NCT01035697|Interleukin-9 (IL-9)
1229141|NCT01035697|Tumor necrosis factor-α (TNF-α)
1229142|NCT01035697|Regulated upon Activation, Normal T-cell Expressed and Secreted (RANTES)
1229143|NCT01035658|Pazopanib
1229144|NCT01035658|Doxil
1229145|NCT01035658|Liposomal doxorubicin
1229146|NCT01035658|Advanced relapsed
1229147|NCT01035658|platinum-sensitive
1229148|NCT01035658|platinum-resistant
1229149|NCT01035645|First time in human
1229150|NCT01035645|Interleukin-18
1229151|NCT01035645|Healthy male subjects
1229152|NCT01035645|Obese male subjects
1229153|NCT01035645|Monoclonal antibody
1229154|NCT01035645|Pharmacokinetics
1229155|NCT01035645|Tolerability
1229156|NCT01035645|Safety
1229157|NCT01035645|Pharmacodynamics
1229158|NCT01035632|Craving
1229159|NCT01035632|Incubation
1229160|NCT01035632|Relapse
1229161|NCT01035632|Smoking Cues
1229162|NCT01035632|Cortisol
1229163|NCT01035619|onchocerciasis; river blindness; moxidectin; pediatric
1229164|NCT01035606|attention
1229165|NCT01035606|rehabilitation
1229166|NCT01035606|training
1229167|NCT01035606|functional MRI
1229168|NCT01035606|executive function
1229169|NCT01035606|brain injury
1229170|NCT01039038|prostate
1229171|NCT01039038|curietherapy
1229172|NCT01039038|radiotherapy
1229173|NCT01039038|intermediate risk
1229174|NCT01039025|Myeloma
1229175|NCT01039025|Topotecan
1229176|NCT01039025|Hycamtin
1229177|NCT01039025|Melphalan
1229178|NCT01039025|Alkeran
1229179|NCT01039025|Cyclophosphamide
1229180|NCT01039025|Cytoxan
1229181|NCT01039025|Neosar
1229182|NCT01039025|Stem Cell Harvest
1229183|NCT01039025|Peripheral Blood Stem Cells
1229184|NCT01039012|bone mineral density
1229185|NCT01039012|osteoporosis
1229186|NCT01039012|exercise
1229187|NCT01039012|bone remodeling
1229188|NCT01039012|biomotion analysis
1229189|NCT01038999|Complementary Therapies
1229190|NCT01038986|chronic wound
1229191|NCT01038986|refractory wound
1229192|NCT01038986|CureXcell
1229193|NCT01038986|activated cell suspension
1229194|NCT01038960|ICD, training
1229195|NCT01038934|Buccal Mucosa
1229196|NCT01038934|DNA
1229197|NCT01038934|Polymerase Chain Reaction
1229198|NCT01038921|Blood Pressure
1229199|NCT01038921|Glucose levels
1229200|NCT01038921|HDL levels
1229201|NCT01038921|Triglyceride levels
1229202|NCT01038921|Waist Circumference
1229203|NCT01038908|sentinel lymph node biopsy (SLNB)
1229204|NCT01038908|axillary lymph node dissection (ALND)
1229205|NCT01038908|lymphatics
1229206|NCT01038908|blue dye
1229207|NCT01038895|Hypertension
1229208|NCT01038895|type 2 diabetes
1229209|NCT01038895|aliskiren
1229210|NCT01038895|ramipril
1229211|NCT01038895|microalbuminuria
1229212|NCT01038895|blood pressure> 130/80 <180/105 mmHg at the end of the wash−out
1229213|NCT01038895|type 2 diabetes mellitus well controlled by medication and / or
1229214|NCT01038895|compliance with diet (HbA1c <7%)
1229215|NCT01038895|Microalbuminuria in the upper range of normal (> 200 <300 mg/24 h)
1229216|NCT01038882|sedation
1229217|NCT01038882|midazolam
1229218|NCT01038882|flexible bronchoscopy
1229219|NCT01038882|tolerance
1229220|NCT01038843|VA106483
1229221|NCT01038843|Nocturia
1229222|NCT01038843|males
1229223|NCT01038843|nocturnal voids
1229224|NCT01038843|anti-diuretic
1229225|NCT01038843|hyponatraemia
1229226|NCT01038817|tooth-decay
1229227|NCT01038817|prevention
1229228|NCT01038817|fluoride-varnish
1229229|NCT01038817|institutionalised elderly people
1229230|NCT01038804|Breast Cancer
1229231|NCT01038804|Metastatic
1229232|NCT01038804|HER2 Negative
1229233|NCT01038804|YM155
1229234|NCT01038791|chronic hypercapnic respiratory failure
1229235|NCT01038791|COPD
1229236|NCT01038791|RTD
1229237|NCT01038791|sleep architecture
1229238|NCT01038791|humidification
1229239|NCT01038765|Recurrent Major Depressive Disorder
1229240|NCT01038765|Mindfulness Based Cognitive Therapy
1229241|NCT01038765|Randomized Controlled Trial
1229242|NCT01038752|NSCLC
1229243|NCT01038752|suramin
1229244|NCT01038752|lung cancer
1229245|NCT01038752|chemotherapy
1229246|NCT01038726|Healthy Aging
1229247|NCT01038700|Circulating endothelial compartment
1229248|NCT01038700|microparticles
1229249|NCT01038700|endothelial progenitors cells
1229250|NCT01038700|circulating endothelial cells
1229251|NCT01038700|transcriptome
1229252|NCT01038700|aging
1229253|NCT01038700|Healthy volunteers
1229254|NCT01038687|functional constipation
1229255|NCT01038687|bile acid
1229256|NCT01038648|Sitagliptin
1229257|NCT01038648|Type 2 diabetes
1229258|NCT01038648|Prevention of type 2 diabetes
1229259|NCT01038635|5-Azacytidine
1229260|NCT01038635|5-Aza
1229261|NCT01038635|Lenalidomide
1229262|NCT01038635|Revlimid
1229263|NCT01038635|CC-5103
1229264|NCT01038635|Myelodysplastic Syndrome
1229265|NCT01038635|MDS
1229266|NCT01038635|Acute Myelogenous Leukemia
1229267|NCT01038635|AML
1229268|NCT01038622|L-arginine
1229269|NCT01038622|Nasal NO
1229270|NCT01038622|Nosocomial infection
1229271|NCT01038622|Immune function
1229272|NCT01038622|HLA-DR expression
1229273|NCT01038622|Critically ill
1229274|NCT01038622|Medical ICU patients
1229275|NCT01038609|Postoperative Pain
1229276|NCT01038596|osteoarthritis, mesenchymal stromal cells, proliferation
1229277|NCT01038583|Aspirin
1229278|NCT01038583|Prevention
1229279|NCT01038583|Healthy
1229280|NCT01038583|Over 65 years old
1229281|NCT01038583|ASPREE
1229282|NCT01038583|Aspirin in Reducing Events in the Elderly
1229283|NCT01038583|Australia
1229284|NCT01038583|Functional disability
1229285|NCT01038583|Dementia
1229286|NCT01038583|Heart Disease/ Stroke
1229287|NCT01038583|Cancer
1229288|NCT01038583|Bleeding
1229289|NCT01038570|Prader Willi syndrome
1229290|NCT01038570|adults
1229291|NCT01038570|social behaviour
1229292|NCT01038570|stress
1229293|NCT01038570|anxiety
1229294|NCT01038570|psychological tests
1229295|NCT01038557|frozen
1229296|NCT01038557|red blood cells
1229297|NCT01038557|transfusion
1229298|NCT01038557|trauma
1229299|NCT01038544|Esophageal Cancer
1229300|NCT01038544|Mediastinal lymph nodes
1229301|NCT01038544|Staging
1229302|NCT01038544|EBUS
1229303|NCT01038544|EUS
1229304|NCT01038544|Endobronchial Ultrasound
1229305|NCT01038544|Endoscopic Ultrasound
1229306|NCT01038531|Acute lung injury (ALI)
1229307|NCT01038531|Adult respiratory distress syndrome (ARDS)
1229308|NCT01038531|Low-tidal-volume strategy
1229309|NCT01038531|ARDS Net
1229310|NCT01038531|airway pressure release ventilation (APRV)
1229311|NCT01038531|biomarkers of lung injury
1229312|NCT01038518|epidemiology
1229313|NCT01038518|risk factors
1229314|NCT01038518|micronutrients
1229315|NCT01038479|Xylitol
1229316|NCT01038479|Mutans streptococci
1229317|NCT01038479|Maternal consumption
1229318|NCT01038479|Early childhood tooth decay
1229319|NCT01038479|Early childhood caries
1229320|NCT01038479|Childsmile
1229321|NCT01038466|CHAT
1229322|NCT01038466|breast cancer
1229323|NCT01038466|non interventional observational study
1229324|NCT01038440|Omega 3 fatty acids
1229325|NCT01038440|Omega 3 Index
1229326|NCT01038440|Stearidonic acid (SDA)
1229327|NCT01038440|Eicosapentaenoic acid (EPA)
1229328|NCT01038440|Red blood cells
1229329|NCT01038440|Lipids
1229330|NCT01038440|Inflammation markers
1229331|NCT01038427|Rhinitis
1229332|NCT01038427|Allergic
1229333|NCT01038427|Seasonal
1229334|NCT01038427|Mometasone Furoate
1229335|NCT01038427|Equivalence
1229336|NCT01038401|HIV infection
1229337|NCT01038401|HAART
1229338|NCT01038401|Viral DNA test positive-10063306
1229339|NCT01038401|Blood HIV RNA 10049826
1229340|NCT01038401|Treatment Experienced
1229341|NCT01038388|Multiple Myeloma
1229342|NCT01038375|hypertension
1229343|NCT01038375|stroke
1229344|NCT01038375|adherence
1229345|NCT01038362|endothelium
1229346|NCT01038362|almonds
1229347|NCT01038362|dietary interventions
1229348|NCT01038362|coronary artery disease
1229349|NCT01038336|Hearing Loss - Noise-Induced
1229350|NCT01038336|Prevention
1229351|NCT01038336|Computer-assisted instruction
1229352|NCT01038323|Fibromyalgia
1229353|NCT01038323|FMS
1229354|NCT01038310|Parkinson´s disease
1229355|NCT01038310|FP-CIT-SPECT
1229356|NCT01038297|Scarring
1229357|NCT01038284|Patient Education
1229358|NCT01038284|Drug Toxicity
1229359|NCT01038271|palliative care
1229360|NCT01038258|neoadjuvant chemotherapy
1229361|NCT01038245|Receptor Up-Regulation
1229362|NCT01038245|Smoking
1229363|NCT01038245|Nicotine
1229364|NCT01038245|Neuroimaging
1229365|NCT01038232|Distress Tolerance
1229366|NCT01038232|Cocaine Dependence
1229367|NCT01038232|Relapse
1229368|NCT01038232|Limbic System
1229369|NCT01038232|Prefrontal Cortex
1229370|NCT01038232|Healthy Volunteer
1229371|NCT01038232|HV
1229372|NCT01038219|fever
1229373|NCT01038219|children
1229374|NCT01038219|SUBJECTIVE ASSESSMENT
1229375|NCT01038206|prevention
1229376|NCT01038206|HIV
1229377|NCT01038206|drugs
1229378|NCT01038206|smoking
1229379|NCT01038206|Hispanic
1229380|NCT01038206|Adolescent
1229381|NCT01038206|Familias Unidas
1229382|NCT01038206|Parent-Preadolescent Training
1229383|NCT01038206|parent-centered
1229384|NCT01038206|unsafe sexual behavior
1229385|NCT01038206|efficacy
1229386|NCT01038206|intervention
1229387|NCT01038193|Cognition, subarachnoid hemorrhage.
1229388|NCT01035580|chemoprevention
1229389|NCT01035580|curcumin
1229390|NCT01035580|pharmacokinetics
1229391|NCT01035580|safety
1229392|NCT01035567|Multivessel coronary artery disease
1229393|NCT01035567|Hybrid revascularization
1229394|NCT01035567|Coronary Artery Bypass Grafting
1229395|NCT01035567|Percutaneous Coronary Interventions
1229396|NCT01035567|Drug eluting stents
1229397|NCT01035554|high blood pressure
1229398|NCT01035541|Major non-cardiac surgery,
1229399|NCT01035541|hemodynamic management,
1229400|NCT01035541|PiCCO,
1229401|NCT01035541|acute kidney injury,
1229402|NCT01035541|renal outcome
1229403|NCT01035528|diastolic function, postmeal glucose, insulin glargine
1229404|NCT01035515|Healthy subjects
1229405|NCT01035502|Cancer
1229406|NCT01035502|CP-4055
1229407|NCT01035502|elacytarabine
1229408|NCT01035502|combination
1229409|NCT01035502|idarubicin
1229410|NCT01035502|Acute myeloid leukaemia (AML)
1229411|NCT01035489|Pacemaker treatment in heart failure
1229412|NCT01035489|Cardiac resynchronization therapy
1229413|NCT01035489|DDD pacemakers
1229414|NCT01035476|ALS
1229415|NCT01035476|nasal ventilation
1229416|NCT01035476|data card recording
1229417|NCT01035450|Coronary stent
1229418|NCT01035437|obstructing
1229419|NCT01038180|pacemaker
1229420|NCT01038180|adverse effects
1229421|NCT01038167|VX-950
1229422|NCT01038154|advanced esophageal cancer and stomach cancer
1229423|NCT01038154|Pravastatin
1229424|NCT01038154|Survival
1229425|NCT01038154|adverse effects
1229426|NCT01038128|Bulimia nervosa
1229427|NCT01038128|Bulimia
1229428|NCT01038128|Body dysmorphic disorder
1229429|NCT01038128|Eating disorders
1229430|NCT01038128|Body image
1229431|NCT01038128|Binge eating
1229432|NCT01038128|purging
1229433|NCT01038115|Catheter Ablation
1229434|NCT01038102|Obesity
1229435|NCT01038102|Diabetes
1229436|NCT01038102|Insulin resistance
1229437|NCT01038102|Fatty liver
1229438|NCT01038102|NAFLD
1229439|NCT01038102|Steatosis
1229440|NCT01038102|Dietary fatty acids
1229441|NCT01038089|endothelium
1229442|NCT01038089|resveratrol
1229443|NCT01038089|diabetes mellitus
1229444|NCT01038076|HIV
1229445|NCT01038076|AIDS
1229446|NCT01038076|adherence
1229447|NCT01038076|antiretroviral
1229448|NCT01038076|aCASI
1229449|NCT01038076|HAART
1229450|NCT01038076|Complementary Therapies
1229451|NCT01038076|Adherence Care Manager
1229452|NCT01038050|Endothelial progenitor cell
1229453|NCT01038050|endothelial function(FMD)
1229454|NCT01038050|Gingko Biloba Extract
1229455|NCT01038050|Type 2 Diabetes mellitus
1229456|NCT01038050|Stable coronary artery disease
1229457|NCT01038050|Endothelial progenitor cells Numbers
1229458|NCT01038037|Lung Cancer
1229459|NCT01038037|Non small cell lung cancer
1229460|NCT01038037|Triple mutational status
1229461|NCT01038037|KRAS
1229462|NCT01038037|BRAF
1229463|NCT01038037|PI3K
1229464|NCT01038024|antioxidant supplement
1229465|NCT01037998|adenocarcinoma
1229466|NCT01037998|non-small-cell lung cancer
1229467|NCT01037998|gefitinib
1229468|NCT01037998|UFUR
1229469|NCT01037985|Scarring
1229470|NCT01037972|Galileo
1229471|NCT01037972|Whole body vibration
1229472|NCT01037972|Osteoarthritis
1229473|NCT01037972|Knee
1229474|NCT01037972|Physiotherapy
1229475|NCT01037959|severe cirrhosis
1229476|NCT01037959|Patients with severe cirrhosis
1229477|NCT01037946|HIV
1229478|NCT01037946|Family interventions
1229479|NCT01037946|Thailand
1229480|NCT01037933|Cancer
1229481|NCT01037933|Humor
1229482|NCT01037933|Distraction
1229483|NCT01037933|Comedy
1229484|NCT01037933|Chemotherapy
1229485|NCT01037907|Oral treatment for MS
1229486|NCT01037907|Oral drug for multiple sclerosis
1229487|NCT01037907|Oral RRMS
1229488|NCT01037907|Oral relapsing remitting multiple sclerosis
1229489|NCT01037907|Gamma Linolenic Acid
1229490|NCT01037907|GLA
1229491|NCT01037907|Fatty acid
1229492|NCT01037907|Triglyceride
1229493|NCT01037907|Structured lipid
1229494|NCT01037907|MRI
1229495|NCT01037907|Magnetic resonance imaging
1229496|NCT01037907|gadolinium enhancing lesions
1229497|NCT01037907|expanded disability status scale
1229498|NCT01037907|EDSS
1229499|NCT01037907|Demyelination
1229500|NCT01037907|Remyelination
1229501|NCT01037907|TGFB1
1229502|NCT01037907|Transforming growth factor beta 1
1229503|NCT01037907|cytokines
1229504|NCT01037907|disease modifying therapy
1229505|NCT01037907|immunomodulator
1229506|NCT01037907|Anti inflammatory
1229507|NCT01037907|Pro inflammatory
1229508|NCT01037907|TNF alpha
1229509|NCT01037907|interleukin 1 beta
1229510|NCT01037907|interferon gamma
1229511|NCT01037907|Fayaz Master
1229512|NCT01037907|Omega 6
1229513|NCT01037907|Polyunsaturated fatty acid
1229514|NCT01037907|Cytokine balance
1229515|NCT01037907|Pleneva TM
1229516|NCT01037907|BGC20-0134
1229517|NCT01037907|RRMS
1229518|NCT01037894|Acupuncture,Intracerebral hemorrhage, Stroke
1229519|NCT01037868|depression
1229520|NCT01037868|alcohol dependency syndrome
1229521|NCT01037868|dual diagnosis
1229522|NCT01037868|SMS text messages
1229523|NCT01037855|Swine Flu H1N1 vaccine
1229524|NCT01037855|Adjuvanted flu cell culture derived
1229525|NCT01037816|Ankle Sprain
1229526|NCT01037803|perioperative sublingual microcirculation SDF
1229527|NCT01037777|individuals at risk for SCA1, SCA2, SCA3, SCA6 and SCA7
1229528|NCT01037764|acute lymphoid leukemia
1229529|NCT01037764|primary complete remission
1229530|NCT01037764|secondary complete remission
1229531|NCT01037764|postremission therapy
1229532|NCT01037764|allogeneic hematopoietic cell transplantation
1229533|NCT01037751|Cancer
1229534|NCT01037751|Symptom burden
1229535|NCT01037751|M. D. Anderson Symptom Inventory
1229536|NCT01037751|MDASI-Ovarian Cancer
1229537|NCT01037751|Symptoms
1229538|NCT01037751|Daily functioning
1229539|NCT01037751|Symptom severity
1229540|NCT01037751|Questionnaire
1229541|NCT01037751|Interview
1229542|NCT01037738|ACL reconstruction
1229543|NCT01037738|autologous conditioned serum
1229544|NCT01037738|Orthokine
1229545|NCT01037738|osteoarthritis
1229546|NCT01037738|interleukin receptor antagonist
1229547|NCT01037738|growth factors
1229548|NCT01037738|WOMAC
1229549|NCT01037738|IKDC
1229550|NCT01037725|Healthy volunteer
1229551|NCT01037725|first time in human
1229552|NCT01037725|food effect
1229553|NCT01037712|Foetuses infection with CMV
1229554|NCT01037712|neurological handicap of infectious origin.
1229555|NCT01037699|Ovarian stimulation
1229556|NCT01037699|In Vitro Fertilization
1229557|NCT01037699|Luteinizing Hormone
1229558|NCT01037699|GnRH antagonist
1229559|NCT01037699|Implantation rate in infertile patients undergoing In vitro fertilization and embryo transfer.
1229560|NCT01037686|PD
1229561|NCT01037686|DBS
1229562|NCT01037660|endothelium
1229563|NCT01037660|cardiovascular disease
1229564|NCT01037660|dietary fat
1229565|NCT01037660|insulin resistance
1229566|NCT01037647|Type 2 diabetes
1229567|NCT01037647|Diabetic dyslipidemia
1229568|NCT01037647|VLDL-TG kinetics
1229569|NCT01037647|VLDL-TG metabolism
1229570|NCT01037634|Avian Influenza
1229571|NCT01037634|H1N1 Influenza
1229572|NCT01037634|Seasonal Influenza
1229573|NCT01037621|Herpes simplex type 2
1229574|NCT01037621|Hepatitis C virus
1229575|NCT01037621|Valacyclovir
1229576|NCT01037621|Herpes Simplex virus type 2 infection
1229577|NCT01037608|Sativex
1229578|NCT01037608|fMRI
1229579|NCT01037608|Alternative Matrices
1229580|NCT01037608|Brain Imaging
1229581|NCT01037608|THC
1229582|NCT01037595|hemodialysis
1229583|NCT01037595|turmeric
1229584|NCT01037595|pruritus
1229585|NCT01037569|Toxicological Screening
1229586|NCT01037569|Drugs
1229587|NCT01037569|Alternative Matrices
1229588|NCT01037569|Urine
1229589|NCT01037569|Children
1229590|NCT01037556|AML
1229591|NCT01037556|Acute Myeloid Leukemia
1229592|NCT01037556|Acute Myelogenous Leukemia
1229593|NCT01037556|Refractory AML
1229594|NCT01037556|Relapsed AML
1229595|NCT01037556|Refractory Acute Myeloid Leukemia
1229596|NCT01037556|Relapsed Acute Myeloid Leukemia
1229597|NCT01037556|Refractory Acute Myelogenous Leukemia
1229598|NCT01037556|Relapsed Acute Myelogenous Leukemia
1229599|NCT01037556|ALL
1229600|NCT01037556|Acute Lymphocytic Leukemia
1229601|NCT01037556|Relapsed Acute Lymphocytic Leukemia
1229602|NCT01037556|Refractory Acute Lymphocytic Leukemia
1229603|NCT01037556|Relapsed ALL
1229604|NCT01037556|Refractory ALL
1229605|NCT01037530|ACE inhibitors
1229606|NCT01037530|Intermittent claudication
1229607|NCT01037530|Ramipril
1229608|NCT01037517|Myeloma
1229609|NCT01037517|Multiple Myeloma or Lymphoma Patients undergoing
1229610|NCT01037517|mobilization for the purpose of autologous stem cell collection
1229611|NCT01037504|safety
1229612|NCT01037504|tolerability
1229613|NCT01037504|healthy
1229614|NCT01037504|inhalation
1229615|NCT01037504|Healthy volunteers
1229616|NCT01037491|aspirin, clopidogrel, peptic ulcer, proton pump inhibitor, rabeprazole, ulcer bleeding
1229617|NCT01037478|Hodgkin's Lymphoma
1229618|NCT01037478|HDAC
1229619|NCT01037478|4SC-201
1229620|NCT01037478|Resminostat
1229621|NCT01037478|Phase II
1229622|NCT01037465|endothelium
1229623|NCT01037465|cell signaling
1229624|NCT01037465|N-acetylcysteine
1229625|NCT01037465|reactive oxygen species
1229626|NCT01037452|Heartburn
1229627|NCT01037452|antacid
1229628|NCT01037452|PPI
1229629|NCT01037452|Lansoprazole
1229630|NCT01037452|calcium carbonate
1229631|NCT01037452|magnesium hydroxide
1229632|NCT01037452|Relief of heartburn following ingestion of a heartburn-inducing meal
1229633|NCT01035424|Batten Disease
1229634|NCT01035424|Late Infantile Neuronal Lipofuscinosis
1229635|NCT01035424|LINCL
1229636|NCT01035411|COPD
1229637|NCT01035398|stage 0 esophageal cancer
1229638|NCT01035398|stage I esophageal cancer
1229639|NCT01035398|stage II esophageal cancer
1229640|NCT01035398|stage III esophageal cancer
1229641|NCT01035398|stage IV esophageal cancer
1229642|NCT01035385|FOFLOX4
1229643|NCT01035385|resectable liver metastasis from colorectal cancer
1229644|NCT01035372|healthy older people
1229645|NCT01035359|radius
1229646|NCT01035359|fracture
1229647|NCT01035359|wrist
1229648|NCT01035359|external
1229649|NCT01035359|fixation
1229650|NCT01035359|volar
1229651|NCT01035359|plate
1229652|NCT01035359|DASH
1229653|NCT01035359|PRWE
1229654|NCT01035346|Fever
1229655|NCT01035346|antipyretic
1229656|NCT01035346|uncomplicated acute viral infection
1229657|NCT01035346|uncomplicated acute bacterial infections
1229658|NCT01035333|gastric bypass surgery
1229659|NCT01035307|childhood acute myeloid leukemia in remission
1229660|NCT01035307|recurrent childhood acute myeloid leukemia
1229661|NCT01035281|Diabetic Neuropathies
1229662|NCT01035281|Neuropathic Pain
1229663|NCT01035281|Cannabinoids
1229664|NCT01035281|Tree Number C10.668.829.300
1229665|NCT01035268|breast cancer treated by conservative surgery
1229666|NCT01035255|chronic heart failure
1229667|NCT01035255|cardiovascular death
1229668|NCT01035255|hospitalization
1229669|NCT01035255|outcome study
1229670|NCT01035255|BNP
1229671|NCT01035255|KCCQ
1229672|NCT01035255|eGFR
1229673|NCT01035242|OCD
1229674|NCT01035242|obsessions
1229675|NCT01035242|cognitive
1229676|NCT01035229|Hepatocellular carcinoma
1229677|NCT01035229|randomized trial
1229678|NCT01035229|medical treatment
1229679|NCT01035229|RAD001
1229680|NCT01035229|placebo
1229681|NCT01035229|Advanced Hepatocellular Carcinoma (HCC)
1229682|NCT01035216|Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
1229683|NCT01037426|SND Sinus Node Disease
1229684|NCT01037426|Falls
1229685|NCT01037426|Fractures
1229686|NCT01037413|Scarring
1229687|NCT01037400|Knee Replacement
1229688|NCT01037400|Arthroplasty
1229689|NCT01037374|risk
1229690|NCT01037374|assessment
1229691|NCT01037374|difficult
1229692|NCT01037374|endotracheal
1229693|NCT01037374|intubation
1229694|NCT01037361|Children and Adolescents
1229695|NCT01037361|Motor Control
1229696|NCT01037361|Movement-Related Potential
1229697|NCT01037361|Stereotypic Movement Disorder
1229698|NCT01037361|Electroencephalogram (EEG)
1229699|NCT01037348|Choroidal Neovascularisation
1229700|NCT01037348|Pathological Myopia
1229701|NCT01037335|bone graft
1229702|NCT01037335|pain
1229703|NCT01037335|chronic
1229704|NCT01037322|crohn's disease
1229705|NCT01037322|ulcerative colitis
1229706|NCT01037322|cannabis
1229707|NCT01037322|cannabidiol
1229708|NCT01037296|catheter ablation
1229709|NCT01037296|robotic navigation
1229710|NCT01037283|Bipolar
1229711|NCT01037283|Depressed
1229712|NCT01037270|Patients with conditions (PE, Afib, DVT) requiring ongoing INR measurements.
1229713|NCT01037231|hyperoxaluria
1229714|NCT01037231|oxalate
1229715|NCT01037231|PH
1229716|NCT01037192|outpatient
1229717|NCT01037192|skin and soft tissue infections
1229718|NCT01037192|vancomycin intravenous
1229719|NCT01037153|Intravenous
1229720|NCT01037153|Rate of Delivery
1229721|NCT01037153|Dose Responses
1229722|NCT01037153|Variable Intervals
1229723|NCT01037153|Multiple Rapid Injections
1229724|NCT01037127|GSK1120212
1229725|NCT01037127|BRAF Inhibitor
1229726|NCT01037127|melanoma
1229727|NCT01037127|MEK Inhibitor
1229728|NCT01037114|Hepatitis A and hepatitis B
1229729|NCT01037101|acrophobia
1229730|NCT01037101|virtual reality
1229731|NCT01037101|exposure therapy
1229732|NCT01037101|In Vivo Exposure Therapy plus D-Cycloserine
1229733|NCT01037101|In Vivo Exposure Therapy plus Placebo
1229734|NCT01037101|Virtual Reality Exposure Therapy plus D-Cycloserine
1229735|NCT01037101|Virtual Reality Exposure Therapy plus Placebo
1229736|NCT01037101|Wait-List
1229737|NCT01037088|cannabis
1229738|NCT01037088|marijuana
1229739|NCT01037088|neuropathy
1229740|NCT01037088|antinociception
1229741|NCT01037088|mood
1229742|NCT01037088|cognition
1229743|NCT01037088|neuropathic pain
1229744|NCT01037075|Schizophrenia
1229745|NCT01037075|Dual Diagnosis
1229746|NCT01037075|Nicotine Nasal Spray
1229747|NCT01037075|Drug Abuse/Dependence
1229748|NCT01037075|Cognitive Processes
1229749|NCT01037049|Rectal Cancer
1229750|NCT01037049|6vs12
1229751|NCT01037049|6 vs 12
1229752|NCT01037049|Cancer
1229753|NCT01037049|CRM
1229754|NCT01037049|Circumferential Resection Margin
1229755|NCT01037049|Quality of Life
1229756|NCT01037049|MRI
1229757|NCT01037049|Radiology
1229758|NCT01037049|Abdominoperineal Excision
1229759|NCT01037049|Anterior Resection
1229760|NCT01037049|Surgery
1229761|NCT01037049|Pathology
1229762|NCT01037049|Radiotherapy
1229763|NCT01037036|Ocular Hypertension
1229764|NCT01037036|Open-Angle Glaucoma
1229765|NCT01037036|Xalatan
1229766|NCT01037036|IOP
1229767|NCT01037023|PMS (post-marketing surveillance)
1229768|NCT01037023|Topotecan
1229769|NCT01036971|Physical Examination
1229770|NCT01036971|Medical Information
1229771|NCT01036971|Assessment
1229772|NCT01036971|Blood Work
1229773|NCT01036971|Screening
1229774|NCT01036958|Pediatric cGVHD
1229775|NCT01036958|Response Criteria
1229776|NCT01036958|Symptoms
1229777|NCT01036958|Quality of Life
1229778|NCT01036958|Graft-Versus-Host Disease
1229779|NCT01036958|GVHD
1229780|NCT01036958|Pediatric GVHD
1229781|NCT01036854|Ondansetron, EUR-1025
1229782|NCT01036841|MNE with nocturnal polyuria
1229783|NCT01036841|monosymptomatic nocturnal enuresis with nocturnal polyuria
1229784|NCT01036802|sickle cell disease
1229785|NCT01036802|pulmonary hypertension
1229786|NCT01036802|coagulation activation
1229787|NCT01036802|platelet activation
1229788|NCT01036802|endothelial activation
1229789|NCT01036711|Attention
1229790|NCT01036711|Working Memory
1229791|NCT01036711|Central Executive Processes
1229792|NCT01036711|Response Preparation
1229793|NCT01036711|Cigarettes
1229794|NCT01036685|Children
1229795|NCT01036685|fMRI
1229796|NCT01036685|Task Development
1229797|NCT01036685|Cognition
1229798|NCT01036659|acute angiotensin converting enzyme inhibitor angioedema
1229799|NCT01036646|Patients on stable OAT therapy for at least 3 months.
1229800|NCT01036633|mucositis
1229801|NCT01036594|Ketoconazole
1229802|NCT01036594|Dexamethasone
1229803|NCT01036581|Magnetic Resonance Imaging (MRI)
1229804|NCT01036581|Functional Brain Imaging
1229805|NCT01036581|Magnetic Resonance Spectroscopy
1229806|NCT01036581|Diffusion Tensor Imaging
1229807|NCT01036581|Drug Abuse
1229808|NCT01036568|Psychosis
1229809|NCT01036568|Smooth Pursuit
1229810|NCT01036568|Motion Perception
1229811|NCT01036568|Neurophysiology
1229812|NCT01036568|fMRI
1229813|NCT01036529|Spinal Cord Stimulation
1229814|NCT01036529|Decompression
1229815|NCT01036529|Fusion with or without instrumentation
1229816|NCT01036529|Discectomy
1229817|NCT01036529|Laminectomy
1229818|NCT01036529|Laminotomy
1229819|NCT01036529|Foraminotomy
1229820|NCT01036516|Drug Cues
1229821|NCT01036516|Dopamine Release
1229822|NCT01036516|Psychomotor Stimulants
1229823|NCT01036516|D2 Dopamine Receptor Subtype
1229824|NCT01036516|Neuroimaging
1229825|NCT01036412|Chlorhexidine
1229826|NCT01036412|Chlorhexidine Gel Therapy
1229827|NCT01036412|1% chlorhexidine gluconate gel
1229828|NCT01036412|Cariogenic Oral Microflora
1229829|NCT01036412|Irradiated Head and Neck Cancer Patients
1229830|NCT01036412|caries-forming organisms
1229831|NCT01036412|Radiation treatment
1229832|NCT01036412|Mouth Cancer
1229833|NCT01036412|Throat Cancer
1229834|NCT01036412|Tooth decay
1229835|NCT01036399|PTCL
1229836|NCT01036360|Obesity
1229837|NCT01036360|Acute exercise
1229838|NCT01036360|Intensity of exercise
1229839|NCT01036360|Energy balance regulation
1229840|NCT01036360|Appetite
1229841|NCT01036308|dietary fibre
1229842|NCT01036308|legumes
1229843|NCT01036308|lupin kernel fibre
1229844|NCT01036308|soy fibre
1229845|NCT01036308|bile acids
1229846|NCT01036308|short-chain fatty acids
1229847|NCT01036308|cholesterol metabolism
1229848|NCT01036308|Subjects
1229849|NCT01036243|digestive tolerance
1229850|NCT01036243|night sleep
1229851|NCT01036243|crying
1229852|NCT01036243|growth
1229853|NCT01036230|fMRI
1229854|NCT01036230|Methylphenidate
1229855|NCT01036230|Taste
1229856|NCT01036230|Olfaction
1229857|NCT01036230|Addiction
1229858|NCT01036217|Recruitment
1229859|NCT01036217|Adult
1229860|NCT01036217|Telephone
1229861|NCT01036217|Selection
1229862|NCT01036217|Testing
1229863|NCT01036139|EDS in Parkinson's Disease
1229864|NCT01036126|Nicotine
1229865|NCT01036126|Cocaine
1229866|NCT01036126|N-Back
1229867|NCT01036126|Craving
1229868|NCT01036126|Dependence
1229869|NCT01036113|EZN-2208 (PEG-SN38)
1229870|NCT01036087|Inflammatory Breast Cancer
1229871|NCT01036087|IBC
1229872|NCT01036087|Primary breast carcinoma
1229873|NCT01036087|HER2 negative overexpression
1229874|NCT01036087|Panitumumab
1229875|NCT01036087|Vectibix
1229876|NCT01036087|Nab-paclitaxel
1229877|NCT01036087|Paclitaxel
1229878|NCT01036087|Abraxane
1229879|NCT01036087|Carboplatin
1229880|NCT01036087|Paraplatin
1229881|NCT01036087|PNC
1229882|NCT01036087|5-fluorouracil
1229883|NCT01036087|5-FU
1229884|NCT01036087|Adrucil
1229885|NCT01036087|Efudex
1229886|NCT01036087|Epirubicin
1229887|NCT01036087|Ellence
1229888|NCT01036087|Cyclophosphamide
1229889|NCT01036087|Cytoxan
1229890|NCT01036087|Neosar
1229891|NCT01036087|FEC
1229892|NCT01036074|Drug Abuse
1229893|NCT01036074|Cocaine
1229894|NCT01036074|Cocaine Dependence
1229895|NCT01036074|Functional MRI
1229896|NCT01036074|Pharmalogical MRI
1229897|NCT01036074|Conditioning
1229900|NCT01036048|saphenous vein graft
1229901|NCT01036048|stent
1229902|NCT01036035|Tolterodine
1229903|NCT01036035|Over active Bladder (OAB)
1229904|NCT01036035|Incontinence
1229905|NCT01036022|GSK1399686
1229906|NCT01036022|mesalazine
1229907|NCT01036022|pharmacokinetics/dynamics
1229908|NCT01036022|ulcerative colitis
1229909|NCT01036009|Hematologic
1229910|NCT01036009|Malignancy
1229911|NCT01036009|Leukemia
1229912|NCT01036009|Pre-leukemic
1229913|NCT01036009|Allogeneic
1229914|NCT01036009|Transplant
1229915|NCT01036009|Pediatric
1229916|NCT01035996|Classical Conditioning
1229917|NCT01035996|fMRI
1229918|NCT01035996|Schizophrenia
1229919|NCT01035996|TD Model
1229920|NCT01035996|Incentive Salience
1229921|NCT01035983|menstrually associated migraine (MAM), Migraines,Menstrual Migraines, menstrually related migraines
1229922|NCT01035944|Chronic wounds
1229923|NCT01035944|Chronic wound debridement
1229924|NCT01035944|Debridement
1229925|NCT01035944|Bedside debridement
1229926|NCT01035944|Surgical debridement
1229927|NCT01035944|Wound debridement
1229928|NCT01035944|Minimize bacterial re-colonization of wounds
1229929|NCT01035944|HemCon ChitoGauze Dressings
1229930|NCT01035944|HemCon Dressings
1229931|NCT01035944|Chitosan-based dressings
1229932|NCT01035190|Preterm Infants
1229933|NCT01035190|Inhaled Corticosteroids
1229934|NCT01035190|Bronchopulmonary Dysplasia
1229935|NCT01035177|Bone Mineral Density (BMD);
1229936|NCT01035177|Cortical bone;
1229937|NCT01035177|Hip fracture;
1229938|NCT01035177|Osteoporosis;
1229939|NCT01035177|Quantitative Computed Tomography (QCT).
1229940|NCT01035164|Alzheimer's Disease
1229941|NCT01035164|Diagnostic Imaging
1229942|NCT01035164|Neuroinflammation
1229943|NCT01035164|PET Diagnosis
1229944|NCT01035164|PET Tracer
1229945|NCT01035151|randomized cluster design
1229946|NCT01035151|tobacco cessation
1229947|NCT01035151|smoking cessation
1229948|NCT01035151|African American
1229949|NCT01035125|Self-management
1229950|NCT01035125|Self-efficacy
1229951|NCT01035125|Coping
1229952|NCT01035125|Health consumer
1229953|NCT01035125|Patient education
1229954|NCT01035125|Health related quality of life
1229955|NCT01035099|Letrozole
1229956|NCT01035099|IVF (in vitro fertilization)
1229957|NCT01035099|Cryopreservation
1229958|NCT01035099|Fertility Preservation
1229959|NCT01035099|Breast Cancer
1229960|NCT01035086|dietary fibre
1229961|NCT01035086|lupin kernel fibre
1229962|NCT01035086|bile acids
1229963|NCT01035086|cholesterol metabolism
1229964|NCT01035086|blood lipids
1229965|NCT01035086|hypercholesterolemia
1229966|NCT01035086|fibre-enriched food
1229967|NCT01035086|moderate hypercholesterolemia
1229968|NCT01035047|Acute Coronary Syndrome
1229969|NCT01035047|Chest pain
1229970|NCT01035047|Cardiac MRI
1229971|NCT01035047|Risk Stratification
1229972|NCT01035047|Emergency Department
1229973|NCT01035008|pancreatic cysts
1229974|NCT01034982|COPD
1229975|NCT01034969|Hereditary angioedema
1229976|NCT01034956|Soft tissue filler
1229977|NCT01034956|Dermal filler
1229978|NCT01034956|Complications
1229979|NCT01034956|Patient satisfaction
1229980|NCT01034943|radius
1229981|NCT01034943|fracture
1229982|NCT01034943|wrist
1229983|NCT01034943|external
1229984|NCT01034943|fixation
1229985|NCT01034943|volar
1229986|NCT01034943|plate
1229987|NCT01034943|DASH
1229988|NCT01034943|PRWE
1229989|NCT01034930|MANDIBLE
1229990|NCT01034930|IMPLANTS
1229991|NCT01034930|OVERDENTURE
1229992|NCT01034917|Active Comparator
1229993|NCT01034917|Placebo Comparator
1229994|NCT01034917|Sham Comparator
1229995|NCT01034917|No intervention
1229996|NCT01034917|Other
1229997|NCT01034917|Treatment Experienced
1229998|NCT01034904|Quality of Life
1229999|NCT01034904|HRQoL
1230000|NCT01034904|Hemophilia A
1230001|NCT01034904|Helixate FS
1230002|NCT01034891|BRCA mutation
1230003|NCT01034891|benign breast disease
1230004|NCT01034891|family history of breast cancer
1230005|NCT01034891|strong family history of breast cancer
1230006|NCT01034891|atypical ductal hyperplasia
1230007|NCT01034891|atypical lobular hyperplasia
1230008|NCT01034891|high risk for breast cancer
1230009|NCT01034852|Atrial Fibrillation
1230010|NCT01034852|Maze
1230011|NCT01034852|Ablation
1230012|NCT01034839|acute myeloid leukemia
1230013|NCT01034839|prognosis
1230014|NCT01034839|cytarabine
1230015|NCT01034826|NGT, IGT, diabetes
1230016|NCT01034813|contractures, range of motion, scar formation
1230017|NCT01034800|HIV Positive
1230018|NCT01034787|CP-675,206
1230019|NCT01034787|Immunotherapy
1230020|NCT01034787|AntiCTLA4
1230021|NCT01034787|Clinical Trial
1230022|NCT01034787|Unresectable or Metastatic
1230023|NCT01034774|Human volunteers
1230024|NCT01034761|Electronic prescribing
1230025|NCT01034761|Inappropriate medications
1230026|NCT01034761|Patient safety
1230027|NCT01034761|Elderly patients in the hospital
1230028|NCT01034748|Radiolabelled
1230029|NCT01034748|Mass Balance
1230030|NCT01034748|Healthy Volunteers
1230031|NCT01034748|Pharmacokinetics
1230032|NCT01034735|Saizen®
1230033|NCT01034735|bioequivalence
1230034|NCT01034735|recombinant human
1230035|NCT01034735|Growth Hormone
1230036|NCT01034735|treatment of growth failure in children
1230037|NCT01034735|growth hormone deficiency in adults
1230038|NCT01034722|Breast Milk
1230039|NCT01034722|Fat Globules
1230040|NCT01034709|Cytomegalovirus
1230041|NCT01034709|CMV
1230042|NCT01034657|MDS
1230043|NCT01034657|bone marrow
1230044|NCT01034657|anemia
1230045|NCT01034657|cytopenia
1230046|NCT01034657|transfusion dependance
1230047|NCT01034657|EPO
1230048|NCT01034657|ESA
1230049|NCT01034657|erythropoietin
1230050|NCT01034657|LBH589
1230051|NCT01034657|Myelodysplastic Syndromes
1230052|NCT01034657|hematopoietic improvement
1230053|NCT01034657|IPSS Low
1230054|NCT01034657|IPSS Int-1
1230055|NCT01034657|HI-E
1230056|NCT01034657|HDAC Inhibitor
1230057|NCT01034657|HDAC-I
1230058|NCT01034657|DAC-I
1230059|NCT01034657|Deacetylase-Inhibitor
1230060|NCT01034657|Histone Deacetylase-Inhibitor
1230061|NCT01034657|red blood cell transfusions
1230062|NCT01034644|Biomarkers
1230063|NCT01034644|Genetic markers
1230064|NCT01034631|Metastatic Kidney Cancer
1230065|NCT01034631|BNC105P
1230066|NCT01034618|Diabetes
1230067|NCT01034618|protein
1230068|NCT01034618|protein hydrolysate
1230069|NCT01034579|Biomarkers
1230070|NCT01034579|Genetic markers
1230071|NCT01034527|Anterior Cruciate Ligament
1230072|NCT01034527|Female Athlete
1230073|NCT01034527|Sports Injuries
1230074|NCT01034527|Injury Prevention
1230075|NCT01034501|periodontitis
1230076|NCT01034501|photodynamic therapy
1230077|NCT01034475|acute myeloid leukemia
1230078|NCT01034475|acute lymphoblastic leukemia
1230079|NCT01034475|multiple myeloma
1230080|NCT01034475|chronic myeloid\ leukemia in blast phase
1230081|NCT01034462|Depression
1230082|NCT01034462|Major Depressive Disorder
1230083|NCT01034449|allo graft
1230084|NCT01034449|cord blood
1230085|NCT01034449|expansion
1230086|NCT01034449|reduced-intensity conditioning
1230087|NCT01034423|Focus: health effects from omega-3 fatty acids, from fish oil with different quality
1230088|NCT01034410|AS1411
1230089|NCT01034410|AML
1230090|NCT01034410|relapsed
1230091|NCT01034410|refractory
1230092|NCT01034410|aptamer
1230093|NCT01034410|nucleolin
1230094|NCT01034384|fMRI
1230095|NCT01034384|Smoking Withdrawal
1230096|NCT01034384|Imaging
1230097|NCT01034384|Memory
1230098|NCT01034384|Mood
1230099|NCT01034371|Coronary Artery Disease; Hybrid Revascularization;
1230100|NCT01034371|Percutaneous Coronary Intervention; Coronary Artery Bypass
1230101|NCT01034358|inflammatory bowel disease
1230102|NCT01034358|Crohn disease
1230103|NCT01034358|ulcerative colitis
1230104|NCT01034358|Papillomavirus vaccines
1230105|NCT01034345|Sirolimus
1230106|NCT01034345|Liver Transplantation
1230107|NCT01034345|Tolerance
1230108|NCT01034345|Immune responses
1230109|NCT01034345|Allograft tolerance
1230110|NCT01034332|Esophageal cancer
1230111|NCT01034332|Esophagectomy
1230112|NCT01034332|Paclitaxel
1230113|NCT01034332|Induction chemotherapy
1230114|NCT01034319|type 2 diabetes
1230115|NCT01034319|genetics
1230116|NCT01034319|genetic counseling
1230117|NCT01034319|diabetes prevention
1230118|NCT01034293|feeding frequency
1230119|NCT01034293|insulin metabolism
1230120|NCT01034293|glucose metabolism
1230121|NCT01034293|substrate partitioning
1230122|NCT01034280|Down Syndrome
1230123|NCT01034280|phenotype
1230124|NCT01034280|genotype
1230125|NCT01034280|patient family
1230126|NCT01034267|Depression
1230127|NCT01034267|Major Depressive Disorder
1230128|NCT01034254|influenza
1230129|NCT01034254|immunization
1230130|NCT01034254|pregnancy
1230131|NCT01034254|efficacy
1230132|NCT01034254|pertussis
1230133|NCT01034254|hepatitis E
1230134|NCT01034241|milk protein
1230135|NCT01034241|overweight
1230136|NCT01034241|insulin metabolism
1230137|NCT01034241|substrate partitioning
1230138|NCT01034228|Diarrhoea
1230139|NCT01034228|L-isoleucine
1230140|NCT01034228|children
1230141|NCT01034228|ORS
1230142|NCT01034228|Antibacterial peptide
1230143|NCT01034215|Behavioral
1230144|NCT01034215|Quality of Life
1230145|NCT01034215|Breast Cancer
1230146|NCT01034189|Esophageal cancer
1230147|NCT01034189|Chemoradiotherapy
1230148|NCT01034189|Paclitaxel
1230149|NCT01034189|Cetuximab
1230150|NCT01034176|BK viremia
1230151|NCT01034176|kidney transplantation
1230152|NCT01034176|BK viremia in kidney transplant recipients
1230153|NCT01034163|Phase III randomized
1230154|NCT01034163|double blind
1230155|NCT01034163|placebo controlled multi-center study
1230156|NCT01034163|panobinostat
1230157|NCT01034163|Hodgkin's lymphoma
1230158|NCT01034163|at risk for relapse
1230159|NCT01034163|autologous stem cell transplant
1230160|NCT01034137|Treat-to-target, tight control, strategy study, TCZ, MTX
1230161|NCT01034124|warfarin
1230162|NCT01034124|midazolam
1230163|NCT01034124|cranberry juice
1230164|NCT01034124|pharmacokinetics
1230165|NCT01034098|Obesity
1230166|NCT01034098|Postmenopausal women
1230167|NCT01034098|Mechanical ventilatory constraints
1230168|NCT01034098|Dynamic lung volume
1230169|NCT01034098|Expiratory flow limitation
1230170|NCT01034085|Nicotine
1230171|NCT01034085|Schizophrenia
1230172|NCT01034085|Cognition
1230173|NCT01034085|Genes
1230174|NCT01034085|Smoking
1230175|NCT01034085|Cigarette Smoking
1230176|NCT01034046|Obesity
1230177|NCT01034033|quality of life
1230178|NCT01034020|Nasal Spray
1230179|NCT01034020|Attention Network Test
1230180|NCT01034020|Continuous Performance Test
1230181|NCT01034020|Attentional Blink Test
1230182|NCT01034007|tissue engineered vascular graft
1230183|NCT01033994|Knee osteoarthritis
1230184|NCT01033994|Fibroblast growth factor 18
1230185|NCT01033994|Sprifermin
1230186|NCT01033981|cost effectiveness
1230187|NCT01033981|Sunitinib Central America and Caribbean Metastatic Renal Cell Carcinoma
1230188|NCT01033968|lasers
1230189|NCT01033968|pain measurement
1230190|NCT01033968|photocoagulation
1230191|NCT01033968|retina
1230192|NCT01033955|critical care
1230193|NCT01033955|H1N1/influenza infection
1230194|NCT01033955|respiration
1230195|NCT01033955|ventilation, artificial
1230196|NCT01033955|critically ill patients
1230197|NCT01033955|invasive mechanical ventilation
1230198|NCT01033955|H1N1/influenza infection (suspected, probable or confirmed)
1230199|NCT01033942|Pre-exposure prophylaxis
1230200|NCT01033942|HIV Prevention
1230201|NCT01033942|Truvada
1230202|NCT01033942|Many Men, Many Voices
1230203|NCT01033942|Emtricitabine
1230204|NCT01033942|Tenofovir disoproxil fumarate
1230205|NCT01033942|Young men who have sex with men
1230206|NCT01033942|HIV Seronegativity
1230207|NCT01033929|tuberculosis
1230208|NCT01033929|ESAT-6
1230209|NCT01033929|CFP-10
1230210|NCT01033929|skin test
1230211|NCT01033929|diagnostic test
1230212|NCT01033916|Blood Glucose
1230213|NCT01033916|Insulin/Administration and Dosage
1230214|NCT01033916|Coronary Artery Bypass
1230215|NCT01033903|Abortion, Spontaneous
1230216|NCT01033903|Randomized Controlled Trial
1230217|NCT01033890|local anesthesia
1230218|NCT01033890|cochlear implant
1230219|NCT01033890|sedation
1230220|NCT01033890|3 patients submitted to cochlear implant surgery with local anesthesia with sedation
1230221|NCT01033877|Immunisation, active
1230222|NCT01033812|Networks
1230223|NCT01033812|Index recruiter
1230224|NCT01033799|Probiotic - Lactobacillus casei DN114-001
1230225|NCT01033799|dairy product - infections - shiftworkers
1230226|NCT01033799|Common infectious diseases,
1230227|NCT01033799|occuring in healthy subjects,
1230228|NCT01033799|including upper respiratory tract infections (defined as rhinopharyngitis, sore throat, sinusitis and otitis),
1230229|NCT01033799|lower respiratory tract infections (defined as bronchitis,
1230230|NCT01033799|pneumopathy and flu and flu-like syndromes), and
1230231|NCT01033799|gastrointestinal tract infection defined as gastroenteritis.
1230232|NCT01033773|Type 2 diabetes mellitus
1230233|NCT01033773|Uncontrolled hyperglycemia
1230234|NCT01033773|Emergency Department
1230235|NCT01033760|Primary HIV-1 infection
1230236|NCT01033760|antiretroviral treatment
1230237|NCT01033760|HIV reservoirs
1230238|NCT01033760|HIV-DNA levels
1230239|NCT01033760|randomized
1230240|NCT01033760|Treatment Naive
1230241|NCT01033747|iron overload
1230242|NCT01033747|iron chelation therapy
1230243|NCT01033747|B-thalassemia
1230244|NCT01033708|Psychotherapy
1230245|NCT01033708|PTSD
1230246|NCT01033708|Borderline personality disorders
1230247|NCT01033695|Endoscopy
1230248|NCT01033695|Endoscopic Ultrasound
1230249|NCT01033695|Endoscopic Sonoelastography
1230250|NCT01033695|Cancer
1230251|NCT01033695|Interobserver agreement
1230252|NCT01033669|Inhalation profiles
1230253|NCT01033669|asthma
1230254|NCT01033669|COPD
1230255|NCT01033656|adult-onset Still's disease
1230256|NCT01033656|anakinra
1230257|NCT01033656|prednisolone
1230258|NCT01033656|disease-modifying antirheumatic drug
1230259|NCT01033656|methotrexate
1230260|NCT01033656|efficacy
1230261|NCT01033656|patients
1230262|NCT01033617|Stem cells
1230263|NCT01033617|Cellular therapy
1230264|NCT01033617|Myocardial repair
1230265|NCT01033591|Primary Health Care
1230266|NCT01033591|Family PractiCe
1230267|NCT01033591|Hearth Failure
1230268|NCT01033591|Exercise
1230269|NCT01033591|Randomized Controlled Trials
1230270|NCT01033591|Multicenter Study
1230271|NCT01033591|Quality of life
1230272|NCT01033565|Impaired sleep maintenance
1230273|NCT01033565|Autism Spectrum Disorders
1230274|NCT01033565|Pediatric
1230275|NCT01033539|Survive
1230276|NCT01033539|safety
1230277|NCT01033539|lactobacillus Reuteri
1230278|NCT01033526|Symptomatic treatment of Common Cold symptoms
1230279|NCT01033487|Safety
1230280|NCT01033487|Pharmacokinetics
1230281|NCT01033487|Pharmacodynamics
1230282|NCT01033487|PF-03635659
1230283|NCT01033487|COPD
1230284|NCT01033474|Infertile Patients
1230285|NCT01033461|probiotic
1230286|NCT01033461|lactobacillus paracasei
1230287|NCT01033461|calcium
1230288|NCT01033461|faecal microbiota
1230289|NCT01033461|cholesterol metabolism
1230290|NCT01033435|Inflammation
1230291|NCT01033435|Oxidative stress
1230292|NCT01033435|HbA1c
1230293|NCT01033435|Hemodialysis
1230294|NCT01033422|Glaucoma
1230295|NCT01033422|Ocular hypertension
1230296|NCT01033422|Intraocular hypertension
1230297|NCT01033409|Salmonella Typhi
1230298|NCT01033409|pneumonia
1230299|NCT01033409|oral
1230300|NCT01033409|vaccine
1230301|NCT01033396|Allergic rhinitis Environmental exposure unit
1230302|NCT01033370|acute
1230303|NCT01033370|aortic
1230304|NCT01033370|emergencies
1230305|NCT01033370|Aortic dissection
1230306|NCT01033357|dialysis
1230307|NCT01033357|hemodialysis
1230308|NCT01033357|neointimal hyperplasia
1230309|NCT01033344|Cat allergy
1230310|NCT01033344|Rhinoconjunctivitis
1230311|NCT01033344|Exposure chamber
1230312|NCT01033344|Immunotherapy
1230313|NCT01033344|Cat-PAD
1230314|NCT01033331|Spinal Muscular atrophy
1230315|NCT01033331|Valproic acid
1230316|NCT01033331|HMAS
1230317|NCT01033331|MRC scale
1230318|NCT01033318|Hypertension
1230319|NCT01033305|UC
1230320|NCT01033292|ovarian
1230321|NCT01033292|cancer
1230322|NCT01033292|sensitive
1230323|NCT01033292|PARP
1230324|NCT01033292|recurrent
1230325|NCT01033292|platinum-resistant recurrent ovarian cancer
1230326|NCT01033279|Coaguchek
1230327|NCT01033279|Portable coagulometer
1230328|NCT01033279|Self-monitoring
1230329|NCT01033279|Coumadin
1230330|NCT01033279|Warfarin
1230331|NCT01033279|Quality of life
1230332|NCT01033279|Pharmacist
1230333|NCT01033227|sickle cell disease
1230334|NCT01033227|sickle cell anemia
1230335|NCT01033227|pain crisis
1230336|NCT01033227|nitric oxide
1230337|NCT01033227|nitrite
1230338|NCT01033227|vaso occlusive crisis
1230339|NCT01033227|pain medication
1230340|NCT01033227|sickled cells
1230341|NCT01033227|blood flow
1230342|NCT01033227|microcirculation
1230343|NCT01033214|TAA
1230344|NCT01033214|Thoracic
1230345|NCT01033214|Descending Thoracic Aorta
1230346|NCT01033214|TAArget
1230347|NCT01033201|Lung rejection
1230348|NCT01033188|double bundle
1230349|NCT01033188|hamstring graft
1230350|NCT01033188|ACL reconstruction
1230351|NCT01033188|single bundle
1230352|NCT01033175|COPD
1230353|NCT01033175|anemia
1230354|NCT01033175|exercise
1230355|NCT01033175|cytokines
1230356|NCT01033175|erythropoietin
1230357|NCT01033123|ovarian
1230358|NCT01033123|cancer
1230359|NCT01033123|sensitive
1230360|NCT01033123|PARP
1230361|NCT01033123|recurrent
1230362|NCT01033123|platinum-sensitive recurrent ovarian cancer
1230363|NCT01033110|inactive
1230364|NCT01033110|>45 years
1230365|NCT01033110|female
1230366|NCT01033097|Dermatitis
1230367|NCT01033097|inflammatory skin disease
1230368|NCT01033097|itch
1230369|NCT01033097|eczema
1230370|NCT01033084|Depressive Disorder, Major
1230371|NCT01033071|Hypertensive
1230372|NCT01033071|Blood Pressure, High
1230373|NCT01033071|Cardiovascular disease
1230374|NCT01033071|Vascular Disease
1230375|NCT01033071|Drug Therapy
1230376|NCT01033058|STEMI
1230377|NCT01033058|atorvastatin
1230378|NCT01033058|PCI
1230379|NCT01033045|Hepatitis C
1230380|NCT01033045|Viral
1230381|NCT01033045|Non-A
1230382|NCT01033045|Non-B
1230383|NCT01033045|Parenterally-Transmitted
1230384|NCT01033032|Metastatic Breast Cancer
1230385|NCT01033032|Amrubicin
1230386|NCT01033019|Basal cell carcinomas,
1230387|NCT01033019|sporadic,
1230388|NCT01033019|superficial and nodular,
1230389|NCT01033019|skin
1230390|NCT01033006|Peripheral Nerves
1230391|NCT01033006|Axillary Block
1230392|NCT01033006|MRI
1230393|NCT01032993|CoQ10
1230394|NCT01032993|Statins
1230395|NCT01032993|Myalgia
1230396|NCT01032993|Muscle Pain
1230397|NCT01032993|Muscle Weakness
1230398|NCT01032980|HUMENZA
1230399|NCT01032980|PANENZA
1230400|NCT01032980|Influenza
1230401|NCT01032980|Swine-Origin Influenza A H1N1 Virus
1230402|NCT01032980|Influenza virus vaccines
1230403|NCT01032967|squamous cell carcinoma
1230404|NCT01032967|esophagectomy
1230405|NCT01032967|chemoradiotherapy
1230406|NCT01032967|chemoradiation
1230407|NCT01032967|Squamous cell carcinomas of the esophagus
1230408|NCT01032954|Botulinum Toxin
1230409|NCT01032954|Rejuvenation
1230410|NCT01032954|Facial dynamic wrinkles
1230411|NCT01032941|Portal Hypertension
1230412|NCT01032941|Portal Pressure Measurement
1230413|NCT01032941|VSL3
1230414|NCT01032941|Cirrhosis
1230415|NCT01032941|End Stage Liver Disease
1230416|NCT01032941|Probiotics
1230417|NCT01032928|Swallowing
1230418|NCT01032928|Dysphagia
1230419|NCT01032928|Breathing and swallowing
1230420|NCT01032928|Oropharyngeal cancer
1230421|NCT01032915|Quiescent uveitis
1230422|NCT01032915|intermediate uveitis
1230423|NCT01032915|panuveitis
1230424|NCT01032915|posterior uveitis
1230425|NCT01032915|uveitis
1230426|NCT01032902|Human immunodeficiency virus
1230427|NCT01032902|Rapid Test
1230428|NCT01032902|HIV
1230429|NCT01032902|HIV Seronegativity
1230430|NCT01032876|Congenital Heart disease
1230431|NCT01032876|Cardiopulmonary bypass
1230432|NCT01032876|Neonatal brain injury
1230433|NCT01032876|Deep Hypothermic Circulatory Arrest
1230434|NCT01032876|Antegrade Cerebral Perfusion
1230435|NCT01032863|Chronic musculoskeletal pain
1230436|NCT01032863|Benign joint hypermobility syndrome
1230437|NCT01032863|Fibromyalgia
1230438|NCT01032850|INST 0820
1230439|NCT01032850|sorafenib
1230440|NCT01032850|capecitabine
1230441|NCT01032850|hepatocellular carcinoma
1230442|NCT01032850|lung
1230443|NCT01032850|nexavar
1230444|NCT01032850|xeloda
1230445|NCT01032850|liver cancer
1230446|NCT01032824|Complementary Therapies
1230447|NCT01032811|ADHD, childhood cancer
1230448|NCT01032811|ADHD/Secondary ADHD Among Survivors of Childhood Cancer
1230449|NCT01032785|Patent Foramen Ovale
1230450|NCT01032785|Patent Ductus Arteriosus
1230451|NCT01032785|PFO
1230452|NCT01032785|PDA
1230453|NCT01032772|alcohol-exposed pregnancy
1230454|NCT01032772|tobacco-exposed pregnancy
1230455|NCT01032772|alcohol
1230456|NCT01032772|contraception
1230457|NCT01032772|smoking
1230458|NCT01032772|pregnancy
1230459|NCT01032746|colon cancer
1230460|NCT01032746|rectal cancer
1230461|NCT01032733|Weight Loss
1230462|NCT01032733|Physical Function
1230463|NCT01032733|Oxidative Stress
1230464|NCT01032733|Inflammation
1230465|NCT01032720|ultrasound
1230466|NCT01032720|osteoarthritis
1230467|NCT01032720|knee
1230468|NCT01032720|corticosteroids
1230469|NCT01032720|intra-articular
1230470|NCT01032720|injections
1230471|NCT01032694|Community-Acquired Pneumonia
1230472|NCT01032694|Azithromycin SR
1230473|NCT01032694|Amoxiclav
1230474|NCT01032681|Solid tumor
1230475|NCT01032681|B-Cell Non-Hodgkin Lymphoma
1230476|NCT01032681|Immunocytokine
1230477|NCT01032681|interleukin-2
1230478|NCT01032681|immunotherapy
1230479|NCT01032681|Metastatic or Locally Advanced Solid Tumors or B-Cell Non-Hodgkin Lymphoma
1230480|NCT01032668|percutaneous coronary intervention, clopidogrel resistance, ASA resistance
1230481|NCT01032655|Helicobacter pylori
1230482|NCT01032655|sequential therapy
1230483|NCT01032655|susceptibility-driven
1230484|NCT01032655|rescue
1230485|NCT01032655|levofloxacin
1230486|NCT01032655|clarithromycin
1230487|NCT01032655|salvage
1230488|NCT01032655|treatment failure
1230489|NCT01032655|those who fail from two standard eradication therapies
1230490|NCT01032642|infertility fallopian tubes
1230491|NCT01032629|Diabetes
1230492|NCT01032629|Type 2 diabetes mellitus
1230493|NCT01032629|Cardiovascular risk
1230494|NCT01032629|Cardiovascular outcomes
1230495|NCT01032629|Canagliflozin (JNJ-28431754)
1230496|NCT01032629|Placebo
1230497|NCT01032616|splanchnic bed
1230498|NCT01032616|theronine and lysine metabolism uptake
1230499|NCT01032616|isotopes
1230500|NCT01032616|metabolism of two indispensable amino acids, threonine and lysine, by the splanchnic bed by Healthy Males
1230501|NCT01032603|IXT
1230502|NCT01032603|Exotropia
1230503|NCT01032603|Strabismus
1230504|NCT01032603|Intermittent exotropia
1230505|NCT01032590|weight changes
1230506|NCT01032590|cancer survivor
1230507|NCT01032590|stage I colon cancer
1230508|NCT01032590|stage II colon cancer
1230509|NCT01032590|stage III colon cancer
1230510|NCT01032590|stage I rectal cancer
1230511|NCT01032590|stage II rectal cancer
1230512|NCT01032590|stage III rectal cancer
1230513|NCT01032577|ischemic cardiomyopathy
1230514|NCT01032577|nonischemic cardiomyopathy
1230515|NCT01032577|implant
1230516|NCT01032577|bipolar sensing
1230517|NCT01032577|extended bipolar sensing
1230518|NCT01032564|estimate the interest of the measure of cervix elasticity degree by elastography in prediction of premature birth within a population of pregnant women
1230519|NCT01032551|Coronary Angiogram
1230520|NCT01032551|Decision Aid
1230521|NCT01032551|Vascular Access
1230522|NCT01032551|Radial
1230523|NCT01032551|Femoral
1230524|NCT01032538|Unicondylar Knee Replacement
1230525|NCT01032525|Crohn's Disease
1230526|NCT01032525|Ulcerative Colitis
1230527|NCT01032525|IBD
1230528|NCT01032525|Inflammatory Bowel Disease in Monroe County, NY
1230529|NCT01032512|IMMUNE-ENHANCING
1230530|NCT01032512|GLUTAMINE
1230531|NCT01032512|ARGININE
1230532|NCT01032512|OMEGA 3 FATTY ACIDS
1230533|NCT01032512|ONCOLOGIC SURGERY
1230534|NCT01032512|PREOPERATIVE NUTRITION
1230535|NCT01032499|Acne Vulgaris
1230536|NCT01032499|Boil
1230537|NCT01032499|Taro Elixir
1230538|NCT01032486|Rasagiline
1230539|NCT01032486|Sleep
1230540|NCT01032486|Sleepiness
1230541|NCT01032486|Parkinson's Disease Sleep Scale
1230542|NCT01032486|Epworth Sleepiness Scale
1230543|NCT01032460|airway
1230544|NCT01032460|airway device
1230545|NCT01032460|cervical spine immobilisation
1230546|NCT01032434|sertraline
1230547|NCT01032434|Polysomnograph
1230548|NCT01032421|women admitted to the In Vitro Fertilization unit
1230549|NCT01032408|Influenza A Virus
1230550|NCT01032408|Virus Diseases
1230551|NCT01032408|Influenza, Human
1230552|NCT01032408|HIV-1
1230553|NCT01032408|Immunodeficiency Virus
1230554|NCT01032408|H1N1
1230555|NCT01032408|HIV Infection
1230556|NCT01032408|Immunogenicity
1230557|NCT01032408|safety
1230558|NCT01032408|tolerability
1230559|NCT01032395|H1N1
1230560|NCT01032395|Pulmonary Disease
1230561|NCT01032395|Heart Disease
1230562|NCT01032395|Diabetes
1230563|NCT01032395|Influenza
1230564|NCT01032395|immunogenicity
1230565|NCT01032395|safety
1230566|NCT01032395|tolerability
1230567|NCT01032382|leishmaniasis
1230568|NCT01032382|cutaneous
1230569|NCT01032382|WR 279,396
1230570|NCT01032382|paromomycin
1230571|NCT01032382|gentamicin
1230572|NCT01032382|pharmacokinetics
1230573|NCT01032382|safety
1230574|NCT01032382|efficacy
1230575|NCT01032369|"Over-weight or obese subjects with learning disability who have completed Nitzan Onim two-year training program and live in housing within the community"
1230576|NCT01032356|Distal Radius fracture
1230577|NCT01032343|Immunosuppression
1230578|NCT01032343|Ultraviolet radiation
1230579|NCT01032343|Nickel
1230580|NCT01032343|Contact hypersensitivity
1230581|NCT01032330|intermittent exotropia
1230582|NCT01032330|IXT
1230583|NCT01032330|natural history
1230584|NCT01032330|occlusion therapy
1230585|NCT01032330|occlusion
1230586|NCT01032330|patching
1230587|NCT01032330|strabismus
1230588|NCT01032330|strabismus treatment
1230589|NCT01032330|stereoacuity
1230590|NCT01032330|motor alignment
1230591|NCT01032317|Arrhythmia
1230592|NCT01032317|Electrophysiology
1230593|NCT01032317|Fibrillation
1230594|NCT01032317|Tachycardia
1230595|NCT01032317|Ablation
1230596|NCT01032317|Atrial Fibrillation (AF)
1230597|NCT01032317|Ischemic Ventricular Tachycardia (VT)
1230598|NCT01032291|Colorectal cancer
1230599|NCT01032291|Revlimid
1230600|NCT01032291|Lenalidomide
1230601|NCT01032291|Cetuximab
1230602|NCT01032291|Erbitux
1230603|NCT01032291|KRAS
1230604|NCT01032278|cardiac toxicity
1230605|NCT01032278|unspecified adult solid tumor, protocol specific
1230606|NCT01032265|female
1230607|NCT01032265|stress urinary incontinence
1230608|NCT01032265|treatment
1230609|NCT01032265|pelvic floor muscle training
1230610|NCT01032265|cognitive behavioral therapy
1230611|NCT01032265|internet
1230612|NCT01032265|life style
1230613|NCT01032265|pamphlet
1230614|NCT01032265|eHealth
1230615|NCT01032252|fall prevention
1230616|NCT01032252|general practitioners setting
1230617|NCT01032252|implementation
1230618|NCT01032252|network
1230619|NCT01032252|community dwelling older adults
1230620|NCT01032252|exercise intervention
1230621|NCT01032239|Severe spasticity in post-stroke patients
1230622|NCT01032200|fatigue
1230623|NCT01032200|cognitive/functional effects
1230624|NCT01032200|adult giant cell glioblastoma
1230625|NCT01032200|adult glioblastoma
1230626|NCT01032200|adult gliosarcoma
1230627|NCT01032200|adult anaplastic astrocytoma
1230628|NCT01032200|adult anaplastic oligodendroglioma
1230629|NCT01032200|adult mixed glioma
1230630|NCT01032200|adult diffuse astrocytoma
1230631|NCT01032200|adult pilocytic astrocytoma
1230632|NCT01032200|adult pineal gland astrocytoma
1230633|NCT01032200|adult subependymal giant cell astrocytoma
1230634|NCT01032200|adult oligodendroglioma
1230635|NCT01032200|adult anaplastic ependymoma
1230636|NCT01032200|adult ependymoma
1230637|NCT01032200|adult myxopapillary ependymoma
1230638|NCT01032200|adult subependymoma
1230639|NCT01032200|adult anaplastic meningioma
1230640|NCT01032200|adult grade I meningioma
1230641|NCT01032200|adult grade II meningioma
1230642|NCT01032200|adult grade III meningioma
1230643|NCT01032200|adult papillary meningioma
1230644|NCT01032200|adult brain stem glioma
1230645|NCT01032187|Visceral leishmaniasis
1230646|NCT01032187|Amphotericin B deoxycholate
1230647|NCT01032187|Meglumine antimoniate
1230648|NCT01032187|Children
1230649|NCT01032187|Brazil
1230650|NCT01032174|Azithromycin SR Amoxiclav 1000 mg Maxillary Sinusitis
1230651|NCT01032161|Delirium
1230652|NCT01032161|Postoperative
1230653|NCT01032161|Non-cardiovascular surgery
1230654|NCT01032161|Post-anaesthesia care unit
1230655|NCT01032161|patients between 3 to 12 years old
1230656|NCT01032161|undergoing selective non-cardiac surgery
1230657|NCT01032161|under general anesthesia
1230658|NCT01032161|surgery
1230659|NCT01032161|general anesthesia
1230660|NCT01032148|Recurrent
1230661|NCT01032148|Refractory
1230662|NCT01032122|melanoma
1230663|NCT01032122|rituximab
1230664|NCT01032122|metastatic
1230665|NCT01032122|stage IIIc/IV
1230666|NCT01032122|stem cell
1230667|NCT01032122|overall survival
1230668|NCT01032122|disease free interval
1230669|NCT01032122|anti-CD20 therapy
1230670|NCT01032083|SSRI antidepressant
1230671|NCT01032083|Negative symptoms
1230672|NCT01032083|Schizophrenia
1230673|NCT01032070|phase 2
1230674|NCT01032070|erlotinib
1230675|NCT01032070|pediatric
1230676|NCT01032070|etoposide
1230677|NCT01032070|ependymoma
1230678|NCT01032057|adenocarcinoma of the pancreas
1230679|NCT01032057|stage II pancreatic cancer
1230680|NCT01032057|stage III pancreatic cancer
1230681|NCT01032044|Barrett's esophagus
1230682|NCT01032044|EsoGastroDuodenoscopy
1230683|NCT01032044|Barrett's carcinoma
1230684|NCT01032044|adenocarcinoma
1230685|NCT01032044|Cellvizio
1230686|NCT01032044|endomicroscopy
1230687|NCT01032044|probe-based Confocal Laser Endomicroscopy
1230688|NCT01032044|pCLE
1230689|NCT01032044|Radio-frequency ablation
1230690|NCT01032044|Endoscopic mucosal resection
1230691|NCT01032044|Photodynamic therapy
1230692|NCT01032031|Green tea
1230693|NCT01032031|Vitamin C
1230694|NCT01032031|Ultraviolet radiation
1230695|NCT01032031|Inflammation
1230696|NCT01032031|Photoageing
1230697|NCT01032018|Acute coronary syndrome
1230698|NCT01032018|Depression
1230699|NCT01032018|Satisfaction with care
1230700|NCT01031992|Hereditary hemorrhagic telangiectasia
1230701|NCT01031992|Rendu-Osler-Weber syndrome
1230702|NCT01031992|Epistaxis
1230703|NCT01031992|Nosebleeds
1230704|NCT01031992|Anemia
1230705|NCT01031992|Tranexamic acid
1230706|NCT01031992|Antifibrinolytics
1230707|NCT01031979|PTSD
1230708|NCT01031979|Prolonged Exposure
1230709|NCT01031979|extinction
1230710|NCT01031979|habituation
1230711|NCT01031979|psychophysiology
1230712|NCT01031966|ESRD
1230713|NCT01031953|nausea and vomiting
1230714|NCT01031953|unspecified adult solid tumor, protocol specific
1230715|NCT01031927|obsessive compulsive disorder
1230716|NCT01031927|sarcosine
1230717|NCT01031927|glycine transporter I
1230718|NCT01031927|NMDA receptor
1230719|NCT01031914|Paced Breathing
1230720|NCT01031914|OSA
1230721|NCT01031914|sleep/wake detection
1230722|NCT01031901|Tuberous Sclerosis
1230723|NCT01031901|Neurofibromatoses
1230724|NCT01031901|Angiofibroma
1230725|NCT01031901|Neurofibroma
1230726|NCT01031901|Sirolimus
1230727|NCT01031888|Corneal re-epithelialization
1230728|NCT01031888|Topical insulin application
1230729|NCT01031888|pars planar vitrectomy
1230730|NCT01031888|diabetic retinopathy
1230731|NCT01031888|penetrating keratoplasty
1230732|NCT01031875|recurrent bladder cancer
1230733|NCT01031875|stage IV bladder cancer
1230734|NCT01031875|recurrent urethral cancer
1230735|NCT01031875|distal urethral cancer
1230736|NCT01031875|proximal urethral cancer
1230737|NCT01031875|urethral cancer associated with invasive bladder cancer
1230738|NCT01031875|metastatic transitional cell cancer of the renal pelvis and ureter
1230739|NCT01031875|recurrent transitional cell cancer of the renal pelvis and ureter
1230740|NCT01031875|stage IV urethral cancer
1230741|NCT01031862|healthy volunteer
1230742|NCT01031862|reverse cholesterol transport
1230743|NCT01031862|RCT
1230744|NCT01031862|3H
1230745|NCT01031849|HIV 1 patients
1230746|NCT01031836|Systemic Lupus Erythematosus
1230747|NCT01031836|Japanese
1230748|NCT01031836|phase 2
1230749|NCT01031836|safety
1230750|NCT01031836|tolerability
1230751|NCT01031836|MEDI-545
1230752|NCT01031836|Autoimmune Disease
1230753|NCT01031836|Immune System Diseases
1230754|NCT01031823|Autism Spectrum Disorder
1230755|NCT01031810|Treatment Resistant depression
1230756|NCT01031810|Major Depression
1230757|NCT01031810|MDD
1230758|NCT01031810|Depression
1230759|NCT01031797|SLE
1230760|NCT01031797|Disease activity score
1230761|NCT01031797|QT dispersion
1230762|NCT01031784|liver metastasis
1230763|NCT01031784|Liver tumors
1230764|NCT01031784|microspheres
1230765|NCT01031784|holmium
1230766|NCT01031784|toxicity
1230767|NCT01031771|Cerebral Palsy
1230768|NCT01031771|Deglutition
1230769|NCT01031771|Deglutition disorders
1230770|NCT01031771|Endoscopy
1230771|NCT01031758|Low HDL
1230772|NCT01031758|High HDL
1230773|NCT01031758|HDL
1230774|NCT01031758|Reverse Cholesterol Transport
1230775|NCT01031758|RCT
1230776|NCT01031758|healthy volunteer
1230777|NCT01031758|3H
1230778|NCT01031758|Average HDL
1230779|NCT01031745|Complementary Therapies
1230780|NCT01031745|Drug Users
1230781|NCT01031732|Minimally invasive
1230782|NCT01031732|Total hip arthroplasty
1230783|NCT01031732|Functional outcome
1230784|NCT01031732|To compare the surgical results of 4 MIS THA techniques
1230785|NCT01031732|To investigate the functional outcomes of 4 MIS THA techniques
1230786|NCT01031732|To study the biochemical parameters after the MIS surgeries.
1230787|NCT01031719|Influenza A Virus
1230788|NCT01031719|Virus Diseases
1230789|NCT01031719|Influenza, Human
1230790|NCT01031719|H1N1
1230791|NCT01031719|Immunogenicity
1230792|NCT01031719|safety
1230793|NCT01031719|tolerability
1230794|NCT01031719|tumors
1230795|NCT01031719|oncology
1230796|NCT01031706|Hypertonic Saline
1230797|NCT01031706|Pediatrics
1230798|NCT01031706|Cystic Fibrosis
1230799|NCT01031706|Mucociliary Clearance
1230800|NCT01031706|Lung Clearance Index
1230801|NCT01031693|Nicotine
1230802|NCT01031693|Cigarettes
1230803|NCT01031693|Tobacco
1230804|NCT01031693|Transcranial Magnetic Stimulation (TMS)
1230805|NCT01031693|Cue-Induced Craving
1230806|NCT01031693|Smoking
1230807|NCT01031680|dapagliflozin
1230808|NCT01031680|diabetes
1230809|NCT01031680|cardiovascular disease
1230810|NCT01031680|hypertension
1230811|NCT01031667|Patients treated with PCI with stent
1230812|NCT01031641|Patient-Reported Outcomes
1230813|NCT01031641|Symptoms
1230814|NCT01031641|Instrument Development
1230815|NCT01031641|Adverse Events
1230816|NCT01031641|Questionnaire
1230817|NCT01031641|Patient Reported Outcomes
1230818|NCT01031628|GIST
1230819|NCT01031628|Gastrointestinal stromal tumors
1230820|NCT01031628|Exon 9
1230821|NCT01031628|Gleevec
1230822|NCT01031628|Imatinib blood levels
1230823|NCT01031615|School age children and adolescents exposed to a potentially traumatic event
1230824|NCT01031602|Cancer
1230825|NCT01031602|Gynecology
1230826|NCT01031602|Sexual Dysfunction
1230827|NCT01031602|Depression
1230828|NCT01031602|Anxiety
1230829|NCT01031602|Underserved
1230830|NCT01031602|Minority
1230831|NCT01031602|Psychological distress
1230832|NCT01031589|TMC278-TiDP15-C158
1230833|NCT01031589|TMC278-C158
1230834|NCT01031589|TMC278
1230835|NCT01031589|HIV
1230836|NCT01031589|Non-nucleoside reverse transcriptase inhibitor
1230837|NCT01031589|HIV Seronegativity
1230838|NCT01031576|Osteoarthritis, posture, knee
1230839|NCT01031563|Risk Taking
1230840|NCT01031563|Schizophrenia
1230841|NCT01031563|Drug Abuse/Dependence
1230842|NCT01031563|Comorbidity
1230843|NCT01031563|Impulsivity
1230844|NCT01031563|Drug Abuse
1230845|NCT01031550|liver resection for liver disease
1230846|NCT01031537|FSME-Immun
1230847|NCT01031537|TBEV
1230848|NCT01031537|TBE Researcher
1230849|NCT01031537|Plavivirus
1230850|NCT01031537|Anti-TBEV Levels
1230851|NCT01031537|Tic-Borne Encephalitis
1230852|NCT01031524|Plasmodium falciparum malaria
1230853|NCT01031511|High-Functioning Autistic Spectrum Disorder
1230854|NCT01031511|Anxiety
1230855|NCT01031511|Cognitive Behavioural Therapy
1230856|NCT01031511|Social Recreational
1230857|NCT01031511|Parent Stress
1230858|NCT01031498|Nausea
1230859|NCT01031498|Vomiting
1230860|NCT01031498|CINV
1230861|NCT01031498|Leukemia
1230862|NCT01031498|High-risk Myelodysplastic syndrome
1230863|NCT01031498|AML
1230864|NCT01031498|Hematologic malignancies
1230865|NCT01031498|Hematologic Disorder
1230866|NCT01031498|Continuous multi-day chemotherapy
1230867|NCT01031498|High-dose cytarabine
1230868|NCT01031498|Palonosetron
1230869|NCT01031498|Aloxi
1230870|NCT01031498|Ondansetron
1230871|NCT01031498|Zofran
1230872|NCT01031485|hypertension
1230873|NCT01031485|blood pressure
1230874|NCT01031485|milk peptides
1230875|NCT01031485|bioactive peptides
1230876|NCT01031485|randomized controlled trial
1230877|NCT01031472|HIV, relative bioavailability, food effect, GSK2248761, healthy subjects
1230878|NCT01031472|HIV Seronegativity
1230879|NCT01031446|stage IV breast cancer
1230880|NCT01031446|Human epidermal growth factor (HER2)-negative breast cancer
1230881|NCT01031446|triple-negative breast cancer
1230882|NCT01031446|hormone-resistant breast cancer
1230883|NCT01031433|Tobacco Craving
1230884|NCT01031433|Virtual Reality
1230885|NCT01031433|Schizophrenia
1230886|NCT01031433|Smoking
1230887|NCT01031420|bladder
1230888|NCT01031420|cancer
1230889|NCT01031420|invasive
1230890|NCT01031407|Adolescents and Adults
1230891|NCT01031407|Autism
1230892|NCT01031407|Functional Magnetic Resonance Imaging (fMRI)
1230893|NCT01031407|MEG
1230894|NCT01031407|Structural MRI
1230895|NCT01031407|HV
1230896|NCT01031407|Autism Spectrum Disorder
1230897|NCT01031407|ASD
1230898|NCT01031407|Autistic Disorder
1230899|NCT01031407|Asperger Syndrome
1230900|NCT01031407|Mental Retardation
1230901|NCT01031407|Healthy Volunteer
1230902|NCT01031394|exercise
1230903|NCT01031394|resistance training
1230904|NCT01031381|Recurrent
1230905|NCT01031381|ovarian
1230906|NCT01031381|fallopian tube
1230907|NCT01031381|primary peritoneal
1230908|NCT01031381|cancer
1230909|NCT01031381|Recurrent ovarian, fallopian tube, primary peritoneal cancer
1230910|NCT01031355|Female Contraception
1230911|NCT01031355|Contraceptives, Oral
1230912|NCT01031342|Colonoscopy
1230913|NCT01031342|Gastrointestinal bleeding
1230914|NCT01031316|Echocardiography
1230915|NCT01031316|Infant, Premature
1230916|NCT01031316|Infant, Very Low Birth Weight
1230917|NCT01031303|Diphtheria
1230918|NCT01031303|Tetanus
1230919|NCT01031303|Pertussis
1230920|NCT01031303|Poliomyelitis
1230921|NCT01031303|PENTAXIM™
1230922|NCT01031303|TETRAXIM™
1230923|NCT01031290|Cue-Induced Craving
1230924|NCT01031290|Cannabis
1230925|NCT01031290|Functional Magnetic Resonance Imaging (fMRI)
1230926|NCT01031290|Repetitive TMS (rTMS)
1230927|NCT01031290|Cannabis Craving
1230928|NCT01031277|Hypercholesterolemia
1230929|NCT01031277|Update NCEP ATP111
1230930|NCT01031277|Survey
1230931|NCT01031264|social drinkers
1230932|NCT01031238|PEM Uptake Value
1230933|NCT01031238|PUV
1230934|NCT01031238|Standardized Uptake Value
1230935|NCT01031238|SUV
1230936|NCT01031238|Malignancies of the Breast
1230937|NCT01031238|[18F]-FDG-PET/CT scanning
1230938|NCT01031238|Tumor
1230939|NCT01031238|positron emission tomography/computed tomography
1230940|NCT01031238|PET/CT scan
1230941|NCT01031225|Synta
1230942|NCT01031225|STA 9090
1230943|NCT01031225|ganetespib)
1230944|NCT01031225|Lung Cancer
1230945|NCT01031225|Non Small Cell Lung Cancer
1230946|NCT01031225|NSCLC
1230947|NCT01031212|cancer
1230948|NCT01031212|neoplasms
1230949|NCT01031212|adult solid tumor
1230950|NCT01031212|antineoplastic agents
1230951|NCT01031199|Multiple sclerosis
1230952|NCT01031199|Diagnostic imaging
1230953|NCT01031199|Neuroinflammation
1230954|NCT01031199|PET diagnosis
1230955|NCT01031199|PET tracer
1230956|NCT01031186|healthy male volunteers
1230957|NCT01031186|GSK356278
1230958|NCT01031186|first time in man
1230959|NCT01031186|major depressive disorder
1230960|NCT01031173|α galactosidase A
1230961|NCT01031173|glycosphingolipid storage disorder
1230962|NCT01031173|agalsidase alfa
1230963|NCT01031173|enzyme replacement therapy
1230964|NCT01031173|Replagal
1230965|NCT01031173|agalsidase beta
1230966|NCT01031173|Fabrazyme
1230967|NCT01031160|Adolescence
1230968|NCT01031160|Obesity
1230969|NCT01031160|Substance Abuse
1230970|NCT01031160|Etiology
1230971|NCT01031160|Social and Environmental Contexts
1230972|NCT01031160|Health Behaviors
1230973|NCT01031147|Magnetic resonance angiography
1230974|NCT01031147|Intracranial aneurysm
1230975|NCT01031147|Digital subtraction angiography
1230976|NCT01031147|Volume rendering
1230977|NCT01031121|Cigarette Smoking
1230978|NCT01031121|Biomarkers
1230979|NCT01031121|Nicotine
1230980|NCT01031121|Cotinine
1230981|NCT01031121|Metabolites
1230982|NCT01031095|percutaneous coronary intervention
1230983|NCT01031095|low dose intracoronary heparin
1230984|NCT01031069|Cervarix
1230985|NCT01031069|Gardasil
1230986|NCT01031069|Immunogenicity
1230987|NCT01031069|Cervical cancer
1230988|NCT01031069|Safety
1230989|NCT01031069|HPV vaccine
1230990|NCT01031043|IEM
1230991|NCT01031030|stage I breast cancer
1230992|NCT01031030|stage II breast cancer
1230993|NCT01031030|stage IIIA breast cancer
1230994|NCT01031030|stage IIIB breast cancer
1230995|NCT01031030|stage IIIC breast cancer
1230996|NCT01031017|twin pregnancies
1230997|NCT01031017|preterm delivery
1230998|NCT01031017|progesterone
1230999|NCT01030991|Heart failure
1231000|NCT01030991|Ejection fraction
1231001|NCT01030991|Diastolic heart failure
1231002|NCT01030991|Diastolic dysfunction
1231003|NCT01030991|Ventricular-arterial coupling
1231004|NCT01030991|Exercise testing
1231005|NCT01030991|Echocardiography
1231006|NCT01030991|Tissue Doppler imaging
1231007|NCT01030991|Arterial tonometry
1231008|NCT01030991|Genetics
1231009|NCT01030991|Epidemiology
1231010|NCT01030978|Impaired Glucose Tolerance
1231011|NCT01030978|PreDiabetes
1231012|NCT01030978|Diabetes Prevention
1231013|NCT01030965|Chronic Bronchitis
1231014|NCT01030965|Anticholinergic
1231015|NCT01030965|Emphysema
1231016|NCT01030965|Long-acting muscarinic antagonist
1231017|NCT01030965|COPD
1231018|NCT01030952|Diabetes Mellitus, Type 2
1231019|NCT01030952|Nateglinide
1231020|NCT01030952|Acarbose
1231021|NCT01030952|glucose fluctuation
1231026|NCT01030913|Chronic Lymphocytic Leukemia
1231027|NCT01030900|Immunosuppression
1231028|NCT01030900|Microenvironment
1231029|NCT01030900|Hodgkin Lymphoma
1231030|NCT01030900|B-Cell Lymphoma
1231031|NCT01030900|Microarray
1231032|NCT01030900|Diffuse Large B-Cell Lymphoma
1231033|NCT01030887|Cancer
1231034|NCT01030887|Exercise
1231035|NCT01030887|Physical Activity
1231036|NCT01030887|Randomized controlled trial
1231037|NCT01030874|hypotension, orthostatic
1231038|NCT01030874|falls
1231039|NCT01030874|rehabilitation
1231040|NCT01030874|blood pressure
1231041|NCT01030874|aging
1231042|NCT01030861|type 1 diabetes
1231043|NCT01030861|pre-diabetic
1231044|NCT01030861|autoantibody positive
1231045|NCT01030861|at risk for type 1 diabetes
1231046|NCT01030861|glucose intolerance
1231047|NCT01030861|relatives of people with type 1 diabetes
1231048|NCT01030835|Screening Protocol
1231049|NCT01030835|Comorbidity
1231050|NCT01030835|Normal Controls
1231051|NCT01030835|Substance Use Disorders
1231052|NCT01030835|Substance Abuse Disorders
1231053|NCT01030822|Catch-up vaccination
1231054|NCT01030822|Safety
1231055|NCT01030822|Pneumococcal vaccine
1231056|NCT01030822|Pneumococcal disease
1231057|NCT01030822|Booster vaccination
1231058|NCT01030822|Immunogenicity
1231059|NCT01030809|Crohn's disease
1231060|NCT01030809|community based gastroenterology practices Canada and Belgium
1231061|NCT01030809|Cluster randomization controlled trial
1231062|NCT01030809|Remission
1231063|NCT01030809|Corticosteroids
1231064|NCT01030809|Documented diagnosis of Crohn's disease
1231065|NCT01030770|Diabetes
1231066|NCT01030770|Vitreous Haemorrhages
1231067|NCT01030757|Liver Cancer
1231068|NCT01030757|Metastatic Liver Cancer
1231069|NCT01030757|Tomotherapy
1231070|NCT01030757|Stereotactic Body Radiation Therapy
1231071|NCT01030744|Gestational Diabetes
1231072|NCT01030744|Self-Monitoring of Blood Glucose
1231073|NCT01030731|Renal Dialysis, Ceftobiprole
1231074|NCT01030731|Skin and soft tissue Infections
1231075|NCT01030731|Staphylococcal Skin Infections
1231076|NCT01030731|Streptococcal Infection
1231077|NCT01030705|Bradycardia
1231078|NCT01030705|pacemaker
1231079|NCT01030692|Cocaine
1231080|NCT01030692|Rivastigmine
1231081|NCT01030692|Huperzine A
1231082|NCT01030679|Diabetes Mellitus, type 2
1231083|NCT01030679|Glitazone
1231084|NCT01030666|periodontal regeneration
1231085|NCT01030666|radiographic bone fill
1231086|NCT01030666|infrabony defects
1231087|NCT01030666|randomized placebo-controlled clinical trial
1231088|NCT01030666|guided tissue regeneration, periodontal
1231089|NCT01030653|Voriconazole
1231090|NCT01030653|Pharmacokinetics
1231091|NCT01030653|Obese
1231092|NCT01030653|Healthy Volunteer
1231093|NCT01030640|intraepidermal nerve fiber density
1231094|NCT01030640|IENF
1231095|NCT01030640|tanezumab
1231096|NCT01030640|subcutaneous
1231097|NCT01030640|healthy volunteers
1231098|NCT01030627|Eclampsia
1231099|NCT01030627|Preeclampsia
1231100|NCT01030627|Magnesium sulfate
1231101|NCT01030614|Laparoscopic cholecystectomy,postoperative symptoms
1231102|NCT01030601|Diabetic
1231103|NCT01030601|Macular Edema
1231104|NCT01030601|Pseudophakic
1231105|NCT01030601|Dexamethasone
1231106|NCT01030601|Intravitreal
1231107|NCT01030601|Cataract surgery
1231114|NCT01030562|adolescent, vaccine, human papillomavirus, HPV
1231115|NCT01030549|cardiovascular magnetic resonance
1231116|NCT01030549|ventricular volumes
1231117|NCT01030549|ventricular function
1231118|NCT01030549|Healthy normal individuals from 20 to 80 years of age
1231119|NCT01030536|NHL
1231120|NCT01030536|CLL
1231121|NCT01030497|Cancer
1231122|NCT01030497|Cervical Lymph Node Metastases
1231123|NCT01030497|High-Resolution PET Imaging System
1231124|NCT01030497|Upper Aerodigestive Tract
1231125|NCT01030497|Head
1231126|NCT01030497|Neck
1231127|NCT01030497|HR PET Imaging System
1231128|NCT01030497|High-Resolution PET
1231129|NCT01030497|PET/CT
1231130|NCT01030497|PEMFlex Solo II
1231131|NCT01030497|positron emission tomography/computed tomography (PET/CT)
1231132|NCT01030484|NAFLD
1231133|NCT01030484|NASH
1231134|NCT01030484|non-alcoholic steatohepatitis
1231135|NCT01030484|fatty liver disease
1231136|NCT01030471|adolescents
1231137|NCT01030471|depression
1231138|NCT01030471|adherence
1231139|NCT01030471|family functioning
1231140|NCT01030471|intervention
1231141|NCT01030458|Blood pressure
1231142|NCT01030458|Hypertension
1231143|NCT01030458|Blacks
1231144|NCT01030458|Africa
1231145|NCT01030458|Blood pressure control
1231146|NCT01030458|Side-effects
1231147|NCT01030445|non-invasive cardiac output monitor
1231148|NCT01030445|electrical velocimetry
1231149|NCT01030445|Aesculon
1231150|NCT01030445|Icon
1231151|NCT01030445|pediatrics
1231152|NCT01030445|normal reference
1231153|NCT01030419|Aging
1231154|NCT01030419|Quality of Life
1231155|NCT01030419|Functional fitness
1231156|NCT01030406|Abuse Liability
1231157|NCT01030406|Abuse Prevention
1231158|NCT01030406|Abuse Resistance
1231159|NCT01030406|Abuse Deterrence
1231160|NCT01030393|hCG
1231161|NCT01030393|pregnancy
1231162|NCT01030393|implantation
1231163|NCT01030393|ICSI
1231164|NCT01030393|IVF
1231165|NCT01030380|Facial toning
1231166|NCT01030380|Facial lift
1231167|NCT01030380|Improve facial complexion
1231168|NCT01030380|Improve facial tone
1231169|NCT01030380|Improve radiance of the face
1231170|NCT01030380|Reduce signs of facial aging
1231171|NCT01030380|firming, lift, tone face
1231172|NCT01030367|Coronary artery disease
1231173|NCT01030354|Satiety
1231174|NCT01030354|Meal Replacements
1231175|NCT01030354|High Protein
1231176|NCT01030354|Standard Protein
1231177|NCT01030341|Diabetes
1231178|NCT01030341|Gastroparesis
1231179|NCT01030315|Erythropoietin
1231180|NCT01030315|Long-acting
1231181|NCT01030315|EPO
1231182|NCT01030302|Bortezomib retreatment
1231183|NCT01030302|Velcade
1231184|NCT01030302|Proteasome inhibitor
1231185|NCT01030302|Bortezomib
1231186|NCT01030289|food cravings
1231187|NCT01030250|Breast Cancer
1231188|NCT01030250|Adjuvant Chemotherapy
1231189|NCT01030237|Dry eye
1231190|NCT01030237|artificial tears
1231191|NCT01030224|Healthy volunteer
1231192|NCT01030224|First time in human
1231193|NCT01030211|Dengue
1231194|NCT01030211|Platelet transfusion
1231195|NCT01030211|Bleeding
1231196|NCT01030211|Prevention
1231197|NCT01030185|ascites
1231198|NCT01030185|liver cirrhosis
1231199|NCT01030159|Cancer Anemia Survey
1231200|NCT01030159|Thai National Cancer Institute
1231201|NCT01030133|pain
1231202|NCT01030120|chronic idiopathic urticaria
1231203|NCT01030120|etanercept
1231204|NCT01030107|sleep
1231205|NCT01030107|obesity
1231206|NCT01030107|children
1231207|NCT01030107|eating behaviors
1231208|NCT01030107|activity
1231209|NCT01030107|leptin
1231210|NCT01030107|ghrelin
1231211|NCT01030094|Topiramate
1231212|NCT01030094|Carbamazepine
1231213|NCT01030094|Valproic acid
1231214|NCT01030094|Epilepsy
1231215|NCT01030094|Bone mineral density
1231216|NCT01030094|Monotherapy
1231217|NCT01030081|24 hour blood pressure
1231218|NCT01030081|morning blood pressure surge
1231219|NCT01030081|amlodipine
1231220|NCT01030081|nifedipine GITS
1231221|NCT01030068|Smoking Cessation
1231222|NCT01030068|Yoga
1231223|NCT01030068|Wellness
1231224|NCT01030068|Feasibility
1231225|NCT01030068|Smoking Cessation Therapy
1231226|NCT01030055|Neoplasms
1231227|NCT01030055|Cancer
1231228|NCT01030055|Tumors
1231229|NCT01030055|Administration, oral
1231230|NCT01030055|Capsules
1231231|NCT01030055|CHIR258
1231232|NCT01030055|CHIR-258
1231233|NCT01030055|CHIR 258
1231234|NCT01030055|TKI258
1231235|NCT01030055|TKI-258
1231236|NCT01030055|TKI 258
1231237|NCT01030055|Bioavailability
1231238|NCT01030055|Food
1231239|NCT01030042|metastatic
1231240|NCT01030042|colorectal cancer
1231241|NCT01030042|two sequences therapy
1231242|NCT01030029|auricular acupuncture
1231243|NCT01030029|postoperative pain
1231244|NCT01030029|opioid consumption
1231245|NCT01030029|laparoscopic surgery
1231246|NCT01030029|ACUPUNCTURE THERAPY (IM) + EAR, EXTERNAL (IM)
1231247|NCT01030016|resistance exercise
1231248|NCT01030016|beta-blockers
1231249|NCT01030016|blood pressure
1231250|NCT01030003|Sleep-Disordered Breathing
1231251|NCT01030003|Snoring
1231252|NCT01030003|Pregnancy
1231253|NCT01030003|Fetal Growth Retardation
1231254|NCT01030003|Pre-Eclampsia
1231255|NCT01029990|participation
1231256|NCT01029990|mass screening
1231257|NCT01029990|cervical neoplasia
1231258|NCT01029990|health economics
1231259|NCT01029990|cost-benefit
1231260|NCT01029964|Childhood obesity
1231261|NCT01029964|Age-dependent
1231262|NCT01029964|Long-term treatment
1231263|NCT01029964|BMI SDS
1231264|NCT01029964|Dropouts
1231265|NCT01029951|Chiropractic; osteopathic physicians; manipulation; neck pain; adverse effects; randomized clinical trial
1231266|NCT01029951|Subacute non-specific neck pain
1231267|NCT01029938|Intracranial aneurysms;
1231268|NCT01029938|Covered stent;
1231269|NCT01029938|Coil embolization
1231270|NCT01029925|metastatic breast cancer
1231271|NCT01029925|lung cancer
1231272|NCT01029925|Previously treated metastatic breast cancer
1231273|NCT01029925|stage IIIb lung cancer
1231274|NCT01029925|stage IV lung cancer
1231275|NCT01029912|Stroke
1231276|NCT01029912|Hemiplegia
1231277|NCT01029912|Footdrop
1231278|NCT01029912|Electrical Stimulation
1231279|NCT01029912|Motor Relearning
1231280|NCT01029912|Neuroplasticity
1231281|NCT01029899|Colonoscopy
1231282|NCT01029899|Force
1231283|NCT01029899|Monitor
1231284|NCT01029899|Endoscopist
1231285|NCT01029899|Trainee
1231286|NCT01029886|diabetes
1231287|NCT01029886|exenatide once weekly
1231288|NCT01029886|Byetta
1231289|NCT01029886|liraglutide
1231290|NCT01029886|Victoza
1231291|NCT01029886|Amylin
1231292|NCT01029886|Lilly
1231293|NCT01029873|cancer
1231294|NCT01029873|immunotherapy
1231295|NCT01029873|targeted
1231296|NCT01029873|metastatic
1231297|NCT01029873|interleukin-2
1231298|NCT01029873|IL-2
1231299|NCT01029873|Cisplatin
1231300|NCT01029873|antitumor
1231301|NCT01029873|melanoma
1231302|NCT01029873|TCR
1231303|NCT01029873|T-cell receptor
1231304|NCT01029873|p53
1231305|NCT01029873|p53 gene
1231306|NCT01029873|p53 tumor suppressor protein
1231307|NCT01029860|Hypertension
1231308|NCT01029860|Ambulatory measurement
1231309|NCT01029847|Patients with axial spondyloarthritis
1231310|NCT01029834|BMI >85%for age and gender
1231311|NCT01029821|Low-Molecular-Weight-Heparin
1231312|NCT01029821|Open Reduction and Internal Fixation
1231313|NCT01029821|Thromboprophylaxis
1231314|NCT01029808|carriers of hemophilia
1231315|NCT01029782|Cellulitis
1231316|NCT01029782|Emergency Department
1231317|NCT01029782|Cefazolin
1231318|NCT01029782|Probenecid
1231319|NCT01029782|Cephalexin
1231320|NCT01029756|Pentax Airway Scope AWS S100
1231321|NCT01029756|Pentax AWS
1231322|NCT01029756|Macintosh
1231323|NCT01029756|Laryngoscope
1231324|NCT01029756|Video Laryngoscope
1231325|NCT01029743|TKR (Total Knee Replacement)
1231326|NCT01029743|THR (Total Hip Replacement)
1231327|NCT01029743|VTE (Venous Thromboembolism)
1231328|NCT01029743|LMWH (Low Molecular Weight Heparin)
1231329|NCT01029743|VKA (Vitamin K antagonist)
1231330|NCT01029730|Low grade lymphoma
1231331|NCT01029730|Previously untreated lymphoma
1231332|NCT01029730|Lymphoma first line
1231333|NCT01029730|bendamustine
1231334|NCT01029730|Treanda
1231335|NCT01029730|bortezomib
1231336|NCT01029730|Velcade
1231337|NCT01029730|rituximab
1231338|NCT01029730|Rituxan
1231339|NCT01029717|Central Venous Catheters
1231340|NCT01029717|blood stream infection
1231341|NCT01029717|children, intensive care
1231342|NCT01029717|Heparin bonded
1231343|NCT01029717|antibiotic coated
1231582|NCT01028976|Antioxidants
1231344|NCT01029717|Children in Paediatric Intensive Care Unit
1231345|NCT01029704|Diabetes Mellitus Type 2
1231346|NCT01029691|Sleep disordered breathing
1231347|NCT01029691|Preeclampsia
1231348|NCT01029691|Positive Airway Pressure
1231349|NCT01029678|Locally advanced lung cancer
1231350|NCT01029678|Elderly patients
1231351|NCT01029678|NSCLC
1231352|NCT01029665|Hernia, Diaphragmatic
1231353|NCT01029665|Asthma
1231354|NCT01029665|Feeding and Eating Disorders of Childhood
1231355|NCT01029665|Growth & Development
1231356|NCT01029652|frequent flares
1231357|NCT01029652|gout
1231358|NCT01029652|anti-interleukin-1β monoclonal antibody
1231359|NCT01029639|Pulsatile intravenous insulin
1231360|NCT01029639|Oral carbohydrate loading
1231361|NCT01029639|Respiratory Quotients
1231362|NCT01029639|Hypoglycemia
1231363|NCT01029639|Diabetes Mellitus, with complications
1231364|NCT01029600|Randomized study capsulotomy vs distention with steroid
1231365|NCT01029587|CAPS
1231366|NCT01029587|Kidney transplant
1231367|NCT01029587|Renal transplant
1231368|NCT01029587|Catastrophic Antiphospholipid Antibody Syndrome
1231369|NCT01029574|Rotator cuff lesions
1231370|NCT01029574|Platelet rich plasma
1231371|NCT01029574|Arthroscopic repair
1231372|NCT01029561|Metabolic syndrome
1231373|NCT01029561|Insulin Resistance
1231374|NCT01029561|Adipokines
1231375|NCT01029561|Proinflammatory markers
1231376|NCT01029561|Obstructive Sleep Apnea Syndrome
1231377|NCT01029561|Continuous Positive Airway Pressure
1231378|NCT01029561|Obesity
1231379|NCT01029561|Bariatric surgery
1231380|NCT01029548|HIV
1231381|NCT01029548|Therapeutic Vaccine
1231382|NCT01029522|Dyslipidemia
1231383|NCT01029509|Advanced Leukemia
1231384|NCT01029509|Acute myeloid leukemia
1231385|NCT01029509|ALL
1231386|NCT01029509|Chronic myeloid leukemia blast crisis
1231387|NCT01029509|CMS
1231388|NCT01029509|Acute lymphocytic leukemia
1231389|NCT01029509|Chronic lymphocytic leukemia
1231390|NCT01029509|Myelodysplastic syndromes
1231391|NCT01029509|MDS
1231392|NCT01029509|OPB 31121
1231393|NCT01029496|umbilical CORD CLAMPING
1231394|NCT01029496|Neonatal anemia
1231395|NCT01029496|Omphalitis
1231396|NCT01029483|Obesity
1231397|NCT01029483|Weight loss
1231398|NCT01029483|low carbohydrate diets
1231399|NCT01029483|high complex carbohydrate diets
1231400|NCT01029483|Healthy adults
1231401|NCT01029483|Body composition
1231402|NCT01029483|Energy Expenditure
1231403|NCT01029470|Luveris
1231404|NCT01029470|hyporesponse
1231405|NCT01029470|pituitary downregulation
1231406|NCT01029470|IVF
1231407|NCT01029470|Infertility women
1231408|NCT01029444|Diabetes
1231409|NCT01029444|Pulsatile intravenous insulin
1231410|NCT01029444|Oral carbohydrate loading
1231411|NCT01029444|Respiratory Quotients
1231412|NCT01029444|Hypoglycemia
1231413|NCT01029444|Hyperglycemia
1231414|NCT01029444|Diabetes Mellitus, with complications
1231415|NCT01029431|intubating laryngeal airway
1231416|NCT01029431|pediatric
1231417|NCT01029418|HCC
1231418|NCT01029418|hepatocellular carcinoma
1231419|NCT01029418|liver cancer
1231420|NCT01029405|Topical
1231421|NCT01029405|Plaque type psoriasis
1231422|NCT01029392|Diabetes
1231423|NCT01029392|Type I
1231424|NCT01029392|Newly Diagnosis Type I Diabetes Mellitus
1231425|NCT01029379|propofol
1231426|NCT01029379|depth of anesthesia
1231427|NCT01029379|pharmacogenetics
1231428|NCT01029379|Depth of anesthesia in correlation to plasma concentrations of propofol
1231429|NCT01029353|NICHD Neonatal Research Network
1231430|NCT01029353|Very Low Birth Weight (VLBW)
1231431|NCT01029353|Extremely Low Birth Weight (ELBW)
1231432|NCT01029353|Prematurity
1231433|NCT01029353|Laparotomy
1231434|NCT01029353|Drainage
1231435|NCT01029353|Isolated intestinal perforation
1231436|NCT01029353|Focal intestinal perforation
1231437|NCT01029340|Hemophilia A
1231438|NCT01029340|Factor VIII
1231439|NCT01029340|Prophylaxis
1231440|NCT01028170|Congestive Heart Failure
1231441|NCT01028170|Renal Insufficiency
1231442|NCT01028170|Cardio-renal Syndrome
1231443|NCT01028157|HIV
1231444|NCT01028157|risk reduction
1231445|NCT01028157|behavioral intervention
1231446|NCT01028144|Exercise
1231447|NCT01028144|Physical Activity
1231448|NCT01028144|Adolescent
1231449|NCT01028144|Minority Health
1231450|NCT01028131|cigarette smoking
1231451|NCT01028131|pregnancy
1231452|NCT01028131|intervention
1231453|NCT01028131|efficacy
1231454|NCT01028131|Motivational Interviewing
1231455|NCT01028131|Contingency Management
1231456|NCT01028118|domestic and sexual violence
1231457|NCT01028118|menopause
1231458|NCT01028118|professional improvement
1231459|NCT01028118|social support network
1231460|NCT01028105|Preoperative screening
1231461|NCT01028105|MRSA
1231462|NCT01028105|Incidence
1231463|NCT01028105|Postoperative infection
1231464|NCT01028105|Preoperative MRSA Screening Incidence
1231465|NCT01028105|Postoperative MRSA Infection Rate
1231466|NCT01028079|Back Pain
1231467|NCT01028079|Acute low back pain
1231468|NCT01028066|nutritional intervention
1231469|NCT01028066|nutritional counseling
1231470|NCT01028066|feeding behavior
1231471|NCT01028066|food consumption
1231472|NCT01028066|angioplasty
1231473|NCT01028053|Mild Cognitive Impairment
1231474|NCT01028053|Positron Emission Tomography
1231475|NCT01028053|National Institute of Neurological and Communicative Disorders and Stroke
1231476|NCT01028053|Alzheimer's Disease and Related Disorders Association
1231477|NCT01028053|Assess Prognostic Usefulness of Flutemetamol Injection for Identifying Subjects who will Convert to Clinically Probable Alzheimer's Disease
1231478|NCT01028040|Phase I
1231479|NCT01028040|AZD3043
1231480|NCT01028040|Japanese healthy volunteer
1231481|NCT01028027|Blepharokeratoconjunctivitis
1231482|NCT01027988|Retinal Microvascularisation
1231483|NCT01027988|Fundus
1231484|NCT01027988|mfERGs
1231485|NCT01027988|CHF
1231486|NCT01027988|Cardiovascular Disease
1231487|NCT01027988|Coronarography
1231488|NCT01027988|Macrovascularisation
1231489|NCT01027988|The objectives are to assess if if any retinal vascular disorder in arterioles and venules can be predictive for cardiovascular morbidity and mortality
1231490|NCT01027975|laparoscopy
1231491|NCT01027975|fundoplication
1231492|NCT01027975|Nissen
1231493|NCT01027975|Thal
1231494|NCT01027975|children
1231495|NCT01027975|operative treatment of gastro-oesophageal reflux disease in children
1231496|NCT01027962|Early Onset Psychosis
1231497|NCT01027962|Laptop Computer
1231498|NCT01027962|Brain Training
1231499|NCT01027936|Healthy Volunteers
1231500|NCT01029314|Thermometry
1231501|NCT01029301|Skin aging
1231502|NCT01029301|Skin Wrinkling
1231503|NCT01029288|Diabetes
1231504|NCT01029288|Decision aid
1231505|NCT01029288|Cardiovascular risk
1231506|NCT01029288|Patient education
1231507|NCT01029275|Acromegaly
1231508|NCT01029275|pituitary adenoma
1231509|NCT01029275|octreotide
1231510|NCT01029275|transsphenoïdal surgery
1231511|NCT01029275|GH
1231512|NCT01029275|IGF-1
1231513|NCT01029262|Myelodysplastic Syndromes
1231514|NCT01029262|MDS
1231515|NCT01029262|transfusion dependent anemia
1231516|NCT01029262|Erythropoiesis stimulating agents
1231517|NCT01029262|non-del 5q
1231518|NCT01029236|obesity
1231519|NCT01029236|metabolism
1231520|NCT01029236|weight loss
1231521|NCT01029236|energy expenditure
1231522|NCT01029236|thermogenesis
1231523|NCT01029236|Metabolism-Boosting Beverages effect on REE
1231524|NCT01029236|Metabolism-Boosting Beverages effect on appetite
1231525|NCT01029210|osteoporosis
1231526|NCT01029210|temporomandibular disorders
1231527|NCT01029210|resonance magnetic
1231528|NCT01029184|weaning
1231529|NCT01029184|cereals
1231530|NCT01029184|allergy
1231531|NCT01029184|atopy
1231532|NCT01029184|open allergenic test
1231533|NCT01029171|falls
1231534|NCT01029171|balance training
1231535|NCT01029171|strength training
1231536|NCT01029158|Healthy volunteers
1231537|NCT01029158|Comparison of two formulations
1231538|NCT01029158|Improvement of scar appearance
1231539|NCT01029145|Bipolar disorder
1231540|NCT01029145|New occured episode: manic depressive or mixed
1231541|NCT01029132|Alzheimer's disease
1231542|NCT01029132|Galantamine
1231543|NCT01029132|Treatment response
1231544|NCT01029132|Efficacy
1231545|NCT01029132|Adverse Event
1231546|NCT01029119|blood pressure
1231547|NCT01029106|SUI
1231548|NCT01029106|Stress Urinary Incontinence
1231549|NCT01029106|Patients with Stress Urinary Incontinence
1231550|NCT01029093|extremity with immobilisation
1231551|NCT01029093|brain platicity
1231552|NCT01029093|deprivation
1231553|NCT01029093|MRI
1231554|NCT01029080|Brain, blood flow
1231555|NCT01029080|Measurement techniques, flow velocity waveform analysis
1231556|NCT01029080|Monitoring, intensive care
1231557|NCT01029080|Sepsis
1231558|NCT01029080|transcranial doppler ultrasound (TCD)
1231559|NCT01029080|Cerebrovascular autoregulation
1231560|NCT01029080|sepsis-associated delir
1231561|NCT01029067|schizophrenia
1231562|NCT01029067|delusion
1231563|NCT01029067|paranoia
1231564|NCT01029067|psychosis
1231565|NCT01029054|Multiple Myeloma
1231566|NCT01029041|fibromyalgia, exercise, strength, stretch
1231567|NCT01029015|OAB
1231568|NCT01029015|Insomnia
1231569|NCT01029015|Bladder function
1231570|NCT01029015|cystometry
1231571|NCT01029015|polysomnography
1231572|NCT01029002|Vitamin D
1231573|NCT01029002|CKD
1231574|NCT01029002|proteinuria
1231575|NCT01028989|Polycystic Ovary Syndrome
1231576|NCT01028989|Insulin
1231577|NCT01028989|Diet
1231578|NCT01028989|Glycemic Load
1231579|NCT01028976|randomized controlled trial
1231580|NCT01028976|primary prevention
1231581|NCT01028976|Vitamin C
1231583|NCT01028976|C-reactive protein
1231584|NCT01028976|inflammation
1231585|NCT01028976|anti-inflammatory agents
1231586|NCT01028976|obesity
1231587|NCT01028950|YM150
1231588|NCT01028950|Bleeding
1231589|NCT01028950|VTE
1231590|NCT01028950|FXa inhibitor
1231591|NCT01028950|Deep Vein Thrombosis
1231592|NCT01028950|Venous thromboembolism
1231593|NCT01028937|Hyperopia correction
1231594|NCT01028937|Laser vision correction
1231595|NCT01028937|Optimal keratoplasty
1231596|NCT01028924|Thorough QTc-Study
1231597|NCT01028924|Short Bowel Syndrome
1231598|NCT01028924|Cardiac safety
1231599|NCT01028911|Phase 1 Alzheimer's disease Safety Tolerability Pharmacokinetics
1231600|NCT01028898|IBS
1231601|NCT01028898|proteomics
1231602|NCT01028898|fluorescent quantitation polymerase chain reaction
1231603|NCT01028898|Western blot
1231604|NCT01028898|immunohistochemistry staining (IHC)
1231605|NCT01028898|ATP content
1231606|NCT01028898|micRNA
1231607|NCT01028872|higher-order aberrations, contrast sensitivity
1231608|NCT01028859|Tubulin polymerization inhibitor
1231609|NCT01028859|CKD-516
1231610|NCT01028859|Phase I
1231611|NCT01028859|Vascular disrupting agent
1231612|NCT01028859|DCE MRI
1231614|NCT01028833|power wheelchairs
1231615|NCT01028833|power mobility
1231616|NCT01028833|young children
1231617|NCT01028820|autism
1231618|NCT01028820|asperger's
1231619|NCT01028820|repetitive
1231620|NCT01028820|restricted
1231621|NCT01028820|compulsions
1231622|NCT01028807|Early feeding
1231623|NCT01028807|Bowel anastomosis
1231624|NCT01028807|Children
1231625|NCT01028794|stroke
1231626|NCT01028794|bone marrow
1231627|NCT01028794|mononuclear cell
1231628|NCT01028794|angiogenesis
1231629|NCT01028794|neurogenesis
1231630|NCT01028768|Renal impairment
1231631|NCT01028768|Renal impairment study
1231632|NCT01028755|Maximum Tolerated Dose
1231633|NCT01028742|Traumatic brain injury
1231634|NCT01028742|Hypopituitarism
1231635|NCT01028742|Incidence
1231636|NCT01028703|Chronic kidney disease
1231637|NCT01028703|left ventricular dysfunction
1231638|NCT01028703|diastolic dysfunction
1231639|NCT01028703|hypertension
1231640|NCT01028690|Helicobacter pylori
1231641|NCT01028690|Eradication therapy
1231642|NCT01028690|Lactobacillus reuteri
1231643|NCT01028690|Dyspeptic symptoms
1231644|NCT01028677|oxytocin
1231645|NCT01028677|social cognition
1231646|NCT01028677|social skill
1231647|NCT01028677|social functioning
1231648|NCT01028677|paranoia
1231649|NCT01028677|psychotic symptoms
1231650|NCT01028677|schizophrenia
1231651|NCT01028677|social deficits
1231652|NCT01028677|intranasal administration
1231653|NCT01028664|Glaucoma and ocular hypertension patients
1231654|NCT01028651|PAH
1231655|NCT01028651|Pulmonary Hypertension
1231656|NCT01028651|Remodulin
1231657|NCT01028651|Treprostinil
1231658|NCT01028651|Quality of Life
1231659|NCT01028638|VEGF imaging
1231660|NCT01028638|everolimus
1231661|NCT01028638|renal cell carcinoma
1231662|NCT01028638|PET
1231663|NCT01028638|bevacizumab
1231664|NCT01028625|Heart failure
1231665|NCT01028625|Depression
1231666|NCT01028625|Self Care
1231667|NCT01028625|Cognitive behavior therapy
1231668|NCT01028599|Heart transplantation
1231669|NCT01028599|Exercise capacity
1231670|NCT01028599|Endothelial function
1231671|NCT01028573|bowel preparation
1231672|NCT01028573|colonoscopy
1231673|NCT01028560|Wheezing
1231674|NCT01028560|Asthma
1231675|NCT01028560|Allergy
1231676|NCT01028560|Immunotherapy
1231677|NCT01028547|PONV
1231678|NCT01028534|Continuous positive pressure ventilation
1231679|NCT01028534|Blood pressure
1231680|NCT01028534|Oxygen desaturation index
1231681|NCT01028534|Endothelial dysfunction
1231682|NCT01028534|Patient reported measurement
1231683|NCT01028521|First time in man, safety study, Cm3.1-AC100
1231684|NCT01028521|Male volunteer aged 18 to 50 years at Screening
1231685|NCT01028508|Depression
1231686|NCT01028508|ECT
1231687|NCT01028508|electroconvulsive therapy
1231688|NCT01028508|mood disorders
1231689|NCT01028508|continuation ECT
1231690|NCT01028508|continuation pharmacotherapy
1231691|NCT01028508|geriatric
1231692|NCT01028508|elderly
1231693|NCT01028508|lithium
1231694|NCT01028508|venlafaxine
1231695|NCT01028482|severity of depression measured by MADRS and CGI
1231696|NCT01028456|Seizures
1231697|NCT01028456|Light Therapy
1231698|NCT01028430|Chronic Lymphocytic Leukemia
1231699|NCT01028417|subcentimetre nodules
1231700|NCT01028365|Fertility
1231701|NCT01028365|Trying to Conceive
1231702|NCT01028365|Trying to Get Pregnant
1231703|NCT01028365|Pregnancy
1231704|NCT01028339|traumatic brain injury
1231705|NCT01028339|PtiO2
1231706|NCT01028339|Cerebral microdialysis
1231707|NCT01028339|Osmotherapy
1231708|NCT01028339|hypertonic saline
1231709|NCT01028339|mannitol
1231710|NCT01028326|Pneumococcal pneumonia vaccine
1231711|NCT01028313|Chronic Graft-Versus-Host Disease
1231712|NCT01028313|GVHD
1231713|NCT01028313|LBH589
1231714|NCT01028313|Panobinostat
1231715|NCT01028300|DDD
1231716|NCT01028287|Diabetic Nephropathy
1231717|NCT01028287|Nephrotic syndrome
1231718|NCT01028274|Hypercholesterolemia
1231719|NCT01028274|Hypertriglyceridemia
1231720|NCT01028274|Fish Oil
1231721|NCT01028274|Red Yeast Rice
1231722|NCT01028261|Obese
1231723|NCT01028261|Obesity
1231724|NCT01028261|Overweight
1231725|NCT01028248|Central Retinal Vein Occlusion
1231726|NCT01028248|Retinal Vein Occlusive disease
1231727|NCT01028235|Eosinophilic Esophagitis
1231728|NCT01028222|Melanoma
1231729|NCT01028222|AMN107
1231730|NCT01028222|c-Kit
1231731|NCT01028222|c-Kit mutated metastatic and/or inoperable melanoma
1231732|NCT01028196|schizophrenia
1231733|NCT01028196|schizoaffective disorder
1231734|NCT01028196|recurrent depression
1231735|NCT01028196|Bipolar disorders
1231736|NCT01028183|therapeutics
1231737|NCT01028183|safety
1231738|NCT01028183|maternal
1231739|NCT01028183|neonatal
1231740|NCT01027910|PCI-24781
1231741|NCT01027910|doxorubicin
1231742|NCT01027897|Pharmacokinetics
1231743|NCT01027897|Pharmacodynamics
1231744|NCT01027897|Doripenem
1231745|NCT01027897|Trauma
1231746|NCT01027897|sepsis
1231747|NCT01027897|Trauma patients with sepsis
1231748|NCT01027884|Idebenone
1231749|NCT01027884|Duchenne Muscular Dystrophy (DMD)
1231750|NCT01027884|Respiratory function
1231751|NCT01027884|Ambulatory and non-ambulatory patients
1231752|NCT01027884|Subjects not using glucocorticoids
1231753|NCT01027858|exercise
1231754|NCT01027858|aerobic exercise training
1231755|NCT01027858|vascular cognitive impairment
1231756|NCT01027858|Mild Sub-cortical Ischaemic Vascular Cognitive Impairment (SIVCI)
1231757|NCT01027845|Pneumococcal disease
1231758|NCT01027845|Immunogenicity
1231759|NCT01027845|Booster vaccination
1231760|NCT01027845|Pneumococcal vaccine
1231761|NCT01027845|Primary vaccination
1231762|NCT01027845|Safety
1231763|NCT01027832|tracheobronchitis
1231764|NCT01027819|Total knee arthroplasty
1231765|NCT01027819|Mobile bearing
1231766|NCT01027819|Fixed bearing
1231767|NCT01027819|Range of motion
1231768|NCT01027819|Knee Society Score
1231769|NCT01027806|Children
1231770|NCT01027806|Sleep
1231771|NCT01027806|Obstructive Sleep Apnea
1231772|NCT01027793|Stretch marks
1231773|NCT01027793|Striae
1231774|NCT01027793|Tretinoin
1231775|NCT01027793|Superficial dermabrasion
1231776|NCT01027780|Mindfulness-Based Stress Reduction
1231777|NCT01027780|MBSR
1231778|NCT01027780|Seniors
1231779|NCT01027780|immune system
1231780|NCT01027780|keyhole limpet hemocyanin (KLH)
1231781|NCT01027767|Breast
1231782|NCT01027767|MBI
1231783|NCT01027767|Molecular
1231784|NCT01027767|Molecular Breast Imaging
1231785|NCT01027767|Dense breast tissue
1231786|NCT01027767|Surgery
1231787|NCT01027767|Radiation
1231788|NCT01027767|BCT
1231789|NCT01027754|methadone maintenance
1231790|NCT01027715|Neonatal Seizures
1231791|NCT01027715|Neonatal encephalopathy
1231792|NCT01027702|Donor Lymphocyte Infusion
1231793|NCT01027702|Immune Recovery
1231794|NCT01027702|T cell depleted transplant
1231795|NCT01027702|Mismatched related donor transplants
1231796|NCT01027702|Unrelated donor transplants
1231797|NCT01027689|alprazolam
1231798|NCT01027689|bioequivalence
1231799|NCT01027689|sublingual
1231800|NCT01027676|Gefitinib
1231801|NCT01027676|Vorinostat
1231802|NCT01027663|anemia
1231803|NCT01027663|malaria
1231804|NCT01027637|breast reconstruction
1231805|NCT01027637|tissue expander
1231806|NCT01027637|Alloderm
1231807|NCT01027637|tissue matrix
1231808|NCT01027624|Pan South African Survey on the Undertreatment of Hypercholesterolaemia
1231809|NCT01027611|Effectiveness of topical pain medicine for control of pain associated with intravitreal injections
1231810|NCT01027611|Eye discomfort
1231811|NCT01027598|Lung Cancer
1231812|NCT01027598|Previously Treated Advanced Non Small Cell Lung Cancer
1231813|NCT01027598|Erlotinib
1231814|NCT01027598|Pazopanib
1231815|NCT01027572|Vegetative state
1231816|NCT01027572|Minimally conscious state
1231817|NCT01027572|Thalamic stimulation
1231818|NCT01027559|Major Depression
1231819|NCT01027559|Functional Magnetic Resonance Imaging
1231820|NCT01027559|Emotional Circuitry
1231821|NCT01027559|Cognitive Behavioral Therapy
1231822|NCT01027546|perioperative blood loss, spinal surgery
1231823|NCT01027533|multifocal intraocular lens
1231824|NCT01027533|visual acuity
1231825|NCT01027533|presbiopia
1231826|NCT01027520|Hand burn
1231827|NCT01027520|skin graft
1231828|NCT01027520|coban dressing
1231829|NCT01027520|range of motion
1231830|NCT01027494|ear tubes
1231831|NCT01027494|ear drainage
1231832|NCT01027494|ear infection
1231833|NCT01027494|ear drops
1231834|NCT01027494|tympanostomy tubes
1231835|NCT01027481|lucentis, macular edema, branch retinal vein occlusion
1231836|NCT01027468|bevacizumab, choroidal neovascularization
1231837|NCT01027442|Stereolithography
1231838|NCT01027442|Dental implants,
1231839|NCT01027442|Prosthetics
1231840|NCT01027442|positioning-errors
1231841|NCT01027442|logistic regression analysis
1231842|NCT01027429|infant
1231843|NCT01027429|newborn
1231844|NCT01027429|sepsis
1231845|NCT01027429|infection
1231846|NCT01027429|community
1231847|NCT01027416|ER positive
1231848|NCT01027416|Tamoxifen
1231849|NCT01027403|Heart failure
1231850|NCT01027403|Adult stem cells
1231851|NCT01027403|Circulating stem cells
1231852|NCT01027403|Acute decompensated heart failure
1231853|NCT01027390|neck/shoulder
1231854|NCT01027351|Children
1231855|NCT01027351|Pre-school
1231856|NCT01027351|Meningococcal disease
1231857|NCT01027351|Prevention
1231858|NCT01027351|Vaccination
1231859|NCT01027325|Resistant Starch
1231860|NCT01027325|Amylose
1231861|NCT01027325|Amylopectin
1231862|NCT01027325|LDL subclasses
1231863|NCT01027325|Dietary carbohydrate
1231864|NCT01027325|Postprandial insulinemia
1231865|NCT01027312|Glaucoma
1231866|NCT01027312|quality of life
1231867|NCT01027312|daily living activities
1231868|NCT01027312|visual fields
1231869|NCT01027312|contrast sensitivity
1231870|NCT01027299|cardiac failure
1231871|NCT01027299|thoracic surgery
1231872|NCT01027299|cardiac pacing, artificial
1231873|NCT01027273|Stroke
1231874|NCT01027273|Ischemic Stroke
1231875|NCT01027273|Transient Ischemic Attack
1231876|NCT01027273|Stroke Recurrence Prevention
1231877|NCT01027273|Cerebrovascular Disorders
1231878|NCT01027273|Brain Ischemia
1231879|NCT01027273|Brain Infraction
1231880|NCT01027273|Brain Diseases
1231881|NCT01027273|Cerebral Infraction
1231882|NCT01027273|Self-management
1231883|NCT01027273|Peer-led
1231884|NCT01027273|Community Based
1231885|NCT01027247|Primary Glaucoma
1231886|NCT01027234|Healthy volunteers
1231887|NCT01027221|Low Dose Radiation
1231888|NCT01027221|pancreatic cancer
1231889|NCT01027221|Immunostimulation
1231890|NCT01027182|HIV
1231891|NCT01027169|Hepatic impairment
1231892|NCT01027169|Liver diseases
1231893|NCT01027169|Pharmacokinetics
1232015|NCT01026727|Sexually Transmitted Diseases, Viral
1232016|NCT01026727|RNA Virus Infections
1231894|NCT01027169|To Investigate Pharmacokinetics of Safinamide in Subjects With Mild and Moderate Hepatic Impairment as Compared to Healthy Subjects With Normal Hepatic Function
1231895|NCT01027156|Public Health
1231896|NCT01027156|Biochemistry
1231897|NCT01027156|Ecological
1231898|NCT01027143|Asthma
1231899|NCT01027143|Obesity
1231900|NCT01027143|Pharmacogenetics
1231901|NCT01027143|Nutrigenetics
1231902|NCT01027117|Bioavailability
1231903|NCT01027117|Revatio
1231904|NCT01027117|Healthy Volunteers
1231905|NCT01027104|injury prevention
1231906|NCT01027104|firearms
1231907|NCT01027104|training
1231908|NCT01027104|counseling
1231909|NCT01027104|medical education
1231910|NCT01027104|safety
1231911|NCT01027104|anticipatory guidance
1231912|NCT01027104|Firearm injury prevention anticipatory guidance
1231913|NCT01027091|hypocalcemia
1231914|NCT01027091|total thyroidectomy
1231915|NCT01027065|interleukin-7
1231916|NCT01027065|immune-based therapies
1231917|NCT01027065|hepatitis B
1231918|NCT01027065|HBe negative
1231919|NCT01027065|HBV vaccination
1231920|NCT01027065|entecavir
1231921|NCT01027065|tenofovir
1231922|NCT01027065|chronic hepatitis
1231923|NCT01027065|immune specific responses to HBV
1231924|NCT01027065|phase 1/2a
1231925|NCT01027065|viral disease
1231926|NCT01027065|liver disease
1231927|NCT01027052|MDA
1231928|NCT01027052|Spice
1231929|NCT01027039|primary open angle glaucoma
1231930|NCT01027039|pigmentary glaucoma
1231931|NCT01027039|exfoliative glaucoma
1231932|NCT01027039|angle closure glaucoma
1231933|NCT01027039|low tension glaucoma
1231934|NCT01027026|Cost analysis
1231935|NCT01027026|Safety
1231936|NCT01027026|Length of stay
1231937|NCT01027026|Randomized controlled trials
1231938|NCT01027026|Early discharge
1231939|NCT01027000|refractory chronic lymphocytic leukemia
1231940|NCT01027000|stage I chronic lymphocytic leukemia
1231941|NCT01027000|stage II chronic lymphocytic leukemia
1231942|NCT01027000|stage III chronic lymphocytic leukemia
1231943|NCT01027000|stage IV chronic lymphocytic leukemia
1231944|NCT01027000|B-cell chronic lymphocytic leukemia
1231945|NCT01027000|contiguous stage II small lymphocytic lymphoma
1231946|NCT01027000|noncontiguous stage II small lymphocytic lymphoma
1231947|NCT01027000|recurrent small lymphocytic lymphoma
1231948|NCT01027000|stage I small lymphocytic lymphoma
1231949|NCT01027000|stage III small lymphocytic lymphoma
1231950|NCT01027000|stage IV small lymphocytic lymphoma
1231951|NCT01026974|Children
1231952|NCT01026974|Pre-school
1231953|NCT01026974|Meningococcal disease
1231954|NCT01026974|Prevention
1231955|NCT01026974|Vaccination
1231956|NCT01026961|Safety
1231957|NCT01026961|heart rate
1231958|NCT01026961|systolic and diastolic blood pressure
1231959|NCT01026961|arrhythmias
1231960|NCT01026948|Induction of labour
1231961|NCT01026948|Intraprtum fetal monitoring
1231962|NCT01026935|open mesh repair
1231963|NCT01026935|sutured
1231964|NCT01026935|non-sutured
1231965|NCT01026935|pro-grip
1231966|NCT01026935|postoperative pain
1231967|NCT01026922|antroduodenal manometry
1231968|NCT01026922|gastric dysmotility
1231969|NCT01026922|intestinal dysmotility
1231970|NCT01026896|Mental practice
1231971|NCT01026896|motor imagery
1231972|NCT01026896|stroke
1231973|NCT01026896|hemiplegia
1231974|NCT01026896|motor recovery
1231975|NCT01026896|neuroplasticity
1231976|NCT01026883|hematocrit
1231977|NCT01026883|layered resonant piezoelectric sensors
1231978|NCT01026844|erlotinib
1231979|NCT01026844|tarceva
1231980|NCT01026844|hydroxychloroquine
1231981|NCT01026844|NSCLC
1231982|NCT01026818|Erectile Dysfunction
1231983|NCT01026818|Radical Prostatectomy
1231984|NCT01026805|morcellator
1231985|NCT01026805|hysteroscope
1231986|NCT01026805|myomectomy
1231987|NCT01026805|polypectomy
1231988|NCT01026805|uterine fibroids
1231989|NCT01026779|rotavirus
1231990|NCT01026779|gastroenteritis
1231991|NCT01026779|vaccine
1231992|NCT01026779|case-control study
1231993|NCT01026779|serotype
1231994|NCT01026766|Hypothermia
1231995|NCT01026766|Obesity
1231996|NCT01026766|Heat and moisture exchanger
1231997|NCT01026766|Warming blanket
1231998|NCT01026766|Warming fluids
1231999|NCT01026766|Gynecological surgery
1232000|NCT01026766|Intravenous anesthesia
1232001|NCT01026766|Obese patients
1232002|NCT01026766|Non obese patients
1232003|NCT01026753|colorectal cancer
1232004|NCT01026753|screening
1232005|NCT01026753|fecal occult blood test
1232006|NCT01026753|randomized control trial
1232007|NCT01026753|primary care oncology
1232008|NCT01026753|web site
1232009|NCT01026753|provincial health contact center
1232010|NCT01026740|Staphylococcal Skin Infections
1232011|NCT01026740|Streptococcal Infections
1232012|NCT01026727|HIV Infections
1232013|NCT01026727|Acquired Immunodeficiency Syndrome
1232014|NCT01026727|Virus Diseases
1232017|NCT01026727|Slow Virus Diseases
1232018|NCT01026727|Immune System Diseases
1232019|NCT01026727|Sexually Transmitted Diseases
1232020|NCT01026727|Lentivirus Infections
1232021|NCT01026727|Infection
1232022|NCT01026727|Retroviridae Infections
1232023|NCT01026727|Immunologic Deficiency Syndromes
1232024|NCT01026727|HIV
1232025|NCT01026727|treatment experienced
1232026|NCT01026727|bevirimat
1232027|NCT01026701|Osteoblst effect
1232028|NCT01026701|Velcade
1232029|NCT01026701|Proteasome inhibitor
1232030|NCT01026701|Bortezomib
1232031|NCT01026701|Multjple Myeloma
1232032|NCT01026688|Pragmatic randomized controlled trial
1232033|NCT01026688|Cardiovascular risk reduction
1232034|NCT01026688|Knowledge translation
1232035|NCT01026688|Clinical practice guidelines
1232036|NCT01026662|Aesthetic dermatology
1232037|NCT01026649|hematoma formation
1232038|NCT01026649|success rate
1232039|NCT01026636|Staphylococcal Skin Infections
1232040|NCT01026636|Skin Infections
1232041|NCT01026636|Streptococcal Infections
1232042|NCT01026610|Chronic hepatitis B
1232043|NCT01026610|LB80380
1232044|NCT01026610|treatment-naive
1232045|NCT01026610|entecavir
1232046|NCT01026571|Bicuspid aortic valve
1232047|NCT01026558|Obesity, Ceftobiprole
1232048|NCT01026558|Skin Infections
1232049|NCT01026558|Staphylococcal Skin Infections
1232050|NCT01026558|Bacterial Skin Infections
1232051|NCT01026558|Streptococcal Infection
1232052|NCT01026545|safety
1232053|NCT01026545|tolerability
1232054|NCT01026545|pharmacokinetics
1232055|NCT01026545|multiple-dose
1232056|NCT01026545|macrolide
1232057|NCT01026506|c9,t11-CLA
1232058|NCT01026506|allergic bronchial asthma
1232059|NCT01026506|children and adolescents
1232060|NCT01026493|adult giant cell glioblastoma
1232061|NCT01026493|adult glioblastoma
1232062|NCT01026493|adult gliosarcoma
1232063|NCT01026493|recurrent adult brain tumor
1232064|NCT01026493|adult anaplastic astrocytoma
1232065|NCT01026493|adult anaplastic ependymoma
1232066|NCT01026493|adult anaplastic oligodendroglioma
1232067|NCT01026493|adult brain stem glioma
1232068|NCT01026493|adult mixed glioma
1232069|NCT01026493|adult pineal gland astrocytoma
1232070|NCT01026480|Ileal Pouch Anal Anastomosis
1232071|NCT01026480|IPAA
1232072|NCT01026480|Pull through
1232073|NCT01026480|IBD
1232074|NCT01026480|Ulcerative colitis
1232075|NCT01026480|Familial adenomatous polyposis
1232076|NCT01026480|FAP
1232077|NCT01026480|Hereditary nonpolyposis colorectal cancer
1232078|NCT01026480|HNPCC
1232079|NCT01026454|HSV
1232080|NCT01026454|HIV
1232081|NCT01026441|Aesthetic
1232082|NCT01026428|safinamide
1232083|NCT01026428|levodopa
1232084|NCT01026428|drug -drug interaction
1232085|NCT01026428|pharmacokinetics
1232086|NCT01026428|Patients diagnosed with idiopathic Parkinson's disease, levodopa-responsive, treated with a stable dose of levodopa/carbidopa
1232087|NCT01026415|Antibody-Drug Conjugate
1232088|NCT01026415|Antigens, CD30
1232089|NCT01026415|Disease, Hodgkin
1232090|NCT01026415|Lymphoma, Large-Cell, Anaplastic
1232091|NCT01026415|Lymphoma, Non-Hodgkin
1232092|NCT01026415|monomethyl auristatin E
1232093|NCT01026415|Drug Therapy
1232094|NCT01026415|Immunotherapy
1232095|NCT01026415|Hematologic Diseases
1232096|NCT01026415|Lymphoma
1232097|NCT01026415|Antibodies, Monoclonal
1232098|NCT01026402|Phase I
1232099|NCT01026402|cancer
1232100|NCT01026402|advanced solid malignancies
1232101|NCT01026402|dose escalation
1232102|NCT01026402|AZD2014
1232103|NCT01026402|mTor kinase inhibitor
1232104|NCT01026402|safety
1232105|NCT01026402|pharmacokinetics
1232106|NCT01026389|MRA-Contrast agent comparison in peripheral disease
1232107|NCT01026376|Myelodysplastic Syndromes
1232108|NCT01026376|Decitabine
1232109|NCT01026363|Vitamin D
1232110|NCT01026363|Chronic Kidney Disease
1232111|NCT01026350|modulating immune response to flu antigen
1232112|NCT01026337|recurrent renal cell cancer
1232113|NCT01026311|Coenzyme q10
1232114|NCT01026311|statins
1232115|NCT01026311|myalgias
1232116|NCT01026311|anaerobic threshold
1232117|NCT01026311|athletic performance
1232122|NCT01026285|Risperdal Consta
1232123|NCT01026272|Endocannabinoid
1232124|NCT01026272|Fish Oil
1232125|NCT01026272|Multiple Sclerosis
1232126|NCT01026272|Monocyte Migration
1232127|NCT01026259|Surgical site infection
1232128|NCT01026259|wound healing
1232129|NCT01026259|tissue oxygen
1232130|NCT01026259|angiogenesis
1232131|NCT01026259|flow cytometry
1232132|NCT01026259|immunohistochemistry
1232133|NCT01026246|Ghana, malaria, vaccine, Plasmodium falciparum
1232134|NCT01026233|Antibodies, Monoclonal
1232135|NCT01026233|Antibody-Drug Conjugate
1232136|NCT01026233|Antigens, CD30
1232137|NCT01026233|Disease, Hodgkin
1232138|NCT01026233|Drug Therapy
1232139|NCT01026233|Hematologic Diseases
1232140|NCT01026233|Immunotherapy
1232141|NCT01026233|Lymphoma
1232142|NCT01026233|monomethylauristatin E
1232143|NCT01026233|Lymphoma, Large-Cell, Anaplastic
1232144|NCT01026207|Diagnostic test
1232145|NCT01026207|polysomnography
1232146|NCT01026207|Obstructive Sleep Apnea Syndrome
1232147|NCT01026207|Chronic Obstructive Pulmonary Disease
1232148|NCT01026194|insulin resistance
1232149|NCT01026155|Obese patients (BMI > 30 kg / m²)
1232150|NCT01026103|gastric bypass
1232151|NCT01026103|Gastric bypass surgery
1232152|NCT01026077|Savella pregnant
1232153|NCT01026077|savella pregnancy
1232154|NCT01026077|fibromyalgia pregnant
1232155|NCT01026077|fibromyalgia pregnancy
1232156|NCT01026077|pregnancy registry savella
1232157|NCT01026064|Macrolides
1232158|NCT01026064|Inflammation
1232159|NCT01026064|Azithromycin
1232160|NCT01026064|Cantharidin induced skin blister model
1232161|NCT01026051|Cancer Vaccine, Immunotherapy, Melanoma
1232162|NCT01026038|Pneumococcal vaccine 13-valent
1232163|NCT01026025|lobectomy
1232164|NCT01026025|segmentectomy
1232165|NCT01026025|pulmonary resection
1232166|NCT01026012|Regadenoson
1232167|NCT01026012|85% predicted heart rate
1232168|NCT01026012|Myocardial perfusion stress testing
1232169|NCT01025999|RYGB
1232170|NCT01025999|Gastrostomy tube
1232171|NCT01025999|DM
1232172|NCT01025999|Gastric Bypass
1232173|NCT01025960|colonoscopy
1232174|NCT01025960|adenoma detection
1232175|NCT01025960|polyps
1232176|NCT01025947|Atrial fibrillation
1232177|NCT01025947|Cryptogenic stroke
1232178|NCT01025947|Implantable loop recorder
1232179|NCT01025921|Tracheobronchitis
1232180|NCT01025921|pneumonia
1232181|NCT01025921|inhaled antibiotics
1232182|NCT01025921|colistin
1232183|NCT01025921|Ventilator associated tracheobronchitis
1232184|NCT01025921|Ventilator associated pneumonia
1232185|NCT01025908|psychotherapy
1232186|NCT01025908|panic disorder
1232187|NCT01025908|anxiety
1232188|NCT01025908|behavior
1232189|NCT01025908|cognition
1232190|NCT01025895|arthroscopic surgical procedure
1232191|NCT01025882|adenocarcinoma of the pancreas
1232192|NCT01025882|stage I pancreatic cancer
1232193|NCT01025882|stage II pancreatic cancer
1232194|NCT01025882|stage III pancreatic cancer
1232195|NCT01025856|liver fat
1232196|NCT01025856|postprandial lipids metabolism
1232197|NCT01025856|diet
1232198|NCT01025856|exercise
1232199|NCT01025856|type 2 diabetes
1232200|NCT01025830|HIV;Bioequivalence;Triomune
1232201|NCT01025817|Kidney transplant
1232202|NCT01025817|renal transplant
1232203|NCT01025817|immunosuppression
1232204|NCT01025817|mycophenolate mofetil
1232205|NCT01025817|tacrolimus
1232206|NCT01025817|everolimus
1232207|NCT01025804|Interfant-06
1232208|NCT01025804|Infant ALL
1232209|NCT01025804|Asparaginase
1232210|NCT01025804|Pharmacokinetics of asparaginase
1232211|NCT01025804|Antibody formation
1232212|NCT01025778|Haploidentical hematopoietic stem cell transplantation
1232213|NCT01025778|Graft versus host disease
1232214|NCT01025778|Donor lymphocyte infusion
1232215|NCT01025778|Graft versus leukemia effect
1232216|NCT01025778|Immunological recovery
1232217|NCT01025778|Bridge to transplant approach
1232218|NCT01025778|Therapy resistant leukemia
1232219|NCT01025778|Hematological malignancy
1232220|NCT01025752|chronic pain
1232221|NCT01025752|cognitive behavior therapy
1232222|NCT01025752|low back pain
1232223|NCT01025739|Gastroesophageal Reflux Disease (GERD)
1232224|NCT01025739|EsophyX
1232225|NCT01025713|Cystic Fibrosis
1232226|NCT01025713|CF
1232227|NCT01025713|Mucociliary Clearance
1232228|NCT01025713|Epithelial Sodium Channel Inhibitor
1232229|NCT01025713|ENaC Inhibitor
1232230|NCT01025713|Airway Hydration
1232231|NCT01025713|Amiloride
1232232|NCT01025700|Efficacy
1232233|NCT01025700|Marijuana
1232234|NCT01025700|Reduction
1232235|NCT01025700|Craving
1232236|NCT01025687|girls
1232237|NCT01025687|obesity
1232238|NCT01025687|television viewing
1232239|NCT01025687|puberty
1232240|NCT01025674|School health program
1232241|NCT01025674|Positive health behavior
1232242|NCT01025674|School-wide climate
1232243|NCT01025674|Mental health
1232244|NCT01025674|Self-esteem
1232245|NCT01025674|Social support
1232246|NCT01025674|Exercise
1232247|NCT01025674|Nutrition
1232248|NCT01025674|Parent involvement
1232249|NCT01025674|Community involvement
1232250|NCT01025661|chiropractic
1232251|NCT01025661|hip osteoarthritis
1232252|NCT01025661|hip arthroplasty
1232253|NCT01025661|pain
1232254|NCT01025661|activities of daily living.
1232255|NCT01025648|Mild to Moderate Asthma
1232256|NCT01025648|Dyspnea
1232257|NCT01025648|Wheezing
1232258|NCT01025648|Status Asthmaticus
1232259|NCT01025635|rosacea
1232260|NCT01025635|papulopustular
1232261|NCT01025635|azelaic acid
1232262|NCT01025635|foam
1232263|NCT01025622|Stem Cells
1232264|NCT01025622|Liver Cirrhosis
1232265|NCT01025622|Cell Therapy
1232266|NCT01025609|spinal cord injury
1232267|NCT01025609|cardiovascular disease
1232268|NCT01025609|dietary patterns
1232269|NCT01025596|interleukin-7
1232270|NCT01025596|immune-based therapies
1232271|NCT01025596|hepatitis C
1232272|NCT01025596|chronic hepatitis
1232273|NCT01025596|resistance to Peg-interferon and ribavirin bi-therapy
1232274|NCT01025596|immune specific responses to HCV
1232275|NCT01025596|phase 1
1232276|NCT01025596|viral disease
1232277|NCT01025596|liver disease
1232278|NCT01025583|acute gastroenteritis
1232279|NCT01025583|intestinal infection
1232280|NCT01025583|intestinal fluid secretion
1232281|NCT01025583|intestinal microflora
1232282|NCT01025583|treatment of childhood acute diarrhea
1232283|NCT01025570|pancreas
1232284|NCT01025570|pancreatic
1232285|NCT01025570|bosutinib
1232286|NCT01025570|SKI-606
1232287|NCT01025570|gemcitabine
1232288|NCT01025570|gemzar
1232289|NCT01025570|Patients with resected pancreatic cancer
1232290|NCT01025557|Food intake
1232291|NCT01025557|Blood glucose
1232292|NCT01025557|Milk
1232293|NCT01025544|Haemophilus influenzae type b (Hib)
1232294|NCT01025544|Vaccine
1232295|NCT01025544|Booster
1232296|NCT01025531|Hepatitis C
1232297|NCT01025518|Head and Neck Neoplasms
1232298|NCT01025518|Resistance training
1232299|NCT01025518|Muscle mass
1232300|NCT01025518|Functional capacity
1232301|NCT01025505|Untreated Ph+ ALL unfit for intense therapy and allo SCT
1232302|NCT01025492|high density lipoprotein
1232303|NCT01025492|arterial compliance
1232304|NCT01025492|brachial artery flow-mediated dilatation
1232305|NCT01025479|Osteoporosis
1232306|NCT01025479|Prostate cancer
1232307|NCT01025479|LHRH agonist and/or anti-androgen agent
1232308|NCT01025479|Korean prostate cancer
1232309|NCT01025453|thyroid
1232310|NCT01025453|follicular cell
1232311|NCT01025453|papillary cell
1232312|NCT01025453|Hurthle cell
1232313|NCT01025453|BAY 43-9006
1232314|NCT01025453|Temsirolimus
1232315|NCT01025453|Sorafenib
1232316|NCT01025453|09-148
1232317|NCT01025427|HIV
1232318|NCT01025427|HIV persistence
1232319|NCT01025427|HIV reservoirs
1232320|NCT01025414|pancreatic fistula
1232321|NCT01025401|epilepsy
1232322|NCT01025401|seizures
1232323|NCT01025401|movement
1232324|NCT01025388|Hypercholesterolemia
1232325|NCT01025388|The study is focusing on the undertreatment of hypercholesterolemia
1232326|NCT01025375|overweight
1232327|NCT01025349|bevacizumab
1232328|NCT01025349|metastatic breast cancer
1232329|NCT01025349|docetaxel
1232330|NCT01025336|Antibody persistence
1232331|NCT01025323|Pre hypertension
1232332|NCT01025323|Lifestyle modification
1232333|NCT01025323|DASH diet
1232334|NCT01025310|eye movements
1232335|NCT01025310|saccades
1232336|NCT01025310|visual
1232337|NCT01025310|stress
1232338|NCT01025310|search coil
1232339|NCT01025310|environment
1232340|NCT01025310|Saccadic eye movements
1232341|NCT01025310|Urban environment
1232342|NCT01025297|interleukin-7
1232343|NCT01025297|immune-based therapies
1232344|NCT01025297|hepatitis C
1232345|NCT01025297|chronic hepatitis
1232346|NCT01025297|resistance to Peg-interferon and ribavirin bi-therapy
1232347|NCT01025297|immune specific responses to HCV
1232348|NCT01025297|phase 1/2a
1232349|NCT01025297|viral disease
1232350|NCT01025297|liver disease
1232351|NCT01025271|meningitis
1232352|NCT01025258|Cystic Fibrosis
1232353|NCT01025258|Medication Adherence
1232354|NCT01025258|Multidisciplinary Team
1232355|NCT01025258|Clinical Outcomes
1232356|NCT01025245|Remifentanil induced postoperative hyperalgesia
1232357|NCT01025232|Antibodies, Monoclonal
1232358|NCT01025232|Immunologic Factors
1232359|NCT01025232|Eye Diseases
1232360|NCT01025232|Retinal Degeneration
1232361|NCT01025232|Macular Degeneration
1232362|NCT01025232|Pharmacologic Actions
1232363|NCT01025232|Retinal Diseases
1232364|NCT01025219|Diagnosis of dependence on cocaine according to DSM-IV-TR criteria
1232365|NCT01025206|Multiple Myeloma
1232366|NCT01025206|monoclonal antibody
1232367|NCT01025206|safety
1232368|NCT01025206|pharmacokinetic
1232369|NCT01025193|belimumab
1232370|NCT01025193|Benlysta
1232371|NCT01025193|LymphoStat B
1232372|NCT01025193|BLyS specific inhibitors
1232373|NCT01025180|safety
1232374|NCT01025180|Procalcitonin
1232375|NCT01025180|PCT
1232376|NCT01025180|SOFA
1232377|NCT01025180|Sepsis
1232378|NCT01025180|Antibiotic
1232379|NCT01025180|Strategy
1232380|NCT01025180|SIRS
1232381|NCT01025180|severe sepsis without obvious infection
1232382|NCT01025167|cancer
1232383|NCT01025167|enteral nutrition
1232384|NCT01025167|omega-3-fatty acids
1232385|NCT01025154|Leukemia
1232386|NCT01025154|AML
1232387|NCT01025154|chemotherapy-naïve
1232388|NCT01025154|Clofarabine
1232389|NCT01025154|Clofarex
1232390|NCT01025154|Clolar
1232391|NCT01025154|Idarubicin
1232392|NCT01025154|Idamycin
1232393|NCT01025154|Cytarabine
1232394|NCT01025154|Ara-C
1232395|NCT01025154|Cytosar
1232396|NCT01025154|DepoCyt
1232397|NCT01025154|Cytosine Arabinosine Hydrochloride
1232398|NCT01025141|MINISCREW
1232399|NCT01025141|space extraction closure
1232400|NCT01025141|anchorage
1232401|NCT01025141|Orthodontic Treatment
1232402|NCT01025141|Extraction of 2 Maxillary Premolar
1232403|NCT01025141|closing of extraction space
1232404|NCT01025141|patient aged from 12 to 50 years old
1232405|NCT01025115|Dietary supplement
1232406|NCT01025115|Diamel
1232407|NCT01025115|Metabolic Syndrome
1232408|NCT01025089|Cetuximab
1232409|NCT01025089|Cisplatin
1232410|NCT01025089|Cyclophosphamide
1232411|NCT01025089|09-038
1232412|NCT01025076|Enlarged gastric pouch and stoma
1232413|NCT01025076|Post bariatric surgery
1232414|NCT01025063|Spectral OCT
1232415|NCT01025063|Choroidal Neovascularization
1232416|NCT01025063|Lucentis
1232417|NCT01025063|Visudyne
1232418|NCT01025063|PDT
1232419|NCT01025063|anti-VEGF
1232420|NCT01025050|Presbyopia
1232421|NCT01025050|Intrastromal
1232422|NCT01025050|Femtosecond Laser
1232423|NCT01025050|minimal-invasive
1232424|NCT01025050|INTRACOR
1232425|NCT01025050|Enhance Near Visual Acuity
1232426|NCT01025037|Rotator Cuff Tear, Large, Massive, Rotator, Cuff. Tear
1232427|NCT01025024|SNP
1232428|NCT01025024|single-nucleotide polymorphism
1232429|NCT01025024|glaucoma
1232430|NCT01025024|primary open angle glaucoma
1232431|NCT01025011|retinal hemoglobin concentration
1232432|NCT01025011|non-invasive hemoglobin measurement
1232433|NCT01024998|Age-Related Macular Degeneration
1232434|NCT01024998|AMD
1232435|NCT01024998|Wet AMD
1232436|NCT01024998|Neovascular AMD
1232437|NCT01024998|Ocular
1232438|NCT01024998|Ocular gene therapy
1232439|NCT01024998|Subretinal neovascularization
1232440|NCT01024985|optic neuritis
1232441|NCT01024985|longitudinally extensive transverse myelitis
1232442|NCT01024985|retinal nerve fiber layer
1232443|NCT01024985|macular thickness
1232444|NCT01024959|Prostate Cancer
1232445|NCT01024959|Prostate Biopsy
1232446|NCT01024959|PCA3
1232447|NCT01024946|mesothelioma
1232448|NCT01024946|pleural
1232449|NCT01024946|RAD001
1232450|NCT01024946|Everolimus
1232451|NCT01024946|09-142
1232452|NCT01024946|thoracic
1232453|NCT01024946|lung
1232454|NCT01024946|epithelioid
1232455|NCT01024946|sarcomatoid
1232456|NCT01024933|Hypertension
1232457|NCT01024933|High Blood Pressure
1232458|NCT01024894|interleukin-7
1232459|NCT01024894|immune-based therapies
1232460|NCT01024894|hepatitis C
1232461|NCT01024894|chronic hepatitis
1232462|NCT01024894|resistance to Peg-interferon and ribavirin bitherapy
1232463|NCT01024894|immune specific responses to HCV
1232464|NCT01024894|taiwan
1232465|NCT01024894|phase 1/2a
1232466|NCT01024894|viral disease
1232467|NCT01024894|liver disease
1232468|NCT01024881|catheterization success rate
1232469|NCT01024868|Transversus Abdominis Plane Block
1232470|NCT01024829|Non small cell lung cancer
1232471|NCT01024829|Inoperable
1232472|NCT01024829|HX4
1232473|NCT01024816|Metabolic Syndrome
1232474|NCT01024816|Restorative Yoga
1232475|NCT01024816|Stretching
1232476|NCT01024816|Visceral adiposity
1232477|NCT01024816|Randomized controlled trial
1232478|NCT01024803|Retina implant, Subretinal
1232479|NCT01024803|Legal blindness
1232480|NCT01024803|Genetic Diseases, Inborn
1232481|NCT01024803|Eye Diseases
1232482|NCT01024803|Retinitis Pigmentosa
1232483|NCT01024803|Retinitis
1232484|NCT01024803|Retinal Degeneration
1232485|NCT01024803|Eye Diseases, Hereditary
1232486|NCT01024803|Retinal Diseases
1232487|NCT01024777|cholecalciferol
1232488|NCT01024777|multiple sclerosis
1232489|NCT01024777|vitamin D
1232490|NCT01024777|D3
1232491|NCT01024764|HIV
1232492|NCT01024764|Tat protein
1232493|NCT01024764|Preventive vaccine
1232494|NCT01024725|A(H1N1)v influenza
1232495|NCT01024725|vaccination
1232496|NCT01024725|pandemic
1232497|NCT01024712|recurrent non-small cell lung cancer
1232498|NCT01024712|stage IIIB non-small cell lung cancer
1232499|NCT01024712|stage IV non-small cell lung cancer
1232500|NCT01024712|adenocarcinoma of the lung
1232501|NCT01024712|bronchoalveolar cell lung cancer
1232502|NCT01024712|large cell lung cancer
1232503|NCT01024673|H1N1
1232504|NCT01024660|Patients with Mild to Moderate Alzheimer's Disease
1232505|NCT01024634|Arterial stiffness
1232506|NCT01024634|Endothelial function
1232507|NCT01024634|Autonomic function
1232508|NCT01024634|Inflammation
1232509|NCT01024621|gastric intestinal metaplasia
1232510|NCT01024621|Confocal laser endomicroscopy
1232511|NCT01024595|HIV
1232512|NCT01024595|Tat protein
1232513|NCT01024582|breast cancer
1232514|NCT01024582|invasive breast cancer
1232515|NCT01024582|adenocarcinoma of the breast
1232516|NCT01024569|Severe Mental Illness
1232517|NCT01024569|Recovery
1232518|NCT01024569|Psychiatric Disability
1232519|NCT01024569|Wellness
1232520|NCT01024569|Peer Service
1232521|NCT01024569|WRAP
1232522|NCT01024556|HIV, HAART
1232523|NCT01024543|Angiotensin II
1232524|NCT01024530|hepatocellular carcinoma
1232525|NCT01024530|HCC
1232526|NCT01024530|NK
1232527|NCT01024530|immune killer cells
1232528|NCT01024517|Safety
1232529|NCT01024517|Tolerability
1232530|NCT01024517|Pharmacokinetics
1232531|NCT01024504|Cancer
1232532|NCT01024504|Colorectal cancer
1232533|NCT01024504|Elderly
1232534|NCT01024504|Chemotherapy
1232535|NCT01024504|Capecitabine
1232536|NCT01024504|Oxaliplatin
1232537|NCT01024504|Bevacizumab
1232538|NCT01024491|premature ejaculation
1232539|NCT01024491|paroxetine
1232540|NCT01024491|daily treatment
1232541|NCT01024478|Coronary Artery
1232542|NCT01024478|Magnetic Resonance Angiography
1232543|NCT01024478|Coronary Artery disease
1232544|NCT01024478|Multicenter Trial
1232545|NCT01024478|Cardiac MRI
1232546|NCT01024465|obesity
1232547|NCT01024465|intragastric balloon
1232548|NCT01024452|anticoagulation
1232549|NCT01024452|warfarin
1232550|NCT01024452|computer systems
1232551|NCT01024452|international normalized ratio
1232552|NCT01024452|nomograms
1232553|NCT01024426|Uganda
1232554|NCT01024426|malaria
1232555|NCT01024426|enhanced health facility-based care
1232556|NCT01024426|febrile illnesses
1232557|NCT01024426|health services
1232558|NCT01024413|Thoracic Neoplasms
1232559|NCT01024413|Molecular Mechanisms of Pharmacological Action
1232560|NCT01024413|Protein Kinase Inhibitors
1232561|NCT01024413|Respiratory Tract Diseases
1232562|NCT01024413|Lung Neoplasms
1232563|NCT01024413|Erlotinib
1232564|NCT01024413|Gefitinib
1232565|NCT01024413|Epidermal growth factor receptor genes
1232566|NCT01024400|Influenza
1232567|NCT01024400|Vaccine
1232568|NCT01024400|Pregnancy
1232569|NCT01024387|AMG 479
1232570|NCT01024361|Preterm infants
1232571|NCT01024361|Nasal CPAP
1232572|NCT01024361|Delivery room
1232573|NCT01024361|Newborn
1232574|NCT01024348|Surgery, knee arthroscopy
1232575|NCT01024348|Pain, postoperative
1232576|NCT01024348|tramadol, extended release
1232577|NCT01024335|opioid dependence
1232578|NCT01024335|naltrexone
1232579|NCT01024335|vivitrol
1232580|NCT01024335|dronabinol
1232581|NCT01024335|marinol
1232582|NCT01024322|Diagnosis of keratoconus, post-LASIK ectasia, FFKC, or pellucid marginal degeneration
1232583|NCT01024309|total hip arthroplasty
1232584|NCT01024283|Heat Shock Protein 90 Inhibitor (HSP90)
1232585|NCT01024283|Pharmacodynamic
1232586|NCT01024283|Blood
1232587|NCT01024283|Biopsy
1232588|NCT01024283|Solid malignancies
1232589|NCT01024270|endometrial pathology of uterus
1232590|NCT01024270|operative hysteroscopy
1232591|NCT01024270|efficacy of misoprostol per different routes
1232592|NCT01024257|beta-irradiation;conjunctival autograft;pterygium;recurrence; clinical trial
1232593|NCT01024205|clear cell renal cell carcinoma
1232594|NCT01024205|stage IV renal cell cancer
1232595|NCT01024179|Optical Coherence Tomography
1232596|NCT01024179|Coronary artery disease
1232597|NCT01024179|Chronic total occlusion
1232598|NCT01024166|Cancer
1232599|NCT01024166|Patient-Reported Outcomes Computer System
1232600|NCT01024166|PRO
1232601|NCT01024166|Palliative Care
1232602|NCT01024166|Symptoms
1232603|NCT01024166|Questionnaire
1232604|NCT01024166|Patients
1232605|NCT01024166|Caregivers
1232606|NCT01024166|Palliative Care Physicians
1232607|NCT01024166|Palliative Care Nurses
1232608|NCT01024153|active video games
1232609|NCT01024153|children
1232610|NCT01024153|physical activity
1232611|NCT01024140|Posttraumatic Stress Disorder
1232612|NCT01024140|Escitalopram
1232613|NCT01024140|Efficacy
1232614|NCT01024114|MBI
1232615|NCT01024114|Molecular Breast Imaging
1232616|NCT01024114|Breast Cancer
1232617|NCT01024114|Positive Molecular Breast Imaging scan.
1232618|NCT01024088|Guillain Barré syndrome
1232619|NCT01024088|Swallowing disorders
1232620|NCT01024088|Respiratory failure
1232621|NCT01024075|Chronic Rhinosinusitis
1232622|NCT01024075|Endoscopic sinus surgery
1232623|NCT01024075|Sinufoam
1232624|NCT01024075|Dexamethasone
1232625|NCT01024075|For patients with Chronic Rhinosinusitis without nasal polyps
1232626|NCT01024075|Focus: Define the postoperative sinonasal mucosal healing status of 2 Sinufoam mixtures
1232627|NCT01024049|heart failure blood left ventricular dysfunction
1232628|NCT01024036|Multicentric Castleman's Disease
1232629|NCT01024036|MCD
1232630|NCT01024036|CNTO 328
1232631|NCT01024036|Best Supportive Care
1232632|NCT01024036|Tumor
1232633|NCT01024036|Symptomatic response
1232634|NCT01024036|Pharmacokinetics
1232635|NCT01024036|Interleukin-6
1232636|NCT01024036|IL6
1232637|NCT01024023|Early Walking Aid
1232638|NCT01024023|Amputee
1232639|NCT01024023|Trans-tibial
1232640|NCT01024023|Quality of life
1232641|NCT01023997|corneal thickness
1232642|NCT01023997|exfoliation
1232643|NCT01023984|RECTAL NEOPLASMS
1232644|NCT01023945|ASP1941
1232645|NCT01023945|Diabetes mellitus
1232646|NCT01023945|Blood glucose
1232647|NCT01023919|Optical coherence tomography
1232648|NCT01023919|Drug eluting stent
1232649|NCT01023919|Coronary Artery Disease
1232650|NCT01023919|Diabetes Mellitus
1232651|NCT01023906|Taste
1232652|NCT01023906|general Labeled Magnitude Scale
1232653|NCT01023906|Aging
1232654|NCT01023906|Chronic Disease Risk
1232655|NCT01023906|Smell
1232656|NCT01023867|Alzheimer's disease
1232657|NCT01023867|Mixed Dementia
1232658|NCT01023867|Donepezil
1232659|NCT01023867|Efficacy
1232660|NCT01023867|Adverse Event
1232661|NCT01023854|Paravertebral block
1232662|NCT01023854|loco regional anesthesia
1232663|NCT01023854|renal surgery
1232664|NCT01023854|PCA morphine
1232665|NCT01023828|K-RAS ONCOGENE MUTATION
1232666|NCT01023828|NON-SMALL CELL LUNG CANCER
1232667|NCT01023828|WOOD SMOKE
1232668|NCT01023815|Immunosuppression
1232669|NCT01023815|renal transplantation
1232670|NCT01023815|once-a-day regimen
1232671|NCT01023815|steroid withdrawal
1232672|NCT01023815|drug minimization
1232673|NCT01023815|immunosuppression for prevention of acute rejections
1232674|NCT01023802|neoadjuvant therapy
1232675|NCT01023802|chemotherapy
1232676|NCT01023802|hormone therapy
1232677|NCT01023802|breast cancer
1232678|NCT01023802|MBI
1232679|NCT01023802|Molecular Breast Imaging
1232680|NCT01023789|Drug eluting stent
1232681|NCT01023789|Stents
1232682|NCT01023789|Angioplasty
1232683|NCT01023789|Bioabsorbable
1232684|NCT01023789|Bioresorbable
1232685|NCT01023789|Scaffold
1232686|NCT01023776|Swine Flu
1232687|NCT01023776|H1N1
1232688|NCT01023763|Nursing homes
1232689|NCT01023763|Intravenous
1232690|NCT01023763|Treatment
1232691|NCT01023763|Patient trajectory
1232692|NCT01023763|Hospital admissions
1232693|NCT01023750|hypertriglyceridemia
1232694|NCT01023750|Triglycerides
1232695|NCT01023750|HDL
1232696|NCT01023750|Insulin resistance
1232697|NCT01023737|Malignant Solid Tumor
1232698|NCT01023737|Solid Tumor
1232699|NCT01023737|Hydroxychloroquine
1232700|NCT01023737|Vorinostat
1232701|NCT01023711|Influenza
1232702|NCT01023698|Diabetic retinopathy
1232703|NCT01023698|Diabetic macular edema
1232704|NCT01023698|Panretinal photocoagulation
1232705|NCT01023685|Active immunization
1232706|NCT01023685|Alzheimer disease
1232707|NCT01023685|Antibody
1232708|NCT01023685|Central Nervous System diseases
1232709|NCT01023685|Neurodegenerative diseases
1232710|NCT01023685|Vaccine
1232711|NCT01023672|Dementia with Lewy Bodies
1232712|NCT01023672|hypersomnolence
1232713|NCT01023672|cognition
1232714|NCT01023672|neuropsychiatric morbidity
1232715|NCT01023672|quality of life
1232716|NCT01023659|Smoking cessation
1232717|NCT01023659|Bupropion
1232718|NCT01023659|Varenicline
1232719|NCT01023659|Population-level
1232720|NCT01023659|Mass distribution
1232721|NCT01023659|Drug Therapy
1232722|NCT01023646|Glycemic Index
1232723|NCT01023646|Glycemic Load
1232724|NCT01023646|Glucose
1232725|NCT01023646|Insulin
1232726|NCT01023646|Lipoproteins
1232727|NCT01023646|Free fatty acids
1232728|NCT01023633|to investigate the efficacy and feasibility of this novel treatment strategy in Chinese mCRC patients
1232729|NCT01023633|Primary Endpoint:DDC
1232730|NCT01023633|Secondary Endpoint:OS, RR,DCR, PFS,safety
1232731|NCT01023620|HIV
1232732|NCT01023620|Lipodystrophy
1232733|NCT01023620|Lipoatrophy
1232734|NCT01023620|Lipohypertrophy
1232735|NCT01023620|Human Immunodeficiency Virus
1232736|NCT01023607|optical coherence tomography
1232737|NCT01023607|intravascular ultrasound
1232738|NCT01023607|Coronary artery disease
1232739|NCT01023607|Hyperlipidemia
1232740|NCT01023594|Pancreatic fistula
1232741|NCT01023594|Pancreatic leakage
1232742|NCT01023594|Pancreatoduodenectomy
1232743|NCT01023594|Pancreatic stent
1232744|NCT01023581|Type 2 Diabetes mellitus
1232745|NCT01023581|Non-insulin dependent diabetes mellitus
1232746|NCT01023581|Drug Therapy
1232747|NCT01023581|Hypoglycemia,
1232748|NCT01023581|Hyperglycemia
1232749|NCT01023568|intubation
1232750|NCT01023568|pediatric
1232751|NCT01023568|videolaryngoscope devices
1232752|NCT01023555|Bacteremia
1232753|NCT01023555|Blood Cultures
1232754|NCT01023555|Sepsis
1232755|NCT01023542|renal impairment
1232756|NCT01023542|MELD>25
1232757|NCT01023542|Liver transplantation
1232758|NCT01023542|CNI-free
1232759|NCT01023542|Bottom-Up
1232760|NCT01023542|Everolimus
1232761|NCT01023529|Prostatic Neoplasms
1232762|NCT01023529|Rectal Neoplasms
1232763|NCT01023529|Palliative treatment
1232764|NCT01023529|Radiotherapy
1232765|NCT01023529|Quality of life
1232766|NCT01023516|Chronic
1232767|NCT01023516|obstructive
1232768|NCT01023516|pulmonary
1232769|NCT01023516|lung
1232770|NCT01023516|respiratory disease
1232771|NCT01023516|efficacy
1232772|NCT01023516|placebo-controlled
1232773|NCT01023516|COPD
1232774|NCT01023516|FEV1
1232775|NCT01023516|St Georges Respiratory Questionnaire
1232776|NCT01023503|Statins
1232777|NCT01023503|Dyslipidemia
1232778|NCT01023503|Spain
1232779|NCT01023503|Rosuvastatin
1232780|NCT01023503|Naive
1232781|NCT01023503|Switching
1232782|NCT01023503|New statins prescriptions in Spain (naive patients and switching)
1232783|NCT01023490|back pain
1232784|NCT01023490|hypovitaminosis D
1232785|NCT01023477|Carcinoma, Intraductal, Noninfiltrating
1232786|NCT01023477|Ductal Carcinoma In Situ
1232787|NCT01023477|DCIS
1232788|NCT01023477|Carcinoma, Intraductal
1232789|NCT01023477|Breast Cancer
1232790|NCT01023477|Breast Tumors
1232791|NCT01023477|chloroquine
1232792|NCT01023477|autophagy
1232793|NCT01023477|Autophagic Cell Death
1232794|NCT01023477|Autophagocytosis
1232795|NCT01023477|Programmed Cell Death, Type II
1232796|NCT01023477|Autophagy, Cellular
1232797|NCT01023477|Autophagic Programmed Cell Death
1232798|NCT01023464|tear film break-up time
1232799|NCT01023451|Pulmonary hypertension
1232800|NCT01023451|Sickle cell disease
1232801|NCT01023451|Pediatric patients
1232802|NCT01023451|Brain Natriuretic Peptide levels
1232803|NCT01023425|naive group
1232804|NCT01023425|switching group
1232805|NCT01023425|treatment response
1232806|NCT01023425|Efficacy
1232807|NCT01023425|Adverse event
1232808|NCT01023412|Immunonutrition
1232809|NCT01023412|cancer
1232810|NCT01023412|GI cancer surgery
1232811|NCT01023386|YM155
1232812|NCT01023386|Mass-balance
1232813|NCT01023386|Phase I
1232814|NCT01023386|Pharmacokinetics
1232815|NCT01023373|Angioplasty
1232938|NCT01022931|Influenza A H1N1
1232816|NCT01023373|Atherosclerotic reno vascular disease (ARVD)
1232817|NCT01023373|Cardio- and cerebro- vascular comorbidity
1232818|NCT01023373|End stage renal disease (ERSD)
1232819|NCT01023373|kidney diseases
1232820|NCT01023373|High blood pressure
1232821|NCT01023373|Hypertension
1232822|NCT01023373|Ischemic nephropathy
1232823|NCT01023373|Percutaneous transluminal renal artery stenting (PTRS)
1232824|NCT01023373|Randomized controlled trials
1232825|NCT01023373|Renal artery stenosis (RAS)
1232826|NCT01023373|Renal insufficiency
1232827|NCT01023373|Vascular diseases
1232828|NCT01023347|NSCLC
1232829|NCT01023334|Topical analgesia
1232830|NCT01023334|FlACC Pain Scale
1232831|NCT01023334|intracameral lignocaine
1232832|NCT01023334|Anesthetics
1232833|NCT01023334|Physiological Effects of Drugs
1232834|NCT01023334|Lidocaine
1232835|NCT01023321|Safety
1232836|NCT01023321|Tolerability
1232837|NCT01023321|Pharmacokinetics
1232838|NCT01023308|Myeloma
1232839|NCT01023308|DACi
1232840|NCT01023308|Bortezomib
1232841|NCT01023308|Combination
1232842|NCT01023308|Panobinostat
1232843|NCT01023308|LBH589D
1232844|NCT01023308|relapsed
1232845|NCT01023308|Velcade®
1232846|NCT01023295|Polypoidal Choroidal Vasculopathy
1232847|NCT01023295|PCV
1232848|NCT01023295|Polypoid
1232849|NCT01023295|oxigene
1232850|NCT01023295|VDA
1232851|NCT01023295|vascular disrupting agent
1232852|NCT01023295|combretastatin
1232853|NCT01023295|fosbretabulin
1232854|NCT01023282|Parkinson's disease
1232855|NCT01023282|Levodopa
1232856|NCT01023282|Dyskinesia
1232857|NCT01023282|ACR325
1232858|NCT01023269|Neurogenic overactive bladder
1232859|NCT01023269|Urinary incontinence due to incomplete spinal cord injury
1232860|NCT01023269|Neuromodulation
1232861|NCT01023269|Neuromodulation for treatment of neurogenic overactive bladder
1232862|NCT01023269|Patients with Urge urinary incontinence and detrusor overactivity
1232863|NCT01023256|Rheumatoid arthritis
1232864|NCT01023256|GM-CSF
1232865|NCT01023256|MOR103
1232866|NCT01023243|foot exam
1232867|NCT01023243|health services
1232868|NCT01023243|practice improvement
1232869|NCT01023243|quality
1232870|NCT01023243|preventive services
1232871|NCT01023243|Natural Language Processing
1232872|NCT01023230|DV-601
1232873|NCT01023230|hepatitis B
1232874|NCT01023230|entecavir
1232875|NCT01023230|therapeutic vaccine
1232876|NCT01023217|Chronic hepatitis B
1232877|NCT01023217|lamivudine
1232878|NCT01023217|adefovir
1232879|NCT01023217|entecavir
1232880|NCT01023191|Dialysis
1232881|NCT01023191|Peritoneal
1232882|NCT01023191|Catheter
1232883|NCT01023191|Surgery
1232884|NCT01023165|Diabetes Mellitus
1232885|NCT01023165|Metabolic Integrity
1232886|NCT01023165|Intravenous Bolus Insulin
1232887|NCT01023139|Adolescent
1232888|NCT01023139|Obesity
1232889|NCT01023139|Pharmacotherapy
1232890|NCT01023139|Sibutramine
1232891|NCT01023126|Obesity
1232892|NCT01023126|Exercise
1232893|NCT01023126|Psychotherapy
1232894|NCT01023113|Diabetic retinopathy
1232895|NCT01023113|laser
1232896|NCT01023113|field loss
1232897|NCT01023113|macular edema
1232898|NCT01023113|Visual field loss
1232899|NCT01023100|taste study open label investigational drug oral therapy
1232900|NCT01023074|MS
1232901|NCT01023074|CAP
1232902|NCT01023048|preimplantation diagnosis
1232903|NCT01023022|CareLink
1232904|NCT01023022|Remote Monitoring
1232905|NCT01023022|Cardiac Pacemaker, Artificial
1232906|NCT01023022|Implantable Cardioverter-Defibrillators
1232907|NCT01023009|Occlusion
1232908|NCT01023009|vitrectomy
1232909|NCT01023009|small gauge vitrectomy
1232910|NCT01023009|Postoperative occlusion
1232911|NCT01022996|Hodgkin's Lymphoma
1232912|NCT01022996|Hodgkin Lymphoma
1232913|NCT01022996|Hodgkin's Disease
1232914|NCT01022996|Hodgkin Disease
1232915|NCT01022996|Lymphoma
1232916|NCT01022996|Lymphoproliferative Disorders
1232917|NCT01022996|Neoplasms by Histological type
1232918|NCT01022996|Lymphatic Diseases
1232919|NCT01022996|Hemic and Lymphatic Diseases
1232920|NCT01022996|Recurrent Lymphoma
1232921|NCT01022996|Refractory Lymphoma
1232922|NCT01022996|Relapsed Lymphoma
1232923|NCT01022996|Classical Hodgkin Lymphoma
1232924|NCT01022996|Classical Hodgkin's Disease
1232925|NCT01022996|Nodular sclerosing Hodgkin Lymphoma
1232926|NCT01022996|Mixed-cellularity Hodgkin Lymphoma
1232927|NCT01022996|Lymphocyte-rich Hodgkin Lymphoma
1232928|NCT01022996|Lymphocyte depleted Hodgkin Lymphoma
1232929|NCT01022970|Esophagitis
1232930|NCT01022970|Digestive System Diseases
1232931|NCT01022970|Esophageal disorder
1232932|NCT01022970|Eosinophilic esophagitis
1232933|NCT01022957|extra renal damages
1232934|NCT01022944|Serous otitis media
1232935|NCT01022944|Biofilm
1232936|NCT01022944|Adenoidectomy
1232937|NCT01022944|Chronic otitis media
1232939|NCT01022931|Children
1232940|NCT01022931|Epidemiology
1232941|NCT01022931|Treatment
1232942|NCT01022931|Oseltamivir
1232943|NCT01022931|Genetics
1232944|NCT01022918|unresectable glioblastoma
1232945|NCT01022905|HIV infection
1232946|NCT01022905|transplant
1232947|NCT01022905|rheumatic disease
1232948|NCT01022905|cancer
1232949|NCT01022905|children
1232950|NCT01022892|Endovascular
1232951|NCT01022892|Abdominal
1232952|NCT01022892|Aortic
1232953|NCT01022892|Aneurysm
1232954|NCT01022892|Repair
1232955|NCT01022892|Surveillance
1232956|NCT01022892|EVAR
1232957|NCT01022892|CT
1232958|NCT01022892|Scan
1232959|NCT01022892|Endoleaks
1232960|NCT01022892|Contrast
1232961|NCT01022892|Enhanced
1232962|NCT01022892|Ultrasound
1232963|NCT01022892|Definity
1232964|NCT01022892|AAA
1232965|NCT01022892|imaging
1232966|NCT01022892|No Endoleaks
1232967|NCT01022879|Pain scale of pain
1232968|NCT01022866|falls
1232969|NCT01022866|older adults
1232970|NCT01022827|stiff shoulder
1232971|NCT01022827|massage
1232972|NCT01022827|muscle stiffness
1232973|NCT01022775|Degenerative rotator cuff disease
1232974|NCT01022775|Impingement syndrome
1232975|NCT01022775|Dynamic humeral centering
1232976|NCT01022775|Randomized clinical trial
1232977|NCT01022749|inflammatory bowel disease (IBD)
1232978|NCT01022749|immunosuppressed or non-immunosuppressed
1232979|NCT01022749|influenza vaccine
1232980|NCT01022749|antibody titers
1232981|NCT01022749|seroprotective titers
1232982|NCT01022749|vaccine-associated adverse events
1232983|NCT01022736|gabapentin
1232984|NCT01022736|pharmacokinetics
1232985|NCT01022736|visual analogue pain scale
1232986|NCT01022736|cardiopulmonary bypass
1232987|NCT01022723|Circulating tumor cells
1232988|NCT01022723|metastasis
1232989|NCT01022723|cancer
1232990|NCT01022723|cell isolation
1232991|NCT01022723|mircofludics
1232992|NCT01022723|cell detection
1232993|NCT01022710|hearing loss
1232994|NCT01022710|otoacoustic emissions
1232995|NCT01022684|atherosclerosis
1232996|NCT01022684|vascular inflammation
1232997|NCT01022684|LpPLA2
1232998|NCT01022684|hsCRP
1232999|NCT01022684|MCP-1
1233000|NCT01022684|18FDG-PET
1233001|NCT01022671|Belotecan
1233002|NCT01022671|Camtobell inj
1233003|NCT01022671|NSCLC
1233004|NCT01022658|Insulin Therapy
1233005|NCT01022658|Vago-sympathetic activity
1233006|NCT01022658|arterial stiffness
1233007|NCT01022658|endothelial function
1233008|NCT01022645|Intrauterine device
1233009|NCT01022645|Gestational diabetes
1233010|NCT01022645|Postpartum contraception
1233011|NCT01022645|Postpartum birth control
1233012|NCT01022632|Depression
1233013|NCT01022619|Sleep apnea
1233014|NCT01022619|high risk pregnancy
1233015|NCT01022619|fetal outcome
1233016|NCT01022619|cord blood
1233017|NCT01022580|nitric oxide
1233018|NCT01022580|surfactant
1233019|NCT01022580|bronchopulmonary dysplasia
1233020|NCT01022580|BPD
1233021|NCT01022580|prematurity
1233022|NCT01022580|neonates
1233023|NCT01022580|iNO
1233024|NCT01022580|pulmonary outcome
1233025|NCT01022580|neurodevelopmental outcome
1233026|NCT01022580|Infasurf
1233027|NCT01022580|lung function
1233028|NCT01022580|Surfactant Dysfunction
1233029|NCT01022528|Elective total abdominal hysterectomy (with or without salpingo-oophorectomy or minor bladder repair) or myomectomy
1233030|NCT01022528|through a lower transverse or low midline incision under general anesthesia
1233031|NCT01022515|pheochromocytoma
1233032|NCT01022515|paraganglioma
1233033|NCT01022515|hypertension
1233034|NCT01022502|psoriasis, indigo naturalis
1233035|NCT01022489|Schizophrenia, auditory hallucinations, TMS
1233036|NCT01022476|Pharmacokinetics
1233037|NCT01022476|Raltegravir
1233038|NCT01022476|Immunosuppressive Agents
1233039|NCT01022476|Severe hepatic insufficiency
1233040|NCT01022476|Liver Transplantation
1233041|NCT01022476|Additional Keywords
1233042|NCT01022476|HIV Infection
1233043|NCT01022476|Hepatocarcinoma
1233044|NCT01022476|Hepatitis C
1233045|NCT01022476|Hepatitis B
1233046|NCT01022450|rhabdomyolysis
1233047|NCT01022450|myopathy
1233048|NCT01022450|acute renal failure
1233049|NCT01022450|neuroleptic malignant syndrome
1233050|NCT01022450|Pharmaceutical Preparations
1233051|NCT01022450|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1233052|NCT01022450|fibrates
1233053|NCT01022450|creatine kinase
1233054|NCT01022424|ADPKD
1233055|NCT01022424|Tolvaptan
1233056|NCT01022424|OPC-41061
1233057|NCT01022411|brown rice
1233058|NCT01022411|white rice
1233059|NCT01022411|diabetes risk
1233060|NCT01022398|Vitamin D3
1233061|NCT01022398|HMG-CoA reductase inhibitors (statin)-related myalgias
1233062|NCT01022359|haemodialysis
1233063|NCT01022359|vascular access
1233064|NCT01022359|central venous catheter
1233065|NCT01022346|Cervical intraepithelial neoplasia
1233066|NCT01022346|RO5217790
1233067|NCT01022333|BRCA1
1233068|NCT01022333|breast cancer
1233069|NCT01022333|3,3'-di-indolylmethane
1233070|NCT01022333|dietary intervention
1233071|NCT01022333|estrogen metabolites
1233072|NCT01022333|mRNA expression
1233073|NCT01022333|BRCA1 protein
1233074|NCT01022333|Estrogen
1233075|NCT01022320|OSA
1233076|NCT01022320|Blood pressure
1233077|NCT01022320|Lateral Pharyngoplasty
1233078|NCT01022307|behavioral data acquisition
1233079|NCT01022307|MRI
1233080|NCT01022294|children
1233081|NCT01022294|analgesia
1233082|NCT01022294|dental treatment
1233083|NCT01022294|inhalation
1233084|NCT01022281|Exfoliation
1233085|NCT01022281|Scanning Laser Polarimetry
1233086|NCT01022281|Corneal Thickness
1233087|NCT01022255|autologous vaccine
1233088|NCT01022255|follicular lymphoma
1233089|NCT01022255|magnICON
1233090|NCT01022255|plant-made vaccines
1233091|NCT01022255|immune response
1233092|NCT01022242|Surgical Adhesions
1233093|NCT01022242|Post-surgical adhesions
1233094|NCT01022242|Flexor tendon
1233095|NCT01022229|Attention Deficit Disorder
1233096|NCT01022229|Pediatrics
1233097|NCT01022229|Attention
1233098|NCT01022229|Impulsivity
1233099|NCT01022229|Complementary Therapies
1233100|NCT01022216|Wound
1233101|NCT01022216|Skin lesion
1233102|NCT01022216|Antimicrobial
1233103|NCT01022216|Bioelectric
1233104|NCT01022216|Diabetic foot
1233105|NCT01022216|Pressure Ulcer
1233106|NCT01022203|Couples Therapy
1233107|NCT01022203|PTSD
1233108|NCT01022190|Arthroplasty
1233109|NCT01022190|Hip
1233110|NCT01022190|Cemented
1233111|NCT01022190|Heterotopic ossification
1233112|NCT01022190|Selective Cyclooxygenase-2 Inhibitors
1233113|NCT01022190|Arthroplasty, Replacement
1233114|NCT01022190|Hip Prosthesis
1233115|NCT01022190|Cyclooxygenase Inhibitors
1233116|NCT01022164|fibrin glue
1233117|NCT01022164|vitrectomy
1233118|NCT01022164|safety and efficacy of fibrin glue
1233119|NCT01022151|Aminophylline
1233120|NCT01022151|sevoflurane
1233121|NCT01022151|anaesthesia
1233122|NCT01022151|recovery
1233123|NCT01022151|cognitive function
1233124|NCT01022151|entropy
1233125|NCT01022138|HER2-negative breast cancer
1233126|NCT01022138|stage IV breast cancer
1233127|NCT01022138|recurrent breast cancer
1233128|NCT01022125|TMC435-TiDP16-C121
1233129|NCT01022125|TMC435-C121
1233130|NCT01022125|TMC435
1233131|NCT01022125|TMC435350
1233132|NCT01022125|Protease inhibitor
1233133|NCT01022125|HCV
1233134|NCT01022125|Hepatitis C
1233135|NCT01022112|TA-7284
1233136|NCT01022112|JNJ-28431754
1233137|NCT01022112|Canagliflozin
1233138|NCT01022112|Type 2 diabetes mellitus
1233139|NCT01022112|Sodium Glucose Co-transporter (SGLT2 inhibitor)
1233140|NCT01022099|Total Knee Arthroplasty
1233141|NCT01022099|Navigation
1233142|NCT01022086|Breast Cancer
1233143|NCT01022086|Cardiotoxicity
1233144|NCT01022086|Trastuzumab
1233145|NCT01022086|Cardiac MRI
1233146|NCT01022073|Deep Brain Stimulation
1233147|NCT01022073|Subthalamic Nucleus
1233148|NCT01022073|Globus Pallidus
1233149|NCT01022073|Parkinson Disease
1233150|NCT01022060|Dietary supplement
1233151|NCT01022060|Renalof
1233152|NCT01022060|Recurrent calcic urolithiasis
1233153|NCT01022060|Renal calculi
1233154|NCT01022034|Rectal prolapse
1233155|NCT01022034|mesh
1233156|NCT01022034|recurrence
1233157|NCT01022021|non-Hodgkin's lymphoma
1233158|NCT01022021|autologous stem cell transplant
1233159|NCT01022008|Exorbitism
1233160|NCT01022008|Upper respiratory airways
1233161|NCT01022008|Osteodistraction
1233162|NCT01022008|Polysomnography
1233163|NCT01021995|Safety of Echinacea in comparison to placebo
1233164|NCT01021982|Pupillometer
1233165|NCT01021982|Retinitis Pigmentosa
1233166|NCT01021982|Glaucoma
1233167|NCT01021982|Objective perimetry
1233168|NCT01021956|Macular Degeneration
1233169|NCT01021956|Age Related Macular Degeneration
1233170|NCT01021956|Choroidal Neovascularization
1233171|NCT01021956|AMD
1233172|NCT01021956|CNV
1233173|NCT01021956|WST11
1233174|NCT01021956|Stakel
1233175|NCT01021956|Photodynamic therapy
1233176|NCT01021956|Vascular Targeted Photodynamic therapy
1233177|NCT01021956|VTP
1233178|NCT01021943|calcineurin inhibitors
1233179|NCT01021943|fibrosis
1233180|NCT01021943|spironolactone
1233181|NCT01021943|Focus of the study is to assess if aldosterone blockade has an effect on interstitial fibrosis amongst kidney transplant recipients
1233182|NCT01021930|Optical coherence tomography
1233183|NCT01021930|Drug eluting stent
1233184|NCT01021930|Coronary heart disease
1233185|NCT01021930|Diabetes mellitus
1233186|NCT01021917|Obesity
1233187|NCT01021917|Weight Loss
1233188|NCT01021917|Meal Replacements
1233189|NCT01021904|Primary prevention
1233190|NCT01021904|HPV Vaccination
1233191|NCT01021904|HPV Infection
1233192|NCT01021904|Cervical Cancer
1233193|NCT01021904|HPV Related Diseases
1233194|NCT01021891|Technosphere® Insulin Inhalation Powder
1233195|NCT01021878|Peritoneal dialysis
1233196|NCT01021878|Renal replacement therapy
1233197|NCT01021878|Dialysis solutions
1233198|NCT01021878|Icodextrin
1233199|NCT01021865|GLP-1
1233200|NCT01021865|Myocardial contrast echocardiography
1233201|NCT01021865|Myocardial perfusion
1233202|NCT01021839|renal dialysis
1233203|NCT01021839|bioprosthesis
1233204|NCT01021839|arteriovenous shunt
1233205|NCT01021839|surgical
1233206|NCT01021826|knee replacement
1233207|NCT01021826|hip replacement
1233208|NCT01021826|hyperglycemia
1233209|NCT01021826|diabetes
1233210|NCT01021826|osteoarthritis
1233211|NCT01021800|Pancreatic tubular adenocarcinoma adjuvant setting
1233212|NCT01021787|Sun Protection
1233213|NCT01021735|Rheumatoid
1233214|NCT01021735|Outcome
1233215|NCT01021735|Cost effectiveness
1233216|NCT01021735|Safety
1233217|NCT01021722|sphincter
1233218|NCT01021722|obstetric tears
1233219|NCT01021722|long-term follow-up
1233220|NCT01021709|depression
1233221|NCT01021709|direct current stimulation
1233222|NCT01021709|extracephalic electrode
1233223|NCT01021696|Dementia
1233224|NCT01021696|Nursing home
1233225|NCT01021696|Pain treatment
1233226|NCT01021696|Pain assessment
1233227|NCT01021696|Agitation
1233228|NCT01021683|Hematological neoplasms
1233229|NCT01021683|Neutropenia
1233230|NCT01021683|Fever
1233231|NCT01021683|Itraconazole
1233232|NCT01021683|Sporanox
1233233|NCT01021683|Antifungal prophylaxis
1233234|NCT01021683|Defeverscence
1233235|NCT01021670|Dapoxetine hydrochloride
1233236|NCT01021670|Priligy
1233237|NCT01021670|Premature ejaculation
1233238|NCT01021670|Non-dapoxetine hydrochloride treatment(s)
1233239|NCT01021657|Glaucoma
1233240|NCT01021657|Tenon's Capsule
1233241|NCT01021657|Lipid profile
1233242|NCT01021657|Assessment of lipid profile in Tenon's capsule in patients with Glaucoma
1233243|NCT01021644|APOE
1233244|NCT01021644|Apolipoprotein E
1233245|NCT01021644|Cognition Disorders
1233246|NCT01021644|Neurocognition
1233247|NCT01021631|Cardiac surgery
1233248|NCT01021631|Strategies of transfusion
1233249|NCT01021631|Red blood cells
1233250|NCT01021631|Liberal
1233251|NCT01021631|Restrictive
1233252|NCT01021631|Anemia
1233253|NCT01020539|Allogeneic Stem Cell Transplantation
1233254|NCT01020539|Targeted Immune Therapy
1233255|NCT01020539|Acute Myelogenous Leukemia
1233256|NCT01020539|Myelodysplastic Syndrome
1233257|NCT01020539|Juvenile Myelomonocytic Leukemia
1233258|NCT01020539|AML
1233259|NCT01020539|MDS
1233260|NCT01020539|JMML
1233261|NCT01021592|Velcade
1233262|NCT01021592|QoL
1233263|NCT01021592|Proteasome inhibitor
1233264|NCT01021592|Bortezomib
1233265|NCT01021592|EORTC QLQ C30
1233266|NCT01021592|EQ 5D
1233267|NCT01021579|Polycystic ovary syndrome
1233268|NCT01021579|Metformin
1233269|NCT01021579|Simvastatin
1233270|NCT01021566|Opiate addiction
1233271|NCT01021566|Withdrawal symptoms
1233272|NCT01021566|hemoperfusion
1233273|NCT01021566|hemodialysis
1233274|NCT01021566|methadone
1233275|NCT01021553|Proof of Concept
1233276|NCT01021553|Double Blind
1233277|NCT01021540|Nephritis,Nephropathy
1233278|NCT01021514|sRAGE
1233279|NCT01021514|SUV
1233280|NCT01021514|TBR
1233281|NCT01021514|FDG PET CT
1233282|NCT01021514|Type 2 DM
1233283|NCT01021501|nifedipine controlled release tablets
1233284|NCT01021501|hypertensive
1233285|NCT01021501|chronic maintenance hemodialysis
1233286|NCT01021501|Pharmacokinetics
1233287|NCT01021488|Thrombosis
1233288|NCT01021488|Vein
1233289|NCT01021488|Statin
1233290|NCT01021488|Prevention
1233291|NCT01021475|Functional Dyspepsia, Visceral Manipulation
1233292|NCT01021449|schizophrenia, BDNF, DNA methylation, histone modification
1233293|NCT01021436|Pneumonia
1233294|NCT01021436|Gram-negative bacteria
1233295|NCT01021423|Mantle Cell Lymphoma
1233296|NCT01021423|Non-Hodgkin's Lymphoma
1233297|NCT01021423|CC-5013
1233298|NCT01021423|Revlimid
1233299|NCT01021423|Lenalidomide
1233300|NCT01021410|acetaminophen
1233301|NCT01021410|paracetamol
1233302|NCT01021410|protein adduct
1233303|NCT01021410|healthy volunteer
1233304|NCT01021410|acetaminophen-protein adduct formation
1233305|NCT01021397|Respiratory Tract Infection
1233306|NCT01021384|Depression,
1233307|NCT01021384|Early Intervention,
1233308|NCT01021384|Behavior Disorder,
1233309|NCT01021384|Parenting Skills,
1233310|NCT01021384|Children with Special Health Care Needs,
1233311|NCT01021384|Developmental Disabilities,
1233312|NCT01021384|Family Support Programs
1233313|NCT01021371|HRQOL
1233314|NCT01021371|Rehabilitation
1233315|NCT01021371|Cancer Patients
1233316|NCT01021371|General Practice
1233317|NCT01021332|Lower Urinary Tract Symptoms
1233318|NCT01021332|Treatment
1233319|NCT01021332|Solifenacin succinate
1233320|NCT01021332|Tamsulosin hydrochloride OCAS
1233321|NCT01021332|Benign Prostatic Hyperplasia
1233322|NCT01021332|EC905
1233323|NCT01021332|Vesomni
1233324|NCT01021319|ischemic stroke
1233325|NCT01021319|thrombolysis
1233326|NCT01021319|magnetic resonance imaging
1233327|NCT01021319|diffusion weighted imaging
1233328|NCT01021319|fluid attenuated inversion recovery
1233329|NCT01021319|time window
1233330|NCT01021293|Poliorix
1233331|NCT01021293|IPV
1233332|NCT01021280|Bartter syndrome,
1233333|NCT01021280|parathyroid hormone,
1233334|NCT01021280|calcium sensing receptor,
1233335|NCT01021280|ROMK channel
1233336|NCT01021280|Barttin gene
1233337|NCT01021280|PTH response to hypo- and hypercalcemia
1233338|NCT01021267|sexual dysfunctions
1233339|NCT01021267|benign prostatic hyperplasia
1233340|NCT01021267|saw palmetto
1233341|NCT01021228|Liver resection
1233342|NCT01021228|Continuous volatile anesthesia
1233343|NCT01021228|Continuous intravenous anesthesia
1233344|NCT01021228|Preconditioning volatile anesthesia
1233345|NCT01021228|Comparing three groups of anesthesia during the liver surgery according to their benefit on liver and outcome.
1233346|NCT01021215|Cancer Prevention
1233347|NCT01021215|Smoking-related lung disease
1233348|NCT01021215|Smoking
1233349|NCT01021215|Celecoxib
1233350|NCT01021215|Celebrex
1233351|NCT01021215|Zileuton
1233352|NCT01021215|Zyflo CR
1233353|NCT01021215|Prevention
1233354|NCT01021202|tracheostomy
1233355|NCT01021202|tracheotomy
1233356|NCT01021202|dilational
1233357|NCT01021202|dilatative
1233358|NCT01021202|critical care
1233359|NCT01021202|intensive care
1233360|NCT01021202|COPD
1233361|NCT01021202|chronic obstructive pulmonary disease
1233362|NCT01021202|lung disease
1233363|NCT01021202|pneumonia
1233364|NCT01021202|prospective study
1233365|NCT01021202|questionnaire
1233366|NCT01021202|quality of life
1233367|NCT01021202|outcome
1233368|NCT01021202|mortality
1233369|NCT01021189|safety
1233370|NCT01021189|tolerability
1233371|NCT01021189|AZD1446
1233372|NCT01021189|AD
1233373|NCT01021189|Japanese
1233374|NCT01021176|Food Intake
1233375|NCT01021176|Hunger
1233376|NCT01021176|Lidocaine
1233377|NCT01021176|Nose
1233378|NCT01021176|smell
1233379|NCT01021137|vestibular function tests
1233380|NCT01021137|postural balance
1233381|NCT01021137|neuroimaging
1233382|NCT01021124|tuberculosis
1233383|NCT01021124|bone marrow transplant
1233384|NCT01021124|diagnosis
1233385|NCT01021098|influenza
1233386|NCT01021098|illness
1233387|NCT01021098|active-duty
1233388|NCT01021098|virus
1233389|NCT01021098|flu
1233390|NCT01021098|military
1233391|NCT01021098|Influenza-like-illnesses
1233392|NCT01021085|Assisted Reproductive Technology
1233393|NCT01021085|circulating cell free fetal DNA
1233394|NCT01021085|First trimester
1233395|NCT01021059|Biological Effects of rhIL-15
1233396|NCT01021059|Estimate Antitumor Activity
1233397|NCT01021059|rhIL-15 Pharmacokinetics
1233398|NCT01021059|Dose and Safety Determination of IL-15
1233399|NCT01021059|Kidney Cancer
1233400|NCT01021059|Melanoma
1233401|NCT01021059|Renal Cell Cancer
1233402|NCT01021046|deep anterior lamellar keratoplasty
1233403|NCT01021046|rejection
1233404|NCT01021046|high risk patients
1233405|NCT01021046|acellular corneal tissue
1233406|NCT01021033|Ischemia
1233407|NCT01021033|Hemorrhage
1233408|NCT01021033|Rehabilitation
1233409|NCT01021033|Stroke
1233410|NCT01021020|bioequivalence
1233411|NCT01021020|fasting
1233412|NCT01021020|fed
1233413|NCT01021020|healthy
1233414|NCT01020994|Superficial infected eczema
1233415|NCT01020994|Superinfected eczema
1233416|NCT01020981|OEF/OIF
1233417|NCT01020981|Peer Group
1233418|NCT01020981|Veterans
1233419|NCT01020968|Ischemic Dilated Cardiomyopathy
1233420|NCT01020968|Non-Ischemic Dilated Cardiomyopathy
1233421|NCT01020968|ixmyelocel-T
1233422|NCT01020955|GH and IGF-I
1233423|NCT01020955|growth hormone deficiency and IGT or diabetes
1233424|NCT01020942|ischemia
1233425|NCT01020942|myocardial infarction
1233426|NCT01020942|prognosis
1233427|NCT01020942|pretreatment
1233428|NCT01020942|electroacupuncture
1233429|NCT01020942|stents
1233430|NCT01020942|troponin
1233431|NCT01020942|percutaneous coronary intervention
1233432|NCT01020916|Induced hypothermia
1233433|NCT01020916|Mild induced hypothermia
1233434|NCT01020916|Therapeutic hypothermia
1233435|NCT01020916|Cardiac arrest
1233436|NCT01020916|Out-of-hospital cardiac arrest
1233437|NCT01020916|Mortality
1233438|NCT01020916|Neurological function
1233439|NCT01020916|Randomised clinical trial
1233440|NCT01020890|GERD diagnosis
1233441|NCT01020890|GERD-Q
1233442|NCT01020890|GERD patients' characteristics
1233443|NCT01020890|GERD
1233444|NCT01020877|Bioequivalence
1233445|NCT01020877|Healthy Subjects
1233446|NCT01020877|Healthy, Normal Subjects
1233447|NCT01020864|Platinum-resistent head and neck cancer
1233448|NCT01020864|Cetuximab
1233449|NCT01020864|Carboplatin
1233450|NCT01020864|Navelbine
1233451|NCT01020864|Phase II trial
1233452|NCT01020864|Combination chemotherapy
1233453|NCT01020851|hypertension
1233454|NCT01020851|stroke
1233455|NCT01020851|cholesterol
1233456|NCT01020851|adherence
1233457|NCT01020838|Florbetaben
1233458|NCT01020838|Amyloid beta-protein
1233459|NCT01020838|Alzheimer's disease
1233460|NCT01020825|Complex perianal fistula
1233461|NCT01020825|Adipose-derived adult stem cells
1233462|NCT01020825|Fibrin glue
1233463|NCT01020799|Depression
1233464|NCT01020786|Non-squamous
1233465|NCT01020773|extubation,Respiration, Artificial
1233466|NCT01020760|Macular hole
1233467|NCT01020760|Vitrectomy
1233468|NCT01020760|Prone posturing
1233469|NCT01020734|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1233470|NCT01020734|adult acute myeloid leukemia with del(5q)
1233471|NCT01020734|adult acute myeloid leukemia with t(16;16)(p13;q22)
1233472|NCT01020734|recurrent adult acute myeloid leukemia
1233473|NCT01020734|adult acute myeloid leukemia in remission
1233474|NCT01020734|childhood acute myeloid leukemia in remission
1233475|NCT01020734|recurrent childhood acute myeloid leukemia
1233476|NCT01020734|adult acute minimally differentiated myeloid leukemia (M0)
1233477|NCT01020734|childhood acute minimally differentiated myeloid leukemia (M0)
1233478|NCT01020734|adult acute myeloblastic leukemia without maturation (M1)
1233479|NCT01020734|childhood acute myeloblastic leukemia without maturation (M1)
1233480|NCT01020734|adult acute myeloblastic leukemia with maturation (M2)
1233481|NCT01020734|childhood acute myeloblastic leukemia with maturation (M2)
1233482|NCT01020734|adult acute myelomonocytic leukemia (M4)
1233483|NCT01020734|childhood acute myelomonocytic leukemia (M4)
1233484|NCT01020734|adult acute monoblastic leukemia (M5a)
1233485|NCT01020734|adult acute monocytic leukemia (M5b)
1233486|NCT01020734|childhood acute monoblastic leukemia (M5a)
1233487|NCT01020734|childhood acute monocytic leukemia (M5b)
1233488|NCT01020734|adult erythroleukemia (M6a)
1233489|NCT01020734|adult pure erythroid leukemia (M6b)
1233490|NCT01020734|childhood acute erythroleukemia (M6)
1233491|NCT01020734|adult acute megakaryoblastic leukemia (M7)
1233492|NCT01020734|childhood acute megakaryocytic leukemia (M7)
1233493|NCT01020721|CYP1B1 gene
1233494|NCT01020708|colitis
1233495|NCT01020708|inflammatory bowel disease
1233496|NCT01020708|ulcerative colitis
1233497|NCT01020708|rectal administration
1233498|NCT01020708|enema
1233499|NCT01020708|mesalamine
1233500|NCT01020695|PTSD
1233501|NCT01020695|EEG
1233502|NCT01020695|QEEG
1233503|NCT01020695|LORETA
1233504|NCT01020682|apathy
1233505|NCT01020682|parkinson
1233506|NCT01020682|agonist dopaminergic
1233507|NCT01020669|fMRI
1233508|NCT01020669|Prenatal Drug Exposure
1233509|NCT01020669|Decision Making
1233510|NCT01020669|Working Memory
1233511|NCT01020669|Vulnerability
1233512|NCT01020656|anticoagulant agents
1233513|NCT01020656|antiplatelet agents
1233514|NCT01020656|vitreoretinal surgery
1233515|NCT01020656|Patients suffered from retinal detachment
1233516|NCT01020630|adenocarcinoma of stomach
1233517|NCT01020630|adenocarcinoma of lower oesophagus
1233518|NCT01020630|sunitinib
1233519|NCT01020630|FOLFIRI
1233520|NCT01020604|BMI
1233521|NCT01020604|Prostate cancer
1233522|NCT01020604|Recurrence
1233523|NCT01020591|knee osteoarthritis
1233524|NCT01020591|manual therapy
1233525|NCT01020591|osteopathy
1233526|NCT01020552|APHIA II
1233527|NCT01020552|AIDS, Population, and Health Integrated Assistance project
1233528|NCT01020552|DCF
1233529|NCT01020552|data collection forms
1233530|NCT01020552|FDA
1233531|NCT01020552|Federal Drug Administration
1233532|NCT01020552|FP
1233533|NCT01020552|family planning
1233534|NCT01020552|IRB
1233535|NCT01020552|Institutional Review Board
1233536|NCT01020552|PAC
1233537|NCT01020552|postabortion care
1233538|NCT01020552|To document the ESD PAC svc pkg including the provision of services, client satisfaction with those services and provider attitudes towards PAC services
1233539|NCT01020552|To examine any differences in implementation of the ESD PAC services package for youth and adult clients
1233540|NCT01020552|To assess the usefulness of five Youth-Friendly PAC Job Aids developed by ESD
1233541|NCT01020487|Reduction of parathyroid hormone levels in pediatric patients with Chronic Kidney Disease Stage 3 and 4
1233542|NCT01020474|juvenile primary fibromyalgia syndrome
1233543|NCT01020474|pediatric fibromyalgia
1233544|NCT01020474|pregabalin
1233545|NCT01020474|and Lyrica
1233546|NCT01020448|Locally advanced or metastatic Prostate Cancer
1233547|NCT01020435|Hypertension
1233548|NCT01020422|breast hypertrophy
1233549|NCT01020422|mammaplasty
1233550|NCT01020422|sexuality
1233551|NCT01020422|depression
1233552|NCT01020409|cardiac surgery
1233553|NCT01020409|cardiopulmonary bypass
1233554|NCT01020409|acute lung injury
1233555|NCT01020409|acute respiratory distress syndrome
1233556|NCT01020409|acute kidney injury
1233557|NCT01020409|atrial fibrillation
1233558|NCT01020409|postoperative psychosis
1233559|NCT01020409|myocardial infarct
1233560|NCT01020409|sepsis
1233561|NCT01020396|Bioequivalence
1233562|NCT01020396|Metronidazole
1233563|NCT01020396|Vaginosis
1233564|NCT01020370|Patients with RRMS who are participating in the CARE MS I and CARE MS II
1233565|NCT01020357|preterm infants
1233566|NCT01020357|very low birthweight
1233567|NCT01020357|apnea of prematurity
1233568|NCT01020357|methylxanthines
1233569|NCT01020357|sleep disturbance
1233570|NCT01020357|obstructive sleep apnea syndrome
1233571|NCT01020357|polysomnography
1233572|NCT01020357|sleep disruption
1233573|NCT01020331|ALS
1233574|NCT01020318|Traumatic Brain Injury
1233575|NCT01020318|TBI
1233576|NCT01020318|Brain Injuries
1233577|NCT01020292|Adult subjects with a diagnosis of Grade IV Glioma
1233578|NCT01020279|muscle pain
1233579|NCT01020279|model
1233580|NCT01020266|brain protection
1233581|NCT01020266|cardiac surgery
1233582|NCT01020266|heart valve replacement
1233583|NCT01020266|electroacupuncture
1233584|NCT01020266|pretreatment
1233585|NCT01020266|preconditioning
1233586|NCT01020266|Thoracic Surgery
1233587|NCT01020253|bisphosphonate, vitamin D3
1233588|NCT01020253|Total Hip arthroplasty
1233589|NCT01020240|Immediate puerperium
1233590|NCT01020240|physiotherapy in postpartum
1233591|NCT01020240|cesarean complications
1233592|NCT01020227|Postoperative Care
1233593|NCT01020227|Quality of Life
1233594|NCT01020227|Integrative Medicine
1233595|NCT01020227|Coronary Artery Bypass Graft Surgery
1233596|NCT01020201|Anesthesia, General
1233597|NCT01020201|Elective Gynecological Operation
1233598|NCT01020201|Chinese female patient
1233599|NCT01020201|Adult
1233600|NCT01020175|allogeneic transplantation
1233601|NCT01020175|Leukemia
1233602|NCT01020175|GvHD
1233603|NCT01020175|MDS
1233604|NCT01020162|Chronic pelvic pain
1233605|NCT01020162|ilioinguinal nerve entrapment
1233606|NCT01020162|randomized study
1233607|NCT01020162|Chronic pelvic pain in women
1233608|NCT01020149|Nerve transsection
1233609|NCT01020136|Bioequivalence Pharmacokinetics
1233610|NCT01020123|Type II Diabetes Mellitus
1233611|NCT01020123|metformin
1233612|NCT01020123|glipizide
1233613|NCT01020110|perfusion chamber
1233614|NCT01020110|thrombus D-Dimer
1233615|NCT01020110|HUVEC
1233616|NCT01020097|Stage 1 squamous cell carcinoma of the larynx
1233617|NCT01020084|Saliva
1233618|NCT01020084|Mastication
1233619|NCT01020084|Communication
1233620|NCT01020071|iridotomy
1233621|NCT01020071|iridoplasty
1233622|NCT01020071|angle closure glaucoma
1233623|NCT01020045|HIV
1233624|NCT01020045|Osteopenia
1233625|NCT01020045|Osteoporosis
1233626|NCT01020032|Music therapy
1233627|NCT01020032|Pain
1233628|NCT01020032|Anxiety
1233629|NCT01020032|Depression
1233630|NCT01020032|Controlled randomized trial
1233631|NCT01020019|Cannabis Dependence
1233632|NCT01020019|Marijuana Dependence
1233633|NCT01020019|Marinol
1233634|NCT01020019|Lofexidine
1233635|NCT01020006|PCI-27483
1233636|NCT01020006|Factor VIIa
1233637|NCT01020006|Gemcitabine
1233638|NCT01020006|4 months life expectancy
1233639|NCT01020006|Pharmacyclics
1233640|NCT01020006|Locally Advanced
1233641|NCT01020006|Metastatic disease
1233642|NCT01019993|Thoracotomy
1233643|NCT01019993|one lung ventilation
1233644|NCT01019993|HFPPV
1233645|NCT01019993|right ventricular function.
1233646|NCT01019980|Antipyretics
1233647|NCT01019980|fever
1233648|NCT01019980|diclofenac
1233649|NCT01019980|acetaminophen
1233650|NCT01019980|children
1233651|NCT01019980|acute upper respiratory tract infections
1233652|NCT01019967|Children and Adolescents
1233653|NCT01019967|Obsessive-Compulsive Disorder
1233654|NCT01019967|Magnetic Resonance Spectroscopy
1233655|NCT01019967|Autism
1233656|NCT01019967|OCD
1233657|NCT01019967|Obsessive Compulsive Disorder
1233658|NCT01019954|Adults with premalignant head and neck tumors and adults who have Carcinoma in situ of the head and neck in whom standard therapy is not indicated
1233659|NCT01019941|Docetaxel
1233660|NCT01019941|CKD-810
1233661|NCT01019941|Taxotere inj.
1233662|NCT01019941|Advanced Solid cancer
1233663|NCT01019941|Pharmacokinetic evaluation
1233664|NCT01019928|GERD
1233665|NCT01019928|patient
1233666|NCT01019928|esophagus
1233667|NCT01019928|pain
1233668|NCT01019915|CRT
1233669|NCT01019915|heart failure
1233670|NCT01019915|left bundle branch block
1233671|NCT01019915|skeletal muscle
1233672|NCT01019915|cytokines
1233673|NCT01019915|VO2
1233674|NCT01019915|pgc1alpha
1233675|NCT01019902|iron
1233676|NCT01019902|pregnancy
1233677|NCT01019902|adolescents
1233678|NCT01019902|auditory brainstem responses
1233679|NCT01019902|anemia
1233680|NCT01019902|neonate
1233681|NCT01019889|upper respiratory tract infections
1233682|NCT01019889|herbal medicine
1233683|NCT01019876|Bone marrow Failure
1233684|NCT01019876|Fanconi
1233685|NCT01019876|SCID
1233686|NCT01019850|disseminated neuroblastoma
1233687|NCT01019850|localized unresectable neuroblastoma
1233688|NCT01019850|recurrent neuroblastoma
1233689|NCT01019850|regional neuroblastoma
1233690|NCT01019837|Vaccine
1233691|NCT01019824|nerve compression
1233692|NCT01019824|compression radiculopathy
1233693|NCT01019824|post-traumatic/post-surgical lumbar radiculopathy
1233694|NCT01019811|Cross-finger flap
1233695|NCT01019811|finger injuries
1233696|NCT01019811|fingertip reconstruction
1233697|NCT01019811|proper digital artery
1233698|NCT01019811|proper digital nerve.
1233699|NCT01019798|non small cell lung cancer
1233700|NCT01019798|sunitinib
1233701|NCT01019798|docetaxel
1233702|NCT01019785|Pregnancy rate (pos test, live fetus at 12 weeks, baby home)
1233703|NCT01019785|Pregnancy complication (Pregnancy hypertension, SGA, diab)
1233704|NCT01019785|Thrombin generation
1233705|NCT01019759|Atrial fibrillation
1233706|NCT01019759|cardiac surgery
1233707|NCT01019759|ablation
1233708|NCT01019759|pulmonary veins
1233709|NCT01019746|Hypnosis with propofol
1233710|NCT01019733|Hypoxia
1233711|NCT01019733|Ischemia
1233712|NCT01019733|Brain
1233713|NCT01019733|Children
1233714|NCT01019733|Cerebral Palsy
1233715|NCT01019707|crystal meth
1233716|NCT01019707|methamphetamine
1233717|NCT01019707|substance abuse
1233718|NCT01019681|Cord blood injection in peripheral vascular disease
1233719|NCT01019668|chorioretinopathy
1233720|NCT01019668|photodynamic therapy
1233721|NCT01019668|reduced fluence
1233722|NCT01019668|reduced dose
1233723|NCT01019655|thrombophilia
1233724|NCT01019655|pregnancy
1233725|NCT01019655|heparin
1233726|NCT01019642|vitamin D
1233727|NCT01019642|diabetes
1233728|NCT01019642|C-reactive protein
1233729|NCT01019642|insulin resistance
1233730|NCT01019629|Fabry, Fabry Disease, Alpha-galactosidase A deficiency, GLA gene, mutations
1233732|NCT01019551|Controlled viremia
1233733|NCT01019551|Viral reservoirs
1233734|NCT01019551|Virus eradication
1233735|NCT01019551|Therapeutic intensification
1233736|NCT01019551|Immunointervention
1233737|NCT01019538|Oxygen
1233738|NCT01019538|Hypoxemia
1233739|NCT01019538|Air travel
1233740|NCT01019525|respiration
1233741|NCT01019525|respiratory disorders
1233742|NCT01019525|Otolaryngology
1233743|NCT01019525|Otorhinolaryngology
1233744|NCT01019525|Posture
1233745|NCT01019499|human
1233746|NCT01019499|intervention
1233747|NCT01019499|blood pressure
1233748|NCT01019499|cardiovascular risk factors
1233749|NCT01019499|polyphenols
1233750|NCT01019499|bioavailability
1233751|NCT01019486|Myocardial blood flow
1233752|NCT01019486|Cardiac magnetic resonance imaging
1233753|NCT01019486|Myocardial perfusion imaging
1233754|NCT01019486|Coronary artery flow reserve
1233755|NCT01019486|Regadenoson
1233756|NCT01019473|Huntington's disease
1233757|NCT01019473|Chorea
1233758|NCT01019473|Dyskinesia
1233759|NCT01019460|Small intestine
1233760|NCT01019460|Magnetic resonance imaging
1233761|NCT01019460|Computed tomography scanning
1233762|NCT01019460|Capsule endoscopy
1233763|NCT01019447|Surgical site infection
1233764|NCT01019447|Antimicrobial triclosan-coated polyglactin 910 suture
1233765|NCT01019447|Length of hospital stay
1233766|NCT01019447|SSI
1233767|NCT01019434|adult glioblastoma
1233768|NCT01019421|Cognition
1233769|NCT01019408|Clinical Trial
1233770|NCT01019408|Chloroquine
1233771|NCT01019408|Refugees
1233772|NCT01019408|Afghanistan
1233773|NCT01019408|Pakistan
1233774|NCT01019395|Gram Positive Infection
1233775|NCT01019395|Concurrent Antibiotic Treatment
1233776|NCT01019382|pancreatic
1233777|NCT01019382|carcinoma
1233778|NCT01019382|cancer
1233779|NCT01019382|fish
1233780|NCT01019382|alternative
1233781|NCT01019369|Contraception
1233782|NCT01019369|Medroxyprogesterone 17-acetate
1233783|NCT01019369|Self administration
1233784|NCT01019356|PCOS
1233785|NCT01019343|Magnetic Resonance Imaging (MRI)
1233786|NCT01019343|Magnetoencephalogram
1233787|NCT01019343|Electroencephalogram (EEG)
1233788|NCT01019343|Transcranial Magnetic Stimulation (TMS)
1233789|NCT01019343|Motor Deficit
1233790|NCT01019343|Dystonia
1233791|NCT01019343|Movement Disorder
1233792|NCT01019343|Parkinson Disease
1233793|NCT01019343|PD
1233794|NCT01019343|Tourette Syndrome
1233795|NCT01019343|TS
1233796|NCT01019343|Tic Disorder
1233797|NCT01019330|radial vs femoral
1233798|NCT01019330|radial artery cardiac catheterization
1233799|NCT01019317|Acute Myelogenous Leukemia
1233800|NCT01019317|High-Risk Myelodysplastic Syndrome
1233801|NCT01019317|Chronic myeloid leukemia
1233802|NCT01019317|CML
1233803|NCT01019317|Blast crisis
1233804|NCT01019317|Cytarabine
1233805|NCT01019317|Ara-C
1233806|NCT01019317|Cytosar
1233807|NCT01019317|DepoCyt
1233808|NCT01019317|Cytosine arabinosine hydrochloride
1233809|NCT01019317|Arabinosine Hydrochloride
1233810|NCT01019317|Fludarabine
1233811|NCT01019317|Fludarabine Phosphate
1233812|NCT01019317|Fludara
1233813|NCT01019317|Gemtuzumab Ozogamicin
1233814|NCT01019317|Mylotarg
1233815|NCT01019291|Indoor pollutants
1233816|NCT01019265|Norspan patch
1233817|NCT01019265|Buprenorphine transdermal patch (BTDS)
1233818|NCT01019265|efficacy
1233819|NCT01019265|buprenorphine
1233820|NCT01019252|Adolescent
1233821|NCT01019252|ADHD
1233822|NCT01019239|Non-faeculant
1233823|NCT01019239|Perforated
1233824|NCT01019239|Diverticulitis
1233825|NCT01019226|myocardium
1233826|NCT01019226|Magnetic resonance imaging
1233827|NCT01019213|His-pacing
1233828|NCT01019200|psoriasis
1233829|NCT01019200|heart disease
1233830|NCT01019200|cardiovascular disease
1233831|NCT01019200|hyperlipidemia
1233832|NCT01019161|Acute Myeloid Leukaemia (AML)
1233833|NCT01019161|AML
1233834|NCT01019161|AZD1152
1233835|NCT01019161|Pharmacokinetics
1233836|NCT01019135|Women
1233837|NCT01019135|Cardiac Care Facilities
1233838|NCT01019135|Patient satisfaction
1233839|NCT01019135|Patient participation
1233840|NCT01019135|Patient compliance
1233841|NCT01019135|Randomized Control Trial
1233842|NCT01019135|Coronary artery bypass
1233843|NCT01019135|Angioplasty, transluminal, percutaneous coronary
1233844|NCT01019122|cerebral palsy
1233845|NCT01019122|DEXA scan
1233846|NCT01019122|bone density
1233847|NCT01019109|scoliosis
1233848|NCT01019096|iron
1233849|NCT01019096|pregnancy
1233850|NCT01019096|heme iron
1233851|NCT01019096|non-heme iron
1233852|NCT01019096|stable isotopes
1233853|NCT01019096|women/adolescents
1233854|NCT01019083|Cholera
1233855|NCT01019083|Typhoid
1233856|NCT01019083|Oral Vaccine
1233857|NCT01019083|Immune response
1233858|NCT01019083|Vaccine Evaluation
1233859|NCT01019083|Nutrition
1233860|NCT01019083|Child Health
1233861|NCT01019057|DDD
1233862|NCT01019057|decompression
1233863|NCT01019057|spinous process plate
1233864|NCT01019044|HIV
1233865|NCT01019044|Viral reservoirs
1233866|NCT01019044|Viral load
1233867|NCT01019018|subtenon block
1233868|NCT01019005|post-operative analgesia
1233869|NCT01019005|opioid
1233870|NCT01019005|catheter
1233871|NCT01019005|tibial nerve block
1233872|NCT01018992|PTSD
1233873|NCT01018992|Anxiety Disorder
1233874|NCT01018992|Corticotropin releasing factor
1233875|NCT01018992|Women
1233876|NCT01018927|Cardiac MR (CMR)
1233877|NCT01018927|Early Myocardial Infiltration
1233878|NCT01018927|Amyloid
1233879|NCT01018927|Light Chain Deposition Disease
1233880|NCT01018927|Multiple Myeloma
1233881|NCT01018914|Prograf
1233882|NCT01018914|Advagraf
1233883|NCT01018914|Myfortic
1233884|NCT01018888|Cornea
1233885|NCT01018888|Transplantation, Cornea
1233886|NCT01018888|Keratoplasty
1233887|NCT01018888|Grafting, Corneal
1233888|NCT01018849|Vitamin D
1233889|NCT01018849|Cardiac Catheterization
1233890|NCT01018849|Cardiovascular event
1233891|NCT01018849|Cardiovascular Disease
1233892|NCT01018836|tumors metastatic to brain
1233893|NCT01018836|unspecified adult solid tumor, protocol specific
1233894|NCT01018810|Psoriasis
1233895|NCT01018797|INTRASTROMAL CORNEAL RING
1233896|NCT01018797|ASTIGMATISM
1233897|NCT01018797|POSTKERATOPLASTY
1233898|NCT01018797|EYES
1233899|NCT01018797|To evaluate the clinical outcomes of ICRS implantation to correct high-degree astigmatism on eyes with prior penetrating keratoplasty (PK)
1233900|NCT01018784|Cancer
1233901|NCT01018784|Mesothelin-positive
1233902|NCT01018771|actifuse
1233903|NCT01018771|INFUSE
1233904|NCT01018771|InductOs
1233905|NCT01018771|DDD
1233906|NCT01018771|Degenerative disc disease
1233907|NCT01018771|PLF
1233908|NCT01018771|posterolateral lumbar fusion
1233909|NCT01018771|bone substitute
1233910|NCT01018771|bone graft
1233911|NCT01018771|synthetic bone substitute
1233912|NCT01018771|spinal surgery
1233913|NCT01018758|Non-Hodgkin's lymphoma
1233914|NCT01018758|Quality of life
1233915|NCT01018758|Chemotherapy toxicity
1233916|NCT01018758|aggressive Non Hodgkin's Lymphomas treated with moderately emetogenic chemotherapy
1233917|NCT01018732|Meningococcal
1233918|NCT01018732|ACWY
1233919|NCT01018732|Conjugate Vaccine
1233920|NCT01018732|Meningitis
1233921|NCT01018732|Adolescents
1233922|NCT01018732|Persistence
1233923|NCT01018719|breast cancer radiotherapy cardiotoxicity multidetector CT
1233924|NCT01018719|Radiotherapy
1233925|NCT01018706|Primary pci
1233926|NCT01018706|Stent
1233927|NCT01018706|Medical Hystory
1233928|NCT01018706|Antiplatelet therapy
1233929|NCT01018706|Compliance
1233930|NCT01018693|Seasonal allergic rhinitis,
1233931|NCT01018693|late phase response,
1233932|NCT01018693|alutard avanz,
1233933|NCT01018693|immunotherapy,
1233934|NCT01018693|visual analogue scale,
1233935|NCT01018693|mini rhinitis quality of life,
1233936|NCT01018693|immune modulation
1233937|NCT01018667|Heart Failure
1233938|NCT01018667|clinical trial
1233939|NCT01018667|biventricular pacing
1233940|NCT01018667|cardiac device
1233941|NCT01018654|Substance Abuse
1233942|NCT01018654|Substance Addiction
1233943|NCT01018641|Staphylococcus aureus
1233944|NCT01018641|Vaccine
1233945|NCT01018615|chronic hepatitis C
1233946|NCT01018615|silymarin
1233947|NCT01018615|green tea catechins
1233948|NCT01018615|green tea extract
1233949|NCT01018615|pharmacokinetics
1233950|NCT01018615|antioxidant activity
1233951|NCT01018589|Post surgical scars
1233952|NCT01018589|Epidermic burn
1233953|NCT01018589|Cicatrix cream
1233954|NCT01018576|delayed cord clamping
1233955|NCT01018576|premature infants
1233956|NCT01018576|hypothermia
1233957|NCT01018576|anemia
1233958|NCT01018576|intraventricular hemorrhage
1233959|NCT01018576|Anemia in premature infants
1233960|NCT01018563|Extension study
1233961|NCT01018563|Epithelial ovarian cancer
1233962|NCT01018537|Multiple Sclerosis
1233963|NCT01018537|NARCOMS
1233964|NCT01018537|Global Patient Registry
1233965|NCT01018524|position of the mesh
1233966|NCT01018524|recurrence rate
1233967|NCT01018524|surgical procedure
1233968|NCT01018524|long time outcome
1233969|NCT01018511|EC905
1233970|NCT01018511|Solifenacin succinate
1233971|NCT01018511|Tamsulosin hydrochloride OCAS
1233972|NCT01018511|Treatment
1233973|NCT01018511|Benign Prostatic Hyperplasia
1233974|NCT01018511|Vesomni
1233975|NCT01018511|Lower Urinary Tract Symptoms
1233976|NCT01018498|Irritable Bowel Syndrome
1233977|NCT01018498|Children
1233978|NCT01018472|cyanotic heart disease
1233979|NCT01018472|congenital heart disease
1233980|NCT01018472|intestinal microbiota
1233981|NCT01018472|probiotics
1233982|NCT01018459|malaria, vaccine, Burkina Faso
1233983|NCT01018446|Hematopoietic stem cell transplantation with busulfan based conditioning
1233984|NCT01018433|self-injury
1233985|NCT01018433|non-suicidal self-injury
1233986|NCT01018433|deliberate self-harm
1233987|NCT01018433|self-mutilation
1233988|NCT01018420|healthy
1233989|NCT01018394|tobacco dependence
1233990|NCT01018394|tobacco reduction
1233991|NCT01018394|chewing tobacco
1233992|NCT01018394|snuff
1233993|NCT01018394|moist snuff
1233994|NCT01018381|HCC
1233995|NCT01018381|HBV
1233996|NCT01018381|MGN-3
1233997|NCT01018381|BioBran
1233998|NCT01018381|Alternative Therapy
1233999|NCT01018355|Patent foramen ovale
1234000|NCT01018355|PFO
1234001|NCT01018355|Stroke
1234002|NCT01018355|TIA
1234003|NCT01018355|Percutaneus closure
1234004|NCT01018355|Intervention
1234005|NCT01018329|Adult Brain Tumor
1234006|NCT01018316|preoxygenation
1234007|NCT01018316|UMOX
1234008|NCT01018303|cystic fibrosis
1234009|NCT01018303|vitamins
1234010|NCT01018303|antioxidants
1234011|NCT01018303|anthropometric measurements
1234012|NCT01018303|pulmonary function
1234013|NCT01018264|Overactive bladder
1234014|NCT01018264|Urinary incontinence
1234015|NCT01018264|Urinary frequency
1234016|NCT01018264|Parkinson's disease
1234017|NCT01018212|Cutaneous Groves
1234018|NCT01018199|C-reactive protein
1234019|NCT01018199|procalcitonin
1234020|NCT01018199|community-acquired pneumonia
1234021|NCT01018199|antibiotic therapy
1234022|NCT01018160|Rabeprazole sodium
1234023|NCT01018160|Gastroesophageal Reflux
1234024|NCT01018160|GERD
1234025|NCT01018160|Observational
1234026|NCT01018147|stage IIIA non-small cell lung cancer
1234027|NCT01018147|stage IIIB non-small cell lung cancer
1234028|NCT01018147|stage IA non-small cell lung cancer
1234029|NCT01018147|stage IB non-small cell lung cancer
1234030|NCT01018147|stage IIA non-small cell lung cancer
1234031|NCT01018147|stage IIB non-small cell lung cancer
1234032|NCT01018134|Psoriasis
1234033|NCT01018134|Topical corticosteroids
1234034|NCT01018134|Plaque psoriasis
1234035|NCT01018121|Behavioral Treatment
1234036|NCT01018121|Preschool Children
1234037|NCT01018121|Obesity Treatment
1234038|NCT01018069|Acute
1234039|NCT01018069|myeloid
1234040|NCT01018069|leukemia
1234041|NCT01018069|antisense
1234042|NCT01018069|chemotherapy
1234043|NCT01018069|idarubicin
1234044|NCT01018069|cytarabine
1234045|NCT01018069|Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen.
1234046|NCT01018056|Tourette syndrome
1234047|NCT01018056|glutamatergic therapy
1234048|NCT01018056|D-serine
1234049|NCT01018056|riluzole
1234050|NCT01018056|glutamate
1234051|NCT01018056|glutamate agonist
1234052|NCT01018056|glutamate antagonist
1234053|NCT01018056|Tourette syndrome treatment study
1234054|NCT01018056|OCD
1234055|NCT01018056|tics
1234056|NCT01018043|Cancer Anemia Survey
1234057|NCT01018043|Chulalongkorn hospital
1234058|NCT01018030|uncomplicated acute rhinosinusitis
1234059|NCT01018030|fluticasone furoate
1234060|NCT01018030|sinusitis
1234061|NCT01018004|stage IB melanoma
1234062|NCT01018004|stage II melanoma
1234063|NCT01017991|infants
1234064|NCT01017991|formula
1234065|NCT01017991|probiotic
1234066|NCT01017991|crying
1234067|NCT01017965|Type 1 diabetes
1234068|NCT01017952|Safety
1234069|NCT01017952|COPD
1234070|NCT01017952|FEV1
1234071|NCT01017952|Efficacy
1234072|NCT01017939|Prostate neoplasms
1234073|NCT01017939|Metastatic castration resistant prostate cancer
1234074|NCT01017939|Metastatic castration refractory prostate cancer
1234075|NCT01017939|Prostate cancer
1234076|NCT01017939|Abiraterone acetate
1234077|NCT01017939|CB7630
1234078|NCT01017926|Triazolam bioequivalence
1234079|NCT01017913|rehabilitation
1234080|NCT01017913|electrotherapy
1234081|NCT01017913|back pain
1234082|NCT01017900|surgery
1234083|NCT01017900|manual rupture
1234084|NCT01017900|dorsal carpal ganglion
1234085|NCT01017887|laparoscopy
1234086|NCT01017887|airseal
1234087|NCT01017887|carbon dioxide
1234088|NCT01017887|insufflation
1234089|NCT01017887|pneumoperitoneum
1234090|NCT01017861|Temporal summation
1234091|NCT01017861|Venipuncture pain
1234092|NCT01017848|diabetes
1234093|NCT01017848|urine pH
1234094|NCT01017848|insulin resistance
1234095|NCT01017848|metabolic syndrome
1234096|NCT01017848|development of diabetes
1234097|NCT01017835|statins
1234098|NCT01017835|isolated hypertension
1234099|NCT01017835|atherosclerosis
1234100|NCT01017835|lipid profile
1234101|NCT01017822|adenocarcinoma of the pancreas
1234102|NCT01017822|stage III pancreatic cancer
1234103|NCT01017809|ovarian
1234104|NCT01017809|chemotherapy
1234105|NCT01017809|nausea
1234106|NCT01017796|Contrast induced nephropathy
1234107|NCT01017770|Uncomplicated malaria
1234108|NCT01017757|Interstitial lung disease
1234109|NCT01017757|Immunosuppressive therapy
1234110|NCT01017757|Renal transplant
1234111|NCT01017744|Anesthetic Conserving Device
1234112|NCT01017744|Anaconda®
1234113|NCT01017744|Sevoflurane
1234114|NCT01017744|Remifentanil
1234115|NCT01017744|Sedation
1234116|NCT01017744|Pressure support ventilation
1234117|NCT01017744|Work of breathing
1234118|NCT01017744|Intrinsic positive end expiratory pressure
1234119|NCT01017744|Ventilatory dead space
1234120|NCT01017744|Intensive care
1234121|NCT01017744|Weaning of mechanical ventilation
1234122|NCT01017744|Ventilated ICU patients in PSV
1234123|NCT01017744|No more in acute state
1234124|NCT01017744|No respiratory distress
1234125|NCT01017744|Sedated by intravenous remifentanil
1234126|NCT01017744|In light sedation as define by a Richmond Agitation Sedation Scale (RASS) of - 1 to - 2.
1234127|NCT01017731|Advanced Solid tumor
1234128|NCT01017731|Antibodies, Monoclonal
1234129|NCT01017731|QTc
1234130|NCT01017731|Metastatic
1234131|NCT01017731|Malignant
1234132|NCT01017718|Diabetes mellitus type I
1234133|NCT01017718|nerve conduction velocity
1234134|NCT01017718|Young score
1234135|NCT01017718|long term vascular complications
1234136|NCT01017666|Healthy Volunteer
1234137|NCT01017653|Panitumumab
1234138|NCT01017653|Vectibix
1234139|NCT01017653|Irinotecan
1234140|NCT01017653|CPT-11
1234141|NCT01017653|Camptosar
1234142|NCT01017653|Malignant glioma
1234143|NCT01017653|Glioblastoma multiforme
1234144|NCT01017653|Gliosarcoma
1234145|NCT01017653|Duke
1234146|NCT01017653|Vredenburgh
1234147|NCT01017653|Pro00015447
1234148|NCT01017627|ESRD
1234149|NCT01017627|Anemia
1234150|NCT01017627|Hospitalizations
1234151|NCT01017627|Mortality
1234152|NCT01017614|Inflammatory Bowel Disease
1234153|NCT01017614|Iron deficiency
1234154|NCT01017614|Iron deficiency anaemia
1234155|NCT01017614|Anaemia
1234156|NCT01017601|extensive stage small cell lung cancer
1234157|NCT01017588|lumbar support
1234158|NCT01017588|rubber tapper
1234159|NCT01017562|To clarify the 18F-fluoride uptake patterns associated with aseptic or septic loosening
1234160|NCT01017549|Stage I
1234161|NCT01017549|Stage II
1234162|NCT01017549|Breast
1234163|NCT01017549|Cancer
1234164|NCT01017536|HIV
1234165|NCT01017536|Tuberculosis
1234166|NCT01017536|Vaccine
1234167|NCT01017523|diabetes
1234168|NCT01017523|relationship
1234169|NCT01017523|social support
1234170|NCT01017523|telemedicine
1234171|NCT01017497|Brain Metastases
1234172|NCT01017484|blood pressure
1234173|NCT01017484|DASH diet
1234174|NCT01017484|hypertension
1234175|NCT01017471|carpal tunnel syndrome
1234176|NCT01017471|surgery
1234177|NCT01017471|PSU retractor
1234178|NCT01017471|carpal tunnel syndrome who failed to conservative treatment
1234179|NCT01017458|Healthy Adults
1234180|NCT01017445|osteoarthritis, exercise
1234181|NCT01017419|hearing aids
1234182|NCT01017419|counseling
1234183|NCT01017406|plantar fasciitis
1234184|NCT01017406|heel cushion
1234185|NCT01017406|treatment
1234186|NCT01017393|preemptive epidural ketamine
1234187|NCT01017393|prevention of chronic post-thoracotomy pain
1234188|NCT01017380|preemptive analgesia
1234189|NCT01017380|cruciate ligament
1234190|NCT01017367|RA
1234191|NCT01017367|inflammatory joint disease
1234192|NCT01017354|vitamin D
1234193|NCT01017354|function
1234194|NCT01017354|falls
1234195|NCT01017354|25-hydroxyvitamin D
1234196|NCT01017354|disability
1234197|NCT01017341|hip fracture
1234198|NCT01017341|back support
1234199|NCT01017328|infants and children undergoing surgery with general anesthesia
1234200|NCT01017315|baby talcum
1234201|NCT01017315|pruritus
1234202|NCT01017315|cast
1234203|NCT01017276|Hyperphosphatemia
1234204|NCT01017276|Peritoneal dialysis
1234205|NCT01017276|CKD
1234206|NCT01017276|ASP1585
1234207|NCT01017263|ADHD
1234208|NCT01017263|Glucose Intolerance
1234209|NCT01017263|Obesity
1234210|NCT01017263|Vyvanse
1234211|NCT01017250|Recurrent
1234212|NCT01017237|Dexmedetomidine sedation
1234213|NCT01017237|Oral surgery sedation
1234214|NCT01017237|Dexmedetomidine amnesia
1234215|NCT01017211|Pain
1234216|NCT01017211|Electromyography
1234217|NCT01017211|Acupuncture
1234218|NCT01017211|Randomized controlled trial
1234219|NCT01017211|Rehabilitation
1234220|NCT01017159|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
1234221|NCT01017159|Subcutaneous immunoglobulin
1234222|NCT01017146|Ance
1234223|NCT01017120|Acne
1234224|NCT01017107|acute pancreatitis
1234225|NCT01017107|treatment
1234226|NCT01017107|organ failure
1234227|NCT01017107|activated protein c
1234228|NCT01017094|Pin-site infection
1234229|NCT01017094|silversulfadiazine
1234230|NCT01017094|open fracture
1234231|NCT01017094|open tibial fracture underwent external fixator
1234232|NCT01017081|physiotherapy
1234233|NCT01017081|children
1234234|NCT01017081|clinical trial
1234235|NCT01017068|GLAUCOMA
1234236|NCT01017042|healthy
1234237|NCT01017042|blood levels
1234238|NCT01017003|healthy
1234239|NCT01017003|pharmacokinetics
1234240|NCT01016990|recurrent adult Hodgkin lymphoma
1234241|NCT01016990|recurrent adult Burkitt lymphoma
1234242|NCT01016990|recurrent adult diffuse large cell lymphoma
1234243|NCT01016990|recurrent adult diffuse mixed cell lymphoma
1234244|NCT01016990|recurrent adult lymphoblastic lymphoma
1234245|NCT01016990|recurrent grade 3 follicular lymphoma
1234246|NCT01016990|recurrent mantle cell lymphoma
1234247|NCT01016990|recurrent grade 1 follicular lymphoma
1234248|NCT01016990|recurrent grade 2 follicular lymphoma
1234249|NCT01016990|recurrent marginal zone lymphoma
1234250|NCT01016990|recurrent small lymphocytic lymphoma
1234251|NCT01016990|refractory chronic lymphocytic leukemia
1234252|NCT01016990|recurrent cutaneous T-cell non-Hodgkin lymphoma
1234253|NCT01016990|peripheral T-cell lymphoma
1234254|NCT01016990|AIDS-related peripheral/systemic lymphoma
1234255|NCT01016990|AIDS-related diffuse large cell lymphoma
1234256|NCT01016990|AIDS-related immunoblastic large cell lymphoma
1234257|NCT01016990|AIDS-related small noncleaved cell lymphoma
1234258|NCT01016990|AIDS-related diffuse mixed cell lymphoma
1234259|NCT01016990|AIDS-related diffuse small cleaved cell lymphoma
1234260|NCT01016990|AIDS-related lymphoblastic lymphoma
1234261|NCT01016990|Waldenström macroglobulinemia
1234262|NCT01016964|Androgenetic Alopecia
1234263|NCT01016964|Hair Loss
1234264|NCT01016964|Female Pattern Baldness
1234265|NCT01016951|Phase I
1234266|NCT01016951|Safety study
1234267|NCT01016951|AZD9164
1234268|NCT01016925|femoral perineural catheter
1234269|NCT01016925|tunnelization
1234270|NCT01016925|complication
1234271|NCT01016925|colonization
1234272|NCT01016925|infection
1234273|NCT01016899|Electronic
1234274|NCT01016899|Brachytherapy
1234275|NCT01016899|Nonmelanoma
1234276|NCT01016899|cancer
1234277|NCT01016886|trastuzumab
1234278|NCT01016886|cardiac MRI
1234279|NCT01016886|beta-blocker
1234280|NCT01016886|biomarkers
1234281|NCT01016886|angiotensin converting enzyme inhibitor
1234282|NCT01016886|cardiotoxicity
1234283|NCT01016886|HER2 positive
1234284|NCT01016873|Oraya
1234285|NCT01016873|Oraya Therapeutics, Inc.
1234637|NCT01015781|Evaluation studies
1234286|NCT01016873|low voltage stereotactic radiotherapy
1234287|NCT01016873|radiotherapy
1234288|NCT01016873|IRay
1234289|NCT01016873|Ranibizumab
1234290|NCT01016873|Lucentis
1234291|NCT01016873|AMD
1234292|NCT01016873|Macular Degeneration
1234293|NCT01016873|xray
1234294|NCT01016873|radiation
1234295|NCT01016873|x ray
1234296|NCT01016873|external beam radiation
1234297|NCT01016873|radiosurgery
1234298|NCT01016860|OSI-906, irinotecan, colorectal cancer
1234299|NCT01016834|migraine
1234300|NCT01016834|treatment satisfaction
1234301|NCT01016821|Oxycodone
1234302|NCT01016821|Labour pain
1234303|NCT01016821|Pregnancy
1234304|NCT01016821|Pregnant women
1234305|NCT01016808|Bunionectomy
1234306|NCT01016808|Opioids
1234307|NCT01016795|SCF
1234308|NCT01016795|Priming
1234309|NCT01016795|Mobilization
1234310|NCT01016795|Lymphoma
1234311|NCT01016795|Clinical Trial
1234312|NCT01016782|Inflammatory Rosacea
1234313|NCT01016782|Rosacea
1234314|NCT01016769|Paclitaxel
1234315|NCT01016769|Carboplatin
1234316|NCT01016769|Temsirolimus
1234317|NCT01016769|Head and Neck
1234318|NCT01016769|recurrent and/or metastatic
1234319|NCT01016769|09-131
1234320|NCT01016756|PHACE syndrome
1234321|NCT01016756|Hemangioma
1234322|NCT01016756|Coarctation of aorta
1234323|NCT01016756|Dandy Walker
1234324|NCT01016756|Brain malformation
1234325|NCT01016756|Eye anomaly
1234326|NCT01016756|Sternal malformation
1234327|NCT01016756|Genetic analysis
1234328|NCT01016756|Cerebral artery anomaly
1234329|NCT01016743|parkinson
1234330|NCT01016743|rTMS
1234331|NCT01016717|clopidogrel
1234332|NCT01016717|platelet function
1234333|NCT01016717|omeprazole
1234334|NCT01016717|pantoprazole
1234335|NCT01016717|coronary disease
1234336|NCT01016665|Breast cancer
1234337|NCT01016665|Short Term
1234338|NCT01016665|Homontherapy
1234339|NCT01016665|aromatase inhibitor
1234340|NCT01016665|Short term hormonetherapy in breast cancer
1234341|NCT01016639|Stomach cancer
1234342|NCT01016639|Gall bladder cancer
1234343|NCT01016639|Bile ductus cancer
1234344|NCT01016639|Pancreas cancer
1234345|NCT01016639|Colorectal cancer
1234346|NCT01016639|Chemo radiotherapy
1234347|NCT01016639|Phase I-II
1234348|NCT01016639|Oxaliplatin
1234349|NCT01016639|Capecitabine
1234350|NCT01016639|Response
1234351|NCT01016626|Pharmacokinetics
1234352|NCT01016626|Healthy volunteers
1234353|NCT01016626|Mycophenolate Mofetil
1234354|NCT01016613|chronic kidney disease
1234355|NCT01016613|glomerulonephritis
1234356|NCT01016613|proteinuria
1234357|NCT01016613|nephrotic syndrome
1234358|NCT01016613|nephropathy
1234359|NCT01016613|biobank
1234360|NCT01016587|symptoms
1234361|NCT01016587|dyspnea
1234362|NCT01016587|pain
1234363|NCT01016587|fatigue
1234364|NCT01016587|anxiety
1234365|NCT01016587|depression
1234366|NCT01016587|sleeplessness
1234367|NCT01016587|genetic markers
1234368|NCT01016587|immune markers
1234369|NCT01016587|COPD
1234370|NCT01016587|Quality of Life
1234371|NCT01016548|Lymphoma
1234372|NCT01016548|Multiple myeloma
1234373|NCT01016548|Leukemia, Lymphocytic, Chronic, B-Cell
1234374|NCT01016548|Influenza A Virus, H1N1 Subtype
1234375|NCT01016548|Influenza Vaccines
1234376|NCT01016548|Bone Marrow Transplantation
1234377|NCT01016535|Family Health Program
1234378|NCT01016535|Hygiene
1234379|NCT01016535|Child Health
1234380|NCT01016522|ALS
1234381|NCT01016522|Ketogenic Diet
1234382|NCT01016509|restenosis
1234383|NCT01016509|insulin
1234384|NCT01016509|hyperglycemia
1234385|NCT01016496|Cerebral Palsy
1234386|NCT01016496|Mirror neurons
1234387|NCT01016496|hemiplegia
1234388|NCT01016496|action observation therapy
1234389|NCT01016496|children affected by hemiplegia as a consequence of Cerebral Palsy
1234396|NCT01016457|Diabetes Mellitus
1234397|NCT01016444|asthma
1234398|NCT01016444|albuterol
1234399|NCT01016444|B2AR receptors
1234400|NCT01016444|Acute asthma responsive and unresponsive to albuterol
1234401|NCT01016431|cardiac pacing
1234402|NCT01016431|heart failure
1234403|NCT01016431|oxygen consumption
1234404|NCT01016431|ventricular dysfunction
1234405|NCT01016431|left, exercise tolerance
1234406|NCT01016431|chronotropic incompetence
1234407|NCT01016431|pacemaker programming
1234408|NCT01016418|NASH
1234409|NCT01016418|fatty liver disease
1234410|NCT01016418|colostrum
1234411|NCT01016405|Dry eye
1234412|NCT01016405|incidence and severity
1234413|NCT01016405|cataract surgery
1234535|NCT01015963|stage IV lymphoepithelioma of the nasopharynx
1234414|NCT01016392|Observational post-authorization safety study on Kuvan®.
1234415|NCT01016379|untreated childhood acute lymphoblastic leukemia
1234416|NCT01016379|recurrent childhood acute lymphoblastic leukemia
1234417|NCT01016366|Friedreich's Ataxia
1234418|NCT01016366|FRDA
1234419|NCT01016366|Neurodegenerative
1234420|NCT01016366|Erythropoietin
1234421|NCT01016366|Carbamylated
1234422|NCT01016366|Neuroprotection
1234423|NCT01016366|Frataxin
1234424|NCT01016353|ABThera
1234425|NCT01016353|Barker's Vacuum Packing Technique
1234426|NCT01016340|Male Oligoasthenospermia
1234427|NCT01016340|MCS
1234428|NCT01016327|Phase I study
1234429|NCT01016327|Advanced Solid Tumors
1234430|NCT01016327|Cdc7 kinase inhibitor
1234431|NCT01016288|EUS-FNA
1234432|NCT01016288|22 Gauge Needle
1234433|NCT01016288|25 Gauge Needle
1234434|NCT01016275|To obtain the first iliac long-term results for a patient cohort treated with nitinol stents only
1234435|NCT01016262|Ulcerative proctitis
1234436|NCT01016262|Proctocolitis
1234437|NCT01016262|Inflammatory Bowel Disease
1234438|NCT01016262|Gastrointestinal Diseases
1234439|NCT01016262|Colonic Diseases
1234440|NCT01016262|Mesalamine
1234441|NCT01016262|5-ASA
1234442|NCT01016249|Bronchiolitis, Viral
1234443|NCT01016249|An acute inflammation of the upper RESPIRATORY TRACT
1234444|NCT01016223|Eosinophilic esophagitis
1234445|NCT01016223|Beclomethasone
1234446|NCT01016223|Ultrasensitive CRP
1234447|NCT01016210|pregnancy
1234448|NCT01016210|IVF
1234449|NCT01016197|Soft tissue mallet finger
1234450|NCT01016184|Quality of life
1234451|NCT01016158|Umbilical cord serum
1234452|NCT01016158|Recurrent corneal erosion
1234453|NCT01016145|Schizophrenia
1234454|NCT01016145|predictors of response
1234455|NCT01016145|antipsychotics
1234456|NCT01016145|18-45 years old
1234457|NCT01016145|non-refractory
1234458|NCT01016106|eczema
1234459|NCT01016106|atopic dermatitis
1234460|NCT01016106|dry skin
1234461|NCT01016106|ichthyosis vulgaris
1234462|NCT01016093|Thalassemia
1234463|NCT01016093|BMT
1234464|NCT01016093|HSCT
1234465|NCT01016080|glutathione
1234466|NCT01016080|melanin
1234467|NCT01016080|whitening
1234468|NCT01016080|UV spots
1234469|NCT01016080|skin pigment
1234470|NCT01016067|Tibia
1234471|NCT01016067|Tibial
1234472|NCT01016067|Fracture
1234473|NCT01016067|Nonunion
1234474|NCT01016067|delayed
1234475|NCT01016067|healing
1234476|NCT01016067|iliac
1234477|NCT01016067|crest
1234478|NCT01016067|autograft
1234479|NCT01016067|INFUSE
1234480|NCT01016067|MASTERGRAFT
1234481|NCT01016067|Fixation
1234482|NCT01016067|Internal
1234483|NCT01016054|Clinical Trial, Phase1
1234484|NCT01016054|Combination Drug Therapy
1234485|NCT01016054|pharmacokinetics
1234486|NCT01016054|safety
1234487|NCT01016054|Ovarian
1234488|NCT01016041|drug-eluting stent
1234489|NCT01016041|stable angina
1234490|NCT01016041|ACS
1234491|NCT01016041|MACE
1234492|NCT01016041|safety
1234493|NCT01016041|stent thrombosis
1234494|NCT01016028|Cancer
1234495|NCT01016028|Colorectum Cancer
1234496|NCT01016028|Colorectal disease
1234497|NCT01016028|neuropathic symptom tool
1234498|NCT01016028|chemotherapy-induced peripheral neuropathy
1234499|NCT01016028|CIPN
1234500|NCT01016028|Pain
1234501|NCT01016028|Quantitative Sensory Testing
1234502|NCT01016028|QST
1234503|NCT01016028|symptom measurement tools
1234504|NCT01016028|platinum agents
1234505|NCT01016028|cisplatin
1234506|NCT01016028|oxaliplatin
1234507|NCT01016028|taxanes
1234508|NCT01016028|bortezomib
1234509|NCT01015989|HIV treatment
1234510|NCT01015989|ART adherence
1234511|NCT01015989|Using new technology to improve adherence
1234512|NCT01015989|CARE+
1234513|NCT01015989|HIV-1 viral loads
1234514|NCT01015976|Gastric Bypass
1234515|NCT01015976|Sertraline
1234516|NCT01015976|Pharmacokinetics
1234517|NCT01015963|recurrent breast cancer
1234518|NCT01015963|stage IIIA breast cancer
1234519|NCT01015963|stage IIIB breast cancer
1234520|NCT01015963|stage IIIC breast cancer
1234521|NCT01015963|stage IV breast cancer
1234522|NCT01015963|extensive stage small cell lung cancer
1234523|NCT01015963|recurrent small cell lung cancer
1234524|NCT01015963|recurrent non-small cell lung cancer
1234525|NCT01015963|stage IIIA non-small cell lung cancer
1234526|NCT01015963|stage IIIB non-small cell lung cancer
1234527|NCT01015963|stage IV non-small cell lung cancer
1234528|NCT01015963|stage IV bladder cancer
1234529|NCT01015963|recurrent bladder cancer
1234530|NCT01015963|stage III bladder cancer
1234531|NCT01015963|recurrent lymphoepithelioma of the nasopharynx
1234532|NCT01015963|recurrent squamous cell carcinoma of the nasopharynx
1234533|NCT01015963|stage III lymphoepithelioma of the nasopharynx
1234534|NCT01015963|stage III squamous cell carcinoma of the nasopharynx
1234636|NCT01015781|Triage
1234536|NCT01015963|stage IV squamous cell carcinoma of the nasopharynx
1234537|NCT01015963|pulmonary carcinoid tumor
1234538|NCT01015963|recurrent basal cell carcinoma of the lip
1234539|NCT01015963|recurrent squamous cell carcinoma of the lip and oral cavity
1234540|NCT01015963|stage III basal cell carcinoma of the lip
1234541|NCT01015963|stage III squamous cell carcinoma of the lip and oral cavity
1234542|NCT01015963|stage IV basal cell carcinoma of the lip
1234543|NCT01015963|stage IV squamous cell carcinoma of the lip and oral cavity
1234544|NCT01015963|recurrent adenoid cystic carcinoma of the oral cavity
1234545|NCT01015963|recurrent mucoepidermoid carcinoma of the oral cavity
1234546|NCT01015963|recurrent verrucous carcinoma of the oral cavity
1234547|NCT01015963|stage III adenoid cystic carcinoma of the oral cavity
1234548|NCT01015963|stage III mucoepidermoid carcinoma of the oral cavity
1234549|NCT01015963|stage III verrucous carcinoma of the oral cavity
1234550|NCT01015963|stage IV adenoid cystic carcinoma of the oral cavity
1234551|NCT01015963|stage IV mucoepidermoid carcinoma of the oral cavity
1234552|NCT01015963|stage IV verrucous carcinoma of the oral cavity
1234553|NCT01015963|recurrent lymphoepithelioma of the oropharynx
1234554|NCT01015963|recurrent squamous cell carcinoma of the oropharynx
1234555|NCT01015963|stage III lymphoepithelioma of the oropharynx
1234556|NCT01015963|stage III squamous cell carcinoma of the oropharynx
1234557|NCT01015963|stage IV lymphoepithelioma of the oropharynx
1234558|NCT01015963|stage IV squamous cell carcinoma of the oropharynx
1234559|NCT01015963|recurrent squamous cell carcinoma of the hypopharynx
1234560|NCT01015963|stage III squamous cell carcinoma of the hypopharynx
1234561|NCT01015963|stage IV squamous cell carcinoma of the hypopharynx
1234562|NCT01015963|recurrent squamous cell carcinoma of the larynx
1234563|NCT01015963|recurrent verrucous carcinoma of the larynx
1234564|NCT01015963|stage III squamous cell carcinoma of the larynx
1234565|NCT01015963|stage III verrucous carcinoma of the larynx
1234566|NCT01015963|stage IV squamous cell carcinoma of the larynx
1234567|NCT01015963|stage IV verrucous carcinoma of the larynx
1234568|NCT01015963|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1234569|NCT01015963|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1234570|NCT01015963|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1234571|NCT01015963|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1234572|NCT01015963|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1234573|NCT01015963|stage III inverted papilloma of the paranasal sinus and nasal cavity
1234574|NCT01015963|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1234575|NCT01015963|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1234576|NCT01015963|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1234577|NCT01015963|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1234578|NCT01015963|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1234579|NCT01015963|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1234580|NCT01015963|recurrent salivary gland cancer
1234581|NCT01015963|stage III salivary gland cancer
1234582|NCT01015963|stage IV salivary gland cancer
1234583|NCT01015963|recurrent metastatic squamous neck cancer with occult primary
1234584|NCT01015963|unspecified adult solid tumor, protocol specific
1234585|NCT01015963|tongue cancer
1234586|NCT01015937|diabetes
1234587|NCT01015937|nephropathy
1234588|NCT01015937|turmeric
1234589|NCT01015937|serum IL8
1234590|NCT01015937|serum TGFb
1234591|NCT01015937|serumINF
1234592|NCT01015937|urinary IL8
1234593|NCT01015937|urine TGFb
1234594|NCT01015924|clavicle
1234595|NCT01015924|TEN
1234596|NCT01015924|Plate osteosynthesis
1234597|NCT01015924|displaced
1234598|NCT01015924|ESIN
1234599|NCT01015924|displaced midshaft clavicular fractures
1234600|NCT01015911|Antibodies, Monoclonal
1234601|NCT01015911|Antibody-Drug Conjugate
1234602|NCT01015911|Antigens, CD70
1234603|NCT01015911|Lymphoma, Non-Hodgkin
1234604|NCT01015911|Carcinoma, Renal Cell
1234605|NCT01015911|Immunotherapy
1234606|NCT01015911|Drug Therapy
1234607|NCT01015911|monomethylauristatin F
1234608|NCT01015898|basal cell carcinoma
1234609|NCT01015898|photodynamic therapy
1234610|NCT01015898|photo chemotherapy
1234611|NCT01015898|basal cell epithelioma
1234612|NCT01015872|sleep apnea syndrome
1234613|NCT01015872|CPAP
1234614|NCT01015872|prostanoids
1234615|NCT01015859|AV conduction
1234616|NCT01015859|Atrial fibrillation
1234617|NCT01015846|Core
1234618|NCT01015846|Redcord
1234619|NCT01015846|RUSI
1234620|NCT01015846|low back
1234621|NCT01015820|Pancreatic Cancer
1234622|NCT01015820|Duodenum
1234623|NCT01015820|Spectroscopy
1234624|NCT01015820|Fiberoptic probe
1234625|NCT01015820|4D-ELF
1234626|NCT01015807|postoperative
1234627|NCT01015807|hyperalgesia
1234628|NCT01015807|pain
1234629|NCT01015807|transversus abdominis plane block
1234630|NCT01015807|TAP block
1234631|NCT01015807|cesarean section
1234632|NCT01015781|Tinnitus
1234633|NCT01015781|Counseling
1234634|NCT01015781|Education
1234635|NCT01015781|Rehabilitation of hearing impaired
1234638|NCT01015781|Quality of health care
1234639|NCT01015768|corneal staining
1234640|NCT01015768|barrier function
1234641|NCT01015768|contact lenses
1234642|NCT01015768|contact lens care solutions
1234643|NCT01015768|contact lens material and care solution bioincompatibility
1234644|NCT01015755|thirst palliation and intensive care unit
1234645|NCT01015755|thirst intensity and distress
1234646|NCT01015755|predictors of thirst
1234647|NCT01015742|AML
1234648|NCT01015742|ALL
1234649|NCT01015742|CML
1234650|NCT01015729|Bioequivalence
1234651|NCT01015729|ASA
1234652|NCT01015729|Esomeprazole
1234653|NCT01015729|peptic ulcer disease
1234654|NCT01015729|pH measurements
1234655|NCT01015716|Weight loss
1234656|NCT01015716|Physical activity
1234657|NCT01015716|Cognitive Behavioral Training
1234658|NCT01015703|Vaccine, hypertension
1234659|NCT01015690|unexplained infertility
1234660|NCT01015690|hCG
1234661|NCT01015690|early pregnancy loss
1234662|NCT01015651|nociception, intraoperative, baroreflex
1234663|NCT01015638|Healthy volunteers
1234664|NCT01015625|breast cancer
1234665|NCT01015625|ABCSG
1234666|NCT01015625|POSYTIVE
1234667|NCT01015625|growth factor
1234668|NCT01015625|median survival
1234669|NCT01015625|surgery on demand
1234670|NCT01015625|surgical therapy
1234671|NCT01015625|blood specimen
1234672|NCT01015625|tissue specimen
1234673|NCT01015625|VEGF
1234674|NCT01015625|TGF
1234675|NCT01015625|circulating tumor cells
1234676|NCT01015625|stem cells
1234677|NCT01015612|Aortic Valve Stenosis
1234678|NCT01015612|Aortic Valve Insufficiency
1234679|NCT01015599|Obesity prevention
1234680|NCT01015599|after-school
1234681|NCT01015599|physical activity
1234682|NCT01015599|fruit
1234683|NCT01015599|vegetable
1234684|NCT01015599|children
1234685|NCT01015586|Alcohol
1234686|NCT01015586|Bipolar Disorder
1234687|NCT01015586|Manic depression
1234688|NCT01015586|Addiction
1234689|NCT01015586|Alcoholism
1234690|NCT01015586|Cognitive impairment
1234691|NCT01015586|Executive function
1234692|NCT01015586|Anxiety
1234693|NCT01015586|Depression
1234694|NCT01015586|Mania
1234695|NCT01015586|Affective disorder
1234696|NCT01015586|Psychosis
1234697|NCT01015586|Carbohydrate deficient transferrin
1234698|NCT01015586|Gammaglutamyltransferase
1234699|NCT01015586|California Verbal Learning Test
1234700|NCT01015586|Wisconsin Card Sort Test
1234701|NCT01015586|Stroop Color and Word Test
1234702|NCT01015586|Alcohol Stroop Test
1234703|NCT01015586|Emotion Stroop Test
1234704|NCT01015586|Point Scoring Reaction Time Test
1234705|NCT01015586|Rey Osterrieth Complex Figure Test
1234706|NCT01015586|Trail Making Test
1234707|NCT01015586|Montgomery Asberg Depression Rating Scale
1234708|NCT01015586|Young Mania Rating Scale
1234709|NCT01015586|Timeline Follow Back
1234710|NCT01015560|bone metastases
1234711|NCT01015560|unspecified adult solid tumor, protocol specific
1234712|NCT01015547|juvenile idiopathic arthritis
1234713|NCT01015547|polyarthritis
1234714|NCT01015547|combination therapy
1234715|NCT01015547|biologic agents
1234716|NCT01015547|TNF antagonists
1234717|NCT01015547|infliximab
1234718|NCT01015534|Brain metastases
1234719|NCT01015534|Temozolomide
1234720|NCT01015534|Whole-brain radiotherapy
1234721|NCT01015534|Phase II trial
1234722|NCT01015521|breast cancer
1234723|NCT01015508|Weight loss and maintenance
1234724|NCT01015508|body composition
1234725|NCT01015508|energy expenditure
1234726|NCT01015508|adipogenic capacity
1234727|NCT01015508|physical activity
1234728|NCT01015495|angioid streaks
1234729|NCT01015495|CNV
1234730|NCT01015495|intra vitreal ranibizumab
1234731|NCT01015482|Sunburn
1234732|NCT01015482|Remifentanil
1234733|NCT01015482|Hyperalgesia
1234734|NCT01015469|bariatric
1234735|NCT01015469|surgery
1234736|NCT01015469|obesity
1234737|NCT01015469|Roux-en-Y
1234738|NCT01015469|gastric
1234739|NCT01015469|medical device
1234740|NCT01015469|bypass
1234741|NCT01015469|adiposity
1234742|NCT01015469|GaBP-Ring
1234743|NCT01015469|BMI
1234744|NCT01015469|banded
1234745|NCT01015469|laparoscopic
1234746|NCT01015456|lupus nephritis
1234747|NCT01015456|mycophenolate sodium
1234748|NCT01015456|cyclophosphamide
1234749|NCT01015443|Non-Small Cell Lung Carcinoma
1234750|NCT01015443|Tecemotide
1234751|NCT01015443|L-BLP25
1234752|NCT01015443|Cyclophosphamide
1234753|NCT01015443|placebo controlled
1234754|NCT01015443|Non-Small Cell Lung Cancer
1234755|NCT01015417|Acute lithiasic cholecystitis
1234756|NCT01015417|Cholecystectomy
1234757|NCT01015417|Postoperative antibiotherapy
1234758|NCT01015417|Surgical site infection
1234759|NCT01015417|Remote surgical site infection
1234760|NCT01015404|Trafermin
1234761|NCT01015404|Periodontitis
1234762|NCT01015391|T2
1234763|NCT01015391|AZA
1234764|NCT01015391|remission
1234765|NCT01015391|Crohn's disease
1234766|NCT01015378|Recurrent sigmoid diverticulitis
1234767|NCT01015378|diverticulitis
1234768|NCT01015378|Colon
1234769|NCT01015378|sigmoid
1234770|NCT01015378|recurrence
1234771|NCT01015365|Chronic infected hip arthroplasty
1234772|NCT01015365|Fast-track
1234773|NCT01015365|One-stage cementless revision
1234774|NCT01015352|Myelodysplastic Syndromes
1234775|NCT01015326|EGFRI
1234776|NCT01015326|HRQL
1234777|NCT01015326|Quality of Life
1234778|NCT01015326|Development of a standardized HRQL instrument for anti-EGFR therapy induced
1234779|NCT01015313|sodium, hypertension, volume overload
1234780|NCT01015300|Hemangioblastoma
1234781|NCT01015300|Von Hippel Lindau
1234782|NCT01015300|VHL
1234783|NCT01015300|lesion
1234784|NCT01015300|EGFR
1234785|NCT01015287|Acute Coronary Syndromes
1234786|NCT01015287|Heart Disease
1234787|NCT01015287|Percutaneous Coronary Intervention
1234788|NCT01015287|P2Y12
1234789|NCT01015287|NSTEMI
1234790|NCT01015261|ALL
1234791|NCT01015261|BMT
1234792|NCT01015261|Chemotherapy
1234793|NCT01015261|Allogenic
1234794|NCT01015248|CD 20 positive
1234795|NCT01015235|Ketorolac / therapeutic use
1234796|NCT01015235|Analgesics. Non-narcotic / therapeutic use
1234797|NCT01015235|Arthroplasty, replacement hip
1234798|NCT01015235|Arthroplasty, replacement knee
1234799|NCT01015235|Pain measurement / drug effect
1234800|NCT01015235|Pain postoperative / drug therapy
1234801|NCT01015222|Advanced Malignancies
1234802|NCT01015222|Metastatic cancer
1234803|NCT01015222|Bevacizumab
1234804|NCT01015222|Avastin
1234805|NCT01015222|Dasatinib
1234806|NCT01015222|Sprycel
1234807|NCT01015222|Paclitaxel
1234808|NCT01015222|Taxol
1234809|NCT01015209|Dry eye syndromes
1234810|NCT01015196|acute myeloid leukemia in first complete remission
1234811|NCT01015183|Mucositis
1234812|NCT01015183|Bone Marrow Transplantation
1234813|NCT01015183|BMT
1234814|NCT01015183|HSCT
1234815|NCT01015170|smoking cessation
1234816|NCT01015170|nicotine addiction
1234817|NCT01015170|Zyban
1234818|NCT01015170|bupropion hydrochloride
1234819|NCT01015157|Gastric bypass
1234820|NCT01015157|staple line reinforcement
1234821|NCT01015157|outcomes
1234822|NCT01015157|per and postoperative blood loss
1234823|NCT01015144|atorvastatin
1234824|NCT01015144|dilated cardiomyopathy
1234825|NCT01015144|heart failure
1234826|NCT01015144|inflammation
1234827|NCT01015105|patients with hip fracture
1234828|NCT01015092|HIV
1234829|NCT01015092|Cardiovascular
1234830|NCT01015092|Coronary hear disease
1234831|NCT01015092|HAART
1234832|NCT01015092|antiretroviral
1234833|NCT01015079|Pap smear screening
1234834|NCT01015066|drug dependence
1234835|NCT01015066|substance abuse
1234836|NCT01015066|substance use disorders
1234837|NCT01015066|buprenorphine
1234838|NCT01015066|naltrexone
1234839|NCT01015066|adolescents
1234840|NCT01015053|postoperative pain
1234841|NCT01015053|pediatric
1234842|NCT01015053|umbilical hernia
1234843|NCT01015053|ropivacaine
1234844|NCT01015053|rectus sheath block
1234845|NCT01015053|regional block
1234846|NCT01015053|ultrasound-guided regional block
1234847|NCT01015053|local infiltration
1234848|NCT01015053|ambulatory surgery
1234849|NCT01015040|solifenacin succinate
1234850|NCT01015040|VESIcare
1234851|NCT01015040|Healthy Volunteers
1234852|NCT01015014|Gram negative
1234853|NCT01015014|bacteria
1234854|NCT01015014|infection
1234855|NCT01015001|refractory schizophrenia
1234856|NCT01015001|rTMS
1234857|NCT01015001|auditory hallucinations
1234858|NCT01014988|pandemic
1234859|NCT01014988|seasonal influenza
1234860|NCT01014988|Influenza B virus
1234861|NCT01014988|H1N1
1234862|NCT01014988|zanamivir
1234863|NCT01014988|Influenza A virus, H1N1 Subtype
1234864|NCT01014988|Relenza
1234865|NCT01014988|influenza
1234866|NCT01014988|neuraminidase inhibitor
1234867|NCT01014975|stroke
1234868|NCT01014975|plasmin
1234869|NCT01014975|thrombus
1234870|NCT01014975|ischemic
1234871|NCT01014975|middle cerebral artery
1234872|NCT01014975|thrombolysis
1234873|NCT01014975|intra-arterial
1234874|NCT01014975|fibrin
1234878|NCT01014936|Phase 1
1234879|NCT01014936|advanced solid tumors
1234880|NCT01014936|refractory to standard therapy
1234881|NCT01014923|motor vehicle
1234882|NCT01014923|accidents, traffic
1234883|NCT01014923|prevention and control
1234884|NCT01014910|Bronchiolitis
1234885|NCT01014910|Hypoxia
1234886|NCT01014910|Pulse
1234887|NCT01014910|Oximetry
1234888|NCT01014910|Hospitalized
1234889|NCT01014897|stroke
1234890|NCT01014897|recovery
1234891|NCT01014897|tDCS
1234892|NCT01014897|direct current
1234893|NCT01014897|electric stimulation
1234894|NCT01014871|Forehead Wrinkles Toxin
1234895|NCT01014858|Parkinson's disease
1234896|NCT01014858|mild dementia
1234897|NCT01014858|donepezil
1234898|NCT01014858|NIHR HTA
1234899|NCT01014845|hepatitis E
1234900|NCT01014845|vaccine
1234901|NCT01014845|efficacy
1234902|NCT01014832|Diabetes, insulin.
1234903|NCT01014819|Dermacorder
1234904|NCT01014819|Electric field
1234905|NCT01014819|basal cell carcinoma
1234906|NCT01014819|Gorlin Syndrome
1234907|NCT01014793|Acromegaly resistant
1234908|NCT01014793|combined-treatment
1234909|NCT01014793|dopamine agonist
1234910|NCT01014780|dry eye
1234911|NCT01014780|tear film
1234912|NCT01014780|thickness
1234913|NCT01014780|artificial tears
1234914|NCT01014767|Choroid Plexus Tumors
1234915|NCT01014767|Brain Tumor
1234916|NCT01014767|Chemotherapy
1234917|NCT01014767|Etoposide
1234918|NCT01014767|Carboplatin
1234919|NCT01014767|Vincristine
1234920|NCT01014767|Cyclophosphamide
1234921|NCT01014767|Methotrexate
1234922|NCT01014767|Doxorubicin
1234923|NCT01014767|Cisplatin
1234924|NCT01014767|Dactinomycin
1234925|NCT01014767|temozolomide
1234926|NCT01014767|irinotecan
1234927|NCT01014767|Pediatrics
1234928|NCT01014741|Atrial Fibrillation
1234929|NCT01014741|Catheter Ablation
1234930|NCT01014741|Complex Fractionate Electrograms
1234932|NCT01014702|Cataract
1234933|NCT01014702|Capsulotomy
1234934|NCT01014702|Capsulorrhexis
1234935|NCT01014702|lens fragmentation
1234936|NCT01014702|phacoemulsification
1234937|NCT01014689|acne vulgaris
1234938|NCT01014676|Costs and Cost Analysis
1234939|NCT01014663|Parkinson's disease
1234940|NCT01014663|exercise
1234941|NCT01014663|training program
1234942|NCT01014663|rehabilitation
1234943|NCT01014663|boxing
1234944|NCT01014650|glycine site partial agonist
1234945|NCT01014650|normal volunteers
1234946|NCT01014650|safety in normal volunteers
1234947|NCT01014637|Dermatomycoses
1234948|NCT01014637|Infection
1234949|NCT01014637|Mycoses
1234950|NCT01014637|Nail diseases
1234951|NCT01014637|Ski diseases
1234952|NCT01014637|Skin diseases/infectious
1234953|NCT01014624|thienopyridine
1234954|NCT01014624|pharmacologic action
1234955|NCT01014624|prasugrel
1234956|NCT01014624|clopidogrel
1234957|NCT01014611|Heart failure
1234958|NCT01014611|Skeletal muscle
1234959|NCT01014611|Calcium
1234960|NCT01014611|Ryanodine receptor
1234961|NCT01014611|Mitochondria
1234962|NCT01014611|Exercise training
1234963|NCT01014611|Muscle biopsy
1234964|NCT01014611|Healthy volunteers
1234965|NCT01014585|Milnacipran
1234966|NCT01014585|Pain
1234967|NCT01014585|Durability of Effect
1234968|NCT01014585|Loss of Therapeutic Response
1234969|NCT01014585|Fatigue
1234970|NCT01014585|Forest Research Institute
1234971|NCT01014585|Savella ®
1234972|NCT01014572|Clinical Trials, Phase II
1234973|NCT01014572|Exercise
1234974|NCT01014572|Exercise Tolerance
1234975|NCT01014572|Aging
1234976|NCT01014559|Constipation
1234977|NCT01014559|Oxycodone
1234978|NCT01014559|Oxycodone hydrochloride
1234979|NCT01014559|Naloxone hydrochloride
1234980|NCT01014559|Naloxone
1234981|NCT01014533|Alcoholism
1234982|NCT01014533|Alcohol dependence
1234983|NCT01014533|Insomnia
1234984|NCT01014533|Dim light melatonin onset
1234985|NCT01014533|Gabapentin
1234986|NCT01014520|Lumbar
1234987|NCT01014520|Diskectomy
1234988|NCT01014520|Laminectomy
1234989|NCT01014481|HIV
1234990|NCT01014481|tuberculosis
1234991|NCT01014481|antiretroviral treatment
1234992|NCT01014481|timing
1234993|NCT01014468|ranibizumab
1234994|NCT01014468|bevacizumab
1234995|NCT01014468|AMD
1234996|NCT01014468|Complications
1234997|NCT01014468|Visual acuity
1234998|NCT01014468|OCt
1234999|NCT01014468|Age Macular Degeneration
1235000|NCT01014455|surgery
1235001|NCT01014429|Phase I dose escalation study
1235002|NCT01014429|Advanced or metastatic solid tumors
1235003|NCT01014429|PLK 1 inhibitor
1235004|NCT01014429|Adult patients
1235005|NCT01014416|Healthy Korean male
1235006|NCT01014403|venous thromboembolism
1235007|NCT01014403|enoxaparin
1235008|NCT01014403|traumatic brain injury
1235009|NCT01014403|Venous thromboembolism prophylaxis after traumatic brain injury
1235010|NCT01014390|benign biliary strictures secondary to chronic pancreatitis/post abdominal surgery/post liver transplant
1235011|NCT01014364|Acute lung injury
1235012|NCT01014364|Acute respiratory distress syndrome
1235013|NCT01014364|corticosteroids
1235014|NCT01014364|inflammation
1235015|NCT01014351|Metastatic Melanoma
1235016|NCT01014351|Everolimus
1235017|NCT01014351|Paclitaxel
1235018|NCT01014351|Carboplatin
1235019|NCT01014312|Depression
1235020|NCT01014299|Intubation
1235021|NCT01014299|Hypoxemia
1235022|NCT01014299|Mechanical ventilation
1235023|NCT01014299|Recruitment maneuver
1235024|NCT01014299|Acute lung injury
1235025|NCT01014299|Bacterial translocation
1235026|NCT01014299|Hypoxemic ICU patients requiring invasive mechanical ventilation
1235027|NCT01014273|Acute Coronary Syndrome
1235028|NCT01014273|PCI
1235029|NCT01014273|Percutaneous Coronary Intervention
1235030|NCT01014273|Radial Access
1235031|NCT01014260|Inflammatory markers of cardiovascular disease
1235032|NCT01014247|Moxifloxacin
1235033|NCT01014234|Immunosuppressive Agents
1235034|NCT01014234|Immune system regulation
1235035|NCT01014234|Regulatory T cells
1235036|NCT01014234|Rapamycin
1235037|NCT01014234|Tolerance
1235038|NCT01014221|acupuncture
1235039|NCT01014221|carpal tunnel syndrome
1235040|NCT01014221|CTS
1235041|NCT01014221|steroid
1235042|NCT01014221|global symptom score (GSS)
1235043|NCT01014208|The All Ireland Cooperative Oncology Research Group
1235044|NCT01014208|GELTAMO
1235045|NCT01014208|National Cancer Research Institute Lymphoma Clinical Studies Group
1235046|NCT01014208|Genmab
1235047|NCT01014208|ofatumumab
1235048|NCT01014208|Japan Clinical Oncology Group
1235049|NCT01014208|Oncology
1235050|NCT01014208|Polish Lymphoma Research Group
1235051|NCT01014208|Salvage chemotherapy
1235052|NCT01014208|refractory
1235053|NCT01014208|HOVON
1235054|NCT01014208|DVD
1235055|NCT01014208|relapsed
1235056|NCT01014208|safety
1235057|NCT01014208|efficacy
1235058|NCT01014208|DHAP
1235059|NCT01014208|rituximab
1235060|NCT01014208|Autologous Stem Cell Transplant
1235061|NCT01014208|Dutch-Belgian Cooperative Trial Group for Hematology-Oncology
1235062|NCT01014208|Grupo Espanol de Linfomas
1235063|NCT01014208|Nordic Lymphoma Group
1235064|NCT01014195|Acute Lymphoblastic Leukemia
1235065|NCT01014195|Neurocognitive function
1235066|NCT01014195|ADHD
1235067|NCT01014195|brain imaging
1235068|NCT01014195|genetic polymorphisms
1235069|NCT01014195|Psychopathology and neurocognitive Impairment in Leukemia Survivors
1235070|NCT01014182|Early PCI
1235071|NCT01014182|Myocardial Infarction
1235072|NCT01014182|Thrombolysis
1235073|NCT01014182|Optimal revascularization therapy in STEMI patients
1235074|NCT01014169|Health education
1235075|NCT01014169|Sudden Infant Death
1235076|NCT01014169|Breast Feeding
1235077|NCT01014169|Infant Equipment
1235078|NCT01014156|pulmonary embolism
1235079|NCT01014156|vasoconstriction
1235080|NCT01014156|right ventricular dysfunction
1235081|NCT01014156|epoprostenol
1235082|NCT01014156|acute pulmonary embolism with right ventricular dysfunction
1235083|NCT01014130|Non Small Cell Lung Cancer
1235084|NCT01014130|Hypofractionated
1235085|NCT01014130|Stereotactic Radiotherapy
1235086|NCT01014104|Ovarian hyper stimulation syndrome
1235087|NCT01014104|Methylprednisolone
1235088|NCT01014104|IVF
1235089|NCT01014091|influenza infection
1235223|NCT01013493|children
1235090|NCT01014091|GSK Bio's influenza vaccine GSK2340272A
1235091|NCT01014065|sunitinib
1235092|NCT01014065|cardiac MRI
1235093|NCT01014065|maximal exercise testing
1235094|NCT01014065|biomarkers
1235095|NCT01014065|pharmacokinetics
1235096|NCT01014026|Mass Screening
1235097|NCT01014026|Polymerase Chain Reaction
1235098|NCT01014026|Vaginal Smears
1235099|NCT01013987|HIV-1
1235100|NCT01013987|triple class failure
1235101|NCT01013987|Maraviroc
1235102|NCT01013987|Raltegravir
1235103|NCT01013987|Darunavir/ritonavir
1235104|NCT01013987|Maraviroc with raltegravir and darunavir/ritonavir
1235105|NCT01013961|chronic lymphocytic leukemia
1235106|NCT01013961|small lymphocytic lymphoma
1235107|NCT01013961|CLL
1235108|NCT01013961|elderly
1235109|NCT01013961|low dose rituximab
1235110|NCT01013961|alemtuzumab
1235111|NCT01013961|monoclonal antibodies
1235112|NCT01013948|Spirometry
1235113|NCT01013948|Bronchitis
1235114|NCT01013948|COPD
1235115|NCT01013948|Chronic Obstructive Pulmonary Disease (COPD)
1235116|NCT01013948|Emphysema
1235117|NCT01013948|Chronic Bronchitis
1235118|NCT01013935|HIV treatment
1235119|NCT01013935|ART adherence
1235120|NCT01013935|Using new technology to improve adherence
1235121|NCT01013935|CARE+
1235122|NCT01013935|HIV-1 viral loads
1235123|NCT01013922|COPD
1235124|NCT01013922|COPD-6
1235125|NCT01013922|Spirometry
1235126|NCT01013922|VC
1235127|NCT01013922|FEV
1235128|NCT01013922|FEV1
1235129|NCT01013909|Bifonazole
1235130|NCT01013909|Terbinafine
1235131|NCT01013909|Reduced treatment duration
1235132|NCT01013909|Efficacy
1235133|NCT01013909|Safety
1235134|NCT01013909|Athlete's foot
1235135|NCT01013909|Moderate severity
1235136|NCT01013883|systolic dysfunction
1235137|NCT01013883|diastolic dysfunction
1235138|NCT01013883|mortality
1235139|NCT01013883|treatment
1235140|NCT01013883|heart rate
1235141|NCT01013870|mild traumatic brain injury
1235142|NCT01013870|post-concussion syndrome
1235143|NCT01013870|acute stress disorder
1235144|NCT01013870|post-traumatic stress disorder
1235145|NCT01013870|atorvastatin
1235146|NCT01013844|skin self-examination
1235147|NCT01013844|SSE
1235148|NCT01013844|melanoma
1235149|NCT01013805|Rectal Cancer
1235150|NCT01013805|Chemotherapy
1235151|NCT01013805|Radiotherapy
1235152|NCT01013792|Diabetic
1235153|NCT01013792|Foot
1235154|NCT01013792|Ulcer
1235155|NCT01013792|Neuropathic
1235156|NCT01013792|Tegaderm Matrix Dressing
1235157|NCT01013792|DFU
1235158|NCT01013792|Wound Care
1235159|NCT01013792|PHI
1235160|NCT01013779|Merkel Cell Cancer
1235161|NCT01013779|PET scanning
1235168|NCT01013740|Neoplasms, Breast
1235169|NCT01013727|Volunteers
1235170|NCT01013727|healthy subjects
1235171|NCT01013714|Sudden cardiac death
1235172|NCT01013714|Ventricular tachycardia
1235173|NCT01013714|Ventricular fibrillation
1235174|NCT01013714|Cardiomyopathy
1235175|NCT01013714|Internal cardiac defibrillator shocks
1235176|NCT01013714|Internal cardiac defibrillator therapies
1235177|NCT01013701|nasal polyps
1235178|NCT01013701|nasal steroid
1235179|NCT01013701|fluticasone furoate
1235180|NCT01013688|Radiofrequency ablation
1235181|NCT01013688|Maze
1235182|NCT01013688|Atrial fibrillation
1235183|NCT01013675|influenza
1235184|NCT01013675|active-controlled
1235185|NCT01013675|Phase 2
1235186|NCT01013662|septic shock
1235187|NCT01013662|glycemic control
1235188|NCT01013662|icu
1235189|NCT01013662|lipid metabolism
1235190|NCT01013662|septic patients
1235191|NCT01013623|melanoma
1235192|NCT01013623|stage IV
1235193|NCT01013623|resectable
1235194|NCT01013623|surgery
1235195|NCT01013623|medical therapy
1235196|NCT01013610|Healthy Elderly Volunteers
1235197|NCT01013597|thyroid
1235198|NCT01013597|medullary
1235199|NCT01013597|differentiated
1235200|NCT01013597|radioiodine-resistant
1235201|NCT01013597|LBH589
1235202|NCT01013597|panobinostat
1235203|NCT01013584|vitamin D
1235204|NCT01013558|fetal pain
1235205|NCT01013558|intrauterine
1235206|NCT01013558|needling
1235207|NCT01013545|joint engagement
1235208|NCT01013545|augmentative communication (AAC)
1235209|NCT01013545|enhanced milieu training
1235210|NCT01013545|autism spectrum disorder
1235211|NCT01013545|language
1235212|NCT01013532|Ischemic Stroke
1235213|NCT01013532|Intracranial Hemorrhage
1235214|NCT01013532|Cilostazol
1235215|NCT01013532|Probucol
1235216|NCT01013506|estrogen receptor-positive breast cancer
1235217|NCT01013506|progesterone receptor-positive breast cancer
1235218|NCT01013506|stage IV breast cancer
1235219|NCT01013506|recurrent breast cancer
1235220|NCT01013493|breastfeeding
1235221|NCT01013493|myopia
1235222|NCT01013493|nearsightedness
1235224|NCT01013480|Fragile X Syndrome
1235225|NCT01013467|blood pressure
1235226|NCT01013467|control
1235227|NCT01013467|adherence
1235228|NCT01013467|behaviour
1235229|NCT01013454|varenicline percutaneous transcutaneous topical transdermal transdermal delivery system patch
1235230|NCT01013441|Chronic Lymphocytic Leukemia
1235231|NCT01013428|Traumatic Rupture of Tendon
1235232|NCT01013415|Infection with HIV-1 with undetectable viral load on HAART therapy
1235233|NCT01013402|Hypoglycemia
1235234|NCT01013402|Home Blood Glucose Monitoring
1235235|NCT01013402|Subjects are being investigated for the integrity of
1235236|NCT01013402|pituitary-adrenal functions by insulin hypoglycemia test.
1235237|NCT01013389|actifuse
1235238|NCT01013389|INFUSE
1235239|NCT01013389|InductOs
1235240|NCT01013389|DDD
1235241|NCT01013389|degenerative disk disease
1235242|NCT01013389|PLIF
1235243|NCT01013389|PITF
1235244|NCT01013389|PLF
1235245|NCT01013389|poterolateral lumber fusion
1235246|NCT01013389|Bone substitute
1235247|NCT01013389|bone graft
1235248|NCT01013389|synthetic bone substitute
1235249|NCT01013363|abortion
1235250|NCT01013363|first trimester
1235251|NCT01013363|suction aspiration
1235252|NCT01013363|vacuum aspiration
1235253|NCT01013363|music
1235254|NCT01013363|anesthesia
1235255|NCT01013363|analgesia
1235256|NCT01013363|anxiolytic
1235257|NCT01013363|pain
1235258|NCT01013363|anxiety
1235259|NCT01013363|blood pressure
1235260|NCT01013363|heart rate
1235261|NCT01013363|satisfaction
1235262|NCT01013350|Multiple Sclerosis
1235263|NCT01013350|Cladribine
1235264|NCT01013350|PREMIERE
1235265|NCT01013350|Observational study
1235266|NCT01013324|endometrial cancer
1235267|NCT01013324|endometrial carcinoma
1235268|NCT01013324|carcinoma of the endometrium
1235269|NCT01013324|cancer of the endometrium
1235270|NCT01013311|Implantable Cardioverter-Defibrillator (ICD)- pre-existing
1235271|NCT01013298|percutaneous tracheostomy
1235272|NCT01013298|paratracheal insertion
1235273|NCT01013298|tracheal injury
1235274|NCT01013298|transtracheal needle
1235275|NCT01013298|ventilatory parameters
1235276|NCT01013285|adult giant cell glioblastoma
1235277|NCT01013285|adult gliosarcoma
1235278|NCT01013285|adult glioblastoma
1235279|NCT01013272|entecavir
1235280|NCT01013272|lamivudine
1235281|NCT01013272|sequential therapy
1235282|NCT01013259|E.coli
1235283|NCT01013259|Mutaflor
1235284|NCT01013259|grass pollen
1235285|NCT01013259|rhinoconjunctivitis
1235286|NCT01013259|rhinoconjunctivitis caused by grass pollen
1235287|NCT01013246|Video games
1235288|NCT01013246|Energy balance
1235289|NCT01013246|Metabolism
1235290|NCT01013246|Appetite control
1235291|NCT01013233|cognitive dysfunction chemotherapy
1235292|NCT01013220|depression
1235293|NCT01013220|depression care management
1235294|NCT01013220|financing
1235295|NCT01013220|absenteeism
1235296|NCT01013220|presenteeism
1235297|NCT01013220|employer decisions to purchase health care benefits
1235298|NCT01013207|CPAP compliance
1235299|NCT01013194|Liver cirrhosis
1235300|NCT01013194|Fetal stem cells
1235301|NCT01013194|Stem cell transplantation
1235302|NCT01013194|Liver transplant candidate
1235303|NCT01013181|Immune Thrombopenia
1235304|NCT01013181|Thrombocytopenia
1235305|NCT01013181|romiplostim
1235306|NCT01013181|compassionate program
1235307|NCT01013168|OncoSorb
1235308|NCT01013168|immune apheresis
1235309|NCT01013168|sTNF-R1
1235310|NCT01013168|sTNF-R2
1235311|NCT01013168|sIL-2R
1235312|NCT01013168|TNF
1235313|NCT01013142|COPD
1235314|NCT01013129|hereditary prostate cancer
1235315|NCT01013129|prostate cancer
1235316|NCT01013090|Epidural anesthesia
1235317|NCT01013090|Spinal anesthesia
1235318|NCT01013090|Combined spinal-epidural anesthesia
1235319|NCT01013090|Fluid therapy
1235320|NCT01013090|Crystalloid
1235321|NCT01013090|Colloid
1235322|NCT01013077|functional vision
1235323|NCT01013077|contrast sensitivity
1235324|NCT01013077|aberrometry
1235325|NCT01013077|reading ability
1235326|NCT01013064|Erythropoietin
1235327|NCT01013064|Long acting
1235328|NCT01013064|EPO
1235329|NCT01013051|obesity
1235330|NCT01013051|gastric bypass
1235331|NCT01013051|metformin
1235332|NCT01013051|pharmacokinetics
1235333|NCT01013051|absorption
1235334|NCT01013038|myocardial infarction
1235335|NCT01013038|percutaneous coronary intervention
1235336|NCT01013038|thrombus aspiration
1235337|NCT01013025|prostate cancer
1235338|NCT01013025|implant retrieval
1235339|NCT01013012|highly susceptible patients following spine surgery
1235342|NCT01012973|Macular Edema
1235343|NCT01012973|Central Retinal Vein Occlusion
1235344|NCT01012973|CRVO
1235345|NCT01012973|VEGF Trap-Eye
1235346|NCT01012973|best-corrected visual acuity
1235347|NCT01012960|methylnaltrexone
1235348|NCT01012960|upper esophageal sphincter
1235349|NCT01012960|lower esophageal sphincter
1235350|NCT01012960|high resolution solid state manometry
1235351|NCT01012960|opioid induced pharyngeal and esophageal dysfunction
1235352|NCT01012947|MMSE
1235353|NCT01012947|activity
1235354|NCT01012921|GBR
1235355|NCT01012921|GTR
1235356|NCT01012921|Dental Implant surgery
1235357|NCT01012869|Coronary chronic total occlusions
1235358|NCT01012856|depressive episode
1235359|NCT01012856|psychotherapy
1235360|NCT01012856|cognitive therapy
1235361|NCT01012856|emotional processing
1235362|NCT01012856|RCT
1235363|NCT01012856|exposure
1235364|NCT01012856|dual process model
1235365|NCT01012856|Implicit Association Test
1235366|NCT01012856|mechanism of change
1235367|NCT01012843|Perianal
1235368|NCT01012843|Abscess
1235369|NCT01012843|Fistulae in ano
1235370|NCT01012843|Antibiotic
1235371|NCT01012843|Anorectal
1235372|NCT01012830|Schizophrenia
1235373|NCT01012830|Cognitive Disorders
1235374|NCT01012830|Dementia
1235375|NCT01012830|Huperzine A
1235376|NCT01012830|HupA
1235377|NCT01012804|stage IV colon cancer
1235378|NCT01012804|recurrent colon cancer
1235379|NCT01012791|Zumba exercise
1235380|NCT01012791|ApoE
1235381|NCT01012778|Performance impairment
1235382|NCT01012778|Yoga
1235383|NCT01012778|Meditation
1235384|NCT01012778|Peer mediated
1235385|NCT01012765|COPD
1235386|NCT01012765|indacaterol
1235387|NCT01012765|QAB149
1235388|NCT01012765|inspiratory capacity
1235389|NCT01012739|asthma
1235390|NCT01012739|QAB149
1235391|NCT01012739|indacaterol
1235392|NCT01012739|pulmonary function
1235393|NCT01012713|Psoriasis
1235394|NCT01012713|Excimer
1235395|NCT01012713|Laser
1235396|NCT01012713|Clobex
1235397|NCT01012713|Vectical
1235398|NCT01012713|clobetasol spray
1235399|NCT01012713|calcitriol
1235400|NCT01012713|Generalized plaque type psoriasis
1235401|NCT01012674|carotid or vertebral artery disease
1235402|NCT01012674|Contrast agent
1235403|NCT01012674|MRA
1235404|NCT01012661|Moderate to severe wrinkles and folds such as nasolabial folds
1235405|NCT01012635|spinal cord injury
1235406|NCT01012635|chronic pain
1235407|NCT01012622|Attention Deficit Hyperactivity Disorder
1235408|NCT01012622|Methylphenidate Hydrochloride
1235409|NCT01012609|high-grade astrocytomas
1235410|NCT01012609|newly diagnosed diffuse pontine tumors
1235411|NCT01012609|External beam radiation therapy
1235412|NCT01012609|cetuximab
1235413|NCT01012609|irinotecan
1235414|NCT01012609|POETIC
1235415|NCT01012596|Natural Family Planning Methods
1235416|NCT01012596|Ovulation Detection
1235417|NCT01012596|Cervix Mucus
1235418|NCT01012596|Intention
1235419|NCT01012596|Behavior
1235420|NCT01012596|Birth Control
1235421|NCT01012596|Contraception
1235422|NCT01012596|Pregnancy
1235423|NCT01012596|Fertility
1235424|NCT01012583|Optical coherence tomography
1235425|NCT01012583|Drug eluting stent
1235426|NCT01012583|Biodegradable polymer
1235427|NCT01012583|Intimal
1235428|NCT01012583|Coverage
1235429|NCT01012583|assess intimal hyperplasia of drug eluting stent with biodegradable polymer
1235430|NCT01012557|H1N1v
1235431|NCT01012557|vaccine
1235432|NCT01012557|pregnant
1235433|NCT01012557|women
1235434|NCT01012557|Assess whether the adjuvanted vaccine offers a meaningful benefit in pregnant women in terms of immune response over the non-adjuvanted vaccine.
1235435|NCT01012557|Assess the persistence of immune response over a 15 month time period after one single vaccination of the pregnant mother.
1235436|NCT01012557|Assess whether the immune response to H1N1 in pregnant women is different from that of non-pregnant women of similar age.
1235437|NCT01012557|Gain insight on safety of the Novartis egg-based MF59 adjuvanted H1N1 vaccine Focetria in pregnant women and their babies.
1235438|NCT01012557|Assess the maternally transferred specific antibodies against H1N1v in the newborn
1235439|NCT01012557|Passive immunity transferred to the infant.
1235440|NCT01012544|clopidogrel
1235441|NCT01012544|pharmacokinetics
1235442|NCT01012544|platelet function tests
1235443|NCT01012544|platelet reactivity
1235444|NCT01012518|percutaneous tracheostomy
1235445|NCT01012518|paratracheal insertion
1235446|NCT01012518|tracheal injury
1235447|NCT01012518|transtracheal needle
1235448|NCT01012518|ventilatory parameters
1235449|NCT01012492|cancer
1235450|NCT01012492|leukemia
1235451|NCT01012492|transplant
1235452|NCT01012492|bone marrow
1235453|NCT01012479|Blood Pressure
1235454|NCT01012479|Blood Pressure, High
1235455|NCT01012479|Drug Therapy
1235456|NCT01012466|pregnancy
1235457|NCT01012466|birth
1235458|NCT01012466|labor
1235459|NCT01012466|labor pain
1235460|NCT01012466|catastrophizing
1235461|NCT01012453|Hand eczema
1235462|NCT01012453|Hand dermatitis
1235463|NCT01012453|Occupational skin disease
1235464|NCT01012453|skindisease in health care workers
1235465|NCT01012453|occupational hand dermatitis
1235466|NCT01012453|occupational hand eczema
1235467|NCT01012427|Kidney
1235468|NCT01012427|Cryoablation
1235469|NCT01012427|09-108
1235470|NCT01012414|Vitamin D
1235471|NCT01012414|Coronary Artery Disease (CAD)
1235472|NCT01012414|Chronic Kidney Disease (CKD)
1235473|NCT01012401|Lung cancer
1235474|NCT01012401|Quality of life
1235475|NCT01012401|Communication with physician
1235476|NCT01012388|Moderate to severe wrinkles and folds such as nasolabial folds
1235477|NCT01012375|Adult ADHD
1235478|NCT01012362|Solid tumor malignancy
1235479|NCT01012362|breast cancer
1235480|NCT01012362|lung cancer
1235481|NCT01012362|colon cancer
1235482|NCT01012362|pancreatic cancer
1235483|NCT01012362|head and neck cancer
1235484|NCT01012362|kidney cancer
1235485|NCT01012362|sarcoma
1235486|NCT01012362|hepatocellular cancer
1235487|NCT01012336|efficacy and safety of Aprepitant/Ramosetron/Dexamethasone in ovary cancer patients with taxol and carboplatin
1235488|NCT01012323|PID
1235489|NCT01012310|pharmacokinetics safety tolerability multiple dosing
1235490|NCT01012284|Moderate Hepatic Impairment
1235491|NCT01012284|Tuberculosis
1235492|NCT01012284|TMC207
1235493|NCT01012284|Mycobacterial adenosine triphosphate (ATP)-synthase
1235494|NCT01012271|Wrist abnormalities
1235495|NCT01012258|antitumor activity
1235496|NCT01012258|safety
1235497|NCT01012258|cetuximab in combination with radiotherapy
1235498|NCT01012258|locally advanced squamous cell head & neck carcinoma
1235499|NCT01012245|Xchange
1235500|NCT01012245|Xalatan
1235501|NCT01012245|Xalacom
1235502|NCT01012245|Betablocker
1235503|NCT01012245|observational
1235504|NCT01012245|longterm
1235505|NCT01012232|total knee arthroplasty
1235506|NCT01012232|postoperative pain
1235507|NCT01012206|Children
1235508|NCT01012206|Overweight
1235509|NCT01012206|Obesity
1235510|NCT01012206|Food habits
1235511|NCT01012206|Dietary assessment
1235512|NCT01012206|Physical activity
1235513|NCT01012193|adjunctive cilostazol
1235514|NCT01012193|high-MD clopidogrel
1235515|NCT01012193|CYP 2C19 polymorphism
1235516|NCT01012193|high risk patients
1235517|NCT01012180|Bipolar Disorder
1235518|NCT01012180|Adaptation
1235519|NCT01012180|Parents
1235520|NCT01012180|Risk
1235521|NCT01012180|Coping
1235522|NCT01012180|Survey
1235523|NCT01012167|Schizophrenia, oxytocin, galantamine
1235524|NCT01012128|Temporal Artery Thermometer
1235525|NCT01012128|Temperature
1235526|NCT01012128|Preterm Infants
1235527|NCT01012115|Histones
1235528|NCT01012115|organ failure
1235529|NCT01012115|sepsis
1235530|NCT01012102|EMD 640744
1235531|NCT01012102|Montanide
1235532|NCT01012102|Advanced solid tumours
1235533|NCT01012089|Hemodialysis
1235534|NCT01012089|Peritoneal dialysis
1235535|NCT01012089|Daptomycin
1235536|NCT01012089|Pharmacokinetics
1235537|NCT01012076|maternal synchrony
1235538|NCT01012076|parent-child
1235539|NCT01012076|parent child play
1235540|NCT01012076|social communication
1235541|NCT01012063|iron
1235542|NCT01012063|erythropoietin
1235543|NCT01012063|hemoglobin
1235544|NCT01012063|Total knee replacement arthroplasty
1235545|NCT01012050|Asthma
1235546|NCT01012050|status asthmatics
1235547|NCT01012011|Carcinoma, Hepatocellular
1235548|NCT01012011|Carcinoma, Renal Cell
1235549|NCT01011998|CML
1235550|NCT01011998|Chronic Myelogenous leukemia
1235551|NCT01011998|INST 0901
1235552|NCT01011998|imatinib
1235553|NCT01011998|valproic acid
1235554|NCT01011998|Gleevec
1235555|NCT01011985|end stage renal disease
1235556|NCT01011985|inflammation
1235557|NCT01011985|vascular access
1235558|NCT01011985|hemodialysis
1235559|NCT01011972|Dose escalation
1235560|NCT01011972|XMT-1107
1235561|NCT01011972|1107
1235562|NCT01011972|Tumor
1235563|NCT01011972|Phase 1
1235564|NCT01011972|Fumagillol
1235565|NCT01011972|PHF
1235566|NCT01011972|Fleximer
1235567|NCT01011972|cancer
1235568|NCT01011972|maximum tolerated dose
1235569|NCT01011972|MTD
1235570|NCT01011920|newly diagnosed primary central nervous system lymphoma
1235571|NCT01011894|Lenalidomide
1235572|NCT01011894|CLL
1235573|NCT01011894|09-045
1235574|NCT01011881|pleuritis
1235575|NCT01011881|empyema
1235576|NCT01011881|procalcitonin
1235577|NCT01011829|methamphetamine
1235578|NCT01011829|crystal meth
1235579|NCT01011829|addiction
1235580|NCT01011829|los angeles
1235581|NCT01011829|medication
1235582|NCT01011829|meth
1235583|NCT01011816|intervertebral disk
1235584|NCT01011803|Deglutition
1235585|NCT01011803|Phonation
1235586|NCT01011790|Healing Rhythms™
1235587|NCT01011790|Meditation
1235588|NCT01011790|Biofeedback
1235589|NCT01011790|Stress
1235590|NCT01011777|bladder exstrophy epispadias complex
1235591|NCT01011777|urinary incontinence
1235592|NCT01011777|muscle derive cell therapy
1235593|NCT01011777|stem cells
1235594|NCT01011764|social networks
1235595|NCT01011764|friendships
1235596|NCT01011764|autism spectrum disorder
1235597|NCT01011751|Drug Therapy
1235598|NCT01011712|Genetics
1235599|NCT01011712|Virus
1235600|NCT01011712|Defense
1235601|NCT01011712|Immune Defects
1235602|NCT01011712|Respiratory Viruses
1235603|NCT01011712|Herpesvirus
1235604|NCT01011712|Cytomegalovirus
1235605|NCT01011712|Human Papillomavirus
1235606|NCT01011712|Adenovirus
1235607|NCT01011699|nicotinamide
1235608|NCT01011699|sevelamer hydrochloride
1235609|NCT01011699|phosphatemia
1235610|NCT01011699|cinacalcet
1235611|NCT01011699|dyslipidemia
1235612|NCT01011699|vascular calcification
1235613|NCT01011699|bone mass loss
1235614|NCT01011673|headache
1235615|NCT01011673|tension-type headache
1235616|NCT01011660|hypertension
1235617|NCT01011660|cardiovascular risk factors
1235618|NCT01011660|drugs intervention
1235619|NCT01011660|lipid-lowering therapy
1235620|NCT01011660|50-79 years of age
1235621|NCT01011660|sign
1235622|NCT01011660|the informed
1235623|NCT01011660|consent
1235624|NCT01011660|forms
1235625|NCT01011634|abortion
1235626|NCT01011634|uterine aspiration
1235627|NCT01011634|pain control
1235628|NCT01011621|Prednisolone acetate
1235629|NCT01011621|Betamethasone valerate
1235630|NCT01011595|lung cancer
1235631|NCT01011595|mediastinoscopy
1235632|NCT01011595|mediastinal lymph nodes
1235633|NCT01011595|staging
1235634|NCT01011595|EBUS
1235635|NCT01011595|EUS
1235636|NCT01011595|Endobronchial Ultrasound
1235637|NCT01011595|Endoscopic Ultrasound
1235638|NCT01011582|To evaluate biomarkers that cause critical illness in patients with novel H1N1 influenza and with seasonal influenza.
1235639|NCT01011569|difference
1235640|NCT01011556|Age Related Osteoporosis
1235641|NCT01011556|Senile Osteoporosis
1235642|NCT01011543|pulmonary tuberculosis
1235643|NCT01011543|negative sputum exam
1235644|NCT01011543|induced sputum
1235645|NCT01011543|endoscopy
1235646|NCT01011530|Melanoma
1235647|NCT01011517|muscadine grapes
1235648|NCT01011517|endothelial function
1235649|NCT01011491|Obesity
1235650|NCT01011491|Weight loss
1235651|NCT01011491|meal replacements
1235652|NCT01011491|inflammation
1235653|NCT01011491|oxidative stress
1235654|NCT01011491|visceral fat
1235655|NCT01011478|adenomatous polyp
1235656|NCT01011478|stage I colon cancer
1235657|NCT01011478|stage II colon cancer
1235658|NCT01011478|adenocarcinoma of the colon
1235659|NCT01011465|Stress
1235660|NCT01011465|Oxytocin
1235661|NCT01011465|Social Support
1235662|NCT01011465|Resilience
1235663|NCT01011452|Acute Asthma Exacerbation
1235664|NCT01011452|Montelukast
1235665|NCT01011452|Management of acute asthma exacerbation
1235666|NCT01011439|B3 and C malignant thymoma
1235667|NCT01011426|laxative
1235668|NCT01011426|postoperative care
1235669|NCT01011426|ob-Gyn population
1235670|NCT01011426|post-operative patients
1235671|NCT01011426|obstetrical and gynecological surgery
1235672|NCT01011413|HIV
1235673|NCT01011413|ART
1235674|NCT01011413|Efavirenz
1235675|NCT01011413|Dose reduction
1235676|NCT01011400|clitoris
1235677|NCT01011387|Diabetic foot ulcers
1235678|NCT01011374|Retinal vein occlusion
1235679|NCT01011374|Ranibizumab
1235680|NCT01011374|Lucentis
1235681|NCT01011374|Depression
1235682|NCT01011348|Gulf War Illness
1235683|NCT01011348|Coenzyme Q10
1235684|NCT01011348|Quality of Life
1235685|NCT01011348|Fatigue
1235686|NCT01011348|oxidative stress
1235687|NCT01011335|Staphylococcus aureus
1235688|NCT01011335|Skin and soft tissue infection
1235689|NCT01011335|Methicillin-resistant Staphylococcus aureus
1235690|NCT01011335|Recombinant alpha-toxoid (rAT)
1235691|NCT01011335|Recombinant LukS subunit of Panton-Valentine Leukocidin (rLukS-PV)
1235692|NCT01011309|Leishmaniasis
1235693|NCT01011309|vaccine
1235694|NCT01011309|immunotherapy
1235695|NCT01011283|MDS
1235696|NCT01011283|Myelodysplastic Syndromes
1235697|NCT01011270|Back pain
1235698|NCT01011270|postural balance
1235699|NCT01011270|RDM
1235700|NCT01011270|industrial operators
1235701|NCT01011257|CAD
1235702|NCT01011231|Gamma Knife radiosurgery
1235703|NCT01011231|recurrent glioma
1235704|NCT01011231|MRI
1235705|NCT01011231|Spectroscopy
1235706|NCT01011231|Recurrent grade IV glioma (glioblastoma), with two additional exploratory arms for patients with recurrent grade II and grade III gliomas
1235707|NCT01011218|quality of life
1235708|NCT01011205|Advagraf
1235709|NCT01011205|Liver
1235710|NCT01011205|Transplant
1235711|NCT01011205|Immunosuppression
1235712|NCT01011192|Intravenous anesthesia
1235713|NCT01011192|propofol
1235714|NCT01011192|pharmacokinetic model
1235715|NCT01011192|Monitoring
1235716|NCT01011192|bispectral index.
1235717|NCT01011179|Teens Taking Charge
1235718|NCT01011179|Managing Arthritis Online
1235719|NCT01011179|juvenile idiopathic arthritis
1235720|NCT01011179|internet
1235721|NCT01011179|self-management
1235722|NCT01011166|Chronic Hepatitis C
1235723|NCT01011166|HepC
1235724|NCT01011166|Hep C
1235725|NCT01011140|Parenteral Hydration
1235726|NCT01011140|Latin American Association for Palliative Care
1235727|NCT01011140|ALCP
1235728|NCT01011140|Spanish Society for Palliative Care
1235729|NCT01011140|SECPAL
1235730|NCT01011140|Online survey
1235731|NCT01011140|Palliative care
1235732|NCT01011140|Physicians' attitudes
1235733|NCT01011140|End of life
1235734|NCT01011140|Latin America
1235735|NCT01011140|Spain
1235736|NCT01011127|Statins
1235737|NCT01011127|Insulin resistance
1235738|NCT01011114|hypophosphatemia
1235739|NCT01011114|hyperparathyroidism
1235740|NCT01011114|renal transplant
1235741|NCT01011101|Saccadic Eye Movements
1235742|NCT01011101|Schizophrenia
1235743|NCT01011101|Healthy Volunteer
1235744|NCT01011101|HV
1235745|NCT01011088|Paternity
1235746|NCT01011088|Psychology
1235747|NCT01011088|Risk factor
1235748|NCT01011075|Lung cancer,
1235749|NCT01011075|Non-small cell lung cancer
1235750|NCT01011075|NSCLC
1235751|NCT01011075|Metastatic
1235752|NCT01011075|Gleevec
1235753|NCT01011075|elderly
1235754|NCT01011062|Adipose tissue
1235755|NCT01011062|Adipokines
1235756|NCT01011049|Influenza
1235757|NCT01011049|Fluzone Vaccine
1235758|NCT01011049|Intradermal Injections
1235759|NCT01011049|Adults
1235760|NCT01011036|healthy study subjects, no disease
1235761|NCT01011023|Bowel anastomosis
1235762|NCT01011023|nasogastric tube
1235763|NCT01011023|children
1235764|NCT01011010|adult primary hepatocellular carcinoma
1235765|NCT01011010|localized unresectable adult primary liver cancer
1235766|NCT01011010|recurrent adult primary liver cancer
1235767|NCT01010997|AMD, CNV
1235768|NCT01010984|metastatic melanoma
1235769|NCT01010984|stage IV melanoma
1235770|NCT01010984|metastatic melanoma to the liver
1235771|NCT01010971|Mountain Cedar
1235772|NCT01010945|Advanced Pancreatic Cancer
1235773|NCT01010945|erlotinib
1235774|NCT01010945|gemcitabine
1235775|NCT01010945|nab-paclitaxel
1235776|NCT01010945|Adenocarcinoma
1235777|NCT01010945|Phase 1b
1235778|NCT01010932|carotid or vertebral artery disease
1235779|NCT01010932|Contrast agent
1235780|NCT01010932|MRA
1235781|NCT01010893|pandemic
1235782|NCT01010893|prevention
1235783|NCT01010893|influenza
1235784|NCT01010893|infection
1235785|NCT01010893|influenza vaccine
1235786|NCT01010893|vaccine
1235787|NCT01010893|influenza in humans
1235788|NCT01010880|Multiple Myeloma
1235789|NCT01010880|CXCR4
1235790|NCT01010880|Stem Cells
1235791|NCT01010880|Mobilization
1235792|NCT01010880|Transplantation
1235793|NCT01010880|Chemotherapy
1235794|NCT01010867|Probiotics
1235795|NCT01010867|Hematopoietic Stem Cell Transplantation
1235796|NCT01010867|Pediatrics
1235797|NCT01010854|breast cancer
1235798|NCT01010854|advanced
1235799|NCT01010854|local
1235800|NCT01010841|Metabolic syndrome
1235801|NCT01010841|Serum lipid
1235802|NCT01010841|Dietary intervention
1235803|NCT01010841|Lifestyle modification
1235804|NCT01010841|Glycemic load
1235805|NCT01010841|Phytochemical
1235806|NCT01010841|Hops
1235807|NCT01010841|Acacia
1235808|NCT01010841|Mediterranean diet
1235809|NCT01010841|Kinase modulator
1235810|NCT01010815|ulcerative colitis
1235811|NCT01010815|gut microbiome
1235812|NCT01010815|metagenomics
1235813|NCT01010802|Neuroprotection
1235814|NCT01010802|Parkinson Disease
1235815|NCT01010802|Erythropoietin
1235816|NCT01010776|Schizophrenia
1235817|NCT01010776|Paliperidone
1235818|NCT01010750|ADHD
1235819|NCT01010737|Multimeric
1235820|NCT01010737|Vaccine
1235821|NCT01010737|Influenza
1235822|NCT01010737|elderly
1235823|NCT01010737|phase 1/2
1235824|NCT01010737|safety
1235825|NCT01010737|efficacy
1235826|NCT01010737|tolerability
1235827|NCT01010737|reactogenicity
1235828|NCT01010737|Montanide
1235829|NCT01010737|hemagglutinin inhibition
1235830|NCT01010737|HAI
1235831|NCT01010737|TIV
1235832|NCT01010711|migraine
1235833|NCT01010711|children
1235834|NCT01010711|dietary supplement
1235835|NCT01010711|q10
1235836|NCT01010711|prevention
1235837|NCT01010698|cimetidine
1235838|NCT01010698|acyclovir
1235839|NCT01010698|pharmacokinetics
1235840|NCT01010698|excipient
1235841|NCT01010698|formulation
1235842|NCT01010685|Natural Orifice Transluminal Endoscopic Surgery (NOTES)
1235843|NCT01010685|Transgastric surgery
1235844|NCT01010685|Surgical Procedures, Minimally Invasive
1235845|NCT01010659|Dacryocystorhinostomy
1235846|NCT01010646|hepatitis C
1235847|NCT01010646|viral kinetics
1235848|NCT01010646|antiviral response
1235849|NCT01010646|Genotype 1 or 4
1235850|NCT01010620|screening
1235851|NCT01010620|research participation
1235852|NCT01010620|substance abuse
1235853|NCT01010620|Schizophrenia
1235854|NCT01010620|nicotine
1235855|NCT01010620|Healthy
1235856|NCT01010620|cigarettes
1235857|NCT01010620|smoking
1235858|NCT01010620|marijuana
1235859|NCT01010620|cocaine
1235860|NCT01010581|Rheumatoid Arthritis
1235861|NCT01010581|SC12267
1235862|NCT01010581|4SC-101
1235863|NCT01010581|Methotrexate
1235864|NCT01010581|Phase II
1235865|NCT01010568|CLL
1235866|NCT01010568|SLL
1235867|NCT01010568|Bendamustine
1235868|NCT01010568|Ofatumumab
1235869|NCT01010542|Single dose psoriasis study
1235870|NCT01010529|Occupational Therapy
1235871|NCT01010529|Parkinson's Disease
1235872|NCT01010529|Feasibility
1235873|NCT01010529|Effectiveness
1235874|NCT01010529|RCT
1235875|NCT01010529|Activities of daily living
1235876|NCT01010529|Participation
1235877|NCT01010529|Caregiver's Burden
1235878|NCT01010490|PACHYMETRY
1235879|NCT01010490|CELL LOSS
1235880|NCT01010490|SAFETY
1235881|NCT01010490|EFFICACY
1235882|NCT01010490|PHACOEMULSIFICATION
1235883|NCT01010490|Intraoperative complications
1235884|NCT01010490|CLOCK TIME
1235885|NCT01010490|FLUID USED
1235886|NCT01010490|CORNEAL THICKNESS
1235887|NCT01010490|ENDOTHELIUM CELL LOSS
1235888|NCT01010477|smoking cessation
1235889|NCT01010477|schizophrenia
1235890|NCT01010477|nicotine nasal spray
1235891|NCT01010477|behavioral counseling
1235892|NCT01010464|Adhesions
1235893|NCT01010464|Open abdomen
1235894|NCT01010464|Laparotomy
1235895|NCT01010451|pulpotomy
1235896|NCT01010451|pulpectomy
1235897|NCT01010451|primary teeth
1235898|NCT01010451|dental care for children
1235899|NCT01010438|sleep studies
1235900|NCT01010438|sleep apnea
1235901|NCT01010438|OSA
1235902|NCT01010438|Referred for sleep studies by a medical professional
1235903|NCT01010412|Ultrasound
1235904|NCT01010412|Nerve blocks
1235905|NCT01010412|Upper extremity
1235906|NCT01010399|HIV
1235907|NCT01010399|triglycerides
1235908|NCT01010399|fosamprenavir
1235909|NCT01010386|Pregnancy
1235910|NCT01010386|Infertility
1235911|NCT01010386|Physiologic Oxygen Tension
1235912|NCT01010386|Atmospheric Oxygen Tension
1235913|NCT01010373|Primary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) induced AML.
1235914|NCT01010360|celiac ganglia
1235915|NCT01010347|fractures
1235916|NCT01010347|casting
1235917|NCT01010347|splinting
1235918|NCT01010347|pediatrics
1235919|NCT01010334|INST 0813
1235920|NCT01010334|Standard of Care
1235921|NCT01010321|skin lesion suspect as BCC or SCC or others
1235922|NCT01010308|infantile hemangioma
1235923|NCT01010308|nadolol
1235924|NCT01010295|NHL of the ocular adnexae
1235925|NCT01010256|To evaluate the phosphate and tension homolog deleted on chromosome ten (PTEN) protein level in leukemia cells from patients with CMML.
1235926|NCT01010256|To identify the PTEN genetic defect in patients with deficient PTEN protein levels.
1235927|NCT01010256|To evaluate the role of PTEN deregulation in CMML pathogenesis.
1235928|NCT01010243|multiple myeloma
1235929|NCT01010243|anti-inflammatory
1235930|NCT01010243|relapsed
1235931|NCT01010243|refractory
1235932|NCT01010243|progressive
1235933|NCT01010230|Childhood cancer survivors
1235934|NCT01010217|Hematologic Neoplasms
1235935|NCT01010217|Blood Disorders
1235936|NCT01010217|Blood Cancer
1235937|NCT01010217|Transplantation, Blood And Marrow
1235938|NCT01010217|Acute myelogenous leukemia
1235939|NCT01010217|Myelodysplastic syndrome
1235940|NCT01010217|Acute lymphocytic leukemia
1235941|NCT01010217|Aplastic anemia
1235942|NCT01010217|Chronic myelogenous leukemia
1235943|NCT01010217|Chronic lymphocytic leukemia
1235944|NCT01010217|Myeloproliferative disease
1235945|NCT01010217|Hodgkin's disease
1235946|NCT01010217|Non-Hodgkin's lymphoma
1235947|NCT01010217|Multiple myeloma
1235948|NCT01010217|Cyclophosphamide
1235949|NCT01010217|Fludarabine
1235950|NCT01010217|Melphalan
1235951|NCT01010217|Mesna
1235952|NCT01010217|Rituximab
1235953|NCT01010217|Tacrolimus
1235954|NCT01010217|Prograf
1235955|NCT01010217|Mycofenolate mofetil
1235956|NCT01010217|MMF
1235957|NCT01010217|CellCept
1235958|NCT01010217|G-CSF
1235959|NCT01010217|Filgrastim
1235960|NCT01010217|Neupogen
1235961|NCT01010204|Varenicline
1235962|NCT01010204|Chantix
1235963|NCT01010204|Smoking
1235964|NCT01010204|Bipolar Disorder
1235965|NCT01010191|irritable bowel syndrome
1235966|NCT01010191|no organic digestive disease
1235967|NCT01010178|COPD
1235968|NCT01010178|Macrolid
1235969|NCT01010178|reversibility
1235970|NCT01010178|Theophylline
1235971|NCT01010178|Corticosteroids
1235972|NCT01010178|symptoms PFT
1235973|NCT01010165|acute arthritis
1235974|NCT01010165|bacteria
1235975|NCT01010165|crystal arthritis
1235976|NCT01010165|proteomic
1235977|NCT01010165|SELDI-TOF
1235978|NCT01010113|infants
1235979|NCT01010113|prebiotics
1235980|NCT01010113|probiotics
1235981|NCT01010113|safety
1235982|NCT01010100|Metabolic Disease
1235983|NCT01010100|IGT Impaired Glucose Tolerance
1235984|NCT01010087|patients admitted to ICU
1235985|NCT01010074|retina, Parkinson's disease, ganglion cell, pupillary
1235986|NCT01010048|ESWL
1235987|NCT01010048|urinary calculus
1235988|NCT01010048|drugs treat
1235989|NCT01010035|type 2 diabetes mellitus
1235990|NCT01010035|dyslipidemia
1235991|NCT01010035|kinetics
1235992|NCT01010022|hypovolemia
1235993|NCT01010022|surgical blood loss
1235994|NCT01010022|orthopedic procedures
1235995|NCT01010022|Treatment of reduced circulating blood volume (hypovolemia) including massive hemorrhage
1235996|NCT01010009|resveratrol
1235997|NCT01010009|cerebral blood flow
1235998|NCT01010009|NIRS
1235999|NCT01010009|cognitive performance
1236000|NCT01009996|Coronary bifurcation lesions
1236001|NCT01009983|triple-negative breast cancer
1236002|NCT01009970|Diffuse Large B-Cell Lymphoma
1236003|NCT01009957|ADPKD
1236004|NCT01009957|CKD
1236005|NCT01009957|Renal disease progression
1236006|NCT01009957|Everolimus
1236007|NCT01009944|High blood pressure
1236008|NCT01009931|Acute Myelogenous Leukemia
1236009|NCT01009931|Relapsed AML
1236010|NCT01009931|Refractory AML
1236011|NCT01009918|cardiac toxicity
1236012|NCT01009918|HER2-positive breast cancer
1236013|NCT01009918|recurrent breast cancer
1236014|NCT01009918|stage IA breast cancer
1236015|NCT01009918|stage IB breast cancer
1236016|NCT01009918|stage II breast cancer
1236017|NCT01009918|stage IIIA breast cancer
1236018|NCT01009918|stage IIIB breast cancer
1236019|NCT01009918|stage IIIC breast cancer
1236020|NCT01009918|male breast cancer
1236021|NCT01009879|rheumatoid arthritis
1236022|NCT01009879|B lymphocytes
1236023|NCT01009866|Malignant brain tumor
1236024|NCT01009866|GBM
1236025|NCT01009866|recurrent brain tumor
1236026|NCT01009866|Supratentorial malignant brain tumor
1236027|NCT01009866|astrocytomas
1236028|NCT01009866|ependymomas
1236029|NCT01009866|Residual, progressive, or recurrent supratentorial malignant brain tumor based on imaging studies with measurable
1236030|NCT01009866|disease (>0.5cm).
1236031|NCT01009840|Multiple Myeloma
1236032|NCT01009840|Bone marrow transplant
1236033|NCT01009840|Stem cell transplant
1236034|NCT01009840|Busulfan
1236035|NCT01009840|Bortezomib
1236036|NCT01009827|Medication adherence
1236037|NCT01009827|Substance use
1236038|NCT01009827|Sexual risk behaviors
1236039|NCT01009814|HIV, HIV attachment inhibitor, attachment inhibitor
1236040|NCT01009801|adult primary hepatocellular carcinoma
1236041|NCT01009801|recurrent adult primary liver cancer
1236042|NCT01009801|localized resectable adult primary liver cancer
1236043|NCT01009788|ABT-888
1236044|NCT01009788|temozolomide
1236045|NCT01009788|TMZ
1236046|NCT01009775|Melanoma, Stage III
1236047|NCT01009775|Melanoma, Stage IV
1236048|NCT01009775|YM 155
1236049|NCT01009775|Metastatic Melanoma
1236050|NCT01009762|VACCINE
1236051|NCT01009762|THERAPY
1236052|NCT01009762|CELLULAR IMMUNITY
1236053|NCT01009762|IMMUNITY
1236054|NCT01009749|HAART
1236055|NCT01009749|HIV
1236056|NCT01009749|Adherence
1236057|NCT01009736|stage I prostate cancer
1236058|NCT01009736|stage IIB prostate cancer
1236059|NCT01009736|stage IIA prostate cancer
1236060|NCT01009736|stage III prostate cancer
1236061|NCT01009736|stage IV prostate cancer
1236062|NCT01009723|Preterm delivery
1236063|NCT01009723|preterm labor
1236064|NCT01009723|maternal-fetal care
1236065|NCT01009723|maternal serum screening biomarkers
1236066|NCT01009723|alphafetoprotein
1236067|NCT01009723|AFP
1236068|NCT01009723|human chorionic gonadotropin
1236069|NCT01009723|hCG
1236070|NCT01009723|unconjugated estriol
1236071|NCT01009723|Inhibin A
1236072|NCT01009723|pregnancy associated plasma protein
1236073|NCT01009723|PAPP-A
1236074|NCT01009723|maternal screening
1236075|NCT01009684|Contraception
1236076|NCT01009684|Estradiol valerate
1236077|NCT01009671|knee osteoarthritis
1236078|NCT01009658|Gastrointestinal motility
1236079|NCT01009658|Gastroesophageal reflux
1236080|NCT01009658|Gastric emptying
1236081|NCT01009658|Sodium glutamate
1236082|NCT01009658|Lower esophageal sphincter
1236083|NCT01009645|education
1236084|NCT01009645|vaccination
1236085|NCT01009645|preventive service
1236086|NCT01009645|Prevention & Control
1236087|NCT01009619|Bronchiolitis Obliterans Syndrome
1236088|NCT01009619|Acute allograft Rejection
1236089|NCT01009619|Lymphocytic bronchiolitis
1236090|NCT01009619|Respiratory infection
1236091|NCT01009619|Survival
1236092|NCT01009619|Mortality
1236093|NCT01009619|Pulmonary function
1236094|NCT01009619|FEV1
1236095|NCT01009619|Broncho-alveolar lavage
1236096|NCT01009619|Neutrophils
1236097|NCT01009619|Interleukin
1236098|NCT01009619|Culture
1236099|NCT01009619|Azithromycin
1236100|NCT01009606|Out-of-hospital
1236101|NCT01009606|Emergency
1236102|NCT01009606|Cardiac arrest
1236103|NCT01009606|Post-traumatic stress disorder
1236104|NCT01009593|Molecular Mechanisms of Pharmacological Action
1236105|NCT01009593|Antineoplastic Agents
1236106|NCT01009593|Growth Substances
1236107|NCT01009593|Physiological Effects of Drugs
1236108|NCT01009593|Enzyme Inhibitors
1236109|NCT01009593|Angiogenesis Inhibitors
1236110|NCT01009593|Inhibitors, Angiogenesis
1236111|NCT01009593|Protein Kinase Inhibitors
1236112|NCT01009593|Pharmacologic Actions
1236113|NCT01009593|Growth Inhibitors
1236114|NCT01009593|Angiogenesis Modulating Agents
1236115|NCT01009593|Sorafenib
1236116|NCT01009567|OHSS
1236117|NCT01009554|Mouthwashes
1236118|NCT01009541|pregabalin pharmacokinetics bioavailability bioequivalence
1236119|NCT01009528|Quality of care
1236120|NCT01009528|General Practice
1236121|NCT01009528|Electronic Feedback System
1236122|NCT01009515|metastatic
1236123|NCT01009515|melanoma
1236124|NCT01009515|skin cancer
1236125|NCT01009515|paclitaxel
1236126|NCT01009515|carboplatin
1236127|NCT01009515|temozolomide
1236128|NCT01009476|Dementia
1236129|NCT01009476|Galantamine
1236130|NCT01009476|Cholinesterase inhibitors
1236131|NCT01009476|Nootropic agents
1236132|NCT01009476|Alzheimer
1236133|NCT01009476|Vascular dementia
1236134|NCT01009476|Cognitive symptoms
1236135|NCT01009476|Behavioural symptoms
1236136|NCT01009476|Care giving times
1236137|NCT01009463|COPD
1236138|NCT01009463|Safety
1236139|NCT01009463|FEV1
1236140|NCT01009463|Efficacy
1236141|NCT01009450|cirrhotic liver, gall bladder stone
1236142|NCT01009437|HER2-negative breast cancer
1236143|NCT01009437|HER2-positive breast cancer
1236144|NCT01009437|estrogen receptor-positive breast cancer
1236145|NCT01009437|triple-negative breast cancer
1236146|NCT01009437|stage I breast cancer
1236147|NCT01009437|stage II breast cancer
1236148|NCT01009437|stage IIIA breast cancer
1236149|NCT01009437|stage IIIB breast cancer
1236150|NCT01009437|stage IIIC breast cancer
1236151|NCT01009437|stage IV breast cancer
1236152|NCT01009437|ductal breast carcinoma in situ
1236153|NCT01009398|Anesthesia and Analgesia
1236154|NCT01009398|Regional anesthesia
1236155|NCT01009398|Thoracic Paravertebral block
1236156|NCT01009398|Catheter location
1236157|NCT01009385|cervical
1236158|NCT01009385|epidural
1236159|NCT01009385|epidural pressure
1236160|NCT01009385|monitoring
1236161|NCT01009372|surgeon's physiology
1236162|NCT01009372|stress response
1236163|NCT01009372|break scheme
1236164|NCT01009359|Alzheimers disease
1236165|NCT01009359|Diagnostic imaging
1236166|NCT01009359|PET/CT diagnosis
1236167|NCT01009359|PET tracer
1236168|NCT01009333|urgency frequency
1236169|NCT01009333|urinary urge incontinence
1236170|NCT01009333|InterStim Therapy
1236171|NCT01009320|Pacemaker
1236172|NCT01009320|Magnets
1236173|NCT01009320|Drape
1236174|NCT01009320|Ferrite
1236175|NCT01009320|Magnetic field
1236176|NCT01009320|Pacemaker interference
1236177|NCT01009307|adult anaplastic astrocytoma
1236178|NCT01009307|adult diffuse astrocytoma
1236179|NCT01009307|adult pilocytic astrocytoma
1236180|NCT01009307|adult subependymal giant cell astrocytoma
1236181|NCT01009307|adult anaplastic ependymoma
1236182|NCT01009307|adult ependymoma
1236183|NCT01009307|adult myxopapillary ependymoma
1236184|NCT01009307|adult subependymoma
1236185|NCT01009307|adult anaplastic oligodendroglioma
1236186|NCT01009307|adult oligodendroglioma
1236187|NCT01009307|adult brain stem glioma
1236188|NCT01009307|adult giant cell glioblastoma
1236189|NCT01009307|adult glioblastoma
1236190|NCT01009307|recurrent adult brain tumor
1236191|NCT01009307|adult gliosarcoma
1236192|NCT01009307|adult mixed glioma
1236193|NCT01009307|adult pineal gland astrocytoma
1236194|NCT01009307|adult ependymoblastoma
1236195|NCT01009307|adult medulloblastoma
1236196|NCT01009307|adult supratentorial primitive neuroectodermal tumor (PNET)
1236197|NCT01009307|adult pineoblastoma
1236198|NCT01009307|adult pineocytoma
1236199|NCT01009294|Duchenne muscular dystrophy
1236200|NCT01009294|Becker muscular dystrophy
1236201|NCT01009294|Nonsense mutation
1236202|NCT01009294|Premature stop codon
1236203|NCT01009294|DMD
1236204|NCT01009294|BMD
1236205|NCT01009294|Ataluren
1236206|NCT01009294|PTC124
1236207|NCT01009281|Crohn's Disease
1236208|NCT01009281|Crohns
1236209|NCT01009281|Bowel disease
1236210|NCT01009281|digestive disorders
1236211|NCT01009281|auto immune
1236212|NCT01009281|diarrhea
1236213|NCT01009281|Inflammatory Bowel Disease (IBD)
1236214|NCT01009281|gastrointestinal diseases
1236215|NCT01009281|digestive system diseases
1236216|NCT01009281|Antibody
1236217|NCT01009281|IL 17
1236218|NCT01009281|anti IL-17
1236219|NCT01009281|monoclonal antibody
1236220|NCT01009281|Crohn's Disease (Chron's, CD)
1236221|NCT01009255|Alzheimer's disease
1236222|NCT01009255|placebo controlled
1236223|NCT01009255|randomised
1236224|NCT01009255|Histamine
1236225|NCT01009255|H3 Antagonist
1236226|NCT01009255|double blind
1236227|NCT01009255|Cognition
1236228|NCT01009242|CDP6038
1236229|NCT01009216|Pharmacokinetics
1236230|NCT01009216|Pharmacology
1236231|NCT01009216|Drug Safety
1236232|NCT01009216|Phase 1 Clinical Trials
1236233|NCT01009203|squamous cell carcinoma
1236234|NCT01009203|head
1236235|NCT01009203|neck
1236236|NCT01009203|aerodigestive
1236237|NCT01009190|Dose finding PARPi Chemotherapy
1236238|NCT01009177|Melanoma
1236239|NCT01009177|Metastatic
1236240|NCT01009177|DTIC
1236241|NCT01009177|Bosentan
1236242|NCT01009151|telemonitoring
1236243|NCT01009151|internet
1236244|NCT01009151|home monitoring system
1236245|NCT01009151|heart failure
1236246|NCT01009151|self management plan
1236247|NCT01009151|web portal
1236248|NCT01009138|Subthreshold Depression
1236249|NCT01009138|Diabetes-related Distress
1236250|NCT01009138|Minor Depression
1236251|NCT01009138|Light affective Disorder
1236252|NCT01009138|Subclinical depressive Symptoms
1236253|NCT01009138|Diabetes mellitus
1236254|NCT01009138|Late Complications
1236255|NCT01009138|Markers of Inflammation
1236256|NCT01009125|questionnaires
1236257|NCT01009125|health care surveys/methods
1236258|NCT01009125|motivation
1236259|NCT01009125|living donors
1236260|NCT01009125|living kidney donation
1236261|NCT01009112|Sleep
1236262|NCT01009112|Sleep Disorder
1236263|NCT01009112|Veterans
1236264|NCT01009112|Active Duty
1236265|NCT01009112|OEF
1236266|NCT01009112|OIF
1236267|NCT01009112|PTSD
1236268|NCT01009099|pulmonary disease
1236269|NCT01009099|COPD
1236270|NCT01009086|Arthritis, Psoriatic
1236271|NCT01009086|Ustekinumab
1236272|NCT01009086|CNTO 1275
1236273|NCT01009086|Stelara
1236274|NCT01009086|Psoriasis
1236275|NCT01009060|H3 Antagonist
1236276|NCT01009060|Schizophrenia
1236277|NCT01009060|double blind
1236278|NCT01009060|Histamine
1236279|NCT01009060|randomised
1236280|NCT01009060|placebo controlled
1236281|NCT01009060|Cognition
1236282|NCT01009047|Schizophrenia
1236283|NCT01009047|Paliperidone
1236284|NCT01009047|Aripiprazole
1236285|NCT01009021|pain
1236286|NCT01009021|retinal photocoagulation
1236287|NCT01009021|potassium diclofenac
1236288|NCT01009008|cancer
1236289|NCT01009008|breast cancer
1236290|NCT01009008|mastectomy
1236291|NCT01009008|breast reconstruction
1236292|NCT01009008|reconstruction
1236293|NCT01009008|tissue expansion
1236294|NCT01009008|two-stage breast reconstruction
1236295|NCT01009008|tissue expander
1236296|NCT01009008|AeroForm
1236297|NCT01009008|AirXpander
1236298|NCT01008995|psoriasis
1236299|NCT01008995|asian patients
1236300|NCT01008995|Chinese
1236301|NCT01008995|ustekinumab
1236302|NCT01008995|CNTO 1275
1236303|NCT01008995|Stelara
1236304|NCT01008982|Belimumab,Sjögren's Syndrome.
1236305|NCT01008982|Have a diagnosis of primary SS according to the updated American European Consensus Group Criteria
1236306|NCT01008969|Prostate
1236307|NCT01008969|SPECT/CT
1236308|NCT01008956|Influenza
1236309|NCT01008956|H1N1
1236310|NCT01008956|Pandemic
1236311|NCT01008956|GSK Bio's influenza vaccine GSK2340274A
1236312|NCT01008930|Peripheral Tumors
1236313|NCT01008930|Arm
1236314|NCT01008930|Leg
1236315|NCT01008930|Head
1236316|NCT01008930|Neck
1236317|NCT01008930|HR PET Imaging System
1236318|NCT01008930|High-Resolution PET
1236319|NCT01008930|PET/CT
1236320|NCT01008930|PEMFlex Solo II
1236321|NCT01008930|positron emission tomography/computed tomography (PET/CT)
1236322|NCT01008917|Hepatocellular carcinoma
1236323|NCT01008917|HCC
1236324|NCT01008917|Liver cancer
1236325|NCT01008917|Hepatoma
1236326|NCT01008904|cancer survivor
1236327|NCT01008904|hot flashes
1236328|NCT01008904|breast cancer
1236329|NCT01008904|unspecified adult solid tumor, protocol specific
1236330|NCT01008891|arthritis
1236331|NCT01008891|ankle pain
1236332|NCT01008891|foot pain
1236333|NCT01008891|hindfoot fracture
1236334|NCT01008891|ankle fracture
1236335|NCT01008891|rheumatoid arthritis
1236336|NCT01008891|arthrosis
1236337|NCT01008891|Foot/Hindfoot Fusion
1236338|NCT01008852|rheumatoid arthritis
1236339|NCT01008852|seropositive
1236340|NCT01008852|methotrexate
1236341|NCT01008839|study sarcopenia, which muscle becomes weaker with age
1236342|NCT01008826|sulforaphane
1236343|NCT01008826|pharmacokinetics
1236344|NCT01008813|HIV infection
1236345|NCT01008813|adjuvanted and non-adjuvanted A(H1N1)v influenza vaccine
1236346|NCT01008813|immunogenicity
1236347|NCT01008813|safety
1236348|NCT01008800|Autism Spectrum Disorder
1236349|NCT01008800|language
1236350|NCT01008800|social
1236351|NCT01008800|toddlers
1236352|NCT01008787|Cancer Prevention
1236353|NCT01008787|Focus Group
1236354|NCT01008787|Interview
1236355|NCT01008787|Physical Activity
1236356|NCT01008787|African American women
1236357|NCT01008787|Exercise
1236358|NCT01008787|Exercise habits
1236359|NCT01008787|Health behavior
1236360|NCT01008761|Pre-school child
1236361|NCT01008761|Wheezy episode
1236362|NCT01008748|Smoking
1236363|NCT01008748|Latinos
1236364|NCT01008748|Mexican American
1236365|NCT01008748|Spanish-speaking smokers
1236366|NCT01008748|Ecological momentary assessment
1236367|NCT01008748|Nicotine patch
1236368|NCT01008748|Smoking cessation counseling
1236369|NCT01008748|Questionnaire
1236370|NCT01008748|EMA
1236371|NCT01008722|Atrial Fibrillation
1236372|NCT01008722|Ablation
1236373|NCT01008696|Reflux esophagitis
1236374|NCT01008696|Rabeprazole
1236375|NCT01008696|Lansoprazole
1236498|NCT01008410|Gastrointestinal Diseases
1236376|NCT01008683|Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccinations
1236377|NCT01008670|Cardiac resynchronization therapy
1236378|NCT01008657|Radiofrequency-Extranodular-Multipolar ablation
1236379|NCT01008657|Recurrence
1236380|NCT01008644|carbon dioxide
1236381|NCT01008644|ventilation
1236382|NCT01008644|gender
1236383|NCT01008644|osmolality
1236384|NCT01008644|menstruation cycle
1236385|NCT01008631|renal failure
1236386|NCT01008631|sodium Thiosulfate
1236387|NCT01008631|pharmakokinetic
1236388|NCT01008618|Chronic pain
1236389|NCT01008618|Osteoarthritis
1236390|NCT01008618|Low back pain
1236391|NCT01008618|Fentanyl
1236392|NCT01008618|JNS020QD
1236393|NCT01008618|Patch, transdermal
1236394|NCT01008618|Opioid analgesics
1236395|NCT01008605|Erectile Dysfunction
1236396|NCT01008592|dermatographism, levocetirizine (Xyzal)
1236397|NCT01008592|chronic idiopathic urticaria, dermatographism
1236398|NCT01008579|Patient Reported Outcome Measures
1236399|NCT01008579|falls
1236400|NCT01008579|older adults
1236401|NCT01008553|Postherpetic Neuralgia
1236402|NCT01008553|Complex Regional Pain Syndromes (CRPS)
1236403|NCT01008553|Postoperative Pain
1236404|NCT01008553|Fentanyl
1236405|NCT01008553|Patch, transdermal
1236406|NCT01008553|Opioid analgesics
1236407|NCT01008540|cytomegalovirus
1236408|NCT01008540|resistance
1236409|NCT01008540|transplantation
1236410|NCT01008540|Patient coming to an French transplantation center for solid organ or bone marrow transplant, with information and signed consent
1236411|NCT01008527|skin
1236412|NCT01008527|cutaneous
1236413|NCT01008527|immunotherapy
1236414|NCT01008527|immunology
1236415|NCT01008527|dose escalation
1236416|NCT01008514|ductal breast carcinoma in situ
1236417|NCT01008514|stage IA breast cancer
1236418|NCT01008514|stage IB breast cancer
1236419|NCT01008514|stage II breast cancer
1236420|NCT01008501|hydatidiform moles
1236421|NCT01008501|complete hydatidiform moles
1236422|NCT01008501|partial hydatidiform moles
1236423|NCT01008501|Molar pregnancy
1236424|NCT01008501|NLRP7
1236425|NCT01008501|pregnancy wastage
1236426|NCT01008501|imprinting
1236427|NCT01008501|sporadic hydatidiform moles
1236428|NCT01008501|recurrent hydatidiform moles
1236429|NCT01008488|colonic diverticulitis
1236430|NCT01008488|diverticular disease
1236431|NCT01008488|antibiotic therapy
1236432|NCT01008475|EMD 525797
1236433|NCT01008475|Cetuximab
1236434|NCT01008475|Irinotecan
1236435|NCT01008475|metastatic colorectal cancer
1236436|NCT01008449|Staples
1236437|NCT01008449|Sutures
1236438|NCT01008449|Cesarean Delivery
1236439|NCT01008449|Wound
1236440|NCT01008449|Skin Closure
1236441|NCT01008449|Wound infection
1236442|NCT01008449|Wound disruption
1236443|NCT01008436|Ability of topical drug to reduce acute and overall bleeding as well as blood transfusions
1236444|NCT01008423|Proctitis
1236445|NCT01008423|Proctosigmoiditis
1236446|NCT01008423|Ulcerative
1236447|NCT01008423|Salix
1236448|NCT01008423|Budesonide foam
1236449|NCT01008423|Budesonide
1236450|NCT01008423|Rectal
1236451|NCT01008423|Gastrointestinal
1236452|NCT01008423|Colitis
1236453|NCT01008423|UC
1236454|NCT01008423|UP
1236455|NCT01008423|UPS
1236456|NCT01008423|Additional relevant MeSH terms:
1236457|NCT01008423|Proctocolitis
1236458|NCT01008423|Ulcer
1236459|NCT01008423|Colitis, Ulcerative
1236460|NCT01008423|Gastroenteritis
1236461|NCT01008423|Gastrointestinal Diseases
1236462|NCT01008423|Digestive System Diseases
1236463|NCT01008423|Rectal Diseases
1236464|NCT01008423|Intestinal Diseases
1236465|NCT01008423|Colonic Diseases
1236466|NCT01008423|Sigmoid Diseases
1236467|NCT01008423|Pathologic Processes
1236468|NCT01008423|Inflammatory Bowel Diseases
1236469|NCT01008423|Bronchodilator Agents
1236470|NCT01008423|Autonomic Agents
1236471|NCT01008423|Peripheral Nervous System Agents
1236472|NCT01008423|Physiological Effects of Drugs
1236473|NCT01008423|Pharmacologic Actions
1236474|NCT01008423|Anti-Asthmatic Agents
1236475|NCT01008423|Respiratory System Agents
1236476|NCT01008423|Therapeutic Uses
1236477|NCT01008423|Glucocorticoids
1236478|NCT01008423|Hormones
1236479|NCT01008423|Hormones, Hormone Substitutes, and Hormone Antagonists
1236480|NCT01008423|Anti-Inflammatory Agents
1236481|NCT01008410|Proctitis
1236482|NCT01008410|Proctosigmoiditis
1236483|NCT01008410|Ulcerative
1236484|NCT01008410|Salix
1236485|NCT01008410|Budesonide foam
1236486|NCT01008410|Budesonide
1236487|NCT01008410|Rectal
1236488|NCT01008410|Gastrointestinal
1236489|NCT01008410|Colitis
1236490|NCT01008410|UC
1236491|NCT01008410|UP
1236492|NCT01008410|UPS
1236493|NCT01008410|Additional relevant MeSH terms:
1236494|NCT01008410|Proctocolitis
1236495|NCT01008410|Ulcer
1236496|NCT01008410|Colitis, Ulcerative
1236497|NCT01008410|Gastroenteritis
1236499|NCT01008410|Digestive System Diseases
1236500|NCT01008410|Rectal Diseases
1236501|NCT01008410|Intestinal Diseases
1236502|NCT01008410|Colonic Diseases
1236503|NCT01008410|Sigmoid Diseases
1236504|NCT01008410|Pathologic Processes
1236505|NCT01008410|Inflammatory Bowel Diseases
1236506|NCT01008410|Bronchodilator Agents
1236507|NCT01008410|Autonomic Agents
1236508|NCT01008410|Peripheral Nervous System Agents
1236509|NCT01008410|Physiological Effects of Drugs
1236510|NCT01008410|Pharmacologic Actions
1236511|NCT01008410|Anti-Asthmatic Agents
1236512|NCT01008410|Respiratory System Agents
1236513|NCT01008410|Therapeutic Uses
1236514|NCT01008410|Glucocorticoids
1236515|NCT01008410|Hormones
1236516|NCT01008410|Hormones, Hormone Substitutes, and Hormone Antagonists
1236517|NCT01008410|Anti-Inflammatory Agents
1236518|NCT01008397|Rhinitis, Allergic, Seasonal
1236519|NCT01008371|Obesity
1236520|NCT01008371|Cholecystokinin
1236521|NCT01008371|Oxytocin
1236522|NCT01008371|Satiety
1236523|NCT01008371|Gastric emptying
1236524|NCT01008371|Anxiety
1236525|NCT01008371|Depression
1236526|NCT01008371|Panic Disorder
1236527|NCT01008332|House Dust Mite Allergy
1236528|NCT01008332|Immunotherapy
1236529|NCT01008332|Rhinoconjunctivitis
1236530|NCT01008332|Toleromune HDM
1236531|NCT01008319|Anovulation
1236532|NCT01008319|Ovulation induction
1236533|NCT01008306|Cardiorespiratory fitness
1236534|NCT01008306|physical activity
1236535|NCT01008306|hypertension
1236536|NCT01008306|overweight and obesity
1236537|NCT01008306|metabolic syndrome
1236538|NCT01008306|Body composition
1236539|NCT01008241|Hospice
1236540|NCT01008241|End of Life
1236541|NCT01008241|Knowledge
1236542|NCT01008241|Attitudes
1236543|NCT01008241|Opinions
1236544|NCT01008241|Advanced Care Planning
1236545|NCT01008241|Death and Dying
1236546|NCT01008241|Communication
1236547|NCT01008241|Knowledge and Attitudes of South Florida Residents on Hospice Care
1236548|NCT01008228|spontaneous
1236549|NCT01008228|primary
1236550|NCT01008228|first episode
1236551|NCT01008215|INR Control
1236552|NCT01008215|Warfarin dosing
1236553|NCT01008215|Family physicians
1236554|NCT01008215|Cluster randomization
1236555|NCT01008176|Hypertension
1236556|NCT01008176|Sleep
1236557|NCT01008176|Blood Pressure
1236558|NCT01008176|Inflammatory Markers
1236559|NCT01008163|diabetes
1236560|NCT01008150|breast cancer
1236561|NCT01008150|neoadjuvant
1236562|NCT01008150|neratinib
1236563|NCT01008150|paclitaxel
1236564|NCT01008150|trastuzumab
1236565|NCT01008150|doxorubicin
1236566|NCT01008150|cyclophosphamide
1236567|NCT01008124|Benign Paroxysmal Positional Vertigo
1236568|NCT01008124|BPPV
1236569|NCT01008124|PC
1236570|NCT01008124|BPPN
1236571|NCT01008124|Vertigo
1236572|NCT01008111|regeneration
1236573|NCT01008111|tissue survival
1236574|NCT01008111|biological processes
1236575|NCT01008111|connective tissue
1236576|NCT01008111|tissue
1236577|NCT01008098|Posttraumatic Stress Disorder
1236578|NCT01008098|Escitalopram
1236579|NCT01008098|Magnetic Resonance Imaging
1236580|NCT01008098|BDNF
1236581|NCT01008085|STEMI
1236582|NCT01008085|self-expandable
1236583|NCT01008085|balloon-expandable
1236584|NCT01008046|Polycystic ovary syndrome
1236585|NCT01008046|clomiphene resistance
1236586|NCT01008046|metformin
1236587|NCT01008046|N-acetyl cysteine
1236588|NCT01008020|tea catechin extracts
1236589|NCT01008020|influenza infection
1236590|NCT01008020|prophylaxis
1236591|NCT01008020|supplements
1236592|NCT01008020|adults over 20 years old
1236593|NCT01008020|both men and women
1236594|NCT01008007|Viusid
1236595|NCT01008007|Dietary supplements
1236596|NCT01008007|Acute fever
1236597|NCT01008007|Viral etiology
1236598|NCT01007994|Nocturnal hypertension
1236599|NCT01007994|Pediatric
1236600|NCT01007994|Renal Transplant
1236601|NCT01007994|Pulse Wave Velocity
1236602|NCT01007994|Echocardiogram
1236603|NCT01007994|Pediatric Renal Transplant Recipient
1236604|NCT01007968|solid tumors
1236605|NCT01007968|hepatic function
1236606|NCT01007968|advanced
1236607|NCT01007968|panobinostat
1236608|NCT01007942|Metastatic breast cancer
1236609|NCT01007942|locally advanced breast cancer
1236610|NCT01007942|HER2/neu positive breast cancer
1236611|NCT01007942|HER2/neu over-expressing
1236612|NCT01007942|progressive-free survival (PFS)
1236613|NCT01007942|over survival (OS)
1236614|NCT01007942|bolero
1236615|NCT01007942|bolero 3
1236616|NCT01007942|Breast cancer
1236617|NCT01007942|everolimus
1236618|NCT01007942|HER+
1236619|NCT01007942|vinorelbine
1236620|NCT01007942|herceptin
1236621|NCT01007942|trastuzumab
1236622|NCT01007942|RAD001
1236623|NCT01007929|ADME
1236624|NCT01007929|safety
1236625|NCT01007929|oral solution
1236626|NCT01007890|ChemoFX
1236627|NCT01007890|Operable
1236628|NCT01007890|Breast
1236629|NCT01007890|Cancer
1236630|NCT01007890|Measurable
1236631|NCT01007890|Disease
1236632|NCT01007877|sleepiness
1236633|NCT01007877|driving
1236634|NCT01007864|Parkinson
1236635|NCT01007864|piribedil
1236636|NCT01007864|vigilance
1236637|NCT01007864|dopamine agonist
1236638|NCT01007864|cognition
1236639|NCT01007851|GnRH agonist
1236640|NCT01007851|GnRH antagonist
1236641|NCT01007851|IVF
1236642|NCT01007851|ICSI
1236643|NCT01007851|assisted reproduction
1236644|NCT01007851|luteal phase
1236645|NCT01007838|Progressive Resistance Training/Exercise
1236646|NCT01007838|Muscle wasting
1236647|NCT01007838|Chronic Kidney Disease
1236648|NCT01007786|Pediatric Hydrocephalus
1236649|NCT01007786|Ultrasound Guided Surgery
1236650|NCT01007773|Dexmedetomidine
1236651|NCT01007773|Intracranial Pressure
1236652|NCT01007773|Traumatic Brain Injury
1236653|NCT01007760|Tobacco smoke
1236654|NCT01007760|Oxidative stress
1236655|NCT01007760|Endothelial Function
1236656|NCT01007760|Atherosclerosis
1236657|NCT01007760|Arterial Stiffness
1236658|NCT01007760|Microvascular Function
1236659|NCT01007747|Geranium oil
1236660|NCT01007747|Neuropathy
1236661|NCT01007734|Quality of life
1236662|NCT01007734|COPD patients
1236663|NCT01007734|Evaluation According to Gender the Determining Independent Factors of Quality of Life Related to Respiratory Status of Patient With Moderate to Severe COPD
1236664|NCT01007695|breast cancer
1236665|NCT01007682|intrusive memories
1236666|NCT01007669|Physical activity
1236667|NCT01007656|healthy adult subjects
1236668|NCT01007656|safety evaluation
1236669|NCT01007656|GD Antrodia camphorata
1236670|NCT01007643|anterior knee pain
1236671|NCT01007643|adolescents
1236672|NCT01007643|female
1236673|NCT01007643|interactive video games
1236674|NCT01007643|patellofemoral syndrome
1236675|NCT01007643|treatment
1236676|NCT01007643|compliance
1236677|NCT01007643|home exercises
1236678|NCT01007630|Parkinson's
1236679|NCT01007630|Parkinsons
1236680|NCT01007630|Parkinson
1236681|NCT01007630|Parkinson's Disease
1236682|NCT01007630|PD
1236683|NCT01007630|Rasagiline
1236684|NCT01007630|Azilect
1236685|NCT01007630|Olfactory
1236686|NCT01007630|Sense of Smell
1236687|NCT01007630|UPSIT
1236688|NCT01007617|Children
1236689|NCT01007617|Cancer
1236690|NCT01007617|Mucositis
1236691|NCT01007617|Laser
1236692|NCT01007617|Prevention
1236693|NCT01007617|Chemotherapy
1236694|NCT01007617|Children with malignancies receiving chemotherapy and/or radiotherapy inducing severe mucositis
1236695|NCT01007604|claudication
1236696|NCT01007604|pneumatic compression device
1236697|NCT01007578|Paclitaxel
1236698|NCT01007578|Paclitaxel-coated balloon catheters
1236699|NCT01007578|Peripheral arterial occlusive disease (PAOD)
1236700|NCT01007578|Plasma levels
1236701|NCT01007578|Femoral artery
1236702|NCT01007578|Popliteal artery
1236703|NCT01007578|Peripheral arterial disease (PAD) including stenotic or occluded femoro-popliteal arteries due to atherosclerosis
1236704|NCT01007565|periarticular injection
1236705|NCT01007552|Biliary Duct Cancer
1236706|NCT01007552|Cancer of the Gallbladder
1236707|NCT01007552|Adenocarcinoma of the Gall Bladder
1236708|NCT01007552|Adenocarcinoma of the Biliary Ducts
1236709|NCT01007552|Cholangiocarcinoma
1236710|NCT01007552|Extrahepatic cholangiocarcinoma
1236711|NCT01007526|Extranodal Lymphoma
1236712|NCT01007526|Natural killer cell
1236713|NCT01007526|T cell
1236714|NCT01007526|Radiotherapy
1236715|NCT01007526|Chemotherapy
1236716|NCT01007513|Prematurity
1236717|NCT01007513|Inflammation
1236718|NCT01007513|Transvaginal ultrasound
1236719|NCT01007513|Vaginal secretion
1236720|NCT01007513|Inflammatory process
1236721|NCT01007513|Neonatal morbidity
1236722|NCT01007500|Postoperative nausea and vomiting after video-assisted thoracoscopic surgery
1236723|NCT01007487|Plastic wound protector
1236724|NCT01007487|Plastic wound retractor
1236725|NCT01007487|Bacterial translocation
1236726|NCT01007487|Surgical site infection
1236727|NCT01007487|Abdominal surgery
1236728|NCT01007487|Wound infection
1236729|NCT01007461|Acute Myocardial Infarction (AMI)
1236730|NCT01007461|STEMI
1236731|NCT01007461|Acute ST-Segment Elevation Myocardial Infraction (STEMI)
1236732|NCT01007448|CTCL
1236733|NCT01007448|bexarotene
1236734|NCT01007448|Targretin
1236735|NCT01007448|Refractory Cutaneous T-cell Lymphoma
1236736|NCT01007448|cutaneous T-cell Lymphoma
1236737|NCT01007448|MF
1236738|NCT01007448|Mycoses fungoides
1236739|NCT01007422|unspecified adult solid tumor, protocol specific
1236740|NCT01007422|pain
1236741|NCT01007409|To assess food effect on the pharmacokinetics of fimasartan in healthy male volunteers
1236742|NCT01007396|Interferon-gamma release assay
1236743|NCT01007383|Safety and tolerability of LEO 27847
1236744|NCT01007370|tracheal intubation
1236745|NCT01007370|supraglottic airway devices
1236746|NCT01007344|flaxseed
1236747|NCT01007344|hypercholesterolemia
1236748|NCT01007344|children
1236749|NCT01007331|Infants
1236750|NCT01007331|Atopic Dermatitis
1236751|NCT01007331|SCORAD
1236752|NCT01007331|IgE
1236753|NCT01007331|Eosinophil Cation Protein
1236754|NCT01007331|Calprotectin
1236755|NCT01007331|Intestinal microflora
1236756|NCT01007292|Non-Hodgkin's Lymphoma
1236757|NCT01007292|relapsed
1236758|NCT01007292|CD20-Positive
1236759|NCT01007292|YM155
1236760|NCT01007279|Percutaneous angioplasty
1236761|NCT01007279|Myocardial Infarction
1236762|NCT01007266|Type 2 Diabetes Mellitus
1236763|NCT01007266|Adolescents
1236764|NCT01007266|Pediatric
1236765|NCT01007266|Patient Partner
1236766|NCT01007266|Buddy
1236767|NCT01007266|Obesity
1236768|NCT01007266|Type 2 Diabetes
1236769|NCT01007240|head and neck carcinoma
1236770|NCT01007240|obturators
1236771|NCT01007240|maxillectomy
1236772|NCT01007240|soft liner
1236773|NCT01007240|nano particles
1236774|NCT01007240|antibacterial properties
1236775|NCT01007240|patients post maxillectomy
1236776|NCT01007214|Prostate cancer
1236777|NCT01007214|Prostatectomy
1236778|NCT01007201|Influenza
1236779|NCT01007201|H1N1
1236780|NCT01007201|vaccine
1236781|NCT01007201|Immunogenicity
1236782|NCT01007188|almond
1236783|NCT01007188|nuts
1236784|NCT01007188|energy value
1236785|NCT01007188|cardiovascular disease
1236786|NCT01007188|phytonutrient
1236787|NCT01007188|gene expression
1236788|NCT01007188|energy value of almonds
1236789|NCT01007188|energy
1236790|NCT01007175|TNF inhibitor
1236791|NCT01007175|Multiple ascending dose study
1236792|NCT01007149|Severe asthma,
1236793|NCT01007149|non-atopic,
1236794|NCT01007149|omalizumab
1236795|NCT01007136|tDCS
1236796|NCT01007136|stroke
1236797|NCT01007136|functional MRI
1236798|NCT01007136|TMS
1236799|NCT01007123|Chronic idiopathic constipation
1236800|NCT01007123|A3309
1236801|NCT01007110|DHA
1236802|NCT01007097|Diabetes Mellitus, Non Insulin Dependent
1236803|NCT01007097|Diabetes Mellitus, Type II
1236804|NCT01007097|Type 2 Diabetes Mellitus
1236805|NCT01007097|Drug Therapy
1236806|NCT01007084|pain
1236807|NCT01007084|trauma
1236808|NCT01007084|propranolol
1236809|NCT01007058|Urinary Bladder
1236810|NCT01007058|Non-muscle-invasive transitional cell carcinoma
1236811|NCT01007058|Intact bladder
1236812|NCT01007058|Intravesical Bladder Cancer Therapy
1236813|NCT01007058|Tumor Recurrence
1236814|NCT01007058|Surrogate markers of response
1236815|NCT01007058|BCG
1236816|NCT01007058|Bacillus Calmette Guérin
1236817|NCT01007058|Interferon-alfa-2b
1236818|NCT01007058|IFN-alfa-2b
1236819|NCT01007058|Interferon
1236820|NCT01007058|Fluorescence in situ hybridization
1236821|NCT01007058|FISH
1236822|NCT01007045|deep vein thrombosis
1236823|NCT01007045|venous thromboembolic disorders
1236824|NCT01007045|diagnostic ultrasound
1236825|NCT01007032|anti-IGF-IR
1236826|NCT01007032|monoclonal
1236827|NCT01007032|solid tumor
1236828|NCT01007032|insulin-like growth factor
1236829|NCT01007019|Safety, tolerability and PK/PD
1236830|NCT01007006|Telepharmacy Robotic Medicine Delivery Unit
1236831|NCT01007006|Brain Injuries
1236832|NCT01007006|Stress Disorders
1236833|NCT01007006|Combat disorders
1236834|NCT01007006|Polytrauma
1236835|NCT01007006|Adherence
1236836|NCT01006967|balance
1236837|NCT01006967|gait
1236838|NCT01006967|physical therapy
1236839|NCT01006967|ActiveStep
1236840|NCT01006954|Poor responder
1236841|NCT01006954|Flare up
1236842|NCT01006954|Micro dose GnRH agonist flare up
1236843|NCT01006954|IVF/ICSI
1236844|NCT01006941|Multiple sclerosis
1236845|NCT01006941|safety
1236846|NCT01006941|MRI
1236847|NCT01006941|immunological
1236848|NCT01006941|Helminths
1236849|NCT01006941|Trichuris suis
1236850|NCT01006928|Subjective health feeling
1236851|NCT01006928|NICU
1236852|NCT01006928|team support
1236853|NCT01006915|Diabetic sensorimotor polyneuropathy
1236854|NCT01006902|Elderly
1236855|NCT01006902|Function
1236856|NCT01006902|Oncologic therapy
1236857|NCT01006902|Functional change with chemotherapy
1236858|NCT01006876|coumadin
1236859|NCT01006876|peri-procedural thromboembolism
1236860|NCT01006876|RFCA
1236861|NCT01006876|high risk atrial fibrillation
1236862|NCT01006863|Ephedrine
1236863|NCT01006863|phenylephrine
1236864|NCT01006863|hypotension
1236865|NCT01006863|propofol
1236866|NCT01006863|anesthesia
1236867|NCT01006863|cardiac valve surgery
1236868|NCT01006850|Acute pain hydromorphone emergency department
1236869|NCT01006837|trauma patients
1236870|NCT01006837|severe injury
1236871|NCT01006837|ISS ≥9
1236872|NCT01006824|Capsule endoscopy
1236873|NCT01006824|gastrointestinal hemorrhage
1236874|NCT01006811|West syndrome
1236875|NCT01006811|Hypsarrhythmia
1236876|NCT01006798|Virus Diseases
1236877|NCT01006798|Respiratory Tract Diseases
1236878|NCT01006798|Vaccine
1236879|NCT01006785|Breast Cancer
1236880|NCT01006785|DLBS 1425
1236881|NCT01006785|Cancer
1236882|NCT01006785|Advanced/Metastatic (Stage IIIB/IV) Breast Cancer
1236883|NCT01006772|Stroke
1236884|NCT01006772|Ankle Foot Orthosis
1236885|NCT01006772|Walking Speed
1236886|NCT01006772|Gait
1236887|NCT01006772|Rehabilitation
1236888|NCT01006772|Hemiplegia
1236889|NCT01006759|Leprosy
1236890|NCT01006759|Disability Evaluation
1236891|NCT01006759|Quality of Life
1236892|NCT01006759|Sensation
1236893|NCT01006746|Remote monitoring
1236894|NCT01006746|Defibrillators
1236895|NCT01006746|Survey
1236896|NCT01006746|Indication for ICD (primary and secondary prevention)
1236897|NCT01006733|pharmacogenetics
1236898|NCT01006733|arthroplasty
1236899|NCT01006733|VKORC1
1236900|NCT01006733|thromboembolism
1236901|NCT01006733|warfarin
1236902|NCT01006720|Residual neuromuscular block
1236903|NCT01006720|post-operative residual curarization
1236904|NCT01006720|PORC
1236905|NCT01006720|sugammadex
1236906|NCT01006720|neostigmine
1236907|NCT01006694|depression
1236908|NCT01006694|collaborative care
1236909|NCT01006694|Vietnam
1236910|NCT01006694|behavioral activation
1236911|NCT01006681|rheumatoid
1236912|NCT01006681|SLE
1236913|NCT01006681|Psoriatic arthritis
1236914|NCT01006681|Ankylosing
1236915|NCT01006681|Influenza H1N1
1236916|NCT01006681|Vaccine
1236917|NCT01006681|Vaccination against H1N1 in rheumatic diseases
1236918|NCT01006668|Neonates
1236919|NCT01006668|Intensive care
1236920|NCT01006668|Endotracheal intubation
1236921|NCT01006668|Neonates in intensive care
1236922|NCT01006655|asthma
1236923|NCT01006655|preschool children
1236924|NCT01006655|bronchial hyperresponsiveness
1236925|NCT01006655|beclometasone dipropionate - HFA
1236926|NCT01006655|Qvar
1236927|NCT01006655|Adenosine Challenge test
1236928|NCT01006629|Efficacy of palivizumab
1236929|NCT01006629|Respiratory syncytial virus (RSV) infection
1236930|NCT01006629|Prevention of severe RSV infection
1236931|NCT01006629|Preterm infants
1236932|NCT01006629|Infants with bronchopulmonary dysplasia
1236933|NCT01006629|Infants with hemodynamically significant congenital heart disease
1236934|NCT01006603|Type 2 Diabetes Mellitus
1236935|NCT01006603|elderly patients
1236936|NCT01006603|saxagliptin
1236937|NCT01006603|randomised
1236938|NCT01006603|double-blind
1236939|NCT01006590|Type 2 Diabetes Mellitus
1236940|NCT01006590|Saxagliptin
1236941|NCT01006590|Randomised
1236942|NCT01006590|Double-blind
1236943|NCT01006577|rectal cancer
1236944|NCT01006577|side-to-end anastomosis
1236945|NCT01006577|colon J pouch
1236946|NCT01006577|fecal incontinence
1236947|NCT01006577|anorectal function
1236948|NCT01006577|Are there differences between side-to-end anastomosis and colon J pouch in
1236949|NCT01006577|bowel function (fecal incontinence, frequency of bowel movements, rectal urgency, incomplete evacuation)
1236950|NCT01006577|quality of life
1236951|NCT01006577|postoperative complications
1236952|NCT01006577|operation time/ institutional costs
1236953|NCT01006564|Magnetic Resonance Imaging
1236954|NCT01006564|Prostate Cancer
1236955|NCT01006564|Magnetic Resonance Spectroscopy
1236956|NCT01006564|Radiotherapy planning
1236957|NCT01006551|Schizophrenia Spectrum Disorders
1236958|NCT01006538|Wet Age-related Macular Degeneration
1236959|NCT01006538|Predominantly classic
1236960|NCT01006538|Minimally classic
1236961|NCT01006538|Occult with no classic
1236962|NCT01006538|Retinal Angiomatous Proliferation (RAP) lesions
1236963|NCT01006499|neonatal sepsis
1236964|NCT01006499|pentoxyfilline
1236965|NCT01006499|pentaglobin
1236966|NCT01006499|biomarker
1236967|NCT01006499|To reduce mortality in neonatal sepsis
1236968|NCT01006486|Oral anticoagulants
1236969|NCT01006486|Warfarin
1236970|NCT01006486|Anticoagulation clinic
1236971|NCT01006486|Thrombosis
1236972|NCT01006486|Hemorrhage
1236973|NCT01006473|Chagas Disease
1236974|NCT01006473|Chagas Cardiomyopathy
1236975|NCT01006473|Exercise Movement Techniques
1236976|NCT01006460|Quality of life and subjective well-being in middle aged women
1236977|NCT01006447|tai chi
1236978|NCT01006447|exercise
1236979|NCT01006447|older adults
1236980|NCT01006447|exercise persistence
1236981|NCT01006434|Stroke
1236982|NCT01006434|Thrombolysis
1236983|NCT01006421|phototherapy
1236984|NCT01006421|Gingko biloba
1236985|NCT01006421|repigmentation
1236986|NCT01006408|Neuropathy
1236987|NCT01006395|Prostate Cancer
1236988|NCT01006395|Androgen deprivation
1236989|NCT01006395|Bone Health
1236990|NCT01006395|Insulin resistance
1236991|NCT01006395|Men with nonmetastatic prostate cancer receiving androgen deprivation
1236992|NCT01006369|stage IV colon cancer
1236993|NCT01006369|stage IV rectal cancer
1236994|NCT01006369|recurrent colon cancer
1236995|NCT01006369|recurrent rectal cancer
1236996|NCT01006356|Hydromorphone hydrochloride Oral Osmotic System
1236997|NCT01006356|Jurnista
1236998|NCT01006317|Maternal health services
1236999|NCT01006317|utilization
1237000|NCT01006317|education
1237001|NCT01006317|randomized controlled trial
1237002|NCT01006317|cost
1237003|NCT01006317|clinical skills
1237004|NCT01006317|rural China
1237005|NCT01006304|JNJ-39439335
1237006|NCT01006304|Placebo
1237007|NCT01006304|Pain
1237008|NCT01006304|Pain Measurements
1237009|NCT01006304|Adults
1237010|NCT01006304|Men
1237011|NCT01006278|biomarker
1237012|NCT01006278|knee arthroscopy
1237013|NCT01006278|pain
1237014|NCT01006252|metastatic
1237015|NCT01006252|second-line
1237016|NCT01006239|Cancer
1237017|NCT01006213|Motivational Intervention
1237018|NCT01006200|granulation tissue
1237019|NCT01006200|benign
1237020|NCT01006200|tracheal stenosis
1237021|NCT01006200|ultraflex
1237022|NCT01006200|COPD
1237023|NCT01006187|Analgesics
1237024|NCT01006187|Influenza
1237025|NCT01006187|Vapocoolant
1237026|NCT01006187|vaccination
1237027|NCT01006187|pain
1237028|NCT01006148|Metopic Craniosynostosis
1237029|NCT01006122|Randomized
1237030|NCT01006122|double-blind
1237031|NCT01006122|placebo-controlled
1237032|NCT01006122|crossover study of PF-03654746 in Excessive Daytime Sleepiness associated with Narcolepsy
1237033|NCT01006109|MEG
1237034|NCT01006109|Repetitive TMS (rTMS)
1237035|NCT01006109|Decision-Making
1237036|NCT01006109|Healthy Volunteers
1237037|NCT01006109|HV
1237038|NCT01006109|Healthy Volunteer
1237039|NCT01006096|Psoriasis
1237040|NCT01006096|double-blind
1237041|NCT01006096|randomized
1237042|NCT01006096|placebo-controlled
1237043|NCT01006096|erlotinib
1237044|NCT01006096|efficacy
1237045|NCT01006083|Aspirin
1237046|NCT01006083|Plavix
1237047|NCT01006083|antiplatelet therapy
1237048|NCT01006083|Hemorrhage
1237049|NCT01006083|ischemic events
1237050|NCT01006070|multiple myeloma
1237051|NCT01006070|spinal disease
1237052|NCT01006044|Glioblastoma multiforme, vaccine, dendritic cells, glioma
1237053|NCT01006031|Liver cirrhosis
1237054|NCT01006031|Hepatitis C virus
1237055|NCT01006031|HIV infection
1237056|NCT01006031|Pegylated interferon alfa-2a
1237057|NCT01006031|Ribavirin
1237058|NCT01006031|Treatment experienced
1237059|NCT01006018|Prediabetic State
1237060|NCT01006005|HIV
1237061|NCT01006005|Treatment experienced
1237062|NCT01005992|Scars secondary to injuries to tissues caused by contact with physical (heat, electricity) o chemical agent.
1237063|NCT01005979|Leukemia, Lymphocytic, Chronic, B-Cell
1237064|NCT01005979|Chronic Lymphocytic Leukemia
1237065|NCT01005979|Lymphoma, Small Lymphocytic
1237066|NCT01005979|Lymphoma
1237067|NCT01005979|Leukemia
1237068|NCT01005966|remineralization
1237069|NCT01005966|enamel
1237070|NCT01005966|in situ
1237071|NCT01005966|fluoride
1237072|NCT01005966|caries
1237073|NCT01005953|Autism
1237074|NCT01005953|Behavioral Observations
1237075|NCT01005953|Electronic diaries
1237076|NCT01005953|Professionals treating children 3-10 with lower functioning autism
1237077|NCT01005940|Sleep Apnea Syndromes
1237078|NCT01005940|Insulin Resistance
1237079|NCT01005940|Mandibular advancement device
1237080|NCT01005927|Calcium
1237081|NCT01005927|Bone and Bones
1237082|NCT01005927|Girls
1237083|NCT01005927|Bone Mineralization
1237084|NCT01005927|Fiber
1237085|NCT01005927|Fructooligosaccharide
1237086|NCT01005927|Female
1237087|NCT01005927|Healthy
1237088|NCT01005927|Adolescents
1237089|NCT01005914|adults
1237090|NCT01005914|Philadelphia chromosome precursor ALL,
1237091|NCT01005914|T-cell ALL
1237092|NCT01005914|untreated ALL
1237093|NCT01005901|COPD
1237094|NCT01005901|NVA
1237095|NCT01005901|FEV1
1237096|NCT01005888|Hereditary angioedema
1237097|NCT01005888|HAE
1237098|NCT01005888|C1 esterase inhibitor (human)
1237099|NCT01005888|C1INH-nf
1237100|NCT01005875|Hepatocellular carcinoma
1237101|NCT01005875|HCC
1237102|NCT01005875|Liver Cancer
1237103|NCT01005875|adult primary hepatocellular carcinoma
1237104|NCT01005862|Alzheimer's disease antibody leucine ABeta
1237105|NCT01005849|Probiotics
1237106|NCT01005849|Traveler's diarrhea
1237107|NCT01005849|Prevention
1237108|NCT01005836|Cognitive behavioral therapy
1237109|NCT01005836|Anxiety treatment
1237110|NCT01005836|Depression treatment
1237111|NCT01005836|Child treatment
1237112|NCT01005836|Usual care
1237113|NCT01005797|Renal Cancer
1237114|NCT01005797|Non Small Cell Lung Cancer (NSCLC)
1237115|NCT01005797|Solid Tumor
1237116|NCT01005797|Soft tissue sarcoma
1237117|NCT01005797|Sorafenib
1237118|NCT01005797|Panobinostat
1237119|NCT01005784|GnRH antagonists
1237120|NCT01005771|Secondarily infected traumatic lesions
1237121|NCT01005758|untreated adult acute lymphoblastic leukemia
1237122|NCT01005758|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
1237123|NCT01005758|L1 adult acute lymphoblastic leukemia
1237124|NCT01005758|L2 adult acute lymphoblastic leukemia
1237125|NCT01005758|T-cell adult acute lymphoblastic leukemia
1237126|NCT01005745|skin
1237127|NCT01005745|adoptive cell therapy
1237128|NCT01005745|tumor-infiltrating lymphocytes (TIL)
1237129|NCT01005745|lymphodepletion
1237130|NCT01005732|hypertrophic
1237131|NCT01005732|scar
1237132|NCT01005732|burn
1237133|NCT01005732|cicatrix
1237134|NCT01005732|pressure
1237135|NCT01005732|garment
1237136|NCT01005693|unspecified adult solid tumor, protocol specific
1237137|NCT01005667|Nulliparous women in spontaneous labor
1237138|NCT01005654|Gene Expression
1237139|NCT01005654|Epigenetics
1237140|NCT01005654|Tissues Histological Evaluations
1237141|NCT01005654|Establishment of Tumor Cell Lines
1237142|NCT01005654|Metabolite and Protein Expression
1237143|NCT01005654|Adrenal Cancer
1237144|NCT01005654|Endocrine Tumor
1237145|NCT01005654|Thyroid Cancer
1237146|NCT01005641|advanced breast cancer
1237147|NCT01005641|hormone-responsive
1237148|NCT01005641|metastatic breast cancer
1237149|NCT01005628|Bortezomib postmarketing surveillance
1237150|NCT01005628|Korea bortezomib PMS
1237151|NCT01005602|Digoxin
1237152|NCT01005602|Pharmacokinetics
1237153|NCT01005602|Dosing
1237154|NCT01005602|Heart Failure
1237155|NCT01005589|Neonatal sepsis
1237156|NCT01005589|Necrotizing enterocolitis
1237157|NCT01005589|CD64 antigen
1237158|NCT01005589|Receptors, IgG
1237159|NCT01005576|Thalassemia
1237160|NCT01005576|Alemtuzumab
1237161|NCT01005576|Hematopoietic cell transplant
1237162|NCT01005576|non-myeloablative
1237163|NCT01005550|Unilateral spinal anaesthesia
1237164|NCT01005550|Hypobaric anaesthesia
1237165|NCT01005550|Ropivacaine
1237166|NCT01005550|Traumatic hip surgery
1237167|NCT01005537|stage IV melanoma
1237168|NCT01005524|brain computer interface
1237169|NCT01005524|P3Speller
1237170|NCT01005524|P300
1237171|NCT01005524|Event Related potential
1237172|NCT01005524|tetraplegia
1237173|NCT01005524|Guillain barre syndrome
1237174|NCT01005524|Feasibility
1237175|NCT01005524|Speed of spelling
1237176|NCT01005524|Accuracy
1237177|NCT01005511|Bruxism
1237178|NCT01005498|Low carbohydrate diet. Dietary treatment of diabetes mellitus.
1237179|NCT01005498|Diabetes mellitus type 2 and dietary treatment.
1237180|NCT01005485|Myocardial Infarction (MI)
1237181|NCT01005485|Circulating Endothelial Cells (CEC)
1237182|NCT01005485|Control Group A: (Vascular Surgery)
1237183|NCT01005485|Control Group B: (Healthy controls)
1237184|NCT01005472|stage III melanoma
1237185|NCT01005472|stage IV melanoma
1237186|NCT01005472|recurrent melanoma
1237187|NCT01005472|ciliary body and choroid melanoma, medium/large size
1237188|NCT01005472|extraocular extension melanoma
1237189|NCT01005472|iris melanoma
1237190|NCT01005472|metastatic intraocular melanoma
1237191|NCT01005472|recurrent intraocular melanoma
1237192|NCT01005459|labor pain
1237193|NCT01005459|combined spinal epidural labor analgesia
1237194|NCT01005459|CSE analgesia
1237195|NCT01005459|labor analgesia
1237196|NCT01005433|dexmedetomidine
1237197|NCT01005433|stress response
1237198|NCT01005433|cesarean delivery
1237199|NCT01005420|Insulin Sensitivity
1237200|NCT01005420|Pre-diabetes
1237201|NCT01005420|Diabetes
1237202|NCT01005420|Blueberries
1237203|NCT01005420|Anthocyanins
1237204|NCT01005407|HBV vaccine
1237205|NCT01005407|Hepatitis B vaccine
1237206|NCT01005407|Hepatitis B
1237207|NCT01005407|Hepatitis
1237208|NCT01005407|HBV
1237209|NCT01005407|Prevention & Control
1237210|NCT01005407|Healthy
1237211|NCT01005407|Healthy volunteers
1237212|NCT01005381|Calcium
1237213|NCT01005381|Vitamin D
1237214|NCT01005381|Particle Size
1237215|NCT01005381|Adolescents
1237216|NCT01005381|Bone
1237217|NCT01005381|Osteoporosis
1237218|NCT01005368|chronic lymphocytic leukemia
1237219|NCT01005355|Solid tumor
1237220|NCT01005355|recombinant human IgG1
1237221|NCT01005355|MAB
1237222|NCT01005355|monoclonal antibody
1237223|NCT01005355|VEGFR 2
1237224|NCT01005355|human vascular endothelial growth factor receptor 2
1237225|NCT01005342|gene expression
1237226|NCT01005342|oats
1237227|NCT01005342|rye
1237228|NCT01005342|sugar beet fiber
1237229|NCT01005342|glucose
1237230|NCT01005342|insulin
1237231|NCT01005342|triglyceride
1237232|NCT01005342|decreased postprandial glucose
1237233|NCT01005342|decreased postprandial insulin
1237234|NCT01005342|glycemic index
1237235|NCT01005316|cohort study
1237236|NCT01005316|allo-antibodies
1237237|NCT01005316|allosensitization
1237238|NCT01005303|Heart Failure
1237239|NCT01005303|Micronutrients
1237240|NCT01005303|Vitamin D
1237241|NCT01005303|Inflammation
1237242|NCT01005303|Oxidative Stress
1237243|NCT01005303|Quality of Life
1237244|NCT01005303|Physical Functioning
1237245|NCT01005290|cardiovascular
1237246|NCT01005290|fixed
1237247|NCT01005290|dose
1237248|NCT01005290|combination
1237249|NCT01005290|pill
1237250|NCT01005290|hypertension
1237251|NCT01005277|childhood acute lymphoblastic leukemia in remission
1237252|NCT01005277|recurrent childhood acute lymphoblastic leukemia
1237253|NCT01005277|childhood acute myeloid leukemia in remission
1237254|NCT01005277|childhood acute myeloid leukemia/other myeloid malignancies
1237255|NCT01005277|recurrent childhood acute myeloid leukemia
1237256|NCT01005277|secondary acute myeloid leukemia
1237257|NCT01005277|adult acute myeloid leukemia with inv(16)(p13;q22)
1237258|NCT01005277|adult acute myeloid leukemia with t(15;17)(q22;q12)
1237259|NCT01005277|adult acute myeloid leukemia with t(8;21)(q22;q22)
1237260|NCT01005264|diabetic foot
1237261|NCT01005264|neuropathic plantar ulcer
1237262|NCT01005264|ulcer healing
1237263|NCT01005264|non-removable total contact cast
1237264|NCT01005264|removable cast walker
1237265|NCT01005251|GERD treatment
1237266|NCT01005251|Acid and non-acid Reflux
1237267|NCT01005251|Heartburn
1237268|NCT01005251|Regurgitation
1237269|NCT01005251|Add-on treatment to PPI
1237270|NCT01005225|Solid tumor
1237271|NCT01005225|prostate cancer
1237272|NCT01005225|colon cancer
1237273|NCT01005212|EVAR
1237274|NCT01005212|Ultrasounds
1237275|NCT01005212|AAA
1237276|NCT01005212|endoleaks after endovascular repair of AAA
1237277|NCT01005199|adult primary hepatocellular carcinoma
1237278|NCT01005199|localized unresectable adult primary liver cancer
1237279|NCT01005173|Acetaminophen
1237280|NCT01005173|APAP
1237281|NCT01005160|Mellitus, type 2
1237282|NCT01005160|pharmacokinetic evaluation
1237283|NCT01005160|drug interaction between CKD-501 and metformin
1237284|NCT01005147|tranexamic acid
1237285|NCT01005147|upper GI bleeding
1237286|NCT01005147|blood transfusion
1237287|NCT01005147|GI bleeding
1237288|NCT01005108|Hot Flashes for Breast Cancer Patients
1237289|NCT01005082|Low salt diet, idiopathic hypercalciuria, calcium stone formers
1237290|NCT01005082|Calcium stone formers with idiopathic hypercalciuria
1237291|NCT01005069|diabetes mellitus
1237292|NCT01005069|DLBS-32
1237293|NCT01005069|fasting plasma glucose
1237294|NCT01005069|insulin resistance
1237295|NCT01005043|non-resectable osteosarcoma
1237296|NCT01005043|heavy ion radiotherapy
1237297|NCT01005043|particle therapy
1237298|NCT01005043|safety
1237299|NCT01005043|toxicity
1237300|NCT01005043|survival
1237301|NCT01005043|radiotherapy
1237302|NCT01005030|Parkinson Disease
1237303|NCT01005030|blood
1237304|NCT01005030|plasma
1237305|NCT01005030|metabolomics
1237306|NCT01005030|spectroscopy
1237307|NCT01005030|oxidative stress.
1237308|NCT01005017|Radiofrequent ablation
1237309|NCT01005017|Percutaneous radiofrequent therapy
1237310|NCT01005004|PMD
1237311|NCT01005004|stem cells
1237312|NCT01005004|Pelizaeus-Merzbacher Disease
1237313|NCT01005004|human stem cells
1237314|NCT01005004|central nervous system stem cells
1237315|NCT01004965|untreated adult acute lymphoblastic leukemia
1237316|NCT01004965|untreated adult acute myeloid leukemia
1237317|NCT01004965|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1237318|NCT01004965|adult acute myeloid leukemia with inv(16)(p13;q22)
1237319|NCT01004965|adult acute myeloid leukemia with t(15;17)(q22;q12)
1237320|NCT01004965|adult acute myeloid leukemia with t(16;16)(p13;q22)
1237321|NCT01004965|adult acute myeloid leukemia with t(8;21)(q22;q22)
1237322|NCT01004952|Skin
1237323|NCT01004952|Sunscreen
1237324|NCT01004952|UVR Protection
1237325|NCT01004952|09-137
1237326|NCT01004939|prophylaxis
1237327|NCT01004939|venous thromboembolism
1237328|NCT01004939|postpartum
1237329|NCT01004939|fondaparinux
1237330|NCT01004939|pregnancy
1237331|NCT01004926|Unilateral trans-tibial amputees
1237332|NCT01004913|Benign paroxysmal positional vertigo
1237333|NCT01004913|Vestibular evoked myogenic potentials
1237334|NCT01004913|Sacculo-colic reflex
1237335|NCT01004900|Glaucoma, Angle Closure
1237336|NCT01004900|Selective laser trabeculoplasty
1237337|NCT01004900|Primary Angle Closure Disease
1237338|NCT01004887|adult anaplastic astrocytoma
1237339|NCT01004887|adult giant cell glioblastoma
1237340|NCT01004887|adult gliosarcoma
1237341|NCT01004887|childhood high-grade cerebellar astrocytoma
1237342|NCT01004887|childhood high-grade cerebral astrocytoma
1237343|NCT01004874|malignant glioma
1237344|NCT01004874|glioblastoma multiforme
1237345|NCT01004874|gliosarcoma
1237346|NCT01004874|Avastin
1237347|NCT01004874|bevacizumab
1237348|NCT01004874|Topotecan
1237349|NCT01004874|Hycamtin
1237350|NCT01004874|Temozolomide
1237351|NCT01004874|Temodar
1237352|NCT01004874|Pro00019960
1237353|NCT01004874|Vredenburgh
1237354|NCT01004874|Duke
1237355|NCT01004861|PVNS
1237356|NCT01004848|Pre-diabetes
1237357|NCT01004848|pre-diabetic state
1237358|NCT01004848|community-based participatory research
1237359|NCT01004848|overweight
1237360|NCT01004848|weight loss intervention, peer-led lifestyle education
1237361|NCT01004835|migraine
1237362|NCT01004822|Treatment Non-Randomized Single Group Assignment Safety Study Neoplasms Carcinoma Cancer Malignancy
1237363|NCT01004809|Dutasteride
1237364|NCT01004796|breast cancer
1237365|NCT01004783|stage I Wilms tumor
1237366|NCT01004783|stage II Wilms tumor
1237367|NCT01004783|epithelial predominant Wilms tumor
1237368|NCT01004770|CECT - Contrast-enhanced computed tomography
1237369|NCT01004770|HCG - Human Chorionic Gonadotropin
1237370|NCT01004770|HU - Hounsfield Units
1237371|NCT01004770|Patient Safety
1237372|NCT01004770|Tolerance
1237373|NCT01004770|Pharmacokinetic
1237374|NCT01004757|diastolic function
1237375|NCT01004757|postmeal glucose
1237376|NCT01004757|insulin resistance
1237377|NCT01004757|low carb diet
1237378|NCT01004757|type 2 diabetes
1237379|NCT01004744|Postmenopausal women
1237380|NCT01004744|ER+
1237381|NCT01004744|Estrogen positive
1237382|NCT01004744|PR+
1237383|NCT01004744|Progesterone positive
1237384|NCT01004731|EGFr
1237385|NCT01004731|cetuximab
1237386|NCT01004731|gemcitabine
1237387|NCT01004731|carboplatin
1237388|NCT01004731|NSCLC
1237389|NCT01004705|cardiovascular
1237390|NCT01004705|fixed
1237391|NCT01004705|dose
1237392|NCT01004705|combination
1237393|NCT01004705|pill
1237394|NCT01004705|LDL
1237395|NCT01004705|cholesterol
1237396|NCT01004666|Breast cancer
1237397|NCT01004666|Scintimammography
1237398|NCT01004666|CZT
1237399|NCT01004666|High-risk
1237400|NCT01004640|chronic myelogenous leukemia
1237401|NCT01004627|fistula
1237402|NCT01004627|ultrasound
1237403|NCT01004627|angioaccess
1237404|NCT01004627|preoperative vein mapping
1237405|NCT01004627|Haemodialysis
1237406|NCT01004627|Angioaccess surgery
1237407|NCT01004601|pretreated failure advanced stage IIIb/IV NSCLC
1237408|NCT01004588|elderly
1237409|NCT01004588|sarcopenia
1237410|NCT01004588|protein drink
1237411|NCT01004588|resistance training
1237412|NCT01004575|stents
1237413|NCT01004575|bare metal stents
1237414|NCT01004562|breast cancer
1237415|NCT01004549|Patients who have previously undergone bilateral intraocular lens implantation
1237416|NCT01004523|childhood low-grade cerebellar astrocytoma
1237417|NCT01004523|childhood low-grade cerebral astrocytoma
1237418|NCT01004523|childhood mixed glioma
1237419|NCT01004523|adult mixed glioma
1237420|NCT01004523|adult diffuse astrocytoma
1237421|NCT01004523|childhood oligodendroglioma
1237422|NCT01004523|adult oligodendroglioma
1237423|NCT01004510|malignant pleural effusion
1237424|NCT01004510|non small cell lung cancer
1237425|NCT01004497|Acute lymphoblastic leukemia, adult, dasatinib
1237426|NCT01004484|non-patients
1237427|NCT01004484|non-diarrhea functional bowel symptoms
1237428|NCT01004471|Nasal dilator strip
1237429|NCT01004471|Sleep disordered breathing
1237430|NCT01004458|fibromyalgia
1237431|NCT01004458|cognitive behavioral therapy
1237432|NCT01004458|women
1237433|NCT01004458|pain
1237434|NCT01004458|stress
1237435|NCT01004458|type A behavior
1237436|NCT01004445|Pneumonia
1237437|NCT01004445|Adjunctive treatment
1237438|NCT01004445|Gram-negative bacteria
1237439|NCT01004432|humira, remicade
1237440|NCT01004432|rheumatoid arthritis
1237441|NCT01004432|enbrel failure
1237442|NCT01004432|humira failure
1237443|NCT01004432|arthritis
1237444|NCT01004432|enbrel
1237445|NCT01004419|non small cell lung cancer
1237446|NCT01004419|vandetanib
1237447|NCT01004419|ZD6474
1237448|NCT01004419|fulvestrant
1237449|NCT01004419|faslodex
1237450|NCT01004419|phase 1
1237451|NCT01004406|plaque
1237452|NCT01004406|LDL
1237453|NCT01004406|statin
1237454|NCT01004406|endothelial
1237455|NCT01004406|apheresis
1237456|NCT01004406|acute coronary syndrome
1237457|NCT01004393|Methylnaltrexone
1237458|NCT01004393|Constipation
1237459|NCT01004393|Narcotic Antagonists
1237460|NCT01004393|Analgesics, Opioid
1237461|NCT01004393|Neoplasms
1237462|NCT01004380|Epithelial Ovarian Cancer
1237463|NCT01004380|Ovarian Cancer
1237464|NCT01004367|Promoting healthy lifestyles in adolescents in Ecuador to prevent overweight
1237465|NCT01004354|Psychiatric illnesses
1237466|NCT01004354|Vitamin D deficiency
1237467|NCT01004354|Obesity
1237468|NCT01004341|pediatric obesity
1237469|NCT01004341|parenting style
1237470|NCT01004341|feeding style
1237471|NCT01004341|behavioral skills
1237472|NCT01004341|parenting skills
1237473|NCT01004341|family meals
1237474|NCT01004328|patient safety
1237475|NCT01004328|care transitions
1237476|NCT01004328|therapeutic monitoring
1237477|NCT01004328|skilled nursing facilities
1237478|NCT01004328|Adverse outcomes after discharge from a SNF to home
1237479|NCT01004315|Overactive bladder
1237480|NCT01004315|Frequency
1237481|NCT01004315|Micturition
1237482|NCT01004315|Urgency
1237483|NCT01004315|Urge urinary incontinence
1237484|NCT01004315|OAB
1237485|NCT01004302|Obsessive-compulsive disorder
1237486|NCT01004302|Radiosurgery
1237487|NCT01004302|Psychosurgery
1237488|NCT01004302|Treatment outcome
1237489|NCT01004302|Randomized Controlled Trials
1237490|NCT01004289|Acute myocardial infarction
1237491|NCT01004289|Primary percutaneous coronary intervention
1237492|NCT01004289|Postconditioning
1237493|NCT01004276|primary health care
1237494|NCT01004276|delivery of health care
1237495|NCT01004276|smoking cessation
1237496|NCT01004276|chronic disease
1237497|NCT01004276|disease management
1237498|NCT01004276|pilot projects
1237499|NCT01004263|acute migraine with or without aura in adolescents
1237500|NCT01004237|insulin resistance
1237501|NCT01004237|hypertensive
1237502|NCT01004237|hypercholesterolemic patients
1237503|NCT01004224|advanced solid tumors
1237504|NCT01004224|lung cancer
1237505|NCT01004224|bladder cancer
1237506|NCT01004224|BGJ398
1237507|NCT01004224|FGFR
1237508|NCT01004224|kinase inhibitor
1237509|NCT01004224|advanced solid malignancies
1237510|NCT01004211|bladder cancer
1237511|NCT01004211|recurrence
1237512|NCT01004198|Trauma
1237513|NCT01004198|Hemorrhage
1237514|NCT01004198|Hemorrhagic shock
1237515|NCT01004198|Lactic acidosis
1237516|NCT01004198|Oxygen carriers
1237517|NCT01004198|Oxygen therapeutics
1237518|NCT01004198|Hemoglobin solutions
1237519|NCT01004198|Hemoglobin substitutes
1237520|NCT01004198|Red cell substitutes
1237521|NCT01004198|PEG-hemoglobin
1237522|NCT01004172|carboplatin
1237523|NCT01004172|bevacizumab
1237524|NCT01004159|Colorectal cancer
1237525|NCT01004159|KRAS wild type tumors
1237526|NCT01004146|incentive spirometry
1237527|NCT01004146|bariatric surgery
1237528|NCT01004146|obesity
1237529|NCT01004133|Age 80 or older
1237530|NCT01004133|No chronic disease
1237531|NCT01004094|children
1237532|NCT01004094|video games
1237533|NCT01004094|internet
1237534|NCT01004094|parents
1237535|NCT01004094|fruit
1237536|NCT01004094|vegetable
1237537|NCT01004094|implementation intention
1237538|NCT01004094|goal setting
1237539|NCT01004094|fruit and vegetable consumption
1237540|NCT01004094|obesity prevention
1237541|NCT01004094|cancer prevention
1237542|NCT01004081|Cancer of Breast
1237543|NCT01004081|Cancer of the Breast
1237544|NCT01004068|Clomiphene
1237545|NCT01004068|Diet
1237546|NCT01004068|Exercise
1237547|NCT01004068|Infertility
1237548|NCT01004068|PCOS
1237549|NCT01004068|Physical activity
1237550|NCT01004068|Treatment
1237551|NCT01004055|Wound
1237552|NCT01004055|Skin lesion
1237553|NCT01004055|Antimicrobial
1237554|NCT01004055|Bioelectric
1237555|NCT01004042|Depression
1237556|NCT01004042|Botulinum toxin
1237557|NCT01004042|Glabella
1237558|NCT01004042|Quality of life
1237559|NCT01004042|Self-steem
1237560|NCT01004029|17P
1237561|NCT01004029|hydroxyprogesterone caproate
1237562|NCT01004029|preterm birth
1237563|NCT01004029|progesterone
1237564|NCT01004029|women with a singleton pregnancy aged 18 years or older with a history of a previous singleton spontaneous preterm delivery
1237565|NCT01004016|Spinocerebellar degeneration
1237566|NCT01004016|Thyrotropin-Releasing Hormone (TRH)
1237567|NCT01004016|SCD
1237568|NCT01003990|Treatment experienced
1237569|NCT01003964|NON-SMALL CELL LUNG CANCER
1237570|NCT01003964|excision repair cross-complementing 1
1237571|NCT01003964|Gemcitabine and cisplatin
1237572|NCT01003964|Irinotecan and cisplatin
1237573|NCT01003964|Pemetrexed
1237574|NCT01003964|Docetaxel
1237575|NCT01003964|advanced NSCLC
1237576|NCT01003951|Lymphedema
1237577|NCT01003951|Acupuncture
1237578|NCT01003951|09-136
1237579|NCT01003938|chemotherapy
1237580|NCT01003938|combination therapy
1237581|NCT01003938|targeted therapy
1237582|NCT01003938|second-line
1237583|NCT01003925|Knee pain, osteoarthritis, non-surgical treatment, age 65+
1237584|NCT01003912|Lysosomal Storage Diseases
1237585|NCT01003912|Inborn Errors of Metabolism
1237586|NCT01003912|Krabbe
1237587|NCT01003912|Infantile metachromatic leukodystrophy disease
1237588|NCT01003912|MLD
1237589|NCT01003912|Tay Sachs
1237590|NCT01003912|Sandhoff
1237591|NCT01003912|GM2 gangliosidoses
1237592|NCT01003912|Pelizaeus-Merzbacher disease
1237593|NCT01003912|PMD
1237594|NCT01003886|post marketing surveillance Filipino benign prostatic hyperplasia BPH Doxazosin GITS
1237595|NCT01003873|morbid obesity
1237596|NCT01003873|bariatric surgery
1237597|NCT01003873|lifestyle intervention
1237598|NCT01003873|endocannabinoids system
1237599|NCT01003860|postoperative analgesia
1237600|NCT01003847|Insulin resistance
1237601|NCT01003834|substance use
1237602|NCT01003834|drug use
1237603|NCT01003834|drug abuse
1237604|NCT01003782|cholangitis
1237605|NCT01003782|antibiotic
1237606|NCT01003782|bacteriobilia
1237607|NCT01003782|bile
1237608|NCT01003782|ERCP
1237609|NCT01003756|Preoperative
1237610|NCT01003756|Exercise
1237611|NCT01003756|Joint Replacement
1237612|NCT01003756|Hip
1237613|NCT01003756|Knee
1237614|NCT01002781|Tocilizumab Still
1237615|NCT01002755|Leukemia
1237616|NCT01002755|CLL
1237617|NCT01002755|SLL
1237618|NCT01002755|Lenalidomide
1237619|NCT01002755|Ofatumumab
1237620|NCT01002742|GVHD
1237621|NCT01002729|Oseltamivir Pharmacokinetics Obesity
1237622|NCT01002729|Oseltamivir Pharmacokinetics in Obesity
1237623|NCT01002716|rheumatoid influenza vaccine cell immunity
1237624|NCT01003730|Intraoperative protective ventilation strategies
1237625|NCT01003691|Phase 1b Advanced Dry Age-Related Macular Degeneration RN6G
1237626|NCT01003678|Myelodysplastic syndrome
1237627|NCT01003678|Clofarabine
1237628|NCT01003678|low-dose oral clofarabine
1237629|NCT01003678|intermediate risk Myelodysplastic syndrome
1237630|NCT01003678|high risk Myelodysplastic syndrome
1237631|NCT01003652|goiter
1237632|NCT01003639|papilledema
1237633|NCT01003639|vision loss
1237634|NCT01003639|headache
1237635|NCT01003639|obesity
1237636|NCT01003639|women
1237637|NCT01003639|diplopia
1237638|NCT01003639|tinnitus
1237639|NCT01003626|Advanced cutaneous melanoma
1237640|NCT01003626|Tumor Pressure
1237641|NCT01003626|Tumor IFP
1237642|NCT01003626|Interstitial Fluid Pressure
1237643|NCT01003626|IFP
1237644|NCT01003626|Transducer-tipped catheter Mikro-Tip SPC-320
1237645|NCT01003626|Transducer Millar
1237646|NCT01003626|Power Lab 8/30 amplifier
1237647|NCT01003613|Tranilast
1237648|NCT01003613|fibrin glue
1237649|NCT01003613|primary pterygium
1237650|NCT01003613|conjunctival autograft
1237651|NCT01003600|Survivorship
1237652|NCT01003600|Quality of Life
1237653|NCT01003600|Questionnaire
1237654|NCT01003600|09-133
1237655|NCT01003587|India
1237656|NCT01003587|evidence-based policy
1237657|NCT01003587|knowledge translation
1237658|NCT01003587|disease control priorities
1237659|NCT01003587|decision-makers
1237660|NCT01003587|health spending
1237661|NCT01003587|health services delivery
1237662|NCT01003587|maternal and child health
1237663|NCT01003587|policy making
1237664|NCT01003587|delivery of health care
1237665|NCT01003574|cardiovascular health outcomes in cancer survivors
1237666|NCT01003561|ultrasonographic exam on upper and lower extremities
1237667|NCT01003548|Embryo culture
1237668|NCT01003548|IVF
1237669|NCT01003548|Microfluidics
1237670|NCT01003548|infertility
1237671|NCT01003535|Parkinson´s disease
1237672|NCT01003535|Acetylcholine receptors
1237673|NCT01003522|Bronchial stents
1237674|NCT01003522|Airway obstruction
1237675|NCT01003522|Non-small cell lung cancer
1237676|NCT01003509|inguinal
1237677|NCT01003509|hernia
1237678|NCT01003509|new
1237679|NCT01003509|repair
1237680|NCT01003509|modified shouldice
1237681|NCT01003509|double
1237682|NCT01003496|Cocaine
1237683|NCT01003496|crack
1237684|NCT01003496|heroin
1237685|NCT01003496|non-prescribed opioids
1237686|NCT01003496|contingency management
1237687|NCT01003496|community reinforcement approach
1237688|NCT01003496|facilitated therapeutic alliance
1237689|NCT01003496|chronic disease treatment models
1237690|NCT01003483|metformin
1237691|NCT01003483|orlistat
1237692|NCT01003483|pcos
1237693|NCT01003483|obese
1237694|NCT01003470|cerebral infarction
1237695|NCT01003470|Paralysis
1237696|NCT01003470|acupuncture
1237697|NCT01003470|rehabilitation
1237698|NCT01003470|trial
1237699|NCT01003444|Muscle biopsy Malonyl CoA Biomarker assay
1237700|NCT01003418|GSK2340272A
1237701|NCT01003418|H1N1 pandemic influenza
1237702|NCT01003405|Overactive bladder
1237703|NCT01003405|Frequency
1237704|NCT01003405|Micturition
1237705|NCT01003405|Urgency
1237706|NCT01003405|Urge urinary incontinence
1237707|NCT01003405|OAB
1237708|NCT01003392|Coronary artery disease
1237709|NCT01003392|Coffee
1237710|NCT01003392|Heart system
1237711|NCT01003379|cognitive dysfunction
1237712|NCT01003379|schizophrenia
1237713|NCT01003379|Phase 2
1237714|NCT01003366|safety during central venous catheterization
1237715|NCT01003353|Stroke
1237716|NCT01003353|Strength training
1237717|NCT01003353|exercise therapy
1237718|NCT01003340|asthma
1237719|NCT01003340|children
1237720|NCT01003340|community health workers
1237721|NCT01003340|home intervention
1237722|NCT01003327|laryngeal mask, leak pressure
1237723|NCT01003327|leak pressure
1237724|NCT01003314|Vaccine
1237725|NCT01003314|Safety
1237726|NCT01003314|Immunogenicity
1237727|NCT01003314|Protection
1237728|NCT01003314|Sporozoite challenge
1237729|NCT01003301|cat allergy
1237730|NCT01003288|H1N1 pandemic vaccine immunogenicity safety
1237731|NCT01003288|Health employees
1237732|NCT01003275|Chronic kidney disease
1237733|NCT01003275|Vitamin D
1237734|NCT01003275|Paricalcitol
1237735|NCT01003275|Placebo
1237736|NCT01003275|Kidney
1237737|NCT01003275|Renal
1237738|NCT01003275|Oxidative Stress
1237739|NCT01003275|Immune cell function
1237740|NCT01003275|Glucose
1237741|NCT01003275|Glucose tolerance
1237742|NCT01003262|Observation Unit
1237743|NCT01003262|Emergency Department
1237744|NCT01003249|over distention of bladder
1237745|NCT01003249|Dysfunctional voiding
1237746|NCT01003249|dysfunctional elimination syndrome
1237747|NCT01003236|Diabetic nephropathy
1237748|NCT01003236|Type II Diabetes
1237749|NCT01003236|Milk Thistle extract
1237750|NCT01003236|Silymarin
1237751|NCT01003223|phosphorus
1237752|NCT01003223|dialysis
1237753|NCT01003223|PhosLo
1237754|NCT01003223|CKD stage V
1237755|NCT01003210|otitis media
1237756|NCT01003210|children
1237757|NCT01003210|homeopathy
1237758|NCT01003197|Development
1237759|NCT01003197|Validation
1237760|NCT01003197|Prediction Score
1237761|NCT01003197|Complication
1237762|NCT01003197|Liver resection
1237763|NCT01003197|develop and validate a score to predict serious complications following liver resection using pre-operative risk factors.
1237764|NCT01003184|diabetes
1237765|NCT01003184|exenatide once weekly
1237766|NCT01003184|Byetta
1237767|NCT01003184|insulin detemir
1237768|NCT01003184|Levemir
1237769|NCT01003184|Amylin
1237770|NCT01003184|Lilly
1237771|NCT01003171|Pharmacokinetics
1237772|NCT01003171|PK
1237773|NCT01003171|MCS
1237774|NCT01003171|Benign Prostatic Hyperplasia
1237775|NCT01003171|Multi-Carotenoids
1237776|NCT01003171|Healthy subjects
1237777|NCT01003158|Cancer
1237778|NCT01003158|tumour
1237779|NCT01003158|metastatic
1237780|NCT01003158|breast cancer
1237781|NCT01003145|Influenza
1237782|NCT01003145|vaccine
1237783|NCT01003145|Immunogenicity
1237784|NCT01003132|Psychosis
1237785|NCT01003132|Distress
1237786|NCT01003132|Mindfulness
1237787|NCT01003132|Acceptance
1237788|NCT01003132|Values
1237789|NCT01003119|Alcohol addiction
1237790|NCT01003119|Alcohol treatment
1237791|NCT01003119|Alcohol recovery
1237792|NCT01003119|Post residential treatment DSM-IV diagnosis of alcohol dependence
1237793|NCT01003106|RVO
1237794|NCT01003106|BRVO
1237795|NCT01003106|CRVO
1237796|NCT01003106|Vein occlusion
1237797|NCT01003093|Tuberculosis
1237798|NCT01003093|Vaccine
1237799|NCT01003093|Ag85B
1237800|NCT01003093|ESAT-6
1237801|NCT01003093|IC31
1237802|NCT01003080|The evaluation of hemostasis during total knee arthroplasty using the aquamantys device.
1237803|NCT01003054|Leukemia
1237804|NCT01003054|CML
1237805|NCT01003054|Busulfan
1237806|NCT01003054|Busulfex
1237807|NCT01003054|Myleran
1237808|NCT01003054|Cyclophosphamide
1237809|NCT01003054|Cytoxan
1237810|NCT01003054|Neosar
1237811|NCT01003054|Imatinib Mesylate
1237812|NCT01003054|Gleevec
1237813|NCT01003054|Autologous Stem Cell Transplantation
1237814|NCT01003054|Stem Cell Transplant
1237815|NCT01003041|healthy normal infants
1237816|NCT01003028|Total intravenous anesthesia
1237817|NCT01003028|Maximum plasma concentration of remifentanil
1237818|NCT01003015|HCC
1237819|NCT01003015|Safety
1237820|NCT01003015|BAY73-4506
1237821|NCT01003002|Parkinson's disease
1237822|NCT01003002|Dyskinesia
1237823|NCT01003002|Movement Disorders
1237824|NCT01002989|ankle brachial index
1237825|NCT01002989|WatchBP Office
1237826|NCT01002989|oscillometric measurement
1237827|NCT01002937|Biomarkers
1237828|NCT01002937|Prognosis response to treatment
1237829|NCT01002937|Renal cancer
1237830|NCT01002924|Cancer
1237831|NCT01002924|Adenocarcinoma
1237832|NCT01002924|Phase II
1237833|NCT01002924|Lung
1237834|NCT01002924|Non-small cell lung cancer
1237835|NCT01002924|NSCLC
1237836|NCT01002924|extension
1237837|NCT01002924|EC145
1237838|NCT01002924|Prior exposure to EC145
1237839|NCT01002911|Device procedure
1237840|NCT01002911|pacemaker
1237841|NCT01002911|ICD
1237842|NCT01002911|antibiotics
1237843|NCT01002898|HIV-1 RNA
1237844|NCT01002898|Treatment experienced
1237845|NCT01002885|Infertility
1237846|NCT01002885|FSH Receptor Polymorphisms
1237847|NCT01002872|FGF23
1237848|NCT01002872|CKD
1237849|NCT01002872|Fosrenol
1237850|NCT01002872|Hyperphosphatemia
1238098|NCT01001871|Sprinkles®
1237851|NCT01002859|Coronary artery bypass graft surgery (CABG)
1237852|NCT01002859|Cardiopulmonary Bypass (CPB)
1237853|NCT01002859|Cyclosporine
1237854|NCT01002859|ischaemia reperfusion
1237855|NCT01002846|Efficacy
1237856|NCT01002846|Acupuncture
1237857|NCT01002846|Hypertension
1237858|NCT01002833|Plasmodium falciparum
1237859|NCT01002833|Malaria
1237860|NCT01002820|Epileptic Seizures
1237861|NCT01002820|Seizure Disorder
1237862|NCT01002820|Seizures
1237863|NCT01002820|Convulsions
1237864|NCT01002820|Anticonvulsant
1237865|NCT01002820|Anticonvulsive
1237866|NCT01002820|Antiepileptic
1237867|NCT01002820|Ganaxolone
1237868|NCT01002794|Degenerative meniscal tear
1237869|NCT01002794|Arthroscopy
1237870|NCT01002794|Exercise therapy
1237871|NCT01002703|Lenalidomide
1237872|NCT01002703|Bendamustine
1237873|NCT01002703|Multiple Myeloma
1237874|NCT01002703|Myeloma
1237875|NCT01002703|Revlimid
1237876|NCT01002703|Phase I/II
1237877|NCT01002703|refractory Myeloma
1237878|NCT01002703|relapsed Myeloma
1237879|NCT01002690|Asthma
1237880|NCT01002690|Allergen challenge
1237881|NCT01002690|Airway responsiveness
1237882|NCT01002690|Prostaglandins
1237883|NCT01002690|Eicosanoids
1237884|NCT01002677|brain injury
1237885|NCT01002677|traumatic brain injury
1237886|NCT01002677|training
1237887|NCT01002677|teaching
1237888|NCT01002677|curriculum
1237889|NCT01002664|Benign Prostatic Hyperplasia
1237890|NCT01002664|Multi-carotenoids
1237891|NCT01002664|MCS-2
1237892|NCT01002664|Lower Urinary Tract Symptoms
1237893|NCT01002664|International prostate symptom scores
1237894|NCT01002651|gastrointestinal health
1237895|NCT01002651|healthy subjects
1237896|NCT01002625|Double-Blind Randomized Placebo-Controlled 2-Way Crossover Polysomnographic Endpoints
1237897|NCT01002612|Nutritional status
1237898|NCT01002612|Thai HIV-infected children
1237899|NCT01002599|bariatric surgery
1237900|NCT01002599|morbidly obese
1237901|NCT01002599|BMI >35
1237902|NCT01002599|CPAP
1237903|NCT01002599|Venturi
1237904|NCT01002599|Boussignac
1237905|NCT01002599|Ventilation
1237906|NCT01002599|Pulmonary function
1237907|NCT01002599|Morbidly Obese Patients undergoing bariatric surgery
1237908|NCT01002586|Alzheimer's dementia
1237909|NCT01002586|Wii-Fit
1237910|NCT01002586|Walking
1237911|NCT01002586|Falls
1237912|NCT01002573|Pediatric
1237913|NCT01002573|Fever
1237914|NCT01002560|Melanoma
1237915|NCT01002560|Novel Prognostic Markers
1237916|NCT01002547|steatohepatitis
1237917|NCT01002547|type 2 diabetes
1237918|NCT01002547|fatty liver
1237919|NCT01002534|Cystic Fibrosis
1237920|NCT01002534|Vardenafil
1237921|NCT01002534|Nasal instillation
1237922|NCT01002534|Nasal Potential difference
1237923|NCT01002521|Diabetes
1237924|NCT01002521|vascular
1237925|NCT01002521|haptoglobin
1237926|NCT01002521|tumor
1237927|NCT01002521|necrosis
1237928|NCT01002521|factor
1237929|NCT01002521|alpha
1237930|NCT01002521|traps
1237931|NCT01002521|impaired
1237932|NCT01002521|wound
1237933|NCT01002521|healing
1237934|NCT01002521|Impaired wound healing in patients with diabetes mellitus
1237935|NCT01002508|influenza vaccine scleroderma immunogenicity safety
1237936|NCT01002495|myocardial
1237937|NCT01002495|ischemia
1237938|NCT01002495|coronary disease
1237939|NCT01002495|angina
1237940|NCT01002482|Hyperglycemia
1237941|NCT01002482|Hypoglycemia
1237942|NCT01002482|Intensive Care Unit
1237943|NCT01002482|Glucose Control
1237944|NCT01002482|Insulin
1237945|NCT01002482|Computer Protocol
1237946|NCT01002482|Metabolic Disorders
1237947|NCT01002469|isotope ratio measurement
1237948|NCT01002469|urea cycle
1237949|NCT01002469|13C acetate
1237950|NCT01002469|Healthy adults
1237951|NCT01002456|Adrenergic beta-Antagonists
1237952|NCT01002456|Guideline Adherence
1237953|NCT01002456|Drug Prescriptions
1237954|NCT01002456|target dose
1237955|NCT01002443|Helicobacter pylori
1237956|NCT01002443|glandular atrophy
1237957|NCT01002443|intestinal metaplasia
1237958|NCT01002443|subtotal gastrectomy
1237959|NCT01002443|gastric cancer
1237960|NCT01002443|Precancerous lesion of gastric cancer
1237961|NCT01002430|Myocardial ischemia
1237962|NCT01002430|Refractory angina pectoris
1237963|NCT01002430|Vascular endothelial growth factor
1237964|NCT01002430|Gene therapy
1237965|NCT01002430|Perfusion
1237966|NCT01002417|Benign Prostatic Hyperplasia
1237967|NCT01002417|Multi-carotenoids
1237968|NCT01002417|MCS-2
1237969|NCT01002417|Lower Urinary Tract Symptoms
1237970|NCT01002417|International prostate symptom scores
1237971|NCT01002404|ERCP
1237972|NCT01002404|deep biliary cannulation
1237973|NCT01002404|guide wire cannulation
1237974|NCT01002404|post-ERCP pancreatitis
1237975|NCT01002404|Success of deep biliary cannulation
1237976|NCT01002404|Rate of post-ERCP pancreatitis
1237977|NCT01002404|Time used to deep biliary cannulation
1237978|NCT01002391|breast hypertrophy
1237979|NCT01002391|mammaplasty
1237980|NCT01002391|bandages
1237981|NCT01002391|surgical site infection
1237982|NCT01002391|skin colonization
1237983|NCT01002352|obesity
1237984|NCT01002352|bariatric
1237985|NCT01002352|BOLD
1237986|NCT01002352|weightloss
1237987|NCT01002352|database
1237988|NCT01002352|data registry
1237989|NCT01002326|Pediatric
1237990|NCT01002326|Body Dysmorphic Disorder
1237991|NCT01002326|BDD
1237992|NCT01002326|CBT
1237993|NCT01002326|Cognitive-Behavioral Therapy
1237994|NCT01002300|Social Cognition
1237995|NCT01002300|Oxytocin
1237996|NCT01002274|Benign Prostatic Hyperplasia
1237997|NCT01002274|BPH
1237998|NCT01002274|MCS-2
1237999|NCT01002274|Multi-Carotenoids
1238000|NCT01002274|Lower Urinary Tract Symptoms
1238001|NCT01002274|International prostate symptom score
1238002|NCT01002261|Galactose
1238003|NCT01002261|PET/CT
1238004|NCT01002261|Liver physiology
1238005|NCT01002261|Liver pathophysiology
1238006|NCT01002248|Multiple Myeloma
1238007|NCT01002248|Relapsed multiple myeloma
1238008|NCT01002248|Refractory multiple myeloma
1238009|NCT01002248|Relapsed refractory multiple myeloma
1238010|NCT01002235|Diabetic
1238011|NCT01002235|Neuropathy
1238012|NCT01002235|peripheral
1238013|NCT01002235|diabetes
1238014|NCT01002222|Benign Prostatic Hyperplasia
1238015|NCT01002222|MCS-2
1238016|NCT01002222|Multi-Carotenoids
1238017|NCT01002222|Lower Urinary Tract Symptoms
1238018|NCT01002222|International prostate symptom score
1238019|NCT01002209|Diabetes
1238020|NCT01002209|Vascular Surgery
1238021|NCT01002209|Hyperbaric oxygen
1238022|NCT01002209|Surgical complications
1238023|NCT01002209|Wound complication
1238024|NCT01002209|Randomized
1238025|NCT01002209|Controlled
1238026|NCT01002196|Selective Mutism
1238027|NCT01002196|Intervention
1238028|NCT01002183|Malaria
1238029|NCT01002183|Plasmodium falciparum
1238030|NCT01002183|acute uncomplicated
1238031|NCT01002170|Tuberculosis
1238032|NCT01002170|Cycloserine
1238033|NCT01002170|Pharmacokinetics
1238034|NCT01002157|Coronary Artery Calcification
1238035|NCT01002157|Vitamin K
1238036|NCT01002157|Trial
1238037|NCT01002157|Treatment
1238038|NCT01002131|Digital Volume Tomography
1238039|NCT01002131|Cone Beam CT
1238040|NCT01002131|impacted and supernumerary teeth
1238041|NCT01002131|dental and maxillofacial radiology
1238042|NCT01002118|heart rate variability
1238043|NCT01002118|Dialysis
1238044|NCT01002105|Baclofen
1238045|NCT01002105|Alcohol
1238046|NCT01002105|Baclofen as add-on to standard treatment of alcohol
1238047|NCT01002092|Osteosarcoma
1238048|NCT01002092|Endostar
1238049|NCT01002092|Chemotherapy
1238050|NCT01002066|Fever
1238051|NCT01002066|Malaria
1238052|NCT01002066|RDT
1238053|NCT01002066|IMCI
1238054|NCT01002066|Children<5 years of age
1238055|NCT01002066|ACT
1238056|NCT01002053|diabetes
1238057|NCT01002053|neuropathy
1238058|NCT01002053|ankle block
1238059|NCT01002053|regional anesthesia
1238060|NCT01002053|ultrasound
1238061|NCT01002053|nerve localization
1238062|NCT01002053|Nerve localization in patients undergoing foot surgery and having ankle block
1238063|NCT01002040|HIV
1238064|NCT01002040|vaccine,
1238065|NCT01002040|H1N1
1238066|NCT01002040|influenza
1238067|NCT01002040|H1N1 Influenza vaccine
1238068|NCT01002040|Arepanrix
1238069|NCT01002040|Pandemic
1238070|NCT01002040|H1N1 2009 Influenza
1238071|NCT01002040|HIV preventive vaccine
1238072|NCT01002027|Postnatal Depression
1238073|NCT01002027|CBT-Counselling
1238074|NCT01002027|Primary care
1238075|NCT01002014|Breast Cancer
1238076|NCT01002014|Skin Sparing Mastectomy
1238077|NCT01002014|Breast Cancer Prophylaxis
1238078|NCT01002014|Nipple Sparing Mastectomy
1238079|NCT01002014|Nipple Areolar Complex
1238080|NCT01002014|Mastectomy
1238081|NCT01002014|Breast Reconstruction
1238082|NCT01002014|Local recurrence following nipple sparing mastectomy
1238083|NCT01002014|Cosmetic outcomes following nipple sparing mastectomy
1238084|NCT01002014|Complications following nipple sparing mastectomy
1238085|NCT01001988|Encephalitis
1238086|NCT01001988|Japanese Encephalitis
1238087|NCT01001988|Japanese Encephalitis Chimeric Virus Vaccine
1238088|NCT01001988|Toddlers
1238089|NCT01001975|Sunscreens
1238090|NCT01001962|Hypertension in type II diabetes
1238091|NCT01001962|Cardiovascular morbidity and mortality
1238092|NCT01001936|PHASE 1 SKI-606 Solid tumor
1238093|NCT01001897|IUD insertion
1238094|NCT01001897|nulliparous women
1238095|NCT01001897|contraception
1238096|NCT01001884|caregiver, psychoeducational, colon
1238097|NCT01001871|Iron deficiency anemia
1238099|NCT01001871|micronutrients
1238100|NCT01001871|malaria incidence
1238101|NCT01001871|iron supplement
1238102|NCT01001858|OSA
1238103|NCT01001858|CPAP compliance
1238104|NCT01001858|nurse domiciliary led
1238105|NCT01001858|sleep disease
1238106|NCT01001845|hemodialysis
1238107|NCT01001845|oxidative stress
1238108|NCT01001845|plasma malondialdehyde
1238109|NCT01001845|Glutathion peroxidase
1238110|NCT01001780|Graft versus Host Disease
1238111|NCT01001780|Allogeneic Hematopoietic Stem Cell Transplant
1238112|NCT01001767|Omega-3 Fatty Acids
1238113|NCT01001767|HIV
1238114|NCT01001767|Heart Disease
1238115|NCT01001767|Treatment experienced
1238116|NCT01001754|Hepatitis C
1238117|NCT01001754|Hepatitis C, Chronic
1238118|NCT01001754|PEGylated recombinant interleukin 29
1238119|NCT01001754|PEG-interferon lambda
1238120|NCT01001754|Interleukin 29
1238121|NCT01001754|Virus
1238122|NCT01001754|Infection
1238123|NCT01001754|Liver Diseases
1238124|NCT01001741|HIV
1238125|NCT01001741|Antiretrovirals
1238126|NCT01001741|Adherence
1238127|NCT01001741|Text messaging
1238128|NCT01001741|Antiretroviral adherence
1238129|NCT01001741|Treatment experienced
1238130|NCT01001728|Breast Cancer
1238131|NCT01001728|Radiotherapy
1238132|NCT01001728|Prone position
1238133|NCT01001702|Open Label
1238134|NCT01001702|Aripiprazole
1238135|NCT01001689|Pregnancy
1238136|NCT01001689|Preventive health care
1238137|NCT01001689|Fitness
1238138|NCT01001689|Nutrition
1238139|NCT01001689|Obesity
1238140|NCT01001689|Diabetes
1238141|NCT01001689|Weight gain
1238142|NCT01001676|renal failure
1238143|NCT01001676|Restenosis
1238144|NCT01001676|Dialysis access
1238145|NCT01001676|Paclitaxel
1238146|NCT01001676|Angioplasty
1238147|NCT01001676|Intimal hyperplasia
1238148|NCT01001663|CAG
1238149|NCT01001650|Malaria Vaccine
1238150|NCT01001650|Plasmodium falciparum
1238151|NCT01001637|curcumin
1238152|NCT01001637|alzheimer's
1238153|NCT01001637|longVida
1238154|NCT01001637|dementia
1238155|NCT01001624|Cosmetic
1238156|NCT01001624|Facial cream
1238157|NCT01001624|Melasma
1238158|NCT01001624|Melanil
1238159|NCT01001611|Diabetes Mellitus, Type 2
1238160|NCT01001611|glitazone
1238161|NCT01001611|Type II Diabetes
1238162|NCT01001611|Hypolipidemic
1238163|NCT01001611|oral hypoglycemic agent
1238164|NCT01001585|mitochondrial disease
1238165|NCT01001585|sevoflurane
1238166|NCT01001585|mitochondrial disease and sevoflurane sensitivity
1238167|NCT01001572|Blood pressure
1238168|NCT01001572|hypertension
1238169|NCT01001572|Exforge
1238170|NCT01001572|valsartan/amlodipine
1238171|NCT01001559|Depression
1238172|NCT01001559|Combination therapy
1238173|NCT01001559|antidepressant
1238174|NCT01001559|Deplin
1238175|NCT01001559|folate
1238176|NCT01001559|methylfolate
1238177|NCT01001546|Veterans
1238178|NCT01001546|Smoking cessation
1238179|NCT01001546|Operation Enduring Freedom
1238180|NCT01001546|Operation Iraqi Freedom
1238181|NCT01001533|Electrical Cardiometry
1238182|NCT01001533|Dexmedetomidine
1238183|NCT01001533|ICON
1238184|NCT01001533|bio-impedance
1238185|NCT01001533|cardiac monitor
1238186|NCT01001520|Genetics
1238187|NCT01001520|Nicotine
1238188|NCT01001520|Cognition
1238189|NCT01001520|fMRI
1238190|NCT01001507|Family planning
1238191|NCT01001507|HIV
1238192|NCT01001507|Integrated services
1238193|NCT01001507|Unintended pregnancy
1238194|NCT01001507|Kenya
1238195|NCT01001494|Chronic Obstructive Pulmonary Disease
1238196|NCT01001494|antimuscarinic
1238197|NCT01001494|COPD
1238198|NCT01001481|Treatment review
1238199|NCT01001481|Schizophrenia
1238200|NCT01001481|Observational
1238201|NCT01001481|Prospective studies
1238202|NCT01001481|Australia
1238203|NCT01001468|Psoriasis
1238204|NCT01001455|BP
1238205|NCT01001442|Multiple myeloma
1238206|NCT01001442|Relapsed
1238207|NCT01001442|Refractory
1238208|NCT01001429|sedation for vitreoretinal surgery
1238209|NCT01001390|Acute Lymphoblastic leukemia
1238210|NCT01001377|Panitumumab
1238211|NCT01001377|Vectibix
1238212|NCT01001377|Colon Cancer
1238213|NCT01001377|Colorectal Cancer
1238214|NCT01001377|Rectal Cancer
1238215|NCT01001377|Cetuximab
1238216|NCT01001377|Erbitux
1238217|NCT01001377|Metastatic
1238218|NCT01001351|Chronic Kidney Disease
1238219|NCT01001351|Arteriovenous Grafts (AVG)
1238220|NCT01001351|Hemodialysis
1238221|NCT01001351|Vascular Access
1238222|NCT01001351|Dialysis
1238223|NCT01001351|Graft
1238224|NCT01001351|Access
1238225|NCT01001351|vonapanitase
1238226|NCT01001351|kidney
1238227|NCT01001351|renal
1238228|NCT01001325|influenza
1238229|NCT01001325|vaccine
1238230|NCT01001325|observer blind
1238231|NCT01001312|Heart Failure
1238232|NCT01001312|Therapeutics
1238233|NCT01001312|Blood volume
1238234|NCT01001286|dropout youth in low income communities in Amman, Jordan
1238235|NCT01001273|Pancreas Transplantation
1238236|NCT01001273|Kidney Transplantation
1238237|NCT01001273|Organ Transplantation
1238238|NCT01001273|Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients
1238239|NCT01001260|Prostaglandins
1238240|NCT01001260|vascular injury
1238241|NCT01001247|TMC278-TiDP6-C154
1238242|NCT01001247|TMC278-C154
1238243|NCT01001247|TMC278
1238244|NCT01001247|Healthy volunteers
1238245|NCT01001247|omeprazole
1238246|NCT01001247|proton pump inhibitor
1238247|NCT01001247|HIV
1238248|NCT01001208|Etanercept
1238249|NCT01001208|Methotrexate
1238250|NCT01001208|Psoriasis
1238251|NCT01001182|observational
1238252|NCT01001182|non-interventional
1238253|NCT01001182|prospective
1238254|NCT01001169|GSK Bio's influenza vaccine GSK2340274A
1238255|NCT01001169|influenza infection
1238256|NCT01001156|Aged
1238257|NCT01001156|Breathing Muscles
1238258|NCT01001156|Strength Muscles
1238259|NCT01001156|Institution of long Permanence for elderly
1238260|NCT01001130|avamys
1238261|NCT01001130|Allergic Rhinitis
1238262|NCT01001130|post marketing surveillance
1238263|NCT01001130|Seasonal Allergic Rhinitis
1238264|NCT01001130|Perennial Allergic Rhinitis (PAR)
1238265|NCT01001117|Cataract
1238266|NCT01001117|Capsulotomy
1238267|NCT01001117|Capsulorrhexis
1238268|NCT01001117|Phacoemulsification
1238269|NCT01001104|Metabolic Diseases
1238270|NCT01001104|Glucose Metabolism Disorders
1238271|NCT01001104|Diabetes
1238272|NCT01001104|GLP-1
1238273|NCT01001104|Lilly
1238274|NCT01001091|Conjunctivitis
1238275|NCT01001091|conjunctival inflammation
1238276|NCT01001091|ocular allergies
1238277|NCT01001078|supraglottic airway devices
1238278|NCT01001078|I-Gel
1238279|NCT01001078|Supreme Laryngeal mask airway
1238280|NCT01001078|Airway leak pressure
1238281|NCT01001078|peak airway pressure
1238282|NCT01001052|Healthy
1238283|NCT01001052|bioavailability
1238284|NCT01001039|chronic sinusitis
1238285|NCT01001039|facial pain
1238286|NCT01001026|vaccine
1238287|NCT01001026|H1N1
1238288|NCT01001026|influenza
1238289|NCT01001026|H1N1 influenza vaccine
1238290|NCT01001026|pandemic
1238291|NCT01000987|alcohol
1238292|NCT01000987|reactivity
1238293|NCT01000987|smoking cessation medications
1238294|NCT01000974|booster vaccination
1238295|NCT01000974|Gram-negative bacterial infections
1238296|NCT01000974|immunogenicity
1238297|NCT01000974|vaccines, conjugate
1238298|NCT01000974|primary vaccination course
1238299|NCT01000974|Haemophilus influenzae type b
1238300|NCT01000974|safety
1238301|NCT01000974|infants, children
1238302|NCT01000961|cystinosis
1238303|NCT01000961|cysteamine
1238304|NCT01000961|inheritable disease
1238305|NCT01000961|orphan disease
1238306|NCT01000961|CTNS protein, human
1238307|NCT01000961|metabolic disease
1238308|NCT01000961|nephropathic cystinosis
1238309|NCT01000948|Prostate cancer
1238310|NCT01000948|Castration resistant
1238311|NCT01000948|Chemotherapy resistant
1238312|NCT01000948|Endothelial receptor A inhibitor
1238313|NCT01000948|ZD4054
1238442|NCT01000493|PTSD
1238314|NCT01000935|Rotator Cuff Decompression Repair
1238315|NCT01000922|Mealtime Insulin
1238316|NCT01000922|Rapid acting insulin
1238317|NCT01000922|Ultra fast VIAject
1238318|NCT01000922|prandial insulin
1238319|NCT01000896|Phase I
1238320|NCT01000896|cancer
1238321|NCT01000896|solid tumors
1238322|NCT01000896|advanced solid malignancies
1238323|NCT01000896|NSCLC
1238324|NCT01000896|epithelial ovarian cancer
1238325|NCT01000896|dose escalation
1238326|NCT01000896|combination treatment
1238327|NCT01000896|src inhibitor
1238328|NCT01000896|Japanese
1238329|NCT01000883|stage IIIA breast cancer
1238330|NCT01000883|stage IIIB breast cancer
1238331|NCT01000883|stage IIIC breast cancer
1238332|NCT01000883|stage IV breast cancer
1238333|NCT01000883|recurrent breast cancer
1238334|NCT01000857|controlled-release tablet
1238335|NCT01000857|repeat dose
1238336|NCT01000857|immediate-release tablet
1238337|NCT01000857|paroxetine
1238338|NCT01000857|safety
1238339|NCT01000857|crossover
1238340|NCT01000857|pharmacokinetics
1238341|NCT01000857|steady-state
1238342|NCT01000857|Japanese healthy male volunteers
1238343|NCT01000857|tolerance
1238344|NCT01000844|Hemophilia
1238345|NCT01000844|Joint
1238346|NCT01000844|Cartilage
1238347|NCT01000844|Damage
1238348|NCT01000844|Prophylaxis
1238349|NCT01000844|Factor VIII
1238350|NCT01000844|FVIII
1238351|NCT01000844|Disease
1238352|NCT01000844|Arthropathy
1238353|NCT01000831|vaccine
1238354|NCT01000831|influenza
1238355|NCT01000831|H1N1 influenza vaccine
1238356|NCT01000831|influenza vaccine
1238357|NCT01000831|Arepanrix
1238358|NCT01000818|Treatment experienced
1238359|NCT01000779|Non Cirrhotic Portal Hypertension, secondary prophylaxis
1238360|NCT01000753|adult diffuse small cleaved cell lymphoma
1238361|NCT01000753|adult diffuse mixed cell lymphoma
1238362|NCT01000753|grade 1 follicular lymphoma
1238363|NCT01000753|grade 2 follicular lymphoma
1238364|NCT01000753|grade 3 follicular lymphoma
1238365|NCT01000753|childhood immunoblastic large cell lymphoma
1238366|NCT01000753|adult immunoblastic large cell lymphoma
1238367|NCT01000753|mantle cell lymphoma
1238368|NCT01000753|marginal zone lymphoma
1238369|NCT01000753|small lymphocytic lymphoma
1238370|NCT01000753|primary central nervous system non-Hodgkin lymphoma
1238371|NCT01000753|cutaneous B-cell non-Hodgkin lymphoma
1238372|NCT01000753|cutaneous T-cell non-Hodgkin lymphoma
1238373|NCT01000753|lymphoproliferative disorder
1238374|NCT01000740|EAP
1238375|NCT01000740|Long term survival (3 years)
1238376|NCT01000740|Gefitinib
1238377|NCT01000740|efficacy
1238378|NCT01000727|Atherosclerosis
1238379|NCT01000727|Heart disease
1238380|NCT01000727|Cardiovascular disease
1238381|NCT01000727|Lp-PLA2 inhibitor
1238382|NCT01000727|The TIMI Study Group
1238383|NCT01000727|Coronary Heart Disease (CHD)
1238384|NCT01000727|Acute Coronary Syndrome (ACS)
1238385|NCT01000701|Inflammation
1238386|NCT01000701|ACS
1238387|NCT01000701|Prevention
1238388|NCT01000701|Education
1238389|NCT01000701|Clinical management
1238390|NCT01000675|aneurysm
1238391|NCT01000675|coils
1238392|NCT01000662|whole breast radiotherapy
1238393|NCT01000662|tumor bed boost
1238394|NCT01000649|V1a agonist
1238395|NCT01000636|Renal transplant patients
1238396|NCT01000636|Actinic Keratoses
1238397|NCT01000636|Metvix PDT
1238398|NCT01000636|Field cancerisation
1238399|NCT01000636|Gene expression
1238405|NCT01000584|vaccine
1238406|NCT01000584|H1N1
1238407|NCT01000584|influenza
1238408|NCT01000584|H1N1 influenza vaccine
1238409|NCT01000584|influenza vaccine
1238410|NCT01000584|seasonal Influenza
1238411|NCT01000571|H1N1 pandemic flu
1238412|NCT01000558|non-Hodgkin lymphoma
1238413|NCT01000545|Diabetes Mellitus
1238414|NCT01000545|Chronic Kidney Disease
1238415|NCT01000545|Glycosaminoglycans
1238416|NCT01000545|Sulodexide
1238417|NCT01000545|Macroalbuminuria
1238418|NCT01000545|Safety and Efficacy
1238419|NCT01000532|steroid, leads, threshold, pacemaker
1238420|NCT01000519|Diabetes mellitus
1238421|NCT01000519|Randomized control trial
1238422|NCT01000519|Exercise
1238423|NCT01000519|Hemoglobin A, Glycosylated
1238424|NCT01000506|Dose-ranging
1238425|NCT01000506|Safety
1238426|NCT01000506|Pharmacodynamics
1238427|NCT01000506|eosinophils
1238428|NCT01000506|SB-240563
1238429|NCT01000506|Efficacy
1238430|NCT01000506|Severe refractory asthma
1238431|NCT01000506|mepolizumab
1238432|NCT01000506|Placebo
1238433|NCT01000493|efficacy
1238434|NCT01000493|double-blind
1238435|NCT01000493|Clinician Administered PTSD Scale
1238436|NCT01000493|placebo
1238437|NCT01000493|Sleep
1238438|NCT01000493|safety
1238439|NCT01000493|CAPS
1238440|NCT01000493|neurokinin-1 antagonist
1238441|NCT01000493|orvepitant
1238443|NCT01000493|randomized
1238444|NCT01000493|Post traumatic stress disorder
1238445|NCT01000493|Phase II
1238446|NCT01000467|PK assessment for healthy male volunteer
1238447|NCT01000467|Healthy male subjects aged 20 to 40 years
1238448|NCT01000441|Rheumatoid arthritis with inadequate response to 1 anti-TNF
1238449|NCT01000428|NSCLC
1238450|NCT01000428|Tarceva
1238451|NCT01000428|Positron emission technology
1238452|NCT01000428|FLT
1238453|NCT01000428|FDG
1238454|NCT01000415|Stage Ib2-early IIb of cervical cancer
1238455|NCT01000415|Neoadjuvant chemotherapy
1238456|NCT01000415|Cisplatin plus gemcitabine
1238457|NCT01000415|Radical hysterectomy with pelvic lymphadenectomy
1238458|NCT01000415|Quality of life
1238459|NCT01000415|Stage Ib2-IIb of cervical cancer patients
1238460|NCT01000402|Bipolar Disorder
1238461|NCT01000402|Attention-Deficit/Hyperactivity Disorder
1238462|NCT01000402|Genetics
1238463|NCT01000402|Environmental Factors
1238464|NCT01000402|Family Factors
1238465|NCT01000376|Cancer
1238466|NCT01000376|solid tumors
1238467|NCT01000350|orthostatic intolerance
1238468|NCT01000350|exercise capacity
1238469|NCT01000350|tachycardia
1238470|NCT01000350|POTS
1238471|NCT01000337|Liver Apoptosis
1238472|NCT01000324|Hepatitis A
1238473|NCT01000324|Hepatitis B
1238719|NCT00999375|Adolescents
1238474|NCT01000311|MenACWY conjugate vaccine in infants
1238475|NCT01000311|Meningococcal vaccine in infants
1238476|NCT01000311|MenACWY
1238477|NCT01000246|mammacarcinoma
1238478|NCT01000246|breastcancer
1238479|NCT01000246|chemotherapy
1238480|NCT01000246|heart failure
1238481|NCT01000246|influenza virus vaccine
1238482|NCT01000233|PATOLOGIC CALCIFICATION
1238483|NCT01000233|AORTIC VALVE STENOSIS
1238484|NCT01000233|INOSITOL HEXAPHOSPHATE
1238485|NCT01000207|Influenza A
1238486|NCT01000207|H1N1 subtype
1238487|NCT01000207|Children/adolescent
1238488|NCT01000207|Vaccine
1238489|NCT01000207|Adjuvant
1238490|NCT01000194|postprandial
1238491|NCT01000194|gene expression profiles
1238492|NCT01000194|microarray
1238493|NCT01000168|Brain Injury
1238494|NCT01000168|Rehabilitation
1238495|NCT01000168|Treadmill therapy
1238496|NCT01000155|fetal hemoglobin
1238497|NCT01000155|vorinostat
1238498|NCT01000155|HDAC inhibitor
1238499|NCT01000155|SAHA
1238500|NCT01000142|Osteopathic
1238501|NCT01000142|Manipulation
1238502|NCT01000142|Preventative
1238503|NCT01000142|Elderly
1238504|NCT01000142|Nursing Home
1238505|NCT01000142|Prevention: General Health Status
1238506|NCT01000129|Radiotherapy
1238507|NCT01000129|Bladder cancer
1238508|NCT01000129|Adaptive planning
1238509|NCT01000116|Tapp
1238510|NCT01000116|Early pain
1238511|NCT01000116|well-being
1238512|NCT01000116|Seroma
1238513|NCT01000116|Haematoma
1238514|NCT01000116|Fibrin glue
1238515|NCT01000116|tacks
1238516|NCT01000103|Stroke
1238517|NCT01000103|Visuospatial neglect
1238518|NCT01000103|Visuospatial extinction
1238519|NCT01000103|Transcranial Magnetic Stimulation (TMS)
1238520|NCT01000103|Non-invasive brain stimulation
1238521|NCT01000103|Neuromodulation
1238522|NCT01000103|Brain parietal cortex
1238523|NCT01000103|Neurological sequels
1238524|NCT01000103|Cognitive rehabilitation
1238525|NCT01000090|Acromegaly
1238526|NCT01000090|Somatostatin analogues
1238527|NCT01000090|Treatment
1238528|NCT01000077|Regenerative Medicine
1238529|NCT01000077|Tissue Collection
1238530|NCT01000077|Cell Culture Systems
1238531|NCT01000077|Routine Surgery
1238532|NCT01000064|Traumatic Brain Injury
1238533|NCT01000064|Attention Deficit
1238534|NCT01000064|TBI
1238535|NCT01000051|Transplant Thrombocytopenia
1238536|NCT01000051|Hematopoietic cell transplantation
1238537|NCT01000051|HCT
1238538|NCT01000051|Low platelet count
1238539|NCT01000051|Bleeding
1238540|NCT01000051|Blood clot
1238541|NCT01000051|Stem Cell Transplant
1238542|NCT01000051|Blood And Marrow Transplantation
1238543|NCT01000051|Eltrombopag
1238544|NCT01000051|Promacta
1238545|NCT01000038|Wii-Fit
1238546|NCT01000038|Assisted living
1238547|NCT01000038|Alzheimer's dementia
1238548|NCT01000025|stage IIIB non-small cell lung cancer
1238549|NCT01000025|stage IV non-small cell lung cancer
1238550|NCT01000025|recurrent non-small cell lung cancer
1238551|NCT00999999|Craniotomy outcome
1238552|NCT00999999|CSF leakage
1238553|NCT00999999|Dural sealant
1238554|NCT00999960|Laparoscopy
1238555|NCT00999960|Prostate
1238556|NCT00999960|Cancer
1238557|NCT00999960|Learning
1238558|NCT00999960|Simulation
1238559|NCT00999960|Simulator
1238560|NCT00999947|genetics
1238561|NCT00999947|mutation screening
1238562|NCT00999947|phenotype-genotype analysis
1238563|NCT00999947|desmosomal genes
1238564|NCT00999921|Fibrocystic Breast Disease
1238565|NCT00999921|Fibroadenoma
1238566|NCT00999921|Mastalgia
1238567|NCT00999908|COPD
1238568|NCT00999908|indacaterol
1238569|NCT00999908|tiotropium
1238570|NCT00999895|Schizophrenia
1238571|NCT00999895|Switch of antipsychotic treatment
1238572|NCT00999895|Outcome evaluation
1238573|NCT00999895|monotherapy
1238574|NCT00999895|Greece
1238575|NCT00999882|mTor Kinase Inhibitor
1238576|NCT00999882|Phase I/II
1238577|NCT00999882|Dose escalation
1238578|NCT00999882|Hepatocellular carcinoma (HCC)
1238579|NCT00999882|Asia
1238580|NCT00999882|HCC
1238581|NCT00999882|Safety and pharmacokinetics
1238582|NCT00999869|Newly diagnosed
1238583|NCT00999869|Alopecia areata
1238584|NCT00999869|Botulinum toxin A
1238585|NCT00999869|Corticosteroid
1238586|NCT00999869|Intralesional injection
1238587|NCT00999856|medical device,
1238588|NCT00999856|sub-conjunctival insert
1238589|NCT00999856|photometer
1238590|NCT00999856|fluorescence
1238591|NCT00999856|subconjunctival interstitial fluid glucose
1238592|NCT00999856|non-invasive measurement
1238593|NCT00999843|Sorafenib
1238594|NCT00999843|Three-dimensional conformal radiation therapy
1238595|NCT00999843|Intensity-modulated radiation therapy
1238596|NCT00999843|Transcatheter arterial chemoembolization
1238597|NCT00999817|Drug-Drug interaction Study CYP2D6 inhibition Healthy Subjects
1238720|NCT00999362|calcineurin activity
1238598|NCT00999804|Locally Advanced Breast Cancer Neoadjuvant Endocrine
1238599|NCT00999778|Autism
1238600|NCT00999778|Social and Communication Deficits in Autism
1238601|NCT00999778|Parent and Caregiver interventions with children with Autism
1238602|NCT00999778|Autism Spectrum Disorder
1238603|NCT00999778|ASD
1238604|NCT00999765|Bipolar Disorder
1238605|NCT00999765|Bipolar Depression
1238606|NCT00999765|Mindfulness-Based Cognitive Therapy
1238607|NCT00999765|MBCT
1238608|NCT00999765|Maintenance
1238609|NCT00999765|Euthymic
1238610|NCT00999765|Efficacy
1238611|NCT00999765|Feasibility
1238612|NCT00999752|Hypertension
1238613|NCT00999752|African Americans
1238614|NCT00999752|Arterial Stiffness
1238615|NCT00999752|Vascular Resistance
1238616|NCT00999739|pneumococcal vaccines
1238617|NCT00999739|HIV
1238618|NCT00999739|antibody response
1238619|NCT00999739|antibody affinity
1238620|NCT00999739|Antibody formation
1238621|NCT00999739|Phagocytosis
1238622|NCT00999713|Acute Lung Injury
1238623|NCT00999713|Cancer
1238624|NCT00999713|Pediatrics
1238625|NCT00999700|Locally advanced HNSCC
1238626|NCT00999700|Chemo-radiation
1238627|NCT00999700|Induction chemotherapy
1238628|NCT00999700|Stage III/IV
1238629|NCT00999700|Unresectable disease
1238630|NCT00999687|Nail psoriasis
1238631|NCT00999687|Indigo naturalis
1238632|NCT00999674|Exercise
1238633|NCT00999648|Tinnitus
1238634|NCT00999648|Myofascial Trigger Points
1238635|NCT00999648|Myofascial Pain Syndrome
1238636|NCT00999648|Controlled Clinical Trial
1238637|NCT00999635|Insoles
1238638|NCT00999635|Prevention of Ulceration
1238639|NCT00999635|Diabetic Foot
1238640|NCT00999635|Neuropathic
1238641|NCT00999622|infection
1238642|NCT00999622|adult anaplastic astrocytoma
1238643|NCT00999622|adult anaplastic oligodendroglioma
1238644|NCT00999622|adult giant cell glioblastoma
1238645|NCT00999622|adult gliosarcoma
1238646|NCT00999622|adult oligodendroglioma
1238647|NCT00999622|adult glioblastoma
1238648|NCT00999622|adult diffuse astrocytoma
1238649|NCT00999622|adult pilocytic astrocytoma
1238650|NCT00999622|adult pineal gland astrocytoma
1238651|NCT00999622|adult subependymal giant cell astrocytoma
1238652|NCT00999609|Adeno-associated virus
1238653|NCT00999609|AAV
1238654|NCT00999609|Leber congenital amaurosis
1238655|NCT00999609|RPE65
1238656|NCT00999609|Gene therapy
1238657|NCT00999609|Gene transfer
1238658|NCT00999596|Breast Cancer
1238659|NCT00999596|Digital Mammography
1238660|NCT00999583|Cardiac arrest
1238661|NCT00999583|erythropoietin
1238662|NCT00999583|post-anoxic encephalopathy
1238663|NCT00999583|neuroprotective drugs
1238664|NCT00999570|outcome
1238665|NCT00999570|quality of life
1238666|NCT00999570|total knee arthroplasty
1238667|NCT00999570|clinical outcome scores post total knee arthroplasty
1238668|NCT00999570|quality of life scores post total knee arthroplasty
1238669|NCT00999557|breast cancer
1238670|NCT00999557|male breast cancer
1238671|NCT00999557|alopecia
1238672|NCT00999544|opioid
1238673|NCT00999544|oxycodone
1238674|NCT00999544|NK1 antagonist
1238675|NCT00999544|aprepitant
1238676|NCT00999544|intranasal
1238677|NCT00999544|abuse
1238678|NCT00999531|Cystic Fibrosis
1238679|NCT00999531|CF
1238680|NCT00999531|Mucociliary Clearance
1238681|NCT00999531|Epithelial Sodium Channel Inhibitor
1238682|NCT00999531|ENaC Inhibitor
1238683|NCT00999531|Airway Hydration
1238684|NCT00999531|Amiloride
1238809|NCT00999102|Nebivololum [Latin]
1238810|NCT00999102|R65,824
1238685|NCT00999518|Randomized double blind placebo-controlled parallel-group dose-range finding interstitial cystitis efficacy pain urinary symptoms safety
1238686|NCT00999505|Schizophrenia
1238687|NCT00999505|Amantadine
1238688|NCT00999505|Residual symptoms
1238689|NCT00999492|Tecnis Multifocal
1238690|NCT00999492|Patients scheduled for cataract or lens replacement surgery with implantation of multifocal intraocular lenses
1238691|NCT00999453|LDL-cholesterol
1238692|NCT00999453|Prevalent peritoneal dialysis patients with hypercholesterolemia
1238693|NCT00999440|Chronic Pain
1238694|NCT00999440|Methadone
1238695|NCT00999440|Perceived Sleep
1238696|NCT00999440|QTc
1238697|NCT00999427|Povidone-iodine
1238698|NCT00999427|prostate cancer
1238699|NCT00999427|biopsy
1238700|NCT00999427|transrectal ultrasound
1238701|NCT00999427|urinary tract infection
1238702|NCT00999427|fever
1238703|NCT00999427|sepsis
1238704|NCT00999427|antisepsis
1238705|NCT00999427|prevention
1238706|NCT00999427|complications
1238707|NCT00999414|MM
1238708|NCT00999388|Lifestyle
1238709|NCT00999388|Environment
1238710|NCT00999388|Neurodegenerative Diseases
1238711|NCT00999388|Elderly
1238712|NCT00999388|Public Health
1238713|NCT00999388|PD
1238714|NCT00999388|Parkinson Disease
1238715|NCT00999375|Type 1 Diabetes
1238716|NCT00999375|Diet
1238717|NCT00999375|Behavioral Intervention
1238718|NCT00999375|Children
1238721|NCT00999362|real-time PCR
1238722|NCT00999362|Gene expression of calcineurin
1238723|NCT00999362|T-lymphocytes
1238724|NCT00999362|interferon-gamma
1238725|NCT00999362|Pharmacodynamics
1238726|NCT00999362|Pharmacokinetics
1238727|NCT00999362|tacrolimus
1238728|NCT00999362|western blot
1238729|NCT00999362|Hoechst
1238730|NCT00999349|iron overload condition
1238731|NCT00999349|regular desferrioxamine administration
1238732|NCT00999349|receiving continuous blood transfusions
1238733|NCT00999336|Betrixaban
1238734|NCT00999336|Renal impairment
1238735|NCT00999336|Healthy
1238736|NCT00999336|Kidney dysfunction
1238737|NCT00999310|Klinefelter syndrome
1238738|NCT00999310|Neuropsychology
1238739|NCT00999310|Neuroradiology
1238740|NCT00999310|Genetics
1238741|NCT00999297|thermogenesis
1238742|NCT00999297|respiratory quotient
1238743|NCT00999297|fat oxidation
1238744|NCT00999284|ZK200775 is tested for its effects on vision on healthy probands.
1238745|NCT00999271|Glucose-dependent insulinotropic polypeptide
1238746|NCT00999271|gastric emptying
1238747|NCT00999271|appetite
1238748|NCT00999271|energy intake
1238749|NCT00999271|lipid metabolism
1238750|NCT00999258|glomerular filtration rate
1238751|NCT00999258|chronic allograft nephropathy
1238752|NCT00999258|Kidney transplantation
1238753|NCT00999258|African American
1238754|NCT00999232|erythromycin
1238755|NCT00999232|prokinetics
1238756|NCT00999232|nasojejunal tubes
1238757|NCT00999232|Bengmark feeding tube
1238758|NCT00999232|post-pyloric feeding
1238759|NCT00999232|pancreatitis
1238760|NCT00999232|Non-critically ill patients having pancreatitis who require jejunal enteral nutrition
1238761|NCT00999219|FK199B
1238762|NCT00999219|Zolpidem
1238763|NCT00999206|Influenza
1238764|NCT00999206|Vaccine
1238765|NCT00999206|CHMP criteria
1238766|NCT00999193|Shoulder
1238767|NCT00999193|Fracture
1238768|NCT00999193|Locking Plate
1238769|NCT00999193|Hemiarthroplasty
1238770|NCT00999193|Conservative
1238771|NCT00999193|Comminuted Proximal Humerus Fracture
1238772|NCT00999180|Botulinum Toxin
1238773|NCT00999180|Rehabilitation
1238774|NCT00999180|Stroke
1238775|NCT00999167|Cirrhosis
1238776|NCT00999167|Episodic Hepatic Encephalopathy
1238777|NCT00999167|HE
1238778|NCT00999167|HPN-100
1238779|NCT00999167|GT4P
1238780|NCT00999167|glycerol phenylbutyrate
1238781|NCT00999154|Energy Expenditure
1238782|NCT00999154|Dietary Intake
1238783|NCT00999154|Physical Activity
1238784|NCT00999154|Body Weight Regulation
1238785|NCT00999154|Sedentary
1238786|NCT00999154|HV
1238787|NCT00999154|Healthy Volunteer
1238788|NCT00999128|PI3K inhibitor
1238789|NCT00999128|PI3 kinase
1238790|NCT00999128|PI3 kinase inhibitor
1238791|NCT00999115|Rectovaginal Fistula
1238792|NCT00999115|Crohn Disease
1238793|NCT00999115|Allogenic
1238794|NCT00999115|Adipose-Derived Stem Cells
1238795|NCT00999102|hypertension
1238796|NCT00999102|beta blockers
1238797|NCT00999102|Metoprolol
1238798|NCT00999102|blood pressure, high
1238799|NCT00999102|antihypertensive agents
1238800|NCT00999102|vascular resistance
1238801|NCT00999102|adrenergic beta-receptor blockaders
1238802|NCT00999102|beta-Adrenergic blockers
1238803|NCT00999102|beta-Adrenergic Blocking Agents
1238804|NCT00999102|beta-Adrenergic Receptor Blockaders
1238805|NCT00999102|beta-Blockers, Adrenergic
1238806|NCT00999102|Bystolic
1238807|NCT00999102|Nebivolol
1238808|NCT00999102|Nebivololum
1238811|NCT00999102|Beloc- Zok
1238812|NCT00999102|H 93/26 succinate
1238813|NCT00999102|Metoprolol succinate
1238814|NCT00999102|Seloken ZOC
1238815|NCT00999102|Selozok
1238816|NCT00999102|Spesicor Dos
1238817|NCT00999102|Toprol XL
1238818|NCT00999102|Toprol-XL
1238819|NCT00999102|UNII-TH25PD4CCB
1238820|NCT00999089|Coronary disease
1238821|NCT00999089|Coronary artery bypass grafting
1238822|NCT00999089|Cardiopulmonary bypass
1238823|NCT00999089|Extracorporeal circulation
1238824|NCT00999089|Cardioplegia
1238825|NCT00999089|Off pump
1238826|NCT00999063|GerdQ
1238827|NCT00999050|type two diabetes
1238828|NCT00999050|gastric bypass surgery
1238829|NCT00999050|overweight or moderately obese
1238830|NCT00999011|critical care
1238831|NCT00999011|inflammatory biomarkers
1238832|NCT00999011|cytokines
1238833|NCT00999011|mechanical ventilation
1238834|NCT00999011|activity
1238835|NCT00999011|mobility therapy
1238836|NCT00999011|More than 48 hours of mechanical ventilation
1238837|NCT00998998|iron deficiency anemia
1238838|NCT00998998|infant behavior
1238839|NCT00998998|infant development
1238840|NCT00998972|kidney graft,
1238841|NCT00998972|delayed graft function
1238842|NCT00998972|N-acetylcysteine
1238843|NCT00998959|Depression
1238844|NCT00998959|Major Depression
1238845|NCT00998946|Relapsed
1238846|NCT00998946|Refractory
1238847|NCT00998946|Non-Hodgkin's
1238848|NCT00998933|Testosterone replacement therapy
1238849|NCT00998920|Healthy volunteers
1238850|NCT00998907|Open Abdominal Surgery
1238851|NCT00998907|Fascial Closure
1238852|NCT00998894|BIS
1238853|NCT00998894|MAC
1238854|NCT00998894|MAP
1238855|NCT00998881|insulin resistance
1238856|NCT00998868|Rotator Cuff
1238857|NCT00998868|Tendinopathy
1238858|NCT00998868|ultrasonography
1238859|NCT00998855|Exercise in obesity
1238860|NCT00998842|ECG
1238861|NCT00998842|EKG
1238862|NCT00998842|healthy subjects
1238863|NCT00998842|electrocardiography, ambulatory
1238864|NCT00998829|psoriasis
1238865|NCT00998829|psoriatic arthritis
1238866|NCT00998829|epidemiology
1238867|NCT00998829|prevalence
1238868|NCT00998816|thoracotomy
1238869|NCT00998816|chronic
1238870|NCT00998816|pain
1238871|NCT00998816|pregabalin
1238872|NCT00998816|Lyrica
1238873|NCT00998803|Influenza virus
1238874|NCT00998790|Urinary Incontinence, Stress
1238875|NCT00998790|Intrinsic sphincter deficiency
1238876|NCT00998790|Secondary
1238877|NCT00998790|TUR
1238878|NCT00998790|TURP
1238879|NCT00998790|Radical prostatectomy
1238880|NCT00998790|Open prostatectomy
1238881|NCT00998790|Post-suprapubic prostatectomy
1238882|NCT00998777|tubing program
1238883|NCT00998777|shoulder strengthening
1238884|NCT00998777|injury prevention
1238885|NCT00998764|antibody
1238886|NCT00998764|immunotherapy
1238887|NCT00998751|cKIT inhibitor
1238888|NCT00998751|GIST
1238889|NCT00998712|gestational diabetes mellitus
1238890|NCT00998712|pregnancy
1238891|NCT00998712|cardiovascular disease risk
1238892|NCT00998699|Diabetes
1238893|NCT00998699|Type 1
1238894|NCT00998686|diabetes
1238895|NCT00998686|DPP4 inhibitor
1238896|NCT00998686|dutogliptin
1238897|NCT00998673|Silica gel fiber
1238898|NCT00998673|Chronic venous leg ulcers
1238899|NCT00998673|Venous ulcer
1238900|NCT00998673|Stasis ulcer
1238901|NCT00998673|Varicose ulcer
1238902|NCT00998660|Parkinson's disease
1238903|NCT00998660|Essential Tremor
1238904|NCT00998660|Dystonia (where indication is approved)
1238905|NCT00998660|Deep brain stimulation
1238906|NCT00998660|Activa RC
1238907|NCT00998647|modified ultrafiltration
1238908|NCT00998647|cardiac surgery
1238909|NCT00998647|ROTEM
1238910|NCT00998647|Multiple Electrode Aggregometry
1238911|NCT00998634|SCA2
1238912|NCT00998634|Lithium
1238913|NCT00998621|Hepatitis C, Chronic
1238914|NCT00998621|HIV Infection
1238915|NCT00998621|Medication Adherence
1238916|NCT00998621|Questionnaire Design
1238917|NCT00998621|Treatment experienced
1238918|NCT00998595|Diabetes, Gestational
1238919|NCT00998595|Postpartum Period
1238920|NCT00998595|Reproductive Health Services
1238921|NCT00998595|Health Promotion
1238922|NCT00998595|Health Personnel
1238923|NCT00998582|Cardiovascular Disease
1238924|NCT00998582|HIV Infection
1238925|NCT00998582|Abacavir
1238926|NCT00998582|Artery Elasticity
1238927|NCT00998582|Treatment experienced
1238928|NCT00998556|Peripartum cardiomyopathy
1238929|NCT00998556|Bromocriptine
1238930|NCT00998543|Smallpox Vaccinia Virus Smallpox Vaccine Variola Virus
1238931|NCT00998530|Trichomonas vaginalis
1238932|NCT00998530|trichomoniasis
1238933|NCT00998530|MLST
1238934|NCT00998530|Multilocus sequence typing
1238935|NCT00998517|Malnutrition
1238936|NCT00998517|Supplemental Food
1238937|NCT00998517|CSB++
1238938|NCT00998517|Supplementary Plumpy
1238939|NCT00998504|impaired fat oxidation
1238940|NCT00998504|fat accumulation
1238941|NCT00998504|mitochondrial dysfunction
1238942|NCT00998504|mitochondrial biogenesis
1238943|NCT00998465|Obesity
1238944|NCT00998465|Hypertension
1238945|NCT00998465|Salt sensitivity
1238946|NCT00998465|Laparoscopic gastric bypass
1238947|NCT00998465|Bariatric surgery
1238948|NCT00998452|Weight
1238949|NCT00998452|Diet
1238950|NCT00998452|Physical Activity
1238951|NCT00998452|Veterans
1238952|NCT00998452|MOVE! Program
1238953|NCT00998439|in stent restenosis
1238954|NCT00998439|paclitaxel coated balloon catheter
1238955|NCT00998439|pepcad
1238956|NCT00998439|drug eluting balloon
1238957|NCT00998426|hepatitis B immune globulin
1238958|NCT00998426|HBIG
1238959|NCT00998426|HepaGam B
1238960|NCT00998426|orthotopic liver transplant
1238961|NCT00998413|asthma
1238962|NCT00998413|overweight
1238963|NCT00998413|obesity
1238964|NCT00998413|children
1238965|NCT00998400|Cognitive-behavioral treatment
1238966|NCT00998400|Well-being therapy
1238967|NCT00998400|Depression
1238968|NCT00998400|Demoralization
1238969|NCT00998400|Acute coronary syndrome
1238970|NCT00998361|Sarcoma
1238971|NCT00998361|allogeneic
1238972|NCT00998361|Hemopoietic stem cell transplant
1238973|NCT00998348|parenting
1238974|NCT00998348|diet
1238975|NCT00998348|physical activity
1238976|NCT00998348|family
1238977|NCT00998348|home
1238978|NCT00998348|child
1238979|NCT00998335|Type 2 diabetes mellitus
1238980|NCT00998335|Insulin therapy
1238981|NCT00998335|Detemir (Levemir)
1238982|NCT00998335|Aspart (Novolog)
1238983|NCT00998335|Hepatic steatosis
1238984|NCT00998322|metastatic
1238985|NCT00998322|pancreatic
1238986|NCT00998322|adenocarcinoma
1238987|NCT00998322|REOLYSIN
1238988|NCT00998322|chemotherapy
1238989|NCT00998322|gemcitabine
1238990|NCT00998309|skin infection
1238991|NCT00998309|soft tissue infection
1238992|NCT00998309|sexually-transmitted infection
1238993|NCT00998309|infection oral
1238994|NCT00998309|Regulatory Post Marketing Commitment Plan
1238995|NCT00998270|MM
1238996|NCT00998257|Contraception
1238997|NCT00998257|Premenstrual Dysphoric Disorder
1238998|NCT00998257|PMDD
1238999|NCT00998257|Acne
1239000|NCT00998244|low carbohydrate
1239001|NCT00998244|low fat
1239002|NCT00998244|diet
1239003|NCT00998244|overweight
1239004|NCT00998244|GERD
1239005|NCT00998244|gastroesophageal reflux disease
1239006|NCT00998244|acid reflux
1239007|NCT00998244|heartburn
1239008|NCT00998218|Sudden Cardiac Death
1239009|NCT00998218|Arrythmias
1239010|NCT00998218|Triggered activity
1239011|NCT00998218|left ventricular dysfunction
1239012|NCT00998192|carcinoma
1239013|NCT00998192|squamous cell
1239014|NCT00998192|lung
1239015|NCT00998192|REOLYSIN
1239016|NCT00998192|chemotherapy
1239017|NCT00998192|carboplatin
1239018|NCT00998192|paclitaxel
1239019|NCT00998192|Carcinoma, Squamous Cell of the Lung
1239020|NCT00998179|TENS
1239021|NCT00998179|acupuncture
1239022|NCT00998179|FEV1
1239023|NCT00998179|Normal Healthy subjects
1239024|NCT00998166|NSCLC
1239025|NCT00998153|substance use
1239026|NCT00998153|PTSD
1239027|NCT00998153|risky behaviors
1239028|NCT00998153|revictimization
1239029|NCT00998140|resuscitation
1239030|NCT00998140|sudden death
1239031|NCT00998140|cardiopulmonary resuscitation
1239032|NCT00998140|emergency medical services
1239033|NCT00998140|termination of resuscitation
1239034|NCT00998140|ventricular fibrillation
1239035|NCT00998140|out-of-hospital cardiac arrest
1239036|NCT00998140|asystole
1239037|NCT00998140|medical futility
1239038|NCT00998140|withdrawing treatment
1239039|NCT00998140|transportation of patients
1239040|NCT00998140|health expenditures
1239041|NCT00998140|healthcare costs
1239042|NCT00998127|Dual Anti-Platelet Therapy
1239043|NCT00998127|Non-adherence
1239044|NCT00998127|MACE
1239045|NCT00998127|NACE
1239046|NCT00998114|Early Cardiac Diastolic Dysfunction
1239047|NCT00998114|Aerobic Exercise
1239048|NCT00998114|Weight Reduction
1239049|NCT00998101|stage IIIB non-small cell lung cancer
1239050|NCT00998101|stage IV non-small cell lung cancer
1239051|NCT00998101|recurrent non-small cell lung cancer
1239052|NCT00998088|Blood management
1239053|NCT00998088|Orthopedic surgery
1239054|NCT00998088|elective
1239055|NCT00998088|randomized study
1239056|NCT00998088|adults
1239057|NCT00998088|hip replacement
1239058|NCT00998088|knee replacement
1239059|NCT00998075|Bioequivalence
1239060|NCT00998075|ASA
1239061|NCT00998075|Esomeprazole
1239062|NCT00998075|peptic ulcer disease
1239063|NCT00998075|primary cardiovascular protection
1239064|NCT00998075|healthy volunteers
1239065|NCT00998062|Dyslipaemia
1239066|NCT00998062|atherosclerosis risk
1239067|NCT00998062|increased hsCRP
1239068|NCT00998062|inflammatory and oxidative status in the Spanish population
1239069|NCT00998036|TNBC
1239070|NCT00998023|Angiogram
1239071|NCT00998023|Catheter Angiogram
1239072|NCT00998010|adult giant cell glioblastoma
1239073|NCT00998010|adult glioblastoma
1239074|NCT00998010|adult gliosarcoma
1239075|NCT00997997|Skin Diseases, Bacterial
1239076|NCT00997997|Product Surveillance
1239077|NCT00997997|Postmarketing
1239078|NCT00997984|ADHD
1239079|NCT00997971|Hydrolysed rice protein formula
1239080|NCT00997971|Cow's milk protein allergy
1239081|NCT00997971|Infant formula
1239082|NCT00997971|Gastrointestinal tolerance
1239083|NCT00997945|Phase I, advanced solid malignancies, advance solid tumour
1239084|NCT00997945|advanced cancer
1239085|NCT00997945|ZD4054 (Zibotentan)
1239086|NCT00997945|china
1239087|NCT00997945|PK
1239088|NCT00997945|pharmacokinetics
1239089|NCT00997932|levonorgestrel releasing intrauterine device
1239090|NCT00997932|levonorgestrel releasing intrauterine contraception
1239091|NCT00997932|unintended pregnancy prevention
1239092|NCT00997932|postpartum contraception
1239093|NCT00997906|stage III lymphoepithelioma of the nasopharynx
1239094|NCT00997906|stage III squamous cell carcinoma of the nasopharynx
1239095|NCT00997906|stage IV lymphoepithelioma of the nasopharynx
1239096|NCT00997906|stage IV squamous cell carcinoma of the nasopharynx
1239097|NCT00997893|menopause
1239098|NCT00997893|hot flashes
1239099|NCT00997893|soy
1239100|NCT00997893|estrogen
1239101|NCT00997893|anxiety
1239102|NCT00997880|rosuvastatin
1239103|NCT00997867|Pain
1239104|NCT00997867|Surgery
1239105|NCT00997867|Catheter
1239106|NCT00997867|Nerve Block
1239107|NCT00997867|Popliteal
1239108|NCT00997867|Sciatic
1239109|NCT00997867|Femoral
1239110|NCT00997867|Interscalene
1239111|NCT00997867|UCSD
1239112|NCT00997867|Moderate-to-severe pain
1239113|NCT00997867|Perineural Catheter
1239114|NCT00997867|Orthopedic Surgery
1239115|NCT00997854|Feeding
1239116|NCT00997854|Intolerance
1239117|NCT00997854|Preterm
1239118|NCT00997854|Bolus
1239119|NCT00997841|POC
1239120|NCT00997841|ROTEM
1239121|NCT00997841|Multiplate
1239122|NCT00997841|bleeding tendency
1239123|NCT00997841|coagulation management
1239124|NCT00997841|amount of transfused red blood cell concentrates,
1239125|NCT00997841|FFP
1239126|NCT00997841|platelet concentrates
1239127|NCT00997841|rate of rethoracotomy
1239128|NCT00997841|ventilation time
1239129|NCT00997828|Coronary Artery Disease
1239130|NCT00997828|stent
1239131|NCT00997828|coronary artery bypass graft surgery
1239132|NCT00997828|multivessel coronary artery disease
1239133|NCT00997815|Recalcitrant
1239134|NCT00997815|Alopecia totalis
1239135|NCT00997815|Alopecia universalis
1239136|NCT00997815|Botulinum toxin A
1239137|NCT00997802|Computed Tomographic Colonography
1239138|NCT00997802|Colonic Polyps
1239139|NCT00997802|Colonic Neoplasms
1239140|NCT00997802|Computer Aided Diagnosis
1239141|NCT00997789|Rebamipide
1239142|NCT00997789|Bioequivalence
1239143|NCT00997789|ABCB1 genetic polymorphisms
1239144|NCT00997776|Hip Fracture
1239145|NCT00997776|Exercise
1239146|NCT00997776|Rehabilitation
1239147|NCT00997776|Functional Performance
1239148|NCT00997763|stenting, XIENCE V, CYPHER
1239149|NCT00997750|ACS
1239150|NCT00997750|Acute Coronary Syndrome
1239151|NCT00997750|NSAID
1239152|NCT00997750|Lornoxicam
1239153|NCT00997750|Xefocam
1239154|NCT00997737|incentive spirometry
1239155|NCT00997737|diaphragm mobility
1239156|NCT00997737|ultrasound
1239157|NCT00997737|diaphragmatic breathing
1239158|NCT00997724|assisted-VATS (video-assisted thoracoscopic surgery)
1239159|NCT00997724|sleeve lobectomy
1239160|NCT00997724|bronchoplasty
1239161|NCT00997711|Diabetes
1239162|NCT00997711|death
1239163|NCT00997711|MI
1239164|NCT00997711|TVR
1239165|NCT00997698|Intracranial aneurysm
1239166|NCT00997698|Magnetic resonance angiography
1239167|NCT00997698|Epidemiology
1239168|NCT00997685|XELOX
1239169|NCT00997685|potentially resectable liver metastasis from CRC
1239170|NCT00997672|MSA
1239171|NCT00997672|Lithium
1239172|NCT00997672|Lithium carbonate
1239173|NCT00997672|MSA-P
1239174|NCT00997672|MSA-C
1239175|NCT00997659|chromium picolinate
1239176|NCT00997659|insulin resistance
1239177|NCT00997659|obesity
1239178|NCT00997646|Performance
1239179|NCT00997646|hospitalist
1239180|NCT00997646|ward
1239181|NCT00997646|hospitalization
1239182|NCT00997633|Intraperitoneal volume
1239183|NCT00997633|peritoneal carcinomatosis
1239184|NCT00997633|cytoreductive surgery
1239185|NCT00997633|SPECT
1239186|NCT00997633|intraperitoneal chemotherapy
1239187|NCT00997620|Hay Fever
1239188|NCT00997620|Daytime somnolence
1239189|NCT00997620|Cognition
1239190|NCT00997607|Vaccine
1239191|NCT00997594|adrenal gland
1239192|NCT00997581|Gout
1239193|NCT00997568|transesophageal
1239194|NCT00997568|transducer
1239195|NCT00997568|TEE
1239196|NCT00997555|inhalation
1239197|NCT00997555|bronchoscopy
1239198|NCT00997555|burn
1239199|NCT00997555|pneumonia
1239200|NCT00997529|Stem cell transplant
1239201|NCT00997529|Non-myeloablative
1239202|NCT00997529|Metastatic Solid Tumor
1239203|NCT00997529|Donor Leukocyte Infusion
1239204|NCT00997516|Laparoscopy
1239205|NCT00997516|Appendicitis
1239206|NCT00997516|Single-incision laparoscopic surgery
1239207|NCT00997516|SILS
1239208|NCT00997490|depression
1239209|NCT00997490|HAMD 21
1239210|NCT00997490|anxiety
1239211|NCT00997490|HAMA
1239212|NCT00997490|Hypericum
1239213|NCT00997490|Valerian
1239214|NCT00997490|Passionflower
1239215|NCT00997490|F32.0
1239216|NCT00997490|F33.0
1239217|NCT00997477|aerolizer
1239218|NCT00997477|formoterol
1239219|NCT00997477|budesonide
1239220|NCT00997477|asthma
1239221|NCT00997451|Medically unexplained chronic fatigue
1239222|NCT00997451|Chronic fatigue syndrome
1239223|NCT00997451|Cognitive-behavior therapy
1239224|NCT00997451|Self-management
1239225|NCT00997451|Primary care
1239226|NCT00997451|Nurses
1239227|NCT00997451|Economic analysis
1239228|NCT00997451|Cost effectiveness
1239229|NCT00997451|One year follow-up
1239230|NCT00997425|wandering
1239231|NCT00997425|subjective exit barriers
1239232|NCT00997399|Ph I
1239233|NCT00997399|panobinostat (DACi)
1239234|NCT00997399|PK & safety
1239235|NCT00997399|solid tumors
1239236|NCT00997399|varying renal function
1239237|NCT00997399|advanced
1239238|NCT00997386|Hematologic malignancies
1239239|NCT00997386|lymphoma, leukemia, MDS (myelodysplastic syndrome)
1239240|NCT00997386|reduced-intensity preparative regimen
1239241|NCT00997386|allogeneic peripheral blood stem cell transplant
1239242|NCT00997386|myelofibrosis or other myeloproliferative syndromes
1239243|NCT00997373|Endometrial Cancer
1239244|NCT00997373|Endometrial Carcinoma
1239245|NCT00997373|Aromatase Inhibitor
1239246|NCT00997373|Letrozole
1239247|NCT00997373|Femara
1239248|NCT00997360|Phase 1
1239249|NCT00997360|Maximum tolerated dose
1239250|NCT00997360|Solid tumors
1239251|NCT00997334|erlotinib
1239252|NCT00997334|EGFR mutation
1239253|NCT00997334|NSCLC
1239254|NCT00997321|ketamine
1239255|NCT00997321|propofol
1239256|NCT00997321|procedural sedation
1239257|NCT00997321|moderate procedural sedation in the ED
1239258|NCT00997308|AZD1446
1239259|NCT00997308|to investigate safety and tolerability in Healthy subjects during 4 weeks of administration
1239260|NCT00997295|low flow gas
1239261|NCT00997295|Heat and moisture exchanger
1239262|NCT00997295|Humidity
1239263|NCT00997295|Temperature
1239264|NCT00997295|Core temperature
1239265|NCT00997295|Women
1239266|NCT00997269|CoQ-10
1239267|NCT00997269|statin
1239268|NCT00997269|muscle pain
1239269|NCT00997269|cardiovascular
1239270|NCT00997256|sleep-EEG
1239271|NCT00997256|sleep architecture
1239272|NCT00997256|sleep duration
1239273|NCT00997256|sleep continuity
1239274|NCT00997256|REM-sleep
1239275|NCT00997256|vigilance
1239276|NCT00997256|well-being
1239277|NCT00997256|Healthy volunteers
1239278|NCT00997243|de novo myelodysplastic syndromes
1239279|NCT00997243|secondary myelodysplastic syndromes
1239280|NCT00997243|chronic myelomonocytic leukemia
1239281|NCT00997243|refractory anemia with excess blasts in transformation
1239282|NCT00997243|refractory anemia with excess blasts
1239283|NCT00997243|refractory anemia with ringed sideroblasts
1239284|NCT00997243|refractory anemia
1239285|NCT00997243|refractory cytopenia with multilineage dysplasia
1239286|NCT00997230|EGFR mutation ,newly diagnosed NSCLC, locally advanced or metastatic NSCLC
1239287|NCT00997217|RIPC
1239288|NCT00997217|cardiac surgery
1239289|NCT00997217|ischemic preconditioning
1239290|NCT00997217|cardiac surgical procedures
1239291|NCT00997204|HAE
1239292|NCT00997204|Type I HAE
1239293|NCT00997204|Type II HAE
1239294|NCT00997191|Bevacizumab
1239295|NCT00997191|Diabetes
1239296|NCT00997191|Intravitreal
1239297|NCT00997191|Macular edema
1239298|NCT00997191|triamcinolone
1239299|NCT00997191|VEGF
1239300|NCT00997178|Diabetes
1239301|NCT00997178|Diabetes Mellitus
1239302|NCT00997178|Periodontal Disease
1239303|NCT00997178|Periodontitis
1239304|NCT00997178|Glycosylated Hemoglobin
1239305|NCT00997178|HbA1c
1239306|NCT00997165|fatty liver
1239307|NCT00997165|adipose tissue
1239308|NCT00997152|Diabetes
1239309|NCT00997139|healthcare
1239310|NCT00997139|staphylococcus aureus
1239311|NCT00997139|nasal
1239312|NCT00997126|propofol
1239313|NCT00997126|alfentanil
1239314|NCT00997126|nitrous oxide
1239315|NCT00997126|moderate procedural sedation
1239316|NCT00997126|Moderate Procedural Sedation in the Emergency Department
1239317|NCT00997113|propofol
1239318|NCT00997113|alfentanil
1239319|NCT00997113|procedural sedation
1239320|NCT00997113|stress biomarkers
1239321|NCT00997113|Deep procedural sedation in the ED
1239322|NCT00997100|Systemic Lupus Erythematosus (SLE)
1239323|NCT00997100|ABR-215757
1239324|NCT00997100|Change in Biomarkers
1239325|NCT00997087|OCD
1239326|NCT00997074|pain after abortion
1239327|NCT00997074|abortion
1239328|NCT00997035|Fungal Infections
1239329|NCT00997035|Eye Disease
1239330|NCT00997035|Fungal Keratitis
1239331|NCT00997035|Visual Acuity
1239332|NCT00997022|HCC
1239333|NCT00997022|High-risk Hepatocellular Cancer
1239334|NCT00997009|EGFR
1239335|NCT00997009|chemotherapy
1239336|NCT00996996|Radioimmunotherapy
1239337|NCT00996996|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody
1239338|NCT00996996|Tositumomab and Iodine I 131 Tositumomab
1239339|NCT00996996|non-Hodgkin's Lymphoma
1239340|NCT00996996|Bexxar
1239341|NCT00996970|HIV
1239342|NCT00996970|H1N1
1239343|NCT00996970|Influenza
1239344|NCT00996970|Vaccination
1239345|NCT00996970|Seroresponse
1239346|NCT00996970|Immunogenicity
1239347|NCT00996970|Vaccine
1239348|NCT00996944|ropinirole
1239349|NCT00996944|haemodialysis
1239350|NCT00996944|restless legs syndrome
1239351|NCT00996931|autistic spectrum disorder
1239352|NCT00996931|lenalidomide
1239353|NCT00996918|antibody
1239354|NCT00996905|Epidural Analgesia
1239355|NCT00996905|Ultrasound
1239356|NCT00996905|Training, Inservice
1239357|NCT00996892|GDC0941
1239358|NCT00996892|GDC0973
1239359|NCT00996892|MEK
1239360|NCT00996892|MEK Inhibitor
1239361|NCT00996892|PI3K
1239362|NCT00996892|PI3K Inhibitor
1239363|NCT00996892|PI3 Kinase
1239364|NCT00996892|PI3 Kinase Inhibitor
1239365|NCT00996879|Human Volunteers
1239366|NCT00996853|safety
1239367|NCT00996853|Influenza
1239368|NCT00996853|vaccine
1239369|NCT00996853|reactogenicity
1239370|NCT00996853|swine flu
1239371|NCT00996840|dilmapimod
1239372|NCT00996840|p38
1239373|NCT00996840|SB-681323
1239374|NCT00996840|Acute Lung Injury (ALI)
1239375|NCT00996840|Acute Respiratory Distress Syndrome (ARDS)
1239376|NCT00996827|Melanoma
1239377|NCT00996827|Skin cancer
1239378|NCT00996827|Vitamin D
1239379|NCT00996827|Vitamin D receptor
1239380|NCT00996827|Sunlight
1239381|NCT00996827|Cytokine
1239382|NCT00996814|Bioethics
1239383|NCT00996788|Patients suffering of dyspepsia due to chronic gastritis
1239384|NCT00996775|Alcohol Consumption
1239385|NCT00996762|bioequivalence, lapatinib, GW572016
1239386|NCT00996736|Fungal Infections
1239387|NCT00996736|Eye Disease
1239388|NCT00996736|Fungal Keratitis
1239389|NCT00996736|Visual Acuity
1239390|NCT00996710|Genome-wide
1239391|NCT00996710|09-068
1239392|NCT00996697|COPD (chronic obstructive pulmonary disease)
1239393|NCT00996684|Wet age related macular degeneration (AMD)
1239394|NCT00996684|Wet AMD
1239395|NCT00996684|Vitreomacular adhesion (VMA)
1239396|NCT00996684|Vitreomacular traction (VMT)
1239397|NCT00996684|Neovascular age related macular degeneration
1239398|NCT00996671|focal adhesion kinase inhibitor
1239399|NCT00996671|healthy volunteers
1239400|NCT00996671|first time in human
1239401|NCT00996645|Diabetes Mellitus, Type 2
1239402|NCT00996645|Coronary Artery Disease
1239403|NCT00996645|Primary Health Care
1239404|NCT00996645|Feedback, Psychological
1239405|NCT00996645|Quality Assurance, Health Care
1239406|NCT00996632|breast cancer
1239407|NCT00996632|ultrasonic knife
1239408|NCT00996632|volume drainage
1239409|NCT00996593|Tositumomab
1239410|NCT00996593|radioimmunotherapy
1239411|NCT00996593|rituximab
1239412|NCT00996593|anti-B1
1239413|NCT00996593|I 131
1239414|NCT00996593|Bexxar
1239415|NCT00996593|iodine
1239416|NCT00996593|non-Hodgkin's lymphoma
1239417|NCT00996580|Contraception
1239418|NCT00996580|Oral contraceptives
1239419|NCT00996567|Malignant mesothelioma
1239420|NCT00996554|Hand-sutured colo-colonic and ileo-colonic anastomoses in elective surgery
1239421|NCT00996541|Runaway youth
1239422|NCT00996541|Homeless youth
1239423|NCT00996541|Family intervention
1239424|NCT00996541|Family functioning
1239425|NCT00996541|HIV risk behavior
1239426|NCT00996541|HIV Seronegativity
1239427|NCT00996528|fetal alcohol syndrome
1239428|NCT00996528|alcohol abuse
1239429|NCT00996528|HIV
1239430|NCT00996528|malnutrition
1239431|NCT00996528|children
1239432|NCT00996528|mentor mother
1239433|NCT00996528|behavioral intervention
1239434|NCT00996528|South Africa
1239435|NCT00996528|Maternal alcohol use
1239436|NCT00996528|HIV-related transmission behaviors
1239437|NCT00996528|low birth weight babies and low-weight children
1239438|NCT00996528|HIV Seronegativity
1239439|NCT00996515|Advanced Solid Tumor Malignancies
1239440|NCT00996515|Erlotinib
1239441|NCT00996515|Vidaza
1239442|NCT00996515|Tarceva
1239443|NCT00996515|5-azacytidine
1239444|NCT00996476|Hepatitis C
1239445|NCT00996476|Hepatitis C virus
1239446|NCT00996476|Interferon Alfa-2a
1239447|NCT00996476|Ribavirin
1239448|NCT00996476|Viral RNA
1239449|NCT00996450|brain tumour
1239450|NCT00996437|vitreous
1239451|NCT00996437|hemorrhage
1239452|NCT00996437|proliferative
1239453|NCT00996437|diabetic
1239454|NCT00996437|retinopathy
1239455|NCT00996437|intravitreal
1239456|NCT00996437|ranibizumab
1239457|NCT00996437|Lucentis
1239458|NCT00996437|saline
1239459|NCT00996437|vitrectomy
1239460|NCT00996411|Healthy volunteers are being studied to evaluate the subject-rated, behavioral, and abuse liability effects of salvinorin A
1239461|NCT00996398|Cryotherapy
1239462|NCT00996398|Joint Position Sense
1239463|NCT00996398|Proprioception
1239464|NCT00996398|Pre Cooling
1239465|NCT00996398|Knee Injury
1239466|NCT00996398|Physical Therapy Modalities
1239467|NCT00996398|Physical Therapy Techniques
1239468|NCT00996398|Weightbearing
1239469|NCT00996398|NonWeightbearing
1239470|NCT00996398|Randomised Control Trial
1239471|NCT00996385|Pleural Mesothelioma
1239472|NCT00996385|Peritoneal Mesothelioma
1239473|NCT00996359|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1239474|NCT00996359|adult acute myeloid leukemia with inv(16)(p13;q22)
1239475|NCT00996359|adult acute myeloid leukemia with t(15;17)(q22;q12)
1239476|NCT00996359|adult acute myeloid leukemia with t(16;16)(p13;q22)
1239477|NCT00996359|adult acute myeloid leukemia with t(8;21)(q22;q22)
1239478|NCT00996359|recurrent adult acute myeloid leukemia
1239479|NCT00996359|adult acute myeloid leukemia in remission
1239480|NCT00996359|recurrent adult acute lymphoblastic leukemia
1239481|NCT00996359|adult acute lymphoblastic leukemia in remission
1239482|NCT00996359|relapsing chronic myelogenous leukemia
1239483|NCT00996359|accelerated phase chronic myelogenous leukemia
1239484|NCT00996359|chronic phase chronic myelogenous leukemia
1239485|NCT00996359|blastic phase chronic myelogenous leukemia
1239486|NCT00996359|refractory chronic lymphocytic leukemia
1239487|NCT00996359|de novo myelodysplastic syndromes
1239488|NCT00996359|previously treated myelodysplastic syndromes
1239489|NCT00996359|secondary myelodysplastic syndromes
1239490|NCT00996359|chronic myelomonocytic leukemia
1239491|NCT00996359|recurrent adult diffuse large cell lymphoma
1239492|NCT00996359|recurrent grade 1 follicular lymphoma
1239493|NCT00996359|recurrent grade 2 follicular lymphoma
1239494|NCT00996359|recurrent grade 3 follicular lymphoma
1239495|NCT00996359|recurrent mantle cell lymphoma
1239496|NCT00996359|recurrent adult diffuse small cleaved cell lymphoma
1239497|NCT00996359|recurrent marginal zone lymphoma
1239498|NCT00996359|recurrent small lymphocytic lymphoma
1239499|NCT00996359|recurrent adult Burkitt lymphoma
1239500|NCT00996359|recurrent adult diffuse mixed cell lymphoma
1239501|NCT00996359|recurrent adult immunoblastic large cell lymphoma
1239502|NCT00996359|recurrent adult lymphoblastic lymphoma
1239503|NCT00996359|recurrent adult T-cell leukemia/lymphoma
1239504|NCT00996359|recurrent cutaneous T-cell non-Hodgkin lymphoma
1239505|NCT00996359|recurrent mycosis fungoides/Sezary syndrome
1239506|NCT00996359|adult nasal type extranodal NK/T-cell lymphoma
1239507|NCT00996359|peripheral T-cell lymphoma
1239508|NCT00996359|hepatosplenic T-cell lymphoma
1239509|NCT00996359|anaplastic large cell lymphoma
1239510|NCT00996359|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1239511|NCT00996359|nodal marginal zone B-cell lymphoma
1239512|NCT00996359|splenic marginal zone lymphoma
1239513|NCT00996359|recurrent adult Hodgkin lymphoma
1239514|NCT00996359|refractory multiple myeloma
1239515|NCT00996359|childhood acute myeloid leukemia in remission
1239516|NCT00996359|recurrent childhood acute myeloid leukemia
1239517|NCT00996359|childhood acute lymphoblastic leukemia in remission
1239518|NCT00996359|recurrent childhood acute lymphoblastic leukemia
1239519|NCT00996359|childhood diffuse large cell lymphoma
1239520|NCT00996359|recurrent childhood large cell lymphoma
1239521|NCT00996359|Burkitt lymphoma
1239522|NCT00996359|childhood immunoblastic large cell lymphoma
1239523|NCT00996359|angioimmunoblastic T-cell lymphoma
1239524|NCT00996359|recurrent childhood lymphoblastic lymphoma
1239525|NCT00996359|recurrent childhood anaplastic large cell lymphoma
1239526|NCT00996359|recurrent childhood grade III lymphomatoid granulomatosis
1239527|NCT00996359|recurrent childhood small noncleaved cell lymphoma
1239528|NCT00996359|childhood nasal type extranodal NK/T-cell lymphoma
1239529|NCT00996346|INST 0909
1239530|NCT00996346|Irinotecan
1239531|NCT00996346|Temsirolimus
1239532|NCT00996346|refractory sarcomas
1239533|NCT00996346|3066K1
1239534|NCT00996346|3066K1-1208
1239535|NCT00996346|20091334
1239536|NCT00996333|Stage IVB
1239537|NCT00996320|Internship and Residency
1239538|NCT00996320|Medical Errors
1239539|NCT00996320|Burnout, Professional
1239540|NCT00996320|Burnout
1239541|NCT00996320|Depression
1239542|NCT00996320|Actigraphy
1239543|NCT00996320|Personnel Staffing and Scheduling
1239544|NCT00996320|Sleep Deprivation
1239545|NCT00996320|Workload
1239546|NCT00996320|Humans
1239547|NCT00996320|Adult
1239548|NCT00996320|Male
1239549|NCT00996320|Female
1239550|NCT00996320|Intensive Care Units
1239551|NCT00996320|Prospective Studies
1239552|NCT00996320|Crossover Studies
1239553|NCT00996320|Work Schedule Tolerance
1239554|NCT00996320|Disorders of Excessive Somnolence
1239555|NCT00996320|Guideline Adherence
1239556|NCT00996320|Internal Medicine Education
1239557|NCT00996307|Swine Flu
1239558|NCT00996307|Flu
1239559|NCT00996307|Vaccine
1239560|NCT00996307|Children
1239561|NCT00996307|Adjuvant
1239562|NCT00996307|A/H1N1 2009 Influenza
1239563|NCT00996281|Hypertensive
1239564|NCT00996281|Blood Pressure, High
1239565|NCT00996281|Cardiovascular disease
1239566|NCT00996281|Vascular Disease
1239567|NCT00996281|Drug Therapy
1239571|NCT00996242|Schizophrenia
1239572|NCT00996242|L-lysine
1239573|NCT00996242|PANSS
1239574|NCT00996229|Diet
1239575|NCT00996229|elderly
1239576|NCT00996229|cognition
1239577|NCT00996229|prevention
1239578|NCT00996229|cognitive decline
1239579|NCT00996229|Lifestyle
1239580|NCT00996216|Peginterferon
1239581|NCT00996216|Platelets
1239582|NCT00996216|Ribavirin
1239583|NCT00996216|Hepatitis C-related thrombocytopenia
1239584|NCT00996216|Thrombocytopenia
1239585|NCT00996216|Hepatitis C
1239586|NCT00996216|Thrombopoietin
1239587|NCT00996190|transthoracic bioreactance
1239588|NCT00996190|noninvasive monitoring
1239589|NCT00996190|vasopressor
1239590|NCT00996190|blood pressure
1239591|NCT00996177|Pain
1239592|NCT00996177|Patient-controlled analgesia
1239593|NCT00996177|Postoperative pain
1239594|NCT00996177|Transdermal fentanyl
1239595|NCT00996177|Surgical pain
1239596|NCT00996177|Opioid analgesics
1239597|NCT00996151|Hypergonadism
1239598|NCT00996151|Testosterone Transfer
1239599|NCT00996138|Influenza A
1239600|NCT00996138|H1N1 subtype
1239601|NCT00996138|Adult
1239602|NCT00996138|Vaccine
1239603|NCT00996138|Adjuvant
1239604|NCT00996138|Swine-Origin Influenza A H1N1 Virus
1239605|NCT00996125|Immunogenicity
1239606|NCT00996125|Safety
1239607|NCT00996125|Human papillomavirus
1239608|NCT00996125|China
1239609|NCT00996125|HPV vaccine
1239610|NCT00996112|primary health care
1239611|NCT00996099|continuous glucose monitoring
1239612|NCT00996099|intensive insulin therapy
1239613|NCT00996099|critically ill
1239614|NCT00996099|cardiac surgery
1239615|NCT00996099|hyperglycemia of critically ill
1239616|NCT00996073|Degenerative disc disease
1239617|NCT00996073|Spondylolisthesis
1239618|NCT00996073|Spinal stenosis
1239619|NCT00996073|Stem cells
1239620|NCT00996073|Adult Stem Cells
1239621|NCT00996073|Spinal Fusion
1239622|NCT00996073|Lumbar Spinal Fusion
1239623|NCT00996073|TLIF
1239624|NCT00996073|PLIF
1239625|NCT00996073|Mesoblast
1239626|NCT00996060|Lung Cancer
1239627|NCT00996060|Advanced Lung Cancer
1239628|NCT00996060|Unresectable Lung cancer
1239629|NCT00996060|Previously treated lung cancer
1239630|NCT00996047|untreated adult acute lymphoblastic leukemia
1239631|NCT00996047|accelerated phase chronic myelogenous leukemia
1239632|NCT00996047|acute undifferentiated leukemia
1239633|NCT00996047|adult acute lymphoblastic leukemia in remission
1239634|NCT00996047|adult acute myeloid leukemia in remission
1239635|NCT00996047|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1239636|NCT00996047|adult acute myeloid leukemia with inv(16)(p13;q22)
1239637|NCT00996047|adult acute myeloid leukemia with t(15;17)(q22;q12)
1239638|NCT00996047|adult acute myeloid leukemia with t(16;16)(p13;q22)
1239639|NCT00996047|adult acute myeloid leukemia with t(8;21)(q22;q22)
1239640|NCT00996047|atypical chronic myeloid leukemia, BCR-ABL1 negative
1239641|NCT00996047|blastic phase chronic myelogenous leukemia
1239642|NCT00996047|childhood acute lymphoblastic leukemia in remission
1239643|NCT00996047|childhood acute myeloid leukemia in remission
1239644|NCT00996047|childhood chronic myelogenous leukemia
1239645|NCT00996047|chronic myelomonocytic leukemia
1239646|NCT00996047|chronic phase chronic myelogenous leukemia
1239647|NCT00996047|juvenile myelomonocytic leukemia
1239648|NCT00996047|mast cell leukemia
1239649|NCT00996047|meningeal chronic myelogenous leukemia
1239650|NCT00996047|progressive hairy cell leukemia, initial treatment
1239651|NCT00996047|prolymphocytic leukemia
1239652|NCT00996047|recurrent adult acute lymphoblastic leukemia
1239653|NCT00996047|recurrent adult acute myeloid leukemia
1239654|NCT00996047|recurrent childhood acute lymphoblastic leukemia
1239655|NCT00996047|recurrent childhood acute myeloid leukemia
1239656|NCT00996047|refractory chronic lymphocytic leukemia
1239657|NCT00996047|refractory hairy cell leukemia
1239658|NCT00996047|relapsing chronic myelogenous leukemia
1239659|NCT00996047|secondary acute myeloid leukemia
1239660|NCT00996047|stage I chronic lymphocytic leukemia
1239661|NCT00996047|stage II chronic lymphocytic leukemia
1239662|NCT00996047|stage III chronic lymphocytic leukemia
1239663|NCT00996047|stage IV chronic lymphocytic leukemia
1239664|NCT00996047|T-cell large granular lymphocyte leukemia
1239665|NCT00996047|untreated adult acute myeloid leukemia
1239666|NCT00996047|untreated childhood acute lymphoblastic leukemia
1239667|NCT00996047|untreated childhood acute myeloid leukemia and other myeloid malignancies
1239668|NCT00996047|untreated hairy cell leukemia
1239669|NCT00996047|childhood myelodysplastic syndromes
1239670|NCT00996047|de novo myelodysplastic syndromes
1239671|NCT00996047|previously treated myelodysplastic syndromes
1239672|NCT00996047|secondary myelodysplastic syndromes
1239673|NCT00996047|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1239674|NCT00996047|myelodysplastic/myeloproliferative neoplasms
1239675|NCT00996034|Nicotine, SPECT, vaccine, receptor
1239676|NCT00996021|GSK1349572
1239677|NCT00996021|moxifloxacin
1239678|NCT00996021|Avelox
1239679|NCT00996021|QTc
1239680|NCT00995982|Influenza
1239681|NCT00995982|Healthy
1239682|NCT00995982|Immunity
1239683|NCT00995982|Preventive
1239684|NCT00995982|Flu
1239685|NCT00995982|HV
1239686|NCT00995982|Healthy Volunteer
1239687|NCT00995969|Mild to moderate psoriasis vulgaris
1239688|NCT00995956|Albumin
1239689|NCT00995956|Mycophenolic acid
1239690|NCT00995956|IMPDH
1239691|NCT00995956|Free fraction
1239692|NCT00995930|Atherosclerosis,
1239693|NCT00995930|Type 2 Diabetes Mellitus, T2DM,
1239694|NCT00995930|Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab
1239695|NCT00995917|acupuncture
1239696|NCT00995917|menstrual pain
1239697|NCT00995917|dysmenorrhea
1239698|NCT00995917|menstrual cramps
1239699|NCT00995917|vitamin K1
1239700|NCT00995904|asthmatic children
1239701|NCT00995891|Laboratory Research Specimens
1239702|NCT00995891|Biologic Samples
1239703|NCT00995891|Sample Collection
1239704|NCT00995891|Tissue Procurement
1239705|NCT00995891|HV
1239706|NCT00995891|Healthy Volunteer
1239707|NCT00995878|Uterine fibroids
1239708|NCT00995878|Fibroids
1239709|NCT00995878|Uterine leiomyomas
1239710|NCT00995878|UAE
1239711|NCT00995878|UFE
1239712|NCT00995878|Magnetic resonance guided focused ultrasound
1239713|NCT00995878|MRgFUS
1239714|NCT00995878|Pelvic pain
1239715|NCT00995865|Prevention of yellow fever virus infection
1239716|NCT00995852|Endoscopic lung volume reduction
1239717|NCT00995852|emphysema
1239718|NCT00995852|COPD
1239719|NCT00995852|Patients with bilateral heterogeneous pulmonary emphysema
1239720|NCT00995839|terlipressin
1239721|NCT00995839|vasopressin
1239722|NCT00995839|sepsis
1239723|NCT00995839|septic shock
1239724|NCT00995839|norepinephrine
1239725|NCT00995813|Intestinal failure
1239726|NCT00995813|Rotavirus vaccine
1239727|NCT00995813|Infants
1239728|NCT00995800|Asthma
1239729|NCT00995787|Type II diabetes mellitus
1239730|NCT00995787|metformin
1239731|NCT00995787|sulfonylurea
1239732|NCT00995774|stroke
1239733|NCT00995774|function
1239734|NCT00995774|arm
1239735|NCT00995774|hand
1239736|NCT00995774|robotic
1239737|NCT00995774|therapy
1239738|NCT00995774|motor
1239739|NCT00995774|movement
1239740|NCT00995774|treatment
1239741|NCT00995761|biweekly
1239742|NCT00995761|docetaxel
1239743|NCT00995761|cisplatin
1239744|NCT00995761|non-small cell lung cancer
1239745|NCT00995735|NOTES
1239746|NCT00995735|Natural Orifice Translumenal Endoscopic surgery
1239747|NCT00995735|Cholecystectomy
1239748|NCT00995735|Appendectomy
1239749|NCT00995735|Endoscopy
1239750|NCT00995735|Laparoscopy
1239751|NCT00995735|Minimally invasive surgery
1239752|NCT00995735|clinical trials
1239753|NCT00995722|Ocular myasthenia gravis
1239754|NCT00995722|Prednisone
1239755|NCT00995722|Steroids
1239756|NCT00995709|Behçet's disease,
1239757|NCT00995709|intermediate uveitis
1239758|NCT00995709|panuveitis
1239759|NCT00995709|posterior uveitis
1239760|NCT00995709|uveitis
1239761|NCT00995696|Interactive Voice Response (IVR)
1239762|NCT00995696|Antidepressant
1239763|NCT00995683|intracranial hypertension
1239764|NCT00995683|neurological outcome
1239765|NCT00995683|osmotherapy
1239766|NCT00995670|hyperglycemia
1239767|NCT00995670|statin
1239768|NCT00995670|blood vessels
1239769|NCT00995670|ischemic preconditioning
1239770|NCT00995670|Anesthesia, inhalational
1239771|NCT00995670|endothelium
1239772|NCT00995670|5% dextrose
1239773|NCT00995644|smoking
1239774|NCT00995644|smoking cessation
1239775|NCT00995644|tobacco use cessation
1239776|NCT00995644|tobacco use disorder
1239777|NCT00995631|liposuction
1239778|NCT00995631|adipose tissue
1239779|NCT00995631|dietary fatty acids
1239780|NCT00995631|triglyceride storage
1239781|NCT00995631|Normal healthy aging
1239782|NCT00995618|Gout
1239783|NCT00995618|Hyperuricemia
1239784|NCT00995592|nutrition
1239785|NCT00995592|child weight
1239786|NCT00995592|undernourishment
1239787|NCT00995592|mentor mother
1239788|NCT00995592|South Africa
1239789|NCT00995579|Physical Activity
1239790|NCT00995579|Energy Expenditure
1239791|NCT00995540|T1DM
1239792|NCT00995540|Regeneration
1239793|NCT00995540|Islet
1239794|NCT00995540|Beta cell
1239795|NCT00995540|INGAP Peptide
1239796|NCT00995527|Post Swine Flu Blood Samples
1239797|NCT00995527|Biologic Sample Collection
1239798|NCT00995527|Laboratory Research Samples
1239799|NCT00995527|H1N1 Vaccine Samples
1239800|NCT00995527|HV
1239801|NCT00995527|Healthy Volunteer
1239802|NCT00995514|acute coronary syndrome
1239803|NCT00995514|cardiovascular death
1239804|NCT00995514|non-fatal MI
1239805|NCT00995514|non-fatal stroke
1239806|NCT00995514|genetic testing
1239807|NCT00995514|CYP2C19
1239808|NCT00995514|clopidogrel
1239809|NCT00995514|prasugrel
1239810|NCT00995514|antiplatelet therapy
1239811|NCT00995514|genotyping
1239812|NCT00995514|bleeding
1239813|NCT00995501|steroid administration
1239814|NCT00995501|tight glucose control
1239815|NCT00995501|light anesthesiReducing inflammatory response to surgical stress
1239816|NCT00995501|a
1239817|NCT00995488|Urothelial Cancer
1239818|NCT00995488|ABI-007
1239819|NCT00995488|Bladder Cancer
1239820|NCT00995488|front-line
1239821|NCT00995449|Rheumatoid Arthritis
1239822|NCT00995449|Biologics-Inadequate
1239823|NCT00995449|KB003
1239824|NCT00995449|GM-CSF
1239825|NCT00995436|Extractions
1239826|NCT00995436|Anchorage supplementation
1239827|NCT00995423|Coronary Artery Disease
1239828|NCT00995423|stent
1239829|NCT00995410|Subjects Who are at Risk for Developing Aspirin-ASA
1239830|NCT00995410|Subject must have a pre-existing condition for which aspirin is already indicated
1239831|NCT00995410|Gastric Ulcers
1239832|NCT00995397|Insect bites
1239833|NCT00995397|Dexchlorpheniramine
1239834|NCT00995397|Lotion
1239835|NCT00995397|Cream
1239836|NCT00995371|Spinal Stenosis
1239837|NCT00995371|Lumbar Spinal Stenosis
1239838|NCT00995371|Laminotomy
1239839|NCT00995371|Laminectomy
1239840|NCT00995371|Spine Surgery
1239841|NCT00995358|Epitope peptide
1239842|NCT00995358|CTL
1239843|NCT00995358|Esophageal cancer
1239844|NCT00995358|Vaccination
1239845|NCT00995345|Type 2 Diabetes
1239846|NCT00995345|Metformin
1239847|NCT00995332|Acute myelogenous leukemia
1239848|NCT00995332|all-trans retinoic acid
1239849|NCT00995332|valproic acid
1239850|NCT00995332|cytarabine
1239851|NCT00995332|Disease stabilization
1239852|NCT00995332|survival
1239853|NCT00995332|toxicity
1239854|NCT00995319|mouth
1239855|NCT00995319|Mucositis
1239856|NCT00995319|Dysphagia
1239857|NCT00995319|malnutrition
1239858|NCT00995319|Xerostomia
1239859|NCT00995319|saliva
1239860|NCT00995319|tooth injuries
1239861|NCT00995306|Active comparator
1239862|NCT00995306|Active civamide cream, 0.075%
1239863|NCT00995306|Active civamide cream, 0.01%
1239864|NCT00995280|follicle flushing
1239865|NCT00995280|oocyte retrieval
1239866|NCT00995280|needle
1239867|NCT00995267|childhood obesity
1239868|NCT00995267|nutrition
1239869|NCT00995267|exercise
1239870|NCT00995267|Alfred Adler
1239871|NCT00995267|schoolchildren
1239872|NCT00995267|intervention study
1239873|NCT00995267|community-based trial
1239874|NCT00995267|parent-child interaction
1239875|NCT00995267|nutritional behaviors
1239876|NCT00995254|secondhand smoke
1239877|NCT00995254|children
1239878|NCT00995254|Chinese
1239879|NCT00995254|respiratory symptoms
1239880|NCT00995254|household smoking policy
1239881|NCT00995254|Respiratory illnesses among children
1239882|NCT00995241|Raltegravir
1239883|NCT00995241|intracellular concentration
1239884|NCT00995241|plasmatic concentration
1239885|NCT00995241|HIV
1239886|NCT00995241|Treatment experienced
1239887|NCT00995228|overhydration
1239888|NCT00995228|fluid restriction
1239889|NCT00995228|post-anesthesia care unit
1239890|NCT00995215|spinal cord injury
1239891|NCT00995215|SCI
1239892|NCT00995215|paralysis
1239893|NCT00995215|cough
1239894|NCT00995215|cervical spinal cord injury
1239895|NCT00995215|thoracic spinal cord injury
1239896|NCT00995202|stage II colon cancer
1239897|NCT00995202|stage II rectal cancer
1239898|NCT00995202|stage III colon cancer
1239899|NCT00995202|stage III rectal cancer
1239900|NCT00995202|adenocarcinoma of the colon
1239901|NCT00995202|adenocarcinoma of the rectum
1239902|NCT00995189|contact lens wear
1239903|NCT00995189|multi-purpose solution
1239904|NCT00995189|corneal staining
1239905|NCT00995176|Prevention
1239906|NCT00995176|HIV
1239907|NCT00995176|HIV seronegativity
1239908|NCT00995163|outcomes study
1239909|NCT00995163|hemodialysis
1239910|NCT00995163|CKD-MBD
1239911|NCT00995150|contraception
1239912|NCT00995150|intrauterine
1239913|NCT00995150|long-term
1239914|NCT00995150|reversible
1239915|NCT00995137|Relapsed or refractory B-Lineage ALL
1239916|NCT00995124|ovicide
1239917|NCT00995124|head lice infestation
1239918|NCT00995098|Acute severe pancreatitis
1239919|NCT00995098|nutritional support
1239920|NCT00995098|enteral nutrition
1239921|NCT00995098|parenteral nutrition
1239922|NCT00995085|ADHD
1239923|NCT00995085|ADD
1239924|NCT00995085|TOVA
1239925|NCT00995085|METADOXINE
1239926|NCT00995072|sexual dysfunction
1239927|NCT00995072|female
1239928|NCT00995072|hypertension
1239929|NCT00995072|high blood pressure
1239930|NCT00995072|beta blockers
1239931|NCT00995072|metoprolol
1239932|NCT00995072|nebivolol
1239933|NCT00995072|Bystolic
1239934|NCT00995072|Toprol XL
1239935|NCT00995059|stage I multiple myeloma
1239936|NCT00995059|stage II multiple myeloma
1239937|NCT00995059|stage III multiple myeloma
1239938|NCT00995046|Hemophilia A
1239939|NCT00995046|prophylaxis
1239940|NCT00995046|thrombin generation test (TGT)
1239941|NCT00995033|Smoking cessation
1239942|NCT00995033|Smoking lapse behavior
1239943|NCT00995033|Smoking Relapse behavior
1239944|NCT00995033|Varenicline
1239945|NCT00995033|Nicotine conjugate vaccine
1239946|NCT00995033|Medication effect on smoking lapse behavior
1239947|NCT00995020|Cone biopsy
1239948|NCT00995020|Conization
1239949|NCT00995020|Loop electrosurgical excisional procedures
1239950|NCT00995020|Large Loop Excision of Transformation Zone
1239951|NCT00995020|Needle Excision of Transformation Zone
1239952|NCT00995020|Straight Wire Excision of Transformation Zone
1239953|NCT00995020|Electrosurgery
1239954|NCT00995007|Brain Tumor
1239955|NCT00995007|Chemotherapy
1239956|NCT00995007|Antiangiogenesis
1239957|NCT00995007|Radiation
1239958|NCT00995007|Progression
1239959|NCT00995007|Glioma
1239960|NCT00995007|Glioblastoma Multiforme
1239961|NCT00994994|pediatric cardiac surgery
1239962|NCT00994994|bleeding
1239963|NCT00994994|tranexamic acid
1239964|NCT00994994|fibrinolysis
1239965|NCT00994994|blood loss in pediatric cardiac surgery
1239966|NCT00994981|magnesium and reperfusion injury
1239967|NCT00994968|stage II breast cancer
1239968|NCT00994968|stage III breast cancer
1239969|NCT00994955|SRT
1239970|NCT00994955|laser
1239971|NCT00994955|diabetic macular edema
1239972|NCT00994955|diabetes
1239973|NCT00994955|Clinically significant diabetic macular edema
1239974|NCT00994929|biologic effects
1239975|NCT00994929|von Willebrand disease
1239976|NCT00994929|hemophilia
1239977|NCT00994929|interleukin-11
1239978|NCT00994929|DDAVp
1239979|NCT00994916|Lambert-Eaton myasthenic syndrome
1239980|NCT00994916|3,4 diaminopyridine
1239981|NCT00994903|Statin
1239982|NCT00994903|Colon
1239983|NCT00994903|Colorectal
1239984|NCT00994903|Intestinal Neoplasms
1239985|NCT00994903|ERAS
1239986|NCT00994903|Perioperative Care
1239987|NCT00994890|Double-blind safety
1239988|NCT00994825|levosimendan
1239989|NCT00994825|cardiac surgery
1239990|NCT00994825|cardiac anesthesia
1239991|NCT00994825|mortality
1239992|NCT00994825|survival
1239993|NCT00994825|inotropic drugs
1239994|NCT00994812|Polycystic ovary syndrome
1239995|NCT00994812|PCOS
1239996|NCT00994812|Metformin
1239997|NCT00994812|Miscarriage
1239998|NCT00994812|Infertility
1239999|NCT00994812|Complications of pregnancy
1240000|NCT00994786|treatment-resistant
1240001|NCT00994786|refractory
1240002|NCT00994786|obsessive compulsive disorder
1240003|NCT00994786|Lyrica
1240004|NCT00994786|pregabalin
1240005|NCT00994786|Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder
1240006|NCT00994773|Hepatitis B
1240007|NCT00994773|simvastatin
1240008|NCT00994773|HBV DNA
1240009|NCT00994760|intranasal fentanyl spray
1240010|NCT00994747|infancy
1240011|NCT00994747|nutrition
1240012|NCT00994747|protein hydrolysate formula
1240013|NCT00994747|flavor preferences
1240014|NCT00994747|food preferences
1240015|NCT00994747|growth
1240016|NCT00994747|emotional development
1240017|NCT00994747|mother-infant interaction
1240018|NCT00994747|infant temperament
1240019|NCT00994747|feeding patterning
1240020|NCT00994747|taste receptor and obesity genotype
1240021|NCT00994747|sensitive period
1240022|NCT00994721|Pancreatic Cancer
1240023|NCT00994695|Trivalent meningococcal polysaccharide vaccine
1240024|NCT00994695|Children
1240025|NCT00994695|Safety
1240026|NCT00994695|Immunogenicity
1240027|NCT00994695|To assess Safety of trivalent meningococcal polysaccharide vaccine in children
1240028|NCT00994695|To assess the immunogenicity of the trivalent polysaccharide vaccine in children
1240029|NCT00994682|Additional relevant MeSH terms:
1240030|NCT00994682|Hypoglycemic Agents
1240031|NCT00994682|Physiological Effects of Drugs
1240032|NCT00994682|Pharmacologic Actions
1240033|NCT00994682|Pioglitazone
1240034|NCT00994656|invasive procedures
1240035|NCT00994656|hypovolemia
1240036|NCT00994643|NHL
1240037|NCT00994643|Non Hodgkin's Lymphoma
1240038|NCT00994643|Lymphoma
1240039|NCT00994591|Nicotine
1240040|NCT00994591|Cotinine
1240041|NCT00994591|CYP2A6
1240042|NCT00994578|Advanced cancer
1240043|NCT00994565|Physical activity
1240044|NCT00994565|health behaviour
1240045|NCT00994565|lifestyle
1240046|NCT00994565|productivity
1240047|NCT00994565|outcomes
1240048|NCT00994526|Colorectal cancer
1240049|NCT00994526|Processed meat
1240050|NCT00994526|Calcium
1240051|NCT00994526|Vitamin E
1240052|NCT00994526|Preventive strategies
1240053|NCT00994513|Antioxidant
1240054|NCT00994513|Obesity
1240055|NCT00994487|Childhood Obesity
1240056|NCT00994487|Breastfeeding
1240057|NCT00994487|Bottle Feeding
1240058|NCT00994487|Dietary Intake
1240059|NCT00994487|Preload
1240060|NCT00994487|Compensation
1240061|NCT00994487|Parental Feeding Style
1240062|NCT00994474|Laser surgery
1240063|NCT00994474|Profilometry
1240064|NCT00994474|Fitzpatrick wrinkle score
1240065|NCT00994474|Patient Benefit Index
1240066|NCT00994474|Patient satisfaction
1240067|NCT00994461|Endoscopy
1240068|NCT00994448|Adolescents
1240069|NCT00994448|Methamphetamine abuse
1240070|NCT00994448|Bupropion
1240071|NCT00994448|Addiction
1240072|NCT00994448|Pharmacotherapy
1240073|NCT00994448|Cognitive Behavioral Therapy
1240074|NCT00994448|Contingency Management
1240075|NCT00994448|Teens
1240076|NCT00994435|obesity
1240077|NCT00994422|PEDICULUS HUMANUS CAPITIS
1240078|NCT00994422|Head Lice
1240079|NCT00994409|Stroke
1240080|NCT00994370|Pro-angiogenic markers
1240081|NCT00994370|SIRT
1240082|NCT00994370|hepatic metastases
1240083|NCT00994357|Real-time Continuous Glucose Monitoring
1240084|NCT00994357|Macrosomia
1240085|NCT00994344|Darunavir
1240086|NCT00994344|Lopinavir
1240087|NCT00994344|Monotherapy
1240088|NCT00994344|Antiretroviral simplification strategy
1240089|NCT00994344|HIV
1240090|NCT00994344|Treatment experienced
1240091|NCT00994331|Percutaneous Coronary Intervention
1240092|NCT00994331|Magnetic Navigation
1240093|NCT00994331|Computed Tomography
1240094|NCT00994318|Ferinject Iron Deficiency Anaemia Chronic Kidney Disease
1240095|NCT00994305|kidney transplantation
1240096|NCT00994305|oxidative stress
1240097|NCT00994305|acetylcysteine
1240098|NCT00994305|graft rejection
1240099|NCT00994292|Factor Xa
1240100|NCT00994292|Anticoagulant
1240101|NCT00994292|YM150
1240102|NCT00994292|Acute Coronary Syndrome
1240103|NCT00994279|fatigue
1240104|NCT00994279|depression
1240105|NCT00994279|sleep disorders
1240106|NCT00994279|stage IA breast cancer
1240107|NCT00994279|stage IB breast cancer
1240108|NCT00994279|stage II breast cancer
1240109|NCT00994279|stage IIIA breast cancer
1240110|NCT00994279|stage IIIB breast cancer
1240111|NCT00994279|stage IIIC breast cancer
1240112|NCT00994279|recurrent breast cancer
1240113|NCT00994266|Type 2 diabetes
1240114|NCT00994266|Diamel
1240115|NCT00994266|Dietary supplement
1240116|NCT00994227|electron microscopy
1240117|NCT00994227|internal limiting membrane
1240118|NCT00994227|macular disease
1240119|NCT00994227|optical coherence tomography
1240120|NCT00994188|Renal tumor
1240121|NCT00994188|Ureteral tumor
1240122|NCT00994188|Ureteral stricture
1240123|NCT00994188|Restored kidney
1240124|NCT00994188|Renal transplantation
1240125|NCT00994188|Family members
1240126|NCT00994175|Pioglitazone
1240127|NCT00994175|Severe, Refractory Asthma
1240128|NCT00994175|Peroxisome Proliferator-Activated Receptor Gamma
1240129|NCT00994175|Airflow Obstruction
1240130|NCT00994175|Airway Inflammation
1240131|NCT00994175|Asthma
1240132|NCT00994162|NPWT
1240133|NCT00994162|Gauze-based filler
1240134|NCT00994162|Acute or Chronic Wounds
1240135|NCT00994162|Efficacy
1240136|NCT00994149|Infants of Diabetic Mothers
1240137|NCT00994149|Hypoglycemia
1240138|NCT00994149|Diazoxide
1240139|NCT00994149|Large for Gestation Infants
1240140|NCT00994136|Catheters, indwelling
1240141|NCT00994136|Catheterization, Central Venous
1240142|NCT00994136|Withdrawal occlusion
1240143|NCT00994136|Heparin lock
1240144|NCT00994123|Non-Small Cell Lung Cancer
1240145|NCT00994123|NSCLC
1240146|NCT00994123|Advanced Non-Small Cell Lung Cancer
1240147|NCT00994123|Metastatic Non-Small Cell Lung Cancer
1240148|NCT00994123|Lung Cancer
1240149|NCT00994123|Erlotinib
1240150|NCT00994123|Tarceva
1240151|NCT00994123|MM-121
1240152|NCT00994123|ErbB3
1240153|NCT00994123|Her3
1240154|NCT00994123|Epidermal Growth Factor Receptor
1240155|NCT00994123|anti-ErbB3 human monoclonal antibody
1240156|NCT00994123|ErbB3 antagonist
1240157|NCT00994110|PANCREAS
1240158|NCT00994110|Pasireotide
1240159|NCT00994110|SOM230
1240160|NCT00994110|saline placebo
1240161|NCT00994110|09-039
1240162|NCT00994097|NGR-hTNF
1240163|NCT00994097|Randomized controlled trial
1240164|NCT00994097|Gemcitabine
1240165|NCT00994097|Cisplatin
1240166|NCT00994097|Pemetrexed
1240167|NCT00994097|Carcinoma, non-small cell lung
1240168|NCT00994084|Obesity
1240169|NCT00994084|Minority children
1240170|NCT00994084|Community intervention program
1240171|NCT00994084|Lifestyle changes
1240172|NCT00994084|Physical activities
1240173|NCT00994084|Nutrition lessons
1240174|NCT00994084|Behavior modification
1240175|NCT00994071|Brain Tumor
1240176|NCT00994071|CNC Tumor
1240177|NCT00994071|Pediatric
1240178|NCT00994071|PARP Inhibitor
1240179|NCT00994071|Oral Chemotherapy
1240180|NCT00994058|Preterm Labor
1240181|NCT00994058|Uterine Inhibitor
1240182|NCT00994058|Electro-Inhibition
1240183|NCT00994045|Thoraco-Abdominal Aneurysm (TAAA)
1240184|NCT00994045|Coagulopathy
1240185|NCT00994045|Fresh Frozen Plasma
1240186|NCT00994045|Fibrinogen Concentrate
1240187|NCT00994032|vertebroplasty
1240188|NCT00994032|disability evaluation
1240189|NCT00994032|outcome assessment
1240190|NCT00994032|pain measurement
1240191|NCT00994019|HPV
1240192|NCT00994019|oral cancer
1240193|NCT00994019|young adults
1240194|NCT00994006|Magnesium
1240195|NCT00994006|nutrition
1240196|NCT00994006|platelets
1240197|NCT00994006|aggregation
1240198|NCT00993993|cleft palate
1240199|NCT00993980|qigong
1240200|NCT00993980|traditional chinese medicine
1240201|NCT00993980|exercise therapy
1240202|NCT00993980|low back pain
1240203|NCT00993967|FRDA
1240204|NCT00993967|idebenone
1240205|NCT00993967|FRDA disease
1240206|NCT00993954|Nurse Treatment
1240207|NCT00993954|Pulled Elbow
1240208|NCT00993941|BMSC
1240209|NCT00993941|Stem cells
1240210|NCT00993941|Liver cirrhosis
1240211|NCT00993941|Transplantation
1240212|NCT00993928|psychosocial effects of cancer and its treatment
1240213|NCT00993928|fatigue
1240214|NCT00993928|sleep disorders
1240215|NCT00993928|cancer survivor
1240216|NCT00993915|Coronary Artery Disease
1240217|NCT00993915|Hyperlipidemia
1240218|NCT00993915|Atorvastatin
1240219|NCT00993902|Double IUI
1240220|NCT00993902|Intrauterine insemination
1240221|NCT00993902|Unexplained infertility
1240222|NCT00993889|Virtual Reality Peds
1240223|NCT00993876|Depression
1240224|NCT00993876|CREB
1240225|NCT00993876|cognitive performance
1240226|NCT00993876|psychotherapy
1240227|NCT00993876|SSRI
1240228|NCT00993876|SNRI
1240229|NCT00993863|delta opioid agonist
1240230|NCT00993863|dental pain
1240231|NCT00993850|Bipolar disorder
1240232|NCT00993850|Insomnia
1240233|NCT00993850|Sleep disturbance
1240234|NCT00993850|Cognitive behavioral therapy
1240235|NCT00993837|endoscopic thyroidectomy
1240236|NCT00993837|thyroid carcinoma
1240237|NCT00993811|male circumcision
1240238|NCT00993811|HIV
1240239|NCT00993811|Africa
1240240|NCT00993811|HIV Seronegativity
1240241|NCT00993798|Post operative pain
1240242|NCT00993798|Local anaesthesia
1240243|NCT00993798|Postoperative pain after arthroscopic shoulder surgery
1240244|NCT00993759|common cold
1240245|NCT00993759|rhinovirus
1240246|NCT00993759|prevention
1240247|NCT00993746|Ultrasound guided infraclavicular brachial plexus block
1240248|NCT00993746|Bupivacaine
1240249|NCT00993746|Bupivacaine plus lidocaine
1240250|NCT00993746|End stage renal disease
1240251|NCT00993746|Arteriovenous fistula
1240252|NCT00993733|hemodiafiltration
1240253|NCT00993733|cost
1240254|NCT00993733|dialysis solution
1240255|NCT00993733|acute renal failure
1240256|NCT00993733|intensive care unit
1240257|NCT00993720|patients with type 1 diabetes mellitus
1240258|NCT00993707|Chronic Obstructive Pulmonary Disease (COPD)
1240259|NCT00993694|methemoglobinemia
1240260|NCT00993694|aplastic anemia
1240261|NCT00993694|accelerated phase chronic myelogenous leukemia
1240262|NCT00993694|acute undifferentiated leukemia
1240263|NCT00993694|atypical chronic myeloid leukemia, BCR-ABL negative
1240264|NCT00993694|blastic phase chronic myelogenous leukemia
1240265|NCT00993694|childhood acute lymphoblastic leukemia in remission
1240266|NCT00993694|childhood acute myeloid leukemia in remission
1240267|NCT00993694|childhood chronic myelogenous leukemia
1240268|NCT00993694|chronic myelomonocytic leukemia
1240269|NCT00993694|chronic phase chronic myelogenous leukemia
1240270|NCT00993694|juvenile myelomonocytic leukemia
1240271|NCT00993694|mast cell leukemia
1240272|NCT00993694|meningeal chronic myelogenous leukemia
1240273|NCT00993694|progressive hairy cell leukemia, initial treatment
1240274|NCT00993694|prolymphocytic leukemia
1240275|NCT00993694|recurrent childhood acute lymphoblastic leukemia
1240481|NCT00993343|allogeneic
1240276|NCT00993694|recurrent childhood acute myeloid leukemia
1240277|NCT00993694|refractory chronic lymphocytic leukemia
1240278|NCT00993694|refractory hairy cell leukemia
1240279|NCT00993694|relapsing chronic myelogenous leukemia
1240280|NCT00993694|secondary acute myeloid leukemia
1240281|NCT00993694|stage 0 chronic lymphocytic leukemia
1240282|NCT00993694|stage I chronic lymphocytic leukemia
1240283|NCT00993694|stage II chronic lymphocytic leukemia
1240284|NCT00993694|stage III chronic lymphocytic leukemia
1240285|NCT00993694|stage IV chronic lymphocytic leukemia
1240286|NCT00993694|T-cell large granular lymphocyte leukemia
1240287|NCT00993694|AIDS-related diffuse large cell lymphoma
1240288|NCT00993694|AIDS-related diffuse mixed cell lymphoma
1240289|NCT00993694|AIDS-related diffuse small cleaved cell lymphoma
1240290|NCT00993694|AIDS-related immunoblastic large cell lymphoma
1240291|NCT00993694|AIDS-related lymphoblastic lymphoma
1240292|NCT00993694|AIDS-related peripheral/systemic lymphoma
1240293|NCT00993694|AIDS-related primary CNS lymphoma
1240294|NCT00993694|AIDS-related small noncleaved cell lymphoma
1240295|NCT00993694|HIV-associated Hodgkin lymphoma
1240296|NCT00993694|recurrent/refractory childhood Hodgkin lymphoma
1240297|NCT00993694|stage I childhood Hodgkin lymphoma
1240298|NCT00993694|stage II childhood Hodgkin lymphoma
1240299|NCT00993694|stage IV childhood Hodgkin lymphoma
1240300|NCT00993694|anaplastic large cell lymphoma
1240301|NCT00993694|angioimmunoblastic T-cell lymphoma
1240302|NCT00993694|cutaneous B-cell non-Hodgkin lymphoma
1240303|NCT00993694|recurrent cutaneous T-cell non-Hodgkin lymphoma
1240304|NCT00993694|stage I cutaneous T-cell non-Hodgkin lymphoma
1240305|NCT00993694|stage II cutaneous T-cell non-Hodgkin lymphoma
1240306|NCT00993694|stage III cutaneous T-cell non-Hodgkin lymphoma
1240307|NCT00993694|stage IV cutaneous T-cell non-Hodgkin lymphoma
1240308|NCT00993694|recurrent mycosis fungoides/Sezary syndrome
1240309|NCT00993694|stage I mycosis fungoides/Sezary syndrome
1240310|NCT00993694|stage II mycosis fungoides/Sezary syndrome
1240311|NCT00993694|stage III mycosis fungoides/Sezary syndrome
1240312|NCT00993694|stage IV mycosis fungoides/Sezary syndrome
1240313|NCT00993694|Waldenstrom macroglobulinemia
1240314|NCT00993694|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1240315|NCT00993694|nodal marginal zone B-cell lymphoma
1240316|NCT00993694|splenic marginal zone lymphoma
1240317|NCT00993694|contiguous stage II grade 1 follicular lymphoma
1240318|NCT00993694|contiguous stage II grade 2 follicular lymphoma
1240319|NCT00993694|contiguous stage II grade 3 follicular lymphoma
1240320|NCT00993694|contiguous stage II mantle cell lymphoma
1240321|NCT00993694|contiguous stage II marginal zone lymphoma
1240322|NCT00993694|contiguous stage II small lymphocytic lymphoma
1240323|NCT00993694|stage I grade 1 follicular lymphoma
1240324|NCT00993694|stage I grade 2 follicular lymphoma
1240325|NCT00993694|stage I grade 3 follicular lymphoma
1240326|NCT00993694|stage I mantle cell lymphoma
1240327|NCT00993694|stage I marginal zone lymphoma
1240328|NCT00993694|stage I small lymphocytic lymphoma
1240329|NCT00993694|noncontiguous stage II grade 1 follicular lymphoma
1240330|NCT00993694|noncontiguous stage II grade 2 follicular lymphoma
1240331|NCT00993694|noncontiguous stage II grade 3 follicular lymphoma
1240332|NCT00993694|noncontiguous stage II mantle cell lymphoma
1240333|NCT00993694|noncontiguous stage II marginal zone lymphoma
1240334|NCT00993694|noncontiguous stage II small lymphocytic lymphoma
1240335|NCT00993694|stage I childhood large cell lymphoma
1240336|NCT00993694|stage I childhood lymphoblastic lymphoma
1240337|NCT00993694|stage I childhood small noncleaved cell lymphoma
1240338|NCT00993694|stage II childhood large cell lymphoma
1240339|NCT00993694|stage II childhood lymphoblastic lymphoma
1240340|NCT00993694|stage II childhood small noncleaved cell lymphoma
1240341|NCT00993694|stage III childhood large cell lymphoma
1240342|NCT00993694|stage III childhood lymphoblastic lymphoma
1240343|NCT00993694|stage III childhood small noncleaved cell lymphoma
1240344|NCT00993694|stage III grade 1 follicular lymphoma
1240345|NCT00993694|stage III grade 2 follicular lymphoma
1240346|NCT00993694|stage III grade 3 follicular lymphoma
1240347|NCT00993694|stage III mantle cell lymphoma
1240348|NCT00993694|stage III marginal zone lymphoma
1240349|NCT00993694|stage III small lymphocytic lymphoma
1240350|NCT00993694|stage IV childhood large cell lymphoma
1240351|NCT00993694|stage IV childhood lymphoblastic lymphoma
1240352|NCT00993694|stage IV childhood small noncleaved cell lymphoma
1240353|NCT00993694|stage IV grade 1 follicular lymphoma
1240354|NCT00993694|stage IV grade 2 follicular lymphoma
1240355|NCT00993694|stage IV grade 3 follicular lymphoma
1240356|NCT00993694|stage IV mantle cell lymphoma
1240357|NCT00993694|stage IV marginal zone lymphoma
1240358|NCT00993694|stage IV small lymphocytic lymphoma
1240359|NCT00993694|recurrent childhood grade III lymphomatoid granulomatosis
1240360|NCT00993694|recurrent childhood large cell lymphoma
1240361|NCT00993694|recurrent childhood lymphoblastic lymphoma
1240362|NCT00993694|recurrent childhood small noncleaved cell lymphoma
1240363|NCT00993694|recurrent grade 1 follicular lymphoma
1240364|NCT00993694|recurrent grade 2 follicular lymphoma
1240365|NCT00993694|recurrent grade 3 follicular lymphoma
1240366|NCT00993694|recurrent mantle cell lymphoma
1240367|NCT00993694|recurrent marginal zone lymphoma
1240368|NCT00993694|recurrent small lymphocytic lymphoma
1240369|NCT00993694|Burkitt lymphoma
1240370|NCT00993694|childhood diffuse large cell lymphoma
1240371|NCT00993694|childhood grade III lymphomatoid granulomatosis
1240372|NCT00993694|childhood immunoblastic large cell lymphoma
1240373|NCT00993694|childhood nasal type extranodal NK/T-cell lymphoma
1240374|NCT00993694|intraocular lymphoma
1240375|NCT00993694|primary central nervous system non-Hodgkin lymphoma
1240376|NCT00993694|post-transplant lymphoproliferative disorder
1240377|NCT00993694|chronic eosinophilic leukemia
1240378|NCT00993694|chronic neutrophilic leukemia
1240379|NCT00993694|primary myelofibrosis
1240380|NCT00993694|essential thrombocythemia
1240381|NCT00993694|polycythemia vera
1240382|NCT00993694|extramedullary plasmacytoma
1240383|NCT00993694|isolated plasmacytoma of bone
1240384|NCT00993694|stage I multiple myeloma
1240385|NCT00993694|stage II multiple myeloma
1240386|NCT00993694|stage III multiple myeloma
1240387|NCT00993694|primary systemic amyloidosis
1240388|NCT00993694|refractory multiple myeloma
1240389|NCT00993694|de novo myelodysplastic syndromes
1240390|NCT00993694|previously treated myelodysplastic syndromes
1240391|NCT00993694|secondary myelodysplastic syndromes
1240392|NCT00993694|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1240393|NCT00993694|childhood myelodysplastic syndromes
1240394|NCT00993694|recurrent childhood anaplastic large cell lymphoma
1240395|NCT00993694|stage I childhood anaplastic large cell lymphoma
1240396|NCT00993694|stage II childhood anaplastic large cell lymphoma
1240397|NCT00993694|stage III childhood anaplastic large cell lymphoma
1240398|NCT00993694|stage IV childhood anaplastic large cell lymphoma
1240399|NCT00993694|stage III childhood Hodgkin lymphoma
1240400|NCT00993681|Prevention of Travelers' Diarrhea
1240401|NCT00993668|influenza
1240402|NCT00993668|vaccine
1240403|NCT00993668|pneumococcal vaccine
1240404|NCT00993668|certolizumab pegol
1240405|NCT00993668|Cimzia
1240406|NCT00993655|peritoneal cavity cancer
1240407|NCT00993655|fallopian tube cancer
1240408|NCT00993655|stage II ovarian epithelial cancer
1240409|NCT00993655|stage III ovarian epithelial cancer
1240410|NCT00993655|stage IV ovarian epithelial cancer
1240411|NCT00993655|malignant pleural effusion
1240412|NCT00993655|ovarian clear cell cystadenocarcinoma
1240413|NCT00993655|ovarian clear cell tumor with proliferating activity
1240414|NCT00993642|estrogen receptor positive tamoxifen resistant breast cancer
1240415|NCT00993629|PTSD
1240416|NCT00993629|Depression
1240417|NCT00993629|Neurosteroids
1240418|NCT00993603|Lifestyle
1240419|NCT00993603|Diabetes Mellitus
1240420|NCT00993603|prevention/onset delay.
1240421|NCT00993590|Persistent asthma
1240422|NCT00993590|Asthma related emergency room visits
1240423|NCT00993590|Asthma control, adolescents
1240424|NCT00993590|Adherence, asthma control medications
1240425|NCT00993577|Stretching
1240426|NCT00993577|Pain
1240427|NCT00993564|Therapeutic hypothermia
1240428|NCT00993564|Head cooling
1240429|NCT00993564|Hypoxic ischemic encephalopathy
1240430|NCT00993564|Newborn
1240431|NCT00993551|cleft palate
1240432|NCT00993551|paediatric
1240433|NCT00993551|pediatric
1240434|NCT00993551|surgery
1240435|NCT00993551|speech
1240436|NCT00993551|velopharyngeal
1240437|NCT00993538|Leukaemia
1240438|NCT00993538|Blood and marrow cells culture
1240439|NCT00993538|Cell growth
1240440|NCT00993538|Cell differentiation
1240441|NCT00993525|diabetic retinopathy
1240442|NCT00993525|ranibizumab
1240443|NCT00993525|new vessels
1240444|NCT00993525|intravitreal injection
1240445|NCT00993525|Persistent retina new vessels
1240446|NCT00993512|photochemical internalisation
1240447|NCT00993512|photosensitiser
1240448|NCT00993512|cutaneous tumour
1240449|NCT00993512|sub-cutaneous tumour
1240450|NCT00993512|dose escalation
1240451|NCT00993486|Haploidentical stem cell transplantation
1240452|NCT00993486|Graft-versus-host disease
1240453|NCT00993486|Immune reconstitution
1240454|NCT00993486|Alloreactive T-cells
1240455|NCT00993486|Photodepletion
1240456|NCT00993486|TH9402
1240457|NCT00993486|Transplant related mortality
1240458|NCT00993486|Hematologic malignancy
1240459|NCT00993460|Obesity
1240460|NCT00993460|Insulin sensitivity
1240461|NCT00993460|Inflammation
1240462|NCT00993447|Dengue
1240463|NCT00993447|Dengue hemorrhagic fever
1240464|NCT00993447|Dengue virus
1240465|NCT00993447|Dengue fever
1240466|NCT00993447|Sanofi pasteur's CYD Dengue vaccine
1240467|NCT00993434|Child
1240468|NCT00993395|addiction
1240469|NCT00993395|peer mentor
1240470|NCT00993395|adherence
1240471|NCT00993369|Prediction of neuro developmental delay
1240472|NCT00993356|Acromegaly
1240473|NCT00993356|Macroadenomas
1240474|NCT00993356|Lanreotide
1240475|NCT00993356|Transsphenoidal neurosurgery
1240476|NCT00993356|Preoperative
1240477|NCT00993343|GVHD
1240478|NCT00993343|tacrolimus
1240479|NCT00993343|sirolimus
1240480|NCT00993343|cyclosporine
1240482|NCT00993343|stem cell transplantation
1240483|NCT00993343|Relapse-free survival
1240484|NCT00993330|macular pigment
1240485|NCT00993330|to measure macular pigment in the retina
1240486|NCT00993317|CDP870
1240487|NCT00993317|Korea
1240488|NCT00993317|CIMZIA
1240489|NCT00993291|Parkinson's Disease
1240490|NCT00993291|DBS
1240491|NCT00993291|Frequency
1240492|NCT00993291|Deep brain stimulation
1240493|NCT00993265|Trichotillomania
1240494|NCT00993265|Hair pulling
1240495|NCT00993265|glutamate
1240496|NCT00993265|N-Acetylcysteine
1240497|NCT00993265|Children
1240498|NCT00993252|head injury
1240499|NCT00993252|radiography
1240500|NCT00993252|clinical impact
1240501|NCT00993252|dissemination
1240502|NCT00993226|Postoperative pain
1240503|NCT00993226|Local anaesthesia
1240504|NCT00993226|Postoperative pain after open abdominal hysterectomy surgery
1240505|NCT00993213|fat mass
1240506|NCT00993213|body composition
1240507|NCT00993200|Warfarin
1240508|NCT00993200|Pharmacogenetic
1240509|NCT00993161|Neuromuscular disorders
1240510|NCT00993161|Evaluation
1240511|NCT00993161|Strength
1240512|NCT00993161|Upper limb
1240513|NCT00993148|Treatment naive
1240514|NCT00993135|renal toxicity
1240515|NCT00993135|childhood acute lymphoblastic leukemia
1240516|NCT00993135|adult acute lymphoblastic leukemia
1240517|NCT00993122|pre treatment
1240518|NCT00993122|therapy compliance
1240519|NCT00993122|SVR
1240520|NCT00993122|sustained virological response
1240521|NCT00993122|TH1 TH2 ratio
1240522|NCT00993109|Nifedipine GITS/OROS (Adalat®)
1240523|NCT00993109|Valsartan (Diovan®)
1240524|NCT00993109|Hypertension
1240525|NCT00993083|Influenza
1240526|NCT00993083|Vaccine
1240527|NCT00993070|capsaicin
1240528|NCT00993070|placebo
1240529|NCT00993070|trial
1240530|NCT00993070|diabetic polyneuropathy
1240531|NCT00993070|neuropathic pain
1240532|NCT00993057|Euglycemia
1240533|NCT00993057|craniotomy
1240534|NCT00993057|neurosurgery
1240535|NCT00993057|hypoglycemia
1240536|NCT00993057|insulin
1240537|NCT00993031|HIV
1240538|NCT00993031|Placental Malaria
1240539|NCT00993031|Pregnancy
1240540|NCT00993031|Uganda
1240541|NCT00993031|Protease inhibitors
1240542|NCT00993031|Trimethoprim-sulfamethoxazole
1240543|NCT00993031|Treatment experienced
1240544|NCT00993018|Diabetic Neuropathy
1240545|NCT00993018|Diabetic painful neuropathy
1240546|NCT00993018|JNJ-42160443
1240547|NCT00993018|Neuropathic pain
1240548|NCT00993018|Pain
1240549|NCT00993018|Pharmacokinetics
1240550|NCT00993005|Hypertrophic scars
1240551|NCT00993005|Keloids
1240552|NCT00993005|Asian Gotu Kola
1240553|NCT00993005|Asian Pennywort
1240554|NCT00992992|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
1240555|NCT00992992|Tositumomab
1240556|NCT00992992|Tositumomab and Iodine I-131 tostumomab
1240557|NCT00992992|Bexxar
1240558|NCT00992992|Iodine-131 Anti-B1 Antibody
1240559|NCT00992992|Mantle Cell
1240560|NCT00992992|radioimmunotherapy
1240561|NCT00992979|Addiction
1240562|NCT00992979|Anxiety
1240563|NCT00992979|Withdrawal
1240564|NCT00992979|Psychoactive Drugs
1240565|NCT00992979|Therapeutic Massage
1240566|NCT00992966|to acquire database of pneumonia cases in children
1240567|NCT00992953|Virtual Reality
1240568|NCT00992953|Post Traumatic Stress Disorder
1240569|NCT00992953|Combat
1240570|NCT00992953|Military
1240571|NCT00992953|Major Depressive Disorder
1240572|NCT00992953|Anxiety
1240573|NCT00992953|Virtual Reality Exposure with Stimulus Control
1240574|NCT00992953|Treatment as Usual
1240575|NCT00992940|awake craniotomy
1240576|NCT00992940|patient-controlled sedation analgesia
1240577|NCT00992940|anesthetist-controlled sedation analgesia
1240578|NCT00992940|remifentanil-propofol
1240579|NCT00992940|tumour surgery
1240580|NCT00992927|Injections, Intra-Articular
1240581|NCT00992927|Range of Motion, Articular
1240582|NCT00992927|Pain
1240583|NCT00992914|Hot flushes (vasomotor symptoms)
1240584|NCT00992901|gastric bypass surgery
1240585|NCT00992901|glucose tolerance
1240586|NCT00992901|Insulin response to meal ingestion
1240587|NCT00992901|Gut hormone and neural response to meal ingestion
1240588|NCT00992888|Alcoholic Hepatitis
1240589|NCT00992888|Alcohol
1240590|NCT00992888|Endotoxin
1240591|NCT00992888|LPS
1240592|NCT00992888|Liver dialysis
1240593|NCT00992888|Innate immunity
1240594|NCT00992888|Toll Like receptors
1240595|NCT00992875|Healthy but stressed individuals
1240596|NCT00992849|Corneal neovascularization
1240597|NCT00992849|bevacizumab
1240598|NCT00992836|Influenza A Virus, H1N1 Subtype
1240599|NCT00992836|Vaccine
1240600|NCT00992836|Children
1240601|NCT00992836|Adolescents
1240602|NCT00992836|HIV-Infected
1240603|NCT00992836|Perinatal HIV Infection
1240604|NCT00992836|Treatment experienced
1240605|NCT00992823|Iron
1240606|NCT00992823|anemia
1240607|NCT00992823|supplementation
1240608|NCT00992823|preschoolers
1240609|NCT00992823|prevalence
1240610|NCT00992823|preschoolers children from public day care centers
1240611|NCT00992810|upper limb
1240612|NCT00992810|hand
1240613|NCT00992810|arm
1240614|NCT00992810|surgery
1240615|NCT00992810|supraclavicular nerve block
1240616|NCT00992810|brachial plexus nerve block
1240617|NCT00992810|ultrasound-guided regional anesthesia
1240618|NCT00992797|Insulin resistance
1240619|NCT00992797|Insulin secretory dysfunction
1240620|NCT00992797|Inflammation
1240621|NCT00992797|Vascular stiffness
1240622|NCT00992784|Influenza Vaccines
1240623|NCT00992784|GSK Bio's influenza vaccine GSK2186877A
1240624|NCT00992784|influenza infection
1240625|NCT00992758|bone marrow
1240626|NCT00992758|Radioimmunotherapy
1240627|NCT00992758|non-Hodgkin's lymphoma
1240628|NCT00992758|Bexxar
1240629|NCT00992758|anti-B1 antibody
1240630|NCT00992758|tositumomab and iodine I-131 tositumomab
1240631|NCT00992758|NHL
1240632|NCT00992758|tositumomab
1240633|NCT00992745|prostate cancer
1240634|NCT00992745|imaging
1240635|NCT00992745|metastases
1240636|NCT00992745|PSMA
1240637|NCT00992745|ProstaScint®
1240638|NCT00992719|H1N1, influenza A viruses, vaccine, pregnant women
1240639|NCT00992706|palmar-plantar erythrodysesthesia
1240640|NCT00992706|stage IV breast cancer
1240641|NCT00992706|male breast cancer
1240642|NCT00992693|Crimean-Congo Hemorrhagic Fever
1240643|NCT00992693|Lassa Fever
1240644|NCT00992693|CCHF
1240645|NCT00992693|LF
1240646|NCT00992693|Viral Hemorrhagic Fever
1240647|NCT00992693|VHF
1240648|NCT00992693|Ribavirin
1240649|NCT00992680|Lung Disease
1240650|NCT00992680|Chronic Airflow Obstruction
1240651|NCT00992680|Chronic Bronchitis
1240652|NCT00992680|Pulmonary Emphysema
1240653|NCT00992680|Walk
1240654|NCT00992667|apocynin
1240655|NCT00992667|asthma
1240656|NCT00992654|Open Label Access Program
1240657|NCT00992654|Treatment experienced
1240658|NCT00992641|Systems biology
1240659|NCT00992641|Nutrition
1240660|NCT00992641|Nordic diet
1240661|NCT00992641|Dietary recommendations
1240662|NCT00992641|Metabolic syndrome
1240663|NCT00992641|Features of metabolic syndrome
1240664|NCT00992628|GlideScope Video Laryngoscope
1240665|NCT00992628|Macintosh Direct Laryngoscope
1240666|NCT00992628|Intubation
1240667|NCT00992628|Applied Forces
1240668|NCT00992628|Elective surgery where endotracheal intubation required
1240669|NCT00992589|Gastroesophageal Reflux
1240670|NCT00992589|Gastroesophageal Reflux Disease
1240671|NCT00992589|GERD
1240672|NCT00992589|Proton Pump Inhibitor
1240673|NCT00992589|PPI
1240674|NCT00992589|Regurgitation
1240675|NCT00992589|Infants
1240676|NCT00992589|AcipHex, PARIET
1240677|NCT00992589|ALFENCE
1240678|NCT00992576|Confirmatory
1240679|NCT00992576|Constipation
1240680|NCT00992576|Pain
1240681|NCT00992576|Hydromorphone
1240682|NCT00992576|Naloxone
1240683|NCT00992563|wet age-related macular degeneration, exudative
1240684|NCT00992550|hookah
1240685|NCT00992550|cigarette
1240686|NCT00992550|smoking
1240687|NCT00992524|Misoprostol
1240688|NCT00992524|Labor, Obstetric
1240689|NCT00992524|Labor, Induced
1240690|NCT00992511|influenza infection
1240691|NCT00992511|GSK Bio's influenza vaccine GSK2340272A
1240692|NCT00992498|COPD (Chronic Obstructive Pulmonary Disease)
1240693|NCT00992498|outpatients
1240694|NCT00992498|rehabilitation
1240695|NCT00992498|comorbidities
1240696|NCT00992498|patient-centered outcome
1240697|NCT00992459|Urea Cycle Disorder (UCD)
1240698|NCT00992459|UCD
1240699|NCT00992459|hyperammonemia
1240700|NCT00992459|Buphenyl (NaPBA)
1240701|NCT00992459|glycerol phenylbutyrate (GPB)
1240702|NCT00992459|Sodium Phenylbutyrate (NaPBA)
1240703|NCT00992446|Autologous stem cell transplant
1240704|NCT00992446|NHL
1240705|NCT00992446|maintenance therapy
1240706|NCT00992433|influenza, H1N1, vaccine, human immunodeficiency virus
1240707|NCT00992420|thienopyridine
1240708|NCT00992420|platelets
1240709|NCT00992420|CYP2C19
1240710|NCT00992420|clopidogrel
1240711|NCT00992420|platelet function tests
1240712|NCT00992420|platelet
1240713|NCT00992420|genes
1240714|NCT00992420|cytochrome P450
1240715|NCT00992420|single nucleotide polymorphisms
1240716|NCT00992420|Platelet Aggregation Inhibitors
1240717|NCT00992407|Schizophrenia
1240718|NCT00992407|Risperidone
1240719|NCT00992407|Risperdal
1240720|NCT00992394|Plaque psoriasis - etanercept - response maintenance
1240721|NCT00992381|GI Pain
1240722|NCT00992381|healthy participants
1240723|NCT00992381|Safety
1240724|NCT00992381|bioavailability
1240725|NCT00992368|Quality-Adjusted Life Years:A measurement index
1240726|NCT00992368|Cost-Benefit Analysis:A method of comparing costs
1240727|NCT00992368|Mammaplasty
1240728|NCT00992368|QALY
1240729|NCT00992368|Health-related quality of life
1240730|NCT00992368|Cost-effectiveness
1240731|NCT00992368|Breast
1240732|NCT00992355|Cataract
1240733|NCT00992355|Phacoemulsification
1240734|NCT00992355|Treatment duration
1240735|NCT00992329|ciprofloxacin
1240736|NCT00992329|pharmacokinetics
1240737|NCT00992329|formulation
1240738|NCT00992316|Inflammatory pain
1240739|NCT00992303|unspecified adult solid tumor, protocol specific
1240740|NCT00992290|cirrhosis
1240741|NCT00992290|hepatic encephalopathy
1240742|NCT00992290|complications
1240743|NCT00992290|probiotic
1240744|NCT00992290|lactobacillus GG
1240745|NCT00992264|Cigarette Smoking
1240746|NCT00992264|Health Behavior
1240747|NCT00992264|Intervention Studies
1240748|NCT00992264|Personal Communication
1240749|NCT00992251|prostate cancer
1240750|NCT00992225|Metastatic
1240751|NCT00992212|Pandemic influenza
1240752|NCT00992212|vaccine
1240753|NCT00992199|intraperitoneal chemotherapy
1240754|NCT00992199|cisplatin
1240755|NCT00992199|fluorouracil
1240756|NCT00992199|advanced gastric cancer
1240757|NCT00992186|Prostate cancer
1240758|NCT00992186|Infusion
1240759|NCT00992186|Carlumab
1240760|NCT00992186|CNTO 888
1240761|NCT00992173|Neuroblastoma
1240762|NCT00992173|MIBG
1240763|NCT00992173|Iobenguane
1240764|NCT00992160|Polysomnography (PSG)
1240765|NCT00992160|Adults
1240766|NCT00992160|Primary Insomnia
1240767|NCT00992134|Lymphoma, Mantle-Cell
1240768|NCT00992134|Bendamustine
1240769|NCT00992134|Cytarabine
1240770|NCT00992134|Rituximab
1240771|NCT00992134|Treatment
1240772|NCT00992134|Combination chemotherapy
1240773|NCT00992121|pazopanib
1240774|NCT00992121|Renal Cell Carcinoma
1240775|NCT00992121|Kidney
1240776|NCT00992121|cancer
1240777|NCT00992121|bevacizumab
1240778|NCT00992108|Bruxism
1240779|NCT00992108|Myofascial pain
1240780|NCT00992108|EMG
1240781|NCT00992108|Ultrasound
1240782|NCT00992108|Masticatory myofascial face pain from bruxism and clenching
1240783|NCT00992082|Postoperative pain
1240784|NCT00992082|Local Infiltration Analgesia
1240785|NCT00992082|Knee arthroplasty
1240786|NCT00992069|ARV
1240787|NCT00992069|Pharmacokinetics
1240788|NCT00992069|TMC207
1240789|NCT00992069|Efavirenz
1240790|NCT00992043|creatine supplementation
1240791|NCT00992043|exercise training
1240792|NCT00992017|Vaccine
1240793|NCT00992017|Pregnant
1240794|NCT00992017|Perinatal
1240795|NCT00992004|Osteoarthritis, Knee
1240796|NCT00992004|Osteoarthritis
1240797|NCT00992004|Joint Diseases
1240798|NCT00992004|Arthritis
1240799|NCT00992004|Rheumatic Diseases
1240800|NCT00991991|stage I melanoma
1240801|NCT00991991|stage II melanoma
1240802|NCT00991991|stage III melanoma
1240803|NCT00991978|breast cancer
1240804|NCT00991978|VEGF
1240805|NCT00991978|Screening
1240806|NCT00991965|Alveolar Ridge Augmentation
1240807|NCT00991965|Dental Implantation, Endosseous
1240808|NCT00991965|Osseointegration
1240809|NCT00991965|Bone Morphogenetic Proteins
1240810|NCT00991939|Immune thrombocytopenic purpura
1240811|NCT00991939|ITP
1240812|NCT00991939|Dexamethasone
1240813|NCT00991939|Prednisone
1240814|NCT00991926|obesity
1240815|NCT00991926|GH/IGF-1 axis
1240816|NCT00991926|postprandial NEFA
1240817|NCT00991913|Delirium
1240818|NCT00991913|Postoperative
1240819|NCT00991913|Non-cardiovascular surgery
1240820|NCT00991913|Post-anaesthesia care unit
1240821|NCT00991887|OTA 13C1
1240822|NCT00991887|OTA 13C2
1240823|NCT00991887|OTA 13C3
1240824|NCT00991887|OTA 21B1
1240825|NCT00991887|OTA 21B2
1240826|NCT00991887|OTA 21B3
1240827|NCT00991887|OTA 21C1
1240828|NCT00991887|OTA 21C2
1240829|NCT00991887|OTA 21C3
1240830|NCT00991887|Distal humerus intraarticular fractures with or without proximal radius/ulna fractures - open or closed
1240831|NCT00991887|Fracture-dislocations of the elbow (ulno-humeral dislocation associated with proximal ulna and/or radius fractures) - open or closed
1240832|NCT00991874|Nitric oxide
1240833|NCT00991874|Asthma
1240834|NCT00991874|Longitudinal studies
1240835|NCT00991874|Child
1240836|NCT00991861|Actinic Keratosis
1240837|NCT00991861|AK
1240838|NCT00991861|NMSC
1240839|NCT00991848|Lidocaine;
1240840|NCT00991848|Fibromyalgia
1240841|NCT00991848|signs
1240842|NCT00991848|symptoms
1240843|NCT00991822|open angle glaucoma
1240844|NCT00991822|timolol
1240845|NCT00991822|dorzolamide
1240846|NCT00991809|opioid induced hyperalgesia
1240847|NCT00991783|Fimasartan
1240848|NCT00991783|Drug interaction
1240849|NCT00991770|Discomfort
1240850|NCT00991770|Port-a-Catheters
1240851|NCT00991770|Complementary and Alternative Medicine
1240852|NCT00991770|Massage
1240853|NCT00991757|RWJ-333369
1240854|NCT00991757|Anticonvulsants
1240855|NCT00991757|Antiepileptic drugs
1240856|NCT00991757|Epilepsy, Focal
1240857|NCT00991757|Seizure Disorder
1240858|NCT00991744|Leukemia
1240859|NCT00991744|Central nervous system
1240860|NCT00991744|Neurotoxicity
1240861|NCT00991744|Liposomal cytarabine
1240862|NCT00991744|Children
1240863|NCT00991744|Acute lymphoblastic leukemia
1240864|NCT00991744|Childhood acute lymphoblastic leukemia
1240865|NCT00991744|Intrathecal
1240866|NCT00991744|Efficacy
1240867|NCT00991744|Safety
1240868|NCT00991731|Physical Activity
1240869|NCT00991731|Faith based
1240870|NCT00991731|Non faith based
1240871|NCT00991731|African American
1240872|NCT00991731|Female
1240873|NCT00991731|Pedometers
1240874|NCT00991718|GDC0449
1240875|NCT00991705|Fimasartan, Atorvastatin
1240876|NCT00991692|Pediatric CI Therapy
1240877|NCT00991692|ACQUIREc Therapy
1240878|NCT00991692|Dosage
1240879|NCT00991692|Occupational Therapy
1240880|NCT00991692|Physical Therapy
1240881|NCT00991692|Cerebral Palsy
1240882|NCT00991692|Hemiparesis
1240883|NCT00991679|Dry eye syndrome
1240884|NCT00991679|CXCL9 chemokine
1240885|NCT00991679|CXCL10 chemokine
1240886|NCT00991679|CXCL11 chemokine
1240887|NCT00991679|CXCR3 receptor
1240888|NCT00991666|AMD
1240889|NCT00991666|rigidity
1240890|NCT00991666|pulsatile ocular blood flow
1240891|NCT00991666|Physiology of the eye
1240892|NCT00991653|Weight
1240893|NCT00991653|Breast
1240894|NCT00991653|Cancer
1240895|NCT00991627|Ephedrine
1240896|NCT00991627|Adrenergic Agents
1240897|NCT00991627|Central Nervous System Stimulants
1240898|NCT00991627|Sympathomimetics
1240899|NCT00991627|Vasoconstrictor Agents
1240900|NCT00991627|Bupivacaine
1240901|NCT00991627|Anesthetics, Local
1240902|NCT00991627|Atropine
1240903|NCT00991627|Adjuvants, Anesthesia
1240904|NCT00991627|Anti-Arrhythmia Agents
1240905|NCT00991627|Bronchodilator Agents
1240906|NCT00991627|Muscarinic Antagonists
1240907|NCT00991627|Mydriatics
1240908|NCT00991627|Parasympatholytics
1240909|NCT00991627|Morphine
1240910|NCT00991627|Analgesics, Opioid
1240911|NCT00991627|Narcotics
1240912|NCT00991627|Ringer's Lactate
1240913|NCT00991627|Isotonic Solutions
1240914|NCT00991627|Hypotension
1240915|NCT00991627|Blood pressure
1240916|NCT00991627|Signs and Symptoms
1240917|NCT00991627|Pregnancy
1240918|NCT00991627|Anesthesia, Obstetrical
1240919|NCT00991627|Inferior Vena Cava
1240920|NCT00991601|liver
1240921|NCT00991601|pancreas
1240922|NCT00991601|cancer
1240923|NCT00991601|tumor
1240924|NCT00991601|FNAC
1240925|NCT00991588|PCL
1240926|NCT00991588|Posterolateral
1240927|NCT00991575|Diabetes mellitus, type1
1240928|NCT00991575|cardiovascular disease
1240929|NCT00991575|diabetes complications
1240930|NCT00991575|Glycation end products, advanced
1240931|NCT00991562|relapsed or relapsed/refractory multiple myeloma
1240932|NCT00991549|overweight
1240933|NCT00991549|obesity
1240934|NCT00991549|glucose intolerance
1240935|NCT00991549|pre-diabetes
1240936|NCT00991523|resistance
1240937|NCT00991523|exercise
1240938|NCT00991523|protein
1240939|NCT00991523|recovery
1240940|NCT00991510|renal transplantation
1240941|NCT00991510|mycophenolate mofetil
1240942|NCT00991510|pharmacokinetics
1240943|NCT00991510|immunosuppression
1240944|NCT00991497|varicose veins
1240945|NCT00991497|foam sclerotherapy
1240946|NCT00991497|compression bandaging
1240947|NCT00991497|duration
1240948|NCT00991484|ventral
1240949|NCT00991484|inguinal
1240950|NCT00991484|hernia
1240951|NCT00991484|inheritance
1240952|NCT00991484|genetics
1240953|NCT00991471|Emergency Department Wait Times
1240954|NCT00991471|Physician Nurse at Triage
1240955|NCT00991471|Overcrowding
1240956|NCT00991471|CostEffectiveness
1240957|NCT00991445|Unicompartmental knee arthroplasty
1240958|NCT00991445|Surgical exposure
1240959|NCT00991445|Minimal invasive surgery
1240960|NCT00991445|Local Infiltration Analgesia
1240961|NCT00991445|Knee Arthroplasty
1240962|NCT00991432|Alveolar Ridge Augmentation
1240963|NCT00991432|Dental Implantation, Endosseous
1240964|NCT00991432|Osseointegration
1240965|NCT00991432|Space Maintenance
1240966|NCT00991432|Bone Morphogenetic Proteins
1240967|NCT00991419|PET
1240968|NCT00991419|Alzheimer's disease
1240969|NCT00991419|diagnostic
1240970|NCT00991406|Electric Stimulation
1240971|NCT00991406|Hemiplegia
1240972|NCT00991406|walking
1240973|NCT00991393|Maxillary Sinus Augmentation
1240974|NCT00991393|Dental Implantation
1240975|NCT00991393|Osseointegration
1240976|NCT00991393|Bone Morphogenetic Proteins
1240977|NCT00991367|Post-surgical scars
1240978|NCT00991367|Asian Gotu Kola
1240979|NCT00991367|Asian Pennywort
1240980|NCT00991354|HIV Seronegativity
1240981|NCT00991354|HIV Preventive Vaccine
1240982|NCT00991341|Cardiac surgery
1240983|NCT00991341|Red blood cell
1240984|NCT00991341|Transfusion
1240985|NCT00991328|PD
1240986|NCT00991328|POCD
1240987|NCT00991328|Post-op Delirium (PD)
1240988|NCT00991328|Post-op Cognitive Dysfunction (POCD)
1240989|NCT00991315|prostate cancer
1240990|NCT00991302|Adherence
1240991|NCT00991302|Behavioral Intervention
1240992|NCT00991302|Antiretroviral Therapy
1240993|NCT00991302|ART
1240994|NCT00991302|Highly Active Antiretroviral Therapy
1240995|NCT00991302|HAART
1240996|NCT00991302|Treatment experienced
1240997|NCT00991289|Hepatitis C genotype 1
1240998|NCT00991289|HCV treatment naive
1240999|NCT00991289|HCV/HIV coinfection
1241000|NCT00991289|Antiretroviral
1241001|NCT00991289|Ribavirin
1241002|NCT00991289|Pegylated Interferon alfa
1241003|NCT00991289|Nitazoxanide
1241004|NCT00991276|restless legs syndrome RLS polysomnography PSG sleep disturbance patient reported outcome
1241005|NCT00991263|stage II breast cancer
1241006|NCT00991263|stage IIIA breast cancer
1241007|NCT00991250|Malignant melanoma
1241008|NCT00991237|NRS
1241009|NCT00991237|GPE
1241010|NCT00991237|pain reduction
1241011|NCT00991237|quality of life
1241012|NCT00991224|HIV
1241013|NCT00991224|HIV therapeutic vaccine
1241014|NCT00991211|Comparison
1241015|NCT00991211|Bendamustine + Rituximab
1241016|NCT00991211|CHOP + Rituximab
1241017|NCT00991211|Progression free survival
1241018|NCT00991211|Overall survival
1241019|NCT00991211|Toxicity
1241020|NCT00991211|Safety
1241021|NCT00991198|Topically dissolved oxygen
1241022|NCT00991198|inflammatory cutaneous disease
1241023|NCT00991198|rosacea
1241024|NCT00991198|acne vulgaris
1241025|NCT00991198|atopic dermatitis
1241026|NCT00991198|seborrheic dermatitis
1241027|NCT00991198|photodamage
1241028|NCT00991185|Infections in Children
1241029|NCT00991172|sciatica
1241030|NCT00991172|sciatic pain
1241031|NCT00991172|pain
1241032|NCT00991172|back pain
1241033|NCT00991159|Endocrinology; Hypercholesterolemia; Hyperlipidemia; Lipid Metabolism Disorders RN316 PF-04950615
1241034|NCT00991146|CAPS
1241035|NCT00991146|FCAS
1241036|NCT00991146|MWS
1241037|NCT00991146|NOMID
1241038|NCT00991146|cryopyrin-associated periodic syndromes
1241039|NCT00991146|Familial Cold Autoinflammatory Syndrome
1241040|NCT00991146|Muckle-Wells Syndrome
1241041|NCT00991146|Neonatal Onset Multisystem Inflammatory Disease
1241042|NCT00991146|canakinumab
1241043|NCT00991146|ACZ885
1241044|NCT00991146|children
1241045|NCT00991146|systemic autoinflammatory disease
1241046|NCT00991146|NALP-3
1241047|NCT00991146|human monoclonal anti-human interleukin-1beta (IL-1beta)antibody
1241048|NCT00991146|autosomal dominant
1241049|NCT00991146|familial autoinflammatory syndrome
1241050|NCT00991107|phase I
1241051|NCT00991107|safety
1241052|NCT00991107|tolerance
1241053|NCT00991107|insulin resistance
1241054|NCT00991107|obese
1241055|NCT00991094|Proton Therapy
1241056|NCT00991094|Proton Therapy Treatment Plan
1241057|NCT00991094|Proton Dose Distributions
1241058|NCT00991094|Side Effects
1241059|NCT00991094|Symptoms
1241060|NCT00991094|Normal Tissue Toxicity
1241061|NCT00991094|Dose Response Relationship
1241062|NCT00991081|pharmacogenetics
1241063|NCT00991081|genetic counseling
1241064|NCT00991081|genetic feedback
1241065|NCT00991081|nicotine replacement
1241066|NCT00991081|bupropion
1241067|NCT00991081|smoking cessation
1241068|NCT00991081|primary care
1241069|NCT00991081|telehealth
1241070|NCT00991081|motivational interviewing
1241071|NCT00991068|Pain
1241072|NCT00991068|Mild to moderate Carpal Tunnel Syndrome
1241073|NCT00991042|Cytokines
1241074|NCT00991042|Low back pain
1241075|NCT00991042|Intervertebral disk displacement
1241076|NCT00991042|Interleukins
1241077|NCT00991042|Tumor necrosis factor-alpha
1241078|NCT00991029|Transient Ischemic Attack
1241079|NCT00991029|TIA
1241080|NCT00991029|minor stroke
1241081|NCT00991003|Colon Capsule Endoscopy
1241082|NCT00991003|Colorectal Cancer
1241083|NCT00991003|Colonoscopy
1241084|NCT00990990|Safety tolerability pharmacokinetics (PK) pharmacodynamics whole blood activity (WBA) PNU-100480 linezolid pyrazinamide multiple dose
1241085|NCT00990977|breast cancer
1241086|NCT00990977|supportive care
1241087|NCT00990977|post-treatment
1241088|NCT00990977|intervention
1241089|NCT00990977|MBSR
1241090|NCT00990977|mindfulness
1241091|NCT00990977|anxiety
1241092|NCT00990977|depression
1241093|NCT00990977|lifestyle
1241094|NCT00990977|diet
1241095|NCT00990977|alcohol consumption
1241096|NCT00990977|smoking
1241097|NCT00990977|exercise
1241098|NCT00990977|spirituality
1241099|NCT00990977|existential well-being
1241100|NCT00990977|physical symptoms
1241101|NCT00990977|women
1241102|NCT00990925|Obesity
1241103|NCT00990925|Schizophrenia
1241104|NCT00990925|Schizoaffective disorder
1241105|NCT00990925|weight loss
1241106|NCT00990899|hypertension
1241107|NCT00990899|obstructive sleep apnea
1241108|NCT00990899|pediatrics
1241109|NCT00990886|Oxybutynin
1241110|NCT00990886|Ditropan
1241111|NCT00990886|Menopause Treatment
1241112|NCT00990886|Vasomotor symptoms
1241113|NCT00990886|Hot Flashes
1241114|NCT00990886|Non-hormonal therapy for Vasomotor symptoms
1241115|NCT00990873|stage I non-small cell lung cancer
1241116|NCT00990860|Combination of TACE With Sorafenib
1241117|NCT00990834|Statin
1241118|NCT00990834|Myopathy
1241119|NCT00990834|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1241120|NCT00990834|Atrogin-1
1241121|NCT00990795|open heart surgery
1241122|NCT00990795|cyclosporine
1241123|NCT00990795|myocardial protection
1241124|NCT00990769|Emergence delirium
1241125|NCT00990769|Bispectral Index
1241126|NCT00990769|Depth of anesthesia
1241127|NCT00990743|Ocular hypertension
1241128|NCT00990743|Glaucoma
1241129|NCT00990743|Beta-blocker
1241130|NCT00990730|rheumatoid arthritis
1241131|NCT00990730|endothelial dysfunction
1241132|NCT00990730|lipoproteins
1241133|NCT00990730|inflammation
1241134|NCT00990730|oxidative stress
1241135|NCT00990730|arterial stiffness
1241136|NCT00990717|natural killer cells
1241137|NCT00990717|leukemia
1241138|NCT00990717|lymphoma
1241139|NCT00990717|myeloma
1241140|NCT00990717|Hodgkin's disease
1241141|NCT00990717|cell therapy
1241142|NCT00990704|Secondary hyperparathyroidism
1241143|NCT00990704|Hemodialysis
1241144|NCT00990704|paricalcitol
1241145|NCT00990704|maxacalcitol
1241146|NCT00990691|Rett syndrome
1241147|NCT00990678|HIV-1
1241148|NCT00990678|humans
1241149|NCT00990678|vitamin D
1241150|NCT00990678|1-hydroxy-vitamin D
1241151|NCT00990678|Rocaltrol
1241152|NCT00990678|calcium
1241153|NCT00990678|complementary therapies
1241154|NCT00990665|CRT
1241155|NCT00990665|Heart Failure
1241156|NCT00990665|LV Leads
1241157|NCT00990652|brain tumor
1241158|NCT00990639|hepatic fibrosis
1241159|NCT00990639|angiotensin II blocking agents
1241160|NCT00990639|alcoholic liver disease
1241161|NCT00990626|Seroquel XR
1241162|NCT00990626|schizophrenia relapse prevention
1241163|NCT00990613|percutaneous transcutaneous dimebon transdermal pharmacokinetics
1241164|NCT00990600|adherence
1241165|NCT00990600|Qol
1241166|NCT00990600|virologic efficacy
1241167|NCT00990600|immunologic efficacy
1241168|NCT00990600|patients' preference
1241169|NCT00990600|once-daily
1241170|NCT00990600|HAART
1241171|NCT00990600|treatment experienced
1241172|NCT00990587|relapsed and refractory hematologic malignancy
1241173|NCT00990587|ALL (acute lymphoid leukemia)
1241174|NCT00990587|CLL (chronic lymphoid leukemia)
1241175|NCT00990587|High risk myelodysplasia (MDS) with an IPSS (International Prognostic Scoring System) score >2.5
1241176|NCT00990587|CML (chronic myelogenous leukemia) blast crisis
1241177|NCT00990587|Relapsed or refractory acute myeloid leukemia (AML)
1241178|NCT00990548|Cardiac Caregivers
1241179|NCT00990548|Cardiac Patient Clinical Outcomes
1241180|NCT00990548|Prevention of CVD
1241181|NCT00990535|neuroendocrine tumors
1241182|NCT00990535|octreotide
1241183|NCT00990535|somatostatin analogues
1241184|NCT00990522|sharp debridment
1241185|NCT00990522|patients with full thickness wounds of greater than 30 days duration
1241186|NCT00990509|Primary ICH
1241187|NCT00990509|Albumin
1241188|NCT00990509|MRI
1241189|NCT00990509|Neuroimaging outcome
1241190|NCT00990509|Placebo-controlled
1241191|NCT00990509|Phase II
1241192|NCT00990509|Blinded
1241193|NCT00990509|Safety
1241194|NCT00990509|Acute ICH
1241195|NCT00990509|ICH
1241196|NCT00990509|Primary acute (< 48 hours) supratentorial ICH
1241197|NCT00990496|Glioblastoma multiforme
1241198|NCT00990496|GBM
1241199|NCT00990496|Cytomegalovirus
1241200|NCT00990496|CMV
1241201|NCT00990496|Cytotoxic T lymphocyte
1241202|NCT00990496|CTL
1241203|NCT00990470|Transplantation
1241204|NCT00990470|Liver
1241205|NCT00990470|Endoscopy
1241206|NCT00990470|Colonoscopy
1241207|NCT00990470|Gastroscopy
1241208|NCT00990457|Exercise
1241209|NCT00990457|Weight loss diet
1241210|NCT00990457|Obesity
1241211|NCT00990457|Overweight
1241212|NCT00990457|Abdominal obesity
1241213|NCT00990457|Cardiovascular function
1241214|NCT00990457|Body composition
1241215|NCT00990444|blood glucose
1241216|NCT00990444|blood insulin
1241217|NCT00990444|dextran
1241218|NCT00990444|diabetes
1241219|NCT00990444|hyperglycemia
1241220|NCT00990444|hypoglycemia
1241221|NCT00990444|oral delivery
1241222|NCT00990444|portal delivery
1241223|NCT00990431|skin aging
1241224|NCT00990431|laser surgery
1241225|NCT00990431|fractional photothermolysis
1241226|NCT00990431|comparative study
1241227|NCT00990431|Ablative fractional treatment of peri-orbital rhytides
1241228|NCT00990418|Postoperative pain
1241229|NCT00990418|E-TRANS System, fentanyl HCl System
1241230|NCT00990418|E-TRANSS (fentanyl HCl) System
1241231|NCT00990418|Acute postoperative pain
1241232|NCT00990405|Rome III criteria
1241233|NCT00990392|Blood stream infections
1241234|NCT00990392|Catheter related infections
1241235|NCT00990392|Central venous catheter related infections
1241236|NCT00990392|Line sepsis
1241237|NCT00990392|Topical antibiotics
1241238|NCT00990392|Bacitracin
1241239|NCT00990392|Polymixin
1241240|NCT00990392|Gramicidin
1241241|NCT00990392|Polysporin Triple Therapy
1241242|NCT00990392|Intensive care unit
1241243|NCT00990379|HIV
1241244|NCT00990379|brain diseases
1241245|NCT00990379|spinal fluid
1241246|NCT00990379|HIV positive
1241247|NCT00990366|antireflux valve
1241248|NCT00990366|biliary obstruction
1241249|NCT00990366|cholangitis
1241250|NCT00990366|biliary stent
1241251|NCT00990353|Spatial neglect
1241252|NCT00990353|hemineglect
1241253|NCT00990353|stroke
1241254|NCT00990353|cognition
1241255|NCT00990353|prism adaptation
1241256|NCT00990353|Hierarchical linear modeling
1241257|NCT00990353|growth curve modeling
1241258|NCT00990327|Coronary artery disease
1241259|NCT00990327|Myocardial Perfusion Imaging
1241260|NCT00990301|Healthy Subjects
1241261|NCT00990301|Bioequivalence
1241262|NCT00990288|To decrease blood loss during knee surgery
1241263|NCT00990262|acute chest pain
1241264|NCT00990262|emergency department
1241265|NCT00990262|cardiac computed tomography
1241266|NCT00990249|Acute Lymphoblastic Leukemia
1241267|NCT00990249|ALL
1241268|NCT00990249|Acute lymphoblastic lymphoma
1241269|NCT00990249|acute biphenotypic leukemia
1241270|NCT00990249|Allogeneic hematopoietic cell transplantation
1241271|NCT00990249|HCT
1241272|NCT00990249|Stem Cell Transplant
1241273|NCT00990249|Treatment-related mortality
1241274|NCT00990249|Tyrosine kinase inhibitors
1241275|NCT00990249|TKI
1241276|NCT00990249|Busulfan
1241277|NCT00990249|Busulfex
1241278|NCT00990249|Myleran
1241279|NCT00990249|Clofarabine
1241280|NCT00990249|Clolar
1241281|NCT00990249|Clofarex
1241282|NCT00990249|Gleevec
1241283|NCT00990249|Imatinib Mesylate
1241284|NCT00990236|deep vein thrombosis
1241285|NCT00990236|superficial venous thrombosis
1241286|NCT00990236|pulmonary embolus
1241287|NCT00990223|Eplerenone Aldosterone and Plasma Renin Activity responses Pharmacodynamics
1241288|NCT00990197|Pilot study
1241289|NCT00990197|Randomized clinical trial
1241290|NCT00990197|Smoking cessation
1241291|NCT00990197|Acute coronary syndrome
1241292|NCT00990197|Transdermal nicotine patch
1241293|NCT00990184|Impaired Fasting Glucose
1241294|NCT00990184|PreDiabetes
1241295|NCT00990171|peritoneal Dialysis
1241296|NCT00990171|wasting and malnutrition
1241297|NCT00990171|nutrition status
1241298|NCT00990171|bioelectrical impedance analysis
1241299|NCT00990171|body composition
1241300|NCT00990158|Vitamin K1 (phytonadione)
1241301|NCT00990158|Randomized controlled trial
1241302|NCT00990158|Warfarin
1241303|NCT00990158|Coagulopathy
1241304|NCT00990158|Time in therapeutic range
1241305|NCT00990158|Bleeding
1241306|NCT00990158|Thrombosis
1241307|NCT00990158|VKORC1 and CYP2C9 genotypes
1241308|NCT00990158|Time INR in therapeutic range
1241309|NCT00990132|COPD
1241310|NCT00990132|Respiratory failure
1241311|NCT00990132|Non-invasive ventilation
1241312|NCT00990132|Home mechanical ventilation
1241313|NCT00990119|high flow therapy
1241314|NCT00990119|high flow nasal cannula
1241315|NCT00990119|chronic obstructive pulmonary disease
1241316|NCT00990119|respiratory insufficiency
1241317|NCT00990106|posttraumatic stress disorder
1241318|NCT00990106|PTSD
1241319|NCT00990106|nightmares
1241320|NCT00990106|prazosin
1241321|NCT00990106|sleep disturbance
1241322|NCT00990106|combat trauma
1241323|NCT00990067|MDMA
1241324|NCT00990067|serotonin
1241325|NCT00990067|norepinephrine
1241326|NCT00990067|Ecstasy
1241327|NCT00990067|stimulant
1241328|NCT00990054|Cytarabine,
1241329|NCT00990054|Daunorubicin,
1241330|NCT00990054|De Novo,
1241331|NCT00990054|Acute Myeloid Leukemia,
1241332|NCT00990054|AML
1241333|NCT00990041|periodontitis
1241334|NCT00990041|find cytokines in blood of periodontal patients
1241335|NCT00990028|moderate head injury
1241336|NCT00990028|rosuvastatin
1241337|NCT00990028|statin
1241338|NCT00990028|amnesia
1241339|NCT00990028|orientation
1241340|NCT00990015|Safety; tolerability; pharmacokinetics/pharmacodynamics
1241341|NCT00989989|DME
1241342|NCT00989989|Diabetic
1241343|NCT00989989|macula
1241344|NCT00989989|edema
1241345|NCT00989989|ranibizumab
1241346|NCT00989989|REVEAL
1241347|NCT00989976|Sleep
1241348|NCT00989976|Diabetes Risk
1241349|NCT00989963|PAH
1241350|NCT00989950|daytrana
1241351|NCT00989950|sleep latency
1241352|NCT00989950|adhd rating scales
1241353|NCT00989950|ADHD
1241354|NCT00989937|oxytocin
1241355|NCT00989924|Diabetes mellitus
1241356|NCT00989924|Coronary heart disease
1241357|NCT00989924|Magnetocardiography
1241358|NCT00989911|Single ventricle congenital heart disease
1241359|NCT00989898|T1D, closed-loop systems, overnight hypoglycaemia
1241360|NCT00989885|Evaluation
1241361|NCT00989885|Obstructive sleep apnea
1241362|NCT00989885|Polysomnography
1241363|NCT00989872|Macrolides
1241364|NCT00989872|Antibiotics
1241365|NCT00989872|Safety
1241366|NCT00989872|Tolerability
1241367|NCT00989872|Pharmacokinetics
1241368|NCT00989872|Phase I
1241369|NCT00989872|MRSA/SSTI
1241370|NCT00989859|monitoring
1241371|NCT00989846|biomarker
1241372|NCT00989846|lung disease
1241373|NCT00989833|Exercise induced asthma
1241374|NCT00989833|Mild intermittent asthma
1241375|NCT00989833|Exercise induced bronchoconstriction
1241376|NCT00989820|osteoradionecrosis
1241377|NCT00989820|mandible
1241378|NCT00989820|radiotherapy
1241379|NCT00989820|hyperbaric oxygen therapy
1241380|NCT00989807|CF
1241381|NCT00989807|Cystic fibrosis
1241382|NCT00989807|Pseudomonas aeruginosa
1241383|NCT00989807|EAP
1241384|NCT00989807|Expanded access
1241385|NCT00989807|AZLI
1241386|NCT00989807|Aztreonam lysine
1241387|NCT00989794|cartilage
1241388|NCT00989794|implantation
1241389|NCT00989794|chondrocyte
1241390|NCT00989794|condyle
1241391|NCT00989781|PCOS, Androgens, ovary, polycystic
1241392|NCT00989768|Botulinum toxin type A
1241393|NCT00989768|field effects
1241394|NCT00989768|dose-equivalence
1241395|NCT00989768|anhydrotic action halos
1241396|NCT00989755|Tobacco dependence treatment in primary health care setting
1241397|NCT00989755|Fax to Quit
1241398|NCT00989755|Fax to Quit plus Enhanced Academic Detailing
1241399|NCT00989755|Fax referral
1241400|NCT00989755|Quitline
1241401|NCT00989742|lymphangioleiomatosis
1241402|NCT00989742|LAM
1241403|NCT00989742|tuberous sclerosis
1241404|NCT00989742|doxycycline
1241405|NCT00989742|matrix metalloproteinases
1241406|NCT00989742|MMP
1241407|NCT00989729|Endovascular Aortic Repair
1241408|NCT00989729|Methylprednisolone
1241409|NCT00989729|Systemic inflammatory response syndrome
1241410|NCT00989703|Safety
1241411|NCT00989703|Tolerability
1241412|NCT00989703|Pharmacokinetics
1241413|NCT00989690|recurrent non-small cell lung cancer
1241414|NCT00989690|stage IIIB non-small cell lung cancer
1241415|NCT00989690|stage IV non-small cell lung cancer
1241416|NCT00989664|non-Hodgkin's Lymphoma
1241417|NCT00989664|radioimmunotherapy
1241418|NCT00989664|NHL
1241419|NCT00989664|Bexxar
1241420|NCT00989664|lymphoma
1241421|NCT00989664|Tositumomab
1241422|NCT00989625|migraine
1241423|NCT00989625|single dose
1241424|NCT00989625|healthy volunteer
1241425|NCT00989625|adolescence
1241426|NCT00989625|pharmacokinetics
1241427|NCT00989612|influenza infection
1241428|NCT00989612|GSK Biologicals' influenza vaccine GSK2340272A
1241429|NCT00989599|phlebitis
1241430|NCT00989599|Chamomilla recutita
1241431|NCT00989599|Catheterization peripheral
1241432|NCT00989586|recurrent mantle cell lymphoma
1241433|NCT00989586|recurrent grade 1 follicular lymphoma
1241434|NCT00989586|recurrent grade 2 follicular lymphoma
1241435|NCT00989586|recurrent grade 3 follicular lymphoma
1241436|NCT00989586|MALT lymphoma
1241437|NCT00989586|nodal marginal zone B-cell lymphoma
1241438|NCT00989586|splenic marginal zone lymphoma
1241439|NCT00989586|recurrent marginal zone lymphoma
1241440|NCT00989586|Waldenstrom macroglobulinemia
1241441|NCT00989534|shift work
1241442|NCT00989534|diabetes
1241443|NCT00989534|Affects of shift work and sleep loss on health
1241444|NCT00989521|Asthma
1241445|NCT00989521|bronchial diseases
1241446|NCT00989521|lung diseases
1241447|NCT00989521|bronchitis
1241448|NCT00989521|respiratory tract diseases
1241449|NCT00989508|Perhexiline
1241450|NCT00989508|Aortic Valve Stenosis
1241451|NCT00989508|Hypertrophy, Left Ventricular
1241452|NCT00989508|Myocardial Reperfusion Injury
1241453|NCT00989508|Cardiac Output, Low
1241454|NCT00989508|Troponin
1241455|NCT00989495|AIS
1241456|NCT00989456|chronic obstructive pulmonary disease
1241457|NCT00989456|Heart failure
1241458|NCT00989456|Stroke
1241459|NCT00989456|quality of life
1241460|NCT00989456|self management education
1241461|NCT00989456|physical exercise
1241462|NCT00989456|primary health care
1241463|NCT00989443|Cervix Intraepithelial Neoplasia grades 2 and 3
1241464|NCT00989430|stroke
1241465|NCT00989430|CVA
1241466|NCT00989430|cerebrovascular accident
1241467|NCT00989430|rehabilitation
1241468|NCT00989417|Remote monitoring
1241469|NCT00989417|Defibrillators, Implantable
1241470|NCT00989417|Home monitoring
1241471|NCT00989417|Shock
1241472|NCT00989417|Implantable cardioverter-defibrillator Therapy
1241473|NCT00989404|pk
1241474|NCT00989404|healthy subjects
1241475|NCT00989404|influenza virus
1241476|NCT00989404|Safety
1241477|NCT00989404|pandemic
1241478|NCT00989391|Phase 1 multiple dose safety toleration pharmacokinetic
1241479|NCT00989378|sleep
1241480|NCT00989378|insulin
1241481|NCT00989378|diabetes
1241482|NCT00989378|determine association between sleep characteristics and diabetes risk
1241483|NCT00989365|Aerobic Exercise
1241484|NCT00989365|Exercise
1241485|NCT00989352|PCNSL
1241486|NCT00989352|Lymphoma
1241487|NCT00989352|Methotrexate
1241488|NCT00989352|Lomustine
1241489|NCT00989352|Procarbazine
1241490|NCT00989352|Rituximab
1241491|NCT00989352|Elderly
1241492|NCT00989352|Chemotherapy
1241493|NCT00989339|lipid emulsion
1241494|NCT00989339|endothelial function
1241495|NCT00989339|inflammatory markers
1241496|NCT00989339|oxidative stress
1241497|NCT00989339|insulin sensitivity
1241498|NCT00989339|carbohydrate metabolism
1241499|NCT00989326|Remote monitoring
1241500|NCT00989326|Pacemaker
1241501|NCT00989326|Follow up
1241502|NCT00989326|Follow-up studies
1241503|NCT00989313|Peplin
1241504|NCT00989313|Actinic keratosis
1241505|NCT00989313|PEP005
1241506|NCT00989300|Drug-Drug interaction
1241507|NCT00989300|Clopidogrel
1241508|NCT00989300|Rabeprazol
1241509|NCT00989300|Omeprazol
1241510|NCT00989300|Pharmacodynamic Study
1241511|NCT00989287|GSK Bio's influenza vaccine GSK2340272A
1241512|NCT00989287|influenza infection
1241513|NCT00989274|Influenza
1241514|NCT00989274|Vaccination
1241515|NCT00989274|Immunology
1241516|NCT00989274|Immunogenicity
1241517|NCT00989274|Reactogenicity
1241518|NCT00989274|Safety
1241519|NCT00989274|Influenza vaccine
1241520|NCT00989274|Immune response
1241521|NCT00989274|Adverse effects
1241522|NCT00989261|AML
1241523|NCT00989261|AC220
1241524|NCT00989261|acute
1241525|NCT00989261|FLT3
1241526|NCT00989261|inhibitor
1241527|NCT00989261|kinase
1241528|NCT00989261|leukemia
1241529|NCT00989261|leukaemia
1241530|NCT00989261|myeloid
1241531|NCT00989261|relapsed
1241532|NCT00989261|refractory
1241533|NCT00989248|Ergospirometry
1241534|NCT00989248|Cardiopulmonary Exercise Test
1241535|NCT00989248|Exercises
1241536|NCT00989248|Immersion
1241537|NCT00989235|NOS
1241538|NCT00989222|Distal radius fractures
1241539|NCT00989222|Fractures of the distal radius
1241540|NCT00989222|Volar plate
1241541|NCT00989222|External fixation
1241542|NCT00989209|facial paralysis
1241543|NCT00989209|asymmetry
1241544|NCT00989209|myofunctional therapy
1241545|NCT00989209|botulinum toxin
1241546|NCT00989209|facial evaluation
1241547|NCT00989183|Ovaries
1241548|NCT00989183|Reproductive Age
1241549|NCT00989183|Oophorectomy
1241550|NCT00989157|Gastric Bypass
1241551|NCT00989157|Duloxetine
1241552|NCT00989157|Cymbalta
1241553|NCT00989157|Pharmacokinetics
1241554|NCT00989144|HIV seronegative
1241555|NCT00989144|acute infection
1241556|NCT00989131|Ovarian Cancer
1241557|NCT00989105|stage I prostate cancer
1241558|NCT00989105|stage IIB prostate cancer
1241559|NCT00989105|stage IIA prostate cancer
1241560|NCT00989105|stage III prostate cancer
1241561|NCT00989105|stage IV prostate cancer
1241562|NCT00989105|recurrent prostate cancer
1241563|NCT00989092|anemia of cancer
1241564|NCT00989092|darbepoetin alfa
1241565|NCT00989092|Aranesp
1241566|NCT00989079|Single Ascending Dose Study in healthy subjects
1241567|NCT00989066|Xience V
1241568|NCT00989066|stent
1241569|NCT00989066|coronary disease
1241570|NCT00989053|depression
1241571|NCT00989053|anxiety
1241572|NCT00989053|stress
1241573|NCT00989053|antidepressant therapy
1241574|NCT00989053|SSRI
1241575|NCT00989053|infertility
1241576|NCT00989053|in vitro fertilization (IVF)
1241577|NCT00989053|immunological factors
1241578|NCT00989053|depressive and anxiety symptoms in women undergoing IVF treatment
1241579|NCT00989040|NPZ
1241580|NCT00989040|Pain
1241581|NCT00989027|Uterine contraction
1241582|NCT00989027|Dose-response
1241583|NCT00989027|Oxytocin pre-treatment
1241584|NCT00989014|Erythematotelangiectatic
1241585|NCT00989014|Rosacea
1241586|NCT00989001|Atrial Fibrillation
1241587|NCT00989001|RSD1235
1241588|NCT00989001|Vernakalant
1241589|NCT00989001|conversion
1241590|NCT00988988|Multiple Sclerosis
1241591|NCT00988988|AGEE
1241592|NCT00988988|histamine response
1241593|NCT00988962|pain
1241594|NCT00988962|opioids
1241595|NCT00988949|Proof of mechanism study
1241596|NCT00988936|[F-18]RGD-K5
1241597|NCT00988936|RGD-K5
1241598|NCT00988936|K5-101
1241599|NCT00988936|Avastin
1241600|NCT00988936|angiogenesis
1241601|NCT00988936|anti-angiogenesis
1241602|NCT00988936|chemotherapy
1241603|NCT00988936|breast cancer
1241604|NCT00988936|colon cancer
1241605|NCT00988936|rectal cancer
1241606|NCT00988936|lung cancer
1241607|NCT00988936|non-squamous
1241608|NCT00988936|non small cell
1241609|NCT00988910|Combined Oral Contraceptives
1241610|NCT00988910|COC
1241611|NCT00988871|PICC (peripherally inserted central venous catheter)
1241612|NCT00988871|CICC (centrally inserted central venous catheter
1241613|NCT00988871|CVP (central venous pressure)
1241614|NCT00988871|LT (liver transplantation)
1241615|NCT00988871|agreement
1241616|NCT00988845|dietary supplement
1241617|NCT00988845|indole 3 carbinol
1241618|NCT00988845|estrogen
1241619|NCT00988806|Advanced heart failure
1241620|NCT00988806|Levosimendan
1241621|NCT00988806|Intermittent long-term infusions
1241622|NCT00988780|Immune reconstitution inflammatory syndrome
1241623|NCT00988780|CCR5 antagonist
1241624|NCT00988780|Maraviroc
1241625|NCT00988780|HIV
1241626|NCT00988780|treatment naive
1241627|NCT00988767|Hepatitis B
1241628|NCT00988767|DNA vaccine
1241629|NCT00988767|immunotherapy
1241630|NCT00988754|Obesity
1241631|NCT00988754|childhood and adolescence
1241632|NCT00988754|school and family-based lifestyle intervention
1241633|NCT00988754|cardiovascular risk
1241634|NCT00988754|Obesity and associated cardiovascular risk in childhood and adolescence,
1241635|NCT00988754|health behaviour
1241636|NCT00988741|Unresectable
1241637|NCT00988741|Hepatocellular
1241638|NCT00988741|Carcinoma
1241639|NCT00988702|Dan Tian Breathing
1241640|NCT00988702|Physiological measurement
1241641|NCT00988702|progressive muscle relaxation
1241642|NCT00988702|Monitoring, Physiologic
1241643|NCT00988689|starch
1241644|NCT00988689|carbohydrates
1241645|NCT00988689|blood glucose
1241646|NCT00988689|food intake
1241647|NCT00988689|satiety
1241648|NCT00988689|appetite
1241649|NCT00988663|electroconvulsive therapy
1241650|NCT00988663|memantine
1241651|NCT00988663|cognitive function
1241652|NCT00988663|memory
1241653|NCT00988650|Metabolic syndrome
1241654|NCT00988650|Mediterranean diet
1241655|NCT00988650|Blood lipids
1241656|NCT00988650|Coronary heart disease
1241657|NCT00988650|Apolipoprotein
1241658|NCT00988624|bioavailability pharmacokinetics Alzheimer's Disease Huntington Disease
1241659|NCT00988611|Reproductive aging
1241660|NCT00988598|phase 1 Alzheimer's disease donepezil
1241661|NCT00988585|Heart Disease Risk Reduction
1241662|NCT00988572|Wrist fractures
1241663|NCT00988572|Vestibular asymmetry
1241664|NCT00988572|Vestibular rehabilitation
1241665|NCT00988572|Fall-related wrist fractures
1241666|NCT00988572|Patients 50 years or older
1241667|NCT00988559|high grade cervical dysplasia
1241668|NCT00988559|treatment vaccine
1241669|NCT00988559|therapeutic
1241670|NCT00988559|HPV
1241671|NCT00988559|DNA vaccine
1241672|NCT00988559|gene therapy
1241673|NCT00988559|gene gun
1241674|NCT00988559|pre-cancerous
1241675|NCT00988546|Disability Evaluation
1241676|NCT00988546|Joint Diseases
1241677|NCT00988546|Joint Disability
1241678|NCT00988533|Head Lice
1241679|NCT00988533|Pediculus
1241680|NCT00988520|Neuromuscular Blocking Agents
1241681|NCT00988481|Bulimia Nervosa
1241682|NCT00988481|Topiramate
1241683|NCT00988481|Augmentation
1241684|NCT00988468|Knee Osteoarthritis
1241685|NCT00988468|Manual Therapy
1241686|NCT00988468|Therapeutic Exercise
1241687|NCT00988468|Ultrasound
1241688|NCT00988468|Effusion
1241689|NCT00988455|basal cell carcinoma
1241690|NCT00988455|photodynamic therapy
1241691|NCT00988455|photo chemotherapy
1241692|NCT00988455|basal cell epithelioma
1241693|NCT00988442|Adherence
1241694|NCT00988442|Treatment
1241695|NCT00988442|Adherence Intervention
1241696|NCT00988442|Telephone Intervention
1241697|NCT00988442|treatment experienced
1241698|NCT00988429|Refractory
1241699|NCT00988429|partial
1241700|NCT00988429|epilepsy
1241701|NCT00988429|efficacy
1241702|NCT00988429|eslicarbazepine
1241703|NCT00988429|safety
1241704|NCT00988416|IPMN
1241705|NCT00988390|mothers living with HIV
1241706|NCT00988390|family intervention
1241707|NCT00988390|family functioning
1241708|NCT00988390|conflict
1241709|NCT00988390|Mental health
1241710|NCT00988390|and physical health
1241711|NCT00988390|Family relationships (functioning and conflict)
1241712|NCT00988377|whey protein
1241713|NCT00988377|subjective appetite
1241714|NCT00988377|shor-term food intake
1241715|NCT00988377|blood glucose
1241716|NCT00988364|Metabolic Syndrome
1241717|NCT00988364|LDL subfraction L5
1241718|NCT00988364|The reduction of LDL Chol in patients with Metabolic Syndrome
1241719|NCT00988364|The prevalence of L5 in patients with Metabolic Syndrome
1241720|NCT00988364|The reduction of L5 subfraction in patients with Metabolic Syndrome
1241721|NCT00988351|sleep apnea
1241722|NCT00988351|positive airway pressure
1241723|NCT00988351|portable monitoring
1241724|NCT00988351|auto positive airway pressure
1241725|NCT00988338|Trinity Evolution
1241726|NCT00988338|Arthrodesis
1241727|NCT00988338|Foot Fusion
1241728|NCT00988338|Ankle Fusion
1241729|NCT00988338|Allograft
1241730|NCT00988312|dendritic cells (DC)
1241731|NCT00988312|idiotype (Id)
1241732|NCT00988312|immunotherapy
1241733|NCT00988299|older
1241734|NCT00988299|NEAT
1241735|NCT00988299|exercise
1241736|NCT00988299|RMR
1241737|NCT00988299|energy expenditure
1241738|NCT00988273|Crohn's disease
1241739|NCT00988273|Ulcerative colitis
1241740|NCT00988273|dysplasia
1241741|NCT00988247|Rhinitis, Allergic, Perennial
1241742|NCT00988247|BDP-HFA
1241743|NCT00988247|Hay fever
1241744|NCT00988247|Allergic rhinitis
1241745|NCT00988234|Lumbar plexus block
1241746|NCT00988234|sciatic nerve block
1241747|NCT00988234|position
1241748|NCT00988234|ultrasound guidance
1241749|NCT00988234|elective lower limb surgery
1241750|NCT00988208|Castrate-Resistant Prostate Cancer
1241751|NCT00988208|Revlimid
1241752|NCT00988208|Lenalidomide
1241753|NCT00988195|Neoplasm
1241754|NCT00988195|Hepatocellular Carcinoma
1241755|NCT00988182|Whey protein
1241756|NCT00988182|Hydrolysate whey protein
1241757|NCT00988182|Blood glucose
1241758|NCT00988182|Insulin
1241759|NCT00988169|AT-101
1241760|NCT00988169|erlotinib
1241761|NCT00988169|Unresectable Stage IIIB
1241762|NCT00988169|09-026
1241763|NCT00988156|Epilepsy
1241764|NCT00988156|Partial
1241765|NCT00988156|Refractory
1241766|NCT00988156|Children
1241767|NCT00988156|Adolescents
1241768|NCT00988156|Adjunctive
1241769|NCT00988156|Randomised
1241770|NCT00988156|Double-blind
1241771|NCT00988156|Placebo-controlled
1241772|NCT00988156|Parallel-group
1241773|NCT00988143|Influenza
1241774|NCT00988143|Trivalent Influenza Virus Vaccine
1241775|NCT00988143|Quadrivalent Influenza Virus Vaccine
1241776|NCT00988130|sexual dysfunction
1241777|NCT00988130|stage I prostate cancer
1241778|NCT00988130|stage IIB prostate cancer
1241779|NCT00988130|stage IIA prostate cancer
1241780|NCT00988130|stage III prostate cancer
1241781|NCT00988117|PDD
1241782|NCT00988117|Parkinson's Disease with Dementia
1241783|NCT00988117|rivastigmine
1241784|NCT00988117|rivastigmine patch
1241785|NCT00988117|open label
1241786|NCT00988117|Parkinson's Disease
1241787|NCT00988117|Parkinsons Disease
1241788|NCT00988117|memory
1241789|NCT00988117|Exelon
1241790|NCT00988117|Exelon Patch
1241791|NCT00988104|Behavior Therapy
1241792|NCT00988104|Randomized Controlled Trial
1241793|NCT00988078|metformin
1241794|NCT00988078|Hyperandrogenism
1241795|NCT00988078|Metabolic Syndrome X
1241796|NCT00988078|adolescents
1241797|NCT00988078|melatonin
1241798|NCT00988078|Polycystic Ovary Syndrome
1241799|NCT00988078|Insulin Resistance
1241800|NCT00988078|Menstrual Cycle
1241801|NCT00988052|Relapsing Multiple Sclerosis
1241802|NCT00988039|Human Immunodeficiency virus
1241803|NCT00988039|second line therapy
1241804|NCT00988039|raltegravir
1241805|NCT00988039|aluvia
1241806|NCT00988039|monotherapy
1241807|NCT00988039|integrase inhibitor
1241808|NCT00988039|protease inhibitor
1241809|NCT00988039|Randomized Controlled Trial
1241810|NCT00988013|total marrow irradiation
1241811|NCT00988013|intensity modulated radiation
1241812|NCT00988013|leukemia
1241813|NCT00988013|hematologic diseases
1241814|NCT00988000|outpatients
1241815|NCT00987987|hematological malignancy
1241816|NCT00987987|allogeneic hematopoietic stem cell transplantation
1241817|NCT00987987|donor lymphocyte infusion
1241818|NCT00987987|antitumor immunotherapy
1241819|NCT00987987|graft-versus-tumor effect
1241820|NCT00987987|regulatory T cells
1241821|NCT00987987|adult
1241822|NCT00987974|ischemia reperfusion injury
1241823|NCT00987974|endothelial dysfunction
1241824|NCT00987974|statins
1241825|NCT00987974|rosuvastatin
1241826|NCT00987974|atorvastatin
1241827|NCT00987974|placebo
1241828|NCT00987974|ecto-5'-nucleotidase
1241829|NCT00987974|flow mediated dilation
1241830|NCT00987961|opioid dependence
1241831|NCT00987961|suboxone
1241832|NCT00987961|HIV risk behavior
1241833|NCT00987948|HIV
1241834|NCT00987948|dementia
1241835|NCT00987948|High HIV DNA within CD14+ PBMCs
1241836|NCT00987948|treatment experienced
1241837|NCT00987922|Stroke
1241838|NCT00987922|Acute
1241839|NCT00987922|Infarction
1241840|NCT00987922|Ischemic
1241841|NCT00987922|Thrombolysis
1241842|NCT00987922|Mild
1241843|NCT00987922|Hypothermia
1241844|NCT00987909|Cat
1241845|NCT00987909|Allergy
1241846|NCT00987909|Immunotherapy
1241847|NCT00987909|Sublingual
1241848|NCT00987909|Exposure chamber
1241849|NCT00987909|Safety
1241850|NCT00987909|Rhinoconjunctivitis
1241851|NCT00987896|colonoscopy
1241852|NCT00987896|polypectomy
1241853|NCT00987896|NOTES
1241854|NCT00987883|Nutritional Support
1241855|NCT00987870|Stable plaque Psoriasis
1241856|NCT00987870|inflammatory skin
1241857|NCT00987870|with or without arthritis
1241858|NCT00987857|esophageal cancer
1241859|NCT00987857|adenocarcinoma of the esophagus
1241860|NCT00987857|Barrett esophagus
1241861|NCT00987831|SLE
1241862|NCT00987831|lupus
1241863|NCT00987831|biomarkers
1241864|NCT00987831|depomedrol
1241865|NCT00987831|flare
1241866|NCT00987831|disease activity
1241867|NCT00987818|Biomarkers
1241868|NCT00987818|Antibiotic therapy
1241869|NCT00987805|Functional dyspepsia
1241870|NCT00987805|Banhasasim-tang
1241871|NCT00987805|Gastrointestinal Symptom score
1241872|NCT00987805|Visual Analogue Scale
1241873|NCT00987805|Functional Dyspepsia-related Quality of Life
1241874|NCT00987805|Electrogastrography
1241875|NCT00987792|Community Acquired Pneumonia
1241876|NCT00987779|Bioequivalence study
1241877|NCT00987779|Food effect study
1241878|NCT00987779|Pharmacokinetics
1241879|NCT00987779|Gabapentin
1241880|NCT00987766|advanced adult primary liver cancer
1241881|NCT00987766|stage III pancreatic cancer
1241882|NCT00987766|stage IV pancreatic cancer
1241883|NCT00987766|periampullary adenocarcinoma
1241884|NCT00987766|small intestine adenocarcinoma
1241885|NCT00987766|adenocarcinoma of the extrahepatic bile duct
1241886|NCT00987766|adenocarcinoma of the gallbladder
1241887|NCT00987766|unresectable extrahepatic bile duct cancer
1241888|NCT00987766|unresectable gallbladder cancer
1241889|NCT00987753|L-377202, prostate cancer, PSA
1241890|NCT00987714|Organ Donors
1241891|NCT00987714|Recipients
1241892|NCT00987701|Neurobehavior
1241893|NCT00987701|Development
1241894|NCT00987701|Fluid management
1241895|NCT00987701|Neuraxial anesthesia
1241896|NCT00987675|stage I prostate cancer
1241897|NCT00987675|stage IIB prostate cancer
1241898|NCT00987675|stage IIA prostate cancer
1241899|NCT00987675|stage III prostate cancer
1241900|NCT00987662|irbesartan
1241901|NCT00987662|amlodipine
1241902|NCT00987662|obesity
1241903|NCT00987662|ambulatory blood pressure monitoring
1241904|NCT00987662|new onset diabetes
1241905|NCT00987649|pelvic mass
1241906|NCT00987649|ovarian cancer
1241907|NCT00987649|adnexal mass
1241908|NCT00987649|CA125
1241909|NCT00987649|HE4
1241910|NCT00987636|Ewing Sarcoma
1241911|NCT00987636|localized
1241912|NCT00987636|disseminated
1241913|NCT00987636|metastases
1241914|NCT00987636|bone
1241915|NCT00987636|soft tissue
1241916|NCT00987610|Percutaneous coronary intervention
1241917|NCT00987610|chronic total occlusion
1241918|NCT00987610|guidewire
1241919|NCT00987610|Angioplasty, Transluminal, Percutaneous Coronary
1241920|NCT00987610|Angioplasty
1241921|NCT00987610|Percutaneous Coronary
1241922|NCT00987597|Smoking
1241923|NCT00987597|nicotine replacement
1241924|NCT00987597|psychological behaviour
1241925|NCT00987597|Smoking > 5 cigarettes per day
1241926|NCT00987597|Hospitalisation for acute coronary syndrome
1241927|NCT00987571|carpal tunnel syndrome
1241928|NCT00987571|median nerve
1241929|NCT00987571|ultrasound
1241930|NCT00987571|electrodiagnosis
1241931|NCT00987571|Normal subjects
1241932|NCT00987558|Eslicarbazepine acetate
1241933|NCT00987558|simvastatin
1241934|NCT00987545|Keloids
1241935|NCT00987545|recurrence
1241936|NCT00987532|preschool
1241937|NCT00987532|participatory intervention
1241938|NCT00987532|cluster-randomization
1241939|NCT00987532|children
1241940|NCT00987532|obesity prevention
1241941|NCT00987519|acute bronchiolitis
1241942|NCT00987519|acute gastroenteritis
1241943|NCT00987519|febrile convulsion
1241944|NCT00987519|viral agents
1241945|NCT00987519|molecular methods
1241946|NCT00987506|drug eluting stents
1241947|NCT00987506|Stents
1241948|NCT00987506|Angioplasty
1241949|NCT00987506|Chronic coronary occlusion
1241950|NCT00987506|Stent thrombosis
1241951|NCT00987506|Vascular disease
1241952|NCT00987506|Myocardial ischemia
1241953|NCT00987506|Coronary artery stenosis
1241954|NCT00987506|Coronary Disease
1241955|NCT00987506|Coronary Artery Disease
1241956|NCT00987506|Coronary Restenosis
1241957|NCT00987493|recurrent adult diffuse large cell lymphoma
1241958|NCT00987493|recurrent grade 3 follicular lymphoma
1241959|NCT00987480|Stem Cell Transplantation
1241960|NCT00987480|Anemia
1241961|NCT00987480|Busulfan
1241962|NCT00987480|Cyclophosphamide
1241963|NCT00987480|Fludarabine
1241964|NCT00987480|08-031
1241965|NCT00987467|Atopic
1241966|NCT00987467|Keratoconjunctivitis
1241967|NCT00987467|Restasis
1241968|NCT00987467|Cyclosporine
1241969|NCT00987441|Neurobehavior
1241970|NCT00987441|Epidural analgesia
1241971|NCT00987441|Local anesthetic
1241972|NCT00987441|Opioid
1241973|NCT00987428|ERCP
1241974|NCT00987428|EUS
1241975|NCT00987428|Pancreatitis biliary
1241976|NCT00987428|Severe
1241977|NCT00987428|Interventional endoscopy
1241978|NCT00987428|Choledocolithiasis
1241979|NCT00987402|Surgery
1241980|NCT00987402|hand scrubbing
1241981|NCT00987402|post-operative infection
1241982|NCT00987402|surgical site infection
1241983|NCT00987402|surgical hand preparation
1241984|NCT00987402|plain soap and water
1241985|NCT00987402|alcohol-based hand rub
1241986|NCT00987402|Cost of surgical hand preparation agent
1241987|NCT00987402|Side effects of use of hand preparation agent
1241988|NCT00987389|Vasculitis
1241989|NCT00987389|Granulomatosis with Polyangiitis
1241990|NCT00987389|Microscopic Polyangiitis
1241991|NCT00987389|Wegener's
1241992|NCT00987389|ANCA-Associated Vasculitis
1241993|NCT00987389|GPA
1241994|NCT00987389|MPA
1241995|NCT00987389|Treatment
1241996|NCT00987389|Plasma exchange
1241997|NCT00987389|Glucocorticoids
1241998|NCT00987389|ANCA-Positive
1241999|NCT00987363|critical limb ischemia (CLI)
1242000|NCT00987363|diabetic foot
1242001|NCT00987363|bone marrow derived mononuclear cells
1242002|NCT00987363|cell therapy
1242003|NCT00987350|Jet Injector
1242004|NCT00987350|Vaccine
1242005|NCT00987350|Influenza
1242006|NCT00987337|Hepatitis C Polymerase Inhibitor PF-00868554 Filibuvir
1242007|NCT00987311|Probiotics
1242008|NCT00987311|intestinal immune system
1242009|NCT00987311|human
1242010|NCT00987311|healthy subjects
1242011|NCT00987311|dairy drink
1242012|NCT00987311|Healthy adults
1242013|NCT00987298|Abdominal Fat
1242014|NCT00987298|Visceral Fat
1242015|NCT00987298|Subcutaneous Fat
1242016|NCT00987298|Dual-energy x-ray absorptiometry
1242017|NCT00987298|DXA
1242018|NCT00987298|Computed Tomography
1242019|NCT00987298|CT
1242020|NCT00987298|Body Mass Index
1242021|NCT00987298|Body composition
1242022|NCT00987298|Percent fat
1242023|NCT00987298|Waist circumference
1242024|NCT00987298|Hip circumference
1242025|NCT00987285|RE AIM model
1242026|NCT00987285|Type 2 Diabetes Mellitus
1242027|NCT00987285|Interactive voice recognition
1242028|NCT00987285|Computer Assisted Self Management
1242029|NCT00987272|Allergies
1242030|NCT00987272|Ocular
1242031|NCT00987259|Myocardial infarction
1242032|NCT00987259|Myocardial oedema
1242033|NCT00987259|Magnetic resonance
1242034|NCT00987246|Actinic Keratosis
1242035|NCT00987246|AK
1242036|NCT00987246|NMSC
1242037|NCT00987246|Combination
1242038|NCT00987220|CSF Biomarkers Acetylcholine
1242039|NCT00987207|Postconditioning
1242040|NCT00987207|cyclosporine A
1242041|NCT00987207|myocardial ischemia
1242042|NCT00987207|cardiac surgery
1242043|NCT00987207|aortic valvulopathy
1242044|NCT00987194|HIV
1242045|NCT00987194|rapid testing
1242046|NCT00987194|HIV seronegativity
1242047|NCT00987181|Pulse wave velocity
1242048|NCT00987181|Non contact
1242049|NCT00987181|Non-invasive
1242050|NCT00987181|Photoplethysmography
1242051|NCT00987181|Doppler flow velocimetry
1242052|NCT00987168|Congenital Hyperinsulinism
1242053|NCT00987168|Hypoglycemia,
1242054|NCT00987168|Sandostatine subcutaneous in 3 daily injections
1242055|NCT00987168|Intramuscular injection of Sandostatine® LP per month
1242056|NCT00987155|Functional electrical stimulation cycling
1242057|NCT00987155|arm crank
1242058|NCT00987155|wheelchair
1242059|NCT00987155|ergometry
1242060|NCT00987155|paraplegia
1242061|NCT00987155|spinal cord injury
1242062|NCT00987155|exercise testing
1242063|NCT00987129|DHA
1242064|NCT00987129|EPA
1242065|NCT00987129|AMD
1242066|NCT00987129|drusen
1242067|NCT00987129|omega-3 fatty acids
1242068|NCT00987129|omega6:omega3 ratio
1242069|NCT00987116|Myasthenia gravis
1242070|NCT00987116|Steroids side effects
1242071|NCT00987116|Comparison of strategies for tapering steroids
1242072|NCT00987116|Generalized MG corresponding to grade III, IV or V of MGFA
1242073|NCT00987103|renal transplantation
1242074|NCT00987103|tacrolimus
1242075|NCT00987103|pharmacokinetics
1242076|NCT00987103|rectal
1242077|NCT00987103|sublingual
1242078|NCT00987103|rectal administration
1242079|NCT00987103|sublingual administration
1242080|NCT00987090|subjects developing symptoms of Alzheimer Disease
1242081|NCT00987077|CSC
1242082|NCT00987077|SRT
1242083|NCT00987064|Protexo
1242084|NCT00987064|Asthma
1242085|NCT00987064|Temperature controlled Laminar Airflow
1242086|NCT00987064|Perennial allergy
1242087|NCT00987064|Quality of life
1242088|NCT00987064|MiniAQLQ
1242089|NCT00987064|FeNO
1242090|NCT00987064|FEV1
1242091|NCT00987064|PEF
1242092|NCT00987051|sentinel node procedure
1242093|NCT00987051|radiocolloid
1242094|NCT00987051|patent blue
1242095|NCT00987038|drug interaction CYP3A4 glucocorticoids midazolam
1242096|NCT00987025|hypertension
1242097|NCT00987025|telehealth
1242098|NCT00987025|nurse monitor
1242099|NCT00987025|nutrition center
1242100|NCT00986999|HIV infected
1242101|NCT00986999|treatment experienced
1242102|NCT00986986|Human immunodeficiency virus
1242103|NCT00986986|Low high density lipoprotein
1242104|NCT00986986|Endothelial function
1242105|NCT00986986|Flow-mediated vasodilation
1242106|NCT00986973|PKU
1242107|NCT00986973|BH4
1242108|NCT00986973|KUVAN
1242109|NCT00986973|PET scan
1242110|NCT00986973|Neurodevelopment
1242111|NCT00986960|multiple sclerosis
1242112|NCT00986960|relapsing remitting
1242113|NCT00986960|RRMS
1242114|NCT00986921|Length of time for procedure to be completed
1242115|NCT00986921|Need for additional dilation
1242116|NCT00986921|Subject satisfaction with procedure
1242117|NCT00986895|HPN-100
1242118|NCT00986895|GT4P
1242119|NCT00986895|Glyceryl tri-(4-phenylbutyrate)
1242120|NCT00986882|Postoperative pain
1242121|NCT00986869|Safety
1242122|NCT00986869|Bronchoscopy
1242123|NCT00986869|Pulmonary
1242124|NCT00986869|Hypertension
1242125|NCT00986843|HM30181A
1242126|NCT00986843|Irinotecan
1242127|NCT00986843|MTD
1242128|NCT00986843|DLT
1242129|NCT00986830|Rhinosinusitis
1242130|NCT00986830|Balloon catheters
1242131|NCT00986830|Office treatment
1242132|NCT00986830|Otorhinolaryngologic Diseases
1242133|NCT00986830|Respiratory Tract Infections
1242134|NCT00986830|Respiratory Tract Diseases
1242135|NCT00986830|FinESS Sinus Treatment
1242136|NCT00986830|endoscopic sinus surgery
1242137|NCT00986817|Refractory ascites
1242138|NCT00986817|Cirrhosis Terlipressin
1242139|NCT00986817|Paracentesis
1242140|NCT00986791|risk reduction
1242141|NCT00986765|Fetal growth restriction
1242142|NCT00986765|Abruptio placentae
1242143|NCT00986765|Perinatal death
1242144|NCT00986752|stent
1242145|NCT00986752|atherectomy
1242146|NCT00986752|paclitaxel-eluting balloon
1242147|NCT00986739|Chronic pathologies
1242148|NCT00986739|elderly
1242149|NCT00986739|atmospheric pollution
1242150|NCT00986739|unplanned hospitalization
1242151|NCT00986739|case-crossover
1242152|NCT00986687|Oocyte cryopreservation
1242153|NCT00986687|vitrification
1242154|NCT00986674|Advanced Non-small Cell Lung Cancer
1242155|NCT00986674|Carboplatin
1242156|NCT00986674|Paclitaxel
1242157|NCT00986674|Cetuximab
1242158|NCT00986674|IMC-A12
1242159|NCT00986648|acute liver failure
1242160|NCT00986648|hepatic encephalopathy
1242161|NCT00986648|acetaminophen toxicity
1242162|NCT00986635|Activated partial thromboplastin time
1242163|NCT00986635|Thrombin clotting Time
1242164|NCT00986635|Anti-Xa-activity
1242165|NCT00986635|Factor X-activity
1242166|NCT00986635|Factor XIII-activity
1242167|NCT00986635|Antithrombin (based on factor II)
1242168|NCT00986635|Antithrombin (based on factor X<9
1242169|NCT00986596|vitamin D
1242170|NCT00986596|skeletal muscle
1242171|NCT00986596|vitamin D receptor
1242172|NCT00986583|Succinylcholine
1242173|NCT00986583|Statins
1242174|NCT00986583|myalgias
1242175|NCT00986583|statins with succinylcholine and pain
1242176|NCT00986570|Botulinum Toxin A
1242177|NCT00986570|Wrinkles
1242178|NCT00986557|cytomegalovirus infection
1242179|NCT00986557|graft versus host disease
1242180|NCT00986544|Laparoscopy
1242181|NCT00986544|cholecystectomy
1242182|NCT00986544|drainage
1242183|NCT00986531|schizophrenia
1242184|NCT00986531|early phase trials
1242185|NCT00986518|Advanced Colorectal Cancer
1242186|NCT00986518|Hepatic and/or lung metastasis
1242187|NCT00986518|Adaptive autologous cell immunotherapy
1242188|NCT00986518|T- regulatory lymphocyte depletion
1242189|NCT00986518|Neo-adjuvant reduced intensity chemotherapeutic conditioning
1242190|NCT00986505|lidocaine
1242191|NCT00986505|fibromyalgia
1242192|NCT00986505|intravenous lidocaine
1242193|NCT00986505|manifestations
1242194|NCT00986492|Sleep deprivation
1242195|NCT00986492|Food intake
1242196|NCT00986492|Motor activity
1242197|NCT00986492|Normal, healthy subjects
1242198|NCT00986479|Patients
1242199|NCT00986466|exercise
1242200|NCT00986466|falls
1242201|NCT00986466|physical functioning
1242202|NCT00986466|vitamin D
1242203|NCT00986466|mobility function
1242204|NCT00986466|neuromuscular functioning¨
1242205|NCT00986466|quality of life
1242206|NCT00986466|number of fallers
1242207|NCT00986466|fall-related injuries including bone fractures
1242208|NCT00986466|bone mass
1242209|NCT00986453|Breast Reduction
1242210|NCT00986453|PlasmaBlade
1242211|NCT00986453|Electrosurgery
1242212|NCT00986453|PEAK Surgical
1242213|NCT00986453|Medtronic Advanced Energy
1242214|NCT00986453|Medtronic
1242215|NCT00986414|Parkinson Disease
1242216|NCT00986414|L-dopa
1242217|NCT00986414|Levodopa
1242218|NCT00986414|dyskinesia
1242219|NCT00986401|Adults
1242220|NCT00986375|Randomized Controlled Trial
1242221|NCT00986375|evidence- and theory-based behavioral intervention
1242222|NCT00986375|expert system
1242223|NCT00986375|stages of change
1242224|NCT00986375|motivational interviewing
1242225|NCT00986375|tailoring
1242226|NCT00986375|Self Care
1242227|NCT00986375|Rehabilitation
1242228|NCT00986375|Expert Systems
1242229|NCT00986375|Behavior
1242230|NCT00986375|Motivation
1242231|NCT00986362|Safety in pediatrics
1242232|NCT00986349|Diabetes
1242233|NCT00986349|Weight Loss
1242234|NCT00986349|GI Dynamics
1242235|NCT00986349|EndoBarrier
1242236|NCT00986336|topiramate
1242237|NCT00986336|risperidone, bipolar disorder
1242238|NCT00986323|Asthma
1242239|NCT00986323|Temperature controlled Laminar Airflow
1242240|NCT00986323|TLA
1242241|NCT00986323|Perennial allergy
1242242|NCT00986323|Quality of life
1242243|NCT00986323|Environmental control
1242244|NCT00986310|fluoxetine
1242245|NCT00986310|epilepsy
1242246|NCT00986310|Prozac
1242247|NCT00986297|recurrent non-small cell lung cancer
1242248|NCT00986297|stage II non-small cell lung cancer
1242249|NCT00986297|stage IIIA non-small cell lung cancer
1242250|NCT00986297|stage IIIB non-small cell lung cancer
1242251|NCT00986297|stage IV non-small cell lung cancer
1242252|NCT00986297|adenocarcinoma of the lung
1242253|NCT00986297|adenosquamous cell lung cancer
1242254|NCT00986297|bronchoalveolar cell lung cancer
1242255|NCT00986297|large cell lung cancer
1242256|NCT00986297|squamous cell lung cancer
1242257|NCT00986284|Non Small Cell Lung Cancer
1242258|NCT00986284|Gefitinib
1242259|NCT00986284|Neoadjuvant Therapy
1242260|NCT00986271|severe sepsis, intensive care units
1242261|NCT00986258|pain assessment
1242262|NCT00986258|tapentadol
1242263|NCT00986258|centrally acting analgesic
1242264|NCT00986245|Parkinson disease
1242265|NCT00986245|Ropinirole
1242266|NCT00986219|Asthma
1242267|NCT00986219|Language
1242268|NCT00986219|Symptoms,
1242269|NCT00986219|Limitation of Daily activities
1242270|NCT00986219|Patients
1242271|NCT00986219|Physicians
1242272|NCT00986219|Greece
1242273|NCT00986206|ovarian epithelial cancer
1242274|NCT00986206|BRCA1 mutation carrier
1242275|NCT00986206|BRCA2 mutation carrier
1242276|NCT00986206|stage IA ovarian epithelial cancer
1242277|NCT00986206|stage IB ovarian epithelial cancer
1242278|NCT00986206|stage IC ovarian epithelial cancer
1242279|NCT00986206|stage IIA ovarian epithelial cancer
1242280|NCT00986206|stage IIB ovarian epithelial cancer
1242281|NCT00986206|stage IIC ovarian epithelial cancer
1242282|NCT00986206|stage IIIA ovarian epithelial cancer
1242283|NCT00986206|stage IIIB ovarian epithelial cancer
1242284|NCT00986206|stage IIIC ovarian epithelial cancer
1242285|NCT00986206|stage IV ovarian epithelial cancer
1242286|NCT00986193|Aortic Valve Stenosis
1242287|NCT00986193|Stent Valve
1242288|NCT00986193|Biological Aortic Valve Prosthesis
1242289|NCT00986180|Acute Low Back Pain
1242290|NCT00986180|Low Back Pain With Leg Pain Below The Knee
1242291|NCT00986180|Radiculopathy, Oxycodone
1242292|NCT00986180|Tapentadol
1242293|NCT00986180|NUCYNTA
1242294|NCT00986167|Psychosis
1242295|NCT00986167|Aggression
1242296|NCT00986167|Acute
1242297|NCT00986167|Quetiapine XR
1242298|NCT00986154|Recurrent Thrombosis
1242299|NCT00986154|Recurrent Pulmonary Embolism
1242300|NCT00986154|Symptomatic Deep Vein Thrombosis
1242301|NCT00986154|Symptomatic Pulmonary Embolism
1242302|NCT00986154|Venous Thromboembolism (VTE)
1242303|NCT00986128|Topiramate
1242304|NCT00986128|Lithium
1242305|NCT00986128|Bipolar disorder
1242306|NCT00986115|epilepsy
1242307|NCT00986115|memory
1242308|NCT00986115|cognition
1242309|NCT00986115|memantine
1242310|NCT00986102|Carbapenem
1242311|NCT00986102|Doripenem
1242312|NCT00986102|Doribax
1242313|NCT00986102|Nosocomial pneumonia, Intra-abdominal infections
1242314|NCT00986102|Urinary tract infection
1242315|NCT00986089|post-placental
1242316|NCT00986089|IUD
1242317|NCT00986089|Copper IUD
1242318|NCT00986089|cesarean section
1242319|NCT00986089|immediate post-partum
1242320|NCT00986089|continuation
1242321|NCT00986076|Pediatric Cataract Surgery
1242322|NCT00986076|Low-Molecular weight Heparin
1242323|NCT00986076|Intraocular infusion
1242324|NCT00986076|Anti-inflammatory effect
1242325|NCT00986063|Nevirapine induced rash
1242326|NCT00986063|Hepatitis
1242327|NCT00986063|Pharmacogenomics
1242328|NCT00986063|AIDS
1242329|NCT00986063|HIV
1242330|NCT00986063|treatment naive
1242331|NCT00986050|STEMI
1242332|NCT00986050|DES
1242333|NCT00986050|BMS
1242334|NCT00986050|abciximab
1242335|NCT00986037|Adverse events
1242336|NCT00986037|Pharmacokinetics
1242337|NCT00986024|Exercise therapy
1242338|NCT00986011|obesity
1242339|NCT00986011|weight changes
1242340|NCT00986011|healthy, no evidence of disease
1242341|NCT00985998|nimotuzumab
1242342|NCT00985998|non-small cell lung cancer
1242343|NCT00985998|chemotherapy
1242344|NCT00985985|smoking cessation
1242345|NCT00985985|nicotine lozenge
1242346|NCT00985985|nicotine replacement therapy
1242347|NCT00985972|PHYSICAL ACTIVITY
1242348|NCT00985972|SCHOOL
1242349|NCT00985972|NUTRITION
1242350|NCT00985972|EDUCATION
1242351|NCT00985972|OVERWEIGHT
1242352|NCT00985959|Multiple myeloma
1242353|NCT00985959|Hematopoietic stem cell transplant
1242354|NCT00985959|HSCT
1242355|NCT00985959|Melphalan
1242356|NCT00985959|Prednisolone
1242357|NCT00985959|Bortezomib
1242358|NCT00985959|JNJ-26866138
1242359|NCT00985933|Healthy normal volunteers
1242360|NCT00985920|blood loss
1242361|NCT00985920|postoperative
1242362|NCT00985907|myeloma
1242363|NCT00985907|DMV
1242364|NCT00985894|Teledermatology
1242365|NCT00985894|Telemedicine
1242366|NCT00985894|Atopic Dermatitis
1242367|NCT00985881|Artificial limbs
1242368|NCT00985881|Gait
1242369|NCT00985881|Posture
1242370|NCT00985881|Prosthesis
1242371|NCT00985881|Vibration
1242372|NCT00985868|unspecified childhood solid tumor, protocol specific
1242373|NCT00985842|Artificial limbs
1242374|NCT00985842|Gait
1242375|NCT00985842|Oximetry
1242376|NCT00985842|Prosthesis
1242377|NCT00985842|Rehabilitation
1242378|NCT00985829|basal cell carcinoma
1242379|NCT00985829|photodynamic therapy
1242380|NCT00985829|photo chemotherapy
1242381|NCT00985829|basal cell epithelioma
1242382|NCT00985816|Preterm
1242383|NCT00985816|newborns
1242384|NCT00985816|Gastric
1242385|NCT00985816|Motility
1242386|NCT00985816|Mucosal
1242387|NCT00985816|immunity
1242388|NCT00985803|Systemic Lupus Erythematosus
1242389|NCT00985803|Activity Physical
1242390|NCT00985803|Activity Disease,trials randomized
1242391|NCT00985790|vaccine
1242392|NCT00985790|Influenza
1242393|NCT00985777|pancreas
1242394|NCT00985777|resectable
1242395|NCT00985777|pancreatic tumor
1242396|NCT00985777|pancreatic ductal adenocarcinoma
1242397|NCT00985777|intraductal papillary mucinous neoplasm of the pancreas
1242398|NCT00985777|mucinous cystic neoplasm
1242399|NCT00985777|pancreatic exocrine neoplasia
1242400|NCT00985751|immunogenicity
1242401|NCT00985751|toddlers
1242402|NCT00985751|Pneumococcal vaccine
1242403|NCT00985751|Haemophilus influenzae
1242404|NCT00985751|safety
1242405|NCT00985751|Streptococcus pneumoniae
1242406|NCT00985751|Streptococcus Pneumoniae Vaccines
1242407|NCT00985738|Prostate Cancer
1242408|NCT00985738|Early Stage Prostate Cancer
1242409|NCT00985725|Major Depressive Disorder
1242410|NCT00985699|non-Hodgkin lymphoma
1242411|NCT00985699|cutaneous B-cell non-Hodgkin lymphoma
1242412|NCT00985699|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1242413|NCT00985699|nodal marginal zone B-cell lymphoma
1242414|NCT00985686|e-mental health
1242415|NCT00985686|Adolescent mental health
1242416|NCT00985686|Spirituality
1242417|NCT00985673|GSK Bio's influenza vaccine GSK2340274A
1242418|NCT00985673|influenza infection
1242419|NCT00985673|GSK Bio's influenza vaccine GSK2340273A
1242420|NCT00985647|HIV
1242421|NCT00985647|HAART
1242422|NCT00985647|ART
1242423|NCT00985647|Pharmacokinetic
1242424|NCT00985647|Healthy volunteers
1242425|NCT00985647|3TC
1242426|NCT00985647|Lamivudine
1242427|NCT00985634|off pump bypass OPCAB
1242428|NCT00985634|OPCAB
1242429|NCT00985621|monoclonal antibody
1242430|NCT00985621|RN624
1242431|NCT00985621|PF-04383119
1242432|NCT00985621|nerve growth factor
1242433|NCT00985621|OA
1242434|NCT00985621|pain
1242435|NCT00985621|arthritis
1242436|NCT00985608|H pylori
1242437|NCT00985608|eradication therapy
1242438|NCT00985595|Adolescent
1242439|NCT00985595|substance abuse
1242440|NCT00985582|Influenza A Virus (H1N1)
1242441|NCT00985569|Constipation
1242442|NCT00985569|Nursing Home
1242443|NCT00985569|Quality Indicator
1242444|NCT00985556|recurrent gastric cancer
1242445|NCT00985556|adenocarcinoma of the stomach
1242446|NCT00985556|stage IIIA gastric cancer
1242447|NCT00985556|stage IIIB gastric cancer
1242448|NCT00985556|stage IIIC gastric cancer
1242449|NCT00985556|stage IV gastric cancer
1242450|NCT00985543|HIV
1242451|NCT00985543|ART
1242452|NCT00985543|HAART
1242453|NCT00985543|Pharmacokinetics
1242454|NCT00985543|Lopinavir/ritonavir
1242455|NCT00985543|Lower dose selection
1242456|NCT00985517|Parkinson's disease
1242457|NCT00985517|Movement Disorders
1242458|NCT00985517|Gene Therapy
1242459|NCT00985517|Neurotrophic Factors
1242460|NCT00985517|GDNF
1242461|NCT00985517|Neurturin
1242462|NCT00985517|DBS
1242463|NCT00985517|Dopamine
1242464|NCT00985504|Major Depressive Disorder
1242465|NCT00985504|Apathy
1242466|NCT00985504|Duloxetine Hydrochloride
1242467|NCT00985504|SSRI
1242468|NCT00985504|Escitalopram
1242469|NCT00985491|obesity
1242470|NCT00985478|First in Man
1242471|NCT00985478|SLV342
1242472|NCT00985478|Atherosclerosis
1242473|NCT00985465|Booster vaccination
1242474|NCT00985465|Pneumococcal vaccine
1242475|NCT00985465|Catch-up vaccination
1242476|NCT00985465|Pneumococcal disease
1242477|NCT00985465|Safety
1242478|NCT00985465|Immunogenicity
1242479|NCT00985452|Medication
1242480|NCT00985452|Adherence
1242481|NCT00985452|Hypertension
1242482|NCT00985426|chronic kidney disease
1242483|NCT00985426|kidney failure
1242484|NCT00985426|kidney failure,chronic
1242485|NCT00985426|chronic kidney failure
1242486|NCT00985426|hepatitis B virus (HBV) vaccine
1242487|NCT00985426|hepatitis B vaccine
1242488|NCT00985426|hepatitis B
1242489|NCT00985426|hepatitis
1242490|NCT00985426|HBV
1242491|NCT00985426|prevention and control
1242492|NCT00985426|dialysis
1242493|NCT00985413|Cockayne Syndrome
1242494|NCT00985413|pediatrics
1242495|NCT00985413|growth
1242496|NCT00985413|hearing
1242497|NCT00985413|Ageing
1242498|NCT00985400|recurrent colon cancer
1242499|NCT00985400|stage IV colon cancer
1242500|NCT00985400|Gastrointestinal
1242501|NCT00985400|Exercise
1242502|NCT00985400|Relaxation
1242503|NCT00985400|Meditation
1242504|NCT00985387|Solifenacin
1242505|NCT00985387|Overactive bladder
1242506|NCT00985387|persistency of the treatment
1242507|NCT00985387|Vesicare
1242508|NCT00985348|Levetiracetam
1242509|NCT00985348|Healthy volunteers
1242510|NCT00985348|Healthy Subjects
1242511|NCT00985322|Hemodialysis
1242512|NCT00985309|unsatisfactory
1242513|NCT00985309|Pap smear
1242514|NCT00985296|Allergic rhinitis
1242515|NCT00985296|Allergic conjunctivitis
1242516|NCT00985283|prevention
1242517|NCT00985283|older adults
1242518|NCT00985283|function
1242519|NCT00985283|participation
1242520|NCT00985283|life satisfaction
1242521|NCT00985283|self-rated health
1242522|NCT00985244|COPD
1242523|NCT00985244|COPD exacerbation
1242524|NCT00985244|macrolide
1242525|NCT00985244|diseae progression
1242526|NCT00985244|bacterial colonisation
1242527|NCT00985218|infertility
1242528|NCT00985218|embryo development
1242529|NCT00985205|Randomized Clinical Trial
1242530|NCT00985205|Glutamine
1242531|NCT00985205|Themal Burn Injuries
1242532|NCT00985205|Nutrition
1242533|NCT00985205|Outcome Assessment
1242534|NCT00985205|Critical Care
1242535|NCT00985205|Total Burn Surface Area
1242536|NCT00985192|adenocarcinoma of the esophagus
1242537|NCT00985192|adenocarcinoma of the stomach
1242538|NCT00985192|recurrent esophageal cancer
1242539|NCT00985192|stage III esophageal cancer
1242540|NCT00985192|stage IV esophageal cancer
1242541|NCT00985192|recurrent gastric cancer
1242542|NCT00985192|stage III gastric cancer
1242543|NCT00985192|stage IV gastric cancer
1242544|NCT00985179|Randomized Controlled Trial
1242545|NCT00985179|evidence- and theory-based behavioral intervention
1242546|NCT00985179|expert system
1242547|NCT00985179|stages of change
1242548|NCT00985179|motivational interviewing
1242549|NCT00985179|tailoring
1242550|NCT00985179|Self Care
1242551|NCT00985179|Expert Systems
1242552|NCT00985127|Hyperuricemia
1242553|NCT00985127|Gout
1242554|NCT00985114|Type II Diabetes
1242555|NCT00985114|Obesity
1242556|NCT00985088|GSK Bio's influenza vaccine GSK2340274A
1242557|NCT00985088|influenza infection
1242558|NCT00985088|GSK Bio's influenza vaccine GSK2340273A
1242559|NCT00985075|Allergic rhinitis
1242560|NCT00985075|Allergic conjunctivitis
1242561|NCT00985062|Folic Acid
1242562|NCT00985062|Homocysteine
1242563|NCT00985062|Ovarian response
1242564|NCT00985062|In Vitro Fertilization
1242565|NCT00985036|glioma
1242566|NCT00985036|meningioma
1242567|NCT00985036|VEGF
1242568|NCT00985023|Unstable
1242569|NCT00985023|Lisfranc
1242570|NCT00985023|fracture
1242571|NCT00985023|dislocation
1242572|NCT00985023|midfoot
1242573|NCT00985010|hepatic encephalopathy
1242574|NCT00985010|hepatitis C
1242575|NCT00985010|manganese
1242576|NCT00985010|mortality
1242577|NCT00985010|prognosis.
1242578|NCT00984997|Superior Sulcus Tumor
1242579|NCT00984997|Lung Cancer
1242580|NCT00984997|Non-Small Cell
1242581|NCT00984997|Multimodality Treatment
1242582|NCT00984997|Surgery
1242583|NCT00984997|Segmentectomy
1242584|NCT00984997|Lobectomy
1242585|NCT00984997|Cisplatin
1242586|NCT00984997|CDDP
1242587|NCT00984997|Etoposide
1242588|NCT00984997|VP-16
1242589|NCT00984997|VePesid
1242590|NCT00984997|Radiation Therapy
1242591|NCT00984997|Radiotherapy
1242592|NCT00984997|Chest Irradiation
1242593|NCT00984997|Prophylactic Cranial Irradiation
1242594|NCT00984997|PCI
1242595|NCT00984971|Microbicides
1242596|NCT00984971|Tenofovir
1242597|NCT00984971|HIV seronegativity
1242598|NCT00984945|pandemic vaccine
1242599|NCT00984945|influenza
1242600|NCT00984945|H5N1
1242601|NCT00984945|Virus Like Particle (VLP)
1242602|NCT00984932|systemic sclerosis
1242603|NCT00984932|pulmonary hypertension
1242604|NCT00984932|rosuvastatin
1242605|NCT00984919|recurrent prostate cancer
1242606|NCT00984919|stage I prostate cancer
1242607|NCT00984919|stage II prostate cancer
1242608|NCT00984919|stage III prostate cancer
1242609|NCT00984919|stage IV prostate cancer
1242610|NCT00984893|Osteoporosis
1242611|NCT00984893|Bone Mineral density
1242612|NCT00984893|fragility fractures
1242613|NCT00984893|zoledronic acid.
1242614|NCT00984893|Treatment
1242615|NCT00984880|Sedation
1242616|NCT00984880|anaesthesia
1242617|NCT00984880|Safety
1242618|NCT00984880|Tolerability
1242619|NCT00984880|Pharmacokinetics
1242620|NCT00984880|Pharmacodynamics
1242621|NCT00984867|Dapagliflozin DPP IV inhibitor add on study
1242622|NCT00984867|Inadequate control
1242623|NCT00984854|Cicatrix
1242624|NCT00984854|Scar
1242625|NCT00984854|Wound-healing
1242626|NCT00984854|Re-epithelialisation
1242627|NCT00984854|RN1004
1242628|NCT00984854|Mannose-6-phosphate
1242629|NCT00984854|M6P
1242630|NCT00984854|Juvidex
1242631|NCT00984841|Diabetes Mellitus targeted mailing
1242632|NCT00984828|multiple myeloma
1242633|NCT00984828|autologous stem cell transplantation
1242634|NCT00984828|velcade
1242635|NCT00984815|NSAID
1242636|NCT00984815|Chronic Pain
1242637|NCT00984815|Osteoarthritis
1242638|NCT00984815|Rheumatoid Arthritis
1242639|NCT00984789|Transdermal Patch
1242640|NCT00984789|Bleeding
1242641|NCT00984789|Pregnancy
1242642|NCT00984776|coronary artery
1242643|NCT00984776|MRI
1242644|NCT00984776|vessel wall imaging
1242645|NCT00984763|Malaria
1242646|NCT00984763|Vaccine
1242647|NCT00984724|Smoking
1242648|NCT00984724|Motivation and Problem Solving
1242649|NCT00984724|MAPS
1242650|NCT00984724|Low Income Smokers
1242651|NCT00984724|HCHD community clinics
1242652|NCT00984724|Telephone-based counseling
1242653|NCT00984698|Posttraumatic Stress Disorder
1242654|NCT00984698|Depression
1242655|NCT00984698|Sleep Initiation and Maintenance Disorders
1242656|NCT00984698|Insomnia
1242657|NCT00984698|Psychotherapy, Group
1242658|NCT00984698|Cognitive Behavioral Therapy
1242659|NCT00984698|Randomized Controlled Trial
1242660|NCT00984698|Veterans
1242661|NCT00984698|Social Rhythms
1242662|NCT00984672|Lumbar Degenerative Disease
1242663|NCT00984672|Bone Morphogenetic Protein
1242664|NCT00984672|TLIF
1242665|NCT00984659|Pulmonary Disease, Chronic Obstructive
1242666|NCT00984659|Dyspnea
1242667|NCT00984646|Cicatrix
1242668|NCT00984646|Scar
1242669|NCT00984646|Wound-healing
1242670|NCT00984646|Prevascar
1242671|NCT00984646|Interleukin-10 (IL-10)
1242672|NCT00984646|Ilodecakin
1242673|NCT00984646|RN1003
1242674|NCT00984633|Neuromuscular Blocking Agents
1242675|NCT00984607|Laparoscopic Gastric Band
1242676|NCT00984607|LAP BAND system
1242677|NCT00984594|allograft
1242678|NCT00984594|knee injury
1242679|NCT00984594|cartilage injury
1242680|NCT00984581|Cicatrix
1242681|NCT00984581|Scar
1242682|NCT00984581|Wound healing
1242683|NCT00984581|Avotermin
1242684|NCT00984581|TGF beta 3
1242685|NCT00984581|Juvista
1242686|NCT00984581|RN1001
1242687|NCT00984555|Biomarkers
1242688|NCT00984555|Semen Exposure
1242689|NCT00984542|recurrent small cell lung cancer
1242690|NCT00984529|Chronic heart failure
1242691|NCT00984529|candesartan cilexetil
1242692|NCT00984529|clinical signs
1242693|NCT00984529|symptoms
1242694|NCT00984516|Cicatrix
1242695|NCT00984516|Scar
1242696|NCT00984516|Wound-healing
1242697|NCT00984516|Juvidex
1242698|NCT00984516|Mannose-6-phosphate
1242699|NCT00984516|M6P
1242700|NCT00984516|RN1004
1242701|NCT00984503|Cicatrix
1242702|NCT00984503|Scar
1242703|NCT00984503|Wound healing
1242704|NCT00984503|Avotermin
1242705|NCT00984503|TGF beta 3
1242706|NCT00984503|Juvista
1242707|NCT00984503|RN1001
1242708|NCT00984490|stage I breast cancer
1242709|NCT00984490|stage II breast cancer
1242710|NCT00984477|Healthy volunteer
1242711|NCT00984477|healthy subjects
1242712|NCT00984477|AZD5122
1242713|NCT00984477|single oral dose
1242714|NCT00984477|phase 1
1242715|NCT00984477|Healthy volunteer phase 1 study
1242716|NCT00984464|metastatic
1242717|NCT00984464|melanoma
1242718|NCT00984464|REOLYSIN
1242719|NCT00984464|chemotherapy
1242720|NCT00984464|carboplatin
1242721|NCT00984464|paclitaxel
1242722|NCT00984451|Antibody Treatment
1242723|NCT00984451|Immune Therapy
1242724|NCT00984451|Infectious Diseases
1242725|NCT00984451|IVIG
1242726|NCT00984451|Plasma Apheresis
1242727|NCT00984451|Influenza A
1242728|NCT00984451|Swine Flu
1242729|NCT00984399|vaginitis
1242730|NCT00984399|Postmenopausal
1242731|NCT00984399|17-β estradiol
1242732|NCT00984399|09-110
1242733|NCT00984386|Cicatrix
1242734|NCT00984386|Scar
1242735|NCT00984386|Wound-healing
1242736|NCT00984386|Zesteem
1242737|NCT00984386|17β-Estradiol
1242738|NCT00984386|RN1002
1242739|NCT00984373|Schizophrenia epidemiology
1242740|NCT00984373|Schizophrenic patients' social and health characteristics
1242741|NCT00984360|Meth
1242742|NCT00984360|Methamphetamine Addiction
1242743|NCT00984360|Methamphetamine Treatment
1242744|NCT00984360|Naltrexone
1242745|NCT00984360|Vivitrol
1242746|NCT00984360|A118G
1242747|NCT00984360|OPRM1
1242748|NCT00984347|nipple stimulation
1242749|NCT00984347|Oxytocin
1242750|NCT00984347|induction of labor
1242751|NCT00984347|term pregnancies
1242752|NCT00984347|grandmultipara
1242753|NCT00984347|VBAC
1242754|NCT00984347|PROM
1242755|NCT00984347|comparison of two methods for induction of labor
1242756|NCT00984334|pain
1242757|NCT00984334|opioid
1242758|NCT00984334|constipation
1242759|NCT00984334|Subjects taking opioids for chronic non-cancer pain, who
1242760|NCT00984334|experience symptoms of opioid induced constipation
1242761|NCT00984321|Geriatric
1242762|NCT00984321|Elderly
1242763|NCT00984321|Counseling
1242764|NCT00984321|Depression
1242765|NCT00984321|Anxiety
1242766|NCT00984321|Intervention
1242767|NCT00984321|Psychoeducational
1242768|NCT00984321|09-116
1242769|NCT00984308|sleep apnea
1242770|NCT00984308|hypertension
1242771|NCT00984308|brain ischemia
1242772|NCT00984282|RAI-Refractory
1242773|NCT00984282|Differentiated
1242774|NCT00984282|Follicular
1242775|NCT00984282|Papillary
1242776|NCT00984282|Hurthle
1242777|NCT00984256|Malaria
1242778|NCT00984256|Prophylaxis
1242779|NCT00984256|Atovaquone
1242780|NCT00984256|Malarone
1242781|NCT00984256|Challenge
1242782|NCT00984243|lung cancer
1242783|NCT00984230|Infant Formula
1242784|NCT00984230|Gut
1242785|NCT00984217|panitumumab
1242786|NCT00984217|salivary gland malignancies
1242787|NCT00984217|radiotherapy
1242788|NCT00984204|cavo-tricuspid dependent
1242789|NCT00984191|Papillary thyroid cancer
1242790|NCT00984191|99mTechnetium MIBI SPECT CT
1242791|NCT00984191|preoperative
1242792|NCT00984191|cervical lymphadenopathy
1242793|NCT00984191|cervical metastasis
1242794|NCT00984178|Reperfusion
1242795|NCT00984178|acute myocardial infarction
1242796|NCT00984178|stem cell therapy
1242797|NCT00984178|GCSF
1242798|NCT00984178|bone marrow mononuclear cells
1242799|NCT00984178|magnetic resonance
1242800|NCT00984165|Allotransplant
1242801|NCT00984165|Relapse
1242802|NCT00984165|Radiation
1242803|NCT00984165|Donor Lymphocyte Infusion
1242804|NCT00984165|Hematologic Malignancies
1242805|NCT00984165|Multiple Myeloma
1242806|NCT00984165|Hodgkin Lymphoma
1242807|NCT00984165|Non-Hodgkin Lymphoma
1242808|NCT00984165|Chronic Lymphocytic Leukemia
1242809|NCT00984152|HIV
1242810|NCT00984152|Raltegravir
1242811|NCT00984152|Women
1242812|NCT00984152|Viral Suppression
1242813|NCT00984152|Viral Reservoir
1242814|NCT00984152|Immune Parameters
1242815|NCT00984152|Gut
1242816|NCT00984152|Genital Tract
1242817|NCT00984139|persistence
1242818|NCT00984139|HBV
1242819|NCT00984139|Long-term
1242820|NCT00984139|Engerix™-B Kinder
1242821|NCT00984139|Hepatitis B
1242822|NCT00984139|adolescent
1242823|NCT00984113|Elinogrel
1242824|NCT00984113|Renal impairment
1242825|NCT00984113|Healthy
1242826|NCT00984113|Kidney dysfunction
1242827|NCT00984100|Cholelithiasis
1242828|NCT00984100|Biliary dyskinesia
1242829|NCT00984087|depression
1242830|NCT00984087|TMS
1242831|NCT00984087|adolescent
1242832|NCT00984087|transcranial magnetic stimulation
1242833|NCT00984087|MDD
1242834|NCT00984087|Major depression
1242835|NCT00984087|mood disorders
1242836|NCT00984074|stage III salivary gland cancer
1242837|NCT00984074|recurrent squamous cell carcinoma of the hypopharynx
1242838|NCT00984074|stage I squamous cell carcinoma of the hypopharynx
1242839|NCT00984074|stage II squamous cell carcinoma of the hypopharynx
1242840|NCT00984074|stage III squamous cell carcinoma of the hypopharynx
1242841|NCT00984074|recurrent squamous cell carcinoma of the larynx
1242842|NCT00984074|recurrent verrucous carcinoma of the larynx
1242843|NCT00984074|stage I squamous cell carcinoma of the larynx
1242844|NCT00984074|stage I verrucous carcinoma of the larynx
1242845|NCT00984074|stage II squamous cell carcinoma of the larynx
1242846|NCT00984074|stage II verrucous carcinoma of the larynx
1242847|NCT00984074|stage III squamous cell carcinoma of the larynx
1242848|NCT00984074|stage III verrucous carcinoma of the larynx
1242849|NCT00984074|recurrent adenoid cystic carcinoma of the oral cavity
1242850|NCT00984074|recurrent mucoepidermoid carcinoma of the oral cavity
1242851|NCT00984074|recurrent verrucous carcinoma of the oral cavity
1242852|NCT00984074|stage I adenoid cystic carcinoma of the oral cavity
1242853|NCT00984074|stage I mucoepidermoid carcinoma of the oral cavity
1242854|NCT00984074|stage I verrucous carcinoma of the oral cavity
1242855|NCT00984074|stage II adenoid cystic carcinoma of the oral cavity
1242856|NCT00984074|stage II mucoepidermoid carcinoma of the oral cavity
1242857|NCT00984074|stage II verrucous carcinoma of the oral cavity
1242858|NCT00984074|stage III adenoid cystic carcinoma of the oral cavity
1242859|NCT00984074|stage III mucoepidermoid carcinoma of the oral cavity
1242860|NCT00984074|stage III verrucous carcinoma of the oral cavity
1242861|NCT00984074|stage I squamous cell carcinoma of the lip and oral cavity
1242862|NCT00984074|stage II squamous cell carcinoma of the lip and oral cavity
1242863|NCT00984074|stage III squamous cell carcinoma of the lip and oral cavity
1242864|NCT00984074|recurrent basal cell carcinoma of the lip
1242865|NCT00984074|recurrent squamous cell carcinoma of the lip and oral cavity
1242866|NCT00984074|stage I basal cell carcinoma of the lip
1242867|NCT00984074|stage II basal cell carcinoma of the lip
1242868|NCT00984074|stage III basal cell carcinoma of the lip
1242869|NCT00984074|recurrent metastatic squamous neck cancer with occult primary
1242870|NCT00984074|untreated metastatic squamous neck cancer with occult primary
1242871|NCT00984074|recurrent lymphoepithelioma of the nasopharynx
1242872|NCT00984074|recurrent squamous cell carcinoma of the nasopharynx
1242873|NCT00984074|stage I lymphoepithelioma of the nasopharynx
1242874|NCT00984074|stage I squamous cell carcinoma of the nasopharynx
1242875|NCT00984074|stage II lymphoepithelioma of the nasopharynx
1242876|NCT00984074|stage II squamous cell carcinoma of the nasopharynx
1242877|NCT00984074|stage III lymphoepithelioma of the nasopharynx
1242878|NCT00984074|stage III squamous cell carcinoma of the nasopharynx
1242879|NCT00984074|recurrent lymphoepithelioma of the oropharynx
1242880|NCT00984074|recurrent squamous cell carcinoma of the oropharynx
1242881|NCT00984074|stage I lymphoepithelioma of the oropharynx
1242882|NCT00984074|stage I squamous cell carcinoma of the oropharynx
1242883|NCT00984074|stage II lymphoepithelioma of the oropharynx
1242884|NCT00984074|stage II squamous cell carcinoma of the oropharynx
1242885|NCT00984074|stage III lymphoepithelioma of the oropharynx
1242886|NCT00984074|stage III squamous cell carcinoma of the oropharynx
1242887|NCT00984074|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1242888|NCT00984074|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1242889|NCT00984074|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1242890|NCT00984074|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1242891|NCT00984074|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1242892|NCT00984074|stage I inverted papilloma of the paranasal sinus and nasal cavity
1242893|NCT00984074|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1242894|NCT00984074|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1242895|NCT00984074|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1242896|NCT00984074|stage II inverted papilloma of the paranasal sinus and nasal cavity
1242897|NCT00984074|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1242898|NCT00984074|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1242899|NCT00984074|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1242900|NCT00984074|stage III inverted papilloma of the paranasal sinus and nasal cavity
1242901|NCT00984074|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1242902|NCT00984074|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1242903|NCT00984074|high-grade salivary gland mucoepidermoid carcinoma
1242904|NCT00984074|low-grade salivary gland mucoepidermoid carcinoma
1242905|NCT00984074|recurrent salivary gland cancer
1242906|NCT00984074|salivary gland acinic cell tumor
1242907|NCT00984074|salivary gland adenocarcinoma
1242908|NCT00984074|salivary gland adenoid cystic carcinoma
1242909|NCT00984074|salivary gland anaplastic carcinoma
1242910|NCT00984074|salivary gland malignant mixed cell type tumor
1242911|NCT00984074|salivary gland poorly differentiated carcinoma
1242912|NCT00984074|salivary gland squamous cell carcinoma
1242913|NCT00984074|stage I salivary gland cancer
1242914|NCT00984074|stage II salivary gland cancer
1242915|NCT00984074|tongue cancer
1242916|NCT00984061|healthy
1242917|NCT00984061|pharmacokinetics
1242918|NCT00984061|drug-drug interaction
1242919|NCT00984048|Colorectal cancer
1242920|NCT00984048|FOLFOX
1242921|NCT00984048|FOLFIRI
1242922|NCT00984048|Avastin
1242923|NCT00984048|Metastases
1242924|NCT00984048|Liver
1242925|NCT00984048|Colon cancer
1242926|NCT00984048|Biomarkers
1242927|NCT00984048|Resistance
1242928|NCT00984048|Biobanking
1242929|NCT00984048|Colorectal cancer with unresectable metastases to the liver
1242930|NCT00984022|abscess
1242931|NCT00984022|MRSA
1242932|NCT00984022|Aquacel dressing
1242933|NCT00984022|Iodoform dressing
1242934|NCT00984009|healthy
1242935|NCT00984009|pharmacokinetics
1242936|NCT00984009|grapefruit juice
1242937|NCT00984009|furanocoumarins
1242938|NCT00984009|cytochrome p450 3A4
1242939|NCT00983983|Amyotrophic Lateral Sclerosis
1242940|NCT00983983|ALS
1242941|NCT00983983|Motor Neuron Disease
1242942|NCT00983983|MND
1242943|NCT00983983|Fat
1242944|NCT00983983|Lipid
1242945|NCT00983983|Cholesterol
1242946|NCT00983983|Omega-3 fatty acid
1242947|NCT00983983|Diet
1242948|NCT00983983|Tube feed
1242949|NCT00983983|Gastrostomy
1242950|NCT00983983|PEG
1242951|NCT00983983|Adults with Amyotrophic Lateral Sclerosis (ALS)
1242952|NCT00983970|Adolescents
1242953|NCT00983970|Obesity
1242954|NCT00983970|Exercise
1242955|NCT00983970|Music
1242956|NCT00983970|Virtual Reality
1242957|NCT00983944|contiguous stage II adult diffuse large cell lymphoma
1242958|NCT00983944|noncontiguous stage II adult diffuse large cell lymphoma
1242959|NCT00983944|stage I adult diffuse large cell lymphoma
1242960|NCT00983944|stage III adult diffuse large cell lymphoma
1242961|NCT00983944|stage IV adult diffuse large cell lymphoma
1242962|NCT00983944|childhood diffuse large cell lymphoma
1242963|NCT00983944|stage I childhood large cell lymphoma
1242964|NCT00983944|stage II childhood large cell lymphoma
1242965|NCT00983944|stage III childhood large cell lymphoma
1242966|NCT00983944|stage IV childhood large cell lymphoma
1242967|NCT00983931|healthy
1242968|NCT00983931|adult
1242969|NCT00983931|colchicine
1242970|NCT00983931|cyclosporine
1242971|NCT00983931|blood levels over time
1242972|NCT00983905|healthy;
1242973|NCT00983905|adult;
1242974|NCT00983905|blood levels over time
1242975|NCT00983892|Cancer
1242976|NCT00983892|caregiver
1242977|NCT00983892|pain
1242978|NCT00983892|symptom
1242979|NCT00983892|information technology
1242980|NCT00983892|palliative care
1242981|NCT00983879|Infantile globoid cell leukodystrophy
1242982|NCT00983879|GLD
1242983|NCT00983879|Krabbe disease
1242984|NCT00983879|Natural History Study
1242985|NCT00983853|VX-950
1242986|NCT00983853|INCIVEK
1242987|NCT00983853|INCIVO
1242988|NCT00983840|diet
1242989|NCT00983840|African-American families
1242990|NCT00983840|web-based
1242991|NCT00983814|Attention Deficit Hyperactivity Disorder
1242992|NCT00983814|ADHD
1242993|NCT00983814|Adult ADHD
1242994|NCT00983814|Adult Attention Deficit Hyperactivity Disorder
1242995|NCT00983788|CPT II
1242996|NCT00983788|VLCAD
1242997|NCT00983775|Pharmacokinetic profile
1242998|NCT00983775|Pharmacodynamic profile
1242999|NCT00983775|insulin
1243000|NCT00983775|jet injector
1243001|NCT00983762|Knee osteoarthritis
1243002|NCT00983762|Leg strength
1243003|NCT00983762|Functional outcomes
1243004|NCT00983762|Minimally Invasive Surgery Mini-Incision (MIS) TKA
1243005|NCT00983762|Unicompartmental knee arthroplasty
1243006|NCT00983762|Standard Para-patellar surgery TKA
1243007|NCT00983762|gait
1243008|NCT00983762|knee arthroplasty
1243009|NCT00983749|External Counterpulsation
1243010|NCT00983749|Counterpulsation, Diastolic
1243011|NCT00983749|Ultrasonography, Doppler, Transcranial
1243012|NCT00983749|Blood Flow Velocity
1243013|NCT00983749|Neurologic Deficit
1243014|NCT00983723|Patient Foramen Ovale
1243015|NCT00983723|PFO
1243016|NCT00983723|Stroke
1243017|NCT00983723|Ischemic Brain Injury
1243018|NCT00983723|Neurovascular Disease
1243019|NCT00983710|prostate neoplasms
1243020|NCT00983697|stage II squamous cell carcinoma of the larynx
1243021|NCT00983697|stage II squamous cell carcinoma of the lip and oral cavity
1243022|NCT00983697|stage II squamous cell carcinoma of the oropharynx
1243023|NCT00983697|stage III squamous cell carcinoma of the larynx
1243024|NCT00983697|stage III squamous cell carcinoma of the lip and oral cavity
1243025|NCT00983697|stage III squamous cell carcinoma of the oropharynx
1243026|NCT00983697|stage IV squamous cell carcinoma of the larynx
1243027|NCT00983697|stage IV squamous cell carcinoma of the lip and oral cavity
1243028|NCT00983697|stage IV squamous cell carcinoma of the oropharynx
1243029|NCT00983697|stage II verrucous carcinoma of the oral cavity
1243030|NCT00983697|stage III verrucous carcinoma of the oral cavity
1243031|NCT00983697|stage IV verrucous carcinoma of the oral cavity
1243032|NCT00983697|tongue cancer
1243033|NCT00983684|Neoplasms by Site
1243034|NCT00983684|Breast Neoplasms
1243035|NCT00983684|Breast Diseases
1243036|NCT00983684|Breast Cancer
1243037|NCT00983684|Cancer of Breast
1243038|NCT00983684|Cancer of the Breast
1243039|NCT00983684|Carcinoma
1243040|NCT00983671|Asthma
1243041|NCT00983671|cystic fibrosis
1243042|NCT00983671|chronic lung disease
1243043|NCT00983671|bronchopulmonary dysplasia
1243044|NCT00983671|pneumonia
1243045|NCT00983658|Anti-OX40L
1243046|NCT00983658|Mild Allergic Asthma
1243047|NCT00983658|Allergies
1243048|NCT00983658|Allergic Asthma
1243049|NCT00983658|Adult Asthma
1243050|NCT00983645|Kidney Transplantation
1243051|NCT00983645|Immunosuppression
1243052|NCT00983632|vagus nerve stimulation
1243053|NCT00983632|heart rate
1243054|NCT00983632|systolic arterial pressure
1243055|NCT00983619|Cancer
1243059|NCT00983554|testosterone
1243060|NCT00983554|insulin
1243061|NCT00983554|obesity
1243062|NCT00983554|aromatase
1243063|NCT00983554|5 alpha reductase
1243064|NCT00983541|intra or extrahepatic cholangiocarcinoma
1243065|NCT00983541|liver cancer
1243066|NCT00983541|liver
1243067|NCT00983541|HCC
1243068|NCT00983541|EHCC
1243069|NCT00983528|cancer
1243070|NCT00983528|lymphoblastic
1243071|NCT00983528|leukemia
1243072|NCT00983502|Idiopathic Chronic Fatigue
1243073|NCT00983502|Chronic Fatigue Syndrome
1243074|NCT00983502|Myalgic encephalomyelitis
1243075|NCT00983489|breast feeding
1243076|NCT00983489|counselling
1243077|NCT00983489|video demonstration
1243078|NCT00983476|Randomized controlled trial
1243079|NCT00983476|Obesity
1243080|NCT00983476|Comparative Effectiveness
1243081|NCT00983476|Clinical practice guidelines
1243082|NCT00983476|Medical Informatics Computing
1243083|NCT00983476|Services, Mental Health
1243084|NCT00983476|Self-care
1243085|NCT00983476|Psychotic disorders
1243086|NCT00983476|Mental Health Care
1243087|NCT00983476|Veterans
1243088|NCT00983463|Nonalcoholic fatty liver disease (NAFLD)
1243089|NCT00983463|Nonalcoholic steatohepatitis (NASH)
1243090|NCT00983463|Obesity
1243091|NCT00983463|Lipidomics
1243092|NCT00983463|Proteomics
1243093|NCT00983424|Breast Cancer
1243094|NCT00983411|non-invasive intermittent positive-pressure ventilation
1243095|NCT00983411|work of breathing
1243096|NCT00983411|Pulse transit time
1243097|NCT00983385|low back pain
1243098|NCT00983385|pain
1243099|NCT00983385|assessment
1243100|NCT00983385|tapentadol
1243101|NCT00983385|centrally acting analgesic
1243102|NCT00983372|healthy; adult; volunteer; colchicine; diltiazem; blood levels over time
1243103|NCT00983359|tumors metastatic to brain
1243104|NCT00983359|unspecified adult solid tumor, protocol specific
1243105|NCT00983346|cancer
1243106|NCT00983346|myeloma
1243107|NCT00983346|multiple myeloma
1243108|NCT00983346|smoldering myeloma
1243109|NCT00983333|Health communication
1243110|NCT00983333|Health literacy
1243111|NCT00983333|Patient
1243112|NCT00983333|Health Care Professional
1243113|NCT00983333|Satisfaction
1243114|NCT00983320|Fibromyalgia
1243115|NCT00983320|pain
1243116|NCT00983320|quetiapine
1243117|NCT00983320|randomized placebo controlled trial
1243118|NCT00983307|Radiation
1243119|NCT00983307|Erlotinib
1243120|NCT00983307|Tarceva
1243121|NCT00983294|blood levels over time;
1243122|NCT00983294|colchicine;
1243123|NCT00983294|azithromycin;
1243124|NCT00983294|healthy
1243125|NCT00983281|Combat casualty care
1243126|NCT00983281|Hextend
1243127|NCT00983281|Colloid
1243128|NCT00983268|periampullary adenocarcinoma
1243129|NCT00983268|stage I pancreatic cancer
1243130|NCT00983268|stage II pancreatic cancer
1243131|NCT00983268|stage III pancreatic cancer
1243132|NCT00983229|difficult airway
1243133|NCT00983229|fibreoptic intubation
1243134|NCT00983229|supraglottic airways
1243135|NCT00983229|laryngeal mask airway
1243136|NCT00983216|blood levels over time;
1243137|NCT00983216|pharmacokinetics;
1243138|NCT00983216|healthy adult;
1243139|NCT00983216|cytochrome p450
1243140|NCT00983203|Dry eye
1243141|NCT00983203|artificial tears
1243142|NCT00983190|HeartMate II
1243143|NCT00983190|BeneMACS
1243144|NCT00983190|LVAD
1243145|NCT00983190|Thoratec Corporation
1243146|NCT00983164|antiviral therapy
1243147|NCT00983164|antioxidant therapy
1243148|NCT00983164|hepatitis C virus
1243149|NCT00983164|oxidative stress
1243150|NCT00983164|vitamin E
1243151|NCT00983125|Labour
1243152|NCT00983125|Epidural analgesia
1243153|NCT00983125|Clonidine
1243154|NCT00983125|Levobupivacaine
1243155|NCT00983125|Opiates
1243156|NCT00983125|Patient-controlled
1243157|NCT00983125|Active spontaneous labour requiring epidural analgesia
1243158|NCT00983112|Gonarthrosis
1243159|NCT00983112|Knee prosthesis insertion
1243160|NCT00983112|Bleeding
1243161|NCT00983112|Undergoing a total knee prothesis surgery
1243162|NCT00983112|knee prothesis surgery
1243163|NCT00983112|Knee arthrosis
1243164|NCT00983112|Thrombosis
1243165|NCT00983086|Flavanones and vascular function
1243166|NCT00983073|Osteoarthritis
1243167|NCT00983073|Pain
1243168|NCT00983073|Assessment
1243169|NCT00983073|Tapentadol
1243170|NCT00983073|Centrally acting analgesic
1243171|NCT00983073|Chronic pain due to osteoarthritis
1243172|NCT00983060|NIM811
1243173|NCT00983060|chronic hepatitis
1243174|NCT00983060|chronic hepatitis C
1243175|NCT00983060|chronic hepatitis C genotype-1
1243176|NCT00983060|HCV
1243177|NCT00983060|HCV-1
1243178|NCT00983060|relapser
1243179|NCT00983047|Nimotuzumab
1243180|NCT00983047|NSCLC
1243181|NCT00983047|Docetaxel
1243182|NCT00983034|nephrotic syndrome
1243183|NCT00983034|Helicobacter pylori infection
1243184|NCT00983034|proteinuria
1243185|NCT00983034|membranous nephropathy
1243186|NCT00983008|Signs and Symptoms
1243187|NCT00983008|Fatigue
1243188|NCT00983008|Sleep Deprivation
1243189|NCT00983008|Internship and Residency
1243190|NCT00983008|Depression
1243191|NCT00983008|Medical Errors
1243192|NCT00983008|Burnout, Professional
1243193|NCT00983008|Burnout
1243194|NCT00983008|Actigraphy
1243195|NCT00983008|Personnel Staffing and Scheduling
1243196|NCT00983008|Workload
1243197|NCT00983008|Humans
1243198|NCT00983008|Adult
1243199|NCT00983008|Male
1243200|NCT00983008|Female
1243201|NCT00983008|Intensive Care Units
1243202|NCT00983008|Prospective Studies
1243203|NCT00983008|Work Schedule Tolerance
1243204|NCT00983008|Disorders of Excessive Somnolence
1243205|NCT00983008|Guideline Adherence
1243206|NCT00983008|Internal Medicine Education
1243212|NCT00982969|tuberculosis
1243213|NCT00982969|pneumonia
1243214|NCT00982969|QuantiFERON-TB Gold in-tube
1243215|NCT00982969|Tuberculin skin test
1243216|NCT00981981|humans
1243217|NCT00981981|randomized clinical trial
1243218|NCT00981981|dietary fiber
1243219|NCT00981981|nutrition
1243220|NCT00981981|beta-glucan
1243221|NCT00981981|oats
1243222|NCT00981981|LDL cholesterol
1243223|NCT00981981|coronary heart disease
1243224|NCT00982930|Tobramycin Inhalation Powder
1243225|NCT00982930|Cystic fibrosis
1243226|NCT00982930|Lung diseases
1243227|NCT00982930|Anti-Bacterial Agents
1243228|NCT00982917|playground
1243229|NCT00982917|injury prevention
1243230|NCT00982904|neglected disease
1243231|NCT00982904|africa
1243232|NCT00982904|new drug
1243233|NCT00982904|oral drug
1243234|NCT00982904|parasite
1243235|NCT00982891|chronic obstructive pulmonary disease
1243236|NCT00982891|palliation
1243237|NCT00982891|opioids
1243238|NCT00982878|treatment experienced
1243239|NCT00982865|MEK inhibitor
1243240|NCT00982865|Cancer
1243241|NCT00982865|Solid tumors
1243242|NCT00982852|Angioplasty
1243243|NCT00982852|Coronary Vessels
1243244|NCT00982852|Heart Disease
1243245|NCT00982852|Cardiology
1243246|NCT00982852|Atherosclerosis
1243247|NCT00982852|Catheterization
1243248|NCT00982826|Phase 1
1243249|NCT00982826|Single and Multiple Ascending Dose
1243250|NCT00982826|Food Effect
1243251|NCT00982813|Periodontal disease
1243252|NCT00982813|Per-term delivery
1243253|NCT00982813|Sulcular bleeding index
1243254|NCT00982813|Bacteriological gingival presence
1243255|NCT00982813|Cytokines
1243256|NCT00982813|Active periodontal disease with sulcular bleeding index
1243257|NCT00982813|Bacteriological sampling in periodontal pocketing
1243258|NCT00982813|Cytokines in the periodontal pocketing
1243259|NCT00982800|gabapentin
1243260|NCT00982800|opioid consumption
1243261|NCT00982800|analgesic
1243262|NCT00982800|anxiety
1243263|NCT00982800|quality of life
1243264|NCT00982787|Epilepsy
1243265|NCT00982787|Seizures
1243266|NCT00982787|Passiflora
1243267|NCT00982774|PKDL
1243268|NCT00982761|occupational drivers
1243269|NCT00982761|health status
1243270|NCT00982748|Fatigue
1243271|NCT00982748|Chemotherapy
1243272|NCT00982748|Yoga
1243273|NCT00982748|Breathing
1243274|NCT00982748|Cancer
1243275|NCT00982748|Anxiety
1243276|NCT00982748|Pranayama
1243277|NCT00982748|Stress
1243278|NCT00982748|Fatigue-associated symptoms in chemotherapy patients
1243279|NCT00982748|Quality of life in chemotherapy patients
1243280|NCT00982722|primary hyperparathyroidism
1243281|NCT00982722|postoperative vitamin D supplementation
1243282|NCT00982696|head and neck cancer
1243283|NCT00982696|opioid growth factor
1243284|NCT00982683|Surgery
1243285|NCT00982683|Moon phases
1243286|NCT00982683|hemorrhage
1243287|NCT00982670|Metabolic syndrome
1243288|NCT00982670|Systemic lupus erythematosus
1243289|NCT00982657|Phase Ib Phase II Advanced solid tumor Clear cell renal cancer Sunitinib plus / minus CVX-060
1243290|NCT00982631|temsirolimus (Torisel®)
1243291|NCT00982631|pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®)
1243292|NCT00982579|HIV preventive vaccine
1243293|NCT00982553|Healthy Volunteers
1243294|NCT00982540|empiric antifungal therapy
1243295|NCT00982540|preemptive antifungal therapy
1243296|NCT00982540|febrile neutropenia
1243297|NCT00982540|risk stratification
1243298|NCT00982540|invasive fungal infection
1243299|NCT00982527|cardiopulmonary bypass
1243300|NCT00982527|pediatric cardiac surgery
1243301|NCT00982527|acute renal failure
1243302|NCT00982527|renal biomarkers
1243303|NCT00982527|fenoldopam
1243304|NCT00982527|Focus on optimization of perfusion during pediatric CPB
1243305|NCT00982514|Asparaginase
1243306|NCT00982514|thrombosis
1243307|NCT00982514|ALL
1243308|NCT00982514|central line
1243309|NCT00982501|(BMI 25-29,9 kg/m2)
1243310|NCT00982475|pulmonary vein isolation
1243311|NCT00982475|robotic navigation
1243312|NCT00982475|atrial fibrillation
1243313|NCT00982462|cognition
1243314|NCT00982462|vision
1243315|NCT00982462|immunology
1243316|NCT00982462|DHA
1243317|NCT00982462|ARA
1243318|NCT00982462|infant
1243319|NCT00982462|nutrition
1243320|NCT00982449|EBV+ malignancies
1243321|NCT00982449|KSHV+ malignancies
1243322|NCT00982449|HIV-associated lymphomas
1243323|NCT00982449|Hodgkin Lymphoma
1243324|NCT00982449|nonHodgkin Lymphoma or
1243325|NCT00982449|nonHodgkins Lymphoproliferative Disease
1243326|NCT00982449|Primary Effusion Lymphoma
1243327|NCT00982449|Kaposi's Sarcoma
1243328|NCT00982449|Gastric Cancer
1243329|NCT00982449|Nasopharyngeal Cancer
1243330|NCT00982436|Combined Modality Therapy
1243331|NCT00982436|Neoadjuvant Therapy
1243332|NCT00982436|Head and neck neoplasms
1243333|NCT00982423|heart failure
1243334|NCT00982423|heart failure with and without kidney dysfunction
1243335|NCT00982410|pain
1243336|NCT00982410|alcohol
1243337|NCT00982410|illicit drugs
1243338|NCT00982410|pain management
1243339|NCT00982384|Chronic obstructive pulmonary disease
1243340|NCT00982384|Disease management
1243341|NCT00982384|Pulmonary rehabilitation
1243342|NCT00982384|Quality of life
1243343|NCT00982371|type 2 diabetes mellitus
1243344|NCT00982371|osteoporosis
1243345|NCT00982371|bone quality
1243346|NCT00982371|magnetic resonance imaging
1243347|NCT00982371|fracture
1243348|NCT00982371|postmenopausal women >65 years old
1243349|NCT00982345|Depression
1243350|NCT00982345|Anxiety
1243351|NCT00982345|Seroquel
1243352|NCT00982345|Quetiapine
1243353|NCT00982345|fMRI
1243354|NCT00982345|pictures
1243355|NCT00982332|polymyalgia rheumatica
1243356|NCT00982319|Broccoli Sprout Extract
1243357|NCT00982319|Breast Cancer
1243358|NCT00982306|alcohol
1243359|NCT00982306|brief interventions
1243360|NCT00982306|counseling
1243361|NCT00982306|harmful/hazardous alcohol drinkers
1243362|NCT00982280|Osteoarthritis
1243363|NCT00982280|pain assessment
1243364|NCT00982280|tapentadol
1243365|NCT00982280|centrally acting analgesic
1243366|NCT00982267|cancer
1243367|NCT00982254|Type 2 Diabetes
1243368|NCT00982254|Oral Insulin
1243369|NCT00982254|Pharmacokinetics
1243370|NCT00982254|Pharmacodynamics
1243371|NCT00982241|OAB
1243372|NCT00982241|urine
1243373|NCT00982241|osmolality
1243374|NCT00982241|urge
1243375|NCT00982241|fluid intake
1243376|NCT00982241|PPIUS
1243377|NCT00982241|urge score
1243378|NCT00982241|bladder
1243379|NCT00982215|Paracetamol
1243380|NCT00982215|per-oral mucosa PMB
1243381|NCT00982215|No disease, healthy volunteers
1243382|NCT00982202|PPAR-gamma
1243383|NCT00982202|inflammation
1243384|NCT00982189|treatment experienced
1243385|NCT00982176|Anatomo-functional determinants
1243386|NCT00982176|cognitive impairment
1243387|NCT00982176|coronary syndrome
1243388|NCT00982176|brain MRI
1243389|NCT00982176|cerebral perfusion scintigraphy
1243390|NCT00982150|Talampanel
1243391|NCT00982150|Open-Label Study
1243392|NCT00982150|Amyotrophic Lateral Sclerosis
1243393|NCT00982137|Japanese Encephalitis
1243394|NCT00982137|Yellow Fever
1243395|NCT00982137|ChimeriVax™-JE
1243396|NCT00982137|STAMARIL®
1243397|NCT00982137|Adult
1243398|NCT00982124|Osteogenesis Imperfecta
1243399|NCT00982124|Infants with moderate to severe Osteogenesis Imperfecta
1243400|NCT00982111|Nonsquamous
1243401|NCT00982111|Non Small Cell Lung Cancer
1243402|NCT00982111|First line treatment
1243403|NCT00982111|Monoclonal
1243404|NCT00982111|Antibodies
1243405|NCT00982111|Epidermal Growth Factor Receptor (EGFR)
1243406|NCT00982098|Prostatectomy
1243407|NCT00982098|Prostatic cancer
1243408|NCT00982098|Urinary incontinence
1243409|NCT00982098|Exercise
1243410|NCT00982098|Electric stimulation therapy
1243411|NCT00982098|Counseling
1243412|NCT00982085|Asthma
1243413|NCT00982085|Allergic rhinitis
1243414|NCT00982085|Military
1243415|NCT00982072|nephrotic minimal change tacrolimus prednisolone
1243416|NCT00982059|Colorectal cancer screening
1243417|NCT00982059|Cancer survivor
1243418|NCT00982059|Radiation therapy
1243419|NCT00982046|contact lenses
1243420|NCT00982046|disinfection solutions
1243421|NCT00982046|contact lens care
1243422|NCT00982033|Heart failure with normal ejection fraction
1243423|NCT00982033|Elderly
1243424|NCT00982020|safety
1243425|NCT00982020|schizophrenia
1243426|NCT00982020|bipolar I (manic or mixed)
1243427|NCT00982020|adolescents
1243428|NCT00982020|weight management
1243429|NCT00982007|IDA
1243430|NCT00981994|respiratory infection
1243431|NCT00981994|antimicrobial drugs
1243432|NCT00981994|decision support
1243433|NCT00981994|Adult patients
1243434|NCT00981955|Caffeine
1243435|NCT00981955|Ltheanine
1243436|NCT00981955|Near Infrared Spectroscopy
1243437|NCT00981955|Cerebral Blood Flow
1243438|NCT00981955|Cognitive Function
1243439|NCT00981955|Mood
1243440|NCT00981942|Nephrogenic systemic fibrosis
1243441|NCT00981942|Imatinib mesylate
1243442|NCT00981942|Glivec
1243443|NCT00981942|Gleevec
1243444|NCT00981929|CYP2D6
1243445|NCT00981929|CYP2C9
1243446|NCT00981929|CYP2C19
1243447|NCT00981929|CYP1A2
1243448|NCT00981916|determination of depth to epidural space using ultrasound
1243449|NCT00981903|VTE in cancer patients
1243450|NCT00981890|Brain Metastases
1243451|NCT00981890|Stereotactic radiosurgery
1243452|NCT00981890|Sunitinib
1243453|NCT00981890|Patients with Brain Metastases
1243454|NCT00981877|acute diarrhea
1243455|NCT00981877|rotavirus
1243456|NCT00981877|probiotic
1243457|NCT00981877|children
1243458|NCT00981864|radiation therapy in breast cancer
1243459|NCT00981864|concurrent radiation
1243460|NCT00981864|Breast cancer patients
1243461|NCT00981851|intervention study
1243462|NCT00981851|interaction
1243463|NCT00981851|COPD
1243464|NCT00981812|PET
1243465|NCT00981812|PEM
1243466|NCT00981812|Positron Emission Mammography
1243467|NCT00981812|Breast Biopsy
1243468|NCT00981799|Relapse
1243469|NCT00981799|T cell
1243470|NCT00981799|Lymphoblastic
1243471|NCT00981799|Leukemia
1243472|NCT00981799|Lymphoma
1243473|NCT00981799|Nelarabine
1243474|NCT00981799|TACL
1243475|NCT00981799|NECTAR
1243476|NCT00981786|24-hour IOP control
1243477|NCT00981786|brinzolamide/timolol
1243478|NCT00981786|brimonidine/timolol
1243479|NCT00981786|travoprost
1243480|NCT00981773|HIV switch
1243481|NCT00981773|HIV
1243482|NCT00981773|treatment experienced
1243483|NCT00981734|Aging
1243484|NCT00981734|functionality
1243485|NCT00981734|life style
1243486|NCT00981734|To have more than sixty years
1243487|NCT00981721|Phase I
1243488|NCT00981721|Advanced solid malignancies
1243489|NCT00981721|Advanced solid tumour
1243490|NCT00981721|Advanced cancer
1243491|NCT00981721|Cediranib (RECENTIN™, AZD2171)
1243492|NCT00981721|China
1243493|NCT00981721|PK
1243494|NCT00981721|pharmacokinetics
1243495|NCT00981708|Amyloidosis
1243496|NCT00981708|lenalidomide
1243497|NCT00981708|newly diagnosed
1243498|NCT00981708|relapsed
1243499|NCT00981708|primary systemic AL amyloidosis
1243500|NCT00981695|HIV
1243501|NCT00981695|Vaccine
1243502|NCT00981695|MVA
1243503|NCT00981695|PMTCT
1243504|NCT00981695|HIV preventive vaccine
1243505|NCT00981695|HIV seronegativity
1243506|NCT00981682|decrease in the number of nocturic episodes for patients with nocturia
1243507|NCT00981669|brazilian pentavalent rotavirus vaccine
1243508|NCT00981669|safety
1243509|NCT00981669|tolerability
1243510|NCT00981669|immunogenicity
1243511|NCT00981656|stage I bladder cancer
1243512|NCT00981656|transitional cell carcinoma of the bladder
1243513|NCT00981643|Meditation
1243514|NCT00981643|Multiple Sclerosis
1243515|NCT00981643|Peripheral Neuropathy
1243516|NCT00981630|Japanese Encephalitis
1243517|NCT00981630|ChimeriVax™-JE Vaccine
1243518|NCT00981630|Adult
1243519|NCT00981604|SILS
1243520|NCT00981604|Laparoscopic Cholecystectomy
1243521|NCT00981604|Children
1243522|NCT00981591|Iloprost
1243523|NCT00981591|Nitric oxide
1243524|NCT00981591|Mechanical ventilator
1243525|NCT00981578|bone cancer
1243526|NCT00981578|pain palliation
1243527|NCT00981578|metastasis
1243528|NCT00981578|breast cancer
1243529|NCT00981578|lung cancer
1243530|NCT00981578|prostate cancer
1243531|NCT00981578|cancer related pain
1243532|NCT00981578|tumors
1243533|NCT00981565|Carpal tunnel syndrome
1243534|NCT00981565|CTS
1243535|NCT00981565|medianus impingement
1243536|NCT00981552|Cervix Cancer
1243537|NCT00981552|IMRT
1243538|NCT00981552|Organ Motion
1243539|NCT00981552|Target Definition
1243540|NCT00981539|The focus of this study is to determine whether it is beneficial to administer enemas before surgery
1243541|NCT00981526|Schizophrenia
1243542|NCT00981526|Cognition
1243543|NCT00981526|Metabolism
1243544|NCT00981526|Antipsychotics
1243545|NCT00981526|Psychopathology
1243546|NCT00981500|obesity
1243547|NCT00981500|gastric bypass
1243548|NCT00981500|gastric banding
1243549|NCT00981500|weight loss
1243550|NCT00981500|insulin sensitivity
1243551|NCT00981500|sleeve gastrectomy
1243552|NCT00981500|fibroblast growth factor 21
1243553|NCT00981500|fibroblast growth factor 19
1243554|NCT00981474|cardiac surgery; brain injury; cerebral autoregulation
1243555|NCT00981461|Andregenetic Alopecia
1243556|NCT00981461|Hair Loss
1243557|NCT00981461|Female Pattern Baldness
1243558|NCT00981448|zinc
1243559|NCT00981448|diabetes
1243560|NCT00981448|genetics
1243561|NCT00981435|Glaucoma
1243562|NCT00981435|Trabeculoplasty
1243563|NCT00981435|Selective laser trabeculoplasty
1243564|NCT00981435|Intraocular pressure
1243565|NCT00981422|glaucoma
1243566|NCT00981422|immunology
1243567|NCT00981422|immunophenotype
1243568|NCT00981409|Fondaparinux sodium
1243569|NCT00981409|contrast-enhanced MDCT
1243570|NCT00981409|Deep Vein Thrombosis
1243571|NCT00981409|Pulmonary thromboembolism
1243572|NCT00981396|smoking
1243573|NCT00981396|EFT (Emotional Freedom Techniques)
1243574|NCT00981396|CBT (cognitive behavior therapy)
1243575|NCT00981396|cravings
1243576|NCT00981396|trauma
1243577|NCT00981383|Fatty Acids, Omega-3
1243578|NCT00981370|Sickle Cell Disease
1243579|NCT00981370|Sickle Cell Anemia
1243580|NCT00981370|Iron Overload
1243581|NCT00981370|Chelation Therapy
1243582|NCT00981370|Iron overload from blood transfusions
1243583|NCT00981370|Heart rate variability
1243584|NCT00981370|Autonomic dysfunction
1243585|NCT00981357|Cross-over evaluate the efficacy of PF-04457845 in relieving pain due to osteoarthritis OA knee osteoarthritis of knee pain due to osteoarthritis
1243586|NCT00981344|wheelchair
1243587|NCT00981344|mobility disability
1243588|NCT00981344|evidence based practice
1243589|NCT00981344|self help devices
1243590|NCT00981344|Veterans prescribed mobility aids
1243591|NCT00981331|Subtalar joint
1243592|NCT00981331|Musculoskeletal Manipulations
1243593|NCT00981331|Manipulation, Chiropractic
1243594|NCT00981331|Ankle sprain
1243595|NCT00981331|Inversion sprain
1243596|NCT00981331|Range of motion, Articular
1243597|NCT00981331|Quaternion
1243598|NCT00981331|Eigen analysis
1243599|NCT00981318|Acquired Immunodeficiency Syndrome
1243600|NCT00981318|HIV
1243601|NCT00981318|AIDS
1243602|NCT00981318|treatment experienced
1243603|NCT00981305|dyspareunia
1243604|NCT00981305|breast cancer
1243605|NCT00981305|sexual dysfunction
1243606|NCT00981305|vaginal lubricant
1243607|NCT00981292|Epigallocatechin Gallate
1243608|NCT00981292|cerebral blood flow
1243609|NCT00981292|Near Infrared spectroscopy
1243610|NCT00981292|Electroencephalography
1243611|NCT00981292|cognitive function
1243612|NCT00981292|mood
1243613|NCT00981292|cerebro-electrical activity
1243614|NCT00981279|Health Profile
1243615|NCT00981279|AIDS
1243616|NCT00981279|Health Promotion
1243617|NCT00981279|HIV
1243618|NCT00981279|treatment experienced
1243619|NCT00981266|Augmentation
1243620|NCT00981266|Augmentation Revision
1243621|NCT00981253|Stress Management Training
1243622|NCT00981253|Cardiac Rehabilitation
1243623|NCT00981253|Stress
1243624|NCT00981253|Depression
1243625|NCT00981227|pain herpetic neuralgia
1243626|NCT00981214|Cystic fibrosis
1243627|NCT00981214|Exocrine Pancreatic Insufficiency
1243628|NCT00981214|Zenpep-1009
1243629|NCT00981201|Smoking
1243630|NCT00981201|Cancer Prevention
1243631|NCT00981201|Celecoxib
1243632|NCT00981201|Celebrex
1243633|NCT00981201|Placebo
1243634|NCT00981175|Japanese Encephalitis
1243635|NCT00981175|Japanese Encephalitis Vaccines
1243636|NCT00981175|Adult
1243637|NCT00981136|Appendicitis
1243638|NCT00981136|Appendectomy
1243639|NCT00981136|Children
1243640|NCT00981136|Laparoscopic
1243641|NCT00981136|SILS
1243642|NCT00981110|Surgical site infections (SSI)
1243643|NCT00981110|Advanced antimicrobial dressing and clean surgery
1243644|NCT00981110|Hydrofibre dressing
1243645|NCT00981097|HIV infection
1243646|NCT00981097|HIV-associated Hodgkin lymphoma
1243647|NCT00981097|stage I adult Hodgkin lymphoma
1243648|NCT00981097|stage II adult Hodgkin lymphoma
1243649|NCT00981097|stage III adult Hodgkin lymphoma
1243650|NCT00981097|stage IV adult Hodgkin lymphoma
1243651|NCT00981097|contiguous stage II adult Burkitt lymphoma
1243652|NCT00981097|noncontiguous stage II adult Burkitt lymphoma
1243653|NCT00981097|stage I adult Burkitt lymphoma
1243654|NCT00981097|stage III adult Burkitt lymphoma
1243655|NCT00981097|stage IV adult Burkitt lymphoma
1243656|NCT00981097|contiguous stage II adult diffuse large cell lymphoma
1243657|NCT00981097|noncontiguous stage II adult diffuse large cell lymphoma
1243658|NCT00981097|stage I adult diffuse large cell lymphoma
1243659|NCT00981097|stage III adult diffuse large cell lymphoma
1243660|NCT00981097|stage IV adult diffuse large cell lymphoma
1243661|NCT00981097|contiguous stage II adult immunoblastic large cell lymphoma
1243662|NCT00981097|noncontiguous stage II adult immunoblastic large cell lymphoma
1243663|NCT00981097|stage I adult immunoblastic large cell lymphoma
1243664|NCT00981097|stage III adult immunoblastic large cell lymphoma
1243665|NCT00981097|stage IV adult immunoblastic large cell lymphoma
1243666|NCT00981071|Tuberculosis
1243667|NCT00981071|QuantiFERON
1243668|NCT00981071|Outbreak
1243669|NCT00981071|Conversion
1243670|NCT00981058|Squamous
1243671|NCT00981058|Non Small Cell Lung Cancer
1243672|NCT00981058|First line treatment
1243673|NCT00981058|Monoclonal
1243674|NCT00981058|Antibodies
1243675|NCT00981058|Epidermal Growth Factor Receptor (EGFR)
1243676|NCT00981045|IDA
1243677|NCT00981032|Aspirin
1243678|NCT00981032|Behavior
1243679|NCT00981032|Cardiovascular Disease
1243680|NCT00981019|survival rates
1243681|NCT00981019|risk communication
1243682|NCT00981019|screening counselling
1243683|NCT00981019|screening recommendation
1243684|NCT00981019|understanding of medical risk
1243685|NCT00981006|ischemic cardiomyopathy (ICM)
1243686|NCT00980993|Prostate
1243687|NCT00980993|Motion
1243688|NCT00980993|Respiration
1243689|NCT00980980|MRSA infection
1243690|NCT00980967|Lung transplantation
1243691|NCT00980967|Chronic lung rejection
1243692|NCT00980967|Obliterative bronchiolitis
1243693|NCT00980967|Predictive factors
1243694|NCT00980954|cervical adenocarcinoma
1243695|NCT00980954|cervical adenosquamous cell carcinoma
1243696|NCT00980954|cervical squamous cell carcinoma
1243697|NCT00980954|stage IA cervical cancer
1243698|NCT00980954|stage IB cervical cancer
1243699|NCT00980954|stage IIA cervical cancer
1243700|NCT00980941|starch
1243701|NCT00980941|carbohydrates
1243702|NCT00980941|blood glucose
1243703|NCT00980941|food intake
1243704|NCT00980941|satiety
1243705|NCT00980941|appetite
1243706|NCT00980915|Acute Lung Injury
1243707|NCT00980915|Acute Respiratory Distress Syndrome
1243708|NCT00980915|Respiratory Distress
1243709|NCT00980915|pneumonia
1243710|NCT00980915|sepsis
1243711|NCT00980915|aspiration
1243712|NCT00980915|pancreatitis
1243713|NCT00980889|bile duct obstruction
1243714|NCT00980889|jaundice
1243715|NCT00980889|metal stent
1243716|NCT00980850|Flu vaccine
1243717|NCT00980850|H1N1 swine flu virus
1243718|NCT00980850|Immunogenicity
1243719|NCT00980850|Reactogenicity
1243720|NCT00980824|cognitive behaviour therapy
1243721|NCT00980824|self harm
1243722|NCT00980824|personality disorder
1243723|NCT00980824|complex comorbidity
1243724|NCT00980824|mental health
1243725|NCT00980798|Osteoarthritis
1243726|NCT00980798|Strong pain killer
1243727|NCT00980798|Strong opioid
1243728|NCT00980798|Low starting dose
1243729|NCT00980798|Fewer side effects
1243730|NCT00980798|Physical functioning
1243731|NCT00980798|Pain control
1243732|NCT00980798|Quality of life
1243733|NCT00980798|Sleep quality
1243734|NCT00980785|Alzheimer's Disease
1243735|NCT00980785|Hypertension
1243736|NCT00980759|Extended-field Irradiation (EFI)
1243737|NCT00980759|Cervical cancer
1243738|NCT00980759|Hypoxia
1243739|NCT00980759|Carbonic anhydrase 9 (CA9)
1243740|NCT00980759|locally advanced uterine cervical cancer
1243741|NCT00980746|pain diabetes neuropathy
1243742|NCT00980733|Micronutrients
1243743|NCT00980733|zinc
1243744|NCT00980733|iron
1243745|NCT00980733|iodine
1243746|NCT00980733|fortification
1243747|NCT00980733|school children
1243748|NCT00980707|versican
1243749|NCT00980707|hyaluronan
1243750|NCT00980707|sputum
1243751|NCT00980694|ubiquinol
1243752|NCT00980694|coenzyme Q10
1243753|NCT00980694|Huntington disease
1243754|NCT00980681|Renal disease
1243755|NCT00980681|Contrast agent
1243756|NCT00980681|MRA
1243757|NCT00980642|surgery
1243758|NCT00980642|thermometer
1243759|NCT00980642|non-invasive
1243760|NCT00980642|interoperative core temperature
1243761|NCT00980642|anesthesia
1243762|NCT00980616|Arthroplasty, hip
1243763|NCT00980616|blood losses
1243764|NCT00980616|pain
1243765|NCT00980616|local analgesia
1243766|NCT00980616|epinephrine
1243767|NCT00980616|Primary total hip arthroplasty
1243768|NCT00980603|gastric cancer
1243769|NCT00980603|metastatic
1243770|NCT00980603|docetaxel
1243771|NCT00980603|cisplatin
1243772|NCT00980603|S-1
1243773|NCT00980590|supine emergency intubations
1243774|NCT00980590|emergency intubations
1243782|NCT00980525|healthy
1243783|NCT00980512|behavior problems
1243784|NCT00980512|parent training
1243785|NCT00980512|foster care
1243786|NCT00980486|Antibiotic Concentration
1243787|NCT00980486|Tissue
1243788|NCT00980486|Obesity
1243789|NCT00980486|Cesarean
1243790|NCT00980473|Primary Angle Closure Disease
1243791|NCT00980447|H5N1
1243792|NCT00980447|Vaccine
1243793|NCT00980447|Influenza H5N1
1243794|NCT00980447|Avian influenza H5N1
1243795|NCT00980447|Pandemic
1243796|NCT00980434|vertebral fracture
1243797|NCT00980434|spinal cord injury
1243798|NCT00980421|iron
1243799|NCT00980421|iron toxicity markers
1243800|NCT00980421|oxidative stress markers
1243801|NCT00980421|iron supplementation
1243802|NCT00980421|NTBI
1243803|NCT00980421|iron over load
1243804|NCT00980421|interleukin levels
1243805|NCT00980421|iron status
1243806|NCT00980421|acut phase reactants
1243807|NCT00980421|preschool children
1243808|NCT00980395|recurrent mantle cell lymphoma
1243809|NCT00980395|stage III mantle cell lymphoma
1243810|NCT00980395|stage IV mantle cell lymphoma
1243811|NCT00980395|recurrent marginal zone lymphoma
1243812|NCT00980395|stage III marginal zone lymphoma
1243813|NCT00980395|stage IV marginal zone lymphoma
1243814|NCT00980395|Waldenstrom macroglobulinemia
1243815|NCT00980395|recurrent small lymphocytic lymphoma
1243816|NCT00980395|stage III small lymphocytic lymphoma
1243817|NCT00980395|stage IV small lymphocytic lymphoma
1243818|NCT00980395|recurrent grade 1 follicular lymphoma
1243819|NCT00980395|recurrent grade 2 follicular lymphoma
1243820|NCT00980395|recurrent grade 3 follicular lymphoma
1243821|NCT00980395|stage III grade 1 follicular lymphoma
1243822|NCT00980395|stage III grade 2 follicular lymphoma
1243823|NCT00980395|stage III grade 3 follicular lymphoma
1243824|NCT00980395|stage IV grade 1 follicular lymphoma
1243825|NCT00980395|stage IV grade 2 follicular lymphoma
1243826|NCT00980395|stage IV grade 3 follicular lymphoma
1243827|NCT00980395|extranodal marginal zone BCL mucosa assoc lymphoid tissue
1243828|NCT00980395|nodal marginal zone B Cell lymphoma
1243829|NCT00980395|splenic marginal zone lymphoma
1243830|NCT00980382|Stomach Neoplasms
1243831|NCT00980382|phase I/II
1243832|NCT00980382|Combination chemotherapy
1243833|NCT00980382|S-1
1243834|NCT00980382|Docetaxel
1243835|NCT00980369|Lateral internal sphincterotomy
1243836|NCT00980369|Anal fissure
1243837|NCT00980369|Surgical technique
1243838|NCT00980369|Incision
1243839|NCT00980369|Wound healing
1243840|NCT00980356|Diabetes Kidney transplantation
1243841|NCT00980356|New onset diabetes mellitus after transplantation
1243842|NCT00980330|Hepatitis C
1243843|NCT00980330|Peginterferon alpha-2a
1243844|NCT00980330|PegIFNalpha-2a
1243845|NCT00980330|RBV
1243846|NCT00980330|Ribavirin
1243847|NCT00980330|Placebo
1243848|NCT00980330|TMC435-TIDP16-C206
1243849|NCT00980330|TMC435-C206
1243850|NCT00980330|TMC435
1243851|NCT00980330|HCV
1243852|NCT00980317|Renal tumor
1243853|NCT00980317|Restored kidney
1243854|NCT00980317|Renal transplantation
1243855|NCT00980317|Third party
1243856|NCT00980304|Diffuse large B cell lymphomas
1243857|NCT00980278|sinus lift
1243858|NCT00980278|tooth extraction
1243859|NCT00980278|dental implant
1243860|NCT00980252|Schizophrenia
1243861|NCT00980252|Cognitive Behavioral Therapy
1243862|NCT00980252|Compliance
1243863|NCT00980252|Medication Adherence
1243864|NCT00980252|Psychotic Disorders
1243865|NCT00980252|Mental Disorders
1243866|NCT00980252|Outcomes
1243867|NCT00980252|Psychoeducation
1243868|NCT00980252|Adherence Attitudes
1243869|NCT00980252|Intervention
1243870|NCT00980252|Nonadherence
1243871|NCT00980252|Schizophrenia and Disorders with Psychotic Features
1243872|NCT00980239|Solid Tumors
1243873|NCT00980239|Liver
1243874|NCT00980239|hepatic arterial infusion
1243875|NCT00980239|HAI
1243876|NCT00980239|Bevacizumab
1243877|NCT00980239|Avastin
1243878|NCT00980239|Cetuximab
1243879|NCT00980239|Erbitux
1243880|NCT00980239|Irinotecan
1243881|NCT00980239|Camptosar
1243882|NCT00980239|Oxaliplatin
1243883|NCT00980239|Eloxatin
1243884|NCT00980213|renal cell cancer
1243885|NCT00980213|sunitinib
1243886|NCT00980213|costs
1243887|NCT00980213|quality of life
1243888|NCT00980200|GW642444
1243889|NCT00980200|once daily dosing
1243890|NCT00980200|asthma
1243891|NCT00980200|efficacy
1243892|NCT00980200|safety
1243893|NCT00980200|FEV1
1243894|NCT00980187|blood tests
1243895|NCT00980187|cardiac function
1243896|NCT00980187|endothelial function
1243897|NCT00980187|arterial function
1243898|NCT00980174|men
1243899|NCT00980174|male
1243900|NCT00980174|denosumab
1243901|NCT00980174|BMD
1243902|NCT00980174|lumbar spine
1243903|NCT00980174|ADAMO
1243904|NCT00980174|The ADAMO Trial
1243905|NCT00980174|male osteoporosis
1243906|NCT00980174|osteoporosis in men
1243907|NCT00980174|males with low bone mineral density
1243908|NCT00980161|Hepatitis C
1243909|NCT00980161|Peginterferon
1243910|NCT00980161|Ribavirin
1243911|NCT00980161|MicroRNA
1243912|NCT00980148|Chlamydia trachomatis, Chlamydia, Doxycycline, Azithromycin
1243913|NCT00980135|Sinecort
1243914|NCT00980135|Hydrocortison
1243915|NCT00980135|Mild atopic dermatitis
1243916|NCT00980135|Efficacy, safety
1243917|NCT00980122|Advanced cancer patients dying in hospital receive aggressive cancer-specific therapy and supportive measures.
1243918|NCT00980109|Influenza Prophylaxis
1243919|NCT00980109|Long Term
1243920|NCT00980109|Oral Oseltamivir
1243921|NCT00980109|Inhaled Zanamivir
1243922|NCT00980083|GLP-1
1243923|NCT00980083|exendin(9-39)
1243924|NCT00980083|gastric emptying
1243925|NCT00980083|incretin
1243926|NCT00980083|human
1243927|NCT00980070|lumbar puncture positioning device
1243928|NCT00980031|Aldosterone Blockade
1243929|NCT00980031|Aldosterone Receptor Blockers
1243930|NCT00980031|cardiac chamber size
1243931|NCT00980031|wall thickness
1243932|NCT00980031|left ventricular ejection fraction
1243933|NCT00980031|left atrial volumes
1243934|NCT00980031|diastolic function
1243935|NCT00980018|CML
1243936|NCT00980018|Leukemia
1243937|NCT00980018|Tasigna
1243938|NCT00980018|nilotinib
1243939|NCT00980018|AMN107
1243940|NCT00980018|CML-CP
1243941|NCT00980018|Chronic Phase
1243942|NCT00980005|GSK Biologicals influenza vaccine GSK1557482A
1243943|NCT00980005|influenza infection
1243944|NCT00979979|Hepatitis C
1243945|NCT00979979|Genotype
1243946|NCT00979979|Realtime PCR
1243947|NCT00979966|Locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC)
1243948|NCT00979953|delta opioid receptor agonist
1243949|NCT00979953|osteoarthritis
1243950|NCT00979953|pain
1243951|NCT00979940|atorvastatin
1243952|NCT00979940|clopidogrel
1243953|NCT00979940|percutaneous intervention
1243954|NCT00979940|periprocedural myonecrosis
1243955|NCT00979927|Antisense
1243956|NCT00979927|miR-122 antagonist
1243957|NCT00979927|safety in healthy Volunteers
1243958|NCT00979927|Hepatitis C
1243959|NCT00979914|osteoarthritis
1243960|NCT00979914|patient education
1243961|NCT00979914|function
1243962|NCT00979914|physio therapy
1243963|NCT00979888|dyspnea
1243964|NCT00979888|depression
1243965|NCT00979888|fatigue
1243966|NCT00979888|anxiety disorder
1243967|NCT00979888|small cell lung cancer
1243968|NCT00979888|non-small cell lung cancer
1243969|NCT00979875|insulin
1243970|NCT00979875|recombinant human hyaluronidase
1243971|NCT00979875|Healthy volunteers
1243972|NCT00979849|safety
1243973|NCT00979849|tolerability
1243974|NCT00979849|healthy
1243975|NCT00979849|inhalation
1243976|NCT00979836|venous
1243977|NCT00979836|ulcer
1243978|NCT00979836|phlebotonic
1243979|NCT00979836|calcium dobesilate
1243980|NCT00979836|clinical trial
1243981|NCT00979810|PET scan
1243982|NCT00979810|CT scan
1243983|NCT00979810|09-060
1243984|NCT00979810|CNS
1243985|NCT00979797|Community IMCI
1243986|NCT00979797|C-IMCI
1243987|NCT00979797|CHW
1243988|NCT00979797|Children
1243989|NCT00979797|Evaluation
1243990|NCT00979797|Behaviour
1243991|NCT00979797|Counselling
1243992|NCT00979797|Under 5 mortality
1243993|NCT00979797|Under 5 Nutrition
1243994|NCT00979784|obesity
1243995|NCT00979784|primary care
1243996|NCT00979771|GSK706769
1243997|NCT00979771|Enbrel
1243998|NCT00979771|Rheumatoid Arthritis
1243999|NCT00979745|Erythropoietic Protoporphyria
1244000|NCT00979745|EPP
1244001|NCT00979745|Afamelanotide
1244002|NCT00979732|high blood pressure
1244003|NCT00979732|dietary supplements
1244004|NCT00979732|nutrition
1244005|NCT00979719|Randomized Controlled Trial
1244006|NCT00979719|evidence- and theory-based behavioral intervention
1244007|NCT00979719|expert system
1244008|NCT00979719|stages of change
1244009|NCT00979719|motivational interviewing
1244010|NCT00979719|tailoring
1244011|NCT00979719|Self Care
1244012|NCT00979719|Rehabilitation
1244013|NCT00979719|Expert Systems
1244014|NCT00979693|anxiety
1244015|NCT00979693|stage IV melanoma
1244016|NCT00979693|depression
1244017|NCT00979693|spirituality
1244018|NCT00979693|pain
1244019|NCT00979680|sphincter preservation
1244020|NCT00979680|neoadjuvant therapy
1244021|NCT00979667|Upper respiratory tract infection
1244022|NCT00979667|Influenza A
1244023|NCT00979667|Human Swine Influenza
1244024|NCT00979654|Sifalimumab
1244025|NCT00979654|MEDI-545
1244026|NCT00979641|breast cancer
1244027|NCT00979641|metastatic
1244028|NCT00979641|chemotherapy
1244029|NCT00979641|bevacizumab
1244030|NCT00979641|docetaxel
1244031|NCT00979641|Phase II
1244032|NCT00979641|first line chemotherapy
1244033|NCT00979641|metastatic breast cancer patients
1244034|NCT00979628|Type 2 Diabetes
1244035|NCT00979628|Inpatient Hyperglycemia
1244036|NCT00979615|vasomotor rhinitis
1244037|NCT00979615|chronic non-allergic rhinitis
1244038|NCT00979615|VMR
1244039|NCT00979602|GSK Bio's influenza vaccine GSK2340274A
1244040|NCT00979602|Influenza Vaccines
1244041|NCT00979602|GSK Bio's influenza vaccine GSK2340273A
1244042|NCT00979602|influenza infection
1244043|NCT00979589|stroke
1244044|NCT00979589|transient ischemic attack
1244045|NCT00979589|acute treatment
1244046|NCT00979589|acute non-disabling cerebrovascular event
1244047|NCT00979589|clopidogrel
1244048|NCT00979589|clopidogrel combined with ASA
1244049|NCT00979589|recurrence of stroke and other vascular events
1244050|NCT00979563|HM30181AK
1244051|NCT00979563|Irinotecan tablet
1244052|NCT00979563|MTD
1244053|NCT00979563|DLT
1244054|NCT00979550|laser
1244055|NCT00979550|pediatric
1244056|NCT00979550|skin pigmentation
1244057|NCT00979524|Depressive symptoms
1244058|NCT00979524|Mental health services
1244059|NCT00979524|Adolescents
1244060|NCT00979524|Young adults
1244061|NCT00979524|African-American
1244062|NCT00979511|osteoporosis
1244063|NCT00979511|calcium
1244064|NCT00979511|weight-bearing exercise
1244065|NCT00979511|bone mass
1244066|NCT00979511|prepubertal girls
1244067|NCT00979485|Pediatric IBD
1244068|NCT00979485|Microparticles
1244069|NCT00979472|Solifenacin
1244070|NCT00979472|Overactive bladder
1244071|NCT00979472|Micturition
1244072|NCT00979472|Urinary urgency
1244073|NCT00979472|Vesicare
1244074|NCT00979446|Interactive phone-based intervention with written materials
1244075|NCT00979446|Older adults
1244076|NCT00979446|Physical activity
1244077|NCT00979446|Cognitive stimulation
1244078|NCT00979446|Social engagement
1244079|NCT00979433|Extubation failure
1244080|NCT00979433|Continuous positive airway pressure
1244081|NCT00979433|Bubble CPAP
1244082|NCT00979420|treatment experienced
1244083|NCT00979407|influenza infection
1244084|NCT00979407|GSK Biologicals' influenza vaccine GSK2340272A and GSK2340274A
1244085|NCT00979394|Diabetes Care at GPs in Austria
1244086|NCT00979394|Characteristic of diabetes patients at GPs in Austria
1244087|NCT00979381|sunitinib
1244088|NCT00979381|sorafenib
1244089|NCT00979381|immune response
1244090|NCT00979355|Whole body
1244091|NCT00979355|SPECT
1244092|NCT00979342|morcellator
1244093|NCT00979342|hysteroscope
1244094|NCT00979342|myomectomy
1244095|NCT00979342|polypectomy
1244096|NCT00979342|uterine fibroids
1244097|NCT00979342|uterine polyps
1244098|NCT00979342|local anesthetic
1244099|NCT00979342|cervical block
1244100|NCT00979342|pain management
1244101|NCT00979329|sunitinib
1244102|NCT00979329|sorafenib
1244103|NCT00979329|fatigue
1244104|NCT00979329|depression
1244105|NCT00979329|quality of life
1244106|NCT00979329|metastatic RCC
1244107|NCT00979329|colorectal cancer
1244108|NCT00979329|GIST
1244109|NCT00979303|Pediatric
1244110|NCT00979303|Electrophysiology
1244111|NCT00979303|Ablation
1244112|NCT00979303|Radiation
1244113|NCT00979303|Devices
1244114|NCT00979303|SVT
1244115|NCT00979290|Fix-dose combination anti-TB drug
1244116|NCT00979290|adverse effect
1244117|NCT00979290|efficiency
1244118|NCT00979264|Quality Improvement
1244119|NCT00979251|Influenza
1244120|NCT00979251|Immunocompromised
1244121|NCT00979251|HIV
1244122|NCT00979251|History of transplant
1244123|NCT00979238|Hemophilia B
1244124|NCT00979238|Factor IX Gene
1244125|NCT00979238|Factor IX Protein
1244126|NCT00979238|Vector
1244127|NCT00979225|health information technology
1244128|NCT00979225|clinical decision support
1244129|NCT00979225|medication management
1244130|NCT00979225|medication adherence
1244131|NCT00979212|stage IIIA non-small cell lung cancer
1244132|NCT00979212|adenocarcinoma of the lung
1244133|NCT00979212|adenosquamous cell lung cancer
1244134|NCT00979212|bronchoalveolar cell lung cancer
1244135|NCT00979212|large cell lung cancer
1244136|NCT00979212|squamous cell lung cancer
1244137|NCT00979199|IHD
1244138|NCT00979199|CAD
1244139|NCT00979199|Non invasive imaging
1244140|NCT00979199|SPECT
1244141|NCT00979199|PET
1244142|NCT00979199|CMR
1244143|NCT00979199|Echocardiography
1244144|NCT00979186|transgastric cholecystectomy
1244145|NCT00979173|malignant glioma
1244146|NCT00979173|glioblastoma multiforme
1244147|NCT00979173|gliosarcoma
1244148|NCT00979173|anaplastic astrocytoma
1244149|NCT00979173|anaplastic oligodendroglioma
1244150|NCT00979173|anaplastic mixed glioma
1244151|NCT00979173|Pro00018751
1244152|NCT00979173|Duke
1244153|NCT00979173|Ambit
1244154|NCT00979173|AC480
1244155|NCT00979147|knee arthritis
1244156|NCT00979147|total knee arthroplasty
1244157|NCT00979147|total knee replacement
1244158|NCT00979147|metal backed tibial component
1244159|NCT00979147|all-polyethylene tibia
1244160|NCT00979147|modular polished tibial baseplate
1244161|NCT00979134|Cancer
1244162|NCT00979134|Tumour
1244163|NCT00979134|Advanced Solid Malignancies
1244164|NCT00979134|FGFR
1244165|NCT00979134|Squamous NSCLC
1244166|NCT00979134|Gastric adenocarcinoma
1244167|NCT00979121|ALI
1244168|NCT00979121|Sepsis
1244169|NCT00979121|statin
1244170|NCT00979108|Radiculopathy
1244171|NCT00979108|Neck pain
1244172|NCT00979108|Physical therapy modalities
1244173|NCT00979108|Rehabilitation
1244174|NCT00979095|multiple hernia
1244175|NCT00979056|Traveller's diarrhoea
1244176|NCT00979056|Prevention
1244177|NCT00979043|knee osteoarthritis
1244178|NCT00979043|weight-loss
1244179|NCT00979043|exercise
1244180|NCT00979043|obesity
1244181|NCT00979043|physical function
1244182|NCT00979043|total mortality
1244183|NCT00979017|malignant glioma
1244184|NCT00979017|glioblastoma multiforme
1244185|NCT00979017|gliosarcoma
1244186|NCT00979017|Avastin
1244187|NCT00979017|bevacizumab
1244188|NCT00979017|Temodar
1244189|NCT00979017|temozolomide
1244190|NCT00979017|Irinotecan
1244191|NCT00979017|CPT-11
1244192|NCT00979017|Pro00019065
1244193|NCT00979017|Vredenburgh
1244194|NCT00979017|Duke
1244195|NCT00979004|Photosensitivity
1244196|NCT00979004|Epilepsy
1244197|NCT00979004|Seizures
1244198|NCT00978991|Benign prostate hyperplasia
1244199|NCT00978991|Erectile dysfunction
1244200|NCT00978965|kidney transplantation
1244201|NCT00978965|immunosuppression
1244202|NCT00978965|single nucleotide polymorphism
1244203|NCT00978965|IMPDH
1244204|NCT00978926|Anti-Vascular Endothelial growth factor
1244205|NCT00978913|dendritic cell
1244206|NCT00978913|cancervaccine
1244207|NCT00978913|breast cancer
1244208|NCT00978913|malignant melanoma
1244209|NCT00978913|Cyclophosphamide
1244210|NCT00978900|satiety peptides
1244211|NCT00978900|GLP-1
1244212|NCT00978900|PYY
1244213|NCT00978900|ghrelin
1244214|NCT00978900|appetite profile
1244215|NCT00978900|Sweetening Agents
1244216|NCT00978887|Facial cream
1244217|NCT00978887|natural product
1244218|NCT00978887|facial wrinkles
1244219|NCT00978874|recurrent cervical cancer
1244220|NCT00978874|stage IB cervical cancer
1244221|NCT00978874|stage IIA cervical cancer
1244222|NCT00978874|stage IIB cervical cancer
1244223|NCT00978874|stage III cervical cancer
1244224|NCT00978874|stage IVA cervical cancer
1244225|NCT00978874|stage IVB cervical cancer
1244226|NCT00978848|trichomonas
1244227|NCT00978848|chlamydia
1244228|NCT00978848|gonorrhea
1244229|NCT00978848|emergency contraception
1244230|NCT00978848|emergency contraception use
1244231|NCT00978835|Diabetes
1244232|NCT00978835|Hypertension
1244233|NCT00978835|Physical Activity
1244234|NCT00978835|Diet
1244235|NCT00978835|Medication Adherence
1244236|NCT00978822|Subarachnoid hemorrhage
1244237|NCT00978822|Hypertension
1244238|NCT00978822|brain Aneurysm
1244239|NCT00978822|intracerebral hemorrhage
1244240|NCT00978822|antihypertensive
1244241|NCT00978822|calcium channel blockers
1244242|NCT00978822|infusion
1244243|NCT00978822|neurocritical care
1244244|NCT00978809|BPPV
1244245|NCT00978809|postural stability
1244246|NCT00978809|Epley
1244247|NCT00978809|Semont
1244248|NCT00978796|Diabetes Mellitus
1244249|NCT00978796|Type 1 diabetes
1244250|NCT00978796|glucose variability
1244251|NCT00978783|Phonation
1244252|NCT00978783|Tracheostomy
1244253|NCT00978783|phonation valve
1244254|NCT00978783|positive end expiratory pressure
1244255|NCT00978770|stage II breast cancer
1244256|NCT00978770|stage IIIA breast cancer
1244257|NCT00978770|stage IIIB breast cancer
1244258|NCT00978770|stage IIIC breast cancer
1244259|NCT00978757|hepatectomy
1244260|NCT00978757|IL 6
1244261|NCT00978757|organ failure
1244262|NCT00978757|ketamine
1244263|NCT00978757|Pringle
1244264|NCT00978744|Clinical Health Record
1244265|NCT00978744|Computerized Decision Support
1244266|NCT00978744|Patient Safety
1244267|NCT00978744|Resource Utilization
1244268|NCT00978718|prostate cancer
1244269|NCT00978705|Keratinocyte Cell
1244270|NCT00978705|severe burn wound
1244271|NCT00978692|Myopia
1244272|NCT00978692|Astigmatism
1244273|NCT00978692|Orthokeratology
1244274|NCT00978692|Corneal thickness
1244275|NCT00978692|Corneal curvatures
1244276|NCT00978692|Corneal biomechanics
1244277|NCT00978679|Children
1244278|NCT00978679|Peripheral refraction
1244279|NCT00978679|Aberration
1244280|NCT00978679|Eyeball length
1244281|NCT00978679|Myopic control
1244282|NCT00978679|Myopia
1244283|NCT00978679|Corneal reshaping
1244284|NCT00978679|Orthokeratology
1244285|NCT00978653|allopurinol
1244286|NCT00978653|chronic kidney disease
1244287|NCT00978653|endothelial dysfunction
1244288|NCT00978653|hyperuricemia
1244289|NCT00978653|uric acid
1244290|NCT00978653|vascular endothelium
1244291|NCT00978653|xanthine oxidase inhibitor
1244292|NCT00978640|Sirt1 activity
1244293|NCT00978601|post-operative analgesia
1244294|NCT00978601|early discharge,
1244295|NCT00978601|fast recovery,
1244296|NCT00978601|minimally invasive myomectomy,
1244297|NCT00978601|laparoscopy,
1244298|NCT00978601|laparoscopically assisted myomectomy
1244299|NCT00978601|patient discharge
1244300|NCT00978601|Anesthesia Recovery Period
1244301|NCT00978575|Iron treatment
1244302|NCT00978575|Upper gastrointestinal bleeding
1244303|NCT00978549|pain
1244304|NCT00978549|nausea and vomiting
1244305|NCT00978549|adenocarcinoma of the esophagus
1244306|NCT00978549|adenocarcinoma of the stomach
1244307|NCT00978549|adenocarcinoma of the gastroesophageal junction
1244308|NCT00978549|recurrent gastric cancer
1244309|NCT00978549|stage IIIA gastric cancer
1244310|NCT00978549|stage IIIB gastric cancer
1244311|NCT00978549|stage IIIC gastric cancer
1244312|NCT00978549|stage IV gastric cancer
1244313|NCT00978549|recurrent esophageal cancer
1244314|NCT00978549|stage IIIA esophageal cancer
1244315|NCT00978549|stage IIIB esophageal cancer
1244316|NCT00978549|stage IIIC esophageal cancer
1244317|NCT00978549|stage IV esophageal cancer
1244318|NCT00978536|Multiple sclerosis
1244319|NCT00978536|cognitive deterioration
1244320|NCT00978536|biomarkers
1244321|NCT00978536|cerebrospinal fluid
1244322|NCT00978536|Alzheimer disease
1244323|NCT00978510|Tuberculosis
1244324|NCT00978510|Disease transmission
1244325|NCT00978510|Exposure to biological agents
1244326|NCT00978510|Health personnel
1244327|NCT00978484|PTSD
1244328|NCT00978484|Depression
1244329|NCT00978484|Anxiety
1244330|NCT00978484|Virtual Reality
1244331|NCT00978484|Computer Therapy
1244332|NCT00978484|Exposure Therapy
1244333|NCT00978484|Prolonged Exposure
1244334|NCT00978484|Military Medicine
1244335|NCT00978484|Combat
1244336|NCT00978484|Iraq
1244337|NCT00978484|Afghanistan
1244338|NCT00978484|Air Force Personnel
1244339|NCT00978484|Armed Forces Personnel
1244340|NCT00978484|Army Personnel
1244341|NCT00978484|Coast Guard
1244342|NCT00978484|psychology
1244343|NCT00978484|military psychiatry
1244344|NCT00978484|combat disorders
1244345|NCT00978484|combat neurosis
1244346|NCT00978484|Marines
1244347|NCT00978484|Military
1244348|NCT00978484|Navy Personnel
1244349|NCT00978484|Sailors
1244350|NCT00978484|Soldiers
1244351|NCT00978471|Conventional chemotherapy
1244352|NCT00978471|cytapheresis
1244353|NCT00978471|Peripheral stem cell autograft
1244354|NCT00978471|Surgical resection
1244355|NCT00978471|Thiotepa
1244356|NCT00978458|neurotoxicity
1244357|NCT00978458|adult diffuse astrocytoma
1244358|NCT00978458|adult oligodendroglioma
1244359|NCT00978458|recurrent adult brain tumor
1244360|NCT00978458|adult mixed glioma
1244361|NCT00978445|Systemic embolic events
1244362|NCT00978445|Thromboembolic Complications with Atrial Fibrillation
1244363|NCT00978445|Prophylaxis with Atrial Fibrillation
1244364|NCT00978445|Mechanical Cardiac Valve Replacement
1244365|NCT00978432|NHL
1244366|NCT00978432|DLBCL
1244367|NCT00978432|recurrent
1244368|NCT00978432|refractory
1244369|NCT00978432|de novo
1244370|NCT00978419|Statins
1244371|NCT00978419|Burns
1244372|NCT00978419|Sedatives
1244373|NCT00978419|Neurocognitive
1244374|NCT00978419|Septic
1244375|NCT00978419|Mortality
1244376|NCT00978419|C Reactive Protein
1244377|NCT00978419|Septic shock
1244378|NCT00978419|Sedation
1244379|NCT00978419|Neurocognitive function
1244380|NCT00978406|Dietary Assessment Methods
1244381|NCT00978406|Measurement of Diet
1244382|NCT00978406|24-Hour Diet Recall
1244383|NCT00978406|Validation
1244384|NCT00978406|Feeding Study
1244385|NCT00978367|Cicatrix
1244386|NCT00978367|Scar
1244387|NCT00978367|Avotermin
1244388|NCT00978367|Juvista
1244389|NCT00978367|RN1001
1244390|NCT00978367|TGF beta 3
1244391|NCT00978354|acute kidney injury
1244392|NCT00978354|acute renal failure
1244393|NCT00978354|loop diuretic
1244394|NCT00978354|critical illness
1244395|NCT00978354|sepsis
1244396|NCT00978354|renal replacement therapy
1244397|NCT00978354|dialysis
1244398|NCT00978354|renal recovery
1244399|NCT00978354|survival
1244400|NCT00978341|Clinical Trial Methodology study Neuropathic pain in Spinal cord injury patients Pain endpoints Crossover design
1244401|NCT00978328|Pain conditions
1244402|NCT00978328|Oxycodone immediate release
1244403|NCT00978328|Percocet®, Tylox®
1244404|NCT00978328|Roxicodone®
1244405|NCT00978328|Registry
1244406|NCT00978328|Side effects
1244407|NCT00978328|Observational
1244408|NCT00978328|Pain management
1244409|NCT00978302|Cicatrix
1244410|NCT00978302|Scar
1244411|NCT00978302|Wound healing
1244412|NCT00978302|Avotermin
1244413|NCT00978302|TGF beta 3
1244414|NCT00978302|Juvista
1244415|NCT00978302|RN1001
1244416|NCT00978289|obesity
1244417|NCT00978289|gastric bypass surgery
1244418|NCT00978276|Receptors
1244419|NCT00978276|Immunohistochemistry
1244420|NCT00978276|Breast
1244421|NCT00978276|Over expression of Hormone receptors in carcinoma of the breast sues
1244422|NCT00978250|DNA Methylation
1244423|NCT00978250|Advanced Cancer
1244424|NCT00978250|Methyltransferase Inhibitor
1244425|NCT00978250|Epigenetics
1244426|NCT00978250|Gene Re-Expression
1244427|NCT00978250|Breast Cancer
1244428|NCT00978250|Head and Neck Cancer
1244429|NCT00978250|Lung Cancer
1244430|NCT00978250|Non-Small Cell Lung Cancer
1244431|NCT00978250|Bladder Cancer
1244432|NCT00978237|HIV - Lipoatrophy
1244433|NCT00978237|treatment experienced
1244434|NCT00978224|dietary supplement
1244435|NCT00978224|hemodialysis
1244436|NCT00978224|Chronic Inflammatory Syndrome
1244437|NCT00978224|Viusid
1244438|NCT00978211|DOTATOC
1244439|NCT00978211|somatostatin
1244440|NCT00978211|radiopeptide
1244441|NCT00978211|Yttrium
1244442|NCT00978211|Lutetium
1244443|NCT00978211|neuroendocrine
1244444|NCT00978211|cancer
1244445|NCT00978198|Pharmacokinetics
1244446|NCT00978198|Safety and tolerability
1244447|NCT00978198|Plasma concentration
1244448|NCT00978198|ASP1517
1244449|NCT00978198|FG-4592
1244450|NCT00978185|nausea and vomiting
1244451|NCT00978185|anxiety disorder
1244452|NCT00978185|unspecified adult solid tumor, protocol specific
1244453|NCT00978159|esomeprazole
1244454|NCT00978159|famotidine
1244455|NCT00978159|aspirin
1244456|NCT00978159|dyspepsia
1244457|NCT00978133|Colectomy
1244458|NCT00978133|Closure
1244459|NCT00978133|Wound
1244460|NCT00978133|Dermabond
1244461|NCT00978133|Propen
1244462|NCT00978120|Influenza A Virus, H1N1 Subtype
1244463|NCT00978120|Vaccine
1244464|NCT00978107|Hepatic tumors
1244465|NCT00978107|Metastatic colorectal cancer
1244466|NCT00978081|precancerous condition
1244467|NCT00978081|stage 0 hypopharyngeal cancer
1244468|NCT00978081|stage 0 laryngeal cancer
1244469|NCT00978081|stage 0 lip and oral cavity cancer
1244470|NCT00978081|stage 0 nasopharyngeal cancer
1244471|NCT00978081|stage 0 oropharyngeal cancer
1244472|NCT00978081|stage 0 paranasal sinus and nasal cavity cancer
1244473|NCT00978068|Pediatric HIV
1244474|NCT00978068|Malaria
1244475|NCT00978068|Uganda
1244476|NCT00978068|Nevirapine
1244477|NCT00978068|Zidovudine
1244478|NCT00978068|Lamivudine
1244479|NCT00978068|Lopinavir/ritonavir
1244480|NCT00978068|Stavudine
1244481|NCT00978068|Efavirenz
1244482|NCT00978068|HIV
1244483|NCT00978029|immunotherapy
1244484|NCT00978016|GERD
1244485|NCT00978003|Vasti Medialis
1244486|NCT00978003|Knee
1244487|NCT00978003|MR Imaging
1244488|NCT00978003|Vasti Lateralis
1244489|NCT00978003|HV
1244490|NCT00978003|Healthy Volunteer
1244491|NCT00977990|Skin Swab
1244492|NCT00977990|Self-Sample
1244493|NCT00977977|Nephrotic Syndrome
1244494|NCT00977977|Renal Disease
1244495|NCT00977977|Autoimmune Diseases
1244496|NCT00977977|Clinical Trial
1244497|NCT00977977|Proteinuria
1244498|NCT00977964|Infant
1244499|NCT00977951|Cicatrix
1244500|NCT00977951|Scar
1244501|NCT00977951|Avotermin
1244502|NCT00977951|Juvista
1244503|NCT00977951|RN1001
1244504|NCT00977951|TGF beta 3
1244505|NCT00977938|Acute Coronary Syndrome
1244506|NCT00977938|Adverse event
1244507|NCT00977938|Antiplatelet therapy
1244508|NCT00977938|Sirolimus
1244509|NCT00977938|Everolimus
1244510|NCT00977938|Paclitaxel
1244511|NCT00977938|Zotarolimus
1244512|NCT00977938|Bare Metal Stent
1244513|NCT00977938|Drug Eluting Stent
1244514|NCT00977938|Clinical Events Committee
1244515|NCT00977938|Dual antiplatelet therapy
1244516|NCT00977938|Harvard Clinical Research Institute
1244517|NCT00977938|Major Adverse Cardiac and Cerebral Event
1244518|NCT00977938|Major Bleeding
1244519|NCT00977938|Myocardial infarction
1244520|NCT00977938|Myocardial ischemia
1244521|NCT00977938|Percutaneous coronary intervention
1244522|NCT00977938|Stent placement
1244523|NCT00977938|Stent Thrombosis
1244524|NCT00977938|Thienopyridine
1244525|NCT00977938|Clopidogrel
1244526|NCT00977938|Prasugrel
1244527|NCT00977925|Hemostasis
1244528|NCT00977912|B. lactis
1244529|NCT00977912|Preterm
1244530|NCT00977912|Necrotizing Enterocolitis (NEC)
1244531|NCT00977899|Plasmodium Falciparum
1244532|NCT00977899|Alum Adsorbed
1244533|NCT00977899|Ookinete Surface Protein
1244534|NCT00977899|Malaria Vaccine
1244535|NCT00977899|Healthy Volunteer
1244536|NCT00977899|HV
1244537|NCT00977860|Prostate
1244538|NCT00977860|Stereotactic
1244539|NCT00977860|Radiosurgery
1244540|NCT00977847|Family History
1244541|NCT00977847|Electronic Health Record
1244542|NCT00977834|Geriatric Assessment
1244543|NCT00977808|Artificial pancreas
1244544|NCT00977808|Closed-Loop control
1244545|NCT00977795|Brain Neoplasms
1244546|NCT00977795|5-ALA
1244547|NCT00977795|Aminolevulinic acid
1244548|NCT00977795|Fluorescence
1244549|NCT00977795|Gliomas
1244550|NCT00977795|Glioblastoma
1244551|NCT00977795|Surgery
1244552|NCT00977769|cesarean delivery
1244553|NCT00977769|blood pressure
1244554|NCT00977769|cardiac output
1244555|NCT00977756|Treatment
1244556|NCT00977756|Children
1244557|NCT00977756|Integrase Inhibitors
1244558|NCT00977756|Entry Inhibitors
1244559|NCT00977756|Treatment Experienced
1244560|NCT00977730|Hepatitis
1244561|NCT00977730|Fatty Liver
1244562|NCT00977730|Non Alcoholic Steatohepatitis
1244563|NCT00977730|Protandim
1244564|NCT00977717|oxaliplatin
1244565|NCT00977717|neuropathy
1244566|NCT00977717|SNPs
1244567|NCT00977704|Correction of peri-oral wrinkles
1244568|NCT00977691|Peripheral Blood Stem Cell Transplantation
1244569|NCT00977691|Anemia, Sickle Cell
1244570|NCT00977691|Graft-Versus-Host Disease
1244571|NCT00977691|Sirolimus (Rapamune )
1244572|NCT00977691|Alemtuzumab (Campath )
1244573|NCT00977691|Thalassemia
1244574|NCT00977691|Sickle Cell Disease
1244575|NCT00977678|open access gastroscopy
1244576|NCT00977652|fecal incontinence
1244577|NCT00977626|Safety
1244578|NCT00977626|Tolerability
1244579|NCT00977626|Healthy
1244580|NCT00977626|Pharmacokinetics
1244581|NCT00977626|Healthy volunteers
1244582|NCT00977613|Treated Stage 2 and Stage 3 colorectal cancer
1244583|NCT00977600|Ammonul
1244584|NCT00977600|Sodium phenylacetate
1244585|NCT00977600|sodium benzoate
1244586|NCT00977600|Buphenyl
1244587|NCT00977600|sodium phenylbutyrate
1244588|NCT00977600|HPN-100
1244589|NCT00977600|GT4P
1244590|NCT00977600|Glyceryl tri-(4-phenylbutyrate)
1244591|NCT00977600|Healthy Volunteers
1244592|NCT00977587|irritable bowel syndrome
1244593|NCT00977587|faecal serine proteases
1244594|NCT00977561|Small Cell Lung Cancer
1244595|NCT00977561|Extensive stage disease
1244596|NCT00977561|SCLC
1244597|NCT00977561|IGF-1R inhibitor
1244598|NCT00977548|MDS
1244599|NCT00977548|blood diseases
1244600|NCT00977548|bone marrow
1244601|NCT00977548|hematopoietic
1244602|NCT00977548|leukemia
1244603|NCT00977522|schizophrenia negative symptoms adjunctive
1244604|NCT00977509|genes
1244605|NCT00977509|mutation
1244606|NCT00977509|non-small cell lung cancer
1244607|NCT00977509|cancer cells
1244608|NCT00977496|hemodialysis
1244609|NCT00977496|microbiota
1244610|NCT00977496|Staphylococcus aureus
1244611|NCT00977470|NSCLC
1244612|NCT00977470|HCQ
1244613|NCT00977470|erlotinib
1244614|NCT00977470|Tarceva
1244615|NCT00977457|stage I prostate cancer
1244616|NCT00977457|stage II prostate cancer
1244617|NCT00977457|stage III prostate cancer
1244618|NCT00977457|stage IV prostate cancer
1244619|NCT00977444|knee
1244620|NCT00977444|osteoarthritis
1244621|NCT00977418|Healthy Aging
1244622|NCT00977418|Exercise
1244623|NCT00977418|Cognition
1244624|NCT00977418|Cognitive Training
1244625|NCT00977418|Keeping healthy seniors as mentally efficient as possible
1244626|NCT00977405|Wound infection
1244627|NCT00977405|Gentamicin
1244628|NCT00977405|Contaminated wounds
1244629|NCT00977392|human papilloma virus infection
1244630|NCT00977392|health status unknown
1244631|NCT00977353|Major depressive disorder
1244632|NCT00977353|Depression
1244633|NCT00977353|Sarcosine
1244634|NCT00977353|N-methylglycine
1244635|NCT00977353|NMDA
1244636|NCT00977340|Chronic nightmare sufferers
1244637|NCT00977340|nightmares
1244638|NCT00977340|Imagery Rehearsal Therapy IRT
1244639|NCT00977340|sleep disturbance
1244640|NCT00977340|treatment of nightmares
1244641|NCT00977340|confrontation
1244642|NCT00977340|People who suffer of chronic nightmares
1244643|NCT00977327|Glioma
1244644|NCT00977327|Intraoperative MR
1244645|NCT00977327|Intraoperative Ultrasound
1244646|NCT00977327|resection
1244647|NCT00977327|Intraoperative navigation
1244648|NCT00977327|Extent of resection
1244649|NCT00977314|Unilateral Hearing Loss
1244650|NCT00977301|HIV infection
1244651|NCT00977301|interaction
1244652|NCT00977301|pharmacokinetics
1244653|NCT00977275|early stage invasive breast cancer
1244654|NCT00977275|Partial breast irradiation
1244655|NCT00977275|interstitial implant
1244656|NCT00977262|fatty acids
1244657|NCT00977262|peripheral blood mononuclear cells
1244658|NCT00977262|inflammation
1244659|NCT00977262|nutrigenomics
1244660|NCT00977249|long term nicotine gum use
1244661|NCT00977249|varenicline
1244662|NCT00977249|adverse effects
1244663|NCT00977236|children
1244664|NCT00977236|corneal reshaping
1244665|NCT00977236|myopia
1244666|NCT00977236|myopia control
1244667|NCT00977236|orthokeratology
1244668|NCT00977223|Aldosterone
1244669|NCT00977223|Substance P
1244670|NCT00977223|Cortisol
1244671|NCT00977223|Aprepitant
1244672|NCT00977223|Adrenal glands
1244673|NCT00977210|Phase 1
1244674|NCT00977210|oxi4503
1244675|NCT00977210|oxigene
1244676|NCT00977210|cruk
1244677|NCT00977210|solid tumors
1244678|NCT00977210|VDA
1244679|NCT00977210|vascular disrupting agent
1244680|NCT00977184|Parkinson's Disease
1244681|NCT00977184|Transcranial Magnetic Stimulation (TMS)
1244682|NCT00977184|Treatment Study
1244683|NCT00977184|PD
1244684|NCT00977184|Parkinson Disease
1244685|NCT00977171|chronic fatigue syndrome
1244686|NCT00977171|CFS
1244687|NCT00977171|neurally mediated hypotension
1244688|NCT00977171|NMH
1244689|NCT00977171|neurogenic orthostatic hypotension
1244690|NCT00977171|NOH
1244691|NCT00977171|orthostatic hypotension
1244692|NCT00977171|droxidopa
1244693|NCT00977158|Cystic Fibrosis
1244694|NCT00977158|Microbiota
1244695|NCT00977158|upper respiratory tract
1244696|NCT00977158|16S rRNA sequence analysis
1244697|NCT00977158|Staphylococcus aureus
1244698|NCT00977158|Pseudomonas aeruginosa
1244699|NCT00977158|Burkholderia cepacia
1244700|NCT00977158|Haemophilus influenzae
1244701|NCT00977158|Streptococcus pneumoniae
1244702|NCT00977145|melanoma
1244703|NCT00977145|peptide vaccine
1244704|NCT00977145|interferon gamma
1244705|NCT00977145|immunotherapy
1244706|NCT00977132|Myelodysplastic Syndromes
1244707|NCT00977132|Valproic acid
1244708|NCT00977132|Lenalidomide
1244709|NCT00977119|breast cancer
1244710|NCT00977119|capecitabine
1244711|NCT00977093|Coronary artery disease
1244712|NCT00977093|Cardiac magnetic resonance imaging
1244713|NCT00977093|single photon emission computed tomography
1244714|NCT00977093|invasive coronary angiography
1244715|NCT00977080|Zemplar
1244716|NCT00977080|paricalcitol
1244717|NCT00977080|IMPACT SHPT
1244718|NCT00977080|Hemodialysis
1244719|NCT00977080|Chronic Kidney Disease Stage 5
1244723|NCT00977054|Hepatitis C
1244724|NCT00977054|Peginterferon alfa-2a
1244725|NCT00977054|Ribavirin
1244726|NCT00977054|Plasmapheresis
1244727|NCT00977054|Genotype 1
1244728|NCT00977041|Neurofeedback
1244729|NCT00977028|Tumescent
1244730|NCT00977028|Local Anesthesia
1244731|NCT00977028|Lidocaine
1244732|NCT00977028|Dosage Maximum
1244733|NCT00977028|Subcutaneous infiltration
1244734|NCT00977028|maximum Safe mg per kg dosage of lidocaine
1244735|NCT00977028|Tumescent Local Anesthesia
1244736|NCT00977002|noninvasive ventilation
1244737|NCT00977002|extubation
1244738|NCT00977002|Respiratory failure
1244739|NCT00977002|reintubation
1244740|NCT00976976|Resected advanced gastric cancer stage IIIB and IV
1244741|NCT00976963|UTI
1244742|NCT00976924|blood glucose
1244744|NCT00976872|omega 3
1244745|NCT00976872|inflammation
1244746|NCT00976872|augmentation index
1244747|NCT00976872|endothelial function
1244748|NCT00976859|childhood sexual abuse
1244749|NCT00976859|CSA
1244750|NCT00976859|posttraumatic stress disorder
1244751|NCT00976859|PTSD, feeling of being polluted
1244752|NCT00976859|mental pollution, mental contamination
1244753|NCT00976859|feeling of being contaminated
1244754|NCT00976859|sexual assault
1244755|NCT00976859|disgust, shame
1244756|NCT00976846|hemodialysis
1244757|NCT00976846|on line
1244758|NCT00976846|postdilution
1244759|NCT00976846|high-flux dialyzer
1244760|NCT00976846|hemodiafiltration
1244761|NCT00976833|Acute Respiratory Failure
1244762|NCT00976833|Early ICU Mobility
1244763|NCT00976833|Early Physical Therapy
1244764|NCT00976833|Critical Care
1244765|NCT00976833|Intensive Care
1244766|NCT00976833|ICU
1244767|NCT00976820|influenza infection
1244768|NCT00976820|Influenza Vaccines
1244769|NCT00976820|GSK Bio's influenza vaccine GSK2340273A
1244770|NCT00976820|GSK Bio's influenza vaccine GSK2340274A
1244771|NCT00976807|critical care
1244772|NCT00976807|intensive care
1244773|NCT00976807|weakness
1244774|NCT00976807|myopathy
1244775|NCT00976807|paresis
1244776|NCT00976807|rehabilitation
1244777|NCT00976794|BD I
1244778|NCT00976768|Advanced gastric cancer
1244779|NCT00976768|FOLFIRI
1244780|NCT00976755|adenocarcinoma of the prostate
1244781|NCT00976755|hormone-resistant prostate cancer
1244782|NCT00976755|stage III prostate cancer
1244783|NCT00976755|stage IV prostate cancer
1244784|NCT00976742|plasma lipoprotein lipids
1244785|NCT00976742|body composition
1244786|NCT00976742|glucose tolerance
1244787|NCT00976742|inflammation markers
1244788|NCT00976742|insulin sensitivity
1244789|NCT00976742|coagulation markers
1244790|NCT00976729|monocyte chemoattractant protein-1 (MCP-1)
1244791|NCT00976729|L-oligonucleotide aptamer
1244792|NCT00976729|Spiegelmer
1244793|NCT00976716|posttraumatic pain
1244794|NCT00976703|cervical foley catheter
1244795|NCT00976690|Crohn's Disease
1244796|NCT00976690|Ileocolic resection
1244797|NCT00976690|Endoscopic recurrence
1244798|NCT00976690|Ileocolic or colon resection (>50cm)
1244799|NCT00976651|infertility
1244800|NCT00976651|ICSI
1244801|NCT00976651|hCG
1244802|NCT00976651|infertility treatment
1244803|NCT00976638|Antimicrobial Resistant Bacteria
1244804|NCT00976638|Hospital acquired infections
1244805|NCT00976638|Colonization
1244806|NCT00976638|Bacteremia
1244807|NCT00976638|MRSA
1244808|NCT00976638|VRE
1244809|NCT00976638|ESBL
1244810|NCT00976638|Intensive Care
1244811|NCT00976638|ICU
1244812|NCT00976625|diastolic function
1244813|NCT00976625|aortic regurgitation
1244814|NCT00976625|aortic valve replacement
1244815|NCT00976625|left ventricular hypertrophy
1244816|NCT00976625|myocardial structure
1244817|NCT00976625|LV remodeling
1244818|NCT00976625|Muscular regression
1244819|NCT00976625|LV fibrous tissue
1244820|NCT00976612|Gastrointestinal stromal tumor
1244821|NCT00976612|pharmacokinetics
1244822|NCT00976612|nilotinib
1244823|NCT00976586|Incontinentia pigmenti
1244824|NCT00976586|recombination
1244825|NCT00976586|IKBKG
1244826|NCT00976586|IKBKGP
1244827|NCT00976573|Stage IV Skin Melanoma
1244828|NCT00976573|recurrent melanoma
1244829|NCT00976560|Lack of interest and energy
1244830|NCT00976560|Psychomotor retardation
1244831|NCT00976560|Cytokines
1244832|NCT00976560|Major Depressive disorder
1244833|NCT00976547|tinnitus
1244834|NCT00976547|depression
1244835|NCT00976547|audiometry
1244836|NCT00976547|measurement
1244837|NCT00976534|Analgesic effect
1244838|NCT00976534|Peripheral Neuropathic pain
1244839|NCT00976534|Posttraumatic Neuralgia (PTN)
1244840|NCT00976534|Postherpetic Neuralgia (PHN)
1244841|NCT00976508|advanced solid tumors cancer refractory cancer figitumumab pegvisomant
1244842|NCT00976482|Cardiovascular
1244843|NCT00976482|Pacemaker
1244844|NCT00976482|Mortality
1244845|NCT00976482|Physiologic pacing
1244846|NCT00976456|lung cancer
1244847|NCT00976456|NSCLC
1244848|NCT00976456|elderly
1244849|NCT00976456|non-squamous
1244850|NCT00976456|Elderly patients at least 65 years old
1244851|NCT00976456|first line therapy
1244852|NCT00976456|non-squamous non-small cell lung cancer stage IIIb or IV
1244853|NCT00976443|Obesity
1244854|NCT00976443|Gastric Emptying
1244855|NCT00976443|Satiation
1244856|NCT00976443|Endosonography
1244857|NCT00976443|Endoscopy
1244858|NCT00976443|Feeding Behavior
1244859|NCT00976430|Autologous Stem Cells.
1244860|NCT00976404|HIV-1 infection
1244861|NCT00976404|Treatment intensification
1244862|NCT00976404|Immunomodulation
1244863|NCT00976404|HIV-rAd5 vaccine
1244864|NCT00976391|open-label
1244865|NCT00976391|albiglutide
1244866|NCT00976391|insulin glargine
1244867|NCT00976391|preprandial insulin
1244868|NCT00976378|stromal cell-derived factor-1 (SDF-1)
1244869|NCT00976378|L-oligonucleotide aptamer
1244870|NCT00976378|Spiegelmer
1244871|NCT00976365|Breast Cancer
1244872|NCT00976352|Gene Therapy
1244873|NCT00976352|Pompe Disease
1244874|NCT00976352|Glycogen Storage Disease
1244875|NCT00976339|Breast cancer
1244876|NCT00976339|Vitamin D
1244877|NCT00976339|Premenopausal
1244878|NCT00976313|thoracic epidural analgesia
1244879|NCT00976313|urinary micturition
1244880|NCT00976313|thoracotomy
1244881|NCT00976300|SLE
1244882|NCT00976300|lupus nephritis
1244883|NCT00976300|cyclosporine A
1244884|NCT00976300|cyclophosphamide
1244885|NCT00976300|active proliferative lupus nephritis (class III or IV according to WHO)
1244886|NCT00976287|Stem cells
1244887|NCT00976287|Liver cirrhosis
1244888|NCT00976287|Radiology
1244889|NCT00976287|Interventional
1244890|NCT00976287|Transplantation
1244891|NCT00976274|Korean red ginseng
1244892|NCT00976274|metabolic syndrome
1244893|NCT00976274|blood pressure
1244894|NCT00976274|arterial stiffness
1244895|NCT00976274|inflammation
1244896|NCT00976274|oxidative stress
1244897|NCT00976261|type 2 diabetes
1244898|NCT00976261|single dose
1244899|NCT00976261|3-O-methylglucose
1244900|NCT00976261|healthy volunteer
1244901|NCT00976261|repeat dose
1244902|NCT00976248|everolimus
1244903|NCT00976248|RAD001
1244904|NCT00976248|WM
1244905|NCT00976235|Macular Degeneration
1244906|NCT00976235|Visual Impairment
1244907|NCT00976235|Quality of Life
1244908|NCT00976235|Telescope Prosthesis
1244909|NCT00976196|Aspirin
1244910|NCT00976196|Blood platelets
1244911|NCT00976196|proteomics
1244912|NCT00976196|Platelet reactivity
1244913|NCT00976183|ovarian cancer
1244914|NCT00976183|gynecologic oncology
1244915|NCT00976183|vorinostat
1244916|NCT00976183|treatment
1244917|NCT00976170|Advanced or metastatic HCC
1244918|NCT00976157|STREM-1
1244919|NCT00976157|BAL
1244920|NCT00976157|VAP
1244932|NCT00976131|Breast Cancer
1244933|NCT00976131|Early Stage Breast Cancer
1244934|NCT00976131|Complementary and Alternative Medicine
1244935|NCT00976131|CAM
1244936|NCT00976118|Dementia of Alzheimer's type
1244937|NCT00976118|mild to moderate Alzheimer's Disease
1244945|NCT00976092|myocardial infarction
1244946|NCT00976092|clopidogrel
1244947|NCT00976092|prasugrel
1244948|NCT00976092|bivalirudin
1244949|NCT00976092|primary PCI
1244950|NCT00976079|Tibial femoral knee osteoarthritis
1244951|NCT00976079|Osteoarthritis
1244959|NCT00976053|Myocardial perfusion imaging
1244960|NCT00976053|Single photon emission computed tomography
1244961|NCT00976053|Positron emission tomography
1244962|NCT00976040|HIV-1
1244963|NCT00976040|Africa
1244964|NCT00976040|Botswana
1244965|NCT00976040|Highly active antiretroviral therapy
1244966|NCT00976040|treatment naive
1244967|NCT00976027|Influenza
1244968|NCT00976027|Respiratory Tract Infections
1244969|NCT00976027|Influenza-like illness
1244970|NCT00976027|Elderly
1244971|NCT00976027|Fluzone®
1244972|NCT00976027|Efficacy
1244973|NCT00976001|Follow-up after stroke
1244974|NCT00975988|PMS (post-marketing surveillance)
1244975|NCT00975988|TYKERB® tablets
1244976|NCT00975975|Paroxysmal nocturnal hemoglobinuria
1244977|NCT00975975|severe aplastic anemia
1244978|NCT00975975|Mantle cell
1244979|NCT00975962|Stroke
1244980|NCT00975962|Neuroprotection
1244981|NCT00975962|remote preconditioning
1244982|NCT00975962|Salvage index (%): Difference in infarct growth (PWI-DWI)
1244983|NCT00975949|fluconazole prophylaxis
1244984|NCT00975949|fungal colonization
1244985|NCT00975949|fungal infection
1244986|NCT00975949|preterm infants
1244987|NCT00975949|long term outcomes
1244988|NCT00975949|quality of life
1244993|NCT00975923|Quality Improvement
1244994|NCT00975923|Critical Care
1244995|NCT00975923|Collaboratives
1244996|NCT00975923|Patient Safety
1244997|NCT00975923|Tool Kit
1244998|NCT00975910|Supratentorial Craniotomy
1244999|NCT00975897|adenocarcinoma of the colon
1245000|NCT00975897|recurrent colon cancer
1245001|NCT00975897|stage III colon cancer
1245002|NCT00975897|stage IV colon cancer
1245003|NCT00975897|adenocarcinoma of the rectum
1245004|NCT00975897|recurrent rectal cancer
1245005|NCT00975897|stage III rectal cancer
1245006|NCT00975897|stage IV rectal cancer
1245007|NCT00975884|GSK Bio's influenza vaccine GSK2340272A
1245008|NCT00975884|influenza infection
1245009|NCT00975884|Influenza vaccine
1245010|NCT00975871|Livedo vasculitis
1245011|NCT00975871|Genetic pleomorphism
1245012|NCT00975858|Symptomatic Coronary Artery Disease Patients
1245013|NCT00975845|ACL
1245014|NCT00975845|Anterior Cruciate Ligament
1245015|NCT00975845|Torn tendon
1245016|NCT00975845|ACL Repair
1245017|NCT00975845|ACL reconstruction
1245018|NCT00975832|The independent effect of PCOS and obesity on adipose expression and plasma levels of adipocytokines
1245019|NCT00975793|Sepsis
1245020|NCT00975793|Severe sepsis
1245021|NCT00975793|Septic shock
1245022|NCT00975780|Pneumonia
1245023|NCT00975780|Lower respiratory tract infection
1245024|NCT00975780|Lower respiratory tract infection other than pneumonia
1245025|NCT00975754|Inhalation
1245026|NCT00975754|lung deposition
1245027|NCT00975741|Asthma
1245028|NCT00975741|Mometasone furoate
1245029|NCT00975741|Inhalation devices
1245030|NCT00975741|Forced expiratory volume
1245031|NCT00975728|Anti-oxidant
1245032|NCT00975728|Açai
1245033|NCT00975728|Food supplement
1245034|NCT00975728|Sun protection
1245035|NCT00975728|Skin erythema prevention
1245036|NCT00975728|Anti-oxidant efficacy
1245037|NCT00975728|Anti-age efficacy
1245038|NCT00975728|Skin photo-induced damage protection
1245039|NCT00975715|Seizures
1245040|NCT00975715|oxcarbazepine
1245041|NCT00975715|child
1245042|NCT00975702|Remote ischemic preconditioning
1245043|NCT00975702|deceased organ donors
1245044|NCT00975702|ischemia reperfusion injury
1245045|NCT00975702|Delayed graft function
1245046|NCT00975702|Clinical outcomes in kidney transplant recipients
1245047|NCT00975702|Clinical outcomes in liver transplant recipients
1245048|NCT00975702|Clinical outcomes in pancreas transplant recipients
1245049|NCT00975689|Niemann-Pick Disease, Type C
1245050|NCT00975689|Biomarkers
1245051|NCT00975689|N-Acetyl Cysteine
1245052|NCT00975689|Oxidized Cholesterol
1245053|NCT00975689|Neurodegeneration
1245054|NCT00975689|NPC
1245055|NCT00975676|estrogen receptor-positive breast cancer
1245056|NCT00975676|progesterone receptor-positive breast cancer
1245057|NCT00975676|stage IA breast cancer
1245058|NCT00975676|stage IB breast cancer
1245059|NCT00975676|stage II breast cancer
1245060|NCT00975676|stage IIIA breast cancer
1245061|NCT00975663|Lung transplantation
1245062|NCT00975663|heart-lung transplantation
1245063|NCT00975663|therapeutic drug monitoring
1245064|NCT00975663|tacrolimus
1245065|NCT00975663|mycophenolate
1245066|NCT00975663|immunosuppressant
1245067|NCT00975663|pharmacokinetics
1245068|NCT00975650|Primary Hypogonadism
1245069|NCT00975650|Secondary Hypogonadism
1245070|NCT00975611|schizophrenia
1245071|NCT00975611|schizoaffective disorder
1245072|NCT00975611|paliperidone ER
1245073|NCT00975611|risperidone Consta
1245074|NCT00975611|prolactin
1245075|NCT00975611|hyperprolactinemia
1245076|NCT00975572|Flu
1245077|NCT00975572|adjuvanted H1N1 vaccine
1245078|NCT00975572|non-adjuvanted H1N1 vaccine
1245079|NCT00975572|Immunogenictiy
1245080|NCT00975572|Safety
1245081|NCT00975546|fertility
1245082|NCT00975546|HIV discordant
1245083|NCT00975546|HIV
1245084|NCT00975546|Infertility in HIV-discordant couples
1245085|NCT00975546|HIV seronegativity
1245086|NCT00975533|type 2 diabetes mellitus
1245087|NCT00975533|obesity
1245088|NCT00975520|Neurotropic
1245089|NCT00975520|Melanoma
1245090|NCT00975520|Observation
1245091|NCT00975520|Radiation Therapy
1245092|NCT00975520|Relapse
1245093|NCT00975494|pde5-inhibition
1245094|NCT00975494|sildenafil
1245095|NCT00975494|LV diastolic function
1245096|NCT00975494|heart failure patients
1245097|NCT00975481|oral single-dose 6-way crossover recreational drug users abuse potential pharmacodynamics safety
1245098|NCT00975468|pressure-controlled
1245099|NCT00975468|volume-controlled
1245100|NCT00975468|one lung
1245101|NCT00975468|ventilation
1245102|NCT00975468|lung injury
1245103|NCT00975468|thoracotomy
1245104|NCT00975442|Elbow
1245105|NCT00975442|Tendinitis
1245106|NCT00975442|Sports Medicine
1245107|NCT00975442|Athletic injuries
1245108|NCT00975429|Prostatic Disease
1245109|NCT00975429|Genital neoplasm, male
1245110|NCT00975429|Urogenital neoplasm
1245111|NCT00975429|Genital disease,male
1245112|NCT00975429|Male urogenital disease
1245113|NCT00975429|Neoplasms
1245114|NCT00975429|Neoplasm by site
1245115|NCT00975429|Prostatic neoplasm
1245116|NCT00975429|Carcinoma
1245117|NCT00975416|Drug Dependence
1245118|NCT00975416|Cognitive Behavior
1245119|NCT00975416|Oxytocin
1245120|NCT00975416|Cocaine
1245121|NCT00975416|Heroin
1245122|NCT00975416|fMRI
1245123|NCT00975403|mild COPD
1245124|NCT00975403|dyspnea
1245125|NCT00975403|exercise
1245126|NCT00975403|respiratory mechanics
1245127|NCT00975403|COPD
1245128|NCT00975390|Glycogen
1245129|NCT00975390|Carbohydrate
1245130|NCT00975390|Protein
1245131|NCT00975390|Caffeine
1245132|NCT00975390|Post exercise muscle glycogen synthesis
1245133|NCT00975390|Sports nutrition
1245134|NCT00975377|hair removal
1245135|NCT00975377|hair clipping
1245136|NCT00975377|surgical site infection
1245137|NCT00975377|incisional infection
1245138|NCT00975377|wound infection
1245139|NCT00975364|Folate
1245140|NCT00975364|Methylenetetrahydrofolate reductase
1245141|NCT00975364|Speciation
1245142|NCT00975364|Nutrient status
1245143|NCT00975364|Bioavailability
1245144|NCT00975364|Polymorphism, single nucleotide
1245145|NCT00975351|folates
1245146|NCT00975351|5-methyltetrahydrofolic acid
1245147|NCT00975351|pharmacokinetics
1245148|NCT00975351|bioavailability
1245149|NCT00975351|biotransformation
1245150|NCT00975338|health care transition, young adults, rehabilitation
1245151|NCT00975325|Bioequivalency
1245152|NCT00975312|lentigo
1245153|NCT00975312|hydroquinone
1245154|NCT00975312|tretinoin
1245155|NCT00975312|fluocinolone acetonide
1245156|NCT00975299|Neoplasm
1245157|NCT00975299|PET/CT diagnosis
1245158|NCT00975299|PET tracer
1245159|NCT00975273|Asthma
1245160|NCT00975273|Dyspnea
1245161|NCT00975273|Paroxysmal
1245162|NCT00975273|Pulmonary
1245163|NCT00975273|Respiratory hypersensitivity
1245164|NCT00975273|Airway inflammation
1245165|NCT00975273|Airway obstruction
1245166|NCT00975273|Wheezing
1245167|NCT00975247|Quality Improvement
1245168|NCT00975247|Colonoscopy
1245169|NCT00975247|Screening
1245170|NCT00975247|Colon Cancer
1245171|NCT00975247|Polyp detection rates
1245172|NCT00975247|Colonoscopy completion rates
1245173|NCT00975247|Scope Withdrawal time
1245174|NCT00975247|Reduce costs through improving bowel prep quality
1245175|NCT00975234|Intra-lesion injection of autologous myoblasts
1245176|NCT00975221|Primary hyperparathyroidism
1245177|NCT00975221|Parathyroidectomy
1245178|NCT00975221|Hypercalcemia
1245179|NCT00975208|Osteogenesis [G07.700.320.500.325.377.625.100.729]
1245180|NCT00975208|Tooth Eruption [G10.549.235.726]
1245181|NCT00975182|PI3K
1245182|NCT00975182|NSCLC
1245183|NCT00975182|Tarceva
1245184|NCT00975143|isotretinoin
1245185|NCT00975143|dermatology
1245186|NCT00975143|skin
1245187|NCT00975117|Dietary supplement
1245188|NCT00975117|male infertility
1245189|NCT00975117|spermatogenesis
1245190|NCT00975104|Aging
1245191|NCT00975104|Frailty
1245192|NCT00975104|Sedentary
1245193|NCT00975104|Immobilization
1245194|NCT00975104|Atrophy
1245195|NCT00975104|Muscle Wasting
1245196|NCT00975104|Physical Activity
1245197|NCT00975078|dexamethasone-suppression-test
1245198|NCT00975078|high dose glucocorticoid treatment
1245199|NCT00975078|Population at Risk
1245200|NCT00975065|Galvus
1245201|NCT00975039|Inoperable
1245202|NCT00975039|Inoperable Cholangiocarcinoma
1245203|NCT00975039|Non-resectable
1245204|NCT00975039|Non-resectable Cholangiocarcinoma
1245205|NCT00975039|Carcinoma
1245206|NCT00975026|Massage
1245207|NCT00975026|Chair Massage
1245208|NCT00975026|Pain
1245209|NCT00975026|Discomfort
1245210|NCT00975026|Stretching
1245211|NCT00975026|Stretching Exercises
1245212|NCT00975026|Sonographer
1245213|NCT00975026|Cardiac Sonographer
1245214|NCT00975013|Laparoscopic Gastric Bypass
1245215|NCT00975013|Morbid Obesity
1245216|NCT00975013|Bone Mineral Density
1245217|NCT00975000|Intervention
1245218|NCT00975000|Cinacalcet
1245219|NCT00975000|Sensipar
1245220|NCT00975000|Mimpara
1245221|NCT00975000|hyperparathyroidism
1245222|NCT00975000|calcium
1245223|NCT00975000|osteodystrophy
1245224|NCT00975000|hypercalcemia
1245225|NCT00975000|renal
1245226|NCT00975000|transplant
1245227|NCT00975000|acute rejection
1245228|NCT00975000|kidney transplant failure
1245229|NCT00975000|hypophosphatemia
1245233|NCT00974974|Parkinson's Disease
1245234|NCT00974961|Levobupivacaine
1245235|NCT00974961|HRV
1245236|NCT00974961|Spinal Anesthesia
1245237|NCT00974961|Responses of ANS to these two drugs
1245238|NCT00974948|Pancreatic cancer
1245239|NCT00974948|Therapy
1245240|NCT00974948|Neurolysis
1245241|NCT00974935|Staphylococcal enterotoxin B, vaccine, Staphylococcus aureus, toxic shock syndrome
1245242|NCT00974922|Vitamin D
1245243|NCT00974922|Hypertension
1245244|NCT00974909|Fecal incontinence
1245245|NCT00974896|Advanced Solid Tumors
1245246|NCT00974896|AMG 479
1245247|NCT00974896|Amgen
1245248|NCT00974896|Oncology
1245249|NCT00974896|Phase 1b
1245250|NCT00974883|ultrasound
1245251|NCT00974883|GCA
1245252|NCT00974883|temporal arteritis
1245253|NCT00974883|biopsy
1245254|NCT00974857|Hemodialysis
1245255|NCT00974857|Left Ventricular Hypertrophy
1245256|NCT00974857|Body Composition Monitor
1245257|NCT00974844|posterior assisted levitation
1245258|NCT00974844|Pars Plana
1245259|NCT00974844|Dropped nucleus
1245260|NCT00974844|cataract
1245261|NCT00974844|complication of
1245262|NCT00974844|surgery
1245263|NCT00974818|Bladder
1245264|NCT00974818|Mitomycin C
1245265|NCT00974818|MMC
1245266|NCT00974818|TheracysR Bacillus Calmette-Guerin
1245267|NCT00974818|BCG
1245268|NCT00974818|intravesical
1245269|NCT00974818|09-118
1245270|NCT00974805|COPD
1245271|NCT00974805|Emphysema
1245272|NCT00974805|Bronchitis
1245273|NCT00974792|stage III adult diffuse large cell lymphoma
1245274|NCT00974792|stage IV adult diffuse large cell lymphoma
1245275|NCT00974779|kidney failure chronic
1245276|NCT00974779|renal dialysis
1245277|NCT00974779|inflammation
1245278|NCT00974779|monocytes
1245279|NCT00974779|end stage renal disease on regular thrice weekly hemodialysis
1245280|NCT00974766|bronchial asthma
1245281|NCT00974766|allergic bronchopulmonary aspergillosis
1245282|NCT00974753|epiretinal membrane
1245283|NCT00974740|type 1 diabetes
1245284|NCT00974727|Childhood overweight
1245285|NCT00974727|Gardening
1245286|NCT00974727|Summer weight gain
1245287|NCT00974714|chronic hypertension in pregnancy
1245288|NCT00974701|symptoms of acute overt upper gastrointestinal hemorrhage
1245289|NCT00974688|Congenital
1245290|NCT00974688|physical activity participation
1245291|NCT00974688|Moderate-to-vigorous physical activity
1245292|NCT00974675|Asthma
1245293|NCT00974675|CAT-354
1245294|NCT00974675|Tralokinumab
1245295|NCT00974662|Non-Small Cell Lung Cancer
1245296|NCT00974662|Lung Cancer
1245297|NCT00974662|NSCLC
1245298|NCT00974649|drop-out
1245299|NCT00974649|predictors of treatment continuation/discontinuation
1245300|NCT00974649|IVF/ICSI
1245301|NCT00974649|infertility
1245302|NCT00974649|counseling
1245303|NCT00974649|psychology
1245304|NCT00974649|Assisted Reproduction
1245305|NCT00974649|Counselling
1245306|NCT00974636|Kidney Disease
1245307|NCT00974636|Albuminuria
1245308|NCT00974636|Glomerular filtration rate
1245309|NCT00974636|Volume status
1245310|NCT00974636|Bioimpedance analysis
1245311|NCT00974623|Bone growth substitute
1245312|NCT00974623|Autograft
1245313|NCT00974623|Allograft
1245314|NCT00974623|Spine fusion
1245315|NCT00974610|stage IV melanoma
1245316|NCT00974610|recurrent melanoma
1245317|NCT00974610|stage IV non-small cell lung cancer
1245318|NCT00974610|recurrent non-small cell lung cancer
1245319|NCT00974610|extensive stage small cell lung cancer
1245320|NCT00974610|recurrent small cell lung cancer
1245321|NCT00974610|stage IV breast cancer
1245322|NCT00974610|recurrent breast cancer
1245323|NCT00974610|male breast cancer
1245324|NCT00974610|stage III pancreatic cancer
1245325|NCT00974610|stage IV pancreatic cancer
1245326|NCT00974610|recurrent pancreatic cancer
1245327|NCT00974610|stage IV colon cancer
1245328|NCT00974610|recurrent colon cancer
1245329|NCT00974610|stage IV rectal cancer
1245330|NCT00974610|recurrent rectal cancer
1245331|NCT00974597|burn
1245332|NCT00974597|donor site
1245333|NCT00974597|treatment of burns
1245334|NCT00974597|Treatment of Donor Sites
1245335|NCT00974584|NSCLC
1245336|NCT00974584|PI3K
1245337|NCT00974584|Avastin
1245338|NCT00974558|dyspnea
1245339|NCT00974558|fan
1245340|NCT00974532|balance
1245341|NCT00974532|chronic kidney disease
1245342|NCT00974532|calcium
1245343|NCT00974532|phosphorus
1245344|NCT00974519|ADIS
1245345|NCT00974519|complementary therapies
1245346|NCT00974506|geriatric patients living in residential community (shared flats), multiple disease-conditions
1245347|NCT00974493|oral
1245348|NCT00974493|intravenous
1245349|NCT00974493|antibiotics
1245350|NCT00974493|bone
1245351|NCT00974493|joint
1245352|NCT00974493|infection
1245353|NCT00974480|Skin
1245354|NCT00974480|Aging
1245355|NCT00974480|Rejuva-a
1245356|NCT00974480|Redermic
1245357|NCT00974454|AIDS
1245358|NCT00974454|complementary therapies
1245359|NCT00974454|treatment experienced
1245360|NCT00974441|Bioequivalence
1245361|NCT00974428|Osteoarthritis
1245362|NCT00974428|Disease of joints
1245363|NCT00974428|Wobenzym® N
1245364|NCT00974428|WOMAC pain score
1245365|NCT00974428|Subject reported pain (VAS)
1245366|NCT00974415|BMI classification-overweight
1245367|NCT00974402|Active duty
1245368|NCT00974402|Afghanistan
1245369|NCT00974402|Anger
1245370|NCT00974402|Anxiety
1245371|NCT00974402|Avoidance
1245372|NCT00974402|BAMC
1245373|NCT00974402|Brooke Army Medical Center
1245374|NCT00974402|Cognitive Behavioral Therapy
1245375|NCT00974402|Combat
1245376|NCT00974402|Combat Disorder
1245377|NCT00974402|Coping
1245378|NCT00974402|Counseling
1245379|NCT00974402|Counselor
1245380|NCT00974402|Deployment
1245381|NCT00974402|Depression
1245382|NCT00974402|Exposure
1245383|NCT00974402|Fear
1245384|NCT00974402|Feeling alone
1245385|NCT00974402|Flashbacks
1245386|NCT00974402|Guard
1245387|NCT00974402|Guilt
1245388|NCT00974402|Hospitalization
1245389|NCT00974402|Iraq
1245390|NCT00974402|Mental Health
1245391|NCT00974402|Military
1245392|NCT00974402|Military member
1245393|NCT00974402|Military personnel
1245394|NCT00974402|Neuroses
1245395|NCT00974402|Nightmares
1245396|NCT00974402|OEF
1245397|NCT00974402|OIF
1245398|NCT00974402|Prolonged Exposure Therapy
1245399|NCT00974402|Psychiatric
1245400|NCT00974402|Psychiatric medication
1245401|NCT00974402|Psychological distress
1245402|NCT00974402|Psychotherapy
1245403|NCT00974402|Reserve
1245404|NCT00974402|Retired
1245405|NCT00974402|Sadness
1245406|NCT00974402|Separated
1245407|NCT00974402|Sleeplessness
1245408|NCT00974402|Soldier
1245409|NCT00974402|Stress
1245410|NCT00974402|Stress disorder
1245411|NCT00974402|Stress management
1245412|NCT00974402|STRONG STAR
1245413|NCT00974402|Suicidal
1245414|NCT00974402|Suicide
1245415|NCT00974402|Therapy
1245416|NCT00974402|Trauma
1245417|NCT00974402|Traumatic Event
1245418|NCT00974402|Trouble Sleeping
1245419|NCT00974402|Veteran
1245420|NCT00974402|Veterans
1245421|NCT00974402|War
1245422|NCT00974402|WHMC
1245423|NCT00974402|Wilford Hall Medical Center
1245424|NCT00974402|PTSD
1245425|NCT00974402|Posttraumatic Stress Disorders
1245426|NCT00974389|stage III colon cancer
1245427|NCT00974389|stage III rectal cancer
1245428|NCT00974389|stage IV colon cancer
1245429|NCT00974389|stage IV rectal cancer
1245430|NCT00974389|recurrent colon cancer
1245431|NCT00974389|recurrent rectal cancer
1245432|NCT00974376|Cannabis Treatment
1245433|NCT00974376|Cannabis Use
1245434|NCT00974376|Cannabis Dependence
1245435|NCT00974376|Executive Functioning
1245436|NCT00974376|Cognitive Deficits
1245437|NCT00974363|meningococcal vaccine GSK 134612
1245438|NCT00974350|Post-operative pain
1245439|NCT00974350|hernia surgery
1245440|NCT00974350|opioid
1245441|NCT00974337|Adrenal insufficiency
1245442|NCT00974337|cortisol
1245443|NCT00974337|preterm
1245444|NCT00974337|shock
1245445|NCT00974337|neonate
1245446|NCT00974324|peripheral T cell lymphoma
1245447|NCT00974324|chemotherapy
1245448|NCT00974324|anti-angiogeneses
1245449|NCT00974311|MDV3100
1245450|NCT00974311|Prostate Cancer
1245451|NCT00974311|Castration-resistant
1245452|NCT00974285|AIDS
1245453|NCT00974285|complementary therapies
1245454|NCT00974259|Hypoxia
1245455|NCT00974259|Ischemia
1245456|NCT00974259|Intracranial hypertension
1245457|NCT00974259|Neurocritical care
1245458|NCT00974246|COPD
1245459|NCT00974246|Depression
1245460|NCT00974246|Nursing Home
1245461|NCT00974233|CLL
1245462|NCT00974233|SLL
1245463|NCT00974220|inhaled fentanyl
1245464|NCT00974220|dyspnea
1245465|NCT00974220|exercise
1245466|NCT00974220|COPD
1245467|NCT00974194|Cholecystolithiasis
1245468|NCT00974194|Cholecystectomy
1245469|NCT00974194|Laparoscopic surgery
1245470|NCT00974194|Single port
1245471|NCT00974168|pain
1245472|NCT00974168|radiation toxicity
1245473|NCT00974168|spinal cord compression
1245474|NCT00974168|unspecified adult solid tumor, protocol specific
1245475|NCT00974155|Major
1245476|NCT00974155|Depression
1245477|NCT00974155|Disorder
1245478|NCT00974142|COPD
1245479|NCT00974142|Chronic Obstructive Pulmonary Disease
1245480|NCT00974142|Cyclosporine
1245481|NCT00974142|Oral Immunotherapy
1245482|NCT00974142|Advanced stage
1245483|NCT00974103|low back pain
1245484|NCT00974103|pelvic pain
1245485|NCT00974103|pelvic girdle pain
1245486|NCT00974103|post partum
1245487|NCT00974090|insulin resistance
1245488|NCT00974077|recurrent depression,
1245489|NCT00974077|mindfulness training
1245490|NCT00974077|attention
1245491|NCT00974077|Evoked EEG potentials
1245492|NCT00974077|Relapse prevention in recurrent depression
1245493|NCT00974064|COPD
1245494|NCT00974064|Lung disease
1245495|NCT00974064|Chronic bronchitis
1245496|NCT00974064|Emphysema
1245497|NCT00974064|Smoking
1245498|NCT00974064|Smoking cessation
1245499|NCT00974064|Quit smoking
1245500|NCT00974064|Healthy smoker
1245501|NCT00974064|Smoker
1245502|NCT00974064|Non-smoker
1245503|NCT00974051|Children
1245504|NCT00974051|Exercise
1245505|NCT00974051|Hypoglycemia
1245506|NCT00974038|Bulimia Nervosa, EDNOS, Adolescents
1245507|NCT00974012|Bioequivalence
1245508|NCT00973999|Botulinum Toxin
1245509|NCT00973999|Saliva
1245510|NCT00973999|Tracheostomy tube
1245511|NCT00973986|atorvastatin
1245512|NCT00973986|genetic polymorphisms
1245513|NCT00973986|coronary heart disease
1245514|NCT00973986|pharmacokinetics
1245515|NCT00973986|CYP3A
1245516|NCT00973973|Pelvic Pain
1245517|NCT00973973|NBI-56418
1245518|NCT00973973|Endometriosis
1245519|NCT00973947|stage I squamous cell carcinoma of the hypopharynx
1245520|NCT00973947|stage II squamous cell carcinoma of the hypopharynx
1245521|NCT00973947|stage III squamous cell carcinoma of the hypopharynx
1245522|NCT00973947|stage IV squamous cell carcinoma of the hypopharynx
1245523|NCT00973947|stage I squamous cell carcinoma of the larynx
1245524|NCT00973947|stage I verrucous carcinoma of the larynx
1245525|NCT00973947|stage II squamous cell carcinoma of the larynx
1245526|NCT00973947|stage II verrucous carcinoma of the larynx
1245527|NCT00973947|stage III squamous cell carcinoma of the larynx
1245528|NCT00973947|stage III verrucous carcinoma of the larynx
1245529|NCT00973947|stage IV squamous cell carcinoma of the larynx
1245530|NCT00973947|stage IV verrucous carcinoma of the larynx
1245531|NCT00973947|stage I adenoid cystic carcinoma of the oral cavity
1245532|NCT00973947|stage I mucoepidermoid carcinoma of the oral cavity
1245533|NCT00973947|stage I verrucous carcinoma of the oral cavity
1245534|NCT00973947|stage II adenoid cystic carcinoma of the oral cavity
1245535|NCT00973947|stage II mucoepidermoid carcinoma of the oral cavity
1245536|NCT00973947|stage II verrucous carcinoma of the oral cavity
1245537|NCT00973947|stage III adenoid cystic carcinoma of the oral cavity
1245538|NCT00973947|stage III mucoepidermoid carcinoma of the oral cavity
1245539|NCT00973947|stage III verrucous carcinoma of the oral cavity
1245540|NCT00973947|stage IV adenoid cystic carcinoma of the oral cavity
1245541|NCT00973947|stage IV mucoepidermoid carcinoma of the oral cavity
1245542|NCT00973947|stage IV verrucous carcinoma of the oral cavity
1245543|NCT00973947|stage I squamous cell carcinoma of the lip and oral cavity
1245544|NCT00973947|stage II squamous cell carcinoma of the lip and oral cavity
1245545|NCT00973947|stage III squamous cell carcinoma of the lip and oral cavity
1245546|NCT00973947|stage IV squamous cell carcinoma of the lip and oral cavity
1245547|NCT00973947|stage I basal cell carcinoma of the lip
1245548|NCT00973947|stage II basal cell carcinoma of the lip
1245549|NCT00973947|stage III basal cell carcinoma of the lip
1245550|NCT00973947|stage IV basal cell carcinoma of the lip
1245551|NCT00973947|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1245645|NCT00973765|cellulitis
1245552|NCT00973947|untreated metastatic squamous neck cancer with occult primary
1245553|NCT00973947|stage I lymphoepithelioma of the nasopharynx
1245554|NCT00973947|stage I squamous cell carcinoma of the nasopharynx
1245555|NCT00973947|stage II lymphoepithelioma of the nasopharynx
1245556|NCT00973947|stage II squamous cell carcinoma of the nasopharynx
1245557|NCT00973947|stage III lymphoepithelioma of the nasopharynx
1245558|NCT00973947|stage III squamous cell carcinoma of the nasopharynx
1245559|NCT00973947|stage IV lymphoepithelioma of the nasopharynx
1245560|NCT00973947|stage IV squamous cell carcinoma of the nasopharynx
1245561|NCT00973947|stage I lymphoepithelioma of the oropharynx
1245562|NCT00973947|stage I squamous cell carcinoma of the oropharynx
1245563|NCT00973947|stage II lymphoepithelioma of the oropharynx
1245564|NCT00973947|stage II squamous cell carcinoma of the oropharynx
1245565|NCT00973947|stage III lymphoepithelioma of the oropharynx
1245566|NCT00973947|stage III squamous cell carcinoma of the oropharynx
1245567|NCT00973947|stage IV lymphoepithelioma of the oropharynx
1245568|NCT00973947|stage IV squamous cell carcinoma of the oropharynx
1245569|NCT00973947|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1245570|NCT00973947|stage I inverted papilloma of the paranasal sinus and nasal cavity
1245571|NCT00973947|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1245572|NCT00973947|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1245573|NCT00973947|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1245574|NCT00973947|stage II inverted papilloma of the paranasal sinus and nasal cavity
1245575|NCT00973947|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1245576|NCT00973947|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1245577|NCT00973947|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1245578|NCT00973947|stage III inverted papilloma of the paranasal sinus and nasal cavity
1245579|NCT00973947|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1245580|NCT00973947|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1245581|NCT00973947|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1245582|NCT00973947|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1245583|NCT00973947|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1245584|NCT00973947|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1245585|NCT00973947|stage I salivary gland cancer
1245586|NCT00973947|stage II salivary gland cancer
1245587|NCT00973947|stage III salivary gland cancer
1245588|NCT00973947|stage IV salivary gland cancer
1245589|NCT00973947|recurrent lymphoepithelioma of the nasopharynx
1245590|NCT00973947|recurrent lymphoepithelioma of the oropharynx
1245591|NCT00973947|recurrent squamous cell carcinoma of the hypopharynx
1245592|NCT00973947|recurrent squamous cell carcinoma of the nasopharynx
1245593|NCT00973947|recurrent squamous cell carcinoma of the oropharynx
1245594|NCT00973947|recurrent squamous cell carcinoma of the larynx
1245595|NCT00973947|recurrent verrucous carcinoma of the larynx
1245596|NCT00973947|recurrent squamous cell carcinoma of the lip and oral cavity
1245597|NCT00973947|recurrent basal cell carcinoma of the lip
1245598|NCT00973947|recurrent adenoid cystic carcinoma of the oral cavity
1245599|NCT00973947|recurrent mucoepidermoid carcinoma of the oral cavity
1245600|NCT00973947|recurrent verrucous carcinoma of the oral cavity
1245601|NCT00973947|recurrent metastatic squamous neck cancer with occult primary
1245602|NCT00973947|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1245603|NCT00973947|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1245604|NCT00973947|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1245605|NCT00973947|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1245606|NCT00973947|recurrent salivary gland cancer
1245607|NCT00973921|Stent
1245608|NCT00973921|under-expansion
1245609|NCT00973921|StentOp
1245610|NCT00973921|StentOptimizer
1245611|NCT00973921|IVUS
1245612|NCT00973921|IC-PRO
1245613|NCT00973921|image enhancement
1245614|NCT00973908|Clostridium difficile associated diarrhoea
1245615|NCT00973908|antibiotic associated diarrhoea
1245616|NCT00973895|Influenza
1245617|NCT00973895|Healthy
1245618|NCT00973895|Immunity
1245619|NCT00973895|Preventive
1245620|NCT00973895|Pandemic
1245621|NCT00973882|Hormone resistant prostate cancer
1245622|NCT00973882|Neuro-endocrine marker
1245623|NCT00973882|Carboplatin-Etoposide combination
1245624|NCT00973882|Neuro-endocrine differentiation
1245625|NCT00973869|colon cancer
1245626|NCT00973869|rectal cancer
1245627|NCT00973830|Changes in HbA1c
1245628|NCT00973817|Hepatitis
1245629|NCT00973817|AOCH
1245630|NCT00973804|Reduced Intensity Conditioning
1245631|NCT00973804|Umbilical Cord Blood Transplant
1245632|NCT00973804|Targeted Immune Depletion
1245633|NCT00973804|Leukemia
1245634|NCT00973804|Lymphoma
1245635|NCT00973804|Multiple Myeloma
1245636|NCT00973804|Non-Hodgkins Lymphoma
1245637|NCT00973804|Hodgkins Lymphoma
1245638|NCT00973791|Spinal anesthesia
1245639|NCT00973791|Fluid therapy
1245640|NCT00973778|Intensity Modulated Radiation Therapy
1245641|NCT00973778|Capecitabine
1245642|NCT00973778|Resectable Rectal Carcinoma
1245643|NCT00973765|abcess
1245644|NCT00973765|MRSA
1245646|NCT00973765|antibiotics
1245647|NCT00973765|uncomplicated abscesses
1245648|NCT00973752|ALL
1245649|NCT00973739|NF-2
1245650|NCT00973739|NF-2 related tumors
1245651|NCT00973739|Schwannoma, Acoustic, Bilateral
1245652|NCT00973739|schwannomas
1245653|NCT00973739|Neurilemmoma of other cranial and peripheral nerves
1245654|NCT00973739|NF2 related benign intracranial tumors including
1245655|NCT00973739|NF2 related meningiomas
1245656|NCT00973739|NF2 related ependymomas
1245657|NCT00973739|NF2 related spinal neurofibromas
1245658|NCT00973739|NF2 related gliomas
1245659|NCT00973713|Advanced cholangiocarcinoma
1245660|NCT00973700|Swine Flu
1245661|NCT00973700|Flu
1245662|NCT00973700|Vaccine
1245663|NCT00973700|Adjuvant
1245664|NCT00973687|pediatric
1245665|NCT00973687|dexamethasone
1245666|NCT00973687|management
1245667|NCT00973687|corticosteroids
1245668|NCT00973687|asthma
1245669|NCT00973661|Overweight
1245670|NCT00973661|Diagnosis
1245671|NCT00973661|Counseling
1245672|NCT00973661|Medical Records Systems, Computerized
1245673|NCT00973648|Tinnitus
1245674|NCT00973648|Ringing in ears
1245675|NCT00973648|Functional connectivity MRI
1245676|NCT00973648|Voluntary control of tinnitus
1245677|NCT00973635|education
1245678|NCT00973635|web-based intervention
1245679|NCT00973635|patient care
1245680|NCT00973622|Tobacco cessation
1245681|NCT00973622|Tobacco dependence
1245682|NCT00973622|Transcranial Magnetic Stimulation
1245683|NCT00973622|Nicotine Dependence
1245684|NCT00973622|Delayed Discounting
1245685|NCT00973609|metastatic colorectal cancer
1245686|NCT00973609|Bevacizumab
1245687|NCT00973609|Avastin®
1245688|NCT00973609|phase 3
1245689|NCT00973609|maintenance treatment
1245690|NCT00973609|treatment pause
1245691|NCT00973609|drug holiday
1245692|NCT00973609|stage IV
1245693|NCT00973583|vitamin D
1245694|NCT00973583|infection
1245695|NCT00973583|Vitamin D for the prevention of respiratory tract infections
1245696|NCT00973570|tobacco cessation
1245697|NCT00973570|evaluation
1245698|NCT00973570|epidémiology
1245699|NCT00973570|adolescent
1245700|NCT00973570|apprentices
1245701|NCT00973557|bevacizumab
1245702|NCT00973544|breast reconstruction complications
1245703|NCT00973544|drains
1245704|NCT00973544|silicone implant
1245705|NCT00973531|Sleep Disordered Breathing
1245706|NCT00973531|Sleep Apnea
1245707|NCT00973531|Hypertension
1245708|NCT00973531|Continuous Positive Airway Pressure
1245709|NCT00973518|Alzheimer's Disease
1245710|NCT00973518|AD
1245711|NCT00973518|Healthy Control
1245712|NCT00973505|Breast neoplasms
1245713|NCT00973505|Aromatase inhibitors
1245714|NCT00973505|Genetic polymorphisms
1245715|NCT00973505|Arthralgia
1245716|NCT00973505|Arthritis
1245717|NCT00973492|type 1 diabetes
1245718|NCT00973492|functional insulinotherapy
1245719|NCT00973479|Arthritis, Rheumatoid
1245720|NCT00973479|Active rheumatoid arthritis
1245721|NCT00973479|Golimumab
1245722|NCT00973479|CNTO148
1245723|NCT00973479|Anti-TNFalpha monoclonal antibody
1245724|NCT00973479|Methotrexate
1245725|NCT00973479|Intravenous
1245726|NCT00973466|HIV-infection
1245727|NCT00973466|Neisseria gonorrhea
1245728|NCT00973466|Chlamydia trachomatis
1245729|NCT00973466|Herpes simplex virus
1245730|NCT00973466|prevalence
1245731|NCT00973453|non-seasonal allergy
1245732|NCT00973453|house dust mite
1245733|NCT00973453|immunotherapy
1245734|NCT00973453|dose tolerability
1245735|NCT00973440|geriatric assessment
1245736|NCT00973427|NSCLC
1245737|NCT00973414|Combined epidural spinal anesthesia
1245738|NCT00973414|Fluid therapy
1245739|NCT00973388|VX-950-TiDP24-C136
1245740|NCT00973388|VX-950-C136
1245741|NCT00973388|VX-950
1245742|NCT00973388|HEPATITIS
1245743|NCT00973388|Telaprevir
1245744|NCT00973388|Moxifloxacin
1245745|NCT00973388|ECG
1245746|NCT00973388|QT
1245747|NCT00973388|QTc
1245748|NCT00973375|Drug-eluting stent
1245749|NCT00973375|coronary restenosis
1245750|NCT00973375|coronary thrombosis
1245751|NCT00973362|Cervix Cancer
1245752|NCT00973362|Cervical Intraepithelial Neoplasia (CIN)
1245753|NCT00973362|Human Papillomavirus Virus (HPV)
1245754|NCT00973362|APTIMA HPV Assay
1245755|NCT00973362|FDA-Approved HPV DNA Test
1245756|NCT00973362|TIGRIS DTS (direct tube sampling) System
1245757|NCT00973362|Clinical Sensitivity (%)
1245758|NCT00973362|Clinical Specificity (%)
1245759|NCT00973362|Positive Predictive Value [PPV] (%)
1245760|NCT00973362|Negative Predictive Value [NPV] (%)
1245761|NCT00973362|Atypical Squamous Cells Undetermined Significance (ASC-US)
1245762|NCT00973362|Relative Risk
1245763|NCT00973349|Swine Flu
1245764|NCT00973349|Flu
1245765|NCT00973349|Vaccine
1245766|NCT00973349|Adults
1245767|NCT00973349|Elderly
1245768|NCT00973349|Non-Elderly
1245769|NCT00973349|Adjuvant
1245770|NCT00973336|postoperative follow-up
1245771|NCT00973323|BAY59-7939
1245772|NCT00973323|Rivaroxaban
1245773|NCT00973323|Non-valvular atrial fibrillation
1245774|NCT00973323|Japanese Patients
1245775|NCT00973323|Phase II
1245776|NCT00973310|Non-small-cell lung cancer
1245777|NCT00973310|Radiation therapy
1245778|NCT00973310|Epidermal growth factor receptor
1245779|NCT00973310|Tyrosine kinase inhibitor
1245780|NCT00973297|Falls
1245781|NCT00973284|Prevention of acute gastroenteritis due to infection with and experimental Norwalk Virus
1245782|NCT00973271|hypertriglyceridemia
1245783|NCT00973245|BAY59-7939
1245784|NCT00973245|Rivaroxaban
1245785|NCT00973245|Non-valvular atrial fibrillation
1245786|NCT00973245|Japanese Patients
1245787|NCT00973245|Phase II
1245788|NCT00973232|Tramadol
1245789|NCT00973232|Acetaminophen
1245790|NCT00973232|combination
1245791|NCT00973232|pharmacokinetics
1245792|NCT00973232|bioavailability
1245793|NCT00973232|Zaldiar
1245794|NCT00973232|Ultracet
1245795|NCT00973232|fed
1245796|NCT00973232|fasted
1245797|NCT00973232|single-dose
1245798|NCT00973232|multiple-dose
1245799|NCT00973232|healthy
1245800|NCT00973232|volunteers
1245801|NCT00973232|Healthy volunteers
1245802|NCT00973219|HBsAg loss
1245803|NCT00973219|HBsAg seroconversion
1245804|NCT00973219|chronic hepatitis B
1245805|NCT00973219|low viral load
1245806|NCT00973219|inactive carrier hepatitis B
1245807|NCT00973206|cardiovascular morbidity
1245808|NCT00973206|mortality community study
1245809|NCT00973193|rectum
1245810|NCT00973193|colorectal
1245811|NCT00973193|cancer
1245812|NCT00973193|adenocarcinoma
1245813|NCT00973193|anti-EGFR
1245814|NCT00973193|monoclonal antibodies
1245815|NCT00973193|neoadjuvant therapy
1245816|NCT00973193|preoperative radiotherapy
1245817|NCT00973180|Prescription medication understanding among diabetic and hypertension patients.
1245818|NCT00973180|Prescription medication use among diabetic and hypertension patients.
1245819|NCT00973180|Hemoglobin A1c changes among diabetic patients.
1245820|NCT00973180|Blood pressure changes among hypertension patients.
1245821|NCT00973167|Fracture rate
1245822|NCT00973167|Fracture risks
1245823|NCT00973154|Pneumonia
1245824|NCT00973154|Corticosteroids
1245825|NCT00973154|clinical stability
1245826|NCT00973141|Moderate to severe, osteoarthritis-related pain
1245827|NCT00973141|Osteoarthritis-related pain
1245828|NCT00973141|Moderate to severe chronic pain
1245829|NCT00973141|JNJ-42160443
1245830|NCT00973089|Primary tooth
1245831|NCT00973089|Caries, Dental
1245832|NCT00973089|Alternative treatment
1245833|NCT00973076|Phase I, cancer
1245834|NCT00973076|solid tumors
1245835|NCT00973076|advanced solid malignancies
1245836|NCT00973076|dose escalation
1245837|NCT00973076|mTOR Kinase Inhibitor
1245838|NCT00973076|Japanese
1245839|NCT00973063|bacteremia
1245840|NCT00973063|blood culture
1245841|NCT00973063|contamination
1245842|NCT00973050|Bioequivalence
1245843|NCT00973037|Breast neoplasms
1245844|NCT00973037|Tamoxifen
1245845|NCT00973037|Genotype
1245846|NCT00973037|CYP2D6
1245847|NCT00973024|JNJ-42160443
1245848|NCT00973024|Low back pain-related pain
1245849|NCT00973024|moderate to severe, chronic pain
1245850|NCT00973011|GA
1245851|NCT00972998|anal sphincter pressure
1245852|NCT00972998|phenyephrine
1245853|NCT00972985|Healthy Control subjects
1245854|NCT00972972|fruit polyphenols
1245855|NCT00972972|phytochemicals
1245856|NCT00972972|neurocognition
1245857|NCT00972972|neuropsychology
1245858|NCT00972972|psychopharmacology
1245859|NCT00972972|gene expression
1245860|NCT00972972|biochemistry
1245861|NCT00972959|multiple myeloma
1245862|NCT00972959|1-3 Prior Lines of Therapy
1245863|NCT00972959|bortezomib (Velcade)
1245864|NCT00972959|zoledronic acid (Zometa)
1245865|NCT00972959|Dexamethasone
1245866|NCT00972959|bone mineral density
1245867|NCT00972959|bone pain
1245868|NCT00972959|bone metabolism
1245869|NCT00972959|osteolytic lesions
1245870|NCT00972959|DEXA-scans
1245871|NCT00972959|X-ray radiography
1245872|NCT00972946|MRI
1245873|NCT00972946|SPIO
1245874|NCT00972933|Immunogenicity Analysis
1245875|NCT00972933|Biomarker Analysis
1245876|NCT00972933|experimental
1245877|NCT00972920|Transversus abdominis plane
1245878|NCT00972920|Acute pain service
1245879|NCT00972920|Ultrasound
1245880|NCT00972907|anal fissure
1245881|NCT00972907|pain
1245882|NCT00972907|nifedipine
1245883|NCT00972894|Group B streptococcus
1245884|NCT00972894|Polymerase chain reaction
1245885|NCT00972894|PCR
1245886|NCT00972894|Intrapartum screening
1245887|NCT00972894|Risk factors
1245888|NCT00972894|arly onset Group B streptococcus infection
1245889|NCT00972881|adenocarcinoma of the rectum
1245890|NCT00972881|Locally advanced rectal cancer
1245891|NCT00972868|Unidirectional mask
1245892|NCT00972868|NPPV
1245893|NCT00972868|COPD
1245894|NCT00972868|respiratory physiology
1245895|NCT00972855|Bioequivalence
1245896|NCT00972842|PTCL
1245897|NCT00972842|Peripheral T-Cell Non-Hodgkin's Lymphoma
1245898|NCT00972842|Vorinostat
1245899|NCT00972842|Lenalidomid
1245900|NCT00972829|Hypercholesterolemia
1245901|NCT00972816|Swine Flu
1245902|NCT00972816|Flu
1245903|NCT00972816|Vaccine
1245904|NCT00972816|Children
1245905|NCT00972816|Adjuvant
1245906|NCT00972803|gingivitis
1245907|NCT00972803|dental plaque
1245908|NCT00972803|mouthrinse
1245909|NCT00972790|brain tumor
1245910|NCT00972790|un-ruptured aneurysm
1245911|NCT00972790|arteriovenous malformation
1245912|NCT00972790|epileptic focus
1245913|NCT00972790|supratentorial
1245914|NCT00972764|Laryngomalacia
1245915|NCT00972764|Factors Associated or Predisposing
1245916|NCT00972751|stage II rectal cancer
1245917|NCT00972751|stage III rectal cancer
1245918|NCT00972751|adenocarcinoma of the rectum
1245919|NCT00972725|Chloroquine
1245920|NCT00972725|Human Immunodeficiency Virus
1245921|NCT00972712|Multiple Myeloma
1245922|NCT00972699|Human Immunodeficiency Virus
1245923|NCT00972699|Acquired Immune Deficiency Syndrome
1245924|NCT00972699|Tuberculosis
1245925|NCT00972699|Women
1245926|NCT00972699|Pregnancy
1245927|NCT00972699|Vertical Transmission of Human Immunodeficiency Virus
1245928|NCT00972699|South Africa
1245929|NCT00972699|Low Birth Weight
1245930|NCT00972686|solid tumors
1245931|NCT00972686|lymphoma
1245932|NCT00972686|Phosphoinositide 3-kinase inhibitor
1245933|NCT00972660|Mesenchymal stem cell
1245934|NCT00972660|Efficacy
1245935|NCT00972660|Safety
1245936|NCT00972647|fracture
1245937|NCT00972647|fixation
1245938|NCT00972647|fluoroscopy
1245939|NCT00972647|laser
1245940|NCT00972647|radiation
1245941|NCT00972634|depression
1245942|NCT00972634|cachexia
1245943|NCT00972634|pain
1245944|NCT00972634|unspecified adult solid tumor, protocol specific
1245945|NCT00972608|congenital heart disease
1245946|NCT00972608|surgical planning
1245947|NCT00972582|leucine intake
1245948|NCT00972582|tolerable upper limit
1245949|NCT00972582|adults
1245950|NCT00972582|amino acid supplements
1245951|NCT00972582|Excessive Leucine Intake
1245952|NCT00972569|BNP with or without PDE-V in heart failure
1245953|NCT00972556|Mineral Trioxide Aggregate
1245954|NCT00972556|Formocresol
1245955|NCT00972556|pulpotomy
1245956|NCT00972556|primary molar
1245957|NCT00972556|treatment outcome
1245958|NCT00972543|Moderate to severe chronic plaque psoriasis
1245959|NCT00972543|palms and/or soles
1245960|NCT00972543|with or without pustules
1245961|NCT00972530|rheumatoid arthritis
1245962|NCT00972530|treatment
1245963|NCT00972517|GSK Bio's influenza vaccine GSK2340272A
1245964|NCT00972517|influenza infection
1245965|NCT00972504|Proof of concept
1245966|NCT00972465|nimotuzumab colorectal cancer chemotherapy
1245967|NCT00972452|Type II Diabetes
1245968|NCT00972452|Insulin Resistance
1245969|NCT00972452|Exercise
1245970|NCT00972452|Continuous Glucose Monitoring
1245971|NCT00972439|Oral Contraceptives
1245972|NCT00972439|Breast Tissue
1245973|NCT00972413|breast cancer
1245974|NCT00972413|cone beam computed tomography
1245975|NCT00972400|psychosocial effects of cancer and its treatment
1245976|NCT00972400|fatigue
1245977|NCT00972400|cancer survivor
1245978|NCT00972400|breast cancer
1245979|NCT00972387|carbohydrate-protein
1245980|NCT00972387|endurance exercise
1245981|NCT00972387|supplement
1245982|NCT00972361|Adenoidectomy
1245983|NCT00972361|Tonsillectomy
1245984|NCT00972361|Ventilation Tubes
1245985|NCT00972361|Preoperational screening
1245986|NCT00972361|Coagulation Profile
1245987|NCT00972361|Lupus anticoagulant
1245988|NCT00972348|HIV
1245989|NCT00972348|Personal Health Record
1245990|NCT00972348|Laboratory values: CD4 cells and HIV Viral load
1245991|NCT00972348|Medication Reconciliation
1245992|NCT00972335|Avastin
1245993|NCT00972335|RAD001
1245994|NCT00972335|Meningioma
1245995|NCT00972335|Bevacizumab
1245996|NCT00972335|Everolimus
1245997|NCT00972335|Brain
1245998|NCT00972309|Epotope-Enhanced TARP Peptide
1245999|NCT00972309|Prostate Cancer
1246000|NCT00972309|TARP Peptide-Pulsed Dendritic Cells
1246001|NCT00972309|PSADT
1246002|NCT00972309|HLA-A*0201
1246003|NCT00972270|Arterial Occlusive Disease
1246004|NCT00972270|Heart Diseases
1246005|NCT00972270|Myocardial Ischemia
1246006|NCT00972270|Vascular Disease
1246007|NCT00972270|Arteriosclerosis
1246008|NCT00972270|Ischemia
1246009|NCT00972257|24-hour IOP control
1246010|NCT00972257|primary open-angle glaucoma
1246011|NCT00972257|brimonidine/timolol
1246012|NCT00972257|dorzolamide/timolol
1246013|NCT00972244|Type 2 diabetes mellitus
1246014|NCT00972244|Japanese
1246015|NCT00972244|phase 2
1246016|NCT00972244|efficacy
1246017|NCT00972244|safety
1246018|NCT00972244|dapagliflozin
1246019|NCT00972231|Thalassemia Major
1246020|NCT00972231|Thalassemia Intermedia
1246021|NCT00972231|Sickle Cell Anemia
1246022|NCT00972231|Sickle Cell Thalassemia
1246023|NCT00972231|Iron Overload
1246024|NCT00972231|Growth Velocity
1246025|NCT00972218|Spondyloarthritis
1246026|NCT00972218|Ankylosing Spondylitis
1246027|NCT00972218|Crohn's disease
1246028|NCT00972218|adalimumab
1246029|NCT00972218|treatment
1246030|NCT00972205|Pgp
1246031|NCT00972205|Solid Tumors
1246032|NCT00972205|Drug Resistance
1246033|NCT00972205|Sestamibi
1246034|NCT00972205|Cancer
1246035|NCT00972205|Solid Tumor
1246036|NCT00972192|HIV testing
1246037|NCT00972192|HIV risk behavior
1246038|NCT00972192|access to care
1246039|NCT00972179|healthy volunteers
1246040|NCT00972153|Decrease in CFU density at surgery site
1246041|NCT00972153|Decrease in airborne particulate at surgery site
1246042|NCT00972140|Patients with stable COPD
1246043|NCT00972101|Blood And Marrow Transplantation
1246044|NCT00972101|Leukemia
1246045|NCT00972101|Lymphoma
1246046|NCT00972101|Pediatrics
1246047|NCT00972101|Etoposide
1246048|NCT00972101|Expanded Cord Blood T Cells
1246049|NCT00972101|Filgrastim
1246050|NCT00972101|Fludarabine
1246051|NCT00972101|Melphalan
1246052|NCT00972101|Mycophenolate Mofetil
1246053|NCT00972101|Rituximab
1246054|NCT00972101|Tacrolimus
1246055|NCT00972101|Thiotepa
1246056|NCT00972101|Thymoglobulin
1246057|NCT00972101|Total Body Irradiation
1246058|NCT00972088|inflammation of the small bowel
1246059|NCT00972075|totally blind subjects
1246060|NCT00972062|Subcutaneous injections
1246061|NCT00972062|Skin abnormalities
1246062|NCT00972049|safety
1246063|NCT00972049|tolerability
1246064|NCT00972049|AZD2516
1246065|NCT00972049|pain
1246066|NCT00972049|Japanese
1246067|NCT00972036|COLON
1246068|NCT00972036|LIVER
1246069|NCT00972036|RECTUM
1246070|NCT00972036|SIR-Spheres
1246071|NCT00972036|09-030
1246072|NCT00972023|triple-negative breast cancer
1246073|NCT00972023|stage I breast cancer
1246074|NCT00972023|stage II breast cancer
1246075|NCT00972023|stage IIIA breast cancer
1246076|NCT00972023|stage IIIB breast cancer
1246077|NCT00972023|stage IIIC breast cancer
1246078|NCT00972010|Breast
1246079|NCT00972010|Cancer
1246080|NCT00972010|Lumpectomies
1246081|NCT00972010|PlasmaBlade
1246082|NCT00972010|Breast conservation therapy
1246083|NCT00971971|Hypotension
1246084|NCT00971971|Acute renal failure
1246085|NCT00971971|acute kidney injury
1246086|NCT00971971|dialysis
1246087|NCT00971971|ICU
1246088|NCT00971958|HIV prevention
1246089|NCT00971958|infant, neonatal, male circumcision
1246090|NCT00971932|Recurrent and/or metastatic
1246091|NCT00971932|SCCHN
1246092|NCT00971919|pain
1246093|NCT00971919|perioperative/postoperative complications
1246094|NCT00971919|breast cancer in situ
1246095|NCT00971919|stage IA breast cancer
1246096|NCT00971919|stage IB breast cancer
1246097|NCT00971919|stage II breast cancer
1246098|NCT00971919|stage IIIA breast cancer
1246099|NCT00971919|stage IIIB breast cancer
1246100|NCT00971919|stage IIIC breast cancer
1246101|NCT00971906|Pandemic influenza
1246102|NCT00971906|Vaccine
1246103|NCT00971893|Acute Exacerbation of Bronchial Asthma Acute Asthma
1246104|NCT00971880|Blood transfusions
1246105|NCT00971880|Adverse events
1246106|NCT00971880|Hepatitis C
1246107|NCT00971880|HIV
1246108|NCT00971854|Dystonia
1246109|NCT00971828|Myositis
1246110|NCT00971828|polymyositis
1246111|NCT00971828|dermatomyositis
1246112|NCT00971815|HPA-axis
1246113|NCT00971815|fetal programming
1246114|NCT00971789|Sirolimus
1246115|NCT00971789|Cowden Syndrome
1246116|NCT00971789|PTEN Mutation
1246117|NCT00971789|Hamartoma Syndrome
1246118|NCT00971776|Patient receiving AB5000 ventricle potentially recoverable
1246119|NCT00971763|stage I adult diffuse large cell lymphoma
1246120|NCT00971763|contiguous stage II adult diffuse large cell lymphoma
1246121|NCT00971763|noncontiguous stage II adult diffuse large cell lymphoma
1246122|NCT00971763|stage III adult diffuse large cell lymphoma
1246123|NCT00971763|stage IV adult diffuse large cell lymphoma
1246124|NCT00971750|ultrasonography
1246125|NCT00971750|gallbladder
1246126|NCT00971750|cholelithiasis
1246127|NCT00971750|laparoscopic
1246128|NCT00971750|gastric bypass
1246129|NCT00971750|obesity
1246130|NCT00971750|bariatric surgery
1246131|NCT00971737|stage IV breast cancer
1246132|NCT00971737|male breast cancer
1246133|NCT00971724|Prednisolone
1246134|NCT00971724|Glucocorticoids
1246135|NCT00971711|IBS
1246136|NCT00971711|irritable bowel syndrome
1246137|NCT00971711|abdominal pain
1246138|NCT00971711|urgency
1246139|NCT00971711|bloating
1246140|NCT00971711|diarrhea
1246141|NCT00971698|Splenectomy
1246142|NCT00971698|Thrombocytosis
1246143|NCT00971698|Infections
1246144|NCT00971698|Spleen
1246145|NCT00971698|Sickle Cell Thalassemia
1246146|NCT00971672|Infants
1246147|NCT00971672|Iron Deficiency
1246148|NCT00971672|Anemia
1246149|NCT00971672|Healthy infants that attend the pediatric community clinics
1246150|NCT00971659|type 2 diabetes
1246151|NCT00971646|overactive bladder
1246152|NCT00971646|self-consciousness
1246153|NCT00971646|perceptual urge sensation
1246154|NCT00971620|Cutaneous Leiomyomas
1246155|NCT00971620|Skin Pain
1246156|NCT00971620|Botox Therapy
1246157|NCT00971620|Hereditary Leiomyomatosis
1246158|NCT00971620|Renal Cell Cancer
1246159|NCT00971620|Cutaneous Leiomyoma
1246160|NCT00971607|Acute myocardial infarction
1246161|NCT00971607|Postconditioning
1246162|NCT00971607|Sevoflurane
1246163|NCT00971594|weight loss
1246164|NCT00971594|glucose metabolism
1246165|NCT00971568|Interstitial cystitis
1246166|NCT00971568|Painful bladder syndrome
1246167|NCT00971555|Transient Hypothyroxinemia
1246168|NCT00971555|Late Preterm Infants
1246169|NCT00971555|Total T4
1246170|NCT00971555|TSH
1246171|NCT00971555|Illness severity
1246172|NCT00971555|NICU
1246173|NCT00971542|Pandemic influenza
1246174|NCT00971542|Vaccine
1246175|NCT00971529|Smoking cessation
1246176|NCT00971529|tea filter
1246177|NCT00971516|diabetes
1246178|NCT00971516|implants
1246179|NCT00971516|cytokines
1246180|NCT00971503|Diabetes type 1
1246181|NCT00971503|Adult Stem cells
1246182|NCT00971503|Local injection
1246183|NCT00971503|Catheter delivery
1246184|NCT00971503|Bone marrow
1246185|NCT00971490|COPD
1246186|NCT00971490|FEV1
1246187|NCT00971490|beta endorphin
1246188|NCT00971490|SGRQ
1246189|NCT00971490|Acu-TENS
1246190|NCT00971477|Teledermatology
1246191|NCT00971477|Telemedicine
1246192|NCT00971477|Psoriasis
1246193|NCT00971464|AMD
1246194|NCT00971464|EV
1246195|NCT00971464|CCTV
1246196|NCT00971464|Reading
1246197|NCT00971464|vision
1246198|NCT00971451|Anterior cruciate ligament
1246199|NCT00971451|ACL
1246200|NCT00971438|appendicitis
1246201|NCT00971438|diagnosis
1246202|NCT00971438|diagnostic imaging
1246203|NCT00971438|clinical scoring system
1246204|NCT00971425|influenza infection
1246205|NCT00971425|GSK Bio's influenza vaccine GSK2340272A
1246206|NCT00971386|Heart Failure
1246207|NCT00971373|antimicrobial
1246208|NCT00971373|epidemiology
1246209|NCT00971373|bacteriology
1246210|NCT00971373|CFU
1246211|NCT00971360|conversion
1246212|NCT00971360|cytokine
1246213|NCT00971360|inflammation
1246214|NCT00971347|obesity
1246215|NCT00971347|overweight
1246216|NCT00971347|weight loss
1246217|NCT00971347|randomized controlled trial
1246218|NCT00971347|chewing gum
1246219|NCT00971334|Down Syndrome
1246220|NCT00971334|Aneuploidy
1246221|NCT00971334|Amniocentesis
1246222|NCT00971334|CVS
1246223|NCT00971321|influenza infection
1246224|NCT00971321|GSK Bio's influenza vaccine GSK2340272A
1246225|NCT00971295|eslicarbazepine acetate
1246226|NCT00971295|zebinix
1246227|NCT00971295|metformin
1246228|NCT00971256|Bladder
1246229|NCT00971256|Cancer
1246230|NCT00971256|Cytology
1246231|NCT00971243|Insulin resistance
1246232|NCT00971230|HIV
1246233|NCT00971230|Human Immunodeficiency Virus
1246234|NCT00971217|Internet based Cognitive-Behavioural Intervention
1246235|NCT00971217|Exercise Intervention
1246236|NCT00971217|Depression
1246237|NCT00971217|Perceived Social Support
1246238|NCT00971217|Physical Self-Concept
1246239|NCT00971204|atrial fibrillation
1246240|NCT00971204|PAF
1246241|NCT00971191|Stage I - III surgical resection molecular change brief pre-operative exposure
1246242|NCT00971178|Analgesia
1246243|NCT00971178|Dental pain
1246244|NCT00971178|Dexmedetomidine
1246245|NCT00971178|Pain
1246246|NCT00971178|Peripheral effects
1246247|NCT00971165|Hypertension
1246248|NCT00971165|Chlorthalidone
1246249|NCT00971165|Amiloride
1246250|NCT00971165|Losartan
1246251|NCT00971165|treatment
1246252|NCT00971152|IVF
1246253|NCT00971152|dose comparison of gonadotrophins
1246254|NCT00971152|poor responder to ovarian stimulation
1246255|NCT00971139|Online patient-provider communication
1246256|NCT00971139|Organizational change
1246257|NCT00971139|Symptom management
1246258|NCT00971126|hepatocellular carcinoma
1246259|NCT00971100|Pandemic influenza
1246260|NCT00971100|Vaccine
1246261|NCT00971087|Breast cancer
1246262|NCT00971087|breast cancer screening
1246263|NCT00971074|Arthralgia
1246264|NCT00971074|Viscosupplementation
1246265|NCT00971074|Knee
1246266|NCT00971074|Menisci, Tibial
1246267|NCT00971074|Surgery, Outpatient
1246268|NCT00971061|Ahmed valve
1246269|NCT00971061|single-plate Molteno implant
1246270|NCT00971061|refractory glaucoma
1246271|NCT00971061|surgical treatment
1246272|NCT00971048|pressure ulcers
1246273|NCT00971048|PU
1246274|NCT00971048|diabetic foot ulcers
1246275|NCT00971048|DFU
1246276|NCT00971048|Bates-Jensen Wound Assessment
1246277|NCT00971035|MILR1444A
1246278|NCT00971022|Low-income populations
1246279|NCT00971022|Chronic health condition
1246280|NCT00971022|Prescription medication
1246281|NCT00971022|Prescription drugs
1246282|NCT00971022|Discount generic prescription programs
1246283|NCT00971022|Survey
1246284|NCT00971022|Awareness
1246285|NCT00971022|Focus Group
1246286|NCT00971022|Houston
1246287|NCT00971009|Symptom management
1246288|NCT00971009|Interactive Health Communication Application
1246289|NCT00971009|Patient-provider communication
1246290|NCT00971009|Health care costs
1246291|NCT00970996|Melanoma
1246292|NCT00970996|Abraxane
1246293|NCT00970996|Nab-paclitaxel
1246294|NCT00970996|Paclitaxel (protein-bound)
1246295|NCT00970996|ABI-007
1246296|NCT00970996|Cisplatin
1246297|NCT00970996|Platinol-AQ
1246298|NCT00970996|Platinol
1246299|NCT00970996|CDDP
1246300|NCT00970996|Interleukin 2
1246301|NCT00970996|IL-2
1246302|NCT00970996|Proleukin
1246303|NCT00970996|Intron A
1246304|NCT00970996|Interferon alpha 2b
1246305|NCT00970996|Interferon alfa-2b
1246306|NCT00970996|Temodar
1246307|NCT00970996|Temozolomide
1246308|NCT00970970|Vascular endothelial growth factor
1246309|NCT00970970|von Hippel Lindau disease
1246310|NCT00970970|molecular imaging
1246311|NCT00970970|biomarker
1246312|NCT00970957|Macular edema
1246313|NCT00970957|Retinal Vein Occlusion
1246314|NCT00970957|Bevacizumab
1246315|NCT00970944|Traumatic Brain Injury
1246316|NCT00970944|Rehabilitation
1246317|NCT00970944|Disorders of Consciousness
1246318|NCT00970944|Functional Outcome
1246319|NCT00970944|Amantadine Hydrochloride
1246320|NCT00970931|hypertension
1246321|NCT00970931|diuretics
1246322|NCT00970918|Cardiovascular disease
1246323|NCT00970918|Carotid Intima Media Thickness
1246324|NCT00970905|Radiation
1246325|NCT00970905|Nausea
1246326|NCT00970905|Vomiting
1246327|NCT00970905|Ondansetron
1246328|NCT00970905|Aprepitant
1246329|NCT00970892|Anticoagulation
1246330|NCT00970892|warfarin
1246331|NCT00970892|VKORC1
1246332|NCT00970892|CYP2C9
1246333|NCT00970892|thromboembolism
1246334|NCT00970892|pharmacogenetics
1246335|NCT00970879|malaria
1246336|NCT00970879|pregnancy
1246337|NCT00970879|HIV
1246338|NCT00970879|prevention
1246339|NCT00970879|cotrimoxazole
1246340|NCT00970879|mefloquine
1246341|NCT00970866|multiple micronutrients
1246342|NCT00970866|home fortification
1246343|NCT00970866|complementary foods
1246344|NCT00970866|infant feeding
1246345|NCT00970866|lipid-based nutrient supplements
1246346|NCT00970853|Evaluate developmental outcomes
1246347|NCT00970853|Evaluate child cognitive, academic, and behavioral outcomes
1246348|NCT00970840|Acceptability
1246349|NCT00970840|Supplements
1246350|NCT00970840|Home-fortification
1246351|NCT00970827|Coronary artery disease
1246352|NCT00970827|PCI
1246353|NCT00970827|Postconditioning
1246354|NCT00970827|Elective or urgent PCI
1246355|NCT00970814|Alcoholism
1246356|NCT00970814|Alcohol Drinking
1246357|NCT00970814|Alcoholic Intoxication
1246358|NCT00970814|Alcohol Abuse
1246359|NCT00970801|Atypical mycobacteria
1246360|NCT00970775|Phase I
1246361|NCT00970775|Japanese healthy volunteer
1246362|NCT00970775|AZD2423
1246363|NCT00970749|chlamydia
1246364|NCT00970749|healthy women
1246365|NCT00970749|history of endocervical chlamydia
1246366|NCT00970749|no history of endocervical chlamydia
1246367|NCT00970736|Motor cortex
1246368|NCT00970736|Motor control
1246369|NCT00970736|Neuroplasticity
1246370|NCT00970736|Aging
1246371|NCT00970736|Swallowing
1246372|NCT00970723|Diabetic retinopathy
1246373|NCT00970723|Macula edema
1246374|NCT00970723|Sleep apnea
1246375|NCT00970723|High blood pressure
1246376|NCT00970697|MARTORELL'S ULCER
1246377|NCT00970697|hydrogel
1246378|NCT00970697|Hypertensive leg ulcer
1246379|NCT00970684|recurrent non-small cell lung cancer
1246380|NCT00970684|stage IIIB non-small cell lung cancer
1246381|NCT00970684|stage IV non-small cell lung cancer
1246382|NCT00970684|adenocarcinoma of the lung
1246383|NCT00970684|bronchoalveolar cell lung cancer
1246384|NCT00970684|large cell lung cancer
1246385|NCT00970671|scar
1246386|NCT00970671|laser therapy
1246387|NCT00970671|lasers, pulsed dye
1246388|NCT00970658|Plaster
1246389|NCT00970658|injuries
1246390|NCT00970658|regions miofasciais articulated
1246391|NCT00970658|Reducing signs, symptoms
1246392|NCT00970645|Non small cell lung cancer
1246393|NCT00970645|mediastinum
1246394|NCT00970645|endobronchial ultrasound fine needle aspiration
1246395|NCT00970645|endoscopic ultrasound
1246396|NCT00970645|mediastinoscopy
1246397|NCT00970645|surgical or minimally invasive evaluation of mediastinum
1246398|NCT00970645|NSCLC
1246399|NCT00970606|ARDS
1246400|NCT00970606|H1N1
1246401|NCT00970606|Influenza
1246402|NCT00970606|Statin
1246403|NCT00970580|BIIB022
1246404|NCT00970580|Stage IV
1246405|NCT00970580|Taxol
1246406|NCT00970580|Stage IIIB
1246407|NCT00970580|Carboplatin
1246408|NCT00970580|Paclitaxel
1246409|NCT00970580|Non Small Cell Lung Cancer
1246410|NCT00970580|Treatment Naive
1246411|NCT00970580|Anti IGF1R
1246412|NCT00970580|NSCLC
1246413|NCT00970580|Open Label
1246414|NCT00970580|IGF1R
1246415|NCT00970580|Paraplatin
1246416|NCT00970580|Cytotoxic
1246417|NCT00970580|Mitotic Inhibitor
1246418|NCT00970580|Taxane
1246419|NCT00970580|Alkylating agent
1246420|NCT00970567|therapy after positive ketone bodies in the blood
1246421|NCT00970567|timepoint of diagnosis
1246422|NCT00970567|timepoint of metabolic normalisation
1246423|NCT00970554|Amblyopia
1246424|NCT00970554|Telescopic magnification
1246425|NCT00970554|Patching
1246426|NCT00970541|Cinnamon
1246427|NCT00970541|PCOS
1246428|NCT00970541|low blood sugar
1246429|NCT00970541|Insulin
1246430|NCT00970541|Glucose
1246431|NCT00970528|Oral Hypoglycemic Agent
1246432|NCT00970515|Laparoscopy
1246433|NCT00970515|Incisional hernia
1246434|NCT00970515|Umbilical hernia
1246435|NCT00970515|Mesh repair
1246436|NCT00970515|Postoperative complications
1246437|NCT00970502|celecoxib
1246438|NCT00970502|erlotinib
1246439|NCT00970502|epidermal growth factor receptor
1246440|NCT00970502|intensity-modulated radiotherapy
1246441|NCT00970502|cyclooxygenase-2
1246442|NCT00970502|reirradiation
1246443|NCT00970489|atrial fibrillation
1246444|NCT00970489|fish oil
1246445|NCT00970463|The GH-system and cardiac function
1246446|NCT00970450|Paracetamol
1246447|NCT00970450|Tropisetron
1246448|NCT00970450|Central analgesic effect
1246449|NCT00970450|Area of allodynia
1246450|NCT00970450|Secondary hyperalgesia
1246451|NCT00970398|Infant formula
1246452|NCT00970398|Bovine milk Osteopontin
1246453|NCT00970398|growth
1246454|NCT00970398|health
1246455|NCT00970398|immune functions
1246456|NCT00970372|Coercion
1246457|NCT00970359|thyroid
1246458|NCT00970359|metastases
1246459|NCT00970359|AZD6244
1246460|NCT00970359|09-048
1246461|NCT00970346|Digestive System Diseases
1246462|NCT00970346|Genetic Diseases
1246463|NCT00970346|Inborn
1246464|NCT00970346|Respiratory Tract Diseases
1246465|NCT00970346|Cystic Fibrosis
1246466|NCT00970346|Lung Disease
1246467|NCT00970346|Pancreatic Diseases
1246468|NCT00970333|Alzheimer disease
1246469|NCT00970333|Parkinson disease
1246470|NCT00970333|Multiple Sclerosis
1246471|NCT00970320|Anal Incontinence
1246472|NCT00970320|urinary incontinence
1246473|NCT00970320|primiparas
1246474|NCT00970320|prevalence
1246475|NCT00970320|pelvic floor exercise treatment
1246476|NCT00970320|Quality of Life (QoL)
1246477|NCT00970294|diabetes
1246478|NCT00970268|COPD
1246479|NCT00970268|Chronic Obstructive Pulmonary Disease
1246480|NCT00970268|Chronic Bronchitis
1246481|NCT00970268|Emphysema
1246482|NCT00970268|Airflow Obstruction, Chronic
1246483|NCT00970268|Chronic Airflow Obstruction
1246484|NCT00970268|Chronic Obstructive Airway Disease
1246485|NCT00970268|Chronic Obstructive Lung Disease
1246486|NCT00970255|Breastfeeding difficulties
1246487|NCT00970255|lingual frenulum
1246488|NCT00970255|labial frenulum
1246489|NCT00970255|frenotomy
1246490|NCT00969475|scar revision
1246491|NCT00969475|intraoperative
1246492|NCT00969475|fractional carbon dioxide laser
1246493|NCT00969462|Doxorubicin
1246494|NCT00969462|pharmacokinetics
1246495|NCT00969462|non-Hodgkin's lymphoma
1246496|NCT00969462|response
1246497|NCT00969462|association between response to chemotherapy
1246498|NCT00969462|myelosuppression degree
1246499|NCT00969462|doxorubicin pharmacokinetics
1246500|NCT00969449|Naproxen Sodium
1246501|NCT00969436|Mumps
1246502|NCT00969436|Immunogenicity
1246503|NCT00969436|Vaccines
1246504|NCT00969436|Safety
1246505|NCT00969436|Rubella
1246506|NCT00969436|Combined Vaccine
1246507|NCT00969436|Varicella Vaccine
1246508|NCT00969436|Children
1246509|NCT00969436|Measles
1246510|NCT00969436|Humans
1246511|NCT00969423|persistent pain
1246512|NCT00969423|neuropathic pain
1246513|NCT00969423|Chronic Pain
1246514|NCT00969423|VATS
1246515|NCT00969423|Primary spontaneous pneumothorax patients
1246516|NCT00969410|Neoplasms
1246517|NCT00969410|Neoplasm metastasis
1246518|NCT00969410|Liver neoplasms
1246519|NCT00969410|Neoplastic processes
1246520|NCT00969410|Pathologic processes
1246521|NCT00969410|Digestive system neoplasms
1246522|NCT00969410|Neoplasms by site
1246523|NCT00969410|Digestive system diseases
1246524|NCT00969410|Liver diseases
1246525|NCT00969397|Birthmark
1246526|NCT00969397|PWS
1246527|NCT00969384|Physical health
1246528|NCT00969384|Mental illness
1246529|NCT00969384|prevention
1246530|NCT00969384|Waist circumference
1246531|NCT00969371|posterior chamber intraocular lens
1246532|NCT00969371|PCIOL
1246533|NCT00969371|IOL
1246534|NCT00969345|Healthy Elderly Subjects
1246535|NCT00969345|Respiratory Yoga Exercises
1246536|NCT00969345|Heart Rate Variability
1246537|NCT00969345|Baroreflex
1246538|NCT00969345|Quality of Life
1246539|NCT00969332|liver
1246540|NCT00969332|Parenteral Nutrition
1246541|NCT00969332|fish oil
1246542|NCT00969332|Omegaven
1246543|NCT00969332|children
1246544|NCT00969319|Octocog alfa
1246545|NCT00969319|Hemophilia A
1246546|NCT00969293|Macular Edema
1246547|NCT00969293|Occlusive retinal vascular disease
1246548|NCT00969293|Central Retinal Vein Occlusion
1246549|NCT00969293|CRVO
1246550|NCT00969280|Acupuncture
1246551|NCT00969280|Dry eye syndrome
1246552|NCT00969280|Ocular Surface Disease Index
1246553|NCT00969280|Schirmer test
1246554|NCT00969280|Tear film Break-up time
1246555|NCT00969267|ear acupuncture
1246556|NCT00969267|obese
1246557|NCT00969267|obese women
1246558|NCT00969267|women
1246559|NCT00969254|Pílulas de Lussen
1246560|NCT00969254|Efficacy
1246561|NCT00969254|Safety
1246562|NCT00969254|Dysuria
1246563|NCT00969254|Symptomatic control
1246564|NCT00969241|saliva
1246565|NCT00969241|free-radicals
1246566|NCT00969241|periodontitis
1246567|NCT00969228|Gastroenteritis
1246568|NCT00970216|HBV DNA non-detectability
1246569|NCT00970203|Vaccine
1246570|NCT00970203|Androgen Ablation
1246571|NCT00970203|PSA Progression
1246572|NCT00970190|sinusitis
1246573|NCT00970177|Pandemic influenza vaccine
1246574|NCT00970151|Fetal Inflammation
1246575|NCT00970151|Birth Outcome
1246576|NCT00970151|Pregnancy
1246577|NCT00970138|Progress free survival
1246578|NCT00970138|Toxicity
1246579|NCT00970138|Response rate
1246580|NCT00970138|Overall survival
1246581|NCT00970138|Quality of live
1246582|NCT00970125|advance care planning
1246583|NCT00970125|cancer
1246584|NCT00970112|pain
1246585|NCT00970112|pain assessment
1246586|NCT00970086|measure of postoperative pain
1246587|NCT00970086|children undergoing groin surgery
1246588|NCT00970073|calcineurin inhibitor delay
1246589|NCT00970073|Kidney
1246590|NCT00970060|neuropathy
1246591|NCT00970060|diabetes
1246592|NCT00970047|pregnant
1246593|NCT00970047|fetal sex determination
1246594|NCT00970047|gender determination
1246595|NCT00970047|noninvasive test
1246596|NCT00970047|fetal DNA
1246597|NCT00970034|Atrial fibrillation, apoptosis, oligonucleotide microarray
1246598|NCT00970008|Osteoarthritis
1246599|NCT00970008|Knee
1246600|NCT00969995|inflammation
1246601|NCT00969995|migraine
1246602|NCT00969995|headache
1246603|NCT00969982|Pregnancy termination
1246604|NCT00969982|abortion
1246605|NCT00969982|medical abortion
1246606|NCT00969982|2nd trimester
1246607|NCT00969982|mifepristone
1246608|NCT00969982|misoprostol
1246609|NCT00969969|First MTP Joint
1246610|NCT00969969|Hallux Rigidus
1246611|NCT00969969|Hallux Limitus
1246612|NCT00969969|Cartilage Replacement
1246613|NCT00969969|Osteoarthritis
1246614|NCT00969969|First MTP Joint Osteoarthritis
1246615|NCT00969969|Big Toe Pain
1246616|NCT00969956|Diabetes, Complication, Cardio-vascular disease
1246617|NCT00969943|HPA axis
1246618|NCT00969930|COMT
1246619|NCT00969930|ApoE
1246620|NCT00969930|BDNF
1246621|NCT00969930|executive function
1246622|NCT00969930|bipolar
1246623|NCT00969930|cognition
1246624|NCT00969930|Cognitive deficits and Bipolar disease type I
1246625|NCT00969878|Cocaine Vaccine, TA-CD 09
1246626|NCT00969865|Atherosclerosis
1246627|NCT00969852|Sertraline
1246628|NCT00969852|PET
1246629|NCT00969852|Serotonin receptor occupancy
1246630|NCT00969852|PK-PD Model
1246631|NCT00969839|Fracture
1246632|NCT00969839|Humerus
1246633|NCT00969839|Intramedullary
1246634|NCT00969839|Fixation
1246635|NCT00969826|GCPGC
1246636|NCT00969826|Pharmacokinetics
1246637|NCT00969826|Pharmacodynamics
1246638|NCT00969813|Hepatic impairment
1246639|NCT00969800|Common cold
1246640|NCT00969800|Influenza
1246641|NCT00969800|Pneumonia
1246642|NCT00969774|Face
1246643|NCT00969774|Cephalometry
1246644|NCT00969774|Anthropometry
1246645|NCT00969774|Photography
1246646|NCT00969774|Diagnosis
1246647|NCT00969774|Adult
1246648|NCT00969774|Morphology
1246649|NCT00969774|Comparative Study
1246650|NCT00969735|Atrial fibrillation
1246651|NCT00969735|Catheter ablation
1246652|NCT00969735|Cryoenergy
1246653|NCT00969735|Implantable loop recorder
1246654|NCT00969735|Pulmonary vein
1246655|NCT00969722|Neuroblastoma
1246656|NCT00969722|3F8
1246657|NCT00969722|Primary refractory
1246658|NCT00969709|Depression
1246659|NCT00969709|Major Depressive Disorder
1246660|NCT00969696|ability to learn, working memory
1246661|NCT00969657|rectal cancer stage I-III
1246662|NCT00969657|concurrent chemoradiotherapie
1246663|NCT00969657|response prediction
1246664|NCT00969631|Polycystic ovary syndrome
1246665|NCT00969631|clomiphene resistance
1246666|NCT00969631|metformin
1246667|NCT00969631|laparoscopic ovarian diathermy
1246668|NCT00969618|ADHD
1246669|NCT00969605|weaning
1246670|NCT00969605|adaptive support ventilation
1246671|NCT00969605|COPD
1246672|NCT00969592|diabetes
1246673|NCT00969579|Cancer
1246674|NCT00969579|Psychosocial Stress
1246675|NCT00969579|Parenting
1246676|NCT00969566|Diabetes
1246677|NCT00969566|Sitagliptin
1246678|NCT00969566|C-peptide
1246679|NCT00969566|Glucagon
1246680|NCT00969540|Back Pain
1246681|NCT00969540|Sleep
1246682|NCT00969527|Oncoxin
1246683|NCT00969527|Viusid
1246684|NCT00969527|dietary supplements
1246685|NCT00969527|rheumatoid arthritis
1246686|NCT00969514|Robotic cystectomy
1246687|NCT00969514|Bladder
1246688|NCT00969488|matern diet
1246689|NCT00969488|obese
1246690|NCT00969488|postpartum
1246691|NCT00969488|body weight change
1246692|NCT00969488|Women with overweight
1246693|NCT00969215|burn scar
1246694|NCT00969215|fractional carbon dioxide laser
1246695|NCT00969215|scar revision
1246696|NCT00969202|Prostate Cancer
1246697|NCT00969202|Cancer of the Prostate
1246698|NCT00969202|Prostate Tumor
1246699|NCT00969202|Novalis Tx
1246700|NCT00969202|Novalis
1246701|NCT00969202|Stereotactic Radiosurgery
1246702|NCT00969202|Radiosurgery
1246703|NCT00969202|Radiation
1246704|NCT00969189|anesthesia
1246705|NCT00969189|child
1246706|NCT00969189|infant
1246707|NCT00969189|laryngeal mask
1246708|NCT00969176|pain
1246709|NCT00969176|fever
1246710|NCT00969176|neonate
1246711|NCT00969176|preterm
1246712|NCT00969176|term
1246713|NCT00969176|newborn
1246714|NCT00969163|Biomarkers of Skin Androgenization
1246715|NCT00969150|Major Depressive Disorder
1246716|NCT00969150|Depression
1246717|NCT00969137|smoking, nicotine, cigarettes
1246718|NCT00969124|colonoscopy
1246719|NCT00969124|polyps
1246720|NCT00969124|adenomas
1246721|NCT00969124|miss rates
1246722|NCT00969111|Proton Radiation, Prostate Cancer
1246723|NCT00969098|Histologically proven of Malignant pleural mesothelioma;
1246724|NCT00969098|Patients not candidate to radical surgery;
1246725|NCT00969098|Candidate to first-line pemetrexed-based chemotherapy;
1246726|NCT00969085|Cutaneous T-cell lymphoma
1246727|NCT00969085|Skin
1246728|NCT00969085|Mycosis fungoides
1246729|NCT00969085|MF
1246730|NCT00969085|Sézary syndrome
1246731|NCT00969085|SS
1246732|NCT00969085|Curcumin
1246733|NCT00969085|Turmeric
1246734|NCT00969072|GI198745
1246735|NCT00969072|Long term extension study
1246736|NCT00969072|BPH
1246737|NCT00969059|peripheral nerve injury
1246738|NCT00969059|p38 kinase inhibitor
1246739|NCT00969059|neuropathic pain
1246740|NCT00969046|Colon cancer
1246741|NCT00969046|MTD
1246742|NCT00969046|DLT
1246743|NCT00969046|EPO906
1246744|NCT00969046|patupilone
1246745|NCT00969020|Length of stay
1246746|NCT00969020|Timed up and go
1246747|NCT00968994|Wound Healing
1246748|NCT00968994|Wound Infection
1246749|NCT00968981|Hedgehog
1246750|NCT00968981|BCC
1246751|NCT00968981|basal cell carcinoma
1246752|NCT00968955|Postoperative acute pain
1246753|NCT00968955|Total hip arthroplasty
1246754|NCT00968955|Local infiltration analgesia
1246755|NCT00968942|Lateral Canthal Lines
1246756|NCT00968942|Crow's Feet
1246757|NCT00968942|Facial Wrinkles
1246758|NCT00968929|pulmonary embolism
1246759|NCT00968929|thrombolysis
1246760|NCT00968929|massive
1246761|NCT00968929|submassive
1246762|NCT00968929|recombinant streptokinase
1246763|NCT00968929|urokinase
1246764|NCT00968903|Hip arthroplasty
1246765|NCT00968903|Methylprednisolone
1246766|NCT00968903|Post-operative pain
1246767|NCT00968890|GSK Bio's influenza vaccine GSK2340272A
1246768|NCT00968890|Influenza infection
1246769|NCT00968877|Renal Insufficiency
1246770|NCT00968877|Cholecalciferol
1246771|NCT00968877|Kidney Disease
1246772|NCT00968877|Kidney Failure
1246773|NCT00968877|Vitamin D
1246774|NCT00968877|Vitamin D Deficiency
1246775|NCT00968877|Vitamin D3
1246776|NCT00968864|T cell depleted
1246777|NCT00968864|Matched unrelated donors
1246778|NCT00968864|Haplocompatible donors
1246779|NCT00968851|Schizophrenia
1246780|NCT00968851|Central nervous System Diseases
1246781|NCT00968851|Cognition
1246782|NCT00968838|White Blood Cell Transfusion
1246783|NCT00968838|Radiated Cells
1246784|NCT00968838|Unradiated Cells
1246785|NCT00968838|Leukocyte Transfusions
1246786|NCT00968838|Life-threatening Infections
1246787|NCT00968825|Lateral Canthal Lines
1246788|NCT00968825|Crow's Feet
1246789|NCT00968825|Facial Wrinkles
1246790|NCT00968812|Diabetes
1246791|NCT00968812|Metformin
1246792|NCT00968812|Glimepiride
1246793|NCT00968812|Hemoglobin A1c
1246794|NCT00968812|Type 2 diabetes mellitus
1246795|NCT00968812|Canagliflozin
1246796|NCT00968799|Ovarian Neoplasms
1246797|NCT00968799|Recurrence
1246798|NCT00968799|Hyperthermia, Induced
1246799|NCT00968799|Peritoneal Neoplasms
1246800|NCT00968799|recurrent epithelial ovarian cancer
1246801|NCT00968799|recurrent fallopian tube carcinoma
1246802|NCT00968786|hypertension
1246803|NCT00968786|type 2 diabetes
1246804|NCT00968786|home monitoring
1246805|NCT00968773|inguinal hernia
1246806|NCT00968773|mesh
1246807|NCT00968773|hernia repair device
1246808|NCT00968760|CD19+ lymphoid malignancies
1246809|NCT00968760|non-Hodgkin's Lymphoma
1246810|NCT00968760|NHL
1246811|NCT00968760|small lymphocytic lymphoma
1246812|NCT00968760|SLL
1246813|NCT00968760|follicular lymphoma
1246814|NCT00968760|mantle cell lymphoma
1246815|NCT00968760|gene cell transfer
1246816|NCT00968760|CD19-specific T cells
1246817|NCT00968760|Stem Cell Transplant
1246818|NCT00968760|T Cell Infusion
1246819|NCT00968760|Chemotherapy
1246820|NCT00968760|Leukapheresis
1246821|NCT00968760|BCNU
1246822|NCT00968760|carmustine
1246823|NCT00968760|Cytarabine
1246824|NCT00968760|Etoposide
1246825|NCT00968760|Interleukin-2
1246826|NCT00968760|Proleukin
1246827|NCT00968760|Melphalan
1246828|NCT00968760|Rituximab
1246829|NCT00968760|T cell therapy
1246830|NCT00968747|Fasting
1246831|NCT00968747|Fast
1246832|NCT00968747|healthy
1246833|NCT00968747|diet
1246834|NCT00968747|study
1246835|NCT00968747|manipulation
1246836|NCT00968747|dietary
1246837|NCT00968747|FGF21
1246838|NCT00968747|Fibroblast growth factor
1246839|NCT00968747|PTRF
1246840|NCT00968747|Polymerase 1 and transcript release factor
1246841|NCT00968747|adipose
1246842|NCT00968747|fat
1246843|NCT00968747|blood
1246844|NCT00968747|inpatient
1246845|NCT00968747|outpatient
1246846|NCT00968747|NAFLD
1246847|NCT00968747|metabolism
1246848|NCT00968734|Vitamin D
1246849|NCT00968734|colecalciferol
1246850|NCT00968734|absorption by Vitamin D
1246851|NCT00968721|Inflammatory bowel disease
1246852|NCT00968721|Crohn's disease
1246853|NCT00968721|Ulcerative colitis
1246854|NCT00968721|medication adherence
1246855|NCT00968721|Decisional influences
1246856|NCT00968708|Diabetes Mellitus - Type 2
1246857|NCT00968708|Diabetes Mellitus
1246858|NCT00968708|cardiovascular outcomes
1246859|NCT00968708|heart attack
1246860|NCT00968708|stroke
1246861|NCT00968708|dipeptidyl-peptidase IV inhibitors
1246862|NCT00968708|metabolic disorders
1246863|NCT00968708|metabolic diseases
1246864|NCT00968708|glucose metabolism disorders
1246865|NCT00968682|cardiac toxicity
1246866|NCT00968682|HER2-positive breast cancer
1246867|NCT00968682|stage IA breast cancer
1246868|NCT00968682|stage IB breast cancer
1246869|NCT00968682|stage II breast cancer
1246870|NCT00968682|stage IIIA breast cancer
1246871|NCT00968682|stage IIIB breast cancer
1246872|NCT00968682|stage IIIC breast cancer
1246873|NCT00968656|Breast cancer
1246874|NCT00968656|Head and Neck Cancer
1246875|NCT00968656|Diffuse Large B-cell lymphoma
1246876|NCT00968656|Cellular proliferation
1246877|NCT00968643|spinal cord compression
1246878|NCT00968643|unspecified adult solid tumor, protocol specific
1246879|NCT00968617|Anemia
1246880|NCT00968604|Pancreatic Cancer
1246881|NCT00968604|Pancreas
1246882|NCT00968604|Liver
1246883|NCT00968604|Liver Tumor Biopsy
1246884|NCT00968604|BikDD Nanoparticle
1246885|NCT00968604|C-VISA BikDD
1246886|NCT00968591|Hepatic insufficiency
1246887|NCT00968591|liver disease
1246888|NCT00968591|cirrhosis
1246889|NCT00968591|pharmacokinetics
1246890|NCT00968578|Knee arthroplasty
1246891|NCT00968578|Methylprednisolone
1246892|NCT00968578|Post-operative pain
1246893|NCT00968565|Heart Defects, Congenital
1246894|NCT00968565|Extracorporeal Membrane Oxygenation
1246895|NCT00968565|Citric Acid
1246896|NCT00968565|Heparin
1246897|NCT00968565|Respiratory Insufficiency
1246898|NCT00968552|Any Gastrointestinal problem that would require an endoscopically placed stent
1246899|NCT00968539|GSK Bio's influenza vaccine GSK2340272A
1246900|NCT00968539|influenza infection
1246901|NCT00968526|influenza infection
1246902|NCT00968526|GSK Bio's influenza vaccine GSK2340272A
1246903|NCT00968513|Smoking Cessation, Inpatient Psychiatry, Stages of Change
1246904|NCT00968500|Grief
1246905|NCT00968500|bereavement
1246906|NCT00968500|questionnaires
1246907|NCT00968500|09-107
1246908|NCT00968487|Lyophilized Plasma
1246909|NCT00968487|Fresh Frozen Plasma
1246910|NCT00968487|Hemorrhage
1246911|NCT00968487|Coagulopathy
1246912|NCT00968487|Autologous
1246913|NCT00968487|HemCon
1246914|NCT00968487|Plasmapheresis
1246915|NCT00968487|Freeze Drying
1246916|NCT00968487|Transfusion
1246917|NCT00968487|Resuscitation
1246918|NCT00968487|Safety of Lyophilized Plasma in Normal, Healthy Volunteers
1246919|NCT00968461|Chronic lymphocytic leukemia
1246920|NCT00968461|CLL
1246921|NCT00968461|PEITC
1246922|NCT00968461|Phenethyl Isothiocyanate
1246923|NCT00968461|Fludarabine
1246924|NCT00968448|respiratory muscle
1246925|NCT00968448|breathing pattern
1246926|NCT00968448|exercise performance
1246927|NCT00968435|bevacizumab
1246928|NCT00968435|cisplatin
1246929|NCT00968435|cetuximab
1246930|NCT00968435|radiation therapy
1246931|NCT00968435|Phase II
1246932|NCT00968435|09-083
1246933|NCT00968422|Pharmacology
1246934|NCT00968422|Drug Safety
1246935|NCT00968422|Phase 1 Clinical Trials
1246936|NCT00968422|Pharmacokinetics
1246937|NCT00968409|Breast Cancer
1246938|NCT00968409|Hormone Receptor
1246939|NCT00968396|Myeloma
1246940|NCT00968396|Ex-Vivo Depletion of Myeloma Cells
1246941|NCT00968396|Peripheral Blood Progenitor Cell Grafts
1246942|NCT00968396|PBPC
1246943|NCT00968396|Stem Cell Transplant
1246944|NCT00968396|Bone marrow stem cells
1246945|NCT00968396|Melphalan
1246946|NCT00968396|Alkeran
1246947|NCT00968396|Apheresis
1246948|NCT00968383|Acute Coronary Syndrome
1246949|NCT00968383|Myocardial infarction
1246950|NCT00968383|Infarct Related Artery
1246951|NCT00968383|Percutaneous Coronary Intervention
1246952|NCT00968383|Medical treatment
1246953|NCT00968383|Tissue Viability
1246954|NCT00968383|Magnetic Resonance
1246955|NCT00968370|Severe and very severe pneumonia
1246956|NCT00968370|severe malnutrition
1246957|NCT00968370|children
1246958|NCT00968370|day-care management
1246959|NCT00968370|hospital management
1246960|NCT00968357|SCV-07
1246961|NCT00968357|relapsers
1246962|NCT00968357|Hepatitis C
1246963|NCT00968331|relapsed and refractory DLBCL
1246964|NCT00968318|Tissue expander
1246965|NCT00968318|seroma
1246966|NCT00968318|extrusion
1246967|NCT00968318|lymphatics
1246968|NCT00968318|deep fascia
1246969|NCT00968318|Rate of seroma formation after excision of strip of deep fascia
1246970|NCT00968305|African American children with stable asthma
1246971|NCT00968305|Asthma severity
1246972|NCT00968305|Interleukin 13 from PHA stimulated PBMC
1246973|NCT00968305|Lung function (FEV1%)
1246974|NCT00968305|Total serum IgE
1246975|NCT00968305|Pediatrics
1246976|NCT00968292|K3 Promoter prosthetic foot Tensegrity Prosthetics Jerome Rifkin
1246977|NCT00968279|Patients with atrial fibrillation
1246978|NCT00968266|Adherence
1246979|NCT00968266|Compliance
1246980|NCT00968266|Rheumatoid Arthritis
1246981|NCT00968266|Intervention
1246982|NCT00968266|Beliefs about medication
1246983|NCT00968266|Motivational Interviewing
1246984|NCT00968266|Medication adherence
1246985|NCT00968266|Patient compliance
1246986|NCT00968266|Intervention studies
1246987|NCT00968253|Acute Lymphocytic Leukemia
1246988|NCT00968253|ALL
1246989|NCT00968253|Hyper-CVAD
1246990|NCT00968253|Everolimus
1246991|NCT00968253|6-mercaptopurine
1246992|NCT00968253|Citrovorum
1246993|NCT00968253|Cyclophosphamide
1246994|NCT00968253|Cytarabine
1246995|NCT00968253|Dexamethasone
1246996|NCT00968253|Doxorubicin
1246997|NCT00968253|G-CSF
1246998|NCT00968253|Methotrexate
1246999|NCT00968253|MESNA
1247000|NCT00968253|Pegfilgrastim
1247001|NCT00968253|Prednisone
1247002|NCT00968253|RAD001
1247003|NCT00968253|Solumedrol
1247004|NCT00968253|Vincristine Sulfate
1247005|NCT00968240|GBM
1247006|NCT00968240|AA
1247007|NCT00968240|AO
1247008|NCT00968240|Brain
1247009|NCT00968240|Tumors
1247010|NCT00968240|Malignant
1247011|NCT00968240|Glioblastoma
1247012|NCT00968240|Multiforme
1247013|NCT00968240|Anaplastic
1247014|NCT00968240|Astrocytoma
1247015|NCT00968227|subarachnoid hemorrhage
1247016|NCT00968227|vasospasm
1247017|NCT00968227|transfusion
1247018|NCT00968227|cerebral oxygen delivery
1247019|NCT00968227|hemoglobin
1247020|NCT00968214|stage IA breast cancer
1247021|NCT00968214|stage IB breast cancer
1247022|NCT00968214|stage II breast cancer
1247023|NCT00968214|stage IIIA breast cancer
1247024|NCT00968214|stage IIIB breast cancer
1247025|NCT00968214|stage IIIC breast cancer
1247026|NCT00968214|estrogen receptor-positive breast cancer
1247027|NCT00968214|progesterone receptor-positive breast cancer
1247028|NCT00968188|HIV Risk
1247029|NCT00968188|Internet Intervention
1247030|NCT00968188|Homosexuality, Male
1247031|NCT00968188|HIV Seronegativity
1247032|NCT00968175|Ultrasound guided celiac plexus neurolysis
1247033|NCT00968175|CPN
1247034|NCT00968175|Pancreatic Cancer
1247035|NCT00968175|Pain Management
1247036|NCT00968162|Bone Marrow Transplant
1247037|NCT00968162|Sickle Cell Disease
1247038|NCT00968136|refractory infantile spasms
1247039|NCT00968110|Milk Allergy
1247040|NCT00968097|Alzheimer' disease
1247041|NCT00968097|SPECT imaging
1247042|NCT00968084|Diagnostic Work Up
1247043|NCT00968084|Normal Volunteers
1247044|NCT00968084|HV
1247045|NCT00968084|Inflammatory Disease
1247046|NCT00968084|Autoimmune Disease
1247047|NCT00968084|Immunologic Disease
1247048|NCT00968084|Healthy Volunteer
1247049|NCT00968071|Leukemia
1247050|NCT00968071|AML
1247051|NCT00968071|MDS
1247052|NCT00968071|High-Risk Myelodysplastic Syndrome
1247053|NCT00968071|Decitabine
1247054|NCT00968071|5-aza-2 deoxycytidine
1247055|NCT00968071|Dacogen
1247056|NCT00968071|Gemtuzumab Ozogamicin
1247057|NCT00968071|Mylotarg
1247058|NCT00968058|Leak Pressure
1247059|NCT00968058|Intubation, Endotracheal
1247060|NCT00968058|Pediatric
1247061|NCT00968058|Temporal Variation
1247062|NCT00968045|Fibrinogen
1247063|NCT00968045|Postoperative bleeding
1247064|NCT00968045|Transfusions
1247065|NCT00968045|CABG
1247066|NCT00968032|PFO
1247067|NCT00968032|Patent Foramen Ovale
1247068|NCT00968006|diabetes
1247069|NCT00968006|endothelium
1247070|NCT00968006|stem cells
1247071|NCT00967993|hyperphosphatemia
1247072|NCT00967993|end-stage renal disease
1247073|NCT00967993|ESRD
1247074|NCT00967993|hemodialysis
1247075|NCT00967993|diabetes
1247076|NCT00967993|dialysis
1247077|NCT00967980|pain
1247078|NCT00967980|Hip Resurfacing
1247079|NCT00967980|catheter
1247080|NCT00967980|nerve block
1247081|NCT00967980|UCSD
1247082|NCT00967980|hip surgery
1247083|NCT00967980|psoas
1247084|NCT00967980|femoral
1247085|NCT00967980|ambulation
1247086|NCT00967980|hip flexion
1247087|NCT00967980|infusion
1247088|NCT00967967|control
1247089|NCT00967967|symptoms
1247090|NCT00967954|stage IIB prostate cancer
1247091|NCT00967954|stage IIA prostate cancer
1247092|NCT00967954|stage III prostate cancer
1247093|NCT00967954|stage IV prostate cancer
1247094|NCT00967941|Vascular Surgery
1247095|NCT00967928|Stage IV or Recurrent Cervical cancer
1247096|NCT00967915|Ankyloglossia
1247097|NCT00967915|Tongue tie
1247098|NCT00967915|Frenotomy
1247099|NCT00967915|Frenulectomy
1247100|NCT00967915|Breast feeding
1247101|NCT00967915|HATLFF
1247102|NCT00967915|IBFAT
1247103|NCT00967902|intracoronary stent
1247104|NCT00967902|drug eluting stent
1247105|NCT00967902|sirolimus
1247106|NCT00967902|endothelial progenitor cells
1247107|NCT00967889|stage III prostate cancer
1247108|NCT00967889|stage IV prostate cancer
1247109|NCT00967889|recurrent prostate cancer
1247110|NCT00967876|Men or women of any ethnic group scheduled to undergo conventional coronary angiography for suspected coronary artery stent stenosis
1247111|NCT00967863|adenocarcinoma of the prostate
1247112|NCT00967863|stage III prostate cancer
1247113|NCT00967863|stage IV prostate cancer
1247114|NCT00967850|High Myopia
1247115|NCT00967850|Bevacizumab
1247116|NCT00967850|Photodynamic therapy
1247117|NCT00967837|Diabetes with complications
1247118|NCT00967837|Wound healing
1247119|NCT00967824|breast cancer
1247120|NCT00967798|cystic fibrosis
1247121|NCT00967798|diabetes
1247122|NCT00967798|inflammation
1247123|NCT00967798|oxidative stress
1247124|NCT00967798|redox balance
1247125|NCT00967798|lung disease
1247126|NCT00967785|WHIM
1247127|NCT00967785|Mozobil (TM)
1247128|NCT00967785|Neutrophil Disorder
1247129|NCT00967785|Plerixafor
1247130|NCT00967772|Pharmacokinetics
1247131|NCT00967772|Safety
1247132|NCT00967772|tolerability
1247133|NCT00967759|common cold
1247134|NCT00967759|treatment
1247135|NCT00967759|inflammatory symptoms of superior air passages affection
1247136|NCT00967694|Glaucoma
1247137|NCT00967694|Nitrous oxide
1247138|NCT00967668|Counseling
1247139|NCT00967668|Veterans
1247140|NCT00967668|Weight loss
1247141|NCT00967668|Physical activity
1247142|NCT00967668|Diet
1247143|NCT00967655|adenocarcinoma of the rectum
1247144|NCT00967655|stage I rectal cancer
1247145|NCT00967655|stage II rectal cancer
1247146|NCT00967655|stage III rectal cancer
1247276|NCT00967239|ductal breast carcinoma in situ
1247147|NCT00967642|Patients with Diabetes Mellitus Submitted to Percutaneous Coronary Intervention with Stent
1247148|NCT00967629|Diabetic nephropathy
1247149|NCT00967629|CKD progression
1247150|NCT00967629|AGEs
1247151|NCT00967629|oxidative stress
1247152|NCT00967629|dietary AGEs
1247153|NCT00967616|metastatic
1247154|NCT00967616|colon
1247155|NCT00967616|rectum
1247156|NCT00967616|combination
1247157|NCT00967616|chemotherapy
1247158|NCT00967603|adenocarcinoma of the pancreas
1247159|NCT00967603|stage IV pancreatic cancer
1247160|NCT00967564|Myelodysplastic Syndrome
1247161|NCT00967564|Quality of Life
1247162|NCT00967564|Anemia
1247163|NCT00967564|Epoetin alfa
1247164|NCT00967564|Eprex
1247165|NCT00967551|Diarrhea
1247166|NCT00967551|Pneumonia
1247167|NCT00967551|Upper respiratory infections
1247168|NCT00967551|Acute gastroenteritis
1247169|NCT00967538|psoriasis
1247170|NCT00967538|etanercept
1247171|NCT00967538|efficacy
1247172|NCT00967538|response
1247173|NCT00967538|anti-TNF alpha
1247174|NCT00967538|treatment efficacy
1247175|NCT00967525|AML
1247176|NCT00967525|ALL
1247177|NCT00967525|leukemia
1247178|NCT00967525|CML
1247179|NCT00967525|Myelodysplastic Syndrome
1247180|NCT00967525|malignancies
1247181|NCT00967525|Undifferentiated leukemia
1247182|NCT00967525|High risk malignancies
1247183|NCT00967512|Oligonucleotides, Antisense
1247184|NCT00967512|Tumor Suppressor Protein p53
1247185|NCT00967512|idarubicin
1247186|NCT00967512|cytarabine
1247187|NCT00967499|PONV
1247188|NCT00967499|rescue
1247189|NCT00967473|Astigmatism
1247190|NCT00967473|cataract
1247191|NCT00967473|corneal astigmatism
1247192|NCT00967473|IOL
1247193|NCT00967473|AcrySof
1247194|NCT00967460|Childhood obesity
1247195|NCT00967460|Children
1247196|NCT00967460|Inactivity
1247197|NCT00967460|Physical activity
1247198|NCT00967460|Motor skills
1247199|NCT00967460|Motor fitness
1247200|NCT00967460|Quality of life
1247201|NCT00967460|Nutrition
1247202|NCT00967460|Family
1247203|NCT00967434|infarction
1247204|NCT00967434|ischemia
1247205|NCT00967434|surgery
1247206|NCT00967434|perioperative
1247207|NCT00967434|statins
1247208|NCT00967421|Driving
1247209|NCT00967421|DUI
1247210|NCT00967421|Driving simulation
1247211|NCT00967421|Drugs
1247212|NCT00967421|Ethanol
1247213|NCT00967408|Stroke
1247214|NCT00967408|Antidepressive Agents,Second-Generation
1247215|NCT00967408|Treatment Outcome
1247216|NCT00967408|Rehabilitation
1247217|NCT00967382|Pregnancy
1247218|NCT00967382|Thrombophilia
1247219|NCT00967382|High-risk pregnancy
1247220|NCT00967382|LMWH prophylaxis
1247221|NCT00967382|Placenta mediated pregnancy complications
1247222|NCT00967369|Lymphoma
1247223|NCT00967369|Classical Hodgkin Lymphoma
1247224|NCT00967369|Cancer
1247225|NCT00967369|Bortezomib
1247226|NCT00967369|Velcade
1247227|NCT00967369|Chemotherapy
1247228|NCT00967369|ICE
1247229|NCT00967369|Ifosfamide
1247230|NCT00967369|Ifex
1247231|NCT00967369|Mesna
1247232|NCT00967369|Mesnex
1247233|NCT00967369|Carboplatin
1247234|NCT00967369|Paraplatin
1247235|NCT00967369|Etoposide
1247236|NCT00967369|VePesid
1247237|NCT00967369|BICE
1247238|NCT00967369|Pegfilgrastim
1247239|NCT00967369|Neulasta
1247240|NCT00967356|Healthy volunteers
1247241|NCT00967343|Haploidentical stem cell transplantation
1247242|NCT00967343|Graft-versus-host disease
1247243|NCT00967343|Immune reconstitution
1247244|NCT00967343|Alloreactive T-cells
1247245|NCT00967343|Photodepletion
1247246|NCT00967343|TH9402
1247247|NCT00967343|Transplant related mortality
1247248|NCT00967343|Hematologic malignancy
1247249|NCT00967317|Auris-Sedina
1247250|NCT00967317|Otitis
1247251|NCT00967317|Efficacy
1247252|NCT00967317|Tolerability
1247253|NCT00967304|Unprovoked Venous thromboembolism
1247254|NCT00967304|Clinical decision rule
1247255|NCT00967304|Anticoagulants
1247256|NCT00967304|Recurrence
1247257|NCT00967304|Prognostic
1247258|NCT00967304|Risk stratification
1247259|NCT00967291|acinar cell adenocarcinoma of the pancreas
1247260|NCT00967291|duct cell adenocarcinoma of the pancreas
1247261|NCT00967291|stage IV pancreatic cancer
1247262|NCT00967291|recurrent pancreatic cancer
1247263|NCT00967278|OPCAB
1247264|NCT00967278|pulmonary artery catheter
1247265|NCT00967278|esophageal doppler
1247266|NCT00967278|hemodynamics
1247267|NCT00967265|Introduction seminar
1247268|NCT00967265|Psychoeducation
1247269|NCT00967265|Waiting list
1247270|NCT00967265|Patient participation
1247271|NCT00967265|Mental disorders
1247272|NCT00967252|surgery
1247273|NCT00967252|inflammation
1247274|NCT00967252|infection
1247275|NCT00967252|statins
1247277|NCT00967239|invasive ductal breast carcinoma
1247278|NCT00967239|invasive lobular breast carcinoma
1247279|NCT00967239|invasive lobular breast carcinoma with predominant in situ component
1247280|NCT00967226|hemangioma
1247281|NCT00967200|adult anaplastic astrocytoma
1247282|NCT00967200|adult diffuse astrocytoma
1247283|NCT00967200|adult glioblastoma
1247284|NCT00967200|adult giant cell glioblastoma
1247285|NCT00967200|adult gliosarcoma
1247286|NCT00967200|adult pilocytic astrocytoma
1247287|NCT00967200|adult pineal gland astrocytoma
1247288|NCT00967200|adult subependymal giant cell astrocytoma
1247289|NCT00967200|adult brain stem glioma
1247290|NCT00967200|adult choroid plexus tumor
1247291|NCT00967200|adult craniopharyngioma
1247292|NCT00967200|adult ependymoblastoma
1247293|NCT00967200|adult medulloblastoma
1247294|NCT00967200|adult supratentorial primitive neuroectodermal tumor (PNET)
1247295|NCT00967200|adult anaplastic ependymoma
1247296|NCT00967200|adult ependymoma
1247297|NCT00967200|adult myxopapillary ependymoma
1247298|NCT00967200|adult subependymoma
1247299|NCT00967200|meningeal melanocytoma
1247300|NCT00967200|adult meningeal hemangiopericytoma
1247301|NCT00967200|adult grade I meningioma
1247302|NCT00967200|adult grade II meningioma
1247303|NCT00967200|adult anaplastic meningioma
1247304|NCT00967200|adult papillary meningioma
1247305|NCT00967200|adult anaplastic oligodendroglioma
1247306|NCT00967200|adult oligodendroglioma
1247307|NCT00967200|adult pineoblastoma
1247308|NCT00967200|adult pineocytoma
1247309|NCT00967200|adult mixed glioma
1247310|NCT00967200|recurrent adult brain tumor
1247311|NCT00967161|knee replacement motion analysis
1247312|NCT00967135|Thoracotomy
1247313|NCT00967135|Neuropathic pain
1247314|NCT00967122|adjustment, hunger
1247315|NCT00967122|Hunger/satiety changes before and after gastric band adjustment
1247316|NCT00967109|Anemia
1247317|NCT00967109|Tissue oxygenation
1247318|NCT00967109|Spine surgery
1247319|NCT00967096|rifaximin
1247320|NCT00967096|acute graft versus host disease
1247321|NCT00967096|bone marrow transplant
1247322|NCT00967096|non-malignancy requiring BMT
1247323|NCT00967083|Quality of Life
1247324|NCT00967083|Questionnaires
1247325|NCT00967083|Interviews
1247326|NCT00967083|family members
1247327|NCT00967083|care givers
1247328|NCT00967083|09-104
1247329|NCT00967057|recurrent childhood acute lymphoblastic leukemia
1247330|NCT00967057|T-cell childhood acute lymphoblastic leukemia
1247331|NCT00967044|Relapsed or Refractory Lymphoma
1247332|NCT00967044|Hodgkin's lymphoma
1247333|NCT00967044|Non Hodgkin's Lymphoma
1247334|NCT00967044|NHL
1247335|NCT00967044|LBH589
1247336|NCT00967044|Panobinostat
1247337|NCT00967044|RAD001
1247338|NCT00967044|Everolimus
1247339|NCT00967031|HER2-positive breast cancer
1247340|NCT00967031|male breast cancer
1247341|NCT00967031|stage IV breast cancer
1247342|NCT00967031|tumors metastatic to brain
1247343|NCT00967018|Safety parameters
1247344|NCT00967018|ECG, blood and urine samples
1247345|NCT00967018|general health state
1247346|NCT00967005|N acetyl cysteine
1247347|NCT00967005|Pathological gambling
1247348|NCT00967005|Nicotine dependence
1247349|NCT00966992|Uterine Cervical Cancer
1247350|NCT00966992|Cancer of Cervix
1247351|NCT00966992|Cervix Cancer
1247352|NCT00966979|Osteoarthritis, Post-traumatic arthritis
1247353|NCT00966966|Alzheimer Disease
1247354|NCT00966940|Glaucoma
1247355|NCT00966940|IOP
1247356|NCT00966940|Travoprost
1247357|NCT00966927|quality of life
1247358|NCT00966927|functional independence
1247359|NCT00966927|spina bifid
1247360|NCT00966888|stage II breast cancer
1247361|NCT00966875|rheumatoid arthritis
1247362|NCT00966875|RA
1247363|NCT00966849|Randomized Controlled Trial
1247364|NCT00966849|Financial Support
1247365|NCT00966849|Poverty
1247366|NCT00966849|Child, Orphaned
1247367|NCT00966849|HIV
1247368|NCT00966836|Heart Transplantation
1247369|NCT00966836|Cardiac Allograft Vasculopathy
1247370|NCT00966836|Cytomegalovirus Infection
1247371|NCT00966836|Everolimus
1247372|NCT00966836|Valganciclovir
1247373|NCT00966836|Mycophenolate
1247374|NCT00966823|Diaphragm
1247375|NCT00966823|Trachea
1247376|NCT00966823|Lung development
1247377|NCT00966823|Lung growth
1247378|NCT00966823|Tracheal occlusion
1247379|NCT00966823|ECMO
1247380|NCT00966823|Neonatal death
1247381|NCT00966810|chronic myelocytic leukemia
1247382|NCT00966810|allogeneic stem cell transplantation
1247383|NCT00966810|T cell depletion
1247384|NCT00966810|donor lymphocyte infusion
1247385|NCT00966810|GvHD
1247386|NCT00966810|transplant related mortality
1247387|NCT00966771|contraception
1247388|NCT00966771|emergency contraception
1247389|NCT00966771|pregnancy prevention after unprotected intercourse
1247390|NCT00966745|surgical field condition
1247391|NCT00966719|Jaundice
1247392|NCT00966719|Breastfeeding
1247393|NCT00966719|Infants
1247394|NCT00966706|adenocarcinoma of the pancreas
1247395|NCT00966706|stage III pancreatic cancer
1247396|NCT00966706|stage IV pancreatic cancer
1247397|NCT00966693|Relapsed/Refractory Multiple Myeloma
1247398|NCT00966693|RRMM
1247399|NCT00966693|Lenalidomide
1247400|NCT00966693|Revlimid
1247401|NCT00966693|CC-5013
1247402|NCT00966693|Thalidomide
1247403|NCT00966693|Thalomid
1247404|NCT00966693|Dexamethasone
1247405|NCT00966693|Decadron
1247406|NCT00966680|general anesthesia
1247407|NCT00966680|spinal anesthesia
1247408|NCT00966680|emergency cesarean delivery
1247409|NCT00966667|cancer survivor
1247410|NCT00966667|stage I colon cancer
1247411|NCT00966667|stage II colon cancer
1247412|NCT00966667|stage III colon cancer
1247413|NCT00966667|stage I rectal cancer
1247414|NCT00966667|stage II rectal cancer
1247415|NCT00966667|stage III rectal cancer
1247416|NCT00966654|CABG
1247417|NCT00966654|Cardiac Surgical Patient
1247418|NCT00966628|pediatric
1247419|NCT00966628|dengue
1247420|NCT00966628|hypertonic sodium lactate
1247421|NCT00966628|fluid resuscitation
1247422|NCT00966628|Ringer's lactate
1247423|NCT00966615|malnutrition
1247424|NCT00966615|fluid status
1247425|NCT00966615|survival
1247426|NCT00966589|groin pain
1247427|NCT00966589|sportsman hernia
1247428|NCT00966589|osteitis pubis
1247429|NCT00966589|laparoscopic surgery
1247430|NCT00966576|Glaucoma
1247431|NCT00966576|IOP
1247432|NCT00966576|AZARGA
1247433|NCT00966563|Mangafodipir
1247434|NCT00966563|Primary Percutaneous Coronary Intervention
1247435|NCT00966563|Myocardial infarction
1247436|NCT00966563|Troponin
1247437|NCT00966563|CK-MB
1247438|NCT00966563|Magnetic Resonance Imaging
1247439|NCT00966550|Tomato
1247440|NCT00966550|Nutrition
1247441|NCT00966537|to study the clinical application of 3D/4D ultrasound for fetal scanning
1247442|NCT00966537|to study the clinical application of 3D/4D ultrasound for pelvic scanning;
1247443|NCT00966537|to demonstrate how to optimally display the different organs.
1247444|NCT00966537|to correlate our findings with other diagnostic tools like MRI, CT;
1247445|NCT00966537|to correlate our findings with clinical outcome.
1247446|NCT00966524|Endotracheal intubation
1247447|NCT00966511|lung cancer
1247448|NCT00966511|lung resection
1247449|NCT00966511|lobectomy
1247450|NCT00966511|pneumonectomy
1247451|NCT00966511|lung function
1247452|NCT00966511|perfusion
1247453|NCT00966498|malignancy
1247454|NCT00966498|solid tumor
1247455|NCT00966498|recurrent
1247456|NCT00966498|high risk
1247457|NCT00966485|ASA resistance
1247458|NCT00966485|coronary stenting
1247459|NCT00966485|platelet function
1247460|NCT00966485|laboratory ASA resistance
1247461|NCT00966485|MACE
1247462|NCT00966485|Positive SPECT
1247463|NCT00966472|Rosuvastatin
1247464|NCT00966472|Erlotinib
1247465|NCT00966472|Squamous Cell Carcinoma
1247466|NCT00966472|Nom-Small Cell Lung Cancer
1247467|NCT00966459|COPD
1247468|NCT00966446|MRSA; household; infection; colonization
1247469|NCT00966433|Proseal™ LMA
1247470|NCT00966433|children
1247471|NCT00966433|ventilation
1247472|NCT00966433|general anesthesia
1247473|NCT00966433|Children under general anesthesia for outpatient surgery
1247474|NCT00966407|Metabolic Syndrome
1247475|NCT00966407|Obesity
1247476|NCT00966407|Genetic risk markers
1247477|NCT00966407|Single Nucleotide Polymorphisms
1247478|NCT00966407|Young adults
1247479|NCT00966407|Fitness testing
1247480|NCT00966394|ADHD, saliva, caries
1247481|NCT00966381|breastfeeding
1247482|NCT00966381|bone mineral density
1247483|NCT00966381|exercise
1247484|NCT00966381|diet
1247485|NCT00966355|Cirrhosis, Esophagus Disorders, Varicose Veins
1247486|NCT00966342|vaccine
1247487|NCT00966342|influenza
1247488|NCT00966342|influenza vaccine
1247489|NCT00966342|pandemic preparedness
1247490|NCT00966329|Switching
1247491|NCT00966329|Maraviroc
1247492|NCT00966329|Virological efficacy
1247493|NCT00966329|Lipid profile
1247494|NCT00966329|Tropism
1247495|NCT00966316|Acute Ischemic Stroke；clinical pathway;TCM；
1247496|NCT00966303|rehabilitation
1247497|NCT00966303|dyspnea
1247498|NCT00966303|strength
1247499|NCT00966290|anticoagulants
1247500|NCT00966290|management
1247501|NCT00966290|anticoagulation clinics
1247502|NCT00966290|randomized comparison
1247503|NCT00966277|Pancreas
1247504|NCT00966277|Primary venous thromboembolism
1247505|NCT00966277|VTE
1247506|NCT00966277|Chemotherapy
1247507|NCT00966277|Deep venous thrombosis
1247508|NCT00966277|Pulmonary embolism
1247509|NCT00966277|Dalteparin
1247510|NCT00966277|Fragmin
1247511|NCT00966277|Thromboprophylaxis
1247512|NCT00966264|randomized controlled trial
1247513|NCT00966264|menorrhagia
1247514|NCT00966264|LNG-IUS
1247515|NCT00966264|hysterectomy
1247516|NCT00966251|Primary Hepatocellular Carcinoma
1247517|NCT00966238|influenza
1247518|NCT00966238|vaccine
1247519|NCT00966199|blood pressure
1247520|NCT00966199|aging
1247521|NCT00966199|cerebrovascular circulation
1247522|NCT00966199|hypertension
1247523|NCT00966186|ProSeal Laryngeal Mask Airway
1247524|NCT00966186|Rotational technique
1247525|NCT00966186|Success rate
1247526|NCT00966186|Postoperative complications
1247527|NCT00966160|treatment naive
1247528|NCT00966134|mountain medicine
1247529|NCT00966134|ghrelin
1247530|NCT00966134|growth hormone
1247531|NCT00966134|hypoxia
1247532|NCT00966134|physiology of hormonal adaptation to high altitude
1247533|NCT00966121|Cirrhosis
1247534|NCT00966121|Esophagus Disorders
1247535|NCT00966121|Varicose Veins
1247536|NCT00966095|prostate cancer
1247537|NCT00966082|Cirrhosis
1247538|NCT00966082|Esophagus Disorders
1247539|NCT00966082|Varicose Veins
1247540|NCT00966069|Respiratory tract infections
1247541|NCT00966069|Viral infections
1247542|NCT00966069|Pediatrics
1247543|NCT00966069|Specimen collection
1247544|NCT00966056|Nasal adhesions
1247545|NCT00966056|Nasal synechiae
1247546|NCT00966056|Mitomycin
1247547|NCT00966056|Mitomycin c
1247548|NCT00966056|Teflon
1247549|NCT00966056|Splints
1247550|NCT00966056|Septal splints
1247551|NCT00966017|PET Scan
1247552|NCT00966004|Urge incontinence
1247553|NCT00966004|YM178
1247554|NCT00966004|Overactive Bladder
1247555|NCT00966004|Urgency
1247556|NCT00966004|Urinary incontinence
1247557|NCT00966004|mirabegron
1247558|NCT00966004|Micturition
1247559|NCT00965991|Gestational diabetes
1247560|NCT00965991|Metformin
1247561|NCT00965991|Glyburide
1247562|NCT00965991|oral agents
1247563|NCT00965978|ONO-5920
1247564|NCT00965978|YM529
1247565|NCT00965978|Minodronic Acid
1247566|NCT00965978|Food Effect
1247567|NCT00965965|health behavior
1247568|NCT00965965|randomized controlled trials
1247569|NCT00965965|self-efficacy
1247570|NCT00965965|patient education
1247571|NCT00965965|comprehension
1247572|NCT00965965|mass screening
1247573|NCT00965965|prevention and control
1247574|NCT00965926|Overactive Bladder
1247575|NCT00965926|Urinary incontinence
1247576|NCT00965926|YM178
1247577|NCT00965926|mirabegron
1247578|NCT00965900|Cirrhosis
1247579|NCT00965900|Esophagus Disorders
1247580|NCT00965900|Varicose Veins
1247581|NCT00965874|Rapid Atrial Fibrillation
1247582|NCT00965874|Magnesium Sulfate
1247583|NCT00965874|Cardiac arrhythmia
1247584|NCT00965861|Tissue Registry
1247585|NCT00965861|Tissue Collection
1247586|NCT00965861|Unknown Primary
1247587|NCT00965861|Breast
1247588|NCT00965861|Lung
1247589|NCT00965861|Gastrointestinal
1247590|NCT00965861|Bone Marrow Transplant
1247591|NCT00965861|Chronic Lymphocytic Leukemia
1247592|NCT00965861|Central Nervous System
1247593|NCT00965861|Head and Neck
1247594|NCT00965861|Melanoma
1247595|NCT00965861|Myelodysplastic syndrome
1247596|NCT00965861|Multiple Myeloma
1247597|NCT00965861|Lymphoma
1247598|NCT00965861|Gynecologic
1247599|NCT00965861|Genitourinary
1247600|NCT00965861|Refractory Malignancy
1247601|NCT00965848|Pneumonia, Ventilator-Associated
1247602|NCT00965848|Intra-abdominal Infections
1247603|NCT00965848|Urinary tract Infections
1247604|NCT00965848|Doripenem
1247605|NCT00965848|Doribax
1247606|NCT00965835|PET Scan
1247607|NCT00965822|URTI
1247608|NCT00965822|Natural Health Products
1247609|NCT00965796|Intravenous lidocaine
1247610|NCT00965796|postoperative analgesia
1247611|NCT00965783|Sleep, Apnea, OSA, obese, middle-aged
1247612|NCT00965770|abortion
1247613|NCT00965770|intrauterine device
1247614|NCT00965770|cost-effectiveness
1247615|NCT00965744|Ligasure vessel sealing system
1247616|NCT00965744|Azygoportal Disconnection
1247617|NCT00965744|Splenectomy
1247618|NCT00965744|Portal hypertension
1247619|NCT00965731|Lung Neoplasms
1247620|NCT00965731|Crizotinib
1247621|NCT00965718|advanced pancreatic cancer
1247622|NCT00965705|Binge Eating Disorder
1247623|NCT00965705|overeating
1247624|NCT00965705|binge eating
1247625|NCT00965705|women
1247626|NCT00965705|overweight
1247627|NCT00965705|compulsive overeating
1247628|NCT00965679|Cardiac CT
1247629|NCT00965679|Iodinated Radiocontrast
1247630|NCT00965679|Ionizing Radiation
1247631|NCT00965679|Aortic Valve Stenosis
1247632|NCT00965679|Percutaneous Aortic Valve Replacement
1247633|NCT00965679|Heart Valve
1247634|NCT00965666|Fanconi Anemia
1247635|NCT00965666|Hemic and Lymphatic Diseases
1247636|NCT00965666|Anti-Rheumatic Agents
1247637|NCT00965666|Anemia, Hypoplastic, Congenital
1247638|NCT00965666|DNA Repair-Deficiency Disorders
1247639|NCT00965666|Congenital, Hereditary, and
1247640|NCT00965666|Neonatal Diseases and Abnormalities
1247641|NCT00965640|male pattern baldness
1247642|NCT00965640|androgenetic alopecia
1247643|NCT00965640|hair loss
1247644|NCT00965614|diagnose cardiac arrhythmia and CAD.
1247645|NCT00965614|we'll try to establish the specific model to detect and diagnose cardiac arrhythmia and CAD.
1247646|NCT00965601|Fibromyalgia
1247647|NCT00965588|Alzheimer's disease
1247648|NCT00965588|amyloid beta
1247649|NCT00965588|vaccine
1247650|NCT00965575|epilepsy
1247651|NCT00965575|sleep
1247652|NCT00965575|seizures
1247653|NCT00965575|cognition
1247654|NCT00965562|Premenstrual syndrome
1247655|NCT00965562|PMS
1247656|NCT00965562|calcium
1247657|NCT00965536|Schizophrenia
1247658|NCT00965536|Bipolar Disorder
1247659|NCT00965536|Manic Disorder
1247660|NCT00965536|Register study
1247661|NCT00965536|Quetiapine
1247662|NCT00965536|Quetiapine Prolong
1247663|NCT00965536|Seroquel
1247664|NCT00965536|Seroquel Prolong
1247665|NCT00965536|Seroquel XR
1247666|NCT00965536|In-patient
1247667|NCT00965523|Cancer
1247668|NCT00965523|breast cancer
1247669|NCT00965523|neoplasm
1247670|NCT00965523|E7389
1247671|NCT00965523|Eribulin
1247672|NCT00965510|diabetes
1247673|NCT00965497|Amyotrophic Lateral Sclerosis
1247674|NCT00965497|ALS
1247675|NCT00965497|Multiple Sclerosis
1247676|NCT00965497|MS
1247677|NCT00965497|Major Depression
1247678|NCT00965497|Depression
1247679|NCT00965497|Major Depressive Disorder
1247680|NCT00965497|antidepressants
1247681|NCT00965497|Escitalopram
1247682|NCT00965497|Lexapro
1247683|NCT00965484|Genotropin Medical device Patient reported outcome
1247684|NCT00965471|percutaneous coronary artery intervention
1247685|NCT00965471|coronary artery bypass graft
1247686|NCT00965471|acute coronary syndrome
1247687|NCT00965458|New-onset Type 1 Diabetes Mellitus
1247688|NCT00965458|New-onset T1DM
1247689|NCT00965458|New-onset T1D
1247690|NCT00965458|Alefacept
1247691|NCT00965458|Amevive®
1247692|NCT00965445|isoprostanes
1247693|NCT00965445|mass spectrometry
1247694|NCT00965406|acute coronary syndrome
1247695|NCT00965406|glucose insulin potassium
1247696|NCT00965393|Ischaemia reperfusion
1247697|NCT00965393|Platelet activation
1247698|NCT00965393|Endothelial function
1247699|NCT00965393|Remote ischaemic preconditioning
1247700|NCT00965393|Bradykinin
1247701|NCT00965380|Trinity Evolution
1247702|NCT00965380|Symptomatic lumbar degenerative disc disease
1247703|NCT00965380|Posterior lumbar interbody fusion
1247704|NCT00965380|Transforaminal lumbar interbody fusion
1247705|NCT00965367|POV tonsillectomy adenoidectomy acupuncture acupressure child
1247706|NCT00965367|Effectiveness of acupuncture on
1247707|NCT00965354|severe
1247708|NCT00965354|acute
1247709|NCT00965354|influenza
1247710|NCT00965354|consortium
1247711|NCT00965354|swine
1247712|NCT00965354|flu
1247713|NCT00965354|influenza A
1247714|NCT00965354|H1N1
1247715|NCT00965354|hospital
1247716|NCT00965354|admission
1247717|NCT00965341|Cancer
1247718|NCT00965341|Fatigue
1247719|NCT00965341|Testosterone Replacement Therapy
1247720|NCT00965341|Depo-Testosterone
1247721|NCT00965341|Testosterone cypionate
1247722|NCT00965341|Testosterone enanthate
1247723|NCT00965341|Hypogonadic
1247724|NCT00965341|Functional Assessment of Cancer Therapy-Fatigue subscale
1247725|NCT00965341|FACIT-F
1247726|NCT00965328|anticoagulation
1247727|NCT00965328|hemofiltration
1247728|NCT00965328|acute kidney injury
1247729|NCT00965328|heparin
1247730|NCT00965328|hemostasis
1247731|NCT00965328|nadroparin
1247732|NCT00965328|anti-Xa
1247733|NCT00965328|endogenous thrombin potential
1247734|NCT00965315|CV (cardiovascular)
1247735|NCT00965315|MI (myocardial infarction)
1247736|NCT00965315|fenofibrate
1247737|NCT00965315|rosuvastatin
1247738|NCT00965315|this trial is to test the hypothesis that the addition of fenofibrate on rosuvastatin would provide a further reduction in the time
1247739|NCT00965302|Obesity
1247740|NCT00965302|Diabetes mellitus, Type 2
1247741|NCT00965302|Sleeve gastrectomy
1247742|NCT00965302|Metabolic surgery
1247743|NCT00965289|Aggressive large B-cell lymphoma (DLBCL)
1247744|NCT00965289|Intensive chemotherapy
1247745|NCT00965289|Rituximab
1247746|NCT00965289|ASCT
1247747|NCT00965276|Adjuvant Therapy
1247748|NCT00965276|Paclitaxel
1247749|NCT00965276|Chemoresistance
1247750|NCT00965276|Serine/Threonine Kinase
1247751|NCT00965276|Cell Survival
1247752|NCT00965276|Breast Cancer
1247753|NCT00965263|Cocaine
1247754|NCT00965263|immunotherapy
1247755|NCT00965263|vaccination
1247756|NCT00965263|antibody
1247757|NCT00965263|addiction
1247758|NCT00965263|dependence
1247759|NCT00965250|Thymic Malignancies
1247760|NCT00965250|IMC-A12
1247761|NCT00965250|Insulin-Like Growth Factor
1247762|NCT00965224|AML (acute myeloid leukemia)
1247763|NCT00965224|CML (chronic myeloid leukemia)
1247764|NCT00965224|MM (multiple myeloma)
1248089|NCT00964288|electrical hyperalgesia
1247765|NCT00965211|Tourette's, OCD, dTMS, YGTSS, YBOCS, supplementary motor cortex
1247766|NCT00965211|Tourette's syndrome and Obsessive compulsive disorder
1247767|NCT00965198|Catheters, Indwelling
1247768|NCT00965198|Biofilms
1247769|NCT00965185|Cardiovascular Disease
1247770|NCT00965185|HIV
1247771|NCT00965185|Atherosclerosis
1247772|NCT00965185|Inflammation
1247773|NCT00965185|Statins
1247774|NCT00965185|treatment experienced
1247775|NCT00965172|Cancer
1247776|NCT00965172|Mucositis
1247777|NCT00965172|Chemotherapy
1247778|NCT00965172|Caphosol
1247779|NCT00965172|Calcium phosphate
1247780|NCT00965172|Sodium Bicarbonate
1247781|NCT00965172|Baking Soda Solution
1247782|NCT00965172|Multi-cycle chemotherapy
1247783|NCT00965146|Osteoarthritis, traumatic arthritis, avascular necrosis
1247784|NCT00965120|Ischaemia reperfusion
1247785|NCT00965120|Bradykinin
1247786|NCT00965120|Platelet activation
1247787|NCT00965120|Endothelial function
1247788|NCT00965068|Autism
1247789|NCT00965068|Autism Spectrum Disorder
1247790|NCT00965068|Cholesterol
1247791|NCT00965068|Smith-Lemli-Opitz Syndrome
1247792|NCT00965068|ASD
1247793|NCT00965068|Pervasive Developmental Disorder
1247794|NCT00965068|PPD-NOS
1247795|NCT00965042|Ceftobiprole
1247796|NCT00965042|ZEVTERA
1247797|NCT00965042|ZEFTERA
1247798|NCT00965042|Intestinal Microflora
1247799|NCT00965029|COPD
1247800|NCT00965029|Spirometry
1247801|NCT00965029|Weaning
1247802|NCT00965016|Extracorporeal membrane oxygenation，induced hypothermia
1247803|NCT00964990|Moderate to severe chronic peripheral neuropathic pain
1247804|NCT00964990|Postherpetic neuralgia
1247805|NCT00964990|Post-traumatic neuralgia
1247806|NCT00964990|Moderate to severe chronic pain
1247807|NCT00964990|JNJ-42160443
1247808|NCT00964977|pN1
1247809|NCT00964977|head and neck cancer
1247810|NCT00964977|radiation
1247811|NCT00964977|prognosis
1247812|NCT00964977|comprehensive cohort design
1247813|NCT00964951|H1N1, influenza A viruses, vaccine, elderly
1247814|NCT00964938|Hemodynamic response
1247815|NCT00964938|Cardiac resynchronization therapy
1247816|NCT00964886|chronic pain
1247817|NCT00964886|back pain
1247818|NCT00964886|antidepressants
1247819|NCT00964873|Synta
1247820|NCT00964873|STA-9090
1247821|NCT00964873|ganetespib
1247822|NCT00964873|Hematologic Cancers
1247823|NCT00964873|Acute Myeloid Leukemia
1247824|NCT00964873|Acute Lymphoblastic Leukemia
1247825|NCT00964873|Blast-phase Chronic Myelogenous Leukemia
1247826|NCT00964873|AML
1247827|NCT00964873|ALL
1247828|NCT00964873|CML
1247829|NCT00964873|HSP90 Inhibitor
1247830|NCT00964847|hypertension
1247831|NCT00964847|cardiovascular disease
1247832|NCT00964847|yoga
1247833|NCT00964821|stage III adult Burkitt lymphoma
1247834|NCT00964821|stage III adult diffuse large cell lymphoma
1247835|NCT00964821|stage III adult diffuse mixed cell lymphoma
1247836|NCT00964821|stage III adult diffuse small cleaved cell lymphoma
1247837|NCT00964821|stage III adult Hodgkin lymphoma
1247838|NCT00964821|stage III adult immunoblastic large cell lymphoma
1247839|NCT00964821|stage III adult lymphoblastic lymphoma
1247840|NCT00964821|stage III grade 1 follicular lymphoma
1247841|NCT00964821|stage III grade 2 follicular lymphoma
1247842|NCT00964821|stage III grade 3 follicular lymphoma
1247843|NCT00964821|stage III mantle cell lymphoma
1247844|NCT00964821|stage III marginal zone lymphoma
1247845|NCT00964821|stage III small lymphocytic lymphoma
1247846|NCT00964821|stage IV adult Burkitt lymphoma
1247847|NCT00964821|stage IV adult diffuse large cell lymphoma
1247848|NCT00964821|stage IV adult diffuse mixed cell lymphoma
1247849|NCT00964821|stage IV adult diffuse small cleaved cell lymphoma
1247850|NCT00964821|stage IV adult Hodgkin lymphoma
1247851|NCT00964821|stage IV adult immunoblastic large cell lymphoma
1247852|NCT00964821|stage IV adult lymphoblastic lymphoma
1247853|NCT00964821|stage IV grade 1 follicular lymphoma
1247854|NCT00964821|stage IV grade 2 follicular lymphoma
1247855|NCT00964821|stage IV grade 3 follicular lymphoma
1247856|NCT00964821|stage IV mantle cell lymphoma
1247857|NCT00964821|stage IV marginal zone lymphoma
1247858|NCT00964821|stage IV small lymphocytic lymphoma
1247859|NCT00964821|recurrent adult Burkitt lymphoma
1247860|NCT00964821|recurrent adult diffuse large cell lymphoma
1247861|NCT00964821|recurrent adult diffuse mixed cell lymphoma
1247862|NCT00964821|recurrent adult diffuse small cleaved cell lymphoma
1247863|NCT00964821|recurrent adult Hodgkin lymphoma
1247864|NCT00964821|recurrent adult immunoblastic large cell lymphoma
1247865|NCT00964821|recurrent adult lymphoblastic lymphoma
1247866|NCT00964821|recurrent childhood large cell lymphoma
1247867|NCT00964821|recurrent cutaneous T-cell non-Hodgkin lymphoma
1247868|NCT00964821|recurrent grade 1 follicular lymphoma
1247869|NCT00964821|recurrent grade 2 follicular lymphoma
1247870|NCT00964821|recurrent grade 3 follicular lymphoma
1247871|NCT00964821|recurrent mantle cell lymphoma
1247872|NCT00964821|recurrent marginal zone lymphoma
1247873|NCT00964821|recurrent small lymphocytic lymphoma
1247874|NCT00964821|recurrent mycosis fungoides/Sezary syndrome
1247875|NCT00964821|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1247876|NCT00964821|nodal marginal zone B-cell lymphoma
1247877|NCT00964821|splenic marginal zone lymphoma
1247878|NCT00964821|noncontiguous stage II adult Burkitt lymphoma
1247879|NCT00964821|noncontiguous stage II adult diffuse large cell lymphoma
1247880|NCT00964821|noncontiguous stage II adult diffuse mixed cell lymphoma
1247881|NCT00964821|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1247882|NCT00964821|noncontiguous stage II adult immunoblastic large cell lymphoma
1247883|NCT00964821|noncontiguous stage II adult lymphoblastic lymphoma
1247884|NCT00964821|noncontiguous stage II grade 1 follicular lymphoma
1247885|NCT00964821|noncontiguous stage II grade 2 follicular lymphoma
1247886|NCT00964821|noncontiguous stage II grade 3 follicular lymphoma
1247887|NCT00964821|noncontiguous stage II mantle cell lymphoma
1247888|NCT00964821|noncontiguous stage II marginal zone lymphoma
1247889|NCT00964821|noncontiguous stage II small lymphocytic lymphoma
1247890|NCT00964821|accelerated phase chronic myelogenous leukemia
1247891|NCT00964821|adult acute lymphoblastic leukemia in remission
1247892|NCT00964821|adult acute myeloid leukemia in remission
1247893|NCT00964821|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1247894|NCT00964821|adult acute myeloid leukemia with inv(16)(p13;q22)
1247895|NCT00964821|adult acute myeloid leukemia with t(15;17)(q22;q12)
1247896|NCT00964821|adult acute myeloid leukemia with t(16;16)(p13;q22)
1247897|NCT00964821|adult acute myeloid leukemia with t(8;21)(q22;q22)
1247898|NCT00964821|atypical chronic myeloid leukemia, BCR-ABL negative
1247899|NCT00964821|blastic phase chronic myelogenous leukemia
1247900|NCT00964821|chronic myelomonocytic leukemia
1247901|NCT00964821|chronic phase chronic myelogenous leukemia
1247902|NCT00964821|recurrent adult acute lymphoblastic leukemia
1247903|NCT00964821|recurrent adult acute myeloid leukemia
1247904|NCT00964821|refractory chronic lymphocytic leukemia
1247905|NCT00964821|refractory hairy cell leukemia
1247906|NCT00964821|relapsing chronic myelogenous leukemia
1247907|NCT00964821|secondary acute myeloid leukemia
1247908|NCT00964821|stage III chronic lymphocytic leukemia
1247909|NCT00964821|stage IV chronic lymphocytic leukemia
1247910|NCT00964821|chronic eosinophilic leukemia
1247911|NCT00964821|primary myelofibrosis
1247912|NCT00964821|chronic neutrophilic leukemia
1247913|NCT00964821|de novo myelodysplastic syndromes
1247914|NCT00964821|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1247915|NCT00964821|previously treated myelodysplastic syndromes
1247916|NCT00964821|secondary myelodysplastic syndromes
1247917|NCT00964821|stage I multiple myeloma
1247918|NCT00964821|stage II multiple myeloma
1247919|NCT00964821|stage III multiple myeloma
1247920|NCT00964821|refractory multiple myeloma
1247921|NCT00964821|aplastic anemia
1247922|NCT00964808|Hip fractures
1247923|NCT00964808|Treatment Outcome
1247924|NCT00964808|Painkiller
1247925|NCT00964795|Eyes
1247926|NCT00964795|Neovascular
1247927|NCT00964795|Macular Degeneration
1247928|NCT00964795|Retina
1247929|NCT00964795|AMD
1247930|NCT00964795|VEGF Trap-Eye
1247931|NCT00964795|Best Corrected Visual Acuity
1247932|NCT00964782|Fontan
1247933|NCT00964782|sildenafil
1247934|NCT00964782|exercise capacity
1247935|NCT00964782|Patients with Fontan Circulation
1247936|NCT00964769|Pneumococcal Vaccine
1247937|NCT00964769|Aged
1247938|NCT00964756|ovarian cancer
1247939|NCT00964756|Recurrent ovarian cancer and other gynecologic cancers
1247940|NCT00964743|Neurologic Oncology
1247941|NCT00964743|Neoplastic Meningitis from solid tumors
1247942|NCT00964743|Brain and Nervous System
1247943|NCT00964743|Breast Cancer
1247944|NCT00964730|Thorough QT Study
1247945|NCT00964730|Talampanel
1247946|NCT00964730|Cardiac Repolarizatiom
1247947|NCT00964730|Healthy Volunteers
1247948|NCT00964717|back pain
1247949|NCT00964717|neck pain
1247950|NCT00964717|anxiety
1247951|NCT00964717|range of motion
1247952|NCT00964691|malaria
1247953|NCT00964691|IPTp
1247954|NCT00964691|Fansidar
1247955|NCT00964691|Intermittent Preventive Treatment in pregnancy
1247956|NCT00964691|pregnancy
1247957|NCT00964691|prophylaxis
1247958|NCT00964691|Chloroquine
1247959|NCT00964691|Anemia
1247960|NCT00964691|Prevention
1247961|NCT00964691|Placental malaria
1247962|NCT00964691|Solomon Islands
1247963|NCT00964691|Low birth weight
1247964|NCT00964665|Hepatitis B,
1247965|NCT00964665|Chronic,
1247966|NCT00964665|Hepatitis B e Antigens positive
1247967|NCT00964652|treadmill
1247968|NCT00964652|body load
1247969|NCT00964652|Parkinson's disease
1247970|NCT00964652|gait
1247971|NCT00964639|Pain
1247972|NCT00964639|Postoperative
1247973|NCT00964639|Local infiltration analgesia
1247974|NCT00964639|Cerebral palsy
1247975|NCT00964639|r-FLACC
1247976|NCT00964626|stage IA ovarian epithelial cancer
1247977|NCT00964626|stage IB ovarian epithelial cancer
1247978|NCT00964626|stage IC ovarian epithelial cancer
1247979|NCT00964626|stage IIA ovarian epithelial cancer
1247980|NCT00964626|stage IIB ovarian epithelial cancer
1247981|NCT00964626|stage IIC ovarian epithelial cancer
1247982|NCT00964626|stage IIIA ovarian epithelial cancer
1247983|NCT00964626|stage IIIB ovarian epithelial cancer
1247984|NCT00964626|stage IIIC ovarian epithelial cancer
1247985|NCT00964626|stage IV ovarian epithelial cancer
1247986|NCT00964613|Pars Plana
1247987|NCT00964613|Surgical Capsulotomy
1247988|NCT00964613|Posterior capsule opacification
1247989|NCT00964613|visual outcome
1247990|NCT00964613|Complications
1247991|NCT00964600|transversus abdominis block
1247992|NCT00964600|postoperative pain
1247993|NCT00964600|cesarean
1247994|NCT00964587|diabetes self management education
1247995|NCT00964587|problem-solving training
1247996|NCT00964587|health behavior change
1247997|NCT00964587|health literacy
1247998|NCT00964548|vasospasm
1247999|NCT00964548|subarachnoid hemorrhage
1248000|NCT00964548|neurocritical care
1248001|NCT00964548|dantrolene
1248002|NCT00964548|vasorelaxation
1248003|NCT00964522|Quality of life
1248004|NCT00964522|Breast Cancer
1248005|NCT00964522|Nursing Care
1248006|NCT00964522|Education
1248007|NCT00964522|Chemotherapy
1248008|NCT00964496|vascular malformation
1248009|NCT00964496|gastrointestinal bleeding
1248010|NCT00964496|thalidomide
1248011|NCT00964483|Hypertension
1248012|NCT00964470|Burn, donor site, skin graft, dressing, AWBAT™-D, XEROFORM™, GLUCAN II™
1248013|NCT00964457|cetuximab
1248014|NCT00964457|rectum cancer
1248015|NCT00964457|radiation
1248016|NCT00964457|MRI
1248017|NCT00964444|Labor and delivery
1248018|NCT00964444|Vaginal delivery
1248019|NCT00963391|Health Production
1248020|NCT00963391|Government Policy; Regulation; Public Health
1248021|NCT00963391|Government Policy; Provision and Effects of Welfare Programs
1248022|NCT00963391|Gastrointestinal diseases
1248023|NCT00963391|Respiratory Tract Infections
1248024|NCT00963391|Diarrhea
1248025|NCT00963391|Ethanol
1248026|NCT00963391|Child, Preschool
1248027|NCT00963391|Handwashing
1248028|NCT00963365|Phase 1
1248029|NCT00963365|Healthy volunteers
1248030|NCT00963352|Colon cancer
1248031|NCT00963352|Open surgery resection
1248032|NCT00963352|Laparoscopic surgery resection
1248033|NCT00963352|Morbidity
1248034|NCT00963352|Mortality
1248035|NCT00963352|Metastases
1248036|NCT00963352|Oncology
1248037|NCT00963352|Freedom of malignant disease recurrence
1248038|NCT00963352|Safety of intervention open and laparoscopic
1248039|NCT00963352|Examination of adverse markers
1248040|NCT00963352|Development of metastases in lungs and other organs
1248041|NCT00963339|AMD
1248042|NCT00963326|stage I squamous cell carcinoma of the hypopharynx
1248043|NCT00963326|stage I squamous cell carcinoma of the larynx
1248044|NCT00963326|stage I squamous cell carcinoma of the nasopharynx
1248045|NCT00963326|stage I squamous cell carcinoma of the oropharynx
1248046|NCT00963326|stage II squamous cell carcinoma of the hypopharynx
1248047|NCT00963326|stage II squamous cell carcinoma of the larynx
1248048|NCT00963326|stage II squamous cell carcinoma of the nasopharynx
1248049|NCT00963326|stage II squamous cell carcinoma of the oropharynx
1248050|NCT00963326|stage III squamous cell carcinoma of the hypopharynx
1248051|NCT00963326|stage III squamous cell carcinoma of the larynx
1248052|NCT00963326|stage III squamous cell carcinoma of the nasopharynx
1248053|NCT00963326|stage III squamous cell carcinoma of the oropharynx
1248054|NCT00963326|stage IV squamous cell carcinoma of the hypopharynx
1248055|NCT00963326|stage IV squamous cell carcinoma of the larynx
1248056|NCT00963326|stage IV squamous cell carcinoma of the nasopharynx
1248057|NCT00963326|stage IV squamous cell carcinoma of the oropharynx
1248058|NCT00963326|recurrent squamous cell carcinoma of the hypopharynx
1248059|NCT00963326|recurrent squamous cell carcinoma of the larynx
1248060|NCT00963326|recurrent squamous cell carcinoma of the nasopharynx
1248061|NCT00963326|recurrent squamous cell carcinoma of the oropharynx
1248062|NCT00963326|recurrent verrucous carcinoma of the oral cavity
1248063|NCT00963326|stage I verrucous carcinoma of the oral cavity
1248064|NCT00963326|stage II verrucous carcinoma of the oral cavity
1248065|NCT00963326|stage III verrucous carcinoma of the oral cavity
1248066|NCT00963326|stage IV verrucous carcinoma of the oral cavity
1248067|NCT00963326|recurrent verrucous carcinoma of the larynx
1248068|NCT00963326|stage I verrucous carcinoma of the larynx
1248069|NCT00963326|stage II verrucous carcinoma of the larynx
1248070|NCT00963326|stage III verrucous carcinoma of the larynx
1248071|NCT00963326|stage IV verrucous carcinoma of the larynx
1248072|NCT00963326|tongue cancer
1248073|NCT00964379|Intra versus extraperitoneal colostomy
1248074|NCT00964353|coumadine
1248075|NCT00964353|genotype
1248076|NCT00964353|genes
1248077|NCT00964353|Warfarin
1248078|NCT00964327|TMC114-C201
1248079|NCT00964327|TMC114
1248080|NCT00964327|HIV
1248081|NCT00964327|darunavir
1248082|NCT00964314|advanced cancer
1248083|NCT00964314|TCM five elements music therapy
1248084|NCT00964314|quality of life (QOL)
1248085|NCT00964301|Asthma
1248086|NCT00964301|Low-income
1248087|NCT00964301|Quality of life
1248088|NCT00964301|Children
1248090|NCT00964288|threshold tracking
1248091|NCT00964288|pain
1248092|NCT00964275|unspecified adult solid tumor, protocol specific
1248093|NCT00964275|thromboembolism
1248094|NCT00964262|diabetes
1248095|NCT00964262|exenatide
1248096|NCT00964262|SR exenatide
1248097|NCT00964262|Peptron
1248098|NCT00964236|sapropterin
1248099|NCT00964236|Kuvan
1248100|NCT00964236|cognition
1248101|NCT00964236|brain
1248102|NCT00964223|Acne vulgaris
1248103|NCT00964210|Juvenile Idiopathic Arthritis
1248104|NCT00964210|Inflammatory Bowel Disease
1248105|NCT00964210|Acute Lymphoblastic Leukemia
1248106|NCT00964210|Chronic Renal Disease
1248107|NCT00964210|Solid Organ Transplant
1248108|NCT00964197|FemmeJock
1248109|NCT00964197|Pelvic Organ Prolapse
1248110|NCT00964184|Maturity onset diabetes of the young 3 protein, human
1248111|NCT00964171|adenocarcinoma of the pancreas
1248112|NCT00964171|recurrent pancreatic cancer
1248113|NCT00964171|stage IV pancreatic cancer
1248114|NCT00964158|influenza infection
1248115|NCT00964158|GSK Bio's influenza vaccine GSK2340272A
1248116|NCT00964145|Nulliparous women
1248117|NCT00964145|ultrasound
1248118|NCT00964132|Non-Small Cell Lung Cancer
1248119|NCT00964132|NSCLC
1248120|NCT00964132|Rexinoid
1248121|NCT00964132|NRX194204
1248122|NCT00964132|Lung Cancer
1248123|NCT00964132|RXR
1248138|NCT00964093|premature
1248139|NCT00964093|infection
1248140|NCT00964093|central line
1248141|NCT00964093|very low birth weight
1248142|NCT00964093|silver alginate
1248143|NCT00964093|Algidex
1248144|NCT00964093|neonatal
1248145|NCT00964093|NICU
1248146|NCT00964067|rehabilitation outcome
1248147|NCT00964067|cardiac patients
1248148|NCT00964067|exercise intensity
1248149|NCT00964054|adolescents
1248150|NCT00964054|exercise
1248151|NCT00964054|depression
1248152|NCT00964054|dose response
1248153|NCT00964054|pilot study
1248154|NCT00964041|Cognitive Impairment
1248155|NCT00964041|Neuroplasticity
1248156|NCT00964041|D-cycloserine
1248157|NCT00964041|N-methyl-D-aspartate (NMDA)
1248158|NCT00964041|Anti-Bacterial Agents
1248159|NCT00964041|Mental Disorders
1248160|NCT00964041|Psychotic Disorders
1248161|NCT00964041|Antitubercular Agents
1248162|NCT00964041|Schizophrenia and Disorders with Psychotic Features
1248163|NCT00964041|Schizoaffective Disorder
1248164|NCT00964028|Combined vaccine
1248165|NCT00964015|colloid fluid
1248166|NCT00964015|crystalloid fluid
1248167|NCT00964015|surgery
1248168|NCT00964015|coronary artery bypass grafting
1248169|NCT00964015|renal function
1248170|NCT00964015|Patients undergoing coronary artery bypass surgery
1248171|NCT00964002|recurrent prostate cancer
1248172|NCT00964002|stage IV prostate cancer
1248173|NCT00963989|Acute stroke
1248174|NCT00963989|Large cerebral vessel occlusion
1248175|NCT00963989|Core infarct volume
1248176|NCT00963989|Penumbra System
1248177|NCT00963989|Revascularization
1248178|NCT00963989|Intracerebral hemorrhage
1248179|NCT00963989|mRS
1248180|NCT00963989|NIHSS
1248181|NCT00963989|Procedural serious adverse events
1248182|NCT00963989|All cause mortality
1248183|NCT00963976|Stroke
1248184|NCT00963976|Hypertension
1248185|NCT00963976|Cerebral Blood Flow
1248186|NCT00963976|CT Perfusion
1248187|NCT00963963|sexual health
1248188|NCT00963963|adolescent health
1248189|NCT00963963|parent education
1248190|NCT00963963|HIV Seronegativity
1248191|NCT00963963|treatment experienced
1248192|NCT00963950|cholecystectomy
1248193|NCT00963937|adolescent
1248194|NCT00963937|sumatriptan
1248195|NCT00963937|children
1248196|NCT00963937|migraine
1248197|NCT00963924|Cognitive Impairment
1248198|NCT00963924|Neuroplasticity
1248199|NCT00963924|D-cycloserine
1248200|NCT00963924|NMDA
1248201|NCT00963924|Anti-Bacterial Agents
1248202|NCT00963924|Mental Disorders
1248203|NCT00963924|Psychotic Disorders
1248204|NCT00963924|Antitubercular Agents
1248205|NCT00963924|Schizophrenia and Disorders with Psychotic Features
1248206|NCT00963924|Schizoaffective Disorder
1248207|NCT00963911|colon cancer
1248208|NCT00963911|rectal cancer
1248209|NCT00963911|non-small cell lung cancer
1248210|NCT00963911|small cell lung cancer
1248211|NCT00963911|hypopharyngeal squamous cell carcinoma
1248212|NCT00963911|laryngeal squamous cell carcinoma
1248213|NCT00963911|laryngeal verrucous carcinoma
1248214|NCT00963911|lip and oral cavity squamous cell carcinoma
1248215|NCT00963911|oral cavity verrucous carcinoma
1248216|NCT00963911|nasopharyngeal squamous cell carcinoma
1248217|NCT00963911|oropharyngeal squamous cell carcinoma
1248218|NCT00963911|paranasal sinus and nasal cavity squamous cell carcinoma
1248219|NCT00963911|salivary gland squamous cell carcinoma
1248220|NCT00963911|prostate cancer
1248221|NCT00963911|breast cancer
1248222|NCT00963911|adult non-Hodgkin lymphoma
1248223|NCT00963898|Intravenous sedation
1248224|NCT00963898|Target controlled infusion
1248225|NCT00963898|Bispectral index
1248226|NCT00963898|Dental treatment
1248227|NCT00963898|Mental Retardation
1248228|NCT00963898|Deep sedation
1248229|NCT00963859|Robotic-assisted laparoscopic surgery
1248230|NCT00963859|Extended pelvic lymph node dissection
1248231|NCT00963859|RA-PLND
1248232|NCT00963859|Second-look open lymph node dissection
1248233|NCT00963859|O-PLND
1248234|NCT00963859|Radical Cystectomy
1248235|NCT00963859|Urinary diversion
1248236|NCT00963859|Bladder
1248237|NCT00963846|schizophrenia
1248238|NCT00963846|cognition
1248239|NCT00963846|functioning
1248240|NCT00963833|Multiple Sclerosis
1248241|NCT00963833|MS
1248242|NCT00963833|Non-interventional
1248243|NCT00963820|Relapsed multiple myeloma
1248244|NCT00963820|Refractory multiple myeloma
1248245|NCT00963820|Drug therapy
1248246|NCT00963794|Rectal cancer
1248247|NCT00963794|Population screening
1248248|NCT00963794|Early detection
1248249|NCT00963781|Coronary Artery Disease
1248250|NCT00963781|Drug-Eluting Stents
1248251|NCT00963781|Coronary Thrombosis
1248252|NCT00963781|Platelet Aggregation Inhibitors
1248253|NCT00963781|Coronary Restenosis
1248254|NCT00963768|Diabetes Mellitus, Type 2
1248255|NCT00963768|JNJ-28431754
1248256|NCT00963768|Canagliflozin
1248257|NCT00963768|Sodium Glucose Co-transporter (SGLT2 inhibitor)
1248258|NCT00963768|Pharmacokinetics
1248259|NCT00963768|Pharmacodynamics
1248260|NCT00963755|Imaging
1248261|NCT00963755|Positron emission tomography
1248262|NCT00963755|F-18-FCH
1248263|NCT00963755|Magnetic resonance imaging
1248264|NCT00963755|Magnetic resonance spectroscopy
1248265|NCT00963742|cataract surgery
1248266|NCT00963742|IOL
1248267|NCT00963742|Intraocular lens
1248268|NCT00963729|estrogen receptor-positive breast cancer
1248269|NCT00963729|recurrent breast cancer
1248270|NCT00963729|stage II breast cancer
1248271|NCT00963729|stage IIIA breast cancer
1248272|NCT00963729|stage IIIB breast cancer
1248273|NCT00963729|stage IIIC breast cancer
1248274|NCT00963716|endobronchial biopsy
1248275|NCT00963716|bronchoscopy
1248276|NCT00963716|interventional pulmonology
1248277|NCT00963677|Shikani optical stylet(SOS)
1248278|NCT00963677|difficult airways
1248279|NCT00963677|intubation
1248280|NCT00963664|melanoma
1248281|NCT00963664|malignant melanoma
1248282|NCT00963664|interferon
1248283|NCT00963664|interferon alfa-2b
1248284|NCT00963664|Intron-A
1248285|NCT00963664|Intron A
1248286|NCT00963664|Intron
1248287|NCT00963664|lovastatin
1248288|NCT00963664|mevinolin
1248289|NCT00963664|Mevacor
1248290|NCT00963664|statin
1248291|NCT00963664|HRI
1248292|NCT00963651|Pulmonary nodule, solitary
1248293|NCT00963651|Multiple pulmonary nodules
1248294|NCT00963625|Blastocyst transfer
1248295|NCT00963625|endometrial receptivity
1248296|NCT00963625|IVF
1248297|NCT00963625|in vitro fertilization
1248298|NCT00963625|embryo cryopreservation
1248299|NCT00963612|Microvascular Invasion
1248300|NCT00963612|Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)
1248301|NCT00963560|ReSTOR +3
1248302|NCT00963547|Documented to be HER2+
1248311|NCT00963521|adult acute myelomonocytic leukemia (M4)
1248312|NCT00963521|adult acute monoblastic leukemia (M5a)
1248313|NCT00963521|adult acute monocytic leukemia (M5b)
1248314|NCT00963521|adult acute myeloid leukemia in remission
1248315|NCT00963521|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1248316|NCT00963521|adult acute myeloid leukemia with inv(16)(p13;q22)
1248317|NCT00963521|adult acute myeloid leukemia with t(16;16)(p13;q22)
1248318|NCT00963508|Head Lice
1248319|NCT00963495|clioquinol
1248320|NCT00963495|relapsed and refractory hematologic malignancy
1248321|NCT00963495|ALL
1248322|NCT00963495|HD
1248323|NCT00963495|CLL
1248324|NCT00963495|High risk myelodysplasia (MDS) with an IPSS score >2.5
1248325|NCT00963495|CML blast crisis
1248326|NCT00963495|Relapsed or refractory acute myeloid leukemia (AML)
1248327|NCT00963482|Smoking
1248328|NCT00963482|Alcohol
1248329|NCT00963482|Outcome
1248330|NCT00963482|Harm reduction
1248331|NCT00963482|Alcohol drinking
1248332|NCT00963482|Treatment outcome
1248333|NCT00963482|Treatment effectiveness
1248334|NCT00963443|Aspirin Complex
1248335|NCT00963443|Acetylsalicylic Acid
1248336|NCT00963443|Pseudoephedrine
1248337|NCT00963443|Common Cold
1248338|NCT00963430|H1N1, influenza A viruses, pregnant women
1248339|NCT00963417|osteoporosis
1248340|NCT00963417|estrogen receptor-positive breast cancer
1248341|NCT00963417|progesterone receptor-positive breast cancer
1248342|NCT00963417|stage IA breast cancer
1248343|NCT00963417|stage IB breast cancer
1248344|NCT00963417|stage II breast cancer
1248345|NCT00963417|stage IIIA breast cancer
1248346|NCT00963404|Image-guided Radiotherapy
1248347|NCT00963404|Fiducial marker
1248348|NCT00963404|Adverse effects
1248349|NCT00963313|Axial psoriatic arthritis
1248350|NCT00963313|Adalimumab
1248351|NCT00963313|Humira
1248352|NCT00963313|anti-TNF
1248353|NCT00963300|adenocarcinoma of the prostate
1248354|NCT00963300|stage I prostate cancer
1248355|NCT00963300|stage IIB prostate cancer
1248356|NCT00963300|stage IIA prostate cancer
1248357|NCT00963300|stage III prostate cancer
1248358|NCT00963300|stage IV prostate cancer
1248359|NCT00963287|alternative medicine
1248360|NCT00963287|traditional Chinese medicine
1248361|NCT00963274|refractory chronic lymphocytic leukemia
1248362|NCT00963274|stage I chronic lymphocytic leukemia
1248363|NCT00963274|stage II chronic lymphocytic leukemia
1248364|NCT00963274|stage III chronic lymphocytic leukemia
1248365|NCT00963274|stage IV chronic lymphocytic leukemia
1248366|NCT00963274|recurrent small lymphocytic lymphoma
1248367|NCT00963274|contiguous stage II small lymphocytic lymphoma
1248368|NCT00963274|noncontiguous stage II small lymphocytic lymphoma
1248369|NCT00963274|stage I small lymphocytic lymphoma
1248370|NCT00963274|stage III small lymphocytic lymphoma
1248371|NCT00963274|stage IV small lymphocytic lymphoma
1248372|NCT00963274|adult nasal type extranodal NK/T-cell lymphoma
1248373|NCT00963274|anaplastic large cell lymphoma
1248374|NCT00963274|angioimmunoblastic T-cell lymphoma
1248375|NCT00963274|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1248376|NCT00963274|hepatosplenic T-cell lymphoma
1248377|NCT00963274|nodal marginal zone B-cell lymphoma
1248378|NCT00963274|peripheral T-cell lymphoma
1248379|NCT00963261|melanoma
1248380|NCT00963261|interferon-a
1248381|NCT00963261|quality of life
1248382|NCT00963261|psychological distress
1248383|NCT00963261|depressive symptoms
1248384|NCT00963261|side effects
1248385|NCT00963248|EBV
1248386|NCT00963248|PTLD
1248387|NCT00963248|RTx
1248388|NCT00963248|pediatric
1248389|NCT00963235|vaccine
1248390|NCT00963235|13-valent pneumococcal conjugate vaccine
1248391|NCT00963235|human immunodeficiency virus
1248392|NCT00963222|Atherosclerosis
1248393|NCT00963222|Coronary Artery Disease
1248394|NCT00963222|Vitamin A
1248395|NCT00963222|CD4-Positive T-Lymphocytes
1248396|NCT00963222|Th1 Cells
1248397|NCT00963222|Th2 Cells
1248398|NCT00963209|endocrine sensitive
1248399|NCT00963209|breast cancer
1248400|NCT00963209|tamoxifen
1248401|NCT00963209|genotyping
1248402|NCT00963209|phenotyping
1248403|NCT00963209|Pharmacokinetics
1248404|NCT00963209|Endoxifen
1248405|NCT00963183|Safety
1248406|NCT00963183|Tolerability
1248407|NCT00963183|Healthy
1248408|NCT00963183|Inhalation
1248409|NCT00963157|H1N1, influenza A viruses, vaccine, elderly
1248410|NCT00963144|Gerd Questionnaire
1248411|NCT00963131|Central serous chorioretinopathy,antioxidants
1248412|NCT00963118|Angelica keiskei
1248413|NCT00963118|Glycine max
1248414|NCT00963118|metabolic syndrome
1248415|NCT00963092|adenocarcinoma of the gastroesophageal junction
1248416|NCT00963092|recurrent gastric cancer
1248417|NCT00963092|stage IV gastric cancer
1248418|NCT00963092|adenocarcinoma of the stomach
1248419|NCT00963092|adenocarcinoma of the esophagus
1248420|NCT00963092|recurrent esophageal cancer
1248421|NCT00963092|stage I esophageal cancer
1248422|NCT00963092|stage II esophageal cancer
1248423|NCT00963092|stage III esophageal cancer
1248424|NCT00963092|stage IV esophageal cancer
1248425|NCT00963092|stage IA gastric cancer
1248426|NCT00963092|stage IB gastric cancer
1248427|NCT00963092|stage IIA gastric cancer
1248428|NCT00963092|stage IIB gastric cancer
1248429|NCT00963092|stage IIIA gastric cancer
1248430|NCT00963092|stage IIIB gastric cancer
1248431|NCT00963092|stage IIIC gastric cancer
1248432|NCT00963079|IVF
1248433|NCT00963079|in vitro fertilization
1248434|NCT00963079|blastocyst transfer
1248435|NCT00963079|endometrial receptivity
1248436|NCT00963079|embryo cryopreservation
1248437|NCT00963066|NAVA
1248438|NCT00963066|Acute Lung Injury
1248439|NCT00963066|Pressure Support Ventilation
1248440|NCT00963066|Intubation
1248441|NCT00963066|Tracheostomy
1248442|NCT00963066|Mechanical ventilation
1248443|NCT00963053|dysmenorrhoea
1248444|NCT00963053|dysmenorrhea
1248445|NCT00963053|pain
1248446|NCT00963053|pre-emptive
1248447|NCT00963040|intranasal oxytocin
1248448|NCT00963040|acute headache treatment
1248449|NCT00963040|chronic daily headache
1248450|NCT00963027|Hypertension, Pulmonary
1248451|NCT00963027|Treprostinil
1248452|NCT00963027|Pharmacokinetics
1248453|NCT00963027|Treprostinil Diethanolamine
1248454|NCT00963027|Pulmonary Arterial Hypertension
1248455|NCT00963027|Esomeprazole
1248456|NCT00963001|Hypertension, Pulmonary
1248457|NCT00963001|Treprostinil
1248458|NCT00963001|Pharmacokinetics
1248459|NCT00963001|Treprostinil Diethanolamine
1248460|NCT00963001|Pulmonary Arterial Hypertension
1248461|NCT00962988|Cerebrovascular disease
1248462|NCT00962988|stroke
1248463|NCT00962988|Transient Ischemic Attack
1248464|NCT00962988|smoking cessation
1248465|NCT00962988|Pharmacotherapy
1248466|NCT00962962|Abnormal fasting glucose
1248467|NCT00962949|POTS
1248468|NCT00962949|Orthostatic intolerance
1248469|NCT00962936|Chronic Hepatitis C
1248470|NCT00962936|HCV Genotype I infection
1248471|NCT00962936|Liver disease
1248472|NCT00962923|Systemic sclerosis
1248473|NCT00962923|Mesenchymal Stem Cells
1248474|NCT00962923|Transplantation
1248475|NCT00962910|Femoral Fractures
1248476|NCT00962910|Critical Pathway
1248477|NCT00962910|Cluster Randomized Controlled Trial
1248478|NCT00962910|Safety
1248479|NCT00962910|Efficiency
1248480|NCT00962897|atherosclerosis
1248481|NCT00962897|covered stent
1248482|NCT00962897|percutaneous intervention
1248483|NCT00962897|stent
1248484|NCT00962897|angioplasty
1248485|NCT00962884|Orthostatic hypotension
1248486|NCT00962884|Breathing
1248487|NCT00962884|Blood pressure
1248488|NCT00962884|standing
1248489|NCT00962845|stage III melanoma
1248490|NCT00962845|stage IV melanoma
1248491|NCT00962832|rhuMAb IFNalpha
1248492|NCT00962832|SLE
1248493|NCT00962819|Mumps
1248494|NCT00962819|Immunity
1248495|NCT00962819|Vaccine
1248496|NCT00962819|Mumps antibodies
1248497|NCT00962819|Mumps immunity
1248498|NCT00962806|Pediatric obesity
1248499|NCT00962806|Insulin resistance
1248500|NCT00962806|Diabetes
1248501|NCT00962806|Mitochondria
1248502|NCT00962793|latent tuberculosis prevalence of health care workers
1248503|NCT00962780|vaccine
1248504|NCT00962780|13-valent pneumococcal conjugate vaccine
1248505|NCT00962780|23-valent pneumococcal polysaccharide vaccine
1248506|NCT00962780|human immunodeficiency virus
1248507|NCT00962767|Oncology comparison study
1248508|NCT00962754|recording fluid balance
1248509|NCT00962754|reliability
1248510|NCT00962754|utility
1248511|NCT00962754|sick neonate
1248512|NCT00962754|fluid balance
1248513|NCT00962754|inpatient
1248514|NCT00962754|sick
1248515|NCT00962728|heart rate
1248516|NCT00962728|tachycardia
1248517|NCT00962728|orthostatic intolerance
1248518|NCT00962715|Leukemia
1248519|NCT00962715|CLL
1248520|NCT00962715|Influenza Vaccine Trivalent Inactivated
1248521|NCT00962715|TIV
1248522|NCT00962715|Flu
1248523|NCT00962715|Pegasys
1248524|NCT00962715|Pegylated interferon
1248525|NCT00962715|Roferon
1248526|NCT00962715|Interferon
1248527|NCT00962702|Exclusion
1248528|NCT00962702|Left Atrial Appendage
1248529|NCT00962702|Surgical
1248530|NCT00962702|Open chest
1248531|NCT00962689|chronic rhinosinusitis
1248532|NCT00962689|biofilm
1248533|NCT00962689|sinus tissue
1248534|NCT00962689|nasal secretions
1248535|NCT00962689|proteomics
1248536|NCT00962689|diagnosis
1248537|NCT00962689|decreased antibiotics
1248538|NCT00962689|Develop a test to identify patients with sinusitis subtypes
1248539|NCT00962676|suspicious of tuberculosis
1248540|NCT00962676|immunocompromised patients
1248541|NCT00962650|abdominal adhesions
1248542|NCT00962650|diagnostic peritoneoscopy
1248543|NCT00962650|Natural Orifice Transluminal Endoscopic Surgery
1248544|NCT00962650|NOTES
1248545|NCT00962637|Secondary Hypogonadism
1248546|NCT00962624|Meningococcal
1248547|NCT00962624|Vaccine
1248548|NCT00962624|Meningitis
1248549|NCT00962611|Solid tumors
1248550|NCT00962611|Advanced cancer
1248551|NCT00962598|Adolescents
1248552|NCT00962598|Major Depressive Disorder
1248553|NCT00962598|Proton Magnetic Resonance Spectroscopy
1248554|NCT00962598|Immune System Activation
1248555|NCT00962598|Omega-3 Fatty Acids
1248556|NCT00962572|Outcomes
1248557|NCT00962572|Cancer
1248558|NCT00962572|Radiotherapy
1248559|NCT00962572|Socio-economic
1248560|NCT00962546|cerebral aneurysm
1248561|NCT00962546|subarachnoid hemorrhage
1248562|NCT00962546|cerebral vasospasm
1248563|NCT00962546|computed tomographic perfusion
1248564|NCT00962546|computed tomographic angiography
1248565|NCT00962533|Chronic Hepatitis B
1248566|NCT00962520|pancreatic cancer
1248567|NCT00962520|resectable
1248568|NCT00962520|Tarceva
1248569|NCT00962507|recurrent adult T-cell leukemia/lymphoma
1248570|NCT00962507|adult nasal type extranodal NK/T-cell lymphoma
1248571|NCT00962507|anaplastic large cell lymphoma
1248572|NCT00962507|angioimmunoblastic T-cell lymphoma
1248573|NCT00962507|splenic marginal zone lymphoma
1248574|NCT00962507|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1248575|NCT00962507|nodal marginal zone B-cell lymphoma
1248576|NCT00962507|recurrent adult Hodgkin lymphoma
1248577|NCT00962507|recurrent adult Burkitt lymphoma
1248578|NCT00962507|recurrent adult diffuse large cell lymphoma
1248579|NCT00962507|recurrent adult diffuse mixed cell lymphoma
1248580|NCT00962507|recurrent adult diffuse small cleaved cell lymphoma
1248581|NCT00962507|recurrent adult grade III lymphomatoid granulomatosis
1248582|NCT00962507|recurrent adult immunoblastic large cell lymphoma
1248583|NCT00962507|recurrent adult lymphoblastic lymphoma
1248584|NCT00962507|recurrent cutaneous T-cell non-Hodgkin lymphoma
1248585|NCT00962507|recurrent mycosis fungoides/Sezary syndrome
1248586|NCT00962507|recurrent grade 1 follicular lymphoma
1248587|NCT00962507|recurrent grade 2 follicular lymphoma
1248588|NCT00962507|recurrent grade 3 follicular lymphoma
1248589|NCT00962507|recurrent mantle cell lymphoma
1248590|NCT00962507|recurrent marginal zone lymphoma
1248591|NCT00962507|recurrent small lymphocytic lymphoma
1248592|NCT00962507|cutaneous B-cell non-Hodgkin lymphoma
1248593|NCT00962507|Waldenstrom macroglobulinemia
1248594|NCT00962507|refractory multiple myeloma
1248595|NCT00962468|Pulmonary Disease, Chronic Obstructive
1248596|NCT00962468|Critical Pathway
1248597|NCT00962468|Cluster Randomized Controlled Trial
1248598|NCT00962468|Safety
1248599|NCT00962468|Efficiency
1248600|NCT00962455|Spirometry
1248601|NCT00962455|Family Practice
1248602|NCT00962455|Randomized Controlled Trial
1248603|NCT00962455|Feedback
1248604|NCT00962455|Intervention Studies
1248605|NCT00962442|alcoholic hepatitis
1248606|NCT00962442|N-Acetylcysteine
1248607|NCT00962442|enteral nutrition
1248608|NCT00962442|oxidative stress
1248609|NCT00962442|severe acute alcoholic hepatitis
1248610|NCT00962429|neuropathy, lipoic acid
1248611|NCT00962416|Drug eluting stent
1248612|NCT00962416|Biolimus
1248613|NCT00962416|Biodegradable stent
1248614|NCT00962416|ST-elevation myocardial infarction
1248615|NCT00962416|Coronary artery disease
1248616|NCT00962403|post traumatic stress disorder
1248617|NCT00962403|yoga
1248618|NCT00962403|meditation
1248619|NCT00962403|military
1248620|NCT00962403|veteran
1248621|NCT00962403|trauma
1248622|NCT00962403|stress
1248623|NCT00962403|depression
1248624|NCT00962403|anxiety
1248625|NCT00962403|insomnia
1248626|NCT00962403|autonomic
1248627|NCT00962377|molecular expression testing
1248628|NCT00962377|right ventricular endomyocardial biopsy
1248629|NCT00962351|total hip replacement
1248630|NCT00962351|primary cementless total hip arthroplasty
1248631|NCT00962351|metal ion
1248632|NCT00962351|metal-on-metal
1248633|NCT00962338|convalescence
1248634|NCT00962338|pain
1248635|NCT00962338|nausea
1248636|NCT00962338|vomiting
1248637|NCT00962338|sexual dysfunction
1248638|NCT00962325|Physical activity
1248639|NCT00962325|Obesity
1248640|NCT00962325|Bariatric surgery
1248641|NCT00962325|Weight Loss
1248642|NCT00962312|adenocarcinoma of the pancreas
1248643|NCT00962312|recurrent pancreatic cancer
1248644|NCT00962312|stage IV pancreatic cancer
1248645|NCT00962299|Child
1248646|NCT00962299|Wheezing
1248647|NCT00962299|Dyspnea
1248648|NCT00962299|Inhaled corticosteroids
1248649|NCT00962286|Furosemide
1248650|NCT00962286|obesity
1248651|NCT00962273|health personnel
1248652|NCT00962273|communicable diseases
1248653|NCT00962273|stress, psychological
1248654|NCT00962273|resilience, psychological
1248655|NCT00962273|disaster planning
1248656|NCT00962273|education
1248657|NCT00962273|online
1248658|NCT00962260|glucocerebrosidase
1248659|NCT00962260|enzyme replacement therapy
1248660|NCT00962260|Gaucher disease
1248661|NCT00962260|plant cell culture
1248662|NCT00962260|splenomegaly
1248663|NCT00962260|hepatomegaly
1248664|NCT00962260|anemia
1248665|NCT00962260|thrombocytopenia
1248666|NCT00962247|physical activity
1248667|NCT00962247|relative reinforcing value
1248668|NCT00962247|sedentary behavior
1248669|NCT00962247|obesity
1248670|NCT00962247|reduce sedentary behaviors in children and increase physical activity
1248671|NCT00962234|Lipogenesis
1248672|NCT00962234|Lipolysis
1248673|NCT00962234|Phospholipids
1248674|NCT00962234|Body Composition
1248675|NCT00962234|Nutritional Status
1248676|NCT00962234|Lipid Metabolism
1248677|NCT00962221|LDL lipoprotein subclasses in subclinical hypothyroidism
1248678|NCT00962208|children
1248679|NCT00962208|corneal reshaping
1248680|NCT00962208|myopia
1248681|NCT00962208|myopia control
1248682|NCT00962208|orthokeratology
1248683|NCT00962195|health
1248684|NCT00962195|blood pressure
1248685|NCT00962195|liver enzymes
1248686|NCT00962195|insulin resistance
1248687|NCT00962182|celiac disease
1248688|NCT00962182|transglutaminase antibody
1248689|NCT00962169|Guideline adherence
1248690|NCT00962169|Implementation
1248691|NCT00962169|Physical therapy
1248692|NCT00962169|Low back pain
1248693|NCT00962169|Health plan implementation
1248694|NCT00962156|Sepsis
1248695|NCT00962156|Shock
1248696|NCT00962156|Fluid therapy
1248697|NCT00962156|Plasma expanders
1248698|NCT00962143|Acute Achilles Tendon Tear
1248699|NCT00962143|Acute Achilles Tendon Repair
1248700|NCT00962130|tissue perfusion
1248701|NCT00962130|reconstructive surgery
1248702|NCT00962130|continuous glucose monitoring
1248703|NCT00962117|Food Reinforcement
1248704|NCT00962117|Energy Intake
1248705|NCT00962117|Obesity
1248706|NCT00962117|Dopamine
1248707|NCT00962104|ADHD
1248708|NCT00962091|Area under the plasma concentration versus time curve (AUC)
1248709|NCT00962091|Maximum plasma concentration (Cmax)
1248710|NCT00962091|Area under the plasma concentration versus time curve zero to the time of the last quantifiable concentration (AUC0-tlast)
1248711|NCT00962091|Confidence intervals (CI)
1248712|NCT00962091|Time of first observed maximum plasma concentration (Tmax)
1248713|NCT00962078|COPD
1248714|NCT00962078|Pre-Lung-Transplantation
1248715|NCT00962078|Intervall versus continuous training
1248716|NCT00962078|6 MWD
1248717|NCT00962039|Abdominal Pain
1248718|NCT00962039|Anxiety
1248719|NCT00962026|Interleukin 1
1248720|NCT00962026|Type 1 diabetes mellitus
1248721|NCT00962026|Rilonacept
1248722|NCT00962026|Arcalyst
1248723|NCT00962000|Hemodialysis
1248724|NCT00962000|Dialysis, Renal
1248725|NCT00961987|Maternity care
1248726|NCT00961987|Interprofessional collaboration
1248727|NCT00961987|Continuity of Care
1248728|NCT00961987|Integration
1248729|NCT00961974|type 1 diabetes
1248730|NCT00961974|hemoglobin A1c
1248731|NCT00961974|family
1248732|NCT00961974|involvement
1248733|NCT00961974|responsibility
1248734|NCT00961974|conflict
1248735|NCT00961974|quality of life
1248736|NCT00961974|children
1248737|NCT00961961|Bipolar Disorder
1248738|NCT00961961|Manic Depression
1248739|NCT00961961|Major Depressive Episode
1248740|NCT00961961|Mania
1248741|NCT00961961|Hypomania
1248742|NCT00961961|Long Term Treatment
1248743|NCT00961948|Indigo carmine dye spraying
1248744|NCT00961948|Narrow band imaging (NBI)
1248745|NCT00961948|Confocal Microscopy
1248746|NCT00961935|bipolar disorder
1248747|NCT00961935|child bipolar disorder
1248748|NCT00961935|adolescent bipolar disorder
1248749|NCT00961935|pediatric bipolar disorder
1248750|NCT00961935|fMRI
1248751|NCT00961935|MRI
1248752|NCT00961935|EEG
1248753|NCT00961935|neurocognitive tasks
1248754|NCT00961922|childhood brain tumour survivors
1248755|NCT00961896|Basal Cell Carcinoma
1248756|NCT00961896|Gorlin Syndrome,
1248757|NCT00961896|Gorlin-Goltz Syndrome,
1248758|NCT00961896|Basal Cell Nevus Syndrome,
1248759|NCT00961896|Nevoid Basal Cell Carcinoma Syndrome,
1248760|NCT00961896|Basal Cell Carcinoma Nevus Syndrome
1248761|NCT00961883|HIV
1248762|NCT00961883|Vaccine
1248763|NCT00961883|HIV Seronegativity
1248764|NCT00961883|Preventive Vaccine
1248765|NCT00961870|bone
1248766|NCT00961870|motor neuron excitability
1248767|NCT00961870|forearm vibration
1248768|NCT00961870|Mechanical Loading
1248769|NCT00961831|Neoplasm
1248770|NCT00961831|PET/CT diagnosis
1248771|NCT00961831|PET tracer
1248772|NCT00961818|Voice
1248773|NCT00961818|Voice Quality
1248774|NCT00961818|Voice Training
1248775|NCT00961818|Evaluation
1248776|NCT00961805|Fibromyalgia
1248777|NCT00961805|Treatment
1248778|NCT00961805|Dance
1248779|NCT00961805|Randomized controlled study
1248780|NCT00961805|Exercise
1248781|NCT00961753|PDA
1248782|NCT00961753|Ibuprofen
1248783|NCT00961753|Preterm
1248784|NCT00961753|Neonate
1248785|NCT00961740|Childhood Obesity
1248786|NCT00961740|CBT
1248787|NCT00961740|Family
1248788|NCT00961740|Lifestyle change
1248789|NCT00961727|Bedside Pews
1248790|NCT00961727|Credit Valley Hospital
1248791|NCT00961727|The Bedside Paediatric Early Warning System
1248792|NCT00961727|clinically deteriorating
1248793|NCT00961714|VCF
1248794|NCT00961688|PCOS
1248795|NCT00961688|polycystic ovary syndrome
1248796|NCT00961688|Polycystic ovarian syndrome
1248797|NCT00961688|infertility
1248798|NCT00961688|ovulation
1248799|NCT00961675|otitis
1248800|NCT00961675|acute
1248801|NCT00961675|externa
1248802|NCT00961675|ear
1248803|NCT00961649|Open-Angle Glaucoma
1248804|NCT00961649|Ocular Hypertension
1248805|NCT00961649|Brinzolamide
1248806|NCT00961649|Brimonidine
1248807|NCT00961649|Intraocular Pressure
1248808|NCT00961610|internet support
1248809|NCT00961610|cancer
1248810|NCT00961610|rehabilitation
1248811|NCT00961597|Meniscus
1248812|NCT00961597|Avascular region
1248813|NCT00961597|Platelet rich plasma
1248814|NCT00961571|colorectal cancer
1248815|NCT00961571|sunitinib
1248816|NCT00961571|capecitabine
1248817|NCT00961558|varicocelectomy
1248818|NCT00961558|male infertility
1248819|NCT00961558|clinical varicoceles
1248820|NCT00961558|randomized control trial
1248821|NCT00961532|intracerebral hemorrhage
1248822|NCT00961532|platelets
1248823|NCT00961506|cholecystectomy
1248824|NCT00961506|gallbladder
1248825|NCT00961506|laparoscopy
1248826|NCT00961506|laparoendoscopic
1248827|NCT00961467|Relapsed/ refractory Multiple Myeloma
1248828|NCT00961454|Major depressive disorder, anxiety disorders, treatments, photobiomodulation, near infra-red phototherapy, cerebral blood flow
1248829|NCT00961441|Levetiracetam
1248830|NCT00961441|Epilepsy
1248831|NCT00961441|Children
1248832|NCT00961441|Adults
1248833|NCT00961428|Anorexia Nervosa
1248834|NCT00961428|Eating Disorders
1248835|NCT00961428|Exercise
1248836|NCT00961428|Physical Activity
1248837|NCT00961402|Exercise
1248838|NCT00961402|PostParum Depression
1248839|NCT00961389|delirium
1248840|NCT00961389|critical care
1248841|NCT00961389|risk factors
1248842|NCT00961389|prediction
1248843|NCT00961389|inflammation
1248844|NCT00961376|melanoma
1248845|NCT00961376|unresectable stage III or IV melanoma
1248846|NCT00961350|PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers.
1248847|NCT00961337|school children
1248848|NCT00961337|influenza vaccination
1248849|NCT00961337|vaccine effectiveness
1248850|NCT00961337|influenza attack rate
1248851|NCT00961337|absenteeism
1248852|NCT00961337|Influenza vaccine
1248853|NCT00961311|Balloon
1248854|NCT00961311|Angioplasty
1248855|NCT00961311|Coronary Artery
1248856|NCT00961311|PCI
1248857|NCT00961311|PTCA
1248858|NCT00961311|Heart Disease
1248859|NCT00961311|Myocardial Ischemia
1248860|NCT00961298|IBS
1248861|NCT00961298|Irritable Bowel Syndrome
1248862|NCT00961298|GAD
1248863|NCT00961298|Generalized Anxiety Disorder
1248864|NCT00961285|pharmacogenomics
1248865|NCT00961285|genotyping
1248866|NCT00961272|Pre-menopausal
1248867|NCT00961272|Pharmacokinetics
1248868|NCT00961272|Raltegravir
1248869|NCT00961272|Women
1248870|NCT00961272|HIV-infected
1248871|NCT00961259|healthy
1248872|NCT00961259|pharmacokinetics
1248873|NCT00961259|therapeutic equivalency
1248874|NCT00961259|fenofibric acid
1248875|NCT00961246|web based intervention
1248876|NCT00961246|individually-tailored
1248877|NCT00961246|Chinese-American children
1248878|NCT00961246|compared the changes in physical activity level
1248879|NCT00961246|changes in dietary intake
1248880|NCT00961246|changes in coping strategy used
1248881|NCT00961246|changes in BMI
1248882|NCT00961233|eosinophilic esophagitis
1248883|NCT00961194|Ketamine
1248884|NCT00961194|pain
1248885|NCT00961194|neuropathic pain
1248886|NCT00961194|chronic
1248887|NCT00961181|paclitaxel
1248888|NCT00961181|in-stent restenosis
1248889|NCT00961181|BMS-ISR
1248890|NCT00961181|DES-ISR
1248891|NCT00961181|drug eluting balloon
1248892|NCT00961168|Mechanical Ventilation
1248893|NCT00961155|asthma
1248894|NCT00961155|children
1248895|NCT00961155|EBC
1248896|NCT00961155|exposure to tabacco
1248897|NCT00961155|antiasthma treatment
1248898|NCT00961142|Haploidentical Transplantation
1248899|NCT00961142|CD3/CD19 Depletion
1248900|NCT00961142|AML
1248901|NCT00961142|ALL
1248902|NCT00961142|Reduced Intensity Conditioning
1248903|NCT00961129|colorectal cancer
1248904|NCT00961129|needs
1248905|NCT00961129|survivors
1248906|NCT00961129|any stage
1248907|NCT00961116|healthy
1248908|NCT00961116|pharmacokinetics
1248909|NCT00961116|therapeutic equivalency
1248910|NCT00961116|fasting
1248911|NCT00961116|procetofen
1248912|NCT00961116|fenofibric acid
1248913|NCT00961103|spinal muscular atrophy
1248914|NCT00961103|motor development
1248915|NCT00961103|orthoses
1248916|NCT00961090|Brain tumor
1248917|NCT00961090|glioma
1248918|NCT00961090|surgical resection
1248919|NCT00961090|ALA
1248920|NCT00961090|ultraviolet light
1248921|NCT00961077|elderly
1248922|NCT00961077|S-1
1248923|NCT00961077|Oxaliplatin
1248924|NCT00961077|relapsed or metastatic gastric cancer
1248925|NCT00961064|Promacta
1248926|NCT00961064|Thrombocytopenia
1248927|NCT00961064|Myelodysplastic Syndrome
1248928|NCT00961064|MDS
1248929|NCT00961051|adapted contact lens wearers
1248930|NCT00961038|Ciprofloxacin
1248931|NCT00961038|Inhalation
1248932|NCT00961038|Pharmacokinetics
1248933|NCT00961038|Safety
1248934|NCT00961038|Tolerability
1248935|NCT00961038|COPD
1248936|NCT00961012|Randomized control trial
1248937|NCT00961012|pressure mapping
1248938|NCT00961012|High Fowler's position
1248939|NCT00961012|bed
1248940|NCT00961012|ventilation
1248941|NCT00961012|slow vital capacity
1248942|NCT00961012|older adult population
1248943|NCT00961012|65 years and older
1248944|NCT00960999|stage I non-small cell lung cancer
1248945|NCT00960999|squamous cell lung cancer
1248946|NCT00960999|adenocarcinoma of the lung
1248947|NCT00960999|large cell lung cancer
1248948|NCT00960973|vitamin K
1248949|NCT00960973|beta cell
1248950|NCT00960973|glucose metabolism
1248951|NCT00960973|insulin resistance
1248952|NCT00960960|MBC
1248953|NCT00960960|PI3K
1248954|NCT00960960|Avastin
1248955|NCT00960960|Herceptin
1248956|NCT00960934|Osteoporosis
1248957|NCT00960934|Postmenopausal
1248958|NCT00960934|MK-5442
1248959|NCT00960921|Pulmonary artery pressure
1248960|NCT00960921|Hypoxia
1248961|NCT00960921|Iron
1248962|NCT00960921|Hypoxia-inducible factor
1248963|NCT00960921|High altitude
1248964|NCT00960908|Zotarolimus
1248965|NCT00960908|Drug eluting stent
1248966|NCT00960908|Endeavor Resolute
1248967|NCT00960895|Lymphangioleiomyomatosis
1248968|NCT00960895|Pulmonary hypertension
1248969|NCT00960882|Pharmacokinetics
1248970|NCT00960882|Diabetes
1248971|NCT00960882|gastric tolerability
1248972|NCT00960869|PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers.
1248973|NCT00960856|pharmacokinetics
1248974|NCT00960843|Morbid Obesity
1248975|NCT00960843|Gastric Banding
1248976|NCT00960843|Bariatric Banding
1248977|NCT00960843|Swedish Adjustable Gastric Band
1248978|NCT00960817|Normal coronary artery with slow blood flow
1248979|NCT00960804|OA
1248980|NCT00960791|Type II diabetes mellitus
1248981|NCT00960791|absorption
1248982|NCT00960791|distribution
1248983|NCT00960791|metabolism
1248984|NCT00960791|excretion
1248985|NCT00960791|14C-labelled
1248986|NCT00960778|gender
1248987|NCT00960778|nicotine dependence
1248988|NCT00960778|nicotine replacement therapy
1248989|NCT00960778|extinction
1248990|NCT00960778|denicotinized cigarettes
1248991|NCT00960765|Type 2 Diabetes Mellitus
1248992|NCT00960765|Gastric Bypass
1248993|NCT00960765|Gastric Banding
1248994|NCT00960765|Endotoxin
1248995|NCT00960752|gp100 peptide
1248996|NCT00960752|MAGE-3 peptide
1248997|NCT00960752|R848
1248998|NCT00960752|Resiquimod
1248999|NCT00960752|Toll Like Receptor
1249000|NCT00960752|TLR
1249001|NCT00960752|T-cells
1249002|NCT00960752|Tumor
1249003|NCT00960752|Metastatic
1249004|NCT00960752|Lesions
1249005|NCT00960752|Injection Site
1249006|NCT00960739|disseminated neuroblastoma
1249007|NCT00960739|localized unresectable neuroblastoma
1249008|NCT00960739|recurrent neuroblastoma
1249009|NCT00960739|stage 4S neuroblastoma
1249010|NCT00960726|Leukemia
1249011|NCT00960726|NOV-002
1249012|NCT00960726|Myelodysplastic Syndrome
1249013|NCT00960726|MDS
1249014|NCT00960713|observational cohort
1249015|NCT00960713|rituximab
1249016|NCT00960713|off-label use
1249017|NCT00960713|auto-immunity
1249018|NCT00960713|cytopenia
1249019|NCT00960700|MFlex
1249020|NCT00960700|Multifocal
1249021|NCT00960700|630F
1249022|NCT00960687|healthy
1249023|NCT00960687|pharmacokinetics
1249024|NCT00960687|therapeutic equivalency
1249025|NCT00960661|diabetes
1249026|NCT00960661|exenatide
1249027|NCT00960661|Byetta
1249028|NCT00960661|insulin lispro
1249029|NCT00960661|Humalog
1249030|NCT00960661|insulin glargine
1249031|NCT00960661|Lantus
1249032|NCT00960661|Amylin
1249033|NCT00960661|Lilly
1249034|NCT00960648|Everolimus
1249035|NCT00960648|Sirolimus
1249036|NCT00960648|Drug eluting stent
1249037|NCT00960635|new-onset
1249038|NCT00960622|treatment experienced
1249039|NCT00960609|Communicating veins
1249040|NCT00960609|hepatic venous anastomosis
1249041|NCT00960609|intra-operative ultrasonography
1249042|NCT00960609|hepatic resection
1249043|NCT00960609|hepatic neoplasm
1249044|NCT00960609|Primary and metastatic liver tumors
1249045|NCT00960596|educational intervention
1249046|NCT00960596|asthma
1249047|NCT00960596|Environmental Tobacco Smoke(ETS)
1249048|NCT00960596|children
1249049|NCT00960583|Chronic low back pain
1249050|NCT00960583|Multidisciplinary rehabilitation
1249051|NCT00960583|Exercise
1249052|NCT00960583|Cost-effectiveness
1249053|NCT00960570|healthy
1249054|NCT00960570|adult
1249055|NCT00960570|efavirenz
1249056|NCT00960570|fenofibric acid
1249057|NCT00960570|blood levels
1249058|NCT00960557|hepatic tumor burden
1249059|NCT00960557|liver cancer
1249060|NCT00960557|liver carcinoma
1249061|NCT00960557|carcinoma
1249062|NCT00960557|hepatic cancer
1249063|NCT00960557|hepatic carcinoma
1249064|NCT00960557|VDA
1249065|NCT00960557|Vascular Disrupting Agent
1249066|NCT00960544|Capecitabine
1249067|NCT00960544|Xeloda
1249068|NCT00960544|Gene expression
1249069|NCT00960544|Pharmacokinetic testing
1249070|NCT00960544|PK sampling
1249071|NCT00960544|DNA analysis
1249072|NCT00960518|HBV-related unresectable HCC
1249073|NCT00960518|TACE
1249074|NCT00960518|adefovir
1249075|NCT00960518|recurrence rate
1249076|NCT00960505|Diet
1249077|NCT00960505|Coronary heart disease
1249078|NCT00960505|Obesity
1249079|NCT00960505|Weight loss
1249080|NCT00960505|Weight maintenance
1249081|NCT00960492|Astrocytic tumor
1249082|NCT00960492|Glioblastoma with oligodendroglial components
1249083|NCT00960466|Stress, Psychological
1249084|NCT00960466|Neoplasms/psychology
1249085|NCT00960466|Psychology
1249086|NCT00960440|randomized double-blind placebo-controlled investigational drug oral therapy safety and efficacy
1249087|NCT00960427|adenocarcinoma of the rectum
1249088|NCT00960427|stage II rectal cancer
1249089|NCT00960427|stage III rectal cancer
1249090|NCT00960414|obesity
1249091|NCT00960414|randomized controlled trial
1249092|NCT00960414|weight loss
1249093|NCT00960414|metabolic syndrome
1249094|NCT00960401|coronary calcium scoring
1249095|NCT00960401|breast cancer patients
1249096|NCT00960401|radiation treatment
1249097|NCT00960375|smoking cessation
1249098|NCT00960375|serious mental illness
1249099|NCT00960349|Gastric cancer
1249100|NCT00960349|Japanese
1249101|NCT00960349|PhI
1249102|NCT00960349|Safety and tolerability
1249103|NCT00960349|Cediranib in combination with cisplatin plus a fluoropyrimidine
1249104|NCT00960349|Cediranib
1249105|NCT00960349|Capecitabine
1249106|NCT00960349|S-1
1249107|NCT00960349|Cisplatin
1249108|NCT00960349|Untreated locally advanced or metastatic unresectable gastric cancer (GC)
1249109|NCT00960336|HER2-negative breast cancer
1249110|NCT00960336|recurrent breast cancer
1249111|NCT00960336|stage IV breast cancer
1249112|NCT00960336|invasive ductal breast carcinoma
1249113|NCT00960336|invasive lobular breast carcinoma
1249114|NCT00960323|pharmacokinetics
1249115|NCT00960310|Treatment
1249116|NCT00960297|Non-Small Cell Lung Cancer
1249117|NCT00960297|NSCLC
1249118|NCT00960297|Preoperative chemotherapy
1249119|NCT00960297|Bevacizumab
1249120|NCT00960297|Avastin
1249121|NCT00960284|stage IB pancreatic cancer
1249122|NCT00960284|stage II pancreatic cancer
1249123|NCT00960284|stage III pancreatic cancer
1249124|NCT00960284|adenocarcinoma of the pancreas
1249125|NCT00960271|Non-small cell lung cancer
1249126|NCT00960271|mediastinal lymph node
1249127|NCT00960271|resectable
1249128|NCT00960271|EBUS
1249129|NCT00960271|stage IIIA
1249130|NCT00960271|significant mediastinal lymph node at thoracic CT Scan
1249131|NCT00960258|Solid Tumors
1249132|NCT00960232|vitamin D
1249133|NCT00960232|blood pressure
1249134|NCT00960232|lipids
1249135|NCT00960232|infection
1249136|NCT00960232|depression
1249137|NCT00960193|blood levels over time
1249138|NCT00960193|colchicine
1249139|NCT00960193|seville orange juice
1249140|NCT00960193|pharmacokinetics
1249141|NCT00960167|HCC
1249142|NCT00960167|radiotherapy
1249143|NCT00960167|dose escalation
1249144|NCT00960167|Toxicity
1249145|NCT00960167|Local control
1249146|NCT00960154|Lumpectomy
1249147|NCT00960154|PlasmaBlade
1249148|NCT00960154|Electrosurgery
1249149|NCT00960154|PEAK Surgical
1249150|NCT00960154|Medtronic Advanced Energy
1249151|NCT00960154|Medtronic
1249152|NCT00960115|NSCLC
1249153|NCT00960115|Stage III
1249154|NCT00960115|EMD531444
1249155|NCT00960115|L-BLP25
1249156|NCT00960115|Cyclophosphamide
1249157|NCT00960115|Immunotherapy
1249158|NCT00960115|Tecemotide
1249159|NCT00960102|cochlear implantation
1249160|NCT00960089|Toenail
1249161|NCT00960089|Fungus
1249162|NCT00960089|Onychomycosis
1249163|NCT00960089|Dermatophyte
1249164|NCT00960076|T2DM
1249165|NCT00960076|Metformin
1249166|NCT00960076|A1c
1249167|NCT00960037|Vitamin D3
1249168|NCT00960037|obesity
1249169|NCT00960037|cholecalciferol
1249170|NCT00960024|Vocational rehabilitation
1249171|NCT00960024|Severe mental illness
1249172|NCT00960024|Psychosis
1249173|NCT00960024|Mental Health
1249174|NCT00960011|Inguinal hernia
1249175|NCT00960011|mesh
1249176|NCT00960011|progrip
1249177|NCT00959998|Persistent Cancer-Related Fatigue
1249178|NCT00959985|compression sleeve
1249179|NCT00959985|compression bandage
1249180|NCT00959972|Varenicline
1249181|NCT00959972|transdermal nicotine patch
1249182|NCT00959972|cardiovascular disease
1249183|NCT00959972|prevention
1249184|NCT00959972|coronary heart disease
1249185|NCT00959972|Smoking cessation
1249186|NCT00959959|CRPC
1249187|NCT00959959|HRPC
1249188|NCT00959959|TOK-001
1249189|NCT00959959|ARMOR
1249190|NCT00959959|ARMOR1
1249191|NCT00959946|Phase 1/2
1249192|NCT00959946|2-part study
1249193|NCT00959946|bosutinib and capecitabine
1249194|NCT00959920|Indwelling bladder catheter
1249195|NCT00959920|Intermittent straight catheterization
1249196|NCT00959920|Labor and Delivery
1249197|NCT00959920|Time to delivery during labor
1249198|NCT00959907|Muscular activity
1249199|NCT00959907|wrinkles in frontal area
1249200|NCT00959907|action halos
1249201|NCT00959894|HIV
1249202|NCT00959894|Infection
1249203|NCT00959894|Treatment Naive
1249204|NCT00959894|Adults
1249205|NCT00959894|Once
1249206|NCT00959894|Daily
1249207|NCT00959894|Etravirine
1249208|NCT00959894|HIV-1 Infection
1249209|NCT00959881|Alzheimer Disease
1249210|NCT00959868|Bladder cancer
1249211|NCT00959868|Superficial bladder cancer (Ta or T1)
1249212|NCT00959868|Muscle invasive bladder cancer (T2)
1249213|NCT00959868|Transurethral resection
1249214|NCT00959868|Radical cystectomy
1249215|NCT00959868|OGX-427
1249216|NCT00959868|Antisense oligonucleotide
1249217|NCT00959868|Heat shock protein 27
1249218|NCT00959868|superficial bladder tumour (Ta or T1) or CIS prior to a transurethral resection
1249219|NCT00959868|Muscle invasive (T2) bladder cancer prior to radical cystectomy
1249220|NCT00959855|COPD
1249221|NCT00959855|Pulmonary Rehabilitation
1249222|NCT00959855|Inflammation
1249223|NCT00959855|Oxidative Stress
1249224|NCT00959855|Steps
1249225|NCT00959855|Free Living Activities
1249226|NCT00959855|Exacerbation
1249227|NCT00959842|hypertriglyceridemia
1249228|NCT00959842|Omega-3 Fatty Acids
1249229|NCT00959842|Lipoprotein
1249230|NCT00959842|Statin
1249231|NCT00959842|Lovaza
1249232|NCT00959829|Communication
1249233|NCT00959829|Complementary Therapies
1249234|NCT00959829|Intensive Care
1249235|NCT00959829|Ethics
1249236|NCT00959816|Volunteers
1249237|NCT00959803|Phase 1
1249238|NCT00959803|Pharmacokinetics
1249239|NCT00959803|Healthy Young Adult
1249240|NCT00959803|Japanese
1249241|NCT00959803|Healthy Elderly
1249242|NCT00959803|Alzheimer disease
1249243|NCT00959790|Health
1249244|NCT00959790|Obesity
1249245|NCT00959790|Oxidative stress
1249246|NCT00959790|Challenge concept
1249247|NCT00959790|Vegetables
1249248|NCT00959751|migraine
1249249|NCT00959738|loop ileostomy
1249250|NCT00959738|quality of life
1249251|NCT00959738|morbidity
1249252|NCT00959738|Rectal Neoplasms
1249253|NCT00959725|Infliximab
1249254|NCT00959725|Diabetes
1249255|NCT00959725|Macular Edema
1249256|NCT00959699|coinfection
1249257|NCT00959699|protease inhibitor
1249258|NCT00959699|HIV
1249259|NCT00959686|Bendamustine refractory or relapsed T-cell lymphoma.
1249260|NCT00959660|Diastolic heart failure
1249261|NCT00959660|Heart Failure
1249262|NCT00959660|Elderly
1249263|NCT00959660|Obesity
1249264|NCT00959647|Hedgehog pathway inhibitor
1249265|NCT00959621|Habitual abortion
1249266|NCT00959621|recurrent abortion
1249267|NCT00959621|hereditary and acquired
1249268|NCT00959621|thrombophilia
1249269|NCT00959621|preeclampsia
1249270|NCT00959621|premature birth
1249271|NCT00959621|miscarriage
1249272|NCT00959621|stillbirth
1249273|NCT00959621|LMWH (low molecular weigh heparin)
1249274|NCT00959621|ASA
1249275|NCT00959621|aspirin
1249276|NCT00959608|Weight Management in adults
1249277|NCT00959608|Reducing Health Disparities
1249278|NCT00959595|Diabetes mellitus
1249279|NCT00959595|neuropathy
1249280|NCT00959595|foot
1249281|NCT00959595|sensibility
1249282|NCT00959595|brain plasticity
1249283|NCT00959582|Relapsed ovarian cancer
1249284|NCT00959569|esmolol
1249285|NCT00959569|cardiac surgery
1249286|NCT00959569|cardiac anesthesia
1249287|NCT00959569|mortality
1249288|NCT00959569|beta blockers
1249289|NCT00959569|beta-blockers
1249290|NCT00959569|cardiac protection
1249291|NCT00959556|recurrent breast cancer
1249292|NCT00959556|stage IA breast cancer
1249293|NCT00959556|stage IB breast cancer
1249294|NCT00959556|stage II breast cancer
1249295|NCT00959556|stage IIIA breast cancer
1249296|NCT00959556|stage IIIB breast cancer
1249297|NCT00959556|stage IIIC breast cancer
1249298|NCT00959556|stage IV breast cancer
1249299|NCT00959530|complete dentures
1249300|NCT00959530|patient satisfaction
1249301|NCT00959530|treatment cost
1249302|NCT00959517|Placebo controlled
1249303|NCT00959517|Efficacy
1249304|NCT00959517|Artemisinin-based combination therapy
1249305|NCT00959517|Primaquine
1249306|NCT00959517|Gametocytes
1249307|NCT00959491|Colonoscopy
1249308|NCT00959491|Occult Blood
1249309|NCT00959491|Fecal
1249310|NCT00959478|Carbon Monoxide (CO)
1249311|NCT00959478|Carbon Monoxide Poisoning
1249312|NCT00959478|Carbon Monoxide Alarm/Detector
1249313|NCT00959478|Precaution Adoption Process Model (PAPM)
1249314|NCT00959478|Injury Prevention
1249315|NCT00959478|Emergency Department
1249316|NCT00959452|Hypochondria
1249317|NCT00959452|Cognitive behavioural therapy
1249318|NCT00959452|Long term follow-up
1249319|NCT00959452|Psychosomatics
1249320|NCT00959452|Psychotherapy
1249321|NCT00959426|- Mutliple Ascending Dose Study in Overweight Subjects - Body Weight - Signs and Symptoms
1249322|NCT00959400|Fentanyl Transdermal
1249323|NCT00959400|Pain
1249324|NCT00959400|Cancer
1249325|NCT00959387|head and neck cancer
1249326|NCT00959387|induction chemotherapy
1249327|NCT00959374|Abdominoplasty
1249328|NCT00959374|Reduction Mammaplasty
1249329|NCT00959374|Mastopexy
1249330|NCT00959361|patient compliance
1249331|NCT00959361|guidelines adherence
1249332|NCT00959361|advance directive adherence
1249333|NCT00959361|treatment refusal
1249334|NCT00959361|directly observed therapy
1249335|NCT00959361|anti-retroviral agents
1249336|NCT00959361|HIV seropositivity
1249337|NCT00959361|HIV infections
1249338|NCT00959361|HIV
1249339|NCT00959361|pharmaceutical services
1249340|NCT00959361|HIV-positives patients
1249341|NCT00959361|treatment experienced
1249342|NCT00959348|Asthma
1249343|NCT00959348|Diabetes
1249344|NCT00959348|Impaired glucose tolerance
1249345|NCT00959348|Insulin resistance
1249346|NCT00959335|treatment
1249347|NCT00959322|Capsulotomy
1249348|NCT00959309|pediatrics
1249349|NCT00959309|media
1249350|NCT00959309|MUPS
1249351|NCT00959296|Registry
1249352|NCT00959296|Pain
1249353|NCT00959296|Chronic Pain
1249354|NCT00959296|Back Pain
1249355|NCT00959296|Intractable Spasticity
1249356|NCT00959296|Parkinson's Disease
1249357|NCT00959296|Essential Tremor
1249358|NCT00959296|Dystonia
1249359|NCT00959296|Implantable Pumps
1249360|NCT00959296|Incontinence
1249361|NCT00959283|acute myeloid leukemia/transient myeloproliferative disorder
1249362|NCT00959257|Asthma
1249363|NCT00959257|Inhaled corticosteroids
1249364|NCT00959257|Cardiovascular morbidities
1249365|NCT00959257|Systemic inflammation
1249366|NCT00959244|ductal breast carcinoma in situ
1249367|NCT00959244|stage I breast cancer
1249368|NCT00959244|stage II breast cancer
1249369|NCT00959244|stage IIIA breast cancer
1249370|NCT00959244|stage IIIB breast cancer
1249371|NCT00959244|stage IIIC breast cancer
1249372|NCT00959244|stage IV breast cancer
1249373|NCT00959231|hematopoietic/lymphoid cancer
1249374|NCT00959218|Dronabinol
1249375|NCT00959218|(-)trans-delta9-tetrahydrocannabinol
1249376|NCT00959218|central neuropathic pain
1249377|NCT00959218|multiple sclerosis
1249378|NCT00959218|analgesic
1249379|NCT00959218|Central neuropathic pain related to multiple sclerosis
1249380|NCT00959179|CHF
1249381|NCT00959166|Acute hepatitis C
1249382|NCT00959166|HIV
1249383|NCT00959166|Neurocognitive function
1249384|NCT00959166|Neuroinflammation
1249385|NCT00959153|Fragmenting of kidney stones
1249386|NCT00959153|extracorporeal shockwave lithotripsy
1249387|NCT00959140|Allo PBSC
1249388|NCT00959140|HSCT
1249389|NCT00959140|Bone Marrow Transplant
1249390|NCT00959140|Allogeneic Bone Marrow Transplant
1249391|NCT00959140|Matched Related Donor Transplant
1249392|NCT00959140|MRD HSCT
1249393|NCT00959127|Colorectal Adenocarcinoma
1249394|NCT00959127|Colon Cancer
1249395|NCT00959127|Rectal Cancer
1249396|NCT00959114|Celiac Disease
1249397|NCT00959114|Coeliac Disease
1249398|NCT00959114|Celiac Sprue
1249399|NCT00959114|Keliakia
1249400|NCT00959075|Thiamin supplementation
1249401|NCT00959075|Thiamin deficiency
1249402|NCT00959075|Heart failure
1249403|NCT00959075|Improve heart function
1249404|NCT00959075|Vitamin B1 supplementation
1249405|NCT00959062|Pilot Study
1249406|NCT00959062|Randomized Controlled Trial
1249407|NCT00959062|Critically Ill
1249408|NCT00959062|Child
1249409|NCT00959062|Pediatric
1249410|NCT00959062|Clonidine
1249411|NCT00959062|Sedation
1249412|NCT00959023|stage I prostate cancer
1249413|NCT00959023|stage IIB prostate cancer
1249414|NCT00959023|stage IIA prostate cancer
1249415|NCT00959023|stage III prostate cancer
1249416|NCT00959023|stage IV prostate cancer
1249417|NCT00959023|recurrent prostate cancer
1249418|NCT00959010|Omega 3
1249419|NCT00959010|Cystic Fibrosis
1249420|NCT00959010|Inflammatory markers
1249421|NCT00958997|diabetes
1249422|NCT00958997|islet
1249423|NCT00958997|pancreas
1249424|NCT00958997|beta cell mass
1249425|NCT00958997|PET imaging
1249426|NCT00958997|FPDTBZ
1249427|NCT00958997|arginine stimulus test
1249428|NCT00958984|pediatric
1249429|NCT00958984|solid organ transplant
1249430|NCT00958984|hemoglobin
1249431|NCT00958971|Breast cancer
1249432|NCT00958971|HER2 negative
1249433|NCT00958971|FGFR1
1249434|NCT00958958|Acute Coronary Syndrome
1249435|NCT00958958|randomized cluster trial
1249436|NCT00958958|quality improvement
1249437|NCT00958945|Postoperative Hematocrit
1249438|NCT00958945|Postoperative Hemoglobin
1249439|NCT00958919|breathlessness intensity
1249440|NCT00958919|breathlessness unpleasantness
1249441|NCT00958919|endorphins
1249442|NCT00958919|resistive breathing loads
1249443|NCT00958906|Infliximab
1249444|NCT00958906|Uveitis
1249445|NCT00958906|Macular Edema
1249446|NCT00958906|Intraocular Inflammation
1249447|NCT00958893|Uterine fibroids
1249448|NCT00958867|Resistance exercise training
1249449|NCT00958867|aerobic exercise training
1249450|NCT00958854|angioimmunoblastic T-cell lymphoma
1249451|NCT00958841|Rare tumors of neuroendocrine origin
1249452|NCT00958841|NETs of the pancreatic
1249453|NCT00958841|Pituitary NETs
1249454|NCT00958841|EAS Tumors
1249455|NCT00958841|Nelson's Syndrome
1249456|NCT00958841|Pancreatic neoplasm
1249457|NCT00958841|pituitary neoplasm
1249458|NCT00958841|Nelson Syndrome
1249459|NCT00958841|ectopic ACTH syndrome
1249460|NCT00958841|pasireotide LAR
1249461|NCT00958841|PNETs
1249462|NCT00958841|PiNETS
1249463|NCT00958815|vascular imaging
1249464|NCT00958815|diabetes
1249465|NCT00958815|rupture prone plaques
1249466|NCT00958815|HIV
1249467|NCT00958815|treatment experienced
1249468|NCT00958802|tissue engineering
1249469|NCT00958776|Influenza
1249470|NCT00958776|Hospitalized
1249471|NCT00958776|Antiviral
1249472|NCT00958776|Flu
1249473|NCT00958763|HCV
1249474|NCT00958763|Alcohol
1249475|NCT00958763|Methadone Maintained
1249476|NCT00958750|Androgenetic alopecia
1249477|NCT00958750|female pattern hair loss
1249478|NCT00958737|stage III colon cancer
1249479|NCT00958737|adenocarcinoma of the colon
1249480|NCT00958724|HKI-272
1249481|NCT00958724|Vinorelbine
1249482|NCT00958724|Combination
1249483|NCT00958724|Solid Tumor
1249484|NCT00958698|psychosocial effects of cancer and its treatment
1249485|NCT00958698|recurrent ovarian epithelial cancer
1249486|NCT00958698|recurrent fallopian tube cancer
1249487|NCT00958698|recurrent primary peritoneal cavity cancer
1249488|NCT00958685|ginger extract
1249489|NCT00958685|ARDS
1249490|NCT00958685|enteral feeding
1249491|NCT00958685|mechanical ventilation
1249492|NCT00958685|ICU
1249493|NCT00958646|OMT
1249494|NCT00958646|biomarker
1249495|NCT00958646|Manipulation, osteopathic
1249496|NCT00958633|Bipolar I disorder
1249497|NCT00958633|Depression
1249498|NCT00958633|Antidepressant
1249499|NCT00958620|Chronic Achilles Tendinopathy
1249500|NCT00958607|Caregivers
1249501|NCT00958607|Stroke
1249502|NCT00958607|Social support
1249503|NCT00958607|Phase specific care
1249504|NCT00958542|cerebral palsy
1249505|NCT00958542|scoliosis
1249506|NCT00958542|children
1249507|NCT00958529|fiber
1249508|NCT00958529|inulin
1249509|NCT00958529|gastrointestinal tolerance
1249510|NCT00958516|volunteers
1249511|NCT00958503|safety
1249512|NCT00958503|biomarker
1249513|NCT00958503|thiamphenicol
1249514|NCT00958503|EAAT2
1249515|NCT00958477|Safety
1249516|NCT00958477|tolerability
1249517|NCT00958477|pharmacokinetics
1249518|NCT00958477|pharmacodynamics of EMD 525797
1249519|NCT00958477|prostate cancer patients
1249520|NCT00958464|MRI
1249521|NCT00958464|Perthes'disease
1249522|NCT00958464|hip
1249523|NCT00958464|cartilage
1249524|NCT00958451|Calcium
1249525|NCT00958451|Vitamin D deficiency
1249526|NCT00958451|Chronic Kidney disease
1249527|NCT00958438|Intercritical Gout
1249528|NCT00958438|Metabolism, Inborn Errors
1249529|NCT00958438|Allopurinol
1249530|NCT00958438|Metabolic Diseases
1249531|NCT00958438|Genetic Diseases, Inborn
1249532|NCT00958438|Musculoskeletal Diseases
1249533|NCT00958438|Joint Diseases
1249534|NCT00958438|Arthritis
1249535|NCT00958438|Rheumatic Diseases
1249536|NCT00958438|Metabolic disorder
1249537|NCT00958438|Purine-Pyrimidine Metabolism, Inborn Errors
1249538|NCT00958438|Gout
1249539|NCT00958412|Endometriosis
1249540|NCT00958412|Pelvic pain
1249541|NCT00958412|Oral progesterone blocker
1249542|NCT00958399|satiety
1249543|NCT00958399|fiber
1249544|NCT00958399|food intake
1249545|NCT00958399|gut hormones
1249546|NCT00958399|visual analog scales
1249547|NCT00958399|microflora
1249548|NCT00958386|colorectal cancer
1249549|NCT00958386|Panitumumab
1249550|NCT00958386|irinotecan
1249551|NCT00958373|Scoliosis
1249552|NCT00958373|adolescent idiopathic scoliosis
1249553|NCT00958373|spine curve
1249554|NCT00958373|pediatric
1249555|NCT00958373|mental health
1249556|NCT00958373|screening
1249557|NCT00958360|vision, low
1249558|NCT00958334|Uterine fibroids
1249559|NCT00958321|adenocarcinoma of the lung
1249560|NCT00958321|large cell lung cancer
1249561|NCT00958321|squamous cell lung cancer
1249562|NCT00958321|malignant pleural effusion
1249563|NCT00958321|stage IIIA non-small cell lung cancer
1249564|NCT00958321|stage IIIB non-small cell lung cancer
1249565|NCT00958321|stage IA non-small cell lung cancer
1249566|NCT00958321|stage IB non-small cell lung cancer
1249567|NCT00958321|stage IIA non-small cell lung cancer
1249568|NCT00958321|stage IIB non-small cell lung cancer
1249569|NCT00958308|Probiotic
1249570|NCT00958308|Antibiotic-Associated Diarrhea (AAD) Prevention
1249571|NCT00958308|Clostridium Difficile-Associated Diarrhea (CDAD)Prevention
1249572|NCT00958295|urinary tract infection
1249573|NCT00958295|cystitis
1249574|NCT00958282|cocaine
1249575|NCT00958282|treatment
1249576|NCT00958282|lisdexamfetamine
1249577|NCT00958282|dependence
1249578|NCT00958282|addiction
1249579|NCT00958282|crack
1249580|NCT00958269|diabetes
1249581|NCT00958269|DPP4 inhibitor
1249582|NCT00958269|dutogliptin
1249583|NCT00958269|PHX1149
1249584|NCT00958256|Mantle Cell Lymphoma
1249585|NCT00958256|Lymphoma
1249586|NCT00958256|Bortezomib
1249587|NCT00958256|Velcade
1249588|NCT00958256|Rituximab
1249589|NCT00958256|Rituxan
1249590|NCT00958256|Cyclophosphamide
1249591|NCT00958256|Cytoxan
1249592|NCT00958256|Neosar
1249593|NCT00958256|Mesna
1249594|NCT00958256|Mesnex
1249595|NCT00958256|G-CSF
1249596|NCT00958256|Filgrastim
1249597|NCT00958256|Neupogen
1249598|NCT00958230|endarterectomy
1249599|NCT00958230|dCell
1249600|NCT00958230|Tissue Regenix Ltd
1249601|NCT00958230|TRL
1249602|NCT00958230|Vascular Patch
1249603|NCT00958230|Treatment
1249604|NCT00958217|Depressive symptoms
1249605|NCT00958217|Substance-related disorders
1249606|NCT00958217|Posttraumatic stress disorders
1249607|NCT00958217|Psychotherapy
1249608|NCT00958204|Depression
1249609|NCT00958204|rating scales
1249610|NCT00958204|RCT
1249611|NCT00958204|combination treatment
1249612|NCT00958204|light therapy
1249613|NCT00958204|negative ion therapy
1249614|NCT00958204|fluoxetine
1249615|NCT00958204|antidepressants
1249616|NCT00958165|Treatment of PAF using EAS-AC
1249617|NCT00958152|VX-950
1249618|NCT00958152|VX-222
1249619|NCT00958152|STAT-C
1249620|NCT00958139|Lyme disease
1249621|NCT00958139|tick
1249622|NCT00958100|raltegravir switch toxicity
1249623|NCT00958100|treatment experienced
1249624|NCT00958061|CVD
1249625|NCT00958048|Amyotrophic Lateral Sclerosis
1249626|NCT00958048|hypoventilation
1249627|NCT00957996|influenza
1249628|NCT00957996|hospitalized
1249629|NCT00957996|flu
1249630|NCT00957996|antiviral
1249631|NCT00957970|Stress shielding
1249632|NCT00957970|Bone mineral density
1249633|NCT00957970|stemless femoral component
1249634|NCT00957944|Rotigotine
1249635|NCT00957944|Neupro®
1249636|NCT00957918|levodopa-induced dyskinesia
1249637|NCT00957918|Parkinson's disease
1249638|NCT00957918|parkinsonian
1249639|NCT00957918|levodopa-induced dyskinesias in Parkinson's disease
1249640|NCT00957892|Healthy Infants
1249641|NCT00957892|Satiation
1249642|NCT00957892|Satiety
1249643|NCT00957892|Intake Regulation
1249644|NCT00957892|Infant Feeding
1249645|NCT00957892|Infant Formula Feeding
1249646|NCT00957879|Vitamin D
1249647|NCT00957879|FGF23
1249648|NCT00957879|FGF-23
1249649|NCT00957879|Phosphate
1249650|NCT00957866|The number of cases in the database thus far (4,477) is clearly sufficient to achieve meaningful results
1249651|NCT00957853|Head and Neck Cancer
1249652|NCT00957853|Squamous cell carcinoma of the head and neck
1249653|NCT00957853|HNSCC
1249654|NCT00957853|Cetuximab
1249655|NCT00957853|IMC-A12
1249656|NCT00957853|Tumor
1249657|NCT00957853|Biomarkers
1249658|NCT00957853|Phospho-AKT
1249659|NCT00957853|Surgical resection
1249660|NCT00957840|Omaya reservoirs
1249661|NCT00957840|cerebral oxygenation
1249662|NCT00957840|VP shunt
1249663|NCT00957840|IVH
1249664|NCT00957840|post hemorrhagic ventricular dilation (PVHD)
1249665|NCT00957814|nutritional education
1249666|NCT00957814|diet adherence
1249667|NCT00957814|nutritional knowledge
1249668|NCT00957814|life quality
1249669|NCT00957814|nutritional status
1249670|NCT00957814|impact of nutritional orientations by a systematic education program applied to outpatients with HF, in comparison to patients in a conventional treatment.
1249671|NCT00957801|Sarcopenia
1249672|NCT00957801|Aging muscle
1249673|NCT00957801|Androgen
1249674|NCT00957801|Cytokines
1249675|NCT00957801|Muscle metabolism
1249676|NCT00957788|tinnitus
1249677|NCT00957788|acouphenes
1249678|NCT00957788|ear
1249679|NCT00957788|ringing
1249680|NCT00957788|buzzing
1249681|NCT00957788|roaring
1249682|NCT00957788|hissing
1249683|NCT00957788|clicking
1249684|NCT00957775|Substance Abuse Treatment
1249685|NCT00957775|Adolescents
1249686|NCT00957775|Substance-Related Disorders
1249687|NCT00957775|Alcohol-Related Disorders
1249688|NCT00957775|Marijuana Abuse
1249689|NCT00957762|Body Composition
1249690|NCT00957762|Glucose Tolerance
1249691|NCT00957762|Insulin Sensitivity
1249692|NCT00957762|Metabolic Syndrome
1249693|NCT00957736|graft versus host disease
1249694|NCT00957736|stage III adult Burkitt lymphoma
1249695|NCT00957736|stage III adult diffuse large cell lymphoma
1249696|NCT00957736|stage III adult diffuse mixed cell lymphoma
1249697|NCT00957736|stage III adult diffuse small cleaved cell lymphoma
1249698|NCT00957736|stage III adult Hodgkin lymphoma
1249699|NCT00957736|stage III adult immunoblastic large cell lymphoma
1249700|NCT00957736|stage III adult lymphoblastic lymphoma
1249701|NCT00957736|stage III grade 1 follicular lymphoma
1249702|NCT00957736|stage III grade 2 follicular lymphoma
1249703|NCT00957736|stage III grade 3 follicular lymphoma
1249704|NCT00957736|stage III mantle cell lymphoma
1249705|NCT00957736|stage III marginal zone lymphoma
1249706|NCT00957736|stage III small lymphocytic lymphoma
1249707|NCT00957736|stage IV adult Burkitt lymphoma
1249708|NCT00957736|stage IV adult diffuse large cell lymphoma
1249709|NCT00957736|stage IV adult diffuse mixed cell lymphoma
1249710|NCT00957736|stage IV adult diffuse small cleaved cell lymphoma
1249711|NCT00957736|stage IV adult Hodgkin lymphoma
1249712|NCT00957736|stage IV adult immunoblastic large cell lymphoma
1249713|NCT00957736|stage IV adult lymphoblastic lymphoma
1249714|NCT00957736|stage IV grade 1 follicular lymphoma
1249715|NCT00957736|stage IV grade 2 follicular lymphoma
1249716|NCT00957736|stage IV grade 3 follicular lymphoma
1249717|NCT00957736|stage IV mantle cell lymphoma
1249718|NCT00957736|stage IV marginal zone lymphoma
1249937|NCT00957151|chronic pancreatitis
1249719|NCT00957736|stage IV small lymphocytic lymphoma
1249720|NCT00957736|recurrent adult Burkitt lymphoma
1249721|NCT00957736|recurrent adult diffuse large cell lymphoma
1249722|NCT00957736|recurrent adult diffuse mixed cell lymphoma
1249723|NCT00957736|recurrent adult diffuse small cleaved cell lymphoma
1249724|NCT00957736|recurrent adult Hodgkin lymphoma
1249725|NCT00957736|recurrent adult immunoblastic large cell lymphoma
1249726|NCT00957736|recurrent adult lymphoblastic lymphoma
1249727|NCT00957736|recurrent childhood large cell lymphoma
1249728|NCT00957736|recurrent childhood lymphoblastic lymphoma
1249729|NCT00957736|recurrent childhood small noncleaved cell lymphoma
1249730|NCT00957736|recurrent cutaneous T-cell non-Hodgkin lymphoma
1249731|NCT00957736|recurrent grade 1 follicular lymphoma
1249732|NCT00957736|recurrent grade 2 follicular lymphoma
1249733|NCT00957736|recurrent grade 3 follicular lymphoma
1249734|NCT00957736|recurrent mantle cell lymphoma
1249735|NCT00957736|recurrent marginal zone lymphoma
1249736|NCT00957736|recurrent small lymphocytic lymphoma
1249737|NCT00957736|recurrent/refractory childhood Hodgkin lymphoma
1249738|NCT00957736|recurrent mycosis fungoides/Sezary syndrome
1249739|NCT00957736|nodal marginal zone B-cell lymphoma
1249740|NCT00957736|splenic marginal zone lymphoma
1249741|NCT00957736|noncontiguous (NC) stage II adult Burkitt lymphoma
1249742|NCT00957736|NC stage II adult diffuse large cell lymphoma
1249743|NCT00957736|NC stage II adult diffuse mixed cell lymphoma
1249744|NCT00957736|NC stage II adult diffuse small cleaved cell lymphoma
1249745|NCT00957736|NC stage II adult immunoblastic large cell lymphoma
1249746|NCT00957736|NC stage II adult lymphoblastic lymphoma
1249747|NCT00957736|NC stage II grade 1 follicular lymphoma
1249748|NCT00957736|NC stage II grade 2 follicular lymphoma
1249749|NCT00957736|NC stage II grade 3 follicular lymphoma
1249750|NCT00957736|NC stage II mantle cell lymphoma
1249751|NCT00957736|NC stage II marginal zone lymphoma
1249752|NCT00957736|NC stage II small lymphocytic lymphoma
1249753|NCT00957736|accelerated phase chronic myelogenous leukemia
1249754|NCT00957736|adult acute lymphoblastic leukemia in remission
1249755|NCT00957736|adult acute myeloid leukemia in remission
1249756|NCT00957736|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1249757|NCT00957736|adult acute myeloid leukemia with inv(16)(p13;q22)
1249758|NCT00957736|adult acute myeloid leukemia with t(15;17)(q22;q12)
1249759|NCT00957736|adult acute myeloid leukemia with t(16;16)(p13;q22)
1249760|NCT00957736|adult acute myeloid leukemia with t(8;21)(q22;q22)
1249761|NCT00957736|atypical chronic myeloid leukemia, BCR-ABL negative
1249762|NCT00957736|blastic phase chronic myelogenous leukemia
1249763|NCT00957736|childhood acute lymphoblastic leukemia in remission
1249764|NCT00957736|childhood acute myeloid leukemia in remission
1249765|NCT00957736|childhood chronic myelogenous leukemia
1249766|NCT00957736|chronic myelomonocytic leukemia
1249767|NCT00957736|chronic phase chronic myelogenous leukemia
1249768|NCT00957736|juvenile myelomonocytic leukemia
1249769|NCT00957736|recurrent adult acute lymphoblastic leukemia
1249770|NCT00957736|recurrent adult acute myeloid leukemia
1249771|NCT00957736|recurrent childhood acute lymphoblastic leukemia
1249772|NCT00957736|recurrent childhood acute myeloid leukemia
1249773|NCT00957736|refractory chronic lymphocytic leukemia
1249774|NCT00957736|refractory hairy cell leukemia
1249775|NCT00957736|relapsing chronic myelogenous leukemia
1249776|NCT00957736|secondary acute myeloid leukemia
1249777|NCT00957736|stage III chronic lymphocytic leukemia
1249778|NCT00957736|stage IV chronic lymphocytic leukemia
1249779|NCT00957736|childhood myelodysplastic syndromes
1249780|NCT00957736|chronic eosinophilic leukemia
1249781|NCT00957736|primary myelofibrosis
1249782|NCT00957736|chronic neutrophilic leukemia
1249783|NCT00957736|de novo myelodysplastic syndromes
1249784|NCT00957736|disseminated neuroblastoma
1249785|NCT00957736|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1249786|NCT00957736|poor prognosis metastatic gestational trophoblastic tumor
1249787|NCT00957736|previously treated childhood rhabdomyosarcoma
1249788|NCT00957736|previously treated myelodysplastic syndromes
1249789|NCT00957736|recurrent Wilms tumor and other childhood kidney tumors
1249790|NCT00957736|recurrent childhood rhabdomyosarcoma
1249791|NCT00957736|recurrent neuroblastoma
1249792|NCT00957736|recurrent ovarian epithelial cancer
1249793|NCT00957736|recurrent ovarian germ cell tumor
1249794|NCT00957736|recurrent malignant testicular germ cell tumor
1249795|NCT00957736|secondary myelodysplastic syndromes
1249796|NCT00957736|stage I multiple myeloma
1249797|NCT00957736|stage II multiple myeloma
1249798|NCT00957736|stage III multiple myeloma
1249799|NCT00957736|stage II ovarian epithelial cancer
1249800|NCT00957736|stage III ovarian epithelial cancer
1249801|NCT00957736|stage IV ovarian epithelial cancer
1249802|NCT00957736|stage III malignant testicular germ cell tumor
1249803|NCT00957736|stage IIIA breast cancer
1249804|NCT00957736|stage IIIB breast cancer
1249805|NCT00957736|stage IIIC breast cancer
1249806|NCT00957736|stage IV breast cancer
1249807|NCT00957736|refractory multiple myeloma
1249808|NCT00957710|progressive aphasia
1249809|NCT00957710|semantic dementia
1249810|NCT00957710|neuroimaging
1249811|NCT00957710|treatment
1249812|NCT00957710|errorless learning
1249813|NCT00957697|Central Neuropathic Pain
1249814|NCT00957697|Central Post-Stroke Pain
1249815|NCT00957697|Stroke
1249816|NCT00957697|Pain
1249817|NCT00957684|refractory
1249818|NCT00957684|partial
1249819|NCT00957684|epilepsy
1249820|NCT00957671|TBI
1249821|NCT00957671|Traumatic Brain injury
1249822|NCT00957671|Growth hormone deficiency
1249823|NCT00957671|Anterior pituitary hormone
1249824|NCT00957658|Osteoarthritis
1249825|NCT00957645|Central post-stroke pain
1249826|NCT00957645|post-stroke pain
1249827|NCT00957645|shoulder pain
1249828|NCT00957619|pentoxyfilline
1249829|NCT00957619|liver regeneration
1249830|NCT00957619|major liver resection
1249831|NCT00957619|reduction of the I/R injury
1249832|NCT00957606|Prostate cancer
1249833|NCT00957606|androgen deprivation therapy
1249834|NCT00957606|osteoporosis
1249835|NCT00957593|Induction of labor in term pregnancies
1249836|NCT00957593|Term pregnancy
1249837|NCT00957593|Cesarean delivery
1249838|NCT00957580|MEK Inhibitor
1249839|NCT00957580|Pimasertib
1249840|NCT00957580|Acute Myeloid Leukemia
1249841|NCT00957580|Hematological Malignancies
1249842|NCT00957580|Elderly Patients
1249843|NCT00957580|Phase II
1249844|NCT00957541|NYHA Class III or IV
1249845|NCT00957541|Implantable Cardiac Defibrillator
1249846|NCT00957541|Cardiac Resynchronization Therapy
1249847|NCT00957528|Low Normal Testosterone
1249848|NCT00957528|Male
1249849|NCT00957528|Aging
1249850|NCT00957489|Orthodontic treatment of Class II division 1 malocclusion
1249851|NCT00957476|Pregnancy
1249852|NCT00957476|Metabolic Diseases
1249853|NCT00957476|Obesity
1249854|NCT00957476|Fetal adiposity
1249855|NCT00957476|Omega-3
1249856|NCT00957476|Inflammation
1249857|NCT00957476|Insulin Resistance
1249858|NCT00957463|endothelial function
1249859|NCT00957450|cervix cancer
1249860|NCT00957450|intra-pelvic organ motion
1249861|NCT00957450|cervical cancer and CBCT
1249862|NCT00957437|Phase 1
1249863|NCT00957437|healthy volunteer
1249864|NCT00957437|male
1249865|NCT00957437|pharmacokinetics
1249866|NCT00957437|AZD1305
1249867|NCT00957424|tobacco use disorder
1249868|NCT00957424|bladder cancer
1249869|NCT00957424|cervical cancer
1249870|NCT00957424|esophageal cancer
1249871|NCT00957424|gastric cancer
1249872|NCT00957424|renal cell carcinoma
1249873|NCT00957424|adult primary liver cancer
1249874|NCT00957424|non-small cell lung cancer
1249875|NCT00957424|small cell lung cancer
1249876|NCT00957424|pancreatic cancer
1249877|NCT00957424|hypopharyngeal cancer
1249878|NCT00957424|laryngeal cancer
1249879|NCT00957424|lip and oral cavity cancer
1249880|NCT00957424|nasopharyngeal cancer
1249881|NCT00957424|oropharyngeal cancer
1249882|NCT00957424|paranasal sinus and nasal cavity cancer
1249883|NCT00957424|adult acute myeloid leukemia
1249884|NCT00957411|stage IB cervical cancer
1249885|NCT00957411|stage IIA cervical cancer
1249886|NCT00957411|stage IIB cervical cancer
1249887|NCT00957411|stage III cervical cancer
1249888|NCT00957411|cervical adenocarcinoma
1249889|NCT00957411|cervical squamous cell carcinoma
1249890|NCT00957398|Irritable Bowel Syndrome
1249891|NCT00957398|Irritable Bowel Syndrome subgroups
1249892|NCT00957398|Motility
1249893|NCT00957385|Leukemia
1249894|NCT00957385|Remission
1249895|NCT00957372|epilepsy
1249896|NCT00957359|Cancer
1249897|NCT00957359|Anxiety
1249898|NCT00957359|Depression
1249899|NCT00957359|Hallucinogens
1249900|NCT00957346|Pregnancy termination
1249901|NCT00957346|abortion
1249902|NCT00957346|medical abortion
1249903|NCT00957346|2nd trimester
1249904|NCT00957346|mifepristone
1249905|NCT00957346|misoprostol
1249906|NCT00957333|ketamine
1249907|NCT00957333|bladder dysfunction
1249908|NCT00957333|bladder mucosa
1249909|NCT00957333|mechanisms
1249910|NCT00957320|leukemia
1249911|NCT00957320|cancer
1249912|NCT00957320|oncology
1249913|NCT00957320|sirolimus
1249914|NCT00957320|ALL
1249915|NCT00957281|Asthma
1249916|NCT00957281|Systemic inflammation
1249917|NCT00957281|Oxidative stress
1249918|NCT00957281|Cardiovascular morbidity
1249919|NCT00957281|Airway inflammation
1249920|NCT00957268|Type 2 diabetes mellitus
1249921|NCT00957268|Non-insulin dependent diabetes mellitus
1249922|NCT00957268|Drug therapy
1249923|NCT00957268|Pediatrics
1249924|NCT00957255|rotator cuff tear
1249925|NCT00957255|rotator cuff repair
1249926|NCT00957242|IPF
1249927|NCT00957242|Warfarin
1249928|NCT00957216|adult onset ataxia
1249929|NCT00957203|Parkinson's disease
1249930|NCT00957203|levodopa
1249931|NCT00957203|end of dose wearing off
1249932|NCT00957203|OFF time
1249933|NCT00957190|Ocular Hypertension
1249934|NCT00957190|Open Angle Glaucoma
1249935|NCT00957164|Chronic pain
1249936|NCT00957164|PTSD
1249938|NCT00957151|exocrine pancreatic insufficiency
1249939|NCT00957151|enzyme therapy
1249940|NCT00957151|patients with chronic pancreatitis and exocrine pancreatic insufficiency
1249941|NCT00957151|taking enzyme replacement therapy
1249942|NCT00957125|Localized primary breast cancer
1249943|NCT00957125|Inflammatory breast cancer
1249944|NCT00957112|anxiety disorder
1249945|NCT00957112|depression
1249946|NCT00957112|fatigue
1249947|NCT00957112|stage IA breast cancer
1249948|NCT00957112|stage IB breast cancer
1249949|NCT00957112|stage II breast cancer
1249950|NCT00957112|stage IIIA breast cancer
1249951|NCT00957086|Phase III Adjuvant Concurrent Chemo-RT +/- nimotuzumab
1249952|NCT00957073|Heart Failure
1249953|NCT00957073|Diastolic dysfunction
1249954|NCT00957047|refractory
1249955|NCT00957047|partial
1249956|NCT00957047|epilepsy
1249957|NCT00957021|Knee
1249958|NCT00956982|Hepatitis C Virus Pegylated Interferon Ribavirin Older
1249959|NCT00956969|headaches
1249960|NCT00956969|stress management
1249961|NCT00956969|assertiveness training
1249962|NCT00956969|relaxation training
1249963|NCT00956969|emotional expression
1249964|NCT00956956|An investigator and subject blinded (sponsor open)
1249965|NCT00956956|multiple dose
1249966|NCT00956956|dose escalation design with PF 04455242 and matching placebo.
1249967|NCT00956943|nicotine dependence
1249968|NCT00956943|nicotine replacement therapy
1249969|NCT00956943|transdermal nicotine
1249970|NCT00956943|nicotine metabolism
1249971|NCT00956943|high dose
1249972|NCT00956930|advanced adult primary liver cancer
1249973|NCT00956930|localized unresectable adult primary liver cancer
1249974|NCT00956930|recurrent adult primary liver cancer
1249975|NCT00956930|adult primary hepatocellular carcinoma
1249976|NCT00956904|Prostate Cancer
1249977|NCT00956904|Prostatectomy
1249978|NCT00956904|Transrectal Ultrasound
1249979|NCT00956904|Tandem RALP
1249980|NCT00956891|short-term effects
1249981|NCT00956891|long-term follow-up
1249982|NCT00956891|liver failure patients
1249983|NCT00956891|autologous MSCs transplantation
1249984|NCT00956878|Cancer
1249985|NCT00956878|Pain
1249986|NCT00956878|SNP
1249987|NCT00956865|Glaucoma
1249988|NCT00956865|Intervention
1249989|NCT00956865|Follow up
1249990|NCT00956839|Tropical calcific pancreatitis
1249991|NCT00956839|Tropical chronic pancreatitis
1249992|NCT00956839|Chronic pancreatitis
1249993|NCT00956839|Vitamin D
1249994|NCT00956839|Vitamin D deficiency
1249995|NCT00956839|Cholecalciferol
1249996|NCT00956839|Intramuscular vitamin D3
1249997|NCT00956826|electrode vacuum delivery
1249998|NCT00956813|menopausal symptoms
1249999|NCT00956813|hot flashes
1250000|NCT00956813|breast cancer
1250001|NCT00956813|unspecified adult solid tumor, protocol specific
1250002|NCT00956787|Myelodysplastic Syndrome
1250003|NCT00956774|HSG
1250004|NCT00956774|Cannula
1250005|NCT00956774|HSG procedure
1250006|NCT00956774|infertility evaluation
1250007|NCT00956761|Influenza vaccine
1250008|NCT00956748|chronic suppurative otitis media with persistent otorrhea
1250009|NCT00956735|Cardiovascular Disease
1250010|NCT00956735|Type II Diabetes
1250011|NCT00956735|Nutrition
1250012|NCT00956735|Pistachios
1250215|NCT00956449|seasonal influenza
1250013|NCT00956735|Cardiovascular disease risk factors in adults with Type II diabetes
1250014|NCT00956696|Epilepsy
1250015|NCT00956696|mental retardation
1250016|NCT00956683|infraclavicular nerve block ultrasound dual endpoint stimulation
1250017|NCT00956657|Randomised Controlled Trial
1250018|NCT00956657|Adherence
1250019|NCT00956657|Patient Participation
1250020|NCT00956631|Spinal Stenosis
1250021|NCT00956631|Lumbar Spinal Stenosis
1250022|NCT00956605|EEG-biofeedback
1250023|NCT00956605|neurofeedback
1250024|NCT00956605|computer attention training systems
1250025|NCT00956605|ADHD
1250026|NCT00956605|ADD
1250027|NCT00956605|child
1250028|NCT00956605|children
1250029|NCT00956592|Video laryngoscopy
1250030|NCT00956592|Intubation success
1250031|NCT00956592|Difficult airway
1250032|NCT00956592|CMAC laryngoscope
1250033|NCT00956579|autism
1250034|NCT00956579|autistic
1250035|NCT00956579|sensory
1250036|NCT00956579|MEG
1250037|NCT00956579|connectivity
1250038|NCT00956579|brain
1250039|NCT00956579|MRI
1250040|NCT00956579|language
1250041|NCT00956579|developmental
1250042|NCT00956579|neurodevelopmental
1250043|NCT00956579|aspergers
1250044|NCT00956579|asperger's
1250045|NCT00956579|dyslexia
1250046|NCT00956579|coherence
1250047|NCT00956553|HPV
1250048|NCT00956553|Human Papilloma Virus
1250049|NCT00956553|Cervical cancer vaccine
1250050|NCT00956540|Tracheostomy
1250051|NCT00956540|decannulation
1250052|NCT00956540|weaning
1250053|NCT00956540|Tracheostomy Weaning
1250054|NCT00956527|Adolescent
1250055|NCT00956527|Substance Use
1250056|NCT00956527|Early Intervention
1250057|NCT00956527|Martial Arts
1250058|NCT00956527|Karate
1250059|NCT00956514|depression
1250060|NCT00956514|major depressive disorder
1250061|NCT00956514|transcranial magnetic stimulation
1250062|NCT00956514|TMS
1250063|NCT00956514|EEG
1250064|NCT00956514|electroencephalography
1250065|NCT00956514|Major Depression,
1250066|NCT00956501|fall
1250067|NCT00956501|balance
1250068|NCT00956488|Exercise for Amyotrophic lateral sclerosis
1250069|NCT00956475|anxiety disorder
1250070|NCT00956475|long-term effects secondary to cancer therapy in adults
1250071|NCT00956475|fatigue
1250072|NCT00956475|pain
1250073|NCT00956475|psychosocial effects of cancer and its treatment
1250074|NCT00956475|cancer survivor
1250075|NCT00956475|accelerated phase chronic myelogenous leukemia
1250076|NCT00956475|acute undifferentiated leukemia
1250077|NCT00956475|adult acute lymphoblastic leukemia in remission
1250078|NCT00956475|adult acute myeloid leukemia in remission
1250079|NCT00956475|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1250080|NCT00956475|adult acute myeloid leukemia with inv(16)(p13;q22)
1250081|NCT00956475|adult acute myeloid leukemia with t(15;17)(q22;q12)
1250082|NCT00956475|adult acute myeloid leukemia with t(16;16)(p13;q22)
1250083|NCT00956475|adult acute myeloid leukemia with t(8;21)(q22;q22)
1250084|NCT00956475|atypical chronic myeloid leukemia
1250085|NCT00956475|blastic phase chronic myelogenous leukemia
1250086|NCT00956475|chronic myelomonocytic leukemia
1250087|NCT00956475|chronic phase chronic myelogenous leukemia
1250088|NCT00956475|mast cell leukemia
1250089|NCT00956475|meningeal chronic myelogenous leukemia
1250090|NCT00956475|progressive hairy cell leukemia, initial treatment
1250091|NCT00956475|prolymphocytic leukemia
1250092|NCT00956475|recurrent adult acute lymphoblastic leukemia
1250093|NCT00956475|recurrent adult acute myeloid leukemia
1250094|NCT00956475|refractory chronic lymphocytic leukemia
1250095|NCT00956475|refractory hairy cell leukemia
1250096|NCT00956475|relapsing chronic myelogenous leukemia
1250097|NCT00956475|secondary acute myeloid leukemia
1250098|NCT00956475|stage I chronic lymphocytic leukemia
1250099|NCT00956475|stage II chronic lymphocytic leukemia
1250100|NCT00956475|stage III chronic lymphocytic leukemia
1250101|NCT00956475|stage IV chronic lymphocytic leukemia
1250102|NCT00956475|T-cell large granular lymphocyte leukemia
1250103|NCT00956475|stage I adult Burkitt lymphoma
1250104|NCT00956475|stage I adult diffuse large cell lymphoma
1250105|NCT00956475|stage I adult diffuse mixed cell lymphoma
1250106|NCT00956475|stage I adult diffuse small cleaved cell lymphoma
1250107|NCT00956475|stage I adult Hodgkin lymphoma
1250108|NCT00956475|stage I adult immunoblastic large cell lymphoma
1250109|NCT00956475|stage I adult lymphoblastic lymphoma
1250110|NCT00956475|stage I adult T-cell leukemia/lymphoma
1250111|NCT00956475|stage I cutaneous T-cell non-Hodgkin lymphoma
1250112|NCT00956475|stage I grade 1 follicular lymphoma
1250113|NCT00956475|stage I grade 2 follicular lymphoma
1250114|NCT00956475|stage I grade 3 follicular lymphoma
1250115|NCT00956475|stage I mantle cell lymphoma
1250116|NCT00956475|stage I marginal zone lymphoma
1250117|NCT00956475|stage I small lymphocytic lymphoma
1250118|NCT00956475|stage II adult Hodgkin lymphoma
1250119|NCT00956475|stage II adult T-cell leukemia/lymphoma
1250120|NCT00956475|stage II cutaneous T-cell non-Hodgkin lymphoma
1250121|NCT00956475|stage III adult Burkitt lymphoma
1250122|NCT00956475|stage III adult diffuse large cell lymphoma
1250123|NCT00956475|stage III adult diffuse mixed cell lymphoma
1250124|NCT00956475|stage III adult diffuse small cleaved cell lymphoma
1250125|NCT00956475|stage III adult Hodgkin lymphoma
1250126|NCT00956475|stage III adult immunoblastic large cell lymphoma
1250127|NCT00956475|stage III adult lymphoblastic lymphoma
1250128|NCT00956475|stage III adult T-cell leukemia/lymphoma
1250129|NCT00956475|stage III cutaneous T-cell non-Hodgkin lymphoma
1250130|NCT00956475|stage III grade 1 follicular lymphoma
1250131|NCT00956475|stage III grade 2 follicular lymphoma
1250132|NCT00956475|stage III grade 3 follicular lymphoma
1250133|NCT00956475|stage III mantle cell lymphoma
1250134|NCT00956475|stage III marginal zone lymphoma
1250135|NCT00956475|stage III small lymphocytic lymphoma
1250136|NCT00956475|stage IV adult Burkitt lymphoma
1250137|NCT00956475|stage IV adult diffuse large cell lymphoma
1250138|NCT00956475|stage IV adult diffuse mixed cell lymphoma
1250139|NCT00956475|stage IV adult diffuse small cleaved cell lymphoma
1250140|NCT00956475|stage IV adult Hodgkin lymphoma
1250141|NCT00956475|stage IV adult immunoblastic large cell lymphoma
1250142|NCT00956475|stage IV adult lymphoblastic lymphoma
1250143|NCT00956475|stage IV adult T-cell leukemia/lymphoma
1250144|NCT00956475|stage IV cutaneous T-cell non-Hodgkin lymphoma
1250145|NCT00956475|stage IV grade 1 follicular lymphoma
1250146|NCT00956475|stage IV grade 2 follicular lymphoma
1250147|NCT00956475|stage IV grade 3 follicular lymphoma
1250148|NCT00956475|stage IV mantle cell lymphoma
1250149|NCT00956475|stage IV marginal zone lymphoma
1250150|NCT00956475|stage IV small lymphocytic lymphoma
1250151|NCT00956475|recurrent adult Burkitt lymphoma
1250152|NCT00956475|recurrent adult diffuse large cell lymphoma
1250153|NCT00956475|recurrent adult diffuse mixed cell lymphoma
1250154|NCT00956475|recurrent adult diffuse small cleaved cell lymphoma
1250155|NCT00956475|recurrent adult grade III lymphomatoid granulomatosis
1250156|NCT00956475|recurrent adult Hodgkin lymphoma
1250157|NCT00956475|recurrent adult immunoblastic large cell lymphoma
1250158|NCT00956475|recurrent adult lymphoblastic lymphoma
1250159|NCT00956475|recurrent adult T-cell leukemia/lymphoma
1250160|NCT00956475|recurrent cutaneous T-cell non-Hodgkin lymphoma
1250161|NCT00956475|recurrent grade 1 follicular lymphoma
1250162|NCT00956475|recurrent grade 2 follicular lymphoma
1250163|NCT00956475|recurrent grade 3 follicular lymphoma
1250164|NCT00956475|recurrent mantle cell lymphoma
1250165|NCT00956475|recurrent marginal zone lymphoma
1250166|NCT00956475|recurrent small lymphocytic lymphoma
1250167|NCT00956475|anaplastic large cell lymphoma
1250168|NCT00956475|angioimmunoblastic T-cell lymphoma
1250169|NCT00956475|recurrent mycosis fungoides/Sezary syndrome
1250170|NCT00956475|stage I mycosis fungoides/Sezary syndrome
1250171|NCT00956475|stage II mycosis fungoides/Sezary syndrome
1250172|NCT00956475|stage III mycosis fungoides/Sezary syndrome
1250173|NCT00956475|stage IV mycosis fungoides/Sezary syndrome
1250174|NCT00956475|adult grade III lymphomatoid granulomatosis
1250175|NCT00956475|adult nasal type extranodal NK/T-cell lymphoma
1250176|NCT00956475|Waldenstrom macroglobulinemia
1250177|NCT00956475|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1250178|NCT00956475|nodal marginal zone B-cell lymphoma
1250179|NCT00956475|splenic marginal zone lymphoma
1250180|NCT00956475|contiguous stage II adult Burkitt lymphoma
1250181|NCT00956475|contiguous stage II adult diffuse large cell lymphoma
1250182|NCT00956475|contiguous stage II adult diffuse mixed cell lymphoma
1250183|NCT00956475|contiguous stage II adult diffuse small cleaved cell lymphoma
1250184|NCT00956475|contiguous stage II adult immunoblastic large cell lymphoma
1250185|NCT00956475|contiguous stage II adult lymphoblastic lymphoma
1250186|NCT00956475|contiguous stage II grade 1 follicular lymphoma
1250187|NCT00956475|contiguous stage II grade 2 follicular lymphoma
1250188|NCT00956475|contiguous stage II grade 3 follicular lymphoma
1250189|NCT00956475|contiguous stage II mantle cell lymphoma
1250190|NCT00956475|contiguous stage II marginal zone lymphoma
1250191|NCT00956475|contiguous stage II small lymphocytic lymphoma
1250192|NCT00956475|noncontiguous stage II adult Burkitt lymphoma
1250193|NCT00956475|noncontiguous stage II adult diffuse large cell lymphoma
1250194|NCT00956475|noncontiguous stage II adult diffuse mixed cell lymphoma
1250195|NCT00956475|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1250196|NCT00956475|noncontiguous stage II adult immunoblastic large cell lymphoma
1250197|NCT00956475|noncontiguous stage II adult lymphoblastic lymphoma
1250198|NCT00956475|noncontiguous stage II grade 1 follicular lymphoma
1250199|NCT00956475|noncontiguous stage II grade 2 follicular lymphoma
1250200|NCT00956475|noncontiguous stage II grade 3 follicular lymphoma
1250201|NCT00956475|noncontiguous stage II mantle cell lymphoma
1250202|NCT00956475|noncontiguous stage II marginal zone lymphoma
1250203|NCT00956475|noncontiguous stage II small lymphocytic lymphoma
1250204|NCT00956475|intraocular lymphoma
1250205|NCT00956475|primary central nervous system lymphoma
1250206|NCT00956475|post-transplant lymphoproliferative disorder
1250207|NCT00956475|cutaneous B-cell non-Hodgkin lymphoma
1250208|NCT00956475|small intestine lymphoma
1250209|NCT00956462|intraocular pressure
1250210|NCT00956462|Ahmed valve
1250211|NCT00956462|NSAIDS
1250212|NCT00956462|steroids
1250213|NCT00956449|flu
1250214|NCT00956449|influenza
1250216|NCT00956449|influenza vaccine antigen
1250217|NCT00956449|immunogenicity
1250218|NCT00956449|safety
1250219|NCT00956449|tolerability
1250220|NCT00956449|antibody response
1250221|NCT00956449|intra muscular
1250222|NCT00956449|elderly
1250223|NCT00956449|non-elderly
1250224|NCT00956436|Liver Cancer
1250225|NCT00956436|Hepatocellular Carcinoma
1250226|NCT00956436|Sorafenib
1250227|NCT00956436|HCC
1250228|NCT00956436|BIIB022
1250229|NCT00956436|Open-Label
1250230|NCT00956436|IGF-1R
1250231|NCT00956436|Nexavar
1250232|NCT00956423|obstructive sleep apnea
1250233|NCT00956423|exercise training
1250234|NCT00956423|aerobic exercise
1250235|NCT00956423|resistance exercise
1250236|NCT00956410|Active immunization
1250237|NCT00956410|Alzheimer disease
1250238|NCT00956410|Antibody
1250239|NCT00956410|Central Nervous System Diseases
1250240|NCT00956410|Neurodegenerative diseases
1250241|NCT00956410|Vaccine
1250242|NCT00956397|Functional Dyspepsia
1250243|NCT00956397|Small Intestinal Bacterial Overgrowth
1250244|NCT00956397|chronic abdominal discomfort
1250245|NCT00956384|Breast reconstruction
1250246|NCT00956384|Early stage
1250247|NCT00956384|Skin-saving mastectomy
1250248|NCT00956384|Prophylactic mastectomy
1250249|NCT00956384|Acellular dermal matrix
1250250|NCT00956384|BRCA Mutation Carriers
1250251|NCT00956371|ONO-7746
1250252|NCT00956371|Healthy adult subjects
1250253|NCT00956358|bronchiolitis obliterans syndrome
1250254|NCT00956332|Peripheral arterial disease (PAD)
1250255|NCT00956332|Peripheral vascular disease (PVD)
1250256|NCT00956332|Critical limb ischemia (CLI)
1250257|NCT00956332|Cell therapy
1250258|NCT00956332|Gene therapy
1250259|NCT00956332|Endothelial cells
1250260|NCT00956332|Smooth muscle cells
1250261|NCT00956332|Angiogenesis
1250262|NCT00956332|Arteriogenesis
1250263|NCT00956332|amputation
1250264|NCT00956332|diabetic foot
1250265|NCT00956319|Insomnia
1250266|NCT00956319|Zolpidem
1250267|NCT00956319|Estazolam
1250268|NCT00956306|Udenafil,DA-8159,hepatic impairment,healthy volunteers
1250269|NCT00956280|The frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC
1250270|NCT00956280|KRAS mutation in population with advanced NSCLC
1250271|NCT00956267|Polycystic ovary syndrome
1250272|NCT00956267|clomiphene resistance
1250273|NCT00956267|letrozole
1250274|NCT00956267|Laparoscopic ovarian diathermy
1250275|NCT00956254|mucositis
1250276|NCT00956254|unspecified adult solid tumor, protocol specific
1250277|NCT00956254|pain
1250278|NCT00956241|rectal cancer
1250279|NCT00956241|colonic pouch
1250280|NCT00956241|side-to-end anastomosis
1250281|NCT00956241|preoperative radiotherapy
1250282|NCT00956215|post operative
1250283|NCT00956215|obese
1250284|NCT00956202|Influenza
1250285|NCT00956202|Pandemic Flu
1250286|NCT00956202|Swine-origin A/H1N1 Influenza
1250287|NCT00956202|Inactivated split-virion vaccine
1250288|NCT00956202|Adjuvant
1250289|NCT00956189|Antipsychotic Agents
1250290|NCT00956189|Metabolic Syndrome X
1250291|NCT00956189|Identification
1250292|NCT00956189|Prediction
1250293|NCT00956176|Cidofovir
1250294|NCT00956176|Vistide
1250295|NCT00956176|Adenovirus
1250296|NCT00956176|BK virus infections
1250297|NCT00956176|HSCT
1250298|NCT00956176|Hemorrhagic Cystitis
1250299|NCT00956176|Foley catheter
1250300|NCT00956176|Viral infection
1250301|NCT00956176|Bladder instillation
1250302|NCT00956176|Intravesical
1250303|NCT00956176|Transurethral catheter
1250304|NCT00956176|Transplantation
1250305|NCT00956150|Chronic Multisymptom Complex
1250306|NCT00956150|Small Intestinal Bacterial Overgrowth
1250307|NCT00956150|Gulf War Syndrome
1250308|NCT00956150|Chronic Multisymptom Illness Complex
1250309|NCT00956137|spinal anesthesia
1250310|NCT00956137|ultrasound
1250311|NCT00956137|palpation
1250312|NCT00956137|knee
1250313|NCT00956137|hip
1250314|NCT00956137|surgery
1250315|NCT00956137|intervertebral space
1250316|NCT00956111|Novel Influenza A/H1N1 Vaccine
1250317|NCT00956111|Immunogenictiy
1250318|NCT00956111|Safety
1250320|NCT00956072|gastrointestinal stromal tumor
1250321|NCT00956059|focal segmental glomerulosclerosis
1250322|NCT00956059|prednisone
1250323|NCT00956059|mycophenolate mofetil
1250324|NCT00956059|FK506
1250325|NCT00956046|Influenza
1250326|NCT00956046|Pandemic Flu
1250327|NCT00956046|Swine-origin A/H1N1 Influenza
1250328|NCT00956046|Swine-origin Influenza Virus
1250329|NCT00956046|Infants
1250330|NCT00956033|Cancer
1250331|NCT00956033|Peripheral Neuropathy
1250332|NCT00956033|Bortezomib
1250333|NCT00956020|platelet rich plasma
1250334|NCT00956020|fibrin matrix
1250335|NCT00956020|dermal filler
1250336|NCT00956007|stage III squamous cell carcinoma of the larynx
1250337|NCT00956007|stage III verrucous carcinoma of the larynx
1250338|NCT00956007|stage IV squamous cell carcinoma of the larynx
1250339|NCT00956007|stage IV verrucous carcinoma of the larynx
1250340|NCT00956007|stage III squamous cell carcinoma of the lip and oral cavity
1250341|NCT00956007|stage IV squamous cell carcinoma of the lip and oral cavity
1250342|NCT00956007|stage III verrucous carcinoma of the oral cavity
1250343|NCT00956007|stage IV verrucous carcinoma of the oral cavity
1250344|NCT00956007|stage III squamous cell carcinoma of the oropharynx
1250345|NCT00956007|stage IV squamous cell carcinoma of the oropharynx
1250346|NCT00956007|tongue cancer
1250347|NCT00955968|HIV Infection
1250348|NCT00955968|HAART
1250349|NCT00955968|Maternal Health
1250350|NCT00955955|Depression
1250351|NCT00955955|Medical food
1250352|NCT00955942|radiation toxicity
1250353|NCT00955942|stage IIIA non-small cell lung cancer
1250354|NCT00955942|stage IIIB non-small cell lung cancer
1250355|NCT00955942|recurrent non-small cell lung cancer
1250356|NCT00955942|stage IV non-small cell lung cancer
1250357|NCT00955929|Penis
1250358|NCT00955929|PLACEBO
1250359|NCT00955929|SILDENAFIL CITRATE
1250360|NCT00955929|TRIMIX
1250361|NCT00955929|Bimix
1250362|NCT00955929|Viagra
1250363|NCT00955929|09-005
1250364|NCT00955929|Erectile Dysfunction following Bilateral Nerve-Sparing
1250365|NCT00955916|relapsed
1250366|NCT00955916|refractory
1250367|NCT00955916|acute
1250368|NCT00955916|myeloid
1250369|NCT00955916|AML
1250370|NCT00955916|CML
1250371|NCT00955916|blast crisis
1250372|NCT00955903|glucose
1250373|NCT00955903|insulin
1250374|NCT00955903|lipids
1250375|NCT00955903|C-reactive protein
1250376|NCT00955903|adiponectin
1250377|NCT00955903|leptin
1250378|NCT00955903|TNF alpha
1250379|NCT00955903|IL-6
1250380|NCT00955903|Quality of Life
1250381|NCT00955903|functional status
1250382|NCT00955890|cardioprotection
1250383|NCT00955890|anthracycline chemotherapy
1250384|NCT00955890|breast cancer
1250385|NCT00955877|extended-release epidural morphine
1250386|NCT00955877|DepoDur
1250387|NCT00955877|Spastic Cerebral Palsy
1250388|NCT00955864|Cervix
1250389|NCT00955864|Colposcope
1250390|NCT00955864|Polarized Light
1250391|NCT00955864|Cervix Structure
1250392|NCT00955864|Collagen
1250393|NCT00955864|HV
1250394|NCT00955864|Healthy Volunteer
1250395|NCT00955864|Healthy Women
1250396|NCT00955825|allergic rhinoconjunctivitis
1250397|NCT00955812|OPB-31121
1250398|NCT00955812|Advanced Solid Tumor
1250399|NCT00955812|STAT3
1250400|NCT00955812|IL-6-induced STAT3 phosphorylation
1250401|NCT00955799|Subjective, Tinnitus
1250402|NCT00955786|Solid Tumors
1250403|NCT00955786|Lymphoma
1250404|NCT00955786|G-Quadruplex
1250405|NCT00955773|GSK1120212, everolimus, solid tumors, pancreatic cancer, non-small lung cancer, KRAS-mutant
1250406|NCT00955773|cancer
1250407|NCT00955760|Healthy subjects
1250408|NCT00955734|wrist
1250409|NCT00955734|fracture
1250410|NCT00955734|motion
1250411|NCT00955734|surgery
1250412|NCT00955721|Cholangiocarcinoma
1250413|NCT00955721|Biliary Tract Cancer
1250414|NCT00955721|Gallbladder Cancer
1250415|NCT00955695|adenocarcinoma of the lung
1250416|NCT00955695|adenosquamous cell lung cancer
1250417|NCT00955695|bronchoalveolar cell lung cancer
1250418|NCT00955695|large cell lung cancer
1250419|NCT00955695|squamous cell lung cancer
1250420|NCT00955695|stage IIIB non-small cell lung cancer
1250421|NCT00955695|stage IV non-small cell lung cancer
1250422|NCT00955682|Meningococcal vaccine GSK134612
1250423|NCT00955669|mesenchymal stem cells
1250424|NCT00955669|mononuclear cells
1250425|NCT00955656|Characteristics of medical practices
1250426|NCT00955656|Practitioners providing care to children with asthma
1250427|NCT00955656|Medically underserved and impoverished Arkansas Delta region
1250428|NCT00955656|Characteristics of medical practices and practitioners
1250429|NCT00955656|Disadvantaged populations
1250430|NCT00955643|periodontitis
1250431|NCT00955643|hyperbaric oxygen therapy
1250432|NCT00955630|Histoplasmosis
1250433|NCT00955630|Lucentis
1250434|NCT00955630|Ranibizumab
1250435|NCT00955630|OHS
1250436|NCT00955617|Dotarem
1250437|NCT00955617|Gadovist
1250438|NCT00955617|Peripheral arterial disease
1250439|NCT00955617|MRA
1250440|NCT00955604|Parkinson's Disease
1250441|NCT00955604|Serotonin Toxicity
1250442|NCT00955604|Rasagiline
1250443|NCT00955604|Antidepressants
1250444|NCT00955604|Chart Review
1250445|NCT00955604|Retrospective
1250446|NCT00955591|human papilloma virus infection
1250447|NCT00955591|anal cancer
1250448|NCT00955591|HIV infection
1250449|NCT00955552|osteoarthritis (OA)
1250450|NCT00955552|knee
1250451|NCT00955539|Heart Failure
1250452|NCT00955539|Cardiac resynchronization therapy
1250453|NCT00955539|Optimization
1250454|NCT00955539|Viability
1250455|NCT00955539|Mechanical dyssynchrony
1250456|NCT00955526|Parkinson's disease
1250457|NCT00955526|levodopa
1250458|NCT00955526|end of dose wearing off
1250459|NCT00955526|OFF time
1250460|NCT00955513|Ankle sprain
1250461|NCT00955513|soft tissue injury
1250462|NCT00955500|Hepatic encephalopathy
1250463|NCT00955500|Cirrhosis
1250464|NCT00955500|Proteins of the diet
1250465|NCT00955500|Branched-chain amino acids
1250466|NCT00955487|Premature Newborns
1250467|NCT00955487|Inhaled Nitric Oxide
1250468|NCT00955448|Anterior pelvic organ prolapse
1250469|NCT00955448|Surgical repair
1250470|NCT00955448|Pelvic floor surgery
1250471|NCT00955448|Randomized clinical trial
1250472|NCT00955435|adenocarcinoma of the prostate
1250473|NCT00955435|stage I prostate cancer
1250474|NCT00955435|stage IIB prostate cancer
1250475|NCT00955435|stage IIA prostate cancer
1250476|NCT00955435|stage III prostate cancer
1250477|NCT00955422|Diagnosis
1250478|NCT00955422|Alzheimer's Disease
1250479|NCT00955422|Memory Disorder
1250480|NCT00955422|Dementia
1250481|NCT00955422|Alzheimer Disease
1250482|NCT00955422|Memory Loss
1250483|NCT00955396|sodium channel blocker
1250484|NCT00955396|ambulatory blood pressure
1250485|NCT00955383|Japanese
1250486|NCT00955370|Uncertainty
1250487|NCT00955370|Undiagnosed
1250488|NCT00955370|Rare Diseases
1250489|NCT00955370|Parents
1250490|NCT00955370|Multiple Abnormalities
1250491|NCT00955357|Epilepsy Treatment
1250492|NCT00955357|Anti-epileptic drugs
1250493|NCT00955357|Seizures
1250494|NCT00955357|Vimpat
1250495|NCT00955344|colorectal cancer screening
1250496|NCT00955344|American Board of Internal Medicine Maintenance of Certification program
1250497|NCT00955344|Currently enrolled in or plan to enroll in the American Board of Internal Medicine Maintenance of Certification program
1250498|NCT00955305|Non-Small Cell Lung Cancer
1250499|NCT00955305|cixutumumab
1250500|NCT00955292|Solid Tumors
1250501|NCT00955292|Lymphoma
1250502|NCT00955292|G-Quadruplex
1250503|NCT00955279|Ustekinumab
1250504|NCT00955279|CNTO 1275
1250505|NCT00955279|Stelara
1250506|NCT00955279|Golimumab
1250507|NCT00955279|CNTO 148
1250508|NCT00955279|Simponi
1250509|NCT00955279|Sarcoidosis
1250510|NCT00955279|Sarcoid
1250511|NCT00955279|Pulmonary Sarcoidosis
1250512|NCT00955279|Skin Sarcoidosis
1250513|NCT00955266|Separation
1250514|NCT00955266|Cardiopulmonary bypass
1250515|NCT00955266|Calcium chloride
1250516|NCT00955253|Neglect
1250517|NCT00955253|Attention
1250518|NCT00955253|Vigilance
1250519|NCT00955253|Stroke
1250520|NCT00955253|Hemineglect
1250521|NCT00955253|Unilateral Neglect
1250522|NCT00955253|Spatial Neglect
1250523|NCT00955240|stage II anal cancer
1250524|NCT00955240|stage IIIA anal cancer
1250525|NCT00955240|stage IIIB anal cancer
1250526|NCT00955240|squamous cell carcinoma of the anus
1250527|NCT00955227|Omega-3 Fatty acid
1250528|NCT00955227|ALA (alpha linolenic acid)
1250529|NCT00955227|Ezetimibe
1250530|NCT00955227|Flaxseed oil capsules
1250531|NCT00955214|TAXUS Liberté
1250532|NCT00955214|Small coronary artery disease
1250533|NCT00955214|Paclitaxel-eluting stent
1250534|NCT00955201|diabetes mellitus
1250535|NCT00955201|diabetic neuropathies
1250536|NCT00955201|Aerobic Exercise
1250537|NCT00955201|Exercise Therapy
1250538|NCT00955201|electromyography
1250539|NCT00955201|United States Veterans
1250540|NCT00955188|colon cancer
1250541|NCT00955188|rectal cancer
1250542|NCT00955175|stage I non-small cell lung cancer
1250543|NCT00955175|stage II non-small cell lung cancer
1250544|NCT00955175|stage IIIA non-small cell lung cancer
1250545|NCT00955175|stage IIIB non-small cell lung cancer
1250546|NCT00955162|Substance Abuse, Intravenous
1250547|NCT00955162|Buprenorphine
1250548|NCT00955149|Primary sclerosing cholangitis
1250549|NCT00955149|Trisomy 7
1250550|NCT00955149|Cholangiocarcinoma
1250551|NCT00955149|Chemoprevention
1250552|NCT00955149|Erlotinib
1250553|NCT00955136|ST elevated myocardial infarction
1250554|NCT00955136|Acute coronary syndrome
1250555|NCT00955136|MRX 801
1250556|NCT00955136|Echocardiography
1250557|NCT00955123|Inflammation
1250558|NCT00955123|Urea synthesis
1250559|NCT00955123|Catabolism
1250560|NCT00955123|Nitrogen balance
1250561|NCT00955110|Opioid
1250562|NCT00955110|Recreational
1250563|NCT00955110|Oxymorphone
1250564|NCT00955110|Oxycodone
1250565|NCT00955110|Extended Release
1250566|NCT00955110|Healthy NonDependent Recreational Opioid Users
1250567|NCT00955097|Definity
1250568|NCT00955097|liver tumors
1250569|NCT00955097|intra operative contrast
1250570|NCT00955097|liver cancer
1250571|NCT00955097|hepatic tumors
1250572|NCT00955097|identify liver tumors
1250573|NCT00955097|surgery liver tumors
1250574|NCT00955097|Patients with known hepatic tumors
1250575|NCT00955071|exercise
1250576|NCT00955071|physical activity
1250577|NCT00955071|diet
1250578|NCT00955071|metabolic risk
1250579|NCT00955071|visceral fat
1250580|NCT00955071|Insulin Resistance
1250581|NCT00955058|PSA
1250582|NCT00955058|PCO
1250583|NCT00955058|PCOS
1250584|NCT00955045|long-term tolerability and safety
1250585|NCT00955045|istradefylline treatment
1250586|NCT00955045|levodopa/carbidopa
1250587|NCT00955032|Parkinson's disease
1250588|NCT00955032|Apathy
1250589|NCT00955032|rTMS
1250590|NCT00955032|Repetitive transcranial magnetic stimulation
1250591|NCT00955032|Depression
1250592|NCT00955019|Barrett's
1250593|NCT00955019|Esophagus
1250594|NCT00955019|Reflux
1250595|NCT00955019|dysplasia
1250596|NCT00955019|adenocarcinoma
1250597|NCT00955006|HIV Seronegativity
1250598|NCT00955006|HIV Preventive Vaccine
1250599|NCT00954993|Hepatitis C Virus (HCV)
1250600|NCT00954993|Vaniprevir
1250601|NCT00954993|MK-7009
1250602|NCT00954980|Varicose Veins
1250603|NCT00954980|Superficial Thrombophlebitis
1250604|NCT00954980|Deep Vein Thrombosis
1250605|NCT00954980|Ulceration
1250606|NCT00954980|leg pain
1250607|NCT00954980|leg swelling
1250608|NCT00954967|Diabetes Mellitus
1250609|NCT00954967|Smoking Cessation
1250610|NCT00954967|Primary Health Care
1250611|NCT00954967|Motivational Interview
1250612|NCT00954954|Arthroplasty
1250613|NCT00954954|Replacement
1250614|NCT00954954|Knee
1250615|NCT00954954|Range of Motion
1250616|NCT00954941|Hematologic Disorder
1250617|NCT00954941|Acute myelogenous leukemia
1250618|NCT00954941|AML
1250619|NCT00954941|High-risk myelodysplastic syndrome
1250620|NCT00954941|HR-MDS
1250621|NCT00954941|Chronic Myelogenous Leukemia
1250622|NCT00954941|CML
1250623|NCT00954941|Ondansetron
1250624|NCT00954941|Zofran
1250625|NCT00954941|Aprepitant
1250626|NCT00954941|Emend
1250627|NCT00954941|L 754030
1250628|NCT00954941|MK 869
1250629|NCT00954941|Emesis
1250630|NCT00954941|Nausea
1250631|NCT00954941|Vomiting
1250632|NCT00954928|hand
1250633|NCT00954928|wrist
1250634|NCT00954928|anticoagulation
1250635|NCT00954928|surgery
1250636|NCT00954928|patients on anticoagulant medication
1250637|NCT00954915|chronic plaque psoriasis
1250638|NCT00954915|psoriatic arthritis
1250639|NCT00954902|Spice
1250640|NCT00954902|responses to stress
1250641|NCT00954902|Inflammatory
1250642|NCT00954837|Thyroid cancer
1250643|NCT00954837|thyroid FNA
1250644|NCT00954837|repeat FNA
1250645|NCT00954837|thyroid screening
1250646|NCT00954837|thyroid ultrasonography
1250647|NCT00954837|FNA screening
1250648|NCT00954811|pregnancy
1250649|NCT00954798|Influenza
1250650|NCT00954798|Pandemic Flu
1250651|NCT00954798|Swine-origin Influenza
1250652|NCT00954798|Inactivated split-virion vaccine
1250653|NCT00954798|Adjuvant
1250654|NCT00954798|Adult
1250655|NCT00954785|ankle
1250656|NCT00954785|ligament
1250657|NCT00954785|sprain
1250658|NCT00954785|non-steroidal anti-inflammatory drugs
1250659|NCT00954785|treatment
1250660|NCT00954785|Acute ankle ligament sprain
1250661|NCT00954772|Staged versus Simultaneous Bilateral DBS
1250662|NCT00954759|Infantile colic
1250663|NCT00954759|Chiropractic
1250664|NCT00954759|Manipulation
1250665|NCT00954759|Randomized controlled trial
1250666|NCT00954746|Advanced Dupuytren's Disease
1250667|NCT00954746|Muscular Diseases
1250668|NCT00954746|Musculoskeletal Diseases
1250669|NCT00954746|Contracture Joint Diseases
1250670|NCT00954746|Connective Tissue Diseases
1250671|NCT00954746|Dupuytren's Contracture
1250672|NCT00954733|Hysteroscopic surgery
1250673|NCT00954733|Hypoventilation
1250674|NCT00954733|Co2
1250675|NCT00954733|Transcutaneous Co2 Monitor
1250676|NCT00954720|AML
1250677|NCT00954720|ALL
1250678|NCT00954720|MDS
1250679|NCT00954720|iron overload
1250680|NCT00954707|Atherosclerosis
1250681|NCT00954681|Cannabis
1250682|NCT00954681|quetiapine
1250683|NCT00954668|Non-ST-elevation myocardial infarction
1250684|NCT00954668|angiography
1250685|NCT00954668|percutaneous coronary intervention
1250686|NCT00954668|timing
1250687|NCT00954655|gastrointestinal stromal tumor
1250688|NCT00954642|Solid Tumor
1250689|NCT00954642|Locally Advanced Solid Tumor
1250690|NCT00954642|Avastin
1250691|NCT00954629|Osteoarthritis
1250692|NCT00954629|Pain
1250693|NCT00954629|Knee
1250694|NCT00954616|Inappropriate Medications Associated
1250695|NCT00954616|Alzheimer's disease
1250696|NCT00954603|delirium rating scale
1250697|NCT00954603|clinical global improvement
1250698|NCT00954603|extrapyramidal side effect
1250699|NCT00954577|obesity
1250700|NCT00954577|diabetes
1250701|NCT00954577|exercise
1250702|NCT00954577|education
1250703|NCT00954577|child
1250704|NCT00954564|arthralgia
1250705|NCT00954564|stage I breast cancer
1250706|NCT00954564|stage II breast cancer
1250707|NCT00954564|stage IIIA breast cancer
1250708|NCT00954525|Pancreatic Cancer
1250709|NCT00954512|Antibodies, neoplasm
1250710|NCT00954499|tactile stimulation
1250711|NCT00954499|pain
1250712|NCT00954499|immunization
1250713|NCT00954499|infant
1250714|NCT00954460|VPRIV
1250715|NCT00954460|Enzyme Replacement Therapy
1250716|NCT00954460|Gaucher disease
1250717|NCT00954460|glucocerebrosidase
1250718|NCT00954460|beta-glucocerebrosidase
1250719|NCT00954460|Acid beta-glucocerebrosidase
1250720|NCT00954460|glucosylceramidase
1250721|NCT00954460|D-glucosyl-N-acylsphingosine glucohydrolase
1250722|NCT00954460|gene activation
1250723|NCT00954460|human
1250724|NCT00954395|vitamin K antagonists, D-dimer,
1250725|NCT00954395|deep vein thrombosis, pulmonary embolism,
1250726|NCT00954382|Down syndrome
1250727|NCT00954382|IQ
1250728|NCT00954382|mental age
1250729|NCT00954382|neuropsychological function
1250730|NCT00954369|Alzheimer's disease
1250731|NCT00954369|AD
1250732|NCT00954369|W372
1250733|NCT00954369|W372000
1250734|NCT00954369|[F-18]W372
1250735|NCT00954369|exploratory
1250736|NCT00954369|imaging
1250737|NCT00954356|Pain following 3rd molar/wisdom tooth extraction
1250738|NCT00954343|Foot Ulcers
1250739|NCT00954343|Extracorporeal Shockwave
1250740|NCT00954343|Chronic wound
1250741|NCT00954330|rct, intervention, surgery, lateral ligament injury of the ankle
1250742|NCT00954330|REturn to pre-injury level
1250743|NCT00954317|epidural
1250744|NCT00954317|labour analgesia
1250745|NCT00954304|Pgp inhibitor
1250746|NCT00954304|P-glycoprotein inhibitor
1250747|NCT00954291|antinauseant and antiemetic
1250748|NCT00954278|non small cell lung cancer
1250749|NCT00954278|phase 1
1250750|NCT00954278|sorafenib
1250751|NCT00954278|intrapatient dose escalation
1250752|NCT00954265|pregnancy occurence
1250753|NCT00954265|OHSS
1250754|NCT00954226|Head & Neck squamous cell carcinoma
1250755|NCT00954226|HN cancer
1250756|NCT00954226|Surgery
1250757|NCT00954226|Erlotinib
1250758|NCT00954226|Biomarkers
1250759|NCT00954226|Phosphorylation of AKT
1250760|NCT00954161|First aid
1250761|NCT00954161|Helping behaviour
1250762|NCT00954161|Health education
1250763|NCT00954161|Myocardial infarction
1250764|NCT00954161|Emergencies
1250765|NCT00954148|cancer
1250766|NCT00954148|colorectal
1250767|NCT00954148|head/neck
1250768|NCT00954148|lung
1250769|NCT00954148|PET/CT
1250770|NCT00954135|neoadjuvant therapy, sorafenib, letrozolo, cyclophosphamide
1250771|NCT00954122|Acute schizophrenia
1250772|NCT00954109|Insulin Resistance
1250773|NCT00954109|Type 2 Diabetes
1250774|NCT00954070|gastroesophageal reflux disease
1250775|NCT00954057|TED
1250776|NCT00954044|randomized clinical trial
1250777|NCT00954044|prostate cancer
1250778|NCT00954044|partnered exercise
1250779|NCT00954005|relapsed indolent lymphoma
1250780|NCT00954005|gemcitabine
1250781|NCT00954005|oxaliplatin
1250782|NCT00954005|rituximab
1250783|NCT00953992|acute kidney disease
1250784|NCT00953992|prognosis
1250785|NCT00953992|oxidative stress
1250786|NCT00953992|inflammation
1250787|NCT00953992|gene polymorphism
1250788|NCT00953979|ankylosing spondylitis
1250789|NCT00953979|treatment
1250790|NCT00953979|Sulfasalazine
1250791|NCT00953979|kunxian capsule
1250792|NCT00953914|pyridostigmine
1250793|NCT00953914|autonomic modulation
1250794|NCT00953914|diabetes mellitus
1250795|NCT00953914|heart rate variability
1250796|NCT00953888|Healthy volunteer
1250797|NCT00953888|Single ascending dose
1250798|NCT00953888|Safety
1250799|NCT00953888|Tolerability
1250800|NCT00953888|Healthy volunteer study
1250801|NCT00953862|ADHD
1250802|NCT00953862|Substance Use Disorder
1250803|NCT00953862|Residential Treatment Facility
1250804|NCT00953849|Calcitriol
1250805|NCT00953849|Celecoxib
1250806|NCT00953849|Immunotherapy
1250807|NCT00953836|kinetics
1250808|NCT00953836|alkylresorcinol metabolites
1250809|NCT00953836|rye fiber
1250810|NCT00953823|Thiamin supplementation
1250811|NCT00953823|Thiamin deficiency
1250812|NCT00953823|Heart failure
1250813|NCT00953823|Heart function
1250814|NCT00953823|Vitamin B1 supplementation
1250815|NCT00953810|heart failure
1250816|NCT00953810|education
1250817|NCT00953810|non-pharmacological management
1250818|NCT00953810|prognosis
1250819|NCT00953797|Resistant Hypertension
1250820|NCT00953797|Endothelial dysfunction
1250821|NCT00953797|Enhanced External Counterpulsation
1250822|NCT00953784|surgery
1250823|NCT00953784|wound infections
1250824|NCT00953784|colorectal
1250825|NCT00953771|TTP
1250826|NCT00953771|Thrombotic Thrombocytopenic Purpura
1250827|NCT00953758|Chronic Myeloid Leukemia Myelofibrosis Myelodysplastic Syndrome Acute myeloid Leukemia Hedgehog inhibitor
1250828|NCT00953745|Depression
1250829|NCT00953745|Neuroimaging
1250830|NCT00953745|Aripiprazole
1250831|NCT00953745|Mood disorder
1250832|NCT00953745|PET Scan
1250833|NCT00953745|fMRI
1250834|NCT00953732|Peplin
1250835|NCT00953732|Actinic keratosis
1250836|NCT00953732|PEP005
1250837|NCT00953719|Hip arthroplasty
1250838|NCT00953719|Acetabular cup
1250839|NCT00953719|Ceramic-on-polyethylene
1250840|NCT00953706|Fibrosis
1250841|NCT00953706|Pancreatic Diseases
1250842|NCT00953706|Digestive System Diseases
1250843|NCT00953706|Lung Diseases
1250844|NCT00953706|Respiratory Tract Diseases
1250845|NCT00953706|Genetic Diseases, Inborn
1250846|NCT00953706|Infant, Newborn, Diseases
1250847|NCT00953706|Pathologic Processes
1250848|NCT00953693|Induced pluripotent stem cells
1250849|NCT00953693|Hepatic disorders
1250850|NCT00953693|Eye disorders
1250851|NCT00953693|Blood groups
1250852|NCT00953654|Generalized Anxiety Disorder
1250853|NCT00953654|Exercise Training
1250854|NCT00953654|Strength Training
1250855|NCT00953654|Mental Health
1250856|NCT00953641|Vaginal Misoprostol
1250857|NCT00953641|Cervical ripening
1250858|NCT00953641|Endometrial biopsy
1250859|NCT00953628|endometrium
1250860|NCT00953628|histology
1250861|NCT00953628|pregnancy
1250862|NCT00953615|PSC
1250863|NCT00953615|Thalidomide
1250864|NCT00953589|treatment naive
1250865|NCT00953576|castration resistant prostate cancer
1250866|NCT00953576|KHAD
1250867|NCT00953563|Venous Leg Ulcers
1250868|NCT00953537|stage IV breast cancer
1250869|NCT00953524|Influenza
1250870|NCT00953524|Pandemic Flu
1250871|NCT00953524|Swine-origin A/H1N1 Influenza
1250872|NCT00953524|Adult
1250873|NCT00953511|esophagus
1250874|NCT00953511|chemoradiation
1251124|NCT00952406|Pelvic Floor Disorders
1250875|NCT00953511|excision repair cross-complementing gene
1250876|NCT00953511|polymorphism
1250877|NCT00953511|response prediction
1250878|NCT00953498|diabetes
1250879|NCT00953498|glitazones
1250880|NCT00953498|HDL
1250881|NCT00953485|Sjogren's Syndrome
1250882|NCT00953485|Mesenchymal Stem Cells
1250883|NCT00953485|Transplantation
1250884|NCT00953472|hypertension treatment
1250885|NCT00953459|extensive stage small cell lung cancer
1250886|NCT00953459|recurrent small cell lung cancer
1250887|NCT00953446|metastatic renal cell carcinoma
1250888|NCT00953446|ASL MRI
1250889|NCT00953446|sunitinib
1250890|NCT00953446|AMG386
1250891|NCT00953433|Intratracheal
1250892|NCT00953420|nasopharyngeal carcinoma
1250893|NCT00953420|Carboplatin
1250894|NCT00953420|Docetaxel
1250895|NCT00953420|Epstein-Barr Virus
1250896|NCT00953420|T Lymphocytes
1250897|NCT00953420|EBV-CTLs
1250898|NCT00953394|octreotide LAR
1250899|NCT00953394|neuroendocrine carcinoma
1250900|NCT00953394|metronomic 5fluorouracil
1250901|NCT00953381|Ilaprazole
1250902|NCT00953381|Proton pump inhibitor
1250903|NCT00953381|Duodenal ulcer
1250904|NCT00953381|Acid suppression
1250905|NCT00953381|Randomized trial
1250906|NCT00953368|remote ischemic preconditioning
1250907|NCT00953368|cognitive function
1250908|NCT00953368|off-pump coronary artery bypass graft
1250909|NCT00953342|AEROBIC EXERCISE
1250910|NCT00953342|ASTHMA CONTROL
1250911|NCT00953342|ASTHMA QUALITY OF LIFE
1250912|NCT00953342|INFLAMMATION
1250913|NCT00953342|TREATMENT
1250914|NCT00953303|heart failure
1250915|NCT00953303|prednisone
1250916|NCT00953303|cardiovascular mortality
1250917|NCT00953303|renal function
1250918|NCT00953290|Cellulite
1250919|NCT00953290|Adipose tissue
1250920|NCT00953290|Circumference
1250921|NCT00953290|Reduction
1250922|NCT00953290|Thigh
1250923|NCT00953277|Nerve Repair
1250924|NCT00953277|Erectile Function
1250925|NCT00953277|Prostate Cancer
1250926|NCT00953277|Robot Assisted Laparoscopic Prostatectomy
1250927|NCT00953277|Continence
1250928|NCT00953251|high sensitive troponin T; non-STEMI; early detection.
1250929|NCT00953251|To detect non-STEMI in a cohort of patients with acute coronary syndrome
1250930|NCT00953225|prostate cancer
1250931|NCT00953225|vitamin D
1250932|NCT00953212|atrial fibrillation
1250933|NCT00953212|cardiac surgery
1250934|NCT00953212|open heart surgery
1250935|NCT00953199|endoscopic retrograde cholangiopancreatography
1250936|NCT00953199|ERCP
1250937|NCT00953199|pancreatitis
1250938|NCT00953199|lidocaine
1250939|NCT00953199|post-ERCP pancreatitis
1250940|NCT00953186|Diabetes
1250941|NCT00953186|Foot ulcer
1250942|NCT00953186|Neuropathy
1250943|NCT00953186|Ischemia
1250944|NCT00953160|Cellulite
1250945|NCT00953160|Adipose tissue
1250946|NCT00953160|Circumference
1250947|NCT00953160|Reduction
1250948|NCT00953160|Thigh
1250949|NCT00953160|Abdomen
1250950|NCT00953160|Flank
1250951|NCT00953134|periconceptional
1250952|NCT00953134|iron
1250953|NCT00953134|folic acid
1250954|NCT00953134|supplementation
1250955|NCT00953121|irinotecan
1250956|NCT00953121|carboplatin
1250957|NCT00953121|bevacizumab
1250958|NCT00953121|Avastin
1250959|NCT00953095|Autism Spectrum Disorder
1250960|NCT00953095|treatment
1250961|NCT00953095|joint attention
1250962|NCT00953095|communication
1250963|NCT00953095|language
1250964|NCT00953043|lubiprostone
1250965|NCT00953043|colon
1250966|NCT00953043|motility
1250967|NCT00953043|sensation
1250968|NCT00953017|Efficacy of bowel cleansing
1250969|NCT00953017|Patient tolerability
1250970|NCT00953017|Amitiza
1250971|NCT00953017|Dulcolax
1250972|NCT00953017|Miralax
1250973|NCT00953017|Colonoscopy preparation
1250974|NCT00953017|Bowel preparation
1250975|NCT00953017|Screening colonoscopy
1250976|NCT00953004|dietary fiber
1250977|NCT00953004|obesity
1250978|NCT00953004|apparent energy digestibility
1250979|NCT00952978|Ilaprazole
1250980|NCT00952978|Proton pump inhibitor
1250981|NCT00952978|Duodenal ulcer
1250982|NCT00952978|Acid suppression
1250983|NCT00952978|Randomized trial
1250984|NCT00952965|BP
1250985|NCT00952939|ciliary body and choroid melanoma, small size
1250986|NCT00952939|iris melanoma
1250987|NCT00952939|intraocular melanoma
1250988|NCT00952939|ciliary body and choroid melanoma, medium/large size
1250989|NCT00952926|Watchful Waiting
1250990|NCT00952926|Rectal cancer
1250991|NCT00952926|Observation
1250992|NCT00952926|Avoid operation
1250993|NCT00952900|TMJMD
1250994|NCT00952900|Acute Pain
1250995|NCT00952900|RDC/TMD
1250996|NCT00952900|Community Treatment Clinics
1250997|NCT00952900|RCT
1250998|NCT00952900|Evidence-Based Outcomes
1250999|NCT00952900|Short- and long-term follow-up
1251000|NCT00952900|Biopsychosocial
1251001|NCT00952900|Assessment and Treatment
1251002|NCT00952900|Ability to read and write English
1251003|NCT00952900|6 months' or less duration of TMD
1251004|NCT00952900|No other pain-related conditions
1251005|NCT00952874|anal cancer
1251006|NCT00952874|Molecular biology
1251007|NCT00952874|HIV status
1251008|NCT00952874|HPV infection
1251009|NCT00952874|Microsatellite instability
1251010|NCT00952874|Biopsy proven Squamous Cell carcinoma of the Anus
1251011|NCT00952874|Squamous Cell carcinoma of the Anus
1251012|NCT00952861|Chronic obstructive pulmonary disease
1251013|NCT00952861|Infection
1251014|NCT00952861|Antibiotics
1251015|NCT00952848|pain
1251016|NCT00952848|neurotoxicity
1251017|NCT00952848|chemotherapeutic agent toxicity
1251018|NCT00952848|unspecified adult solid tumor, protocol specific
1251019|NCT00952848|peripheral neuropathy
1251020|NCT00952835|Asthma
1251021|NCT00952835|rhinitis
1251022|NCT00952835|EIB
1251023|NCT00952835|Exhaled Nitric oxide
1251024|NCT00952835|lung function
1251025|NCT00952835|vitamin d
1251026|NCT00952796|intra-abdominal infection
1251027|NCT00952796|moxifloxacin
1251028|NCT00952796|ampicillin/sulbactam
1251029|NCT00952783|Peplin
1251030|NCT00952783|Actinic keratosis
1251031|NCT00952783|PEP005
1251032|NCT00952770|Coronary artery disease
1251033|NCT00952770|Coronary intervention
1251034|NCT00952770|intima-media thickness
1251035|NCT00952757|APS-related hyperprolactinaemia
1251036|NCT00952757|Quetiapine
1251037|NCT00952757|Schizophrenia
1251038|NCT00952757|Bipolar
1251039|NCT00952744|acute myocardial infarction
1251040|NCT00952744|ST-segment elevation myocardial infarction
1251041|NCT00952744|STEMI
1251042|NCT00952744|non-ST-segment elevation myocardial infarction
1251043|NCT00952744|NSTEMI
1251044|NCT00952744|unstable angina
1251045|NCT00952744|unstable angina pectoris
1251046|NCT00952744|UA
1251047|NCT00952744|UAP
1251048|NCT00952692|breast cancer
1251049|NCT00952692|HER2
1251050|NCT00952692|Lapatinib
1251051|NCT00952692|dHER2 ASCI
1251052|NCT00952692|overexpressing HER2
1251053|NCT00952692|refractory to trastuzumab
1251054|NCT00952679|The investigators evaluated the new method by comparing lymph nodes defined by CT and traditional ways.
1251055|NCT00952666|Prostate Cancer
1251056|NCT00952666|Transrectal Ultrasound Imaging of Prostate
1251057|NCT00952666|Neurovascular Bundles
1251058|NCT00952666|Robot Assisted Laparoscopic Radical Prostatectomy
1251059|NCT00952653|depression
1251060|NCT00952640|vitamin A
1251061|NCT00952640|post-partum
1251062|NCT00952640|infant
1251063|NCT00952640|acute phase response
1251064|NCT00952627|Cardiac fibrosis
1251065|NCT00952627|Diastolic dysfunction
1251066|NCT00952627|Hypertension
1251067|NCT00952614|retinal vein occlusion
1251068|NCT00952614|sustained drug delivery implant
1251069|NCT00952614|steroid
1251070|NCT00952614|macular edema
1251071|NCT00952601|Tourette
1251072|NCT00952601|Atkins
1251073|NCT00952601|Ketosis
1251074|NCT00952601|Tic
1251075|NCT00952588|Acute Myeloid Leukaemia,
1251076|NCT00952588|AML
1251077|NCT00952575|Prevention of foeto-maternal allo-immunisation
1251078|NCT00952562|vitamin d
1251079|NCT00952562|calcium
1251080|NCT00952562|blood pressure
1251081|NCT00952536|Randomised controlled trial
1251082|NCT00952536|Double blind fully masked
1251083|NCT00952536|Dietary supplement
1251084|NCT00952523|acne
1251085|NCT00952523|irritation
1251086|NCT00952523|objective sensory methods
1251087|NCT00952510|Range of motion, articular
1251088|NCT00952510|Cervical spine
1251089|NCT00952497|Gastric Cancer
1251090|NCT00952497|Gastro-Esophageal Cancer
1251091|NCT00952497|GE-Junction
1251092|NCT00952497|Advanced Gastric Cancer
1251093|NCT00952484|Hypophosphatasia
1251094|NCT00952484|HPP
1251095|NCT00952484|Bone Disease
1251096|NCT00952484|Soft Bones
1251097|NCT00952484|Low Alkaline Phosphatase
1251098|NCT00952484|genetic metabolic disorder
1251099|NCT00952484|alkaline phosphatase
1251100|NCT00952484|tissue non-specific alkaline phosphatase
1251101|NCT00952484|rickets
1251102|NCT00952484|osteomalacia
1251103|NCT00952471|Asthma
1251104|NCT00952471|Children
1251105|NCT00952471|CPOE
1251106|NCT00952471|Decision Support
1251107|NCT00952471|Framing
1251108|NCT00952471|Heuristic
1251109|NCT00952471|Order Sets
1251110|NCT00952458|Safety
1251111|NCT00952458|Midazolam and propofol sedation
1251112|NCT00952458|ERCP
1251113|NCT00952458|Bispectral Index monitoring
1251114|NCT00952432|Carpal Tunnel Syndrome
1251115|NCT00952432|Multiple Excitability Test
1251116|NCT00952432|Nerve Conduction Study
1251117|NCT00952432|QtracW
1251118|NCT00952432|carbamazepine
1251119|NCT00952432|Acupuncture
1251120|NCT00952419|Influenza
1251121|NCT00952419|Pandemic Flu
1251122|NCT00952419|Swine-origin A/H1N1 Influenza
1251123|NCT00952419|Children
1251125|NCT00952406|Sexual Function
1251126|NCT00952406|Incontinence
1251127|NCT00952406|Pelvic Organ Prolapse
1251128|NCT00952393|receptors nicotinic
1251129|NCT00952380|VTE
1251130|NCT00952354|Down syndrome
1251131|NCT00952354|MLU
1251132|NCT00952354|language development
1251133|NCT00952354|language assessment
1251134|NCT00952341|CINV
1251135|NCT00952328|breastfeeding outcomes
1251136|NCT00952328|breastfeeding self-efficacy
1251137|NCT00952328|infant weight loss
1251138|NCT00952315|kidney stones
1251139|NCT00952315|intracorporeal lithotriptors
1251140|NCT00952315|kidney stone removal
1251141|NCT00952302|Hypoxia
1251142|NCT00952302|Iron
1251143|NCT00952302|Hypoxia-Inducible Factor 1
1251144|NCT00952302|Chronic mountain sickness
1251145|NCT00952289|Myelofibrosis
1251146|NCT00952289|Post-Polycythemia Vera Myelofibrosis
1251147|NCT00952289|Post-Essential Thrombocythemia Myelofibrosis
1251148|NCT00952276|Influenza Pandemic Flu Swine-origin A/H1N1 Influenza Adults
1251149|NCT00952263|Hepatitis C
1251150|NCT00952263|Phase I
1251151|NCT00952263|Infusion
1251152|NCT00952263|Pharmacokinetics
1251153|NCT00952263|MBL-HCV1
1251154|NCT00952263|Monoclonal antibody
1251155|NCT00952263|Safety Assessment
1251156|NCT00952250|quality improvement
1251157|NCT00952237|Autologous Peripheral Blood Stem Cell Transplant
1251158|NCT00952237|IL-2
1251159|NCT00952237|GM-CSF
1251160|NCT00952224|myocardial salvage
1251161|NCT00952224|cardiovascular magnetic resonance
1251162|NCT00952224|magnetic resonance imaging
1251163|NCT00952224|myocardial infarction
1251164|NCT00952224|prognosis
1251165|NCT00952211|stroke
1251166|NCT00952211|obstructive sleep apnea
1251167|NCT00952211|fatigue
1251168|NCT00952211|quality of life
1251169|NCT00952185|viral infection
1251170|NCT00952185|aplastic anemia
1251171|NCT00952185|accelerated phase chronic myelogenous leukemia
1251172|NCT00952185|acute undifferentiated leukemia
1251173|NCT00952185|adult acute lymphoblastic leukemia in remission
1251174|NCT00952185|adult acute myeloid leukemia in remission
1251175|NCT00952185|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1251176|NCT00952185|adult acute myeloid leukemia with inv(16)(p13;q22)
1251177|NCT00952185|adult acute myeloid leukemia with t(15;17)(q22;q12)
1251178|NCT00952185|adult acute myeloid leukemia with t(16;16)(p13;q22)
1251179|NCT00952185|adult acute myeloid leukemia with t(8;21)(q22;q22)
1251180|NCT00952185|atypical chronic myeloid leukemia, BCR-ABL negative
1251181|NCT00952185|blastic phase chronic myelogenous leukemia
1251182|NCT00952185|chronic myelomonocytic leukemia
1251183|NCT00952185|chronic phase chronic myelogenous leukemia
1251184|NCT00952185|mast cell leukemia
1251185|NCT00952185|meningeal chronic myelogenous leukemia
1251186|NCT00952185|progressive hairy cell leukemia, initial treatment
1251187|NCT00952185|prolymphocytic leukemia
1251188|NCT00952185|recurrent adult acute lymphoblastic leukemia
1251189|NCT00952185|recurrent adult acute myeloid leukemia
1251190|NCT00952185|recurrent adult T-cell leukemia/lymphoma
1251191|NCT00952185|refractory chronic lymphocytic leukemia
1251192|NCT00952185|refractory hairy cell leukemia
1251193|NCT00952185|relapsing chronic myelogenous leukemia
1251194|NCT00952185|secondary acute myeloid leukemia
1251195|NCT00952185|stage 0 chronic lymphocytic leukemia
1251196|NCT00952185|stage I adult T-cell leukemia/lymphoma
1251197|NCT00952185|stage I chronic lymphocytic leukemia
1251198|NCT00952185|stage II adult T-cell leukemia/lymphoma
1251199|NCT00952185|stage II chronic lymphocytic leukemia
1251200|NCT00952185|stage III adult T-cell leukemia/lymphoma
1251201|NCT00952185|stage III chronic lymphocytic leukemia
1251202|NCT00952185|stage IV adult T-cell leukemia/lymphoma
1251203|NCT00952185|stage IV chronic lymphocytic leukemia
1251204|NCT00952185|T-cell large granular lymphocyte leukemia
1251205|NCT00952185|recurrent adult Hodgkin lymphoma
1251206|NCT00952185|stage I adult Hodgkin lymphoma
1251207|NCT00952185|stage II adult Hodgkin lymphoma
1251208|NCT00952185|stage III adult Hodgkin lymphoma
1251209|NCT00952185|stage IV adult Hodgkin lymphoma
1251210|NCT00952185|anaplastic large cell lymphoma
1251211|NCT00952185|angioimmunoblastic T-cell lymphoma
1251212|NCT00952185|cutaneous B-cell non-Hodgkin lymphoma
1251213|NCT00952185|recurrent cutaneous T-cell non-Hodgkin lymphoma
1251214|NCT00952185|stage I cutaneous T-cell non-Hodgkin lymphoma
1251215|NCT00952185|stage II cutaneous T-cell non-Hodgkin lymphoma
1251216|NCT00952185|stage III cutaneous T-cell non-Hodgkin lymphoma
1251217|NCT00952185|stage IV cutaneous T-cell non-Hodgkin lymphoma
1251218|NCT00952185|recurrent mycosis fungoides/Sezary syndrome
1251219|NCT00952185|stage I mycosis fungoides/Sezary syndrome
1251220|NCT00952185|stage II mycosis fungoides/Sezary syndrome
1251221|NCT00952185|stage III mycosis fungoides/Sezary syndrome
1251222|NCT00952185|stage IV mycosis fungoides/Sezary syndrome
1251223|NCT00952185|adult grade III lymphomatoid granulomatosis
1251224|NCT00952185|adult nasal type extranodal NK/T-cell lymphoma
1251225|NCT00952185|Waldenstrom macroglobulinemia
1251226|NCT00952185|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1251227|NCT00952185|nodal marginal zone B-cell lymphoma
1251228|NCT00952185|splenic marginal zone lymphoma
1251229|NCT00952185|contiguous stage II adult Burkitt lymphoma
1251230|NCT00952185|contiguous stage II adult diffuse large cell lymphoma
1251231|NCT00952185|contiguous stage II adult diffuse mixed cell lymphoma
1251232|NCT00952185|contiguous stage II adult diffuse small cleaved cell lymphoma
1251233|NCT00952185|contiguous stage II adult immunoblastic large cell lymphoma
1251234|NCT00952185|contiguous stage II adult lymphoblastic lymphoma
1251235|NCT00952185|contiguous stage II grade 1 follicular lymphoma
1251236|NCT00952185|contiguous stage II grade 2 follicular lymphoma
1251237|NCT00952185|contiguous stage II grade 3 follicular lymphoma
1251238|NCT00952185|contiguous stage II mantle cell lymphoma
1251239|NCT00952185|contiguous stage II marginal zone lymphoma
1251240|NCT00952185|contiguous stage II small lymphocytic lymphoma
1251241|NCT00952185|stage I adult Burkitt lymphoma
1251242|NCT00952185|stage I adult diffuse large cell lymphoma
1251243|NCT00952185|stage I adult diffuse mixed cell lymphoma
1251244|NCT00952185|stage I adult diffuse small cleaved cell lymphoma
1251245|NCT00952185|stage I adult immunoblastic large cell lymphoma
1251246|NCT00952185|stage I adult lymphoblastic lymphoma
1251247|NCT00952185|stage I grade 1 follicular lymphoma
1251248|NCT00952185|stage I grade 2 follicular lymphoma
1251249|NCT00952185|stage I grade 3 follicular lymphoma
1251250|NCT00952185|stage I mantle cell lymphoma
1251251|NCT00952185|stage I marginal zone lymphoma
1251252|NCT00952185|stage I small lymphocytic lymphoma
1251253|NCT00952185|noncontiguous stage II adult Burkitt lymphoma
1251254|NCT00952185|noncontiguous stage II adult diffuse large cell lymphoma
1251255|NCT00952185|noncontiguous stage II adult diffuse mixed cell lymphoma
1251256|NCT00952185|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1251257|NCT00952185|noncontiguous stage II adult immunoblastic large cell lymphoma
1251258|NCT00952185|noncontiguous stage II adult lymphoblastic lymphoma
1251259|NCT00952185|noncontiguous stage II grade 1 follicular lymphoma
1251260|NCT00952185|noncontiguous stage II grade 2 follicular lymphoma
1251261|NCT00952185|noncontiguous stage II grade 3 follicular lymphoma
1251262|NCT00952185|noncontiguous stage II mantle cell lymphoma
1251263|NCT00952185|noncontiguous stage II marginal zone lymphoma
1251264|NCT00952185|noncontiguous stage II small lymphocytic lymphoma
1251265|NCT00952185|stage III adult Burkitt lymphoma
1251266|NCT00952185|stage III adult diffuse large cell lymphoma
1251267|NCT00952185|stage III adult diffuse mixed cell lymphoma
1251268|NCT00952185|stage III adult diffuse small cleaved cell lymphoma
1251269|NCT00952185|stage III adult immunoblastic large cell lymphoma
1251270|NCT00952185|stage III adult lymphoblastic lymphoma
1251271|NCT00952185|stage III grade 1 follicular lymphoma
1251272|NCT00952185|stage III grade 2 follicular lymphoma
1251273|NCT00952185|stage III grade 3 follicular lymphoma
1251274|NCT00952185|stage III mantle cell lymphoma
1251275|NCT00952185|stage III marginal zone lymphoma
1251276|NCT00952185|stage III small lymphocytic lymphoma
1251277|NCT00952185|stage IV adult Burkitt lymphoma
1251278|NCT00952185|stage IV adult diffuse large cell lymphoma
1251279|NCT00952185|stage IV adult diffuse mixed cell lymphoma
1251280|NCT00952185|stage IV adult diffuse small cleaved cell lymphoma
1251281|NCT00952185|stage IV adult immunoblastic large cell lymphoma
1251282|NCT00952185|stage IV adult lymphoblastic lymphoma
1251283|NCT00952185|stage IV grade 1 follicular lymphoma
1251284|NCT00952185|stage IV grade 2 follicular lymphoma
1251285|NCT00952185|stage IV grade 3 follicular lymphoma
1251286|NCT00952185|stage IV mantle cell lymphoma
1251287|NCT00952185|stage IV marginal zone lymphoma
1251288|NCT00952185|stage IV small lymphocytic lymphoma
1251289|NCT00952185|recurrent adult Burkitt lymphoma
1251290|NCT00952185|recurrent adult diffuse large cell lymphoma
1251291|NCT00952185|recurrent adult diffuse mixed cell lymphoma
1251292|NCT00952185|recurrent adult diffuse small cleaved cell lymphoma
1251293|NCT00952185|recurrent adult grade III lymphomatoid granulomatosis
1251294|NCT00952185|recurrent adult immunoblastic large cell lymphoma
1251295|NCT00952185|recurrent adult lymphoblastic lymphoma
1251296|NCT00952185|recurrent grade 1 follicular lymphoma
1251297|NCT00952185|recurrent grade 2 follicular lymphoma
1251298|NCT00952185|recurrent grade 3 follicular lymphoma
1251299|NCT00952185|recurrent mantle cell lymphoma
1251300|NCT00952185|recurrent marginal zone lymphoma
1251301|NCT00952185|recurrent small lymphocytic lymphoma
1251302|NCT00952185|intraocular lymphoma
1251303|NCT00952185|primary central nervous system non-Hodgkin lymphoma
1251304|NCT00952185|primary central nervous system Hodgkin lymphoma
1251305|NCT00952185|post-transplant lymphoproliferative disorder
1251306|NCT00952185|chronic eosinophilic leukemia
1251307|NCT00952185|chronic neutrophilic leukemia
1251308|NCT00952185|primary myelofibrosis
1251309|NCT00952185|essential thrombocythemia
1251310|NCT00952185|polycythemia vera
1251311|NCT00952185|extramedullary plasmacytoma
1251312|NCT00952185|isolated plasmacytoma of bone
1251313|NCT00952185|stage I multiple myeloma
1251314|NCT00952185|stage II multiple myeloma
1251315|NCT00952185|stage III multiple myeloma
1251316|NCT00952185|primary systemic amyloidosis
1251317|NCT00952185|refractory multiple myeloma
1251318|NCT00952185|de novo myelodysplastic syndromes
1251319|NCT00952185|previously treated myelodysplastic syndromes
1251320|NCT00952185|secondary myelodysplastic syndromes
1251321|NCT00952185|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1251322|NCT00952172|Stair stepping training
1251323|NCT00952172|OSAS
1251324|NCT00952172|cardiopulmonary fitness
1251325|NCT00952172|sleep disturbance
1251326|NCT00952172|Actigraphy
1251327|NCT00952159|tramadol
1251328|NCT00952159|CYP2D6
1251329|NCT00952159|O-demethyl-tramadol
1251330|NCT00952159|poor metabolizer
1251331|NCT00952159|genotyping
1251332|NCT00952159|phenotyping
1251333|NCT00952146|NOTES
1251334|NCT00952146|Transgastric
1251335|NCT00952146|Appendectomy
1251336|NCT00952146|Safety
1251337|NCT00952146|Feasibility
1251338|NCT00952133|PONV
1251339|NCT00952133|Outpatient surgery
1251340|NCT00952133|Laparoscopic abdominal surgery
1251341|NCT00952133|Laparoscopic gynecologic surgery
1251342|NCT00952120|Wound healing
1251343|NCT00952120|Negative pressure wound therapy
1251344|NCT00952120|Skin graft
1251345|NCT00952107|breast cancer
1251346|NCT00952107|breast reconstructive surgery
1251347|NCT00952107|flap assessment
1251348|NCT00952094|Healthy volunteer
1251349|NCT00952081|Hypertension
1251350|NCT00952081|Neurosurgery
1251351|NCT00952081|bloodpressure control
1251352|NCT00952081|brain tumor resection
1251353|NCT00952081|epilepsy focus resection
1251354|NCT00952068|Back Pain
1251355|NCT00952055|neopterin
1251356|NCT00952055|macrophage
1251357|NCT00952055|inflammation
1251358|NCT00952042|Tendinopathy, Achilles, Eccentric training, Heavy slow resistance training
1251359|NCT00952029|stage IV colon cancer
1251360|NCT00952029|stage IV rectal cancer
1251361|NCT00952016|colorectal cancer
1251362|NCT00952016|MSH2
1251363|NCT00952016|metastatic
1251364|NCT00952003|Avastin
1251365|NCT00952003|Campto
1251366|NCT00952003|Oxaliplatin
1251367|NCT00952003|Taxotere
1251368|NCT00951977|End Stage Renal Disease (ESRD)
1251369|NCT00951977|Transplantation
1251370|NCT00951977|Living Kidney Donation
1251371|NCT00951977|Kidney Transplant
1251372|NCT00951938|Trinity Evolution
1251373|NCT00951938|Anterior Cervical Discectomy and Fusion
1251374|NCT00951938|Allograft
1251375|NCT00951925|Any patient undergoing diagnostic bone marrow biopsies
1251376|NCT00951925|Any patient undergoing bone marrow harvesting for autologous bone marrow transplantation.
1251377|NCT00951912|genistein
1251378|NCT00951912|daidzein
1251379|NCT00951912|impaired glucose regulation
1251380|NCT00951912|glucose metabolism
1251381|NCT00951912|lipids metabolism
1251382|NCT00951912|inflammation
1251383|NCT00951912|women
1251384|NCT00951899|Incretins
1251385|NCT00951899|colesevelam
1251386|NCT00951899|hepatobiliary circulation
1251387|NCT00951886|Ataxia Teleangiectasia
1251388|NCT00951886|Spirometry
1251389|NCT00951886|Respiratory rare diseases
1251390|NCT00951860|Fullterm Birth
1251391|NCT00951860|Neonate
1251392|NCT00951860|Prematurity
1251393|NCT00951860|Neurodevelopment
1251394|NCT00951860|Autonomic Nervous System activity
1251395|NCT00951847|Oxcarbazepine oral suspension fed study
1251396|NCT00951834|Alzheimer´s Disease
1251397|NCT00951834|Epigallocatechin-Gallate
1251398|NCT00951834|Neuroprotection
1251399|NCT00951834|ADAS-COG
1251400|NCT00951834|early stage of Alzheimer's Disease
1251401|NCT00951821|Suicidal Ideation
1251402|NCT00951821|Suicide Attempts
1251403|NCT00951808|Anemia, Sickle Cell
1251404|NCT00951808|Acute Chest Syndrome
1251405|NCT00951808|Secretory phospholipase A2(sPLA2)
1251406|NCT00951795|HIV
1251407|NCT00951795|AIDS
1251408|NCT00951795|CD4
1251409|NCT00951782|COPD
1251410|NCT00951756|Dietary fat
1251411|NCT00951756|Microbiome composition
1251412|NCT00951756|Controlled feeding experiment
1251413|NCT00951743|AIDS
1251414|NCT00951743|HIV
1251415|NCT00951743|mDAPTA
1251416|NCT00951730|Down Syndrome
1251417|NCT00951730|Adult
1251418|NCT00951730|Children
1251419|NCT00951730|Sleep apnea
1251420|NCT00951730|Sleep hypopnea
1251421|NCT00951730|Polysomnography
1251422|NCT00951717|Postpartum Depressive Symptoms
1251423|NCT00951717|Physical Symptoms
1251424|NCT00951717|Emotional Symptoms
1251425|NCT00951717|Infant Colic
1251426|NCT00951717|Social Support
1251427|NCT00951717|Breastfeeding
1251428|NCT00951704|Open-chest
1251429|NCT00951704|CPR
1251430|NCT00951704|Tissue Perfusion
1251431|NCT00951704|invasive arterial pressure
1251432|NCT00951704|exhaled carbon dioxide
1251433|NCT00951704|Quality of life
1251434|NCT00951704|Quality of chest compressions
1251435|NCT00951704|Epidemiology of sudden cardiac arrest(OHCA)
1251436|NCT00951691|Elderly
1251437|NCT00951691|Acute Medical Rehabilitation
1251438|NCT00951678|ultrasound
1251439|NCT00951678|femoral vein
1251440|NCT00951678|internal jugular vein
1251441|NCT00951665|Trastuzumab DM1 (T-DM1)
1251442|NCT00951665|Trastuzumab emtansine
1251443|NCT00951665|Armed Herceptin
1251444|NCT00951665|HER2
1251445|NCT00951665|HER2+
1251446|NCT00951665|HER2 Positive Breast Cancer
1251447|NCT00951652|CBT
1251448|NCT00951652|GAD
1251449|NCT00951652|Interpersonal Therapy
1251450|NCT00951652|Emotion-Focused Therapy
1251451|NCT00951639|Cassia
1251452|NCT00951639|Cinnamon
1251453|NCT00951639|Blood Glucose
1251454|NCT00951639|Endurance exercise
1251455|NCT00951639|Acute exercise
1251456|NCT00951639|Overweight
1251457|NCT00951639|Obesity
1251458|NCT00951639|Women
1251459|NCT00951626|psychosocial effects of cancer and its treatment
1251460|NCT00951626|therapy-related toxicity
1251461|NCT00951626|stage III adult Burkitt lymphoma
1251462|NCT00951626|stage III adult diffuse large cell lymphoma
1251463|NCT00951626|stage III adult diffuse mixed cell lymphoma
1251464|NCT00951626|stage III adult diffuse small cleaved cell lymphoma
1251465|NCT00951626|stage III adult Hodgkin lymphoma
1251466|NCT00951626|stage III adult immunoblastic large cell lymphoma
1251467|NCT00951626|stage III adult lymphoblastic lymphoma
1251468|NCT00951626|stage III grade 1 follicular lymphoma
1251469|NCT00951626|stage III grade 2 follicular lymphoma
1251470|NCT00951626|stage III grade 3 follicular lymphoma
1251471|NCT00951626|stage III mantle cell lymphoma
1251472|NCT00951626|stage III marginal zone lymphoma
1251473|NCT00951626|stage III small lymphocytic lymphoma
1251474|NCT00951626|stage IV adult Burkitt lymphoma
1251475|NCT00951626|stage IV adult diffuse large cell lymphoma
1251476|NCT00951626|stage IV adult diffuse mixed cell lymphoma
1251477|NCT00951626|stage IV adult diffuse small cleaved cell lymphoma
1251478|NCT00951626|stage IV adult Hodgkin lymphoma
1251479|NCT00951626|stage IV adult immunoblastic large cell lymphoma
1251480|NCT00951626|stage IV adult lymphoblastic lymphoma
1251481|NCT00951626|stage IV grade 1 follicular lymphoma
1251482|NCT00951626|stage IV grade 2 follicular lymphoma
1251483|NCT00951626|stage IV grade 3 follicular lymphoma
1251484|NCT00951626|stage IV mantle cell lymphoma
1251485|NCT00951626|stage IV marginal zone lymphoma
1251486|NCT00951626|stage IV small lymphocytic lymphoma
1251487|NCT00951626|recurrent adult Burkitt lymphoma
1251488|NCT00951626|recurrent adult diffuse large cell lymphoma
1251489|NCT00951626|recurrent adult diffuse mixed cell lymphoma
1251490|NCT00951626|recurrent adult diffuse small cleaved cell lymphoma
1251491|NCT00951626|recurrent adult Hodgkin lymphoma
1251492|NCT00951626|recurrent adult immunoblastic large cell lymphoma
1251493|NCT00951626|recurrent adult lymphoblastic lymphoma
1251494|NCT00951626|recurrent cutaneous T-cell non-Hodgkin lymphoma
1251495|NCT00951626|recurrent grade 1 follicular lymphoma
1251496|NCT00951626|recurrent grade 2 follicular lymphoma
1251497|NCT00951626|recurrent grade 3 follicular lymphoma
1251498|NCT00951626|recurrent mantle cell lymphoma
1251499|NCT00951626|recurrent marginal zone lymphoma
1251500|NCT00951626|recurrent small lymphocytic lymphoma
1251501|NCT00951626|recurrent mycosis fungoides/Sezary syndrome
1251502|NCT00951626|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1251503|NCT00951626|nodal marginal zone B-cell lymphoma
1251504|NCT00951626|splenic marginal zone lymphoma
1251505|NCT00951626|noncontiguous stage II adult Burkitt lymphoma
1251506|NCT00951626|noncontiguous stage II adult diffuse large cell lymphoma
1251507|NCT00951626|noncontiguous stage II adult diffuse mixed cell lymphoma
1251508|NCT00951626|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1251509|NCT00951626|noncontiguous stage II adult immunoblastic large cell lymphoma
1251510|NCT00951626|noncontiguous stage II adult lymphoblastic lymphoma
1251511|NCT00951626|noncontiguous stage II grade 1 follicular lymphoma
1251512|NCT00951626|noncontiguous stage II grade 2 follicular lymphoma
1251513|NCT00951626|noncontiguous stage II grade 3 follicular lymphoma
1251514|NCT00951626|noncontiguous stage II mantle cell lymphoma
1251515|NCT00951626|noncontiguous stage II marginal zone lymphoma
1251516|NCT00951626|noncontiguous stage II small lymphocytic lymphoma
1251517|NCT00951626|accelerated phase chronic myelogenous leukemia
1251518|NCT00951626|adult acute lymphoblastic leukemia in remission
1251519|NCT00951626|adult acute myeloid leukemia in remission
1251520|NCT00951626|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1251521|NCT00951626|adult acute myeloid leukemia with inv(16)(p13;q22)
1251522|NCT00951626|adult acute myeloid leukemia with t(15;17)(q22;q12)
1251523|NCT00951626|adult acute myeloid leukemia with t(16;16)(p13;q22)
1251524|NCT00951626|adult acute myeloid leukemia with t(8;21)(q22;q22)
1251525|NCT00951626|atypical chronic myeloid leukemia, BCR-ABL negative
1251526|NCT00951626|blastic phase chronic myelogenous leukemia
1251527|NCT00951626|recurrent adult acute lymphoblastic leukemia
1251528|NCT00951626|recurrent adult acute myeloid leukemia
1251529|NCT00951626|refractory chronic lymphocytic leukemia
1251530|NCT00951626|refractory hairy cell leukemia
1251531|NCT00951626|relapsing chronic myelogenous leukemia
1251532|NCT00951626|secondary acute myeloid leukemia
1251533|NCT00951626|stage III chronic lymphocytic leukemia
1251534|NCT00951626|stage IV chronic lymphocytic leukemia
1251535|NCT00951626|chronic eosinophilic leukemia
1251536|NCT00951626|primary myelofibrosis
1251537|NCT00951626|chronic neutrophilic leukemia
1251538|NCT00951626|de novo myelodysplastic syndromes
1251539|NCT00951626|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1251540|NCT00951626|previously treated myelodysplastic syndromes
1251541|NCT00951626|secondary myelodysplastic syndromes
1251542|NCT00951626|refractory multiple myeloma
1251543|NCT00951613|small cell lung cancer
1251544|NCT00951613|carcinoma, lung
1251545|NCT00951613|Sensitive-relapsed or refractory-relapsed small cell lung cancer
1251546|NCT00951600|Oxcarbazepine oral suspension fasting study
1251547|NCT00951587|Colonic Diseases
1251548|NCT00951574|thromboembolism
1251549|NCT00951574|cancer
1251550|NCT00951574|chemotherapy
1251551|NCT00951574|low-molecular-weight-heparin
1251552|NCT00951574|nadroparin
1251553|NCT00951561|Dysmenorrhea
1251554|NCT00951548|Probiotics
1251555|NCT00951548|VSL#3
1251556|NCT00951548|Double-blind
1251557|NCT00951548|Placebo controlled
1251558|NCT00951535|stage I prostate cancer
1251559|NCT00951535|stage IIB prostate cancer
1251560|NCT00951535|stage IIA prostate cancer
1251561|NCT00951535|stage III prostate cancer
1251562|NCT00951522|Cystic Fibrosis
1251563|NCT00951522|CF
1251564|NCT00951522|Mucociliary Clearance
1251565|NCT00951522|Epithelial Sodium Channel Inhibitor
1251566|NCT00951522|ENaC Inhibitor
1251567|NCT00951522|Airway Hydration
1251568|NCT00951522|Amiloride
1251569|NCT00951509|Electric power wheelchair driving
1251570|NCT00951509|rehabilitation
1251571|NCT00951509|driving assessments
1251572|NCT00951483|Cardiovascular Biomarkers
1251573|NCT00951483|Depression
1251574|NCT00951483|Quetiapine
1251575|NCT00951470|Head and neck lymphedema
1251576|NCT00951470|Complete Decongestive Therapy
1251577|NCT00951470|CDT
1251578|NCT00951470|Oral cavity cancer
1251579|NCT00951470|Oropharyngeal cancer
1251580|NCT00951457|CLL
1251581|NCT00951457|pretreated
1251582|NCT00951457|immune therapy
1251583|NCT00951457|dose escalation
1251584|NCT00951457|maintenance therapy
1251585|NCT00951457|Bendamustine
1251586|NCT00951457|Alemtuzumab
1251587|NCT00951444|adenosquamous cell lung cancer
1251588|NCT00951444|squamous cell lung cancer
1251589|NCT00951444|recurrent non-small cell lung cancer
1251590|NCT00951444|stage IIIB non-small cell lung cancer
1251591|NCT00951444|stage IV non-small cell lung cancer
1251592|NCT00951431|Functional dyspepsia
1251593|NCT00951431|PPI
1251594|NCT00951431|postprandial fullness
1251595|NCT00951431|delayed gastric emptying
1251596|NCT00951418|clozapine
1251597|NCT00951418|schizophrenia
1251598|NCT00951418|cognition
1251599|NCT00951418|t-wave morphology
1251600|NCT00951392|Insulin sensitivity
1251601|NCT00951392|aging
1251602|NCT00951392|lipid metabolism
1251603|NCT00951392|hyperinsulinemic clamp
1251604|NCT00951392|gene expression
1251605|NCT00951392|sirtuins
1251611|NCT00951353|Transplantation
1251612|NCT00951353|Kidney Failure
1251613|NCT00951353|End Stage Renal Disease
1251614|NCT00951353|Pediatric
1251615|NCT00951340|CBT
1251616|NCT00951340|Emotional-Focused Therapy
1251617|NCT00951340|Interpersonal Therapy
1251618|NCT00951327|Primary sclerosing cholangitis
1251619|NCT00951314|Genetic Polymorphisms
1251620|NCT00951314|Metabotropic Glutamate Receptors
1251621|NCT00951314|Positron Emission Tomograhy (PET)
1251622|NCT00951314|Cocaine Dependence
1251623|NCT00951314|Cue-Induced Craving
1251624|NCT00951314|Drug Abuse
1251625|NCT00951288|AMD
1251626|NCT00951288|Retinal Function
1251627|NCT00951288|Neuroprotection
1251628|NCT00951262|life review
1251629|NCT00951262|quality of life
1251630|NCT00951262|advanced cancer patients
1251631|NCT00951249|MSM
1251632|NCT00951249|HIV infections
1251633|NCT00951249|HIV Seronegativity
1251634|NCT00951236|Trigger Finger
1251635|NCT00951236|Trigger Thumb
1251636|NCT00951210|Peripheral Artery Disease
1251637|NCT00951210|Peripheral Vascular Disease
1251638|NCT00951210|Critical limb ischemia
1251639|NCT00951210|PAD
1251640|NCT00951210|CLI
1251641|NCT00951197|dementia
1251642|NCT00951197|Alzheimer's Disease
1251643|NCT00951197|diagnostic
1251644|NCT00951197|biomarkers
1251645|NCT00951197|neuroimaging
1251646|NCT00951197|PET
1251647|NCT00951197|MRI
1251648|NCT00951197|mild cognitive impairment
1251649|NCT00951184|depression
1251650|NCT00951184|unspecified adult solid tumor, protocol specific
1251651|NCT00951158|Conjugated Linoleic Acid
1251652|NCT00951158|Clarinol
1251653|NCT00951158|S14 Expression
1251654|NCT00951132|Inflammation
1251655|NCT00951132|Atherosclerosis
1251656|NCT00951132|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1251657|NCT00951119|type 2 diabetes
1251658|NCT00951119|hypertension
1251659|NCT00951119|treatment
1251660|NCT00951119|non-medical
1251661|NCT00951106|Peru
1251662|NCT00951106|Sulfadoxine-pyrimethamine
1251663|NCT00951106|Drug resistance
1251664|NCT00951093|GERD
1251665|NCT00951093|Gastric bypass
1251666|NCT00951080|ulcer
1251667|NCT00951080|venous
1251668|NCT00951080|diabetic
1251669|NCT00951080|wounds and injuries
1251670|NCT00951067|Lymphedema
1251671|NCT00951067|Breast Cancer
1251672|NCT00951067|Upper Extremity
1251673|NCT00951067|Arm
1251674|NCT00951054|breast cancer
1251675|NCT00951054|triple negative
1251676|NCT00951054|ER-negative
1251677|NCT00951054|PR-negative
1251678|NCT00951054|HER2-negative
1251679|NCT00951054|ER-, PR-, HER2- (Triple Negative) breast cancer
1251680|NCT00951041|influenza infection
1251681|NCT00951041|GSK Bio's influenza vaccine GSK2340272A
1251682|NCT00951028|Adherence
1251683|NCT00951015|GSK1349572
1251684|NCT00951015|emtricitabine
1251685|NCT00951015|tenofovir
1251686|NCT00951015|efavirenz
1251687|NCT00951015|abacavir
1251688|NCT00951015|antiretroviral therapy naive
1251689|NCT00951015|dose selection
1251690|NCT00951015|HIV-1 Infection
1251691|NCT00951015|integrase inhibitor
1251692|NCT00951015|HIV infection
1251693|NCT00951015|once daily
1251694|NCT00951015|lamivudine
1251695|NCT00951002|anal fistula
1251696|NCT00951002|acellular dermal matrix
1251697|NCT00951002|treatment
1251698|NCT00951002|postoperative complications
1251699|NCT00951002|recurrence
1251700|NCT00950989|Autoimmune Diseases
1251701|NCT00950989|Musculoskeletal Diseases
1251702|NCT00950989|Joint Diseases
1251703|NCT00950989|Arthritis
1251704|NCT00950989|Connective Tissue Diseases
1251705|NCT00950989|Arthritis, Rheumatoid
1251706|NCT00950989|Rheumatic Diseases
1251707|NCT00950963|Diabetes, Nurse phone intervention, lipid control
1251708|NCT00950950|Amgen
1251709|NCT00950950|Postmenopausal
1251710|NCT00950950|Bone Density
1251711|NCT00950924|Hyperopia
1251712|NCT00950924|Refractive Error
1251713|NCT00950924|Ocular Biometrics
1251714|NCT00950924|Axial Length
1251715|NCT00950924|Contact Lenses
1251716|NCT00950924|Bifocal Contact Lenses
1251717|NCT00950911|Bone metastases
1251718|NCT00950911|Hormone-refractory prostate cancer
1251719|NCT00950911|Multiple myeloma
1251720|NCT00950911|Denosumab
1251721|NCT00950911|Breast cancer
1251722|NCT00950911|20050103
1251723|NCT00950911|20050136
1251724|NCT00950911|20050244
1251725|NCT00950911|Advanced cancer
1251726|NCT00950911|Tumor
1251727|NCT00950911|Prostate cancer
1251728|NCT00950911|Zoledronic acid
1251729|NCT00950898|coffee
1251730|NCT00950898|caffeine
1251731|NCT00950898|glucose metabolism
1251732|NCT00950898|insulin sensitivity
1251733|NCT00950898|diabetes
1251734|NCT00950885|sleep
1251735|NCT00950885|alertness
1251736|NCT00950885|performance
1251737|NCT00950885|vigilance
1251738|NCT00950885|circadian
1251739|NCT00950859|treatment experienced
1251740|NCT00950859|HIV Infection
1251741|NCT00950859|raltegravir resistance
1251742|NCT00950859|GSK1349572
1251743|NCT00950859|optimized background regimen
1251744|NCT00950859|integrase inhibitor
1251745|NCT00950846|Congenital Pediatric Disorders
1251746|NCT00950846|Umbilical Cord Blood Transplant
1251747|NCT00950846|Congenital Abnormalities
1251748|NCT00950846|Cord Blood Stem Cell Transplantation
1251749|NCT00950846|Busulfan
1251750|NCT00950846|Cytoxan
1251751|NCT00950846|Cyclophosphamide
1251752|NCT00950846|Fludarabine
1251753|NCT00950833|Catch-up vaccination
1251754|NCT00950833|Pneumococcal vaccine
1251755|NCT00950833|Immune memory
1251756|NCT00950833|Nasopharyngeal carriage
1251757|NCT00950833|Immunogenicity
1251758|NCT00950833|Pneumococcal disease
1251759|NCT00950833|Safety
1251760|NCT00950820|Open-label
1251761|NCT00950820|Phase-II-Study
1251762|NCT00950820|Randomized
1251763|NCT00950820|Metastatic
1251764|NCT00950820|Colorectal
1251765|NCT00950820|Cancer
1251766|NCT00950820|Panitumumab
1251767|NCT00950820|Vectibix®
1251768|NCT00950820|second-line-treatment
1251769|NCT00950820|KRAS
1251770|NCT00950807|Dose ranging
1251771|NCT00950807|Chronic Bronchitis
1251772|NCT00950807|Long-acting muscarinic antagonist
1251773|NCT00950807|cross-over
1251774|NCT00950807|COPD
1251775|NCT00950807|Emphysema
1251776|NCT00950807|Chronic Obstructive Pulmonary Disease (COPD)
1251777|NCT00950807|anticholinergic
1251778|NCT00950794|Long acting beta2-agonist
1251779|NCT00950781|Menopause
1251780|NCT00950781|Cortisol
1251781|NCT00950781|ACTH
1251782|NCT00950768|Myeloma
1251783|NCT00950768|Melphalan
1251784|NCT00950768|Autologous transplantation
1251785|NCT00950729|car driving simulator
1251786|NCT00950729|orthopedic leg immobilisation
1251787|NCT00950729|braking time
1251788|NCT00950729|braking force
1251789|NCT00950716|type II diabetes
1251790|NCT00950716|peer support
1251791|NCT00950716|empowerment
1251792|NCT00950703|Assessing the perceptions of Canadian Primary care physicians towards global Cardiovascular risk assessment.
1251793|NCT00950690|observational safety study
1251794|NCT00950677|Diabetes
1251795|NCT00950677|pramlintide
1251796|NCT00950677|Symlin
1251797|NCT00950677|exenatide
1251798|NCT00950677|byetta
1251799|NCT00950677|glucagon
1251800|NCT00950677|gastric emptying
1251801|NCT00950664|cervical dystonia
1251802|NCT00950664|botulinum toxin
1251803|NCT00950638|AMD
1251804|NCT00950625|intraperitoneal analgesia
1251805|NCT00950625|laparoscopic cholecystectomy
1251806|NCT00950625|lignocaine
1251807|NCT00950625|bupevacaine
1251808|NCT00950612|Tuberculosis vaccine
1251809|NCT00950586|Drug interaction
1251810|NCT00950586|Saftey
1251811|NCT00950586|Pharmacokinetics
1251812|NCT00950586|Cognition
1251813|NCT00950573|cardiovascular disease
1251814|NCT00950573|endstage renal disease
1251815|NCT00950547|Blood Transfusion
1251816|NCT00950547|Cell Saver
1251817|NCT00950547|Cardiac Surgery
1251818|NCT00950547|Evaluate the efficacy of cell salvage CardioPAT routinely used in cardiac surgery in reducing blood transfusions.
1251819|NCT00950521|Stroke
1251820|NCT00950521|Stem Cell
1251821|NCT00950521|Cell Therapy
1251822|NCT00950521|CD34 Stem cell
1251823|NCT00950521|Peripheral blood Stem cell
1251824|NCT00950495|Parallel design
1251825|NCT00950495|Oral appliance
1251826|NCT00950495|Mandibular advancement device
1251827|NCT00950495|Continuous positive airway pressure
1251828|NCT00950495|Placebo
1251829|NCT00950495|Therapy
1251830|NCT00950495|Side-effects
1251831|NCT00950495|Compliance
1251832|NCT00950482|Menopause
1251833|NCT00950482|Acupuncture
1251834|NCT00950482|Hotflash
1251835|NCT00950469|high sensitive troponin T; cardiac necrosis; early detection; myoglobin; h-FABP
1251836|NCT00950469|early identification and risk stratification of patients with suspicious acute coronary syndrome
1251837|NCT00950443|Upper airway obstruction
1251838|NCT00950443|child
1251839|NCT00950443|acoustic reflection method
1251840|NCT00950443|endoscopy
1251841|NCT00950443|work of breathing
1251842|NCT00950443|sleep study
1251843|NCT00950443|CT scan
1251844|NCT00950430|Imaging
1251845|NCT00950430|PET
1251846|NCT00950430|PiB
1251847|NCT00950430|FDG
1251848|NCT00950430|MCI
1251849|NCT00950430|Dementia
1251850|NCT00950430|Alzheimer's Disease
1251851|NCT00950430|Brain Amyloid
1251852|NCT00950417|nimotuzumab esophageal chemo-radiotherapy
1251853|NCT00950404|Bioavailability Pharmacokinetic Formulation
1251854|NCT00950391|peripheral nerve injury
1251855|NCT00950391|peripheral nerve surgery
1251856|NCT00950391|nerve repair
1251857|NCT00950391|nerve graft
1251858|NCT00950378|edema
1251859|NCT00950378|blood supply
1251860|NCT00950378|lower legs
1251861|NCT00950378|venous stasis
1251862|NCT00950365|recurrent non-small cell lung cancer
1251863|NCT00950365|stage IIIB non-small cell lung cancer
1251864|NCT00950365|stage IV non-small cell lung cancer
1251865|NCT00950365|progressive or recurrent stage III or stage IV non-small cell lung cancer
1251866|NCT00950352|methamphetamine
1251867|NCT00950352|Citicoline
1251868|NCT00950352|CDP-Choline
1251869|NCT00950352|Neuroimaging
1251870|NCT00950352|MRI
1251871|NCT00950352|Brain
1251872|NCT00950352|MRS
1251873|NCT00950352|DTI
1251874|NCT00950339|GI bleeding
1251875|NCT00950339|clopidogrel
1251876|NCT00950339|aspirin
1251877|NCT00950339|prevention
1251878|NCT00950339|angiography
1251879|NCT00950326|osteoarthritis
1251880|NCT00950326|hydrotherapy
1251881|NCT00950326|affusion
1251882|NCT00950326|conventional physiotherapy
1251883|NCT00950326|comparison
1251884|NCT00950313|Diabetes
1251885|NCT00950313|Screening
1251886|NCT00950313|Risk
1251887|NCT00950313|Self assessment
1251888|NCT00950287|apnea-bradycardias
1251889|NCT00950287|preterm infants
1251890|NCT00950274|Cell therapy
1251891|NCT00950274|Bone marrow
1251892|NCT00950274|CD133
1251893|NCT00950274|Bypass surgery
1251894|NCT00950274|Stem cells
1251895|NCT00950274|Myocardial infarction
1251896|NCT00950274|Myocardial ischemia
1251897|NCT00950261|Cervical neoplasms
1251898|NCT00950261|Cisplatin
1251899|NCT00950261|Concurrent Chemoradiation
1251907|NCT00950235|obese
1251908|NCT00950235|pregnant
1251909|NCT00950235|large for gestational age
1251910|NCT00950235|large for gestational age baby
1251911|NCT00950222|Intensive care unit
1251912|NCT00950222|Ventilator associated pneumonia
1251913|NCT00950222|Gram negative bacilli infection
1251914|NCT00950222|Empirical antibiotic therapy
1251915|NCT00950222|Pharmacokinetic / pharmacodynamic
1251916|NCT00950222|Imipenem
1251917|NCT00950222|Amikacin
1251918|NCT00950222|Gram negative bacilli
1251919|NCT00950209|type 2 diabetic patients in the fed state
1251920|NCT00950183|cryotherapy
1251921|NCT00950183|postoperative pain
1251922|NCT00950183|Iceman
1251923|NCT00950183|primary first metatarsal osteotomy (PMO)
1251924|NCT00950183|lateral ankle ligament reconstruction (LAR)
1251925|NCT00950170|ReFacto AF
1251926|NCT00950170|factor VIII
1251927|NCT00950170|inhibitors
1251928|NCT00950170|antibodies
1251929|NCT00950144|pain
1251930|NCT00950144|depression
1251931|NCT00950144|fatigue
1251932|NCT00950144|stage III colon cancer
1251933|NCT00950144|stage IV colon cancer
1251934|NCT00950144|recurrent colon cancer
1251935|NCT00950144|stage III rectal cancer
1251936|NCT00950144|stage IV rectal cancer
1251937|NCT00950144|recurrent rectal cancer
1251938|NCT00950144|stage III pancreatic cancer
1251939|NCT00950144|stage IV pancreatic cancer
1251940|NCT00950144|recurrent pancreatic cancer
1251941|NCT00950144|adult primary hepatocellular carcinoma
1251942|NCT00950144|advanced adult primary liver cancer
1251943|NCT00950144|localized unresectable adult primary liver cancer
1251944|NCT00950144|recurrent adult primary liver cancer
1251945|NCT00950118|Congenital Diaphragmatic Hernia (CDH)
1251946|NCT00950118|Genes
1251947|NCT00950118|Genetic
1251948|NCT00950118|chromosome
1251949|NCT00950118|chromosome microarray
1251950|NCT00950118|microarray
1251951|NCT00950105|CPSI2364
1251952|NCT00950105|Semapimod
1251953|NCT00950105|Anti TNF alpha
1251954|NCT00950105|Crohn's Disease
1251955|NCT00950105|Safety
1251956|NCT00950105|Tolerability
1251957|NCT00950105|Pharmacokinetics
1251958|NCT00950092|AF
1251959|NCT00950092|atrial fibrillation
1251960|NCT00950092|ablation
1251961|NCT00950092|surgical ablation
1251962|NCT00950092|afib
1251963|NCT00950092|coagulation
1251964|NCT00950092|RF
1251965|NCT00950092|epicardial
1251966|NCT00950092|Arrhythmias
1251967|NCT00950079|sodium bicarbonate
1251968|NCT00950079|diabetes mellitus
1251969|NCT00950079|coronary angiography or intervention
1251970|NCT00950040|At-risk drinking
1251971|NCT00950040|Type 2 diabetes
1251972|NCT00950040|Treatment adherence
1251973|NCT00950040|At-risk drinking among Type 2 diabetic patients
1251974|NCT00950014|Numeracy
1251975|NCT00950001|Brain tumors
1251976|NCT00950001|Metastatic brain disease
1251977|NCT00950001|Post-surgical
1251978|NCT00950001|Stereotactic radiosurgery
1251979|NCT00950001|SRS
1251980|NCT00950001|Whole brain radiotherapy
1251981|NCT00950001|MRI
1251982|NCT00950001|Magnetic Resonance Imaging
1251983|NCT00950001|Outpatient radiation procedure
1251984|NCT00949988|Chronic Lymphocytic Leukemia
1251985|NCT00949988|CLL
1251986|NCT00949988|Dasatinib
1251987|NCT00949988|Rituximab
1251988|NCT00949988|Relapsed
1251989|NCT00949988|Refractory
1251990|NCT00949975|Chronic
1251991|NCT00949975|Obstructive
1251992|NCT00949975|Pulmonary
1251993|NCT00949975|Lung
1251994|NCT00949975|Respiratory disease
1251995|NCT00949975|Efficacy
1251996|NCT00949975|Safety and tolerability
1251997|NCT00949975|Placebo-controlled
1251998|NCT00949975|Pharmacokinetics
1251999|NCT00949975|COPD
1252000|NCT00949962|stage I prostate cancer
1252001|NCT00949962|stage IIB prostate cancer
1252002|NCT00949962|stage IIA prostate cancer
1252003|NCT00949962|stage III prostate cancer
1252004|NCT00949936|Spine surgery
1252005|NCT00949923|Postmenopausal women
1252006|NCT00949923|Suspicious for breast ca
1252007|NCT00949897|Adult Acquired Flatfoot
1252008|NCT00949897|Biofoam Porous Metal Implant
1252009|NCT00949897|Allograft Bone Wedge
1252010|NCT00949871|stage I breast cancer
1252011|NCT00949871|stage II breast cancer
1252012|NCT00949871|stage IIIA breast cancer
1252013|NCT00949871|stage IIIB breast cancer
1252014|NCT00949871|stage IIIC breast cancer
1252015|NCT00949871|stage IV breast cancer
1252016|NCT00949871|cancer survivor
1252017|NCT00949858|Sleep Disorders
1252018|NCT00949858|Obstructive Sleep Apnea
1252019|NCT00949858|Restless Leg Syndrome
1252020|NCT00949858|Insomnia
1252021|NCT00949858|Actigraphy
1252022|NCT00949845|Effect of Inflammatory challenge on depressed mood
1252023|NCT00949845|Effect of inflammatory challenge on social pain
1252024|NCT00949832|rickets
1252025|NCT00949832|calcium
1252026|NCT00949832|vitamin D
1252027|NCT00949832|nutrition
1252028|NCT00949832|child
1252029|NCT00949819|Prostate Cancer
1252030|NCT00949819|Low risk
1252031|NCT00949819|Gleason 6
1252032|NCT00949819|Active surveillance
1252033|NCT00949806|Botulinum toxin
1252034|NCT00949793|Pathology
1252035|NCT00949793|Microscopy, Confocal
1252036|NCT00949793|Microscopy, Fluorescence
1252037|NCT00949793|Intraoperative Procedures
1252038|NCT00949780|ABR
1252039|NCT00949780|Chloral Hydrate
1252040|NCT00949780|Sedation
1252041|NCT00949780|Children
1252042|NCT00949754|honeybee venom
1252043|NCT00949754|osteoarthritis
1252044|NCT00949754|pain
1252045|NCT00949754|knees
1252046|NCT00949728|Pterygium
1252047|NCT00949728|Autologous Transplantation
1252048|NCT00949728|Conjunctiva
1252049|NCT00949728|Fibrin Tissue Adhesive
1252050|NCT00949728|Recurrence
1252051|NCT00949715|Pacemaker
1252052|NCT00949715|Implantable Pulse Generator (IPG)
1252053|NCT00949715|AV Conduction Disturbance
1252054|NCT00949715|Selective Site Pacing
1252055|NCT00949689|adolescence
1252056|NCT00949689|insomnia
1252057|NCT00949689|depression
1252058|NCT00949689|sleep problems
1252059|NCT00949689|cognitive therapy
1252060|NCT00949663|Diabetes
1252061|NCT00949663|Blood Sugar
1252062|NCT00949663|Xenin-25
1252063|NCT00949663|GIP
1252064|NCT00949663|Insulin
1252065|NCT00949637|obesity prevention
1252066|NCT00949637|girl scouts
1252067|NCT00949637|physical activity
1252068|NCT00949637|family meals
1252069|NCT00949637|fruits and vegetables
1252070|NCT00949637|health promotion
1252071|NCT00949624|PDGFr Inhibition;
1252072|NCT00949624|VEGFr inhibition;
1252073|NCT00949624|targeted therapy
1252074|NCT00949611|Decision Aid
1252075|NCT00949611|Shared Decision Making
1252076|NCT00949611|Shared Medical Decision Making
1252077|NCT00949598|estrogen receptor-positive breast cancer
1252078|NCT00949598|stage IA breast cancer
1252079|NCT00949598|stage IB breast cancer
1252080|NCT00949598|stage II breast cancer
1252081|NCT00949598|stage IIIA breast cancer
1252082|NCT00949585|randomized, controlled feeding study;
1252083|NCT00949585|crossover design
1252084|NCT00949585|potassium intake
1252085|NCT00949572|mucosal immunity
1252086|NCT00949572|immunization
1252087|NCT00949572|sublingual
1252088|NCT00949520|patients
1252089|NCT00949520|functional evaluation
1252090|NCT00949520|known coronary artery lesion
1252091|NCT00949494|knee osteoarthritis, synvisc, hyaluronan, dGEMRIC,cartilage
1252092|NCT00949481|postpartum
1252093|NCT00949481|family planning
1252094|NCT00949481|job aid
1252095|NCT00949481|immunization
1252096|NCT00949481|pregnancy test
1252097|NCT00949468|Keratitis
1252098|NCT00949455|stage IV bladder cancer
1252099|NCT00949455|transitional cell carcinoma of the bladder
1252100|NCT00949429|postoperative pain
1252101|NCT00949429|cardiac surgery
1252102|NCT00949429|risk factors
1252103|NCT00949416|genetic
1252104|NCT00949403|Non-Alcoholic Fatty Liver disease
1252105|NCT00949390|Advanced Cancer
1252106|NCT00949390|Advanced Malignancy
1252107|NCT00949390|Complementary and Alternative Medicine
1252108|NCT00949390|CAM
1252109|NCT00949390|Investigational Cancer Therapeutics
1252110|NCT00949390|Phase I Clinical Trials
1252111|NCT00949377|Constipation
1252112|NCT00949377|opioid
1252113|NCT00949364|Myeloproliferative Neoplasms
1252114|NCT00949364|Pomalidomide
1252115|NCT00949364|Fibrotic Stage
1252116|NCT00949364|Patients with Myeloproliferative Neoplasms in Fibrotic Stage
1252117|NCT00949351|ACEI, ARB, DN, aliskiren, proteinuria
1252118|NCT00949338|stage I prostate cancer
1252119|NCT00949338|stage IIB prostate cancer
1252120|NCT00949338|stage IIA prostate cancer
1252121|NCT00949338|stage III prostate cancer
1252122|NCT00949338|stage IV prostate cancer
1252123|NCT00949338|recurrent prostate cancer
1252124|NCT00949325|osteosarcoma
1252125|NCT00949325|soft tissue sarcoma
1252126|NCT00949325|rhabdomyosarcoma
1252127|NCT00949325|leiomyosarcoma
1252128|NCT00949325|Ewing's sarcoma
1252129|NCT00949325|chondrosarcoma
1252130|NCT00949325|liposarcoma
1252131|NCT00949325|malignant fibrous histiocytoma
1252132|NCT00949325|malignant peripheral nerve sheath tumor
1252133|NCT00949325|pleiomorphic sarcoma
1252134|NCT00949325|spindle cell sarcoma
1252135|NCT00949325|synovial sarcoma
1252136|NCT00949325|cancer stem cell
1252137|NCT00949312|stage II colon cancer
1252138|NCT00949286|Diabetes Mellitus, Type 2
1252139|NCT00949273|cylindrical abdominoperineal resection
1252140|NCT00949273|rectal cancer
1252141|NCT00949273|acellular dermal matrix
1252142|NCT00949273|pelvic reconstruction
1252143|NCT00949273|circumferential resection margin
1252144|NCT00949273|overall survival
1252145|NCT00949260|PIH
1252146|NCT00949260|pregnancy induced hypertension
1252147|NCT00949260|pregnancy
1252148|NCT00949260|bioimpedance
1252149|NCT00949260|noninvasive monitoring
1252150|NCT00949260|Cardiac Output
1252151|NCT00949260|Blood Pressure
1252152|NCT00949247|stage I breast cancer
1252153|NCT00949247|stage II breast cancer
1252154|NCT00949247|stage IIIA breast cancer
1252155|NCT00949247|stage IIIB breast cancer
1252156|NCT00949247|stage IIIC breast cancer
1252157|NCT00949247|HER2-positive breast cancer
1252158|NCT00949234|post exposure prophylaxis
1252159|NCT00949234|biomedical prevention
1252160|NCT00949234|HIV seronegativity
1252161|NCT00949221|Type 1 diabetes
1252162|NCT00949221|Paediatric
1252163|NCT00949221|Real Time Continuous Glucose Monitoring
1252164|NCT00949221|Glycemic control
1252165|NCT00949221|Therapeutic education
1252166|NCT00949208|Healthy people
1252167|NCT00949195|COPD
1252168|NCT00949195|healthy patients
1252169|NCT00949195|PAP
1252170|NCT00949195|CPX
1252171|NCT00949195|SSE
1252172|NCT00949195|hsCRP
1252173|NCT00949195|FMD
1252174|NCT00949182|localized unresectable adult primary liver cancer
1252175|NCT00949182|adult primary hepatocellular carcinoma
1252176|NCT00949169|Atherosclerosis
1252177|NCT00949169|Carotid IMT
1252178|NCT00949169|Multidetector CT
1252179|NCT00949169|Type 2 diabetes
1252180|NCT00949156|Craniopharyngiomas
1252181|NCT00949156|Classification
1252182|NCT00949156|Membranous structure
1252183|NCT00949156|Pituitary stalk
1252184|NCT00949156|Obesity
1252185|NCT00949156|panhypopituitarism
1252186|NCT00949143|wheelchair user
1252187|NCT00949117|malnutrition
1252188|NCT00949117|weight changes
1252189|NCT00949117|childhood acute lymphoblastic leukemia in remission
1252190|NCT00949117|recurrent childhood acute lymphoblastic leukemia
1252191|NCT00949117|untreated childhood acute lymphoblastic leukemia
1252192|NCT00949117|childhood acute myeloid leukemia in remission
1252193|NCT00949117|recurrent childhood acute myeloid leukemia
1252194|NCT00949117|untreated childhood acute myeloid leukemia
1252195|NCT00949117|other myeloid malignancies
1252196|NCT00949117|stage I childhood Hodgkin lymphoma
1252197|NCT00949117|stage II childhood Hodgkin lymphoma
1252198|NCT00949117|stage III childhood Hodgkin lymphoma
1252199|NCT00949117|stage IV childhood Hodgkin lymphoma
1252200|NCT00949117|recurrent/refractory childhood Hodgkin lymphoma
1252201|NCT00949117|recurrent childhood anaplastic large cell lymphoma
1252202|NCT00949117|stage I childhood anaplastic large cell lymphoma
1252203|NCT00949117|stage II childhood anaplastic large cell lymphoma
1252204|NCT00949117|stage III childhood anaplastic large cell lymphoma
1252205|NCT00949117|stage IV childhood anaplastic large cell lymphoma
1252206|NCT00949117|recurrent childhood grade III lymphomatoid granulomatosis
1252207|NCT00949117|childhood diffuse large cell lymphoma
1252208|NCT00949117|childhood immunoblastic large cell lymphoma
1252209|NCT00949117|recurrent childhood large cell lymphoma
1252210|NCT00949117|stage I childhood large cell lymphoma
1252211|NCT00949117|stage II childhood large cell lymphoma
1252212|NCT00949117|stage III childhood large cell lymphoma
1252213|NCT00949117|stage IV childhood large cell lymphoma
1252214|NCT00949117|recurrent childhood lymphoblastic lymphoma
1252215|NCT00949117|stage I childhood lymphoblastic lymphoma
1252216|NCT00949117|stage II childhood lymphoblastic lymphoma
1252217|NCT00949117|stage III childhood lymphoblastic lymphoma
1252218|NCT00949117|stage IV childhood lymphoblastic lymphoma
1252219|NCT00949117|childhood nasal type extranodal NK/T-cell lymphoma
1252220|NCT00949117|childhood Burkitt lymphoma
1252221|NCT00949117|recurrent childhood small noncleaved cell lymphoma
1252222|NCT00949117|stage I childhood small noncleaved cell lymphoma
1252223|NCT00949117|stage II childhood small noncleaved cell lymphoma
1252224|NCT00949117|stage III childhood small noncleaved cell lymphoma
1252225|NCT00949117|stage IV childhood small noncleaved cell lymphoma
1252226|NCT00949117|childhood myelodysplastic syndromes
1252227|NCT00949117|de novo myelodysplastic syndromes
1252228|NCT00949117|previously treated myelodysplastic syndromes
1252229|NCT00949117|secondary myelodysplastic syndromes
1252230|NCT00949117|unspecified childhood solid tumor, protocol specific
1252231|NCT00949104|Sucrose
1252232|NCT00949104|pain
1252233|NCT00949104|neonate
1252234|NCT00949104|preterm
1252235|NCT00949104|orogastric tube
1252236|NCT00949091|Diabetes Mellitus, Non Insulin Dependent
1252237|NCT00949091|Diabetes Mellitus, Type II
1252238|NCT00949091|Type 2 Diabetes Mellitus
1252239|NCT00949091|Drug Therapy
1252240|NCT00949078|peanut
1252241|NCT00949078|allergy
1252242|NCT00949065|complex regional pain syndrome
1252243|NCT00949065|sympathetic reflex dystrophy
1252244|NCT00949065|intravenous immunoglobulins
1252245|NCT00949065|autoimmune disease
1252246|NCT00949052|cancer survivor
1252247|NCT00949052|stage III adult Burkitt lymphoma
1252248|NCT00949052|stage III adult diffuse large cell lymphoma
1252249|NCT00949052|stage III adult diffuse mixed cell lymphoma
1252250|NCT00949052|stage III adult diffuse small cleaved cell lymphoma
1252251|NCT00949052|stage III adult Hodgkin lymphoma
1252252|NCT00949052|stage III adult immunoblastic large cell lymphoma
1252253|NCT00949052|stage III adult lymphoblastic lymphoma
1252254|NCT00949052|stage III grade 1 follicular lymphoma
1252255|NCT00949052|stage III grade 2 follicular lymphoma
1252256|NCT00949052|stage III grade 3 follicular lymphoma
1252257|NCT00949052|stage III mantle cell lymphoma
1252258|NCT00949052|stage III marginal zone lymphoma
1252259|NCT00949052|stage III small lymphocytic lymphoma
1252260|NCT00949052|stage IV adult Burkitt lymphoma
1252261|NCT00949052|stage IV adult diffuse large cell lymphoma
1252262|NCT00949052|stage IV adult diffuse mixed cell lymphoma
1252263|NCT00949052|stage IV adult diffuse small cleaved cell lymphoma
1252264|NCT00949052|stage IV adult Hodgkin lymphoma
1252265|NCT00949052|stage IV adult immunoblastic large cell lymphoma
1252266|NCT00949052|stage IV adult lymphoblastic lymphoma
1252267|NCT00949052|stage IV grade 1 follicular lymphoma
1252268|NCT00949052|stage IV grade 2 follicular lymphoma
1252269|NCT00949052|stage IV grade 3 follicular lymphoma
1252270|NCT00949052|stage IV mantle cell lymphoma
1252271|NCT00949052|stage IV marginal zone lymphoma
1252272|NCT00949052|stage IV small lymphocytic lymphoma
1252273|NCT00949052|recurrent adult Burkitt lymphoma
1252274|NCT00949052|recurrent adult diffuse large cell lymphoma
1252275|NCT00949052|recurrent adult diffuse mixed cell lymphoma
1252276|NCT00949052|recurrent adult diffuse small cleaved cell lymphoma
1252277|NCT00949052|recurrent adult Hodgkin lymphoma
1252278|NCT00949052|recurrent adult immunoblastic large cell lymphoma
1252279|NCT00949052|recurrent adult lymphoblastic lymphoma
1252280|NCT00949052|recurrent childhood large cell lymphoma
1252281|NCT00949052|recurrent childhood lymphoblastic lymphoma
1252282|NCT00949052|recurrent childhood small noncleaved cell lymphoma
1252283|NCT00949052|recurrent cutaneous T-cell non-Hodgkin lymphoma
1252284|NCT00949052|recurrent grade 1 follicular lymphoma
1252285|NCT00949052|recurrent grade 2 follicular lymphoma
1252286|NCT00949052|recurrent grade 3 follicular lymphoma
1252287|NCT00949052|recurrent mantle cell lymphoma
1252288|NCT00949052|recurrent marginal zone lymphoma
1252289|NCT00949052|recurrent small lymphocytic lymphoma
1252290|NCT00949052|recurrent/refractory childhood Hodgkin lymphoma
1252291|NCT00949052|recurrent mycosis fungoides/Sezary syndrome
1252292|NCT00949052|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1252293|NCT00949052|nodal marginal zone B-cell lymphoma
1252294|NCT00949052|splenic marginal zone lymphoma
1252295|NCT00949052|noncontiguous stage II adult Burkitt lymphoma
1252296|NCT00949052|noncontiguous stage II adult diffuse large cell lymphoma
1252297|NCT00949052|noncontiguous stage II adult diffuse mixed cell lymphoma
1252298|NCT00949052|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1252299|NCT00949052|noncontiguous stage II adult immunoblastic large cell lymphoma
1252300|NCT00949052|noncontiguous stage II adult lymphoblastic lymphoma
1252301|NCT00949052|noncontiguous stage II grade 1 follicular lymphoma
1252302|NCT00949052|noncontiguous stage II grade 2 follicular lymphoma
1252303|NCT00949052|noncontiguous stage II grade 3 follicular lymphoma
1252304|NCT00949052|noncontiguous stage II mantle cell lymphoma
1252305|NCT00949052|noncontiguous stage II marginal zone lymphoma
1252306|NCT00949052|noncontiguous stage II small lymphocytic lymphoma
1252307|NCT00949052|accelerated phase chronic myelogenous leukemia
1252308|NCT00949052|adult acute lymphoblastic leukemia in remission
1252309|NCT00949052|adult acute myeloid leukemia in remission
1252310|NCT00949052|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1252311|NCT00949052|adult acute myeloid leukemia with inv(16)(p13;q22)
1252312|NCT00949052|adult acute myeloid leukemia with t(15;17)(q22;q12)
1252313|NCT00949052|adult acute myeloid leukemia with t(16;16)(p13;q22)
1252314|NCT00949052|adult acute myeloid leukemia with t(8;21)(q22;q22)
1252546|NCT00948259|safety
1252315|NCT00949052|atypical chronic myeloid leukemia, BCR-ABL negative
1252316|NCT00949052|blastic phase chronic myelogenous leukemia
1252317|NCT00949052|childhood acute lymphoblastic leukemia in remission
1252318|NCT00949052|childhood acute myeloid leukemia in remission
1252319|NCT00949052|childhood chronic myelogenous leukemia
1252320|NCT00949052|chronic myelomonocytic leukemia
1252321|NCT00949052|chronic phase chronic myelogenous leukemia
1252322|NCT00949052|juvenile myelomonocytic leukemia
1252323|NCT00949052|recurrent adult acute lymphoblastic leukemia
1252324|NCT00949052|recurrent adult acute myeloid leukemia
1252325|NCT00949052|recurrent childhood acute lymphoblastic leukemia
1252326|NCT00949052|recurrent childhood acute myeloid leukemia
1252327|NCT00949052|refractory chronic lymphocytic leukemia
1252328|NCT00949052|refractory hairy cell leukemia
1252329|NCT00949052|relapsing chronic myelogenous leukemia
1252330|NCT00949052|secondary acute myeloid leukemia
1252331|NCT00949052|stage III chronic lymphocytic leukemia
1252332|NCT00949052|stage IV chronic lymphocytic leukemia
1252333|NCT00949052|childhood myelodysplastic syndromes
1252334|NCT00949052|chronic eosinophilic leukemia
1252335|NCT00949052|primary myelofibrosis
1252336|NCT00949052|chronic neutrophilic leukemia
1252337|NCT00949052|de novo myelodysplastic syndromes
1252338|NCT00949052|disseminated neuroblastoma
1252339|NCT00949052|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1252340|NCT00949052|poor prognosis metastatic gestational trophoblastic tumor
1252341|NCT00949052|previously treated childhood rhabdomyosarcoma
1252342|NCT00949052|previously treated myelodysplastic syndromes
1252343|NCT00949052|recurrent Wilms tumor and other childhood kidney tumors
1252344|NCT00949052|recurrent childhood rhabdomyosarcoma
1252345|NCT00949052|recurrent neuroblastoma
1252346|NCT00949052|recurrent ovarian epithelial cancer
1252347|NCT00949052|recurrent ovarian germ cell tumor
1252348|NCT00949052|recurrent malignant testicular germ cell tumor
1252349|NCT00949052|secondary myelodysplastic syndromes
1252350|NCT00949052|stage I multiple myeloma
1252351|NCT00949052|stage II multiple myeloma
1252352|NCT00949052|stage III multiple myeloma
1252353|NCT00949052|stage II ovarian epithelial cancer
1252354|NCT00949052|stage III ovarian epithelial cancer
1252355|NCT00949052|stage IV ovarian epithelial cancer
1252356|NCT00949052|stage III malignant testicular germ cell tumor
1252357|NCT00949052|stage IIIA breast cancer
1252358|NCT00949052|stage IIIB breast cancer
1252359|NCT00949052|stage IIIC breast cancer
1252360|NCT00949052|stage IV breast cancer
1252361|NCT00949052|refractory multiple myeloma
1252362|NCT00949026|Brain Cancer
1252363|NCT00949026|Brain Neoplasms, Malignant
1252364|NCT00949013|stage IA breast cancer
1252365|NCT00949013|stage IB breast cancer
1252366|NCT00949013|stage II breast cancer
1252367|NCT00949013|stage IIIA breast cancer
1252368|NCT00949013|stage IIIB breast cancer
1252369|NCT00949013|stage IIIC breast cancer
1252370|NCT00948987|aspirin resistance
1252371|NCT00948987|cardiovascular risk
1252372|NCT00948987|prostaglandins
1252373|NCT00948987|platelet inhibition
1252374|NCT00948974|social anxiety
1252375|NCT00948974|treatment
1252376|NCT00948974|Cognitive Behavioral Therapy
1252377|NCT00948974|Acceptance and Commitment Therapy
1252378|NCT00948974|Cognitive Therapy
1252379|NCT00948961|NYESO1
1252380|NCT00948961|cancer vaccine
1252381|NCT00948961|immunotherapy
1252382|NCT00948961|breast cancer
1252383|NCT00948961|ovarian cancer
1252384|NCT00948961|non-small cell lung cancer
1252385|NCT00948961|myeloma
1252386|NCT00948961|sarcoma
1252387|NCT00948961|melanoma
1252388|NCT00948961|Resiquimod
1252389|NCT00948961|Poly-ICLC
1252390|NCT00948961|Hiltonol
1252391|NCT00948961|esophageal cancer
1252392|NCT00948961|bladder cancer
1252393|NCT00948961|chondrosarcoma
1252394|NCT00948961|adenocarcinoma
1252395|NCT00948935|Biliary Cancer
1252396|NCT00948935|Cholangiocarcinoma
1252397|NCT00948935|Panitumumab
1252398|NCT00948922|multiple myeloma
1252399|NCT00948922|myeloma
1252400|NCT00948922|myeloma proteins
1252401|NCT00948922|autologous
1252402|NCT00948922|allogeneic
1252403|NCT00948896|Chemoprevention
1252404|NCT00948896|Uganda
1252405|NCT00948896|Malaria
1252406|NCT00948896|Trimethoprim-sulfamethoxazole
1252407|NCT00948896|Sulfadoxine-pyrimethamine
1252408|NCT00948896|Dihydroartemisinin-piperaquine
1252409|NCT00948883|organ transplant
1252410|NCT00948883|cancer
1252411|NCT00948883|biobank
1252412|NCT00948883|immunosuppressive drugs
1252413|NCT00948883|lymphoma
1252414|NCT00948870|alternative medicine
1252415|NCT00948857|DHEA
1252416|NCT00948857|POF
1252417|NCT00948857|Pregnancy
1252418|NCT00948857|Ovarian Failure
1252419|NCT00948857|Otherwise Unexplained infertility
1252420|NCT00948857|Ovarian aging
1252421|NCT00948844|falls
1252422|NCT00948844|Missteps
1252423|NCT00948831|biologics
1252424|NCT00948831|fusion rates
1252425|NCT00948831|lumbar fusion
1252426|NCT00948831|ALIF
1252547|NCT00948259|GSK inhibitor
1252427|NCT00948818|Irritable Bowel Syndrome
1252428|NCT00948818|Constipation
1252429|NCT00948818|Linaclotide
1252430|NCT00948805|corpus luteum rescue
1252431|NCT00948805|Gonadotropin Releasing Hormone (GnRH agonist)
1252432|NCT00948805|human Chorionic Gonadotropin (hCG)
1252433|NCT00948805|infertility
1252434|NCT00948805|pregnancy rate
1252435|NCT00948792|platelets
1252436|NCT00948792|transfusion
1252437|NCT00948792|thrombocytopenia
1252438|NCT00948779|Patient education
1252439|NCT00948779|Antibiotic
1252440|NCT00948779|Child
1252441|NCT00948779|Respiratory tract infection
1252442|NCT00948779|Patient satisfaction
1252443|NCT00948779|Parental knowledge
1252444|NCT00948779|Adherence
1252445|NCT00948766|Alzheimer's disease
1252446|NCT00948766|dementia
1252447|NCT00948766|Alzheimer's type
1252448|NCT00948753|Graft-versus-host disease
1252449|NCT00948753|GVHD
1252450|NCT00948753|Maraviroc
1252451|NCT00948753|non-myeloablative allogeneic stem-cell transplantation
1252452|NCT00948753|Hematopoietic stem cell transplantation
1252453|NCT00948740|vitamin D
1252454|NCT00948701|Breast cancer
1252455|NCT00948701|Exercise
1252456|NCT00948701|Physical activity
1252457|NCT00948701|Community volunteers
1252458|NCT00948701|Peer mentors
1252459|NCT00948701|Peer coaches
1252460|NCT00948701|Social support
1252461|NCT00948688|Zolinza
1252462|NCT00948675|Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology
1252463|NCT00948675|Advanced Lung Cancer
1252464|NCT00948675|Non-Small Cell Lung Cancer
1252465|NCT00948675|Lung Cancer
1252466|NCT00948662|Safety
1252467|NCT00948662|tolerability
1252468|NCT00948662|ascending single doses
1252469|NCT00948662|healthy subjects
1252470|NCT00948649|Varenicline, Working memory
1252471|NCT00948623|COPD
1252472|NCT00948623|physical activity
1252473|NCT00948623|pulmonary rehabilitation
1252474|NCT00948623|counseling
1252475|NCT00948610|Rheumatoid Arthritis
1252476|NCT00948597|propofol
1252477|NCT00948597|elective surgical procedure
1252478|NCT00948597|Obese subjects
1252479|NCT00948584|Diabetes Mellitus, Type 2
1252480|NCT00948584|Insulin dose titration system
1252481|NCT00948571|Vital capacity, FEV1, airway resistance
1252609|NCT00948090|Bone marrow transplant
1252482|NCT00948571|perioperative changes in lung function
1252483|NCT00948558|citrate anticoagulation
1252484|NCT00948558|pharmacokinetic
1252485|NCT00948558|critically ill
1252486|NCT00948558|acute kidney failure
1252487|NCT00948545|Autonomic nervous system
1252488|NCT00948545|Bariatric surgery
1252489|NCT00948545|Observational study for individuals having bariatric surgery
1252490|NCT00948532|degenerative disc disease
1252491|NCT00948532|lumbar spine
1252492|NCT00948532|XLIF
1252493|NCT00948532|Degenerative conditions
1252494|NCT00948519|Rhinosinusitis, sinusitis, chronic, nasal polyps, phototherapy, laser,laser therapy, antibiotic, safety laser, ICG, indocyanine green
1252495|NCT00948519|Chronic Rhinosinusitis with or without nasal polyposis
1252496|NCT00948493|diabetes
1252497|NCT00948493|insulin therapy
1252498|NCT00948480|autologous tumor cell vaccine
1252499|NCT00948480|metastatic melanoma
1252500|NCT00948480|sargramostim (GM-CSF)
1252501|NCT00948467|Advanced nonhematologic malignancies
1252502|NCT00948467|Advanced metastatic melanoma
1252503|NCT00948467|BRAF gene
1252504|NCT00948454|smoking
1252505|NCT00948441|intestinal insufficiency
1252506|NCT00948441|central venous catheter
1252507|NCT00948441|Catheter-Related Infections
1252508|NCT00948441|pediatrics
1252509|NCT00948441|ethanol
1252510|NCT00948428|actinic keratoses
1252511|NCT00948428|imiquimod
1252512|NCT00948428|therapeutic equivalence
1252513|NCT00948428|bioequivalence
1252514|NCT00948415|Obesity
1252515|NCT00948415|Weight loss
1252516|NCT00948415|Internet
1252517|NCT00948402|PED/PEA-15 protein
1252518|NCT00948402|PCOS
1252519|NCT00948402|IR
1252520|NCT00948402|metformin
1252521|NCT00948402|OCP
1252522|NCT00948402|Oral Contraceptive
1252523|NCT00948376|Natural history
1252524|NCT00948376|IFT80
1252525|NCT00948376|short ribs
1252526|NCT00948376|multivisceral involvement
1252531|NCT00948350|cervical instability
1252532|NCT00948350|awake intubation
1252533|NCT00948350|laryngeal anesthesia
1252534|NCT00948324|ype 2 diabetes mellitus, continuous subcutaneous insulin infusion,
1252535|NCT00948324|α-lipoic acid ,rosiglitazone ,metformin，therapy
1252536|NCT00948298|cardiovascular disease
1252537|NCT00948298|vitamin D
1252538|NCT00948298|african american
1252539|NCT00948298|low vitamin D levels
1252540|NCT00948285|breast cancer
1252541|NCT00948285|magnetic resonance imaging
1252542|NCT00948272|Rabies
1252543|NCT00948272|Rabies virus
1252544|NCT00948272|Purified Vero Rabies Vaccine
1252545|NCT00948272|Serum Free
1252548|NCT00948259|Alzheimer
1252549|NCT00948233|Tobacco
1252550|NCT00948233|Smoking Cessation
1252551|NCT00948233|Prevention
1252552|NCT00948233|Smokeless tobacco
1252553|NCT00948233|Habit
1252554|NCT00948220|HCV
1252555|NCT00948220|hepatitis C virus
1252556|NCT00948220|CHC
1252557|NCT00948220|chronic hepatitis c
1252558|NCT00948220|interferon
1252559|NCT00948220|ribavirin
1252560|NCT00948220|DEXA
1252561|NCT00948220|BMD
1252562|NCT00948220|bone mineral density
1252563|NCT00948220|osteoporosis
1252564|NCT00948220|osteopenia
1252565|NCT00948220|osteodystrophy
1252566|NCT00948220|osteodensitometry
1252567|NCT00948220|Bone Density
1252568|NCT00948220|Hepatitis, Viral, Human
1252569|NCT00948220|Anti-Infective Agents
1252570|NCT00948220|peginterferon alfa-2a
1252571|NCT00948207|Metastatic Cancer
1252572|NCT00948207|Recurrent Cancer
1252573|NCT00948207|Distributed Hematological Cancer
1252574|NCT00948207|Advanced Cancer
1252575|NCT00948207|Terminal Cancer
1252576|NCT00948207|Stage III Cancer
1252577|NCT00948207|Stage IV Cancer
1252578|NCT00948194|Extended Donor Criteria
1252579|NCT00948181|Epinephrine, Norepinephrine, normetanephrine
1252580|NCT00948181|Catecholamine concentrations during surgery
1252581|NCT00948168|T2DM
1252582|NCT00948168|exenatide
1252583|NCT00948168|HbA1c
1252584|NCT00948168|weight
1252585|NCT00948168|waist circumference
1252586|NCT00948168|insulin sensitivity
1252587|NCT00948168|beta-cell function
1252588|NCT00948155|smoking
1252589|NCT00948155|nicotine
1252590|NCT00948155|varenicline
1252591|NCT00948142|Acute Bacterial Skin and Skin Struction Infections; Bacterial Skin Diseases; Staphylococcal Skin Infections; MRSA
1252592|NCT00948129|Smoking Cessation
1252593|NCT00948129|Low-Income
1252594|NCT00948129|Cigarette smoking
1252595|NCT00948129|Uninsured and underinsured
1252596|NCT00948129|NRT
1252597|NCT00948129|Nicoderm CQ
1252598|NCT00948129|Habits
1252599|NCT00948116|Diabetes mellitus
1252600|NCT00948116|Renal Impairment
1252601|NCT00948116|Acute Kidney Injury
1252602|NCT00948116|Coronary revascularisation
1252603|NCT00948116|eGFR <60ml/min
1252604|NCT00948103|Nitrous Oxide
1252605|NCT00948103|Administration, Intravesical Drug
1252606|NCT00948103|Botulinum toxin
1252607|NCT00948090|Hodgkin Lymphoma
1252608|NCT00948090|Non-Hodgkin's Lymphoma
1252610|NCT00948090|stem cell transplant
1252611|NCT00948090|busulfan
1252612|NCT00948090|cyclophosphamide
1252613|NCT00948090|etoposide
1252614|NCT00948077|tuberculosis
1252615|NCT00948077|pharmacokinetic
1252616|NCT00948077|first-line drugs
1252617|NCT00948064|Leukemia
1252618|NCT00948064|Acute Myelogenous Leukemia
1252619|NCT00948064|AML
1252620|NCT00948064|Myelodysplastic Syndrome
1252621|NCT00948064|MDS
1252622|NCT00948064|Vorinostat
1252623|NCT00948064|SAHA
1252624|NCT00948064|Suberoylanilide Hydroxamic Acid
1252625|NCT00948064|MSK-390
1252626|NCT00948064|Zolinza
1252627|NCT00948064|Azacitidine
1252628|NCT00948064|5-Azacitidine
1252629|NCT00948064|5-Aza
1252630|NCT00948064|Vidaza
1252631|NCT00948064|5-AZC
1252632|NCT00948064|AZA-CR
1252633|NCT00948064|Ladakamycin
1252634|NCT00948064|NSC-102816
1252635|NCT00948038|Inflammation
1252636|NCT00948038|Oxidative stress
1252637|NCT00948025|Peripheral Nerve Repair
1252638|NCT00948025|Conduit
1252639|NCT00948025|AVANCE
1252640|NCT00948025|Neuroma Resection
1252641|NCT00948025|Nerve Gap Repair
1252642|NCT00948025|Digital Nerve Repair
1252643|NCT00948012|Sickle Cell Anemia
1252644|NCT00948012|Pulmonary Hypertension
1252645|NCT00948012|Exercise echocardiography
1252646|NCT00948012|Echocardiography
1252647|NCT00947973|Attention Deficit Hyperactivity Disorder
1252648|NCT00947973|ADHD
1252649|NCT00947973|School Based
1252650|NCT00947973|Intervention
1252651|NCT00947973|Psychosocial
1252652|NCT00947973|Academic Intervention
1252653|NCT00947973|Behavioral
1252654|NCT00947960|Adult Polyglucosan Body Disease (APBD)
1252655|NCT00947960|Glycogen Brancher Enzyme (GBE1) Deficiency
1252656|NCT00947947|condom use
1252657|NCT00947947|HIV prevention
1252658|NCT00947947|African American
1252659|NCT00947947|Behavioral intervention
1252660|NCT00947947|HIV Seronegativity
1252661|NCT00947934|Alzheimer disease,hypothalamus,Deep Brain Stimulation
1252662|NCT00947921|Functional MItral regurgitation
1252663|NCT00947908|Hymenoptera venom allergy
1252664|NCT00947908|Dendritic cells (DC)
1252665|NCT00947895|ACTH
1252666|NCT00947895|Acthar gel
1252667|NCT00947895|adrenocorticotropin
1252668|NCT00947895|methylprednisolone
1252669|NCT00947895|solumedrol
1252670|NCT00947895|MS
1252671|NCT00947895|multiple
1252672|NCT00947895|sclerosis
1252673|NCT00947895|relapse
1252674|NCT00947895|exacerbation
1252675|NCT00947895|sub-responsive
1252676|NCT00947895|IV
1252677|NCT00947856|Antibodies, Monoclonal
1252678|NCT00947856|Antibody-Drug Conjugate
1252679|NCT00947856|Antigens, CD30
1252680|NCT00947856|Drug Therapy
1252681|NCT00947856|Hematologic Diseases
1252682|NCT00947856|Immunotherapy
1252683|NCT00947856|Monomethylauristatin E
1252684|NCT00947843|CHD
1252685|NCT00947843|CHD equivalents
1252686|NCT00947830|CML
1252687|NCT00947830|intracellular imatinib level
1252688|NCT00947830|OCT-1
1252689|NCT00947804|Acute Coronary Artery Syndrome Risk Stratification Score
1252690|NCT00947791|Bipolar Disorder
1252691|NCT00947791|Depression
1252692|NCT00947791|Treatment-Resistant
1252693|NCT00947791|ketamine
1252694|NCT00947791|antidepressant
1252695|NCT00947791|glutamate
1252696|NCT00947765|Tennis Elbow
1252697|NCT00947765|Epicondylitis, Lateral Humeral
1252698|NCT00947752|Multiple Sclerosis
1252699|NCT00947752|Relapsing Remitting Multiple Sclerosis (RRMS)
1252700|NCT00947752|Glatiramer Acetate (GA)
1252701|NCT00947739|CZ
1252702|NCT00947739|Stehlin
1252703|NCT00947739|Lymphomas
1252704|NCT00947713|Human chorionic gonadotropin
1252705|NCT00947713|Clomiphene citrate
1252706|NCT00947713|chronic anovulation
1252707|NCT00947713|Polycystic Ovary Syndrome
1252708|NCT00947713|Follicolugenesis
1252709|NCT00947700|Infants
1252710|NCT00947700|Risk markers
1252711|NCT00947700|ERP
1252712|NCT00947700|Parent child interaction
1252713|NCT00947700|Promoting First Relations
1252714|NCT00947700|Social Communication
1252715|NCT00947687|influenza
1252716|NCT00947687|healthy subject
1252717|NCT00947687|virus inoculation
1252718|NCT00947687|symptom scores
1252719|NCT00947687|viral shedding
1252720|NCT00947687|bioaerosol output
1252721|NCT00947674|Cellsorba EX
1252722|NCT00947661|glaucoma latanoprost
1252723|NCT00947648|acute myelogenous leukemia
1252724|NCT00947648|AML
1252725|NCT00947648|myelodysplastic syndrome
1252726|NCT00947648|MDS
1252727|NCT00947648|Neutropenia
1252728|NCT00947648|raw fruits and vegetables
1252729|NCT00947635|Type 1 diabetes
1252730|NCT00947635|Transplants
1252731|NCT00947635|Immunosuppression
1252732|NCT00947635|Hyperlipidemia
1252733|NCT00947635|Nutrition Therapy
1252734|NCT00947622|Fibromyalgia
1252735|NCT00947622|Neuromodulation
1252863|NCT00947102|gemcitabine
1252736|NCT00947622|Transcranial Direct Current Stimulation
1252737|NCT00947622|Occipital
1252738|NCT00947609|Latent tuberculosis
1252739|NCT00947609|HIV
1252740|NCT00947609|Children
1252741|NCT00947609|Interferon gamma release assays
1252742|NCT00947609|Thailand
1252743|NCT00947609|QuantiFERON TB Gold In-tube
1252744|NCT00947609|T-Spot.TB
1252745|NCT00947596|Atropine
1252746|NCT00947596|Aerosol
1252747|NCT00947596|Inhaler
1252748|NCT00947596|Dry Powder
1252749|NCT00947583|fusion rates
1252750|NCT00947583|TLIF
1252751|NCT00947583|Osteocel Plus
1252752|NCT00947583|biologics
1252753|NCT00947583|lumbar fusion
1252754|NCT00947570|Cognitive Behavioral Therapy
1252755|NCT00947570|Functional Brain Imaging
1252756|NCT00947570|Psychotherapy
1252757|NCT00947570|Treatment
1252758|NCT00947570|Brain Imaging
1252759|NCT00947544|Urea Cycle Disorder
1252760|NCT00947544|UCD
1252761|NCT00947544|GT4P
1252762|NCT00947544|Buphenyl
1252763|NCT00947544|hyperammonemia
1252764|NCT00947544|sodium phenylbutyrate
1252765|NCT00947518|chlorhexidine
1252766|NCT00947518|preterm
1252767|NCT00947518|newborn
1252768|NCT00947518|skin condition
1252769|NCT00947518|temperature
1252770|NCT00947518|skin flora
1252771|NCT00947505|Androgenetic alopecia
1252772|NCT00947505|Hair loss
1252773|NCT00947505|Male Pattern baldness
1252774|NCT00947492|Rheumatoid Arthritis patients
1252775|NCT00947492|treated with new immunosuppressive drugs : Orencia* (abatacept) and RoActemra* (tocilizumab).
1252776|NCT00947479|obstructive sleep apnea
1252777|NCT00947479|pulse-wave velocity,
1252778|NCT00947479|acute kidney injury
1252779|NCT00947479|biomarkers of acute kidney injury
1252780|NCT00947466|Buprenorphine transdermal patch (BTDS)
1252781|NCT00947466|Moderate to severe mouth pain
1252782|NCT00947466|Chemotherapy induced mucositis
1252783|NCT00947466|Pharmacokinetic
1252784|NCT00947453|asthma
1252785|NCT00947453|montelukast
1252786|NCT00947440|Phase 1
1252787|NCT00947440|Bioavailability
1252788|NCT00947427|type 1 diabetes
1252789|NCT00947427|newly diagnosed T1D
1252790|NCT00947427|T1D
1252791|NCT00947427|canakinumab
1252792|NCT00947427|anti IL-1
1252793|NCT00947414|cellulite; shockwave; microcirculation; skin
1252794|NCT00947401|Surgery, elective
1252795|NCT00947401|Fluids
1252796|NCT00947401|Post Anesthesia Care Unit
1252797|NCT00947401|PACU
1252798|NCT00947401|Fluid management
1252799|NCT00947388|Refractory Chronic Lymphocytic Leukemia
1252800|NCT00947388|Bendamustine
1252801|NCT00947388|Alemtuzumab
1252802|NCT00947388|Phase I
1252803|NCT00947388|CLL
1252804|NCT00947375|schizophrenia
1252805|NCT00947375|lamictal TM
1252806|NCT00947375|haloperidol decanoate
1252807|NCT00947323|simvastatin
1252808|NCT00947323|endothelial dysfunction
1252809|NCT00947323|erectile dysfunction
1252810|NCT00947310|Inappropriate therapy
1252811|NCT00947310|ICD therapy
1252812|NCT00947310|Primary prevention
1252813|NCT00947297|Urea Cycle Disorder
1252814|NCT00947297|UCD
1252815|NCT00947297|hyperammonemia
1252816|NCT00947297|Buphenyl
1252817|NCT00947297|Sodium Phenylbutyrate
1252818|NCT00947271|STD
1252819|NCT00947271|STI
1252820|NCT00947271|Sexual Behavior
1252821|NCT00947271|Prevention
1252822|NCT00947271|HIV seronegativity
1252823|NCT00947258|Muscle Strength
1252824|NCT00947258|Torque
1252825|NCT00947258|Muscle Stretching Exercises
1252826|NCT00947258|Range of Motion
1252827|NCT00947232|major depressive disorder
1252828|NCT00947232|physical activity
1252829|NCT00947232|aging with physical disability
1252830|NCT00947232|motivational interviewing
1252831|NCT00947219|Androgenetic Alopecia
1252832|NCT00947219|Hair Loss
1252833|NCT00947219|Male Pattern Baldness
1252834|NCT00947206|Chinese Americans
1252835|NCT00947206|lay health worker outreach
1252836|NCT00947206|colorectal cancer screening
1252837|NCT00947193|Hemophilia A
1252838|NCT00947193|Hemophilia B
1252839|NCT00947193|Factor VIII
1252840|NCT00947193|Factor IX
1252841|NCT00947193|FVIII
1252842|NCT00947193|FIX
1252843|NCT00947193|Nonsense mutation
1252844|NCT00947193|Premature stop codon
1252845|NCT00947193|HA
1252846|NCT00947193|HB
1252847|NCT00947193|PTC124
1252848|NCT00947193|Ataluren
1252849|NCT00947180|Biofeedback
1252850|NCT00947180|Pelvic floor
1252851|NCT00947180|Levator ani syndrome
1252852|NCT00947180|Chronic proctalgia
1252853|NCT00947180|Electrogalvanic stimulation
1252854|NCT00947180|Massage
1252855|NCT00947154|trichotillomania
1252856|NCT00947154|aripiprazole
1252857|NCT00947154|treatment
1252858|NCT00947141|Optimising treatment of cytomegalovirus infection
1252859|NCT00947128|Antiemetic
1252860|NCT00947115|Cervical cancer
1252861|NCT00947115|HPV vaccine
1252862|NCT00947102|pancreatic tubular adenocarcinoma
1252864|NCT00947102|gene expression
1252865|NCT00947102|immunological status
1252866|NCT00947102|serological status
1252867|NCT00947102|pancreatic tubular adenocarcinoma adjuvant setting
1252868|NCT00947089|ORC (oxidized regenerated cellulose)
1252869|NCT00947089|SSI (Surgical site infections)
1252870|NCT00947076|Antidepressant
1252871|NCT00947063|Antihistamine
1252872|NCT00947050|CAD
1252873|NCT00947050|prompt physical exercise
1252874|NCT00947050|collateral function
1252875|NCT00947011|Healthy volunteers
1252876|NCT00947011|GLP-1
1252877|NCT00947011|Januvia
1252878|NCT00947011|Sitagliptin
1252879|NCT00946998|Chronic Kidney Disease
1252880|NCT00946998|Depression
1252881|NCT00946998|Antidepressants
1252882|NCT00946998|randomized controlled trial
1252883|NCT00946998|treatment
1252884|NCT00946998|Sertraline
1252885|NCT00946985|Schizophrenia
1252886|NCT00946985|Risperidone
1252887|NCT00946985|Risperdal
1252888|NCT00946985|Paliperidone Palmitate
1252889|NCT00946985|Invega Sustenna
1252890|NCT00946972|Diabetes Mellitus, Type 2
1252891|NCT00946959|cardiac surgery
1252892|NCT00946959|angioplasty
1252893|NCT00946959|cognitive decline
1252894|NCT00946946|Randomized
1252895|NCT00946946|Crohn's Disease
1252896|NCT00946946|Prevention
1252897|NCT00946946|Azathioprine
1252898|NCT00946946|mesalazine
1252899|NCT00946946|mesalamine
1252900|NCT00946946|TPMT
1252901|NCT00946933|acid-base balance
1252902|NCT00946933|ventilatory control
1252903|NCT00946933|dyspnea
1252904|NCT00946933|exercise
1252905|NCT00946933|modified rebreathing procedure
1252906|NCT00946933|Normal
1252907|NCT00946933|older
1252908|NCT00946907|acute pericarditis
1252909|NCT00946907|treatment
1252910|NCT00946907|recurrence
1252911|NCT00946894|Total thyroidectomy
1252912|NCT00946894|Subtotal thyroidectomy
1252913|NCT00946894|Dunhill operation
1252914|NCT00946894|Recurrent nodular goiter
1252915|NCT00946894|Completion thyroidectomy
1252916|NCT00946894|Recurrent laryngeal nerve palsy
1252917|NCT00946894|Hypoparathyroidism following thyroidectomy
1252918|NCT00946894|Recurrent goiter
1252919|NCT00946881|Prostatic disease
1252920|NCT00946881|genital neoplasm, male
1252921|NCT00946881|Urogenital neoplasm
1252922|NCT00946881|Genital disease
1252923|NCT00946881|male
1252924|NCT00946881|Male urogenital disease
1252925|NCT00946881|Neoplasms
1252926|NCT00946881|Neoplasm by site
1252927|NCT00946881|prostatic neoplasm
1252928|NCT00946881|Carcinoma
1252929|NCT00946868|intermittent claudication
1252930|NCT00946868|metabolic syndrome
1252931|NCT00946855|soccer
1252932|NCT00946855|laboratory
1252933|NCT00946855|reference
1252934|NCT00946855|exercise
1252935|NCT00946855|variability
1252936|NCT00946855|season
1252937|NCT00946855|elite athletes
1252938|NCT00946855|Define reference blood parameters in elite athletes
1252939|NCT00946842|Healthy
1252940|NCT00946842|Bioavailability
1252941|NCT00946842|Relative bioavailability
1252942|NCT00946842|TMC207
1252943|NCT00946842|Fed condition
1252944|NCT00946842|Fasted condition
1252945|NCT00946803|Pain
1252946|NCT00946803|Fatigue
1252947|NCT00946803|Sleep
1252948|NCT00946803|Cancer
1252949|NCT00946803|Complementary therapies
1252950|NCT00946790|Immunosuppressant and Antirheumatic
1252951|NCT00946777|Dry Eye Signs
1252952|NCT00946777|barrier function
1252953|NCT00946764|Antidepressant
1252954|NCT00946751|Anticonvulsant
1252955|NCT00946738|Raynaud's phenomenon
1252956|NCT00946738|biofeedback
1252957|NCT00946738|deep oscillation
1252958|NCT00946738|systemic sclerosis
1252959|NCT00946738|physiotherapy
1252960|NCT00946725|Angina (Chest Pain)
1252961|NCT00946725|Hypertension
1252962|NCT00946660|Contingency Management
1252963|NCT00946660|Drug Self-Administration
1252964|NCT00946647|Myelodysplastic Syndromes
1252965|NCT00946647|Chronic Myelomonocytic Leukemia
1252966|NCT00946647|Acute Myeloid Leukemia
1252967|NCT00946647|hypomethylating therapy
1252968|NCT00946647|deacetylase inhibitor
1252969|NCT00946647|MDS
1252970|NCT00946647|CMML
1252971|NCT00946647|AML
1252972|NCT00946608|Antihistamine
1252973|NCT00946595|Undetectable
1252974|NCT00946595|HIV infections
1252975|NCT00946595|Monotherapy
1252976|NCT00946595|Lopinavir/ritonavir
1252977|NCT00946595|Protease inhibitor
1252978|NCT00946595|Treatment experienced
1252979|NCT00946582|parenting management program
1252980|NCT00946582|ADHD
1252981|NCT00946569|Asthma
1252982|NCT00946569|Persistent asthma
1252983|NCT00946569|Adults with persistent asthma
1252984|NCT00946569|Chronic asthma
1252985|NCT00946569|JNJ-39758979
1252986|NCT00946569|Placebo
1252987|NCT00946556|herpes simplex virus type 2
1252988|NCT00946556|HIV
1252989|NCT00946556|genital immunology
1252990|NCT00946556|CD4+ T cell
1252991|NCT00946556|valacyclovir
1252992|NCT00946556|HIV seronegativity
1252993|NCT00946543|stage IIB prostate cancer
1252994|NCT00946543|stage IIA prostate cancer
1252995|NCT00946543|stage III prostate cancer
1252996|NCT00946543|stage IV prostate cancer
1252997|NCT00946491|Typical Antipsychotic
1252998|NCT00946478|atopic dermatitis
1252999|NCT00946478|elidel
1253000|NCT00946478|pimecrolimus
1253001|NCT00946478|CASM981
1253002|NCT00946478|immunity
1253003|NCT00946478|cathelicidin
1253004|NCT00946478|antimicrobial peptide
1253005|NCT00946478|eczema
1253006|NCT00946452|Control
1253007|NCT00946452|Satisfaction
1253008|NCT00946439|training exercise gait
1253009|NCT00946413|CBT, Depressed and suicidal adolescents
1253010|NCT00946400|Heparin-induced thrombocytopenia
1253011|NCT00946400|HIT
1253012|NCT00946400|4Ts
1253013|NCT00946400|Chong scale
1253014|NCT00946400|interobserver variability
1253015|NCT00946387|Antiemetic
1253016|NCT00946374|Mantle-Cell-Lymphoma
1253017|NCT00946374|MCL
1253018|NCT00946374|Non Hodgkin´s Lymphoma
1253019|NCT00946374|NHL
1253020|NCT00946374|Immunochemotherapy
1253021|NCT00946374|R-CHOP
1253022|NCT00946374|CHOP
1253023|NCT00946374|High-dose chemotherapy
1253024|NCT00946374|BEAM
1253025|NCT00946374|HD-BEAM
1253026|NCT00946374|Autologous stem cell transplantation
1253027|NCT00946374|Reduced conditioning regimen
1253028|NCT00946374|Unrelated donor
1253029|NCT00946374|Sibling donor
1253030|NCT00946374|Total Body Irradiation
1253031|NCT00946374|TBI
1253032|NCT00946374|Allogenic stem cell transplantation
1253033|NCT00946374|ABSCT
1253034|NCT00946374|ASCT
1253035|NCT00946374|Fludarabine+TBI
1253036|NCT00946348|Dronabinol
1253037|NCT00946348|Schizophrenia
1253038|NCT00946348|Dual Diagnosis
1253039|NCT00946348|Substance Abuse
1253040|NCT00946348|Cannabis Use Disorder
1253041|NCT00946322|post-traumatic stress disorder
1253042|NCT00946322|alcohol-related disorders
1253043|NCT00946322|substance use disorders
1253044|NCT00946322|couple therapy
1253045|NCT00946296|Graves Disease
1253046|NCT00946283|stage III adult Burkitt lymphoma
1253047|NCT00946283|stage III adult diffuse large cell lymphoma
1253048|NCT00946283|stage III adult diffuse mixed cell lymphoma
1253049|NCT00946283|stage III adult diffuse small cleaved cell lymphoma
1253050|NCT00946283|stage III adult Hodgkin lymphoma
1253051|NCT00946283|stage III adult immunoblastic large cell lymphoma
1253052|NCT00946283|stage III adult lymphoblastic lymphoma
1253053|NCT00946283|stage III grade 1 follicular lymphoma
1253054|NCT00946283|stage III grade 2 follicular lymphoma
1253055|NCT00946283|stage III grade 3 follicular lymphoma
1253056|NCT00946283|stage III mantle cell lymphoma
1253057|NCT00946283|stage III marginal zone lymphoma
1253058|NCT00946283|stage III small lymphocytic lymphoma
1253059|NCT00946283|stage IV adult Burkitt lymphoma
1253060|NCT00946283|stage IV adult diffuse large cell lymphoma
1253061|NCT00946283|stage IV adult diffuse mixed cell lymphoma
1253062|NCT00946283|stage IV adult diffuse small cleaved cell lymphoma
1253063|NCT00946283|stage IV adult Hodgkin lymphoma
1253064|NCT00946283|stage IV adult immunoblastic large cell lymphoma
1253065|NCT00946283|stage IV adult lymphoblastic lymphoma
1253066|NCT00946283|stage IV grade 1 follicular lymphoma
1253067|NCT00946283|stage IV grade 2 follicular lymphoma
1253068|NCT00946283|stage IV grade 3 follicular lymphoma
1253069|NCT00946283|stage IV mantle cell lymphoma
1253070|NCT00946283|stage IV marginal zone lymphoma
1253071|NCT00946283|stage IV small lymphocytic lymphoma
1253072|NCT00946283|recurrent adult Burkitt lymphoma
1253073|NCT00946283|recurrent adult diffuse large cell lymphoma
1253074|NCT00946283|recurrent adult diffuse mixed cell lymphoma
1253075|NCT00946283|recurrent adult diffuse small cleaved cell lymphoma
1253076|NCT00946283|recurrent adult Hodgkin lymphoma
1253077|NCT00946283|recurrent adult immunoblastic large cell lymphoma
1253078|NCT00946283|recurrent adult lymphoblastic lymphoma
1253079|NCT00946283|recurrent cutaneous T-cell non-Hodgkin lymphoma
1253080|NCT00946283|recurrent grade 1 follicular lymphoma
1253081|NCT00946283|recurrent grade 2 follicular lymphoma
1253082|NCT00946283|recurrent grade 3 follicular lymphoma
1253083|NCT00946283|recurrent mantle cell lymphoma
1253084|NCT00946283|recurrent marginal zone lymphoma
1253085|NCT00946283|recurrent small lymphocytic lymphoma
1253086|NCT00946283|recurrent mycosis fungoides/Sezary syndrome
1253087|NCT00946283|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1253088|NCT00946283|nodal marginal zone B-cell lymphoma
1253089|NCT00946283|splenic marginal zone lymphoma
1253090|NCT00946283|noncontiguous stage II adult Burkitt lymphoma
1253091|NCT00946283|noncontiguous stage II adult diffuse large cell lymphoma
1253092|NCT00946283|noncontiguous stage II adult diffuse mixed cell lymphoma
1253093|NCT00946283|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1253094|NCT00946283|noncontiguous stage II adult immunoblastic large cell lymphoma
1253095|NCT00946283|noncontiguous stage II adult lymphoblastic lymphoma
1253096|NCT00946283|noncontiguous stage II grade 1 follicular lymphoma
1253207|NCT00946010|genotype
1253097|NCT00946283|noncontiguous stage II grade 2 follicular lymphoma
1253098|NCT00946283|noncontiguous stage II grade 3 follicular lymphoma
1253099|NCT00946283|noncontiguous stage II mantle cell lymphoma
1253100|NCT00946283|noncontiguous stage II marginal zone lymphoma
1253101|NCT00946283|noncontiguous stage II small lymphocytic lymphoma
1253102|NCT00946283|accelerated phase chronic myelogenous leukemia
1253103|NCT00946283|adult acute lymphoblastic leukemia in remission
1253104|NCT00946283|adult acute myeloid leukemia in remission
1253105|NCT00946283|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1253106|NCT00946283|adult acute myeloid leukemia with inv(16)(p13;q22)
1253107|NCT00946283|adult acute myeloid leukemia with t(15;17)(q22;q12)
1253108|NCT00946283|adult acute myeloid leukemia with t(16;16)(p13;q22)
1253109|NCT00946283|adult acute myeloid leukemia with t(8;21)(q22;q22)
1253110|NCT00946283|atypical chronic myeloid leukemia, BCR-ABL negative
1253111|NCT00946283|blastic phase chronic myelogenous leukemia
1253112|NCT00946283|chronic myelomonocytic leukemia
1253113|NCT00946283|chronic phase chronic myelogenous leukemia
1253114|NCT00946283|recurrent adult acute lymphoblastic leukemia
1253115|NCT00946283|recurrent adult acute myeloid leukemia
1253116|NCT00946283|refractory chronic lymphocytic leukemia
1253117|NCT00946283|refractory hairy cell leukemia
1253118|NCT00946283|relapsing chronic myelogenous leukemia
1253119|NCT00946283|secondary acute myeloid leukemia
1253120|NCT00946283|stage III chronic lymphocytic leukemia
1253121|NCT00946283|stage IV chronic lymphocytic leukemia
1253122|NCT00946283|chronic eosinophilic leukemia
1253123|NCT00946283|primary myelofibrosis
1253124|NCT00946283|chronic neutrophilic leukemia
1253125|NCT00946283|de novo myelodysplastic syndromes
1253126|NCT00946283|disseminated neuroblastoma
1253127|NCT00946283|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1253128|NCT00946283|previously treated myelodysplastic syndromes
1253129|NCT00946283|recurrent neuroblastoma
1253130|NCT00946283|recurrent ovarian epithelial cancer
1253131|NCT00946283|recurrent ovarian germ cell tumor
1253132|NCT00946283|recurrent malignant testicular germ cell tumor
1253133|NCT00946283|secondary myelodysplastic syndromes
1253134|NCT00946283|stage II multiple myeloma
1253135|NCT00946283|stage III multiple myeloma
1253136|NCT00946283|stage II ovarian epithelial cancer
1253137|NCT00946283|stage III ovarian epithelial cancer
1253138|NCT00946283|stage IV ovarian epithelial cancer
1253139|NCT00946283|stage III malignant testicular germ cell tumor
1253140|NCT00946283|stage IIIA breast cancer
1253141|NCT00946283|stage IIIB breast cancer
1253142|NCT00946283|stage IIIC breast cancer
1253143|NCT00946283|stage IV breast cancer
1253144|NCT00946283|refractory multiple myeloma
1253145|NCT00946270|CC-4047
1253146|NCT00946270|Pomalidomide
1253147|NCT00946270|polycythemia vera
1253148|NCT00946270|essential thrombocythemia myelofibrosis
1253149|NCT00946257|Type 1 Diabetes Mellitus
1253150|NCT00946244|Early intervention
1253151|NCT00946244|Mother-child interaction
1253152|NCT00946244|Neurodevelopment
1253153|NCT00946244|Parenting
1253154|NCT00946244|Prematurity
1253155|NCT00946244|Preschool age
1253156|NCT00946231|Heart Failure
1253157|NCT00946231|BNP
1253158|NCT00946231|B-type natriuretic peptide
1253159|NCT00946231|home testing
1253160|NCT00946205|rectal prolapse
1253161|NCT00946205|laparoscopic rectopexy
1253162|NCT00946205|obstructed defecation
1253163|NCT00946192|Amenorrhea
1253164|NCT00946192|Adolescent
1253165|NCT00946192|Endurance
1253166|NCT00946192|Athletes
1253167|NCT00946192|Females
1253168|NCT00946192|Osteopenia
1253169|NCT00946192|Osteoporosis
1253170|NCT00946192|Estrogen
1253171|NCT00946179|Influenza
1253172|NCT00946179|Influenza virus vaccine
1253173|NCT00946179|Split virion
1253174|NCT00946166|pneumonia
1253175|NCT00946166|statins
1253176|NCT00946166|cytokines
1253177|NCT00946153|Carcinoma
1253178|NCT00946153|Hepatocellular
1253179|NCT00946140|Ovary
1253180|NCT00946140|MRI
1253181|NCT00946140|08-132
1253182|NCT00946127|Normal Pressure Hydrocephalus
1253183|NCT00946127|Communicating Hydrocephalus
1253184|NCT00946127|Gait disorder
1253185|NCT00946127|Cognition
1253186|NCT00946127|Shunt
1253187|NCT00946127|Endoscopic Third Ventriculostomy.
1253188|NCT00946101|randomized, double-blind, placebo-controlled
1253189|NCT00946062|low vision
1253190|NCT00946062|ophthalmology
1253191|NCT00946062|randomised controlled trial
1253192|NCT00946062|mobility
1253193|NCT00946062|orientation
1253194|NCT00946062|cane
1253195|NCT00946062|aged
1253196|NCT00946049|Checking clinical antibacterial effect of Vicryl Plus compared to conventional Vicryl in intraoral surgery
1253197|NCT00946049|Bacteria
1253198|NCT00946023|lymphoma
1253199|NCT00946023|non hodgkin lymphoma
1253200|NCT00946023|allogeneic
1253201|NCT00946023|bone marrow transplantation
1253202|NCT00946023|nonmyeloablative
1253203|NCT00946023|cyclophosphamide
1253204|NCT00946023|rituximab
1253205|NCT00946010|Hepatitis B
1253206|NCT00946010|Hepatitis C
1253208|NCT00946010|DNA level
1253209|NCT00946010|RNA level
1253210|NCT00946010|Taiwan
1253211|NCT00945997|misoprostol
1253212|NCT00945997|mifepristone
1253213|NCT00945997|medical abortion
1253214|NCT00945997|randomised controlled trial
1253215|NCT00945984|Localized renal cell carcinoma
1253216|NCT00945971|Attention Deficit Hyperactivity Disorder
1253217|NCT00945971|Catecholamine
1253218|NCT00945971|Children
1253219|NCT00945971|Physical Activity
1253220|NCT00945958|Glaucoma
1253221|NCT00945958|Ocular hypertension
1253222|NCT00945945|Osteoarthritis, Knee
1253223|NCT00945945|Pain
1253224|NCT00945932|asthma
1253225|NCT00945932|GW870086X
1253226|NCT00945932|Efficacy
1253227|NCT00945932|FEV1
1253228|NCT00945932|repeat-dose
1253229|NCT00945919|Oral morphine
1253230|NCT00945919|oxycodone
1253231|NCT00945919|OPANA
1253232|NCT00945919|Oxymorphone
1253233|NCT00945919|pain
1253234|NCT00945919|nociceptive
1253235|NCT00945919|neuropathic
1253236|NCT00945919|rotation
1253237|NCT00945919|titration
1253238|NCT00945919|mixed origin non-cancer pain
1253239|NCT00945906|Hereditary Factor XIII deficiency
1253240|NCT00945906|Factor XIII
1253241|NCT00945880|HCV
1253242|NCT00945880|Hepatitis C
1253243|NCT00945880|Hepatitis
1253244|NCT00945867|flecainide
1253245|NCT00945867|pharmacogenetics
1253246|NCT00945854|wholegrain cereals
1253247|NCT00945854|glycemic index
1253248|NCT00945854|metabolic syndrome
1253249|NCT00945854|insulin sensitivity
1253250|NCT00945841|influenza vaccine
1253251|NCT00945841|vaccine
1253252|NCT00945828|pediatric cancer, neurocognitive outcomes for pediatric cancer
1253253|NCT00945828|acute lymphoblastic leukemia
1253254|NCT00945828|central nervous system tumors
1253255|NCT00945828|lymphoma
1253256|NCT00945815|B-cell adult acute lymphoblastic leukemia
1253257|NCT00945815|L1 adult acute lymphoblastic leukemia
1253258|NCT00945815|L2 adult acute lymphoblastic leukemia
1253259|NCT00945815|recurrent adult acute lymphoblastic leukemia
1253260|NCT00945789|Asphyxia neonatorum
1253261|NCT00945789|Infants
1253262|NCT00945789|EEG
1253263|NCT00945789|Brain MRI
1253264|NCT00945789|Nitric oxide
1253265|NCT00945776|OSA
1253266|NCT00945776|CPAP
1253267|NCT00945763|Dental Pain
1253268|NCT00945737|hypercholesterolemia
1253269|NCT00945737|cholesterol
1253270|NCT00945737|soy
1253271|NCT00945711|dual diagnosis
1253272|NCT00945698|Stunting
1253273|NCT00945698|Growth failure
1253274|NCT00945698|Malnutrition
1253275|NCT00945698|Lipid based nutrient supplement
1253276|NCT00945698|LNS
1253277|NCT00945698|Prevention
1253278|NCT00945698|Malawi
1253279|NCT00945698|Sub-Saharan Africa
1253280|NCT00945698|Dietary supplementation
1253281|NCT00945698|Efficacy
1253282|NCT00945685|Skin Aging
1253283|NCT00945685|Skin Wrinkling
1253284|NCT00945672|Alzheimer's disease amyloid imaging antibody
1253285|NCT00945633|Obesity
1253286|NCT00945633|unhealthy weight gain
1253287|NCT00945620|Trans-abdominis block
1253288|NCT00945620|post-cesarean
1253289|NCT00945607|Complementary Medicine
1253290|NCT00945607|Alternative Medicine
1253291|NCT00945607|Breast Cancer
1253292|NCT00945594|flexible cystoscopy
1253293|NCT00945594|rigid cystoscopy
1253294|NCT00945594|bladder
1253295|NCT00945594|outcome assessment
1253296|NCT00945594|pain measurement
1253297|NCT00945581|Healthy Elderly volunteers
1253298|NCT00945568|QOL
1253299|NCT00945568|liver
1253300|NCT00945555|Antibacterials
1253301|NCT00945555|Classification of antibacterial agent
1253302|NCT00945555|Febrile neutropenia
1253303|NCT00945555|Turkey
1253304|NCT00945542|Trauma
1253305|NCT00945542|Coagulopathy
1253306|NCT00945542|Transfusion
1253307|NCT00945542|Plasma
1253308|NCT00945542|Massive Transfusion
1253309|NCT00945529|Fontan
1253310|NCT00945516|Metal stent
1253311|NCT00945516|Bile duct stricture
1253312|NCT00945516|Stent migration
1253313|NCT00945516|Feasibility
1253314|NCT00945516|Safety
1253315|NCT00945516|Removability
1253316|NCT00945503|Glycine Tranporter
1253317|NCT00945503|MRI
1253318|NCT00945503|PET
1253319|NCT00945490|Benign prostatic hyperplasia
1253320|NCT00945490|BPH
1253321|NCT00945490|Enlarged prostate
1253322|NCT00945451|stage IIIA non-small cell lung cancer
1253323|NCT00945451|stage IIIB non-small cell lung cancer
1253324|NCT00945451|stage II non-small cell lung cancer
1253325|NCT00945438|Influenza
1253326|NCT00945438|Influenza virus vaccine
1253327|NCT00945438|Split virion
1253328|NCT00945438|Intradermal
1253329|NCT00945425|Phase I
1253330|NCT00945425|Volunteer
1253331|NCT00945412|microdebrider tonsillotomy
1253332|NCT00945412|Post-tonsillectomy hemorrhage
1253333|NCT00945386|children
1253334|NCT00945386|critically ill
1253335|NCT00945386|furosemide
1253336|NCT00945386|acoustic emission
1253337|NCT00945373|rosacea
1253338|NCT00945373|telangiectasias
1253339|NCT00945373|topical treatment
1253340|NCT00945373|pulsed dye laser
1253341|NCT00945360|Leiomyoma
1253342|NCT00945360|perimenopause
1253343|NCT00945360|aromatase inhibitor
1253344|NCT00945347|Cystic fibrosis
1253345|NCT00945347|miglustat
1253346|NCT00945347|nasal instillation
1253347|NCT00945347|nasal potential difference
1253348|NCT00945334|Constipation predominant Irritable Bowel Syndrome
1253349|NCT00945308|Primary PCI
1253350|NCT00945308|Acute myocardial infarction
1253351|NCT00945308|Myocardial blush
1253352|NCT00945308|Primary coronary intervention in acute myocardial infarction
1253353|NCT00945308|focusing on the effect of the study drug on the immediate TIMI
1253354|NCT00945308|flow at the infarct related artery and on the myocardial
1253355|NCT00945308|perfusion evaluated by the TIMI myocardial perfusion grade or
1253356|NCT00945308|blush
1253357|NCT00945295|Cerebrovascular Accident/Rehabilitation
1253358|NCT00945295|Muscle Spasticity
1253359|NCT00945295|Botulinum Neurotoxin Type A
1253360|NCT00945295|Post-stroke focal upper limb spasticity
1253361|NCT00945282|IDX12899
1253362|NCT00945282|adaptive
1253363|NCT00945282|monotherapy
1253364|NCT00945282|pharmacokinetics
1253365|NCT00945282|Treatment-naive
1253366|NCT00945282|HIV-1
1253367|NCT00945282|GSK2248761
1253368|NCT00945282|NNRTI
1253369|NCT00945282|HIV Infections
1253370|NCT00945282|treatment naive
1253371|NCT00945256|metabolism
1253372|NCT00945256|exercise
1253373|NCT00945256|sodium nitroprusside
1253374|NCT00945243|SCDD
1253375|NCT00945230|Neurosurgical outcome
1253376|NCT00945230|Actigraphy
1253377|NCT00945230|Treatment Response Measurement
1253378|NCT00945217|Atherogenic dyslipidemia
1253379|NCT00945217|Non-HDL-C
1253380|NCT00945217|Postmenopausal women
1253381|NCT00945217|SAH gene family
1253382|NCT00945204|type 2 diabetes
1253383|NCT00945204|intermediate care
1253384|NCT00945204|primary care
1253385|NCT00945204|randomised controlled trial
1253386|NCT00945191|ovarian
1253387|NCT00945191|cancer
1253388|NCT00945191|metastatic
1253389|NCT00945191|locally
1253390|NCT00945191|advanced
1253391|NCT00945191|chemotherapy
1253392|NCT00945191|neoplasm
1253393|NCT00945178|Safety
1253394|NCT00945178|Tolerability
1253395|NCT00945178|Healthy
1253396|NCT00945178|Pharmacokinetics
1253397|NCT00945165|Continuous Glucose Monitoring System
1253398|NCT00945165|Exercise
1253399|NCT00945152|Elimination of MRSA in open wounds
1253400|NCT00945152|MRSA infected open wounds
1253401|NCT00945126|Allogeneic stem cell transplantation in pediatric patients
1253402|NCT00945126|CD3/CD19 depleted stem cells
1253403|NCT00945126|malignant and non-malignant high risk diseases
1253404|NCT00945113|pilot
1253405|NCT00945113|stammer
1253406|NCT00945113|stutter
1253407|NCT00945113|children
1253408|NCT00945113|randomised controlled trial
1253409|NCT00945113|RCT
1253410|NCT00945113|Speech and Language Therapy
1253411|NCT00945113|Stuttering
1253412|NCT00945100|Amblyopia
1253413|NCT00945100|patching
1253414|NCT00945100|occlusion
1253415|NCT00945087|bacteriophage
1253416|NCT00945087|bacteriophage preparation
1253417|NCT00945087|bacterial infection
1253418|NCT00945087|antibiotic-resistant infection
1253419|NCT00945087|multidrug-resistant bacteria
1253420|NCT00945087|MRSA
1253421|NCT00945074|Acupuncture
1253422|NCT00945074|Moxibustion
1253423|NCT00945074|Traditional Chinese Medicine
1253424|NCT00945074|Complementary Medicine
1253425|NCT00945074|Irritable Bowel Syndrome
1253426|NCT00945074|IBS
1253427|NCT00945061|ductal breast carcinoma in situ
1253428|NCT00945061|recurrent breast cancer
1253429|NCT00945061|invasive ductal breast carcinoma
1253430|NCT00945061|medullary ductal breast carcinoma with lymphocytic infiltrate
1253431|NCT00945061|mucinous ductal breast carcinoma
1253432|NCT00945061|papillary ductal breast carcinoma
1253433|NCT00945061|tubular ductal breast carcinoma
1253434|NCT00945061|male breast cancer
1253435|NCT00945022|General Surgery
1253436|NCT00944996|PACAP (Pituitary Adenylate Cyclase Activating Polypeptide)
1253437|NCT00944996|Major Depression
1253438|NCT00944996|Receptors
1253439|NCT00944996|Gene polymorphism
1253440|NCT00944996|PACAP signaling system
1253441|NCT00944996|Etiology of major depression
1253442|NCT00944996|Mechanism of antidepressants action
1253443|NCT00944996|PACAP receptors gene polymorphism
1253444|NCT00944996|Pathogenesis of major depression
1253445|NCT00944996|Responsiveness to the antidepressant drugs
1253446|NCT00944983|Hypertension
1253447|NCT00944983|Hypotension
1253448|NCT00944983|Clinical Validation
1253449|NCT00944983|Blood Pressure Accuracy
1253450|NCT00944983|ISO 81600 Standard
1253451|NCT00944983|British Hypertension Society
1253452|NCT00944983|European Society of Hypertension
1253453|NCT00944983|International Protocol
1253454|NCT00944970|Coronary artery disease
1253455|NCT00944970|Angina
1253456|NCT00944970|Anginal symptoms
1253457|NCT00944970|Ischemic heart disease
1253458|NCT00944970|Ischemia
1253459|NCT00944970|Single photon emission computed tomography
1253460|NCT00944970|Pharmacologic stress
1253461|NCT00944970|Myocardial perfusion imaging
1253462|NCT00944970|Suspected coronary artery disease
1253463|NCT00944970|known coronary artery disease
1253464|NCT00944970|typical or atypical anginal symptoms
1253465|NCT00944957|Raltegravir
1253466|NCT00944957|efavirenz
1253467|NCT00944957|anxiety
1253468|NCT00944957|depression
1253469|NCT00944957|sleep quality
1253470|NCT00944957|HIV
1253471|NCT00944957|NNRTI
1253472|NCT00944957|Tritherapy
1253473|NCT00944957|compliance
1253474|NCT00944957|stocrin
1253475|NCT00944957|treatment experienced
1253476|NCT00944944|CORPUS UTERI,
1253477|NCT00944944|ENDOMETRIUM
1253478|NCT00944944|FALLOPIAN TUBE
1253479|NCT00944944|OVARY
1253480|NCT00944944|VAGINA
1253481|NCT00944944|Lymphedema
1253482|NCT00944944|Questionnaire
1253483|NCT00944944|Quality of Life
1253484|NCT00944944|09-077
1253485|NCT00944944|Fallopian Tubes
1253486|NCT00944931|Cerebral Cortex
1253487|NCT00944931|Cognition
1253488|NCT00944931|Motor Cortex
1253489|NCT00944931|Cognitive Enhancement
1253490|NCT00944931|Prefrontal Cortex
1253491|NCT00944931|Healthy Volunteer
1253492|NCT00944918|Breast Cancer
1253493|NCT00944879|HIV
1253494|NCT00944879|vaccine
1253495|NCT00944879|prevention
1253496|NCT00944879|HPV
1253497|NCT00944879|adolescents
1253498|NCT00944853|zinc supplement
1253499|NCT00944853|prevention
1253500|NCT00944853|zinc deficiency
1253501|NCT00944853|plasma zinc concentration
1253502|NCT00944840|Intermittent Preventive Treatment
1253503|NCT00944840|Home based management of malaria
1253504|NCT00944827|Green Tea Extract
1253505|NCT00944827|Catechins
1253506|NCT00944827|Statin
1253507|NCT00944827|atorvastatin
1253508|NCT00944827|body composition
1253509|NCT00944827|visceral fat
1253510|NCT00944827|steatosis
1253511|NCT00944827|oxidative stress
1253512|NCT00944827|quality of life
1253513|NCT00944827|OGTT
1253514|NCT00944827|OGIS
1253515|NCT00944827|ISI matsuda
1253516|NCT00944814|Lipid-based nutrient supplement
1253517|NCT00944814|Prevention of malnutrition
1253518|NCT00944814|Prevention of micronutrient deficiencies
1253519|NCT00944814|Zinc
1253520|NCT00944801|glioblastoma
1253521|NCT00944801|first-line
1253522|NCT00944801|clinical trial
1253523|NCT00944801|PEG-liposomal doxorubicin
1253524|NCT00944801|temozolomide
1253525|NCT00944801|radiotherapy
1253526|NCT00944801|phase 1
1253527|NCT00944801|phase 2
1253528|NCT00944788|physical activity
1253529|NCT00944788|aging
1253530|NCT00944788|inpatients
1253531|NCT00944788|quality of life
1253532|NCT00944788|depression
1253533|NCT00944775|Exercise
1253534|NCT00944775|Dialysis
1253535|NCT00944775|Non-invasive cardiac measures
1253536|NCT00944775|Exercise trained patients
1253537|NCT00944775|Controls
1253538|NCT00944762|Stroke
1253539|NCT00944749|H- ATG
1253540|NCT00944749|Anti -Thymocyte Globulin
1253541|NCT00944749|Lymphocyte Immune Globulin
1253542|NCT00944749|Aplastic Anemia
1253543|NCT00944736|Crohn's Disease
1253544|NCT00944736|Pediatric
1253545|NCT00944736|VSL#3
1253546|NCT00944736|Permeability
1253547|NCT00944736|Probiotic
1253548|NCT00944736|Zonulin
1253549|NCT00944723|zinc fortification
1253550|NCT00944723|zinc supplementation
1253551|NCT00944723|plasma zinc concentration
1253552|NCT00944710|Amblyopia
1253553|NCT00944710|atropine
1253554|NCT00944710|Plano lens
1253555|NCT00944684|Chronic hepatitis C
1253556|NCT00944684|Antiviral treatment
1253557|NCT00944684|Ribavirin
1253558|NCT00944684|Sustained virological response
1253559|NCT00944684|Hemolytic anemia
1253560|NCT00944684|Erythropoetin
1253561|NCT00944658|Ankylosing spondylitis
1253562|NCT00944658|Imaging
1253563|NCT00944580|MAGE-A1
1253564|NCT00944580|MAGE-A3
1253565|NCT00944580|NY-ESO-1
1253566|NCT00944580|antigen
1253567|NCT00944580|vaccine
1253568|NCT00944580|dendritic cells
1253569|NCT00944580|immunohistochemistry
1253570|NCT00944580|immunology
1253571|NCT00944567|Primary Mediastinal B-Cell Lymphoma
1253572|NCT00944567|Positron emission tomography
1253573|NCT00944554|Relapse
1253574|NCT00944554|Smoking Cessation
1253575|NCT00944554|Substance Abuse
1253576|NCT00944541|maraviroc
1253577|NCT00944541|immune restoration
1253578|NCT00944541|treatment intensification
1253579|NCT00944528|Cancer of Breast
1253580|NCT00944528|Cancer of the Breast
1253581|NCT00944528|Neoplasms, Breast
1253582|NCT00944528|Single dose radiation
1253583|NCT00944528|Radiotherapy
1253584|NCT00944528|Preoperative
1253585|NCT00944515|sinusitis
1253586|NCT00944515|azithromycin
1253587|NCT00944502|Neuralgy
1253588|NCT00944502|Dexamethasone
1253589|NCT00944502|Complex Vitamins
1253590|NCT00944502|Injection
1253591|NCT00944502|Symptoms of neuralgy of various origins
1253592|NCT00944489|Hypertension
1253593|NCT00944489|Health-Related Quality of Life Adherence to the antihypertension treatment
1253594|NCT00944489|Ambulatory Patients
1253595|NCT00944489|MINICHAL score
1253596|NCT00944489|Treatment Adherence Scale (MMAS)
1253597|NCT00944489|Quality of life
1253598|NCT00944489|Adherence to treatment
1253599|NCT00944476|Sarcoma
1253600|NCT00944476|soft tissue
1253601|NCT00944476|MRI
1253602|NCT00944476|Questionnaire
1253603|NCT00944476|09-078
1253604|NCT00944463|advanced pancreatic cancer
1253605|NCT00944463|gemcitabine
1253606|NCT00944463|simvastatin
1253607|NCT00944463|placebo
1253608|NCT00944437|Ventilation, Mechanical
1253609|NCT00944437|Positive-Pressure Respiration
1253610|NCT00944437|Continuous Positive Airway Pressure
1253611|NCT00944424|Vitamin D in patients with metastatic breast cancer
1253612|NCT00943358|influenza
1253613|NCT00943358|immunogenicity
1253614|NCT00943358|vaccine
1253615|NCT00943345|GI
1253616|NCT00943345|gastrointestinal
1253617|NCT00943345|permeability
1253618|NCT00943345|indometacin
1253619|NCT00943345|indomethacin
1253620|NCT00943345|coeliac
1253621|NCT00943332|Orthopedic Procedures
1253622|NCT00943332|Fracture Fixation, Internal
1253623|NCT00943332|Fracture Fixation, External
1253624|NCT00943332|femur fracture
1253625|NCT00943332|pediatrics
1253626|NCT00943319|Cancers of the blood
1253627|NCT00943306|Homozygous
1253628|NCT00943306|Familial
1253629|NCT00943306|Hypercholesterolemia
1253630|NCT00943306|MTP
1253631|NCT00943306|Apheresis
1253632|NCT00943306|lomitapide
1253633|NCT00943306|Homozygous Familial Hypercholesterolemia (HoFH)
1253634|NCT00944398|Zinc fortification
1253635|NCT00944398|Plasma zinc concentration
1253636|NCT00944398|Assessment of zinc status
1253637|NCT00944372|Tumor
1253638|NCT00944372|somatostatin receptor
1253639|NCT00944359|zinc supplementation
1253640|NCT00944359|diarrhea management
1253641|NCT00944359|zinc deficiency
1253642|NCT00944359|malaria
1253643|NCT00944333|second generation DES
1253644|NCT00944333|clopidogrel
1253645|NCT00944333|dual platelet therapy
1253646|NCT00944333|patients with documented silent ischemia
1253647|NCT00944333|unstable angina pectoris (Braunwald Classification)
1253648|NCT00944333|Diagnosis of angina pectoris (CCS)
1253653|NCT00944294|Coronary artery disease
1253654|NCT00944294|Angina
1253655|NCT00944294|Anginal symptoms
1253656|NCT00944294|Ischemic heart disease
1253657|NCT00944294|Ischemia
1253658|NCT00944294|Single photon emission computed tomography
1253659|NCT00944294|Pharmacologic stress
1253660|NCT00944294|Myocardial perfusion imaging
1253661|NCT00944294|typical or atypical anginal symptoms
1253662|NCT00944294|Suspected coronary artery disease
1253663|NCT00944294|known coronary artery disease
1253664|NCT00944281|point-of-use fortification
1253665|NCT00944281|zinc supplement
1253666|NCT00944281|lipid-based nutrient supplement
1253667|NCT00944281|zinc deficiency
1253668|NCT00944281|micronutrient deficiency
1253669|NCT00944281|anemia
1253670|NCT00944268|Passiflora, Crataegus and Salix
1253671|NCT00944268|Mild and Moderate anxiety
1253672|NCT00944268|Tablet
1253673|NCT00944268|To evaluate the efficacy and tolerability of the combination
1253674|NCT00944229|Heart Failure
1253675|NCT00944229|omega 3
1253676|NCT00944229|lovaza
1253677|NCT00944229|VO2 max
1253678|NCT00944216|keratosis pilaris
1253679|NCT00944203|jellyfish
1253680|NCT00944203|jellyfish venom
1253681|NCT00944203|jellyfish dermatitis
1253682|NCT00944203|jellyfish stings
1253683|NCT00944203|Ipomea pes-caprae
1253684|NCT00944190|pain
1253685|NCT00944190|fatigue
1253686|NCT00944190|depression
1253687|NCT00944190|cognitive difficulties
1253688|NCT00944190|self-management
1253689|NCT00944151|pain
1253690|NCT00944151|UCSD
1253691|NCT00944151|catheter
1253692|NCT00944151|nerve block
1253693|NCT00944151|hernia
1253694|NCT00944151|post-surgery pain
1253695|NCT00944151|abdominal pain
1253696|NCT00944151|pelvic pain
1253697|NCT00944151|Transversus abdominal plane
1253698|NCT00944151|Hernia Repair
1253699|NCT00944151|Transversus Abdominal Plane Block
1253700|NCT00944138|Obesity
1253701|NCT00944138|meditation
1253702|NCT00944138|chronic kidney disease
1253703|NCT00944112|Intensive care
1253704|NCT00944112|Blood Transfusion
1253705|NCT00944112|Anemia
1253706|NCT00944099|intervention studies
1253707|NCT00944099|feeding behavior
1253708|NCT00944099|eating frequency
1253709|NCT00944099|weight loss
1253710|NCT00944099|dietary intake
1253711|NCT00944086|Recruitment
1253712|NCT00944086|Oxygen Concentration
1253713|NCT00944086|pneumoperitoneum
1253714|NCT00944086|laparoscopy
1253715|NCT00944073|H1N1, influenza A viruses, vaccine, infants, children
1253716|NCT00944047|invasive breast cancer
1253717|NCT00944047|HER2
1253718|NCT00944047|primary breast cancer
1253719|NCT00944047|neo-adjuvant therapy
1253720|NCT00944047|Trastuzumab
1253721|NCT00944047|Nab-paclitaxel
1253722|NCT00944034|Meningococcal meningitis
1253723|NCT00944034|prevention
1253724|NCT00944034|vaccination
1253725|NCT00944034|toddler
1253726|NCT00944021|Early Bactericidal Activity
1253727|NCT00944021|EBA
1253728|NCT00944021|Pulmonary Tuberculosis
1253729|NCT00944021|PA-824
1253730|NCT00944021|pretomanid
1253731|NCT00944008|Acute Lymphoblastic Leukemia (ALL)
1253732|NCT00944008|Depocyte®
1253733|NCT00944008|Neuromeningeal relapse
1253734|NCT00944008|Between 16 and 30 years old
1253735|NCT00944008|Standard risk
1253736|NCT00943995|End Stage Kidney Disease
1253737|NCT00943995|Kidney Failure
1253738|NCT00943995|Short stature
1253739|NCT00943995|Growth Hormone therapy
1253740|NCT00943982|Cystoid Macular Edema
1253741|NCT00943982|Intermediate Uveitis
1253742|NCT00943982|Uveitis
1253743|NCT00943982|OCT
1253744|NCT00943982|Interferon-Gamma (IFN-Gamma)
1253745|NCT00943969|obesity
1253746|NCT00943969|gastric bypass
1253747|NCT00943969|morphine
1253748|NCT00943969|pharmacokinetic
1253749|NCT00943969|absorption
1253750|NCT00943956|stage III prostate cancer
1253751|NCT00943956|stage IV prostate cancer
1253752|NCT00943943|acute myelogenous leukemia
1253753|NCT00943943|AML
1253754|NCT00943943|Leukemia
1253755|NCT00943943|myeloid leukemias
1253756|NCT00943943|mutated fms-like tyrosine kinase receptor-3
1253757|NCT00943943|FLT3 Mutations
1253758|NCT00943943|G-CSF
1253759|NCT00943943|Granulocyte Colony Stimulating Factor
1253760|NCT00943943|Filgrastim
1253761|NCT00943943|Neupogen
1253762|NCT00943943|Plerixafor
1253763|NCT00943943|Mobozil
1253764|NCT00943943|Sorafenib
1253765|NCT00943943|BAY 43-9006
1253766|NCT00943904|urinary leakage associated with urinary urgency
1253767|NCT00943904|unable to fully empty bladder
1253768|NCT00943904|Comparison: Motor&Sensory Response to Interstim Stimulation
1253769|NCT00943878|H1N1, influenza A viruses, vaccine, elderly, TIV
1253770|NCT00943865|metabolic syndrome
1253771|NCT00943865|lifestyle
1253772|NCT00943865|exercise
1253773|NCT00943865|endothelial dysfunction
1253774|NCT00943865|insulin sensitivity
1253775|NCT00943865|lipids
1253776|NCT00943839|stage IV renal cell cancer
1253777|NCT00943813|communication
1253778|NCT00943813|survey
1253779|NCT00943813|video
1253780|NCT00943813|09-043
1253781|NCT00943800|Appropriate candidate for transplantation
1253782|NCT00943800|An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.
1253783|NCT00943774|Physiology
1253784|NCT00943774|Phenotype
1253785|NCT00943774|Genetics
1253786|NCT00943774|Genomics
1253787|NCT00943774|Stress
1253788|NCT00943774|Baroreflex
1253789|NCT00943774|Blood Pressure
1253790|NCT00943774|Arterial stiffness
1253791|NCT00943761|hepatitis C
1253792|NCT00943735|Overactive Bladder Incontinence Adherence Behavioral interventions
1253793|NCT00943709|hyperglycemia
1253794|NCT00943709|recurrent adult acute lymphoblastic leukemia
1253795|NCT00943709|untreated adult acute lymphoblastic leukemia
1253796|NCT00943709|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1253797|NCT00943709|adult acute myeloid leukemia with inv(16)(p13;q22)
1253798|NCT00943709|adult acute myeloid leukemia with t(15;17)(q22;q12)
1253799|NCT00943709|adult acute myeloid leukemia with t(16;16)(p13;q22)
1253800|NCT00943709|adult acute myeloid leukemia with t(8;21)(q22;q22)
1253801|NCT00943709|recurrent adult acute myeloid leukemia
1253802|NCT00943709|untreated adult acute myeloid leukemia
1253803|NCT00943670|MBC
1253804|NCT00943670|TDM1
1253805|NCT00943670|Armed Herceptin
1253806|NCT00943670|Herceptin
1253807|NCT00943670|Trastuzumab emtansine
1253808|NCT00943644|MBI
1253809|NCT00943644|Breast
1253810|NCT00943644|Breast Cancer
1253811|NCT00943631|H1N1, influenza A viruses, vaccine, elderly
1253812|NCT00943618|Smoking Cessation
1253813|NCT00943618|Nicotine Withdrawal
1253814|NCT00943618|Smoking Reduction
1253815|NCT00943618|Varenicline
1253816|NCT00943618|Chantix
1253817|NCT00943618|Bupropion
1253818|NCT00943618|Zyban
1253819|NCT00943605|Mastectomy
1253820|NCT00943605|PlasmaBlade
1253821|NCT00943605|Electrosurgery
1253822|NCT00943605|PEAK Surgical
1253823|NCT00943605|Medtronic Advanced Energy
1253824|NCT00943605|Medtronic
1253825|NCT00943592|Melphalan
1253826|NCT00943592|Alemtuzumab
1253827|NCT00943592|Clofarabine
1253828|NCT00943579|autism
1253829|NCT00943579|autistic disorder
1253830|NCT00943579|tetrahydrobiopterin
1253831|NCT00943579|sapropterin
1253832|NCT00943579|treatment
1253833|NCT00943566|Pain
1253834|NCT00943566|Cancer
1253835|NCT00943566|Morphine
1253836|NCT00943553|AML
1253837|NCT00943540|pharmacokinetics
1253838|NCT00943540|single dose
1253839|NCT00943540|raltegravir
1253840|NCT00943540|Treatment experienced
1253841|NCT00943527|Breast
1253842|NCT00943527|Menstrual Cycle
1253843|NCT00943527|Breast Cancer
1253844|NCT00943527|Hormone
1253845|NCT00943527|MBI
1253846|NCT00943527|Molecular Breast Imaging
1253847|NCT00943527|Breast Imaging
1253854|NCT00943488|influenza A viruses, H1N1, elderly
1253855|NCT00943475|DPNB, pain, hemodynamics effects, circumcision
1253856|NCT00943449|Hepatocellular Carcinoma
1253857|NCT00943449|Sorafenib
1253858|NCT00943449|HDAC
1253859|NCT00943449|4SC-201
1253860|NCT00943449|Phase II
1253861|NCT00943449|Resminostat
1253862|NCT00943436|Exercise
1253863|NCT00943436|Sedentary
1253864|NCT00943436|Energy Expenditure
1253865|NCT00943436|Energy Balance
1253866|NCT00943436|Macronutrient Intake
1253867|NCT00943436|Energy and Macronutrient intake
1253868|NCT00943436|Exercise and Energy Balance
1253869|NCT00943423|stage I adult Hodgkin lymphoma
1253870|NCT00943423|stage II adult Hodgkin lymphoma
1253871|NCT00943410|HER2-positive breast cancer
1253872|NCT00943410|inflammatory breast cancer
1253873|NCT00943410|recurrent breast cancer
1253874|NCT00943410|stage IIIA breast cancer
1253875|NCT00943410|stage IIIB breast cancer
1253876|NCT00943410|stage IIIC breast cancer
1253877|NCT00943410|stage IV breast cancer
1253878|NCT00943293|GVHD
1253879|NCT00943280|probability of patient participation in each of the Groups 1, 2 and 3.
1253880|NCT00943280|Identification of factors predicting poor participation in screening for Barrett's esophagus.
1253881|NCT00943267|Activated Protein C
1253882|NCT00943267|Lipopolysaccharides
1253883|NCT00943267|Inflammation, Pulmonary
1253884|NCT00943254|Metabolic Cardiovascular Syndrome
1253885|NCT00943241|Breast
1253886|NCT00943241|Breast Cancer
1253887|NCT00943241|MBI
1253888|NCT00943241|Molecular Breast Imaging
1253889|NCT00943241|Molecular Imaging
1253890|NCT00943228|Renal transplantation
1253891|NCT00943228|Adequate exposure
1253892|NCT00943228|Acute rejection
1253893|NCT00943228|mycophenolate mofetil
1253894|NCT00943228|immunosuppression
1253895|NCT00943215|CALERIE II Follow-up
1253896|NCT00943202|H1N1, influenza A viruses, TIV, vaccine, infants, children
1253897|NCT00943189|Fetal anomalies scan at the time of NT study
1253898|NCT00943176|Fatigue
1253899|NCT00943163|cyclorotation
1253900|NCT00943163|pupil
1253901|NCT00943163|laser refractive surgery
1253902|NCT00943150|Abdominoplasty
1253903|NCT00943150|PlasmaBlade
1253904|NCT00943150|Electrosurgery
1253905|NCT00943150|PEAK Surgical
1253906|NCT00943150|Medtronic Advanced Energy
1253907|NCT00943150|Medtronic
1253908|NCT00943111|Gaucher disease,
1253909|NCT00943111|Genz-112638,
1253910|NCT00943111|beta-glucosidase,
1253911|NCT00943111|acid ß-glucosidase,
1253912|NCT00943111|glucocerebrosidase,
1253913|NCT00943111|glucosylceramide,
1253914|NCT00943111|D-glucosyl-N-acylsphingosine glucohydrolase,
1253915|NCT00943111|substrate reduction therapy
1253916|NCT00943085|Early Signs of Bipolar Disorder
1253917|NCT00943085|High Risk Youth
1253918|NCT00943085|Adolescence
1253919|NCT00943085|Childhood
1253920|NCT00943072|Macular edema
1253921|NCT00943072|Retinal vein occlusion
1253922|NCT00943072|CRVO
1253923|NCT00943072|VEGF Trap-Eye
1253924|NCT00943072|best-corrected visual acuity
1253925|NCT00943072|Regeneron
1253926|NCT00943072|COPERNICUS
1253927|NCT00943059|Mitochondrial function
1253928|NCT00943059|Diabetes
1253929|NCT00943059|Cardiomyopathy
1253930|NCT00943059|insulin resistance
1253931|NCT00943059|lipid lowering
1253932|NCT00943059|triglycerides
1253933|NCT00943059|Acipimox
1253934|NCT00943046|leads
1253935|NCT00943046|pacemaker
1253936|NCT00943046|efficacy
1253937|NCT00943046|safety
1253938|NCT00943033|MBCT
1253939|NCT00943033|Mindfulness-Based Cognitive Therapy
1253940|NCT00943033|Mindfulness
1253941|NCT00943033|Meditation
1253942|NCT00943033|Relapse Prevention
1253943|NCT00943033|Recurrent Depression
1253944|NCT00943033|Depression
1253945|NCT00943033|Major Depressive Disorder
1253946|NCT00943020|Dietary supplement
1253947|NCT00943020|Carbohydrate loading
1253948|NCT00943020|Healthy volunteers
1253949|NCT00943020|Anaesthesia
1253950|NCT00943020|Surgery
1253951|NCT00943020|Glutamine
1253952|NCT00942994|Hypertension
1253953|NCT00942994|Aliskiren
1253954|NCT00942994|Amlodipine
1253955|NCT00942994|HCTZ
1253956|NCT00942994|Systolic blood pressure
1253957|NCT00942994|Diastolic blood pressure
1253958|NCT00942994|Stage II
1253959|NCT00942994|Combination
1253960|NCT00942981|PET Study
1253961|NCT00942981|(18F) Fallypride
1253962|NCT00942981|(11C)NNC-112
1253963|NCT00942981|Schizoaffective Disorder
1253964|NCT00942981|Schizophrenia
1253965|NCT00942981|Healthy Volunteer
1253966|NCT00942981|HV
1253967|NCT00942929|anorexia nervosa
1253968|NCT00942929|adolescents
1253969|NCT00942929|lung function tests
1253970|NCT00942929|refeeding
1253971|NCT00942916|Make sure the difference of the serum inflammatory marker between the two groups
1253972|NCT00942903|HME
1253973|NCT00942903|Provox
1253974|NCT00942903|voice prosthesis
1253975|NCT00942903|laryngectomy
1253976|NCT00942890|Case Management
1253977|NCT00942890|Amputation
1253978|NCT00942890|Muscle strength
1253979|NCT00942890|phantom limb pain
1253986|NCT00942851|Dystonia
1253987|NCT00942851|Blepharospasm
1253988|NCT00942851|Botulinum Toxin
1253989|NCT00942851|Treatment
1253990|NCT00942851|Clinical Trial
1253991|NCT00942851|Focal Dystonia
1253992|NCT00942838|Recurrent Ovarian Carcinoma
1253993|NCT00942838|Cancer
1253994|NCT00942825|NSCL
1253995|NCT00942825|non-squamous non small cell lung cancer
1253996|NCT00942825|Lung Cancer
1253997|NCT00942825|Lung
1253998|NCT00942825|non-squamous
1253999|NCT00942825|metastatic
1254000|NCT00942825|pleural effusion
1254001|NCT00942825|Stage IIIb
1254002|NCT00942825|Stage IV
1254003|NCT00942825|NSCLC
1254004|NCT00942812|Children
1254005|NCT00942812|Recovery
1254006|NCT00942812|Diarrhea Pack
1254007|NCT00942812|Social Marketing
1254008|NCT00942799|Genz-644282
1254009|NCT00942799|Topoisomerase I inhibitors
1254010|NCT00942799|Top1
1254011|NCT00942799|solid tumors
1254012|NCT00942799|dose-escalation
1254013|NCT00942799|pharmacokinetic (PK)
1254014|NCT00942799|MTD (Maximum Tolerated Dose)
1254015|NCT00942799|oncology
1254016|NCT00942799|cancer
1254017|NCT00942786|natriuretic peptides
1254018|NCT00942786|emergency non-cardiac surgery
1254019|NCT00942773|Healthy volunteer
1254020|NCT00942747|temsirolimus, primary CNS lymphoma, PCNSL, salvage treatment
1254021|NCT00942734|Head and Neck
1254022|NCT00942734|Squamous Cell Carcinoma
1254023|NCT00942734|RAD001
1254024|NCT00942734|Erlotinib
1254025|NCT00942734|Everolimus
1254026|NCT00942734|OSI-774
1254027|NCT00942734|Tarceva
1254028|NCT00942721|Web-based Intervention
1254029|NCT00942721|CBT Treatment
1254030|NCT00942708|Pulmonary Arterial Hypertension
1254031|NCT00942708|Pulmonary Hypertension
1254032|NCT00942695|pistachio
1254033|NCT00942695|nuts
1254034|NCT00942695|energy value
1254035|NCT00942695|cardiovascular disease
1254036|NCT00942695|phytonutrient
1254037|NCT00942695|gene expression
1254038|NCT00942695|energy value of pistachio nuts
1254039|NCT00942682|sorafenib
1254040|NCT00942682|RAD001
1254041|NCT00942669|Sleep Apnea Syndrome
1254042|NCT00942669|SAS
1254043|NCT00942669|SleepStrip OTC
1254044|NCT00942656|trans fatty acids
1254045|NCT00942656|ruminant
1254046|NCT00942656|cardiovascular disease
1254047|NCT00942630|percutaneous
1254048|NCT00942630|transhepatic
1254049|NCT00942630|biliary
1254050|NCT00942630|drainage
1254051|NCT00942630|cholangioscopy
1254052|NCT00942617|platelet aggregation
1254053|NCT00942617|granule secretion
1254054|NCT00942617|thromboxane production
1254055|NCT00942617|cyclooxygenase-1
1254056|NCT00942617|ATP release
1254057|NCT00942617|aspirin resistance
1254058|NCT00942617|platelet activation
1254059|NCT00942617|flow cytometry
1254060|NCT00942617|Platelet aggregation in healthy volunteers
1254061|NCT00942604|Peplin
1254062|NCT00942604|Actinic keratosis
1254063|NCT00942604|PEP005
1254064|NCT00942591|multiple sclerosis
1254065|NCT00942591|interferon beta
1254066|NCT00942591|atorvastatin
1254067|NCT00942578|Dual Antiangiogenic Combination Therapy for mCRPC
1254068|NCT00942578|Efficacy and Toxicity Profile
1254069|NCT00942578|Single Stage Phase 2 With Early Stopping, Run In Phase For Toxicity
1254070|NCT00942578|Correlative Measurements
1254071|NCT00942578|Overall Survival Assessment
1254072|NCT00942578|Metastatic Prostate Cancer
1254073|NCT00942578|Prostate Cancer
1254074|NCT00942565|Open gynecological surgery
1254075|NCT00942539|Neonates
1254076|NCT00942526|esophageal cancer
1254077|NCT00942526|anastomotic leakage
1254078|NCT00942526|Prevention of anastomotic leakage after esophageal surgery
1254079|NCT00942513|substrate absorption
1254080|NCT00942513|substrate oxidation
1254081|NCT00942513|glucose regulation
1254082|NCT00942513|whey protein
1254083|NCT00942513|soy protein
1254084|NCT00942513|sucrose
1254085|NCT00942513|fructose
1254086|NCT00942513|lactose
1254087|NCT00942500|Post-conditioning
1254088|NCT00942500|ST-elevation myocardial infarction
1254089|NCT00942500|Angioplasty, Transluminal, Percutaneous Coronary
1254090|NCT00942487|arterial hypertension
1254091|NCT00942474|The focus of the study is to assess the ability of the nerve access tool to facilitate nerve lead placement
1254092|NCT00942461|a-defensins
1254093|NCT00942461|TLRs
1254094|NCT00942461|Inflammatory Cytokines
1254095|NCT00942461|CRP
1254096|NCT00942461|No metastases
1254097|NCT00942461|No other obvious inflammation
1254098|NCT00942461|No chronic diseases
1254099|NCT00942435|YM150
1254100|NCT00942435|Bleeding
1254101|NCT00942435|VTE
1254102|NCT00942435|FXa inhibitor
1254103|NCT00942435|Deep Vein Thrombosis
1254104|NCT00942435|Venous thromboembolism
1254105|NCT00942422|monoclonal gammopathy of undetermined significance
1254106|NCT00942422|smoldering multiple myeloma
1254107|NCT00942396|Mammography
1254108|NCT00942383|liver tumor
1254109|NCT00942383|liver tumors
1254110|NCT00942383|liver cancer
1254111|NCT00942383|hepatocellular carcinoma
1254112|NCT00942383|metastatic colorectal cancer
1254113|NCT00942383|metastatic cancer to the liver
1254114|NCT00942383|metastatic cancer
1254115|NCT00942383|metastatic neuroendocrine cancer
1254116|NCT00942383|liver
1254117|NCT00942383|liver surgery
1254118|NCT00942383|radiofrequency ablation
1254119|NCT00942383|microwave ablation
1254120|NCT00942370|mechanography
1254121|NCT00942370|electromyography
1254122|NCT00942370|effort cough
1254123|NCT00942344|Amlodipine
1254124|NCT00942344|Losartan
1254125|NCT00942344|Hypertension
1254126|NCT00942318|Type 2 Diabetes Mellitus
1254127|NCT00942318|Continuous subcutaneous insulin infusion
1254128|NCT00942318|Insulin external pump
1254129|NCT00942318|Multiple daily injections
1254130|NCT00942318|Basal-bolus regimen
1254131|NCT00942318|Education
1254132|NCT00942305|Allogeneic stem cell transplant
1254133|NCT00942305|CMV seropositive (R+)
1254134|NCT00942305|transplant
1254135|NCT00942305|Allogeneic stem cell transplant recipients who were CMV seropositive (R+) at the time of transplant will be eligible for enrollment
1254136|NCT00942292|Hepatic
1254137|NCT00942292|colorectal
1254138|NCT00942292|metastases
1254139|NCT00942292|TPN
1254140|NCT00942292|Fish oil
1254141|NCT00942253|RLS
1254142|NCT00942253|Muscle
1254143|NCT00942253|Dialysis
1254144|NCT00942253|exercise
1254145|NCT00942253|dopamine agonist
1254146|NCT00942253|Sleep
1254147|NCT00942227|Sciatica
1254148|NCT00942227|Radiculopathy
1254149|NCT00942227|Physical therapy modalities
1254150|NCT00942227|Rehabilitation
1254151|NCT00942214|Multiple sclerosis
1254152|NCT00942214|natalizumab
1254153|NCT00942214|pharmacogenomics
1254154|NCT00942201|Asthma
1254155|NCT00942201|Dexamethasone
1254156|NCT00942201|Emergency Department
1254157|NCT00942188|Diabetes
1254158|NCT00942188|Type 2 Diabetes
1254159|NCT00942175|Pharmacology
1254160|NCT00942175|Stomach Ulcer
1254161|NCT00942175|Esophagitis, Peptic
1254162|NCT00942175|Zollinger-Ellison Syndrome
1254163|NCT00942175|Platelet function
1254164|NCT00942175|PPI
1254165|NCT00942175|clopidogrel
1254166|NCT00942175|Pharmacokinetics and Pharmacodynamics
1254167|NCT00942162|PREDICT
1254168|NCT00942162|ASCI
1254169|NCT00942162|Tumor antigen
1254170|NCT00942162|Melanoma
1254171|NCT00942162|Immunotherapeutic
1254172|NCT00942149|Infants
1254173|NCT00942149|Daptomycin
1254174|NCT00942136|HIV
1254175|NCT00942136|GSK1349572
1254176|NCT00942136|omeprazole
1254177|NCT00942136|Prilosec
1254178|NCT00942136|supratherapeutic dose
1254179|NCT00942136|pharmacokinetics
1254180|NCT00942136|drug interaction
1254181|NCT00942136|HIV Infections
1254182|NCT00942110|Postprandial glucose, lipid metabolism
1254183|NCT00942110|humoral factors
1254184|NCT00942097|Homeopathy
1254185|NCT00942097|overweight
1254186|NCT00942097|obesity
1254187|NCT00942097|mental disorder
1254188|NCT00942097|pregnancy
1254189|NCT00942097|Overweight pregnant women with suspicious mental disorder
1254190|NCT00942084|HSV
1254191|NCT00942084|Acyclovir
1254192|NCT00942084|Pharmacokinetics
1254193|NCT00942084|Neonate
1254194|NCT00942084|Premature
1254195|NCT00942084|Sepsis
1254196|NCT00942071|Influenza
1254197|NCT00942071|Vaccine
1254198|NCT00942058|biological markers
1254199|NCT00942058|CA9 protein
1254200|NCT00942058|metastatic conventional renal cell cancer
1254201|NCT00942058|kidney cancer
1254202|NCT00942045|cervical spine
1254203|NCT00942045|ACDF
1254204|NCT00942045|biologics
1254205|NCT00942045|fusion rates
1254206|NCT00942019|BMI
1254207|NCT00942019|obesity
1254208|NCT00942019|CO
1254209|NCT00942019|tobacco smoking
1254210|NCT00942019|adolescents
1254211|NCT00942006|Lyme neuroborreliosis
1254212|NCT00942006|Lyme borreliosis
1254213|NCT00942006|erythema migrans
1254214|NCT00942006|doxycycline treatment
1254215|NCT00942006|ceftriaxone treatment
1254216|NCT00942006|outcome
1254217|NCT00942006|subjective symptoms
1254218|NCT00941980|biologics
1254219|NCT00941980|fusion rates
1254220|NCT00941980|PLIF
1254221|NCT00941980|lumbar fusion
1254222|NCT00941967|adult primary hepatocellular carcinoma
1254223|NCT00941967|localized unresectable adult primary liver cancer
1254224|NCT00941967|recurrent adult primary liver cancer
1254225|NCT00941967|advanced adult primary liver cancer
1254226|NCT00941954|Physical activity
1254227|NCT00941954|Diabetes
1254228|NCT00941954|Prevention
1254229|NCT00941954|Pedometer
1254230|NCT00941954|Walking
1254231|NCT00941954|Structured education
1254232|NCT00941954|Randomized
1254233|NCT00941954|Risk score
1254234|NCT00941954|Impaired glucose regulation
1254235|NCT00941941|Inguinal
1254236|NCT00941941|Hernia
1254237|NCT00941941|Hernia-repair
1254238|NCT00941941|Non-mesh
1254239|NCT00941941|Mesh
1254240|NCT00941941|Desarda
1254241|NCT00941941|Lichtenstein
1254242|NCT00941928|Blood And Marrow Transplantation
1254243|NCT00941928|Relapsed Acute Lymphoblastic Leukemia
1254244|NCT00941928|ALL
1254245|NCT00941928|Leukemia
1254246|NCT00941928|Pediatrics
1254247|NCT00941928|Haploidentical NK cells
1254248|NCT00941928|Cyclophosphamide
1254249|NCT00941928|Cytoxan
1254250|NCT00941928|Neosar
1254251|NCT00941928|Epratuzumab
1254252|NCT00941928|Fludarabine
1254253|NCT00941928|Fludarabine Phosphate
1254254|NCT00941928|Fludara
1254255|NCT00941928|Interleukin-2
1254256|NCT00941928|IL-2
1254257|NCT00941928|Proleukin
1254258|NCT00941928|Low-dose interleukin
1254259|NCT00941928|Mesna
1254260|NCT00941928|Mesnex
1254261|NCT00941928|Natural Killer Cells
1254262|NCT00941928|NK Cells Transplant
1254263|NCT00941915|CaP
1254264|NCT00941915|SBRT
1254265|NCT00941915|Prostate
1254266|NCT00941915|ExacTrac
1254267|NCT00941915|Calypso
1254268|NCT00941915|IMRT
1254269|NCT00941915|Radiation
1254270|NCT00941915|Cancer of Prostate
1254271|NCT00941915|Prostatic Neoplasms
1254272|NCT00941902|human asialoglycoprotein receptor (ASGPR)
1254273|NCT00941902|hepatocytes
1254274|NCT00941902|bariatric surgery
1254275|NCT00941889|HIV
1254276|NCT00941889|HPV
1254277|NCT00941889|Anal condylomata
1254278|NCT00941889|Vaccine
1254279|NCT00941889|HIV positive patients
1254280|NCT00941889|Anal condylomata or anal warts
1254281|NCT00941876|AE
1254282|NCT00941876|adverse event
1254283|NCT00941876|AIDS
1254284|NCT00941876|acquired immunodeficiency syndrome
1254285|NCT00941876|ALT (SGPT)
1254286|NCT00941876|alanine aminotransferase
1254287|NCT00941876|ART
1254288|NCT00941876|antiretroviral therapy
1254289|NCT00941876|AST (SGOT)
1254290|NCT00941876|aspartate aminotransferase
1254291|NCT00941876|DCF
1254292|NCT00941876|data collection forms
1254293|NCT00941876|DMC
1254294|NCT00941876|Data Monitoring Committee
1254295|NCT00941876|FDA
1254296|NCT00941876|(U.S.) Food and Drug Administration
1254297|NCT00941876|GCP
1254298|NCT00941876|Good Clinical Practice guidelines
1254299|NCT00941876|HB sAg
1254300|NCT00941876|Hepatitis B surface antigen
1254301|NCT00941876|ICH
1254302|NCT00941876|International Conference of Harmonisation
1254303|NCT00941876|IND
1254304|NCT00941876|Investigational New Drug Application
1254305|NCT00941876|IRB
1254306|NCT00941876|Institutional Review Board
1254307|NCT00941876|IU
1254308|NCT00941876|International units
1254309|NCT00941876|mg
1254310|NCT00941876|milligram(s)
1254311|NCT00941876|mm3
1254312|NCT00941876|cubic millimeter(s)
1254313|NCT00941876|PCR
1254314|NCT00941876|polymerase chain reaction
1254315|NCT00941876|SAE
1254316|NCT00941876|serious adverse event
1254317|NCT00941876|µg
1254318|NCT00941876|microgram
1254319|NCT00941876|ULN
1254320|NCT00941876|upper limit of the normal range
1254321|NCT00941876|WB
1254322|NCT00941876|Western Blot
1254323|NCT00941876|To inform the Ministry of Health strategy for integrating FP and HIV/AIDS Care and Treatment Services in Tanzania
1254324|NCT00941876|HIV seronegativity
1254325|NCT00941863|Sorafenib
1254326|NCT00941863|Advanced Solid Tumors
1254327|NCT00941863|Maximum tolerated dose
1254328|NCT00941863|Carboplatin and paclitaxel chemotherapy combination
1254329|NCT00941850|Cardiac resynchronizton therapy
1254330|NCT00941850|CRT
1254331|NCT00941850|Heart failure
1254332|NCT00941850|Dyssynchrony
1254333|NCT00941850|Echocardiography
1254334|NCT00941850|Pacemakers
1254335|NCT00941850|Nonresponders
1254336|NCT00941837|Palm olein
1254337|NCT00941837|homocsyteine
1254338|NCT00941837|Cholesterol
1254339|NCT00941837|lipoproteins
1254340|NCT00941837|Interleukins
1254341|NCT00941837|CRP
1254342|NCT00941837|Blood Pressure
1254343|NCT00941837|Total homocystein
1254344|NCT00941837|Serum lipid profile
1254345|NCT00941837|Serum apolipoproteins
1254346|NCT00941837|Inflammatory markers
1254347|NCT00941824|pharmacokinetic
1254348|NCT00941824|mycophénolate acid
1254349|NCT00941824|kidney transplantation
1254350|NCT00941798|Asthma
1254351|NCT00941798|LABA
1254352|NCT00941798|Safety
1254353|NCT00941785|Malaria
1254354|NCT00941785|Intermittent Preventive Treatment
1254355|NCT00941785|IPTc
1254356|NCT00941785|sIPTc
1254357|NCT00941785|Burkina Faso
1254358|NCT00941772|Nasogastric tube verification with ultrasonography
1254359|NCT00941772|ultrasonography
1254360|NCT00941759|Breast
1254361|NCT00941759|Blood and tissue collection
1254362|NCT00941759|Epidemiologic
1254363|NCT00941759|Questionnaire
1254364|NCT00941759|TBCRC (Translational Breast Cancer Research Consortium)
1254365|NCT00941759|09-056
1254366|NCT00941733|BTK
1254367|NCT00941733|CLI
1254368|NCT00941733|PTA
1254369|NCT00941720|stage I multiple myeloma
1254370|NCT00941720|stage II multiple myeloma
1254371|NCT00941720|stage III multiple myeloma
1254372|NCT00941707|Rheumatoid Arthritis
1254373|NCT00941707|JNJ-38518168
1254374|NCT00941694|asthma
1254375|NCT00941694|aged
1254376|NCT00941694|self care
1254377|NCT00941681|omecamtiv mecarbil
1254378|NCT00941655|Gastric Carcinoma
1254379|NCT00941655|Chemotherapy
1254380|NCT00941655|Liver Tumors
1254381|NCT00941655|Peritoneal Tumors
1254382|NCT00941655|Metastatic Gastric Cancer
1254383|NCT00941655|Stomach Cancer
1254384|NCT00941655|Gastric Cancer
1254385|NCT00941642|Nonalcoholic Fatty Liver Disease (NAFLD)
1254386|NCT00941642|Lovaza
1254387|NCT00941642|Steatosis
1254388|NCT00941642|Non-Alcoholic steatohepatitis (NASH)
1254389|NCT00941629|PTSD
1254390|NCT00941629|Telemedicine
1254391|NCT00941629|Clinical Trial
1254392|NCT00941629|Psychotherapy
1254393|NCT00941616|Von Willebrand Disease
1254394|NCT00941590|tick borne encephalitis
1254395|NCT00941590|clinical outcome
1254396|NCT00941590|postencephalitic symptoms
1254397|NCT00941577|Hypersensitivity
1254398|NCT00941577|Lung Diseases, Obstructive
1254399|NCT00941577|Immune System Diseases
1254400|NCT00941577|Respiratory Tract Diseases
1254401|NCT00941577|Bronchial Diseases
1254402|NCT00941577|Lung Diseases
1254403|NCT00941577|Hypersensitivity, Immediate
1254404|NCT00941577|Asthma
1254405|NCT00941577|Respiratory Hypersensitivity
1254406|NCT00941551|Thyroid lobectomy,
1254407|NCT00941551|prophylactic levothyroxine treatment,
1254408|NCT00941551|recurrent nodular goiter,
1254409|NCT00941551|iodine deficiency,
1254410|NCT00941551|long-term follow-up,
1254411|NCT00941551|completion thyroidectomy
1254412|NCT00941538|nasopharyngeal cancer
1254413|NCT00941538|screening
1254414|NCT00941538|biomarker
1254415|NCT00941538|early detection
1254416|NCT00941538|epidemiological survey
1254417|NCT00941525|Central corneal thickness
1254418|NCT00941525|24hour fluctuation of intraocular pressure
1254419|NCT00941525|Open angle glaucoma
1254420|NCT00941525|Ocular hypertension
1254421|NCT00941512|Colposcopy
1254422|NCT00941499|Advanced Cancers
1254423|NCT00941499|Liver
1254424|NCT00941499|Oxaliplatin
1254425|NCT00941499|Eloxatin
1254426|NCT00941499|Bevacizumab
1254427|NCT00941499|Avastin
1254428|NCT00941499|Anit-VEGF monoclonal antibody
1254429|NCT00941499|rhuMAb-VEGF
1254430|NCT00941499|5-fluorouracil
1254431|NCT00941499|5-FU
1254432|NCT00941499|Adrucil
1254433|NCT00941499|Efudex
1254434|NCT00941499|Leucovorin
1254435|NCT00941499|Citrovorum
1254436|NCT00941499|Wellcovorin
1254437|NCT00941499|Cetuximab
1254438|NCT00941499|C225
1254439|NCT00941499|Erbitux
1254440|NCT00941499|IMC-C225
1254441|NCT00941473|Epidural Injection
1254442|NCT00941473|Bone Density
1254443|NCT00941460|progressive or recurrent glioblastoma
1254444|NCT00941460|temozolomide
1254445|NCT00941460|dose intensification
1254446|NCT00941460|comparison of two dosing regimens
1254447|NCT00941447|Type 2 Diabetes
1254448|NCT00941447|Obesity
1254449|NCT00941447|Self-Regulation
1254450|NCT00941447|Self-Efficacy
1254451|NCT00941434|RUTF
1254452|NCT00941434|SAM
1254453|NCT00941434|Nutributter
1254462|NCT00941382|sibutramine
1254463|NCT00941382|metformin
1254464|NCT00941382|obesity
1254465|NCT00941356|MRSA nasal colonisation
1254466|NCT00941356|Probiotics
1254467|NCT00941330|Breast, Male
1254468|NCT00941330|Breast, Female
1254469|NCT00941317|onychomycosis
1254470|NCT00941317|micro-drilling
1254471|NCT00941291|idiopathic macular hole
1254472|NCT00941291|cataract
1254473|NCT00941291|edema
1254474|NCT00941291|Reopening
1254475|NCT00941265|treatment of anomia
1254476|NCT00941265|levodopa
1254477|NCT00941265|"patient with aphasia hospitalised at the Service de neurorehabilitation with presence of anomia"
1254478|NCT00941239|Metformin ER
1254479|NCT00941239|Pharmacokinetics
1254480|NCT00941239|Tolerability
1254481|NCT00941239|Healthy volunteers
1254482|NCT00941226|Cerebral Palsy
1254483|NCT00941226|Caregivers
1254484|NCT00941226|Quality of Life
1254485|NCT00941213|fractures of vertebral bodies Th10-L2
1254486|NCT00941213|(AO A1 with kyphosis, A2.3, B or C-type)
1254487|NCT00941187|pulmonary embolism
1254488|NCT00941187|pulmonary capillary blood volume
1254489|NCT00941187|double diffusion NO/CO method
1254490|NCT00941174|(13C5) Calcium Leucovorin
1254491|NCT00941174|Folate absorption across the large intestine
1254492|NCT00941174|Folate Bioavailability
1254493|NCT00941122|MRSA, VRE
1254494|NCT00941109|MDS
1254495|NCT00941096|Glaucoma
1254496|NCT00941096|Ocular Hypertension
1254497|NCT00941096|Lumigan
1254498|NCT00941096|Ganfort
1254499|NCT00941083|Simplification from protease inhibitors to raltegravir
1254500|NCT00941083|Treatment Experienced
1254501|NCT00941083|HIV-1 Infections
1254502|NCT00941044|non-invasive ventilation
1254503|NCT00941044|diaphragm
1254504|NCT00941044|electrical activity
1254505|NCT00941044|neurally adjusted ventilatory assist
1254506|NCT00941044|volunteers
1254507|NCT00941031|Moderate to severe chronic plaque-type psoriasis
1254508|NCT00941031|AIN457
1254509|NCT00941031|dermatology
1254510|NCT00941018|Resolvins
1254511|NCT00941018|RvE1
1254512|NCT00941018|Healthy volunteers
1254513|NCT00940979|Integuseal microbial sealant
1254514|NCT00940979|Infection prophylaxis
1254515|NCT00940979|Postoperative wound infection
1254516|NCT00940979|Arterial bypass surgery
1254517|NCT00940966|ADA diet
1254518|NCT00940966|low carbohydrate diet
1254519|NCT00940966|Metabolic syndrome
1254520|NCT00940927|Albuterol
1254521|NCT00940927|Forced expiratory volume in one second
1254522|NCT00940927|Dose at fifty percent of maximum effect
1254523|NCT00940927|Maximum effective dose
1254524|NCT00940927|Metered dose inhaler
1254525|NCT00940927|Nebulizer
1254526|NCT00940914|Parkinson's disease
1254527|NCT00940914|pain
1254528|NCT00940914|dopamine transporters imaging
1254529|NCT00940901|priapism
1254530|NCT00940901|sickle cell disease
1254531|NCT00940901|sildenafil
1254532|NCT00940901|phosphodiesterase type 5 inhibitor
1254533|NCT00940888|ICD
1254534|NCT00940888|CRTD
1254535|NCT00940888|Heart Failure
1254536|NCT00940888|DF4
1254537|NCT00940862|psoriasis
1254538|NCT00940862|vascular inflammation
1254539|NCT00940862|coronary atherosclerosis
1254540|NCT00940836|Anti-cold
1254541|NCT00940836|Cold preparation
1254542|NCT00940836|RCT
1254543|NCT00940823|Glaucoma Drainage Device
1254544|NCT00940823|Aqueous Shunt Implant
1254545|NCT00940823|Ahmed Valve
1254546|NCT00940823|Baerveldt Tube
1254547|NCT00940823|Refractory Glaucoma
1254548|NCT00940797|diabetes
1254549|NCT00940797|Type 2
1254550|NCT00940797|monotherapy
1254551|NCT00940797|antidiabetics
1254552|NCT00940797|metformin
1254553|NCT00940771|HIV
1254554|NCT00940771|Lipids
1254555|NCT00940771|Atazanavir
1254556|NCT00940771|Pediatric
1254557|NCT00940771|treatment experienced
1254558|NCT00940745|HICH
1254559|NCT00940745|Suction drainages
1254560|NCT00940745|TTAC
1254561|NCT00940732|Help-seeking
1254562|NCT00940732|Mental Health
1254563|NCT00940732|Athletes
1254564|NCT00940719|Multiple Sclerosis
1254565|NCT00940719|Regulatory T cell function
1254566|NCT00940719|Vitamin D
1254567|NCT00940719|Vitamin D3
1254568|NCT00940719|25-hydroxyvitamin D
1254569|NCT00940706|Cerebral Palsy
1254570|NCT00940706|Activity monitoring
1254571|NCT00940706|Treadmill
1254572|NCT00940706|Group training
1254573|NCT00940706|Physical active life style
1254574|NCT00940693|Attention Deficit Disorder with Hyperactivity
1254575|NCT00940693|Duloxetine
1254576|NCT00940693|Adult
1254577|NCT00940693|ADDH
1254578|NCT00940693|ADHD
1254579|NCT00940680|Amlodipine
1254580|NCT00940680|Losartan
1254581|NCT00940680|hypertension
1254582|NCT00940667|Amlodipine
1254583|NCT00940667|Losartan
1254584|NCT00940667|hypertension
1254585|NCT00940654|Fever
1254586|NCT00940654|Antipyretic
1254587|NCT00940654|Infection
1254588|NCT00940654|Mortality
1254589|NCT00940654|Cooling
1254590|NCT00940654|Non steroid anti inflammatory drugs
1254591|NCT00940654|Acetaminophen
1254592|NCT00940654|Steroid
1254593|NCT00940654|ICU
1254594|NCT00940654|Intensive care
1254595|NCT00940654|Critically ill
1254596|NCT00940641|Healthy Volunteer
1254597|NCT00940615|traumatic brain injury
1254598|NCT00940615|aerobic exercise
1254599|NCT00940615|Diffusion Tensor Imaging
1254600|NCT00940615|Neuropsychology
1254601|NCT00940615|Rehabilitation
1254602|NCT00940602|TELESTO
1254603|NCT00940602|MDS Study
1254604|NCT00940602|Myelodysplastic Syndromes
1254605|NCT00940602|Myelodysplastic Syndromes (low-int-1 risk)
1254606|NCT00940589|Alzheimer's Disease
1254607|NCT00940589|Acetylcholinesterase inhibitor
1254608|NCT00940589|cognitive function
1254609|NCT00940589|Circadin
1254610|NCT00940589|Sleep disturbances
1254611|NCT00940576|mare's milk, Crohn's disease, ulcerative colitis, clinical
1254612|NCT00940563|GIST
1254613|NCT00940563|imatinib
1254614|NCT00940563|advanced GIST
1254615|NCT00940537|Obese
1254616|NCT00940537|MRS
1254617|NCT00940537|hepatic triglyceride content
1254618|NCT00940537|MR spectroscopy
1254619|NCT00940524|Leukemia
1254620|NCT00940524|ALL
1254621|NCT00940524|ALLOPURINOL
1254622|NCT00940524|CARMUSTINE (BCNU)
1254623|NCT00940524|CYCLOPHOSPHAMIDE (CYTOXAN)
1254624|NCT00940524|CYTARABINE (ARA-C)
1254625|NCT00940524|DACTINOMYCIN
1254626|NCT00940524|DASATINIB
1254627|NCT00940524|DEXAMETHASONE
1254628|NCT00940524|DOXORUBICIN/ADRIAMYCIN
1254629|NCT00940524|ETOPOSIDE (VP-16)
1254630|NCT00940524|MERCAPTOPURINE
1254631|NCT00940524|METHOTREXATE
1254632|NCT00940524|MITOXANTRONE
1254633|NCT00940524|PEGASPERGASE
1254634|NCT00940524|VINCRISTINE
1254635|NCT00940511|All conditions faced by disabled Medicaid recipients
1254636|NCT00940498|Phase 1
1254637|NCT00940498|Dose Finding
1254638|NCT00940498|Solid Tumors
1254639|NCT00940498|Tumors
1254640|NCT00940498|PF-05212384
1254641|NCT00940472|type 2 diabetes
1254642|NCT00940472|monotherapy
1254643|NCT00940472|antidiabetics
1254644|NCT00940472|metformin
1254645|NCT00940459|contact lenses
1254646|NCT00940459|conjunctival staining
1254647|NCT00940459|contact lens wear
1254648|NCT00940446|Insorb staples
1254649|NCT00940446|Metal Staples
1254650|NCT00940433|Minimally invasive
1254651|NCT00940433|Inguinal hernia
1254652|NCT00940433|Pro-peritoneal repair
1254653|NCT00940407|dry AMD
1254654|NCT00940407|light treatment
1254655|NCT00940407|ARMD
1254656|NCT00940407|photobiomodulation
1254657|NCT00940407|macular
1254658|NCT00940407|eye disease
1254659|NCT00940407|ageing eye disease
1254660|NCT00940394|mutual support group
1254661|NCT00940394|psychoeducation group
1254662|NCT00940394|family caregivers
1254663|NCT00940394|schizophrenia
1254664|NCT00940381|Advanced Malignancies
1254665|NCT00940381|Sirolimus
1254666|NCT00940381|Rapamune
1254667|NCT00940381|Cetuximab
1254668|NCT00940381|C225
1254669|NCT00940381|Erbitux
1254670|NCT00940381|IMC-225
1254671|NCT00940368|Nausea
1254672|NCT00940368|Vomiting
1254673|NCT00940368|Chemotherapy
1254674|NCT00940355|COPD
1254675|NCT00940355|Health Status
1254676|NCT00940355|Intervention
1254677|NCT00940355|Secondary prevention
1254678|NCT00940355|patient-tailored treatment
1254679|NCT00940342|Chronic Lymphocytic Leukemia
1254680|NCT00940342|Rituximab
1254681|NCT00940342|Leukemia
1254682|NCT00940342|Sargramostim
1254683|NCT00940342|GM-CSF
1254684|NCT00940329|Drug interactions
1254685|NCT00940329|Pharmacodynamic interactions
1254686|NCT00940329|Pharmacokinetic interactions
1254687|NCT00940329|Formoterol
1254688|NCT00940329|Healthy subjects
1254689|NCT00940329|Phase I study
1254690|NCT00940329|Roflumilast
1254691|NCT00940316|recurrent colon cancer
1254692|NCT00940316|stage IV colon cancer
1254693|NCT00940316|recurrent rectal cancer
1254694|NCT00940316|stage IV rectal cancer
1254695|NCT00940290|practice guideline as topic
1254696|NCT00940290|decision making
1254697|NCT00940290|evidence based medicine
1254698|NCT00940277|women couples counseling groups support intervention marriage
1254699|NCT00940264|symptomatic cholecystolithiasis
1254700|NCT00940251|Ayurvedic formulation
1254701|NCT00940251|type 2 diabetes mellitus
1254702|NCT00940251|secondary failure to oral hypoglycemic agents
1254703|NCT00940251|antidiabetic
1254704|NCT00940225|Breast Cancer
1254705|NCT00940225|Melanoma
1254706|NCT00940225|Stomach or Gastroesophageal Junction Carcinoma
1254707|NCT00940225|Hepatocellular Carcinoma (HCC)
1254708|NCT00940225|Small Cell Lung Cancer (SCLC)
1254709|NCT00940225|Non-Small Cell Lung Cancer (NSCLC)
1254710|NCT00940225|Ovarian Cancer
1254711|NCT00940225|Pancreatic Cancer
1254712|NCT00940225|Prostate Cancer
1254713|NCT00940212|Safety
1254714|NCT00940212|tolerability
1254715|NCT00940212|healthy
1254716|NCT00940212|pharmacokinetics
1254717|NCT00940199|Breast cancer, sentinel lymph node mapping, biopsy
1254718|NCT00940173|xenotransplantation
1254719|NCT00940173|type I diabetes
1254720|NCT00940173|porcine islets
1254721|NCT00940160|Asthma
1254722|NCT00940134|obesity
1254723|NCT00940134|energy expenditure
1254724|NCT00940134|incretins
1254725|NCT00940134|appetite regulation
1254726|NCT00940134|GLP-1
1254727|NCT00940134|PYY
1254728|NCT00940134|ad libitum energy intake
1254729|NCT00940121|Healthy volunteer subjects
1254730|NCT00940121|pharmacokinetics
1254731|NCT00940121|YM178
1254732|NCT00940121|mirabegron
1254733|NCT00940121|IV infusion
1254734|NCT00940121|oral administration
1254735|NCT00940095|Aneurysmal
1254736|NCT00940095|Subarachnoid
1254737|NCT00940095|Hemorrhage
1254738|NCT00940095|vasospasm
1254739|NCT00940095|clazosentan
1254740|NCT00940095|PIVLAZ
1254741|NCT00940095|Actelion
1254742|NCT00940095|surgical clipping
1254743|NCT00940082|Diabetes;
1254744|NCT00940082|Echocardiography;
1254745|NCT00940082|High-sensitive C-reactive protein;
1254746|NCT00940082|homocysteine;
1254747|NCT00940082|TNF-α
1254748|NCT00940069|TS
1254749|NCT00940069|polymorphism
1254750|NCT00940069|lung cancer
1254751|NCT00940069|adenocarcinoma
1254752|NCT00940069|pemetrexed
1254753|NCT00940056|Atrial fibrillation
1254754|NCT00940056|Ablation
1254755|NCT00940056|Thoracoscopy
1254756|NCT00940056|Atrial function
1254757|NCT00940043|bedside test
1254758|NCT00940043|interleukins
1254759|NCT00940043|inflammation
1254760|NCT00940043|vaginal secretions
1254761|NCT00940030|Mechanical Bowel Preparation (MBP)
1254762|NCT00940030|enema
1254763|NCT00940017|PK
1254764|NCT00940017|fungal infection
1254765|NCT00940004|dendritic cell vaccination
1254766|NCT00940004|melanoma
1254767|NCT00940004|toll like receptor ligands
1254768|NCT00940004|vaccines
1254769|NCT00939991|GBM
1254770|NCT00939965|localized unresectable neuroblastoma
1254771|NCT00939965|recurrent neuroblastoma
1254772|NCT00939965|stage 4S neuroblastoma
1254773|NCT00939952|ertapenem
1254774|NCT00939952|CAPD
1254775|NCT00939952|dialysis
1254776|NCT00939913|contrast nephropathy
1254777|NCT00939913|intravenous n-acetlycysteine
1254778|NCT00939900|avascular necrosis of femoral head
1254779|NCT00939900|bisphosphonate
1254780|NCT00939900|collapse
1254781|NCT00939874|HIV+
1254782|NCT00939874|Raltegravir
1254783|NCT00939874|Tenofovir
1254784|NCT00939874|osteopenia
1254785|NCT00939874|osteoporosis
1254786|NCT00939874|bone markers
1254787|NCT00939874|treatment experienced
1254788|NCT00939861|colorectal endometriosis, laparoscopy, laparotomy
1254789|NCT00939861|gynecologic and digestive symptoms
1254790|NCT00939861|quality of life (SF-36 questionnaire)
1254791|NCT00939861|morbidity
1254792|NCT00939861|fertility
1254793|NCT00939848|Disease-Free Survival
1254838|NCT00939757|Healthy volunteer subjects
1254839|NCT00939757|pharmacokinetics
1254840|NCT00939757|YM178
1254841|NCT00939757|mirabegron
1254842|NCT00939757|food
1254843|NCT00939744|contractile activity
1254844|NCT00939744|eicosanoids
1254845|NCT00939744|pregnant women
1254846|NCT00939744|obstetrics complications
1254847|NCT00939731|bioavailability, capsule, tablet, healthy volunteer
1254848|NCT00939718|depression;vitamin B12;randomized control trial
1254849|NCT00939679|obesity
1254850|NCT00939679|bariatric surgery
1254851|NCT00939679|energy expenditure
1254852|NCT00939679|incretins
1254853|NCT00939679|appetite regulation
1254854|NCT00939679|body composition
1254855|NCT00939679|GLP-1
1254856|NCT00939666|Rectal cancer
1254857|NCT00939666|Chemoradiation
1254858|NCT00939666|Response
1254859|NCT00939666|Wait-and-see policy
1254860|NCT00939666|Transanal endoscopic microsurgery
1254861|NCT00939653|relapsed
1254862|NCT00939653|relapse
1254863|NCT00939653|refractory
1254864|NCT00939653|AML
1254865|NCT00939653|Acute myelogenous leukemia
1254866|NCT00939653|Relapsed AML
1254867|NCT00939640|Diet
1254868|NCT00939640|Sodium
1254869|NCT00939640|Hypertension
1254870|NCT00939640|Potassium
1254871|NCT00939640|Antioxidants
1254872|NCT00939640|congestive heart failure
1254873|NCT00939640|Heart failure with normal ejection fraction
1254874|NCT00939640|Heart failure with preserved systolic function
1254875|NCT00939601|Obstructive Sleep Apnea
1254876|NCT00939601|OSA
1254877|NCT00939601|Adherence
1254878|NCT00939601|CPAP
1254879|NCT00939601|Cognition
1254880|NCT00939588|Aliskiren,
1254881|NCT00939588|hypertension,
1254882|NCT00939588|renin-angiotensin-aldosterone system
1254883|NCT00939575|preeclampsia, metabolomics, blood, urine
1254884|NCT00939562|Bioequivalence
1254885|NCT00939549|High dose cyclophosphamide
1254886|NCT00939523|recurrent nonfunctioning adenoma
1254887|NCT00939523|prolactinomas
1254888|NCT00939523|resistant pituitary tumors
1254889|NCT00939523|aggressive pituitary tumors
1254890|NCT00939523|malignant pituitary adenomas
1254891|NCT00939510|adenocarcinoma of the prostate
1254892|NCT00939510|hormone-resistant prostate cancer
1254893|NCT00939510|recurrent prostate cancer
1254894|NCT00939510|stage IV prostate cancer
1254895|NCT00939432|incontinence
1254896|NCT00939432|urinary
1254897|NCT00939432|taboo
1254898|NCT00939432|shame
1254899|NCT00939432|embarrassment
1254900|NCT00939432|treatment
1254901|NCT00939432|depression
1254902|NCT00939432|cancer
1254903|NCT00939419|Tuberculosis care
1254904|NCT00939419|community tuberculosis care
1254905|NCT00939419|Health facility based tuberculosis care
1254906|NCT00939380|hematopoietic stem cell transplant
1254907|NCT00939380|bone marrow transplant
1254908|NCT00939380|children
1254909|NCT00939380|parents
1254910|NCT00939380|counseling
1254911|NCT00939380|depression
1254912|NCT00939354|Asthma in subjects over the age of 65
1254913|NCT00939341|Symbicort SMART
1254914|NCT00939328|B-cell chronic lymphocytic leukemia
1254915|NCT00939328|refractory chronic lymphocytic leukemia
1254916|NCT00939315|Glioma, diagnosis
1254917|NCT00939315|Imaging
1254918|NCT00939315|Positron emission tomography
1254919|NCT00939315|Magnetic resonance imaging
1254920|NCT00939315|Magnetic resonance spectroscopy
1254921|NCT00939289|Continuous glucose monitoring
1254922|NCT00939276|cataract surgery
1254923|NCT00939276|macular edema
1254924|NCT00939276|prevention
1254925|NCT00939263|deglutition disorders
1254926|NCT00939263|esophageal diseases
1254927|NCT00939263|eosinophilia
1254928|NCT00939250|Diabetes
1254929|NCT00939250|Depression
1254930|NCT00939250|Disease Self Management
1254931|NCT00939250|Measurement Based Care
1254932|NCT00939237|Coronary heart disease
1254933|NCT00939237|Carotid intima-media thickness
1254934|NCT00939237|Biomarkers
1254935|NCT00939224|Near-infrared spectroscopy (NIRS)
1254936|NCT00939224|Regional oxygen saturation
1254937|NCT00939224|Pediatrics
1254938|NCT00939224|Cardiac catheterization
1254939|NCT00939224|Congenital heart disease
1254940|NCT00939211|Chronic Obstructive Pulmonary Disease (COPD)
1254941|NCT00939211|efficacy
1254942|NCT00939211|safety
1254943|NCT00939211|inhalation
1254944|NCT00939211|long-acting muscarinic receptor antagonist (LAMA)
1254945|NCT00939198|Hookworm
1254946|NCT00939198|Allergy
1254947|NCT00939198|Vaccine
1254948|NCT00939198|Skin Test
1254949|NCT00939198|Immediate-type hypersensitivity to Na-ASP-2 hookworm antigen
1254950|NCT00939185|Compliance and Safety Study in Children with Upper and Lower Respiratory Tract Infections
1254951|NCT00939172|Advanced Refractory Solid Malignancies
1254952|NCT00939172|Solid tumor
1254953|NCT00939172|Lymphoma
1254954|NCT00939172|TTP607
1254955|NCT00939159|Low or Intermediate-1 Risk Myelodysplastic Syndrome
1254956|NCT00939159|MDS
1254957|NCT00939159|Cancer
1254958|NCT00939159|LBH589
1254959|NCT00939146|self management
1254960|NCT00939146|quality of life
1254961|NCT00939146|end of life
1254962|NCT00939133|acne
1254963|NCT00939133|tretinoin
1254964|NCT00939133|isotretinoin
1254965|NCT00939133|recurrence
1254966|NCT00939133|Retin A micro
1254967|NCT00939120|Benign prostatic hyperplasia (BPH)
1254968|NCT00939120|dutasteride
1254969|NCT00939120|tolterodine ER
1254970|NCT00939107|low back pain
1254971|NCT00939107|Intervertebral disc
1254972|NCT00939107|McKenzie
1254973|NCT00939107|Physical Therapy
1254974|NCT00939107|Spinal manipulation
1254975|NCT00939107|Chiropractics
1254976|NCT00939107|Patient education
1254977|NCT00939107|Exercise therapy
1254978|NCT00939107|Random allocation
1254979|NCT00939094|Pain, Mechanical Hypersensitivity
1254980|NCT00939094|Allodynia
1254981|NCT00939094|Efficacy
1254982|NCT00939094|analgesia
1254983|NCT00939094|Neuropathic
1254984|NCT00939081|Obesity
1254985|NCT00939081|Women's health
1254986|NCT00939081|Minority health
1254987|NCT00939081|Obesity prevention
1254988|NCT00939068|Chronic hepatitis B, Telbivudine, Intrauterine transmission
1254989|NCT00939029|tobacco use
1254990|NCT00939029|smokeless tobacco
1254991|NCT00939029|chewing tobacco
1254992|NCT00939029|snuff
1254993|NCT00939029|nicotine replacement
1254994|NCT00939029|tobacco dependence
1254995|NCT00939029|tobacco cessation
1254996|NCT00939029|tobacco abstinence
1254997|NCT00939016|Dietary Assessment
1254998|NCT00939016|24-hour dietary recall
1254999|NCT00939016|Dietary Restraint
1255000|NCT00939016|Social Desirability
1255001|NCT00939016|Portion estimation
1255002|NCT00939016|Underreporting
1255003|NCT00938977|Obesity Hypoventilation syndrome
1255004|NCT00938977|cytokines
1255005|NCT00938977|Adipokines
1255006|NCT00938977|continuous positive airway pressure
1255007|NCT00938977|bilevel support ventilation
1255008|NCT00938977|Response to continuous positive airway pressure
1255009|NCT00938964|Cognition
1255010|NCT00938951|Dry Eye
1255011|NCT00938951|Visual Performance
1255012|NCT00938938|risk communication
1255013|NCT00938938|medical reporting
1255014|NCT00938938|Mass media
1255015|NCT00938925|aggressive debridement
1255016|NCT00938925|nail lacquer
1255017|NCT00938925|onychomycosis
1255018|NCT00938925|podiatry
1255019|NCT00938925|chiropody
1255020|NCT00938925|podiatry care
1255022|NCT00938899|TMC435350-TiDP16-C101
1255023|NCT00938899|TMC435350-C101
1255024|NCT00938899|TMC435350
1255025|NCT00938899|HCV
1255026|NCT00938873|MBCT
1255027|NCT00938873|identity
1255028|NCT00938873|depression
1255029|NCT00938873|recurrent
1255030|NCT00938873|homework
1255031|NCT00938860|Hepatitis C
1255032|NCT00938860|liver transplantation
1255033|NCT00938860|anti-viral therapy
1255034|NCT00938847|left ventricular dysfunction
1255035|NCT00938847|myocardial infarction
1255036|NCT00938847|left ventricular dysfunction (LVDF) after acute myocardial infarction
1255037|NCT00938808|Osteoarthritis
1255038|NCT00938808|Obesity
1255039|NCT00938808|Weight loss
1255040|NCT00938808|Dietary instruction
1255041|NCT00938808|Formula diet
1255042|NCT00938808|Attention
1255043|NCT00938795|liver disease
1255044|NCT00938795|uncertainty
1255045|NCT00938795|self management
1255046|NCT00938769|cancer
1255047|NCT00938769|caregiver
1255048|NCT00938769|symptom
1255049|NCT00938769|self management
1255050|NCT00938756|leptomeningeal metastases
1255051|NCT00938756|male breast cancer
1255052|NCT00938756|stage IV breast cancer
1255053|NCT00938756|tumors metastatic to brain
1255054|NCT00938756|adult meningioma
1255055|NCT00938743|ADHD
1255056|NCT00938743|adults
1255057|NCT00938743|driving performance
1255058|NCT00938743|atomoxetine
1255059|NCT00938730|Nonvalvular Atrial Fibrillation (NVAF)
1255060|NCT00938730|Factor Xa Inhibitor
1255061|NCT00938730|Stroke
1255062|NCT00938730|Thromboembolism
1255063|NCT00938730|Transient Ischemic attack
1255064|NCT00938730|Anticoagulants
1255065|NCT00938730|Prevention
1255066|NCT00938730|YM150
1255067|NCT00938730|Warfarin
1255068|NCT00938717|IBS
1255069|NCT00938691|Scar
1255070|NCT00938691|Appearance
1255071|NCT00938691|Spread
1255072|NCT00938678|Healthy volunteers
1255073|NCT00938665|Alzheimer
1255074|NCT00938665|Memory disorder
1255075|NCT00938665|dementia
1255076|NCT00938665|cognitive behavioral decline
1255077|NCT00938665|vascular dementia
1255078|NCT00938665|front temporal dementia
1255079|NCT00938652|triple negative breast cancer
1255080|NCT00938652|metastatic breast cancer
1255081|NCT00938652|Triple negative metastatic breast cancer
1255082|NCT00938626|refractory multiple myeloma
1255083|NCT00938626|stage I multiple myeloma
1255084|NCT00938626|stage II multiple myeloma
1255085|NCT00938626|stage III multiple myeloma
1255086|NCT00938613|SAR
1255087|NCT00938600|pharmacokinetics
1255088|NCT00938600|safety
1255089|NCT00938587|Rheumatoid Arthritis Glucocorticoids Prednisone
1255090|NCT00938561|Chronic Kidney Disease
1255091|NCT00938561|Glomerular Filtration Rate
1255092|NCT00938561|Kidney function
1255093|NCT00938561|Markers
1255094|NCT00938548|mastectomy
1255095|NCT00938548|pain, postoperative
1255096|NCT00938548|pregabalin
1255097|NCT00938535|Obesity
1255098|NCT00938535|Women's health
1255099|NCT00938535|Minority health
1255100|NCT00938535|Obesity prevention
1255101|NCT00938522|Cilostazol loading
1255102|NCT00938522|Angioplasty, Transluminal, Percutaneous Coronary
1255103|NCT00938509|IBUPROFEN
1255104|NCT00938509|CHILDREN
1255105|NCT00938509|FEVER
1255106|NCT00938483|infant formula
1255107|NCT00938483|cow's milk allergy
1255108|NCT00938470|adenocarcinoma of the esophagus
1255109|NCT00938470|adenocarcinoma of the gastroesophageal junction
1255110|NCT00938470|stage IIIA gastric cancer
1255111|NCT00938470|stage IIIB gastric cancer
1255112|NCT00938470|stage IIIC gastric cancer
1255113|NCT00938470|stage IIIA esophageal cancer
1255114|NCT00938470|stage IIIB esophageal cancer
1255115|NCT00938470|stage IIIC esophageal cancer
1255116|NCT00938457|protocol specific
1255117|NCT00938444|Patients with moderate to severe RA
1255118|NCT00938431|Lacosamide
1255119|NCT00938431|Vimpat
1255120|NCT00938431|Children
1255121|NCT00938431|Epilepsy
1255122|NCT00938431|Seizures
1255123|NCT00938431|Anti-epileptic
1255124|NCT00938405|type 1 diabetes mellitus
1255125|NCT00938405|colesevelam
1255126|NCT00938405|LDL
1255127|NCT00938405|cholesterol
1255128|NCT00938405|A1c
1255129|NCT00938405|target range glucose values
1255130|NCT00938392|influenza infection
1255131|NCT00938392|GSK Bio's influenza vaccine GSK2186877A
1255132|NCT00938379|mosquito
1255133|NCT00938379|repellent
1255134|NCT00938379|vector control
1255135|NCT00938379|malaria
1255136|NCT00938353|Moderate croup (Westley score 3-8)
1255137|NCT00938340|Cardiovascular Disease
1255138|NCT00938327|Gastroenteritis
1255139|NCT00938301|healthy volunteer, first in human, safety and tolerability
1255140|NCT00938288|Antithrombin
1255141|NCT00938288|Thrombosis
1255142|NCT00938288|Pharmacokinetics
1255143|NCT00938288|Hereditary Antithrombin Deficiency
1255144|NCT00938288|Congenital Antithrombin Deficiency
1255145|NCT00938249|Moderately Elevated Serum Triglyceride
1255146|NCT00938236|lung transplant
1255147|NCT00938236|lung transplant recipient
1255148|NCT00938236|bronchiolitis obliterans syndrome
1255149|NCT00938236|bronchiolitis obliterans
1255150|NCT00938236|single lung transplant
1255151|NCT00938236|double lung transplant
1255152|NCT00938236|heart-lung transplant
1255153|NCT00938236|Aerosol
1255154|NCT00938223|melanoma
1255155|NCT00938223|peptide
1255156|NCT00938223|vaccine
1255157|NCT00938223|adjuvant
1255158|NCT00938223|advanced
1255159|NCT00938210|Colonic surgery
1255160|NCT00938210|Postoperative care
1255161|NCT00938210|Fatigue
1255162|NCT00938210|Physical function
1255163|NCT00938210|Quality of life
1255164|NCT00938197|Fimasartan
1255165|NCT00938197|Drug interaction
1255166|NCT00938184|tolerance
1255167|NCT00938184|single dose
1255168|NCT00938184|paroxetine
1255169|NCT00938184|controlled-release tablet
1255170|NCT00938184|safety
1255171|NCT00938184|pharmacokinetics
1255172|NCT00938184|Japanese healthy male subjects
1255173|NCT00938171|Cytokine
1255174|NCT00938171|Anesthesia
1255175|NCT00938171|Local anesthesia
1255176|NCT00938171|surgery
1255177|NCT00938171|breast cancer
1255178|NCT00938158|albiglutide
1255179|NCT00938158|hemodialysis
1255180|NCT00938158|pharmacokinetics
1255181|NCT00938158|renal
1255182|NCT00938145|recurrent bladder cancer
1255183|NCT00938145|stage II bladder cancer
1255184|NCT00938145|stage III bladder cancer
1255185|NCT00938145|stage IV bladder cancer
1255186|NCT00938132|fimasartan
1255187|NCT00938132|drug interaction
1255188|NCT00938119|Cardiovascular disease
1255189|NCT00938119|Diabetes
1255190|NCT00938106|Intra-uterine Brachytherapy
1255191|NCT00938106|cervix cancer
1255192|NCT00938106|Patients suitable for intra-uterine brachytherapy for invasive carcinoma of the cervix.
1255193|NCT00938067|Injuries, Trauma
1255194|NCT00938054|Outcome
1255195|NCT00938054|Autism
1255196|NCT00938054|Pervasive Developmental Disorder
1255197|NCT00938028|microbiome
1255198|NCT00938028|metabolome
1255199|NCT00938028|stool
1255200|NCT00938028|fecal samples
1255201|NCT00938028|handling
1255202|NCT00938028|toddler
1255203|NCT00938015|postmarketing surveillance
1255204|NCT00938015|Enbrel
1255205|NCT00938015|psoriatic arthritis
1255206|NCT00937989|ductal breast carcinoma in situ
1255207|NCT00937989|lobular breast carcinoma in situ
1255208|NCT00937989|male breast cancer
1255209|NCT00937989|stage I breast cancer
1255210|NCT00937989|stage II breast cancer
1255211|NCT00937989|stage IIIA breast cancer
1255212|NCT00937989|stage IIIB breast cancer
1255213|NCT00937989|stage IIIC breast cancer
1255214|NCT00937976|Hemodialysis and peritoneal dialysis
1255215|NCT00937963|cholesterol
1255216|NCT00937963|cardiovascular
1255217|NCT00937963|CVD
1255218|NCT00937963|Triglycerides
1255219|NCT00937963|Heart
1255220|NCT00937950|HPV
1255221|NCT00937950|Papillomavirus
1255222|NCT00937950|Human papillomavirus
1255223|NCT00937950|Cervical cancer
1255224|NCT00937950|HPV vaccine
1255225|NCT00937924|EUS
1255226|NCT00937924|ERCP
1255227|NCT00937924|Sedation Level
1255228|NCT00937924|Adverse Symptoms
1255229|NCT00937924|Recovery time
1255230|NCT00937911|YM150
1255231|NCT00937911|Bleeding
1255232|NCT00937911|Anticoagulant
1255233|NCT00937911|Venous thromboembolism
1255234|NCT00937911|FXa inhibitor
1255235|NCT00937898|lean beef
1255236|NCT00937898|cholesterol
1255237|NCT00937898|lipids
1255238|NCT00937898|diet intervention
1255239|NCT00937885|Reminiscence
1255240|NCT00937885|Nursing home staff
1255241|NCT00937885|Nursing home residents
1255242|NCT00937885|Elderly
1255247|NCT00937833|prostate cancer
1255248|NCT00937833|prostatectomy
1255249|NCT00937833|incontinence
1255250|NCT00937820|YM150
1255251|NCT00937820|Bleeding
1255252|NCT00937820|VTE
1255253|NCT00937820|FXa inhibitor
1255254|NCT00937820|Venous thromboembolism
1255255|NCT00937807|hemodynamic stability
1255256|NCT00937807|xenon
1255257|NCT00937807|carotid surgery
1255258|NCT00937807|general anesthesia
1255259|NCT00937781|stage III melanoma
1255260|NCT00937781|recurrent melanoma
1255261|NCT00937755|schizophrenia
1255262|NCT00937755|antipsychotics
1255263|NCT00937755|glucose homeostasis
1255264|NCT00937755|metabolic disturbance
1255265|NCT00937742|cardiovascular disease
1255266|NCT00937742|Lycopene
1255267|NCT00937742|Tomato
1255268|NCT00937729|uncompliant patients with virological failure
1255269|NCT00937729|Treatment experienced
1255270|NCT00937716|schizophrenia
1255271|NCT00937716|treatment response
1255272|NCT00937716|risperidone
1255273|NCT00937716|functional magnetic resonance
1255274|NCT00937716|functional magnetic spectroscopy
1255275|NCT00937690|melanoma
1255276|NCT00937690|cutaneous
1255277|NCT00937690|imaging
1255278|NCT00937677|Tysabri
1255279|NCT00937677|VWMTR
1255280|NCT00937664|Phase I
1255281|NCT00937664|cancer
1255282|NCT00937664|solid tumors
1255283|NCT00937664|advanced solid malignancies
1255284|NCT00937664|dose escalation
1255285|NCT00937664|combination treatment
1255286|NCT00937664|CHK inhibitor
1255287|NCT00937664|Japanese
1255288|NCT00937651|Fimasartan
1255289|NCT00937651|Essential Hypertension
1255290|NCT00937638|Metabolic syndrome
1255291|NCT00937638|Lean Beef
1255292|NCT00937638|CVD
1255293|NCT00937612|Head and Neck Neoplasms
1255294|NCT00937612|Chemotherapy
1255295|NCT00937612|Radiotherapy, Adjuvant
1255296|NCT00937612|Surgery
1255297|NCT00937599|obese
1255298|NCT00937599|brazil nuts
1255299|NCT00937599|oxidative stress
1255300|NCT00937599|microcirculatory
1255301|NCT00937599|metabolic profile
1255302|NCT00937586|Metastatic Prostate Cancer
1255303|NCT00937586|Prostate Cancer Risk Assessment
1255304|NCT00937573|stents
1255305|NCT00937573|mortality
1255306|NCT00937573|revascularization
1255307|NCT00937573|stent thrombosis
1255308|NCT00937573|Drug-Eluting Stents
1255309|NCT00937547|cervical cancer
1255310|NCT00937547|Human Papillomavirus Infection
1255311|NCT00937534|Fimasartan
1255312|NCT00937534|healthy elderly and young male volunteer
1255313|NCT00937534|pharmacokinetic
1255314|NCT00937521|Immunogenicity
1255315|NCT00937521|Meningitis
1255316|NCT00937521|Antibody
1255317|NCT00937521|Infants
1255318|NCT00937508|smoking
1255319|NCT00937508|quitting
1255320|NCT00937508|varenicline
1255321|NCT00937508|preoperative
1255322|NCT00937508|long term abstinence
1255323|NCT00937469|Social skills training for children with ADHD
1255324|NCT00937469|Children with ADHD
1255325|NCT00937456|Esophagus
1255326|NCT00937456|Cancer
1255327|NCT00937456|Surgery
1255328|NCT00937456|Laparoscopy
1255329|NCT00937456|Randomized trial
1255330|NCT00937456|Esophageal cancer deemed to be resectable
1255331|NCT00937443|Physical Activity
1255332|NCT00937443|Cardiac Heart Failure
1255333|NCT00937443|Exercise Regimen
1255334|NCT00937443|Cardioreparative Factors
1255335|NCT00937430|Pelvic organ prolapse
1255336|NCT00937430|Bowel preparation
1255337|NCT00937417|unspecified adult solid tumor, protocol specific
1255338|NCT00937417|recurrent non-small cell lung cancer
1255339|NCT00937417|stage IV non-small cell lung cancer
1255340|NCT00937417|stage IV breast cancer
1255341|NCT00937417|recurrent squamous cell carcinoma of the hypopharynx
1255342|NCT00937417|stage IV squamous cell carcinoma of the hypopharynx
1255343|NCT00937417|recurrent squamous cell carcinoma of the larynx
1255344|NCT00937417|recurrent verrucous carcinoma of the larynx
1255345|NCT00937417|stage IV squamous cell carcinoma of the larynx
1255346|NCT00937417|stage IV verrucous carcinoma of the larynx
1255347|NCT00937417|recurrent adenoid cystic carcinoma of the oral cavity
1255348|NCT00937417|recurrent mucoepidermoid carcinoma of the oral cavity
1255349|NCT00937417|recurrent squamous cell carcinoma of the lip and oral cavity
1255350|NCT00937417|recurrent verrucous carcinoma of the oral cavity
1255351|NCT00937417|recurrent basal cell carcinoma of the lip
1255352|NCT00937417|stage IV adenoid cystic carcinoma of the oral cavity
1255353|NCT00937417|stage IV basal cell carcinoma of the lip
1255354|NCT00937417|stage IV mucoepidermoid carcinoma of the oral cavity
1255355|NCT00937417|stage IV squamous cell carcinoma of the lip and oral cavity
1255356|NCT00937417|stage IV verrucous carcinoma of the oral cavity
1255357|NCT00937417|recurrent metastatic squamous neck cancer with occult primary
1255358|NCT00937417|recurrent lymphoepithelioma of the nasopharynx
1255359|NCT00937417|recurrent squamous cell carcinoma of the nasopharynx
1255360|NCT00937417|stage IV lymphoepithelioma of the nasopharynx
1255361|NCT00937417|stage IV squamous cell carcinoma of the nasopharynx
1255362|NCT00937417|recurrent lymphoepithelioma of the oropharynx
1255363|NCT00937417|recurrent squamous cell carcinoma of the oropharynx
1255364|NCT00937417|stage IV lymphoepithelioma of the oropharynx
1255365|NCT00937417|stage IV squamous cell carcinoma of the oropharynx
1255366|NCT00937417|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1255367|NCT00937417|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1255368|NCT00937417|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1255369|NCT00937417|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1255370|NCT00937417|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1255371|NCT00937417|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1255372|NCT00937417|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1255373|NCT00937417|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1255374|NCT00937417|recurrent salivary gland cancer
1255375|NCT00937417|stage IV salivary gland cancer
1255376|NCT00937417|anaplastic thyroid cancer
1255377|NCT00937417|stage IV follicular thyroid cancer
1255378|NCT00937417|insular thyroid cancer
1255379|NCT00937417|stage IV papillary thyroid cancer
1255380|NCT00937417|recurrent thyroid cancer
1255381|NCT00937417|thyroid gland medullary carcinoma
1255382|NCT00937417|recurrent prostate cancer
1255383|NCT00937417|hormone-resistant prostate cancer
1255384|NCT00937417|recurrent breast cancer
1255385|NCT00937417|stage IV prostate cancer
1255386|NCT00937417|male breast cancer
1255387|NCT00937404|IPV
1255388|NCT00937391|MRI agents
1255389|NCT00937391|Magnevist
1255390|NCT00937365|Pregnancy
1255391|NCT00937365|Pain
1255392|NCT00937365|Low back pain
1255393|NCT00937365|Pubic symphysis pain
1255394|NCT00937365|CAM
1255395|NCT00937365|Complementary & Alternative Medicine
1255396|NCT00937365|Exercise
1255397|NCT00937365|Chiropractic
1255398|NCT00937365|Spinal manipulation
1255399|NCT00937365|Adjustments
1255400|NCT00937365|Neuroemotional technique
1255401|NCT00937365|Mind body
1255402|NCT00937365|Mind body therapy
1255403|NCT00937365|Attachment
1255404|NCT00937365|Maternal Fetal relationship
1255405|NCT00937365|Intrauterine attachment
1255406|NCT00937365|Heart rate variability
1255407|NCT00937365|VAS
1255408|NCT00937365|Visual analog scale
1255409|NCT00937365|Roland Morris Disability Index
1255410|NCT00937352|Mild to moderate Alzheimer's disease
1255411|NCT00937339|cerebrovascular accident
1255412|NCT00937339|bone
1255413|NCT00937339|muscle
1255414|NCT00937339|vibration
1255415|NCT00937287|HPV
1255416|NCT00937287|African American
1255417|NCT00937287|Rural
1255418|NCT00937274|ETEC EPEC diarrhoea
1255419|NCT00937274|phage therapy
1255420|NCT00937274|ORS
1255421|NCT00937248|Cone Beam CT in rectal cancer patients
1255422|NCT00937248|Immobilizing rectal cancer patients
1255423|NCT00937248|Image guided radiotherapy in rectal cancer patients
1255424|NCT00937235|Smoking Cessation
1255425|NCT00937235|Anxiety
1255426|NCT00937235|Behavior Therapy
1255427|NCT00937235|Varenicline
1255428|NCT00937222|diabetes
1255429|NCT00937222|cholesterol
1255430|NCT00937222|peanuts
1255431|NCT00937222|peanut butter
1255432|NCT00937222|dietary intervention
1255433|NCT00937222|HDL cholesterol
1255434|NCT00937183|Waldenström macroglobulinemia
1255435|NCT00937183|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1255436|NCT00937183|stage I grade 1 follicular lymphoma
1255437|NCT00937183|stage I grade 2 follicular lymphoma
1255438|NCT00937183|stage I grade 3 follicular lymphoma
1255439|NCT00937183|stage II grade 1 follicular lymphoma
1255440|NCT00937183|stage II grade 2 follicular lymphoma
1255441|NCT00937183|stage II grade 3 follicular lymphoma
1255442|NCT00937183|stage III grade 1 follicular lymphoma
1255443|NCT00937183|stage III grade 2 follicular lymphoma
1255444|NCT00937183|stage III grade 3 follicular lymphoma
1255445|NCT00937183|stage I small lymphocytic lymphoma
1255446|NCT00937183|stage II small lymphocytic lymphoma
1255447|NCT00937183|stage III small lymphocytic lymphoma
1255448|NCT00937183|stage I marginal zone lymphoma
1255449|NCT00937183|stage II marginal zone lymphoma
1255450|NCT00937183|stage III marginal zone lymphoma
1255451|NCT00937183|stage I adult diffuse large cell lymphoma
1255452|NCT00937183|stage II adult diffuse large cell lymphoma
1255453|NCT00937183|stage III adult diffuse large cell lymphoma
1255454|NCT00937183|recurrent mantle cell lymphoma
1255455|NCT00937183|stage I mantle cell lymphoma
1255456|NCT00937183|stage II mantle cell lymphoma
1255457|NCT00937183|stage III mantle cell lymphoma
1255458|NCT00937183|stage I multiple myeloma
1255459|NCT00937183|stage II multiple myeloma
1255460|NCT00937183|stage III multiple myeloma
1255461|NCT00937183|B-cell chronic lymphocytic leukemia
1255462|NCT00937183|stage I chronic lymphocytic leukemia
1255463|NCT00937183|stage II chronic lymphocytic leukemia
1255464|NCT00937183|stage III chronic lymphocytic leukemia
1255465|NCT00937170|Total Knee Replacement
1255466|NCT00937170|Gender Specific Design
1255467|NCT00937157|Inflammation
1255468|NCT00937157|Multiple Sclerosis
1255469|NCT00937157|Glatiramer Acetate
1255470|NCT00937157|Gd enhancing lesions
1255471|NCT00937157|1.5T protocol
1255472|NCT00937157|3T protocol
1255473|NCT00937157|Magnetization transfer imaging (MTI)
1255474|NCT00937157|Lesion activity analysis
1255475|NCT00937157|Copaxone
1255476|NCT00937144|endothelial function
1255477|NCT00937144|endothelial progenitor stem cells
1255478|NCT00937118|laparotomy
1255479|NCT00937118|duodenal injury
1255480|NCT00937118|pancreatic injury
1255481|NCT00937118|trauma
1255482|NCT00937092|Heart Failure
1255483|NCT00937092|Dopamine
1255484|NCT00937092|Furosemide
1255485|NCT00937092|Worsening Renal Function
1255486|NCT00937092|Hypokalemia
1255487|NCT00937092|Outcomes
1255488|NCT00937092|Prognosis
1255489|NCT00937079|Glucagon-like peptide-1 receptor targeting
1255490|NCT00937079|Insulinoma imaging
1255491|NCT00937079|Exendin-4
1255492|NCT00937079|molecular imaging
1255493|NCT00937066|Cost-effectiveness analysis
1255494|NCT00937066|Symbicort
1255495|NCT00937053|Neutropenia
1255496|NCT00937053|Transfusions
1255497|NCT00937053|Hemoglobin
1255498|NCT00937053|Bone marrow transplant
1255499|NCT00937053|Hematopoietic stem cell transplant
1255500|NCT00937040|Osmotic Release Oral System (OROS®) Extended Release Methylphenidate HCl
1255501|NCT00937040|CONCERTA® (OROS MPH)
1255502|NCT00937027|Antifolate
1255503|NCT00937027|Psoriasis
1255504|NCT00937027|Antiinflammatory drug
1255505|NCT00937027|Autoimmune disease
1255506|NCT00937027|Treatment
1255507|NCT00937014|infant formula
1255508|NCT00937014|growth
1255509|NCT00937014|weight
1255510|NCT00937001|myopathy
1255511|NCT00937001|respiratory failure
1255512|NCT00937001|cognitive impairment
1255513|NCT00937001|delirium
1255514|NCT00936988|Hyperparathyroidism, Primary
1255515|NCT00936988|cinacalcet
1255516|NCT00936962|Meningococcal C vaccine
1255517|NCT00936962|Meningitis study
1255518|NCT00936962|Canadian vaccine schedule
1255519|NCT00936962|Prevention of Meningococcal C disease
1255520|NCT00936949|total hip arthroplasty
1255521|NCT00936949|posterolateral
1255522|NCT00936949|modified lateral
1255523|NCT00936936|Testis
1255524|NCT00936936|Relapsed Testicular Cancer
1255525|NCT00936936|Bevacizumab
1255526|NCT00936936|Avastin
1255527|NCT00936936|Anti-VEGF monoclonal antibody
1255528|NCT00936936|rhuMAb-VEGF
1255529|NCT00936936|Carboplatin
1255530|NCT00936936|Paraplatin
1255531|NCT00936936|Docetaxel
1255532|NCT00936936|Taxotere
1255533|NCT00936936|Etoposide
1255534|NCT00936936|VePesid
1255535|NCT00936936|Gemcitabine
1255536|NCT00936936|Gemcitabine Hydrochloride
1255537|NCT00936936|Gemzar
1255538|NCT00936936|Ifosfamide
1255539|NCT00936936|Ifex
1255540|NCT00936936|Melphalan
1255541|NCT00936936|Alkeran
1255542|NCT00936923|CAPD
1255543|NCT00936923|Diuretics
1255544|NCT00936923|Residual Renal Function
1255545|NCT00936923|furosemide
1255546|NCT00936910|central line fungal infections
1255547|NCT00936910|antifungal lock therapy
1255548|NCT00936910|Ambisome lock therapy
1255549|NCT00936884|Opioid Induced Constipation
1255550|NCT00936871|lersivirine QT QTc ECG HIV NNRTI
1255551|NCT00936858|radioiodine refractory thyroid cancer
1255552|NCT00936858|RAD001
1255553|NCT00936832|stage IV rectal cancer
1255554|NCT00936832|adenocarcinoma of the rectum
1255555|NCT00936832|liver metastases
1255556|NCT00936832|lung metastases
1255557|NCT00936819|Stent
1255558|NCT00936819|endothelial progenitor cells
1255559|NCT00936819|nitric oxide
1255560|NCT00936819|myocardial infarction
1255561|NCT00936819|MRI
1255562|NCT00936806|Intracranial tumor patients
1255563|NCT00936793|Drug Interaction
1255564|NCT00936793|Asthma
1255565|NCT00936793|HIV
1255566|NCT00936793|Beclomethasone
1255567|NCT00936793|Protease Inhibitors
1255568|NCT00936793|HV
1255569|NCT00936793|Healthy Volunteer
1255570|NCT00936793|HIV Infections
1255571|NCT00936780|Coronary Artery Disease
1255572|NCT00936780|Restenosis
1255573|NCT00936780|Stent thrombosis
1255574|NCT00936780|Coronary stents
1255575|NCT00936780|Angioplasty
1255576|NCT00936780|Drug Eluting Stents (DES)
1255577|NCT00936767|falciparum malaria
1255578|NCT00936767|artemisone
1255579|NCT00936767|artesunate
1255580|NCT00936767|resistance
1255581|NCT00936754|Glycemic index
1255582|NCT00936754|Reduction of glycemic index of ingested foods
1255583|NCT00936741|Cushing's Disease
1255584|NCT00936741|Cushing's Syndrome
1255585|NCT00936741|Cushings
1255586|NCT00936741|Pituitary
1255587|NCT00936741|ACTH
1255588|NCT00936741|Adrenocorticotropic hormone
1255589|NCT00936741|Ectopic
1255590|NCT00936741|Adrenal adenoma
1255591|NCT00936741|Adrenal carcinoma
1255592|NCT00936741|Adrenal autonomy
1255593|NCT00936741|Cortisol
1255594|NCT00936741|Hypercortisolemia
1255595|NCT00936741|Cushingoid
1255596|NCT00936741|Moon facies
1255597|NCT00936741|Dorsocervical fat
1255598|NCT00936741|Plethora
1255599|NCT00936741|Hirsutism
1255600|NCT00936741|Violaceous striae
1255601|NCT00936741|Hormone
1255602|NCT00936741|Contraceptive
1255603|NCT00936741|Endocrine
1255604|NCT00936741|Cushing Syndrome
1255605|NCT00936741|Ectopic ACTH Secretion
1255606|NCT00936715|prevention of chronic hepatitis B recurrence
1255607|NCT00936715|post orthotopic liver transplant
1255608|NCT00936715|prevention of chronic hepatitis B recurrence in patients who have undergone orthotopic liver transplant
1255609|NCT00936702|Newly Diagnosed Carcinoma of Unknown Primary Origin
1255610|NCT00936702|Squamous Cell Carcinoma of Unknown Primary Origin
1255611|NCT00936702|Undifferentiated Carcinoma of Unknown Primary
1255612|NCT00936702|newly diagnosed carcinoma of unknown primary
1255613|NCT00936689|Hepatocellular carcinoma;
1255614|NCT00936689|Chemoembolization;
1255615|NCT00936689|DC-Beads.
1255616|NCT00936676|parkinson's
1255617|NCT00936676|long-term effects
1255618|NCT00936676|adagio
1255619|NCT00936676|rasagiline
1255620|NCT00936676|delayed start
1255621|NCT00936663|Diabetes
1255622|NCT00936663|Kidney Transplant
1255623|NCT00936663|Sitagliptin
1255624|NCT00936650|Hyperparathyroidism, Primary
1255625|NCT00936650|cinacalcet
1255626|NCT00936624|Persistent asthma
1255627|NCT00936611|LBH589
1255628|NCT00936611|WM
1255629|NCT00936611|panobinostat
1255630|NCT00936611|relapsed
1255631|NCT00936611|waldenstrom
1255632|NCT00936611|macroglobulinemia
1255633|NCT00936598|Sleep
1255634|NCT00936598|Endometrial Neoplasms
1255635|NCT00936598|Pain
1255636|NCT00936585|Crohn's Disease
1255637|NCT00936585|Infusion
1255638|NCT00936585|Anti IL-17 Monoclonal Antibody
1255639|NCT00936585|Placebo
1255640|NCT00936585|Crohn Disease
1255641|NCT00936585|Inflammatory Bowel Disease
1255642|NCT00936572|Probiotics
1255643|NCT00936572|La1
1255644|NCT00936572|BB536
1255645|NCT00936572|Colorectal surgery
1255646|NCT00936572|Intestinal immunity
1255647|NCT00936572|Dendritic cells
1255648|NCT00936572|Lymphocyte
1255649|NCT00936572|Microbiota
1255650|NCT00936559|rotator cuff tear repair
1255651|NCT00936559|open surgical technique
1255652|NCT00936559|safety
1255653|NCT00936520|Diabetic Macular Edema
1255654|NCT00936520|DME
1255655|NCT00936520|Pars Plana Vitrectomy
1255656|NCT00936520|Ocular Inflammation
1255657|NCT00936507|energy density
1255658|NCT00936507|portion size
1255659|NCT00936507|child feeding
1255660|NCT00936494|obstructive sleep apnea
1255661|NCT00936494|sleep related breathing disorder
1255662|NCT00936494|snoring
1255663|NCT00936494|disturbed sleeping
1255664|NCT00936494|open mouth breathing
1255665|NCT00936494|upper airway resistance syndrome
1255666|NCT00936481|OSA
1255667|NCT00936468|Elderly influenza vaccine
1255668|NCT00936455|telemedicine
1255669|NCT00936455|telephone
1255670|NCT00936455|outcomes
1255671|NCT00936442|Compliance
1255672|NCT00936442|Early Breast Cancer
1255673|NCT00936429|Dengue fever
1255674|NCT00936429|Dengue hemorrhagic fever
1255675|NCT00936429|Dengue shock syndrome
1255676|NCT00936429|Vaccine
1255677|NCT00936429|Hawaii Biotech
1255678|NCT00936416|Glomerular Filtration Rate
1255679|NCT00936416|Renal Blood Flow
1255680|NCT00936416|MRI
1255681|NCT00936416|Inulin
1255682|NCT00936416|Para-Aminohippuric Acid
1255683|NCT00936390|adenocarcinoma of the prostate
1255684|NCT00936390|stage IIB prostate cancer
1255685|NCT00936390|stage IIA prostate cancer
1255686|NCT00936351|schizophrenia
1255687|NCT00936351|intervention studies
1255688|NCT00936351|mindfulness meditation
1255689|NCT00936351|vocational rehabilitation
1255690|NCT00936351|schizoaffective disorder
1255691|NCT00936351|psychotic disorders
1255692|NCT00936338|anterior disc displacement without reduction of temporomandibular disorders
1255695|NCT00936299|Adolescents
1255696|NCT00936299|Substance Use Disorder
1255697|NCT00936299|Attention Deficit Hyperactivity Disorder
1255698|NCT00936299|Cognitive Behavioral Therapy
1255699|NCT00936286|Obstructive Sleep Apnea Syndrome
1255700|NCT00936286|Respiratory Muscle Training
1255701|NCT00936286|Normocapnic Hyperpnea
1255702|NCT00936286|SpiroTiger
1255703|NCT00936286|Polysomnography
1255704|NCT00936273|Sleep apnea syndrome
1255705|NCT00936273|SAS
1255706|NCT00936273|double loop gain
1255707|NCT00936273|DLI
1255708|NCT00936273|double loop index
1255709|NCT00936273|periodic breathing
1255710|NCT00936273|polysomnography
1255711|NCT00936260|osteoporosis
1255712|NCT00936260|postmenopausal
1255713|NCT00936260|alendronate
1255714|NCT00936234|CAD
1255715|NCT00936234|diabetes
1255716|NCT00936234|SDF-1
1255717|NCT00936234|endothelial function
1255718|NCT00936221|BRAF mutation positive
1255719|NCT00936221|advanced melanoma
1255720|NCT00936221|Advanced cutaneous melanoma
1255721|NCT00936221|Unknown primary melanoma
1255722|NCT00936195|HIV
1255723|NCT00936195|pregnancy
1255724|NCT00936195|breastfeeding
1255725|NCT00936195|PMTCT
1255726|NCT00936195|ARV treatment
1255727|NCT00936195|treatment naive
1255728|NCT00936169|Patients with at least one complex lesion suitable for implantation of a drug-eluting stent
1255729|NCT00936143|Spondylitis, Ankylosing
1255730|NCT00936143|infliximab
1255731|NCT00936143|Antibodies, Monoclonal
1255732|NCT00936130|Roux-en-Y gastric bypass surgery
1255733|NCT00936130|Sleeve gastrectomy (SGx) surgery
1255734|NCT00936130|Gastric banding (GBx) surgery
1255735|NCT00936130|Low calorie diet program
1255736|NCT00936117|Cancer of the Blood
1255737|NCT00936117|Cancer of Bone Marrow
1255738|NCT00936117|Acute Leukemia
1255739|NCT00936117|AML
1255740|NCT00936117|Fungal infection
1255741|NCT00936117|Prophylaxis
1255742|NCT00936117|Posaconazole
1255743|NCT00936117|SCH 56592
1255744|NCT00936117|Noxafil
1255745|NCT00936117|Chemotherapy
1255746|NCT00936104|pancreas
1255747|NCT00936104|cancer
1255748|NCT00936104|stem cell
1255749|NCT00936091|intestinal parasitic infections
1255750|NCT00936091|malnutrition
1255751|NCT00936091|Anemia
1255752|NCT00936078|kidney transplantation
1255753|NCT00936078|cohort study
1255754|NCT00936078|qualitative research
1255755|NCT00936078|health services research
1255756|NCT00936078|hypertension
1255757|NCT00936065|Etanercept
1255758|NCT00936065|Acitretin
1255759|NCT00936065|Psoriasis
1255760|NCT00936052|glioblastomas
1255761|NCT00936052|GBM
1255762|NCT00936052|gliosarcoma
1255763|NCT00936052|blastoma
1255764|NCT00936052|sarcoma
1255765|NCT00936013|novel influenza A(H1N1)
1255766|NCT00936013|chinese medicinal herbs
1255767|NCT00936000|alcohol abuse
1255768|NCT00936000|alveolar capillary permeability
1255769|NCT00935987|Primary Myelofibrosis
1255770|NCT00935987|Post-Polycythemia Vera
1255771|NCT00935987|Post-Essential Thrombocythemia
1255772|NCT00935987|CYT387
1255773|NCT00934921|Bioequivalence
1255774|NCT00934908|Zyprexa®
1255775|NCT00934908|Green Tea
1255776|NCT00934908|ALL
1255777|NCT00934895|stage IIIA breast cancer
1255778|NCT00934895|stage IIIB breast cancer
1255779|NCT00934895|stage IIIC breast cancer
1255780|NCT00934895|stage IV breast cancer
1255781|NCT00934895|HER2-negative breast cancer
1255782|NCT00934895|recurrent breast cancer
1255783|NCT00934882|Colorectal cancer
1255784|NCT00934882|Targeted therapy
1255785|NCT00934882|Multi-kinase inhibitor
1255786|NCT00934882|FOLFOX
1255787|NCT00934882|FOLFIRI
1255788|NCT00935961|CISPLATIN
1255789|NCT00935961|RAD001
1255790|NCT00935961|TAXOTERE (DOCETAXEL)
1255791|NCT00935961|09-028
1255792|NCT00935961|Squamous Cell Carcinoma
1255793|NCT00935961|Local-Regional Advanced Head and Neck
1255794|NCT00935948|hemorrhoids
1255795|NCT00935948|hemorrhoidal disease
1255796|NCT00935948|water smartweed
1255797|NCT00935948|hamamelis
1255798|NCT00935948|RCT
1255799|NCT00935935|Treatment experienced
1255800|NCT00935922|Flaxseed
1255801|NCT00935922|Weight loss
1255802|NCT00935922|Heart health
1255803|NCT00935922|Diabetes
1255804|NCT00935909|IV cannulation
1255805|NCT00935896|Ventilator-associated lung injury
1255806|NCT00935896|Tumor necrosis factor-alpha
1255807|NCT00935896|Interleukin-8
1255808|NCT00935896|Mechanical ventilation
1255809|NCT00935896|Low tidal volume ventilation
1255810|NCT00935896|Normal lungs
1255811|NCT00935883|Age Related macular Degeneration
1255812|NCT00935883|Macular Degeneration
1255813|NCT00935883|Drusen
1255814|NCT00935883|Geographic atrophy
1255815|NCT00935883|Eculizumab
1255816|NCT00935883|Soliris
1255817|NCT00935857|Balloon Enteroscopy
1255818|NCT00935857|Looping
1255819|NCT00935844|Advanced solid tumors
1255820|NCT00935844|Lymphoma
1255821|NCT00935831|Tolerability
1255822|NCT00935831|Safety
1255823|NCT00935831|Pharmacokinetics
1255824|NCT00935831|Pharmacodynamics
1255825|NCT00935818|smoking
1255826|NCT00935818|nicotine
1255827|NCT00935818|tobacco
1255828|NCT00935818|dependence
1255829|NCT00935818|cessation
1255830|NCT00935818|abstinence
1255831|NCT00935805|Diabetes Mellitus
1255832|NCT00935805|Arterial Hypertension
1255833|NCT00935805|Treatment
1255834|NCT00935805|Primary Care
1255835|NCT00935792|hematopoietic cancer
1255836|NCT00935792|lymphoid cancer
1255837|NCT00935779|Stomach Neoplasms
1255838|NCT00935779|Peritoneum
1255839|NCT00935766|Latinos Using Cardio Health Actions to Reduce Risk
1255840|NCT00935766|Omega three Fatty Acids
1255841|NCT00935766|Vascular Function and Inflammation
1255842|NCT00935753|Lesch-Nyhan Disease
1255843|NCT00935753|self-mutilating behavior
1255844|NCT00935740|thromboembolic disease
1255845|NCT00935740|thromboplastin
1255846|NCT00935740|hypercoagulability
1255847|NCT00935740|congestive heart failure
1255848|NCT00935727|renal transplant
1255849|NCT00935727|ultrasound
1255850|NCT00935727|elastography
1255851|NCT00935714|Arm
1255852|NCT00935714|Lymphedema
1255853|NCT00935714|Breast Cancer
1255854|NCT00935714|Exercise
1255855|NCT00935714|Breast Cancer related Lymphedema
1255856|NCT00935701|Autism Spectrum Disorder
1255857|NCT00935701|Acupressure
1255858|NCT00935701|Acupuncture
1255859|NCT00935688|malaria
1255860|NCT00935688|rapid diagnostic tests
1255861|NCT00935688|afghanistan
1255862|NCT00935688|Non-specific fever
1255863|NCT00935675|Patients with head and neck squamous cell carcinomas
1255864|NCT00935675|head and neck squamous cell carcinomas
1255865|NCT00935662|First time in man
1255866|NCT00935662|Safety study
1255867|NCT00935662|AZD8329
1255868|NCT00935649|Toenail Fungus
1255869|NCT00935649|PinPointe
1255870|NCT00935649|FootLaser
1255871|NCT00935649|Onychomycosis
1255872|NCT00935649|Fungal nails
1255873|NCT00935636|Intubation
1255874|NCT00935623|Malaria, Plasmodium vivax
1255875|NCT00935610|Elderly persons
1255876|NCT00935610|Muscle function and strength
1255877|NCT00935610|Body composition
1255878|NCT00935610|Inflammatory cytokine levels
1255879|NCT00935610|Cognitive functions
1255880|NCT00935610|Cysteine-rich whey protein isolate
1255881|NCT00935610|Immunocal
1255882|NCT00935610|Resistance training
1255883|NCT00935610|Improved muscle function
1255884|NCT00935610|Improved quality of life
1255885|NCT00935610|Aging processes
1255886|NCT00935610|Quality of life
1255887|NCT00935597|Relapsed Non-Hodgkin's Lymphoma
1255888|NCT00935597|Hodgkin's Disease
1255889|NCT00935597|Multiple Myeloma
1255890|NCT00935597|Chronic Lymphocytic Lymphoma
1255891|NCT00935597|Relapsed Non-Hodgkin's lymphoma (excluding follicular lymphoma and marginal zone lymphoma)
1255892|NCT00935584|Communication
1255893|NCT00935584|Doctor-patient relations
1255894|NCT00935584|medical informatics
1255895|NCT00935584|patient-centered care
1255896|NCT00935584|medical records systems, computerized
1255897|NCT00935558|dendritic cell
1255898|NCT00935558|cancer vaccine
1255899|NCT00935558|breast cancer
1255900|NCT00935558|aromatase inhibitor
1255901|NCT00935558|Zadaxin
1255902|NCT00935545|Brain Tumors
1255903|NCT00935545|High Grade
1255904|NCT00935545|CNS
1255905|NCT00935532|diabetes; exenatide once weekly; Byetta; glargine; Lantus; Amylin; Lilly
1255906|NCT00935519|total hip arthroplasty, ceramic, survival
1255907|NCT00935493|guanfacine
1255908|NCT00935493|aging
1255909|NCT00935493|cognitive aging
1255910|NCT00935493|prefrontal cognitive function
1255911|NCT00935493|executive function
1255912|NCT00935493|prefrontal cortex
1255913|NCT00935480|HIV
1255914|NCT00935480|INTEGRASE INHIBITOR
1255915|NCT00935480|Inhibitor on the lymphoid reservoir
1255916|NCT00935480|Residual HIV replication
1255917|NCT00935480|treatment experienced
1255918|NCT00935454|hepatocyte matrix implantation
1255919|NCT00935454|endstage liver disease
1255920|NCT00935454|liver cirrhosis
1255921|NCT00935454|impaired liver parenchyma
1255922|NCT00935454|improvement of liver function
1255923|NCT00935441|Diabetes mellitus
1255924|NCT00935441|chronic care
1255925|NCT00935441|case management
1255926|NCT00935441|telemedicine
1255927|NCT00935428|Equestrian injury
1255928|NCT00935428|Horse injury
1255929|NCT00935428|Trauma
1255930|NCT00935428|Horse
1255931|NCT00935428|Equestrian
1255932|NCT00935415|asthma
1255933|NCT00935415|exercise-induced bronchoconstriction
1255934|NCT00935415|montelukast
1255935|NCT00935415|clinical protection
1255936|NCT00935415|children
1255937|NCT00935415|time effect
1255938|NCT00935402|Energy balance
1255939|NCT00935402|Weight management
1255940|NCT00935402|Food intake
1255941|NCT00935402|Energy expenditure
1255942|NCT00935376|Sleep Management
1255943|NCT00935376|Awareness Training Programs
1255944|NCT00935376|Mindfulness Meditation
1255945|NCT00935376|Mind Body Bridging
1255946|NCT00935363|glyburide
1255947|NCT00935363|pharmacokinetics
1255948|NCT00935363|pharmacodynamics
1255949|NCT00935363|drug interaction
1255950|NCT00935363|Healthy Volunteers
1255951|NCT00935350|viscous
1255952|NCT00935350|fibre
1255953|NCT00935350|polysaccharide
1255954|NCT00935350|blood glucose
1255955|NCT00935350|postprandial
1255956|NCT00935337|Sleep problems
1255957|NCT00935337|Awareness training program
1255958|NCT00935337|Mind body bridging
1255959|NCT00935324|allo-SCT, GvHD, CK18-F
1255960|NCT00935298|Renal Transplantation
1255961|NCT00935298|Tacrolimus
1255962|NCT00935298|CYP3A5
1255963|NCT00935298|Genotyping
1255964|NCT00935285|Ventilator-associated pneumonia (VAP)
1255965|NCT00935285|Intensive care unit (ICU)
1255966|NCT00935285|Toll-like receptors
1255967|NCT00935259|Hypercholesterolemia, Dyslipidemia, simvastatin, Zocor
1255968|NCT00935246|Genomic devices
1255969|NCT00935246|Prediction of Escitalopram Response
1255970|NCT00935246|Depressed Patients
1255971|NCT00935233|ductal breast carcinoma in situ
1255972|NCT00935207|Pain
1255973|NCT00935207|Pediatric Pain
1255974|NCT00935207|Pain Diary
1255975|NCT00935207|Pediatric Pain Measurement
1255976|NCT00935207|Pain Measurement
1255977|NCT00935194|Novel Influenza A(H1N1)
1255978|NCT00935194|Oseltamivir
1255979|NCT00935194|Chinese Medicinal Herbs
1255980|NCT00935181|COPD
1255981|NCT00935181|diaphragm
1255982|NCT00935181|muscle
1255983|NCT00935181|stretching
1255984|NCT00935181|exercises
1255985|NCT00935181|dyspnea
1255986|NCT00935181|respiratory muscle stretching
1255987|NCT00935181|pulmonary rehabilitation
1255988|NCT00935181|exercise training
1256425|NCT00933647|Inflammation
1255989|NCT00935181|improved exercise capacity, dyspnea, quality of life
1255990|NCT00935168|Intensive Care
1255991|NCT00935168|Fluid Resuscitation
1255992|NCT00935168|Saline
1255993|NCT00935168|Hydroxy-ethyl starch
1255994|NCT00935155|exercise therapy
1255995|NCT00935155|Knee arthroplasty
1255996|NCT00935155|Acupuncture Analgesia
1255997|NCT00935155|Arthroplasty, Replacement, Knee
1255998|NCT00935155|rehabilitation
1255999|NCT00935142|stage IV cancer with no treatment options
1256000|NCT00935142|non-curative
1256001|NCT00935129|Treatment satisfaction
1256002|NCT00935129|OmniPod
1256003|NCT00935129|Insulin pump
1256004|NCT00935129|diabetes
1256005|NCT00935103|Addiction
1256006|NCT00935103|Psychoeducation
1256007|NCT00935103|Risk reduction behaviour
1256008|NCT00935103|Drop in center (DIC)
1256009|NCT00935090|unspecified adult solid tumor, protocol specific
1256010|NCT00935090|accelerated phase chronic myelogenous leukemia
1256011|NCT00935090|acute undifferentiated leukemia
1256012|NCT00935090|adult acute lymphoblastic leukemia in remission
1256013|NCT00935090|adult acute myeloid leukemia in remission
1256014|NCT00935090|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1256015|NCT00935090|adult acute myeloid leukemia with inv(16)(p13;q22)
1256016|NCT00935090|adult acute myeloid leukemia with t(15;17)(q22;q12)
1256017|NCT00935090|adult acute myeloid leukemia with t(16;16)(p13;q22)
1256018|NCT00935090|adult acute myeloid leukemia with t(8;21)(q22;q22)
1256019|NCT00935090|atypical chronic myeloid leukemia, BCR-ABL negative
1256020|NCT00935090|blastic phase chronic myelogenous leukemia
1256021|NCT00935090|chronic myelomonocytic leukemia
1256022|NCT00935090|chronic phase chronic myelogenous leukemia
1256023|NCT00935090|mast cell leukemia
1256024|NCT00935090|meningeal chronic myelogenous leukemia
1256025|NCT00935090|progressive hairy cell leukemia, initial treatment
1256026|NCT00935090|prolymphocytic leukemia
1256027|NCT00935090|recurrent adult acute lymphoblastic leukemia
1256028|NCT00935090|recurrent adult acute myeloid leukemia
1256029|NCT00935090|recurrent adult T-cell leukemia/lymphoma
1256030|NCT00935090|refractory chronic lymphocytic leukemia
1256031|NCT00935090|refractory hairy cell leukemia
1256032|NCT00935090|relapsing chronic myelogenous leukemia
1256033|NCT00935090|secondary acute myeloid leukemia
1256034|NCT00935090|stage I adult T-cell leukemia/lymphoma
1256035|NCT00935090|stage I chronic lymphocytic leukemia
1256036|NCT00935090|stage II adult T-cell leukemia/lymphoma
1256037|NCT00935090|stage II chronic lymphocytic leukemia
1256038|NCT00935090|stage III adult T-cell leukemia/lymphoma
1256039|NCT00935090|stage III chronic lymphocytic leukemia
1256040|NCT00935090|stage IV adult T-cell leukemia/lymphoma
1256041|NCT00935090|stage IV chronic lymphocytic leukemia
1256042|NCT00935090|T-cell large granular lymphocyte leukemia
1256043|NCT00935090|untreated adult acute lymphoblastic leukemia
1256044|NCT00935090|untreated adult acute myeloid leukemia
1256045|NCT00935090|untreated hairy cell leukemia
1256046|NCT00935090|recurrent adult Hodgkin lymphoma
1256047|NCT00935090|stage I adult Hodgkin lymphoma
1256048|NCT00935090|stage II adult Hodgkin lymphoma
1256049|NCT00935090|stage III adult Hodgkin lymphoma
1256050|NCT00935090|stage IV adult Hodgkin lymphoma
1256051|NCT00935090|anaplastic large cell lymphoma
1256052|NCT00935090|angioimmunoblastic T-cell lymphoma
1256053|NCT00935090|cutaneous B-cell non-Hodgkin lymphoma
1256054|NCT00935090|recurrent cutaneous T-cell non-Hodgkin lymphoma
1256055|NCT00935090|stage I cutaneous T-cell non-Hodgkin lymphoma
1256056|NCT00935090|stage II cutaneous T-cell non-Hodgkin lymphoma
1256057|NCT00935090|stage III cutaneous T-cell non-Hodgkin lymphoma
1256058|NCT00935090|stage IV cutaneous T-cell non-Hodgkin lymphoma
1256059|NCT00935090|recurrent mycosis fungoides/Sezary syndrome
1256060|NCT00935090|stage I mycosis fungoides/Sezary syndrome
1256061|NCT00935090|stage II mycosis fungoides/Sezary syndrome
1256062|NCT00935090|stage III mycosis fungoides/Sezary syndrome
1256063|NCT00935090|stage IV mycosis fungoides/Sezary syndrome
1256064|NCT00935090|adult grade III lymphomatoid granulomatosis
1256065|NCT00935090|adult nasal type extranodal NK/T-cell lymphoma
1256066|NCT00935090|Waldenstrom macroglobulinemia
1256067|NCT00935090|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1256068|NCT00935090|nodal marginal zone B-cell lymphoma
1256069|NCT00935090|splenic marginal zone lymphoma
1256070|NCT00935090|contiguous stage II adult Burkitt lymphoma
1256071|NCT00935090|contiguous stage II adult diffuse large cell lymphoma
1256072|NCT00935090|contiguous stage II adult diffuse mixed cell lymphoma
1256073|NCT00935090|contiguous stage II adult diffuse small cleaved cell lymphoma
1256074|NCT00935090|contiguous stage II adult immunoblastic large cell lymphoma
1256075|NCT00935090|contiguous stage II adult lymphoblastic lymphoma
1256076|NCT00935090|contiguous stage II grade 1 follicular lymphoma
1256077|NCT00935090|contiguous stage II grade 2 follicular lymphoma
1256078|NCT00935090|contiguous stage II grade 3 follicular lymphoma
1256079|NCT00935090|contiguous stage II mantle cell lymphoma
1256080|NCT00935090|contiguous stage II marginal zone lymphoma
1256081|NCT00935090|contiguous stage II small lymphocytic lymphoma
1256082|NCT00935090|stage I adult Burkitt lymphoma
1256083|NCT00935090|stage I adult diffuse large cell lymphoma
1256084|NCT00935090|stage I adult diffuse mixed cell lymphoma
1256085|NCT00935090|stage I adult diffuse small cleaved cell lymphoma
1256086|NCT00935090|stage I adult immunoblastic large cell lymphoma
1256087|NCT00935090|stage I adult lymphoblastic lymphoma
1256088|NCT00935090|stage I grade 1 follicular lymphoma
1256089|NCT00935090|stage I grade 2 follicular lymphoma
1256090|NCT00935090|stage I grade 3 follicular lymphoma
1256091|NCT00935090|stage I mantle cell lymphoma
1256092|NCT00935090|stage I marginal zone lymphoma
1256093|NCT00935090|stage I small lymphocytic lymphoma
1256094|NCT00935090|noncontiguous stage II adult Burkitt lymphoma
1256095|NCT00935090|noncontiguous stage II adult diffuse large cell lymphoma
1256096|NCT00935090|noncontiguous stage II adult diffuse mixed cell lymphoma
1256097|NCT00935090|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1256098|NCT00935090|noncontiguous stage II adult immunoblastic large cell lymphoma
1256099|NCT00935090|noncontiguous stage II adult lymphoblastic lymphoma
1256100|NCT00935090|noncontiguous stage II grade 1 follicular lymphoma
1256101|NCT00935090|noncontiguous stage II grade 2 follicular lymphoma
1256102|NCT00935090|noncontiguous stage II grade 3 follicular lymphoma
1256103|NCT00935090|noncontiguous stage II mantle cell lymphoma
1256104|NCT00935090|noncontiguous stage II marginal zone lymphoma
1256105|NCT00935090|noncontiguous stage II small lymphocytic lymphoma
1256106|NCT00935090|stage III adult Burkitt lymphoma
1256107|NCT00935090|stage III adult diffuse large cell lymphoma
1256108|NCT00935090|stage III adult diffuse mixed cell lymphoma
1256109|NCT00935090|stage III adult diffuse small cleaved cell lymphoma
1256110|NCT00935090|stage III adult immunoblastic large cell lymphoma
1256111|NCT00935090|stage III adult lymphoblastic lymphoma
1256112|NCT00935090|stage III grade 1 follicular lymphoma
1256113|NCT00935090|stage III grade 2 follicular lymphoma
1256114|NCT00935090|stage III grade 3 follicular lymphoma
1256115|NCT00935090|stage III mantle cell lymphoma
1256116|NCT00935090|stage III marginal zone lymphoma
1256117|NCT00935090|stage III small lymphocytic lymphoma
1256118|NCT00935090|stage IV adult Burkitt lymphoma
1256119|NCT00935090|stage IV adult diffuse large cell lymphoma
1256120|NCT00935090|stage IV adult diffuse mixed cell lymphoma
1256121|NCT00935090|stage IV adult diffuse small cleaved cell lymphoma
1256122|NCT00935090|stage IV adult immunoblastic large cell lymphoma
1256123|NCT00935090|stage IV adult lymphoblastic lymphoma
1256124|NCT00935090|stage IV grade 1 follicular lymphoma
1256125|NCT00935090|stage IV grade 2 follicular lymphoma
1256126|NCT00935090|stage IV grade 3 follicular lymphoma
1256127|NCT00935090|stage IV mantle cell lymphoma
1256128|NCT00935090|stage IV marginal zone lymphoma
1256129|NCT00935090|stage IV small lymphocytic lymphoma
1256130|NCT00935090|recurrent adult Burkitt lymphoma
1256131|NCT00935090|recurrent adult diffuse large cell lymphoma
1256132|NCT00935090|recurrent adult diffuse mixed cell lymphoma
1256133|NCT00935090|recurrent adult diffuse small cleaved cell lymphoma
1256134|NCT00935090|recurrent adult grade III lymphomatoid granulomatosis
1256135|NCT00935090|recurrent adult immunoblastic large cell lymphoma
1256136|NCT00935090|recurrent adult lymphoblastic lymphoma
1256137|NCT00935090|recurrent grade 1 follicular lymphoma
1256138|NCT00935090|recurrent grade 2 follicular lymphoma
1256139|NCT00935090|recurrent grade 3 follicular lymphoma
1256140|NCT00935090|recurrent mantle cell lymphoma
1256141|NCT00935090|recurrent marginal zone lymphoma
1256142|NCT00935090|recurrent small lymphocytic lymphoma
1256143|NCT00935090|intraocular lymphoma
1256144|NCT00935090|primary central nervous system non-Hodgkin lymphoma
1256145|NCT00935090|primary central nervous system Hodgkin lymphoma
1256146|NCT00935090|post-transplant lymphoproliferative disorder
1256147|NCT00935090|chronic eosinophilic leukemia
1256148|NCT00935090|chronic neutrophilic leukemia
1256149|NCT00935090|primary myelofibrosis
1256150|NCT00935090|essential thrombocythemia
1256151|NCT00935090|polycythemia vera
1256152|NCT00935090|extramedullary plasmacytoma
1256153|NCT00935090|isolated plasmacytoma of bone
1256154|NCT00935090|stage I multiple myeloma
1256155|NCT00935090|stage II multiple myeloma
1256156|NCT00935090|stage III multiple myeloma
1256157|NCT00935090|primary systemic amyloidosis
1256158|NCT00935090|refractory multiple myeloma
1256159|NCT00935090|de novo myelodysplastic syndromes
1256160|NCT00935090|previously treated myelodysplastic syndromes
1256161|NCT00935090|secondary myelodysplastic syndromes
1256162|NCT00935090|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1256163|NCT00935077|Hypertension
1256164|NCT00935077|Pharmacist Physician Collaborative Management of Hypertension
1256165|NCT00935064|Diabetes
1256166|NCT00935051|type 1 diabetes
1256167|NCT00935051|type 2 diabetes
1256168|NCT00935051|Diabetic foot ulcer
1256169|NCT00935025|Phase I
1256170|NCT00935025|Japanese healthy volunteer
1256171|NCT00935025|AZD1305
1256172|NCT00935025|Japanese and Caucasian
1256173|NCT00934986|Chronic Lymphocytic Leukemia
1256174|NCT00934986|NK Cells
1256175|NCT00934973|irritable bowel syndrome
1256176|NCT00934973|treatment
1256177|NCT00934960|vision
1256178|NCT00934960|Intraocular lenses
1256179|NCT00934947|Burns
1256180|NCT00934947|Pain
1256181|NCT00934934|Candida
1256182|NCT00934934|ventilator associated pneumonia
1256183|NCT00934934|respiratory tract infection
1256184|NCT00934934|antifungal
1256185|NCT00934934|biomarker
1256186|NCT00934843|Cardiopulmonary Bypass (CPB)
1256187|NCT00934843|System Inflammatory Response
1256188|NCT00934843|Low Cardiac Output Syndrome (LCOS) in Neonates
1256189|NCT00934843|Methylprednisolone
1256190|NCT00934843|Cardiopulmonary Bypass (CPB) in Neonates
1256191|NCT00934843|Glucocorticoid Use in Neonatal Cardiac Surgery
1256192|NCT00934843|Steroid
1256193|NCT00934830|Antibiotic
1256194|NCT00934830|Ultrasound
1256195|NCT00934830|Efficacy
1256196|NCT00934830|Treatment
1256197|NCT00934817|Volunteer
1256198|NCT00934804|refractive surgery
1256199|NCT00934791|Kidney Transplant
1256200|NCT00934791|Autosomal dominant polycystic kidney disease
1256201|NCT00934791|Polycystic liver disease
1256202|NCT00934778|Confocal microscopy
1256203|NCT00934778|Endocytoscopy
1256204|NCT00934778|Diffuse lung disease
1256205|NCT00934778|Minimally invasive
1256206|NCT00934778|Lung cancer and dysplasia
1256207|NCT00934765|overweight, obesity, male, fertility
1256208|NCT00934752|de novo stenotic lesions
1256209|NCT00934739|High-Risk Oral Cavity Cancer,
1256210|NCT00934739|Anti-Angiogenesis
1256211|NCT00934726|Quality of Life
1256212|NCT00934726|Patient satisfaction
1256213|NCT00934726|Schizophrenia
1256214|NCT00934726|Investigate quality of life in schizophrenia
1256215|NCT00934713|montelukast, very young children, lung function tests
1256216|NCT00934700|perinatal asphyxia
1256217|NCT00934700|encephalopathy
1256218|NCT00934700|neuroprotection
1256219|NCT00934687|depression
1256220|NCT00934687|depressive
1256221|NCT00934687|botulinum
1256222|NCT00934687|botox
1256223|NCT00934674|Healthy Subjects
1256224|NCT00934661|hip resurfacing
1256225|NCT00934661|hip arthroplasty
1256226|NCT00934635|D2-receptor occupancy
1256227|NCT00934635|Antipsychotic drugs
1256228|NCT00934635|Paliperidone ER, Oral risperidone
1256229|NCT00934635|Dopamine
1256230|NCT00934635|Fallypride
1256231|NCT00934635|Plasma concentration
1256232|NCT00934635|Therapeutic window, Healthy controls
1256233|NCT00934622|AcrySof
1256234|NCT00934622|ReSTOR
1256235|NCT00934622|Aspheric IOL
1256236|NCT00934622|Cataract
1256237|NCT00934609|Exercise
1256238|NCT00934609|heart failure
1256239|NCT00934609|dilated cardiomyopathy
1256240|NCT00934609|Endurance training
1256241|NCT00934596|Cardiac de-airing
1256242|NCT00934596|CO2 insufflation
1256243|NCT00934596|Air emboli
1256244|NCT00934596|Trans cranial doppler
1256245|NCT00934596|Intraoperative echocardiography
1256246|NCT00934583|Bulimia Nervosa
1256247|NCT00934583|Binge Eating
1256248|NCT00934583|Binge-Eating Disorder
1256249|NCT00934570|Obesity
1256250|NCT00934570|Metformin
1256251|NCT00934570|Physical activity
1256252|NCT00934570|Cardiovascular health
1256253|NCT00934544|Myelofibrosis
1256254|NCT00934544|Post-Polycythemia Vera Myelofibrosis
1256255|NCT00934544|Post-Essential Thrombocythemia Myelofibrosis
1256256|NCT00934531|Mild Cognitive Impairment (MCI)
1256257|NCT00934531|Falls
1256258|NCT00934531|donepezil
1256259|NCT00934531|gait variability
1256260|NCT00934518|Squamous cell carcinoma, Head and Neck cancer
1256261|NCT00934505|Positron-Emission Tomography
1256262|NCT00934505|PET Scan
1256263|NCT00934505|FDG
1256264|NCT00934505|oesophageal cancer
1256265|NCT00934505|chemo-Radiation Oncology
1256266|NCT00934505|SUV
1256267|NCT00934492|Malnutrition
1256268|NCT00934492|Wasting
1256269|NCT00934492|Kwashiorkor
1256270|NCT00934492|Immune deficiency
1256271|NCT00934492|Infection
1256272|NCT00934492|Prophylaxis
1256273|NCT00934492|Mortality
1256274|NCT00934492|Kenya
1256275|NCT00934479|Chronic Constipation
1256276|NCT00934479|Constipation Predominant Irritable Bowel Syndrome
1256277|NCT00934479|Intestinal Microecology
1256278|NCT00934453|Healthy adult volunteers
1256279|NCT00934453|Lactobacillus rhamnosus GG
1256280|NCT00934453|probiotic
1256281|NCT00934453|dietary supplement
1256282|NCT00934453|safety
1256283|NCT00934453|Safety Assessment
1256284|NCT00934440|kidney cancer
1256285|NCT00934440|renal cell
1256286|NCT00934427|Raynaud's
1256287|NCT00934427|scleroderma
1256288|NCT00934427|nitroglycerin
1256289|NCT00934427|MQX-503
1256290|NCT00934427|treatment
1256291|NCT00934401|FLT
1256292|NCT00934401|fluorolabeled thymidine
1256293|NCT00934401|breast cancer
1256294|NCT00934401|Positron-Emission Mammography
1256295|NCT00934388|Sportsmans groin, Gilmores groin
1256296|NCT00934375|Mild Cognitive Impairment
1256297|NCT00934349|Comoro Island
1256298|NCT00934349|vit B1 intake
1256299|NCT00934349|Thiamine status
1256300|NCT00934349|Genetic factor
1256301|NCT00934323|volunteer
1256302|NCT00934310|Patient Safety
1256303|NCT00934310|Team work
1256304|NCT00934310|Communication
1256305|NCT00934310|Ambulatory surgical patients
1256306|NCT00934297|MRI visible breast lesions that are occult under ultrasound
1256307|NCT00934284|sciatic neuropathy
1256308|NCT00934284|physical therapy
1256309|NCT00934284|spinal injections
1256310|NCT00934271|acromegaly
1256311|NCT00934271|irradiation
1256312|NCT00934271|remission
1256313|NCT00934271|pituitary function
1256314|NCT00934258|genes
1256315|NCT00934258|rosuvastatin
1256316|NCT00934258|fenofibrate
1256317|NCT00934258|Cardiovascular (CV) diseases
1256318|NCT00934258|dyslipidemia
1256319|NCT00934258|metabolic syndrome
1256320|NCT00934258|identify genetic determinants of the wide range of interindividual variability in phenotypic and clinical response to the lipid-lowering drug classes
1256321|NCT00934258|identify genetic susceptibility to drug-related side effects.
1256322|NCT00934245|Influenza
1256323|NCT00934245|India
1256324|NCT00934245|Children
1256325|NCT00934245|Trivalent Influenza Vaccine (TIV)
1256326|NCT00934245|Inactivated poliovirus vaccine (IPV)
1256327|NCT00934245|Direct vaccine effectiveness
1256328|NCT00934245|Indirect vaccine effectiveness
1256329|NCT00934232|cancer
1256330|NCT00934232|myeloma
1256331|NCT00934219|hypertriglyceridemia
1256332|NCT00934219|triglycerides
1256333|NCT00934219|familial hypertriglyceridemia
1256334|NCT00934206|Exercise
1256335|NCT00934206|healthy subjects
1256336|NCT00934180|Bioequivalence
1256337|NCT00934154|multiple myeloma
1256338|NCT00934154|thalidomide
1256339|NCT00934154|melphalan
1256340|NCT00934154|prednisolone
1256341|NCT00934154|newly diagnosed
1256342|NCT00934154|elderly
1256343|NCT00934154|not eligible for transplantation
1256344|NCT00934141|Organizational change
1256345|NCT00934141|process improvement
1256346|NCT00934141|addiction treatment
1256347|NCT00934141|cost effectiveness study
1256348|NCT00934128|Advanced Cancer
1256349|NCT00934128|Persistent Dyspnea
1256350|NCT00934128|Shortness of breath
1256351|NCT00934128|Specialized breathing devices
1256352|NCT00934128|Bilevel positive airway pressure device
1256353|NCT00934128|BIPAP
1256354|NCT00934128|High flow oxygen delivery device
1256355|NCT00934128|VapoTherm
1256356|NCT00934128|Edmonton Symptom Assessment Scale
1256357|NCT00934128|ESAS
1256358|NCT00934115|To define the incidence, categories of infections by organ systems, etiologic agents and risk
1256359|NCT00934037|Coronary Artery Disease
1256360|NCT00934037|Computed Tomography
1256361|NCT00934037|Myoperfusion
1256362|NCT00934037|Angiography
1256363|NCT00934037|SPECT
1256364|NCT00934024|nicotine dependence
1256365|NCT00934024|tobacco
1256366|NCT00934024|smoking
1256367|NCT00934011|C-reactive protein
1256368|NCT00934011|procalcitonin
1256369|NCT00934011|sepsis
1256370|NCT00934011|antibiotic therapy
1256371|NCT00933998|DPN
1256372|NCT00933959|Sleep problems
1256373|NCT00933959|Awareness training program
1256374|NCT00933959|Mind body bridging
1256375|NCT00933920|Aliskiren,
1256376|NCT00933920|hypertension,
1256377|NCT00933920|renin-angiotensin-aldosterone system,
1256378|NCT00933920|pharmacokinetics,
1256379|NCT00933920|pharmacodynamics
1256380|NCT00933894|VX-950-TiDP24-C133
1256381|NCT00933894|VX-950-C133
1256382|NCT00933894|VX950
1256383|NCT00933894|HCV
1256384|NCT00933894|telaprevir
1256385|NCT00933894|escitalopram
1256386|NCT00933881|GDM
1256387|NCT00933868|A stroke that occurred three months to four years ago
1256388|NCT00933855|Training Workshop
1256389|NCT00933855|Communication
1256390|NCT00933855|Questionnaires
1256391|NCT00933855|Multiple Diseases
1256392|NCT00933829|absorbable sutures
1256393|NCT00933829|non-absorbable sutures
1256394|NCT00933829|wound management
1256395|NCT00933816|sorafenib
1256396|NCT00933816|intraarterial infusion chemotherapy
1256397|NCT00933816|Low dose FP
1256398|NCT00933816|cisplatin
1256399|NCT00933816|fluorouracil
1256400|NCT00933790|TB
1256401|NCT00933790|HIV
1256402|NCT00933790|ARR
1256403|NCT00933790|Short course chemotherapy
1256404|NCT00933790|Drug resistance
1256405|NCT00933751|central venous oxygen saturation
1256406|NCT00933751|oxygen transport
1256407|NCT00933751|physiologic monitoring
1256408|NCT00933751|tissue oxygenation
1256409|NCT00933751|Patients before high risk abdominal surgery
1256410|NCT00933738|Patients needing OAT (Oral Anticoagulation Therapy)
1256411|NCT00933725|menopausal syndrome
1256412|NCT00933725|TCM intervention
1256413|NCT00933673|NK/T cell lymphoma
1256414|NCT00933673|DICE
1256415|NCT00933673|L-asparaginase
1256416|NCT00933660|Education
1256417|NCT00933660|Retention
1256418|NCT00933660|Retrieval
1256419|NCT00933647|Camellia sinensis
1256420|NCT00933647|Ilex paraguariensis
1256421|NCT00933647|Green tea
1256422|NCT00933647|Yerba mate tea
1256423|NCT00933647|Maté
1256424|NCT00933647|Dyslipidemia
1256426|NCT00933647|Obesity
1256427|NCT00933634|atrial fibrillation
1256428|NCT00933634|electrical cardioversion
1256429|NCT00933634|pharmacological cardioversion
1256430|NCT00933608|subjective memory complaints
1256431|NCT00933608|cognitively healthy
1256432|NCT00933608|family history
1256433|NCT00933608|AD
1256434|NCT00933595|HIV
1256435|NCT00933595|Lung
1256436|NCT00933582|Osteoarthritis, Knee
1256437|NCT00933582|Knee Pain
1256438|NCT00933582|Pain Measurement
1256439|NCT00933582|Naproxen
1256440|NCT00933582|Placebo
1256441|NCT00933582|Treatment Outcome
1256442|NCT00933556|infection
1256443|NCT00933556|probiotics
1256444|NCT00933543|Acne Vulgaris
1256445|NCT00933543|Moderate to severe
1256446|NCT00933517|breast cancer, neoadjuvant therapies, chemotherapy, targeted therapy
1256447|NCT00933491|healthy
1256448|NCT00933478|Patulous Eustachian Tube Dysfunction
1256449|NCT00933465|Fecal incontinence
1256450|NCT00933452|duloxetine
1256451|NCT00933452|pharmacokinetics
1256452|NCT00933452|antidepressant
1256453|NCT00933452|antidepressive agents
1256454|NCT00933452|depression
1256455|NCT00933452|psychotropic drugs
1256456|NCT00933452|safety
1256457|NCT00933452|Chinese
1256458|NCT00933452|HAN
1256459|NCT00933452|BDNF
1256460|NCT00933439|Depression
1256461|NCT00933439|Major Depressive Disorder
1256462|NCT00933439|Cognitive Function
1256463|NCT00933439|Psychosocial Function
1256464|NCT00933426|Castration-Resistant Prostate Cancer
1256465|NCT00933426|CRPC
1256466|NCT00933426|Prostate
1256467|NCT00933426|Lenalidomide
1256468|NCT00933426|Revlimid
1256469|NCT00933426|CC-5103
1256470|NCT00933426|Paclitaxel
1256471|NCT00933426|Taxol
1256472|NCT00933426|Taxanes
1256473|NCT00933400|Computed Tomography
1256474|NCT00933400|CTA
1256475|NCT00933400|Cardiac CT
1256476|NCT00933400|CT
1256477|NCT00933400|Cardiac CTA
1256478|NCT00933400|Chest Pain
1256479|NCT00933400|Heart Attack
1256480|NCT00933400|Emergency Department
1256481|NCT00933400|Myocardial Infarction
1256482|NCT00933400|Cost Effectiveness
1256483|NCT00933400|Acute Coronary Event
1256484|NCT00933400|Heart Imaging
1256485|NCT00933387|oral squamous cell carcinoma
1256486|NCT00933387|neoadjuvant bio-chemotherapy
1256487|NCT00933387|concurrent bio-radiotherapy
1256488|NCT00933387|biomarker
1256489|NCT00933374|bladder cancer
1256490|NCT00933374|RAD001
1256491|NCT00933374|Paclitaxel
1256492|NCT00933361|Adult
1256493|NCT00933348|ulcer
1256494|NCT00933348|venous
1256495|NCT00933348|pressure
1256496|NCT00933348|wound
1256497|NCT00933348|treatment
1256498|NCT00933322|ruminant
1256499|NCT00933322|industrial
1256500|NCT00933322|endothelial function
1256501|NCT00933322|flow-mediated dilation
1256502|NCT00933322|blood lipids
1256503|NCT00933322|nutrition
1256504|NCT00933322|trans fatty acids
1256505|NCT00933322|coronary disease
1256506|NCT00933322|endothelial function of the brachial artery
1256507|NCT00933322|inflammation
1256508|NCT00933322|insulin resistancy
1256509|NCT00933322|coagulation
1256510|NCT00933309|Breast
1256511|NCT00933309|Obese
1256512|NCT00933309|Obesity Treatment
1256513|NCT00933309|Exemestane
1256514|NCT00933309|Aromasin
1256515|NCT00933309|Metformin and Rosiglitazone
1256516|NCT00933309|Avandamet
1256517|NCT00933309|Postmenopausal
1256518|NCT00933309|Hormone-sensitive
1256519|NCT00933309|Hormone-receptive-positive breast cancer
1256520|NCT00933296|Schnitzler syndrome
1256521|NCT00933296|Waldentsröm's disease
1256522|NCT00933296|anakinra
1256523|NCT00933283|Healthy participants
1256524|NCT00933283|Pharmacokinetics
1256525|NCT00933283|Pharmacodynamic
1256526|NCT00933283|Potential interaction
1256527|NCT00933283|VX-950-TiDP24-C135
1256528|NCT00933283|VX-950
1256529|NCT00933283|Methadone
1256530|NCT00933283|Telaprevir
1256531|NCT00933283|Steady-state
1256532|NCT00933270|Superficial Femoral Artery or SFA
1256533|NCT00933244|Vitamin D
1256534|NCT00933244|Cholecalciferol
1256535|NCT00933244|Parathyroid Hormone
1256536|NCT00933244|Calcium Absorption
1256537|NCT00933244|Bone Mineral Density
1256538|NCT00933244|Muscle Function
1256539|NCT00933231|Tacrolimus
1256540|NCT00933231|Kidney Transplantation
1256541|NCT00933231|Advagraf
1256542|NCT00933231|Immunosuppression
1256543|NCT00933231|Angiotensin-Converting Enzyme Inhibitors
1256544|NCT00933179|Prevention of pregnancy
1256545|NCT00933153|Elderly
1256546|NCT00933153|Malnutrition
1256547|NCT00933153|Oral Nutrition Supplement
1256548|NCT00933153|Meals on Wheels
1256549|NCT00933140|HIV
1256550|NCT00933140|women
1256551|NCT00933140|anal cytology
1256552|NCT00933127|contiguous stage II grade 1 follicular lymphoma
1256673|NCT00932581|Bradykinesia
1256553|NCT00933127|contiguous stage II grade 2 follicular lymphoma
1256554|NCT00933127|contiguous stage II grade 3 follicular lymphoma
1256555|NCT00933127|noncontiguous stage II grade 1 follicular lymphoma
1256556|NCT00933127|noncontiguous stage II grade 2 follicular lymphoma
1256557|NCT00933127|noncontiguous stage II grade 3 follicular lymphoma
1256558|NCT00933127|stage III grade 1 follicular lymphoma
1256559|NCT00933127|stage III grade 2 follicular lymphoma
1256560|NCT00933127|stage III grade 3 follicular lymphoma
1256561|NCT00933127|stage IV grade 1 follicular lymphoma
1256562|NCT00933127|stage IV grade 2 follicular lymphoma
1256563|NCT00933127|stage IV grade 3 follicular lymphoma
1256564|NCT00933114|DCE MRI
1256565|NCT00933114|PET
1256566|NCT00933114|Perfusion
1256567|NCT00933114|Permeability
1256568|NCT00933114|Cancer of the head and neck
1256569|NCT00933114|Head, Neck neoplasms
1256570|NCT00933088|adolescent coping strategies
1256571|NCT00933088|stress response
1256572|NCT00933088|breast cancer
1256573|NCT00933049|Efficacy
1256574|NCT00933049|children
1256575|NCT00933049|pneumonia
1256576|NCT00933049|cotrimoxazole
1256577|NCT00933049|amoxicillin
1256578|NCT00933036|Osteoporosis
1256579|NCT00933036|VCF
1256580|NCT00933036|PVA
1256581|NCT00933036|Vertebroplasty
1256582|NCT00933036|Kyphoplasty
1256583|NCT00933036|Vertebral fracture
1256584|NCT00933036|Pathologic fracture
1256585|NCT00933036|Vertebral augmentation
1256586|NCT00933010|metabolic syndrome
1256587|NCT00933010|lipids
1256588|NCT00933010|waist circumference
1256589|NCT00933010|HDL
1256590|NCT00933010|hypertension
1256591|NCT00932997|psychosocial effects of cancer and its treatment
1256592|NCT00932997|stage I breast cancer
1256593|NCT00932997|stage II breast cancer
1256594|NCT00932997|stage IIIA breast cancer
1256595|NCT00932997|cancer survivor
1256596|NCT00932958|Myocardial Infarction
1256597|NCT00932919|Agoraphobia
1256598|NCT00932919|Cognitive therapy
1256599|NCT00932919|Thought field therapy
1256600|NCT00932919|Psychotherapy research
1256601|NCT00932906|Education
1256602|NCT00932906|Retention
1256603|NCT00932906|Retrieval
1256604|NCT00932906|Self training
1256605|NCT00932893|Lung Neoplasms ALK gene crizotinib
1256606|NCT00932867|Arterial Hypertension
1256607|NCT00932854|Mediastinal lymphadenopathy
1256608|NCT00932854|EBUS
1256609|NCT00932854|Bronchoscopy
1256610|NCT00932854|Sarcoidosis
1256611|NCT00932828|Peanut allergy
1256612|NCT00932802|Non-Interventional
1256613|NCT00932802|Observational
1256614|NCT00932802|NIS
1256615|NCT00932802|Moxifloxacin
1256616|NCT00932802|MXF
1256617|NCT00932802|Avelox
1256618|NCT00932802|AECB
1256619|NCT00932750|Body composition
1256620|NCT00932750|Weight loss
1256621|NCT00932750|Weight management
1256622|NCT00932750|Beverages
1256623|NCT00932750|Diet
1256624|NCT00932724|Metastatic
1256625|NCT00932724|Colorectal
1256626|NCT00932724|Cancer
1256627|NCT00932724|refractory
1256628|NCT00932724|Phase II
1256629|NCT00932724|randomised
1256630|NCT00932724|double-blind
1256631|NCT00932724|controlled
1256632|NCT00932724|multicenter
1256633|NCT00932724|CY-503
1256634|NCT00932724|Cytavis
1256635|NCT00932711|COPD
1256636|NCT00932698|Relapsed multiple myeloma
1256637|NCT00932698|Refractory multiple myeloma
1256638|NCT00932698|IXAZOMIB Proteasome inhibitor
1256639|NCT00932685|pediatric emergence agitation and pain
1256640|NCT00932672|Prostate Cancer
1256641|NCT00932672|Atkins
1256642|NCT00932659|End-Stage Renal Disease
1256643|NCT00932659|Hemodialysis
1256644|NCT00932659|Cardiac Arrhythmias
1256645|NCT00932633|neonatal brain injury
1256646|NCT00932633|congenital heart disease
1256647|NCT00932633|magnetic resonance imaging
1256648|NCT00932633|cardiopulmonary bypass
1256649|NCT00932633|neurodevelopmental outcome
1256650|NCT00932620|hypercholesterolemia
1256651|NCT00932620|statins
1256652|NCT00932620|simvastatin
1256653|NCT00932620|ezetimibe
1256654|NCT00932620|LDL particles
1256655|NCT00932607|seasonal
1256656|NCT00932607|rhinitis
1256657|NCT00932607|rhinoconjunctivitis
1256658|NCT00932607|birch pollen
1256659|NCT00932607|immunotherapy
1256660|NCT00932607|sublingual
1256661|NCT00932594|Create the New Serial Treatment of TMD
1256662|NCT00932594|Promote the Classification of Biodynamics in the TMD
1256663|NCT00932594|Evaluate the Effect of Adjusting TMJ Treatment
1256664|NCT00932594|Establish the New Standard of the TMJ Treatment
1256665|NCT00932594|Invent New Device to Measure Pressure without Trauma
1256666|NCT00932581|Parkinson's Disease
1256667|NCT00932581|Movement Disorders
1256668|NCT00932581|Unified Parkinson's Disease Rating Scale
1256669|NCT00932581|Short Parkinson's Evaluation Scale
1256670|NCT00932581|Scales for Outcomes in Parkinson's Disease
1256671|NCT00932581|Motor Evaluation
1256672|NCT00932581|Schwab and England activities of daily living
1256674|NCT00932581|psychometrics
1256675|NCT00932581|order effects
1256676|NCT00932581|hoehn yahr aging
1256677|NCT00932581|assessments
1256678|NCT00932555|Octocog alfa
1256679|NCT00932555|Hemophilia A
1256680|NCT00932542|Hemorrhoidectomy
1256681|NCT00932529|Antipsychotic drugs
1256682|NCT00932529|Treatment effectiveness
1256683|NCT00932529|Randomized controlled trial
1256684|NCT00932516|South Beach Diet™
1256685|NCT00932516|overweight
1256686|NCT00932516|obesity
1256687|NCT00932516|satiety
1256688|NCT00932516|weight loss
1256689|NCT00932503|Vicryl plus
1256690|NCT00932503|wound infection
1256691|NCT00932503|coated suture material
1256692|NCT00932503|open abdominal surgery
1256693|NCT00932503|transverse laparotomy
1256694|NCT00932451|Lung Neoplasms ALK gene Crizotinib
1256695|NCT00932438|colon cancer
1256696|NCT00932438|liver metastases
1256697|NCT00932425|Stroke
1256698|NCT00932425|Cryptogenic
1256699|NCT00932425|Cardioembolic
1256700|NCT00932425|Atrial Fibrillation
1256701|NCT00932412|Younger Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML).
1256702|NCT00932386|Lower extremity surgery with tourniquet use
1256703|NCT00932373|HER2-positive breast cancer
1256704|NCT00932373|MBC
1256705|NCT00932373|Trastuzumab emtansine
1256706|NCT00932373|Herceptin
1256707|NCT00932373|T-DM1
1256708|NCT00932360|Fibromyalgia
1256709|NCT00932360|Transcutaneous Electrical Nerve Stimulation (TENS)
1256710|NCT00932347|Camellia sinensis
1256711|NCT00932347|volatile sulfur compounds
1256712|NCT00932334|kidney
1256713|NCT00932334|transplant
1256714|NCT00932334|donation
1256715|NCT00932321|Contraception
1256716|NCT00932295|tobacco
1256717|NCT00932295|cigarette
1256718|NCT00932295|nicotine
1256719|NCT00932282|Peanut
1256720|NCT00932282|Allergy
1256721|NCT00932282|Hypersensitivity
1256722|NCT00932269|Diphtheria
1256723|NCT00932269|Tetanus
1256724|NCT00932269|Pertussis
1256725|NCT00932269|Polio
1256726|NCT00932269|Haemophilus influenzae type B
1256727|NCT00932269|Hib
1256728|NCT00932269|Measles
1256729|NCT00932269|Mumps
1256730|NCT00932269|Rubella
1256731|NCT00932269|Hepatitis B
1256732|NCT00932269|Vaccine
1256733|NCT00932269|Vaccination
1256734|NCT00932269|Immunity
1256735|NCT00932269|Vaccination program
1256736|NCT00932269|Sweden
1256737|NCT00932269|ELISA
1256738|NCT00932256|Rhinitis, Allergic, Seasonal
1256739|NCT00932243|bacteremia
1256740|NCT00932243|sepsis
1256741|NCT00932243|Toll-Like-Receptors (TLRs)
1256742|NCT00932204|obsessive-compulsive disorder
1256743|NCT00932204|repetitive transcranial magnetic stimulation
1256744|NCT00932204|right dorsolateral prefrontal cortex
1256745|NCT00932204|supplementary motor area (SMA)
1256746|NCT00932191|Cataract
1256747|NCT00932191|Corneal endothelial cell loss
1256748|NCT00932191|Ultrasound power
1256749|NCT00932191|Corneal endothelium
1256750|NCT00932178|Anxiety
1256751|NCT00932178|Worry
1256752|NCT00932178|nervousness
1256753|NCT00932178|Older Adult
1256754|NCT00932152|advanced non-small cell lung cancer
1256755|NCT00932152|postmenopausal
1256756|NCT00932152|bevacizumab
1256757|NCT00932152|fulvestrant
1256758|NCT00932152|anastrozole
1256759|NCT00932139|Hypertension
1256760|NCT00932139|blood pressure
1256761|NCT00932139|arrhythmias
1256762|NCT00932139|mild to moderate hypertension (145-199/90-110)
1256763|NCT00932126|Phase 1 dose escalation dose finding pharmacokinetic and pharmacodynamic study
1256764|NCT00932113|tumor necrosis factor (TNF) inhibitor
1256765|NCT00932113|tumor necrosis factor (TNF) blockade
1256766|NCT00932113|Methotrexate
1256767|NCT00932113|treatment
1256768|NCT00932113|mechanism
1256769|NCT00932113|psoriasis
1256770|NCT00932100|ACS
1256771|NCT00932100|Acute Coronary Syndrome
1256772|NCT00932100|Catheterization
1256773|NCT00932087|Platelet function
1256774|NCT00932087|diabetes
1256775|NCT00932087|metabolic syndrome
1256776|NCT00932074|Atopic Dermatitis
1256777|NCT00932061|Fibromyalgia
1256778|NCT00932061|Healthy controls
1256779|NCT00932061|Acupuncture
1256780|NCT00932061|Sham Acupuncture
1256781|NCT00932061|fMRI
1256782|NCT00932061|Biological marker
1256783|NCT00932048|Diabetes Mellitus
1256784|NCT00932048|Statins
1256785|NCT00932048|PET
1256786|NCT00932035|breast cancer
1256787|NCT00932035|axillary mapping
1256788|NCT00932035|lymphedema
1256789|NCT00932009|Human papillomavirus infection
1256790|NCT00932009|Tanzanian men
1256791|NCT00932009|Prevalence
1256792|NCT00931996|schizophrenia
1256793|NCT00931996|antipsychotic
1256794|NCT00931996|risperidone
1256795|NCT00931983|Incomplete spinal cord injuries
1256796|NCT00931983|Walking
1256797|NCT00931983|Treadmill
1256798|NCT00931983|Training
1256799|NCT00931970|Hemodialysis
1256800|NCT00931970|Peritoneal dialysis
1256801|NCT00931970|Mortality
1256802|NCT00931970|Prospective cohort
1256803|NCT00931970|Clinical study
1256804|NCT00931957|Etanercept
1256805|NCT00931957|Behcet's syndrome
1256806|NCT00931957|Behcet's Disease
1256807|NCT00931957|Ocular Lesions
1256808|NCT00931957|Uveitis
1256809|NCT00931957|Retinal Vasculitis
1256810|NCT00931944|ALS
1256811|NCT00931944|Amyotrophic Lateral Sclerosis
1256812|NCT00931944|Lou Gehrig
1256813|NCT00931944|Lou Gehrig's
1256814|NCT00931944|Lou Gehrig's disease
1256815|NCT00931944|Motor Neuron Disease
1256816|NCT00931944|Nervous System Diseases
1256817|NCT00931944|KNS-760704
1256818|NCT00931944|RTPB
1256819|NCT00931905|This study included workers exposed to lead.
1256820|NCT00931892|celiac disease
1256821|NCT00931892|gluten challenge
1256822|NCT00931866|diclofenac
1256823|NCT00931866|acute pain
1256824|NCT00931866|topical
1256825|NCT00931866|patch
1256826|NCT00931866|Acute Pain due to Mild to Moderate Soft Tissue Injury
1256827|NCT00931840|EZN-2208 (PEG-SN38)
1256828|NCT00931827|Contraception
1256829|NCT00931814|Depression
1256830|NCT00931814|physical function
1256831|NCT00931814|Quality of life
1256832|NCT00931801|AIDS
1256833|NCT00931801|HIV
1256834|NCT00931801|Atazanavir
1256835|NCT00931801|Raltegravir
1256836|NCT00931801|Tenofovir
1256837|NCT00931801|protease inhibitors
1256838|NCT00931788|Management of hypertension and cholesterol
1256839|NCT00931788|stroke
1256840|NCT00931788|TIA
1256841|NCT00931775|Major depressive disorder, citalopram, pindolol, HDRS
1256842|NCT00931762|Bone marrow
1256843|NCT00931762|Myelofibrosis
1256844|NCT00931762|JAK2mutation
1256845|NCT00931762|Post-Polycythemia Vera
1256846|NCT00931762|Post-Essential Thrombocytopenia
1256847|NCT00931749|ultrasound therapy
1256848|NCT00931749|knee cartilage thickness
1256849|NCT00931749|knee cartilage volume
1256850|NCT00931749|mild knee osteoarthritis
1256851|NCT00931749|moderate knee osteoarthritis
1256852|NCT00931736|Tuberculosis
1256853|NCT00931723|Acute Mania
1256854|NCT00931723|Mania, Adults
1256855|NCT00931723|Seroquel
1256856|NCT00931723|Acute Mania in Adult Patients
1256857|NCT00931710|Hypertension
1256858|NCT00931710|combination therapy
1256859|NCT00931710|valsartan
1256860|NCT00931710|cardiovascular diseases
1256861|NCT00931697|Mefloquine
1256862|NCT00931697|Malaria
1256863|NCT00931697|(+) Mefloquine
1256864|NCT00931697|Pharmacokinetics
1256865|NCT00931671|Physical fitness
1256866|NCT00931671|Cerebral circulation
1256867|NCT00931671|Walking
1256868|NCT00931645|Chronic lymphocytic leukemia,
1256869|NCT00931645|autologous stem cell transplantation
1256870|NCT00931632|Bronchopulmonary Dysplasia, BPD
1256871|NCT00931619|Fluorine-18 Fluorodeoxyglucose
1256872|NCT00931619|Epilepsy
1256873|NCT00931619|Epileptic Focus
1256874|NCT00931619|Temporal Lobe Epilepsy
1256875|NCT00931619|Depression
1256876|NCT00931619|Major Depressive Disorder
1256877|NCT00931619|Healthy Volunteer
1256878|NCT00931619|HV
1256879|NCT00931606|anemia
1256880|NCT00931606|metastatic
1256881|NCT00931606|breast
1256882|NCT00931606|cancer
1256883|NCT00931593|Transient lower esophageal sphincter relaxation
1256884|NCT00931593|high resolution manometry
1256885|NCT00931593|dentsleeve probe
1256886|NCT00931593|healthy volunteers
1256887|NCT00931580|Vitamin D
1256888|NCT00931580|Adolescent
1256889|NCT00931580|African American
1256890|NCT00931580|White
1256891|NCT00931541|Safety
1256892|NCT00931541|Tolerability
1256893|NCT00931541|Healthy
1256894|NCT00931528|sexual dysfunction
1256895|NCT00931528|stage IIB prostate cancer
1256896|NCT00931528|stage IIA prostate cancer
1256897|NCT00931528|adenocarcinoma of the prostate
1256898|NCT00931515|DDD
1256899|NCT00931502|Stent thrombosis
1256900|NCT00931502|Acute Coronary Syndrome
1256901|NCT00931502|ACS
1256902|NCT00931502|Stenting
1256903|NCT00931502|Interventional Cardiology
1256904|NCT00931502|Cardiology
1256905|NCT00931502|Cardiovascular Research
1256906|NCT00931502|Registry
1256907|NCT00931489|Age Related Macular Degeneration
1256908|NCT00931489|Lucentis
1256909|NCT00931489|Ranibizumab
1256910|NCT00931489|Antibodies
1256911|NCT00931489|Retinal and RPE Autoimmunity
1256912|NCT00931463|second line therapy
1256913|NCT00931463|combination antiretroviral therapy
1256914|NCT00931463|first-line failure
1256915|NCT00931463|AIDS
1256916|NCT00931463|treatment experienced
1256917|NCT00931450|estrogen receptor-positive breast cancer
1256918|NCT00931450|HER2-negative breast cancer
1256919|NCT00931450|stage IA breast cancer
1256920|NCT00931450|stage IB breast cancer
1256921|NCT00931450|stage II breast cancer
1256922|NCT00931450|stage IIIA breast cancer
1256923|NCT00931450|stage IIIB breast cancer
1256924|NCT00931437|vitamin K
1256925|NCT00931437|Bio-availability
1256926|NCT00931424|Primary Chronic Venous Insufficiency
1256927|NCT00931424|surgery
1256928|NCT00931424|reconstruction
1256929|NCT00931424|valve
1256930|NCT00931411|Atopic Dermatitis
1256931|NCT00931411|Vitamin B3
1256932|NCT00931372|Insulin release
1256933|NCT00931372|Diabetes mellitus type 2
1256934|NCT00931372|GLP-1 agonist
1256935|NCT00931359|axillary
1256936|NCT00931359|hyperhidrosis
1256937|NCT00931359|primary focal
1256938|NCT00931346|HIV
1256939|NCT00931346|Human Immunodeficiency Virus
1256940|NCT00931333|Vertebroplasty
1256941|NCT00931333|spine
1256942|NCT00931333|vertebra height
1256943|NCT00931333|adverse events
1256944|NCT00931333|calcium phosphate bone cement
1256945|NCT00931320|Ratio improvement
1256946|NCT00931320|LDL-C
1256947|NCT00931320|HDL-C
1256948|NCT00931320|Ratio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol Improvement
1256949|NCT00931320|High Density Lipoprotein Cholesterol
1256950|NCT00931281|Multiple Ascending Doses
1256951|NCT00931268|Lipoatrophy
1256952|NCT00931268|Buttock treatment
1256953|NCT00931255|kidney transplant
1256954|NCT00931255|tacrolimus
1256955|NCT00931255|sirolimus
1256956|NCT00931255|delayed graft function
1256957|NCT00931255|Graft survival
1256958|NCT00931255|Acute rejection
1256959|NCT00931255|Chronic allograft nephropathy
1256960|NCT00931242|eczema
1256961|NCT00931242|dermatitis
1256962|NCT00931242|TNF blockade
1256963|NCT00931242|PDE4 inhibitor
1256964|NCT00931242|T cell inhibitor
1256965|NCT00931229|hepatitis B reactivation
1256966|NCT00931216|PMTCT
1256967|NCT00931216|Vertical transmission of HIV
1256968|NCT00931216|Pregnant women
1256969|NCT00931216|Infant HIV testing
1256970|NCT00931216|Kenya
1256971|NCT00931216|AIDS
1256972|NCT00931164|phase I/II study
1256973|NCT00931164|effects of sodium oxybate
1256974|NCT00931164|cohort of 6 children and young adults
1256975|NCT00931164|AHC
1256976|NCT00931138|Acute Myeloid Leukemia in adults
1256977|NCT00931138|Newly-diagnosed untreated AML
1256978|NCT00931138|Patient aged 50 to 70 years
1256979|NCT00931125|Severe proliferative diabetic retinopathy
1256980|NCT00931112|Peripheral Arterial Disease
1256981|NCT00931112|Walking ability
1256982|NCT00931112|Quality of life
1256983|NCT00931112|Exercise training
1256984|NCT00931099|pregnancy
1256985|NCT00931099|sleep disordered breathing
1256986|NCT00931099|obstructive sleep apnea
1256987|NCT00931086|Rheumatoid Arthritis
1256988|NCT00931086|RA
1256989|NCT00931073|Drug Interactions
1256990|NCT00931073|pharmacokinetics
1256991|NCT00931073|CYP2D6
1256992|NCT00931073|CYP2C19
1256993|NCT00931073|ketoconazole
1256994|NCT00931073|omeprazole
1256995|NCT00931060|Ammonia
1256996|NCT00931060|Citric acid cycle
1256997|NCT00931060|Branched Chain Amino Acids
1256998|NCT00931034|South Beach Diet™
1256999|NCT00931034|overweight
1257000|NCT00931034|obesity
1257001|NCT00931034|satiety
1257002|NCT00931034|weight loss
1257003|NCT00931034|diabetes
1257004|NCT00931008|Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1257005|NCT00930982|Ciprofloxacin
1257006|NCT00930982|Airway infection
1257007|NCT00930982|Bronchiectasis
1257008|NCT00930969|Cardiac Ischemia
1257009|NCT00930969|ST segment elevated Myocardial Infarction (STEMI)
1257010|NCT00930969|Non-ST Segment elevated Myocardial Infarction (NSTEMI)
1257011|NCT00930969|Implantable Cardioverter Defibrillator (ICD)
1257012|NCT00930969|Cardiac Electrogram (EGM)
1257013|NCT00930969|Coronary Artery Disease (CAD)
1257014|NCT00930956|Diabetes
1257015|NCT00930956|Obesity
1257016|NCT00930956|Hyperglycemia
1257017|NCT00930956|Dietary Fiber
1257018|NCT00930956|Wheat
1257019|NCT00930956|Grain
1257020|NCT00930943|opioid tolerant
1257021|NCT00930943|chronic pain
1257022|NCT00930930|triple-negative breast cancer
1257023|NCT00930930|stage II breast cancer
1257024|NCT00930930|stage IIIA breast cancer
1257025|NCT00930930|stage IIIB breast cancer
1257026|NCT00930930|stage IIIC breast cancer
1257027|NCT00930930|male breast cancer
1257028|NCT00930917|delivery room, polyethylene cap, preterm infant, temperature
1257029|NCT00930891|Extensive-Disease Small-Cell Lung Cancer
1257030|NCT00930878|registry
1257031|NCT00930878|drug eluting coronary stent system
1257032|NCT00930878|observational
1257033|NCT00930878|prospective
1257034|NCT00930878|open-label
1257035|NCT00930852|Migraine
1257036|NCT00930852|Children
1257037|NCT00930852|Primary headache disorders
1257038|NCT00930852|Appetite
1257039|NCT00930852|Obesity
1257040|NCT00930852|Feeding Behavior
1257041|NCT00930839|Niacin
1257042|NCT00930839|Prostaglandin D2
1257043|NCT00930839|Flushing
1257044|NCT00930839|Nicotinic acid stimulated release of prostaglandin D2
1257170|NCT00930345|Imagery
1257045|NCT00930826|The effect of bronchial asthma on school performance
1257046|NCT00930813|Drug coated balloon
1257047|NCT00930813|SFA disease
1257048|NCT00930813|Femoropopliteal disease
1257049|NCT00930813|Angioplasty
1257050|NCT00930813|PAD
1257051|NCT00930813|Paclitaxel
1257052|NCT00930813|Tubulin modulators
1257053|NCT00930813|Antineoplastic Agents
1257054|NCT00930813|Mitosis Modulators
1257055|NCT00930813|Balloon angioplasty
1257056|NCT00930813|Local drug delivery
1257057|NCT00930813|Restenosis
1257058|NCT00930813|Drug-coated balloon
1257059|NCT00930800|Exercise capacity
1257060|NCT00930800|Physical activity
1257061|NCT00930800|Quality of life
1257062|NCT00930787|hernia repair, surgical mesh, co-morbidities
1257063|NCT00930774|traumatic brain injury
1257064|NCT00930774|rehabilitation
1257065|NCT00930774|auditory processing disorder
1257066|NCT00930761|breast feeding
1257067|NCT00930761|music therapy
1257068|NCT00930761|maternal welfare
1257069|NCT00930761|infant, newborn
1257070|NCT00930722|Quinapril non-interventional/observational study safety
1257071|NCT00930709|Botulinum Toxin Type A
1257072|NCT00930709|Exercise
1257073|NCT00930709|Randomized Controlled Trial
1257074|NCT00930709|Muscle Stretching Exercises
1257075|NCT00930709|Strength Training
1257076|NCT00930709|Treatment Outcome
1257077|NCT00930696|endometriosis
1257078|NCT00930696|abdominal lavage
1257079|NCT00930696|bowel perforation
1257080|NCT00930696|discoid resection
1257081|NCT00930696|laparoscopy
1257082|NCT00930670|ranitidine
1257083|NCT00930670|pantoprazole
1257084|NCT00930670|esomeprazole
1257085|NCT00930670|omeprazole
1257086|NCT00930670|atorvastatin
1257087|NCT00930670|rosuvastatin
1257088|NCT00930670|statin
1257089|NCT00930670|clopidogrel resistance
1257090|NCT00930670|antiplatelet therapy
1257091|NCT00930670|coronary artery disease
1257092|NCT00930670|percutaneous coronary intervention
1257093|NCT00930670|stent
1257094|NCT00930670|clopidogrel
1257095|NCT00930670|proton pump inhibitors
1257096|NCT00930670|drug interactions
1257097|NCT00930670|drug resistance
1257098|NCT00930670|genetic polymorphism
1257099|NCT00930657|Panic Disorder
1257100|NCT00930657|Separation Anxiety
1257101|NCT00930657|Familial
1257102|NCT00930657|Risk
1257103|NCT00930657|Respiratory Physiology
1257104|NCT00930644|short bowel syndrome
1257105|NCT00930644|parenteral nutrition
1257106|NCT00930644|PN
1257107|NCT00930644|HPN
1257108|NCT00930644|TPN
1257109|NCT00930644|SBS
1257110|NCT00930631|CAD
1257111|NCT00930631|Pharmacokinetics
1257112|NCT00930631|BMS747158
1257113|NCT00930618|Prolonged pregnancy
1257114|NCT00930618|Nulliparity
1257115|NCT00930618|Cervical ripening
1257116|NCT00930618|Induced labor
1257117|NCT00930618|Cesarean section
1257118|NCT00930592|Psoriasis
1257119|NCT00930592|Metabolic Syndrome
1257120|NCT00930592|Cardiovascular Risk
1257121|NCT00930566|Allogeneic Hematopoietic Stem Cell Transplantation
1257122|NCT00930566|Extracorporeal Photopheresis
1257123|NCT00930553|Multiple Sclerosis
1257124|NCT00930501|chemotherapy
1257125|NCT00930501|cancer
1257126|NCT00930501|AMH
1257127|NCT00930501|gonadotoxicity
1257128|NCT00930501|ovarian reserve
1257129|NCT00930501|patients exposed to chemotherapy
1257130|NCT00930488|Moxifloxacin
1257131|NCT00930488|MXF
1257132|NCT00930488|Avelox
1257133|NCT00930488|Sinusitis
1257134|NCT00930488|Acute bacterial sinusitis, ABS
1257135|NCT00930462|colonoscopy
1257136|NCT00930462|cap
1257137|NCT00930462|hood
1257138|NCT00930462|cecal intubation time
1257139|NCT00930462|polyp detection rate
1257140|NCT00930462|performance
1257141|NCT00930449|Pediatrics
1257142|NCT00930449|Attention-Deficit Hyperactivity Disorder
1257143|NCT00930449|Learning Disorder
1257144|NCT00930449|Computerized Working Memory Training Program
1257145|NCT00930436|chronic kidney disease
1257146|NCT00930410|pancreas neoplasms
1257147|NCT00930410|bile duct diseases
1257148|NCT00930410|Cholangiopancreatography, Endoscopic Retrograde
1257149|NCT00930410|ERCP
1257150|NCT00930397|Pre-eclampsia
1257151|NCT00930397|UTERO-placental unit vascularization
1257152|NCT00930397|Hypertension, pregnancy- induced
1257153|NCT00930397|IUGR
1257154|NCT00930397|Screening
1257155|NCT00930397|3D Doppler Ultrasound
1257156|NCT00930384|psoriasis
1257157|NCT00930384|fatty liver
1257158|NCT00930384|metabolic syndrome
1257159|NCT00930371|fatty liver
1257160|NCT00930371|insulin resistance
1257161|NCT00930371|diet
1257162|NCT00930371|inflammation
1257163|NCT00930371|oxidative stress
1257164|NCT00930358|Sedation
1257165|NCT00930358|Colonoscopy
1257166|NCT00930358|General anesthesia
1257167|NCT00930345|Renal cell carcinoma
1257168|NCT00930345|Antiangiogenics
1257169|NCT00930345|Biomarkers
1257171|NCT00930332|sleep disorders
1257172|NCT00930332|nausea and vomiting
1257173|NCT00930332|unspecified adult solid tumor, protocol specific
1257174|NCT00930332|pain
1257175|NCT00930306|Chronic Pain
1257176|NCT00930306|AZD2066
1257177|NCT00930293|Interpersonal Psychotherapy
1257178|NCT00930280|stroke
1257179|NCT00930280|brain attack
1257180|NCT00930280|hemorrhagic stroke
1257181|NCT00930280|risk factors
1257182|NCT00930267|fever
1257183|NCT00930267|children
1257184|NCT00930267|cancer
1257185|NCT00930267|leukemia
1257186|NCT00930267|stem cell transplantation
1257187|NCT00930267|infections in pediatric cancer patients presenting with fever during or following chemotherapy.
1257188|NCT00930254|pediatric nursing
1257189|NCT00930254|peripheral catheterization
1257190|NCT00930254|ultrasonics
1257191|NCT00930254|intravenous infusions
1257192|NCT00930241|Lung Transplantation
1257193|NCT00930241|Tacrolimus
1257194|NCT00930241|Deterioration of graft function
1257195|NCT00930228|Luteinizing hormone
1257196|NCT00930228|Testosterone
1257197|NCT00930215|Healthy volunteer
1257198|NCT00930215|Japanese males
1257199|NCT00930215|homo-EM
1257200|NCT00930215|Bioequivalence study
1257201|NCT00930202|Traumatic Brain Injury
1257202|NCT00930202|Conivaptan
1257203|NCT00930202|Vaprisol
1257204|NCT00930202|Sodium
1257205|NCT00930189|age related macular degeneration
1257206|NCT00930163|Adult Asthma
1257207|NCT00930150|Schizoaffective Disorder
1257208|NCT00930137|Cardiovascular disease
1257209|NCT00930137|Trans fatty acids
1257210|NCT00930137|Ruminant
1257211|NCT00930137|Blood lipids
1257212|NCT00930137|Lipoproteins
1257213|NCT00930137|Women
1257214|NCT00930124|cleft lip and palate
1257215|NCT00930124|distraction osteogenesis
1257216|NCT00930124|conventional orthognathic surgery
1257217|NCT00930124|stability
1257218|NCT00930124|morbidity
1257219|NCT00930124|soft tissue changes
1257220|NCT00930124|psychological adjustment
1257221|NCT00930124|speech changes
1257222|NCT00930124|velopharyngeal function
1257223|NCT00930111|inpatient
1257224|NCT00930111|hospitalists
1257225|NCT00930111|residency
1257226|NCT00930111|job satisfaction
1257227|NCT00930111|burnout, professional
1257228|NCT00930111|professional practice
1257229|NCT00930111|medical education
1257230|NCT00930098|acute lymphoblastic leukemia
1257231|NCT00930098|clolar
1257232|NCT00930098|evoltra
1257233|NCT00930098|clofarabine
1257234|NCT00930098|refractory/relapsed acute leukemia
1257235|NCT00930098|pediatric acute leukemia
1257236|NCT00930085|sepsis
1257237|NCT00930085|septic shock
1257238|NCT00930059|Alzheimer's disease
1257239|NCT00930059|PF-04447943
1257240|NCT00930059|efficacy
1257241|NCT00930059|safety
1257242|NCT00930059|plasma concentrations
1257243|NCT00930046|ropivacaine
1257244|NCT00930046|pediatric
1257245|NCT00930046|children
1257246|NCT00930046|continuous
1257247|NCT00930046|wound
1257248|NCT00930046|catheter
1257249|NCT00930046|infusion
1257250|NCT00930046|pyeloplasty
1257251|NCT00930033|Nephrectomy,
1257252|NCT00930033|metastatic renal cell carcinoma,
1257253|NCT00930033|sunitinib
1257254|NCT00930020|ischemic stroke recovery
1257255|NCT00930020|minocycline
1257256|NCT00930020|neuroprotection
1257257|NCT00930020|acute stroke
1257258|NCT00930007|Luteinizing hormone
1257259|NCT00930007|Puberty
1257260|NCT00929994|cardiac rehab
1257261|NCT00929981|Contact Dermatitis
1257262|NCT00929981|Allergic Dermatitis
1257263|NCT00929968|Allergic rhinitis,
1257264|NCT00929968|atopic patients,
1257265|NCT00929968|seasonal allergy,
1257266|NCT00929968|ragweed allergy
1257267|NCT00929955|Anti inflammatory
1257268|NCT00929955|Schizophrenia
1257269|NCT00929955|Simvastatin
1257270|NCT00929955|ondansetron
1257271|NCT00929942|lung transplantation
1257272|NCT00929942|bronchial stenosis
1257273|NCT00929942|biodegradable stent
1257274|NCT00929929|Aging
1257275|NCT00929929|Functionality
1257276|NCT00929929|Sarcopenia
1257277|NCT00929929|Leucine
1257278|NCT00929929|Progressive resistance exercise
1257279|NCT00929916|colonoscopy
1257280|NCT00929916|MoviPrep
1257281|NCT00929890|Obesity
1257282|NCT00929890|Exercise
1257283|NCT00929890|Diet
1257284|NCT00929890|Lifestyle
1257285|NCT00929890|Vascular reactivity
1257286|NCT00929890|Body composition
1257287|NCT00929890|Lipids
1257288|NCT00929890|Glucose
1257289|NCT00929890|Insulin resistance
1257290|NCT00929838|Diabetes Mellitus, Type 2
1257291|NCT00929838|Diabetes Mellitus, Adult-Onset
1257292|NCT00929838|Diabetes Mellitus, Non-Insulin-Dependent
1257293|NCT00929838|African Americans
1257294|NCT00929838|Blacks
1257295|NCT00929838|Randomized Controlled Trial
1257296|NCT00929838|Controlled Clinical Trial
1257297|NCT00929838|Behavioral Research
1257298|NCT00929838|Behavioral Medicine
1257299|NCT00929825|Salivary stimulation
1257300|NCT00929825|Transplantation of hematopoietic stem cells
1257301|NCT00929825|Hyperboloid
1257302|NCT00929825|Transcutaneous Electrical Stimulation
1257303|NCT00929812|obesity
1257304|NCT00929812|food intake
1257305|NCT00929812|glucagon
1257306|NCT00929812|ghrelin
1257307|NCT00929812|glucose
1257308|NCT00929812|insulin
1257309|NCT00929786|Plasma levels isoniazid rifampicin pyrazinamide
1257310|NCT00929760|Chronic Kidney disease
1257311|NCT00929760|Nephrologists
1257312|NCT00929760|Primary Care
1257313|NCT00929760|Death
1257314|NCT00929760|Renal Replacement Therapy
1257315|NCT00929760|Specialised renal care
1257316|NCT00929747|Cataract
1257317|NCT00929747|Toric
1257318|NCT00929747|IOL
1257319|NCT00929747|AcrySof, LRI
1257320|NCT00929734|Inflammation
1257321|NCT00929734|Atherosclerosis
1257322|NCT00929734|Hydroxymethylglutaryl-coenzyme A Reductase Inhibitors
1257323|NCT00929721|CAP
1257324|NCT00929708|COPD
1257325|NCT00929708|Efficacy
1257326|NCT00929708|Safety
1257327|NCT00929708|Inhalation
1257328|NCT00929682|Labor
1257329|NCT00929682|Epidural analgesia
1257330|NCT00929682|Local anesthetics
1257331|NCT00929682|Levobupivacaine
1257332|NCT00929682|Opiates
1257333|NCT00929682|Patient-controlled
1257334|NCT00929682|Active spontaneous labor requiring epidural analgesia
1257335|NCT00929669|pituitary tumor
1257336|NCT00929669|endocrine
1257337|NCT00929656|Rehabilitation
1257338|NCT00929656|Neurophysiology
1257339|NCT00929656|Upper Extremity
1257340|NCT00929643|health care costs
1257341|NCT00929643|Intra-Abdominal Infection
1257342|NCT00929630|fibrin glue
1257343|NCT00929630|transsphincteric anal fistulas
1257344|NCT00929630|seton
1257345|NCT00929630|incontinence
1257346|NCT00929630|prospective randomised trial
1257347|NCT00929617|breast cancer
1257348|NCT00929617|physical activity
1257349|NCT00929617|exercise
1257350|NCT00929617|quality of life
1257351|NCT00929617|doubly labeled water
1257352|NCT00929604|HIV
1257353|NCT00929604|AIDS
1257354|NCT00929604|Zambia
1257355|NCT00929604|viral load
1257356|NCT00929604|antiretroviral therapy
1257357|NCT00929604|cluster randomization
1257358|NCT00929604|ART monitoring
1257359|NCT00929604|treatment failure
1257360|NCT00929604|randomized clinical trial
1257361|NCT00929604|treatment naive
1257362|NCT00929591|stage II breast cancer
1257363|NCT00929591|stage IIIA breast cancer
1257364|NCT00929578|Psoriasis
1257365|NCT00929578|T-lymphocytes
1257366|NCT00929578|Fluphenazine
1257367|NCT00929565|hemoptysis
1257368|NCT00929552|Blood pressure
1257369|NCT00929552|Insulin sensitivity
1257370|NCT00929552|Blood lipid profile
1257371|NCT00929539|Diabetes
1257372|NCT00929526|HPV vaccine
1257373|NCT00929526|cervical intraepithelial neoplasia (CIN)
1257374|NCT00929526|including new onset of autoimmune disease [NOAD])
1257375|NCT00929526|new onset of chronic disease (NOCD)
1257376|NCT00929526|medically significant condition (MSC)
1257377|NCT00929487|contact lens wear
1257378|NCT00929487|contact lens solution
1257379|NCT00929487|corneal staining
1257380|NCT00929461|omega-3 fatty acids
1257381|NCT00929461|lactate
1257382|NCT00929461|surgery
1257383|NCT00929461|gastric cancer
1257384|NCT00929461|address the effect of postoperative administration of omega-3 fatty acids on cellular hypoperfusion associated with major gastric surgery.
1257385|NCT00929448|Traumatic brain injury
1257386|NCT00929435|MRSA
1257387|NCT00929435|Contact isolation
1257388|NCT00929435|Incidence
1257389|NCT00929422|spinal cord injury
1257390|NCT00929422|PET
1257391|NCT00929422|cerebral function
1257392|NCT00929422|cortical reorganization
1257393|NCT00929409|Postpartum anemia, iron-deficiency
1257394|NCT00929396|Tuberculosis
1257395|NCT00929396|Vaccine
1257396|NCT00929396|Ag85B
1257397|NCT00929396|ESAT-6
1257398|NCT00929396|IC31
1257399|NCT00929383|Intracranial Atherosclerosis
1257400|NCT00929383|Stenosis
1257401|NCT00929383|ICAD
1257402|NCT00929383|atherosclerotic lesions
1257403|NCT00929383|stenting
1257404|NCT00929370|Schizophrenia
1257405|NCT00929370|GSK1018921
1257406|NCT00929370|GlyT-1 inhibitor
1257407|NCT00929370|Healthy Volunteers
1257408|NCT00929370|CSF
1257409|NCT00929370|Patient
1257410|NCT00929370|Midazolam
1257411|NCT00929344|Alcohol
1257412|NCT00929344|Alcohol treatment
1257413|NCT00929344|Alcoholism
1257414|NCT00929344|Alcohol Abuse
1257415|NCT00929344|Alcohol Dependence
1257416|NCT00929331|Influenza
1257417|NCT00929331|Fluviral®
1257418|NCT00929305|chronic pain
1257419|NCT00929305|neck
1257420|NCT00929305|shoulder
1257421|NCT00929305|musculoskeletal origin
1257422|NCT00929292|Infant formula
1257423|NCT00929292|Alpha-lactalbumin
1257424|NCT00929292|Protein composition
1257425|NCT00929292|Colic
1257426|NCT00929292|Probiotics
1257427|NCT00929279|Acute coronary syndrome
1257428|NCT00929279|Abciximab
1257429|NCT00929279|Bolus
1257430|NCT00929279|Infusion
1257431|NCT00929279|platelet inhibition
1257432|NCT00929279|Non ST segment elevation acute coronary syndrome
1257433|NCT00929266|peripheral stem cells (PSC) donors
1257434|NCT00929266|cultured red blood cells
1257435|NCT00929266|In vivo half life
1257436|NCT00929253|Opioid Dependence
1257437|NCT00929253|Opiates
1257438|NCT00929253|Hydrocodone
1257439|NCT00929253|Oxycodone
1257440|NCT00929253|Oxycontin
1257441|NCT00929253|Narcotic Abuse
1257442|NCT00929227|Atherosclerosis
1257443|NCT00929227|Myocardial Ischemia
1257444|NCT00929227|Diagnostic Testing
1257445|NCT00929227|Cardiac Commuted Tomography
1257446|NCT00929227|Cardiac Magnetic Resonance Imaging
1257447|NCT00929227|Coronary Artery Disease
1257448|NCT00929214|Breast Cancer
1257449|NCT00929214|Metastasized
1257450|NCT00929214|Limited bone-only metastasis
1257451|NCT00929214|Local Therapy
1257452|NCT00929214|Radiation
1257453|NCT00929214|Radiation Therapy
1257454|NCT00929214|RT
1257455|NCT00929214|Surgery
1257456|NCT00929214|Standard Therapy
1257457|NCT00929214|Chemotherapy
1257458|NCT00929214|Endocrine Therapy
1257459|NCT00929188|Moderate to severe chronic, cancer-related pain related to an active cancer
1257460|NCT00929188|Cancer-related pain
1257461|NCT00929188|Moderate to severe chronic pain
1257462|NCT00929188|JNJ-42160443
1257463|NCT00929175|Hypertension
1257464|NCT00929175|Resistant Hypertension
1257465|NCT00929175|Sleep apnea syndrome
1257466|NCT00929175|Treatment
1257467|NCT00929162|ovarian
1257468|NCT00929162|cancer
1257469|NCT00929162|chemotherapy
1257470|NCT00929162|sensitive
1257471|NCT00929162|ZD4054
1257472|NCT00929136|Endotoxin
1257473|NCT00929136|Insulin resistance
1257474|NCT00929136|Lipolysis
1257475|NCT00929136|Proteolysis
1257476|NCT00929136|Intracellular Insulin Signaling
1257477|NCT00929136|Regional effects of inflammation/endotoxin
1257478|NCT00929123|manual therapy
1257479|NCT00929123|carpal tunnel syndrome
1257480|NCT00929123|central sensitization
1257481|NCT00929110|COPD
1257482|NCT00929110|NVA237
1257483|NCT00929110|glycopyrronium bromide
1257484|NCT00929097|Colorectal Neoplasms, (Hereditary Nonpolyposis)
1257485|NCT00929097|Guideline
1257486|NCT00929097|Health Plan Implementation
1257487|NCT00929097|Decision Support Techniques
1257488|NCT00929097|Risk assessment
1257489|NCT00929097|Familial colorectal cancer risk
1257490|NCT00929097|Risk assessment tool
1257491|NCT00929084|Race Disparities
1257492|NCT00929084|Breast Cancer
1257493|NCT00929084|Quality of Life
1257494|NCT00929084|Treatment Adherence
1257495|NCT00929071|wrinkles
1257496|NCT00929071|dermal filler
1257497|NCT00929071|collagen
1257498|NCT00929071|soft tissue augmentation
1257499|NCT00929071|lidocaine
1257500|NCT00929071|aesthetic
1257501|NCT00929045|Growth Hormone replacement
1257502|NCT00929045|subject 8 to 21
1257503|NCT00929045|moderate to severe traumatic brain injury
1257504|NCT00929045|growth hormone deficient
1257505|NCT00929032|Liver Transplantation
1257506|NCT00929032|Immunosystem of the Liver
1257507|NCT00929032|Marginal and Non-marginal grafts
1257508|NCT00929019|uveal melanoma
1257509|NCT00929019|chromosome 3
1257510|NCT00929019|high risk
1257511|NCT00929019|immunotherapy
1257512|NCT00929019|adjuvant
1257513|NCT00929019|high risk genetic profile
1257514|NCT00929019|loss of chromosome 3
1257515|NCT00929006|hyperandrogenemia
1257516|NCT00929006|pubertal
1257517|NCT00929006|polycystic ovary syndrome
1257518|NCT00928993|actigraphy
1257519|NCT00928993|polysomnography
1257520|NCT00928993|pediatrics
1257521|NCT00928993|sleep
1257522|NCT00928993|To validate Actigraphy against polysomnography
1257523|NCT00928980|Recurrent Major Depressive Disorder
1257524|NCT00928980|Mindfulness Based Cognitive Therapy
1257525|NCT00928980|Cost-effectiveness
1257526|NCT00928980|Antidepressant medication
1257527|NCT00928980|Randomized Controlled Trial
1257528|NCT00928967|Multiple Sclerosis
1257529|NCT00928967|Quality of life
1257530|NCT00928954|gabapentin
1257531|NCT00928954|memantine
1257532|NCT00928954|nystagmus
1257533|NCT00928954|Drug treatment
1257534|NCT00928941|PTSD
1257535|NCT00928941|rehabilitation
1257536|NCT00928928|Lipid peroxidation
1257537|NCT00928928|Protein peroxidation
1257538|NCT00928928|DNA peroxidation
1257539|NCT00928928|RNA peroxidation
1257540|NCT00928928|Cytokines
1257541|NCT00928928|hsCRP
1257542|NCT00928928|Oxidative stress markers
1257543|NCT00928928|Open surgery
1257544|NCT00928928|Laparoscopic surgery
1257917|NCT00927433|Fatigue
1257545|NCT00928915|Intracranial Hemorrhages
1257546|NCT00928915|Vitamin-K antagonist
1257547|NCT00928915|Hemostatic treatment
1257548|NCT00928915|Prothrombin complex
1257549|NCT00928915|Fresh frozen plasma
1257550|NCT00928915|Intracranial Hemorrhages related to vitamin-K antagonist
1257551|NCT00928902|melanoma
1257552|NCT00928902|vaccine
1257553|NCT00928902|peptides
1257554|NCT00928902|adjuvant
1257555|NCT00928902|immunogenicity
1257556|NCT00928902|stage IIB, stage III or resected stage IV
1257557|NCT00928889|diabetes mellitus, type 2
1257558|NCT00928889|nateglinide
1257559|NCT00928889|acarbose
1257560|NCT00928889|hyperglycemia
1257561|NCT00928889|dyslipidemias
1257562|NCT00928889|C-reactive protein
1257563|NCT00928876|anakinra
1257564|NCT00928876|Diabetes mellitus, type 2
1257565|NCT00928876|Insulin resistance
1257566|NCT00928876|Interleukin-1beta
1257567|NCT00928863|haemorrhagia postpartum
1257568|NCT00928863|implementation guidelines
1257569|NCT00928863|maternal morbidity
1257570|NCT00928863|management of obstetrics and trauma
1257571|NCT00928850|Prostate
1257572|NCT00928850|Radical Prostatectomy
1257573|NCT00928850|urethral irrigation
1257574|NCT00928850|fascial suturing
1257575|NCT00928850|09-051
1257576|NCT00928811|Simulect
1257577|NCT00928811|de novo kidney transplant subjects
1257578|NCT00928811|calcineurin inhibitors
1257579|NCT00928811|Prograf
1257580|NCT00928785|Tetanus Vaccine
1257581|NCT00928785|Tdap-IPV vaccine
1257582|NCT00928772|Cranial Electro Stimulation
1257583|NCT00928772|First Eye Cataract Surgery
1257584|NCT00928772|Preoperative sedation
1257585|NCT00928772|Perioperative sedation
1257586|NCT00928759|Obesity
1257587|NCT00928759|Polycystic Ovary Syndrome
1257588|NCT00928733|Permeability
1257589|NCT00928733|tight junctions
1257590|NCT00928733|cytokines
1257591|NCT00928733|inflammatory bowel diseases
1257592|NCT00928733|The effect of alcohol on the intestinal permeability may have major consequences on health.
1257593|NCT00928733|It's generally accepted that an increased intestinal permeability in alcoholic subjects lead
1257594|NCT00928733|to translocation of bacterial endotoxins from the gut lumen into the portal vein and then to the liver.
1257595|NCT00928733|In the liver, endotoxins trigger the immune system and activate the resident macrophages, Kupffer cells.
1257596|NCT00928733|Activation of Kupffer cells leads to production of chemokines (IL-8) and
1257597|NCT00928733|proinflammatory cytokines (IL-1, TNFα),resulting in hepatocytes damage, inflammation, fibrosis and finally cirrhosis.
1257598|NCT00928720|fibromyalgia
1257599|NCT00928720|pain
1257600|NCT00928720|sleep disturbance
1257601|NCT00928720|fatigue
1257602|NCT00928720|depression
1257603|NCT00928720|functional magnetic resonance imaging
1257604|NCT00928707|Polycythemia Vera
1257605|NCT00928707|GIVINOSTAT
1257606|NCT00928707|ITF2357
1257607|NCT00928655|apnea
1257608|NCT00928655|sleep
1257609|NCT00928655|altitude
1257610|NCT00928655|hypoxia
1257611|NCT00928655|treatment
1257612|NCT00928655|CPAP
1257613|NCT00928642|ovarian
1257614|NCT00928642|cancer
1257615|NCT00928642|peritoneal
1257616|NCT00928642|endometrioid
1257617|NCT00928642|mucinous
1257618|NCT00928642|serous
1257619|NCT00928642|clear cell
1257620|NCT00928629|Peripheral Arterial Disease
1257621|NCT00928629|Cardiovascular Disease
1257622|NCT00928629|Vascular Disease
1257623|NCT00928616|hyperlipidemia
1257624|NCT00928616|plant sterols
1257625|NCT00928616|monocytes
1257626|NCT00928603|prostate cancer
1257627|NCT00928603|therapy
1257628|NCT00928590|open-angle glaucoma
1257629|NCT00928590|ocular hypertension
1257630|NCT00928590|pseudoexfoliation
1257631|NCT00928590|pigment dispersion
1257632|NCT00928577|Smallpox
1257633|NCT00928577|Smallpox Vaccine
1257634|NCT00928577|Vaccinia virus
1257635|NCT00928577|Military
1257636|NCT00928564|Pelvic floor muscle spasm
1257637|NCT00928564|Pelvic pain
1257638|NCT00928564|physical therapy
1257639|NCT00928564|pudendal block
1257640|NCT00928538|Female Contraception
1257641|NCT00928538|Home Visits
1257642|NCT00928538|CONTRACEPTIVE AGENTS
1257643|NCT00928538|CONTRACEPTIVE DEVICES
1257644|NCT00928525|PDGFr alpha
1257645|NCT00928525|PDGFr beta
1257646|NCT00928525|KIT
1257647|NCT00928512|Rheumatoid Arthritis, RA, ACR, inflammatory joints
1257648|NCT00928499|urge/frequency
1257649|NCT00928499|urge incontinence
1257650|NCT00928499|Interstim
1257651|NCT00928499|after success Interstim planning IPG placement
1257652|NCT00928460|Electrocardiogram
1257653|NCT00928460|Electrocardiography
1257654|NCT00928460|Perioperative care
1257655|NCT00928460|Preoperative care
1257656|NCT00928460|Preanesthesia Evaluation
1257657|NCT00928460|Acute Coronary Syndrome
1257658|NCT00928460|Postoperative Myocardial Infarction
1257659|NCT00928460|Myocardial ischaemia
1257660|NCT00928460|Postoperative Cardiac Death
1257661|NCT00928460|Intraoperative complications
1257662|NCT00928460|Postoperative complications
1257663|NCT00928460|Cost-effectiveness analysis
1257664|NCT00928447|rHuPH20
1257665|NCT00928447|Recombinant Human hyaluronidase
1257666|NCT00928421|Varicose Veins
1257667|NCT00928395|Urgent PC
1257668|NCT00928395|Overactive Bladder
1257669|NCT00928395|SUmiT Trial
1257670|NCT00928395|Overactive Urinary Bladder
1257671|NCT00928382|Spinal Cord
1257672|NCT00928382|Healthy Volunteer
1257673|NCT00928382|Metastasis
1257674|NCT00928382|Samples
1257675|NCT00928382|Spinal Cord Vertebrae
1257676|NCT00928382|Cancer
1257677|NCT00928382|HV
1257678|NCT00928356|Coronary Artery Disease
1257679|NCT00928356|Robotic Coronary Artery Bypass Surgery
1257680|NCT00928356|Percutaneous Coronary Intervention
1257681|NCT00928356|Hybrid Coronary Revascularization
1257682|NCT00928343|Safety
1257683|NCT00928343|Tolerability
1257684|NCT00928343|Pharmacokinetics
1257685|NCT00928330|TDM-1
1257686|NCT00928330|HER2
1257687|NCT00928330|HER2+
1257688|NCT00928330|HER2+ Breast Cancer
1257689|NCT00928330|HER-2
1257690|NCT00928330|MBC
1257691|NCT00928330|Trastuzumab emtansine
1257692|NCT00928304|Amyloid beta-protein
1257693|NCT00928304|Down Syndrome
1257694|NCT00928291|procalcitonin
1257695|NCT00928291|neutropenia
1257696|NCT00928291|febrile neutropenia
1257697|NCT00928291|antibiotic therapy
1257698|NCT00928291|neutropenic patients
1257699|NCT00928265|intracranial
1257700|NCT00928265|stenting
1257701|NCT00928265|endovascular treatment
1257702|NCT00928265|stent-assisted coiling
1257703|NCT00928265|cerebrovascular disease
1257704|NCT00928252|Hormone Refractory Prostate Cancer
1257705|NCT00928252|Castrate Resistant Prostate Cancer
1257706|NCT00928239|vaginal vault prolapse
1257707|NCT00928239|laparoscopic sacropexy
1257708|NCT00928213|Preeclampsia
1257709|NCT00928213|IUGR
1257710|NCT00928213|GH
1257711|NCT00928213|PP13
1257712|NCT00928213|Doppler
1257713|NCT00928213|placenta
1257714|NCT00928213|PTD
1257715|NCT00928213|Preterm delivery
1257716|NCT00928200|Relapsed
1257717|NCT00928200|Allergy
1257718|NCT00928200|Erwinia
1257719|NCT00928200|Acute
1257720|NCT00928200|Lymphoblastic
1257721|NCT00928200|Leukemia
1257722|NCT00928187|HIV
1257723|NCT00928187|Second line treatment
1257724|NCT00928187|WHO recommendations
1257725|NCT00928187|Africa
1257726|NCT00928187|Treatment strategies
1257727|NCT00928187|treatment experienced
1257728|NCT00928174|Androgen insensitive prostate cancer
1257729|NCT00928161|Reflux Disease
1257730|NCT00928161|Acid-reflux
1257731|NCT00928161|Head and Neck Cancer
1257732|NCT00928161|HNC
1257733|NCT00928161|Radiation Therapy
1257734|NCT00928161|Mucositis
1257735|NCT00928161|Radiation-induced xerostomia
1257736|NCT00928161|RIX
1257737|NCT00928161|Dry Mouth
1257738|NCT00928161|Heartburn
1257739|NCT00928161|Dexlansoprazole
1257740|NCT00928161|Prevacid
1257741|NCT00928161|Prevacid Solu-Tab
1257742|NCT00928161|GERD
1257743|NCT00928109|eating disorders
1257744|NCT00928109|couples therapy
1257745|NCT00928096|Lymphoma
1257746|NCT00928096|Radiotherapy
1257747|NCT00928096|Positron-Emission Tomography
1257748|NCT00928096|CT scan
1257749|NCT00928083|Phase I
1257750|NCT00928083|Safety and tolerability
1257751|NCT00928083|Pharmacokinetic
1257752|NCT00928083|synthetic peroxide
1257753|NCT00928083|trioxolane
1257754|NCT00928083|treatment of erythrocytic stages of malaria
1257755|NCT00928070|Urgency Urinary Incontinence OAB
1257756|NCT00928057|Pen Needle
1257757|NCT00928057|Diabetes
1257758|NCT00928057|Insulin
1257759|NCT00928057|Glycemic
1257760|NCT00928057|Pain
1257761|NCT00928057|Fructosamine
1257762|NCT00928057|Leakage
1257763|NCT00928057|Hypoglycemia
1257764|NCT00928057|Hyperglycemia
1257765|NCT00928018|allogeneic stem cell transplant
1257766|NCT00928018|reduced intensity conditioning
1257767|NCT00928018|graft versus host disease
1257768|NCT00928018|GVHD
1257769|NCT00928018|RIC transplantation
1257770|NCT00928005|Weight loss diet
1257771|NCT00928005|Exercise training
1257772|NCT00928005|Type 2 diabetes
1257773|NCT00928005|Prediabetes
1257774|NCT00928005|Cardiovascular health
1257775|NCT00927966|RAD001
1257776|NCT00927966|CP-751,871
1257777|NCT00927966|advanced sarcoma
1257778|NCT00927966|advanced malignant solid tumor
1257779|NCT00927953|West Nile virus
1257780|NCT00927953|WNV
1257781|NCT00927953|Encephalitis
1257782|NCT00927953|Meningitis
1257783|NCT00927953|Acute Flaccid Paralysis
1257784|NCT00927953|Monoclonal Antibody
1257785|NCT00927953|WNND
1257786|NCT00927953|West Nile Fever
1257787|NCT00927953|WNF
1257788|NCT00927940|TARGET VESSEL REVASCULARIZATION (TVR)
1257789|NCT00927940|MYOCARDIAL INFARCTION (MI)
1257790|NCT00927940|TARGET VESSEL FAILURE (TVF)
1257791|NCT00927940|TARGET LESION REVASCULARIZATION (TLR)
1257792|NCT00927940|TARGET LESION FAILURE (TLF)
1257793|NCT00927940|STENT THROMBOSIS
1257794|NCT00927940|RESTENOTIC LESION
1257795|NCT00927940|PERCUTANEOUS CORONARY INTERVENTION (PCI)
1257796|NCT00927901|QAB149
1257797|NCT00927901|asthma
1257798|NCT00927901|indacaterol salts (acetate, maleate, and xinafoate)
1257799|NCT00927901|orally inhaled indacaterol salts
1257800|NCT00927901|persistent asthma
1257801|NCT00927862|warfarin metabolism
1257802|NCT00927862|CYP2C9
1257803|NCT00927862|genotyping
1257804|NCT00927862|VKORC1
1257805|NCT00927862|anticoagulation
1257806|NCT00927862|atrial fibrillation
1257807|NCT00927862|deep vein thrombosis
1257808|NCT00927862|pulmonary embolism
1257809|NCT00927862|Patients initiating warfarin for thromboembolic conditions
1257810|NCT00927849|anal hypertonia
1257811|NCT00927849|sphincterotomy
1257812|NCT00927849|incontinence
1257813|NCT00927849|manometry
1257814|NCT00927810|Gout
1257815|NCT00927810|Gouty arthritis
1257816|NCT00927810|Gout flares
1257817|NCT00927810|Anti-interleukin-1β monoclonal antibody
1257818|NCT00927797|immunochemotherapy
1257819|NCT00927797|Pentostatin
1257820|NCT00927797|Cyclophosphamide
1257821|NCT00927797|Rituximab
1257822|NCT00927797|Maintenance
1257823|NCT00927797|indolent B-NHL
1257824|NCT00927797|B-CLL
1257825|NCT00927797|B-NHL
1257826|NCT00927784|Mesenchymal Precursor Cells
1257827|NCT00927784|Left Ventricular Assist Device
1257828|NCT00927784|LVAD
1257829|NCT00927784|Congestive Heart Failure
1257830|NCT00927784|Stem Cells
1257831|NCT00927771|melanosis
1257832|NCT00927771|melasma
1257833|NCT00927771|azelaic acid
1257834|NCT00927771|hydroquinone
1257835|NCT00927745|Respiration Artificial
1257836|NCT00927745|Positive-Pressure Respiration
1257837|NCT00927745|Critical Care
1257838|NCT00927745|Intensive Care Units
1257839|NCT00927732|Brugada
1257840|NCT00927732|hydroquinidine
1257841|NCT00927732|ventricular arrhythmia
1257842|NCT00927732|patients with Brugada syndrome, high cardiac arrhythmic risk and implanted with an implantable cardioverter defibrillator
1257847|NCT00927706|Assistive Technology
1257848|NCT00927706|Mobility Limitation
1257849|NCT00927706|Physical Disability
1257850|NCT00927706|Caregiver
1257851|NCT00927706|Participation
1257852|NCT00927693|Atherosclerosis
1257853|NCT00927693|Coronary Artery Disease
1257854|NCT00927693|Cardiac Risk Factors
1257855|NCT00927693|Coronary Calcium Scan
1257856|NCT00927693|Prevention
1257857|NCT00927680|Colorectal Cancer
1257858|NCT00927680|Familial Colorectal Cancer
1257859|NCT00927680|Genetics
1257860|NCT00927680|Hispanics
1257861|NCT00927667|Hemophilia A
1257862|NCT00927667|Joint Status
1257863|NCT00927667|Bleeds
1257864|NCT00927667|Magnetic Resonce Imaging
1257865|NCT00927654|Iloprost
1257866|NCT00927654|pulmonary hypertension
1257867|NCT00927654|cardio pulmonary morbidity
1257868|NCT00927654|high risk cardiac surgical patients
1257869|NCT00927641|Ankle Sprain
1257870|NCT00927628|vitrectomy
1257871|NCT00927628|macular hole
1257872|NCT00927628|ILM peeling
1257873|NCT00927615|myocardial infarction
1257874|NCT00927615|glycoprotein IIb/IIIa
1257875|NCT00927615|percutaneous coronary intervention
1257876|NCT00927615|thrombus aspiration
1257877|NCT00927615|myocardial perfusion
1257878|NCT00927602|renal failure
1257879|NCT00927602|medical patient
1257880|NCT00927602|venous thromboembolism
1257881|NCT00927602|prophylaxis
1257882|NCT00927602|fondaparinux
1257883|NCT00927589|HER2+ Metastatic Cancer
1257884|NCT00927589|HER2+ Locally Advanced Inoperable Cancer
1257885|NCT00927589|HER2+ Solid Malignancy
1257886|NCT00927576|cognitive training
1257887|NCT00927576|neuroplasticity
1257888|NCT00927576|cognitive impairment
1257889|NCT00927576|recovery of function
1257890|NCT00927576|memory
1257891|NCT00927576|attention
1257892|NCT00927563|Gambling
1257893|NCT00927563|Addiction
1257894|NCT00927550|resistant depression
1257895|NCT00927550|lithium
1257896|NCT00927550|RCT
1257897|NCT00927550|lithium therapy
1257898|NCT00927550|standard therapy
1257899|NCT00927537|Hypertension
1257900|NCT00927524|Insulin analogs
1257901|NCT00927524|diabetes
1257902|NCT00927511|metastatic hormone-responsive breast cancer menopausal women
1257903|NCT00927498|Acute myeloid Leukemia
1257904|NCT00927498|patient aged 50 to 70 years
1257905|NCT00927485|Familial Adenomatous Polyposis (FAP)
1257906|NCT00927485|Curcumin
1257907|NCT00927485|Colorectal polyps
1257908|NCT00927485|Duodenal polyps
1257909|NCT00927472|Head Lice
1257910|NCT00927459|cholesterol
1257911|NCT00927459|coronary artery disease
1257912|NCT00927446|esophageal cancer
1257913|NCT00927446|head and neck cancer
1257914|NCT00927446|narrow band imaging
1257915|NCT00927446|endoscopy
1257916|NCT00927446|screening
1257918|NCT00927433|Cancer
1257919|NCT00927433|Radiation therapy
1257920|NCT00927433|Chemotherapy
1257921|NCT00927433|Hormones
1257922|NCT00927433|Surgery
1257923|NCT00927433|Breast cancer
1257924|NCT00927420|Bipolar disorder
1257925|NCT00927420|adherence
1257926|NCT00927420|treatment
1257927|NCT00927420|real life practice
1257928|NCT00927407|Head Lice
1257929|NCT00927394|Hypertension, Type II Diabetes, Aliskiren, Valsartan,
1257930|NCT00927394|Systolic blood pressure, Diastolic blood pressure,
1257931|NCT00927394|Stage II, Combination
1257932|NCT00927368|TKA
1257933|NCT00927368|total knee replacement
1257934|NCT00927355|pioglitazone
1257935|NCT00927355|human bone marrow stem cells
1257936|NCT00927355|adipocytes
1257937|NCT00927355|osteoblasts
1257938|NCT00927355|bone mineral density
1257939|NCT00927355|adiponectin
1257940|NCT00927355|leptin
1257941|NCT00927355|CTX
1257942|NCT00927355|P1NP
1257943|NCT00927355|Osteocalcin
1257944|NCT00927342|Air leak
1257945|NCT00927342|Thoracic Surgery
1257946|NCT00927342|Sealants
1257947|NCT00927329|Dermatophagoides
1257948|NCT00927329|farinae
1257949|NCT00927329|allergen
1257950|NCT00927329|dust
1257951|NCT00927329|allergic
1257952|NCT00927329|mite
1257953|NCT00927329|allergy
1257954|NCT00927316|Report of Urinary Tract Infection episode
1257955|NCT00927303|retinal thickness
1257956|NCT00927303|threshold algorithm
1257957|NCT00927303|optical coherence tomography
1257958|NCT00927290|hepatitis C; insulin resistance; glitazones; pioglitazone; steatosis; viral kinetics; antiviral response
1257959|NCT00927264|tobacco smoke exposure smoking
1257960|NCT00927251|heart failure
1257961|NCT00927251|cardiac pacing
1257962|NCT00927251|cardiac resynchronization therapy
1257963|NCT00927251|left ventricular lead
1257964|NCT00927238|Single Level
1257965|NCT00927238|Lumbar Disc Disease
1257966|NCT00927238|DDD
1257967|NCT00927199|High-Oleic Canola Oil
1257968|NCT00927199|Flaxseed Oil
1257969|NCT00927199|Monounsaturated Fatty Acids
1257970|NCT00927199|Polyunsaturated Fatty Acids
1257971|NCT00927199|Alpha Linolenic Acid
1257972|NCT00927199|Cardiovascular
1257973|NCT00927199|Hypercholesterolemia
1257974|NCT00927199|Lipids
1257975|NCT00927199|Inflammation
1257976|NCT00927199|Metabolism
1257977|NCT00927186|osteoporosis
1257978|NCT00927186|teriparatide
1257979|NCT00927186|zoledronic acid
1257980|NCT00927186|histomorphometry
1257981|NCT00927186|bone biopsy
1257982|NCT00927186|postmenopausal
1257983|NCT00927173|TMS
1257984|NCT00927173|Transcranial Magnetic Stimulation
1257985|NCT00927173|MDD
1257986|NCT00927173|Major Depressive Disorder
1257987|NCT00927160|Mobile Acute Care of the Elderly Unit
1257988|NCT00927160|Geriatric Models of Care
1257989|NCT00927147|head and neck cancer
1257990|NCT00927147|boron neutron capture therapy
1257991|NCT00927147|cetuximab
1257992|NCT00927147|epidermal growth factor receptor
1257993|NCT00927147|safety
1257994|NCT00927147|efficacy
1257995|NCT00927147|survival
1257996|NCT00927134|Chronic Granulomatous Disease in children (=or< 18 years)
1257997|NCT00927108|Adult Progenitor Stem cells
1257998|NCT00927108|Alzheimer's disease
1257999|NCT00927108|Parkinson's disease
1258000|NCT00927108|Multiple sclerosis
1258001|NCT00927095|PMDD
1258002|NCT00927095|Oral contraceptives
1258003|NCT00927095|steroid hormones
1258004|NCT00927095|neurosteroids
1258005|NCT00927069|Adalimumab
1258006|NCT00927030|Autism
1258007|NCT00927030|children
1258008|NCT00927030|sleep
1258009|NCT00927030|insomnia
1258010|NCT00927017|Healthy volunteers
1258011|NCT00927004|mechanical hyperalgesia
1258012|NCT00927004|cold hyperalgesia
1258013|NCT00927004|chronic pain
1258014|NCT00926978|Thyroid
1258015|NCT00926978|I-124
1258016|NCT00926965|tardive dyskinesia
1258017|NCT00926965|neurocognitive function
1258018|NCT00926952|Actinic keratoses
1258019|NCT00926952|actinic keratosis
1258020|NCT00926952|methylamonolevulinate
1258021|NCT00926952|photodynamic therapy
1258022|NCT00926952|without occlusion
1258023|NCT00926952|short incubation
1258024|NCT00926939|Cigarette
1258025|NCT00926939|Nicotine
1258026|NCT00926939|Smoking
1258027|NCT00926939|Contingency Management
1258028|NCT00926939|Voucher reinforcement
1258029|NCT00926939|Smoking Abstinence
1258030|NCT00926939|Internet-based treatment
1258031|NCT00926926|Healthy volunteer
1258032|NCT00926913|Macular Degeneration
1258033|NCT00926900|Alcoholism
1258034|NCT00926900|D-cycloserine
1258035|NCT00926900|extinction
1258036|NCT00926900|cue-exposure
1258037|NCT00926874|ischaemic stroke
1258038|NCT00926874|acute coronary syndrome
1258039|NCT00926874|obstructive sleep apnea syndrome
1258040|NCT00926874|brachial endothelial function
1258041|NCT00926874|blood pressure
1258042|NCT00926874|aortic stiffness
1258043|NCT00926861|age-related macular degeneration
1258044|NCT00926861|detachment of the posterior hyaloid
1258045|NCT00926861|AMD
1258046|NCT00926848|coronary heart disease
1258047|NCT00926848|cardiac rehabilitation
1258048|NCT00926848|lifestyle change
1258049|NCT00926848|coronary artery bypass graft
1258050|NCT00926848|social support
1258051|NCT00926848|social cognitive learning theory
1258052|NCT00926809|endoscopic mucosal resection
1258053|NCT00926809|iatrogenic
1258054|NCT00926796|gonorrhea, gonococcal infections, Neisseria gonorrhoeae
1258055|NCT00926783|paroxysmal
1258056|NCT00926783|persistent
1258057|NCT00926783|targeted
1258058|NCT00926783|generalized
1258059|NCT00926783|CFAE
1258060|NCT00926757|lymphoma
1258061|NCT00926757|CD20
1258062|NCT00926757|Hepatitis B virus
1258063|NCT00926757|reactivation
1258064|NCT00926757|Rituximab
1258065|NCT00926744|physical activity
1258066|NCT00926744|nutrition
1258067|NCT00926744|cardiovascular diseases
1258068|NCT00926744|musculo-skeletal problems
1258069|NCT00926731|Acute Myeloid Leukaemia (AML)
1258070|NCT00926718|BIS monitor
1258071|NCT00926718|rocuronium
1258072|NCT00926718|The effect of the neuromuscular blocking drug rocuronium on the response of the Composite Variability Index to laryngoscopy
1258073|NCT00926705|Dexmedetomidine
1258074|NCT00926705|Fentanyl
1258075|NCT00926705|Pain
1258076|NCT00926705|Pediatrics
1258077|NCT00926692|B-cells
1258078|NCT00926692|CD5+
1258079|NCT00926692|B1 Cells
1258080|NCT00926692|Healthy Controls
1258081|NCT00926666|Ageing
1258082|NCT00926666|Pain
1258083|NCT00926666|Pharmacology
1258084|NCT00926666|Imaging
1258085|NCT00926666|Anaesthesiology
1258086|NCT00926666|Musculoskeletal disease
1258087|NCT00926653|Geriatric Depression
1258094|NCT00926627|endothelin receptor antagonist
1258095|NCT00926627|bosentan
1258096|NCT00926614|GT1
1258097|NCT00926614|HCV
1258098|NCT00926614|non responder
1258099|NCT00926614|relapser
1258100|NCT00926588|Pain
1258101|NCT00926588|Telecare
1258102|NCT00926588|Collaborative care
1258103|NCT00926575|BDP
1258104|NCT00926575|orBec
1258105|NCT00926575|GVHD
1258106|NCT00926575|beclomethasone dipropionate
1258107|NCT00926575|bone marrow transplant
1258108|NCT00926575|hematopoietic cell transplant
1258109|NCT00926575|HCT
1258110|NCT00926575|stem cell transplant
1258111|NCT00926575|marrow transplant
1258112|NCT00926575|SCT
1258113|NCT00926575|beclomethasone 17,21-dipropionate
1258114|NCT00926562|Contrast Induced Nephropathy
1258115|NCT00926562|CIN
1258116|NCT00926562|Cardiac Catheterization
1258117|NCT00926549|spectral domain-OCT
1258118|NCT00926549|macular thickness
1258119|NCT00926549|myopia
1258120|NCT00926549|hypermetropia
1258121|NCT00926549|normal
1258122|NCT00926523|Pulmonary Hypertension
1258123|NCT00926523|Pulmonary Arterial Hypertension
1258124|NCT00926523|Interstitial Lung Disease
1258125|NCT00926523|MIF
1258126|NCT00926497|antibiotic therapy
1258127|NCT00926497|early-onset sepsis
1258128|NCT00926497|interventions study
1258129|NCT00926497|procalcitonin
1258130|NCT00926497|term and near-term neonates
1258131|NCT00926484|Dentin hypersensitivity
1258132|NCT00926484|Tooth Mousse
1258133|NCT00926484|fluoride varnish
1258134|NCT00926471|Autism
1258135|NCT00926471|Anxiety
1258136|NCT00926471|Autism Spectrum Disorders with Comorbid Anxiety
1258137|NCT00926458|stress echocardiography
1258138|NCT00926458|coronary angiography
1258139|NCT00926458|coronary artery disease
1258140|NCT00926445|Pain behavior
1258141|NCT00926432|Balance
1258142|NCT00926432|Spine disorders
1258143|NCT00926432|equilibrium
1258144|NCT00926419|Varicella
1258145|NCT00926419|Hepatitis A
1258146|NCT00926419|Vaccine
1258147|NCT00926419|Injector
1258148|NCT00926419|Fractional dose
1258149|NCT00926419|Intradermal
1258150|NCT00926419|Children
1258151|NCT00926406|Environmental lead exposure, maintenance hemodialysis; blood lead levels, EDTA chelating agents, malnutrition, anemia, inflammation, mortality.
1258152|NCT00926406|To determine whether lead chelation therapy improves the anemia, malnutrition, inflammation, morbidity or mortality in hemodialysis patients.
1258153|NCT00926393|inpatient
1258154|NCT00926393|bipolar depression
1258155|NCT00926393|quetiapine
1258156|NCT00926393|Seroquel IR
1258157|NCT00926393|Seroquel XR
1258158|NCT00926393|safety
1258159|NCT00926393|tolerability
1258160|NCT00926380|osteoporosis
1258161|NCT00926380|postmenopausal
1258162|NCT00926380|denosumab
1258163|NCT00926380|teriparatide
1258164|NCT00926380|Forteo®
1258165|NCT00926380|DXA
1258166|NCT00926380|Bone Mineral Density
1258167|NCT00926380|pQCT
1258168|NCT00926367|Acne
1258169|NCT00926341|Metabolic syndrome
1258170|NCT00926341|inflammatory markers
1258171|NCT00926341|Thiazolidinediones
1258172|NCT00926341|Angiotensin receptor blockers
1258173|NCT00926328|Gingivitis and Plaque
1258174|NCT00926315|Breast Neoplasms
1258175|NCT00926315|Calcitriol
1258176|NCT00926315|Postmenopausal
1258177|NCT00926315|Cell Proliferation
1258178|NCT00926315|Gene Expression Profiling
1258179|NCT00926302|The bioequivalence of Levetiracetam vs. Keppra
1258180|NCT00926302|volunteer
1258181|NCT00926276|Gastroesophageal Reflux Disease (GERD)
1258182|NCT00926276|Bronchopulmonary Dysplasia (BPD)
1258183|NCT00926276|Fundoplication
1258184|NCT00926263|Pharmacokinetics
1258185|NCT00926263|Pharmacodynamics
1258186|NCT00926263|QTc interval prolongation
1258187|NCT00926250|Sarcopenia
1258188|NCT00926237|Tinnitus
1258189|NCT00926237|Transcranial Magnetic Stimulation
1258190|NCT00926237|TMS
1258191|NCT00926237|rTMS
1258192|NCT00926224|Adult patients with chronic liver disease scheduled for a liver biopsy and a BMI superior or equal to 28 kg/m²
1258193|NCT00926198|Upper airway infections
1258194|NCT00926198|pharyngotonsillitis
1258195|NCT00926198|GABHS
1258196|NCT00926185|Dry Eye
1258197|NCT00926185|ophthalmic delivery
1258198|NCT00926172|Magnetic resonance angiography
1258199|NCT00926172|Intracranial aneurysm
1258200|NCT00926172|cerebral aneurysm
1258201|NCT00926172|unruptured aneurysm
1258202|NCT00926172|Epidemiology
1258203|NCT00926172|Magnetic Resonance Imaging
1258204|NCT00926159|Cardiomyopathies
1258205|NCT00926146|Hepatitis B and C
1258206|NCT00926146|HIV
1258207|NCT00926146|nurse case management
1258208|NCT00926146|HIV seronegativity
1258209|NCT00926120|Chronic Hepatitis C
1258210|NCT00926081|Peripheral Artery Disease
1258211|NCT00926081|Quality of Life
1258212|NCT00926081|Outcome
1258213|NCT00926081|Endothelial Progenitor Cells
1258214|NCT00926081|Microcirculation
1258215|NCT00926068|Diabetes Mellitus
1258216|NCT00926068|Foot Ulcer
1258217|NCT00926068|DFU
1258218|NCT00926068|Wound healing
1258219|NCT00926055|high risk patients in atherosclerosis
1258220|NCT00926042|Healthy
1258221|NCT00926042|volunteer
1258222|NCT00926042|Healthy controls
1258223|NCT00926042|Normal controls
1258224|NCT00926016|Hepatitis C
1258225|NCT00926003|HIV
1258226|NCT00926003|Children
1258227|NCT00926003|Africa
1258228|NCT00926003|Neuropsychology
1258229|NCT00926003|cognitive rehabilitation
1258230|NCT00926003|computers
1258231|NCT00925990|HCV
1258232|NCT00925990|interferon-naive
1258233|NCT00925977|treatment satisfaction
1258234|NCT00925977|insulin Glargine
1258235|NCT00925977|insulin Apidra
1258236|NCT00925977|NPH insulin
1258237|NCT00925951|Persistent Non-specific Low Back Pain
1258238|NCT00925951|wet cupping
1258239|NCT00925951|cupping
1258240|NCT00925951|Numerical Rating Scale
1258241|NCT00925938|Hysteroscopy
1258242|NCT00925938|Cervical priming
1258243|NCT00925938|Cervical dilatation
1258244|NCT00925938|Misoprostol
1258245|NCT00925938|Endoscopy, uterine
1258246|NCT00925925|Low birth weight
1258247|NCT00925925|small for gestational age
1258248|NCT00925925|B-cell function
1258249|NCT00925925|epigenetics
1258250|NCT00925925|B1a
1258251|NCT00925925|B1b
1258252|NCT00925925|CD19
1258253|NCT00925925|CD5
1258254|NCT00925912|Hemorrhoidectomy
1258255|NCT00925912|perianal block
1258256|NCT00925912|local anesthesia
1258257|NCT00925912|spinal anesthesia
1258258|NCT00925899|Melatonin
1258259|NCT00925899|Palliative care
1258260|NCT00925899|Advanced cancer
1258261|NCT00925899|Symptoms
1258262|NCT00925899|Quality of life
1258263|NCT00925899|Randomized controlled trial
1258264|NCT00925886|Astigmatism
1258265|NCT00925886|Cataract
1258266|NCT00925873|Fludarabine
1258267|NCT00925873|AML
1258268|NCT00925873|elderly patients
1258269|NCT00925847|Amyotrophic lateral sclerosis
1258270|NCT00925847|Lithium
1258271|NCT00925847|Survival
1258272|NCT00925834|Coronary angiography
1258273|NCT00925834|Placebo effect
1258274|NCT00925834|Suggestion
1258275|NCT00925821|Allogeneic stem cell transplantation
1258276|NCT00925821|Lenalidomide
1258277|NCT00925821|IMiD
1258278|NCT00925808|Unsuspected Venous Thromboembolism
1258279|NCT00925808|VTE
1258280|NCT00925808|Routine Computed Tomography
1258281|NCT00925808|CT Scans
1258282|NCT00925795|HIV
1258283|NCT00925795|atherosclerosis
1258284|NCT00925795|extra virgin olive oil
1258285|NCT00925795|Alternative therapies
1258286|NCT00925795|Treatment experienced+
1258287|NCT00925782|autologous stem cell transplantation
1258288|NCT00925756|HIV
1258289|NCT00925756|low CD4 recovery
1258290|NCT00925756|Low CD4 recovery despite HIV control
1258291|NCT00925756|Treatment experienced
1258292|NCT00925743|Phase 1
1258293|NCT00925743|XRP6258
1258294|NCT00925743|cisplatin
1258413|NCT00925314|Melanoma
1258295|NCT00925743|Antineoplastic Combined Chemotherapy Protocols
1258296|NCT00925730|Atopic dermatitis
1258297|NCT00925730|AD
1258298|NCT00925730|pimecrolimus
1258299|NCT00925730|blood
1258300|NCT00925730|absorption
1258301|NCT00925730|systemic
1258302|NCT00925717|ADA recommendation
1258303|NCT00925665|Intubation
1258304|NCT00925665|Glidescope
1258305|NCT00925665|Macintosh
1258306|NCT00925665|Abscess
1258307|NCT00925665|Difficult intubations in patients with odontogenic abscesses
1258308|NCT00925652|CM
1258309|NCT00925652|bevacizumab
1258310|NCT00925652|cyclophosphamide
1258311|NCT00925652|methotrexate
1258312|NCT00925652|exercise intervention
1258313|NCT00925652|diet intervention
1258314|NCT00925639|phytoestrogen
1258315|NCT00925639|coagulation
1258316|NCT00925639|menopause
1258317|NCT00925639|ddimer
1258318|NCT00925639|antithrombin
1258319|NCT00925639|hypercoagulation
1258320|NCT00925613|Exchanging double lumen tube with laryngeal mask Proseal
1258321|NCT00925613|Exchange double lumen tube with tracheal tube
1258322|NCT00925613|Exchange double lumen tube before emergence decrease cough
1258323|NCT00925613|thoracoscopy and postoperative respiratory complications
1258324|NCT00925613|thoracostomy and postoperative respiratory complications
1258325|NCT00925613|postoperative cough
1258326|NCT00925613|postoperative respiratory complications
1258327|NCT00925613|laryngeal mask and postoperative respiratory complications
1258328|NCT00925600|Lens Opacification
1258329|NCT00925600|Bone Loss
1258330|NCT00925600|Androgen Deprivation Therapy
1258331|NCT00925600|Non-metastatic prostate cancer
1258332|NCT00925587|CKD
1258333|NCT00925587|Anemia
1258334|NCT00925587|correction
1258335|NCT00925587|darbepoetin alfa
1258336|NCT00925574|CNTO 1959
1258337|NCT00925574|Healthy Volunteers
1258338|NCT00925574|Psoriasis
1258339|NCT00925561|Coronary Artery Calcification
1258340|NCT00925548|Phase III trial
1258341|NCT00925548|randomized
1258342|NCT00925548|cancer vaccine
1258343|NCT00925548|MUC1
1258344|NCT00925548|BLP25
1258345|NCT00925548|advanced breast cancer
1258346|NCT00925548|postmenopausal breast cancer
1258347|NCT00925548|immunotherapy of breast cancer
1258348|NCT00925548|Inoperable locally advanced, recurrent, or metastatic endocrine-sensitive Breast Cancer
1258349|NCT00925535|Pharmacokinetics HIV Tuberculosis Lersivirine UK-453
1258350|NCT00925535|061 Rifabutin
1258351|NCT00925535|HIV Infections
1258352|NCT00925509|upper digestive tract cancer
1258353|NCT00925509|implants
1258354|NCT00925509|implants insertion
1258355|NCT00925509|radio-surgical guidance
1258356|NCT00925509|accuracy of implants insertion
1258357|NCT00925509|cranial/facial radiotherapy or brachytherapy and/or microvascular fibula transfer.
1258358|NCT00925509|Bone volume sufficient to support an implant
1258359|NCT00925496|Omarthrosis shoulder joint
1258360|NCT00925483|left ventricular mass
1258361|NCT00925483|cardiac MRI
1258362|NCT00925483|long dialysis
1258363|NCT00925483|daily dialysis
1258364|NCT00925470|Target organs impairment
1258365|NCT00925470|High blood pressure
1258366|NCT00925470|Evaluation of target organs impairment on patients suffering from high blood pressure without known cardiovascular or renal disease
1258367|NCT00925457|Serious ventricular arrhythmia
1258368|NCT00925457|Sudden cardiac death
1258369|NCT00925457|Domperidone
1258370|NCT00925457|Case-control study
1258371|NCT00925457|Saskatchewan residents
1258372|NCT00925457|Observational Study
1258373|NCT00925444|Absorbable implants
1258374|NCT00925444|Humans
1258375|NCT00925444|Alginates
1258376|NCT00925444|Pneumonectomy/methods
1258377|NCT00925444|Pneumonectomy/instrumentation
1258378|NCT00925444|Surgical Stapling
1258379|NCT00925444|Thoracic surgery
1258380|NCT00925444|Tissue Adhesives
1258381|NCT00925444|Prospective studies
1258382|NCT00925418|Neoplasm
1258383|NCT00925418|breast Neoplasm
1258384|NCT00925418|docetaxel
1258385|NCT00925418|Glove
1258386|NCT00925405|Breast Cancer
1258387|NCT00925405|Hodgkin's lymphoma
1258388|NCT00925405|Mantle-field Irradiation
1258389|NCT00925405|Mammogram
1258390|NCT00925405|Magnetic resonance imaging
1258391|NCT00925405|MRI Breast Cancer Screening
1258392|NCT00925392|doripenem
1258393|NCT00925392|epithelial lining fluid
1258394|NCT00925392|alveolar macrophages
1258395|NCT00925392|pharmacokinetics
1258396|NCT00925392|Healthy adult subjects
1258397|NCT00925366|Shoulder
1258398|NCT00925366|MRI
1258399|NCT00925366|MR arthrography
1258400|NCT00925366|CT arthrography
1258401|NCT00925366|Rotator cuff tear
1258402|NCT00925366|Arthroscopy
1258403|NCT00925353|lidocaine
1258404|NCT00925353|pre-medication
1258405|NCT00925353|mammography
1258406|NCT00925353|pain
1258407|NCT00925353|safety
1258408|NCT00925340|Alcohol
1258409|NCT00925340|Substance Abuse
1258410|NCT00925340|Adolescent
1258411|NCT00925340|Family functioning
1258412|NCT00925314|Stage III Melanoma
1258414|NCT00925314|TLI
1258415|NCT00925314|Transgenic Lymphocyte Immunization
1258416|NCT00925314|CB-10-01-02
1258417|NCT00925301|AmicusTherapeutics
1258418|NCT00925301|AT1001
1258419|NCT00925301|Migalastat
1258420|NCT00925301|Pharmacokinetics
1258421|NCT00925301|Substrate
1258422|NCT00925288|Female sex worker
1258423|NCT00925288|Peru
1258424|NCT00925288|Cervical infection
1258425|NCT00925288|Cervical abnormality
1258426|NCT00925288|Serum antibody
1258427|NCT00925288|Vaccine acceptance
1258428|NCT00925288|Alternative schedule
1258429|NCT00925288|Viral infections
1258430|NCT00925288|Human papillomavirus vaccine
1258431|NCT00925288|Human papillomavirus (HPV)
1258432|NCT00925288|non inferiority
1258433|NCT00925275|Solid tumors
1258434|NCT00925275|Refractory
1258435|NCT00925275|Relapsed
1258436|NCT00925275|Radiation
1258437|NCT00925275|Dosimetry
1258438|NCT00925275|Radiopharmaceutical
1258439|NCT00925275|Biodistribution
1258440|NCT00925275|Pharmacokinetics
1258441|NCT00925275|Cancer
1258442|NCT00925275|Phase I
1258443|NCT00925262|mental health
1258444|NCT00925262|randomized controlled trial
1258445|NCT00925262|torture
1258446|NCT00925249|rheumatoid arthritis
1258447|NCT00925249|RA
1258448|NCT00925249|TB
1258449|NCT00925249|tuberculosis
1258450|NCT00925249|anti-TNF therapy
1258451|NCT00925249|biologic therapy
1258452|NCT00925249|quantiferon
1258453|NCT00925249|IGRA
1258454|NCT00925249|Newly diagnosed rheumatoid arthritis (RA) in the Tricare system
1258455|NCT00925236|MYH9 gene
1258456|NCT00925236|macrothrombocytopenia
1258457|NCT00925236|leukocyte inclusions
1258458|NCT00925236|cataracts deafness
1258459|NCT00925236|nephritis
1258460|NCT00925236|MYH9 Related Disorders
1258461|NCT00925223|IBS
1258462|NCT00925223|BDNf
1258463|NCT00925223|visceral hypersensitivity
1258464|NCT00925210|Endobronchial ultrasound
1258465|NCT00925210|Electromagnetic Navigation Bronchoscopy
1258466|NCT00925210|Bronchoscopy
1258467|NCT00925210|Ultrasonography
1258468|NCT00925197|anticoagulation
1258469|NCT00925197|fluindione
1258470|NCT00925197|patient self-testing
1258471|NCT00925197|coaguchek
1258472|NCT00925197|inratio
1258473|NCT00925197|Post operative antivitamin K therapy
1258474|NCT00925184|questionnaire, medical education, medical students.
1258475|NCT00925171|Chronic obstructive pulmonary disease
1258476|NCT00925171|Pulmonary rehabilitation
1258477|NCT00925171|Chronic Respiratory Questionnaire
1258478|NCT00925158|Rhytidoplasty
1258479|NCT00925158|Video-Assisted Surgery
1258480|NCT00925158|Surgical instruments
1258481|NCT00925158|Dissection
1258482|NCT00925158|Innovative therapies
1258483|NCT00925158|Face
1258484|NCT00925158|Aging
1258485|NCT00925158|Premature aging
1258486|NCT00925158|Rejuvenation
1258487|NCT00925132|Metastatic
1258488|NCT00925132|Melanoma
1258489|NCT00925132|Epigenetic
1258490|NCT00925132|Temozolomide
1258491|NCT00925132|Decitabine
1258492|NCT00925132|Panobinostat
1258493|NCT00925132|LBH589
1258494|NCT00925119|Diabetes
1258495|NCT00925119|Atenolol
1258496|NCT00925119|Genetic
1258497|NCT00925106|Bioavailability, pharmacokinetics, celecoxib
1258498|NCT00925093|vancomycin
1258499|NCT00925093|teicoplanin
1258500|NCT00925093|linezolid
1258501|NCT00925093|intravenous
1258502|NCT00925093|cerebrospinal fluid
1258503|NCT00925093|CSF
1258504|NCT00925093|pharmacokinetics
1258505|NCT00925093|penetration
1258506|NCT00925093|blood-brain barrier
1258507|NCT00925093|Pharmacokinetics of three antibiotics in relation to cerebrospinal fluid
1258508|NCT00925067|Inguinal hernia
1258509|NCT00925067|Laparoscopic repair
1258510|NCT00925067|Prostheses
1258511|NCT00925067|Male fertility
1258512|NCT00925054|PKU
1258513|NCT00925054|PEG PAL
1258514|NCT00925054|BioMarin
1258515|NCT00924989|ACC
1258516|NCT00924989|Adrenocortical carcinoma
1258517|NCT00924989|OSI-906
1258518|NCT00924989|Insulin-like growth factor-1 receptor (IGF-1R)
1258519|NCT00924989|GALACCTIC
1258520|NCT00924963|Pain of venipuncture or IV insertion
1258521|NCT00924950|Psoriasis
1258522|NCT00924950|Plaque psoriasis, with bilateral symmetrical lesions.
1258523|NCT00924950|A diagnosis of stable plaque-type psoriasis vulgaris
1258524|NCT00924950|with at least one pair of symmetric lesions on either
1258525|NCT00924950|the trunk, arms, or legs that would serve as target lesions.
1258526|NCT00924937|Cardiovascular events
1258527|NCT00924937|Blood pressure
1258528|NCT00924937|Incidence of Cancer
1258529|NCT00924937|Cognitive decline
1258530|NCT00924937|Mediterranean Diet
1258531|NCT00924937|Secondary Prevention
1258532|NCT00924937|Low fat diet
1258533|NCT00924924|health promotion
1258534|NCT00924924|prevention
1258535|NCT00924924|worksite wellness
1258536|NCT00924924|behavior change
1258537|NCT00924924|healthy volunteers
1258538|NCT00924911|GSK1322322, relative bioavailability, single dose, food effect, H2 blocker, healthy subjects, open label, PIB, tablet
1258539|NCT00924898|Acute HIV
1258540|NCT00924898|HIV
1258541|NCT00924898|Acute Infections
1258542|NCT00924898|Acute Infection
1258543|NCT00924885|Reproductive Medicine
1258544|NCT00924885|Fertilization in Vitro
1258545|NCT00924885|Oocyte retrieval
1258546|NCT00924885|Local anaesthesia
1258547|NCT00924885|Aspiration needle
1258548|NCT00924872|stroke
1258549|NCT00924872|power wheelchair skills
1258550|NCT00924872|training
1258551|NCT00924872|safety
1258552|NCT00924859|cerebral venous thrombosis
1258553|NCT00924859|stroke
1258554|NCT00924859|coagulation
1258555|NCT00924846|high frequency oscillatory ventilation
1258556|NCT00924846|respiratory failure
1258557|NCT00924846|children
1258558|NCT00924846|inhaled nitric oxide
1258559|NCT00924833|hypoxia
1258560|NCT00924833|autonomic nervous system
1258561|NCT00924833|blood pressure
1258562|NCT00924833|heart rate
1258563|NCT00924833|exercise
1258564|NCT00924833|heart failure
1258565|NCT00924833|receptors, adrenergic, beta.
1258566|NCT00924820|Neoplastic Meningitis
1258567|NCT00924820|NM
1258568|NCT00924820|Advanced Cancers
1258569|NCT00924820|Brain Cancer
1258570|NCT00924820|Advanced Cancer
1258571|NCT00924820|Brain Diseases
1258572|NCT00924820|Central Nervous System Disorders
1258573|NCT00924820|CNS
1258574|NCT00924820|Bevacizumab
1258575|NCT00924820|Avastin
1258576|NCT00924820|Anti-VEGF monoclonal antibody
1258577|NCT00924820|rhuMAb-VEGF
1258578|NCT00924820|Spinal Cord
1258579|NCT00924820|meninges
1258580|NCT00924820|cerebrospinal fluid
1258581|NCT00924820|CSF
1258582|NCT00924807|Prostate Cancer
1258583|NCT00924807|Combined Androgen Blockade
1258584|NCT00924807|Radiotherapy
1258585|NCT00924807|Sorafenib
1258586|NCT00924781|Anemia associated with chronic kidney disease (CKD)
1258587|NCT00924781|Hemodialysis
1258588|NCT00924768|Otherwise healthy current cigarette smokers
1258589|NCT00924768|current cigarette smokers
1258590|NCT00924755|Surgical mesh
1258591|NCT00924742|The PK of Tapimycin
1258592|NCT00924742|volunteer
1258593|NCT00924690|Colon
1258594|NCT00924690|Cancer
1258595|NCT00924690|Screening
1258596|NCT00924690|Prevention
1258597|NCT00924690|Information
1258598|NCT00924677|genicular nerve
1258599|NCT00924677|osteoarthritis
1258600|NCT00924677|knee
1258601|NCT00924677|neurotomy
1258602|NCT00924664|low back pain monoclonal antibody nerve growth factor
1258603|NCT00924651|fatigue
1258604|NCT00924651|unspecified adult solid tumor, protocol specific
1258605|NCT00924638|atrial fibrillation
1258606|NCT00924638|cryptogenic stroke
1258607|NCT00924638|continuous monitoring
1258608|NCT00924638|implantable loop recorder
1258609|NCT00924638|insertable cardiac monitor
1258610|NCT00924612|Primary hypogonadism
1258611|NCT00924612|Secondary hypogonadism
1258612|NCT00924599|Recurring Gestational Diabetes
1258613|NCT00924599|Prevention
1258614|NCT00924573|Glimepiride
1258615|NCT00924573|Metformin
1258616|NCT00924573|Combination Drug Therapy
1258617|NCT00924560|Adolescents
1258618|NCT00924560|Bone Mineral Density
1258619|NCT00924560|Oral Contraceptive
1258620|NCT00924547|Cystic Fibrosis
1258621|NCT00924547|Docosahexanoic Acid
1258622|NCT00924547|DHA
1258623|NCT00924547|isoprostanes
1258624|NCT00924547|fatty acid
1258625|NCT00924534|type 2 diabetes
1258626|NCT00924534|interventional
1258627|NCT00924534|placebo
1258628|NCT00924534|controlled
1258629|NCT00924534|PK
1258630|NCT00924534|PD
1258631|NCT00924534|safety
1258632|NCT00924521|grains
1258633|NCT00924521|fiber
1258634|NCT00924521|metabolic syndrome
1258635|NCT00924521|insulin
1258636|NCT00924508|eczema
1258637|NCT00924508|at least 3 patches of eczema
1258638|NCT00924495|low back pain
1258639|NCT00924495|motor control
1258640|NCT00924495|cortical regulation
1258641|NCT00924495|transcranial magnetic stimulation
1258642|NCT00924482|cardiac output
1258643|NCT00924482|ECOM
1258644|NCT00924482|Endotracheal Cardiac Output Monitor
1258645|NCT00924482|Perioperative medical care
1258646|NCT00924469|Prostate cancer
1258647|NCT00924469|Abiraterone acetate
1258648|NCT00924469|Leuprolide acetate
1258649|NCT00924469|Prednisone
1258650|NCT00924469|CB7630
1258651|NCT00924469|Testosterone
1258652|NCT00924456|Transcendental Meditation
1258653|NCT00924456|blood pressure
1258654|NCT00924456|psychological distress
1258655|NCT00924456|high psychological distress
1258656|NCT00924443|acute myelogenous leukemia
1258657|NCT00924443|acute myeloid leukemia
1258658|NCT00924443|clolar
1258659|NCT00924443|evoltra
1258660|NCT00924443|clofarabine
1258661|NCT00924443|untreated acute leukemia
1258662|NCT00924443|adult acute leukemia
1258663|NCT00924430|Interaction SLV337 and simvastatin
1258664|NCT00924430|Type 2 diabetes mellitus
1258665|NCT00924417|Pain associated with peripheral intravenous line placement
1258666|NCT00924404|Xylitol
1258667|NCT00924404|sinusitis
1258668|NCT00924404|Comparing efficacy of twice daily xylitol nasal rinse with saline rinse presently current standard, comparing outcomes like quality of life and exacerbations
1258669|NCT00924391|cholesterol
1258670|NCT00924391|plant sterols
1258671|NCT00924391|cholesterol absorption
1258672|NCT00924365|Children
1258673|NCT00924365|AIDS
1258674|NCT00924365|Toxicity
1258675|NCT00924365|Development
1258676|NCT00924365|Puberty
1258677|NCT00924365|HIV
1258678|NCT00924365|Pediatrics
1258679|NCT00924365|HIV Infections
1258680|NCT00924352|Metastatic Breast Cancer
1258681|NCT00924339|soy protein
1258682|NCT00924339|familial hypercholesterolaemia
1258683|NCT00924339|children and adolescents
1258684|NCT00924339|isoflavones
1258685|NCT00924339|FH
1258694|NCT00924313|Prostate Cancer
1258695|NCT00924313|MRI
1258696|NCT00924313|C-11 Acetate
1258697|NCT00924313|PET
1258698|NCT00924300|feasibility of MEG in pediatric populations
1258699|NCT00924287|Metastatic Cancer
1258700|NCT00924287|Tumor Regression
1258701|NCT00924287|Immunotherapy
1258702|NCT00924287|Safety
1258703|NCT00924287|Cancer
1258704|NCT00924261|hip
1258705|NCT00924261|gait
1258706|NCT00924261|walking
1258707|NCT00924261|falls
1258708|NCT00924261|stretching
1258709|NCT00924261|Flexibility
1258710|NCT00924261|Aged
1258711|NCT00924248|Liver MRI
1258712|NCT00924209|Neoadjuvant
1258713|NCT00924209|Stage IIIA (N2)
1258714|NCT00924209|Cisplatin
1258715|NCT00924209|Gemcitabine
1258716|NCT00924209|Bevacizumab
1258717|NCT00924209|Non-Small Cell Lung Cancer
1258718|NCT00924209|NSCLC
1258719|NCT00924196|Plexiform Neurofibroma
1258720|NCT00924196|Optic Pathway Tumor
1258721|NCT00924196|Neurofibroma
1258722|NCT00924196|Malignant Peripheral Nerve Sheath Tumor
1258723|NCT00924196|Volumetric MRI
1258724|NCT00924196|Neurofibromatosis Type 1
1258725|NCT00924196|NF1
1258726|NCT00924196|Optic Glioma
1258727|NCT00924183|Depression
1258728|NCT00924183|Symptom scales
1258729|NCT00924183|Symptom measures
1258730|NCT00924183|Vancouver Semi-Structured Interview for Depression
1258731|NCT00924183|V-SID
1258732|NCT00924183|VSID
1258733|NCT00924183|treatment-as-usual
1258734|NCT00924183|treatment as usual
1258735|NCT00924183|open-label
1258736|NCT00924183|open label
1258737|NCT00924183|Major Depressive Episode
1258738|NCT00924183|MDE
1258739|NCT00924170|Immunotoxin
1258740|NCT00924170|CD25
1258741|NCT00924170|Immunogenicity
1258742|NCT00924170|Neutralization
1258743|NCT00924170|Neutralizing Antibodies
1258744|NCT00924170|Adult T-Cell Leukemia
1258745|NCT00924170|Leukemia
1258746|NCT00924170|ATL
1258747|NCT00924131|Late Effects
1258748|NCT00924131|Radiation
1258749|NCT00924131|Chemotherapy
1258750|NCT00924131|Hodgkin's Disease
1258751|NCT00924131|Lymphoma
1258752|NCT00924131|Hodgkin Disease
1258753|NCT00924118|Acute myocardial infarction
1258754|NCT00924118|Reperfusion injury
1258755|NCT00924118|Nitric oxide
1258756|NCT00924092|Immunotherapy
1258757|NCT00924092|Lung Cancer
1258758|NCT00924092|Colorectal Cancer
1258759|NCT00924092|Head and Neck Cancer
1258760|NCT00924092|Prostate
1258761|NCT00924092|Breast Cancer
1258762|NCT00924079|Analysis of plasma concentration of nalbuphine
1258763|NCT00924066|Ixabepilone
1258764|NCT00924066|BMS-247550
1258765|NCT00924066|Ixempra
1258766|NCT00924066|Cervical Cancer
1258767|NCT00924066|Epothilone
1258768|NCT00924053|Diabetes Mellitus Type 2
1258769|NCT00924040|BL22 in HCL after Immunotoxin
1258770|NCT00924040|Hairy Cell Leukemia
1258771|NCT00924040|Leukemia
1258777|NCT00924014|heart failure
1258778|NCT00924001|Clinical Response
1258779|NCT00924001|Immunotherapy
1258780|NCT00924001|Cancer
1258781|NCT00924001|Cytokines
1258782|NCT00924001|Adoptive Cell Therapy
1258783|NCT00924001|Melanoma
1258784|NCT00924001|Metastatic Melanoma
1258785|NCT00923988|Secondhand smoke
1258786|NCT00923988|passive smoking
1258787|NCT00923988|platelet function
1258788|NCT00923988|endothelial function
1258789|NCT00923962|Basic science
1258790|NCT00923962|Type 2 Diabetes mellitus
1258791|NCT00923962|Glucagon like peptid-1
1258792|NCT00923962|Coronary Bloodflow
1258793|NCT00923962|Metabolite uptake
1258794|NCT00923949|NSCLC Stage Ia-IIb
1258795|NCT00923949|Resectable NSCLC
1258796|NCT00923949|Non-Small Cell Lung Cancer
1258797|NCT00923949|NSCLC
1258798|NCT00923936|Kaposi's Sarcoma
1258799|NCT00923936|HIV
1258800|NCT00923936|Doxil
1258801|NCT00923936|VEGF
1258802|NCT00923936|Bevacizumab
1258803|NCT00923923|stress reactivity
1258804|NCT00923923|PTSD
1258805|NCT00923923|alcohol dependence
1258806|NCT00923923|drinking
1258807|NCT00923923|craving
1258808|NCT00923910|WT1 Peptide Dendritic Cell Vaccine
1258809|NCT00923910|Hematologic Malignancies
1258810|NCT00923910|Relapse After Allogeneic Stem Cell Transplantation
1258811|NCT00923910|Donor Lymphocyte Infusions
1258812|NCT00923910|WT1-Positive
1258813|NCT00923910|Dendritic Cell Vaccine
1258814|NCT00923910|Tumor Immunotherapy
1258815|NCT00923910|Allogeneic Adoptive Immunotherapy
1258816|NCT00923910|Hodgkins Lymphoma
1258817|NCT00923910|Leukemia
1258818|NCT00923910|Acute Myelogenous Leukemia
1258819|NCT00923910|AML
1258820|NCT00923910|Acute Lymphocytic Leukemia
1258821|NCT00923910|ALL
1258822|NCT00923910|Chronic Myelogenous Leukemia
1258823|NCT00923910|CML
1258824|NCT00923910|Myelodysplasia Syndrome
1258825|NCT00923910|Non-Hodgkin Lymphoma
1258826|NCT00923897|Hepatocellular Carcinoma
1258827|NCT00923897|Hepatic Metastasis
1258828|NCT00923897|Palliative Radiation Therapy
1258829|NCT00923897|Locally advanced HCC and Hepatic Metastasis
1258836|NCT00923871|CBCT
1258837|NCT00923871|Breast Cancer
1258838|NCT00923858|Rotator Cuff
1258839|NCT00923858|Ultrasound
1258840|NCT00923858|Pain
1258841|NCT00923858|Tear Progression
1258842|NCT00923845|Metastatic Renal Cell Carcinoma
1258843|NCT00923845|Allogeneic Hematopoietic Stem Cell Transplant
1258844|NCT00923845|Th2 Cells
1258845|NCT00923845|Sirolimus
1258846|NCT00923845|Pentostatin
1258847|NCT00923845|Kidney Cancer
1258848|NCT00923845|Renal Cell Carcinoma
1258849|NCT00923845|Metastatic Renal Cell Cancer
1258850|NCT00923832|Fungal Infections
1258851|NCT00923832|PCR Assays
1258852|NCT00923832|Cell Wall Derived Biomarkers
1258853|NCT00923832|EORTC/MSG Definitions
1258854|NCT00923832|Molecular Assays
1258855|NCT00923832|Lung Fungal Infection
1258856|NCT00923832|Invasive Pulmonary Fungal Infection
1258857|NCT00923832|Invasive Pulmonary Aspegillosis
1258858|NCT00923832|Invasive Pulmonary Zycomycosis
1258859|NCT00923819|Adolescents
1258860|NCT00923819|Gastric Bypass
1258861|NCT00923819|Quality of Life
1258862|NCT00923819|Mental Health
1258863|NCT00923819|Lifestyle
1258864|NCT00923806|Metastatic Cancer
1258865|NCT00923806|Tumor Regression
1258866|NCT00923806|Safety
1258867|NCT00923806|Immunotherapy
1258868|NCT00923793|skull defects
1258869|NCT00923793|Hydroxylapatite implant
1258870|NCT00923793|Titanium implant
1258871|NCT00923793|calotte defects without the possibility to be covered with the missing own bone
1258872|NCT00923780|Tissue Acquisition
1258873|NCT00923780|Gene Expression
1258874|NCT00923780|Class Predictor Model
1258875|NCT00923780|Endocrine Tumor
1258876|NCT00923741|Lung Cancer
1258877|NCT00923741|Immunity
1258878|NCT00923741|Clinical Response
1258879|NCT00923741|Cytokines
1258880|NCT00923741|Elispot Assay
1258881|NCT00923741|Non-Small Cell Lung Cancer
1258882|NCT00923741|NSCLC
1258883|NCT00923728|AVN - 944
1258884|NCT00923728|Phase I
1258885|NCT00923728|Adult Solid Tumors
1258886|NCT00923728|Cancer
1258887|NCT00923728|Solid Tumor
1258888|NCT00923715|Diabetes Mellitus, Type 1
1258889|NCT00923715|Exenatide
1258890|NCT00923715|Pramlintide
1258891|NCT00923676|Hyperlipidemia
1258892|NCT00923676|LDL-cholesterol
1258893|NCT00923676|HDL-cholesterol
1258894|NCT00923676|triglycerides
1258895|NCT00923676|IIEF
1258896|NCT00923676|FSFI
1258897|NCT00923676|Male and female sexual dysfunctions
1258898|NCT00923663|MALT lymphoma
1258899|NCT00923663|Advanced or Helicobacter pylori-refractory MALT lymphoma
1258900|NCT00923650|Informed Consent
1258901|NCT00923650|Pediatric Phase I Clinical Trials
1258902|NCT00923650|Assent
1258903|NCT00923650|Questionnaires
1258904|NCT00923650|Osteosarcoma
1258905|NCT00923650|Ewing's Sarcoma
1258906|NCT00923650|Neuroblastoma
1258907|NCT00923650|Brain Tumors
1258908|NCT00923650|Leukemia
1258909|NCT00923637|Non small cell lung cancer
1258910|NCT00923637|video assisted thoracic surgery
1258911|NCT00923637|Adjuvant chemotherapy
1258912|NCT00923637|Pemetrexed
1258913|NCT00923637|Oxaliplatin
1258914|NCT00923624|electronic medical record
1258915|NCT00923624|antiretroviral medication adherence
1258916|NCT00923611|Hypertension
1258917|NCT00923611|Fimasartan
1258918|NCT00923598|TKA
1258919|NCT00923598|Bilateral
1258920|NCT00923598|Cleveland Clinic
1258921|NCT00923598|UCSD
1258922|NCT00923598|Catheter
1258923|NCT00923598|Nerve block
1258924|NCT00923598|Postoperative pain
1258925|NCT00923598|Femoral Catheter
1258926|NCT00923598|Bilateral Total Knee Arthroplasty
1258927|NCT00923598|Bilateral Femoral Catheter
1258928|NCT00923572|Oral contraceptive
1258929|NCT00923533|Fimasartan
1258930|NCT00923533|Drug interaction
1258931|NCT00923520|Solid Tumors
1258932|NCT00923520|Phase I
1258933|NCT00923520|Lymphoma
1258934|NCT00923520|Dimethane Sulfonate (DMS612, NSC 281612)
1258935|NCT00923520|Cancer
1258936|NCT00923520|Solid Tumor
1258937|NCT00923520|Renal Cell Cancer
1258938|NCT00923520|Kidney Cancer
1258939|NCT00923520|Breast Cancer
1258940|NCT00923520|Colon Cancer
1258941|NCT00923520|Lung Disease
1258942|NCT00923520|Non-Hodgkin Lymphoma
1258943|NCT00923520|NHL
1258944|NCT00923507|Gene Expression
1258945|NCT00923507|Prognosis
1258946|NCT00923507|Watch and Wait
1258947|NCT00923507|Molecular Genetics
1258948|NCT00923507|Biologic Markers
1258949|NCT00923507|Leukemia
1258950|NCT00923507|Lymphoma
1258951|NCT00923494|Anesthesia
1258952|NCT00923481|Multi-Kinase Inhibitor
1258953|NCT00923481|Neoplasms
1258954|NCT00923481|Advanced Cancer
1258955|NCT00923481|Kidney Cancer
1258956|NCT00923481|Liver Cancer
1258957|NCT00923481|Pheochromocytoma
1258958|NCT00923481|Non-Small Cell Lung Cancer
1258959|NCT00923481|Colorectal Cancer
1258960|NCT00923481|Head and Neck Cancer
1258961|NCT00923468|Pharmacokinetics
1258962|NCT00923468|Phase I Trials
1258963|NCT00923468|Children
1258964|NCT00923468|Relaspsed Solid Tumors
1258965|NCT00923468|Relapsed Leukemia
1258966|NCT00923468|Relapsed Brain Tumors
1258967|NCT00923442|Acute Lymphoblastic Leukemia
1258968|NCT00923442|Acute Lymphocytic Leukemia
1258969|NCT00923442|Pediatric Blood Disorders
1258970|NCT00923442|Hodgkins and non-Hodgkins lymphoma
1258971|NCT00923442|MDS
1258972|NCT00923429|Manual therapy
1258973|NCT00923429|Low back pain
1258974|NCT00923429|Pain
1258975|NCT00923429|Return to work
1258976|NCT00923416|Intra-Prostate Markers
1258977|NCT00923416|Transrectal Ultrasound
1258978|NCT00923416|Prostate Cancer Patients
1258979|NCT00923403|plant sterols
1258980|NCT00923403|diet
1258981|NCT00923403|soymilk
1258982|NCT00923403|cholesterol
1258983|NCT00923390|Renal Cancer
1258984|NCT00923390|Immunotherapy
1258985|NCT00923390|Clinical Response
1258986|NCT00923390|Toxicity
1258987|NCT00923390|Gene Therapy
1258988|NCT00923390|Kidney Cancer
1258989|NCT00923377|Breast Cancer
1258990|NCT00923377|Breast Cancer Prevention
1258991|NCT00923377|High Risk
1258992|NCT00923377|Breast Stem Cells
1258993|NCT00923377|Mammographic Density
1258994|NCT00923377|Breast Cancer Risk
1258995|NCT00923364|GATA2
1258996|NCT00923364|Transplant
1258997|NCT00923364|Immunodeficiency
1258998|NCT00923364|Myelodysplasia
1258999|NCT00923364|MonoMAC
1259000|NCT00923351|Vaccine
1259001|NCT00923351|Immunotherapy
1259002|NCT00923351|Cancer
1259003|NCT00923351|Chemotherapy
1259004|NCT00923351|Ewings Sarcoma
1259005|NCT00923351|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
1259006|NCT00923351|Neuroblastoma
1259007|NCT00923351|Autologous Lymphocyte Infusion
1259008|NCT00923351|Ewing's Sarcoma
1259009|NCT00923351|Rhabdomyosarcoma
1259010|NCT00923338|fistula
1259011|NCT00923338|vesico-vaginal fistula
1259012|NCT00923325|Biomarker Analysis
1259013|NCT00923325|Sarcomas
1259014|NCT00923325|Ewing's Sarcoma
1259015|NCT00923325|Osteosarcoma
1259016|NCT00923325|Rhabdomyosarcoma
1259017|NCT00923325|Synovial Sarcoma
1259018|NCT00923325|Other Sarcoma
1259019|NCT00923299|stage IV pancreatic cancer
1259020|NCT00923299|recurrent pancreatic cancer
1259021|NCT00923299|adenocarcinoma of the pancreas
1259022|NCT00923273|Pemetrexed
1259023|NCT00923273|Sirolimus
1259024|NCT00923273|Non-Small Cell Lung Cancer
1259025|NCT00923273|Phase I/II
1259026|NCT00923273|mTOR Inhibitor
1259027|NCT00923273|NSCLC
1259028|NCT00923273|Lung Cancer
1259029|NCT00923260|Omentectomy
1259030|NCT00923260|metabolic syndrome
1259031|NCT00923260|acute phase reactants
1259032|NCT00923247|Vandetanib
1259033|NCT00923247|Bortezomib
1259034|NCT00923247|Medullary Thyroid
1259035|NCT00923247|Proteasome Inhibitor
1259036|NCT00923247|Cancer
1259037|NCT00923247|Solid Tumor
1259038|NCT00923247|Thyroid Cancer
1259039|NCT00923247|Medullary Thyroid Cancer
1259040|NCT00923234|monosomy 5
1259041|NCT00923234|del5q
1259042|NCT00923234|lenalidomide
1259043|NCT00923234|azacitidine
1259044|NCT00923221|Blood
1259045|NCT00923221|Prostate Cancer
1259046|NCT00923221|Genotyping
1259047|NCT00923195|Metastatic Melanoma
1259048|NCT00923195|Tumor Regression
1259049|NCT00923195|Safety
1259050|NCT00923195|Immunotherapy
1259051|NCT00923182|Relapsed or Refractory Chronic Lymphocytic Leukemia,
1259052|NCT00923182|CLL
1259053|NCT00923169|Renal Cell
1259054|NCT00923169|Melanoma
1259055|NCT00923169|Monoclonal Antibodies
1259056|NCT00923169|Phase I
1259057|NCT00923169|TGF-B
1259058|NCT00923156|Heart failure
1259059|NCT00923156|Systolic
1259060|NCT00923156|Aliskiren
1259061|NCT00923156|Ramipril
1259062|NCT00923156|Angiotensin II
1259063|NCT00923156|Ang II
1259064|NCT00923156|Plasma Renin Activity
1259065|NCT00923156|PRA
1259066|NCT00923156|Plasma Renin Concentration
1259067|NCT00923156|PR,
1259068|NCT00923156|brain natriuretic peptide
1259069|NCT00923156|BNP
1259070|NCT00923156|urinary aldosterone
1259071|NCT00923156|Escape
1259072|NCT00923156|Pharmacokinetic
1259073|NCT00923156|PK
1259074|NCT00923130|Renal Cell Carcinoma
1259075|NCT00923130|Bevacizumab
1259076|NCT00923130|Ixabepilone
1259077|NCT00923130|Phase II
1259078|NCT00923117|Glioblastoma
1259079|NCT00923117|Chemotherapy
1259080|NCT00923117|Anti-Angiogenesis
1259081|NCT00923117|Radiation
1259082|NCT00923117|Brain Tumor
1259083|NCT00923117|Malignant Glioma
1259084|NCT00923117|Glioblastoma Multiforme
1259085|NCT00923104|Radiation
1259086|NCT00923104|Blister
1259087|NCT00923104|Healthy Volunteer
1259088|NCT00923104|Samples
1259089|NCT00923104|Prostate Cancer
1259090|NCT00923104|Breast Cancer
1259091|NCT00923104|HV
1259092|NCT00923091|triple combination
1259093|NCT00923091|parallel group
1259094|NCT00923091|dual combination
1259095|NCT00923078|schizophrenia
1259096|NCT00923078|cognitive remediation
1259097|NCT00923078|rehabilitation
1259098|NCT00923078|evoked potentials
1259099|NCT00923078|neuropsychology
1259100|NCT00923065|Cancer
1259101|NCT00923065|Oncology
1259102|NCT00923065|Standard Care
1259103|NCT00923052|Cancer Stem Cells
1259104|NCT00923052|Biomarkers
1259105|NCT00923052|Surgery
1259106|NCT00923052|Solid Organ Cancers
1259107|NCT00923052|Natural History
1259108|NCT00923052|Cancer
1259109|NCT00923052|Solid Organ Cancer
1259110|NCT00923052|Liver Cancer
1259111|NCT00923052|Colorectal Cancer
1259112|NCT00923052|Breast Cancer
1259113|NCT00923052|Gastric Cancer
1259114|NCT00923052|Pancreatic Ductal Cancer
1259115|NCT00923039|The early origin of cardiovascular disease
1259123|NCT00923013|Hairy Cell Leukemia
1259124|NCT00923013|Cladribine
1259125|NCT00923013|Rituximab
1259126|NCT00923013|Minimal Residual Disease
1259127|NCT00923013|Leukemia
1259128|NCT00923000|Herb Drug
1259129|NCT00923000|volunteers
1259130|NCT00922987|lyrica pregabalin epilepsy partial seizures
1259131|NCT00922974|spinal bone metastases
1259132|NCT00922974|pain
1259133|NCT00922961|brachytherapy, late cutaneous toxicity
1259134|NCT00922948|Radiofrequency ablation
1259135|NCT00922948|Cryosurgery
1259136|NCT00922948|Renal cancers
1259137|NCT00922896|Gemcitabine
1259138|NCT00922896|Cisplatin
1259139|NCT00922896|Erlotinib
1259140|NCT00922883|Promacta
1259141|NCT00922883|SAA
1259142|NCT00922883|Aplastic Anemia
1259143|NCT00922883|Thrombocytopenia
1259144|NCT00922857|Respiratory Insufficiency
1259145|NCT00922857|Muscular Atrophy
1259146|NCT00922857|Respiratory rehabilitation
1259147|NCT00922844|hypotension
1259148|NCT00922844|low blood pressure
1259149|NCT00922844|vasopressor need
1259150|NCT00922831|Cognition, Affective MS symptoms
1259151|NCT00922818|Perineal
1259152|NCT00922818|Prostatectomy
1259153|NCT00922818|Nerve
1259154|NCT00922818|Anatomic
1259155|NCT00922818|Surgery
1259156|NCT00922818|Neoplasms, Prostatic
1259157|NCT00922818|Prostate Cancer
1259158|NCT00922818|Prostate Neoplasms
1259159|NCT00922818|Prostatic Cancer
1259160|NCT00922818|Prostate
1259161|NCT00922818|Cancer
1259162|NCT00922818|Recurrent
1259163|NCT00922805|Pediatrics, short bowel syndrome, soluble fiber
1259164|NCT00922766|dalteparin non-ST segment elevated acute coronary syndromes
1259165|NCT00922753|Preoxygenation
1259166|NCT00922753|Inspiratory
1259167|NCT00922753|Support
1259168|NCT00922753|Healthy
1259169|NCT00922753|EndtidalO2
1259170|NCT00922740|Nocturia
1259171|NCT00922740|Pharmacokinetics
1259172|NCT00922740|Pharmacodynamics
1259173|NCT00922740|Water-loading
1259174|NCT00922740|Elderly
1259175|NCT00922740|Males
1259176|NCT00922727|L. reuteri
1259177|NCT00922727|Cytokines
1259178|NCT00922727|Toll like receptors
1259179|NCT00922727|Healthy Adults
1259180|NCT00922727|Probiotics
1259181|NCT00922714|Glutamine
1259182|NCT00922714|ICU patients
1259183|NCT00922714|Critically ill
1259184|NCT00922714|Nutrition
1259185|NCT00922701|Peritoneal dialysis
1259186|NCT00922701|L-carnitine
1259187|NCT00922688|Dipeptide Alanyl-Glutamine
1259188|NCT00922688|Insulin sensitivity
1259189|NCT00922688|Intracellular signaling
1259190|NCT00922688|Antioxidant/oxidant parameters
1259191|NCT00922688|Lipolysis
1259192|NCT00922688|Inflammatory response in the liver
1259193|NCT00922675|ST-elevation myocardial infarction
1259194|NCT00922662|coronary artery disease
1259195|NCT00922662|chest pain
1259196|NCT00922662|CCTA
1259197|NCT00922623|Nasolabial folds
1259198|NCT00922597|Continuous infusion
1259199|NCT00922597|Surgery
1259200|NCT00922597|Severe haemophilia A
1259201|NCT00922584|non-small cell lung cancer
1259202|NCT00922584|Sorafenib
1259203|NCT00922584|targeted therapy
1259204|NCT00922571|Cataract
1259205|NCT00922571|Femtosecond laser
1259206|NCT00922558|tetra-axiametric posturography
1259207|NCT00922558|postural control
1259208|NCT00922558|tetrax
1259209|NCT00922558|children
1259210|NCT00922545|Chronic obstructive pulmonary disease
1259211|NCT00922545|Quality of life
1259212|NCT00922545|Primary health care
1259213|NCT00922532|Hypoxic Respiratory Failure (HRF), Pulmonary Hypertension
1259214|NCT00922519|Positron Emission Tomography
1259215|NCT00922519|Sodium 18F-Fluoride
1259216|NCT00922519|99mTc-MDP
1259217|NCT00922519|Bone Scan
1259218|NCT00922506|Overactive bladder
1259219|NCT00922506|Benign prostate hyperplasia
1259220|NCT00922506|Doxazosin
1259221|NCT00922506|Tolterodine
1259222|NCT00922493|weaning
1259223|NCT00922493|inspiratory muscle training
1259224|NCT00922493|maximum inspiratory pressure (MIP)
1259225|NCT00922493|index of Tobin (IT)
1259226|NCT00922493|intubated
1259227|NCT00922493|intensive care unit
1259228|NCT00922493|elderly
1259229|NCT00922480|Hypertension
1259230|NCT00922480|Losartan
1259231|NCT00922454|patients will be matched based on AAA neck length and neck and iliac angulation
1259232|NCT00922441|Fimasartan
1259233|NCT00922441|Essential Hypertension
1259234|NCT00922441|24hour ABPM
1259235|NCT00922441|Population PK
1259236|NCT00922428|rheumatism
1259237|NCT00922428|arthralgia
1259238|NCT00922428|myalgia
1259239|NCT00922428|lumbago
1259240|NCT00922428|homoeopathy
1259241|NCT00922428|injection
1259242|NCT00922428|PASCOE-Agil HOM Injektopas
1259243|NCT00922428|efficacy
1259244|NCT00922428|tolerability
1259245|NCT00922428|acceptance
1259246|NCT00922428|safety
1259247|NCT00922415|Crohn's disease
1259248|NCT00922415|calprotectin
1259249|NCT00922402|Acute
1259250|NCT00922402|heart failure
1259251|NCT00922402|hyperglycemia
1259252|NCT00922402|Acute heart failure with high levels of glycemia
1259253|NCT00922389|Diabetes Complications
1259254|NCT00922389|Lower limb ischemia
1259255|NCT00922389|Adult stem cells
1259256|NCT00922389|peripheral blood stem cells
1259257|NCT00922376|Diabetes
1259258|NCT00922376|self- management
1259259|NCT00922376|glycemic control
1259260|NCT00922376|telehealth
1259261|NCT00922376|mhealth
1259262|NCT00922363|safety
1259263|NCT00922363|vaccine
1259264|NCT00922363|tuberculosis
1259265|NCT00922363|CAF01
1259266|NCT00922363|Ag85B-ESAT-6
1259267|NCT00922363|prevention
1259268|NCT00922350|asthma
1259269|NCT00922350|heliox
1259270|NCT00922350|bronchodilators
1259271|NCT00922350|posture
1259272|NCT00922337|distal embolization
1259273|NCT00922337|thrombotic lesions
1259274|NCT00922337|AMI
1259275|NCT00922337|ACS
1259276|NCT00922337|SVG
1259277|NCT00922324|Healthy volunteers
1259278|NCT00922311|Proteinuria
1259279|NCT00922285|psychosocial effects of cancer and its treatment
1259280|NCT00922285|health status unknown
1259281|NCT00922272|Schizophrenia
1259282|NCT00922259|Flu
1259283|NCT00922259|Influenza
1259284|NCT00922259|Vaccine
1259285|NCT00922259|Prevention
1259286|NCT00922246|overuse injuries
1259287|NCT00922246|conscript
1259288|NCT00922246|prevention
1259289|NCT00922233|Contraception
1259290|NCT00922220|low back pain
1259291|NCT00922220|spinal manipulation
1259292|NCT00922220|central sensitization
1259293|NCT00922220|manual therapy
1259294|NCT00922194|Type 2 diabetes
1259295|NCT00922194|Obesity
1259296|NCT00922194|Extended Release Metformin
1259297|NCT00922181|malignancy
1259298|NCT00922181|liver
1259299|NCT00922181|microwave
1259300|NCT00922181|surgery
1259301|NCT00922168|Sleep
1259302|NCT00922168|apnea
1259303|NCT00922168|obstructive
1259304|NCT00922168|central
1259305|NCT00922155|endobronchial ultrasound
1259306|NCT00922155|guide sheath
1259307|NCT00922155|peripheral pulmonary lesions
1259308|NCT00922129|Sirolimus
1259309|NCT00922129|Calcineurin inhibitor
1259310|NCT00922129|prostate cancer
1259311|NCT00922103|Colitis, Ulcerative
1259312|NCT00922103|Ileo Neo Rectal Anastomosis
1259313|NCT00922103|Ileal Pouch Anal Anastomosis
1259314|NCT00922103|Quality of Life
1259315|NCT00922103|functional results
1259316|NCT00922103|reconstructive surgery
1259317|NCT00922103|surgery
1259318|NCT00922090|Schizophrenia
1259319|NCT00922090|Seroquel XR
1259320|NCT00922090|CGI-CB
1259321|NCT00922090|SWN-K
1259322|NCT00922051|COPD
1259323|NCT00922051|FEV1
1259324|NCT00922051|beta endorphin
1259325|NCT00922051|TENS
1259326|NCT00922051|acupuncture
1259327|NCT00922025|NSCLC
1259328|NCT00922025|Male
1259329|NCT00922025|Smoking Pattern
1259330|NCT00922025|Efficacy
1259331|NCT00922012|Electromagnetic Stimulation Therapy
1259332|NCT00922012|Chronic Prostatitis
1259333|NCT00922012|Chronic Pelvic Pain Syndrome
1259334|NCT00921999|Chickenpox
1259335|NCT00921999|Shingles
1259336|NCT00921999|Varicella
1259337|NCT00921999|Zoster
1259338|NCT00921999|Vaccine
1259339|NCT00921986|genetics
1259340|NCT00921986|biorepository
1259341|NCT00921986|cardiac death
1259342|NCT00921986|atrial fibrillation
1259343|NCT00921986|ventricular fibrillation
1259344|NCT00921986|ventricular tachycardia
1259345|NCT00921986|supraventricular tachycardias
1259346|NCT00921986|premature ventricular complexes
1259347|NCT00921986|premature atrial complexes
1259348|NCT00921986|atrioventricular and intraventricular blocks
1259349|NCT00921986|sinus node dysfunction
1259350|NCT00921986|syncope
1259351|NCT00921986|vasovagal reactivity
1259352|NCT00921986|postural orthostatic tachycardia syndrome
1259353|NCT00921973|influenza
1259354|NCT00921973|universal influenza vaccine
1259355|NCT00921960|Left ventricular dysfunction
1259356|NCT00921960|Left ventricular systolic dysfunction
1259357|NCT00921960|Left ventricular diastolic dysfunction
1259358|NCT00921960|Myocardial Infarction
1259359|NCT00921960|Hypertension
1259360|NCT00921960|Diabetes
1259361|NCT00921960|Obesity
1259362|NCT00921960|Dyslipidaemia
1259363|NCT00921960|Heart Failure
1259364|NCT00921960|Prevention
1259365|NCT00921960|Screening
1259366|NCT00921960|Cardiovascular Risk Factors
1259367|NCT00921960|Echocardiography
1259368|NCT00921960|Natriuretic Peptides
1259369|NCT00921947|influenza vaccine
1259370|NCT00921947|M2e
1259371|NCT00921947|Universal influenza vaccine
1259372|NCT00921934|Herpes
1259373|NCT00921934|Shingles
1259374|NCT00921934|virus disease
1259375|NCT00921934|vitamin C
1259376|NCT00921934|ascorbic acid
1259377|NCT00921934|antioxidant
1259378|NCT00921934|oxidative stress
1259379|NCT00921908|total hip arthroplasty
1259380|NCT00921895|Pink Eye,
1259381|NCT00921895|Viral conjunctivitis
1259382|NCT00921895|Adenoviral conjunctivitis
1259383|NCT00921895|Keratoconjunctivitis
1259384|NCT00921882|Type 2 diabetes
1259385|NCT00921882|Post-partum screening
1259386|NCT00921869|Cancer
1259387|NCT00921869|Gastrointestinal Cancer
1259388|NCT00921856|Acetylcholine
1259389|NCT00921843|Pediatric patients undergoing surgery
1259390|NCT00921830|ibuprofen
1259391|NCT00921830|healthy volunteers
1259392|NCT00921830|bioavailability
1259393|NCT00921830|pharmacokinetics
1259394|NCT00921830|suppository
1259395|NCT00921817|healthy children
1259396|NCT00921804|Schizophrenia
1259397|NCT00921804|Hallucinations
1259398|NCT00921804|Paranoia
1259399|NCT00921804|Inpatient schizophrenia clinical trial
1259400|NCT00921791|Hypertension
1259401|NCT00921791|Blood pressure
1259402|NCT00921791|Home Blood Pressure Monitoring
1259403|NCT00921791|Ambulatory Blood Pressure Monitoring
1259404|NCT00921791|Pharmaceutical care
1259405|NCT00921778|Laparoscopic supracervical hysterectomy
1259406|NCT00921778|Vaginal bleeding
1259407|NCT00921778|Patient satisfaction
1259408|NCT00921778|vaginal bleeding after laparoscopic hysterectomy
1259409|NCT00921765|Pain
1259410|NCT00921765|Naloxone
1259411|NCT00921765|Ketamine
1259412|NCT00921765|Third Molar
1259413|NCT00921765|Surgery
1259414|NCT00921752|Lipid therapy
1259415|NCT00921752|high CV risk
1259416|NCT00921752|lipid goal attainment
1259417|NCT00921752|High cardiovascular risk patients
1259418|NCT00921739|Non small cell lung cancer
1259419|NCT00921739|Small cell lung cancer
1259420|NCT00921739|Thymoma unresectable
1259421|NCT00921739|Thymic carcinoma unresectable
1259422|NCT00921726|Drug Interaction
1259423|NCT00921713|Early cancer care
1259424|NCT00921700|Paracetamol
1259425|NCT00921700|Acetaminophen
1259426|NCT00921700|Ibuprofen
1259427|NCT00921700|Pain
1259428|NCT00921700|Postoperative pain
1259429|NCT00921700|third molar
1259430|NCT00921674|therapeutic equivalency
1259431|NCT00921674|pharmacokinetics
1259432|NCT00921674|food
1259433|NCT00921674|Healthy Volunteers
1259434|NCT00921661|oxaliplatin
1259435|NCT00921661|5-FU
1259436|NCT00921661|Folinic Acid
1259437|NCT00921648|EEG
1259438|NCT00921648|general paresis
1259439|NCT00921648|MRI
1259440|NCT00921648|neurosyphilis
1259441|NCT00921635|Haemoglobin
1259442|NCT00921622|Blood pressure
1259443|NCT00921622|Vitamin C
1259444|NCT00921622|Vitamin D
1259445|NCT00921609|Acromegaly
1259446|NCT00921609|OGTT
1259447|NCT00921609|post-op
1259448|NCT00921596|Surgical Procedures, Cardiac
1259449|NCT00921596|Minimally Invasive Surgical Procedures
1259450|NCT00921596|Thoracoscopes
1259451|NCT00921596|Cardiopulmonary Bypass
1259452|NCT00921583|survival rate
1259453|NCT00921583|success rate
1259454|NCT00921570|TWEAK
1259455|NCT00921570|FMD
1259456|NCT00921570|PTX3
1259457|NCT00921570|Valsartan
1259458|NCT00921570|Amlodipine
1259459|NCT00921570|Renin Angiotensin System
1259460|NCT00921557|Bone mineral density
1259461|NCT00921544|ROP
1259462|NCT00921544|sucrose
1259463|NCT00921544|pain
1259464|NCT00921531|Hepatocellular carcinoma
1259465|NCT00921531|thalidomide
1259466|NCT00921531|TACE
1259467|NCT00921531|Child-Pugh Class A or B
1259468|NCT00921518|Cardiac surgery
1259469|NCT00921518|Sodium bicarbonate
1259470|NCT00921518|Acute kidney injury
1259471|NCT00921518|Saline
1259472|NCT00921505|Acetaminophen
1259473|NCT00921505|Ibuprofen
1259474|NCT00921505|Platelets
1259475|NCT00921505|Leukocytes
1259476|NCT00921505|Oxygen species
1259477|NCT00921505|Humans
1259478|NCT00921505|Blood Platelets
1259479|NCT00921505|Reactive Oxygen Species
1259480|NCT00921505|Platelet Activation
1259481|NCT00921492|Luteinizing hormone
1259482|NCT00921492|Cortisol
1259483|NCT00921492|HPA axis
1259484|NCT00921492|HPO axis
1259485|NCT00921492|Ovulation
1259486|NCT00921492|Heart rate variability
1259487|NCT00921492|Psychological distress and quality of life
1259488|NCT00921479|third molar
1259489|NCT00921479|quality of life
1259490|NCT00921479|postoperative swelling
1259491|NCT00921479|postoperative pain
1259492|NCT00921479|Surgical Procedures, Operative
1259493|NCT00921479|Postoperative Period
1259494|NCT00921466|Evaluate the clinical content of the e-SSRS-IVR
1259495|NCT00921453|Internet
1259496|NCT00921453|Information supply
1259497|NCT00921453|Tailoring
1259498|NCT00921453|Patient empowerment
1259499|NCT00921453|Headaches
1259500|NCT00921453|Meta-search
1259501|NCT00921453|Consumer Health Information
1259502|NCT00921453|Information Services
1259503|NCT00921453|Information Storage and Retrieval
1259504|NCT00921453|Information Systems
1259505|NCT00921440|coronary artery
1259506|NCT00921440|stenosis
1259507|NCT00921427|Hemianopia
1259508|NCT00921427|Rehabilitation
1259509|NCT00921427|Transcranial direct current stimulation
1259510|NCT00921427|Visual field
1259511|NCT00921414|Mantle cell lymphoma
1259512|NCT00921414|R DHAP
1259513|NCT00921414|ASCT
1259514|NCT00921414|Rituximab Maintenance
1259515|NCT00921388|Smoking Cessation
1259516|NCT00921388|Exercise
1259517|NCT00921388|Postmenopausal women
1259518|NCT00921388|CHANTIX
1259519|NCT00921388|varenicline
1259520|NCT00921362|Schizophrenia
1259521|NCT00921349|Prophylaxis
1259522|NCT00921349|ligation
1259523|NCT00921349|beta blockers
1259524|NCT00921349|First bleeding rate
1259525|NCT00921336|subjects with advanced Solid tumor who have not responded to standard therapy or for whom no standard therapy is available
1259526|NCT00921323|Obesity
1259527|NCT00921323|Physical activity
1259528|NCT00921323|pedometers
1259529|NCT00921323|children
1259530|NCT00921310|Temsirolimus and pemetrexed for recurrent or refractory NSCLC
1259531|NCT00921297|Alzheimer's Disease
1259532|NCT00921297|vision impairment
1259533|NCT00921297|cataract
1259534|NCT00921297|quality of life
1259535|NCT00921297|retinal nerve fiber layer
1259536|NCT00921271|Compartment syndrome
1259537|NCT00921258|latent prostate cancer
1259538|NCT00921258|Patient with latent prostate cancer
1259539|NCT00921258|PSA ≤ 10 ng/ml
1259540|NCT00921258|Clinical stage T1c or T2a
1259541|NCT00921258|Patient who accept just be control
1259542|NCT00921245|Overactive Bladder
1259543|NCT00921232|Life-ending patient
1259544|NCT00921232|caregiver
1259545|NCT00921219|therapeutic equivalency
1259546|NCT00921219|pharmacokinetics
1259547|NCT00921219|food
1259548|NCT00921219|Healthy volunteers
1259549|NCT00921206|influenza
1259550|NCT00921206|influenza vaccine
1259551|NCT00921206|universal influenza vaccine
1259552|NCT00921206|Matrix 2e protein
1259553|NCT00921206|M2e
1259554|NCT00921206|Immune response
1259555|NCT00921193|Prostate
1259556|NCT00921193|fiducials
1259557|NCT00921193|radiation Therapy
1259558|NCT00921193|Tracking
1259559|NCT00921193|Localization
1259560|NCT00921180|Hepatitis B, chronic
1259561|NCT00921180|Peginterferon alfa-2a
1259562|NCT00921180|Entecavir
1259563|NCT00921167|Glioblastoma
1259564|NCT00921167|Astrocytoma
1259565|NCT00921167|Chemotherapy
1259566|NCT00921154|therapeutic equivalency
1259567|NCT00921154|pharmacokinetics
1259568|NCT00921154|fasting
1259569|NCT00921154|Healthy Volunteers
1259570|NCT00921141|Implantable central venous access ports, cancer
1259571|NCT00921128|Muscimol
1259572|NCT00921128|Convection-Enhanced Delivery
1259573|NCT00921128|Parkinson's Disease
1259574|NCT00921128|Deep Brain Stimulation
1259575|NCT00921128|Parkinson Disease
1259576|NCT00921128|PD
1259577|NCT00921115|hormone receptor positive
1259578|NCT00921115|invasive breast cancer
1259579|NCT00921115|endocrine therapy
1259580|NCT00921115|Anastrazole
1259581|NCT00921115|Fulvestrant
1259582|NCT00921115|breast tumors
1259583|NCT00921115|postmenopausal
1259584|NCT00921102|Atropine
1259585|NCT00921102|Morphine
1259586|NCT00921102|Analgesics, Opioid
1259587|NCT00921102|Antiemetics
1259588|NCT00921089|Atherosclerosis
1259589|NCT00921089|Cardiovascular disease
1259590|NCT00921089|Hemodialysis
1259591|NCT00921089|Inflammation
1259592|NCT00921089|Vascular calcification
1259593|NCT00921050|subclinical hypothyroidism
1259594|NCT00921050|elderly
1259595|NCT00921050|mild cognitive impairment
1259596|NCT00921050|neuropsychological test
1259597|NCT00921050|NEUROPSI
1259598|NCT00921037|Neurofibromatosis Type 1
1259599|NCT00921037|Morbus Recklinghausen
1259600|NCT00921037|cutaneous neurofibromas
1259601|NCT00921037|Erbium-YAG-Laser
1259602|NCT00921037|Vaporisation
1259603|NCT00921037|Thermal Necrosis
1259604|NCT00921024|Complicated Urinary Tract Infection
1259605|NCT00921024|Pyelonephritis
1259606|NCT00921024|Antimicrobial
1259607|NCT00921024|Cephalosporin
1259608|NCT00921024|Intravenous
1259609|NCT00921011|hypertension
1259610|NCT00921011|diabetes
1259611|NCT00921011|smoking
1259612|NCT00921011|hyperlipidemia
1259613|NCT00921011|atherosclerosis risk
1259614|NCT00920998|Z-338
1259615|NCT00920998|YM443
1259616|NCT00920998|healthy volunteers
1259617|NCT00920985|Pregnancy prevention
1259618|NCT00920985|Female contraception
1259619|NCT00920985|Patch
1259620|NCT00920972|Bone marrow
1259621|NCT00920972|Transplant
1259622|NCT00920972|Transplantation
1259623|NCT00920972|Hematopoietic
1259624|NCT00920972|Umbilical cord
1259625|NCT00920972|Related
1259626|NCT00920972|Unrelated
1259627|NCT00920972|Reduced
1259628|NCT00920972|Non-myeloablative
1259629|NCT00920972|Nonmyeloablative
1259630|NCT00920972|Non-malignant
1259631|NCT00920972|Nonmalignant
1259632|NCT00920946|Huntington
1259633|NCT00920946|Dimebon
1259634|NCT00920946|HD
1259635|NCT00920946|Huntingtin
1259636|NCT00920933|Ozone challenge
1259637|NCT00920933|airway neutrophilia
1259638|NCT00920933|induced sputum
1259639|NCT00920933|Healthy volunteers
1259640|NCT00920920|3D-4D MRI-based Brachytherapy
1259641|NCT00920920|Cervical Cancer
1259642|NCT00920920|Multicenter Clinical Study
1259643|NCT00920920|Locally advanced cervical cancer
1259644|NCT00920881|Continuous glucose monitoring
1259645|NCT00920881|Accuracy
1259646|NCT00920881|Continuous glucose-error grid analysis
1259647|NCT00920868|Phase I
1259648|NCT00920868|Solid Tumor
1259649|NCT00920868|Colorectal
1259650|NCT00920868|Dasatinib
1259651|NCT00920868|Sprycel
1259652|NCT00920868|Bevacizumab
1259653|NCT00920868|Avastin
1259654|NCT00920868|Oxaliplatin
1259655|NCT00920868|Eloxatin
1259656|NCT00920868|Capecitabine
1259657|NCT00920868|Xeloda
1259658|NCT00920868|Duke
1259659|NCT00920868|Any Solid Tumor (Phase I)
1259660|NCT00920868|Metastatic Colorectal Cancer (Expanded Cohort)
1259661|NCT00920842|metabolic syndrome
1259662|NCT00920842|long-term effects secondary to cancer therapy in children
1259663|NCT00920842|cardiovascular complications
1259664|NCT00920842|cancer survivor
1259665|NCT00920842|childhood acute lymphoblastic leukemia in remission
1259666|NCT00920842|childhood acute myeloid leukemia in remission
1259667|NCT00920842|childhood chronic myelogenous leukemia
1259668|NCT00920842|juvenile myelomonocytic leukemia
1259669|NCT00920842|stage I chronic lymphocytic leukemia
1259670|NCT00920842|stage II chronic lymphocytic leukemia
1259671|NCT00920842|stage III chronic lymphocytic leukemia
1259672|NCT00920842|stage IV chronic lymphocytic leukemia
1259673|NCT00920829|Alcohol Dependence
1259674|NCT00920829|Alcoholism
1259675|NCT00920829|Naltrexone
1259676|NCT00920829|Substance Abuse
1259677|NCT00920829|Genetics
1259678|NCT00920816|Axitinib in First & Second Line Treatment of Patients With Metastatic Renal Cell Cancer
1259679|NCT00920777|CBT
1259680|NCT00920777|Fukuda criteria
1259681|NCT00920777|Mental functioning
1259682|NCT00920777|Physical functioning
1259683|NCT00920764|CKD Stages 3&4
1259684|NCT00920764|Endothelin antagonist
1259685|NCT00920764|Proteinuria
1259686|NCT00920751|water infusion
1259687|NCT00920751|air insufflation
1259688|NCT00920751|colonoscopy
1259689|NCT00920751|colorectal cancer screening
1259690|NCT00920738|metabolic syndrome
1259691|NCT00920738|cancer survivor
1259692|NCT00920738|childhood soft tissue sarcoma
1259693|NCT00920738|unspecified childhood solid tumor, protocol specific
1259694|NCT00920738|childhood acute lymphoblastic leukemia
1259813|NCT00920348|COPD
1259695|NCT00920738|childhood chronic myelogenous leukemia
1259696|NCT00920738|childhood Hodgkin lymphoma
1259697|NCT00920738|childhood non-Hodgkin lymphoma
1259698|NCT00920738|childhood acute myeloid leukemia/other myeloid malignancies
1259699|NCT00920738|chronic lymphocytic leukemia
1259700|NCT00920738|childhood brain stem glioma
1259701|NCT00920738|childhood cerebellar astrocytoma
1259702|NCT00920738|childhood cerebral astrocytoma/malignant glioma
1259703|NCT00920738|childhood choroid plexus tumor
1259704|NCT00920738|childhood craniopharyngioma
1259705|NCT00920738|childhood embryonal tumor
1259706|NCT00920738|childhood ependymoma
1259707|NCT00920738|childhood oligodendroglioma
1259708|NCT00920738|childhood pineal parenchymal tumor
1259709|NCT00920738|childhood mixed glioma
1259710|NCT00920738|childhood subependymal giant cell astrocytoma
1259711|NCT00920738|childhood visual pathway and hypothalamic glioma
1259712|NCT00920725|DKA
1259713|NCT00920712|chronic atrophic gastritis
1259714|NCT00920712|Traditional Chinese Medicine
1259715|NCT00920686|Migraine
1259716|NCT00920686|aura
1259717|NCT00920673|child
1259718|NCT00920647|hunters syndrome
1259719|NCT00920647|hunter's syndrome
1259720|NCT00920647|hunter disease
1259721|NCT00920647|hunters disease
1259722|NCT00920647|hunter's disease
1259723|NCT00920647|Mucopolysaccharidosis(MPS) II
1259724|NCT00920647|Mucopolysaccharidosis(MPS)2
1259725|NCT00920647|Mucopolysaccharidosis (MPS) 2
1259726|NCT00920647|Mucopolysaccharidosis (mps) ii
1259727|NCT00920647|mucopolysaccharides
1259728|NCT00920647|lysosomal storage disease
1259729|NCT00920647|lysosomal storage disorder
1259730|NCT00920647|chronic ear infection
1259731|NCT00920647|enlarged adenoids
1259732|NCT00920647|mps symptoms
1259733|NCT00920647|mps diagnosis
1259734|NCT00920647|ert treatment
1259735|NCT00920647|elaprase
1259736|NCT00920647|idursulfase
1259737|NCT00920647|iduronate sulfatase
1259738|NCT00920647|iduronate 2 sulfatase
1259739|NCT00920647|enzyme replacement therapy
1259740|NCT00920647|hunter syndrome treatment
1259741|NCT00920647|hunter's syndrome treatment
1259742|NCT00920647|hunter syndrome therapy
1259743|NCT00920647|hunter's disease treatment
1259744|NCT00920647|mps society
1259745|NCT00920621|Asthma
1259746|NCT00920621|Vitamin D
1259747|NCT00920621|Randomized Control Trial
1259748|NCT00920608|AZD9056
1259749|NCT00920608|Pharmacokinetics
1259750|NCT00920608|interaction
1259751|NCT00920608|Methotrexate
1259752|NCT00920608|Rheumatoid Arthritis
1259753|NCT00920595|Cancer
1259754|NCT00920582|Teplizumab
1259755|NCT00920582|Protege
1259756|NCT00920582|Protege Encore
1259757|NCT00920582|MGA031
1259758|NCT00920582|Monoclonal antibody
1259759|NCT00920582|Type 1 Diabetes Mellitus
1259760|NCT00920582|T1DM
1259761|NCT00920582|MacroGenics
1259762|NCT00920582|Recent Onset Diabetes
1259763|NCT00920582|hOKT3γ1 (Ala-Ala)
1259764|NCT00920582|Encore
1259765|NCT00920569|cardiac output
1259766|NCT00920569|recirculation
1259767|NCT00920569|oxygenator blood volume
1259768|NCT00920569|venoarterial extracorporeal membrane oxygenation
1259769|NCT00920569|venovenous extracorporeal membrane oxygenation
1259770|NCT00920530|Screening
1259771|NCT00920530|real time PCR
1259772|NCT00920530|Streptococcus agalactiae
1259773|NCT00920530|Pregnant women
1259774|NCT00920504|Mesh: patient education as topic
1259775|NCT00920504|Mesh: neoplasms
1259776|NCT00920504|Mesh: medication therapy management
1259777|NCT00920504|pain self management
1259778|NCT00920504|symptom management
1259779|NCT00920504|education of patients with pain from neoplasm metastases
1259780|NCT00920491|Chief complaint
1259781|NCT00920491|non-specific symptoms
1259782|NCT00920491|general weakness / general deterioration
1259783|NCT00920491|risk assessment in ED patients with non-specific symptoms
1259784|NCT00920478|Rheumatoid arthritis
1259785|NCT00920478|Musculoskeletal Ultrasound
1259786|NCT00920478|Synovitis
1259787|NCT00920478|DMARD
1259788|NCT00920478|Etanercept
1259789|NCT00920478|Biomarkers
1259790|NCT00920478|Undifferentiated Inflammatory Polyarthritis
1259791|NCT00920452|implantable cardioverter defibrillator (ICD)
1259792|NCT00920452|defibrillation leads, cardiac resynchronization therapy (CRT)
1259793|NCT00920439|Poliomyelitis Vaccines
1259794|NCT00920439|IPV
1259795|NCT00920426|HIV
1259796|NCT00920426|naive
1259797|NCT00920426|Phase II
1259798|NCT00920426|integrase inhibitor
1259799|NCT00920426|GSK1265744
1259800|NCT00920426|newly diagnosed
1259801|NCT00920426|pharmacokinetics
1259802|NCT00920426|AIDS
1259803|NCT00920426|integrase
1259804|NCT00920426|HIV Infections
1259805|NCT00920426|Treatment naive
1259806|NCT00920387|Anxiety
1259807|NCT00920387|quality of life
1259808|NCT00920387|psychotherapy
1259809|NCT00920387|potentially fatal illness
1259810|NCT00920387|lysergic acid diethylamide
1259811|NCT00920374|Influenza
1259812|NCT00920348|Chronic obstructive pulmonary disease
1259814|NCT00920348|Cohort study
1259815|NCT00920348|prospective longitudinal study
1259816|NCT00920348|tissue bank
1259817|NCT00920335|Adult intracranial ependymoma
1259818|NCT00920322|Depression
1259819|NCT00920322|Transcranial Magnetic Stimulation
1259820|NCT00920309|Autosomal Dominant Polycystic Kidney Disease
1259821|NCT00920309|rapamycin
1259822|NCT00920309|ADPKD
1259823|NCT00920296|drug interaction
1259824|NCT00920296|integrase inhibitor
1259825|NCT00920283|Stents
1259826|NCT00920283|Bare Metal Stents
1259827|NCT00920283|PCI
1259828|NCT00920283|Coronary Artery Disease
1259829|NCT00920283|Coronary Artery Stenosis
1259830|NCT00920283|Stent Thrombosis
1259831|NCT00920283|Vascular Disease
1259832|NCT00920283|Myocardial Ischemia
1259833|NCT00920270|Hospital-Acquired Pneumonia
1259834|NCT00920270|Gram Negative Bacteria
1259835|NCT00920257|lymphoma
1259836|NCT00920257|breast cancer
1259837|NCT00920257|oncology
1259838|NCT00920257|solid tumors
1259839|NCT00920257|AKT inhibitor
1259840|NCT00920257|endometrial cancer
1259841|NCT00920257|first time in human
1259842|NCT00920257|GSK2141795
1259843|NCT00920244|Resuscitation
1259844|NCT00920244|Cardiac arrest
1259845|NCT00920244|State-transitions
1259846|NCT00920244|Markov
1259847|NCT00920218|Vaccine
1259848|NCT00920218|Immunogenicity
1259849|NCT00920218|Stem cell transplantation
1259850|NCT00920218|Safety
1259851|NCT00920218|Herpes Zoster
1259852|NCT00920205|MPC-3100
1259853|NCT00920205|HSP90 inhibitor
1259854|NCT00920205|oral drug
1259855|NCT00920205|cancer
1259856|NCT00920192|c-MET
1259857|NCT00920192|VEGFR2
1259858|NCT00920192|Advanced hepatocellular carcinoma
1259859|NCT00920179|dry eye, in vivo confocal microscopy, inflammation, acinar unit density, lacrimal gland
1259860|NCT00920166|Infant formula
1259861|NCT00920166|Alpha-lactalbumin
1259862|NCT00920166|Symbiotic
1259863|NCT00920166|Allergy
1259864|NCT00920166|Gastrointestinal tolerance
1259865|NCT00920166|Bacterial colonization
1259866|NCT00920166|Faecal IgA analysis
1259867|NCT00920153|stage I adult Hodgkin lymphoma
1259868|NCT00920153|stage II adult Hodgkin lymphoma
1259869|NCT00920153|stage III adult Hodgkin lymphoma
1259870|NCT00920153|stage IV adult Hodgkin lymphoma
1259871|NCT00920140|Oncology, GSK1120212, MEK inhibitor, hematological malignancies, AML
1259872|NCT00920140|CMML
1259873|NCT00920140|MDS
1259874|NCT00920127|AKL1
1259875|NCT00920127|COPD
1259876|NCT00920101|atherosclerotic plaques
1259877|NCT00920101|hypercholesterolemia
1259878|NCT00920101|HMG-CoA reductase inhibitor
1259879|NCT00920101|statin
1259880|NCT00920101|lipid-lowering therapy
1259881|NCT00920088|probes
1259882|NCT00920088|NNRTI
1259883|NCT00920088|drug interaction
1259884|NCT00920088|protease inhitibor
1259885|NCT00920075|Juvenile Osteoporosis
1259886|NCT00920075|Bone Mineral Density
1259887|NCT00920075|Fosamax
1259888|NCT00920075|Dual Energy X-Ray Absorptiometry
1259889|NCT00920075|Fracture
1259890|NCT00920062|recirculation
1259891|NCT00920062|ultrasound dilution
1259892|NCT00920062|venovenous extracorporeal membrane oxygenation
1259893|NCT00920049|Driving
1259894|NCT00920049|Injury
1259895|NCT00920049|Prevention
1259896|NCT00920049|Intervention
1259897|NCT00920049|Parents
1259898|NCT00920036|PTSD
1259899|NCT00920036|Combat
1259900|NCT00920036|Biofeedback
1259901|NCT00920036|Psychophysiology
1259902|NCT00920023|SPIO MRI
1259903|NCT00920023|Feridex
1259904|NCT00920010|non-small cell lung cancer
1259905|NCT00920010|small cell lung cancer
1259906|NCT00919997|human papilloma virus infection
1259907|NCT00919997|HIV infection
1259908|NCT00919997|HIV Infections
1259909|NCT00919984|OVARIAN NEOPLASMS
1259910|NCT00919984|ADJUVANT CHEMOTHERAPY
1259911|NCT00919984|INTRAPERITONEAL CHEMOTHERAPY
1259912|NCT00919971|Bi spectral Index
1259913|NCT00919971|Sedation depth monitoring
1259914|NCT00919971|Out of hospital ventilated patients
1259915|NCT00919958|Peripheral Artery Disease
1259916|NCT00919958|Peripheral Vascular Disease
1259917|NCT00919958|Critical limb ischemia
1259918|NCT00919945|Neonates
1259919|NCT00919945|Congenital Heart Disease
1259920|NCT00919945|Postoperative Feeding
1259921|NCT00919945|Splanchnic Blood Flow
1259922|NCT00919932|Depression
1259923|NCT00919932|CBT
1259924|NCT00919932|Texting
1259925|NCT00919932|SMS
1259926|NCT00919919|menopause
1259927|NCT00919919|Endometrial Thickness
1259928|NCT00919919|progesterone
1259929|NCT00919906|haptic
1259930|NCT00919906|rehabilitation
1259931|NCT00919906|fine-motor skill
1259932|NCT00919906|handwriting
1259933|NCT00919893|chronic prostatitis symptom index
1259934|NCT00919893|male
1259935|NCT00919893|inflammatory
1259936|NCT00919893|CP-CPPS
1259937|NCT00919893|Cernilton
1259938|NCT00919893|pelvic pain
1259939|NCT00919893|symptoms
1259940|NCT00919867|Normal, healthy volunteers (for this Phase 1 study)
1259941|NCT00919854|Human immunodeficiency virus 1
1259942|NCT00919854|HIV-1
1259943|NCT00919854|Darunavir
1259944|NCT00919854|Ritonavir
1259945|NCT00919854|Norvir
1259946|NCT00919841|postpartum
1259947|NCT00919841|involution
1259948|NCT00919841|three-dimension sonography
1259949|NCT00919841|size of the uterus
1259950|NCT00919815|Leprosy
1259951|NCT00919815|Type 1 Reactions
1259952|NCT00919815|Prednisolone
1259953|NCT00919815|Ciclosporin
1259954|NCT00919802|Interstitial cystitis (IC)
1259955|NCT00919802|Oxytocin
1259956|NCT00919802|Bladder
1259957|NCT00919802|Void
1259958|NCT00919776|Leprosy
1259959|NCT00919776|ENL
1259960|NCT00919776|Erythema Nodosum Leprosum
1259961|NCT00919776|Prednisolone
1259962|NCT00919776|Ciclosporin
1259963|NCT00919763|Atopic Dermatitis
1259964|NCT00919737|NPC-08
1259965|NCT00919737|carmustine
1259966|NCT00919737|nitrosourea
1259967|NCT00919737|safety
1259968|NCT00919724|AIDS
1259969|NCT00919724|Endothelial Function
1259970|NCT00919724|Inflammation
1259971|NCT00919724|Immune Activation
1259972|NCT00919724|treatment naive
1259973|NCT00919711|Menopausal Osteoporosis
1259974|NCT00919698|Hypnotics and Sedatives
1259975|NCT00919698|Respiration, Artificial
1259976|NCT00919698|Ventilators, Mechanical
1259977|NCT00919698|Critical care
1259978|NCT00919698|Intensive care
1259979|NCT00919672|Irritable bowel syndrome
1259980|NCT00919672|Sacral nerve stimulation
1259981|NCT00919672|Motility
1259982|NCT00919672|Pain perception
1259983|NCT00919672|GSRS-IBS
1259984|NCT00919672|IBS-IS
1259985|NCT00919659|parenteral nutrition
1259986|NCT00919659|cancer cachexia
1259987|NCT00919659|pancreatic cancer
1259988|NCT00918658|childhood chronic myelogenous leukemia
1259989|NCT00918658|chronic myelogenous leukemia
1259990|NCT00918658|adult acute lymphoblastic leukemia
1259991|NCT00918658|childhood acute lymphoblastic leukemia
1259992|NCT00918658|adult acute myeloid leukemia
1259993|NCT00918658|childhood acute myeloid leukemia/other myeloid malignancies
1259994|NCT00918658|multiple myeloma
1259995|NCT00918645|stage IV prostate cancer
1259996|NCT00918645|recurrent prostate cancer
1259997|NCT00918645|bone metastases
1259998|NCT00918632|food-effect pharmacokinetics AG-013736 food fasting
1259999|NCT00918619|randomized,
1260000|NCT00918619|controlled,
1260001|NCT00918619|haemostatic agents,
1260002|NCT00918619|Sangustop,
1260003|NCT00918619|Tachosil,
1260004|NCT00918619|liver resection,
1260005|NCT00918619|haemostasis
1260006|NCT00916669|SCLC
1260007|NCT00916669|enoxaparin sodium
1260008|NCT00916669|cisplatin
1260009|NCT00916669|etoposide
1260010|NCT00916656|Congenital fibrinogen deficiency
1260011|NCT00916643|Hypercholesterolemia
1260012|NCT00916643|FH
1260013|NCT00916643|LDL-C
1260014|NCT00916643|CHD
1260015|NCT00916630|recurrent
1260016|NCT00916630|alimta
1260017|NCT00916630|pemetrexed
1260018|NCT00916630|CNS lymphoma
1260019|NCT00916630|Primary CNS lymphoma
1260020|NCT00916630|Metastatic lymphoma to brain
1260021|NCT00916617|open-label
1260022|NCT00916617|safety
1260023|NCT00916617|antibody
1260024|NCT00916604|AZD1656
1260025|NCT00916604|Safety
1260026|NCT00916604|Pharmacokinetics
1260027|NCT00916604|Pharmacodynamic
1260028|NCT00916604|Multiple ascending doses
1260029|NCT00916604|Japanese
1260030|NCT00916604|T2DM
1260031|NCT00916591|gastroesophageal reflux
1260032|NCT00916591|respiratory aspiration
1260033|NCT00916578|Advanced Inflammatory Breast Cancer
1260034|NCT00916578|Non-Inflammatory Breast Cancer
1260035|NCT00916578|Capecitabine
1260036|NCT00916578|Xeloda
1260037|NCT00916578|Concomitant Radiation
1260038|NCT00916578|Radiation Therapy
1260039|NCT00916578|Radiotherapy
1260040|NCT00916578|Women
1260041|NCT00916565|optimize nutritional content of infant formula
1260042|NCT00916565|Infant
1260043|NCT00916552|Erythropoietin
1260044|NCT00916552|Epo
1260045|NCT00916552|depression
1260046|NCT00916552|bipolar disorder
1260047|NCT00916552|cognition
1260048|NCT00916552|cognitive function
1260049|NCT00916552|antidepressant
1260050|NCT00916526|Chronic cough
1260051|NCT00916526|Inhaled corticosteroid treatment
1260052|NCT00916526|Bronchial provocation test with mannitol
1260053|NCT00916526|Methacholine
1260054|NCT00916513|Diabetes
1260055|NCT00916513|Treatment Satisfaction
1260056|NCT00916513|Quality of Life
1260057|NCT00916513|HbA1c levels and goals
1260058|NCT00916513|Healthcare resources consumption
1260059|NCT00916500|CERVICAL CANCER, CONCURRENT CHEMORADIATION, CISPLATIN
1260060|NCT00919633|hepatitis C
1260061|NCT00919633|HCV
1260062|NCT00919633|genotype
1260063|NCT00919633|sustained virological response
1260064|NCT00919633|rapid virological response
1260065|NCT00919633|interferon
1260066|NCT00919620|Psychotic disorders
1260067|NCT00919620|Psychoses
1260068|NCT00919607|quetiapine fumarate(SEROQUEL) extended-release(XR) China PK Study
1260069|NCT00919607|pharmacokinetics parameters
1260070|NCT00919594|Interpersonal Psychotherapy
1260071|NCT00919594|Depression
1260072|NCT00919594|Mothers
1260073|NCT00919581|Spinal cord injury
1260074|NCT00919555|ALS Treatment
1260075|NCT00919555|Tretinoin
1260076|NCT00919555|Pioglitazone HCL
1260077|NCT00919555|Actos
1260078|NCT00919555|Tau levels
1260079|NCT00919555|ALS
1260080|NCT00919542|Leprosy
1260081|NCT00919542|ENL
1260082|NCT00919542|Erythema Nodosum Leprosum
1260083|NCT00919542|Prednisolone
1260084|NCT00919542|Ciclosporin
1260085|NCT00919516|Bone marrow transplantation
1260086|NCT00919516|Ischemia
1260087|NCT00919516|Neoangiogenesis
1260088|NCT00919516|Peripheral arterial disease
1260089|NCT00919516|Stem cell therapy
1260090|NCT00919503|nonmalignant diseases
1260091|NCT00919503|nonmalignant inherited disorders
1260092|NCT00919503|primary immunodeficiency diseases
1260093|NCT00919503|primary immune deficiency disorders
1260094|NCT00919503|chronic granulomatous
1260095|NCT00919503|disease
1260096|NCT00919503|IPEX syndrome
1260097|NCT00919503|hemophagocytic lymphohistiocytosis
1260098|NCT00919503|Wiskott Aldrich Syndrome
1260099|NCT00919503|bone marrow failure syndromes
1260100|NCT00919503|Shwachman Diamond Syndrome
1260101|NCT00919503|Dyskeratosis Congenita
1260102|NCT00919503|Diamond Blackfan Anemia
1260103|NCT00919503|inborn errors of metabolism
1260104|NCT00919503|metabolic diseases
1260105|NCT00919503|hemoglobinopathies
1260106|NCT00919503|sickle cell disease
1260107|NCT00919503|thalassemia
1260108|NCT00919503|reduced intensity transplantation
1260109|NCT00919503|hematopoietic cell transplantation
1260110|NCT00919503|bone marrow transplantation
1260111|NCT00919503|umbilical cord blood transplantation
1260112|NCT00919490|Healthy Volunteers
1260113|NCT00919477|Prostate cancer
1260114|NCT00919477|Casodex
1260115|NCT00919477|Monotherapy
1260116|NCT00919464|Compartment pressure
1260117|NCT00919464|compartment syndrome
1260118|NCT00919464|femur fracture
1260119|NCT00919451|Leprosy
1260120|NCT00919451|Type 1 Reaction
1260121|NCT00919451|Prednisolone
1260122|NCT00919451|Ciclosporin
1260123|NCT00919425|stage 0 chronic lymphocytic leukemia
1260124|NCT00919425|stage I chronic lymphocytic leukemia
1260125|NCT00919425|stage II chronic lymphocytic leukemia
1260126|NCT00919425|stage III chronic lymphocytic leukemia
1260127|NCT00919425|stage IV chronic lymphocytic leukemia
1260128|NCT00919425|recurrent adult acute myeloid leukemia
1260129|NCT00919425|recurrent adult acute lymphoblastic leukemia
1260130|NCT00919425|relapsing chronic myelogenous leukemia
1260131|NCT00919425|refractory chronic lymphocytic leukemia
1260132|NCT00919425|chronic phase chronic myelogenous leukemia
1260133|NCT00919425|accelerated phase chronic myelogenous leukemia
1260134|NCT00919425|blastic phase chronic myelogenous leukemia
1260135|NCT00919425|meningeal chronic myelogenous leukemia
1260136|NCT00919425|untreated adult acute lymphoblastic leukemia
1260137|NCT00919425|untreated adult acute myeloid leukemia
1260138|NCT00919425|adult acute myeloid leukemia with t(8;21)(q22;q22)
1260139|NCT00919425|adult acute myeloid leukemia with t(16;16)(p13;q22)
1260140|NCT00919425|adult acute myeloid leukemia with inv(16)(p13;q22)
1260141|NCT00919425|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1260142|NCT00919425|adult acute myeloid leukemia with t(15;17)(q22;q12)
1260143|NCT00919425|adult acute lymphoblastic leukemia in remission
1260144|NCT00919425|childhood acute lymphoblastic leukemia in remission
1260145|NCT00919425|adult acute myeloid leukemia in remission
1260146|NCT00919425|childhood acute myeloid leukemia in remission
1260147|NCT00919425|recurrent childhood acute myeloid leukemia
1260148|NCT00919425|untreated childhood acute myeloid leukemia and other myeloid malignancies
1260149|NCT00919425|recurrent childhood acute lymphoblastic leukemia
1260150|NCT00919425|untreated childhood acute lymphoblastic leukemia
1260151|NCT00919425|childhood chronic myelogenous leukemia
1260152|NCT00919425|de novo myelodysplastic syndromes
1260153|NCT00919425|previously treated myelodysplastic syndromes
1260154|NCT00919425|secondary myelodysplastic syndromes
1260155|NCT00919425|secondary acute myeloid leukemia
1260156|NCT00919425|atypical chronic myeloid leukemia, BCR-ABL1 negative
1260157|NCT00919425|chronic myelomonocytic leukemia
1260158|NCT00919425|juvenile myelomonocytic leukemia
1260159|NCT00919425|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1260160|NCT00919425|childhood myelodysplastic syndromes
1260161|NCT00919412|Non Invasive Biomarkers Preterm Delivery
1260162|NCT00919399|breast cancer
1260163|NCT00919399|locally advanced
1260164|NCT00919399|Menopausal patient
1260165|NCT00919399|aromasin
1260166|NCT00919399|tamoxifen
1260167|NCT00919399|efficacy
1260168|NCT00919386|Ureteric Measurement
1260169|NCT00919373|Catheter Ablation
1260170|NCT00919373|Defibrillators, Implantable
1260171|NCT00919347|Cardiovascular Autonomic Neuropathy
1260172|NCT00919347|Diabetic Autonomic Neuropathy
1260173|NCT00919347|Autonomic Dysfunction
1260174|NCT00919334|Myopia progression
1260175|NCT00919334|Myopia control
1260176|NCT00919334|Simultaneous vision
1260177|NCT00919334|Myopic defocus
1260178|NCT00919321|CLL
1260179|NCT00919321|PPV
1260180|NCT00919321|PCV
1260181|NCT00919308|Simulation
1260182|NCT00919308|Invasive procedures
1260183|NCT00919295|Fibromyalgia syndrome
1260184|NCT00919295|mirtazapine
1260185|NCT00919295|randomized controlled trial
1260186|NCT00919295|pilot study
1260187|NCT00919282|pancreatic cancer
1260188|NCT00919282|gemcitabine
1260189|NCT00919282|combination
1260190|NCT00919243|prednisone
1260191|NCT00919243|allopurinol
1260192|NCT00919243|heart failure
1260193|NCT00919243|hyperuricemia
1260194|NCT00919230|Hip fracture
1260195|NCT00919230|iron therapy
1260196|NCT00919230|anaemia
1260197|NCT00919217|Multiple Sclerosis
1260198|NCT00919217|MS
1260199|NCT00919217|Relapsing-remitting multiple sclerosis
1260200|NCT00919217|RR-MS
1260201|NCT00919217|Women
1260202|NCT00919204|AG-013736, axitinib, pharmacokinetics, healthy, Chinese
1260203|NCT00919191|acne
1260204|NCT00919191|irritation
1260205|NCT00919191|objective sensory methods
1260206|NCT00919178|Dengue virus
1260207|NCT00919178|Vaccine
1260208|NCT00919178|DEN4
1260209|NCT00919178|Dengue
1260210|NCT00919165|carotid stenting
1260211|NCT00919165|cognitive function
1260212|NCT00919165|pre and post stent
1260213|NCT00919165|severe carotid artery stenosis
1260214|NCT00919152|stress ulcer prophylaxis
1260215|NCT00919152|intensive care
1260216|NCT00919152|Critically ill
1260217|NCT00919152|proton pump inhibitors
1260218|NCT00919152|pharmacoeconomics
1260219|NCT00919139|multiple myeloma
1260220|NCT00919139|Waldenström macroglobulinemia
1260221|NCT00919139|monoclonal gammopathy of undetermined significance
1260222|NCT00919139|primary systemic amyloidosis
1260223|NCT00919126|Xenon in Anaesthesia
1260224|NCT00919113|Bladder Pain
1260225|NCT00919113|GAG replacement therapy
1260226|NCT00919113|IC/PBS
1260227|NCT00919100|pediatric
1260228|NCT00919100|venipuncture
1260229|NCT00919100|pain
1260230|NCT00919100|vibration
1260231|NCT00919100|vapocoolant
1260232|NCT00919074|Patients undergoing endoscopic retrograde cholangiopancreatography for the first time
1260233|NCT00919074|Particular focus on patients who meet predefined criteria for a difficult bile duct cannulation
1260234|NCT00919061|GALL BLADDER
1260235|NCT00919061|BILE DUCTS
1260236|NCT00919061|BAY 43-9006
1260237|NCT00919061|SORAFENIB
1260238|NCT00919061|CISPLATIN
1260239|NCT00919061|GEMCITABINE
1260240|NCT00919061|09-029
1260241|NCT00919035|prostate cancer
1260242|NCT00919035|androgen-independent prostate cancer (AIPC) Prostate Cancer
1260243|NCT00919022|Inoperable Prostate Cancer
1260244|NCT00919022|Erectile Dysfunction
1260245|NCT00919009|TACE
1260246|NCT00919009|Sorafenib
1260247|NCT00918996|Cesarean Section
1260248|NCT00918996|Bladder Flap
1260249|NCT00918996|Operating time
1260250|NCT00918983|Benign prostatic hyperplasia
1260251|NCT00918983|BPH
1260252|NCT00918983|Enlarged prostate
1260253|NCT00918970|autonomous nervous system
1260254|NCT00918970|brain death
1260255|NCT00918970|organs transplantation
1260256|NCT00918957|Tobramycin Inhalation Powder
1260257|NCT00918957|Cystic fibrosis
1260258|NCT00918957|Lung diseases
1260259|NCT00918957|Anti-Bacterial Agents
1260260|NCT00918957|Treatment of infections with P. aeruginosa in cystic fibrosis subjects
1260261|NCT00918944|clinical decision support tool
1260262|NCT00918944|electronic health record
1260263|NCT00918944|control tool
1260264|NCT00918944|spirometry
1260265|NCT00918944|quality of life survey
1260266|NCT00918944|provider survey
1260267|NCT00918931|Leukemia
1260268|NCT00918931|Systemic Mastocytosis
1260269|NCT00918931|SM
1260270|NCT00918931|Obatoclax mesylate
1260271|NCT00918931|GX15-070MS
1260272|NCT00918918|Alcohol Consumption
1260273|NCT00918918|High Density Lipoprotein (HDL)
1260274|NCT00918918|lipopolysaccharides (LPS)
1260275|NCT00918918|Apolipoproteins
1260276|NCT00918918|Inflammation
1260277|NCT00918905|pervasive healthcare
1260278|NCT00918905|telecare
1260279|NCT00918905|telemedicine
1260280|NCT00918905|COPD
1260281|NCT00918892|breast cancer
1260282|NCT00918892|estrogen receptor-negative breast cancer
1260283|NCT00918892|estrogen receptor-positive breast cancer
1260284|NCT00918892|progesterone receptor-negative breast cancer
1260285|NCT00918892|progesterone receptor-positive breast cancer
1260286|NCT00918892|triple-negative breast cancer
1260287|NCT00918892|HER2-negative breast cancer
1260288|NCT00918892|HER2-positive breast cancer
1260289|NCT00918879|DPP-4 inhibitors
1260290|NCT00918879|HbA1c
1260291|NCT00918879|Incretins
1260292|NCT00918866|Phase 4
1260293|NCT00918866|DEFINITY®
1260294|NCT00918866|hemodynamics
1260295|NCT00918866|pulmonary artery pressure
1260296|NCT00918853|pancreas
1260297|NCT00918853|adenocarcinoma
1260298|NCT00918840|HIV
1260299|NCT00918840|Vaccine
1260300|NCT00918840|Immune Therapy
1260301|NCT00918840|DermaVir
1260302|NCT00918840|Treatment experienced
1260303|NCT00918827|adenocarcinoma of the colon
1260304|NCT00918827|stage III colon cancer
1260305|NCT00918801|T1DM
1260306|NCT00918801|MRI
1260307|NCT00918788|breast cancer
1260308|NCT00918775|Renal Cell Carcinoma
1260309|NCT00918775|RCC
1260310|NCT00918775|Kidney
1260311|NCT00918775|Metastasectomy
1260312|NCT00918775|Surgery
1260313|NCT00918775|Tumor Removal
1260314|NCT00918762|perioperative/postoperative complications
1260315|NCT00918762|precancerous condition
1260316|NCT00918762|stage I squamous cell carcinoma of the hypopharynx
1260317|NCT00918762|stage II squamous cell carcinoma of the hypopharynx
1260318|NCT00918762|stage III squamous cell carcinoma of the hypopharynx
1260319|NCT00918762|stage I squamous cell carcinoma of the larynx
1260320|NCT00918762|stage I verrucous carcinoma of the larynx
1260321|NCT00918762|stage II squamous cell carcinoma of the larynx
1260322|NCT00918762|stage II verrucous carcinoma of the larynx
1260323|NCT00918762|stage III squamous cell carcinoma of the larynx
1260324|NCT00918762|stage III verrucous carcinoma of the larynx
1260325|NCT00918762|stage I lymphoepithelioma of the nasopharynx
1260326|NCT00918762|stage I squamous cell carcinoma of the nasopharynx
1260327|NCT00918762|stage II lymphoepithelioma of the nasopharynx
1260328|NCT00918762|stage II squamous cell carcinoma of the nasopharynx
1260329|NCT00918762|stage III lymphoepithelioma of the nasopharynx
1260330|NCT00918762|stage III squamous cell carcinoma of the nasopharynx
1260331|NCT00918762|stage I lymphoepithelioma of the oropharynx
1260332|NCT00918762|stage I squamous cell carcinoma of the oropharynx
1260333|NCT00918762|stage II lymphoepithelioma of the oropharynx
1260334|NCT00918762|stage II squamous cell carcinoma of the oropharynx
1260335|NCT00918762|stage III lymphoepithelioma of the oropharynx
1260336|NCT00918762|stage III squamous cell carcinoma of the oropharynx
1260337|NCT00918736|Ankle joint
1260338|NCT00918736|Balance
1260339|NCT00918736|Hyaluronic acid
1260340|NCT00918736|Osteoarthritis
1260341|NCT00918710|Squamous cell carcinoma of Oropharynx
1260342|NCT00918710|Human papillomavirus.
1260343|NCT00918710|Biological prognostic markers.
1260344|NCT00918697|photorefractive keratectomy
1260345|NCT00918697|PRK
1260346|NCT00918697|alcohol-assisted debridement
1260347|NCT00918697|mechanical debridement
1260348|NCT00918697|confocal scan
1260349|NCT00918697|confocal microscopy
1260350|NCT00918684|Depression
1260351|NCT00918671|Headache
1260352|NCT00918671|Medication overuse
1260353|NCT00918671|chronic
1260354|NCT00918671|relapse
1260355|NCT00918593|Metastases
1260356|NCT00918593|Cutaneous
1260357|NCT00918593|Ulcerating
1260358|NCT00918593|Palliative
1260359|NCT00918593|ulcerating metastases
1260360|NCT00918567|ADHD
1260361|NCT00918567|impact of atomoxetine with and and without behavior therapy at school and home
1260362|NCT00918554|Sarcoid-associated uveitis
1260363|NCT00918554|Macular oedema
1260364|NCT00918554|Methotrexate
1260365|NCT00918554|Conventional corticosteroids sparing agent.
1260366|NCT00918541|atherosclerotic disease
1260367|NCT00918541|progression
1260368|NCT00918541|natural progression of atherosclerotic disease
1260369|NCT00918541|natural history of atherosclerosis at the level of the carotid artery as evaluated by MRI
1260370|NCT00918528|Urethral stricture
1260371|NCT00918528|Mitomycin C
1260372|NCT00918528|Internal Urethrotomy
1260373|NCT00918515|Sedation
1260374|NCT00918515|Anaesthesia
1260375|NCT00918515|Safety
1260376|NCT00918515|tolerability
1260377|NCT00918515|pharmacokinetics
1260378|NCT00918515|pharmacodynamics
1260379|NCT00918515|healthy male volunteers
1260380|NCT00918489|soft tissue sarcoma
1260381|NCT00918489|metastatic
1260382|NCT00918489|vorinostat
1260383|NCT00918463|lymphoma
1260384|NCT00918463|diffuse
1260385|NCT00918463|refractory
1260386|NCT00918437|uvulopalatoplasty
1260387|NCT00918437|postoperative pain
1260388|NCT00918437|quality of life
1260389|NCT00918411|diarrhea
1260390|NCT00918411|IBS
1260391|NCT00918411|Colonic diseases
1260392|NCT00918411|YM060
1260393|NCT00918385|hormone resistant prostate cancer
1260394|NCT00918385|castration resistant prostate cancer
1260395|NCT00918385|hormone refractory prostate cancer
1260396|NCT00918385|metastatic prostate cancer
1260397|NCT00918385|hormonal therapy
1260398|NCT00918385|antiandrogen therapy
1260399|NCT00918385|androgen receptor
1260400|NCT00918385|nilutamide
1260401|NCT00918385|dasatinib
1260402|NCT00918385|genomics
1260403|NCT00918385|genomic signature
1260404|NCT00918385|genomic predictor
1260405|NCT00918385|genomic analysis
1260406|NCT00918385|genomic expression profile
1260407|NCT00918372|MSCTA
1260408|NCT00918372|Marathon runners
1260409|NCT00918346|Ocular hypertension
1260410|NCT00918320|Temozolomide
1260411|NCT00918320|Topotecan
1260412|NCT00918320|paediatric solid tumours
1260413|NCT00918320|Miscellaneous other solid tumours
1260414|NCT00918307|Tobacco Dependence
1260415|NCT00918307|HIV infection
1260416|NCT00918307|varenicline
1260417|NCT00918294|CRT
1260418|NCT00918294|heart failure
1260419|NCT00918294|optimization
1260420|NCT00918294|Timing cycle optimization methods
1260421|NCT00918268|Influenza vaccine
1260422|NCT00918255|Hidradenitis Suppurativa
1260423|NCT00918255|Adalimumab
1260424|NCT00918255|Nodule
1260425|NCT00918255|Abscess
1260426|NCT00918255|Fistula
1260427|NCT00918255|Physicians Global Assessment
1260428|NCT00918255|Hurley Stage
1260429|NCT00918255|Sartorius Scale
1260430|NCT00918242|Coronary Heart Disease
1260431|NCT00918242|computed tomography
1260432|NCT00918242|prevalence of coronary artery disease
1260433|NCT00918229|Prostate
1260434|NCT00918229|cancer
1260435|NCT00918229|radiation
1260436|NCT00918229|biodegradable implantable balloon
1260437|NCT00918229|intrarectal balloon
1260438|NCT00918216|breast cancer
1260439|NCT00918203|Lung neoplasms
1260440|NCT00918203|IMC-3G3
1260441|NCT00918203|carboplatin
1260442|NCT00918203|paclitaxel
1260443|NCT00918203|PDGFr
1260444|NCT00918190|Postoperative nausea and vomiting
1260445|NCT00918190|Pediatric
1260446|NCT00918190|Strabismus
1260447|NCT00918190|Late onset postoperative nausea and vomiting
1260448|NCT00918112|Parkinson's Disease
1260449|NCT00918099|Mesh
1260450|NCT00918099|vaginal prolapse
1260451|NCT00918099|Recurrence rate
1260452|NCT00918086|Vitamin D
1260453|NCT00918086|Tuberculosis
1260454|NCT00918073|HIV infected smokers
1260455|NCT00918073|HIV
1260456|NCT00918034|BPH
1260457|NCT00918034|LUTS
1260458|NCT00918034|talaporfin sodium
1260459|NCT00918008|URINARY BLADDER
1260460|NCT00918008|Bladder
1260461|NCT00918008|Blood sample
1260462|NCT00918008|Lymph Nodes
1260463|NCT00917995|parastomal hernia
1260464|NCT00917995|prophylactic mesh
1260465|NCT00917995|colostomy
1260466|NCT00917995|hernia
1260467|NCT00917956|Lithium
1260468|NCT00917956|IBM
1260469|NCT00917956|InclusionIBM
1260470|NCT00917956|Myositis
1260471|NCT00917943|smoking
1260472|NCT00917943|pregnancy
1260473|NCT00917943|counseling
1260474|NCT00917943|prevention
1260475|NCT00917943|tailored intervention
1260476|NCT00917943|postpartum
1260477|NCT00917943|women
1260478|NCT00917943|cessation
1260479|NCT00917930|exercise training
1260480|NCT00917930|functional recovery
1260481|NCT00917930|heart diseases
1260482|NCT00917930|altered glucose metabolism early after an acute cardiac event
1260483|NCT00917930|non diabetes CAD patients
1260484|NCT00917930|glycometabolic state
1260485|NCT00917917|Metabolic syndrome
1260486|NCT00917917|exercise training
1260487|NCT00917917|abdominal fat mass
1260488|NCT00917917|endothelial function
1260489|NCT00917917|diastolic function
1260490|NCT00917904|HIV Infections
1260491|NCT00917904|Acquired Immunodeficiency Syndrome
1260492|NCT00917904|Healthy
1260493|NCT00917904|HIV seronegativity
1260494|NCT00917891|HIV Infections
1260495|NCT00917891|Acquired Immunodeficiency Syndrome
1260496|NCT00917891|Healthy
1260497|NCT00917891|HIV seronegativity
1260498|NCT00917878|Milk
1260499|NCT00917878|Postprandial hyperlipidemia
1260500|NCT00917878|Postprandial inflammation
1260501|NCT00917878|Overweight
1260502|NCT00917852|aorta
1260503|NCT00917852|trauma
1260504|NCT00917852|transection
1260505|NCT00917839|neuroprotection
1260506|NCT00917839|multiple sclerosis
1260507|NCT00917839|brain atrophy
1260508|NCT00917839|mr-spectroscopy
1260509|NCT00917813|HIV
1260510|NCT00917813|monoclonal antibody
1260511|NCT00917813|KD-247
1260512|NCT00917813|treatment naive
1260513|NCT00917800|angiography
1260514|NCT00917800|exercise testing
1260515|NCT00917800|high frequency ECG
1260516|NCT00917800|coronary artery disease
1260517|NCT00917787|Asthma
1260518|NCT00917774|gender specific knee
1260519|NCT00917774|osteoarthritis
1260520|NCT00917774|total knee arthroplasty
1260521|NCT00917761|Hepatitis B, chronic
1260522|NCT00917761|Peginterferon alfa-2a
1260523|NCT00917761|Entecavir
1260524|NCT00917735|Green tea
1260525|NCT00917735|Breast cancer
1260526|NCT00917735|Prevention
1260527|NCT00917735|COMT genotype
1260528|NCT00917735|EGCG (Epigallocatechin gallate)
1260529|NCT00917735|Mammographic density
1260530|NCT00917735|Reproductive hormones
1260531|NCT00917735|IGF axis proteins
1260532|NCT00917735|Oxidative stress
1260533|NCT00917722|Parkinson's Disease
1260534|NCT00917722|STN DBS
1260535|NCT00917722|Deep Brain Stimulation
1260536|NCT00917709|dementia with Lewy bodies
1260537|NCT00917709|imaging
1260538|NCT00917709|acetylcholine
1260539|NCT00917709|dopamine
1260540|NCT00917709|IBVM
1260541|NCT00917709|DATSCAN
1260542|NCT00917670|trabecular meshwork
1260543|NCT00917670|electron microscopy
1260544|NCT00916695|Stents
1260545|NCT00916695|Angioplasty
1260546|NCT00916695|Coronary Artery Disease
1260547|NCT00916695|Bifurcation Coronary Lesions
1260548|NCT00917657|photorefractive keratectomy
1260549|NCT00917657|hyperopia
1260550|NCT00917657|radial keratotomy
1260551|NCT00917657|refractive surgery
1260552|NCT00917644|Bioqeuivalence, Pharmacokinetics, Atorvastatin
1260553|NCT00917631|Co-bedding
1260554|NCT00917631|Procedural pain
1260555|NCT00917631|Twin
1260556|NCT00917631|Comfort
1260557|NCT00917631|RCT
1260558|NCT00917618|osteoarthritis
1260559|NCT00917618|knee
1260560|NCT00917618|exercise
1260561|NCT00917618|cycling
1260562|NCT00917592|Diverticulitis
1260563|NCT00917579|Bioequivalence, pharmacokinetics, atorvastatin
1260564|NCT00917566|Airtraq
1260565|NCT00917566|Pediatric
1260566|NCT00917553|diabetic retinopathy
1260567|NCT00917553|diabetes
1260568|NCT00917553|diabetic eye studies
1260569|NCT00917527|Subjects with family history of coronary heart disease
1260570|NCT00917514|Dosing Tool
1260571|NCT00917514|Compliance
1260572|NCT00917514|User Friendly
1260573|NCT00917514|Crohn's Disease
1260574|NCT00917514|Ulcerative Colitis
1260575|NCT00917501|Mania
1260576|NCT00917501|Adolescents at risk for Mania
1260577|NCT00917488|Allergen extract Standardization
1260578|NCT00917475|preterm infants
1260579|NCT00917462|ESOPHAGUS
1260580|NCT00917462|BAY 43-9006 (SORAFENIB)
1260581|NCT00917462|09-016
1260582|NCT00917462|Nexavar®.
1260583|NCT00917449|Metabolic Syndrome
1260584|NCT00917449|Impaired glucose tolerance
1260585|NCT00917449|Type 2 diabetes mellitus
1260586|NCT00917449|Endothelial dysfunction
1260587|NCT00917449|L-arginine
1260588|NCT00917449|Insulin resistance
1260589|NCT00917423|Anorexia Nervosa
1260590|NCT00917423|Exercise
1260591|NCT00917423|Physical Activity
1260592|NCT00917397|Traumatized refugee
1260593|NCT00917397|treatment
1260594|NCT00917397|antidepressants
1260595|NCT00917397|psychotherapy
1260596|NCT00917397|PTSD in traumatized refugees
1260597|NCT00917384|IMC-1121B
1260598|NCT00917384|Monoclonal antibody (MAb)
1260599|NCT00917384|Vascular endothelial growth factor (VEGF)
1260600|NCT00917384|Human vascular endothelial growth factor receptor-2 (VEGFR-2)
1260601|NCT00917384|Platinum resistant
1260602|NCT00917384|platinum refractory
1260603|NCT00917384|Gastric
1260604|NCT00917384|Gastroesophageal Junction Adenocarcinoma
1260605|NCT00917384|metastatic
1260606|NCT00917384|Angiogenesis
1260607|NCT00917371|adults with attention-deficit hyperactivity disorder
1260608|NCT00917371|atomoxetine
1260609|NCT00917371|neuropsychological functioning
1260610|NCT00917371|brain imaging studies
1260611|NCT00917358|Hepatitis C
1260612|NCT00917358|Dialysis
1260613|NCT00917358|Interferon
1260614|NCT00917345|ARC
1260615|NCT00917345|PRA
1260616|NCT00917345|primary aldosteronism
1260617|NCT00917345|captopril test
1260618|NCT00917345|aldosterone-renin ratio
1260619|NCT00917345|Primary aldosteronism (PA) than PRA and establish thresholds for the diagnosis using ARC.
1260620|NCT00917332|pain
1260621|NCT00917332|childbirth
1260622|NCT00917332|relaxation
1260623|NCT00917332|guided imagery
1260624|NCT00917332|VAS
1260625|NCT00917332|epidural
1260626|NCT00917306|Peplin
1260627|NCT00917306|Actinic keratosis
1260628|NCT00917306|PEP005
1260629|NCT00917293|Tardive Dyskinesia
1260630|NCT00917293|Schizophrenia
1260631|NCT00917293|Pyridoxal 5'-phosphate
1260632|NCT00917280|Parkinson's Disease
1260633|NCT00917267|diabetes
1260634|NCT00917267|exenatide
1260635|NCT00917267|once weekly
1260636|NCT00917267|Byetta
1260637|NCT00917267|Amylin
1260638|NCT00917267|Lilly
1260639|NCT00917254|YM150
1260640|NCT00917254|Thrombosis
1260641|NCT00917254|VTE
1260642|NCT00917254|Knee Replacement
1260643|NCT00917254|Anticoagulant
1260644|NCT00917254|FXa inhibitor
1260645|NCT00917241|Graves' disease
1260646|NCT00917241|dexamethasone
1260647|NCT00917241|relapse
1260648|NCT00917241|methimazole
1260649|NCT00917215|Asthma
1260650|NCT00917215|Acupuncture
1260651|NCT00917215|Pulmonary function
1260652|NCT00917215|Quality of life
1260653|NCT00917189|VCFS
1260654|NCT00917189|Chromosome 22q Deletion Syndrome
1260655|NCT00917189|Learning Disorders
1260656|NCT00917163|coronary artery disease
1260657|NCT00917163|restenosis
1260658|NCT00917163|stent thrombosis
1260659|NCT00917163|coronary stents
1260660|NCT00917163|angioplasty
1260661|NCT00917163|drug eluting stents
1260662|NCT00917150|chronic obstructive pulmonary disease
1260663|NCT00917150|COPD
1260664|NCT00917150|emphysema
1260665|NCT00917137|Lung cancer
1260666|NCT00917137|Lung nodule
1260667|NCT00917137|Transbronchial needle aspiration
1260668|NCT00917137|Transbronchial lung biopsy
1260669|NCT00917137|Bronchoscopy
1260670|NCT00917124|cerebral oximetry
1260671|NCT00917124|NIRS
1260672|NCT00917124|INVOS
1260673|NCT00917111|Randomized
1260674|NCT00917111|Double-Blind
1260675|NCT00917111|Multi-Center
1260676|NCT00917111|Placebo-Controlled
1260677|NCT00917111|Phase II
1260678|NCT00917111|Nasal Carbon Dioxide
1260679|NCT00917111|Carbon Dioxide
1260680|NCT00917111|Efficacy
1260681|NCT00917111|Safety
1260682|NCT00917111|Total Nasal Symptom Score
1260683|NCT00917098|Behavior Therapy
1260684|NCT00917098|Supportive Counseling
1260685|NCT00917098|Child
1260686|NCT00917098|Adolescent
1260687|NCT00917098|Hair Pulling
1260688|NCT00917098|CBT
1260689|NCT00917085|Preterm infant
1260690|NCT00917085|Skin-to-skin contact
1260691|NCT00917085|kangaroo care
1260692|NCT00917085|temperature
1260693|NCT00917085|behavioral state
1260694|NCT00917072|Clinical Handoff
1260695|NCT00917072|Medical Education
1260696|NCT00917072|Simulation
1260697|NCT00917072|Residency and Internship
1260698|NCT00917059|Major Depressive Disorder
1260699|NCT00917059|SSRI
1260700|NCT00917059|EEG
1260701|NCT00917046|All-cause heart failure patients
1260702|NCT00917046|coronary artery disease etiology
1260703|NCT00917046|dilated cardiomyopathy etiology
1260704|NCT00917020|Randomized
1260705|NCT00917020|Double-Blind
1260706|NCT00917020|Multi-Center
1260707|NCT00917020|Phase II
1260708|NCT00917020|Nasal Carbon Dioxide
1260709|NCT00917020|Carbon Dioxide
1260710|NCT00917020|Efficacy
1260711|NCT00917020|Safety
1260712|NCT00917020|Total Nasal Symptom Score
1260713|NCT00917007|ABO incompatibility
1260714|NCT00917007|hemolysis
1260715|NCT00917007|jaundice
1260716|NCT00917007|hyperbilirubinemia
1260717|NCT00917007|newborn
1260718|NCT00916994|Rotator Cuff Tear
1260719|NCT00916981|pseudarthrosis
1260720|NCT00916981|Treatment
1260721|NCT00916981|osteoblast grafting
1260722|NCT00916981|cell therapy
1260723|NCT00916981|nonunion
1260724|NCT00916968|Gender specific
1260725|NCT00916968|cruciate retaining
1260726|NCT00916968|total knee arthroplasty
1260727|NCT00916968|Bilateral Osteoarthritis of the knee joint
1260728|NCT00916955|22q11.2 deletion syndrome
1260729|NCT00916955|velo-cardio-facial syndrome
1260730|NCT00916955|congenital anomalies
1260731|NCT00916955|mental illness
1260732|NCT00916955|congenital heart disease
1260733|NCT00916942|Tolerability study
1260734|NCT00916916|Acromegaly
1260735|NCT00916916|Lanreotide
1260736|NCT00916903|Talus
1260737|NCT00916903|Neuroserpin
1260738|NCT00916903|mental retardation
1260739|NCT00916903|epilepsy
1260740|NCT00916903|FENIB
1260741|NCT00916903|XLMR
1260742|NCT00916890|Opioid pharmacogenetics
1260743|NCT00916890|Opioid pharmacokinetic
1260744|NCT00916890|Long-term opioid treatment
1260745|NCT00916890|Cancer pain
1260746|NCT00916877|Prophylactic Cranial Irradiation
1260747|NCT00916877|Her-2-positive met breast cancer
1260748|NCT00916851|attention-deficit hyperactivity disorder
1260749|NCT00916851|autism spectrum disorders
1260750|NCT00916851|normally developing children and adolescents
1260751|NCT00916851|cognitive functions
1260752|NCT00916851|emotion/behaviors
1260753|NCT00916851|brain imaging
1260754|NCT00916851|genotypes
1260755|NCT00916838|Type 1 Diabetes Mellitis
1260756|NCT00916838|MRI
1260757|NCT00916825|breast cancer
1260758|NCT00916825|quality of life
1260759|NCT00916825|children of somatically ill parents
1260760|NCT00916825|psychological adaptation
1260761|NCT00916812|Difficult intubation
1260762|NCT00916812|Hyomental distance
1260763|NCT00916812|Obstetric
1260764|NCT00916812|Mallampati classification
1260765|NCT00916812|Thyromental distance
1260766|NCT00916812|Sternomental distance
1260767|NCT00916799|telehealth
1260768|NCT00916799|oximetry
1260769|NCT00916799|copd
1260770|NCT00916786|Attention-deficit/hyperactivity disorder
1260771|NCT00916786|pharmacogenetics
1260772|NCT00916786|molecular genetics
1260773|NCT00916786|medication response
1260774|NCT00916773|Obstructive sleep apnea
1260775|NCT00916773|Airway inflammation
1260776|NCT00916773|Exercise-induced bronchoconstriction
1260777|NCT00916773|Continuous positive airway pressure
1260778|NCT00916760|allergic, rhinoconjunctivitis, Immunotherapy
1260779|NCT00916747|Progeria
1260780|NCT00916734|McKenzie
1260781|NCT00916734|thrust manipulation
1260782|NCT00916734|clinical prediction rule
1260783|NCT00916721|Smoking cessation
1260784|NCT00916721|propranolol
1260785|NCT00916721|memory reconsolidation blockade
1260786|NCT00916721|craving
1260787|NCT00916708|endometrial cancer
1260788|NCT00916708|follow up
1260789|NCT00916708|relapse
1260790|NCT00916461|First episode psychosis
1260791|NCT00916461|Schizophrenia
1260792|NCT00916461|Minocycline
1260793|NCT00916461|neuroprotection
1260794|NCT00916461|First episode non affective psychosis
1260795|NCT00916461|With in first five years of illness
1260796|NCT00916448|Endotoxin
1260797|NCT00916448|Bilirubin
1260798|NCT00916448|Inflammation
1260799|NCT00916448|Sepsis
1260800|NCT00916448|Multi organ dysfunction syndrome
1260801|NCT00916448|Oxidative Stress
1260802|NCT00916448|Heme oxygenase
1260803|NCT00916435|Arrhythmia
1260804|NCT00916435|Cardiac Arrest
1260805|NCT00916435|Cardiomyopathy
1260806|NCT00916435|Heart Failure
1260807|NCT00916422|Immunotherapy
1260808|NCT00916422|Allergoid
1260809|NCT00916422|Depigmented
1260810|NCT00916422|Polymerized
1260811|NCT00916422|Allergen-extract
1260812|NCT00916422|Rhinoconjunctivitis
1260813|NCT00916409|Glioblastoma Multiforme
1260814|NCT00916409|Glioblastoma
1260815|NCT00916409|GBM
1260816|NCT00916409|Brain tumor
1260817|NCT00916409|Treatment
1260818|NCT00916409|Minimal toxicity
1260819|NCT00916409|Newly Diagnosed
1260820|NCT00916409|TTFields
1260821|NCT00916409|Tumor Treating Fields
1260822|NCT00916409|NovoCure
1260823|NCT00916383|Skin Irritation
1260824|NCT00916383|Donepezil Transdermal Patch System
1260825|NCT00916383|Elderly
1260826|NCT00916383|Alzheimer's subjects
1260827|NCT00916383|Skin Irritation in elderly Alzheimer's subjects
1260828|NCT00916370|drug eluting stents
1260829|NCT00916370|stents
1260830|NCT00916370|Angioplasty
1260831|NCT00916370|myocardial ischemia
1260832|NCT00916370|coronary artery stenosis
1260833|NCT00916370|Coronary Disease
1260834|NCT00916370|Coronary Artery Disease
1260835|NCT00916370|Coronary Restenosis
1260836|NCT00916370|Long lesion
1260837|NCT00916357|recombinant human hyaluronidase PH20 (rHuPH20)
1260838|NCT00916357|Insulin lispro
1260839|NCT00916357|Regular human insulin
1260840|NCT00916331|total knee replacement arthroplasty
1260841|NCT00916331|subcutaneous indwelling
1260842|NCT00916331|blood loss
1260843|NCT00916331|complications
1260844|NCT00916331|functional status
1260845|NCT00916305|deafness noise tinnitus hearingloss
1260846|NCT00916292|Diabetes
1260847|NCT00916292|dermal ulcers
1260848|NCT00916279|Bare Metal In-Stent Restenosis
1260849|NCT00916279|Paclitaxel Coated Balloon Catheter
1260850|NCT00916279|Drug Coated Balloon
1260851|NCT00916279|Coronary Artery Disease
1260852|NCT00916266|Seizure frequency
1260853|NCT00916266|Hippocampal volume
1260854|NCT00916266|Adverse effects
1260855|NCT00916253|Sleep
1260856|NCT00916253|real driving
1260857|NCT00916253|simulated driving
1260858|NCT00916253|MWT
1260859|NCT00916240|Adolescents
1260860|NCT00916240|African American
1260861|NCT00916227|Low or Intermediate-1 Risk Myelodysplastic Syndrome
1260862|NCT00916201|schizophrenia
1260863|NCT00916188|Black Tea
1260864|NCT00916188|Oxidative Stress
1260865|NCT00916188|Blood Lipids
1260866|NCT00916188|Insulin Sensitivity
1260867|NCT00916175|hyperglycemia
1260868|NCT00916175|overweight
1260869|NCT00916175|functional food
1260870|NCT00916175|aloe vera
1260871|NCT00916175|cnidoscolus chayamansa
1260872|NCT00916162|aromatase inhibitor
1260873|NCT00916149|Epilepsy
1260874|NCT00916149|Cognition
1260875|NCT00916149|Lamictal
1260876|NCT00916149|Lamotrigine
1260877|NCT00916149|Keppra
1260878|NCT00916149|Levetiracetam
1260879|NCT00916136|Pre-operative Traction
1260880|NCT00916136|Traction
1260881|NCT00916136|Proximal Femur Fracture
1260882|NCT00916136|Femoral Fractures
1260883|NCT00916136|Femoral Fracture
1260884|NCT00916136|Skeletal Traction
1260885|NCT00916136|Cutaneous Traction
1260886|NCT00916123|castrate-resistant prostate cancer
1260887|NCT00916123|CRPC
1260888|NCT00916110|healthy subjects
1260889|NCT00916071|Bulimia Nervosa
1260890|NCT00916071|Eating Disorder NOS
1260891|NCT00916071|Attention Deficit Hyperactivity Disorder
1260892|NCT00916071|ADHD
1260893|NCT00916058|Multiple Myeloma
1260894|NCT00916058|Autologous Stem Cell Transplant
1260895|NCT00916058|ASCT
1260896|NCT00916058|MM
1260897|NCT00916019|gene expression
1260898|NCT00916019|skeletal muscle
1260899|NCT00916019|Healthy men
1260900|NCT00916006|Peplin
1260901|NCT00916006|Actinic keratosis
1260902|NCT00916006|PEP005
1260903|NCT00915993|stage IV renal cell cancer
1260904|NCT00915993|recurrent renal cell cancer
1260905|NCT00915980|Meal-test
1260906|NCT00915980|reduced OGTT
1260907|NCT00915980|gastric bypass surgery and glucose metabolism
1261033|NCT00915538|Formoterol
1260908|NCT00915980|Glucose metabolism before and after gastric bypass
1260909|NCT00915980|Different OGTT
1260910|NCT00915980|New meal- test
1260911|NCT00915967|Infection
1260912|NCT00915967|Vancomycin
1260913|NCT00915967|Neurosurgery
1260914|NCT00915967|Stimulator
1260915|NCT00915967|Pump
1260916|NCT00915967|Deep Brain Stimulation
1260917|NCT00915967|Intrathecal Pump
1260918|NCT00915954|Acromegaly
1260919|NCT00915954|Type 2 diabetes mellitus
1260920|NCT00915954|recombinant human IGF1
1260921|NCT00915954|oral glucose tolerance test
1260922|NCT00915915|Female contraception
1260923|NCT00915915|Ovulation inhibition
1260924|NCT00915889|psychosocial effects of cancer and its treatment
1260925|NCT00915889|stage IA cervical cancer
1260926|NCT00915889|stage IB cervical cancer
1260927|NCT00915889|stage IIA cervical cancer
1260928|NCT00915889|stage IIB cervical cancer
1260929|NCT00915889|stage III cervical cancer
1260930|NCT00915889|cancer survivor
1260931|NCT00915876|chronic kidney disease
1260932|NCT00915876|Vitamin D
1260933|NCT00915863|pancreaticoduodenectomy
1260934|NCT00915863|pancreatic fistula
1260935|NCT00915863|reconstruction
1260936|NCT00915863|isolated Roux-en-Y
1260937|NCT00915837|DME
1260938|NCT00915824|Drug therapy
1260939|NCT00915824|Prescribing
1260940|NCT00915824|Appropriateness
1260941|NCT00915824|Randomized controlled trial
1260942|NCT00915824|STOPP/START criteria
1260943|NCT00915824|Appropriateness of prescribing in older patients
1260944|NCT00915824|Prescription Drugs
1260945|NCT00915811|Myelodysplastic Syndromes
1260946|NCT00915811|Leukemia, Myeloid, Acute
1260947|NCT00915811|Haematopoietic stem cell transplantation
1260948|NCT00915811|Fludarabine
1260949|NCT00915811|Busulphan
1260950|NCT00915811|Thymoglobuline
1260951|NCT00915759|ProKera
1260952|NCT00915759|Amniotic membrane
1260953|NCT00915759|Photorefractive Keratectomy
1260954|NCT00915759|PRK
1260955|NCT00915759|time to re-epithelialization
1260956|NCT00915746|Phase I
1260957|NCT00915746|ketoconazole
1260958|NCT00915746|CYP3A4 inhibitor
1260959|NCT00915746|drug interaction
1260960|NCT00915746|metabolism
1260961|NCT00915746|Healthly Volunteer
1260962|NCT00915746|JNJ-31001074
1260963|NCT00915733|acute myocardial infarction
1260964|NCT00915733|inhibition of platelet aggregation
1260965|NCT00915733|triple antiplatelet therapy
1260966|NCT00915733|high maintenance-dose clopidogrel.
1260967|NCT00915733|CYP2C19 polymorphism
1260968|NCT00915733|High posttreatment platelet reactivity
1260969|NCT00915733|Platelet Aggregation Inhibitors
1260970|NCT00915733|CYP2C19, human
1260971|NCT00915720|Atrial Fibrillation
1260972|NCT00915720|Surgical Ablation
1260973|NCT00915720|Implanted loop recorder
1260974|NCT00915720|Atrial Fibrillation Ablation
1260975|NCT00915707|obesity
1260976|NCT00915707|diabetes, risk
1260977|NCT00915707|obesity, diabetes risk related to sleep
1260978|NCT00915694|adult giant cell glioblastoma
1260979|NCT00915694|adult gliosarcoma
1260980|NCT00915694|adult glioblastoma
1260981|NCT00915681|amatoxin
1260982|NCT00915681|amanita
1260983|NCT00915681|mushroom poisoning
1260984|NCT00915681|hepatic failure
1260985|NCT00915681|milk thistle
1260986|NCT00915681|Silibinin
1260987|NCT00915681|Legalon
1260988|NCT00915668|Healthy women
1260989|NCT00915668|Non-childbearing potential
1260990|NCT00915668|Drug-drug interaction
1260991|NCT00915668|Oral contraceptive
1260992|NCT00915668|OC
1260993|NCT00915668|Ovral-L
1260994|NCT00915668|ethinyl estradiol
1260995|NCT00915668|EE
1260996|NCT00915668|levonorgestrel
1260997|NCT00915668|JNJ-31001074
1260998|NCT00915655|HIV Infections
1260999|NCT00915655|TMC114-TiDP29-C230
1261000|NCT00915655|TMC114-C230
1261001|NCT00915655|TMC114
1261002|NCT00915655|HIV-1
1261003|NCT00915655|Darunavir
1261004|NCT00915655|Ritonavir
1261005|NCT00915655|NRTI
1261006|NCT00915655|Treatment Naive
1261007|NCT00915642|Obesity
1261008|NCT00915642|Weight loss rate
1261009|NCT00915642|Sleep
1261010|NCT00915642|Vigil
1261011|NCT00915642|Metabolism
1261012|NCT00915642|Actigraphy
1261013|NCT00915642|Normal
1261014|NCT00915603|Metastatic Breast Cancer
1261015|NCT00915603|Paclitaxel
1261016|NCT00915603|Bevacizumab
1261017|NCT00915603|Everolimus
1261018|NCT00915577|Multiple Sclerosis
1261019|NCT00915577|interferon beta-1a
1261020|NCT00915577|Avonex
1261021|NCT00915577|liquid Avonex
1261022|NCT00915564|Hepatitis C
1261023|NCT00915564|HCV
1261024|NCT00915564|Hepatitis C Virus
1261025|NCT00915564|HCV negative
1261026|NCT00915564|Protease inhibitor
1261027|NCT00915564|Methadone
1261028|NCT00915564|TMC435
1261029|NCT00915551|Peplin
1261030|NCT00915551|Actinic keratosis
1261031|NCT00915551|PEP005
1261032|NCT00915538|Asthma
1261034|NCT00915538|LABA
1261035|NCT00915538|Symbicort
1261036|NCT00915538|Aerochamber
1261037|NCT00915512|Schizophrenia
1261038|NCT00915512|Paliperidone
1261039|NCT00915512|Invega
1261040|NCT00915486|Diabetic
1261041|NCT00915486|ulcer
1261042|NCT00915486|topical
1261043|NCT00915486|PDGF
1261044|NCT00915486|GSoC
1261045|NCT00915460|Multiple Sclerosis
1261046|NCT00915460|Avonex
1261047|NCT00915460|Interferon beta-1a
1261048|NCT00915460|patients at high risk to develop multiple sclerosis
1261049|NCT00915447|Cat Allergic Rhinitis
1261050|NCT00915434|Healthy volunteer
1261051|NCT00915434|Phase I
1261052|NCT00915434|Non-childbearing potential
1261053|NCT00915434|JNJ-31001074
1261054|NCT00915434|Food
1261055|NCT00915434|Pharmacokinetics
1261056|NCT00915421|cardiac arrest
1261057|NCT00915421|therapeutic hypothermia
1261058|NCT00915421|Postresuscitative disease
1261059|NCT00915408|Multiple Myeloma
1261060|NCT00915408|Cyclophosphamide
1261061|NCT00915408|Dexamethasone
1261062|NCT00915408|Lenalidomide
1261063|NCT00915356|AZD1305
1261064|NCT00915356|intravenous cardioversion of Atrial Fibrillation
1261065|NCT00915343|Adrenal insufficiency
1261066|NCT00915343|Primary adrenal insufficiency
1261067|NCT00915343|Addison's disease
1261068|NCT00915343|Hydrocortisone
1261069|NCT00915343|Modified release
1261070|NCT00915330|Transbronchial needle aspiration
1261071|NCT00915330|Bronchoscopy
1261072|NCT00915330|Rapid on-site cytopathologic evaluation
1261073|NCT00915330|Mediastinal lymphadenopathy
1261074|NCT00915330|Hilar Lymphadenopathy
1261075|NCT00915304|Clinical Decision Support System
1261076|NCT00915304|Automatic reminder
1261077|NCT00915304|Primary care
1261078|NCT00915304|Evidence-Based Medicine
1261079|NCT00915291|medical education
1261080|NCT00915291|clinical decisionmaking
1261081|NCT00915291|pharmaceutical marketing
1261082|NCT00915278|Neoplasms
1261083|NCT00915278|monoclonal antibody
1261084|NCT00915278|PF-04605412
1261085|NCT00915278|advanced metastatic solid tumors
1261086|NCT00915265|Epidural analgesia
1261087|NCT00915265|Continuous preperitoneal analgesia
1261088|NCT00915265|Surgery
1261089|NCT00915265|Open colorectal surgery
1261090|NCT00915265|Fast-track surgery
1261091|NCT00915265|ERAS
1261092|NCT00915252|Acute Myeloid Leukemia
1261093|NCT00915252|azacitidine
1261094|NCT00915252|elderly
1261095|NCT00915252|demethylating agent
1261096|NCT00915252|flt3
1261097|NCT00915252|AML
1261098|NCT00915239|volunteers
1261099|NCT00915226|Optic disk
1261100|NCT00915226|Regional blood flow
1261101|NCT00915226|Autoregulation
1261102|NCT00915213|E. Coli
1261103|NCT00915213|Prostate Biopsy
1261104|NCT00915200|Diabetic Nephropathies
1261105|NCT00915200|Proteinuria
1261106|NCT00915200|Renal Insufficiency, Chronic
1261107|NCT00915200|Monocytes
1261108|NCT00915200|Oxidative stress
1261109|NCT00915200|Inflammation
1261110|NCT00915200|Antioxidants
1261111|NCT00915200|Glutathione
1261112|NCT00915200|Silymarin
1261113|NCT00915200|Acetylcysteine
1261114|NCT00915200|Dietary Supplements
1261115|NCT00915200|Complementary Therapies
1261116|NCT00915187|Vaccination, influenza prevention
1261117|NCT00915174|drug-drug interaction study
1261118|NCT00915161|ventilation
1261119|NCT00915161|oxygenation
1261120|NCT00915148|Prolonged labor
1261121|NCT00915148|Ultrasound
1261122|NCT00915148|Caeserian section
1261123|NCT00915135|Insomnia
1261124|NCT00915135|Sleep Initiation and Maintenance Disorders
1261125|NCT00915135|Drug Therapy
1261126|NCT00915122|IMRT treatment for Prostate cancer patients
1261127|NCT00915122|Radiation treatment for prostate cancer
1261128|NCT00915122|cancer of the prostate
1261129|NCT00915122|Patients with high risk adenocarcinoma of the prostate
1261130|NCT00915109|amputees
1261131|NCT00915109|lower limb
1261132|NCT00915096|Follicular Lymphoma
1261133|NCT00915096|PET
1261134|NCT00915096|GELA
1261135|NCT00915070|BQ-123
1261136|NCT00915070|Optic Nerve Head Blood Flow
1261137|NCT00915070|Intraocular Pressure
1261138|NCT00915070|Regional Blood Flow
1261139|NCT00915070|Ocular Physiology
1261140|NCT00915070|Optic Disk
1261141|NCT00915044|IBD
1261142|NCT00915031|Robotic prostatectomy
1261143|NCT00915031|Hypothermia
1261144|NCT00915031|Potency
1261145|NCT00915018|ErbB-2 positive advanced breast cancer
1261146|NCT00915005|Locally-advanced non-small-cell lung carcinoma
1261147|NCT00915005|NSCLC
1261148|NCT00915005|Lung Cancer
1261149|NCT00915005|Image-Guided Adaptive Conformal Photon
1261150|NCT00915005|Proton Therapy
1261151|NCT00915005|Chemotherapy
1261152|NCT00915005|Treatment Related Pneumonitis
1261153|NCT00914992|optic disk
1261154|NCT00914992|regional blood flow
1261155|NCT00914992|autoregulation
1261156|NCT00914979|Angiosculpt
1261157|NCT00914979|Bifurcation Lesion
1261158|NCT00914979|Side branch
1261159|NCT00914979|IVUS
1261160|NCT00914953|social isolation
1261161|NCT00914953|cooperative behavior
1261162|NCT00914953|depression
1261163|NCT00914953|loneliness
1261164|NCT00914953|happiness
1261165|NCT00914953|empathy
1261166|NCT00914940|graft versus host disease
1261167|NCT00914940|adult acute lymphoblastic leukemia in remission
1261168|NCT00914940|recurrent adult acute lymphoblastic leukemia
1261169|NCT00914940|childhood acute lymphoblastic leukemia in remission
1261170|NCT00914940|recurrent childhood acute lymphoblastic leukemia
1261171|NCT00914940|adult acute myeloid leukemia in remission
1261172|NCT00914940|recurrent adult acute myeloid leukemia
1261173|NCT00914940|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1261174|NCT00914940|adult acute myeloid leukemia with inv(16)(p13;q22)
1261175|NCT00914940|adult acute myeloid leukemia with t(15;17)(q22;q12)
1261176|NCT00914940|adult acute myeloid leukemia with t(16;16)(p13;q22)
1261177|NCT00914940|adult acute myeloid leukemia with t(8;21)(q22;q22)
1261178|NCT00914940|childhood acute myeloid leukemia in remission
1261179|NCT00914940|recurrent childhood acute myeloid leukemia
1261180|NCT00914940|childhood myelodysplastic syndromes
1261181|NCT00914940|previously treated myelodysplastic syndromes
1261182|NCT00914940|refractory anemia with excess blasts
1261183|NCT00914940|de novo myelodysplastic syndromes
1261184|NCT00914940|secondary myelodysplastic syndromes
1261185|NCT00914927|Thrombocytopenia
1261186|NCT00914927|chronic liver disease
1261187|NCT00914901|Asthma
1261188|NCT00914901|Doping
1261189|NCT00914901|Salmeterol
1261190|NCT00914901|Beta-agonist
1261191|NCT00914901|Urine concentrations
1261192|NCT00914888|children
1261193|NCT00914888|pediatry
1261194|NCT00914888|pneumonia
1261195|NCT00914888|intra-abdominal
1261196|NCT00914888|infection
1261197|NCT00914875|kidney function tests
1261198|NCT00914875|anti-inflammatory agents, non-steroidal
1261199|NCT00914875|laparoscopic cholecystectomy
1261200|NCT00914875|adult
1261201|NCT00914862|Sleep Initiation and Maintenance Disorders
1261202|NCT00914862|Drug Therapy
1261203|NCT00914836|shoulder
1261204|NCT00914836|subacromion
1261205|NCT00914836|corticosteroid
1261206|NCT00914836|bursitis
1261207|NCT00914836|tendinitis
1261208|NCT00914836|calcific tendonitis
1261209|NCT00914836|subacromial bursitis
1261210|NCT00914836|rotator cuff tendinitis
1261211|NCT00914810|Chronic obstructive pulmonary disease
1261212|NCT00914810|Vitamin D
1261213|NCT00914810|Cholecalciferol
1261214|NCT00914810|Skeletal muscle
1261215|NCT00914797|Asthma
1261216|NCT00914797|Doping
1261217|NCT00914797|Beta agonist
1261218|NCT00914797|Terbutaline
1261219|NCT00914797|Pharmacokinetics
1261220|NCT00914784|TRALI
1261221|NCT00914784|Transfusion
1261222|NCT00914784|dyspnea
1261223|NCT00914784|pulmonary infiltrates
1261224|NCT00914771|Pandemic Influenza
1261225|NCT00914771|H5N1
1261226|NCT00914771|Adults and Elderly
1261227|NCT00914771|antigen dose
1261228|NCT00914758|multiple sclerosis
1261229|NCT00914758|cognition
1261230|NCT00914758|cognitive functioning
1261231|NCT00914758|Campath
1261232|NCT00914758|Rebif
1261233|NCT00914758|alemtuzumab
1261234|NCT00914758|interferon
1261235|NCT00914732|IMVAMUNE®, smallpox, vaccine
1261236|NCT00914719|sexual risk behavior among adolescents
1261237|NCT00914719|alcohol and drug use among adolescents
1261238|NCT00914706|Diabetes
1261239|NCT00914693|Fertility control
1261240|NCT00914693|Contraception
1261241|NCT00914667|Overactive Bladder Urgency Frequency
1261242|NCT00914654|Asthma
1261243|NCT00914654|Doping
1261244|NCT00914654|Formoterol
1261245|NCT00914654|Urinary concentrations
1261246|NCT00914654|Beta-agonists
1261247|NCT00914641|formulation; sustained release; modified release; extended release
1261248|NCT00914628|high risk acute leukemia
1261249|NCT00914628|HSV-TK
1261250|NCT00914628|Haploidentical HCT
1261251|NCT00914628|GvHD
1261252|NCT00914628|GvL
1261253|NCT00914628|Immunoreconstitution
1261254|NCT00914615|Stereotactic Body Radiation Therapy
1261255|NCT00914615|Liver Metastasis from colorectal cancer
1261256|NCT00914615|Patients with Liver Metastasis
1261257|NCT00914576|Endotoxin, Escherichia Coli
1261258|NCT00914576|Retina
1261259|NCT00914576|Regional Blood Flow
1261260|NCT00914563|Burned shock
1261261|NCT00914563|Volume resuscitative patterns
1261262|NCT00914563|Non-invasive hemodynamic monitoring
1261263|NCT00914550|Pneumonia
1261264|NCT00914550|Lung Infiltrates
1261265|NCT00914550|Antibiotic discontinuation
1261266|NCT00914550|De-escalation therapy
1261267|NCT00914537|Anal Cancer
1261268|NCT00914537|AIN
1261269|NCT00914537|HPV
1261270|NCT00914537|Cytology
1261271|NCT00914537|HIV
1261272|NCT00914537|HIV Positive
1261273|NCT00914524|Chronic Glomerulonephritis
1261274|NCT00914524|Diabetic Nephropathy
1261275|NCT00914524|Angiotensin II Receptor Blocker
1261276|NCT00914524|Urinary Protein
1261277|NCT00914511|Semen
1261278|NCT00914511|Sperm
1261279|NCT00914511|Avanafil
1261280|NCT00914511|Pharmacokinetics
1261281|NCT00914511|Elderly
1261282|NCT00914498|Xylocaine
1261283|NCT00914498|Casarean section
1261284|NCT00914498|Post operative pain
1261285|NCT00914498|Scar quality
1261286|NCT00914472|Preventing the thrombi formation
1261287|NCT00914459|hemophilia A
1261288|NCT00914446|Steatohepatitis
1261289|NCT00914433|COPD
1261290|NCT00914420|OCT
1261291|NCT00914420|Reendothelialisation
1261292|NCT00914420|Intrepide
1261293|NCT00914420|Trapidil
1261294|NCT00914420|Taxus
1261295|NCT00914407|Ocular physiology
1261296|NCT00914394|L-NG-Monomethyl Arginine
1261297|NCT00914394|Optic Nerve Head Blood Flow
1261298|NCT00914394|Intraocular Pressure
1261299|NCT00914394|Regional Blood Flow
1261300|NCT00914394|Ocular Physiology
1261301|NCT00914394|Optic Disk
1261302|NCT00914381|Community reinforcement approach
1261303|NCT00914381|Contingency management
1261304|NCT00914381|12-step facilitation counseling
1261305|NCT00914381|Cocaine dependence
1261306|NCT00914381|Women
1261307|NCT00914368|Platelet Aggregation Inhibitors
1261308|NCT00914368|Aspirin
1261309|NCT00914368|Clopidogrel
1261310|NCT00914368|Pathologic Processes
1261311|NCT00914368|Disease
1261312|NCT00914368|Therapeutic Uses
1261313|NCT00914368|Syndrome
1261314|NCT00914368|Hematologic Agents
1261315|NCT00914368|Cardiovascular Diseases
1261316|NCT00914368|Pharmacologic Actions
1261317|NCT00914355|Hepatocellular Carcinoma
1261318|NCT00914355|Stereotactic Body Radiation
1261319|NCT00914355|Unresectable liver cancer
1261320|NCT00914355|Patients with Hepatocellular Carcinoma
1261321|NCT00914342|Gerd
1261322|NCT00914342|GerdQ questionnaire
1261323|NCT00914342|work productivity
1261324|NCT00914342|Greece
1261325|NCT00914329|stress provoked
1261326|NCT00914329|healthy volunteers
1261327|NCT00914329|gelsemium
1261328|NCT00914329|homeopathy
1261329|NCT00914316|Lower leg claudication
1261330|NCT00914316|Poor circulation of the leg muscles
1261331|NCT00914316|Cramping or discomfort in the lower legs
1261332|NCT00914316|Lower leg pain
1261333|NCT00914316|Peripheral arterial disease
1261334|NCT00914316|PAD
1261335|NCT00914303|Safety
1261336|NCT00914303|tolerability
1261337|NCT00914303|healthy
1261338|NCT00914303|Healthy volunteer study
1261339|NCT00914277|Rho-kinase inhibitor
1261340|NCT00914277|male impotence
1261341|NCT00914264|chronic obstructive airway disease
1261342|NCT00914264|obstructive sleep apnea
1261343|NCT00914264|continuous positive airway pressure
1261344|NCT00914251|endothelial
1261345|NCT00914251|metabolic syndrome
1261346|NCT00914251|hesperidin
1261347|NCT00914238|Randomized clinical trial
1261348|NCT00914238|first episode psychosis of schizophrenia and schizotypal disorder
1261349|NCT00914238|rehabilitation
1261350|NCT00914238|psychosocial
1261351|NCT00914238|health service research
1261352|NCT00914238|schizotypal Disorder
1261353|NCT00914225|Human immunodeficiency virus
1261354|NCT00914225|malaria
1261355|NCT00914225|plasmodium falciparum
1261356|NCT00914225|diarrhea
1261357|NCT00914225|helminth
1261358|NCT00914225|HIV
1261359|NCT00914225|Treatment naive
1261360|NCT00914199|PCI
1261361|NCT00914199|Bifurcation lesion
1261362|NCT00914186|Atopic Dermatitis
1261363|NCT00914186|Pruritus
1261364|NCT00914160|Anti-inflammatory
1261365|NCT00914147|unspecified adult solid tumor, protocol specific
1261366|NCT00914134|Parkinson's disease
1261367|NCT00914134|Autonomic nervous system
1261368|NCT00914134|Levodopa infusion
1261369|NCT00914108|Preterm Infants
1261370|NCT00914108|Developmental Care
1261371|NCT00914108|NIDCAP
1261372|NCT00914108|Intrauterine Growth Restriction
1261373|NCT00914108|APIB
1261374|NCT00914108|EEG
1261375|NCT00914108|Neurobehavior
1261376|NCT00914095|Parkinson's disease
1261377|NCT00914095|Freezing of Gait
1261378|NCT00914095|Methylphenidate
1261379|NCT00914095|Dopamine transporter inhibitor
1261380|NCT00914095|Noradrenaline
1261381|NCT00914082|Self hypnosis
1261382|NCT00914082|Hypnosis
1261383|NCT00914082|mental training
1261384|NCT00914082|antenatal training
1261385|NCT00914082|pregnancy
1261386|NCT00914082|pain control
1261387|NCT00914082|Childbirth
1261388|NCT00914082|Analgesia
1261389|NCT00914043|fatigue
1261390|NCT00914043|HER2-negative breast cancer
1261391|NCT00914043|stage II breast cancer
1261392|NCT00914043|stage IIIA breast cancer
1261393|NCT00914043|stage IIIB breast cancer
1261394|NCT00914030|Visual perception
1261395|NCT00914030|Local/global processing
1261396|NCT00914030|Attention
1261397|NCT00914030|Visual priming
1261398|NCT00914030|Collinearity
1261399|NCT00914030|Grouping
1261400|NCT00914017|Breast Cancer
1261401|NCT00914017|Breast Cancer Prevention
1261402|NCT00914017|Mammographic Density
1261403|NCT00914017|Breast Density
1261404|NCT00914017|Breast Cancer Biomarkers
1261405|NCT00914004|Antidepressant
1261406|NCT00913991|Nitric Oxide
1261407|NCT00913978|Normothermia
1261408|NCT00913978|Abdominal Surgery
1261409|NCT00913978|Bair Paws
1261410|NCT00913952|Antidepressant
1261411|NCT00913939|Prostate Cancer
1261412|NCT00913939|HDR Brachytherapy
1261413|NCT00913939|Prostate Brachytherapy
1261414|NCT00913926|Climacteric symptoms
1261415|NCT00913913|Renal Cell Carcinoma
1261416|NCT00913900|Arterial Occlusive Diseases
1261417|NCT00913900|Vascular Disease
1261418|NCT00913887|Anti-Inflammatory
1261419|NCT00913861|endoscopy
1261420|NCT00913861|comfort
1261421|NCT00913861|non-pharmacological
1261422|NCT00913848|Treatment of Epilepsy and Bipolar Disorder
1261423|NCT00913835|Liposomal Doxorubicin
1261424|NCT00913835|IMC-3G3
1261425|NCT00913835|3G3
1261426|NCT00913835|Platinum resistant
1261427|NCT00913835|Platinum refractory
1261428|NCT00913835|Ovary
1261429|NCT00913835|Neoplasm
1261430|NCT00913835|PDGFr
1261431|NCT00913822|Antidepressant
1261432|NCT00913809|Antidepressant
1261433|NCT00913796|Renal transplantation
1261434|NCT00913796|Metabolic acidosis
1261435|NCT00913796|Physical capacity
1261436|NCT00913796|Bone histology
1261437|NCT00913796|Bone histomorphometry
1261438|NCT00913796|Parathyroid function
1261439|NCT00913796|Calcium and phosphate metabolism
1261440|NCT00913783|Antidepressant
1261441|NCT00913770|opioid dependence
1261442|NCT00913770|buprenorphine
1261443|NCT00913770|brief intervention
1261444|NCT00913757|Hepatocellular Carcinoma
1261445|NCT00913757|Liver Cancer
1261446|NCT00913757|Chronic Liver Disease
1261447|NCT00913757|Genome Wide Association Study
1261448|NCT00913757|Gene Expression Profiling
1261449|NCT00913744|AMD
1261450|NCT00913731|Psychotic symptom assessments
1261451|NCT00913731|Observational assessments of patients with acute psychotic symptoms
1261452|NCT00913705|NATCH
1261453|NCT00913705|LUNG
1261454|NCT00913705|OPERABLE NSCLC
1261455|NCT00913705|SURGERY PLUS ADJUVANT THERAPY
1261456|NCT00913705|SURGERY PLUS NEOADJUVANT THERAPY
1261457|NCT00913692|Glutamine
1261458|NCT00913692|Herpes Labialis
1261459|NCT00913692|Herpes Simplex Virus
1261460|NCT00913692|Cold Sore
1261461|NCT00913679|osteonecrosis
1261462|NCT00913679|femoral neck fracture
1261463|NCT00913679|implant fixation
1261464|NCT00913679|implant failure
1261465|NCT00913679|periprosthetic bone mineral density
1261466|NCT00913679|gait function
1261467|NCT00913679|gait analysis
1261468|NCT00913679|patient recovery
1261469|NCT00913666|Multiple Sclerosis
1261470|NCT00913653|Heart failure
1261471|NCT00913653|LCZ696
1261472|NCT00913640|Prospective Memory Performance
1261473|NCT00913640|Prospective Memory Outcome
1261474|NCT00913640|Parkinson's Disease
1261475|NCT00913627|Extended-release, ibuprofen
1261476|NCT00913614|insomnia pediatric safety
1261477|NCT00913601|Idiopathic Fecal Incontinence
1261478|NCT00913601|Fecal Incontinence
1261479|NCT00913601|Sacral Nerve Stimulation
1261480|NCT00913601|Sacral Nerve Neuromodulation
1261481|NCT00913575|neuromuscular training
1261482|NCT00913575|preoperative exercise
1261483|NCT00913575|physiotherapy
1261484|NCT00913575|total knee replacement
1261485|NCT00913575|knee osteoarthritis
1261486|NCT00913562|Ocular Physiology
1261487|NCT00913562|Regional Blood Flow
1261488|NCT00913549|Antihistamine
1261489|NCT00913536|Bladder Cancer
1261490|NCT00913536|Cone Beam CT
1261491|NCT00913536|On-line image guidance
1261492|NCT00913536|Radiation therapy in bladder cancer patients
1261493|NCT00913523|tampons
1261494|NCT00913523|Glycerol Monolaurate
1261495|NCT00913523|vaginal microflora
1261496|NCT00913523|microbes
1261497|NCT00913523|Vaginal Tampon
1261498|NCT00913497|Type 1 diabetes mellitus in children
1261499|NCT00913497|insulin glulisine
1261500|NCT00913497|insulin aspart
1261501|NCT00913497|post prandial
1261502|NCT00913484|Disulfiram
1261503|NCT00913484|Buprenorphine
1261504|NCT00913484|Cocaine dependence
1261505|NCT00913484|Opioid dependence
1261506|NCT00913484|Dopamine-Beta-Hydroxylase
1261507|NCT00913471|Spinal cord injury
1261508|NCT00913471|SCI
1261509|NCT00913471|Neuropathic pain
1261510|NCT00913471|Pain
1261511|NCT00913445|Appendicitis
1261512|NCT00913445|appendicectomy
1261513|NCT00913445|stitches
1261514|NCT00913445|wound healing
1261515|NCT00913445|cosmetic results
1261516|NCT00913432|rheumatoid arthritis
1261517|NCT00913432|methotrexate
1261518|NCT00913432|DMARD
1261519|NCT00913432|c-kit inhibitor
1261520|NCT00913419|Antidepressant
1261521|NCT00913406|Effect of lutein fortification growth healthy term infants
1261522|NCT00913367|Type 2 Diabetes Mellitus
1261523|NCT00913354|infertility
1261524|NCT00913354|ivf
1261525|NCT00913354|acupuncture
1261526|NCT00913328|Asthma
1261527|NCT00913328|Airway responsiveness
1261528|NCT00913328|Dose-response plateau
1261529|NCT00913328|Montelukast
1261530|NCT00913328|Add-on to inhaled corticosteroids
1261531|NCT00913315|prostatitis
1261532|NCT00913315|Adrenergic alpha-Antagonists
1261533|NCT00913315|tolterodine
1261534|NCT00913302|Ankylosing Spondylitis
1261535|NCT00913302|Education
1261536|NCT00913302|Physical fitness
1261537|NCT00913289|Liver Cirrhosis
1261538|NCT00913263|Prostate cancer
1261539|NCT00913250|Multiple Sclerosis
1261540|NCT00913250|Interferon beta-1a
1261541|NCT00913237|Antidepressant
1261542|NCT00913224|Anti-inflammatory
1261543|NCT00913198|Pancreas
1261544|NCT00913198|Advanced adenocarcinoma
1261545|NCT00913198|CP-4126
1261546|NCT00913185|Acne
1261547|NCT00913172|TB
1261548|NCT00913172|cost
1261549|NCT00913172|HEWs
1261550|NCT00913172|Cost-effectiveness
1261551|NCT00913172|treatment success rate
1261552|NCT00913159|Renal stones
1261553|NCT00913159|lithotripsy
1261554|NCT00913159|stone free rate
1261555|NCT00913146|Management of fever
1261556|NCT00913146|Malaria
1261557|NCT00913146|Malaria rapid diagnostic test
1261558|NCT00913146|Clinical trial
1261559|NCT00913133|Anticoagulation
1261560|NCT00913133|Prophylaxis
1261561|NCT00913133|Desirudin
1261562|NCT00913133|Direct thrombin inhibitor
1261563|NCT00913133|Heparin-induced thrombocytopenia
1261564|NCT00913120|YM150
1261565|NCT00913120|FXa inhibitor
1261566|NCT00913120|Thrombosis
1261567|NCT00913120|Anticoagulant
1261568|NCT00913120|Venous thromboembolism
1261569|NCT00913120|Arthroplasty, replacement, hip
1261570|NCT00913107|Trigeminal Neuralgia
1261571|NCT00913107|Lamotrigine
1261572|NCT00913107|Carbamazepine
1261573|NCT00913107|Lamictal®
1261574|NCT00913107|Tegretol®
1261575|NCT00913094|Hypertension
1261576|NCT00913081|Skin
1261577|NCT00913081|pharmacology
1261578|NCT00913081|metabolism
1261579|NCT00913081|lipid
1261580|NCT00913068|radical prostatectomy
1261581|NCT00913055|S-LAR
1261582|NCT00913055|Octreotide
1261583|NCT00913055|Implant
1261584|NCT00913042|Febrile neutropenia
1261585|NCT00913042|Blood culture
1261586|NCT00913042|Bacteremia
1261587|NCT00913042|Bacterial DNA testing
1261588|NCT00913029|primary open angle glaucoma (POAG)
1261589|NCT00913029|OAG
1261590|NCT00913029|glaucoma
1261591|NCT00913016|hormonal therapy(letrozole)
1261592|NCT00913016|postmenopausal breast cancer
1261593|NCT00913016|quality of life
1261594|NCT00913003|Lidocaine
1261595|NCT00913003|Mastectomy
1261596|NCT00913003|Pain
1261597|NCT00912990|Pediatric
1261598|NCT00912977|Parkinsons disease
1261599|NCT00912977|dyskinesia
1261600|NCT00912977|measurement
1261601|NCT00912964|Overactive Bladder
1261602|NCT00912964|Frequency
1261603|NCT00912964|Micturition
1261604|NCT00912964|Urgency
1261605|NCT00912964|Urinary incontinence
1261606|NCT00912964|Urinary urgency incontinence
1261607|NCT00912964|Mirabegron
1261608|NCT00912964|YM178
1261609|NCT00912938|metastatic breast cancer
1261610|NCT00912938|bone remodeling markers
1261611|NCT00912938|zoledronic acid
1261612|NCT00912912|Genitourinary
1261613|NCT00912912|Testis
1261614|NCT00912912|Refractory Germ Cell Tumors
1261615|NCT00912912|Advanced germ cell tumors
1261616|NCT00912912|GCTs
1261617|NCT00912912|Sunitinib Malate
1261618|NCT00912912|Sutent
1261619|NCT00912912|SU011248
1261620|NCT00912899|Refractory Multiple Myeloma
1261621|NCT00912899|CB3304
1261622|NCT00912899|Noscapine HCl
1261623|NCT00912899|Multiple Myeloma
1261624|NCT00912886|alzheimer
1261625|NCT00912886|memory
1261626|NCT00912886|neurosteroids
1261627|NCT00912873|pain
1261628|NCT00912873|catheter
1261629|NCT00912873|nerve block
1261630|NCT00912873|UCSD
1261631|NCT00912873|range of motion
1261632|NCT00912873|hip surgery
1261633|NCT00912873|psoas compartment
1261634|NCT00912860|multiple sclerosis
1261635|NCT00912860|interferon beta-1a
1261636|NCT00912860|avonex
1261637|NCT00912847|HBV carriers
1261638|NCT00912834|hematuria
1261639|NCT00912834|urinary tract infection
1261640|NCT00912821|Renal Replacement Therapy
1261641|NCT00912821|Peritoneal dialysis
1261642|NCT00912808|parkinsons disease
1261643|NCT00912808|falling
1261644|NCT00912795|Smoking Cessation
1261645|NCT00912795|technology
1261646|NCT00912795|developing countries
1261647|NCT00912782|ESRD
1261648|NCT00912782|Vitamin D
1261649|NCT00912782|Arteriovenous Fistulae
1261650|NCT00912782|Dialysis Vascular Access
1261651|NCT00912769|Total knee replacement
1261652|NCT00912769|Subvastus
1261653|NCT00912769|Midvastus
1261654|NCT00912769|Isokinetic
1261655|NCT00912769|Quadriceps
1261656|NCT00912756|endovascular therapy
1261657|NCT00912756|restenosis
1261658|NCT00912756|cilostazol
1261659|NCT00912756|femoropopliteal artery lesions
1261660|NCT00912756|Chronic arteriosclerosis obliterans afflicting the femoropopliteal artery area
1261661|NCT00912743|Colorectal cancer
1261662|NCT00912743|Olaparib
1261663|NCT00912743|MSI status
1261664|NCT00912743|Stage IV
1261665|NCT00912743|Measurable Colorectal Cancer
1261666|NCT00912743|Stratified by MSI Status
1261667|NCT00912730|melanoma
1261668|NCT00912730|imaging
1261669|NCT00912730|sentinel node
1261670|NCT00912730|biopsy
1261671|NCT00912704|Hemodialysis patients
1261672|NCT00912704|Kidney
1261673|NCT00912704|Physician attitudes
1261674|NCT00912704|Family wishes
1261675|NCT00912704|30 numbers require maximum
1261676|NCT00912691|Autism
1261677|NCT00912678|Kidney transplantation
1261678|NCT00912678|Old for old kidney transplantation
1261679|NCT00912678|European senior program
1261680|NCT00912678|Calcineurin inhibitor free immunosuppression
1261681|NCT00912665|Optic Nerve Head Blood Flow
1261682|NCT00912665|Intraocular Pressure
1261683|NCT00912665|Regional Blood Flow
1261684|NCT00912665|Ocular Physiology
1261685|NCT00912665|Optic Disk
1261686|NCT00912652|obesity
1261687|NCT00912652|rural health
1261688|NCT00912652|exercise
1261689|NCT00912639|recurrent breast cancer
1261690|NCT00912639|Genexol-PM
1261691|NCT00912626|siblings
1261692|NCT00912626|family
1261693|NCT00912626|child behavior
1261694|NCT00912626|critical illness
1261695|NCT00912626|social support
1261696|NCT00912613|Critical illness
1261697|NCT00912613|ICU Diaries
1261698|NCT00912613|Post Traumatic Stress Disorder
1261699|NCT00912613|Incidence
1261700|NCT00912600|Intensive Care Units
1261701|NCT00912600|Triage
1261702|NCT00912600|Aged, 80 and over
1261703|NCT00912600|Death
1261704|NCT00912600|Activities of Daily Living
1261705|NCT00912600|Health Services Research
1261706|NCT00912600|Health Care Quality, Access, and Evaluation
1261707|NCT00912574|Melanoma
1261708|NCT00912574|adjuvant
1261709|NCT00912574|dendritic cells
1261710|NCT00912574|vaccine
1261711|NCT00912561|chronic brain ischaemia
1261712|NCT00912561|stroke prevention
1261713|NCT00912561|exercise
1261714|NCT00912561|physical training
1261715|NCT00912561|Chronic, extra- or intracranial stenoses of brain supplying arteries
1261716|NCT00912548|premenopause
1261717|NCT00912548|ovarian function suppression
1261718|NCT00912548|tamoxifen
1261719|NCT00912535|Primary Anxiety Disorders
1261720|NCT00912535|Mood Disorders with Comorbid Anxiety Symptoms
1261721|NCT00912522|reward
1261722|NCT00912522|TMS
1261723|NCT00912522|cognition
1261724|NCT00912522|Motivation
1261725|NCT00912522|Perception
1261726|NCT00912522|Decision making
1261727|NCT00912509|infectious keratitis
1261728|NCT00912509|cross linking
1261729|NCT00912509|corneal ulcer
1261730|NCT00912509|corneal infection
1261731|NCT00912509|collagen cross linking
1261732|NCT00912496|Influenza, H5N1, vaccine, avian influenza
1261733|NCT00912483|VTE
1261734|NCT00912470|genetic vascular risc factors
1261735|NCT00912470|ocular blood flow
1261736|NCT00912470|progressive glaucoma
1261737|NCT00912457|sleep apnea
1261738|NCT00912457|donepezil
1261739|NCT00912457|pharmacological
1261740|NCT00912457|cholinergic
1261741|NCT00912444|Breast Neoplasms
1261742|NCT00912444|Neoadjuvant
1261743|NCT00912444|Chemotherapy
1261744|NCT00912444|Docetaxel
1261745|NCT00912444|Cyclophosphamide
1261746|NCT00912444|Anthracycline
1261747|NCT00912431|Healthy Volunteers
1261748|NCT00912418|melanoma
1261749|NCT00912418|vaccine
1261750|NCT00912418|IL2 low dose
1261751|NCT00912405|Patients diagnosed with Chronic Sinusitis undergoing functional endoscopic surgery (FESS)
1261752|NCT00912366|VATS
1261753|NCT00912366|Lung cancer
1261754|NCT00912366|NSCLC
1261755|NCT00912353|Phase I
1261756|NCT00912353|Japanese healthy volunteer
1261757|NCT00912353|AZD7268
1261758|NCT00912340|Breast Cancer
1261759|NCT00912327|Colorectal
1261760|NCT00912327|KRAS mutation
1261761|NCT00912327|Stage IV
1261762|NCT00912327|Imprime PGG
1261763|NCT00912327|Cetuximab
1261764|NCT00912327|Immunotherapy
1261765|NCT00912314|OAB
1261766|NCT00912314|overactive bladder
1261767|NCT00912314|ptns
1261768|NCT00912314|posterior tibial nerve stimulation
1261769|NCT00912314|percutaneous tibial nerve stimulation
1261770|NCT00912301|chenodeoxycholate, IBS, transit, colon, constipation
1261771|NCT00912288|Alzheimer disease moderate-to-severe memantine safety and efficacy
1261772|NCT00912262|Analgesics
1261773|NCT00912262|Capsaicin
1261774|NCT00912249|Horticulture Therapy
1261775|NCT00912249|Psychiatric Rehabilitation
1261776|NCT00912249|Nature-assisted psychotherapy
1261777|NCT00912249|Day Care
1261778|NCT00912236|Obesity
1261779|NCT00912236|HDL
1261780|NCT00912236|HDL functionality
1261781|NCT00912223|Follicular Non-Hodgkin's Lymphoma
1261782|NCT00912223|Hematopoietic Stem Cell Transplant (HSCT)
1261783|NCT00912223|Non-Myeloablative Transplant (NST)
1261784|NCT00912184|Kidney failure, acute
1261785|NCT00912184|Shock
1261786|NCT00912184|Toxins, biological
1261787|NCT00912184|Hemofiltration
1261788|NCT00912184|High cut off/super high flux membranes
1261789|NCT00912171|obstructive sleep apnea syndrome
1261790|NCT00912171|snoring
1261791|NCT00912171|adenotonsillar hypertrophy
1261792|NCT00912171|polysomnography
1261793|NCT00912171|intranasal steroids
1261794|NCT00912171|Anti-leukotrienes
1261795|NCT00912158|CPE
1261796|NCT00912158|CPAP
1261797|NCT00912158|BiPAP
1261798|NCT00912158|non invasive mechanical ventilation
1261799|NCT00912132|Fetal Growth
1261800|NCT00912132|Pregnancy
1261801|NCT00912119|craniofacial surgery
1261802|NCT00912119|pharmacokinetics
1261803|NCT00912119|cranial vault abnormalities
1261804|NCT00912119|homologous blood products
1261805|NCT00912119|wide scalp dissections
1261806|NCT00912119|transfusion requirements
1261807|NCT00912106|osteoarthritis
1261808|NCT00912106|HA
1261809|NCT00912106|synovial fluid
1261810|NCT00912106|lubrication
1261811|NCT00912093|HAE
1261812|NCT00912093|Type I HAE
1261813|NCT00912093|Type II HAE
1261814|NCT00912080|genomic signature
1261815|NCT00912080|lymph nodes
1261816|NCT00912080|no metastases
1261817|NCT00912054|OAG
1261818|NCT00912054|OH
1261819|NCT00912041|Brain computer interface
1261820|NCT00912041|Assistive device
1261821|NCT00912041|Environmental control
1261822|NCT00912041|Communication device
1261823|NCT00912041|quadriplegia
1261824|NCT00912041|tetraplegia
1261825|NCT00911989|Obesity
1261826|NCT00911989|Weight Loss
1261827|NCT00911976|Coronary artery bypass
1261828|NCT00911976|Stents
1261829|NCT00911976|Angioplasty, Transluminal, Percutaneous Coronary
1261830|NCT00911976|Coronary Restenosis
1261831|NCT00911976|Everolimus
1261832|NCT00911976|Saphenous vein grafts
1261833|NCT00911963|VX-222
1261834|NCT00911937|incontinence OAB urgency nocturia
1261835|NCT00911924|primary open angle glaucoma (POAG)
1261836|NCT00911924|OAG
1261837|NCT00911924|glaucoma
1261838|NCT00911911|Breast cancer
1261839|NCT00911911|Neo-adjuvant chemotherapy
1261840|NCT00911911|Proteomic
1261841|NCT00911911|Histological response
1261842|NCT00911898|Her2 amplified solid tumors
1261843|NCT00911898|Breast Cancer
1261844|NCT00911898|Her3/ErbB3
1261845|NCT00911898|Bispecific Antibody
1261846|NCT00911885|Weight
1261847|NCT00911885|Diet
1261848|NCT00911885|Lipids
1261849|NCT00911872|wrinkles
1261850|NCT00911872|dermal filler
1261851|NCT00911872|collagen
1261852|NCT00911872|soft tissue augmentation
1261853|NCT00911872|aesthetic
1261854|NCT00911859|Multiple Myeloma
1261855|NCT00911859|CNTO328
1261856|NCT00911859|Interleukin-6 (IL-6)
1261857|NCT00911859|Monoclonal antibody
1261858|NCT00911859|Anti-IL-6 monoclonal antibody
1261859|NCT00911859|Bortezomib
1261860|NCT00911859|Velcade
1261861|NCT00911859|Melphalan
1261862|NCT00911859|Prednisone
1261863|NCT00911846|opioid dependence substitution buprenorphine methadone
1261864|NCT00911846|"substitution"
1261865|NCT00911833|Trust
1261866|NCT00911807|Clinical Trial, Phase II
1261867|NCT00911807|Randomized Controlled Trial
1261868|NCT00911807|Multicenter Study
1261869|NCT00911807|Cerebrolysin
1261870|NCT00911807|Donepezil
1261871|NCT00911794|Dyspnea
1261872|NCT00911794|Written Disclosure Therapy
1261873|NCT00911794|COPD
1261874|NCT00911794|Pulmonary Fibrosis
1261875|NCT00911794|Chronic Lung Diseases
1261876|NCT00911794|Pulmonary Rehabilitation
1261877|NCT00911781|Infantile hemangioma
1261878|NCT00911768|Xerostomia
1261879|NCT00911768|Panax ginseng(Korean Red Ginseng)
1261880|NCT00911768|Visual Analogue Scale
1261881|NCT00911768|Salivary Flow Rates
1261882|NCT00911755|Laryngoscopy
1261883|NCT00911755|Glidescope
1261884|NCT00911729|paraganglioma
1261885|NCT00911729|pheochromocytoma
1261886|NCT00911716|estrogen receptor-negative breast cancer
1261887|NCT00911716|estrogen receptor-positive breast cancer
1261888|NCT00911716|HER2-negative breast cancer
1261889|NCT00911716|stage IA breast cancer
1261890|NCT00911716|stage IB breast cancer
1261891|NCT00911716|stage II breast cancer
1261892|NCT00911716|stage IIIA breast cancer
1261893|NCT00911716|male breast cancer
1261894|NCT00911690|Dementia
1261895|NCT00911690|Alzheimers Disease
1261896|NCT00911690|Cognitive Disorders
1261897|NCT00911690|Tissue Banking
1261898|NCT00911677|Delirium (MeSH Unique ID D003693)
1261899|NCT00911677|Cognition Disorders (MeSH Unique ID D003072)
1261900|NCT00911677|Postoperative Complications (MeSH Unique ID D011183)
1261901|NCT00911677|Apolipoproteins E (MeSH Unique ID D001057)
1261902|NCT00911664|Vitamin D
1261903|NCT00911664|HIV-Infected children
1261904|NCT00911664|CD4 count
1261905|NCT00911651|COPD
1261906|NCT00911651|salbutamol
1261907|NCT00911651|ipratropium bromide
1261908|NCT00911651|computational fluid dynamics
1261909|NCT00911651|functional imaging
1261910|NCT00911651|central and peripheral airways
1261911|NCT00911638|Patient decision aids
1261912|NCT00911638|Patient preferences
1261913|NCT00911638|Osteoarthritis
1261914|NCT00911638|Joint replacement
1261915|NCT00911638|Waiting times
1261916|NCT00911625|glargine
1261917|NCT00911625|glulisine
1261918|NCT00911625|type 2 diabetes
1261919|NCT00911625|renal insufficiency
1261920|NCT00911612|bile acid
1261921|NCT00911612|malabsorption
1261922|NCT00911612|permeability
1261923|NCT00911612|diarrhea
1261924|NCT00911612|IBS
1261925|NCT00911612|stool
1261926|NCT00911599|Individuals undergoing unilateral total hip replacement.
1261927|NCT00911573|pediatry
1261928|NCT00911573|children
1261929|NCT00911573|skin
1261930|NCT00911573|bacteria
1261931|NCT00911573|MRSA
1261932|NCT00911560|BETA-D-GLUCAN
1261933|NCT00911560|OPT-821
1261934|NCT00911560|GD2-KLH
1261935|NCT00911560|GD3-KLH
1261936|NCT00911560|QS 21
1261937|NCT00911560|Vaccine
1261938|NCT00911560|05-075
1261939|NCT00911547|chronic asthma
1261940|NCT00911534|Gastroesophageal Reflux Disease
1261941|NCT00911534|GERD
1261942|NCT00911521|human papillomavirus
1261943|NCT00911521|vaccine
1261944|NCT00911521|lupus
1261945|NCT00911508|Atrial Fibrillation
1261946|NCT00911508|Left Atrial Ablation
1261947|NCT00911508|Pulmonary Vein Isolation
1261948|NCT00911508|Catheter Ablation
1261949|NCT00911508|Antiarrhythmic Drug Therapy
1261950|NCT00911495|Sickle Cell Disease
1261951|NCT00911482|Type 2 Diabetes
1261952|NCT00911482|Dyslipidemia
1261953|NCT00911482|FFA
1261954|NCT00911482|Triglycerides
1261955|NCT00911482|Tracers
1261956|NCT00911469|Knee osteoarthritis
1261957|NCT00911469|fibroblast growth factor 18
1261958|NCT00911430|Staphylococcus Aureus (S. Areus)
1261959|NCT00911430|Recurrent Staphylococcal Infection
1261960|NCT00911430|Atopic Dermatitis
1261961|NCT00911430|Immunodeficiency
1261962|NCT00911430|Community Associated Staphylococcal Infection
1261963|NCT00911430|Staphylococcal Infection
1261964|NCT00911430|Invasive Staphylococcal Infection
1261965|NCT00911430|Staph Infection
1261966|NCT00911417|peripheral arterial disease
1261967|NCT00911417|peripheral vascular disease
1261968|NCT00911404|Gestational diabetes
1261969|NCT00911404|Carbohydrate
1261970|NCT00911404|Diet
1261971|NCT00911404|Insulin
1261972|NCT00911391|Doppler
1261973|NCT00911391|Colectomy
1261974|NCT00911391|ERAS
1261975|NCT00911391|Fluid
1261976|NCT00911391|Perioperative Care
1261977|NCT00911378|weaning
1261978|NCT00911378|mechanical ventilation
1261979|NCT00911365|voluntary participants
1261980|NCT00911365|75 years old or less
1261981|NCT00911352|Cryotherapy
1261982|NCT00911352|Hand toxicity
1261983|NCT00911352|Nail toxicity
1261984|NCT00911352|Infection control
1261985|NCT00911326|HNSCC
1261986|NCT00911313|Polycystic ovary syndrome
1261987|NCT00911313|clomiphene resistance
1261988|NCT00911313|letrozole
1261989|NCT00911300|Cardioversion, Electric
1261990|NCT00911300|Pathological Conditions, Sings and Symptoms
1261991|NCT00911300|Cardiovascular Diseases
1261992|NCT00911300|Heart Diseases
1261993|NCT00911300|Atrial Fibrillation
1261994|NCT00911300|Arrhythmias, Cardiac
1261995|NCT00911300|Pathologic Processes
1261996|NCT00911300|Anticoagulants
1261997|NCT00911287|Chronic pain
1261998|NCT00911287|Extended Release
1261999|NCT00911287|Long-Acting Opioid
1262000|NCT00911287|Opioid
1262001|NCT00911287|Opioid-Naive
1262002|NCT00911287|Oxymorphone
1262003|NCT00911274|Bioequivalence
1262004|NCT00911274|Healthy Subjects
1262005|NCT00911261|Cancer Pain
1262006|NCT00911261|Neuropathic Pain
1262007|NCT00911261|Extended Release
1262008|NCT00911261|Long-Acting Opioid
1262009|NCT00911261|Oxymorphone
1262010|NCT00911248|Angiogenesis
1262011|NCT00911248|Neurofibromatosis
1262012|NCT00911248|Post-transcriptional control
1262013|NCT00911248|PTC299
1262014|NCT00911248|VEGF
1262015|NCT00911235|The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
1262016|NCT00911222|antiemetic therapy
1262017|NCT00911222|emesis
1262018|NCT00911222|vomiting
1262019|NCT00911222|nausea
1262020|NCT00911222|moderately and highly emetogenic chemotherapy
1262021|NCT00911222|cisplatin
1262022|NCT00911222|carboplatin
1262023|NCT00911222|oxaliplatin
1262024|NCT00911222|anthracycline
1262025|NCT00911222|cyclophosphamid
1262026|NCT00911209|Heart Disease
1262027|NCT00911209|Obesity
1262028|NCT00911196|Prognosis
1262029|NCT00911196|Markers
1262030|NCT00911196|Expression analysis
1262031|NCT00911196|Hepatocellular carcinoma
1262032|NCT00911183|contiguous stage II adult diffuse large cell lymphoma
1262033|NCT00911183|noncontiguous stage II adult diffuse large cell lymphoma
1262034|NCT00911183|stage III adult diffuse large cell lymphoma
1262035|NCT00911183|stage IV adult diffuse large cell lymphoma
1262036|NCT00911170|adenocarcinoma of the colon or rectum
1262037|NCT00911170|febrile neutropenia
1262038|NCT00911170|Bevacizumab
1262039|NCT00911170|Avastin
1262040|NCT00911170|5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX)
1262041|NCT00911170|5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
1262042|NCT00911157|Pulmonary thromboembolism
1262043|NCT00911157|contrast-enhanced MDCT
1262044|NCT00911157|Deep Vein Thrombosis
1262045|NCT00911157|Fondaparinux sodium
1262046|NCT00911144|Safety
1262047|NCT00911144|Pneumococcal vaccine
1262048|NCT00911144|Immunogenicity
1262049|NCT00911144|Pneumococcal disease
1262050|NCT00911144|Booster vaccination
1262051|NCT00911131|Small grade esophageal varices
1262052|NCT00911131|capsule endoscopy
1262053|NCT00911131|PillCam ESO
1262054|NCT00911131|abdominal binder
1262055|NCT00911118|prostate
1262056|NCT00911118|radiation
1262057|NCT00911118|09-035
1262058|NCT00911105|Multiple Myeloma
1262059|NCT00911105|Non-interventional study
1262060|NCT00911105|Lenalidomide
1262061|NCT00911105|Dexamethasone
1262062|NCT00911105|Observational
1262063|NCT00911105|Time to progression
1262064|NCT00911105|Clinical routine
1262065|NCT00911105|Germany
1262066|NCT00911105|Plasmacytoma
1262067|NCT00911092|Oesophageal cancer
1262068|NCT00911092|exclusive concomitant radiochemotherapy
1262069|NCT00911079|Stage III, IV cervical cancer
1262070|NCT00911079|Rising prostate specific antigen (PSA) after local therapy
1262071|NCT00911053|melatonin
1262072|NCT00911053|sleep
1262073|NCT00911053|blindness
1262074|NCT00911053|blind individuals
1262075|NCT00911027|Prostate
1262076|NCT00911027|Cancer
1262077|NCT00911027|Biopsy
1262078|NCT00911027|Guided
1262079|NCT00911027|Contrast
1262080|NCT00911027|Enhanced
1262081|NCT00911027|SonoVue
1262082|NCT00911027|Suspicion of prostate cancer
1262083|NCT00911001|Arthroplasty
1262084|NCT00911001|Antithrombotic prophylaxis treatment
1262085|NCT00911001|Replacement
1262086|NCT00911001|Knee
1262087|NCT00910988|healthy
1262088|NCT00910988|sedentary
1262089|NCT00910988|men
1262090|NCT00910988|acute effects of antipsychotic
1262091|NCT00910988|blood sugar
1262092|NCT00910988|insulin sensitivity
1262093|NCT00910975|Hepatitis C virus
1262094|NCT00910975|Real-time PCR
1262095|NCT00910975|Treatment
1262096|NCT00910962|NSTEMI, acute coronary syndrome, p38 MAPK inhibitor, GW856553, percutaneous coronary intervention
1262097|NCT00910949|persistent pain
1262098|NCT00910949|neuropathic pain
1262099|NCT00910949|Thoracotomy
1262100|NCT00910949|Chronic Pain
1262101|NCT00910936|HIV
1262102|NCT00910936|Exercise
1262103|NCT00910936|Inflammation
1262104|NCT00910936|Quality of life
1262105|NCT00910936|Lipodystrophia
1262106|NCT00910923|Diabetes Mellitus, Type 2
1262107|NCT00910897|Newly Diagnosed
1262108|NCT00910897|multiple myeloma
1262109|NCT00910897|induction
1262110|NCT00910897|Thalidomide
1262111|NCT00910884|stage I breast cancer
1262112|NCT00910884|stage II breast cancer
1262113|NCT00910884|stage IIIA breast cancer
1262114|NCT00910884|male breast cancer
1262115|NCT00910884|stage I uterine sarcoma
1262116|NCT00910884|stage II uterine sarcoma
1262117|NCT00910884|stage I prostate cancer
1262118|NCT00910884|stage II prostate cancer
1262119|NCT00910871|Tuberculosis
1262120|NCT00910871|TMC207-TiDP13-C209
1262121|NCT00910871|TMC207-C209
1262122|NCT00910871|TMC207
1262123|NCT00910871|TB
1262124|NCT00910871|MDR-TB
1262125|NCT00910832|Dyschesia treatment
1262126|NCT00910832|Rehabilitation
1262127|NCT00910832|Dyschesia
1262128|NCT00910819|Colorectal Cancer
1262129|NCT00910819|Advanced Colorectal Cancer
1262130|NCT00910819|Epidemiology
1262131|NCT00910819|Health Services Research
1262132|NCT00910819|Germany
1262133|NCT00910819|Registry
1262134|NCT00910819|Palliative Care
1262135|NCT00910819|Palliative Treatment
1262136|NCT00910819|Adjuvant Drug Therapy
1262137|NCT00910819|Nutrition Assessment
1262138|NCT00910819|Physical Activity
1262139|NCT00910806|TMC207-TiDP13-C117
1262140|NCT00910806|TMC207-C110
1262141|NCT00910806|TMC207
1262142|NCT00910806|drug-drug interaction
1262143|NCT00910806|Tuberculosis
1262144|NCT00910806|HIV
1262145|NCT00910806|nevirapine
1262146|NCT00910806|open-label
1262147|NCT00910806|Pharmacokinetics
1262148|NCT00910793|Asthma
1262149|NCT00910793|Formoterol
1262150|NCT00910793|Beclomethasone Dipropionate
1262151|NCT00910793|Computational Fluid Dynamics
1262152|NCT00910793|Functional Imaging
1262153|NCT00910793|Central and Peripheral Airways
1262154|NCT00910754|Prostate neoplasms
1262155|NCT00910754|Metastatic castration resistant prostate cancer
1262156|NCT00910754|Abiraterone acetate
1262157|NCT00910754|CB7630
1262158|NCT00910741|pancreatic cancer
1262159|NCT00910741|Gemcitabine
1262160|NCT00910728|Primary Myelofibrosis (PMF)
1262161|NCT00910728|Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF)
1262162|NCT00910728|Myeloproliferative diseases
1262163|NCT00910728|Phase I
1262164|NCT00910728|Phase II
1262165|NCT00910728|Bone marrow
1262166|NCT00910715|erythema migrans
1262167|NCT00910715|Lyme borreliosis
1262168|NCT00910715|doxycycline treatment
1262169|NCT00910715|outcome
1262170|NCT00910715|subjective symptoms
1262171|NCT00910702|retinal detachment, vitreous body substitute
1262172|NCT00910689|Migraine Headache
1262173|NCT00910689|Preventive Therapy
1262174|NCT00910689|Beta Blocker Medication
1262175|NCT00910689|Behavior Therapy
1262176|NCT00910689|Clinical Trial
1262177|NCT00910676|EGF-R inhibitors
1262178|NCT00910663|Bioequivalence
1262179|NCT00910663|Healthy Subjects
1262180|NCT00910650|Adoptive transfer therapy
1262181|NCT00910650|Dendritic cell vaccines
1262182|NCT00910637|Pregnancy prevention
1262183|NCT00910637|Female contraception
1262184|NCT00910637|Patch
1262185|NCT00910611|pediatric
1262186|NCT00910611|immunization
1262187|NCT00910611|pain
1262188|NCT00910611|analgesia
1262189|NCT00910611|Immunization pain
1262190|NCT00910598|clinically isolated syndrome
1262191|NCT00910598|relapsing remitting multiple sclerosis
1262192|NCT00910598|glatiramer acetate
1262193|NCT00910598|Optical Coherence Tomography
1262194|NCT00910585|childhood
1262195|NCT00910585|asthma
1262196|NCT00910572|Yttrium-90
1262197|NCT00910572|Radiation
1262198|NCT00910572|Radioembolization
1262199|NCT00910572|Hepatoma
1262200|NCT00910572|BCLC classification
1262201|NCT00910572|Hepatic loco-regional treatments
1262202|NCT00910572|Yttrium
1262203|NCT00910572|Microspheres
1262204|NCT00910559|Autism Spectrum Disorder
1262205|NCT00910559|Autism
1262206|NCT00910559|Asperger Syndrome
1262207|NCT00910559|Pervasive Developmental Disorders- Not Otherwise Specified
1262208|NCT00910546|Lung Cancer
1262209|NCT00910546|Stereotactic radiotherapy
1262210|NCT00910546|Image guidance
1262211|NCT00910546|breathing adaption
1262212|NCT00910546|tumor motion
1262213|NCT00910546|implanted marker
1262214|NCT00910533|Lyme neuroborreliosis
1262215|NCT00910507|Diabetes Mellitus, Type 2
1262216|NCT00910507|Exercise
1262217|NCT00910507|Counseling
1262218|NCT00910507|Behavior
1262219|NCT00910494|Rectal neoplasm C04.588.274.476.411.307.790
1262220|NCT00910494|Intraoperative Radiotherapy
1262221|NCT00910481|Coronary Artery Disease
1262222|NCT00910481|Percutaneous Transluminal Coronary Angioplasty
1262223|NCT00910481|Intraaortic Balloon Pumping
1262224|NCT00910481|Left Ventricular Dysfunction
1262225|NCT00910481|High Risk
1262226|NCT00910455|Phase 1
1262227|NCT00910455|Safety
1262228|NCT00910455|Tolerability
1262229|NCT00910455|Pharmacokinetics
1262230|NCT00910429|Chronic thromboembolic Hypertension
1262231|NCT00910429|PH
1262232|NCT00910429|soluble Guanylate Cyclase Stimulator
1262233|NCT00910429|sGC
1262234|NCT00910416|Anesthesia
1262235|NCT00910416|Monitoring, Intraoperative
1262236|NCT00910416|Electroencephalography/*drug effects
1262237|NCT00910403|Presbyopia
1262238|NCT00910403|LASIK
1262239|NCT00910403|Hyperopes
1262240|NCT00910390|IVF
1262241|NCT00910390|embryo cryopreservation
1262242|NCT00910390|vitrification
1262243|NCT00910390|Human Embryo
1262244|NCT00910390|Embryonic development
1262245|NCT00910390|Pregnancy rate
1262246|NCT00910377|breastfeeding
1262247|NCT00910377|exclusive breastfeeding
1262248|NCT00910377|lactation counseling
1262249|NCT00910377|teenagers
1262250|NCT00910377|complementary food
1262251|NCT00910377|adolescent
1262252|NCT00910377|caregivers
1262253|NCT00910364|Lower extremity DVT
1262254|NCT00910364|Clot
1262255|NCT00910364|leg clot
1262256|NCT00910364|Deep vein thrombosis
1262257|NCT00910364|Thrombosis
1262258|NCT00910364|Warfarin
1262259|NCT00910351|Cystic Fibrosis
1262260|NCT00910351|Pharmacokinetics
1262261|NCT00910351|Pediatrics
1262262|NCT00910351|Inhalation
1262263|NCT00910351|Sputum
1262264|NCT00910338|Pelvic Floor Muscle Training
1262265|NCT00910338|Extracorporeal Biofeedback
1262266|NCT00910325|Female
1262267|NCT00910325|Cholelithiasis
1262268|NCT00910325|Natural Orifice Surgery
1262269|NCT00910325|Laparoscopic- Assisted
1262270|NCT00910325|Transvaginal
1262271|NCT00910299|Clopidogrel
1262272|NCT00910299|VerifyNow
1262273|NCT00910299|PRU Measurements
1262274|NCT00910299|Drug Eluting Stents (DES)
1262275|NCT00910299|Heart Disease
1262276|NCT00910299|Percutaneous Coronary Intervention (PCI)
1262277|NCT00910299|P2Y12
1262278|NCT00910299|Platelets
1262279|NCT00910299|Platelet Reactivity
1262280|NCT00910286|Pressure support ventilation
1262281|NCT00910286|cycling off criteria
1262282|NCT00910286|expiratory trigger
1262283|NCT00910286|patient-ventilator interaction
1262284|NCT00910286|patient comfort
1262285|NCT00910273|IMT evaluation in AS patients treated with etanercept
1262286|NCT00910260|vitamin D level under phototherapy
1262287|NCT00910247|Seizures
1262288|NCT00910247|Epilepsy
1262289|NCT00910247|Anticonvulsant
1262290|NCT00910247|Monotherapy
1262291|NCT00910247|Epilepsy with simple or complete partial onset seizures
1262292|NCT00910234|Periventricular leukomalacia (PVL)
1262293|NCT00910234|Erythropoietin (EPO)
1262294|NCT00910234|Retinopathy of prematurity (ROP)
1262295|NCT00910234|Hypoxia-ischemia
1262296|NCT00910221|Cardiac surgery
1262297|NCT00910221|Cardiopulmonary bypass
1262298|NCT00910221|Oxidative stress
1262299|NCT00910221|Acute renal dysfunction
1262300|NCT00910221|Atorvastatin
1262301|NCT00910208|Pain
1262302|NCT00910208|Analgesia
1262303|NCT00910208|Analgesia, Patient-controlled
1262304|NCT00910208|Emergency Medicine
1262305|NCT00910195|Obstructive sleep apnea
1262306|NCT00910195|CPAP
1262307|NCT00910195|Bi-Level
1262308|NCT00910182|Splenic rupture
1262309|NCT00910182|abdominal injuries
1262310|NCT00910182|Surgery
1262311|NCT00910182|Angiography
1262312|NCT00910182|Embolisation
1262313|NCT00910182|Computed tomography
1262314|NCT00910182|Classification
1262315|NCT00910169|Anorexia nervosa
1262316|NCT00910169|treatment
1262317|NCT00910169|inpatient
1262318|NCT00910169|efficacy
1262319|NCT00910169|outcome
1262320|NCT00910143|Rectal cancer
1262321|NCT00910143|Colorectal Surgery
1262322|NCT00910143|Surgery
1262323|NCT00910143|Local neoplasm recurrence
1262324|NCT00910143|survival
1262325|NCT00910143|Follow-up Study
1262326|NCT00910130|Retinol Binding Protein 4
1262327|NCT00910130|Insulin Resistance
1262328|NCT00910130|Diabetes
1262329|NCT00910130|End Stage Renal Disease
1262330|NCT00910130|Dialysis
1262331|NCT00910130|Nutrition
1262332|NCT00910117|HNSCC
1262333|NCT00910117|induction chemotherapy
1262334|NCT00910117|nimotuzumab
1262335|NCT00910104|PNALD
1262336|NCT00910104|Omegaven
1262337|NCT00910104|Parenteral Nutrition Associated Liver Disease
1262338|NCT00910104|Cholestasis
1262339|NCT00910104|Short Bowel Syndrome
1262340|NCT00910091|Endometrial cancer
1262341|NCT00910091|Antitumour efficacy in women with advanced endometrial cancer
1262342|NCT00910078|Total kappa and lambda ratio
1262343|NCT00910078|Stem cell transplantation
1262344|NCT00910078|Serum immunofixation
1262345|NCT00910065|Acute Coronary Syndrome
1262346|NCT00910065|ACS
1262347|NCT00910065|Aspirin
1262348|NCT00910052|randomised
1262349|NCT00910052|controlled
1262350|NCT00910052|double blinded
1262351|NCT00910039|cognitive/functional effects
1262352|NCT00910039|tumors metastatic to brain
1262353|NCT00910039|unspecified adult solid tumor, protocol specific
1262354|NCT00910026|EBC and mechanical ventilation
1262355|NCT00910026|low tidal volume ventilation
1262356|NCT00910026|high tidal volume ventilation
1262357|NCT00910026|inflammatory and oxidative stress EBC biomarkers
1262358|NCT00910026|Ventilator induced lung injury
1262359|NCT00910013|TKR
1262360|NCT00910013|Femoral block
1262361|NCT00910013|Ropivacaïne
1262362|NCT00910013|intra-articular ropivacaïne
1262363|NCT00910013|post-operative analgesia
1262364|NCT00910000|carboplatin
1262365|NCT00910000|gemcitabine
1262366|NCT00910000|vorinostat
1262367|NCT00909987|rectum
1262368|NCT00909987|intermediate risk cancer rectum
1262369|NCT00909987|neoadjuvant
1262370|NCT00909974|multiple micronutrients
1262371|NCT00909974|energy deficiency
1262372|NCT00909961|Osteoporosis
1262373|NCT00909961|Bone Mineral Density
1262374|NCT00909961|Biomarkers
1262375|NCT00909948|Related stem cell transplant,
1262376|NCT00909948|TBI,
1262377|NCT00909948|Mismatched stem cell transplant
1262378|NCT00909948|Fludarabine
1262379|NCT00909948|Non-myeloablative
1262380|NCT00909948|Lymphoma
1262381|NCT00909948|Multiple myeloma
1262382|NCT00909935|To determine pharmacokinetics of dexmedetomidine in children
1262383|NCT00909922|Amputation
1262384|NCT00909922|Amputees
1262385|NCT00909922|Artificial Limbs
1262386|NCT00909922|Leg Length Inequality
1262387|NCT00909922|Lower Extremity
1262388|NCT00909922|Pelvis
1262389|NCT00909922|Posture
1262390|NCT00909922|Prostheses
1262391|NCT00909922|Range of Motion
1262392|NCT00909922|Trunk Muscles
1262393|NCT00909909|ductal breast carcinoma in situ
1262394|NCT00909909|invasive ductal breast carcinoma
1262395|NCT00909909|invasive lobular breast carcinoma
1262396|NCT00909909|medullary ductal breast carcinoma with lymphocytic infiltrate
1262397|NCT00909909|mucinous ductal breast carcinoma
1262398|NCT00909909|papillary ductal breast carcinoma
1262399|NCT00909909|tubular ductal breast carcinoma
1262400|NCT00909909|stage I breast cancer
1262401|NCT00909909|stage II breast cancer
1262402|NCT00909909|stage IIIA breast cancer
1262403|NCT00909896|endometrial
1262404|NCT00909896|pain
1262405|NCT00909883|Idiopathic Parkinson's disease
1262406|NCT00909883|Foot (Tiptoe) dystonia
1262407|NCT00909883|Botulinum Toxin
1262408|NCT00909883|Muscles : Flexor digitorum longus/ Flexor digitorum brevis/ quadratus plantae
1262409|NCT00909870|Venous leg ulcer
1262410|NCT00909870|randomized trial
1262411|NCT00909870|clinical trial
1262412|NCT00909870|Dermagraft
1262413|NCT00909870|compression therapy
1262414|NCT00909870|surgical debridement
1262415|NCT00909870|venous stasis
1262416|NCT00909870|chronic ulcer
1262417|NCT00909870|chronic wound
1262418|NCT00909870|fibroblasts
1262419|NCT00909857|Primary Dysmenorrhea
1262420|NCT00909857|Oral Contraception
1262421|NCT00909831|unspecified adult solid tumor, protocol specific
1262422|NCT00909805|dermabond glue
1262423|NCT00909805|suture
1262424|NCT00909805|children
1262425|NCT00909779|Chronic obstructive pulmonary disease (COPD)
1262426|NCT00909779|respiratory
1262427|NCT00909779|long-acting beta agonist (LABA)
1262428|NCT00909753|Bioequivalence
1262429|NCT00909753|Healthy Subjects
1262430|NCT00909740|Solid Tumor
1262431|NCT00909740|Cancer
1262432|NCT00909727|Fibrosis
1262433|NCT00909727|Pancreatic Diseases
1262434|NCT00909727|Digestive System Diseases
1262435|NCT00909727|Lung Diseases
1262436|NCT00909727|Respiratory Tract Diseases
1262437|NCT00909727|Genetic Diseases, Inborn
1262438|NCT00909727|Infant, Newborn, Diseases
1262439|NCT00909727|Pathologic Processes
1262445|NCT00909701|Dietary supplement
1262446|NCT00909701|healthy volunteers
1262447|NCT00909701|Anaesthesia for surgery
1262448|NCT00909688|Healthy Subjects
1262449|NCT00909662|cognitive/functional effects
1262450|NCT00909662|long-term effects secondary to cancer therapy in adults
1262451|NCT00909662|fatigue
1262452|NCT00909662|stage I breast cancer
1262453|NCT00909662|stage II breast cancer
1262454|NCT00909662|stage IIIA breast cancer
1262455|NCT00909662|stage IIIB breast cancer
1262456|NCT00909662|stage IIIC breast cancer
1262457|NCT00909649|fibrin glue
1262458|NCT00909649|seroma
1262459|NCT00909649|mastectomy
1262460|NCT00909636|multiple ascending doses (MAD)
1262461|NCT00909610|Bioequivalence
1262462|NCT00909610|Healthy Subjects
1262463|NCT00909584|Hematology
1262464|NCT00909584|Neutropenia
1262465|NCT00909584|SCN
1262466|NCT00909584|Severe Chronic Neutropenia
1262467|NCT00909584|Idiopathic
1262468|NCT00909584|Telintra
1262469|NCT00909584|ezatiostat hydrochloride
1262470|NCT00909584|ezatiostat
1262471|NCT00909584|TLK199
1262472|NCT00909584|Glutathione
1262473|NCT00909584|Glutathione analog
1262474|NCT00909584|Glutathione Transferase
1262475|NCT00909584|Glutathione Transferase inhibitor
1262476|NCT00909584|Glutathione Transferase P1-1 inhibitor
1262477|NCT00909584|GSTp1-1 inhibitor
1262478|NCT00909584|Apoptosis
1262479|NCT00909584|Differentiation
1262480|NCT00909584|Enzyme inhibitor
1262481|NCT00909571|FK506E
1262482|NCT00909571|MR4
1262483|NCT00909571|Prograf
1262484|NCT00909571|Tacrolimus
1262485|NCT00909571|Living Liver Transplantation
1262486|NCT00909558|metastatic malignancies
1262487|NCT00909558|tumor markers
1262488|NCT00909558|chemotherapy
1262489|NCT00909558|cancer
1262490|NCT00909558|breast cancer
1262491|NCT00909558|glioma
1262492|NCT00909558|hepatocellular cancer
1262493|NCT00909558|squamous cell lung cancer
1262494|NCT00909558|pancreatic cancer
1262495|NCT00909558|colon cancer
1262496|NCT00909558|prostate cancer
1262497|NCT00909545|Early Parkinson disease
1262498|NCT00909532|Fibrosis
1262499|NCT00909532|Pancreatic Diseases
1262500|NCT00909532|Lung Diseases
1262501|NCT00909532|Respiratory Tract Diseases
1262502|NCT00909532|Genetic Diseases, Inborn
1262503|NCT00909532|Infant, Newborn, Diseases
1262504|NCT00909532|Pathologic Processes
1262505|NCT00909493|Improvement of patient care as measured by self-rated health and improve physician satisfaction with chronic pain management
1262506|NCT00909454|Vitamin D deficiency
1262507|NCT00909454|Adolescents
1262508|NCT00909454|African Americans
1262509|NCT00909454|Overweight
1262510|NCT00909454|Obesity
1262511|NCT00909441|Breast Cancer
1262512|NCT00909441|Node Positive Breast Cancer
1262513|NCT00909441|Sentinel Lymph Node Biopsy
1262514|NCT00909441|Breast Surgery
1262515|NCT00909441|Axillary Lymph Node Dissection
1262516|NCT00909441|Neoadjuvant Chemotherapy
1262517|NCT00909428|Bladder
1262518|NCT00909428|Urinary Urgency
1262519|NCT00909428|Solifenacin
1262520|NCT00909428|Vesicare(R)
1262521|NCT00909415|patients with anorectal malformation
1262522|NCT00909376|Pregnancy
1262523|NCT00909376|Ultrasonography
1262524|NCT00909376|outcome
1262525|NCT00909376|adverse
1262526|NCT00909350|Barrett's esophagus
1262527|NCT00909350|BE
1262528|NCT00909350|esophageal adenocarcinoma
1262529|NCT00909350|Micro-RNA
1262530|NCT00909350|miR expression
1262531|NCT00909324|Post LASIK dry eye
1262532|NCT00909324|Pre LASIK dry eye
1262533|NCT00909324|Hypromellose
1262534|NCT00909311|Food effect
1262535|NCT00909298|Left ventricular assist devices
1262536|NCT00909298|Cardiac Disease
1262537|NCT00909298|Heart Failure
1262538|NCT00909298|Anticoagulant for Left Ventricular Assist Devices
1262539|NCT00909285|Alzheimer
1262540|NCT00909285|TMS
1262541|NCT00909285|cognitive training
1262542|NCT00909272|ultrasound
1262543|NCT00909272|diagnostic
1262544|NCT00909272|lumbar
1262545|NCT00909272|median branch
1262546|NCT00909272|block
1262547|NCT00909272|Lumbar facet joint pain
1262548|NCT00909259|Sleep Disordered Breathing
1262549|NCT00909259|Periodic Breathing
1262550|NCT00909259|Cheyne-Stokes Respiration
1262551|NCT00909259|Sleep Apnea
1262552|NCT00909233|Erectile dysfunction,
1262553|NCT00909233|Phosphodiesterase Inhibitors
1262554|NCT00909220|Major Depressive Disorder
1262555|NCT00909207|Advanced Cancers
1262556|NCT00909207|Hematologic Disorders
1262557|NCT00909207|Solid Tumors
1262558|NCT00909207|Cognitive Interview
1262559|NCT00909207|Patient-Reported Outcomes
1262560|NCT00909207|PRO
1262561|NCT00909207|Common Terminology Criteria for Adverse Events
1262562|NCT00909207|CTCAE
1262563|NCT00909207|PRO-CTCAE
1262564|NCT00909207|Cancer Symptoms
1262565|NCT00909207|Interview
1262566|NCT00909194|Juvenile Primary Fibromyalgia
1262567|NCT00909194|Adolescents
1262568|NCT00909194|Psychiatry
1262569|NCT00909168|Induction chemotherapy
1262570|NCT00909168|Fludarabine
1262571|NCT00909168|Gemtuzumab Ozogamicin
1262572|NCT00909155|Major Depressive Disorder
1262573|NCT00909142|Breast cancer
1262574|NCT00909142|Prostate cancer
1262575|NCT00909142|Multiple myeloma
1262576|NCT00909129|HIV-1
1262577|NCT00909129|Chronic hepatitis C
1262578|NCT00909129|Immune activation
1262579|NCT00909129|HCV kinetics
1262580|NCT00909129|IP-10
1262581|NCT00909116|ODS
1262582|NCT00909116|chronic constipation
1262583|NCT00909116|internal rectal prolapse
1262584|NCT00909116|rectocele
1262585|NCT00909116|Stapled Transanal Rectal Resection
1262586|NCT00909116|Contour Transtar
1262587|NCT00909116|STARR
1262588|NCT00909103|Endoscopic Ultrasound Elastography
1262589|NCT00909103|Pancreatic adenocarcinoma
1262590|NCT00909103|Chronic Pancreatitis
1262591|NCT00909090|macular pigment
1262592|NCT00909090|glare disability
1262593|NCT00909090|lutein
1262594|NCT00909090|photostress
1262595|NCT00909077|ITP-Rituximab-dexamethasone
1262596|NCT00909051|Diabetes Mellitus
1262597|NCT00909012|phenylketonuria
1262598|NCT00909012|docosahexaenoic acid
1262599|NCT00909012|visually evoked potential
1262600|NCT00909012|choice-reaction time
1262601|NCT00908999|anosognosia fMRI amnestic MCI Alzheimer
1262602|NCT00908999|anosognosia in AD and MCI
1262603|NCT00908986|Lupus Membranous Nephritis
1262604|NCT00908973|Obesity
1262605|NCT00908973|Gastric bypass
1262606|NCT00908973|Gut hormone
1262607|NCT00908973|Intestinal transit time
1262608|NCT00908960|enoxaparin
1262609|NCT00908947|SFA
1262610|NCT00908947|Stent
1262611|NCT00908947|Popliteal
1262612|NCT00908947|infrainguinal
1262613|NCT00908947|LifeStent
1262614|NCT00908947|Peripheral
1262615|NCT00908947|Arterial
1262616|NCT00908934|Relative Bioavailability
1262617|NCT00908934|AZD9056
1262618|NCT00908908|Advanced Solid Tumors
1262619|NCT00908908|Failure of Multiple Prior Chemotherapy Regimens
1262620|NCT00908895|Radius fractures
1262621|NCT00908895|Radio-radial fixator
1262622|NCT00908895|Percutaneous pinning
1262623|NCT00908895|Grip strength
1262624|NCT00908882|Nursing Care
1262625|NCT00908882|Veterans
1262626|NCT00908869|advanced neoplasm
1262627|NCT00908869|adult advanced neoplasm
1262628|NCT00908856|stroke cell therapy repair autologous
1262629|NCT00908843|Contrast nephropathy
1262630|NCT00908843|Renal failure
1262631|NCT00908817|postoperative sore throat
1262632|NCT00908817|tracheal intubation
1262633|NCT00908817|lubrication
1262634|NCT00908817|triamcinolone
1262635|NCT00908804|acute appendicitis
1262636|NCT00908791|Conjugated Linoleic Acid
1262637|NCT00908791|Proof of Principle
1262638|NCT00908791|Lipogenic Pathway
1262639|NCT00908791|Clarinol
1262640|NCT00908778|Diabetic Retinopathy
1262641|NCT00908765|Exercise Training COPD
1262642|NCT00908752|HCC
1262643|NCT00908739|stage I renal cell cancer
1262644|NCT00908739|stage III renal cell cancer
1262645|NCT00908739|recurrent renal cell cancer
1262646|NCT00908739|clear cell renal cell carcinoma
1262647|NCT00908739|childhood renal cell carcinoma
1262648|NCT00908713|Severe CAP
1262649|NCT00908713|Adjuvant therapy
1262650|NCT00908713|Glucocorticoids
1262651|NCT00908713|CAP Fine V with C-reactive protein >= 15 mg/100 mL
1262652|NCT00908700|Atrial fibrillation
1262653|NCT00908700|Stroke
1262654|NCT00908700|left atrial appendage
1262655|NCT00908700|Re-exploration for bleeding
1262656|NCT00908661|Parastomal, hernia
1262657|NCT00908648|screening colonoscopy
1262658|NCT00908648|narrow band imaging
1262659|NCT00908635|sepsis
1262660|NCT00908635|organ failure
1262661|NCT00908622|Percutaneous implantation of autologous myoblasts
1262662|NCT00908609|Breast Cancer Diagnosis
1262663|NCT00908609|Optical Imaging
1262664|NCT00908609|Ultrasound Imaging
1262665|NCT00908609|Monitoring Neoadjuvant Chemotherapy Response
1262666|NCT00908596|Nephrogenic Systemic Fibrosis (NSF)
1262667|NCT00908596|Primovist / Eovist
1262668|NCT00908583|Alloantibody
1262669|NCT00908583|Desensitization
1262670|NCT00908583|Kidney Transplantation
1262671|NCT00908583|Nephrology
1262672|NCT00908583|Plasma Cells
1262673|NCT00908583|Translational Research/Science
1262674|NCT00908570|estrogen
1262675|NCT00908570|estriol
1262676|NCT00908570|cream
1262677|NCT00908570|vagina
1262678|NCT00908570|infection prevention
1262679|NCT00908557|Lexicosyntactic readability improvement
1262680|NCT00908557|phase II/III trials
1262681|NCT00908557|ethic
1262682|NCT00908557|Informed consent
1262683|NCT00908544|HIV-infection
1262684|NCT00908544|Primary HIV-infection
1262685|NCT00908544|Proviral DNA
1262686|NCT00908544|Eradication
1262687|NCT00908544|Multi drug class HAART
1262688|NCT00908531|Breast neoplasms
1262689|NCT00908531|Randomised trial
1262690|NCT00908531|Aromatase Inhibitors
1262691|NCT00908531|Preoperative care
1262692|NCT00908531|Age 60 or older
1262693|NCT00908531|Hormone receptor positive tumor
1262694|NCT00908531|Tumor lager than 2 cm
1262695|NCT00908531|No distant metastasis
1262696|NCT00908518|Cognitive dysfunction
1262697|NCT00908518|Cardiac morbidity
1262698|NCT00908518|anesthesia
1262699|NCT00908505|Cystic fibrosis
1262700|NCT00908505|physiotherapy
1262701|NCT00908505|pulmonary function test
1262702|NCT00908492|Randomized control trial
1262703|NCT00908492|Dementia caregivers
1262704|NCT00908492|Occupational Therapy
1262705|NCT00908492|Caregivers
1262706|NCT00908479|Exercise
1262707|NCT00908479|Rehabilitation
1262708|NCT00908479|leg function
1262709|NCT00908479|in patient
1262710|NCT00908479|RCT
1262711|NCT00908466|Non-infectious
1262712|NCT00908466|Uveitis
1262713|NCT00908466|Panuveitis
1262714|NCT00908453|NPC-06
1262715|NCT00908453|fosphenytoin
1262716|NCT00908453|phenytoin
1262717|NCT00908453|pharmacokinetics
1262718|NCT00908453|safety
1262719|NCT00908440|Decision Aid
1262720|NCT00908440|Posttraumatic Stress Disorder
1262721|NCT00908440|evidence-based treatments
1262722|NCT00908427|benign prostatic hyperplasia
1262723|NCT00908427|KTP laser
1262724|NCT00908427|transurethral resection of prostate
1262725|NCT00908427|urinary bladder neck obstruction
1262726|NCT00908414|PEPI-TiDP23-C104
1262727|NCT00908414|PEPI-C104
1262728|NCT00908414|PEPI
1262729|NCT00908414|TMC589337
1262730|NCT00908414|TMC589354
1262731|NCT00908414|TMC310911
1262732|NCT00908414|Healthy Volunteers
1262733|NCT00908401|breastmilk
1262734|NCT00908401|oral sucrose
1262735|NCT00908401|analgesia
1262736|NCT00908401|preterm neonates
1262737|NCT00908401|Neonates
1262738|NCT00908388|Acute, Complicated Type B Dissection
1262739|NCT00908375|Pregabalin
1262740|NCT00908375|Radicular pain
1262741|NCT00908375|Failed back surgery
1262742|NCT00908375|Of greater than 3 months duration
1262743|NCT00908362|Dendritic cells
1262744|NCT00908362|Airway
1262745|NCT00908362|Smoker
1262746|NCT00908362|COPD
1262747|NCT00908336|Adenocarcinoma
1262748|NCT00908336|Carcinoma, Non-Small Cell
1262749|NCT00908336|Lung Neoplasms
1262750|NCT00908336|Docetaxel
1262751|NCT00908336|Erlotinib
1262752|NCT00908336|Chemotherapy
1262753|NCT00908323|HIV Seronegativity
1262754|NCT00908323|HIV Preventive Vaccine
1262755|NCT00908310|CKD - Chronic Kidney Disease
1262756|NCT00908310|GBCA - Gadolinium-based contrast agent
1262757|NCT00908310|GFR - Glomerular Filtration Rate
1262758|NCT00908310|MRI - Magnetic Resonance Imaging
1262759|NCT00908310|NSF - Nephrogenic Systemic Fibrosis
1262760|NCT00908310|Known or suspected CKD with an eGFR greater than or equal to 30mL & less than 60 mL/min/1.73m2 as measured within 30 days prior to the OMNISCAN.
1262761|NCT00908297|Cardiovascular disease
1262762|NCT00908297|End stage renal disease
1262763|NCT00908297|Atherosclerosis
1262764|NCT00908297|Oxidative stress
1262765|NCT00908297|Antioxidants
1262766|NCT00908284|AIDS
1262767|NCT00908284|Acquired Immune Deficiency Syndrome Virus
1262768|NCT00908284|Human Immunodeficiency Virus
1262769|NCT00908284|Exercise Physiology
1262770|NCT00908284|Endothelial Dysfunction
1262771|NCT00908245|Preconditioning
1262772|NCT00908245|Hepatectomy
1262773|NCT00908245|Clamping
1262774|NCT00908232|multiple myeloma
1262775|NCT00908232|bortezomib
1262776|NCT00908232|hematology
1262777|NCT00908232|bone marrow cancer
1262778|NCT00908232|immunoglobulin
1262779|NCT00908232|refractory
1262780|NCT00908232|progression
1262781|NCT00908232|dexamethasone
1262782|NCT00908232|lenalidomide
1262783|NCT00908232|cyclophosphamide
1262784|NCT00908219|malignant ascites
1262785|NCT00908219|bevacizumab
1262786|NCT00908219|vascular endothelial growth factor (VEGF)
1262787|NCT00908219|paracentesis
1262788|NCT00908206|Alcoholism
1262789|NCT00908206|Craving
1262790|NCT00908206|Dependence
1262791|NCT00908206|Alcohol
1262792|NCT00908193|Treatment of abdominal ruptured
1262793|NCT00908193|Digestive system disease
1262794|NCT00908193|Coelioscopy
1262795|NCT00908193|Assistance robotics
1262796|NCT00908193|Medical device
1262797|NCT00908193|DA VINCI Robot
1262798|NCT00908193|Pain patient
1262799|NCT00908193|Morphine consumption
1262800|NCT00908193|Comparative Randomized study
1262801|NCT00908193|patient over 18 years
1262802|NCT00908193|with ruptured abdominal
1262803|NCT00908193|with an indication of treatment of ruptured
1262804|NCT00908180|recurrent adult Hodgkin lymphoma
1262805|NCT00908167|sorafenib
1262806|NCT00908167|cytarabine
1262807|NCT00908167|clofarabine
1262808|NCT00908167|acute myeloid leukemia
1262809|NCT00908167|acute promyelocytic leukemia
1262810|NCT00908167|acute lymphoblastic leukemia
1262811|NCT00908154|sodium channel blocker
1262812|NCT00908154|bipolar disorder
1262813|NCT00908154|repeat dose
1262814|NCT00908141|adenocarcinoma of the prostate
1262815|NCT00908141|recurrent prostate cancer
1262816|NCT00908128|Bioequivalence
1262817|NCT00908128|Healthy Subjects
1262818|NCT00908102|low back pain
1262819|NCT00908102|recurrent
1262820|NCT00908102|subacute
1262821|NCT00908102|secondary prevention
1262822|NCT00908102|primary care
1262823|NCT00908102|occupational health
1262824|NCT00908102|back book
1262825|NCT00908102|rehabilitation
1262826|NCT00908089|rheumatoid arthritis
1262827|NCT00908089|methotrexate
1262828|NCT00908089|sulfasalazine
1262829|NCT00908089|hydroxychloroquine
1262830|NCT00908089|infliximab
1262831|NCT00908076|constipation
1262832|NCT00908076|Parkinson's disease
1262833|NCT00908063|TBI
1262834|NCT00908063|Traumatic Brain Injury
1262835|NCT00908050|bruxism, botulinum toxin, sleep study
1262836|NCT00908037|idiopathic thrombocytopenic purpura
1262837|NCT00908037|ITP
1262838|NCT00908037|pharmacokinetics
1262839|NCT00908037|chronic ITP
1262840|NCT00908037|eltrombopag
1262841|NCT00908037|thrombocytopenia
1262842|NCT00908037|pharmacodynamics
1262843|NCT00908037|pediatrics
1262844|NCT00908011|Hypercholesterolemia
1262845|NCT00908011|HIV
1262846|NCT00908011|Ezetimibe
1262847|NCT00908011|Statin
1262848|NCT00908011|Apolipoprotein B100/Apolipoprotein A1 ratio
1262849|NCT00907998|Coronary heart disease
1262850|NCT00907998|APL180
1262851|NCT00907985|Healthy Volunteer
1262852|NCT00907985|Resting motor threshold (rMT)
1262853|NCT00907985|Transcranial magnetic stimulation (TMS)
1262854|NCT00907972|Parkinson's Disease
1262855|NCT00907972|Parkinson Disease
1262856|NCT00907972|PD
1262857|NCT00907972|Movement Disorder
1262858|NCT00907946|Renal stones
1262859|NCT00907907|Bioequivalence
1262860|NCT00907907|Subjects
1262861|NCT00907894|Chronic hepatitis B,
1262862|NCT00907894|telbivudine,
1262863|NCT00907894|pharmacokinetics,
1262864|NCT00907894|safety,
1262865|NCT00907894|tolerability,
1262866|NCT00907894|pediatric
1262867|NCT00907868|ductal breast carcinoma in situ
1262868|NCT00907855|Ischemic Heart Disease
1262869|NCT00907855|Duke Activity Status Index
1262870|NCT00907855|Stress Myocardial Perfusion Imaging
1262871|NCT00907842|stoma
1262872|NCT00907829|stroke
1262873|NCT00907829|fingertip force
1262874|NCT00907829|muscle coordination
1262875|NCT00907816|this study does not look at patient conditions
1262876|NCT00907803|Orthopoxvirus
1262877|NCT00907803|Smallpox
1262878|NCT00907803|This is a safety study only
1262879|NCT00907803|ST-246 is being studied for treatment of Orthopoxviruses
1262880|NCT00907790|Irritable Bowel Syndrome
1262881|NCT00907790|Cognitive Therapy
1262882|NCT00907790|Abdominal Pain
1262883|NCT00907790|Quality of Life
1262884|NCT00907777|Haemophilus influenzae
1262885|NCT00907777|Streptococcus pneumoniae
1262886|NCT00907777|safety
1262887|NCT00907777|Pneumococcal conjugate vaccine
1262888|NCT00907777|immunogenicity
1262889|NCT00907725|medical abortion
1262890|NCT00907725|serum BhCG follow-up
1262891|NCT00907725|ultrasonographic follow-up
1262892|NCT00907725|follow-up methods
1262893|NCT00907712|amputation
1262894|NCT00907712|vascular
1262895|NCT00907712|below knee
1262896|NCT00907712|above knee
1262897|NCT00907712|cardiovascular
1262898|NCT00907712|echo
1262899|NCT00907712|cardiovascular assessment
1262900|NCT00907699|recurrent non-small cell lung cancer
1262901|NCT00907699|stage IIIB non-small cell lung cancer
1262902|NCT00907699|stage IV non-small cell lung cancer
1262903|NCT00907686|Transfusion Transmitted Cytomegalovirus (TT-CMV)
1262904|NCT00907686|Low birthweight infants (LBWIs)
1262905|NCT00907686|Leukoreduction and filter failure
1262906|NCT00907686|CMV Seronegative blood products
1262907|NCT00907660|Obesity
1262908|NCT00907660|Weight loss
1262909|NCT00907660|Meal replacements
1262910|NCT00907660|Health services research
1262911|NCT00907634|cervix
1262912|NCT00907634|cervical
1262913|NCT00907634|radiation
1262914|NCT00907621|Infant Colic
1262915|NCT00907621|Acupuncture
1262916|NCT00907621|General Practice
1262917|NCT00907595|Huntington's chorea
1262918|NCT00907595|Huntington's Disease
1262919|NCT00907595|Parkinson's Disease
1262920|NCT00907595|Parkinsonism
1262921|NCT00907595|Dementia
1262922|NCT00907595|Dementia with Lewy Bodies
1262923|NCT00907595|Actigraphy
1262924|NCT00907595|Circadian dysregulation
1262925|NCT00907595|Sleep Disorders
1262926|NCT00907595|Circadian rhythm
1262927|NCT00907582|PCR negative
1262928|NCT00907569|Small cell lung cancer
1262929|NCT00907569|radiotherapy dose escalation
1262930|NCT00907543|esophageal carcinoma
1262931|NCT00907543|chemotherapy
1262932|NCT00907543|radiation
1262933|NCT00907543|surgery
1262934|NCT00907543|randomized clinical trial
1262935|NCT00907543|Clinical Trial
1262936|NCT00907543|Radiotherapy
1262937|NCT00907491|Cough
1262938|NCT00907491|Wheeze Rate
1262939|NCT00907491|Respiratory Function Tests
1262940|NCT00907478|Idiopathic Thrombocytopenic Purpura
1262941|NCT00907478|Idiopathic Thrombocytopenia Purpura
1262942|NCT00907478|Immune Thrombocytopenic Purpura
1262943|NCT00907478|Immune Thrombocytopenia
1262944|NCT00907478|ITP
1262945|NCT00907452|Pharmacogenomics
1262946|NCT00907452|prediction response
1262947|NCT00907452|prediction adverse event
1262948|NCT00907439|Diastole, physiopathology
1262949|NCT00907439|coronary artery disease
1262950|NCT00907439|volatile anesthetic
1262951|NCT00907439|sevoflurane
1262952|NCT00907426|eyelashes
1262953|NCT00907413|cancer
1262954|NCT00907413|bile duct
1262955|NCT00907400|Phase 1
1262956|NCT00907400|Healthy Volunteer
1262957|NCT00907400|Healthy Volunteer Study
1262958|NCT00907387|Lateral Canthal Lines
1262959|NCT00907387|Crow's Feet
1262960|NCT00907387|Facial Wrinkles
1262961|NCT00907374|Microalbuminuria
1262962|NCT00907374|Carotid intima media thickness
1262963|NCT00907374|Endothelial dysfunction
1262964|NCT00907374|Renin angiotensin system
1262965|NCT00907374|Diabetic nephropathy
1262966|NCT00907361|pacemaker
1262967|NCT00907361|ICD
1262968|NCT00907361|Implantable Cardioverter Defibrillator
1262969|NCT00907361|MRI
1262970|NCT00907361|Magnetic Resonance Imaging
1262971|NCT00907348|NHL
1262972|NCT00907348|Non Hodgkin Lymphoma
1262973|NCT00907348|Follicular Lymphoma
1262974|NCT00907335|acne
1262975|NCT00907335|irritation
1262976|NCT00907335|objective sensory methods
1262977|NCT00907322|oral, single ascending doses; CYP2D6 metabolizer status; healthy subjects; safety, tolerability, pharmacokinetics
1262978|NCT00907309|alcohol abuse
1262979|NCT00907309|marijuana abuse
1262980|NCT00907309|drug abuse
1262981|NCT00907309|tobacco use
1262982|NCT00907309|tobacco dependence
1262983|NCT00907296|Fracture Healing
1262984|NCT00907296|Tibial Diaphyseal Fracture
1262985|NCT00907283|NBIA
1262986|NCT00907283|Iron overload AND brain
1262987|NCT00907283|Iron chelation AND neurodegeneration
1262988|NCT00907283|Brain iron Overload
1262989|NCT00907283|Neurodegeneration
1262990|NCT00907283|Brain iron Accumulation
1262991|NCT00907257|acne
1262992|NCT00907257|irritation
1262993|NCT00907257|objective sensory methods
1262994|NCT00907218|ADHD
1262995|NCT00907218|Attention Deficit Hyperactivity Disorder
1262996|NCT00907218|ADHD medication
1262997|NCT00907218|Chantix
1262998|NCT00907218|varenicline
1262999|NCT00907218|smoking
1263000|NCT00907218|smoking cessation
1263001|NCT00907218|quit smoking
1263002|NCT00907205|Advanced Solid Tumors
1263003|NCT00907205|Metastatic Solid Tumors
1263004|NCT00907205|PI3K
1263005|NCT00907205|PI3K Inhibitors
1263006|NCT00907205|PI3 Kinase Inhibitors
1263007|NCT00907205|mTORC inhibitor
1263008|NCT00907205|mTORC1 inhibitor
1263009|NCT00907205|mTORC2 inhibitor
1263010|NCT00907205|vascular targeted
1263011|NCT00907205|conjugate
1263012|NCT00907192|Cancer
1263013|NCT00907192|Opioid analgesic prescriptions
1263014|NCT00907192|Narcotic pain drugs
1263015|NCT00907192|Self-report
1263016|NCT00907192|Questionnaire
1263017|NCT00907192|Interview
1263018|NCT00907192|Actual use
1263019|NCT00907192|Doctor-prescribed use
1263020|NCT00907192|Frequency of deviation
1263021|NCT00907166|Cornerstone Pharmaceuticals, Inc.
1263022|NCT00907166|CPI-613
1263023|NCT00907166|Altered Energy Metabolism Directed Compound
1263024|NCT00907166|Phase I
1263025|NCT00907166|Phase II
1263026|NCT00907166|Cancer
1263027|NCT00907166|Carcinoma of the Pancreas
1263028|NCT00907166|Pancreatic Cancer
1263029|NCT00907166|Pancreatic Carcinoma
1263030|NCT00907153|Polycystic Ovary Syndrome
1263031|NCT00907153|Vitamin D
1263032|NCT00907153|Insulin resistance
1263033|NCT00907153|Inflammation
1263034|NCT00907140|Cervical Cancer
1263035|NCT00907140|Positron Emission Tomography
1263036|NCT00907140|Fluorodeoxyglucose
1263037|NCT00907127|Metabolic
1263038|NCT00907127|Syndrome
1263039|NCT00907127|CAN
1263040|NCT00907114|proliferative diabetic retinopathy
1263041|NCT00907114|macular edema
1263042|NCT00907114|panphotocoagulation
1263043|NCT00907114|topic ketorolac
1263044|NCT00907114|efficacy
1263045|NCT00907114|treatment
1263046|NCT00907088|Iron depletion
1263047|NCT00907088|Children
1263048|NCT00907088|Educational intervention
1263049|NCT00907088|Office-based
1263050|NCT00907075|diabetes
1263051|NCT00907075|nutrition
1263052|NCT00907075|diet
1263053|NCT00907075|foods
1263054|NCT00907062|vitiligo
1263055|NCT00907062|leucoderma
1263056|NCT00907049|quality of sleep
1263057|NCT00907049|neck pain
1263058|NCT00907049|disability
1263059|NCT00907049|catastrophizing
1263060|NCT00907049|depression
1263061|NCT00907036|recurrent adult Hodgkin lymphoma
1263062|NCT00907023|solid organ transplant
1263063|NCT00907023|hospital discharge
1263064|NCT00907010|Ageing
1263065|NCT00907010|Sarcopenia
1263066|NCT00907010|Muscular contraction
1263067|NCT00906997|Colorectal cancer
1263068|NCT00906997|Screening
1263069|NCT00906997|Prevention
1263070|NCT00906997|Fecal occult blood test
1263071|NCT00906997|Colonoscopy
1263072|NCT00906997|Colorectal neoplasm
1263073|NCT00906997|Randomized clinical trial
1263074|NCT00906984|Hepatocellular carcinoma
1263075|NCT00906984|Liver cancer
1263076|NCT00906984|Primary liver cancer
1263077|NCT00906984|Unresectable liver cancer
1263078|NCT00906984|Unresectable hepatocellular carcinoma
1263079|NCT00906984|TheraSphere
1263080|NCT00906971|Physical Therapy
1263081|NCT00906971|Chronic Functional Constipation
1263082|NCT00906971|Children
1263083|NCT00906945|stem cell mobilization
1263084|NCT00906945|chemosensitization
1263085|NCT00906945|CXCR4
1263086|NCT00906945|SDF-1
1263087|NCT00906945|CXCL-12
1263088|NCT00906932|Fiberoptic intubation
1263089|NCT00906932|direct laryngoscopy
1263090|NCT00906932|Trachview
1263091|NCT00906932|Comparison of a fiberoptic intubating videoscope to direct laryngoscopy.
1263092|NCT00906919|self-efficacy
1263093|NCT00906919|health behavior
1263094|NCT00906919|patient education
1263095|NCT00906919|health education
1263096|NCT00906893|[18F]-FMISO uptake
1263097|NCT00906893|Glioblastoma
1263098|NCT00906893|Hypoxia
1263099|NCT00906893|tumours
1263100|NCT00906880|Human African Trypanosomiasis
1263101|NCT00906880|HAT
1263102|NCT00906880|sleeping sickness
1263103|NCT00906880|combination treatment
1263104|NCT00906880|nifurtimox
1263105|NCT00906880|eflornithine
1263106|NCT00906880|Human African Trypanosomiasis in the meningo-encephalitic phase (stage 2 HAT)
1263107|NCT00906867|Vocal cord dysfunction
1263108|NCT00906867|Laryngoscopy
1263109|NCT00906867|Methacholine challenge
1263110|NCT00906867|Pulmonary function testing
1263111|NCT00906854|urinary incontinence
1263112|NCT00906854|physical exercise
1263113|NCT00906841|Disseminated diffuse large B-cell lymphoma
1263114|NCT00906841|first line treatment
1263115|NCT00906841|R CHOP
1263116|NCT00906841|90Y-DOTA-hLL2
1263117|NCT00906841|Patients older than 60 years
1263118|NCT00906828|Levodopa/carbidopa infusion
1263119|NCT00906828|entacapone
1263120|NCT00906828|tolcapone
1263121|NCT00906828|efficacy
1263122|NCT00906828|pharmacokinetic
1263123|NCT00906828|pharmacodynamics
1263124|NCT00906802|pancreaticoduodenectomy
1263125|NCT00906802|reconstruction
1263126|NCT00906789|Lung Cancer
1263127|NCT00906789|Chest Radiograph
1263128|NCT00906789|Computer-aided Detection
1263129|NCT00906789|Image processing
1263130|NCT00906763|Parkinson's disease
1263131|NCT00906763|Neurodegenerative Disorders
1263132|NCT00906763|Biogenic amines
1263133|NCT00906763|Chocolate
1263134|NCT00906763|Cocoa
1263135|NCT00906750|FLuMIST
1263136|NCT00906750|Inactivated influenza vaccine
1263137|NCT00906750|Study of FluMist versus inactivated influenza vaccine in children with cancer
1263138|NCT00906737|Multiple Sclerosis
1263139|NCT00906737|Gait
1263140|NCT00906737|foot-drop
1263141|NCT00906737|Ankle-Bot
1263142|NCT00906737|Physical Therapy
1263143|NCT00906737|Gait Abnormalities
1263144|NCT00906711|Aging
1263145|NCT00906711|Postural Balance
1263146|NCT00906685|CRVO
1263147|NCT00906685|anti-VEGF
1263148|NCT00906685|Macular edema
1263149|NCT00906672|Dermal substitute Integra®
1263150|NCT00906672|Flap
1263151|NCT00906672|graft
1263152|NCT00906672|traumatic wound
1263153|NCT00906672|medico economic costs
1263154|NCT00906672|esthetical and functional scar results
1263155|NCT00906659|center point thickness
1263156|NCT00906659|diabetic retinopathy
1263157|NCT00906659|diabetic macular edema
1263158|NCT00906659|macular volume
1263159|NCT00906659|visual capacity
1263160|NCT00906659|visual function
1263161|NCT00906646|cardiac
1263162|NCT00906646|surgery
1263163|NCT00906646|metabolic
1263164|NCT00906646|supplements
1263165|NCT00906646|antioxidant
1263166|NCT00906633|antifungal therapies
1263167|NCT00906620|Data on student's healthy and at-risk lifestyles and their relation with health measured by well-being, depression and suicidality
1263168|NCT00906607|Urinary Incontinence
1263169|NCT00906581|Depression
1263170|NCT00906568|Cystic fibrosis
1263171|NCT00906568|Sensitization to Aspergillus
1263172|NCT00906568|Bronchial allergen challenge
1263173|NCT00906568|Induced Sputum
1263174|NCT00906568|Bronchial inflammation
1263175|NCT00906568|Small airways disease (SAD)
1263176|NCT00906542|acute stroke
1263177|NCT00906542|ischemic stroke
1263178|NCT00906542|pneumonia
1263179|NCT00906542|chest infection
1263180|NCT00906542|brain lesion
1263181|NCT00906542|lesion topology
1263182|NCT00906542|dysphagia
1263183|NCT00906542|sympathetic activation
1263184|NCT00906542|immunosuppression
1263185|NCT00906529|Type 2 Diabetes
1263186|NCT00906529|Inpatient
1263187|NCT00906529|Length of Stay
1263188|NCT00906529|Blood Glucose Control
1263189|NCT00906516|Recurrent Glioblastoma multiforme (GBM)
1263190|NCT00906516|Recurrent Brain Tumor
1263191|NCT00906516|Recurrent Brain Disease
1263192|NCT00906516|Neuradiab
1263193|NCT00906516|Avastin
1263194|NCT00906516|Bevacizumab
1263195|NCT00906503|pulmonary nodule
1263196|NCT00906490|Glucose Monitoring
1263197|NCT00906490|Accurate Blood Glucose Monitoring in critical care setting
1263198|NCT00906451|myocardial infarction
1263199|NCT00906451|inflammation
1263200|NCT00906451|endothelial dysfunction
1263201|NCT00906425|Dental Implant
1263202|NCT00906412|Essential Tremor
1263203|NCT00906399|interferon
1263204|NCT00906399|injectable
1263205|NCT00906399|MS
1263206|NCT00906399|SC
1263207|NCT00906399|PEGylated
1263208|NCT00906399|Interferon beta-1a
1263209|NCT00906399|relapsing
1263210|NCT00906399|PEG
1263211|NCT00906399|multiple sclerosis
1263212|NCT00906399|subcutaneous
1263213|NCT00906386|Varenicline
1263214|NCT00906373|Hepatocellular Carcinoma
1263215|NCT00906373|Liver Neoplasms
1263216|NCT00906373|Antibodies, Monoclonal
1263217|NCT00906347|Labor augmentation
1263218|NCT00906347|Oral misoprostol
1263219|NCT00906334|Myelodysplastic Syndrome
1263220|NCT00906334|Trisomy 8
1263221|NCT00906334|Intermediate-2 Risk Group
1263222|NCT00906334|High-Risk Group
1263223|NCT00906334|azacitidine
1263224|NCT00906334|azacytidine
1263225|NCT00906334|Vidaza
1263226|NCT00906334|decitabine
1263227|NCT00906334|Dacogen
1263228|NCT00906321|Web-Based Decision Support
1263229|NCT00906321|Breast Cancer Risk
1263230|NCT00906295|Hemoglobin
1263231|NCT00906295|Ambulation
1263232|NCT00906282|neoadjuvant NSCLC
1263233|NCT00906282|NSCLC
1263234|NCT00906282|pemetrexed
1263235|NCT00906269|impotence
1263236|NCT00906269|prostatic neoplasms
1263237|NCT00906269|hyperbaric oxygenation
1263238|NCT00906269|Phosphodiesterase Inhibitors
1263239|NCT00906256|Hepatitis C
1263240|NCT00906256|Pharmacokinetics
1263241|NCT00906256|AZD7295
1263242|NCT00906256|Healthy volunteers
1263243|NCT00906217|colonoscopy
1263244|NCT00906217|preparation
1263245|NCT00906217|safety
1263246|NCT00906217|elderly
1263247|NCT00906204|Renal transplantation
1263248|NCT00906204|Kidney transplantation
1263249|NCT00906178|HIV prevention
1263250|NCT00906178|technology
1263251|NCT00906178|adolescent
1263252|NCT00906178|developing countries
1263253|NCT00906152|quality of sleep
1263254|NCT00906152|low back pain
1263255|NCT00906152|disability
1263256|NCT00906152|catastrophizing
1263257|NCT00906152|depression
1263258|NCT00906139|Propofol
1263259|NCT00906139|Midazolam
1263260|NCT00906139|Cirrhosis
1263261|NCT00906139|Gastrointestinal endoscopy
1263262|NCT00906139|Complications
1263263|NCT00906139|Sedation
1263264|NCT00906126|oral misoprostol
1263265|NCT00906126|labor augmentation
1263266|NCT00906126|arrest of dilation
1263267|NCT00906126|nulliparous
1263268|NCT00906113|Retinoblastoma
1263269|NCT00906100|Biventricular ICD
1263270|NCT00906100|AV delay
1263271|NCT00906087|Myocilin gene
1263272|NCT00906087|Glaucoma
1263273|NCT00906087|dorzolamide and timolol combination eyedrop
1263274|NCT00906074|Surgical Wound Infection
1263275|NCT00906074|Surgical Site Infection
1263276|NCT00906074|Abdominal Surgery
1263277|NCT00906061|Carcinoma, Small Cell
1263278|NCT00906061|Lung Neoplasms
1263279|NCT00906061|Docetaxel
1263280|NCT00906061|Gemcitabine
1263281|NCT00906061|ECOG 2
1263282|NCT00906035|Peripheral Arterial Disease
1263283|NCT00906035|PAD
1263284|NCT00906035|Claudication
1263285|NCT00906035|Peripheral Vascular Disease
1263286|NCT00906022|Below the Knee
1263287|NCT00906022|Infrapopliteal arteries
1263288|NCT00906022|nitinol
1263289|NCT00906022|limb ischemia
1263290|NCT00906022|claudication
1263291|NCT00906022|self-expanding stent
1263292|NCT00906022|duplex
1263293|NCT00906022|angiography
1263294|NCT00905177|Atrial Fibrillation
1263295|NCT00905177|deep vein thrombosis
1263296|NCT00905177|anticoagulation
1263297|NCT00905177|warfarin
1263298|NCT00905177|coumadin
1263299|NCT00905164|Bioequivalence
1263300|NCT00905164|Healthy Subjects
1263301|NCT00905151|HIV positive
1263302|NCT00905151|AIDS
1263303|NCT00905151|antiretroviral
1263304|NCT00905151|Kidney disease
1263305|NCT00905151|Antiretroviral Therapy
1263306|NCT00905138|Safety
1263307|NCT00905138|Tolerability
1263308|NCT00905138|Pharmacokinetics
1263309|NCT00905125|influenza, trivalent, vaccine, pregnant women
1263310|NCT00905112|Pregnancy
1263311|NCT00905112|Pain
1263312|NCT00905112|Musculoskeletal manipulations
1263313|NCT00905112|Exercise
1263314|NCT00905086|cognitive/functional effects
1263315|NCT00905086|psychosocial effects of cancer and its treatment
1263316|NCT00905086|stage I breast cancer
1263317|NCT00905086|stage II breast cancer
1263318|NCT00905086|stage IIIA breast cancer
1263319|NCT00905086|stage IIIB breast cancer
1263320|NCT00905086|stage IIIC breast cancer
1263321|NCT00905086|stage I colon cancer
1263322|NCT00905086|stage II colon cancer
1263323|NCT00905086|stage III colon cancer
1263324|NCT00905086|stage I rectal cancer
1263325|NCT00905086|stage II rectal cancer
1263326|NCT00905086|stage III rectal cancer
1263327|NCT00905086|stage I non-small cell lung cancer
1263328|NCT00905086|stage II non-small cell lung cancer
1263329|NCT00905086|stage IIIA non-small cell lung cancer
1263330|NCT00905086|stage IIIB non-small cell lung cancer
1263331|NCT00905086|stage I prostate cancer
1263332|NCT00905086|stage II prostate cancer
1263333|NCT00905086|stage III prostate cancer
1263334|NCT00905086|extensive stage small cell lung cancer
1263335|NCT00905086|limited stage small cell lung cancer
1263336|NCT00905073|type 1 diabetes mellitus
1263337|NCT00905073|cyclosporin
1263338|NCT00905073|methotrexate
1263339|NCT00905073|renal function
1263340|NCT00905060|Newly Diagnosed Glioblastoma Multiforme, vaccine
1263341|NCT00905047|colo-rectal cancer
1263342|NCT00905047|advanced
1263343|NCT00905047|metastatic
1263344|NCT00905047|locally advanced or metastatic colo-rectal cancer
1263345|NCT00905034|Acute lymphoblastic leukemia
1263346|NCT00905034|ALL
1263347|NCT00905034|Leukemia
1263348|NCT00905034|Methotrexate
1263349|NCT00905034|Vincristine
1263350|NCT00905034|PEG-l-asparaginase
1263351|NCT00905034|PEG asparaginase
1263352|NCT00905034|Pegaspargase
1263353|NCT00905034|Oncaspar
1263354|NCT00905034|Polyethylene Glycol Conjugated Lasparaginase-H
1263355|NCT00905034|Dexamethasone
1263356|NCT00905034|Decadron
1263357|NCT00905034|Rituximab
1263358|NCT00905034|Rituxan
1263359|NCT00905021|Breast Cancer
1263360|NCT00905021|Metastatic
1263361|NCT00905021|Hormone Receptor Positive
1263362|NCT00905008|drug-eluting stent
1263363|NCT00905008|bare-metal stent
1263364|NCT00905008|long-term safety
1263365|NCT00905008|mortality
1263366|NCT00905008|stent thrombosis
1263367|NCT00905008|Angioplasty
1263368|NCT00905008|Transluminal
1263369|NCT00905008|Percutaneous Coronary
1263370|NCT00904995|Leukemia
1263371|NCT00904995|Cancer of the blood
1263372|NCT00904995|Cancer of the bone marrow
1263373|NCT00904995|Hematologic malignancy
1263374|NCT00904995|Invasive fungal infection
1263375|NCT00904995|Voriconazole
1263376|NCT00904995|Vfend
1263377|NCT00904995|antifungal prophylaxis
1263378|NCT00904982|warfarin
1263379|NCT00904982|coumadin
1263380|NCT00904982|adherence
1263381|NCT00904982|mechanical heart valves
1263382|NCT00904969|Urinary Incontinence, Stress
1263383|NCT00904969|Intrinsic sphincter deficiency
1263384|NCT00904969|Secondary
1263385|NCT00904969|TUR
1263386|NCT00904969|TURP
1263387|NCT00904969|Radical prostatectomy
1263388|NCT00904969|Open prostatectomy
1263389|NCT00904969|Post-suprapubic prostatectomy
1263390|NCT00905983|Carcinoma, Non-Small-Cell
1263391|NCT00905983|Elderly patients
1263392|NCT00905983|Docetaxel
1263393|NCT00905983|Gemcitabine
1263394|NCT00905957|transversus abdominis plane block
1263395|NCT00905957|relief
1263396|NCT00905944|Left ventricular failure
1263397|NCT00905944|chronic heart failure
1263398|NCT00905944|Pacemaker
1263399|NCT00905944|Resynchronisation therapy
1263400|NCT00905944|Exercise
1263401|NCT00905944|Endurance exercise
1263402|NCT00905931|Aneurysmal subarachnoid hemorrhage (aSAH)
1263403|NCT00905931|Cerebral vasospasm
1263404|NCT00905931|impaired cerebral autoregulation
1263405|NCT00905931|transient hyperaemic response test
1263406|NCT00905931|delayed ischaemic neurological deficits
1263407|NCT00905918|colon cancer
1263408|NCT00905918|rectal cancer
1263409|NCT00905905|myocardial infarction
1263410|NCT00905905|systemic inflammatory activity
1263411|NCT00905905|endothelial function
1263412|NCT00905892|overfeeding
1263413|NCT00905892|stable isotopes
1263414|NCT00905892|lipoprotein metabolism
1263415|NCT00905892|lipid oxidation
1263416|NCT00905892|fat distribution
1263417|NCT00905892|gene expression
1263418|NCT00905892|endotoxemia
1263419|NCT00905892|mass spectrometry/gas chromatography
1263420|NCT00905879|Magnetic Resonance Imaging (MRI)
1263421|NCT00905879|Observational study
1263422|NCT00905879|Gadobutrol
1263423|NCT00905866|Quality of life
1263424|NCT00905866|Hyperparathyroidism
1263425|NCT00905853|Ventricular Tachycardia
1263426|NCT00905853|Catheter Ablation
1263427|NCT00905853|ICD therapy
1263428|NCT00905853|Antiarrhythmic Drug Therapy
1263429|NCT00905853|Ischemic Heart Disease
1263430|NCT00905827|suicide
1263431|NCT00905827|assessment
1263432|NCT00905827|management
1263433|NCT00905827|Provider Training
1263434|NCT00905827|health services
1263435|NCT00905814|Bioequivalence
1263436|NCT00905801|Non small cell lung cancer
1263437|NCT00905801|NSCLC
1263438|NCT00905801|CTP
1263439|NCT00905801|Perfusion
1263440|NCT00905801|Imaging
1263441|NCT00905788|Embryo transfer
1263442|NCT00905788|IVF/ICSI
1263443|NCT00905788|Embryo expulsion
1263444|NCT00905775|Isoflurane;
1263445|NCT00905775|Propofol
1263446|NCT00905775|Renal functions tests
1263447|NCT00905775|Cardiovascular tests
1263448|NCT00905775|revascularization surgery of the myocardium
1263449|NCT00905775|extracorporeal circulation
1263450|NCT00905762|pharmacokinetics
1263451|NCT00905736|tendon
1263452|NCT00905736|healing
1263453|NCT00905736|microcurrent
1263454|NCT00905736|chronic tennis elbow
1263455|NCT00905723|climacterium
1263456|NCT00905723|sexual life
1263457|NCT00905723|isoflavone
1263458|NCT00905723|estrogen
1263459|NCT00905723|McCoy's sexual questionnaire
1263460|NCT00905723|Kupperman index
1263461|NCT00905710|colorectal adenomas
1263462|NCT00905710|colorectal cancer
1263463|NCT00905710|Lynch syndrome
1263464|NCT00905710|chromoendoscopy
1263465|NCT00905697|Living donor lung transplantation
1263466|NCT00905697|Health-related quality of life
1263467|NCT00905697|Prognosis
1263468|NCT00905697|Patient reported outcome
1263469|NCT00905684|Compliance
1263470|NCT00905684|Hormonal Contraception
1263471|NCT00905671|Lipid Core Plaque
1263472|NCT00905671|LCP
1263473|NCT00905671|Bifurcation
1263474|NCT00905671|Stenosis
1263475|NCT00905671|Lesion
1263476|NCT00905671|Angioplasty
1263477|NCT00905658|stage IVA cervical cancer
1263478|NCT00905658|stage IVB cervical cancer
1263479|NCT00905658|fallopian tube cancer
1263480|NCT00905658|stage IV ovarian epithelial cancer
1263481|NCT00905658|stage IV ovarian germ cell tumor
1263482|NCT00905658|ovarian sarcoma
1263483|NCT00905658|ovarian stromal cancer
1263484|NCT00905658|stage IV endometrial carcinoma
1263485|NCT00905658|stage IV uterine sarcoma
1263486|NCT00905658|stage IVA vaginal cancer
1263487|NCT00905658|stage IVB vaginal cancer
1263488|NCT00905658|stage IV vulvar cancer
1263489|NCT00905645|Breast Augmentation
1263490|NCT00905645|Breast Reconstruction
1263491|NCT00905645|Breast Revision
1263492|NCT00905645|Silicone breast implants
1263493|NCT00905606|Bioequivalence
1263494|NCT00905606|Healthy Subjects
1263495|NCT00905593|chronic myeloid leukemia,
1263496|NCT00905593|blast crisis,
1263497|NCT00905593|accelerated phase,
1263498|NCT00905593|nilotinib,
1263499|NCT00905593|imatinib,
1263500|NCT00905593|resistant,
1263501|NCT00905593|intolerant,
1263502|NCT00905593|chronic phase
1263503|NCT00905580|thyroidectomy
1263504|NCT00905580|pain, postoperative
1263505|NCT00905580|pregabalin
1263506|NCT00905567|Bioequivalence
1263507|NCT00905567|Healthy Subjects
1263508|NCT00905554|sedation
1263509|NCT00905554|warm water
1263510|NCT00905528|type 2 diabetes mellitus
1263511|NCT00905528|endothelial function
1263512|NCT00905528|renal hemodynamics
1263513|NCT00905515|Kidney Transplantation
1263514|NCT00905515|Immunosuppressive Agents
1263515|NCT00905502|Obesity
1263516|NCT00905502|fluid management
1263517|NCT00905502|postoperative complications
1263518|NCT00905502|bariatric surgery
1263519|NCT00905502|hemostasis
1263520|NCT00905476|NPPV
1263521|NCT00905476|Prognosis
1263522|NCT00905476|Health-related quality of life
1263523|NCT00905476|Patient reported outcomes
1263524|NCT00905463|Lung transplant candidates
1263525|NCT00905463|Health-related quality of life
1263526|NCT00905463|patient reported outcome
1263527|NCT00905463|Prognosis
1263528|NCT00905450|Surgery
1263529|NCT00905437|perioperative
1263530|NCT00905437|pregabalin
1263531|NCT00905437|total hip replacement
1263532|NCT00905437|post-operative pain
1263533|NCT00905411|Overweight
1263534|NCT00905411|blood pressure
1263535|NCT00905411|DASH diet
1263536|NCT00905411|Pacific
1263537|NCT00905411|children
1263538|NCT00905398|Leukemia
1263539|NCT00905398|Lymphoblastic
1263540|NCT00905398|Acute
1263541|NCT00905398|Philadelphia
1263542|NCT00905398|BCR-ABL
1263543|NCT00905398|Nilotinib
1263544|NCT00905398|Treatment
1263545|NCT00905385|nontypeable Haemophilus influenzae, NTHi
1263546|NCT00905346|Bioequivalence
1263547|NCT00905346|Healthy Subjects
1263548|NCT00905333|pharmacokinetics
1263549|NCT00905333|candesartan
1263550|NCT00905333|felodipine
1263551|NCT00905333|test formulations
1263552|NCT00905333|Atacand®
1263553|NCT00905333|Splendil®
1263554|NCT00905333|healthy volunteers
1263555|NCT00905333|blood samples
1263556|NCT00905333|after meal intake interaction
1263557|NCT00905333|Kinetic interaction amongst test formulations of Candesartan and Felodipine and the brands Atacand® and Splendil® in healthy volunteers after a fasting period.
1263558|NCT00905320|Hernia repair
1263559|NCT00905307|Schizophrenia
1263560|NCT00905307|Relapsed
1263561|NCT00905281|Metastatic breast cancer
1263562|NCT00905281|Supportive care
1263563|NCT00905281|Third or fourth line of chemotherapy
1263564|NCT00905281|Quality of life
1263565|NCT00905281|Treatment preferences
1263566|NCT00905268|FRDA
1263567|NCT00905268|idebenone
1263568|NCT00905268|FRDA disease
1263569|NCT00905255|hyperglycemia
1263570|NCT00905255|GLP-1
1263571|NCT00905242|Kidney Transplantation
1263572|NCT00905242|Gastrointestinal Agents
1263573|NCT00905229|hip fracture
1263574|NCT00905229|warfarin
1263575|NCT00905229|vitamin k
1263576|NCT00905229|Phytonadione
1263577|NCT00905229|INR level
1263578|NCT00905216|heparin
1263579|NCT00905203|Postmenopausal women
1263580|NCT00905203|Diabetes
1263581|NCT00905203|Skin microcirculation
1263582|NCT00905203|Exercise capacity
1263583|NCT00905203|Skeletal muscle oxygenation
1263584|NCT00905203|Dose-response relationship
1263585|NCT00905203|postmenopausal diabetic women
1263586|NCT00904956|Latent Tuberculosis Infection
1263587|NCT00904956|High Resolution Scanners
1263588|NCT00904956|Dynamic Hypothesis of Latent Tuberculosis Infection
1263589|NCT00904943|Bioequivalence
1263590|NCT00904943|Healthy Subjects
1263591|NCT00904930|Tooth mobility assessment
1263592|NCT00904930|Splinting
1263593|NCT00904930|Splint Rigidity
1263594|NCT00904917|African American Mothers
1263595|NCT00904917|Children
1263596|NCT00904917|African American Families
1263597|NCT00904917|Parental Depression
1263598|NCT00904917|Preventive Intervention
1263599|NCT00904891|Adolescents
1263600|NCT00904891|Prevention
1263601|NCT00904891|Bibliotherapy
1263602|NCT00904878|pregnant IBD patients
1263603|NCT00904865|Single port access
1263604|NCT00904865|Laparoscopy
1263605|NCT00904865|cholecystectomy
1263606|NCT00904865|cholangiography
1263607|NCT00904865|cosmesis
1263608|NCT00904826|NMO
1263609|NCT00904826|Devic's disease
1263610|NCT00904826|Neuromyelitis optica
1263611|NCT00904826|NMO-IgG
1263612|NCT00904826|Aquaporin-4 antibody
1263613|NCT00904826|Eculizumab
1263614|NCT00904826|Complement
1263615|NCT00904813|Rectal cancer
1263616|NCT00904813|Preoperative radiotherapy
1263617|NCT00904813|Timing of Surgery
1263618|NCT00904813|Prognosis
1263619|NCT00904800|Phase I
1263620|NCT00904800|Healthy volunteers
1263621|NCT00904787|Leukemia
1263622|NCT00904787|Hematologic neoplasms
1263623|NCT00904774|bronchopulmonary dysplasia
1263624|NCT00904774|neonates
1263625|NCT00904774|lung development
1263626|NCT00904774|prematurity
1263627|NCT00904761|diabetes mellitus
1263628|NCT00904761|autonomic neuropathy
1263629|NCT00904761|exercise training
1263630|NCT00904761|exercise capacity
1263631|NCT00904761|heart rate variability
1263632|NCT00904748|Sildenafil
1263633|NCT00904748|Bio-equivalence
1263634|NCT00904735|adult grade I meningioma
1263635|NCT00904735|adult grade II meningioma
1263636|NCT00904735|adult anaplastic meningioma
1263637|NCT00904735|adult papillary meningioma
1263638|NCT00904735|recurrent adult brain tumor
1263639|NCT00904722|Follicular lymphoma
1263640|NCT00904722|Immunotherapy
1263641|NCT00904722|CT-011
1263642|NCT00904722|Monoclonal Antibody CT-011
1263643|NCT00904722|Rituximab
1263644|NCT00904722|Rituxan
1263645|NCT00904696|Irritable bowel syndrome
1263646|NCT00904696|probiotics
1263647|NCT00904670|Hyperactivity Attention Deficit Disorder
1263648|NCT00904670|ADHD
1263649|NCT00904670|Pediatric Patients
1263650|NCT00904670|Quillivant
1263651|NCT00904670|methylphenidate
1263652|NCT00904657|pharmacokinetic/pharmacodynamic modeling
1263653|NCT00904657|biomarkers (growth factors) as a possible tool of drug effect
1263654|NCT00904644|HIV
1263655|NCT00904644|antiretroviral treatment
1263656|NCT00904644|Swiss HIV Cohort Study
1263657|NCT00904644|drug resistance
1263658|NCT00904644|integrase inhibitor
1263659|NCT00904644|Treatment
1263660|NCT00904618|Suburethral slings
1263661|NCT00904618|Urethra
1263662|NCT00904618|Urinary incontinence
1263663|NCT00904618|Urinary stress incontinence
1263664|NCT00904592|diabetic retinopathy
1263665|NCT00904592|traditional chinese medicine
1263666|NCT00904579|Organ Transplants
1263667|NCT00904579|Immunosuppression
1263668|NCT00904579|Cancer
1263669|NCT00904579|End Stage Renal Disease
1263670|NCT00904579|ESRD
1263671|NCT00904579|Cancer Risk
1263672|NCT00904566|microarray
1263673|NCT00904566|gene expression profiling
1263674|NCT00904566|MammaPrint
1263675|NCT00904566|breast cancer
1263676|NCT00904553|Brain
1263677|NCT00904553|metastases
1263678|NCT00904527|Relaxation (Schultz)
1263679|NCT00904527|Migraine
1263680|NCT00904527|antipain center
1263681|NCT00904514|recurrent adult Hodgkin lymphoma
1263682|NCT00904514|stage IV cutaneous T-cell non-Hodgkin lymphoma
1263683|NCT00904514|recurrent cutaneous T-cell non-Hodgkin lymphoma
1263684|NCT00904514|Waldenström macroglobulinemia
1263685|NCT00904514|recurrent adult acute myeloid leukemia
1263686|NCT00904514|recurrent adult acute lymphoblastic leukemia
1263687|NCT00904514|relapsing chronic myelogenous leukemia
1263688|NCT00904514|refractory chronic lymphocytic leukemia
1263689|NCT00904514|refractory hairy cell leukemia
1263690|NCT00904514|recurrent small lymphocytic lymphoma
1263691|NCT00904514|recurrent grade 1 follicular lymphoma
1263692|NCT00904514|recurrent grade 2 follicular lymphoma
1263693|NCT00904514|recurrent grade 3 follicular lymphoma
1263694|NCT00904514|recurrent adult diffuse small cleaved cell lymphoma
1263695|NCT00904514|recurrent adult diffuse mixed cell lymphoma
1263696|NCT00904514|recurrent adult diffuse large cell lymphoma
1263697|NCT00904514|recurrent adult immunoblastic large cell lymphoma
1263698|NCT00904514|recurrent adult lymphoblastic lymphoma
1263699|NCT00904514|recurrent adult Burkitt lymphoma
1263700|NCT00904514|stage I adult T-cell leukemia/lymphoma
1263701|NCT00904514|stage II adult T-cell leukemia/lymphoma
1263702|NCT00904514|stage III adult T-cell leukemia/lymphoma
1263703|NCT00904514|stage IV adult T-cell leukemia/lymphoma
1263704|NCT00904514|recurrent adult T-cell leukemia/lymphoma
1263705|NCT00904514|prolymphocytic leukemia
1263706|NCT00904514|recurrent mantle cell lymphoma
1263707|NCT00904514|stage IV mycosis fungoides/Sezary syndrome
1263708|NCT00904514|recurrent mycosis fungoides/Sezary syndrome
1263709|NCT00904514|recurrent marginal zone lymphoma
1263710|NCT00904514|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1263711|NCT00904514|nodal marginal zone B-cell lymphoma
1263712|NCT00904514|splenic marginal zone lymphoma
1263713|NCT00904514|stage IV colon cancer
1263714|NCT00904514|stage IV breast cancer
1263715|NCT00904514|recurrent breast cancer
1263716|NCT00904514|stage IV gastric cancer
1263717|NCT00904514|recurrent gastric cancer
1263718|NCT00904514|recurrent non-small cell lung cancer
1263719|NCT00904514|recurrent pancreatic cancer
1263720|NCT00904514|recurrent colon cancer
1263721|NCT00904514|stage IV esophageal cancer
1263722|NCT00904514|recurrent esophageal cancer
1263723|NCT00904514|recurrent bladder cancer
1263724|NCT00904514|stage IV bladder cancer
1263725|NCT00904514|recurrent ovarian epithelial cancer
1263726|NCT00904514|epithelial mesothelioma
1263727|NCT00904514|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1263728|NCT00904514|recurrent salivary gland cancer
1263729|NCT00904514|recurrent squamous cell carcinoma of the nasopharynx
1263730|NCT00904514|stage III cervical cancer
1263731|NCT00904514|recurrent cervical cancer
1263732|NCT00904514|stage IVB cervical cancer
1263733|NCT00904514|stage IVA cervical cancer
1263734|NCT00904514|squamous cell lung cancer
1263735|NCT00904514|stage III ovarian epithelial cancer
1263736|NCT00904514|stage IV ovarian epithelial cancer
1263737|NCT00904514|advanced malignant mesothelioma
1263738|NCT00904514|recurrent malignant mesothelioma
1263739|NCT00904514|stage IIIA non-small cell lung cancer
1263740|NCT00904514|stage IIIB non-small cell lung cancer
1263741|NCT00904514|stage IV non-small cell lung cancer
1263742|NCT00904514|recurrent metastatic squamous neck cancer with occult primary
1263743|NCT00904514|ovarian undifferentiated adenocarcinoma
1263744|NCT00904514|ovarian mixed epithelial carcinoma
1263745|NCT00904514|ovarian serous cystadenocarcinoma
1263746|NCT00904514|ovarian endometrioid adenocarcinoma
1263747|NCT00904514|ovarian clear cell cystadenocarcinoma
1263748|NCT00904514|cervical squamous cell carcinoma
1263749|NCT00904514|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1263750|NCT00904514|stage III squamous cell carcinoma of the lip and oral cavity
1263751|NCT00904514|stage IV squamous cell carcinoma of the lip and oral cavity
1263752|NCT00904514|recurrent squamous cell carcinoma of the lip and oral cavity
1263753|NCT00904514|stage III squamous cell carcinoma of the oropharynx
1263754|NCT00904514|stage IV squamous cell carcinoma of the oropharynx
1263755|NCT00904514|recurrent squamous cell carcinoma of the oropharynx
1263756|NCT00904514|stage III squamous cell carcinoma of the nasopharynx
1263757|NCT00904514|stage IV squamous cell carcinoma of the nasopharynx
1263758|NCT00904514|stage III squamous cell carcinoma of the hypopharynx
1263759|NCT00904514|stage IV squamous cell carcinoma of the hypopharynx
1263760|NCT00904514|recurrent squamous cell carcinoma of the hypopharynx
1263761|NCT00904514|stage III squamous cell carcinoma of the larynx
1263762|NCT00904514|stage IV squamous cell carcinoma of the larynx
1263763|NCT00904514|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1263764|NCT00904514|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1263765|NCT00904514|fallopian tube cancer
1263766|NCT00904514|primary peritoneal cavity cancer
1263767|NCT00904514|ovarian carcinosarcoma
1263768|NCT00904514|Brenner tumor
1263769|NCT00904514|untreated metastatic squamous neck cancer with occult primary
1263770|NCT00904514|salivary gland squamous cell carcinoma
1263771|NCT00904514|stage III salivary gland cancer
1263772|NCT00904514|stage IV salivary gland cancer
1263773|NCT00904514|stage II pancreatic cancer
1263774|NCT00904514|stage III pancreatic cancer
1263775|NCT00904514|ovarian mucinous cystadenocarcinoma
1263776|NCT00904514|stage IV pancreatic cancer
1263777|NCT00904514|recurrent squamous cell carcinoma of the larynx
1263778|NCT00904514|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1263779|NCT00904514|adult acute myeloid leukemia with inv(16)(p13;q22)
1263780|NCT00904514|adult acute myeloid leukemia with t(15;17)(q22;q12)
1263781|NCT00904514|adult acute myeloid leukemia with t(16;16)(p13;q22)
1263782|NCT00904514|adult acute myeloid leukemia with t(8;21)(q22;q22)
1263783|NCT00904501|Limb ischemia
1263784|NCT00904501|Cell Therapy
1263785|NCT00904488|Acute Decompensated Heart Failure
1263786|NCT00904488|Diuretics
1263787|NCT00904436|Tetraplegia
1263788|NCT00904436|Breathing Patterns
1263789|NCT00904436|Dyspnea
1263790|NCT00904410|adenocarcinoma
1263791|NCT00904410|breast
1263792|NCT00904384|HIV+
1263793|NCT00904384|COPD
1263794|NCT00904384|emphysema
1263795|NCT00904358|internal jugular vein
1263796|NCT00904358|cross sectional area
1263797|NCT00904358|ultrasound
1263798|NCT00904358|central venous pressure
1263799|NCT00904345|SCC Head and Neck Cancer
1263800|NCT00904332|Transcranial Magnetic Stimulation (TMS)
1263801|NCT00904332|Electroencephalogram (EEG)
1263802|NCT00904332|Motor Learning
1263803|NCT00904332|Health Volunteer
1263804|NCT00904332|HV
1263805|NCT00904319|osteoarthritis
1263806|NCT00904319|knee pain
1263807|NCT00904319|power training
1263808|NCT00904319|rehabilitation
1263809|NCT00904306|binge eating
1263810|NCT00904306|chromium
1263811|NCT00904306|mood
1263812|NCT00904306|glucose
1263813|NCT00904306|appetite
1263814|NCT00904293|warfarin
1263815|NCT00904293|CYP2C9
1263816|NCT00904293|VKOR
1263817|NCT00904293|Coumadin
1263818|NCT00904293|pharmacogenetics
1263819|NCT00904293|pharmacogenomics
1263820|NCT00904293|anticoagulation
1263821|NCT00904293|genotype-guided therapy
1263822|NCT00904254|cerebrovascular disorders
1263823|NCT00904254|symptomatic carotid artery stenosis
1263824|NCT00904254|asymptomatic carotid artery stenosis
1263825|NCT00904254|monoclonal antibody
1263826|NCT00904254|diagnostics
1263827|NCT00904254|molecular target
1263828|NCT00904254|immunoglobulin Fab fragments
1263829|NCT00904254|physiological effects of drugs
1263830|NCT00904254|Tc99m-pertechnetate
1263831|NCT00904254|Fab-fragment of Anti-human CD4
1263832|NCT00904254|Antibodies, Monoclonal
1263833|NCT00904254|Antibodies
1263834|NCT00904228|hypothermia
1263835|NCT00904228|euthermia
1263836|NCT00904228|hyperthermia
1263837|NCT00904228|mortality
1263838|NCT00904228|morbidity
1263839|NCT00904228|sepsis
1263840|NCT00904228|bronchopulmonary dysplasia
1263841|NCT00904228|intraventricular hemorrhage
1263842|NCT00904228|ventilator days
1263843|NCT00904150|menstruation
1263844|NCT00904150|migraine
1263845|NCT00904150|menstrual migraine
1263846|NCT00904150|genetics
1263847|NCT00904137|Supracondylar fracture
1263848|NCT00904137|humerus
1263849|NCT00904137|elbow
1263850|NCT00904124|Dietary fiber
1263851|NCT00904124|guar gum
1263852|NCT00904124|alginate
1263853|NCT00904124|cellulose
1263854|NCT00904124|food intake
1263855|NCT00904124|eating behaviour
1263856|NCT00904098|migraine
1263857|NCT00904072|CDSS
1263858|NCT00904072|prescribing error
1263859|NCT00904072|prescribing errors influenced by CDSS
1263860|NCT00904072|CPOE
1263861|NCT00904046|Uric acid
1263862|NCT00904046|Nephrolithiasis
1263863|NCT00904007|Educational Technology
1263864|NCT00904007|Hypertension
1263865|NCT00904007|Education, Professional
1263866|NCT00903994|Acute Pain
1263867|NCT00903968|refractory
1263868|NCT00903968|relapsed
1263869|NCT00903968|bortezomib
1263870|NCT00903968|AMD3100
1263871|NCT00903968|plerixafor
1263872|NCT00903955|Mucus
1263873|NCT00903955|COPD
1263874|NCT00903955|Chronic Bronchitis
1263875|NCT00903916|antipsychotic
1263876|NCT00903916|ghrelin
1263877|NCT00903916|PYY
1263878|NCT00903916|appetite
1263879|NCT00903916|weight gain
1263880|NCT00903903|active synovitis
1263881|NCT00902993|MAD
1263882|NCT00902993|NNR
1263883|NCT00902993|to investigate safety and tolerability in a multiple ascending dose study in Healthy subjects
1263884|NCT00902993|AZD1446
1263885|NCT00902980|Kidney transplantation
1263886|NCT00902980|Tacrolimus
1263887|NCT00902980|Immunosuppression
1263888|NCT00902967|Postoperative pain
1263889|NCT00902967|atorvastatin
1263890|NCT00902967|analgesic
1263891|NCT00902967|antiinflammatory
1263892|NCT00902954|Disease free survival
1263893|NCT00902954|Distant disease free survival
1263894|NCT00902954|Toxicity
1263895|NCT00902954|Overall survival
1263896|NCT00902941|Parkinson´s disease
1263897|NCT00902941|olfaction
1263898|NCT00902941|rasagiline
1263899|NCT00902941|smell testing
1263900|NCT00902928|Elective hip replacement surgery
1263901|NCT00902928|Factor Xa
1263902|NCT00902928|Venous Thromboembolism
1263903|NCT00902928|Thrombosis
1263904|NCT00902928|Anticoagulants
1263905|NCT00902928|Prevention
1263906|NCT00902928|YM150
1263907|NCT00902915|multiple myeloma renal insufficiency
1263908|NCT00902902|Hepatocellular carcinoma
1263909|NCT00902889|Globus pallidus
1263910|NCT00902889|Huntington's Disease
1263911|NCT00902889|Deep Brain Stimulation
1263912|NCT00902889|Movement Disorders
1263913|NCT00902876|root coverage
1263914|NCT00902876|gingival recession
1263915|NCT00902876|keratinized gingiva
1263916|NCT00902863|chronic pain
1263917|NCT00902863|mindfulness
1263918|NCT00902863|yoga
1263919|NCT00902863|quality of life
1263920|NCT00902863|stress
1263921|NCT00902837|randomised
1263922|NCT00902837|double-blind
1263923|NCT00902837|double-dummy
1263924|NCT00902837|parallel-group
1263925|NCT00902837|non-inferiority
1263926|NCT00902837|pain locomotor function
1263927|NCT00902837|improvement in symptoms of constipation
1263928|NCT00902837|moderate to severe pain due to osteoarthritis (OA)
1263929|NCT00902837|OXN PR
1263930|NCT00902837|OxyPR
1263931|NCT00902837|Moderate to severe chronic nonmalignant OA
1263932|NCT00902824|HIV
1263933|NCT00903838|Parkinson's disease
1263934|NCT00903825|femoral artery puncture
1263935|NCT00903825|local anesthesia
1263936|NCT00903825|ultrasound guided
1263937|NCT00903799|Drug-refractory gastroparesis
1263938|NCT00903799|diabetes mellitus induced gastroparesis
1263939|NCT00903799|Gastric electrical stimulation
1263940|NCT00903799|Long-term multicenter study
1263941|NCT00903786|Seizure
1263942|NCT00903786|epilepsy
1263943|NCT00903773|VX-950-TiDP24-C132
1263944|NCT00903773|VX-950-C132
1263945|NCT00903773|VX-950
1263946|NCT00903773|HCV
1263947|NCT00903760|Myelodysplastic Syndrome
1263948|NCT00903760|MDS
1263949|NCT00903760|Leukemia
1263950|NCT00903760|Decitabine
1263951|NCT00903760|clofarabine
1263952|NCT00903760|Dacogen®
1263953|NCT00903760|Clolar®
1263954|NCT00903747|Prucalopride
1263955|NCT00903747|safety study
1263956|NCT00903734|Metastatic Cancer
1263957|NCT00903734|Histology-independent
1263958|NCT00903734|EGFR Mutation
1263959|NCT00903734|EGFR inhibitor-sensitive mutation
1263960|NCT00903734|Erlotinib Hydrochloride
1263961|NCT00903734|Tarceva
1263962|NCT00903734|OSI-774
1263963|NCT00903734|Cetuximab
1263964|NCT00903734|Bortezomib
1263965|NCT00903734|Dasatinib
1263966|NCT00903708|Advanced Cancers
1263967|NCT00903708|LY2275796
1263968|NCT00903708|Eukaryotic initiation factor 4E
1263969|NCT00903708|eIF-4E
1263970|NCT00903695|Memory XL
1263971|NCT00903695|Mild Cognitive Impairment
1263972|NCT00903695|cognitive status
1263973|NCT00903682|HIV
1263974|NCT00903682|Intelence
1263975|NCT00903682|etravirine
1263976|NCT00903682|ETR
1263977|NCT00903682|TMC125
1263978|NCT00903682|Sustiva
1263979|NCT00903682|efavirenz
1263980|NCT00903682|EFV
1263981|NCT00903682|Non-nucleoside Reverse Transcriptase Inhibitor
1263982|NCT00903682|NNRTI
1263983|NCT00903682|treatment-naive
1263984|NCT00903669|Facial paralysis
1263985|NCT00903669|Muscle tonus
1263986|NCT00903669|Rehabilitation
1263987|NCT00903669|Myofunctional
1263988|NCT00903669|Stomatognathic system
1263989|NCT00903656|metastatic breast cancer
1263990|NCT00903656|Her2
1263991|NCT00903656|Lapatinib
1263992|NCT00903656|Caelyx
1263993|NCT00903656|cardiotoxic
1263994|NCT00903643|Painful Bladder Syndrome
1263995|NCT00903643|Urinary Bladder
1263996|NCT00903630|recurrent ovarian epithelial cancer
1263997|NCT00903630|fallopian tube cancer
1263998|NCT00903630|peritoneal cavity cancer
1263999|NCT00903617|lipids
1264000|NCT00903617|HM74A
1264001|NCT00903604|Cardiac surgery
1264002|NCT00903604|coronary artery bypass grafting
1264003|NCT00903604|valve surgery
1264004|NCT00903604|aortic root or ascending aortic aneurysm repair surgery
1264005|NCT00903604|Acute kidney injury
1264006|NCT00903591|Breast
1264007|NCT00903591|cancer
1264008|NCT00903591|09-040
1264009|NCT00903591|blood sample
1264010|NCT00903591|saliva sample
1264011|NCT00903591|WECARE
1264012|NCT00903591|GWA
1264013|NCT00903578|FGF-23
1264014|NCT00903578|vitamin D
1264015|NCT00903578|phosphate
1264016|NCT00903578|allograft dysfunction
1264017|NCT00903578|mortality
1264024|NCT00903539|Peripherally Inserted Central Catheter
1264025|NCT00903539|Central Venous Catheter
1264026|NCT00903539|Intravenous Catheter
1264027|NCT00903539|StatLock
1264028|NCT00903539|Patients indicated to have an intravenous catheter placed
1264029|NCT00903526|fungal susceptibility
1264030|NCT00903474|anxiety disorder
1264031|NCT00903474|depression
1264032|NCT00903474|cognitive/functional effects
1264033|NCT00903474|psychosocial effects of cancer and its treatment
1264034|NCT00903474|cancer survivor
1264035|NCT00903474|breast cancer
1264160|NCT00903071|Primary Care
1264036|NCT00903448|Normal Healthy Subject Population
1264037|NCT00903435|Cystitis
1264038|NCT00903435|Urinary
1264039|NCT00903435|Bladder
1264040|NCT00903422|de novo AML
1264041|NCT00903422|sAML/MDS
1264042|NCT00903422|Thrombopoietin
1264043|NCT00903422|secondary Acute Myeloid Leukemia after MDS
1264044|NCT00903422|MDS
1264045|NCT00903422|Eltrombopag
1264046|NCT00903422|Platelets
1264047|NCT00903422|TPO-R agonist
1264048|NCT00903422|Advanced Myelodysplastic Syndrome
1264049|NCT00903422|Thrombocytopenia
1264050|NCT00903422|Thrombopoietin receptor agonist
1264051|NCT00903409|High triglycerides
1264052|NCT00903409|Lovaza
1264053|NCT00903409|simvastatin
1264054|NCT00903409|omega-3-acid ethyl esters
1264055|NCT00903396|nausea and vomiting
1264056|NCT00903396|gastrointestinal carcinoid tumor
1264057|NCT00903396|anal cancer
1264058|NCT00903396|carcinoma of the appendix
1264059|NCT00903396|colon cancer
1264060|NCT00903396|rectal cancer
1264061|NCT00903396|extrahepatic bile duct cancer
1264062|NCT00903396|gallbladder cancer
1264063|NCT00903396|gastric cancer
1264064|NCT00903396|liver and intrahepatic biliary tract cancer
1264065|NCT00903396|pancreatic cancer
1264066|NCT00903396|small intestine cancer
1264067|NCT00903396|primary peritoneal cavity cancer
1264068|NCT00903370|Mitral Valve Regurgitation
1264069|NCT00903370|Mitral Valve Surgery
1264070|NCT00903370|Mitral Valve Disease
1264071|NCT00903370|Ablation, Catheter
1264072|NCT00903370|Catheter Ablation, Radiofrequency
1264073|NCT00903357|Atopic dermatitis
1264074|NCT00903357|Montelukast
1264075|NCT00903331|idiopathic pulmonary fibrosis
1264076|NCT00903331|MUSIC
1264077|NCT00903318|Endocrine
1264078|NCT00903318|Environmental Chemicals
1264079|NCT00903318|Male:Female Birth Ratio
1264080|NCT00903318|Phthalate Exposure
1264081|NCT00903318|Generational sex ratio trends
1264082|NCT00903318|Mexican American
1264083|NCT00903318|Baytown
1264084|NCT00903318|Rio Grande Valley
1264085|NCT00903318|Hidalgo County
1264086|NCT00903318|Texas
1264087|NCT00903305|pain
1264088|NCT00903305|fatigue
1264089|NCT00903305|nausea and vomiting
1264090|NCT00903305|stage I breast cancer
1264091|NCT00903305|stage II breast cancer
1264092|NCT00903305|stage IIIA breast cancer
1264093|NCT00903305|stage IIIB breast cancer
1264094|NCT00903305|stage IIIC breast cancer
1264095|NCT00903292|EGFR
1264096|NCT00903292|NSCLC
1264097|NCT00903292|EGFR mutation rate
1264098|NCT00903279|MRSA colonization
1264099|NCT00903279|Orthopedic Surgery
1264100|NCT00903279|Altabax
1264101|NCT00903279|Placebo
1264102|NCT00903266|Aphasia
1264103|NCT00903266|Speech Impairment
1264104|NCT00903266|Stroke
1264105|NCT00903266|Cerebrovascular Accident
1264106|NCT00903266|Cerebral Infarction
1264107|NCT00903266|Brain Ischemia
1264108|NCT00903266|Brain Infarction
1264109|NCT00903266|Cerebrovascular Disorder
1264110|NCT00903227|Asthma
1264111|NCT00903227|Allergic rhinitis
1264112|NCT00903227|fluticasone
1264113|NCT00903227|methacholine
1264114|NCT00903214|stage I breast cancer
1264115|NCT00903214|stage II breast cancer
1264116|NCT00903214|stage IIIA breast cancer
1264117|NCT00903201|cystic fibrosis
1264118|NCT00903188|Renal Transplantation
1264119|NCT00903188|graft function
1264120|NCT00903188|cardiovascular events
1264121|NCT00903188|malignancy
1264122|NCT00903188|cyclosporin
1264123|NCT00903188|steroids
1264124|NCT00903188|mycophenolate
1264125|NCT00903188|everolimus
1264126|NCT00903188|renal biopsies
1264127|NCT00903188|pharmacokinetics
1264128|NCT00903175|RAD001
1264129|NCT00903175|everolimus
1264130|NCT00903175|sunitinib
1264131|NCT00903175|renal cell carcinoma
1264132|NCT00903175|kidney cancer
1264133|NCT00903175|metastatic renal cell cancer
1264134|NCT00903175|advanced kidney cancer
1264135|NCT00903162|hormone-receptor positive
1264136|NCT00903162|tamoxifen
1264137|NCT00903162|letrozole
1264138|NCT00903162|zoledronic acid
1264139|NCT00903162|leuprolide
1264140|NCT00903149|Premature babies
1264141|NCT00903149|Social interaction
1264142|NCT00903149|Psychoeducative intervention
1264143|NCT00903149|Mother Infant Transaction Program
1264144|NCT00903149|Three years follow-up
1264145|NCT00903149|Late preterm
1264146|NCT00903149|Cognitive development
1264147|NCT00903149|Social development
1264148|NCT00903149|Emotional development
1264149|NCT00903149|Motor development
1264150|NCT00903149|Children born preterm and their parents
1264151|NCT00903136|Barrett esophagus
1264152|NCT00903136|esophageal cancer
1264153|NCT00903136|adenocarcinoma of the esophagus
1264154|NCT00903084|Pharmacokinetics in Hair
1264155|NCT00903084|Tenofovir
1264156|NCT00903084|Pharmacokinetics
1264157|NCT00903084|Concentrations
1264158|NCT00903084|Hair
1264159|NCT00903071|Hypertension
1264161|NCT00903071|Physician Learning
1264162|NCT00903045|Overactive bladder
1264163|NCT00903045|Propiverin
1264164|NCT00903032|compliance/adherence
1264165|NCT00903019|Homebound
1264166|NCT00903019|Older Adults
1264167|NCT00903019|Disability
1264168|NCT00903019|Videoconferencing
1264169|NCT00903006|Breast
1264170|NCT00903006|Hormone receptor-positive metastatic breast cancer
1264171|NCT00903006|Fulvestrant
1264172|NCT00903006|Faslodex
1264173|NCT00903006|MK-0646
1264174|NCT00903006|Dasatinib
1264175|NCT00903006|BMS-354825
1264176|NCT00903006|Sprycel
1264177|NCT00903006|Adjuvant hormonal therapy
1264178|NCT00902811|uncomplicated falciparum malaria
1264179|NCT00902811|artemisinin combination therapy
1264180|NCT00902798|Autism
1264181|NCT00902798|Autism Spectrum Disorders
1264182|NCT00902798|Asperger's Syndrome
1264183|NCT00902798|Pervasive Developmental Disorder
1264184|NCT00902798|Cognition
1264185|NCT00902798|Social Cognition
1264186|NCT00902798|Psychosocial Treatment
1264187|NCT00902798|Cognitive Enhancement Therapy
1264188|NCT00902798|Enriched Supportive Therapy
1264189|NCT00902798|Therapy
1264190|NCT00902798|Psychotherapy
1264191|NCT00902785|exploratory
1264192|NCT00902785|observational
1264193|NCT00902785|non-interventional study age-related macular degeneration (AMD) choroidal neovascularization (CNV)
1264194|NCT00902772|Recreational CNS depressant
1264195|NCT00902772|Abuse liability
1264196|NCT00902772|Abuse potential
1264197|NCT00902772|Healthy Recreational CNS Depressant Users
1264198|NCT00902759|Surgery
1264199|NCT00902759|Chemotherapy
1264200|NCT00902759|Radiation Therapy
1264201|NCT00902759|Pancreatic cancer
1264202|NCT00902759|Fatigue
1264203|NCT00902733|pain
1264204|NCT00902733|fatigue
1264205|NCT00902733|nausea and vomiting
1264206|NCT00902733|recurrent pancreatic cancer
1264207|NCT00902733|stage I pancreatic cancer
1264208|NCT00902733|stage II pancreatic cancer
1264209|NCT00902733|stage III pancreatic cancer
1264210|NCT00902733|stage IV pancreatic cancer
1264211|NCT00902720|Ovarian
1264212|NCT00902720|Tissue
1264213|NCT00902720|Cryopreservation
1264214|NCT00902707|healthy nonsmokers
1264215|NCT00902694|Serious Mental Illness
1264216|NCT00902694|Weight Loss
1264217|NCT00902681|Bioequivalence, Pharmacokinetics
1264218|NCT00902668|radiation toxicity
1264219|NCT00902668|stage IA breast cancer
1264220|NCT00902668|stage IB breast cancer
1264221|NCT00902668|stage II breast cancer
1264222|NCT00902668|breast cancer in situ
1264223|NCT00902655|Nocturnal polyuria
1264224|NCT00902655|Nocturnal bladder capacity
1264225|NCT00902642|Physical therapy,
1264226|NCT00902642|musculoskeletal pain,
1264227|NCT00902642|psychosocial factors,
1264228|NCT00902642|dissimilation,
1264229|NCT00902642|evidence based,
1264230|NCT00902642|education
1264231|NCT00902629|Epiretinal Fibrosis
1264232|NCT00902629|Macular Pucker
1264233|NCT00902616|Type 2 diabetes
1264234|NCT00902616|Peripheral neuropathy
1264235|NCT00902616|Microcirculation
1264236|NCT00902603|pulmonary arterial hypertension
1264237|NCT00902603|Ventavis®
1264238|NCT00902603|iloprost
1264239|NCT00902590|renal pelvis
1264240|NCT00902590|ureter
1264241|NCT00902590|bladder
1264242|NCT00902590|09-025
1264243|NCT00902590|Renal Pelvis, Ureter, Bladder Cancer
1264244|NCT00902564|Generalized Anxiety Disorder
1264245|NCT00902564|GAD
1264246|NCT00902564|Antidepressant
1264247|NCT00902564|Anxiolytic
1264248|NCT00902551|DNA cytometry
1264249|NCT00902551|Cytology
1264250|NCT00902551|Diagnosis accuracy
1264251|NCT00902538|Add on treatment
1264252|NCT00902538|essential hypertension
1264253|NCT00902525|two sequential doses of 90Y-Ibritumomab Tiuxetan
1264254|NCT00902499|functional magnetic resonance imaging
1264255|NCT00902486|Rheumatoid arthritis
1264256|NCT00902473|Topiramate fed study
1264257|NCT00902460|drug interactions CYP3A4 CYP3A5 midazolam anti-rheumatic agents
1264258|NCT00902447|Human Blood Cell Disorders
1264259|NCT00902447|lymphoid, myeloid and erythroid proliferative disease
1264260|NCT00902434|Non-Hodgkin's Lymphoma
1264261|NCT00902421|Overactive bladder
1264262|NCT00902421|SSRI
1264263|NCT00902421|Antimuscarinics
1264264|NCT00902395|Preschool children
1264265|NCT00902382|Infertility
1264266|NCT00902382|Ovulation stimulation
1264267|NCT00902382|Pregnancy
1264268|NCT00902369|AK106-001616
1264269|NCT00902356|Amgen
1264270|NCT00902356|Phase 1
1264271|NCT00902356|First in Human
1264272|NCT00902356|Postmenopausal
1264273|NCT00902343|Liver
1264274|NCT00902343|Cancer
1264275|NCT00902343|Primary
1264276|NCT00902343|Metastatic
1264277|NCT00902343|transfusions
1264278|NCT00902343|08-158
1264279|NCT00902330|depression
1264280|NCT00902330|anxiety disorder
1264281|NCT00902330|fatigue
1264282|NCT00902330|pain
1264283|NCT00902330|sleep disorders
1264284|NCT00902330|stage IA breast cancer
1264285|NCT00902330|stage IB breast cancer
1264286|NCT00902330|stage II breast cancer
1264287|NCT00902330|stage IIIA breast cancer
1264288|NCT00902304|Hypertension
1264289|NCT00902304|valsartan
1264290|NCT00902291|Clinical Trial, Phase II
1264291|NCT00902291|Combination Drug Therapy
1264292|NCT00902291|Gemcitabine
1264293|NCT00902291|AGS-1C4D4
1264294|NCT00902291|Pancreatic Cancer
1264295|NCT00902278|influenzavirus A
1264296|NCT00902278|influenzavirus B
1264297|NCT00902278|human influenza
1264298|NCT00902278|T lymphocytes
1264299|NCT00902278|influenza vaccines
1264300|NCT00902226|Social Anxiety Disorder
1264301|NCT00902226|SAD
1264302|NCT00902226|Antidepressant
1264303|NCT00902226|Anxiolytic
1264304|NCT00902200|Glaucoma
1264305|NCT00902200|Intraocular pressure
1264306|NCT00902187|Bioequivalence
1264307|NCT00902174|Pulmonary arterial hypertension
1264308|NCT00902174|Imatinib
1264309|NCT00902174|6MWD
1264310|NCT00902174|Borg scale
1264311|NCT00902174|Pulmonary hypertension
1264312|NCT00902148|Surgery
1264313|NCT00902148|Colectomy
1264314|NCT00902148|Proctocolectomy
1264315|NCT00902148|Adhesions
1264316|NCT00902135|Multiple Sclerosis
1264317|NCT00902135|Interferon beta-1b
1264318|NCT00902122|p53 gene
1264319|NCT00902122|thyroid
1264320|NCT00902122|gene therapy
1264321|NCT00902122|malignant tumors
1264322|NCT00902109|visual field
1264323|NCT00902109|perimetry
1264324|NCT00902109|progression
1264325|NCT00902109|POAG
1264326|NCT00902109|glaucoma
1264327|NCT00902096|cord blood
1264328|NCT00902096|IgE
1264329|NCT00902096|prenatal
1264330|NCT00902096|predictor
1264331|NCT00902083|p53 gene
1264332|NCT00902083|Oral and Maxillofacial
1264333|NCT00902083|gene therapy
1264334|NCT00902083|malignant tumors
1264335|NCT00902044|Refractory Sarcoma
1264336|NCT00902044|Metastatic Sarcoma
1264337|NCT00902044|Sarcoma
1264338|NCT00902044|HER2-positive
1264339|NCT00902044|Gene Therapy
1264340|NCT00902044|HER2-specific T cells
1264341|NCT00902031|Docusate
1264342|NCT00902031|Constipation
1264343|NCT00902031|Colace
1264344|NCT00902031|Palliative Care
1264345|NCT00902031|Sennoside
1264346|NCT00902031|Senokot
1264347|NCT00902031|Terminally Ill
1264348|NCT00902031|Stool
1264349|NCT00902031|Randomized Trial
1264350|NCT00902018|ITP
1264351|NCT00902005|Endothelial dysfunction
1264352|NCT00902005|Bone and cartilage markers
1264353|NCT00902005|Inflammatory disease activity
1264354|NCT00902005|Rheumatoid arthritis
1264355|NCT00902005|Psoriatic arthritis
1264356|NCT00902005|Ankylosing Spondylitis
1264357|NCT00901992|type 2 diabetes
1264358|NCT00901992|education
1264359|NCT00901992|self-management
1264360|NCT00901992|insulin therapy
1264361|NCT00901979|Type 2 Diabetes
1264362|NCT00901966|Melanoma
1264363|NCT00901966|Sun Exposure History
1264364|NCT00901966|Sun Exposure
1264365|NCT00901953|migraine
1264366|NCT00901953|migrainous vertigo
1264367|NCT00901953|vestibular evoked myogenic potentials
1264368|NCT00901953|vestibular function test
1264369|NCT00901953|vestibular disorders
1264370|NCT00901927|Lymphoma
1264371|NCT00901927|Non-Hodgkin's Lymphoma
1264372|NCT00901927|Untreated High Risk Follicular Lymphoma
1264373|NCT00901927|Bendamustine hydrochloride
1264374|NCT00901927|Bendamustine HCI
1264375|NCT00901927|Bendamustine
1264376|NCT00901927|CEP-18083
1264377|NCT00901927|SDX-105
1264378|NCT00901927|Treanda
1264379|NCT00901927|Mitoxantrone
1264380|NCT00901927|Novantrone
1264381|NCT00901927|Rituximab
1264382|NCT00901927|Rituxan
1264383|NCT00901914|Hypersensitivity
1264384|NCT00901914|Allergy
1264385|NCT00901914|Birch, allergy, Sublingual Immunotherapy
1264386|NCT00901901|Sorafenib (Nexavar)
1264387|NCT00901901|Erlotinib (Tarceva)
1264388|NCT00901901|First Line
1264389|NCT00901901|HCC
1264390|NCT00901888|Renin Angiotensin System
1264391|NCT00901875|Buprenorphine
1264392|NCT00901875|Naloxone
1264393|NCT00901875|Suboxone
1264394|NCT00901862|Migraine
1264395|NCT00901862|therapy
1264396|NCT00901862|magnetic therapy
1264397|NCT00901862|prophylaxis
1264398|NCT00901862|prevention
1264399|NCT00901836|Sarcoma
1264400|NCT00901810|Length Determination
1264401|NCT00901810|Working Length
1264402|NCT00901810|Electronic Apex Locator
1264403|NCT00901810|Root Canal Therapy
1264404|NCT00901810|Endodontics
1264405|NCT00901797|ABD
1264406|NCT00901797|ABDuction
1264407|NCT00901797|ABR
1264408|NCT00901797|Arthroscopic Bankart Repair
1264409|NCT00901797|ACJ
1264410|NCT00901797|AcromioClavicular Joint
1264411|NCT00901797|AD
1264412|NCT00901797|Anterior Drawer
1264413|NCT00901797|ARIC
1264414|NCT00901797|Arthroscopic Rotator Interval Closure
1264415|NCT00901797|BL
1264416|NCT00901797|Bankart Lesion
1264417|NCT00901797|CHL
1264418|NCT00901797|CoracoHumeral Ligament
1264419|NCT00901797|ER
1264420|NCT00901797|External Rotation
1264421|NCT00901797|FF
1264422|NCT00901797|Forward Flexion
1264423|NCT00901797|GHJ
1264424|NCT00901797|GlenoHumeral Joint
1264425|NCT00901797|HSL
1264426|NCT00901797|HillSacs Lesion
1264427|NCT00901797|IR
1264428|NCT00901797|Internal Rotation
1264429|NCT00901797|ISP
1264430|NCT00901797|InfraSPinatus
1264431|NCT00901797|PD
1264432|NCT00901797|Posterior Drawer
1264433|NCT00901797|RI
1264434|NCT00901797|Rotator Interval
1264435|NCT00901797|ROM
1264436|NCT00901797|Range Of Motion
1264437|NCT00901797|SGHL
1264438|NCT00901797|Superior GlenoHumeral Ligament
1264439|NCT00901797|SSC
1264440|NCT00901797|SubSCapularis
1264441|NCT00901797|SSP
1264442|NCT00901797|SupraSPinatus
1264443|NCT00901784|Topiramate fasting study
1264444|NCT00901771|Sleep
1264445|NCT00901771|Sleep Apnea, Obstructive
1264446|NCT00901771|OSA
1264447|NCT00901771|OSAH
1264448|NCT00901745|Renin angiotensin system
1264449|NCT00901745|Apelin
1264450|NCT00901745|Vasodilatation
1264451|NCT00901745|Heart disease
1264452|NCT00901745|Vascular biology
1264453|NCT00901732|Caphosol
1264454|NCT00901732|Oral Mucositis
1264455|NCT00901732|Eusa Pharma
1264456|NCT00901732|Moffitt Cancer Center
1264457|NCT00901719|Renin angiotensin system
1264458|NCT00901719|Apelin
1264459|NCT00901719|Cardiac output
1264460|NCT00901719|Vasodilatation
1264461|NCT00901706|Self-Neglect
1264462|NCT00901706|Comprehensive Geriatric Assessment (CGA)
1264463|NCT00901706|Geriatric Syndromes
1264464|NCT00901706|Quality of Life
1264465|NCT00901706|Basic Activities of Daily Living
1264466|NCT00901706|Instrumental Activities of Daily Living
1264467|NCT00901693|pink eye
1264468|NCT00901693|eye infection
1264469|NCT00901693|conjunctivitis
1264470|NCT00901680|Tissue Bank
1264471|NCT00899574|toll-like receptor
1264472|NCT00899574|toll-like receptor agonist
1264473|NCT00899574|recurrent breast cancer
1264474|NCT00899574|breast cancer metastasized to skin and/or chestwall
1264475|NCT00899574|immunomodulator
1264476|NCT00899561|Chronic rhinosinusitis
1264477|NCT00899561|Computed tomography
1264478|NCT00899561|Histology
1264479|NCT00899561|Middle turbinate
1264480|NCT00899561|Morphometry
1264481|NCT00899561|osteomyelitis
1264482|NCT00899561|polyps
1264483|NCT00899548|stage IV breast cancer
1264484|NCT00899548|recurrent breast cancer
1264485|NCT00899535|adenocarcinoma of the lung
1264486|NCT00899535|large cell lung cancer
1264487|NCT00899535|squamous cell lung cancer
1264488|NCT00899535|stage I non-small cell lung cancer
1264489|NCT00899535|stage II non-small cell lung cancer
1264490|NCT00899522|Fanconi anemia
1264491|NCT00899522|unspecified adult solid tumor, protocol specific
1264492|NCT00899522|unspecified childhood solid tumor, protocol specific
1264493|NCT00899509|stage II breast cancer
1264494|NCT00899509|stage IIIA breast cancer
1264495|NCT00899496|stage IV bladder cancer
1264496|NCT00899496|stage IV colon cancer
1264497|NCT00899496|stage IV non-small cell lung cancer
1264498|NCT00899496|stage IV pancreatic cancer
1264499|NCT00899496|stage IV rectal cancer
1264500|NCT00899496|stage IV renal cell cancer
1264501|NCT00899496|stage IV melanoma
1264502|NCT00899496|stage III multiple myeloma
1264503|NCT00899496|extensive stage small cell lung cancer
1264504|NCT00899496|stage IV adult soft tissue sarcoma
1264505|NCT00899496|stage III malignant testicular germ cell tumor
1264506|NCT00899496|stage IV breast cancer
1264507|NCT00899496|stage IV ovarian epithelial cancer
1264508|NCT00899496|stage IV prostate cancer
1264509|NCT00899496|stage IV endometrial carcinoma
1264510|NCT00899496|unspecified adult solid tumor, protocol specific
1264511|NCT00899496|metastatic osteosarcoma
1264512|NCT00899496|stage IV uterine sarcoma
1264513|NCT00899496|stage III ovarian epithelial cancer
1264514|NCT00899496|ovarian sarcoma
1264515|NCT00899496|stage IV adult Burkitt lymphoma
1264516|NCT00899496|stage III adult diffuse large cell lymphoma
1264517|NCT00899496|stage III adult diffuse mixed cell lymphoma
1264518|NCT00899496|stage III adult diffuse small cleaved cell lymphoma
1264519|NCT00899496|stage IV adult diffuse large cell lymphoma
1264520|NCT00899496|stage IV adult diffuse mixed cell lymphoma
1264521|NCT00899496|stage IV adult diffuse small cleaved cell lymphoma
1264522|NCT00899496|stage III adult Burkitt lymphoma
1264523|NCT00899496|stage III adult immunoblastic large cell lymphoma
1264524|NCT00899496|stage IV adult immunoblastic large cell lymphoma
1264525|NCT00899496|stage III adult lymphoblastic lymphoma
1264526|NCT00899496|stage IV adult lymphoblastic lymphoma
1264527|NCT00899496|stage IV grade 1 follicular lymphoma
1264528|NCT00899496|stage IV grade 2 follicular lymphoma
1264529|NCT00899496|stage IV grade 3 follicular lymphoma
1264530|NCT00899496|stage III mantle cell lymphoma
1264531|NCT00899496|stage IV mantle cell lymphoma
1264532|NCT00899496|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1264533|NCT00899496|nodal marginal zone B-cell lymphoma
1264534|NCT00899496|splenic marginal zone lymphoma
1264535|NCT00899496|stage III marginal zone lymphoma
1264536|NCT00899496|stage IV marginal zone lymphoma
1264537|NCT00899496|stage III small lymphocytic lymphoma
1264538|NCT00899496|stage IV small lymphocytic lymphoma
1264539|NCT00899496|stage III mycosis fungoides/Sezary syndrome
1264540|NCT00899496|stage IV mycosis fungoides/Sezary syndrome
1264541|NCT00899496|cutaneous B-cell non-Hodgkin lymphoma
1264542|NCT00899496|stage III cutaneous T-cell non-Hodgkin lymphoma
1264543|NCT00899496|stage IV cutaneous T-cell non-Hodgkin lymphoma
1264544|NCT00899496|stage III adult T-cell leukemia/lymphoma
1264545|NCT00899496|stage IV adult T-cell leukemia/lymphoma
1264546|NCT00899496|anaplastic large cell lymphoma
1264547|NCT00899496|angioimmunoblastic T-cell lymphoma
1264548|NCT00899496|adult nasal type extranodal NK/T-cell lymphoma
1264549|NCT00899496|Waldenstrom macroglobulinemia
1264550|NCT00899496|adult grade III lymphomatoid granulomatosis
1264551|NCT00899496|primary central nervous system non-Hodgkin lymphoma
1264552|NCT00899496|intraocular lymphoma
1264553|NCT00901654|Vaccination
1264554|NCT00901654|Diarrhea
1264555|NCT00901654|Traveler's Diarrhea
1264556|NCT00901654|ETEC
1264557|NCT00901654|Enterotoxigenic E. coli
1264558|NCT00901641|cognitive training
1264559|NCT00901641|insomnia
1264560|NCT00901628|periarticular multimodal drug injection
1264561|NCT00901615|lymphoma
1264562|NCT00901615|lenalidomide
1264563|NCT00901615|gela
1264564|NCT00901602|streptococcus pneumoniae
1264565|NCT00901602|pneumococcus
1264566|NCT00901602|pneumonia
1264567|NCT00901602|meningitis
1264568|NCT00901602|serotypes
1264569|NCT00901602|bacteremia
1264570|NCT00901602|sepsis
1264571|NCT00901589|n-3 PUFAs
1264572|NCT00901589|menopause
1264573|NCT00901589|adipose tissue
1264574|NCT00901589|estrogens
1264575|NCT00901589|Incorporation of fishoil in pre- and postmenopausal women
1264576|NCT00901589|Marine n-3 PUFAs influence on female hormones in blood
1264577|NCT00901576|Healthy volunteers
1264578|NCT00901563|Gap Junctions
1264579|NCT00901563|Rotigaptide
1264580|NCT00901563|Ischaemia reperfusion
1264581|NCT00901563|t-PA
1264582|NCT00901563|Fibrinolysis
1264583|NCT00901563|Endothelial function
1264584|NCT00901563|Venous occlusion plethysmography
1264585|NCT00901550|MTX
1264586|NCT00901550|anti-TNF
1264587|NCT00901550|Early RA
1264588|NCT00901537|Non-small Cell Lung Cancer
1264589|NCT00901537|Head and Neck Cancer
1264590|NCT00901537|Azacitidine
1264591|NCT00901537|Vidaza
1264592|NCT00901537|Cisplatin
1264593|NCT00901524|HCV Genotype 1, 4
1264594|NCT00901524|Virological response
1264595|NCT00901524|Ribavirin
1264596|NCT00901524|PegPegIFN- alpha 2a
1264597|NCT00901524|Viral Hepatitis (HCV)
1264598|NCT00901511|Whole lung lavage
1264599|NCT00901511|Pulmonary surfactant
1264600|NCT00901511|GM-CSF
1264601|NCT00901511|Autoantibodies anti GM-CSF
1264602|NCT00901485|Respiratory insufficiency
1264603|NCT00901485|Hypercapnia
1264604|NCT00901485|Hypoventilation
1264605|NCT00901485|Sleep
1264606|NCT00901485|Polysomnography
1264607|NCT00901485|Hypoxia
1264608|NCT00901485|Titration
1264609|NCT00901485|Non Invasive Ventilation
1264610|NCT00901472|Type 2 diabetes,
1264611|NCT00901472|obstructive sleep apnea
1264612|NCT00901459|Repetitive Transcranial Magnetic Stimulation
1264613|NCT00901459|Cigarette Smoker
1264614|NCT00901459|Cigarette Dependence
1264615|NCT00901459|To block cue-elicited craving in dependent cigarette smokers
1264616|NCT00901433|Asthma
1264617|NCT00901433|Wheeze Rate
1264618|NCT00901433|Respiratory Function Tests
1264619|NCT00901420|Prostate
1264620|NCT00901420|Urodynamic Evaluation
1264621|NCT00901420|Prostatectomy
1264622|NCT00901420|Salvage prostatectomy
1264623|NCT00901420|Bladder compliance
1264624|NCT00901420|Radiation Therapy
1264625|NCT00901420|External beam radiation therapy
1264626|NCT00901420|Quality-of-life
1264627|NCT00901407|augmentation
1264628|NCT00901407|depression
1264629|NCT00901407|resistance
1264630|NCT00901394|Nitrous oxide
1264631|NCT00901394|cobalamin
1264632|NCT00901394|homocysteine
1264633|NCT00901394|vitamin B12
1264634|NCT00901394|folate
1264635|NCT00901394|No specific diseases targeted
1264636|NCT00901381|Ischemic stroke
1264637|NCT00901381|Stem cells
1264638|NCT00901381|Colony-stimulating factors
1264639|NCT00901381|Filgrastim
1264640|NCT00901381|Randomized controlled trial
1264641|NCT00901355|Blood pressure
1264642|NCT00901355|Arterial stiffness
1264643|NCT00901355|Morbidity
1264644|NCT00901355|Mortality
1264645|NCT00901355|Elderly
1264646|NCT00901342|Androgen independent prostate cancer (AIPC)
1264647|NCT00901342|CRPC
1264648|NCT00901342|prostate cancer
1264649|NCT00901342|prostate
1264650|NCT00901342|immune therapy
1264651|NCT00901342|immunotherapy
1264652|NCT00901342|vaccine
1264653|NCT00901342|dendritic cells
1264654|NCT00901342|antigen-presenting cells
1264655|NCT00901342|antigen presenting cells
1264656|NCT00901342|cancer vaccine
1264657|NCT00901342|prostate specific antigen (PSA)
1264658|NCT00901342|prostatic adenocarcinoma
1264659|NCT00901329|TKA
1264660|NCT00901329|functional outcome
1264661|NCT00901329|pain
1264662|NCT00901329|ROM
1264663|NCT00901329|gait
1264664|NCT00901316|Skin and Soft Tissue Infections
1264665|NCT00901316|Abscesses
1264666|NCT00901316|Boils
1264667|NCT00901316|Clorox Baths
1264668|NCT00901316|Colonization
1264669|NCT00901316|Staph
1264670|NCT00901316|MRSA
1264671|NCT00901316|MSSA
1264672|NCT00901316|Recurrent Infections
1264673|NCT00901316|Prevention CA-SA Infections
1264674|NCT00901316|Community-Acquired Staphylococcus in Children
1264675|NCT00901290|oral contraceptive
1264676|NCT00901277|Post MI
1264677|NCT00901264|Chemosensitivity, chemotherapy, all cancers, personalized chemotherapy, personalized cancer treatment
1264678|NCT00901264|Cancer Patients for whom chemotherapy is planned.
1264679|NCT00901251|OABSS
1264680|NCT00901238|retinoblastoma
1264681|NCT00901238|intra-arterial chemotherapy
1264682|NCT00901238|chemosurgery
1264683|NCT00901238|melphalan
1264684|NCT00901238|topotecan
1264685|NCT00901225|NHL
1264686|NCT00901212|Heart Failure
1264687|NCT00901212|resynchronisation
1264688|NCT00901212|ICD
1264689|NCT00901199|Thalassemia
1264690|NCT00901199|Chelation
1264691|NCT00901199|Iron Overload
1264692|NCT00901199|Thalassemia patients with Iron overload
1264693|NCT00901186|Diabetic Macular Edema
1264694|NCT00901186|Ranibizumab
1264695|NCT00901186|Laser Treatment
1264696|NCT00901186|Visual impairment
1264697|NCT00901173|Case-Control Study
1264698|NCT00901173|Esophageal Squamous Cell Carcinoma
1264699|NCT00901173|Risk Factors
1264700|NCT00901160|thromboelastography
1264701|NCT00901160|post-operative complications
1264702|NCT00901160|anti-platelet agents
1264703|NCT00901160|prospective
1264704|NCT00901160|pilot
1264705|NCT00901160|patients taking anti-platelet agents
1264706|NCT00901147|t-cell lymphoma
1264707|NCT00901147|peripheral t-cell lymphoma
1264708|NCT00901147|nk/t-cell lymphoma, nasal type
1264709|NCT00901147|bortezomib
1264710|NCT00901147|velcade
1264711|NCT00901147|panobinostat
1264712|NCT00901147|LBH589b
1264713|NCT00901147|histone deacetylase inhibitor
1264714|NCT00901147|proteasome inhibitor
1264715|NCT00901134|therapeutic hypothermia after cardiac arrest
1264716|NCT00901121|maxillary sinus lift
1264717|NCT00901121|Histomorphometric evaluation
1264718|NCT00901121|bone graft
1264719|NCT00901121|bone augmentation
1264720|NCT00901108|open angle glaucoma
1264721|NCT00901108|trabectome
1264722|NCT00901108|trabeculectomy
1264723|NCT00901108|cataract
1264724|NCT00901082|chronic pain
1264725|NCT00901082|anxiety
1264726|NCT00901082|intervention
1264727|NCT00901082|information
1264728|NCT00901082|relaxation
1264729|NCT00901056|ED
1264730|NCT00901056|Erectile Dysfunction
1264731|NCT00901056|Erectile dysfunction treated with PDE-5 inhibitors
1264732|NCT00901030|platelet function
1264733|NCT00901030|perioperative complications
1264734|NCT00901030|thromboelastography
1264735|NCT00901030|coronary stents
1264736|NCT00901030|non-cardiac surgery
1264737|NCT00901004|Minimal Change
1264738|NCT00901004|GERD
1264739|NCT00901004|GERDQ
1264740|NCT00900991|Pandemic Influenza A Vaccine
1264741|NCT00900991|Immunogenictiy
1264742|NCT00900991|Safety
1264743|NCT00900978|Streptococcus pneumoniae
1264744|NCT00900978|carriage
1264745|NCT00900978|Resistance
1264746|NCT00900978|Serotype
1264747|NCT00900978|vaccination
1264748|NCT00900978|Colonization of S. pneumoniae
1264749|NCT00900965|irritable bowel syndrome
1264750|NCT00900965|IBS
1264751|NCT00900965|fMRI
1264752|NCT00900965|acupuncture
1264753|NCT00900965|functional
1264754|NCT00900965|brain
1264755|NCT00900900|Cigarette Smokers
1264756|NCT00900900|DHEA
1264757|NCT00900900|dehydroepiandrosterone
1264758|NCT00900900|pregnenolone
1264759|NCT00900900|Nicotine withdrawal symptoms
1264760|NCT00900887|diabetic retinopathy
1264761|NCT00900887|clinically significant macular edema
1264762|NCT00900887|selective photocoagulation
1264763|NCT00900887|topic ketorolac
1264764|NCT00900887|topic nepafenac
1264765|NCT00900887|efficacy
1264766|NCT00900887|treatment
1264767|NCT00900874|Formoterol
1264768|NCT00900874|Rapid bronchodilation
1264769|NCT00900861|asthma control level
1264770|NCT00900861|visual analogue scale
1264771|NCT00900848|Posterior tibial artery bypass
1264772|NCT00900848|Iliofemoral artery injury
1264773|NCT00900848|Shock
1264774|NCT00900848|Reconstruction
1264775|NCT00900835|fatigue
1264776|NCT00900835|pain
1264777|NCT00900835|recurrent breast cancer
1264778|NCT00900835|stage I breast cancer
1264779|NCT00900835|stage II breast cancer
1264780|NCT00900835|stage IIIA breast cancer
1264781|NCT00900835|stage IIIB breast cancer
1264782|NCT00900835|stage IIIC breast cancer
1264783|NCT00900835|stage IV breast cancer
1264784|NCT00900835|recurrent prostate cancer
1264785|NCT00900835|stage I prostate cancer
1264786|NCT00900835|stage II prostate cancer
1264787|NCT00900835|stage III prostate cancer
1264788|NCT00900835|stage IV prostate cancer
1264789|NCT00900835|recurrent colon cancer
1264790|NCT00900835|stage I colon cancer
1264791|NCT00900835|stage II colon cancer
1264792|NCT00900835|stage III colon cancer
1264793|NCT00900835|stage IV colon cancer
1264794|NCT00900835|extensive stage small cell lung cancer
1264795|NCT00900835|limited stage small cell lung cancer
1264796|NCT00900835|recurrent non-small cell lung cancer
1264797|NCT00900835|recurrent small cell lung cancer
1264798|NCT00900835|stage I non-small cell lung cancer
1264799|NCT00900835|stage II non-small cell lung cancer
1264800|NCT00900835|stage IIIA non-small cell lung cancer
1264801|NCT00900835|stage IIIB non-small cell lung cancer
1264802|NCT00900835|stage IV non-small cell lung cancer
1264803|NCT00900822|bone grafting
1264804|NCT00900822|sinus elevation
1264805|NCT00900822|sinus augmentation
1264806|NCT00900809|Acute Myeloid Leukemia
1264807|NCT00900809|Neukoplast™
1264808|NCT00900809|NK-92
1264809|NCT00900809|Refractory
1264810|NCT00900809|Refractory or Relapsed Acute Myeloid Leukemia
1264811|NCT00900796|Ankylosing spondylitis;predictive factors
1264812|NCT00900783|herpes zoster
1264813|NCT00900783|shingles
1264814|NCT00900783|Phase II
1264815|NCT00900783|FV-100
1264816|NCT00900783|Inhibitex
1264817|NCT00900770|dementia
1264818|NCT00900770|mild cognitive impairment
1264819|NCT00900770|beta amyloid
1264820|NCT00900757|Primary Glioma
1264821|NCT00900757|Palonosetron
1264822|NCT00900757|Standard Radiotherapy
1264823|NCT00900757|Temozolomide
1264824|NCT00900744|Tamoxifen
1264825|NCT00900744|Breast Cancer
1264826|NCT00900731|COPD
1264827|NCT00900731|indacaterol
1264828|NCT00900731|beta 2 agonist
1264829|NCT00900731|tiotropium
1264830|NCT00899457|squamous cell lung cancer
1264831|NCT00899457|non-small cell lung cancer
1264832|NCT00899457|small cell lung cancer
1264833|NCT00899457|healthy, no evidence of disease
1265427|NCT00900094|stage IV breast cancer
1264834|NCT00899431|Nonmyeloablative Stem Cell Transplantation
1264835|NCT00899431|Chronic Lymphocytic Leukemia
1264836|NCT00899431|CLL
1264837|NCT00899431|Immunomanipulation
1264838|NCT00899431|Fludarabine
1264839|NCT00899431|Lenalidomide
1264840|NCT00899431|Rituximab
1264841|NCT00899431|Thymoglobulin
1264842|NCT00899431|Stem Cell Transplantation
1264843|NCT00899418|recurrent breast cancer
1264844|NCT00899418|stage IV breast cancer
1264845|NCT00899405|lung cancer
1264846|NCT00899392|consent
1264847|NCT00899392|Anxiety
1264848|NCT00899392|Satisfaction
1264849|NCT00899392|Efficiency
1264850|NCT00899392|Questions
1264851|NCT00899392|Attainment of Informed Consent (Consent-20)
1264852|NCT00899392|Procedural State Anxiety (STAI)
1264853|NCT00899392|Subject Satisfaction (mGHAA-9)
1264854|NCT00899392|Duration in Endoscopy Suite
1264855|NCT00899392|Number of questions asked
1264856|NCT00899366|T-cell adult acute lymphoblastic leukemia
1264857|NCT00899366|T-cell childhood acute lymphoblastic leukemia
1264858|NCT00899366|untreated adult acute lymphoblastic leukemia
1264859|NCT00899366|untreated childhood acute lymphoblastic leukemia
1264860|NCT00899366|recurrent adult acute lymphoblastic leukemia
1264861|NCT00899366|recurrent childhood acute lymphoblastic leukemia
1264862|NCT00899366|adult acute lymphoblastic leukemia in remission
1264863|NCT00899366|childhood acute lymphoblastic leukemia in remission
1264864|NCT00900692|Excessive pronation
1264865|NCT00900692|CVA
1264866|NCT00900692|Forearm
1264867|NCT00900692|Excessive pronation following CVA
1264868|NCT00900679|transitional care planning
1264869|NCT00900679|stage I ovarian epithelial cancer
1264870|NCT00900679|stage II ovarian epithelial cancer
1264871|NCT00900679|stage III ovarian epithelial cancer
1264872|NCT00900679|stage IV ovarian epithelial cancer
1264873|NCT00900666|Stiff knee gait
1264874|NCT00900666|Gait analysis
1264875|NCT00900666|Traumatic Brain Injury
1264876|NCT00900666|Acquired Brain Injury
1264877|NCT00900653|urinary tract infections
1264878|NCT00900653|postmenopause
1264879|NCT00900653|lactobacillus
1264880|NCT00900653|estriol
1264881|NCT00900627|Cancer
1264882|NCT00900627|Tumour
1264883|NCT00900627|Breast cancer
1264884|NCT00900627|Metastatic
1264885|NCT00900627|Secondary
1264886|NCT00900614|Hematologic malignancy
1264887|NCT00900614|Prostate carcinoma
1264888|NCT00900614|Hematologic cancer
1264889|NCT00900614|Prostate cancer
1264890|NCT00900601|Sacroiliac pain
1264891|NCT00900601|Sacroiliac instability
1264892|NCT00900601|Pelvic girdle pain
1264893|NCT00900601|Sacroiliac arthrodesis
1264894|NCT00900601|Arthrodesis
1264895|NCT00900601|Surgery
1264896|NCT00900588|immunogenictiy
1264897|NCT00900588|safety
1264898|NCT00900588|pandemic influenza A vaccine
1264899|NCT00900575|cervical cancer
1264900|NCT00900575|LEEP
1264901|NCT00900575|colposcopy
1264902|NCT00900562|Zalypsis
1264903|NCT00900562|Cancer
1264904|NCT00900562|Endometrial
1264905|NCT00900562|Uterine Cervical
1264906|NCT00900562|PharmaMar
1264907|NCT00900549|Heart failure
1264908|NCT00900549|Cardiac resynchronization therapy
1264909|NCT00900549|ICD
1264910|NCT00900536|clear cell renal cell carcinoma
1264911|NCT00900536|stage I renal cell cancer
1264912|NCT00900536|stage II renal cell cancer
1264913|NCT00900536|stage III renal cell cancer
1264914|NCT00900536|stage IV renal cell cancer
1264915|NCT00900536|papillary renal cell carcinoma
1264916|NCT00900523|recurrent ovarian epithelial cancer
1264917|NCT00900523|stage I ovarian epithelial cancer
1264918|NCT00900523|stage II ovarian epithelial cancer
1264919|NCT00900523|stage III ovarian epithelial cancer
1264920|NCT00900523|stage IV ovarian epithelial cancer
1264921|NCT00900510|subcutaneous abscess
1264922|NCT00900510|Incision and drainage
1264923|NCT00900510|Methicillin-resistant staphylococcus aureus
1264924|NCT00900497|granulocytes
1264925|NCT00900497|Graft-vs-Host-Disease
1264926|NCT00900484|stage I adult diffuse large cell lymphoma
1264927|NCT00900484|stage I adult diffuse mixed cell lymphoma
1264928|NCT00900484|stage I adult diffuse small cleaved cell lymphoma
1264929|NCT00900484|stage II adult diffuse large cell lymphoma
1264930|NCT00900484|stage II adult diffuse mixed cell lymphoma
1264931|NCT00900484|stage II adult diffuse small cleaved cell lymphoma
1264932|NCT00900484|stage III adult diffuse large cell lymphoma
1264933|NCT00900484|stage III adult diffuse mixed cell lymphoma
1264934|NCT00900484|stage III adult diffuse small cleaved cell lymphoma
1264935|NCT00900484|stage IV adult diffuse large cell lymphoma
1264936|NCT00900484|stage IV adult diffuse mixed cell lymphoma
1264937|NCT00900484|stage IV adult diffuse small cleaved cell lymphoma
1264938|NCT00900484|stage I grade 3 follicular lymphoma
1264939|NCT00900484|stage II grade 3 follicular lymphoma
1264940|NCT00900484|stage III grade 3 follicular lymphoma
1264941|NCT00900484|stage IV grade 3 follicular lymphoma
1264942|NCT00900484|stage I adult immunoblastic large cell lymphoma
1264943|NCT00900484|stage II adult immunoblastic large cell lymphoma
1266280|NCT00898690|recurrent breast cancer
1264944|NCT00900484|stage III adult immunoblastic large cell lymphoma
1264945|NCT00900484|stage IV adult immunoblastic large cell lymphoma
1264946|NCT00900484|stage I adult lymphoblastic lymphoma
1264947|NCT00900484|stage II adult lymphoblastic lymphoma
1264948|NCT00900484|stage III adult lymphoblastic lymphoma
1264949|NCT00900484|stage IV adult lymphoblastic lymphoma
1264950|NCT00900484|stage I adult Burkitt lymphoma
1264951|NCT00900484|stage II adult Burkitt lymphoma
1264952|NCT00900484|stage III adult Burkitt lymphoma
1264953|NCT00900484|stage IV adult Burkitt lymphoma
1264954|NCT00900471|unspecified adult solid tumor, protocol specific
1264955|NCT00900471|unspecified childhood solid tumor, protocol specific
1264956|NCT00900458|preeclampsia
1264957|NCT00900458|low vs high plasma volume
1264958|NCT00900445|childhood acute lymphoblastic leukemia in remission
1264959|NCT00900445|untreated childhood acute lymphoblastic leukemia
1264960|NCT00900432|recurrent colon cancer
1264961|NCT00900432|stage I colon cancer
1264962|NCT00900432|stage II colon cancer
1264963|NCT00900432|stage III colon cancer
1264964|NCT00900432|stage IV colon cancer
1264965|NCT00900419|non-small cell lung cancer
1264966|NCT00900419|small cell lung cancer
1264967|NCT00900419|squamous lung dysplasia
1264968|NCT00900419|hypopharyngeal cancer
1264969|NCT00900419|laryngeal cancer
1264970|NCT00900419|lip and oral cavity cancer
1264971|NCT00900419|metastatic squamous neck cancer with occult primary
1264972|NCT00900419|nasopharyngeal cancer
1264973|NCT00900419|oropharyngeal cancer
1264974|NCT00900419|paranasal sinus and nasal cavity cancer
1264975|NCT00900419|salivary gland cancer
1264976|NCT00900419|esophageal cancer
1264977|NCT00900419|pulmonary carcinoid tumor
1264978|NCT00900419|tongue cancer
1264979|NCT00900380|adult acute monocytic leukemia (M5b)
1264980|NCT00900380|adult acute megakaryoblastic leukemia (M7)
1264981|NCT00900380|adult acute myeloblastic leukemia with maturation (M2)
1264982|NCT00900380|adult acute myeloblastic leukemia without maturation (M1)
1264983|NCT00900380|adult acute myelomonocytic leukemia (M4)
1264984|NCT00900380|adult acute monoblastic leukemia (M5a)
1264985|NCT00900380|secondary acute myeloid leukemia
1264986|NCT00900380|untreated adult acute myeloid leukemia
1264987|NCT00900380|adult acute minimally differentiated myeloid leukemia (M0)
1264988|NCT00900380|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1264989|NCT00900380|adult acute myeloid leukemia with inv(16)(p13;q22)
1264990|NCT00900380|adult acute myeloid leukemia with t(16;16)(p13;q22)
1264991|NCT00900380|adult acute myeloid leukemia with t(8;21)(q22;q22)
1264992|NCT00900380|adult erythroleukemia (M6a)
1264993|NCT00900380|adult pure erythroid leukemia (M6b)
1264994|NCT00900367|breast cancer
1264995|NCT00900354|unspecified childhood solid tumor, protocol specific
1264996|NCT00900341|adult soft tissue sarcoma
1264997|NCT00900341|childhood soft tissue sarcoma
1264998|NCT00900328|adenocarcinoma of the lung
1264999|NCT00900328|recurrent non-small cell lung cancer
1265000|NCT00900328|stage 0 non-small cell lung cancer
1265001|NCT00900328|stage I non-small cell lung cancer
1265002|NCT00900328|stage II non-small cell lung cancer
1265003|NCT00900328|stage IIIA non-small cell lung cancer
1265004|NCT00900328|stage IIIB non-small cell lung cancer
1265005|NCT00900328|stage IV non-small cell lung cancer
1265006|NCT00900302|male breast cancer
1265007|NCT00900302|recurrent breast cancer
1265008|NCT00900302|stage IA breast cancer
1265009|NCT00900302|stage IB breast cancer
1265010|NCT00900302|stage II breast cancer
1265011|NCT00900302|stage IIIA breast cancer
1265012|NCT00900302|stage IIIB breast cancer
1265013|NCT00900302|stage IIIC breast cancer
1265014|NCT00900302|stage IV breast cancer
1265015|NCT00900302|unspecified adult solid tumor, protocol specific
1265016|NCT00900302|unspecified childhood solid tumor, protocol specific
1265017|NCT00900302|squamous cell carcinoma of the anus
1265018|NCT00900302|squamous cell carcinoma of the bladder
1265019|NCT00900302|squamous cell carcinoma of the esophagus
1265020|NCT00900302|squamous cell carcinoma of the gallbladder
1265021|NCT00900302|squamous cell carcinoma of the skin
1265022|NCT00900302|squamous cell carcinoma of the vulva
1265023|NCT00900302|squamous cell lung cancer
1265024|NCT00900302|vaginal squamous cell carcinoma
1265025|NCT00900302|stage I squamous cell carcinoma of the hypopharynx
1265026|NCT00900302|stage II squamous cell carcinoma of the hypopharynx
1265027|NCT00900302|stage III squamous cell carcinoma of the hypopharynx
1265028|NCT00900302|stage IV squamous cell carcinoma of the hypopharynx
1265029|NCT00900302|recurrent squamous cell carcinoma of the hypopharynx
1265030|NCT00900302|stage I squamous cell carcinoma of the larynx
1265031|NCT00900302|stage I verrucous carcinoma of the larynx
1265032|NCT00900302|stage II squamous cell carcinoma of the larynx
1265033|NCT00900302|stage II verrucous carcinoma of the larynx
1265034|NCT00900302|stage III squamous cell carcinoma of the larynx
1265035|NCT00900302|stage III verrucous carcinoma of the larynx
1265036|NCT00900302|stage IV squamous cell carcinoma of the larynx
1265037|NCT00900302|stage IV verrucous carcinoma of the larynx
1265038|NCT00900302|recurrent squamous cell carcinoma of the larynx
1265039|NCT00900302|recurrent verrucous carcinoma of the larynx
1265040|NCT00900302|stage I squamous cell carcinoma of the lip and oral cavity
1265041|NCT00900302|stage II squamous cell carcinoma of the lip and oral cavity
1265042|NCT00900302|stage III squamous cell carcinoma of the lip and oral cavity
1265043|NCT00900302|stage IV squamous cell carcinoma of the lip and oral cavity
1265044|NCT00900302|recurrent squamous cell carcinoma of the lip and oral cavity
1265045|NCT00900302|stage I verrucous carcinoma of the oral cavity
1265046|NCT00900302|stage II verrucous carcinoma of the oral cavity
1265047|NCT00900302|stage III verrucous carcinoma of the oral cavity
1265048|NCT00900302|stage IV verrucous carcinoma of the oral cavity
1265049|NCT00900302|recurrent verrucous carcinoma of the oral cavity
1265050|NCT00900302|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1265051|NCT00900302|recurrent metastatic squamous neck cancer with occult primary
1265052|NCT00900302|untreated metastatic squamous neck cancer with occult primary
1265053|NCT00900302|stage I squamous cell carcinoma of the nasopharynx
1265054|NCT00900302|stage II squamous cell carcinoma of the nasopharynx
1265055|NCT00900302|stage III squamous cell carcinoma of the nasopharynx
1265056|NCT00900302|stage IV squamous cell carcinoma of the nasopharynx
1265057|NCT00900302|recurrent squamous cell carcinoma of the nasopharynx
1265058|NCT00900302|stage I squamous cell carcinoma of the oropharynx
1265059|NCT00900302|stage II squamous cell carcinoma of the oropharynx
1265060|NCT00900302|stage III squamous cell carcinoma of the oropharynx
1265061|NCT00900302|stage IV squamous cell carcinoma of the oropharynx
1265062|NCT00900302|recurrent squamous cell carcinoma of the oropharynx
1265063|NCT00900302|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1265064|NCT00900302|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1265065|NCT00900302|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1265066|NCT00900302|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1265067|NCT00900302|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1265068|NCT00900302|salivary gland squamous cell carcinoma
1265069|NCT00900302|stage I salivary gland cancer
1265070|NCT00900302|stage II salivary gland cancer
1265071|NCT00900302|stage III salivary gland cancer
1265072|NCT00900302|stage IV salivary gland cancer
1265073|NCT00900302|recurrent salivary gland cancer
1265074|NCT00900302|squamous cell carcinoma of unknown primary
1265075|NCT00900302|cervical squamous cell carcinoma
1265076|NCT00900302|penile squamous cell carcinoma
1265077|NCT00900302|recurrent anal cancer
1265078|NCT00900302|stage I anal cancer
1265079|NCT00900302|stage II anal cancer
1265080|NCT00900302|stage IIIA anal cancer
1265081|NCT00900302|stage IIIB anal cancer
1265082|NCT00900302|stage IV anal cancer
1265083|NCT00900302|recurrent bladder cancer
1265084|NCT00900302|stage I bladder cancer
1265085|NCT00900302|stage II bladder cancer
1265086|NCT00900302|stage III bladder cancer
1265087|NCT00900302|stage IV bladder cancer
1265088|NCT00900302|recurrent esophageal cancer
1265089|NCT00900302|stage I esophageal cancer
1265090|NCT00900302|stage II esophageal cancer
1265091|NCT00900302|stage III esophageal cancer
1265092|NCT00900302|stage IV esophageal cancer
1265093|NCT00900302|localized gallbladder cancer
1265094|NCT00900302|recurrent gallbladder cancer
1265095|NCT00900302|unresectable gallbladder cancer
1265096|NCT00900302|recurrent vulvar cancer
1265097|NCT00900302|stage I vulvar cancer
1265098|NCT00900302|stage II vulvar cancer
1265099|NCT00900302|stage III vulvar cancer
1265100|NCT00900302|stage IV vulvar cancer
1265101|NCT00900302|recurrent cervical cancer
1265102|NCT00900302|stage IA cervical cancer
1265103|NCT00900302|stage IB cervical cancer
1265104|NCT00900302|stage IIA cervical cancer
1265105|NCT00900302|stage IIB cervical cancer
1265106|NCT00900302|stage III cervical cancer
1265107|NCT00900302|stage IVA cervical cancer
1265108|NCT00900302|stage IVB cervical cancer
1265109|NCT00900302|recurrent non-small cell lung cancer
1265110|NCT00900302|stage I non-small cell lung cancer
1265111|NCT00900302|stage II non-small cell lung cancer
1265112|NCT00900302|stage IIIA non-small cell lung cancer
1265113|NCT00900302|stage IIIB non-small cell lung cancer
1265114|NCT00900302|stage IV non-small cell lung cancer
1265115|NCT00900302|recurrent skin cancer
1265116|NCT00900302|newly diagnosed carcinoma of unknown primary
1265117|NCT00900302|recurrent carcinoma of unknown primary
1265118|NCT00900302|recurrent penile cancer
1265119|NCT00900302|stage I penile cancer
1265120|NCT00900302|stage II penile cancer
1265121|NCT00900302|stage III penile cancer
1265122|NCT00900302|stage IV penile cancer
1265123|NCT00900302|recurrent melanoma
1265124|NCT00900302|stage IA melanoma
1265125|NCT00900302|stage IB melanoma
1265126|NCT00900302|stage IIA melanoma
1265127|NCT00900302|stage IIB melanoma
1265128|NCT00900302|stage IIC melanoma
1265129|NCT00900302|stage IIIA melanoma
1265130|NCT00900302|stage IIIB melanoma
1265131|NCT00900302|stage IIIC melanoma
1265132|NCT00900302|stage IV melanoma
1265133|NCT00900289|stage IC ovarian epithelial cancer
1265134|NCT00900289|stage IIA ovarian epithelial cancer
1265135|NCT00900289|stage IIB ovarian epithelial cancer
1265136|NCT00900289|stage IIC ovarian epithelial cancer
1265137|NCT00900289|stage IIIA ovarian epithelial cancer
1265138|NCT00900289|stage IIIB ovarian epithelial cancer
1265139|NCT00900289|stage IIIC ovarian epithelial cancer
1265140|NCT00900289|stage IV ovarian epithelial cancer
1265141|NCT00900276|localized transitional cell cancer of the renal pelvis and ureter
1265142|NCT00900276|metastatic transitional cell cancer of the renal pelvis and ureter
1265143|NCT00900276|recurrent transitional cell cancer of the renal pelvis and ureter
1265144|NCT00900276|regional transitional cell cancer of the renal pelvis and ureter
1265145|NCT00900276|transitional cell carcinoma of the bladder
1265146|NCT00900276|stage I renal cell cancer
1265147|NCT00900276|stage II renal cell cancer
1265148|NCT00900276|recurrent renal cell cancer
1265149|NCT00900276|recurrent bladder cancer
1265150|NCT00900276|stage I bladder cancer
1265151|NCT00900276|stage II bladder cancer
1265152|NCT00900276|stage III bladder cancer
1265153|NCT00900276|stage IV bladder cancer
1265154|NCT00900276|anterior urethral cancer
1265155|NCT00900276|posterior urethral cancer
1265156|NCT00900276|recurrent urethral cancer
1265157|NCT00900276|urethral cancer associated with invasive bladder cancer
1265158|NCT00900263|stage I multiple myeloma
1265159|NCT00900263|isolated plasmacytoma of bone
1265160|NCT00900263|monoclonal gammopathy of undetermined significance
1265161|NCT00900237|Partial
1265162|NCT00900237|Epilepsy
1265163|NCT00900237|Eslicarbazepine acetate
1265164|NCT00900237|Pharmacokinetics
1265165|NCT00900237|Tolerability
1265166|NCT00900224|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265167|NCT00900224|adult acute myeloid leukemia with inv(16)(p13;q22)
1265168|NCT00900224|adult acute myeloid leukemia with t(15;17)(q22;q12)
1265169|NCT00900224|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265170|NCT00900224|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265171|NCT00900224|untreated adult acute myeloid leukemia
1265172|NCT00900224|untreated childhood acute myeloid leukemia and other myeloid malignancies
1265173|NCT00900224|secondary acute myeloid leukemia
1265174|NCT00900211|recurrent adult soft tissue sarcoma
1265175|NCT00900211|stage I adult soft tissue sarcoma
1265176|NCT00900211|stage II adult soft tissue sarcoma
1265177|NCT00900211|stage III adult soft tissue sarcoma
1265178|NCT00900211|adult synovial sarcoma
1265179|NCT00900211|adult angiosarcoma
1265180|NCT00900211|adult epithelioid sarcoma
1265181|NCT00900211|adult extraskeletal chondrosarcoma
1265182|NCT00900211|adult leiomyosarcoma
1265183|NCT00900211|adult liposarcoma
1265184|NCT00900211|adult malignant fibrous histiocytoma
1265185|NCT00900211|adult malignant hemangiopericytoma
1265186|NCT00900211|adult malignant mesenchymoma
1265187|NCT00900211|adult fibrosarcoma
1265188|NCT00900211|adult neurofibrosarcoma
1265194|NCT00900185|recurrent prostate cancer
1265195|NCT00900185|stage I prostate cancer
1265196|NCT00900185|stage IIB prostate cancer
1265197|NCT00900185|stage IIA prostate cancer
1265198|NCT00900185|stage III prostate cancer
1265199|NCT00900185|stage IV prostate cancer
1265200|NCT00900172|stage IIIB non-small cell lung cancer
1265201|NCT00900172|stage IV non-small cell lung cancer
1265202|NCT00900172|recurrent non-small cell lung cancer
1265203|NCT00900172|adenocarcinoma of the lung
1265204|NCT00900172|bronchoalveolar cell lung cancer
1265205|NCT00900159|Shift-work
1265206|NCT00900159|SWSD
1265207|NCT00900159|eszopiclone
1265208|NCT00900159|MWT
1265209|NCT00900159|shiftworkers
1265210|NCT00900146|type 2 diabetes
1265211|NCT00900146|canakinumab
1265212|NCT00900133|stage I breast cancer
1265213|NCT00900133|stage II breast cancer
1265214|NCT00900133|stage IIIA breast cancer
1265215|NCT00900133|stage IIIB breast cancer
1265216|NCT00900133|stage IIIC breast cancer
1265217|NCT00900120|aplastic anemia
1265218|NCT00900120|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1265219|NCT00900120|unspecified adult solid tumor, protocol specific
1265220|NCT00900120|unspecified childhood solid tumor, protocol specific
1265221|NCT00900120|secondary myelodysplastic syndromes
1265222|NCT00900120|accelerated phase chronic myelogenous leukemia
1265223|NCT00900120|acute undifferentiated leukemia
1265224|NCT00900120|adult acute lymphoblastic leukemia in remission
1265225|NCT00900120|adult acute myeloid leukemia in remission
1265226|NCT00900120|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265227|NCT00900120|adult acute myeloid leukemia with inv(16)(p13;q22)
1265228|NCT00900120|adult acute myeloid leukemia with t(15;17)(q22;q12)
1265229|NCT00900120|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265230|NCT00900120|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265231|NCT00900120|atypical chronic myeloid leukemia, BCR-ABL negative
1265232|NCT00900120|blastic phase chronic myelogenous leukemia
1265233|NCT00900120|childhood acute lymphoblastic leukemia in remission
1265234|NCT00900120|childhood acute myeloid leukemia in remission
1265235|NCT00900120|childhood chronic myelogenous leukemia
1265236|NCT00900120|chronic myelomonocytic leukemia
1265237|NCT00900120|chronic phase chronic myelogenous leukemia
1265238|NCT00900120|juvenile myelomonocytic leukemia
1265239|NCT00900120|mast cell leukemia
1265240|NCT00900120|meningeal chronic myelogenous leukemia
1265241|NCT00900120|progressive hairy cell leukemia, initial treatment
1265242|NCT00900120|prolymphocytic leukemia
1265243|NCT00900120|recurrent adult acute lymphoblastic leukemia
1265244|NCT00900120|recurrent adult acute myeloid leukemia
1265245|NCT00900120|recurrent adult T-cell leukemia/lymphoma
1265246|NCT00900120|recurrent childhood acute lymphoblastic leukemia
1265247|NCT00900120|recurrent childhood acute myeloid leukemia
1265248|NCT00900120|refractory chronic lymphocytic leukemia
1265249|NCT00900120|refractory hairy cell leukemia
1265250|NCT00900120|relapsing chronic myelogenous leukemia
1265251|NCT00900120|secondary acute myeloid leukemia
1265252|NCT00900120|stage 0 chronic lymphocytic leukemia
1265253|NCT00900120|stage I adult T-cell leukemia/lymphoma
1265254|NCT00900120|stage I chronic lymphocytic leukemia
1265255|NCT00900120|stage II adult T-cell leukemia/lymphoma
1265256|NCT00900120|stage II chronic lymphocytic leukemia
1265257|NCT00900120|stage III adult T-cell leukemia/lymphoma
1265258|NCT00900120|stage III chronic lymphocytic leukemia
1265259|NCT00900120|stage IV adult T-cell leukemia/lymphoma
1265260|NCT00900120|stage IV chronic lymphocytic leukemia
1265261|NCT00900120|T-cell large granular lymphocyte leukemia
1265262|NCT00900120|untreated adult acute lymphoblastic leukemia
1265263|NCT00900120|untreated adult acute myeloid leukemia
1265264|NCT00900120|untreated childhood acute lymphoblastic leukemia
1265265|NCT00900120|untreated childhood acute myeloid leukemia and other myeloid malignancies
1265266|NCT00900120|untreated hairy cell leukemia
1265267|NCT00900120|AIDS-related diffuse large cell lymphoma
1265268|NCT00900120|AIDS-related diffuse mixed cell lymphoma
1265269|NCT00900120|AIDS-related diffuse small cleaved cell lymphoma
1265270|NCT00900120|AIDS-related immunoblastic large cell lymphoma
1265271|NCT00900120|AIDS-related lymphoblastic lymphoma
1265272|NCT00900120|AIDS-related peripheral/systemic lymphoma
1265273|NCT00900120|AIDS-related primary CNS lymphoma
1265274|NCT00900120|AIDS-related small noncleaved cell lymphoma
1265275|NCT00900120|HIV-associated Hodgkin lymphoma
1265276|NCT00900120|recurrent adult Hodgkin lymphoma
1265277|NCT00900120|recurrent/refractory childhood Hodgkin lymphoma
1265278|NCT00900120|stage I adult Hodgkin lymphoma
1265279|NCT00900120|stage I childhood Hodgkin lymphoma
1265280|NCT00900120|stage II adult Hodgkin lymphoma
1265281|NCT00900120|stage II childhood Hodgkin lymphoma
1265282|NCT00900120|stage III adult Hodgkin lymphoma
1265283|NCT00900120|stage III childhood Hodgkin lymphoma
1265284|NCT00900120|stage IV adult Hodgkin lymphoma
1265285|NCT00900120|stage IV childhood Hodgkin lymphoma
1265286|NCT00900120|anaplastic large cell lymphoma
1265287|NCT00900120|angioimmunoblastic T-cell lymphoma
1265288|NCT00900120|cutaneous B-cell non-Hodgkin lymphoma
1265289|NCT00900120|recurrent cutaneous T-cell non-Hodgkin lymphoma
1265290|NCT00900120|stage I cutaneous T-cell non-Hodgkin lymphoma
1265291|NCT00900120|stage II cutaneous T-cell non-Hodgkin lymphoma
1265292|NCT00900120|stage III cutaneous T-cell non-Hodgkin lymphoma
1265293|NCT00900120|stage IV cutaneous T-cell non-Hodgkin lymphoma
1265294|NCT00900120|recurrent mycosis fungoides/Sezary syndrome
1265295|NCT00900120|stage I mycosis fungoides/Sezary syndrome
1265296|NCT00900120|stage II mycosis fungoides/Sezary syndrome
1265297|NCT00900120|stage III mycosis fungoides/Sezary syndrome
1265298|NCT00900120|stage IV mycosis fungoides/Sezary syndrome
1265299|NCT00900120|adult grade III lymphomatoid granulomatosis
1265300|NCT00900120|adult nasal type extranodal NK/T-cell lymphoma
1265301|NCT00900120|Waldenstrom macroglobulinemia
1265302|NCT00900120|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1265303|NCT00900120|nodal marginal zone B-cell lymphoma
1265304|NCT00900120|splenic marginal zone lymphoma
1265305|NCT00900120|contiguous stage II adult Burkitt lymphoma
1265306|NCT00900120|contiguous stage II adult diffuse large cell lymphoma
1265307|NCT00900120|contiguous stage II adult diffuse mixed cell lymphoma
1265308|NCT00900120|contiguous stage II adult diffuse small cleaved cell lymphoma
1265309|NCT00900120|contiguous stage II adult immunoblastic large cell lymphoma
1265310|NCT00900120|contiguous stage II adult lymphoblastic lymphoma
1265311|NCT00900120|contiguous stage II grade 1 follicular lymphoma
1265312|NCT00900120|contiguous stage II grade 2 follicular lymphoma
1265313|NCT00900120|contiguous stage II grade 3 follicular lymphoma
1265314|NCT00900120|contiguous stage II mantle cell lymphoma
1265315|NCT00900120|contiguous stage II marginal zone lymphoma
1265316|NCT00900120|contiguous stage II small lymphocytic lymphoma
1265317|NCT00900120|stage I adult Burkitt lymphoma
1265318|NCT00900120|stage I adult diffuse large cell lymphoma
1265319|NCT00900120|stage I adult diffuse mixed cell lymphoma
1265320|NCT00900120|stage I adult diffuse small cleaved cell lymphoma
1265321|NCT00900120|stage I adult immunoblastic large cell lymphoma
1265322|NCT00900120|stage I adult lymphoblastic lymphoma
1265323|NCT00900120|stage I grade 1 follicular lymphoma
1265324|NCT00900120|stage I grade 2 follicular lymphoma
1265325|NCT00900120|stage I grade 3 follicular lymphoma
1265326|NCT00900120|stage I mantle cell lymphoma
1265327|NCT00900120|stage I marginal zone lymphoma
1265328|NCT00900120|stage I small lymphocytic lymphoma
1265329|NCT00900120|noncontiguous stage II adult Burkitt lymphoma
1265330|NCT00900120|noncontiguous stage II adult diffuse large cell lymphoma
1265331|NCT00900120|noncontiguous stage II adult diffuse mixed cell lymphoma
1265332|NCT00900120|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1265426|NCT00900094|stage IIIB breast cancer
1265333|NCT00900120|noncontiguous stage II adult immunoblastic large cell lymphoma
1265334|NCT00900120|noncontiguous stage II adult lymphoblastic lymphoma
1265335|NCT00900120|noncontiguous stage II grade 1 follicular lymphoma
1265336|NCT00900120|noncontiguous stage II grade 2 follicular lymphoma
1265337|NCT00900120|noncontiguous stage II grade 3 follicular lymphoma
1265338|NCT00900120|noncontiguous stage II mantle cell lymphoma
1265339|NCT00900120|noncontiguous stage II marginal zone lymphoma
1265340|NCT00900120|noncontiguous stage II small lymphocytic lymphoma
1265341|NCT00900120|stage I childhood large cell lymphoma
1265342|NCT00900120|stage I childhood lymphoblastic lymphoma
1265343|NCT00900120|stage I childhood small noncleaved cell lymphoma
1265344|NCT00900120|stage II childhood large cell lymphoma
1265345|NCT00900120|stage II childhood lymphoblastic lymphoma
1265346|NCT00900120|stage II childhood small noncleaved cell lymphoma
1265347|NCT00900120|stage III adult Burkitt lymphoma
1265348|NCT00900120|stage III adult diffuse large cell lymphoma
1265349|NCT00900120|stage III adult diffuse mixed cell lymphoma
1265350|NCT00900120|stage III adult diffuse small cleaved cell lymphoma
1265351|NCT00900120|stage III adult immunoblastic large cell lymphoma
1265352|NCT00900120|stage III adult lymphoblastic lymphoma
1265353|NCT00900120|stage III childhood large cell lymphoma
1265354|NCT00900120|stage III childhood lymphoblastic lymphoma
1265355|NCT00900120|stage III childhood small noncleaved cell lymphoma
1265356|NCT00900120|stage III grade 1 follicular lymphoma
1265357|NCT00900120|stage III grade 2 follicular lymphoma
1265358|NCT00900120|stage III grade 3 follicular lymphoma
1265359|NCT00900120|stage III mantle cell lymphoma
1265360|NCT00900120|stage III marginal zone lymphoma
1265361|NCT00900120|stage III small lymphocytic lymphoma
1265362|NCT00900120|stage IV adult Burkitt lymphoma
1265363|NCT00900120|stage IV adult diffuse large cell lymphoma
1265364|NCT00900120|stage IV adult diffuse mixed cell lymphoma
1265365|NCT00900120|stage IV adult diffuse small cleaved cell lymphoma
1265366|NCT00900120|stage IV adult immunoblastic large cell lymphoma
1265367|NCT00900120|stage IV adult lymphoblastic lymphoma
1265368|NCT00900120|stage IV childhood large cell lymphoma
1265369|NCT00900120|stage IV childhood lymphoblastic lymphoma
1265370|NCT00900120|stage IV childhood small noncleaved cell lymphoma
1265371|NCT00900120|stage IV grade 1 follicular lymphoma
1265372|NCT00900120|stage IV grade 2 follicular lymphoma
1265373|NCT00900120|stage IV grade 3 follicular lymphoma
1265374|NCT00900120|stage IV mantle cell lymphoma
1265375|NCT00900120|stage IV marginal zone lymphoma
1265376|NCT00900120|stage IV small lymphocytic lymphoma
1265377|NCT00900120|recurrent adult Burkitt lymphoma
1265378|NCT00900120|recurrent adult diffuse large cell lymphoma
1265379|NCT00900120|recurrent adult diffuse mixed cell lymphoma
1265380|NCT00900120|recurrent adult diffuse small cleaved cell lymphoma
1265381|NCT00900120|recurrent adult grade III lymphomatoid granulomatosis
1265382|NCT00900120|recurrent adult immunoblastic large cell lymphoma
1265383|NCT00900120|recurrent adult lymphoblastic lymphoma
1265384|NCT00900120|recurrent childhood grade III lymphomatoid granulomatosis
1265385|NCT00900120|recurrent childhood large cell lymphoma
1265386|NCT00900120|recurrent childhood lymphoblastic lymphoma
1265387|NCT00900120|recurrent childhood small noncleaved cell lymphoma
1265388|NCT00900120|recurrent grade 1 follicular lymphoma
1265389|NCT00900120|recurrent grade 2 follicular lymphoma
1265390|NCT00900120|recurrent grade 3 follicular lymphoma
1265391|NCT00900120|recurrent mantle cell lymphoma
1265392|NCT00900120|recurrent marginal zone lymphoma
1265393|NCT00900120|recurrent small lymphocytic lymphoma
1265394|NCT00900120|Burkitt lymphoma
1265395|NCT00900120|childhood diffuse large cell lymphoma
1265396|NCT00900120|childhood grade III lymphomatoid granulomatosis
1265397|NCT00900120|childhood immunoblastic large cell lymphoma
1265398|NCT00900120|childhood nasal type extranodal NK/T-cell lymphoma
1265399|NCT00900120|intraocular lymphoma
1265400|NCT00900120|primary central nervous system non-Hodgkin lymphoma
1265401|NCT00900120|primary central nervous system Hodgkin lymphoma
1265402|NCT00900120|post-transplant lymphoproliferative disorder
1265403|NCT00900120|chronic eosinophilic leukemia
1265404|NCT00900120|chronic neutrophilic leukemia
1265405|NCT00900120|primary myelofibrosis
1265406|NCT00900120|essential thrombocythemia
1265407|NCT00900120|polycythemia vera
1265408|NCT00900120|extramedullary plasmacytoma
1265409|NCT00900120|isolated plasmacytoma of bone
1265410|NCT00900120|stage I multiple myeloma
1265411|NCT00900120|stage II multiple myeloma
1265412|NCT00900120|stage III multiple myeloma
1265413|NCT00900120|primary systemic amyloidosis
1265414|NCT00900120|refractory multiple myeloma
1265415|NCT00900120|de novo myelodysplastic syndromes
1265416|NCT00900120|previously treated myelodysplastic syndromes
1265417|NCT00900120|childhood myelodysplastic syndromes
1265418|NCT00900120|recurrent childhood anaplastic large cell lymphoma
1265419|NCT00900120|stage I childhood anaplastic large cell lymphoma
1265420|NCT00900120|stage II childhood anaplastic large cell lymphoma
1265421|NCT00900120|stage III childhood anaplastic large cell lymphoma
1265422|NCT00900120|stage IV childhood anaplastic large cell lymphoma
1265423|NCT00900094|stage I breast cancer
1265424|NCT00900094|stage II breast cancer
1265425|NCT00900094|stage IIIA breast cancer
1265428|NCT00900094|adenocarcinoma of the colon
1265429|NCT00900094|stage I colon cancer
1265430|NCT00900094|stage II colon cancer
1265431|NCT00900094|stage III colon cancer
1265432|NCT00900094|stage IV colon cancer
1265433|NCT00900094|adenocarcinoma of the esophagus
1265434|NCT00900094|squamous cell carcinoma of the esophagus
1265435|NCT00900094|stage I esophageal cancer
1265436|NCT00900094|stage II esophageal cancer
1265437|NCT00900094|stage III esophageal cancer
1265438|NCT00900094|stage IV esophageal cancer
1265439|NCT00900094|stage I non-small cell lung cancer
1265440|NCT00900094|stage II non-small cell lung cancer
1265441|NCT00900094|stage IIIA non-small cell lung cancer
1265442|NCT00900094|stage IIIB non-small cell lung cancer
1265443|NCT00900094|stage IV non-small cell lung cancer
1265444|NCT00900094|stage I ovarian epithelial cancer
1265445|NCT00900094|stage II ovarian epithelial cancer
1265446|NCT00900094|stage III ovarian epithelial cancer
1265447|NCT00900094|stage IV ovarian epithelial cancer
1265448|NCT00900094|localized unresectable adult primary liver cancer
1265449|NCT00900094|advanced adult primary liver cancer
1265450|NCT00900094|adenocarcinoma of the pancreas
1265451|NCT00900094|stage II pancreatic cancer
1265452|NCT00900094|stage III pancreatic cancer
1265453|NCT00900094|extensive stage small cell lung cancer
1265454|NCT00900094|stage IIIC breast cancer
1265455|NCT00900094|stage IV pancreatic cancer
1265456|NCT00900094|recurrent breast cancer
1265457|NCT00900094|recurrent colon cancer
1265458|NCT00900094|recurrent esophageal cancer
1265459|NCT00900094|recurrent non-small cell lung cancer
1265460|NCT00900094|recurrent ovarian epithelial cancer
1265461|NCT00900094|recurrent adult primary liver cancer
1265462|NCT00900094|adult primary hepatocellular carcinoma
1265463|NCT00900094|recurrent small cell lung cancer
1265464|NCT00900081|cervical squamous cell carcinoma
1265465|NCT00900081|stage IA cervical cancer
1265466|NCT00900081|stage 0 cervical cancer
1265467|NCT00900081|cervical intraepithelial neoplasia grade 1
1265468|NCT00900081|cervical intraepithelial neoplasia grade 2
1265469|NCT00900081|cervical intraepithelial neoplasia grade 3
1265470|NCT00900068|nausea and vomiting
1265471|NCT00900068|stage III adult Burkitt lymphoma
1265472|NCT00900068|stage III adult diffuse large cell lymphoma
1265473|NCT00900068|stage III adult diffuse mixed cell lymphoma
1265474|NCT00900068|stage III adult diffuse small cleaved cell lymphoma
1265475|NCT00900068|stage III adult Hodgkin lymphoma
1265476|NCT00900068|stage III adult immunoblastic large cell lymphoma
1265477|NCT00900068|stage III adult lymphoblastic lymphoma
1265478|NCT00900068|stage III grade 1 follicular lymphoma
1265479|NCT00900068|stage III grade 2 follicular lymphoma
1265480|NCT00900068|stage III grade 3 follicular lymphoma
1265481|NCT00900068|stage III mantle cell lymphoma
1265482|NCT00900068|stage III marginal zone lymphoma
1265483|NCT00900068|stage III small lymphocytic lymphoma
1265484|NCT00900068|stage IV adult Burkitt lymphoma
1265485|NCT00900068|stage IV adult diffuse large cell lymphoma
1265486|NCT00900068|stage IV adult diffuse mixed cell lymphoma
1265487|NCT00900068|stage IV adult diffuse small cleaved cell lymphoma
1265488|NCT00900068|stage IV adult Hodgkin lymphoma
1265489|NCT00900068|stage IV adult immunoblastic large cell lymphoma
1265490|NCT00900068|stage IV adult lymphoblastic lymphoma
1265491|NCT00900068|stage IV grade 1 follicular lymphoma
1265492|NCT00900068|stage IV grade 2 follicular lymphoma
1265493|NCT00900068|stage IV grade 3 follicular lymphoma
1265494|NCT00900068|stage IV mantle cell lymphoma
1265495|NCT00900068|stage IV marginal zone lymphoma
1265496|NCT00900068|stage IV small lymphocytic lymphoma
1265497|NCT00900068|recurrent adult Burkitt lymphoma
1265498|NCT00900068|recurrent adult diffuse large cell lymphoma
1265499|NCT00900068|recurrent adult diffuse mixed cell lymphoma
1265500|NCT00900068|recurrent adult diffuse small cleaved cell lymphoma
1265501|NCT00900068|recurrent adult Hodgkin lymphoma
1265502|NCT00900068|recurrent adult immunoblastic large cell lymphoma
1265503|NCT00900068|recurrent adult lymphoblastic lymphoma
1265504|NCT00900068|recurrent cutaneous T-cell non-Hodgkin lymphoma
1265505|NCT00900068|recurrent grade 1 follicular lymphoma
1265506|NCT00900068|recurrent grade 2 follicular lymphoma
1265507|NCT00900068|recurrent grade 3 follicular lymphoma
1265508|NCT00900068|recurrent mantle cell lymphoma
1265509|NCT00900068|recurrent marginal zone lymphoma
1265510|NCT00900068|recurrent small lymphocytic lymphoma
1265511|NCT00900068|recurrent mycosis fungoides/Sezary syndrome
1265512|NCT00900068|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1265513|NCT00900068|nodal marginal zone B-cell lymphoma
1265514|NCT00900068|splenic marginal zone lymphoma
1265515|NCT00900068|noncontiguous stage II adult Burkitt lymphoma
1265516|NCT00900068|noncontiguous stage II adult diffuse large cell lymphoma
1265517|NCT00900068|noncontiguous stage II adult diffuse mixed cell lymphoma
1265518|NCT00900068|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1265519|NCT00900068|noncontiguous stage II adult immunoblastic large cell lymphoma
1265520|NCT00900068|noncontiguous stage II adult lymphoblastic lymphoma
1265521|NCT00900068|noncontiguous stage II grade 1 follicular lymphoma
1265522|NCT00900068|noncontiguous stage II grade 2 follicular lymphoma
1266542|NCT00898508|stage II breast cancer
1265523|NCT00900068|noncontiguous stage II grade 3 follicular lymphoma
1265524|NCT00900068|noncontiguous stage II mantle cell lymphoma
1265525|NCT00900068|noncontiguous stage II marginal zone lymphoma
1265526|NCT00900068|noncontiguous stage II small lymphocytic lymphoma
1265527|NCT00900068|accelerated phase chronic myelogenous leukemia
1265528|NCT00900068|adult acute lymphoblastic leukemia in remission
1265529|NCT00900068|adult acute myeloid leukemia in remission
1265530|NCT00900068|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265531|NCT00900068|adult acute myeloid leukemia with inv(16)(p13;q22)
1265532|NCT00900068|adult acute myeloid leukemia with t(15;17)(q22;q12)
1265533|NCT00900068|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265534|NCT00900068|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265535|NCT00900068|atypical chronic myeloid leukemia, BCR-ABL negative
1265536|NCT00900068|blastic phase chronic myelogenous leukemia
1265537|NCT00900068|chronic myelomonocytic leukemia
1265538|NCT00900068|chronic phase chronic myelogenous leukemia
1265539|NCT00900068|recurrent adult acute lymphoblastic leukemia
1265540|NCT00900068|recurrent adult acute myeloid leukemia
1265541|NCT00900068|refractory chronic lymphocytic leukemia
1265542|NCT00900068|refractory hairy cell leukemia
1265543|NCT00900068|relapsing chronic myelogenous leukemia
1265544|NCT00900068|secondary acute myeloid leukemia
1265545|NCT00900068|stage III chronic lymphocytic leukemia
1265546|NCT00900068|stage IV chronic lymphocytic leukemia
1265547|NCT00900068|chronic eosinophilic leukemia
1265548|NCT00900068|primary myelofibrosis
1265549|NCT00900068|chronic neutrophilic leukemia
1265550|NCT00900068|de novo myelodysplastic syndromes
1265551|NCT00900068|disseminated neuroblastoma
1265552|NCT00900068|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1265553|NCT00900068|poor prognosis metastatic gestational trophoblastic tumor
1265554|NCT00900068|previously treated myelodysplastic syndromes
1265555|NCT00900068|recurrent neuroblastoma
1265556|NCT00900068|recurrent ovarian epithelial cancer
1265557|NCT00900068|recurrent ovarian germ cell tumor
1265558|NCT00900068|recurrent malignant testicular germ cell tumor
1265559|NCT00900068|secondary myelodysplastic syndromes
1265560|NCT00900068|stage I multiple myeloma
1265561|NCT00900068|stage II multiple myeloma
1265562|NCT00900068|stage III multiple myeloma
1265563|NCT00900068|stage II ovarian epithelial cancer
1265564|NCT00900068|stage III ovarian epithelial cancer
1265565|NCT00900068|stage IV ovarian epithelial cancer
1265566|NCT00900068|stage III malignant testicular germ cell tumor
1265567|NCT00900068|stage IIIA breast cancer
1265568|NCT00900068|stage IIIB breast cancer
1265569|NCT00900068|stage IIIC breast cancer
1265570|NCT00900068|stage IV breast cancer
1265571|NCT00900068|refractory multiple myeloma
1265572|NCT00900055|Fanconi anemia
1265573|NCT00900055|multiple myeloma and other plasma cell neoplasms
1265574|NCT00900055|chronic myeloproliferative disorders
1265575|NCT00900055|myelodysplastic/myeloproliferative neoplasms
1265576|NCT00900042|stage IV renal cell cancer
1265577|NCT00900029|Venous Leg Ulcer
1265578|NCT00900029|Venous Stasis Ulcer
1265579|NCT00900029|VLU
1265580|NCT00900029|VSU
1265581|NCT00900029|Leg Ulcer
1265582|NCT00900029|Leg Wound
1265583|NCT00900016|adenocarcinoma of the pancreas
1265584|NCT00900016|recurrent pancreatic cancer
1265585|NCT00900016|stage I pancreatic cancer
1265586|NCT00900016|stage II pancreatic cancer
1265587|NCT00900003|stage I pancreatic cancer
1265588|NCT00900003|stage II pancreatic cancer
1265589|NCT00900003|stage III pancreatic cancer
1265590|NCT00900003|stage IV pancreatic cancer
1265591|NCT00899977|refractory hypertension
1265592|NCT00899977|hypertension
1265593|NCT00899951|unspecified adult solid tumor, protocol specific
1265594|NCT00899951|accelerated phase chronic myelogenous leukemia
1265595|NCT00899951|acute undifferentiated leukemia
1265596|NCT00899951|adult acute lymphoblastic leukemia in remission
1265597|NCT00899951|adult acute myeloid leukemia in remission
1265598|NCT00899951|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265599|NCT00899951|adult acute myeloid leukemia with inv(16)(p13;q22)
1265600|NCT00899951|adult acute myeloid leukemia with t(15;17)(q22;q12)
1265601|NCT00899951|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265602|NCT00899951|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265603|NCT00899951|atypical chronic myeloid leukemia, BCR-ABL1 negative
1265604|NCT00899951|blastic phase chronic myelogenous leukemia
1265605|NCT00899951|chronic myelomonocytic leukemia
1265606|NCT00899951|chronic phase chronic myelogenous leukemia
1265607|NCT00899951|mast cell leukemia
1265608|NCT00899951|meningeal chronic myelogenous leukemia
1265609|NCT00899951|progressive hairy cell leukemia, initial treatment
1265610|NCT00899951|prolymphocytic leukemia
1265611|NCT00899951|recurrent adult acute lymphoblastic leukemia
1265612|NCT00899951|recurrent adult acute myeloid leukemia
1265613|NCT00899951|recurrent adult T-cell leukemia/lymphoma
1265614|NCT00899951|refractory chronic lymphocytic leukemia
1265615|NCT00899951|refractory hairy cell leukemia
1265616|NCT00899951|relapsing chronic myelogenous leukemia
1265617|NCT00899951|secondary acute myeloid leukemia
1265618|NCT00899951|stage 0 chronic lymphocytic leukemia
1265619|NCT00899951|stage I adult T-cell leukemia/lymphoma
1265620|NCT00899951|stage I chronic lymphocytic leukemia
1265621|NCT00899951|stage II adult T-cell leukemia/lymphoma
1265622|NCT00899951|stage II chronic lymphocytic leukemia
1265623|NCT00899951|stage III adult T-cell leukemia/lymphoma
1265624|NCT00899951|stage III chronic lymphocytic leukemia
1265625|NCT00899951|stage IV adult T-cell leukemia/lymphoma
1265626|NCT00899951|stage IV chronic lymphocytic leukemia
1265627|NCT00899951|T-cell large granular lymphocyte leukemia
1265628|NCT00899951|recurrent adult Hodgkin lymphoma
1265629|NCT00899951|stage I adult Hodgkin lymphoma
1265630|NCT00899951|stage II adult Hodgkin lymphoma
1265631|NCT00899951|stage III adult Hodgkin lymphoma
1265632|NCT00899951|stage IV adult Hodgkin lymphoma
1265633|NCT00899951|anaplastic large cell lymphoma
1265634|NCT00899951|angioimmunoblastic T-cell lymphoma
1265635|NCT00899951|cutaneous B-cell non-Hodgkin lymphoma
1265636|NCT00899951|recurrent cutaneous T-cell non-Hodgkin lymphoma
1265637|NCT00899951|stage I cutaneous T-cell non-Hodgkin lymphoma
1265638|NCT00899951|stage II cutaneous T-cell non-Hodgkin lymphoma
1265639|NCT00899951|stage III cutaneous T-cell non-Hodgkin lymphoma
1265640|NCT00899951|stage IV cutaneous T-cell non-Hodgkin lymphoma
1265641|NCT00899951|recurrent mycosis fungoides/Sezary syndrome
1265642|NCT00899951|stage I mycosis fungoides/Sezary syndrome
1265643|NCT00899951|stage II mycosis fungoides/Sezary syndrome
1265644|NCT00899951|stage III mycosis fungoides/Sezary syndrome
1265645|NCT00899951|stage IV mycosis fungoides/Sezary syndrome
1265646|NCT00899951|adult grade III lymphomatoid granulomatosis
1265647|NCT00899951|adult nasal type extranodal NK/T-cell lymphoma
1265648|NCT00899951|Waldenström macroglobulinemia
1265649|NCT00899951|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1265650|NCT00899951|nodal marginal zone B-cell lymphoma
1265651|NCT00899951|splenic marginal zone lymphoma
1265652|NCT00899951|contiguous stage II adult Burkitt lymphoma
1265653|NCT00899951|contiguous stage II adult diffuse large cell lymphoma
1265654|NCT00899951|contiguous stage II adult diffuse mixed cell lymphoma
1265655|NCT00899951|contiguous stage II adult diffuse small cleaved cell lymphoma
1265656|NCT00899951|contiguous stage II adult immunoblastic large cell lymphoma
1265657|NCT00899951|contiguous stage II adult lymphoblastic lymphoma
1265658|NCT00899951|contiguous stage II grade 1 follicular lymphoma
1265659|NCT00899951|contiguous stage II grade 2 follicular lymphoma
1265660|NCT00899951|contiguous stage II grade 3 follicular lymphoma
1265661|NCT00899951|contiguous stage II mantle cell lymphoma
1265662|NCT00899951|contiguous stage II marginal zone lymphoma
1265663|NCT00899951|contiguous stage II small lymphocytic lymphoma
1265664|NCT00899951|stage I adult Burkitt lymphoma
1265665|NCT00899951|stage I adult diffuse large cell lymphoma
1265666|NCT00899951|stage I adult diffuse mixed cell lymphoma
1265667|NCT00899951|stage I adult diffuse small cleaved cell lymphoma
1265668|NCT00899951|stage I adult immunoblastic large cell lymphoma
1265669|NCT00899951|stage I adult lymphoblastic lymphoma
1265670|NCT00899951|stage I grade 1 follicular lymphoma
1265671|NCT00899951|stage I grade 2 follicular lymphoma
1265672|NCT00899951|stage I grade 3 follicular lymphoma
1265673|NCT00899951|stage I mantle cell lymphoma
1265674|NCT00899951|stage I marginal zone lymphoma
1265675|NCT00899951|stage I small lymphocytic lymphoma
1265676|NCT00899951|noncontiguous stage II adult Burkitt lymphoma
1265677|NCT00899951|noncontiguous stage II adult diffuse large cell lymphoma
1265678|NCT00899951|noncontiguous stage II adult diffuse mixed cell lymphoma
1265679|NCT00899951|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1265680|NCT00899951|noncontiguous stage II adult immunoblastic large cell lymphoma
1265681|NCT00899951|noncontiguous stage II adult lymphoblastic lymphoma
1265682|NCT00899951|noncontiguous stage II grade 1 follicular lymphoma
1265683|NCT00899951|noncontiguous stage II grade 2 follicular lymphoma
1265684|NCT00899951|noncontiguous stage II grade 3 follicular lymphoma
1265685|NCT00899951|noncontiguous stage II mantle cell lymphoma
1265686|NCT00899951|noncontiguous stage II marginal zone lymphoma
1265687|NCT00899951|noncontiguous stage II small lymphocytic lymphoma
1265688|NCT00899951|stage III adult Burkitt lymphoma
1265689|NCT00899951|stage III adult diffuse large cell lymphoma
1265690|NCT00899951|stage III adult diffuse mixed cell lymphoma
1265691|NCT00899951|stage III adult diffuse small cleaved cell lymphoma
1265692|NCT00899951|stage III adult immunoblastic large cell lymphoma
1265693|NCT00899951|stage III adult lymphoblastic lymphoma
1265694|NCT00899951|stage III grade 1 follicular lymphoma
1265695|NCT00899951|stage III grade 2 follicular lymphoma
1265696|NCT00899951|stage III grade 3 follicular lymphoma
1265697|NCT00899951|stage III mantle cell lymphoma
1265698|NCT00899951|stage III marginal zone lymphoma
1265699|NCT00899951|stage III small lymphocytic lymphoma
1265700|NCT00899951|stage IV adult Burkitt lymphoma
1265701|NCT00899951|stage IV adult diffuse large cell lymphoma
1265702|NCT00899951|stage IV adult diffuse mixed cell lymphoma
1265703|NCT00899951|stage IV adult diffuse small cleaved cell lymphoma
1265704|NCT00899951|stage IV adult immunoblastic large cell lymphoma
1265705|NCT00899951|stage IV adult lymphoblastic lymphoma
1265706|NCT00899951|stage IV grade 1 follicular lymphoma
1265707|NCT00899951|stage IV grade 2 follicular lymphoma
1265708|NCT00899951|stage IV grade 3 follicular lymphoma
1265709|NCT00899951|stage IV mantle cell lymphoma
1265710|NCT00899951|stage IV marginal zone lymphoma
1265711|NCT00899951|stage IV small lymphocytic lymphoma
1265712|NCT00899951|recurrent adult Burkitt lymphoma
1265713|NCT00899951|recurrent adult diffuse large cell lymphoma
1265714|NCT00899951|recurrent adult diffuse mixed cell lymphoma
1265715|NCT00899951|recurrent adult diffuse small cleaved cell lymphoma
1265716|NCT00899951|recurrent adult grade III lymphomatoid granulomatosis
1265717|NCT00899951|recurrent adult immunoblastic large cell lymphoma
1265718|NCT00899951|recurrent adult lymphoblastic lymphoma
1265719|NCT00899951|recurrent grade 1 follicular lymphoma
1265720|NCT00899951|recurrent grade 2 follicular lymphoma
1265721|NCT00899951|recurrent grade 3 follicular lymphoma
1265722|NCT00899951|recurrent mantle cell lymphoma
1265723|NCT00899951|recurrent marginal zone lymphoma
1265724|NCT00899951|recurrent small lymphocytic lymphoma
1265725|NCT00899951|intraocular lymphoma
1265726|NCT00899951|primary central nervous system non-Hodgkin lymphoma
1265727|NCT00899951|primary central nervous system Hodgkin lymphoma
1265728|NCT00899951|post-transplant lymphoproliferative disorder
1265729|NCT00899951|chronic eosinophilic leukemia
1265730|NCT00899951|chronic neutrophilic leukemia
1265731|NCT00899951|primary myelofibrosis
1265732|NCT00899951|essential thrombocythemia
1265733|NCT00899951|polycythemia vera
1265734|NCT00899951|extramedullary plasmacytoma
1265735|NCT00899951|isolated plasmacytoma of bone
1265736|NCT00899951|monoclonal gammopathy of undetermined significance
1265737|NCT00899951|stage I multiple myeloma
1265738|NCT00899951|stage II multiple myeloma
1265739|NCT00899951|stage III multiple myeloma
1265740|NCT00899951|primary systemic amyloidosis
1265741|NCT00899951|refractory multiple myeloma
1265742|NCT00899951|de novo myelodysplastic syndromes
1265743|NCT00899951|previously treated myelodysplastic syndromes
1265744|NCT00899951|secondary myelodysplastic syndromes
1265745|NCT00899951|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1265746|NCT00899951|pain
1265747|NCT00899912|stage IIB prostate cancer
1265748|NCT00899912|stage IIA prostate cancer
1265749|NCT00899912|adenocarcinoma of the prostate
1265750|NCT00899899|adult acute lymphoblastic leukemia in remission
1265751|NCT00899899|childhood acute lymphoblastic leukemia in remission
1265752|NCT00899899|recurrent adult acute lymphoblastic leukemia
1265753|NCT00899899|recurrent childhood acute lymphoblastic leukemia
1265754|NCT00899873|chronic lymphocytic leukemia
1265755|NCT00899860|recurrent renal cell cancer
1265756|NCT00899860|stage I renal cell cancer
1265757|NCT00899860|stage II renal cell cancer
1265758|NCT00899860|stage III renal cell cancer
1265759|NCT00899860|stage IV renal cell cancer
1265760|NCT00899834|adult brain stem glioma
1265761|NCT00899834|childhood brain stem glioma
1265762|NCT00899821|recurrent metastatic squamous neck cancer with occult primary
1265763|NCT00899821|untreated metastatic squamous neck cancer with occult primary
1265764|NCT00899821|stage I squamous cell carcinoma of the hypopharynx
1265765|NCT00899821|stage I squamous cell carcinoma of the larynx
1265766|NCT00899821|stage I squamous cell carcinoma of the lip and oral cavity
1265767|NCT00899821|stage I squamous cell carcinoma of the nasopharynx
1265768|NCT00899821|stage I squamous cell carcinoma of the oropharynx
1265769|NCT00899821|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1265770|NCT00899821|stage II squamous cell carcinoma of the hypopharynx
1265771|NCT00899821|stage II squamous cell carcinoma of the larynx
1265772|NCT00899821|stage II squamous cell carcinoma of the lip and oral cavity
1265773|NCT00899821|stage II squamous cell carcinoma of the nasopharynx
1265774|NCT00899821|stage II squamous cell carcinoma of the oropharynx
1265775|NCT00899821|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1265776|NCT00899821|stage III squamous cell carcinoma of the hypopharynx
1265777|NCT00899821|stage III squamous cell carcinoma of the larynx
1265778|NCT00899821|stage III squamous cell carcinoma of the lip and oral cavity
1265779|NCT00899821|stage III squamous cell carcinoma of the nasopharynx
1265780|NCT00899821|stage III squamous cell carcinoma of the oropharynx
1265781|NCT00899821|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1265782|NCT00899821|stage IV squamous cell carcinoma of the hypopharynx
1265783|NCT00899821|stage IV squamous cell carcinoma of the larynx
1265784|NCT00899821|stage IV squamous cell carcinoma of the lip and oral cavity
1265785|NCT00899821|stage IV squamous cell carcinoma of the nasopharynx
1265786|NCT00899821|stage IV squamous cell carcinoma of the oropharynx
1265787|NCT00899821|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1265788|NCT00899821|recurrent squamous cell carcinoma of the hypopharynx
1265789|NCT00899821|recurrent squamous cell carcinoma of the larynx
1265790|NCT00899821|recurrent squamous cell carcinoma of the lip and oral cavity
1265791|NCT00899821|recurrent squamous cell carcinoma of the nasopharynx
1265792|NCT00899821|recurrent squamous cell carcinoma of the oropharynx
1265793|NCT00899821|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1265794|NCT00899821|recurrent salivary gland cancer
1265795|NCT00899821|salivary gland squamous cell carcinoma
1265796|NCT00899821|stage I salivary gland cancer
1265797|NCT00899821|stage II salivary gland cancer
1265798|NCT00899821|stage III salivary gland cancer
1265799|NCT00899821|stage IV salivary gland cancer
1267192|NCT00897481|stage IIIB melanoma
1265800|NCT00899808|unspecified adult solid tumor, protocol specific
1265801|NCT00899808|unspecified childhood solid tumor, protocol specific
1265802|NCT00899808|hematopoietic/lymphoid cancer
1265803|NCT00899795|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265804|NCT00899795|adult acute myeloid leukemia with inv(16)(p13;q22)
1265805|NCT00899795|adult acute myeloid leukemia with t(15;17)(q22;q12)
1265806|NCT00899795|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265807|NCT00899795|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265808|NCT00899795|de novo myelodysplastic syndromes
1265809|NCT00899795|previously treated myelodysplastic syndromes
1265810|NCT00899795|recurrent adult acute myeloid leukemia
1265811|NCT00899795|secondary acute myeloid leukemia
1265812|NCT00899795|secondary myelodysplastic syndromes
1265813|NCT00899795|untreated adult acute myeloid leukemia
1265814|NCT00899795|childhood myelodysplastic syndromes
1265815|NCT00899769|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1265816|NCT00899769|recurrent squamous cell carcinoma of the hypopharynx
1265817|NCT00899769|recurrent squamous cell carcinoma of the larynx
1265818|NCT00899769|recurrent squamous cell carcinoma of the lip and oral cavity
1265819|NCT00899769|recurrent squamous cell carcinoma of the nasopharynx
1265820|NCT00899769|recurrent squamous cell carcinoma of the oropharynx
1265821|NCT00899769|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1265822|NCT00899769|stage I squamous cell carcinoma of the hypopharynx
1265823|NCT00899769|stage I squamous cell carcinoma of the larynx
1265824|NCT00899769|stage I squamous cell carcinoma of the lip and oral cavity
1265825|NCT00899769|stage I squamous cell carcinoma of the nasopharynx
1265826|NCT00899769|stage I squamous cell carcinoma of the oropharynx
1265827|NCT00899769|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1265828|NCT00899769|stage II squamous cell carcinoma of the hypopharynx
1265829|NCT00899769|stage II squamous cell carcinoma of the larynx
1265830|NCT00899769|stage II squamous cell carcinoma of the lip and oral cavity
1265831|NCT00899769|stage II squamous cell carcinoma of the nasopharynx
1265832|NCT00899769|stage II squamous cell carcinoma of the oropharynx
1265833|NCT00899769|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1265834|NCT00899769|stage III squamous cell carcinoma of the hypopharynx
1265835|NCT00899769|stage III squamous cell carcinoma of the larynx
1265836|NCT00899769|stage III squamous cell carcinoma of the lip and oral cavity
1265837|NCT00899769|stage III squamous cell carcinoma of the nasopharynx
1265838|NCT00899769|stage III squamous cell carcinoma of the oropharynx
1265839|NCT00899769|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1265840|NCT00899769|stage IV squamous cell carcinoma of the hypopharynx
1265841|NCT00899769|stage IV squamous cell carcinoma of the larynx
1265842|NCT00899769|stage IV squamous cell carcinoma of the lip and oral cavity
1265843|NCT00899769|stage IV squamous cell carcinoma of the nasopharynx
1265844|NCT00899769|stage IV squamous cell carcinoma of the oropharynx
1265845|NCT00899769|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1265846|NCT00899769|untreated metastatic squamous neck cancer with occult primary
1265847|NCT00899769|recurrent metastatic squamous neck cancer with occult primary
1265848|NCT00899769|recurrent salivary gland cancer
1265849|NCT00899769|salivary gland squamous cell carcinoma
1265850|NCT00899769|stage I salivary gland cancer
1265851|NCT00899769|stage II salivary gland cancer
1265852|NCT00899769|stage III salivary gland cancer
1265853|NCT00899769|stage IV salivary gland cancer
1265854|NCT00899756|recurrent non-small cell lung cancer
1265855|NCT00899756|stage IIIA non-small cell lung cancer
1265856|NCT00899756|stage IIIB non-small cell lung cancer
1265857|NCT00899756|stage IV non-small cell lung cancer
1265858|NCT00899743|adult erythroleukemia (M6a)
1265859|NCT00899743|adult pure erythroid leukemia (M6b)
1265860|NCT00899743|adult acute megakaryoblastic leukemia (M7)
1265861|NCT00899743|adult acute minimally differentiated myeloid leukemia (M0)
1265862|NCT00899743|adult acute monoblastic leukemia (M5a)
1265863|NCT00899743|adult acute monocytic leukemia (M5b)
1265864|NCT00899743|adult acute myeloblastic leukemia with maturation (M2)
1265865|NCT00899743|adult acute myeloblastic leukemia without maturation (M1)
1265866|NCT00899743|adult acute myelomonocytic leukemia (M4)
1265867|NCT00899743|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265868|NCT00899743|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265869|NCT00899743|adult acute myeloid leukemia with inv(16)(p13;q22)
1265870|NCT00899743|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265871|NCT00899743|untreated adult acute myeloid leukemia
1265872|NCT00899717|Temporomandibular Joint Disorders (TMD)
1265873|NCT00899717|Orofacial pain
1265874|NCT00899717|Limited mouth opening
1265875|NCT00899717|Craniomandibular dysfunction syndrome
1265876|NCT00899717|Axiography
1265877|NCT00899717|Gnatography
1265878|NCT00899717|Preferred chewing side
1265879|NCT00899717|Occlusal adjustment
1265880|NCT00899717|Selective grinding
1265881|NCT00899717|Handedness
1265882|NCT00899717|Bruxism
1265883|NCT00899717|TMD
1265884|NCT00899717|Costen's Syndrome
1265885|NCT00899717|Myofascial pain
1265886|NCT00899717|TMD treatment
1265887|NCT00899717|Pain
1265888|NCT00899704|stage I squamous cell carcinoma of the lip and oral cavity
1267193|NCT00897481|stage IIIC melanoma
1265889|NCT00899704|stage II squamous cell carcinoma of the lip and oral cavity
1265890|NCT00899704|tongue cancer
1265891|NCT00899691|unspecified adult solid tumor, protocol specific
1265892|NCT00899678|Certolizumab Pegol
1265893|NCT00899678|Cimzia ®
1265894|NCT00899678|Crohn's Disease
1265895|NCT00899665|stage IV prostate cancer
1265896|NCT00899665|bone metastases
1265897|NCT00899665|anemia
1265898|NCT00899665|monoclonal gammopathy of undetermined significance
1265899|NCT00899665|de novo myelodysplastic syndromes
1265900|NCT00899665|previously treated myelodysplastic syndromes
1265901|NCT00899665|secondary myelodysplastic syndromes
1265902|NCT00899652|childhood acute myelomonocytic leukemia (M4)
1265903|NCT00899652|childhood acute monocytic leukemia (M5b)
1265904|NCT00899652|childhood acute monoblastic leukemia (M5a)
1265905|NCT00899652|secondary acute myeloid leukemia
1265906|NCT00899652|untreated childhood acute lymphoblastic leukemia
1265907|NCT00899652|untreated childhood acute myeloid leukemia and other myeloid malignancies
1265908|NCT00899652|recurrent childhood acute lymphoblastic leukemia
1265909|NCT00899652|recurrent childhood acute myeloid leukemia
1265910|NCT00899639|stage I breast cancer
1265911|NCT00899639|stage II breast cancer
1265912|NCT00899639|stage IIIA breast cancer
1265913|NCT00899639|estrogen receptor-positive breast cancer
1265914|NCT00899639|male breast cancer
1265915|NCT00899626|colon cancer
1265916|NCT00899626|esophageal cancer
1265917|NCT00899626|gastric cancer
1265918|NCT00899626|pancreatic cancer
1265919|NCT00899626|adenomatous polyp
1265920|NCT00899613|localized malignant mesothelioma
1265921|NCT00899613|lung metastases
1265922|NCT00899613|malignant pleural effusion
1265923|NCT00899600|chronic pain
1265924|NCT00899600|back surgery
1265925|NCT00899600|opioid dependent
1265926|NCT00899600|NMDA receptor antagonism
1265927|NCT00899600|Ketamine
1265928|NCT00899600|Central sensitization
1265929|NCT00899353|ES-CLL
1265930|NCT00899353|MGUS
1265931|NCT00899353|SMM
1265932|NCT00899353|Early Stage - Chronic Lymphocytic Leukemia
1265933|NCT00899340|recurrent squamous cell carcinoma of the oropharynx
1265934|NCT00899340|stage I squamous cell carcinoma of the oropharynx
1265935|NCT00899340|stage II squamous cell carcinoma of the oropharynx
1265936|NCT00899340|stage III squamous cell carcinoma of the oropharynx
1265937|NCT00899340|stage IV squamous cell carcinoma of the oropharynx
1265938|NCT00899327|myelodysplastic syndromes
1265939|NCT00899327|acute myeloid leukemia
1265940|NCT00899301|breast cancer
1265941|NCT00899301|stage IA breast cancer
1265942|NCT00899301|stage IB breast cancer
1265943|NCT00899301|stage II breast cancer
1265944|NCT00899301|stage IIIA breast cancer
1265945|NCT00899301|stage IIIB breast cancer
1265946|NCT00899301|stage IIIC breast cancer
1265947|NCT00899301|stage IV breast cancer
1265948|NCT00899288|osteoporosis
1265949|NCT00899288|stage I breast cancer
1265950|NCT00899288|stage II breast cancer
1265951|NCT00899288|stage IIIA breast cancer
1265952|NCT00899275|osteosarcoma
1265953|NCT00899262|lung cancer
1265954|NCT00899262|tobacco use disorder
1265955|NCT00899210|liver metastases
1265956|NCT00899210|adenocarcinoma of the colon
1265957|NCT00899210|stage IV colon cancer
1265958|NCT00899210|adenocarcinoma of the rectum
1265959|NCT00899210|stage IV rectal cancer
1265960|NCT00899210|recurrent colon cancer
1265961|NCT00899210|recurrent rectal cancer
1265962|NCT00899197|stage I breast cancer
1265963|NCT00899197|stage II breast cancer
1265964|NCT00899197|stage IIIA breast cancer
1265965|NCT00899197|stage IIIB breast cancer
1265966|NCT00899184|recurrent prostate cancer
1265967|NCT00899184|stage IV prostate cancer
1265968|NCT00899184|stage I prostate cancer
1265969|NCT00899184|stage IIB prostate cancer
1265970|NCT00899184|stage IIA prostate cancer
1265971|NCT00899184|stage III prostate cancer
1265972|NCT00899171|adult acute myeloid leukemia in remission
1265973|NCT00899171|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1265974|NCT00899171|adult acute myeloid leukemia with inv(16)(p13;q22)
1265975|NCT00899171|adult acute myeloid leukemia with t(15;17)(q22;q12)
1265976|NCT00899171|adult acute myeloid leukemia with t(16;16)(p13;q22)
1265977|NCT00899171|adult acute myeloid leukemia with t(8;21)(q22;q22)
1265978|NCT00899171|recurrent adult acute myeloid leukemia
1265979|NCT00899171|untreated adult acute myeloid leukemia
1265980|NCT00899171|adult acute erythroid leukemia (M6)
1265981|NCT00899171|adult acute megakaryoblastic leukemia (M7)
1265982|NCT00899171|adult acute minimally differentiated myeloid leukemia (M0)
1265983|NCT00899171|adult acute monoblastic leukemia (M5a)
1265984|NCT00899171|adult acute monocytic leukemia (M5b)
1265985|NCT00899171|adult acute myeloblastic leukemia with maturation (M2)
1265986|NCT00899171|adult acute myeloblastic leukemia without maturation (M1)
1265987|NCT00899171|adult acute myelomonocytic leukemia (M4)
1265988|NCT00899171|secondary acute myeloid leukemia
1265989|NCT00899158|recurrent pancreatic cancer
1265990|NCT00899158|stage I pancreatic cancer
1265991|NCT00899158|stage II pancreatic cancer
1265992|NCT00899158|stage III pancreatic cancer
1265993|NCT00899158|stage IV pancreatic cancer
1265994|NCT00899158|cachexia
1265995|NCT00899132|skin cancer
1265996|NCT00899132|small intestine cancer
1265997|NCT00899132|pancreatic cancer
1265998|NCT00899132|malignant testicular germ cell tumor
1265999|NCT00899132|testicular teratoma
1266000|NCT00899119|Waldenström macroglobulinemia
1266001|NCT00899080|stage I multiple myeloma
1266002|NCT00899080|stage II multiple myeloma
1266003|NCT00899080|stage III multiple myeloma
1266004|NCT00899041|Prosthesis
1266005|NCT00899028|stage 0 non-small cell lung cancer
1266006|NCT00899028|stage I non-small cell lung cancer
1266007|NCT00899028|extensive stage small cell lung cancer
1266008|NCT00899028|limited stage small cell lung cancer
1266009|NCT00899028|stage II non-small cell lung cancer
1266010|NCT00899028|stage IV non-small cell lung cancer
1266011|NCT00899028|stage IIIA non-small cell lung cancer
1266012|NCT00899028|stage IIIB non-small cell lung cancer
1266013|NCT00899015|recurrent childhood acute myeloid leukemia
1266014|NCT00899015|childhood acute promyelocytic leukemia (M3)
1266015|NCT00899015|recurrent childhood acute lymphoblastic leukemia
1266016|NCT00899015|recurrent childhood large cell lymphoma
1266017|NCT00899015|recurrent childhood lymphoblastic lymphoma
1266018|NCT00899015|recurrent childhood small noncleaved cell lymphoma
1266019|NCT00899015|recurrent/refractory childhood Hodgkin lymphoma
1266020|NCT00899015|childhood chronic myelogenous leukemia
1266021|NCT00899015|atypical chronic myeloid leukemia, BCR-ABL1 negative
1266022|NCT00899002|childhood hepatocellular carcinoma
1266023|NCT00899002|childhood liver cancer
1266024|NCT00899002|adult primary liver cancer
1266025|NCT00899002|adult primary hepatocellular carcinoma
1266026|NCT00898976|stage I breast cancer
1266027|NCT00898976|stage II breast cancer
1266028|NCT00898976|stage IV breast cancer
1266029|NCT00898976|stage IIIA breast cancer
1266030|NCT00898976|breast cancer in situ
1266031|NCT00898976|recurrent breast cancer
1266032|NCT00898976|stage IIIB breast cancer
1266033|NCT00898976|inflammatory breast cancer
1266034|NCT00898976|stage IIIC breast cancer
1266035|NCT00898963|stage III grade 1 follicular lymphoma
1266036|NCT00898963|stage III grade 2 follicular lymphoma
1266037|NCT00898963|stage III grade 3 follicular lymphoma
1266038|NCT00898963|stage IV grade 1 follicular lymphoma
1266039|NCT00898963|stage IV grade 2 follicular lymphoma
1266040|NCT00898963|stage IV grade 3 follicular lymphoma
1266041|NCT00898950|diabetes
1266042|NCT00898950|aspirin
1266043|NCT00898950|oxidative stress
1266044|NCT00898950|insulin resistance
1266045|NCT00898950|endothelial function
1266046|NCT00898950|inflammation
1266047|NCT00898950|photoplethysmography
1266048|NCT00898950|dysglycaemia
1266049|NCT00898937|breast cancer
1266050|NCT00898924|stage IIIA non-small cell lung cancer
1266051|NCT00898924|stage IIIB non-small cell lung cancer
1266052|NCT00898911|recurrent squamous cell carcinoma of the hypopharynx
1266053|NCT00898911|stage IV squamous cell carcinoma of the hypopharynx
1266054|NCT00898911|stage IV squamous cell carcinoma of the larynx
1266055|NCT00898911|stage IV verrucous carcinoma of the larynx
1266056|NCT00898911|recurrent squamous cell carcinoma of the larynx
1266057|NCT00898911|recurrent verrucous carcinoma of the larynx
1266058|NCT00898911|recurrent squamous cell carcinoma of the lip and oral cavity
1266059|NCT00898911|stage IV squamous cell carcinoma of the lip and oral cavity
1266060|NCT00898911|recurrent verrucous carcinoma of the oral cavity
1266061|NCT00898911|stage IV verrucous carcinoma of the oral cavity
1266062|NCT00898911|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1266063|NCT00898911|recurrent metastatic squamous neck cancer with occult primary
1266064|NCT00898911|recurrent squamous cell carcinoma of the nasopharynx
1266065|NCT00898911|stage IV squamous cell carcinoma of the nasopharynx
1266066|NCT00898911|recurrent squamous cell carcinoma of the oropharynx
1266067|NCT00898911|stage IV squamous cell carcinoma of the oropharynx
1266068|NCT00898911|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1266069|NCT00898911|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1266070|NCT00898911|recurrent salivary gland cancer
1266071|NCT00898911|salivary gland squamous cell carcinoma
1266072|NCT00898911|stage IV salivary gland cancer
1266073|NCT00898898|stage IA breast cancer
1266074|NCT00898898|stage IB breast cancer
1266075|NCT00898898|stage II breast cancer
1266076|NCT00898898|stage IIIA breast cancer
1266077|NCT00898898|HER2-positive breast cancer
1266078|NCT00898885|oral manifestations
1266079|NCT00898885|bone marrow transplantation
1266080|NCT00898885|adverse effects
1266081|NCT00898872|recurrent grade 3 follicular lymphoma
1266082|NCT00898872|recurrent adult diffuse small cleaved cell lymphoma
1266083|NCT00898872|recurrent adult diffuse mixed cell lymphoma
1266084|NCT00898872|recurrent adult diffuse large cell lymphoma
1266085|NCT00898872|recurrent adult immunoblastic large cell lymphoma
1266086|NCT00898872|recurrent adult lymphoblastic lymphoma
1266087|NCT00898872|recurrent adult Burkitt lymphoma
1266088|NCT00898872|recurrent adult grade III lymphomatoid granulomatosis
1266089|NCT00898872|recurrent grade 1 follicular lymphoma
1266090|NCT00898872|recurrent grade 2 follicular lymphoma
1266091|NCT00898872|recurrent mantle cell lymphoma
1266092|NCT00898872|recurrent marginal zone lymphoma
1266093|NCT00898872|recurrent small lymphocytic lymphoma
1266094|NCT00898872|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1266095|NCT00898872|nodal marginal zone B-cell lymphoma
1266096|NCT00898872|splenic marginal zone lymphoma
1266097|NCT00898872|Waldenström macroglobulinemia
1266098|NCT00898872|adult nasal type extranodal NK/T-cell lymphoma
1266099|NCT00898872|recurrent childhood grade III lymphomatoid granulomatosis
1266100|NCT00898872|recurrent childhood large cell lymphoma
1266101|NCT00898872|recurrent childhood lymphoblastic lymphoma
1266102|NCT00898872|recurrent childhood small noncleaved cell lymphoma
1266103|NCT00898872|childhood diffuse large cell lymphoma
1266104|NCT00898872|childhood immunoblastic large cell lymphoma
1266105|NCT00898872|childhood Burkitt lymphoma
1266106|NCT00898872|childhood nasal type extranodal NK/T-cell lymphoma
1266107|NCT00898859|ADAM
1266108|NCT00898859|epithelial
1266109|NCT00898859|COPD
1266110|NCT00898846|stage II colon cancer
1266111|NCT00898846|stage II rectal cancer
1266112|NCT00898846|adenocarcinoma of the colon
1266113|NCT00898846|adenocarcinoma of the rectum
1266114|NCT00898833|recurrent prostate cancer
1266115|NCT00898833|stage III prostate cancer
1266116|NCT00898833|stage IV prostate cancer
1266117|NCT00898833|adenocarcinoma of the prostate
1266118|NCT00898820|stage IIIB non-small cell lung cancer
1266119|NCT00898820|stage IV non-small cell lung cancer
1266120|NCT00898820|recurrent non-small cell lung cancer
1266121|NCT00898807|neuropsychiatric symptoms
1266122|NCT00898807|aggression
1266123|NCT00898807|mood lability
1266124|NCT00898794|unspecified adult solid tumor, protocol specific
1266125|NCT00898794|unspecified childhood solid tumor, protocol specific
1266126|NCT00898781|male breast cancer
1266127|NCT00898781|stage IV breast cancer
1266128|NCT00898781|stage IV ovarian epithelial cancer
1266129|NCT00898781|stage IV ovarian germ cell tumor
1266130|NCT00898781|stage IV pancreatic cancer
1266131|NCT00898781|stage IV colon cancer
1266132|NCT00898781|ovarian sarcoma
1266133|NCT00898768|Lynch syndrome
1266134|NCT00898768|HNPCC
1266135|NCT00898768|Capsule endoscopy
1266136|NCT00898768|Small bowel cancer
1266137|NCT00898768|Double balloon endoscopy
1266138|NCT00898755|childhood acute lymphoblastic leukemia in remission
1266139|NCT00898755|unspecified childhood solid tumor, protocol specific
1266140|NCT00898755|childhood acute myeloid leukemia in remission
1266141|NCT00898755|childhood central nervous system germ cell tumor
1266142|NCT00898755|childhood choroid plexus tumor
1266143|NCT00898755|childhood chronic myelogenous leukemia
1266144|NCT00898755|childhood craniopharyngioma
1266145|NCT00898755|childhood diffuse large cell lymphoma
1266146|NCT00898755|childhood extragonadal germ cell tumor
1266147|NCT00898755|childhood grade III lymphomatoid granulomatosis
1266148|NCT00898755|childhood infratentorial ependymoma
1266149|NCT00898755|childhood teratoma
1266150|NCT00898755|childhood grade I meningioma
1266151|NCT00898755|childhood grade II meningioma
1266152|NCT00898755|childhood grade III meningioma
1266153|NCT00898755|childhood supratentorial ependymoma
1266154|NCT00898755|childhood high-grade cerebral astrocytoma
1266155|NCT00898755|childhood low-grade cerebral astrocytoma
1266156|NCT00898755|metastatic childhood soft tissue sarcoma
1266157|NCT00898755|newly diagnosed childhood ependymoma
1266158|NCT00898755|nonmetastatic childhood soft tissue sarcoma
1266159|NCT00898755|previously treated childhood rhabdomyosarcoma
1266160|NCT00898755|previously untreated childhood rhabdomyosarcoma
1266161|NCT00898755|recurrent childhood acute lymphoblastic leukemia
1266162|NCT00898755|recurrent childhood acute myeloid leukemia
1266163|NCT00898755|recurrent childhood brain stem glioma
1266164|NCT00898755|recurrent childhood cerebellar astrocytoma
1266165|NCT00898755|recurrent childhood cerebral astrocytoma
1266166|NCT00898755|recurrent childhood ependymoma
1266167|NCT00898755|recurrent childhood grade III lymphomatoid granulomatosis
1266168|NCT00898755|recurrent childhood large cell lymphoma
1266169|NCT00898755|recurrent childhood lymphoblastic lymphoma
1266170|NCT00898755|recurrent childhood malignant germ cell tumor
1266171|NCT00898755|recurrent childhood medulloblastoma
1266172|NCT00898755|recurrent childhood rhabdomyosarcoma
1266173|NCT00898755|recurrent childhood small noncleaved cell lymphoma
1266174|NCT00898755|recurrent childhood soft tissue sarcoma
1266175|NCT00898755|recurrent childhood supratentorial primitive neuroectodermal tumor
1266176|NCT00898755|recurrent childhood visual pathway and hypothalamic glioma
1266177|NCT00898755|recurrent Wilms tumor and other childhood kidney tumors
1266178|NCT00898755|recurrent/refractory childhood Hodgkin lymphoma
1266179|NCT00898755|stage I childhood Hodgkin lymphoma
1266180|NCT00898755|stage I childhood large cell lymphoma
1266181|NCT00898755|stage I childhood liver cancer
1266182|NCT00898755|stage I childhood lymphoblastic lymphoma
1266183|NCT00898755|stage I childhood small noncleaved cell lymphoma
1266184|NCT00898755|stage II childhood Hodgkin lymphoma
1266185|NCT00898755|stage II childhood large cell lymphoma
1266186|NCT00898755|stage II childhood lymphoblastic lymphoma
1266187|NCT00898755|stage II childhood small noncleaved cell lymphoma
1266188|NCT00898755|stage III childhood Hodgkin lymphoma
1266189|NCT00898755|stage III childhood large cell lymphoma
1266190|NCT00898755|stage III childhood lymphoblastic lymphoma
1266191|NCT00898755|stage III childhood small noncleaved cell lymphoma
1266192|NCT00898755|stage IV childhood Hodgkin lymphoma
1266193|NCT00898755|stage IV childhood large cell lymphoma
1266194|NCT00898755|stage IV childhood lymphoblastic lymphoma
1266195|NCT00898755|stage IV childhood small noncleaved cell lymphoma
1266196|NCT00898755|untreated childhood acute lymphoblastic leukemia
1266197|NCT00898755|untreated childhood acute myeloid leukemia and other myeloid malignancies
1266198|NCT00898755|untreated childhood brain stem glioma
1266199|NCT00898755|untreated childhood cerebellar astrocytoma
1266200|NCT00898755|untreated childhood medulloblastoma
1266201|NCT00898755|untreated childhood supratentorial primitive neuroectodermal tumor
1266202|NCT00898755|untreated childhood visual pathway and hypothalamic glioma
1266203|NCT00898755|childhood hepatoblastoma
1266204|NCT00898755|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
1266205|NCT00898755|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1266206|NCT00898755|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1266207|NCT00898755|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1266208|NCT00898755|childhood hepatocellular carcinoma
1266209|NCT00898755|childhood immunoblastic large cell lymphoma
1266210|NCT00898755|childhood malignant ovarian germ cell tumor
1266211|NCT00898755|childhood malignant testicular germ cell tumor
1266212|NCT00898755|childhood Langerhans cell histiocytosis
1266213|NCT00898755|alveolar childhood rhabdomyosarcoma
1266214|NCT00898755|childhood Burkitt lymphoma
1266215|NCT00898755|de novo myelodysplastic syndromes
1266216|NCT00898755|previously treated myelodysplastic syndromes
1266217|NCT00898755|secondary myelodysplastic syndromes
1266218|NCT00898755|disseminated neuroblastoma
1266219|NCT00898755|localized resectable neuroblastoma
1266220|NCT00898755|localized unresectable neuroblastoma
1266221|NCT00898755|recurrent neuroblastoma
1266222|NCT00898755|regional neuroblastoma
1266223|NCT00898755|stage 4S neuroblastoma
1266224|NCT00898755|childhood germ cell tumor
1266225|NCT00898755|recurrent childhood liver cancer
1266226|NCT00898755|localized osteosarcoma
1266227|NCT00898755|metastatic osteosarcoma
1266228|NCT00898755|recurrent osteosarcoma
1266229|NCT00898755|extraocular retinoblastoma
1266230|NCT00898755|intraocular retinoblastoma
1266231|NCT00898755|recurrent retinoblastoma
1266232|NCT00898755|stage I Wilms tumor
1266233|NCT00898755|stage II Wilms tumor
1266234|NCT00898755|stage III Wilms tumor
1266235|NCT00898755|stage IV Wilms tumor
1266236|NCT00898755|stage II childhood liver cancer
1266237|NCT00898755|stage III childhood liver cancer
1266238|NCT00898755|stage IV childhood liver cancer
1266239|NCT00898755|unusual cancers of childhood
1266240|NCT00898755|stage V Wilms tumor
1266241|NCT00898755|childhood myelodysplastic syndromes
1266242|NCT00898755|childhood atypical teratoid/rhabdoid tumor
1266243|NCT00898755|rhabdoid tumor of the kidney
1266244|NCT00898755|childhood extracranial germ cell tumor
1266245|NCT00898755|childhood central nervous system choriocarcinoma
1266246|NCT00898755|childhood central nervous system embryonal tumor
1266247|NCT00898755|recurrent childhood central nervous system embryonal tumor
1266248|NCT00898755|childhood central nervous system germinoma
1266249|NCT00898755|childhood central nervous system mixed germ cell tumor
1266250|NCT00898755|childhood central nervous system teratoma
1266251|NCT00898755|childhood central nervous system yolk sac tumor
1266252|NCT00898742|recurrent squamous cell carcinoma of the hypopharynx
1266253|NCT00898742|stage IV squamous cell carcinoma of the hypopharynx
1266254|NCT00898742|stage IV squamous cell carcinoma of the larynx
1266255|NCT00898742|stage IV verrucous carcinoma of the larynx
1266256|NCT00898742|recurrent squamous cell carcinoma of the larynx
1266257|NCT00898742|recurrent verrucous carcinoma of the larynx
1266258|NCT00898742|recurrent squamous cell carcinoma of the lip and oral cavity
1266259|NCT00898742|stage IV squamous cell carcinoma of the lip and oral cavity
1266260|NCT00898742|recurrent verrucous carcinoma of the oral cavity
1266261|NCT00898742|stage IV verrucous carcinoma of the oral cavity
1266262|NCT00898742|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1266263|NCT00898742|recurrent metastatic squamous neck cancer with occult primary
1266264|NCT00898742|recurrent squamous cell carcinoma of the nasopharynx
1266265|NCT00898742|stage IV squamous cell carcinoma of the nasopharynx
1266266|NCT00898742|recurrent squamous cell carcinoma of the oropharynx
1266267|NCT00898742|stage IV squamous cell carcinoma of the oropharynx
1266268|NCT00898742|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1266269|NCT00898742|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1266270|NCT00898742|recurrent salivary gland cancer
1266271|NCT00898742|salivary gland squamous cell carcinoma
1266272|NCT00898742|stage IV salivary gland cancer
1266273|NCT00898703|breast cancer
1266274|NCT00898690|stage I breast cancer
1266275|NCT00898690|stage II breast cancer
1266276|NCT00898690|stage IIIA breast cancer
1266277|NCT00898690|stage IIIB breast cancer
1266278|NCT00898690|stage IIIC breast cancer
1266279|NCT00898690|stage IV breast cancer
1266281|NCT00898664|stage I squamous cell carcinoma of the hypopharynx
1266282|NCT00898664|stage II squamous cell carcinoma of the hypopharynx
1266283|NCT00898664|stage III squamous cell carcinoma of the hypopharynx
1266284|NCT00898664|stage IV squamous cell carcinoma of the hypopharynx
1266285|NCT00898664|recurrent squamous cell carcinoma of the hypopharynx
1266286|NCT00898664|stage I squamous cell carcinoma of the larynx
1266287|NCT00898664|stage II squamous cell carcinoma of the larynx
1266288|NCT00898664|stage III squamous cell carcinoma of the larynx
1266289|NCT00898664|stage IV squamous cell carcinoma of the larynx
1266290|NCT00898664|recurrent squamous cell carcinoma of the larynx
1266291|NCT00898664|stage I squamous cell carcinoma of the lip and oral cavity
1266292|NCT00898664|stage II squamous cell carcinoma of the lip and oral cavity
1266293|NCT00898664|stage III squamous cell carcinoma of the lip and oral cavity
1266294|NCT00898664|stage IV squamous cell carcinoma of the lip and oral cavity
1266295|NCT00898664|recurrent squamous cell carcinoma of the lip and oral cavity
1266296|NCT00898664|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1266297|NCT00898664|recurrent metastatic squamous neck cancer with occult primary
1266298|NCT00898664|untreated metastatic squamous neck cancer with occult primary
1266299|NCT00898664|stage I squamous cell carcinoma of the nasopharynx
1266300|NCT00898664|stage II squamous cell carcinoma of the nasopharynx
1266301|NCT00898664|stage III squamous cell carcinoma of the nasopharynx
1266302|NCT00898664|stage IV squamous cell carcinoma of the nasopharynx
1266303|NCT00898664|recurrent squamous cell carcinoma of the nasopharynx
1266304|NCT00898664|stage I squamous cell carcinoma of the oropharynx
1266305|NCT00898664|stage II squamous cell carcinoma of the oropharynx
1266306|NCT00898664|stage III squamous cell carcinoma of the oropharynx
1266307|NCT00898664|stage IV squamous cell carcinoma of the oropharynx
1266308|NCT00898664|recurrent squamous cell carcinoma of the oropharynx
1266309|NCT00898664|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1266310|NCT00898664|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1266311|NCT00898664|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1266312|NCT00898664|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1266313|NCT00898664|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1266314|NCT00898664|salivary gland squamous cell carcinoma
1266315|NCT00898664|stage I salivary gland cancer
1266316|NCT00898664|stage II salivary gland cancer
1266317|NCT00898664|stage III salivary gland cancer
1266318|NCT00898664|stage IV salivary gland cancer
1266319|NCT00898664|recurrent salivary gland cancer
1266320|NCT00898638|stage I squamous cell carcinoma of the hypopharynx
1266321|NCT00898638|stage II squamous cell carcinoma of the hypopharynx
1266322|NCT00898638|stage III squamous cell carcinoma of the hypopharynx
1266323|NCT00898638|stage IV squamous cell carcinoma of the hypopharynx
1266324|NCT00898638|recurrent squamous cell carcinoma of the hypopharynx
1266325|NCT00898638|stage I squamous cell carcinoma of the larynx
1266326|NCT00898638|stage I verrucous carcinoma of the larynx
1266327|NCT00898638|stage II squamous cell carcinoma of the larynx
1266328|NCT00898638|stage II verrucous carcinoma of the larynx
1266329|NCT00898638|stage III squamous cell carcinoma of the larynx
1266330|NCT00898638|stage III verrucous carcinoma of the larynx
1266331|NCT00898638|stage IV squamous cell carcinoma of the larynx
1266332|NCT00898638|stage IV verrucous carcinoma of the larynx
1266333|NCT00898638|recurrent squamous cell carcinoma of the larynx
1266334|NCT00898638|recurrent verrucous carcinoma of the larynx
1266335|NCT00898638|stage I adenoid cystic carcinoma of the oral cavity
1266336|NCT00898638|stage I basal cell carcinoma of the lip
1266337|NCT00898638|stage I mucoepidermoid carcinoma of the oral cavity
1266338|NCT00898638|stage I squamous cell carcinoma of the lip and oral cavity
1266339|NCT00898638|stage I verrucous carcinoma of the oral cavity
1266340|NCT00898638|stage II adenoid cystic carcinoma of the oral cavity
1266341|NCT00898638|stage II basal cell carcinoma of the lip
1266342|NCT00898638|stage II mucoepidermoid carcinoma of the oral cavity
1266343|NCT00898638|stage II squamous cell carcinoma of the lip and oral cavity
1266344|NCT00898638|stage II verrucous carcinoma of the oral cavity
1266345|NCT00898638|stage III adenoid cystic carcinoma of the oral cavity
1266346|NCT00898638|stage III basal cell carcinoma of the lip
1266347|NCT00898638|stage III mucoepidermoid carcinoma of the oral cavity
1266348|NCT00898638|stage III squamous cell carcinoma of the lip and oral cavity
1266349|NCT00898638|stage III verrucous carcinoma of the oral cavity
1266350|NCT00898638|stage IV adenoid cystic carcinoma of the oral cavity
1266351|NCT00898638|stage IV basal cell carcinoma of the lip
1266352|NCT00898638|stage IV mucoepidermoid carcinoma of the oral cavity
1266353|NCT00898638|stage IV squamous cell carcinoma of the lip and oral cavity
1266354|NCT00898638|stage IV verrucous carcinoma of the oral cavity
1266355|NCT00898638|recurrent adenoid cystic carcinoma of the oral cavity
1266356|NCT00898638|recurrent basal cell carcinoma of the lip
1266357|NCT00898638|recurrent mucoepidermoid carcinoma of the oral cavity
1266358|NCT00898638|recurrent squamous cell carcinoma of the lip and oral cavity
1266359|NCT00898638|recurrent verrucous carcinoma of the oral cavity
1266360|NCT00898638|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1266361|NCT00898638|recurrent metastatic squamous neck cancer with occult primary
1266362|NCT00898638|untreated metastatic squamous neck cancer with occult primary
1266363|NCT00898638|stage I lymphoepithelioma of the nasopharynx
1266364|NCT00898638|stage I squamous cell carcinoma of the nasopharynx
1266365|NCT00898638|stage II lymphoepithelioma of the nasopharynx
1266366|NCT00898638|stage II squamous cell carcinoma of the nasopharynx
1266367|NCT00898638|stage III lymphoepithelioma of the nasopharynx
1266368|NCT00898638|stage III squamous cell carcinoma of the nasopharynx
1266369|NCT00898638|stage IV lymphoepithelioma of the nasopharynx
1266370|NCT00898638|stage IV squamous cell carcinoma of the nasopharynx
1266371|NCT00898638|recurrent lymphoepithelioma of the nasopharynx
1266372|NCT00898638|recurrent squamous cell carcinoma of the nasopharynx
1266373|NCT00898638|stage I lymphoepithelioma of the oropharynx
1266374|NCT00898638|stage I squamous cell carcinoma of the oropharynx
1266375|NCT00898638|stage II lymphoepithelioma of the oropharynx
1266376|NCT00898638|stage II squamous cell carcinoma of the oropharynx
1266377|NCT00898638|stage III lymphoepithelioma of the oropharynx
1266378|NCT00898638|stage III squamous cell carcinoma of the oropharynx
1266379|NCT00898638|stage IV lymphoepithelioma of the oropharynx
1266380|NCT00898638|stage IV squamous cell carcinoma of the oropharynx
1266381|NCT00898638|recurrent lymphoepithelioma of the oropharynx
1266382|NCT00898638|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266383|NCT00898638|stage I inverted papilloma of the paranasal sinus and nasal cavity
1266384|NCT00898638|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1266385|NCT00898638|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1266386|NCT00898638|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266387|NCT00898638|stage II inverted papilloma of the paranasal sinus and nasal cavity
1266388|NCT00898638|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1266389|NCT00898638|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1266390|NCT00898638|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266391|NCT00898638|stage III inverted papilloma of the paranasal sinus and nasal cavity
1266392|NCT00898638|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1266393|NCT00898638|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1266394|NCT00898638|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266395|NCT00898638|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1266396|NCT00898638|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1266397|NCT00898638|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1266398|NCT00898638|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266399|NCT00898638|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1266400|NCT00898638|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1266401|NCT00898638|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1266402|NCT00898638|stage I salivary gland cancer
1266403|NCT00898638|stage II salivary gland cancer
1266404|NCT00898638|stage III salivary gland cancer
1266405|NCT00898638|stage IV salivary gland cancer
1266406|NCT00898638|recurrent salivary gland cancer
1266407|NCT00898638|recurrent squamous cell carcinoma of the oropharynx
1266408|NCT00898612|stage III adult Burkitt lymphoma
1266409|NCT00898612|stage III adult diffuse large cell lymphoma
1266410|NCT00898612|stage III adult diffuse mixed cell lymphoma
1266411|NCT00898612|stage III adult diffuse small cleaved cell lymphoma
1266412|NCT00898612|stage III adult Hodgkin lymphoma
1266413|NCT00898612|stage III adult immunoblastic large cell lymphoma
1266414|NCT00898612|stage III adult lymphoblastic lymphoma
1266415|NCT00898612|stage III grade 1 follicular lymphoma
1266416|NCT00898612|stage III grade 2 follicular lymphoma
1266417|NCT00898612|stage III grade 3 follicular lymphoma
1266418|NCT00898612|stage III mantle cell lymphoma
1266419|NCT00898612|stage III marginal zone lymphoma
1266420|NCT00898612|stage III small lymphocytic lymphoma
1266421|NCT00898612|stage IV adult Burkitt lymphoma
1266422|NCT00898612|stage IV adult diffuse large cell lymphoma
1266423|NCT00898612|stage IV adult diffuse mixed cell lymphoma
1266424|NCT00898612|stage IV adult diffuse small cleaved cell lymphoma
1266425|NCT00898612|stage IV adult Hodgkin lymphoma
1266426|NCT00898612|stage IV adult immunoblastic large cell lymphoma
1266427|NCT00898612|stage IV adult lymphoblastic lymphoma
1266428|NCT00898612|stage IV grade 1 follicular lymphoma
1266429|NCT00898612|stage IV grade 2 follicular lymphoma
1266430|NCT00898612|stage IV grade 3 follicular lymphoma
1266431|NCT00898612|stage IV mantle cell lymphoma
1266432|NCT00898612|stage IV marginal zone lymphoma
1266433|NCT00898612|stage IV small lymphocytic lymphoma
1266434|NCT00898612|recurrent adult Burkitt lymphoma
1266435|NCT00898612|recurrent adult diffuse large cell lymphoma
1266436|NCT00898612|recurrent adult diffuse mixed cell lymphoma
1266437|NCT00898612|recurrent adult diffuse small cleaved cell lymphoma
1266438|NCT00898612|recurrent adult Hodgkin lymphoma
1266439|NCT00898612|recurrent adult immunoblastic large cell lymphoma
1266440|NCT00898612|recurrent adult lymphoblastic lymphoma
1266441|NCT00898612|recurrent childhood large cell lymphoma
1266442|NCT00898612|recurrent childhood lymphoblastic lymphoma
1266443|NCT00898612|recurrent childhood small noncleaved cell lymphoma
1266444|NCT00898612|recurrent cutaneous T-cell non-Hodgkin lymphoma
1266445|NCT00898612|recurrent grade 1 follicular lymphoma
1266446|NCT00898612|recurrent grade 2 follicular lymphoma
1266447|NCT00898612|recurrent grade 3 follicular lymphoma
1266448|NCT00898612|recurrent mantle cell lymphoma
1266449|NCT00898612|recurrent marginal zone lymphoma
1266450|NCT00898612|recurrent small lymphocytic lymphoma
1266451|NCT00898612|recurrent/refractory childhood Hodgkin lymphoma
1266452|NCT00898612|recurrent mycosis fungoides/Sezary syndrome
1266453|NCT00898612|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1266454|NCT00898612|nodal marginal zone B-cell lymphoma
1266455|NCT00898612|splenic marginal zone lymphoma
1266456|NCT00898612|noncontiguous stage II adult Burkitt lymphoma
1266457|NCT00898612|noncontiguous stage II adult diffuse large cell lymphoma
1266458|NCT00898612|noncontiguous stage II adult diffuse mixed cell lymphoma
1266459|NCT00898612|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1266460|NCT00898612|noncontiguous stage II adult immunoblastic large cell lymphoma
1266461|NCT00898612|noncontiguous stage II adult lymphoblastic lymphoma
1266462|NCT00898612|noncontiguous stage II grade 1 follicular lymphoma
1266463|NCT00898612|noncontiguous stage II grade 2 follicular lymphoma
1266464|NCT00898612|noncontiguous stage II grade 3 follicular lymphoma
1266465|NCT00898612|noncontiguous stage II mantle cell lymphoma
1266466|NCT00898612|noncontiguous stage II marginal zone lymphoma
1266467|NCT00898612|noncontiguous stage II small lymphocytic lymphoma
1266468|NCT00898612|accelerated phase chronic myelogenous leukemia
1266469|NCT00898612|adult acute lymphoblastic leukemia in remission
1266470|NCT00898612|adult acute myeloid leukemia in remission
1266471|NCT00898612|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1266472|NCT00898612|adult acute myeloid leukemia with inv(16)(p13;q22)
1266473|NCT00898612|adult acute myeloid leukemia with t(15;17)(q22;q12)
1266474|NCT00898612|adult acute myeloid leukemia with t(16;16)(p13;q22)
1266475|NCT00898612|adult acute myeloid leukemia with t(8;21)(q22;q22)
1266476|NCT00898612|atypical chronic myeloid leukemia, BCR-ABL negative
1266477|NCT00898612|blastic phase chronic myelogenous leukemia
1266478|NCT00898612|childhood acute lymphoblastic leukemia in remission
1266479|NCT00898612|childhood acute myeloid leukemia in remission
1266480|NCT00898612|childhood chronic myelogenous leukemia
1266481|NCT00898612|chronic myelomonocytic leukemia
1266482|NCT00898612|chronic phase chronic myelogenous leukemia
1266483|NCT00898612|juvenile myelomonocytic leukemia
1266484|NCT00898612|recurrent adult acute lymphoblastic leukemia
1266485|NCT00898612|recurrent adult acute myeloid leukemia
1266486|NCT00898612|recurrent childhood acute lymphoblastic leukemia
1266487|NCT00898612|recurrent childhood acute myeloid leukemia
1266488|NCT00898612|refractory chronic lymphocytic leukemia
1266489|NCT00898612|refractory hairy cell leukemia
1266490|NCT00898612|relapsing chronic myelogenous leukemia
1266491|NCT00898612|secondary acute myeloid leukemia
1266492|NCT00898612|stage III chronic lymphocytic leukemia
1266493|NCT00898612|stage IV chronic lymphocytic leukemia
1266494|NCT00898612|childhood myelodysplastic syndromes
1266495|NCT00898612|chronic eosinophilic leukemia
1266496|NCT00898612|primary myelofibrosis
1266497|NCT00898612|chronic neutrophilic leukemia
1266498|NCT00898612|de novo myelodysplastic syndromes
1266499|NCT00898612|disseminated neuroblastoma
1266500|NCT00898612|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1266501|NCT00898612|poor prognosis metastatic gestational trophoblastic tumor
1266502|NCT00898612|previously treated childhood rhabdomyosarcoma
1266503|NCT00898612|previously treated myelodysplastic syndromes
1266504|NCT00898612|recurrent Wilms tumor and other childhood kidney tumors
1266505|NCT00898612|recurrent childhood rhabdomyosarcoma
1266506|NCT00898612|recurrent neuroblastoma
1266507|NCT00898612|recurrent ovarian epithelial cancer
1266508|NCT00898612|recurrent ovarian germ cell tumor
1266509|NCT00898612|recurrent malignant testicular germ cell tumor
1266510|NCT00898612|secondary myelodysplastic syndromes
1266511|NCT00898612|stage I multiple myeloma
1266512|NCT00898612|stage II multiple myeloma
1266513|NCT00898612|stage III multiple myeloma
1266514|NCT00898612|stage II ovarian epithelial cancer
1266515|NCT00898612|stage III ovarian epithelial cancer
1266516|NCT00898612|stage IV ovarian epithelial cancer
1266517|NCT00898612|stage III malignant testicular germ cell tumor
1266518|NCT00898612|stage IIIA breast cancer
1266519|NCT00898612|stage IIIB breast cancer
1266520|NCT00898612|stage IIIC breast cancer
1266521|NCT00898612|stage IV breast cancer
1266522|NCT00898612|refractory multiple myeloma
1266523|NCT00898573|breast cancer
1266524|NCT00898560|Partial
1266525|NCT00898560|Epilepsy
1266526|NCT00898560|Eslicarbazepine acetate
1266527|NCT00898560|Combined oral contraceptive
1266528|NCT00898560|Pharmacokinetics
1266529|NCT00898560|Tolerability
1266530|NCT00898547|advanced malignant mesothelioma
1266531|NCT00898547|recurrent malignant mesothelioma
1266532|NCT00898547|epithelial mesothelioma
1266533|NCT00898547|sarcomatous mesothelioma
1266534|NCT00898534|Pediatrics
1266535|NCT00898534|Hemoglobin A1c
1266536|NCT00898534|Point of Care testing
1266537|NCT00898508|invasive ductal breast carcinoma
1266538|NCT00898508|invasive lobular breast carcinoma
1266539|NCT00898508|ductal breast carcinoma in situ
1266540|NCT00898508|lobular breast carcinoma in situ
1266541|NCT00898508|stage I breast cancer
1266543|NCT00898508|stage IIIA breast cancer
1266544|NCT00898508|stage IIIB breast cancer
1266545|NCT00898508|stage IIIC breast cancer
1266546|NCT00898508|stage IV breast cancer
1266547|NCT00898495|adenocarcinoma of the esophagus
1266548|NCT00898495|stage II esophageal cancer
1266549|NCT00898495|stage III esophageal cancer
1266550|NCT00898495|stage IV esophageal cancer
1266551|NCT00898495|stage I esophageal cancer
1266552|NCT00898482|adenocarcinoma of the pancreas
1266553|NCT00898482|recurrent pancreatic cancer
1266554|NCT00898482|stage I pancreatic cancer
1266555|NCT00898482|stage II pancreatic cancer
1266556|NCT00898482|stage III pancreatic cancer
1266557|NCT00898482|stage IV pancreatic cancer
1266558|NCT00898469|childhood acute lymphoblastic leukemia
1266559|NCT00898456|adult acute myeloid leukemia
1266560|NCT00898456|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1266561|NCT00898456|adult acute myeloid leukemia with inv(16)(p13;q22)
1266562|NCT00898456|adult acute myeloid leukemia with t(16;16)(p13;q22)
1266563|NCT00898456|adult acute myeloid leukemia with t(8;21)(q22;q22)
1266564|NCT00898456|adult acute minimally differentiated myeloid leukemia (M0)
1266565|NCT00898456|adult acute myeloblastic leukemia without maturation (M1)
1266566|NCT00898456|adult acute myeloblastic leukemia with maturation (M2)
1266567|NCT00898456|adult acute myelomonocytic leukemia (M4)
1266568|NCT00898456|adult acute monoblastic leukemia (M5a)
1266569|NCT00898456|adult acute monocytic leukemia (M5b)
1266570|NCT00898456|adult erythroleukemia (M6a)
1266571|NCT00898456|adult pure erythroid leukemia (M6b)
1266572|NCT00898456|adult acute megakaryoblastic leukemia (M7)
1266573|NCT00898456|adult acute basophilic leukemia
1266574|NCT00898456|adult acute eosinophilic leukemia
1266575|NCT00898430|stage III squamous cell carcinoma of the hypopharynx
1266576|NCT00898430|stage IV squamous cell carcinoma of the hypopharynx
1266577|NCT00898430|stage III squamous cell carcinoma of the larynx
1266578|NCT00898430|stage III verrucous carcinoma of the larynx
1266579|NCT00898430|stage IV squamous cell carcinoma of the larynx
1266580|NCT00898430|stage IV verrucous carcinoma of the larynx
1266581|NCT00898430|stage III squamous cell carcinoma of the lip and oral cavity
1266582|NCT00898430|stage IV squamous cell carcinoma of the lip and oral cavity
1266583|NCT00898430|stage III verrucous carcinoma of the oral cavity
1266584|NCT00898430|stage IV verrucous carcinoma of the oral cavity
1266585|NCT00898430|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1266586|NCT00898430|untreated metastatic squamous neck cancer with occult primary
1266587|NCT00898430|stage III squamous cell carcinoma of the nasopharynx
1266588|NCT00898430|stage IV squamous cell carcinoma of the nasopharynx
1266589|NCT00898430|stage III squamous cell carcinoma of the oropharynx
1266590|NCT00898430|stage IV squamous cell carcinoma of the oropharynx
1266591|NCT00898430|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1266592|NCT00898430|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1266593|NCT00898430|salivary gland squamous cell carcinoma
1266594|NCT00898430|stage III salivary gland cancer
1266595|NCT00898430|stage IV salivary gland cancer
1266596|NCT00898417|stage IIIB non-small cell lung cancer
1266597|NCT00898417|recurrent non-small cell lung cancer
1266598|NCT00898417|stage IV non-small cell lung cancer
1266599|NCT00898417|adenocarcinoma of the lung
1266600|NCT00898417|bronchoalveolar cell lung cancer
1266601|NCT00898378|healthy, no evidence of disease
1266602|NCT00898378|stage I colon cancer
1266603|NCT00898378|stage II colon cancer
1266604|NCT00898378|stage III colon cancer
1266605|NCT00898378|stage IV colon cancer
1266606|NCT00898378|stage I rectal cancer
1266607|NCT00898378|stage II rectal cancer
1266608|NCT00898378|stage III rectal cancer
1266609|NCT00898378|stage IV rectal cancer
1266610|NCT00898378|recurrent rectal cancer
1266611|NCT00898378|recurrent colon cancer
1266612|NCT00898378|adenomatous polyp
1266613|NCT00898352|stage III vulvar cancer
1266614|NCT00898352|squamous cell carcinoma of the vulva
1266615|NCT00898326|stage I prostate cancer
1266616|NCT00898326|stage IIB prostate cancer
1266617|NCT00898326|stage IIA prostate cancer
1266618|NCT00898313|lung cancer
1266619|NCT00898300|stage I squamous cell carcinoma of the hypopharynx
1266620|NCT00898300|stage II squamous cell carcinoma of the hypopharynx
1266621|NCT00898300|stage III squamous cell carcinoma of the hypopharynx
1266622|NCT00898300|stage IV squamous cell carcinoma of the hypopharynx
1266623|NCT00898300|stage I squamous cell carcinoma of the larynx
1266624|NCT00898300|stage II squamous cell carcinoma of the larynx
1266625|NCT00898300|stage III squamous cell carcinoma of the larynx
1266626|NCT00898300|stage IV squamous cell carcinoma of the larynx
1266627|NCT00898300|stage I verrucous carcinoma of the larynx
1266628|NCT00898300|stage II verrucous carcinoma of the larynx
1266629|NCT00898300|stage III verrucous carcinoma of the larynx
1266630|NCT00898300|stage IV verrucous carcinoma of the larynx
1266631|NCT00898300|stage I basal cell carcinoma of the lip
1266632|NCT00898300|stage II basal cell carcinoma of the lip
1266633|NCT00898300|stage III basal cell carcinoma of the lip
1266634|NCT00898300|stage IV basal cell carcinoma of the lip
1266635|NCT00898300|stage I mucoepidermoid carcinoma of the oral cavity
1266636|NCT00898300|stage II mucoepidermoid carcinoma of the oral cavity
1266637|NCT00898300|stage III mucoepidermoid carcinoma of the oral cavity
1266638|NCT00898300|stage IV mucoepidermoid carcinoma of the oral cavity
1266639|NCT00898300|stage I verrucous carcinoma of the oral cavity
1266640|NCT00898300|stage II verrucous carcinoma of the oral cavity
1266641|NCT00898300|stage III verrucous carcinoma of the oral cavity
1266642|NCT00898300|stage IV verrucous carcinoma of the oral cavity
1266643|NCT00898300|stage I adenoid cystic carcinoma of the oral cavity
1266644|NCT00898300|stage II adenoid cystic carcinoma of the oral cavity
1266645|NCT00898300|stage III adenoid cystic carcinoma of the oral cavity
1266646|NCT00898300|stage IV adenoid cystic carcinoma of the oral cavity
1266647|NCT00898300|stage I squamous cell carcinoma of the lip and oral cavity
1266648|NCT00898300|stage II squamous cell carcinoma of the lip and oral cavity
1266649|NCT00898300|stage III squamous cell carcinoma of the lip and oral cavity
1266650|NCT00898300|stage IV squamous cell carcinoma of the lip and oral cavity
1266651|NCT00898300|metastatic squamous neck cancer with occult primary
1266652|NCT00898300|stage I lymphoepithelioma of the nasopharynx
1266653|NCT00898300|stage II lymphoepithelioma of the nasopharynx
1266654|NCT00898300|stage III lymphoepithelioma of the nasopharynx
1266655|NCT00898300|stage IV lymphoepithelioma of the nasopharynx
1266656|NCT00898300|stage I squamous cell carcinoma of the nasopharynx
1266657|NCT00898300|stage II squamous cell carcinoma of the nasopharynx
1266658|NCT00898300|stage III squamous cell carcinoma of the nasopharynx
1266659|NCT00898300|stage IV squamous cell carcinoma of the nasopharynx
1266660|NCT00898300|stage I lymphoepithelioma of the oropharynx
1266661|NCT00898300|stage II lymphoepithelioma of the oropharynx
1266662|NCT00898300|stage III lymphoepithelioma of the oropharynx
1266663|NCT00898300|stage IV lymphoepithelioma of the oropharynx
1266664|NCT00898300|stage I squamous cell carcinoma of the oropharynx
1266665|NCT00898300|stage II squamous cell carcinoma of the oropharynx
1266666|NCT00898300|stage III squamous cell carcinoma of the oropharynx
1266667|NCT00898300|stage IV squamous cell carcinoma of the oropharynx
1266668|NCT00898300|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266669|NCT00898300|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266670|NCT00898300|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266671|NCT00898300|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267129|NCT00897728|stage II breast cancer
1266672|NCT00898300|stage I inverted papilloma of the paranasal sinus and nasal cavity
1266673|NCT00898300|stage II inverted papilloma of the paranasal sinus and nasal cavity
1266674|NCT00898300|stage III inverted papilloma of the paranasal sinus and nasal cavity
1266675|NCT00898300|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1266676|NCT00898300|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1266677|NCT00898300|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1266678|NCT00898300|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1266679|NCT00898300|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1266680|NCT00898300|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1266681|NCT00898300|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1266682|NCT00898300|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1266683|NCT00898300|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1266684|NCT00898300|stage I salivary gland cancer
1266685|NCT00898300|stage II salivary gland cancer
1266686|NCT00898300|stage III salivary gland cancer
1266687|NCT00898300|stage IV salivary gland cancer
1266688|NCT00898300|recurrent squamous cell carcinoma of the hypopharynx
1266689|NCT00898300|recurrent squamous cell carcinoma of the larynx
1266690|NCT00898300|recurrent squamous cell carcinoma of the lip and oral cavity
1266691|NCT00898300|recurrent squamous cell carcinoma of the nasopharynx
1266692|NCT00898300|recurrent squamous cell carcinoma of the oropharynx
1266693|NCT00898300|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1266694|NCT00898300|recurrent adenoid cystic carcinoma of the oral cavity
1266695|NCT00898300|recurrent basal cell carcinoma of the lip
1266696|NCT00898300|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1266697|NCT00898300|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1266698|NCT00898300|recurrent lymphoepithelioma of the nasopharynx
1266699|NCT00898300|recurrent lymphoepithelioma of the oropharynx
1266700|NCT00898300|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1266701|NCT00898300|recurrent mucoepidermoid carcinoma of the oral cavity
1266702|NCT00898300|recurrent salivary gland cancer
1266703|NCT00898300|recurrent verrucous carcinoma of the larynx
1266704|NCT00898300|recurrent verrucous carcinoma of the oral cavity
1266705|NCT00898300|recurrent metastatic squamous neck cancer with occult primary
1266706|NCT00898287|Locally advanced or metastatic adenocarcinoma of pancreas
1266707|NCT00898274|prostate cancer
1266708|NCT00898274|high grade prostatic intraepithelial neoplasia
1266709|NCT00898261|adult acute lymphoblastic leukemia in remission
1266710|NCT00898235|primary systemic amyloidosis
1266711|NCT00898222|healthy volunteers
1266712|NCT00898222|aspirin
1266713|NCT00898222|Normal healthy subjects
1266714|NCT00898209|stage I non-small cell lung cancer
1266715|NCT00898209|stage II non-small cell lung cancer
1266716|NCT00898209|stage IIIA non-small cell lung cancer
1266717|NCT00898209|stage IIIB non-small cell lung cancer
1266718|NCT00898209|stage IV non-small cell lung cancer
1266719|NCT00898183|stage III melanoma
1266720|NCT00898183|stage IV melanoma
1266721|NCT00898183|recurrent melanoma
1266722|NCT00898170|myoma
1266723|NCT00898170|hypertension
1266724|NCT00898170|erythropoetin
1266725|NCT00898170|blood pressure
1266726|NCT00898170|erythropoetin level
1266727|NCT00898157|contiguous stage II adult diffuse large cell lymphoma
1266728|NCT00898157|noncontiguous stage II adult diffuse large cell lymphoma
1266729|NCT00898157|recurrent adult diffuse large cell lymphoma
1266730|NCT00898157|stage I adult diffuse large cell lymphoma
1266731|NCT00898157|stage III adult diffuse large cell lymphoma
1266732|NCT00898157|stage IV adult diffuse large cell lymphoma
1266733|NCT00898144|cervical cancer
1266734|NCT00898144|cervical intraepithelial neoplasia grade 2
1266735|NCT00898144|cervical intraepithelial neoplasia grade 3
1266736|NCT00898144|cervical adenocarcinoma
1266737|NCT00898144|atypical squamous cells of undetermined significance
1266738|NCT00898131|breast cancer
1266739|NCT00898118|refractory cytopenia with multilineage dysplasia
1266740|NCT00898118|childhood myelodysplastic syndromes
1266741|NCT00898118|previously treated myelodysplastic syndromes
1266742|NCT00898118|secondary myelodysplastic syndromes
1266743|NCT00898092|adult acute minimally differentiated myeloid leukemia (M0)
1266744|NCT00898092|adult acute myeloblastic leukemia without maturation (M1)
1266745|NCT00898092|adult acute myeloblastic leukemia with maturation (M2)
1266746|NCT00898092|adult acute myelomonocytic leukemia (M4)
1266747|NCT00898092|adult acute monoblastic leukemia (M5a)
1266748|NCT00898092|adult acute monocytic leukemia (M5b)
1266749|NCT00898092|adult erythroleukemia (M6a)
1266750|NCT00898092|adult pure erythroid leukemia (M6b)
1266751|NCT00898092|adult acute megakaryoblastic leukemia (M7)
1266752|NCT00898092|adult acute eosinophilic leukemia
1266753|NCT00898092|adult acute basophilic leukemia
1266754|NCT00898092|untreated adult acute myeloid leukemia
1266755|NCT00898066|Waldenstrom macroglobulinemia
1266756|NCT00898066|monoclonal gammopathy of undetermined significance
1266757|NCT00898066|primary systemic amyloidosis
1266758|NCT00898066|stage I multiple myeloma
1266759|NCT00898066|stage II multiple myeloma
1266760|NCT00898066|stage III multiple myeloma
1266761|NCT00898040|stage I multiple myeloma
1266762|NCT00898040|stage II multiple myeloma
1266763|NCT00898040|stage III multiple myeloma
1266764|NCT00898040|refractory multiple myeloma
1266765|NCT00898027|unspecified adult solid tumor, protocol specific
1266766|NCT00898014|stage IV breast cancer
1266767|NCT00897988|recurrent squamous cell carcinoma of the oropharynx
1266768|NCT00897988|stage I squamous cell carcinoma of the oropharynx
1266769|NCT00897988|stage II squamous cell carcinoma of the oropharynx
1266770|NCT00897988|stage III squamous cell carcinoma of the oropharynx
1266771|NCT00897988|stage IV squamous cell carcinoma of the oropharynx
1266772|NCT00897975|statin associated myalgias
1266773|NCT00897975|hyperlipidemia
1266774|NCT00897975|red yeast rice
1266775|NCT00897975|phytosterols
1266776|NCT00897975|therapeutic lifestyle changes
1266777|NCT00897975|compliance
1266778|NCT00897962|stage IV breast cancer
1266779|NCT00897936|adult acute myeloid leukemia in remission
1266780|NCT00897936|recurrent adult acute myeloid leukemia
1266781|NCT00897936|untreated adult acute myeloid leukemia
1266782|NCT00897936|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1266783|NCT00897936|adult acute myeloid leukemia with inv(16)(p13;q22)
1266784|NCT00897936|adult acute myeloid leukemia with t(15;17)(q22;q12)
1266785|NCT00897936|adult acute myeloid leukemia with t(16;16)(p13;q22)
1266786|NCT00897936|adult acute myeloid leukemia with t(8;21)(q22;q22)
1266787|NCT00897923|AIDS-related peripheral/systemic lymphoma
1266788|NCT00897923|AIDS-related primary CNS lymphoma
1266789|NCT00897923|anaplastic large cell lymphoma
1266790|NCT00897923|angioimmunoblastic T-cell lymphoma
1266791|NCT00897923|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1266792|NCT00897923|intraocular lymphoma
1266793|NCT00897923|nodal marginal zone B-cell lymphoma
1266794|NCT00897923|primary central nervous system non-Hodgkin lymphoma
1266795|NCT00897923|recurrent adult Burkitt lymphoma
1266796|NCT00897923|recurrent adult diffuse large cell lymphoma
1266797|NCT00897923|recurrent adult diffuse mixed cell lymphoma
1266798|NCT00897923|recurrent adult diffuse small cleaved cell lymphoma
1266799|NCT00897923|recurrent adult immunoblastic large cell lymphoma
1266800|NCT00897923|recurrent adult lymphoblastic lymphoma
1266801|NCT00897923|recurrent adult T-cell leukemia/lymphoma
1266802|NCT00897923|recurrent cutaneous T-cell non-Hodgkin lymphoma
1266803|NCT00897923|recurrent grade 1 follicular lymphoma
1266804|NCT00897923|recurrent grade 2 follicular lymphoma
1266805|NCT00897923|recurrent grade 3 follicular lymphoma
1266806|NCT00897923|recurrent mantle cell lymphoma
1266807|NCT00897923|recurrent marginal zone lymphoma
1266808|NCT00897923|recurrent mycosis fungoides/Sezary syndrome
1266809|NCT00897923|recurrent small lymphocytic lymphoma
1266810|NCT00897923|small intestine lymphoma
1266811|NCT00897923|splenic marginal zone lymphoma
1266812|NCT00897923|stage III adult Burkitt lymphoma
1266813|NCT00897923|stage III adult diffuse large cell lymphoma
1266814|NCT00897923|stage III adult diffuse mixed cell lymphoma
1266815|NCT00897923|stage III adult diffuse small cleaved cell lymphoma
1266816|NCT00897923|stage III adult immunoblastic large cell lymphoma
1266817|NCT00897923|stage III adult lymphoblastic lymphoma
1266818|NCT00897923|stage III adult T-cell leukemia/lymphoma
1266819|NCT00897923|stage III cutaneous T-cell non-Hodgkin lymphoma
1266820|NCT00897923|stage III grade 1 follicular lymphoma
1266821|NCT00897923|stage III grade 2 follicular lymphoma
1266822|NCT00897923|stage III grade 3 follicular lymphoma
1266823|NCT00897923|stage III mantle cell lymphoma
1266824|NCT00897923|stage III marginal zone lymphoma
1266825|NCT00897923|stage III mycosis fungoides/Sezary syndrome
1266826|NCT00897923|stage III small lymphocytic lymphoma
1266827|NCT00897923|stage IV adult Burkitt lymphoma
1266828|NCT00897923|stage IV adult diffuse large cell lymphoma
1266829|NCT00897923|stage IV adult diffuse mixed cell lymphoma
1266830|NCT00897923|stage IV adult diffuse small cleaved cell lymphoma
1266831|NCT00897923|stage IV adult immunoblastic large cell lymphoma
1266832|NCT00897923|stage IV adult lymphoblastic lymphoma
1266833|NCT00897923|stage IV adult T-cell leukemia/lymphoma
1266834|NCT00897923|stage IV cutaneous T-cell non-Hodgkin lymphoma
1266835|NCT00897923|stage IV grade 1 follicular lymphoma
1266836|NCT00897923|stage IV grade 2 follicular lymphoma
1266837|NCT00897923|stage IV grade 3 follicular lymphoma
1266838|NCT00897923|stage IV mantle cell lymphoma
1266839|NCT00897923|stage IV marginal zone lymphoma
1266840|NCT00897923|stage IV mycosis fungoides/Sezary syndrome
1266841|NCT00897923|stage IV small lymphocytic lymphoma
1266842|NCT00897923|Waldenström macroglobulinemia
1266843|NCT00897923|stage I adult Burkitt lymphoma
1266844|NCT00897923|stage I adult diffuse large cell lymphoma
1266845|NCT00897923|stage I adult diffuse mixed cell lymphoma
1266846|NCT00897923|stage I adult diffuse small cleaved cell lymphoma
1266847|NCT00897923|stage I adult immunoblastic large cell lymphoma
1266848|NCT00897923|stage I adult lymphoblastic lymphoma
1266849|NCT00897923|stage I adult T-cell leukemia/lymphoma
1266850|NCT00897923|stage I cutaneous T-cell non-Hodgkin lymphoma
1266851|NCT00897923|stage I grade 1 follicular lymphoma
1266852|NCT00897923|stage I grade 2 follicular lymphoma
1266853|NCT00897923|stage I grade 3 follicular lymphoma
1266854|NCT00897923|stage I mantle cell lymphoma
1266855|NCT00897923|stage I marginal zone lymphoma
1266856|NCT00897923|stage I small lymphocytic lymphoma
1266857|NCT00897923|stage II adult T-cell leukemia/lymphoma
1266858|NCT00897923|adult grade III lymphomatoid granulomatosis
1266859|NCT00897923|adult nasal type extranodal NK/T-cell lymphoma
1266860|NCT00897923|recurrent adult grade III lymphomatoid granulomatosis
1266861|NCT00897923|contiguous stage II adult Burkitt lymphoma
1266862|NCT00897923|contiguous stage II adult diffuse large cell lymphoma
1266863|NCT00897923|contiguous stage II adult diffuse mixed cell lymphoma
1266864|NCT00897923|contiguous stage II adult diffuse small cleaved cell lymphoma
1266865|NCT00897923|contiguous stage II adult immunoblastic large cell lymphoma
1266866|NCT00897923|contiguous stage II adult lymphoblastic lymphoma
1266867|NCT00897923|contiguous stage II grade 1 follicular lymphoma
1266868|NCT00897923|contiguous stage II grade 2 follicular lymphoma
1266869|NCT00897923|contiguous stage II grade 3 follicular lymphoma
1266870|NCT00897923|contiguous stage II mantle cell lymphoma
1266871|NCT00897923|contiguous stage II marginal zone lymphoma
1266872|NCT00897923|contiguous stage II small lymphocytic lymphoma
1266873|NCT00897923|noncontiguous stage II adult Burkitt lymphoma
1266874|NCT00897923|noncontiguous stage II adult diffuse large cell lymphoma
1266875|NCT00897923|noncontiguous stage II adult diffuse mixed cell lymphoma
1266876|NCT00897923|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1266877|NCT00897923|noncontiguous stage II adult immunoblastic large cell lymphoma
1266878|NCT00897923|noncontiguous stage II adult lymphoblastic lymphoma
1266879|NCT00897923|noncontiguous stage II grade 1 follicular lymphoma
1266880|NCT00897923|noncontiguous stage II grade 2 follicular lymphoma
1266881|NCT00897923|noncontiguous stage II grade 3 follicular lymphoma
1266882|NCT00897923|noncontiguous stage II mantle cell lymphoma
1266883|NCT00897923|noncontiguous stage II marginal zone lymphoma
1266884|NCT00897923|noncontiguous stage II small lymphocytic lymphoma
1266885|NCT00897923|stage I mycosis fungoides/Sezary syndrome
1266886|NCT00897923|stage II mycosis fungoides/Sezary syndrome
1266887|NCT00897923|stage II cutaneous T-cell non-Hodgkin lymphoma
1266888|NCT00897910|stage I multiple myeloma
1266889|NCT00897910|stage II multiple myeloma
1266890|NCT00897910|stage III multiple myeloma
1266891|NCT00897910|refractory multiple myeloma
1266892|NCT00897897|Uterine Leiomyomas
1266893|NCT00897897|Fibroids
1266894|NCT00897897|HIFU
1266895|NCT00897897|Ablation
1266896|NCT00897897|High Intensity Focused Ultrasound
1266897|NCT00897884|breast cancer
1266898|NCT00897884|metformin
1266899|NCT00897884|breast surgery
1266900|NCT00897871|unspecified childhood solid tumor, protocol specific
1266901|NCT00897858|childhood central nervous system germ cell tumor
1266902|NCT00897858|childhood choroid plexus tumor
1266903|NCT00897858|childhood grade I meningioma
1266904|NCT00897858|childhood grade II meningioma
1266905|NCT00897858|childhood grade III meningioma
1266906|NCT00897858|childhood atypical teratoid/rhabdoid tumor
1266907|NCT00897858|untreated childhood visual pathway glioma
1266908|NCT00897858|childhood infratentorial ependymoma
1266909|NCT00897858|childhood supratentorial ependymoma
1266910|NCT00897858|newly diagnosed childhood ependymoma
1266911|NCT00897858|childhood craniopharyngioma
1266912|NCT00897858|untreated childhood medulloblastoma
1266913|NCT00897858|untreated childhood cerebellar astrocytoma
1266914|NCT00897858|untreated childhood supratentorial primitive neuroectodermal tumor
1266915|NCT00897858|untreated childhood brain stem glioma
1266916|NCT00897858|untreated childhood visual pathway and hypothalamic glioma
1266917|NCT00897858|childhood high-grade cerebral astrocytoma
1266918|NCT00897858|childhood low-grade cerebral astrocytoma
1266919|NCT00897858|childhood central nervous system choriocarcinoma
1266920|NCT00897858|childhood central nervous system embryonal tumor
1266921|NCT00897858|childhood central nervous system germinoma
1266922|NCT00897858|childhood central nervous system mixed germ cell tumor
1266923|NCT00897858|childhood central nervous system teratoma
1266924|NCT00897858|childhood central nervous system yolk sac tumor
1266925|NCT00897845|stage II breast cancer
1266926|NCT00897845|stage IIIA breast cancer
1266927|NCT00897845|stage IIIB breast cancer
1266928|NCT00897832|pancreatic cancer
1266929|NCT00897819|recurrent colon cancer
1266930|NCT00897819|recurrent rectal cancer
1266931|NCT00897819|stage III colon cancer
1266932|NCT00897819|stage III rectal cancer
1266933|NCT00897819|stage IV colon cancer
1266934|NCT00897819|stage IV rectal cancer
1266935|NCT00897819|adenocarcinoma of the colon
1266936|NCT00897819|adenocarcinoma of the rectum
1266937|NCT00897806|stage III ovarian epithelial cancer
1266938|NCT00897806|stage IV ovarian epithelial cancer
1266939|NCT00897806|peritoneal cavity cancer
1266940|NCT00897793|recurrent squamous cell carcinoma of the hypopharynx
1266941|NCT00897793|stage I squamous cell carcinoma of the hypopharynx
1266942|NCT00897793|stage II squamous cell carcinoma of the hypopharynx
1266943|NCT00897793|stage III squamous cell carcinoma of the hypopharynx
1266944|NCT00897793|stage IV squamous cell carcinoma of the hypopharynx
1266945|NCT00897793|recurrent squamous cell carcinoma of the larynx
1266946|NCT00897793|recurrent verrucous carcinoma of the larynx
1266947|NCT00897793|stage I squamous cell carcinoma of the larynx
1266948|NCT00897793|stage I verrucous carcinoma of the larynx
1266949|NCT00897793|stage II squamous cell carcinoma of the larynx
1266950|NCT00897793|stage II verrucous carcinoma of the larynx
1266951|NCT00897793|stage III squamous cell carcinoma of the larynx
1266952|NCT00897793|stage III verrucous carcinoma of the larynx
1266953|NCT00897793|stage IV squamous cell carcinoma of the larynx
1266954|NCT00897793|stage IV verrucous carcinoma of the larynx
1266955|NCT00897793|recurrent adenoid cystic carcinoma of the oral cavity
1266956|NCT00897793|recurrent mucoepidermoid carcinoma of the oral cavity
1266957|NCT00897793|recurrent verrucous carcinoma of the oral cavity
1266958|NCT00897793|stage I adenoid cystic carcinoma of the oral cavity
1266959|NCT00897793|stage I mucoepidermoid carcinoma of the oral cavity
1266960|NCT00897793|stage I verrucous carcinoma of the oral cavity
1266961|NCT00897793|stage II adenoid cystic carcinoma of the oral cavity
1266962|NCT00897793|stage II mucoepidermoid carcinoma of the oral cavity
1266963|NCT00897793|stage II verrucous carcinoma of the oral cavity
1266964|NCT00897793|stage III adenoid cystic carcinoma of the oral cavity
1266965|NCT00897793|stage III mucoepidermoid carcinoma of the oral cavity
1266966|NCT00897793|stage III verrucous carcinoma of the oral cavity
1266967|NCT00897793|stage IV adenoid cystic carcinoma of the oral cavity
1266968|NCT00897793|stage IV mucoepidermoid carcinoma of the oral cavity
1266969|NCT00897793|stage IV verrucous carcinoma of the oral cavity
1266970|NCT00897793|stage I squamous cell carcinoma of the lip and oral cavity
1266971|NCT00897793|stage II squamous cell carcinoma of the lip and oral cavity
1266972|NCT00897793|stage III squamous cell carcinoma of the lip and oral cavity
1266973|NCT00897793|stage IV squamous cell carcinoma of the lip and oral cavity
1266974|NCT00897793|recurrent basal cell carcinoma of the lip
1266975|NCT00897793|recurrent squamous cell carcinoma of the lip and oral cavity
1266976|NCT00897793|stage I basal cell carcinoma of the lip
1266977|NCT00897793|stage II basal cell carcinoma of the lip
1266978|NCT00897793|stage III basal cell carcinoma of the lip
1266979|NCT00897793|stage IV basal cell carcinoma of the lip
1266980|NCT00897793|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1266981|NCT00897793|recurrent metastatic squamous neck cancer with occult primary
1266982|NCT00897793|untreated metastatic squamous neck cancer with occult primary
1266983|NCT00897793|recurrent lymphoepithelioma of the nasopharynx
1266984|NCT00897793|recurrent squamous cell carcinoma of the nasopharynx
1266985|NCT00897793|stage I lymphoepithelioma of the nasopharynx
1266986|NCT00897793|stage I squamous cell carcinoma of the nasopharynx
1266987|NCT00897793|stage II lymphoepithelioma of the nasopharynx
1266988|NCT00897793|stage II squamous cell carcinoma of the nasopharynx
1266989|NCT00897793|stage III lymphoepithelioma of the nasopharynx
1266990|NCT00897793|stage III squamous cell carcinoma of the nasopharynx
1266991|NCT00897793|stage IV lymphoepithelioma of the nasopharynx
1266992|NCT00897793|stage IV squamous cell carcinoma of the nasopharynx
1266993|NCT00897793|recurrent lymphoepithelioma of the oropharynx
1266994|NCT00897793|recurrent squamous cell carcinoma of the oropharynx
1266995|NCT00897793|stage I lymphoepithelioma of the oropharynx
1266996|NCT00897793|stage I squamous cell carcinoma of the oropharynx
1266997|NCT00897793|stage II lymphoepithelioma of the oropharynx
1266998|NCT00897793|stage II squamous cell carcinoma of the oropharynx
1266999|NCT00897793|stage III lymphoepithelioma of the oropharynx
1267000|NCT00897793|stage III squamous cell carcinoma of the oropharynx
1267001|NCT00897793|stage IV lymphoepithelioma of the oropharynx
1267002|NCT00897793|stage IV squamous cell carcinoma of the oropharynx
1267003|NCT00897793|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267004|NCT00897793|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1267005|NCT00897793|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1267006|NCT00897793|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1267007|NCT00897793|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267008|NCT00897793|stage I inverted papilloma of the paranasal sinus and nasal cavity
1267009|NCT00897793|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1267010|NCT00897793|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1267011|NCT00897793|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267012|NCT00897793|stage II inverted papilloma of the paranasal sinus and nasal cavity
1267013|NCT00897793|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1267014|NCT00897793|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1267015|NCT00897793|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267016|NCT00897793|stage III inverted papilloma of the paranasal sinus and nasal cavity
1267017|NCT00897793|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1267018|NCT00897793|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1267019|NCT00897793|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267020|NCT00897793|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1267021|NCT00897793|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1267022|NCT00897793|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1267023|NCT00897793|high-grade salivary gland mucoepidermoid carcinoma
1267024|NCT00897793|low-grade salivary gland mucoepidermoid carcinoma
1267025|NCT00897793|recurrent salivary gland cancer
1267026|NCT00897793|salivary gland acinic cell tumor
1267027|NCT00897793|salivary gland adenocarcinoma
1267028|NCT00897793|salivary gland adenoid cystic carcinoma
1267029|NCT00897793|salivary gland anaplastic carcinoma
1267030|NCT00897793|salivary gland malignant mixed cell type tumor
1267031|NCT00897793|salivary gland poorly differentiated carcinoma
1267032|NCT00897793|salivary gland squamous cell carcinoma
1267033|NCT00897793|stage I salivary gland cancer
1267034|NCT00897793|stage II salivary gland cancer
1267035|NCT00897793|stage III salivary gland cancer
1267036|NCT00897793|stage IV salivary gland cancer
1267037|NCT00897793|limited stage small cell lung cancer
1267038|NCT00897793|recurrent non-small cell lung cancer
1267039|NCT00897793|recurrent small cell lung cancer
1267040|NCT00897793|stage I non-small cell lung cancer
1267041|NCT00897793|stage II non-small cell lung cancer
1267042|NCT00897793|stage IIIA non-small cell lung cancer
1267043|NCT00897793|stage IIIB non-small cell lung cancer
1267044|NCT00897793|stage IV non-small cell lung cancer
1267045|NCT00897793|extensive stage small cell lung cancer
1267046|NCT00897793|male breast cancer
1267047|NCT00897793|recurrent breast cancer
1267048|NCT00897793|stage I breast cancer
1267049|NCT00897793|stage II breast cancer
1267050|NCT00897793|stage IIIA breast cancer
1267051|NCT00897793|stage IIIB breast cancer
1267052|NCT00897793|stage IIIC breast cancer
1267053|NCT00897793|stage IV breast cancer
1267054|NCT00897793|recurrent colon cancer
1267055|NCT00897793|stage I colon cancer
1267056|NCT00897793|stage II colon cancer
1267057|NCT00897793|stage III colon cancer
1267058|NCT00897793|stage IV colon cancer
1267059|NCT00897793|recurrent rectal cancer
1267060|NCT00897793|stage I rectal cancer
1267061|NCT00897793|stage II rectal cancer
1267062|NCT00897793|stage III rectal cancer
1267063|NCT00897793|stage IV rectal cancer
1267064|NCT00897793|recurrent prostate cancer
1267065|NCT00897793|stage I prostate cancer
1267066|NCT00897793|stage II prostate cancer
1267067|NCT00897793|stage III prostate cancer
1267068|NCT00897793|stage IV prostate cancer
1267069|NCT00897780|Headache
1267070|NCT00897780|Pediatric
1267071|NCT00897780|Virtual Reality
1267072|NCT00897780|Biofeedback
1267073|NCT00897767|accelerated phase chronic myelogenous leukemia
1267074|NCT00897767|atypical chronic myeloid leukemia, BCR-ABL1 negative
1267075|NCT00897767|blastic phase chronic myelogenous leukemia
1267076|NCT00897767|childhood chronic myelogenous leukemia
1267077|NCT00897767|chronic myelomonocytic leukemia
1267078|NCT00897767|chronic phase chronic myelogenous leukemia
1267079|NCT00897767|juvenile myelomonocytic leukemia
1267080|NCT00897767|meningeal chronic myelogenous leukemia
1267081|NCT00897767|progressive hairy cell leukemia, initial treatment
1267082|NCT00897767|recurrent adult acute lymphoblastic leukemia
1267083|NCT00897767|recurrent adult acute myeloid leukemia
1267084|NCT00897767|recurrent adult T-cell leukemia/lymphoma
1267085|NCT00897767|recurrent childhood acute lymphoblastic leukemia
1267086|NCT00897767|recurrent childhood acute myeloid leukemia
1267087|NCT00897767|refractory chronic lymphocytic leukemia
1267088|NCT00897767|refractory hairy cell leukemia
1267089|NCT00897767|relapsing chronic myelogenous leukemia
1267090|NCT00897767|stage I adult T-cell leukemia/lymphoma
1267091|NCT00897767|stage I chronic lymphocytic leukemia
1267092|NCT00897767|stage II adult T-cell leukemia/lymphoma
1267093|NCT00897767|stage II chronic lymphocytic leukemia
1267094|NCT00897767|stage III adult T-cell leukemia/lymphoma
1267095|NCT00897767|stage III chronic lymphocytic leukemia
1267096|NCT00897767|stage IV adult T-cell leukemia/lymphoma
1267097|NCT00897767|stage IV chronic lymphocytic leukemia
1267098|NCT00897767|untreated adult acute lymphoblastic leukemia
1267099|NCT00897767|untreated adult acute myeloid leukemia
1267100|NCT00897767|untreated childhood acute lymphoblastic leukemia
1267101|NCT00897767|untreated childhood acute myeloid leukemia and other myeloid malignancies
1267102|NCT00897767|T-cell large granular lymphocyte leukemia
1267103|NCT00897767|adult acute myeloid leukemia in remission
1267104|NCT00897767|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1267105|NCT00897767|adult acute myeloid leukemia with inv(16)(p13;q22)
1267106|NCT00897767|adult acute myeloid leukemia with t(15;17)(q22;q12)
1267107|NCT00897767|adult acute myeloid leukemia with t(16;16)(p13;q22)
1267108|NCT00897767|adult acute myeloid leukemia with t(8;21)(q22;q22)
1267109|NCT00897767|secondary acute myeloid leukemia
1267110|NCT00897767|childhood acute myeloid leukemia in remission
1267111|NCT00897767|acute undifferentiated leukemia
1267112|NCT00897767|mast cell leukemia
1267113|NCT00897767|adult acute lymphoblastic leukemia in remission
1267114|NCT00897767|childhood acute lymphoblastic leukemia in remission
1267115|NCT00897767|prolymphocytic leukemia
1267116|NCT00897767|untreated hairy cell leukemia
1267117|NCT00897754|adenocarcinoma of the colon
1267118|NCT00897754|adenocarcinoma of the rectum
1267119|NCT00897754|recurrent rectal cancer
1267120|NCT00897754|stage III rectal cancer
1267121|NCT00897754|stage IV rectal cancer
1267122|NCT00897754|recurrent colon cancer
1267123|NCT00897754|stage III colon cancer
1267124|NCT00897754|stage IV colon cancer
1267125|NCT00897741|recurrent pancreatic cancer
1267126|NCT00897741|stage IV pancreatic cancer
1267127|NCT00897728|stage IA breast cancer
1267128|NCT00897728|stage IB breast cancer
1267130|NCT00897728|stage IIIA breast cancer
1267131|NCT00897728|stage IIIB breast cancer
1267132|NCT00897728|stage IIIC breast cancer
1267133|NCT00897728|HER2-positive breast cancer
1267134|NCT00897728|triple-negative breast cancer
1267135|NCT00897728|estrogen receptor-negative breast cancer
1267136|NCT00897715|CKD
1267137|NCT00897715|inflammation
1267138|NCT00897715|CVD
1267139|NCT00897702|recurrent breast cancer
1267140|NCT00897702|male breast cancer
1267141|NCT00897702|stage IV breast cancer
1267142|NCT00897676|Hyperinsulinism
1267143|NCT00897676|Hypoglycemia
1267144|NCT00897676|KATP channel
1267145|NCT00897663|adult giant cell glioblastoma
1267146|NCT00897663|adult gliosarcoma
1267147|NCT00897663|adult glioblastoma
1267148|NCT00897650|lung cancer
1267149|NCT00897624|metastatic intraocular melanoma
1267150|NCT00897624|ciliary body and choroid melanoma, medium/large size
1267151|NCT00897624|ciliary body and choroid melanoma, small size
1267152|NCT00897611|adult anaplastic astrocytoma
1267153|NCT00897611|adult anaplastic oligodendroglioma
1267154|NCT00897611|adult giant cell glioblastoma
1267155|NCT00897611|recurrent adult brain tumor
1267156|NCT00897611|adult glioblastoma
1267157|NCT00897611|adult gliosarcoma
1267158|NCT00897559|adult acute megakaryoblastic leukemia (M7)
1267159|NCT00897546|recurrent melanoma
1267160|NCT00897546|stage IV melanoma
1267161|NCT00897546|stage IA melanoma
1267162|NCT00897546|stage IB melanoma
1267163|NCT00897546|stage IIA melanoma
1267164|NCT00897546|stage IIB melanoma
1267165|NCT00897546|stage IIC melanoma
1267166|NCT00897546|stage IIIA melanoma
1267167|NCT00897546|stage IIIB melanoma
1267168|NCT00897546|stage IIIC melanoma
1267169|NCT00897533|recurrent non-small cell lung cancer
1267170|NCT00897533|stage IIIB non-small cell lung cancer
1267171|NCT00897533|stage IV non-small cell lung cancer
1267172|NCT00897533|adenocarcinoma of the lung
1267173|NCT00897533|squamous cell lung cancer
1267174|NCT00897533|bronchoalveolar cell lung cancer
1267175|NCT00897520|stage II melanoma
1267176|NCT00897520|stage III melanoma
1267177|NCT00897520|stage IV melanoma
1267178|NCT00897507|childhood acute lymphoblastic leukemia in remission
1267179|NCT00897507|recurrent childhood acute lymphoblastic leukemia
1267180|NCT00897494|stage I pancreatic cancer
1267181|NCT00897494|stage II pancreatic cancer
1267182|NCT00897494|stage III pancreatic cancer
1267183|NCT00897494|stage IV pancreatic cancer
1267184|NCT00897481|stage IV melanoma
1267185|NCT00897481|recurrent melanoma
1267186|NCT00897481|stage IA melanoma
1267187|NCT00897481|stage IB melanoma
1267188|NCT00897481|stage IIA melanoma
1267189|NCT00897481|stage IIB melanoma
1267190|NCT00897481|stage IIC melanoma
1267191|NCT00897481|stage IIIA melanoma
1267194|NCT00897468|breast cancer
1267195|NCT00897455|breast cancer
1267196|NCT00897455|BRCA1 mutation carrier
1267197|NCT00897455|BRCA2 mutation carrier
1267198|NCT00897429|stage IIA colon cancer
1267199|NCT00897429|stage IIB colon cancer
1267200|NCT00897429|stage IIC colon cancer
1267201|NCT00897416|breast cancer
1267202|NCT00897416|stage I breast cancer
1267203|NCT00897416|stage II breast cancer
1267204|NCT00897416|stage IIIA breast cancer
1267205|NCT00897416|stage IIIB breast cancer
1267206|NCT00897416|stage IIIC breast cancer
1267207|NCT00897416|stage IV breast cancer
1267208|NCT00897403|colon cancer
1267209|NCT00897403|health status unknown
1267210|NCT00897364|non-small cell lung cancer
1267211|NCT00897364|small cell lung cancer
1267212|NCT00897364|squamous lung dysplasia
1267213|NCT00897351|recurrent prostate cancer
1267214|NCT00897338|stage IV breast cancer
1267215|NCT00897312|stage IV melanoma
1267216|NCT00897312|hepatitis C infection
1267217|NCT00897312|melanoma (skin)
1267218|NCT00897312|precancerous/nonmalignant condition
1267219|NCT00897299|estrogen receptor
1267220|NCT00897299|HER-2
1267221|NCT00897299|PgR
1267222|NCT00897299|stage II breast cancer
1267223|NCT00897299|stage IIIA breast cancer
1267224|NCT00897299|stage IIIB breast cancer
1267225|NCT00897286|childhood atypical teratoid/rhabdoid tumor
1267226|NCT00897286|childhood choroid plexus tumor
1267227|NCT00897286|childhood medulloblastoma
1267228|NCT00897286|recurrent childhood medulloblastoma
1267229|NCT00897286|childhood infratentorial ependymoma
1267230|NCT00897286|childhood supratentorial ependymoma
1267231|NCT00897286|recurrent childhood ependymoma
1267232|NCT00897286|recurrent childhood supratentorial primitive neuroectodermal tumor
1267233|NCT00897286|untreated childhood supratentorial primitive neuroectodermal tumor
1267234|NCT00897286|gliomas
1267235|NCT00897273|recurrent squamous cell carcinoma of the oropharynx
1267236|NCT00897273|oropharyngeal cancer
1267237|NCT00897273|oropharyngeal squamous cell carcinoma
1267238|NCT00897273|infection
1267239|NCT00897273|precancerous condition
1267240|NCT00897273|human papilloma virus infection
1267241|NCT00897260|Unrelated Umbilical Cord Blood Transplant
1267242|NCT00897260|Multiple cord blood
1267243|NCT00897247|malignant mesothelioma
1267244|NCT00897247|pulmonary complications
1267245|NCT00897234|recurrent non-small cell lung cancer
1267246|NCT00897234|stage I non-small cell lung cancer
1267247|NCT00897234|stage II non-small cell lung cancer
1267248|NCT00897234|stage IIIA non-small cell lung cancer
1267249|NCT00897234|stage IIIB non-small cell lung cancer
1267250|NCT00897234|stage IV non-small cell lung cancer
1267251|NCT00897221|Friedreich's ataxia
1267252|NCT00897208|breast cancer
1267253|NCT00897208|ductal breast carcinoma in situ
1267254|NCT00897208|breast cancer in situ
1267255|NCT00897208|stage IA breast cancer
1267256|NCT00897208|stage IB breast cancer
1267257|NCT00897208|stage II breast cancer
1267258|NCT00897182|adult acute myeloid leukemia in remission
1267259|NCT00897182|adult acute myeloid leukemia with inv(16)(p13;q22)
1267260|NCT00897182|adult acute myeloid leukemia with t(15;17)(q22;q12)
1267261|NCT00897182|adult acute myeloid leukemia with t(8;21)(q22;q22)
1267262|NCT00897182|childhood acute myeloid leukemia in remission
1267263|NCT00897182|recurrent adult acute myeloid leukemia
1267264|NCT00897182|recurrent childhood acute myeloid leukemia
1267265|NCT00897182|secondary acute myeloid leukemia
1267266|NCT00897182|untreated adult acute myeloid leukemia
1267267|NCT00897182|untreated childhood acute myeloid leukemia and other myeloid malignancies
1267268|NCT00897143|non-small cell lung cancer
1267269|NCT00897143|malignant pleural effusion
1267270|NCT00897143|small cell lung cancer
1267271|NCT00897130|low-risk (IPSS 0-INT1) MDS according to WHO classification
1267272|NCT00897117|stage I non-small cell lung cancer
1267273|NCT00897117|stage II non-small cell lung cancer
1267274|NCT00897091|stage II breast cancer
1267275|NCT00897091|stage IIIA breast cancer
1267276|NCT00897078|cancer survivor
1267277|NCT00897078|healthy, no evidence of disease
1267278|NCT00897078|long-term effects secondary to cancer therapy in children
1267279|NCT00897078|childhood acute lymphoblastic leukemia in remission
1267280|NCT00897065|stage IA breast cancer
1267281|NCT00897065|stage IB breast cancer
1267282|NCT00897065|stage II breast cancer
1267283|NCT00897065|stage IIIA breast cancer
1267284|NCT00897065|estrogen receptor-positive breast cancer
1267285|NCT00897065|progesterone receptor-positive breast cancer
1267286|NCT00897052|stage II squamous cell carcinoma of the lip and oral cavity
1267287|NCT00897052|stage III squamous cell carcinoma of the lip and oral cavity
1267288|NCT00897052|stage IV squamous cell carcinoma of the lip and oral cavity
1267289|NCT00897052|stage II squamous cell carcinoma of the oropharynx
1267290|NCT00897052|stage III squamous cell carcinoma of the oropharynx
1267291|NCT00897052|stage IV squamous cell carcinoma of the oropharynx
1267292|NCT00897052|stage II squamous cell carcinoma of the hypopharynx
1267293|NCT00897052|stage III squamous cell carcinoma of the hypopharynx
1267294|NCT00897052|stage IV squamous cell carcinoma of the hypopharynx
1267295|NCT00897052|stage II squamous cell carcinoma of the larynx
1267296|NCT00897052|stage III squamous cell carcinoma of the larynx
1267297|NCT00897052|stage IV squamous cell carcinoma of the larynx
1267298|NCT00897039|ovarian serous cystadenocarcinoma
1267299|NCT00897039|ovarian undifferentiated adenocarcinoma
1267300|NCT00897039|recurrent ovarian epithelial cancer
1267301|NCT00897039|ovarian clear cell cystadenocarcinoma
1267302|NCT00897039|ovarian endometrioid adenocarcinoma
1267303|NCT00897039|ovarian mucinous cystadenocarcinoma
1267304|NCT00897039|stage IA ovarian epithelial cancer
1267305|NCT00897039|stage IB ovarian epithelial cancer
1267306|NCT00897039|stage IC ovarian epithelial cancer
1267307|NCT00897039|stage IIA ovarian epithelial cancer
1267308|NCT00897039|stage IIB ovarian epithelial cancer
1267309|NCT00897039|stage IIC ovarian epithelial cancer
1267310|NCT00897039|stage IIIA ovarian epithelial cancer
1267311|NCT00897039|stage IIIB ovarian epithelial cancer
1267312|NCT00897039|stage IIIC ovarian epithelial cancer
1267313|NCT00897039|recurrent primary peritoneal cavity cancer
1267314|NCT00897039|stage IA primary peritoneal cavity cancer
1267315|NCT00897039|stage IB primary peritoneal cavity cancer
1267316|NCT00897039|stage IC primary peritoneal cavity cancer
1267317|NCT00897039|stage IIA primary peritoneal cavity cancer
1267318|NCT00897039|stage IIB primary peritoneal cavity cancer
1267319|NCT00897039|stage IIC primary peritoneal cavity cancer
1267320|NCT00897039|stage IIIA primary peritoneal cavity cancer
1267321|NCT00897039|stage IIIB primary peritoneal cavity cancer
1267322|NCT00897039|stage IIIC primary peritoneal cavity cancer
1267323|NCT00897039|recurrent fallopian tube cancer
1267324|NCT00897039|stage IA fallopian tube cancer
1267325|NCT00897039|stage IB fallopian tube cancer
1267326|NCT00897039|stage IC fallopian tube cancer
1267327|NCT00897039|stage IIA fallopian tube cancer
1267328|NCT00897039|stage IIB fallopian tube cancer
1267329|NCT00897039|stage IIC fallopian tube cancer
1267330|NCT00897039|stage IIIA fallopian tube cancer
1267331|NCT00897039|stage IIIB fallopian tube cancer
1267332|NCT00897039|stage IIIC fallopian tube cancer
1267333|NCT00897026|stage II breast cancer
1267334|NCT00897026|stage IIIA breast cancer
1267335|NCT00896987|Epilepsy
1267336|NCT00896987|lamotrigine
1267337|NCT00896987|cognitive function
1267338|NCT00896948|head and neck cancer
1267339|NCT00896935|cancer
1267340|NCT00896922|contiguous stage II grade 1 follicular lymphoma
1267341|NCT00896922|contiguous stage II grade 2 follicular lymphoma
1267342|NCT00896922|contiguous stage II grade 3 follicular lymphoma
1267343|NCT00896922|noncontiguous stage II grade 1 follicular lymphoma
1267344|NCT00896922|noncontiguous stage II grade 2 follicular lymphoma
1267345|NCT00896922|noncontiguous stage II grade 3 follicular lymphoma
1267346|NCT00896922|stage III grade 1 follicular lymphoma
1267347|NCT00896922|stage III grade 2 follicular lymphoma
1267348|NCT00896922|stage III grade 3 follicular lymphoma
1267349|NCT00896922|stage IV grade 1 follicular lymphoma
1267350|NCT00896922|stage IV grade 2 follicular lymphoma
1267351|NCT00896922|stage IV grade 3 follicular lymphoma
1267352|NCT00896909|recurrent non-small cell lung cancer
1267353|NCT00896909|stage IIIB non-small cell lung cancer
1267354|NCT00896909|stage IV non-small cell lung cancer
1267355|NCT00896896|stage I squamous cell carcinoma of the hypopharynx
1267356|NCT00896896|stage II squamous cell carcinoma of the hypopharynx
1267357|NCT00896896|stage III squamous cell carcinoma of the hypopharynx
1267358|NCT00896896|stage IV squamous cell carcinoma of the hypopharynx
1267359|NCT00896896|recurrent squamous cell carcinoma of the hypopharynx
1267360|NCT00896896|stage I squamous cell carcinoma of the larynx
1267361|NCT00896896|stage I verrucous carcinoma of the larynx
1267362|NCT00896896|stage II squamous cell carcinoma of the larynx
1267363|NCT00896896|stage II verrucous carcinoma of the larynx
1267364|NCT00896896|stage III squamous cell carcinoma of the larynx
1267365|NCT00896896|stage III verrucous carcinoma of the larynx
1267366|NCT00896896|stage IV squamous cell carcinoma of the larynx
1267367|NCT00896896|stage IV verrucous carcinoma of the larynx
1267368|NCT00896896|recurrent squamous cell carcinoma of the larynx
1267369|NCT00896896|recurrent verrucous carcinoma of the larynx
1267370|NCT00896896|stage I adenoid cystic carcinoma of the oral cavity
1267371|NCT00896896|stage I basal cell carcinoma of the lip
1267372|NCT00896896|stage I mucoepidermoid carcinoma of the oral cavity
1267373|NCT00896896|stage I squamous cell carcinoma of the lip and oral cavity
1267374|NCT00896896|stage I verrucous carcinoma of the oral cavity
1267375|NCT00896896|stage II adenoid cystic carcinoma of the oral cavity
1267376|NCT00896896|stage II basal cell carcinoma of the lip
1267377|NCT00896896|stage II mucoepidermoid carcinoma of the oral cavity
1267378|NCT00896896|stage II squamous cell carcinoma of the lip and oral cavity
1267379|NCT00896896|stage II verrucous carcinoma of the oral cavity
1267380|NCT00896896|stage III adenoid cystic carcinoma of the oral cavity
1267381|NCT00896896|stage III basal cell carcinoma of the lip
1267382|NCT00896896|stage III mucoepidermoid carcinoma of the oral cavity
1267383|NCT00896896|stage III squamous cell carcinoma of the lip and oral cavity
1267384|NCT00896896|stage III verrucous carcinoma of the oral cavity
1267385|NCT00896896|stage IV adenoid cystic carcinoma of the oral cavity
1267386|NCT00896896|stage IV basal cell carcinoma of the lip
1267387|NCT00896896|stage IV mucoepidermoid carcinoma of the oral cavity
1267388|NCT00896896|stage IV squamous cell carcinoma of the lip and oral cavity
1267389|NCT00896896|stage IV verrucous carcinoma of the oral cavity
1267390|NCT00896896|recurrent adenoid cystic carcinoma of the oral cavity
1267391|NCT00896896|recurrent basal cell carcinoma of the lip
1267392|NCT00896896|recurrent mucoepidermoid carcinoma of the oral cavity
1267393|NCT00896896|recurrent squamous cell carcinoma of the lip and oral cavity
1267394|NCT00896896|recurrent verrucous carcinoma of the oral cavity
1267395|NCT00896896|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1267396|NCT00896896|recurrent metastatic squamous neck cancer with occult primary
1267397|NCT00896896|stage I lymphoepithelioma of the nasopharynx
1267398|NCT00896896|stage I squamous cell carcinoma of the nasopharynx
1267399|NCT00896896|stage II lymphoepithelioma of the nasopharynx
1267400|NCT00896896|stage II squamous cell carcinoma of the nasopharynx
1267401|NCT00896896|stage III lymphoepithelioma of the nasopharynx
1267402|NCT00896896|stage III squamous cell carcinoma of the nasopharynx
1267403|NCT00896896|stage IV lymphoepithelioma of the nasopharynx
1267404|NCT00896896|stage IV squamous cell carcinoma of the nasopharynx
1267405|NCT00896896|recurrent lymphoepithelioma of the nasopharynx
1267406|NCT00896896|recurrent squamous cell carcinoma of the nasopharynx
1267407|NCT00896896|stage I lymphoepithelioma of the oropharynx
1267408|NCT00896896|stage I squamous cell carcinoma of the oropharynx
1267409|NCT00896896|stage II lymphoepithelioma of the oropharynx
1267410|NCT00896896|stage II squamous cell carcinoma of the oropharynx
1267411|NCT00896896|stage III lymphoepithelioma of the oropharynx
1267412|NCT00896896|stage III squamous cell carcinoma of the oropharynx
1267413|NCT00896896|stage IV lymphoepithelioma of the oropharynx
1267414|NCT00896896|stage IV squamous cell carcinoma of the oropharynx
1267415|NCT00896896|recurrent lymphoepithelioma of the oropharynx
1267416|NCT00896896|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267417|NCT00896896|stage I inverted papilloma of the paranasal sinus and nasal cavity
1267418|NCT00896896|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1267419|NCT00896896|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1267420|NCT00896896|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267421|NCT00896896|stage II inverted papilloma of the paranasal sinus and nasal cavity
1267422|NCT00896896|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1267423|NCT00896896|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1267424|NCT00896896|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267425|NCT00896896|stage III inverted papilloma of the paranasal sinus and nasal cavity
1267426|NCT00896896|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1267427|NCT00896896|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1267428|NCT00896896|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267429|NCT00896896|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1267430|NCT00896896|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1267431|NCT00896896|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1267432|NCT00896896|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267433|NCT00896896|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1267434|NCT00896896|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1267435|NCT00896896|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1267436|NCT00896896|stage I salivary gland cancer
1267437|NCT00896896|stage II salivary gland cancer
1267438|NCT00896896|stage III salivary gland cancer
1267439|NCT00896896|stage IV salivary gland cancer
1267440|NCT00896896|recurrent salivary gland cancer
1267441|NCT00896896|recurrent squamous cell carcinoma of the oropharynx
1267442|NCT00896896|recurrent colon cancer
1267443|NCT00896896|stage IV colon cancer
1267444|NCT00896896|recurrent rectal cancer
1267445|NCT00896896|stage IV rectal cancer
1267446|NCT00896896|adenocarcinoma of the colon
1267447|NCT00896883|turbinate
1267448|NCT00896883|implant
1267449|NCT00896883|sinus surgery
1267450|NCT00896883|Turbinates
1267451|NCT00896857|breast cancer
1267452|NCT00896857|ductal breast carcinoma in situ
1267453|NCT00896844|emotional disclosure
1267454|NCT00896844|expressive writing
1267455|NCT00896844|students
1267456|NCT00896831|minimal hepatic encephalopathy
1267457|NCT00896831|L-ornithine-L-aspartate
1267458|NCT00896831|psychometric test
1267459|NCT00896831|critical flicker frequency
1267460|NCT00896831|quality of life
1267461|NCT00896831|Treatment
1267462|NCT00896831|Health-related quality of life
1267463|NCT00896818|breast cancer
1267464|NCT00896792|unspecified adult solid tumor, protocol specific
1267465|NCT00896792|hematopoietic/lymphoid cancer
1267466|NCT00896766|childhood acute lymphoblastic leukemia in remission
1267467|NCT00896766|B-cell childhood acute lymphoblastic leukemia
1267468|NCT00896753|stage IV colon cancer
1267469|NCT00896753|liver metastases
1267470|NCT00896753|lung metastases
1267471|NCT00896753|recurrent colon cancer
1267472|NCT00896740|Fanconi anemia
1267473|NCT00896727|stage IA breast cancer
1267474|NCT00896727|stage IB breast cancer
1267475|NCT00896727|stage II breast cancer
1267476|NCT00896727|stage IIIA breast cancer
1267477|NCT00896701|adult acute myeloid leukemia in remission
1267478|NCT00896701|recurrent adult acute myeloid leukemia
1267479|NCT00896701|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1267480|NCT00896701|adult acute myeloid leukemia with inv(16)(p13;q22)
1267481|NCT00896701|adult acute myeloid leukemia with t(15;17)(q22;q12)
1267482|NCT00896701|adult acute myeloid leukemia with t(16;16)(p13;q22)
1267483|NCT00896701|adult acute myeloid leukemia with t(8;21)(q22;q22)
1267484|NCT00896688|cervical branch block
1267485|NCT00896688|fluoroscopic guidance
1267486|NCT00896688|ultrasound guidance
1267487|NCT00896675|recurrent squamous cell carcinoma of the hypopharynx
1267488|NCT00896675|stage IV squamous cell carcinoma of the hypopharynx
1267489|NCT00896675|recurrent squamous cell carcinoma of the larynx
1267490|NCT00896675|stage IV squamous cell carcinoma of the larynx
1267491|NCT00896675|stage IV squamous cell carcinoma of the lip and oral cavity
1267492|NCT00896675|recurrent squamous cell carcinoma of the lip and oral cavity
1267493|NCT00896675|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1267494|NCT00896675|recurrent metastatic squamous neck cancer with occult primary
1267495|NCT00896675|recurrent squamous cell carcinoma of the nasopharynx
1267496|NCT00896675|stage IV squamous cell carcinoma of the nasopharynx
1267497|NCT00896675|recurrent squamous cell carcinoma of the oropharynx
1267498|NCT00896675|stage IV squamous cell carcinoma of the oropharynx
1267499|NCT00896675|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1267500|NCT00896675|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1267501|NCT00896675|salivary gland squamous cell carcinoma
1267502|NCT00896675|stage IV salivary gland cancer
1267503|NCT00896675|recurrent salivary gland cancer
1267504|NCT00896662|unspecified adult solid tumor, protocol specific
1267505|NCT00896662|recurrent adult Burkitt lymphoma
1267506|NCT00896662|stage IV adult Burkitt lymphoma
1267507|NCT00896662|recurrent adult diffuse large cell lymphoma
1267508|NCT00896662|recurrent adult diffuse mixed cell lymphoma
1267509|NCT00896662|recurrent adult diffuse small cleaved cell lymphoma
1267510|NCT00896662|stage IV adult diffuse large cell lymphoma
1267511|NCT00896662|stage IV adult diffuse mixed cell lymphoma
1267512|NCT00896662|stage IV adult diffuse small cleaved cell lymphoma
1267513|NCT00896662|recurrent adult immunoblastic large cell lymphoma
1267514|NCT00896662|stage IV adult immunoblastic large cell lymphoma
1267515|NCT00896662|recurrent adult lymphoblastic lymphoma
1267516|NCT00896662|stage IV adult lymphoblastic lymphoma
1267517|NCT00896662|recurrent grade 1 follicular lymphoma
1267518|NCT00896662|recurrent grade 2 follicular lymphoma
1267519|NCT00896662|recurrent grade 3 follicular lymphoma
1267520|NCT00896662|stage IV grade 1 follicular lymphoma
1267521|NCT00896662|stage IV grade 2 follicular lymphoma
1267522|NCT00896662|stage IV grade 3 follicular lymphoma
1267523|NCT00896662|recurrent mantle cell lymphoma
1267524|NCT00896662|stage IV mantle cell lymphoma
1267525|NCT00896662|recurrent marginal zone lymphoma
1267526|NCT00896662|splenic marginal zone lymphoma
1267527|NCT00896662|stage IV marginal zone lymphoma
1267528|NCT00896662|nodal marginal zone B-cell lymphoma
1267529|NCT00896662|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1267530|NCT00896662|recurrent small lymphocytic lymphoma
1267531|NCT00896662|stage IV small lymphocytic lymphoma
1267532|NCT00896649|breast cancer
1267533|NCT00896636|breast cancer
1267534|NCT00896636|healthy, no evidence of disease
1267535|NCT00896623|stage I breast cancer
1267536|NCT00896623|stage II breast cancer
1267537|NCT00896610|Diabetes Mellitus
1267538|NCT00896610|Type 1 Diabetes
1267539|NCT00896610|Complications
1267540|NCT00896610|Anti Beta-Cell Autoantibodies
1267541|NCT00896610|T-Lymphocyte Assays
1267542|NCT00896610|Type 2 Diabetes
1267543|NCT00896610|Autoimmune Diabetes
1267544|NCT00896610|At Risk Diabetes
1267545|NCT00896584|Chronic obstructive pulmonary disease
1267546|NCT00896584|Hypoxemia
1267547|NCT00896584|Pre-flight evaluation
1267548|NCT00896584|Hypobaria
1267549|NCT00896584|COPD
1267550|NCT00896584|Pulseoximetry
1267551|NCT00896584|Air travel
1267552|NCT00896584|Exercise desaturation
1267553|NCT00896571|Fertility control
1267554|NCT00896571|Contraception
1267556|NCT00896519|stage III grade 1 follicular lymphoma
1267557|NCT00896519|stage III grade 2 follicular lymphoma
1267558|NCT00896519|stage III grade 3 follicular lymphoma
1267559|NCT00896519|stage IV grade 1 follicular lymphoma
1267560|NCT00896519|stage IV grade 2 follicular lymphoma
1267561|NCT00896519|stage IV grade 3 follicular lymphoma
1267562|NCT00896480|ASCI (Antigen-Specific Cancer Immunotherapeutic)
1267563|NCT00896480|Cancer immunotherapeutic
1267564|NCT00896480|Malignant melanoma
1267565|NCT00896480|MAGE-A3
1267566|NCT00896467|anxiety disorder
1267567|NCT00896467|depression
1267568|NCT00896467|stage IV breast cancer
1267569|NCT00896467|stage IV renal cell cancer
1267570|NCT00896467|stage IV non-small cell lung cancer
1267571|NCT00896467|extensive stage small cell lung cancer
1267572|NCT00896467|stage IV gastric cancer
1267573|NCT00896467|stage IV anal cancer
1267574|NCT00896467|stage IV pancreatic cancer
1267575|NCT00896467|stage IV esophageal cancer
1267576|NCT00896467|advanced adult primary liver cancer
1267577|NCT00896467|unresectable gallbladder cancer
1267578|NCT00896467|small intestine cancer
1267579|NCT00896454|hypercalcemia
1267580|NCT00896454|calcium
1267581|NCT00896454|bisphosphonates
1267582|NCT00896454|denosumab
1267583|NCT00896454|amgen
1267584|NCT00896454|malignancy
1267585|NCT00896454|20070315
1267586|NCT00896454|HMC
1267587|NCT00896454|oncology
1267588|NCT00896454|hematology
1267589|NCT00896428|Asthma
1267590|NCT00896428|gallopamil
1267591|NCT00896428|airway remodelling
1267592|NCT00896428|smooth muscle
1267593|NCT00896415|on two models of CT scanner acquire CT images of the abdomen pelvis and midthigh in 20 Postmenopausal female volunteers
1267594|NCT00896402|chloraprep
1267595|NCT00896402|betadine
1267596|NCT00896402|colonization
1267597|NCT00896402|femoral catheter
1267598|NCT00896389|hypertension
1267599|NCT00896389|hydrochlorothiazide
1267600|NCT00896389|HCTZ
1267601|NCT00896389|salt sensitivity
1267602|NCT00896389|Hydrochlorothiazide induced hyperglycemia
1267603|NCT00896376|stage IV breast cancer
1267604|NCT00896376|HER2-positive breast cancer
1267605|NCT00896363|anti-depressant
1267606|NCT00896363|Severe Depression
1267607|NCT00896363|Efficacy
1267608|NCT00896363|Major Depressive Disorder
1267609|NCT00896363|Major Depressive Episode
1267610|NCT00896350|stage III squamous cell carcinoma of the hypopharynx
1267611|NCT00896350|stage III squamous cell carcinoma of the larynx
1267612|NCT00896350|stage III squamous cell carcinoma of the lip and oral cavity
1267613|NCT00896350|stage III squamous cell carcinoma of the nasopharynx
1267614|NCT00896350|stage III squamous cell carcinoma of the oropharynx
1267615|NCT00896350|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1267616|NCT00896350|stage IV squamous cell carcinoma of the hypopharynx
1267617|NCT00896350|stage IV squamous cell carcinoma of the larynx
1267618|NCT00896350|stage IV squamous cell carcinoma of the lip and oral cavity
1267619|NCT00896350|stage IV squamous cell carcinoma of the nasopharynx
1267620|NCT00896350|stage IV squamous cell carcinoma of the oropharynx
1267621|NCT00896350|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1267622|NCT00896350|stage III lymphoepithelioma of the nasopharynx
1267623|NCT00896350|stage III lymphoepithelioma of the oropharynx
1267624|NCT00896350|stage III verrucous carcinoma of the larynx
1267625|NCT00896350|stage IV lymphoepithelioma of the nasopharynx
1267626|NCT00896350|stage IV lymphoepithelioma of the oropharynx
1267627|NCT00896350|stage IV verrucous carcinoma of the larynx
1267628|NCT00896350|stage III basal cell carcinoma of the lip
1267629|NCT00896350|stage IV basal cell carcinoma of the lip
1267630|NCT00896350|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267631|NCT00896350|stage III inverted papilloma of the paranasal sinus and nasal cavity
1267632|NCT00896350|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1267633|NCT00896350|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1267634|NCT00896350|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1267635|NCT00896350|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1267636|NCT00896350|tongue cancer
1267637|NCT00896337|iliac artery stenosis
1267638|NCT00896337|claudication
1267639|NCT00896337|atherosclerotic iliac disease
1267640|NCT00896337|peripheral vascular disease
1267641|NCT00896324|Quality of life
1267642|NCT00896298|Lipodystrophy
1267643|NCT00896298|Insulin secretory response
1267644|NCT00896285|Pleural malignancy
1267645|NCT00896285|pleural effusion
1267646|NCT00896285|pleurodesis
1267647|NCT00896285|chest tube
1267648|NCT00896285|cancer
1267649|NCT00896285|cancer pain management
1267650|NCT00896272|Klinefelter Syndrome
1267651|NCT00896272|47,XXY
1267652|NCT00896272|XXY
1267653|NCT00896259|Unilateral total hip arthroplasty
1267654|NCT00896233|Staging of liver fibrosis prior to clinical trials for treatment of Hepatitis C Virus
1267655|NCT00896220|chronic critical illness
1267656|NCT00896220|mechanical ventilation
1267657|NCT00896220|outcomes
1267658|NCT00896220|weakness
1267659|NCT00896220|quality of life
1267660|NCT00896220|Critically Ill patients and their family caregiver
1267661|NCT00896194|Overweight
1267662|NCT00896194|Obesity
1267663|NCT00896194|Self-Efficacy
1267664|NCT00896194|Treatment Adherence
1267665|NCT00896168|Arthritis, Rheumatoid
1267666|NCT00896168|Infliximab
1267667|NCT00896168|Methotrexate
1267668|NCT00896155|Breast cancer
1267669|NCT00896155|Pulmonary fibrosis
1267670|NCT00896155|tamoxifen
1267671|NCT00896155|radiotherapy
1267672|NCT00896142|ischemic cardiomyopathy
1267673|NCT00896142|cardiac resynchronization therapy
1267674|NCT00896142|LV structure and function
1267675|NCT00896129|Health Outcomes Research
1267676|NCT00896129|CML
1267677|NCT00896077|healthy subjects
1267678|NCT00896064|Pneumococcal vaccine
1267679|NCT00896064|Streptococcus pneumoniae
1267680|NCT00896064|Young adults
1267681|NCT00896051|HIV Infections
1267682|NCT00896051|Acquired Immunodeficiency Syndrome
1267683|NCT00896051|TMC125-TiDP2-C238
1267684|NCT00896051|TMC125-C238
1267685|NCT00896051|Etravirine
1267686|NCT00896051|Intelence
1267687|NCT00896051|HIV
1267688|NCT00896051|HIV-1
1267689|NCT00896051|Pharmacokinetics
1267690|NCT00896038|Alcohol Dependence
1267691|NCT00896038|Alcohol Treatment
1267692|NCT00896038|Alcoholics
1267693|NCT00896038|Alcoholism
1267694|NCT00896038|Posttraumatic Stress Disorder
1267695|NCT00896038|PTSD
1267696|NCT00896025|Liver disease
1267697|NCT00896012|Kidney Transplant
1267698|NCT00896012|Immunosuppression drugs
1267699|NCT00896012|Rapamune
1267700|NCT00896012|tacrolimus
1267701|NCT00896012|calcineurin inhibitor
1267702|NCT00896012|Kidney Biopsy, Needle
1267703|NCT00895986|Diabetes
1267704|NCT00895986|Education
1267705|NCT00895960|Brain
1267706|NCT00895960|CNS Disease
1267707|NCT00895960|CNS
1267708|NCT00895960|Intracranial Supratentorial GBM
1267709|NCT00895960|Gliosarcoma
1267710|NCT00895960|GS
1267711|NCT00895960|Glioblastoma
1267712|NCT00895960|GBM
1267713|NCT00895960|Dasatinib
1267714|NCT00895960|Sprycel
1267715|NCT00895960|Temozolomide
1267716|NCT00895960|TMZ
1267717|NCT00895960|Temodar
1267718|NCT00895960|Radiation Therapy
1267719|NCT00895960|Radiotherapy
1267720|NCT00895960|RT
1267721|NCT00895947|Prophylaxis
1267722|NCT00895947|Treatment
1267723|NCT00895947|Symptoms
1267724|NCT00895947|Winter Colds and Flu
1267725|NCT00895921|Insulin Resistance
1267726|NCT00895921|Antipsychotic Medications
1267727|NCT00895908|ADHD
1267728|NCT00895908|Psychosocial Intervention
1267729|NCT00895908|Social Skills Training
1267730|NCT00895869|Screening
1267731|NCT00895869|Retinopathy
1267732|NCT00895869|Prematurity
1267733|NCT00895869|Pain
1267734|NCT00895856|Physiotherapy
1267735|NCT00895856|Aged
1267736|NCT00895856|Functionality
1267737|NCT00895856|Physiotherapic assistance
1267738|NCT00895856|Functional capacity
1267739|NCT00895843|Third molar
1267740|NCT00895817|Eosinophilic esophagitis
1267741|NCT00895817|acid reflux
1267742|NCT00895804|MDMA
1267743|NCT00895804|beta adrenergic
1267744|NCT00895804|Ecstasy
1267745|NCT00895791|coronary bifurcation
1267746|NCT00895791|stent implantation
1267747|NCT00895791|PCI
1267748|NCT00895791|Optical Coherence Tomography
1267749|NCT00895778|Neuromuscular blockade
1267750|NCT00895778|post-operative pain
1267751|NCT00895778|post-operative pulmonary function
1267752|NCT00895765|Melamine
1267753|NCT00895765|Calculus
1267754|NCT00895765|Kidney
1267755|NCT00895765|Child
1267756|NCT00895739|aplastic anemia
1267757|NCT00895726|cachexia
1267758|NCT00895726|neoplasms
1267759|NCT00895713|Hepatitis B
1267760|NCT00895713|HBV
1267761|NCT00895713|Anti-hepatitis B antibodies
1267762|NCT00895713|Immunoglobulins
1267763|NCT00895713|liver transplantation
1267764|NCT00895713|Protective levels
1267765|NCT00895713|Recurrence
1267766|NCT00895713|Intramuscular
1267767|NCT00895700|Anxiety
1267768|NCT00895700|ICD concerns
1267769|NCT00895700|Quality of life
1267770|NCT00895687|Metastatic Cancer
1267771|NCT00895687|Bortezomib
1267772|NCT00895687|Velcade
1267773|NCT00895687|Erlotinib
1267774|NCT00895687|Erlotinib Hydrochloride
1267775|NCT00895687|Tarceva
1267776|NCT00895687|EGFR
1267777|NCT00895687|EGFR mutations
1267778|NCT00895674|Advanced Renal Cell Carcinoma
1267779|NCT00895661|rituximab
1267780|NCT00895648|Meso
1267781|NCT00895648|mesothelioma
1267782|NCT00895648|pleura
1267783|NCT00895648|pleural
1267784|NCT00895635|Claudication
1267785|NCT00895635|Peripheral Arterial Disease
1267786|NCT00895635|Exercise Rehabilitation
1267787|NCT00895635|Cardiovascular Function
1267788|NCT00895622|adult grade I meningioma
1267789|NCT00895622|adult grade II meningioma
1267790|NCT00895622|adult grade III meningioma
1267791|NCT00895622|adult anaplastic meningioma
1267792|NCT00895622|adult papillary meningioma
1267793|NCT00895622|recurrent adult brain tumor
1267794|NCT00895609|Residual neuromuscular block
1267795|NCT00895609|post-operative residual curarization
1267796|NCT00895609|PORC
1267797|NCT00895609|sugammadex
1267798|NCT00895609|neostigmine
1267799|NCT00895609|Shallow neuromuscular block (TOF-ratio of 0.5)
1267800|NCT00895596|Chronic hepatitis B
1267801|NCT00895596|Lamivudine resistant
1267802|NCT00895596|YMDD mutant type
1267803|NCT00895583|renal transplant
1267804|NCT00895583|immunosuppression
1267805|NCT00895583|sirolimus/rapamune
1267806|NCT00895583|planned transition
1267807|NCT00895570|sleep restriction
1267808|NCT00895570|glucose metabolism
1267809|NCT00895570|modafinil
1267810|NCT00895570|euglycemic clamp
1267811|NCT00895570|insulin sensitivity
1267812|NCT00895570|insulin release
1267813|NCT00895557|varenicline
1267814|NCT00895557|cocaine
1267815|NCT00895557|brain imaging
1267816|NCT00895531|Knee Replacement, Total
1267817|NCT00895531|Morphine
1267818|NCT00895518|PTSD
1267819|NCT00895505|DVT
1267820|NCT00895505|Venous thromboembolism
1267821|NCT00895505|D-Dimer
1267822|NCT00895505|thrombophilia
1267823|NCT00895505|secondary prophylaxis
1267824|NCT00895505|secondary prophylaxis using oral anticoagulant treatment (OAT)
1267825|NCT00895505|higher risk of recurrence in patients showing increased levels
1267826|NCT00895505|of D-Dimer after withdrawal of OAT
1267827|NCT00895505|D-Dimer-based treatment
1267828|NCT00895492|diarrhea
1267829|NCT00895492|rotavirus
1267830|NCT00895492|genotype
1267831|NCT00895492|VP4
1267832|NCT00895492|VP7
1267833|NCT00895479|End Stage Renal Disease
1267834|NCT00895479|ESRD
1267835|NCT00895479|Hemodialysis
1267836|NCT00895479|Access Graft
1267837|NCT00895466|prostatic diseases
1267838|NCT00895466|neoplasms
1267839|NCT00895466|prostatic neoplasms
1267840|NCT00895466|hormones
1267841|NCT00895466|androgen antagonists
1267842|NCT00895466|vaccines
1267843|NCT00895466|peptide vaccines
1267844|NCT00895466|adjuvants, immunological
1267845|NCT00895453|recurrent vulvovaginal candidiasis
1267846|NCT00895453|itraconazole
1267847|NCT00895453|classic homeopathy
1267848|NCT00895440|Diabetes
1267849|NCT00895440|Diabetic neuropathy
1267850|NCT00895440|neuropad
1267851|NCT00895440|Painless peripheral diabetic neuropathy
1267852|NCT00895440|Painful peripheral diabetic neuropathy
1267853|NCT00895440|Autonomic peripheral neuropathy
1267854|NCT00895440|Charcot neuroarthropathy
1267855|NCT00895427|Coronary artery calcification
1267856|NCT00895414|stage I breast cancer
1267857|NCT00895414|stage II breast cancer
1267858|NCT00895414|stage IIIA breast cancer
1267859|NCT00895414|stage IIIB breast cancer
1267860|NCT00895414|stage IIIC breast cancer
1267861|NCT00895414|stage IV breast cancer
1267862|NCT00895401|Nutritional supplement
1267863|NCT00895401|Malnutrition
1267864|NCT00895401|Hemodialysis
1267865|NCT00895401|Nepro with Carb Steady
1267866|NCT00895388|Urinary function
1267867|NCT00895388|Anal function
1267868|NCT00895375|Dermatology
1267869|NCT00895375|Skin
1267870|NCT00895375|Psoriasis
1267871|NCT00895375|Sleep
1267872|NCT00895375|Wake Forest
1267873|NCT00895375|Insomnia
1267874|NCT00895362|Advanced Cancer
1267875|NCT00895362|EGFR mutation
1267876|NCT00895362|Erlotinib
1267877|NCT00895362|Erlotinib Hydrochloride
1267878|NCT00895362|Tarceva
1267879|NCT00895362|OSI-774
1267880|NCT00895362|Cetuximab
1267881|NCT00895362|C225
1267882|NCT00895362|Erbitux
1267883|NCT00895362|IMC-C225
1267884|NCT00895349|Positron Emission Tomography (PET)
1267885|NCT00895349|Diagnostic Intervention
1267886|NCT00895349|Locally Advanced Cervical Cancer
1267887|NCT00895336|Pediatric Ulcerative Colitis
1267888|NCT00895323|stage I colon cancer
1267889|NCT00895323|stage II colon cancer
1267890|NCT00895323|stage III colon cancer
1267891|NCT00895323|stage IV colon cancer
1267892|NCT00895323|stage I rectal cancer
1267893|NCT00895323|stage II rectal cancer
1267894|NCT00895323|stage III rectal cancer
1267895|NCT00895323|stage IV rectal cancer
1267896|NCT00895323|recurrent colon cancer
1267897|NCT00895323|recurrent rectal cancer
1267898|NCT00895310|PSA
1267899|NCT00895310|Ketoconazole
1267900|NCT00895310|Prostate Cancer
1267901|NCT00895310|Hormone Refractory
1267902|NCT00895310|Chemotherapy Regimen
1267903|NCT00895297|Relapsing after allogeneic transplantation
1267904|NCT00895297|Dasatinib
1267905|NCT00895297|Sprycel
1267906|NCT00895297|Philadelphia Chromosomes
1267907|NCT00895284|robotic
1267908|NCT00895284|laparoscopic surgical procedures
1267918|NCT00895258|Schizoaffective Disorder
1267919|NCT00895258|Major Depressive Disorder
1267920|NCT00895258|Supported Employment
1267921|NCT00895258|Work
1267922|NCT00895258|Rehabilitation
1267923|NCT00895258|Severe Mental Illness
1267924|NCT00895258|Cognitive Training
1267925|NCT00895258|Cognitive Rehabilitation
1267926|NCT00895258|Cognitive Remediation
1267927|NCT00895219|Hyperventilation
1267928|NCT00895219|Dysfunctional breathing
1267929|NCT00895219|Physiotherapy
1267930|NCT00895219|Musculoskeletal techniques
1267931|NCT00895193|Niacin
1267932|NCT00895193|Hypercholesterolemia
1267933|NCT00895193|Flushing
1267934|NCT00895180|recurrent adult brain tumor
1267935|NCT00895180|adult glioblastoma
1267936|NCT00895180|adult giant cell glioblastoma
1267937|NCT00895180|adult gliosarcoma
1267938|NCT00895167|Heme Oxygenase
1267939|NCT00895167|Genetic Polymorphism
1267940|NCT00895167|Healthy Subjects
1267941|NCT00895154|Sickle Cell Disease
1267942|NCT00895154|Sickle Cell
1267943|NCT00895154|Memory
1267944|NCT00895154|Learning
1267945|NCT00895154|Achievement
1267946|NCT00895141|Saturated fat
1267947|NCT00895141|LDL size
1267948|NCT00895141|Large LDL
1267949|NCT00895141|Large HDL
1267950|NCT00895128|Advanced Cancer
1267951|NCT00895128|EGFR mutations
1267952|NCT00895128|Dasatinib
1267953|NCT00895128|Sprycel
1267954|NCT00895128|Erlotinib
1267955|NCT00895128|Erlotinib Hydrochloride
1267956|NCT00895128|Tarceva
1267957|NCT00895115|prostate cancer
1267958|NCT00895102|Bioavailability (BA)
1267959|NCT00895102|Single Ascending Dose (SAD)
1267960|NCT00895089|liver abscess
1267961|NCT00895089|moxifloxacin
1267962|NCT00895089|ceftriaxone
1267963|NCT00895089|treatment
1267964|NCT00895063|Spasmodic Dysphonia
1267965|NCT00895063|Botulinum Toxin
1267966|NCT00895063|Vocal Exercise
1267967|NCT00895024|Caregiver
1267968|NCT00895024|Questionnaire
1267969|NCT00895024|Home Hospice Care
1267970|NCT00895024|Family Evaluation of Hospice Care
1267971|NCT00895024|FEHC
1267972|NCT00895024|The Texas Revised Inventory of Grief
1267973|NCT00895024|TRIG
1267974|NCT00895024|Cross-ethnic differences
1267975|NCT00895024|Parenteral Hydration
1267976|NCT00895024|Grief
1267977|NCT00895011|Erectile Dysfunction
1267978|NCT00895011|E.D.
1267979|NCT00894998|heparin cardiac surgery
1267980|NCT00894985|heparin cardiac surgery
1267981|NCT00894959|heparin cardiac surgery
1267982|NCT00894946|recurrent IVF implantation failure
1267983|NCT00894933|Prostate Cancer
1267984|NCT00894933|Radical Prostatectomy
1267985|NCT00894933|Vesico-Urethral Anastomosis
1267986|NCT00894920|biotin
1267987|NCT00894920|deficiency
1267988|NCT00894920|pregnancy
1268242|NCT00893763|Endotracheal intubation
1267989|NCT00894920|lymphocyte propionyl-CoA carboxylase
1267990|NCT00894907|Severe pancreatitis
1267991|NCT00894907|acute pancreatitis
1267992|NCT00894907|haemodynamic monitoring
1267993|NCT00894907|PiCCO
1267994|NCT00894894|MP470
1267995|NCT00894894|MP-470
1267996|NCT00894894|SuperGen
1267997|NCT00894894|Tyrosine
1267998|NCT00894894|Kinase
1267999|NCT00894894|Inhibitor
1268000|NCT00894894|Solid Malignancies
1268001|NCT00894894|Oncology
1268002|NCT00894881|colonoscopy
1268003|NCT00894881|Healthy individuals before colonoscopy
1268004|NCT00894868|Congestive Heart Failure
1268005|NCT00894868|CHF, vildagliptin
1268006|NCT00894868|metabolic disease
1268007|NCT00894868|cardiovascular disease
1268008|NCT00894868|T2DM
1268009|NCT00894855|skin cancer prevention
1268010|NCT00894855|SHADE
1268011|NCT00894855|Beach
1268012|NCT00894842|Schizophrenia
1268013|NCT00894842|Pregnenolone
1268014|NCT00894842|Neurocognition
1268015|NCT00894829|heparin cardiac surgery
1268016|NCT00894816|Prevention
1268017|NCT00894816|Probiotics
1268018|NCT00894816|Eczema
1268019|NCT00894816|Allergy
1268020|NCT00894816|Asthma
1268021|NCT00894816|Obesity
1268022|NCT00894816|Caries
1268023|NCT00894816|Gut microbiota
1268024|NCT00894803|acute ischemic stroke
1268025|NCT00894803|stroke
1268026|NCT00894803|rt-PA, thrombolytic
1268027|NCT00894803|t-PA
1268028|NCT00894803|recombinant tissue plasminogen activator
1268029|NCT00894803|Activase
1268030|NCT00894803|eptifibatide
1268031|NCT00894803|Integrilin
1268032|NCT00894803|fibrinolytic agents
1268033|NCT00894803|clot dissolving
1268034|NCT00894803|blood clot
1268035|NCT00894790|Treatment of the acute pain due to cervical
1268036|NCT00894790|sprain
1268037|NCT00894790|Celecoxib
1268038|NCT00894790|NSAID
1268039|NCT00894790|Diclofenac
1268040|NCT00894777|Psoriasis
1268041|NCT00894764|Childhood
1268042|NCT00894764|Pneumonia
1268043|NCT00894764|Pneumococcal
1268044|NCT00894764|pneumococcus
1268045|NCT00894764|Carriage
1268046|NCT00894751|dexmedetomidine and propofol for MRI
1268047|NCT00894751|quality of care between two anesthetic agents for MRI
1268048|NCT00894738|pediatric
1268049|NCT00894738|mental illness
1268050|NCT00894738|antipsychotic
1268051|NCT00894738|cardiometabolic risk
1268052|NCT00894738|Antipsychotic agents
1268053|NCT00894738|Mental disorders diagnosed in childhood
1268054|NCT00894725|left colon cancer
1268055|NCT00894712|Radiation Therapy
1268056|NCT00894699|procedural sedation
1268057|NCT00894673|heparin cardiac surgery
1268058|NCT00894660|Bioequivalence, Healthy Volunteers
1268059|NCT00894647|actinic keratosis
1268060|NCT00894647|skin disease
1268061|NCT00894621|Shock
1268062|NCT00894621|Respiration, artificial
1268063|NCT00894621|Norepinephrine
1268064|NCT00894608|letrozole
1268065|NCT00894608|ovarian stimulation
1268066|NCT00894608|PCOS
1268067|NCT00894608|IVF-ET
1268068|NCT00894595|Incidence of ACL injury
1268069|NCT00894595|Risk factors for ACL injury
1268070|NCT00894595|Prevention of ACL injury or any acute knee injury
1268071|NCT00894582|massive ventral hernia
1268072|NCT00894582|abdominal volume
1268073|NCT00894582|pulmonary function
1268074|NCT00894582|components separation
1268075|NCT00894582|abdominal compartments syndrome
1268076|NCT00894569|carcinoma of unknown primary
1268077|NCT00894569|cancer of unknown primary
1268078|NCT00894569|CUP
1268079|NCT00894569|carboplatin
1268080|NCT00894569|paclitaxel
1268081|NCT00894569|cetuximab
1268082|NCT00894556|Treatment of acute migraine with or without aura in adults
1268083|NCT00894543|Hot flashes
1268084|NCT00894543|Menopause
1268085|NCT00894543|Vasomotor symptoms
1268086|NCT00894504|Metastatic Breast Cancer
1268087|NCT00894504|Triple Negative
1268088|NCT00894504|Panitumumab
1268089|NCT00894504|Vectibix
1268090|NCT00894504|Gemcitabine
1268091|NCT00894504|Gemzar
1268092|NCT00894504|Carboplatin
1268093|NCT00894491|alternative medicine
1268094|NCT00894491|complementary medicine
1268095|NCT00894491|acupuncture
1268096|NCT00894491|Chinese herbals
1268097|NCT00894478|MRI-Negative
1268098|NCT00894478|Diffusion tensor imaging
1268099|NCT00894478|Localization-related epilepsy
1268100|NCT00894478|Partial Epilepsy
1268101|NCT00894478|Children
1268102|NCT00894465|Midazolam
1268103|NCT00894465|VCUG
1268104|NCT00894465|Anxiety
1268105|NCT00894452|Methadone
1268106|NCT00894452|CYP
1268107|NCT00894452|OPRM1
1268108|NCT00894452|MDR1
1268109|NCT00894452|COMT
1268110|NCT00894452|Midazolam challenge
1268111|NCT00894426|COPD
1268112|NCT00894426|Symptom
1268113|NCT00894426|Morning activity
1268114|NCT00894426|Questionnaire
1268115|NCT00894400|AF
1268116|NCT00894400|catheter ablation
1268117|NCT00894400|fractionated electrogram
1268118|NCT00894400|complex fractionated atrial electrogram (CFAE)
1268119|NCT00894387|elevated BNP
1268120|NCT00894387|reduced LVEF
1268121|NCT00894387|Acute Heart Failure
1268122|NCT00894387|Cardiovascular death
1268123|NCT00894387|CHF
1268124|NCT00894387|hospitalization
1268125|NCT00894387|morbi-mortality trial
1268126|NCT00894387|outcome study
1268127|NCT00894387|endpoint driven
1268128|NCT00894387|plasma renin activity
1268129|NCT00894387|renin angiotensin
1268130|NCT00894387|aldosterone system
1268131|NCT00894387|direct renin inhibitors
1268132|NCT00894387|BNP
1268133|NCT00894387|KCCQ
1268134|NCT00894387|eGFR
1268135|NCT00894374|Bio-equivalence, Healthy Volunteers
1268136|NCT00894361|knee arthritis
1268137|NCT00894361|total knee arthroplasty
1268138|NCT00894361|total knee replacement
1268139|NCT00894361|mobile bearing design
1268140|NCT00894361|all-polyethylene tibia
1268141|NCT00894348|ERCP
1268142|NCT00894348|Positive Biliary Brush Cytology
1268143|NCT00894335|retroperitoneoscopic adrenalectomy
1268144|NCT00894335|intraoperative arterial-alveolar Carbon dioxide Difference
1268145|NCT00894322|diabetes
1268146|NCT00894322|exenatide once weekly
1268147|NCT00894322|Byetta
1268148|NCT00894322|Amylin
1268149|NCT00894322|Lilly
1268150|NCT00894296|MEG
1268151|NCT00894296|schizophrenia
1268152|NCT00894296|negative symptoms
1268153|NCT00894283|DVT
1268154|NCT00894283|PE
1268155|NCT00894283|MRV
1268156|NCT00894283|bariatric surgery
1268157|NCT00894270|Diabetes
1268158|NCT00894270|Injection
1268159|NCT00894270|Needle
1268160|NCT00894257|HCV infected pregnant women
1268161|NCT00894244|None- Normal healthy upper arm skin will be used.
1268162|NCT00894205|neuropsychological function
1268163|NCT00894205|cognitive function
1268164|NCT00894205|exercise
1268165|NCT00894205|older adult
1268166|NCT00894192|This study tests functional ability of patients with refractive error or normal vision while using different types of eyeglasses.
1268167|NCT00894179|coronary artery disease
1268168|NCT00894179|stress echocardiography
1268169|NCT00894179|regadenoson
1268170|NCT00894179|atropine
1268171|NCT00894179|coronary angiogram
1268172|NCT00894166|Smoking Cessation
1268173|NCT00894166|Chantix
1268174|NCT00894166|varenicline
1268175|NCT00894166|Nicotine Replacement Therapy
1268176|NCT00894166|Nicotine Patches
1268177|NCT00894166|Zyban
1268178|NCT00894166|bupropion
1268179|NCT00894166|Quit Smoking
1268180|NCT00894153|p53 gene
1268181|NCT00894153|head and neck malignent tumors
1268182|NCT00894153|gene therapy
1268183|NCT00894140|Hip
1268184|NCT00894140|Cementless
1268185|NCT00894140|Conservative
1268186|NCT00894127|Lung Cancer
1268187|NCT00894127|Porphyrin
1268188|NCT00894127|Fluorescence
1268189|NCT00894127|Diagnostic
1268190|NCT00894127|Sputum Cytology
1268191|NCT00894127|Early Detection
1268192|NCT00894075|genetic metabolic disorder
1268193|NCT00894075|alkaline phosphatase
1268194|NCT00894075|tissue non-specific alkaline phosphatase
1268195|NCT00894075|rickets
1268196|NCT00894075|osteomalacia
1268197|NCT00894036|esbl children Switzerland
1268198|NCT00894036|Colonization
1268199|NCT00894036|ESBL-producing gram-negative bacilli
1268200|NCT00894036|Infection
1268201|NCT00894023|Patients with AMI
1268202|NCT00894010|Photosensitive epilepsy
1268203|NCT00894010|Photosensitivity
1268204|NCT00894010|Seizures
1268205|NCT00894010|Epilepsy
1268206|NCT00893997|myelodysplastic syndrome
1268207|NCT00893997|MDS
1268208|NCT00893997|PR1 Peptide Vaccine
1268209|NCT00893984|Intolerance
1268210|NCT00893984|Beta blocker
1268211|NCT00893971|Healthy Volunteers
1268212|NCT00893932|SIRS leptin outcome sepsis
1268213|NCT00893906|influenza
1268214|NCT00893906|influenza vaccine
1268215|NCT00893906|vaccine effectiveness
1268216|NCT00893906|cluster randomized
1268217|NCT00893906|Africa
1268218|NCT00893893|Obesity
1268219|NCT00893893|Lipid metabolism
1268220|NCT00893893|VLDL
1268221|NCT00893880|Tinea Pedis
1268222|NCT00893880|Athletes Foot
1268223|NCT00893880|Nitric Oxide
1268224|NCT00893867|acute ischemic stroke
1268225|NCT00893867|neuroprotective agent
1268226|NCT00893841|bipolar
1268227|NCT00893841|bipolar depression
1268228|NCT00893841|bipolar disorder
1268229|NCT00893841|depression
1268230|NCT00893841|quetiapine
1268231|NCT00893841|pramipexole
1268232|NCT00893841|Seroquel XR
1268233|NCT00893841|Mirapex
1268234|NCT00893815|HIV
1268235|NCT00893815|Neurocognitive function
1268236|NCT00893802|periodontal disease
1268237|NCT00893802|pregnancy
1268238|NCT00893802|periodontal treatment
1268239|NCT00893763|Nosocomial (Hospital-Acquired) Infections
1268240|NCT00893763|Ventilator-Associated Pneumonia
1268241|NCT00893763|Mechanical ventilation
1268243|NCT00893750|Vulnerable Youths in Northern Uganda
1268244|NCT00893750|Formerly Abducted Children
1268245|NCT00893750|Reintegration and Reconciliation
1268246|NCT00893750|Trauma Treatment
1268247|NCT00893750|Narrative Exposure Therapy
1268248|NCT00893750|Reconciliation
1268249|NCT00893750|Revenge Feelings
1268250|NCT00893737|Migraine
1268251|NCT00893737|Headache, Migraine
1268252|NCT00893724|DME
1268253|NCT00893724|NAMD
1268254|NCT00893724|Oxidative damage
1268255|NCT00893724|Nutritional supplements/vitamins
1268256|NCT00893724|DNA repair
1268257|NCT00893724|NAMD/wet AMD
1268258|NCT00893711|infantile colic
1268259|NCT00893711|lactobacillus
1268260|NCT00893711|gut microflora
1268261|NCT00893711|FISH
1268262|NCT00893685|Telemedicine
1268263|NCT00893672|Radiography, Thoracic
1268264|NCT00893672|Intensive Care Units
1268265|NCT00893672|Ventilation, mechanical
1268266|NCT00893672|Matched-Pair Analysis
1268267|NCT00893659|Beta-glucan
1268268|NCT00893659|faecal microflora
1268269|NCT00893659|polypectomized
1268270|NCT00893659|Precancerous Nonmalignant Condition
1268271|NCT00893646|abdominal obesity
1268272|NCT00893646|weight reduction
1268273|NCT00893646|diet
1268274|NCT00893646|exercise training
1268275|NCT00893646|lifestyle activity
1268276|NCT00893646|health-related fitness
1268277|NCT00893646|walking
1268278|NCT00893646|actigraphy
1268279|NCT00893646|lifestyle modification
1268280|NCT00893646|sleep
1268281|NCT00893646|sleep hygiene
1268282|NCT00893646|alertness
1268283|NCT00893646|daytime sleepiness
1268284|NCT00893646|metabolic syndrome
1268285|NCT00893646|counselling
1268286|NCT00893646|health education
1268287|NCT00893646|truck drivers
1268288|NCT00893646|bus drivers
1268289|NCT00893646|randomized controlled trial
1268290|NCT00893633|neuromuscular diseases
1268291|NCT00893633|critical illness
1268292|NCT00893633|mechanical ventilation
1268293|NCT00893633|phrenic nerve
1268294|NCT00893633|nerve conduction studies
1268295|NCT00893620|iliac aneurysm
1268296|NCT00893620|endovascular repair
1268297|NCT00893594|migraine
1268298|NCT00893594|migraine with aura
1268299|NCT00893594|headache
1268300|NCT00893581|mania
1268301|NCT00893581|adolescent
1268302|NCT00893581|bipolar
1268303|NCT00893568|Post traumatic stress disorder PTSD
1268304|NCT00893555|Invasive fungal infection
1268305|NCT00893555|hematological malignancy
1268306|NCT00893555|voriconazole
1268307|NCT00893555|therapeutic drug monitoring
1268308|NCT00893529|overweight
1268309|NCT00893529|children
1268310|NCT00893529|intervention
1268311|NCT00893529|sugar-sweetened beverages
1268312|NCT00893516|non cutaneous peripheral t-cell lymphoma with nodal involvement
1268313|NCT00893477|stage II grade 1 follicular lymphoma
1268314|NCT00893477|stage II grade 2 follicular lymphoma
1268315|NCT00893477|stage II grade 3 follicular lymphoma
1268316|NCT00893477|stage III grade 1 follicular lymphoma
1268317|NCT00893477|stage III grade 2 follicular lymphoma
1268318|NCT00893477|stage III grade 3 follicular lymphoma
1268319|NCT00893477|stage IV grade 1 follicular lymphoma
1268320|NCT00893477|stage IV grade 2 follicular lymphoma
1268321|NCT00893477|stage IV grade 3 follicular lymphoma
1268322|NCT00893451|renal disease
1268323|NCT00893451|renal impairment
1268324|NCT00893451|chronic kidney disease stage 3-4
1268325|NCT00893451|25(OH) vitamin D
1268326|NCT00893451|cholecalciferol
1268327|NCT00893451|vitamin D deficiency
1268328|NCT00893451|insulin resistance
1268329|NCT00893451|insulin-glucose clamp
1268330|NCT00893451|non-diabetic
1268331|NCT00893438|Chronic Fatigue Syndrome (CFS)
1268332|NCT00893438|Adolescence
1268333|NCT00893438|Cognitive behaviour therapy (CBT)
1268334|NCT00893438|Web-based
1268335|NCT00893438|Internet
1268336|NCT00893438|Efficacy
1268337|NCT00893425|CD95
1268338|NCT00893425|ADMA
1268339|NCT00893425|proteinuria
1268340|NCT00893425|diabetic nephropathy
1268341|NCT00893425|CD95 and ADMA levels
1268342|NCT00893412|HSG
1268343|NCT00893412|analgesia
1268344|NCT00893412|tramadol
1268345|NCT00893412|metal cannula
1268346|NCT00893412|balloon catheter
1268347|NCT00893399|adult patients
1268348|NCT00893399|NPM1 mutation
1268349|NCT00893386|Extraction
1268350|NCT00893386|Removal
1268351|NCT00893386|Lead
1268352|NCT00893386|Heart Failure
1268353|NCT00893373|AML
1268354|NCT00893373|sorafenib
1268355|NCT00893360|Adult Stem cells
1268356|NCT00893360|Cardiosphere derived stem cells
1268357|NCT00893360|Myocardial infarction
1268358|NCT00893347|Mild traumatic brain injury
1268359|NCT00893347|Concussion
1268360|NCT00893347|Post-Concussion Syndrome
1268361|NCT00893347|Cognitive-Behavioural Therapy
1268362|NCT00893334|Duchenne and Becker muscular dystrophy
1268363|NCT00893334|muscular dystrophy
1268364|NCT00892255|Liver cancer
1268365|NCT00892255|Tumors
1268366|NCT00892242|Neoadjuvant zoledronic acid in resectable pancreas cancer
1268367|NCT00892229|First trimester missed abortion
1268368|NCT00892229|Misoprostol
1268369|NCT00892229|buccal
1268370|NCT00892229|vaginal
1268371|NCT00892229|cervical ripening
1268372|NCT00892229|first trimester
1268373|NCT00892229|missed abortion
1268374|NCT00892216|PONV
1268375|NCT00892216|NUSS procedure
1268376|NCT00892216|Acupressure
1268377|NCT00892216|Pectus Excavatum
1268378|NCT00892203|Migraine
1268379|NCT00892203|Headache
1268380|NCT00893295|colon cancer
1268381|NCT00893295|rectal cancer
1268382|NCT00893282|renal
1268383|NCT00893282|calculi
1268384|NCT00893282|kidney
1268385|NCT00893282|stones
1268386|NCT00893269|marijuana
1268387|NCT00893269|cannabis
1268388|NCT00893269|dependence
1268389|NCT00893269|withdrawal
1268390|NCT00893256|schizophrenia
1268391|NCT00893256|risperidone
1268392|NCT00893256|citalopram
1268393|NCT00893256|secondary negative symptoms
1268394|NCT00893230|atopic dermatitis
1268395|NCT00893230|chemokines
1268396|NCT00893230|probiotics
1268397|NCT00893178|eNOS Polymorphism
1268398|NCT00893178|TNF alpha polymorphism
1268399|NCT00893178|pulmonary pressure
1268400|NCT00893178|polymorphism of vasoactive substances
1268401|NCT00893165|inflammation
1268402|NCT00893165|cardiovascular disease
1268403|NCT00893139|Dry Eye
1268404|NCT00893126|psoriasis
1268405|NCT00893126|coronary arteriosclerosis
1268406|NCT00893126|coronary events
1268407|NCT00893126|rheumatoid arthritis
1268408|NCT00893126|arthritis
1268409|NCT00893087|Ventilatory care, children, intensive care, asynchrony, triggering
1268410|NCT00893087|Children needing ventilatory care
1268411|NCT00893074|withdrawal
1268412|NCT00893074|acute effects
1268413|NCT00893074|cognitive performance
1268414|NCT00893074|Marijuana Use
1268415|NCT00893074|Marijuana Abstinence
1268416|NCT00893061|stage IA breast cancer
1268417|NCT00893061|stage IB breast cancer
1268418|NCT00893061|stage II breast cancer
1268419|NCT00893061|stage IIIA breast cancer
1268420|NCT00893061|stage IIIB breast cancer
1268421|NCT00893061|stage IIIC breast cancer
1268422|NCT00893061|estrogen receptor-positive breast cancer
1268423|NCT00893061|progesterone receptor-positive breast cancer
1268424|NCT00893048|prednisone
1268425|NCT00893048|cellulitis
1268426|NCT00893048|erysipelas
1268427|NCT00893048|steroids
1268428|NCT00893048|oral
1268429|NCT00893035|Radiotherapy
1268430|NCT00893035|Late side effects
1268431|NCT00893035|Predictive assay
1268432|NCT00893009|Forced expiratory volume in one second
1268433|NCT00893009|Inspiratory capacity
1268434|NCT00893009|endurance time
1268435|NCT00893009|residual volume
1268436|NCT00892996|Intrathecal morphine
1268437|NCT00892996|Cesarean section
1268438|NCT00892996|Nausea and vomiting
1268439|NCT00892996|Prevention
1268440|NCT00892983|Obesity
1268441|NCT00892983|Sleep
1268442|NCT00892983|Physical activity
1268443|NCT00892983|Breast feeding
1268444|NCT00892983|Depression
1268445|NCT00892957|Vascular Surgery
1268446|NCT00892957|Arterio-arterial bypasses
1268447|NCT00892957|Arterio-venous (AV) shunts
1268448|NCT00892944|Positron Emission Tomography
1268449|NCT00892944|Phase 1
1268450|NCT00892944|Healthy volunteers
1268451|NCT00892944|AZD2516
1268452|NCT00892931|Glioblastoma
1268453|NCT00892931|Brain Neoplasms
1268454|NCT00892931|Recurrence
1268455|NCT00892918|pterygium
1268456|NCT00892918|gatifloxacin
1268457|NCT00892918|moxifloxacin
1268458|NCT00892918|corneal epithelial defect
1268459|NCT00892905|coagulation
1268460|NCT00892905|INR
1268461|NCT00892905|aPTT
1268462|NCT00892905|point of care
1268463|NCT00892905|laboratory
1268464|NCT00892905|CABG
1268465|NCT00892905|surgery
1268466|NCT00892892|sympatholytic treatment
1268467|NCT00892892|sympathetic nerve activity
1268468|NCT00892853|calcification
1268469|NCT00892853|osteoporosis
1268470|NCT00892827|Rituximab
1268471|NCT00892827|Mabthera
1268472|NCT00892827|FFP
1268473|NCT00892827|Fresh Frozen Plasma
1268474|NCT00892827|CLL
1268475|NCT00892827|Complement
1268476|NCT00892827|Response
1268477|NCT00892827|Overall response rate of FFP+Rituximab combined therapy
1268478|NCT00892827|Analysis of complement activation pathways prior to, during and
1268479|NCT00892827|after the study treatment.
1268480|NCT00892827|Time to disease progression
1268481|NCT00892827|Time to re-treatment (See Appendix I).
1268482|NCT00892827|Safety of the combination treatment of FFP and RTX.
1268483|NCT00892801|tumors metastatic to brain
1268484|NCT00892801|recurrent non-small cell lung cancer
1268485|NCT00892801|stage IV non-small cell lung cancer
1268486|NCT00892788|Overweight
1268487|NCT00892788|Obesity
1268488|NCT00892788|Contingency Management
1268489|NCT00892775|Working seed virus
1268490|NCT00892775|Rubella
1268491|NCT00892775|Mumps
1268492|NCT00892775|Varicella
1268493|NCT00892775|Combined measles-mumps-rubella-varicella vaccine
1268494|NCT00892775|Pediatric immunization
1268495|NCT00892775|Measles
1268496|NCT00892762|Open Angle Glaucoma
1268497|NCT00892762|Ocular hypertension
1268498|NCT00892762|OAG
1268499|NCT00892762|OH
1268500|NCT00892749|hyperphosphatemia
1268501|NCT00892749|hemodialysis
1268502|NCT00892749|CKD
1268503|NCT00892749|ASP1585
1268504|NCT00892723|AZX100
1268505|NCT00892723|Patient and Observer Scar Assessment Scale
1268506|NCT00892723|POSAS
1268507|NCT00892723|Visual Analog Scale
1268508|NCT00892723|VAS
1268509|NCT00892723|Keloid
1268510|NCT00892723|Scarring
1268511|NCT00892723|Scar reduction
1268512|NCT00892723|Scar prevention
1268513|NCT00892710|Non small cell lung cancer
1268514|NCT00892710|NSCLC
1268515|NCT00892710|Pemetrexed
1268516|NCT00892710|Bevacizumab
1268517|NCT00892710|Avastin
1268518|NCT00892710|Carboplatin
1268519|NCT00892710|Stage IIIB/IV
1268520|NCT00892697|hepatitis C
1268521|NCT00892697|FNA
1268522|NCT00892697|intrahepatic
1268523|NCT00892684|Randomized
1268524|NCT00892684|Placebo controlled
1268525|NCT00892684|Double blind
1268526|NCT00892684|Omega-3 fatty acids
1268527|NCT00892684|Pregnancy
1268528|NCT00892684|Childhood allergy
1268529|NCT00892684|Cytokines
1268530|NCT00892684|Eicosanoids
1268531|NCT00892684|Polyunsaturated fatty acids
1268532|NCT00892671|Perceived effectiveness
1268533|NCT00892658|Sorafenib
1268534|NCT00892658|Hepatocellular carcinoma
1268535|NCT00892632|Biliary Strictures
1268536|NCT00892632|Cholangiocarcinoma
1268537|NCT00892632|ERCP
1268538|NCT00892619|Epiretinal Membrane
1268539|NCT00892619|Vitreomacular traction
1268540|NCT00892619|MVR blade
1268541|NCT00892619|Tano brush
1268542|NCT00892619|ILM forceps
1268543|NCT00892619|surgical technique
1268544|NCT00892606|Surgery, Orthopedic
1268545|NCT00892606|Pain, Postoperative
1268546|NCT00892593|colon
1268547|NCT00892593|neoplasia
1268548|NCT00892593|polyp
1268549|NCT00892593|adenoma
1268550|NCT00892593|FIT
1268551|NCT00892593|cancer
1268552|NCT00892580|fragile X syndrome
1268553|NCT00892580|biomarkers
1268554|NCT00892567|breast cancer
1268555|NCT00892567|peptide vaccine
1268556|NCT00892567|immunotherapy
1268557|NCT00892554|Phenylketonurias
1268558|NCT00892554|Docosahexaenoic Acids
1268559|NCT00892554|Neuropsychological Tests
1268560|NCT00892554|Female
1268561|NCT00892554|Adolescent
1268562|NCT00892554|Adult
1268563|NCT00892541|Schizophrenia
1268564|NCT00892541|Mood disorders
1268565|NCT00892541|Antipsychotic drugs
1268566|NCT00892541|Renal secretion
1268567|NCT00892541|ER OROS paliperidone
1268568|NCT00892515|breast cancer
1268569|NCT00892515|healthy, no evidence of disease
1268570|NCT00892502|haematology
1268571|NCT00892502|haematological
1268572|NCT00892502|hematology
1268573|NCT00892502|hematological
1268574|NCT00892502|malignancy
1268575|NCT00892502|lymphoma
1268576|NCT00892502|myeloma
1268577|NCT00892502|leukemia
1268578|NCT00892502|blood diseases
1268579|NCT00892502|malignant
1268580|NCT00892502|bismuth
1268581|NCT00892489|Schizophrenia, Mood disorders, Antipsychotics
1268582|NCT00892489|ER OROS Paliperidone
1268583|NCT00892476|myopia
1268584|NCT00892476|calcium supplementation
1268585|NCT00892476|prematurity
1268586|NCT00892463|Major Depressive Disorder
1268587|NCT00892463|Seroquel XR
1268588|NCT00892463|Quetiapine
1268589|NCT00892450|Overactive bladder symptoms
1268590|NCT00892450|Parkinson's disease
1268591|NCT00892450|darifenacin
1268592|NCT00892450|oxybutynin
1268593|NCT00892450|cognition
1268594|NCT00892437|HIV
1268595|NCT00892437|HIV-1
1268596|NCT00892437|Antiretroviral Treatment-Naive
1268597|NCT00892424|Liver metastasis
1268598|NCT00892424|sorafenib
1268599|NCT00892424|Liver metastasis from cancer
1268600|NCT00892411|Neuroplasticity
1268601|NCT00892411|Prognosis
1268602|NCT00892398|Trabeculectomy
1268603|NCT00892398|Vascular Endothelial Growth Factor A
1268604|NCT00892398|Wound Healing
1268605|NCT00892398|Angiogenesis Inhibitors
1268606|NCT00892385|unspecified adult solid tumor, protocol specific
1268607|NCT00892372|body weight
1268608|NCT00892372|glycohemoglobin
1268609|NCT00892359|pharmacokinetics
1268610|NCT00892359|renal replacement therapy
1268611|NCT00892359|hemofiltration
1268612|NCT00892359|anidulafungin
1268613|NCT00892346|autologous hematopoietic stem cell transplantation
1268614|NCT00892346|maintenance
1268615|NCT00892333|Repair of a large hernia with SurgiMend 3.0, a biologic mesh
1268616|NCT00892320|Schizophrenia, mood stabilizers, antipsychotics
1268617|NCT00892320|ER OROS paliperidone
1268618|NCT00892307|Diagnostic Imaging
1268619|NCT00892307|Dual Source Multidetector Computed Tomography
1268620|NCT00892307|Computed Tomography
1268621|NCT00892307|CT
1268622|NCT00892307|Single Photon Emission Computed Tomography
1268623|NCT00892307|SPECT
1268624|NCT00892307|Myocardial Perfusion
1268625|NCT00892307|Atherosclerosis
1268626|NCT00892268|menopausal symptoms
1268627|NCT00892268|estrogen receptor-positive breast cancer
1268628|NCT00892268|progesterone receptor-positive breast cancer
1268629|NCT00892268|breast cancer
1268630|NCT00892268|pain
1268631|NCT00892190|AML
1268632|NCT00892190|Dasatinib
1268633|NCT00892190|all trans retinoic acid
1268634|NCT00892190|relapsed AML
1268635|NCT00892190|refractory AML
1268636|NCT00892190|Relapsed/Refractory Acute myelogenous leukemia
1268637|NCT00892190|Elderly subjects (age 65 or older) with acute myelogenous leukemia
1268638|NCT00892190|Myelodysplastic Syndrome
1268639|NCT00892190|MDS
1268640|NCT00892177|adult giant cell glioblastoma
1268641|NCT00892177|adult glioblastoma
1268642|NCT00892177|adult gliosarcoma
1268643|NCT00892177|adult mixed glioma
1268644|NCT00892177|recurrent adult brain tumor
1268645|NCT00892177|adult anaplastic oligodendroglioma
1268646|NCT00892177|adult oligodendroglioma
1268647|NCT00892177|adult anaplastic astrocytoma
1268648|NCT00892164|thyroid surgery
1268649|NCT00892164|total thyroidectomy
1268650|NCT00892164|harmonic scalpel
1268651|NCT00892164|electrothermal bipolar vessel sealer
1268652|NCT00892164|hemostatic device
1268653|NCT00892138|mindfulness training
1268654|NCT00892138|medical students
1268655|NCT00892138|psychology students
1268656|NCT00892138|stress management
1268657|NCT00892138|personal development
1268658|NCT00892138|stress
1268659|NCT00892125|Schizophrenia
1268660|NCT00892125|Bipolar I disorder
1268661|NCT00892125|mood disorders
1268662|NCT00892125|antipsychotic drugs
1268663|NCT00892125|enzyme inducer
1268664|NCT00892125|Paliperidone ER
1268665|NCT00892112|Immunoglobulins, Intravenous
1268666|NCT00892112|Cardiomyopathies
1268667|NCT00892112|Parvo B19, Human
1268668|NCT00892099|end stage renal disease
1268669|NCT00892099|hemodialysis
1268670|NCT00892086|geriatric syndrome
1268671|NCT00892086|immobility
1268672|NCT00892073|Craniopharyngioma surgery
1268673|NCT00892073|Hypothalamic Obesity
1268674|NCT00892073|Children
1268675|NCT00892073|Combined Diazoxide and Metformin
1268676|NCT00892047|Depression
1268677|NCT00892047|Aripiprazole
1268678|NCT00892047|Venlafaxine
1268679|NCT00892047|Partial Remission
1268680|NCT00892047|Augmentation strategy
1268681|NCT00892047|Treatment resistance
1268682|NCT00892047|Elderly
1268683|NCT00892047|Late-life
1268684|NCT00892008|pregabalin
1268685|NCT00892008|neuropathic pain
1268686|NCT00892008|safety
1268687|NCT00891995|Type 1 Diabetes
1268688|NCT00891995|Closed Loop Therapy
1268689|NCT00891995|Continuous Glucose Monitor
1268690|NCT00891982|Acne Vulgaris
1268691|NCT00891969|stage I breast cancer
1268692|NCT00891969|stage II breast cancer
1268693|NCT00891969|stage IIIA breast cancer
1268694|NCT00891956|Rett Syndrome
1268695|NCT00891943|Obesity
1268696|NCT00891943|Overweight
1268697|NCT00891943|Randomised controlled trial
1268698|NCT00891943|Primary Care
1268699|NCT00891943|Weight
1268700|NCT00891943|Cardiovascular Risk
1268701|NCT00891943|Diabetes
1268702|NCT00891943|Quality of life
1268703|NCT00891930|wild-type KRAS
1268704|NCT00891930|panitumumab
1268705|NCT00891930|biomarker
1268706|NCT00891930|mechanisms of acquired resistance
1268707|NCT00891930|metastatic colorectal cancer
1268708|NCT00891917|Down syndrome
1268709|NCT00891917|coenzyme Q10
1268710|NCT00891917|language function
1268711|NCT00891917|behavior
1268712|NCT00891904|recurrent squamous cell carcinoma of the hypopharynx
1268713|NCT00891904|recurrent squamous cell carcinoma of the larynx
1268714|NCT00891904|recurrent squamous cell carcinoma of the lip and oral cavity
1268715|NCT00891904|recurrent squamous cell carcinoma of the nasopharynx
1268716|NCT00891904|recurrent squamous cell carcinoma of the oropharynx
1268717|NCT00891904|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1268718|NCT00891891|spina bifida, psychosocial adjustment, adolescence, emerging adulthood
1268719|NCT00891878|adenocarcinoma of the esophagus
1268720|NCT00891878|adenocarcinoma of the gastroesophageal junction
1268721|NCT00891878|recurrent esophageal cancer
1268722|NCT00891878|stage IV esophageal cancer
1268723|NCT00891878|stage III esophageal cancer
1268724|NCT00891865|lung transplant
1268725|NCT00891865|BOS
1268726|NCT00891865|OB
1268727|NCT00891865|Respiratory Viral Infection (RVI)
1268728|NCT00891865|Lung disease
1268729|NCT00891826|Bipolar disorders
1268730|NCT00891826|Omega-3 fatty acids
1268731|NCT00891826|Heart rate
1268732|NCT00891800|Cancer
1268733|NCT00891800|Breast
1268734|NCT00891800|Liver
1268735|NCT00891787|Probiotics
1268736|NCT00891787|Isoagglutinins
1268737|NCT00891787|Anti-A
1268738|NCT00891787|Anti-B
1268739|NCT00891787|Hemolysis
1268740|NCT00891787|Healthy Volunteer
1268741|NCT00891787|HV
1268742|NCT00891761|cisplatin
1268743|NCT00891761|nausea
1268744|NCT00891761|vomiting
1268745|NCT00891761|cancer
1268746|NCT00891761|lung cancer
1268747|NCT00891735|Lucentis
1268748|NCT00891735|AMD
1268749|NCT00891735|Age-related macular degeneration
1268750|NCT00891735|Subfoveal neovascular age-related macular degeneration
1268751|NCT00891735|Wet AMD
1268752|NCT00891735|Macular degeneration
1268753|NCT00891735|Ranibizumab
1268754|NCT00891722|recurrent childhood brain stem glioma
1268755|NCT00891722|untreated childhood brain stem glioma
1268756|NCT00891722|recurrent childhood cerebellar astrocytoma
1268757|NCT00891722|untreated childhood cerebellar astrocytoma
1268758|NCT00891722|childhood low-grade cerebral astrocytoma
1268759|NCT00891722|recurrent childhood cerebral astrocytoma
1268760|NCT00891722|childhood oligodendroglioma
1268761|NCT00891722|recurrent childhood visual pathway and hypothalamic glioma
1268762|NCT00891722|untreated childhood visual pathway and hypothalamic glioma
1268763|NCT00891722|childhood mixed glioma
1268764|NCT00891696|Sarcopenia
1268765|NCT00891696|Aging
1268766|NCT00891696|Metabolism
1268767|NCT00891696|Muscle
1268768|NCT00891696|mTOR
1268769|NCT00891696|Essential Amino Acids
1268770|NCT00891696|Exercise
1268771|NCT00891696|Rapamycin
1268772|NCT00891683|Diabetic
1268773|NCT00891683|peripheral
1268774|NCT00891683|neuropathy
1268775|NCT00891683|pain
1268776|NCT00891683|hyperalgesia
1268777|NCT00891683|allodynia
1268778|NCT00891670|CYP2C19 polymorphism
1268779|NCT00891670|platelet
1268780|NCT00891670|Adjunctive cilostazol
1268781|NCT00891670|high maintenance dose clopidogrel
1268782|NCT00891670|P2Y12 Reaction Unit
1268783|NCT00891657|Adhesion
1268784|NCT00891657|Fibroid
1268785|NCT00891657|Myoma
1268786|NCT00891657|Leiomyoma
1268787|NCT00891657|Myomectomy
1268788|NCT00891644|HIV
1268789|NCT00891644|Care-seeking
1268790|NCT00891631|tobacco
1268791|NCT00891631|alcohol
1268792|NCT00891631|marijuana
1268793|NCT00891631|drug use
1268794|NCT00891631|seat-belt
1268795|NCT00891631|weapons
1268796|NCT00891631|depression
1268797|NCT00891631|suicidality
1268798|NCT00891631|sexual risk behaviors
1268799|NCT00891618|Lymphoma
1268800|NCT00891618|Myeloma
1268801|NCT00891618|Multiple Myeloma
1268802|NCT00891618|MM
1268803|NCT00891618|Non-Hodgkin's Lymphoma
1268804|NCT00891618|NHL
1268805|NCT00891618|Acupuncture
1268806|NCT00891618|Treatment-induced Peripheral Neuropathy
1268807|NCT00891618|Thalidomide
1268808|NCT00891618|Bortezomib
1268809|NCT00891618|Neuropathy
1268810|NCT00891618|Peripheral Neuropathy
1268811|NCT00891605|Paclitaxel
1268812|NCT00891605|Solid Tumors
1268813|NCT00891592|AML
1268814|NCT00891592|MDS
1268815|NCT00891592|ALL
1268816|NCT00891592|NHL
1268817|NCT00891592|Multiple Myeloma
1268818|NCT00891592|Hodgkin's
1268819|NCT00891579|NSCLC
1268820|NCT00891579|EGFR
1268821|NCT00891579|Pemetrexed
1268822|NCT00891579|Gefitinib
1268823|NCT00891579|without EGFR mutations
1268824|NCT00891566|medium to large tear
1268825|NCT00891566|rotator cuff tear
1268826|NCT00891566|arthroscopic repair
1268827|NCT00891566|repair integrity
1268828|NCT00891566|immobilization
1268829|NCT00891553|bone mineral density
1268830|NCT00891553|calcium-sensing receptor antagonist
1268831|NCT00891553|ronacaleret
1268832|NCT00891553|postmenopausal osteoporosis
1268833|NCT00891527|Pulmonary Vein Stenosis,
1268834|NCT00891527|Avastin and Gleevec,
1268835|NCT00891527|Targeting VEGF and PDGF
1268836|NCT00891514|Exercise
1268837|NCT00891514|Inflammation
1268838|NCT00891514|Insulin Sensitivity
1268839|NCT00891501|autologous bone marrow mesenchymal stem cells
1268840|NCT00891501|cartilage repair
1268841|NCT00891501|osteoarthritis
1268842|NCT00891501|osteochondral defects
1268843|NCT00891488|VO2 max
1268844|NCT00891488|stress
1268845|NCT00891488|cortisol
1268846|NCT00891488|fitness
1268847|NCT00891475|metastatic renal cell carcinoma
1268848|NCT00891475|radiofrequency ablation
1268849|NCT00891462|COPD
1268850|NCT00891462|Chronic Obstructive Pulmonary Disease
1268851|NCT00891462|Chronic Bronchitis
1268852|NCT00891462|Emphysema
1268853|NCT00891462|Airflow Obstruction, Chronic
1268854|NCT00891462|Chronic Airflow Obstruction
1268855|NCT00891462|Chronic Obstructive Airway Disease
1268856|NCT00891462|Chronic Obstructive Lung Disease
1268857|NCT00891449|space flight simulation study
1268858|NCT00891449|medical research study
1268859|NCT00891449|bed rest
1268860|NCT00891449|microgravity
1268861|NCT00891449|weightlessness
1268862|NCT00891449|The effects of long duration microgravity on humans
1268863|NCT00891423|Meropenem
1268864|NCT00891423|extended infusion
1268865|NCT00891423|prolonged infusion
1268866|NCT00891423|Time above MIC
1268867|NCT00891397|CPRS
1268868|NCT00891397|stellate ganglion block
1268869|NCT00891397|pregabalin
1268870|NCT00891397|pain
1268871|NCT00891397|Type I
1268872|NCT00891384|Multiple Myeloma
1268873|NCT00891384|maintenance therapy
1268874|NCT00891384|lenalidomide
1268875|NCT00891371|symptomatic treatment of patients with refractory diarrhea
1268876|NCT00891358|Adolescent Medicine Trials Network for HIV/AIDS Interventions
1268877|NCT00891358|Human Immunodeficiency Virus
1268878|NCT00891358|HIV seronegativity
1268879|NCT00891345|hormone-refractory prostate cancer
1268880|NCT00891345|Immunotherapy
1268881|NCT00891319|hand
1268882|NCT00891319|stroke
1268883|NCT00891319|hemiplegia
1268884|NCT00891319|electrical stimulation
1268885|NCT00891319|recovery
1268886|NCT00891306|LPLD, Lipoprotein Lipase Deficiency
1268887|NCT00891306|Chylomicronemia
1268888|NCT00891306|Gene therapy
1268889|NCT00891306|AAV
1268890|NCT00891306|Lipoprotein Lipase
1268891|NCT00891306|Alipogene tiparvovec
1268892|NCT00891306|AMT-011
1268893|NCT00891293|omega-3-acid ethyl esters
1268894|NCT00891293|Very high triglycerides
1268895|NCT00891293|Lovaza
1268896|NCT00891293|fenofibrate
1268897|NCT00891280|Inflammatory breast cancer
1268898|NCT00891280|Castleman's Disease
1268899|NCT00891280|Multiple Myeloma
1268900|NCT00891280|Breast cancer
1268901|NCT00891280|Solid tumors
1268902|NCT00891280|CK2 inhibitor
1268903|NCT00891267|Inflammatory markers
1268904|NCT00891267|Vascular protection
1268905|NCT00891267|OM Effect
1268906|NCT00891267|Metabolic syndrome
1268907|NCT00891267|Hypertension
1268908|NCT00891254|Incisional hernia
1268909|NCT00891254|Intraperitoneal mesh repair
1268910|NCT00891254|On-lay repair
1268911|NCT00891254|Prosthetic mesh
1268912|NCT00891254|First repair (no recurrent hernia will be included)
1268913|NCT00891254|Recurrence
1268914|NCT00891254|Complications
1268915|NCT00891241|Heart Failure, PET Imaging, Implantable Cardioverter-Defibrillator, Dosimetry
1268916|NCT00891228|Contraception
1268917|NCT00891228|Male Contraception
1268918|NCT00891228|Suppression of Sperm Production
1268919|NCT00891202|Gaucher,
1268920|NCT00891202|beta-glucosidase,
1268921|NCT00891202|acid ß-glucosidase,
1268922|NCT00891202|glucocerebrosidase,
1268923|NCT00891202|glucosylceramide,
1268924|NCT00891202|D-glucosyl-N-acylsphingosine glucohydrolase,
1268925|NCT00891202|substrate reduction therapy
1268926|NCT00891189|Circadian Rhythm
1268927|NCT00891176|Conjugate vaccines
1268928|NCT00891176|Meningococcal serogroup C vaccine
1268929|NCT00891176|Antibody persistence
1268930|NCT00891176|Pneumococcal vaccine
1268931|NCT00891176|Haemophilus Influenzae type b vaccine
1268932|NCT00891163|Topical anesthesia
1268933|NCT00891163|Analgesia
1268934|NCT00891137|adult acute myeloid leukemia 11q23 (MLL) abnormalities
1268935|NCT00891137|adult acute myeloid leukemia inv(16)(p13;q22)
1268936|NCT00891137|adult acute myeloid leukemia t(15;17)(q22;q12)
1268937|NCT00891137|adult acute myeloid leukemia t(16;16)(p13;q22)
1268938|NCT00891137|adult acute myeloid leukemia t(8;21)(q22;q22)
1268939|NCT00891137|accelerated phase chronic myelogenous leukemia
1268940|NCT00891137|adult acute lymphoblastic leukemia in remission
1268941|NCT00891137|adult acute myeloid leukemia in remission
1268942|NCT00891137|childhood acute lymphoblastic leukemia in remission
1268943|NCT00891137|childhood acute myeloid leukemia in remission
1268944|NCT00891137|childhood chronic myelogenous leukemia
1268945|NCT00891137|blastic phase chronic myelogenous leukemia
1268946|NCT00891137|childhood diffuse large cell lymphoma
1268947|NCT00891137|childhood immunoblastic large cell lymphoma
1268948|NCT00891137|chronic phase chronic myelogenous leukemia
1268949|NCT00891137|de novo myelodysplastic syndromes
1268950|NCT00891137|extranodal marginal zone B-cell lymphoma
1268951|NCT00891137|mucosa-associated lymphoid tissue
1268952|NCT00891137|nodal marginal zone B-cell lymphoma
1268953|NCT00891137|stage I adult Burkitt lymphoma
1268954|NCT00891137|contiguous stage II adult Burkitt lymphoma
1268955|NCT00891137|noncontiguous stage II adult Burkitt lymphoma
1268956|NCT00891137|Waldenstrom macroglobulinemia
1268957|NCT00891137|noncontiguous stage II adult immunoblastic
1268958|NCT00891137|contiguous stage II adult immunoblastic
1268959|NCT00891137|large cell lymphoma
1268960|NCT00891137|stage I adult immunoblastic large cell lymphoma
1268961|NCT00891137|previously treated myelodysplastic syndromes
1268962|NCT00891137|recurrent adult Burkitt lymphoma
1268963|NCT00891137|recurrent adult diffuse large cell lymphoma
1268964|NCT00891137|recurrent adult immunoblastic large cell lymphoma
1268965|NCT00891137|recurrent adult lymphoblastic lymphoma
1268966|NCT00891137|recurrent grade 1 follicular lymphoma
1268967|NCT00891137|recurrent grade 2 follicular lymphoma
1268968|NCT00891137|recurrent grade 3 follicular lymphoma
1269078|NCT00890903|Vinorelbine
1268969|NCT00891137|recurrent marginal zone lymphoma
1268970|NCT00891137|recurrent small lymphocytic lymphoma
1268971|NCT00891137|refractory multiple myeloma
1268972|NCT00891137|relapsing chronic myelogenous leukemia
1268973|NCT00891137|secondary acute myeloid leukemia
1268974|NCT00891137|secondary myelodysplastic syndromes
1268975|NCT00891137|splenic marginal zone lymphoma
1268976|NCT00891137|stage I multiple myeloma
1268977|NCT00891137|stage II multiple myeloma
1268978|NCT00891137|stage III multiple myeloma
1268979|NCT00891137|stage III adult Burkitt lymphoma
1268980|NCT00891137|stage III adult diffuse large cell lymphoma
1268981|NCT00891137|stage III adult immunoblastic large cell lymphoma
1268982|NCT00891137|stage III adult lymphoblastic lymphoma
1268983|NCT00891137|stage IV adult immunoblastic large cell lymphoma
1268984|NCT00891137|stage IV adult lymphoblastic lymphoma
1268985|NCT00891137|refractory anemia with excess blasts in transformation
1268986|NCT00891137|refractory anemia with excess blasts
1268987|NCT00891137|refractory anemia
1268988|NCT00891137|prolymphocytic leukemia
1268989|NCT00891137|contiguous stage II adult diffuse large cell lymphoma
1268990|NCT00891137|noncontiguous stage II adult diffuse large cell lymphoma
1268991|NCT00891137|refractory chronic lymphocytic leukemia
1268992|NCT00891137|stage IV adult Burkitt lymphoma
1268993|NCT00891137|stage I childhood small noncleaved cell lymphoma
1268994|NCT00891137|stage II childhood small noncleaved cell lymphoma
1268995|NCT00891137|stage III childhood small noncleaved cell lymphoma
1268996|NCT00891137|stage IV childhood small noncleaved cell lymphoma
1268997|NCT00891137|recurrent childhood small noncleaved cell lymphoma
1268998|NCT00891137|stage I childhood large cell lymphoma
1268999|NCT00891137|stage II childhood large cell lymphoma
1269000|NCT00891137|stage III childhood large cell lymphoma
1269001|NCT00891137|stage IV childhood large cell lymphoma
1269002|NCT00891137|contiguous stage II mantle cell lymphoma
1269003|NCT00891137|contiguous stage II adult lymphoblastic lymphoma
1269004|NCT00891137|noncontiguous stage II adult lymphoblastic lymphoma
1269005|NCT00891137|noncontiguous stage II mantle cell lymphoma
1269006|NCT00891137|stage III mantle cell lymphoma
1269007|NCT00891137|stage IV mantle cell lymphoma
1269008|NCT00891137|stage I mantle cell lymphoma
1269009|NCT00891137|stage I adult lymphoblastic lymphoma
1269010|NCT00891137|stage I adult diffuse large cell lymphoma
1269011|NCT00891137|stage IV adult diffuse large cell lymphoma
1269012|NCT00891137|recurrent childhood large cell lymphoma
1269013|NCT00891137|stage I childhood lymphoblastic lymphoma
1269014|NCT00891137|stage II childhood lymphoblastic lymphoma
1269015|NCT00891137|stage III childhood lymphoblastic lymphoma
1269016|NCT00891137|stage IV childhood lymphoblastic lymphoma
1269017|NCT00891137|recurrent childhood lymphoblastic lymphoma
1269018|NCT00891137|childhood myelodysplastic syndromes
1269019|NCT00891137|Burkitt lymphoma
1269020|NCT00891124|Hypertension
1269021|NCT00891124|Type II DM
1269022|NCT00891124|Hyperlipidemia
1269023|NCT00891124|Glycemia
1269024|NCT00891124|ADA 2008 guideline
1269025|NCT00891124|Patient Consultation
1269026|NCT00891111|Health Risk Assessment
1269027|NCT00891111|Incentives
1269028|NCT00891111|Preventative Healthcare
1269029|NCT00891111|Encouraging Health Risk Assessments
1269030|NCT00891085|ventilation
1269031|NCT00891085|ards
1269032|NCT00891085|ali
1269033|NCT00891085|trauma
1269270|NCT00890188|THALIDOMIDE
1269034|NCT00891085|Trauma Patients with ISS > 25
1269035|NCT00891059|Cognitive Impairment
1269036|NCT00891059|Diskus Inhaler
1269037|NCT00891059|Nursing Home
1269038|NCT00891046|Flare
1269039|NCT00891046|arthritis
1269040|NCT00891046|IL-1beta antagonist
1269041|NCT00891046|systemic juvenile idiopathic arthritis
1269042|NCT00891046|CHAQ
1269043|NCT00891046|steroids
1269044|NCT00891046|ACR pediatric response
1269045|NCT00891046|Systemic juvenile idiopathic arthritis with active flare
1269046|NCT00891033|cancer
1269047|NCT00891007|Measles
1269048|NCT00891007|Virus Disease
1269049|NCT00891007|Paediatric Diseases
1269050|NCT00891007|Paramyoxyviridae
1269051|NCT00890994|MBI
1269052|NCT00890994|Molecular Breast Imaging
1269053|NCT00890994|Breast Cancer
1269054|NCT00890994|DCIS
1269055|NCT00890994|Breast
1269056|NCT00890994|Calcifications
1269057|NCT00890994|Microcalcifications
1269058|NCT00890968|hand dermatitis
1269059|NCT00890968|hand eczema
1269060|NCT00890968|triamcinolone acetonide
1269061|NCT00890955|Solid tumors
1269062|NCT00890942|pruritus
1269063|NCT00890942|intrathecal morphine
1269064|NCT00890929|Acute myeloid leukemia
1269065|NCT00890929|Acute myeloblastic leukemia
1269066|NCT00890929|AML
1269067|NCT00890916|spinal cord injury
1269068|NCT00890916|neuroprosthesis
1269069|NCT00890916|functional electrical stimulation
1269070|NCT00890916|quadriplegia
1269071|NCT00890903|NSCLC
1269072|NCT00890903|non small cell lung carcinoma
1269073|NCT00890903|metastatic breast cancer
1269074|NCT00890903|MBC
1269075|NCT00890903|advanced breast cancer
1269076|NCT00890903|Navelbine
1269077|NCT00890903|Navelbine-ORAL
1269079|NCT00890903|Vinorelbine-ORAL
1269080|NCT00890903|daily routine
1269081|NCT00890903|concomitant antiemetic therapy
1269082|NCT00890903|patient compliance
1269083|NCT00890903|germany
1269084|NCT00890903|non-interventional study
1269085|NCT00890903|oral anti cancer therapy
1269086|NCT00890903|quality of life
1269087|NCT00890877|asthma
1269088|NCT00890877|treatment
1269089|NCT00890877|placebo
1269090|NCT00890877|efficacy
1269091|NCT00890877|safety
1269092|NCT00890864|Breast screening
1269093|NCT00890864|Mammogram
1269094|NCT00890864|Routine screening programme
1269095|NCT00890851|Radiofrequency
1269096|NCT00890851|Mini invasin surgery
1269097|NCT00890851|Outpatient treatment
1269098|NCT00890851|Men health
1269099|NCT00890838|IVFO
1269100|NCT00890838|Inflammation
1269101|NCT00890838|Valvular surgery
1269102|NCT00890838|Inflammatory status
1269103|NCT00890838|Infectious complications
1269104|NCT00890825|Non small cell lung cancer (NSCLC)
1269105|NCT00890825|KRAS mutation
1269106|NCT00890812|Acute Ischemic Stroke
1269107|NCT00890799|transcatheter closure
1269108|NCT00890799|ventricular septal defects
1269109|NCT00890760|Malaria
1269110|NCT00890760|Vaccine
1269111|NCT00890747|HIV Infections
1269112|NCT00890747|treatment experienced
1269113|NCT00890721|Hemorrhoid
1269114|NCT00890721|Hemorrhoidectomy
1269115|NCT00890721|Postoperative pain
1269116|NCT00890721|Analgesia
1269117|NCT00890695|supplementary feeding
1269118|NCT00890695|moderate malnutrition
1269119|NCT00890695|acute infection
1269120|NCT00890695|developing country
1269121|NCT00890695|children
1269122|NCT00890682|Bunion
1269123|NCT00890682|Bunionectomy
1269124|NCT00890682|Osteotomy
1269125|NCT00890669|treadmill training
1269126|NCT00890669|body load
1269127|NCT00890669|quality of life
1269128|NCT00890669|Parkinson's disease
1269129|NCT00890669|Motor Symptoms
1269130|NCT00890656|Acute Lymphoblastic Leukemia
1269131|NCT00890656|ALL
1269132|NCT00890656|Leukemia
1269133|NCT00890656|Hyper-CVAD
1269134|NCT00890643|Stress disorders, post-traumatic
1269135|NCT00890643|Combat Disorders
1269136|NCT00890643|prazosin
1269137|NCT00890643|cognition
1269138|NCT00890643|neurophysiology
1269139|NCT00890617|lung metastases
1269140|NCT00890617|stage I non-small cell lung cancer
1269141|NCT00890591|hypertension
1269142|NCT00890591|angiotensin II type 1 receptor blocker
1269143|NCT00890591|olmesartan
1269144|NCT00890578|Histoacryl
1269145|NCT00890578|closure of surgical incisions
1269146|NCT00890565|Electrocardiogram
1269147|NCT00890565|Effect on electrocardiogram
1269148|NCT00890565|Granisetron
1269149|NCT00890565|Moxifloxacin
1269150|NCT00890565|Pharmacokinetic profile
1269151|NCT00890565|Sancuso® patch
1269152|NCT00890565|Transdermal
1269153|NCT00890526|Tinnitus Retraining Therapy (TRT)
1269154|NCT00890474|Breech presentation at 34 to 36 weeks of gestation
1269155|NCT00890461|ECG
1269156|NCT00890461|ICD
1269157|NCT00890448|Alanine Transaminase elevation
1269158|NCT00890448|Genetic Markers
1269159|NCT00890448|DNA Markers
1269271|NCT00890188|UFUR
1269160|NCT00890435|unspecified adult solid tumor, protocol specific
1269161|NCT00890435|unspecified childhood solid tumor, protocol specific
1269162|NCT00890435|recurrent childhood brain stem glioma
1269163|NCT00890435|recurrent childhood cerebellar astrocytoma
1269164|NCT00890435|recurrent childhood cerebral astrocytoma
1269165|NCT00890435|recurrent childhood medulloblastoma
1269166|NCT00890435|recurrent childhood supratentorial primitive neuroectodermal tumor
1269167|NCT00890435|recurrent childhood ependymoma
1269168|NCT00890435|recurrent childhood pineoblastoma
1269169|NCT00890435|recurrent childhood subependymal giant cell astrocytoma
1269170|NCT00890435|recurrent childhood visual pathway and hypothalamic glioma
1269171|NCT00890435|recurrent childhood acute lymphoblastic leukemia
1269172|NCT00890435|recurrent childhood acute myeloid leukemia
1269173|NCT00890435|childhood choroid plexus tumor
1269174|NCT00890435|childhood craniopharyngioma
1269175|NCT00890435|childhood ependymoblastoma
1269176|NCT00890435|childhood medulloepithelioma
1269177|NCT00890435|childhood meningioma
1269178|NCT00890435|childhood mixed glioma
1269179|NCT00890435|childhood oligodendroglioma
1269180|NCT00890435|adult astrocytic tumors
1269181|NCT00890435|adult brain stem glioma
1269182|NCT00890435|adult choroid plexus tumor
1269183|NCT00890435|adult craniopharyngioma
1269184|NCT00890435|adult ependymoblastoma
1269185|NCT00890435|adult medulloblastoma
1269186|NCT00890435|adult supratentorial primitive neuroectodermal tumor (PNET)
1269187|NCT00890435|adult ependymal tumors
1269188|NCT00890435|adult meningeal tumor
1269189|NCT00890435|adult mixed glioma
1269190|NCT00890435|adult oligodendroglial tumors
1269191|NCT00890435|adult pineal parenchymal tumor
1269192|NCT00890435|recurrent adult brain tumor
1269193|NCT00890435|relapsing chronic myelogenous leukemia
1269194|NCT00890435|recurrent adult acute lymphoblastic leukemia
1269195|NCT00890435|recurrent adult acute myeloid leukemia
1269196|NCT00890435|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1269197|NCT00890435|adult acute myeloid leukemia with inv(16)(p13;q22)
1269198|NCT00890435|adult acute myeloid leukemia with t(15;17)(q22;q12)
1269199|NCT00890435|adult acute myeloid leukemia with t(16;16)(p13;q22)
1269200|NCT00890435|adult acute myeloid leukemia with t(8;21)(q22;q22)
1269201|NCT00890435|secondary acute myeloid leukemia
1269202|NCT00890435|acute undifferentiated leukemia
1269203|NCT00890435|mast cell leukemia
1269204|NCT00890435|atypical chronic myeloid leukemia, BCR-ABL1 negative
1269205|NCT00890435|T-cell large granular lymphocyte leukemia
1269206|NCT00890435|refractory chronic lymphocytic leukemia
1269207|NCT00890435|childhood chronic myelogenous leukemia
1269208|NCT00890435|chronic myelomonocytic leukemia
1269209|NCT00890435|juvenile myelomonocytic leukemia
1269210|NCT00890435|refractory hairy cell leukemia
1269211|NCT00890435|prolymphocytic leukemia
1269212|NCT00890422|encephalitis
1269213|NCT00890422|FSME
1269214|NCT00890422|central european encephalitis
1269215|NCT00890409|hypothermia
1269216|NCT00890409|neonate
1269217|NCT00890409|hypoxic-ischemic encephalopathy
1269218|NCT00890409|efficacy
1269219|NCT00890409|safety
1269220|NCT00890396|Sickle Cell Anemia
1269221|NCT00890396|Hydroxyurea
1269222|NCT00890383|trauma resuscitation
1269223|NCT00890383|abdominal hypertension
1269224|NCT00890383|abdominal compartment syndrome
1269225|NCT00890370|Cystic fibrosis
1269226|NCT00890370|Airway clearance
1269227|NCT00890344|PeaPod
1269228|NCT00890344|BIA
1269229|NCT00890344|Anthropometry
1269230|NCT00890344|Body Composition
1269231|NCT00890344|Fat Mass
1269232|NCT00890344|Total Body Water
1269233|NCT00890344|Neonatology
1269234|NCT00890305|Metastatic colorectal cancer
1269235|NCT00890305|FOLFOX chemotherapy
1269236|NCT00890292|Attention Deficit Hyperactivity Disorder
1269237|NCT00890292|ADHD
1269238|NCT00890292|JNJ-31001074
1269239|NCT00890279|Autosomal Dominant Polycystic Kidney Disease
1269240|NCT00890279|Hypertension
1269241|NCT00890279|Angiotensin-II Receptor Blocker
1269242|NCT00890279|Calcium Channel Blocker
1269243|NCT00890279|Angiotensin converting enzyme inhibitor
1269244|NCT00890279|Kidney Volume
1269245|NCT00890279|eGFR
1269246|NCT00890266|keratoconus
1269247|NCT00890266|collagen cross-linking
1269248|NCT00890266|riboflavin
1269249|NCT00890266|UV light
1269250|NCT00890253|Renal impairment
1269251|NCT00890253|Liver transplantation
1269252|NCT00890253|Chronic Renal Insufficiency
1269253|NCT00890240|Attention Deficit Hyperactivity Disorder
1269254|NCT00890240|ADHD
1269255|NCT00890240|JNJ-31001074
1269256|NCT00890227|scoliosis
1269257|NCT00890227|kyphosis
1269258|NCT00890227|Surgical treatment
1269259|NCT00890214|Anticoagulation
1269260|NCT00890214|Prostacyclin
1269261|NCT00890214|Heparin
1269262|NCT00890214|Renal Replacement Therapy
1269263|NCT00890214|Kidney failure acute
1269264|NCT00890214|Platelet aggregation
1269265|NCT00890201|Pancreaticobiliary reflux
1269266|NCT00890201|Normal pancreaticobiliary junction
1269267|NCT00890201|Gallstones
1269268|NCT00890201|Cholelithiasis
1269269|NCT00890201|Cholecystectomy
1269272|NCT00890188|Colorectal cancer
1269273|NCT00890188|Oxaliplatin
1269274|NCT00890175|Asthma, Staccato loxapine
1269282|NCT00890149|alcohol abuse
1269283|NCT00890149|binge drinking
1269284|NCT00890149|severe drinking
1269285|NCT00890149|alcoholism
1269286|NCT00890149|heavy drinking
1269287|NCT00890136|Chronic Obstructive Pulmonary Disease (COPD)
1269288|NCT00890123|Omega 3 Fatty Acids
1269289|NCT00890123|Inflammation
1269290|NCT00890123|Hip Surgery
1269291|NCT00890123|Inflammatory status
1269292|NCT00890123|Infectious complications
1269293|NCT00890110|Renal cell cancer
1269294|NCT00890110|sunitinib
1269295|NCT00890110|autologous vaccine
1269296|NCT00890110|metastatic RCC
1269297|NCT00890097|Geographic Atrophy
1269298|NCT00890097|GA
1269299|NCT00890097|Age-Related Macular Degeneration
1269300|NCT00890097|AMD
1269301|NCT00890071|Fluid responsiveness
1269302|NCT00890071|Ultrasound
1269303|NCT00890071|Cardiac output
1269304|NCT00890058|Arthritis
1269305|NCT00890058|Synovitis
1269306|NCT00890058|Aromatase Inhibitor
1269307|NCT00890058|Arthralgia Syndrome
1269308|NCT00890045|Vascular access hemodialysis
1269309|NCT00890045|ePTFE graft
1269310|NCT00890045|Graft-eligible
1269311|NCT00890045|Long-term vascular access for hemodialysis
1269312|NCT00890032|adult giant cell glioblastoma
1269313|NCT00890032|adult glioblastoma
1269314|NCT00890032|adult gliosarcoma
1269315|NCT00890032|adult astrocytoma
1269316|NCT00890032|recurrent adult brain tumor
1269317|NCT00890006|Prostate cancer
1269318|NCT00890006|Magnetic resonance imaging
1269319|NCT00889993|Food intake
1269320|NCT00889993|Gut hormones
1269321|NCT00889993|Fiber
1269322|NCT00889993|Visual analog scales
1269323|NCT00889967|Pseudomonas aeruginosa
1269324|NCT00889967|antimicrobial
1269325|NCT00889967|inhalation
1269326|NCT00889967|ciprofloxacin
1269327|NCT00889967|Non-Cystic Fibrosis Bronchiectasis
1269328|NCT00889954|EBV+
1269329|NCT00889954|Her2
1269330|NCT00889954|TGFBeta
1269331|NCT00889954|EBV positive
1269332|NCT00889954|HER 2 positive malignancy
1269333|NCT00889954|cytotoxic T lymphocytes
1269334|NCT00889928|gallbladder disease
1269335|NCT00889928|cholecystectomy
1269336|NCT00889928|gallbladder disease indicated for cholecystectomy
1269337|NCT00889915|ADHD
1269338|NCT00889915|Methylphenidate
1269339|NCT00889915|Amphetamine
1269340|NCT00889902|Molecular Markers
1269341|NCT00889902|Cervical Cancer
1269342|NCT00889902|Screening
1269343|NCT00889902|Makov
1269344|NCT00889889|Influenza
1269345|NCT00889889|Phase II
1269346|NCT00889889|Placebo-controlled
1269347|NCT00889876|Obesity
1269348|NCT00889876|Adolescents
1269349|NCT00889876|Nocturnal blood pressure reduction
1269350|NCT00889876|Insulin metabolism
1269351|NCT00889876|Cardiovascular structure and function
1269352|NCT00889876|Treatment
1269353|NCT00889876|Exercise
1269354|NCT00889876|Metformin
1269355|NCT00889876|Insulin
1269356|NCT00889876|Blood glucose
1269357|NCT00889876|Impaired nocturnal blood pressure reduction
1269358|NCT00889863|Flare
1269359|NCT00889863|arthritis
1269360|NCT00889863|IL-1beta antagonist
1269361|NCT00889863|systemic juvenile idiopathic arthritis
1269362|NCT00889863|Juvenile rheumatoid
1269363|NCT00889850|Healthy
1269364|NCT00889850|Bioavailability
1269365|NCT00889850|Bioequivalence
1269366|NCT00889850|Esomeprazole
1269367|NCT00889850|Bioavailability, Therapeutical Indication Not Studied
1269368|NCT00889837|Staccato Loxapine
1269369|NCT00889837|COPD
1269370|NCT00889837|pulmonary safety
1269371|NCT00889824|Chronic imbalance
1269372|NCT00889824|vestibular disorders
1269373|NCT00889824|balance prosthesis
1269374|NCT00889811|OPCAB
1269375|NCT00889811|RIPC
1269376|NCT00889798|Malignant lymphatic disease
1269377|NCT00889798|therapy-reality
1269378|NCT00889798|observation
1269379|NCT00889798|registry
1269380|NCT00889798|therapy sequences
1269381|NCT00889798|NHL
1269382|NCT00889798|CLL
1269383|NCT00889798|Germany
1269384|NCT00889798|lenalidomide
1269385|NCT00889798|alemtuzumab
1269386|NCT00889798|rituximab
1269387|NCT00889798|bendamustin
1269388|NCT00889798|thalidomide
1269389|NCT00889798|bortezomib
1269390|NCT00889798|ibritumomab-tiuxetan
1269391|NCT00889798|G-CSF
1269392|NCT00889798|chronic lymphocytic leukaemia
1269393|NCT00889798|follicular lymphoma
1269394|NCT00889798|gastric MALT lymphoma
1269395|NCT00889798|nongastric MALT lymphoma
1269396|NCT00889798|nodal marginal zone lymphoma
1269397|NCT00889798|splenic marginal zone lymphoma
1269398|NCT00889798|mantle cell lymphoma
1269399|NCT00889798|diffuse large b-cell lymphoma
1269400|NCT00889785|Adolescents
1269401|NCT00889785|Type 2 Diabetes
1269402|NCT00889785|Behavioral Research
1269403|NCT00889772|Respiratory distress, adult
1269404|NCT00889772|risk
1269405|NCT00889772|emergency room
1269406|NCT00889772|high risk surgery
1269407|NCT00889772|sepsis
1269408|NCT00889772|trauma
1269409|NCT00889772|aspiration
1269410|NCT00889772|pneumonia
1269411|NCT00889759|Tuberculosis
1269412|NCT00889759|Outbreaks
1269413|NCT00888966|heart arrest
1269414|NCT00888966|oxidative stress
1269415|NCT00888966|lactic acid
1269416|NCT00888966|outcome
1269417|NCT00888953|Falls
1269418|NCT00888953|Nursing Homes
1269419|NCT00888953|Elderly
1269420|NCT00888953|Prevention
1269421|NCT00888953|Spain
1269422|NCT00888953|Cluster Randomized Clinical Trial
1269423|NCT00888927|T-Cell Lymphoma
1269424|NCT00888927|PTCL
1269425|NCT00888927|CTCL
1269426|NCT00888914|Lateral Canthal Lines
1269427|NCT00888914|Crow's Feet
1269428|NCT00888914|Facial Wrinkles
1269429|NCT00888901|ITP
1269430|NCT00888901|eltrombopag
1269431|NCT00888901|platelet function
1269432|NCT00888901|thrombocytopenia
1269433|NCT00888901|Platelet function in patients with cAITP on eltrombopag
1269434|NCT00888888|Acute appendicitis
1269435|NCT00888888|Colonic diverticulitis
1269436|NCT00888888|Colonic tumors
1269437|NCT00888888|Colonic resections
1269438|NCT00888875|i-gel
1269439|NCT00888875|Fastrach
1269440|NCT00888875|intubation
1269441|NCT00888875|fiberoptic
1269442|NCT00888875|difficult airway
1269443|NCT00888875|Patients undergoing elective surgery requiring tracheal intubation
1269444|NCT00888875|Presenting at least one sign of difficult intubation
1269445|NCT00888862|depression
1269446|NCT00888862|desvenlafaxine
1269447|NCT00888862|menopause
1269448|NCT00888862|imaging
1269449|NCT00888862|FMRI
1269450|NCT00888849|Stapling
1269451|NCT00888849|hand sutured anastamosis
1269452|NCT00888849|colorectal disease
1269453|NCT00888836|bariatric surgery
1269454|NCT00888836|GBP
1269455|NCT00888836|BPD
1269456|NCT00888836|type 2 diabetes
1269457|NCT00889720|smoking cessation
1269458|NCT00889720|varenicline
1269459|NCT00889720|elective surgery
1269460|NCT00889720|wound infections
1269461|NCT00889720|post-operative complications
1269462|NCT00889707|Benign Prostatic Hyperplasia
1269463|NCT00889707|BPH
1269464|NCT00889707|Enlarged Prostate
1269465|NCT00889668|Glucose monitoring
1269466|NCT00889668|GlucoTrack
1269467|NCT00889668|Self glucose monitoring
1269468|NCT00889655|efficacy of bowel cleansing
1269469|NCT00889655|patient tolerability
1269470|NCT00889655|Golytely
1269471|NCT00889655|MiraLax
1269472|NCT00889655|colonoscopy preparation
1269473|NCT00889655|bowel preparation
1269474|NCT00889655|screening colonoscopy
1269475|NCT00889629|kidney transplantation
1269476|NCT00889629|kidney transplant recipients
1269477|NCT00889616|Malaria
1269478|NCT00889616|Asexual Blood Stafe
1269479|NCT00889616|Plasmodium Falciparum
1269480|NCT00889616|Immunogenicity
1269481|NCT00889616|Safety
1269482|NCT00889616|Vaccine
1269483|NCT00889603|Aricept® Evess
1269484|NCT00889603|non-interventional study
1269485|NCT00889603|Alzheimer's Disease
1269486|NCT00889603|Vascular Dementia
1269487|NCT00889603|efficacy
1269488|NCT00889603|tolerability
1269489|NCT00889603|safety.
1269490|NCT00889590|GCT
1269491|NCT00889590|Bisfosfonates
1269492|NCT00889564|Vascular access for hemodialysis
1269493|NCT00889564|Catheter dependent patients
1269494|NCT00889564|Access challenged patients
1269495|NCT00889564|Bacteremia
1269496|NCT00889564|HeRO Vascular Access Device
1269497|NCT00889538|Autism
1269498|NCT00889538|Severe Behavior Disorder
1269499|NCT00889538|Glutathione
1269500|NCT00889538|Antioxidants
1269501|NCT00889525|Cabergoline
1269502|NCT00889486|gastroparesis
1269503|NCT00889486|diabetes mellitus
1269504|NCT00889486|delayed gastric emptying
1269505|NCT00889473|Celiac Disease
1269506|NCT00889473|Gluten
1269507|NCT00889460|rBet v 1
1269508|NCT00889460|Birch pollen allergy
1269509|NCT00889460|Sublingual Immunotherapy
1269510|NCT00889447|Chronic Obstructive Pulmonary disease (COPD)
1269511|NCT00889434|Cystic fibrosis
1269512|NCT00889434|splicing mutations
1269513|NCT00889434|molecular therapy
1269514|NCT00889434|EGCG
1269515|NCT00889434|Tocotrienol
1269516|NCT00889434|Splicing-mutation-mediated Cystic Fibrosis
1269517|NCT00889421|uveitis
1269518|NCT00889421|apremilast
1269519|NCT00889408|refractory chronic lymphocytic leukemia
1269520|NCT00889408|childhood diffuse large cell lymphoma
1269521|NCT00889408|childhood grade III lymphomatoid granulomatosis
1269522|NCT00889408|childhood immunoblastic large cell lymphoma
1269523|NCT00889408|B-cell adult acute lymphoblastic leukemia
1269524|NCT00889408|recurrent adult acute lymphoblastic leukemia
1269525|NCT00889408|B-cell childhood acute lymphoblastic leukemia
1269526|NCT00889408|recurrent childhood acute lymphoblastic leukemia
1269636|NCT00889148|gabapentin
1269527|NCT00889408|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1269528|NCT00889408|adult acute myeloid leukemia with inv(16)(p13;q22)
1269529|NCT00889408|adult acute myeloid leukemia with t(15;17)(q22;q12)
1269530|NCT00889408|adult acute myeloid leukemia with t(16;16)(p13;q22)
1269531|NCT00889408|adult acute myeloid leukemia with t(8;21)(q22;q22)
1269532|NCT00889408|recurrent adult acute myeloid leukemia
1269533|NCT00889408|recurrent childhood acute myeloid leukemia
1269534|NCT00889408|secondary acute myeloid leukemia
1269535|NCT00889408|B-cell chronic lymphocytic leukemia
1269536|NCT00889408|relapsing chronic myelogenous leukemia
1269537|NCT00889408|childhood chronic myelogenous leukemia
1269538|NCT00889408|cutaneous B-cell non-Hodgkin lymphoma
1269539|NCT00889408|recurrent adult grade III lymphomatoid granulomatosis
1269540|NCT00889408|Waldenström macroglobulinemia
1269541|NCT00889408|recurrent adult Burkitt lymphoma
1269542|NCT00889408|recurrent adult diffuse large cell lymphoma
1269543|NCT00889408|recurrent adult diffuse mixed cell lymphoma
1269544|NCT00889408|recurrent adult diffuse small cleaved cell lymphoma
1269545|NCT00889408|recurrent adult immunoblastic large cell lymphoma
1269546|NCT00889408|recurrent adult lymphoblastic lymphoma
1269547|NCT00889408|recurrent grade 1 follicular lymphoma
1269548|NCT00889408|recurrent grade 2 follicular lymphoma
1269549|NCT00889408|recurrent grade 3 follicular lymphoma
1269550|NCT00889408|recurrent mantle cell lymphoma
1269551|NCT00889408|recurrent marginal zone lymphoma
1269552|NCT00889408|recurrent small lymphocytic lymphoma
1269553|NCT00889408|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1269554|NCT00889408|nodal marginal zone B-cell lymphoma
1269555|NCT00889408|splenic marginal zone lymphoma
1269556|NCT00889408|recurrent childhood grade III lymphomatoid granulomatosis
1269557|NCT00889408|recurrent childhood large cell lymphoma
1269558|NCT00889408|recurrent childhood lymphoblastic lymphoma
1269559|NCT00889408|recurrent childhood small noncleaved cell lymphoma
1269560|NCT00889408|childhood Burkitt lymphoma
1269561|NCT00889408|intraocular lymphoma
1269562|NCT00889408|noncutaneous extranodal lymphoma
1269563|NCT00889408|prolymphocytic leukemia
1269564|NCT00889395|MISC
1269565|NCT00889395|caregivers
1269566|NCT00889395|children
1269567|NCT00889395|psychosocial gains
1269568|NCT00889395|cognitive benefits
1269569|NCT00889382|Ovarian Cancer
1269570|NCT00889382|Ovarian
1269571|NCT00889382|Paclitaxel
1269572|NCT00889382|OSI-906
1269573|NCT00889382|IGF-1R
1269574|NCT00889382|Solid Tumors
1269575|NCT00889369|depression
1269576|NCT00889369|duloxetine
1269577|NCT00889369|menopause
1269578|NCT00889369|imaging
1269579|NCT00889369|FMRI
1269580|NCT00889369|Menopausal staging
1269581|NCT00889369|vasomotor symptoms
1269582|NCT00889343|Second-line therapy of metastatic colorectal cancer
1269583|NCT00889343|Sorafenib
1269584|NCT00889343|Colorectal Neoplasms
1269585|NCT00889343|palliative therapy
1269586|NCT00889343|after progression of firstline therapy with an Oxaliplatin- or Irinotecan based Fluoropyrimidine containing regimen ± bevacizumab
1269587|NCT00889304|HTO, high tibial osteotomy, open wedge, medial arthritis
1269588|NCT00889291|End stage renal disease
1269589|NCT00889291|Bacteremia
1269590|NCT00889291|HeRO Vascular Access Device
1269591|NCT00889291|Access challenged
1269592|NCT00889291|Catheter dependent
1269593|NCT00889291|End stage renal disease requiring vascular access. See HeRO device instructions for use for appropriate patient population
1269594|NCT00889278|Lymphoma
1269595|NCT00889278|Autologous Peripheral Blood Stem Cell Transplant
1269596|NCT00889278|APBSCT
1269597|NCT00889278|Pneumococcal Conjugate Vaccine
1269598|NCT00889265|Alveolar Bone Augmentation
1269599|NCT00889265|Implant Surgery
1269600|NCT00889265|Guided Bone Regeneration (GBR)
1269601|NCT00889265|Guided Tissue Regeneration (GTR)
1269602|NCT00889265|Bone Graft
1269603|NCT00889265|Periodontal Surgery
1269604|NCT00889239|ceramic
1269605|NCT00889239|wear rate
1269606|NCT00889239|opposing enamel
1269607|NCT00889226|pitavastatin
1269608|NCT00889226|PWV
1269609|NCT00889226|ESPRIT
1269610|NCT00889226|Pitavastatin and Atorvastatin
1269611|NCT00889226|Adiponectin
1269612|NCT00889226|fasting insulin
1269613|NCT00889226|hs-CRP
1269614|NCT00889226|baPWV
1269615|NCT00889213|pancreatectomy
1269616|NCT00889213|fistula
1269617|NCT00889213|fibrin glue
1269618|NCT00889213|falciform patch
1269619|NCT00889213|surgery
1269620|NCT00889213|complications
1269621|NCT00889187|radiation therapy
1269622|NCT00889187|capecitabine
1269623|NCT00889174|Genetic Disorders of the White Matter
1269624|NCT00889174|Leukodystrophies
1269625|NCT00889174|Myelin
1269626|NCT00889174|White Matter Disorder
1269627|NCT00889174|Genetic Disorder
1269628|NCT00889161|Crohn's disease
1269629|NCT00889161|ulcerative colitis
1269630|NCT00889161|curcumin
1269631|NCT00889161|pediatric
1269632|NCT00889161|inflammatory bowel disease
1269633|NCT00889148|hip
1269634|NCT00889148|arthroplasty
1269635|NCT00889148|postoperative pain
1269637|NCT00889122|Obesity
1269638|NCT00889122|Exergames
1269639|NCT00889122|Videogames
1269640|NCT00889122|Prevention
1269641|NCT00889122|Family
1269642|NCT00889122|Dance Dance Revolution
1269643|NCT00889122|Pedometer
1269644|NCT00889096|memory
1269645|NCT00889096|heart rate
1269646|NCT00889096|skin conductance
1269647|NCT00889096|α-amylase
1269648|NCT00889096|propranolol
1269649|NCT00889096|tolerability
1269650|NCT00889083|Sepsis
1269651|NCT00889083|Peritonitis
1269652|NCT00889083|Mitochondria
1269653|NCT00889083|Liver
1269654|NCT00889057|osteosarcoma
1269655|NCT00889057|sorafenib
1269656|NCT00889057|target therapy
1269657|NCT00889031|CLL
1269658|NCT00889018|intraocular retinoblastoma
1269659|NCT00889018|chemotherapy
1269660|NCT00889005|Post-traumatic Stress Disorder
1269661|NCT00889005|Acute Stress Disorder
1269662|NCT00889005|Cognitive behavioral therapy
1269663|NCT00889005|Secondary Prevention
1269664|NCT00889005|Anxiety disorders
1269665|NCT00889005|Service Delivery
1269666|NCT00888992|Smoking
1269667|NCT00888992|Cessation
1269668|NCT00888992|Quitline
1269669|NCT00888992|Counseling
1269670|NCT00888979|Smoking Cessation during Pregnancy
1269671|NCT00888979|Nicotrol Inhaler
1269672|NCT00888823|Fractionated stereotactic radiotherapy
1269673|NCT00888823|Medically inoperable
1269674|NCT00888823|Image-guided radiotherapy
1269675|NCT00888810|ovarian - cancer - relapse - topotecan - lapatinib
1269676|NCT00888771|Colorectal cancer
1269677|NCT00888771|polyps
1269678|NCT00888771|colonoscopy
1269679|NCT00888771|advanced imaging
1269680|NCT00888758|Stents
1269681|NCT00888745|RA
1269682|NCT00888732|Diabetes
1269683|NCT00888680|Migraine
1269684|NCT00888680|Headaches
1269685|NCT00888680|Migraine headaches
1269686|NCT00888680|Head pain
1269687|NCT00888667|ICD patients with PVCs and EGM recordings
1269688|NCT00888654|adenocarcinoma of the prostate
1269689|NCT00888654|stage I prostate cancer
1269690|NCT00888654|stage II prostate cancer
1269691|NCT00888628|Type I diabetes
1269692|NCT00888628|Islet after Kidney Transplant
1269693|NCT00888628|Islet transplantation
1269694|NCT00888589|MBI
1269695|NCT00888589|Molecular Breast Imaging
1269696|NCT00888589|Breast
1269697|NCT00888589|Breast Cancer
1269698|NCT00888589|Molecular Imaging
1269699|NCT00888563|Fatigue
1269700|NCT00888563|Depression
1269701|NCT00888563|Healthy Volunteer
1269702|NCT00888563|HV
1269703|NCT00888537|Decision aid
1269704|NCT00888537|Heart attack
1269705|NCT00888537|myocardial infarction
1269706|NCT00888524|head out water immersion,
1269707|NCT00888524|high intensity exercise,
1269708|NCT00888524|evidence-based physiotherapy;
1269709|NCT00888524|aquatics;
1269710|NCT00888524|hydrotherapy
1269711|NCT00888524|aquatics therapy
1269712|NCT00888524|exercise therapy
1269713|NCT00888511|Lung cancer
1269714|NCT00888511|Non-small cell lung cancer
1269715|NCT00888511|Tarceva
1269716|NCT00888511|Radiotherapy
1269717|NCT00888511|Local-regionally advanced non-small cell lung cancer
1269718|NCT00888498|Sprains and Strains
1269719|NCT00888498|Ankle
1269720|NCT00888498|Manual Therapies
1269721|NCT00888498|Outcome Studies
1269722|NCT00888472|Extracorporeal leukocytapheresis
1269723|NCT00888459|tobacco
1269724|NCT00888459|chew
1269725|NCT00888459|nrt
1269726|NCT00888459|nicotine lozenges
1269727|NCT00888459|self-help
1269728|NCT00888446|HIV
1269729|NCT00888446|HIV seronegativity
1269730|NCT00888446|preventative vaccine
1269731|NCT00888433|hypertension
1269732|NCT00888433|renal denervation
1269733|NCT00888433|sympathetic nervous system
1269734|NCT00888433|RDN
1269735|NCT00888420|Chronic Pain
1269736|NCT00888407|Asian American Health
1269737|NCT00888407|Cancer
1269738|NCT00888407|Hepatitis
1269739|NCT00888407|Hepatitis B
1269740|NCT00888407|Liver Cancer
1269741|NCT00888394|chiropody
1269742|NCT00888394|podiatry
1269743|NCT00888394|insoles
1269744|NCT00888394|foot orthesis
1269745|NCT00888342|Pulmonary Disease
1269746|NCT00888342|Chronic Obstructive
1269747|NCT00888342|Hypercapnia
1269748|NCT00888342|Hypoxemia
1269749|NCT00888342|Arrhythmias, Cardiac
1269750|NCT00888342|Polysomnography
1269751|NCT00888342|Capnography
1269752|NCT00888342|Electrocardiography, Holter
1269753|NCT00888329|Elective hysterectomy
1269754|NCT00888316|iron overload
1269755|NCT00888290|metabolic acidosis
1269756|NCT00888290|chronic kidney disease
1269757|NCT00888290|Estimated GFR 15-45
1269758|NCT00888264|Antipsychotics
1269759|NCT00888264|Bipolar Disorder
1269760|NCT00888264|Depressive episodes
1269761|NCT00888264|Bipolar I or II Disorders
1269762|NCT00888251|Obesity
1269763|NCT00888251|Meal replacement
1269764|NCT00888251|Obesity treatment
1269765|NCT00888251|Weight management
1269766|NCT00888225|Tennis elbow
1269767|NCT00888225|Epicondylitis
1269768|NCT00888225|Pain
1269769|NCT00888225|Muscle strength
1269770|NCT00888225|Quality of life
1269771|NCT00888225|RCT
1269772|NCT00888225|Tendinitis
1269773|NCT00888225|Chronic tennis elbow
1269774|NCT00888199|amputation
1269775|NCT00888199|amputee
1269776|NCT00888199|prosthetic
1269777|NCT00888199|foot
1269778|NCT00888199|prosthesis
1269779|NCT00888199|Tensegrity
1269780|NCT00888199|Prosthetics
1269781|NCT00888199|K3 Promoter
1269782|NCT00888186|Dyskinesias
1269783|NCT00888186|Duodenal levodopa infusion
1269784|NCT00888186|Dose optimization
1269785|NCT00888186|Pharmacokinetics
1269786|NCT00888186|Pharmacodynamics
1269787|NCT00888147|Tube feeding
1269788|NCT00888147|Fiber
1269789|NCT00888147|Constipation
1269790|NCT00888095|deep brain stimulation
1269791|NCT00888095|caudal Zona incerta
1269792|NCT00888095|Nucleus subthalamicus
1269793|NCT00888095|Parkinson's disease
1269794|NCT00888095|randomized
1269795|NCT00888095|blinded
1269796|NCT00888095|Movement disorder
1269797|NCT00888082|adjuvant chemotherapy
1269798|NCT00888082|breast cancer
1269799|NCT00888082|goserelin acetate
1269800|NCT00888082|ovarian function
1269801|NCT00888082|Chemotherapy
1269802|NCT00888082|Primary invasive breast cancer
1269803|NCT00888069|Parathyroid Diseases
1269804|NCT00888069|Renal Insufficiency
1269805|NCT00888069|Kidney Failure, Chronic
1269806|NCT00888069|Hyperparathyroidism, Secondary
1269807|NCT00888069|Vitamin D
1269808|NCT00888069|Hyperparathyroidism
1269809|NCT00888069|Renal Insufficiency, Chronic
1269810|NCT00888069|Kidney Diseases
1269811|NCT00888069|Kidney Failure
1269812|NCT00888043|solid tumors
1269813|NCT00888043|avastin
1269814|NCT00888043|Phase I
1269815|NCT00888043|combination therapy
1269816|NCT00888043|bevacizumab
1269817|NCT00888030|p-cresol
1269818|NCT00888030|indoxyl sulfate
1269819|NCT00888030|chronic kidney disease
1269820|NCT00888030|outcome
1269821|NCT00888017|bone density
1269822|NCT00888017|proton pump inhibitors
1269823|NCT00888017|premature infants
1269824|NCT00888004|Parkinson's
1269825|NCT00888004|L-dopa
1269826|NCT00888004|dyskinesia
1269827|NCT00887991|Randomised trial
1269828|NCT00887991|breast pumps
1269829|NCT00887991|efficacy
1269830|NCT00887991|preterm
1269831|NCT00887991|Mothers of preterm infants who plan to express milk for their infants.
1269832|NCT00887965|Low Bone Mass
1269833|NCT00887965|Low Bone Mineral Density
1269834|NCT00887965|Osteoporosis
1269835|NCT00887965|Postmenopausal Osteoporosis
1269836|NCT00887965|Bone Biopsy
1269837|NCT00887965|Transiliac Crest Bone Histology
1269838|NCT00887965|Histomorphometry
1269839|NCT00887952|Deep caries lesion
1269840|NCT00887952|dentine caries removal
1269841|NCT00887952|dental restoration
1269842|NCT00887952|stepwise excavation
1269843|NCT00887939|Physical Urticaria
1269844|NCT00887939|Pathogenesis
1269845|NCT00887939|Inflammasome
1269846|NCT00887939|IL-1
1269847|NCT00887939|Mast Cell
1269848|NCT00887939|Urticaria
1269849|NCT00887926|AML
1269850|NCT00887926|Leukemia
1269851|NCT00887926|Acute Myeloid Leukemia
1269852|NCT00887926|Antibodies, Monoclonal
1269853|NCT00887900|lamellar keratoplasty
1269854|NCT00887900|keratoconus
1269855|NCT00887900|penetrated keratoplasty
1269856|NCT00887900|Visual acuity
1269857|NCT00887887|liver surgery
1269858|NCT00887887|gene polymorphisms
1269859|NCT00887887|innate immune response
1269860|NCT00887887|infectious complications
1269861|NCT00887887|post-resectional liver failure
1269862|NCT00887887|mortality
1269863|NCT00887861|epilepsy
1269864|NCT00887861|seizure
1269865|NCT00887861|monotherapy trials
1269866|NCT00887861|partial seizure
1269867|NCT00887861|Partial seizures and undergoing evaluation for epilepsy surgery
1269868|NCT00887848|Child
1269869|NCT00887848|Robotic-assisted treadmill training
1269870|NCT00887848|Rehabilitation
1269871|NCT00887835|PERPOS fusion
1269872|NCT00887809|Bevacizumab (avastin)
1269873|NCT00887809|Gemcitabine
1269874|NCT00887809|Taxotere (docetaxel)
1269875|NCT00887809|09-015
1269876|NCT00887809|Soft tissue
1269877|NCT00887783|Induction chemotherapy
1269878|NCT00887783|Non-small cell lung cancer
1269879|NCT00887783|Randomized phase II study
1269880|NCT00887783|Navelbine Oral (R)
1269881|NCT00887783|3D-conformal radiotherapy
1269882|NCT00887783|Chemo-radiotherapy
1269883|NCT00887783|Local-regionally advanced non-small cell lung cancer
1269884|NCT00887770|QTcF
1269885|NCT00887770|Crossover
1269886|NCT00887770|ICH E14
1269887|NCT00887770|QT/QTc prolongation
1269888|NCT00887770|Moxifloxacin
1269889|NCT00887770|QT/QTc Interval
1269890|NCT00887744|Degenerative Lumbar Spinal Stenosis
1269891|NCT00887744|Neurogenic Intermittent Claudication
1269892|NCT00887744|Interpinous Device
1269893|NCT00887744|Percutaneous
1269894|NCT00887731|closed loop oxygen controller
1269895|NCT00887731|premature infants
1269896|NCT00887731|oxygen exposure
1269897|NCT00887718|PET scan and Hodgkin's Lymphoma
1269898|NCT00887718|PET scan and Non Hodgkin's Lymphoma
1269899|NCT00887718|PET scan
1269900|NCT00887705|COPD
1269901|NCT00887705|Pulmonary Rehabilitation
1269902|NCT00887705|ADL-Training
1269903|NCT00887705|COPD Rehabilitation
1269904|NCT00887679|Escitalopram
1269905|NCT00887679|Anxiety Disorder
1269906|NCT00887679|HIV and AIDS
1269907|NCT00887679|treatment experienced
1269908|NCT00887640|metastatic
1269909|NCT00887640|Temsirolimus
1269910|NCT00887640|prostate
1269911|NCT00887640|cancer
1269912|NCT00887627|Pharmacokinetics
1269913|NCT00887627|Protein Binding
1269914|NCT00887627|Conivaptan
1269915|NCT00887627|Vaprisol
1269916|NCT00887627|Kidney Diseases
1269917|NCT00887614|mindfulness
1269918|NCT00887614|meditation
1269919|NCT00887614|stress
1269920|NCT00887614|rumination
1269921|NCT00887614|emotion regulation
1269922|NCT00887614|sleep quality
1269923|NCT00887614|spirituality
1269924|NCT00887614|quality of life
1269925|NCT00887588|Chronic heart failure
1269926|NCT00887588|preserved ejection fraction
1269927|NCT00887588|cardiovascular disease
1269928|NCT00887588|NT-proBNP
1269929|NCT00887588|biomarkers
1269930|NCT00887588|Heart failure with preserved left-ventricular ejection
1269931|NCT00887588|fraction
1269932|NCT00887575|Breast Cancer
1269933|NCT00887575|Triple-Negative
1269934|NCT00887575|Paclitaxel
1269935|NCT00887575|Carboplatin
1269936|NCT00887575|Sunitinib
1269937|NCT00887575|Sutent
1269938|NCT00887575|Neoadjuvant
1269939|NCT00887536|National Surgical Adjuvant Breast and Bowel Project (NSABP)
1269940|NCT00887536|Taxotere
1269941|NCT00887536|Docetaxel
1269942|NCT00887536|Doxorubicin
1269943|NCT00887536|Cyclophosphamide
1269944|NCT00887536|Bevacizumab
1269945|NCT00887536|Breast Neoplasms
1269946|NCT00887536|Adenocarcinoma
1269947|NCT00887536|Breast Diseases
1269948|NCT00887536|Carcinoma
1269949|NCT00887536|HER2 negative
1269950|NCT00887536|Node negative
1269951|NCT00887536|High risk node positive
1269952|NCT00887536|Adjuvant Therapy
1269953|NCT00887510|Metabolic Syndrome
1269954|NCT00887510|High Blood Pressure
1269955|NCT00887510|Abdominal Obesity
1269956|NCT00887510|Impaired Glucose Tolerance
1269957|NCT00887484|Acne
1269958|NCT00887484|Acne Vulgaris
1269959|NCT00887471|Sleep-disordered breathing
1269960|NCT00887471|Obstructive sleep apnea
1269961|NCT00887471|Polysomnography
1269962|NCT00887471|Tonsillectomy
1269963|NCT00887471|Microdebrider assisted partial intracapsular tonsillectomy
1269964|NCT00887458|metastatic prostate cancer
1269965|NCT00887458|castration resistant prostate cancer
1269966|NCT00887458|rising PSA
1269967|NCT00887445|First in Man
1269968|NCT00887445|SLV341
1269969|NCT00887445|diabetes
1269972|NCT00887406|first time in human study
1269973|NCT00887406|COPD
1269974|NCT00887406|long-acting bronchodilator
1269975|NCT00887393|morbid obesity
1269976|NCT00887393|non-alcoholic fatty liver disease
1269977|NCT00887393|bariatric surgery
1269978|NCT00887393|low fat diet
1269979|NCT00887393|low carbohydrate diet
1269980|NCT00887380|Breast Cancer
1269981|NCT00887380|Timing of Radiotherapy
1269982|NCT00887380|Local control
1269983|NCT00887367|Healthy volunteers
1269984|NCT00887367|Substance dependence
1269985|NCT00887367|Alcohol dependence
1269986|NCT00887354|Low bone mass
1269987|NCT00887354|Recent pertrochanteric hip fracture
1269988|NCT00887328|ischemic stroke
1269989|NCT00887328|ischemic penumbra
1269990|NCT00887328|magnetic resonance imaging
1269991|NCT00887328|MRI
1269992|NCT00887328|diffusion imaging
1269993|NCT00887328|DWI
1269994|NCT00887328|perfusion imaging
1269995|NCT00887328|PWI
1269996|NCT00887328|thrombolysis
1269997|NCT00887328|alteplase
1269998|NCT00887328|tPA
1269999|NCT00887328|EPITHET
1270000|NCT00887315|NSCLC
1270001|NCT00887315|Metastatic Stage IV NSCLC
1270002|NCT00887315|Limited Volume Stage IV Non-small Cell Lung Cancer
1270003|NCT00887276|Ampicillin
1270004|NCT00887276|Amoxicillin
1270005|NCT00887276|Moxifloxacin
1270006|NCT00887276|Community-Acquired Pneumonia
1270007|NCT00887237|Heart failure
1270008|NCT00887237|Cardiac resynchronization
1270009|NCT00887237|Triple site ventricular pacing
1270010|NCT00887224|Major Depressive Disorder
1270011|NCT00887211|stent
1270012|NCT00887211|coronary artery disease
1270013|NCT00887198|Prostate cancer
1270014|NCT00887198|Abiraterone acetate
1270015|NCT00887198|CB7630
1270016|NCT00887198|CRPC
1270017|NCT00887198|Metastatic castration-resistant prostate cancer
1270018|NCT00887198|hormone refractory prostate cancer
1270019|NCT00887185|Surgical Simulation
1270020|NCT00887185|Surgical skills training
1270021|NCT00887185|Temporal bone surgery
1270022|NCT00887185|Computer simulation
1270023|NCT00887172|Acute upper respiratory tract infections
1270027|NCT00887120|Second line treatment
1270028|NCT00887120|therapeutic drug monitoring
1270029|NCT00887120|Asia
1270030|NCT00887120|LPV
1270031|NCT00887120|children
1270032|NCT00887120|pharmacokinetic
1270033|NCT00887120|To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in Protease inhibitor (PI)- naive HIV-1 infected Thai patients.
1270034|NCT00887120|To study clinical and immunological efficacy after 48-weeks of lopinavir/ritonavir-based antiretroviral therapy in PI naive HIV-1 infected Thai patients.
1270035|NCT00887094|Diabetes mellitus
1270036|NCT00887094|Exercise
1270037|NCT00887094|Endurance
1270038|NCT00887094|Resistance
1270039|NCT00887094|Continuous glucose monitoring system
1270040|NCT00887081|antiviral treatment in hemoglobinopathies
1270041|NCT00887081|management of chronic viral hepatitis C infection
1270042|NCT00887081|antiviral treatment
1270043|NCT00887068|Leukemia
1270044|NCT00887068|Acute myelogenous leukemia
1270045|NCT00887068|AML
1270046|NCT00887068|Myelodysplastic syndrome
1270047|NCT00887068|MDS
1270048|NCT00887068|Remission
1270049|NCT00887068|Allogeneic stem cell transplant
1270050|NCT00887068|Allotx
1270051|NCT00887068|Azacitidine
1270052|NCT00887068|5-Azacitidine
1270053|NCT00887068|5-aza
1270054|NCT00887068|Vidaza
1270055|NCT00887068|5-AZC
1270056|NCT00887068|AZA-CR
1270057|NCT00887068|Ladakamycin
1270058|NCT00887068|NSC-102816
1270059|NCT00887042|Acute myeloid leukemia
1270060|NCT00887042|Cord blood transplantation
1270061|NCT00887042|Pediatric
1270062|NCT00887029|Topical prostaglandin analogue
1270063|NCT00887029|glaucoma
1270064|NCT00887029|POAG
1270065|NCT00887029|OHT
1270066|NCT00887029|OAG
1270067|NCT00887029|ocular hypertension
1270068|NCT00887029|fixed combination protaglandin analogue therapy
1270069|NCT00887029|DuoTrav
1270070|NCT00887029|timolol
1270071|NCT00887029|travoprost
1270072|NCT00887029|24 hour post dose
1270073|NCT00887029|IOP
1270074|NCT00887029|dosing preference
1270075|NCT00887003|epidural
1270076|NCT00887003|volume
1270077|NCT00887003|dose
1270078|NCT00887003|pain relief
1270079|NCT00887003|steroid
1270080|NCT00886990|single- and double-boosted PI
1270081|NCT00886990|second line regimen
1270082|NCT00886990|NNRTI failure
1270083|NCT00886990|HIV-infected children
1270084|NCT00886990|Compare virological efficacy and safety of single- or double-boosted PI regimens as second line therapy in children with NNRTI-based treatment failure
1270085|NCT00886990|treatment experienced
1270086|NCT00886977|ALS
1270087|NCT00886964|HBV vaccine
1270088|NCT00886964|HIV children
1270089|NCT00886964|immune recovery
1270090|NCT00886964|HBV antibody
1270091|NCT00886964|Intradermal
1270092|NCT00886964|Intramuscular
1270093|NCT00886964|antibody response after HBV vaccine
1270094|NCT00886964|treatment experienced
1270095|NCT00886938|tinnitus
1270096|NCT00886925|Hepatic encephalopathy
1270097|NCT00886925|Cirrhosis
1270098|NCT00886925|Albumin
1270099|NCT00886912|mountain sickness
1270100|NCT00886899|CTO
1270101|NCT00886899|chronic total occlusion
1270102|NCT00886899|CAD
1270103|NCT00886899|coronary artery disease
1270104|NCT00886899|interventional cardiology
1270105|NCT00886899|revascularization
1270106|NCT00886899|recanalization
1270107|NCT00886886|MDMA
1270108|NCT00886886|norepinephrine
1270109|NCT00886886|Ecstasy
1270110|NCT00886886|stimulant
1270111|NCT00886873|Uterine fibroids
1270112|NCT00886873|Mifepristone
1270113|NCT00886873|Antiprogestins
1270114|NCT00886860|Efficacy
1270115|NCT00886860|Cervical ripening/Labor induction
1270116|NCT00886860|Titrated oral misoprostol/Conventional oral misoprostol
1270117|NCT00886860|Term pregnancy
1270118|NCT00886847|Lung
1270119|NCT00886847|Lymphadenopathy
1270120|NCT00886847|Enlarged hilar or/and mediastinal lymph adenopathy
1270121|NCT00886847|Benign
1270122|NCT00886847|Malignant
1270123|NCT00886847|Mediastinal lymph nodes
1270124|NCT00886847|Hilar lymph nodes
1270125|NCT00886847|Fine Needle Aspiration
1270126|NCT00886847|FNA
1270127|NCT00886847|Fine Needle Capillary Sampling
1270128|NCT00886847|FNC
1270129|NCT00886847|Endobronchial Ultrasound-Guided Biopsy
1270130|NCT00886847|EBUS
1270131|NCT00886847|Tissue Sample
1270132|NCT00886847|Suction
1270133|NCT00886834|IUD insertion
1270134|NCT00886834|Nulliparous women
1270135|NCT00886834|Contraception
1270136|NCT00886834|Family Planning
1270137|NCT00886834|IUD insertion in nulliparous women
1270138|NCT00886821|Phase 1 Type 2 diabetes CVX-096 diabetes mellitus
1270139|NCT00886821|adult-onset diabetes mellitus
1270140|NCT00886821|non-insulin dependent
1270141|NCT00886808|DME, Diabetic Retinopathy, Diabetic Macular Edema
1270142|NCT00886795|hives
1270143|NCT00886795|rash
1270144|NCT00886795|pruritis
1270145|NCT00886782|Advanced and/or Metastatic solid cancers
1270146|NCT00886769|Flare
1270147|NCT00886769|arthritis
1270148|NCT00886769|IL-1beta antagonist
1270149|NCT00886769|systemic juvenile idiopathic arthritis
1270150|NCT00886769|Juvenile Rheumatoid
1270151|NCT00886769|Systemic juvenile idiopathic arthritis with active flare
1270152|NCT00886756|Phase I
1270153|NCT00886756|Japanese healthy volunteer
1270154|NCT00886756|AZD8529
1270155|NCT00886730|Depressive disorder
1270156|NCT00886730|Primary care
1270157|NCT00886730|Internet
1270158|NCT00886730|Social support
1270159|NCT00886730|Feasibility
1270160|NCT00886717|stage IIIA ovarian epithelial cancer
1270161|NCT00886717|stage IIIB ovarian epithelial cancer
1270162|NCT00886717|stage IIIC ovarian epithelial cancer
1270163|NCT00886717|stage IV ovarian epithelial cancer
1270164|NCT00886717|stage IIIA ovarian germ cell tumor
1270165|NCT00886717|stage IIIB ovarian germ cell tumor
1270166|NCT00886717|stage IIIC ovarian germ cell tumor
1270167|NCT00886717|stage IV ovarian germ cell tumor
1270168|NCT00886704|Omega-3 fatty acids
1270169|NCT00886704|dietary supplementation
1270170|NCT00886704|atherosclerosis
1270171|NCT00886691|recurrent ovarian epithelial cancer
1270172|NCT00886691|recurrent fallopian tube cancer
1270173|NCT00886691|recurrent primary peritoneal cavity cancer
1270174|NCT00886678|Non-Small Cell Lung Cancer
1270175|NCT00886678|pemetrexed
1270176|NCT00886678|radiation
1270177|NCT00886665|Diabetic Neuropathy
1270178|NCT00886665|Nerve Conduction Studies
1270179|NCT00886665|Clinical Trial
1270180|NCT00886652|Scoliosis
1270181|NCT00886652|Muscle Strength
1270182|NCT00886652|Respiratory function tests
1270183|NCT00886652|Exercise therapy
1270184|NCT00886639|COPD III/IV
1270185|NCT00886639|Oxygen Supply
1270186|NCT00886639|Six-Minute-Walking-Test
1270187|NCT00886639|Oxygen Responder
1270188|NCT00886626|Obesity
1270189|NCT00886626|Impaired Glucose Tolerance
1270190|NCT00886626|Children
1270191|NCT00886587|eczema
1270192|NCT00886574|Cilostazol versus Aspirin
1270193|NCT00886574|Anti-PLT drug
1270194|NCT00886574|Primary Prevention of Atherosclerotic Events
1270195|NCT00886574|Type 2 DM
1270196|NCT00886574|Intima media thickness (IMT)
1270197|NCT00886561|HIV prevention, female sex workers
1270198|NCT00886561|HIV seronegativity
1270199|NCT00886535|breast cancer
1270200|NCT00886535|hot flashes
1270201|NCT00886535|tamoxifen
1270202|NCT00886522|Anti-thymocyte globulin Fresenius
1270203|NCT00886522|Busulfan
1270204|NCT00886522|Cord blood
1270205|NCT00886522|Cyclophosphamide
1270206|NCT00886522|Fludarabine
1270207|NCT00886522|Human Leucocyte Antigen
1270208|NCT00886522|Hematopoietic Stem Cell
1270209|NCT00886522|Hematopoietic Stem Cell Transplant
1270210|NCT00886522|Graft-versus-Host-Disease
1270211|NCT00886522|Graft-versus-Host-Disease prophylaxis
1270212|NCT00886522|Intrabone infusion
1270213|NCT00886522|Thiotepa
1270214|NCT00886509|Coronary Artery Disease
1270215|NCT00886509|Stable
1270216|NCT00886509|Coronary Collaterals
1270217|NCT00886509|Therapeutic Collateral Promotion (TCP)
1270218|NCT00886496|unspecified childhood solid tumor, protocol specific
1270219|NCT00886496|fever, sweats, and hot flashes
1270220|NCT00886496|neutropenia
1270221|NCT00886496|infection
1270222|NCT00886496|recurrent childhood small noncleaved cell lymphoma
1270223|NCT00886496|stage I and II childhood small noncleaved cell lymphoma
1270224|NCT00886496|stage I childhood small noncleaved cell lymphoma
1270225|NCT00886496|stage II childhood small noncleaved cell lymphoma
1270226|NCT00886496|stage III and IV childhood small noncleaved cell lymphoma
1270227|NCT00886496|stage III childhood small noncleaved cell lymphoma
1270228|NCT00886496|stage IV childhood small noncleaved cell lymphoma
1270229|NCT00886496|recurrent childhood lymphoblastic lymphoma
1270230|NCT00886496|stage I and II childhood lymphoblastic lymphoma
1270231|NCT00886496|stage I childhood lymphoblastic lymphoma
1270232|NCT00886496|stage II childhood lymphoblastic lymphoma
1270233|NCT00886496|stage III and IV childhood lymphoblastic lymphoma
1270234|NCT00886496|stage III childhood lymphoblastic lymphoma
1270235|NCT00886496|stage IV childhood lymphoblastic lymphoma
1270236|NCT00886496|childhood Burkitt lymphoma
1270237|NCT00886496|recurrent/refractory childhood Hodgkin lymphoma
1270238|NCT00886496|stage I childhood Hodgkin lymphoma
1270239|NCT00886496|stage II childhood Hodgkin lymphoma
1270240|NCT00886496|stage III childhood Hodgkin lymphoma
1270241|NCT00886496|stage IV childhood Hodgkin lymphoma
1270242|NCT00886496|childhood acute lymphoblastic leukemia in remission
1270243|NCT00886496|recurrent childhood acute lymphoblastic leukemia
1270244|NCT00886496|untreated childhood acute lymphoblastic leukemia
1270245|NCT00886496|de novo myelodysplastic syndromes
1270246|NCT00886496|previously treated myelodysplastic syndromes
1270247|NCT00886496|secondary myelodysplastic syndromes
1270248|NCT00886496|childhood acute myeloid leukemia in remission
1270249|NCT00886496|recurrent childhood acute myeloid leukemia
1270250|NCT00886496|untreated childhood acute myeloid leukemia and other myeloid malignancies
1270251|NCT00886496|childhood grade III lymphomatoid granulomatosis
1270252|NCT00886496|childhood nasal type extranodal NK/T-cell lymphoma
1270253|NCT00886496|recurrent childhood grade III lymphomatoid granulomatosis
1270254|NCT00886496|childhood diffuse large cell lymphoma
1270255|NCT00886496|childhood immunoblastic large cell lymphoma
1270256|NCT00886496|recurrent childhood large cell lymphoma
1270257|NCT00886496|stage I childhood large cell lymphoma
1270258|NCT00886496|stage II childhood large cell lymphoma
1270259|NCT00886496|stage III and IV childhood large cell lymphoma
1270260|NCT00886496|stage III childhood large cell lymphoma
1270261|NCT00886496|stage IV childhood large cell lymphoma
1270262|NCT00886483|Neurofeedback
1270263|NCT00886470|cytokines
1270264|NCT00886470|pain
1270265|NCT00886470|scarring
1270266|NCT00886470|vascularity
1270267|NCT00886457|Biopsy proven cancer, which is metastatic or unresectable
1270268|NCT00886431|IVF
1270269|NCT00886431|embryo cryopreservation
1270270|NCT00886431|vitrification
1270271|NCT00886431|slow cooling
1270272|NCT00886431|slow freezing
1270273|NCT00886431|surplus embryos
1270274|NCT00886431|Human Reproduction
1270275|NCT00886405|Nitroglycerin
1270276|NCT00886405|Locally advanced non small-cell lung cancer
1270277|NCT00886405|Vascular endothelial growth factor
1270278|NCT00886405|Hypoxia Inducible Factor
1270279|NCT00886405|Clinical stage IIIA and/or IIIB (without pleural effusion)
1270280|NCT00886392|Clinically Significant Macular Edema
1270281|NCT00886392|Diabetic Macular Edema
1270282|NCT00886392|Optical Coherence Tomography
1270283|NCT00886392|Diabetic Retinopathy
1270284|NCT00886392|Severity
1270285|NCT00886379|vitamin d
1270286|NCT00886379|children
1270287|NCT00886379|Mongolia
1270288|NCT00886366|Type II Diabetes
1270289|NCT00886353|RAS
1270290|NCT00886353|ACE2
1270291|NCT00886353|Cardiovascular
1270292|NCT00886353|Pulmonary
1270293|NCT00886353|Angiotensin II
1270294|NCT00886353|Angiotensin 1-7
1270295|NCT00886340|diabetes prevention, primary care
1270296|NCT00886327|Colonic capsule endoscopy
1270297|NCT00886327|Crohn's disease
1270298|NCT00886327|Capsule endoscopy
1270299|NCT00886314|children
1270300|NCT00886314|surgery
1270301|NCT00886314|anxiety
1270302|NCT00886301|overweight
1270303|NCT00886301|obesity
1270304|NCT00886301|steatohepatitis
1270305|NCT00886301|ectopic fat
1270306|NCT00886275|Postoperative sedation in intensive care
1270307|NCT00886262|liver transplantation
1270308|NCT00886262|vasopressin
1270309|NCT00886262|renal function
1270310|NCT00886262|hypotension
1270311|NCT00886262|creatinine
1270312|NCT00886262|urine output
1270313|NCT00886262|diuretics
1270314|NCT00886262|vasopressors
1270315|NCT00886262|hemodynamic stability
1270316|NCT00886249|Vision
1270317|NCT00886249|Eye
1270318|NCT00886249|Cataract
1270319|NCT00886236|Gastric Bypass
1270320|NCT00886236|Gabapentin
1270321|NCT00886236|Postoperative Nausea and Vomiting
1270322|NCT00886236|Analgesics, Opioids
1270323|NCT00886236|Sleep Apnea, Obstructive
1270324|NCT00886236|Respiratory Depression
1270325|NCT00886236|Oximetry
1270326|NCT00886223|vaginal vault prolapse repair
1270327|NCT00886223|robot-assisted laparoscopic sacropexy
1270328|NCT00886223|robot-assisted laparoscopic sacrocolpopexy
1270329|NCT00886223|robotic laparoscopic sacropexy
1270330|NCT00886210|drain
1270331|NCT00886210|laparoscopic cholecystectomy
1270332|NCT00886210|pneumoperitonum
1270333|NCT00886197|reflux
1270334|NCT00886197|GERD
1270335|NCT00886184|Hypothermia
1270336|NCT00886184|Cardiac arrest
1270337|NCT00886184|Biomarkers
1270338|NCT00886184|Pre hospital cardiac arrest
1270339|NCT00886171|social skills
1270340|NCT00886171|physical activity
1270341|NCT00886171|peer relationships
1270342|NCT00886171|childhood obesity
1270343|NCT00886171|changes in physical activity
1270344|NCT00886171|changes in social involvement
1270345|NCT00886158|Organ Transplants
1270346|NCT00886145|Spinal Cord Injuries
1270347|NCT00886145|Mechanical Stimulation
1270348|NCT00886145|Vibration Plate
1270349|NCT00886132|Phase 2 Study
1270350|NCT00886132|Sunitinib
1270351|NCT00886132|Recurrent
1270352|NCT00886132|Metastatic
1270353|NCT00886132|Adenoid Cystic Carcinoma
1270354|NCT00886132|Salivary Glands
1270355|NCT00886132|Metastasis
1270356|NCT00886106|Capsaicin
1270357|NCT00886106|Remifentanil
1270358|NCT00886106|Hyperalgesia
1270359|NCT00886093|pharmacokinetics, single dose, crossover, fed vs fasted state
1270360|NCT00886080|Atrial fibrillation
1270361|NCT00886080|Health related Quality of Life
1270362|NCT00886080|Add-on surgery
1270363|NCT00886080|Ablation
1270364|NCT00886080|Randomised controlled trial
1270365|NCT00886080|SF-36
1270366|NCT00886080|EuroQoL
1270367|NCT00886080|MFI-20
1270368|NCT00886067|AZD1446
1270369|NCT00886067|PET examination
1270370|NCT00886054|Transcranial Doppler
1270371|NCT00886054|Transcranial color-coded duplex sonography
1270372|NCT00886054|Neurocritical patients
1270373|NCT00886041|laparoscopy
1270374|NCT00886041|unexplained infertility
1270375|NCT00886028|Malignant pleural mesothelioma
1270376|NCT00886028|Liposomal doxorubicin
1270377|NCT00886028|Progression free survival
1270378|NCT00886028|Patients who received LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles
1270379|NCT00886028|Patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM
1270380|NCT00886015|Trachoma
1270381|NCT00886015|trichiasis
1270382|NCT00886015|bilamellar tarsal rotation procedure
1270383|NCT00886002|Healthy volunteers
1270384|NCT00885989|SLV338
1270385|NCT00885989|phase I
1270386|NCT00885989|healthy volunteers
1270387|NCT00885950|colorectal liver metastases
1270388|NCT00885950|neoadjuvant chemotherapy
1270389|NCT00885950|oxaliplatin
1270390|NCT00885950|sinusoidal obstruction syndrome
1270391|NCT00885950|anticoagulants
1270392|NCT00885937|Dexpanthenol
1270393|NCT00885937|Safety,
1270394|NCT00885937|New formulation
1270395|NCT00885937|Topical administration
1270396|NCT00885924|postoperative Hemorrhage
1270397|NCT00885924|Hemorrhage
1270398|NCT00885924|Vasopressin
1270399|NCT00885924|Blood Loss, Surgical
1270400|NCT00885911|Intubating laryngeal airway
1270401|NCT00885911|pediatric
1270402|NCT00885911|observational study
1270403|NCT00885898|Respiratory Insufficiency
1270404|NCT00885898|Respiratory Failure
1270405|NCT00885885|Colorectal Cancer
1270406|NCT00885885|Panitumumab
1270407|NCT00885885|FOLFOX-4
1270408|NCT00885885|FOLFIRI
1270409|NCT00885846|Qigong
1270410|NCT00885846|Breathing management
1270411|NCT00885846|Glucose
1270412|NCT00885833|Wiskott-Aldrich syndrome
1270413|NCT00885833|HSCT
1270414|NCT00885820|Kidney Transplantation
1270415|NCT00885820|Tacrolimus
1270416|NCT00885820|Immunosuppression
1270417|NCT00885820|Graft Survival
1270418|NCT00885807|ADHD
1270419|NCT00885807|WFIRS
1270420|NCT00885807|WSR
1270421|NCT00885794|Clinically Significant Diabetic Macular Edema
1270422|NCT00885794|Focal Laser
1270423|NCT00885794|GRID-Laser
1270424|NCT00885794|Ranibizumab
1270425|NCT00885794|Lucentis
1270426|NCT00885794|Microperimetry
1270427|NCT00885794|High-Definition OCT
1270428|NCT00885794|Randomized
1270429|NCT00885794|Observer-Blinded
1270430|NCT00885794|Ineffective Treatment with Focal Laser or GRID-Laser
1270431|NCT00885768|RAS(renal Artery Stenosis)
1270432|NCT00885768|Atherosclerosis
1270433|NCT00885768|angiography
1270434|NCT00885742|Hereditary Factor XIII deficiency
1270435|NCT00885742|Factor XIII
1270436|NCT00885729|Cartilage defect
1270437|NCT00885729|chondrocytes
1270438|NCT00885729|mesenchymal stem cells (MSC)
1270439|NCT00885729|femoral condyle
1270440|NCT00885729|knee
1270441|NCT00885703|CM
1270442|NCT00885703|HIV
1270443|NCT00885703|Meningitis
1270444|NCT00885690|Schizophrenia
1270445|NCT00885690|Antipsychotic
1270446|NCT00885690|Cognition
1270447|NCT00885664|HIV
1270448|NCT00885664|immune reconstitution
1270449|NCT00885664|treatment naive
1270450|NCT00885651|SNP
1270451|NCT00885651|catecholamines
1270452|NCT00885651|metoprolole
1270453|NCT00885651|healthy subjects
1270454|NCT00885651|physiological stress
1270455|NCT00885638|GLP-1
1270456|NCT00885638|Insulin secretion
1270457|NCT00885638|Macronutrients
1270458|NCT00885625|invasive pneumococcal disease
1270459|NCT00885625|pneumococcal conjugated vaccine
1270460|NCT00885612|CHD-Risk
1270461|NCT00885612|Breast Cancer
1270462|NCT00885612|Aromatase Inhibitors
1270463|NCT00885612|postmenopausal early breast cancer
1270464|NCT00885599|gingivitis
1270465|NCT00885599|natural remedy
1270466|NCT00885599|inflammation
1270467|NCT00885599|C-reactive protein
1270468|NCT00885599|mouthwash
1270469|NCT00885586|herpes zoster
1270470|NCT00885586|neuropathic pain
1270471|NCT00885586|acupuncture
1270472|NCT00885586|randomised controlled trial
1270473|NCT00885586|acute herpes zoster
1270474|NCT00885573|sleep apnea
1270475|NCT00885573|pharyngeal sensitivity
1270476|NCT00885573|pharyngeal dilator reflex
1270477|NCT00885573|diagnosis algorithm
1270478|NCT00885573|patients with suspected sleep apnea syndrome
1270479|NCT00885560|ADHD
1270480|NCT00885560|SNAP 25
1270481|NCT00885560|amphetamine
1270482|NCT00885560|methylphenidate
1270483|NCT00885534|skin cancer
1270484|NCT00885534|CISPLATIN
1270485|NCT00885534|TEMOZOLOMIDE
1270486|NCT00885534|VINBLASTINE
1270487|NCT00885534|09-017
1270488|NCT00885508|MDS
1270489|NCT00885508|AML
1270490|NCT00885508|deletion 5q
1270491|NCT00885508|Documented diagnosis of MDS, or CMML
1270492|NCT00885508|with WBC < 13,000/mm3 that meets IPSS criteria for intermediate-2
1270493|NCT00885508|or high-risk disease, or AML with an associated del 5q[31]
1270494|NCT00885508|(the deleted chromosomal region must include 5q[31]),
1270495|NCT00885508|with or without additional cytogenetic abnormalities
1270496|NCT00885495|HIV
1270497|NCT00885495|dyslipidemia
1270498|NCT00885495|statins
1270499|NCT00885495|protease inhibitors
1270500|NCT00885482|HIV/AIDS
1270501|NCT00885482|HAART
1270502|NCT00885482|Simplification
1270503|NCT00885482|Atazanavir
1270504|NCT00885482|Lamivudine
1270505|NCT00885482|treatment experienced
1270506|NCT00885469|known Barrett's Esophagus
1270507|NCT00885469|Suspected Barrett's Esophagus
1270508|NCT00885469|chronic GERD
1270509|NCT00885469|known Barrett's Esophagus or chronic GERD
1270510|NCT00885456|stroke
1270511|NCT00885456|secondary prevention
1270512|NCT00885456|vascular risk
1270513|NCT00885456|behavioral change
1270514|NCT00885456|exercise
1270515|NCT00885456|lifestyle modification
1270516|NCT00885443|propofol
1270517|NCT00885443|sevoflurane
1270518|NCT00885443|pediatric
1270519|NCT00885443|emergence delirium
1270520|NCT00885443|Induction of sedation
1270521|NCT00885430|colonoscopy
1270522|NCT00885430|preparation
1270523|NCT00885417|Helicobacter pylori
1270524|NCT00885417|sequential therapy
1270525|NCT00885417|levofloxacin
1270526|NCT00885417|clarithromycin
1270527|NCT00885417|rescue
1270528|NCT00885417|salvage
1270529|NCT00885417|treatment failure
1270530|NCT00885417|For those who fail from one standard eradication therapy for H. pylori infection
1270531|NCT00885404|chloride
1270532|NCT00885404|acidosis
1270533|NCT00885391|Atrial Fibrillation
1270534|NCT00885391|Cardioversion
1270535|NCT00885391|Direct Current Cardioversion
1270536|NCT00885391|QT Interval
1270537|NCT00885365|cystic fibrosis
1270538|NCT00885365|P. aeruginosa
1270539|NCT00885365|tobramycin
1270540|NCT00885339|Colonic Diseases
1270541|NCT00885326|recurrent neuroblastoma
1270542|NCT00885313|NAFLD
1270543|NCT00885313|NASH
1270544|NCT00885313|fibrosis
1270545|NCT00885287|uncomplicated malaria
1270546|NCT00885287|HIV/AIDS
1270547|NCT00885287|drug interactions
1270548|NCT00885287|antimalarial drug efficacy
1270549|NCT00885287|antiretrovirals
1270550|NCT00885287|pharmacovigilance
1270551|NCT00885287|Tanzania
1270552|NCT00885261|chronic pain and metabolic syndrome
1270553|NCT00885248|pancreatic cancer
1270554|NCT00885248|integrated PET-CT
1270555|NCT00885235|Bowel Diseases
1270556|NCT00885222|Parkinson's disease
1270557|NCT00885222|Major depressive disorder
1270558|NCT00885222|Deep brain stimulation
1270559|NCT00885209|Colonic Diseases
1270560|NCT00885196|Psoriasis
1270561|NCT00885196|plaque psoriasis
1270562|NCT00885196|inflammatory skin disease
1270563|NCT00885196|scaly patches
1270564|NCT00885196|AEB071
1270565|NCT00885183|breast cancer
1270566|NCT00885183|chemotherapy
1270567|NCT00885183|adjuvant therapy
1270568|NCT00885183|acupuncture
1270569|NCT00885183|fatigue
1270570|NCT00885183|Early stage breast cancer patients
1270571|NCT00885157|Poliomyelitis
1270572|NCT00885157|intradermal
1270573|NCT00885144|Stunting
1270574|NCT00885144|Growth failure
1270575|NCT00885144|Malnutrition
1270576|NCT00885144|Lipid based nutrient supplement
1270577|NCT00885144|LNS
1270578|NCT00885144|Prevention
1270579|NCT00885144|Malawi
1270580|NCT00885144|Sub-Saharan Africa
1270581|NCT00885144|Dietary supplementation
1270582|NCT00885131|Reward Processing
1270583|NCT00885131|Motor Cortex
1270584|NCT00885131|HV
1270585|NCT00885131|Healthy Volunteer
1270586|NCT00885105|Fluzone® vaccine
1270587|NCT00885105|Influenza
1270588|NCT00885092|Contact lenses
1270589|NCT00885092|Disinfecting solutions
1270590|NCT00885066|stage III pancreatic cancer
1270591|NCT00885066|stage IV pancreatic cancer
1270592|NCT00885066|adenocarcinoma of the pancreas
1270593|NCT00885066|recurrent pancreatic cancer
1270594|NCT00885053|Inflammation
1270595|NCT00885053|Fatty acids, Omega 3
1270596|NCT00885053|Leukotrienes
1270597|NCT00885053|Adiponectin
1270598|NCT00885053|Adipose tissue
1270599|NCT00885053|RNA, Messenger
1270600|NCT00885040|Neurofeedback
1270601|NCT00885040|Tourette Syndrome
1270602|NCT00885040|Healthy Volunteer
1270603|NCT00885040|Movement Disorder
1270604|NCT00885040|Brain Activity
1270605|NCT00885040|fMRI
1270606|NCT00885040|HV
1270607|NCT00885014|Depressive disorder
1270608|NCT00885014|Behavior therapy
1270609|NCT00885014|Workplace
1270610|NCT00885014|Subthreshold depression
1270611|NCT00884988|ankle fracture
1270612|NCT00884988|edema
1270613|NCT00884988|surgical repair
1270614|NCT00884988|homeopathy
1270615|NCT00884988|lymphomyosot
1270616|NCT00884975|Chronic obstructive pulmonary disease
1270617|NCT00884975|exacerbations
1270618|NCT00884975|quality of life
1270619|NCT00884975|emphysema
1270620|NCT00884962|emphysema
1270621|NCT00884962|aeris
1270622|NCT00884962|PLVR
1270623|NCT00884962|BLVR
1270624|NCT00884962|germany
1270625|NCT00884962|treatment
1270626|NCT00884962|device
1270627|NCT00884962|breathing
1270628|NCT00884949|Mucopolysaccharidosis IV type A
1270629|NCT00884949|MPS IV Type A
1270630|NCT00884949|Mucopolysaccharidosis IVA
1270631|NCT00884949|MPS IVA
1270632|NCT00884949|Morquio A Syndrome
1270633|NCT00884949|Lysosomal Storage Disorder
1270634|NCT00884949|LSD
1270635|NCT00884949|N-acetylgalactosamine-6-sulfatase
1270636|NCT00884949|N-acetylgalactosamine-6-sulfate sulfatase
1270637|NCT00884949|galactose-6-sulfatase
1270638|NCT00884949|GALNS
1270639|NCT00884949|enzyme replacement therapy
1270640|NCT00884949|ERT
1270641|NCT00884936|Skin
1270642|NCT00884936|Aging
1270643|NCT00884936|Dermogenomics
1270644|NCT00884936|Genetic
1270645|NCT00884936|Biomarker
1270646|NCT00884936|Dermatology
1270647|NCT00884910|laryngectomy
1270648|NCT00884910|Provox Vega
1270649|NCT00884910|voice prosthesis
1270650|NCT00884897|Social Cognition
1270651|NCT00884897|Schizophrenia
1270652|NCT00884897|Oxytocin
1270653|NCT00884884|Alcohol dependence
1270654|NCT00884884|alcohol abuse
1270655|NCT00884884|topiramate
1270656|NCT00884884|aripiprazole
1270657|NCT00884871|pelvic floor disorders
1270658|NCT00884871|weight loss
1270659|NCT00884858|HIV-1
1270660|NCT00884858|CD4
1270661|NCT00884858|INR
1270662|NCT00884858|HIV-1 infection
1270663|NCT00884858|extreme immunological compromission
1270664|NCT00884858|treatment experienced
1270665|NCT00884845|PM2734
1270666|NCT00884845|Tumors
1270667|NCT00884845|PharmaMar
1270668|NCT00884845|Erlotinib
1270669|NCT00884845|Tarceva
1270670|NCT00884832|fecal incontinence
1270671|NCT00884832|stool leakage
1270672|NCT00884832|incontinence
1270673|NCT00884832|FI
1270674|NCT00884832|Urge predominant fecal incontinence
1270675|NCT00884819|polycystic ovary syndrome
1270676|NCT00884819|hepatic adiposity
1270677|NCT00884819|diabetes
1270678|NCT00884819|hormones
1270679|NCT00884819|cardiovascular disease
1270680|NCT00884806|Contact lenses
1270681|NCT00884806|Disinfecting solutions
1270682|NCT00884793|HIV
1270683|NCT00884793|persistence
1270684|NCT00884793|reservoirs
1270685|NCT00884793|residual replication
1270686|NCT00884793|gut
1270687|NCT00884793|gut-associated lymphoid tissue
1270688|NCT00884793|treatment experienced
1270689|NCT00884780|Electronic Diary
1270690|NCT00884780|Body Map
1270691|NCT00884780|Electronic Measure of Pediatric Pain
1270692|NCT00884767|neurotoxicity
1270693|NCT00884767|chemotherapeutic agent toxicity
1270694|NCT00884767|recurrent colon cancer
1270695|NCT00884767|stage I colon cancer
1270696|NCT00884767|stage II colon cancer
1270697|NCT00884767|stage III colon cancer
1270698|NCT00884767|stage IV colon cancer
1270699|NCT00884767|recurrent rectal cancer
1270700|NCT00884767|stage I rectal cancer
1270701|NCT00884767|stage II rectal cancer
1270702|NCT00884767|stage III rectal cancer
1270703|NCT00884767|stage IV rectal cancer
1270704|NCT00884728|Scabies
1270705|NCT00884728|Impetigo
1270706|NCT00884728|Pyoderma
1270707|NCT00884728|Streptococcal infections
1270708|NCT00884702|Sleep
1270709|NCT00884702|14C-Leucine
1270710|NCT00884702|Cerebral Protein Synthesis
1270711|NCT00884702|Memory
1270712|NCT00884702|Positron Emission Tomography (PET)
1270713|NCT00884702|HV
1270714|NCT00884702|Healthy Volunteer
1270715|NCT00884689|Symbicort SMART
1270716|NCT00884689|Free Combination GCS/LABA treatment
1270717|NCT00884676|unspecified adult solid tumor, protocol specific
1270718|NCT00884650|Pain
1270719|NCT00884650|Pain management
1270720|NCT00884650|Cerebral Palsy
1270721|NCT00884637|HMP
1270722|NCT00884637|CNV
1270723|NCT00884637|AMD
1270724|NCT00884637|PHP
1270725|NCT00884637|HPHP
1270726|NCT00884637|foresee home
1270727|NCT00884624|Bowel Diseases
1270728|NCT00884598|adult tumors metastatic to brain
1270729|NCT00884598|extensive stage small cell lung cancer
1270730|NCT00884598|stage IV non-small cell lung cancer
1270731|NCT00884559|Leadership
1270732|NCT00884559|Team building
1270733|NCT00884559|Resuscitation
1270734|NCT00884533|QTc
1270735|NCT00884533|pharmacokinetics
1270736|NCT00884533|rosiglitazone XR
1270737|NCT00884533|cardiac conduction
1270738|NCT00884533|healthy volunteers
1270739|NCT00884520|[F-18]VM4-037
1270740|NCT00884520|VM4-037
1270741|NCT00884520|hypoxia
1270742|NCT00884520|CA-IX
1270743|NCT00884520|CAIX
1270744|NCT00884520|carbonic anhydrase IX
1270745|NCT00884520|hypoxia marker
1270746|NCT00884520|lung cancer
1270747|NCT00884520|renal carcinoma
1270748|NCT00884520|squamous cell carcinoma
1270749|NCT00884520|hepatic carcinoma
1270750|NCT00884520|head and neck cancer
1270751|NCT00884520|advanced stage lung cancer
1270752|NCT00884520|exploratory
1270753|NCT00884494|Obesity
1270754|NCT00884494|Insulin resistance
1270755|NCT00884494|Ghrelin
1270756|NCT00884468|Anxiety and depression in patients with psoriatic arthritis
1270757|NCT00884455|tissue banking, research
1270758|NCT00884442|Healthy
1270759|NCT00884442|Bioavailability
1270760|NCT00884442|Nifedipine
1270761|NCT00884429|Chest physiotherapy
1270762|NCT00884416|high grade glioma
1270763|NCT00884416|glioblastoma
1270764|NCT00884416|gliosarcoma
1270765|NCT00884416|anaplastic astrocytoma
1270766|NCT00884416|anaplastic oligoastrocytoma
1270767|NCT00884416|anaplastic oligodendroglioma
1270768|NCT00884416|phase I
1270769|NCT00884416|first line treatment
1270770|NCT00884416|sorafenib
1270771|NCT00884416|temozolomide
1270772|NCT00884416|radiation therapy
1270773|NCT00884416|safety
1270774|NCT00884416|tolerability
1270775|NCT00884416|protein kinase inhibitors
1270776|NCT00884403|abortion
1270777|NCT00884403|pregnancy dating
1270778|NCT00884403|gestational age
1270779|NCT00884403|ultrasound
1270780|NCT00884390|Hemophilia A
1270781|NCT00884364|Lymphoma
1270782|NCT00884364|Leukemia
1270783|NCT00884364|Multiple myeloma
1270784|NCT00884364|Hodgkin´s disease
1270785|NCT00884364|Exercise
1270786|NCT00884364|Sport
1270787|NCT00884364|Fatigue
1270788|NCT00884364|Hematological neoplastic diseases
1270789|NCT00884351|Epilepsy
1270790|NCT00884351|MEG
1270791|NCT00884351|Seizures
1270792|NCT00884338|Fatigue
1270793|NCT00884338|Cancer
1270794|NCT00884338|Cognitive impairment
1270795|NCT00884338|Exercise
1270796|NCT00884338|Sport
1270797|NCT00884338|Peripheral blood stem cell transplantation
1270798|NCT00884338|High-dose chemotherapy
1270799|NCT00884325|Itching
1270800|NCT00884325|Atopic Dermatitis
1270801|NCT00884312|Multiple myeloma
1270802|NCT00884312|proteasome
1270803|NCT00884312|Hematological
1270804|NCT00884312|carfilzomib
1270805|NCT00884312|PR-171
1270806|NCT00884299|Lung function
1270807|NCT00884299|Chronic obstructive pulmonary disease
1270808|NCT00884299|Antioxidants
1270809|NCT00884286|Aplidin
1270810|NCT00884286|Aggressive Non Hodgkin Lymphoma
1270811|NCT00884286|Leukemia-Lymphoma, Adult T-Cell and B-cell
1270812|NCT00884260|Contraception
1270813|NCT00884260|Intrauterine contraception system
1270814|NCT00884247|GERD
1270815|NCT00884247|Quality of life
1270816|NCT00884247|Structured treatment
1270817|NCT00884234|Lateral Canthal Lines
1270818|NCT00884234|Crow's Feet
1270819|NCT00884234|Facial Wrinkles
1270820|NCT00884234|Lateral Canthal Area
1270821|NCT00884195|Obesity
1270822|NCT00884182|Influenza
1270823|NCT00884182|Orthomyxoviruses
1270824|NCT00884182|Split Virion Pandemic Influenza Vaccine
1270825|NCT00884182|A/H5N1
1270826|NCT00884143|tamoxifen
1270827|NCT00884143|arimidex
1270828|NCT00884143|adjuvant hormonal therapies
1270829|NCT00884143|breast cancer
1270830|NCT00884143|post-menopausal
1270831|NCT00884143|Adjuvant hormonal therapy in patients post menopausal with breast cancer
1270832|NCT00884130|Laparoscopy
1270833|NCT00884130|Colorectal surgery
1270834|NCT00884130|Quality of life
1270835|NCT00884130|economic analysis
1270836|NCT00884130|Patients undergoing laparoscopic colorectal surgery
1270837|NCT00884104|Solifenacin
1270838|NCT00884104|Tamsulosin
1270839|NCT00884104|OAB
1270840|NCT00884091|Chinese
1270841|NCT00884091|Glucagon-like peptide 1
1270842|NCT00884091|Glucagon
1270843|NCT00884091|Insulin
1270844|NCT00884091|Mixed meals
1270845|NCT00884091|Healthy Adults
1270846|NCT00884078|Self harm in south asian women
1270847|NCT00884078|depression
1270848|NCT00884078|suicidal ideations
1270849|NCT00884078|problem solving training
1270850|NCT00884065|Physiotherapy
1270851|NCT00884065|Manual therapy
1270852|NCT00884065|Painful Shoulder
1270853|NCT00884065|Diacutaneous Fibrolysis
1270854|NCT00884052|Neonatal seizures
1270855|NCT00884039|cornea
1270856|NCT00884039|transplant
1270857|NCT00884039|intraocular pressure
1270858|NCT00884039|steroid response
1270859|NCT00884026|Cesarean delivery
1270860|NCT00884026|hypotension
1270861|NCT00884026|Augmentation Index
1270862|NCT00884026|Pulse Wave analysis
1270863|NCT00884026|spinal anesthesia
1270864|NCT00884026|Hypotension following spinal anesthesia for cesarean delivery
1270865|NCT00884013|Pay for Quality
1270866|NCT00884013|Provider
1270867|NCT00884013|Clinical Decision Support
1270868|NCT00884013|Quality Reporting
1270869|NCT00884013|Quality Measurement
1270870|NCT00883974|preterm bith
1270871|NCT00883974|neurodevelopment
1270872|NCT00883974|sensitivity training
1270873|NCT00883974|magnetic resonance imaging (MRI)
1270874|NCT00883974|Infant neurodevelopment following preterm birth
1270875|NCT00883961|High-dose chemotherapy
1270876|NCT00883961|Hematological neoplasties
1270877|NCT00883961|Fatigue
1270878|NCT00883961|Cancer
1270879|NCT00883961|Exercise
1270880|NCT00883961|Sport
1270881|NCT00883961|Hematologic neoplastic disorders
1270882|NCT00883948|Acute Lung Injury
1270883|NCT00883948|Acute Respiratory Distress Syndrome
1270884|NCT00883948|Feeding
1270885|NCT00883948|Critical Care
1270886|NCT00883948|Ventilator
1270887|NCT00883935|GSK1349572
1270888|NCT00883935|Atazanavir
1270889|NCT00883935|Ritonavir
1270890|NCT00883935|Reyataz
1270891|NCT00883935|Norvir
1270892|NCT00883935|healthy
1270893|NCT00883935|pharmacokinetic
1270894|NCT00883909|Prostate Cancer
1270895|NCT00883909|Benign Prostatic Hyperplasia
1270896|NCT00883896|Rheumatoid Arthritis
1270897|NCT00883896|ACR
1270898|NCT00883896|Methotrexate
1270899|NCT00883896|Interleukin-22
1270900|NCT00883883|Antibiotic
1270901|NCT00883870|mesenchymal stem cells
1270902|NCT00883870|critical limb ischemia
1270903|NCT00883844|Hepatitis B
1270904|NCT00883844|sustained response
1270905|NCT00883844|peginterferon
1270906|NCT00883844|nucleos(t)ide analogues
1270907|NCT00883831|Acupuncture
1270908|NCT00883831|Hemodialysis
1270909|NCT00883831|Symptom
1270910|NCT00883831|end stage renal disease
1270911|NCT00883831|chronic kidney disease
1270912|NCT00883831|supportive care
1270913|NCT00883818|Overactive bladder
1270914|NCT00883818|Mycoplasma
1270915|NCT00883805|Metal Ion Concentration
1270916|NCT00883805|Osteolysis
1270917|NCT00883766|Polycystic Ovary Syndrome
1270918|NCT00883766|GnRH Antagonist
1270919|NCT00883766|Long Agonist Protocol
1270920|NCT00883766|OHSS
1270921|NCT00883740|Fibromyalgia sleep maintenance disturbance pregabalin
1270922|NCT00883727|mesenchymal stem cells
1270923|NCT00883727|myocardial infarction
1270924|NCT00883714|Exercise
1270925|NCT00883714|sport
1270926|NCT00883714|Allogeneic blood stem cell transplantation
1270927|NCT00883714|Blood stem cell transplantation
1270928|NCT00883714|Fatigue
1270929|NCT00883714|Cancer
1270930|NCT00883714|Physical performance
1270931|NCT00883714|Mood
1270932|NCT00883714|Complications
1270933|NCT00883701|Chronic Obstructive Pulmonary Disease
1270934|NCT00883701|exacerbations
1270935|NCT00883701|perforin
1270936|NCT00883701|granzymes
1270937|NCT00883688|Brain Tumor
1270938|NCT00883688|Recurrent Ependymoma
1270939|NCT00883688|Refractory Ependymoma
1270940|NCT00883688|Intracranial ependymoma
1270941|NCT00883688|Ependymoblastoma
1270942|NCT00883688|Subependymoma
1270943|NCT00883688|Myxopapillary
1270944|NCT00883688|Clear cell
1270945|NCT00883688|Anaplastic
1270946|NCT00883688|Bevacizumab
1270947|NCT00883688|Avastin
1270948|NCT00883688|Anti-VEGF Monoclonal Antibody
1270949|NCT00883688|rhuMAb-VEGF
1270950|NCT00883688|Lapatinib
1270951|NCT00883688|Tykerb
1270952|NCT00883688|GW572016
1270953|NCT00883675|Lung cancer
1270954|NCT00883675|Adjuvant therapy
1270955|NCT00883649|Keratoconjunctivitis Sicca
1270956|NCT00883649|Dry Eyes
1270957|NCT00883649|Post-menopausal
1270958|NCT00883636|Podocyte Protein
1270959|NCT00883636|Podocyte Mutation
1270960|NCT00883623|AL-Amyloidosis
1270961|NCT00883623|Lenalidomide
1270962|NCT00883610|QT Interval
1270963|NCT00883610|Dual Chamber Pacemaker
1270964|NCT00883610|Atrial Fibrillation
1270965|NCT00883584|Proof of Concept
1270966|NCT00883584|Inflammatory Markers
1270967|NCT00883584|Lung Function
1270968|NCT00883584|Chronic Obstructive Pulmonary Disease
1270969|NCT00883584|COPD
1270970|NCT00883571|anal stenosis
1270971|NCT00883571|flaps
1270972|NCT00883571|anoplasty
1270973|NCT00883558|recombinant human hyaluronidase (rHuPH20)
1270974|NCT00883558|Insulin lispro
1270975|NCT00883558|regular human insulin
1270976|NCT00883545|Adherence to screening colonoscopy in women
1270977|NCT00883532|Preterm infant
1270978|NCT00883532|Respiratory distress syndrome
1270979|NCT00883532|chronic lung disease
1270980|NCT00883532|budesonide
1270981|NCT00883532|surfactant
1270982|NCT00883493|Acute bipolar depression
1270983|NCT00883493|Lithium carbonate
1270984|NCT00883493|quetiapine fumarate
1270985|NCT00883493|MADRS
1270986|NCT00883480|NSCLC
1270987|NCT00883467|Ischemic Preconditioning
1270988|NCT00883467|functional MRI
1270989|NCT00883467|BOLD
1270990|NCT00883467|Reperfusion
1270991|NCT00883454|hepatocellular carcinoma
1270992|NCT00883454|liver tumor
1270993|NCT00883454|cirrhosis
1270994|NCT00883454|liver resection
1270995|NCT00883454|tumor staging
1270996|NCT00883454|liver disease staging
1270997|NCT00883441|IMPLEMENTATION RESEARCH
1270998|NCT00883441|AEDES
1270999|NCT00883441|VECTOR CONTROL
1271000|NCT00883428|low back pain
1271001|NCT00883428|pelvic pain
1271002|NCT00883428|pregnancy
1271003|NCT00883415|metabolism
1271004|NCT00883415|myocardium
1271005|NCT00883415|chronic kidney disease
1271006|NCT00883402|Carotid stenosis
1271007|NCT00883402|CEA
1271008|NCT00883402|CAS
1271009|NCT00883402|Stenting
1271010|NCT00883389|patient safety
1271011|NCT00883389|chronic kidney disease
1271012|NCT00883389|med-alert
1271013|NCT00883376|Classification of Stanford for Snoring
1271014|NCT00883376|OSAS
1271015|NCT00883376|Apnea-Hipopnea Index
1271016|NCT00883363|precondition
1271017|NCT00883363|ruptured abdominal aortic aneurysm
1271018|NCT00883363|myocardial infarction
1271019|NCT00883350|Body weight changes
1271020|NCT00883350|Overweight
1271021|NCT00883350|Obesity
1271022|NCT00883337|Relapsing-remitting multiple sclerosis
1271023|NCT00883324|fFN
1271024|NCT00883324|fetal fibronectin
1271025|NCT00883324|non-speculum
1271026|NCT00883324|risk of preterm delivery
1271027|NCT00883311|Efficacy
1271028|NCT00883298|temozolomide
1271029|NCT00883298|bevacizumab
1271030|NCT00883298|Temodar
1271031|NCT00883298|Avastin
1271032|NCT00883298|glioblastoma multiforme
1271033|NCT00883298|gliosarcoma
1271034|NCT00883298|glioma
1271035|NCT00883298|GBM
1271036|NCT00883298|brain tumor
1271037|NCT00883272|Menopause
1271038|NCT00883272|Thrombophilia
1271039|NCT00883272|factor V Leiden
1271040|NCT00883272|Estrogen Replacement Therapy
1271041|NCT00883272|Hypercoagulability
1271042|NCT00883272|Venous Thrombosis
1271043|NCT00883259|High-risk patients
1271044|NCT00883259|Metformin
1271045|NCT00883259|PCOS
1271046|NCT00883259|Pregnancy complications
1271047|NCT00883259|Previous gestational DM
1271048|NCT00883246|PAD
1271049|NCT00883233|Acne
1271050|NCT00883220|self management
1271051|NCT00883220|chronic condition
1271052|NCT00883220|urinary catheter
1271053|NCT00883207|Depression
1271054|NCT00883207|family therapy
1271055|NCT00883207|dialogical processes
1271056|NCT00883207|Developing couple therapy for depression
1271057|NCT00883194|Experimental Pain Model
1271058|NCT00883155|Antidepressant
1271059|NCT00883142|Lokomat
1271060|NCT00883142|Suspended walking
1271061|NCT00883142|Body Weight Supported
1271062|NCT00883142|Treadmill Training
1271063|NCT00883129|Systemic Sclerosis
1271064|NCT00883129|Mycophenolate Mofetil
1271065|NCT00883129|Cyclophosphamide
1271066|NCT00883129|High Resolution Computerized Tomography
1271067|NCT00883129|Pulmonary Function
1271068|NCT00883129|Dyspnea
1271069|NCT00883129|Health Related Quality of Life
1271070|NCT00883103|female urethral catheterization
1271071|NCT00883103|Lidocaine
1271072|NCT00883103|lubricant
1271073|NCT00883103|Q-tip test
1271074|NCT00883103|Q tip test
1271075|NCT00883103|K-Y jelly
1271076|NCT00883103|pain perception
1271077|NCT00883103|straight catheterization
1271078|NCT00883090|Factor XIII
1271079|NCT00883077|permeability
1271080|NCT00883077|inflammatory bowel disease
1271081|NCT00883077|confocal laser endomicroscopy
1271082|NCT00883077|irritable bowel syndrome
1271083|NCT00883051|COL-144
1271084|NCT00883051|acute treatment
1271085|NCT00883051|migraine
1271086|NCT00883038|insulin resistance
1271087|NCT00883038|vegetarian diet
1271088|NCT00883025|Friedman Classification
1271089|NCT00883025|Apnea-Hypopnea Index
1271090|NCT00883025|Obstructive Sleep Apnea Syndrome
1271091|NCT00883012|Viral-confirmed
1271092|NCT00882999|Relapsing
1271093|NCT00882999|Remitting
1271094|NCT00882999|Multiple Sclerosis
1271095|NCT00882999|Multiple
1271096|NCT00882999|Sclerosis
1271097|NCT00882999|MS
1271098|NCT00882999|LY2127399
1271099|NCT00882986|insulin resistance
1271100|NCT00882960|pre-hospital
1271101|NCT00882960|intra-nasal fentanyl
1271102|NCT00882960|patients requiring analgesia
1271103|NCT00882947|Primary Pulmonary Hypertension (PPH)
1271104|NCT00882934|Placebo
1271105|NCT00882934|Placebo Effect
1271106|NCT00882934|Sexual Dysfunction
1271107|NCT00882934|Erectile Dysfunction
1271108|NCT00882934|Clinical Trial
1271109|NCT00882921|Hunter syndrome
1271110|NCT00882921|hunters syndrome
1271111|NCT00882921|hunter's syndrome
1271112|NCT00882921|hunter disease
1271113|NCT00882921|hunters disease
1271114|NCT00882921|hunter's disease
1271115|NCT00882921|MPS II
1271116|NCT00882921|MPSII
1271117|NCT00882921|MPS2
1271118|NCT00882921|MPS 2
1271119|NCT00882921|mucopolysaccharides
1271120|NCT00882921|lysosomal storage disease
1271121|NCT00882921|lysosomal storage disorder
1271122|NCT00882921|chronic ear infection
1271123|NCT00882921|enlarged adenoids
1271124|NCT00882921|mps symptoms
1271125|NCT00882921|mps diagnosis
1271126|NCT00882921|mps ii therapy
1271127|NCT00882921|MPS II treatment
1271128|NCT00882921|ert treatment
1271129|NCT00882921|elaprase
1271130|NCT00882921|idursulfase
1271131|NCT00882921|iduronate sulfatase
1271132|NCT00882921|iduronate 2 sulfatase
1271133|NCT00882921|enzyme replacement therapy
1271134|NCT00882921|hunter syndrome treatment
1271135|NCT00882921|hunter's syndrome treatment
1271136|NCT00882921|hunter syndrome therapy
1271137|NCT00882921|hunter's disease treatment
1271138|NCT00882921|mps society
1271139|NCT00882908|Hepatitis C
1271140|NCT00882908|TMC435
1271141|NCT00882908|Peginterferon alpha-2a
1271142|NCT00882908|PegIFNalpha-2a
1271143|NCT00882908|RBV
1271144|NCT00882908|Ribavirin
1271145|NCT00882908|Placebo
1271146|NCT00882895|Lymphoma, Non-Hodgkin
1271147|NCT00882895|Transplantation, Autologous
1271148|NCT00882895|Transplantation, Homologous
1271149|NCT00882895|Total Lymphoid Irradiation
1271150|NCT00882895|Anti-thymocyte globulin
1271151|NCT00882869|Advanced Hepatocellular carcinoma
1271152|NCT00882869|liver
1271153|NCT00882869|cancer
1271154|NCT00882869|antisense
1271155|NCT00882869|sorafenib
1271156|NCT00882856|Clozapine
1271157|NCT00882856|Sinustachycardia
1271158|NCT00882856|Heartrate variability
1271159|NCT00882856|Cardiomyopathy
1271160|NCT00882843|Vibrating plate
1271161|NCT00882843|Mechanical Stimulation
1271162|NCT00882843|Osteoporosis
1271163|NCT00882830|ICU
1271164|NCT00882830|myopathy
1271165|NCT00882830|neuropathy
1271166|NCT00882830|EMS
1271167|NCT00882830|critical illness polyneuromyopathy
1271168|NCT00882830|NIRS
1271169|NCT00882830|muscle biopsy
1271170|NCT00882830|microdialysis
1271171|NCT00882830|CIPNM
1271172|NCT00882817|ILD
1271173|NCT00882804|hemin, heme oxygenase, humans, HO-1
1271174|NCT00882791|Skin Cancer
1271175|NCT00882791|Basal Cell
1271176|NCT00882791|Mohs surgery
1271177|NCT00882765|adenocarcinoma of the pancreas
1271178|NCT00882765|stage I pancreatic cancer
1271179|NCT00882765|stage II pancreatic cancer
1271180|NCT00882765|stage III pancreatic cancer
1271181|NCT00882752|Ulcerative Colitis (UC)
1271182|NCT00882739|angiography
1271183|NCT00882739|percutaneous coronary intervention
1271184|NCT00882739|Platelet Aggregation Inhibitors
1271185|NCT00882739|Platelet Function Tests
1271186|NCT00882726|Diabetes Mellitus, Type 2
1271187|NCT00882726|CNTO 3649
1271188|NCT00882726|safety
1271189|NCT00882726|Phase I
1271190|NCT00882726|healthy adults
1271191|NCT00882726|Type 2 Diabetes Mellitus
1271192|NCT00882700|Antibiotic
1271193|NCT00882661|Neck Pain
1271194|NCT00882661|Arm Pain
1271195|NCT00882648|Drug dependence during pregnancy
1271196|NCT00882635|STEMI
1271197|NCT00882635|acute coronary syndromes
1271198|NCT00882635|primary percutaneous coronary intervention
1271199|NCT00882622|Ischemic Preconditioning
1271200|NCT00882622|Cardiac Surgery
1271201|NCT00882609|bone metastasis
1271202|NCT00882609|bone metastases
1271203|NCT00882609|Sodium Fluoride
1271204|NCT00882609|F18 Fluoride
1271205|NCT00882609|bone scan
1271206|NCT00882596|Contura
1271207|NCT00882596|Cancer
1271208|NCT00882596|Accelerated
1271209|NCT00882596|Partial
1271210|NCT00882596|Breast
1271211|NCT00882596|Irradiation
1271212|NCT00882583|HNSCC
1271213|NCT00882583|Dasatinib
1271214|NCT00882583|Cetuximab
1271215|NCT00882583|Cisplatin
1271216|NCT00882570|Antibiotic
1271217|NCT00882557|End-stage renal disease
1271218|NCT00882557|hemodialysis
1271219|NCT00882557|chronic renal failure
1271220|NCT00882544|hydronephrosis
1271221|NCT00882544|robotic pyeloplasty
1271222|NCT00882544|pediatric pyeloplasty
1271223|NCT00882518|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)
1271224|NCT00882518|qualified PANSS assessment
1271225|NCT00882492|Cardiac
1271226|NCT00882492|Surgery
1271227|NCT00882492|Glycemia
1271228|NCT00882466|erythropoietin
1271229|NCT00882453|Physical Activity
1271230|NCT00882453|Fatigue
1271231|NCT00882453|RRMS
1271232|NCT00882453|CIS
1271233|NCT00882427|algorithm
1271234|NCT00882427|tight glycemic control
1271235|NCT00882427|glucose control
1271236|NCT00882427|intensive care
1271237|NCT00882427|insulin
1271238|NCT00882427|ICU
1271239|NCT00882414|ferric carboxymaltose
1271240|NCT00882414|platelet
1271241|NCT00882414|thrombocyte
1271242|NCT00882414|ferritin
1271243|NCT00882414|hemoglobin
1271244|NCT00882414|transferrin
1271245|NCT00882388|celecoxib
1271246|NCT00882388|platelet
1271247|NCT00882388|thrombosis
1271248|NCT00882388|Volunteers
1271249|NCT00882375|Smoking Cessation
1271250|NCT00882336|Cardiovascular risk management
1271251|NCT00882336|Hyperlipidemia
1271252|NCT00882336|Hypertension
1271253|NCT00882336|Diabetes
1271254|NCT00882336|Obesity
1271255|NCT00882310|Pancreatic cancer
1271256|NCT00882310|Gemzar
1271257|NCT00882310|Taxotere
1271258|NCT00882310|Xeloda
1271259|NCT00882310|GTX
1271260|NCT00882297|Ultrasoundography
1271261|NCT00882297|catheterization
1271262|NCT00882297|central venous subclavian vein methods
1271263|NCT00882284|NICHD Neonatal Research Network
1271264|NCT00882284|Blood Pressure Management
1271265|NCT00882271|Fibromyalgia
1271266|NCT00882271|Acupuncture
1271267|NCT00882271|Pain
1271268|NCT00882258|Uterine fibroids
1271269|NCT00882232|prostate
1271270|NCT00882232|cancer
1271271|NCT00882232|cross-linked
1271272|NCT00882232|hyaluronan
1271273|NCT00882232|gel
1271274|NCT00882232|Hylaform
1271275|NCT00882232|rectal
1271276|NCT00882232|toxicity
1271277|NCT00882219|Drug eluting stent
1271278|NCT00882219|Stents
1271279|NCT00882219|Angioplasty
1271280|NCT00882219|Chronic coronary occlusion
1271281|NCT00882219|Stent thrombosis
1271282|NCT00882219|Vascular disease
1271283|NCT00882219|Myocardial ischemia
1271284|NCT00882219|Coronary artery stenosis
1271285|NCT00882219|Coronary Disease
1271286|NCT00882219|Coronary Artery Disease
1271287|NCT00882219|Coronary Restenosis
1271288|NCT00882206|recurrent adult lymphoblastic lymphoma
1271289|NCT00882206|recurrent childhood lymphoblastic lymphoma
1271290|NCT00882206|recurrent adult acute lymphoblastic leukemia
1271291|NCT00882206|recurrent childhood acute lymphoblastic leukemia
1271292|NCT00882193|Chronic hepatitis C
1271293|NCT00882193|Genotype 1
1271294|NCT00882193|Nonresponder
1271295|NCT00882193|Relapser
1271296|NCT00882193|Betaine
1271297|NCT00882193|Antiviral therapy
1271298|NCT00882180|Liver
1271299|NCT00882180|Solid Tumors
1271300|NCT00882180|Advanced Solid Tumors with Liver Involvement
1271301|NCT00882154|Antibiotic
1271302|NCT00882141|Exercise
1271303|NCT00882141|Obesity
1271304|NCT00882141|Insulin Sensitivity
1271305|NCT00882128|Asthma seasonal respiratory symptoms
1271306|NCT00882128|Asthmatic patients with increase of respiratory symptoms
1271307|NCT00882115|DEP
1271308|NCT00882115|Broccoli Sprout Extract
1271309|NCT00882115|Allergies
1271310|NCT00882102|Acute Myelogenous Leukemia
1271311|NCT00882102|High-Risk Myelodysplastic Syndrome
1271312|NCT00882102|AML
1271313|NCT00882102|MDS
1271314|NCT00882102|Leukemia
1271315|NCT00882102|Decitabine
1271316|NCT00882102|Gemtuzumab Ozogamicin
1271317|NCT00882102|Dacogen
1271318|NCT00882102|Mylotarg
1271319|NCT00882089|Contura
1271320|NCT00882089|Cancer
1271321|NCT00882089|Accelerated
1271322|NCT00882089|Partial
1271323|NCT00882089|Breast
1271324|NCT00882089|Irradiation
1271325|NCT00882076|acute lymphoblastic leukemia
1271326|NCT00882076|chronic lymphocytic leukemia
1271327|NCT00882063|Multiple Myeloma
1271328|NCT00882037|Methamphetamine Dependence
1271329|NCT00882037|Substance Abuse Treatment
1271330|NCT00882037|Rural and Urban
1271331|NCT00882037|Latino and Non-Latino
1271332|NCT00882024|Rheumatoid arthritis
1271333|NCT00882011|T-lymphoblastic lymphoma
1271334|NCT00882011|Intensive chemo/radiotherapy
1271335|NCT00882011|Intensive chemotherapy
1271336|NCT00882011|Transplant
1271337|NCT00882011|Adult patients
1271338|NCT00881998|Evaluate early functional outcomes of two anterior approaches to total hip arthroplasty
1271339|NCT00881985|obstructive sleep apnea
1271340|NCT00881985|resistant hypertension
1271341|NCT00881985|refractory hypertension
1271342|NCT00881985|continuous positive airway pressure
1271343|NCT00881985|blood pressure control
1271344|NCT00881959|exposed Root Surface or Tooth
1271345|NCT00881959|Tooth Sensitivity Miller Class I
1271346|NCT00881959|Miller Class II
1271347|NCT00881959|Gingival Margin
1271348|NCT00881946|chronic lymphocytic leukemia
1271349|NCT00881946|aggressive lymphoma
1271350|NCT00881946|non-Hodgkin's lymphoma
1271351|NCT00881946|Hodgkin's lymphoma
1271352|NCT00881946|chronic myelogenous leukemia
1271353|NCT00881946|multiple myeloma
1271354|NCT00881946|acute lymphoblastic leukemia
1271355|NCT00881946|acute myeloid leukemia
1271356|NCT00881933|Fludarabine, Cyclophosphamide, TBI, severe aplastic anemia,
1271357|NCT00881933|cord blood transplantation, pediatric
1271358|NCT00881920|Lymphocytic
1271359|NCT00881920|Leukemia
1271360|NCT00881920|B Cell
1271361|NCT00881920|Non-Hodgkin
1271362|NCT00881920|Multiple Myeloma
1271363|NCT00881920|Lymphoma
1271364|NCT00881907|Regeneration (revascularization) of dental pulp
1271365|NCT00881907|Immature Permanent Tooth With a Diagnosis of Pulpal Necrosis
1271366|NCT00881894|Rotigotine
1271367|NCT00881894|Neupro®
1271368|NCT00881894|Transdermal Patch
1271369|NCT00881855|Antibiotics
1271370|NCT00881842|Influenza
1271371|NCT00881842|Vaccine
1271372|NCT00881842|CHMP criteria
1271373|NCT00881829|Pulse Oximetry
1271374|NCT00881829|Temperature
1271375|NCT00881829|Respiratory Rate
1271376|NCT00881829|Respiratory Gases
1271377|NCT00881829|This study determine the measurement accuracy of the physiological parameters
1271378|NCT00881816|Liposomal Paclitaxel
1271379|NCT00881816|Capecitabine
1271380|NCT00881816|Maximum tolerated dose
1271381|NCT00881816|Dose limiting toxicity
1271382|NCT00881803|Spinal Cord Injuries
1271383|NCT00881803|Ascorbic Acid
1271384|NCT00881803|Vitamin C
1271385|NCT00881803|Iron
1271386|NCT00881803|Dietary Supplements
1271387|NCT00881777|Heart Failure
1271388|NCT00881777|Cardiomyopathy
1271389|NCT00881777|Ventricular Dysfunction
1271390|NCT00881777|Heart Disease
1271391|NCT00881764|Anesthesia
1271392|NCT00881764|New York
1271393|NCT00881764|Columbia
1271394|NCT00881764|Children
1271395|NCT00881764|Neurodevelopment
1271396|NCT00881764|Child development
1271397|NCT00881764|Pediatric
1271398|NCT00881751|adult primary hepatocellular carcinoma
1271399|NCT00881751|advanced adult primary liver cancer
1271400|NCT00881751|recurrent adult primary liver cancer
1271401|NCT00881738|Antibiotic
1271402|NCT00881725|Metformin
1271403|NCT00881725|Prostate Cancer
1271404|NCT00881725|Radical Prostatectomy
1271405|NCT00881725|Neoadjuvant Intervention
1271406|NCT00881725|PTEN/AKT Pathway
1271407|NCT00881725|Tumour Expression
1271408|NCT00881725|Ki67 Expression
1271409|NCT00881712|Non-small cell lung Cancer
1271410|NCT00881712|Proton Radiation
1271411|NCT00881712|Stage III
1271412|NCT00881699|HIV Information
1271413|NCT00881699|HIV Prevention
1271414|NCT00881699|Severe Mental Illness
1271415|NCT00881699|HIV seronegativity
1271416|NCT00881686|Ischemic Preconditioning, Myocardial
1271417|NCT00881686|Adenosine
1271418|NCT00881673|Conjunctivitis
1271419|NCT00881660|Fetal Tracheal Occlusion
1271420|NCT00881660|congenital diaphragmatic hernia
1271421|NCT00881660|FETO plug-unplug
1271422|NCT00881660|Goldvalve balloon
1271423|NCT00881660|Severe Congenital Diaphragmatic Hernia
1271424|NCT00881660|Extremely Severe Congenital Diaphragmatic Hernia
1271425|NCT00881660|Goldbal balloon
1271426|NCT00881660|FETO
1271427|NCT00881647|PTSD
1271428|NCT00881647|Insomnia Disorder
1271429|NCT00881647|Insomnia
1271430|NCT00881647|CBT
1271431|NCT00881621|Pancreas cancer
1271432|NCT00881621|lapatinib
1271433|NCT00881621|capecitabine
1271434|NCT00881608|Menstruation
1271435|NCT00881595|Sarcomas
1271436|NCT00881595|High-Risk Soft Tissue Sarcomas
1271437|NCT00881582|Hepatitis c
1271438|NCT00881582|Renal transplantation
1271439|NCT00881582|Pegylated interferon
1271440|NCT00881556|Allogeneic Stem Cell Transplant
1271441|NCT00881556|AlloSCT
1271442|NCT00881556|RDEB
1271443|NCT00881556|recessive dystrophic epidermolysis bullosa
1271444|NCT00881543|Sitagliptin
1271445|NCT00881543|Diets
1271446|NCT00881543|Diabetes type 2
1271447|NCT00881543|Näive patients
1271448|NCT00881517|human cytomegalovirus
1271449|NCT00881517|immune globulin
1271450|NCT00881517|congenital infection
1271451|NCT00881517|prevention
1271452|NCT00881517|pregnancy
1271453|NCT00881504|Biliary
1271454|NCT00881504|Oxaliplatin
1271455|NCT00881504|Bevacizumab
1271456|NCT00881491|Regeneration (revascularization) of dental pulp
1271457|NCT00881491|Immature permanent tooth with a diagnosis of
1271458|NCT00881478|Obesity
1271459|NCT00881478|Children
1271460|NCT00881478|Dyslipidemia
1271461|NCT00881478|Hypertension
1271462|NCT00881465|Obsessive compulsive disorder
1271463|NCT00881452|Autism
1271464|NCT00881439|Heart failure
1271465|NCT00881439|Renal Failure
1271466|NCT00881439|Cardiorenal Syndrome
1271467|NCT00881439|Renin inhibition
1271468|NCT00881439|Aliskiren
1271469|NCT00881426|Antibiotic
1271470|NCT00881413|Peptic ulcer bleeding
1271471|NCT00881413|Proton pump inhibitor
1271472|NCT00881413|Esomeprazole
1271473|NCT00881413|Pantoprazole
1271474|NCT00881413|Recurrent bleeding
1271475|NCT00881413|bleeding
1271476|NCT00881400|Antibiotic
1271477|NCT00881387|recurrent adult Hodgkin lymphoma
1271478|NCT00881387|adult lymphocyte depletion Hodgkin lymphoma
1271479|NCT00881387|adult lymphocyte predominant Hodgkin lymphoma
1271480|NCT00881387|adult mixed cellularity Hodgkin lymphoma
1271481|NCT00881387|adult nodular sclerosis Hodgkin lymphoma
1271482|NCT00881361|stage II breast cancer
1271483|NCT00881361|stage IIIA breast cancer
1271484|NCT00881361|stage IIIB breast cancer
1271485|NCT00881335|geriatric
1271486|NCT00881335|pulmonary disease
1271487|NCT00881335|flutter
1271488|NCT00881335|sputum
1271489|NCT00881335|physical therapy techniques
1271490|NCT00881296|Elder Patients
1271491|NCT00881296|Non-Small Cell Lung Cancer
1271492|NCT00881296|Previously Untreated
1271493|NCT00881296|Advanced
1271494|NCT00881283|Cushing's disease
1271495|NCT00881257|Peripheral Vascular Disease
1271496|NCT00881257|Peripheral Artery Disease
1271497|NCT00881257|Radiofrequency
1271498|NCT00881218|myocardial ischemia, perfusion imaging, cardiac MRI
1271499|NCT00881205|Multiple Sclerosis
1271500|NCT00881205|Cognition
1271501|NCT00881205|Rivastigmine
1271502|NCT00881205|Patch
1271503|NCT00881192|CABG
1271504|NCT00881192|coronary surgery
1271505|NCT00881192|intra-aortic balloon pump
1271506|NCT00881192|CABG operation
1271507|NCT00881179|Antibiotic
1271508|NCT00881166|MP-470
1271509|NCT00881166|Multi-targeted Tyrosine Kinase Inhibitor
1271510|NCT00881166|Malignant disease
1271511|NCT00881153|Antibiotic
1271512|NCT00881140|oral mifepristone
1271513|NCT00881140|vaginal tablets
1271514|NCT00881114|Head and neck cancer
1271515|NCT00881114|pharmacogenetics
1271516|NCT00881114|chemoradiotherapy
1271517|NCT00881101|Liposomal Paclitaxel
1271518|NCT00881101|Maximum tolerated dose
1271519|NCT00881101|Dose limiting toxicity
1271520|NCT00881088|Deep vein trombosis
1271521|NCT00881088|Profylaxis
1271522|NCT00881088|Below knee plaster cast
1271523|NCT00881088|Ankle fracture
1271524|NCT00881075|Magnetic resonance imaging
1271525|NCT00881075|Heart diseases
1271526|NCT00881075|myocardial infarction
1271527|NCT00881075|contrast agents
1271528|NCT00881075|manganese
1271529|NCT00881062|ABSORPTION
1271530|NCT00881062|METABOLISM
1271531|NCT00881062|EXCRETION
1271532|NCT00881049|metastatic acral or mucosal melanoma with c-kit mutation or copy number increase
1271533|NCT00881036|Hepatitis B
1271534|NCT00881010|Breast Cancer
1271535|NCT00881010|Pain Intervention
1271536|NCT00881010|Underserved minority patients
1271537|NCT00881010|African American
1271538|NCT00881010|Hispanic
1271539|NCT00881010|Automated Telephone System for measuring symptoms
1271540|NCT00881010|Interactive voice response
1271541|NCT00881010|IVR
1271542|NCT00880997|Cocaine Dependence
1271543|NCT00880997|Substance Related Disorders
1271544|NCT00880984|Colon Anastomosis
1271545|NCT00880984|Rectum Anastomosis
1271546|NCT00880984|Intestine
1271547|NCT00880984|Colorectal Surgery
1271548|NCT00880984|Colorectal Anastomosis
1271549|NCT00880971|Lung
1271550|NCT00880971|Carcinoma
1271551|NCT00880971|radiotherapy
1271552|NCT00880971|Surgery
1271553|NCT00880945|FBS
1271554|NCT00880945|coin lesions
1271555|NCT00880945|ENB
1271556|NCT00880945|ROSE
1271557|NCT00880932|warfarin
1271558|NCT00880932|NSAID
1271559|NCT00880932|The condition is the concomitant prescription of
1271560|NCT00880919|Borderline Personality Disorder
1271561|NCT00880919|BPD
1271562|NCT00880919|Seroquel
1271563|NCT00880919|Seroquel XR
1271564|NCT00880919|quetiapine
1271565|NCT00880919|quetiapine extended-release
1271566|NCT00880906|eosinophilic esophagitis
1271567|NCT00880906|esophageal food impaction
1271568|NCT00880906|dysphagia
1271569|NCT00880893|Dengue virus
1271570|NCT00880893|Dengue fever
1271571|NCT00880893|Dengue hemorrhagic fever
1271572|NCT00880893|Dengue diseases
1271573|NCT00880893|Sanofi Pasteur's CYD Dengue Vaccine
1271574|NCT00880880|urinary incontinence
1271575|NCT00880880|fecal incontinence
1271576|NCT00880880|communication
1271577|NCT00880867|Low Grade Recurrent B and T Cell Lymphoma
1271578|NCT00880854|bladder cancer
1271579|NCT00880854|BCG-resistant localized transitional cell of the bladder
1271582|NCT00880828|Cervical Radiculopathy
1271583|NCT00880828|Radicular Pain
1271584|NCT00880828|Acute neck pain
1271585|NCT00880828|Cervicobrachial pain
1271586|NCT00880828|Far-infrared ray
1271587|NCT00880828|FIR
1271588|NCT00880828|Cervical collar
1271589|NCT00880828|Cervical device
1271590|NCT00880828|FIR Device
1271591|NCT00880815|Leukemia
1271592|NCT00880815|Lymphoma
1271593|NCT00880815|Lymphoid Malignancies
1271594|NCT00880815|Non-myeloablative Allogeneic Conditioning
1271595|NCT00880815|Non-myeloablative Allogeneic Hematopoietic Transplantation
1271596|NCT00880815|Stem Cell Transplant
1271597|NCT00880815|SCT
1271598|NCT00880815|Bendamustine HCI
1271599|NCT00880815|Bendamustine
1271600|NCT00880815|Bendamustine Hydrochloride
1271601|NCT00880815|CEP-18083
1271602|NCT00880815|SDX-105
1271603|NCT00880815|Treanda
1271604|NCT00880815|Fludarabine
1271605|NCT00880815|Fludarabine Phosphate
1271606|NCT00880815|Fludara
1271607|NCT00880815|Rituximab
1271608|NCT00880815|Rituxan
1271609|NCT00880815|FBR
1271610|NCT00880815|Graft-versus-host disease
1271611|NCT00880815|GVHD
1271612|NCT00880802|Acute Coronary Syndromes
1271613|NCT00880802|Non ST-Segment Elevation Myocardial Infarction
1271614|NCT00880802|ST-Segment Elevation Myocardial Infarction
1271615|NCT00880802|Unstable Angina
1271616|NCT00880789|Cord Blood Transplant
1271617|NCT00880789|cytomegalovirus
1271618|NCT00880789|CMV
1271619|NCT00880789|Adenovirus
1271620|NCT00880789|ADV
1271621|NCT00880750|End stage Renal disease
1271622|NCT00880724|COPD
1271623|NCT00880724|Emphysema
1271624|NCT00880724|Bronchoscopic Treatment
1271625|NCT00880724|Interventional Bronchoscopy
1271626|NCT00880711|Fiona
1271627|NCT00880711|Faslodex
1271628|NCT00880711|Advanced Breast Cancer
1271629|NCT00880711|Real life data
1271630|NCT00880711|Collect real life data in clinical practice across Austria
1271631|NCT00880698|Rotavirus
1271632|NCT00880698|Rotavirus vaccine
1271633|NCT00880685|Compulsive Stealing
1271634|NCT00880685|Compulsive Shoplifting
1271635|NCT00880672|prostate, dutasteride
1271636|NCT00880672|vascular endothelial growth factor
1271637|NCT00880672|hypoxia inducible factor
1271638|NCT00880659|Influenza
1271639|NCT00880659|secondary transmission
1271640|NCT00880659|handwashing
1271641|NCT00880633|EUS
1271642|NCT00880633|periampullary neoplasms
1271643|NCT00880620|Parkinson's disease
1271644|NCT00880607|Pain
1271645|NCT00880607|Pediatric
1271646|NCT00880607|Spinal Fusion
1271647|NCT00880607|pain management
1271648|NCT00880555|Magnetic Resonance Imaging
1271649|NCT00880555|Alzheimer disease
1271650|NCT00880555|Mild cognitive impairment
1271651|NCT00880555|Continuous arterial spin labeling
1271652|NCT00880555|Semantic memory
1271653|NCT00880542|localized osteosarcoma
1271654|NCT00880542|stage II adult soft tissue sarcoma
1271655|NCT00880542|stage III adult soft tissue sarcoma
1271656|NCT00880529|rib fractures
1271657|NCT00880529|ventilator
1271658|NCT00880529|ON-Q
1271659|NCT00880529|analgesia
1271660|NCT00880503|Multidrug Resistance Molecular Target Analysis
1271661|NCT00880490|COPD
1271662|NCT00880464|autologous vaccination
1271663|NCT00880464|GM-CSF
1271664|NCT00880464|adenoviral mediated gene transfer
1271665|NCT00880464|Stage IV breast cancer
1271666|NCT00880451|Children and Adolescents
1271667|NCT00880451|Aging
1271668|NCT00880451|Brain Imaging
1271669|NCT00880451|MRI (Magnetic Resonance Imaging)
1271670|NCT00880412|safety
1271671|NCT00880412|efficacy
1271672|NCT00880412|Alzheimer's disease
1271673|NCT00880412|treatment
1271674|NCT00880412|phase II
1271675|NCT00880412|study
1271676|NCT00880412|cholinesterase inhibitor
1271677|NCT00880399|depression
1271678|NCT00880399|QIDS-SR
1271679|NCT00880399|HAMD-17
1271680|NCT00880399|orvepitant
1271681|NCT00880399|MDD
1271682|NCT00880399|neurokinin-1 antagonist
1271683|NCT00880399|double-blind
1271684|NCT00880399|Phase II
1271685|NCT00880399|randomized
1271686|NCT00880399|efficacy
1271687|NCT00880399|placebo
1271688|NCT00880399|safety
1271689|NCT00880386|dyspnea
1271690|NCT00880386|stage I non-small cell lung cancer
1271691|NCT00880386|stage II non-small cell lung cancer
1271692|NCT00880386|stage IIIA non-small cell lung cancer
1271693|NCT00880386|stage IIIB non-small cell lung cancer
1271694|NCT00880386|pulmonary complications
1271695|NCT00880386|radiation fibrosis
1271696|NCT00880373|Sickle Cell Disease
1271697|NCT00880373|Pain
1271698|NCT00880373|Ibuprofen
1271699|NCT00880373|Morphine
1271700|NCT00880373|Diamorphine
1271701|NCT00880373|Patient Controlled Analgesia
1271702|NCT00880360|Epithelial Ovarian Cancer
1271703|NCT00880360|FIGO (International Federation of Gynecology and Obstetrics )Stage III or Stage IV
1271704|NCT00880360|Extraovarian Peritoneal Cancer
1271705|NCT00880360|Fallopian Tube Carcinoma Failing
1271706|NCT00880347|Alzheimer's disease
1271707|NCT00880347|Other dementia
1271708|NCT00880347|Vascular dementia
1271709|NCT00880347|Mixed dementia
1271710|NCT00880347|Parkinson's Disease dementia
1271711|NCT00880347|Lewy bodies dementia
1271712|NCT00880347|Frontotemporal dementia
1271713|NCT00880347|Blood signature
1271714|NCT00880347|Diagnosis
1271715|NCT00880347|SpliceArray (tm)
1271716|NCT00880347|Alzheimer's Disease and other non-AD dementia
1271717|NCT00880334|TCC
1271718|NCT00880334|Zactima
1271719|NCT00880334|docetaxel
1271720|NCT00880334|ZD6474
1271721|NCT00880334|taxotere
1271722|NCT00880321|first time in human
1271723|NCT00880321|BRAF inhibitor
1271724|NCT00880321|dose escalation
1271725|NCT00880308|Advanced tumors
1271726|NCT00880308|hedgehog
1271727|NCT00880308|smoothened inhibitor
1271728|NCT00880269|Acute myeloid leukemia
1271729|NCT00880269|AML
1271730|NCT00880269|relapsed acute myeloid leukemia
1271731|NCT00880269|refractory AML
1271732|NCT00880269|refractory de novo AML
1271733|NCT00880269|refractory secondary AML
1271734|NCT00880269|secondary AML
1271735|NCT00880269|AML following myelodysplastic syndrome (MDS)
1271736|NCT00880269|AML following antecedent hematological disorder (AHD)
1271737|NCT00880269|AML resistant to therapy
1271738|NCT00880256|irritable bowel
1271739|NCT00880256|mindfulness
1271740|NCT00880256|stress
1271741|NCT00880256|meditation
1271742|NCT00880243|Acute myeloid leukemia
1271743|NCT00880243|Priming
1271744|NCT00880243|GM-CSF
1271745|NCT00880243|Timed-sequential chemotherapy
1271746|NCT00880243|Prognosis
1271747|NCT00880230|Iliac Artery Stenting
1271748|NCT00880230|Peripheral Artery Disease
1271749|NCT00880217|Attention Deficit Hyperactivity Disorder
1271750|NCT00880217|Attention Deficit Disorders with Hyperactivity
1271751|NCT00880217|Adult ADHD
1271752|NCT00880217|JNJ-31001074
1271753|NCT00880204|Cluster Randomized Trial
1271754|NCT00880204|ESS-EMCH
1271755|NCT00880204|Neonatal
1271756|NCT00880204|Maternal
1271757|NCT00880204|Life threatening emergency event
1271758|NCT00880191|nausea and vomiting
1271759|NCT00880191|unspecified adult solid tumor, protocol specific
1271760|NCT00880178|Simvastatin
1271761|NCT00880178|Niacin
1271762|NCT00880178|Vascular Disease
1271763|NCT00880178|Magnetic Resonance Imaging
1271764|NCT00880178|High Density Lipoprotein
1271765|NCT00880178|Oxidation
1271766|NCT00880178|Proteomics
1271767|NCT00880178|Stroke
1271768|NCT00880178|Cerebrovascular Accident
1271769|NCT00880165|Polysomnogram
1271770|NCT00880165|Continuous positive airway pressure
1271771|NCT00880152|stress
1271772|NCT00880152|mindfulness
1271773|NCT00880152|trauma
1271774|NCT00880139|Diabetes mellitus, type 1
1271775|NCT00880139|Inflammation
1271776|NCT00880139|Cytokines
1271777|NCT00880139|Vascular reactivity
1271778|NCT00880126|Individualized Implementation
1271779|NCT00880126|Community Development Teams
1271780|NCT00880113|CT-perfusion
1271781|NCT00880113|CT-angiography
1271782|NCT00880100|Steatorrhea
1271783|NCT00880100|Malabsorption of fat
1271784|NCT00880100|Pancreatic enzymes
1271785|NCT00880100|Abdominal pain
1271786|NCT00880100|Greasy stools
1271787|NCT00880087|Cardiac Arrest
1271788|NCT00880087|Cardiopulmonary Arrest
1271789|NCT00880087|Pediatric Cardiac Arrest
1271790|NCT00880087|VABS
1271791|NCT00880087|Vineland Adaptive Behavior Scale
1271792|NCT00880087|POPC/PCPC
1271793|NCT00880087|hypoxic-ischemic encephalopathy
1271794|NCT00880074|Advanced Cancers
1271795|NCT00880074|FLT-PET
1271796|NCT00880074|Positron Emission Tomography
1271797|NCT00880074|PET
1271798|NCT00880074|[18F] fluorothymidine
1271799|NCT00880074|[F-18]-fluoro-L-thymidine
1271800|NCT00880074|FLT
1271801|NCT00880061|Diffuse Infiltrating Pontine Glioma
1271802|NCT00880061|Supratentorial High Grade Glioma
1271803|NCT00880061|Convection-Enhanced Delivery
1271804|NCT00880061|Pediatric Brain Tumor
1271805|NCT00880061|Brain Tumor
1271806|NCT00880061|Glioma
1271807|NCT00880048|depression
1271808|NCT00880048|safety
1271809|NCT00880048|HAMD
1271810|NCT00880048|QIDS-SR
1271811|NCT00880048|NK-1 antagonist
1271812|NCT00880048|efficacy
1271813|NCT00880048|orvepitant
1271814|NCT00880048|placebo
1271815|NCT00880048|MDD
1271816|NCT00880048|video-rating
1271817|NCT00880035|sedative drug
1271818|NCT00880035|stress
1271819|NCT00880035|music
1271820|NCT00880035|mechanical ventilation
1271821|NCT00880035|IL-6
1271822|NCT00880035|cortisol
1271823|NCT00880035|prolactin
1271824|NCT00880035|CRP
1271825|NCT00880035|copeptin
1271826|NCT00880022|compression
1271827|NCT00880022|Flexitouch
1271828|NCT00880022|breast cancer
1271829|NCT00880022|lymphedema
1271830|NCT00879996|Opiate Addiction
1271831|NCT00879996|Narcotic Addiction
1271832|NCT00879996|Drug Addiction
1271833|NCT00879996|Pain
1271834|NCT00879983|azithromycin, pharmacokinetics
1271835|NCT00879970|Cardiovascular Outcomes
1271836|NCT00879957|Infant, Premature
1271837|NCT00879957|Infant
1271838|NCT00879957|Central venous catheterization
1271839|NCT00879957|Anticoagulants
1271840|NCT00879944|Psoriasis
1271841|NCT00879944|Obesity
1271842|NCT00879944|BMI
1271843|NCT00879944|Atopic Dermatitis
1271844|NCT00879918|Cigarette Smoking in African Americans
1271845|NCT00879905|Phase I
1271846|NCT00879905|Adults
1271847|NCT00879905|HSP990
1271848|NCT00879905|Advanced Solid Tumors
1271849|NCT00879905|Hsp90 inhibitor
1271850|NCT00879905|Cancer
1271851|NCT00879892|xenon
1271852|NCT00879892|hypothermia
1271853|NCT00879892|out-of-hospital cardiac arrest
1271854|NCT00879879|precancerous condition
1271855|NCT00879866|NSCLC
1271856|NCT00879866|immunocytokine
1271857|NCT00879866|radiation
1271858|NCT00879866|interleukin-2
1271859|NCT00879866|immunotherapy
1271860|NCT00879866|maintenance therapy
1271861|NCT00879853|PTSD
1271862|NCT00879853|Depression
1271863|NCT00879853|Anger
1271864|NCT00879853|Domestic Violence
1271865|NCT00879853|Refugee
1271866|NCT00879853|Asylum Seeker
1271867|NCT00879853|Community Therapist
1271868|NCT00879853|Paraprofessional Therapists
1271869|NCT00879840|Screening
1271870|NCT00879840|Modalities
1271871|NCT00879840|Gynecological Cancers
1271872|NCT00879801|prevention of diabetes
1271873|NCT00879801|susceptibility genes
1271874|NCT00879801|type 2 diabetes
1271875|NCT00879801|insulin resistance
1271876|NCT00879801|beta-cell funtion
1271877|NCT00879788|Ramipril fed condition
1271878|NCT00879775|Pain
1271879|NCT00879775|Cancer patients
1271880|NCT00879775|Caffeine
1271881|NCT00879775|Adjuvant analgesics
1271882|NCT00879775|Sedation
1271883|NCT00879775|Confusion
1271884|NCT00879775|Quality of life
1271885|NCT00879775|Fatigue
1271886|NCT00879762|smallpox, vaccine, IMVAMUNE®
1271887|NCT00879736|Doctor-patient communication
1271888|NCT00879736|Encounters
1271889|NCT00879736|Patient education training
1271890|NCT00879723|post-burn recovery
1271891|NCT00879723|oxidative stress
1271892|NCT00879723|micronutrient protocol
1271893|NCT00879710|Diabetes Mellitus
1271894|NCT00879710|Hypercholesterolemia
1271895|NCT00879710|Simvastatin
1271896|NCT00879710|Ezetimibe.
1271897|NCT00879697|peripheral arterial disease
1271898|NCT00879697|exercise
1271899|NCT00879697|resistance training
1271900|NCT00879697|cardiac rehabilitation
1271901|NCT00879684|Phase 1
1271902|NCT00879684|Tumors
1271903|NCT00879684|CVX-060
1271904|NCT00879671|lutein
1271905|NCT00879671|nonexudative AMD
1271906|NCT00879671|MPOD
1271907|NCT00879671|Supplementary Concepts
1271908|NCT00879658|Multiple Sclerosis
1271909|NCT00879658|Relapsing-Remitting
1271910|NCT00879658|Demyelinating Autoimmune Diseases
1271911|NCT00879645|Renal Impairment
1271912|NCT00879645|Renal Disease
1271913|NCT00879645|Sodium Sulfide
1271914|NCT00879606|Sepsis
1271915|NCT00879606|Acute Lung Injury
1271916|NCT00879606|Acute Respiratory Distress Syndrome
1271917|NCT00879606|ALI/ARDS
1271918|NCT00879606|Lung Disease
1271919|NCT00879580|aneurysm
1271920|NCT00879580|stent
1271921|NCT00879580|intracranial aneurysm
1271922|NCT00879580|Ruptured Intracranial Aneurysm
1271923|NCT00879554|Phase 1
1271924|NCT00879554|Solid Tumors
1271925|NCT00879554|CVX-045
1271926|NCT00879541|Hemophilia A
1271927|NCT00879528|Hodgkin's Lymphoma
1271928|NCT00879528|stem cell reinfusion
1271929|NCT00879515|Fragile X Premutation
1271930|NCT00879515|Fragile X Syndrome
1271931|NCT00879515|Down Syndrome
1271932|NCT00879502|Fragile X Premutation
1271933|NCT00879502|FMR1
1271934|NCT00879502|Premutation
1271935|NCT00879502|Fragile X
1271936|NCT00879502|Brain Function
1271937|NCT00879489|Stage IV histologically proven breast cancer
1271938|NCT00879476|Bioequivalence ramipril fasting condition
1271939|NCT00879463|Blood transfusion in cardiac operations under CPB
1271940|NCT00879463|Infrared spectrophotoscopy
1271941|NCT00879450|Congenital muscular torticollis
1271942|NCT00879437|brain tumor
1271943|NCT00879437|bevacizumab
1271944|NCT00879437|valproic acid
1271945|NCT00879437|radiation therapy
1271946|NCT00879424|vitamin D
1271947|NCT00879424|atopic dermatitis
1271948|NCT00879424|eczema
1271949|NCT00879424|winter
1271950|NCT00879385|KRAS wild-type
1271951|NCT00879385|Colon
1271952|NCT00879385|Cancer
1271953|NCT00879385|colorectal
1271954|NCT00879385|metastatic colorectal
1271955|NCT00879385|advanced colorectal
1271956|NCT00879372|Bipolar Disorder
1271957|NCT00879372|cognitive impairment
1271958|NCT00879372|depression
1271959|NCT00879346|Healthy Volunteers
1271960|NCT00879346|ADME
1271961|NCT00879346|Healthy male volunteers
1271962|NCT00879333|Gastric cancer,
1271963|NCT00879333|advanced gastric cancer,
1271964|NCT00879333|stomach neoplasm,
1271965|NCT00879333|stomach disease,
1271966|NCT00879333|adenocarcinoma of stomach,
1271967|NCT00879333|GI neoplasm
1271968|NCT00879320|ADHD
1271969|NCT00879320|health
1271970|NCT00879320|healthy lifestyle
1271971|NCT00879294|Perforated appendicitis
1271972|NCT00879294|Ruptured appendicitis
1271973|NCT00879294|Acute appendicitis with perforation
1271974|NCT00879281|COPD
1271975|NCT00879281|emphysema
1271976|NCT00879281|chronic bronchitis
1271977|NCT00879268|Liver Transplantation
1271978|NCT00879268|Organ Preservation
1271979|NCT00879268|Liver Preservation
1271980|NCT00879268|Machine Perfusion
1271981|NCT00879268|Vasosol
1271982|NCT00879268|Machine Preservation
1271983|NCT00879255|cognitive processing therapy
1271984|NCT00879255|combat
1271985|NCT00879255|veterans
1271986|NCT00879255|PTSD
1271987|NCT00879255|Telemental Health
1271988|NCT00879255|Videoteleconference
1271989|NCT00879255|outcome
1271990|NCT00879255|Rural
1271991|NCT00879255|Remote
1271992|NCT00879255|CPT
1271993|NCT00879255|VTC
1271994|NCT00879242|Thalassemia
1271995|NCT00879242|cardiac MRI T2*
1271996|NCT00879229|Idiopathic Pulmonary Fibrosis
1271997|NCT00879229|Pulmonary Hypertension
1271998|NCT00879229|PH
1271999|NCT00879229|IPF
1272000|NCT00879229|Ambrisentan
1272001|NCT00879229|ERA
1272002|NCT00879229|Endothelin Receptor Antagonist
1272003|NCT00879229|Cardiovascular
1272004|NCT00879216|Nocturia
1272005|NCT00879216|Hyptotension
1272006|NCT00879216|Elderly
1272007|NCT00879216|Males
1272008|NCT00879203|Type 1 Diabetes Mellitis
1272009|NCT00879203|Youth
1272010|NCT00879203|Hypoglycemia
1272011|NCT00879203|Hyperglycemia
1272012|NCT00879203|Cognition
1272013|NCT00879203|Memory
1272014|NCT00879203|Brain Growth & Development
1272015|NCT00879203|Magnetic Resonance Imaging
1272016|NCT00879177|smoking
1272017|NCT00879177|varenicline
1272018|NCT00879177|behavioral therapy
1272019|NCT00879177|ABPM
1272020|NCT00879177|hypertension
1272021|NCT00879164|hot flashes
1272022|NCT00879125|Gastric by-pass on patients with T2DM
1272023|NCT00879112|Hyperlipidemia
1272024|NCT00879099|Interaction
1272025|NCT00879099|healthy volunteers
1272026|NCT00879099|Interaction study for healthy volunteers
1272027|NCT00879086|Breast Cancer
1272028|NCT00879086|Oncology
1272029|NCT00879073|Brain and Nervous System
1272030|NCT00879060|Fibrosis
1272031|NCT00879060|Hypertrophic cardiomyopathy
1272032|NCT00879060|MRI
1272033|NCT00879060|To evaluate the efficacy of spironolactone in decreasing myocardial fibrosis in Hypertrophic cardiomyopathy
1272034|NCT00879047|HIV
1272035|NCT00879047|Hepatitis C
1272036|NCT00879021|The outcome is to prevent Central Neuropathic Pain
1272037|NCT00879021|participants will have suffered spinal cord trauma
1272038|NCT00879008|Disease Exacerbation
1272039|NCT00879008|Acute Exacerbations of Chronic Bronchitis
1272040|NCT00879008|AECB
1272041|NCT00879008|Avelox
1272042|NCT00879008|Bronchitis
1272043|NCT00878995|stage IIB cervical cancer
1272044|NCT00878995|stage III cervical cancer
1272045|NCT00878995|recurrent cervical cancer
1272046|NCT00878995|cachexia
1272047|NCT00878995|advanced head/neck carcinoma
1272048|NCT00878995|recurrent head/neck carcinoma
1272049|NCT00877162|Cognitive and behavioural intervention
1272050|NCT00877162|trial
1272051|NCT00877162|group
1272052|NCT00877162|Behavioral sleep problems
1272053|NCT00877149|Chronic HBV
1272054|NCT00877136|Liver tumors
1272055|NCT00877136|Liver cancer
1272056|NCT00877136|Adult primary hepatocellular carcinoma
1272057|NCT00877136|HCC
1272058|NCT00877136|Hepatoma
1272059|NCT00877136|Neoplasms
1272060|NCT00877123|fasting glucose
1272061|NCT00877123|obesity
1272062|NCT00877123|arab women
1272063|NCT00877123|interleukin
1272064|NCT00877123|diabetes
1272065|NCT00877123|impaired fasting glucose (IFG)
1272066|NCT00877110|BETA-D-GLUCAN
1272067|NCT00877110|CYCLOPHOSPHAMIDE (CYTOXAN)
1272068|NCT00877110|MAB 131 I - 3F8
1272069|NCT00877110|TOPOTECAN
1272070|NCT00877110|VINCRISTINE
1272071|NCT00877110|Neuroblastoma
1272072|NCT00877110|09-011
1272073|NCT00877097|osteoporosis
1272074|NCT00877097|Bone mineral density
1272075|NCT00877097|clodronate
1272076|NCT00877097|HRT
1272077|NCT00877097|postmenopausal
1272078|NCT00878969|Hemodialysis
1272079|NCT00878969|fibrinolysis
1272080|NCT00878969|oxidative stress
1272081|NCT00878969|systemic inflammatory reaction
1272082|NCT00878969|endothelial dysfunction
1272083|NCT00878969|carotid intima media thickness (IMT
1272084|NCT00878969|angiotensin receptor blockade
1272085|NCT00878969|angiotensin converting enzyme inhibition
1272086|NCT00878956|Cardiac surgery
1272087|NCT00878956|Cardiopulmonary bypass
1272088|NCT00878956|Oxidative stress
1272089|NCT00878956|Acute renal dysfunction
1272090|NCT00878956|Sodium bicarbonate
1272091|NCT00878943|Open label access
1272092|NCT00878943|sildenafil
1272093|NCT00878943|pulmonary arterial hypertension
1272094|NCT00878930|Breast cancer
1272095|NCT00878930|Fulvestrant
1272096|NCT00878930|Faslodex
1272097|NCT00878930|Acceptability
1272098|NCT00878930|Compliance
1272099|NCT00878930|Efficacy
1272100|NCT00878917|Equivalence Study
1272101|NCT00878917|Eye Drops Solution
1272102|NCT00878917|Dorzolamide
1272103|NCT00878917|Open Angle Glaucoma
1272104|NCT00878917|Ocular Hypertension
1272105|NCT00878904|unspecified adult solid tumor, protocol specific
1272106|NCT00878891|Microdialysis
1272107|NCT00878891|realtime
1272108|NCT00878891|glucose sensor
1272109|NCT00878891|coronary artery bypass
1272110|NCT00878878|Pulmonary artery systolic pressure (PASP)
1272111|NCT00878878|Pulmonary Vascular Resistance (PVR)
1272112|NCT00878878|Right Heart Catheterization
1272113|NCT00878878|Pulmonary hemodynamics
1272114|NCT00878865|Alprazolam
1272115|NCT00878865|bioequivalence
1272116|NCT00878839|Cataract
1272117|NCT00878839|Toric IOL
1272118|NCT00878839|Corneal Aberration
1272119|NCT00878839|Astigmatism
1272120|NCT00878839|AcrySof
1272121|NCT00878813|Copeptin
1272122|NCT00878813|Vasopressin
1272123|NCT00878813|Stroke
1272124|NCT00878813|Transient ischemic attack
1272125|NCT00878813|Thrombolytic therapy
1272126|NCT00878813|Prognosis
1272127|NCT00878813|Complications
1272128|NCT00878800|Phase I/II trial
1272129|NCT00878800|Solid tumors
1272130|NCT00878800|Soft tissue sarcoma
1272131|NCT00878800|PXD101
1272132|NCT00878800|Doxorubicin
1272133|NCT00878774|Ragweed allergy
1272134|NCT00878774|Immunotherapy
1272135|NCT00878774|Rhinoconjunctivitis
1272136|NCT00878774|Toleromune Ragweed
1272137|NCT00878761|Renal transplant
1272138|NCT00878761|Interstitial fibrosis and tubular atrophy
1272139|NCT00878761|Chronic allograft dysfunction
1272140|NCT00878761|Chronic allograft nephropathy
1272141|NCT00878761|kidney transplant
1272142|NCT00878735|Meditation
1272143|NCT00878735|Mindfulness
1272144|NCT00878735|fMRI
1272145|NCT00878735|cancer
1272146|NCT00878735|stress
1272147|NCT00878735|anxiety
1272148|NCT00878735|depression
1272149|NCT00878735|attention
1272150|NCT00878735|Neuroscience
1272151|NCT00878735|Neuroimaging
1272152|NCT00878735|Psychobiology
1272153|NCT00878735|Healthy volunteers (regular meditators and non-meditators)
1272154|NCT00878722|Acute Myeloid Leukemia
1272155|NCT00878722|PXD101
1272156|NCT00878722|Belinostat
1272157|NCT00878722|Idarubicin
1272158|NCT00878709|HER-2/erbB-2 positive breast cancer
1272159|NCT00878709|breast cancer
1272160|NCT00878709|adjuvant therapy
1272161|NCT00878709|neratinib
1272162|NCT00878709|HKI-272
1272163|NCT00878657|adenocarcinoma of the pancreas
1272164|NCT00878657|stage III pancreatic cancer
1272165|NCT00878644|Cardiac Arrest
1272166|NCT00878644|Cardiopulmonary Arrest
1272167|NCT00878644|Pediatric Cardiac Arrest
1272168|NCT00878644|VABS
1272169|NCT00878644|Vineland Adaptive Behavior Survey
1272170|NCT00878644|POPC/PCPC
1272171|NCT00878644|hypoxic-ichemic encephalopathy
1272172|NCT00878631|emergency medical services
1272173|NCT00878631|traumatic brain injury
1272174|NCT00878631|hypertonic saline with dextran
1272175|NCT00878631|fluid resuscitation
1272176|NCT00878618|Healthy volunteers
1272177|NCT00878605|Diabetes
1272178|NCT00878605|Cyclo-Z
1272179|NCT00878592|Post liver transplant
1272180|NCT00878592|weight reduction classes
1272181|NCT00878592|obesity
1272182|NCT00878592|weight management
1272183|NCT00878592|dietary and lifestyle modification
1272184|NCT00878579|back pain
1272185|NCT00878579|Spine
1272186|NCT00878579|Spinal
1272187|NCT00878579|Lower back pain
1272188|NCT00878579|Lumbar
1272189|NCT00878579|Lumbar Pain
1272190|NCT00878579|DDD
1272191|NCT00878579|Degenerative Disc Disease
1272192|NCT00878566|hypertension
1272193|NCT00878566|pharmacists
1272194|NCT00878566|rural health
1272195|NCT00878566|prescribing
1272196|NCT00878553|insomnia
1272197|NCT00878553|middle of the night
1272198|NCT00878553|sleep maintenance
1272199|NCT00878540|mirtazapine
1272200|NCT00878540|metabolism
1272201|NCT00878540|depression
1272202|NCT00878540|Healthy males
1272203|NCT00878527|Heart Failure
1272204|NCT00878527|Partial Circulatory Assist
1272205|NCT00878527|NYHA Class IIIb
1272206|NCT00878527|NYHA Class IV
1272207|NCT00878527|Ventricular Assist Device
1272208|NCT00878527|VAD
1272209|NCT00878514|Alprazolam
1272210|NCT00878514|Bioequivalence
1272211|NCT00878501|Phase II
1272212|NCT00878501|Pain
1272213|NCT00878475|Quantitative Capnometry
1272214|NCT00878475|N-Terminal Pro-Brain Natriuretic Peptide
1272215|NCT00878475|Acute Heart Failure
1272216|NCT00878475|Diagnostic Accuracy
1272217|NCT00878436|histone deacetylase inhibitor
1272218|NCT00878436|hormone therapy
1272219|NCT00878436|androgen-independent
1272220|NCT00878436|PSA
1272221|NCT00878436|androgen receptor
1272222|NCT00878423|HSP90
1272223|NCT00878423|Metastatic solid tumor including lymphoma which are
1272224|NCT00878423|refractory to standard therapy
1272225|NCT00878397|malaria
1272226|NCT00878397|long lasting insecticide nets
1272227|NCT00878397|anaemia
1272228|NCT00878397|schools
1272229|NCT00878384|Atrial Fibrillation
1272230|NCT00878384|Heart Failure
1272231|NCT00878384|Heart Rate Control
1272232|NCT00878384|Catheter Ablation
1272233|NCT00878371|morphine
1272234|NCT00878371|blood brain barrier
1272235|NCT00878371|surgery induced peripheral inflammatory response
1272236|NCT00878358|Osteoarthritis
1272237|NCT00878358|Total knee replacement
1272238|NCT00878345|Pediatric sedation
1272239|NCT00878345|Pentobarbital
1272240|NCT00878345|Dexmedetomidine
1272241|NCT00878345|Procedural sedation in children
1272242|NCT00878332|edentulous
1272243|NCT00878332|fixed dental rehabilitation
1272244|NCT00878332|insufficient bone height
1272245|NCT00878332|Partially edentulous patients
1272246|NCT00878332|Patients interested in fixed non removable dental rehabilitation by dental implants.
1272247|NCT00878332|The recipient bone with insufficient bone height for dental implant insertion.
1272248|NCT00878332|Adult patients
1272249|NCT00878319|Humeral
1272250|NCT00878319|diaphyseal (mid-shaft)
1272251|NCT00878319|fracture
1272252|NCT00878319|operative
1272253|NCT00878319|non-operative
1272254|NCT00878306|Treatment of drug dependency with HIV medications
1272255|NCT00878306|HIV
1272256|NCT00878293|analgesic
1272257|NCT00878293|diabetes mellitus
1272258|NCT00878293|chronic neuropathic pain
1272259|NCT00878293|painful polyneuropathy caused by diabetes mellitus type I or II
1272260|NCT00878267|Cancer
1272261|NCT00878267|Computer Program
1272262|NCT00878267|Palliative Care
1272263|NCT00878267|Patient-Reported Outcomes
1272264|NCT00878267|PRO
1272265|NCT00878267|Palliative and Hospice Care Practice
1272266|NCT00878267|Electronic Health Record
1272267|NCT00878267|EHR
1272268|NCT00878267|Interview
1272269|NCT00878254|Mantle Cell Lymphoma
1272270|NCT00878254|Non-Hodgkin's Lymphoma
1272271|NCT00878254|MCL
1272272|NCT00878254|NHL
1272273|NCT00878241|Colon Anastomosis
1272274|NCT00878241|Rectum Anastomosis
1272275|NCT00878241|Intestine
1272276|NCT00878241|Colorectal Surgery
1272277|NCT00878241|Colorectal Anastomosis
1272278|NCT00878215|Image Guided Liver Surgery
1272279|NCT00878189|Phase 1 dose escalation study in advanced solid tumor malignancy and leukemia
1272280|NCT00878176|sacral neuromodulation therapy
1272281|NCT00878176|urinary retention
1272282|NCT00878176|screening
1272283|NCT00878176|non obstructive urinary retention
1272284|NCT00878150|traumatic brain injury
1272285|NCT00878150|TBI
1272286|NCT00878150|head injury
1272287|NCT00878150|brain injury
1272288|NCT00878150|depression
1272289|NCT00878150|major depressive disorder
1272290|NCT00878150|cognitive behavioral therapy
1272291|NCT00878150|CBT
1272292|NCT00878150|counseling
1272293|NCT00878124|Poor ovarian response
1272294|NCT00878124|Chromosomal aberrations
1272295|NCT00878124|poor pregnancy outcome
1272296|NCT00878124|Late maternal age
1272297|NCT00878111|NGR-hTNF
1272298|NCT00878111|Solid tumours
1272299|NCT00878111|High doses
1272300|NCT00878098|DDT
1272301|NCT00878098|Malaria
1272302|NCT00878098|Pregnancy Outcome
1272303|NCT00878098|Spontaneous Abortion
1272304|NCT00878098|HIV
1272305|NCT00878098|Pregnancy
1272306|NCT00878085|Robot Therapy
1272307|NCT00878085|Upper Limb
1272308|NCT00878085|Stroke
1272309|NCT00878085|Rehabilitation
1272310|NCT00878085|fMRI
1272311|NCT00878085|DTI
1272312|NCT00878072|Herpes labialis
1272313|NCT00878072|cold sores
1272314|NCT00878072|herpes simplex type 1
1272315|NCT00878046|Hip
1272316|NCT00878046|Cementless
1272317|NCT00878046|Conservative
1272318|NCT00878007|Anaemia
1272319|NCT00878007|Malaria
1272320|NCT00878007|Literacy
1272321|NCT00878007|Kenya
1272322|NCT00877994|Disordered Eating
1272323|NCT00877994|Parenting
1272324|NCT00877994|Mothers
1272325|NCT00877981|hyperparathyroidism
1272326|NCT00877981|surgery
1272327|NCT00877981|minimal invasive
1272328|NCT00877981|videoassited
1272329|NCT00877968|Pea flour
1272330|NCT00877968|Glycemic response
1272331|NCT00877968|Diabetes
1272332|NCT00877968|Sensory
1272333|NCT00877968|Functional food
1272334|NCT00877968|Diabetes control and prevention
1272335|NCT00877955|bioequivalence
1272336|NCT00877955|pharmacokinetic
1272337|NCT00877955|alprazolam
1272338|NCT00877955|sublingual
1272339|NCT00877903|Acute myocardial infarction
1272340|NCT00877903|AMI
1272341|NCT00877903|Myocardial infarction
1272342|NCT00877903|Heart attack
1272343|NCT00877903|Mesenchymal stem cells
1272344|NCT00877903|MSC
1272345|NCT00877903|Adult human stem cells
1272346|NCT00877903|Osiris
1272347|NCT00877890|diabetes
1272348|NCT00877890|exenatide once weekly
1272349|NCT00877890|Byetta
1272350|NCT00877890|Amylin
1272351|NCT00877890|Lilly
1272352|NCT00877890|Bydureon
1272353|NCT00877877|HPV vaccine
1272354|NCT00877877|cervical cancer
1272355|NCT00877864|diabetes
1272356|NCT00877864|exercise
1272357|NCT00877864|printed materials
1272358|NCT00877851|Diet
1272359|NCT00877851|Physical activity
1272360|NCT00877851|Self management
1272361|NCT00877851|Goal setting
1272362|NCT00877838|Headache
1272363|NCT00877838|Migraine
1272364|NCT00877838|Aura
1272365|NCT00877838|Acute
1272366|NCT00877838|Attack
1272367|NCT00877838|Clinical
1272368|NCT00877838|Trial
1272369|NCT00877838|Intervention
1272370|NCT00877838|Nitrogen Oxide
1272371|NCT00877838|NOS
1272372|NCT00877838|nNOS
1272373|NCT00877838|Triptan
1272374|NCT00877838|5HT
1272375|NCT00877838|Serotonin
1272376|NCT00877825|Diet Therapy
1272377|NCT00877812|Vitamin B6
1272378|NCT00877812|Vitamin B6 deficiency
1272379|NCT00877812|Amino acids
1272380|NCT00877812|pyridoxine
1272381|NCT00877799|pain
1272382|NCT00877799|acute pain
1272383|NCT00877799|visceral pain
1272384|NCT00877799|kappa agonist
1272385|NCT00877799|opioid analgesics
1272386|NCT00877799|peripheral nervous system agents
1272387|NCT00877799|physiological effects of drugs
1272388|NCT00877799|surgery
1272389|NCT00877799|hysterectomy
1272390|NCT00877799|post-operative
1272391|NCT00877799|post-operative complications
1272392|NCT00877773|Advanced cancer
1272393|NCT00877773|Advanced Cancer with genetic mutation
1272394|NCT00877773|Phosphoinositides 3-kinase
1272395|NCT00877773|PI3K
1272396|NCT00877773|PIK3 mutations
1272397|NCT00877773|Temsirolimus
1272398|NCT00877773|CCI-779
1272399|NCT00877773|Torisel
1272400|NCT00877773|mTOR inhibitor
1272401|NCT00877760|Hepatitis B Entecavir pegylated interferon a-2a
1272402|NCT00877747|PET
1272403|NCT00877734|alcohol dependence
1272404|NCT00877734|baclofen
1272405|NCT00877734|pharmacotherapy
1272406|NCT00877734|women
1272407|NCT00877721|Postural Control
1272408|NCT00877721|Gait
1272409|NCT00877721|Falls
1272410|NCT00877721|Elderly
1272411|NCT00877721|Old adults (65 years old and older) with low risk of falls
1272412|NCT00877708|E. Coli
1272413|NCT00877708|isolates
1272414|NCT00877695|HIV
1272415|NCT00877695|HIV Seronegativity
1272416|NCT00877695|prevention
1272417|NCT00877695|Hispanic
1272418|NCT00877695|Latino
1272419|NCT00877695|MSM
1272420|NCT00877695|men
1272421|NCT00877682|Prostate Cancer
1272422|NCT00877682|Prostate Tumor
1272423|NCT00877682|Adenocarcinoma of the Prostate
1272424|NCT00877682|PCA
1272425|NCT00877682|Regional Prostate Cryoablation
1272426|NCT00877682|Cryotherapy
1272427|NCT00877682|Cryoablation
1272428|NCT00877682|Health Related Quality of Life
1272429|NCT00877682|HRQOL
1272430|NCT00877617|Quality of Life
1272431|NCT00877617|QOL
1272432|NCT00877617|Questionnaire
1272433|NCT00877617|High Risk localized Prostate Cancer
1272434|NCT00877617|HRLPC
1272435|NCT00877617|Neoadjuvant Investigational Therapy
1272436|NCT00877617|Radical Prostatectomy
1272437|NCT00877604|ALS
1272438|NCT00877604|Therapy
1272439|NCT00877604|Tauroursodeoxycholic acid
1272440|NCT00877604|TUDCA
1272441|NCT00877604|antioxidant
1272442|NCT00877604|antiapoptotic drug
1272443|NCT00877604|neuroprotective drug
1272444|NCT00877591|Interaction of Buprenorphine with HIV and TB Medications
1272445|NCT00877578|elderly patient
1272446|NCT00877578|malnutrition
1272447|NCT00877578|new nutritional support
1272448|NCT00877578|micronutrients
1272449|NCT00877578|elderly patient malnutrition
1272450|NCT00877565|LVF
1272451|NCT00877565|Left ventricular systolic function
1272452|NCT00877552|Schizophrenia
1272453|NCT00877552|brain development
1272454|NCT00877552|MRI
1272455|NCT00877539|Asthma Allergen Challenge
1272456|NCT00877513|Smoking
1272457|NCT00877513|Insulin resistance
1272458|NCT00877513|Metabolic syndrome
1272459|NCT00877513|Body fat distribution
1272460|NCT00877513|Cigarette smoking
1272461|NCT00877500|HER2/neu-negative Breast Cancer
1272462|NCT00877500|Residual Breast Cancer
1272463|NCT00877500|Surgery
1272464|NCT00877500|Neoadjuvant Systemic Therapy
1272465|NCT00877500|NST
1272466|NCT00877500|Ixabepilone
1272467|NCT00877500|BMS-247550
1272468|NCT00877500|Epothilone B analogue
1272469|NCT00877487|ADHD
1272470|NCT00877474|PM01183
1272471|NCT00877474|Solid tumors
1272472|NCT00877474|PharmaMar USA
1272473|NCT00877448|INFLUENZA
1272474|NCT00877448|VACCINE
1272475|NCT00877448|UNIVERSAL
1272476|NCT00877448|SAFETY
1272477|NCT00877422|vitamin deficiency
1272478|NCT00877409|Acnase
1272479|NCT00877409|Acne Vulgaris
1272480|NCT00877409|Safety
1272481|NCT00877409|Efficacy
1272482|NCT00877383|chronic obstructive pulmonary disease
1272483|NCT00877383|COPD
1272484|NCT00877383|indacaterol
1272485|NCT00877383|tiotropium
1272486|NCT00877383|bronchodilation
1272487|NCT00877370|ertapenem
1272488|NCT00877370|continuous hemodialysis
1272489|NCT00877370|pharmacokinetics
1272490|NCT00877357|Vaccine
1272491|NCT00877357|Prevention
1272492|NCT00877357|Diphtheria
1272493|NCT00877357|Tetanus
1272494|NCT00877357|Pertussis
1272495|NCT00877357|Hepatitis B
1272496|NCT00877357|Haemophilus influenzae type b
1272497|NCT00877357|Lot Consistency
1272498|NCT00877357|Long Term Immunogenicity
1272499|NCT00877357|Reactogenicity
1272500|NCT00877357|Healthy infants
1272501|NCT00877344|Pregnancy
1272502|NCT00877344|IUC
1272503|NCT00877344|abortion
1272504|NCT00877344|contraception
1272505|NCT00877331|Drug Abuse
1272506|NCT00877331|Drug Addiction
1272507|NCT00877331|Drug Dependence
1272508|NCT00877331|Drug Usage
1272509|NCT00877331|Drug Use Disorders
1272510|NCT00877331|Substance Abuse
1272511|NCT00877331|Substance Addiction
1272512|NCT00877331|Substance Dependence
1272513|NCT00877331|Substance Use Disorders
1272514|NCT00877305|Ischemic Preconditioning
1272515|NCT00877305|Cognitive function
1272516|NCT00877292|Down Syndrome
1272517|NCT00877292|trisomy 21
1272518|NCT00877292|prenatal testing
1272519|NCT00877292|pregnant women
1272520|NCT00877279|Facial wrinkles
1272521|NCT00877279|Nasolabial folds
1272522|NCT00877266|catheter
1272523|NCT00877266|ultrasound guidance
1272524|NCT00877266|nerve stimulation
1272525|NCT00877266|electrical stimulation
1272526|NCT00877266|nerve block
1272527|NCT00877266|UCSD
1272528|NCT00877266|timed placement
1272529|NCT00877266|surgery
1272530|NCT00877266|Catheter Placement Time
1272531|NCT00877227|CVA
1272532|NCT00877227|stroke
1272533|NCT00877227|newborns
1272534|NCT00877227|homocysteine
1272535|NCT00877227|folinic acid
1272536|NCT00877214|Bendamustine
1272537|NCT00877214|Rituximab
1272538|NCT00877214|Significance of maintenance therapy
1272539|NCT00877214|Efficacy and safety
1272540|NCT00877201|Accommodation
1272541|NCT00877201|visual display terminal (VDT)
1272542|NCT00877201|antioxidant
1272543|NCT00877188|breast cancer
1272544|NCT00877188|exercise
1272545|NCT00877188|upper extremity function
1272546|NCT00877188|quality of life
1272547|NCT00877175|preterm infants
1272548|NCT00877175|mydriasis
1272549|NCT00877175|pupil dilation
1272550|NCT00877084|exacerbation
1272551|NCT00877084|COPD
1272552|NCT00877084|Resistance training
1272553|NCT00877084|Muscle force
1272554|NCT00877058|Frailty
1272555|NCT00877058|health promotion
1272556|NCT00877058|prevention
1272557|NCT00877058|self management
1272558|NCT00877058|intervention
1272559|NCT00877045|Gastrointestinal Stromal Tumors
1272560|NCT00877045|GIST
1272561|NCT00877045|tyrosine kinase inhibitors
1272562|NCT00877045|Imatinib
1272563|NCT00877045|Gleevec
1272564|NCT00877045|Suntinib
1272565|NCT00877045|Sutent
1272566|NCT00877032|Phase 1
1272567|NCT00877032|Dry Age Related Macular Degeneration
1272568|NCT00877032|RN6G
1272569|NCT00877019|sonic brushes
1272570|NCT00877019|time effectiveness
1272571|NCT00877019|brush head design
1272572|NCT00877019|ADA-toothbrush
1272573|NCT00877019|professional brushing
1272574|NCT00877019|time dependence
1272575|NCT00877019|efficacy
1272576|NCT00877019|toothbrush
1272577|NCT00876980|Obstructive sleep apnea
1272578|NCT00876980|Type II diabetes mellitus
1272579|NCT00876980|Randomized controlled trial
1272580|NCT00876967|anesthesiology
1272581|NCT00876967|randomized
1272582|NCT00876967|laryngoscope
1272583|NCT00876967|intubation
1272584|NCT00876967|laryngeal exposition
1272585|NCT00876967|laryngoscope blades
1272586|NCT00876967|plastic single use blade
1272587|NCT00876967|metallic single use blade
1272588|NCT00876967|metallic reusable blade
1272589|NCT00876967|success to intubation at first attempt
1272590|NCT00876967|Cormack and lehanne modify grade
1272591|NCT00876941|Drug
1272592|NCT00876941|Drug Use
1272593|NCT00876941|Screening
1272594|NCT00876941|Brief Intervention
1272595|NCT00876941|Primary Care
1272596|NCT00876941|Utilization
1272597|NCT00876928|pre-diabetes
1272598|NCT00876928|minorities
1272599|NCT00876928|oral glucose tolerance test
1272600|NCT00876928|disposition index
1272601|NCT00876928|insulin secretion
1272602|NCT00876928|insulin sensitivity
1272603|NCT00876928|diabetes
1272604|NCT00876915|prevention of VTE and PE in high risk cancer patients
1272605|NCT00876902|liver transplantation
1272606|NCT00876902|cadaveric liver transplantation
1272607|NCT00876902|ischemic reperfusion injury
1272608|NCT00876902|primary non-function
1272609|NCT00876902|delayed non-Function
1272610|NCT00876902|poor early graft function
1272611|NCT00876902|YSPSL
1272612|NCT00876902|recombinant PSGL-Ig
1272613|NCT00876889|spinal cord injury
1272614|NCT00876889|riluzole
1272615|NCT00876889|pharmacokinetics
1272616|NCT00876889|Acute Traumatic Spinal Cord Injury
1272617|NCT00876876|hypervolemic hyponatremia
1272618|NCT00876876|serum sodium
1272619|NCT00876876|fluid overload
1272620|NCT00876876|heartfailure
1272621|NCT00876876|acute heart failure
1272622|NCT00876876|vasopressin antagonist
1272623|NCT00876863|Alzheimer's disease
1272624|NCT00876863|Dementia
1272625|NCT00876863|Memory loss
1272626|NCT00876863|Cognitive impairment
1272627|NCT00876863|Nerve growth factor
1272628|NCT00876863|NGF
1272629|NCT00876863|Neurotrophic factors
1272630|NCT00876863|Gene therapy
1272631|NCT00876850|cSSI
1272632|NCT00876850|Abscess
1272633|NCT00876850|Would
1272634|NCT00876850|Cellulitis
1272635|NCT00876850|Complicated Skin and Skin Structure Infections (cSSSI)
1272636|NCT00876824|Black Fever
1272637|NCT00876824|Kala-Azar
1272638|NCT00876824|Amphotericin B lipid emulsion
1272639|NCT00876824|Liposomal Amphotericin B
1272640|NCT00876811|raspberry
1272641|NCT00876811|fruit
1272642|NCT00876811|antioxidants
1272643|NCT00876811|polyphenols
1272644|NCT00876811|oxidative stress
1272645|NCT00876811|dietary intervention
1272646|NCT00876798|Euvolemic Hyponatremia
1272647|NCT00876798|SIADH
1272648|NCT00876798|Serum Sodium
1272649|NCT00876785|Rye bread satiety breakfast
1272650|NCT00876772|ALS
1272651|NCT00876772|olanazapine
1272652|NCT00876772|Loss of Apptetite
1272653|NCT00876772|Appetite Loss
1272654|NCT00876772|Malnutrition
1272655|NCT00876772|Cachexia
1272656|NCT00876772|Zyprexa
1272657|NCT00876759|cerebral metastases
1272658|NCT00876746|Pain
1272659|NCT00876746|surgery
1272660|NCT00876746|catheter
1272661|NCT00876746|nerve block
1272662|NCT00876746|supraclavicular
1272663|NCT00876746|infraclavicular
1272664|NCT00876746|UCSD
1272665|NCT00876746|moderate-to-severe pain
1272666|NCT00876746|Supraclavicular catheter
1272667|NCT00876746|Infraclavicular catheter
1272668|NCT00876720|Tinnitus
1272669|NCT00876720|chronic subjective tinnitus
1272670|NCT00876720|transcranial magnetic stimulation
1272671|NCT00876720|sensation disorders
1272672|NCT00876720|hearing disorders
1272673|NCT00876707|wavefront
1272674|NCT00876707|multifocal IOL
1272675|NCT00876707|modulation transfer function
1272676|NCT00876707|intraocular lenses
1272677|NCT00876707|wavefront data
1272678|NCT00876707|Visual performance
1272679|NCT00876694|COPD, Chronic Obstructive Pulmonary Disease, Indacaterol, long acting β2-agonist
1272680|NCT00876681|Catheter
1272681|NCT00876681|Ultrasound-guidance
1272682|NCT00876681|Nerve Stimulation
1272683|NCT00876681|Electrical stimulation
1272684|NCT00876681|nerve block
1272685|NCT00876681|UCSD
1272686|NCT00876681|Orthopedic surgery
1272687|NCT00876681|Foot/ankle pain
1272688|NCT00876681|Foot/ankle numbness
1272689|NCT00876681|Popliteal-Sciatic Catheters
1272690|NCT00876668|Peripheral Vascular diseases
1272691|NCT00876668|Microcirculation
1272692|NCT00876668|fluorescence angiography
1272693|NCT00876642|Radiation dermatitis
1272694|NCT00876642|best supportive care
1272695|NCT00876642|Aloe vera gel
1272696|NCT00876642|phase III study was to assess the effectiveness of aloe vera and vitamin E.
1272697|NCT00876629|MR Elastography
1272698|NCT00876629|kidney
1272699|NCT00876629|fibrosis
1272700|NCT00876616|lupus nephritis;multi-target therapy; MMF; FK506
1272701|NCT00876603|cervical spondylotic myelopathy
1272702|NCT00876603|anterior decompression and fusion
1272703|NCT00876603|cervical laminoplasty
1272704|NCT00876577|Acute Exacerbations of Chronic Bronchitis
1272705|NCT00876577|Avelox
1272706|NCT00876577|Bronchitis
1272707|NCT00876564|Triage precision
1272708|NCT00876551|Negative-Pressure Wound Therapy
1272709|NCT00876551|Endoscopic/endoluminal V.A.C. therapy
1272710|NCT00876551|Esophagectomy
1272711|NCT00876551|Anastomotic leakage
1272712|NCT00876551|Anastomosis, Surgical
1272713|NCT00876538|Chemotherapy Induced Peripheral Neuropathy
1272714|NCT00876538|TR019622
1272715|NCT00876538|Trophos
1272716|NCT00876525|Heart diseases.
1272717|NCT00876525|Aortic valve diseases.
1272718|NCT00876525|Aortic valve insufficiency.
1272719|NCT00876525|Aortic valve stenosis.
1272720|NCT00876512|thienopyridine resistance
1272721|NCT00876512|stable effort angina
1272722|NCT00876512|platelet activation
1272723|NCT00876512|ADAMTS13
1272724|NCT00876512|von Willebrand Factor
1272725|NCT00876499|Primary Brain Tumor
1272726|NCT00876499|PBT
1272727|NCT00876499|Brain Cancer
1272728|NCT00876499|Primary glioma
1272729|NCT00876499|Astrocytoma
1272730|NCT00876499|Oligodendroglioma
1272731|NCT00876499|Oligo-astrocytoma
1272732|NCT00876499|Ependymoma
1272733|NCT00876499|Anaplastic astrocytoma
1272734|NCT00876499|Anaplastic oligodendroglioma
1272735|NCT00876499|Anaplastic oligo-astrocytoma
1272736|NCT00876499|Anaplastic ependymoma
1272737|NCT00876499|Fatigue
1272738|NCT00876499|Cytokines
1272739|NCT00876499|Questionnaires
1272740|NCT00876499|Actigraphy
1272741|NCT00876499|Sleep Disturbance
1272742|NCT00876499|Radiation Therapy
1272743|NCT00876473|CPAP
1272744|NCT00876473|Acute Respiratory Failure
1272745|NCT00876434|Sirolimus
1272746|NCT00876434|Anterior Uveitis
1272747|NCT00876434|Autoimmune Disease
1272748|NCT00876434|Uveitis
1272749|NCT00876421|ONO-8539
1272750|NCT00876421|Overactive bladder
1272751|NCT00876421|OAB
1272752|NCT00876408|RT-PCR molecular profiling assay
1272753|NCT00876408|Molecular Profiling-Real Time Polymerase Chain Reaction
1272754|NCT00876408|Unknown Primary
1272755|NCT00876408|UPC
1272756|NCT00876408|CUP
1272757|NCT00876395|Breast Cancer
1272758|NCT00876395|HER2+
1272759|NCT00876395|mTOR
1272760|NCT00876395|everolimus
1272761|NCT00876395|RAD001
1272762|NCT00876395|first line
1272763|NCT00876395|metastatic
1272764|NCT00876395|locally advanced
1272765|NCT00876382|advanced renal cell carcinoma
1272766|NCT00876382|renal cancer
1272767|NCT00876382|renal cell
1272768|NCT00876382|Sorafenib
1272769|NCT00876382|Nexavar
1272770|NCT00876382|Bevacizumab
1272771|NCT00876382|Avastin
1272772|NCT00876382|Sunitinib
1272773|NCT00876382|Sutent
1272774|NCT00876369|urticaria
1272775|NCT00876369|angioedema
1272776|NCT00876369|vitamin D
1272777|NCT00876369|allergy
1272778|NCT00876356|Asthma
1272779|NCT00876356|Conjugated Linoleic Acid (CLA)
1272780|NCT00876356|dietary supplement
1272781|NCT00876330|Clinical Decision Support Systems
1272782|NCT00876330|Hyperlipidemia
1272783|NCT00876330|Hypertension
1272784|NCT00876317|Tenosynovitis
1272785|NCT00876317|Bursitis
1272786|NCT00876304|PF-04802540 multiple dose safety study
1272787|NCT00876278|Cataract
1272788|NCT00876278|Intraocular Lens (IOL)
1272789|NCT00876278|Mesotest II
1272790|NCT00876278|Evaluation of usability of Mesotest II for assessment of night driving capacity of pseudo-phakic patients
1272791|NCT00876265|Facial wrinkles
1272792|NCT00876265|Nasolabial fold
1272793|NCT00876226|Citalopram
1272794|NCT00876226|Pharmacokinetics
1272795|NCT00876226|Short Bowel Syndrome
1272796|NCT00876213|Amylin
1272797|NCT00876213|GLP-1
1272798|NCT00876213|gastric emptying
1272799|NCT00876213|appetite and food intake
1272800|NCT00876200|Williams Beuren syndrome
1272801|NCT00876200|Cardiovascular abnormalities
1272802|NCT00876200|Cardiovascular structure
1272803|NCT00876187|randomized controlled trial
1272804|NCT00876187|monoclonal antibody
1272805|NCT00876187|nerve growth factor
1272806|NCT00876187|naproxen
1272807|NCT00876174|Chronic hepatitis C
1272808|NCT00876174|Genotype 1
1272809|NCT00876161|Healthy Adults
1272810|NCT00876148|Incidence of hepatitis B after allografting
1272811|NCT00876148|Risk of hepatitis B reactivation
1272812|NCT00876148|Lamivudine prophylaxis
1272813|NCT00876122|NHL
1272814|NCT00876122|Metastatic Solid Tumors
1272815|NCT00876122|PI3K Inhibitors
1272816|NCT00876122|PI3K
1272817|NCT00876109|Metastatic Solid Tumors
1272818|NCT00876109|PI3K
1272819|NCT00876109|PI3K Inhibitors
1272820|NCT00876096|Diagnosis, Differential
1272821|NCT00876083|Drug utilization review
1272822|NCT00876070|Metastatic Breast Cancer
1272823|NCT00876070|Breast Cancer
1272824|NCT00876070|MBC
1272825|NCT00876070|Abraxane
1272826|NCT00876070|Paclitaxel
1272827|NCT00876070|Taxol
1272828|NCT00876070|Docetaxel
1272829|NCT00876070|Taxotere
1272830|NCT00876057|psychological well-being
1272831|NCT00876057|recovery
1272832|NCT00876057|time in hospital
1272833|NCT00876057|sick-leave
1272834|NCT00876057|complications
1272835|NCT00876057|Sexual well-being
1272836|NCT00876031|pediatric soft tissue sarcoma
1272837|NCT00876031|rhabdomyosarcoma
1272838|NCT00876031|extraosseous Ewing family tumours
1272839|NCT00876031|synovial sarcoma
1272840|NCT00876031|undifferentiated sarcoma
1272841|NCT00876018|physical performance
1272842|NCT00876018|micronutrients
1272843|NCT00876018|physical fitness
1272844|NCT00876018|healthy children
1272845|NCT00876005|Wound infection
1272846|NCT00875979|MBC
1272847|NCT00875979|Breast Cancer
1272848|NCT00875979|HER2+
1272849|NCT00875979|HER2+ breast cancer
1272850|NCT00875979|HER2 positive breast cancer
1272851|NCT00875979|herceptin
1272852|NCT00875979|Trastuzumab emtansine
1272853|NCT00875953|squamous cell carcinoma
1272854|NCT00875953|head and neck cancer
1272855|NCT00875953|neck dissection
1272856|NCT00875927|Halitosis
1272857|NCT00875914|AV-node reentry tachycardia
1272858|NCT00875914|radiofrequency ablation
1272859|NCT00875914|magnetic navigation system
1272860|NCT00875901|Lung Cancer
1272861|NCT00875901|Stage I Non-Small Cell Lung Cancer
1272862|NCT00875901|Proton Radiation
1272863|NCT00875901|HypoIGRT
1272864|NCT00875875|Diarrhea, travelers
1272865|NCT00875875|Acute travelers' diarrhea
1272866|NCT00875862|UCSD
1272867|NCT00875862|pain
1272868|NCT00875862|quality-of-life
1272869|NCT00875862|range-of-motion
1272870|NCT00875862|interscalene catheter
1272871|NCT00875862|nerve block
1272872|NCT00875862|shoulder
1272873|NCT00875862|Shoulder Manipulation
1272874|NCT00875849|recurrent squamous cell carcinoma of the hypopharynx
1272990|NCT00875368|treatment experienced
1272875|NCT00875849|stage I squamous cell carcinoma of the hypopharynx
1272876|NCT00875849|stage II squamous cell carcinoma of the hypopharynx
1272877|NCT00875849|stage III squamous cell carcinoma of the hypopharynx
1272878|NCT00875849|recurrent squamous cell carcinoma of the larynx
1272879|NCT00875849|stage I squamous cell carcinoma of the larynx
1272880|NCT00875849|stage II squamous cell carcinoma of the larynx
1272881|NCT00875849|stage III squamous cell carcinoma of the larynx
1272882|NCT00875849|stage I squamous cell carcinoma of the lip and oral cavity
1272883|NCT00875849|stage II squamous cell carcinoma of the lip and oral cavity
1272884|NCT00875849|stage III squamous cell carcinoma of the lip and oral cavity
1272885|NCT00875849|recurrent squamous cell carcinoma of the lip and oral cavity
1272886|NCT00875849|recurrent squamous cell carcinoma of the oropharynx
1272887|NCT00875849|stage I squamous cell carcinoma of the oropharynx
1272888|NCT00875849|stage II squamous cell carcinoma of the oropharynx
1272889|NCT00875849|stage III squamous cell carcinoma of the oropharynx
1272890|NCT00875849|tongue cancer
1272891|NCT00875836|Marijuana
1272892|NCT00875836|Buspirone
1272893|NCT00875836|Contingency management
1273140|NCT00874627|children > 5 years old
1272894|NCT00875836|Motivational enhancement therapy
1272895|NCT00875823|PH
1272896|NCT00875823|Primary Hyperoxaluria
1272897|NCT00875823|Type I
1272898|NCT00875823|Type II
1272899|NCT00875823|NonI-NonII
1272900|NCT00875823|Kidney stones
1272901|NCT00875823|oxalate
1272902|NCT00875823|oxalosis
1272903|NCT00875797|enteral
1272904|NCT00875797|parenteral
1272905|NCT00875797|glutamine
1272906|NCT00875797|intestinal permeability
1272907|NCT00875797|infection
1272908|NCT00875784|Sumatriptan exposure
1272909|NCT00875771|metastatic colorectal cancer
1272910|NCT00875771|BEVACIZUMAB
1272911|NCT00875771|CAPECITABINE
1272912|NCT00875771|IRINOTECAN
1272913|NCT00875758|preterm infants
1272914|NCT00875758|IVH
1272915|NCT00875758|germinal matrix
1272916|NCT00875758|intraventricular hemorrhage
1272917|NCT00875758|hydrocephalus
1272918|NCT00875732|Resynchronization
1272919|NCT00875732|Device
1272920|NCT00875732|Bradycardia
1272921|NCT00875732|atrioventricular block
1272922|NCT00875732|Cardiac Resynchronization
1272923|NCT00875719|COPD patients with respiratory failure
1272924|NCT00875706|Nursing Homes
1272925|NCT00875706|Implementation of innovative programs
1272926|NCT00875706|Nursing staff
1272927|NCT00875706|Nurses' aides
1272928|NCT00875706|Educational models
1272929|NCT00875693|AML
1272930|NCT00875693|leukemia
1272931|NCT00875693|MDS
1272932|NCT00875667|Mantle Cell Lymphoma
1272933|NCT00875667|Relapsed Mantle Cell Lymphoma
1272934|NCT00875667|Refractory Mantle Cell Lymphoma
1272935|NCT00875667|Lymphoma
1272936|NCT00875667|MCL
1272937|NCT00875654|Cell therapy
1272938|NCT00875654|Stroke
1272939|NCT00875654|Neuronal Plasticity
1272940|NCT00875654|Recovery
1272941|NCT00875654|Mesenchymal Stem Cells
1272942|NCT00875654|Transplantation
1272943|NCT00875628|Japanese Healthy volunteers HCV pharmacokinetics PF-00868554 filibuvir
1272944|NCT00875615|adult primary hepatocellular carcinoma
1272945|NCT00875615|localized unresectable adult primary liver cancer
1272946|NCT00875615|advanced adult primary liver cancer
1272947|NCT00875602|All hospitalized patients in a general Med/ Surg unit
1272948|NCT00875589|Traumatic Brain Injury
1272949|NCT00875589|Eye movement recording
1272950|NCT00875576|social influences
1272951|NCT00875576|meals
1272952|NCT00875576|obesity
1272953|NCT00875576|amount of food consumed
1272954|NCT00875550|Intubated and mechanically ventilated PICU subjects
1272955|NCT00875537|Burning mouth syndrome
1272956|NCT00875537|neuropathy
1272957|NCT00875537|inflammation
1272958|NCT00875537|tongue mucosa
1272959|NCT00875537|tongue innervation
1272960|NCT00875537|dysgeusia
1272961|NCT00875524|Dengue virus
1272962|NCT00875524|Dengue fever
1272963|NCT00875524|Dengue hemorrhagic fever
1272964|NCT00875524|Dengue diseases
1272965|NCT00875524|Dengue vaccine
1272966|NCT00875511|peer rejection
1272967|NCT00875511|obesity
1272968|NCT00875511|amount of food chosen
1272969|NCT00875511|amount of social time chosen
1272970|NCT00875498|iTBS
1272971|NCT00875498|Negative Symptoms
1272972|NCT00875485|Monovalent Hepatitis A
1272973|NCT00875485|hepatitis B vaccine
1272974|NCT00875485|Belgium and Czech Republic
1272975|NCT00875472|social influences
1272976|NCT00875472|food purchases
1272977|NCT00875472|childhood obesity
1272978|NCT00875472|amount of energy dense food and beverage items purchased
1272979|NCT00875472|amount of nutrient dense food and beverage items purchased
1272980|NCT00875420|hot flashes
1272981|NCT00875420|hot flushes
1272982|NCT00875420|vasomotor symptoms
1272983|NCT00875420|postmenopausal
1272984|NCT00875381|Melanocytes
1272985|NCT00875368|HIV-1
1272986|NCT00875368|HAART
1272987|NCT00875368|CD4 cell
1272988|NCT00875368|Immunologic non-responders
1272989|NCT00875368|Immunology
1272991|NCT00875355|tumors metastatic to brain
1272992|NCT00875355|stage IV breast cancer
1272993|NCT00875342|Traumatic Event
1272994|NCT00875342|Trauma Survivor
1272995|NCT00875342|Exposure Therapy
1272996|NCT00875342|PTSD DCS
1272997|NCT00875342|Telemedicine
1272998|NCT00875342|Telepsychiatry
1272999|NCT00875342|Telemental health
1273000|NCT00875329|Brain Injury
1273001|NCT00875316|Parkinson's disease
1273002|NCT00875316|Phase I
1273003|NCT00875303|Parents' plans to discipline their children
1273004|NCT00875290|Diabetes Mellitus, Type I
1273005|NCT00875290|Children
1273006|NCT00875290|Insulin pump therapy
1273007|NCT00875290|Continuous glucose monitor
1273008|NCT00875264|CEP-11981
1273009|NCT00875264|TIE-2
1273010|NCT00875264|VEGF-R
1273011|NCT00875251|body composition
1273012|NCT00875251|preterm infant
1273013|NCT00875251|anthropometry
1273014|NCT00875238|cardiac toxicity
1273015|NCT00875238|cardiovascular complications
1273016|NCT00875238|stage I breast cancer
1273017|NCT00875238|stage II breast cancer
1273018|NCT00875238|stage IIIA breast cancer
1273019|NCT00875238|stage IIIB breast cancer
1273020|NCT00875238|stage IIIC breast cancer
1273021|NCT00875225|Hypertension
1273022|NCT00875225|Adherence to medications
1273023|NCT00875212|Calcium glycerophosphate
1273024|NCT00875212|Fluoride
1273025|NCT00875212|Dentifrice
1273026|NCT00875212|Biofilm
1273027|NCT00875212|Dental caries
1273028|NCT00875199|Overweight
1273029|NCT00875199|Obesity
1273030|NCT00875199|Contingency Management
1273031|NCT00875186|bariatric surgery
1273032|NCT00875186|co-morbidities
1273033|NCT00875186|aerobic physical exercise
1273034|NCT00875173|Selenium
1273035|NCT00875173|Chagas disease
1273036|NCT00875173|Chagasic cardiopathy
1273037|NCT00875147|neoadjuvant chemotherapy
1273038|NCT00875147|bevacizumab
1273039|NCT00875121|Food reinforcement
1273040|NCT00875121|social reinforcers
1273041|NCT00875121|overweight
1273042|NCT00875121|children
1273043|NCT00875095|sperm DNA integrity
1273044|NCT00875095|Toluidine blue staining
1273045|NCT00875082|Asthma
1273046|NCT00875082|Children
1273047|NCT00875082|Remodelling
1273048|NCT00875082|Metalloproteinases
1273049|NCT00875082|Montelukast
1273050|NCT00875069|Nosocomial infection
1273051|NCT00875069|Catheterization
1273052|NCT00875069|Central Venous Ethanol
1273053|NCT00875069|lock solution
1273054|NCT00875069|intensive care units
1273055|NCT00875069|Renal replacement therapy in ICU
1273056|NCT00875043|ischemic optic neuropathy
1273057|NCT00875043|cortical blindness
1273058|NCT00875030|Bioequivalence study-artesunate sachets-arsuamoon tablet
1273059|NCT00875004|anemia
1273060|NCT00875004|unspecified adult solid tumor, protocol specific
1273061|NCT00874991|Cardiac deformation
1273062|NCT00874991|Cardiopulmonary bypass
1273063|NCT00874991|TEE
1273064|NCT00874991|Cardiac Surgery
1273065|NCT00874991|Left ventricular function
1273066|NCT00874991|Pulmonary Artery catheter
1273067|NCT00874991|Tissue Doppler
1273068|NCT00874991|Left ventricular function in cardiac surgery
1273069|NCT00874978|Lenalidomide
1273070|NCT00874978|myelodysplastic syndromes
1273071|NCT00874965|Chronic Obstructive Pulmonary Disease (COPD)
1273072|NCT00874965|Electrostimulation
1273073|NCT00874965|Muscle function
1273074|NCT00874965|Exercise ventilation
1273075|NCT00874965|Anabolism/catabolism pathway
1273076|NCT00874952|Metabolic syndrome
1273077|NCT00874952|Lipids
1273078|NCT00874952|Waist Circumference
1273079|NCT00874952|HDL
1273080|NCT00874952|hypertension
1273081|NCT00874926|Octocog alfa
1273082|NCT00874926|Haemophilia A
1273083|NCT00874913|blood flow
1273084|NCT00874913|obstructive sleep apnea syndrome
1273085|NCT00874913|normal tension glaucoma
1273086|NCT00874874|stage III adult soft tissue sarcoma
1273087|NCT00874874|stage IV adult soft tissue sarcoma
1273088|NCT00874874|recurrent adult soft tissue sarcoma
1273089|NCT00874874|adult angiosarcoma
1273090|NCT00874861|cancer
1273091|NCT00874861|brain
1273092|NCT00874861|tumor
1273093|NCT00874861|vaccine
1273094|NCT00874848|Imprime PGG
1273095|NCT00874848|NSCLC
1273096|NCT00874848|Cetuximab
1273097|NCT00874835|Endothelial Keratoplasty
1273098|NCT00874835|EK
1273099|NCT00874835|Descemet Stripping Endothelial Keratoplasty
1273100|NCT00874835|Corneal Transplantation
1273101|NCT00874835|Keratoplasty
1273102|NCT00874835|DSEK
1273103|NCT00874835|DSAEK
1273104|NCT00874809|insulin pump
1273105|NCT00874809|DM Type 2
1273106|NCT00874809|CGMS
1273107|NCT00874809|basal rate
1273108|NCT00874796|apoptosis
1273109|NCT00874796|liver inflammation
1273110|NCT00874796|hepatitis C
1273111|NCT00874783|Amyotrophic Lateral Sclerosis
1273112|NCT00874783|Familial Dysautonomia
1273113|NCT00874783|Parkinson's Disease
1273114|NCT00874783|Alzheimer's Disease
1273115|NCT00874783|Age Related Macular Degeneration
1273116|NCT00874783|Retinitis Pigmentosa
1273117|NCT00874783|Huntington's Disease
1273118|NCT00874783|Machado - Joseph Disease
1273119|NCT00874783|SMA - Spinal Muscular Atrophy
1273120|NCT00874783|Ataxia Telangiectasia
1273121|NCT00874770|Antivirals
1273122|NCT00874757|Statins, anti-inflammatory
1273123|NCT00874757|Healthy subjects study
1273124|NCT00874744|Diabetic macular edema
1273125|NCT00874744|intravitreal injection
1273126|NCT00874744|Pharmacological treatment
1273127|NCT00874718|repetitive strain injury
1273128|NCT00874718|quality of life
1273129|NCT00874718|functional capacity
1273130|NCT00874718|workers
1273131|NCT00874692|tap water temperature
1273132|NCT00874692|social housing
1273133|NCT00874692|scald reduction
1273134|NCT00874692|Temperature (degrees Celsius) of hot tap water at point of delivery.
1273135|NCT00874666|garlic
1273136|NCT00874666|allicin
1273137|NCT00874666|allyl methyl sulfide
1273138|NCT00874666|healthy persons
1273139|NCT00874640|Drug utilization review
1273141|NCT00874627|IgE-mediated
1273142|NCT00874627|cow milk allergy
1273143|NCT00874627|IgE-mediated cow milk allergy persisting after 5 years
1273144|NCT00874614|radiotherapy
1273145|NCT00874614|MIBG
1273146|NCT00874614|Azedra
1273147|NCT00874614|neuroendocrine tumors
1273148|NCT00874614|Iobenguane I 131
1273149|NCT00874614|progenics
1273150|NCT00874601|acute ischemic stroke
1273151|NCT00874601|blood pressure
1273152|NCT00874601|valsartan
1273153|NCT00874601|death
1273154|NCT00874601|dependancy
1273155|NCT00874575|HMB
1273156|NCT00874575|Vitamin D
1273157|NCT00874575|Older Adults
1273158|NCT00874562|rapamycin
1273159|NCT00874562|corticosteroid
1273160|NCT00874562|ALL
1273161|NCT00874549|Meningococcal Vaccine
1273162|NCT00874549|Menactra®
1273163|NCT00874549|Menomune®
1273164|NCT00874536|ADHD
1273165|NCT00874536|methylphenidate
1273166|NCT00874536|omega-3
1273167|NCT00874523|raltegravir
1273168|NCT00874523|atazanavir
1273169|NCT00874523|HIV infections
1273170|NCT00874523|pharmacokinetics
1273171|NCT00874523|antiretroviral agents
1273172|NCT00874523|treatment experienced
1273173|NCT00874510|sleep deprivation
1273174|NCT00874510|fatigue
1273175|NCT00874458|ductal breast carcinoma in situ
1273176|NCT00874432|cardiovascular disease
1273177|NCT00874432|angiotensin converting enzyme inhibitors
1273178|NCT00874432|chronic kidney disease
1273179|NCT00874432|cardiovascular disease in elderly patients with CKD
1273180|NCT00874419|EGFR mutation
1273181|NCT00874419|EGFR-TKI
1273182|NCT00874419|Chemotherapy
1273183|NCT00874406|colorectal cancer
1273184|NCT00874406|liver metastasis
1273185|NCT00874406|neoadjuvant chemotherapy
1273186|NCT00874393|NICHD Neonatal Research Network
1273187|NCT00874393|Very Low Birth Weight (VLBW)
1273188|NCT00874393|Extremely Low Birth Weight (ELBW)
1273189|NCT00874393|Prematurity
1273190|NCT00874393|Blood Pressure Management
1273191|NCT00874393|Dopamine
1273192|NCT00874393|Hydrocortisone
1273193|NCT00874380|Fiber
1273194|NCT00874380|Dialysis
1273195|NCT00874380|Renal Replacement Therapy
1273196|NCT00874380|Food Frequency Questionnaire
1273197|NCT00874380|FFQ
1273198|NCT00874380|Dietary counseling
1273199|NCT00874367|NICHD Neonatal Research Network
1273200|NCT00874367|Very Low Birth Weight (VLBW)
1273201|NCT00874367|Extremely Low Birth Weight (ELBW)
1273202|NCT00874367|Prematurity
1273203|NCT00874367|Early Onset Sepsis
1273204|NCT00874354|Myocardial Infarction
1273205|NCT00874354|Heart Attack
1273206|NCT00874354|Infarct
1273207|NCT00874354|Stem Cells
1273208|NCT00874354|Bone Marrow Derived Mononuclear Cells
1273209|NCT00874354|CHF
1273210|NCT00874354|Congestive Heart Failure
1273211|NCT00874354|Stent
1273212|NCT00874354|PCI
1273213|NCT00874354|Percutaneous Coronary Intervention
1273214|NCT00874341|Fruit
1273215|NCT00874341|Vegetables
1273216|NCT00874341|Intervention
1273217|NCT00874341|Insulin resistance
1273218|NCT00874341|Cardiovascular disease risk
1273219|NCT00874341|Dose response
1273220|NCT00874341|High risk of cardiovascular disease
1273221|NCT00874328|Non small cell lung cancer
1273222|NCT00874328|Irinotecan plus Cisplatin plus S-1
1273223|NCT00874328|Phase I/II trial
1273224|NCT00874315|recurrent or refractory neuroblastoma
1273225|NCT00874302|Uterine fibroids
1273226|NCT00874289|NGAL
1273227|NCT00874289|Heart failure
1273228|NCT00874276|DCA
1273229|NCT00874276|Dichloroacetate
1273230|NCT00874276|Trichloroacetate
1273231|NCT00874263|Probe-based imaging of GI pre-malignant or malignant lesions
1273232|NCT00874237|Staccato loxapine
1273233|NCT00874237|QTc
1273234|NCT00874237|healthy volunteers
1273235|NCT00874224|Colorectal cancer liver metastasis
1273236|NCT00874224|Benign liver disease
1273237|NCT00874211|bone metastases
1273238|NCT00874211|unspecified adult solid tumor, protocol specific
1273239|NCT00874211|refractory multiple myeloma
1273240|NCT00874211|stage I multiple myeloma
1273241|NCT00874211|stage II multiple myeloma
1273242|NCT00874211|stage III multiple myeloma
1273243|NCT00874211|male breast cancer
1273244|NCT00874211|recurrent breast cancer
1273245|NCT00874211|stage IA breast cancer
1273246|NCT00874211|stage IB breast cancer
1273247|NCT00874211|stage II breast cancer
1273248|NCT00874211|stage IIIA breast cancer
1273249|NCT00874211|stage IIIB breast cancer
1273250|NCT00874211|stage IIIC breast cancer
1273251|NCT00874211|stage IV breast cancer
1273252|NCT00874211|recurrent prostate cancer
1273253|NCT00874211|stage I prostate cancer
1273254|NCT00874211|stage IIB prostate cancer
1273255|NCT00874211|stage IIA prostate cancer
1273256|NCT00874211|stage III prostate cancer
1273257|NCT00874211|stage IV prostate cancer
1273258|NCT00874211|recurrent non-small cell lung cancer
1273259|NCT00874211|stage I non-small cell lung cancer
1273260|NCT00874211|stage II non-small cell lung cancer
1273261|NCT00874211|stage IIIA non-small cell lung cancer
1273262|NCT00874211|stage IIIB non-small cell lung cancer
1273263|NCT00874211|stage IV non-small cell lung cancer
1273264|NCT00874211|extensive stage small cell lung cancer
1273265|NCT00874211|limited stage small cell lung cancer
1273266|NCT00874211|recurrent small cell lung cancer
1273267|NCT00874198|normal pressure hydrocephalus
1273268|NCT00874198|cerebrospinal fluid dynamic test
1273269|NCT00874198|cerebrospinal fluid outflow resistance
1273270|NCT00874198|cerebrospinal compliance
1273271|NCT00874198|outcome
1273272|NCT00874198|shunt surgery
1273273|NCT00874198|normal pressure hydrocephalus guidelines
1273274|NCT00874198|biomarkers
1273275|NCT00874198|shunt surgery selection
1273276|NCT00874198|Outcome measures
1273277|NCT00874198|Outcomes assessment
1273278|NCT00874198|Outcome and process assessment
1273279|NCT00874185|satisfaction
1273280|NCT00874172|Anemia
1273281|NCT00874172|Sickle Cell
1273282|NCT00874172|Analgesic
1273283|NCT00874172|Pain
1273284|NCT00874172|Emergency treatment
1273285|NCT00874172|Quality of life
1273286|NCT00874107|NSCLC
1273287|NCT00874107|Phase 2
1273288|NCT00874107|Randomized
1273289|NCT00874107|Efficacy
1273290|NCT00874107|Safety
1273291|NCT00874107|Imprime PGG
1273292|NCT00874107|Bevacizumab
1273293|NCT00874094|nasolabial folds
1273294|NCT00874094|platelet rich plasma
1273295|NCT00874094|fibrin matrix
1273296|NCT00874094|facial rhytids
1273297|NCT00874094|dermal filler
1273298|NCT00874068|term infants
1273299|NCT00874068|preterm infants
1273300|NCT00874068|bone strength
1273301|NCT00874068|Speed of sound (SOS)
1273302|NCT00874068|Ultrasound
1273303|NCT00874055|social influence
1273304|NCT00874055|friends
1273305|NCT00874055|eating behavior
1273306|NCT00874055|childhood overweight
1273307|NCT00874042|dose escalation
1273308|NCT00874042|safety
1273309|NCT00874042|tolerability
1273310|NCT00874042|tumor
1273311|NCT00874042|PK
1273312|NCT00874029|Uterine Fibroids
1273313|NCT00874029|Myomas
1273314|NCT00874016|intubation
1273315|NCT00874016|Airtraq
1273316|NCT00874016|pediatric
1273317|NCT00874016|airway
1273318|NCT00874003|alcohol dependence
1273319|NCT00874003|anti-depressant
1273320|NCT00874003|5-HT
1273321|NCT00874003|NE
1273322|NCT00873990|fissure sealant
1273323|NCT00873990|self etch
1273324|NCT00873990|total etch
1273325|NCT00873977|Adherence
1273326|NCT00873977|Continuous Positive Airway Pressure
1273327|NCT00873964|Metabolic Syndrome
1273328|NCT00873964|Obesity
1273329|NCT00873964|Elderly
1273330|NCT00873964|Insulin Resistance
1273331|NCT00873938|Artesunate-Amodiaquine
1273332|NCT00873938|Compliance
1273333|NCT00873938|Malaria
1273334|NCT00873925|Type 1 Diabetes
1273335|NCT00873912|influenza
1273336|NCT00873912|FluMist
1273337|NCT00873899|Heart Failure
1273338|NCT00873899|Implantable defibrillator
1273339|NCT00873899|Remote Monitoring
1273340|NCT00873873|Asthma Progression
1273341|NCT00873873|Airway Wall Thickness
1273342|NCT00873873|Corticosteroid Resistance
1273343|NCT00873873|Biomarkers
1273344|NCT00873873|Pulmonary Physiology
1273345|NCT00873860|CAT-354
1273346|NCT00873860|Tralokinumab
1273347|NCT00873860|Asthma
1273348|NCT00873847|NICHD Neonatal Research Network
1273349|NCT00873847|Very Low Birth Weight (VLBW)
1273350|NCT00873847|Extremely Low Birth Weight (ELBW)
1273351|NCT00873847|Prematurity
1273352|NCT00873847|Amplitude-integrated Electroencephalography (aEEG)
1273353|NCT00873834|autism
1273354|NCT00873834|fluoxetine
1273355|NCT00873834|Comparative
1273356|NCT00873834|double blind
1273357|NCT00873834|placebo
1273358|NCT00873834|controlled trial
1273359|NCT00873834|anatomy-functional imaging
1273360|NCT00873834|children
1273361|NCT00873834|DSM-IV-R criteria for autism and CARS score (of 30 or above)
1273362|NCT00873808|breast cancer
1273363|NCT00873795|efficacy
1273364|NCT00873795|tolerability
1273365|NCT00873795|combination of aripiprazole and SSRI(sertraline)
1273366|NCT00873782|Limb Perfusion
1273367|NCT00873782|Gene Therapy
1273368|NCT00873769|Staccato Loxapine
1273369|NCT00873769|pharmacokinetics
1273370|NCT00873769|smokers
1273371|NCT00873769|non-smokers
1273372|NCT00873756|CRC
1273373|NCT00873756|Colon Cancer
1273374|NCT00873756|Avastin
1273375|NCT00873756|Apo2L/TRAIL
1273376|NCT00873743|lower pain intensity with combination drug after cesarian section in first 48h postoperatively
1273377|NCT00873730|Effect of etanercept in subjects with ankylosing spondylitis
1273378|NCT00873717|elderly
1273379|NCT00873717|long-term facilities
1273380|NCT00873717|nutritional status
1273381|NCT00873691|Patients indicated for an ICD/ CRT-D
1273382|NCT00873678|Molar tooth
1273383|NCT00873678|AHI1 gene
1273384|NCT00873678|CEP290 gene
1273385|NCT00873678|ciliopathies
1273386|NCT00873652|Hepatitis B vaccine
1273387|NCT00873652|Booster dose
1273388|NCT00873652|Persistence
1273389|NCT00873652|Immune response
1273390|NCT00873652|Healthy children
1273391|NCT00873626|Urinary tract infection
1273392|NCT00873626|treatment duration
1273393|NCT00873626|acute pyelonephritis
1273394|NCT00873626|good use of antibiotics
1273395|NCT00873600|cognitive/functional effects
1273396|NCT00873600|psychosocial effects of cancer and its treatment
1273397|NCT00873600|stage I breast cancer
1273398|NCT00873600|stage II breast cancer
1273399|NCT00873600|stage IIIA breast cancer
1273400|NCT00873600|stage IIIB breast cancer
1273401|NCT00873600|stage IIIC breast cancer
1273402|NCT00873600|adenocarcinoma of the colon
1273403|NCT00873600|stage I colon cancer
1273404|NCT00873600|stage II colon cancer
1273405|NCT00873600|stage III colon cancer
1273406|NCT00873587|Thoracotomy
1273407|NCT00873587|Inspiration
1273408|NCT00873587|Expiration
1273409|NCT00873587|Chest Tube
1273410|NCT00873587|pneumothorax
1273411|NCT00873587|Method of chest tube removal
1273412|NCT00873574|Familial myeloproliferative disorders
1273413|NCT00873574|JAK-STAT
1273414|NCT00873574|V617
1273415|NCT00873574|JAK2
1273416|NCT00873561|diabetes
1273417|NCT00873561|type 1
1273418|NCT00873561|adult
1273419|NCT00873561|adolescent
1273420|NCT00873561|new onset
1273421|NCT00873535|Nicotine
1273422|NCT00873535|Nicotine dependence
1273423|NCT00873535|Smoking cessation
1273424|NCT00873535|Alcohol
1273425|NCT00873535|Alcohol dependence
1273426|NCT00873535|Alcohol cessation
1273427|NCT00873535|Treatment
1273428|NCT00873535|Smoking
1273429|NCT00873535|Cigarette
1273430|NCT00873535|Heavy drinkers
1273431|NCT00873535|Social drinkers
1273432|NCT00873535|Co-morbidity of alcohol and nicotine dependence
1273433|NCT00873535|Nicotine receptor
1273434|NCT00873535|Nicotinic receptor
1273435|NCT00873535|Nicotinic acetycholine receptor
1273436|NCT00873535|Alpha-4-beta-2 nicotinic acetycholine receptor
1273437|NCT00873535|Cholinergic receptor
1273438|NCT00873535|Dopamine
1273439|NCT00873535|Craving
1273440|NCT00873535|Diary
1273441|NCT00873535|Cue induced
1273442|NCT00873535|Pharmacotherapy
1273443|NCT00873535|Varenicline
1273444|NCT00873535|Chantix
1273445|NCT00873535|Champix
1273446|NCT00873522|pneumonia
1273447|NCT00873509|Autism
1273448|NCT00873496|Sjögren's Syndrome
1273449|NCT00873496|hyposalivation
1273450|NCT00873496|mouth dryness
1273451|NCT00873496|complications
1273452|NCT00873483|Pregnancy prevention
1273453|NCT00873483|female contraception
1273454|NCT00873483|patch
1273455|NCT00873457|B-Cell Chronic Lymphocytic Leukemia
1273456|NCT00873457|Leukemia
1273457|NCT00873444|Hip
1273458|NCT00873444|Cementless
1273459|NCT00873444|Ceramic-on-Metal
1273460|NCT00873444|Metal-on-Metal
1273461|NCT00873431|Prevention of pneumococcal infections
1273462|NCT00873418|Heart Failure
1273463|NCT00873418|Intervention
1273464|NCT00873418|Cognitive Behavior Therapy
1273465|NCT00873418|Quality of Life
1273466|NCT00873405|Type 2 diabetes mellitus
1273467|NCT00873405|Metabolic control
1273468|NCT00873405|Bariatric Surgery
1273469|NCT00873405|Weight Loss
1273470|NCT00873405|Sleeve gastrectomy
1273471|NCT00873405|BMI reduction
1273472|NCT00873405|Waist circumference reduction
1273473|NCT00873405|Percentage of excess BMI loss
1273474|NCT00873405|Glucose homeostasis
1273475|NCT00873392|Parkinson's disease
1273476|NCT00873392|Motor fluctuation
1273477|NCT00873392|Nicotine
1273478|NCT00873392|Drug treatment
1273479|NCT00873392|neuroprotection
1273480|NCT00873366|stage I breast cancer
1273481|NCT00873366|stage II breast cancer
1273482|NCT00873366|stage IIIA breast cancer
1273483|NCT00873366|stage IIIB breast cancer
1273484|NCT00873366|stage IIIC breast cancer
1273485|NCT00873353|Metastatic Adenocarcinoma of the Pancreas
1273486|NCT00873340|MS
1273487|NCT00873340|Multiple Sclerosis
1273488|NCT00873340|Betaferon
1273489|NCT00873340|Colombia
1273490|NCT00873327|presumed sepsis
1273491|NCT00873301|vulvodynia
1273492|NCT00873301|vestibulectomy
1273493|NCT00873301|surgery
1273494|NCT00873301|vestibulitis
1273495|NCT00873288|cervical intraepithelial neoplasia
1273496|NCT00873288|atypical squamous cells of undetermined significance
1273497|NCT00873288|high-grade squamous intraepithelial lesion
1273498|NCT00873288|low-grade squamous intraepithelial lesion
1273499|NCT00873275|stage IV colon cancer
1273500|NCT00873275|stage IV rectal cancer
1273501|NCT00873275|recurrent colon cancer
1273502|NCT00873275|recurrent rectal cancer
1273503|NCT00873275|adenocarcinoma of the colon
1273504|NCT00873275|adenocarcinoma of the rectum
1273505|NCT00873262|PreMenstrual Syndrome
1273506|NCT00873262|Hormones
1273507|NCT00873262|Skin tests
1273508|NCT00873262|Desensitization
1273509|NCT00873262|Allergen Immunotherapy
1273510|NCT00873249|Schizophrenia
1273511|NCT00873249|Therapeutic adherence
1273512|NCT00873249|Short message system
1273513|NCT00873249|Mobile phone
1273514|NCT00873236|stage III renal cell cancer
1273515|NCT00873236|stage IV renal cell cancer
1273516|NCT00873210|renal cell carcinoma
1273517|NCT00873210|sunitinib malate
1273518|NCT00873197|Co-administration of transdermal and intravenous granisetron
1273519|NCT00873197|Granisetron
1273520|NCT00873197|Healthy subjects
1273521|NCT00873197|Intravenous
1273522|NCT00873197|Pharmacokinetic profile
1273523|NCT00873197|Sancuso® patch
1273524|NCT00873197|Transdermal
1273525|NCT00873197|Pharmacokinetics
1273526|NCT00873184|massage therapy in patients with brain tumors
1273527|NCT00873171|Osteopathic Manipulation
1273528|NCT00873158|Adhesive Capsulitis
1273529|NCT00873158|ROM
1273530|NCT00873158|Dynasplint
1273531|NCT00873145|Survival
1273532|NCT00873145|Function
1273533|NCT00873145|Infection
1273534|NCT00873145|Revision
1273535|NCT00873145|Loosening
1273536|NCT00873119|Belinostat
1273537|NCT00873119|PXD101
1273538|NCT00873119|Carboplatin
1273539|NCT00873119|Paclitaxel
1273540|NCT00873119|CUP
1273541|NCT00873119|Carcinoma of unknown primary
1273542|NCT00873119|Occult primary
1273543|NCT00873080|reliability
1273544|NCT00873080|photogrammetry
1273545|NCT00873067|Atrial fibrillation
1273546|NCT00873067|Complex fractionated electrograms
1273547|NCT00873067|CFAE
1273548|NCT00873041|Thalassemia
1273549|NCT00873041|thalassemia intermedia
1273550|NCT00873041|alpha-thalassemia
1273551|NCT00873041|beta-thalassemia
1273552|NCT00873041|deferasirox
1273553|NCT00873041|iron overload
1273554|NCT00873041|non-transfusion dependent
1273555|NCT00873028|Physical therapy
1273556|NCT00873028|Inspiratory muscles
1273557|NCT00873028|Exercise
1273558|NCT00873015|Cerebral aneurysm
1273559|NCT00873015|Subarachnoid hemorrhage
1273560|NCT00873015|Nitrite
1273561|NCT00873002|adult primary hepatocellular carcinoma
1273562|NCT00873002|advanced adult primary liver cancer
1273563|NCT00873002|recurrent adult primary liver cancer
1273564|NCT00873002|localized unresectable adult primary liver cancer
1273565|NCT00872989|recurrent ovarian epithelial cancer
1273566|NCT00872989|recurrent fallopian tube cancer
1273567|NCT00872989|recurrent primary peritoneal cavity cancer
1273568|NCT00872963|malaria vaccine
1273569|NCT00872963|RTS,S,
1273570|NCT00872950|LEMS
1273571|NCT00872950|CMS
1273572|NCT00872950|3,4 DIAMINOPYRIDINE
1273573|NCT00872950|3,4 DAP
1273574|NCT00872924|Bioequivalence
1273575|NCT00872911|Sarcopenia
1273576|NCT00872911|nutrition
1273577|NCT00872911|aging
1273578|NCT00872911|metabolism
1273579|NCT00872911|exercise
1273580|NCT00872898|autism
1273581|NCT00872898|memantine
1273582|NCT00872898|pediatric
1273583|NCT00872898|Forest Laboratories
1273584|NCT00872898|Autism in pediatric patients
1273585|NCT00872885|analgesic
1273586|NCT00872885|bunionectomy
1273587|NCT00872885|surgery
1273588|NCT00872885|post operative pain
1273589|NCT00872885|single Hallux valgus repair
1273590|NCT00872872|NVP
1273591|NCT00872872|PMTCT
1273592|NCT00872872|pregnancy
1273593|NCT00872872|resistance
1273594|NCT00872859|Breast Cancer
1273595|NCT00872859|Cancer of Breast
1273596|NCT00872859|Reconstructive Surgery
1273597|NCT00872846|Body weight
1273598|NCT00872846|Signs and symptoms
1273599|NCT00872846|Obesity
1273600|NCT00872846|Metabolic disease
1273601|NCT00872846|Diabetes mellitus type 2
1273602|NCT00872846|Diabetes mellitus
1273603|NCT00872846|Nutrition disorder
1273604|NCT00872846|Endocrine system diseases
1273605|NCT00872846|Overweight
1273606|NCT00872846|Overnutrition
1273607|NCT00872846|Glucose metabolic disorder
1273608|NCT00872833|Transfusion-Dependant Thalassemia
1273609|NCT00872833|Pain
1273610|NCT00872833|Mild Pain
1273611|NCT00872820|Social Anxiety
1273612|NCT00872820|Social Anxiety Treatment
1273613|NCT00872820|Cognitive Therapy
1273614|NCT00872820|Mindfulness
1273615|NCT00872820|Social Phobia
1273616|NCT00872820|Social Phobia Treatment
1273617|NCT00872807|childhood
1273618|NCT00872807|therapy
1273619|NCT00872807|life style
1273620|NCT00872807|motor activity
1273621|NCT00872807|obesity
1273622|NCT00872807|overweight
1273623|NCT00872807|body mass index
1273624|NCT00872807|treatment
1273625|NCT00872794|Hip
1273626|NCT00872794|Conservative
1273627|NCT00872794|Metal on Metal
1273628|NCT00872794|Resurfacing
1273629|NCT00872781|Bioequivalence fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
1273630|NCT00872742|Impulse Control Disorders
1273631|NCT00872742|Behavior Therapy
1273632|NCT00872742|Acceptance
1273633|NCT00872742|Habit Reversal
1273634|NCT00872729|cystinosis
1273635|NCT00872729|cysteamine
1273636|NCT00872729|inheritable disease
1273637|NCT00872729|orphan disease
1273638|NCT00872729|CTNS protein, human
1273639|NCT00872729|nephropathic cystinosis
1273640|NCT00872716|specific phobia
1273641|NCT00872716|simple phobia
1273642|NCT00872716|anxiety disorder
1273643|NCT00872703|CMV
1273644|NCT00872703|Prenatal Diagnosis
1273645|NCT00872703|Ultrasound
1273646|NCT00872703|MRI
1273647|NCT00872690|Multiple Trauma
1273648|NCT00872690|Blast Injuries
1273649|NCT00872690|Brain Injuries
1273650|NCT00872690|Rehabilitation, Vocational
1273651|NCT00872690|Consumer participation
1273652|NCT00872677|weight changes
1273653|NCT00872677|obesity
1273654|NCT00872677|stage I breast cancer
1273655|NCT00872677|stage II breast cancer
1273656|NCT00872677|stage IIIA breast cancer
1273657|NCT00872664|ROP
1273658|NCT00872664|anti-oxidants
1273659|NCT00872664|carotenoids
1273660|NCT00872651|Glaucoma
1273661|NCT00872651|intraocular pressure
1273662|NCT00872651|travoprost/timolol
1273663|NCT00872651|timolol
1273664|NCT00872638|wound edge eversion
1273665|NCT00872638|cosmetic outcomes
1273666|NCT00872638|surgical incisions
1273667|NCT00872625|stage IA breast cancer
1273668|NCT00872625|stage IB breast cancer
1273669|NCT00872625|stage II breast cancer
1273670|NCT00872625|stage IIIA breast cancer
1273671|NCT00872625|stage IIIB breast cancer
1273672|NCT00872625|stage IIIC breast cancer
1273673|NCT00872625|recurrent breast cancer
1273674|NCT00872612|Sarcoidosis
1273675|NCT00872612|Diagnosis
1273676|NCT00872612|Non-caseating granulomas
1273677|NCT00872612|BAL
1273678|NCT00872612|EUS-FNA
1273679|NCT00872612|EBUS-TBNA
1273680|NCT00872612|TBLB
1273681|NCT00872599|Hypertension
1273682|NCT00872599|Phenotyping
1273683|NCT00872599|High Salt intake
1273684|NCT00872599|frequently sampled IV glucose tolerance test(FSIVGTT)
1273685|NCT00872599|fenofibrate
1273686|NCT00872599|epoxyeicosatrienoic acids
1273687|NCT00872599|hydroxyeicosatetraenoic acids
1273688|NCT00872599|dihydroxyeicosatrienoic acid
1273689|NCT00872599|PPAR Alpha Agonist
1273690|NCT00872599|CYP Monooxygenase Activity
1273691|NCT00872573|Hip
1273692|NCT00872573|Cemented
1273693|NCT00872547|Hip
1273694|NCT00872547|Resurfacing
1273695|NCT00872547|Metal-on-Metal
1273696|NCT00872547|Large Heads
1273697|NCT00872547|XL Head
1273698|NCT00872547|ASR - osteoarthritis (primary)
1273699|NCT00872534|To evaluate the acute gastrointestinal safety of PL-2100.
1273700|NCT00872521|Multiple Myeloma
1273701|NCT00872521|transplant eligible
1273702|NCT00872521|doxorubicin
1273703|NCT00872521|dexamethasone
1273704|NCT00872521|bortezomib
1273705|NCT00872521|bortezomib resistance
1273706|NCT00872521|PAD induction
1273707|NCT00872521|PIMMS Trial
1273708|NCT00872495|Urothelial Cancer
1273709|NCT00872495|Cancer
1273710|NCT00872495|Bladder Neoplasms
1273711|NCT00872495|Urinary Bladder Cancer
1273712|NCT00872482|non-small cell lung cancer
1273713|NCT00872482|NSCLC
1273714|NCT00872482|Brain metastases
1273715|NCT00872482|nimotuzumab
1273716|NCT00872482|TheraCIM
1273717|NCT00872482|h-R3
1273718|NCT00872482|Radiation
1273719|NCT00872469|Postpartum haemorrhage
1273720|NCT00872469|randomised controlled trial
1273721|NCT00872469|tranexamic acid
1273722|NCT00872469|antifibrinolytic
1273723|NCT00872456|Diabetes Mellitus
1273724|NCT00872456|Cardiovascular Disease
1273725|NCT00872456|Haptoglobin
1273726|NCT00872430|constipation
1273727|NCT00872430|RCT
1273728|NCT00872430|phytotherapy
1273729|NCT00872417|HIV/AIDS
1273730|NCT00872417|antiretroviral therapy
1273731|NCT00872417|immune reconstitution
1273732|NCT00872404|CP-751,871
1273733|NCT00872404|squamous cell carcinoma
1273734|NCT00872404|recurrent or metastatic
1273735|NCT00872404|after 1st line chemotherapy
1273736|NCT00872378|Morbid Obesity
1273737|NCT00872378|LAP Band
1273738|NCT00872378|Adjustable Gastric Band
1273739|NCT00872378|Exenatide
1273740|NCT00872378|Byetta
1273741|NCT00872378|Weight Loss
1273742|NCT00872378|Bariatric Surgery
1273743|NCT00872365|Pregnancy
1273744|NCT00872365|Exercise
1273745|NCT00872365|Nutrition
1273746|NCT00872365|Micronutrients
1273747|NCT00872365|non-transmissible chronic diseases
1273748|NCT00872365|Endothelium
1273749|NCT00872352|Multiple Myeloma
1273750|NCT00872352|Bortezomib
1273751|NCT00872352|Peripheral Neuropathy
1273752|NCT00872352|evaluation
1273753|NCT00872352|evaluation of electrophysiological changes related to the dose and time of bortezomib administration
1273754|NCT00872352|investigation of correlation between the incidence of BIPN and the subtype of myeloma
1273755|NCT00872339|Transfusion-Dependent Thalassemia
1273756|NCT00872339|Non-Transfusion-Dependent Thalassemia
1273757|NCT00872326|Diabetes Complications
1273758|NCT00872326|Lower limb ischemia
1273759|NCT00872326|Adult stem cells
1273760|NCT00872313|Labor
1273761|NCT00872313|Psychology
1273762|NCT00872313|Postpartum Psychology
1273763|NCT00872287|minimally invasive surgery
1273764|NCT00872287|scarless cholecystectomy
1273765|NCT00872287|new techniques in laparoscopy
1273766|NCT00872287|invisible scar
1273767|NCT00872287|single port access
1273768|NCT00872287|abdominal pain
1273769|NCT00872287|shoulder pain
1273770|NCT00872274|Bioequivalence
1273771|NCT00872261|Clinical Trials as Topic
1273772|NCT00872261|Adolescent Psychology
1273773|NCT00872261|Patient Acceptance of Health Care
1273774|NCT00872261|HIV Risk Behaviors
1273775|NCT00872261|Adolescents
1273776|NCT00872261|Clinical Trial Recruitment
1273777|NCT00872261|Microbicide Acceptability
1273778|NCT00872261|Ethics
1273779|NCT00872261|Mixed Methods
1273780|NCT00872261|HIV
1273781|NCT00872248|Restless leg syndrome
1273782|NCT00872248|Spinal anesthesia
1273783|NCT00872248|Epidural anesthesia
1273784|NCT00872248|Neuraxial block
1273785|NCT00872235|Bioequivalence fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
1273786|NCT00872222|Hip
1273787|NCT00872222|Cementless
1273788|NCT00872222|Ceramic-on-Ceramic
1273789|NCT00872209|swimmer's ear
1273790|NCT00872209|ear drops
1273791|NCT00872209|ear foam
1273792|NCT00872209|otic foam
1273793|NCT00872209|ear infection
1273794|NCT00872209|ear pain
1273795|NCT00872209|ear inflammation
1273796|NCT00872183|Motor Learning
1273797|NCT00872183|Mirror Neurons
1273798|NCT00872183|Healthy Volunteer
1273799|NCT00872183|HV
1273800|NCT00872170|Pulmonary Hypertension
1273801|NCT00872157|Castrate-Resistant Prostate Cancer
1273802|NCT00872157|Prostate
1273803|NCT00872157|High-Volume Osseous Metastases
1273804|NCT00872157|BMTP-11
1273805|NCT00872157|Prostate State Antigen
1273806|NCT00872157|PSA
1273807|NCT00872131|Anxiety
1273808|NCT00872131|Social Phobia
1273809|NCT00872131|Generalized Social Anxiety Disorder
1273810|NCT00872118|alcohol consumption
1273811|NCT00872118|social anxiety
1273812|NCT00872118|brief intervention
1273813|NCT00872118|motivational interviewing
1273814|NCT00872118|cognitive behavioral
1273815|NCT00872105|clavicle
1273816|NCT00872105|fractures
1273817|NCT00872105|distal
1273818|NCT00872092|small bowel
1273819|NCT00872092|bacterial overgrowth
1273820|NCT00872079|warfarin
1273821|NCT00872079|pharmacokinetics
1273822|NCT00872079|pharmacodynamics
1273823|NCT00872066|Hip
1273824|NCT00872066|Bone Cement
1273825|NCT00872053|robot
1273826|NCT00872053|treadmill
1273827|NCT00872053|foot drop
1273828|NCT00872053|rehabilitation
1273829|NCT00872053|gait
1273830|NCT00872040|Sexual function
1273831|NCT00872040|Pelvic floor disorders
1273832|NCT00872040|Delivery mode
1273833|NCT00872027|Critical Illness
1273834|NCT00872027|Intensive Care Unit
1273835|NCT00872027|Acute Respiratory Failure
1273836|NCT00872027|Prolonged Mechanical Ventilation
1273837|NCT00871975|LUTS
1273838|NCT00871975|OAB
1273839|NCT00871962|long-term oxygen therapy
1273840|NCT00871962|COPD patients on necessity of long-term oxygen therapy
1273841|NCT00871949|Safety tolerability pharmacokinetics PK first in human FIH
1273842|NCT00871923|Non-small cell lung cancer
1273843|NCT00871923|NSCLC
1273844|NCT00871923|Brain Metastases
1273845|NCT00871923|Brain Cancer
1273846|NCT00871923|Lung Cancer
1273847|NCT00871923|Tarceva
1273848|NCT00871923|Erlotinib Hydrochloride
1273849|NCT00871923|OSI-774
1273850|NCT00871923|Radiation Therapy
1273851|NCT00871923|Whole Brain Radiation Therapy
1273852|NCT00871923|WBRT
1273853|NCT00871897|Neuropsychology
1273854|NCT00871897|Cardiac Rehabilitation
1273855|NCT00871884|Post Concussion Syndrome
1273856|NCT00871884|Cognitive Behavioral Therapy
1273857|NCT00871884|Anxiety Sensitivity
1273858|NCT00871884|Mild Head Injury
1273859|NCT00871884|Psychotherapy
1273860|NCT00871884|Chronic Post Concussion Symptoms
1273861|NCT00871858|stage II breast cancer
1273862|NCT00871858|stage IIIA breast cancer
1273863|NCT00871858|stage IIIB breast cancer
1273864|NCT00871858|estrogen receptor-positive breast cancer
1273865|NCT00871858|progesterone receptor-positive breast cancer
1273866|NCT00871845|obesity
1273867|NCT00871845|hepatitis C
1273868|NCT00871845|insulin resistance
1273869|NCT00871845|metabolic syndrome
1273870|NCT00871832|hyperglycemia
1273871|NCT00871832|HgA1c
1273872|NCT00871832|mortality
1273873|NCT00871819|Spinal Cord Stimulation
1273874|NCT00871806|Pharmacokinetics
1273875|NCT00871806|eletriptan
1273876|NCT00871806|bioavailability
1273877|NCT00871806|oral disintegrating tablet
1273878|NCT00871780|TYSABRI naive
1273879|NCT00871780|Relapsing-remitting multiple sclerosis (RRMS)
1273880|NCT00871767|AZD5672
1273881|NCT00871767|relative bioavailability
1273882|NCT00871767|rheumatoid arthritis (RA)
1273883|NCT00871754|Bladder Cancer
1273884|NCT00871754|Cancer, bladder
1273885|NCT00871754|Urinary Bladder Cancer
1273886|NCT00871741|Combined vaccine
1273887|NCT00871741|Primary vaccination
1273888|NCT00871728|Onychomycosis, Toe
1273889|NCT00871728|Itraconazole
1273890|NCT00871728|Sporanox
1273891|NCT00871715|stroke
1273892|NCT00871715|hemiparesis
1273893|NCT00871715|physical therapy
1273894|NCT00871715|occupational therapy
1273895|NCT00871715|neurorehabilitation
1273896|NCT00871715|patient focused
1273897|NCT00871715|motor learning
1273898|NCT00871715|motor control
1273899|NCT00871715|skill acquisition
1273900|NCT00871715|skill training
1273901|NCT00871715|motor recovery
1273902|NCT00871715|task oriented training
1273903|NCT00871715|task specific training
1273904|NCT00871715|arm function
1273905|NCT00871715|hand function
1273906|NCT00871715|upper extremity
1273907|NCT00871715|arm therapy
1273908|NCT00871715|physical rehabilitation
1273909|NCT00871715|arm rehabilitation
1273910|NCT00871715|motor function
1273911|NCT00871702|Leukemia
1273912|NCT00871702|Lymphoma, Non-Hodgkin
1273913|NCT00871702|Hodgkin Disease
1273914|NCT00871702|Myelodysplastic Syndromes
1273915|NCT00871702|Multiple Myeloma
1273916|NCT00871689|recurrent adult acute myeloid leukemia
1273917|NCT00871689|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1273918|NCT00871689|adult acute myeloid leukemia with inv(16)(p13;q22)
1273919|NCT00871689|adult acute myeloid leukemia with t(15;17)(q22;q12)
1273920|NCT00871689|adult acute myeloid leukemia with t(16;16)(p13;q22)
1273921|NCT00871689|adult acute myeloid leukemia with t(8;21)(q22;q22)
1273922|NCT00871689|recurrent childhood acute myeloid leukemia
1273923|NCT00871689|secondary acute myeloid leukemia
1273924|NCT00871689|childhood acute myeloid leukemia with 11q23 (MLL) abnormalities
1273925|NCT00871689|childhood acute myeloid leukemia with inv(16)(p13;q22)
1273926|NCT00871689|childhood acute myeloid leukemia with t(15;17)(q22;q12)
1273927|NCT00871689|childhood acute myeloid leukemia with t(16;16)(p13;q22)
1273928|NCT00871689|childhood acute myeloid leukemia with t(8;21)(q22;q22)
1273929|NCT00871650|Post Traumatic Stress Disorder
1273930|NCT00871650|PTSD
1273931|NCT00871650|Brain
1273932|NCT00871650|Imaging
1273933|NCT00871650|PET
1273934|NCT00871650|Neural
1273935|NCT00871650|Sleep
1273936|NCT00871650|REM Sleep
1273937|NCT00871637|Pulmonary disease, chronic obstructive
1273938|NCT00871637|Airway macrophages
1273939|NCT00871637|Sputum milieu
1273940|NCT00871637|Airway inflammation
1273941|NCT00871637|Occupational diseases
1273942|NCT00871611|Hereditary
1273943|NCT00871611|Anderson-Fabry
1273944|NCT00871611|prevalence
1273945|NCT00871611|heart
1273946|NCT00871611|hypertrophy
1273947|NCT00871611|urine
1273948|NCT00871611|globotriaosylceramide
1273949|NCT00871611|isoforms
1273950|NCT00871611|α - Galactosidase
1273951|NCT00871598|plaque psoriasis
1273952|NCT00871598|BTT1023
1273953|NCT00871598|safety
1273954|NCT00871598|pharmacokinetics
1273955|NCT00871585|bicalutamide
1273956|NCT00871585|PSA
1273957|NCT00871585|advanced prostate cancer
1273958|NCT00871572|Diabetes Mellitus, Type 2
1273959|NCT00871533|Biochemical Marker
1273960|NCT00871533|Biochemical Markers
1273961|NCT00871533|Biologic Marker
1273962|NCT00871533|Biologic Markers
1273963|NCT00871533|Biomarkers
1273964|NCT00871533|Clinical Marker
1273965|NCT00871533|Clinical Markers
1273966|NCT00871533|Immune Marker
1273967|NCT00871533|Immune Markers
1273968|NCT00871533|Immunologic Marker
1273969|NCT00871533|Immunologic Markers
1273970|NCT00871533|Laboratory Marker
1273971|NCT00871533|Laboratory Markers
1273972|NCT00871533|Marker, Biochemical
1273973|NCT00871533|Marker, Biological
1273974|NCT00871533|Marker, Clinical
1273975|NCT00871533|Marker, Immunologic
1273976|NCT00871533|Marker, Laboratory
1273977|NCT00871533|Marker, Serum
1273978|NCT00871533|Marker, Surrogate
1273979|NCT00871533|Markers, Biochemical
1273980|NCT00871533|Markers, Biological
1273981|NCT00871533|Markers, Clinical
1273982|NCT00871533|Markers, Immunologic
1273983|NCT00871533|Markers, Laboratory
1273984|NCT00871533|Markers, Serum
1273985|NCT00871533|Markers, Surrogate
1273986|NCT00871533|Markers, Viral
1273987|NCT00871533|Serum Marker
1273988|NCT00871533|Serum Markers
1273989|NCT00871533|Surrogate End Point
1273990|NCT00871533|Surrogate End Points
1273991|NCT00871533|Surrogate Endpoint
1273992|NCT00871533|Surrogate Endpoints
1273993|NCT00871533|Surrogate Marker
1273994|NCT00871533|Surrogate Markers
1273995|NCT00871533|Viral Marker
1273996|NCT00871533|Viral Markers
1273997|NCT00871520|Palliative Care
1273998|NCT00871520|Predictive Value of Tests
1273999|NCT00871520|Prospective Studies
1274000|NCT00871520|Survival Analysis
1274001|NCT00871520|Survival prediction
1274002|NCT00871507|Diabetes Mellitus, Type 2
1274003|NCT00871455|Spinal Cord Injury
1274004|NCT00871455|Baclofen
1274005|NCT00871455|Growth Hormone, Pituitary
1274006|NCT00871455|Insulin-Like Growth Factor I
1274007|NCT00871442|PCEA
1274008|NCT00871442|labor and delivery
1274009|NCT00871442|pain
1274010|NCT00871442|epidural
1274011|NCT00871442|anesthesia
1274012|NCT00871442|pregnant women
1274013|NCT00871429|skin toxicity
1274014|NCT00871429|cancer patients
1274015|NCT00871429|adverse effects
1274016|NCT00871403|GW786034
1274017|NCT00871403|pazopanib
1274018|NCT00871403|pemetrexed
1274019|NCT00871403|cisplatin
1274020|NCT00871403|non-small cell lung cancer
1274021|NCT00871403|NSCLC
1274022|NCT00871390|Paroxysmal Atrial Fibrillation
1274023|NCT00871390|Permanent/Persistent Atrial Fibrillation
1274024|NCT00871377|epilepsy
1274025|NCT00871377|cardiac risk factors
1274026|NCT00871377|memory
1274027|NCT00871377|cognition
1274028|NCT00871377|n-3 fatty acids
1274029|NCT00871377|fish oil
1274030|NCT00871377|EPA
1274031|NCT00871377|DHA
1274032|NCT00871377|seizures
1274033|NCT00871364|Bioequivalence
1274034|NCT00871364|venlafaxine
1274035|NCT00871364|Healthy subjects
1274036|NCT00871338|combined
1274037|NCT00871338|Vaccines
1274038|NCT00871325|Gastric emptying
1274039|NCT00871325|Small bowel transit
1274040|NCT00871325|Colonic transit
1274041|NCT00871325|Whole gut transit
1274042|NCT00871325|Postoperative Ileus
1274043|NCT00871312|diabetes
1274044|NCT00871312|diabetic
1274045|NCT00871312|wound
1274046|NCT00871312|ulcer
1274047|NCT00871312|lower extremity
1274048|NCT00871312|foot
1274049|NCT00871312|oxygen
1274050|NCT00871312|hyperbaric
1274051|NCT00871312|topical wound oxygen
1274052|NCT00871299|Treatment-resistant depression, meditation, mindfulness
1274053|NCT00871286|Chronic rhinosinusitis
1274054|NCT00871286|Chronic sinusitis
1274055|NCT00871286|CRS
1274056|NCT00871273|capecitabine
1274057|NCT00871273|total gastrectomy
1274058|NCT00871273|pharmacokinetic
1274059|NCT00871260|Coronary Disease
1274060|NCT00871260|Stress Testing
1274061|NCT00871260|Lexiscan (regadenoson)
1274062|NCT00871260|Cardiac Magnetic Resonance Imaging
1274063|NCT00871247|Bioequivalence
1274064|NCT00871247|finasteride
1274065|NCT00871247|Healthy subjects
1274066|NCT00871234|HIV
1274067|NCT00871234|Endothelial function
1274068|NCT00871234|Etravirine
1274069|NCT00871208|Atopic Dermatitis
1274070|NCT00871208|pruritus
1274071|NCT00871208|quality of life
1274072|NCT00871195|Rhesus D
1274073|NCT00871195|RHD
1274074|NCT00871195|genotype
1274075|NCT00871195|phenotype
1274076|NCT00871195|neonatal
1274077|NCT00871195|noninvasive
1274078|NCT00871195|fetal
1274079|NCT00871195|MassARRAY
1274080|NCT00871195|DNA
1274081|NCT00871182|COPD
1274082|NCT00871182|obstructive lung diseases
1274083|NCT00871182|Tiotropium
1274084|NCT00871169|Irinotecan
1274085|NCT00871169|Oxaliplatin
1274086|NCT00871169|Cetuximab
1274087|NCT00871169|Advanced or metastatic pancreatic cancer
1274088|NCT00871156|Drug-Drug Interaction
1274089|NCT00871143|CBT
1274090|NCT00871143|BDD
1274091|NCT00871130|Thyroid gland
1274092|NCT00871130|bariatric surgery
1274093|NCT00871130|weight loss
1274094|NCT00871130|thyroid hormones
1274095|NCT00871130|adult
1274096|NCT00871130|morbid obesity
1274097|NCT00871130|cohort
1274098|NCT00871117|Co-administration
1274099|NCT00871117|Immunization
1274100|NCT00871117|Preschool
1274101|NCT00871117|Booster
1274102|NCT00871104|Infective endocarditis
1274103|NCT00871091|CAD/CAM
1274104|NCT00871091|orthodontics
1274105|NCT00871091|fixed appliance
1274106|NCT00871091|tooth movement
1274107|NCT00871065|Cerebral Vasospasm
1274108|NCT00871065|Vasospasm
1274109|NCT00871065|Subarachnoid Hemorrhage
1274110|NCT00871065|Sildenafil citrate
1274111|NCT00871065|Aneurysm
1274112|NCT00871065|Intracranial aneurysm
1274113|NCT00871052|Polymorphic light eruption
1274114|NCT00871052|UV radiation
1274115|NCT00871052|Vitamin D
1274116|NCT00871052|Immune suppression
1274117|NCT00871052|Prevention
1274118|NCT00871039|Alcoholism
1274119|NCT00871039|Mechanical ventilation
1274120|NCT00871026|CAD/CAM
1274121|NCT00871026|orthodontics
1274122|NCT00871026|fixed appliance
1274123|NCT00871026|tooth movement
1274124|NCT00871026|Adverse Effects
1274125|NCT00871026|Time Factors
1274126|NCT00871026|Treatment Outcome
1274127|NCT00871013|This study is being done in an attempt to improve the remission rate and the survival time for participants with high-risk myeloma
1274128|NCT00871000|Boostrix Polio
1274129|NCT00871000|dTpa-IPV
1274130|NCT00870987|Malaria
1274131|NCT00870987|Vaccine
1274132|NCT00870974|Parkinson
1274133|NCT00870974|Huntington's
1274134|NCT00870974|Fragile X
1274135|NCT00870974|Autistic Spectrum
1274136|NCT00870974|Alzheimer's
1274137|NCT00870974|MCI
1274138|NCT00870961|colon cancer
1274139|NCT00870961|rectal cancer
1274140|NCT00870961|adenomatous polyp
1274141|NCT00870948|Open Label
1274142|NCT00870948|Healthy Volunteers
1274143|NCT00870935|Balloon catheter
1274144|NCT00870935|Cervical vacuum cup
1274145|NCT00870935|Hysterosalpingography
1274146|NCT00870935|Infertility
1274147|NCT00870935|Pain
1274148|NCT00870935|Fallopian Tube Patency Tests
1274149|NCT00870935|Female Infertility
1274150|NCT00870896|capsaicin
1274151|NCT00870896|COPD
1274152|NCT00870896|COPD with chronic bronchitis
1274153|NCT00870870|Tumors
1274154|NCT00870870|Antibodies, Monoclonal
1274155|NCT00870870|Stage IIIb Metastatic Non-Small Cell Lung Cancer
1274156|NCT00870870|Stage IV Metastatic Non-Small Cell Lung Cancer
1274157|NCT00870857|Lungs
1274158|NCT00870857|antiretrovirals
1274159|NCT00870857|HIV
1274160|NCT00870857|COPD
1274161|NCT00870844|Acute ischemic stroke
1274162|NCT00870844|Erythropoietin
1274163|NCT00870844|Carbamylated
1274164|NCT00870844|Neuroprotection
1274165|NCT00870831|diabetes
1274166|NCT00870818|Teplizumab
1274167|NCT00870818|Protege
1274168|NCT00870818|MGA031
1274169|NCT00870818|Monoclonal antibody
1274170|NCT00870818|Type 1 Diabetes Mellitus
1274171|NCT00870818|T1DM
1274172|NCT00870818|MacroGenics
1274173|NCT00870792|HIV
1274174|NCT00870792|antiretroviral therapy
1274175|NCT00870792|medication adherence
1274176|NCT00870792|Treatment Experienced
1274177|NCT00870779|Fluorescence
1274178|NCT00870779|Brain Tumor
1274179|NCT00870779|Malignant Glioma
1274180|NCT00870779|Pituitary Tumor
1274181|NCT00870779|Skull Base Tumor
1274182|NCT00870779|Brain Lesions
1274183|NCT00870779|Brain Metastases
1274184|NCT00870779|Meningioma
1274185|NCT00870753|Eating disorders
1274186|NCT00870753|yoga
1274187|NCT00870753|body awareness
1274188|NCT00870753|depression
1274189|NCT00870753|anxiety
1274190|NCT00870740|MS
1274191|NCT00870740|Multiple Sclerosis
1274192|NCT00870727|PDD NOS
1274193|NCT00870714|Prostate Cancer
1274194|NCT00870714|Neoadjuvant
1274195|NCT00870701|sarcoma
1274196|NCT00870701|soft tissue
1274197|NCT00870701|members
1274198|NCT00870701|radiotherapy
1274199|NCT00870701|absence of radiotherapy
1274200|NCT00870688|valproate
1274201|NCT00870688|epilepsy
1274202|NCT00870688|compliance
1274203|NCT00870688|sustained released minitablet
1274204|NCT00870688|Orfiril long
1274205|NCT00870675|Ventriculomegaly
1274206|NCT00870675|ultrasound
1274207|NCT00870675|MRI
1274208|NCT00870675|fetus
1274209|NCT00870649|Schistosomiasis vaccine
1274210|NCT00870649|therapeutic vaccine
1274211|NCT00870649|Bilhvax
1274212|NCT00870636|Pan-Vascular Endothelial Growth Factor Blockade
1274213|NCT00870636|Safety
1274214|NCT00870636|ROP
1274215|NCT00870636|Bevacizumab
1274216|NCT00870636|Avastin
1274217|NCT00870610|jugular venous oxygen saturation
1274218|NCT00870610|hypothermia
1274219|NCT00870597|Floaters
1274220|NCT00870597|multifocal IOL
1274221|NCT00870597|visual complaints
1274222|NCT00870597|vitrectomy
1274223|NCT00870584|Asthma; asthma management; asthma impairment ; Xolair ; omalizumab
1274224|NCT00870571|Bioequivalence
1274225|NCT00870571|amlodipine besylate
1274226|NCT00870571|amlodipine
1274227|NCT00870571|Healthy subjects
1274228|NCT00870558|adult primary hepatocellular carcinoma
1274229|NCT00870558|advanced adult primary liver cancer
1274230|NCT00870558|localized resectable adult primary liver cancer
1274231|NCT00870558|localized unresectable adult primary liver cancer
1274232|NCT00870545|spouses
1274233|NCT00870545|social support
1274234|NCT00870545|reintegration
1274235|NCT00870545|families
1274236|NCT00870545|military
1274237|NCT00870545|post deployment
1274238|NCT00870545|OEF/OIF
1274239|NCT00870532|Phase I
1274240|NCT00870532|Combination
1274241|NCT00870532|Anti-angiogenic
1274242|NCT00870532|Sorafenib
1274243|NCT00870532|Metronomic oral vinorelbine
1274244|NCT00870519|Alzheimer disease
1274245|NCT00870506|Randomized Controlled Trial
1274246|NCT00870506|Healthcare Disparities
1274247|NCT00870493|proteinuria
1274248|NCT00870493|renal failure
1274249|NCT00870493|glomerulonephritis
1274250|NCT00870480|Bioequivalence
1274251|NCT00870480|finasteride
1274252|NCT00870480|Healthy subjects
1274253|NCT00870467|Rheumatoid Arthritis
1274254|NCT00870454|Diabetic neuropathies
1274255|NCT00870454|Diabetic neuropathy, painful
1274256|NCT00870454|Carisbamate
1274257|NCT00870454|Neurotherapeutic agents
1274258|NCT00870441|ASP2151
1274259|NCT00870441|Valacyclovir
1274260|NCT00870441|Healthy Volunteers
1274261|NCT00870428|Preeclampsia
1274262|NCT00870428|proteinuria
1274263|NCT00870415|stage IA breast cancer
1274264|NCT00870415|stage IB breast cancer
1274265|NCT00870415|stage II breast cancer
1274266|NCT00870415|stage IIIA breast cancer
1274267|NCT00870415|stage IIIC breast cancer
1274268|NCT00870415|ductal breast carcinoma
1274269|NCT00870415|invasive ductal breast carcinoma
1274270|NCT00870402|aldosterone
1274271|NCT00870402|albuminuria
1274272|NCT00870402|diastolic disfunction
1274273|NCT00870402|hyperkalemia
1274274|NCT00870376|lower urinary tract symptoms
1274275|NCT00870376|biomarkers
1274276|NCT00870376|urodynamic studies
1274277|NCT00870363|HIV
1274278|NCT00870363|HIV positive
1274279|NCT00870363|Gastrointestinal Associated Lymphoid Tissue (GALT)
1274280|NCT00870363|GALT Immune Reconstruction
1274281|NCT00870363|treatment naive
1274282|NCT00870350|immunogenicity
1274283|NCT00870350|safety
1274284|NCT00870350|tetanus
1274285|NCT00870350|diphtheria
1274286|NCT00870350|acellular
1274287|NCT00870350|pertussis
1274288|NCT00870350|vaccine
1274289|NCT00870350|booster
1274290|NCT00870350|adverse event
1274291|NCT00870350|adverse reaction
1274292|NCT00870350|DT1aP
1274293|NCT00870350|DT5ap
1274294|NCT00870350|FHA
1274295|NCT00870350|fimbriae
1274296|NCT00870350|pertactin
1274297|NCT00870350|SMI
1274298|NCT00870350|Smittskyddsinstitutet
1274299|NCT00870350|Immune response and safety profile to a Tdap booster
1274300|NCT00870337|recurrent endometrial carcinoma
1274301|NCT00870337|stage IV endometrial carcinoma
1274302|NCT00870337|endometrial adenocarcinoma
1274303|NCT00870324|ICD
1274304|NCT00870324|Tachyarrhythmias
1274305|NCT00870324|Atrial Fibrillation
1274306|NCT00870324|Patients who meets current ICD or CRT-D implant indications
1274307|NCT00870311|Lithium
1274308|NCT00870311|Neuroprotection
1274309|NCT00870311|Neurotrophic
1274310|NCT00870311|bcl2
1274311|NCT00870311|gsk3
1274312|NCT00870311|pkc
1274313|NCT00870311|MRI
1274314|NCT00870311|myoinositol
1274315|NCT00870311|MRS
1274316|NCT00870311|Alzheimers Disease
1274317|NCT00870298|drug orders
1274318|NCT00870285|Psoriasis
1274319|NCT00870285|Biologic
1274320|NCT00870285|Ustekinumab
1274321|NCT00870285|UVB-311nm narrowband
1274322|NCT00870285|phototherapy
1274323|NCT00870285|half-side comparison
1274324|NCT00870272|Medical Abortion
1274325|NCT00870272|Mifepristone
1274326|NCT00870272|Misoprostol
1274327|NCT00870272|Sublingual administration
1274328|NCT00870272|Buccal administration
1274329|NCT00870259|Weight loss
1274330|NCT00870259|Weight maintenance
1274331|NCT00870246|COPD
1274332|NCT00870246|pulmonary emphysema
1274333|NCT00870233|Gynecologic cancers
1274334|NCT00870233|Quality of Life
1274335|NCT00870233|08-155
1274336|NCT00870233|Surgery
1274337|NCT00870220|Turner's Syndrome
1274338|NCT00870207|Feasibility of implementing TSSC in worksite environment
1274339|NCT00870194|diabetes
1274340|NCT00870194|exenatide
1274341|NCT00870194|Byetta
1274342|NCT00870194|sitagliptin
1274343|NCT00870194|Januvia
1274344|NCT00870194|Amylin
1274345|NCT00870194|Lilly
1274346|NCT00870168|stage IV breast cancer
1274347|NCT00870168|estrogen receptor-negative breast cancer
1274348|NCT00870168|progesterone receptor-negative breast cancer
1274349|NCT00870142|Bioequivalence
1274350|NCT00870142|amlodipine besylate
1274351|NCT00870142|amlodipine
1274352|NCT00870142|Healthy subjects
1274353|NCT00870129|brain tumor
1274354|NCT00870129|radiation
1274355|NCT00870129|MRI
1274356|NCT00870129|09-009
1274357|NCT00870116|SBRT
1274358|NCT00870116|non-operated
1274359|NCT00870116|non-metastatic
1274360|NCT00870116|non-small-cell lung cancer
1274361|NCT00870116|conformational radiotherapy
1274362|NCT00870116|non-operated non-metastatic non-small-cell lung cancer
1274363|NCT00870103|Cataract
1274364|NCT00870077|Intrahepatic fat
1274365|NCT00870077|obesity
1274366|NCT00870077|body fat
1274367|NCT00870077|impaired glucose tolerance
1274368|NCT00870064|Surgical Procedures, Operative
1274369|NCT00870064|Fractures, Open
1274370|NCT00870064|Fracture Fixation
1274371|NCT00870051|Endurant
1274372|NCT00870051|Stent Graft
1274373|NCT00870051|Abdominal Aortic Aneurysm
1274374|NCT00870038|PCI
1274375|NCT00870038|stent
1274376|NCT00870038|drug eluting stent
1274377|NCT00870038|reendothelialization
1274378|NCT00870038|restenosis
1274379|NCT00870038|Percutaneous Coronary Angioplasty
1274380|NCT00870025|androgens
1274381|NCT00870025|hCG
1274382|NCT00870025|low response
1274383|NCT00870025|IVF
1274384|NCT00870025|Ovarian response in women with previous low response
1274385|NCT00869999|rituximab
1274386|NCT00869999|everolimus
1274387|NCT00869999|DLBCL
1274388|NCT00869999|mTOR
1274389|NCT00869973|aprepitant
1274390|NCT00869973|delayed emesis
1274391|NCT00869973|cyclophosphamide plus anthracyclines
1274392|NCT00869973|breast cancer
1274393|NCT00869973|antiemetic
1274394|NCT00869960|Healthy Volunteers
1274395|NCT00869947|Unilateral below the knee amputation
1274396|NCT00869934|Insomnia
1274397|NCT00869934|Sleep disorders
1274398|NCT00869934|Treatment
1274399|NCT00869934|Sleep disturbances
1274400|NCT00869895|Advanced solid tumors
1274401|NCT00869882|Spondylolisthesis
1274402|NCT00869882|degeneration
1274403|NCT00869882|spinal fusion
1274404|NCT00869869|Heart Failure
1274405|NCT00869869|Sleep Disorders
1274406|NCT00869869|Melatonin
1274407|NCT00869869|Antioxidants
1274408|NCT00869869|Molecular Mechanisms of Pharmacological Action
1274409|NCT00869869|Nervous System Diseases
1274410|NCT00869869|Physiological Effects of Drugs
1274411|NCT00869869|Vascular Diseases
1274412|NCT00869869|Central Nervous System Depressants
1274413|NCT00869869|Protective Agents
1274414|NCT00869869|Pharmacologic Actions
1274415|NCT00869869|Signs and Symptoms
1274416|NCT00869869|Mental Disorders
1274417|NCT00869869|Therapeutic Uses
1274418|NCT00869869|Neurologic Manifestations
1274419|NCT00869869|Cardiovascular Diseases
1274420|NCT00869869|Central Nervous System Agents
1274421|NCT00869856|Treatment associated with CRI
1274422|NCT00869843|Metastatic colorectal cancer
1274423|NCT00869830|Biofeedback
1274424|NCT00869830|constipation
1274425|NCT00869830|Parkinson's disease
1274426|NCT00869817|Alzheimer's disease
1274427|NCT00869817|antecedent biomarkers
1274428|NCT00869817|Amyloid Precursor Protein (APP) mutation
1274429|NCT00869817|presenilin I (PS1) mutation
1274430|NCT00869817|presenilin 2 (PS2) mutation
1274431|NCT00869817|Autosomal Dominant Alzheimer's Disease
1274432|NCT00869804|breast cancer
1274433|NCT00869804|chemotherapy-induced peripheral neuropathy
1274434|NCT00869804|exercise
1274435|NCT00869791|Parkinson's
1274436|NCT00869778|Chronic Hepatitis B
1274437|NCT00869778|HBeAg positive
1274438|NCT00869778|Therapeutic HBV Vaccine
1274439|NCT00869778|HBV-specific Cytotoxic T Lymphocyte
1274440|NCT00869765|Depression
1274441|NCT00869765|Treatment
1274442|NCT00869765|Transcranial direct current stimulation
1274443|NCT00869765|D-cycloserine
1274444|NCT00869752|combined type small cell lung cancer
1274445|NCT00869752|fusiform type small cell lung cancer
1274446|NCT00869752|polygonal type small cell lung cancer
1274447|NCT00869752|lymphocyte-like type small cell lung cancer
1274448|NCT00869752|extensive stage small cell lung cancer
1274449|NCT00869739|cancer survivor
1274450|NCT00869739|depression
1274451|NCT00869739|psychosocial effects of cancer and its treatment
1274452|NCT00869739|male erectile disorder
1274453|NCT00869739|urinary complications
1274454|NCT00869739|gastrointestinal complications
1274455|NCT00869739|stage I prostate cancer
1274456|NCT00869739|stage IIB prostate cancer
1274457|NCT00869739|stage IIA prostate cancer
1274458|NCT00869739|stage III prostate cancer
1274459|NCT00869713|Hemorrhagic Fever
1274460|NCT00869713|Viral Infections
1274461|NCT00869713|Neurologic diseases
1274462|NCT00869713|Arbovirus Infections
1274463|NCT00869713|RVF
1274464|NCT00869700|HIV
1274465|NCT00869700|Malaria
1274466|NCT00869700|Pharmacokinetics
1274467|NCT00869700|Treatment Experienced
1274468|NCT00869674|GeneSearch
1274469|NCT00869674|Breast cancer
1274470|NCT00869648|Airway
1274471|NCT00869648|Anaesthesia
1274472|NCT00869648|Resuscitation
1274473|NCT00869648|Ventilation
1274474|NCT00869635|Cholangiocarcinoma
1274475|NCT00869635|Photodynamic therapy
1274476|NCT00869635|S-1
1274477|NCT00869622|osteoporosis
1274478|NCT00869622|bone mineral density
1274479|NCT00869622|fracture
1274480|NCT00869622|antiepileptic drug
1274481|NCT00869622|seizure
1274482|NCT00869622|Prevention of bone loss
1274483|NCT00869622|Prevention of osteoporosis
1274484|NCT00869622|Prevention of Fractures
1274485|NCT00869609|Diabetes Prevention
1274486|NCT00869609|CVD Risk Reduction
1274487|NCT00869609|Lifestyle Intervention
1274488|NCT00869596|Sputum inflammatory biomarkers
1274489|NCT00869583|Women
1274490|NCT00869583|Physical Activity
1274491|NCT00869583|Hispanic
1274492|NCT00869583|Overweight
1274493|NCT00869570|adenocarcinoma of the rectum
1274494|NCT00869570|stage II rectal cancer
1274495|NCT00869570|stage III rectal cancer
1274496|NCT00869557|HIV
1274497|NCT00869557|HIV-1
1274498|NCT00869557|Antiretroviral Treatment-Naive
1274499|NCT00869557|treatment naive
1274500|NCT00869544|HIV
1274501|NCT00869544|smoker
1274502|NCT00869544|emphysema
1274503|NCT00869544|antiretrovirals
1274504|NCT00869544|COPD
1274505|NCT00869531|Obesity
1274506|NCT00869531|wholegrain
1274507|NCT00869531|wheat
1274508|NCT00869531|cardiovascular disease
1274509|NCT00869518|Staphylococcus aureus
1274510|NCT00869518|colonization
1274511|NCT00869518|eradication
1274512|NCT00869518|HIV
1274513|NCT00869518|rifabutin
1274514|NCT00869505|To evaluate the effectiveness of memantine as an augmenting agent for standard intensive residential treatment of severe obsessive-compulsive disorder (OCD)
1274515|NCT00869492|Acne
1274516|NCT00869492|Nadifloxacin
1274517|NCT00869492|benzoyl peroxide
1274518|NCT00869479|Nephrogenic Systemic Fibrosis
1274519|NCT00869479|Screening
1274520|NCT00869466|weight changes
1274521|NCT00869466|stage IA breast cancer
1274522|NCT00869466|stage IB breast cancer
1274523|NCT00869466|stage II breast cancer
1274524|NCT00869466|stage IIIA breast cancer
1274525|NCT00869466|stage IIIB breast cancer
1274526|NCT00869466|stage IIIC breast cancer
1274527|NCT00869453|Gut hormone
1274528|NCT00869453|hyperglycaemic clamp
1274529|NCT00869453|glucose turnver
1274530|NCT00869440|CNS 7056
1274531|NCT00869440|Procedural Sedation
1274532|NCT00869440|Sedation
1274533|NCT00869440|Endoscopy
1274534|NCT00869427|UVI
1274535|NCT00869427|Spinal cord injury
1274536|NCT00869427|Prevention
1274537|NCT00869427|Vitamin C
1274538|NCT00869414|hypoglycemia
1274539|NCT00869414|type 1 diabetes
1274540|NCT00869414|split dosing insulin glargine
1274541|NCT00869414|continuous glucose monitoring
1274542|NCT00869401|adult giant cell glioblastoma
1274543|NCT00869401|adult glioblastoma
1274544|NCT00869401|adult gliosarcoma
1274545|NCT00869388|malignant
1274546|NCT00869388|resistant
1274547|NCT00869388|solid tumor
1274548|NCT00869375|acute or critical limb ischemia with angiographic thrombus
1274549|NCT00869349|Rheumatoid Arthritis
1274550|NCT00869349|IFS
1274551|NCT00869349|psychosocial
1274552|NCT00869349|social support
1274553|NCT00869336|Tinea Pedis
1274554|NCT00869336|Athlete's Foot
1274555|NCT00869323|post-transplant lymphoproliferative disorder
1274556|NCT00869310|aprepitant
1274557|NCT00869310|delayed emesis
1274558|NCT00869310|cisplatin
1274559|NCT00869310|antiemetic
1274560|NCT00869284|High-dose chemotherapy
1274561|NCT00869284|aggressive NHL
1274562|NCT00869284|high-risk
1274563|NCT00869284|PBSC
1274564|NCT00869271|liver metastasis
1274565|NCT00869271|colorectal cancer
1274566|NCT00869258|Pancreatic cancer
1274567|NCT00869258|Gemcitabine
1274568|NCT00869258|Docetaxel
1274569|NCT00869258|Capecitabine
1274570|NCT00869245|ACS
1274571|NCT00869245|Acute Coronary Syndrome
1274572|NCT00869245|Chest pain
1274573|NCT00869245|Cardiac MRI
1274574|NCT00869245|CMR
1274575|NCT00869245|Risk Stratification
1274576|NCT00869245|Emergency Department
1274577|NCT00869232|Multiple Myeloma
1274578|NCT00869219|Pain
1274579|NCT00869219|Pain after eyedrops
1274580|NCT00869206|pain
1274581|NCT00869206|Prostate Adenocarcinoma
1274582|NCT00869206|urinary complications
1274583|NCT00869206|stage IV breast cancer
1274584|NCT00869206|Recurrent Breast Carcinoma
1274585|NCT00869206|stage IV prostate cancer
1274586|NCT00869206|recurrent prostate cancer
1274587|NCT00869206|Recurrent Prostate Carcinoma
1274588|NCT00869206|stage I multiple myeloma
1274589|NCT00869206|stage II multiple myeloma
1274590|NCT00869206|Refractory Plasma Cell Myeloma
1274591|NCT00869206|bone metastases
1274592|NCT00869193|Blood pressure
1274593|NCT00869193|Grape seed
1274594|NCT00869180|diclofenac
1274595|NCT00869180|ankle sprain
1274596|NCT00869180|acute pain
1274597|NCT00869180|topical
1274598|NCT00869180|patch
1274599|NCT00869180|Acute Pain due to Mild to Moderate Ankle Sprain
1274600|NCT00869154|Mild TBI
1274725|NCT00868569|oxaliplatine
1274601|NCT00869154|TBI (Traumatic Brain Injury)
1274602|NCT00869154|Traumatic Brain Injury
1274603|NCT00869154|Injury, Brain, Traumatic
1274604|NCT00869154|Injuries, Acute Brain
1274605|NCT00869154|Brain Injuries, Traumatic
1274606|NCT00869154|Acute Brain Injuries
1274607|NCT00869141|Glaucoma tube shunt procedure
1274608|NCT00869128|melatonin
1274609|NCT00869128|insomnia
1274610|NCT00869128|diabetes
1274611|NCT00869128|sleep
1274612|NCT00869115|Digoxin
1274613|NCT00869115|Inotropes
1274614|NCT00869115|Lusitropic agents
1274615|NCT00869115|Istaroxime
1274616|NCT00869115|Debio 0614
1274617|NCT00869102|IGT
1274618|NCT00869102|IFG
1274619|NCT00869089|PN
1274620|NCT00869076|Diabetes Mellitus
1274621|NCT00869076|Pharmacist
1274622|NCT00869063|wrist
1274623|NCT00869063|sprain
1274624|NCT00869063|strain
1274625|NCT00869063|contusion
1274626|NCT00869063|diclofenac
1274627|NCT00869063|patch
1274628|NCT00869063|acute pain
1274629|NCT00869063|acute pain due to mild to moderate wrist sprain, strain or contusion
1274630|NCT00869050|Pancreatic cancer
1274631|NCT00869050|Neuroendocrine tumors
1274632|NCT00869050|Carcinoid tumors
1274633|NCT00869050|Pheochromocytomas
1274634|NCT00869050|Gastrinomas
1274635|NCT00869050|Zollinger-Ellison syndrome
1274636|NCT00869050|MEN Type I/II
1274637|NCT00869050|Somatostatinomas
1274638|NCT00869050|VIPomas
1274639|NCT00869050|Merkel cell tumors
1274640|NCT00869050|medullary thyroid carcinoma
1274641|NCT00869037|Randomized controlled study
1274642|NCT00869037|Total knee arthroplasty
1274643|NCT00869037|Post operative pain
1274644|NCT00869037|Continuous Femoral Nerve Block
1274645|NCT00869037|Posterior Capsular injection
1274646|NCT00869037|Periarticular injection
1274647|NCT00869024|Heart failure
1274648|NCT00869024|Left ventricular assist device
1274649|NCT00869024|Stem cells
1274650|NCT00869011|Cancer
1274651|NCT00869011|renal cell carcinoma
1274652|NCT00869011|fatigue
1274653|NCT00869011|exercise
1274654|NCT00868998|Biliary Cancer
1274655|NCT00868972|Renal Artery Obstruction
1274656|NCT00868972|renovascular hypertension
1274657|NCT00868972|stent
1274658|NCT00868972|Kidney Failure
1274659|NCT00868972|embolic protection
1274660|NCT00868959|Bipolar
1274661|NCT00868959|Depression
1274662|NCT00868959|Lurasidone
1274663|NCT00868959|Latuda
1274664|NCT00868946|Ribavirin
1274665|NCT00868946|Hemorrhagic Fever with Renal Syndrome
1274666|NCT00868946|Dobrava Virus
1274667|NCT00868946|Puumala Virus
1274668|NCT00868881|Hypertension
1274669|NCT00868881|Therapeutic diagnostic attitude
1274670|NCT00868881|Blood pressure
1274671|NCT00868868|Pedometer
1274672|NCT00868868|Prostate
1274673|NCT00868868|Cancer
1274674|NCT00868868|Hormonotherapy
1274675|NCT00868868|Exercise
1274676|NCT00868855|Coronary Artery Disease
1274677|NCT00868842|Penicillin
1274678|NCT00868842|Allergy
1274679|NCT00868842|Prevention
1274680|NCT00868842|Anaphylaxis
1274681|NCT00868842|Clinically proven history of penicillin allergy
1274682|NCT00868842|preventing anaphylaxis
1274683|NCT00868829|Stent
1274684|NCT00868829|FireBird2
1274685|NCT00868829|Coronary Heart Disease
1274686|NCT00868816|oxaliplatine
1274687|NCT00868816|colorectal cancer
1274688|NCT00868816|chemotherapy
1274689|NCT00868803|prostate cancer
1274690|NCT00868777|Implant site development
1274691|NCT00868777|Bone grafting
1274692|NCT00868777|Dental implants
1274693|NCT00868764|Effect of age
1274694|NCT00868764|Effect of body fat
1274695|NCT00868764|Granisetron
1274696|NCT00868764|Pharmacokinetic profile
1274697|NCT00868764|Sancuso® patch
1274698|NCT00868764|Transdermal
1274699|NCT00868751|Antibodies, Monoclonal
1274700|NCT00868751|Interleukin 6
1274701|NCT00868738|Calcium
1274702|NCT00868738|Vitamin D
1274703|NCT00868738|Magnesium
1274704|NCT00868738|Zinc
1274705|NCT00868725|oral cavity
1274706|NCT00868725|carcinoma
1274707|NCT00868725|thermal imaging
1274708|NCT00868712|coronary calcification
1274709|NCT00868712|vitamin K dependent proteins
1274710|NCT00868712|warfarin
1274711|NCT00868699|Bipolar I, Depression
1274712|NCT00868673|Role of Fructose in overweight and obesity
1274713|NCT00868673|Fructose and metabolic syndrome
1274714|NCT00868673|Low fructose diet study
1274715|NCT00868673|Effects of fructose in blood pressure and hypertension
1274716|NCT00868673|Somatometry changes observed in fructose diets
1274717|NCT00868673|Fructose induced overweight and obesity
1274718|NCT00868673|Fructose induced metabolic syndrome
1274719|NCT00868673|Fructose induced hyperuricemia
1274720|NCT00868608|Refractory Indolent NHL
1274721|NCT00868608|lymphoma
1274722|NCT00868582|Patients with proven or suspected cancer referred for NaF-18 PET to identify bone metastasis
1274723|NCT00868569|liver metastasis
1274724|NCT00868569|colorectal cancer
1274726|NCT00868569|transartery chemotherapy
1274727|NCT00868569|embolision
1274728|NCT00868569|Unresectable Liver Metastasis of Colorectal Cancer
1274729|NCT00868556|fMRI scans
1274730|NCT00868556|episodic migraine sufferers
1274731|NCT00868556|chronic migraine sufferers
1274732|NCT00868556|non migraine sufferers (controls)
1274733|NCT00868543|Gastric bypass
1274734|NCT00868543|obesity
1274735|NCT00868543|superobese
1274736|NCT00868530|On-demand treatment; Hemostatic Efficacy Assessments; Factor VIII recovery; Factor VIII Inhibitor; Chinese
1274737|NCT00868517|Veterans
1274738|NCT00868517|Operation Iraqi Freedom
1274739|NCT00868517|Operation Enduring Freedom
1274740|NCT00868517|Combat Disorders
1274741|NCT00868517|Acupuncture
1274742|NCT00868517|Complementary Therapies
1274743|NCT00868504|GI tract
1274744|NCT00868504|Tumors
1274745|NCT00868504|Temperatures
1274746|NCT00868491|head and neck cancer
1274747|NCT00868491|inoperable
1274748|NCT00868491|induction chemotherapy
1274749|NCT00868491|concomitant radiochemotherapy
1274750|NCT00868491|biological agent
1274751|NCT00868491|efficacy
1274752|NCT00868491|toxicity
1274753|NCT00868478|humanized monoclonal antibody
1274754|NCT00868452|Bipolar I
1274755|NCT00868452|Latuda
1274756|NCT00868452|Lurasidone
1274757|NCT00868439|HF
1274758|NCT00868439|Heart failure
1274759|NCT00868439|hyperkalemia
1274760|NCT00868439|chronic kidney disease
1274761|NCT00868439|prevention of hyperkalemia in heart failure participants
1274762|NCT00868426|Healthy volunteer study
1274763|NCT00868400|Preoperative care
1274764|NCT00868400|colorectal surgery
1274765|NCT00868400|carbohydrate
1274766|NCT00868400|fasting
1274767|NCT00868387|weight reduction
1274768|NCT00868387|low-carbohydrate
1274769|NCT00868387|body fat
1274770|NCT00868387|telemedicine
1274771|NCT00868387|cardiovascular risk markers
1274772|NCT00868361|Mass Balance
1274773|NCT00868361|Talampanel
1274774|NCT00868361|Pharmacokinetics
1274775|NCT00868361|Metabolism
1274776|NCT00868361|Metabolites
1274777|NCT00868361|Healthy Volunteers
1274778|NCT00868348|Total Knee Arthroplasty
1274779|NCT00868335|Cervical degenerative disc disease
1274780|NCT00868335|Anterior cervical discectomy
1274781|NCT00868335|Cervical disc prosthesis
1274782|NCT00868335|Activ-C
1274783|NCT00868335|Mobility
1274784|NCT00868335|Movement
1274785|NCT00868309|Snake Bite
1274786|NCT00868309|Venom and antivenom kinetics
1274787|NCT00868296|Safety
1274788|NCT00868257|AIDS
1274789|NCT00868257|Adherence to Antiretroviral Therapy
1274790|NCT00868257|Pediatric
1274791|NCT00868257|Resource Limited Setting
1274792|NCT00868257|Treatment experienced
1274793|NCT00868244|facial patterns
1274794|NCT00868244|bruxism
1274795|NCT00868244|masticatory muscles
1274796|NCT00868231|COPD
1274797|NCT00868231|Antimuscarinic
1274798|NCT00868218|Influenza A
1274799|NCT00868218|pandemic
1274800|NCT00868218|vaccine
1274801|NCT00868218|immunogenicity
1274802|NCT00868218|Virus
1274803|NCT00868218|H5N1
1274804|NCT00868205|oxidative stress
1274805|NCT00868205|Comet assay
1274806|NCT00868205|antioxidants
1274807|NCT00868179|Thrombosis
1274808|NCT00868179|total knee replacement
1274809|NCT00868166|Amyotrophic Lateral Sclerosis
1274810|NCT00868166|TRO19622
1274811|NCT00868166|Trophos
1274812|NCT00868127|Hyperlipidemia
1274813|NCT00868127|Drug Therapy
1274814|NCT00868127|Dyslipidemia
1274815|NCT00868114|Inoperable pancreatic cancer
1274816|NCT00868114|Dendritic Cell Vaccine
1274817|NCT00868114|Locally advanced or low volume metatstatic pancreatic cancer
1274818|NCT00868101|ischemic
1274819|NCT00868101|preconditioning
1274820|NCT00868101|congenital heart disease
1274821|NCT00868088|AC
1274822|NCT00868088|SCC
1274823|NCT00868088|SCC-is
1274824|NCT00868088|PDT
1274825|NCT00868088|Mohs
1274826|NCT00868075|Physiotherapy
1274827|NCT00868075|Rehabilitation
1274828|NCT00868075|Bronchiectasis
1274829|NCT00868062|The responses of patients to 1L infusions of Gelofusine (succinylated gelatine 40g/L) and Voluven (6% hydroxyethyl starch in 0.9% saline) intraoperatively.
1274830|NCT00868049|chewing
1274831|NCT00868049|deglutition
1274832|NCT00868049|orofacial motricity
1274833|NCT00868049|obesity
1274834|NCT00868036|urticaria
1274835|NCT00868036|hives
1274836|NCT00868036|dermatitis
1274837|NCT00868036|rash
1274838|NCT00868036|contact dermatitis
1274839|NCT00868036|contact
1274840|NCT00868036|contact sensitization
1274841|NCT00868036|allergy
1274842|NCT00868036|allergen
1274843|NCT00868036|patch testing
1274844|NCT00868036|IgG
1274845|NCT00868036|delayed-hypersensitivity reaction
1274846|NCT00868036|hypersensitivity
1274847|NCT00868010|stroke
1274848|NCT00868010|donepezil
1274849|NCT00868010|recovery
1274850|NCT00867997|Noncarious Cervical Lesions
1274851|NCT00867997|Hypersensitivity
1274852|NCT00867997|Teeth
1274853|NCT00867997|Dentistry
1274854|NCT00867997|Practice-based research network
1274855|NCT00867984|CRT, resynchronization,
1274856|NCT00867958|Colon Anastomosis
1274857|NCT00867958|Rectum Anastomosis
1274858|NCT00867958|Intestine
1274859|NCT00867958|Colorectal Surgery
1274860|NCT00867958|Colorectal Anastomosis
1274861|NCT00867932|Paroxysmal Nocturnal Hemoglobinuria (PNH)
1274862|NCT00867906|Cat allergy
1274863|NCT00867906|Immunotherapy
1274864|NCT00867906|Cat-PAD
1274865|NCT00867880|To evaluate the Pharmacokinetic Profile of IVIb
1274866|NCT00867867|Iron deficiency anemia
1274867|NCT00867867|Helicobacter pylori
1274868|NCT00867867|Iron absorption
1274869|NCT00867867|Iron fortification
1274870|NCT00867867|ferrous sulphate
1274871|NCT00867867|ferrous fumarate
1274872|NCT00867854|de-intensification
1274873|NCT00867854|HAART
1274874|NCT00867854|monotherapy
1274875|NCT00867854|persistent low-level viremia (LLV)
1274876|NCT00867854|treatment experienced
1274877|NCT00867841|pneumonia, community-acquired
1274878|NCT00867841|polymerase chain reaction
1274879|NCT00867841|pneumococcus
1274880|NCT00867841|mycoplasma
1274881|NCT00867841|chlamydophila
1274882|NCT00867841|anti-bacterial agents
1274883|NCT00867828|Decline of global cognitive function
1274884|NCT00867828|Neuropsychological Test Battery (NTB)
1274885|NCT00867828|Early stage Alzheimer's disease
1274886|NCT00867815|Non-arteritic Anterior Ischemic Optic Neuropathy
1274887|NCT00867815|NAION
1274888|NCT00867815|PDE5 inhibitors
1274889|NCT00867815|vardenafil
1274890|NCT00867815|Levitra
1274891|NCT00867815|sildenafil
1274892|NCT00867815|Viagra
1274893|NCT00867815|Tadalafil
1274894|NCT00867815|Cialis
1274895|NCT00867815|acute vision loss
1274896|NCT00867815|vision loss
1274897|NCT00867815|blurred vision
1274898|NCT00867815|optic neuropathy
1274899|NCT00867815|erectile dysfunction.
1274900|NCT00867802|MICAS
1274901|NCT00867802|MBSR
1274902|NCT00867789|abscess
1274903|NCT00867789|outcomes
1274904|NCT00867789|antibiotics
1274905|NCT00867789|incision and drainage
1274906|NCT00867789|skin abscess
1274907|NCT00867776|Depression
1274908|NCT00867776|African Americans
1274909|NCT00867776|Exercise
1274910|NCT00867776|Culturally tailored intervention
1274911|NCT00867776|Health disparities
1274912|NCT00867763|Polycystic ovaries,
1274913|NCT00867763|Tubal occlusion
1274914|NCT00867763|Unexplained infertility
1274915|NCT00867763|Low ovarian reserve
1274916|NCT00867763|Male factor infertility
1274917|NCT00867750|HCC
1274918|NCT00867750|RE
1274919|NCT00867750|Yttrium-90
1274920|NCT00867750|SIR-Spheres microspheres
1274921|NCT00867750|TACE
1274922|NCT00867750|Radioembolisation
1274923|NCT00867750|Transarterial Chemoembolisation
1274924|NCT00867737|Asthma
1274925|NCT00867737|Forced Oscillation
1274926|NCT00867737|Impulse Oscillometry
1274927|NCT00867737|Electrical-equivalent respiratory system model
1274928|NCT00867724|polyp
1274929|NCT00867698|Hepatic encephalopathy
1274930|NCT00867698|Mild hepatic encephalopathy
1274931|NCT00867698|HE
1274932|NCT00867698|MHE
1274933|NCT00867698|Cognitive impairment
1274934|NCT00867698|Cognitive dysfunction
1274935|NCT00867698|Liver Disease
1274936|NCT00867698|Cirrhosis
1274937|NCT00867685|Healthy Volunteers
1274938|NCT00867672|Acute Myeloid Leukemia
1274939|NCT00867672|Low-dose Decitabine
1274940|NCT00867672|Valproic acid
1274941|NCT00867672|All-trans retinoic acid
1274942|NCT00867672|Older Patients
1274943|NCT00867659|ovarian hyperstimulation syndrome
1274944|NCT00867659|cetrotide acetate
1274945|NCT00867659|GnRH antagonist
1274946|NCT00867659|oocyte donors
1274947|NCT00867646|PT
1274948|NCT00867646|DVT
1274949|NCT00867633|urothelial carinoma
1274950|NCT00867633|aristolochic acid
1274951|NCT00867633|DNA
1274952|NCT00867633|adduct
1274953|NCT00867607|Contact dermatitis
1274954|NCT00867607|Eczema
1274955|NCT00867581|middle cerebral artery
1274956|NCT00867581|infarction
1274957|NCT00867581|chronic stage
1274958|NCT00867581|hippocampal volume
1274959|NCT00867581|MRI
1274960|NCT00867581|MRS
1274961|NCT00867581|neuropsychologic assessment
1274962|NCT00867568|Relapsed Neuroblastoma
1274963|NCT00867568|Refractory Neuroblastoma
1274964|NCT00867568|Relapsed Medulloblastoma
1274965|NCT00867568|Refractory Medulloblastoma
1274966|NCT00867542|past IUGR
1274967|NCT00867542|ECC
1274968|NCT00867542|oral findings in children with past IUGR
1274969|NCT00867503|ovarian cancer
1274970|NCT00867503|bendamustine
1274971|NCT00867490|Hypertension
1274972|NCT00867490|aliskiren
1274973|NCT00867490|cardiovascular diseases
1274974|NCT00867477|Cancer of esophagus
1274975|NCT00867477|Gastrointestine
1274976|NCT00867477|esophagus cancer
1274977|NCT00867477|Positron emission tomography
1274978|NCT00867477|PET scan
1274979|NCT00867477|Nitric oxide
1274980|NCT00867477|NO
1274981|NCT00867477|NO Breathing Test
1274982|NCT00867477|Respiratory symptoms questionnaire
1274983|NCT00867464|Vaccine Efficacy
1274984|NCT00867464|Long-Term Protection
1274985|NCT00867464|Immune Response
1274986|NCT00867464|Human Papillomavirus
1274987|NCT00867464|HPV
1274988|NCT00867464|Vaccine
1274989|NCT00867451|Attention Deficit Hyperactivity Disorder (ADHD)
1274990|NCT00867438|ulcerative colitis
1274991|NCT00867438|Left-sided, mild to moderate ulcerative colitis
1274992|NCT00867425|Diabetes
1274993|NCT00867425|Internet
1274994|NCT00867425|Obesity
1274995|NCT00867425|Obesity with high cardiovascular risks
1274996|NCT00867412|NSCLC
1274997|NCT00867412|PET/CT
1274998|NCT00867412|Surgery
1274999|NCT00867412|FDG
1275000|NCT00867412|staging
1275001|NCT00867373|Obesity
1275002|NCT00867373|Weight perceptions
1275245|NCT00866671|T-LBL
1275003|NCT00867347|transitional cell carcinoma of the bladder
1275004|NCT00867347|stage II bladder cancer
1275005|NCT00867347|stage III bladder cancer
1275006|NCT00867334|colorectal neoplasm
1275007|NCT00867334|colorectal cancer
1275008|NCT00867334|imatinib mesylate
1275009|NCT00867334|Gleevec
1275010|NCT00867334|Physiological Effects of Drugs
1275011|NCT00867334|panitumumab
1275012|NCT00867334|Vectibix
1275013|NCT00867334|c-kit receptor
1275014|NCT00867334|Receptor
1275015|NCT00867334|Platelet-Derived Growth Factor alpha
1275016|NCT00867321|adult primary hepatocellular carcinoma
1275017|NCT00867321|advanced adult primary liver cancer
1275018|NCT00867321|localized unresectable adult primary liver cancer
1275019|NCT00867321|recurrent adult primary liver cancer
1275020|NCT00867308|IPSS Int-2
1275021|NCT00867308|high risk myelodysplastic syndrome
1275022|NCT00867308|MDS)
1275023|NCT00867308|5q31.1 deletions
1275024|NCT00867295|implantable catheters
1275025|NCT00867295|Indwelling Catheters
1275026|NCT00867295|infection
1275027|NCT00867295|cefazolin sodium
1275028|NCT00867295|prophylactic
1275029|NCT00867295|antibiotic
1275030|NCT00867295|totally implantable venous access device
1275031|NCT00867295|cancer patients
1275038|NCT00866164|back pain
1275039|NCT00866164|intractable pain
1275040|NCT00866164|implantable infusion pump
1275041|NCT00866164|morphine
1275042|NCT00866151|genetic biomarker
1275043|NCT00866151|biomarker
1275044|NCT00866151|molecular diagnostics
1275045|NCT00866151|genes
1275046|NCT00866151|genetics
1275047|NCT00866151|overweight management
1275048|NCT00866151|weight management
1275049|NCT00866151|weight reduction
1275050|NCT00866151|SNPs
1275051|NCT00866151|single nucleotide polymorphisms
1275052|NCT00866138|multiple myeloma
1275053|NCT00866138|t(4/14)
1275054|NCT00866138|relapsing
1275055|NCT00866138|refractory
1275056|NCT00866125|Polymyositis
1275057|NCT00866125|Dermatomyositis
1275058|NCT00866125|Grip force
1275059|NCT00866125|Quality of life
1275060|NCT00866125|Activity performance
1275061|NCT00866112|Wheelchair use
1275062|NCT00866112|Spinal cord injury
1275063|NCT00866112|Multiple sclerosis
1275064|NCT00866112|Muscular dystrophy
1275065|NCT00866112|Cerebral palsy
1275066|NCT00866112|Spina bifida
1275067|NCT00866112|Amputation
1275068|NCT00866112|Arthritis
1275069|NCT00866112|Stroke
1275070|NCT00866099|Dementia
1275071|NCT00866099|primary care
1275072|NCT00866099|early diagnosis
1275073|NCT00866099|psychosocial interventions
1275074|NCT00866099|cholinesterase inhibitors
1275075|NCT00866086|stage I non-small cell lung cancer
1275076|NCT00866086|stage II non-small cell lung cancer
1275077|NCT00866086|stage IIIA non-small cell lung cancer
1275078|NCT00866086|stage IIIB non-small cell lung cancer
1275079|NCT00866086|stage IV non-small cell lung cancer
1275080|NCT00866086|recurrent non-small cell lung cancer
1275081|NCT00866086|pulmonary carcinoid tumor
1275082|NCT00866086|extensive stage small cell lung cancer
1275083|NCT00866086|limited stage small cell lung cancer
1275084|NCT00866086|recurrent small cell lung cancer
1275085|NCT00866073|AML
1275086|NCT00866073|Acute myeloid leukemia
1275087|NCT00866073|Decitabine
1275088|NCT00866060|donepezil
1275089|NCT00866060|memantine
1275090|NCT00866060|moderately severe Alzheimer's disease
1275091|NCT00866060|severe Alzheimer's disease
1275092|NCT00867243|Hepatitis C virus
1275093|NCT00867243|HCV
1275094|NCT00867243|Hepatitis C (and cirrhosis)
1275095|NCT00867243|Liver cirrhosis not due to HCV infection
1275096|NCT00867230|Myelodysplastic Syndrome
1275097|NCT00867230|Chronic Myelomonocytic Leukemia
1275098|NCT00867230|Acute Myeloid Leukemia
1275099|NCT00867230|Acute Lymphocytic Leukemia
1275359|NCT00866411|post traumatic stress
1275100|NCT00867230|Chronic Lymphocytic Leukemia
1275101|NCT00867230|Chronic Myelogenous Leukemia
1275102|NCT00867230|Agnogenic Myeloid Metaplasia
1275103|NCT00867230|FTS
1275104|NCT00867230|S-Trans, Trans-Farnesylthiosalicylic Acid
1275105|NCT00867204|ERCP
1275106|NCT00867204|Study focus was to compare the performance of the ERCP short-wire device versus the Long-wire device.
1275107|NCT00867165|heterozygous familial hypercholesterolemia
1275108|NCT00867165|nonfamilial hypercholesterolemia
1275109|NCT00867152|ritonavir
1275110|NCT00867152|GSK1349572
1275111|NCT00867152|integrase
1275112|NCT00867152|lopinavir
1275113|NCT00867152|darunavir
1275114|NCT00867152|etravirine
1275115|NCT00867139|Influenza
1275116|NCT00867139|Immunocompromised
1275117|NCT00867139|Antiviral
1275118|NCT00867126|stage IV pancreatic cancer
1275119|NCT00867126|adenocarcinoma of the pancreas
1275120|NCT00867126|recurrent pancreatic cancer
1275121|NCT00867113|Imatinib
1275122|NCT00867113|Protein Kinase Inhibitors
1275123|NCT00867113|Gastrointestinal Stromal Tumors
1275124|NCT00867113|Digestive System Diseases
1275125|NCT00867113|Digestive System Neoplasms
1275126|NCT00867113|Gastrointestinal Diseases
1275127|NCT00867113|Gastrointestinal Neoplasms
1275128|NCT00867113|Adjuvant
1275129|NCT00867113|PERSIST
1275130|NCT00867113|PERSIS-5
1275131|NCT00867087|Diffuse large b-cell lymphoma
1275132|NCT00867087|inotuzumab ozogamicin
1275133|NCT00867087|autologous stem cell transplant
1275138|NCT00867048|highly active antiretroviral therapy (HAART)
1275139|NCT00867048|CD4 Count
1275140|NCT00867048|Early Intervention
1275141|NCT00867048|HIV
1275142|NCT00867048|HIV Infection
1275143|NCT00867048|HIV Infections
1275144|NCT00867048|treatment naive
1275145|NCT00867022|Inflammatory factors
1275146|NCT00867022|Coagulation factors
1275147|NCT00867022|Sympathetic activity
1275148|NCT00866996|Attention deficit hyperactivity disorder
1275149|NCT00866996|Methylphenidate
1275150|NCT00866996|Atomoxetine
1275151|NCT00866996|Concerta
1275152|NCT00866983|Open label
1275153|NCT00866983|sildenafil
1275154|NCT00866983|PAH
1275155|NCT00866983|Brazil
1275156|NCT00866970|Lung Cancer
1275157|NCT00866970|Fatigue
1275158|NCT00866970|Cachexia
1275159|NCT00866944|Colorectal carcinoma
1275160|NCT00866944|Liver metastases (only)
1275161|NCT00866944|R0 resection
1275162|NCT00866944|R0 resection of liver metastases from colorectal cancer
1275163|NCT00866905|Breast Cancer
1275164|NCT00866905|Ixabepilone
1275165|NCT00866905|Ixempra
1275166|NCT00866905|Cyclophosphamide
1275167|NCT00866905|Cytoxan
1275168|NCT00866905|Neoadjuvant Therapy
1275169|NCT00866879|Sirolimus
1275170|NCT00866879|Rapamune
1275171|NCT00866879|Immunosuppression
1275172|NCT00866879|Renal allograft function
1275173|NCT00866879|Lymphocytes function
1275174|NCT00866853|TMC435350
1275175|NCT00866853|HCV
1275176|NCT00866853|Hepatitis C
1275177|NCT00866853|TMC435
1275178|NCT00866853|protease inhibitor
1275179|NCT00866853|CYP
1275180|NCT00866853|Cooperstown 5+1 cocktail
1275181|NCT00866840|stage III melanoma
1275182|NCT00866840|stage IV melanoma
1275183|NCT00866840|recurrent melanoma
1275184|NCT00866827|Airway
1275185|NCT00866827|Hemangiomas
1275186|NCT00866827|Venous Malformations
1275187|NCT00866827|Lymphatic Malformations
1275188|NCT00866814|hernia
1275189|NCT00866814|open
1275190|NCT00866801|coronary blood flow
1275191|NCT00866801|coronary flow reserve
1275192|NCT00866801|cardiac sympathetic innervation
1275193|NCT00866801|general anesthesia
1275194|NCT00866801|thoracic epidural
1275195|NCT00866801|autonomic dysfunction
1275196|NCT00866801|autonomic neuropathy
1275197|NCT00866788|Xolair
1275198|NCT00866788|CIU
1275199|NCT00866775|Seizure
1275200|NCT00866775|Epilepsy
1275201|NCT00866775|Anticonvulsant
1275202|NCT00866775|Historical Control
1275203|NCT00866775|Monotherapy
1275204|NCT00866762|Polycythaemia Vera
1275205|NCT00866762|Polycythemia Vera
1275206|NCT00866762|Essential Thrombocythaemia
1275207|NCT00866762|Essential Thrombocythemia
1275208|NCT00866762|HDAC-inhibitor
1275209|NCT00866762|Haematology
1275210|NCT00866762|Hematology
1275211|NCT00866762|Haematological disorder
1275212|NCT00866762|Haematological disease
1275213|NCT00866762|Hematological disorder
1275214|NCT00866762|Hematological disease
1275215|NCT00866749|acute lymphoblastic leukemia
1275216|NCT00866749|acute lymphoblastic lymphoma
1275217|NCT00866749|Leukemia
1275218|NCT00866749|ALL
1275219|NCT00866749|6-Thioguanine
1275220|NCT00866749|Cyclophosphamide
1275221|NCT00866749|Cytarabine
1275222|NCT00866749|Daunorubicin
1275223|NCT00866749|Doxorubicin
1275224|NCT00866749|Methotrexate
1275225|NCT00866749|PEG-L-Asparaginase
1275226|NCT00866749|Vincristine
1275227|NCT00866749|Intrathecal Methotrexate
1275228|NCT00866749|Mercaptopurine
1275229|NCT00866736|chronic myeloid leukemia
1275230|NCT00866736|dasatinib
1275231|NCT00866736|chronic phase myeloid leukemia
1275232|NCT00866723|Avastin
1275233|NCT00866723|bevacizumab
1275234|NCT00866697|fallopian tube cancer
1275235|NCT00866697|pazopanib
1275236|NCT00866697|anti-angiogenesis
1275237|NCT00866697|ovarian cancer
1275238|NCT00866697|primary peritoneal cancer
1275239|NCT00866697|tyrosine kinase inhibitors
1275240|NCT00866697|gynecologic cancer
1275241|NCT00866684|renal transplant-patients with high-risk for skin cancer
1275242|NCT00866671|T-ALL
1275243|NCT00866671|Safety
1275244|NCT00866671|Post Authorisation Safety Study
1275246|NCT00866671|Lymphoblastic Lymphoma
1275247|NCT00866671|Acute Lymphoblastic Leukemia
1275248|NCT00866658|hyperglycemia
1275249|NCT00866658|GLP-1
1275250|NCT00866658|sulfonylurea
1275251|NCT00866658|insulin
1275252|NCT00866645|Agitation
1275253|NCT00866645|Schizophrenia
1275254|NCT00866645|Randomized
1275255|NCT00866645|Blind
1275256|NCT00866645|Parallel
1275257|NCT00866645|Intramuscular Haloperidol
1275258|NCT00866645|Controlled
1275259|NCT00866645|Multicenter
1275260|NCT00866645|Clinical Trial
1275261|NCT00866645|Efficacy
1275262|NCT00866645|Safety
1275263|NCT00866645|Intramuscular Levosulpiride
1275264|NCT00866645|Chinese
1275265|NCT00866645|PANSS-EC
1275266|NCT00866645|ACES
1275267|NCT00866645|CGI
1275268|NCT00866645|BPRS
1275269|NCT00866645|PANSS
1275270|NCT00866645|RSESE
1275271|NCT00866645|BAS
1275272|NCT00866632|Depression
1275273|NCT00866632|Anxiety
1275274|NCT00866632|Brain Injury
1275275|NCT00866632|Cognitive Therapy
1275276|NCT00866632|Coping Skills
1275277|NCT00866606|On-demand treatment
1275278|NCT00866606|Hemostatic efficacy
1275279|NCT00866606|Factor IX activity
1275280|NCT00866606|Factor IX recovery
1275281|NCT00866606|Factor IX inhibitor
1275282|NCT00866606|Chinese
1275283|NCT00866593|major depressive disorder(MDD)
1275284|NCT00866593|depression
1275285|NCT00866593|antidepressant
1275286|NCT00866593|escitalpram oxalate
1275287|NCT00866593|generic
1275288|NCT00866593|innovator
1275289|NCT00866593|Lexapro
1275290|NCT00866593|efficacy
1275291|NCT00866593|safety
1275292|NCT00866593|multicenter
1275293|NCT00866593|double-blind
1275294|NCT00866593|randomized
1275295|NCT00866593|chinese
1275296|NCT00866593|HAMD
1275297|NCT00866593|MADRS
1275298|NCT00866593|HAMA
1275299|NCT00866593|VAS-PI
1275300|NCT00866593|SDS
1275301|NCT00866593|CGI
1275302|NCT00866580|Pandemic influenza
1275303|NCT00866567|prematurity
1275304|NCT00866567|VLBW
1275305|NCT00866567|sepsis
1275306|NCT00866567|innate immunity
1275307|NCT00866554|Prostate
1275308|NCT00866554|Brachytherapy
1275309|NCT00866554|Cytoreduction
1275310|NCT00866554|Sexual function
1275311|NCT00866554|Toxicity
1275312|NCT00866541|resistance
1275313|NCT00866541|flow proportional pressure support
1275314|NCT00866541|pressure support ventilation
1275315|NCT00866541|volunteers
1275316|NCT00866541|assistant breathing
1275317|NCT00866541|breathing comfort and objective breathing data
1275318|NCT00866528|NSCLC
1275319|NCT00866528|non-small cell lung cancer
1275320|NCT00866528|GW786034
1275321|NCT00866528|pazopanib
1275322|NCT00866528|Advanced Non-Small Cell Lung Cancer
1275323|NCT00866528|Advanced Solid Tumor
1275324|NCT00866528|Metastatic Non-Small Cell Lung Cancer
1275325|NCT00866528|paclitaxel
1275326|NCT00866515|Healthy volunteer
1275327|NCT00866515|pharmacodynamics
1275328|NCT00866515|Ketoconazole
1275329|NCT00866515|Drug Interaction
1275330|NCT00866515|pharmacokinetcs
1275331|NCT00866515|GW642444M
1275332|NCT00866515|pharmacokinetics
1275333|NCT00866502|Parkinson
1275334|NCT00866502|Safety
1275335|NCT00866502|PDGF
1275336|NCT00866502|Intracerebroventricular
1275337|NCT00866502|Infusion
1275338|NCT00866502|Device
1275339|NCT00866489|Experimental
1275340|NCT00866476|Shigella
1275341|NCT00866476|Vaccine
1275342|NCT00866476|Mucosal immunity
1275343|NCT00866463|Sildenafil, Pharmacokinetics, Healthy Volunteer
1275344|NCT00866437|PMS
1275345|NCT00866437|Hormones
1275346|NCT00866437|Skin tests
1275347|NCT00866437|Allergen Immunotherapy
1275348|NCT00866424|trigeminal neuralgia
1275349|NCT00866424|pain
1275350|NCT00866424|HBO
1275351|NCT00866424|VAS
1275352|NCT00866424|MGPQ
1275353|NCT00866411|cranial electrotherapy stimulation
1275354|NCT00866411|anxiety
1275355|NCT00866411|depression
1275356|NCT00866411|pain
1275357|NCT00866411|sleep disturbance
1275358|NCT00866411|combat exposure
1275360|NCT00866411|health status
1275361|NCT00866411|medication use
1275362|NCT00866411|soldiers
1275363|NCT00866398|coronary heart disease
1275364|NCT00866398|chd
1275365|NCT00866398|stent
1275366|NCT00866385|Healthy Volunteer
1275367|NCT00866385|AZD8566
1275368|NCT00866385|Food Effect
1275369|NCT00866385|Microtracer
1275370|NCT00866346|Chronic Myelogenous Leukemia
1275371|NCT00866346|CML
1275372|NCT00866346|Allogeneic Hematopoietic Transplantation
1275373|NCT00866346|Bone Marrow Transplant
1275374|NCT00866346|PR1-Specific Cytotoxic T-Lymphocyte Infusion
1275375|NCT00866333|Hodgkin's Lymphoma
1275376|NCT00866333|Relapsed Hodgkin's Lymphoma
1275377|NCT00866333|Refractory Hodgkin's Lymphoma
1275378|NCT00866320|clear cell renal cell carcinoma
1275379|NCT00866320|recurrent renal cell cancer
1275380|NCT00866320|stage IV renal cell cancer
1275381|NCT00866294|Immediate-release formulation of paroxetine (paroxetine IR)
1275382|NCT00866294|HAM-D (17 items)
1275383|NCT00866294|Controlled-release formulation of paroxetine (paroxetine CR)
1275384|NCT00866281|Acute Myeloid Leukemia
1275385|NCT00866281|AML
1275386|NCT00866281|Acute Lymphoblastic Leukemia
1275387|NCT00866281|ALL
1275388|NCT00866281|midostaurin
1275389|NCT00866281|PKC412
1275390|NCT00866281|Pediatric relapsed or refractory FLT3 positive Acute Myeloid Leukemia
1275391|NCT00866281|Pediatric relapsed or refractory Mixed-lineage leukemia gene rearranged Acute Lymphoblastic leukemia
1275392|NCT00866268|Blood loss
1275393|NCT00866268|Total knee arthroplasty
1275394|NCT00866268|Adults
1275395|NCT00866268|Drain
1275396|NCT00866268|Drainage system
1275397|NCT00866255|endotracheal tube
1275398|NCT00866255|endotracheal pressure
1275399|NCT00866255|airway pressure
1275400|NCT00866255|pressure drop
1275401|NCT00866255|calculation
1275402|NCT00866255|continuous calculation
1275403|NCT00866242|Shigella
1275404|NCT00866242|Vaccine
1275405|NCT00866242|Mucosal immunity
1275406|NCT00866190|Mycobacterium tuberculosis, SQ109
1275407|NCT00866047|Antigens, CD30
1275408|NCT00866047|Antibody-Drug Conjugate
1275409|NCT00866047|Antibodies, Monoclonal
1275410|NCT00866047|Lymphoma, Non-Hodgkin
1275411|NCT00866047|Lymphoma, Large-Cell, Anaplastic
1275412|NCT00866047|monomethyl auristatin E
1275413|NCT00866047|Drug Therapy
1275414|NCT00866047|Immunotherapy
1275415|NCT00866047|Hematologic Diseases
1275416|NCT00866047|Lymphoma
1275417|NCT00866034|Cetrotide
1275418|NCT00866034|IVF
1275419|NCT00866034|ICSI
1275420|NCT00866034|Treatment protocol
1275421|NCT00866021|HIV infection
1275422|NCT00866021|HCV infection
1275423|NCT00866021|treatment experienced
1275424|NCT00866008|IVF
1275425|NCT00866008|In vitro implantation
1275426|NCT00866008|Preimplantation genetic screening
1275427|NCT00866008|Aneuploidy
1275428|NCT00865995|pepsin
1275429|NCT00865995|aspiration
1275430|NCT00865995|GE reflux
1275431|NCT00865982|adenocarcinoma of the stomach, gastro-esophageal junction or distal esophagus
1275432|NCT00865982|gastric cancer
1275433|NCT00865982|esophageal cancer
1275434|NCT00865982|gastro-esophageal junction
1275435|NCT00865982|docetaxel
1275436|NCT00865982|capecitabine
1275437|NCT00865982|cisplatin
1275438|NCT00865982|perioperative chemotherapy
1275439|NCT00865969|Belinostat
1275440|NCT00865969|peripheral T-cell lymphoma
1275441|NCT00865969|PXD101
1275442|NCT00865969|PTCL
1275443|NCT00865969|HDAC inhibitor
1275444|NCT00865969|histone deacetylase inhibitor
1275445|NCT00865956|disease management
1275446|NCT00865956|substance use disorders
1275447|NCT00865956|behavioral incentives
1275448|NCT00865943|Bioequivalence
1275449|NCT00865943|Citalopram
1275450|NCT00865943|Healthy subjects
1275451|NCT00865917|POTS
1275452|NCT00865904|∆F508
1275453|NCT00865904|F508del
1275454|NCT00865904|Cystic Fibrosis Transmembrane Conductance Regulator
1275455|NCT00865904|CFTR
1275456|NCT00865904|Pancreatic diseases
1275457|NCT00865904|Lung diseases
1275458|NCT00865904|Genetic disease, inborn
1275459|NCT00865904|Infant, newborn, diseases
1275460|NCT00865891|Bioequivalence
1275461|NCT00865891|Nifedipine
1275462|NCT00865891|Healthy subjects
1275463|NCT00865878|Actinic Keratoses
1275464|NCT00865878|Skin Neoplasms
1275465|NCT00865878|Photodynamic Therapy
1275466|NCT00865878|Transplants
1275467|NCT00865865|Knee
1275468|NCT00865865|Computer
1275469|NCT00865865|Gap
1275470|NCT00865865|Soft tissue
1275471|NCT00865865|Balancing
1275472|NCT00865865|Replacement
1275473|NCT00865865|Arthroplasty
1275474|NCT00865852|Bioequivalence
1275475|NCT00865852|Metformin
1275476|NCT00865852|Healthy subjects
1275477|NCT00865839|Bioequivalence
1275478|NCT00865839|Metformin
1275479|NCT00865839|Healthy subjects
1275480|NCT00865826|Pulmonary Tuberculosis
1275481|NCT00865826|Myobacterium Infections
1275482|NCT00865813|Punch biopsy,
1275483|NCT00865813|periocular
1275484|NCT00865813|tumors.
1275485|NCT00865774|Trauma
1275486|NCT00865774|Alcohol
1275487|NCT00865774|Brief Intervention
1275488|NCT00865761|Bioequivalence
1275489|NCT00865761|Alprazolam
1275490|NCT00865761|Healthy subjects
1275491|NCT00865748|Bioequivalence
1275492|NCT00865748|Metformin
1275493|NCT00865748|Healthy subjects
1275494|NCT00865722|Remote Postconditioning
1275495|NCT00865722|Myocardial reperfusion Injury
1275496|NCT00865722|Myocardial Infarction
1275497|NCT00865722|Primary PCI
1275498|NCT00865709|Colorectal Cancer
1275499|NCT00865709|Metastasis
1275500|NCT00865709|Stage IV
1275501|NCT00865709|Liver Metastasis
1275502|NCT00865696|Bioequivalence
1275503|NCT00865696|Mirtazapine
1275504|NCT00865696|Healthy subjects
1275505|NCT00865683|Gestational Diabetes
1275506|NCT00865683|Pregnancy
1275507|NCT00865683|Docosahexaenoic Acid
1275508|NCT00865683|DHA
1275509|NCT00865683|Maternal-Fetal Exchange
1275510|NCT00865657|Bioequivalence
1275511|NCT00865657|Alprazolam
1275512|NCT00865657|Healthy subjects
1275513|NCT00865644|imiquimod 5% cream
1275514|NCT00865631|Bioequivalence
1275515|NCT00865631|Gabapentin
1275516|NCT00865631|Healthy subjects
1275517|NCT00865605|bioequivalence
1275518|NCT00865605|Vasoconstriction
1275519|NCT00865605|Halobetasol
1275520|NCT00865605|Healthy subjects
1275521|NCT00865592|diabetes
1275522|NCT00865592|DPP4 inhibitor
1275523|NCT00865592|dutogliptin
1275524|NCT00865592|PHX1149
1275525|NCT00865579|MAO inhibitors
1275526|NCT00865579|motor fluctuations
1275527|NCT00865579|dyskinesia
1275528|NCT00865579|Parkinson's Disease
1275529|NCT00865566|HIV Seronegativity
1275530|NCT00865566|HIV Preventive Vaccine
1275531|NCT00865566|HIV Treatment Vaccine
1275532|NCT00865566|Adenovirus
1275533|NCT00865553|tobacco use disorder
1275534|NCT00865540|cataract
1275535|NCT00865540|pupillary dilation
1275536|NCT00865540|anti-inflammatory
1275537|NCT00865540|therapeutic use
1275538|NCT00865527|Colorectal cancer
1275539|NCT00865527|Colon cancer
1275540|NCT00865527|Adenomatous polyps
1275541|NCT00865527|Screening
1275542|NCT00865527|Fecal occult blood test
1275543|NCT00865527|Computed tomographic colonography
1275544|NCT00865527|Colonoscopy
1275545|NCT00865514|dichloroacetate
1275546|NCT00865514|tyrosine
1275547|NCT00865514|maleylacetoacetate
1275548|NCT00865514|trichloroethylene
1275549|NCT00865514|leucine
1275550|NCT00865514|haplotype
1275551|NCT00865501|primary hypertension
1275552|NCT00865501|aldosterone
1275553|NCT00865501|left ventricular hypertrophy
1275554|NCT00865475|HIV infection
1275555|NCT00865475|Treatment Experienced
1275556|NCT00865462|Bioequivalence
1275557|NCT00865462|Bupropion
1275558|NCT00865462|Healthy subjects
1275559|NCT00865449|spironolactone
1275560|NCT00865449|peritoneal fibrosis
1275561|NCT00865449|peritoneal dialysis
1275562|NCT00865436|Bioequivalence
1275563|NCT00865436|Metformin
1275564|NCT00865436|Glyburide
1275565|NCT00865436|Healthy subjects
1275566|NCT00865423|Bioequivalence
1275567|NCT00865423|Gabapentin
1275568|NCT00865423|Healthy subjects
1275569|NCT00865410|Bioequivalence
1275570|NCT00865410|Bupropion
1275571|NCT00865410|Healthy subjects
1275572|NCT00865384|Bioequivalence
1275573|NCT00865384|Mirtazapine
1275574|NCT00865384|Healthy subjects
1275575|NCT00865371|Bioequivalence
1275576|NCT00865371|Bupropion
1275577|NCT00865371|Healthy subjects
1275578|NCT00865358|yoga
1275579|NCT00865358|complementary alternative medicine
1275580|NCT00865358|low back pain
1275581|NCT00865358|minority health
1275582|NCT00865358|health care disparities
1275583|NCT00865358|community health centers
1275584|NCT00865345|blood sugar
1275585|NCT00865345|glucose
1275586|NCT00865345|sensor
1275587|NCT00865332|PET
1275588|NCT00865332|fMRI
1275589|NCT00865332|D-Amphetamine
1275590|NCT00865332|Cocaine Addiction
1275591|NCT00865332|Methylphenidate
1275592|NCT00865319|Non Small Cell Lung Cancer
1275593|NCT00865319|Spect CT Imaging
1275594|NCT00865319|PET CT Imaging as Comparator
1275595|NCT00865306|Cognitive behavioral therapy
1275596|NCT00865306|Anxiety
1275597|NCT00865306|Preschoolers
1275598|NCT00865306|Young Children
1275599|NCT00865306|Parents
1275600|NCT00865306|At-risk
1275601|NCT00865306|Behavioral Inhibition
1275602|NCT00865293|Obesity
1275603|NCT00865293|expiratory flow limitation
1275604|NCT00865293|EFL
1275605|NCT00865293|posture
1275606|NCT00865293|small airways obstruction
1275607|NCT00865293|FOT
1275608|NCT00865280|CSSI
1275609|NCT00865280|Abscess
1275610|NCT00865280|Wound
1275611|NCT00865280|Cellulitis
1275739|NCT00864695|Perioperative care
1275612|NCT00865280|Complicated Skin and Skin Structure Infections (cSSSI)
1275613|NCT00865267|Vasoconstriction
1275614|NCT00865267|Halobetasol
1275615|NCT00865267|Healthy adult subjects
1275616|NCT00865254|Nicotine Dependence
1275617|NCT00865254|Smoking
1275618|NCT00865254|Smoking Cessation
1275619|NCT00865254|Contingency Management
1275620|NCT00865241|Bioequivalence
1275621|NCT00865241|Metformin
1275622|NCT00865241|Glyburide
1275623|NCT00865241|Healthy subjects
1275624|NCT00865228|Hyperlipidemia
1275625|NCT00865228|Dyslipidemia
1275626|NCT00865228|High Cholesterol
1275627|NCT00865228|Drug Therapy
1275628|NCT00865215|Bioequivalence
1275629|NCT00865215|Propranolol
1275630|NCT00865215|Healthy subjects
1275631|NCT00865202|delirium
1275632|NCT00865202|surgery
1275633|NCT00865202|operation
1275634|NCT00865202|geriatric
1275635|NCT00865202|complication
1275636|NCT00865163|Percutaneous Coronary Intervention
1275637|NCT00865163|anticoagulation
1275638|NCT00865163|PCI
1275639|NCT00865150|Prematurity
1275640|NCT00865150|Neonatal screening
1275641|NCT00865150|Parenteral nutrition
1275642|NCT00865150|Amino acids
1275643|NCT00865150|Acylcarnitine
1275644|NCT00865137|Kidney Transplantation
1275645|NCT00865137|Pharmacokinetics
1275646|NCT00865137|Tacrolimus modified release
1275647|NCT00865137|FK506E
1275648|NCT00865111|Bioequivalence
1275649|NCT00865111|Bupropion
1275650|NCT00865111|Healthy subjects
1275651|NCT00865098|Newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN)
1275652|NCT00865085|Bioequivalence
1275653|NCT00865085|Citalopram
1275654|NCT00865085|Healthy subjects
1275655|NCT00865072|Bioequivalence
1275656|NCT00865072|Metformin
1275657|NCT00865072|Healthy subjects
1275658|NCT00865059|Bioequivalence
1275659|NCT00865059|Gabapentin
1275660|NCT00865059|Healthy subjects
1275661|NCT00865046|acupuncture
1275662|NCT00865020|Hypertension
1275663|NCT00865020|ABPM
1275664|NCT00865020|systolic blood pressure
1275665|NCT00865020|diastolic blood pressure
1275666|NCT00865020|cardiovascular disease
1275667|NCT00865020|aliskiren
1275668|NCT00865020|telmisartan
1275669|NCT00865007|Lipodystrophy
1275670|NCT00865007|treatment experienced
1275671|NCT00864994|COPD
1275672|NCT00864994|Inflammation
1275673|NCT00864994|Smoking
1275674|NCT00864994|Multiorgan pathology
1275675|NCT00864994|Extra pulmonary manifestations
1275676|NCT00864968|Bioequivalence
1275677|NCT00864968|Nabumetone
1275678|NCT00864968|Healthy subjects
1275679|NCT00864955|UV-A irradiation
1275680|NCT00864955|Cyclobutane-Pyrimidine Dimer
1275681|NCT00864955|Oxidative lesions
1275682|NCT00864955|cutaneous phototype
1275683|NCT00864955|UV-B irradiation
1275684|NCT00864955|DNA damages
1275685|NCT00864942|CLL
1275686|NCT00864942|NHL
1275687|NCT00864942|lymphoma
1275688|NCT00864929|Non-interventional study
1275689|NCT00864929|Vietnam
1275690|NCT00864929|inappropriate treatment
1275691|NCT00864929|nosocomial infection
1275692|NCT00864916|Endothelial Function
1275693|NCT00864916|Pentoxifylline
1275694|NCT00864916|Antiretroviral Therapy
1275695|NCT00864916|Inflammation
1275696|NCT00864903|enterovirus
1275697|NCT00864903|aseptic meningitis
1275698|NCT00864903|real time PCR
1275699|NCT00864903|diagnostics
1275700|NCT00864890|Bioequivalence
1275701|NCT00864890|Citalopram
1275702|NCT00864890|Healthy subjects
1275703|NCT00864877|retrospective
1275704|NCT00864877|comparison
1275705|NCT00864877|biodegradable
1275706|NCT00864877|implant
1275707|NCT00864877|ankle fracture
1275708|NCT00864864|sunitinib
1275709|NCT00864838|intraocular pressure
1275710|NCT00864838|bevacizumab
1275711|NCT00864838|acetazolamide
1275712|NCT00864838|brimonidine
1275713|NCT00864838|anterior chamber paracentesis
1275714|NCT00864825|Schizophrenia
1275715|NCT00864825|Allopurinol
1275716|NCT00864825|Add-on-treatment
1275717|NCT00864799|Abortion
1275718|NCT00864799|Misoprostol
1275719|NCT00864799|Mifepristone
1275720|NCT00864799|Pregnancy
1275721|NCT00864799|Fetus
1275722|NCT00864786|Multiple dose safety and pharmacokinetics study
1275723|NCT00864760|Bioequivalence
1275724|NCT00864760|Gabapentin
1275725|NCT00864760|Healthy subjects
1275726|NCT00864747|Bioequivalence
1275727|NCT00864747|Propranolol
1275728|NCT00864747|Healthy subjects
1275729|NCT00864734|Bioequivalence
1275730|NCT00864734|Metformin
1275731|NCT00864734|Glyburide
1275732|NCT00864734|Healthy subjects
1275733|NCT00864721|Untreated NSCLC in patients > 70
1275734|NCT00864708|Functional Electrical Stimulation
1275735|NCT00864695|Anesthesia
1275736|NCT00864695|Ethics
1275737|NCT00864695|Trends
1275738|NCT00864695|Manpower
1275740|NCT00864682|propofol
1275741|NCT00864682|lidocaine
1275742|NCT00864682|injection pain
1275743|NCT00864669|Bioequivalence
1275744|NCT00864669|Metformin
1275745|NCT00864669|Healthy subjects
1275746|NCT00864656|adrenergic alpha-agonists
1275747|NCT00864656|phenylephrine
1275748|NCT00864656|drug effects
1275749|NCT00864656|diagnostic use
1275750|NCT00864643|Hyperlipidemia
1275751|NCT00864643|Drug Therapy
1275752|NCT00864643|Dyslipidemia
1275753|NCT00864617|Bioequivalence
1275754|NCT00864617|Nifedipine
1275755|NCT00864617|Healthy subjects
1275756|NCT00864604|Bioequivalence
1275757|NCT00864604|Nabumetone
1275758|NCT00864604|Healthy subjects
1275759|NCT00864591|SPECT Imaging
1275760|NCT00864591|Stress adenosine CMR
1275761|NCT00864578|POAG
1275762|NCT00864578|IOP
1275763|NCT00864578|Forskolin
1275764|NCT00864578|Food supplement
1275765|NCT00864565|Bioequivalence
1275766|NCT00864565|Fentanyl
1275767|NCT00864565|Healthy subjects
1275768|NCT00864552|Hemophilia A
1275769|NCT00864552|Recombinant Factor VIII
1275770|NCT00864539|vitamin D fortification
1275771|NCT00864539|milk
1275772|NCT00864539|orange juice
1275773|NCT00864539|supplement
1275774|NCT00864539|efficacy
1275775|NCT00864526|Bioequivalence
1275776|NCT00864526|Oxycodone
1275777|NCT00864526|Ibuprofen
1275778|NCT00864526|Healthy subjects
1275779|NCT00864513|pancreas
1275780|NCT00864513|metastatic
1275781|NCT00864513|recurrent
1275782|NCT00864500|Bio-Equivalence
1275783|NCT00864500|Vasoconstriction
1275784|NCT00864500|Clobetasol
1275785|NCT00864500|Healthy adult females
1275786|NCT00864461|Down syndrome
1275787|NCT00864461|Metabolic syndrome X
1275788|NCT00864461|Insulin resistance
1275789|NCT00864448|Bioequivalence
1275790|NCT00864448|Ramipril
1275791|NCT00864448|Healthy subjects
1275792|NCT00864435|Bioequivalence
1275793|NCT00864435|Carvedilol
1275794|NCT00864435|Healthy subjects
1275795|NCT00864422|low back pain
1275796|NCT00864422|motor training
1275797|NCT00864422|motor cortex
1275798|NCT00864422|brain plasticity
1275799|NCT00864409|postoperative pain
1275800|NCT00864409|total hip arthroplasty
1275801|NCT00864396|Laryngopharyngeal reflux
1275802|NCT00864396|Gastroesophageal reflux disease
1275803|NCT00864396|GERD
1275804|NCT00864370|Psychiatry
1275805|NCT00864370|Pregnancy
1275806|NCT00864370|Bipolar Disorder
1275807|NCT00864357|Bioequivalence
1275808|NCT00864357|Oxycodone
1275809|NCT00864357|Ibuprofen
1275810|NCT00864357|Healthy subjects
1275811|NCT00864344|Bioequivalence
1275812|NCT00864344|Sertralin
1275813|NCT00864344|Healthy subjectse
1275814|NCT00864331|lung cancer
1275815|NCT00864331|nonsmall cell lung cancer
1275816|NCT00864331|radiation therapy
1275817|NCT00864331|chemotherapy
1275818|NCT00864331|Locally advanced and metastatic nonsmall cell lung cancer
1275819|NCT00864318|refractory
1275820|NCT00864318|germ cell tumors
1275821|NCT00864318|relapse
1275822|NCT00864318|bad prognosis
1275823|NCT00864318|Refractory germ cell tumors with relapse and bad prognosis
1275824|NCT00864305|Bioequivalence
1275825|NCT00864305|Gabapentin
1275826|NCT00864305|Healthy subjects
1275827|NCT00864279|Bioequivalence
1275828|NCT00864279|Cetirizine
1275829|NCT00864279|Healthy subjects
1275830|NCT00864266|Non small cell lung carcinoma
1275831|NCT00864266|Chemotherapy
1275832|NCT00864266|Response prediction
1275833|NCT00864253|Melanoma
1275834|NCT00864253|Malignant
1275835|NCT00864253|Abraxane
1275836|NCT00864253|ABI-007
1275837|NCT00864253|Dacarbazine
1275838|NCT00864253|Dtic-Dome
1275839|NCT00864240|Vasoconstriction
1275840|NCT00864240|Clobetasol
1275841|NCT00864240|Healthy adult females
1275842|NCT00864227|Acute Lymphoblastic Leukemia/Lymphoma
1275843|NCT00864227|Acute Myelogenous Leukemia
1275844|NCT00864227|Mantel-Cell Lymphoma
1275845|NCT00864227|Hematopoietic Transplant
1275846|NCT00864227|Umbilical Cord Blood (UCB)
1275847|NCT00864227|Non-Myeloablative Transplant
1275848|NCT00864214|bioidentical hormone
1275849|NCT00864214|menopause
1275850|NCT00864214|estrogen
1275851|NCT00864214|progesterone
1275852|NCT00864188|skin health
1275853|NCT00864188|probiotics
1275854|NCT00864188|dairy
1275855|NCT00864188|oral
1275856|NCT00864162|Bioequivalence
1275857|NCT00864162|Ramipril
1275858|NCT00864162|Healthy subjects
1275859|NCT00864149|Bioequivalence
1275860|NCT00864149|Carvedilol
1275861|NCT00864149|Healthy subjects
1275862|NCT00864123|Obsessive-compulsive disorder
1275863|NCT00864110|Non small cell lung cancer
1275864|NCT00864110|SPECT CT imaging
1275865|NCT00864110|Pharmacokinetic
1275866|NCT00864110|Radiation Dosimetry
1275867|NCT00864110|PET CT comparison
1275868|NCT00864097|Arthritis monoclonal antibody nerve growth factor (NGF) anti-NGF tanezumab PF-04383119 RN-624 OA
1275869|NCT00864071|Bioequivalence
1275870|NCT00864071|Griseofulvin
1275871|NCT00864071|Healthy subjects
1275872|NCT00864058|Bioequivalence
1275873|NCT00864058|Gabapentin
1275874|NCT00864058|Healthy subjects
1275875|NCT00864032|Soft tissue sarcoma of the extremity and body wall
1275876|NCT00864019|Bioequivalence
1275877|NCT00864019|Sertraline
1275878|NCT00864019|Healthy subjects
1275879|NCT00863980|angiotensin
1275880|NCT00863980|receptor
1275881|NCT00863980|vulnerable plaque
1275882|NCT00863980|coronary artery
1275883|NCT00863967|physical examination
1275884|NCT00863967|diagnostic techniques and procedures
1275885|NCT00863967|diagnosis
1275886|NCT00863967|immunologic tests
1275887|NCT00863967|diagnostic tests
1275888|NCT00863967|causality
1275889|NCT00863967|genetic test
1275890|NCT00863967|biomarker
1275891|NCT00863941|Bioequivalence
1275892|NCT00863941|Bupropion
1275893|NCT00863941|Healthy subjects
1275894|NCT00863915|Bioequivalence
1275895|NCT00863915|Ramipril
1275896|NCT00863915|Healthy subjects
1275897|NCT00863902|Bioequivalence
1275898|NCT00863902|Cetirizine
1275899|NCT00863902|Healthy subjects
1275900|NCT00863876|wavefront measurements of the entire eye
1275901|NCT00863863|Bioequivalence
1275902|NCT00863863|Griseofulvin
1275903|NCT00863863|Healthy subjects
1275904|NCT00863837|Acute variceal bleeding
1275905|NCT00863837|banding ligation
1275906|NCT00863837|vasoconstrictor
1275907|NCT00863837|proton pump inhibitor
1275908|NCT00863824|NNAL
1275909|NCT00863824|Cotinine
1275910|NCT00863824|Second hand smoke
1275911|NCT00863824|NNAL is a known lung carcinogen. So, we are studying an agent that can potentially cause lung cancer.
1275912|NCT00863811|POAG
1275913|NCT00863811|IOP
1275914|NCT00863811|Forskolin
1275915|NCT00863811|beta-blockers
1275916|NCT00863811|prostaglandins
1275917|NCT00863798|Major Depressive Disorder
1275918|NCT00863785|Acute Alcoholic Hepatitis
1275919|NCT00863785|Cirrhosis
1275920|NCT00863785|Alcohol
1275921|NCT00863785|Alcoholic Liver disease
1275922|NCT00863759|intra-ocular lenses
1275923|NCT00863759|comparative study
1275924|NCT00863759|Ocular aberrations
1275925|NCT00863759|Contrast Sensitivity
1275926|NCT00863746|Non-Small Cell Lung Cancer (NSCLC)
1275927|NCT00863746|Sorafenib
1275928|NCT00863707|regadenoson
1275929|NCT00863707|chronic kidney disease stage III
1275930|NCT00863707|chronic kidney disease stage IV
1275931|NCT00863707|renal impairment
1275932|NCT00863707|coronary artery disease
1275933|NCT00863694|cystic fibrosis
1275934|NCT00863694|calprotectin
1275935|NCT00863694|elastase
1275936|NCT00863681|Pulmonary arterial hypertension
1275937|NCT00863681|PH
1275938|NCT00863681|Stimulator
1275939|NCT00863668|Infection
1275940|NCT00863668|HIV 1
1275941|NCT00863668|HIV
1275942|NCT00863668|treatment naive
1275943|NCT00863655|Breast Cancer
1275944|NCT00863655|Estrogen Receptor positive
1275945|NCT00863655|ER+
1275946|NCT00863655|exemestane
1275947|NCT00863655|mTOR
1275948|NCT00863655|everolimus
1275949|NCT00863655|refractory
1275950|NCT00863655|NSAI
1275951|NCT00863642|Early cholecystectomy
1275952|NCT00863642|gallstone pancreatitis
1275953|NCT00863629|myocardial infarction
1275954|NCT00863629|oxidative stress
1275955|NCT00863629|stem cells
1275956|NCT00863629|glycemic control
1275957|NCT00863616|COPD
1275958|NCT00863616|Mucus hypersecretion
1275959|NCT00863616|HRQL
1275960|NCT00863616|ESWT
1275961|NCT00863616|HFCWO
1275962|NCT00863603|Supplemental oxygen
1275963|NCT00863603|Intimal hyperplasia
1275964|NCT00863603|Graft patency
1275965|NCT00863577|Healthy volunteers
1275966|NCT00863564|Postprandial Period
1275967|NCT00863564|Postprandial Lipaemia
1275968|NCT00863564|Incretins
1275969|NCT00863564|Subclinical Inflammation
1275970|NCT00863564|Obesity
1275971|NCT00863564|Atherosclerosis
1275972|NCT00863564|Triglyceride
1275973|NCT00863564|Lipoproteins
1275974|NCT00863564|Postprandial inflammation
1275975|NCT00863538|Spinocerebellar degeneration
1275976|NCT00863538|Thyrotropin-Releasing Hormone (TRH)
1275977|NCT00863538|SCD
1275978|NCT00863512|stage IA non-small cell lung cancer
1275979|NCT00863512|stage IB non-small cell lung cancer
1275980|NCT00863512|stage IIA non-small cell lung cancer
1275981|NCT00863512|adenocarcinoma of the lung
1275982|NCT00863512|adenosquamous cell lung cancer
1275983|NCT00863512|bronchoalveolar cell lung cancer
1275984|NCT00863512|large cell lung cancer
1275985|NCT00863512|squamous cell lung cancer
1275986|NCT00863499|Attention Deficit/Hyperactivity Disorder
1275987|NCT00863499|Attention Deficit Disorder
1275988|NCT00863499|ADHD
1275989|NCT00863499|ADD
1275990|NCT00863499|iSPOT
1275991|NCT00863473|Proximal Humerus Fracture in elderly
1275992|NCT00863421|Sleep disordered breathing
1275993|NCT00863421|Prevalence
1275994|NCT00863421|Chronic heart failure
1275995|NCT00863421|Incidence
1275996|NCT00863421|Sleep apnea
1275997|NCT00863421|Cheyne-Stokes-Breathing
1275998|NCT00863408|Mosquito
1275999|NCT00863408|Human Landing Collection
1276000|NCT00863408|Malaria
1276001|NCT00863395|pruritis
1276002|NCT00863395|itch
1276003|NCT00863395|CTCL
1276004|NCT00863382|atrial fibrillation
1276005|NCT00863369|recurrent adult Burkitt lymphoma
1276006|NCT00863369|recurrent adult diffuse large cell lymphoma
1276007|NCT00863369|recurrent adult diffuse mixed cell lymphoma
1276008|NCT00863369|recurrent adult diffuse small cleaved cell lymphoma
1276009|NCT00863369|recurrent adult grade III lymphomatoid granulomatosis
1276010|NCT00863369|recurrent adult immunoblastic large cell lymphoma
1276011|NCT00863369|recurrent adult lymphoblastic lymphoma
1276012|NCT00863369|recurrent grade 3 follicular lymphoma
1276013|NCT00863369|recurrent mantle cell lymphoma
1276014|NCT00863369|adult grade III lymphomatoid granulomatosis
1276015|NCT00863356|Epistaxis
1276016|NCT00863356|Chitosan
1276017|NCT00863356|Hemostatic
1276018|NCT00863356|Nose bleed
1276019|NCT00863356|Nasal bleeding
1276020|NCT00863356|Nasal pack
1276021|NCT00863356|Sealant
1276022|NCT00863356|ChitoFlex®
1276023|NCT00863356|HemCon
1276024|NCT00863356|HemCon® ChitoFlex Surgical Dressing
1276025|NCT00863356|HemCon® Nasal Plugs
1276026|NCT00863356|Biocompatible dressing
1276027|NCT00863343|Influenza infections
1276028|NCT00863343|Orthomyxoviridae infections
1276029|NCT00863330|stage IV melanoma
1276030|NCT00863330|recurrent melanoma
1276031|NCT00863317|Bronchiolitis
1276032|NCT00863317|montelukast
1276033|NCT00863317|leukotriene inhibitor
1276034|NCT00863304|monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth factor OA pain arthritis
1276035|NCT00863291|Depression
1276036|NCT00863291|suicidality
1276037|NCT00863291|buprenorphine
1276038|NCT00863265|Phytosterols
1276039|NCT00863265|Ezetimibe
1276040|NCT00863265|Cholesterol Excretion
1276041|NCT00863265|Cholesterol Absorption
1276042|NCT00863265|Diet
1276043|NCT00863265|Mass Spectrometry
1276044|NCT00863265|Deuterium
1276045|NCT00863252|proteinuria
1276046|NCT00863252|creatinine
1276047|NCT00863252|kidney survival
1276048|NCT00863252|ESRD
1276049|NCT00863239|treatment naive
1276050|NCT00863239|genotype 1
1276051|NCT00863226|Quality of Life issues in Parkinson's disease
1276052|NCT00863213|Catheter Ablation, Radiofrequency
1276053|NCT00863213|Atrial fibrillation
1276054|NCT00863213|Antiarrhythmic Drugs
1276055|NCT00863200|Depression
1276056|NCT00863200|Cancer
1276057|NCT00863200|African Americans
1276058|NCT00863200|Latinos
1276059|NCT00863200|Hispanics
1276060|NCT00863200|Interactive voice response
1276061|NCT00863200|IVR
1276062|NCT00863200|Behavioral Intervention
1276063|NCT00863174|Multiple myeloma
1276064|NCT00863174|Bio-equivalence
1276065|NCT00863161|Safety
1276066|NCT00863161|tolerability
1276067|NCT00863161|exposure
1276068|NCT00863161|healthy
1276069|NCT00863161|renally impaired subjects
1276070|NCT00863148|MDS
1276071|NCT00863148|AML
1276072|NCT00863148|ALL
1276073|NCT00863148|RIC
1276074|NCT00863148|clofarabine
1276075|NCT00863148|allo-HSCT
1276076|NCT00863148|high-risk MDS/AML
1276077|NCT00863135|obstructive sleep apnea
1276078|NCT00863135|refractory arterial hypertension
1276079|NCT00863135|continuous positive airways pressure
1276080|NCT00863122|Lapatinib
1276081|NCT00863122|Tykerb
1276082|NCT00863122|EGFR inhibitor
1276083|NCT00863122|ErbB2 inhibitor
1276084|NCT00863122|Pharmacokinetics
1276085|NCT00863096|HPV
1276086|NCT00863096|acceptability
1276087|NCT00863083|pediatric obesity
1276088|NCT00863083|pediatric overweight
1276089|NCT00863083|multi-family group weight management intervention
1276090|NCT00863083|financial rewards
1276091|NCT00863070|Bladder exstrophy
1276092|NCT00863070|Abnormal gait
1276093|NCT00863070|anatomy
1276094|NCT00863070|urinary bladder disease
1276095|NCT00863070|urogenital abnormalities
1276096|NCT00863057|HIV Infections
1276097|NCT00863057|Neuropathy
1276098|NCT00863057|Pain
1276099|NCT00863044|off pump coronary bypass
1276100|NCT00863044|high frequency ventilation
1276101|NCT00863044|cerebral oxygen saturation
1276102|NCT00863044|vasopressors used
1276103|NCT00863044|right and left ventricular function
1276104|NCT00863044|arterial blood pressure
1276105|NCT00863044|heart rate
1276106|NCT00863031|mental health
1276107|NCT00863031|problem-solving therapy
1276108|NCT00863031|elderly
1276109|NCT00863031|health-related quality of life
1276110|NCT00863031|primary care
1276111|NCT00863031|Chinese
1276112|NCT00863018|Corneal endothelial cell
1276113|NCT00863018|Specular microscopy
1276114|NCT00863018|Glaucoma implant surgery
1276115|NCT00863018|Ahmed glaucoma valve
1276116|NCT00863018|Trabeculectomy
1276117|NCT00862992|schizophrenia
1276118|NCT00862992|antipsychotics
1276119|NCT00862992|dopamine D3/D2 antagonist
1276120|NCT00862979|Heart Transplantation
1276121|NCT00862979|Cardiac Transplantation
1276122|NCT00862979|CNI-sparing
1276123|NCT00862979|renal function
1276124|NCT00862979|CNI
1276125|NCT00862979|Cyclosporine A
1276126|NCT00862979|Everolimus
1276127|NCT00862979|enteric coated mycophenolic acid
1276128|NCT00862953|low carbohydrate
1276129|NCT00862953|high protein diet
1276130|NCT00862940|Memantine
1276131|NCT00862940|Neuroimaging
1276132|NCT00862940|MRI
1276133|NCT00862940|Brain atrophy
1276134|NCT00862927|Smoking Cessation
1276135|NCT00862927|Cigarette Smoking
1276136|NCT00862927|Tobacco Smoking
1276137|NCT00862927|Cue Reactivity
1276138|NCT00862927|Virtual Reality
1276139|NCT00862927|VR
1276140|NCT00862927|Contextual Cues
1276141|NCT00862927|Explicit Smoking Cues
1276142|NCT00862927|Craving
1276143|NCT00862927|Physiological Arousal
1276144|NCT00862927|Nicotine Dependence
1276145|NCT00862927|Breath Sample
1276146|NCT00862927|Saliva Test
1276147|NCT00862927|Questionnaire
1276148|NCT00862914|Skin
1276149|NCT00862914|MicroRNA
1276150|NCT00862914|miRNA
1276151|NCT00862914|Dicer
1276152|NCT00862914|Malignant Melanoma
1276153|NCT00862901|cancer
1276154|NCT00862901|skin metastases
1276155|NCT00862901|chest wall progression of breast cancer
1276156|NCT00862901|malignant melanoma
1276157|NCT00862901|photodynamic therapy
1276158|NCT00862901|photophrin
1276159|NCT00862901|satellite and in-transit metastases of malignant melanoma
1276160|NCT00862901|skin cancer
1276161|NCT00862875|Insulin initiation
1276162|NCT00862875|oral therapy failure
1276163|NCT00862862|infection
1276164|NCT00862862|staphylococcus aureus
1276165|NCT00862862|vancomycin
1276166|NCT00862862|pharmacodynammics
1276167|NCT00862849|rHuPH20
1276168|NCT00862849|Recombinant Human Hyaluronidase
1276169|NCT00862849|Insulin Lispro
1276170|NCT00862849|Regular Human Insulin
1276171|NCT00862836|ZD6474
1276172|NCT00862836|Vandetanib
1276173|NCT00862836|Zactima
1276174|NCT00862836|Ovarian Cancer
1276175|NCT00862836|Phase I
1276176|NCT00862836|Phase II
1276177|NCT00862836|Randomized
1276178|NCT00862836|Safety
1276179|NCT00862823|Healthy Volunteers
1276180|NCT00862810|Human papillomavirus
1276181|NCT00862810|Cervical cancer
1276182|NCT00862810|Genital warts
1276183|NCT00862810|Vaccine
1276184|NCT00862810|Immunogenicity
1276185|NCT00862797|endotracheal tube
1276186|NCT00862797|swallowing
1276187|NCT00862797|aspiration
1276188|NCT00862797|cuff pressure
1276189|NCT00862797|pneumonia
1276190|NCT00862784|Colorectal carcinoma
1276191|NCT00862784|CRC
1276192|NCT00862784|Colon Cancer
1276193|NCT00862758|juvenile idiopathic arthritis
1276194|NCT00862732|active suicidal ideation
1276195|NCT00862732|cognitive behavioural therapy
1276196|NCT00862732|Sri Lanka
1276197|NCT00862732|RCT
1276198|NCT00862706|Chronic HBV
1276199|NCT00862693|Immunoglobulin A
1276200|NCT00862693|Antibodies
1276201|NCT00862693|treatment
1276202|NCT00862680|Lung Colorectum
1276203|NCT00862680|Colorectal cancer
1276204|NCT00862680|Lung Cancer
1276205|NCT00862680|Liver Cancer
1276206|NCT00862680|Non-small cell lung cancer
1276207|NCT00862680|NSCLC
1276208|NCT00862680|4D PET/CT Imaging
1276209|NCT00862680|Positron emission tomography/computed tomography
1276210|NCT00862680|PET/CT scan
1276211|NCT00862680|Breathing motion
1276212|NCT00862667|Pharmacokinetics
1276213|NCT00862641|regadenoson
1276214|NCT00862641|CVT 3146
1276215|NCT00862641|asthma
1276216|NCT00862641|coronary artery disease
1276217|NCT00862641|pulmonary disease, chronic obstructive
1276218|NCT00862615|Ageing
1276219|NCT00862615|Inflammation
1276220|NCT00862615|Muscle protein synthesis
1276221|NCT00862615|Osteopenia
1276222|NCT00862615|Sarcopenia
1276223|NCT00862602|GDM
1276224|NCT00862602|gestational diabetes
1276225|NCT00862602|pregnancy
1276226|NCT00862602|diabetes
1276227|NCT00862602|walking
1276228|NCT00862602|exercise
1276229|NCT00862602|pedometer
1276230|NCT00862602|online
1276231|NCT00862589|glucagon
1276232|NCT00862589|GLP-1
1276233|NCT00862589|hyperglycemia
1276234|NCT00862576|Burning Mouth Syndrome
1276235|NCT00862576|Sleep
1276236|NCT00862576|Neuropathic pain
1276237|NCT00862576|Glossodynia
1276238|NCT00862576|Chronic pain
1276239|NCT00862576|Orofacial pain
1276240|NCT00862563|Alcoholism
1276241|NCT00862563|Alcohol Dependence
1276242|NCT00862563|Alcohol Abuse
1276243|NCT00862563|Substance Abuse
1276244|NCT00862563|Alcoholic Intoxication
1276245|NCT00862550|Head and Neck Cancer
1276246|NCT00862550|HNC
1276247|NCT00862550|Nasopharyngeal carcinoma
1276248|NCT00862550|Acupuncture
1276249|NCT00862550|Radiation-Induced Xerostomia
1276250|NCT00862550|Xerostomia
1276251|NCT00862550|Dry Mouth
1276252|NCT00862550|Radiation
1276253|NCT00862511|metal ion concentration
1276254|NCT00862511|total knee arthroplasty
1276255|NCT00862511|metal hypersensitivity
1276256|NCT00862498|PTSD
1276257|NCT00862498|Written Disclosure
1276258|NCT00862498|Written Emotional Disclosure
1276259|NCT00862498|Narrative Exposure
1276260|NCT00862498|Narrative Writing
1276261|NCT00862498|Motor Vehicle Accident
1276262|NCT00862472|open-angle glaucoma
1276263|NCT00862472|ocular hypertension
1276264|NCT00862472|open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)
1276265|NCT00862459|Contrast Agents
1276266|NCT00862446|Parenteral nutrition associate liver disease
1276267|NCT00862446|TPN cholestasis
1276268|NCT00862446|TPN Associated Liver Disease
1276269|NCT00862433|Vitamin C
1276270|NCT00862433|Antioxidant
1276271|NCT00862433|Lipid Peroxidation
1276272|NCT00862433|Non-Insulin Requiring Diabetics
1276273|NCT00862433|Alpha-Tocopherol
1276274|NCT00862433|Health Volunteer
1276275|NCT00862433|HV
1276276|NCT00862433|Normal Weight
1276277|NCT00862433|Overweight
1276278|NCT00862433|Type 2 Diabetes
1276279|NCT00862420|Platelet aggregation inhibitors
1276280|NCT00862420|Peripheral arterial disease (PAD)
1276281|NCT00862407|Cardiopulmonary bypass
1276282|NCT00862407|Non-pulsatile perfusion
1276283|NCT00862407|Pulsatile perfusion
1276284|NCT00862407|plasma proteins
1276285|NCT00862381|shock
1276286|NCT00862381|Tracheal Intubation
1276287|NCT00862381|reanimation
1276288|NCT00862381|suprarenal insufficiency
1276289|NCT00862381|Etomidate
1276290|NCT00862381|Adrenocorticotropic Hormone
1276291|NCT00862381|hydrocortisone
1276292|NCT00862368|Motivational Interviewing
1276293|NCT00862368|Pediatric Asthma
1276294|NCT00862368|Smoking Cessation
1276295|NCT00862368|Environmental Tobacco Smoke
1276296|NCT00862368|Second hand smoke
1276297|NCT00862368|Biomarker
1276298|NCT00862368|Asthma
1276299|NCT00862368|Asthma Education
1276300|NCT00862368|Family Intervention
1276301|NCT00862368|Smoking
1276302|NCT00862368|Nicotine Patch
1276303|NCT00862368|Parents
1276304|NCT00862368|Caregivers
1276305|NCT00862368|Child Wellness
1276306|NCT00862355|Carcinoma
1276307|NCT00862355|Ovary
1276308|NCT00862355|Carcinoma Ovary
1276309|NCT00862342|colorectal cancer
1276310|NCT00862342|Bevacizumab
1276311|NCT00862329|Healthy subjects
1276312|NCT00862316|Eligible for Unicompartmental Knee Arthritis
1276313|NCT00862303|autologous cytokine induced killer cells
1276314|NCT00862303|dendritic cell
1276315|NCT00862303|vaccine
1276316|NCT00862303|renal cell carcinoma
1276317|NCT00862290|sepsis
1276318|NCT00862290|microRNA
1276319|NCT00862277|Menactra®
1276320|NCT00862277|Menomune®
1276321|NCT00862277|Meningitis
1276322|NCT00862277|Meningococcal Infections
1276323|NCT00862251|cardiovascular disorder
1276324|NCT00862225|rhinomanometry
1276325|NCT00862225|mode of action
1276326|NCT00862225|grass pollen
1276327|NCT00862212|anxiety
1276328|NCT00862212|social anxiety
1276329|NCT00862212|social anxiety disorder
1276330|NCT00862212|coping behaviors
1276331|NCT00862212|alcohol abuse
1276332|NCT00862186|Neoplasms
1276333|NCT00862186|Fatigue
1276334|NCT00862186|Self Care
1276335|NCT00862173|Gene-expression profile
1276336|NCT00862173|Central nervous system metastasis
1276337|NCT00862173|Non-small-cell lung cancer
1276338|NCT00862160|coronary artery bypass surgery
1276339|NCT00862160|cardiopulmonary bypass
1276340|NCT00862160|heart lung machine
1276341|NCT00862160|acute cerebrovascular event
1276342|NCT00862160|intracranial embolism
1276343|NCT00862160|embolism, air
1276344|NCT00862160|outcome assessment (health care)
1276345|NCT00862160|neuropsychological tests
1276346|NCT00862160|magnetic resonance imaging
1276347|NCT00862160|saccadic eye movement test
1276348|NCT00862147|Child psychosocial Functioning
1276349|NCT00862108|Attention Deficit Hyperactivity Disorder
1276350|NCT00862108|Polymorphism, Single Nucleotide
1276351|NCT00862108|SLC6A2 protein, human
1276352|NCT00862108|ADRA2A protein, human
1276353|NCT00862056|asymptomatic
1276354|NCT00862056|coronary artery disease
1276355|NCT00862043|Secondary Pulmonary Hypertension
1276356|NCT00862043|Valvular Heart Disease
1276357|NCT00862043|Phosphodiesterase-Inhibitors
1276358|NCT00862043|Sildenafil
1276359|NCT00862043|Outcomes Research
1276360|NCT00862030|Palliative radiotherapy
1276361|NCT00862030|Treatment planning
1276362|NCT00862030|Non-small cell lung cancer
1276363|NCT00862017|Physiology
1276364|NCT00862004|video-assisted thoracoscopic surgery (VATS)
1276365|NCT00862004|systematic node dissection (SND)
1276366|NCT00862004|stage IIIA non-small cell lung cancer
1276367|NCT00861991|medical communication
1276368|NCT00861991|empathy
1276369|NCT00861991|medical education
1276370|NCT00861991|standardized patients
1276371|NCT00861991|"enhancing patient satisfaction"
1276372|NCT00861978|mild to moderate depression with atypical features according to DSM-IV
1276373|NCT00861965|Leukemia
1276374|NCT00861965|Lymphoma
1276375|NCT00861965|Multiple Myeloma
1276376|NCT00861952|Diabetic peripheral neuropathies
1276377|NCT00861952|Neuralgia
1276378|NCT00861952|Complementary medicine
1276379|NCT00861952|Analgesia
1276380|NCT00861926|Maintenance and Reliever Treatments
1276381|NCT00861887|Clostridium difficile
1276382|NCT00861887|colitis
1276383|NCT00861887|recurrence
1276384|NCT00861887|relapse
1276385|NCT00861887|Vancomycin
1276386|NCT00861861|Pitavastatin
1276387|NCT00861861|Atorvastatin
1276388|NCT00861861|CAD
1276389|NCT00861861|HDL-C
1276390|NCT00861861|Adiponectin
1276391|NCT00861822|Anemia
1276392|NCT00861822|Cardiac surgery
1276393|NCT00861822|RBC transfusion
1276394|NCT00861822|Acute Kidney Injury
1276395|NCT00861822|Cardiac surgery with cardiopulmonary bypass
1276396|NCT00861809|single dose
1276397|NCT00861809|gut motility
1276398|NCT00861809|Type I Diabetes Mellitus patients
1276399|NCT00861809|tolerability
1276400|NCT00861809|phase II
1276401|NCT00861809|13C octanoic acid breath test
1276402|NCT00861809|pharmacodynamics
1276403|NCT00861809|gastric emtpying
1276404|NCT00861809|pharmacokinetics
1276410|NCT00861770|Congestive Heart Failure
1276411|NCT00861770|Ultrafiltration
1276412|NCT00861770|Blood Volume Measurement
1276413|NCT00861744|Measles, Mumps, Rubella, Varicella Vaccine
1276414|NCT00861744|Children
1276415|NCT00861744|Immunogenicity
1276416|NCT00861744|Safety
1276417|NCT00861744|Humans
1276418|NCT00861744|Combined Vaccine
1276419|NCT00861744|Vaccines
1276420|NCT00861731|chronic renal failure
1276421|NCT00861731|proteinuria
1276422|NCT00861731|apolipoprotein
1276423|NCT00861731|c reactive protein
1276424|NCT00861718|Phase 1
1276425|NCT00861718|Healthy Volunteer
1276426|NCT00861692|Argatroban
1276427|NCT00861692|heparin induced thrombocytopenia (HIT)
1276428|NCT00861692|direct thrombin inhibitor (DTI)
1276429|NCT00861679|HSCT
1276430|NCT00861679|ALL
1276431|NCT00861679|GvHD
1276432|NCT00861666|Forgiveness
1276433|NCT00861666|Writing
1276434|NCT00861666|PTSD
1276435|NCT00861666|OEF
1276436|NCT00861666|OIF
1276437|NCT00861666|Veterans
1276438|NCT00861653|Atherosclerosis
1276439|NCT00861653|Subjects diagnosed with atherosclerosis
1276440|NCT00861640|rabeprazole
1276441|NCT00861640|omeprazole
1276442|NCT00861640|upper gastrointestinal bleeding
1276443|NCT00861627|REOLYSIN
1276444|NCT00861627|reovirus
1276445|NCT00861627|non-small cell lung cancer
1276446|NCT00861627|carcinoma
1276447|NCT00861627|oncolytics virus
1276448|NCT00861627|chemotherapy
1276449|NCT00861627|paclitaxel
1276450|NCT00861627|carboplatin
1276451|NCT00861588|complementary & alternative medicine
1276452|NCT00861588|randomized control trial
1276453|NCT00861588|uroflowmetry
1276454|NCT00861588|quality of life
1276455|NCT00861588|benign prostate hyperplasia
1276456|NCT00861575|Cardiovascular
1276457|NCT00861562|constipation
1276458|NCT00861562|hemorrhoids
1276459|NCT00861562|water smartweed
1276460|NCT00861562|RCT
1276461|NCT00861549|Bioavailability
1276462|NCT00861549|Pharmacokinetics
1276463|NCT00861549|Safety Evaluation
1276464|NCT00861536|risk factors
1276465|NCT00861536|immunology
1276466|NCT00861523|nausea
1276467|NCT00861523|vomiting
1276468|NCT00861523|pregnancy
1276469|NCT00861523|thiamine
1276470|NCT00861523|promethazine
1276471|NCT00861523|nausea and vomiting in pregnancy
1276472|NCT00861510|Small Lymphocytic Lymphoma (SLL)
1276473|NCT00861510|Prolymphocytic Lymphoma (PLL)
1276474|NCT00861510|Hairy Cell Leukemia (HCL)
1276475|NCT00861510|Mantle Cell Lymphoma
1276476|NCT00861510|MCL
1276477|NCT00861510|Chronic Lymphocytic Leukemia
1276478|NCT00861510|CLL
1276479|NCT00861510|Multiple Myeloma
1276480|NCT00861510|MM
1276481|NCT00861497|Open-label
1276482|NCT00861497|Flexible-dose
1276483|NCT00861497|Extension
1276484|NCT00861497|Safety study
1276485|NCT00861471|hormone refractory prostate cancer
1276486|NCT00861471|tyrosine kinase inhibitor
1276487|NCT00861471|Gleevec
1276488|NCT00861471|PSA
1276489|NCT00861471|prostate specific antigen
1276490|NCT00861471|growth factor receptor inhibitor
1276491|NCT00861471|androgen independent
1276492|NCT00861445|Lacosamide, Vimpat®
1276493|NCT00861432|Life quality
1276494|NCT00861432|questionnaire
1276495|NCT00861432|tumor patients
1276496|NCT00861419|AMG 386
1276497|NCT00861419|AMG 706
1276498|NCT00861419|Bevacizumab
1276499|NCT00861419|Sorafenib
1276500|NCT00861419|Angiogenesis Inhibitors
1276501|NCT00861419|Combination Therapy
1276502|NCT00861419|Peptibody
1276503|NCT00861419|Sunitinib
1276504|NCT00861406|Melanoma
1276505|NCT00861406|Stage II melanoma
1276506|NCT00861406|Pegylated Interferon-alfa 2b
1276507|NCT00861406|PEG Interferon alfa-2b
1276508|NCT00861406|PEG Intron
1276509|NCT00861406|Melanoma Peptide Vaccine
1276510|NCT00861406|GP100 Vaccine
1276511|NCT00861406|gp100
1276512|NCT00861406|peptide vaccine
1276513|NCT00861406|Leukapheresis
1276514|NCT00861406|Immune-cell response
1276515|NCT00861380|Pneumococcal conjugate vaccine
1276516|NCT00861380|Invasive disease
1276517|NCT00861380|Respiratory tract infections
1276518|NCT00861380|Haemophilus influenzae
1276519|NCT00861380|Streptococcus pneumoniae
1276520|NCT00861380|Acute otitis media
1276521|NCT00861380|Pneumonia
1276522|NCT00861367|aspirin
1276523|NCT00861367|blood loss
1276524|NCT00861367|transurethral surgery
1276525|NCT00861354|atrial fibrillation
1276526|NCT00861354|home blood pressure monitoring
1276527|NCT00861341|Pioglitazone
1276528|NCT00861341|Thiazolidinediones
1276529|NCT00861341|Platelet Function
1276530|NCT00861341|Platelet aggregation
1276531|NCT00861341|Diabetic
1276532|NCT00861341|Aspirin.
1276538|NCT00861315|Pneumonia
1276539|NCT00861315|Nebulization
1276540|NCT00861315|Amikacin
1276541|NCT00861276|Smoking Cessation
1276542|NCT00861276|Nicotine
1276543|NCT00861276|Administration and dosage
1276544|NCT00861276|Randomized Controlled Trial
1276545|NCT00861250|Bortezomib plus dexamethasone induction therapy
1276546|NCT00861250|Autologous stem cell transplantation
1276547|NCT00861250|Molecular remission
1276548|NCT00861237|Nux vomica
1276549|NCT00861237|homeopathy
1276550|NCT00861237|heart lung machine
1276551|NCT00861237|heart surgery
1276552|NCT00861237|postoperatively studied
1276553|NCT00861211|asthma
1276554|NCT00861211|inflammation
1276555|NCT00861211|bronchoconstriction
1276556|NCT00861211|allergen challenge
1276557|NCT00861211|KCa3.1
1276558|NCT00861185|bronchospasm
1276559|NCT00861185|exercise asthma
1276560|NCT00861185|inflammation
1276561|NCT00861185|KCa3.1
1276562|NCT00861172|Multiple sclerosis
1276563|NCT00861172|Active plaque
1276564|NCT00861172|Multimodal analysis
1276565|NCT00861172|3T MRI
1276566|NCT00861172|Weekly follow-up
1276567|NCT00861172|Physiopathology
1276568|NCT00861172|Physiopathology of active lesions formation in Multiple Sclerosis using multimodal MR sequences
1276569|NCT00861159|RLIP76 Auto Antibodies
1276570|NCT00861146|nicotine dependence
1276571|NCT00861146|tobacco dependence
1276572|NCT00861146|smoking cessation
1276573|NCT00861146|alcoholism
1276574|NCT00861146|self-efficacy
1276575|NCT00861146|relapse
1276576|NCT00861133|cardiac monitor
1276577|NCT00861133|loop recorder
1276578|NCT00861133|stroke
1276579|NCT00861133|ECG
1276580|NCT00861133|Implantable Loop Recorder
1276581|NCT00861133|cryptogenic
1276582|NCT00861133|ILR
1276583|NCT00861120|Ovarian cancer
1276584|NCT00861120|KRAS wildtype
1276585|NCT00861120|Platinum resistant
1276586|NCT00861107|Colorectal cancer
1276587|NCT00861107|Breast Cancer
1276588|NCT00861107|Melanoma
1276589|NCT00861107|GI cancer
1276590|NCT00861107|Prostate cancer
1276591|NCT00861107|Kidney cancer
1276592|NCT00861107|Lung cancer
1276593|NCT00861107|all types metastatic cancer where at least one tumor lesion is accessable for percutaneous cryoablation
1276594|NCT00861094|adenocarcinoma of the esophagus
1276595|NCT00861094|squamous cell carcinoma of the esophagus
1276596|NCT00861094|stage IIA esophageal cancer
1276597|NCT00861094|stage IIB esophageal cancer
1276598|NCT00861094|stage IIIA esophageal cancer
1276599|NCT00861094|stage IIIB esophageal cancer
1276600|NCT00861094|stage IIIC esophageal cancer
1276601|NCT00861094|stage IV esophageal cancer
1276602|NCT00861081|Group Clinics
1276603|NCT00861081|Self Management
1276604|NCT00861068|Lacosamide, Vimpat®
1276605|NCT00861042|Lacosamide, Vimpat®
1276606|NCT00861029|GW786034, pazopanib, moxifloxacin, ECG intervals and morphology, QTc, Holter monitor, pharmacokinetics, safety, cancer
1276607|NCT00861016|Post marketing study
1276608|NCT00861003|schizophrenia
1276609|NCT00861003|adherence
1276610|NCT00860977|HIV
1276611|NCT00860977|Herpes simplex virus type II
1276612|NCT00860977|Genital herpes
1276613|NCT00860977|Treatment Naive
1276614|NCT00860964|estradiol valerate
1276615|NCT00860964|Medroxyprogesterone
1276616|NCT00860964|menopause
1276617|NCT00860964|Lipid
1276618|NCT00860964|Bone mineral density
1276619|NCT00860964|Body Composition
1276620|NCT00860951|Normal
1276621|NCT00860938|Inhaled corticosteroids
1276622|NCT00860938|COPD
1276623|NCT00860938|mannitol
1276624|NCT00860925|Randomized Controlled Trial
1276625|NCT00860925|Blinded
1276626|NCT00860925|Clonidine
1276627|NCT00860925|acetyl-salicylic acid (ASA)
1276628|NCT00860925|Perioperative vascular complications
1276629|NCT00860925|Noncardiac surgery
1276630|NCT00860912|Veritas
1276631|NCT00860912|Cystocele
1276632|NCT00860912|Prolapse
1276633|NCT00860899|clonidine
1276634|NCT00860899|levobupivacaine
1276635|NCT00860899|preoperative analgesia
1276636|NCT00860899|postoperative pain
1276637|NCT00860899|systemic inflammatory stress response
1276638|NCT00860899|epidural analgesia
1276639|NCT00860899|Anesthetics, Local
1276640|NCT00860886|Mongolia
1276641|NCT00860886|Asia
1276642|NCT00860886|GROWTH FACTORS
1276643|NCT00860886|Hormones
1276644|NCT00860886|Premenopausal
1276645|NCT00860886|Breast Cancer
1276646|NCT00860860|radioimmunotherapy
1276647|NCT00860860|pretargeting
1276648|NCT00860860|bispecific antibody
1276649|NCT00860860|lutetium 177
1276650|NCT00860860|phase I clinical trial
1276651|NCT00860847|Progression of Atherosclerosis
1276652|NCT00860847|Aged garlic extract
1276653|NCT00860847|Biomarkers of inflammation
1276654|NCT00860847|Coronary Plaque Volume and coronary Stenosis
1276655|NCT00860847|Vascular function
1276656|NCT00860834|Consumer Participation
1276657|NCT00860834|Telephone Coaching Program
1276658|NCT00860821|Healthy subjects
1276659|NCT00860821|LPS
1276660|NCT00860821|Effect
1276661|NCT00860821|Intranasally
1276662|NCT00860808|tinnitus
1276663|NCT00860795|Echinacea
1276664|NCT00860795|prevention
1276665|NCT00860795|immune modulation
1276666|NCT00860782|Sickle Cell Disease
1276667|NCT00860782|Educational Outcomes
1276668|NCT00860782|Neurodevelopmental Functioning
1276669|NCT00860756|sleep
1276670|NCT00860756|disturbance
1276671|NCT00860756|deployment
1276672|NCT00860756|intervention
1276673|NCT00860756|actigraph
1276674|NCT00860743|intermittent hypoxia
1276675|NCT00860743|ventilatory long-term facilitation
1276676|NCT00860743|autonomic nervous system plasticity
1276677|NCT00860730|Aortic valve replacement
1276678|NCT00860730|Aortic stenosis
1276679|NCT00860730|Biological valve
1276680|NCT00860730|Sutureless valve
1276681|NCT00860730|Stented valve
1276682|NCT00860730|Aortic Valve Disease
1276683|NCT00860717|Leprosy
1276684|NCT00860717|Ulcers
1276685|NCT00860717|Laser
1276686|NCT00860704|goal directed fluid therapy
1276687|NCT00860704|lean patients
1276688|NCT00860704|obese patients
1276689|NCT00860704|crystalloids
1276690|NCT00860704|Esophageal Doppler
1276691|NCT00860704|tissue oxygenation
1276692|NCT00860704|Fluid management during surgery
1276693|NCT00860704|Fluid management
1276694|NCT00860691|Curative surgical resection
1276695|NCT00860691|Laparoscopic technique
1276696|NCT00860665|colorectal cancer
1276697|NCT00860665|prevention
1276698|NCT00860665|colonoscopy
1276699|NCT00860665|screening
1276700|NCT00860665|quality assessment
1276701|NCT00860665|colorectal cancer prevention
1276702|NCT00860652|Oncology
1276703|NCT00860652|Prostate Cancer
1276704|NCT00860652|Radiotherapy
1276705|NCT00860652|Radical Prostatectomy
1276706|NCT00860652|Prior Radical Prostatectomy (RP)
1276707|NCT00860652|Histological Confirmation of adenocarcinoma of the prostate
1276708|NCT00860652|Positive margins and/or extraprostatic extension (EPE)
1276709|NCT00860639|AML
1276710|NCT00860639|gemtuzumab ozogamycin
1276711|NCT00860613|gestational diabetes
1276712|NCT00860613|medical nutrition therapy program
1276713|NCT00860613|glucose monitoring
1276714|NCT00860613|metabolic control
1276715|NCT00860613|nutritional status
1276716|NCT00860613|cost effectiveness
1276717|NCT00860600|Idiopathic Thrombocytopenic Purpura (ITP)
1276718|NCT00860600|Platelet Response
1276719|NCT00860600|PG2 Treatment
1276720|NCT00860600|Quality of Life
1276721|NCT00860600|Fatigue
1276722|NCT00860600|WHO Bleeding score
1276723|NCT00860587|Antibiotic resistance
1276724|NCT00860587|Antibiotic treatment
1276725|NCT00860561|Efficacy profile
1276726|NCT00860561|Safety profile
1276727|NCT00860561|Faslodex
1276728|NCT00860522|relapsed leukemia
1276729|NCT00860522|refractory leukemia
1276730|NCT00860509|phytosterols
1276731|NCT00860509|cholesterol excretion
1276732|NCT00860509|cholesterol absorption
1276733|NCT00860509|diet
1276734|NCT00860509|mass spectrometry
1276735|NCT00860509|deuterium
1276736|NCT00860496|Immunosuppression, JAK3 inhibitor, calcineurin inhibitors, tacrolimus, cyclosporine, pharmacokinetics, safety, tolerability
1276737|NCT00860483|Comparison of experienced and novice laparoscopic surgeons
1276738|NCT00860470|micronutrients
1276739|NCT00860470|deficiency
1276740|NCT00860470|pregnancy
1276741|NCT00860470|birth outcomes
1276742|NCT00860470|infant mortality
1276743|NCT00860470|neonatal mortality
1276744|NCT00860470|malnutrition
1276745|NCT00860470|antenatal
1276746|NCT00860457|Leukemia
1276747|NCT00860444|Primary Care
1276748|NCT00860444|Diet
1276749|NCT00860444|Physical Activity
1276750|NCT00860418|asthma
1276751|NCT00860418|feedback
1276752|NCT00860418|anti-inflammatory
1276753|NCT00860418|ED visits
1276754|NCT00860366|Acute ischemic stroke
1276755|NCT00860366|thrombolysis
1276756|NCT00860366|alteplase
1276757|NCT00860366|uric acid
1276758|NCT00860366|neuroprotection
1276759|NCT00860366|oxidative stress
1276760|NCT00860353|Healthy Volunteer
1276761|NCT00860353|Single Ascending Dose
1276762|NCT00860353|Safety
1276763|NCT00860353|Tolerability
1276764|NCT00860353|AZD2551
1276765|NCT00860353|Healthy Volunteer Study
1276766|NCT00860340|Congestive Heart Failure
1276767|NCT00860340|Hemodynamics
1276768|NCT00860340|Echocardiographs
1276769|NCT00860327|Pediatric Heart Disease
1276770|NCT00860327|Congenital Heart Disease
1276771|NCT00860327|Congenital Heart Defects
1276772|NCT00860327|Developmental Biology
1276773|NCT00860327|Contractile Function
1276774|NCT00860314|external electrical cardioversion
1276775|NCT00860314|typical atrial flutter
1276776|NCT00860314|electrode position
1276777|NCT00860314|antero-lateral
1276778|NCT00860314|antero-posterior
1276779|NCT00860314|biphasic cardioversion
1276780|NCT00860314|step-up protocol
1276781|NCT00860301|infantile colic
1276782|NCT00860288|Type 2 Diabetes
1276783|NCT00860288|vildagliptin
1276784|NCT00860249|education
1276785|NCT00860249|preventive service
1276786|NCT00860249|screening
1276787|NCT00860249|Colorectal Cancer Screening
1276788|NCT00860249|Prevention & Control
1276789|NCT00860236|CFS
1276790|NCT00860236|Giardia
1276791|NCT00860236|Fatigue
1276792|NCT00860236|Cognitive behavioural therapy
1276793|NCT00860236|CBT
1276794|NCT00860236|Chronic fatigue syndrome
1276795|NCT00860223|Healthy Subjects
1276796|NCT00860197|Coffee
1276797|NCT00860197|Elderly
1276798|NCT00860197|Immune response
1276799|NCT00860197|Inflammatory status
1276800|NCT00860184|carotid artery
1276801|NCT00860184|atherosclerosis
1276802|NCT00860184|stroke
1276803|NCT00860184|transient ischemic attack
1276804|NCT00860184|MRI
1276805|NCT00860184|software
1276806|NCT00860184|risk
1276807|NCT00860145|epilepsy
1276808|NCT00860145|radiosurgery
1276809|NCT00860145|temporal lobectomy
1276810|NCT00860132|hip fracture elderly orthogeriatric
1276811|NCT00860132|cost effectiveness of hip fracture patients
1276812|NCT00860119|Bioequivalence, Pharmacokinetics, Alprazolam, Sublingual
1276813|NCT00860106|VTE
1276814|NCT00860106|VKA treatment
1276815|NCT00860106|VKA treatment cessation
1276816|NCT00860093|Kidney Calculi
1276817|NCT00860093|Urolithiasis
1276818|NCT00860093|Lithotripsy
1276819|NCT00860093|potassium compounds
1276820|NCT00860093|magnesium compounds
1276821|NCT00860080|post-surgery adhesion formation
1276822|NCT00860067|influenza, FluMist, adults, vaccine
1276823|NCT00860054|phytosterols
1276824|NCT00860054|cholesterol excretion
1276825|NCT00860054|cholesterol absorption
1276826|NCT00860054|diet
1276827|NCT00860054|mass spectrometry
1276828|NCT00860054|deuterium
1276829|NCT00860041|pain
1276830|NCT00860041|neurotoxicity
1276831|NCT00860041|chemotherapeutic agent toxicity
1276832|NCT00860041|unspecified adult solid tumor, protocol specific
1276833|NCT00860028|Smoking cessation
1276834|NCT00860028|Smoking
1276835|NCT00860028|Tobacco
1276836|NCT00860028|Varenicline
1276837|NCT00860028|Alcohol
1276838|NCT00860002|myomectomy
1276839|NCT00860002|uterine artery occlusion
1276840|NCT00860002|uterine vessel occlusion
1276841|NCT00860002|fibroids
1276842|NCT00860002|leiomyomas
1276843|NCT00860002|Surgical technique, patient suffering and outcomes
1276844|NCT00859989|breast cancer
1276845|NCT00859989|weight changes
1276846|NCT00859989|obesity
1276847|NCT00859976|BoneMaster
1276848|NCT00859976|Total Hip Replacement
1276849|NCT00859976|Bone Density
1276850|NCT00859976|Patients suitable for Total Hip Replacement
1276852|NCT00859950|Sleep Apnea
1276853|NCT00859950|Vascular Occlusion
1276854|NCT00859950|Nocturnal Polysomnography
1276855|NCT00859950|Continuous Positive Airway Pressure
1276856|NCT00859911|micronutrients
1276857|NCT00859898|Diabetes Mellitus, Type 2
1276858|NCT00859898|Diabetes Mellitus
1276859|NCT00859898|Endocrine System Diseases
1276860|NCT00859898|Glucose Metabolism Disorders
1276861|NCT00859898|Metabolic Diseases
1276862|NCT00859898|Metformin
1276863|NCT00859898|Dapagliflozin
1276864|NCT00859898|Hypoglycemic Agents
1276865|NCT00859898|Pharmacologic Actions
1276866|NCT00859898|Physiological Effects of Drugs
1276867|NCT00859885|patent foramen ovale
1276868|NCT00859885|ischemic stroke
1276869|NCT00859885|transient ischemic attack
1276870|NCT00859885|secondary prevention
1276871|NCT00859885|medical treatment
1276872|NCT00859885|percutaneous device closure
1276873|NCT00859872|acute psychotic agitation
1276874|NCT00859872|schizophrenia
1276875|NCT00859872|risperidone oral solution
1276876|NCT00859872|clonazepam
1276877|NCT00859872|haloperidol
1276878|NCT00859846|Arterial line
1276879|NCT00859846|Ultrasound
1276880|NCT00859846|Anesthesia
1276881|NCT00859846|Pediatric
1276882|NCT00859833|adenosine
1276883|NCT00859833|regadenoson
1276884|NCT00859833|adenosine receptor subtypes
1276885|NCT00859807|Amodiaquine suspension
1276886|NCT00859807|Flavoquine tablets
1276887|NCT00859807|Bioequivalence study
1276888|NCT00859794|Epilepsy
1276889|NCT00859794|fMRI
1276890|NCT00859794|Electrophysiology
1276891|NCT00859794|Cortical Mapping
1276892|NCT00859794|Neurosurgery
1276893|NCT00859781|Prostate
1276894|NCT00859768|Cancer
1276895|NCT00859729|DNA
1276896|NCT00859729|Vaccine
1276897|NCT00859729|Electroporation
1276898|NCT00859729|xenogenic
1276899|NCT00859729|PSA
1276900|NCT00859716|Vaccination
1276901|NCT00859716|Diarrhea
1276902|NCT00859716|Traveler's Diarrhea
1276903|NCT00859716|Campylobacter jejuni
1276904|NCT00859716|C. jejuni
1276905|NCT00859716|Campylobacter
1276906|NCT00859716|Campy
1276907|NCT00859703|Aromatase inhibitor treatment
1276908|NCT00859703|osteoporosis
1276909|NCT00859703|breast cancer
1276910|NCT00859703|bisphosphonates
1276911|NCT00859690|Obstructive Sleep Apnea
1276912|NCT00859690|Thrombosis
1276913|NCT00859690|Adenosine Deaminase
1276914|NCT00859690|Sleep Disorder
1276915|NCT00859677|HIV
1276916|NCT00859677|Methicillin-resistant Staphylococcus aureus (MRSA)
1276917|NCT00859677|HIV and Staphylococcus aureus infection
1276918|NCT00859651|breast cancer chemoprevention
1276919|NCT00859651|vitamin D
1276920|NCT00859651|breast density
1276921|NCT00859625|colonoscopy
1276922|NCT00859625|adenoma detection rate
1276923|NCT00859599|Monochromatic Phototherapy
1276924|NCT00859599|Diabetic Foot Ulcers
1276925|NCT00859599|Wound healing
1276926|NCT00859599|Bacterial colonisation
1276927|NCT00859586|Acute Myelogenous Leukemia (AML)
1276928|NCT00859586|Acute Lymphoblastic Leukemia (ALL)
1276929|NCT00859586|Chronic Lymphocytic Leukemia
1276930|NCT00859586|Myelodysplastic Syndrome (MDS)
1276931|NCT00859586|Acute Myelogenous Leukemia
1276932|NCT00859586|AML
1276933|NCT00859586|Acute Lymphoblastic Leukemia
1276934|NCT00859586|ALL
1276935|NCT00859586|Myelodysplastic Syndrome
1276936|NCT00859586|MDS
1276937|NCT00859560|Breast cancer
1276938|NCT00859560|post-menopausal women
1276939|NCT00859560|Arimidex
1276940|NCT00859560|bone fracture
1276941|NCT00859534|Solar Urticaria
1276942|NCT00859521|Bioequivalence
1276943|NCT00859521|Healthy Subjects
1276944|NCT00859508|dura repair following cranial surgery
1276945|NCT00859482|natalizumab
1276946|NCT00859482|multiple sclerosis
1276947|NCT00859469|Mesothelioma
1276948|NCT00859430|Bioequivalence
1276949|NCT00859430|Healthy Subjects
1276950|NCT00859417|correction of anterior prolapse
1276951|NCT00859417|prosthetic trans-obturator way kit
1276952|NCT00859417|randomized study
1276953|NCT00859404|Mild to moderate persistent asthma
1276954|NCT00859391|Celiac Disease
1276955|NCT00859378|Hip
1276956|NCT00859378|Hip endoprosthesis
1276957|NCT00859378|Hip fracture
1276958|NCT00859378|Femoral fracture
1276959|NCT00859378|Bone cement
1276960|NCT00859378|Non-cemented
1276961|NCT00859365|back pain
1276962|NCT00859365|neck pain
1276963|NCT00859365|anxiety
1276964|NCT00859365|range of motion
1276965|NCT00859339|TCC
1276966|NCT00859300|myocardial infarction
1276967|NCT00859300|ventricular fibrillation
1276968|NCT00859300|sudden death
1276969|NCT00859300|polymorphism
1276970|NCT00859287|Reflux esophagitis
1276971|NCT00859287|Omepral®
1276972|NCT00859287|QOLRAD
1276973|NCT00859235|Percutaneous endoscopic gastrostomy
1276974|NCT00859235|peristomal wound infection
1276975|NCT00859235|antibiotic mouth wash solution
1276976|NCT00859235|prophylaxis prior Percutaneous endoscopic gastrostomy (PEG)
1276977|NCT00859222|LBH589
1276978|NCT00859222|bevacizumab
1276979|NCT00859222|Avastin
1276980|NCT00859222|Panobinostat
1276981|NCT00859209|HVF
1276982|NCT00859209|Premature infants
1276983|NCT00859209|ETCO2
1276984|NCT00859196|Wound healing
1276985|NCT00859196|Cell proliferation
1276986|NCT00859196|Gene expression
1276987|NCT00859183|in-stent restenosis
1276988|NCT00859183|stents
1276989|NCT00859183|sirolimus
1276990|NCT00859170|kidney stones
1276991|NCT00859170|ureter
1276992|NCT00859170|laser lithotripsy
1277003|NCT00859144|HIV Prevention
1277004|NCT00859144|Youth
1277005|NCT00859144|Adolescent
1277006|NCT00859144|Community Collaboration
1277007|NCT00859144|Community Mentorship
1277008|NCT00859144|Minority
1277009|NCT00859144|Urban
1277010|NCT00859144|Sexual Risk Behaviors
1277011|NCT00859144|HIV seronegativity
1277012|NCT00859079|diabetes mellitus type 2, GLP-1, insulin infusion
1277013|NCT00859040|recurrent intracranial meningioma(s)
1277014|NCT00859040|progressive intracranial meningioma(s)
1277015|NCT00859027|Non-metastatic
1277016|NCT00858975|renal tumor
1277017|NCT00858975|cryotherapy
1277018|NCT00858975|cytokine
1277019|NCT00858962|HIV
1277020|NCT00858962|Pharmacokinetics
1277021|NCT00858962|Pharmacodynamics
1277022|NCT00858962|Buprenorphine
1277023|NCT00858962|Raltegravir
1277024|NCT00858962|HIV seronegativity
1277025|NCT00858962|Interaction
1277026|NCT00858949|Outpatient surgery
1277027|NCT00858949|Postoperative nausea and vomiting
1277028|NCT00858949|Costs
1277029|NCT00858949|Observational
1277030|NCT00858936|CABG(coronary artery bypass graft)
1277031|NCT00858936|Ischemia
1277032|NCT00858936|Heart surgery
1277033|NCT00858936|Heart damage
1277034|NCT00858923|Extracorporeal Photophoresis
1277035|NCT00858923|immuno-therapy
1277036|NCT00858923|treatment naive
1277037|NCT00858910|Motor imagery
1277038|NCT00858910|Motor skill
1277039|NCT00858910|Performance improvement
1277040|NCT00858897|Glutathione
1277041|NCT00858884|Systemic lupus erythematosus
1277042|NCT00858884|Libman-Sacks endocarditis
1277043|NCT00858884|Stroke
1277044|NCT00858884|Transient ischemic attack
1277045|NCT00858884|Neuropsychiatric systemic lupus erythematosus
1277046|NCT00858884|Transesophageal echocardiography
1277047|NCT00858884|Magnetic resonance imaging
1277048|NCT00858845|Leg Weakness
1277049|NCT00858845|Skeletal Myopathy
1277050|NCT00858845|Sympathetic Nerve Activity
1277051|NCT00858819|Osteoporosis
1277052|NCT00858819|Fractures
1277053|NCT00858819|Bone Mineral Density
1277054|NCT00858819|Quantitative Computed Tomography
1277055|NCT00858793|AIDS
1277056|NCT00858793|HIV
1277057|NCT00858793|Lymphoma
1277058|NCT00858793|Stem Cell Transplantation
1277059|NCT00858793|gene-modified Stem Cells
1277060|NCT00858793|treatment experienced
1277061|NCT00858767|vitamin K2
1277062|NCT00858767|absorption
1277063|NCT00858767|efficacy
1277064|NCT00858754|opioid induced constipation
1277065|NCT00858754|Cancer patients
1277066|NCT00858754|methylnaltrexone
1277067|NCT00858741|bone metastases from any histological subtype.
1277068|NCT00858728|Natural killer cell cytotoxicity
1277069|NCT00858728|Antibody response
1277070|NCT00858728|Tetanus toxoid vaccination
1277071|NCT00858728|Pneumovax II vaccination
1277072|NCT00858728|Total serum immunoglobulins
1277073|NCT00858728|IgG subclasses
1277074|NCT00858715|Clopidogrel
1277075|NCT00858715|Aspirin
1277076|NCT00858715|Antithrombotic therapy
1277077|NCT00858715|Platelet function testing
1277078|NCT00858702|Essential hypertension
1277079|NCT00858702|Combination therapy
1277080|NCT00858689|Clinical Drug Trial
1277081|NCT00858676|acarbose
1277082|NCT00858676|diabetes mellitus
1277083|NCT00858676|impaired glucose tolerance
1277084|NCT00858676|coronary artery disease
1277085|NCT00858663|RAD001(Everolimus)
1277086|NCT00858663|Cisplatin
1277087|NCT00858663|08-138
1277088|NCT00858650|registry
1277089|NCT00858650|natural history
1277090|NCT00858637|Chronic Kidney Disease
1277091|NCT00858637|Dialysis
1277092|NCT00858637|Dyslipidemia
1277093|NCT00858637|Bile acid sequestrant
1277094|NCT00858624|Cough
1277095|NCT00858624|Cough reflex
1277096|NCT00858624|NMDA receptor
1277097|NCT00858624|central sensitisation
1277098|NCT00858611|Influenza
1277099|NCT00858611|Healthy
1277100|NCT00858611|Immunity
1277101|NCT00858611|Preventive
1277102|NCT00858611|Flu
1277103|NCT00858611|Healthy Volunteer
1277104|NCT00858611|HV
1277110|NCT00858585|Bone metastasis, SNP concordance
1277111|NCT00858572|Synta
1277112|NCT00858572|STA-9090
1277113|NCT00858572|AML
1277114|NCT00858572|CML
1277115|NCT00858572|MDS
1277116|NCT00858572|myeloproliferative disorder
1277117|NCT00858572|hematologic malignancy
1277118|NCT00858572|ganetespib
1277119|NCT00858559|Implantable cardioverter defibrillator
1277120|NCT00858559|Remote monitoring
1277121|NCT00858559|Follow-up
1277122|NCT00858533|early intervention
1277123|NCT00858533|sickness absence
1277124|NCT00858533|return to work
1277125|NCT00858533|primary care
1277126|NCT00858520|COPD
1277127|NCT00858520|Lung cancer
1277128|NCT00858520|genes
1277129|NCT00858520|DNA
1277130|NCT00858494|upper respiratory tract infection
1277131|NCT00858494|children
1277132|NCT00858494|homeopathic
1277133|NCT00858481|Pediculosis capitis
1277134|NCT00858481|Head Lice
1277135|NCT00858468|Influenza
1277136|NCT00858468|Influenza vaccine
1277137|NCT00858455|Healthy Volunteers
1277138|NCT00858455|Drug interation, Pharmacokinetics
1277139|NCT00858442|Burn sequelae
1277140|NCT00858442|PRP
1277141|NCT00858442|Children
1277142|NCT00858429|advanced adult primary liver cancer
1277143|NCT00858429|liver metastases
1277144|NCT00858429|adult primary cholangiocellular carcinoma
1277145|NCT00858403|Advanced Non-small Cell Lung Cancer
1277146|NCT00858377|Amgen
1277147|NCT00858377|Phase 1
1277148|NCT00858377|First in Human
1277149|NCT00858377|Advanced Solid Tumors
1277150|NCT00858377|Clinical Trial
1277151|NCT00858377|Aurora kinase inhibitor
1277152|NCT00858377|Open-label
1277153|NCT00858377|Oncology
1277154|NCT00858364|darbepoetin alfa
1277155|NCT00858364|non-small cell lung cancer
1277156|NCT00858364|Aranesp
1277157|NCT00858364|chemotherapy
1277158|NCT00858364|chemotherapy induce anemia
1277159|NCT00858364|advanced lung cancer
1277160|NCT00858364|malignant pleural effusion
1277161|NCT00858364|metastatic lung cancer
1277162|NCT00858364|NSCLC
1277163|NCT00858364|anemia
1277164|NCT00858364|lung cancer
1277165|NCT00858364|pleural effusion
1277166|NCT00858364|Stage IIIB lung cancer
1277167|NCT00858364|Stage IV lung cancer
1277168|NCT00858351|Diabetes
1277169|NCT00858351|Neuropathy
1277170|NCT00858351|Peripheral
1277171|NCT00858351|Painful
1277172|NCT00858351|Thermal
1277173|NCT00858351|Temperature
1277174|NCT00858351|Biofeedback
1277175|NCT00858351|Relaxation
1277176|NCT00858351|Diabetic
1277177|NCT00858338|stomach cancer
1277178|NCT00858338|gastroesophageal junction cancer
1277179|NCT00858338|GEJ cancer
1277180|NCT00858338|intraperitoneal
1277181|NCT00858338|adjuvant chemoradiation therapy
1277182|NCT00858338|resection of advanced stomach cancer
1277183|NCT00858338|locally advanced stomach cancer
1277184|NCT00858325|Cubicin
1277185|NCT00858325|PK
1277186|NCT00858325|China Registration
1277187|NCT00858325|Pharmacokinetics
1277188|NCT00858312|dairy foods
1277189|NCT00858312|weight loss
1277190|NCT00858312|fat loss
1277191|NCT00858312|metabolic regulation
1277192|NCT00858299|proteinuria
1277193|NCT00858299|chronic kidney disease
1277194|NCT00858299|renin-angiotensin system
1277195|NCT00858299|angiotensinogen
1277196|NCT00858273|Glutathione
1277197|NCT00858260|Klotho
1277198|NCT00858260|calcium
1277199|NCT00858260|phosphate
1277200|NCT00858260|parathormone
1277201|NCT00858260|survival
1277202|NCT00858260|dialysis
1277203|NCT00858260|Adult patients undergoing maintenance dialysis since at leat three months
1277204|NCT00858247|vitamin D
1277205|NCT00858247|Obesity
1277206|NCT00858247|Insulin sensitivity
1277207|NCT00858247|Adolescent Obesity
1277208|NCT00858221|obesity
1277209|NCT00858221|genes
1277210|NCT00858221|polymorphisms
1277211|NCT00858221|weight loss
1277212|NCT00858221|haplotype
1277213|NCT00858221|diplotype
1277214|NCT00858208|efficacy and safety of Macugen in routine clinical practice
1277215|NCT00858195|Anti-inflammatory
1277216|NCT00858182|L-Carnitine
1277217|NCT00858182|Xylitol
1277218|NCT00858182|Peritoneal Dialysis
1277219|NCT00858169|three-dimensional power Doppler ultrasonography
1277220|NCT00858169|wrist
1277221|NCT00858169|knee
1277222|NCT00858169|rheumatoid arthritis
1277223|NCT00858156|Pharmacokinetics
1277224|NCT00858143|Open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study
1277225|NCT00858130|Veinoplus
1277226|NCT00858130|post thrombotic syndrome
1277227|NCT00858130|deep vein thrombosis
1277228|NCT00858130|electrical muscle stimulator
1277229|NCT00858130|Venous stasis syndrome
1277230|NCT00858130|venous insufficiency syndrome
1277231|NCT00858130|Postphlebitic syndrome
1277232|NCT00858130|history of deep vein thrombosis
1277233|NCT00858117|B-cell chronic lymphocytic leukemia
1277234|NCT00858117|stage I chronic lymphocytic leukemia
1277235|NCT00858117|stage II chronic lymphocytic leukemia
1277236|NCT00858117|stage III chronic lymphocytic leukemia
1277237|NCT00858117|stage IV chronic lymphocytic leukemia
1277238|NCT00858078|Qualitative Research
1277239|NCT00858078|Semi-Structured Telephone Interview
1277240|NCT00858078|BRCA 1/2
1277241|NCT00858078|Psychosocial/Behavioral Research
1277242|NCT00858078|Hereditary Cancer Risk
1277243|NCT00858078|BRCA
1277244|NCT00858078|BRCA1 Gene
1277245|NCT00858078|BRCA2 Gene
1277246|NCT00858065|Adolescent alcohol and other drug use
1277247|NCT00858065|Choice
1277248|NCT00858065|Family-based
1277249|NCT00858065|Prevention
1277250|NCT00858052|breast implants
1277251|NCT00858052|saline
1277252|NCT00858026|weaning
1277253|NCT00858026|breastfeeding
1277254|NCT00858026|infant formula
1277255|NCT00858026|fermented formula
1277256|NCT00858013|Type 2 Diabetes Mellitus
1277257|NCT00858013|Nateglinide
1277258|NCT00858013|Pancreatic beta cell function
1277259|NCT00858000|markers
1277260|NCT00858000|expression analysis
1277261|NCT00857987|IRA, Guaifenesin, Etaphedrine, Doxilamine
1277262|NCT00857974|Physical Activity
1277263|NCT00857974|Renal Transplant Candidate
1277264|NCT00857974|Physical Function
1277265|NCT00857974|Body Composition
1277266|NCT00857948|head lice
1277267|NCT00857948|Pediculus humanus capitis
1277268|NCT00857948|ivermectin
1277269|NCT00857935|Pediculosis Capitis
1277270|NCT00857935|Head Lice
1277271|NCT00857922|Neurological
1277272|NCT00857922|Neurosurgical
1277273|NCT00857896|Study of fesoterodine in pediatric overactive bladder patients
1277274|NCT00857883|Obesity
1277275|NCT00857883|Food Effect
1277276|NCT00857883|Pharmacokinetics
1277277|NCT00857883|First-Time-In-Humans
1277278|NCT00857883|Pharmacodynamics
1277279|NCT00857883|Healthy Volunteers
1277280|NCT00857857|asthma
1277281|NCT00857857|late phase response
1277282|NCT00857857|allergen
1277283|NCT00857857|challenge
1277284|NCT00857857|GW870086X
1277285|NCT00857844|Chronic Nephrotoxicity
1277286|NCT00857844|Kidney dysfunction post liver transplant
1277287|NCT00857844|Urinary biomarkers of chronic nephrotoxicity from CI
1277288|NCT00857831|spinal cord injury
1277289|NCT00857831|Vitamin D deficiency
1277290|NCT00857831|Functional Electrical Stimulation
1277291|NCT00857805|Transarterial chemoembolization
1277292|NCT00857805|Carcinoma, Hepatocellular
1277293|NCT00857805|Proton Beam Radiotherapy
1277294|NCT00857792|Coronary Disease
1277295|NCT00857792|Cardiac CT Imaging
1277296|NCT00857792|Stress Testing
1277297|NCT00857792|Lexiscan (regadenoson)
1277298|NCT00857779|allergen immunotherapy
1277299|NCT00857779|allergy to grass pollen
1277300|NCT00857766|Chronic Obstructive Pulmonary Disease
1277301|NCT00857766|arterial stiffness
1277302|NCT00857766|Computed Tomography
1277303|NCT00857766|pulse wave velocity
1277304|NCT00857766|Pulse wave analysis
1277305|NCT00857727|Dexmedetomidine
1277306|NCT00857727|Emergence Delirium
1277307|NCT00857727|Agitation
1277308|NCT00857727|Pediatric
1277309|NCT00857727|Anesthesia
1277310|NCT00857714|DCIS
1277311|NCT00857714|breast
1277312|NCT00857701|total knee arthroplasty
1277313|NCT00857701|Dynamic Splinting
1277314|NCT00857701|Knee extension
1277315|NCT00857701|knee
1277316|NCT00857701|Reduced knee flexion after total knee arthroscopy
1277317|NCT00857688|aphtous
1277318|NCT00857688|bismuth
1277319|NCT00857688|procain
1277320|NCT00857688|neomycin
1277321|NCT00857688|Efficacy of the Association in Treatment of Aphtous
1277322|NCT00857675|HBV DNA suppression
1277323|NCT00857675|ALT normalisation
1277324|NCT00857675|Viral resistance
1277325|NCT00857675|HBeAg seroconversion
1277326|NCT00857662|US Multicenter
1277327|NCT00857662|Randomized
1277328|NCT00857662|Onyx
1277329|NCT00857662|Brain Arteriovenous Malformation (BAVMs)
1277330|NCT00857649|Alzheimer's Disease
1277331|NCT00857636|Ethnic minority women
1277332|NCT00857636|Cancer screening
1277333|NCT00857636|Health literacy
1277334|NCT00857636|Behavioral intervention
1277335|NCT00857636|Breast Cancer screening
1277336|NCT00857636|Cervical Cancer screening
1277337|NCT00857623|Pain
1277338|NCT00857623|Diabetic Neuropathy
1277339|NCT00857623|PDN
1277340|NCT00857623|Analgesia
1277341|NCT00857623|Efficacy
1277342|NCT00857610|Aged skin
1277343|NCT00857610|Photoaged skin
1277344|NCT00857610|Retinol
1277345|NCT00857610|Topical retinoids
1277346|NCT00857597|GERD
1277347|NCT00857597|endoscopic
1277348|NCT00857597|fundoplication
1277349|NCT00857597|Proton Pump Inhibitors
1277350|NCT00857597|heartburn
1277351|NCT00857597|anti-reflux surgery
1277352|NCT00857584|Bipolar disorder
1277353|NCT00857584|Bipolar depression
1277354|NCT00857584|quetiapine
1277355|NCT00857584|sertraline
1277356|NCT00857571|Dose Response Bioavailability Study
1277357|NCT00857532|amyloid burden
1277358|NCT00857532|Parkinson's disease
1277359|NCT00857532|florbetapir PET
1277360|NCT00857532|amyloid PET imaging
1277361|NCT00857519|retinoblastoma
1277362|NCT00857519|Intraarterial
1277363|NCT00857519|Chemotherapy
1277364|NCT00857519|Melphalan
1277365|NCT00857519|Carboplatin
1277366|NCT00857506|Cognitive outcome
1277367|NCT00857506|18F-AV-45 PET scan
1277368|NCT00857506|Amyloid PET scan
1277369|NCT00857506|Florbetapir F 18 amyloid PET scan
1277370|NCT00857506|Normal cognition
1277371|NCT00857506|Change in cognitive status in relation to brain amyloid on PET
1277372|NCT00857415|florbetapir F 18 PET
1277373|NCT00857415|amyloid imaging
1277374|NCT00857415|Amyloid pathology in the brain
1277375|NCT00857402|Arginine
1277376|NCT00857402|Nitric oxide
1277377|NCT00857402|Peanuts
1277378|NCT00857402|Sedimentation rate
1277379|NCT00857389|Cancer
1277380|NCT00857389|Blood And Marrow Transplantation
1277381|NCT00857389|Stem Cell
1277382|NCT00857389|Leukemia
1277383|NCT00857389|Lymphoma
1277384|NCT00857389|Pediatrics
1277385|NCT00857389|Bone marrow
1277386|NCT00857389|Lymph node system
1277387|NCT00857389|Allogeneic Stem Cell Transplant
1277388|NCT00857389|ASCT
1277389|NCT00857389|Busulfan
1277390|NCT00857389|Busulfex
1277391|NCT00857389|Myleran
1277392|NCT00857389|Clofarabine
1277393|NCT00857389|Clofarex
1277394|NCT00857389|Clolar
1277395|NCT00857389|Thiotepa
1277396|NCT00857389|Antithymocyte globulin
1277397|NCT00857389|ATG
1277398|NCT00857389|Thymoglobulin
1277399|NCT00857389|G-CSF
1277400|NCT00857389|Filgrastim
1277401|NCT00857389|Neupogen
1277402|NCT00857389|Cyclophosphamide
1277403|NCT00857389|Cytoxan
1277404|NCT00857389|Neosar
1277405|NCT00857389|Mesna
1277406|NCT00857389|Mesnex
1277407|NCT00857389|Tacrolimus
1277408|NCT00857389|Prograf
1277409|NCT00857389|Methotrexate
1277410|NCT00857376|Heart disease risk factors
1277411|NCT00857376|Risk factor management
1277412|NCT00857376|Pre-Diabetes
1277413|NCT00857376|Hypertension
1277414|NCT00857376|obesity
1277415|NCT00857376|glucose intolerance
1277416|NCT00857376|high cholesterol
1277417|NCT00857376|abdominal obesity
1277418|NCT00857376|enlarged waist
1277419|NCT00857363|capsule
1277420|NCT00857363|constipation
1277421|NCT00857363|whole gut transit
1277422|NCT00857363|colonic transit
1277423|NCT00857363|gastric emptying
1277424|NCT00857363|small bowel transit
1277425|NCT00857350|HIV
1277426|NCT00857350|resistance
1277427|NCT00857350|opioid dependence
1277428|NCT00857324|Refractory or relapsed patients
1277429|NCT00857324|dose-finding
1277430|NCT00857324|Vorinostat
1277431|NCT00857298|HIV
1277432|NCT00857298|Metabolic Syndrome
1277433|NCT00857298|Obesity
1277434|NCT00857298|Treatment Experienced
1277435|NCT00857272|colonoscopy
1277436|NCT00857272|bowel preparation
1277437|NCT00857259|AMD
1277438|NCT00857259|macular degeneration
1277439|NCT00857259|Everolimus
1277440|NCT00857259|Lucentis
1277441|NCT00857259|Ranibizumab
1277442|NCT00857259|Choroidal Neo-Vascular (CNV) age-onset macular degeneration
1277443|NCT00857259|Age-related Macular Degeneration (AMD)
1277444|NCT00857246|stomach cancer
1277445|NCT00857246|biologics
1277446|NCT00857246|antibody
1277447|NCT00857246|chemotherapy
1277448|NCT00857246|chemoradiation
1277449|NCT00857246|adjuvant therapy
1277450|NCT00857246|neoadjuvant therapy
1277451|NCT00857246|epidermal growth factor receptor
1277452|NCT00857246|combination therapy
1277453|NCT00857233|Alzheimer's Disease
1277454|NCT00857220|Hypnotic
1277455|NCT00857220|Eszopiclone
1277456|NCT00857220|Attention Deficit Hyperactivity Disorder
1277457|NCT00857220|Insomnia
1277458|NCT00857220|Children
1277459|NCT00857220|Adolescent
1277462|NCT00857194|Coronary Heart Disease
1277463|NCT00857194|spinal cord injury
1277464|NCT00857194|risk factor
1277465|NCT00857194|postprandial lipemia
1277466|NCT00857181|Liver Cirrhosis
1277467|NCT00857181|Infection
1277468|NCT00857181|Inflammation
1277469|NCT00857181|Cytokines
1277470|NCT00857155|Coronary Artery Disease
1277471|NCT00857155|CABG
1277472|NCT00857155|Clopidogrel
1277473|NCT00857155|Aspirin
1277474|NCT00857155|Point of Care devices
1277475|NCT00857129|"normal birth"
1277476|NCT00857129|"birth outcome"
1277477|NCT00857129|"low risk birth"
1277478|NCT00857129|"low risk units"
1277479|NCT00857129|If type of birth care unit have effect on birth outcome
1277480|NCT00857129|Apgar score
1277481|NCT00857129|breast feeding frequency
1277482|NCT00857129|patient satisfaction
1277483|NCT00857116|Deworming
1277484|NCT00857116|Tuberculosis
1277485|NCT00857116|TB-score
1277486|NCT00857116|Albendazole
1277487|NCT00857116|Helminths
1277488|NCT00857103|computer support
1277489|NCT00857103|patient-provider communication
1277490|NCT00857103|patient-centered care
1277491|NCT00857103|cancer
1277492|NCT00857090|Urinary Calculi
1277493|NCT00857090|Urinary Stones
1277494|NCT00857090|Urinary Tract Stones
1277495|NCT00857090|Renal Calculi
1277496|NCT00857090|Kidney Stones
1277497|NCT00857090|Calculi
1277498|NCT00857090|Urolithotomy
1277499|NCT00857090|Ureteroscopy
1277500|NCT00857077|incidence of anaemia
1277501|NCT00857064|Schizophrenia
1277502|NCT00857064|antipsychotics
1277503|NCT00857064|social functioning
1277504|NCT00857064|subjective well being
1277505|NCT00857064|Patients suffering from Schizophrenia
1277506|NCT00857051|Stress
1277507|NCT00857038|COPD
1277508|NCT00857038|Inflammation
1277509|NCT00857038|Neutrophilic
1277510|NCT00857038|Myeloperoxidase
1277511|NCT00857038|Doxycycline
1277512|NCT00857025|stage IIIA non-small cell lung cancer
1277513|NCT00857025|stage IIIB non-small cell lung cancer
1277514|NCT00857025|stage IV non-small cell lung cancer
1277515|NCT00857025|recurrent non-small cell lung cancer
1277516|NCT00857012|Primary early MCa
1277517|NCT00857012|Arimidex
1277518|NCT00856999|Glabellar lines of moderate severity at maximum frown
1277519|NCT00856973|Hypnotic
1277520|NCT00856973|Eszopiclone
1277521|NCT00856973|Attention Deficit/Hyperactivity Disorder
1277522|NCT00856973|Insomnia
1277523|NCT00856973|Children
1277524|NCT00856973|Adolescent
1277525|NCT00856973|Polysomnography
1277526|NCT00856973|Actigraphy
1277527|NCT00856947|wheeze
1277528|NCT00856947|infections
1277529|NCT00856947|allergy
1277530|NCT00856947|eczema
1277531|NCT00856947|vitamin D
1277532|NCT00856934|Skin graft donor site healing
1277533|NCT00856934|skin
1277534|NCT00856934|wound
1277535|NCT00856934|platelet concentrate
1277536|NCT00856934|keratinocytes
1277537|NCT00856934|burns
1277538|NCT00856921|Relationship between achalasia and AAAS gene
1277539|NCT00856908|Type II Diabetes
1277540|NCT00856895|Improved Life Quality
1277541|NCT00856856|Bioabsorbable
1277542|NCT00856856|Coronary Stent
1277543|NCT00856856|Everolimus
1277544|NCT00856856|drug eluting stents
1277545|NCT00856856|stents
1277546|NCT00856856|angioplasty
1277547|NCT00856856|coronary artery disease
1277548|NCT00856856|total coronary occlusion
1277549|NCT00856856|coronary artery restenosis
1277550|NCT00856856|stent thrombosis
1277551|NCT00856856|vascular disease
1277552|NCT00856856|myocardial ischemia
1277553|NCT00856856|coronary artery stenosis
1277554|NCT00856856|CAD
1277555|NCT00856856|CAOD
1277556|NCT00856843|colonoscopy
1277557|NCT00856843|bowel preparation
1277558|NCT00856830|Small cell lung cancer
1277559|NCT00856830|Chemonaive
1277560|NCT00856830|Bendamustine
1277561|NCT00856830|Irinotecan
1277562|NCT00856830|Etoposide
1277563|NCT00856830|Carboplatin
1277564|NCT00856804|Thalidomide
1277565|NCT00856804|Hepatitis C
1277566|NCT00856804|Interferon resistance
1277567|NCT00856804|Immunomodulators
1277568|NCT00856791|Ovarian
1277569|NCT00856791|Cancer
1277570|NCT00856791|Cisplatin
1277571|NCT00856791|Carboplatin
1277572|NCT00856778|Male sling
1277573|NCT00856778|stress urinary incontinence
1277574|NCT00856778|urinary incontinence
1277575|NCT00856739|obesity
1277576|NCT00856739|arthritis
1277577|NCT00856700|GLP-1
1277578|NCT00856700|Endothelial Function
1277579|NCT00856700|Metabolic Syndrome
1277580|NCT00856687|Asthma Allergen Challenge
1277581|NCT00856674|IgA nephropathy
1277582|NCT00856674|chemokine fusion protein
1277583|NCT00856674|leukocyte population modulator
1277584|NCT00856674|phase-1
1277585|NCT00856661|Acute ischemic stroke
1277586|NCT00856661|Angiography
1277587|NCT00856661|Desmoteplase
1277588|NCT00856661|Thrombolytic
1277589|NCT00856622|open-angle glaucoma ocular hypertension glaucoma
1277590|NCT00856609|Weight Loss
1277591|NCT00856609|Byetta (Exenatide)
1277592|NCT00856609|Energy Expenditure
1277593|NCT00856609|Obesity
1277594|NCT00856609|Food Intake
1277595|NCT00856596|Tinea pedis
1277596|NCT00856596|Fungus
1277597|NCT00856596|Pruritus
1277598|NCT00856596|Dermatophyte
1277599|NCT00856596|Athlete's foot
1277600|NCT00856596|Dermatomycosis
1277601|NCT00856596|Skin manifestation
1277602|NCT00856596|Infectious skin disease
1277603|NCT00856596|Foot diseases
1277604|NCT00856570|YM178
1277605|NCT00856570|Mirabegron
1277606|NCT00856570|DDI
1277607|NCT00856570|Phase I
1277608|NCT00856570|Warfarin
1277609|NCT00856570|Pharmacokinetics
1277610|NCT00856557|Patients with complex psychosocial needs
1277611|NCT00856544|Arthritis
1277612|NCT00856544|Rheumatoid
1277613|NCT00856544|Antirheumatic Agents
1277614|NCT00856544|Clinical Trial
1277615|NCT00856531|Möbius syndrome
1277616|NCT00856531|Language
1277617|NCT00856531|Speech, Language and Hearing Sciences
1277618|NCT00856518|Multiple Sclerosis
1277619|NCT00856518|Parkinson's disease
1277620|NCT00856518|Dysphagia
1277621|NCT00856505|Hematopoietic Stem Cell Transplantation
1277622|NCT00856505|Drug Therapy, Combination
1277623|NCT00856505|Immunosuppression
1277624|NCT00856492|inflammatory breast cancer
1277625|NCT00856492|stage II breast cancer
1277626|NCT00856492|stage IIIA breast cancer
1277627|NCT00856492|stage IIIB breast cancer
1277628|NCT00856492|HER2-negative breast cancer
1277629|NCT00856492|estrogen receptor-negative breast cancer
1277630|NCT00856492|estrogen receptor-positive breast cancer
1277751|NCT00856076|Thrombophilia
1277631|NCT00856492|progesterone receptor-negative breast cancer
1277632|NCT00856492|progesterone receptor-positive breast cancer
1277633|NCT00856492|stage IIIC breast cancer
1277634|NCT00856479|Infuse
1277635|NCT00856479|cost analysis
1277636|NCT00856479|Non union diaphyseal fracture
1277637|NCT00856479|The efficacy of Infuse BMP 2 in Non union diaphyseal fractures. Also the cost analysis with the amount of time spent in hospital post op.
1277638|NCT00856453|fatigue
1277639|NCT00856453|depression
1277640|NCT00856453|recurrent ovarian epithelial cancer
1277641|NCT00856453|recurrent ovarian germ cell tumor
1277642|NCT00856453|stage I ovarian epithelial cancer
1277643|NCT00856453|stage I ovarian germ cell tumor
1277644|NCT00856453|stage II ovarian epithelial cancer
1277645|NCT00856453|stage II ovarian germ cell tumor
1277646|NCT00856453|stage III ovarian epithelial cancer
1277647|NCT00856453|stage III ovarian germ cell tumor
1277648|NCT00856453|stage IV ovarian epithelial cancer
1277649|NCT00856453|stage IV ovarian germ cell tumor
1277650|NCT00856440|SCI
1277651|NCT00856427|stage IIIA non-small cell lung cancer
1277652|NCT00856427|stage IIIB non-small cell lung cancer
1277653|NCT00856427|stage IA non-small cell lung cancer
1277654|NCT00856427|stage IB non-small cell lung cancer
1277655|NCT00856427|stage IIA non-small cell lung cancer
1277656|NCT00856427|stage IIB non-small cell lung cancer
1277657|NCT00856401|hypoparathyroidism
1277658|NCT00856401|hypopara
1277659|NCT00856401|PTH
1277660|NCT00856401|parathyroid hormone
1277661|NCT00856401|CL-11-040
1277662|NCT00856401|CL1-11 Study
1277663|NCT00856401|NPSP 558
1277664|NCT00856401|RELAY
1277665|NCT00856401|RACE
1277666|NCT00856401|REPLACE
1277667|NCT00856401|HEXT
1277668|NCT00856401|c10-007
1277669|NCT00856401|c10-008
1277670|NCT00856401|NPSP558
1277671|NCT00856401|Columbia study
1277672|NCT00856401|Columbia studies
1277673|NCT00856401|HPTH
1277674|NCT00856401|PTH1-84
1277675|NCT00856375|colorectal cancer
1277676|NCT00856375|Colorectal cancer, second line
1277677|NCT00856362|Healthy Subjects
1277678|NCT00856349|Implantable Cardioverter Defibrillator (ICD)
1277679|NCT00856349|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
1277680|NCT00856349|Lead Integrity Alert (LIA)
1277681|NCT00856349|Therapy Programming Report (TPR)
1277682|NCT00856323|Methamphetamine
1277683|NCT00856323|HIV
1277684|NCT00856323|Post-exposure prophylaxis
1277685|NCT00856323|HIV seronegativity
1277686|NCT00856310|Healthy volunteers
1277687|NCT00856297|Meningococcal
1277688|NCT00856297|ACWY
1277689|NCT00856297|Conjugate Vaccine
1277690|NCT00856297|Meningitis
1277691|NCT00856297|Adolescents
1277692|NCT00856297|Persistence
1277693|NCT00856284|Diabetes Mellitus
1277694|NCT00856284|Drug Therapy
1277695|NCT00856284|Hyperinsulinism
1277696|NCT00856284|Hyperglycemia
1277697|NCT00856284|Glucose Intolerance
1277698|NCT00856258|Multiple dose in healthy volunteers
1277699|NCT00856245|non-Hodgkins
1277700|NCT00856245|lymphoma
1277701|NCT00856245|stem cell transplant
1277702|NCT00856232|Headache
1277703|NCT00856232|Cephalgia
1277704|NCT00856232|Migraine
1277705|NCT00856219|Immune System
1277706|NCT00856206|Metabolism, Inborn Errors
1277707|NCT00856206|Allopurinol
1277708|NCT00856206|Metabolic Disease
1277709|NCT00856206|Genetic Diseases, Inborn
1277710|NCT00856206|Musculoskeletal Diseases
1277711|NCT00856206|Joint Diseases
1277712|NCT00856206|Arthritis
1277713|NCT00856206|Rheumatic Diseases
1277714|NCT00856206|Metabolic disorder
1277715|NCT00856206|Purine Pyrimidine Metabolism, Inborn Errors
1277716|NCT00856206|Gout
1277717|NCT00856206|Intercritical Gout
1277718|NCT00856193|COPD
1277719|NCT00856193|Bronchodilator
1277720|NCT00856180|avastin
1277721|NCT00856180|bevacizumab
1277722|NCT00856180|cyclophosphamide
1277723|NCT00856180|cytoxan
1277724|NCT00856180|mullerian malignancies
1277725|NCT00856167|temporomandibular dysfunction
1277726|NCT00856167|TMD
1277727|NCT00856167|TMJ
1277728|NCT00856167|Traditional Chinese Medicine
1277729|NCT00856167|TCM
1277730|NCT00856154|HIV-1
1277731|NCT00856154|HLA-A2
1277732|NCT00856154|Therapeutic
1277733|NCT00856154|Vaccine
1277734|NCT00856154|treatment vaccine
1277735|NCT00856154|treatment naive
1277736|NCT00856141|IOP measurement
1277737|NCT00856141|IOP fluctuation
1277738|NCT00856141|in-vivo IOP measuring device
1277739|NCT00856141|intraocular pressure measurement
1277740|NCT00856115|stage I colon cancer
1277741|NCT00856115|stage II colon cancer
1277742|NCT00856115|stage III colon cancer
1277743|NCT00856115|stage IV colon cancer
1277744|NCT00856115|stage I rectal cancer
1277745|NCT00856115|stage II rectal cancer
1277746|NCT00856115|stage III rectal cancer
1277747|NCT00856115|stage IV rectal cancer
1277748|NCT00856076|Venous thromboembolism
1277749|NCT00856076|Intrauterine fetal death
1277750|NCT00856076|Risk factor
1277752|NCT00856076|Venous thromboembolism (in pregnancy)
1277753|NCT00856063|Attention Deficit Hyperactivity Disorder
1277754|NCT00856063|Atomoxetine
1277755|NCT00856063|Electrodermal Response
1277756|NCT00856063|Impulsivity
1277757|NCT00856063|Preschool Children
1277758|NCT00856050|estrogen receptor positive
1277759|NCT00856050|progesterone receptor positive
1277760|NCT00856050|letrozole
1277761|NCT00855998|Thymidine Kinase 1
1277762|NCT00855998|BRCA1 and BRCA2 mutations
1277763|NCT00855998|hereditary breast/ovarian cancer
1277764|NCT00855985|Pancreatic anastomosis
1277765|NCT00855985|Whipple operation
1277766|NCT00855959|Asthma
1277767|NCT00855959|Pulmicort Respules
1277768|NCT00855946|tumor response
1277769|NCT00855946|rectal adenocarcinoma
1277770|NCT00855946|preoperative radiochemotherapy
1277771|NCT00855946|Proteomic analysis
1277772|NCT00855946|MALDI-TOF-TOF
1277773|NCT00855946|rectal adenocarcinoma, tumor response after preoperative radiochemotherapy
1277774|NCT00855920|Metabolism, Inborn Errors
1277775|NCT00855920|Allopurinol
1277776|NCT00855920|Metabolic Diseases
1277777|NCT00855920|Genetic Diseases, Inborn
1277778|NCT00855920|Musculoskeletal Diseases
1277779|NCT00855920|Joint Diseases
1277780|NCT00855920|Arthritis
1277781|NCT00855920|Rheumatic Diseases
1277782|NCT00855920|Metabolic disorder
1277783|NCT00855920|Purine-Pyrimidine Metabolism, Inborn Errors
1277784|NCT00855920|Gout
1277785|NCT00855920|Flare
1277786|NCT00855907|IBD
1277787|NCT00855907|inflammatory bowel disease
1277788|NCT00855907|fatty liver
1277789|NCT00855894|Tarceva
1277790|NCT00855894|NSCLC
1277791|NCT00855881|adjuvant chemotherapy for head and neck cancer
1277792|NCT00855868|Amyloid imaging
1277793|NCT00855868|Positron Emission Tomography
1277794|NCT00855868|18F-AV-45
1277795|NCT00855868|florbetapir F 18
1277796|NCT00855868|Diagnostic imaging
1277803|NCT00855842|second trimester abortion
1277804|NCT00855842|labor induction abortion
1277805|NCT00855842|second trimester medical abortion
1277806|NCT00855842|pregnancy
1277807|NCT00855803|spinal cord metastases
1277808|NCT00855803|unspecified adult solid tumor, protocol specific
1277809|NCT00855803|pain
1277810|NCT00855790|evaluate the effectiveness of one bite polypectomy with the RJ3 biopsy forcep versus the RJ4 biopsy forcep
1277811|NCT00855777|third molar extraction
1277812|NCT00855777|etoricoxib
1277813|NCT00855777|ibuprofen
1277814|NCT00855777|analgesic efficacy
1277815|NCT00855777|pain
1277816|NCT00855738|epilepsy antiepileptic biotherapy
1277817|NCT00855725|Epilepsy
1277818|NCT00855725|Depression
1277819|NCT00855725|Neurology
1277820|NCT00855725|fMRI
1277821|NCT00855725|Healthy Controls
1277822|NCT00855712|Heart Failure
1277823|NCT00855712|Transplant
1277824|NCT00855712|Warm Perfusion
1277825|NCT00855712|Organ Care
1277826|NCT00855712|Resting Mode
1277827|NCT00855699|Alcohol detoxification
1277828|NCT00855686|Memantine
1277829|NCT00855686|Cognition
1277830|NCT00855686|Parkinson's Disease Dementia
1277831|NCT00855686|Dementia With Lewy Bodies
1277832|NCT00855673|Claudication
1277833|NCT00855673|Peripheral Arterial Disease
1277834|NCT00855673|Intermittent Compression
1277835|NCT00855673|Mechanical Compression
1277836|NCT00855673|Flowmedic
1277837|NCT00855660|Bone Metabolism
1277838|NCT00855634|Pancreatic cancer
1277839|NCT00855634|metastasis
1277840|NCT00855634|venous infiltration
1277841|NCT00855634|Pancreatic cancer with minimal metastatic disease or venous infiltration
1277842|NCT00855621|deep brain stimulation
1277843|NCT00855621|subthalamic nucleus
1277844|NCT00855608|choroidal neovascularization
1277845|NCT00855608|diabetic retinopathy
1277846|NCT00855608|uveitis
1277847|NCT00855608|refractory cases of uveitis
1277848|NCT00855595|Rosacea
1277849|NCT00855582|Erectile Dysfunction
1277850|NCT00855582|Benign Prostatic Hyperplasia
1277851|NCT00855569|allografting
1277852|NCT00855530|Depression
1277853|NCT00855504|preeclampsia
1277854|NCT00855504|periodontitis
1277855|NCT00855504|cytokines
1277856|NCT00855491|PCO
1277857|NCT00855491|POCO
1277858|NCT00855465|Chronic thromboembolic pulmonary hypertension
1277859|NCT00855465|PH
1277860|NCT00855465|soluble Guanylate Cyclase Stimulator
1277861|NCT00855465|sGC
1277862|NCT00855452|GVL
1277863|NCT00855452|rIL-2(LAK)
1277864|NCT00855452|GVHD
1277865|NCT00855452|MST
1277866|NCT00855452|alloCT
1277867|NCT00855452|alloBMT
1277868|NCT00855439|Diabetes
1277869|NCT00855439|Neuropathy
1277870|NCT00855439|Glucose
1277871|NCT00855439|Control
1277872|NCT00855439|Peripheral
1277873|NCT00855439|Autonomic
1277874|NCT00855413|Acute HIV
1277875|NCT00855413|HIV
1277876|NCT00855413|Treatment Naive
1277877|NCT00855413|Acute Infections
1277878|NCT00855400|Amyotrophic Lateral Sclerosis
1277879|NCT00855400|Bone marrow
1277880|NCT00855400|Stem cells
1277881|NCT00855400|Autologous
1277882|NCT00855400|Safety
1277883|NCT00855387|Clinical outcome (complications), in-hospital costs
1277884|NCT00855387|The influence and impact of postoperative complications on in-hospital costs
1277885|NCT00855361|Gastroesophageal Reflux
1277886|NCT00855361|Erosive Gastroesophageal Reflux Disease
1277887|NCT00855361|Ulcerative Gastroesophageal Reflux Disease
1277888|NCT00855361|Endoscopy
1277889|NCT00855361|Pediatrics
1277890|NCT00855361|GERD
1277891|NCT00855361|Rabeprazole, Rabeprazole sodium
1277892|NCT00855361|AcipHex
1277893|NCT00855348|colorectal cancer
1277894|NCT00855348|early detection
1277895|NCT00855348|methylation, biomarker
1277896|NCT00855335|HIV-1
1277897|NCT00855335|HIV
1277898|NCT00855335|Pregnancy
1277899|NCT00855335|Postpartum
1277900|NCT00855335|Human immunodeficiency virus
1277901|NCT00855335|PREZISTA
1277902|NCT00855335|INTELENCE
1277903|NCT00855335|NORVIR
1277904|NCT00855335|TMC114
1277905|NCT00855335|TMC125
1277906|NCT00855335|darunavir
1277907|NCT00855335|ritonavir
1277908|NCT00855335|etravirine
1277909|NCT00855335|rilpivirine
1277910|NCT00855335|TMC278
1277911|NCT00855335|Cobicistat
1277912|NCT00855335|treatment experienced
1277913|NCT00855322|Arthritis, Rheumatoid
1277914|NCT00855322|Exercise
1277915|NCT00855322|Biological Therapy
1277916|NCT00855309|chemotherapeutic agent toxicity
1277917|NCT00855309|renal toxicity
1277918|NCT00855309|infection
1277919|NCT00855309|neutropenia
1277920|NCT00855270|PTSD
1277921|NCT00855257|Acid nicotinique
1277922|NCT00855257|FLOW MEDIATED DILATATION (FMD)
1277923|NCT00855257|HDL-C< 0.4 G/L
1277924|NCT00855244|Bone marrow transplantation
1277925|NCT00855231|Acute coronary syndrome
1277926|NCT00855231|Coronary artery disease
1277927|NCT00855231|cardiac imaging
1277928|NCT00855231|computed tomography
1277929|NCT00855218|Sorafenib
1277930|NCT00855218|TACE
1277931|NCT00855218|DC bead
1277932|NCT00855218|Combination
1277933|NCT00855205|pulmonary sarcoidosis
1277934|NCT00855192|anxiety
1277935|NCT00855192|depression
1277936|NCT00855192|pregnancy
1277937|NCT00855192|antenatal
1277938|NCT00855192|prenatal
1277939|NCT00855192|mindfulness-based therapy
1277940|NCT00855192|interpersonal therapy
1277941|NCT00855192|support groups
1277942|NCT00855166|Dapagliflozin
1277943|NCT00855166|Metformin
1277944|NCT00855166|Type 2 diabetes
1277945|NCT00855166|body weight
1277946|NCT00855153|PTSD
1277947|NCT00855153|burns
1277948|NCT00855153|virtual reality exposure
1277949|NCT00855153|D-Cycloserine
1277950|NCT00855153|Combat related psychological trauma in burned servicemembers
1277951|NCT00855140|Insomnia
1277952|NCT00855140|Primary insomnia
1277953|NCT00855140|Insomnia disorder
1277954|NCT00855140|Acupuncture
1277955|NCT00855127|Biological Markers
1277956|NCT00855127|Renal Replacement Therapy
1277957|NCT00855127|Mortality
1277958|NCT00855114|stage II breast cancer
1277959|NCT00855114|stage III breast cancer
1277960|NCT00855114|stage IIIA breast cancer
1277961|NCT00855101|Pharmacokinetics and safety of voriconazole intravenous oral adults
1277962|NCT00855088|HIV seronegativity
1277963|NCT00855075|Sedation
1277964|NCT00855075|Analgesia
1277965|NCT00855075|Mechanical ventilation
1277966|NCT00855075|Cerebral State Monitor
1277967|NCT00855075|Cerebral State Index
1277968|NCT00855062|Human immunodeficiency virus (HIV)
1277969|NCT00855062|HIV associated cognitive impairment
1277970|NCT00855062|HIV dementia
1277971|NCT00855062|Uganda
1277972|NCT00855062|Acquired immune deficiency syndrome (AIDS)
1277973|NCT00855062|Treatment Naive
1277974|NCT00855049|Pharmacokinetics
1277975|NCT00855049|Acetaminophen
1277976|NCT00855049|Intranasal
1277977|NCT00855049|Absorption
1277978|NCT00855036|blunt renal injury
1277979|NCT00855036|kidney laceration
1277980|NCT00855023|anterior cruciate ligament
1277981|NCT00855023|Knee Joint
1277982|NCT00855010|Pioglitazone
1277983|NCT00855010|prediabetes
1277984|NCT00855010|diabetes
1277985|NCT00855010|obesity
1277986|NCT00855010|Pancreatic fat
1277987|NCT00854997|Obstructive sleep apnea; myocardial infarction
1277988|NCT00854984|Depression
1277989|NCT00854984|diabetes
1277990|NCT00854984|Coronary heart disease
1277991|NCT00854984|CBT
1277992|NCT00854984|Cognitive behavioural therapy
1277993|NCT00854971|NKCell
1277994|NCT00854971|FOLFOX-4
1277995|NCT00854971|advanced or unresectable colorectal cancer
1277996|NCT00854958|Oral
1277997|NCT00854958|Allergy
1277998|NCT00854958|Syndrome
1277999|NCT00854958|Food
1278000|NCT00854958|Pollen
1278001|NCT00854945|Myelodysplastic Syndrome
1278002|NCT00854945|Refractory Cytopenia
1278003|NCT00854945|Refractory Anemia
1278004|NCT00854945|Dysplasia
1278005|NCT00854945|Acute Myeloid Leukemia
1278006|NCT00854932|procalcitonin
1278007|NCT00854932|sepsis
1278008|NCT00854932|newborn
1278009|NCT00854932|intervention study
1278010|NCT00854919|obsessive-compulsive disorder
1278011|NCT00854919|augmentation treatment
1278012|NCT00854919|SSRI-refractory
1278013|NCT00854906|dry eye
1278014|NCT00854906|keratometer
1278015|NCT00854906|fluorescein
1278016|NCT00854893|stroke
1278017|NCT00854893|aphasia
1278018|NCT00854893|aging
1278019|NCT00854893|language learning
1278020|NCT00854880|Erosive Gastritis
1278021|NCT00854867|Solid tumour neoplastic meningitis
1278022|NCT00854867|STNM
1278023|NCT00854867|leptomeningeal metastases
1278024|NCT00854867|DepoCyte
1278025|NCT00854867|WBRT
1278026|NCT00854867|Whole Brain Radiotherapy
1278027|NCT00854867|Liposomal cytarabine intrathecal
1278028|NCT00854867|Solid Tumour Neoplastic Meningitis with or without brain metastasis
1278029|NCT00854854|NKCell
1278030|NCT00854854|FOLFOX-4
1278031|NCT00854854|gastric cancer
1278032|NCT00854841|CML
1278033|NCT00854841|suboptimal response
1278034|NCT00854841|dasatinib
1278035|NCT00854841|imatinib
1278036|NCT00854828|Symptomatic 40-80 y/o w/lumbar Cobb of 30 degrees
1278037|NCT00854828|All Participants must be reasonable surgical candidate at enrollment
1278038|NCT00854815|Perforated appendicitis
1278039|NCT00854815|laparoscopic appendectomy
1278040|NCT00854815|children
1278041|NCT00854815|irrigation
1278042|NCT00854802|Hepatitis
1278043|NCT00854802|Hepatitis C
1278044|NCT00854789|Breast cancer
1278045|NCT00854776|aspirin
1278046|NCT00854776|clopidogrel
1278047|NCT00854776|proton pump inhibitor
1278048|NCT00854776|peptic ulcer
1278049|NCT00854776|ulcer complications
1278050|NCT00854750|Multiple Sclerosis, hx of unilateral ON, evidence of thermal sensitivity, and no evidence of an ocular motor syndrome
1278051|NCT00854750|Multiple Sclerosis, no evidence of ON, and evidence of thermal sensitivity
1278052|NCT00854750|Healthy age/gender matched controls
1278053|NCT00854737|bipolar disorder
1278054|NCT00854737|bipolar depression
1278055|NCT00854737|bipolar mania
1278056|NCT00854737|manic depression
1278057|NCT00854737|depression
1278058|NCT00854737|mania
1278059|NCT00854737|hypomania
1278060|NCT00854711|ST elevated Myocardical infraction
1278061|NCT00854698|THE LEFT VENTRICULAR REMODELING AFTER MECHANICAL AORTIC VALVE REPLACEMENT
1278062|NCT00854698|exercise training
1278063|NCT00854672|Sarcoidosis
1278064|NCT00854672|muscle strength
1278065|NCT00854672|exercise intolerance
1278066|NCT00854672|QOL
1278072|NCT00854633|Pre-term infants
1278073|NCT00854633|Pre-term infants 750 to 1500 grams
1278074|NCT00854594|Diabetes
1278075|NCT00854594|Telemedicine
1278076|NCT00854594|Shared Medical Appointments
1278077|NCT00854581|recurrent adult T-cell leukemia/lymphoma
1278078|NCT00854581|stage I adult T-cell leukemia/lymphoma
1278079|NCT00854581|stage II adult T-cell leukemia/lymphoma
1278080|NCT00854581|stage III adult T-cell leukemia/lymphoma
1278081|NCT00854581|stage IV adult T-cell leukemia/lymphoma
1278082|NCT00854581|HTLV-1 infection
1278083|NCT00854568|B-cell lymphoma
1278084|NCT00854568|CHOP
1278085|NCT00854568|CEOP
1278086|NCT00854568|Cardiotoxicity
1278087|NCT00854555|incomplete spinal cord injury
1278088|NCT00854555|locomotor activity
1278089|NCT00854555|walking function
1278090|NCT00854555|gait
1278091|NCT00854542|Telepsychiatry
1278092|NCT00854542|Culturally Sensitive Collaborative Treatment
1278093|NCT00854542|Chinese Americans
1278094|NCT00854542|Depression
1278095|NCT00854529|bevacizumab
1278096|NCT00854529|subconjunctival injection
1278097|NCT00854529|trabeculectomy
1278098|NCT00854529|bleb
1278099|NCT00854529|mitomycin c
1278100|NCT00854516|compression therapy
1278101|NCT00854516|3M
1278102|NCT00854503|Statins administration in diabetic dyslipidemia
1278103|NCT00854477|capecitabine
1278104|NCT00854477|Post whipples
1278105|NCT00854477|pancreatico-duodenectomy
1278106|NCT00854477|pancreatic adenocarcinoma
1278107|NCT00854477|pharmacokinetic
1278108|NCT00854464|Arsenic Methylation Capability
1278109|NCT00854464|Arsenic Methylation Enzymes
1278110|NCT00854464|Cigarette Metabolites
1278111|NCT00854464|Cigarette Metabolic Enzymes
1278112|NCT00854464|DNA Repair Enzymes
1278113|NCT00854464|Inflammatory Factors
1278114|NCT00854464|Urothelial Carcinoma
1278115|NCT00854451|Helicobacter pylori
1278116|NCT00854451|CYP2C19 genotype
1278117|NCT00854451|intragastric pH
1278118|NCT00854451|dual therapy
1278119|NCT00854451|antibiotic resistance
1278120|NCT00854438|anticholinergic drugs
1278121|NCT00854438|adverse events
1278122|NCT00854438|elderly
1278123|NCT00854438|clinical pharmacist
1278124|NCT00854438|Evaluate the clinical effects of reducing anticholinergic in elderly
1278125|NCT00854412|Obesity
1278126|NCT00854412|Weight loss
1278127|NCT00854412|Very low-calorie diet
1278128|NCT00854412|Mannose-binding lectin
1278129|NCT00854412|Insulin resistance
1278130|NCT00854386|fluid management
1278131|NCT00854386|VATS
1278132|NCT00854386|ALI
1278133|NCT00854386|ARDS
1278134|NCT00854373|Infertility
1278135|NCT00854373|Pregnancy
1278136|NCT00854373|in vitro fertilization
1278137|NCT00854360|Seasonal Allergic Rhinitis
1278138|NCT00854360|Hayfever
1278139|NCT00854347|hyperglycemia
1278140|NCT00854347|diabetes
1278141|NCT00854347|intensive care
1278142|NCT00854347|prevalence
1278143|NCT00854334|Sleep
1278144|NCT00854334|Overweight
1278145|NCT00854334|Physical activity
1278146|NCT00854334|Appetite
1278147|NCT00854334|NEAT
1278148|NCT00854321|rheumatoid arthritis
1278149|NCT00854321|rituximab
1278150|NCT00854321|therapy
1278151|NCT00854308|Tarceva
1278152|NCT00854308|Lung Cancer
1278153|NCT00854308|NSCLC
1278154|NCT00854295|arthritis
1278155|NCT00854295|osteoarthritis
1278156|NCT00854295|degenerative knee disease
1278157|NCT00854295|avascular necrosis
1278158|NCT00854295|total knee replacement
1278159|NCT00854295|TKA
1278160|NCT00854256|glaucoma
1278161|NCT00854230|HIV
1278162|NCT00854230|alcohol
1278163|NCT00854230|naltrexone
1278164|NCT00854230|Treatment Experienced
1278165|NCT00854204|Innovation-TiFP4-C101
1278166|NCT00854204|Innovation-C101
1278167|NCT00854204|Innovation
1278168|NCT00854204|TMC114/TMC41629
1278169|NCT00854204|controlled-release coformulations
1278170|NCT00854204|immediate-release coformulation
1278171|NCT00854204|Pharmacokinetics
1278172|NCT00854191|mechanical simulator
1278173|NCT00854191|ERCP
1278174|NCT00854191|training
1278175|NCT00854178|isoflurane
1278176|NCT00854178|propofol
1278177|NCT00854178|genotoxicity
1278178|NCT00854178|gene expression
1278179|NCT00854178|cytokines
1278180|NCT00854178|apoptosis
1278181|NCT00854165|lung transplantation
1278182|NCT00854165|respiratory failure
1278183|NCT00854165|ECMO
1278184|NCT00854165|Lung transplants in respiratory failure patients
1278185|NCT00854152|NHL
1278186|NCT00854152|Tumors
1278187|NCT00854152|Carcinogenic Tumors
1278188|NCT00854139|Multiple myeloma
1278189|NCT00854139|Renal failure
1278190|NCT00854139|Kidney transplant
1278191|NCT00854126|NHL
1278192|NCT00854126|Solid Tumors
1278193|NCT00854126|Carcinogenic Tumors
1278194|NCT00854113|Diabetes Mellitus Type 2
1278195|NCT00854100|Adjunctive
1278196|NCT00854100|Depression
1278197|NCT00854100|Major Depressive Disorder (MDD)
1278198|NCT00854087|Hepatitis C Virus
1278199|NCT00854087|HCV
1278200|NCT00854087|Herbal treatment
1278201|NCT00854087|Herbs
1278202|NCT00854087|San Diego
1278203|NCT00854087|Non responder
1278204|NCT00854087|Relapser
1278205|NCT00854087|Treatment failure
1278206|NCT00854087|Antifibrotic
1278207|NCT00854087|Anti-fibrotic
1278208|NCT00854087|Fibrosis
1278209|NCT00854087|Failure of previous Interferon based therapy
1278210|NCT00854087|Refuse Interferon based therapy
1278211|NCT00854087|Intolerance to Interferon
1278212|NCT00854087|Male or female 18-70 years of age
1278213|NCT00854074|Post-operative Paralytic Ileus
1278214|NCT00854074|Neuromodulation
1278215|NCT00854074|Neurostimulation
1278216|NCT00854074|Extended loss of functional bowel motility
1278217|NCT00854048|Pediatric
1278218|NCT00854048|Oxygen Saturation
1278219|NCT00854048|Cardiopulmonary bypass
1278220|NCT00854035|MK-0431/ONO-5435
1278221|NCT00854035|Type 2 diabetes mellitus
1278222|NCT00854009|Healthy Subjects
1278223|NCT00853983|Healthy Volunteers
1278224|NCT00853983|ADME
1278225|NCT00853970|Pain and Inflammation as a function of cataract surgery
1278226|NCT00853957|Hypertension
1278227|NCT00853957|African Americans
1278228|NCT00853957|Aliskiren
1278229|NCT00853957|Amlodipine
1278230|NCT00853957|Systolic blood pressure
1278231|NCT00853957|Diastolic blood pressure
1278232|NCT00853957|Stage II
1278233|NCT00853957|Combination
1278234|NCT00853944|islet transplantation
1278235|NCT00853944|type 1 diabetes
1278236|NCT00853944|incretin
1278237|NCT00853931|KRAS wild type
1278238|NCT00853931|metastatic colorectal cancer
1278239|NCT00853931|KRAS wild type metastatic colorectal cancer with no prior exposure to EGFR inhibitors
1278240|NCT00853918|Physician survey
1278241|NCT00853918|Mail survey
1278242|NCT00853918|Response rate
1278243|NCT00853905|open angle glaucoma (POAG)
1278244|NCT00853905|angle closure glaucoma (PACG)
1278245|NCT00853905|pigmentary glaucoma
1278246|NCT00853905|pseudoexfoliation glaucoma
1278247|NCT00853905|neovascular glaucoma
1278248|NCT00853905|traumatic glaucoma
1278249|NCT00853892|Healthy Subjects
1278250|NCT00853892|Bioequivalence
1278251|NCT00853866|stroke
1278252|NCT00853866|reboxetine
1278253|NCT00853866|noradrenaline
1278254|NCT00853866|motor cortex
1278255|NCT00853866|transcranial direct current stimulation
1278256|NCT00853866|motor function
1278257|NCT00853866|rehabilitation
1278258|NCT00853866|Jebsen Taylor test
1278259|NCT00853853|Hemorrhoidectomy
1278260|NCT00853853|Hemorrhoids
1278261|NCT00853840|pharmacodynamics. maraviroc, vardenafil, blood pressure
1278262|NCT00853827|CAD
1278263|NCT00853827|coronary artery disease
1278264|NCT00853827|coronary atherosclerosis
1278265|NCT00853827|coronary angiography
1278266|NCT00853827|IVUS
1278267|NCT00853827|intravascular ultrasound
1278268|NCT00853827|plasma renin activity
1278269|NCT00853827|renin angiotensin aldosterone system,
1278270|NCT00853827|direct renin inhibitors
1278271|NCT00853827|coronary atheroma
1278272|NCT00853814|adolescence
1278273|NCT00853814|obesity
1278274|NCT00853814|physical activity
1278275|NCT00853814|built environment
1278276|NCT00853814|neighborhood environment
1278277|NCT00853814|children
1278278|NCT00853814|youth
1278279|NCT00853814|increasing physical activity
1278280|NCT00853814|changing dietary intake
1278281|NCT00853814|reducing zBMI
1278282|NCT00853801|Pre-Diabetes
1278283|NCT00853801|Metabolic Syndrome
1278284|NCT00853801|Type 2 Diabetes
1278285|NCT00853801|Diabetes Prevention
1278286|NCT00853801|Lifestyle Modification
1278287|NCT00853801|Diet Therapy
1278288|NCT00853801|Provider Education
1278289|NCT00853788|systemic sclerosis
1278290|NCT00853788|biomarkers
1278291|NCT00853788|microarray
1278292|NCT00853775|heart disease
1278293|NCT00853775|cardiovascular disease
1278294|NCT00853775|lipoproteins
1278295|NCT00853775|lipoprotein(a)
1278296|NCT00853775|Lp(a)
1278297|NCT00853775|apolipoprotein(a)
1278298|NCT00853775|apo(a)
1278299|NCT00853775|fats
1278300|NCT00853775|proteins
1278301|NCT00853775|metabolism
1278302|NCT00853749|Immune response
1278303|NCT00853749|pneumococcal conjugate vaccine
1278304|NCT00853749|polysaccharide
1278305|NCT00853736|Healthy Subjects
1278306|NCT00853736|Bioequivalence
1278307|NCT00853723|osteoporosis
1278308|NCT00853723|post-menopausal
1278309|NCT00853723|bone anabolic agents
1278310|NCT00853710|Prostate-Specific Antigen
1278311|NCT00853710|Prostate Cancer
1278312|NCT00853710|Cancer
1278313|NCT00853710|Assay
1278314|NCT00853697|Prostate
1278315|NCT00853697|DUTASTERIDE
1278316|NCT00853697|TESTOSTERONE
1278317|NCT00853697|09-008
1278318|NCT00853697|Consortium Protocol LOI# c09-028
1278319|NCT00853684|Advanced Colorectal Cancer
1278320|NCT00853684|Oxaliplatin
1278321|NCT00853684|Capecitabine
1278322|NCT00853684|Endostar
1278323|NCT00853684|efficacy
1278324|NCT00853671|Coronary Artery Disease
1278325|NCT00853671|Multidetector Computed Tomography
1278326|NCT00853671|Myocardial Perfusion Imaging
1278327|NCT00853658|Chronic Heart Failure
1278328|NCT00853658|Cardiovascular death
1278329|NCT00853658|CHF hospitalization
1278330|NCT00853658|morbi-mortality trial
1278331|NCT00853658|outcome study
1278332|NCT00853658|endpoint driven
1278333|NCT00853658|plasma renin activity
1278334|NCT00853658|renin angiotensin aldosterone system
1278335|NCT00853658|direct renin inhibitors
1278336|NCT00853658|BNP
1278337|NCT00853658|KCCQ
1278338|NCT00853658|eGFR
1278339|NCT00853658|(NYHA class II to IV) with elevated
1278340|NCT00853658|BNP and reduced LVEF
1278341|NCT00853632|Mitral valve
1278342|NCT00853632|pericardial bioprostheses
1278343|NCT00853632|PERIMOUNT
1278344|NCT00853632|bovine pericardial leaflets
1278345|NCT00853632|mitral valve replacement
1278346|NCT00853632|mitral valve regurgitation
1278347|NCT00853632|Heart valve disease
1278348|NCT00853619|clinical decision support
1278349|NCT00853619|knowledge management
1278350|NCT00853619|knowledge representation
1278351|NCT00853619|clinical guidelines
1278352|NCT00853619|coronary artery disease
1278353|NCT00853619|myocardial ischemia
1278354|NCT00853619|diabetes mellitus
1278355|NCT00853619|hypertension
1278356|NCT00853606|ED
1278357|NCT00853606|Erectile Dysfunction
1278358|NCT00853606|Dysfunction
1278359|NCT00853606|Erectile
1278360|NCT00853593|heart failure
1278361|NCT00853593|cardiac pacing
1278362|NCT00853593|cardiac resynchronization therapy
1278363|NCT00853593|left ventricular lead
1278364|NCT00853580|Neurofibromatosis Type 1, Neurocognitive, Phase II
1278365|NCT00853567|Uterine Fibroids
1278366|NCT00853554|Healthy Subjects
1278367|NCT00853554|Bioequivalence
1278368|NCT00853541|renal impairment
1278369|NCT00853541|heart failure
1278370|NCT00853541|hyperphosphatemia
1278371|NCT00853541|coronary artery calcification
1278372|NCT00853528|spinal cord metastases
1278373|NCT00853502|anorexia nervosa
1278374|NCT00853502|testosterone
1278375|NCT00853502|disordered eating
1278376|NCT00853502|hypogonadism
1278377|NCT00853502|bone
1278378|NCT00853489|Open tibia fractures
1278379|NCT00853489|rhBMP-2
1278380|NCT00853489|critical size defects
1278381|NCT00853489|bone grafting
1278382|NCT00853463|Pulmonary Embolism
1278383|NCT00853463|Deep Vein Thrombosis
1278384|NCT00853463|Prophylaxis
1278385|NCT00853463|Venous thromboembolism
1278386|NCT00853463|Prevention
1278387|NCT00853463|Medical patients
1278388|NCT00853450|Antiplatelet
1278389|NCT00853437|Comparison of CO by new method to clinician's estimate and implied CO from the measurement of arteriovenous oxygen content difference.
1278390|NCT00853424|diabetic retinopathy
1278391|NCT00853424|diabetic macular edema
1278392|NCT00853424|type 1 diabetes
1278393|NCT00853424|intensive medical therapy
1278394|NCT00853424|islet cell transplantation
1278395|NCT00853424|visual acuity
1278396|NCT00853424|diabetic eye disease
1278397|NCT00853411|Moderate to severe asthma
1278398|NCT00853398|Primary Osteoarthritis of the knee.
1278399|NCT00853385|oral DMARD
1278400|NCT00853385|JAK inhibitor
1278401|NCT00853385|clinical trial
1278402|NCT00853346|Depression
1278403|NCT00853346|Parkinson's Disease
1278404|NCT00853346|Major Depression
1278405|NCT00853346|Cognitive Behavioral Therapy
1278406|NCT00853333|Pain
1278407|NCT00853333|Propofol
1278408|NCT00853333|Dexmedetomidine
1278409|NCT00853333|Midazolam
1278410|NCT00853333|Effects of sedation on pain perception.
1278411|NCT00853320|Healthy Subjects
1278412|NCT00853320|Bioequivalence
1278413|NCT00853294|Healthy Subjects
1278414|NCT00853294|Bioequivalence
1278415|NCT00853281|Forest malaria prevention
1278416|NCT00853281|Long-lasting insecticidal hammocks
1278417|NCT00853281|Cluster randomized trial
1278418|NCT00853281|Central Vietnam
1278419|NCT00853268|Healthy Subjects
1278420|NCT00853268|Bioequivalence
1278421|NCT00853255|Bird Flu
1278422|NCT00853242|Chronic Kidney Disease
1278423|NCT00853242|Phosphate Binder
1278424|NCT00853242|Phosphate
1278425|NCT00853242|Hyperphosphatemia
1278426|NCT00853229|vulvodynia
1278427|NCT00853229|vulvar vestibulitis
1278428|NCT00853229|chronic vulvar pain
1278429|NCT00853229|generalized vulvodynia
1278430|NCT00853229|localized vulvodynia
1278431|NCT00853216|Healthy Subjects
1278432|NCT00853216|Bioequivalence
1278433|NCT00853203|Colorectal Cancer
1278434|NCT00853203|Rectal Cancer
1278435|NCT00853203|Psychosocial
1278436|NCT00853203|Expressive Disclosure
1278437|NCT00853203|Questionnaires
1278438|NCT00853203|Quality of life
1278439|NCT00853203|QOL
1278440|NCT00853203|Electronically Activated Recorder
1278441|NCT00853203|EAR
1278442|NCT00853190|Healthy Subjects
1278443|NCT00853177|Oocyte retrieval
1278444|NCT00853177|pain
1278445|NCT00853177|surgery
1278446|NCT00853177|anaesthesiology
1278447|NCT00853177|Assisted Reproductive Technologies
1278448|NCT00853164|prostate cancer
1278449|NCT00853164|aerobic exercise
1278450|NCT00853164|resistance training
1278451|NCT00853138|cognitive-behavioral therapy
1278452|NCT00853138|chronic pain
1278453|NCT00853138|randomized controlled trial
1278454|NCT00853138|pediatrics
1278455|NCT00853125|clear cell renal cell carcinoma
1278456|NCT00853125|stage IV renal cell cancer
1278457|NCT00853112|PAH pulmonary hypertension pulmonary arterial hypertension
1278458|NCT00853099|Ulcerative Colitis
1278459|NCT00853073|failing blebs
1278460|NCT00853073|failing express shunt
1278461|NCT00853073|avastin
1278462|NCT00853073|bevacizumab
1278463|NCT00853073|glaucoma
1278464|NCT00853073|prior trabeculectomy
1278465|NCT00853073|Express shunt placed under a scleral flap
1278466|NCT00853073|subsequent filtration failure
1278467|NCT00853060|energy expenditure
1278468|NCT00853060|mechanical ventilation
1278469|NCT00853060|weaning
1278470|NCT00853060|pressure support ventilation
1278471|NCT00853060|T-tube
1278472|NCT00853034|gastrointestinal effects
1278473|NCT00853034|prebiotic
1278474|NCT00853021|clear cell renal cell carcinoma
1278475|NCT00853021|recurrent renal cell cancer
1278476|NCT00853021|stage IV renal cell cancer
1278477|NCT00853008|Acute Lymphoblastic Leukemia
1278478|NCT00853008|High-Risk (HR)
1278479|NCT00853008|Philadelphia Chromosome-Negative
1278480|NCT00852995|Venous Leg Ulcer (VLU)
1278481|NCT00852995|Venous Stasis Ulcer (VSU)
1278482|NCT00852995|VLU
1278483|NCT00852995|VSU
1278484|NCT00852995|Leg Ulcer
1278485|NCT00852995|Leg Wound
1278486|NCT00852982|Exercise
1278487|NCT00852982|Risk factors
1278488|NCT00852982|Primary health care
1278489|NCT00852969|Chronic Kidney Disease
1278490|NCT00852969|Niacin
1278491|NCT00852969|HDL
1278492|NCT00852969|Endothelial Function
1278493|NCT00852956|Betahistine
1278494|NCT00852956|Olanzapine
1278495|NCT00852956|Safety of co-administration of Betahistien and Olanzapine
1278496|NCT00852943|Mast Cells
1278497|NCT00852943|Piebaldism
1278498|NCT00852943|Anaphylaxis
1278499|NCT00852943|Allergy
1278500|NCT00852943|Genetics
1278501|NCT00852930|lymphedema
1278502|NCT00852930|quality of life
1278503|NCT00852930|breast cancer
1278504|NCT00852930|symptoms
1278505|NCT00852930|lymphedema in breast cancer survivors
1278506|NCT00852917|Pain due to Osteoarthritis of the Knee
1278507|NCT00852904|Childhood Growth and Development
1278508|NCT00852904|Genetics
1278509|NCT00852904|Children
1278510|NCT00852904|Environment
1278511|NCT00852904|Longitudinal Study
1278512|NCT00852904|National Children's Study
1278513|NCT00852891|weaning
1278514|NCT00852891|echocardiogram
1278515|NCT00852891|diastolic dysfunction
1278516|NCT00852891|Mechanical ventilation
1278517|NCT00852878|Recurrent Abdominal Pain
1278518|NCT00852878|Biofeedback
1278519|NCT00852878|Heart Rate Variability
1278520|NCT00852865|Inflammation
1278521|NCT00852865|Pain
1278522|NCT00852852|ESRA-C 2
1278523|NCT00852852|computerized assessment
1278524|NCT00852839|Dry mouth
1278525|NCT00852839|Sjogren's syndrome
1278526|NCT00852839|Xerostomia
1278527|NCT00852826|axillary seroma
1278528|NCT00852826|axillary lymphadenectomy
1278529|NCT00852826|morbidity
1278530|NCT00852826|morbidity postlymphadenectomy
1278531|NCT00852826|Lymphadenectomy
1278532|NCT00852813|tolerance
1278533|NCT00852813|prebiotic
1278534|NCT00852813|gastrointestinal effects
1278535|NCT00852800|spontaneous bacterial peritonitis
1278536|NCT00852800|albumin
1278537|NCT00852800|renal impairment
1278538|NCT00852800|mortality
1278539|NCT00852787|Digoxin like substances
1278540|NCT00852787|digibind
1278541|NCT00852787|digoxin immune fab
1278542|NCT00852787|end-stage-renal-disease
1278543|NCT00852787|marinobufagenin
1278544|NCT00852761|Psoriasis
1278545|NCT00852748|headache
1278546|NCT00852735|Cardiovascular diseases
1278547|NCT00852735|Rapeseed oil
1278548|NCT00852735|Micronutriments
1278549|NCT00852735|HDL cholesterol
1278550|NCT00852735|Oxidative stress
1278551|NCT00852735|Tocopherols
1278552|NCT00852735|Sterols
1278553|NCT00852735|Prevention of cardiovascular diseases
1278554|NCT00852722|Multiple sclerosis
1278555|NCT00852722|Diet
1278556|NCT00852709|Myelodysplastic syndrome that has transformed to AML (AML/MDS)
1278557|NCT00852709|Treatment-related AML
1278558|NCT00852709|AML evolving from myeloproliferative disorders (MPD)
1278559|NCT00852709|Acute lymphocytic leukemia (ALL)
1278560|NCT00852709|Acute promyelocytic leukemia (APL) refractory to arsenic therapy or retinoic acid therapy
1278561|NCT00852709|Relapsed and/or refractory acute leukemia with progressive disease since last therapy
1278562|NCT00852709|Chronic myelogenous leukemia (CML) in accelerated phase or blast crisis refractory to imatinib
1278563|NCT00852709|High-risk MPD including myelofibrosis, chronic myelomonocytic leukemia (CMML, and relapsed or refractory juvenile myelomonocytic leukemia (JMML).
1278564|NCT00852696|Overactive Bladder
1278565|NCT00852696|Incontinence
1278566|NCT00852696|Solifenacin
1278567|NCT00852696|Women
1278568|NCT00852696|Postoperative
1278569|NCT00852657|Rotator cuff tear
1278570|NCT00852657|surgical repair
1278571|NCT00852657|Physiotherapy
1278572|NCT00852657|Treatment benefit
1278573|NCT00852657|Surgery
1278574|NCT00852644|stage I non-small cell lung cancer
1278575|NCT00852644|stage II non-small cell lung cancer
1278576|NCT00852631|Quetiapine efficacy in schizophrenia
1278577|NCT00852618|HIV Integrase Inhibitors
1278578|NCT00852618|HIV Nucleoside Reverse Transcriptase Inhibitors
1278579|NCT00852618|Treatment Naive
1278580|NCT00852618|Viral Load
1278581|NCT00852605|Acute Lung Injury after allogeneic transplantation
1278582|NCT00852592|Bipolar Disorder Depression Midday Light Therapy
1278583|NCT00852592|Bipolar Disorder Type I or II
1278584|NCT00852579|Asthma
1278585|NCT00852579|Smoker
1278586|NCT00852579|Macrolide
1278587|NCT00852566|Chronic myeloid leukemia
1278588|NCT00852566|tyrosine kinase inhibitor
1278589|NCT00852566|stem cell
1278590|NCT00852566|Philadelphia chromosome
1278591|NCT00852566|dasatinib
1278592|NCT00852553|intestinal
1278593|NCT00852553|smooth
1278594|NCT00852553|muscle
1278595|NCT00852553|GI
1278596|NCT00852553|motility
1278597|NCT00852540|impetigo
1278598|NCT00852540|methicillin-resistant Staphylococcus aureus
1278599|NCT00852540|linezolid
1278600|NCT00852540|secondarily-infected traumatic lesion
1278601|NCT00852540|uncomplicated skin infection
1278602|NCT00852540|retapamulin
1278603|NCT00852527|Traumatic Brain Injury
1278604|NCT00852527|Screening
1278605|NCT00852527|Diagnosis
1278606|NCT00852527|Rehabilitation Outcome
1278607|NCT00852514|Bioimpedance
1278608|NCT00852514|ultrafiltration
1278609|NCT00852514|blood pressure
1278610|NCT00852514|pulse pressure
1278611|NCT00852501|Non-functioning pituitary adenoma
1278612|NCT00852501|RTPCR
1278613|NCT00852501|Hormonal receptors
1278614|NCT00852475|MUFA
1278615|NCT00852475|PUFA
1278616|NCT00852475|MOVE! program
1278617|NCT00852462|SAMI
1278618|NCT00852462|Symptom Assessment and Management Intervention Program
1278619|NCT00852449|Intraoperative fluid
1278620|NCT00852449|Monitoring
1278621|NCT00852449|Oesophageal Doppler
1278622|NCT00852449|Abdominal surgery
1278623|NCT00852449|major abdominal surgery
1278624|NCT00852436|neuropathic pain
1278625|NCT00852436|orofacial pain
1278626|NCT00852436|clinical trials
1278627|NCT00852436|pregabalin
1278628|NCT00852436|randomized controlled trial
1278629|NCT00852423|Malaria in pregnancy
1278630|NCT00852423|Sub-saharan Africa
1278631|NCT00852423|Treatment
1278632|NCT00852423|Artemisinin containing Therapy
1278633|NCT00852423|Efficacy
1278634|NCT00852423|Safety
1278635|NCT00852410|Endoscopic sinus surgery
1278636|NCT00852384|Anesthesia induction
1278637|NCT00852384|Obese patients
1278638|NCT00852384|Noninvasive ventilation
1278639|NCT00852384|Alveolar recruitment
1278640|NCT00852371|Malaria
1278641|NCT00852371|Intermittent preventive treatment
1278642|NCT00852371|Efficacy
1278643|NCT00852371|Safety
1278644|NCT00852371|Tolerability
1278645|NCT00852371|Schoolchildren
1278646|NCT00852371|Uganda
1278647|NCT00852358|mucopolysaccharidosis
1278648|NCT00852358|Hurler-Scheie
1278649|NCT00852358|Scheie
1278650|NCT00852358|laronidase
1278651|NCT00852358|cognitive decline
1278652|NCT00852358|central nervous system
1278653|NCT00852358|enzyme replacement therapy
1278654|NCT00852358|intrathecal
1278655|NCT00852358|LA Biomed
1278656|NCT00852345|multibacillary leprosy
1278657|NCT00852345|leprosy
1278658|NCT00852345|clofazamine
1278659|NCT00852332|male breast cancer
1278660|NCT00852332|stage IIIB breast cancer
1278661|NCT00852332|stage IIIC breast cancer
1278662|NCT00852332|stage IV breast cancer
1278663|NCT00852332|recurrent breast cancer
1278664|NCT00852332|stage IIIA breast cancer
1278665|NCT00852332|HER2-negative breast cancer
1278666|NCT00852319|Interpregnancy Care
1278667|NCT00852319|Preconceptual Care
1278668|NCT00852319|Premature Birth
1278669|NCT00852319|Preterm Delivery
1278670|NCT00852306|oocyte freezing
1278671|NCT00852306|vitrification
1278672|NCT00852306|slow freeze
1278673|NCT00852306|fertility preservation
1278674|NCT00852293|liver disease
1278675|NCT00852293|Chitinase 3 like-1 protein
1278676|NCT00852280|scars
1278677|NCT00852280|late effect of burn
1278678|NCT00852280|burn
1278679|NCT00852280|pulsed-dye laser
1278680|NCT00852267|cholesterol
1278681|NCT00852267|diet
1278682|NCT00852267|protein
1278683|NCT00852267|carbohydrate
1278684|NCT00852267|saturated fat
1278685|NCT00852267|LDL subclass
1278686|NCT00852267|healthy volunteers
1278687|NCT00852254|Cardiac Index
1278688|NCT00852254|Ultrasound Dilution
1278689|NCT00852254|Accuracy of ultrasound dilution cardiac index.
1278690|NCT00852228|colorectal cancer
1278691|NCT00852228|unresectable metastases
1278692|NCT00852228|neo-adjuvant chemotherapy
1278693|NCT00852228|liver metastases
1278694|NCT00852228|chronotherapy
1278695|NCT00852228|cetuximab
1278696|NCT00852228|irinotecan
1278697|NCT00852228|oxaliplatin
1278698|NCT00852228|5-fluorouracil
1278699|NCT00852228|hepatic artery infusion
1278700|NCT00852228|Unresectable hepatic lesions
1278701|NCT00852228|1 to 3 prior chemotherapy regimens
1278702|NCT00852215|Angioplasty, Transluminal, Percutaneous Coronary
1278703|NCT00852215|Paclitaxel-eluting stent
1278704|NCT00852215|Vision stent
1278705|NCT00852202|bipolar
1278706|NCT00852202|depression
1278707|NCT00852189|Cancer
1278708|NCT00852189|Phase 1
1278709|NCT00852189|EC0489
1278710|NCT00852189|EC20
1278711|NCT00852189|Refractory
1278712|NCT00852189|Metastatic
1278713|NCT00852189|Experimental
1278714|NCT00852176|Coronary brachytherapy
1278715|NCT00852176|Coronary restenosis
1278716|NCT00852176|Coronary in stent restenosis
1278717|NCT00852163|conditioning, preparative
1278718|NCT00852163|clofarabine; transplant
1278719|NCT00852163|Busulfan
1278720|NCT00852163|leukemia
1278721|NCT00852163|myelodysplastic syndrome
1278722|NCT00852150|gastritis
1278723|NCT00852150|duodenitis
1278724|NCT00852150|inter-rater reliability
1278725|NCT00852150|intra-rater reliablity
1278726|NCT00852150|gastroscopy
1278727|NCT00852150|duodenoscopy
1278728|NCT00852137|Peplin
1278729|NCT00852137|PEP005
1278730|NCT00852137|Actinic Keratosis
1278731|NCT00852124|Asthma
1278732|NCT00852124|Probiotic
1278733|NCT00852124|VSL#3
1278734|NCT00852111|Fatigue
1278735|NCT00852111|Radiotherapy
1278736|NCT00852111|Cancer Therapy
1278737|NCT00852111|Cancer
1278738|NCT00852098|Fundoplication
1278739|NCT00852098|gastroesophageal reflux
1278740|NCT00852098|gastric vessels
1278741|NCT00852098|surgery
1278742|NCT00852085|Counseling
1278743|NCT00852085|Crime
1278744|NCT00852085|Adolescent
1278745|NCT00852072|common bile duct stones
1278746|NCT00852072|mechanical lithotripsy
1278747|NCT00852072|balloon sphincteroplasty
1278748|NCT00852059|ADHD
1278749|NCT00852059|children
1278750|NCT00852059|adolescents
1278751|NCT00852059|methylphenidate
1278752|NCT00852059|adherence
1278753|NCT00852059|immediate release
1278754|NCT00852059|extended release
1278755|NCT00852059|efficacy
1278756|NCT00852046|Mechanical ventilation
1278757|NCT00852033|alcoholism
1278758|NCT00852033|alcohol abuse
1278759|NCT00852033|prevention
1278760|NCT00852033|behavior modification
1278761|NCT00852033|parent offspring interaction
1278762|NCT00852033|university student
1278763|NCT00852033|substance abuse related behavior
1278764|NCT00852033|adolescence
1278765|NCT00852007|prostate cancer
1278766|NCT00852007|dendritic cells
1278767|NCT00852007|MUC-1
1278768|NCT00852007|immune therapy
1278769|NCT00851994|Patients having surgery
1278770|NCT00851981|Alcohol Liver Disease
1278771|NCT00851968|hepatectomy
1278772|NCT00851968|Selective HepaticVascular Clamping
1278773|NCT00851942|Volunteer
1278774|NCT00851942|Hypoadrenalism
1278775|NCT00851942|Hypopituitarism
1278776|NCT00851942|Healthy volunteers
1278777|NCT00851929|sarcoidosis
1278778|NCT00851929|pulmonary hypertension
1278779|NCT00851929|dyspnea
1278780|NCT00851929|sarcoidosis associated pulmonary hypertension
1278781|NCT00851877|stage III squamous cell carcinoma of the oropharynx
1278782|NCT00851877|stage IV squamous cell carcinoma of the oropharynx
1278783|NCT00851877|stage III squamous cell carcinoma of the hypopharynx
1278784|NCT00851877|stage IV squamous cell carcinoma of the hypopharynx
1278785|NCT00851877|stage II squamous cell carcinoma of the larynx
1278786|NCT00851877|stage IV squamous cell carcinoma of the larynx
1278787|NCT00851877|tongue cancer
1278788|NCT00851864|anticoagulation
1278789|NCT00851864|pregnancy
1278790|NCT00851851|Surgical patients
1278791|NCT00851838|Peritoneal dialysis
1278792|NCT00851838|L-carnitine
1278793|NCT00851825|autonomic modulation
1278794|NCT00851825|heart rate
1278795|NCT00851825|pressure support ventilation
1278796|NCT00851825|T-tube
1278797|NCT00851825|Mechanical ventilation
1278798|NCT00851812|Exercise
1278799|NCT00851812|Breast cancer
1278800|NCT00851812|fatigue
1278801|NCT00851799|ART
1278802|NCT00851799|Antiretroviral therapy
1278803|NCT00851799|Treatment naive
1278804|NCT00851799|Highly active antiretroviral therapy (HAART)
1278805|NCT00851786|Herpes Zoster Vaccine
1278806|NCT00851786|Herpes Zoster Virus
1278807|NCT00851786|HIV
1278808|NCT00851721|Hemophilia A
1278809|NCT00851721|Factor VIII Inhibitor
1278810|NCT00851721|Factor IX Inhibitor
1278811|NCT00851721|Hemophilia B
1278812|NCT00851708|kidney
1278813|NCT00851708|deceased kidney transplant
1278814|NCT00851708|oxidative stress
1278815|NCT00851708|renal function measurements
1278816|NCT00851695|Lung Function Decline
1278817|NCT00851695|Lung Function
1278818|NCT00851695|Allergy
1278819|NCT00851695|COPD
1278820|NCT00851695|Vitamin D
1278821|NCT00851682|Prostate Cancer
1278822|NCT00851682|Dynamic Contrast Enhanced MRI
1278823|NCT00851682|Non-invasive Prostate Cancer Detection
1278824|NCT00851669|depression
1278825|NCT00851669|alcohol dependence
1278826|NCT00851669|women
1278827|NCT00851669|psychotherapy
1278828|NCT00851669|men
1278829|NCT00851630|HIV
1278830|NCT00851630|Tuberculosis
1278831|NCT00851630|Treatment Naive
1278832|NCT00851617|Mechanical ventilator weaning
1278833|NCT00851617|Respiratory Muscle Training
1278834|NCT00851617|Ventilator dependent
1278835|NCT00851604|ProGRP
1278836|NCT00851604|CgA
1278837|NCT00851604|NSE
1278838|NCT00851604|TUM2-PK
1278839|NCT00851604|Neuroendocrine Tumors
1278840|NCT00851591|fenugreek
1278841|NCT00851591|galactogogue
1278842|NCT00851591|breastmilk
1278843|NCT00851591|Trigonella foenum-graecum
1278844|NCT00851591|Bird's Foot
1278845|NCT00851591|Greek Clover
1278846|NCT00851591|Greek Hay
1278847|NCT00851591|Hu Lu Ba
1278848|NCT00851591|Trigonella
1278849|NCT00851578|AF
1278850|NCT00851578|atrial fibrillation
1278851|NCT00851578|LAA occlusion
1278852|NCT00851552|recurrent adult diffuse large cell lymphoma
1278853|NCT00851552|recurrent adult immunoblastic large cell lymphoma
1278854|NCT00851552|anaplastic large cell lymphoma
1278855|NCT00851539|HIV
1278856|NCT00851539|Teenagers
1278857|NCT00851539|Adolescent
1278858|NCT00851539|HIV Testing
1278859|NCT00851539|HIV Seronegativity
1278860|NCT00851526|Coronary bifurcation lesion
1278861|NCT00851526|Drug-eluting stent
1278862|NCT00851513|Pudendal neuralgia
1278863|NCT00851513|pudendal nerve
1278864|NCT00851513|Alcock's canal syndrome
1278865|NCT00851513|Canal syndrome
1278866|NCT00851513|neuropathic pain
1278867|NCT00851513|infiltration
1278868|NCT00851513|randomized protocol
1278869|NCT00851513|pain scales
1278870|NCT00851500|atherosclerosis
1278871|NCT00851500|carotid artery disease
1278872|NCT00851487|ARI
1278873|NCT00851487|LRTI
1278874|NCT00851474|COstatus(R)
1278875|NCT00851474|Ultrasound Dilution
1278876|NCT00851474|Cardiac Output
1278877|NCT00851474|Blood Volumes
1278878|NCT00851474|Comparison of COstatus(R) cardiac output with other methods
1278879|NCT00851461|Spinobulbar muscular atrophy
1278880|NCT00851461|Kennedy's disease
1278881|NCT00851461|Goserelin
1278882|NCT00851461|Electrophysiologic study
1278883|NCT00851461|Inclusion body
1278884|NCT00851435|Pneumonia
1278885|NCT00851435|Nosocomial pneumonia
1278886|NCT00851435|Pseudomonas aeruginosa
1278887|NCT00851435|Monoclonal antibody
1278888|NCT00851435|Hospital-Acquired Pneumonia
1278889|NCT00851422|Ultrasound Dilution
1278890|NCT00851422|Cardiac Output
1278891|NCT00851422|Validation of measured ultrasound dilution cardiac output
1278892|NCT00851396|Vitamin D deficiency
1278893|NCT00851396|Insulin resistance
1278894|NCT00851396|Glucose- Insulin dynamics
1278895|NCT00851396|Obese adolescents
1278896|NCT00851383|HIV
1278897|NCT00851383|Human Immunodeficiency Virus
1278898|NCT00851383|HIV Seronegativity
1278899|NCT00851383|Preventive Vaccine
1278900|NCT00851370|COPD
1278901|NCT00851370|Exacerbation
1278902|NCT00851357|Nicotine Replacement Therapy
1278903|NCT00851357|Nicotine Patch
1278904|NCT00851357|Smoking cessation
1278905|NCT00851357|Telephone
1278906|NCT00851357|Tobacco cessation
1278907|NCT00851357|Counseling
1278908|NCT00851357|Nicotine
1278909|NCT00851357|Self-Help
1278910|NCT00851357|Smoking abstinence
1278911|NCT00851357|Tobacco Use Disorder
1278912|NCT00851344|Proof-of-Concept
1278913|NCT00851344|Allergic Rhinitis
1278914|NCT00851331|Benign childhood epilepsy
1278915|NCT00851318|Rheumatoid Arthritis
1278916|NCT00851318|Certolizumab Pegol
1278917|NCT00851318|Cimzia
1278918|NCT00851305|Stomach
1278919|NCT00851305|endoscopy
1278920|NCT00851305|neoplasms
1278921|NCT00851292|prostate cancer
1278922|NCT00851292|biopsy
1278923|NCT00851292|TRUS
1278924|NCT00851292|diagnosis
1278925|NCT00851279|arrhythmia
1278926|NCT00851279|ventricular tachycardia
1278927|NCT00851279|ablation
1278928|NCT00851279|mapping
1278929|NCT00851279|electrophysiology
1278930|NCT00851253|recurrent adenoid cystic carcinoma of the oral cavity
1278931|NCT00851253|recurrent mucoepidermoid carcinoma of the oral cavity
1278932|NCT00851253|recurrent verrucous carcinoma of the oral cavity
1278933|NCT00851253|stage II adenoid cystic carcinoma of the oral cavity
1278934|NCT00851253|stage II mucoepidermoid carcinoma of the oral cavity
1278935|NCT00851253|stage II verrucous carcinoma of the oral cavity
1278936|NCT00851253|stage III adenoid cystic carcinoma of the oral cavity
1278937|NCT00851253|stage III mucoepidermoid carcinoma of the oral cavity
1278938|NCT00851253|stage III verrucous carcinoma of the oral cavity
1278939|NCT00851253|stage II squamous cell carcinoma of the lip and oral cavity
1278940|NCT00851253|stage III squamous cell carcinoma of the lip and oral cavity
1278941|NCT00851253|recurrent basal cell carcinoma of the lip
1278942|NCT00851253|recurrent squamous cell carcinoma of the lip and oral cavity
1278943|NCT00851253|stage II basal cell carcinoma of the lip
1278944|NCT00851253|stage III basal cell carcinoma of the lip
1278945|NCT00851253|recurrent lymphoepithelioma of the nasopharynx
1278946|NCT00851253|recurrent squamous cell carcinoma of the nasopharynx
1278947|NCT00851253|stage II lymphoepithelioma of the nasopharynx
1278948|NCT00851253|stage II squamous cell carcinoma of the nasopharynx
1278949|NCT00851253|stage III lymphoepithelioma of the nasopharynx
1278950|NCT00851253|stage III squamous cell carcinoma of the nasopharynx
1278951|NCT00851253|recurrent lymphoepithelioma of the oropharynx
1278952|NCT00851253|recurrent squamous cell carcinoma of the oropharynx
1278953|NCT00851253|stage II lymphoepithelioma of the oropharynx
1278954|NCT00851253|stage II squamous cell carcinoma of the oropharynx
1278955|NCT00851253|stage III lymphoepithelioma of the oropharynx
1278956|NCT00851253|stage III squamous cell carcinoma of the oropharynx
1279077|NCT00850941|Radiation Therapy
1278957|NCT00851253|high-grade salivary gland mucoepidermoid carcinoma
1278958|NCT00851253|low-grade salivary gland mucoepidermoid carcinoma
1278959|NCT00851253|recurrent salivary gland cancer
1278960|NCT00851253|salivary gland acinic cell tumor
1278961|NCT00851253|salivary gland adenocarcinoma
1278962|NCT00851253|salivary gland adenoid cystic carcinoma
1278963|NCT00851253|salivary gland anaplastic carcinoma
1278964|NCT00851253|salivary gland malignant mixed cell type tumor
1278965|NCT00851253|salivary gland poorly differentiated carcinoma
1278966|NCT00851253|salivary gland squamous cell carcinoma
1278967|NCT00851253|stage II salivary gland cancer
1278968|NCT00851253|stage III salivary gland cancer
1278969|NCT00851253|stage IV adenoid cystic carcinoma of the oral cavity
1278970|NCT00851253|stage IV mucoepidermoid carcinoma of the oral cavity
1278971|NCT00851253|stage IV squamous cell carcinoma of the lip and oral cavity
1279099|NCT00850915|tuberculosis incidence
1278972|NCT00851253|stage IV verrucous carcinoma of the oral cavity
1278973|NCT00851253|stage IV salivary gland cancer
1278974|NCT00851253|stage IV lymphoepithelioma of the nasopharynx
1278975|NCT00851253|stage IV lymphoepithelioma of the oropharynx
1278976|NCT00851253|stage IV squamous cell carcinoma of the nasopharynx
1278977|NCT00851253|stage IV squamous cell carcinoma of the oropharynx
1278978|NCT00851253|stage IV basal cell carcinoma of the lip
1278979|NCT00851240|rheumatoid arthritis
1278980|NCT00851240|safety
1278981|NCT00851227|Pharmacokinetics
1278982|NCT00851227|Protein Binding
1278983|NCT00851227|Conivaptan
1278984|NCT00851227|Vaprisol
1278985|NCT00851227|Liver Disease
1278986|NCT00851214|Non-invasive hemodynamic monitoring
1278987|NCT00851214|Emergency Department patients
1278988|NCT00851214|trauma with an ISS>15
1278989|NCT00851214|Non-invasive continuous hemodynamic monitoring
1278990|NCT00851201|children
1278991|NCT00851201|obesity
1278992|NCT00851201|weight loss
1278993|NCT00851201|prevention
1278994|NCT00851201|diabetes risk
1278995|NCT00851201|cardiometabolic
1278996|NCT00851162|Bone defect
1278997|NCT00851162|Benign bone lesions
1278998|NCT00851162|Stem cells
1278999|NCT00851149|aorta
1279000|NCT00851149|disease
1279001|NCT00851149|abdominal
1279002|NCT00851149|surgery
1279003|NCT00851149|Osteoarthritis, Hip
1279004|NCT00851149|replacement
1279005|NCT00851149|blood
1279006|NCT00851149|autolog
1279007|NCT00851149|transfusion
1279008|NCT00851149|cytokines
1279009|NCT00851136|CRC
1279010|NCT00851136|Colon cancer
1279011|NCT00851136|Avastin
1279012|NCT00851136|APM4566g
1279013|NCT00851123|Stroke
1279014|NCT00851123|arm paresis
1279015|NCT00851123|mCIMT
1279016|NCT00851123|bimanual training
1279017|NCT00851123|rehabilitation
1279018|NCT00851110|high dose
1279019|NCT00851110|breast cancer
1279020|NCT00851110|adjuvant
1279021|NCT00851084|Angiogenesis
1279022|NCT00851084|Colon cancer
1279023|NCT00851084|Rectal cancer
1279024|NCT00851084|Oxaliplatin
1279025|NCT00851071|Anxiety
1279026|NCT00851071|Implantable Cardioverter Defibrillator (ICD)
1279027|NCT00851071|Defibrillators, Implantable
1279028|NCT00851058|Behavioral research
1279029|NCT00851058|Motivational counseling
1279030|NCT00851058|Group Counseling
1279031|NCT00851058|Motivational Interviewing
1279032|NCT00851058|Vicarious Learning
1279033|NCT00851058|Risky alcohol use
1279034|NCT00851058|Recidivism
1279035|NCT00851058|Motor Vehicles
1279036|NCT00851058|Crime
1279037|NCT00851032|Advanced Cancer
1279038|NCT00851032|Initiative for Molecular Profiling in Advanced Cancer Therapy
1279039|NCT00851032|IMPACT
1279040|NCT00851032|Molecular Profile-Based Study
1279041|NCT00851032|Investigational Cancer Therapeutics Program
1279042|NCT00851032|Molecular profiling
1279043|NCT00851032|Phase I Therapies
1279044|NCT00851032|Tissue Bank
1279045|NCT00851019|Exercise
1279046|NCT00851019|Video game
1279047|NCT00851019|Type 2 diabetes
1279048|NCT00851019|Dance
1279049|NCT00851006|Depression
1279050|NCT00851006|Females
1279051|NCT00851006|Adolescents
1279052|NCT00850993|Hemolysis
1279053|NCT00850954|Lung Cancer
1279054|NCT00850954|Cancer
1279055|NCT00850954|Smoke
1279056|NCT00850954|Mexican American
1279057|NCT00850954|Indoor Air Policy
1279058|NCT00850954|Secondhand smoke
1279059|NCT00850954|SHS
1279060|NCT00850954|Smoking cessation programs
1279061|NCT00850954|Smokers
1279062|NCT00850954|Tobacco
1279063|NCT00850954|Nicotine
1279064|NCT00850954|Chronic diseases
1279065|NCT00850954|Transtheoretical model of change
1279066|NCT00850954|TTM
1279067|NCT00850941|Registry
1279068|NCT00850941|Research Database
1279069|NCT00850941|Prostate cancer
1279070|NCT00850941|Casodex
1279071|NCT00850941|Flutamide
1279072|NCT00850941|Goserelin Acetate
1279073|NCT00850941|Leuprolide Acetate
1279074|NCT00850941|Radiation
1279075|NCT00850941|PSA
1279076|NCT00850941|Post-prostatectomy
1279078|NCT00850941|Prostate Specific Antigen
1279079|NCT00850941|Adenocarcinoma
1279080|NCT00850941|Radical Prostatectomy
1279081|NCT00850941|Bicalutamide
1279082|NCT00850941|Zoladex
1279083|NCT00850941|Lupron Depot
1279084|NCT00850941|Tissue banking
1279085|NCT00850941|Hormones
1279086|NCT00850928|Postoperative Cognitive Dysfunction
1279087|NCT00850928|MCI
1279088|NCT00850928|Mild Cognitive Impairment
1279089|NCT00850928|Aβ40
1279090|NCT00850928|Aβ42
1279091|NCT00850928|Apolipoprotein E
1279092|NCT00850928|Inflammatory Markers
1279093|NCT00850928|Apolipoprotein E Profile
1279094|NCT00850928|Serum Beta Amyloid Profile
1279095|NCT00850928|Inflammatory Markers Profile
1279096|NCT00850915|tuberculosis
1279097|NCT00850915|community IPT
1279098|NCT00850915|isoniazid adverse events
1279100|NCT00850902|ELBW
1279101|NCT00850902|Humidity
1279102|NCT00850902|BPD
1279103|NCT00850889|Aesthetic correction of nasolabial folds
1279104|NCT00850863|COPD
1279105|NCT00850863|Inflammation
1279106|NCT00850863|Smoking
1279107|NCT00850863|Susceptibility
1279108|NCT00850850|PACU
1279109|NCT00850850|Physostigmine
1279110|NCT00850850|Recovery
1279111|NCT00850850|Postanesthesia Nursing
1279112|NCT00850850|Wakefulness
1279113|NCT00850850|General anesthesia
1279114|NCT00850850|General Anesthetics
1279115|NCT00850850|Postoperative Period
1279116|NCT00850837|Microbicide
1279117|NCT00850837|HIV Seronegativity
1279118|NCT00850824|T2DM
1279119|NCT00850811|Peplin
1279120|NCT00850811|PEP005
1279121|NCT00850798|Type 2 diabetes
1279122|NCT00850798|Elder patients
1279123|NCT00850798|Glycemic control
1279124|NCT00850798|Men or women aged ≥80 years at time of randomization. There is no upper age limit.
1279125|NCT00850798|Be able to walk by themselves
1279126|NCT00850798|They had their first diagnosis of type 2 diabetes mellitus at age 30 years or older.
1279127|NCT00850772|Enteral nutrition
1279128|NCT00850772|Ovarian cancer
1279129|NCT00850772|Peritoneal cancer
1279130|NCT00850772|Fallopian tube cancer
1279131|NCT00850772|Malnutrition
1279132|NCT00850772|Surgery
1279133|NCT00850772|Gynecological Cancer
1279134|NCT00850772|Suspected advanced epithelial ovarian cancer
1279135|NCT00850759|pedestrian safety
1279136|NCT00850759|street-crossing ability
1279137|NCT00850759|road-crossing
1279138|NCT00850759|children
1279139|NCT00850759|injury prevention
1279140|NCT00850746|QT interval
1279141|NCT00850746|Cardiac Repolarization
1279142|NCT00850746|Cardiac Conduction
1279143|NCT00850746|Healthy Subjects
1279144|NCT00850746|YM443 (Z-338, acotiamide hydrochloride)
1279145|NCT00850746|Evaluation of QT Interval
1279146|NCT00850720|Biological Response Modifiers
1279147|NCT00850720|Bypass Surgery
1279148|NCT00850720|Cardiology
1279149|NCT00850720|Congenital Heart Disease
1279150|NCT00850720|Endocrinology
1279151|NCT00850720|Hormone Dysfunction
1279152|NCT00850720|Hormones
1279153|NCT00850720|Neuroendocrinology
1279154|NCT00850720|Pediatric Surgery
1279155|NCT00850707|AVF
1279156|NCT00850707|AVG
1279157|NCT00850707|TCC
1279158|NCT00850707|inflammation
1279159|NCT00850707|monocite senescence
1279160|NCT00850694|Vitamin D deficiency
1279161|NCT00850694|Obesity
1279162|NCT00850694|Insulin resistance
1279163|NCT00850694|Glucose tolerance
1279164|NCT00850681|Peplin
1279165|NCT00850681|PEP005
1279166|NCT00850668|Food Allergy
1279167|NCT00850668|Peanut Allergy
1279168|NCT00850642|Sputum cell counts
1279169|NCT00850642|Neutrophils
1279170|NCT00850642|Severe Asthma
1279171|NCT00850642|ICS
1279172|NCT00850642|Inhaled corticosteroids
1279173|NCT00850629|weight regain
1279174|NCT00850629|endocrine counterregulation
1279175|NCT00850616|HIV
1279176|NCT00850616|HIV Seronegativity
1279177|NCT00850616|Preventive Vaccine
1279178|NCT00850603|Menomune® - A/C/Y/W-135
1279179|NCT00850603|Meningococcal Infections
1279180|NCT00850603|Meningitis
1279181|NCT00850564|growth hormone releasing hormone
1279182|NCT00850551|Early Intervention
1279183|NCT00850551|Pulmonary Exacerbation
1279184|NCT00850551|Cystic Fibrosis
1279185|NCT00850551|Lung Function
1279186|NCT00850551|Spirometry
1279187|NCT00850551|Phillips Telemonitor
1279188|NCT00850551|Home Spirometry
1279189|NCT00850551|PiKo-6
1279190|NCT00850551|Home Monitoring
1279191|NCT00850538|Bone Marrow Lesion
1279192|NCT00850538|BML
1279193|NCT00850538|Arthroplasty
1279194|NCT00850538|Replacement
1279195|NCT00850538|Knee
1279196|NCT00850538|Discarded tissue
1279197|NCT00850486|women
1279198|NCT00850486|ischemic heart disease
1279199|NCT00850486|high frequency ECG
1279200|NCT00850486|exercise stress testing
1279201|NCT00850486|signal processing
1279202|NCT00850486|ischemic heart disease in women
1279203|NCT00850473|PET
1279204|NCT00850473|CT
1279205|NCT00850473|Heart Attack
1279206|NCT00850473|Coronary Artery disease
1279207|NCT00850473|Cardiac Catheterization
1279208|NCT00850447|Posttraumatic stress disorder
1279209|NCT00850447|Cognition
1279210|NCT00850447|Neuropsychological Tests
1279211|NCT00850421|migraine headache
1279212|NCT00850421|Botulinum Toxin Type A
1279213|NCT00850421|BOTOX
1279214|NCT00850421|BTX-A
1279215|NCT00850408|Stroke
1279216|NCT00850408|rTMS
1279217|NCT00850408|TMS
1279218|NCT00850408|Rehabilitation
1279219|NCT00850408|Upper Extremity
1279220|NCT00850395|HIV-1
1279221|NCT00850395|non-interventional
1279222|NCT00850395|CCR-5 tropic virus
1279223|NCT00850395|therapy experienced patients
1279224|NCT00850382|CBF AML
1279225|NCT00850382|Dasatinib
1279226|NCT00850382|Core Binding Factor (CBF)
1279227|NCT00850369|Pulmonary hypertension
1279228|NCT00850369|Sickle cell disease
1279229|NCT00850356|Bariatric Surgery
1279230|NCT00850356|Body Weight
1279231|NCT00850356|Health care costs
1279232|NCT00850356|Obesity
1279233|NCT00850356|Obesity Complications
1279234|NCT00850356|Prolonged wait times
1279235|NCT00850356|Quality of Life
1279236|NCT00850343|Rheumatoid Arthritis
1279237|NCT00850343|Certolizumab Pegol
1279238|NCT00850343|Cimzia
1279239|NCT00850330|Drug interactions
1279240|NCT00850330|Drug interaction software
1279241|NCT00850330|Older patients
1279242|NCT00850330|Hospitalization
1279243|NCT00850304|AML
1279245|NCT00850278|Brain tumor
1279246|NCT00850278|[18F]FLT
1279247|NCT00850278|[11C]MET
1279248|NCT00850278|TEP-imaging
1279249|NCT00850278|tumor cell proliferation
1279250|NCT00850265|Asthma
1279251|NCT00850265|Formoterol
1279252|NCT00850265|Beclomethasone
1279253|NCT00850265|Extrafine formulation
1279254|NCT00850265|Spacer
1279255|NCT00850265|Moderate
1279256|NCT00850265|Severe
1279257|NCT00850265|Stable
1279258|NCT00850252|Lifeline
1279259|NCT00850252|Tissue engineered blood vessel
1279260|NCT00850252|A-V shunt
1279261|NCT00850239|diabetes
1279262|NCT00850239|DPP4 inhibitor
1279263|NCT00850239|dutogliptin
1279264|NCT00850226|test anxiety
1279265|NCT00850200|Hodgkin Lymphoma, Proton Radiation
1279266|NCT00850187|Knee cartilage diseases
1279267|NCT00850174|Bioequivalence
1279268|NCT00850174|Healthy Subjects
1279269|NCT00850161|Type 1 Diabetes
1279270|NCT00850161|Nasal Insulin
1279271|NCT00850161|Insulin Deficiency
1279272|NCT00850161|Insulin-Dependent
1279273|NCT00850148|Anwar
1279274|NCT00850148|Melles
1279275|NCT00850148|Keratoconus
1279276|NCT00850096|Phase 2 Study for novel insulin delivery of type 2 diabetes
1279277|NCT00850083|Fever
1279278|NCT00850083|Children
1279279|NCT00850070|autism
1279280|NCT00850044|FIH
1279281|NCT00850044|SAD
1279282|NCT00850031|Presbyopia
1279283|NCT00850031|Accommodation
1279284|NCT00850031|Near visual acuity
1279285|NCT00850031|LASIK
1279286|NCT00850018|Sickle Cell Disease
1279287|NCT00850018|Sickle Cell Anemia
1279288|NCT00850018|Hemoglobin SS
1279289|NCT00850018|Hemoglobin SB0
1279290|NCT00850005|neuropathic pain
1279291|NCT00850005|resistant
1279292|NCT00850005|neuroinflammation
1279293|NCT00850005|neuroinflammatory markers
1279294|NCT00850005|Neuropathic pain that has not responded to standard therapy
1279295|NCT00849992|Actinic cheilitis
1279296|NCT00849992|Imiquimod 5%
1279297|NCT00849992|Photodynamic therapy
1279298|NCT00849979|Colorectal
1279299|NCT00849979|Gastric
1279300|NCT00849979|Gastrointestinal
1279301|NCT00849979|GI
1279302|NCT00849979|Liver
1279303|NCT00849979|Pancreas
1279304|NCT00849979|Gastrointestinal Cancers
1279305|NCT00849979|Gastro-Intestinal Chemotherapy
1279306|NCT00849979|M.D. Anderson Symptom Inventory
1279307|NCT00849979|MDASI-GI
1279308|NCT00849979|Medical Oncology
1279309|NCT00849966|Celebrex
1279310|NCT00849966|celecoxib
1279311|NCT00849966|Cyclooxygenase Inhibitors
1279312|NCT00849966|Anti-Inflammatory Agents Non-Steroidal
1279313|NCT00849966|Adverse drug events
1279314|NCT00849966|quality of life
1279315|NCT00849966|Pain Postoperative
1279316|NCT00849966|Tonsillectomy
1279317|NCT00849966|Adenotonsillectomy
1279318|NCT00849966|Otologic Surgical Procedures
1279319|NCT00849940|Spectroscopy
1279320|NCT00849940|Near infrared
1279321|NCT00849940|Oximetry
1279322|NCT00849940|Hypoxemia
1279323|NCT00849940|Tissue oxygenation
1279324|NCT00849940|Pediatric
1279325|NCT00849927|shoulder instability
1279326|NCT00849927|labral lesions
1279327|NCT00849927|arthroscopic labral repair
1279328|NCT00849927|SLAP
1279329|NCT00849927|triple labrum
1279330|NCT00849927|circumferential labrum
1279331|NCT00849927|Pan-labral lesion
1279332|NCT00849888|Thymus Transplantation
1279333|NCT00849888|DiGeorge Anomaly
1279334|NCT00849888|Athymia
1279335|NCT00849888|Low T cell numbers
1279336|NCT00849888|Immunoreconstitution
1279337|NCT00849888|Immunodeficiency
1279338|NCT00849875|ASCI
1279339|NCT00849875|Dacarbazine
1279340|NCT00849875|Cancer immunotherapeutic
1279341|NCT00849875|MAGE-A3
1279342|NCT00849875|Malignant melanoma
1279343|NCT00849862|Bioequivalence
1279344|NCT00849862|Healthy Subjects
1279345|NCT00849849|postgestational diabetes
1279346|NCT00849849|diabetes mellitus
1279347|NCT00849849|OGTT
1279348|NCT00849849|insulin sensitivity
1279349|NCT00849849|insulin secretion
1279350|NCT00849823|African American
1279351|NCT00849823|Men
1279352|NCT00849823|Condoms
1279353|NCT00849823|Randomization
1279354|NCT00849823|Brief Intervention
1279355|NCT00849823|HIV
1279356|NCT00849823|HIV Seronegativity
1279357|NCT00849810|Hypertension
1279358|NCT00849810|Beta-blockers
1279359|NCT00849810|Ambulatory blood pressure
1279360|NCT00849810|Basal metabolic rate
1279361|NCT00849810|Quality of life
1279362|NCT00849797|Bioequivalence
1279363|NCT00849797|Healthy Subjects
1279364|NCT00849771|Displaced Scapula Fracture
1279365|NCT00849771|Scapula Fracture
1279366|NCT00849771|Extraarticular Scapula Fractures
1279367|NCT00849771|Clavicle
1279368|NCT00849758|breast cancer
1279369|NCT00849758|elderly
1279370|NCT00849758|biomarker
1279371|NCT00849745|severe autoimmune diseases
1279372|NCT00849745|allogeneic stem cell transplant
1279373|NCT00849732|HIV Seronegativity
1279374|NCT00849732|Preventive Vaccine
1279375|NCT00849719|visual analog scale
1279376|NCT00849719|patient controlled analgesia
1279377|NCT00849719|post operative pain
1279378|NCT00849719|rescue drug
1279379|NCT00849706|sleep deprivation
1279380|NCT00849706|workload
1279381|NCT00849706|increased workload
1279382|NCT00849680|HIV Seronegativity
1279383|NCT00849680|Preventive Vaccine
1279384|NCT00849667|ovarian cancer
1279385|NCT00849667|relapsed ovarian cancer
1279386|NCT00849667|Platinum-sensitive Ovarian Cancer
1279387|NCT00849654|PCI-32765
1279388|NCT00849654|Lymphoma
1279389|NCT00849654|Lymphoma, Non-Hodgkin
1279390|NCT00849654|Lymphoma, B-Cell
1279391|NCT00849654|Burkitt Lymphoma
1279392|NCT00849654|Lymphoma, B-Cell, Marginal Zone
1279393|NCT00849654|Lymphoma, B-Cell, Diffuse
1279394|NCT00849654|Lymphoma, Follicular
1279395|NCT00849654|Lymphoma, Mantle Cell
1279396|NCT00849654|Leukemia, Lymphoid
1279397|NCT00849654|Leukemia, B-Cell
1279398|NCT00849654|Waldenstrom macroglobulinemia
1279399|NCT00849654|Bruton's Tyrosine Kinase
1279400|NCT00849641|decompensation
1279401|NCT00849641|septic shock
1279402|NCT00849641|tissue oxygenation
1279403|NCT00849641|near infrared spectroscopy
1279404|NCT00849628|Aged
1279405|NCT00849628|Polypharmacy
1279406|NCT00849628|Adverse effects
1279407|NCT00849628|Nursing homes
1279408|NCT00849589|Screening
1279409|NCT00849589|Brief intervention
1279410|NCT00849589|Underage drinking
1279411|NCT00849563|predictive genomics
1279412|NCT00849563|personalized medicine
1279413|NCT00849563|personal genomics
1279414|NCT00849563|genetic knowledge
1279415|NCT00849563|genetic attitudes
1279416|NCT00849563|prevention
1279417|NCT00849563|health outcomes
1279418|NCT00849563|behavioral
1279419|NCT00849550|Advanced Solid Tumors
1279420|NCT00849550|Cancer
1279421|NCT00849550|Capecitabine
1279422|NCT00849550|XELOX
1279423|NCT00849550|Neoplasms
1279424|NCT00849550|Oxaliplatin
1279425|NCT00849550|Bevacizumab
1279426|NCT00849550|RAD001
1279427|NCT00849537|Triamcinolon
1279428|NCT00849537|Cataract
1279429|NCT00849537|Diabetic retinopathy
1279430|NCT00849537|non-proliferative retinopathy
1279431|NCT00849511|Migraine prevention
1279432|NCT00849511|Crossover
1279433|NCT00849511|Melatonin
1279434|NCT00849485|Bioequivalence
1279435|NCT00849485|Healthy Subjects
1279436|NCT00849472|Neoadjuvant Breast Cancer
1279437|NCT00849472|Pazopanib (GW786034)
1279438|NCT00849472|NSABP Foundation, Inc.
1279439|NCT00849472|cyclophosphamide
1279440|NCT00849472|Paclitaxel
1279441|NCT00849472|Doxorubicin
1279442|NCT00849459|recurrent breast cancer
1279443|NCT00849459|stage IV breast cancer
1279444|NCT00849433|Inflammation
1279445|NCT00849433|epithelial
1279446|NCT00849433|integrity
1279447|NCT00849433|ECIS
1279448|NCT00849394|bevacizumab
1279449|NCT00849394|proteinuria
1279450|NCT00849381|HPV
1279451|NCT00849381|HPV vaccine
1279452|NCT00849381|papillomavirus
1279453|NCT00849381|cervical cancer
1279454|NCT00849381|human papillomavirus
1279703|NCT00848289|Bladder cancer
1279455|NCT00849329|lapatinib (GW572016), subject, pharmacokinetic, esomeprazole, proton-pump inhibitor, drug interaction, Phase 1
1279456|NCT00849303|stroke
1279457|NCT00849303|rehabilitation
1279458|NCT00849303|gait
1279459|NCT00849303|timing
1279460|NCT00849303|transcranial magnetic stimulation
1279461|NCT00849277|Respiratory Tract Infections
1279462|NCT00849277|Influenza, Human
1279463|NCT00849277|Probiotics
1279464|NCT00849264|hepatocellular carcinoma
1279465|NCT00849264|portal vein tumor thrombus
1279466|NCT00849264|surgical comprehensive treatment
1279467|NCT00849212|Seizures
1279468|NCT00849212|epilepsy
1279469|NCT00849199|screening
1279470|NCT00849199|early detection
1279471|NCT00849199|prevention
1279472|NCT00849199|cancer
1279473|NCT00849199|high risk
1279474|NCT00849199|ovarian cancer
1279475|NCT00849199|breast cancer
1279476|NCT00849186|stage I renal cell cancer
1279477|NCT00849186|stage II renal cell cancer
1279478|NCT00849186|stage III renal cell cancer
1279479|NCT00849186|stage IV renal cell cancer
1279480|NCT00849173|Endometriosis
1279481|NCT00849173|Infertility
1279482|NCT00849173|Tubal Ligation
1279483|NCT00849173|Chronic Pelvic Pain
1279484|NCT00849173|Quality of Life
1279485|NCT00849160|Treatment Experienced
1279486|NCT00849147|Acute Lymphoblastic Leukemia/Lymphoma
1279487|NCT00849147|Acute Myelogenous Leukemia
1279488|NCT00849147|Mantel-Cell Lymphoma
1279489|NCT00849147|Hematopoietic Transplant
1279490|NCT00849147|Haplo-Identical Transplant
1279491|NCT00849147|Non-Myeloablative Transplant
1279492|NCT00849134|First-Time-in-Human
1279493|NCT00849134|Tolerability
1279494|NCT00849134|Pharmacodynamics
1279495|NCT00849134|Safety
1279496|NCT00849134|Food Effect
1279497|NCT00849134|Pharmacokinetics
1279498|NCT00849134|Healthy Volunteers
1279499|NCT00849121|Vaccine
1279500|NCT00849121|pTVG-HP
1279501|NCT00849121|Prostate Cancer
1279502|NCT00849121|Castrate Resistant
1279503|NCT00849108|Myocardial Perfusion
1279504|NCT00849108|PET imaging
1279505|NCT00849108|SPECT imaging
1279506|NCT00849108|Coronary artery disease
1279507|NCT00849108|Subjects that are male and nonpregnant female patients
1279508|NCT00849108|presenting with reversible ischemia as characterized by a
1279509|NCT00849108|rest/stress SPECT imaging study using
1279510|NCT00849108|Technetium(99mTc)-labeled tracers
1279511|NCT00849095|Adult
1279512|NCT00849095|Asthma
1279513|NCT00849095|Bronchodilator Agents
1279514|NCT00849095|Budesonide
1279515|NCT00849095|Double-Blind Method
1279516|NCT00849095|Drug Therapy, Combination
1279517|NCT00849095|Ethanolamines
1279518|NCT00849095|Female
1279519|NCT00849095|Forced Expiratory Volume
1279520|NCT00849095|Humans
1279521|NCT00849095|Male
1279522|NCT00849095|Terbutaline
1279523|NCT00849082|stage IIB prostate cancer
1279524|NCT00849082|stage IIA prostate cancer
1279525|NCT00849082|stage III prostate cancer
1279526|NCT00849082|stage IV prostate cancer
1279527|NCT00849069|Streptococcus pneumoniae
1279528|NCT00849069|Vaccine
1279529|NCT00849069|Non-typable Haemophilus influenza
1279530|NCT00849069|Adults and Elderly Adults
1279531|NCT00849056|diabetes
1279532|NCT00849043|obstructive sleep apnea hypopnea
1279533|NCT00849043|OSA
1279534|NCT00849043|OSAH
1279535|NCT00849017|placebo
1279536|NCT00849017|albiglutide
1279537|NCT00849017|monotherapy
1279538|NCT00849017|diabetes
1279539|NCT00849004|keloid
1279540|NCT00849004|silicone sheet
1279541|NCT00849004|silicone gel
1279542|NCT00849004|paper tape
1279543|NCT00849004|steri-strip
1279544|NCT00848991|precedex
1279545|NCT00848991|propofol
1279546|NCT00848978|Functional capacity
1279547|NCT00848978|Quality of life
1279548|NCT00848978|Depression
1279549|NCT00848978|Falls
1279550|NCT00848978|Body composition
1279551|NCT00848978|Physical activity
1279552|NCT00848965|fluticasone propionate
1279553|NCT00848965|Vienna Challenge Chamber
1279554|NCT00848965|glucocorticosteroids
1279555|NCT00848965|allergic rhinitis
1279556|NCT00848939|systemic sclerosis
1279557|NCT00848939|scleroderma
1279558|NCT00848939|pharmacokinetics
1279559|NCT00848939|treprostinil diethanolamine
1279560|NCT00848926|Antigens, CD30
1279561|NCT00848926|Antibody-Drug Conjugate
1279562|NCT00848926|Antibodies, Monoclonal
1279563|NCT00848926|Disease, Hodgkin
1279564|NCT00848926|Hematologic Diseases
1279565|NCT00848926|Lymphoma
1279566|NCT00848926|monomethylauristatin E
1279567|NCT00848926|Drug Therapy
1279568|NCT00848926|Immunotherapy
1279569|NCT00848913|strength deficit
1279570|NCT00848913|physical function
1279571|NCT00848887|Influenza
1279572|NCT00848887|Flu
1279573|NCT00848887|Vaccine
1279574|NCT00848887|Adjuvant
1279575|NCT00848861|propofol sedation
1279576|NCT00848861|colonoscopy
1279577|NCT00848861|recovery time
1279578|NCT00848861|recovery time after sedation for colonoscopy
1279579|NCT00848848|Influenza
1279580|NCT00848848|Flu
1279581|NCT00848848|Vaccine
1279582|NCT00848848|Intradermal
1279583|NCT00848848|Adjuvant
1279584|NCT00848835|defibrillator
1279585|NCT00848822|Pediatrics
1279586|NCT00848822|Sleep
1279587|NCT00848822|Glucose regulation
1279588|NCT00848822|Type 1 Diabetes Mellitus
1279589|NCT00848809|Acute kidney injury
1279590|NCT00848809|Vancomycin therapy
1279591|NCT00848809|Slow-low efficiency daily dialysis
1279592|NCT00848809|Intermittent Hemodialysis
1279593|NCT00848809|Kidney
1279594|NCT00848809|Vancomycin
1279595|NCT00848809|Hemofiltration
1279596|NCT00848796|Heparin Leo
1279597|NCT00848796|Hepalean
1279598|NCT00848796|CPB Cardiopuilmonary Bypass
1279599|NCT00848796|CABG Coronary Artery Bypass Grafting
1279600|NCT00848796|Anticoagulation efficacy
1279601|NCT00848783|gastric cancer
1279602|NCT00848783|gastroesophageal junction
1279603|NCT00848783|stomach cancer
1279604|NCT00848783|intraperitoneal infusion
1279605|NCT00848783|capecitabine
1279606|NCT00848783|irinotecan
1279607|NCT00848783|cisplatin
1279608|NCT00848783|floxuridine
1279609|NCT00848770|Stroke, Acute
1279610|NCT00848770|Systolic Pressure of Blood
1279611|NCT00848757|Diabetes
1279612|NCT00848757|Lifestyle Intervention
1279613|NCT00848744|Acne
1279614|NCT00848731|pulmonary hypertension
1279615|NCT00848731|venous thromboembolism
1279616|NCT00848718|Tumors, cancer
1279617|NCT00848705|type 1 diabetes, adolescent, self-management
1279618|NCT00848692|Chronic Fatigue Syndrome
1279619|NCT00848692|CFS
1279620|NCT00848692|Myalgic Encephalomyelitis
1279621|NCT00848692|Rituximab
1279622|NCT00848692|B-lymphocyte depletion
1279623|NCT00848692|B-cell depletion
1279624|NCT00848679|Pre-eclampsia
1279625|NCT00848679|Pregnancy
1279626|NCT00848679|Uteroplacental blood flow
1279627|NCT00848679|Epidural
1279628|NCT00848679|Anesthesia
1279629|NCT00848627|Bladder cancer
1279630|NCT00848627|Smokers
1279631|NCT00848627|Hematuria
1279632|NCT00848601|SGI-1776
1279633|NCT00848601|PIM
1279634|NCT00848601|Hormone & Docetaxel refractory Prostate Cancer
1279635|NCT00848601|Refractory non-Hodgkin's Lymphoma
1279636|NCT00848588|agonal breathing
1279637|NCT00848588|cardiac arrest
1279638|NCT00848588|9-1-1 call taker
1279639|NCT00848588|survey
1279640|NCT00848562|sudden cardiac death
1279641|NCT00848549|Epilepsy
1279642|NCT00848549|Monotherapy
1279643|NCT00848536|OAG
1279644|NCT00848536|OHT
1279645|NCT00848523|LBH859
1279646|NCT00848523|Panobinostat
1279647|NCT00848523|GBM
1279648|NCT00848523|Glioma
1279649|NCT00848523|Glioblastoma
1279650|NCT00848523|Astrocytoma
1279651|NCT00848523|oligodendroglioma
1279652|NCT00848523|oligoastrocytoma
1279653|NCT00848523|gliosarcoma
1279654|NCT00848523|anaplastic
1279655|NCT00848497|hormone replacement therapy
1279656|NCT00848497|radical prostatectomy
1279657|NCT00848497|erectile dysfunctions
1279658|NCT00848497|scheduled for removal of prostate gland
1279659|NCT00848471|Indirect calorimeter
1279660|NCT00848471|Validation
1279661|NCT00848471|Energy expenditure
1279662|NCT00848471|Healthy volunteers
1279663|NCT00848458|Azelaic Acid
1279664|NCT00848458|Iontophoresis
1279665|NCT00848432|Schizophrenia
1279666|NCT00848432|Risperidone
1279667|NCT00848432|Maintenance treatment
1279668|NCT00848432|Relapse
1279669|NCT00848419|Epidural
1279670|NCT00848419|Analgesia
1279671|NCT00848419|Methadone
1279672|NCT00848419|Morphine
1279673|NCT00848419|Pharmacokinetic-pharmacodynamic
1279674|NCT00848419|Experimental pain - analgesic response
1279675|NCT00848406|bronchial
1279676|NCT00848406|COPD
1279677|NCT00848406|Asthma
1279678|NCT00848406|sputum
1279679|NCT00848406|biopsies
1279680|NCT00848393|pediatric cardiac surgery
1279681|NCT00848393|stress response
1279682|NCT00848393|early extubation
1279683|NCT00848393|Dexmedetomidine
1279684|NCT00848393|TOF
1279685|NCT00848393|VSD
1279686|NCT00848393|AVSD
1279687|NCT00848380|Hypertension
1279688|NCT00848380|hyperlipidemia
1279689|NCT00848354|enbrel
1279690|NCT00848354|moderate arthritis
1279691|NCT00848354|severe arthritis
1279692|NCT00848354|rheumatoid arthritis
1279693|NCT00848328|recurrent small lymphocytic lymphoma
1279694|NCT00848328|recurrent grade 1 follicular lymphoma
1279695|NCT00848328|recurrent grade 2 follicular lymphoma
1279696|NCT00848328|recurrent grade 3 follicular lymphoma
1279697|NCT00848315|cognitive behavioral intervention
1279698|NCT00848315|low literate/illiterate Hispanic patients
1279699|NCT00848302|peripheral vascular disease
1279700|NCT00848302|endothelial dysfunction
1279701|NCT00848302|intravascular ultrasound
1279702|NCT00848302|L-Arginine
1279704|NCT00848289|Genetic susceptibility
1279705|NCT00848289|Increased Risk
1279706|NCT00848276|PCSK9
1279707|NCT00848276|Lipoprotein metabolism
1279708|NCT00848276|testosterone
1279709|NCT00848276|estradiol
1279710|NCT00848263|Fracture
1279711|NCT00848263|Radius
1279712|NCT00848263|Surgery
1279713|NCT00848263|Osteosynthesis
1279714|NCT00848250|Cardiopulmonary Bypass
1279715|NCT00848250|ACE inhibitor
1279716|NCT00848250|Pediatrics
1279717|NCT00848237|Barrett's Esophagus
1279718|NCT00848237|Dysplasia
1279719|NCT00848237|Intestinal Metaplasia
1279720|NCT00848224|coronary heart disease
1279721|NCT00848224|lipid lowering medication
1279722|NCT00848224|NCEP guidelines
1279723|NCT00848211|HIV
1279724|NCT00848211|vaccine
1279725|NCT00848211|lipopeptide
1279726|NCT00848211|Tat
1279727|NCT00848211|TUTI-16
1279728|NCT00848211|THYMON
1279729|NCT00848211|Treatment Naive
1279730|NCT00848198|Dry Eye Disease
1279731|NCT00848198|Dry Eye Syndrome
1279732|NCT00848198|Dry Eye
1279733|NCT00848185|VEGF
1279734|NCT00848185|Trigger
1279735|NCT00848185|OHSS
1279736|NCT00848172|Essential Tremor
1279737|NCT00848172|Octanol
1279738|NCT00848172|Octanoic Acid
1279739|NCT00848172|Ethanol
1279740|NCT00848172|Accelerometry
1279741|NCT00848159|Osteoporosis
1279742|NCT00848159|kyphosis
1279743|NCT00848159|photogrammetry
1279744|NCT00848107|systemic sclerosis
1279745|NCT00848107|scleroderma
1279746|NCT00848107|digital ulcers
1279747|NCT00848107|vasculopathy
1279748|NCT00848094|hepatocellular carcinoma
1279749|NCT00848094|radiation therapy
1279750|NCT00848094|3-dimensional conformal radiation therapy (3-DCRT)
1279751|NCT00848094|intensity modulated radiation therapy (IMRT)
1279752|NCT00848094|active breathing control
1279753|NCT00848081|Prostate
1279754|NCT00848081|BPH
1279755|NCT00848081|Benign Prostatic Hyperplasia
1279756|NCT00848081|BPH-LUTS
1279757|NCT00848081|LUTS
1279758|NCT00848081|Phosphodiesterase Inhibitors
1279759|NCT00848081|tadalafil
1279760|NCT00848081|alpha blockers
1279761|NCT00848068|lipid layer thickness
1279762|NCT00848042|cancer
1279763|NCT00848042|head and neck
1279764|NCT00848042|laser
1279765|NCT00848042|ablation
1279766|NCT00848029|Influenza vaccine
1279767|NCT00848003|Probiotics
1279768|NCT00848003|BB-12
1279769|NCT00848003|Yogurt
1279770|NCT00848003|Antibiotics
1279771|NCT00847990|Down syndrome
1279772|NCT00847990|aneuploidy
1279773|NCT00847990|chromosome abnormality
1279774|NCT00847990|amniocentesis
1279775|NCT00847990|chorionic villus sampling
1279776|NCT00847990|Laboratory Developed Test (LDT)
1279777|NCT00847977|Acute head trauma
1279778|NCT00847964|Heart Failure
1279779|NCT00847951|renal
1279780|NCT00847951|neonates
1279781|NCT00847938|neostigmine
1279782|NCT00847938|neuromuscular blocking agent
1279783|NCT00847938|train of four
1279784|NCT00847938|anesthesia
1279785|NCT00847912|NMSC
1279786|NCT00847912|nonmelanoma skin cancer
1279787|NCT00847912|topical 5-FU 5% cream
1279788|NCT00847912|Neoplasms
1279789|NCT00847912|Antineoplastic Agents
1279790|NCT00847912|Therapeutic Uses
1279791|NCT00847912|Dermatologic Agents
1279792|NCT00847912|Neoplasms by Site
1279793|NCT00847912|carcinoma, basal cell
1279794|NCT00847912|carcinoma, squamous cell
1279795|NCT00847899|hypertension
1279796|NCT00847899|impaired glucose tolerance
1279797|NCT00847899|s-EH enzyme inhibition
1279798|NCT00847899|pre-diabetes
1279799|NCT00847873|intimate partner violence
1279800|NCT00847873|domestic violence
1279801|NCT00847873|alcohol abuse
1279802|NCT00847873|alcohol dependence
1279803|NCT00847873|drug abuse
1279804|NCT00847873|drug dependence
1279805|NCT00847873|addiction
1279806|NCT00847860|cognition
1279807|NCT00847847|ALS
1279808|NCT00847847|Motor neuron
1279809|NCT00847847|Pathophysiology
1279810|NCT00847847|Neuromuscular junction
1279811|NCT00847847|Neuromuscular transmission
1279812|NCT00847847|Microelectrodes
1279813|NCT00847808|Esophageal Reflux
1279814|NCT00847808|Gastro-Esophageal Reflux
1279815|NCT00847808|Gastroesophageal Reflux Disease
1279816|NCT00847808|GERD
1279817|NCT00847808|Regurgitation, Gastric
1279818|NCT00847808|Heartburn
1279819|NCT00847808|Drug Therapy
1279820|NCT00847769|Ankle Sprain
1279821|NCT00847756|Otitis media
1279822|NCT00847756|demography
1279823|NCT00847756|Streptococcus pneumoniae
1279824|NCT00847756|Haemophilus influenzae
1279825|NCT00847756|Moraxella catarrhalis
1279826|NCT00847756|rhinovirus
1279827|NCT00847756|children, 0-5 years of age
1279828|NCT00847756|diagnosed rAOM, COME or CSOM by an otorhinolaryngologist
1279829|NCT00847756|primary and secondary hospital Nijmegen, the Netherlands
1279830|NCT00847743|oxidative stress
1279831|NCT00847743|aging
1279832|NCT00847743|ischemia-reperfusion
1279833|NCT00847730|Ease of dressing application, dressing conformability and ease of dressing removal on diabetic foot ulcers using the ActiVAC therapy
1279834|NCT00847717|Oral
1279835|NCT00847717|cancer
1279836|NCT00847717|surgery
1279837|NCT00847717|neck dissection
1279838|NCT00847717|spinal accessory nerve
1279839|NCT00847704|Stroke
1279840|NCT00847704|Rehabilitation
1279841|NCT00847704|Robotics
1279842|NCT00847691|economic evaluation
1279843|NCT00847691|diagnostics
1279844|NCT00847691|sarcoma
1279845|NCT00847678|Cryptococcal Meningitis
1279846|NCT00847665|Pressure ulcers
1279847|NCT00847665|Repositioning
1279848|NCT00847665|Prevention
1279849|NCT00847665|Mechanical Ventilation
1279850|NCT00847665|Critical care
1279851|NCT00847639|Multiple Myeloma
1279852|NCT00847639|lenalidomide
1279853|NCT00847639|Revlimid
1279854|NCT00847639|Allogeneic Hematopoietic Cell Transplantation
1279855|NCT00847626|Hypertensive
1279856|NCT00847626|Blood Pressure, High
1279857|NCT00847626|Vascular Disease
1279858|NCT00847626|Cardiovascular Disease
1279859|NCT00847626|Drug Therapy
1279860|NCT00847613|double-blind placebo-controlled investigational drug oral therapy safety and efficacy hand and feet x-rays
1279861|NCT00847600|Schizophrenia
1279862|NCT00847600|Neurosteroids
1279863|NCT00847600|Pregnenolone
1279864|NCT00847600|Augmentation
1279865|NCT00847587|Contraceptive
1279866|NCT00847587|Implant
1279867|NCT00847587|Postpartum period
1279868|NCT00847587|etonogestrel-releasing
1279869|NCT00847587|lactogenesis
1279870|NCT00847587|Breastfeeding
1279871|NCT00847574|Weight loss
1279872|NCT00847574|Weight maintenance
1279873|NCT00847574|Weight management
1279874|NCT00847574|Cardiovascular disease risk
1279875|NCT00847574|Dietary Guidelines
1279876|NCT00847574|Diet and exercise
1279877|NCT00847574|Prevention
1279878|NCT00847561|Anxiety
1279879|NCT00847548|intimate partner violence
1279880|NCT00847548|domestic violence
1279881|NCT00847548|substance abuse
1279882|NCT00847548|alcohol abuse
1279883|NCT00847548|drug abuse
1279884|NCT00847548|addiction
1279885|NCT00847522|melanoma
1279886|NCT00847522|skin cancer
1279887|NCT00847522|lymph node
1279888|NCT00847522|sentinel lymph node
1279889|NCT00847522|malignant melanoma
1279890|NCT00847522|mapping
1279891|NCT00847509|lung cancer
1279892|NCT00847509|head and neck cancer
1279893|NCT00847509|radiotherapy
1279894|NCT00847509|chemoradiotherapy
1279895|NCT00847509|radiation
1279896|NCT00847509|chemoradiation
1279897|NCT00847509|FLT
1279898|NCT00847509|[F-18]FLT
1279899|NCT00847509|FDG
1279900|NCT00847509|[F-18]FDG
1279901|NCT00847496|Partial Thickness burn
1279902|NCT00847496|Biological Dressing
1279903|NCT00847483|glaucoma
1279904|NCT00847483|ocular hypertension
1279905|NCT00847483|latanoprost
1279906|NCT00847483|travoprost
1279907|NCT00847483|bimatoprost
1279908|NCT00847470|Dental caries
1279909|NCT00847470|Assessments
1279910|NCT00847470|dental materials
1279911|NCT00847457|Exercise
1279912|NCT00847457|Stretching
1279913|NCT00847457|Adolescents
1279914|NCT00847431|Subthalamic Nucleus
1279915|NCT00847431|Deep Brain Stimulation
1279916|NCT00847431|Depression
1279917|NCT00847431|Anxiety
1279918|NCT00847431|Parkinson's Disease
1279919|NCT00847418|pharmacokinetics
1279920|NCT00847418|ketamine
1279921|NCT00847418|Anesthetics, Dissociative
1279922|NCT00847405|Bioequivalence
1279923|NCT00847405|Healthy Subjects
1279924|NCT00847392|Urethral catheterization
1279925|NCT00847392|Emergency Department
1279926|NCT00847392|Ultrasound
1279927|NCT00847392|Urinary tract infection
1279928|NCT00847392|Pediatric
1279929|NCT00847379|Duchenne muscular dystrophy
1279930|NCT00847379|Becker muscular dystrophy
1279931|NCT00847379|Nonsense mutation
1279932|NCT00847379|Premature stop codon
1279933|NCT00847379|DMD
1279934|NCT00847379|BMD
1279935|NCT00847379|Ataluren
1279936|NCT00847379|PTC124
1279937|NCT00847366|Perifosine
1279938|NCT00847353|high frequency ECG
1279939|NCT00847353|normal values
1279940|NCT00847353|asymptomatic
1279941|NCT00847353|obese
1279942|NCT00847340|Genital warts
1279943|NCT00847340|HPV typing
1279944|NCT00847340|HPV infections
1279945|NCT00847340|Condyloma Acuminata
1279946|NCT00847327|Type 1 Diabetes
1279947|NCT00847327|Parenting
1279948|NCT00847327|Young Children
1279949|NCT00847314|Hypogonadism
1279950|NCT00847314|Abdominal obesity
1279951|NCT00847314|Physical exercise
1279952|NCT00847314|Testosterone
1279953|NCT00847288|Heart Failure
1279954|NCT00847288|Implantable Cardioverter Defibrillator (ICD)
1279955|NCT00847288|Cardiac Resynchronization Therapy with Defibrillator (CRT D)
1279956|NCT00847288|OptiVol®
1279957|NCT00847275|Elderly patients
1279958|NCT00847275|renal insufficiency
1279959|NCT00847275|gerontologic evaluation
1279960|NCT00847262|Hypertension
1279961|NCT00847262|Abdominal obesity
1279962|NCT00847262|Diabetes
1279963|NCT00847262|Treatment
1279964|NCT00847249|safety
1279965|NCT00847249|tolerability
1279966|NCT00847249|healthy
1279967|NCT00847249|inhalation
1279968|NCT00847249|Healthy males
1279969|NCT00847236|Polymyalgia Rheumatica
1279970|NCT00847236|Rheumatoid Arthritis
1279971|NCT00847236|Rheumatic Disease
1279972|NCT00847236|PMR
1279973|NCT00847223|Mantle cell lymphoma
1279974|NCT00847223|Lymphoma
1279975|NCT00847223|relapsed, refractory or progressive MCL
1279976|NCT00847223|Mantle cell lymphoma (relapsed, refractory or progressive)
1279977|NCT00847210|Esophageal Reflux
1279978|NCT00847210|Gastro-Esophageal Reflux
1279979|NCT00847210|Gastroesophageal Reflux Disease
1279980|NCT00847210|GERD
1279981|NCT00847210|Regurgitation, Gastric
1279982|NCT00847210|Heartburn
1279983|NCT00847210|Drug Therapy
1279984|NCT00847210|Adolescent
1279985|NCT00847184|nasal intubation
1279986|NCT00847184|Aitraq
1279987|NCT00847184|difficult intubation
1279988|NCT00847171|male breast cancer
1279989|NCT00847171|stage II breast cancer
1279990|NCT00847171|stage IIIA breast cancer
1279991|NCT00847171|stage IIIB breast cancer
1279992|NCT00847171|stage IIIC breast cancer
1279993|NCT00847171|stage IV breast cancer
1279994|NCT00847171|HER2-positive breast cancer
1279995|NCT00847158|POAG
1279996|NCT00847158|Combination glaucoma & cataract procedure
1279997|NCT00847158|trabecular micro-bypass stent
1279998|NCT00847158|iStent
1279999|NCT00847145|toddler
1280000|NCT00847145|Meningococcal disease
1280001|NCT00847145|prevention
1280002|NCT00847145|vaccination
1280003|NCT00847132|Collaborative Care
1280004|NCT00847119|rectum
1280005|NCT00847119|adenocarcinoma
1280006|NCT00847119|neoadjuvant
1280007|NCT00847119|bevacizumab
1280008|NCT00847119|capecitabine
1280009|NCT00847119|radiotherapy
1280010|NCT00847119|locally
1280011|NCT00847119|advanced
1280012|NCT00847119|resectable
1280013|NCT00847119|resectable locally advanced adenocarcinoma of the rectum
1280014|NCT00847119|xeberecto
1280015|NCT00847106|Dendritic Cells
1280016|NCT00847106|Regulatory T cells
1280017|NCT00847106|CD25
1280018|NCT00847106|Melanoma
1280019|NCT00847106|Immunotherapy
1280020|NCT00847106|Daclizumab
1280021|NCT00847106|Stage IV Melanoma
1280022|NCT00847080|Reactive hypoglycemia
1280023|NCT00847080|Sitagliptin
1280024|NCT00847080|Glucagon-Like Peptide 1
1280025|NCT00847080|Incretins
1280026|NCT00847080|Prediabetes
1280027|NCT00847054|Solid Tumor
1280028|NCT00847054|Endosialin
1280029|NCT00847028|Newborn
1280030|NCT00847028|Pain
1280031|NCT00847028|glucose solution
1280032|NCT00847028|venipuncture
1280033|NCT00847028|non-pharmacologic pain relief.
1280034|NCT00847015|Bladder
1280035|NCT00847015|Urinary
1280036|NCT00847015|CISPLATIN
1280037|NCT00847015|GEMCITABINE
1280038|NCT00847015|SU011248 (Sunitinib Malate)
1280039|NCT00847015|08-159
1280040|NCT00847002|Flexitouch system
1280041|NCT00847002|FarrowWrap
1280042|NCT00847002|venous stasis ulcer
1280043|NCT00846989|glaucoma,
1280044|NCT00846989|primary open-angle glaucoma (POAG),
1280045|NCT00846989|ocular hypertension (OH),
1280046|NCT00846989|intraocular pressure (IOP)
1280047|NCT00846976|Safety
1280048|NCT00846963|parenteral nutrition associated cholestasis in neonates
1280049|NCT00846963|parenteral nutrition induced cholestasis in preterms
1280050|NCT00846963|Bile duct obstruction
1280051|NCT00846963|biliary stasis
1280052|NCT00846950|H1-antagonist
1280053|NCT00846950|Event Related Potentials
1280054|NCT00846950|Memory
1280055|NCT00846950|Information processing
1280056|NCT00846950|The effects of an H1 antagonist (dexchlorpheniramine) on human cognition
1280057|NCT00846937|Cholesterol
1280058|NCT00846937|Plant stanolester
1280059|NCT00846937|Beverage
1280060|NCT00846937|Ileostoma
1280061|NCT00846937|Serum cholesterol level
1280062|NCT00846937|serum LDL-cholesterol level
1280063|NCT00846937|Intestinal cholesterol absorption efficiency
1280064|NCT00846924|Stroke
1280065|NCT00846924|Transient Ischemic Attack
1280066|NCT00846924|Atrial fibrillation
1280067|NCT00846924|Atrial flutter
1280068|NCT00846911|Acute Exacerbation of Chronic Bronchitis (AECB) patients
1280069|NCT00846898|blood sugar
1280070|NCT00846898|cholesterol
1280071|NCT00846898|cinnamon
1280072|NCT00846898|HbA1c
1280073|NCT00846885|Bioequivalence
1280074|NCT00846885|Healthy Subjects
1280075|NCT00846872|GHRP-3
1280076|NCT00846872|Insulin Resistance
1280077|NCT00846872|Markers of inflammation
1280078|NCT00846872|Endothelial Dysfunction
1280079|NCT00846872|Flow Mediated Dilation
1280080|NCT00846872|GH/IGF-1 axis
1280081|NCT00846872|Post menopausal
1280082|NCT00846859|alcohol dependence
1280083|NCT00846859|nicotine dependence
1280084|NCT00846859|alcohol abuse
1280085|NCT00846859|varenicline
1280086|NCT00846859|Champix
1280087|NCT00846859|Chantix
1280088|NCT00846859|smoking
1280089|NCT00846859|drinking
1280090|NCT00846859|snuffing
1280091|NCT00846859|diary
1280092|NCT00846859|phosphatidyl ethanol
1280093|NCT00846859|PEth
1280094|NCT00846833|Melanoma, Experimental
1280095|NCT00846079|coronary artery disease
1280096|NCT00846079|stress testing
1280097|NCT00846066|educational research,
1280098|NCT00846066|instructional methods,
1280099|NCT00846066|Hands on training,
1280100|NCT00846066|Web based training,
1280101|NCT00846066|pediatric residents
1280102|NCT00846066|preventive oral health,
1280103|NCT00846066|dental caries,
1280104|NCT00846066|Instructional strategies in Preventive Oral health
1280105|NCT00846066|Web-based training on Preventive Oral Health
1280106|NCT00846066|Hands on Training on Preventive Oral Health
1280107|NCT00846040|Obesity
1280108|NCT00846040|Weight Loss
1280109|NCT00846040|Carbohydrate
1280110|NCT00846040|Fat
1280111|NCT00846040|Macronutrient Balance
1280112|NCT00846040|Healthy Volunteer
1280113|NCT00846014|asthma
1280114|NCT00846014|exacerbation
1280115|NCT00846014|Helium
1280116|NCT00846014|MRI
1280117|NCT00846014|Lung imaging
1280118|NCT00846001|Resynchronization Therapy
1280119|NCT00845988|Bipolar disorder
1280120|NCT00845988|metabolic complication
1280121|NCT00845988|Aripiprazole
1280122|NCT00845988|Weight gain
1280123|NCT00845988|Clinical Trial
1280124|NCT00845988|Antipsychotic
1280125|NCT00845988|Metabolic syndrome
1280126|NCT00845988|Psychopharmacology
1280127|NCT00845988|Open Label
1280128|NCT00845962|bupivacaine
1280129|NCT00845962|chloroprocaine
1280130|NCT00845962|spinal
1280131|NCT00845962|anesthesia
1280132|NCT00845962|elective surgery
1280133|NCT00845962|ambulatory surgery
1280134|NCT00846755|Thyroid
1280135|NCT00846755|Pregnancy
1280136|NCT00846742|Hodgkin Lymphoma
1280137|NCT00846716|Type 2 Diabetes Mellitus
1280138|NCT00846716|Diabetic Nephropathy
1280139|NCT00846716|Diabetic Retinopathy
1280140|NCT00846716|pioglitazone
1280141|NCT00846690|topical anesthetics
1280142|NCT00846690|topical anesthesia
1280143|NCT00846690|20% benzocaine
1280144|NCT00846690|TAC alternate gel
1280145|NCT00846690|combination topical anesthetics
1280146|NCT00846690|dental anesthesia
1280147|NCT00846677|Healthy
1280148|NCT00846677|Infants
1280149|NCT00846677|Vitamin D
1280150|NCT00846651|spinal anesthesia
1280151|NCT00846651|cesarean section
1280152|NCT00846638|Risk drinking
1280153|NCT00846638|Women
1280154|NCT00846638|Medical problems
1280155|NCT00846625|Biomedical research
1280156|NCT00846625|Macular Edema
1280157|NCT00846625|Uveitis
1280158|NCT00846625|Ranibizumab
1280159|NCT00846625|Steroids
1280160|NCT00846612|refractory
1280161|NCT00846612|avastin
1280162|NCT00846612|doxil
1280163|NCT00846612|relapsed
1280164|NCT00846612|ovarian cancer
1280165|NCT00846612|platinum-resistant
1280166|NCT00846599|brachial artery ultrasound
1280167|NCT00846599|brachial artery reactivity
1280168|NCT00846599|HIV
1280169|NCT00846599|human immunodeficiency virus
1280170|NCT00846599|cardiovascular risk
1280171|NCT00846599|omega three
1280172|NCT00846599|saturated fat
1280173|NCT00846599|sustiva
1280174|NCT00846599|atripla
1280175|NCT00846599|kaletra
1280176|NCT00846599|treatment naive
1280177|NCT00846586|chronic obstructive pulmonary disease
1280178|NCT00846586|COPD
1280179|NCT00846586|indacaterol
1280180|NCT00846586|tiotropium
1280181|NCT00846586|bronchodilation
1280182|NCT00846573|Helium
1280183|NCT00846573|MRI
1280184|NCT00846573|Hyperpolarized Helium
1280185|NCT00846573|Hyperpolarized Noble Gas
1280186|NCT00846547|Autism
1280187|NCT00846547|Autism Spectrum Disorders
1280188|NCT00846547|irritability
1280189|NCT00846547|aberrant behavior
1280190|NCT00846534|Oxidative stress markers
1280191|NCT00846534|Cardiac surgery
1280192|NCT00846534|Atrial Fibrillation
1280193|NCT00846521|Pediatric Obesity
1280194|NCT00846521|Insulin Resistance
1280195|NCT00846521|Glucose Tolerance
1280196|NCT00846521|Adolescents
1280197|NCT00846521|Acarbose
1280198|NCT00846521|Continuous Glucose Monitoring (CGMS)
1280199|NCT00846521|Endothelial Dysfunction
1280200|NCT00846508|cervical cancer
1280201|NCT00846508|Cisplatin
1280202|NCT00846508|chemoradiation
1280203|NCT00846495|Migraine
1280204|NCT00846495|Migraine prevention
1280205|NCT00846495|Prodrome
1280206|NCT00846495|Premonitory phase
1280207|NCT00846495|Preemptive therapy
1280208|NCT00846482|Colorectal cancer
1280209|NCT00846482|Oxaliplatin
1280210|NCT00846482|ERCC-1
1280211|NCT00846456|Tumor setm cell
1280212|NCT00846443|non-small cell lung cancer
1280213|NCT00846430|Neurofibromas
1280214|NCT00846430|Neurofibromatosis 1
1280215|NCT00846430|Celecoxib
1280216|NCT00846430|Celebrex
1280217|NCT00846430|Peg-Interferon alpha-2b
1280218|NCT00846430|PEG-Intron
1280219|NCT00846430|Temozolomide
1280220|NCT00846430|Temodar
1280221|NCT00846430|Vincristine Sulfate
1280222|NCT00846430|Oncovin
1280223|NCT00846417|myocardial infarction
1280224|NCT00846417|heart failure
1280225|NCT00846417|arrhythmia
1280226|NCT00846404|heart failure
1280227|NCT00846404|cardiomyopathy
1280228|NCT00846404|diastolic dysfunction
1280229|NCT00846378|ST segment elevation myocardial infarction (STEMI)
1280230|NCT00846378|timed balloon inflations
1280231|NCT00846378|post conditioning
1280232|NCT00846365|Essential Hypertension
1280233|NCT00846365|Hypertensive
1280234|NCT00846365|Blood Pressure, High
1280235|NCT00846365|Vascular Disease
1280236|NCT00846365|Cardiovascular Disease
1280237|NCT00846365|Drug Therapy
1280238|NCT00846352|Bone Marrow Transplantation
1280239|NCT00846352|Hematopoietic Stem Cell Transplantation
1280240|NCT00846352|Bronchoscopy
1280241|NCT00846339|Smoking cessation
1280242|NCT00846339|Bupropion
1280243|NCT00846326|allergic rhinitis
1280244|NCT00846326|rhinitis medicamentosa
1280245|NCT00846326|imidazolines
1280246|NCT00846326|corticosteroid
1280247|NCT00846313|Dietary intake
1280248|NCT00846313|Dietary counseling
1280249|NCT00846313|Weight loss
1280250|NCT00846313|Body composition
1280251|NCT00846313|Resting energy expenditure
1280252|NCT00846313|Quality of life
1280253|NCT00846300|Patient compliance
1280254|NCT00846300|Hispanics
1280255|NCT00846300|Health Behavior
1280256|NCT00846300|Family Physicians
1280257|NCT00846300|Primary Healthcare
1280258|NCT00846287|COPD
1280259|NCT00846287|aformoterol
1280260|NCT00846287|Helium
1280261|NCT00846287|Hyperpolarized helium
1280262|NCT00846287|Hyperpolarized Noble Gas
1280263|NCT00846287|MRI
1280264|NCT00846274|Healthy Male subjects
1280265|NCT00846261|infected
1280266|NCT00846261|Ilizarov
1280267|NCT00846248|diabetes
1280268|NCT00846248|insulin resistance
1280269|NCT00846248|chromium
1280270|NCT00846248|healthy volunteers
1280271|NCT00846235|Dermatitis
1280272|NCT00846235|Atopic
1280273|NCT00846235|Moisturising cream
1280274|NCT00846235|Skin
1280275|NCT00846209|prescription drug
1280276|NCT00846209|warnings
1280277|NCT00846209|health literacy
1280278|NCT00846209|enhanced language
1280279|NCT00846183|local injury
1280280|NCT00846183|implantation rate
1280281|NCT00846183|endometrial receptivity
1280282|NCT00846183|IVF
1280283|NCT00846170|Irritable bowel syndrome probiotics
1280284|NCT00846157|natural killer cell
1280285|NCT00846157|DLBCL (Diffuse Large B Cell Lymphoma)
1280286|NCT00846144|Glucose stimulated insulin secretion
1280287|NCT00846144|copper
1280288|NCT00846144|cytokines
1280289|NCT00846144|diabetes
1280290|NCT00846144|Reduction in insulin secretion
1280291|NCT00846131|Subjects with primary hepatocellular carcinoma, intended for liver transplantation.
1280292|NCT00846118|Pitavastatin
1280293|NCT00846118|Hemodialysis
1280294|NCT00846118|Mortality
1280295|NCT00846118|Cardiovascular disease
1280296|NCT00846105|methicillin resistant Staphylococcus aureus
1280297|NCT00846105|MRSA
1280298|NCT00846105|cross-infection
1280299|NCT00846105|staphylococcal infection
1280300|NCT00846105|infection control
1280301|NCT00846092|Diabetic Retinopathy
1280302|NCT00846092|Diabetic Macular Edema
1280303|NCT00846092|NIR
1280304|NCT00846092|Near-infrared Light Therapy
1280305|NCT00845949|chemokines synovium
1280306|NCT00845936|Atypical antipsychotics
1280307|NCT00845936|Weight
1280308|NCT00845936|adolecsents
1280309|NCT00845936|pediatric
1280310|NCT00845936|Metformin
1280311|NCT00845923|Postherpetic neuralgia of at least 6 months
1280312|NCT00845897|Diabetes mellitus
1280313|NCT00845897|plantar ulcers
1280314|NCT00845897|peripheral neuropathy
1280315|NCT00845884|Gastric
1280316|NCT00845884|Cancer
1280317|NCT00845884|Advanced
1280318|NCT00845884|Docetaxel
1280319|NCT00845884|Cisplatin
1280320|NCT00845884|Capecitabine
1280321|NCT00845884|Bevacizumab
1280322|NCT00845871|Exjade
1280323|NCT00845871|deferasirox
1280324|NCT00845871|palatability
1280325|NCT00845871|tolerability
1280326|NCT00845871|food
1280327|NCT00845871|iron overload
1280328|NCT00845871|Serum Iron overload due to transfusions
1280329|NCT00845858|Gastroparesis
1280330|NCT00845858|Diabetic Gastroparesis
1280331|NCT00845858|Diabetes
1280332|NCT00845858|Diabetes Mellitus
1280333|NCT00845858|Delayed Gastric Emptying
1280334|NCT00845845|Non-alcoholic steatohepatitis
1280335|NCT00845845|Omega-3 fatty acids
1280336|NCT00845845|MRI
1280337|NCT00845845|NASH
1280338|NCT00845819|oral mucositis
1280339|NCT00845819|intensive chemotherapy
1280340|NCT00845819|stem cell transplantation
1280341|NCT00845819|epidermal growth factor
1280342|NCT00845806|Diacritics
1280343|NCT00845806|Neuronal Processing
1280344|NCT00845806|fMRI
1280345|NCT00845806|Arabic
1280346|NCT00845793|Type 2 diabetes
1280347|NCT00845793|Nutrition
1280348|NCT00845793|Lifestyle modifications
1280349|NCT00845780|persistent atrial fibrillation
1280350|NCT00845780|amiodarone
1280351|NCT00845780|late recurrence atrial fibrillation
1280352|NCT00845780|adverse events
1280353|NCT00845767|Nitric Oxide
1280354|NCT00845767|Nitric Oxide Synthase
1280355|NCT00845767|Air Pollution
1280356|NCT00845767|Endothelial Dysfunction
1280357|NCT00845767|Diesel Exhaust
1280358|NCT00845754|Post-operative febrile morbidity
1280359|NCT00845754|Post-operative pain management
1280360|NCT00845728|Indacaterol
1280361|NCT00845728|Tiotropium
1280362|NCT00845728|COPD
1280363|NCT00845715|rotator cuff
1280364|NCT00845715|rehabilitation
1280365|NCT00845715|range of motion
1280366|NCT00845702|Renal artery stenosis
1280367|NCT00845702|Contrast agent
1280368|NCT00845702|MRA
1280369|NCT00845689|liver surgery
1280370|NCT00845676|Hepatitis C virus
1280371|NCT00845676|Acute hepatitis C infection
1280372|NCT00845676|HIV
1280373|NCT00845676|HCV
1280374|NCT00845663|certolizumab pegol
1280375|NCT00845663|Cimzia
1280376|NCT00845663|bioequivalence
1280377|NCT00845663|Comparison Bioequivalence Study
1280378|NCT00845650|Anthrax
1280379|NCT00845650|Human Anthrax Immune Globulin Intravenous
1280380|NCT00845650|Safety
1280381|NCT00845650|Pharmacokinetics
1280382|NCT00845637|eggplant
1280383|NCT00845637|dyslipidemia
1280384|NCT00845637|postprandial lipemia
1280385|NCT00845624|oxygen saturation
1280386|NCT00845624|retinopathy of prematurity
1280387|NCT00845624|long term outcomes
1280388|NCT00845624|hypoxia
1280389|NCT00845624|hyperoxia
1280390|NCT00845611|peptide vaccine
1280391|NCT00845611|URLC10
1280392|NCT00845598|Allergic Rhinitis
1280393|NCT00845585|arterial reconstruction
1280394|NCT00845585|bypass
1280395|NCT00845585|below knee
1280396|NCT00845585|PZFE
1280397|NCT00845585|Ovine graft
1280398|NCT00845585|Omniflow II
1280399|NCT00845585|graft patency
1280400|NCT00845572|Schizophrenia
1280401|NCT00845572|Schizoaffective
1280402|NCT00845572|Risperdal Consta
1280403|NCT00845572|Medication Adherence
1280404|NCT00845572|Antipsychotic
1280405|NCT00845559|Childhood Obesity
1280406|NCT00845559|Insulin resistance
1280407|NCT00845559|Impaired Glucose Tolerance
1280408|NCT00845559|Cardiovascular Disease
1280409|NCT00845559|Type 2 Diabetes Mellitus
1280410|NCT00845559|Continuous Glucose Monitoring (CGMS)
1280411|NCT00845559|Exenatide
1280412|NCT00845559|Oral Glucose Tolerance Test
1280413|NCT00845546|Bioequivalence 10 mg Loratadine 240 mg Pseudoephedrine Sulfate Extended Release Tablets
1280414|NCT00845507|weight gain
1280415|NCT00845494|Medication history
1280416|NCT00845494|medication errors
1280417|NCT00845494|Reduction of admission medication history errors
1280418|NCT00845468|coronary flow reserve
1280419|NCT00845468|diabetes mellitus
1280420|NCT00845468|acute myocardial infarction
1280421|NCT00845468|transthoracic echocardiography
1280422|NCT00845442|Bilateral vocal cord paralyses
1280423|NCT00845442|Implanted laryngeal stimulator
1280424|NCT00845442|vocal cord opening
1280425|NCT00845442|pulmonary function tests
1280426|NCT00845429|Influenza
1280427|NCT00845429|Orthomyxoviruses
1280428|NCT00845429|Split-virion inactivated influenza vaccine
1280429|NCT00845429|cell-based vaccine
1280430|NCT00845429|Adults
1280431|NCT00845416|TREC
1280432|NCT00845416|T cell
1280433|NCT00845416|Primary Immunodeficiency
1280434|NCT00845416|PID
1280435|NCT00845416|Navajo
1280436|NCT00845416|SCID
1280437|NCT00845403|Hepatitis B carrier
1280438|NCT00845377|Depression
1280439|NCT00845377|Aging
1280440|NCT00845377|Psychological well-being
1280441|NCT00845377|Psychosocial intervention
1280442|NCT00845364|Perhexiline
1280443|NCT00845364|Coronary artery bypass
1280444|NCT00845364|Myocardial reperfusion injury
1280445|NCT00845364|Cardiac output, low
1280446|NCT00845364|Troponin
1280447|NCT00845351|Cushing's
1280448|NCT00845338|Darifenacin
1280449|NCT00845338|Multiple Sclerosis
1280450|NCT00845338|Open Label Study
1280451|NCT00845325|Carpal tunnel release
1280452|NCT00845325|Rehabilitation
1280453|NCT00845325|Early motion
1280454|NCT00845312|Age
1280455|NCT00845312|Mortality
1280456|NCT00845299|glaucoma
1280457|NCT00845299|ocular hypertension
1280458|NCT00845286|exercise, myocardial dysfunction, endothelial dysfunction,
1280459|NCT00845286|polymorphism
1280460|NCT00845273|Subfoveal choroidal neovascularization secondary to age-related macular degeneration
1280461|NCT00845247|Case Management
1280462|NCT00845234|behavioral intervention
1280463|NCT00845234|implantable cardioverter defibrillator
1280464|NCT00845234|psychosocial education
1280465|NCT00845234|anxiety
1280466|NCT00845234|depression
1280467|NCT00845208|Network Support
1280468|NCT00845208|AA
1280469|NCT00845208|Contingency Management
1280470|NCT00845195|Rhinitis
1280471|NCT00845195|Allergy
1280472|NCT00845195|Nasal Spray
1280473|NCT00845195|Antihistamine
1280474|NCT00845195|Intranasal Corticosteroid
1280475|NCT00845182|Type 2 diabetes pathogenesis, thiazolidinediones
1280476|NCT00845182|impaired glucose tolerance
1280477|NCT00845182|Incretins
1280478|NCT00845182|Insulin secretion
1280479|NCT00845169|Air Pollution
1280480|NCT00845169|Nitric Oxide
1280481|NCT00845169|Nitric Oxide Synthase
1280482|NCT00845169|Diesel exhaust
1280483|NCT00845169|endothelial dysfunction
1280484|NCT00845156|Diabetes
1280485|NCT00845156|Insulin resistance
1280486|NCT00845156|healthy controls
1280487|NCT00845156|anti oxidants
1280488|NCT00845143|Non-small cell lung cancer
1280489|NCT00845143|surgery
1280490|NCT00845143|lung function
1280491|NCT00845130|Diabetes
1280492|NCT00845130|MR imaging
1280493|NCT00845130|Vitamin C
1280494|NCT00845117|Aniridia,
1280495|NCT00845117|Steven Johnsons Syndrome,
1280496|NCT00845117|Ocular burns,
1280497|NCT00845117|Pterygium
1280498|NCT00845091|Parasympathetic activity
1280499|NCT00845091|Exercise
1280500|NCT00845091|Education
1280501|NCT00845091|Arrhythmias
1280502|NCT00845091|Defibrillators, Implantable
1280503|NCT00845078|Breast
1280504|NCT00845078|Radiotherapy
1280505|NCT00845078|Esthetics
1280506|NCT00845078|Treatment Outcome
1280507|NCT00845078|Reconstructive Surgical Procedures
1280508|NCT00845052|Housestaff
1280509|NCT00845052|Patient Safety
1280510|NCT00845052|Patient Care
1280511|NCT00845052|Focus of Study: To assess safety climate amongst housestaff
1280512|NCT00845039|Tumors
1280513|NCT00845039|Antibodies, Monoclonal
1280514|NCT00845039|Colorectal Neoplasms
1280515|NCT00845039|Metastatic K-RAS Wild-Type Carcinoma of the Colon or Rectum
1280516|NCT00845013|HIV infection
1280517|NCT00845013|pulmonary hypertension
1280518|NCT00845013|endothelial function
1280519|NCT00845013|antiretroviral medication
1280520|NCT00845013|Treatment Experienced
1280521|NCT00844987|PDGF
1280522|NCT00844987|HGF
1280523|NCT00844987|VEGF
1280524|NCT00844987|ACS
1280525|NCT00844987|markers of myocardial injury
1280526|NCT00844987|Vascular Endothelial Growth Factor
1280527|NCT00844987|Hepatocyte Growth Factor
1280528|NCT00844987|Platelet Derived Growth Factor
1280529|NCT00844987|Strategies in ACS
1280530|NCT00844961|IBS
1280531|NCT00844961|CBT
1280532|NCT00844961|Internet treatment
1280533|NCT00844961|Cognitive behavior therapy
1280534|NCT00844948|Depression
1280535|NCT00844935|Heart rate variability, mechanical ventilation, weaning,
1280536|NCT00844935|spontaneous breathing trial
1280537|NCT00844909|CNTO 136
1280538|NCT00844909|safety
1280539|NCT00844909|pharmacokinetics
1280540|NCT00844909|healthy Japanese
1280541|NCT00844909|healthy Caucasian
1280542|NCT00844909|Phase I
1280543|NCT00844909|antibody
1280544|NCT00844909|male.
1280545|NCT00844896|Pathological stress & PTSD in preschool children & parents
1280546|NCT00844896|Child and parent resilience after burn trauma
1280547|NCT00844883|primary liver cancer
1280548|NCT00844883|sorafenib
1280549|NCT00844883|Nexavar
1280550|NCT00844883|doxorubicin
1280551|NCT00844883|drug eluting beads
1280552|NCT00844883|transarterial chemoembolization
1280553|NCT00844870|rehabilitation, reaching, stroke
1280554|NCT00844857|Bipolar I Depression
1280555|NCT00844844|aHUS
1280556|NCT00844831|Constipation
1280557|NCT00844831|small intestinal bacterial overgrowth
1280558|NCT00844831|stool bacteria
1280559|NCT00844818|smoking cessation
1280560|NCT00844818|parents
1280561|NCT00844792|Male Urogenital Diseases
1280562|NCT00844792|Antioxidants
1280563|NCT00844792|Vitamin E
1280564|NCT00844792|Vitamin D
1280565|NCT00844792|Lycopene
1280566|NCT00844792|Selenium
1280567|NCT00844779|Metabolic syndrome- hepatic steatosis- steatohepatitis - gene expression
1280568|NCT00844779|Non alcoholic fatty liver disease (NFALD)
1280569|NCT00844766|Lactose intolerance
1280570|NCT00844766|Lactose
1280571|NCT00844766|Home-screening test
1280572|NCT00844766|Validate
1280573|NCT00844753|Autism
1280574|NCT00844753|PDD NOS
1280575|NCT00844753|Attention Deficit Hyperactivity Disorder
1280576|NCT00844753|Parent Management Training
1280577|NCT00844740|Familial hypophosphatemic rickets
1280578|NCT00844740|Cinacalcet
1280579|NCT00844740|hyperparathyroidism
1280580|NCT00844714|endothelial function
1280581|NCT00844714|rheumatoid arthritis
1280582|NCT00844714|cardiovascular risk
1280583|NCT00844714|rituxan therapy
1280584|NCT00844701|nicotine
1280585|NCT00844701|addiction
1280586|NCT00844701|fMRI
1280587|NCT00844701|neuroimaging
1280588|NCT00844701|neurobiology
1280589|NCT00844701|craving
1280590|NCT00844688|Hepatocellular Carcinoma
1280591|NCT00844688|Sorafenib
1280592|NCT00844688|Gemcitabine
1280593|NCT00844675|endoscopic mucosal resection
1280594|NCT00844675|Proton Pump Inhibitor
1280595|NCT00844675|gastrointestinal hemorrhage
1280596|NCT00844675|rabeprazole
1280597|NCT00844662|Hyperphosphataemia
1280598|NCT00844662|phosphate binder
1280599|NCT00844636|Needlestick injuries
1280600|NCT00844636|Glove perforations
1280601|NCT00844636|Blunt Needles
1280602|NCT00844636|Glove perforations of surgeons, assistants
1280603|NCT00844636|Needlestick injuries of same
1280604|NCT00844623|primary liver cancer, hepatoma
1280605|NCT00844584|Atrial fibrillation
1280606|NCT00844584|radiofrequency
1280607|NCT00844584|totally thoracoscope
1280608|NCT00844584|epicardial
1280609|NCT00844571|child abuse and neglect
1280610|NCT00844571|child maltreatment
1280611|NCT00844571|non accidental injury
1280612|NCT00844571|training
1280613|NCT00844571|educational program
1280614|NCT00844558|osteoarthritis
1280615|NCT00844558|knee pain
1280616|NCT00844558|gait training
1280617|NCT00844558|power training
1280618|NCT00844558|rehabilitation
1280619|NCT00844558|physical therapy
1280620|NCT00844545|aHUS
1280621|NCT00844532|Atherosclerosis
1280622|NCT00844532|Peripheral artery disease
1280623|NCT00844532|Peripheral vascular disease
1280624|NCT00844532|PAD
1280625|NCT00844532|Claudication
1280626|NCT00844532|Peripheral Arterial Occlusive Disease
1280627|NCT00844532|Stent
1280628|NCT00844532|PAOD
1280629|NCT00844532|PVD
1280630|NCT00844519|Treatment Experienced
1280631|NCT00844519|CCR5 receptor
1280632|NCT00844519|maraviroc
1280633|NCT00844506|Ovarian cancer patients with recurrent disease
1280634|NCT00844493|diarrhea
1280635|NCT00844493|vaccine
1280636|NCT00844493|enterotoxigenic E coli
1280637|NCT00844493|colonization factor antigen
1280638|NCT00844493|volunteer study
1280639|NCT00844480|spinal cord injury
1280640|NCT00844480|osteoporosis
1280641|NCT00844480|bone loss
1280642|NCT00844480|zoledronic acid
1280643|NCT00844480|bisphosphonate
1280644|NCT00844467|Risk factors
1280645|NCT00844467|Case fatality
1280646|NCT00844467|disease burden
1280647|NCT00844467|Resistance
1280648|NCT00844467|Benefits of pneumococcal vaccination
1280649|NCT00844454|hepatocellular carcinoma
1280650|NCT00844454|PEI
1280651|NCT00844454|RF ablation
1280652|NCT00844454|tumor ablation
1280653|NCT00844441|de novo myelodysplastic syndromes
1280654|NCT00844441|previously treated myelodysplastic syndromes
1280655|NCT00844441|secondary myelodysplastic syndromes
1280656|NCT00844441|recurrent adult acute myeloid leukemia
1280657|NCT00844441|untreated adult acute myeloid leukemia
1280658|NCT00844441|adult acute myeloid leukemia with inv(16)(p13;q22)
1280659|NCT00844441|adult acute myeloid leukemia with t(16;16)(p13;q22)
1280660|NCT00844441|adult acute myeloid leukemia with t(8;21)(q22;q22)
1280661|NCT00844441|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1280662|NCT00844441|adult acute minimally differentiated myeloid leukemia (M0)
1280663|NCT00844441|adult acute myeloblastic leukemia without maturation (M1)
1280664|NCT00844441|adult acute myeloblastic leukemia with maturation (M2)
1280665|NCT00844441|adult acute myelomonocytic leukemia (M4)
1280666|NCT00844441|adult acute monoblastic leukemia (M5a)
1280667|NCT00844441|adult acute eosinophilic leukemia
1280668|NCT00844441|adult acute monocytic leukemia (M5b)
1280669|NCT00844441|adult acute megakaryoblastic leukemia (M7)
1280670|NCT00844441|adult acute basophilic leukemia
1280671|NCT00844441|acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
1280672|NCT00844441|adult erythroleukemia (M6a)
1280673|NCT00844441|adult pure erythroid leukemia (M6b)
1280674|NCT00844402|Cholestasis
1280675|NCT00844402|Atherosclerosis
1280676|NCT00844402|Statins
1280677|NCT00844402|Vascular function
1280678|NCT00844389|Open Angle Glaucoma
1280679|NCT00844389|Biophotomodulation
1280680|NCT00844389|Near to Infrared light stimulation
1280681|NCT00844389|Neuroprotection
1280682|NCT00844376|Cardiovascular Diseases
1280683|NCT00844350|Oxytocin
1280684|NCT00844350|Letrozole
1280685|NCT00844350|Induction of ovulation
1280686|NCT00844337|antibiotic regimens
1280687|NCT00844337|sepsis
1280688|NCT00844337|young infants
1280689|NCT00844337|Bangladeshi
1280690|NCT00844337|outpatient treatment
1280691|NCT00844337|Suspected sepsis in young infants
1280692|NCT00844324|Candesartan
1280693|NCT00844324|Bioequivalence
1280694|NCT00844311|hCG
1280695|NCT00844311|human chorionic gonadotropin
1280696|NCT00844298|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
1280697|NCT00844298|untreated adult acute lymphoblastic leukemia
1280698|NCT00844285|Certolizumab Pegol, Cimzia ®
1280699|NCT00844285|Crohn's Disease
1280700|NCT00844272|Opiate Dependence
1280701|NCT00844272|Chronic Hepatitis C
1280702|NCT00844259|Down syndrome
1280703|NCT00844259|Pragmatics
1280704|NCT00844259|Language Development
1280705|NCT00844246|Developmental delays
1280706|NCT00844246|Early intervention services
1280707|NCT00844220|Suspected coronary artery disease
1280708|NCT00844207|Bioavailability
1280709|NCT00844155|Prevention or treatment of influenza in ventilated patients
1280710|NCT00844142|ankylosing spondylitis
1280711|NCT00844142|axial spondyloarthritis
1280712|NCT00844142|magnetic resonance imaging
1280713|NCT00844142|etanercept
1280714|NCT00844142|sulfasalazine
1280715|NCT00844129|neurofibromatosis type 1
1280716|NCT00844129|spinal abnormalities
1280717|NCT00844129|scoliosis
1280718|NCT00844116|COPD
1280719|NCT00844116|spirometry
1280720|NCT00844116|Telematic spirometry
1280721|NCT00844103|Volunteer
1280722|NCT00844103|Safety
1280723|NCT00844103|Tolerability
1280724|NCT00844103|AZD8566
1280725|NCT00844090|Apathy
1280726|NCT00844090|Diabetes
1280727|NCT00844090|Self-care behaviors
1280728|NCT00844077|Barrett's Intestinal Metaplasia
1280729|NCT00844064|Pancreatic cancer
1280730|NCT00844064|Metastatic melanoma
1280731|NCT00844064|Advanced tumor
1280732|NCT00844064|Targeted therapy
1280733|NCT00844064|Antisense
1280734|NCT00844064|Transforming Growth Factor beta 2
1280735|NCT00844064|Dose escalation
1280736|NCT00844051|Influenza
1280737|NCT00844051|influenza vaccination
1280738|NCT00844051|school-based vaccination
1280739|NCT00844038|Steven-Johnson syndrome
1280740|NCT00844038|erythema multiform
1280741|NCT00844038|autoimmune disease
1280742|NCT00844025|Adverse drug reaction
1280743|NCT00844025|Inappropriate medication
1280744|NCT00844025|Pharmacist
1280745|NCT00844025|Pharmaceutical care
1280746|NCT00843986|hyponatremia
1280747|NCT00843986|euvolemic hyponatremia
1280748|NCT00843986|hypervolemic hyponatremia
1280749|NCT00843986|acute decompensated heart failure
1280750|NCT00843986|conivaptan
1280751|NCT00843986|Vaprisol
1280754|NCT00843934|Carcinoma, Hepatocellular
1280755|NCT00843934|Trans arterial chemoembolization
1280756|NCT00843934|Epirubicin
1280757|NCT00843934|Cisplatin
1280758|NCT00843921|Hyperammonemia
1280759|NCT00843908|Stress incontinence
1280760|NCT00843908|Surgical Treatments
1280761|NCT00843908|Minislings
1280762|NCT00843895|Laboratory based study
1280763|NCT00843895|antibiotic susceptibilty
1280764|NCT00843895|invasive strains
1280765|NCT00843843|Circadian Rhythms
1280766|NCT00843817|cystic fibrosis
1280767|NCT00843804|nosocomial infection
1280768|NCT00843804|bloodstream infection
1280769|NCT00843804|central venous catheter
1280770|NCT00843804|invasive Aspergillosis
1280771|NCT00843804|Clostridium difficile associated disease
1280772|NCT00843791|obesity
1280773|NCT00843778|Rheumatoid Arthritis
1280774|NCT00843778|Moderate to Low Disease Activity
1280775|NCT00843778|Certolizumab Pegol
1280776|NCT00843765|Stroke
1280777|NCT00843765|Traditional Chinese Medicine
1280778|NCT00843765|Rehabilitation
1280779|NCT00842673|Dementia
1280780|NCT00842673|Alzheimer Type Senile Dementia
1280781|NCT00842673|Cognitive impairment
1280782|NCT00842660|Cervical cancer
1280783|NCT00842660|concurrent chemoradiotherapy
1280784|NCT00842660|gemcitabine
1280785|NCT00842647|Sensitivity
1280786|NCT00842647|specificity
1280787|NCT00842647|positive rate
1280788|NCT00842647|negative rate
1280789|NCT00842634|HIV
1280790|NCT00842634|Treatment Experienced
1280791|NCT00842621|Sickle Cell Disease, Hemolytic Anemia
1280792|NCT00842621|Hemolysis
1280793|NCT00842608|confusion
1280794|NCT00842608|dementia
1280795|NCT00842595|relapsed aggressive B-cell lymphoma
1280796|NCT00842595|Chemotherapy
1280797|NCT00842582|Ovarian cancer
1280798|NCT00842582|chemotherapy
1280799|NCT00842582|azacitidine
1280800|NCT00842569|obesity
1280801|NCT00842569|cognitive process
1280802|NCT00842569|reward
1280803|NCT00842569|P300
1280804|NCT00842569|ERP
1280805|NCT00842569|Event-related potential during oddball paradigm
1280806|NCT00842569|brain electrophysiological patterns
1280807|NCT00842569|externalizing factor
1280808|NCT00843739|Breathing
1280809|NCT00843739|Cough
1280810|NCT00843739|Speech
1280811|NCT00843739|Swallow
1280812|NCT00843739|Parkinson's disease
1280813|NCT00843726|stage I non-small cell lung cancer
1280814|NCT00843726|stage II non-small cell lung cancer
1280815|NCT00843713|HIV
1280816|NCT00843713|endothelium
1280817|NCT00843713|inflammation
1280818|NCT00843713|Treatment Experienced
1280819|NCT00843687|Schizophrenia
1280820|NCT00843687|Risperidone
1280821|NCT00843687|Long-acting injectable
1280822|NCT00843687|Intramuscular injection
1280823|NCT00843687|Pharmacokinetics
1280824|NCT00843661|Treatment Experienced
1280825|NCT00843648|antibody immune profile
1280826|NCT00843648|preterm
1280827|NCT00843648|c-section
1280828|NCT00843648|breastfeeding
1280829|NCT00843635|stage I squamous cell carcinoma of the lip and oral cavity
1280830|NCT00843635|stage I squamous cell carcinoma of the oropharynx
1280831|NCT00843635|stage II squamous cell carcinoma of the lip and oral cavity
1280832|NCT00843635|stage II squamous cell carcinoma of the oropharynx
1280833|NCT00843635|stage III squamous cell carcinoma of the oropharynx
1280834|NCT00843635|stage III squamous cell carcinoma of the lip and oral cavity
1280835|NCT00843635|stage IV squamous cell carcinoma of the oropharynx
1280836|NCT00843635|stage IV squamous cell carcinoma of the lip and oral cavity
1280837|NCT00843635|stage I verrucous carcinoma of the oral cavity
1280838|NCT00843635|stage II verrucous carcinoma of the oral cavity
1280839|NCT00843635|stage III verrucous carcinoma of the oral cavity
1280840|NCT00843635|stage IV verrucous carcinoma of the oral cavity
1280841|NCT00843622|Smoking
1280842|NCT00843622|Smoking cessation
1280843|NCT00843622|Smokeless tobacco
1280844|NCT00843622|Snus
1280845|NCT00843609|diabetes mellitus, type 1
1280846|NCT00843609|hypoglycemia
1280847|NCT00843609|continuous glucose monitoring
1280848|NCT00843609|HbA1c
1280849|NCT00843609|glycemic variability
1280850|NCT00843596|cardiac surgery requiring ECC
1280851|NCT00843583|prevalence
1280852|NCT00843583|obstructive sleep apnea
1280853|NCT00843583|resistant hypertension
1280854|NCT00843570|IVF
1280855|NCT00843570|Frozen Embryo Replacement
1280856|NCT00843557|critical illness
1280857|NCT00843557|intensive care
1280858|NCT00843557|nosocomial infection
1280859|NCT00843531|neuroendocrine
1280860|NCT00843531|islet cell
1280861|NCT00843531|carcinoid
1280862|NCT00843531|pancreatic neuroendocrine
1280863|NCT00843531|paraganglioma
1280864|NCT00843531|pheochromocytoma
1280865|NCT00843531|RAD001
1280866|NCT00843531|everolimus
1280867|NCT00843531|erlotinib
1280868|NCT00843531|Tarceva
1280869|NCT00843518|Agitation and Aggression
1280870|NCT00843505|Smoking Cessation
1280871|NCT00843505|Motivational Interviewing
1280872|NCT00843505|Quitline
1280873|NCT00843505|Telemedicine
1280874|NCT00843505|Stop Smoking Medication
1280875|NCT00843492|deep vein thrombosis
1280876|NCT00843492|immobilization
1280877|NCT00843492|nadroparin
1280878|NCT00843492|isolated lower-extremity injuries distal to the knee
1280879|NCT00843492|plaster cast
1280880|NCT00843492|non-surgical leg injury
1280881|NCT00843492|venous thromboembolism
1280882|NCT00843492|bleeding events
1280883|NCT00843492|fondaparinux
1280884|NCT00843479|diabetes mellitus, type 2
1280885|NCT00843479|Insulin resistance
1280886|NCT00843479|Aging
1280887|NCT00843479|Incretins
1280888|NCT00843479|DPP-IV protein, human
1280889|NCT00843479|Glucagon-Like Peptide 1
1280890|NCT00843479|Gastric Inhibitory Polypeptide
1280891|NCT00843479|insulin
1280892|NCT00843479|glucagon
1280893|NCT00843479|ghrelin
1280894|NCT00843466|Hand dermatitis
1280895|NCT00843453|vitamin B12 deficiency
1280896|NCT00843453|cyanocobalamin deficiency
1280897|NCT00843453|proton pump inhibitors
1280898|NCT00843453|omeprazole
1280899|NCT00843440|Antiangiogenic therapies
1280900|NCT00843440|Bevacuzimab
1280901|NCT00843440|Hemorrhagic Hereditary Telangiectasia (HHT) with severe liver involvement
1280902|NCT00843427|aphasia
1280903|NCT00843427|stroke
1280904|NCT00843427|functional magnetic resonance imaging
1280905|NCT00843427|fMRI
1280906|NCT00843427|language recovery after stroke
1280907|NCT00843427|constraint-induced aphasia therapy
1280908|NCT00843427|CIAT
1280909|NCT00843414|Emphysema
1280910|NCT00843414|Sarcoidosis
1280911|NCT00843414|Interstitial Pulmonary Fibrosis
1280912|NCT00843401|Low oxygen saturation
1280913|NCT00843401|Anticipated need for pulse oximetry monitoring
1280914|NCT00843401|Arterial line in place as indicated per patient's clinical management needs
1280915|NCT00843401|Availability to analyze arterial blood saturation by Co-Oximeter or
1280916|NCT00843401|Blood Gas Analyzer
1280917|NCT00843349|Phosphorus
1280918|NCT00843349|Fibroblast Growth Factor-23
1280919|NCT00843349|Kidney Disease
1280920|NCT00843336|fertility monitoring
1280921|NCT00843336|contraception
1280922|NCT00843310|multiple myeloma
1280923|NCT00843310|frontline treatment
1280924|NCT00843310|first-line treatment
1280925|NCT00843297|Sudden Cardiac Arrest
1280926|NCT00843297|Hypothermia
1280927|NCT00843297|Outcome, neurological
1280928|NCT00843297|Coolgard
1280929|NCT00843297|ArcticSun
1280930|NCT00843284|neuropathic, pain, pregabalin, Lyrica
1280931|NCT00843271|COPD MESA LUNG BIOMARKERS
1280932|NCT00843258|therapy
1280933|NCT00843258|ultrasound
1280934|NCT00843258|mild dysplasia
1280935|NCT00843245|Heart Failure
1280936|NCT00843245|Electric bioimpedance
1280937|NCT00843245|Body composition
1280938|NCT00843245|Diagnosis
1280939|NCT00843245|monitoring
1280940|NCT00843245|Prognosis
1280941|NCT00843245|Total body water
1280942|NCT00843232|diabetes mellitus, type 2
1280943|NCT00843232|Insulin resistance
1280944|NCT00843232|Aging
1280945|NCT00843232|Incretins
1280946|NCT00843232|DPP-IV protein, human
1280947|NCT00843232|Glucagon-Like Peptide 1
1280948|NCT00843232|Gastric Inhibitory Polypeptide
1280949|NCT00843232|insulin
1280950|NCT00843232|glucagon
1280951|NCT00843232|ghrelin
1280952|NCT00843219|Lung
1280953|NCT00843219|Lung Cancer
1280954|NCT00843219|Non-small cell Lung Cancer
1280955|NCT00843219|NSCLC
1280956|NCT00843219|Motion Correction
1280957|NCT00843219|PET/CT Scan
1280958|NCT00843219|PET
1280959|NCT00843219|Positron Emission Tomography
1280960|NCT00843219|CT
1280961|NCT00843219|Computed Tomography
1280962|NCT00843219|Amplitude Gating
1280963|NCT00843193|Asthma
1280964|NCT00843193|Asthma control questionnaire
1280965|NCT00843180|Bone Marrow Transplant
1280966|NCT00843180|Massage
1280967|NCT00843180|Pediatric Oncology
1280968|NCT00843180|children undergoing bone marrow transplantation
1280969|NCT00843167|mammography
1280970|NCT00843167|biopsy
1280971|NCT00843167|ductal breast carcinoma in situ
1280972|NCT00843167|atypical ductal breast hyperplasia
1280973|NCT00843154|Natriuretic Peptide, Brain
1280974|NCT00843154|Biological Markers
1280975|NCT00843154|Biomarkers
1280976|NCT00843154|Cardiac Failure
1280977|NCT00843154|Congestive Heart Failure
1280978|NCT00843154|Heart Decompensation
1280979|NCT00843154|Drug Therapy
1280980|NCT00843141|ADHD
1280981|NCT00843141|Executive functions
1280982|NCT00843141|Quality of life
1280983|NCT00843115|Alzheimer's Disease, naturalistic study
1280984|NCT00843102|atherosclerosis
1280985|NCT00843102|pulmonary hypertension
1280986|NCT00843089|coronary artery disease
1280987|NCT00843089|CABG
1280988|NCT00843063|pantoprazole
1280989|NCT00843063|famotidine
1280990|NCT00843063|aspirin
1280991|NCT00843063|dyspepsia
1280992|NCT00843063|gastrointestinal bleeding
1280993|NCT00843063|peptic ulcer / erosion
1280994|NCT00843050|CKD inhibitor
1280995|NCT00843050|Mantle Cell Lymphoma
1280996|NCT00843037|PARAGANGLIOMA
1280997|NCT00843037|PHEOCHROMOCYTOMA
1280998|NCT00843037|SUNITINIB
1280999|NCT00843037|PHASE II
1281000|NCT00843037|Metastatic or locally advanced malignant paraganglioma
1281001|NCT00843037|Metastatic or locally advanced malignant pheochromocytoma
1281002|NCT00843024|Migraine with or without aura
1281003|NCT00843024|Migraine efficacy
1281004|NCT00843024|Migraine
1281005|NCT00843024|Migraine headache
1281006|NCT00843024|Adolescent migraine
1281007|NCT00843024|TREXIMET
1281008|NCT00843024|Sumatriptan succinate
1281009|NCT00843024|Naproxen sodium
1281010|NCT00843024|Migraine, acute
1281011|NCT00843011|NK1 antagonist
1281012|NCT00843011|effect of food
1281013|NCT00843011|safety and tolerability
1281014|NCT00843011|pharmacokinetics
1281015|NCT00843011|formulation
1281016|NCT00842998|breast cancer
1281017|NCT00842998|HER2
1281018|NCT00842998|Trastuzumab
1281019|NCT00842998|Lapatinib
1281020|NCT00842998|HER2 gene-amplification
1281021|NCT00842985|Cannabis Abuse
1281022|NCT00842985|Cannabis Dependence
1281023|NCT00842985|Cannabis-Related Disorder
1281024|NCT00842985|Marijuana Dependence
1281025|NCT00842985|Marihuana Abuse
1281026|NCT00842959|Improvement of adjustment accuracy of intraocular lenses and imaging quality
1281027|NCT00842933|Septic shock
1281028|NCT00842933|Acute adrenal insufficiency
1281029|NCT00842920|amnestic MCI
1281030|NCT00842907|Brazil
1281031|NCT00842907|isotretinoin
1281032|NCT00842907|photodamage
1281033|NCT00842907|photoaging
1281034|NCT00842881|Healingstone
1281035|NCT00842868|atherosclerosis
1281036|NCT00842868|contrast induced nephropathy
1281037|NCT00842868|renal impairment
1281038|NCT00842868|catheterization
1281039|NCT00842855|GERD
1281040|NCT00842855|PPI
1281041|NCT00842855|partial responders
1281042|NCT00842842|surgical fixation devices
1281043|NCT00842842|postoperative pain
1281044|NCT00842842|ventral hernia
1281045|NCT00842842|fibrin tissue adhesive
1281046|NCT00842842|laparoscopy
1281047|NCT00842842|quality of life
1281048|NCT00842842|fatigue
1281049|NCT00842829|Breakthrough Cancer Pain
1281050|NCT00842816|Dementia
1281051|NCT00842816|Alzheimer Type Senile Dementia
1281052|NCT00842816|Cognitive impairment
1281053|NCT00842803|Liver
1281054|NCT00842803|transplant
1281055|NCT00842803|albumin
1281056|NCT00842803|outcome
1281057|NCT00842803|Liver transplant recipients canadian transplant status 1 or 2
1281058|NCT00842790|Carcinoma, Renal Cell [C04.557.470.200.025.390]
1281059|NCT00842790|Angiogenesis Inhibitors [D27.505.954.248.025]
1281060|NCT00842790|Tomography Scanners, X-Ray Computed [E07.913]
1281061|NCT00842790|Magnetic Resonance Imaging [E01.370.350.825.500]
1281062|NCT00842790|Diffusion Magnetic Resonance Imaging [E01.370.350.825.500.150]
1281063|NCT00842790|Perfusion [E05.680]
1281064|NCT00842777|Childhood obesity
1281065|NCT00842777|Quality of life
1281066|NCT00842777|Self-esteem
1281067|NCT00842777|BMI
1281068|NCT00842777|parental group treatment
1281069|NCT00842777|Body image
1281070|NCT00842764|eyelid fat pads
1281071|NCT00842751|5α-reductase
1281072|NCT00842751|androgen
1281073|NCT00842751|dihydrotestosterone (DHT)
1281074|NCT00842751|drug delivery
1281075|NCT00842751|oestradiol
1281076|NCT00842738|Screening
1281077|NCT00842738|Cervical cancer
1281078|NCT00842738|Cervical dysplasia
1281079|NCT00842738|Adverse psychosocial effects
1281080|NCT00842738|Alternative treatment
1281081|NCT00842712|First-line treatment for subjects with advanced NSCLC,
1281082|NCT00842712|integrin receptor antagonist, EGFR chimerized monoclonal antibody, chemotherapy
1281083|NCT00842712|safety run-in + randomization part, MTD, PFS, Overall survival time, best overall response
1281084|NCT00842686|rectal cancer
1281085|NCT00842686|capecitabine
1281086|NCT00842686|bevacizumab
1281087|NCT00842686|radiotherapy
1281088|NCT00842543|Nutrition
1281089|NCT00842543|Oxidative Stress
1281090|NCT00842543|Insulin Resistance
1281091|NCT00842543|Whole Food Supplement
1281092|NCT00842543|Pediatric
1281093|NCT00842543|Retinoids
1281094|NCT00842543|Antioxidants
1281095|NCT00842543|Dietary Supplements
1281096|NCT00842530|Dengue virus
1281097|NCT00842530|Dengue fever
1281098|NCT00842530|Dengue hemorrhagic fever
1281099|NCT00842530|Dengue diseases
1281100|NCT00842530|Dengue vaccine
1281101|NCT00842517|Cocaine Dependence
1281102|NCT00842517|Cocaine Abuse
1281103|NCT00842517|Substance Abuse
1281104|NCT00842517|Contingency Management
1281105|NCT00842517|Drug Treatment
1281106|NCT00842504|Anti-fungal
1281107|NCT00842504|Immunocompromised
1281108|NCT00842504|Pharmacokinetic
1281109|NCT00842504|Prophylaxis
1281110|NCT00842504|Pharmacokinetics
1281111|NCT00842465|Breast diseases,
1281112|NCT00842465|human mutation,
1281113|NCT00842465|prolactin receptor;
1281114|NCT00842465|breast cancer
1281115|NCT00842452|recurrent ovarian epithelial cancer
1281116|NCT00842452|stage III ovarian epithelial cancer
1281117|NCT00842452|stage IV ovarian epithelial cancer
1281118|NCT00842452|recurrent ovarian germ cell tumor
1281119|NCT00842452|stage III ovarian germ cell tumor
1281120|NCT00842452|stage IV ovarian germ cell tumor
1281121|NCT00842452|recurrent endometrial carcinoma
1281122|NCT00842452|stage III endometrial carcinoma
1281123|NCT00842452|stage IV endometrial carcinoma
1281124|NCT00842452|recurrent uterine sarcoma
1281125|NCT00842452|stage III uterine sarcoma
1281126|NCT00842452|stage IV uterine sarcoma
1281127|NCT00842452|recurrent vaginal cancer
1281128|NCT00842452|stage III vaginal cancer
1281129|NCT00842452|stage IVA vaginal cancer
1281130|NCT00842452|stage IVB vaginal cancer
1281131|NCT00842452|recurrent vulvar cancer
1281132|NCT00842452|stage III vulvar cancer
1281133|NCT00842452|stage IV vulvar cancer
1281134|NCT00842452|recurrent cervical cancer
1281135|NCT00842452|stage III cervical cancer
1281136|NCT00842452|stage IVA cervical cancer
1281137|NCT00842452|stage IVB cervical cancer
1281138|NCT00842452|fallopian tube cancer
1281139|NCT00842452|ovarian sarcoma
1281140|NCT00842452|ovarian stromal cancer
1281141|NCT00842439|aggression
1281142|NCT00842439|Prevention and treatment of youth aggression
1281143|NCT00842426|Diabetes
1281144|NCT00842426|Cardiovascular disease
1281145|NCT00842426|Metabolic syndrome
1281146|NCT00842426|Cardiometabolic
1281147|NCT00842413|Prefrontal cortex
1281148|NCT00842413|visual consciousness
1281149|NCT00842413|focal lesions
1281150|NCT00842413|action perception
1281151|NCT00842400|Obesity
1281152|NCT00842387|gastroesophageal reflux disease
1281153|NCT00842387|reflux, heartburn
1281154|NCT00842387|regurgitation
1281155|NCT00842387|acid control
1281156|NCT00842387|PPI
1281157|NCT00842387|antiacid
1281158|NCT00842387|primary care
1281159|NCT00842387|esophagitis
1281160|NCT00842348|Lanreotide
1281161|NCT00842348|Somatuline
1281162|NCT00842348|Neuroendocrine tumour
1281163|NCT00842348|NET
1281164|NCT00842335|solid tumors
1281165|NCT00842335|angiogenesis inhibitor
1281166|NCT00842335|dose escalation
1281167|NCT00842335|maximum tolerated dose
1281168|NCT00842335|JI-101
1281169|NCT00842322|chronic kidney disease
1281170|NCT00842322|transplantation
1281171|NCT00842322|kidney function
1281172|NCT00842322|fluid intake
1281173|NCT00842322|osmolarity
1281174|NCT00842296|GSV
1281175|NCT00842296|RadioFrequency
1281176|NCT00842283|dermatologic diseases
1281177|NCT00842270|severe asthma
1281178|NCT00842270|corticosteroids dependent
1281179|NCT00842270|asthma exacerbation
1281180|NCT00842270|weaning
1281181|NCT00842270|tyrosine kinase inhibitor
1281182|NCT00842270|severe persistent corticosteroid dependent asthma
1281183|NCT00842257|panitumumab
1281184|NCT00842257|cetuximab
1281185|NCT00842257|KRAS wild-type
1281186|NCT00842231|Corneal astigmatism
1281187|NCT00842231|post-cataract surgery
1281188|NCT00842231|visual performance
1281189|NCT00842231|Corneal astigmatism 0.5-0.75 Diopter
1281190|NCT00842218|Gait
1281191|NCT00842218|scoliosis
1281192|NCT00842218|energy
1281193|NCT00842218|mechanics
1281194|NCT00842205|hepatitis C
1281195|NCT00842205|NASH
1281196|NCT00842205|Hem Oxygenase
1281197|NCT00842205|Gene polymorphism
1281198|NCT00842179|Perclose
1281199|NCT00842153|Psoriasis
1281200|NCT00842153|Plaque Type Psoriasis
1281201|NCT00842140|Polycystic ovary syndrome
1281202|NCT00842140|Oral Contraceptives, Hormonal
1281203|NCT00842140|Cardiovascular Disease
1281204|NCT00842140|Endothelium
1281205|NCT00842127|Methylphenidate
1281206|NCT00842127|ADHD
1281207|NCT00842127|Multidrug resistance(MDR)polymorphism
1281208|NCT00842127|OROS methylphenidate
1281209|NCT00842114|Intermediate-high FLIPI score
1281210|NCT00842114|Follicular Lymphoma
1281211|NCT00842114|Progression free survival
1281212|NCT00842101|Intramedullary nails
1281213|NCT00842101|Compartmental syndrome
1281214|NCT00842101|Fractures
1281215|NCT00842075|type 1 diabetes
1281216|NCT00842075|adolescents
1281217|NCT00842075|post prandial glucose
1281218|NCT00842049|Subarachnoid haemorrhage
1281219|NCT00842049|Aneurysm
1281220|NCT00842049|Cerebrospinal fluid drainage
1281221|NCT00842036|Family Therapy
1281222|NCT00842036|Relationship Dysfunction
1281223|NCT00842036|Family Dysfunction
1281224|NCT00842036|Family Relations
1281225|NCT00842036|Stimulant Dependence
1281226|NCT00842036|Opiate Dependence
1281227|NCT00842036|Alcohol Dependence
1281228|NCT00842036|Behavior Therapy
1281229|NCT00842036|Drug Treatment
1281230|NCT00842036|Substance Abuse
1281231|NCT00842036|Drug Addiction
1281232|NCT00842023|Natriuretic peptides
1281233|NCT00842023|BNP
1281234|NCT00842023|Heart Failure
1281235|NCT00842023|Nitoglycerin
1281236|NCT00842023|Biomarkers
1281237|NCT00842010|Diabetes
1281238|NCT00842010|Inpatient
1281239|NCT00842010|Hospital
1281240|NCT00842010|Hyperglycemia
1281241|NCT00841984|Magnetic resonance spectroscopy
1281242|NCT00841984|neurological diseases
1281243|NCT00841984|metabolic
1281244|NCT00841984|inborn errors of metabolism
1281245|NCT00841984|Complex neurological diseases of unknown cause
1281246|NCT00841945|Diffuse B larg cell lymphoma
1281247|NCT00841945|Chemotherapy
1281248|NCT00841945|Radiotherapy
1281249|NCT00841932|Fractional Flow Reserve
1281250|NCT00841932|Without anticoagulation
1281251|NCT00841919|Diabetes
1281252|NCT00841919|Inpatient
1281253|NCT00841919|Insulin
1281254|NCT00841919|Insulin pen
1281255|NCT00841893|Thermogenesis
1281256|NCT00841893|Meal-induced thermogenesis
1281257|NCT00841893|Energy expenditure
1281258|NCT00841893|Fat oxidation
1281259|NCT00841893|Carbohydrate oxidation
1281260|NCT00841893|Bioactive ingredient
1281261|NCT00841893|Spice
1281262|NCT00841867|Impaired Glucose Tolerance
1281263|NCT00841867|Diabetes
1281264|NCT00841854|Helicobacter pylori
1281265|NCT00841854|Bismuth
1281266|NCT00841854|Salvage treatment
1281267|NCT00841854|Metronidazole
1281268|NCT00841841|Analgesia
1281269|NCT00841841|molar third
1281270|NCT00841841|acetaminophen
1281271|NCT00841841|dipyrone
1281272|NCT00841815|Bioequivalence
1281273|NCT00841815|Healthy Subjects
1281274|NCT00841802|Chronic sinusitis
1281275|NCT00841802|Chronic rhinosinusitis
1281276|NCT00841802|Nasal polyps
1281277|NCT00841789|Etanercept
1281278|NCT00841776|Acne Vulgaris
1281279|NCT00841776|Acne
1281280|NCT00841763|virus
1281281|NCT00841763|pandemic influenza
1281282|NCT00841763|vaccine
1281283|NCT00841750|Chest Tubes
1281284|NCT00841750|Thoracic Surgery, Video-Assisted
1281285|NCT00841750|Lung Diseases, Interstitial
1281286|NCT00841750|Pulmonary Nodule, Solitary
1281287|NCT00841737|Depressive Disorders;
1281288|NCT00841737|Primary Health Care;
1281289|NCT00841737|Nurses;
1281290|NCT00841737|Health education.
1281291|NCT00841724|Allogeneic stem cell transplantation
1281292|NCT00841724|Reduced-intensity conditioning
1281293|NCT00841724|Reduced-toxicity conditioning
1281294|NCT00841724|Hematological malignancies
1281295|NCT00841724|IV Busulfan
1281296|NCT00841711|HIV
1281297|NCT00841711|AIDS
1281298|NCT00841711|Buprenorphine
1281299|NCT00841711|Intensive Case Management
1281300|NCT00841711|Money Management
1281301|NCT00841711|Rapid Testing
1281302|NCT00841711|Substance Abuse
1281303|NCT00841711|Opioid Dependance
1281304|NCT00841711|Inmate Population
1281305|NCT00841698|Bioequivalence
1281306|NCT00841698|Healthy Subjects
1281307|NCT00841672|Hypertension
1281308|NCT00841672|systolic blood pressure
1281309|NCT00841672|cardiovascular disease
1281310|NCT00841672|aliskiren
1281311|NCT00841672|amlodipine
1281312|NCT00841659|Bioequivalence
1281313|NCT00841659|Healthy Subjects
1281314|NCT00841646|Influenza vaccine
1281315|NCT00841633|subarachnoid hemorrhage
1281316|NCT00841633|ischemia
1281317|NCT00841633|vasospasm
1281318|NCT00841633|CT
1281319|NCT00841633|perfusion
1281320|NCT00841633|induced hypertension
1281321|NCT00841633|delayed cerebral ischemia
1281322|NCT00841620|Symptoms
1281323|NCT00841620|Postoperative pain
1281324|NCT00841620|Postoperative complications
1281325|NCT00841620|Milligan
1281326|NCT00841620|Anopxy
1281327|NCT00841607|whipple
1281328|NCT00841607|pancreas
1281329|NCT00841607|reconstruction
1281330|NCT00841607|leak
1281331|NCT00841607|fistula
1281332|NCT00841594|healthy volunteers
1281333|NCT00841581|Age Related Macular Degeneration
1281334|NCT00841581|Pigment Epithelial Detachment
1281335|NCT00841581|Intravitreal Detachment
1281336|NCT00841581|Anti-VEGF
1281337|NCT00841568|ADPKD
1281338|NCT00841568|Tolvaptan
1281339|NCT00841555|adult giant cell glioblastoma
1281340|NCT00841555|adult gliosarcoma
1281341|NCT00841555|adult anaplastic astrocytoma
1281342|NCT00841555|adult glioblastoma
1281343|NCT00841555|GBM/AA
1281344|NCT00841542|Bioequivalence
1281345|NCT00841542|Healthy Subjects
1281346|NCT00841529|left atrial appendage
1281347|NCT00841529|LAA
1281348|NCT00841529|atrial fibrillation
1281349|NCT00841529|AF
1281350|NCT00841516|Specific immunotherapy
1281351|NCT00841516|SIT
1281352|NCT00841516|SCIT
1281353|NCT00841516|recombinant
1281354|NCT00841516|Type 1 - Allergy
1281355|NCT00841503|functional food study
1281356|NCT00841490|Helicobacter pylori
1281357|NCT00841490|Oral Health
1281358|NCT00841490|Intellectually & Developmentally Disabled
1281359|NCT00841477|druguser,HB vaccine adherence, HBV, HCV, HIV incidence
1281360|NCT00841464|Parkinson's disease
1281361|NCT00841464|Transcranial Magnetic Stimulation
1281362|NCT00841451|Atrial Fibrillation
1281363|NCT00841451|Persistent
1281364|NCT00841451|Paroxysmal
1281365|NCT00841451|Pulmonary Vein isolation
1281366|NCT00841451|Omega three fatty acids
1281367|NCT00841451|Fish Oils
1281368|NCT00841438|Angioplasty
1281369|NCT00841438|Transluminal
1281370|NCT00841438|Percutaneous Coronary
1281371|NCT00841412|Usual Care Control Group
1281372|NCT00841399|Breast cancer
1281373|NCT00841386|Cornea
1281374|NCT00841386|Keratoconus
1281375|NCT00841386|Ectasia
1281376|NCT00841386|Riboflavin
1281377|NCT00841386|Collagen cross-linking
1281378|NCT00841373|Retinal ischemia: Iris/Angle Neovascularization
1281379|NCT00841360|Social network
1281380|NCT00841360|Asymptomatic HIV
1281381|NCT00841347|Obesity
1281382|NCT00841347|Glucose metabolism disorders
1281383|NCT00841347|Appetite regulation
1281384|NCT00841347|Sleep
1281385|NCT00841347|Adolescent
1281386|NCT00841347|Randomized controlled trials
1281387|NCT00841334|Adolescent
1281388|NCT00841334|Overweight
1281389|NCT00841334|Obesity
1281390|NCT00841334|Weight loss
1281391|NCT00841334|Nutrition
1281392|NCT00841334|Physical activity
1281393|NCT00841334|Community-based participatory research
1281394|NCT00841334|School-based
1281395|NCT00841334|Primary Care
1281396|NCT00841334|Motivational interviewing
1281397|NCT00841321|Ginkgo biloba
1281398|NCT00841321|Multiple Sclerosis
1281399|NCT00841321|Cognition
1281400|NCT00841321|Neuropsychological Tests
1281401|NCT00841321|Neurobehavioral Manifestations
1281402|NCT00841321|Quality of life
1281403|NCT00841321|Randomized Controlled Trials
1281404|NCT00841321|Placebos
1281405|NCT00841321|Double-Blind Method
1281406|NCT00841282|Colorectal cancer screening
1281407|NCT00841282|Optical colonoscopy
1281408|NCT00841282|Water method
1281409|NCT00841282|Sedation
1281410|NCT00841269|Bipolar Manic Depression
1281411|NCT00841256|specific immunotherapy
1281412|NCT00841256|SIT
1281413|NCT00841256|SLIT
1281414|NCT00841256|sublingual
1281415|NCT00841243|Hepatitis C
1281416|NCT00841243|Antiviral therapy
1281417|NCT00841243|weight loss
1281418|NCT00841243|dietary support
1281419|NCT00841243|dietary advise
1281420|NCT00841230|Tinnitus
1281421|NCT00841217|Drug treatment
1281422|NCT00841191|Resistant to anti-EGFR
1281423|NCT00841191|Interleukin-6
1281424|NCT00841191|Neoplasms by Histologic Type
1281425|NCT00841191|Immunologic Factors
1281426|NCT00841191|Mol Physiological Effects of Drugs
1281427|NCT00841191|KRAS protein, human
1281428|NCT00841191|CNTO 328
1281671|NCT00840203|Healthy Subjects
1281429|NCT00841178|Randomised controlled trial
1281430|NCT00841178|Venous insufficiency
1281431|NCT00841178|Varicose veins
1281432|NCT00841178|Quality of Life
1281433|NCT00841178|Clinical effectiveness
1281434|NCT00841178|Cost effectiveness
1281435|NCT00841165|Carbon Monoxide Toxicity
1281436|NCT00841165|Carbon
1281437|NCT00841165|Monoxide
1281438|NCT00841165|Poisoning
1281439|NCT00841165|Toxicity
1281440|NCT00841165|Treatment
1281441|NCT00841165|CPAP
1281442|NCT00841165|Hyperbaric
1281443|NCT00841165|Oxygen
1281444|NCT00841152|Bone tumors
1281445|NCT00841152|Surgery
1281446|NCT00841152|Bone graft substitutes
1281447|NCT00841152|Bioactive glass
1281448|NCT00841152|Bioceramics
1281449|NCT00841152|Bone autograft
1281450|NCT00841152|Bone allograft
1281451|NCT00841139|perhexiline
1281452|NCT00841139|idiopathic dilated cardiomyopathy
1281453|NCT00841139|magnetic resonance spectroscopy
1281454|NCT00841139|cardiac energetics
1281455|NCT00841126|Hyperphosphatemia
1281456|NCT00841126|Phosphate binder
1281457|NCT00841113|Prostate cancer
1281458|NCT00841113|Advanced
1281459|NCT00841113|Metastatic
1281460|NCT00841100|PKU
1281461|NCT00841100|Kuvan
1281462|NCT00841100|BH4
1281463|NCT00841100|tetrahydrobiopterin
1281464|NCT00841074|Pneumonia
1281465|NCT00841074|Elderly
1281466|NCT00841074|Chlorhexidine
1281467|NCT00841074|Respiratory pathogens
1281468|NCT00841048|Safety and tolerability
1281469|NCT00841035|Pancreatic
1281470|NCT00841035|Cancer
1281471|NCT00841035|Assay
1281472|NCT00841035|Biomarkers
1281473|NCT00841022|anxiety
1281474|NCT00841022|anaesthesia
1281475|NCT00841022|child
1281476|NCT00841022|RCT
1281477|NCT00841022|Elective surgery
1281478|NCT00841009|gastric bypass
1281479|NCT00841009|obesity
1281480|NCT00840996|Spine Surgery
1281481|NCT00840996|Intraocular pressure
1281482|NCT00840996|Lidocaine
1281483|NCT00840996|Epidural Anesthetic
1281484|NCT00840983|delayed cord clamping
1281485|NCT00840983|very low birthweight infant
1281486|NCT00840983|bronchopulmonary dysplasia
1281487|NCT00840983|intraventricular hemorrhage
1281488|NCT00840983|motor function
1281489|NCT00840944|gonadotropin releasing hormone agonist
1281490|NCT00840944|growth hormone
1281491|NCT00840944|final height
1281492|NCT00840944|bone density
1281493|NCT00840944|puberty
1281494|NCT00840931|Myeloid
1281495|NCT00840931|Monocytic
1281496|NCT00840931|Immunotherapy
1281497|NCT00840931|Vaccine
1281498|NCT00840931|MDS
1281499|NCT00840931|High Risk Myelodysplastic Syndrome
1281500|NCT00840918|Cardiac surgery
1281501|NCT00840918|Lidocaine
1281502|NCT00840918|Quality of life
1281503|NCT00840905|HPV
1281504|NCT00840879|Bioequivalence
1281505|NCT00840879|Healthy Subjects
1281506|NCT00840866|Bioequivalence
1281507|NCT00840866|Healthy Subjects
1281508|NCT00840853|Stem cell transplant
1281509|NCT00840853|Acute Lymphoblastic Leukemia (ALL)
1281510|NCT00840853|Chronic Lymphocytic Leukemia (CLL)
1281511|NCT00840853|Non Hodgkin's Lymphoma
1281512|NCT00840853|Cytotoxic T lymphocytes
1281513|NCT00840853|CTL
1281514|NCT00840853|CD-19
1281515|NCT00840853|chimeric receptor
1281516|NCT00840840|Bioequivalence
1281517|NCT00840840|Healthy Subjects
1281518|NCT00840827|stage (IPSS low and INT-1)
1281519|NCT00840827|RBC transfusion-dependent
1281520|NCT00840827|non-del 5q MDS
1281521|NCT00840814|lymphedema
1281522|NCT00840814|stage I squamous cell carcinoma of the hypopharynx
1281523|NCT00840814|stage II squamous cell carcinoma of the hypopharynx
1281524|NCT00840814|stage III squamous cell carcinoma of the hypopharynx
1281525|NCT00840814|stage I squamous cell carcinoma of the larynx
1281526|NCT00840814|stage I verrucous carcinoma of the larynx
1281527|NCT00840814|stage II squamous cell carcinoma of the larynx
1281528|NCT00840814|stage II verrucous carcinoma of the larynx
1281529|NCT00840814|stage III squamous cell carcinoma of the larynx
1281530|NCT00840814|stage III verrucous carcinoma of the larynx
1281531|NCT00840814|stage I squamous cell carcinoma of the lip and oral cavity
1281532|NCT00840814|stage II squamous cell carcinoma of the lip and oral cavity
1281533|NCT00840814|stage III squamous cell carcinoma of the lip and oral cavity
1281534|NCT00840814|stage I verrucous carcinoma of the oral cavity
1281535|NCT00840814|stage II verrucous carcinoma of the oral cavity
1281536|NCT00840814|stage III verrucous carcinoma of the oral cavity
1281537|NCT00840814|stage I squamous cell carcinoma of the nasopharynx
1281538|NCT00840814|stage II squamous cell carcinoma of the nasopharynx
1281539|NCT00840814|stage III squamous cell carcinoma of the nasopharynx
1281540|NCT00840814|stage I squamous cell carcinoma of the oropharynx
1281541|NCT00840814|stage II squamous cell carcinoma of the oropharynx
1281542|NCT00840814|stage III squamous cell carcinoma of the oropharynx
1281543|NCT00840814|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1281544|NCT00840814|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1281545|NCT00840814|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1281546|NCT00840814|salivary gland squamous cell carcinoma
1281547|NCT00840814|stage I salivary gland cancer
1281548|NCT00840814|stage II salivary gland cancer
1281549|NCT00840814|stage III salivary gland cancer
1281550|NCT00840788|skin adhesive
1281551|NCT00840788|tissue adhesive
1281552|NCT00840788|mediolateral episiotomy
1281553|NCT00840788|perineal repair
1281554|NCT00840788|labor and delivery
1281555|NCT00840788|repair
1281556|NCT00840775|Stent
1281557|NCT00840775|interventional cardiology
1281558|NCT00840775|catheterization
1281559|NCT00840775|symptomatic ischemic heart disease
1281560|NCT00840762|HIV-1
1281561|NCT00840762|HIV
1281562|NCT00840762|HIV Genotypic testing
1281563|NCT00840762|resistance
1281564|NCT00840749|STARS
1281565|NCT00840749|Early Stage Non Small Cell Lung Cancer
1281566|NCT00840749|NSCLC
1281567|NCT00840749|CyberKnife
1281568|NCT00840749|Surgery
1281569|NCT00840749|Accuray
1281570|NCT00840736|VBG
1281571|NCT00840736|LAGB
1281572|NCT00840736|long term results
1281573|NCT00840736|Weight loss
1281574|NCT00840736|Complications
1281575|NCT00840736|Reoperations
1281576|NCT00840736|Conversion
1281577|NCT00840723|Healthy smokers
1281578|NCT00840723|Current cigarette smokers
1281579|NCT00840723|No lung disease
1281580|NCT00840710|women in active labor
1281581|NCT00840697|low back pain
1281582|NCT00840697|neck pain
1281583|NCT00840697|return to work
1281584|NCT00840697|exercises
1281585|NCT00840697|cognitive intervention
1281586|NCT00840684|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1281587|NCT00840684|untreated adult acute myeloid leukemia
1281588|NCT00840671|Cerebrolysin
1281589|NCT00840671|Alteplase
1281590|NCT00840671|Ischemic Stroke
1281591|NCT00840671|Modified Rankin Scale
1281592|NCT00840671|NIH Stroke Scale
1281593|NCT00840671|Barthel Index
1281594|NCT00840671|Glasgow Outcome Score
1281595|NCT00840658|HIV
1281596|NCT00840658|Injection drug users
1281597|NCT00840658|Female sex workers
1281598|NCT00840658|STIs
1281599|NCT00840658|HIV Seronegativity
1281600|NCT00840645|YM178
1281601|NCT00840645|Urinary Bladder, Overactive
1281602|NCT00840645|Mirabegron
1281603|NCT00840632|Bioequivalence
1281604|NCT00840632|Healthy Subjects
1281605|NCT00840606|Bioequivalence
1281606|NCT00840606|Healthy Subjects
1281607|NCT00840593|Acromioclavicular Joint
1281608|NCT00840593|Dislocation
1281609|NCT00840593|Trials, Randomized Clinical
1281610|NCT00840593|Surgical Procedures, Operative
1281611|NCT00840580|Cataract, Cornea, Vigamox, Cravit
1281612|NCT00840567|Stem cells
1281613|NCT00840554|Fatigue
1281614|NCT00840554|Cancer-related fatigue
1281615|NCT00840554|High grade glioma
1281616|NCT00840554|Quality of life
1281617|NCT00840554|Exercise
1281618|NCT00840554|Physical Therapy
1281619|NCT00840554|HGG
1281620|NCT00840554|QOL
1281621|NCT00840528|ozone
1281622|NCT00840502|malaria
1281623|NCT00840502|ultrasound
1281624|NCT00840502|pregnancy
1281625|NCT00840502|Pregnant women (infected with malaria and without)
1281626|NCT00840476|Bioequivalence
1281627|NCT00840476|Healthy Subjects
1281628|NCT00840463|Pulmonary Hypertension
1281629|NCT00840463|Diastolic Heart Failure
1281630|NCT00840450|ovarian cancer
1281631|NCT00840450|recurrent
1281632|NCT00840450|Gleevec
1281633|NCT00840450|Paclitaxel
1281634|NCT00840450|Taxane
1281635|NCT00840450|mullerian
1281636|NCT00840437|angina
1281637|NCT00840437|health related quality of life
1281638|NCT00840411|Bioequivalence
1281639|NCT00840411|Healthy Subjects
1281640|NCT00840398|Bioequivalence
1281641|NCT00840398|Healthy Subjects
1281642|NCT00840385|Peripheral T-cell lymphomas (PTCL)
1281643|NCT00840385|Fludarabine
1281644|NCT00840372|Blunt needles
1281645|NCT00840372|Semi-blunt needles
1281646|NCT00840372|Buttonhole cannulation method
1281647|NCT00840359|Cutaneous leishmaniasis
1281648|NCT00840359|Photodynamic therapy
1281649|NCT00840346|Acute Myeloblastic Leukaemia (AML)
1281650|NCT00840346|Panobinostat
1281653|NCT00840307|Obesity
1281654|NCT00840307|Type 2 Diabetes
1281655|NCT00840307|Gastric Banding
1281656|NCT00840294|Men with Elevated PSA
1281657|NCT00840281|Bioequivalence
1281658|NCT00840281|Healthy Subjects
1281659|NCT00840268|OSDI
1281660|NCT00840268|corneal staining
1281661|NCT00840268|Dry Eye
1281662|NCT00840268|Dry Eye Signs and Symptoms in Dry Eye Patients
1281663|NCT00840255|Chronic Insomnia lasting more than 1 month
1281664|NCT00840229|adhesive capsulitis
1281665|NCT00840229|corticosteroids
1281666|NCT00840229|injection
1281667|NCT00840229|pain
1281668|NCT00840216|Bioequivalence
1281669|NCT00840216|Healthy Subjects
1281670|NCT00840203|Bioequivalence
1281672|NCT00840177|recurrent adult acute myeloid leukemia
1281673|NCT00840177|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1281674|NCT00840177|adult acute myeloid leukemia with inv(16)(p13;q22)
1281675|NCT00840177|adult acute myeloid leukemia with t(15;17)(q22;q12)
1281676|NCT00840177|adult acute myeloid leukemia with t(16;16)(p13;q22)
1281677|NCT00840177|adult acute myeloid leukemia with t(8;21)(q22;q22)
1281678|NCT00840164|small-fiber sensory neuropathy
1281679|NCT00840164|nerve pathology
1281680|NCT00840164|vasculature pathology
1281681|NCT00840164|amputation
1281682|NCT00840164|diabetic foot wound
1281683|NCT00840164|sensory neuropathy
1281684|NCT00840164|below knee amputation
1281685|NCT00840151|Substance Abuse
1281686|NCT00840151|Contingency Management
1281687|NCT00840125|NSCLC
1281688|NCT00840125|ERLOTINIB
1281689|NCT00840125|DOCETAXEL
1281690|NCT00840125|first line treatment
1281691|NCT00840125|Stage IIIB /IV
1281692|NCT00840125|not previously treated
1281693|NCT00840125|ECOG PS 2 or age over 65
1281694|NCT00840112|Long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD)
1281695|NCT00840112|Mitochondrial trifunctional protein (TFP)
1281696|NCT00840112|LCHAD/TFP deficiency with peripheral neuropathy
1281697|NCT00840099|Bioequivalence
1281698|NCT00840099|Healthy Subjects
1281699|NCT00840073|Bioequivalence
1281700|NCT00840073|Healthy Subjects
1281701|NCT00840047|Pediatric brain tumor
1281702|NCT00840047|Pediatric solid tumor
1281703|NCT00840047|Pediatric solid neoplasms
1281704|NCT00840008|peptic ulcer bleeding
1281705|NCT00840008|upper GI hemorrhage
1281706|NCT00840008|adherence to guidelines
1281707|NCT00840008|knowledge transfer
1281708|NCT00839995|To determine the efficacy of ROTEM on assessing coagulation profiles.
1281709|NCT00839969|overactive bladder syndrome
1281710|NCT00839969|voiding
1281711|NCT00839969|pressure flow studies
1281712|NCT00839969|urethral dilatation
1281713|NCT00839943|ozone
1281714|NCT00839943|clean air
1281715|NCT00839930|Bioequivalence
1281716|NCT00839930|Healthy Subjects
1281717|NCT00839917|Measles
1281718|NCT00839917|Mumps
1281719|NCT00839917|Rubella
1281720|NCT00839917|Varicella
1281721|NCT00839904|children
1281722|NCT00839904|cancer
1281723|NCT00839904|exercise
1281724|NCT00839904|fitness
1281725|NCT00839904|body composition
1281726|NCT00839891|TQT, QTc
1281727|NCT00839865|Evidence-based evaluation
1281728|NCT00839865|Multi-center randomized controlled clinical trials
1281729|NCT00839865|Traditional Chinese Medicine
1281730|NCT00839865|therapy
1281731|NCT00839865|diabetic foot ulcer
1281732|NCT00839865|clinical trails
1281733|NCT00839839|infertility
1281734|NCT00839839|egg freezing
1281735|NCT00839839|fertility preservation
1281736|NCT00839826|Prevention of Thromboembolism after total hip replacement
1281737|NCT00839813|Yoga
1281738|NCT00839813|Posttraumatic Stress Disorder
1281739|NCT00839813|PTSD
1281740|NCT00839813|women's health
1281741|NCT00839800|Asthma
1281742|NCT00839800|Symbicort Turbuhaler
1281743|NCT00839774|Peas
1281744|NCT00839774|Cardiovascular
1281745|NCT00839774|Diabetes
1281746|NCT00839774|Insulin
1281747|NCT00839774|Insulin resistance
1281748|NCT00839774|Abdominal fat
1281749|NCT00839748|asthma
1281750|NCT00839748|registry for future asthmatic studies
1281751|NCT00839748|questionnaires
1281752|NCT00839748|lung function tests
1281753|NCT00839735|COPD
1281754|NCT00839722|Uterine embolization
1281755|NCT00839722|leiomyomas
1281756|NCT00839722|fertility
1281757|NCT00839722|myomectomies
1281758|NCT00839709|liver disease
1281759|NCT00839709|liver transplantation
1281760|NCT00839709|depletion immunosuppression
1281761|NCT00839709|non-depletion immunosuppression
1281762|NCT00839696|Breast
1281763|NCT00839696|Estrogens
1281764|NCT00839696|Mammography
1281765|NCT00839670|1- Constraint induced therapy
1281766|NCT00839670|2- Stroke
1281767|NCT00839670|3- Upper limb
1281768|NCT00839670|4- Rehabilitation
1281769|NCT00839670|5- Motor training
1281770|NCT00839670|1- First time clinical ischemic or hemorrhagic stroke
1281771|NCT00839670|2- At least 10° of active wrist extension
1281772|NCT00839670|3- At least 10° of thumb abduction/ extension
1281773|NCT00839670|4- At least 10° of extension in at least 2 additional digits
1281774|NCT00839670|3- Adequate balance while wearing the restraint.
1281775|NCT00839657|Embolism
1281776|NCT00839657|Thrombosis
1281777|NCT00839644|cystic fibrosis
1281778|NCT00839644|Chest Wall Oscillation
1281779|NCT00839644|drainage, postural
1281780|NCT00839644|Medication Adherence
1281781|NCT00839644|patient dropouts
1281782|NCT00839631|subjects with advanced solid tumors refractory to standard therapy or for whom no effective therapy is available.
1281783|NCT00839605|Thoracic surgery one lung ventilation
1281784|NCT00839605|airway reconstruction
1281785|NCT00839592|Insomnia
1281786|NCT00839592|Acupuncture
1281787|NCT00839592|Electroacupuncture
1281788|NCT00839592|Randomized Clinical Trial
1281789|NCT00839592|Traditional Chinese Medicine
1281790|NCT00839579|slightly overweight
1281791|NCT00839579|males 35-45 years
1281792|NCT00839566|Atrial Fibrillation
1281793|NCT00839566|Heart Failure
1281794|NCT00839540|candidemia
1281795|NCT00839540|echinocandin
1281796|NCT00839540|micafungin
1281797|NCT00839540|caspofungin
1281798|NCT00839527|diabetes
1281799|NCT00839514|Parkinson's disease
1281800|NCT00839514|Trichloroethylene
1281801|NCT00839488|pantoprazole
1281802|NCT00839488|famotidine
1281803|NCT00839488|stomach ulcer
1281804|NCT00839488|digestive system surgical procedure
1281805|NCT00839475|colposcopy
1281806|NCT00839475|Cervical intraepithelial neoplasia
1281807|NCT00839475|cervical cancer
1281808|NCT00839475|cervical precancer
1281809|NCT00839462|Thermal Erythema
1281810|NCT00839462|Dexpanthenol
1281811|NCT00839462|Erythema
1281812|NCT00839462|Efficacy
1281813|NCT00839449|subarachnoid hemorrhage
1281814|NCT00839449|cerebral vasospasm
1281815|NCT00839449|eicosapentaenoic acid
1281816|NCT00839436|Idiopathic CD4+ T-Lymphocytopenia
1281817|NCT00839436|Interleukin-7
1281818|NCT00839436|Clinical Trial
1281819|NCT00839436|T-Lymphocytes
1281820|NCT00839436|Idiopathic CD4 Lymphocytopenia (ICL)
1281821|NCT00839436|ICL
1281822|NCT00839423|Major depressive disorder
1281823|NCT00839423|Placebo-controlled
1281824|NCT00839423|Active reference
1281825|NCT00839423|Multicenter study
1281826|NCT00839423|Randomised study
1281827|NCT00839423|Acute treatment
1281828|NCT00839410|skin cancer
1281829|NCT00839410|melanoma
1281830|NCT00839410|sentinel lymph node biopsy
1281831|NCT00839410|bio bank
1281832|NCT00839410|genetic polymorphism
1281833|NCT00839410|prospective cohort
1281834|NCT00839410|cohort
1281835|NCT00839410|sentinel lymph nodes
1281836|NCT00839410|tissue samples
1281837|NCT00839371|bispectral analysis
1281838|NCT00839371|bronchoscopy
1281839|NCT00839371|midazolam
1281840|NCT00839371|propofol
1281841|NCT00839371|recovery
1281842|NCT00839371|sedation
1281843|NCT00839358|cirrhosis
1281844|NCT00839358|renal failure
1281845|NCT00839358|midodrine
1281846|NCT00839358|albumine
1281847|NCT00839345|platelet
1281848|NCT00839345|clopidogrel
1281849|NCT00839345|VerifyNow
1281850|NCT00839345|ticlopidine
1281851|NCT00839345|thrombosis
1281852|NCT00839332|Pancreas
1281853|NCT00839332|metastatic cancer
1281854|NCT00839332|advanced cancer
1281855|NCT00839332|Pancreatic cancer
1281856|NCT00839319|hCG
1281857|NCT00839319|testosterone
1281858|NCT00839319|Acyline
1281859|NCT00839319|Intratesticular hormone
1281860|NCT00839306|Gastroesophageal
1281861|NCT00839306|Reflux
1281862|NCT00839306|Disease
1281863|NCT00839306|GERD
1281864|NCT00839293|Bioavailability
1281865|NCT00839280|Dry skin
1281866|NCT00839280|Dexpanthenol
1281867|NCT00839280|Moisturizing effect
1281868|NCT00839267|platelet
1281869|NCT00839267|VASP
1281870|NCT00839267|clopidogrel
1281871|NCT00839267|cardiogenic shock
1281872|NCT00839267|myocardial infarction
1281873|NCT00839267|percutaneous coronary intervention
1281874|NCT00839254|Streptococcus pneumoniae
1281875|NCT00839254|acute otitis media
1281876|NCT00839254|Pneumococcal conjugate vaccine
1281877|NCT00839254|nasopharyngeal carriage
1281878|NCT00839254|Haemophilus influenzae
1281879|NCT00839254|immunogenicity
1281880|NCT00839254|invasive disease
1281881|NCT00839228|diastolic dysfunction
1281882|NCT00839228|cardiac energetics
1281883|NCT00839228|perhexiline
1281884|NCT00839228|magnetic resonance spectroscopy
1281885|NCT00839202|factor VIII
1281886|NCT00839202|hemophilia A
1281887|NCT00839202|assay
1281888|NCT00839189|CCRE
1281889|NCT00839189|endotoxin
1281890|NCT00839189|LPS
1281891|NCT00839189|asthma
1281892|NCT00839189|allergies
1281893|NCT00839189|allergic rhinitis
1281894|NCT00839176|Major Depressive Disorder (MDD)
1281895|NCT00839176|Serdaxin
1281896|NCT00839176|Rexahn
1281897|NCT00839163|Embolism and Thrombosis
1281898|NCT00839163|Pulmonary embolism
1281899|NCT00839163|Embolism
1281900|NCT00839163|Thrombosis
1281901|NCT00839150|Diabetic retinopathy
1281902|NCT00839150|Color vision
1281903|NCT00839150|Contrast sensitivity
1281904|NCT00839150|Electroretinogram
1281905|NCT00839150|Flicker-induced vasodilatation
1281906|NCT00839150|Dynamic Vessel Analyzer
1281907|NCT00839137|asthma
1281908|NCT00839137|exercise therapy
1281909|NCT00839124|normal volunteer
1281910|NCT00839124|healthy control volunteer
1281911|NCT00839124|healthy subjects
1281912|NCT00839124|asthma
1281913|NCT00839124|allergy
1281914|NCT00839124|allergic asthma
1281915|NCT00839111|Progression free survival
1281916|NCT00839111|Toxicity
1281917|NCT00839111|Response rate
1281918|NCT00839111|overall survival
1281919|NCT00839098|power wheelchairs
1281920|NCT00839098|assistive technology
1281921|NCT00839098|rehabilitation
1281922|NCT00839085|CABG
1281923|NCT00839085|on pump
1281924|NCT00839085|Grape seed extract
1281925|NCT00839085|Vit C
1281926|NCT00839085|Oxidative stress
1281927|NCT00839072|bioavailability
1281928|NCT00839072|pharmacokinetics
1281929|NCT00839072|healthy
1281930|NCT00839072|crossover
1281931|NCT00839072|trazodone
1281932|NCT00839059|AML
1281933|NCT00839059|lenalidomide
1281934|NCT00839046|Pediatric Asthma
1281935|NCT00839046|Air Filters
1281936|NCT00839046|Indoor Particulate Matter
1281937|NCT00839033|Cough assisted device
1281938|NCT00839033|Neuromuscular disease
1281939|NCT00839033|Respiratory exacerbation
1281940|NCT00839033|Invasive ventilation,
1281941|NCT00839033|Chest physiotherapy
1281942|NCT00839033|Congenital myopathies
1281943|NCT00839020|Surgical Procedures, Minimally Invasive
1281944|NCT00839020|Range of Motion
1281945|NCT00839020|Articular Arthroplasty, Replacement, Knee
1281946|NCT00839007|ADHF
1281947|NCT00839007|AHF
1281948|NCT00839007|HF
1281949|NCT00838994|Insomnia
1281950|NCT00838994|Depression
1281951|NCT00838994|Electroacupuncture
1281952|NCT00838994|Acupuncture
1281953|NCT00838994|Randomized Clinical Trial
1281954|NCT00838994|Traditional Chinese Medicine
1281955|NCT00838981|Treatment for addiction
1281956|NCT00838981|Methadone given for opioid dependence
1281957|NCT00838981|Cocaine
1281958|NCT00838981|Opiates
1281959|NCT00838968|hepatocellular carcinoma
1281960|NCT00838968|interferon-alpha
1281961|NCT00838968|p48
1281962|NCT00838955|Hodgkin's lymphoma
1281963|NCT00838955|relapsed Hodgkin's lymphoma
1281964|NCT00838955|refractory Hodgkin's lymphoma
1281965|NCT00838955|Temsirolimus
1281966|NCT00838942|Eyes disease and dementia.
1281967|NCT00838942|Cataract surgery in the patient with dementia.
1281968|NCT00838942|Visual hallucinations
1281969|NCT00838942|Visual acuity,
1281970|NCT00838942|Specific eye pathologies in Alzheimer's disease.
1281971|NCT00838942|Improvement of behaviour,
1281972|NCT00838942|Improvement of autonomy
1281973|NCT00838942|Improvement of mood
1281974|NCT00838942|Cataract extraction in Alzheimer disease patient
1281975|NCT00838929|brain metastases
1281976|NCT00838929|radiation
1281977|NCT00838929|vorinostat
1281978|NCT00838929|lung cancer
1281979|NCT00838929|breast cancer
1281980|NCT00838916|diabetes
1281981|NCT00838903|diabetes
1281982|NCT00838877|Alzheimer's Disease
1281983|NCT00838877|PET
1281984|NCT00838877|Phase 1
1281985|NCT00838877|Positron Emission Tomography
1281986|NCT00838864|variceal bleeding
1281987|NCT00838864|antibiotic prophylaxis
1281988|NCT00838864|ceftrioxone
1281989|NCT00838851|endotoxin
1281990|NCT00838851|CCRE
1281991|NCT00838851|LPS
1281992|NCT00838838|Testosterone replacement therapy
1281993|NCT00838838|Hypogonadism
1281994|NCT00838838|Osteoporosis
1281995|NCT00838838|Immobilisation
1281996|NCT00838838|Paraplegia
1281997|NCT00838838|Testosterone
1281998|NCT00838825|diabetes
1281999|NCT00838825|chronic care management
1282000|NCT00838825|resource utilization
1282001|NCT00838825|outcome
1282002|NCT00838825|glycohemoglobin
1282003|NCT00838825|hospitalization
1282004|NCT00838812|clindamycin
1282005|NCT00838812|tretinoin
1282006|NCT00838812|acne vulgaris
1282007|NCT00838812|Acne vulgaris mild to moderate
1282008|NCT00838799|diabetic
1282009|NCT00838799|peripheral
1282010|NCT00838799|neuropathic
1282011|NCT00838799|pain
1282012|NCT00838799|chronic
1282013|NCT00838799|diabetes
1282014|NCT00838760|PEPI-TiDP23-C103
1282015|NCT00838760|PEPI-C103
1282016|NCT00838760|PEPI
1282017|NCT00838760|TMC558445
1282018|NCT00838760|TMC310911
1282019|NCT00838760|Darunavir, Healthy volunteers
1282020|NCT00838760|Pharmacokinetics
1282021|NCT00838760|HIV Infections
1282022|NCT00838747|folate receptor
1282023|NCT00838747|blood samples
1282024|NCT00838747|ovarian cancer
1282025|NCT00838747|development of measure of folate receptor in blood samples
1282026|NCT00838747|possible selection of patients for treatment with FR targeted agents
1282027|NCT00838734|CORNEAL TOPOGRAPHY
1282028|NCT00838734|KERATOPLASTY
1282029|NCT00838721|Open Angle Glaucoma
1282030|NCT00838721|Ocular Hypertension
1282031|NCT00838721|Laser Trabeculoplasty
1282032|NCT00838695|Hand vein sensitivity
1282033|NCT00838695|phenylephrine
1282034|NCT00838695|nitroglycerin
1282035|NCT00838682|peptic ulcer bleeding
1282036|NCT00838682|rabeprazole
1282037|NCT00838682|proton pump inhibitor
1282038|NCT00838669|Schizophrenia
1282039|NCT00838669|Mood disorders
1282040|NCT00838669|Antipsychotic drugs
1282041|NCT00838669|Extended release OROS paliperidone
1282042|NCT00838656|ovarian carcinosarcoma
1282043|NCT00838656|stage IIIA ovarian epithelial cancer
1282044|NCT00838656|stage IIIB ovarian epithelial cancer
1282045|NCT00838656|stage IIIC ovarian epithelial cancer
1282046|NCT00838656|stage IV ovarian epithelial cancer
1282047|NCT00838656|stage IIIA primary peritoneal cavity cancer
1282048|NCT00838656|stage IIIB primary peritoneal cavity cancer
1282049|NCT00838656|stage IIIC primary peritoneal cavity cancer
1282050|NCT00838656|stage IV primary peritoneal cavity cancer
1282051|NCT00838656|stage IIIA fallopian tube cancer
1282052|NCT00838656|stage IIIB fallopian tube cancer
1282053|NCT00838656|stage IIIC fallopian tube cancer
1282054|NCT00838656|stage IV fallopian tube cancer
1282055|NCT00838643|allogeneic transplantation
1282056|NCT00838643|Invasive aspergillosis
1282057|NCT00838630|Bioequivalence
1282058|NCT00838630|Healthy Subjects
1282059|NCT00838617|Amyotrophic Lateral Sclerosis
1282060|NCT00838617|Ultrasonography
1282061|NCT00838617|Atrophy
1282062|NCT00838591|MN-221
1282063|NCT00838591|Asthma
1282064|NCT00838591|Acute
1282065|NCT00838591|Exacerbation
1282066|NCT00838578|KRN330
1282067|NCT00838578|Colorectal Cancer
1282068|NCT00838578|Antimetabolites
1282069|NCT00838578|Antimetabolites, Antineoplastic
1282070|NCT00838578|Digestive System Neoplasms
1282071|NCT00838578|Immunologic Factors
1282072|NCT00838578|Molecular Mechanisms of Pharmacological Action
1282073|NCT00838578|Antineoplastic Agents
1282074|NCT00838578|Gastrointestinal Diseases
1282075|NCT00838578|Physiological Effects of Drugs
1282076|NCT00838578|Colonic Diseases
1282077|NCT00838578|Irinotecan
1282078|NCT00838578|Enzyme Inhibitors
1282079|NCT00838578|Intestinal Diseases
1282080|NCT00838578|Immunosuppressive Agents
1282081|NCT00838578|Rectal Diseases
1282082|NCT00838578|Pharmacologic Actions
1282083|NCT00838578|Intestinal Neoplasms
1282084|NCT00838578|Neoplasms by Site
1282085|NCT00838578|Digestive System Diseases
1282086|NCT00838578|Therapeutic Uses
1282087|NCT00838578|Fluorouracil
1282088|NCT00838578|Neoplasms
1282089|NCT00838578|Gastrointestinal Neoplasms
1282090|NCT00838578|Antineoplastic Agents, Phytogenic
1282091|NCT00838578|Colorectal Neoplasms
1282092|NCT00838565|Safety and tolerability Pharmacokinetics Pharmacodynamics PF-04236921
1282093|NCT00838552|asthma inflammation bronchoscopy
1282094|NCT00838539|Neratinib in combination with Temsirolimus
1282095|NCT00838539|solid tumors
1282096|NCT00838539|phase 1
1282097|NCT00838539|dose finding study
1282098|NCT00838526|Gastroesophageal
1282099|NCT00838526|Reflux
1282100|NCT00838526|Disease
1282101|NCT00838526|GERD
1282102|NCT00838513|aHUS
1282103|NCT00838500|Venous insufficiency
1282104|NCT00838500|Leg ulcer
1282105|NCT00838500|balneology
1282106|NCT00838500|hydrotherapy
1282107|NCT00838500|Modified Rutherford score
1282108|NCT00838500|Euroquol EQ 5d scale
1282109|NCT00838500|CIVIQ2 scale
1282110|NCT00838500|Visual analogic Scale
1282111|NCT00838500|SPA treatment
1282112|NCT00838487|chondroitin
1282113|NCT00838487|glucosamine
1282114|NCT00838487|osteoarthritis
1282115|NCT00838474|metabolic rate
1282116|NCT00838474|music
1282117|NCT00838474|preterm infants
1282118|NCT00838474|energy expenditure
1282119|NCT00838474|NIDCA
1282120|NCT00838448|exercise
1282121|NCT00838448|cannabis use
1282122|NCT00838448|visual cues
1282123|NCT00838435|Phenylketonuria
1282124|NCT00838435|PKU
1282125|NCT00838435|Kuvan
1282126|NCT00838435|Phenoptin
1282127|NCT00838435|Biopten
1282128|NCT00838435|Neurocognitive Function
1282129|NCT00838435|Phenylalanine
1282130|NCT00838383|multi-center, placebo-controlled, randomized study of sitaxsentan administered to subjects post-cross-clamp release and 12 hours post-CPB
1282131|NCT00838370|Pharmacogenetics
1282132|NCT00838370|cost-benefit analysis
1282133|NCT00838370|toxicity
1282134|NCT00838370|antineoplastic drugs
1282135|NCT00838370|Dihydropyrimidine Dehydrogenase
1282136|NCT00838357|Mobilisation stem cells
1282137|NCT00838357|G-CSF Mobilisation Regimen
1282138|NCT00838357|Lymphoma
1282139|NCT00838357|Multiple Myeloma
1282140|NCT00838344|medication adherence
1282141|NCT00838344|medication persistence
1282142|NCT00838344|pharmacist interventions
1282143|NCT00838344|diabetes
1282144|NCT00838344|persistence
1282145|NCT00838344|adherence
1282146|NCT00838331|Blood Transfusions
1282147|NCT00838318|Colorectal CancerScreening
1282148|NCT00838318|CRC
1282149|NCT00838318|Hispanic
1282150|NCT00838318|CRC Patients
1282151|NCT00838318|First-Degree Relatives
1282152|NCT00838318|FDRs
1282153|NCT00838318|Interviews
1282154|NCT00838318|Colorectal cancer screening
1282155|NCT00838318|CRCS
1282156|NCT00838318|Key Informants
1282157|NCT00838305|MDMA
1282158|NCT00838305|citalopram
1282159|NCT00838305|serotonin
1282160|NCT00838305|psychedelic
1282161|NCT00838292|food supplementation
1282162|NCT00838292|HIV
1282163|NCT00838292|malnutrition
1282164|NCT00838279|Bioequivalence
1282165|NCT00838279|Healthy Subjects
1282166|NCT00838266|mouthrinse
1282167|NCT00838266|grape seed extract
1282168|NCT00838266|fluor
1282169|NCT00838266|plaque index
1282170|NCT00838253|Acute Heart Failure
1282171|NCT00838253|Inotropes
1282172|NCT00838253|Lusitropic agents
1282173|NCT00838253|Istaroxime
1282174|NCT00838253|Debio 0614
1282175|NCT00838240|adult acute minimally differentiated myeloid leukemia (M0)
1282176|NCT00838240|adult acute myeloblastic leukemia without maturation (M1)
1282177|NCT00838240|adult acute myeloblastic leukemia with maturation (M2)
1282178|NCT00838240|adult acute myelomonocytic leukemia (M4)
1282179|NCT00838240|adult acute monoblastic leukemia (M5a)
1282180|NCT00838240|adult acute monocytic leukemia (M5b)
1282181|NCT00838240|adult erythroleukemia (M6a)
1282182|NCT00838240|adult pure erythroid leukemia (M6b)
1282183|NCT00838240|adult acute megakaryoblastic leukemia (M7)
1282184|NCT00838240|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1282185|NCT00838240|adult acute myeloid leukemia with t(16;16)(p13;q22)
1282186|NCT00838240|adult acute myeloid leukemia with t(8;21)(q22;q22)
1282187|NCT00838240|adult acute myeloid leukemia with inv(16)(p13;q22)
1282188|NCT00838240|untreated adult acute myeloid leukemia
1282189|NCT00838240|de novo myelodysplastic syndromes
1282190|NCT00838240|secondary acute myeloid leukemia
1282191|NCT00838227|Schizophrenia
1282192|NCT00838227|Cognition
1282193|NCT00838227|Obesity
1282194|NCT00838227|Sedation
1282195|NCT00838201|Androgen deprivation therapy for non-metastatic prostate cancer
1282196|NCT00838188|Metabolic rate
1282197|NCT00838188|indirect calorimetry
1282198|NCT00838188|oral feeding
1282199|NCT00838175|Peripheral Venous Catheterization
1282200|NCT00838162|Human immunodeficiency virus type 1
1282201|NCT00838162|HIV-1
1282202|NCT00838162|HIV-1 treatment-naive
1282203|NCT00838162|TMC310911
1282204|NCT00838162|Protease inhibitor
1282205|NCT00838162|Ritonavir
1282206|NCT00838162|Antiviral Activity
1282207|NCT00838162|HIV Infections
1282208|NCT00838162|Treatment Naive
1282209|NCT00838136|Bioequivalence
1282210|NCT00838136|Healthy Subjects
1282211|NCT00838110|Alzheimer's Disease
1282212|NCT00838110|Dimebon
1282213|NCT00838110|Safety
1282214|NCT00838110|Tolerability
1282215|NCT00838097|CKD
1282216|NCT00838097|Paediatric
1282217|NCT00838097|Darbepoetin Alfa
1282218|NCT00838071|Hepatitis B
1282219|NCT00838071|HBV
1282220|NCT00838071|Anti-hepatitis B antibodies
1282221|NCT00838071|Immunoglobulins
1282222|NCT00838071|liver transplantation
1282223|NCT00838071|Protective levels
1282224|NCT00838071|Recurrence
1282225|NCT00838071|Intravenous
1282226|NCT00838058|pharmacology formulation normal healthy volunteers food effect
1282227|NCT00838032|acute schizophrenic patients
1282228|NCT00838006|post-traumatic stress disorder
1282229|NCT00838006|post-deployment
1282230|NCT00838006|prediction
1282231|NCT00838006|prevention
1282232|NCT00837993|Advanced Stage Serous Carcinoma of the Ovary
1282233|NCT00837993|serous ovarian carcinoma
1282234|NCT00837993|Ovary
1282235|NCT00837993|GOG Protocol 158
1282236|NCT00837993|Survival Analysis
1282237|NCT00837993|Pathology Slides
1282238|NCT00837993|Two-tier Grading System
1282239|NCT00837993|Ancillary Study
1282240|NCT00837980|head and neck cancer
1282241|NCT00837980|DW MRI
1282242|NCT00837980|PET
1282243|NCT00837980|DCE MRI
1282244|NCT00837980|functional imaging
1282245|NCT00837980|IMRT
1282246|NCT00837967|Asthma
1282247|NCT00837967|Symbicort Turbuhaler
1282248|NCT00837954|PTFE Graft
1282249|NCT00837954|Suture Hole Bleeding
1282250|NCT00837954|Hemostasis
1282251|NCT00837928|unspecified adult solid tumor, protocol specific
1282252|NCT00837928|tumors metastatic to brain
1282253|NCT00837915|Bioequivaelnce Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended Release Tablets
1282254|NCT00837902|Atenolol
1282255|NCT00837902|Exercise
1282256|NCT00837902|Genotype
1282257|NCT00837902|Healthy volunteers
1282258|NCT00837889|cognition
1282259|NCT00837889|decompensation
1282260|NCT00837889|heart failure
1282261|NCT00837889|recompensation
1282262|NCT00837876|recurrent pancreatic cancer
1282263|NCT00837876|stage III pancreatic cancer
1282264|NCT00837876|stage IV pancreatic cancer
1282265|NCT00837876|adenocarcinoma of the pancreas
1282266|NCT00837850|total hip arthroplasty
1282267|NCT00837850|Charnley stem
1282268|NCT00837850|RSA
1282269|NCT00837850|non-inflammatory arthritis
1282270|NCT00837837|pharmacokinetics
1282271|NCT00837837|children
1282272|NCT00837837|adolescents
1282273|NCT00837837|antihistamine
1282274|NCT00837824|Fabry Disease patients with Severe Renal Disease
1282275|NCT00837811|Arthritis
1282276|NCT00837772|Alignment
1282277|NCT00837759|Type I Diabetes
1282278|NCT00837759|Preserve Beta Cell Function
1282279|NCT00837759|Sitagliptin
1282280|NCT00837759|Lansoprazole
1282281|NCT00837759|GAD65 (Diamyd)
1282282|NCT00837759|Diabetes
1282283|NCT00837759|Type 1 Diabetes
1282284|NCT00837759|T1DM
1282285|NCT00837733|Endometrial biopsy
1282286|NCT00837733|IVF/ICSI
1282287|NCT00837733|Pregnancy outcome
1282288|NCT00837733|Recurrent implantation failure
1282289|NCT00837720|hypertension
1282290|NCT00837720|blood pressure
1282291|NCT00837720|Atacand®
1282292|NCT00837720|candesartan
1282293|NCT00837707|aripiprazole
1282294|NCT00837707|Tardive Dyskinesia
1282295|NCT00837694|BMI
1282296|NCT00837694|obesity
1282297|NCT00837694|sensitization
1282298|NCT00837694|food reinforcement
1282299|NCT00837694|snack food
1282300|NCT00837694|Portion size of daily snacks
1282301|NCT00837694|Weight status
1282302|NCT00837681|Bone Marrow Transplant
1282303|NCT00837681|hematopoietic stem cell transplantation
1282304|NCT00837668|sarcoidosis
1282305|NCT00837668|stromal gene expression
1282306|NCT00837668|pulmonary sarcoidosis
1282307|NCT00837668|bronchoscopy
1282308|NCT00837655|Chronic kidney disease
1282309|NCT00837655|End-stage renal disease
1282310|NCT00837655|phosphate binder
1282311|NCT00837655|insulin resistance
1282312|NCT00837655|glucose intolerance
1282313|NCT00837655|sevelamer
1282314|NCT00837642|Vascular function in offspring of ART
1282315|NCT00837629|chronic obstructive pulmonary disease
1282316|NCT00837629|COPD
1282317|NCT00837629|Symbicort Turbuhaler
1282318|NCT00837616|Turner Syndrome
1282319|NCT00837616|Hypogonadism
1282320|NCT00837616|GH
1282321|NCT00837616|Estrogen
1282322|NCT00837616|Estrogen Patches
1282323|NCT00837616|IGF-I
1282324|NCT00837616|Body Composition
1282325|NCT00837616|Protein Metabolism
1282326|NCT00837616|Lipid Oxidation
1282327|NCT00837616|Estradiol assay by LCMSMS
1282328|NCT00837616|Recombinant Cell Bioassay
1282329|NCT00837603|tga
1282330|NCT00837603|atrial switch
1282331|NCT00837603|training
1282332|NCT00837590|Vascular function
1282333|NCT00837590|Glucose tolerance
1282334|NCT00837590|Obesity
1282335|NCT00837590|Pre-diabetes
1282336|NCT00837564|chronic depression
1282337|NCT00837564|CBASP
1282338|NCT00837564|Escitalopram
1282339|NCT00837564|depression
1282340|NCT00837564|trauma
1282341|NCT00837551|Non-steroid
1282342|NCT00837551|Small molecule
1282343|NCT00837551|Topical cream
1282344|NCT00837551|Inflammatory disease
1282345|NCT00837551|Skin
1282346|NCT00837538|Spinal sagittal range of motion
1282347|NCT00837538|Intersegmental range of motion
1282348|NCT00837538|Spinal Mouse
1282349|NCT00837512|microneedle continuous subcutaneous insulin infusion
1282350|NCT00837499|Breast
1282351|NCT00837499|Breast Cancer
1282352|NCT00837499|Risk Factors
1282353|NCT00837499|Mexican Women
1282354|NCT00837499|Mexican-American Women
1282355|NCT00837499|African-American Women
1282356|NCT00837499|Epidemiological
1282357|NCT00837499|Questionnaire
1282358|NCT00837499|Survey
1282359|NCT00837499|Interview
1282360|NCT00837486|Treatment Resistant Depression
1282361|NCT00837486|Treatment Refractory Depression
1282362|NCT00837486|Deep Brain Stimulation
1282363|NCT00837486|Depression
1282364|NCT00837473|Bone Void Filler
1282365|NCT00837473|Iliac Crest Bone Void Filler
1282366|NCT00837473|Back Surgery and Autograft Bone
1282367|NCT00837473|Autograft Bone
1282368|NCT00837473|Allograft Bone
1282369|NCT00837460|Hand
1282370|NCT00837460|Rehabilitation
1282371|NCT00837434|tumor necrosis factor (TNF) blockade
1282372|NCT00837434|inflammatory autoimmune disorder
1282373|NCT00837421|sepsis
1282374|NCT00837421|registry
1282375|NCT00837408|Diabetes
1282376|NCT00837408|Genetics
1282377|NCT00837408|Asians
1282378|NCT00837408|Type 2 Diabetes
1282379|NCT00837395|premenstrual increase in asthma symptoms
1282380|NCT00837369|Stress echocardiography
1282381|NCT00837369|SPECT
1282382|NCT00837369|Myocardial perfusion imaging
1282383|NCT00837343|Bipolar disorder
1282384|NCT00837330|polypoidal choroidal vasculopathy
1282385|NCT00837330|choroidal neovascularization
1282386|NCT00837330|ranibizumab
1282387|NCT00837330|Lucentis
1282388|NCT00837317|Phenols
1282389|NCT00837317|Laser-Doppler
1282390|NCT00837317|Olive Oil
1282391|NCT00837317|Sunflower Oil
1282392|NCT00837317|Dimethylpolysiloxane
1282393|NCT00837317|Postprandial
1282394|NCT00837317|Inflammation
1282395|NCT00837317|Oxidative Stress
1282396|NCT00837291|osteoarthritis
1282397|NCT00837291|knee
1282398|NCT00837291|CF101
1282399|NCT00837278|IVF
1282400|NCT00837278|angiogenic factors
1282401|NCT00837278|cytokines
1282402|NCT00837265|Breast Cancer Supportive Care Neutropenia
1282403|NCT00837252|Central Serous Chorioretinopathy
1282404|NCT00837252|Finasteride
1282405|NCT00837252|Proscar
1282406|NCT00837252|Retinal Eye Disease
1282407|NCT00837239|HuaChanSu
1282408|NCT00837239|HCS
1282409|NCT00837239|Gastrointestinal
1282410|NCT00837239|Gastrointestinal Disease
1282411|NCT00837239|Metastases
1282412|NCT00837239|Cancer
1282413|NCT00837239|Pancreatic cancer
1282414|NCT00837239|Placebo
1282415|NCT00837239|Gemcitabine
1282416|NCT00837239|Gemcitabine Hydrocholoride
1282417|NCT00837239|Gemzar
1282418|NCT00837239|Fudan UniversityCancer Hospital
1282419|NCT00837213|Acne
1282420|NCT00837200|lymphoma
1282421|NCT00837200|myeloma
1282422|NCT00837187|dexmedetomidine
1282423|NCT00837187|intranasal
1282424|NCT00837187|pharmacokinetics
1282425|NCT00837187|pharmacodynamics
1282426|NCT00837174|non-Hodgkin Lymphoma
1282427|NCT00837174|aggressive lymphoma
1282428|NCT00837174|indolent lymphoma
1282429|NCT00837174|B cell lymphoma
1282430|NCT00837174|T cell lymphoma
1282431|NCT00837174|Diffuse large B cell lymphoma
1282432|NCT00837174|anaplastic large B cell lymphoma
1282433|NCT00837174|lymphoblastic lymphoma
1282434|NCT00837174|Burkitt's lymphoma
1282435|NCT00837174|transformed follicular center cell lymphoma
1282436|NCT00837174|transformed marginal zone lymphoma
1282437|NCT00837174|transformed small lymphocytic lymphoma
1282438|NCT00837174|grade 3 follicular center cell lymphoma
1282439|NCT00837174|blastic form marginal zone lymphoma
1282440|NCT00837174|transformed cutaneous T cell lymphoma
1282441|NCT00837174|mycosis fungoides stage IV
1282442|NCT00837174|angioimmunoblastic lymphadenopathy-like T-cell lymphoma
1282443|NCT00837174|nasal NK/T cell lymphoma
1282444|NCT00837174|peripheral T-cell lymphoma
1282445|NCT00837174|small lymphocytic lymphoma
1282446|NCT00837174|lymphoplasmacytic lymphoma
1282447|NCT00837174|follicular center cell lymphoma grade 1
1282448|NCT00837174|follicular center cell lymphoma grade 2
1282449|NCT00837174|mantle cell lymphoma
1282450|NCT00837174|marginal zone lymphoma
1282451|NCT00837174|mycosis fungoides
1282452|NCT00837161|High Intensity Focused Ultrasound Ablation
1282453|NCT00837161|Uterine Fibroids
1282454|NCT00837161|Leiomyomata
1282455|NCT00837161|Non-Invasive Treatment of Uterine Fibroids
1282456|NCT00837161|MRI-Guided
1282457|NCT00837161|Fibroids
1282458|NCT00837161|Uterine Leiomyomata
1282459|NCT00837148|Sarcoma
1282460|NCT00837148|Bone
1282461|NCT00837148|BAY 43-9006 (SORAFENIB)
1282462|NCT00837148|DACARBAZINE
1282463|NCT00837148|08-068
1282464|NCT00837135|Pancreatic Cancer
1282465|NCT00837122|Diabetes
1282466|NCT00837122|Genetics
1282467|NCT00837122|Type 2 Diabetes
1282468|NCT00837083|hypercholesterolemia
1282469|NCT00837083|cholesterol
1282470|NCT00837083|LDL-cholesterol
1282471|NCT00837083|rosuvastatin
1282472|NCT00837083|Crestor
1282473|NCT00837070|Zygapophyseal
1282474|NCT00837070|joint
1282475|NCT00837070|cyst
1282476|NCT00837070|Fluoroscopy
1282477|NCT00837070|guided
1282478|NCT00837070|percutaneous
1282479|NCT00837070|Lumbar
1282480|NCT00837031|Pancreatic
1282481|NCT00837031|Pancreatic Cancer
1282482|NCT00837031|Lenalidomide
1282483|NCT00837031|Revlimid
1282484|NCT00837031|Gemcitabine
1282485|NCT00837018|OSAS
1282486|NCT00837018|exercise
1282487|NCT00837018|metabolic
1282488|NCT00837018|cardio-vascular
1282489|NCT00837005|dobutamine stress
1282490|NCT00837005|inducible ischemia
1282491|NCT00837005|CAD
1282492|NCT00836992|anal cancer
1282493|NCT00836992|colon cancer
1282494|NCT00836992|rectal cancer
1282495|NCT00836992|esophageal cancer
1282496|NCT00836992|extrahepatic bile duct cancer
1282497|NCT00836992|gallbladder cancer
1282498|NCT00836992|gastric cancer
1282499|NCT00836992|adult primary liver cancer
1282500|NCT00836992|pancreatic cancer
1282501|NCT00836992|small intestine cancer
1282502|NCT00836992|non-small cell lung cancer
1282503|NCT00836992|small cell lung cancer
1282504|NCT00836992|head and neck cancer
1282505|NCT00836979|Urinary Incontinence
1282506|NCT00836979|Incontinence
1282507|NCT00836979|bladder problems
1282508|NCT00836979|bladder dysfunction
1282509|NCT00836953|Influenza
1282510|NCT00836953|Fluzone®
1282511|NCT00836953|Children
1282512|NCT00836940|Type 2 diabetes mellitus
1282513|NCT00836940|GRC 8200
1282514|NCT00836914|Allergic Rhinitis
1282515|NCT00836914|Allergy
1282516|NCT00836914|Phosphatidylinositol 3-kinase
1282517|NCT00836901|Bioequivalence
1282518|NCT00836901|Healthy Subjects
1282519|NCT00836888|ONO-4538
1282520|NCT00836888|MDX-1106
1282521|NCT00836888|solid tumors
1282522|NCT00836875|Pediatrics voriconazole invasive fungal infection invasive aspergillosis immunocompromized
1282523|NCT00836862|Hemodialysis
1282524|NCT00836862|Vascular access
1282525|NCT00836862|Arteriovenous fistula
1282526|NCT00836849|Bioequivalence
1282527|NCT00836849|Healthy Subjects
1282528|NCT00836836|Childhood epilepsy
1282529|NCT00836836|ketogenic diet
1282530|NCT00836823|Patient-reported most bothersome symptom
1282531|NCT00836823|Patient-reported symptom-specific goal achievement
1282532|NCT00836823|Medical treatment
1282533|NCT00836810|Circadian variations of cytokines in PMR
1282534|NCT00836810|effect of TRT Prednisone in cytokines
1282535|NCT00836797|Alveolar Bone Loss
1282536|NCT00836797|Alveolar ridge
1282537|NCT00836797|Alveolar Process
1282538|NCT00836784|Old tooth brush
1282539|NCT00836784|Plaque removal
1282540|NCT00836771|Infant formula
1282541|NCT00836771|Probiotic microorganisms
1282542|NCT00836771|prebiotic
1282543|NCT00836745|Advanced renal cell Cancer
1282544|NCT00836745|Non interventional study
1282545|NCT00836745|Renal Cancer
1282546|NCT00836745|Sutent
1282547|NCT00836745|Metastatic
1282548|NCT00836745|Advanced Renal Cell Carcinoma
1282549|NCT00836732|celle therapy
1282550|NCT00836732|cell culture
1282551|NCT00836732|mesenchymal stem cells
1282552|NCT00836719|Multiple sclerosis
1282553|NCT00836719|safety
1282554|NCT00836719|open label
1282555|NCT00836719|Polyphenon E
1282556|NCT00836719|EGCG
1282557|NCT00836719|NAA
1282558|NCT00836719|N-acetyl-aspartate
1282559|NCT00836719|MRI
1282560|NCT00836706|Bioequivalence
1282561|NCT00836706|Healthy Subjects
1282562|NCT00836693|Erectile Dysfunction
1282563|NCT00836667|Bioequivalence
1282564|NCT00836667|Healthy Subjects
1282565|NCT00836654|EpCAM positive tumor
1282566|NCT00836654|malignant ascites
1282567|NCT00836654|intraperitoneal
1282568|NCT00836641|preschool asthma
1282569|NCT00836641|sequential pneumococcal immunization
1282570|NCT00836641|immunogenicity
1282571|NCT00836641|safety
1282572|NCT00836589|Long-term safety and reliability of ICD leads
1282573|NCT00836576|Bioequivalence
1282574|NCT00836576|Healthy Subjects
1282575|NCT00836563|Hemodialysis
1282576|NCT00836563|Arteriovenous Graft
1282577|NCT00836550|HIV
1282578|NCT00836550|HIV knowledge measure
1282579|NCT00836550|Teen HIV testing
1282580|NCT00836550|HIV Seronegativity
1282581|NCT00836537|Bioequivalence
1282582|NCT00836537|Healthy Subjects
1282583|NCT00836524|IUGR
1282584|NCT00836524|Preeclampsia
1282585|NCT00836524|ultrasound
1282586|NCT00836524|YKL-40
1282587|NCT00836472|Bioequivalence
1282588|NCT00836472|Healthy Subjects
1282589|NCT00836459|Humans
1282590|NCT00836459|Middle Aged
1282591|NCT00836459|Behavior Therapy
1282592|NCT00836459|Directive Counseling
1282593|NCT00836459|Health Behavior
1282594|NCT00836459|Interview, Psychological
1282595|NCT00836459|Motivation
1282596|NCT00836459|Exercise
1282597|NCT00836459|Physical Fitness
1282598|NCT00836459|Self Efficacy
1282599|NCT00836459|Life Style
1282600|NCT00836459|Health Promotion
1282601|NCT00836459|Health Knowledge, Attitudes, Practice
1282602|NCT00836459|Body Mass Index
1282603|NCT00836459|Monitoring, Ambulatory
1282604|NCT00836459|Walking
1282605|NCT00836446|school-aged
1282606|NCT00836446|children
1282607|NCT00836446|obesity
1282608|NCT00836446|cardiovascular risk
1282609|NCT00836446|physical activity
1282610|NCT00836433|staff education
1282611|NCT00836433|complexity science
1282612|NCT00836433|social constructivist theory
1282613|NCT00836420|ammonia
1282614|NCT00836420|acute liver failure
1282615|NCT00836420|brain edema
1282616|NCT00836420|oxidative metabolism
1282617|NCT00836420|intracranial pressure
1282618|NCT00836407|pancreatic cancer
1282619|NCT00836407|vaccine
1282620|NCT00836407|immunotherapy
1282621|NCT00836407|antibody
1282622|NCT00836407|CTLA-4
1282623|NCT00836394|arthritis
1282624|NCT00836394|juvenile idiopathic arthritis
1282625|NCT00836394|pediatric
1282626|NCT00836394|intervention
1282627|NCT00836394|vibration therapy
1282628|NCT00836394|JIA
1282629|NCT00836381|Overactive bladder
1282630|NCT00836381|Antimuscarinics
1282631|NCT00836381|Patient-reported goal achievement
1282632|NCT00836368|Asthma
1282633|NCT00836368|Asthmatic
1282634|NCT00836368|Allergy
1282635|NCT00836368|Allergic
1282636|NCT00836368|Gamma-tocopherol
1282637|NCT00836368|Vitamin
1282638|NCT00836368|Vitamin E
1282639|NCT00836355|stroke
1282640|NCT00836355|magnetic resonance imaging
1282641|NCT00836355|enoxaparin
1282642|NCT00836355|minocycline
1282643|NCT00836355|NIH stroke scale
1282644|NCT00836355|modified Rankin scale
1282645|NCT00836355|neuroprotection
1282646|NCT00836342|Non-melanoma skin cancer
1282647|NCT00836342|Basal cell carcinoma
1282648|NCT00836342|Squamous cell carcinoma
1282649|NCT00836329|Neurologic
1282650|NCT00836329|Diabetes
1282651|NCT00836329|Cardiac Surgery
1282652|NCT00836329|Stroke
1282653|NCT00836316|laparoscopic cholecystectomy
1282654|NCT00836290|risk reduction
1282655|NCT00836290|HIV prevention
1282656|NCT00836290|HIV education
1282657|NCT00836290|HIV Seronegativity
1282658|NCT00836277|Panitumumab
1282659|NCT00836277|Irinotecan
1282660|NCT00836277|Esophageal Adenocarcinoma
1282661|NCT00836277|Phase II
1282662|NCT00836264|Morphine
1282663|NCT00836264|Phenotype
1282664|NCT00836264|Genotype
1282665|NCT00836264|Tonsillectomy
1282666|NCT00836264|Adenoidectomy
1282667|NCT00836264|Opioid Receptors
1282668|NCT00836264|Genome-Wide Association
1282669|NCT00836264|Pharmacokinetics
1282670|NCT00836251|energy expenditure
1282671|NCT00836251|schizophrenia
1282672|NCT00836238|Prostate Cancer
1282673|NCT00836238|Neural Functioning Assessment
1282674|NCT00836238|Physical Assessment
1282675|NCT00836238|Questionnaire
1282676|NCT00836238|Objective Measures of Functional Status
1282677|NCT00836238|Physical Function
1282678|NCT00836238|Symptom Assessment Interview
1282679|NCT00836238|Elderly
1282680|NCT00836225|diabetes
1282681|NCT00836225|SGLT2 inhibitor
1282682|NCT00836212|HIV
1282683|NCT00836212|Adjusting Antiretroviral Therapy
1282684|NCT00836212|Dosage using Therapeutic Drug Monitoring
1282685|NCT00836212|Swiss HIV Cohort Study
1282686|NCT00836212|HIV Geneva
1282687|NCT00836212|lopinavir
1282688|NCT00836212|efavirenz
1282689|NCT00836212|Treatment Experienced
1282690|NCT00836199|smoking cessation
1282691|NCT00836199|NicVAX
1282692|NCT00836199|smoking vaccine
1282693|NCT00836199|smoking abstinence
1282694|NCT00836199|smoking
1282695|NCT00836199|tobacco cessation
1282696|NCT00836173|CARBOPLATIN
1282697|NCT00836173|DEXAMETHASONE
1282698|NCT00836173|DIFFUSE LARGE B-CELL LYMPHOMA
1282699|NCT00836173|ETOPOSIDE
1282700|NCT00836173|GALLIUM NITRATE
1282701|NCT00836173|IFOSFAMIDE
1282702|NCT00836173|PHASE II
1282703|NCT00836173|RELAPSED OR REFRACTORY
1282704|NCT00836173|RITUXIMAB
1282705|NCT00836160|EGFR-TKI therapy
1282706|NCT00836160|NSCLC
1282707|NCT00836160|Efficacy
1282708|NCT00836134|pain relief after umbilical hernia repair
1282709|NCT00836134|morphine consumption
1282710|NCT00836134|plasma bupivacaine levels
1282711|NCT00836121|Teratoma
1282712|NCT00836121|Mediastinum
1282713|NCT00836108|Lung Diseases, Obstructive
1282714|NCT00836108|Breathing Exercises
1282715|NCT00836108|Exercise Tolerance
1282716|NCT00836108|Dyspnea
1282717|NCT00836108|Arm Exercise
1282718|NCT00836095|laryngeal mask, proseal
1282719|NCT00836082|Healthy volunteers
1282720|NCT00836069|Generalized Anxiety Disorder
1282721|NCT00836056|Bioequivalence
1282722|NCT00836056|Healthy Subjects
1282723|NCT00836043|CLL
1282724|NCT00836043|alemtuzumab
1282725|NCT00836004|Bioequivalence
1282726|NCT00836004|Healthy Subjects
1282727|NCT00835991|Bioequivalence
1282728|NCT00835991|Healthy Subjects
1282729|NCT00835978|axitinib or AG-013736 dose titration (increase) renal cell carcinoma
1282730|NCT00835978|kidney cancer
1282731|NCT00835965|Laparoscopic
1282732|NCT00835965|Surgery
1282733|NCT00835965|Postoperative
1282734|NCT00835965|Nausea
1282735|NCT00835965|Vomiting
1282736|NCT00835965|Aprepitant
1282737|NCT00835965|Dexamethasone
1282738|NCT00835965|Postoperative Nausea, Postoperative Vomiting
1282739|NCT00835939|Achilles
1282740|NCT00835939|Tendinopathy
1282741|NCT00835939|Sclerotherapy
1282742|NCT00835939|Neovascularisation
1282743|NCT00835939|sports medicine
1282744|NCT00835939|interventional radiology
1282745|NCT00835926|Influenza
1282746|NCT00835926|Fluzone®
1282747|NCT00835913|Autonomic nervous system
1282748|NCT00835913|Sepsis shock
1282749|NCT00835913|severe sepsis
1282750|NCT00835913|sinusal change
1282751|NCT00835913|Myocardiac fixing
1282752|NCT00835913|NTproBNP
1282753|NCT00835913|Patient in intensive care unit with sepsis shock or severe
1282754|NCT00835913|Sepsis
1282755|NCT00835900|smoking cessation
1282756|NCT00835900|varenicline
1282757|NCT00835900|smoking cessation treatment
1282758|NCT00835874|probiotic
1282759|NCT00835874|preterm
1282760|NCT00835874|lactation
1282761|NCT00835874|breast feeding
1282762|NCT00835874|necrotizing enterocolitis
1282763|NCT00835874|sepsis
1282764|NCT00835874|bacterial cultures
1282765|NCT00835874|lactating mother
1282766|NCT00835874|breast feeding of at least 50% of enteric feeding volume
1282767|NCT00835874|Infant, very low birth weight
1282768|NCT00835861|Non Insulin Dependent Diabetes
1282769|NCT00835861|Pregnancy
1282770|NCT00835848|ST-segment elevation myocardial infarction
1282771|NCT00835848|Primary PCI
1282772|NCT00835848|Postconditioning
1282773|NCT00835835|Multiple Sclerosis
1282774|NCT00835835|gait
1282775|NCT00835835|falls
1282776|NCT00835835|lokomat
1282777|NCT00835835|body-weight support treadmill training
1282778|NCT00835822|Chronic Venous Insufficiency, Venocur Triplex®
1282902|NCT00835185|Colorectal Neoplasms
1282779|NCT00835809|Acute respiratory insufficiency respiratory
1282780|NCT00835809|Biomarkers
1282781|NCT00835809|Emergency
1282782|NCT00835809|Intensive care unit
1282783|NCT00835809|Prospective
1282784|NCT00835809|Patient hospitalize in emergency or in intensive care unit
1282785|NCT00835809|for acute respiratory insufficiency
1282786|NCT00835796|Bioequivalence
1282787|NCT00835796|Healthy Subjects
1282788|NCT00835770|relapsing
1282789|NCT00835770|multiple sclerosis
1282790|NCT00835770|remitting
1282791|NCT00835770|oral
1282792|NCT00835744|ovulation induction
1282793|NCT00835744|clomiphene citrate
1282794|NCT00835744|gonadotropins
1282795|NCT00835731|induced abortion
1282796|NCT00835731|misoprostol
1282797|NCT00835731|cervical ripening
1282798|NCT00835731|second trimester abortion
1282799|NCT00835731|Dilapan-S
1282800|NCT00835705|Bioequivalence
1282801|NCT00835705|Healthy Subjects
1282802|NCT00835692|Bioequivalence
1282803|NCT00835692|Healthy Subjects
1282804|NCT00835666|Bioequivalence
1282805|NCT00835666|Healthy Subjects
1282806|NCT00835640|Bioequivalence
1282807|NCT00835640|Healthy Subjects
1282808|NCT00835627|Treatment
1282809|NCT00835627|Cognitive Behavior Therapy
1282810|NCT00835627|pharmacotherapy
1282811|NCT00835627|psychogenic nonepileptic seizures
1282812|NCT00835627|pseudoseizures
1282813|NCT00835627|dissociative seizures
1282814|NCT00835627|conversion disorder
1282815|NCT00835614|Bioequivalence
1282816|NCT00835614|Healthy Subjects
1282817|NCT00835588|Bioequivalence
1282818|NCT00835588|Healthy Subjects
1282819|NCT00835575|Bioequivalence
1282820|NCT00835575|Healthy Subjects
1282821|NCT00835562|Shoulder fractures
1282822|NCT00835562|Proximal humeral fractures
1282823|NCT00835562|Randomised clinical trial
1282824|NCT00835562|elderly
1282825|NCT00835562|Displaced four-part fractures of the proximal humerus
1282826|NCT00835549|Bioequivalence
1282827|NCT00835549|Healthy Subjects
1282828|NCT00835536|Bioequivalence
1282829|NCT00835536|Healthy Subjects
1282830|NCT00835523|frozen-thawed embryo replacement
1282831|NCT00835523|GnRH agonist
1282832|NCT00835523|GnRH antagonist
1282833|NCT00835523|ovarian hyperstimulation
1282834|NCT00835510|Tinea pedis
1282835|NCT00835497|Bioequivalence
1282836|NCT00835497|Healthy Subjects
1282837|NCT00835484|Bioequivalence
1282838|NCT00835484|Healthy Subjects
1282839|NCT00835471|Lung cancer
1282840|NCT00835471|non-small-cell
1282841|NCT00835471|erlotinib
1282842|NCT00835471|chemotherapy
1282843|NCT00835458|gastric fistula
1282844|NCT00835458|perforation
1282845|NCT00835458|endoscopy
1282846|NCT00835458|closure
1282847|NCT00835458|endolumenal
1282848|NCT00835432|Lateral augmentation
1282849|NCT00835432|GBR
1282850|NCT00835432|BoneCeramic
1282851|NCT00835432|collagen membrane
1282852|NCT00835432|histomorphometry
1282853|NCT00835432|morphometry
1282854|NCT00835432|reentry
1282855|NCT00835432|biopsy
1282856|NCT00835419|metastatic malignant melanoma with cyclin D1 positivity
1282857|NCT00835406|Bioequivalence
1282858|NCT00835406|Healthy Subjects
1282859|NCT00835393|Bioequivalence
1282860|NCT00835393|Healthy Subjects
1282861|NCT00835367|Bioequivalence
1282862|NCT00835367|Healthy Subjects
1282863|NCT00835354|Bioequivalence
1282864|NCT00835354|Healthy Subjects
1282865|NCT00835341|oral epithelial dysplasia
1282866|NCT00835341|p16 methylation
1282867|NCT00835341|prognosis
1282868|NCT00835341|malignant transformation
1282869|NCT00835341|oral squamous cell carcinoma
1282870|NCT00835328|hyperinsulinism
1282871|NCT00835328|hypoglycemia
1282872|NCT00835328|ATP- sensitive potassium channel (KATP)
1282873|NCT00835315|interdigital psoriasis (psoriasis alba)
1282874|NCT00835302|Cervical
1282875|NCT00835302|Thoracic
1282876|NCT00835302|Manipulation
1282877|NCT00835302|Mobilization
1282878|NCT00835302|Clinical prediction rule
1282879|NCT00835302|Shoulder pain.
1282880|NCT00835289|Clinical Trials, Randomized
1282881|NCT00835276|Bioequivalence
1282882|NCT00835276|Healthy Subjects
1282883|NCT00835263|Bioequivalence
1282884|NCT00835263|Healthy Subjects
1282885|NCT00835250|Transvaginal cholecystectomy
1282886|NCT00835250|NOTES
1282887|NCT00835250|Minilaparoscopy
1282888|NCT00835250|Endoscopic surgery
1282889|NCT00835250|Cholecystectomy
1282890|NCT00835250|Surgical translumenal endoscopic surgery
1282891|NCT00835250|Transvaginal translumenal endoscopic surgery
1282892|NCT00835237|Boostrix®
1282893|NCT00835237|adults
1282894|NCT00835224|Spinal Cord Injury
1282895|NCT00835224|Orthostatic Hypotension
1282896|NCT00835224|Blood Pressure
1282897|NCT00835224|Midodrine Hydrochloride
1282898|NCT00835224|L-NAME
1282899|NCT00835211|Bioequivalence
1282900|NCT00835211|Healthy Subjects
1282901|NCT00835185|Antibodies, Monoclonal
1282903|NCT00835172|Bioequivalence
1282904|NCT00835172|Healthy Subjects
1282905|NCT00835159|Postoperative Delirium
1282906|NCT00835159|Postoperative Cognitive Dysfunction
1282907|NCT00835159|Rivastigmine
1282908|NCT00835159|Exelon
1282909|NCT00835159|Memory impairment
1282910|NCT00835159|Delirium
1282911|NCT00835159|Cognitive function
1282912|NCT00835146|Bioequivalence
1282913|NCT00835146|Healthy Subjects
1282914|NCT00835133|family
1282915|NCT00835133|history
1282916|NCT00835133|pancreas
1282917|NCT00835133|cancer
1282918|NCT00835133|melanoma
1282919|NCT00835133|genetic
1282920|NCT00835107|Bipolar Depression
1282921|NCT00835107|Sleep
1282922|NCT00835107|Polysomnograph
1282923|NCT00835107|Slow Wave Sleep
1282924|NCT00835107|Ziprasidone
1282925|NCT00835107|Antipsychotic
1282926|NCT00835107|Placebo
1282927|NCT00835081|Bioequivalence
1282928|NCT00835081|Healthy Subjects
1282929|NCT00835068|Hemophilia B
1282930|NCT00835068|observational
1282931|NCT00835068|post marketing study
1282932|NCT00835055|rectal cancer with neoadjuvant treatment
1282933|NCT00835055|standardized clinical tests
1282934|NCT00835055|tumor markers on tumor tissue
1282935|NCT00835042|Bioequivalence
1282936|NCT00835042|Healthy Subjects
1282937|NCT00835029|oral
1282938|NCT00835029|candida
1282939|NCT00835029|denture
1282940|NCT00835029|clotrimazole
1282941|NCT00835029|slow releases
1282942|NCT00835016|Early psychosocial stimulation, RCT, Depressed mother
1282943|NCT00835003|Neonatal admission
1282944|NCT00835003|Elective Caesarean Section
1282945|NCT00835003|Timing
1282946|NCT00835003|Choice behavior
1282947|NCT00835003|Intraoperative complications
1282948|NCT00835003|Postoperative complications
1282949|NCT00834990|Bioequivalence
1282950|NCT00834990|Healthy Subjects
1282951|NCT00834977|Bioequivalence
1282952|NCT00834977|Healthy Subjects
1282953|NCT00834964|Bioequivalence
1282954|NCT00834964|Healthy Subjects
1282955|NCT00834951|Diffuse large B-cell lymphoma
1282956|NCT00834951|Elderly patients
1282957|NCT00834951|Low dose total body irradiation
1282958|NCT00834951|RCHOP14
1282959|NCT00834938|diabetes mellitus, type 2
1282960|NCT00834938|Insulin resistance
1282961|NCT00834938|bariatric surgery
1282962|NCT00834938|Glucagon-Like Peptide 1
1282963|NCT00834938|Gastric Inhibitory Polypeptide
1282964|NCT00834938|insulin
1282965|NCT00834938|glucagon
1282966|NCT00834938|ghrelin
1282967|NCT00834938|adiponectin
1282968|NCT00834938|Cytokines
1282969|NCT00834938|gastric bypass
1282970|NCT00834938|Obesity
1282971|NCT00834925|atrial fibrillation with rapid ventricular response
1282972|NCT00834912|Healthy Subjects
1282973|NCT00834899|Sickle cell disease
1282974|NCT00834899|Pain crisis
1282975|NCT00834899|Acute pain episode
1282976|NCT00834899|Eptifibatide
1282977|NCT00834899|Antiplatelet therapy
1282978|NCT00834899|Safety
1282979|NCT00834899|Treatment
1282980|NCT00834873|Bioequivalence
1282981|NCT00834873|Healthy Subjects
1282982|NCT00834860|chronic hepatitis C
1282983|NCT00834860|sustained virological response
1282984|NCT00834860|peginterferon
1282985|NCT00834860|ribavirin
1282986|NCT00834860|neoplasm
1282987|NCT00834847|Bioequivalence
1282988|NCT00834847|Healthy Subjects
1282989|NCT00834834|Suicidal and Self-Injurious Behavior
1282990|NCT00834821|Attention Deficit Hyperactivity Disorder
1282991|NCT00834821|ADHD, Predominantly Inattentive Type
1282992|NCT00834821|Inattention
1282993|NCT00834821|Psychosocial Intervention
1282994|NCT00834821|Behavioral Intervention
1282995|NCT00834808|Healthy volunteers
1282996|NCT00834795|Bioequivalence
1282997|NCT00834795|Healthy Subjects
1282998|NCT00834782|PK
1282999|NCT00834782|IOP
1283000|NCT00833807|Melanoma
1283001|NCT00833807|Metastatic Melanoma to the Liver
1283002|NCT00833807|Liver metastasis
1283003|NCT00833807|Nab-paclitaxel
1283004|NCT00833807|Abraxane
1283005|NCT00833807|Paclitaxel (protein-bound)
1283006|NCT00833807|intraarterial intrahepatic administration
1283007|NCT00833807|Hepatic Artery
1283008|NCT00833807|Hepatic Arterial Infusion
1283009|NCT00833807|Hepatic Administration
1283010|NCT00833781|HIV vaccine
1283011|NCT00833781|Dendritic cells
1283012|NCT00833781|treatment experienced
1283013|NCT00833755|Pain
1283014|NCT00833755|Chronic pain
1283015|NCT00833755|Opioid induced hyperalgesia
1283016|NCT00833755|Opioid therapy
1283017|NCT00833742|somatization
1283018|NCT00833742|psychosomatic
1283019|NCT00833742|short-term
1283020|NCT00833742|dynamic
1283021|NCT00833742|psychotherapy
1283022|NCT00833729|psoriasis
1283023|NCT00833729|etanercept
1283024|NCT00833729|adalimumab
1283025|NCT00833729|moderate to severe plaque psoriasis
1283026|NCT00833703|cyanotic congenital heart disease
1283027|NCT00833703|shunt palliation
1283028|NCT00833703|thrombosis
1283029|NCT00833703|clopidogrel
1283030|NCT00833690|Parkinson's disease
1283031|NCT00833690|Parkinson disease
1283032|NCT00833690|PD
1283033|NCT00833690|inosine
1283034|NCT00833690|urate
1283035|NCT00833690|uric acid
1283036|NCT00833690|cerebrospinal fluid
1283037|NCT00833677|Coping skills
1283038|NCT00833677|Chinese
1283039|NCT00833677|Immigrant
1283040|NCT00833677|Type 2 Diabetes Mellitus
1283041|NCT00833677|Family research
1283042|NCT00834756|Bioequivalence
1283043|NCT00834756|Healthy Subjects
1283044|NCT00834743|Bioequivalence
1283045|NCT00834743|Healthy Subjects
1283046|NCT00834717|Bioequivalence
1283047|NCT00834717|Healthy Subjects
1283048|NCT00834704|PEGPH20
1283049|NCT00834704|PEGylated recombinant human hyaluronidase
1283050|NCT00834704|Metastatic or locally advanced solid tumor
1283051|NCT00834691|Inflammation
1283052|NCT00834691|Oxidative stress
1283053|NCT00834691|Estimated glomerular filtration rate
1283054|NCT00834678|male breast cancer
1283055|NCT00834678|recurrent breast cancer
1283056|NCT00834678|stage IIIB breast cancer
1283057|NCT00834678|stage IIIC breast cancer
1283058|NCT00834678|stage IV breast cancer
1283059|NCT00834678|estrogen receptor-negative breast cancer
1283060|NCT00834678|HER2-negative breast cancer
1283061|NCT00834678|progesterone receptor-negative breast cancer
1283062|NCT00834678|triple-negative breast cancer
1283063|NCT00834652|Metabolic Diseases
1283064|NCT00834652|Depressive Disorder, Major
1283065|NCT00834652|Depressive Disorder
1283066|NCT00834652|Glucose Metabolism Disorders
1283067|NCT00834652|Depression Recurrence
1283068|NCT00834639|Bioequivalence
1283069|NCT00834639|Healthy Subjects
1283070|NCT00834626|Ileal Interposition
1283071|NCT00834626|Sleeve Gastrectomy
1283072|NCT00834626|Type-2 Diabetes
1283073|NCT00834613|Bioequivalence
1283074|NCT00834613|Healthy Subjects
1283075|NCT00834587|Bioequivalence
1283076|NCT00834587|Healthy Subjects
1283077|NCT00834574|Bioequivalence
1283078|NCT00834574|Healthy Subjects
1283079|NCT00834561|Bioequivalence
1283080|NCT00834561|Healthy Subjects
1283081|NCT00834548|Magnetic resonance
1283082|NCT00834548|whole body
1283083|NCT00834548|angiography
1283084|NCT00834548|hybrid protocol
1283085|NCT00834548|MRI
1283086|NCT00834535|Bioequivalence
1283087|NCT00834535|Healthy Subjects
1283088|NCT00834522|Bioequivalence
1283089|NCT00834522|Healthy Subjects
1283090|NCT00834483|Safety
1283091|NCT00834483|Efficacy
1283092|NCT00834483|Cost-savings
1283093|NCT00834483|Cosmesis
1283094|NCT00834483|Safety and efficacy of wound closure
1283095|NCT00834483|Cost-savings potential
1283096|NCT00834483|Cosmesis of the wound/scar
1283097|NCT00834457|AIDS-related Kaposi's sarcoma
1283098|NCT00834457|antiretroviral therapy
1283099|NCT00834444|Bioequivalence
1283100|NCT00834444|Healthy Subjects
1283101|NCT00834431|Bioequivalence
1283102|NCT00834431|Healthy Subjects
1283103|NCT00834418|Bioequivalence
1283104|NCT00834418|Healthy Subjects
1283105|NCT00834405|Bioequivalence
1283106|NCT00834405|Healthy Subjects
1283107|NCT00834379|Bioequivalence
1283108|NCT00834379|Healthy Subjects
1283109|NCT00834366|Healthy volunteers
1283110|NCT00834340|Bioequivalence
1283111|NCT00834340|Healthy Subjects
1283112|NCT00834327|Restless Legs Syndrome
1283113|NCT00834301|End Stage Renal Disease
1283114|NCT00834301|Inflammation
1283115|NCT00834288|Healthy subjects
1283116|NCT00834288|Pharmacokinetics
1283117|NCT00834288|Bioavailability
1283118|NCT00834275|Bioequivalence
1283119|NCT00834275|Healthy Subjects
1283120|NCT00834249|Bioequivalence
1283121|NCT00834249|Healthy Subjects
1283122|NCT00834236|gastric cancer
1283123|NCT00834236|proteomics
1283124|NCT00834236|gastric juice
1283125|NCT00834223|refractory chronic forms of open angle glaucoma (OAG)
1283126|NCT00834223|OAG
1283127|NCT00834223|glaucoma
1283128|NCT00834197|Bioequivalence
1283129|NCT00834197|Healthy Subjects
1283130|NCT00834184|nikkomycin Z
1283131|NCT00834184|evaluate safety, tolerance and pharmacokinetics of nikkomycin Z
1283132|NCT00834158|Hepatocellular Carcinoma
1283133|NCT00834158|Hepatitis B
1283134|NCT00834158|Transarterial chemoembolization (TACE)
1283135|NCT00834158|Portal vein embolization (PVE)
1283136|NCT00834158|Surgical resection
1283137|NCT00834158|Disease-free survival
1283138|NCT00834158|Overall survival
1283139|NCT00834145|Edema
1283140|NCT00834145|Right heart failure
1283141|NCT00834145|Cor pulmonale
1283142|NCT00834145|Pump
1283143|NCT00834145|Leg compression
1283144|NCT00834132|Bioequivalence
1283145|NCT00834132|Healthy Subjects
1283146|NCT00834106|HPV 6/11/16/18 Infection
1283147|NCT00834093|Epstein-Barr Virus
1283148|NCT00834093|NPC
1283149|NCT00834093|EBV
1283150|NCT00834093|immunotherapy
1283151|NCT00834080|opioid dependence
1283152|NCT00834080|VIVITROL
1283153|NCT00834080|opioid-related disorders
1283154|NCT00834067|Bioequivalence
1283155|NCT00834067|Healthy Subjects
1283156|NCT00834041|aliskiren
1283157|NCT00834041|pediatric
1283158|NCT00834041|hypertension
1283159|NCT00834041|pharmacokinetics (PK)
1283160|NCT00834041|pharmacodynamics (PD)
1283161|NCT00834041|plasma renin activity
1283162|NCT00834041|mini-tablet formulation
1283163|NCT00834028|hepatocellular carcinoma
1283164|NCT00834028|vascular endothelial growth factor
1283165|NCT00834028|angiopoietin
1283166|NCT00834028|cathepsin
1283167|NCT00834015|spinal fusion
1283168|NCT00834015|pain
1283169|NCT00834015|disability
1283170|NCT00834015|muscle strength
1283171|NCT00834015|mobility
1283172|NCT00834015|quality of life
1283173|NCT00834015|lumbar
1283174|NCT00834015|isthmic or degenerative spondylolisthesis
1283175|NCT00834002|AML in remission
1283176|NCT00833950|Tinnitus
1283177|NCT00833950|Phase Out
1283178|NCT00833937|Bioequivalence
1283179|NCT00833937|Healthy Subjects
1283180|NCT00833924|Low Profile
1283181|NCT00833924|Abdominal Aortic Aneurysms
1283182|NCT00833924|Endovascular
1283183|NCT00833911|Moderate to severe symptomatic osteoarthritis of the knee
1283184|NCT00833898|depression
1283185|NCT00833898|stress
1283186|NCT00833898|caregiving
1283187|NCT00833898|anxiety
1283188|NCT00833898|psychoeducation intervention
1283189|NCT00833898|psycho-oncology
1283190|NCT00833885|Non pharmaceutical measures
1283191|NCT00833859|stereotactic radiosurgery
1283192|NCT00833859|borderline resectable pancreatic cancer
1283193|NCT00833859|gastrointestinal
1283194|NCT00833859|pancreas
1283195|NCT00833846|Mitochondria in Platelets
1283196|NCT00833846|Mitochondria in Diabetes
1283197|NCT00833846|Insulin Resistance and Mitochondria
1283198|NCT00833846|Diabetes
1283199|NCT00833846|Insulin Resistance
1283200|NCT00833820|ALS
1283201|NCT00833820|transcranial brain stimulation
1283202|NCT00833664|Bioequivalence
1283203|NCT00833664|Healthy Subjects
1283204|NCT00833651|Transplant
1283205|NCT00833651|Immunology
1283206|NCT00833651|Immunosuppression
1283207|NCT00833638|Erectile Dysfunction
1283208|NCT00833625|Gastrointestinal
1283209|NCT00833625|Esophagus
1283210|NCT00833625|Cancer of the esophagus
1283211|NCT00833625|Biopsy
1283212|NCT00833625|EGD
1283213|NCT00833625|Esophagogastroduodenoscopy
1283214|NCT00833625|PET/CT
1283215|NCT00833625|Positive Emission Tomography/Computerized Tomography
1283216|NCT00833625|Esophageal Cancer
1283217|NCT00833625|Chemoradiation
1283218|NCT00833625|Chemotherapy
1283219|NCT00833625|Radiation Therapy
1283220|NCT00833612|IABC
1283221|NCT00833612|AMI
1283222|NCT00833599|Lymphedema
1283223|NCT00833599|Genetic
1283224|NCT00833599|Lymphatic Disorder
1283225|NCT00833599|Lipedema
1283226|NCT00833599|Vascular Malformation
1283227|NCT00833599|Vascular Anomaly
1283228|NCT00833586|Bioequivalence
1283229|NCT00833586|Healthy Subjects
1283230|NCT00833573|GERD digestive expression
1283231|NCT00833573|ages
1283232|NCT00833560|Multiple Myeloma
1283233|NCT00833560|Untreated multiple myeloma
1283234|NCT00833560|Bortezomib
1283235|NCT00833560|VELCADE
1283236|NCT00833560|Cyclophosphamide
1283237|NCT00833560|Dexamethasone
1283238|NCT00833560|Chemotherapy
1283239|NCT00833560|Remission therapy
1283240|NCT00833560|Induction therapy
1283241|NCT00833560|Stem Cell Transplantation
1283242|NCT00833547|sleep
1283243|NCT00833547|schizophrenia
1283244|NCT00833547|procedural learning
1283245|NCT00833547|motor skill
1283246|NCT00833534|stage I chronic lymphocytic leukemia
1283247|NCT00833534|stage II chronic lymphocytic leukemia
1283248|NCT00833534|stage III chronic lymphocytic leukemia
1283249|NCT00833534|stage IV chronic lymphocytic leukemia
1283250|NCT00833534|stage I small lymphocytic lymphoma
1283251|NCT00833534|stage III small lymphocytic lymphoma
1283252|NCT00833534|stage IV small lymphocytic lymphoma
1283253|NCT00833534|contiguous stage II small lymphocytic lymphoma
1283254|NCT00833534|noncontiguous stage II small lymphocytic lymphoma
1283255|NCT00833521|Bioequivalence
1283256|NCT00833521|Healthy Subjects
1283257|NCT00833508|Exercise capacity
1283258|NCT00833508|Chemoradiotherapy
1283259|NCT00833508|Colorectal cancer
1283260|NCT00833469|women
1283261|NCT00833469|postpartum depression
1283262|NCT00833469|anxiety
1283263|NCT00833456|schizophrenia
1283264|NCT00833456|Seroquel SR
1283265|NCT00833456|atypical antipsychotics
1283266|NCT00833456|assessment of functioning
1283267|NCT00833456|GAF scale
1283268|NCT00833443|Methamphetamine
1283269|NCT00833443|Addiction
1283270|NCT00833443|Pharmacogenomics
1283271|NCT00833443|Amphetamine
1283272|NCT00833443|Bupropion
1283273|NCT00833443|Meth
1283274|NCT00833443|Crank
1283275|NCT00833443|Crystal
1283276|NCT00833430|AVN
1283277|NCT00833430|Femoral Head Collapse
1283278|NCT00833417|BCC
1283279|NCT00833417|Hedgehog Pathway Inhibitor
1283280|NCT00833417|Hedgehog
1283281|NCT00833417|Basal Cell Cancer
1283282|NCT00833404|Smoking
1283283|NCT00833404|Smoking Cessation
1283284|NCT00833404|Quit Smoking
1283285|NCT00833404|Stop Smoking
1283286|NCT00833404|Nicotine Patch
1283287|NCT00833404|Nicotine Replacement Therapy
1283288|NCT00833404|Sexual Functioning
1283289|NCT00833404|Erectile Functioning
1283290|NCT00833404|Sexual Health
1283291|NCT00833391|healthy volunteer
1283292|NCT00833391|formulations
1283293|NCT00833391|bioavailability
1283294|NCT00833391|pharmacokinetics
1283295|NCT00833378|Drug interaction, SB-497115 (eltrombopag), Kaletra (Lopinavir, Ritonavir),thrombocytopenia, pharmacokinetics
1283296|NCT00833365|premature infants
1283297|NCT00833365|PDA
1283298|NCT00833365|ibuprofen
1283299|NCT00833313|Atrial fibrillation
1283300|NCT00833313|Gene expression
1283301|NCT00833313|Genetic
1283302|NCT00833300|Delirium
1283303|NCT00833300|Agitation
1283304|NCT00833300|Intensive Care
1283305|NCT00833300|Critical Care
1283306|NCT00833300|Antipsychotics
1283307|NCT00833300|Olanzapine
1283308|NCT00833300|Haloperidol
1283309|NCT00833287|immunoregulatory
1283310|NCT00833287|dysfunction
1283311|NCT00833287|obesity
1283312|NCT00833261|recurrent squamous cell carcinoma of the hypopharynx
1283313|NCT00833261|recurrent squamous cell carcinoma of the larynx
1283314|NCT00833261|recurrent verrucous carcinoma of the larynx
1283315|NCT00833261|recurrent squamous cell carcinoma of the lip and oral cavity
1283316|NCT00833261|recurrent verrucous carcinoma of the oral cavity
1283317|NCT00833261|recurrent metastatic squamous neck cancer with occult primary
1283318|NCT00833261|recurrent squamous cell carcinoma of the oropharynx
1283319|NCT00833261|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1283320|NCT00833261|tongue cancer
1283321|NCT00833222|premature birth
1283322|NCT00833209|Orbitofrontal cortex
1283323|NCT00833209|Medication Overuse Headache
1283324|NCT00833209|Chronic headache
1283325|NCT00833209|withdrawal
1283326|NCT00833170|pediatric inflammatory bowel disease
1283327|NCT00833170|multiple site study
1283328|NCT00833157|Knee Osteoarthritis
1283329|NCT00833157|exercise
1283330|NCT00833157|strength training
1283331|NCT00833157|Glucosamine
1283332|NCT00833157|Dietary supplement
1283333|NCT00833157|Ibuprofen
1283334|NCT00833157|NSAID
1283335|NCT00833144|heart failure
1283336|NCT00833144|dyspnea
1283337|NCT00833144|ultrasound
1283338|NCT00833131|Rectal cancer
1283339|NCT00833131|Preoperative radiotherapy and consolidating chemotherapy
1283340|NCT00833118|Surgery
1283341|NCT00833118|General Anesthesia
1283342|NCT00833118|Intubation
1283343|NCT00833105|Incomplete Spinal Cord Injury
1283344|NCT00833105|Rehabilitation
1283345|NCT00833105|Upper Extremity
1283346|NCT00833105|AMES device
1283347|NCT00833105|Incomplete SCI
1283348|NCT00833105|Quadriplegia
1283349|NCT00833092|magnesium
1283350|NCT00833092|Nutritional Requirements
1283351|NCT00833092|Sleep
1283352|NCT00833079|Atopic Dermatitis
1283353|NCT00833066|hay fever
1283354|NCT00833066|grass pollen allergy
1283355|NCT00833040|Cancer breakthrough pain
1283356|NCT00833001|Anterior vaginal prolapse (medial, lateral,apical cystocele)
1283357|NCT00833001|Posterior vaginal prolapse (rectocele and/or enterocele)
1283358|NCT00833001|Vault prolapse (enterocele, uterine/vaginal vault prolapse)
1283359|NCT00832988|pacing thresholds
1283360|NCT00832988|sensing
1283361|NCT00832988|impedance
1283362|NCT00832962|Rhesus D
1283363|NCT00832962|Anti-D allo-immunization
1283364|NCT00832962|Fetal RHD genotyping
1283365|NCT00832962|anti-D immunoglobulins
1283366|NCT00832962|anti-D prophylaxis
1283367|NCT00832949|Mixed methods research (qualitative and quantitative)
1283368|NCT00832949|Peer support
1283369|NCT00832949|Early inflammatory arthritis
1283370|NCT00832949|Self-management
1283371|NCT00832949|Patient education
1283372|NCT00832923|parental empowerment
1283373|NCT00832923|parent self-efficacy
1283374|NCT00832910|Body image
1283375|NCT00832910|Rheumatoid Arthritis
1283376|NCT00832897|Keratoconus
1283377|NCT00832897|riboflavin
1283378|NCT00832897|cornea
1283379|NCT00832897|crosslinking
1283380|NCT00832884|partial
1283381|NCT00832884|onset
1283382|NCT00832884|epilepsy
1283383|NCT00832884|pediatric
1283384|NCT00832884|lacosamide
1283385|NCT00832884|partial onset epilepsy
1283386|NCT00832884|vimpat
1283387|NCT00832871|Mifepristone
1283388|NCT00832871|RU-486
1283389|NCT00832871|Compassionate Use
1283390|NCT00832871|Antiprogesterone
1283391|NCT00832845|Late-life schizophrenia (LLS)
1283392|NCT00832845|Cognitive Behavioural Social Skills Training (CBSST)
1283393|NCT00832845|Randomized
1283394|NCT00832832|Glaucoma
1283395|NCT00832832|Eye drop
1283396|NCT00832832|Intraocular pressure
1283397|NCT00832832|Eyelid closure
1283398|NCT00832819|Cancer
1283399|NCT00832819|Lung Cancer
1283400|NCT00832806|smoking
1283401|NCT00832806|Champix
1283402|NCT00832806|Integrated Voice Response technology
1283403|NCT00832793|Mixed methods research (qualitative and quantitative)
1283404|NCT00832793|Peer support
1283405|NCT00832793|Early inflammatory arthritis
1283406|NCT00832793|Self-management
1283407|NCT00832793|Patient education
1283408|NCT00832780|Lung cancer
1283409|NCT00832780|radiation therapy
1283410|NCT00832780|SBRT
1283411|NCT00832780|Stereotactic Body Radiation Therapy
1283412|NCT00832780|Tomotherapy
1283413|NCT00832780|other solid tumors
1283414|NCT00832767|Laparoscopic Cholecystectomy
1283415|NCT00832767|Single Incision Laparoscopic Surgery
1283416|NCT00832767|Surgical Procedures, Minimally Invasive
1283417|NCT00832754|malaria
1283418|NCT00832754|rapid diagnostic test
1283419|NCT00832754|artemisinin
1283420|NCT00832754|Ghana
1283421|NCT00832741|GLP-1
1283422|NCT00832741|Type 1 diabetes
1283423|NCT00832741|Glycemic control
1283424|NCT00832741|Incretin hormone
1283425|NCT00832715|Lung
1283426|NCT00832715|Lung Cancer
1283427|NCT00832715|NSCLC
1283428|NCT00832715|Non Small Cell Lung Cancer
1283429|NCT00832715|Squamous Cell
1283430|NCT00832715|Adenocarcinoma
1283431|NCT00832715|Large Cell
1283432|NCT00832715|Endobronchial Ultrasound Transbronchial Needle Aspiration
1283433|NCT00832715|Mediastinal lymph node negative disease
1283434|NCT00832715|Mediastinal Nodal Metastasis
1283435|NCT00832715|EBUS-FNA
1283436|NCT00832715|Endobronchial Ultrasound Fine Needle Aspiration
1283437|NCT00832715|EBUS guided needle mediastinal lymph node biopsy
1283438|NCT00832715|Biopsy
1283439|NCT00832715|PET scan
1283440|NCT00832715|Positron Emission Tomography
1283441|NCT00832715|CT Scans
1283442|NCT00832715|Computed Tomography Scans
1283443|NCT00832715|Lymph node
1283444|NCT00832715|Mediastinoscopy
1283445|NCT00832715|Bronchoscope
1283446|NCT00832702|Cardiac
1283447|NCT00832702|MRI
1283448|NCT00832702|Coronary Vascular Dysfunction
1283449|NCT00832689|toxicity
1283450|NCT00832676|Mixed methods research (qualitative and quantitative)
1283451|NCT00832676|Peer support
1283452|NCT00832676|Early inflammatory arthritis
1283453|NCT00832676|Self-management
1283454|NCT00832676|Patient education
1283455|NCT00832663|Muscle regeneration
1283456|NCT00832663|Satellite cells
1283457|NCT00832663|electrical stimulation
1283458|NCT00832663|eccentric contractions
1283459|NCT00832663|myogenic precursor cells
1283460|NCT00832650|Healthy; Fesoterodine; Solifenacin
1283461|NCT00832637|Liver
1283462|NCT00832637|Gallbladder
1283463|NCT00832637|Bile duct
1283464|NCT00832637|Gemzar
1283465|NCT00832637|Eloxatin
1283466|NCT00832637|Tarceva
1283467|NCT00832637|erlotinib
1283468|NCT00832637|Gem-ox
1283469|NCT00832611|Lung Disease
1283470|NCT00832611|Chronic Airflow Obstruction
1283471|NCT00832611|Chronic Bronchitis
1283472|NCT00832611|Chronic Emphysema
1283473|NCT00832598|18F-FACBC
1283474|NCT00832598|PET scan imaging
1283475|NCT00832598|08-142
1283476|NCT00832585|Atopic
1283477|NCT00832585|Dermatitis
1283478|NCT00832585|chronic
1283479|NCT00832585|skin
1283480|NCT00832572|Coronary Artery Disease
1283481|NCT00832572|Pain
1283482|NCT00832572|Peripheral Neuropathy
1283483|NCT00832572|Polyneuropathy
1283484|NCT00832559|CAVATAK
1283485|NCT00832559|Coxsackievirus A21
1283486|NCT00832559|CVA21
1283487|NCT00832559|Oncolytic virotherapy
1283488|NCT00832533|Vitamin D
1283489|NCT00832533|Serum 25-Hydroxyvitamin D
1283490|NCT00832533|UV exposure
1283491|NCT00832533|Ultraviolet Light Exposure
1283492|NCT00832533|Skin Melanoma Advanced
1283493|NCT00832520|Advanced cancer
1283494|NCT00832520|weight loss
1283495|NCT00832520|Remeron
1283496|NCT00832520|body weight
1283497|NCT00832507|PAH
1283498|NCT00832507|pulmonary hypertension
1283499|NCT00832507|cicletanine
1283500|NCT00832507|cicletanine HCL
1283501|NCT00832507|cardiovascular
1283502|NCT00832507|endothelin receptor antagonist
1283503|NCT00832507|ERA
1283504|NCT00832507|monotherapy
1283505|NCT00832507|combination therapy
1283506|NCT00832507|phosphodiesterase type-5 inhibitor
1283507|NCT00832507|PDE5i
1283508|NCT00832507|parenteral prostanoid
1283509|NCT00832507|PH
1283510|NCT00832507|pulmonary
1283511|NCT00832481|Repaglinide
1283512|NCT00832481|Metformin
1283513|NCT00832468|insomnia
1283514|NCT00832468|ear acupressure
1283515|NCT00832442|Beta blocker
1283516|NCT00832442|Heart Failure
1283517|NCT00832442|Meta analysis
1283518|NCT00832442|Individual patient data
1283643|NCT00831883|Behavioral Intervention
1283519|NCT00832429|Sebaceous Gland Carcinoma of the Eyelid
1283520|NCT00832429|Eyelid Sebaceous Gland Carcinoma
1283521|NCT00832429|Cancer of the eyelid
1283522|NCT00832429|Eye Cancer
1283523|NCT00832429|Tumors of the Eye
1283524|NCT00832429|Sentinel Lymph Node Localization and Biopsy
1283525|NCT00832429|SLN
1283526|NCT00832429|Metastatic Disease
1283527|NCT00832429|Metastatic Cancer of the Eyelid
1283528|NCT00832429|Lymphatic Mapping
1283529|NCT00832429|SLN Mapping/Biopsy
1283530|NCT00832429|SLN Biopsy Procedure
1283531|NCT00832429|SLN Biopsy
1283532|NCT00832429|Lymph Nodes
1283533|NCT00832429|Tc99m-Sulfur Colloid
1283534|NCT00832429|Single Photon Emission Computed Tomography
1283535|NCT00832429|Computed Tomography
1283536|NCT00832429|SPECT/CT
1283537|NCT00832403|atrophic rhinitis
1283538|NCT00832403|implants
1283539|NCT00832403|Polytetrafluoroethylene
1283540|NCT00832364|Psoriasis
1283541|NCT00832364|Moderate to Severe Plaque Psoriasis
1283542|NCT00832351|Stroke
1283543|NCT00832351|Brain infarction
1283544|NCT00832351|Intracerebral hemorrhage
1283545|NCT00832351|Early Mobilisation
1283546|NCT00832338|Breast cancer
1283547|NCT00832338|Tumors, Breast
1283548|NCT00832338|Cancer of the breast
1283549|NCT00832325|Childhood Survivor
1283550|NCT00832325|survivors
1283551|NCT00832325|Young Adult Cancer Survivors
1283552|NCT00832325|Childhood cancers
1283553|NCT00832325|09-001
1283554|NCT00832312|Osteoarthritis
1283555|NCT00832312|Knee
1283556|NCT00832312|Pain management
1283557|NCT00832312|Ozone therapy
1283558|NCT00832312|Intraarticular injection
1283559|NCT00832286|genomic techniques,intestinal microbiome
1283560|NCT00832273|Expanded access to ELAD® in patients with liver failure
1283561|NCT00832247|Hepatitis C
1283562|NCT00832247|Cirrhosis
1283563|NCT00832247|Stem cell
1283564|NCT00832234|Morbus Waldenstrom
1283565|NCT00832234|Waldenstroms Macroglobulinemia
1283566|NCT00832234|Therapy
1283567|NCT00832234|Rituximab
1283568|NCT00832234|Dexamethasone
1283569|NCT00832234|Bortezomib
1283570|NCT00832221|PET
1283571|NCT00832221|Phase 1
1283572|NCT00832221|Depression
1283573|NCT00832221|SEROQUEL
1283574|NCT00832221|Positron Emission Tomography
1283575|NCT00832221|Drug profile comparison
1283576|NCT00832195|running
1283577|NCT00832195|injury
1283578|NCT00832195|pronation
1283579|NCT00832195|footwear.
1283580|NCT00832169|Pain
1283581|NCT00832156|Burns
1283582|NCT00832156|Cultured autologous keratinocytes
1283583|NCT00832156|Wound healing
1283584|NCT00832156|Wound closure
1283585|NCT00832156|Scar quality
1283586|NCT00832143|neonatal illness
1283587|NCT00832143|qualified care seeking
1283588|NCT00832143|Behaviour change
1283589|NCT00832143|Urban slums
1283590|NCT00832143|India
1283591|NCT00832143|Neonatal morbidity
1283592|NCT00832143|Care seeking for neonatal illnesses
1283593|NCT00832143|Qualified medical care seeking
1283594|NCT00832143|Integrated management of neonatal and childhood illnesses (IMNCI)
1283595|NCT00832117|Lung Cancer (NSCLC)
1283596|NCT00832091|Venous Stasis Ulcers
1283597|NCT00832091|venous insufficiency
1283598|NCT00832091|leg ulcers
1283599|NCT00832091|Thymosin Beta 4
1283600|NCT00832091|Laminin-5
1283601|NCT00832065|Sleep Apnea Syndrome
1283602|NCT00832065|Sleep Apnea
1283603|NCT00832065|CPAP
1283604|NCT00832065|Low testosterone
1283605|NCT00832065|Sexual Dysfunction
1283606|NCT00832052|elderly, multi-dose, safety, efficacy
1283607|NCT00832039|sepsis
1283608|NCT00832039|adjunctive therapy
1283609|NCT00832039|sodium-selenite
1283610|NCT00832039|procalcitonin
1283611|NCT00832026|sleep apnea
1283612|NCT00832026|snoring
1283613|NCT00832026|sleep apnea treatment
1283614|NCT00832026|TNI
1283615|NCT00832026|Trans nasal insuflation
1283616|NCT00832026|Open CPAP
1283617|NCT00832013|Propofol
1283618|NCT00832013|sedation
1283619|NCT00832013|pediatric
1283620|NCT00832013|Induction of sedation
1283621|NCT00831987|Fluzone®
1283622|NCT00831987|Influenza
1283623|NCT00831987|Adults
1283624|NCT00831974|mastocytosis
1283625|NCT00831974|indolent
1283626|NCT00831974|handicap
1283627|NCT00831974|wild-type
1283628|NCT00831974|systemic
1283629|NCT00831974|not D816V mutated
1283630|NCT00831961|Antibiotic resistance, Conjunctival flora, Intravitreal injections
1283631|NCT00831935|Acoustic properties of voice in depression
1283632|NCT00831922|Rheumatoid Arthritis
1283633|NCT00831922|DMARD failure
1283634|NCT00831922|ACR
1283635|NCT00831909|Lung Cancer
1283636|NCT00831909|NSCLC management
1283637|NCT00831909|NSCLC use of health care resources
1283638|NCT00831883|Adolescent
1283639|NCT00831883|Adolescent behavior
1283640|NCT00831883|Health behavior
1283641|NCT00831883|Sexual Behavior
1283642|NCT00831883|Incarceration
1283644|NCT00831883|Risk Reduction Behavior
1283645|NCT00831870|EndoSure Sensor
1283646|NCT00831870|s2 Sensor
1283647|NCT00831870|abdominal aortic aneurysm
1283648|NCT00831831|perinatal
1283649|NCT00831831|intimate partner violence
1283650|NCT00831831|randomized controlled trial
1283651|NCT00831831|preterm
1283652|NCT00831831|hemorrhage
1283653|NCT00831831|safety
1283654|NCT00831818|breastfeeding
1283655|NCT00831818|ghrelin
1283656|NCT00831818|PYY
1283657|NCT00831818|appetite-regulation
1283658|NCT00831805|geriatrics
1283659|NCT00831805|psycho-cognitive troubles
1283660|NCT00831805|elderly
1283661|NCT00831805|mobile unit
1283662|NCT00831805|elderly patients
1283663|NCT00831792|Prostate Cancer
1283664|NCT00831792|Advanced Prostate Cancer
1283665|NCT00831792|Castrate Resistant Prostate Cancer
1283666|NCT00831792|Prostate Specific Antigen
1283667|NCT00831792|PSA
1283668|NCT00831792|Castration-Resistant Prostate Cancer Patients
1283669|NCT00831792|TK1258
1283670|NCT00831792|CHIR-258
1283671|NCT00831766|Hematopoietic
1283672|NCT00831766|Myeloid and Monocytic Leukemia
1283673|NCT00831766|AML
1283674|NCT00831753|Diphtheria
1283675|NCT00831753|Tetanus
1283676|NCT00831753|Pertussis
1283677|NCT00831753|whooping cough
1283678|NCT00831753|Haemophilus influenzae type b
1283679|NCT00831753|Hepatitis B
1283680|NCT00831753|Poliomyelitis
1283681|NCT00831740|Stroke
1283682|NCT00831740|Communication
1283683|NCT00831740|Speech and Language Therapy
1283684|NCT00831727|expressive writing
1283685|NCT00831727|trauma
1283686|NCT00831727|intervention
1283687|NCT00831727|posttraumatic stress
1283688|NCT00831714|Prophylaxis of Venous Thromboembolism
1283689|NCT00831701|Adrenergic alpha antagonists
1283690|NCT00831701|drug therapy
1283691|NCT00831701|tamsulosin
1283692|NCT00831701|ureter
1283693|NCT00831688|Meniere
1283694|NCT00831688|vertigo
1283695|NCT00831688|overpressure treatment
1283696|NCT00831688|caloric irrigation
1283697|NCT00831688|hearing levels
1283698|NCT00831688|vertigo severity
1283699|NCT00831688|functional disability scale
1283700|NCT00831675|Influenza
1283701|NCT00831675|Fluzone® vaccine
1283702|NCT00831675|Infants
1283703|NCT00831675|Toddlers
1283704|NCT00831636|CP-4055
1283705|NCT00831636|Cancer
1283706|NCT00831636|Metastatic
1283707|NCT00831636|Solid tumors
1283708|NCT00831636|advanced ovarian cancer
1283709|NCT00831636|stage III and IV ovarian cancer
1283710|NCT00831636|advanced epithelian ovarian cancer
1283711|NCT00831623|hypofractionation
1283712|NCT00831623|proton beam radiation
1283713|NCT00831610|bariatric surgery
1283714|NCT00831610|plastic surgery
1283715|NCT00831610|abdominal wall
1283716|NCT00831610|skin
1283717|NCT00831610|sensation
1283718|NCT00831610|abdominoplasty
1283719|NCT00831597|Lymphoma
1283720|NCT00831597|B-Cell
1283721|NCT00831571|oxaliplatin
1283722|NCT00831571|hypersensitivity
1283723|NCT00831532|Dimebon Hepatic Impairment
1283724|NCT00831506|digoxin dimebon drug-drug interaction study
1283725|NCT00831493|Pancreas
1283726|NCT00831493|Pancreatic Cancer
1283727|NCT00831493|Locally Advanced Pancreatic Cancer
1283728|NCT00831493|LAPC
1283729|NCT00831493|Non-Metastatic
1283730|NCT00831493|Unresectable
1283731|NCT00831493|Vorinostat
1283732|NCT00831493|XRT
1283733|NCT00831493|RT
1283734|NCT00831493|Radiation Therapy
1283735|NCT00831493|SAHA
1283736|NCT00831493|Suberoylanilide Hydroxamic Acid
1283737|NCT00831493|MSK-390
1283738|NCT00831480|Renal cell carcinoma
1283739|NCT00831480|Everolimus
1283740|NCT00831480|Neoadjuvant
1283741|NCT00831480|advanced kidney cancer
1283742|NCT00831467|Hormonal refractory prostate cancer
1283743|NCT00831467|RNA vaccine
1283744|NCT00831441|NOS
1283745|NCT00831428|asthma
1283746|NCT00831428|rhinitis
1283747|NCT00831428|swimmers
1283748|NCT00831428|mannitol
1283749|NCT00831415|Open-label Long-term extension study
1283750|NCT00831402|woman
1283751|NCT00831376|Asthma
1283752|NCT00831376|Genotype
1283753|NCT00831376|Beta2adrenoreceptor
1283754|NCT00831376|Levosalbutamol
1283755|NCT00831363|gait analysis
1283756|NCT00831363|minimal invasive approach
1283757|NCT00831363|transgluteal approach
1283758|NCT00831363|THA
1283759|NCT00831350|RVO
1283760|NCT00831350|PVD
1283761|NCT00831337|VSL3
1283762|NCT00831337|Probiotics
1283763|NCT00831337|Gut microbiota
1283764|NCT00831337|Cytokines
1283765|NCT00831337|Portal hypertension
1283766|NCT00831337|Chemokines
1283767|NCT00831337|Liver cirrhosis
1283768|NCT00831311|Diphtheria
1283769|NCT00831311|Tetanus
1283770|NCT00831311|Pertussis
1283771|NCT00831311|Whooping cough
1283772|NCT00831311|Hepatitis B
1283773|NCT00831311|Poliomyelitis
1283774|NCT00831311|Haemophilus influenzae type b
1283775|NCT00831298|alzheimer disease
1283776|NCT00831298|sleep disturbance
1283777|NCT00831298|apathy
1283778|NCT00831298|memory loss
1283779|NCT00831285|Healthy volunteers
1283780|NCT00831259|stroke
1283781|NCT00831259|PFO
1283782|NCT00831259|embolism
1283783|NCT00831246|Ileus,
1283784|NCT00831246|Gynecologic surgery,
1283785|NCT00831246|Post-operative,
1283786|NCT00831246|Flatus
1283787|NCT00831220|COPD
1283788|NCT00831220|exacerbations
1283789|NCT00831220|EPCs
1283790|NCT00831220|Erythropoietin
1283791|NCT00831220|C-RP
1283792|NCT00831220|COPD and endothelial dysfunction
1283793|NCT00831207|B-2 microglobulin
1283794|NCT00831207|Serum cytokines
1283795|NCT00831207|HIV-1
1283796|NCT00831207|Resistance
1283797|NCT00831207|HAART
1283798|NCT00831207|Therapeutic failure
1283799|NCT00831207|Genotyping.
1283800|NCT00831194|Type 2 Diabetes
1283801|NCT00831194|Obesity
1283802|NCT00831194|Weight loss
1283803|NCT00831194|PDA
1283804|NCT00831194|Stress
1283805|NCT00831194|Dietary lapse
1283806|NCT00831194|salivary alpha amylase
1283807|NCT00831181|stage II rectal cancer
1283808|NCT00831181|stage III rectal cancer
1283809|NCT00831181|adenocarcinoma of the rectum
1283810|NCT00831168|neonatal
1283811|NCT00831168|premature babies
1283812|NCT00831168|healthcare research
1283813|NCT00831168|Babies born before 27 weeks gestation
1283814|NCT00831155|smoking
1283815|NCT00831155|nicotine patches
1283816|NCT00831155|extinction based treatment
1283817|NCT00831142|Prostate Cancer
1283818|NCT00831142|MRI
1283819|NCT00831142|Prostatectomy
1283820|NCT00831116|near infrared spectroscopy
1283821|NCT00831116|LipiScan
1283822|NCT00831116|lipid core
1283823|NCT00831116|percutaneous coronary intervention
1283824|NCT00831116|myocardial infarction
1283825|NCT00831116|NIRS
1283826|NCT00831116|intravascular imaging
1283827|NCT00831103|EPB348
1283828|NCT00831103|Valomaciclovir Stearate
1283829|NCT00831103|Valacyclovir
1283830|NCT00831103|Herpes Zoster
1283831|NCT00831103|Shingles
1283832|NCT00831077|Healthy volunteers
1283833|NCT00831064|bowel preparation quality
1283834|NCT00831064|colonoscopy
1283835|NCT00831051|Bunionectomy
1283836|NCT00831038|pulmonary function tests
1283837|NCT00831038|infants
1283838|NCT00831038|chronic lung disease
1283839|NCT00831038|dysphagia
1283840|NCT00831038|chronic aspiration
1283841|NCT00831025|Immunotherapy
1283842|NCT00831025|Allergoid
1283843|NCT00831025|Depigmented
1283844|NCT00831025|Polymerized
1283845|NCT00831025|Allergen-extract
1283846|NCT00831025|Rhinoconjunctivitis
1283847|NCT00831012|Dengue Vaccine
1283848|NCT00831012|Dengue Virus
1283849|NCT00831012|Dengue Hemorrhagic Fever
1283850|NCT00831012|Dengue Shock Syndrome
1283851|NCT00830999|fat metabolism
1283852|NCT00830999|exercise
1283853|NCT00830999|liver
1283854|NCT00830999|lipoproteins
1283855|NCT00830999|triglycerides
1283856|NCT00830986|Mental Cognition Change
1283857|NCT00830986|Fat Embolism
1283858|NCT00830986|Bone Marrow Debris Emboli
1283859|NCT00830986|Computer Assisted Total Knee Arthroplasty
1283860|NCT00830986|Conventional Instrumented Total Knee Arthroplasty
1283861|NCT00830973|Estrogen Antagonists
1283862|NCT00830973|Antineoplastic Agents, Hormonal
1283863|NCT00830973|Hormone Antagonists
1283864|NCT00830973|Hormones
1283865|NCT00830973|Hormone Substitutes
1283866|NCT00830973|Selective Estrogen Receptor Modulators
1283867|NCT00830973|Estrogen Receptor Modulators
1283868|NCT00830973|Neoplasms
1283869|NCT00830973|Neoplasms by Site
1283870|NCT00830947|Orthodontic
1283871|NCT00830947|Extraction
1283872|NCT00830947|Device
1283873|NCT00830947|Space Closure
1283874|NCT00830947|Orthodontic malocclusion
1283875|NCT00830934|pelvic girdle pain
1283876|NCT00830934|symphysio pubic dysfunction
1283877|NCT00830934|group care
1283878|NCT00830934|individual care
1283879|NCT00830921|Histocytologically proven thoracic malignancy
1283880|NCT00830908|seborrheic dermatitis
1283881|NCT00830895|Renal cell carcinoma
1283882|NCT00830895|Non-clear cell
1283883|NCT00830895|RAD001
1283884|NCT00830895|Metastatic, non-clear cell, renal cell carcinoma
1283885|NCT00830882|asthma
1283886|NCT00830882|levosalbutamol
1283887|NCT00830882|genotype
1283888|NCT00830882|bronchoprotection
1283889|NCT00830856|Cryptococcal Meningitis
1283890|NCT00830856|HIV
1283891|NCT00830856|Fluconazole
1283892|NCT00830856|Antiretroviral therapy
1283893|NCT00830856|Africa
1283894|NCT00830856|treatment naive
1283895|NCT00830843|SAH
1283896|NCT00830843|sedation
1283897|NCT00830843|anesthesia
1283898|NCT00830817|Topical cream application
1283899|NCT00830817|Mild to moderate psoriasis
1283900|NCT00830804|Treatment Naive
1283901|NCT00830778|pancreas
1283902|NCT00830778|surgery
1283903|NCT00830778|cancer
1283904|NCT00830778|pancreaticoduodenectomy (PD)
1283905|NCT00830778|peri-ampullary tumours (ampulla, duodenum, distal bile duct, and miscellaneous tumours)
1283906|NCT00830778|pancreatic tumors
1283907|NCT00830778|peri-ampullary tumors
1283908|NCT00830752|alexithymia
1283909|NCT00830739|Smoking Cessation
1283910|NCT00830739|Dopamine
1283911|NCT00830739|Cognitive Control
1283912|NCT00830739|Reward Processing
1283913|NCT00830739|Varenicline
1283914|NCT00830726|Aquaporin
1283915|NCT00830726|Epithelial Sodium Channels
1283916|NCT00830726|Heart Failure
1283917|NCT00830726|Valvular heart disease
1283918|NCT00830726|Ischemic heart disease
1283919|NCT00830713|vitiligo
1283920|NCT00830713|skin transplantation
1283921|NCT00830713|non-cultured
1283922|NCT00830713|melanocyte
1283923|NCT00830713|surgery
1283924|NCT00830700|ADHD
1283925|NCT00830700|telemental health
1283926|NCT00830700|TMH
1283927|NCT00830700|telepsychiatry
1283928|NCT00830700|rural mental health services for children
1283929|NCT00830687|subcapital femoral fractures
1283930|NCT00830687|transcervical femoral fractures
1283931|NCT00830687|TARGON FN
1283932|NCT00830674|XLH
1283933|NCT00830661|transsphincteric anal fistula
1283934|NCT00830661|cryptoglandular origin
1283935|NCT00830661|anal fistula repair
1283936|NCT00830661|Ligation of Intersphincteric Fistula Track (LIFT) procedure
1283937|NCT00830661|anal fistula plug (Plug)
1283938|NCT00830661|surgical repair
1283939|NCT00830648|varicella-zoster virus
1283940|NCT00830648|varicella
1283941|NCT00830635|long-term effects of cancer treatment
1283942|NCT00830635|psychosocial effects of cancer and its treatment
1283943|NCT00830635|depression
1283944|NCT00830635|stage IA breast cancer
1283945|NCT00830635|stage IB breast cancer
1283946|NCT00830635|stage II breast cancer
1283947|NCT00830635|stage I prostate cancer
1283948|NCT00830635|stage II prostate cancer
1283949|NCT00830622|HIV/AIDS
1283950|NCT00830622|Adherence
1283951|NCT00830622|Antiretroviral Therapy, ART, ARV
1283952|NCT00830622|Mobile phone, cell phone, telephone
1283953|NCT00830622|Text message, SMS
1283954|NCT00830622|Telemedicine
1283955|NCT00830622|Africa
1283956|NCT00830622|Resource-limited setting
1283957|NCT00830622|Counseling, support
1283958|NCT00830622|treatment experienced
1283959|NCT00830609|Chronic Hepatitis C
1283960|NCT00830609|Genotype 3
1283961|NCT00830609|High viral load
1283962|NCT00830570|CYP2C9
1283963|NCT00830570|VKORC1
1283964|NCT00830570|polymorphism
1283965|NCT00830570|warfarin
1283966|NCT00830570|Coumadin
1283967|NCT00830557|recurrent pancreatic cancer
1283968|NCT00830557|stage I pancreatic cancer
1283969|NCT00830557|stage II pancreatic cancer
1283970|NCT00830557|stage III pancreatic cancer
1283971|NCT00830557|stage IV pancreatic cancer
1283972|NCT00830557|recurrent islet cell carcinoma
1283973|NCT00830557|pancreatic alpha cell carcinoma
1283974|NCT00830557|pancreatic beta islet cell carcinoma
1283975|NCT00830557|pancreatic delta cell carcinoma
1283976|NCT00830557|pancreatic G-cell carcinoma
1283977|NCT00830544|neoadjuvant chemotherapy breast cancer
1283978|NCT00830544|Breast cancer patients with tumors over one cm
1283979|NCT00830531|Hypoxic-ischemic encephalopathy
1283980|NCT00830531|Neonatal stroke
1283981|NCT00830531|Intracranial hemorrhage
1283982|NCT00830531|Perinatal asphyxia
1283983|NCT00830531|Neonatal Seizures
1283984|NCT00830505|fluticasone
1283985|NCT00830505|salmeterol
1283986|NCT00830505|bronchoprotection
1283987|NCT00830492|clomiphene citrate
1283988|NCT00830492|GnRH agonist
1283989|NCT00830492|GnRH antagonist
1283990|NCT00830492|in vitro fertilization
1283991|NCT00830492|clinical pregnancy
1283992|NCT00830492|pregnancy
1283993|NCT00830466|port wine stain
1283994|NCT00830453|Brain injury with sequelae from stroke, anoxia, or trauma
1283995|NCT00830427|asthma bronchial diseases
1283996|NCT00830414|Bioequivalence
1283997|NCT00830414|Healthy Subjects
1283998|NCT00830401|intra-uterine abnormalities
1283999|NCT00830401|intracavitary pathology
1284000|NCT00830401|hysteroscopy
1284001|NCT00830401|IVF
1284002|NCT00830401|ICSI
1284003|NCT00830401|polyp
1284004|NCT00830401|myoma
1284005|NCT00830401|adhesion
1284006|NCT00830401|septum
1284007|NCT00830401|endometritis
1284008|NCT00830388|tinea versicolor
1284009|NCT00830388|ketoconazole
1284010|NCT00830375|Buying
1284011|NCT00830375|Shopping
1284012|NCT00830375|Impulse Control
1284013|NCT00830362|cocaine
1284014|NCT00830362|cocaine-dependent
1284015|NCT00830362|propranolol
1284016|NCT00830362|craving
1284017|NCT00830362|beta-blockade
1284018|NCT00830362|cue exposure
1284019|NCT00830362|drug
1284020|NCT00830362|addiction
1284021|NCT00830362|memory
1284022|NCT00830362|addictive behavior
1284023|NCT00830349|Bioequivalence
1284024|NCT00830349|Healthy Subjects
1284025|NCT00830336|Bioequivalence
1284026|NCT00830336|Healthy Subjects
1284027|NCT00830310|Patient Non-Adherence
1284028|NCT00830310|Patient Non-Compliance
1284029|NCT00830310|Patient Nonadherence
1284030|NCT00830310|Patient Noncompliance
1284031|NCT00830310|Patient Refusal of Treatment
1284032|NCT00830310|Refusal of Treatment
1284033|NCT00830310|Treatment Refusal
1284034|NCT00830297|TIP
1284035|NCT00830297|NODAT
1284036|NCT00830297|hyperglycemia
1284037|NCT00830297|long-acting insulin
1284038|NCT00830297|post-transplant hyperglycemia
1284039|NCT00830284|Pediatric Acute Respiratory Distress Syndrome (ARDS)
1284040|NCT00830284|Pediatric Acute Lung Injury (ALI)
1284041|NCT00830271|surgical site infection
1284042|NCT00830271|wound complications
1284043|NCT00830271|suture
1284044|NCT00830271|antiseptic
1284045|NCT00830271|wound closure
1284046|NCT00830258|Bioequivalence
1284047|NCT00830258|Healthy Subjects
1284048|NCT00830245|EGFR mutation
1284049|NCT00830245|Erlotinib
1284050|NCT00830245|Lung cancer
1284051|NCT00830245|leptomeningeal carcinomatosis in EGFR mutation positive non-small cell lung cancer
1284052|NCT00830232|Stroke
1284053|NCT00830232|Carotid stenosis
1284054|NCT00830232|stents
1284055|NCT00830219|Bioequivalence
1284056|NCT00830219|Healthy Subjects
1284057|NCT00830206|Bioequivalence
1284058|NCT00830206|Healthy Subjects
1284059|NCT00830193|N-acetylcysteine
1284060|NCT00830193|prevention
1284061|NCT00830193|contrast-induced nephropathy
1284062|NCT00830193|critically ill adults
1284063|NCT00830180|Cancer pain
1284064|NCT00830180|NGF
1284065|NCT00830180|open-label extension
1284066|NCT00830154|stutter
1284067|NCT00830154|stuttering
1284068|NCT00830154|Adults with a history of stuttering
1284069|NCT00830141|Ghrelin
1284070|NCT00830141|obesity
1284071|NCT00830141|idiopathic short stature (ISS)
1284072|NCT00830115|PPI therapy
1284073|NCT00830115|Pantoprazole
1284074|NCT00830115|eGERD (Erosive Gastroesophageal Reflux Disease)
1284075|NCT00830115|NERD (Non-Erosive Reflux Disease)
1284076|NCT00830102|Mild to Moderate Asthma
1284077|NCT00830089|Transversus abdominis plane block
1284078|NCT00830089|Laparoscopic colorectal surgery
1284079|NCT00830089|Analgesia
1284080|NCT00830063|monoclonal antibody
1284081|NCT00830063|RN624
1284082|NCT00830063|PF-04383119
1284083|NCT00830063|nerve growth factor
1284084|NCT00830063|anti-nerve growth factor
1284085|NCT00830063|OA
1284086|NCT00830063|pain
1284087|NCT00830050|fMRI functional magnetic resonance imaging Pain
1284088|NCT00830037|anemia
1284089|NCT00830037|iron
1284090|NCT00830037|kidney disease
1284091|NCT00830037|progression
1284092|NCT00830037|glomerular filtration rate
1284093|NCT00830024|Bioequivalence
1284094|NCT00830024|Healthy Subjects
1284095|NCT00830011|diabetes
1284096|NCT00830011|neuropathy
1284097|NCT00830011|chronic pain
1284098|NCT00830011|Cognitive behavioral therapy
1284099|NCT00829998|Bioequivalence
1284100|NCT00829998|Healthy Subjects
1284101|NCT00829985|Rhinitis, Allergic, Perennial
1284102|NCT00829985|Rhinitis, Allergic, Seasonal
1284103|NCT00829985|Immunotherapy
1284104|NCT00829985|Asthma
1284105|NCT00829985|Nasal Allergies
1284106|NCT00829985|Hypersensitivity
1284107|NCT00829959|Ovary, Cancer
1284108|NCT00829959|Ovarian Cancer
1284109|NCT00829959|Breast Cancer
1284110|NCT00829959|Hereditary Breast and Ovarian Cancer Syndrome
1284111|NCT00829959|HBOC
1284112|NCT00829959|Genetic testing
1284113|NCT00829959|Pregnancy
1284114|NCT00829959|Fertility
1284115|NCT00829959|Prenatal diagnostic testing
1284116|NCT00829946|Strength training
1284117|NCT00829946|Anorexia
1284118|NCT00829946|Girls
1284119|NCT00829946|Quality of life
1284120|NCT00829946|Functional mobility
1284121|NCT00829933|Atrial fibrillation
1284122|NCT00829933|Factor Xa inhibition
1284123|NCT00829920|Bladder cancer
1284124|NCT00829907|Healthy volunteer study
1284125|NCT00829894|Bioequivalence
1284126|NCT00829894|Healthy Subjects
1284127|NCT00829881|Attention
1284128|NCT00829868|Bioequivalence
1284129|NCT00829868|Healthy Subjects
1284130|NCT00829855|pulmonary edema
1284131|NCT00829855|hypertension
1284132|NCT00829855|echocardiography
1284133|NCT00829842|chlorexidine
1284134|NCT00829842|ventilator-associated pneumonia
1284135|NCT00829842|nosocomial pneumonia
1284136|NCT00829842|heart surgery
1284137|NCT00829842|oral hygiene
1284138|NCT00829829|Metabolism, Inborn Errors
1284139|NCT00829829|Allopurinol
1284140|NCT00829829|Metabolic Diseases
1284141|NCT00829829|Genetic Diseases, Inborn
1284142|NCT00829829|Musculoskeletal Diseases
1284143|NCT00829829|Joint Diseases
1284144|NCT00829829|Arthritis
1284145|NCT00829829|Rheumatic Diseases
1284146|NCT00829829|Metabolic disorder
1284147|NCT00829829|Purine-Pyrimidine Metabolism, Inborn Errors
1284148|NCT00829829|Gout
1284149|NCT00829816|Alzheimers disease
1284150|NCT00829816|donepezil
1284151|NCT00829816|memantine
1284152|NCT00829803|To acquire developmental data to prospectively support SNAP
1284153|NCT00829803|II index ranges at the studied anesthetic states.
1284154|NCT00829790|Bioequivalence
1284155|NCT00829790|Healthy Subjects
1284156|NCT00829777|Naloxone
1284157|NCT00829777|6β-Naltrexol
1284158|NCT00829777|Opioid-dependent
1284159|NCT00829777|Pharmacokinetics
1284160|NCT00829777|peripheral effects of withdrawal
1284161|NCT00829777|central effects of withdrawal
1284162|NCT00829764|Bioequivalence
1284163|NCT00829764|Healthy Subjects
1284164|NCT00829751|staining
1284165|NCT00829751|toxicity
1284166|NCT00829751|fluorometry
1284167|NCT00829751|dye diffusion
1284168|NCT00829751|anterior chamber
1284169|NCT00829738|PPI therapy
1284170|NCT00829738|pantoprazole
1284171|NCT00829738|GERD (Erosive Gastroesophageal Reflux Disease)
1284172|NCT00829725|subcapital femoral fractures
1284173|NCT00829725|transcervical femoral fractures
1284174|NCT00829725|TARGON FN
1284175|NCT00829712|Bioequivalence
1284176|NCT00829712|Healthy Subjects
1284177|NCT00829699|endothelial function
1284178|NCT00829699|fibrinolytic balance
1284179|NCT00829686|abscess
1284180|NCT00829686|cellulitis
1284181|NCT00829686|antibiotics
1284182|NCT00829686|MRSA
1284183|NCT00829673|Bioequivalence
1284184|NCT00829673|Healthy Subjects
1284185|NCT00829660|Acarbose
1284186|NCT00829647|CLL
1284187|NCT00829647|dasatinib
1284188|NCT00829647|lenalidomide
1284189|NCT00829647|sprycel
1284190|NCT00829647|revlimid
1284191|NCT00829647|CLL relapsed or refractory to fludarabine
1284192|NCT00829634|methamphetamine
1284193|NCT00829634|inpatient
1284194|NCT00829634|d-MA
1284195|NCT00829634|l-MA
1284196|NCT00829634|APRL
1284197|NCT00829634|San Francisco
1284198|NCT00829634|metabolism
1284199|NCT00829634|Metabolism of methamphetamine
1284200|NCT00829621|BMP-2
1284201|NCT00829621|Incisional Vacuum Assisted Closure (IVAC)
1284202|NCT00829608|RRP
1284203|NCT00829608|Recurrent Respiratory Papillomatosis
1284204|NCT00829608|HPV vaccine
1284205|NCT00829608|HPV
1284206|NCT00829595|inflammatory bowel disease
1284207|NCT00829595|Crohn disease
1284208|NCT00829595|ulcerative colitis
1284209|NCT00829595|immunosuppression
1284210|NCT00829595|anti tumor necrosis alpha
1284211|NCT00829595|pneumovax
1284212|NCT00829595|pneumococcal vaccine
1284213|NCT00829569|Intralipid
1284214|NCT00829569|Omegaven
1284215|NCT00829569|fish oil
1284216|NCT00829569|hyperinsulinemic isoglycemic clamps
1284217|NCT00829569|C-peptide glucagon test
1284218|NCT00829569|indirect calorimetry
1284219|NCT00829569|F2-isoprostanes
1284220|NCT00829543|Spodyloarthropathy
1284221|NCT00829543|Guide-free sacroiliac injection
1284222|NCT00829530|Bioequivalence
1284223|NCT00829530|Healthy Subjects
1284224|NCT00829517|Contraception
1284225|NCT00829517|sexually transmitted diseases
1284226|NCT00829504|Bioequivalence
1284227|NCT00829504|Healthy Subjects
1284228|NCT00829491|Cardiovascular Disease Prevention
1284229|NCT00829491|Behavior change
1284230|NCT00829491|Risk Reduction
1284231|NCT00829478|Atrial fibrillation
1284232|NCT00829478|Cerebrovascular accident
1284233|NCT00829478|Anticoagulation
1284234|NCT00829478|Decision-making
1284235|NCT00829452|Bioequivalence
1284236|NCT00829452|Healthy Subjects
1284237|NCT00829439|Angelman syndrome
1284238|NCT00829439|Levodopa
1284239|NCT00829439|Carbidopa
1284240|NCT00829439|L-dopa
1284241|NCT00829426|Bioequivalence
1284242|NCT00829426|Healthy Subjects
1284243|NCT00829400|Neuropsychology
1284244|NCT00829400|Cognitive Remediation
1284245|NCT00829400|Vocational Rehabilitation
1284246|NCT00829400|Schizophrenia
1284247|NCT00829400|Severe and persistent mental illness
1284248|NCT00829400|Chronic and disabling mental illness
1284249|NCT00829387|Diabetes
1284250|NCT00829387|Pain
1284251|NCT00829387|Neuropathic Pain
1284252|NCT00829374|Alzheimer's disease
1284253|NCT00829374|clinical trial
1284254|NCT00829374|mitochondria
1284255|NCT00829374|memory loss
1284256|NCT00829374|neurodegenerative disease
1284257|NCT00829374|dementia
1284258|NCT00829374|investigational drug
1284259|NCT00829361|Telemedicine
1284260|NCT00829361|Acute stroke
1284261|NCT00829361|Rural
1284262|NCT00829361|thrombosis
1284263|NCT00829361|consultation
1284264|NCT00829361|Stroke
1284265|NCT00829361|Cerebral Infarction
1284266|NCT00829361|Vascular diseases
1284267|NCT00829361|brain ischemia
1284268|NCT00829361|brain infarction
1284269|NCT00829361|brain diseases
1284270|NCT00829361|cerebrovascular disorders
1284271|NCT00829348|Compliance
1284272|NCT00829348|Chronic
1284273|NCT00829348|Pharmacotherapy
1284274|NCT00829348|Statins
1284275|NCT00829335|Intraoperative ultrasound
1284276|NCT00829335|Segmentectomy
1284277|NCT00829335|HCC
1284278|NCT00829309|Bioequivalence
1284279|NCT00829309|Healthy Subjects
1284280|NCT00829296|diabetes
1284281|NCT00829296|hypertension
1284282|NCT00829296|aortic impedance
1284283|NCT00829283|Experimental
1284284|NCT00829283|Comparator
1284285|NCT00829244|Infertility
1284286|NCT00829244|Assisted reproductive technology
1284287|NCT00829231|Liver disease
1284288|NCT00829218|Irritable Bowel Syndrome
1284289|NCT00829218|Fibromyalgia
1284290|NCT00829218|Glutamate
1284291|NCT00829218|Diet
1284292|NCT00829218|Food additives
1284293|NCT00829205|recurrent adult diffuse large cell lymphoma
1284294|NCT00829192|Actinic keratoses (AK)
1284295|NCT00829192|Squamous cell carcinomas (SCC)
1284296|NCT00829192|CUV1647
1284297|NCT00829192|Afamelanotide
1284298|NCT00829192|Clinuvel
1284299|NCT00829192|Photoprotection
1284300|NCT00829192|Organ transplant
1284301|NCT00829179|Asthma
1284302|NCT00829153|Fistula patency
1284303|NCT00829127|volunteers
1284304|NCT00829114|AE
1284305|NCT00829114|AIDS
1284306|NCT00829114|ALT
1284307|NCT00829114|ART
1284308|NCT00829114|AST
1284309|NCT00829114|DCF
1284310|NCT00829114|DMC
1284311|NCT00829114|FDA
1284312|NCT00829114|GCP
1284313|NCT00829114|HB sAg
1284314|NCT00829114|ICH
1284315|NCT00829114|IND
1284316|NCT00829114|IRB
1284317|NCT00829114|IU
1284318|NCT00829114|mg
1284319|NCT00829114|mm3
1284320|NCT00829114|PCR
1284321|NCT00829114|SAE
1284322|NCT00829114|ULN
1284323|NCT00829114|WB
1284324|NCT00829114|COC
1284325|NCT00829114|Combined Oral Contraceptives
1284326|NCT00829101|unilateral cleft lip and palate
1284327|NCT00829101|primary palatal surgery
1284328|NCT00829101|articulation
1284329|NCT00829101|phonology
1284330|NCT00829101|one stage palatal repair
1284331|NCT00829101|two stage palatal repair
1284332|NCT00829088|Mass balance
1284333|NCT00829088|AZD2066
1284334|NCT00829088|Pain
1284335|NCT00829088|Pain conditions
1284336|NCT00829062|Type 1 diabetes
1284337|NCT00829062|Insulin pump
1284338|NCT00829062|Glycemic variability
1284339|NCT00829036|Rehabilitation
1284340|NCT00829036|Sensory Aid
1284341|NCT00829023|Positive aerobic or anaerobic cultures
1284342|NCT00829010|Human Immunodeficiency Virus
1284343|NCT00829010|Booster vaccination
1284344|NCT00829010|Safety
1284345|NCT00829010|Primary vaccination
1284346|NCT00829010|Pneumococcal vaccine
1284347|NCT00829010|Immunogenicity
1284348|NCT00829010|Pneumococcal disease
1284349|NCT00828997|rheumatoid arthritis
1284350|NCT00828997|spondylarthropathy
1284351|NCT00828997|immunological response following vaccination with Prevenar
1284352|NCT00828971|Complicated skin and skin structure infections
1284353|NCT00828971|cSSSI
1284354|NCT00828958|schizophrenia
1284355|NCT00828958|Risperidone
1284356|NCT00828958|Long acting injectable
1284357|NCT00828958|Intradeltoidal injection
1284358|NCT00828919|VEGFR inhibitor
1284359|NCT00828919|angi-angiogenic
1284360|NCT00828919|tyrosine kinase inhibitor
1284361|NCT00828906|Glaucoma
1284362|NCT00828906|IOP
1284363|NCT00828906|DuoTrav
1284364|NCT00828893|drain under scanner
1284367|NCT00828854|breast cancer
1284368|NCT00828854|estrogen receptor postive
1284369|NCT00828828|Influenza Vaccine
1284370|NCT00828828|Sarcoidosis
1284371|NCT00828828|Antibody
1284372|NCT00828815|HIV-negative
1284373|NCT00828815|buprenorphine/nalaxone
1284374|NCT00828815|norbuprenorphine
1284375|NCT00828815|opioid-dependent
1284376|NCT00828815|TMC125-TiDP2-C188
1284377|NCT00828815|TMC125-C188
1284378|NCT00828815|TMC125
1284379|NCT00828815|HIV Infections
1284380|NCT00828802|Myelodysplastic Syndromes
1284381|NCT00828802|MDS
1284382|NCT00828789|Hepatitis C
1284383|NCT00828789|HCV
1284384|NCT00828789|HIV
1284385|NCT00828789|AIDS
1284386|NCT00828789|Telaprevir
1284387|NCT00828789|Efavirenz
1284388|NCT00828789|Tenofovir disproxil fumarate
1284389|NCT00828789|Healthy volunteer
1284390|NCT00828789|VX-950-C134
1284391|NCT00828789|VX-950-TiDP24-C134
1284392|NCT00828789|HIV Infections
1284393|NCT00828776|TTPa
1284394|NCT00828776|Anti-Xa
1284395|NCT00828776|Adverse Reactions
1284396|NCT00828763|healthy volunteer
1284397|NCT00828763|radiolabelled
1284398|NCT00828750|eltrombopag
1284399|NCT00828750|thrombopoietin receptor agonist
1284400|NCT00828750|ITP
1284401|NCT00828750|blood platelet
1284738|NCT00827554|Liver Diseases
1284402|NCT00828711|Misoprostol vaginal insert
1284403|NCT00828711|Induction of labor
1284404|NCT00828711|Cervical ripening
1284405|NCT00828711|Rate of cesarean section
1284406|NCT00828698|Death, sudden
1284407|NCT00828698|All cause mortality
1284408|NCT00828685|Return to Work
1284409|NCT00828685|CRPP
1284410|NCT00828685|ORIF
1284411|NCT00828685|Distal Radius
1284412|NCT00828672|assess activity
1284413|NCT00828672|bevacizumab
1284414|NCT00828672|capecitabine
1284415|NCT00828672|radiation therapy
1284416|NCT00828672|oxaliplatin
1284417|NCT00828672|pre-operative treatment
1284418|NCT00828672|TME (total mesorectal excision).
1284419|NCT00828659|Abuse potential
1284420|NCT00828646|Healthy Subjects
1284421|NCT00828633|stage I prostate cancer
1284422|NCT00828633|stage II prostate cancer
1284423|NCT00828607|Contrast Enhanced Ultrasound (CEUS)
1284424|NCT00828607|Liver tumors
1284425|NCT00828607|Hepatocellular carcinoma
1284426|NCT00828607|Hemangioma
1284427|NCT00828607|Focal Nodular Hyperplasia
1284428|NCT00828607|Hepatic metastases
1284429|NCT00828594|Hepatocellular carcinoma
1284430|NCT00828594|dose-finding study
1284431|NCT00828594|randomized trial
1284432|NCT00828594|medical treatment
1284433|NCT00828594|RAD001
1284434|NCT00828594|sorafenib
1284435|NCT00828594|Advanced hepatocellular cancer (HCC)
1284436|NCT00828568|Actinic Keratosis
1284437|NCT00828555|HPV vaccine
1284438|NCT00828555|Tdap vaccine
1284439|NCT00828542|Adverse Effects
1284440|NCT00828542|Etonogestrel
1284441|NCT00828542|Postpartum period
1284442|NCT00828542|Contraception
1284443|NCT00828542|Hemostasis
1284444|NCT00828542|Metabolism
1284445|NCT00828529|TMC207-TiDP13-C110
1284446|NCT00828529|TMC207-C110
1284447|NCT00828529|TMC207
1284448|NCT00828529|Drug-drug interaction
1284449|NCT00828529|Tuberculosis
1284450|NCT00828529|HIV
1284451|NCT00828529|Kaletra
1284452|NCT00828529|Lopinavir
1284453|NCT00828529|Ritonavir
1284454|NCT00828529|Open-label
1284455|NCT00828529|HIV Infections
1284456|NCT00828516|lymphedema
1284457|NCT00828516|male breast cancer
1284458|NCT00828516|stage IA breast cancer
1284459|NCT00828516|stage IB breast cancer
1284460|NCT00828516|stage II breast cancer
1284461|NCT00828516|recurrent breast cancer
1284462|NCT00828516|recurrent squamous cell carcinoma of the hypopharynx
1284463|NCT00828516|stage I squamous cell carcinoma of the hypopharynx
1284464|NCT00828516|stage II squamous cell carcinoma of the hypopharynx
1284465|NCT00828516|recurrent squamous cell carcinoma of the larynx
1284466|NCT00828516|recurrent verrucous carcinoma of the larynx
1284467|NCT00828516|stage I squamous cell carcinoma of the larynx
1284468|NCT00828516|stage I verrucous carcinoma of the larynx
1284469|NCT00828516|stage II squamous cell carcinoma of the larynx
1284470|NCT00828516|stage II verrucous carcinoma of the larynx
1284471|NCT00828516|recurrent adenoid cystic carcinoma of the oral cavity
1284472|NCT00828516|recurrent mucoepidermoid carcinoma of the oral cavity
1284473|NCT00828516|recurrent verrucous carcinoma of the oral cavity
1284474|NCT00828516|stage I adenoid cystic carcinoma of the oral cavity
1284475|NCT00828516|stage I mucoepidermoid carcinoma of the oral cavity
1284476|NCT00828516|stage I verrucous carcinoma of the oral cavity
1284477|NCT00828516|stage II adenoid cystic carcinoma of the oral cavity
1284478|NCT00828516|stage II mucoepidermoid carcinoma of the oral cavity
1284479|NCT00828516|stage II verrucous carcinoma of the oral cavity
1284480|NCT00828516|stage I squamous cell carcinoma of the lip and oral cavity
1284481|NCT00828516|stage II squamous cell carcinoma of the lip and oral cavity
1284482|NCT00828516|recurrent basal cell carcinoma of the lip
1284483|NCT00828516|recurrent squamous cell carcinoma of the lip and oral cavity
1284484|NCT00828516|stage I basal cell carcinoma of the lip
1284485|NCT00828516|stage II basal cell carcinoma of the lip
1284486|NCT00828516|recurrent metastatic squamous neck cancer with occult primary
1284487|NCT00828516|recurrent lymphoepithelioma of the nasopharynx
1284488|NCT00828516|recurrent squamous cell carcinoma of the nasopharynx
1284489|NCT00828516|stage I lymphoepithelioma of the nasopharynx
1284490|NCT00828516|stage I squamous cell carcinoma of the nasopharynx
1284491|NCT00828516|stage II lymphoepithelioma of the nasopharynx
1284492|NCT00828516|stage II squamous cell carcinoma of the nasopharynx
1284493|NCT00828516|recurrent lymphoepithelioma of the oropharynx
1284494|NCT00828516|recurrent squamous cell carcinoma of the oropharynx
1284495|NCT00828516|stage I lymphoepithelioma of the oropharynx
1284496|NCT00828516|stage I squamous cell carcinoma of the oropharynx
1284497|NCT00828516|stage II lymphoepithelioma of the oropharynx
1284498|NCT00828516|stage II squamous cell carcinoma of the oropharynx
1284499|NCT00828516|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1284500|NCT00828516|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1284501|NCT00828516|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1284502|NCT00828516|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1284503|NCT00828516|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1284739|NCT00827554|Digestive System Diseases
1284504|NCT00828516|stage I inverted papilloma of the paranasal sinus and nasal cavity
1284505|NCT00828516|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1284506|NCT00828516|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1284507|NCT00828516|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1284508|NCT00828516|stage II inverted papilloma of the paranasal sinus and nasal cavity
1284509|NCT00828516|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1284510|NCT00828516|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1284511|NCT00828516|low-grade salivary gland mucoepidermoid carcinoma
1284512|NCT00828516|recurrent salivary gland cancer
1284513|NCT00828516|salivary gland acinic cell tumor
1284514|NCT00828516|salivary gland adenocarcinoma
1284515|NCT00828516|salivary gland adenoid cystic carcinoma
1284516|NCT00828516|salivary gland anaplastic carcinoma
1284517|NCT00828516|salivary gland malignant mixed cell type tumor
1284518|NCT00828516|salivary gland poorly differentiated carcinoma
1284519|NCT00828516|salivary gland squamous cell carcinoma
1284520|NCT00828516|stage I salivary gland cancer
1284641|NCT00827905|Rate
1284521|NCT00828516|stage II salivary gland cancer
1284522|NCT00828516|tongue cancer
1284523|NCT00828503|Certi-CMV
1284524|NCT00828503|immunosuppressive switch (to Certican)
1284525|NCT00828503|renal transplant
1284526|NCT00828490|Fraud and Abuse
1284527|NCT00828490|opioids
1284528|NCT00828464|Dermatosis, Dermatitis, Dry skin, Irritated skin
1284529|NCT00828451|newborn
1284530|NCT00828451|necrotizing enterocolitis
1284531|NCT00828451|genetics
1284532|NCT00828451|growth factors
1284533|NCT00828451|metabolism
1284534|NCT00828425|Diabetes Mellitus
1284535|NCT00828425|retinopathy
1284536|NCT00828425|Management of diabetic patients with retinopathy
1284537|NCT00828399|Radiotherapy
1284538|NCT00828399|Diarrhoea
1284539|NCT00828399|Glutamine
1284540|NCT00828399|Oxydative stress
1284541|NCT00828399|Calprotectin
1284542|NCT00828399|Citrulline
1284543|NCT00828386|Nasopharyngeal cancers
1284544|NCT00828386|induction chemotherapy
1284545|NCT00828386|radiochemotherapy
1284546|NCT00828360|Heart Failure
1284547|NCT00828360|CRT
1284548|NCT00828360|Dobutamine echocardiography
1284549|NCT00828321|Bioequivalency
1284550|NCT00828321|Healthy Volunteers
1284551|NCT00828308|localized
1284552|NCT00828308|high risk
1284553|NCT00828308|prostate cancer
1284554|NCT00828308|neoadjuvant treatment
1284555|NCT00828295|Postoperative Nausea and Vomiting
1284556|NCT00828295|palonosetron
1284557|NCT00828295|pediatric
1284558|NCT00828282|Chronic Lymphocytic Leukemia
1284559|NCT00828282|Simvastatin
1284560|NCT00828282|Zocor
1284561|NCT00828269|Patients with Chronic Hepatitis C
1284562|NCT00828256|arthroscopic repair
1284563|NCT00828256|rotator cuff
1284564|NCT00828256|tears
1284565|NCT00828256|shoulder
1284566|NCT00828256|chronic tear of rotator cuff
1284567|NCT00828243|Pulmonary surfactants
1284568|NCT00828243|Pulmonary surfactant associated protein B
1284569|NCT00828243|Pulmonary surfactant associated protein C
1284570|NCT00828243|ATP-binding cassette protein sub member family A3
1284571|NCT00828230|budesonide
1284572|NCT00828230|placebo
1284573|NCT00828230|acute radiation proctitis
1284574|NCT00828230|late radiation proctitis
1284575|NCT00828230|Prevention of acute radiation proctitis
1284576|NCT00828230|Prevention of late radiation proctitis
1284577|NCT00828217|adapted physical activity
1284578|NCT00828217|hospital
1284579|NCT00828217|health-related quality of life
1284580|NCT00828217|satisfaction with care
1284581|NCT00828217|child
1284582|NCT00828217|adolescent
1284583|NCT00828217|randomized controlled trial
1284584|NCT00828217|physical activity
1284585|NCT00828217|quality of life
1284586|NCT00828191|Luteal support in IVF
1284587|NCT00828178|SLE
1284588|NCT00828178|atherosclerosis
1284589|NCT00828178|omega-3
1284590|NCT00828126|Metastatic Melanoma
1284591|NCT00828126|AJCC Stage III Melanoma
1284592|NCT00828126|AJCC stage IV Melanoma
1284593|NCT00828126|PET-CT
1284594|NCT00828126|Positron Emission Tomography-Computed Tomography
1284595|NCT00828126|Contrast-enhanced Computed Tomography Scan
1284596|NCT00828126|CT
1284597|NCT00828126|Conventional Imaging
1284598|NCT00828126|False Positive Rate
1284599|NCT00828126|Fluorodeoxyglucose
1284600|NCT00828126|FDG
1284601|NCT00828126|Surgery
1284602|NCT00828113|smoking
1284603|NCT00828113|relapse
1284604|NCT00828113|withdrawal
1284605|NCT00828087|acute myocardial infarction
1284606|NCT00828087|primary percutaneous coronary intervention
1284607|NCT00828087|drug-eluting stent
1284608|NCT00828074|stage IV breast cancer
1284609|NCT00828074|recurrent breast cancer
1284610|NCT00828035|robotics
1284611|NCT00828035|laparoscopy
1284612|NCT00828035|surgery
1284613|NCT00828035|computer assisted
1284614|NCT00828022|measles-positive NSCLC
1284615|NCT00828022|measles vaccine
1284616|NCT00828022|consolidation
1284969|NCT00826735|childbirth
1284617|NCT00828022|Stage 3B with pleural effusion or stage 4 non-small cell lung cancer in remission
1284618|NCT00828009|stage IIIA non-small cell lung cancer
1284619|NCT00828009|stage IIIB non-small cell lung cancer
1284620|NCT00828009|adenocarcinoma of the lung
1284621|NCT00828009|bronchoalveolar cell lung cancer
1284622|NCT00828009|large cell lung cancer
1284623|NCT00827996|Apocrine glands
1284624|NCT00827996|abcesses
1284625|NCT00827983|Luteal Phase Support in IVF patients
1284626|NCT00827970|mass screening
1284627|NCT00827957|Hypothermia
1284628|NCT00827957|Internal cooling
1284629|NCT00827957|External cooling
1284630|NCT00827957|Cardiac arrest
1284631|NCT00827944|Uncomplicated primary inguinal hernias
1284632|NCT00827931|tranexamic acid
1284633|NCT00827931|major abdominal surgery
1284634|NCT00827931|blood loss
1284635|NCT00827918|Acute Exacerbation of Schizophrenia
1284636|NCT00827905|Non-Contact
1284637|NCT00827905|Radar
1284638|NCT00827905|Respiratory
1284639|NCT00827905|Respiration
1284640|NCT00827905|Breathing
1284642|NCT00827905|Frequency
1284643|NCT00827905|Respiratory Mechanics
1284644|NCT00827905|Respiratory Rate Measurement
1284645|NCT00827892|Intracerebral Hemorrhage
1284646|NCT00827892|Treatment
1284647|NCT00827892|MRI
1284648|NCT00827879|Intimate partner aggression
1284649|NCT00827879|Couples intervention
1284650|NCT00827879|PTSD
1284651|NCT00827879|Veterans
1284652|NCT00827879|Prevention
1284653|NCT00827879|Violence Prevention
1284654|NCT00827879|Prevention of pertetration of intimate partner aggression.
1284655|NCT00827866|Tobacco quitline
1284656|NCT00827866|Childhood cancer survivors
1284657|NCT00827866|Adult-onset cancer survivors
1284658|NCT00827853|Diabetes
1284659|NCT00827853|Peripheral Vascular Disease (PVD)
1284660|NCT00827853|Superficial Femoral Artery (SFA)
1284661|NCT00827853|Cryoplasty
1284662|NCT00827853|Restenosis
1284663|NCT00827827|Stroke
1284664|NCT00827827|Exercise
1284665|NCT00827827|Strength Training
1284666|NCT00827827|Skeletal Muscle
1284667|NCT00827827|Insulin Sensitivity
1284668|NCT00827801|Cancer
1284669|NCT00827801|Heart Failure
1284670|NCT00827801|HF
1284671|NCT00827801|Cancer and Concurrent Heart Failure
1284672|NCT00827801|MDASI-HF Symptom Management Program
1284673|NCT00827801|MDASI-HF
1284674|NCT00827801|MDASI-HF questionnaire
1284675|NCT00827801|M. D. Anderson Symptom Inventory - Heart Failure
1284676|NCT00827801|Questionnaire
1284677|NCT00827801|Symptom Management Gap
1284678|NCT00827788|contrast media
1284679|NCT00827788|angiography
1284680|NCT00827788|percutaneous coronary intervention
1284681|NCT00827775|Hypertension
1284682|NCT00827775|Hemodialysis
1284683|NCT00827762|phenylketonuria
1284684|NCT00827762|Kuvan
1284685|NCT00827762|sapropterin
1284686|NCT00827762|behavior
1284687|NCT00827762|cognition
1284688|NCT00827762|executive abilities
1284689|NCT00827762|attention
1284690|NCT00827749|swallowing disorders
1284691|NCT00827749|geriatrics
1284692|NCT00827736|anal fissure
1284693|NCT00827736|fissura ani
1284694|NCT00827736|botox
1284695|NCT00827736|ISDN
1284696|NCT00827736|Nitric oxide donor
1284697|NCT00827723|Hepatic functional reserve
1284698|NCT00827723|Hepatocellular carcinoma (HCC)
1284699|NCT00827723|Indocyanine Green retention rate at 15 minutes (ICG-R15')
1284700|NCT00827723|Portal Pressure (PP)
1284701|NCT00827723|Hepatic Portal Venous Gradient (HPVG)
1284702|NCT00827723|Alcoholic and Viral Cirrhosis
1284703|NCT00827723|Makuuchi criteria
1284704|NCT00827723|Barcelona Clinic of Liver Cancer (BCLC)
1284705|NCT00827723|Hepatic resection
1284706|NCT00827710|diabetes
1284707|NCT00827710|registry
1284708|NCT00827710|computer
1284709|NCT00827710|self management
1284710|NCT00827697|Gonorrhea
1284711|NCT00827697|Chlamydia
1284712|NCT00827697|Rectal
1284713|NCT00827684|KRAS mutation
1284714|NCT00827658|anesthesia, local
1284715|NCT00827658|ulnar nerve
1284716|NCT00827658|hand
1284717|NCT00827658|surgery, plastic
1284718|NCT00827658|blinded
1284719|NCT00827658|randomized
1284720|NCT00827658|prospective
1284721|NCT00827658|local anesthesia
1284722|NCT00827658|volar wrist block
1284723|NCT00827658|hypothenar palm block
1284724|NCT00827658|hand surgery
1284725|NCT00827632|Ovarian Suppression
1284726|NCT00827632|Oral Contraceptives
1284727|NCT00827632|Obese and Normal BMI
1284728|NCT00827619|Peripheral Arterial Disease
1284729|NCT00827606|pediatric heterozygous familial hypercholesterolemia
1284730|NCT00827580|HFS
1284731|NCT00827580|patients with breast or colon cancer receiving capecitabine
1284732|NCT00827567|Breast cancer
1284733|NCT00827567|metastatic breast
1284734|NCT00827567|triple negative
1284735|NCT00827567|ER/PR negative
1284736|NCT00827567|Her2 Neu negative
1284737|NCT00827554|Liver Neoplasms
1284740|NCT00827554|Digestive System Neoplasms
1284741|NCT00827554|Carcinoma, Hepatocellular
1284742|NCT00827554|Gastrointestinal Neoplasms
1284743|NCT00827554|Adenocarcinoma
1284744|NCT00827554|Hepatocellular carcinoma
1284745|NCT00827554|Neoplasms
1284746|NCT00827554|Transarterial chemoembolization
1284747|NCT00827554|Nadroparin
1284748|NCT00827554|low-molecular-weight heparin
1284749|NCT00827554|chemoembolization
1284750|NCT00827541|tigecycline
1284751|NCT00827541|complicated intra-abdominal infections (cIAI)
1284752|NCT00827541|complicated skin and soft tissue infections (cSSTI).
1284753|NCT00827528|Pelvic Organ Prolapse
1284754|NCT00827528|Surgical Treatment
1284755|NCT00827515|Relative Bioavailability Effect of food
1284756|NCT00827502|TRULIMAX (AZITHROMYCIN ) NON-INTERVENTIONAL STUDY
1284757|NCT00827489|schizophrenia
1284758|NCT00827476|ovary
1284759|NCT00827476|human
1284760|NCT00827476|transplantaion
1284761|NCT00827476|ovarian failure
1284762|NCT00827463|aneamia
1284763|NCT00827463|aneamia during the maternity
1284764|NCT00827450|hepatic steatosis
1284765|NCT00827450|coffee
1284766|NCT00827450|fructose
1284767|NCT00827450|lipids
1284768|NCT00827424|physical activity (PA)
1284769|NCT00827424|obesity
1284770|NCT00827424|life style modification
1284771|NCT00827424|physical activity
1284772|NCT00827424|diet
1284773|NCT00827424|BMI reduction
1284774|NCT00827424|clinical and metabolic measure
1284775|NCT00827424|health expenditure
1284776|NCT00827424|improvement of patient readiness for lifestyle change
1284777|NCT00827411|Drug Eluting Stent
1284778|NCT00827411|Percutaneous coronary intervention
1284779|NCT00827411|Oral antiplatelet therapy
1284780|NCT00827411|Clopidogrel/Aspirin
1284781|NCT00827411|Acute Coronary Syndrome
1284782|NCT00827398|MSC
1284783|NCT00827398|GVHD
1284784|NCT00827398|Adults
1284785|NCT00827398|Children
1284786|NCT00827398|steroid refractory acute GVHD occurring after allogeneic stem cell transplantation
1284788|NCT00827333|recurrent non-small cell lung cancer
1284789|NCT00827333|stage I non-small cell lung cancer
1284790|NCT00827333|stage II non-small cell lung cancer
1284791|NCT00827333|stage IIIA non-small cell lung cancer
1284792|NCT00827333|stage IIIB non-small cell lung cancer
1284793|NCT00827333|stage IV non-small cell lung cancer
1284794|NCT00827307|breast carcinoma; goserelin; Mammographic density
1284795|NCT00827294|Phantom limb pain
1284796|NCT00827294|Mirror therapy
1284797|NCT00827294|amputation
1284798|NCT00827294|Limb loss
1284799|NCT00827294|treatment
1284800|NCT00827281|DCS
1284801|NCT00827281|CBT
1284802|NCT00827281|smoking
1284803|NCT00827281|tobacco
1284804|NCT00827268|Dyslexia
1284805|NCT00827268|Reading
1284806|NCT00827268|Aphasia
1284807|NCT00827268|Stroke
1284808|NCT00827242|Signs and Symptoms
1284809|NCT00827242|Prostatic Hyperplasia
1284810|NCT00827242|Hyperplasia
1284811|NCT00827242|Genital Diseases, Male
1284812|NCT00827242|Prostatic Diseases
1284813|NCT00827242|BPH-LUTS
1284814|NCT00827229|Active labor
1284815|NCT00827229|Term pregnancy
1284816|NCT00827229|Vertex presentation
1284817|NCT00827229|Single fetus
1284818|NCT00827216|Gastric emptying
1284819|NCT00827216|emergency anesthesia
1284820|NCT00827216|intravenous erythromycin
1284821|NCT00827203|cancer
1284822|NCT00827203|metastatic
1284823|NCT00827203|Elesclomol Sodium
1284824|NCT00827203|tumor
1284825|NCT00827203|Advanced solid tumors that are metastatic and unresectable
1284826|NCT00827190|Acute Ischemic Stroke
1284827|NCT00827177|dose escalation
1284828|NCT00827177|safety
1284829|NCT00827177|tolerability
1284830|NCT00827177|tumor
1284831|NCT00827177|PK
1284832|NCT00827177|hepatocellular carcinoma
1284833|NCT00827177|renal cell carcinoma
1284834|NCT00827177|melanoma
1284835|NCT00827177|non-small cell lung cancer
1284836|NCT00827177|breast cancer
1284837|NCT00827164|head and neck cancer
1284838|NCT00827164|resistance training
1284839|NCT00827164|nutrition counseling
1284840|NCT00827164|radiation therapy
1284841|NCT00827164|pharyngeal or laryngeal cancer
1284842|NCT00827151|amenorrhea
1284843|NCT00827151|athletes
1284844|NCT00827151|bone loss
1284845|NCT00827151|eumenorrhea
1284846|NCT00827125|active stage
1284847|NCT00827125|labor
1284848|NCT00827125|progression
1284849|NCT00827125|pregnant woman during active phases of labor
1284850|NCT00827112|CCR5-tropic HIV-1 virus
1284851|NCT00827099|accelerated phase cml
1284852|NCT00827099|adult ALL in remission
1284853|NCT00827099|adult AML in remission
1284854|NCT00827099|adult AML with 11q23 (MLL) abnormalities
1284855|NCT00827099|adult AML with inv(16)(p13;q22)
1284856|NCT00827099|adult acute myeloid leukemia with t(15;17)(q22;q12)
1284857|NCT00827099|adult acute myeloid leukemia with t(16;16)(p13;q22)
1284858|NCT00827099|adult acute myeloid leukemia with t(8;21)(q22;q22)
1284859|NCT00827099|blastic phase chronic myelogenous leukemia
1284860|NCT00827099|chronic myelomonocytic leukemia
1284861|NCT00827099|chronic phase chronic myelogenous leukemia
1284862|NCT00827099|prolymphocytic leukemia
1284863|NCT00827099|recurrent adult T-cell leukemia/lymphoma
1284864|NCT00827099|relapsing chronic myelogenous leukemia
1284865|NCT00827099|secondary acute myeloid leukemia
1284866|NCT00827099|refractory chronic lymphocytic leukemia
1284867|NCT00827099|stage I chronic lymphocytic leukemia
1284868|NCT00827099|stage II chronic lymphocytic leukemia
1284869|NCT00827099|stage III chronic lymphocytic leukemia
1284870|NCT00827099|stage IV chronic lymphocytic leukemia
1284871|NCT00827099|recurrent adult Hodgkin lymphoma
1284872|NCT00827099|anaplastic large cell lymphoma
1284873|NCT00827099|angioimmunoblastic T-cell lymphoma
1284874|NCT00827099|cutaneous B-cell non-Hodgkin lymphoma
1284875|NCT00827099|recurrent cutaneous T-cell non-Hodgkin lymphoma
1284876|NCT00827099|recurrent mycosis fungoides/Sezary syndrome
1284877|NCT00827099|adult grade III lymphomatoid granulomatosis
1284878|NCT00827099|adult nasal type extranodal NK/T-cell lymphoma
1284879|NCT00827099|Waldenstrom macroglobulinemia
1285126|NCT00826098|Total knee replacement
1284880|NCT00827099|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1284881|NCT00827099|nodal marginal zone B-cell lymphoma
1284882|NCT00827099|splenic marginal zone lymphoma
1284883|NCT00827099|recurrent adult diffuse large cell lymphoma
1284884|NCT00827099|recurrent adult diffuse mixed cell lymphoma
1284885|NCT00827099|recurrent adult diffuse small cleaved cell lymphoma
1284886|NCT00827099|recurrent adult grade III lymphomatoid granulomatosis
1284887|NCT00827099|recurrent grade 1 follicular lymphoma
1284888|NCT00827099|recurrent grade 2 follicular lymphoma
1284889|NCT00827099|recurrent grade 3 follicular lymphoma
1284890|NCT00827099|recurrent mantle cell lymphoma
1284891|NCT00827099|recurrent marginal zone lymphoma
1284892|NCT00827099|recurrent small lymphocytic lymphoma
1284893|NCT00827099|chronic idiopathic myelofibrosis
1284894|NCT00827099|stage I multiple myeloma
1284895|NCT00827099|stage II multiple myeloma
1284896|NCT00827099|stage III multiple myeloma
1284897|NCT00827099|refractory multiple myeloma
1284898|NCT00827099|de novo myelodysplastic syndromes
1284899|NCT00827099|previously treated myelodysplastic syndromes
1284900|NCT00827099|secondary myelodysplastic syndromes
1284901|NCT00827086|influencing factors (smoking, nutrition, education)
1284902|NCT00827060|primary care
1284903|NCT00827060|procalcitonin
1284904|NCT00827060|acute respiratory tract infection
1284905|NCT00827047|hepatocellular carcinoma
1284906|NCT00827047|Surgical resection
1284907|NCT00827047|total hemihepatic vascular exclusion
1284908|NCT00827047|occlusion
1284909|NCT00827047|bleeding
1284910|NCT00827047|overall survival
1284911|NCT00827034|Dimebon Warfarin Drug-Drug Interaction
1284912|NCT00826995|patient Education
1284913|NCT00826995|dermatology Patient Education
1284914|NCT00826995|melanoma
1284915|NCT00826995|melanoma education
1284916|NCT00826995|malignant melanoma
1284917|NCT00826995|melanoma detection
1284918|NCT00826969|Asthma
1284919|NCT00826969|Ciclesonide
1284920|NCT00826943|Allergic Rhinitis
1284921|NCT00826930|High Grade Glioma
1284922|NCT00826930|Brain Tumor
1284923|NCT00826930|Solid Tumor
1284924|NCT00826930|Partial Debulking
1284925|NCT00826930|Tumor Resection
1284926|NCT00826930|Tumor Tissue Hypoxia
1284927|NCT00826930|Radiation Sensitizer
1284928|NCT00826930|Cancerous Tumor
1284929|NCT00826917|3D, 2D, ultrasound, volumetry, multiplanar, VOCALTM, XI VOCALTM, fetal, gestational sac, placenta
1284930|NCT00826904|Fetal programming
1284931|NCT00826904|Fetal macrosomia
1284932|NCT00826904|Fetal health
1284933|NCT00826904|Gestational diabetes
1284934|NCT00826904|Maternal health
1284935|NCT00826904|Maternal obesity
1284936|NCT00826878|tivozanib
1284937|NCT00826878|AV-951
1284938|NCT00826839|In vitro fertilization
1284939|NCT00826839|Poor responder patients
1284940|NCT00826839|Randomized clinical trial
1284941|NCT00826839|Estrogen patch
1284942|NCT00826839|Gonadotropin-releasing hormone antagonist
1284943|NCT00826839|Oral contraceptive pill
1284944|NCT00826839|Microdose lupron
1284945|NCT00826826|Atrial fibrillation
1284946|NCT00826826|Amiodarone
1284947|NCT00826826|Arrhythmias, Cardiac
1284948|NCT00826826|Catheter ablation
1284949|NCT00826813|Dysphagia
1284950|NCT00826813|esophageal cancer
1284951|NCT00826813|stent
1284952|NCT00826813|brachytherapy
1284953|NCT00826800|BEVACIZUMAB (AVASTIN)
1284954|NCT00826800|FLUOROURACIL
1284955|NCT00826800|LEUCOVORIN
1284956|NCT00826800|OXALIPLATIN
1284957|NCT00826800|Chemotherapy
1284958|NCT00826774|Body Weight
1284959|NCT00826774|Overweight
1284960|NCT00826774|Hypertension
1284961|NCT00826774|Hyperglycemia
1284962|NCT00826748|COPD
1284963|NCT00826748|inhaled steroids
1284964|NCT00826748|gene expression
1284965|NCT00826748|smoker's lungs
1284966|NCT00826735|third stage of labor
1284967|NCT00826735|bleeding
1284968|NCT00826735|guided imagery
1284970|NCT00826696|preeclampsia
1284971|NCT00826683|Non-small cell lung cancer
1284972|NCT00826683|Endothelial cell progenitor
1284973|NCT00826683|Angiogenesis
1284974|NCT00826683|Vascular endothelial cell growth factor
1284975|NCT00826683|Healthy control
1284976|NCT00826683|COPD patients
1284977|NCT00826683|NSCLC patients
1284978|NCT00826670|Antibiotic resistance
1284979|NCT00826670|ESBL carriage
1284980|NCT00826657|B12 deficiency
1284981|NCT00826657|methylmalonic acid
1284982|NCT00826657|homocystein
1284983|NCT00826657|vitamin B12 supplementation intervention
1284984|NCT00826644|Small cell lung cancer
1284985|NCT00826644|Camptothecin
1284986|NCT00826644|Response rate
1284987|NCT00826631|weight
1284988|NCT00826631|metabolism
1284989|NCT00826631|cholesterol
1284990|NCT00826631|insulin
1284991|NCT00826618|Uveitis
1284992|NCT00826618|Cystoid Macular Edema
1284993|NCT00826605|Weight loss, urobilinogen
1284994|NCT00826592|patient education
1284995|NCT00826592|dermatology patient education
1284996|NCT00826592|atopic dermatitis
1284997|NCT00826592|atopic dermatitis education
1284998|NCT00826592|atopic eczema
1284999|NCT00826592|infantile eczema
1285000|NCT00826592|hand eczema
1285001|NCT00826579|Sentinel lymph node
1285002|NCT00826579|Lymph node analysis
1285003|NCT00826579|Bone marrow analysis
1285004|NCT00826566|COPD
1285005|NCT00826566|caffeine
1285006|NCT00826566|chronic systemic inflammation
1285007|NCT00826566|oxidative stress
1285008|NCT00826566|supplementation
1285009|NCT00826566|stable COPD GOLD stage II with CRP levels ≥ 3 mg/l
1285010|NCT00826553|sedative
1285011|NCT00826553|GABA
1285012|NCT00826553|alpha 2 agonist
1285013|NCT00826553|propofol
1285014|NCT00826553|midazolam
1285015|NCT00826553|lorazepam
1285016|NCT00826553|dexmedetomidine
1285017|NCT00826553|sleep
1285018|NCT00826553|electroencephalogram
1285019|NCT00826553|polysomnogram
1285020|NCT00826553|ICU
1285021|NCT00826514|Chronic Prostatis
1285022|NCT00826488|Breast Cancer
1285023|NCT00826488|Mammography
1285024|NCT00826488|Benign masses
1285025|NCT00826488|Breast Lump
1285026|NCT00826488|Breast Biopsy
1285027|NCT00826488|Breast Mass
1285028|NCT00826475|Migraine
1285029|NCT00826475|Headache
1285030|NCT00826462|Randomised
1285031|NCT00826462|Placebo-controlled
1285032|NCT00826462|double blind
1285033|NCT00826462|Intervention study
1285034|NCT00826462|Primary health care
1285035|NCT00826449|Advanced Solid Tumors
1285036|NCT00826449|Advanced Cancer
1285037|NCT00826449|Non-Small Cell Lung Cancer
1285038|NCT00826449|NSCLC
1285039|NCT00826449|Solid Tumor Malignancy
1285040|NCT00826449|Dasatinib
1285041|NCT00826449|BMS-354825
1285042|NCT00826449|Sprycel®
1285043|NCT00826449|Erlotinib
1285044|NCT00826449|Erlotinib hydrochloride
1285045|NCT00826449|Tarceva
1285046|NCT00826449|OSI-774
1285047|NCT00826423|treatment with Triple antibiotic therapy
1285048|NCT00826410|Laparotomy
1285049|NCT00826410|Surgical site infection
1285050|NCT00826410|Drainage
1285051|NCT00826397|aromatase inhibitors
1285052|NCT00826397|joint pain
1285053|NCT00826397|symptoms control
1285054|NCT00826384|hepatocellular carcinoma
1285055|NCT00826384|transcatheter arterial chemoembolization
1285056|NCT00826384|overall survival
1285057|NCT00826371|AMD
1285058|NCT00826371|Ranibizumab
1285059|NCT00826358|Adverse events
1285060|NCT00826358|Pharmacokinetic
1285061|NCT00826345|Peripheral Neuropathy
1285062|NCT00826345|Neuropathy
1285063|NCT00826345|HIV
1285064|NCT00826345|AIDS
1285065|NCT00826345|DSP
1285066|NCT00826345|alternative therapies
1285067|NCT00826332|ultrasound
1285068|NCT00826332|IVF
1285069|NCT00826332|Embryo transfer
1285070|NCT00826332|Pregnancy rate
1285071|NCT00826332|female patient undergoing IVF
1285072|NCT00826319|Chronic Kidney Disease
1285073|NCT00826319|Renal Insufficiency
1285074|NCT00826319|Biomarkers
1285075|NCT00826319|Observational
1285076|NCT00826306|patient education
1285077|NCT00826306|dermatology patient education
1285078|NCT00826306|sunscreen
1285079|NCT00826306|sunscreen education
1285080|NCT00826306|skin cancer
1285081|NCT00826280|coronary artery disease (CAD)
1285082|NCT00826280|ischemia
1285083|NCT00826280|pharmacologic stress
1285084|NCT00826254|vitamin K
1285085|NCT00826254|Bone Mineral Density
1285086|NCT00826254|undercarboxylated osteocalcin
1285087|NCT00826241|Brain Tumor
1285088|NCT00826241|Central Nervous System
1285089|NCT00826241|CNS
1285090|NCT00826241|Spinal Cord Tumor
1285091|NCT00826241|Anaplastic Ependymoma
1285092|NCT00826241|Supratentorial Ependymoma
1285093|NCT00826241|Infratentorial Ependymoma
1285094|NCT00826241|Spinal Cord Ependymoma
1285095|NCT00826241|Lapatinib
1285096|NCT00826241|GW572016
1285097|NCT00826241|Temozolomide
1285098|NCT00826241|Temodar
1285099|NCT00826215|mechanical
1285100|NCT00826215|neck pain
1285101|NCT00826215|chronic
1285102|NCT00826215|acupuncture
1285103|NCT00826215|chronic mechanical neck pain
1285104|NCT00826202|schizophrenia
1285105|NCT00826202|d-serine
1285106|NCT00826202|prodrome
1285107|NCT00826189|Probiotics
1285108|NCT00826189|Asthma
1285109|NCT00826189|Allergic Rhinitis
1285110|NCT00826150|ovarian cancer
1285111|NCT00826150|H19 gene
1285112|NCT00826150|plasmid
1285113|NCT00826137|prebiotics
1285114|NCT00826137|Antibiotic-associated diarrhea
1285115|NCT00826124|low back pain
1285116|NCT00826124|radiculopathy
1285117|NCT00826124|sciatica
1285118|NCT00826111|Magnetic Resonance Spectroscopy
1285119|NCT00826111|Glutamate
1285120|NCT00826111|Glutamine
1285121|NCT00826111|GABA
1285122|NCT00826111|Lexapro
1285123|NCT00826111|Lunesta
1285124|NCT00826111|Escitalopram
1285125|NCT00826111|Eszopiclone
1285127|NCT00826098|Platelet Rich Plasma
1285128|NCT00826098|PRP
1285129|NCT00826098|Biologic
1285130|NCT00826098|Randomized
1285131|NCT00826085|Breast Cancer
1285132|NCT00826085|Recurrent Chest Wall Cancer
1285133|NCT00826085|Loco-regional Recurrent Breast Cancer
1285134|NCT00826085|Breast Cancer Recurrence at the Chest Wall
1285135|NCT00826072|Single Nucleotide Polymorphism
1285136|NCT00826072|cardiopulmonary bypass
1285137|NCT00826072|cardiac surgery
1285138|NCT00826059|acute ischemic stroke
1285139|NCT00826059|randomized clinical trial
1285140|NCT00826059|effectiveness
1285141|NCT00826059|safety
1285142|NCT00826046|GVHD
1285143|NCT00826046|Prochymal
1285144|NCT00826046|Graft vs Host Disease
1285145|NCT00826033|Fluorine-18-α-methyltyrosine
1285146|NCT00826033|Positron emission tomography
1285147|NCT00826033|Lung cancer
1285148|NCT00826033|chemotherapy
1285149|NCT00826033|monitoring
1285150|NCT00826020|PN
1285151|NCT00826020|parenteral nutrition
1285152|NCT00826020|fat emulsions
1285153|NCT00826020|omega-6 fatty acid
1285154|NCT00826020|liver disease
1285155|NCT00826020|fatty acid deficiency
1285156|NCT00826007|perioperative hypoglycemia diabetes surgery
1285157|NCT00826007|surgery
1285158|NCT00825994|menopause
1285159|NCT00825994|perimenopause
1285160|NCT00825994|postmenopause
1285161|NCT00825994|depression
1285162|NCT00825994|mood
1285163|NCT00825994|sleep
1285164|NCT00825994|hot flashes
1285165|NCT00825968|Electrophysiological
1285166|NCT00825968|Heart Disease
1285167|NCT00825968|Cardiology
1285168|NCT00825968|Atrial Fibrillation
1285169|NCT00825968|Risk Factors
1285170|NCT00825968|Follow-up
1285171|NCT00825968|Outcomes
1285172|NCT00825942|Asteroid hyalosis
1285173|NCT00825942|Opthalmic Study
1285174|NCT00825929|pharmacokinetics
1285175|NCT00825929|pregnancy
1285176|NCT00825929|antiretrovirals
1285177|NCT00825929|neonates
1285178|NCT00825929|HIV
1285179|NCT00825929|treatment experienced
1285180|NCT00825916|AZX100
1285181|NCT00825916|Patient and Observer Scar Assessment Scale
1285182|NCT00825916|POSAS
1285183|NCT00825916|Visual Analog Scale
1285184|NCT00825916|VAS
1285185|NCT00825916|Keloid
1285186|NCT00825916|Scarring
1285187|NCT00825916|Scar reduction
1285188|NCT00825916|Scar prevention
1285189|NCT00825903|aquatic exercise
1285190|NCT00825903|asthma
1285191|NCT00825890|high cup disc ratio
1285192|NCT00825890|glaucoma suspect
1285193|NCT00825877|Hepatitis C
1285194|NCT00825877|Sustained Virological Response
1285195|NCT00825877|HALT-C
1285196|NCT00825877|Peginterferon and Ribavirin
1285197|NCT00825877|HCV RNA
1285198|NCT00825838|Body weight
1285199|NCT00825838|Body composition
1285200|NCT00825838|Resting metabolic rate and fat oxidation in men
1285201|NCT00825838|class I obese
1285202|NCT00825825|Citalopram
1285203|NCT00825825|Escitalopram
1285204|NCT00825825|Celexa
1285205|NCT00825825|Lexapro
1285206|NCT00825825|fMRI
1285207|NCT00825825|antidepressant
1285208|NCT00825825|healthy volunteers
1285209|NCT00825799|biomarker
1285210|NCT00825799|depression
1285211|NCT00825799|blood test
1285212|NCT00825786|surgery for arm hand or elbow
1285213|NCT00825786|mepivacaine
1285214|NCT00825786|ropivacaine
1285215|NCT00825786|hand surgery
1285216|NCT00825786|elbow surgery
1285217|NCT00825786|forearm surgery
1285218|NCT00825773|TVF
1285219|NCT00825773|TLF
1285220|NCT00825773|MACE
1285221|NCT00825773|Ischemia-driven Target Vessel Failure (TVF) at 12 months.
1285222|NCT00825773|Ischemia-driven Target Lesion Failure (TLF) at 12 months defined as a
1285223|NCT00825773|composite of cardiac death that can not be clearly attributed to a vessel
1285224|NCT00825773|other than the target vessel, target vessel MI (Q and Non-Q wave) and
1285225|NCT00825773|ischemia-driven TLR.
1285226|NCT00825773|Rates of stent thrombosis, defined (per ARC definition) as definite or probable
1285227|NCT00825773|and categorized as early, late or very late.
1285228|NCT00825773|Major Adverse Cardiac Events (MACE) defined as cardiac death, target
1285229|NCT00825773|vessel MI (Q and Non-Q wave), or target lesion revascularization (TLR) at 30
1285230|NCT00825773|days, 6 months, 12 months and 2 to 5 years annually.
1285231|NCT00825760|Antimicrobial Photodynamic Therapy
1285232|NCT00825760|Photodynamic Therapy
1285233|NCT00825760|PDT
1285234|NCT00825760|Red light
1285235|NCT00825760|Visible light
1285236|NCT00825760|Antimicrobial
1285237|NCT00825760|Antibacterial
1285238|NCT00825760|Wound healing
1285239|NCT00825760|Wound management
1285240|NCT00825760|Leg ulcer
1285241|NCT00825760|Chronic venous leg ulcer
1285242|NCT00825760|Chronic wound
1285243|NCT00825760|Wound therapy
1285244|NCT00825760|Antimicrobial therapy
1285245|NCT00825747|Cataract
1285246|NCT00825747|Cataract surgery
1285247|NCT00825747|intraocular lens
1285248|NCT00825747|Aspheric lens
1285249|NCT00825734|Metastatic Breast Cancer
1285250|NCT00825734|Sorafenib
1285251|NCT00825734|Nexavar
1285252|NCT00825734|Ixabepilone
1285253|NCT00825734|Ixempra
1285254|NCT00825721|Cataract Study
1285255|NCT00825721|Ophthalmic Study
1285256|NCT00825721|Agerelated cataract
1285257|NCT00825721|Nuclear Cataract
1285258|NCT00825721|Low grade nuclear cataracts
1285259|NCT00825708|ADHD
1285260|NCT00825682|Breast cancer
1285261|NCT00825682|Radiation therapy
1285262|NCT00825682|Reflexology
1285263|NCT00825682|Fatigue
1285264|NCT00825682|Quality of life
1285265|NCT00825682|Sleep disturbance
1285266|NCT00825669|hepatocellular carcinoma
1285267|NCT00825669|Portal vein tumor thrombus
1285268|NCT00825669|laser ablation
1285269|NCT00825656|Allergic Rhinitis
1285270|NCT00825656|Capsaicin
1285271|NCT00825656|Homeopathic
1285272|NCT00825656|Sinol
1285273|NCT00825656|Sinol-M
1285274|NCT00825630|HP
1285275|NCT00825630|UBT
1285276|NCT00825630|PPI
1285277|NCT00825617|TS
1285278|NCT00825617|HRT
1285279|NCT00825617|Liver function tests
1285280|NCT00825604|stable coronary artery disease
1285281|NCT00825604|quality of life
1285282|NCT00825604|target achievement
1285283|NCT00825604|physical training
1285284|NCT00825604|percutaneous coronary intervention
1285285|NCT00825591|optic nerve hypoplasia
1285286|NCT00825591|septo-optic dysplasia
1285287|NCT00825591|melatonin
1285288|NCT00825591|circadian rhythm
1285289|NCT00825578|intrabronchial valve
1285290|NCT00825578|heterogeneous emphysema
1285291|NCT00825578|non-upper lobe
1285292|NCT00825565|Epidermolysis bullosa
1285293|NCT00825552|Risperidone
1285294|NCT00825552|Severe mood dysregulation
1285295|NCT00825552|bipolar
1285296|NCT00825552|children
1285297|NCT00825539|Schizophrenia
1285298|NCT00825539|Manic depression
1285299|NCT00825539|anxiety
1285300|NCT00825526|Mindfulness Based Stress Reduction (MBSR)
1285301|NCT00825526|Stress Reduction
1285302|NCT00825526|hypertension
1285303|NCT00825526|high blood pressure
1285304|NCT00825526|ambulatory blood pressure monitoring
1285305|NCT00825500|Migraine headache
1285306|NCT00825500|Loxapine
1285307|NCT00825500|Staccato
1285308|NCT00825487|metastatic
1285309|NCT00825487|hematologic
1285310|NCT00825487|malignancy
1285311|NCT00825487|multiple
1285312|NCT00825487|myeloma
1285313|NCT00825487|malignant
1285314|NCT00825487|lymphoma
1285315|NCT00825487|chronic
1285316|NCT00825487|lymphocytic
1285317|NCT00825487|leukemia
1285318|NCT00825487|acute
1285319|NCT00825487|myelogenous
1285320|NCT00825487|promyelocytic
1285321|NCT00825487|dose escalation
1285322|NCT00825487|safety
1285323|NCT00825487|tolerability
1285324|NCT00825487|pharmacodynamics
1285325|NCT00825487|tumor
1285326|NCT00825487|PK
1285327|NCT00825474|small hepatocellular carcinoma
1285328|NCT00825474|partial hepatectomy
1285329|NCT00825474|TACE plus PEI
1285330|NCT00825461|Anorexia Nervosa
1285331|NCT00825448|alcohol addiction
1285332|NCT00825435|Coronary CT angiogram
1285333|NCT00825435|Cardiac imaging
1285334|NCT00825435|Cost analysis
1285335|NCT00825435|acute chest pain
1285336|NCT00825435|risk stratification
1285337|NCT00825435|cumulative costs over 90-days of providing treatment services
1285338|NCT00825422|Posterior lumbar arthrodesis
1285339|NCT00825422|Degenerative spine
1285340|NCT00825422|Postoperative analgesia
1285341|NCT00825422|Local anesthesic
1285342|NCT00825422|Continuous wound infusion catheter
1285343|NCT00825422|Pain
1285344|NCT00825422|lumbar vertebrae
1285345|NCT00825422|Spinal fusion
1285346|NCT00825383|Diabetes
1285347|NCT00825383|lipids
1285348|NCT00825383|fiber
1285349|NCT00825370|Hydromorphone
1285350|NCT00825370|acute pain
1285351|NCT00825370|Protocolized
1285352|NCT00825370|Efficacy
1285353|NCT00825370|Safety
1285354|NCT00825357|biological markers
1285355|NCT00825357|sepsis
1285356|NCT00825357|acute lung injury
1285357|NCT00825344|postoperative pain
1285358|NCT00825344|inguinal hernia
1285359|NCT00825344|chronic postsurgical pain
1285360|NCT00825344|cytokine
1285361|NCT00825344|preemptive analgesia
1285362|NCT00825344|patients with inguinal hernia scheduled for surgery
1285363|NCT00825331|guide wire
1285364|NCT00825331|cardiac catheterization
1285365|NCT00825331|ultrasound-guided examination of the access site
1285366|NCT00825331|graduated scheme
1285367|NCT00825331|elective and non elective cardiac catheterization
1285368|NCT00825318|End-stage renal disease
1285369|NCT00825318|Chronic kidney disease
1285370|NCT00825318|Hemodialysis
1285371|NCT00825305|vaccine
1285372|NCT00825305|prevention
1285373|NCT00825305|rabies
1285374|NCT00825305|Rabies disease
1285375|NCT00825292|colon polyps, colon adenomas
1285376|NCT00825279|Biodegradable polymer
1285377|NCT00825279|Drug Eluting Stent
1285378|NCT00825279|In stent restenosis
1285379|NCT00825279|stent thrombosis
1285380|NCT00825279|Bare Metal Stent
1285381|NCT00825266|pulmonary hypertension & insulin resistance
1285382|NCT00825240|Colorectal Cancer
1285383|NCT00825240|Cancer Survivorship Study
1285384|NCT00825240|Questionnaires
1285385|NCT00825240|Survivorship
1285386|NCT00825240|Survivor Health
1285387|NCT00825240|Health Promotion
1285388|NCT00825240|Behavior Changes
1285389|NCT00825240|Computer-assisted intervention program
1285390|NCT00825227|Cancer
1285391|NCT00825227|Fatigue
1285392|NCT00825227|Taxanes
1285393|NCT00825201|peritoneal carcinomatosis
1285394|NCT00825201|peritoneal cavity cancer
1285395|NCT00825201|stage IV ovarian epithelial cancer
1285396|NCT00825201|recurrent ovarian epithelial cancer
1285397|NCT00825201|unspecified adult solid tumor, protocol specific
1285398|NCT00825175|Down syndrome
1285399|NCT00825175|Gait
1285400|NCT00825175|Motor Development
1285401|NCT00825175|Orthoses
1285402|NCT00825136|Panic Disorder
1285403|NCT00825136|Temperature Biofeedback
1285404|NCT00825136|Internet
1285405|NCT00825123|healthy individuals
1285406|NCT00825110|colorectal
1285407|NCT00825110|cancer
1285408|NCT00825110|gene expression
1285409|NCT00825110|biomarker
1285410|NCT00825110|genomic mismatch repair
1285411|NCT00825097|Spastic equinovarus foot
1285412|NCT00825097|Stroke
1285413|NCT00825097|Tibial neurotomy
1285414|NCT00825097|Botulinum toxin type A
1285415|NCT00825097|Selective tibial neurotomy
1285416|NCT00825084|Dimebon, Japanese and Western population, pharmacokinetics
1285417|NCT00825071|Postoperative Nausea and Vomiting
1285418|NCT00825071|Ondansetron
1285419|NCT00825071|Dexamethasone
1285420|NCT00825058|Depression
1285421|NCT00825045|dopamine
1285422|NCT00825045|D2
1285423|NCT00825045|D3
1285424|NCT00825045|caudate
1285425|NCT00825045|putamen
1285426|NCT00825045|globus pallidus
1285427|NCT00825045|antipsychotic
1285428|NCT00825045|risperidone
1285429|NCT00825045|geriatric
1285430|NCT00825045|Brief Psychiatric Rating Scale
1285431|NCT00825045|PET
1285432|NCT00825045|radiotracer
1285433|NCT00825045|[11C]-(+)-PHNO
1285434|NCT00825045|[11C]-raclopride
1285435|NCT00825032|Pulmonary disease, chronic obstructive
1285436|NCT00825032|Upper extremity
1285437|NCT00825032|Exercise therapy
1285438|NCT00825019|Depression
1285439|NCT00825006|Cardiac resynchronization therapy
1285440|NCT00825006|Anodal stimulation
1285441|NCT00824993|Blood Cancer
1285442|NCT00824993|Calcium
1285443|NCT00824993|Vitamin D
1285444|NCT00824993|Ibandronate
1285445|NCT00824993|Boniva
1285446|NCT00824993|Hematological Malignancies
1285447|NCT00824993|Bone Marrow Transplantation
1285448|NCT00824993|BMT
1285449|NCT00824993|Osteoporosis
1285450|NCT00824993|Bone Loss
1285451|NCT00824993|Allogeneic Bone Marrow Transplantation
1285452|NCT00824954|0 to 30 years
1285453|NCT00824954|Refractory Acute GVHD
1285454|NCT00824941|Abdominal Pain
1285455|NCT00824941|Women's Health and Disease
1285456|NCT00824941|Gut
1285457|NCT00824941|Symptoms
1285458|NCT00824941|Brain
1285459|NCT00824941|Chronic Abdominal Pain
1285460|NCT00824928|Prostate Cancer
1285461|NCT00824928|Recurrent Prostate Cancer
1285462|NCT00824928|Prostate Cancer Recurrence
1285463|NCT00824928|Radiation Failure
1285464|NCT00824928|Salvage Cryotherapy
1285465|NCT00824915|Lead Integrity Algorithm
1285466|NCT00824902|Prostate Cancer
1285467|NCT00824902|Prostate
1285468|NCT00824902|Radical Prostatectomy
1285469|NCT00824902|Tissue Elastography
1285470|NCT00824902|Tissue Elastography Imaging
1285471|NCT00824902|Software Program Measuring Prostate Elasticity
1285472|NCT00824902|Elasticity/Tissue Strain-Hardening Imaging
1285473|NCT00824902|Ultrasound
1285474|NCT00824876|Mammae cancer patients
1285475|NCT00824863|pityrosporum folliculitis
1285476|NCT00824863|ketoconazole 2% foam
1285477|NCT00824850|Single site
1285478|NCT00824850|single dose
1285479|NCT00824850|Participated in Wyeth D118-P8
1285480|NCT00824837|beta 2 microglobulin
1285481|NCT00824837|haemodialysis
1285482|NCT00824837|albumin
1285483|NCT00824824|Retinal Vascular Autoregulation
1285484|NCT00824811|Epiphora
1285485|NCT00824811|Breast Cancer
1285486|NCT00824811|Lung Cancer
1285487|NCT00824811|Prostate Cancer
1285488|NCT00824811|Non-small cell lung cancer
1285489|NCT00824811|Bladder Cancer
1285490|NCT00824811|Esophageal Cancer
1285491|NCT00824811|Head and Neck Cancer
1285492|NCT00824811|HNC
1285493|NCT00824811|Small Cell Lung Cancer
1285494|NCT00824811|SCLC
1285495|NCT00824811|Ovarian Cancer
1285496|NCT00824811|Stomach Cancer
1285497|NCT00824811|Canalicular Stenosis
1285498|NCT00824811|Excessive tearing
1285499|NCT00824811|Eye inflammation
1285500|NCT00824811|Cyclosporine Ophthalmic Emulsion 0.05%
1285501|NCT00824811|Docetaxel
1285502|NCT00824811|Taxotere
1285503|NCT00824811|Restasis®
1285504|NCT00824811|Cyclosporine
1285505|NCT00824811|Cyclosporine eye drops
1285506|NCT00824811|FML Forte®
1285507|NCT00824811|Fluorometholone 0.25% ophthalmic suspension
1285508|NCT00824811|Fluorometholone eye drops
1285509|NCT00824811|Fluorometholone
1285510|NCT00824811|Refresh Endura™
1285511|NCT00824811|Lubricant eye drops
1285512|NCT00824811|Eye drops
1285513|NCT00824798|gait
1285514|NCT00824798|haemophilia
1285515|NCT00824798|arthropathy
1285516|NCT00824785|epirubicin
1285517|NCT00824785|oxaliplatin
1285518|NCT00824785|capecitabine
1285519|NCT00824785|panitumumab
1285520|NCT00824772|pharmacogenetics
1285521|NCT00824759|Healthy subjects
1285522|NCT00824759|CABG
1285523|NCT00824759|Patients undergoing coronary artery bypass graft under cardiopulmonary bypass
1285524|NCT00824746|Gefitinib
1285525|NCT00824746|Recurrence
1285526|NCT00824746|Carcinoma, Non-Small-Cell Lung
1285527|NCT00824733|recurrent breast cancer
1285528|NCT00824733|stage IV breast cancer
1285529|NCT00824733|stage IIIA breast cancer
1285530|NCT00824733|stage IIIB breast cancer
1285531|NCT00824733|stage IIIC breast cancer
1285532|NCT00824733|HER2-positive breast cancer
1285533|NCT00824733|male breast cancer
1285534|NCT00824707|primary liver cancer
1285535|NCT00824707|hepatitis B virus
1285536|NCT00824707|anti-virus therapy
1285537|NCT00824694|Glucose
1285538|NCT00824694|Diabetes Mellitus, Type 2
1285539|NCT00824694|HbA1c
1285540|NCT00824681|Psychological adjustment of family
1285541|NCT00824681|family of patients
1285542|NCT00824681|children of patients
1285543|NCT00824681|intensive care unit
1285544|NCT00824681|burn
1285545|NCT00824681|music therapy
1285546|NCT00824681|music
1285547|NCT00824681|music program
1285548|NCT00824681|anxiety
1285549|NCT00824681|coping
1285550|NCT00824681|adjustment
1285551|NCT00824681|psychological stressor
1285552|NCT00824681|emotional stressor
1285553|NCT00824655|Healthy Subjects
1285554|NCT00824655|Vaccines
1285555|NCT00824655|Pneumococcal
1285556|NCT00824642|Asthma
1285557|NCT00824642|Exercise training
1285558|NCT00824642|TENS
1285559|NCT00824642|Acupuncture
1285560|NCT00824642|FEV1
1285561|NCT00824629|Embryo transfer
1285562|NCT00824629|IVF
1285563|NCT00824629|Ultrasound embryo transfer
1285564|NCT00824590|Dimebon
1285565|NCT00824590|renal impairment
1285566|NCT00824590|pharmacokinetics
1285567|NCT00824577|heart rate variability
1285568|NCT00824577|autonomic function
1285569|NCT00824577|heart function
1285570|NCT00824564|Tranexamic Acid
1285571|NCT00824564|Blood Loss
1285572|NCT00824564|Long Bone Fracture Surgery
1285573|NCT00824551|Acute Thermal Burns
1285574|NCT00824551|Hyperbaric Oxygen Therapy
1285575|NCT00824551|Burns conversion
1285576|NCT00824538|stage IA breast cancer
1285577|NCT00824538|stage IB breast cancer
1285578|NCT00824538|stage II breast cancer
1285579|NCT00824538|stage IIIA breast cancer
1285580|NCT00824538|stage IIIB breast cancer
1285581|NCT00824538|stage IIIC breast cancer
1285582|NCT00824486|child
1285583|NCT00824486|injury prevention
1285584|NCT00824460|Hemodialysis
1285585|NCT00824447|randomised
1285586|NCT00824447|double-blind
1285587|NCT00824447|placebo-controlled
1285588|NCT00824447|long-term efficacy and safety
1285589|NCT00824447|Oralgen® Grass Pollen
1285590|NCT00824447|allergic rhinoconjunctivitis
1285591|NCT00824447|Allergy
1285592|NCT00824447|Rhinoconjunctivitis
1285593|NCT00824447|Immunotherapy
1285594|NCT00824447|Grass pollen extract
1285595|NCT00824434|Atherosclerosis
1285596|NCT00824434|Coronary Artery Disease
1285597|NCT00824421|HIV-1. Treatment Naive
1285598|NCT00824421|HIV Infections
1285599|NCT00824421|treatment naive
1285600|NCT00824395|diabetes
1285601|NCT00824395|type 1
1285602|NCT00824395|type 2
1285603|NCT00824395|metabolic syndrome
1285604|NCT00824395|mitochondria
1285605|NCT00824369|HIV-1
1285606|NCT00824369|Rollover
1285607|NCT00824369|Safety.
1285608|NCT00824369|HIV Infections
1285609|NCT00824369|treatment experienced
1285610|NCT00824356|Allergic Rhinitis
1285611|NCT00824356|Proof-of-Concept
1285612|NCT00824330|Aging
1285613|NCT00824330|Type 2 diabetes
1285614|NCT00824330|exercise
1285615|NCT00824330|walking
1285616|NCT00824330|glucose metabolism
1285617|NCT00824330|arterial baroreceptors
1285618|NCT00824330|heart rate variability
1285619|NCT00824330|cerebral autoregulation
1285620|NCT00824330|tilt table study
1285621|NCT00824330|transcranial Doppler
1285622|NCT00824330|autonomic nervous system
1285623|NCT00824304|cognitive performance
1285624|NCT00824304|growth
1285625|NCT00824304|iron
1285626|NCT00824304|zinc
1285627|NCT00824291|Major Depressive Disorder
1285635|NCT00824265|Relapsed
1285636|NCT00824265|Oncology
1285637|NCT00824265|Safety
1285638|NCT00824265|Chronic Lymphocytic Leukemia
1285639|NCT00824265|Ofatumumab
1285640|NCT00824265|Efficacy
1285641|NCT00824252|Head And Neck Cancer
1285642|NCT00824252|HNC
1285643|NCT00824252|Radiation Therapy
1285644|NCT00824252|Spousal Support
1285645|NCT00824252|Emotional Disclosure
1285646|NCT00824252|Observational
1285647|NCT00824252|Social Constraints
1285648|NCT00824252|Questionnaires
1285649|NCT00824252|Videotaped Interview
1285650|NCT00824252|Quality of Life
1285651|NCT00824239|critical care
1285652|NCT00824239|sedation
1285653|NCT00824239|Mechanically ventilated patients
1285654|NCT00824226|primary hypoparathyroidism
1285655|NCT00824226|secondary hypoparathyroidism
1285656|NCT00824226|magnesium
1285657|NCT00824213|Whole Body SPECT imaging
1285658|NCT00824200|Sleep
1285659|NCT00824200|Quality of life
1285660|NCT00824200|nocturia
1285661|NCT00824187|Premenstrual Dysphoric Disorder ( PMDD)
1285662|NCT00824187|Oral contraceptive
1285663|NCT00824174|Questionnaire
1285664|NCT00824174|Head and Neck Cancer
1285665|NCT00824174|Skin Cancer
1285666|NCT00824174|Body Image
1285667|NCT00824174|Surgical Treatment
1285668|NCT00824174|Oral Cavity Cancer
1285669|NCT00824174|Cutaneous Cancer
1285670|NCT00824148|Real-time glucose monitoring system
1285671|NCT00824148|HbA1c
1285672|NCT00824148|Quality of life
1285673|NCT00824148|Hypoglycemia
1285674|NCT00824135|Stem Cell Transplantation, Hematopoietic
1285675|NCT00824135|Peripheral Blood Stem Cell Transplantation
1285676|NCT00824135|Maximal Tolerated Dose
1285677|NCT00824135|Clofarabine
1285678|NCT00824135|Hematological Malignancies
1285679|NCT00824135|Apheresis
1285680|NCT00824109|Aneurysmal disease of the abdominal aorta
1285681|NCT00824109|Occlusive disease of the abdominal aorta
1285682|NCT00824096|endotracheal intubation
1285683|NCT00824096|cuff-leak test
1285684|NCT00824096|post-extubation stridor
1285685|NCT00824096|bronchoscopy
1285686|NCT00824096|corticosteroids
1285687|NCT00824096|Cuff-leak volume less than 24%
1285688|NCT00824083|bone tumors
1285689|NCT00824083|long-term function
1285690|NCT00824083|daily activity
1285691|NCT00824083|late sequelae
1285692|NCT00824070|Bioavailability
1285693|NCT00824057|Phase I
1285694|NCT00824044|Major Depressive Disorder (MDD)
1285695|NCT00824044|Cognitive Behavioral Therapy (CBT)
1285696|NCT00824044|Escitalopram
1285697|NCT00824044|Quantitative EEG (QEEG)
1285698|NCT00824031|schizophrenia
1285699|NCT00824031|medical mental care
1285700|NCT00824031|caregiver
1285701|NCT00824031|Sapin
1285702|NCT00823264|Anticonvulsants
1285703|NCT00823264|Toxicology
1285704|NCT00823264|multidose charcoal
1285705|NCT00823264|phenytoin
1285706|NCT00823225|Diabetes
1285707|NCT00823225|urokinase
1285708|NCT00823225|ulcer healing
1285709|NCT00823225|major amputation
1285710|NCT00823225|survival
1285711|NCT00823212|drug-eluting stents
1285712|NCT00823212|DES
1285713|NCT00823212|atherosclerotic
1285714|NCT00824005|Congestive Heart Failure
1285715|NCT00824005|Regional Wall Motion
1285716|NCT00824005|Perfusion Defects
1285717|NCT00823979|HIV-1 NNRTI Treatment Experienced
1285718|NCT00823979|may have Protease inhibitor experience
1285719|NCT00823953|diabetes type 2
1285720|NCT00823940|FTIH
1285721|NCT00823940|Glucagon
1285722|NCT00823940|Safety
1285723|NCT00823940|GSK1362885
1285724|NCT00823940|Pharmacokinetics
1285725|NCT00823940|Tolerability
1285726|NCT00823940|Pharmacodynamics
1285727|NCT00823927|lung damage
1285728|NCT00823927|cigarette smoking
1285729|NCT00823927|HIV-seropositive
1285730|NCT00823927|emphysema
1285731|NCT00823914|Psoriasis
1285732|NCT00823914|Quality of Life
1285733|NCT00823901|rosacea
1285734|NCT00823901|clindamycin
1285735|NCT00823901|tretinoin
1285736|NCT00823901|clinical study
1285737|NCT00823901|treatment
1285738|NCT00823888|Knee Osteoarthritis
1285739|NCT00823888|pneumatic bracing
1285740|NCT00823862|HCV
1285741|NCT00823862|Immunostimulatory sequence (ISS)
1285742|NCT00823862|TLR9 (toll-like receptor 9)
1285743|NCT00823862|interferon (IFN)
1285744|NCT00823862|ribavirin
1285745|NCT00823849|type 2 diabetes mellitus, with Arteriosclerosis obliterans
1285746|NCT00823836|Ropinirole, advanced Parkinson's disease, L-dopa adjunctive therapy
1285747|NCT00823823|Casting techniques
1285748|NCT00823823|Bivalved cast
1285749|NCT00823823|Circumferential cast
1285750|NCT00823823|Displaced distal radius fracture
1285751|NCT00823823|Children
1285752|NCT00823810|Colorectal cancer
1285753|NCT00823810|Response to treatment
1285754|NCT00823810|FDG PET/CT
1285755|NCT00823784|hemorrhoids
1285756|NCT00823784|stapler
1285757|NCT00823784|Doppler
1285758|NCT00823784|artery ligation
1285759|NCT00823784|outcome
1285760|NCT00823784|recurrence
1285761|NCT00823758|Acetaminophen
1285762|NCT00823758|Liver
1285763|NCT00823758|Centers for Education and Research on Therapeutics
1285764|NCT00823758|CERTS
1285765|NCT00823758|Over-the-counter Acetaminophen
1285766|NCT00823758|OTC
1285767|NCT00823758|Self-administration
1285768|NCT00823758|Parental administration
1285769|NCT00823758|Houston
1285770|NCT00823758|Texas
1285771|NCT00823758|Liver toxicity
1285772|NCT00823758|Qualitative study
1285773|NCT00823758|Pharmacists
1285774|NCT00823758|Adolescents
1285775|NCT00823758|Primary care physicians
1285776|NCT00823758|Family Practitioners
1285777|NCT00823758|General Internist
1285778|NCT00823732|stage IIIB non-small cell lung cancer
1285779|NCT00823732|stage IV non-small cell lung cancer
1285780|NCT00823732|recurrent non-small cell lung cancer
1285781|NCT00823719|Salvage chemotherapy
1285782|NCT00823719|relapsed
1285783|NCT00823719|grade 3B follicular lymphoma
1285784|NCT00823719|efficacy
1285785|NCT00823719|safety
1285786|NCT00823719|DHAP
1285787|NCT00823719|ofatumumab
1285788|NCT00823719|refractory
1285789|NCT00823719|Non-Hodgkin's Lymphoma
1285790|NCT00823719|Diffuse Large B Cell Lymphoma (DLBCL)
1285791|NCT00823719|Oncology
1285792|NCT00823719|ICE
1285793|NCT00823719|Transformed follicular lymphoma
1285794|NCT00823706|chronic angle closure hyperopia
1285795|NCT00823667|stage I non-small cell lung cancer
1285796|NCT00823667|stage II non-small cell lung cancer
1285797|NCT00823667|stage IIIA non-small cell lung cancer
1285798|NCT00823654|Breast
1285799|NCT00823654|Questionaires
1285800|NCT00823654|Blood draw
1285801|NCT00823654|BRCA1
1285802|NCT00823654|BRCA2
1285803|NCT00823654|08-156
1285804|NCT00823641|HAM/TSP
1285805|NCT00823641|HTLV-I
1285806|NCT00823602|GnRH antagonist
1285807|NCT00823602|GnRH agonist
1285808|NCT00823602|pregnancy rate
1285809|NCT00823602|Ovarian stimulation
1285810|NCT00823589|ELDERLY POPULATION
1285811|NCT00823576|Arthodeses rachis lombar
1285812|NCT00823576|Spinal Surgery
1285813|NCT00823550|Chronic hepatitis B
1285814|NCT00823550|Advanced fibrosis
1285815|NCT00823550|Lamivudine
1285816|NCT00823550|Entecavir
1285817|NCT00823524|accelerated phase chronic myelogenous leukemia
1285818|NCT00823524|acute undifferentiated leukemia
1285819|NCT00823524|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1285820|NCT00823524|adult acute myeloid leukemia with inv(16)(p13;q22)
1285821|NCT00823524|adult acute myeloid leukemia with t(15;17)(q22;q12)
1285822|NCT00823524|adult acute myeloid leukemia with t(16;16)(p13;q22)
1285823|NCT00823524|adult acute myeloid leukemia with t(8;21)(q22;q22)
1285824|NCT00823524|atypical chronic myeloid leukemia, BCR-ABL1 negative
1285825|NCT00823524|blastic phase chronic myelogenous leukemia
1285826|NCT00823524|chronic myelomonocytic leukemia
1285827|NCT00823524|chronic phase chronic myelogenous leukemia
1285828|NCT00823524|mast cell leukemia
1285829|NCT00823524|meningeal chronic myelogenous leukemia
1285830|NCT00823524|progressive hairy cell leukemia, initial treatment
1285831|NCT00823524|prolymphocytic leukemia
1285832|NCT00823524|recurrent adult acute lymphoblastic leukemia
1285833|NCT00823524|recurrent adult acute myeloid leukemia
1285834|NCT00823524|recurrent adult T-cell leukemia/lymphoma
1285835|NCT00823524|refractory chronic lymphocytic leukemia
1285836|NCT00823524|refractory hairy cell leukemia
1285837|NCT00823524|relapsing chronic myelogenous leukemia
1285838|NCT00823524|secondary acute myeloid leukemia
1285839|NCT00823524|stage III adult T-cell leukemia/lymphoma
1285840|NCT00823524|stage III chronic lymphocytic leukemia
1285841|NCT00823524|stage IV adult T-cell leukemia/lymphoma
1285842|NCT00823524|stage IV chronic lymphocytic leukemia
1285843|NCT00823524|T-cell large granular lymphocyte leukemia
1285844|NCT00823524|adult grade III lymphomatoid granulomatosis
1285845|NCT00823524|adult nasal type extranodal NK/T-cell lymphoma
1285846|NCT00823524|anaplastic large cell lymphoma
1285847|NCT00823524|angioimmunoblastic T-cell lymphoma
1285848|NCT00823524|splenic marginal zone lymphoma
1285849|NCT00823524|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1285850|NCT00823524|nodal marginal zone B-cell lymphoma
1285851|NCT00823524|stage III adult Burkitt lymphoma
1285852|NCT00823524|stage III adult diffuse large cell lymphoma
1285853|NCT00823524|stage III adult diffuse mixed cell lymphoma
1285854|NCT00823524|stage III adult diffuse small cleaved cell lymphoma
1285855|NCT00823524|stage III adult Hodgkin lymphoma
1285856|NCT00823524|stage III adult immunoblastic large cell lymphoma
1285857|NCT00823524|stage III adult lymphoblastic lymphoma
1285858|NCT00823524|stage III cutaneous T-cell non-Hodgkin lymphoma
1285859|NCT00823524|stage III mycosis fungoides/Sezary syndrome
1285860|NCT00823524|stage III grade 1 follicular lymphoma
1285861|NCT00823524|stage III grade 2 follicular lymphoma
1285862|NCT00823524|stage III grade 3 follicular lymphoma
1285863|NCT00823524|stage III mantle cell lymphoma
1285864|NCT00823524|stage III marginal zone lymphoma
1285865|NCT00823524|stage III small lymphocytic lymphoma
1285866|NCT00823524|stage IV adult Burkitt lymphoma
1285867|NCT00823524|stage IV adult diffuse large cell lymphoma
1285868|NCT00823524|stage IV adult diffuse mixed cell lymphoma
1285869|NCT00823524|stage IV adult diffuse small cleaved cell lymphoma
1285870|NCT00823524|stage IV adult Hodgkin lymphoma
1285871|NCT00823524|stage IV adult immunoblastic large cell lymphoma
1285872|NCT00823524|stage IV adult lymphoblastic lymphoma
1285873|NCT00823524|stage IV cutaneous T-cell non-Hodgkin lymphoma
1285874|NCT00823524|stage IV mycosis fungoides/Sezary syndrome
1285875|NCT00823524|stage IV grade 1 follicular lymphoma
1285876|NCT00823524|stage IV grade 2 follicular lymphoma
1285877|NCT00823524|stage IV grade 3 follicular lymphoma
1285878|NCT00823524|stage IV mantle cell lymphoma
1285879|NCT00823524|stage IV marginal zone lymphoma
1285880|NCT00823524|stage IV small lymphocytic lymphoma
1285881|NCT00823524|recurrent adult Hodgkin lymphoma
1285882|NCT00823524|recurrent adult Burkitt lymphoma
1285883|NCT00823524|recurrent adult diffuse large cell lymphoma
1285884|NCT00823524|recurrent adult diffuse mixed cell lymphoma
1285885|NCT00823524|recurrent adult diffuse small cleaved cell lymphoma
1285886|NCT00823524|recurrent adult grade III lymphomatoid granulomatosis
1285887|NCT00823524|recurrent adult immunoblastic large cell lymphoma
1285888|NCT00823524|recurrent adult lymphoblastic lymphoma
1285889|NCT00823524|recurrent cutaneous T-cell non-Hodgkin lymphoma
1285890|NCT00823524|recurrent mycosis fungoides/Sezary syndrome
1285891|NCT00823524|recurrent grade 1 follicular lymphoma
1285892|NCT00823524|recurrent grade 2 follicular lymphoma
1285893|NCT00823524|recurrent grade 3 follicular lymphoma
1285894|NCT00823524|recurrent mantle cell lymphoma
1285895|NCT00823524|recurrent marginal zone lymphoma
1285896|NCT00823524|recurrent small lymphocytic lymphoma
1285897|NCT00823524|intraocular lymphoma
1285898|NCT00823524|primary central nervous system non-Hodgkin lymphoma
1285899|NCT00823524|primary central nervous system Hodgkin lymphoma
1285900|NCT00823524|post-transplant lymphoproliferative disorder
1285901|NCT00823524|chronic eosinophilic leukemia
1285902|NCT00823524|chronic neutrophilic leukemia
1285903|NCT00823524|primary myelofibrosis
1285904|NCT00823524|essential thrombocythemia
1285905|NCT00823524|polycythemia vera
1285906|NCT00823524|extramedullary plasmacytoma
1285907|NCT00823524|isolated plasmacytoma of bone
1285908|NCT00823524|stage II multiple myeloma
1285909|NCT00823524|stage III multiple myeloma
1285910|NCT00823524|primary systemic amyloidosis
1285911|NCT00823524|refractory multiple myeloma
1285912|NCT00823524|de novo myelodysplastic syndromes
1285913|NCT00823524|previously treated myelodysplastic syndromes
1285914|NCT00823524|secondary myelodysplastic syndromes
1285915|NCT00823524|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1285916|NCT00823524|cutaneous B-cell non-Hodgkin lymphoma
1285917|NCT00823524|Waldenström macroglobulinemia
1285918|NCT00823524|unspecified adult solid tumor, protocol specific
1285919|NCT00823511|HPV
1285920|NCT00823511|Human Papillomavirus Infection
1285921|NCT00823511|Cervix Uteri
1285922|NCT00823511|Cancer Control
1285923|NCT00823511|Risk Assessment, Detection & Intervention
1285924|NCT00823511|Sexually Transmitted
1285925|NCT00823511|Neoplasia
1285926|NCT00823511|Carcinogenesis
1285927|NCT00823511|Cervix
1285928|NCT00823498|Cancer Prevention
1285929|NCT00823498|African American
1285930|NCT00823498|African American Parents
1285931|NCT00823498|African American Youth
1285932|NCT00823498|Public Housing
1285933|NCT00823498|Physical Activity
1285934|NCT00823498|Focus Groups
1285935|NCT00823498|Housing Developments
1285936|NCT00823498|Houston Public Housing
1285937|NCT00823498|Photovoice Project
1285938|NCT00823498|Prevention
1285939|NCT00823472|embryonic structures
1285940|NCT00823472|sperm injections, intracytoplasmic
1285941|NCT00823472|IVF
1285942|NCT00823472|GnRH antagonist
1285943|NCT00823472|ovarian stimulation
1285944|NCT00823472|cycle day 2 versus cycle day 5
1285945|NCT00823459|Low-grade glioma
1285946|NCT00823459|astrocytoma
1285947|NCT00823459|oligodendroglioma
1285948|NCT00823459|mixed oligoastrocytoma
1285949|NCT00823433|Penicillin
1285950|NCT00823433|Group B Streptococcus
1285951|NCT00823433|Pregnancy
1285952|NCT00823433|Labor
1285953|NCT00823420|PCOS and normal ovulatory patients
1285954|NCT00823420|aneuploidy
1285955|NCT00823420|in-vitro maturation of oocytes
1285956|NCT00823407|MDA
1285957|NCT00823407|MDMA
1285958|NCT00823407|Ecstasy
1285959|NCT00823407|entactogen
1285960|NCT00823407|pharmacokinetics
1285961|NCT00823407|pharmacodynamics
1285962|NCT00823407|Pharmacokinetics and pharmacodynamics of MDA studies in healthy volunteers
1285963|NCT00823394|African American
1285964|NCT00823394|Adults
1285965|NCT00823394|African American Cancer Prevention Project
1285966|NCT00823394|Health Disparities
1285967|NCT00823394|Questionnaire
1285968|NCT00823394|Body Measurements
1285969|NCT00823394|Self-help
1285970|NCT00823394|Cancer Rates
1285971|NCT00823394|Prevention
1285972|NCT00823381|obesity
1285973|NCT00823381|metabolic syndrome
1285974|NCT00823381|diabetes
1285975|NCT00823381|aging
1285976|NCT00823381|calorie restriction
1285977|NCT00823381|resveratrol
1285978|NCT00823381|antioxidant
1285979|NCT00823368|fragile X syndrome
1285980|NCT00823368|biomarkers
1285981|NCT00823342|HBe, Hepatitis, Vireda (TENOFOVIR, CLEVUDINE), HBV, HBe Ag negative
1285982|NCT00823329|measurement of energy expenditure of physical activity
1285983|NCT00823329|analysis of body composition and hydration status
1285984|NCT00823316|Mesenchymal Stem Cells
1285985|NCT00823316|Allogeneic Transplantation
1285986|NCT00823316|Engraftment
1285987|NCT00823316|GvHD
1285988|NCT00823316|Childhood
1285989|NCT00823316|unrelated HSCT
1285990|NCT00823303|PTH
1285991|NCT00823303|Active Vitamin D
1285992|NCT00823303|hypercalcemia
1285993|NCT00823303|Chronic Kidney Disease
1285994|NCT00823290|HCC
1285995|NCT00823290|sorafenib
1285996|NCT00823290|HDAC
1285997|NCT00823290|LBH589
1285998|NCT00823290|Panobinostat
1285999|NCT00823186|cervical carcinoma
1286000|NCT00823186|neoadjuvant chemotherapy
1286001|NCT00823173|Uveitis
1286002|NCT00823173|TNF-alpha
1286003|NCT00823173|Topical
1286004|NCT00823173|ESBA105
1286005|NCT00823173|scFv antibody fragment
1286006|NCT00823173|ocular inflammation
1286007|NCT00823160|Pericardial window
1286008|NCT00823160|Sternotomy
1286009|NCT00823160|Haemopericardium
1286010|NCT00823147|Pain
1286011|NCT00823147|Systemic Inflammation
1286012|NCT00823147|Pain Catastrophizing
1286013|NCT00823121|Fresh embryo transfer
1286014|NCT00823121|frozen- thawed embryo transfer
1286015|NCT00823121|vitrification
1286016|NCT00823121|endometrial receptivity
1286017|NCT00823121|implantation rate
1286018|NCT00823121|pregnancy
1286019|NCT00823121|ART
1286020|NCT00823108|GIK, septic shock, sepsis
1286021|NCT00823095|chronic cutaneous ulcers
1286022|NCT00823095|Nitric Oxide
1286023|NCT00823095|topically applied
1286024|NCT00823095|Biofilm
1286025|NCT00823095|Colonized chronic non-healing ulcers
1286026|NCT00823082|antithrombin
1286027|NCT00823082|ATIII
1286028|NCT00823082|acquired deficiency
1286029|NCT00823082|anticoagulants
1286030|NCT00823082|cardiopulmonary bypass
1286031|NCT00823082|surgery
1286032|NCT00823082|complications
1286033|NCT00823082|postoperative outcomes
1286034|NCT00823069|Correction of Nasolabial Folds
1286035|NCT00823056|Probiotics
1286036|NCT00823056|Infections
1286037|NCT00823056|Children
1286038|NCT00823030|Interstitial Cystitis
1286039|NCT00823030|Intravesical Lidocaine
1286040|NCT00823017|ICU environment
1286041|NCT00823017|Auditory stimulation
1286042|NCT00823017|Properties of relaxation music
1286043|NCT00823017|music
1286044|NCT00823017|music therapy
1286045|NCT00823017|pain
1286046|NCT00823017|anxiety
1286047|NCT00823017|cortisol
1286048|NCT00823017|IgA
1286049|NCT00823017|biomarkers
1286050|NCT00823017|relaxation music
1286051|NCT00823004|controlled ovarian hyperstimulation
1286052|NCT00823004|pregnancy rate
1286053|NCT00823004|Poor responders
1286054|NCT00823004|GnRH antagonist
1286055|NCT00823004|GnRH agonist
1286056|NCT00823004|letrozole
1286057|NCT00823004|in vitro fertilization
1286058|NCT00822991|Sonazoid
1286059|NCT00822991|Early detection
1286060|NCT00822991|Hepatocellular carcinoma
1286061|NCT00822991|Liver cirrhosis
1286062|NCT00822978|healthy
1286063|NCT00822978|volunteers
1286064|NCT00822978|subjects
1286065|NCT00822965|Pacemakers
1286066|NCT00822965|PM
1286067|NCT00822965|Implantable cardioverter-defibrillators
1286068|NCT00822965|ICD
1286069|NCT00822965|Implantable pulse generators
1286070|NCT00822965|Educational Interventions
1286071|NCT00822913|Botulinum A toxin
1286072|NCT00822913|Parkinson's disease
1286073|NCT00822900|Trauma
1286074|NCT00822900|Brain Injury
1286075|NCT00822887|malignant
1286076|NCT00822887|gliomas
1286077|NCT00822874|PCOS and normal ovulatory patients
1286078|NCT00822874|aneuploidy
1286079|NCT00822874|in-vitro maturation of oocytes
1286080|NCT00822848|stage II adult soft tissue sarcoma
1286081|NCT00822848|stage III adult soft tissue sarcoma
1286082|NCT00822822|Questionnaire
1286083|NCT00822822|Electronic Health History
1286084|NCT00822809|Cancer
1286085|NCT00822809|Neoplasms
1286086|NCT00822809|Carcinoma
1286087|NCT00822809|Malignant Ascites
1286088|NCT00822809|Drug therapy
1286089|NCT00822809|Antineoplastic Protocols
1286090|NCT00822809|Immunotherapy
1286091|NCT00822809|Phase III
1286092|NCT00822809|trifunctional antibody
1286093|NCT00822809|monoclonal antibody
1286094|NCT00822809|EpCAM
1286095|NCT00822796|Hypothermia
1286096|NCT00822796|Severe burns
1286097|NCT00822796|Warming catheter
1286098|NCT00822796|Thermogard™
1286099|NCT00822796|Coagulopathy
1286100|NCT00822783|Serum IgE levels
1286101|NCT00822783|inflammatory cells in the skin
1286102|NCT00822783|inflammatory cells in the blood
1286103|NCT00822783|IgE
1286104|NCT00822783|IgE depletion
1286105|NCT00822783|atopic dermatitis
1286106|NCT00822783|atopic eczema
1286107|NCT00822783|Omalizumab
1286108|NCT00822770|Blood Stem Cell Transplantation
1286109|NCT00822770|Bone Marrow Transplantation
1286110|NCT00822770|Bone Marrow Cell Transplantation
1286111|NCT00822770|Stem Cell Transplantation
1286112|NCT00822770|Allogeneic Hematopoietic Transplantation
1286113|NCT00822770|Advanced Myeloid Leukemia
1286114|NCT00822770|Acute Myeloid Leukemia
1286115|NCT00822770|AML
1286116|NCT00822770|Myelodysplastic syndrome
1286117|NCT00822770|MDS
1286118|NCT00822770|Chronic Myeloid Leukemia
1286119|NCT00822770|CML
1286120|NCT00822770|Graft Versus Host Disease
1286121|NCT00822770|GVHD
1286122|NCT00822770|ATG
1286123|NCT00822770|Busulfan
1286124|NCT00822770|Busulfex™
1286125|NCT00822770|Myleran®
1286126|NCT00822770|Filgrastim
1286127|NCT00822770|Neupogen
1286128|NCT00822770|Fludarabine
1286129|NCT00822770|Fludarabine Phosphate
1286130|NCT00822770|Fludara™
1286131|NCT00822770|G-CSF
1286132|NCT00822770|Plerixafor
1286133|NCT00822770|Antithymocyte globulin
1286134|NCT00822770|Thymoglobulin
1286135|NCT00822757|study in healthy subjects
1286136|NCT00822744|Depression
1286137|NCT00822744|Major Depressive Episode
1286138|NCT00822744|Antidepressant
1286139|NCT00822731|Lymphoma
1286140|NCT00822731|prognosis
1286141|NCT00822731|morbidity
1286142|NCT00822718|obestatin
1286143|NCT00822718|ghrelin
1286144|NCT00822718|stomach cancer
1286145|NCT00822718|distal gastrectomy
1286146|NCT00822705|Appetite, energy consumption, gastrointestinal hormones
1286147|NCT00822692|Abscess
1286148|NCT00822692|Cellulitis
1286149|NCT00822692|Antibiotics
1286150|NCT00822692|MRSA
1286151|NCT00822679|Acute Coronary Syndrome
1286152|NCT00822679|cytokines
1286153|NCT00822679|pro-coagulant mediators
1286154|NCT00822679|sleep disorders
1286155|NCT00822666|Platelet aggregation
1286156|NCT00822666|Platelet
1286157|NCT00822666|Thrombosis
1286158|NCT00822666|Clopidogrel
1286159|NCT00822653|hemodialysis treatment
1286160|NCT00822653|pump stimulation
1286161|NCT00822653|reduce hypotensive episodes
1286162|NCT00822640|Prosthesis Design
1286163|NCT00822640|Range of Motion, Articular
1286164|NCT00822640|Arthroplasty, Replacement, Knee
1286165|NCT00822627|Influenza
1286166|NCT00822627|vaccination
1286167|NCT00822627|Emergency Department
1286168|NCT00822614|Pain
1286169|NCT00822601|Repetitive Transcranial Magnetic Stimulation
1286170|NCT00822601|Supplementary Motor Area
1286171|NCT00822601|Obsessive-Compulsive Disorder
1286172|NCT00822601|Sham rTMS
1286173|NCT00822601|Placebo-controlled
1286174|NCT00822601|Randomized
1286175|NCT00822601|Double-blind
1286176|NCT00822601|fMRI
1286177|NCT00822601|DSM-IV Obsessive-Compulsive Disorder
1286178|NCT00822575|mosquito bites
1286179|NCT00822575|itching
1286180|NCT00822562|hepatocellular carcinoma
1286181|NCT00822562|surgery
1286182|NCT00822549|Morphine titration
1286183|NCT00822549|Sub acute pain
1286184|NCT00822549|Major orthopaedic surgery
1286185|NCT00822549|Pharmacokinetics
1286186|NCT00822549|Pharmacodynamics
1286187|NCT00822549|Genetic polymorphism
1286188|NCT00822549|PACU
1286189|NCT00822549|Patients undergoing major scheduled orthopaedic surgery
1286190|NCT00822536|Drug-eluting stent
1286191|NCT00822536|Clopidogrel
1286192|NCT00822536|Stent thrombosis
1286193|NCT00822536|Myocardial infarction
1286194|NCT00822510|Psychosocial Intervention
1286195|NCT00822510|Men with Prostate Cancer & Partners
1286196|NCT00822497|music therapy
1286197|NCT00822497|pain
1286198|NCT00822497|anxiety
1286199|NCT00822497|muscle tension
1286200|NCT00822471|Diabetes
1286201|NCT00822471|Self-Management Education
1286202|NCT00822471|Library
1286203|NCT00822471|Emergency Department Visits
1286204|NCT00822471|African American
1286205|NCT00822471|CVD prevention
1286206|NCT00822471|Prevention
1286207|NCT00822471|Uncontrolled diabetes
1286208|NCT00822445|Biomarker
1286209|NCT00822445|S100 protein
1286210|NCT00822445|Traumatic brain injury
1286211|NCT00822445|Craniocerebral tomodensitometry
1286212|NCT00822445|Neurological sequelae
1286213|NCT00822432|biomarkers
1286214|NCT00822432|ABC transporters
1286215|NCT00822432|MRP2
1286216|NCT00822432|MTX pharmacokinetics
1286217|NCT00822419|sternotomy pain
1286218|NCT00822406|allergy
1286219|NCT00822406|rhinitis
1286220|NCT00822406|homeopathy
1286221|NCT00822406|double-blind
1286222|NCT00822393|Treosulfan
1286223|NCT00822393|Busulfan
1286224|NCT00822393|Conditioning
1286225|NCT00822393|Allogeneic
1286226|NCT00822393|Transplantation
1286227|NCT00822380|Anemia
1286228|NCT00822380|Iron
1286229|NCT00822380|Children
1286230|NCT00822380|Micronutrients
1286231|NCT00822354|Secondary Raynaud's Phenomenon
1286232|NCT00822328|Probiotics
1286233|NCT00822328|Lactobacillus
1286234|NCT00822328|Intestine
1286235|NCT00822328|Flora
1286236|NCT00822315|HIV
1286237|NCT00822315|Tuberculosis
1286238|NCT00822315|Pharmacokinetics
1286239|NCT00822315|Raltegravir
1286240|NCT00822315|France
1286241|NCT00822315|Brazil
1286242|NCT00822315|treatment naive
1286243|NCT00822302|atherosclerosis
1286244|NCT00822302|stroke
1286245|NCT00822302|ischaemia
1286246|NCT00822289|radioactive iodine
1286247|NCT00822289|Helicobacter pylori
1286248|NCT00822289|Thyroid diseases
1286249|NCT00822289|CagA
1286250|NCT00822276|Methicillin-resistant Staphylococcus aureus
1286251|NCT00822276|MRSA
1286252|NCT00822276|Methicillin-sensitive Staphylococcus aureus
1286253|NCT00822276|MSSA
1286254|NCT00822276|Atopic Dermatitis
1286255|NCT00822276|Eczema Herpeticum
1286256|NCT00822263|mild traumatic brain injury
1286257|NCT00822263|anti-oxidant
1286258|NCT00822263|early treatment
1286259|NCT00822224|acute pain
1286260|NCT00822224|MEOPA
1286261|NCT00822224|Dementia
1286262|NCT00822211|Diabetes Mellitus
1286263|NCT00822211|HbA1c reduction
1286264|NCT00822211|vildagliptin
1286265|NCT00822211|add-on to metformin
1286266|NCT00822211|Chinese patients
1286267|NCT00822198|peripheral neuropathy
1286268|NCT00822198|diabetes
1286269|NCT00822198|plantar vibration
1286270|NCT00822172|Peripheral Vascular Disease
1286271|NCT00822172|Peripheral Arterial Disease
1286272|NCT00822172|Intermittent Claudication
1286273|NCT00822172|Peak Walking Time
1286274|NCT00822172|Claudication Onset Time
1286275|NCT00822172|Cilostazol
1286276|NCT00822172|Carnitine
1286277|NCT00822159|Fixation failure
1286278|NCT00822159|Bone strength
1286279|NCT00822159|DensiProbe
1286280|NCT00822146|CRT
1286281|NCT00822133|ketamine
1286282|NCT00822133|preemption
1286283|NCT00822133|postoperative
1286284|NCT00822133|pain
1286285|NCT00822133|safety
1286286|NCT00822120|stage III adult Hodgkin lymphoma
1286287|NCT00822120|stage IV adult Hodgkin lymphoma
1286288|NCT00822120|adult lymphocyte depletion Hodgkin lymphoma
1286289|NCT00822120|adult lymphocyte predominant Hodgkin lymphoma
1286290|NCT00822120|adult mixed cellularity Hodgkin lymphoma
1286291|NCT00822120|adult nodular sclerosis Hodgkin lymphoma
1286292|NCT00822120|HIV infection
1286293|NCT00822107|Hypokalemia
1286294|NCT00822107|Bartter Syndrome
1286295|NCT00822107|Salt Wasting
1286296|NCT00822094|Acute
1286297|NCT00822094|Myeloid
1286298|NCT00822094|Leukemia
1286299|NCT00822094|Adult
1286300|NCT00822094|First
1286301|NCT00822094|Relapse
1286302|NCT00822094|AML
1286303|NCT00822094|Acute Myelogenous leukemia
1286304|NCT00822094|Leukemia, Myeloid
1286305|NCT00822094|Leukemia, Myeloid, Acute
1286306|NCT00822094|Acute myelocytic leukemia
1286307|NCT00822068|stroke
1286308|NCT00822068|aphasia
1286309|NCT00822068|rehabilitation
1286310|NCT00822068|transcranial direct current stimulation
1286311|NCT00822068|intensive training
1286312|NCT00822068|chronic aphasia after stroke
1286313|NCT00822042|Lipodystrophy
1286314|NCT00822042|Adipokines
1286315|NCT00822042|Glucocorticoids
1286316|NCT00822042|Patients with glucocorticoids
1286317|NCT00822016|Best Supportive Care
1286318|NCT00822016|Protocol of Standard Practice
1286319|NCT00822016|Carcinoma of the Lung
1286320|NCT00822003|GLP-1
1286321|NCT00822003|insulin
1286322|NCT00822003|glucose
1286323|NCT00821990|Failed after previous chemotherapy
1286324|NCT00821977|Type 2 Diabetes
1286325|NCT00821977|Vildagliptin
1286326|NCT00821964|Breast Cancer
1286327|NCT00821964|Stage IV
1286328|NCT00821964|cream
1286329|NCT00821964|topical
1286330|NCT00821938|Narrow QRS
1286331|NCT00821938|CRT
1286332|NCT00821197|obesity
1286333|NCT00821197|laparoscopy
1286334|NCT00821197|bariatric
1286335|NCT00821197|super obesity
1286336|NCT00821925|osteoporosis
1286337|NCT00821899|diabetes type 1
1286338|NCT00821899|bone marrow transplantation
1286339|NCT00821886|Breast Cancer
1286340|NCT00821886|Neoadjuvant
1286341|NCT00821886|Ixabepilone
1286342|NCT00821886|Carboplatin
1286343|NCT00821886|Trastuzumab
1286344|NCT00821873|Cartilage injury
1286345|NCT00821873|OATS
1286346|NCT00821873|Knee injury
1286347|NCT00821873|allograft
1286348|NCT00821873|autograft
1286349|NCT00821860|epithelial mesothelioma
1286350|NCT00821860|recurrent malignant mesothelioma
1286351|NCT00821860|sarcomatous mesothelioma
1286352|NCT00821860|malignant pleural effusion
1286353|NCT00821860|stage IA malignant mesothelioma
1286354|NCT00821860|stage IB malignant mesothelioma
1286355|NCT00821860|stage II malignant mesothelioma
1286356|NCT00821860|stage III malignant mesothelioma
1286357|NCT00821860|stage IV malignant mesothelioma
1286358|NCT00821847|HIV
1286359|NCT00821847|glomerular filtration rate
1286360|NCT00821847|cockcroft
1286361|NCT00821847|MDRD formula
1286362|NCT00821847|creatinine
1286363|NCT00821847|cystatin C
1286364|NCT00821847|isotopic clearance
1286365|NCT00821847|EDTA-51Cr
1286366|NCT00821847|DEXA scan
1286367|NCT00821834|Old Myocardial infarction
1286368|NCT00821834|Platelet Aggregation Inhibitors
1286369|NCT00821834|Angioplasty
1286370|NCT00821834|Transluminal
1286371|NCT00821834|Percutaneous Coronary
1286372|NCT00821834|Stents
1286373|NCT00821795|Diabetes Mellitus, Type 2
1286374|NCT00821795|insulin
1286375|NCT00821795|therapy
1286376|NCT00821782|Bacteria
1286377|NCT00821782|Oral flora bacteria
1286378|NCT00821782|Resistance
1286379|NCT00821756|Suicidal behaviour
1286380|NCT00821756|Attempted suicide
1286381|NCT00821756|Self harm
1286382|NCT00821756|Suicide
1286383|NCT00821756|Health system contacts
1286384|NCT00821756|Contacts with health system
1286385|NCT00821730|Mixed methods research (qualitative and quantitative)
1286386|NCT00821730|Peer support
1286387|NCT00821730|Early inflammatory arthritis
1286388|NCT00821730|Self-management
1286389|NCT00821730|Patient education
1286390|NCT00821717|Chronic Heart Failure
1286391|NCT00821717|Iron deficiency
1286392|NCT00821717|Iron deficiency anaemia
1286393|NCT00821717|Anaemia
1286394|NCT00821717|Heart disease
1286395|NCT00821691|cerebral infarction
1286396|NCT00821678|telemedicine
1286397|NCT00821678|rural
1286398|NCT00821678|veterans
1286399|NCT00821678|care management
1286400|NCT00821678|psychotherapy
1286401|NCT00821665|Type 2 diabetes
1286402|NCT00821665|Glycemic control
1286403|NCT00821665|(postprandial) Hyperglycemia
1286404|NCT00821665|Sucrose
1286405|NCT00821652|Tumor
1286406|NCT00821652|NY-ESO-1 expression
1286407|NCT00821652|Tumors that often express NY-ESO-1.
1286408|NCT00821626|Influenza
1286409|NCT00821626|Rapid flu test
1286410|NCT00821626|Returning travelers with fever
1286411|NCT00821600|Risperidone
1286412|NCT00821600|Antipsychotic
1286413|NCT00821600|Pharmacokinetic
1286414|NCT00821600|Long-acting Injectable
1286415|NCT00821587|Hepatitis C Post Liver Transplant
1286416|NCT00821574|Hypertension, dyslipidemia
1286417|NCT00821561|Persistent
1286418|NCT00821561|cornea
1286419|NCT00821561|defect
1286420|NCT00821561|Nexagon
1286421|NCT00821561|Coda
1286422|NCT00821548|facioscapulohumeral muscular dystrophy
1286423|NCT00821548|electrostimulation
1286424|NCT00821548|training
1286425|NCT00821535|pharmacokinetics, Japanese, healthy volunteer, maraviroc
1286426|NCT00821522|Acute Kidney Insufficiency
1286427|NCT00821522|Acute Renal Insufficiency
1286428|NCT00821522|Acute Kidney Injury
1286429|NCT00821522|Cardiac Surgical Procedures
1286430|NCT00821522|Ischemic Preconditioning
1286431|NCT00821509|virus infection
1286432|NCT00821509|hygiene
1286433|NCT00821509|transmission
1286434|NCT00821509|intervention
1286435|NCT00821496|Multiple dose administration
1286436|NCT00821496|Oral Contraceptives
1286437|NCT00821470|osteonecrosis
1286438|NCT00821470|bone marrow
1286439|NCT00821470|core decompression
1286440|NCT00821470|femoral head
1286565|NCT00820859|agitation
1286441|NCT00821457|existing scars the are two to six months old
1286442|NCT00821444|schizophrenia, pharmacokinetics, bioavailability, food effect
1286443|NCT00821405|Number : 250~300 patients
1286444|NCT00821405|Correlation between PET, glucose loading and peritoneal thickness/calcification
1286445|NCT00821379|PCOS
1286446|NCT00821379|Polycystic Ovary Syndrome
1286447|NCT00821379|Pregnancy Complications
1286448|NCT00821379|Gestational Diabetes
1286449|NCT00821379|Pre eclampsia
1286450|NCT00821379|Prediction Model
1286451|NCT00821379|Pre conceptional
1286452|NCT00821366|HIV/AIDS
1286453|NCT00821366|Food security
1286454|NCT00821366|treatment experienced
1286455|NCT00821353|Atrial fibrillation
1286456|NCT00821353|Hypertrophic cardiomyopathy
1286457|NCT00821353|RF ablation
1286458|NCT00821353|Antiarrhythmic drugs
1286459|NCT00821340|Leber congenital amaurosis
1286460|NCT00821340|LCA
1286461|NCT00821340|RPE65
1286462|NCT00821340|RPE65-associated Leber congenital amaurosis
1286463|NCT00821340|Retinal disease due to RPE65 mutations
1286464|NCT00821301|Multiple myeloma
1286465|NCT00821288|cancer survivorship
1286466|NCT00821288|survivorship prescription
1286467|NCT00821288|cancer related anxiety
1286468|NCT00821275|Uterine Artery Embolization
1286469|NCT00821275|Leiomyoma
1286470|NCT00821275|myomectomy
1286471|NCT00821275|hysterectomy
1286472|NCT00821275|pregnancy
1286473|NCT00821275|complication
1286474|NCT00821275|ovarian function
1286475|NCT00821275|quality of life
1286476|NCT00821262|Sevoflurane
1286477|NCT00821262|Anesthesia
1286478|NCT00821262|Troponin
1286479|NCT00821262|Myocardial Preconditioning
1286480|NCT00821262|Surgery, Cardiac
1286481|NCT00821262|Stents
1286482|NCT00821262|Non-cardiac Surgery
1286483|NCT00821262|Surgery
1286484|NCT00821249|plasma cell dyscrasia
1286485|NCT00821249|plasmacytoma
1286486|NCT00821249|kinesin spindle protein
1286487|NCT00821249|anti-mitotic
1286488|NCT00821236|Myopia
1286489|NCT00821236|LASIK
1286490|NCT00821236|Astigmatism
1286491|NCT00821236|Laser Vision Correction
1286492|NCT00821236|Excimer Laser
1286493|NCT00821223|phacoemulsification
1286494|NCT00821223|manual small incision cataract surgery
1286495|NCT00821223|visual acuity
1286496|NCT00821223|contrast sensitivity
1286497|NCT00821223|quality of vision
1286498|NCT00821210|Obstructive sleep apnea
1286499|NCT00821210|myocardial infarction
1286500|NCT00821184|urinary incontinence
1286501|NCT00821184|overactive bladder
1286502|NCT00821184|urinary frequency
1286503|NCT00821145|abdominal aortic aneurysms
1286504|NCT00821132|FALS
1286505|NCT00821132|ALS
1286506|NCT00821132|ALS/FTD
1286507|NCT00821132|SALS
1286508|NCT00821132|MND
1286509|NCT00821132|PLS
1286510|NCT00821119|non invasive ventilation
1286511|NCT00821119|mechanical ventilation
1286512|NCT00821119|pulmonary morbidity
1286513|NCT00821119|preterm infant
1286514|NCT00821119|Respiratory distress syndrome
1286515|NCT00821119|nasal intermittent positive pressure
1286516|NCT00821119|nasal continuous positive pressure
1286517|NCT00821119|bronchopulmonary dysplasia
1286518|NCT00821106|Coronary angiography
1286519|NCT00821106|percutaneous coronary intervention
1286520|NCT00821106|Transradial approach
1286521|NCT00821093|respiratory
1286522|NCT00821093|dyspnea
1286523|NCT00821093|breathlessness
1286524|NCT00821093|COPD
1286525|NCT00821093|indacaterol
1286526|NCT00821093|long-acting β2-agonist
1286527|NCT00821080|vandetanib
1286528|NCT00821080|sirolimus
1286529|NCT00821080|recurrent glioblastoma
1286530|NCT00821054|Phase I Food Effect
1286531|NCT00821041|insomnia
1286532|NCT00821041|online systems
1286533|NCT00821028|atherosclerosis
1286534|NCT00821028|angioplasty
1286535|NCT00821028|peripheral arterial disease
1286536|NCT00821015|cryoablation
1286537|NCT00821015|recurring arrhythmia
1286538|NCT00821015|stroke
1286539|NCT00821015|RF ablation
1286540|NCT00821015|LA ablation
1286541|NCT00821015|nodal ablation
1286542|NCT00821015|catheter ablation
1286543|NCT00821002|Glaucoma
1286544|NCT00820989|Healthy Immune System
1286545|NCT00820976|G-CSF
1286546|NCT00820976|AML
1286547|NCT00820976|survival
1286548|NCT00820963|adult giant cell glioblastoma
1286549|NCT00820963|adult glioblastoma
1286550|NCT00820963|adult gliosarcoma
1286551|NCT00820924|HER-2
1286552|NCT00820924|Circulating Tumour Cell (CTC)
1286553|NCT00820924|EGFR
1286554|NCT00820924|Lapatinib (GW572016)
1286555|NCT00820924|Breast Cancer
1286556|NCT00820911|Kidney transplant
1286557|NCT00820911|AEB071
1286558|NCT00820872|male breast cancer
1286559|NCT00820872|stage I breast cancer
1286560|NCT00820872|stage II breast cancer
1286561|NCT00820872|stage IIIA breast cancer
1286562|NCT00820872|stage IIIB breast cancer
1286563|NCT00820859|Cognition disorder
1286564|NCT00820859|nursing home residents
1286566|NCT00820859|behavior disorder
1286567|NCT00820846|HIV Seronegativity
1286568|NCT00820846|HIV Preventive Vaccine
1286569|NCT00820833|infant formula
1286570|NCT00820833|obesity
1286571|NCT00820833|growth
1286572|NCT00820820|Atopic Dermatitis
1286573|NCT00820820|immunosuppression
1286574|NCT00820820|Measles vaccine
1286575|NCT00820820|T lymphocytes
1286576|NCT00820820|Atopic Dermatitis in adults
1286577|NCT00820807|dietary fiber
1286578|NCT00820807|fiber
1286579|NCT00820807|insulin sensitivity
1286580|NCT00820807|insulin resistance
1286581|NCT00820807|glucose metabolism
1286582|NCT00820794|Drug-drug interaction, lithium, PD 0332334, pharmacokinetics
1286583|NCT00820781|bleeding gastric varices
1286584|NCT00820781|cirrhosis of the liver
1286585|NCT00820781|portacaval shunt
1286586|NCT00820781|endoscopic variceal sclerotherapy
1286587|NCT00820781|endoscopic variceal ligation
1286588|NCT00820781|Bleeding gastric varices due to cirrhosis of the liver
1286589|NCT00820742|A5751025
1286590|NCT00820729|interstitial lung disease
1286591|NCT00820729|pulmonary hypertension
1286592|NCT00820729|biomarkers
1286593|NCT00820729|NT-pro-BNP
1286594|NCT00820729|von Willebrand factor
1286595|NCT00820729|D-dimer
1286596|NCT00820729|Exhaled NO
1286597|NCT00820729|Troponin-t
1286598|NCT00820716|Asthma
1286599|NCT00820716|Asthmatic subjects
1286600|NCT00820716|Exercise training
1286601|NCT00820716|Constant load
1286602|NCT00820716|Alternate load
1286603|NCT00820703|Nexagon
1286604|NCT00820703|CoDa
1286605|NCT00820703|ulcer
1286606|NCT00820703|diabetic
1286607|NCT00820703|foot
1286608|NCT00820690|neoadjuvant chemotherapy
1286609|NCT00820690|advanced breast cancer
1286610|NCT00820690|microarray
1286611|NCT00820690|correlation analysis
1286612|NCT00820690|oncoplastic surgery
1286613|NCT00820651|Nonalcoholic steatohepatitis
1286614|NCT00820651|Insulinresistance
1286615|NCT00820651|Diet and exercise
1286616|NCT00820651|Nutritional supplement
1286617|NCT00820651|Nonalcoholic fatty liver disease
1286618|NCT00820651|Lifestyle modifications
1286619|NCT00820638|neurorobotics
1286620|NCT00820638|occupational therapy
1286621|NCT00820599|Sapien Valve
1286622|NCT00820599|Cardiovascular Diseases
1286623|NCT00820599|Valvular Heart Disease
1286624|NCT00820599|Aortic Stenosis
1286625|NCT00820599|Heart Valve Therapy
1286626|NCT00820599|Transfemoral
1286627|NCT00820599|Transcatheter
1286628|NCT00820586|Intramyocardial
1286629|NCT00820586|Autologous
1286630|NCT00820586|Bone
1286631|NCT00820586|Marrow
1286632|NCT00820586|Randomized
1286633|NCT00820586|Percutaneous
1286634|NCT00820586|CD34+
1286635|NCT00820586|Refractory
1286636|NCT00820586|Angina
1286637|NCT00820586|Pectoris.
1286638|NCT00820573|Diabetes
1286639|NCT00820547|inflammatory breast cancer
1286640|NCT00820547|stage IIIA breast cancer
1286641|NCT00820547|stage IIIB breast cancer
1286642|NCT00820547|stage IIIC breast cancer
1286643|NCT00820547|male breast cancer
1286644|NCT00820547|HER2-negative breast cancer
1286645|NCT00820534|cold sore
1286646|NCT00820508|Haematological disease
1286647|NCT00820508|Lymphoid malignancy
1286648|NCT00820508|Histone deacetylase inhibitor
1286649|NCT00820508|dose escalation
1286650|NCT00820495|Smokeless tobacco
1286651|NCT00820495|Chewing Tobacco
1286652|NCT00820495|Internet
1286653|NCT00820495|Adolescent
1286654|NCT00820469|Rituximab
1286655|NCT00820469|Plasma exchange
1286656|NCT00820469|Autoimmune diseases
1286657|NCT00820456|colorectal cancer
1286658|NCT00820456|colorectal neoplasm
1286659|NCT00820456|colorectal neoplasms
1286660|NCT00820456|metastasis
1286661|NCT00820456|metastases
1286662|NCT00820456|liver
1286663|NCT00820456|hepatic metastasis
1286664|NCT00820456|liver metastasis
1286665|NCT00820456|perfusion imaging
1286666|NCT00820456|MRI
1286667|NCT00820456|magnetic resonance imaging
1286668|NCT00820456|dynamic contrast enhanced MRI
1286669|NCT00820456|dynamic contrast enhanced magnetic resonance imaging
1286670|NCT00820430|osteoarthritis
1286671|NCT00820430|knee
1286672|NCT00820430|magnetic resonance imaging
1286673|NCT00820430|knee cartilage
1286674|NCT00820430|reproducibility
1286675|NCT00820417|cetuximab
1286676|NCT00820417|monoclonal
1286677|NCT00820417|antibody
1286678|NCT00820417|epidermal
1286679|NCT00820417|growth
1286680|NCT00820417|factor
1286681|NCT00820417|receptor
1286682|NCT00820417|EGFR
1286683|NCT00820417|Gefitinib
1286684|NCT00820417|tyrosine
1286685|NCT00820417|kinase
1286686|NCT00820417|inhibitor
1286687|NCT00820417|advanced
1286688|NCT00820417|cancer
1286689|NCT00820391|Post-traumatic Stress disorder (PTSD)
1286690|NCT00820378|Aortic dimension
1286691|NCT00820378|Atherosclerosis
1286692|NCT00820378|Vascular disease
1286693|NCT00820378|Risk factors
1286694|NCT00820365|Inflammatory Bowel Disease (IBD)
1286695|NCT00820365|Crohn's Disease
1286696|NCT00820365|Ulcerative Colitis
1286697|NCT00820365|SC12267
1286698|NCT00820365|4SC-101
1286699|NCT00820365|Phase II
1286700|NCT00820352|HFNEF
1286701|NCT00820352|HFPEF
1286702|NCT00820352|Secondary Pulmonary Hypertension
1286703|NCT00820352|Endothelin Receptor Blockade
1286704|NCT00820339|hepatocellular carcinoma
1286705|NCT00820339|hepatic vein
1286706|NCT00820339|Surgical resection
1286707|NCT00820339|occlusion
1286708|NCT00820339|time to recurrence
1286709|NCT00820339|overall survival
1286710|NCT00820313|Coronary Heart Disease
1286711|NCT00820313|Biomarkers of Cardiovascular Disease
1286712|NCT00820313|Health Related Quality of Life
1286713|NCT00820313|Diabetes
1286714|NCT00820313|Diet
1286715|NCT00820287|Testicular cancer
1286716|NCT00820287|incidence
1286717|NCT00820287|young men
1286718|NCT00820261|Genotypes
1286719|NCT00820261|Epidemiology
1286720|NCT00820261|Diarrhea
1286721|NCT00820248|stage III squamous cell carcinoma of the hypopharynx
1286722|NCT00820248|stage III squamous cell carcinoma of the larynx
1286723|NCT00820248|stage III verrucous carcinoma of the larynx
1286724|NCT00820248|stage III squamous cell carcinoma of the oropharynx
1286725|NCT00820248|stage IV squamous cell carcinoma of the hypopharynx
1286726|NCT00820248|stage IV squamous cell carcinoma of the larynx
1286727|NCT00820248|stage IV verrucous carcinoma of the larynx
1286728|NCT00820248|stage IV squamous cell carcinoma of the oropharynx
1286729|NCT00820248|stage III verrucous carcinoma of the oral cavity
1286730|NCT00820248|stage III squamous cell carcinoma of the lip and oral cavity
1286731|NCT00820248|stage IV verrucous carcinoma of the oral cavity
1286732|NCT00820248|stage IV squamous cell carcinoma of the lip and oral cavity
1286733|NCT00820222|ErbB2
1286734|NCT00820222|HERCEPTIN
1286735|NCT00820222|XELODA
1286736|NCT00820222|ErbB1
1286737|NCT00820222|TYKERB
1286738|NCT00820222|metastatic breast cancer
1286739|NCT00820222|trastuzumab
1286740|NCT00820222|breast cancer
1286741|NCT00820222|capecitabine
1286742|NCT00820222|lapatinib
1286743|NCT00820222|brain metastases
1286744|NCT00820222|HER2 positive
1286745|NCT00820222|TYVERB
1286746|NCT00820196|Venous ulcer
1286747|NCT00820196|Nexagon
1286748|NCT00820196|CoDa
1286749|NCT00820183|Hypertension
1286750|NCT00820183|Intervention
1286751|NCT00820183|Primary Care
1286752|NCT00820183|Quality improvement
1286753|NCT00820170|Breast
1286754|NCT00820170|Cancer
1286755|NCT00820170|DASATINIB
1286756|NCT00820170|TAXOL (PACLITAXEL)
1286757|NCT00820170|08-122
1286758|NCT00820157|Carcinoma, Hepatocellular
1286759|NCT00820157|Chemoembolization, Therapeutic
1286760|NCT00820157|Cytoreductive
1286761|NCT00820144|immune response
1286762|NCT00820144|b-subunit of cholera toxin
1286763|NCT00820144|mucosal way
1286764|NCT00820144|healthy volonteers
1286765|NCT00820144|vaccine
1286766|NCT00820118|ANTIRETROVIRAL THERAPY
1286767|NCT00820118|STRUCTURED TREATMENT INTERRUPTIONS
1286768|NCT00820118|treatment naive
1286769|NCT00820105|Migraine
1286770|NCT00820105|Aura
1286771|NCT00820105|Migraine headache
1286772|NCT00820092|Xerecept
1286773|NCT00820092|Pharmacokinetics
1286774|NCT00820092|Japanese versus Caucasians
1286775|NCT00820079|Gastroesophageal reflux
1286776|NCT00820079|Heartburn
1286777|NCT00820079|Regurgitation
1286778|NCT00820053|hepatocellular carcinoma
1286779|NCT00820053|adjuvant therapy
1286780|NCT00820053|TACE
1286781|NCT00820053|time to recurrence
1286782|NCT00820053|overall survival
1286783|NCT00819208|fatigue
1286784|NCT00819208|sleep disorders
1286785|NCT00819208|depression
1286786|NCT00819208|anxiety disorder
1286787|NCT00819208|psychosocial effects of cancer and its treatment
1286788|NCT00819208|cognitive/functional effects
1286789|NCT00819208|stage II colon cancer
1286790|NCT00819208|stage III colon cancer
1286791|NCT00819208|adenocarcinoma of the colon
1286792|NCT00819195|relapsing-remitting
1286793|NCT00819195|multiple sclerosis
1286794|NCT00819195|Copaxone
1286795|NCT00819195|glatiramer acetate
1286796|NCT00819195|MS
1286797|NCT00819182|Menopause
1286798|NCT00819182|Breast Cancer
1286799|NCT00819182|Hot Flash
1286800|NCT00819182|Night Sweats
1286801|NCT00819169|AMG 655
1286802|NCT00819169|AMG 479
1286803|NCT00819169|Apoptosis
1286804|NCT00819169|Monoclonal Antibody
1286805|NCT00819169|Tumor Necrosis Factor
1286806|NCT00819169|Insulin-like Growth Factor
1286807|NCT00819143|Tissue Procurement
1286808|NCT00819143|Sample Collection
1286809|NCT00819143|Chronic Myelogenous Leukemia
1286810|NCT00819143|Laboratory Research
1286811|NCT00817622|diabetes mellitus type 2
1286812|NCT00817622|EPA
1286813|NCT00817622|leptin
1286814|NCT00817622|adiponectin
1286815|NCT00817609|Angongniuhuang Pill
1286816|NCT00817609|consciousness level of patients who suffered from a stroke
1286817|NCT00817583|Phase 2 Clinical Trial
1286818|NCT00817583|NPC
1286819|NCT00817583|neoadjuvant chemotherapy
1286820|NCT00817583|concurrent chemoradiation
1286821|NCT00817570|Trans Femoral Amputees Balance Reactions
1286822|NCT00817557|Contact lenses
1286823|NCT00817557|Loteprednol
1286824|NCT00817557|Effect on CL dryness
1286825|NCT00820014|ESBA105
1286826|NCT00820014|scFv antibody fragment
1286827|NCT00820014|cataract surgery
1286828|NCT00820014|pharmacokinetics
1286829|NCT00820014|biodistribution
1286830|NCT00820014|Irvine-Gass syndrome
1286831|NCT00820001|Cognitive Behavioral Therapy
1286832|NCT00820001|Multimodal Treatment
1286833|NCT00820001|Physiological Parameters
1286834|NCT00820001|Hormone Concentration in pubertal development
1286835|NCT00820001|Treatment as usual comparison
1286836|NCT00819988|Postoperative
1286837|NCT00819988|Perioperative
1286838|NCT00819988|Orthopedic surgery
1286839|NCT00819988|Vascular surgery
1286840|NCT00819988|Gabapentinoid
1286841|NCT00819975|Casein
1286842|NCT00819975|Whey
1286843|NCT00819975|postprandial
1286844|NCT00819975|Triglyceride
1286845|NCT00819975|Free fatty acids
1286846|NCT00819975|Retinyl palmitate
1286847|NCT00819975|Incretins
1286848|NCT00819975|Type 2 Diabetes
1286849|NCT00819949|Robot
1286850|NCT00819949|Treadmill
1286851|NCT00819949|Rehabilitation
1286852|NCT00819949|Freezing of gait
1286853|NCT00819936|abdominal aorta surgery
1286854|NCT00819936|Physical Training
1286855|NCT00819936|backward walking
1286856|NCT00819936|physiotherapy
1286857|NCT00819923|Titanium
1286858|NCT00819923|everolimus
1286859|NCT00819923|drug eluting stent
1286860|NCT00819923|stent thrombosis
1286861|NCT00819923|restenosis
1286862|NCT00819923|percutaneous coronary intervention
1286863|NCT00819923|acute coronary syndrome
1286864|NCT00819910|Type 4 hyperlipidemia
1286865|NCT00819910|Rosiglitazone
1286866|NCT00819910|Fenofibrate
1286867|NCT00819897|MS
1286868|NCT00819897|CIS
1286869|NCT00819897|IFN
1286870|NCT00819897|MRI
1286871|NCT00819897|OCT
1286872|NCT00819897|QOL
1286873|NCT00819884|Type II Diabetes
1286874|NCT00819884|24 hour glucose profile
1286875|NCT00819858|weight loss
1286876|NCT00819858|weight gain
1286877|NCT00819858|malnutrition
1286878|NCT00819858|convalescence
1286879|NCT00819858|malaria
1286880|NCT00819858|RUTF
1286881|NCT00819858|RUF
1286882|NCT00819858|supplementation
1286883|NCT00819858|nutrition
1286884|NCT00819845|Duchenne
1286885|NCT00819845|Becker muscular dystrophy
1286886|NCT00819845|cardioprotective therapy
1286887|NCT00819845|cardiac magnetic resonance
1286888|NCT00819845|ultrasound tissue characterization
1286889|NCT00819832|vertebral compression fractures
1286890|NCT00819832|VCF
1286891|NCT00819832|Spinal
1286892|NCT00819832|Broken spinal bones
1286893|NCT00819832|Kyphoplasty
1286894|NCT00819832|vertebroplasty
1286895|NCT00819832|Cavity SpineWand
1286896|NCT00819832|Circulating Tumor Cell Burden
1286897|NCT00819832|CTCB
1286898|NCT00819832|Spine pain
1286899|NCT00819832|Coblation
1286900|NCT00819832|plasma radiofrequency ablation
1286901|NCT00819832|Plasma-mediated ablation technology
1286902|NCT00819832|precise molecular dissociation (ablation) process
1286903|NCT00819832|medical cement
1286904|NCT00819793|Cardiac Dysfunction
1286905|NCT00819793|Failure-to-wean from CPB
1286906|NCT00819793|CentriMag
1286907|NCT00819793|Levitronix
1286908|NCT00819793|Thoratec Corporation
1286909|NCT00819780|Colon Cancer
1286910|NCT00819780|Colorectal Cancer
1286911|NCT00819780|Rectal Cancer
1286912|NCT00819780|Panitumumab
1286913|NCT00819780|Vectibix
1286914|NCT00819780|modified FOLFOX 6
1286915|NCT00819780|mFOLFOX 6
1286916|NCT00819780|FOLFOX
1286917|NCT00819780|Bevacizumab
1286918|NCT00819780|Avastin
1286919|NCT00819780|First-Line
1286920|NCT00819780|metastatic
1286921|NCT00819767|hypertension
1286922|NCT00819767|systolic blood pressure
1286923|NCT00819767|exercise test
1286924|NCT00819767|cardiovascular disease
1286925|NCT00819767|aliskiren
1286926|NCT00819767|valsartan
1286927|NCT00819715|Preterm infants
1286928|NCT00819715|small for gestational age
1286929|NCT00819715|electrogastrography
1286930|NCT00819702|child abuse prevention
1286931|NCT00819702|primary care
1286932|NCT00819702|professional education in primary care
1286933|NCT00819650|hepatocellular carcinoma
1286934|NCT00819650|adjuvant therapy
1286935|NCT00819650|Licartin
1286936|NCT00819650|time to recurrence
1286937|NCT00819650|overall survival
1286938|NCT00819637|Acute asthma
1286939|NCT00819637|Arformoterol
1286940|NCT00819637|Long acting beta agonists
1286941|NCT00819624|fibromyalgia methodology pain sleep fatigue
1286942|NCT00819611|Attention deficit disorder with hyperactivity
1286943|NCT00819611|Working memory training
1286944|NCT00819611|Placebo
1286945|NCT00819611|Behavioral symptoms
1286946|NCT00819611|Neuropsychology
1286947|NCT00819611|Electropsychophysiology
1286948|NCT00819585|Gout
1286949|NCT00819585|Chronic Gout
1286950|NCT00819585|Gouty arthritis
1286951|NCT00819585|Gout flares
1286952|NCT00819572|Osteoarthritis
1286953|NCT00819572|TNF-alpha
1286954|NCT00819572|DLX105
1286955|NCT00819572|scFv antibody fragment
1286956|NCT00819572|pain
1286957|NCT00819572|fragment
1286958|NCT00819572|antibody fragment
1286959|NCT00819559|Rectal neoplasm
1286960|NCT00819559|Clinical stage
1286961|NCT00819559|T3N0
1286962|NCT00819559|Preoperative chemoradiotherapy
1286963|NCT00819559|Laparoscopic
1286964|NCT00819559|Open resection
1286965|NCT00819546|AML
1286966|NCT00819546|MDS
1286967|NCT00819520|pediculosis capitis
1286968|NCT00819520|pediculus
1286969|NCT00819507|Skin barrier
1286970|NCT00819507|Atopic Dermatitis
1286971|NCT00819507|Corticosteroid
1286972|NCT00819507|Effects on skin severity and barrier function
1286973|NCT00819494|Contrast media skin test
1286974|NCT00819494|Skin test
1286975|NCT00819494|hypersensitivity
1286976|NCT00819494|contrast media
1286977|NCT00819481|Total knee replacement
1286978|NCT00819455|Diabetes
1286979|NCT00819455|Prevention of Diabetes
1286980|NCT00819455|Lifestyle Modification
1286981|NCT00819455|Text messages
1286982|NCT00819442|heart failure
1286983|NCT00819442|desmin
1286984|NCT00819442|ubiquitin
1286985|NCT00819429|Attention Deficit Hyperactivity Disorder
1286986|NCT00819429|Conduct Disorder
1286987|NCT00819429|Oppositional Defiant Disorder
1286988|NCT00819429|Omega 3 Supplements
1286989|NCT00819429|Social Skills Training
1286990|NCT00819429|Dietary Intake
1286991|NCT00819429|Aggression
1286992|NCT00819429|Nutrition
1286993|NCT00819429|Disruptive Behaviors Disorder
1286994|NCT00819416|randomized controlled trial
1286995|NCT00819416|clinical trial
1286996|NCT00819403|triglycerides
1286997|NCT00819403|hypertension
1286998|NCT00819403|low hdl
1286999|NCT00819403|obesity
1287000|NCT00819377|Valvular surgery
1287001|NCT00819377|pulmonary artery pressure
1287002|NCT00819364|Autism
1287003|NCT00819364|early intervention
1287004|NCT00819364|BCRI model
1287005|NCT00819351|acute lymphoblastic leukemia
1287006|NCT00819351|child
1287007|NCT00819351|PEG-Asparaginase
1287008|NCT00819351|EFS
1287009|NCT00819351|efficacy
1287010|NCT00819351|childhood acute lymphoblastic leukemia
1287011|NCT00819338|Non-alcoholic fatty liver disease
1287012|NCT00819338|Polyunsaturated fatty acids
1287013|NCT00819338|Omega-3
1287014|NCT00819325|diabetes
1287015|NCT00819325|stents
1287016|NCT00819325|restenosis
1287017|NCT00819325|thiazolidinediones
1287018|NCT00819325|coronary atherosclerosis
1287019|NCT00819312|Contraceptives,
1287020|NCT00819312|Oral Hormonal;
1287021|NCT00819312|Contraceptive Methods;
1287022|NCT00819312|Female
1287023|NCT00819286|open heart surgery
1287024|NCT00819273|hsCRP
1287025|NCT00819260|Mammaplasty
1287026|NCT00819260|Electrocoagulation
1287027|NCT00819260|Breast
1287028|NCT00819234|Leptin
1287029|NCT00819234|Pramlintide
1287030|NCT00819234|Obese
1287031|NCT00819234|Symlin
1287032|NCT00819234|Amylin
1287033|NCT00819221|advanced tumors
1287034|NCT00819221|solid tumors
1287035|NCT00819221|dose escalation
1287036|NCT00819221|combination
1287037|NCT00819221|AZD2281
1287038|NCT00819221|liposomal doxorubicin
1287039|NCT00819221|pharmacology
1287040|NCT00819221|phase I
1287041|NCT00819221|multicenter
1287042|NCT00819117|Epicardial leads
1287043|NCT00819117|Cardiac Resynchronization Therapy
1287044|NCT00819104|Primary hypertension
1287045|NCT00819104|Metoprolol XL
1287046|NCT00819104|Amlodipine
1287047|NCT00819078|adolescent
1287048|NCT00819078|bupropion
1287049|NCT00819078|smoking
1287050|NCT00819078|cessation
1287051|NCT00819078|depression
1287052|NCT00819065|Botulinum toxin A
1287053|NCT00819065|Spasticity
1287054|NCT00819065|Randomized Clinical Trial
1287055|NCT00819000|Specialty Pharmacy
1287056|NCT00819000|Therapy Management
1287057|NCT00819000|Medication Compliance
1287058|NCT00819000|Medication Adherence
1287059|NCT00819000|Medication Persistence
1287060|NCT00819000|Health Outcomes
1287061|NCT00818987|Operative
1287062|NCT00818987|Non operative
1287063|NCT00818961|accelerated phase chronic myelogenous leukemia
1287064|NCT00818961|adult acute lymphoblastic leukemia in remission
1287065|NCT00818961|adult acute myeloid leukemia in remission
1287066|NCT00818961|adult AML with 11q23 (MLL) abnormalities
1287067|NCT00818961|blastic phase chronic myelogenous leukemia
1287068|NCT00818961|chronic myelomonocytic leukemia
1287069|NCT00818961|chronic phase chronic myelogenous leukemia
1287070|NCT00818961|prolymphocytic leukemia
1287071|NCT00818961|recurrent adult T-cell leukemia/lymphoma
1287072|NCT00818961|refractory chronic lymphocytic leukemia
1287073|NCT00818961|relapsing chronic myelogenous leukemia
1287074|NCT00818961|secondary acute myeloid leukemia
1287075|NCT00818961|stage I adult T-cell leukemia/lymphoma
1287076|NCT00818961|stage I chronic lymphocytic leukemia
1287077|NCT00818961|stage II adult T-cell leukemia/lymphoma
1287078|NCT00818961|stage II chronic lymphocytic leukemia
1287079|NCT00818961|stage III adult T-cell leukemia/lymphoma
1287080|NCT00818961|stage III chronic lymphocytic leukemia
1287081|NCT00818961|stage IV adult T-cell leukemia/lymphoma
1287082|NCT00818961|stage IV chronic lymphocytic leukemia
1287083|NCT00818961|recurrent adult Hodgkin lymphoma
1287084|NCT00818961|anaplastic large cell lymphoma
1287085|NCT00818961|angioimmunoblastic T-cell lymphoma
1287086|NCT00818961|cutaneous B-cell non-Hodgkin lymphoma
1287087|NCT00818961|recurrent cutaneous T-cell NHL
1287088|NCT00818961|stage I cutaneous T-cell NHL
1287089|NCT00818961|stage II cutaneous T-cell NHL
1287090|NCT00818961|stage III cutaneous T-cell NHL
1287091|NCT00818961|stage IV cutaneous T-cell NHL
1287092|NCT00818961|extranodal marginal zone B-cell lymphoma of mucosal tissue
1287196|NCT00818766|Thoracic Surgery
1287093|NCT00818961|nodal marginal zone B-cell lymphoma
1287094|NCT00818961|splenic marginal zone lymphoma
1287095|NCT00818961|contiguous st II adult diffuse large cell lymphoma
1287096|NCT00818961|contiguous st II adult diffuse mixed cell lymphoma
1287097|NCT00818961|contiguous st II adult diffuse sm cleaved cell lymphoma
1287098|NCT00818961|contiguous st II grade 1 follicular lymphoma
1287099|NCT00818961|contiguous st II grade 2 follicular lymphoma
1287100|NCT00818961|contiguous st II grade 3 follicular lymphoma
1287101|NCT00818961|contiguous st II mantle cell lymphoma
1287102|NCT00818961|contiguous st II marginal zone lymphoma
1287103|NCT00818961|contiguous st II small lymphocytic lymphoma
1287104|NCT00818961|stage I adult diffuse large cell lymphoma
1287105|NCT00818961|stage I adult diffuse mixed cell lymphoma
1287106|NCT00818961|stage I adult diffuse small cleaved cell lymphoma
1287107|NCT00818961|stage I grade 1 follicular lymphoma
1287108|NCT00818961|stage I grade 2 follicular lymphoma
1287109|NCT00818961|stage I grade 3 follicular lymphoma
1287110|NCT00818961|stage I mantle cell lymphoma
1287111|NCT00818961|stage I marginal zone lymphoma
1287112|NCT00818961|stage I small lymphocytic lymphoma
1287113|NCT00818961|noncontiguous st II adult diffuse large cell lymphoma
1287114|NCT00818961|noncontiguous st II adult diffuse mixed cell lymphoma
1287115|NCT00818961|noncontiguous st II adult diffuse sm cleaved cell lymphoma
1287116|NCT00818961|noncontiguous st II grade 1 follicular lymphoma
1287117|NCT00818961|noncontiguous st II grade 2 follicular lymphoma
1287118|NCT00818961|noncontiguous st II grade 3 follicular lymphoma
1287119|NCT00818961|noncontiguous st II mantle cell lymphoma
1287120|NCT00818961|noncontiguous st II marginal zone lymphoma
1287121|NCT00818961|noncontiguous st II small lymphocytic lymphoma
1287122|NCT00818961|stage III adult diffuse large cell lymphoma
1287123|NCT00818961|stage III adult diffuse mixed cell lymphoma
1287124|NCT00818961|stage III adult diffuse small cleaved cell lymphoma
1287125|NCT00818961|stage III grade 1 follicular lymphoma
1287126|NCT00818961|stage III grade 2 follicular lymphoma
1287127|NCT00818961|stage III grade 3 follicular lymphoma
1287128|NCT00818961|stage III mantle cell lymphoma
1287129|NCT00818961|stage III marginal zone lymphoma
1287130|NCT00818961|stage III small lymphocytic lymphoma
1287131|NCT00818961|stage IV adult diffuse large cell lymphoma
1287132|NCT00818961|stage IV adult diffuse mixed cell lymphoma
1287133|NCT00818961|stage IV adult diffuse small cleaved cell lymphoma
1287134|NCT00818961|stage IV grade 1 follicular lymphoma
1287135|NCT00818961|stage IV grade 2 follicular lymphoma
1287136|NCT00818961|stage IV grade 3 follicular lymphoma
1287137|NCT00818961|stage IV mantle cell lymphoma
1287138|NCT00818961|stage IV marginal zone lymphoma
1287139|NCT00818961|stage IV small lymphocytic lymphoma
1287140|NCT00818961|recurrent adult diffuse large cell lymphoma
1287141|NCT00818961|recurrent adult diffuse mixed cell lymphoma
1287142|NCT00818961|recurrent adult diffuse small cleaved cell lymphoma
1287143|NCT00818961|recurrent adult gr III lymphomatoid granulomatosis
1287144|NCT00818961|recurrent grade 1 follicular lymphoma
1287145|NCT00818961|recurrent grade 2 follicular lymphoma
1287146|NCT00818961|recurrent grade 3 follicular lymphoma
1287147|NCT00818961|recurrent mantle cell lymphoma
1287148|NCT00818961|recurrent marginal zone lymphoma
1287149|NCT00818961|recurrent small lymphocytic lymphoma
1287150|NCT00818961|de novo MDS
1287151|NCT00818961|previously treated MDS
1287152|NCT00818961|secondary myelodysplastic syndromes
1287153|NCT00818961|Waldenstrom macroglobulinemia
1287154|NCT00818961|myelodysplastic/myeloproliferative disease
1287155|NCT00818948|Lupus
1287156|NCT00818948|Nephritis
1287157|NCT00818909|Dry eye
1287158|NCT00818909|Systane
1287159|NCT00818909|Moderate to severe dry eye
1287160|NCT00818896|thyroid deficiency
1287161|NCT00818896|pregnancy
1287162|NCT00818896|post-partum thyroid dysfunction
1287163|NCT00818896|permanent hypothyroidism
1287164|NCT00818883|Essential Hypertension
1287165|NCT00818883|Hypertensive
1287166|NCT00818883|Blood Pressure, High
1287167|NCT00818883|Vascular Disease
1287168|NCT00818883|Cardiovascular Disease
1287169|NCT00818883|Drug Therapy
1287170|NCT00818870|Gastroesophageal Reflux
1287171|NCT00818870|GERD
1287172|NCT00818870|Nocturnal GERD
1287173|NCT00818870|Heartburn
1287174|NCT00818870|Nighttime Heartburn
1287175|NCT00818870|Nocturnal Heartburn
1287176|NCT00818857|cancer screening
1287177|NCT00818857|screening disparities
1287178|NCT00818857|underserved populations
1287179|NCT00818844|Nepafenac
1287180|NCT00818844|vitrectomy surgery
1287181|NCT00818844|Epiretinal membrane surgery
1287182|NCT00818831|Advanced, refractory solid tumors
1287183|NCT00818818|Leishmaniasis
1287184|NCT00818818|Cutaneous leishmaniasis
1287185|NCT00818818|Leishmania braziliensis
1287186|NCT00818818|Pentavalent antimonial
1287187|NCT00818818|Glucantime
1287188|NCT00818805|conjunctivitis
1287189|NCT00818792|Percutaneous coronary intervention
1287190|NCT00818792|Drug-eluting stent
1287191|NCT00818792|Chronic kidney disease
1287192|NCT00818792|Restenosis
1287193|NCT00818779|diabetes
1287194|NCT00818779|heart disease
1287195|NCT00818779|atherosclerosis
1287197|NCT00818766|Antibiotic Prophylaxis
1287198|NCT00818766|Chest Tube
1287199|NCT00817752|stress
1287200|NCT00817752|inflammation
1287201|NCT00817752|natural remedy
1287202|NCT00817752|cytokines
1287203|NCT00817752|interleukin
1287204|NCT00817752|inflammatory conditions
1287205|NCT00817752|auto-immune disorders
1287206|NCT00817739|Drug therapy
1287207|NCT00817726|Rapid Eye Movement Sleep Behavior Disorder
1287208|NCT00817726|Parkinson's Disease
1287209|NCT00817726|Parkinsonian Syndromes
1287210|NCT00817726|Atypical Parkinson's
1287211|NCT00817726|RBD
1287212|NCT00817726|PD
1287213|NCT00817726|fMRI
1287214|NCT00817726|PSP
1287215|NCT00817726|MSA
1287216|NCT00817713|Human Immunodeficiency Virus
1287217|NCT00817713|Helminthiasis
1287218|NCT00817713|treatment naive
1287219|NCT00817713|co-infection
1287220|NCT00817713|immune modulation
1287221|NCT00817700|Sleep
1287222|NCT00817700|young adults
1287223|NCT00817700|middle-age adults
1287224|NCT00817700|older adults
1287225|NCT00817674|CKD
1287226|NCT00817674|Kidney Disease
1287227|NCT00817674|poor sleep
1287228|NCT00817674|CKD progression
1287229|NCT00817661|vitamin A
1287230|NCT00817661|influenza vaccine
1287231|NCT00817661|passive immunity
1287232|NCT00817661|pregnant mothers
1287233|NCT00817661|vitamin A suplementation
1287234|NCT00817661|Influenza vaccination
1287235|NCT00817661|Infant immune responses
1287236|NCT00817648|schizophrenia
1287237|NCT00817648|antipsychotics
1287238|NCT00817648|quetiapine
1287239|NCT00817648|risperidone
1287240|NCT00817648|efficacy
1287241|NCT00817648|safety
1287242|NCT00817648|multicenter
1287243|NCT00817648|rater-blind
1287244|NCT00817648|randomized
1287245|NCT00817648|chinese
1287246|NCT00817648|han
1287247|NCT00817635|Blood Pressure
1287248|NCT00817635|Hypertension
1287249|NCT00817635|Resistant Hypertension
1287250|NCT00818727|Bone density
1287251|NCT00818727|SSRI
1287252|NCT00818727|newborn infants
1287253|NCT00818714|IIIA, selected IIIB
1287254|NCT00818714|(T1N2-3M0, T2N2-3M0, T3N1-3M0)
1287255|NCT00818701|Congestive Heart Failure
1287256|NCT00818701|Congestive Heart Failure with a NYHF Class 2-3
1287257|NCT00818701|Ejection Fraction of 35 or less
1287258|NCT00818688|Superficial thrombophlebitis (ST)
1287259|NCT00818688|Deep-vein thrombosis
1287260|NCT00818688|Symptomatic pulmonary embolism
1287261|NCT00818688|Symptomatic Superficial Thrombophlebitis of the lower limbs
1287262|NCT00818662|Alzheimer´s
1287263|NCT00818662|Dementia
1287264|NCT00818662|Dementia of Alzheimer Type
1287265|NCT00818662|Immunoglobulins
1287266|NCT00818662|Gammaglobulins
1287267|NCT00818662|Immune Globulin Intravenous (IGIV)
1287268|NCT00818662|Intravenous Immune Globulin (IVIG)
1287269|NCT00818662|Antibodies
1287270|NCT00818662|Amyloid
1287271|NCT00818662|Immunotherapy
1287272|NCT00818649|de novo myelodysplastic syndromes
1287273|NCT00818649|previously treated myelodysplastic syndromes
1287274|NCT00818649|secondary myelodysplastic syndromes
1287275|NCT00818649|refractory anemia with excess blasts
1287276|NCT00818649|adult acute myeloblastic leukemia with maturation (M2)
1287277|NCT00818649|adult acute myeloblastic leukemia without maturation (M1)
1287278|NCT00818649|adult acute minimally differentiated myeloid leukemia (M0)
1287279|NCT00818649|adult acute myelomonocytic leukemia (M4)
1287280|NCT00818649|adult acute monoblastic leukemia (M5a)
1287281|NCT00818649|adult acute monocytic leukemia (M5b)
1287282|NCT00818649|adult erythroleukemia (M6a)
1287283|NCT00818649|adult pure erythroid leukemia (M6b)
1287284|NCT00818649|adult acute megakaryoblastic leukemia (M7)
1287285|NCT00818649|recurrent adult acute myeloid leukemia
1287286|NCT00818649|untreated adult acute myeloid leukemia
1287287|NCT00818649|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1287288|NCT00818649|adult acute myeloid leukemia with inv(16)(p13;q22)
1287289|NCT00818649|adult acute myeloid leukemia with t(16;16)(p13;q22)
1287290|NCT00818649|adult acute myeloid leukemia with t(8;21)(q22;q22)
1287291|NCT00818636|expressive writing
1287292|NCT00818636|ruminating
1287293|NCT00818636|ruminative thinking
1287294|NCT00818636|experiential avoidance
1287295|NCT00818636|depression
1287296|NCT00818636|alcohol
1287297|NCT00818636|drinking
1287298|NCT00818636|emotional processing
1287299|NCT00818610|Community-acquired infections
1287300|NCT00818610|Pneumonia
1287301|NCT00818610|Clinical Stability
1287302|NCT00818610|Antibiotics
1287303|NCT00818610|Combination therapy
1287304|NCT00818610|Atypical bacteria
1287305|NCT00818597|septic shock
1287306|NCT00818597|immunoparalysis
1287307|NCT00818597|extracorporeal
1287308|NCT00818597|granulocyte bioreactor
1287309|NCT00818597|plasmapheresis
1287310|NCT00818584|Micafungin
1287311|NCT00818584|Candida
1287312|NCT00818584|Neonates
1287313|NCT00818584|Mycamine
1287314|NCT00818584|FK463
1287315|NCT00818571|Renal impairment
1287316|NCT00818571|Diabetes
1287317|NCT00818571|vildagliptin
1287318|NCT00818571|Galvus
1287319|NCT00818571|Eucreas
1287320|NCT00818558|non small cell lung cancer
1287321|NCT00818545|aging
1287322|NCT00818545|barrier function
1287323|NCT00818545|transcriptomic
1287324|NCT00818532|Corneal astigmatism
1287325|NCT00818532|Low diopter
1287326|NCT00818532|Corneal measurement
1287327|NCT00818532|Corneal astigmatism < 1 Diopter
1287328|NCT00818519|Moderate Acne Vulgaris
1287329|NCT00818519|Oral contraceptive
1287330|NCT00818519|Female
1287331|NCT00818506|Depression
1287332|NCT00818506|Major depressive disorder
1287333|NCT00818506|Coronary artery disease
1287334|NCT00818506|White Matter Hyperintensities
1287335|NCT00818506|White Matter Lesions
1287336|NCT00818506|Coronary artery calcification
1287337|NCT00818493|total knee arthroplasty
1287338|NCT00818493|total hip arthroplasty
1287339|NCT00818480|prostate cancer
1287340|NCT00818480|melanoma
1287341|NCT00818480|lymphoma
1287342|NCT00818480|YM155
1287343|NCT00818467|Skin tone
1287344|NCT00818467|Vitamin D
1287345|NCT00818441|lung cancer adenocarcinoma HER2
1287346|NCT00818428|Phonological Awareness
1287347|NCT00818428|Speech Articulation Disorder
1287348|NCT00818428|Development Articulation Disorder
1287349|NCT00818428|Phonological Impairment
1287350|NCT00818428|Dyslexia
1287351|NCT00818428|Speech Therapy
1287352|NCT00818428|School Transition
1287353|NCT00818402|Quality of life
1287354|NCT00818402|symptoms
1287355|NCT00818389|Amyotrophic lateral sclerosis
1287356|NCT00818389|ALS
1287357|NCT00818389|Lou Gehrig's disease
1287358|NCT00818389|riluzole
1287359|NCT00818389|lithium
1287360|NCT00818389|neurodegeneration
1287361|NCT00818376|Chlorhexidine
1287362|NCT00818376|adverse effects
1287363|NCT00818376|staining
1287364|NCT00818376|dental calculus
1287365|NCT00818376|dental plaque
1287366|NCT00818363|Postoperative pain
1287367|NCT00818363|shoulder surgery
1287368|NCT00818363|opioid
1287369|NCT00818311|Light emitting diode
1287370|NCT00818311|tolerance
1287371|NCT00818311|photomodulation
1287372|NCT00818298|schizophrenia
1287373|NCT00818298|schizoaffective disorder
1287374|NCT00818298|PET Scan
1287375|NCT00818298|ziprasidone
1287376|NCT00818298|dopamine
1287377|NCT00818298|D2
1287378|NCT00818298|receptor
1287379|NCT00818298|antagonist
1287380|NCT00818298|occupancy
1287381|NCT00818298|dissociation
1287382|NCT00818298|affinity
1287383|NCT00818298|constant
1287384|NCT00818298|Ki
1287385|NCT00818298|ligand
1287386|NCT00818298|raclopride
1287387|NCT00818298|half-life
1287388|NCT00818298|striatal
1287389|NCT00818298|plasma dynamics
1287390|NCT00818298|central dynamics
1287391|NCT00818298|plasma drug level
1287392|NCT00818298|compliance
1287393|NCT00818298|antipsychotic
1287394|NCT00818298|pharmacotherapy
1287395|NCT00818298|twice daily dosing
1287396|NCT00818298|BID dosing
1287397|NCT00818298|once daily dosing
1287398|NCT00818298|od dosing
1287399|NCT00818298|qd dosing
1287400|NCT00818298|dosing schedule
1287401|NCT00818233|dynamic contour tonometry
1287402|NCT00818233|variability
1287403|NCT00818233|pulse amplitude
1287404|NCT00818233|Ocular pulse amplitude
1287405|NCT00818220|intraventricular hemorrhage
1287406|NCT00818220|sepsis
1287407|NCT00818220|motor function
1287408|NCT00818220|motor functioning at 7 months corrected age
1287409|NCT00818220|cytokines in cord blood and at 6 and 20 hours of age
1287410|NCT00818220|stem cells in cord blood and at 20 hours of age
1287411|NCT00818207|Smoking cessation
1287412|NCT00818207|quit rates
1287413|NCT00818207|reimbursement
1287414|NCT00818207|drug coverage
1287415|NCT00818207|effectiveness
1287416|NCT00818207|cost-effectiveness
1287417|NCT00818207|health policy
1287418|NCT00818207|drug utilization
1287419|NCT00818207|adherence
1287420|NCT00818207|urine cotinine.
1287421|NCT00818194|Tacrolimus
1287422|NCT00818194|cyclosporine A
1287423|NCT00818194|renal plasma flow
1287424|NCT00818194|glomerular filtration rate
1287425|NCT00818194|human
1287426|NCT00818194|pharmacodynamics
1287427|NCT00818194|pharmacokinetics
1287428|NCT00818194|Pharmacodynamics of tacrolimus
1287429|NCT00818181|Type I - Allergy, rhinoconjunctivitis
1287430|NCT00818129|Phase I
1287431|NCT00818129|Japan
1287432|NCT00818129|Japanese
1287433|NCT00818129|oral solution
1287434|NCT00818116|Cataract
1287435|NCT00818116|visual acuity
1287436|NCT00818116|AcrySof ReSTOR Aspheric Intraoculare Lens
1287437|NCT00818116|Bilateral cataract
1287438|NCT00818103|Multiple Sclerosis,Genetics,Pathogenesis,Pathology,Therapy
1287439|NCT00818090|thymic epithelial tumor
1287440|NCT00818090|paclitaxel
1287441|NCT00818090|cisplatin
1287442|NCT00818090|thymic carcinoma
1287443|NCT00818090|invasive thymoma
1287444|NCT00818051|stage IA breast cancer
1287445|NCT00818051|stage IB breast cancer
1287446|NCT00818051|stage II breast cancer
1287447|NCT00818051|stage IIIA breast cancer
1287448|NCT00818038|RRMS
1287449|NCT00818038|Relapsing Remitting
1287450|NCT00818038|MS
1287451|NCT00818025|Transplantation
1287452|NCT00818025|Self-care agency
1287453|NCT00818025|Self-care behaviors
1287454|NCT00818025|Hand-held device
1287455|NCT00818012|atrial fibrillation
1287456|NCT00818012|atrial electromechanical interval
1287457|NCT00818012|direct current cardioversion
1287458|NCT00818012|pulse wave velocity
1287459|NCT00817999|Platelet Aggregation Inhibition
1287460|NCT00817986|Acute back pain in the lumbar region
1287461|NCT00817973|Whey protein
1287462|NCT00817973|gluten
1287463|NCT00817973|casein
1287464|NCT00817973|cod protein
1287465|NCT00817973|GLP-1
1287466|NCT00817973|postprandial
1287467|NCT00817973|triglyceride
1287468|NCT00817973|free fatty acids
1287469|NCT00817973|chylomicrons
1287470|NCT00817973|retinyl palmitate
1287471|NCT00817973|type 2 diabetes
1287472|NCT00817973|GIP
1287473|NCT00817973|Postprandial incretins
1287474|NCT00817960|Dual tasking
1287475|NCT00817960|Postural Control
1287476|NCT00817960|Methylphenidate (Ritalin)
1287477|NCT00817960|old adults
1287478|NCT00817947|Airway clearance
1287479|NCT00817947|Cystic fibrosis
1287480|NCT00817947|High frequency chest wall oscillation
1287481|NCT00817934|Efficacy
1287482|NCT00817934|patient's tolerance
1287483|NCT00817934|patient's safety
1287484|NCT00817921|premature renal function
1287485|NCT00817921|ibuprofen
1287486|NCT00817921|blood pressure
1287487|NCT00817921|Renal function
1287488|NCT00817908|liver transplant
1287489|NCT00817908|lung transplant
1287490|NCT00817908|kidney transplant
1287491|NCT00817908|heart transplant
1287492|NCT00817908|CMV CMI
1287493|NCT00817908|Transplant
1287494|NCT00817895|hepatocellular carcinoma
1287495|NCT00817895|liver resection
1287496|NCT00817895|intraoperative chemotherapy
1287497|NCT00817882|vocational
1287498|NCT00817882|rehabilitation
1287499|NCT00817882|work
1287500|NCT00817882|ability
1287501|NCT00817882|low back pain
1287502|NCT00817869|Floors and Floorcoverings
1287503|NCT00817869|Health Services for the Aged
1287504|NCT00817869|Fractures, bone
1287505|NCT00817869|Delirium, Dementia, Amnestic, Cognitive Disorders
1287506|NCT00817869|Frail Elderly
1287507|NCT00817869|Aged, 80 and over
1287508|NCT00817843|Postprandial hypertriglyceridemia
1287509|NCT00817843|Metabolic syndrome
1287510|NCT00817843|Endothelial function
1287511|NCT00817843|Flow mediated dilatation
1287512|NCT00817843|EndoPAT
1287513|NCT00817843|Simvastatin
1287514|NCT00817843|Ezetimibe
1287515|NCT00817830|Coronaropathy
1287516|NCT00817830|lodenafil carbonate
1287517|NCT00817830|Erectile dysfunction
1287518|NCT00817830|Treatment
1287519|NCT00817830|QT interval
1287520|NCT00817830|Phosphodiesterase inhibitors
1287521|NCT00817830|Cardiac arrhythmia
1287522|NCT00817830|Effort testPhosphodiesterase 5 inhibitors
1287523|NCT00817830|Cardiovascular test
1287524|NCT00817804|noninvasive ventilation
1287525|NCT00817791|CABG
1287526|NCT00817791|hyperbaric oxygen
1287527|NCT00817791|preconditioning
1287528|NCT00817791|S100B
1287529|NCT00817791|NSE
1287530|NCT00817791|Troponin I
1287531|NCT00817791|CABG surgery
1287532|NCT00817791|neuroprotection
1287533|NCT00817778|Type II Diabetes
1287534|NCT00817765|interaction
1287535|NCT00817765|pharmacokinetics
1287536|NCT00817765|boosting
1287537|NCT00817765|drug-drug interaction
1287538|NCT00817765|safety
1287539|NCT00817544|3098004
1287540|NCT00817544|Healthy volunteers
1287541|NCT00817531|Breast Cancer
1287542|NCT00817505|Type I diabetes
1287543|NCT00817505|bioavailability
1287544|NCT00817492|Sleep
1287545|NCT00817492|CKD
1287546|NCT00817492|kidney
1287547|NCT00817492|PSG
1287548|NCT00817492|polysomnography
1287549|NCT00817492|Decreased sleep time
1287550|NCT00817492|Decreased sleep quality
1287551|NCT00817479|Subject has intraabdominal disease either proven or strongly
1287552|NCT00817479|suspected to be ovarian or primary peritoneal cancer
1287553|NCT00817466|bronchiolitis
1287554|NCT00817466|infants
1287555|NCT00817466|racemic adrenaline
1287556|NCT00817466|inhalations
1287557|NCT00817466|treatment
1287558|NCT00817453|Parkinson's Disease
1287559|NCT00817440|growth hormone insulin signaltransduction signalpathways
1287560|NCT00817440|growth hormone and insulin signalpathways
1287561|NCT00817427|Chronic Kidney Disease
1287562|NCT00817427|Poor sleep
1287563|NCT00817427|CKD
1287564|NCT00817427|Kidney Failure
1287565|NCT00817414|Blood Pressure
1287566|NCT00817414|Hypertension
1287567|NCT00817414|Cortisol
1287568|NCT00817401|asphyxia
1287569|NCT00817401|hypothermia
1287570|NCT00817401|hypoxic-ischemic encephalopathy
1287571|NCT00817401|neonates
1287572|NCT00817388|Interstitial cystitis
1287573|NCT00817388|pelvic pain
1287574|NCT00817375|Pharmacogenomics
1287575|NCT00817375|Prediction of Antidepressant Response
1287576|NCT00817375|Depressed Patients
1287577|NCT00817362|Breast Cancer
1287578|NCT00817362|Advanced Breast Cancer
1287579|NCT00817362|Metastatic Breast Cancer
1287580|NCT00817362|HER2 Positive Breast Cancer
1287581|NCT00817362|Cancer of the breast
1287582|NCT00817362|Trastuzumab
1287583|NCT00817362|Herceptin
1287584|NCT00817349|Angio-Seal
1287585|NCT00817349|Peripheral vascular disease
1287586|NCT00817349|Vascular closure device
1287587|NCT00817349|Arterial closure
1287588|NCT00817349|Coronary artery disease
1287589|NCT00817349|Arterial hemostasis
1287590|NCT00817349|Coronary cardiac catheterization
1287591|NCT00817349|Percutaneous coronary intervention
1287592|NCT00817349|Interventional catheterization
1287593|NCT00817349|Diagnostic catheterization
1287594|NCT00817349|Common femoral artery
1287595|NCT00817349|Manual compression
1287596|NCT00817349|Vascular intervention
1287597|NCT00817349|Angiogram
1287598|NCT00817349|Coronary intervention
1287599|NCT00817349|Coronary angioplasty
1287600|NCT00817349|Angiography
1287601|NCT00817349|Arteriotomy
1287602|NCT00817349|Vascular access
1287603|NCT00817336|biomarker
1287604|NCT00817336|EEG
1287605|NCT00817336|schizophrenia
1287606|NCT00817336|NMDA
1287607|NCT00817336|D-serine
1287608|NCT00817323|bipolar depression
1287609|NCT00817323|atypical antipsychotic
1287610|NCT00817323|remission
1287611|NCT00817323|depletion
1287612|NCT00817323|mood
1287613|NCT00817297|noninvasive ventilation
1287614|NCT00817284|Newly diagnosed patients with glioblastoma multiforme.
1287615|NCT00817284|Performance status 0-2.
1287616|NCT00817271|Type II Diabetes
1287617|NCT00817271|Counter-regulatory response
1287618|NCT00817271|Hypoglycemia
1287619|NCT00817258|Phase 2 Clinical Trial
1287620|NCT00817258|NPC
1287621|NCT00817258|radiation therapy
1287622|NCT00817258|chemotherapy
1287623|NCT00817245|CSR
1287624|NCT00817245|Helicobacter pylori
1287625|NCT00817232|tennis elbow
1287626|NCT00817232|microcurrent
1287627|NCT00817232|tissue healing
1287628|NCT00817206|kidney transplantation
1287629|NCT00817206|renal transplantation
1287630|NCT00817206|maintenance immunosuppression
1287631|NCT00817206|tacrolimus
1287632|NCT00817206|Prevention of acute allograft rejection
1287633|NCT00817193|Clinical trial
1287634|NCT00817193|Short Physical Performance Battery
1287635|NCT00817193|Disability
1287636|NCT00817193|Senior Housing
1287637|NCT00817193|Aging
1287638|NCT00817180|physiotherapy
1287639|NCT00817180|airway clearance techniques
1287640|NCT00817180|Positive Expiratory Pressure Technique
1287641|NCT00817180|high frequency Chest Wall Oscillation
1287642|NCT00817180|vest
1287643|NCT00817167|Known or suspected lung disease
1287644|NCT00817167|Candidates for non-emergency bronchoscopy
1287645|NCT00817154|Older persons with SMI
1287646|NCT00817128|Complex Regional Pain Syndrome Type I
1287647|NCT00817128|Sympathetic Reflex Dystrophy
1287648|NCT00817128|Pain Exposure Physical Therapy
1287649|NCT00817128|Pharmacological treatment
1287650|NCT00817128|Functional recovery
1287651|NCT00817115|Region-of-Interest Imaging
1287652|NCT00817115|X-ray Fovea Imaging
1287653|NCT00817115|Cardiovascular Diseases
1287654|NCT00817115|Radiation Dosage
1287655|NCT00817115|Radiographic Image Enhancement
1287656|NCT00817115|Radiography, Interventional
1287657|NCT00817102|coronary artery stenoses
1287658|NCT00817063|retinoid treatment
1287659|NCT00817063|fingertip dermatitis
1287660|NCT00817063|hyperkeratotic hand eczema
1287661|NCT00817063|vesicular hand eczema
1287662|NCT00817063|pompholyx
1287663|NCT00817037|Chronic kidney disease
1287664|NCT00817037|Proteinuria
1287665|NCT00817037|Blood pressure
1287666|NCT00817037|Arterial stiffness
1287667|NCT00817037|Endothelin antagonist
1287668|NCT00817037|Sitaxsentan
1287669|NCT00817024|Coronary Heart Disease
1287670|NCT00817024|PCI
1287671|NCT00817024|Traditional Chinese Medicine
1287672|NCT00817024|Quality of Life
1287673|NCT00817011|depression
1287674|NCT00817011|pharmacogenomics
1287675|NCT00817011|antidepressant response
1287676|NCT00817011|biological markers
1287677|NCT00817011|clinical variables
1287678|NCT00816998|Radius fractures
1287679|NCT00816985|Female
1287680|NCT00816985|Lymphedema
1287681|NCT00816959|Lymphocytic Predominant Hodgkin's Lymphoma
1287682|NCT00816959|Late, widespread and recurrent LPHD
1287683|NCT00816946|malnutrition
1287684|NCT00816946|growth
1287685|NCT00816933|pain
1287686|NCT00816933|operative times
1287687|NCT00816933|complication
1287688|NCT00816933|time to return for normal life
1287689|NCT00816933|pain using VAS score
1287690|NCT00816920|distal DVT
1287691|NCT00816920|calf DVT
1287692|NCT00816920|DVT diagnosis
1287693|NCT00816920|management of patients with suspected leg DVT
1287694|NCT00816907|Schizoaffective Disorder
1287695|NCT00816894|schizophrenia
1287696|NCT00816894|treatment resistance
1287697|NCT00816894|D-serine
1287698|NCT00816894|Olanzapine
1287699|NCT00816894|treatment refractory schizophrenia
1287700|NCT00816881|Pulmonary Disease, Chronic Obstructive
1287701|NCT00816881|flutter
1287702|NCT00816881|airway clearance
1287703|NCT00816881|sputum
1287704|NCT00816881|Physical Therapy Techniques
1287705|NCT00816868|stage IIIB/IV adenocarcinoma non-small cell lung cancer
1287706|NCT00816855|Phase 2 Clinical Trial
1287707|NCT00816855|NPC
1287708|NCT00816855|neoadjuvant chemotherapy
1287709|NCT00816855|concurrent chemoradiation
1287710|NCT00816842|citrulline
1287711|NCT00816842|malabsorption
1287712|NCT00816842|Villous atrophy
1287713|NCT00816842|enteropathy
1287714|NCT00816829|Dyslipidemia
1287715|NCT00816829|Sleep Apnea Syndromes
1287716|NCT00816829|Fenofibrate
1287717|NCT00816829|Obese
1287718|NCT00816829|Overweight or obese patients
1287719|NCT00816816|Phase 2 Clinical Trial
1287720|NCT00816816|NPC
1287721|NCT00816816|neoadjuvant chemotherapy
1287722|NCT00816816|concurrent chemoradiation
1287723|NCT00816803|Spinal cord injury
1287724|NCT00816790|Septic shock
1287725|NCT00816790|Acute Renal Failure
1287726|NCT00816790|Antimicrobial
1287727|NCT00816790|Drug Dosing
1287728|NCT00816790|Feasibility Study
1287729|NCT00816777|Cancer
1287730|NCT00816777|Carcinoma
1287731|NCT00816777|Colon Cancer
1287732|NCT00816777|Colorectal Cancer
1287733|NCT00816777|Gastric Cancer
1287734|NCT00816777|Gastrointestinal Cancer
1287735|NCT00816777|Metastases
1287736|NCT00816777|Metastatic Cancer
1287737|NCT00816777|Metastatic Colorectal Cancer
1287738|NCT00816777|Oncology
1287739|NCT00816777|Rectal Cancer
1287740|NCT00816764|clinical trial, phase 1
1287741|NCT00816764|carcinoma
1287742|NCT00816764|pharmacokinetics
1287743|NCT00816764|safety
1287744|NCT00816764|ovarian
1287745|NCT00816751|Local anesthesia
1287746|NCT00816751|Paracervical
1287747|NCT00816751|Intracervical
1287748|NCT00816751|Abortion
1287749|NCT00816751|Pain
1287750|NCT00816751|Local anesthesia for elective first trimester abortion
1287751|NCT00816738|Nd: YAG laser
1287752|NCT00816738|recurrent corneal erosions
1287753|NCT00816738|trauma
1287754|NCT00816738|anterior stromal puncture
1287755|NCT00816725|Postnatal Depression
1287756|NCT00816725|Cognitive Behavioral Therapy
1287757|NCT00816725|Mood Management
1287758|NCT00816725|Self-help
1287759|NCT00816725|Internet
1287760|NCT00816712|Males with low-normal serum total testosterone levels.
1287761|NCT00816699|Anxiety
1287762|NCT00816699|preprint anesthetic risk information
1287763|NCT00816686|clinical trial, phase 1
1287764|NCT00816686|carcinoma, advanced renal cell
1287765|NCT00816686|kidney
1287766|NCT00816686|pharmacokinetics
1287767|NCT00816686|safety
1287768|NCT00816686|AGS-16M18
1287769|NCT00816673|Insomnia
1287770|NCT00816673|Primary insomnia
1287771|NCT00816673|sleep latency
1287772|NCT00816673|non restorative sleep
1287773|NCT00816673|sleep quality
1287774|NCT00816673|Double-Blind
1287775|NCT00816673|Placebo Controlled
1287776|NCT00816673|Parallel-Group
1287777|NCT00816673|Sleep Laboratory Study
1287778|NCT00816647|Patella
1287779|NCT00816647|Dislocation
1287780|NCT00816647|Knee
1287781|NCT00816647|Medial Patellofemoral Ligament
1287782|NCT00816634|First line chemotherapy
1287783|NCT00816634|Advanced or recurrent esophageal squamous cell carcinoma
1287784|NCT00816621|Internationally Adopted Children
1287785|NCT00816621|Adoption
1287786|NCT00816621|Attachment
1287787|NCT00816621|Inattention
1287788|NCT00816621|Prevention
1287789|NCT00816608|diabetes
1287790|NCT00816608|prediabetes
1287791|NCT00816608|impaired fasting glucose (IFG)
1287792|NCT00816608|impaired glucose tolerance (IGT)
1287793|NCT00816608|body weight
1287794|NCT00816595|B-cell chronic lymphocytic leukemia
1287795|NCT00816595|stage 0 chronic lymphocytic leukemia
1287796|NCT00816595|stage I chronic lymphocytic leukemia
1287797|NCT00816595|stage II chronic lymphocytic leukemia
1287798|NCT00816595|stage III chronic lymphocytic leukemia
1287799|NCT00816595|stage IV chronic lymphocytic leukemia
1287800|NCT00816595|stage I small lymphocytic lymphoma
1287801|NCT00816595|stage III small lymphocytic lymphoma
1287802|NCT00816595|stage IV small lymphocytic lymphoma
1287803|NCT00816595|contiguous stage II small lymphocytic lymphoma
1287804|NCT00816595|noncontiguous stage II small lymphocytic lymphoma
1287805|NCT00816582|Post-menopausal hormone receptor positive recurrent/metastatic breast cancer.
1287806|NCT00816582|PET/CT
1287807|NCT00816582|Recurrent or metastatic
1287808|NCT00816569|Orthokeratology
1287809|NCT00816569|Keratoconus
1287810|NCT00816530|breast
1287811|NCT00816530|breast cancer
1287812|NCT00816530|breast screening
1287813|NCT00816530|breast cancer screening
1287814|NCT00816530|ultrasound
1287815|NCT00816530|ultrasonography
1287816|NCT00816530|mammogram
1287817|NCT00816530|mammography
1287818|NCT00816530|breast density
1287819|NCT00816530|dense breasts
1287820|NCT00816530|early detection
1287821|NCT00816530|somo v
1287822|NCT00816530|somo•v
1287823|NCT00816530|U-Systems
1287824|NCT00816530|Automated Breast Ultrasound
1287825|NCT00816530|Ultrasonography, Mammary
1287826|NCT00816530|Breast Neoplasms
1287827|NCT00816530|Breast Density > 50% (BI-RADS III & IV)
1287828|NCT00816517|Psoriasis
1287829|NCT00816517|Botulinum toxin
1287830|NCT00816504|FSGS
1287831|NCT00816504|Permeability factor
1287832|NCT00816504|Galactose
1287833|NCT00816504|Primary FSGS, resistant to immunosuppressive medication
1287834|NCT00816491|patient with long-standing UC
1287835|NCT00816478|FSGS
1287836|NCT00816478|Permeability factor
1287837|NCT00816478|Galactose
1287838|NCT00816478|Primary FSGS, resistant to immunosuppressive medication
1287839|NCT00816465|Hoodia gordoni
1287840|NCT00816465|NASH
1287841|NCT00816465|NAFLD
1287842|NCT00816452|Osteoporosis
1287843|NCT00816452|Prostate Cancer
1287844|NCT00816452|Osteoporosis in male with Prostate Cancer
1287845|NCT00816439|Positron Emission Tomography
1287846|NCT00816439|Brain Imaging
1287847|NCT00816439|Alcoholism
1287848|NCT00816426|Tuberculosis
1287849|NCT00816426|Lesions
1287850|NCT00816426|Pharmacokinetics
1287851|NCT00816426|Maldistribution
1287852|NCT00816426|Histopathology
1287853|NCT00816413|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1287854|NCT00816413|adult acute myeloid leukemia with inv(16)(p13;q22)
1287855|NCT00816413|adult acute myeloid leukemia with t(15;17)(q22;q12)
1287856|NCT00816413|adult acute myeloid leukemia with t(16;16)(p13;q22)
1287857|NCT00816413|adult acute myeloid leukemia with t(8;21)(q22;q22)
1287858|NCT00816413|adult acute myeloid leukemia in remission
1287859|NCT00816413|recurrent adult acute myeloid leukemia
1287860|NCT00816413|secondary acute myeloid leukemia
1287861|NCT00816413|adult acute lymphoblastic leukemia in remission
1287862|NCT00816413|recurrent adult acute lymphoblastic leukemia
1287863|NCT00816413|accelerated phase chronic myelogenous leukemia
1287864|NCT00816413|blastic phase chronic myelogenous leukemia
1287865|NCT00816413|chronic phase chronic myelogenous leukemia
1287866|NCT00816413|relapsing chronic myelogenous leukemia
1287867|NCT00816413|chronic myelomonocytic leukemia
1287868|NCT00816413|de novo myelodysplastic syndromes
1287869|NCT00816413|previously treated myelodysplastic syndromes
1287870|NCT00816413|secondary myelodysplastic syndromes
1287871|NCT00816413|essential thrombocythemia
1287872|NCT00816413|polycythemia vera
1287873|NCT00816413|primary myelofibrosis
1287874|NCT00816413|stage III mantle cell lymphoma
1287875|NCT00816413|stage IV mantle cell lymphoma
1287876|NCT00816413|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1287877|NCT00816413|nodal marginal zone B-cell lymphoma
1287878|NCT00816413|splenic marginal zone lymphoma
1287879|NCT00816413|stage III adult lymphoblastic lymphoma
1287880|NCT00816413|stage IV adult lymphoblastic lymphoma
1287881|NCT00816413|aplastic anemia
1287882|NCT00816413|chronic eosinophilic leukemia
1287883|NCT00816413|chronic neutrophilic leukemia
1287884|NCT00816413|contiguous stage II adult diffuse small cleaved cell lymphoma
1287885|NCT00816413|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1287886|NCT00816413|stage I adult diffuse small cleaved cell lymphoma
1287887|NCT00816413|stage III adult diffuse small cleaved cell lymphoma
1287888|NCT00816413|stage IV adult diffuse small cleaved cell lymphoma
1287889|NCT00816413|contiguous stage II grade 1 follicular lymphoma
1287890|NCT00816413|contiguous stage II grade 2 follicular lymphoma
1287891|NCT00816413|noncontiguous stage II grade 1 follicular lymphoma
1287892|NCT00816413|noncontiguous stage II grade 2 follicular lymphoma
1287893|NCT00816413|stage I grade 1 follicular lymphoma
1287894|NCT00816413|stage I grade 2 follicular lymphoma
1287895|NCT00816413|stage III grade 1 follicular lymphoma
1287896|NCT00816413|stage III grade 2 follicular lymphoma
1287897|NCT00816413|stage IV grade 1 follicular lymphoma
1287898|NCT00816413|stage IV grade 2 follicular lymphoma
1287899|NCT00816413|contiguous stage II marginal zone lymphoma
1287900|NCT00816413|noncontiguous stage II marginal zone lymphoma
1287901|NCT00816413|stage I marginal zone lymphoma
1287902|NCT00816413|stage III marginal zone lymphoma
1287903|NCT00816413|stage IV marginal zone lymphoma
1287904|NCT00816413|contiguous stage II small lymphocytic lymphoma
1287905|NCT00816413|noncontiguous stage II small lymphocytic lymphoma
1287906|NCT00816413|stage I small lymphocytic lymphoma
1287907|NCT00816413|stage III small lymphocytic lymphoma
1287908|NCT00816413|stage IV small lymphocytic lymphoma
1287909|NCT00816413|contiguous stage II mantle cell lymphoma
1287910|NCT00816413|noncontiguous stage II mantle cell lymphoma
1288033|NCT00815984|lung function
1287911|NCT00816413|stage I mantle cell lymphoma
1287912|NCT00816413|contiguous stage II adult lymphoblastic lymphoma
1287913|NCT00816413|noncontiguous stage II adult lymphoblastic lymphoma
1287914|NCT00816413|stage I adult lymphoblastic lymphoma
1287915|NCT00816413|stage I chronic lymphocytic leukemia
1287916|NCT00816413|stage II chronic lymphocytic leukemia
1287917|NCT00816413|stage III chronic lymphocytic leukemia
1287918|NCT00816413|stage IV chronic lymphocytic leukemia
1287919|NCT00816374|cutaneous malignant melanoma
1287920|NCT00816374|CMM
1287921|NCT00816374|total cutaneous examination
1287922|NCT00816374|TCE
1287923|NCT00816374|skin self-examination
1287924|NCT00816374|SSE
1287925|NCT00816374|first degree relatives
1287926|NCT00816374|FDR
1287927|NCT00816374|skin cancer protection
1287928|NCT00816374|skin cancer screening
1287929|NCT00816348|Cholestasis
1287930|NCT00816348|Parenteral Nutrition Associated Liver Disease
1287931|NCT00816335|unspecified adult solid tumor, protocol specific
1287932|NCT00816309|physiotherapy
1287933|NCT00816309|bronchiectasis
1287934|NCT00816296|NAFLD
1287935|NCT00816296|Obesity
1287936|NCT00816296|Microbiome
1287937|NCT00816283|accelerated phase chronic myelogenous leukemia
1287938|NCT00816283|blastic phase chronic myelogenous leukemia
1287939|NCT00816283|relapsing chronic myelogenous leukemia
1287940|NCT00816283|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
1287941|NCT00816283|recurrent adult acute lymphoblastic leukemia
1287942|NCT00816283|untreated adult acute lymphoblastic leukemia
1287943|NCT00816270|Blepharoptosis
1287944|NCT00816270|Dermatochalasis
1287945|NCT00816270|octyl 2-cyanoacrylate
1287946|NCT00816270|Suture Techniques
1287947|NCT00816270|Tissue Adhesive
1287948|NCT00816257|lung tissue repository
1287949|NCT00816244|Breast cancer
1287950|NCT00816244|Postmenopausal
1287951|NCT00816244|Neo-adjuvant
1287952|NCT00816244|Tumor proliferation
1287953|NCT00816244|Statin
1287954|NCT00816244|Atorvastatin
1287955|NCT00816244|Ki67
1287956|NCT00816244|Translational research
1287957|NCT00816244|Cell cycle regulators
1287958|NCT00816244|Gene expression
1287959|NCT00816244|Genomic profiling
1287960|NCT00816244|Apoptosis
1287961|NCT00816244|Window-of-opportunity
1287962|NCT00816231|Prevention Intervention
1287963|NCT00816231|Alcohol
1287964|NCT00816231|Tobacco
1287965|NCT00816231|Nicotine
1287966|NCT00816231|Craving
1287967|NCT00816231|Cue Reactivity
1287968|NCT00816231|Cross Cue Reactions
1287969|NCT00816192|FA
1287970|NCT00816192|Atrial fibrillation
1287971|NCT00816192|Catheter
1287972|NCT00816192|Ablation
1287973|NCT00816192|RF
1287974|NCT00816179|Pancreatic head mass
1287975|NCT00816179|Pancreatic cancer
1287976|NCT00816179|NOTES
1287977|NCT00816179|Endoscopic peritoneoscopy
1287978|NCT00816179|Whipple
1287979|NCT00816179|palliative gastrojejunostomy
1287980|NCT00816166|Ischemic stroke
1287981|NCT00816166|Transient Ischemic Attack
1287982|NCT00816166|Intracranial Stenting
1287983|NCT00816153|Pleth variability Index
1287984|NCT00816153|Fluid management
1287985|NCT00816153|Fluid management during surgery
1287986|NCT00816140|Helicobacter pylori
1287987|NCT00816140|levofloxacin
1287988|NCT00816140|clarithromycin
1287989|NCT00816140|ERADICATION RATE
1287990|NCT00816127|liver cirrhosis
1287991|NCT00816127|coagulopathy
1287992|NCT00816127|desmopressin
1287993|NCT00816127|blood transfusion
1287994|NCT00816114|Imatinib
1287995|NCT00816114|Gleevec
1287996|NCT00816114|Chronic Myelogenous Leukemia
1287997|NCT00816114|CML
1287998|NCT00816101|Curettage and electrodesiccation
1287999|NCT00816101|acute wounds
1288000|NCT00816101|partial thickness wounds
1288001|NCT00816088|chemotherapy
1288002|NCT00816088|Stem cell transplantation
1288003|NCT00816075|distilled water
1288004|NCT00816075|recurrent
1288005|NCT00816075|bladder
1288006|NCT00816075|mitomycin
1288007|NCT00816062|Aortic Aneurysm
1288008|NCT00816062|Aneurysm
1288009|NCT00816062|Abdominal Aortic Aneurysm
1288010|NCT00816062|Talent
1288011|NCT00816062|Medtronic
1288012|NCT00816049|acute lymphoblastic leukemia
1288013|NCT00816049|child
1288014|NCT00816049|6-mercaptopurine
1288015|NCT00816049|minimal residual disease
1288016|NCT00816049|efficacy
1288017|NCT00816049|childhood acute lymphoblastic leukemia
1288018|NCT00816036|Smoking Cessation
1288019|NCT00816036|Practice Guidelines
1288020|NCT00816036|Inpatient
1288021|NCT00816036|Effectiveness Trial
1288022|NCT00816036|Veterans Administration
1288023|NCT00816036|Relapse prevention
1288024|NCT00816010|drug compliance
1288025|NCT00816010|lifestyle modification
1288026|NCT00815997|radial artery
1288027|NCT00815997|transradial intervention
1288028|NCT00815997|stent
1288029|NCT00815984|Asthma
1288030|NCT00815984|Allergic Rhinitis
1288031|NCT00815984|Atopic Dermatitis
1288032|NCT00815984|Children
1288034|NCT00815984|skin prick tests
1288035|NCT00815984|FeNO
1288036|NCT00815971|EGFR mutations
1288037|NCT00815971|EGFR inhibitor
1288038|NCT00815971|erlotinib
1288039|NCT00815958|knee replacement surgery
1288040|NCT00815958|Reamer-Irrigator-Aspirator
1288041|NCT00815958|femoral reaming
1288042|NCT00815958|fat embolism
1288043|NCT00815945|leiomyosarcoma
1288044|NCT00815945|carcinosarcoma
1288045|NCT00815945|mixed epithelial mesenchymal tumor
1288046|NCT00815945|endometrial stroma sarcomas
1288047|NCT00815945|Müllerian mixed tumors
1288048|NCT00815945|carcinosarcoma of the uterus
1288049|NCT00815945|mesenchymal tumors of the ovary or uterus
1288050|NCT00815945|mixed epithelial mesenchymal tumors of the ovary or uterus
1288051|NCT00815919|cGVHD
1288052|NCT00815919|Velcade
1288053|NCT00815919|bortezomib
1288054|NCT00815893|Dexmedetomidine
1288055|NCT00815893|Fiberoptic nasal intubation
1288056|NCT00815893|satisfaction
1288057|NCT00815880|Heart Failure
1288058|NCT00815880|Device
1288059|NCT00815880|Implantable
1288060|NCT00815880|Active
1288061|NCT00815880|Class III and Class IV
1288062|NCT00815880|Counterpulsation
1288063|NCT00815867|kidney failure
1288064|NCT00815867|kidney transplant
1288065|NCT00815867|graft function
1288066|NCT00815867|haemoglobin
1288067|NCT00815867|epoetin
1288068|NCT00815854|Antipsychotic
1288069|NCT00815854|Metabolic Syndrome
1288070|NCT00815854|Insulin Resistance
1288071|NCT00815854|Endothelial Function
1288072|NCT00815841|Determine the effect of MPH on a diagnostic continuous performance task that assesses attention and on a decision making test in young healthy adults
1288073|NCT00815828|Gestational Diabetes
1288074|NCT00815828|Resistance Exercise
1288075|NCT00815828|Pregnancy
1288076|NCT00815828|Insulin
1288077|NCT00815815|Anorexia Nervosa
1288078|NCT00815802|Children in day care centers
1288079|NCT00815802|cytomegalovirus excretion
1288080|NCT00815776|Temporomandibular disorders
1288081|NCT00815763|randomized trial
1288082|NCT00815763|ischemic stroke
1288083|NCT00815763|Ginsenoside-Rd
1288084|NCT00815750|Prostate Cancer
1288085|NCT00815737|Lung Infection After Cerebral Hemorrhage
1288086|NCT00815737|Prevention of Pneumonia
1288087|NCT00815737|Rhubarb
1288088|NCT00815724|Daily Inhaled Corticosteroids
1288089|NCT00815724|Distributed Learning
1288090|NCT00815724|E-learning
1288091|NCT00815711|IPF
1288092|NCT00815698|pain
1288093|NCT00815685|n-3 fatty acids
1288094|NCT00815685|nutritional treatment
1288095|NCT00815685|molecular pathogenesis
1288096|NCT00815672|Exercise
1288097|NCT00815672|Prostate cancer
1288098|NCT00815672|Fatigue
1288099|NCT00815659|plasma lipid profile
1288100|NCT00815659|metabolic syndrome
1288101|NCT00815646|Immersion pulmonary edema
1288102|NCT00815646|Diving
1288103|NCT00815646|Swimming
1288104|NCT00815646|Pulmonary edema
1288105|NCT00815646|Cold water immersion
1288106|NCT00815633|PRP
1288107|NCT00815633|Pityriasis Rubra Pilaris
1288108|NCT00815633|Amevive
1288109|NCT00815633|Alefacept
1288110|NCT00815633|Biologic
1288111|NCT00815633|Immunosuppressant
1288112|NCT00815633|Severe skin disease
1288113|NCT00815620|neuroendocrine tumors
1288114|NCT00815620|transcatheter arterial chemoembolization
1288115|NCT00815620|selective internal radiotherapy
1288116|NCT00815620|surgery
1288117|NCT00815620|radio-frequency ablation
1288118|NCT00815620|peptide-receptor radiotherapy
1288119|NCT00815620|progression-free survival
1288120|NCT00815620|quality of life
1288121|NCT00815620|overall survival
1288122|NCT00815620|weight
1288123|NCT00815620|time of hospitalization
1288124|NCT00815607|melanoma
1288125|NCT00815607|biologic
1288126|NCT00815607|immunotherapy
1288127|NCT00815607|cancer
1288128|NCT00815594|bleb
1288129|NCT00815594|vascular change
1288130|NCT00815594|bevacizumab
1288131|NCT00815594|trabeculectomy
1288132|NCT00815594|Bleb vascularity associated with increased scarring activity
1288133|NCT00815594|Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery
1288134|NCT00815594|the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.
1288135|NCT00815581|children between 1 to 10 years old
1288136|NCT00815581|amblyopy
1288137|NCT00815568|fludarabine
1288138|NCT00815568|busulfan
1288139|NCT00815568|total body irradiation
1288140|NCT00815568|conditioning regimen
1288141|NCT00815555|receptor positive breast cancer
1288142|NCT00815555|Tamoxifen treatment
1288143|NCT00815555|CYP2D6 status
1288144|NCT00815555|relapse
1288145|NCT00815529|Acupuncture
1288146|NCT00815529|Chronic low back pain
1288147|NCT00815529|Qualitative study
1288148|NCT00815516|candidiasis
1288149|NCT00815516|candida
1288150|NCT00815516|Neonate
1288151|NCT00815516|candidemia
1288152|NCT00815516|Micafungin
1288153|NCT00815516|Mycamine
1288154|NCT00815516|amphotericin B deoxycholate
1288155|NCT00815503|Anesthetics
1288156|NCT00815503|Local infiltration
1288157|NCT00815503|Periacetabular osteotomy
1288158|NCT00815490|Spectroscopy, near infrared
1288159|NCT00815490|Oximetry
1288160|NCT00815490|Hypoxemia
1288161|NCT00815490|Tissue oxygenation
1288162|NCT00815464|Chronic Hepatitis B
1288163|NCT00815464|Liquid Acupuncture(Herb Acupoint Injection)
1288164|NCT00815464|Therapeutics
1288165|NCT00815464|Herbalist
1288166|NCT00815464|Acupoint
1288167|NCT00815438|Transvaginal
1288168|NCT00815438|Cholecystectomy
1288169|NCT00815438|NOTES
1288170|NCT00815438|Endoscopic
1288171|NCT00815425|African American
1288172|NCT00815386|mitral valve
1288173|NCT00815386|heart failure
1288174|NCT00815386|mitral regurgitation
1288175|NCT00815386|annuloplasty
1288176|NCT00815386|coronary sinus
1288177|NCT00815373|Ocular Blood flow
1288178|NCT00815373|Ocular hypertension
1288179|NCT00815373|POAG
1288180|NCT00815373|Ocular hemodynamics
1288181|NCT00815373|Xalacom
1288182|NCT00815373|Cosopt
1288183|NCT00815360|diabetic macular edema
1288184|NCT00815347|Asthma
1288185|NCT00815334|vesicoureteral reflux
1288186|NCT00815334|low compliant bladder
1288187|NCT00815321|chronic myeloid leukemia
1288188|NCT00815321|autologous cytokine induced killer cells
1288189|NCT00815321|Chronic myeloid leukemia in blast crisis treated with chemotherapy or kinase inhibitors
1288190|NCT00815321|Chronic myeloid leukemia with mutation resistant to kinase inhibitors
1288191|NCT00815321|chronic myeloid leukemia with good response to kinase inhibitor and stable persistence of residual disease
1288192|NCT00815308|Therapeutic
1288193|NCT00815308|Drug Therapy, combination
1288194|NCT00815308|Radiotherapy
1288195|NCT00815295|squamous cell cancer, head and neck
1288196|NCT00815269|Inhalant anesthetic
1288197|NCT00815269|Vasodilation
1288198|NCT00815269|General anesthesia
1288199|NCT00815269|Ultrasonography
1288200|NCT00815256|Cornea degeneration
1288201|NCT00815256|keratoconus
1288202|NCT00815256|collagen cross linking
1288203|NCT00815256|CXL
1288204|NCT00815256|Riboflavin
1288205|NCT00815243|fracture
1288206|NCT00815243|coxarthrosis
1288207|NCT00815243|complication
1288208|NCT00815243|congenital abnormalities
1288209|NCT00815243|bone
1288210|NCT00815243|joint
1288211|NCT00815243|telemedicine
1288212|NCT00815243|transportation
1288213|NCT00815243|decision making
1288214|NCT00815243|outcomes
1288215|NCT00815230|radiation injury
1288216|NCT00815230|computed tomography
1288217|NCT00815230|reactive oxygen species
1288218|NCT00815230|free radicals
1288219|NCT00815217|Lipoaspirate
1288220|NCT00815217|Diabetes Mellitus
1288221|NCT00815217|Mesenchymal Stem cells
1288222|NCT00815217|Fat grafts
1288223|NCT00815217|venous stasis
1288224|NCT00815204|PTSD
1288225|NCT00815204|HPA axis
1288226|NCT00815204|Pituitary volume
1288227|NCT00815191|temperature
1288228|NCT00815191|surgery
1288229|NCT00815191|heating device
1288230|NCT00815178|inspiratory muscle weakness
1288231|NCT00815178|autonomic modulation
1288232|NCT00815178|diabetes mellitus
1288233|NCT00815178|heart rate variability
1288234|NCT00815178|functional capacity
1288235|NCT00815165|cytomegalovirus, CMV, cell-mediated immunity, children, sub-study
1288236|NCT00815152|high grade glioma
1288237|NCT00815152|Coping skills intervention
1288238|NCT00815152|caregivers
1288239|NCT00815139|Coronary artery disease, stent
1288240|NCT00815113|Gastric cancer
1288241|NCT00815113|screening
1288242|NCT00815113|high-risk
1288243|NCT00815113|relatives
1288244|NCT00815113|gastroscopy
1288245|NCT00815100|Ivabradine
1288246|NCT00815100|Acute coronary syndrome.
1288247|NCT00815100|Inflammation
1288248|NCT00815100|C-reactive protein
1288249|NCT00815100|Atherosclerosis
1288250|NCT00815087|Nasopharyngeal carcinoma
1288251|NCT00815087|functional electrical stimulation
1288252|NCT00815074|Military Women
1288253|NCT00815074|Women's Health
1288254|NCT00815074|Genitourinary Symptoms
1288255|NCT00815074|Illness Behaviors
1288256|NCT00815074|To determine how women manage genitourinary symptoms while deployed.
1288257|NCT00815061|prevalence
1288258|NCT00815061|Incidence
1288259|NCT00815061|crohn's disease
1288260|NCT00815061|ulcerative colitis
1288261|NCT00815061|Epidemiology
1288262|NCT00815048|Remifentanil
1288263|NCT00815048|Endotracheal intubation
1288264|NCT00815048|Premedication
1288265|NCT00815048|Sedation
1288266|NCT00815048|Endotracheal Intubation in Neonates
1288267|NCT00815035|Peanut Allergy
1288268|NCT00815022|Temperature
1288269|NCT00815022|Spinal anesthesia
1288270|NCT00815022|Cesarean section
1288271|NCT00815022|Cephalad sensory blockade
1288272|NCT00815022|Regional anesthesia
1288273|NCT00815009|NAFLD
1288274|NCT00815009|NASH
1288275|NCT00814983|myeloablative
1288276|NCT00814983|stem cell
1288277|NCT00814983|naive T-cell depleted
1288278|NCT00814983|allogeneic
1288279|NCT00814970|PAD
1288280|NCT00814970|peripheral arterial disease
1288281|NCT00814970|stent
1288282|NCT00814970|SFA
1288283|NCT00814970|PPA
1288284|NCT00814957|positron emission tomography
1288285|NCT00814957|addiction
1288286|NCT00814944|dry eye
1288287|NCT00814944|sirolimus
1288288|NCT00814944|rapamycin
1288289|NCT00814918|acne vulgaris
1288290|NCT00814918|acne
1288291|NCT00814918|dermatalogy
1288292|NCT00814905|chorioamnionitis
1288293|NCT00814905|antibiotics
1288294|NCT00814905|cesarean
1288295|NCT00814905|vaginal delivery
1288296|NCT00814892|adenocarcinoma of the prostate
1288297|NCT00814892|recurrent prostate cancer
1288298|NCT00814892|stage I prostate cancer
1288299|NCT00814892|stage IIB prostate cancer
1288300|NCT00814892|stage IIA prostate cancer
1288301|NCT00814892|stage III prostate cancer
1288302|NCT00814892|stage IV prostate cancer
1288303|NCT00814879|Acquired Immune Deficiency Syndrome
1288304|NCT00814879|AIDS
1288305|NCT00814879|Anti-Infective Agents
1288306|NCT00814879|Antiretroviral
1288307|NCT00814879|Antiviral Agents
1288308|NCT00814879|Atazanavir
1288309|NCT00814879|Human Immunodeficiency Virus
1288310|NCT00814879|HIV
1288311|NCT00814879|HIV Protease Inhibitors
1288312|NCT00814879|NRTI
1288313|NCT00814879|Nucleoside Reverse Transcriptase Inhibitors
1288314|NCT00814879|Raltegravir
1288315|NCT00814879|Resistance
1288316|NCT00814879|treatment experienced
1288317|NCT00814866|Rheumatoid arthritis
1288318|NCT00814866|arthritis
1288319|NCT00814866|osteoclasts
1288320|NCT00814866|bone
1288321|NCT00814853|Extubation
1288322|NCT00814853|testing
1288323|NCT00814853|ventilator weaning
1288324|NCT00814853|Pediatric extubation
1288325|NCT00814840|Heart failure
1288326|NCT00814840|Dyssynchrony
1288327|NCT00814840|Cardiac resynchronization
1288328|NCT00814840|Triple-site pacing
1288329|NCT00814827|Interferon-Gamma
1288330|NCT00814827|Autoantibodies
1288331|NCT00814827|Mycobacteria
1288332|NCT00814827|Opportunistic Infections
1288333|NCT00814827|Immunodeficiency
1288334|NCT00814801|Alzheimer's Disease
1288335|NCT00814801|Cognitive dysfunction
1288336|NCT00814801|Dementia
1288337|NCT00814801|Galantamine
1288338|NCT00814801|R113675
1288339|NCT00814788|stage IV prostate cancer
1288340|NCT00814788|adenocarcinoma of the prostate
1288341|NCT00814788|recurrent prostate cancer
1288342|NCT00814775|Laryngeal mask
1288343|NCT00814775|Difficult intubation
1288344|NCT00814762|immunogenicity
1288345|NCT00814762|HIV
1288346|NCT00814762|reactogenicity
1288347|NCT00814762|safety
1288348|NCT00814762|vaccine
1288349|NCT00814762|HIV Infections
1288350|NCT00814749|stress urinary incontinence
1288351|NCT00814749|urodynamics
1288352|NCT00814749|randomized clinical trial
1288353|NCT00814749|surgery
1288354|NCT00814710|Pneumococcal disease
1288355|NCT00814710|Pneumococcal vaccine
1288356|NCT00814710|Safety
1288357|NCT00814710|Primary vaccination
1288358|NCT00814710|Immunogenicity
1288359|NCT00814697|Alzheimer
1288360|NCT00814697|Language
1288361|NCT00814697|Treatment
1288362|NCT00814697|TMS
1288363|NCT00814697|rTMS
1288364|NCT00814671|Tuberculosis
1288365|NCT00814671|Pharmacokinetics
1288366|NCT00814658|Dementia
1288367|NCT00814658|Mixed Dementia
1288368|NCT00814658|Galantamine
1288369|NCT00814658|Reminyl ER
1288370|NCT00814658|Nimodipine
1288371|NCT00814632|vulvodynia
1288372|NCT00814632|pelvic pain
1288373|NCT00814632|vulvar pain
1288374|NCT00814619|adenocarcinoma of the rectum
1288375|NCT00814619|stage III rectal cancer
1288376|NCT00814619|stage II rectal cancer
1288377|NCT00814606|genotype 1 hepatitis C
1288378|NCT00814606|hepatitis C
1288379|NCT00814606|HCV
1288380|NCT00814606|liver
1288381|NCT00814593|adult giant cell glioblastoma
1288382|NCT00814593|adult gliosarcoma
1288383|NCT00814593|adult glioblastoma
1288384|NCT00814580|analgesia
1288385|NCT00814580|postoperative pain
1288386|NCT00814580|opioid
1288387|NCT00814580|rotator cuff repair
1288388|NCT00814580|labral tear repair
1288389|NCT00814580|Bankart procedure
1288390|NCT00814580|oxycodone
1288391|NCT00814580|tapentadol
1288392|NCT00814580|arthroscopic shoulder surgery
1288393|NCT00814567|recurrent breast cancer
1288394|NCT00814567|stage IA breast cancer
1288395|NCT00814567|stage II breast cancer
1288396|NCT00814567|invasive ductal breast carcinoma
1288397|NCT00814567|invasive ductal breast carcinoma with predominant intraductal component
1288398|NCT00814554|obesity
1288399|NCT00814554|nutrition
1288400|NCT00814554|cluster randomized trial
1288401|NCT00814554|high school
1288402|NCT00814554|primary prevention
1288403|NCT00814541|refractory multiple myeloma
1288404|NCT00814541|stage I multiple myeloma
1288405|NCT00814541|stage II multiple myeloma
1288406|NCT00814541|stage III multiple myeloma
1288407|NCT00814528|actinic keratosis
1288408|NCT00814528|skin lesions
1288409|NCT00814528|5-ALA
1288410|NCT00814528|AK
1288411|NCT00814528|Blu-Light
1288412|NCT00814515|Moderate
1288413|NCT00814515|Severe
1288414|NCT00814515|Dry
1288415|NCT00814515|Eye
1288416|NCT00814515|Ciclosporin
1288417|NCT00814515|Cyclosporine
1288418|NCT00814502|Alzheimer disease
1288419|NCT00814502|Dementia, vascular
1288420|NCT00814502|Actigraphy
1288421|NCT00814502|Circadian dysregulation
1288422|NCT00814502|Sleep Disorders
1288423|NCT00814502|Circadian rhythm
1288424|NCT00814489|Non-typable Haemophilus influenzae
1288425|NCT00814489|protein vaccine
1288426|NCT00814489|Streptococcus pneumoniae
1288427|NCT00814489|young adults
1288428|NCT00814476|Medtronic CareLink
1288429|NCT00814476|therapy management
1288430|NCT00814476|diabetes
1288431|NCT00814476|insulin pump
1288432|NCT00814476|Blood glucose monitor
1288433|NCT00814463|tumors metastatic to brain
1288434|NCT00814463|unspecified adult solid tumor, protocol specific
1288435|NCT00814450|Biopsy
1288436|NCT00814450|Fine needle aspiration
1288437|NCT00813449|Endostar
1288438|NCT00813449|advanced melanoma
1288439|NCT00813449|combined chemotherapy
1288440|NCT00813436|ToM
1288441|NCT00813436|Theory of Mind
1288442|NCT00813436|Simulation
1288443|NCT00813436|Empathy
1288444|NCT00813436|Oxytocin
1288445|NCT00813436|Schizophrenia
1288446|NCT00813384|Cancer
1288447|NCT00813384|Solid Tumors
1288448|NCT00813384|Phase 1
1288449|NCT00813384|C-met inhibitor
1288450|NCT00813384|Clinical Trial
1288451|NCT00813371|Acute Respiratory Distress Syndrome
1288452|NCT00813371|acute lung injury
1288453|NCT00813371|Airway Pressure Release Ventilation
1288454|NCT00813371|ARDSnet
1288455|NCT00813371|Bi-level
1288456|NCT00813371|respiratory failure
1288457|NCT00813371|trauma
1288458|NCT00813371|APRV
1288459|NCT00814424|EtCO2
1288460|NCT00814424|supplemental oxygen delivery
1288461|NCT00814424|ERCP
1288462|NCT00814411|contraception
1288463|NCT00814411|noninferiority
1288464|NCT00814411|intention
1288465|NCT00814411|family planning counseling
1288466|NCT00814411|post abortion care
1288467|NCT00814411|Family planning intention among women with unmet need
1288468|NCT00814398|Infertility
1288469|NCT00814398|IVF
1288470|NCT00814398|SET
1288471|NCT00814398|DET
1288472|NCT00814398|Blastocyst
1288473|NCT00814359|mucositis
1288474|NCT00814359|radiation
1288475|NCT00814359|magic mouthwash
1288476|NCT00814359|sucralfate
1288477|NCT00814359|benzydamine
1288478|NCT00814359|diphenhydramine
1288479|NCT00814359|dexamethasone
1288480|NCT00814359|nystatin
1288481|NCT00814346|Mild Alzheimer's disease (AD) patients
1288482|NCT00814346|Memory complaint patients with cognitive impairment (MC)
1288483|NCT00814346|Memory complaint patients cognitively normal (CNE)
1288484|NCT00814333|epistaxis
1288485|NCT00814307|Antirheumatic Agents Clinical Trial
1288486|NCT00814294|Type 2
1288487|NCT00814281|particulate air pollution
1288488|NCT00814281|leukotriene
1288489|NCT00814281|asthma
1288490|NCT00814281|montelukast
1288491|NCT00814281|vascular endothelial dysfunction
1288492|NCT00814281|nitric oxide(NO)endothelin (ET) system
1288493|NCT00814255|Primary FSGS
1288494|NCT00814255|Steroid Resistant
1288495|NCT00814255|Rosiglitazone
1288496|NCT00814255|Adalimumab
1288497|NCT00814255|Resistant primary FSGS
1288498|NCT00814255|GALACTOSE
1288499|NCT00814242|Hepatocellular Carcinoma
1288500|NCT00814242|Adjacent to Major Blood Vessels
1288501|NCT00814242|Surgical resection
1288502|NCT00814242|Ppercutaneous radiationfrequency ablation
1288503|NCT00814242|Time to recurrence
1288504|NCT00814242|Disease-free survival
1288505|NCT00814242|Overall survival
1288506|NCT00814229|influenza
1288507|NCT00814229|H9N2
1288508|NCT00814229|vaccine
1288509|NCT00814216|Efficacy
1288510|NCT00814216|safety
1288511|NCT00814216|QAV680
1288512|NCT00814216|pharmacokinetics
1288513|NCT00814216|corticosteroid
1288514|NCT00814216|asthma
1288515|NCT00814203|COPD
1288516|NCT00814190|Type 2 Diabetes
1288517|NCT00814190|Internet Therapeutic Intervention
1288518|NCT00814177|warfarin
1288519|NCT00814177|dosing
1288520|NCT00814177|prothrombin time
1288521|NCT00814177|Heart valve prosthesis
1288522|NCT00814164|adult erythroleukemia (M6a)
1288523|NCT00814164|adult pure erythroid leukemia (M6b)
1288524|NCT00814164|adult acute megakaryoblastic leukemia (M7)
1288525|NCT00814164|adult acute minimally differentiated myeloid leukemia (M0)
1288526|NCT00814164|adult acute monoblastic leukemia (M5a)
1288527|NCT00814164|adult acute monocytic leukemia (M5b)
1288528|NCT00814164|adult acute myeloblastic leukemia with maturation (M2)
1288529|NCT00814164|adult acute myeloblastic leukemia without maturation (M1)
1288530|NCT00814164|adult acute myelomonocytic leukemia (M4)
1288531|NCT00814164|untreated adult acute myeloid leukemia
1288532|NCT00814164|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1288533|NCT00814164|adult acute myeloid leukemia with inv(16)(p13;q22)
1288534|NCT00814164|adult acute myeloid leukemia with t(16;16)(p13;q22)
1288535|NCT00814164|adult acute myeloid leukemia with t(8;21)(q22;q22)
1288536|NCT00814164|secondary acute myeloid leukemia
1288537|NCT00814151|Blood culture
1288538|NCT00814151|Staphylococcus aureus
1288539|NCT00814151|Bacteremia
1288540|NCT00814151|MRSA
1288541|NCT00814151|MSSA
1288542|NCT00814151|MicroPhage
1288543|NCT00814138|myasthenia gravis
1288544|NCT00814125|Endometrial
1288545|NCT00814125|Endometrial histological findings
1288546|NCT00814099|Acute Respiratory Failure
1288547|NCT00814099|Acute Lung Injury
1288548|NCT00814073|Mastocytosis with handicap
1288549|NCT00814073|Mastocytosis
1288550|NCT00814073|Smouldering systemic mastocytosis
1288551|NCT00814073|Indolent systemic mastocytosis
1288552|NCT00814073|Cutaneous mastocytosis
1288553|NCT00814073|Mast cell
1288554|NCT00814073|Mast cell infiltration
1288555|NCT00814073|Skin
1288556|NCT00814073|Bone marrow
1288557|NCT00814073|Pruritus
1288558|NCT00814073|Flushes
1288559|NCT00814073|c-kit
1288560|NCT00814073|c-kit mutation
1288561|NCT00814073|Wild Type
1288562|NCT00814073|Mutation Asp-816-Val(D816V)
1288563|NCT00814047|ultrasonography
1288564|NCT00814034|Aromatase Inhibitors
1288565|NCT00814034|Coagulation parameters
1288566|NCT00814034|Tamoxifen
1288567|NCT00814021|recurrent renal cell cancer
1288568|NCT00814021|stage IV renal cell cancer
1288569|NCT00814021|tumors metastatic to brain
1288570|NCT00813969|Mesenchymal Stem Cell
1288571|NCT00813969|MSC
1288572|NCT00813969|Autologous
1288573|NCT00813969|Multiple Sclerosis
1288574|NCT00813956|triple negative breast cancer
1288575|NCT00813943|Newly diagnosed Glioblastoma (WHO Grade IV)
1288576|NCT00813943|Cilengitide
1288577|NCT00813943|Temozolomide
1288578|NCT00813943|Radiotherapy
1288579|NCT00813930|Diabetes
1288580|NCT00813930|Lifestyle Intervention
1288581|NCT00813930|Cardiovascular risk reduction
1288582|NCT00813891|ranibizumab
1288583|NCT00813891|verteporfin
1288584|NCT00813878|breast cancer
1288585|NCT00813878|breast cancer in situ
1288586|NCT00813852|obstructive sleep apnea
1288587|NCT00813852|skeletal muscle
1288588|NCT00813852|magnetic stimulation
1288589|NCT00813852|magnetic resonance spectroscopy
1288590|NCT00813852|inflammatory markers
1288591|NCT00813852|exercise
1288592|NCT00813839|SmartCare
1288593|NCT00813839|Spontaneous Breathing Trials
1288594|NCT00813839|Mechanical Ventilation
1288595|NCT00813839|Weaning
1288596|NCT00813839|Patients requiring prolonged mechanical ventilation (>72 hours)
1288597|NCT00813826|PHN
1288598|NCT00813826|Pain after Shingles
1288599|NCT00813800|Smoking
1288600|NCT00813800|Bipolar Disorder
1288601|NCT00813800|Depression
1288602|NCT00813787|Magnetic Resonance Imaging
1288603|NCT00813787|Glioma
1288604|NCT00813774|Cimzia
1288605|NCT00813774|certolizumab pegol
1288606|NCT00813774|Bioavailability
1288607|NCT00813774|Healthy volunteers
1288608|NCT00813748|Asthma
1288609|NCT00813748|Anaphylaxis
1288610|NCT00813735|Insomnia
1288611|NCT00813735|Major Depression
1288612|NCT00813735|Geriatric
1288613|NCT00813722|adherence
1288614|NCT00813722|blood pressure
1288615|NCT00813722|hypertension
1288616|NCT00813722|compliance
1288617|NCT00813722|atenolol
1288618|NCT00813722|hydrochlorothiazide
1288619|NCT00813722|amlodipine
1288620|NCT00813722|losartan
1288621|NCT00813709|Interferon 1-beta
1288622|NCT00813709|Clinical Definite Multiple Sclerosis
1288623|NCT00813696|chemotherapy
1288624|NCT00813696|advanced cancer
1288625|NCT00813696|inoperable
1288626|NCT00813696|Stage II, III, IV
1288627|NCT00813683|Acupuncture, moxybustion,
1288628|NCT00813683|Cephalic version,
1288629|NCT00813683|Breech presentation
1288630|NCT00813631|Malignant fungating wound
1288631|NCT00813631|Head and neck
1288632|NCT00813631|Ionic silver-releasing dressing
1288633|NCT00813631|Wound care
1288634|NCT00813631|RCT
1288635|NCT00813618|Acute GvHD of at least Grade II severity
1288636|NCT00813605|AMG 655
1288637|NCT00813605|AMG 479
1288638|NCT00813605|Colon Cancer
1288639|NCT00813605|Rectal Cancer
1288640|NCT00813605|Monoclonal Antibody
1288641|NCT00813605|Clinical Trial
1288642|NCT00813605|Colorectal Cancer
1288643|NCT00813605|metastatic colorectal cancer
1288644|NCT00813605|metastatic cancer
1288645|NCT00813605|antibody-2nd line
1288646|NCT00813605|KRAS
1288647|NCT00813605|adenocarcinoma
1288648|NCT00813592|meningioma
1288649|NCT00813592|brain
1288650|NCT00813579|assess the safety of living kidney donation
1288651|NCT00813566|cancer
1288652|NCT00813566|imaging
1288653|NCT00813566|PET scanning
1288654|NCT00813553|physical fitness
1288655|NCT00813553|exercise
1288656|NCT00813553|amino acid
1288657|NCT00813540|Colonic Neoplasms
1288658|NCT00813540|Aerobic Exercise
1288659|NCT00813540|Weight Lifting
1288660|NCT00813540|Body Composition
1288661|NCT00813527|Drug Therapy
1288662|NCT00813527|Lipid Metabolism Disorders
1288663|NCT00813527|Hyperlipidemias
1288664|NCT00813527|Hypercholesterolemia
1288665|NCT00813527|Hypertriglyceridemia
1288666|NCT00813514|AMD
1288667|NCT00813514|VEGF genotyping
1288668|NCT00813514|complement H gene polymorphism
1288669|NCT00813514|Vascular Endothelial Growth Factor A
1288670|NCT00813501|graft versus host disease
1288671|NCT00813501|infection
1288672|NCT00813501|therapy-related toxicity
1288673|NCT00813501|stage III adult Burkitt lymphoma
1288674|NCT00813501|stage III adult diffuse large cell lymphoma
1288675|NCT00813501|stage III adult diffuse mixed cell lymphoma
1288676|NCT00813501|stage III adult diffuse small cleaved cell lymphoma
1288677|NCT00813501|stage III adult Hodgkin lymphoma
1288678|NCT00813501|stage III adult immunoblastic large cell lymphoma
1288679|NCT00813501|stage III adult lymphoblastic lymphoma
1288680|NCT00813501|stage III grade 1 follicular lymphoma
1288681|NCT00813501|stage III grade 2 follicular lymphoma
1288682|NCT00813501|stage III grade 3 follicular lymphoma
1288683|NCT00813501|stage III mantle cell lymphoma
1288684|NCT00813501|stage III marginal zone lymphoma
1288685|NCT00813501|stage III small lymphocytic lymphoma
1288686|NCT00813501|stage IV adult Burkitt lymphoma
1288687|NCT00813501|stage IV adult diffuse large cell lymphoma
1288688|NCT00813501|stage IV adult diffuse mixed cell lymphoma
1288689|NCT00813501|stage IV adult diffuse small cleaved cell lymphoma
1288690|NCT00813501|stage IV adult Hodgkin lymphoma
1288691|NCT00813501|stage IV adult immunoblastic large cell lymphoma
1288692|NCT00813501|stage IV adult lymphoblastic lymphoma
1288693|NCT00813501|stage IV grade 1 follicular lymphoma
1288694|NCT00813501|stage IV grade 2 follicular lymphoma
1288695|NCT00813501|stage IV grade 3 follicular lymphoma
1288696|NCT00813501|stage IV mantle cell lymphoma
1288697|NCT00813501|stage IV marginal zone lymphoma
1288698|NCT00813501|stage IV small lymphocytic lymphoma
1288699|NCT00813501|recurrent adult Burkitt lymphoma
1288700|NCT00813501|recurrent adult diffuse large cell lymphoma
1288701|NCT00813501|recurrent adult diffuse mixed cell lymphoma
1288702|NCT00813501|recurrent adult diffuse small cleaved cell lymphoma
1288703|NCT00813501|recurrent adult Hodgkin lymphoma
1288704|NCT00813501|recurrent adult immunoblastic large cell lymphoma
1288705|NCT00813501|recurrent adult lymphoblastic lymphoma
1288706|NCT00813501|recurrent cutaneous T-cell non-Hodgkin lymphoma
1288707|NCT00813501|recurrent grade 1 follicular lymphoma
1288708|NCT00813501|recurrent grade 2 follicular lymphoma
1288709|NCT00813501|recurrent grade 3 follicular lymphoma
1288710|NCT00813501|recurrent mantle cell lymphoma
1288711|NCT00813501|recurrent marginal zone lymphoma
1288712|NCT00813501|recurrent small lymphocytic lymphoma
1288713|NCT00813501|recurrent mycosis fungoides/Sezary syndrome
1288714|NCT00813501|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1288715|NCT00813501|nodal marginal zone B-cell lymphoma
1288716|NCT00813501|splenic marginal zone lymphoma
1288717|NCT00813501|noncontiguous stage II adult Burkitt lymphoma
1288718|NCT00813501|noncontiguous stage II adult diffuse large cell lymphoma
1288719|NCT00813501|noncontiguous stage II adult diffuse mixed cell lymphoma
1288720|NCT00813501|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1288721|NCT00813501|noncontiguous stage II adult immunoblastic large cell lymphoma
1288722|NCT00813501|noncontiguous stage II adult lymphoblastic lymphoma
1288723|NCT00813501|noncontiguous stage II grade 1 follicular lymphoma
1288724|NCT00813501|noncontiguous stage II grade 2 follicular lymphoma
1288725|NCT00813501|noncontiguous stage II grade 3 follicular lymphoma
1288726|NCT00813501|noncontiguous stage II mantle cell lymphoma
1288727|NCT00813501|noncontiguous stage II marginal zone lymphoma
1288728|NCT00813501|noncontiguous stage II small lymphocytic lymphoma
1288729|NCT00813501|accelerated phase chronic myelogenous leukemia
1288730|NCT00813501|adult acute lymphoblastic leukemia in remission
1288731|NCT00813501|adult acute myeloid leukemia in remission
1288732|NCT00813501|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1288733|NCT00813501|adult acute myeloid leukemia with inv(16)(p13;q22)
1288734|NCT00813501|adult acute myeloid leukemia with t(15;17)(q22;q12)
1288735|NCT00813501|adult acute myeloid leukemia with t(16;16)(p13;q22)
1288736|NCT00813501|adult acute myeloid leukemia with t(8;21)(q22;q22)
1288737|NCT00813501|atypical chronic myeloid leukemia, BCR-ABL negative
1288738|NCT00813501|blastic phase chronic myelogenous leukemia
1288739|NCT00813501|chronic myelomonocytic leukemia
1288740|NCT00813501|chronic phase chronic myelogenous leukemia
1288741|NCT00813501|recurrent adult acute lymphoblastic leukemia
1288742|NCT00813501|recurrent adult acute myeloid leukemia
1288743|NCT00813501|refractory chronic lymphocytic leukemia
1288865|NCT00813111|Postsurgical pain
1288744|NCT00813501|refractory hairy cell leukemia
1288745|NCT00813501|relapsing chronic myelogenous leukemia
1288746|NCT00813501|secondary acute myeloid leukemia
1288747|NCT00813501|stage III chronic lymphocytic leukemia
1288748|NCT00813501|stage IV chronic lymphocytic leukemia
1288749|NCT00813501|chronic eosinophilic leukemia
1288750|NCT00813501|primary myelofibrosis
1288751|NCT00813501|chronic neutrophilic leukemia
1288752|NCT00813501|de novo myelodysplastic syndromes
1288753|NCT00813501|disseminated neuroblastoma
1288754|NCT00813501|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1288755|NCT00813501|previously treated myelodysplastic syndromes
1288756|NCT00813501|secondary myelodysplastic syndromes
1288757|NCT00813501|stage I multiple myeloma
1288758|NCT00813501|stage II multiple myeloma
1288759|NCT00813501|stage III multiple myeloma
1288760|NCT00813501|refractory multiple myeloma
1288761|NCT00813488|Breakthrough Pain
1288762|NCT00813488|Opioid-tolerant
1288763|NCT00813488|Chronic Pain
1288764|NCT00813475|cardio vascular outcome
1288765|NCT00813358|Endovascular Aneurysm Repair
1288766|NCT00813358|Aortic Aneurysm
1288767|NCT00813358|Thoracic
1288768|NCT00813345|anesthesia propofol ambulatory rhythm
1288769|NCT00813332|Endostar
1288770|NCT00813332|NSCLC
1288771|NCT00813332|Docetaxel
1288772|NCT00813332|Combined therapy
1288773|NCT00813332|second-line chemotherapy
1288774|NCT00813319|GARDASIL
1288775|NCT00813319|HPV
1288776|NCT00813319|Vaccination
1288777|NCT00813306|GERD
1288778|NCT00813306|TLESR
1288779|NCT00813306|reflux
1288780|NCT00813293|Hepatocellular Cancer
1288781|NCT00813293|HCC
1288782|NCT00813293|Liver Cancer
1288783|NCT00813293|radiofrequency ablation
1288784|NCT00813293|RFA
1288785|NCT00813293|sorafenib
1288786|NCT00813293|nexavaar
1288787|NCT00813293|liver directed therapy
1288788|NCT00813293|interventional radiology
1288789|NCT00813267|Mesenchymal Stem Cells
1288790|NCT00813267|Osteonecrosis of the Femoral Head
1288791|NCT00813254|Platinum-Resistant Ovarian Cancer
1288792|NCT00813254|Platinum-based chemotherapy
1288793|NCT00813254|Ovarian Cancer
1288794|NCT00813254|Ovary
1288795|NCT00813254|Epithelial ovarian cancer
1288796|NCT00813254|Quality of Life
1288797|NCT00813254|Cost Utility Analysis
1288798|NCT00813254|Sexual functioning
1288799|NCT00813254|Questionnaire
1288800|NCT00813254|Caregiver
1288801|NCT00813241|Ankylosing spondylitis,Rheumatoid Arthritis,Adenomatous Polyposis Coli,Osteoarthritis,Dysmenorrhoea,pharmacokinetic study
1288802|NCT00813228|Immune Function
1288803|NCT00813228|DDP-4
1288804|NCT00813228|Sitagliptin
1288805|NCT00813228|GLP-1
1288806|NCT00813228|TGF Beta
1288807|NCT00813215|Type 2 diabetes mellitus
1288808|NCT00813215|Postprandial dysmetabolism
1288809|NCT00813215|Postprandial inflammation
1288810|NCT00813215|Relatives
1288811|NCT00813215|Meal challenge
1288812|NCT00813202|Nesiritide
1288813|NCT00813202|Natrecor
1288814|NCT00813202|Quanke
1288815|NCT00813202|Acute Decompensated Heart Failure
1288816|NCT00813189|glucocorticoid therapy
1288817|NCT00813189|muscle function
1288818|NCT00813189|growth hormone treatment
1288819|NCT00813176|Obesity
1288820|NCT00813176|One-Lung Ventilation
1288821|NCT00813176|Anesthesia
1288822|NCT00813176|Thoracic
1288823|NCT00813176|One-lung ventilation in the morbidly obese patient
1288824|NCT00813163|Phase II study
1288825|NCT00813163|Second line
1288826|NCT00813163|Pancreatic cancer
1288827|NCT00813163|Metastatic
1288828|NCT00813150|Multiple myeloma
1288829|NCT00813150|Bortezomib
1288830|NCT00813150|Dexamethasone
1288831|NCT00813150|Cyclophosphamide
1288832|NCT00813150|Oncology
1288833|NCT00813137|Colorectal Cancer
1288834|NCT00813137|chemotherapy
1288835|NCT00813137|recombinant human endostatin
1288836|NCT00813124|Chronic Myelogenous Leukemia
1288837|NCT00813124|CML
1288838|NCT00813124|Donor stem cell transplant
1288839|NCT00813124|Allogeneic stem cell transplantation
1288840|NCT00813124|Stem cell transplant
1288841|NCT00813124|ATG
1288842|NCT00813124|Antithymocyte globulin
1288843|NCT00813124|Vidaza
1288844|NCT00813124|Azacitidine
1288845|NCT00813124|5-Azacitidine
1288846|NCT00813124|5-Aza
1288847|NCT00813124|5-AZC
1288848|NCT00813124|Ladakamycin
1288849|NCT00813124|NSC-102816
1288850|NCT00813124|allotx
1288851|NCT00813124|Busulfan
1288852|NCT00813124|Busulfex
1288853|NCT00813124|Myleran
1288854|NCT00813124|Fludarabine
1288855|NCT00813124|Fludarabine Phosphate
1288856|NCT00813124|Tacrolimus
1288857|NCT00813124|Methotrexate
1288858|NCT00813124|Azacitidine maintenance therapy
1288859|NCT00813124|molecular remission
1288860|NCT00813124|HLA compatible donor
1288861|NCT00813124|Engraftment
1288862|NCT00813124|Chimerism
1288863|NCT00813124|Graft vs host disease
1288864|NCT00813124|GVHD
1288866|NCT00813111|Analgesia
1288867|NCT00813111|Breast augmentation
1288868|NCT00813085|Diabetes
1288869|NCT00813085|Computerized clinical decision support
1288870|NCT00813085|shared care
1288871|NCT00813085|patient self-monitoring
1288872|NCT00813085|quality of care
1288873|NCT00813085|complex interventions
1288874|NCT00813085|composite outcomes
1288875|NCT00813072|Gastric Cancer
1288876|NCT00813072|Stomach Cancer
1288877|NCT00813072|Gastroesophageal
1288878|NCT00813072|Gastroesophageal Junction
1288879|NCT00813072|Esophageal Cancer
1288880|NCT00813072|phase II
1288881|NCT00813072|PEP02
1288882|NCT00813072|randomization
1288883|NCT00813072|randomisation
1288884|NCT00813072|adenocarcinoma
1288885|NCT00813072|locally advanced
1288886|NCT00813072|metastatic
1288887|NCT00813072|simon's two
1288888|NCT00813059|NAION
1288889|NCT00813059|bevacizumab
1288890|NCT00813033|create a patient decision aid for endoscopy
1288891|NCT00813033|evaluate efficacy of a patient decision aid for endoscopy
1288892|NCT00813007|Cervical Cancer
1288893|NCT00813007|Cervix
1288894|NCT00813007|Questionnaire
1288895|NCT00813007|Adenocarcinoma of uterine cervix
1288896|NCT00813007|Squamous cell carcinoma of uterine cervix
1288897|NCT00813007|Adenosquamous carcinoma of uterine cervix
1288898|NCT00813007|Abdominal radical trachelectomy
1288899|NCT00813007|Trachelectomy
1288900|NCT00813007|Quality of life
1288901|NCT00813007|Sexual functioning
1288902|NCT00812994|Depression
1288903|NCT00812994|BDNF
1288904|NCT00812994|neurotrophic factor
1288905|NCT00812994|neurosetroid
1288906|NCT00812994|allopregnanolone
1288907|NCT00812981|Pandemic influenza
1288908|NCT00812968|Myelodysplastic Syndromes
1288909|NCT00812968|Lenalidomide
1288910|NCT00812955|Dyslipidemia
1288911|NCT00812955|Hypercholesterolemia
1288912|NCT00812955|Hypertriglyceridemia
1288913|NCT00812942|average-risk subjects for
1288914|NCT00812929|Asthma, Exercise Induced Asthma, Exercise Induced Bronchospasm
1288915|NCT00812916|Persistent or longstanding persistent atrial fibrillation
1288916|NCT00812903|Neck
1288917|NCT00812903|Pain
1288918|NCT00812903|Exercise
1288919|NCT00812903|Pilots
1288920|NCT00812903|Crew
1288921|NCT00812877|pulp capping
1288922|NCT00812877|MTA
1288923|NCT00812877|CaOH
1288924|NCT00812877|Mineral Trioxide Aggregate
1288925|NCT00812877|Calcium Hydroxide
1288926|NCT00812864|Capecitabine
1288927|NCT00812864|pharmacocinetics
1288928|NCT00812864|Breast metastatic cancer
1288929|NCT00812864|colorectal metastatic cancer
1288930|NCT00812864|Elderly patients
1288931|NCT00812851|ALS
1288932|NCT00812851|cramps
1288933|NCT00812851|THC
1288934|NCT00812851|Dronabinol
1288935|NCT00812825|Safety Tolerability Pharmacokinetics/pharmacodynamics
1288936|NCT00812812|paroxetine
1288937|NCT00812812|selective serotonin reuptake inhibitor
1288938|NCT00812812|CDRS-R
1288939|NCT00812812|children and adolescents
1288940|NCT00812799|randomised
1288941|NCT00812799|double-blind
1288942|NCT00812799|placebo-controlled
1288943|NCT00812799|efficacy and safety
1288944|NCT00812799|Oralgen® Grass Pollen
1288945|NCT00812799|allergic rhinoconjunctivitis
1288946|NCT00812799|allergy
1288947|NCT00812799|rhinoconjunctivitis
1288948|NCT00812799|immunotherapy
1288949|NCT00812799|grass pollen extract
1288950|NCT00812786|heart transplantation
1288951|NCT00812786|immunosuppressive drugs
1288952|NCT00812786|individual dose adjustment
1288953|NCT00812786|harmacokinetics
1288954|NCT00812786|modelling
1288955|NCT00812773|GSK2190915
1288956|NCT00812773|Repeat
1288957|NCT00812773|Oral
1288958|NCT00812773|Dose
1288959|NCT00812773|Challenge
1288960|NCT00812773|Asthma
1288961|NCT00812773|Allergen
1288962|NCT00812760|Electroretinography
1288963|NCT00812760|levodopa
1288964|NCT00812747|surgical wound infection
1288965|NCT00812747|risk factor
1288966|NCT00812734|Neuropathic pain
1288967|NCT00812734|chronic pain
1288968|NCT00812734|postoperative
1288969|NCT00812734|surgery
1288970|NCT00812734|anesthesiology
1288971|NCT00812734|Scheduled surgery
1288972|NCT00812721|higher order aberrations
1288973|NCT00812721|tear blur
1288974|NCT00812708|aniridia
1288975|NCT00812708|Morcher iris diaphragms
1288976|NCT00812708|modified capsule tension ring
1288977|NCT00812708|artificial iris
1288978|NCT00812708|iris reconstruction lens
1288979|NCT00812708|glare sensitivity
1288980|NCT00812708|photophobia
1288981|NCT00812695|Obstructive sleep apnea
1288982|NCT00812695|Refractory hypertension
1288983|NCT00812695|Heart remodeling
1288984|NCT00812695|Arterial stiffness
1288985|NCT00812695|CPAP
1288986|NCT00812682|SYMBICORT AMD
1288987|NCT00812669|B-cell chronic lymphocytic leukemia
1288988|NCT00812669|refractory chronic lymphocytic leukemia
1289110|NCT00812058|Bipolar Depression
1288989|NCT00812669|stage I chronic lymphocytic leukemia
1288990|NCT00812669|stage II chronic lymphocytic leukemia
1288991|NCT00812669|stage III chronic lymphocytic leukemia
1288992|NCT00812669|stage IV chronic lymphocytic leukemia
1288993|NCT00812643|pharmacokinetics
1288994|NCT00812630|male hormonal contraception
1288995|NCT00812630|Blood pressure, sperm concentration
1288996|NCT00812578|Type 2 diabetes
1288997|NCT00812578|Vitamin D insufficiency
1288998|NCT00812578|Insulin secretion
1288999|NCT00812578|Insulin sensitivity
1289000|NCT00812578|Pulsatility
1289001|NCT00812539|Diabetes
1289002|NCT00812539|Blood glucose monitoring
1289003|NCT00812539|Internet
1289004|NCT00812526|Choroid
1289005|NCT00812526|Regional blood flow
1289006|NCT00812526|Autoregulation
1289007|NCT00812526|Laser Doppler flowmetry
1289008|NCT00812513|rhPDGF-BB
1289009|NCT00812513|Platelet derived growth factor
1289010|NCT00812513|Burns
1289011|NCT00812513|Thermal burns
1289012|NCT00812513|Electric burns
1289013|NCT00812500|assess the effect of age on the EAR and RDA for protein
1289014|NCT00812487|congestive heart failure
1289015|NCT00812487|diabetes mellitus
1289016|NCT00812487|hyperglycemia
1289017|NCT00812474|cerebral blood flow
1289018|NCT00812461|Pharmacologic Actions
1289019|NCT00812461|Alcohol-Related Disorders
1289020|NCT00812461|Alcoholism
1289021|NCT00812461|Mental Disorders
1289022|NCT00812461|Central Nervous System Agents
1289023|NCT00812448|prophylaxis
1289024|NCT00812448|influenza infection
1289025|NCT00812448|catechins
1289026|NCT00812448|prophylaxis of influenza infection
1289027|NCT00812435|STEMI
1289028|NCT00812435|Patients
1289029|NCT00812435|male or female
1289030|NCT00812435|greater than 18 years of age
1289031|NCT00812435|presenting with ST elevation myocardial infarction
1289032|NCT00812422|Fever due to acute upper respiratory tract infection
1289033|NCT00812409|Measuring markers of metabolic syndrome in overweight and obese adults.
1289034|NCT00812396|Biomarkers of muscle anabolism
1289035|NCT00812370|DVT
1289036|NCT00812370|Deep Venous Thrombosis
1289037|NCT00812370|UNBLOCK
1289038|NCT00812370|Bivalirudin
1289039|NCT00812370|Angiomax
1289040|NCT00812357|Symbicort Turbuhaler
1289041|NCT00812357|asthma
1289042|NCT00812357|cohort study
1289043|NCT00812357|France
1289044|NCT00812344|pharmacokinetics
1289045|NCT00812331|Hepatitis C
1289046|NCT00812331|TMC435
1289047|NCT00812318|HIV infected subjects
1289048|NCT00812318|Healthy volunteer
1289049|NCT00812318|GSK1265744.
1289050|NCT00812292|TMC278
1289051|NCT00812292|TMC278-C145
1289052|NCT00812292|TMC278-TiDP38-C145
1289053|NCT00812292|concept pediatric formulations of TMC278
1289054|NCT00812292|HIV Infections
1289055|NCT00812279|Smokers with acceptable health conditions
1289056|NCT00812266|SCLC
1289057|NCT00812266|Extensive disease
1289058|NCT00812266|topotecan
1289059|NCT00812253|Heart failure
1289060|NCT00812253|Hyperglycemia
1289061|NCT00812253|Hospital
1289062|NCT00812253|Diabetes Mellitus
1289063|NCT00812240|Gastro-Intestinal Stromal Tumour
1289064|NCT00812240|GIST
1289065|NCT00812240|non resectable
1289066|NCT00812240|recurrent post-surgery
1289067|NCT00812240|first line of treatment
1289068|NCT00812240|metastatic
1289069|NCT00812240|locally advanced
1289070|NCT00812227|Depression
1289071|NCT00812227|Psychotherapy
1289072|NCT00812227|Neuroimaging
1289073|NCT00812227|Subjects with Major Depressive Disorder (MDD)
1289074|NCT00812214|insomnia
1289075|NCT00812214|migraine
1289076|NCT00812214|eszopiclone
1289077|NCT00812214|insomnia in migraineurs
1289078|NCT00812201|Heart failure
1289079|NCT00812201|auto threshold
1289080|NCT00812201|pacing
1289081|NCT00812201|CRT-P or CRT-D recipients, threshold measurements
1289082|NCT00812188|Morphea
1289083|NCT00812188|Plaque morphea
1289084|NCT00812188|Localized Scleroderma
1289085|NCT00812175|Hepatocellular Carcinoma
1289086|NCT00812175|HCC
1289087|NCT00812175|Sorafenib
1289088|NCT00812149|Type-2 Deiodinase
1289089|NCT00812149|Genetic Polymorphism
1289090|NCT00812149|Triiodothyronine (T3)
1289091|NCT00812149|Thyrotropin Releasing Hormone (TRH) Test
1289092|NCT00812136|Using Parent Mentors to Improve Asthma Care for Urban Minority Children
1289093|NCT00812123|kidney transplantation
1289094|NCT00812123|calcineurin inhibitor free
1289095|NCT00812123|protocol biopsy
1289096|NCT00812123|Cyclosporin A
1289097|NCT00812123|Sirolimus
1289098|NCT00812110|Influenza prevention
1289099|NCT00812097|Breast Augmentation
1289100|NCT00812097|Breast Reconstruction
1289101|NCT00812097|Breast Revision
1289102|NCT00812097|Silicone gel
1289103|NCT00812097|Contour Profile Gel
1289104|NCT00812097|Siltex®
1289105|NCT00812084|Quality of life
1289106|NCT00812084|health resources
1289107|NCT00812084|costs
1289108|NCT00812084|community-acquired pneumonia
1289109|NCT00812071|volunteers
1289111|NCT00812058|Bipolar Disease
1289112|NCT00812058|Bipolar Disorder
1289113|NCT00812058|Bipolar
1289114|NCT00812058|Manic Depression
1289115|NCT00812058|Manic Depressive Disorder
1289116|NCT00812045|Induced sputum
1289117|NCT00812045|cystic fibrosis
1289118|NCT00812045|biomarker
1289119|NCT00812045|CYBER
1289120|NCT00812032|NIDDM
1289121|NCT00812032|Aspirin
1289122|NCT00812032|platelet inhibition
1289123|NCT00812032|Aspirin treatment
1289124|NCT00812019|H5N1 Influenza
1289125|NCT00812019|Pandemic Flu
1289126|NCT00812019|MF59 Adjuvant
1289127|NCT00812019|Cell Culture-Derived
1289128|NCT00812019|Safety
1289129|NCT00812019|Immunogenicity
1289130|NCT00812019|Vaccination
1289131|NCT00812019|H5N1 influenza pandemic
1289132|NCT00811954|Treatment naive
1289133|NCT00811954|Treatment inexperienced
1289134|NCT00811941|Pharmacologic Actions
1289135|NCT00811941|Alcohol-Related Disorders
1289136|NCT00811941|Alcoholism
1289137|NCT00811941|Mental Disorders
1289138|NCT00811941|Central Nervous System Agents
1289139|NCT00811928|high-risk leukopenic patients
1289140|NCT00811915|Sirolimus
1289141|NCT00811915|Tacrolimus
1289142|NCT00811915|Kidney transplantation
1289143|NCT00811915|Kidney Transplant Recipients
1289144|NCT00811902|Multiple sclerosis
1289145|NCT00811876|Prostate cancer
1289146|NCT00811863|Nephrogenic Systemic Fibrosis
1289147|NCT00811863|Renal Insufficiency
1289148|NCT00811863|Gadoversetamide
1289149|NCT00811863|OptiMARK
1289150|NCT00811863|Magnetic Resonance Imaging
1289151|NCT00811837|Sunburn
1289152|NCT00811837|Remifentanil
1289153|NCT00811837|Hyperalgesia
1289154|NCT00811824|Weight loss
1289155|NCT00811824|Physical activity
1289156|NCT00811824|Dietary change
1289157|NCT00811811|Hypertension
1289158|NCT00811811|Biofeedback
1289159|NCT00811811|Relaxation training
1289160|NCT00811798|Hong Kong
1289161|NCT00811798|Human papillomavirus
1289162|NCT00811798|Safety
1289167|NCT00811772|Randomized controlled trial
1289168|NCT00811772|Bare metal stent
1289169|NCT00811772|Drug eluting stent
1289170|NCT00811759|stage IV melanoma
1289171|NCT00811759|stage III melanoma
1289172|NCT00811759|recurrent melanoma
1289173|NCT00811746|obstructive sleep apnea
1289174|NCT00811746|eszopiclone
1289175|NCT00811746|ramelteon
1289176|NCT00811746|polysomnography
1289177|NCT00811733|Waldenstrom's Macroglobulinemia
1289178|NCT00811733|Ofatumumab
1289179|NCT00811720|Alcohol-Related Disorders
1289180|NCT00811720|Alcoholism
1289181|NCT00811720|Mental Disorders
1289182|NCT00811720|Central Nervous System Agents
1289183|NCT00811707|ultrasound image
1289184|NCT00811707|epidural space
1289185|NCT00811694|glaucoma
1289186|NCT00811694|ficker stimulation
1289187|NCT00811694|ocular blood flow
1289188|NCT00811681|Friedreich's ataxia
1289189|NCT00811681|Pioglitazone
1289190|NCT00811668|Sleep Apnea Syndromes
1289191|NCT00811668|heart diseases
1289192|NCT00811655|tumors metastatic to brain
1289193|NCT00811655|unspecified adult solid tumor, protocol specific
1289194|NCT00811642|refractory or first line medication intolerable invasive fungal infection
1289195|NCT00811629|Receptor for advanced glycation end products (RAGE)
1289196|NCT00811629|Soluble RAGE (sRAGE)
1289197|NCT00811629|Acute Lung Injury (ALI)
1289325|NCT00811252|Acute treatment
1289198|NCT00811629|Acute respiratory distress syndrome (ARDS)
1289199|NCT00811629|Severe sepsis
1289200|NCT00811629|Septic shock
1289201|NCT00811629|Alveolar epithelium
1289202|NCT00811629|Mechanical ventilation
1289203|NCT00811629|Intensive Care Unit (ICU)
1289204|NCT00811616|Coronary artery disease
1289205|NCT00811616|Supralimus-Core™
1289206|NCT00811616|de novo native coronary artery lesion
1289207|NCT00811603|Antibiotic
1289208|NCT00811603|Prophylaxis
1289209|NCT00811603|Cesarean
1289210|NCT00811603|Infection
1289211|NCT00811603|Antibiotic prophylaxis
1289212|NCT00811590|Cancer
1289213|NCT00811590|Polyps
1289214|NCT00811577|AZX100
1289215|NCT00811577|Patient and Observer Scar Assessment Scale
1289216|NCT00811577|POSAS
1289217|NCT00811577|Visual Analog Scale
1289218|NCT00811577|VAS
1289219|NCT00811577|Trocar
1289220|NCT00811577|Scarring
1289221|NCT00811577|Scar reduction
1289222|NCT00811577|Scar prevention
1289223|NCT00811551|Heart Failure
1289224|NCT00811551|Impedance Monitoring
1289225|NCT00811551|Wedge Pressure
1289226|NCT00811538|ischemic stroke
1289227|NCT00811538|endovascular treatment
1289228|NCT00811538|Thrombolysis
1289229|NCT00811538|outcome
1289230|NCT00811525|Breast Augmentation
1289231|NCT00811525|Breast Reconstruction
1289232|NCT00811525|Breast Revision
1289233|NCT00811525|Silicone gel
1289234|NCT00811525|Contour Profile Gel
1289235|NCT00811525|Siltex
1289236|NCT00811512|retina
1289237|NCT00811512|fold
1289238|NCT00811512|fovea
1289239|NCT00811473|Bipolar Depression
1289240|NCT00811473|Depression
1289241|NCT00811473|Children
1289242|NCT00811473|Adolescents
1289243|NCT00811473|Seroquel
1289244|NCT00811473|Bipolar Depression in Children and Adolescents
1289245|NCT00811434|encephalopathy
1289246|NCT00811434|pediatric liver disease
1289247|NCT00811434|pediatric cirrhosis
1289248|NCT00811434|serum ammonia levels
1289249|NCT00811421|Malaria
1289250|NCT00811421|Pregnancy
1289251|NCT00811421|HIV
1289252|NCT00811421|Prevention
1289253|NCT00811421|Malaria prevention
1289254|NCT00811408|human papilloma virus infection
1289255|NCT00811408|cervical squamous cell carcinoma
1289256|NCT00811408|cervical adenocarcinoma
1289257|NCT00811408|stage IB cervical cancer
1289258|NCT00811408|stage II cervical cancer
1289259|NCT00811408|stage III cervical cancer
1289260|NCT00811408|stage IVA cervical cancer
1289261|NCT00811382|CRT
1289262|NCT00811382|therapy of AF
1289263|NCT00811382|telecardiology
1289264|NCT00811382|home monitoring
1289265|NCT00811382|cardiovascular hospitalization
1289266|NCT00811382|cardiovascular mortality
1289267|NCT00811369|Breast Cancer
1289268|NCT00811369|Bone Metastases
1289269|NCT00811369|Telopeptide
1289270|NCT00811369|Zactima
1289271|NCT00811369|Fulvestrant
1289272|NCT00811356|Food Effect
1289273|NCT00811356|Drug-Drug Interaction
1289274|NCT00811356|Antimalarial
1289275|NCT00811356|First Time In Human
1289276|NCT00811356|Single Dose
1289277|NCT00811356|Repeat Dose
1289278|NCT00811343|anti TNF Therapy
1289279|NCT00811343|Tuberculosis
1289280|NCT00811343|Tuberculin test
1289281|NCT00811343|QFTB-G
1289282|NCT00811343|T-SPOT.TB
1289283|NCT00811343|Need anti TNF Therapy
1289284|NCT00811330|Left ventricular hypertrophy
1289285|NCT00811330|Aortic valve stenosis
1289286|NCT00811330|Aortic valve replacement
1289287|NCT00811330|Cardiopulmonary bypass
1289288|NCT00811330|Statins
1289289|NCT00811330|Myocardial preconditioning
1289290|NCT00811330|Left ventricular reverse remodeling
1289291|NCT00811317|diabetes
1289292|NCT00811317|glucose
1289293|NCT00811317|hyperglycemia
1289294|NCT00811317|hypoglycemia
1289295|NCT00811317|insulin
1289296|NCT00811317|glucagon
1289297|NCT00811317|counter-regulation
1289298|NCT00811317|closed-loop
1289299|NCT00811317|feedback
1289300|NCT00811317|control
1289301|NCT00811317|dual-infusion
1289302|NCT00811317|subcutaneous
1289303|NCT00811317|automated
1289304|NCT00811317|artificial pancreas
1289305|NCT00811317|intensive insulin therapy
1289306|NCT00811304|ultrasound
1289307|NCT00811304|labor epidural
1289308|NCT00811304|failed epidural
1289309|NCT00811304|outcome
1289310|NCT00811304|Epidural insertion under realtime ultrasound guidance
1289311|NCT00811291|B-vitamins
1289312|NCT00811291|Folic-Acid
1289313|NCT00811291|kindergarten kids
1289314|NCT00811291|cognitive tests
1289315|NCT00811291|Healthy kids
1289316|NCT00811291|second part low urine vitamine-B-metabolites
1289317|NCT00811278|inhaled corticosteroids
1289318|NCT00811265|ExAblate MRgFUS
1289319|NCT00811265|Focused ultrasound
1289320|NCT00811265|Magnetic resonance imaging
1289321|NCT00811265|Prostate cancer
1289322|NCT00811265|Radical prostatectomy candidate
1289323|NCT00811252|Depression
1289324|NCT00811252|Elderly
1289326|NCT00811239|antivenom
1289327|NCT00811239|snake bite
1289328|NCT00811239|Bungarus multicinctus
1289329|NCT00811239|Vietnam
1289330|NCT00811226|Hypertension Stage I
1289331|NCT00811226|Hypertension Stage II
1289332|NCT00811200|radiation
1289333|NCT00811200|retinopathy
1289334|NCT00811200|maculopathy
1289335|NCT00811200|choroidopathy
1289336|NCT00811200|uveal
1289337|NCT00811200|melanoma
1289338|NCT00811200|lucentis
1289339|NCT00811200|ranibizumab
1289340|NCT00811200|kenalog
1289341|NCT00811200|triamcinolone acetonide
1289342|NCT00811200|radiation retinopathy after irradiation of uveal melanoma
1289343|NCT00811200|radiation maculopathy after irradiation of uveal melanoma
1289344|NCT00811200|radiation choroidopathy after irradiation of uveal melanoma
1289345|NCT00811187|Hysteroscopy
1289346|NCT00811187|Pain medication
1289347|NCT00811187|Lidocaine
1289348|NCT00811187|Office Procedures
1289349|NCT00811161|Remodeling
1289350|NCT00811161|Airgent
1289351|NCT00811161|Hyaluronic acid
1289352|NCT00811161|Collagen formation
1289353|NCT00811148|Brain Neoplasms
1289354|NCT00811148|Central Nervous System Diseases
1289355|NCT00811148|Central Nervous System Neoplasms
1289356|NCT00811148|Brain Diseases
1289357|NCT00811148|Nervous System Neoplasms
1289358|NCT00811122|Alzheimer's disease
1289359|NCT00811122|AD
1289360|NCT00811122|Frontotemporal dementia
1289361|NCT00811122|FTD
1289362|NCT00811109|Acute Kidney Injury
1289363|NCT00811109|Critical care
1289364|NCT00811109|Hypotension
1289365|NCT00811109|Renal replacement therapy
1289366|NCT00811109|Efficacy
1289367|NCT00811109|Tolerance
1289368|NCT00811109|Outcome
1289369|NCT00811096|Malaria, Vivax/*drug therapy
1289370|NCT00811096|Tinidazole/pharmacology/*therapeutic use
1289371|NCT00811096|Recurrence
1289372|NCT00811096|Plasmodium vivax/*drug effects
1289373|NCT00811083|autism
1289374|NCT00811083|toxic metals
1289375|NCT00811083|DMSA
1289376|NCT00811083|dimercaptosuccinic acid
1289377|NCT00811083|chelation
1289378|NCT00811070|CML. Chronic myelocytic leukemia. Philadelphia Chromosome. Japanese. SKI-606. Bosutinib. Imatinib resistant. Imatinib intolerant
1289379|NCT00811057|Preterm Labor in Pregnancy
1289380|NCT00811044|diabetes
1289381|NCT00811044|genetics
1289382|NCT00811044|oral glucose tolerance testing
1289383|NCT00811044|family history of diabetes
1289384|NCT00811044|gestational diabetes
1289385|NCT00811031|Prostate
1289386|NCT00811031|prostate gland
1289387|NCT00811031|prostate cancer markers
1289388|NCT00811031|Taxotere®
1289389|NCT00811031|Docetaxel
1289390|NCT00811031|Prednisone
1289391|NCT00811031|Castration Resistant Prostate Cancer
1289392|NCT00811031|adenocarcinoma of the prostate
1289393|NCT00811018|Open-label study
1289394|NCT00811005|acitretin
1289395|NCT00811005|fumaric acid ester
1289396|NCT00811005|pustular palmoplantar psoriasis
1289397|NCT00811005|PUVA
1289398|NCT00810992|dietary, behavior
1289399|NCT00810992|IDF criteria
1289400|NCT00810992|coronary artery disease
1289401|NCT00810992|Traditional Tibetan Medicine
1289402|NCT00810992|coronary artery disease in patients, who have an increased cardiovascular risk profile according to the criteria by the International Diabetes Federation (IDF)
1289403|NCT00810940|TBI
1289404|NCT00810940|closed head injury
1289405|NCT00810940|severe head trauma
1289406|NCT00810940|traumatic brain injury
1289407|NCT00810914|Patient controlled epidural anesthesia
1289408|NCT00810914|Pain control in labor
1289409|NCT00810901|ethnic minority adolescents
1289410|NCT00810901|designated organ donor
1289411|NCT00810888|intracerebral hemorrhage
1289412|NCT00810888|ICH
1289413|NCT00810888|computed tomography angiography
1289414|NCT00810888|CTA
1289415|NCT00810888|recombinant activated factor seven
1289416|NCT00810888|rFVIIa
1289417|NCT00810888|NovoSeven
1289418|NCT00810888|recombinant activated factor VII
1289419|NCT00810875|pregnancy
1289420|NCT00810875|immunity
1289421|NCT00810875|cord blood
1289422|NCT00810875|influenza vaccines
1289423|NCT00810875|disease transmission, vertical
1289424|NCT00810862|African American children
1289425|NCT00810849|Tuberculosis, pericardium
1289426|NCT00810823|Diabetes
1289427|NCT00810823|gastric bypass
1289428|NCT00810823|type 2 diabetes and gastric bypass
1289429|NCT00810810|Blood Component Transfusion
1289430|NCT00810810|Leukoreduction
1289431|NCT00810810|HLA antibody
1289432|NCT00810810|Immunosuppression
1289433|NCT00810797|recurrent breast cancer
1289434|NCT00810797|stage IV breast cancer
1289435|NCT00810784|Venous Thromboembolism
1289436|NCT00810784|Prevention
1289437|NCT00810784|Quality Improvement
1289438|NCT00810784|Education
1289439|NCT00810784|Compliance with VTE prophylaxis
1289440|NCT00810771|Hospitals, Veterans
1289441|NCT00810771|Mass Screening/utilization
1289442|NCT00810771|Patient Preference
1289443|NCT00810771|Prevention & Control
1289444|NCT00810771|Epidemiology
1289445|NCT00810758|HCV
1289446|NCT00810758|Toll-like receptor 7
1289447|NCT00810758|Multiple oral dose escalation study of PF-04878691
1289448|NCT00810745|ODS
1289449|NCT00810745|stapled transanal rectal resection
1289450|NCT00810732|This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.
1289451|NCT00810732|B1321005
1289452|NCT00810719|recurrent pancreatic cancer
1289453|NCT00810719|stage IV pancreatic cancer
1289454|NCT00810706|Breast Cancer
1289455|NCT00810706|Aromatase inhibitors
1289456|NCT00810706|Exemestane
1289457|NCT00810706|Tamoxifen
1289458|NCT00810706|Lipids
1289459|NCT00810693|Pulmonary arterial hypertension
1289460|NCT00810693|PH
1289461|NCT00810693|Stimulator
1289462|NCT00810680|chronic lymphocytic leukemia
1289463|NCT00810680|relapsed
1289464|NCT00810680|refractory
1289465|NCT00810680|valproic acid
1289466|NCT00810680|valproate
1289467|NCT00810667|Schizophrenia
1289468|NCT00810667|Cognition
1289469|NCT00810667|BACS
1289470|NCT00810667|Risperidone
1289471|NCT00810667|Augmentation therapy
1289472|NCT00810667|Add-on therapy
1289473|NCT00810667|Lu AE58054
1289474|NCT00810654|Celiac disease
1289475|NCT00810654|Coeliac disease
1289476|NCT00810654|treatment
1289477|NCT00810654|AN-PEP
1289478|NCT00810654|prolyl endoprotease
1289479|NCT00810654|gluten
1289480|NCT00810641|BPPV(benign paroxysmal positional vertigo)
1289481|NCT00810641|HC-BPPV(BPPV involving the horizontal semicircular canal)
1289482|NCT00810641|Nystagmus
1289483|NCT00810641|Treatment outcome
1289484|NCT00810641|Horizontal Canal Benign Paroxysmal Positional Vertigo
1289485|NCT00810628|Parkinson's disease
1289486|NCT00810628|depression
1289487|NCT00810628|Parkinson's disease with mild to moderate depression.
1289488|NCT00810615|chronic TBI
1289489|NCT00810615|cognitive function
1289490|NCT00810615|PTSD
1289491|NCT00810615|HBO
1289492|NCT00810615|hyperbaric
1289493|NCT00810615|oxygen
1289494|NCT00810615|chronic brain injury
1289495|NCT00810576|Relapsed T-Cell Non-Hodgkin's Lymphoma
1289496|NCT00810576|Refractory T-Cell Non-Hodgkin's Lymphoma
1289497|NCT00810576|NHL
1289498|NCT00810576|T-cell NHL
1289499|NCT00810576|vorinostat
1289500|NCT00810576|SAHA
1289501|NCT00810576|Suberoylanilide Hydroxamic Acid
1289502|NCT00810576|MSK-390
1289503|NCT00810576|Zolinza
1289504|NCT00810576|Bortezomib
1289505|NCT00810576|Velcade
1289506|NCT00810576|LDP-341
1289507|NCT00810576|MLN341
1289508|NCT00810576|PS-341
1289509|NCT00810576|Peripheral T-cell lymphoma
1289510|NCT00810576|CD 30 + anaplastic large cell lymphoma
1289511|NCT00810576|Angioimmunoblastic T-cell lymphoma
1289512|NCT00810576|Angiocentric/nasal type T/NK-cell lymphoma
1289513|NCT00810576|Intestinal T-cell lymphoma
1289514|NCT00810576|Hepatosplenic gamma delta T-cell lymphoma
1289515|NCT00810576|Subcutaneous panniculitic T-cell lymphoma
1289516|NCT00810576|Transformed Mycosis fungoides
1289517|NCT00810563|pain
1289518|NCT00810563|tubal ligation
1289519|NCT00810563|bupivacaine
1289520|NCT00810563|laparoscopy
1289521|NCT00810524|Chronic hepatitis B
1289522|NCT00810524|antiviral treatment
1289523|NCT00810524|long term prognosis
1289524|NCT00810485|Gastroesophageal reflux
1289525|NCT00810485|Proton pump inhibitor
1289526|NCT00810485|Heartburn
1289527|NCT00810485|Regurgitation
1289528|NCT00810472|Penetrating keratoplasty
1289529|NCT00810472|HLA matching
1289530|NCT00810472|Corneal diseases that require penetrating keratoplasty
1289531|NCT00810420|Hypoglycemia
1289532|NCT00810420|EEG
1289533|NCT00810420|type 1 diabetes
1289534|NCT00810420|neuroglycopenia
1289535|NCT00810420|Hypoglycemia is a potential dangerous condition
1289536|NCT00810420|EEG is changed during hypoglycemia
1289537|NCT00810420|A hypoglycemia alarm based on EEG-measures may prevent development of severe hypoglycemia
1289538|NCT00810394|unspecified adult solid tumor, protocol specific
1289539|NCT00810381|Nitrovasodilators
1289540|NCT00810381|ONH blood flow
1289541|NCT00810381|Choroidal blood flow
1289542|NCT00810381|Nitroglycerin
1289543|NCT00810381|Isosorbide Dinitrate
1289544|NCT00810381|Sodium nitroprusside
1289545|NCT00810381|Laser-Doppler Flowmetry
1289546|NCT00810381|Regional Blood Flow
1289547|NCT00810368|Carnosine
1289548|NCT00810368|antioxidant
1289549|NCT00810368|Persian Gulf War
1289550|NCT00810368|Gulf War Syndrome
1289551|NCT00810368|GWI
1289552|NCT00810368|Gulf War Illness
1289553|NCT00810368|Exercise
1289554|NCT00810368|Chronic Fatigue
1289555|NCT00810368|Fibromyalgia
1289556|NCT00810368|Veterans
1289557|NCT00810368|Irritable Bowel Syndrome
1289558|NCT00810368|Migraine headaches
1289559|NCT00810368|Neuropathy
1289560|NCT00810368|Multiple Chemical Sensitivity
1289561|NCT00810355|Schizophrenia Spectrum Disorders
1289562|NCT00810355|Cognitive Behavior Therapy
1289563|NCT00810355|work
1289564|NCT00810342|physical activity standard
1289565|NCT00810342|exercise
1289566|NCT00810329|CFS,FM,CSF,Proteomics,Pain,Fatigue,GWI,IBS,IC,MCS.
1289567|NCT00810316|Alprazolam
1289568|NCT00810316|Alprazolam extended release
1289569|NCT00810316|Clonazepam
1289570|NCT00810316|Pharmacokinetics
1289571|NCT00810316|Mexican population
1289572|NCT00810316|Healthy
1289573|NCT00810290|Metabolic syndrome
1289574|NCT00810290|Latino health
1289575|NCT00810290|Community participatory research
1289576|NCT00810290|Translational Research
1289578|NCT00810251|rib fracture
1289579|NCT00810251|flail chest
1289580|NCT00810251|plate
1289581|NCT00810251|chest trauma
1289582|NCT00810251|osteosynthesis
1289583|NCT00810251|mechanical ventilation
1289584|NCT00810251|respirator
1289585|NCT00810238|Heart failure
1289586|NCT00810238|Cell therapy
1289587|NCT00810225|CNDP1
1289588|NCT00810225|carnosine dipeptidase 1
1289589|NCT00810225|Persian Gulf War
1289590|NCT00810225|Gulf War Syndrome
1289591|NCT00810225|GWI
1289592|NCT00810225|Gulf War Illness
1289593|NCT00810225|Exercise
1289594|NCT00810225|Chronic Fatigue
1289595|NCT00810225|Fibromyalgia
1289596|NCT00810225|Veterans
1289597|NCT00810225|Irritable Bowel Syndrome
1289598|NCT00810225|Migraine headaches
1289599|NCT00810225|Neuropathy
1289600|NCT00810225|Multiple Chemical Sensitivity
1289601|NCT00810212|Degenerative disc disease
1289602|NCT00810212|Spondylolisthesis
1289603|NCT00810212|Spinal stenosis
1289604|NCT00810212|Stem cell
1289605|NCT00810212|Spinal Fusion
1289606|NCT00810173|type 2 diabetes
1289607|NCT00810173|physical activity
1289608|NCT00810173|behavior change
1289609|NCT00810173|profile personality
1289610|NCT00810173|phone call support
1289611|NCT00810160|probiotic
1289612|NCT00810160|prebiotic
1289613|NCT00810160|oligosaccharides
1289614|NCT00810160|GOS
1289615|NCT00810160|galacto oligosaccharides
1289616|NCT00810160|Bifidobacterium infantis
1289617|NCT00810160|Bifidobacterium animalis
1289618|NCT00810134|Superficial femoral artery occlusion (TASC II B or C)
1289619|NCT00810108|HIV/AIDS
1289620|NCT00810108|pediatrics
1289621|NCT00810108|resource-limited settings
1289622|NCT00810108|lopinavir
1289623|NCT00810108|ritonavir
1289624|NCT00810108|Kaletra®
1289625|NCT00810108|antiretroviral treatment
1289626|NCT00810108|crushed tablets
1289627|NCT00810108|treatment experienced
1289628|NCT00810095|Cerebral Infarction
1289629|NCT00810095|Stroke
1289630|NCT00810095|Vascular Diseases
1289631|NCT00810095|Central Nervous System Diseases
1289632|NCT00810095|Penumbra
1289633|NCT00810095|Functional Outcome
1289634|NCT00810095|Aphasia
1289635|NCT00810095|Hemiplegia
1289636|NCT00810095|Left sided weakness
1289637|NCT00810095|Right Sided weakness
1289638|NCT00810069|Major Depressive Disorder
1289639|NCT00810069|MDD
1289640|NCT00810069|Depression
1289641|NCT00810056|Child abuse and neglect
1289642|NCT00810056|Out-of-home care
1289643|NCT00810056|Mentoring
1289644|NCT00810056|Skills groups
1289645|NCT00810056|Assessment
1289646|NCT00810030|ferric carboxymaltose
1289647|NCT00810030|iron sucrose
1289648|NCT00810030|Iron-Deficiency Anemia
1289649|NCT00810030|Crohn's Disease
1289650|NCT00810030|Ulcerative Colitis
1289651|NCT00810030|Ferritin
1289652|NCT00810030|Transferrin
1289653|NCT00810017|Her2 Positive
1289654|NCT00810017|Breast Cancer
1289655|NCT00810017|Metastatic
1289656|NCT00809991|Prostate Cancer
1289657|NCT00809965|Rivaroxaban
1289658|NCT00809965|Acute Coronary Syndrome
1289659|NCT00809965|ACS
1289660|NCT00809965|Aspirin
1289661|NCT00809965|Thienopyridine
1289662|NCT00809965|Unstable Angina
1289663|NCT00809965|Myocardial Infarction
1289664|NCT00809965|Anticoagulation
1289665|NCT00809965|Clopidogrel (Plavix)
1289666|NCT00809939|preterm delivery
1289667|NCT00809939|short cervical length
1289668|NCT00809939|progesterone
1289669|NCT00809926|Hypertension, aliskiren and valsartan
1289670|NCT00809913|Urinary Tract Infection
1289671|NCT00809913|Fever
1289672|NCT00809913|Acute Pyelonephritis
1289673|NCT00809913|Treatment duration
1289674|NCT00809913|Febrile Urinary Tract Infection Treatment Duration
1289675|NCT00809887|catheter fungal infections, antimicrobial lock therapy, micafungin, central venous catheter
1289676|NCT00809874|Postprandial Period
1289677|NCT00809874|Postprandial Lipaemia
1289678|NCT00809874|Incretins
1289679|NCT00809874|Subclinical Inflammation
1289680|NCT00809874|Obesity
1289681|NCT00809874|Atherosclerosis
1289682|NCT00809874|Triglyceride
1289683|NCT00809874|Lipoproteins
1289684|NCT00809835|Cocaine
1289685|NCT00809835|Methadone
1289686|NCT00809835|CBT
1289687|NCT00809822|IVIG in pemphigoid
1289688|NCT00809822|Patients with bullous pemphigoid unresponsive to corticosteroids
1289689|NCT00809809|Cold sores
1289690|NCT00809809|Zinc
1289691|NCT00809809|HSL
1289692|NCT00809809|Herpes simple labialis
1289693|NCT00809783|Tanezumab OA arthritis
1289694|NCT00809770|stimulant abuse
1289695|NCT00809770|drug abuse
1289696|NCT00809770|schizophrenia
1289697|NCT00809770|bipolar disorder
1289698|NCT00809770|major depressive disorder
1289699|NCT00809770|contingency management
1289700|NCT00809770|psychosocial treatment
1289701|NCT00809757|Asthma
1289702|NCT00809731|Schizophrenia remission status by 8-item PANSS
1289703|NCT00809718|Raltegravir
1289704|NCT00809718|Pharmacokinetics
1289705|NCT00809718|Rifapentine
1289706|NCT00809718|Drug Kinetics
1289707|NCT00809692|histamine biotransformation
1289708|NCT00809692|laser Doppler flowimetry
1289709|NCT00809692|pediatric pharmacology
1289710|NCT00809679|Postherpetic neuralgia
1289711|NCT00809679|Varicella Zoster
1289712|NCT00809679|Shingles
1289713|NCT00809679|Neuropathic pain
1289714|NCT00809679|Analgesia
1289715|NCT00809679|Pain
1289716|NCT00809666|pregnancy
1289717|NCT00809666|hypertension
1289718|NCT00809666|mercury sphygmomanometry
1289719|NCT00809666|blood pressure
1289720|NCT00809666|automated blood pressure
1289721|NCT00809666|pre eclampsia
1289722|NCT00809666|Hypertension in pregnancy
1289723|NCT00809653|Air pollution
1289724|NCT00809653|Face mask
1289725|NCT00809653|Myocardial ischaemia
1289726|NCT00809653|Heart rate variability
1289727|NCT00809653|Angina pectoris
1289728|NCT00809653|Coronary heart disease
1289729|NCT00809640|low back pain
1289730|NCT00809640|prevention
1289731|NCT00809640|schoolchildren
1289732|NCT00809640|education campaign
1289733|NCT00809627|headache
1289734|NCT00809627|caffeine
1289735|NCT00809627|pain
1289736|NCT00809614|Psoriatic arthritis
1289737|NCT00809614|IgG1K monoclonal antibody
1289738|NCT00809614|Interleukin -17A neutralizing
1289739|NCT00809588|vaccination
1289740|NCT00809588|GM-CSF
1289741|NCT00809588|autologous
1289742|NCT00809588|irradiated
1289743|NCT00809575|adult
1289744|NCT00809575|de novo myelodysplastic syndromes
1289745|NCT00809575|Quality of life
1289746|NCT00809575|Patient reported outcomes
1289747|NCT00809549|Stroke
1289748|NCT00809549|GCSF
1289749|NCT00809549|Hematopoeitic
1289750|NCT00809549|Neupogen
1289751|NCT00809549|Filgrastim
1289752|NCT00809536|metformin, PD 0332334, organic cation transporter, OCT2, pharmacokinetics
1289753|NCT00809523|SAD
1289754|NCT00809523|winter depression
1289755|NCT00809497|PLC for treatment of peripheral arterial diseases
1289756|NCT00809484|Arimidex
1289757|NCT00809484|Bone Mineral density
1289758|NCT00809484|Bisphosphonates
1289759|NCT00809484|Aromatase Inhibitors
1289760|NCT00809471|ED
1289761|NCT00809471|Erectile Dysfunction
1289762|NCT00809471|Dysfunction
1289763|NCT00809471|Diabetic
1289764|NCT00809471|Erectile
1289765|NCT00809458|Vitamin E
1289766|NCT00809458|Prostate Cancer
1289767|NCT00809458|Alpha-tocopherol (α-tocopherol)
1289768|NCT00809432|Air pollution
1289769|NCT00809432|Heart rate
1289770|NCT00809432|Heart rate variability
1289771|NCT00809432|Blood pressure
1289772|NCT00809432|Face mask
1289773|NCT00809419|Brachytherapy
1289774|NCT00809419|EpiRad
1289775|NCT00809419|Macular Degeneration
1289776|NCT00809419|Ranibizumab
1289777|NCT00809393|Antifibrinolytic
1289778|NCT00809393|Tranexamic acid
1289779|NCT00809393|Cardiopulmonary bypass
1289780|NCT00809393|Transfusion
1289781|NCT00809393|Hemorrhage
1289782|NCT00809380|Conscious sedation
1289783|NCT00809380|Parental presence
1289784|NCT00809380|Invasive procedure
1289785|NCT00809380|Children
1289786|NCT00809380|Anxiety
1289787|NCT00809367|MDS
1289788|NCT00809367|AML
1289789|NCT00809367|banking study
1289790|NCT00809354|monoclonal antibody
1289791|NCT00809354|nerve growth factor (NGF)
1289792|NCT00809354|anti-NGF
1289793|NCT00809354|tanezumab
1289794|NCT00809354|PF-04383119
1289795|NCT00809354|RN624
1289796|NCT00809354|osteoarthritis (OA)
1289797|NCT00809341|B-Cell
1289798|NCT00809341|non-Hodgkin's
1289799|NCT00809341|Lymphoma
1289800|NCT00809315|Child abuse and neglect
1289801|NCT00809315|Out-of-home care
1289802|NCT00809315|Mentoring
1289803|NCT00809315|Skills groups
1289804|NCT00809315|Assessment
1289805|NCT00809315|Functioning as a result of maltreatment and placement in out-of-home care
1289806|NCT00809289|Thorough QT/QTc study
1289807|NCT00809276|Acute lymphocytic leukemia (ALL)
1289808|NCT00809276|Acute myeloid leukemia (AML)
1289809|NCT00809276|Acute Leukemia
1289810|NCT00809276|Refractory or Relapsed AML
1289811|NCT00809276|Myelodysplastic syndrome (MDS)
1289812|NCT00809276|Chronic myeloid leukemia (CML)
1289813|NCT00809276|Chronic myelomonocytic leukemia
1289814|NCT00809276|Hodgkin's Lymphoma
1289815|NCT00809276|Non-Hodgkin's lymphoma
1289816|NCT00809276|Philadelphia-negative myeloproliferative disorder
1289817|NCT00809276|Hematologic Malignancies
1289818|NCT00809276|Transplantation
1289819|NCT00809276|Busulfan
1289820|NCT00809276|Fludarabine
1289821|NCT00809276|Cytoxan
1289822|NCT00809276|Bone Marrow
1289823|NCT00809276|Allogeneic
1289824|NCT00809276|Related donor
1289825|NCT00809276|unrelated donor
1289826|NCT00809263|homeopathy
1289827|NCT00809263|homeopathic drug proving
1289828|NCT00809263|Document symptoms associated with administration of a homeopathic remedy.
1289829|NCT00809250|vaccination
1289830|NCT00809250|AML
1289831|NCT00809250|CMML
1289832|NCT00809250|MDS-RAEB
1289833|NCT00809237|Non-small cell lung cancer
1289834|NCT00809237|Gefitinib
1289835|NCT00809237|Hydroxychloroquine
1289836|NCT00809224|ALS
1289837|NCT00809224|amyotrophic lateral sclerosis
1289838|NCT00809224|brain-computer interface
1289839|NCT00809224|functional magnetic resonance imaging
1289840|NCT00809224|radiology
1289841|NCT00809224|fMRI
1289842|NCT00809211|chronic myelogenous leukemia, BCR-ABL1 positive
1289843|NCT00809211|chronic phase chronic myelogenous leukemia
1289844|NCT00809198|Sodium Hyaluronate, Kynex, Carboxymethylcellulose sodium
1289845|NCT00809198|Refresh Plus
1289846|NCT00809198|Dry Eye
1289847|NCT00809198|Cornea Staining
1289848|NCT00809198|TBUT
1289849|NCT00809185|de novo myelodysplastic syndromes
1289850|NCT00809185|secondary myelodysplastic syndromes
1289956|NCT00808925|stress
1289851|NCT00809185|previously treated myelodysplastic syndromes
1289852|NCT00809172|Atopic-dermatitis
1289853|NCT00809172|scorad
1289854|NCT00809172|methotrexate
1289855|NCT00809172|ciclosporin
1289856|NCT00809159|ankylosing spondylitis
1289857|NCT00809146|Status Epilepticus
1289858|NCT00809146|Emergency Medical Services
1289859|NCT00809146|Anticonvulsants
1289860|NCT00809146|Drug Administration Routes
1289861|NCT00809146|Seizures
1289862|NCT00809120|Electrostimulation
1289863|NCT00809120|COPD
1289864|NCT00809120|Tolerance
1289865|NCT00809120|Muscle fatigue
1289866|NCT00809120|Cardio-respiratory response
1289867|NCT00809107|natural cycle
1289868|NCT00809107|FET
1289869|NCT00809107|spontaneous LH pic
1289870|NCT00809107|HCG
1289871|NCT00809081|periampullar carcinoma
1289872|NCT00809081|Pancreaticoduodenectomy
1289873|NCT00809081|Enteral feeding
1289874|NCT00809081|Total Parenteral Support
1289875|NCT00809068|Menopause
1289876|NCT00809068|menopausal symptoms
1289877|NCT00809068|tibolone
1289878|NCT00809068|HDL-C
1289879|NCT00809068|fenofibrate
1289880|NCT00809042|Hydroxyurea
1289881|NCT00809042|magnesium chloride
1289882|NCT00809042|L-carnitine
1289883|NCT00809042|β-thalassemia intermedia
1289884|NCT00809029|GIP
1289885|NCT00809029|OBESITY
1289886|NCT00809029|HSL
1289887|NCT00809029|LPL
1289888|NCT00809029|ADIPOCYTOKINES
1289889|NCT00809029|BARIATRIC SURGERY
1289890|NCT00809016|recurrent squamous cell carcinoma of the hypopharynx
1289891|NCT00809016|stage III squamous cell carcinoma of the hypopharynx
1289892|NCT00809016|stage IV squamous cell carcinoma of the hypopharynx
1289893|NCT00809016|recurrent squamous cell carcinoma of the larynx
1289894|NCT00809016|stage III squamous cell carcinoma of the larynx
1289895|NCT00809016|stage IV squamous cell carcinoma of the larynx
1289896|NCT00809016|recurrent verrucous carcinoma of the larynx
1289897|NCT00809016|stage III verrucous carcinoma of the larynx
1289898|NCT00809016|stage IV verrucous carcinoma of the larynx
1289899|NCT00809016|recurrent adenoid cystic carcinoma of the oral cavity
1289900|NCT00809016|recurrent mucoepidermoid carcinoma of the oral cavity
1289901|NCT00809016|recurrent verrucous carcinoma of the oral cavity
1289902|NCT00809016|stage III adenoid cystic carcinoma of the oral cavity
1289903|NCT00809016|stage III mucoepidermoid carcinoma of the oral cavity
1289904|NCT00809016|stage III verrucous carcinoma of the oral cavity
1289905|NCT00809016|stage IV adenoid cystic carcinoma of the oral cavity
1289906|NCT00809016|stage IV mucoepidermoid carcinoma of the oral cavity
1289907|NCT00809016|stage IV verrucous carcinoma of the oral cavity
1289908|NCT00809016|recurrent basal cell carcinoma of the lip
1289909|NCT00809016|recurrent squamous cell carcinoma of the lip and oral cavity
1289910|NCT00809016|stage III basal cell carcinoma of the lip
1289911|NCT00809016|stage III squamous cell carcinoma of the lip and oral cavity
1289912|NCT00809016|stage IV basal cell carcinoma of the lip
1289913|NCT00809016|stage IV squamous cell carcinoma of the lip and oral cavity
1289914|NCT00809016|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1289915|NCT00809016|recurrent metastatic squamous neck cancer with occult primary
1289916|NCT00809016|untreated metastatic squamous neck cancer with occult primary
1289917|NCT00809016|recurrent lymphoepithelioma of the oropharynx
1289918|NCT00809016|recurrent squamous cell carcinoma of the oropharynx
1289919|NCT00809016|stage III lymphoepithelioma of the oropharynx
1289920|NCT00809016|stage III squamous cell carcinoma of the oropharynx
1289921|NCT00809016|stage IV lymphoepithelioma of the oropharynx
1289922|NCT00809016|stage IV squamous cell carcinoma of the oropharynx
1289923|NCT00809016|high-grade salivary gland mucoepidermoid carcinoma
1289924|NCT00809016|low-grade salivary gland mucoepidermoid carcinoma
1289925|NCT00809016|recurrent salivary gland cancer
1289926|NCT00809016|salivary gland acinic cell tumor
1289927|NCT00809016|salivary gland adenocarcinoma
1289928|NCT00809016|salivary gland adenoid cystic carcinoma
1289929|NCT00809016|salivary gland anaplastic carcinoma
1289930|NCT00809016|salivary gland malignant mixed cell type tumor
1289931|NCT00809016|salivary gland poorly differentiated carcinoma
1289932|NCT00809016|salivary gland squamous cell carcinoma
1289933|NCT00809016|stage III salivary gland cancer
1289934|NCT00809016|stage IV salivary gland cancer
1289935|NCT00809003|Non dry eyed(normals)
1289936|NCT00808990|Non Alcoholic Fatty Liver Disease
1289937|NCT00808990|Non Alcoholic SteatoHepatitis
1289938|NCT00808990|Small bowel bacterial overgrowth
1289939|NCT00808990|Probiotics
1289940|NCT00808990|Patients with Non Alcoholic Fatty Liver Disease
1289941|NCT00808964|CABG
1289942|NCT00808964|anticoagulant
1289943|NCT00808964|Off-Pump CABG
1289944|NCT00808951|Uncomplicated malaria
1289945|NCT00808951|P falciparum
1289946|NCT00808951|Children
1289947|NCT00808951|National treatment protocol
1289948|NCT00808951|Burkina Faso
1289949|NCT00808951|Artemether-lumefantrine
1289950|NCT00808951|Artesunate-amodiaquine
1289951|NCT00808951|In vivo efficacy
1289952|NCT00808951|In vitro efficacy
1289953|NCT00808925|acclimation
1289954|NCT00808925|heat
1289955|NCT00808925|cytokines
1289957|NCT00808925|inflammation
1289958|NCT00808912|phosphodiesterase
1289959|NCT00808912|sildenafil
1289960|NCT00808912|pulmonary hypertension
1289961|NCT00808912|exercise performance
1289962|NCT00808912|air pollution
1289963|NCT00808899|Neuroblastoma
1289964|NCT00808886|cataract
1289965|NCT00808886|locs3
1289966|NCT00808886|pentacam
1289967|NCT00808873|attempted suicide
1289968|NCT00808873|socio-educational intervention
1289969|NCT00808873|follow up study
1289970|NCT00808860|Herbal medicine
1289971|NCT00808860|Type 2 diabetes
1289972|NCT00808860|Gynostemma pentaphyllum Tea
1289973|NCT00808860|Insulin sensitivity
1289974|NCT00808860|add-on
1289975|NCT00808808|FluMist, TIV, vaccination rates
1289976|NCT00808795|Acute kidney injury
1289977|NCT00808795|contrast-induced nephropathy
1289978|NCT00808795|Chronic kidney disease
1289979|NCT00808795|Diabetes mellitus
1289980|NCT00808795|N-acetylcysteine
1289981|NCT00808782|Pervasive Developmental Disorders
1289982|NCT00808782|Asperger Syndrome
1289983|NCT00808782|Autism
1289984|NCT00808756|Carbohydrates
1289985|NCT00808756|Infant
1289986|NCT00808756|Intestine
1289987|NCT00808756|Faeces
1289988|NCT00808756|Growth
1289989|NCT00808756|Diet
1289990|NCT00808743|Familial adenomatous polyposis
1289991|NCT00808743|Adenomatous Polyposis Coli
1289992|NCT00808743|Digestive System Neoplasms
1289993|NCT00808743|Gastrointestinal Disease
1289994|NCT00808743|Intestinal disease
1289995|NCT00808743|Intestinal neoplasms
1289996|NCT00808743|Gastrointestinal neoplasms
1289997|NCT00808743|Polyps
1289998|NCT00808743|Adenoma
1289999|NCT00808743|Adenomatous Polyps
1290000|NCT00808743|Neoplastic Syndromes, Hereditary
1290001|NCT00808743|Digestive System Diseases
1290002|NCT00808743|Genetic Diseases, Inborn
1290003|NCT00808743|Chemoprevention
1290004|NCT00808743|Celecoxib
1290005|NCT00808743|Ursodeoxycholic acid
1290006|NCT00808743|Anti-Inflammatory agents, Non-Steroidal
1290007|NCT00808743|Cyclooxygenase Inhibitors
1290008|NCT00808730|Asthma, airway remodelling, smooth muscle, mitochondria
1290009|NCT00808717|Myocardial Infarction
1290010|NCT00808717|Coronary Angioplasty
1290011|NCT00808717|Myocardial infarction, Angioplasty, Transluminal, Percutaneous Coronary
1290012|NCT00808704|asphyxia
1290013|NCT00808704|erythropoietin
1290014|NCT00808704|neonates
1290015|NCT00808678|Adverse Events
1290016|NCT00808665|Lumbar Fusion
1290017|NCT00808665|Inflammation
1290018|NCT00808665|Dexmedetomidine
1290019|NCT00808665|Length of Hospital Stay
1290020|NCT00808665|General Anesthesia
1290021|NCT00808665|Anti-inflammatory
1290022|NCT00808665|GPCR
1290023|NCT00808665|Cytokine
1290024|NCT00808665|Immune Response
1290025|NCT00808639|pegfilgrastim
1290026|NCT00808639|MVAC
1290027|NCT00808600|lung transplantation
1290028|NCT00808600|heart-lung transplantation
1290029|NCT00808600|rehabilitation
1290030|NCT00808600|resource-activating training
1290031|NCT00808600|anaerobic exercise training
1290032|NCT00808587|Genomic Scan
1290033|NCT00808587|Personalized Medicine
1290034|NCT00808587|Gene testing
1290035|NCT00808574|Obstructive sleep apnea
1290036|NCT00808574|Internet
1290037|NCT00808574|Screening
1290038|NCT00808574|Health belief model
1290039|NCT00808548|stress
1290040|NCT00808548|carer's experiences
1290041|NCT00808548|Prader-willi syndrome
1290042|NCT00808548|personal experiences
1290043|NCT00808535|Endothelial dysfunction
1290044|NCT00808535|Cardiac Perfusion MRI
1290045|NCT00808535|Vasomotor Stress
1290046|NCT00808535|Cold Pressor Test
1290047|NCT00808535|Adenosine Stress
1290048|NCT00808522|Breast Cancer
1290049|NCT00808522|Chemoprevention
1290050|NCT00808522|Tamoxifen
1290051|NCT00808522|Breast density
1290052|NCT00808522|Hcg
1290053|NCT00808509|adalimumab,Remission,drug discontinuation
1290054|NCT00808496|Magnetic resonance imaging
1290055|NCT00808496|Radiography
1290056|NCT00808496|Randomized controlled trial
1290057|NCT00808496|Antirheumatic agents
1290058|NCT00808483|total hip arthroplasty
1290059|NCT00808483|physical functioning
1290060|NCT00808483|training program
1290061|NCT00808483|self-efficacy
1290062|NCT00808483|exercise therapy
1290063|NCT00808483|walking
1290064|NCT00808470|Noise
1290065|NCT00808470|Hearing Loss
1290066|NCT00808470|Tinnitus
1290067|NCT00808470|Antioxidant
1290068|NCT00808470|Vasodilator
1290069|NCT00808470|Beta-Carotene
1290070|NCT00808470|Vitamin C
1290071|NCT00808470|Vitamin E
1290072|NCT00808470|Magnesium
1290073|NCT00808457|chest ultrasound
1290074|NCT00808457|pneumonia
1290075|NCT00808457|X-ray
1290076|NCT00808457|CT
1290077|NCT00808457|Sensitivity and specificity of chest ultrasound in diagnosing pneumonia
1290078|NCT00808444|Pneumococcal vaccine
1290079|NCT00808444|Immunogenicity
1290080|NCT00808444|Primary vaccination
1290081|NCT00808444|Safety
1290082|NCT00808444|Pneumococcal disease
1290083|NCT00808431|Obesity
1290084|NCT00808431|Diabetes
1290085|NCT00808431|Physical Activity
1290086|NCT00808431|Child Feeding
1290087|NCT00808431|Growth Trajectories
1290088|NCT00808431|Family based
1290089|NCT00808418|prostate
1290090|NCT00808418|cancer
1290091|NCT00808418|metastatic
1290092|NCT00808418|castration
1290093|NCT00808418|refractory
1290094|NCT00808418|elesclomol
1290095|NCT00808418|sodium
1290096|NCT00808418|docetaxel
1290097|NCT00808418|prednisone
1290098|NCT00808405|herpes simplex virus
1290099|NCT00808405|acyclovir
1290100|NCT00808405|HSV shedding
1290101|NCT00808405|women
1290102|NCT00808405|Africa
1290103|NCT00808392|vaccine
1290104|NCT00808392|prevention
1290105|NCT00808392|haemophilus influenzae type b
1290106|NCT00808392|children
1290107|NCT00808379|Unresectable rectal cancers
1290108|NCT00808353|CVD
1290109|NCT00808327|Cesarean section
1290110|NCT00808327|Spinal
1290111|NCT00808314|Lexiscan(TM)
1290112|NCT00808314|Dipyridamole
1290113|NCT00808314|Myocardial Perfusion
1290114|NCT00808314|Positron Emission Computed Tomography
1290115|NCT00808301|Coeliac disease
1290116|NCT00808301|Oat
1290117|NCT00808288|COPD Respiratory Long acting beta agonist
1290118|NCT00808275|dietary calcium
1290119|NCT00808275|weight loss
1290120|NCT00808262|anti-TNFa
1290121|NCT00808262|immunization
1290122|NCT00808262|kinoid
1290123|NCT00808262|crohn's disease
1290124|NCT00808249|Generalized Anxiety Disorder
1290125|NCT00808249|GAD
1290126|NCT00808249|Anxiety
1290127|NCT00808236|Cardiac Arrest
1290128|NCT00808236|Pre-hospital
1290129|NCT00808236|Mild hypothermia
1290130|NCT00808236|Resuscitation
1290131|NCT00808223|alefacept
1290132|NCT00808223|adolescent
1290133|NCT00808223|psoriasis
1290134|NCT00808210|RA
1290135|NCT00808210|Arthritis
1290136|NCT00808197|AMD
1290137|NCT00808197|choroidal blood flow
1290138|NCT00808197|fellow eye in patients with unilateral choroidal neovascularisation
1290139|NCT00808184|Histologically or cytologically proven solid tumour for which CPT-11 given by the Folfiri regimen
1290140|NCT00808171|lumbar punction
1290141|NCT00808171|myelogram
1290142|NCT00808171|pain assessment
1290143|NCT00808171|nitrous oxide and EMLA
1290144|NCT00808171|Leukemia and non Hodgkin lymphoma
1290145|NCT00808145|Treatment of advanced liver cancer
1290146|NCT00808132|Postmenopausal Women
1290147|NCT00808132|Bazedoxifene/Conjugated Estrogens
1290148|NCT00808106|Albinism
1290149|NCT00808106|Oculocutaneous Albinism
1290150|NCT00808106|Pigmentation
1290151|NCT00808106|Natural History
1290152|NCT00808106|Vesical Biology
1290153|NCT00808093|Food Effect
1290154|NCT00808093|GSK256073F
1290155|NCT00808093|TRIS Salt
1290156|NCT00808080|AML
1290157|NCT00808054|Pain
1290158|NCT00808054|preterm neonate
1290159|NCT00808054|pain assessment
1290160|NCT00808054|EMLA
1290161|NCT00808054|oral glucose
1290162|NCT00808041|Neoadjuvant Treatment
1290163|NCT00808041|Therapy Response
1290164|NCT00808041|Breast Computed Tomography
1290165|NCT00808015|Observational non-interventional trial
1290166|NCT00808002|Maraviroc
1290167|NCT00808002|CCR5 antagonists
1290168|NCT00808002|Primary HIV Infection
1290169|NCT00808002|HIV-1 reservoir
1290170|NCT00808002|eradication
1290171|NCT00808002|treatment naive
1290172|NCT00807976|Diabetes mellitus
1290173|NCT00807976|Elderly
1290174|NCT00807976|Orthostatic hypotension
1290175|NCT00807963|Pharmacokinetics
1290176|NCT00807963|rHuPH20
1290177|NCT00807937|Generalized Anxiety Disorder
1290178|NCT00807937|GAD
1290179|NCT00807937|Anxiety
1290180|NCT00807924|Fibroadenomas
1290181|NCT00807924|Papillomas
1290182|NCT00807924|Breast
1290183|NCT00807924|Minimally invasive
1290184|NCT00807924|Interstitial laser therapy
1290185|NCT00807924|Laser ablation
1290186|NCT00807924|Benign
1290187|NCT00807924|Non-cancerous
1290188|NCT00807924|Breast lesion
1290189|NCT00807924|Breast tumor
1290190|NCT00807911|rectal cancer
1290191|NCT00807911|adjuvant chemotherapy
1290192|NCT00807911|FOLFOX
1290193|NCT00807898|Gardasil
1290194|NCT00807898|HPV vaccine
1290195|NCT00807898|decision making
1290196|NCT00807898|mother
1290197|NCT00807898|daughter
1290198|NCT00807885|dehydration
1290199|NCT00807885|fluid therapy
1290200|NCT00807885|hyaluronoglucosaminidase
1290201|NCT00807885|hyaluronidase
1290202|NCT00807885|hypodermoclysis
1290203|NCT00807885|clysis
1290204|NCT00807885|subcutaneous hydration
1290205|NCT00807885|subcutaneous rehydration
1290206|NCT00807885|hyaluronan
1290207|NCT00807885|rHuPH20
1290208|NCT00807872|Radioimmunoimaging
1290209|NCT00807872|AL Amyloidosis
1290210|NCT00807872|PET/CT
1290211|NCT00807859|AMG 386
1290212|NCT00807859|Paclitaxel
1290213|NCT00807859|Trastuzumab
1290214|NCT00807859|Capecitabine
1290215|NCT00807859|Lapatinib
1290216|NCT00807859|HER2-positive
1290217|NCT00807859|metastatic breast cancer
1290218|NCT00807859|locally recurrent breast cancer
1290219|NCT00807859|Taxol
1290220|NCT00807859|Herceptin
1290221|NCT00807859|Xeloda
1290222|NCT00807859|Tykerb
1290223|NCT00807859|anti-angiogenic therapy
1290224|NCT00807846|Juvenile Arthritis; Juvenile Rheumatoid Arthritis;Blood Pressure;Juvenile Idiopathic Arthritis
1290225|NCT00807833|SAH
1290226|NCT00807833|TBI
1290227|NCT00807820|Prostate Cancer
1290228|NCT00807807|Plasma Homocysteine Concentration
1290229|NCT00807807|Folate
1290230|NCT00807807|Homocysteine
1290231|NCT00807807|Supplements
1290232|NCT00807807|Folic Acid
1290233|NCT00807755|unspecified adult solid tumor, protocol specific
1290234|NCT00807755|extensive stage small cell lung cancer
1290235|NCT00807755|recurrent small cell lung cancer
1290236|NCT00807742|Contingency management for smoking for substance abusers
1290237|NCT00807742|Contingency reinforcement for smoking abstinence
1290238|NCT00807742|Contingency Management
1290239|NCT00807742|Noncontingent Reinforcement
1290240|NCT00807729|Laparoscopy
1290241|NCT00807729|Endoscopic retrograde cholangiopancreatography
1290242|NCT00807729|Sphincterotomy
1290243|NCT00807729|Common bile duct stones
1290244|NCT00807729|Laparoscoopic common bile duct exploration
1290245|NCT00807729|Cost efficiency
1290246|NCT00807729|Examination of efficacy, safety, cost of intervention for patients with choleclithiasis and likely common bile duct stones
1290247|NCT00807716|physiotherapy
1290248|NCT00807716|functional outcome
1290249|NCT00807716|activity level
1290250|NCT00807716|self efficacy
1290251|NCT00807716|task oriented exercises
1290252|NCT00807703|Parkinson
1290253|NCT00807703|deep brain stimulation (DBS)
1290254|NCT00807703|subthalamic nucleus (STN)
1290255|NCT00807703|Parkinson patients
1290256|NCT00807690|vitiligo
1290257|NCT00807690|tacrolimus ointment 0.1%
1290258|NCT00807690|narrowband UVB (TL01)
1290259|NCT00807677|Chronic myelogenous leukemia (CML) in chronic phase, accelerated phase, or blast crisis
1290260|NCT00807677|Intermediate or high risk myelodysplastic syndrome
1290261|NCT00807677|Philadelphia chromosome-negative CML (including blast phase)
1290262|NCT00807677|All subtypes of myeloid metaplasia with myelofibrosis; advanced polycythemia
1290263|NCT00807651|Diabetes Mellitus
1290264|NCT00807651|Stem cells
1290265|NCT00807651|Autologous stem cell transplantation
1290266|NCT00807651|Autoimmune diseases
1290267|NCT00807625|HIV/AIDS
1290268|NCT00807625|Contraception
1290269|NCT00807625|Birth control
1290270|NCT00807625|CD4+
1290271|NCT00807625|Viral Load
1290272|NCT00807625|T-cell activation
1290273|NCT00807625|B-cell activation
1290274|NCT00807625|Hormonal
1290275|NCT00807625|Intrauterine device
1290276|NCT00807625|Depo Provera
1290277|NCT00807625|Women
1290278|NCT00807625|IUCD
1290279|NCT00807625|treatment naive
1290280|NCT00807612|AMG 479
1290281|NCT00807612|IGF-1R
1290282|NCT00807612|Apoptosis
1290283|NCT00807612|Monoclonal Antibody
1290284|NCT00807612|Advanced Squamous Non-Small Cell Lung Cancer
1290285|NCT00807612|antibody 1st-line
1290286|NCT00807599|CYCLOPHOSPHAMIDE (CYTOXAN)
1290287|NCT00807599|DEXAMETHASONE
1290288|NCT00807599|G-CSF
1290289|NCT00807599|Lenalidomide
1290290|NCT00807599|MELPHALAN
1290291|NCT00807599|PEG-FILGRASTIM (NEULASTA)
1290292|NCT00807599|08-121
1290293|NCT00807586|Atrial Fibrillation
1290294|NCT00807586|Corticosteroid
1290295|NCT00807586|Radiofrequency catheter ablation for atrial fibrillation
1290296|NCT00807573|BEVACIZUMAB (AVASTIN)
1290297|NCT00807573|PEMETREXED (ALTIMA)
1290298|NCT00807573|TAXOL (PACLITAXEL)
1290299|NCT00807573|08-109
1290300|NCT00807560|Overweight
1290301|NCT00807560|Obesity
1290302|NCT00807560|Adolescents
1290303|NCT00807560|Family Therapy
1290304|NCT00807534|Chronic Obstructive Pulmonary Disease (COPD)
1290305|NCT00807534|Exercise
1290306|NCT00807534|3-min constant rate stepping test
1290307|NCT00807534|3-min constant rate walking test
1290308|NCT00807534|Bronchodilation
1290309|NCT00807534|Ipratropium bromide
1290310|NCT00807495|MLN8237
1290311|NCT00807495|alisertib
1290312|NCT00807482|Primary Ciliary Dyskinesia
1290313|NCT00807482|Mucociliary Clearance
1290314|NCT00807482|Genetic Mutation
1290315|NCT00807469|COPD
1290316|NCT00807469|smoking
1290317|NCT00807469|susceptibility
1290318|NCT00807469|inflammation
1290319|NCT00807469|genetic
1290320|NCT00807443|HIV-1
1290321|NCT00807443|integrase inhibitor (raltegravir)
1290322|NCT00807443|the cell reservoir of HIV-1
1290323|NCT00807443|treatment experienced
1290324|NCT00807430|Bruxism
1290325|NCT00807430|EMG
1290326|NCT00807430|Biofeedback
1290327|NCT00807404|ductal intraepithelial neoplasia
1290328|NCT00807391|lung cancer
1290329|NCT00807391|transbronchial biopsy
1290330|NCT00807391|transbronchial catheter aspiration
1290331|NCT00807391|transbronchial needle aspiration
1290332|NCT00807391|peripheral pulmonary lesion
1290333|NCT00807391|bronchoscopy
1290334|NCT00807378|CNS viral infection
1290335|NCT00807378|PCR
1290336|NCT00807378|HYBRIDIZATION
1290337|NCT00807365|Growth Hormone-Releasing Hormone
1290338|NCT00807365|Growth Hormone Insufficiency
1290339|NCT00807365|Aging
1290340|NCT00807365|Growth Hormone
1290341|NCT00807365|Physiological Effects of Drugs
1290342|NCT00807365|Hormones, Hormone Substitutes, and Hormone Antagonists
1290343|NCT00807365|Hormones
1290344|NCT00807352|Triage
1290345|NCT00807352|Pediatrics
1290346|NCT00807352|Emergency Department
1290347|NCT00807339|CyberKnife
1290348|NCT00807326|Antidiarrheals
1290349|NCT00807313|Oligometastatic disease
1290350|NCT00807313|Colorectal cancer
1290351|NCT00807313|Stereotactic body radiotherapy
1290352|NCT00807313|Tomotherapy
1290353|NCT00807313|Metabolic response
1290354|NCT00807313|Stage IV
1290355|NCT00807300|percutaneous treatment
1290356|NCT00807287|jejunal tube placement
1290357|NCT00807274|Adult congenital heart disease
1290358|NCT00807274|Heart failure
1290359|NCT00807274|Renal failure
1290360|NCT00807274|Proteinuria
1290361|NCT00807235|Lucinactant
1290362|NCT00807235|Nasal continuous positive airway pressure (nCPAP)
1290363|NCT00807235|Respiratory distress syndrome (RDS)
1290364|NCT00807235|Pediatric
1290365|NCT00807235|Premature
1290366|NCT00807222|ADHD
1290367|NCT00807222|Vyvanse
1290368|NCT00807222|lisdexamfetamine dimesylate
1290369|NCT00807222|LDX
1290370|NCT00807222|sleep
1290371|NCT00807209|Pain
1290372|NCT00807209|postoperative
1290373|NCT00807209|thoracotomy
1290374|NCT00807196|Allogeneic Stem Cell Transplantation
1290375|NCT00807196|Zevalin
1290376|NCT00807196|Non-Hodgkins Lymphoma
1290377|NCT00807170|Non-small Cell Lung Cancer (NSCLC)
1290378|NCT00807170|Whole Brain Radiotherapy
1290379|NCT00807170|metastasis
1290380|NCT00807157|PROBIOSTICK®
1290381|NCT00807157|Probiotic
1290382|NCT00807157|Anxiety
1290383|NCT00807157|Daily stress
1290384|NCT00807144|Kidney transplant
1290385|NCT00807144|Rejection
1290386|NCT00807144|Adherence
1290387|NCT00807144|Quality of life
1290388|NCT00807131|pharmacy care
1290389|NCT00807131|hypertension
1290390|NCT00807131|primary care
1290391|NCT00807131|adherence
1290392|NCT00807118|bioequivalence, food effect
1290393|NCT00807105|MOOD EVALUATION
1290394|NCT00807079|recurrent cervical cancer
1290395|NCT00807079|stage IVB cervical cancer
1290396|NCT00807079|stage IVA cervical cancer
1290397|NCT00807079|cervical adenocarcinoma
1290398|NCT00807079|cervical adenosquamous cell carcinoma
1290399|NCT00807079|cervical squamous cell carcinoma
1290400|NCT00807066|QUALITY OF LIFE
1290401|NCT00807053|Seasonal Allergic Rhinitis
1290402|NCT00807053|Ciclesonide
1290403|NCT00807053|SAR
1290404|NCT00807040|Ischemic Mitral Regurgitation
1290405|NCT00807040|Mitral Valve Disease
1290406|NCT00807040|Severe Mitral Regurgitation
1290407|NCT00807027|Glioblastoma
1290408|NCT00807027|Newly diagnosed Glioblastoma
1290409|NCT00807014|Differin
1290410|NCT00807014|quality of life
1290411|NCT00807014|Acne
1290412|NCT00807014|Duac
1290413|NCT00807014|Acne Vulgaris
1290414|NCT00807001|Hepatitis C, HCV, treatment-naive
1290415|NCT00806988|Ischemic Mitral Regurgitation
1290416|NCT00806988|Mitral Valve Regurgitation
1290417|NCT00806910|Heart Failure
1290418|NCT00806910|conivaptan
1290419|NCT00806910|Diuresis
1290420|NCT00806884|Cystic Fibrosis
1290421|NCT00806884|Musculoskeletal Physiotherapy
1290422|NCT00806884|Manual therapy
1290423|NCT00806884|Posture
1290424|NCT00806884|Pain
1290425|NCT00806845|HIV
1290426|NCT00806845|B-lymphocyte
1290427|NCT00806832|Medical clowns
1290428|NCT00806832|Cataract surgery
1290429|NCT00806832|Blood pressure
1290430|NCT00806832|Heart rate
1290431|NCT00806806|pain management
1290432|NCT00806806|postoperative
1290433|NCT00806780|gallstones
1290434|NCT00806780|cholangiography
1290435|NCT00806767|stage III adult Burkitt lymphoma
1290436|NCT00806767|stage III adult diffuse large cell lymphoma
1290437|NCT00806767|stage III adult diffuse mixed cell lymphoma
1290438|NCT00806767|stage III adult diffuse small cleaved cell lymphoma
1290439|NCT00806767|stage III adult Hodgkin lymphoma
1290440|NCT00806767|stage III adult immunoblastic large cell lymphoma
1290441|NCT00806767|stage III adult lymphoblastic lymphoma
1290442|NCT00806767|stage III grade 1 follicular lymphoma
1290443|NCT00806767|stage III grade 2 follicular lymphoma
1290444|NCT00806767|stage III grade 3 follicular lymphoma
1290445|NCT00806767|stage III mantle cell lymphoma
1290446|NCT00806767|stage III marginal zone lymphoma
1290447|NCT00806767|stage III small lymphocytic lymphoma
1290448|NCT00806767|stage IV adult Burkitt lymphoma
1290449|NCT00806767|stage IV adult diffuse large cell lymphoma
1290450|NCT00806767|stage IV adult diffuse mixed cell lymphoma
1290451|NCT00806767|stage IV adult diffuse small cleaved cell lymphoma
1290452|NCT00806767|stage IV adult Hodgkin lymphoma
1290453|NCT00806767|stage IV adult immunoblastic large cell lymphoma
1290454|NCT00806767|stage IV adult lymphoblastic lymphoma
1290455|NCT00806767|stage IV grade 1 follicular lymphoma
1290456|NCT00806767|stage IV grade 2 follicular lymphoma
1290457|NCT00806767|stage IV grade 3 follicular lymphoma
1290458|NCT00806767|stage IV mantle cell lymphoma
1290459|NCT00806767|stage IV marginal zone lymphoma
1290460|NCT00806767|stage IV small lymphocytic lymphoma
1290461|NCT00806767|recurrent adult Burkitt lymphoma
1290462|NCT00806767|recurrent adult diffuse large cell lymphoma
1290463|NCT00806767|recurrent adult diffuse mixed cell lymphoma
1290464|NCT00806767|recurrent adult diffuse small cleaved cell lymphoma
1290465|NCT00806767|recurrent adult Hodgkin lymphoma
1290466|NCT00806767|recurrent adult immunoblastic large cell lymphoma
1290467|NCT00806767|recurrent adult lymphoblastic lymphoma
1290468|NCT00806767|recurrent cutaneous T-cell non-Hodgkin lymphoma
1290469|NCT00806767|recurrent grade 1 follicular lymphoma
1290470|NCT00806767|recurrent grade 2 follicular lymphoma
1290471|NCT00806767|recurrent grade 3 follicular lymphoma
1290472|NCT00806767|recurrent mantle cell lymphoma
1290473|NCT00806767|recurrent marginal zone lymphoma
1290474|NCT00806767|recurrent small lymphocytic lymphoma
1290475|NCT00806767|recurrent mycosis fungoides/Sezary syndrome
1290476|NCT00806767|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1290477|NCT00806767|nodal marginal zone B-cell lymphoma
1290478|NCT00806767|splenic marginal zone lymphoma
1290479|NCT00806767|noncontiguous stage II adult Burkitt lymphoma
1290480|NCT00806767|noncontiguous stage II adult diffuse large cell lymphoma
1290481|NCT00806767|noncontiguous stage II adult diffuse mixed cell lymphoma
1290482|NCT00806767|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1290483|NCT00806767|noncontiguous stage II adult immunoblastic large cell lymphoma
1290484|NCT00806767|noncontiguous stage II adult lymphoblastic lymphoma
1290485|NCT00806767|noncontiguous stage II grade 1 follicular lymphoma
1290486|NCT00806767|noncontiguous stage II grade 2 follicular lymphoma
1290487|NCT00806767|noncontiguous stage II grade 3 follicular lymphoma
1290488|NCT00806767|noncontiguous stage II mantle cell lymphoma
1290489|NCT00806767|noncontiguous stage II marginal zone lymphoma
1290490|NCT00806767|noncontiguous stage II small lymphocytic lymphoma
1290491|NCT00806767|accelerated phase chronic myelogenous leukemia
1290492|NCT00806767|adult acute lymphoblastic leukemia in remission
1290493|NCT00806767|adult acute myeloid leukemia in remission
1290494|NCT00806767|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1290495|NCT00806767|adult acute myeloid leukemia with inv(16)(p13;q22)
1290496|NCT00806767|adult acute myeloid leukemia with t(15;17)(q22;q12)
1290497|NCT00806767|adult acute myeloid leukemia with t(16;16)(p13;q22)
1290498|NCT00806767|adult acute myeloid leukemia with t(8;21)(q22;q22)
1290499|NCT00806767|atypical chronic myeloid leukemia, BCR-ABL1 negative
1290500|NCT00806767|blastic phase chronic myelogenous leukemia
1290501|NCT00806767|chronic myelomonocytic leukemia
1290502|NCT00806767|chronic phase chronic myelogenous leukemia
1290503|NCT00806767|recurrent adult acute lymphoblastic leukemia
1290504|NCT00806767|recurrent adult acute myeloid leukemia
1290505|NCT00806767|recurrent childhood acute lymphoblastic leukemia
1290506|NCT00806767|recurrent childhood acute myeloid leukemia
1290507|NCT00806767|refractory chronic lymphocytic leukemia
1290508|NCT00806767|refractory hairy cell leukemia
1290509|NCT00806767|relapsing chronic myelogenous leukemia
1290510|NCT00806767|secondary acute myeloid leukemia
1290511|NCT00806767|stage III chronic lymphocytic leukemia
1290512|NCT00806767|stage IV chronic lymphocytic leukemia
1290513|NCT00806767|chronic eosinophilic leukemia
1290514|NCT00806767|primary myelofibrosis
1290515|NCT00806767|chronic neutrophilic leukemia
1290516|NCT00806767|de novo myelodysplastic syndromes
1290517|NCT00806767|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1290518|NCT00806767|previously treated myelodysplastic syndromes
1290519|NCT00806767|secondary myelodysplastic syndromes
1290520|NCT00806767|stage I multiple myeloma
1290521|NCT00806767|stage II multiple myeloma
1290522|NCT00806767|stage III multiple myeloma
1290523|NCT00806767|refractory multiple myeloma
1290524|NCT00806754|Perennial Allergic Rhinitis
1290525|NCT00806754|Ciclesonide
1290526|NCT00806754|PAR
1290527|NCT00806741|L-NG-Monomethyl Arginine
1290528|NCT00806741|Optic Nerve Head blood flow
1290529|NCT00806741|Intraocular Pressure
1290530|NCT00806741|Regional blood flow
1290531|NCT00806741|Ocular Physiology
1290532|NCT00806741|Optic Disk
1290533|NCT00806715|hemochromatosis
1290534|NCT00806715|Iron overload
1290535|NCT00806715|Stem cell transplant
1290536|NCT00806715|Pediatrics
1290537|NCT00806715|Pediatric Stem cell transplant
1290538|NCT00806689|heart rhythm surveillance
1290539|NCT00806689|follow-up
1290540|NCT00806689|atrial fibrillation success
1290541|NCT00806676|chronic kidney disease
1290542|NCT00806676|children
1290543|NCT00806676|dialysis
1290544|NCT00806676|kidney transplant
1290545|NCT00806676|human papilloma virus
1290546|NCT00806676|Gardasil
1290547|NCT00806676|Chronic kidney disease (non-dialysis, dialysis, and kidney transplant) secondary to any cause.
1290548|NCT00806663|mCRC
1290549|NCT00806663|colorectal cancer
1290550|NCT00806663|FOLFIRI
1290551|NCT00806663|sunitinib
1290552|NCT00806663|DCE-MRI
1290553|NCT00806663|DCE-USI
1290554|NCT00806650|stage I renal cell cancer
1290555|NCT00806650|stage II renal cell cancer
1290556|NCT00806650|stage III renal cell cancer
1290557|NCT00806650|stage IV renal cell cancer
1290558|NCT00806637|Vessel sealing system
1290559|NCT00806637|uvulopalatoplasty
1290560|NCT00806637|UPPP
1290561|NCT00806637|uvulopalatal flap
1290562|NCT00806637|bleeding
1290563|NCT00806637|operative time
1290564|NCT00806637|adverse effects
1290565|NCT00806611|pancreatic cancer
1290566|NCT00806611|periampullary cancer
1290567|NCT00806611|resectable
1290568|NCT00806611|unresectable
1290569|NCT00806611|celiac plexus neurolysis
1290570|NCT00806611|surgery
1290571|NCT00806598|Myelodysplastic Syndrome
1290572|NCT00806598|Aplastic Anemia
1290573|NCT00806598|Thymoglobulin
1290574|NCT00806598|Cyclosporine
1290575|NCT00806598|Methylprednisolone
1290576|NCT00806598|G-CSF
1290577|NCT00806572|Diabetes, juvenile diabetes, teplizumab
1290578|NCT00806559|effects clinical space
1290579|NCT00806559|follow-up appointments
1290580|NCT00806520|Continuous Glucose Monitoring
1290581|NCT00806520|Exenatide Once Weekly or
1290582|NCT00806520|Januvia or
1290583|NCT00806520|Actos
1290584|NCT00806507|Tissue Doppler Imaging
1290585|NCT00806507|B-type natriuretic peptide
1290586|NCT00806507|Advia Centaur immunoassay system
1290587|NCT00806507|GE Vivid ultrasound machine
1290588|NCT00806507|Roche 2010 system
1290589|NCT00806507|Echocardiography
1290590|NCT00806507|Herceptin
1290591|NCT00806494|Fesoterodine
1290592|NCT00806494|Open Label
1290593|NCT00806494|Flexible Dose
1290594|NCT00806494|OAB
1290595|NCT00806481|Phosphate
1290596|NCT00806468|nycturia
1290597|NCT00806468|Parkinson syndrome
1290598|NCT00806468|desmopressin
1290599|NCT00806468|Nocturnal polyuria in patients with Parkinson syndrome
1290600|NCT00806455|to determine how often exercise-induced bronchospasm
1290601|NCT00806455|occurs in cystic fibrosis
1290602|NCT00806455|Exercise-induced bronchospasm in cystic fibrosis
1290603|NCT00806442|Asthma
1290604|NCT00806442|Fatty acids
1290605|NCT00806442|Leukotrienes
1290606|NCT00806442|Diet
1290607|NCT00806429|appendicitis
1290608|NCT00806429|surgery
1290609|NCT00806429|laparoscopy
1290610|NCT00806429|natural orifice transluminal surgery
1290611|NCT00806403|thrombolysis
1290612|NCT00806403|primary PCI
1290613|NCT00806403|abciximab
1290614|NCT00806403|ST-segment resolution
1290615|NCT00806403|TIMI flow
1290616|NCT00806390|ejection fraction
1290617|NCT00806390|anthracyclines
1290618|NCT00806390|beta-adrenergic blockade
1290619|NCT00806390|Patients receiving anthracyclines
1290620|NCT00806377|Electromagnetic field
1290621|NCT00806377|Oversensing
1290622|NCT00806377|Non-thoracic surgery
1290623|NCT00806364|Healthy Volunteers
1290624|NCT00806364|Allergy
1290625|NCT00806364|Bone Marrow
1290626|NCT00806364|Buccal Mucosa
1290627|NCT00806364|HV
1290628|NCT00806364|Healthy Volunteer
1290629|NCT00806351|Candidiasis; Invasive Candidiasis; Candida; Candidemia; Fungal Infection; Neutropenia
1290630|NCT00806325|Severe Sepsis
1290631|NCT00806325|Acute Myeloid Leukemia
1290632|NCT00806325|Sepsis in patients being treated for Acute Myeloid Leukemia
1290633|NCT00806312|MiRNA
1290634|NCT00806312|pulmonary arterial hypertension
1290635|NCT00806273|debridement
1290636|NCT00806273|root canal
1290637|NCT00806260|Overweight
1290638|NCT00806260|Obesity
1290639|NCT00806260|coordination
1290640|NCT00806260|psychomotor
1290641|NCT00806247|Tapentadol
1290642|NCT00806247|Bunionectomy
1290643|NCT00806247|Analgesia
1290644|NCT00806247|Acute pain
1290645|NCT00806247|Postsurgical pain
1290646|NCT00806234|Weight Gain
1290647|NCT00806234|Obesity
1290648|NCT00806234|IMPACT
1290649|NCT00806234|Antipsychotic Treatment
1290650|NCT00806234|Excessive Weight Gain Associated With Antipsychotic Treatment
1290651|NCT00806234|Hybrid Efficacy/Effectiveness Design
1290652|NCT00806234|Reducing Weight Gain
1290653|NCT00806234|Improving Metabolic Parameters
1290654|NCT00806234|Aripiprazole
1290655|NCT00806234|Metformin
1290656|NCT00806234|Risperdal
1290657|NCT00806234|Seroquel
1290658|NCT00806234|Quetiapine
1290659|NCT00806234|Olanzapine
1290660|NCT00806234|Zyprexa
1290661|NCT00806234|Geodon
1290662|NCT00806234|Risperidone
1290663|NCT00806234|Abilify
1290664|NCT00806234|Trilafon
1290665|NCT00806234|Perphenazine
1290666|NCT00806234|Glucophage
1290667|NCT00806234|Paliperidone
1290668|NCT00806234|Olanzapine/fluoxetine
1290669|NCT00806221|Atopic Dermatitis
1290670|NCT00806221|Prevention
1290671|NCT00806221|Skin Barrier
1290672|NCT00806195|vaccine
1290673|NCT00806195|infants
1290674|NCT00806195|healthy
1290675|NCT00806195|meningitis
1290676|NCT00806195|meningococcal
1290677|NCT00806182|paraneoplastic
1290678|NCT00806182|neuroblastoma
1290679|NCT00806182|Kinsbourne syndrome
1290680|NCT00806182|autoimmune disease
1290681|NCT00806182|immunotherapy
1290682|NCT00806182|ataxia
1290683|NCT00806169|combined therapy
1290684|NCT00806169|DRP
1290685|NCT00806169|efficacy
1290686|NCT00806169|safety
1290687|NCT00806169|sustainability
1290688|NCT00806169|macular edema due to DRP
1290689|NCT00806143|Depression
1290690|NCT00806143|TMS
1290691|NCT00806117|Cervical cancer
1290692|NCT00806117|Concurrent chemoradiation
1290693|NCT00806117|Randomized controlled clinical trials
1290694|NCT00806091|AM proteomes will be compared between smokers with and without COPD
1290695|NCT00806078|Healthy
1290696|NCT00806078|Bioequivalence
1290697|NCT00806078|Pharmacokinetics
1290698|NCT00804973|Migraine
1290699|NCT00804973|Headache
1290700|NCT00804960|Cost of Infertility Treatment
1290701|NCT00804960|Ovulation Induction
1290702|NCT00804960|Letrozole
1290703|NCT00804960|In Vitro Fertilization
1290704|NCT00804947|Autologous transplantation
1290705|NCT00804947|Multiple Myeloma
1290706|NCT00804947|Intravenous Busulfan
1290707|NCT00804921|bevacizumab
1290708|NCT00804921|intra-ocular pressure
1290709|NCT00804921|acetazolamide
1290710|NCT00804921|anterior chamber paracentesis
1290711|NCT00804921|brimonidine
1290712|NCT00804921|macular edema secondary to diabetic retinopathy or macular degeneration
1290713|NCT00804908|Temozolomide
1290714|NCT00804908|Skin cancer
1290715|NCT00804908|Melanoma
1290716|NCT00804908|Metastatic Melanoma
1290717|NCT00804908|ABT-888
1290718|NCT00804908|MM
1290719|NCT00804895|cluster headache
1290720|NCT00804895|greater occipital nerve block
1290721|NCT00804895|cortivazol
1290722|NCT00804882|Metabolic syndrome
1290723|NCT00804882|Heart failure
1290724|NCT00804882|Mexican Americans
1290725|NCT00804882|Ethnic differences
1290726|NCT00804882|Echocardiography
1290727|NCT00804830|adjuvant
1290728|NCT00804830|Anaplastic thyroid cancer
1290729|NCT00806039|Kidney Failure, Acute
1290730|NCT00806039|Renal Insufficiency, Acute
1290731|NCT00806039|Kidney Failure
1290732|NCT00806039|Renal Insufficiency
1290733|NCT00806026|RLS
1290734|NCT00806013|genotype
1290735|NCT00806000|Prevalence of Exercised induced asthma in athletes
1290736|NCT00805974|diapasom
1290737|NCT00805974|sleep quality
1290738|NCT00805974|type I diabete
1290739|NCT00805974|blood pressure
1290740|NCT00805974|plasma glucose
1290741|NCT00805974|daytime and nighttime variations
1290742|NCT00805961|Glioblastoma Multiforme
1290743|NCT00805961|Radiation Therapy
1290744|NCT00805961|Temozolomide
1290745|NCT00805961|Bevacizumab
1290746|NCT00805961|Everolimus
1290747|NCT00805948|thoracic aneurysm
1290748|NCT00805948|thoracic aortic aneurysms
1290749|NCT00805948|Thoracic Endovascular Aneurysm Repair (TEVAR)
1290750|NCT00805948|Talent Thoracic Stent Graft
1290751|NCT00805935|pre-menopausal women
1290752|NCT00805935|PCOS
1290753|NCT00805935|polycystic ovarian syndrome
1290754|NCT00805935|infertility
1290755|NCT00805935|IVF
1290756|NCT00805935|in vitro fertilization
1290757|NCT00805883|Prostate Neoplasm
1290758|NCT00805883|Localized
1290759|NCT00805883|Photothermal
1290760|NCT00805883|Radical Prostatectomy
1290761|NCT00805844|Spine
1290762|NCT00805844|Motor Evoked Potentials
1290763|NCT00805831|sutureless vascular bypass
1290764|NCT00805805|Copper
1290765|NCT00805805|ceruloplasmin
1290766|NCT00805805|tetrathiomolybdate
1290767|NCT00805792|Ischemic stroke
1290768|NCT00805792|treatment
1290769|NCT00805792|recovery
1290770|NCT00805792|donepezil
1290771|NCT00805792|Aricept
1290772|NCT00805779|Overactive Bladder
1290773|NCT00805779|Overactive Urinary Bladder
1290774|NCT00805779|Bladder, Overactive
1290775|NCT00805779|Overactive Detrusor
1290776|NCT00805779|Detrusor, Overactive
1290777|NCT00805779|Overactive Detrusor Function
1290778|NCT00805779|Detrusor Function, Overactive
1290779|NCT00805766|Infliximab
1290780|NCT00805766|REMICADE
1290781|NCT00805766|Crohn's disease
1290782|NCT00805740|Candidiasis; Invasive Candidiasis; Deep Tissue Candidiasis; Candida; Candidemia; Fungal Infection
1290783|NCT00805714|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1290784|NCT00805701|prostate
1290785|NCT00805701|cancer
1290786|NCT00805701|avodart
1290787|NCT00805701|dutasteride
1290788|NCT00805701|mitcheson
1290789|NCT00805688|Questionnaire
1290790|NCT00805688|Pancreas
1290791|NCT00805688|Pancreatic Cancer
1290792|NCT00805688|Metastatic Disease
1290793|NCT00805688|symptom outcomes
1290794|NCT00805688|Biomarkers
1290795|NCT00805688|Pedometer
1290796|NCT00805688|MDASI-GI symptom assessment
1290797|NCT00805688|interactive voice response telephone system
1290798|NCT00805688|IVRS
1290799|NCT00805675|Chronic HBV
1290800|NCT00805675|Asian adult subjects with chronic HBV, in immune tolerant phase, and positive for hepatitis B e antigen (HBeAg)
1290801|NCT00805662|IUI
1290802|NCT00805662|oxytocin
1290803|NCT00805649|ARMD
1290804|NCT00805649|combined therapy
1290805|NCT00805649|efficacy
1290806|NCT00805649|safety
1290807|NCT00805636|cell death
1290808|NCT00805636|PET imaging
1290809|NCT00805636|brain metastases
1290810|NCT00805636|stereotactic radiosurgery
1290811|NCT00805623|sucrose
1290812|NCT00805623|sucking
1290813|NCT00805623|pain relief
1290814|NCT00805623|infant
1290815|NCT00805623|require venous puncture
1290816|NCT00805610|Liver Failure
1290817|NCT00805610|Hepatocyte Transplantation
1290818|NCT00805610|Liver Transplantation
1290819|NCT00805597|breast cancer
1290820|NCT00805597|mastectomy
1290821|NCT00805597|one to three positive nodes
1290822|NCT00805597|radiotherapy
1290823|NCT00805571|Rejection
1290824|NCT00805571|Infection
1290825|NCT00805571|Side effect of immunosuppressive drug (nephrotoxicity)
1290826|NCT00805558|Chronic Periodontitis
1290827|NCT00805558|antibiotics
1290828|NCT00805532|PTSD
1290829|NCT00805532|depression
1290830|NCT00805532|behavior therapy
1290831|NCT00805532|veterans
1290832|NCT00805532|behavioral activation
1290833|NCT00805532|usual care
1290834|NCT00805519|Osteoarthritis of the Knee
1290835|NCT00805519|Glucosamine Chondroitin sulfate
1290836|NCT00805519|Prednisolone
1290837|NCT00805519|Chloroquine
1290838|NCT00805506|continuous glucose monitoring accuracy
1290839|NCT00805493|Mania
1290840|NCT00805493|Bipolar
1290841|NCT00805493|Bipolar Disorder
1290842|NCT00805493|Bipolar Manic-Depressive Illness
1290843|NCT00805493|Bipolar Mood Disorder
1290844|NCT00805480|Plaque
1290845|NCT00805480|psoriasis
1290846|NCT00805480|inflammatory skin disease
1290847|NCT00805480|skin condition, thickening
1290848|NCT00805480|flaking
1290849|NCT00805480|scaly patches
1290850|NCT00805480|skin disease
1290851|NCT00805467|RA
1290852|NCT00805454|Healthy Volunteers
1290853|NCT00805454|Phase I
1290854|NCT00805454|Pet Scan
1290855|NCT00805441|Alcoholic
1290856|NCT00805415|Oral Contraceptive
1290857|NCT00805415|Ovulation Inhibition
1290858|NCT00805389|Adjuvant Systems
1290859|NCT00805389|Hepatitis B
1290860|NCT00805376|Brain
1290861|NCT00805376|Brain Cancer
1290862|NCT00805376|Central Nervous System Diseases
1290863|NCT00805376|CNS
1290864|NCT00805376|Conditionally Replication-Competent Adenovirus
1290865|NCT00805376|Delta-24-RGD
1290866|NCT00805376|DNX-2401
1290867|NCT00805376|Recurrent Malignant Gliomas
1290868|NCT00805376|malignant brain tumor
1290869|NCT00805350|Insomnia
1290870|NCT00805350|Sleep Maintenance
1290871|NCT00805350|Polysomnography
1290999|NCT00804713|TB
1290872|NCT00805337|Cancer amplitude-modulated electromagnetic fields
1290873|NCT00805311|Internal Carotid Artery Stenosis
1290874|NCT00805311|Carotid Endarterectomy
1290875|NCT00805311|Stroke
1290876|NCT00805311|Cerebrovascular
1290877|NCT00805311|Atherosclerosis
1290878|NCT00805298|third molar
1290879|NCT00805298|postoperative pain
1290880|NCT00805298|thermography
1290881|NCT00805298|postoperative inflammation
1290882|NCT00805298|methylprednisolone
1290883|NCT00805298|local anaesthetic
1290884|NCT00805298|postoperative pain after removal of lower third molars
1290885|NCT00805298|inflammation after removal of lower third molars
1290886|NCT00805285|Inflammatory Bowel Disease
1290887|NCT00805285|Ulcerative Colitis
1290888|NCT00805285|Budesonide
1290889|NCT00805285|Corticosteroids
1290890|NCT00805272|HIV
1290891|NCT00805272|tuberculosis
1290892|NCT00805272|IGRA
1290893|NCT00805272|diagnosis
1290894|NCT00805272|treatment naive
1290895|NCT00805259|cognitive function
1290896|NCT00805259|elderly
1290897|NCT00805259|technology
1290898|NCT00805259|financial incentives
1290899|NCT00805259|General maintenance of cognitive function
1290900|NCT00805246|Pulmonary embolism
1290901|NCT00805246|PE
1290902|NCT00805246|CT
1290903|NCT00805246|Biomarker
1290904|NCT00805246|Prognosis
1290905|NCT00805246|Risk Prediction
1290906|NCT00805233|Neovascular
1290907|NCT00805233|AMD
1290908|NCT00805233|Treatment
1290909|NCT00805233|Lucentis
1290910|NCT00805233|Bromfenac
1290911|NCT00805220|frail elderly walking capacity walk training Nordic Walking
1290912|NCT00805207|PCOS
1290913|NCT00805207|sleep apnea
1290914|NCT00805207|obese
1290915|NCT00805207|VLDL metabolism
1290916|NCT00805207|isotope tracer
1290917|NCT00805207|women
1290918|NCT00805168|Gram-negative Pneumonia
1290919|NCT00805168|Pneumonia
1290920|NCT00805168|Intubation
1290921|NCT00805168|Mechanical ventilation
1290922|NCT00805168|Amikacin
1290923|NCT00805155|Bioequivalence
1290924|NCT00805155|Mometasone Furoate
1290925|NCT00805142|Pain
1290926|NCT00805142|Cancer
1290927|NCT00805142|Tapentadol
1290928|NCT00805129|URETER
1290929|NCT00805129|URINARY BLADDER
1290930|NCT00805129|RAD001
1290931|NCT00805129|Everolimus
1290932|NCT00805129|Urothelium
1290933|NCT00805129|08-123
1290934|NCT00805103|Brain Metastases
1290935|NCT00805103|Stereotactic radiosurgery (SRS)
1290936|NCT00805103|Hypofractionated stereotactic radiotherapy (HSRT)
1290937|NCT00805103|Recurrent Brain Metastases
1290938|NCT00805090|Renal
1290939|NCT00805090|Hepatic
1290940|NCT00805090|Healthy
1290941|NCT00805077|interoperative care
1290942|NCT00805077|Tidal volume
1290943|NCT00805077|Postoperative complications
1290944|NCT00805077|Pneumonectomy
1290945|NCT00805077|Lobectomy
1290946|NCT00805077|Mechanical ventilation
1290947|NCT00805051|Aortic stenosis
1290948|NCT00805051|aortic valve replacement
1290949|NCT00805051|von Willebrand disease
1290950|NCT00805051|blood loss
1290951|NCT00805012|S-1
1290952|NCT00805012|docetaxel
1290953|NCT00805012|head and neck cancer
1290954|NCT00805012|Recurrent or metastatic head and neck squamous cell carcinoma
1290955|NCT00804999|confocal microscopy
1290956|NCT00804999|contact lens wear
1290957|NCT00804999|contact lens solutions
1290958|NCT00804999|sodium fluorescein
1290959|NCT00804817|self management
1290960|NCT00804817|adherence
1290961|NCT00804817|activity enhancement
1290962|NCT00804817|oral mucositis prevention
1290963|NCT00804817|and mal nutrition prevention
1290964|NCT00804817|cancer
1290965|NCT00804817|hematopoietic stem cell transplantation (HSCT)
1290966|NCT00804817|loss of activity
1290967|NCT00804804|Sleep
1290968|NCT00804804|aging
1290969|NCT00804804|cognitives processes
1290970|NCT00804804|constant routine
1290971|NCT00804791|dry eye
1290972|NCT00804791|autofluorescence
1290973|NCT00804791|residence time
1290974|NCT00804778|CAD
1290975|NCT00804778|CABG
1290976|NCT00804778|CO
1290977|NCT00804778|CI
1290978|NCT00804778|thermodilution
1290979|NCT00804778|USCOM
1290980|NCT00804765|Prevention
1290981|NCT00804765|child obesity
1290982|NCT00804765|pregnancy
1290983|NCT00804765|overweight women
1290984|NCT00804765|obese women
1290985|NCT00804752|Patients with Chronic Hepatitis C
1290986|NCT00804739|Major Depression
1290987|NCT00804739|Postpartum Depression
1290988|NCT00804739|Perinatal Depression
1290989|NCT00804739|Treatment Feasibility
1290990|NCT00804739|Treatment Engagement
1290991|NCT00804739|Treatment Adherence
1290992|NCT00804739|Postpartum
1290993|NCT00804739|Interpersonal Psychotherapy
1290994|NCT00804739|IPT
1290995|NCT00804739|Sertraline
1290996|NCT00804739|Zoloft
1290997|NCT00804726|Cataract extraction
1290998|NCT00804726|Phacoemulsification
1291000|NCT00804713|tuberculosis diagnosis
1291001|NCT00804713|TB screening
1291002|NCT00804700|synchronous
1291003|NCT00804700|exercise
1291004|NCT00804700|music
1291005|NCT00804700|heartbeat
1291006|NCT00804700|tunes
1291007|NCT00804687|Allergy
1291008|NCT00804687|Rhinitis
1291009|NCT00804687|Allergic Rhinitis
1291010|NCT00804687|JNJ-39220675
1291011|NCT00804687|Pseudoephedrine
1291012|NCT00804674|bupivacain
1291013|NCT00804674|breast
1291014|NCT00804674|reconstruction
1291015|NCT00804674|diep
1291016|NCT00804674|pain
1291017|NCT00804674|postoperative
1291018|NCT00804674|catheter
1291019|NCT00804674|anesthesia
1291020|NCT00804661|sleep
1291021|NCT00804661|nocturnal hypoventilation
1291022|NCT00804661|sleep quality
1291023|NCT00804661|lung function
1291024|NCT00804622|HBeAg positive compensated chronic hepatitis B
1291025|NCT00804583|Cystic Fibrosis
1291026|NCT00804583|Liver Disease
1291027|NCT00804583|Genetic Modifiers
1291028|NCT00804557|Male Urinary Disorders
1291029|NCT00804557|Urinary catheterization
1291030|NCT00804557|Urinary retention
1291031|NCT00804544|Integrated SPECT/CT
1291032|NCT00804544|99mTc-sestMIBI
1291033|NCT00804544|Chemosensitivity
1291034|NCT00804531|Low back pain
1291035|NCT00804531|steroid injection
1291036|NCT00804531|inter-vertebral disc
1291037|NCT00804531|randomized trial
1291038|NCT00804531|Lack of efficacy of usual recommended treatments
1291039|NCT00804531|More than 40 on the pain numeric scale (0-100)
1291040|NCT00804531|Inflammatory discopathy (MODIC I) on MRI
1291041|NCT00804518|Aging
1291042|NCT00804518|Diastolic dysfunction
1291043|NCT00804518|Systolic function
1291044|NCT00804518|Exercise
1291045|NCT00804518|Echocardiography
1291046|NCT00804518|tissue Doppler imaging
1291047|NCT00804518|Cardiac function
1291048|NCT00804505|Substantial equivalence to control device
1291049|NCT00804492|To organize a multidisciplinary team for integrated falls prevention
1291050|NCT00804492|To draft a guideline for falls prevention in the elderly
1291051|NCT00804492|To set up a multidisciplinary fall clinic
1291052|NCT00804492|To set up a falls prevention classroom
1291053|NCT00804492|To enhance cooperate between hospitals and primary care units for falls prevention
1291054|NCT00804466|Human Papillomavirus
1291055|NCT00804466|Natural History
1291056|NCT00804466|Cervical Cancer
1291057|NCT00804466|Screening
1291058|NCT00804453|Chronic Kidney Failure
1291059|NCT00804453|Hemodialysis
1291060|NCT00804453|Biocompatibility
1291061|NCT00804440|bioequivalency
1291062|NCT00804440|ibuprofen
1291063|NCT00804427|Fish oil
1291064|NCT00804427|Triglycerides
1291065|NCT00804427|Low-density Lipoprotein (LDL) cholesterol
1291066|NCT00804427|Low-density Lipoprotein (LDL) subclass
1291067|NCT00804427|Low-density Lipoprotein (LDL) particle size
1291068|NCT00804427|Low-density Lipoprotein (LDL) phenotype
1291069|NCT00804414|Diabetes
1291070|NCT00804414|Diabetic ulcer
1291071|NCT00804414|Chronic ulcer
1291072|NCT00804414|SBG
1291073|NCT00804401|bioequivalency
1291074|NCT00804401|Naproxen
1291075|NCT00804388|Vitamine E
1291076|NCT00804388|E-poly
1291077|NCT00804388|Hip
1291078|NCT00804388|Degenerative joint disease
1291079|NCT00804375|stump pain
1291080|NCT00804349|Heart Decompensation
1291081|NCT00804349|Heart Failure, Congestive
1291082|NCT00804349|Heart Failure, Left-Sided
1291083|NCT00804349|Heart Failure, Right-Sided
1291084|NCT00804349|Apnea, Sleep
1291085|NCT00804349|Sleep Apnea, Mixed Central and Obstructive
1291086|NCT00804349|Sleep Hypopnea
1291087|NCT00804349|Sleep-Disordered Breathing
1291088|NCT00804336|pasireotide
1291089|NCT00804336|SOM230
1291090|NCT00804336|RAD001
1291091|NCT00804310|unspecified adult solid tumor, protocol specific
1291092|NCT00804297|Hypoglycemia
1291093|NCT00804297|Diabetes Mellitus
1291094|NCT00804297|Octreotide
1291095|NCT00804284|DAPTACEL®
1291096|NCT00804284|PENTACEL®
1291097|NCT00804284|Diphtheria
1291098|NCT00804284|Tetanus
1291099|NCT00804284|Pertussis
1291100|NCT00804284|Haemophilus influenzae type b
1291101|NCT00804258|recurrent ovarian epithelial cancer
1291102|NCT00804258|recurrent ovarian germ cell tumor
1291103|NCT00804258|stage I ovarian epithelial cancer
1291104|NCT00804258|stage I ovarian germ cell tumor
1291105|NCT00804258|stage II ovarian epithelial cancer
1291106|NCT00804258|stage II ovarian germ cell tumor
1291107|NCT00804258|stage III ovarian epithelial cancer
1291108|NCT00804258|stage III ovarian germ cell tumor
1291109|NCT00804258|stage IV ovarian epithelial cancer
1291110|NCT00804258|stage IV ovarian germ cell tumor
1291111|NCT00804245|adenocarcinoma of the prostate
1291112|NCT00804245|stage I prostate cancer
1291113|NCT00804245|stage II prostate cancer
1291114|NCT00804245|stage III prostate cancer
1291115|NCT00804245|stage IV prostate cancer
1291116|NCT00804232|Diabetes type1; children
1291239|NCT00803725|duration of anesthesia
1291117|NCT00804219|low responsiveness after vaccination
1291118|NCT00804206|Intravitreal injection of Bevacizumab
1291119|NCT00804206|Visual acuity
1291120|NCT00804206|central retinal thickness
1291121|NCT00804206|color studies, Farnsworth-Munsell
1291122|NCT00804206|electroretinogram studies
1291123|NCT00804193|Tinea Pedis
1291124|NCT00804193|Ciclopirox Olamine
1291125|NCT00804180|anxiety
1291126|NCT00804180|injection
1291127|NCT00804180|needle
1291128|NCT00804180|pediatric
1291129|NCT00804180|youth
1291130|NCT00804180|children
1291131|NCT00804180|adolescents
1291132|NCT00804180|cognitive behavioral
1291133|NCT00804180|behavioral
1291134|NCT00804180|exposure
1291135|NCT00804180|group
1291136|NCT00804180|treatment
1291137|NCT00804180|chronic illness
1291138|NCT00804180|adherence
1291139|NCT00804167|Hypertensive patients aged of 75 years and older
1291140|NCT00804167|renal damage
1291141|NCT00804167|Clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage
1291142|NCT00804154|Pain
1291143|NCT00804154|Vanilloid
1291144|NCT00804154|Capsaicin
1291145|NCT00804154|Cancer Pain
1291146|NCT00804154|Resiniferatoxin
1291147|NCT00804141|treatment for opioid-induced constipation
1291148|NCT00804128|ductal breast carcinoma in situ
1291149|NCT00804115|Exfoliation Syndrome
1291150|NCT00804115|Latanoprost
1291151|NCT00804115|Timolol
1291152|NCT00804115|Pilocarpine
1291153|NCT00804102|Retinitis pigmentosa
1291154|NCT00804102|Macula off
1291155|NCT00804102|Primary open angle Glaucoma
1291156|NCT00804102|Hereditary Macular Degeneration
1291157|NCT00804102|Treated Retina detachment
1291285|NCT00803543|treatment experienced
1291158|NCT00804102|Retinal Artery Occlusion
1291159|NCT00804102|Retinal Vein Occlusion,
1291160|NCT00804102|Non-Arthritic-Anterior-Ischemic Optic-Neuropathy
1291161|NCT00804102|Hereditary autosomal dominant Optic atrophy
1291162|NCT00804102|dry Age-related Macular Degeneration
1291163|NCT00804102|Ischemic Macula edema
1291164|NCT00804089|Low Back Pain, Chronic
1291165|NCT00804089|Acupuncture
1291166|NCT00804089|Dry Needling
1291167|NCT00804089|Acupressure
1291168|NCT00804089|Acupuncture Points
1291169|NCT00804089|Trigger Points, Myofascial
1291170|NCT00804076|gene therapy
1291171|NCT00804076|replication defective HSV vector
1291172|NCT00804076|pain
1291173|NCT00804076|enkephalin
1291174|NCT00804076|intradermal
1291175|NCT00804063|glaucoma
1291176|NCT00804063|citrate
1291177|NCT00804050|Myelodysplastic Syndromes
1291178|NCT00804050|Erythropoietin
1291179|NCT00804050|Acid 13-Cis-Retinoic
1291180|NCT00804050|Dihydroxyvitamin D3
1291181|NCT00804050|low or intermediate-1 IPSS
1291182|NCT00804050|MDS low risk
1291183|NCT00804037|Snoring and Mild Apnea
1291184|NCT00804024|Heart Diseases. Vascular Diseases.
1291185|NCT00804011|Snakebite
1291186|NCT00804011|Weaning
1291187|NCT00804011|Mechanical ventilation
1291188|NCT00803985|Inguinal hernia
1291189|NCT00803985|TEP
1291190|NCT00803985|Lichtenstein
1291191|NCT00803985|mesh
1291192|NCT00803985|Randomized
1291193|NCT00803985|Chronic pain
1291194|NCT00803985|Sexual dysfunction
1291195|NCT00803972|Humalog
1291196|NCT00803972|Humulin R
1291197|NCT00803972|rHuPH20
1291198|NCT00803972|Hylenex
1291199|NCT00803959|Stress urinary incontinence, Mixed, Urge
1291200|NCT00803946|bioequivalency
1291201|NCT00803946|ibuprofen
1291202|NCT00803933|first stage
1291203|NCT00803933|Trypanosoma brucei gambiense
1291204|NCT00803933|T. b. gambiense
1291205|NCT00803933|sleeping sickness
1291206|NCT00803933|First stage T. b. gambiense sleeping sickness
1291207|NCT00803920|exenatide twice daily or once weekly
1291208|NCT00803920|continuous glucose monitoring
1291209|NCT00803907|immunomodulator
1291210|NCT00803907|Carcinoma, Basal Cell
1291211|NCT00803894|Biomarkers of Notch inhibition
1291212|NCT00803855|single dose
1291213|NCT00803855|pharmacokinetics
1291214|NCT00803855|safety
1291215|NCT00803855|healthy volunteers
1291216|NCT00803855|food interaction
1291217|NCT00803855|AZD1446
1291218|NCT00803842|erlotinib
1291219|NCT00803842|rash
1291220|NCT00803842|supportive care
1291221|NCT00803816|endogoneous
1291222|NCT00803816|posterior
1291223|NCT00803816|intermediate
1291224|NCT00803803|Pilocarpine
1291225|NCT00803803|POAG
1291226|NCT00803803|IOP
1291227|NCT00803803|Concentration
1291228|NCT00803803|Frequency
1291229|NCT00803803|Primary open-angle glaucoma
1291230|NCT00803803|Primary open-angle glaucoma suspect
1291231|NCT00803764|bioequivalency
1291232|NCT00803764|naproxen
1291233|NCT00803751|Laryngoscopy [E04.580.373]
1291234|NCT00803738|Vulvovaginal Candidiasis
1291235|NCT00803738|Terconazole
1291236|NCT00803725|spinal anesthesia
1291237|NCT00803725|mepivacaine
1291238|NCT00803725|fentanyl
1291240|NCT00803725|knee arthroscopy
1291241|NCT00803725|regional anesthesia
1291242|NCT00803725|Spinal anesthesia for knee arthroscopy
1291243|NCT00803699|selenium
1291244|NCT00803673|Healthy volunteers
1291245|NCT00803673|New formulation
1291246|NCT00803660|hypertension
1291247|NCT00803660|BP
1291248|NCT00803660|diabetes
1291249|NCT00803660|anti-hypertensive treatment
1291250|NCT00803660|ACE-I
1291251|NCT00803660|ARB
1291252|NCT00803647|NSABP
1291253|NCT00803647|Cetuximab
1291254|NCT00803647|FOLFOX7
1291255|NCT00803647|Oxaliplatin
1291256|NCT00803647|Leucovorin
1291257|NCT00803647|5-FU
1291258|NCT00803647|colorectal cancer
1291259|NCT00803647|KRAS wild type
1291260|NCT00803647|metastatic colorectal cancer
1291261|NCT00803647|Erbitux
1291262|NCT00803647|Eloxatin
1291263|NCT00803647|Liver resection
1291264|NCT00803647|Liver ablation
1291265|NCT00803647|Metastasectomy
1291266|NCT00803634|Hypertension
1291267|NCT00803634|Antihypertensive Agent
1291268|NCT00803634|Calcium Channel Blocker
1291269|NCT00803608|Plantar
1291270|NCT00803608|Ulcer
1291271|NCT00803608|Diabetes
1291272|NCT00803595|Influenza
1291273|NCT00803595|Neuraminidase inhibitor
1291274|NCT00803569|recurrent ovarian epithelial cancer
1291275|NCT00803569|stage II ovarian epithelial cancer
1291276|NCT00803569|stage III ovarian epithelial cancer
1291277|NCT00803569|stage IV ovarian epithelial cancer
1291278|NCT00803569|fallopian tube cancer
1291279|NCT00803569|peritoneal cavity cancer
1291280|NCT00803543|HSV-2
1291281|NCT00803543|Herpes Simplex
1291282|NCT00803543|HSV Type 2
1291283|NCT00803543|HIV
1291284|NCT00803543|HIV/HSV
1291286|NCT00803530|myelodysplastic syndromes
1291287|NCT00803530|arsenic trioxide
1291288|NCT00803530|ascorbic acid
1291289|NCT00803517|chronic central serous chorioretinopathy
1291290|NCT00803517|multifocal electroretinogram
1291291|NCT00803517|central retinal function after treatment in chronic serous chorioretinopathy
1291292|NCT00803504|optic disc morphology
1291293|NCT00803504|ocular blood flow
1291294|NCT00803504|retina
1291295|NCT00803504|ocular physiology
1291296|NCT00803491|Rheumatic diseases
1291297|NCT00803491|Problem based learning
1291298|NCT00803491|Health-related quality of life
1291299|NCT00803491|Empowerment
1291300|NCT00803491|Self-care
1291301|NCT00803478|IntraLase LASIK for primary myopia
1291302|NCT00803465|Bioequivalence
1291303|NCT00803465|Fluticasone Propionate
1291304|NCT00803452|Meibomian gland dysfunction
1291305|NCT00803452|Lid margin disease
1291306|NCT00803452|doxycycline
1291307|NCT00803452|azithromycin
1291308|NCT00803452|essential fatty acid
1291309|NCT00803439|Bioequivalence
1291310|NCT00803439|Clobetasol Propionate
1291311|NCT00803426|ultrasound-guided regional anesthesia
1291312|NCT00803426|nerve block
1291313|NCT00803426|popliteal fossa
1291314|NCT00803426|sciatic nerve
1291315|NCT00803426|common peroneal nerve
1291316|NCT00803426|tibial nerve
1291317|NCT00803426|onset time
1291318|NCT00803426|ankle surgery
1291319|NCT00803426|foot surgery
1291320|NCT00803413|Chronic low back pain
1291321|NCT00803413|Back School
1291322|NCT00803413|Walking
1291323|NCT00803413|Physical activity
1291324|NCT00803400|Panic disorder
1291325|NCT00803400|Exercise
1291326|NCT00803400|Alprazolam
1291327|NCT00803400|Aerobic
1291328|NCT00803387|ocular dryness
1291329|NCT00803387|ocular irritation
1291330|NCT00803387|open-angle glaucoma
1291331|NCT00803387|ocular hypertension
1291332|NCT00803387|TravatanZ
1291333|NCT00803387|Xalatan
1291334|NCT00803361|anxiety
1291335|NCT00803348|continuous femoral nerve blockade
1291336|NCT00803348|knee arthroplasty
1291337|NCT00803348|knee replacement
1291338|NCT00803348|regional anesthesia
1291339|NCT00803348|readiness to discharge
1291340|NCT00803348|Femoral nerve blockade for total knee arthroplasty
1291341|NCT00803335|pelvic organ prolapse
1291342|NCT00803335|vaginal atrophy
1291343|NCT00803335|atrophic vaginitis
1291344|NCT00803335|postmenopausal
1291345|NCT00803335|posthysterectomy
1291346|NCT00803335|vaginal health
1291347|NCT00803335|vaginal cytology
1291348|NCT00803335|vaginal maturity index
1291349|NCT00803335|vaginal histology
1291350|NCT00803335|quality of life questionnaires
1291351|NCT00803322|TB
1291352|NCT00803322|community
1291353|NCT00803322|community health workers
1291354|NCT00803322|Ethiopia
1291355|NCT00803322|identify suspects of pulmonary tuberculosis
1291356|NCT00803322|collect sputum specimen for examination
1291357|NCT00803322|treat smear positive cases in the community
1291358|NCT00803309|Chronic HCV-genotype 2/3
1291359|NCT00803309|Efficacy of treatment extension
1291360|NCT00803309|PegIntron
1291361|NCT00803309|pegylated interferon alpha-2b
1291362|NCT00803309|Rebetol
1291363|NCT00803309|ribavirin
1291364|NCT00803283|Pain
1291365|NCT00803283|Hydromorphone hydrochloride OROS
1291366|NCT00803283|Morphine
1291367|NCT00803270|Stress urinary incontinence, Mixed, Urge
1291368|NCT00803257|Carpal Tunnel Syndrome
1291369|NCT00803257|Splint
1291370|NCT00803257|Hand exercises
1291371|NCT00803244|allergic rhinoconjunctivitis
1291372|NCT00803218|Bioequivalence
1291373|NCT00803218|Fluticasone Propionate
1291374|NCT00803205|Cystic fibrosis
1291375|NCT00803205|Nonsense mutation
1291376|NCT00803205|Premature stop codon
1291377|NCT00803205|PTC124
1291378|NCT00803205|Ataluren
1291379|NCT00803192|bioavailability
1291380|NCT00803192|famotidine
1291381|NCT00803179|CF
1291382|NCT00803166|Bioequivalence
1291383|NCT00803166|Halobetasol Propionate
1291384|NCT00803153|Panretinal photocoagulation
1291385|NCT00803153|Bruch rupture
1291386|NCT00803153|Choroidal detachment
1291387|NCT00803153|complication rates
1291388|NCT00803140|scarring
1291389|NCT00803127|vaginal infection, color appearance
1291390|NCT00803114|Postpartum perineal pain
1291391|NCT00803114|Epidural morphine
1291392|NCT00803114|Randomised clinical trial
1291393|NCT00803101|Anticoagulant reversal
1291394|NCT00803101|Prothrombin Complex Concentrate
1291395|NCT00803101|Coagulopathy
1291396|NCT00803101|Coumarin derivatives
1291397|NCT00803101|Emergency surgery
1291398|NCT00803101|Invasive procedures
1291399|NCT00803101|Vitamin K
1291400|NCT00803101|Reversal of coagulopathy induced by coumarin derivatives
1291401|NCT00803101|Kcentra
1291402|NCT00803049|Multiple Sclerosis
1291403|NCT00803049|Oral treatment
1291404|NCT00803036|spreading cortical depression
1291405|NCT00803036|electroencephalography
1291406|NCT00803036|traumatic brain injury
1291407|NCT00803036|intensive care
1291408|NCT00803036|vascular hypotension
1291409|NCT00803036|intracranial hypertension
1291410|NCT00803010|Acute Graft Versus Host Disease (aGVHD)
1291411|NCT00803010|GVHD
1291412|NCT00803010|graft-versus-host disease
1291413|NCT00803010|tacrolimus
1291414|NCT00803010|sirolimus
1291415|NCT00803010|methotrexate
1291416|NCT00803010|combination therapy
1291417|NCT00803010|GVHD prophylaxis
1291418|NCT00802971|Reactive hypoglycaemia
1291419|NCT00802971|Fiber
1291420|NCT00802971|Prevalence
1291421|NCT00802971|Randomised controlled trial
1291422|NCT00802971|Idiopathic reactive hypoglycemia
1291423|NCT00802958|Bioequivalence
1291424|NCT00802958|Halobetasol Propionate
1291425|NCT00802932|breast cancer
1291426|NCT00802932|female
1291427|NCT00802932|metallic markers
1291428|NCT00802932|image guided radiation therapy
1291429|NCT00802932|IGRT
1291430|NCT00802919|schizophrenia
1291431|NCT00802919|smoking
1291432|NCT00802919|nicotine
1291433|NCT00802919|cognitive deficits
1291434|NCT00802919|DNMT1 mRNA
1291435|NCT00802919|nicotinic receptors
1291436|NCT00802919|Cognitive Deficits in Schizophrenia
1291437|NCT00802906|micropulselaserphotocoagulation
1291438|NCT00802906|bevacizumab
1291439|NCT00802906|CSC
1291440|NCT00802893|Isolated Systolic Hypertension with Endothelial Dysfunction
1291441|NCT00802867|DAPTACEL®
1291442|NCT00802867|PENTACEL™
1291443|NCT00802867|Diphtheria
1291444|NCT00802867|Tetanus
1291445|NCT00802867|Pertussis
1291446|NCT00802867|Haemophilus influenzae type b
1291447|NCT00802854|anidulafungin
1291448|NCT00802854|safety
1291449|NCT00802854|efficacy
1291450|NCT00802841|Chronic
1291451|NCT00802841|Myelogenous
1291452|NCT00802841|Leukemia
1291453|NCT00802841|CML
1291454|NCT00802841|Chronic Phase
1291455|NCT00802841|Suboptimal Response
1291456|NCT00802828|bioavailability
1291457|NCT00802828|famotidine
1291458|NCT00802763|VAGINAL INFECTION
1291459|NCT00802763|COLOR APPEARANCE
1291460|NCT00802763|ELEVATED Ph
1291461|NCT00802737|Maintenance
1291462|NCT00802737|Retreatment
1291463|NCT00802737|Chronic lymphocytic leukemia
1291464|NCT00802737|B-Cell Chronic Lymphocytic Leukemia
1291465|NCT00802737|Ofatumumab
1291466|NCT00802724|low back pain
1291467|NCT00802724|classification
1291468|NCT00802724|spine
1291469|NCT00802711|stage IA breast cancer
1291470|NCT00802711|stage IB breast cancer
1291471|NCT00802711|stage II breast cancer
1291472|NCT00802711|invasive ductal breast carcinoma
1291473|NCT00802698|Biphasic waveform
1291474|NCT00802698|Central retinal artery occlusion
1291475|NCT00802698|To describe the effect of Transcorneal Electrical Stimulation (TES) with a non conventional biphasic bipolar waveform
1291476|NCT00802698|in central retinal artery occlusion
1291477|NCT00802685|Patent ductus arteriosus
1291478|NCT00802685|Respiratory outcome
1291479|NCT00802672|Tinea Pedis
1291480|NCT00802672|Ciclopirox Olamine
1291481|NCT00802646|first-time mother
1291482|NCT00802646|epidural request
1291483|NCT00802646|vaginal childbirth
1291484|NCT00802633|Tissue sealing device
1291485|NCT00802633|Articulating stapling device
1291486|NCT00802633|Radical cystectomy
1291487|NCT00802620|Amniotic membrane
1291488|NCT00802620|Conjunctival autograft
1291489|NCT00802620|Recurrent pterygia
1291490|NCT00802620|compare amniotic membrane associated with conjunctival autograft versus conjunctival autograft alone in the treatment of recurrent pterygia
1291491|NCT00802607|Bone Diseases
1291492|NCT00802607|Connective Tissue Diseases
1291493|NCT00802594|first stage
1291494|NCT00802594|T.b. gambiense
1291495|NCT00802594|sleeping sickness
1291496|NCT00802594|Patients with first stage T.b. gambiense sleeping sickness
1291497|NCT00802581|sciatic nerve block
1291498|NCT00802581|local anesthetic
1291499|NCT00802581|lidocaine
1291500|NCT00802581|ankle surgery
1291501|NCT00802581|foot surgery
1291502|NCT00802581|ultrasound-guided regional anesthesia
1291503|NCT00802581|circumferential spread
1291504|NCT00802581|anesthetic infiltration
1291505|NCT00802568|stage I multiple myeloma
1291506|NCT00802568|stage II multiple myeloma
1291507|NCT00802568|stage III multiple myeloma
1291508|NCT00802568|refractory multiple myeloma
1291509|NCT00802568|osteolytic lesions of multiple myeloma
1291510|NCT00802555|HCC
1291511|NCT00802555|Cirrhotic Patients with Hepatocellular Carcinoma
1291512|NCT00802542|Hypertension
1291513|NCT00802542|blood pressure
1291514|NCT00802542|Atacand
1291515|NCT00802529|Meniere's disease
1291516|NCT00802529|transtympanic steroids
1291517|NCT00802529|Randomised controlled trial
1291518|NCT00802503|Critically ill
1291519|NCT00802503|nutrition
1291520|NCT00802503|randomised controlled clinical trial
1291521|NCT00802503|human
1291522|NCT00802503|adult
1291523|NCT00802503|Supplemental parenteral nutrition
1291524|NCT00802490|Attention Deficit Hyperactivity Disorder
1291525|NCT00802490|Electroencephalogram biofeedback
1291526|NCT00802490|Inattention
1291527|NCT00802490|Brain-Computer Interface System
1291528|NCT00802477|mastectomy
1291529|NCT00802477|seroma
1291530|NCT00802477|lymph node dissection
1291531|NCT00802464|Cytokine
1291532|NCT00802464|Vaccine
1291533|NCT00802464|Herpes Zoster (HZ)
1291534|NCT00802464|Cell mediated immunity (CMI)
1291535|NCT00802464|Antibody response
1291536|NCT00802464|Varicella Zoster Virus (VZV)
1291537|NCT00802464|Shingles
1291538|NCT00802451|Bioavailability
1291539|NCT00802451|Mesalamine
1291543|NCT00802425|Sudden hearing loss
1291544|NCT00802425|Sudden deafness
1291545|NCT00802425|Acoustic trauma
1291546|NCT00802425|Noise trauma
1291547|NCT00802412|tobacco use disorders
1291548|NCT00802412|alcoholism
1291549|NCT00802399|Cornea
1291550|NCT00802399|Dry eye
1291551|NCT00802399|lacrimal punctual occlusion
1291552|NCT00802399|lacrimal film
1291553|NCT00802399|ocular surface
1291554|NCT00802386|BACTERIAL VAGINOSIS
1291555|NCT00802386|IUD INSERTION
1291556|NCT00802373|Overactive Bladder
1291557|NCT00802360|Healthy, pre-menopausal women, age 18-42 with a history of infertility and requiring IVF
1291558|NCT00802347|Delayed Graft Function
1291559|NCT00802347|Kidney Transplant
1291560|NCT00802347|Renal Transplant
1291561|NCT00802347|small interfering ribonucleic acid (siRNA)
1291562|NCT00802334|generic lopinavir/ritonavir
1291563|NCT00802334|therapeutic drug monitoring
1291564|NCT00802334|safety and efficacy
1291565|NCT00802321|steroid 5AReductase
1291566|NCT00802321|genetic polymorphism
1291567|NCT00802321|GABA receptor
1291568|NCT00802295|Ovarian
1291569|NCT00802295|hyperstimulation
1291570|NCT00802295|Embryo
1291571|NCT00802295|Aneuploidy
1291572|NCT00802295|Ovarian hyperstimulation and Embryo Aneuploidy Rates
1291573|NCT00802282|healthy volunteers
1291574|NCT00802282|spirituality
1291575|NCT00802282|psilocybin
1291576|NCT00802282|meditation
1291577|NCT00802269|Proliferative diabetic retinopathy
1291578|NCT00802269|Laser photocoagulation
1291579|NCT00802269|Pain
1291580|NCT00802256|pulpotomy
1291581|NCT00802256|primary molar teeth
1291582|NCT00802256|MTA
1291583|NCT00802256|NEC
1291584|NCT00802256|CEM
1291585|NCT00802256|Primary Molar Teeth Which Require Pulpotomy Treatment
1291586|NCT00802243|Bullous pemphigoid
1291587|NCT00802243|leflunomide
1291588|NCT00802243|corticosteroid treatment reduction
1291589|NCT00802243|Patients are screened by: the physicians in different departments of the hospital, the liberal dermatologists and the general practicioners.
1291590|NCT00802243|Phase I: Patients will be referred to the investigators of Dupuytren Hospital Dermatology Department.
1291591|NCT00802243|Phase II: Patients will be referred to the investigators of Purpan (Toulouse), Haut Leveque (Pessac) and Dupuytren (Limoges) Hospitals.
1291592|NCT00802217|Pharmacokinetics
1291593|NCT00802217|Safety
1291594|NCT00802217|Tolerability
1291595|NCT00802217|Healthy Volunteers
1291596|NCT00802204|Obesity
1291597|NCT00802204|Insulin Resistance
1291598|NCT00802204|Neuroendocrine regulation
1291599|NCT00802204|Eating behaviors
1291600|NCT00802204|Dopamine signaling
1291601|NCT00802165|Asymptomatic normals
1291602|NCT00802152|Diabetes
1291603|NCT00802152|Hypertension
1291604|NCT00802139|iron deficiency anemia
1291605|NCT00802139|pregnant women with iron deficiency anemia
1291606|NCT00802113|Autologous Stem Cell Transplant
1291607|NCT00802113|Cord Blood Transplant
1291608|NCT00802113|Allogeneic Stem Cell Transplant
1291609|NCT00802113|Relapsed Lymphoma
1291610|NCT00802100|Schizoaffective Disorder
1291611|NCT00802087|Hydrocodone
1291612|NCT00802087|Pharmacokinetics
1291613|NCT00802087|Safety & Tolerability
1291614|NCT00802074|Healthy Subjects
1291615|NCT00802074|Pharmacokinetics study
1291616|NCT00802074|Pharmacokinetics of medications
1291617|NCT00802061|progressive glaucoma despite controlled IOP
1291618|NCT00802048|Sternotomy
1291619|NCT00802048|Postoperative hyperalgesia
1291620|NCT00802048|Intralesional anesthetic infusion
1291621|NCT00802048|Ropivacaïne
1291622|NCT00802048|Chronic
1291623|NCT00802048|Postoperative pain
1291624|NCT00802048|Cardiac surgery
1291625|NCT00802048|Sternum
1291626|NCT00802048|Cardiac surgical procedures
1291627|NCT00802035|ALK29
1291628|NCT00802035|Alcohol Dependence
1291629|NCT00802035|Pharmacokinetics
1291630|NCT00802022|diabetic neuropathies
1291631|NCT00802022|electric stimulation therapy
1291632|NCT00802009|ultrasound-guided regional anesthesia
1291633|NCT00802009|nerve block
1291634|NCT00802009|brachial plexus
1291635|NCT00802009|mepivicaine
1291636|NCT00802009|dexamethasone
1291637|NCT00802009|hand wrist surgery
1291638|NCT00802009|duration
1291639|NCT00802009|anesthetic duration following brachial plexus/nerve block for hand/wrist surgery
1291640|NCT00801996|prostate cancer
1291641|NCT00801996|genetics
1291642|NCT00801970|Fear of childbirth
1291643|NCT00801970|Tokophobia
1291644|NCT00801970|Anxiety
1291645|NCT00801970|Labor
1291646|NCT00801970|Pregnancy
1291647|NCT00801970|Cognitive-behavioral
1291648|NCT00801970|Psychoanalysis
1291649|NCT00801970|Group Therapy
1291650|NCT00801970|etiology
1291651|NCT00801957|atopic dermatitis
1291652|NCT00801957|meningitis
1291653|NCT00801957|vaccination
1291654|NCT00801957|tacrolimus
1291655|NCT00801957|steroids
1291656|NCT00801957|equivalence response
1291657|NCT00801957|meningococcal vaccine
1291658|NCT00801944|Overactive Bladder
1291659|NCT00801931|Cord Blood Transplant
1291660|NCT00801931|Allogeneic Stem Cell Transplant
1291661|NCT00801918|lymphoma
1291662|NCT00801918|pediatric
1291663|NCT00801918|adolescent
1291664|NCT00801918|relapsed
1291665|NCT00801918|refractory
1291666|NCT00801918|denileukin diftitox
1291667|NCT00801918|Ontak
1291668|NCT00801905|Macular thickening
1291669|NCT00801905|Macular edema
1291670|NCT00801905|Pan-retinal photocoagulation
1291671|NCT00801905|Nepafenac
1291672|NCT00801905|Topical non-steroidal anti inflammatory agents
1291673|NCT00801892|daytime sleepiness
1291674|NCT00801892|obstructive sleep apnea
1291675|NCT00801892|type 2 diabetes mellitus
1291676|NCT00801892|diabetes management
1291677|NCT00801879|mupirocin
1291678|NCT00801879|Staphylococcus aureus
1291679|NCT00801879|colonization
1291680|NCT00801879|infection
1291681|NCT00801879|HIV
1291682|NCT00801866|Panretinal Photocoagulation
1291683|NCT00801866|Macular Edema
1291684|NCT00801866|Intravitreal Bevacizumab
1291685|NCT00801853|asthma
1291686|NCT00801853|allergy
1291687|NCT00801853|atopy
1291688|NCT00801853|atopic
1291689|NCT00801853|wheeze
1291690|NCT00801827|Obesity
1291691|NCT00801827|Addiction
1291692|NCT00801827|PET imaging
1291693|NCT00801814|viscous
1291694|NCT00801814|fibre
1291695|NCT00801814|polysaccharide
1291696|NCT00801814|blood glucose
1291697|NCT00801814|post prandial
1291698|NCT00801801|Docetaxel
1291699|NCT00801801|Sorafenib
1291700|NCT00801775|calorimetry
1291701|NCT00801736|Recurrent non-small cell lung cancer
1291702|NCT00801736|Stage IIIB non-small cell lung cancer
1291703|NCT00801736|Stage IV non-small cell lung cancer
1291704|NCT00801723|Ulcerative Colitis
1291705|NCT00801697|HIV Seronegativity
1291706|NCT00801697|HIV Preventive Vaccine
1291707|NCT00801697|Adenovirus
1291708|NCT00801684|COPD
1291709|NCT00801684|pulmonary
1291710|NCT00801684|inhalation
1291711|NCT00801671|obstructive sleep apnea
1291712|NCT00801671|obstructive sleep apnea syndrome
1291713|NCT00801671|hypertension
1291714|NCT00801671|systemic hypertension
1291715|NCT00801671|ambulatory blood pressure monitoring
1291716|NCT00801658|glaucoma
1291717|NCT00801658|SLT
1291718|NCT00801658|Laser treatment
1291719|NCT00801658|IOP
1291720|NCT00801658|glaucoma treated with eye drops but IOP not controlled
1291721|NCT00801645|Obesity
1291722|NCT00801645|Cardiovascular disease
1291723|NCT00801645|Endothelial function
1291724|NCT00801645|Blood pressure
1291725|NCT00801645|Exercise
1291726|NCT00801645|Physical activity
1291727|NCT00801645|Metabolic syndrome
1291728|NCT00801645|Children
1291729|NCT00801645|Pediatric
1291730|NCT00801632|renal allograft tolerance
1291731|NCT00801632|mixed chimerism
1291732|NCT00801632|kidney transplant
1291733|NCT00801632|bone marrow transplant
1291734|NCT00801632|antirejection
1291735|NCT00801632|immunosuppression
1291736|NCT00801606|Micronutrient
1291737|NCT00801606|Childhood Tuberculosis
1291738|NCT00801593|JIA
1291739|NCT00801580|relapsed ALL
1291740|NCT00801580|refractory ALL
1291741|NCT00801580|relapsed adult acute lymphoid leukemia
1291742|NCT00801567|Bipolar disorder
1291743|NCT00801567|Schizophrenia
1291744|NCT00801567|Healthy volunteer
1291745|NCT00801567|Brain imaging
1291746|NCT00801567|Photic stimulation
1291747|NCT00801554|Autism Spectrum Disorder
1291748|NCT00801554|ASD
1291749|NCT00801554|Autism
1291750|NCT00801554|Asperger's Syndrome
1291751|NCT00801554|PDD-NOS
1291752|NCT00801554|Pervasive Developmental Disorders- Not Otherwise Specified
1291753|NCT00801554|Adults
1291754|NCT00801554|Children
1291755|NCT00801541|AMD
1291756|NCT00801528|ropivacaine
1291757|NCT00801528|diclofenac
1291758|NCT00801528|local anesthetic instillation
1291759|NCT00801515|Compassionate
1291760|NCT00801515|HIV
1291761|NCT00801515|CCR5
1291762|NCT00801502|Omega-3
1291763|NCT00801502|Oily fish
1291764|NCT00801502|Antioxidant
1291765|NCT00801502|Selenium
1291766|NCT00801502|Atopic disease
1291767|NCT00801502|Pregnancy
1291768|NCT00801502|Nutrient status
1291769|NCT00801489|Leukemia
1291770|NCT00801489|Acute Myelogenous Leukemia
1291771|NCT00801489|AML
1291772|NCT00801476|Breast Cancer
1291773|NCT00801476|Magnetic Resonance Imaging
1291774|NCT00801476|Preoperative MRI
1291775|NCT00801463|Focal Segmental Glomerulosclerosis
1291776|NCT00801463|Prednisone
1291777|NCT00801463|Tripterygium Wilfordii
1291778|NCT00801450|diabetes
1291779|NCT00801450|macular edema
1291780|NCT00801450|triamcinolone
1291781|NCT00801450|cataract
1291782|NCT00801450|refractory diabetic macular edema
1291783|NCT00801437|glaucoma, open-angle, non-interventional study, safety, tolerability
1291784|NCT00801424|abdominal surgery
1291785|NCT00801424|hypothermia
1291786|NCT00801424|wound dessication
1291787|NCT00801424|warming
1291788|NCT00801411|stage II breast cancer
1291789|NCT00801398|Opioid tolerant
1291790|NCT00801398|Pediatric
1291791|NCT00801398|Pain
1291792|NCT00801398|Non malignant
1291793|NCT00801398|Malignant
1291794|NCT00801385|recurrent non-small cell lung cancer
1291795|NCT00801385|stage IIIB non-small cell lung cancer
1291796|NCT00801385|stage IV non-small cell lung cancer
1291797|NCT00801372|pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy.
1291798|NCT00801372|pregnant healthy couples older than 18 who signed an informed consent for a c-section.
1291799|NCT00801372|healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent.
1291800|NCT00801359|cataract
1291801|NCT00801359|phacoemulsification
1291802|NCT00801359|irrigation solution
1291803|NCT00801359|endothelial cell density
1291804|NCT00801359|corneal thickness
1291805|NCT00801346|fatigue
1291806|NCT00801346|long-term effects secondary to cancer therapy in children
1291807|NCT00801346|childhood acute lymphoblastic leukemia in remission
1291808|NCT00801346|B-cell childhood acute lymphoblastic leukemia
1291809|NCT00801346|T-cell childhood acute lymphoblastic leukemia
1291810|NCT00801333|ALS
1291811|NCT00801320|tumor harvest
1291812|NCT00801320|tumor collection
1291813|NCT00801320|tumor storage
1291814|NCT00801307|evaluate Inspiratory Capacity (IC) measured by spirometry
1291815|NCT00801281|Lymphoma
1291816|NCT00801281|Immunochemotherapy
1291817|NCT00801281|Induction therapy
1291818|NCT00801281|Maintenance therapy
1291819|NCT00801281|Follicular lymphoma grade 1,2,3a
1291820|NCT00801281|Marginal zone lymphoma, including MALT type
1291821|NCT00801281|Small lymphocytic lymphoma (BM inv. <30%)
1291822|NCT00801268|polycystic kidney disease
1291823|NCT00801268|tripterygium wilfordii
1291824|NCT00801229|ADHD
1291825|NCT00801229|young adults
1291826|NCT00801229|driving
1291827|NCT00801229|Vyvanse
1291828|NCT00801229|lisdexamfetamine
1291829|NCT00801216|B-cell lymphomas
1291830|NCT00801216|lymphomatous meningitis
1291831|NCT00801216|liposomal cytarabine
1291832|NCT00801216|autologous transplant
1291833|NCT00801216|CNS involvement
1291834|NCT00801216|Secondary CNS lymphomas
1291835|NCT00801203|Stress Urinary Incontinence
1291836|NCT00801190|colloid
1291837|NCT00801190|CABG
1291838|NCT00801190|cardiopulmonary bypass
1291839|NCT00801190|bleeding
1291840|NCT00801177|Tumors
1291841|NCT00801177|Antibodies, Monoclonal
1291842|NCT00801164|Diabetes Type 2
1291843|NCT00801164|Periodontitis
1291844|NCT00801138|ropivacaine
1291845|NCT00801138|bupivacaine
1291846|NCT00801138|glucocorticoid
1291847|NCT00801112|Bioimpedance
1291848|NCT00801112|Fluid status
1291849|NCT00801112|Peritoneal Dialysis
1291850|NCT00801112|Extra-cellular fluid volume
1291851|NCT00801099|Postoperative wound infection
1291852|NCT00801099|surgical site infection
1291853|NCT00801099|antimicrobial prophylaxis
1291854|NCT00801099|developing countries
1291855|NCT00801099|Sub-Saharan Africa
1291856|NCT00801099|reduction of SSI using preoperative antibiotics
1291857|NCT00801086|Alopecia
1291858|NCT00801086|Hair loss
1291859|NCT00801086|Radiation
1291860|NCT00801086|Whole brain radiotherapy
1291861|NCT00801086|Radiation-induced alopecia
1291862|NCT00801073|Amniotic membrane
1291863|NCT00801073|Cornea
1291864|NCT00801073|Scleral thinning
1291865|NCT00801060|Fludara
1291866|NCT00801060|CD23
1291867|NCT00801060|Cyclophosphamide
1291868|NCT00801060|Antibody
1291869|NCT00801060|Fludarabine
1291870|NCT00801060|CLL
1291871|NCT00801060|Rituximab
1291872|NCT00801060|Mabthera
1291873|NCT00801060|Biogen Idec
1291874|NCT00801060|Lumiliximab
1291875|NCT00801060|Rituxan
1291876|NCT00801060|Cytoxan
1291877|NCT00801060|Chronic Lymphocytic Leukemia
1291878|NCT00801047|Epidural
1291879|NCT00801047|Labor
1291880|NCT00801047|Remifentanil
1291881|NCT00801034|hypertension
1291882|NCT00801034|potassium
1291883|NCT00801034|blood pressure
1291884|NCT00801021|Cystitis
1291885|NCT00801021|Urinary Tract Infections
1291886|NCT00801008|young adult
1291887|NCT00801008|cancer
1291888|NCT00801008|exercise
1291889|NCT00801008|relaxation
1291890|NCT00800995|ARMD
1291891|NCT00800995|SOD
1291892|NCT00800982|Obese patients (BMI>30)
1291893|NCT00800982|Patients with moderate to severe psoriasis
1291894|NCT00800969|Adenocarcinoma of the stomach and esophagogastric junction
1291895|NCT00800956|Radiolabel ADME study Healthy volunteers
1291896|NCT00800943|Leukemia
1291897|NCT00800943|Chronic
1291898|NCT00800943|Chronic Lymphocytic Leukemia
1291899|NCT00800943|CAMPATH
1291900|NCT00800943|Alemtuzumab
1291901|NCT00800943|MabCampath
1291902|NCT00800943|Subcutaneous
1291903|NCT00800943|CLL
1291904|NCT00800943|C-CLL
1291905|NCT00800943|Residual
1291906|NCT00800930|Shigellosis
1291907|NCT00800930|sodium butyrate
1291908|NCT00800930|antimicrobial peptides
1291909|NCT00800930|LL-37
1291910|NCT00800930|innate immunity
1291911|NCT00800930|The aims are to assess efficacy of sodium butyrate enema in
1291912|NCT00800930|marked improvement in clinical features
1291913|NCT00800930|endoscopic findings
1291914|NCT00800930|histological features
1291915|NCT00800930|Induction of LL-37 in the rectum.
1291916|NCT00800904|Asthma
1291917|NCT00800904|Inhaled corticosteroid
1291918|NCT00800904|Thai patient eligibility
1291919|NCT00800904|Persistent asthma
1291920|NCT00800878|Chronic Kidney Disease
1291921|NCT00800878|Renal insufficiency
1291922|NCT00800852|adiponectin
1291923|NCT00800852|adiponectin receptor
1291924|NCT00800852|Prader-Willi syndrome
1291925|NCT00800839|Post-allogeneic transplantation
1291926|NCT00800839|Graft-versus-Host Disease Prophylaxis
1291927|NCT00800839|Graft-versus-Host Disease
1291928|NCT00800839|GVHD
1291929|NCT00800839|Hematologic malignancies
1291930|NCT00800839|Leukemia
1291931|NCT00800839|Lymphoma
1291932|NCT00800839|Myeloma
1291933|NCT00800839|Human Leukocyte Antigen
1291934|NCT00800839|HLA
1291935|NCT00800839|Busulfan
1291936|NCT00800839|Cyclophosphamide
1291937|NCT00800839|Fludarabine
1291938|NCT00800839|Mesna
1291939|NCT00800839|Cytoxan®
1291940|NCT00800839|Neosar®
1291941|NCT00800839|Busulfex
1291942|NCT00800839|Myleran®
1291943|NCT00800839|Fludarabine Phosphate
1291944|NCT00800813|Prostate
1291945|NCT00800813|Erectile function
1291946|NCT00800813|Peyronie's Plaque
1291947|NCT00800813|08-135
1291948|NCT00800800|progression of aortic stenosis
1291949|NCT00800787|Chronic hepatitis B liver disease
1291950|NCT00800774|LASIK
1291951|NCT00800774|safety
1291952|NCT00800774|efficacy
1291953|NCT00800774|stability
1291954|NCT00800774|high anisometropia
1291955|NCT00800774|patients 8 to 15 years old
1291956|NCT00800774|conventional treatments have failed
1291957|NCT00800722|hypervascular anomalies
1291958|NCT00800709|Alzheimer's Disease
1291959|NCT00800709|tau protein
1291960|NCT00800709|PET
1291961|NCT00800709|Memantine
1291962|NCT00800696|antibiotics
1291963|NCT00800696|Hospitalization
1291964|NCT00800696|oral care
1291965|NCT00800670|tuberculosis
1291966|NCT00800670|vaccine
1291967|NCT00800670|adenovirus
1292316|NCT00799604|Hypertension
1291968|NCT00800657|Cardiac Resynchronization
1291969|NCT00800657|Dilated Cardiomyopathy
1291970|NCT00800657|Stem Cells Therapy
1291971|NCT00800657|Heart Failure
1291972|NCT00800657|Stem Cells/Cardiac Pacing, Artificial
1291973|NCT00800644|Cervical Cancer
1291974|NCT00800644|Endometrial Cancer
1291975|NCT00800644|Vaginal Cancer
1291976|NCT00800644|Cervix
1291977|NCT00800644|Endometrial
1291978|NCT00800644|X-ray
1291979|NCT00800644|Computed tomography
1291980|NCT00800644|Magnetic resonance imaging
1291981|NCT00800644|Vagina
1291982|NCT00800644|Pelvic radiation therapy
1291983|NCT00800644|Bone density
1291984|NCT00800644|Bone mineral density test
1291985|NCT00800644|Pelvic fractures
1291986|NCT00800644|Gynecologic Oncology
1291987|NCT00800644|Bone turnover
1291988|NCT00800592|Sildenafil, Revatio, PAH, IV, Bolus
1291989|NCT00800579|cystic fibrosis
1291990|NCT00800579|CF
1291991|NCT00800579|mucociliary clearance
1291992|NCT00800579|amiloride
1291993|NCT00800579|ENaC
1291994|NCT00800579|ENaC Inhibitor
1291995|NCT00800579|airway hydration
1291996|NCT00800579|epithelial sodium channel inhibitor
1291997|NCT00800566|Clofarabine
1291998|NCT00800566|Leukemia
1291999|NCT00800566|Chronic Lymphocytic Leukemia
1292000|NCT00800553|sleep deprivation
1292001|NCT00800553|fMRI
1292002|NCT00800553|double blind crossover study
1292003|NCT00800540|glaucoma
1292004|NCT00800540|ocular perfusion pressure
1292005|NCT00800540|ocular blood flow
1292006|NCT00800540|open angle glaucoma requiring more than one IOP-lowering medication
1292007|NCT00800527|sternotomy
1292008|NCT00800527|pain
1292009|NCT00800527|paresthesia
1292010|NCT00800527|Poststernotomy chest pain
1292011|NCT00800527|Poststernotomy chest paresthesia
1292012|NCT00800514|perception of time, traumatic brain injury, amantadine
1292013|NCT00800501|ALS
1292014|NCT00800501|VEGF165
1292015|NCT00800501|Safety
1292016|NCT00800501|Intracerebroventricular
1292017|NCT00800501|Infusion
1292018|NCT00800501|Implantable
1292019|NCT00800488|Fever
1292020|NCT00800488|Infant
1292021|NCT00800488|Procalcitonin
1292022|NCT00800488|Serious Bacterial Infection
1292023|NCT00800475|bioavailability
1292024|NCT00800475|Gemfibrozil
1292025|NCT00800449|Haptoglobin
1292026|NCT00800449|sepsis
1292027|NCT00800449|premature babies
1292028|NCT00800423|corneal edema
1292029|NCT00800423|postoperative corneal edema
1292030|NCT00800423|central corneal thickness
1292031|NCT00800423|visual acuity
1292032|NCT00800423|postoperative
1292033|NCT00800423|brimonidine
1292034|NCT00800423|timolol
1292035|NCT00800423|cataract surgery
1292036|NCT00800410|Randomized Controlled Trial
1292037|NCT00800371|JIA
1292038|NCT00800358|Secondary hyperparathyroidism
1292039|NCT00800358|End stage renal disease
1292040|NCT00800358|Haemodialysis
1292041|NCT00800358|Peritoneal dialysis
1292042|NCT00800358|Paricalcitol (Zemplar)
1292043|NCT00800358|Calcitriol
1292044|NCT00800345|Gynecologic tumors
1292045|NCT00800332|Rhinoconjunctivitis due to house dust mite allergy
1292046|NCT00800319|Alcohol dependence
1292047|NCT00800319|Opioid antagonist
1292048|NCT00800319|RDC-0313
1292049|NCT00800306|sepsis
1292050|NCT00800306|septic shock
1292051|NCT00800306|microcirculation
1292052|NCT00800306|levosimendan
1292053|NCT00800306|dobutamine
1292054|NCT00800306|inotropes
1292055|NCT00800306|inhaled nitric oxide
1292056|NCT00800293|bioequivalence
1292057|NCT00800293|betamethasone dipropionate
1292058|NCT00800293|Bioequivalency
1292059|NCT00800280|cimetidine, PD 0332334, organic cation transporter, OCT2, pharmacokinetics
1292060|NCT00800267|glaucoma
1292061|NCT00800267|ocular hypertension
1292062|NCT00800267|Fixed combination latanoprost-timolol
1292063|NCT00800267|latanoprost
1292064|NCT00800267|timolol
1292065|NCT00800254|electrical stimulation
1292066|NCT00800254|total knee arthroplasty
1292067|NCT00800254|quadriceps
1292068|NCT00800254|muscle
1292069|NCT00800254|arthroscopy
1292070|NCT00800241|Asthma
1292071|NCT00800241|Symbicort SMART
1292072|NCT00800241|Thai patient eligibility
1292073|NCT00800241|Persistent asthma
1292074|NCT00800228|salt
1292075|NCT00800228|blood pressure
1292076|NCT00800228|breathing
1292077|NCT00800215|Epilepsy
1292078|NCT00800150|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1292079|NCT00800150|adult acute myeloid leukemia with inv(16)(p13;q22)
1292080|NCT00800150|adult acute myeloid leukemia with t(15;17)(q22;q12)
1292081|NCT00800150|adult acute myeloid leukemia with t(16;16)(p13;q22)
1292082|NCT00800150|adult acute myeloid leukemia with t(8;21)(q22;q22)
1292083|NCT00800150|recurrent adult acute lymphoblastic leukemia
1292084|NCT00800150|recurrent adult acute myeloid leukemia
1292085|NCT00800150|recurrent adult T-cell leukemia/lymphoma
1292086|NCT00800150|secondary acute myeloid leukemia
1292087|NCT00800150|stage III adult T-cell leukemia/lymphoma
1292088|NCT00800150|stage IV adult T-cell leukemia/lymphoma
1292089|NCT00800150|adult grade III lymphomatoid granulomatosis
1292090|NCT00800150|adult nasal type extranodal NK/T-cell lymphoma
1292091|NCT00800150|anaplastic large cell lymphoma
1292092|NCT00800150|angioimmunoblastic T-cell lymphoma
1292093|NCT00800150|splenic marginal zone lymphoma
1292094|NCT00800150|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1292095|NCT00800150|nodal marginal zone B-cell lymphoma
1292096|NCT00800150|stage III adult Burkitt lymphoma
1292097|NCT00800150|stage III adult diffuse large cell lymphoma
1292098|NCT00800150|stage III adult diffuse mixed cell lymphoma
1292099|NCT00800150|stage III adult diffuse small cleaved cell lymphoma
1292100|NCT00800150|stage III adult immunoblastic large cell lymphoma
1292101|NCT00800150|stage III adult lymphoblastic lymphoma
1292102|NCT00800150|stage III cutaneous T-cell non-Hodgkin lymphoma
1292103|NCT00800150|stage III mycosis fungoides/Sezary syndrome
1292104|NCT00800150|stage III grade 1 follicular lymphoma
1292105|NCT00800150|stage III grade 2 follicular lymphoma
1292106|NCT00800150|stage III grade 3 follicular lymphoma
1292107|NCT00800150|stage III mantle cell lymphoma
1292108|NCT00800150|stage III marginal zone lymphoma
1292109|NCT00800150|stage III small lymphocytic lymphoma
1292110|NCT00800150|stage IV adult Burkitt lymphoma
1292111|NCT00800150|stage IV adult diffuse large cell lymphoma
1292112|NCT00800150|stage IV adult diffuse mixed cell lymphoma
1292113|NCT00800150|stage IV adult diffuse small cleaved cell lymphoma
1292114|NCT00800150|stage IV adult immunoblastic large cell lymphoma
1292115|NCT00800150|stage IV adult lymphoblastic lymphoma
1292116|NCT00800150|stage IV cutaneous T-cell non-Hodgkin lymphoma
1292117|NCT00800150|stage IV mycosis fungoides/Sezary syndrome
1292118|NCT00800150|stage IV grade 1 follicular lymphoma
1292119|NCT00800150|stage IV grade 2 follicular lymphoma
1292120|NCT00800150|stage IV grade 3 follicular lymphoma
1292121|NCT00800150|stage IV mantle cell lymphoma
1292122|NCT00800150|stage IV marginal zone lymphoma
1292123|NCT00800150|stage IV small lymphocytic lymphoma
1292124|NCT00800150|recurrent adult Burkitt lymphoma
1292125|NCT00800150|recurrent adult diffuse large cell lymphoma
1292126|NCT00800150|recurrent adult diffuse mixed cell lymphoma
1292127|NCT00800150|recurrent adult diffuse small cleaved cell lymphoma
1292128|NCT00800150|recurrent adult grade III lymphomatoid granulomatosis
1292129|NCT00800150|recurrent adult immunoblastic large cell lymphoma
1292130|NCT00800150|recurrent adult lymphoblastic lymphoma
1292131|NCT00800150|recurrent cutaneous T-cell non-Hodgkin lymphoma
1292132|NCT00800150|recurrent mycosis fungoides/Sezary syndrome
1292133|NCT00800150|recurrent grade 1 follicular lymphoma
1292134|NCT00800150|recurrent grade 2 follicular lymphoma
1292135|NCT00800150|recurrent grade 3 follicular lymphoma
1292136|NCT00800150|recurrent mantle cell lymphoma
1292137|NCT00800150|recurrent marginal zone lymphoma
1292138|NCT00800150|recurrent small lymphocytic lymphoma
1292139|NCT00800150|intraocular lymphoma
1292140|NCT00800150|primary central nervous system non-Hodgkin lymphoma
1292141|NCT00800150|primary myelofibrosis
1292142|NCT00800150|stage II multiple myeloma
1292143|NCT00800150|stage III multiple myeloma
1292144|NCT00800150|refractory multiple myeloma
1292145|NCT00800150|de novo myelodysplastic syndromes
1292146|NCT00800150|previously treated myelodysplastic syndromes
1292147|NCT00800150|secondary myelodysplastic syndromes
1292148|NCT00800150|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1292149|NCT00800150|cutaneous B-cell non-Hodgkin lymphoma
1292150|NCT00800150|Waldenstrom macroglobulinemia
1292151|NCT00800137|coumadin
1292152|NCT00800137|device surgery
1292153|NCT00800137|pocket hematoma
1292154|NCT00800137|Pocket hematoma and device surgery
1292155|NCT00800124|hip fracture
1292156|NCT00800124|hemiprosthesis
1292157|NCT00800124|bone cement
1292158|NCT00800124|clinical outcome
1292159|NCT00800111|failed penetrating keratoplasty
1292160|NCT00800085|first degree relatives of type 1 diabetes patients
1292161|NCT00800085|hyperglycemic clamp test
1292162|NCT00800072|to verify accurrancy of data collected by the NOWOX
1292163|NCT00800059|Relapse
1292164|NCT00800059|Refractory
1292165|NCT00800046|Mitral valve
1292166|NCT00800046|Mitral regurgitation
1292167|NCT00800046|Functional mitral regurgitation
1292168|NCT00800046|MR
1292169|NCT00800046|FMR
1292170|NCT00800046|Heart valve
1292171|NCT00800046|Mitral valve insufficiency
1292172|NCT00800046|Valve repair
1292173|NCT00800046|Valve disorder
1292174|NCT00800046|Cardiac surgery
1292175|NCT00800033|metabolic syndrome
1292176|NCT00800033|lipids
1292177|NCT00800033|blood pressure
1292178|NCT00800033|body composition
1292179|NCT00800007|Hepatitis C, HCV, ANZ-521, Listeria
1292180|NCT00799994|glaucoma
1292181|NCT00799994|intraocular pressure
1292182|NCT00799994|multifocal visually evoked potentials
1292183|NCT00799968|Thrombolytic therapy
1292184|NCT00799968|Urokinase
1292185|NCT00799968|Efficacy
1292186|NCT00799968|Safety
1292187|NCT00799955|Cesarean delivery
1292188|NCT00799955|post-operative analgesia
1292189|NCT00799955|TAP block
1292190|NCT00799955|ultrasound
1292191|NCT00799942|Nystagmus, congenital idiopathic
1292192|NCT00799929|IVF Research Study
1292193|NCT00799929|Infertility Sudy
1292194|NCT00799929|in vitro fertilization
1292195|NCT00799929|Mini IVF
1292196|NCT00799929|Conventional IVF
1292197|NCT00799916|Sepsis
1292198|NCT00799916|Fluid resuscitation
1292199|NCT00799916|Voluven
1292200|NCT00799916|Colloids
1292201|NCT00799916|Saline solution
1292202|NCT00799916|Crystalloids
1292203|NCT00799916|Sublingual microcirculation
1292204|NCT00799903|heart disease
1292205|NCT00799903|Lp-PLA2 inhibitor
1292206|NCT00799903|cardiovascular disease
1292207|NCT00799903|coronary heart disease
1292208|NCT00799903|CV risk
1292209|NCT00799903|Atherosclerosis
1292210|NCT00799890|primary or secondary chronic-progressive
1292211|NCT00799890|sunphenon egcg
1292212|NCT00799890|brain atrophy
1292213|NCT00799890|T2 lesions
1292214|NCT00799877|Chronic Plaque Psoriasis
1292215|NCT00799877|Severe Chronic Plaque Psoriasis
1292216|NCT00799877|Registry
1292217|NCT00799877|Psoriasis
1292218|NCT00799877|Severe Psoriasis
1292219|NCT00799877|Moderate Psoriasis
1292227|NCT00799851|advanced liver disease
1292228|NCT00799851|esophageal varices
1292229|NCT00799851|band ligation
1292230|NCT00799851|cyanoacrylate injection
1292231|NCT00799825|papillomavirus
1292232|NCT00799825|HPV vaccine
1292233|NCT00799825|cervical cancer
1292234|NCT00799825|HPV
1292235|NCT00799825|human papillomavirus
1292236|NCT00799812|antimicrobial
1292237|NCT00799812|antisepsis
1292238|NCT00799799|Nk cells infusion
1292239|NCT00799799|minimal residual disease in AML patients
1292240|NCT00799799|trafficking of NK cells after infusion
1292241|NCT00799799|cytolytic effects on leukemic cells
1292242|NCT00799773|TTP
1292243|NCT00799773|Rituximab
1292244|NCT00799773|Plasma Exchange
1292245|NCT00799760|influenza A
1292246|NCT00799760|neuraminidase inhibitor
1292247|NCT00799760|oseltamivir
1292248|NCT00799760|zanamivir
1292249|NCT00799760|treatment outcome
1292250|NCT00799760|resistance
1292251|NCT00799760|mutation
1292252|NCT00799760|combination therapy
1292253|NCT00799760|monotherapy
1292254|NCT00799760|pandemic
1292255|NCT00799760|primary care
1292256|NCT00799760|randomized controlled trials
1292257|NCT00799760|antiviral agent
1292258|NCT00799747|safety
1292259|NCT00799747|tolerability
1292260|NCT00799747|pharmacokinetics
1292261|NCT00799747|AZD4017Japanese
1292262|NCT00799734|hot flushes
1292263|NCT00799734|night sweats
1292264|NCT00799734|menopausal symptoms
1292265|NCT00799734|osteoporosis
1292266|NCT00799734|complementary and alternative medicine
1292267|NCT00799721|ROP
1292268|NCT00799721|VLBW
1292269|NCT00799721|Epo
1292270|NCT00799721|IUGR
1292271|NCT00799721|VEGF
1292272|NCT00799721|sFLT-1
1292273|NCT00799721|very low birth weight infants
1292274|NCT00799721|retinopathy of prematurity
1292275|NCT00799721|erythropoietin therapy and risk of ROP
1292276|NCT00799708|Biomarkers of estrogen receptor beta activation
1292277|NCT00799695|diabetic retinopathy
1292278|NCT00799695|screening
1292279|NCT00799695|annual
1292280|NCT00799682|Dry Eye
1292281|NCT00799682|Monotherapy for Ocular Hypertension, Glaucoma
1292282|NCT00799682|Ocular Hypertension
1292283|NCT00799682|Chronic Open-Angle Glaucoma
1292284|NCT00799682|Chronic Angle-Closure Glaucoma
1292285|NCT00799682|Iridotomy
1292286|NCT00799682|Iridectomy
1292287|NCT00799682|Pseudo Exfoliate
1292288|NCT00799682|Pigmentary Glaucoma
1292289|NCT00799682|Systemic Non-Glaucoma Medications
1292290|NCT00799682|Hyperemia
1292291|NCT00799669|hypopharyngeal cancer
1292292|NCT00799669|laryngeal cancer
1292293|NCT00799669|lip and oral cavity cancer
1292294|NCT00799669|nasopharyngeal cancer
1292295|NCT00799669|oropharyngeal cancer
1292296|NCT00799669|paranasal sinus and nasal cavity cancer
1292297|NCT00799669|tobacco use disorder
1292298|NCT00799656|Diabetic neuropathy
1292299|NCT00799656|painful pain
1292300|NCT00799656|postoperative
1292301|NCT00799643|Type 2 Diabetes Mellitus (T2D)
1292302|NCT00799643|Inflammation
1292303|NCT00799643|Obesity
1292304|NCT00799643|Metabolic Syndrome
1292305|NCT00799643|Salicylates
1292306|NCT00799630|energy drink
1292307|NCT00799630|exercise
1292308|NCT00799630|BCAA
1292309|NCT00799630|peripheral and central fatigue
1292310|NCT00799617|Testosterone
1292311|NCT00799617|Mobility disability
1292312|NCT00799617|Decreased libido
1292313|NCT00799617|Age associated memory impairment
1292314|NCT00799617|Low vitality
1292315|NCT00799617|Anemia
1292317|NCT00799604|Antihypertensive Agent
1292318|NCT00799604|Calcium Channel Blocker
1292319|NCT00799591|Registre MONTRAVERS
1292320|NCT00799578|NASH, NAFLD,nonalcoholic steatohepatitis
1292321|NCT00799565|Mitral Valve prolapse
1292322|NCT00799565|echography
1292323|NCT00799565|genetic study
1292324|NCT00799565|study case-witness
1292325|NCT00799565|Patients with a Mitral Valve Prolapse
1292326|NCT00799552|Keratoconjunctivitis Sicca
1292327|NCT00799552|Dry eye
1292328|NCT00799552|Resolvin
1292329|NCT00799539|Prednisone
1292330|NCT00799539|Bortezomib
1292331|NCT00799539|Melphalan
1292332|NCT00799526|Ex Vivo Conjunctival Epithelial Cell
1292333|NCT00799526|Transplantation
1292334|NCT00799513|Lenalidomide
1292335|NCT00799513|revlimid
1292336|NCT00799513|large B-cell lymphoma
1292337|NCT00799513|relapse
1292338|NCT00799487|ADHD
1292339|NCT00799487|Attention Deficit Hyperactivity Disorder
1292340|NCT00799435|Diabetes
1292341|NCT00799435|Diastolic Heart Failure
1292342|NCT00799435|Aortic Stiffness
1292343|NCT00799435|Exenatide
1292344|NCT00799422|Conjunctival Staining
1292345|NCT00799422|lens parameters
1292346|NCT00799422|lens fit
1292347|NCT00799409|ADHD
1292348|NCT00799409|Attention Deficit Hyperactivity Disorder
1292349|NCT00799383|Risperidone
1292350|NCT00799383|hyperprolactinemia
1292351|NCT00799383|children
1292352|NCT00799383|adolescents
1292353|NCT00799383|antipsychotics
1292354|NCT00799383|prevention
1292355|NCT00799383|calcium
1292356|NCT00799383|vitamin D
1292357|NCT00799383|Risperidone-induced hyperprolactinemia
1292358|NCT00799370|Osteotomy
1292359|NCT00799370|Weight bearing
1292360|NCT00799370|Opening wedge
1292361|NCT00799357|ultrasound
1292362|NCT00799344|Coronary Stent
1292363|NCT00799331|Healthy volunteers
1292364|NCT00799279|smoking
1292365|NCT00799279|cessation
1292366|NCT00799279|family medicine
1292367|NCT00799279|evidence-based
1292368|NCT00799279|knowledge translation
1292369|NCT00799279|smoking cessation, primary care
1292370|NCT00799266|Osteoporosis, children and adolescents, zoledronic acid, chronic inflammation, Duchenne muscular dystrophy, glucocorticoids
1292371|NCT00799240|lung cancer
1292372|NCT00799240|stage IIIb
1292373|NCT00799240|pleural effusion
1292374|NCT00799240|stage IV
1292375|NCT00799240|metastatic lung cancer
1292376|NCT00799240|non squamous lung cancer
1292377|NCT00799240|IGF-1R
1292378|NCT00799240|Pemetrexed
1292379|NCT00799240|Cisplatin
1292380|NCT00799214|bacterial vaginosis
1292381|NCT00799214|intravaginal
1292382|NCT00799214|boric acid
1292383|NCT00799214|metronidazole
1292384|NCT00799214|placebo controlled
1292385|NCT00799214|double-blind
1292386|NCT00799214|randomized
1292387|NCT00799214|multicenter
1292388|NCT00799214|non-inferiority
1292389|NCT00799201|Enteral nutrition
1292390|NCT00799201|Constipation
1292391|NCT00799201|Gastrointestinal motility
1292392|NCT00799201|Naloxone
1292393|NCT00799201|Docusate
1292394|NCT00799201|Bowel stimulant
1292395|NCT00799201|Stool softener
1292396|NCT00799188|Cardiac Transplantation
1292397|NCT00799188|Skin cancer
1292398|NCT00799188|Everolimus
1292399|NCT00799175|Postoperative pain
1292400|NCT00799175|Local infiltration analgesia
1292401|NCT00799175|Knee arthroplasty
1292402|NCT00799149|Post-operative pain
1292403|NCT00799149|Knee arthroscopy
1292404|NCT00799149|Gabapentin
1292405|NCT00799149|Etoricoxib
1292406|NCT00799149|Elective ambulatory knee arthroscopy
1292407|NCT00799136|Lymphoma Large B Cell Diffuse
1292408|NCT00799136|Acquired Immunodeficiency
1292409|NCT00799123|NT-proBNP
1292410|NCT00799110|dendritic cells
1292411|NCT00799110|fusion vaccines
1292412|NCT00799110|GM-CSF
1292413|NCT00799110|imiquimod
1292414|NCT00799084|symptom management
1292415|NCT00799084|cancer
1292416|NCT00799084|chemotherapy treatment
1292417|NCT00799084|Behavioral Research
1292418|NCT00799084|Physiological Effects of Drugs
1292419|NCT00799084|Clinical Trial, Phase II
1292420|NCT00799071|prophylaxis
1292421|NCT00799071|CGD
1292422|NCT00799071|pharmacokinetics
1292423|NCT00799058|HIV-1 infections
1292424|NCT00799045|Migraine
1292425|NCT00799045|atrial septal defects
1292426|NCT00799045|transcatheter
1292427|NCT00799045|clopidogrel
1292428|NCT00799032|Coronary Stent
1292429|NCT00799019|EPO antibody mediated PRCA
1292430|NCT00799019|Erythropoiesis stimulating agents
1292431|NCT00799006|Single Ascending Dose Study in Overweight subjects
1292432|NCT00798993|Chronic kidney failure
1292433|NCT00798993|25 hydroxyvitamin D
1292434|NCT00798993|falls
1292435|NCT00798993|exercise
1292436|NCT00798993|quadriceps strength
1292437|NCT00798980|Mirena
1292438|NCT00798980|Nulliparous
1292439|NCT00798980|Intrauterine Devices
1292440|NCT00798967|SBS
1292441|NCT00798967|short bowel syndrome
1292442|NCT00798967|TPN
1292443|NCT00798967|parenteral nutrition
1292444|NCT00798967|PN
1292445|NCT00798915|Diabetes
1292446|NCT00798915|Blood Sugar
1292447|NCT00798915|Xenin-25
1292448|NCT00798915|GIP
1292449|NCT00798915|Insulin
1292450|NCT00798902|DDD
1292451|NCT00798902|Spondylolisthesis
1292452|NCT00798902|Spine Fusion
1292453|NCT00798902|Lumbar Spine
1292454|NCT00798902|Bone Graft
1292455|NCT00798889|Solid tumors
1292456|NCT00798863|submandibular gland
1292457|NCT00798863|video assisted neck surgery
1292458|NCT00798850|Claudication
1292459|NCT00798850|Vascular claudication
1292460|NCT00798850|Peripheral Vascular Disease
1292461|NCT00798850|Peripheral arterial disease
1292462|NCT00798850|Peripheral arterial occlusive disease
1292463|NCT00798850|Angioplasty
1292464|NCT00798850|Femoral angioplasty
1292465|NCT00798850|Superficial femoral artery
1292466|NCT00798850|Femoral arterial disease
1292467|NCT00798850|Exercise
1292468|NCT00798850|Supervised exercise
1292469|NCT00798850|Exercise therapy
1292470|NCT00798850|Exercise programme
1292471|NCT00798850|Infrainuginal
1292472|NCT00798850|Quality of life
1292473|NCT00798850|SF36
1292474|NCT00798850|Questionnaire
1292475|NCT00798850|VascuQol
1292476|NCT00798850|Randomised
1292477|NCT00798850|Randomised trial
1292478|NCT00798850|Combination therapy
1292479|NCT00798850|Intermittent Claudication due to Femoropopliteal Disease
1292480|NCT00798837|prostate
1292481|NCT00798837|cancer
1292482|NCT00798837|IMRT
1292483|NCT00798837|radiation
1292484|NCT00798824|tube feeding
1292485|NCT00798824|premature infant
1292486|NCT00798811|brain tumor
1292487|NCT00798811|high-dose chemotherapy
1292488|NCT00798811|autologous stem cell transplantation
1292489|NCT00798811|infant
1292490|NCT00798785|diabetes mellitus type 1
1292491|NCT00798785|pancreatic beta cell
1292492|NCT00798785|transplantation
1292493|NCT00798772|HIV infection
1292494|NCT00798772|Micronutrients
1292495|NCT00798772|Antioxidants
1292496|NCT00798759|Open-angle glaucoma
1292497|NCT00798759|Ocular hypertension
1292498|NCT00798746|Esophageal cancer
1292499|NCT00798746|pyloric drainage
1292500|NCT00798746|pyloric drainage procedure
1292501|NCT00798746|reflux
1292502|NCT00798746|reflux symptoms
1292503|NCT00798746|esophagectomy
1292504|NCT00798746|Quality of Life
1292505|NCT00798746|Health-related quality of life
1292506|NCT00798746|HRQL
1292507|NCT00798720|non small cell lung cancer
1292508|NCT00798720|HDAC
1292509|NCT00798720|proteasome inhibitor
1292510|NCT00798707|Major Depressive Disorder
1292511|NCT00798694|glaucoma
1292512|NCT00798694|impression cytology
1292513|NCT00798694|ocular surface changes
1292514|NCT00798694|prostaglandins
1292515|NCT00798681|parenteral nutrition
1292516|NCT00798681|ready-to-use
1292517|NCT00798681|customized nutrition formulation
1292518|NCT00798681|olive oil
1292519|NCT00798681|soybean oil
1292520|NCT00798681|LCT/MCT
1292521|NCT00798681|Clinoleic
1292522|NCT00798681|oliclinomel
1292523|NCT00798681|number of infections associated with TPN delivery system
1292524|NCT00798681|BSI
1292525|NCT00798681|Infection rates
1292526|NCT00798668|Endocrine and Gastrointestinal Response to Food
1292527|NCT00798655|panitumumab
1292528|NCT00798655|cisplatin
1292529|NCT00798655|radiation
1292530|NCT00798642|Hypnotherapy
1292531|NCT00798642|Ulcerative Colitis
1292532|NCT00798642|Inflammatory Bowel Disease
1292533|NCT00798642|Gastrointestinal Diseases
1292534|NCT00798642|Digestive System Diseases
1292535|NCT00798642|Intestinal Diseases
1292536|NCT00798642|Colonic Diseases
1292537|NCT00798629|stage III melanoma
1292538|NCT00798629|stage IV melanoma
1292539|NCT00798629|recurrent melanoma
1292540|NCT00798629|mucosal melanoma
1292541|NCT00798616|bronchiolitis
1292542|NCT00798616|steroids
1292543|NCT00798616|corticosteroids
1292544|NCT00798616|albuterol
1292545|NCT00798616|child
1292546|NCT00798616|infant
1292547|NCT00798616|pediatric
1292548|NCT00798603|stage IIIB non-small cell lung cancer
1292549|NCT00798603|stage IV non-small cell lung cancer
1292550|NCT00798603|recurrent non-small cell lung cancer
1292551|NCT00798603|adenocarcinoma of the lung
1292552|NCT00798603|adenosquamous cell lung cancer
1292553|NCT00798590|Intensive insulin therapy (IIT)
1292554|NCT00798590|Insulin infusion
1292555|NCT00798590|Tight glycemic control
1292556|NCT00798590|Intensive Care Units
1292557|NCT00798577|Bacterial Conjunctivitis
1292558|NCT00798564|Exercise
1292559|NCT00798564|Mannitol
1292560|NCT00798538|Buprenorphine
1292561|NCT00798538|HIV
1292562|NCT00798538|Drug Abuse
1292563|NCT00798538|Drug Addiction
1292564|NCT00798538|Drug Dependence
1292565|NCT00798538|Drug Use Disorders
1292566|NCT00798538|Drug Use Disorder
1292567|NCT00798538|Substance Abuse
1292568|NCT00798538|Opiate Addiction
1292569|NCT00798538|Substance-related disorders
1292570|NCT00798525|thrombocytopenia
1292571|NCT00798525|Heparin
1292572|NCT00798525|Lepirudin
1292573|NCT00798525|Argatroban
1292574|NCT00798525|critically ill patients
1292575|NCT00798512|carotid artery stenting
1292576|NCT00798512|cerebral protection
1292577|NCT00798512|stroke
1292578|NCT00798512|ischemic lesion
1292579|NCT00798512|DW-MRI
1292580|NCT00798499|haemophilia
1292581|NCT00798499|patients with haemophilia
1292582|NCT00798473|Crohn's disease
1292583|NCT00798473|Osteopenia
1292584|NCT00798473|Osteoporosis
1292585|NCT00798473|Bisphosphonates
1292586|NCT00798473|Zoledronate
1292587|NCT00798460|Chronic hepatitis B
1292588|NCT00798460|lamivudine resistance
1292589|NCT00798460|clevudine
1292590|NCT00798447|post OP
1292591|NCT00798434|Overactive bladder syndrome
1292592|NCT00798434|fesoterodine
1292593|NCT00798434|elderly
1292594|NCT00798434|flexible dose regimen
1292595|NCT00798434|urgency
1292596|NCT00798434|frequency
1292597|NCT00798434|urge urinary incontinence
1292598|NCT00798434|anticholinergic
1292599|NCT00798434|antimuscarinic
1292600|NCT00798421|Influenza, transmission
1292601|NCT00798408|Evaluate the effects of energy-yielding fluids and solids endocrine and metabolic response to food in the elderly
1292602|NCT00798369|Acute flares
1292603|NCT00798369|Gout
1292604|NCT00798369|Anti-interleukin-1β monoclonal antibody
1292605|NCT00798369|Colchicine
1292606|NCT00798369|Triamcinolone acetonide
1292607|NCT00798356|atrial fibrillation, yoga
1292608|NCT00798343|Influenza, heterosubtypic immune responses
1292609|NCT00798330|Cancer
1292610|NCT00798330|Blood stream infections
1292611|NCT00798330|Bacteremia
1292612|NCT00798330|Dental procedure
1292613|NCT00798330|Central venous catheters
1292614|NCT00798330|Mediport
1292615|NCT00798330|PICC line
1292616|NCT00798304|Meningococcal B vaccine
1292617|NCT00798304|infants
1292618|NCT00798304|safety
1292619|NCT00798304|immunogenicity
1292620|NCT00798278|Empyema
1292621|NCT00798278|Urokinase
1292622|NCT00798278|Thoracoscopic
1292623|NCT00798278|Childhood
1292624|NCT00798265|HPV Vaccination
1292625|NCT00798265|HPV Immunogenicity
1292626|NCT00798265|HIV Infection
1292627|NCT00798265|HIV Negative
1292628|NCT00798265|Adolescents and Young Adults
1292629|NCT00798265|Healthy Volunteer
1292630|NCT00798265|HV
1292631|NCT00798265|Adolescent
1292632|NCT00798252|metastatic, chemotherapy combination
1292633|NCT00798239|DDD
1292634|NCT00798239|Spondylolisthesis
1292635|NCT00798239|Spine Fusion
1292636|NCT00798239|Lumbar Spine
1292637|NCT00798239|Bone Graft
1292638|NCT00798226|Asthma
1292639|NCT00798226|Eczema
1292640|NCT00798226|Sensitization
1292641|NCT00798226|Allergy
1292642|NCT00798200|Cancer
1292643|NCT00798200|Oncology
1292644|NCT00798200|Rehabilitation
1292645|NCT00798200|Endurance
1292646|NCT00798200|Strength
1292647|NCT00798187|Prostate Cancer
1292648|NCT00798187|Breast Cancer
1292649|NCT00798187|Behavioral Intervention
1292650|NCT00798187|Cancer Support Programs
1292651|NCT00798187|Social Comparison
1292652|NCT00798187|Heterogeneous support group
1292653|NCT00798187|Homogeneous support group
1292654|NCT00798174|DFT
1292655|NCT00798174|CHF
1292656|NCT00798174|ICD
1292657|NCT00798148|Neuroblastoma
1292658|NCT00798148|MIBG
1292659|NCT00798148|Autologous Peripheral Stem Cell Transplantation
1292660|NCT00798122|sex
1292661|NCT00798122|acute coronary syndromes
1292662|NCT00798122|normal angiogram
1292663|NCT00798122|no obstruction at angiography
1292664|NCT00798122|women
1292665|NCT00798109|Schizophrenia
1292666|NCT00798109|Cannabis misuse comorbidity
1292667|NCT00798109|Motivational interview
1292668|NCT00798109|Randomised open trial
1292669|NCT00798096|T Cell Lymphoma
1292670|NCT00798096|Lymphoma
1292671|NCT00798070|Lymph node positive or high risk lymph node negative breast
1292672|NCT00798070|cancer
1292673|NCT00798057|Pituitary tumor
1292674|NCT00798057|Outcomes
1292675|NCT00798057|Proton radiation
1292676|NCT00798044|quality improvement
1292677|NCT00798044|feedback
1292678|NCT00798044|substance use disorders
1292679|NCT00798031|dental implant
1292680|NCT00798031|upper jaw
1292681|NCT00798031|posterior tooth loss
1292682|NCT00798031|short dental implant
1292683|NCT00798031|Adults, 18 years of age and older
1292684|NCT00798031|Missing a minimum of two posterior teeth in their upper jaw
1292685|NCT00798031|Subjects in need of dental implants
1292686|NCT00798031|the research study is survival and function of the implants
1292687|NCT00798018|lidocaine
1292688|NCT00798018|tetracaine
1292689|NCT00798018|tracheal intubation
1292690|NCT00798018|pharyngitis
1292691|NCT00798005|NV1FGF
1292692|NCT00798005|PAOD
1292693|NCT00798005|CLI
1292694|NCT00797992|Bevacizumab
1292695|NCT00797992|Myopia
1292696|NCT00797992|Complications
1292697|NCT00797992|Neovascularization
1292698|NCT00797992|OCT
1292699|NCT00797979|Craniotomy
1292700|NCT00797979|Skull fixation
1292701|NCT00797979|Skull Grip
1292702|NCT00797979|Reconstructive cranial surgery
1292703|NCT00797966|OPC-34712, Major Depressive Disorder, Adjunctive Treatment
1292704|NCT00797953|Angina Pectoris Treatment
1292705|NCT00797940|GBM
1292706|NCT00797940|Glioblastoma
1292707|NCT00797940|Glioblastoma Multiforme
1292708|NCT00797940|Brain Tumor
1292709|NCT00797940|Brain Cancer
1292710|NCT00797940|Glioma
1292711|NCT00797927|schizophrenia
1292712|NCT00797927|quetiapine
1292713|NCT00797927|conventional antipsychotics
1292714|NCT00797927|magnetic resonance spectroscopy
1292715|NCT00797914|Colonoscopy
1292716|NCT00797914|Instrumentation
1292717|NCT00797914|Force Monitoring
1292718|NCT00797914|Quality Control
1292719|NCT00797914|Training
1292720|NCT00797888|diabetes
1292721|NCT00797888|behavioral intervention
1292722|NCT00797888|HbA1c
1292723|NCT00797888|health disparities
1292724|NCT00797875|proprioceptive neuromuscular facilitation stretching technique, total knee arthroplasty, range of motion
1292725|NCT00797862|Aliskiren
1292726|NCT00797862|Amlodipine
1292727|NCT00797862|Hypertension
1292728|NCT00797862|SPA1000
1292729|NCT00797862|Norvasc
1292730|NCT00797849|phantom limb pain
1292731|NCT00797849|amputees
1292732|NCT00797849|Farabloc
1292733|NCT00797849|Phantom limb pain in the missing limb of Veteran amputees
1292734|NCT00797836|Occupational Diseases
1292735|NCT00797836|Tuberculosis
1292736|NCT00797836|Tuberculin Test
1292737|NCT00797836|Immunoassay
1292738|NCT00797823|diabetes
1292739|NCT00797823|pancreas
1292740|NCT00797823|beta cell
1292741|NCT00797823|glucagon
1292742|NCT00797823|insulin
1292743|NCT00797823|hypoglycemia
1292744|NCT00797810|Acute lymphoblastic leukemia of the mature B-cell type
1292745|NCT00797810|High-grade non-Hodgkin's lymphoma
1292746|NCT00797797|fibromyalgia
1292747|NCT00797797|milnacipran
1292748|NCT00797797|pregabalin
1292749|NCT00797797|treatment
1292750|NCT00797797|Forest Research Institute
1292751|NCT00797771|Insulin delivery
1292752|NCT00797758|Cord blood transplantation
1292753|NCT00797758|Conditioning regimen
1292754|NCT00797758|Acute myeloid leukaemia
1292755|NCT00797758|SORROR comorbidity index
1292756|NCT00797758|Quality of life
1292757|NCT00797758|Innate immunity
1292758|NCT00797758|Immune reconstitution post transplant
1292759|NCT00797758|Umbilical Cord Blood Stem Cell Transplantation
1292760|NCT00797758|Hematopoietic Stem Cell Transplantation
1292761|NCT00797745|genotype 1 infection
1292762|NCT00797732|acupuncture
1292763|NCT00797732|dysphagia
1292764|NCT00797732|chemoradiation related effects
1292765|NCT00797732|squamous cell carcinoma of the head and neck
1292766|NCT00797732|nasopharyngeal cancer
1292767|NCT00797732|oropharynx cancer
1292768|NCT00797732|hypopharynx cancer
1292769|NCT00797732|larynx cancer
1292770|NCT00797719|MPM
1292771|NCT00797719|Short hemithoracic IMRT
1292772|NCT00797693|First trimester
1292773|NCT00797693|missed abortion
1292774|NCT00797693|misoprostol
1292775|NCT00797693|cervical ripening
1292776|NCT00797693|oral
1292777|NCT00797693|vaginal
1292778|NCT00797693|first trimester missed abortion
1292779|NCT00797680|Pediatric cardiac arrest
1292780|NCT00797654|Sexual Risks for HIV
1292781|NCT00797654|Psychosocial Sequelae Relating to Childhood Sexual Abuse
1292782|NCT00797641|bleeding
1292783|NCT00797641|ulcer
1292784|NCT00797641|hemorrhage
1292785|NCT00797641|gastrointestinal diseases
1292786|NCT00797641|digestive system disease
1292787|NCT00797641|peptic ulcer
1292788|NCT00797641|proton pump inhibitor
1292789|NCT00797602|Chordomas
1292790|NCT00797602|Chondrosarcomas
1292791|NCT00797602|Cancer
1292792|NCT00797602|Outcomes
1292793|NCT00797602|Proton radiation
1292794|NCT00797589|aorta valve
1292795|NCT00797589|mitral valve
1292796|NCT00797589|coronary artery bypass grafting surgery
1292797|NCT00797589|perfusion
1292798|NCT00797589|priming
1292799|NCT00797576|left atrial appendage thrombi
1292800|NCT00797576|transesophageal echocardiogram
1292801|NCT00797576|cardiac magnetic resonance imaging
1292802|NCT00797576|atrial fibrillation
1292803|NCT00797576|cardioversion
1292804|NCT00797550|posterolateral spine fusion
1292805|NCT00797550|bone graft
1292806|NCT00797537|Inflammation of bone and cartilage
1292807|NCT00797511|Diphtheria
1292808|NCT00797511|Tetanus
1292809|NCT00797511|Pertussis
1292810|NCT00797511|Poliomyelitis
1292811|NCT00797498|Nasal Cavity
1292812|NCT00797498|Paranasal Sinuses
1292813|NCT00797498|Proton Radiation
1292814|NCT00797498|Outcomes
1292815|NCT00797485|stage IV colon cancer
1292816|NCT00797485|stage IV rectal cancer
1292817|NCT00797472|Hodgkin's Lymphoma
1292818|NCT00797472|R-mabHD
1292819|NCT00797472|ABVD treatment
1292820|NCT00797472|Hodgkin's Disease
1292821|NCT00797459|Correction of Nasolabial Folds
1292822|NCT00797446|Oropharyngeal
1292823|NCT00797446|cancer
1292824|NCT00797446|proton
1292825|NCT00797446|radiation
1292826|NCT00797446|outcomes
1292827|NCT00797433|testosterone
1292828|NCT00797433|mechanical ventilation
1292829|NCT00797420|fluconazole
1292830|NCT00797420|pharmacokinetic
1292831|NCT00797420|candidiasis
1292832|NCT00797420|sepsis
1292833|NCT00797420|pediatric
1292834|NCT00797420|infants
1292835|NCT00797420|antifungal
1292836|NCT00797420|candidemia
1292837|NCT00797420|fungemia
1292838|NCT00797420|loading dose
1292839|NCT00797407|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1292840|NCT00797407|Creatine
1292841|NCT00797407|Adverse Effects
1292842|NCT00797407|Muscle Toxicity
1292843|NCT00797394|prostate
1292844|NCT00797394|dietary supplements
1292845|NCT00797394|saw palmetto
1292846|NCT00797394|canada
1292847|NCT00797381|MK-0518
1292848|NCT00797381|HIV
1292849|NCT00797381|AIDS
1292850|NCT00797381|hemophilia
1292851|NCT00797381|treatment experienced
1292852|NCT00797368|ankle sprain
1292853|NCT00797368|manual therapy
1292854|NCT00797368|exercise
1292855|NCT00797368|physical therapy
1292856|NCT00797368|Patients who have sustained an inversion ankle sprain
1292857|NCT00797342|rheumatoid arthritis First in human safety pharmacokinetics pharmacodynamics
1292858|NCT00797329|psychiatric patients with violent behavior
1292859|NCT00797316|Hypertension
1292860|NCT00797316|Metabolic Syndrome
1292861|NCT00797316|aliskiren
1292862|NCT00797316|hydrochlorothiazide
1292863|NCT00797316|systolic blood pressure
1292864|NCT00797316|diastolic blood pressure
1292865|NCT00797316|stage 2
1292866|NCT00797303|bevacizumab
1292867|NCT00797303|cornea
1292868|NCT00797303|neovascularization
1292869|NCT00797290|Nasopharynx Cancer, Proton Radiation, Outcomes
1292870|NCT00797277|schizophrenia
1292871|NCT00797277|schizoaffective disorder
1292872|NCT00797277|olanzapine
1292873|NCT00797277|haloperidol
1292874|NCT00797277|lorazepam
1292875|NCT00797277|agitation
1292876|NCT00797264|Ketamine
1292877|NCT00797264|Morphine
1292878|NCT00797264|PCA
1292879|NCT00797264|Hyperalgesia
1292880|NCT00797264|Nor-ketamine
1292881|NCT00797251|Colorectal liver metastasis
1292882|NCT00797251|hepatocellular carcinoma
1292883|NCT00797251|liver surgery
1292884|NCT00797251|intraoperative ultrasound
1292885|NCT00797251|finger-compression
1292886|NCT00797238|Gene Expression
1292887|NCT00797238|Carcinoma, Non-Small-Cell Lung
1292888|NCT00797238|Chemotherapy
1292889|NCT00797225|bone mineral density
1292890|NCT00797225|Endometriosis
1292891|NCT00797225|Pelvic Pain
1292892|NCT00797199|Breast Cancer Risk
1292893|NCT00797199|Hormone Replacement Therapy
1292894|NCT00797199|Optical Transillumination Spectroscopy
1292895|NCT00797199|Optical Breast Spectroscopy
1292896|NCT00797199|Transillumination Breast Spectroscopy
1292897|NCT00797186|diabetes
1292898|NCT00797186|dyslipidemia
1292899|NCT00797186|microvascular dysfunction
1292900|NCT00797186|imaging
1292901|NCT00797160|propofol
1292902|NCT00797160|midazolam
1292903|NCT00797160|neonate
1292904|NCT00797160|tracheal intubation
1292905|NCT00797121|Cholangiocarcinoma
1292906|NCT00797121|Drainage
1292907|NCT00797095|Adolescence
1292908|NCT00797095|Obesity
1292909|NCT00797095|Substance use
1292910|NCT00797095|Prevalence
1292911|NCT00797095|Social and Environmental Contexts
1292912|NCT00797095|Survey
1292913|NCT00797082|Diabetic
1292914|NCT00797082|Coronary disease
1292915|NCT00797082|Atherosclerosis
1292916|NCT00797082|Magnetic resonance imaging
1292917|NCT00797082|Myocardial Perfusion Scintigraphy
1292918|NCT00797082|Coronary angiography
1292919|NCT00797056|G-CSF
1292920|NCT00797056|angiogenesis
1292921|NCT00797056|endothelial progenitor cell
1292922|NCT00797056|limb ischemia
1292923|NCT00797056|revascularization
1292924|NCT00797043|Carcinoma of the skin of the head and neck
1292925|NCT00797043|Proton radiation
1292926|NCT00797043|Outcomes
1292927|NCT00797030|dry eye syndromes
1292928|NCT00797030|keratoconjuntivitis sicca / drug therapy
1292929|NCT00797030|cyclosporine
1292930|NCT00797030|ophthalmic solutions
1292931|NCT00797030|HIV seropositivity
1292932|NCT00797017|Chronic Pain
1292933|NCT00797017|Fentanyl Matrix
1292934|NCT00797017|Spinal disorder-related pain
1292935|NCT00797004|olfactory dysfunction
1292936|NCT00796991|Untreated Advanced Melanoma
1292937|NCT00796978|stage I breast cancer
1292938|NCT00796978|stage II breast cancer
1292939|NCT00796978|stage IIIA breast cancer
1292940|NCT00796978|stage IIIB breast cancer
1292941|NCT00796978|stage IIIC breast cancer
1292942|NCT00796978|HER2-positive breast cancer
1292943|NCT00796965|Phase 1
1292944|NCT00796952|Head/ neck cancer
1292945|NCT00796952|Swallowing
1292946|NCT00796952|behavioral treatment
1292947|NCT00796939|Delayed Sleep Phase Syndrome
1292948|NCT00796939|Sleep
1292949|NCT00796900|Hyperthermia
1292950|NCT00796900|subarachnoidal hemorrhage
1292951|NCT00796900|placebo controlled
1292952|NCT00796900|double blinded
1292953|NCT00796900|Dantrolene
1292954|NCT00796887|Ischemic Stroke
1292955|NCT00796887|Recovery of Function
1292956|NCT00796887|Extended-release niacin
1292957|NCT00796874|stage I prostate cancer
1292958|NCT00796874|stage II prostate cancer
1292959|NCT00796861|malignant ascites
1292960|NCT00796835|Schizophrenia
1292961|NCT00796835|Mood disorders
1292962|NCT00796835|Antipsychotic drugs
1292963|NCT00796835|ER OROS Paliperidone
1292964|NCT00796822|Endothelial Function
1292965|NCT00796822|Inflammation
1292966|NCT00796809|TNF inhibitors
1292967|NCT00796809|Biologic agents
1292968|NCT00796809|coccidioidomycosis
1292969|NCT00796809|Rheumatoid arthritis
1292970|NCT00796796|Non-small cell lung cancer
1292971|NCT00796796|temsirolimus
1292972|NCT00796796|radiation therapy
1292973|NCT00796783|Cushing's Disease
1292974|NCT00796783|Cushing's Syndrome
1292975|NCT00796783|Cushings
1292976|NCT00796783|Pituitary
1292977|NCT00796783|ACTH
1292978|NCT00796783|Adrenocorticotropic hormone
1292979|NCT00796783|Ectopic
1292980|NCT00796783|Adrenal adenoma
1292981|NCT00796783|Adrenal carcinoma
1292982|NCT00796783|Adrenal autonomy
1292983|NCT00796783|Cortisol
1292984|NCT00796783|Hypercortisolemia
1292985|NCT00796783|Cushinoid
1292986|NCT00796783|Moon facies
1292987|NCT00796783|Dorsalcervical fat
1292988|NCT00796783|Plethora
1292989|NCT00796783|Hirsutism
1292990|NCT00796783|Violaceous striae
1292991|NCT00796783|Hormone
1292992|NCT00796783|Contraceptive
1292993|NCT00796783|Endocrine
1292994|NCT00796783|Cushing Syndrome
1292995|NCT00796783|Ectopic ACTH Secretion
1292996|NCT00796770|HIV
1292997|NCT00796770|Vaccine
1292998|NCT00796770|HAART
1292999|NCT00796770|HIV-1
1293000|NCT00796770|AIDS
1293001|NCT00796770|Dendritic Cells
1293002|NCT00796770|DALIA
1293003|NCT00796744|Diabetes mellitus
1293004|NCT00796744|Diabetic neuropathy
1293005|NCT00796744|Peripheral vascular disease
1293006|NCT00796744|Infection
1293007|NCT00796744|Topical application
1293008|NCT00796744|plantar foot ulcers
1293009|NCT00796731|B-cell lymphoma
1293010|NCT00796731|NHL
1293011|NCT00796692|Heparin
1293012|NCT00796692|Low molecular weight heparin
1293013|NCT00796692|Safety
1293014|NCT00796692|Efficacy
1293015|NCT00796692|Cost effective
1293016|NCT00796679|paricalcitol
1293017|NCT00796679|chronic kidney disease
1293018|NCT00796679|cardiac hypertrophy
1293019|NCT00796666|endothelin receptor antagonist (ETRA)
1293020|NCT00796666|Sitaxsentan
1293021|NCT00796640|Schizophrenia
1293022|NCT00796640|Mood disorders
1293023|NCT00796640|Antipsychotic drugs
1293024|NCT00796640|ER Paliperidone
1293025|NCT00796627|Wound Healing
1293026|NCT00796627|Burns
1293027|NCT00796627|HIF-1
1293028|NCT00796627|EPC
1293029|NCT00796614|tamsulosin
1293030|NCT00796614|pediatric
1293031|NCT00796614|neurogenic bladder
1293032|NCT00796601|double-blind placebo-controlled maintenance of efficacy
1293033|NCT00796588|preconditioning
1293034|NCT00796588|remote
1293035|NCT00796575|multiple ascending dose healthy volunteers
1293036|NCT00796575|pharmacokinetics
1293037|NCT00796575|pharmacodynamics
1293038|NCT00796562|Leukemia
1293039|NCT00796562|Lymphoma
1293040|NCT00796562|Hematologic malignancies
1293041|NCT00796562|ALL
1293042|NCT00796562|AML
1293043|NCT00796562|MDS
1293044|NCT00796562|Transplantation
1293045|NCT00796562|Mismatched
1293046|NCT00796562|Haploidentical
1293047|NCT00796562|Busulfan
1293048|NCT00796562|Cyclophosphamide
1293049|NCT00796562|Cellcept
1293050|NCT00796562|Tacrolimus
1293051|NCT00796562|TBI
1293052|NCT00796562|CMMOL
1293053|NCT00796562|CML
1293054|NCT00796562|JMML
1293055|NCT00796536|Acute Pain
1293056|NCT00796536|Low Back Pain
1293057|NCT00796536|Back Pain
1293058|NCT00796536|Functional Magnetic Resonance Imaging (fMRI)
1293059|NCT00796536|Cognitive Behavioral Therapy
1293060|NCT00796536|Pain Education
1293061|NCT00796523|colic
1293062|NCT00796523|crying
1293063|NCT00796523|clinical trial
1293064|NCT00796510|endothelin receptor antagonist (ETRA)
1293065|NCT00796510|sitaxsentan
1293191|NCT00795925|anticholinergics
1293066|NCT00796497|Obsessive Compulsive Disorder
1293067|NCT00796497|5-ht3
1293068|NCT00796497|ondansetron
1293069|NCT00796484|Cancer
1293070|NCT00796484|Solid Tumors
1293071|NCT00796471|Schizophrenia
1293072|NCT00796471|Mood Disorders
1293073|NCT00796471|Antipsychotic drugs
1293074|NCT00796471|Paliperidone ER
1293075|NCT00796458|pain
1293076|NCT00796458|adenocarcinoma of the prostate
1293077|NCT00796458|recurrent prostate cancer
1293078|NCT00796458|stage IV prostate cancer
1293079|NCT00796458|stage III prostate cancer
1293080|NCT00796445|DERMA
1293081|NCT00796445|Tumor antigen
1293082|NCT00796445|Immunotherapeutic
1293083|NCT00796445|Adjuvant cancer therapy
1293084|NCT00796445|Melanoma
1293085|NCT00796445|ASCI
1293086|NCT00796432|Schizophrenia
1293087|NCT00796432|mood disorders
1293088|NCT00796432|antipsychotic drugs
1293089|NCT00796432|dopamine
1293090|NCT00796432|receptor occupancy
1293091|NCT00796432|OROS paliperidone
1293092|NCT00796419|Acute lung injury (ALI)
1293093|NCT00796419|Acute respiratory distress syndrome (ARDS)
1293094|NCT00796419|Respiratory failure
1293095|NCT00796367|Obesity
1293096|NCT00796354|Constipation
1293097|NCT00796354|Irritable Bowel Syndrome
1293098|NCT00796341|invitro-fertilization ,embryo transfer,endometrial injury
1293099|NCT00796315|Pharmacokinetic study
1293100|NCT00796302|Conduct Disorder
1293101|NCT00796302|Attention Deficit and Disruptive Behavior Disorders
1293102|NCT00796289|anovulatory/oligoovulatory infertility
1293103|NCT00796276|Schizophrenia
1293104|NCT00796276|Mood disorders
1293105|NCT00796276|Antipsychotics
1293106|NCT00796276|Pharmacokinetics
1293107|NCT00796276|Enantiomer
1293108|NCT00796276|IR OROS Paliperidone
1293109|NCT00796276|ER OROS Paliperidone
1293110|NCT00796263|Acute HIV infection
1293111|NCT00796237|stroke
1293112|NCT00796237|bone
1293113|NCT00796237|gait
1293114|NCT00796237|muscle
1293115|NCT00796237|vibration
1293116|NCT00796237|motor balance
1293117|NCT00796224|azithromycin, pharmacokinetics, pediatrics
1293118|NCT00796211|Psoriasis
1293119|NCT00796211|CRx-197
1293120|NCT00796211|nortriptyline
1293121|NCT00796211|loratadine
1293122|NCT00796211|CombinatoRx
1293123|NCT00796211|Dermatology
1293124|NCT00796211|Erythema
1293125|NCT00796211|Pruritus
1293126|NCT00796198|Glaucoma
1293127|NCT00796198|Intraocular pressure
1293128|NCT00796198|Ocular diastolic perfusion pressure
1293129|NCT00796198|Dorzolamide/timolol Fixed combination
1293130|NCT00796198|Heidelberg Retina Flowmeter
1293131|NCT00796185|Schizophrenia
1293132|NCT00796185|Schizoaffective Disorder
1293133|NCT00796185|Mood Disorders
1293134|NCT00796185|Antipsychotic drugs
1293135|NCT00796185|Paliperidone ER
1293136|NCT00796172|Hypertension
1293137|NCT00796172|High Blood Pressure
1293138|NCT00796172|Blood Lipid Management
1293139|NCT00796159|Efficacy; Tolerability; Safety; Essential Hypertension
1293140|NCT00796133|NES/E2
1293141|NCT00796133|transdermal gel delivery
1293142|NCT00796133|contraception
1293143|NCT00796133|ovulation
1293144|NCT00796133|bleeding patterns
1293145|NCT00796120|Sarcomas
1293146|NCT00796120|Trabectedin
1293147|NCT00796120|Doxorubicin
1293148|NCT00796120|Ifosfamide
1293149|NCT00796120|YONDELIS
1293150|NCT00796081|Schizophrenia
1293151|NCT00796081|Schizoaffective disorder
1293152|NCT00796081|Schizophreniform disorders
1293153|NCT00796081|Mood disorders
1293154|NCT00796081|Antipshychotic drugs
1293155|NCT00796081|Pediatrics
1293156|NCT00796081|ER OROS Paliperidone, Paliperidone ER
1293157|NCT00796042|Pressure Ulcer
1293158|NCT00796042|Bed Sores
1293159|NCT00796042|Bedsore
1293160|NCT00796042|Decubitus Ulcer
1293161|NCT00796042|Pressure Sore
1293162|NCT00796042|Best rest
1293163|NCT00796042|mobility
1293164|NCT00796042|pressure management
1293165|NCT00796029|Schizophrenia
1293166|NCT00796029|Mood disorders
1293167|NCT00796029|Antipsychotic drugs: 14C-paliperidone
1293168|NCT00796003|Myelodysplastic syndrome
1293169|NCT00796003|MDS
1293170|NCT00796003|Decitabine
1293171|NCT00796003|JNJ-30979754
1293172|NCT00795990|Efficacy of early vs late use of ibuprofen for PDA closure
1293173|NCT00795977|preoperative
1293174|NCT00795977|intratumor
1293175|NCT00795977|dendritic cells
1293176|NCT00795977|pancreatic cancer
1293177|NCT00795977|OK-432
1293178|NCT00795964|tidal volume
1293179|NCT00795964|predicted body weight
1293180|NCT00795964|lung function
1293181|NCT00795964|respiratory outcome
1293182|NCT00795964|Respiratory Function Tests
1293183|NCT00795964|surgery
1293184|NCT00795951|allergic
1293185|NCT00795951|contact dermatitis
1293186|NCT00795951|contact allergy
1293187|NCT00795951|Type IV
1293188|NCT00795951|Children
1293189|NCT00795951|TRUE TEST
1293190|NCT00795925|propiverine
1293192|NCT00795925|urinary incontinence
1293193|NCT00795925|overactive bladder
1293194|NCT00795925|children
1293195|NCT00795925|dose-finding in children aged 5-10 years
1293196|NCT00795912|Systolic heart failure
1293197|NCT00795912|HMG CoA reductase inhibitors
1293198|NCT00795912|B-type natriuretic peptide
1293199|NCT00795912|Inflammation
1293200|NCT00795912|Myocardial collagen turnover
1293201|NCT00795899|Safety and efficacy of experimental treatment
1293202|NCT00795886|ALL
1293203|NCT00795886|Cancer
1293204|NCT00795886|Stem Cell Transplant
1293205|NCT00795873|Heart failure
1293206|NCT00795873|cardiac resynchronization therapy
1293207|NCT00795860|Insulin sensitivity
1293208|NCT00795860|fat metabolism
1293209|NCT00795860|inflammation
1293210|NCT00795847|Hypertensive patients with morning hypertension
1293211|NCT00795834|polyphenolics
1293212|NCT00795834|flavonols
1293213|NCT00795834|lipids
1293214|NCT00795834|endothelial function
1293215|NCT00795834|vascular risk factors
1293216|NCT00795808|Polycystic ovary syndrome
1293217|NCT00795808|PCOS
1293218|NCT00795808|Anovulation
1293219|NCT00795808|Infertility
1293220|NCT00795808|Anovulatory polycystic ovary syndrome (PCOS)
1293221|NCT00795795|Chromosomal abnormalities in preimplantation embryos
1293222|NCT00795782|Papillary thyroid carcinoma
1293223|NCT00795782|Lymph node dissection
1293224|NCT00795782|Lymph node metastasis
1293225|NCT00795782|Prophylactic node dissection
1293226|NCT00795782|Central lymph node metastasis
1293227|NCT00795756|Adults
1293228|NCT00795756|Central nervous system prophylaxis
1293229|NCT00795756|Minimal residual disease
1293230|NCT00795743|Central Venous Catheterization
1293231|NCT00795743|coagulopathy
1293232|NCT00795743|thromboelastography
1293233|NCT00795730|Alzheimer's Disease
1293234|NCT00795730|schizophrenia
1293235|NCT00795717|HIV
1293236|NCT00795717|cardiovascular risk
1293237|NCT00795717|atherogenic lipid profile
1293238|NCT00795717|brachial artery reactivity
1293239|NCT00795717|omega three fatty acids
1293240|NCT00795704|Herbal Supplement
1293241|NCT00795704|Type 2 Diabetes
1293242|NCT00795704|Mulberry
1293243|NCT00795704|Hemoglobin A1C
1293244|NCT00795691|diabetes
1293245|NCT00795691|low-carbohydrate diet
1293246|NCT00795691|weight loss
1293247|NCT00795691|obesity
1293248|NCT00795691|dietary intervention
1293249|NCT00795678|tumors metastatic to brain
1293250|NCT00795678|stage IV breast cancer
1293251|NCT00795665|adult anaplastic astrocytoma
1293252|NCT00795665|adult glioblastoma
1293253|NCT00795665|adult gliosarcoma
1293254|NCT00795665|adult giant cell glioblastoma
1293255|NCT00795665|adult anaplastic oligodendroglioma
1293256|NCT00795665|adult mixed glioma
1293257|NCT00795665|recurrent adult brain tumor
1293258|NCT00795652|Postpartum depression
1293259|NCT00795652|Distance therapy
1293260|NCT00795652|depression
1293261|NCT00795652|Distance Treatment
1293262|NCT00795652|Barriers to care
1293263|NCT00795639|Sitaxsentan
1293264|NCT00795639|endothelin receptor antagonist
1293265|NCT00795626|nursing education
1293266|NCT00795626|cardiovascular risk factors
1293267|NCT00795626|coronary heart disease
1293268|NCT00795613|PET
1293269|NCT00795574|Hidradenitis Suppurativa
1293270|NCT00795561|Hyperemesis gravidarum
1293271|NCT00795561|nausea
1293272|NCT00795561|vomiting
1293273|NCT00795561|pregnancy
1293274|NCT00795561|day care
1293275|NCT00795561|inpatient management
1293276|NCT00795561|Nausea and vomiting of pregnancy
1293277|NCT00795548|Myelodysplastic syndrome (MDS)
1293278|NCT00795548|Acute myeloid leukemia (AML)
1293279|NCT00795548|Stem cell transplantation
1293280|NCT00795548|5-Azacitidine
1293281|NCT00795548|Donor lymphocyte infusion
1293282|NCT00795548|MDS or AML relapsed after stem cell transplantation
1293283|NCT00795535|Injury
1293284|NCT00795496|Atopic dermatitis
1293285|NCT00795496|Bronchial hyperreactivity
1293286|NCT00795496|Skin prick tests
1293287|NCT00795496|Serum IgE
1293288|NCT00795496|Mantoux test
1293289|NCT00795483|Osteoporosis
1293290|NCT00795483|HIV infection
1293291|NCT00795483|Bisphosphonates
1293292|NCT00795483|Zoledronic acid
1293293|NCT00795470|urinary tract infection
1293294|NCT00795470|critically ill
1293295|NCT00795470|ICU
1293296|NCT00795470|antimicrobial
1293297|NCT00795470|Catheter associated urinary tract infections
1293298|NCT00795457|vaccine
1293299|NCT00795457|WHO Grade II Astrocytoma
1293300|NCT00795457|WHO Grade II Oligo-Astrocytoma
1293301|NCT00795444|HIV-1
1293302|NCT00795444|CCR5 coreceptor antagonist (Maraviroc)
1293303|NCT00795444|the cell reservoir of HIV-1
1293304|NCT00795418|Active immunization
1293305|NCT00795418|Alzheimer's disease
1293306|NCT00795418|Antibody
1293307|NCT00795418|Vaccine
1293308|NCT00795418|Central Nervous System Diseases
1293309|NCT00795418|Neurodegenerative diseases
1293310|NCT00795405|sporting events
1293311|NCT00795405|stress
1293312|NCT00795405|myocardial ischemia
1293313|NCT00795405|ST-segment depression
1293314|NCT00795405|blood pressure
1293315|NCT00795392|Psychology
1293316|NCT00795392|Postoperative outcome
1293317|NCT00795392|Surgical Operation
1293318|NCT00795379|Psychotherapy
1293319|NCT00795366|TBI, trauma, brain
1293320|NCT00795353|plaque psoriasis
1293321|NCT00795353|psoriasis
1293322|NCT00795353|alefacept
1293323|NCT00795353|Amevive
1293324|NCT00795340|stage IIIB non-small cell lung cancer
1293325|NCT00795340|stage IV non-small cell lung cancer
1293326|NCT00795340|recurrent non-small cell lung cancer
1293327|NCT00795314|Opioids
1293328|NCT00795314|General anesthesia
1293329|NCT00795301|tumor
1293330|NCT00795288|subarachnoid hemorrhage
1293331|NCT00795288|vasospasm
1293332|NCT00795288|cerebral blood flow
1293333|NCT00795288|cerebral metabolism
1293334|NCT00795288|autoregulation
1293335|NCT00795288|statin
1293336|NCT00795288|Vasospasm associated with Subarachnoid hemorrhage
1293337|NCT00795275|pre-diabetes
1293338|NCT00795275|isotopes
1293339|NCT00795275|insulin secretion
1293340|NCT00795275|insulin action
1293341|NCT00795275|GLP-1
1293342|NCT00795275|simple obesity
1293343|NCT00795275|impaired fasting glucose
1293344|NCT00795262|brachial artery reactivity
1293345|NCT00795236|melatonin
1293346|NCT00795210|HIV lipodystrophy
1293347|NCT00795210|growth hormone
1293348|NCT00795210|growth hormone releasing hormone
1293349|NCT00795197|Gaucher Disease,
1293350|NCT00795197|acid B-glucosidase,
1293351|NCT00795197|gluco cerebrosidase,
1293352|NCT00795197|glucosylceramide,
1293353|NCT00795184|Barrett's Esophagus
1293354|NCT00795184|EsoGastroDuodenoscopy
1293355|NCT00795184|Barrett's Carcinoma
1293356|NCT00795184|adenocarcinoma
1293357|NCT00795184|Cellvizio
1293358|NCT00795184|endomicroscopy
1293359|NCT00795184|random biopsy
1293360|NCT00795145|Linezolid, QTc interval, pharmacokinetics, therapeutic dose, supra-therapeutic dose
1293361|NCT00795132|cancer
1293362|NCT00795132|Hematologic Malignancies
1293363|NCT00795132|Hematopoietic Cell Transplantation
1293364|NCT00795119|Near Infrared Spectroscopy
1293365|NCT00795119|Diagnosis
1293366|NCT00795119|Children
1293367|NCT00795106|Capsaicin
1293368|NCT00795106|hydrogel
1293369|NCT00795106|myofascial pain syndrome
1293370|NCT00795106|neck pain
1293371|NCT00795093|GERD
1293372|NCT00795093|PPI
1293373|NCT00795093|partial responders
1293374|NCT00795080|CVJ malformations
1293375|NCT00795054|Stem cell transplantation
1293376|NCT00795054|Financial impact
1293377|NCT00795041|vitrification
1293378|NCT00795041|ovarian stimulation
1293379|NCT00795041|reproductive medicine
1293380|NCT00795028|older women
1293381|NCT00795028|hip fracture
1293382|NCT00795028|exercise intervention
1293383|NCT00795015|postoperative blood glucose control
1293384|NCT00795015|IV insulin infusion
1293385|NCT00794989|breast cancer
1293386|NCT00794989|atypical ductal breast hyperplasia
1293387|NCT00794989|lobular breast carcinoma in situ
1293388|NCT00794989|ductal breast carcinoma in situ
1293389|NCT00794989|breast cancer prevention
1293390|NCT00794989|high risk breast cancer
1293391|NCT00794950|Bladder Cancer
1293392|NCT00794950|High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
1293393|NCT00794924|probiotics
1293394|NCT00794924|elderly
1293395|NCT00794924|motility
1293396|NCT00794924|diarrhea
1293397|NCT00794911|Liver Transplantation
1293398|NCT00794911|Quality of Life
1293399|NCT00794911|Chronic HCV
1293400|NCT00794911|Hepatitis C Virus
1293401|NCT00794911|Cirrhosis
1293402|NCT00794911|Liver disease
1293403|NCT00794885|hypertension
1293404|NCT00794885|stroke
1293405|NCT00794885|cardiovascular events
1293406|NCT00794885|enalapril
1293407|NCT00794885|folic acid
1293408|NCT00794885|randomized controlled trial
1293409|NCT00794885|MTHFR C677T genotype
1293410|NCT00794872|Cardiovascular autonomic neuropathy
1293411|NCT00794872|Chemoreflex sensitivity
1293412|NCT00794872|Chronic kidney disease
1293413|NCT00794872|Sudden cardiac arrest
1293414|NCT00794820|Chronic Lymphocytic Leukemia
1293415|NCT00794820|CLL
1293416|NCT00794820|Leukemia
1293417|NCT00794820|Fludarabine phosphate
1293418|NCT00794820|Cyclophosphamide
1293419|NCT00794820|Rituximab
1293420|NCT00794820|FCR
1293421|NCT00794820|Cytoxan®
1293422|NCT00794820|Neosar®
1293423|NCT00794820|Rituxan®
1293424|NCT00794807|Alefacept
1293425|NCT00794807|Skin Diseases
1293426|NCT00794807|Psoriasis
1293427|NCT00794807|Skin Diseases, Papulosquamos
1293428|NCT00794807|Therapeutic Uses
1293429|NCT00794807|Dermatologic Agents
1293430|NCT00794781|Cancer
1293431|NCT00794781|solid tumors
1293432|NCT00794755|Vitamin K
1293433|NCT00794755|Vitamin K1 (Phytonadione)
1293434|NCT00794755|Unstable INR
1293435|NCT00794755|VTE or Thrombosis
1293436|NCT00794755|Warfarin
1293437|NCT00794755|Anticoagulation Control
1293438|NCT00794755|Patients on warfarin with unstable anticoagulation control
1293439|NCT00794742|Burn
1293440|NCT00794742|Antimicrobial
1293441|NCT00794742|Bacteria
1293442|NCT00794742|Resistance
1293443|NCT00794742|Biofilm
1293444|NCT00794742|Pathogen
1293445|NCT00794729|Healthy Volunteers
1293446|NCT00794729|Consents
1293447|NCT00794703|Antifungal
1293448|NCT00794703|micafungin
1293449|NCT00794703|itraconazole
1293450|NCT00794690|cimicifuga racemosa
1293451|NCT00794690|liver blood flow and functions
1293452|NCT00794677|Hypercholesterolemia
1293453|NCT00794677|Oxysterol
1293454|NCT00794677|Ezetimibe
1293455|NCT00794677|Zetia
1293456|NCT00794651|osteoarthritis
1293457|NCT00794651|testing kit
1293458|NCT00794651|knee
1293459|NCT00794638|Non-Hodgkin's Lymphoma
1293460|NCT00794638|Diffuse Large B-Cell Lymphoma
1293461|NCT00794638|Mantle cell Lymphoma
1293462|NCT00794638|Transformed lymphoma, transformed to diffuse large B-cell lymphoma
1293463|NCT00794638|Follicular Lymphoma
1293464|NCT00794625|Attention-Deficit/Hyperactivity Disorder
1293465|NCT00794625|Aggressive Behavior
1293466|NCT00794625|Oppositional Defiant Disorder
1293467|NCT00794625|Conduct Disorder
1293468|NCT00794586|cystic fibrosis
1293469|NCT00794586|CF
1293470|NCT00794586|inhaled antibiotic
1293471|NCT00794586|antipseudomonal antibiotic
1293472|NCT00794586|tobramycin
1293473|NCT00794586|fosfomycin
1293474|NCT00794586|lung infection
1293475|NCT00794586|pseudomonal infection
1293476|NCT00794586|FTI
1293477|NCT00794573|Smoking Cessation
1293478|NCT00794573|Cardiac Population
1293479|NCT00794573|Acute Coronary Syndrome
1293480|NCT00794573|Varenicline
1293481|NCT00794573|Champix
1293482|NCT00794560|Heparin, Low-Molecular-Weight
1293483|NCT00794560|compliance
1293484|NCT00794560|drug safety
1293485|NCT00794560|self-administration
1293486|NCT00794560|ambulatory Care
1293487|NCT00794560|Pharmaceutical Services
1293488|NCT00794547|lung cancer; nsclc
1293489|NCT00794508|Severe Combined Immune Deficiency
1293490|NCT00794508|Adenosine Deaminase Deficiency
1293491|NCT00794508|Gene Therapy
1293492|NCT00794508|Hematopoietic Stem Cells
1293493|NCT00794508|Retroviral Vector
1293494|NCT00794508|ADA-deficient SCID
1293495|NCT00794469|Resting metabolic rate
1293496|NCT00794456|Passiflora
1293497|NCT00794456|Crataegus
1293498|NCT00794456|Herbal
1293499|NCT00794456|Valeriana
1293500|NCT00794456|anxiety
1293501|NCT00794443|ONO-5920
1293502|NCT00794443|YM529
1293503|NCT00794443|Bone mineral density
1293504|NCT00794443|Minodronic acid
1293505|NCT00794430|Safety
1293506|NCT00794430|Tolerability
1293507|NCT00794430|Efficacy
1293508|NCT00794430|Patients
1293509|NCT00794430|Diabetic peripheral neuropathic pain.
1293510|NCT00794417|advanced cancer
1293511|NCT00794417|lung cancer
1293512|NCT00794417|NSCLC
1293513|NCT00794417|Non-small Cell Lung Cancer
1293514|NCT00794417|aflibercept
1293515|NCT00794417|chemotherapy
1293516|NCT00794391|Vulnerable Populations
1293517|NCT00794391|Injecting drug users
1293518|NCT00794391|IDU
1293519|NCT00794391|Risky injecting practices
1293520|NCT00794391|Psychotherapy, brief
1293521|NCT00794391|Motivational interviewing
1293522|NCT00794391|Educational activities
1293523|NCT00794391|Clinical trial
1293524|NCT00794391|Risk behavior
1293525|NCT00794391|risk reduction behavior
1293526|NCT00794365|Smoking; smoking cessation; Philippines; Varenicline
1293527|NCT00794352|Inflammation
1293528|NCT00794352|Multiple Sclerosis
1293529|NCT00794352|Neuroimmunology
1293530|NCT00794352|Immune Disorder
1293531|NCT00794352|Neuroimaging
1293532|NCT00794352|Central Nervous System Disease
1293533|NCT00794352|Healthy Volunteers
1293534|NCT00794352|HV
1293535|NCT00794339|cervical squamous cell carcinoma
1293536|NCT00794339|stage IIB cervical cancer
1293537|NCT00794339|stage III cervical cancer
1293538|NCT00794339|stage IV cervical cancer
1293539|NCT00794339|stage IVA cervical cancer
1293540|NCT00794339|stage IB cervical cancer
1293541|NCT00794339|stage IIA cervical cancer
1293542|NCT00794326|Chronic Kidney Failure
1293543|NCT00794326|Peritoneal Dialysis
1293544|NCT00794326|Low sodium solution
1293545|NCT00794326|Hypertension
1293546|NCT00794326|Total Body Water
1293547|NCT00794313|Parkinsons disease
1293548|NCT00794313|dyskinesia
1293549|NCT00794313|amantadine
1293550|NCT00794313|efficacy
1293551|NCT00794300|reproducibility
1293552|NCT00794300|contrast agent
1293553|NCT00794300|magnetic resonance imaging
1293554|NCT00794300|infarct size
1293555|NCT00794300|myocardial salvage index
1293556|NCT00794300|myocardial salvage assessment
1293557|NCT00794274|Sarcodiosis
1293558|NCT00794274|tumor necrosis factor
1293559|NCT00794261|Myeloma
1293560|NCT00794261|lymphoma
1293561|NCT00794261|high-dose chemotherapy
1293562|NCT00794261|PSC infusion, autologous
1293563|NCT00794261|neutropenia
1293564|NCT00794261|thrombocytopenia
1293565|NCT00794261|hospital stay
1293566|NCT00794261|infection
1293567|NCT00794261|Autologous PSC transplantation for patients with lymphoma or myeloma treated with high-dose chemotherapy
1293568|NCT00794222|Cellular phones
1293569|NCT00794222|mental health
1293570|NCT00794222|Early intervention
1293571|NCT00794222|prevention
1293572|NCT00794222|momentary sampling
1293573|NCT00794222|Adolescent
1293574|NCT00794209|AeroLEF, fentanyl, liposome encapsulated, opioid
1293575|NCT00794196|Medication adherence
1293576|NCT00794196|Antidepressive agents
1293577|NCT00794196|Primary care
1293578|NCT00794196|Pharmaceutical care
1293579|NCT00794183|heart failure
1293580|NCT00794183|CRT
1293581|NCT00794183|CHF
1293582|NCT00794170|Treatment Compliance
1293583|NCT00794157|COPD
1293584|NCT00794157|chronic obstructive pulmonary disease
1293585|NCT00794157|indacaterol
1293586|NCT00794157|long acting β2-agonist
1293587|NCT00794144|Allergic Rhinitis
1293588|NCT00794144|Pediatric
1293589|NCT00794144|PATANASE
1293590|NCT00794131|cancer
1293591|NCT00794131|vaccinia virus
1293592|NCT00794131|vaccinia
1293593|NCT00794131|oncolytic
1293594|NCT00794131|oncolytic virus
1293595|NCT00794131|biological
1293596|NCT00794131|imaging
1293597|NCT00794105|Gas
1293598|NCT00794105|Middle ear
1293599|NCT00794079|Healthy volunteers
1293600|NCT00794079|young adults
1293601|NCT00794079|Aged
1293602|NCT00794066|PAD
1293603|NCT00794066|Stroke
1293604|NCT00794066|ICH
1293605|NCT00794066|prevalence
1293606|NCT00794053|Sentinel lymph node
1293607|NCT00794053|thyroid cancer
1293608|NCT00794053|neck dissection
1293609|NCT00794040|Irritability
1293610|NCT00794040|Attention Deficit Hyperactivity Disorder
1293611|NCT00794040|Explosive
1293612|NCT00794040|Tantrums
1293613|NCT00794040|Bipolar Mood Disorder
1293614|NCT00794040|Mood Disorder
1293615|NCT00794040|Childhood Mood Disorder
1293616|NCT00794040|ADHD
1293617|NCT00794027|heart failure
1293618|NCT00794027|yoga
1293619|NCT00794027|quality of life
1293620|NCT00794014|Angioplasty, Transluminal, Percutaneous Coronary
1293621|NCT00794001|myocardial infarction
1293622|NCT00794001|angioplasty
1293623|NCT00794001|data feedback
1293624|NCT00794001|continuous quality improvement
1293625|NCT00794001|STEMI
1293626|NCT00794001|Feedback
1293627|NCT00794001|Quality Assurance, Health Care
1293628|NCT00794001|Emergency service hospital
1293629|NCT00793988|vibration
1293630|NCT00793988|local anaesthesia
1293631|NCT00793988|ptosis surgery
1293632|NCT00793988|blepharoplasty
1293633|NCT00793988|Upper eyelid surgery
1293634|NCT00793988|dermatochalasis +/- blepharoptosis
1293635|NCT00793975|Tumors
1293636|NCT00793975|Antibodies, Monoclonal
1293637|NCT00793962|breast cancer
1293638|NCT00793962|mastectomy
1293639|NCT00793962|radiotherapy
1293640|NCT00793962|fractionation
1293641|NCT00793936|Right Double Lumen Tube
1293642|NCT00793923|Exudative Age Related Macular Degeneration
1293643|NCT00793910|Gabapentin
1293644|NCT00793910|PRK
1293645|NCT00793910|pain
1293646|NCT00793897|Subjects with Advanced or Metastatic Solid Tumors or Neoplasms
1293647|NCT00793884|Diabetes
1293648|NCT00793884|Latino population
1293649|NCT00793871|sunitinib
1293650|NCT00793871|Phase IV
1293651|NCT00793871|gastrointestinal stomal tumor
1293652|NCT00793871|imatinib resistant or intolerant
1293653|NCT00793871|Chinese
1293654|NCT00793845|tandem high-dose chemotherapy for high-risk neuroblastoma
1293655|NCT00793832|weight loss
1293656|NCT00793819|nocturia
1293657|NCT00793819|BPH
1293658|NCT00793819|benign prostate hyperplasia
1293659|NCT00793819|nocturia in men with benign prostate hyperplasia
1293660|NCT00793806|chronic kidney disease
1293661|NCT00793780|obesity
1293662|NCT00793780|schizophrenia
1293663|NCT00793780|schizoaffective disorder
1293664|NCT00793780|weight loss
1293665|NCT00793767|Erythropoietin
1293666|NCT00793767|human muscle tissue
1293667|NCT00793767|insulin sensitivity
1293668|NCT00793767|substrate metabolism
1293669|NCT00793741|Type 1 diabetes
1293670|NCT00793741|Hypoglycemia unawareness
1293671|NCT00793741|Islet transplant
1293672|NCT00793728|Morbid obesity
1293673|NCT00793728|High risk
1293674|NCT00793715|acute pancreatitis
1293675|NCT00793715|abdominal compartment syndrome
1293676|NCT00793715|decompressive laparotomy
1293677|NCT00793715|percutaneous abdominal puncture
1293678|NCT00793715|Mortality of patients treated in both arms
1293679|NCT00793702|tuberculosis
1293680|NCT00793702|diagnosis
1293681|NCT00793702|ESAT-6
1293682|NCT00793702|CFP-10
1293683|NCT00793702|skin test
1293684|NCT00793702|Skin test for the diagnosis of tuberculosis infection
1293685|NCT00793689|parathyroid
1293686|NCT00793689|thyroidectomy
1293687|NCT00793689|hypoparathyroidism
1293688|NCT00793689|Parathyroid function after total thyroidectomy
1293689|NCT00793676|GPCR expression
1293690|NCT00793676|transcriptomic
1293691|NCT00793676|white blood cells
1293692|NCT00793676|diagnostic
1293693|NCT00793676|Control
1293694|NCT00793663|Xenon
1293695|NCT00793663|Sevoflurane
1293696|NCT00793663|Postoperative Nausea and vomiting
1293697|NCT00793663|Depth of anaesthesia
1293698|NCT00793650|Cancer
1293699|NCT00793650|Multiple Myeloma
1293700|NCT00793650|Peripheral Blood Stem Cell Transplant
1293701|NCT00793637|Angular stable locking system
1293702|NCT00793637|Handling test
1293703|NCT00793637|Complications
1293704|NCT00793611|Overactive Bladder
1293705|NCT00793611|Hypnotherapy
1293706|NCT00793598|CMX001
1293707|NCT00793598|Kidney transplant
1293708|NCT00793598|HSCT transplant
1293709|NCT00793598|BK Virus
1293710|NCT00793598|Post kidney transplant patients with BK virus viruria > 10^4
1293711|NCT00793598|Post HSCT transplant patients with BK virus viruria > 10^4
1293712|NCT00793585|IgA nephropathy
1293713|NCT00793559|septic shock refractory to catecholamines
1293714|NCT00793546|Bosutinib
1293715|NCT00793546|Exemestane
1293716|NCT00793546|postmenopausal
1293717|NCT00793546|breast cancer
1293718|NCT00793520|fibromyalgia
1293719|NCT00793520|milnacipran
1293720|NCT00793520|Forest Laboratories
1293721|NCT00793507|childhood caries
1293722|NCT00793494|Irritable bowel syndrome
1293723|NCT00793494|Children
1293724|NCT00793494|Pediatrics
1293725|NCT00793494|Probiotics
1293726|NCT00793481|Metabolic Syndrome
1293727|NCT00793468|nicotine dependence
1293728|NCT00793468|smoking
1293729|NCT00793468|pharmacological treatment
1293730|NCT00793468|relapse prevention
1293731|NCT00793455|education
1293732|NCT00793455|preventive service
1293733|NCT00793455|screening
1293734|NCT00793442|sepsis
1293735|NCT00793442|severe sepsis
1293736|NCT00793442|septic shock
1293737|NCT00793442|endothelium
1293738|NCT00793442|microcirculation
1293739|NCT00793442|biomarkers
1293740|NCT00793429|electrocardiographic safety
1293741|NCT00793429|pharmacokinetics
1293742|NCT00793416|Normal Pressure Hydrocephalus
1293743|NCT00793416|Valve Adjustment
1293744|NCT00793416|Blocked Shunt in NPH patients
1293745|NCT00793416|Diagnosis of blockage
1293746|NCT00793403|Observational cohort
1293747|NCT00793403|prospectives
1293748|NCT00793403|multicentre
1293749|NCT00793403|the Italian study RA patient CLARA and PRO-CLARA
1293750|NCT00793390|Case-Control
1293751|NCT00793390|Inflammatory Breast Cancer
1293752|NCT00793390|North Africa
1293753|NCT00793390|IBC
1293754|NCT00793364|Cholesterol, stanol-ester, mediterranean diet, cardiac risk
1293755|NCT00793351|reduced intensity stem cell transplantation for neuroblastoma
1293756|NCT00793351|relapsed neuroblastoma after high-dose chemotherapy and autologous stem cell rescue
1293757|NCT00793338|Heart failure
1293758|NCT00793338|Sildenafil
1293759|NCT00793338|Cardiopulmonary exercise test
1293760|NCT00793338|quality of life
1293761|NCT00793338|6 minute walk test
1293762|NCT00793286|inguinal hernia
1293763|NCT00793286|laparoscopy
1293764|NCT00793286|mesh
1293765|NCT00793234|TKR
1293766|NCT00793234|VTE
1293767|NCT00793234|DVT
1293768|NCT00793221|Coronary stent.
1293769|NCT00793221|Restenosis.
1293770|NCT00793221|Coronary artery disease.
1293771|NCT00793221|Chronic total occlusion.
1293772|NCT00793208|Lung cancer
1293773|NCT00793208|non small cell
1293774|NCT00793208|vaccine
1293775|NCT00793208|carcinoma
1293776|NCT00793208|immunization
1293777|NCT00793208|autologous Tumor
1293778|NCT00793208|vaccination
1293779|NCT00793195|Neonates
1293780|NCT00793195|Short Bowel Syndrome
1293781|NCT00793195|Intestinal Failure
1293782|NCT00793195|Liver Failure
1293783|NCT00793195|Parenteral Nutrition
1293784|NCT00793195|Intralipid
1293785|NCT00793195|SMOF
1293786|NCT00793182|Renal
1293787|NCT00793182|Kidney
1293788|NCT00793182|Contrast Induced Nephropathy
1293789|NCT00793169|squamous cell carcinoma of the head or neck
1293790|NCT00793156|uremic pruritus
1293791|NCT00793143|morbid obesity
1293792|NCT00793143|laparoscopic sleeve gastrectomy
1293793|NCT00793143|LSG
1293794|NCT00793143|laparoscopic gastric bypass
1293795|NCT00793143|LGB
1293796|NCT00793143|comorbidities
1293797|NCT00793143|diabetes
1293798|NCT00793143|excessive weight loss
1293799|NCT00793143|weight loss
1293800|NCT00793130|Ulcerative
1293801|NCT00793130|Colitis
1293802|NCT00793130|Coltect
1293803|NCT00793130|Curcumin
1293804|NCT00793130|Green tea
1293805|NCT00793130|Selenium
1293806|NCT00793130|inflammation
1293807|NCT00793130|bowel
1293808|NCT00793117|chronic sinusitis
1293809|NCT00793117|FESS
1293810|NCT00793117|packing
1293811|NCT00793104|allograft
1293812|NCT00793104|knee injury
1293813|NCT00793104|cartilage injury
1293814|NCT00793104|Osteochondral defects in the articular femoral cartilage
1293815|NCT00793078|sepsis
1293816|NCT00793078|arterial blood pressure
1293817|NCT00793078|complexity
1293818|NCT00793078|variability
1293819|NCT00793065|electronic health records
1293820|NCT00793065|health information technology
1293821|NCT00793065|physician incentives
1293822|NCT00793065|quality of health care
1293823|NCT00793052|trismus
1293824|NCT00793052|Edema
1293825|NCT00793052|pain
1293826|NCT00793013|Acute Lung Injury
1293827|NCT00793013|Adult Respiratory Distress Syndrome
1293828|NCT00793013|Airway Pressure Release Ventilation
1293829|NCT00793013|Acute Kidney Injury
1293830|NCT00793013|Pressure Trial
1293831|NCT00793000|Safety tolerability pharmacokinetics PK first in human FIH
1293832|NCT00792974|Cognitive behavioral education
1293833|NCT00792974|COPD (Chronic Obstructive Pulmonary Disease), GOLD II-IV
1293834|NCT00792961|Prostate cancer
1293835|NCT00792961|Robotic surgery
1293836|NCT00792961|Endomicroscopy
1293837|NCT00792922|Trachoma
1293838|NCT00792922|Azithromycin
1293839|NCT00792922|Mass treatment
1293840|NCT00792909|Pneumococcal vaccine
1293841|NCT00792909|Pneumococcal disease
1293842|NCT00792909|Safety
1293843|NCT00792909|Immunogenicity
1293844|NCT00792883|PICU
1293845|NCT00792883|BIA
1293846|NCT00792883|Phase angle
1293847|NCT00792883|RQ
1293848|NCT00792883|EEM
1293849|NCT00792883|Compliance
1293850|NCT00792883|Resistance
1293851|NCT00792883|Curves
1293852|NCT00792883|Polymorphisms
1293853|NCT00792883|NF-kappa B
1293854|NCT00792883|Scores
1293855|NCT00792883|PIM 2
1293856|NCT00792883|PRISM I
1293857|NCT00792870|Obesity
1293858|NCT00792870|Weight loss
1293859|NCT00792870|Internet
1293860|NCT00792857|Parathyroid Diseases
1293861|NCT00792857|Renal Insufficiency
1293862|NCT00792857|Kidney Failure, Chronic
1293863|NCT00792857|Hyperparathyroidism, Secondary
1293864|NCT00792857|Vitamin D
1293865|NCT00792857|Hyperparathyroidism
1293866|NCT00792857|Renal Insufficiency, Chronic
1293867|NCT00792857|Kidney Diseases
1293868|NCT00792857|Kidney Failure
1293869|NCT00792818|Osteoarthritis, Knee, Curcumin, Multicenter, RCT
1293870|NCT00792805|COPD
1293871|NCT00792805|indacaterol
1293872|NCT00792805|long-acting β2-agonist
1293873|NCT00792805|adults
1293874|NCT00792792|tissue transfer
1293875|NCT00792779|Morbid obesity
1293876|NCT00792779|General anaesthesia
1293877|NCT00792779|Propofol
1293878|NCT00792779|Sevoflurane
1293879|NCT00792766|Tuberous Sclerosis Complex (TSC)
1293880|NCT00792766|Angiolipoma
1293881|NCT00792766|mTOR
1293882|NCT00792766|Everolimus
1293883|NCT00792753|Coronary Artery Disease
1293884|NCT00792727|Pain
1293885|NCT00792727|Knee
1293886|NCT00792727|Arthritis
1293887|NCT00792727|Knee pain
1293888|NCT00792701|stage I non-small cell lung cancer
1293889|NCT00792688|burn wounds
1293890|NCT00792688|wound healing
1293891|NCT00792675|exercise
1293892|NCT00792675|disease activity
1293893|NCT00792675|inflammation
1293894|NCT00792675|resistance training
1293895|NCT00792675|rehabilitation
1293896|NCT00792662|Diabetes Mellitus
1293897|NCT00792662|Alzheimer's Disease
1293898|NCT00792662|Apathy
1293899|NCT00792662|Methylphenidate
1293900|NCT00792662|Dementia
1293901|NCT00792636|sumatriptan and naproxen sodium
1293902|NCT00792636|migraine with or without aura
1293903|NCT00792636|naproxen sodium
1293904|NCT00792636|sumatriptan
1293905|NCT00792636|blood pressure
1293906|NCT00792636|migraine headaches
1293907|NCT00792623|Varicella
1293908|NCT00792623|VarilrixTM
1293909|NCT00792610|youth
1293910|NCT00792610|hepatitis B
1293911|NCT00792610|vaccination
1293912|NCT00792610|booster
1293913|NCT00792610|immunity response
1293914|NCT00792584|etravirine
1293915|NCT00792584|efavirenz
1293916|NCT00792584|anxiety
1293917|NCT00792584|depression
1293918|NCT00792584|sleep quality
1293919|NCT00792584|HIV
1293920|NCT00792584|NNRTI
1293921|NCT00792584|Tritherapy
1293922|NCT00792584|compliance
1293923|NCT00792584|stocrin
1293924|NCT00792584|To replace efavirenz in long-term users with etravirine
1293925|NCT00792584|To investigate effect of such replacement on patient preference, sleep quality, daytime sleepiness, and anxiety
1293926|NCT00792519|alcohol use
1293927|NCT00792519|HIV
1293928|NCT00792519|cognitive behavioral treatment
1293929|NCT00792519|Kenya
1293930|NCT00792519|hazardous/binge drinking
1293931|NCT00792519|alcohol abuse/dependence
1293932|NCT00792493|Healthy volunteer study
1293933|NCT00792480|Obesity
1293934|NCT00792480|Pregnancy
1293935|NCT00792480|Exercise
1293936|NCT00792480|Nutrition
1293937|NCT00792480|obesity in pregnancy
1293938|NCT00792454|Chronic kidney disease
1293939|NCT00792454|End stage renal disease
1293940|NCT00792454|Exercise
1293941|NCT00792454|Cardiovascular disease
1293942|NCT00792441|Specific inspiratory muscle training(SIMT)
1293943|NCT00792441|Loaded deep breathing
1293944|NCT00792441|Weaning
1293945|NCT00792441|Mechanical ventilation
1293946|NCT00792441|Respiratory muscle
1293947|NCT00792428|Stroke
1293948|NCT00792428|Ischemia
1293949|NCT00792428|Infarction
1293950|NCT00792428|Cerebrovascular Disorder
1293951|NCT00792428|Central Nervous System Diseases
1293952|NCT00792428|Brain Infarction
1293953|NCT00792428|Brain Ischemia
1293954|NCT00792428|Rehabilitation
1293955|NCT00792428|Recovery
1293956|NCT00792428|Neurorehabilitation
1293957|NCT00792428|Plasticity
1293958|NCT00792415|Abstinence syndrome symptoms
1293959|NCT00792415|Withdrawal symptoms
1293960|NCT00792415|Opioid dependence
1293961|NCT00792402|chronic heart failure
1293962|NCT00792402|Computerized clinical guidelines
1293963|NCT00792402|Primary care
1293964|NCT00792389|Gallstones
1293965|NCT00792389|Gallbladder
1293966|NCT00792389|Cholecystectomy
1293967|NCT00792389|Gallstone disease
1293968|NCT00792376|NSAID
1293969|NCT00792376|tendon
1293970|NCT00792376|pain
1293971|NCT00792376|stiffness
1293972|NCT00792376|Achilles
1293973|NCT00792363|KRAS
1293974|NCT00792350|Carcinoma, Hepatocellular
1293975|NCT00792350|Sorafenib
1293976|NCT00792311|Tsui test
1293977|NCT00792311|Epidural Analgesia
1293978|NCT00792285|Colon cancer
1293979|NCT00792285|Prevention
1293980|NCT00792285|Screening
1293981|NCT00792285|Telephone
1293982|NCT00792272|aspirin resistance
1293983|NCT00792272|aspirin resistance in hemodialysis patients
1293984|NCT00792246|pharmacokinetics
1293985|NCT00792246|pediatric
1293986|NCT00792246|bioavailability
1293987|NCT00792233|Poly JIA
1293988|NCT00792233|TNF
1293989|NCT00792233|Remission
1293990|NCT00792220|stroke
1293991|NCT00792220|mobile stroke unit
1293992|NCT00792220|thrombolysis
1293993|NCT00792220|stroke management
1293994|NCT00792220|computerized tomography
1293995|NCT00792194|Cystic fibrosis
1293996|NCT00792194|Exercise training
1293997|NCT00792194|Home training
1293998|NCT00792194|Aerobic capacity
1293999|NCT00792181|The focus is the pain reduce in the first 15 minutes for patients suffering an acute myocardial infarction, treated by caregivers in Ambulance service.
1294000|NCT00792155|PKD
1294001|NCT00792142|neurotoxicity
1294002|NCT00792142|stage I multiple myeloma
1294003|NCT00792142|stage II multiple myeloma
1294004|NCT00792142|stage III multiple myeloma
1294005|NCT00792129|MIS
1294006|NCT00792129|Minimally invasive
1294007|NCT00792129|Atavi
1294008|NCT00792129|Flex Posure
1294009|NCT00792129|retractor
1294010|NCT00792129|Patients with chronic low back and/or leg pain who are candidates for elective lumbar interbody fusion through a posterior unilateral approach,
1294011|NCT00792129|for inclusion in the study.
1294012|NCT00792129|If the patient meets all of the eligibility criteria,
1294013|NCT00792129|they will be enrolled into the study and have either the MiLIF or open procedure depending on the surgeon they present to
1294014|NCT00792129|(i.e., what group their surgeon agreed to participate in.)
1294015|NCT00792090|allergy
1294016|NCT00792090|cow's milk
1294017|NCT00792090|sensibilisation
1294018|NCT00792090|fermented milk
1294019|NCT00792090|infant formula
1294020|NCT00792077|Leukemia
1294021|NCT00792077|Lenalidomide
1294022|NCT00792077|Actigraph
1294023|NCT00792077|Sleep Test Study
1294024|NCT00792077|Chronic Lymphocytic Leukemia
1294025|NCT00792077|CC-5013
1294026|NCT00792077|Revlimid
1294027|NCT00792064|quality of life
1294028|NCT00792064|adverse effects
1294029|NCT00792051|influenza
1294030|NCT00792051|vaccination
1294031|NCT00792051|children
1294032|NCT00792051|Influenza-like illness
1294033|NCT00792038|Psychological tests
1294034|NCT00792038|Magnetic Resonance Imaging
1294035|NCT00792038|Cognitive therapy
1294036|NCT00792025|metastatic transitional cell cancer of the renal pelvis and ureter
1294037|NCT00792025|recurrent transitional cell cancer of the renal pelvis and ureter
1294038|NCT00792025|regional transitional cell cancer of the renal pelvis and ureter
1294039|NCT00792025|stage III bladder cancer
1294040|NCT00792025|stage IV bladder cancer
1294041|NCT00792025|transitional cell carcinoma of the bladder
1294042|NCT00792025|recurrent bladder cancer
1294043|NCT00792012|Glioblastoma Multiforme
1294044|NCT00791999|Rheumatoid Arthritis
1294045|NCT00791999|Certolizumab Pegol
1294046|NCT00791999|Cimzia
1294047|NCT00791986|Breathing exercise
1294048|NCT00791986|blood pressure
1294049|NCT00791986|hypertension
1294050|NCT00791960|Cesarean Section
1294051|NCT00791960|Dimenhydrinate
1294052|NCT00791960|Gravol
1294053|NCT00791960|Antiemetics
1294054|NCT00791921|Rheumatoid Arthritis
1294055|NCT00791921|Certolizumab Pegol
1294056|NCT00791921|Cimzia
1294057|NCT00791869|bupropion
1294058|NCT00791869|smoking
1294059|NCT00791869|pharmacokinetics
1294060|NCT00791869|Pharmacokinetics of bupropion
1294061|NCT00791843|CHF
1294062|NCT00791830|Residual renal function
1294063|NCT00791830|Haemodialysis
1294064|NCT00791830|Applanation tonometry
1294065|NCT00791830|Cardiac output
1294066|NCT00791830|Quality of life
1294067|NCT00791830|Angiotensin II Type 1 Receptor Blockers
1294068|NCT00791817|pharmacokinetics study
1294069|NCT00791804|Pain
1294070|NCT00791804|Post Op pain
1294071|NCT00791804|Fentanyl
1294072|NCT00791804|Pain Control
1294073|NCT00791804|Surgery
1294074|NCT00791791|Anesthesia General
1294075|NCT00791791|Anesthetics Inhalation
1294076|NCT00791791|Stress measurement
1294077|NCT00791791|Surgical Stress
1294078|NCT00791791|Diagnostic Techniques and Procedures
1294079|NCT00791778|Peritoneal Neoplasma
1294080|NCT00791765|Scalp
1294081|NCT00791765|Psoriasis
1294082|NCT00791765|Plaque Psoriasis
1294083|NCT00791765|Skin Diseases
1294084|NCT00791765|Moderate to severe plaque psoriasis
1294085|NCT00791765|etanercept
1294086|NCT00791752|Safety and Tolerability
1294087|NCT00791739|fibromyalgia
1294088|NCT00791739|trazodone
1294089|NCT00791739|pregabalin
1294090|NCT00791739|Fibromyalgia Impact Questionnaire (FIQ)
1294091|NCT00791739|Pittsburgh Sleep Quality Inventory (PSQI)
1294092|NCT00791739|Brief Pain Inventory (BPI)
1294093|NCT00791726|microperimetry
1294094|NCT00791726|macular edema
1294095|NCT00791726|uveitis
1294096|NCT00791726|Retinal sensitivity as measured with fundus related microperimetry
1294097|NCT00791713|Paliperidone ER
1294098|NCT00791713|Antipsychotic drugs
1294099|NCT00791713|Selective serotonin reuptake inhibitors
1294100|NCT00791713|Mood disorders
1294101|NCT00791713|Schizophrenia
1294102|NCT00791700|Open label pharmacokinetic safety and efficacy in HIV-1 infected pediatrics
1294103|NCT00791687|Antioxidant enzymes
1294104|NCT00791687|Glutathione
1294105|NCT00791687|Oxidative stress
1294106|NCT00791687|Prematurity
1294107|NCT00791687|Respiratory distress
1294108|NCT00791687|Non enzymatic antioxidant defense system
1294109|NCT00791687|Enzymatic antioxidant defense system
1294110|NCT00791674|Opiates
1294111|NCT00791674|sleep apnea
1294112|NCT00791674|ventilatory failure
1294113|NCT00791648|aki
1294114|NCT00791648|delirium
1294115|NCT00791648|statin
1294116|NCT00791648|short-term
1294117|NCT00791648|cardiac
1294118|NCT00791635|Cervical Cancer
1294119|NCT00791635|Vaginal Cancer
1294120|NCT00791635|Endometrial Cancer
1294121|NCT00791635|Cervix
1294122|NCT00791635|Endometrial
1294123|NCT00791635|Pelvic Exenteration
1294124|NCT00791635|Pelvic Exenteration Surgery
1294125|NCT00791635|Questionnaire
1294126|NCT00791635|Gynecologic Cancer
1294127|NCT00791635|Vagina
1294128|NCT00791635|Vulva
1294129|NCT00791635|Gynecologic Malignancy
1294130|NCT00791622|Paliperidone ER
1294131|NCT00791622|Schizophernia
1294132|NCT00791622|Mood Disorders, Antipsychotic drugs
1294133|NCT00791622|Cardiovascular
1294134|NCT00791622|Schizoaffective Disorder
1294135|NCT00791609|cancer
1294136|NCT00791596|Ergonomic intervention
1294137|NCT00791596|Musculoskeletal disorders
1294138|NCT00791596|Low back pain
1294139|NCT00791596|Posture
1294140|NCT00791596|Video display terminal
1294141|NCT00791583|Emergency Medicine (EM)
1294142|NCT00791583|Central Venous Catheter (CVC)
1294143|NCT00791583|Maximal Barrier Precaution (MBP)
1294144|NCT00791583|Precaution Technique during Central Venous Cathether Placement
1294145|NCT00791544|monoclonal antibody, anti IGF1R
1294146|NCT00791531|Methotrexate
1294147|NCT00791531|Malaria
1294148|NCT00791518|Chronic Obstructive Pulmonary Disease (COPD)
1294149|NCT00791518|Spirometry
1294150|NCT00791505|chronic obstructive pulmonary disease
1294151|NCT00791505|pulmonary infection
1294152|NCT00791505|antibiotic
1294153|NCT00791492|FAP
1294154|NCT00791492|Familial Amyloid Polyneuropathy
1294155|NCT00791492|ATTR-PN
1294156|NCT00791492|transthyretin
1294157|NCT00791492|TTR
1294158|NCT00791492|amyloid
1294159|NCT00791492|polyneuropathy
1294160|NCT00791492|familial
1294161|NCT00791492|hereditary
1294162|NCT00791492|amyloidosis
1294163|NCT00791492|FoldRx
1294164|NCT00791479|Diabetes, type 2 diabetes
1294165|NCT00791466|Iodine deficiency
1294166|NCT00791466|Pregnancy
1294167|NCT00791466|Thyroid function
1294168|NCT00791466|Infant development
1294169|NCT00791466|Growth
1294170|NCT00791453|Diabetic patients at the Clarksdale Diabetes
1294171|NCT00791453|and Metabolism Clinic and must be between the
1294172|NCT00791453|ages of 18 and 64 years of age.
1294173|NCT00791440|Schizophrenia
1294174|NCT00791440|Schizoaffective
1294175|NCT00791440|Schizophreniform
1294176|NCT00791440|Psychosis
1294177|NCT00791440|Psychotic
1294178|NCT00791440|Hallucinations
1294179|NCT00791440|Delusions
1294180|NCT00791440|Paranoia
1294181|NCT00791440|Paranoid
1294182|NCT00791440|Voices
1294183|NCT00791440|CBT
1294184|NCT00791440|Cognitive Behavior Therapy
1294185|NCT00791440|Cognitive Therapy
1294186|NCT00791401|Schizophrenia
1294187|NCT00791401|Mood disorders
1294188|NCT00791401|Antipsychotic drugs
1294189|NCT00791401|ER OROS Paliperidone
1294190|NCT00791388|Pharmacokinetics
1294191|NCT00791375|young adult
1294192|NCT00791375|cancer
1294193|NCT00791375|exercise
1294194|NCT00791375|physical activity
1294195|NCT00791362|accreditation
1294196|NCT00791362|cardiovascular disease
1294197|NCT00791362|primary care
1294198|NCT00791349|Schizophrenia
1294199|NCT00791349|Schizoaffective Disorder
1294200|NCT00791349|Mood Disorders
1294201|NCT00791349|Antipsychotic drugs
1294202|NCT00791349|Cardiovascular
1294203|NCT00791349|Immediate release (IR) Paliperidone
1294204|NCT00791336|NSCLC
1294205|NCT00791336|chemotherapy
1294206|NCT00791336|radiation therapy
1294207|NCT00791336|nelfinavir
1294208|NCT00791336|NFV
1294209|NCT00791310|Medical ICU
1294210|NCT00791310|Severe sepsis
1294211|NCT00791297|CDB-2914
1294212|NCT00791297|Contraceptive Vaginal Rings
1294213|NCT00791297|ovulation
1294214|NCT00791297|endometrial changes
1294215|NCT00791297|bleeding patterns
1294216|NCT00791297|normal cycling women
1294217|NCT00791297|Inhibition of ovulation, endometrial changes and bleeding patterns in normal cycling women
1294218|NCT00791284|Schizophrenia
1294219|NCT00791284|Mood disorders
1294220|NCT00791284|Antipsychotic drugs
1294221|NCT00791284|intermediate release (IR) Paliperidone
1294222|NCT00791271|Melanoma
1294223|NCT00791271|Malignant melanoma
1294224|NCT00791271|Unresectable
1294225|NCT00791271|Decitabine
1294226|NCT00791271|PEG Interferon Alpha-2b
1294227|NCT00791271|PEG Intron
1294228|NCT00791271|5-Aza-Deoxycytidine
1294229|NCT00791271|Dacogen
1294230|NCT00791245|ISTO Technologies, Inc
1294231|NCT00791245|cartilage repair
1294232|NCT00791245|arthroscopy
1294233|NCT00791245|361 HCT/P
1294234|NCT00791245|human tissue
1294235|NCT00791245|biologic
1294236|NCT00791245|knee
1294237|NCT00791232|Extended-release paliperidone
1294238|NCT00791232|Schizophrenia, Mood disorders, Antipsychotic drugs
1294239|NCT00791232|ER OROS paliperidone
1294240|NCT00791219|Onychomycosis
1294241|NCT00791206|exercise
1294242|NCT00791206|ischemia
1294243|NCT00791206|MRI
1294244|NCT00791206|MRI spectroscopy
1294245|NCT00791206|Ischemia preconditioning
1294246|NCT00791193|Paliperidone ER
1294247|NCT00791193|Antipsychotic drugs
1294248|NCT00791193|Schizophrenia
1294249|NCT00791193|Mood disorders
1294250|NCT00791180|dynamic stabilization
1294251|NCT00791180|Dynesys
1294252|NCT00791180|fusion success
1294253|NCT00791180|Immobilization of spinal segments as an adjunct to fusion in the treatment of the following:
1294254|NCT00791180|acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine
1294255|NCT00791180|degenerative spondylolisthesis with objective evidence of neurologic impairment
1294256|NCT00791180|failed previous fusion (pseudarthrosis).
1294257|NCT00791167|Mood Disorders, Antipsychotic drugs
1294258|NCT00791167|Schizophrenia
1294259|NCT00791167|Paliperidone ER
1294260|NCT00791154|Extensive disease
1294261|NCT00791154|Extrathoracic metasasis
1294262|NCT00791154|Malignant pericardial effusion
1294263|NCT00791154|Malignant pleural effusion
1294264|NCT00791154|Contralateral hilar adenopathy
1294265|NCT00791141|Head and Neck Cancer
1294266|NCT00791141|Radiation therapy
1294267|NCT00791141|Chemotherapy
1294268|NCT00791141|Chemoradiotherapy
1294269|NCT00791141|adjuvant cetuximab administration
1294270|NCT00791128|Type 2 Diabetes
1294271|NCT00791115|Prostate cancer
1294272|NCT00791115|prostatectomy
1294273|NCT00791115|radiotherapy
1294274|NCT00791115|prostatectomy after radiotherapy
1294275|NCT00791089|Radiofrequency Ablation
1294276|NCT00791089|atrial fibrillation
1294277|NCT00791076|Insulin pump therapy
1294278|NCT00791076|Type 1 diabetic
1294279|NCT00791076|Chronic pancreatitis
1294280|NCT00791076|Pancreatic resection
1294281|NCT00791076|Pancreatic polypeptide
1294282|NCT00791063|cell death
1294283|NCT00791063|Apoptosis
1294284|NCT00791063|PET imaging
1294285|NCT00791063|brain metastases
1294286|NCT00791063|whole brain radiation therapy
1294287|NCT00791050|Hypothermia/complications/etiology
1294288|NCT00791050|coronary artery bypass/adverse effects
1294289|NCT00791024|Analgesia Tests
1294290|NCT00791024|Analog Pain Scale
1294291|NCT00791024|Pain Measurement
1294292|NCT00791011|Lymphoma
1294293|NCT00791011|AMG 655
1294294|NCT00791011|Trail receptor
1294295|NCT00791011|Apoptosis
1294296|NCT00791011|Vorinostat
1294297|NCT00791011|Bortezomib
1294298|NCT00791011|SAHA
1294299|NCT00791011|Velcade
1294300|NCT00790998|onchocerciasis
1294301|NCT00790998|river blindness
1294302|NCT00790998|onchocerca volvulus
1294303|NCT00790998|moxidectin
1294304|NCT00790998|ivermectin
1294305|NCT00790972|MRSA
1294306|NCT00790972|sinofresh
1294307|NCT00790972|nasal spray
1294308|NCT00790959|Intimate Partner Violence
1294309|NCT00790959|HIV/AIDS
1294310|NCT00790959|Gender
1294311|NCT00790959|Prevention
1294312|NCT00790959|Community mobilisation
1294313|NCT00790959|Uganda
1294314|NCT00790946|valsartan
1294315|NCT00790946|Metabolic syndrome
1294316|NCT00790933|Drug therapy
1294317|NCT00790920|Acute ischemic stroke
1294318|NCT00790920|Angiography
1294319|NCT00790920|Desmoteplase
1294320|NCT00790920|Thrombolytic
1294321|NCT00790907|Unstable angina
1294322|NCT00790907|Non ST elevation myocardial infarction
1294323|NCT00790907|PCI
1294324|NCT00790907|unfractionated heparin
1294325|NCT00790907|fondaparinux
1294326|NCT00790907|acute coronary syndrome
1294327|NCT00790881|malaria
1294328|NCT00790881|HIV
1294329|NCT00790881|AIDS
1294330|NCT00790881|nevirapine
1294331|NCT00790881|lumefantrine
1294332|NCT00790881|artemether
1294333|NCT00790881|drug interaction
1294334|NCT00790881|pharmacokinetics
1294335|NCT00790868|Panic Disorder
1294336|NCT00790868|Anxiety
1294337|NCT00790868|D-cycloserine
1294338|NCT00790868|DCS
1294339|NCT00790868|Cognitive Behavioral Therapy
1294340|NCT00790868|CBT
1294341|NCT00790855|Bendamustine
1294342|NCT00790855|Acute Leukemia
1294343|NCT00790855|Leukemia
1294344|NCT00790855|Acute myeloid leukemia
1294345|NCT00790855|Myelodysplastic Syndrome
1294346|NCT00790855|Acute lymphoblastic leukemia
1294347|NCT00790855|Chronic myeloid leukemia
1294348|NCT00790855|MDS
1294349|NCT00790855|ALL
1294350|NCT00790855|AML
1294351|NCT00790855|CML
1294352|NCT00790842|Refractory Multiple Myeloma
1294353|NCT00790842|Relapsed Multiple Myeloma
1294354|NCT00790842|Multiple Myeloma with Renal Dysfunction
1294355|NCT00790842|Stage I Multiple Myeloma
1294356|NCT00790842|Stage II Multiple Myeloma
1294357|NCT00790842|Stage III Multiple Myeloma
1294358|NCT00790829|preemptive
1294359|NCT00790829|Nicotine Patch
1294360|NCT00790829|Open Abdominal Surgery
1294361|NCT00790816|Cancer
1294362|NCT00790816|lapatinib
1294363|NCT00790816|Combination therapy
1294364|NCT00790816|Chronic administration
1294365|NCT00790803|uveitis
1294366|NCT00790803|cystoid macular edema
1294367|NCT00790777|Paliperidone ER
1294368|NCT00790777|Schizophrenia, Mood disorders, Antipsychotic drugs
1294369|NCT00790751|ED
1294370|NCT00790751|Erectile Dysfunction
1294371|NCT00790751|Dysfunction
1294372|NCT00790751|Erectile
1294373|NCT00790738|bipolar disorder
1294374|NCT00790738|depression
1294375|NCT00790738|treatment
1294376|NCT00790738|randomized controlled trial
1294377|NCT00790699|diabetes
1294378|NCT00790699|Symlin
1294379|NCT00790699|pramlintide acetate
1294380|NCT00790699|insulin
1294381|NCT00790699|multiple injection port
1294382|NCT00790699|I-PORT
1294383|NCT00790686|Ureteral obstruction
1294384|NCT00790686|Urologic surgical procedure
1294385|NCT00790686|Stents
1294386|NCT00790686|Endoscopy
1294387|NCT00790686|Urology
1294388|NCT00790673|Hepatitis C
1294389|NCT00790673|Viral hepatitis
1294390|NCT00790660|Type 2 Diabetes Mellitus
1294391|NCT00790660|ASP1941
1294392|NCT00790647|primary systemic amyloidosis
1294393|NCT00790595|Prostatectomy
1294394|NCT00790582|ALS
1294395|NCT00790582|Amyotrophic Lateral Sclerosis
1294396|NCT00790582|Lou Gehrig's Disease
1294397|NCT00790582|Lithium
1294398|NCT00790582|Lithium Carbonate
1294399|NCT00790569|bladder cancer
1294400|NCT00790569|cervical cancer
1294401|NCT00790569|esophageal cancer
1294402|NCT00790569|gastric cancer
1294403|NCT00790569|renal cell carcinoma
1294404|NCT00790569|adult primary liver cancer
1294405|NCT00790569|non-small cell lung cancer
1294406|NCT00790569|small cell lung cancer
1294407|NCT00790569|pancreatic cancer
1294408|NCT00790569|hypopharyngeal cancer
1294409|NCT00790569|laryngeal cancer
1294410|NCT00790569|lip and oral cavity cancer
1294411|NCT00790569|nasopharyngeal cancer
1294412|NCT00790569|oropharyngeal cancer
1294413|NCT00790569|paranasal sinus and nasal cavity cancer
1294414|NCT00790569|adult acute myeloid leukemia
1294415|NCT00790569|tobacco use disorder
1294416|NCT00790543|Crohn's Disease
1294417|NCT00790543|Inflammatory Bowel Disease
1294418|NCT00790530|Diabetes
1294419|NCT00790530|Information Technology
1294420|NCT00790530|Health Plans
1294421|NCT00790517|Weight loss
1294422|NCT00790517|Diabetes prevention
1294423|NCT00790517|Serious mental illness
1294424|NCT00790517|Antipsychotic medications
1294425|NCT00790517|Lifestyle intervention
1294426|NCT00790517|Antipsychotic Agents
1294427|NCT00790504|Pelvic floor
1294428|NCT00790504|Transperineal ultrasound
1294429|NCT00790504|Multiple pregnancy
1294430|NCT00790504|Singleton pregnancy
1294431|NCT00790504|Female pelvic floor
1294432|NCT00790491|reduction in risk of heart disease and diabetes
1294433|NCT00790478|Ulcerative Colitis
1294434|NCT00790478|Melatonin
1294435|NCT00790478|Gastrointestinal
1294436|NCT00790478|Irritable Bowel syndrome
1294437|NCT00790478|Sleep
1294438|NCT00790478|Pilot Study
1294439|NCT00790465|achalasia
1294440|NCT00790465|lower esophageal sphincter
1294441|NCT00790465|nitric oxide
1294442|NCT00790465|dark chocolate
1294443|NCT00790465|flavanols
1294444|NCT00790452|Brain
1294445|NCT00790452|Hematologic Disorder
1294446|NCT00790452|Venous Thromboembolism
1294447|NCT00790452|Glioblastoma
1294448|NCT00790452|Aspirin
1294449|NCT00790452|Placebo
1294450|NCT00790452|VTE
1294451|NCT00790452|ASA
1294452|NCT00790452|DVT
1294453|NCT00790439|Insulin dependence
1294454|NCT00790426|Advanced urothelial cancer
1294455|NCT00790413|Radiotherapy
1294456|NCT00790413|Immunotherapy
1294457|NCT00790413|Hematopoietic Stem Cell Transplantation
1294458|NCT00790400|Angiomyolipoma
1294459|NCT00790400|AML
1294460|NCT00790400|Tuberous Sclerosis Complex
1294461|NCT00790400|TSC
1294462|NCT00790400|mTOR
1294463|NCT00790400|RAD001
1294464|NCT00790400|Mammalian Target of Rapamycin
1294465|NCT00790400|Everolimus
1294466|NCT00790400|Afinitor
1294467|NCT00790400|SEGA
1294468|NCT00790400|Subependymal Giant Cell Astrocytoma
1294469|NCT00790400|Seizures
1294470|NCT00790400|Tuberous sclerosis complex (TSC)
1294471|NCT00790400|Tuberous sclerosis
1294472|NCT00790400|benign tumors of brain
1294473|NCT00790400|kidney
1294474|NCT00790400|heart
1294475|NCT00790400|eyes
1294476|NCT00790400|lungs
1294477|NCT00790400|skinTSC1
1294478|NCT00790400|TSC2
1294479|NCT00790400|hamaratin
1294480|NCT00790400|tuberin, tumor growth suppressors
1294481|NCT00790400|gyri
1294482|NCT00790400|tubers
1294483|NCT00790400|Sporadic Lymphangioleiomyomatosis.
1294484|NCT00790400|Lymphangioleiomyomatosis (LAM)
1294485|NCT00790400|rare lung disease
1294486|NCT00790387|enoxaparin
1294487|NCT00790387|tirofiban
1294488|NCT00790387|percutaneous intervention
1294489|NCT00790387|platelet inhibition
1294490|NCT00790387|CD40L
1294491|NCT00790387|Mac-1
1294492|NCT00790387|prothrombin fragment 1+2.
1294493|NCT00790374|Pharmacodynamic profile and safety of BN83495
1294494|NCT00790361|cervical spondylotic myelopathy
1294495|NCT00790361|spinal cord compression
1294496|NCT00790361|magnetic resonance spectroscopy
1294497|NCT00790361|functional magnetic resonance imaging
1294498|NCT00790361|brain plasticity
1294499|NCT00790335|deep vein thrombosis
1294500|NCT00790335|deep venous thrombosis
1294501|NCT00790335|post thrombotic syndrome
1294502|NCT00790335|blood clot
1294503|NCT00790335|thrombolysis
1294504|NCT00790335|tissue plasminogen activator
1294505|NCT00790335|rt-PA
1294506|NCT00790335|Activase
1294507|NCT00790335|mechanical thrombectomy
1294508|NCT00790335|pharmacomechanical
1294509|NCT00790335|ATTRACT
1294510|NCT00790322|Cancer
1294511|NCT00790322|Radiation therapy
1294512|NCT00790322|Radiotherapy
1294513|NCT00790322|Oral Mucositis
1294514|NCT00790322|SBG
1294515|NCT00790309|Obesity
1294516|NCT00790309|Diabetes
1294517|NCT00790309|Bariatric surgery
1294518|NCT00790296|cancer fatigue
1294519|NCT00790283|Treatment of de novo lesions in native coronary arteries
1294520|NCT00790270|Cervical strain
1294521|NCT00790270|whiplash
1294522|NCT00790270|ibuprofen
1294523|NCT00790270|cyclobenzaprine
1294524|NCT00790257|Diabetes
1294525|NCT00790257|Islets transplantation
1294526|NCT00790257|Encapsulation
1294527|NCT00790244|Soft-tissue sarcomas
1294528|NCT00790244|prognostic factors
1294529|NCT00790244|adjuvant
1294530|NCT00790244|chemotherapy
1294531|NCT00790244|radiotherapy
1294532|NCT00790244|metastases-free survival
1294533|NCT00790244|toxicity
1294534|NCT00790244|High malignancy grade
1294535|NCT00790244|High-risk for metastases
1294536|NCT00790244|Adult
1294537|NCT00790231|urinary bladder
1294538|NCT00790231|thoracic epidural analgesia
1294539|NCT00790231|urodynamics
1294540|NCT00790231|open kidney surgery with lumbotomy
1294541|NCT00790218|Hepatocellular carcinoma
1294542|NCT00790218|Hepatoma
1294543|NCT00790218|HCC
1294544|NCT00790192|Schizophrenia
1294545|NCT00790192|SM-13496
1294546|NCT00790192|Latuda
1294547|NCT00790192|Lurasidone
1294548|NCT00790179|Continuous lumbar plexus,Femoral,hydromorphone
1294549|NCT00790153|Type 2 diabetes, hormonal response
1294550|NCT00790140|Esophageal Cancer
1294551|NCT00790140|esophagectomy
1294552|NCT00790140|enteral feeding
1294553|NCT00790140|body composition
1294554|NCT00790140|immunology
1294555|NCT00790114|Phase I
1294556|NCT00790088|Diabetes Mellitus, Type 1
1294557|NCT00790088|continuous glucose monitoring
1294558|NCT00790088|sensor-augmented pump therapy
1294559|NCT00790075|agitation
1294560|NCT00790075|Episodes of agitation regardless of diagnosis
1294561|NCT00790062|Uterine atony
1294562|NCT00790062|Postpartum hemorrhage
1294563|NCT00790062|clinical trial
1294564|NCT00790062|Prophylactic oxytocin
1294565|NCT00790036|Diffuse large B cell lymphoma
1294566|NCT00790036|poor risk
1294567|NCT00790036|R-IPI 3-5
1294568|NCT00790036|adjuvant therapy
1294569|NCT00790036|after R-CHOP or R-EPOCH
1294570|NCT00790036|after R-CHOP
1294571|NCT00790023|SAR
1294572|NCT00790010|bevacizumab
1294573|NCT00790010|ipilimumab
1294574|NCT00790010|unresectable stage III melanoma
1294575|NCT00790010|unresectable stage IV melanoma
1294576|NCT00789997|COPD Exacerbation
1294577|NCT00789997|Etanercept
1294578|NCT00789997|TNF alpha
1294579|NCT00789997|Randomized
1294580|NCT00789984|Keratic precipitates
1294581|NCT00789971|orbital floor triamcinolone
1294582|NCT00789971|phacoemulsification
1294583|NCT00789971|post op inflammation
1294584|NCT00789971|cmo
1294585|NCT00789958|cholangiocarcinoma of the extrahepatic bile duct
1294586|NCT00789958|cholangiocarcinoma of the gallbladder
1294587|NCT00789958|localized extrahepatic bile duct cancer
1294588|NCT00789958|localized gallbladder cancer
1294589|NCT00789958|unresectable extrahepatic bile duct cancer
1294590|NCT00789958|unresectable gallbladder cancer
1294591|NCT00789958|metastatic extrahepatic bile duct cancer
1294592|NCT00789958|metastatic gallbladder cancer
1294593|NCT00789945|type 1 diabetes
1294594|NCT00789945|continuous glucose monitoring
1294595|NCT00789945|Intensive Insulin therapy
1294596|NCT00789919|Mild Preeclampsia
1294597|NCT00789906|Computerized Neuropsychological Assessment
1294598|NCT00789906|Development of Population Norms of the Computerized Neuropsychological Assessment
1294599|NCT00789893|external beam pelvic radiation
1294600|NCT00789893|brachytherapy
1294601|NCT00789880|Vitamin D3
1294602|NCT00789880|Atopic Dermatitis
1294603|NCT00789880|Antimicrobial Peptide Expression
1294604|NCT00789867|Single dose
1294605|NCT00789867|Pilot
1294606|NCT00789867|Safety
1294607|NCT00789867|Gene expression
1294608|NCT00789867|Tolerability
1294609|NCT00789867|CFTR gene
1294610|NCT00789867|Cystic fibrosis
1294611|NCT00789867|Non-viral
1294612|NCT00789854|Depression
1294613|NCT00789854|MDD
1294614|NCT00789854|TRD
1294615|NCT00789841|Neuroendocrine tumor
1294616|NCT00789841|Carcinoid syndrome
1294617|NCT00789841|Motility
1294618|NCT00789841|Transit time
1294619|NCT00789828|SEGA
1294620|NCT00789828|Tuberous Sclerosis
1294621|NCT00789828|Subependymal Giant Cell Astrocytoma
1294622|NCT00789828|mTOR
1294623|NCT00789828|RAD001
1294624|NCT00789828|Mamalian Target Rapamycin
1294625|NCT00789828|Everolimus
1294626|NCT00789828|TSC
1294627|NCT00789815|flexible bronchoscopy
1294628|NCT00789815|sedation
1294629|NCT00789815|bispectral index
1294630|NCT00789802|contraception
1294631|NCT00789802|progestin contraception
1294632|NCT00789802|intrauterine contraception
1294633|NCT00789802|unscheduled bleeding
1294634|NCT00789802|placebo
1294635|NCT00789789|Cohort
1294636|NCT00789789|HIV uninfected volunteers
1294637|NCT00789789|HIV preventive vaccine
1294638|NCT00789789|Long term safety
1294639|NCT00789763|pancreatic cancer
1294640|NCT00789763|Pancreatic cancer locally advanced
1294641|NCT00789724|acute myocardial infarction
1294642|NCT00789698|Schizophrenia
1294643|NCT00789698|SM-13496
1294644|NCT00789698|Latuda
1294645|NCT00789698|Lurasidone
1294646|NCT00789685|Open label
1294647|NCT00789672|Amblyopia
1294648|NCT00789672|Patching
1294649|NCT00789672|Levodopa
1294650|NCT00789659|Fracture fixation, internal
1294651|NCT00789659|Obesity
1294652|NCT00789659|Pelvis
1294653|NCT00789659|Negative pressure wound therapy
1294654|NCT00789659|Vacuum-assisted closure
1294655|NCT00789646|corneal ulcer
1294656|NCT00789646|painless
1294657|NCT00789646|subconjunctival injection
1294658|NCT00789646|antibiotics
1294659|NCT00789646|antifungal
1294660|NCT00789646|lidocaine
1294661|NCT00789633|Pancreatic cancer
1294662|NCT00789633|Advanced pancreatic cancer
1294663|NCT00789633|Metastatic pancreatic cancer
1294664|NCT00789633|Gemcitabine
1294665|NCT00789633|Chemo-naive
1294666|NCT00789620|intravenous lidocaine
1294667|NCT00789620|laparoscopic urological surgery
1294668|NCT00789620|hospital stay
1294669|NCT00789620|pain
1294670|NCT00789620|fatigue
1294671|NCT00789620|length of stay
1294672|NCT00789607|prostate cancer
1294673|NCT00789607|individualized radiotherapy
1294674|NCT00789607|fiducial markers
1294675|NCT00789607|MRI
1294676|NCT00789607|ultrasound
1294677|NCT00789607|High-Risk Localized Prostate Cancer
1294678|NCT00789594|Monitoring
1294679|NCT00789594|Testing
1294680|NCT00789594|Medications
1294681|NCT00789594|Patients receiving medications and having laboratory tests
1294682|NCT00789581|Breast Cancer
1294683|NCT00789581|Adjuvant
1294684|NCT00789581|Doxorubicin
1294685|NCT00789581|Cyclophosphamide
1294686|NCT00789581|Paclitaxel
1294687|NCT00789581|Ixabepilone
1294688|NCT00789581|TITAN
1294689|NCT00789568|Hyperphenylalanemia due to Phenylketonuria
1294690|NCT00789555|nasal allergy
1294691|NCT00789555|nasal spray
1294692|NCT00789555|seasonal allergy
1294693|NCT00789555|perennial allergy
1294694|NCT00789542|stroke
1294695|NCT00789542|deep vein thrombosis
1294696|NCT00789542|doppler
1294697|NCT00789529|Contact lenses, wettability, Contact Lens Disinfectant Solutions, pre-lens tear film
1294698|NCT00789516|Coagulation markers, thalassemia disease post SCT
1294699|NCT00789503|dietary fortification
1294700|NCT00789503|Vitamin D3
1294701|NCT00789503|Osteomalacia
1294702|NCT00789503|bread
1294703|NCT00789503|bone mineral density
1294704|NCT00789503|geriatrics
1294705|NCT00789503|cholecalciferol
1294706|NCT00789503|calcidiol
1294707|NCT00789503|osteoporosis
1294708|NCT00789503|dual-energy photon absorptiometry
1294709|NCT00789503|bread fortification
1294710|NCT00789490|pregnancy
1294711|NCT00789490|relative bioavailability
1294712|NCT00789490|iron
1294713|NCT00789490|folic acid
1294714|NCT00789490|ferric pyrophosphate
1294715|NCT00789490|Study focus is to compare the relative bioavailability of SuppleFem Sprinkles to the current tradtional tablet Materna in pregnant women
1294716|NCT00789464|Urinary Tract Infection
1294717|NCT00789464|Probiotics
1294718|NCT00789464|Dietary Supplements
1294719|NCT00789464|Bacteriuria
1294720|NCT00789451|Ischaemia reperfusion
1294721|NCT00789451|t-PA
1294722|NCT00789451|Fibrinolysis
1294723|NCT00789451|Endothelial function
1294724|NCT00789438|Analgesia
1294725|NCT00789438|Sedation
1294726|NCT00789438|Spinal
1294727|NCT00789438|Stress
1294728|NCT00789438|Surgical
1294729|NCT00789438|Surgical Stress
1294730|NCT00789438|Pain
1294731|NCT00789425|osteoporosis
1294732|NCT00789425|osteopenia
1294733|NCT00789425|olive extract
1294734|NCT00789425|oleuropein
1294735|NCT00789412|Analgesia
1294736|NCT00789412|Sedation
1294737|NCT00789412|Critical Illness
1294738|NCT00789412|Intensive Care
1294739|NCT00789399|deep vein thrombosis
1294740|NCT00789399|coronary artery bypass surgery
1294741|NCT00789399|Venous thromboembolism
1294742|NCT00789386|Capsaicin
1294743|NCT00789386|Remifentanil
1294744|NCT00789386|Hyperalgesia
1294745|NCT00789360|Healthy volunteers
1294746|NCT00789347|Neuropathic pain
1294747|NCT00789347|Cortical excitability
1294748|NCT00789347|Transcranial magnetic stimulation
1294749|NCT00789347|Contact Heat evoked potential
1294750|NCT00789347|peripheral nerve stimulation
1294751|NCT00789347|neurotrophic factors
1294752|NCT00789308|Insulin dependence
1294753|NCT00789295|Mediterranean diet
1294754|NCT00789295|Postprandial lipids
1294755|NCT00789295|Postprandial glucose
1294756|NCT00789295|High fibre diet
1294757|NCT00789295|Low- CHO diet
1294758|NCT00789295|High MUFA diet
1294759|NCT00789295|Dietary approach
1294760|NCT00789282|chronic disease
1294761|NCT00789282|Family Physician
1294762|NCT00789282|primary care network
1294763|NCT00789282|practice-based model
1294764|NCT00789282|type 2 diabetes
1294765|NCT00789282|complications
1294766|NCT00789282|sequelae
1294767|NCT00789269|lung infection after ischemic Stroke
1294768|NCT00789269|prevention of pneumonia
1294769|NCT00789269|rhubarb
1294770|NCT00789256|Acute Myelogenous Leukemia
1294771|NCT00789256|AML
1294772|NCT00789256|Myelodysplastic Syndromes
1294773|NCT00789256|MDS
1294774|NCT00789256|Melphalan
1294775|NCT00789256|Bortezomib
1294776|NCT00789256|Velcade
1294777|NCT00789243|Ischaemia reperfusion
1294778|NCT00789243|t-PA
1294779|NCT00789243|Fibrinolysis
1294780|NCT00789243|Endothelial function
1294781|NCT00789243|Local and remote ischaemic preconditioning
1294782|NCT00789230|umbilical
1294783|NCT00789230|hernia
1294784|NCT00789230|mesh
1294785|NCT00789217|Penicillin
1294786|NCT00789217|Beta-Lactams
1294787|NCT00789217|Allergy
1294788|NCT00789217|Hypersensitivity
1294789|NCT00789204|exercise
1294790|NCT00789204|low back pain
1294791|NCT00789204|posture
1294792|NCT00789204|rehabilitation
1294793|NCT00789178|memory disturbances
1294794|NCT00789165|Brugada syndrome
1294795|NCT00789165|quinidine
1294796|NCT00789165|Asymptomatic Brugada Syndrome
1294797|NCT00789113|lamotrigine
1294798|NCT00789113|epilepsy
1294799|NCT00789113|metabolism
1294800|NCT00789113|bipolar disorder
1294801|NCT00789113|bipolar depression
1294802|NCT00789113|glucuronidation
1294803|NCT00789100|telehealth
1294804|NCT00789100|telemonitor
1294805|NCT00789100|telemedicine
1294806|NCT00789100|Co-morbidities
1294807|NCT00789087|Pleural Effusion.
1294808|NCT00789087|Talc.
1294809|NCT00789087|Pleurodesis.
1294810|NCT00789087|Quality of Life.
1294811|NCT00789087|Thoracoscopy.
1294812|NCT00789074|Smoking cessation
1294813|NCT00789074|Tobacco dependence
1294814|NCT00789074|Varenicline
1294815|NCT00789074|Preloading
1294816|NCT00789061|Acute hearing loss in patients with SLC26A4 mutations
1294817|NCT00789048|hip
1294818|NCT00789048|arthroplasty
1294819|NCT00789048|radiograph
1294820|NCT00789022|First-Psychotic-Episode (FPE)
1294821|NCT00789022|Glutamatergic system
1294822|NCT00789022|Glycine
1294823|NCT00789022|D-Serine
1294824|NCT00789022|Oxytocin
1294825|NCT00789022|Estrogen
1294826|NCT00789009|HIV
1294827|NCT00789009|Natural History
1294828|NCT00789009|Stored Sample
1294829|NCT00789009|AIDS
1294830|NCT00788996|Tobacco Smoke Pollution/prevention and control
1294831|NCT00788996|Parent-Child Relations
1294832|NCT00788996|Environmental Tobacco Smoke (ETS)
1294833|NCT00788983|Induced hypoxia
1294834|NCT00788983|Pulse oximeter
1294835|NCT00788983|Nonin Medical
1294836|NCT00788983|Verification of SpO2 accuracy
1294837|NCT00788970|Acupressure
1294838|NCT00788970|Shiatsu
1294839|NCT00788970|Schizophrenia
1294840|NCT00788957|panitumumab
1294841|NCT00788957|vectibix
1294842|NCT00788957|AMG 102
1294843|NCT00788957|AMG 479
1294844|NCT00788957|colon cancer
1294845|NCT00788957|rectal cancer
1294846|NCT00788957|colorectal cancer
1294847|NCT00788957|metastatic colorectal cancer
1294848|NCT00788957|EGFR inhibitor
1294849|NCT00788957|IGF inhibitor
1294850|NCT00788957|c-MET inhibitor
1294851|NCT00788931|Breast Cancer
1294852|NCT00788931|HER2 positive
1294853|NCT00788931|adult-female
1294854|NCT00788931|LBH589
1294855|NCT00788931|HDAC inhibitor
1294856|NCT00788931|panobinostat
1294857|NCT00788931|metastatic breast
1294858|NCT00788931|adult female patients
1294859|NCT00788918|Chronic Hepatitis C
1294860|NCT00788918|cognitive dysfunction
1294861|NCT00788918|MRI
1294862|NCT00788918|MR spectroscopy
1294863|NCT00788918|interferon
1294864|NCT00788918|ribavirin
1294865|NCT00788918|sustained virologic response, major depressive disorder
1294866|NCT00788905|Hemodialysis
1294867|NCT00788892|Acute
1294868|NCT00788892|Myeloid
1294869|NCT00788892|Leukemia
1294870|NCT00788892|elderly
1294871|NCT00788892|Newly
1294872|NCT00788892|Diagnosed
1294873|NCT00788879|Behavioral Journalism
1294874|NCT00788879|Mexican-Americans
1294875|NCT00788879|Obesity
1294876|NCT00788879|Nutrition
1294877|NCT00788879|Physical Activity
1294878|NCT00788879|Border Health
1294879|NCT00788866|Neuroprotection
1294880|NCT00788866|Antioxidants
1294881|NCT00788866|Neonatal brain injury
1294882|NCT00788866|Pomegranate juice
1294883|NCT00788853|DiabCare Asia 2008, Cross-sectional survey, Glycemic control, Psychosocial well-being, Diabetic complications, Quality of life.
1294884|NCT00788827|diabetes type I
1294885|NCT00788827|diabetes type 2
1294886|NCT00788827|renal transplant
1294887|NCT00788827|stem cells
1294888|NCT00788827|successful renal transplant
1294889|NCT00788788|Airway obstruction
1294890|NCT00788788|Heliox
1294891|NCT00788788|Different Helium content
1294892|NCT00788775|nilotinib
1294893|NCT00788762|glaucoma
1294894|NCT00788762|myocilin
1294895|NCT00788749|chronic rhinosinusitis
1294896|NCT00788749|nasal polyps
1294897|NCT00788749|oral steroid
1294898|NCT00788749|intranasal steroid
1294899|NCT00788749|medical polypectomy
1294900|NCT00788736|venous thromboembolism
1294901|NCT00788736|long-term oral anticoagulant therapy
1294902|NCT00788736|warfarin
1294903|NCT00788736|bleeding risk
1294904|NCT00788736|clinical prediction rule
1294905|NCT00788736|predictors
1294906|NCT00788736|deep vein thrombosis
1294907|NCT00788736|pulmonary embolism
1294908|NCT00788736|vitamin k antagonist
1294909|NCT00788736|side effect
1294910|NCT00788723|Severe Brain Injury
1294911|NCT00788723|Excitability
1294912|NCT00788723|Transcranial Magnetic Stimulation
1294913|NCT00788684|Navitoclax
1294914|NCT00788684|Rituximab
1294915|NCT00788684|CD20-Positive Lymphoid Malignancies
1294916|NCT00788684|ABT-263
1294917|NCT00788684|Chronic Lymphoid Leukemia
1294918|NCT00788684|Non-Hodgkin's Lymphoma
1294919|NCT00788684|Hematological Malignancies
1294920|NCT00788671|Endometrioid Endometrial Carcinoma
1294921|NCT00788671|Complex Atypical Hyperplasia
1294922|NCT00788671|Levonorgestrel Intrauterine Device
1294923|NCT00788671|Endometrial Biopsy
1294924|NCT00788671|Endometrium
1294925|NCT00788671|Hyperplasia of lining of the uterus (womb)
1294926|NCT00788671|Questionnaires
1294927|NCT00788671|Progesterone
1294928|NCT00788671|Estrogen
1294929|NCT00788671|Postmenopausal
1294930|NCT00788671|Endometrial
1294931|NCT00788671|Mirena
1294932|NCT00788671|Intrauterine Device
1294933|NCT00788671|Birth control
1294934|NCT00788671|IUD
1294935|NCT00788671|LIUD
1294936|NCT00788671|CAH
1294937|NCT00788671|G1EEC
1294938|NCT00788671|Grade 1 endometrial cancer
1294939|NCT00788671|Early endometrial cancer
1294940|NCT00788658|Obstructed constipation
1294941|NCT00788658|Quality of life
1294942|NCT00788645|Smoking
1294943|NCT00788645|COPD
1294944|NCT00788645|Chronic Obstructive Lung Disease
1294945|NCT00788645|COPD Exacerbations
1294946|NCT00788645|Viruses and Bacteria associated with COPD exacerbations
1294947|NCT00788632|Osteoporosis
1294948|NCT00788632|BMD
1294949|NCT00788632|Bisphosphonates
1294950|NCT00788632|Educational materials
1294951|NCT00788632|Patient Stories
1294952|NCT00788619|Infertility
1294953|NCT00788619|Assisted reproductive technology
1294954|NCT00788619|Nitric oxide
1294955|NCT00788606|diffused large B cell lymphoma, DLBCL, R-Chop, bevacizumab
1294956|NCT00788606|Diffuse large B-cell non-Hodgkin's lymphoma.
1294957|NCT00788593|Chronic Pancreatitis
1294958|NCT00788593|Exocrine Pancreatic Insufficiency
1294959|NCT00788580|unspecified adult solid tumor, protocol specific
1294960|NCT00788554|groin
1294961|NCT00788554|inguinal
1294962|NCT00788554|hernia
1294963|NCT00788554|lichtenstein
1294964|NCT00788554|TEP
1294965|NCT00788541|Open-Angle Glaucoma
1294966|NCT00788541|Intraocular Pressure
1294967|NCT00788541|Anecortave Acetate
1294968|NCT00788528|Obesity
1294969|NCT00788515|insomnia
1294970|NCT00788515|sleep maintenance
1294971|NCT00788489|breast cancer
1294972|NCT00788489|FDG-PET
1294973|NCT00788489|MRI
1294974|NCT00788489|chemotherapy
1294975|NCT00788489|ultrasonography
1294976|NCT00788476|Needs Assessment Survey
1294977|NCT00788476|Childhood Cancer Survivors
1294978|NCT00788476|Parents
1294979|NCT00788476|Primary Caregiver
1294980|NCT00788476|Survey
1294981|NCT00788463|administration, intranasal
1294982|NCT00788463|aerosol
1294983|NCT00788463|beclomethasone
1294984|NCT00788463|QVAR
1294985|NCT00788463|corticosteroids
1294986|NCT00788463|nasal polyps
1294987|NCT00788463|rhinomanometry
1294988|NCT00788463|Rhinitis Quality of Life Questionnaire
1294989|NCT00788463|Quality of Life
1294990|NCT00788424|AS101 Psoriasis
1294991|NCT00788385|Hydrocephalus
1294992|NCT00788385|High Pressure
1294993|NCT00788385|Shunt Blockage
1294994|NCT00788372|Chronic pain
1294995|NCT00788372|Fentanyl Patch
1294996|NCT00788359|cystic fibrosis
1294997|NCT00788359|pulmonary exacerbation
1294998|NCT00788359|biomarkers
1294999|NCT00788346|Heavily marketed medications
1295000|NCT00788346|Prescribing
1295001|NCT00788346|Health information technology
1295002|NCT00788346|Education
1295003|NCT00788333|Advanced or Metastatic Her-2-positive Breast Cancer
1295004|NCT00788320|Tuberculosis
1295005|NCT00788320|vitamin D
1295006|NCT00788320|immune system
1295007|NCT00788307|adenocarcinoma of the prostate
1295008|NCT00788307|recurrent prostate cancer
1295009|NCT00788307|stage I prostate cancer
1295010|NCT00788307|stage II prostate cancer
1295011|NCT00788294|Pharmacokinetics tanezumab subcutaneous bioavailability intravenous Japanese subjects
1295012|NCT00788242|Cardiac surgery
1295013|NCT00788242|Cardioprotection
1295014|NCT00788242|Aortocoronary bypass graft
1295015|NCT00788242|Aortic stenosis
1295016|NCT00788229|Dry Eye Syndromes
1295017|NCT00788229|Keratoconjunctivitis Sicca
1295018|NCT00788229|artificial tears
1295019|NCT00788229|carboxymethylcellulose sodium
1295020|NCT00788229|sodium hyaluronate
1295021|NCT00788216|Radical hysterectomy
1295022|NCT00788216|Whole pelvic radiation
1295023|NCT00788216|Brachytherapy
1295024|NCT00788216|Chemoradiation
1295025|NCT00788216|Complications
1295026|NCT00788216|Quality of Life
1295027|NCT00788190|Distal Radius Fracture
1295028|NCT00788190|Elderly
1295029|NCT00788190|Prospective randomized trial
1295030|NCT00788190|Outcomes
1295031|NCT00788190|Pain and Function
1295032|NCT00788190|Surgical Vs. conservative management
1295033|NCT00788190|Fractures with borderline alignment
1295034|NCT00788177|age-related macular degeneration
1295035|NCT00788177|subretinal injection
1295036|NCT00788177|Pegaptanib
1295037|NCT00788177|Macugen
1295038|NCT00788164|cervical cancer
1295039|NCT00788164|cervical intraepithelial neoplasia grade 3
1295040|NCT00788164|therapeutic vaccine
1295041|NCT00788164|treatment
1295042|NCT00788164|CIN
1295043|NCT00788164|HPV
1295044|NCT00788164|vaccine
1295045|NCT00788164|Hopkins
1295046|NCT00788164|Trimble
1295047|NCT00788151|Dengue virus
1295048|NCT00788151|Dengue fever
1295049|NCT00788151|Dengue hemorrhagic fever
1295050|NCT00788151|Dengue diseases
1295051|NCT00788151|Dengue vaccine
1295052|NCT00788138|Cystic Fibrosis
1295053|NCT00788138|Vitamin D
1295054|NCT00788138|Anti-microbial peptides
1295055|NCT00788125|previously treated childhood rhabdomyosarcoma
1295056|NCT00788125|metastatic childhood soft tissue sarcoma
1295057|NCT00788125|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1295058|NCT00788125|metastatic osteosarcoma
1295059|NCT00788125|recurrent childhood rhabdomyosarcoma
1295060|NCT00788125|recurrent childhood soft tissue sarcoma
1295061|NCT00788125|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1295062|NCT00788125|recurrent osteosarcoma
1295063|NCT00788125|unspecified childhood solid tumor, protocol specific
1295064|NCT00788125|recurrent Wilms tumor and other childhood kidney tumors
1295065|NCT00788125|recurrent neuroblastoma
1295066|NCT00788125|stage 4S neuroblastoma
1295067|NCT00788125|childhood extracranial germ cell tumor
1295068|NCT00788125|childhood malignant ovarian germ cell tumor
1295069|NCT00788125|childhood malignant testicular germ cell tumor
1295070|NCT00788125|childhood teratoma
1295071|NCT00788125|clear cell sarcoma of the kidney
1295072|NCT00788125|childhood renal cell carcinoma
1295073|NCT00788125|recurrent renal cell cancer
1295074|NCT00788125|congenital mesoblastic nephroma
1295075|NCT00788125|cystic nephroma
1295076|NCT00788125|peripheral primitive neuroectodermal tumor of the kidney
1295077|NCT00788125|rhabdoid tumor of the kidney
1295078|NCT00788125|disseminated neuroblastoma
1295079|NCT00788125|recurrent malignant testicular germ cell tumor
1295080|NCT00788125|recurrent ovarian germ cell tumor
1295081|NCT00788125|recurrent childhood liver cancer
1295082|NCT00788125|stage IV childhood liver cancer
1295083|NCT00788125|angioimmunoblastic T-cell lymphoma
1295084|NCT00788125|stage IV childhood Hodgkin lymphoma
1295085|NCT00788125|stage IV childhood large cell lymphoma
1295086|NCT00788125|stage IV childhood lymphoblastic lymphoma
1295087|NCT00788125|stage IV childhood small noncleaved cell lymphoma
1295088|NCT00788125|recurrent childhood grade III lymphomatoid granulomatosis
1295089|NCT00788125|recurrent childhood large cell lymphoma
1295090|NCT00788125|recurrent childhood lymphoblastic lymphoma
1295091|NCT00788125|recurrent childhood small noncleaved cell lymphoma
1295092|NCT00788125|recurrent/refractory childhood Hodgkin lymphoma
1295093|NCT00788125|childhood diffuse large cell lymphoma
1295094|NCT00788125|childhood grade III lymphomatoid granulomatosis
1295095|NCT00788125|childhood immunoblastic large cell lymphoma
1295096|NCT00788125|childhood nasal type extranodal NK/T-cell lymphoma
1295097|NCT00788125|Burkitt lymphoma
1295098|NCT00788125|primary central nervous system non-Hodgkin lymphoma
1295099|NCT00788125|recurrent childhood anaplastic large cell lymphoma
1295100|NCT00788125|stage IV childhood anaplastic large cell lymphoma
1295101|NCT00788125|childhood central nervous system choriocarcinoma
1295102|NCT00788125|childhood central nervous system embryonal tumor
1295103|NCT00788125|childhood central nervous system germ cell tumor
1295104|NCT00788125|childhood central nervous system germinoma
1295105|NCT00788125|childhood central nervous system mixed germ cell tumor
1295106|NCT00788125|childhood central nervous system teratoma
1295107|NCT00788125|childhood central nervous system yolk sac tumor
1295108|NCT00788125|recurrent childhood central nervous system embryonal tumor
1295109|NCT00788125|childhood choroid plexus tumor
1295110|NCT00788125|childhood craniopharyngioma
1295111|NCT00788125|childhood ependymoblastoma
1295112|NCT00788125|childhood medulloepithelioma
1295113|NCT00788125|childhood infratentorial ependymoma
1295114|NCT00788125|childhood supratentorial ependymoma
1295115|NCT00788125|childhood oligodendroglioma
1295116|NCT00788125|childhood pineal parenchymal tumor
1295117|NCT00788125|childhood grade I meningioma
1295118|NCT00788125|childhood grade II meningioma
1295119|NCT00788125|childhood grade III meningioma
1295120|NCT00788125|recurrent childhood cerebellar astrocytoma
1295121|NCT00788125|recurrent childhood cerebral astrocytoma
1295122|NCT00788125|recurrent childhood ependymoma
1295123|NCT00788125|recurrent childhood medulloblastoma
1295124|NCT00788125|recurrent childhood pineoblastoma
1295125|NCT00788125|recurrent childhood supratentorial primitive neuroectodermal tumor
1295126|NCT00788125|recurrent childhood visual pathway and hypothalamic glioma
1295127|NCT00788125|recurrent uterine sarcoma
1295128|NCT00788125|childhood high-grade cerebellar astrocytoma
1295129|NCT00788125|childhood high-grade cerebral astrocytoma
1295130|NCT00788125|childhood low-grade cerebellar astrocytoma
1295131|NCT00788125|childhood low-grade cerebral astrocytoma
1295132|NCT00788125|childhood atypical teratoid/rhabdoid tumor
1295133|NCT00788125|primary central nervous system Hodgkin lymphoma
1295134|NCT00788125|childhood extragonadal germ cell tumor
1295135|NCT00788125|recurrent childhood malignant germ cell tumor
1295136|NCT00788125|recurrent childhood brain stem glioma
1295137|NCT00788125|recurrent childhood subependymal giant cell astrocytoma
1295138|NCT00788125|recurrent childhood brain tumor
1295139|NCT00788125|recurrent childhood spinal cord neoplasm
1295140|NCT00788112|ductal breast carcinoma in situ
1295141|NCT00788099|Aplidin
1295142|NCT00788099|Plitidepsin
1295143|NCT00788099|Tumors
1295144|NCT00788099|Lymphomas
1295145|NCT00788073|fragile X syndrome
1295146|NCT00788073|irritability
1295147|NCT00788073|behavior problems
1295148|NCT00788060|Renal Cell Carcinoma
1295149|NCT00788060|Rad001
1295150|NCT00788060|Sutent
1295151|NCT00788034|Relapse prevention
1295152|NCT00788034|GAD
1295153|NCT00788034|Maintenance
1295154|NCT00788034|Double-blind
1295155|NCT00788034|Multicentre
1295156|NCT00788021|Transplant
1295157|NCT00788021|Immunity
1295158|NCT00788021|Immunosuppression
1295159|NCT00788008|spinal, joint
1295160|NCT00787995|Mucopolysaccharidosis IV type A
1295161|NCT00787995|MPS IV Type A
1295162|NCT00787995|Mucopolysaccharidosis IVA
1295163|NCT00787995|MPS IVA
1295164|NCT00787995|Morquio A Syndrome
1295165|NCT00787995|Lysosomal Storage Disorder
1295166|NCT00787995|LSD
1295167|NCT00787995|N-acetylgalactosamine-6-sulfatase
1295168|NCT00787995|galactose-6-sulfatase
1295169|NCT00787995|GALNS
1295170|NCT00787995|enzyme replacement therapy
1295171|NCT00787995|ERT
1295172|NCT00787982|brain
1295173|NCT00787982|metastasis
1295174|NCT00787982|neoplasm
1295175|NCT00787982|tumor
1295176|NCT00787982|Patients with secondary brain neoplasms
1295177|NCT00787982|laser therapy
1295178|NCT00787982|laser interstitial thermal therapy
1295179|NCT00787969|stage I mantle cell lymphoma
1295180|NCT00787969|Stage II Contiguous Mantle Cell Lymphoma
1295181|NCT00787969|Stage II Non-Contiguous Mantle Cell Lymphoma
1295182|NCT00787969|Stage III Mantle Cell Lymphoma
1295183|NCT00787969|Stage IV Mantle Cell Lymphoma
1295184|NCT00787943|Acne
1295185|NCT00787930|BPD
1295186|NCT00787917|Cystic Fibrosis
1295187|NCT00787917|Allergic Bronchopulmonary Aspergillosis
1295188|NCT00787917|omalizumab
1295189|NCT00787917|oral corticosteroid use
1295190|NCT00787917|anti-immunoglobulin E
1295191|NCT00787904|Osteoporosis, T-cells
1295192|NCT00787891|Gastroesophageal Reflux Disease (GERD)
1295193|NCT00787891|Erosive Gastroesophageal Reflux Disease
1295194|NCT00787891|Ulcerative Gastroesophageal Reflux Disease
1295195|NCT00787891|Endoscopy
1295196|NCT00787891|Pediatrics
1295197|NCT00787891|Rabeprazole
1295198|NCT00787865|Diffusion Tensor Imaging
1295199|NCT00787865|DTI
1295200|NCT00787865|Newborn
1295201|NCT00787865|Krabbe Disease
1295202|NCT00787865|Motor Development
1295203|NCT00787865|Motor Disability
1295204|NCT00787852|dasatinib
1295205|NCT00787852|radiation
1295206|NCT00787852|paclitaxel
1295207|NCT00787852|carboplatin
1295208|NCT00787852|NSCLC
1295209|NCT00787852|safety addition of dasatinib to chemo RT stage III NSCLC
1295210|NCT00787839|type 2 diabetes mellitus
1295211|NCT00787839|prediabetic state
1295212|NCT00787839|mass screening
1295213|NCT00787839|glucose tolerance test
1295214|NCT00787826|Live Vaccine Strain (LVS)
1295215|NCT00787813|N-acetyl cysteine (NAC)
1295216|NCT00787813|Cervical cerclage
1295217|NCT00787813|cervical cerclage for cervical insufficiency
1295218|NCT00787800|Shock prevention
1295219|NCT00787800|Single vs. Dual Chamber
1295220|NCT00787800|Reduce ventricular pacing
1295221|NCT00787800|Atrial Fibrillation
1295222|NCT00787800|Remote Monitoring
1295223|NCT00787800|ICD
1295224|NCT00787800|Implantable Cardioverter Defibrillator
1295225|NCT00787774|HIV
1295226|NCT00787774|resistance
1295227|NCT00787774|integrase
1295228|NCT00787761|accelerated phase CML
1295229|NCT00787761|blastic phase CML
1295230|NCT00787761|Philadelphia chromosome positive CML
1295231|NCT00787761|stage I CLL
1295232|NCT00787761|stage II CLL
1295233|NCT00787761|stage III CLL
1295234|NCT00787761|stage IV CLL
1295235|NCT00787761|stage I multiple myeloma
1295236|NCT00787761|stage II multiple myeloma
1295237|NCT00787761|stage III multiple myeloma
1295238|NCT00787761|adult AML with 11q23 (MLL) abnormalities
1295239|NCT00787761|adult CML in remission
1295240|NCT00787761|adult ALL in remission
1295241|NCT00787761|stage IV renal cell cancer
1295242|NCT00787761|de novo MDS
1295243|NCT00787761|previously treated MDS
1295244|NCT00787761|secondary MDS
1295245|NCT00787761|atypical CML, BCR-ABL negative
1295246|NCT00787761|chronic myelomonocytic leukemia
1295247|NCT00787761|MDS/myeloproliferative neoplasm, unclassifiable
1295248|NCT00787761|primary myelofibrosis
1295249|NCT00787761|chronic neutrophilic leukemia
1295250|NCT00787761|recurrent adult Hodgkin lymphoma
1295251|NCT00787761|clear cell renal cell carcinoma
1295252|NCT00787761|adult AML with inv(16)(p13;q22)
1295253|NCT00787761|adult AML with t(15;17)(q22;q12)
1295254|NCT00787761|adult AML with t(16;16)(p13;q22)
1295255|NCT00787761|adult AML with t(8;21)(q22;q22)
1295256|NCT00787761|adult nasal type extranodal NK/T-cell lymphoma
1295257|NCT00787761|AML/transient myeloproliferative disorder
1295258|NCT00787761|Burkitt lymphoma
1295259|NCT00787761|chronic phase CML
1295260|NCT00787761|extranodal marginal zone B-cell lymphoma of mucosa tissue
1295261|NCT00787761|nodal marginal zone B-cell lymphoma
1295262|NCT00787761|stage III adult Burkitt lymphoma
1295263|NCT00787761|stage IV adult Burkitt lymphoma
1295264|NCT00787761|recurrent adult Burkitt lymphoma
1295265|NCT00787761|stage III adult diffuse large cell lymphoma
1295266|NCT00787761|stage III adult diffuse mixed cell lymphoma
1295267|NCT00787761|recurrent adult diffuse large cell lymphoma
1295268|NCT00787761|stage IV adult diffuse large cell lymphoma
1295269|NCT00787761|stage IV adult diffuse mixed cell lymphoma
1295270|NCT00787761|recurrent adult diffuse mixed cell lymphoma
1295271|NCT00787761|stage III adult immunoblastic large cell lymphoma
1295272|NCT00787761|stage IV adult immunoblastic large cell lymphoma
1295273|NCT00787761|stage III adult lymphoblastic lymphoma
1295274|NCT00787761|stage IV adult lymphoblastic lymphoma
1295275|NCT00787761|recurrent adult immunoblastic large cell lymphoma
1295276|NCT00787761|recurrent adult lymphoblastic lymphoma
1295277|NCT00787761|recurrent grade 3 follicular lymphoma
1295278|NCT00787761|stage III grade 3 follicular lymphoma
1295279|NCT00787761|stage IV grade 3 follicular lymphoma
1295280|NCT00787761|recurrent mantle cell lymphoma
1295281|NCT00787761|stage III mantle cell lymphoma
1295282|NCT00787761|stage IV mantle cell lymphoma
1295283|NCT00787761|contiguous st II adult diffuse small cleaved cell lymphoma
1295284|NCT00787761|noncontiguous st II diffuse small cleaved cell lymphoma
1295285|NCT00787761|recurrent adult diffuse small cleaved cell lymphoma
1295286|NCT00787761|stage III adult diffuse small cleaved cell lymphoma
1295287|NCT00787761|stage IV adult diffuse small cleaved cell lymphoma
1295288|NCT00787761|contiguous stage II grade 1 follicular lymphoma
1295289|NCT00787761|contiguous stage II grade 2 follicular lymphoma
1295290|NCT00787761|noncontiguous stage II grade 1 follicular lymphoma
1295291|NCT00787761|noncontiguous stage II grade 2 follicular lymphoma
1295292|NCT00787761|recurrent grade 1 follicular lymphoma
1295293|NCT00787761|recurrent grade 2 follicular lymphoma
1295294|NCT00787761|stage III grade 1 follicular lymphoma
1295295|NCT00787761|stage III grade 2 follicular lymphoma
1295296|NCT00787761|stage IV grade 1 follicular lymphoma
1295297|NCT00787761|stage IV grade 2 follicular lymphoma
1295298|NCT00787761|contiguous stage II marginal zone lymphoma
1295299|NCT00787761|noncontiguous stage II marginal zone lymphoma
1295300|NCT00787761|recurrent marginal zone lymphoma
1295301|NCT00787761|stage III marginal zone lymphoma
1295302|NCT00787761|stage IV marginal zone lymphoma
1295303|NCT00787761|contiguous stage II small lymphocytic lymphoma
1295304|NCT00787761|noncontiguous stage II small lymphocytic lymphoma
1295305|NCT00787761|recurrent small lymphocytic lymphoma
1295306|NCT00787761|stage III small lymphocytic lymphoma
1295307|NCT00787761|stage IV small lymphocytic lymphoma
1295308|NCT00787761|recurrent adult grade III lymphomatoid granulomatosis
1295309|NCT00787761|relapsing chronic myelogenous leukemia
1295310|NCT00787761|refractory chronic lymphocytic leukemia
1295311|NCT00787761|splenic marginal zone lymphoma
1295312|NCT00787761|Waldenstrom macroglobulinemia
1295313|NCT00787761|recurrent adult T-cell leukemia/lymphoma
1295314|NCT00787761|stage III adult T-cell leukemia/lymphoma
1295315|NCT00787761|stage IV adult T-cell leukemia/lymphoma
1295316|NCT00787761|anaplastic large cell lymphoma
1295317|NCT00787761|angioimmunoblastic T-cell lymphoma
1295318|NCT00787748|Cardiovascular
1295319|NCT00787748|COPD
1295320|NCT00787748|Population
1295321|NCT00787748|Prevalence
1295322|NCT00787748|Underdiagnosis
1295323|NCT00787722|High dose immunosuppressive therapy
1295324|NCT00787722|Hematopoietic stem cell support
1295325|NCT00787709|Obesity prevention
1295326|NCT00787709|Health promotion
1295327|NCT00787709|School based curriculum
1295328|NCT00787696|HIV prevention
1295329|NCT00787696|female adolescent offenders
1295330|NCT00787696|sexual risk reduction
1295331|NCT00787696|alcohol and other drug abuse
1295332|NCT00787683|Patients with ventricular arrhythmias and the prevention of sudden cardiac death
1295333|NCT00787670|Obese
1295334|NCT00787670|Type 2 Diabetes Mellitus
1295335|NCT00787670|Gastric Bypass surgery
1295336|NCT00787670|Risk of cardiovascular diseases
1295337|NCT00787657|Clinically Isolated Syndrome (CIS)
1295338|NCT00787644|Asthma
1295339|NCT00787644|Adipose Tissue
1295340|NCT00787644|Asthmatics
1295341|NCT00787644|Pioglitazone
1295342|NCT00787644|Actos
1295343|NCT00787644|Obesity
1295344|NCT00787644|Exacerbation
1295345|NCT00787644|Fat
1295346|NCT00787644|Overweight
1295347|NCT00787644|Leptin
1295348|NCT00787644|Adiponectin
1295349|NCT00787644|Wheezing
1295350|NCT00787644|Vermont
1295351|NCT00787644|Pulmonary
1295352|NCT00787644|Lung
1295353|NCT00787631|birch pollen pollen allergy
1295354|NCT00787631|oral allergy syndrome to apple
1295355|NCT00787631|cross reactivity
1295356|NCT00787631|bet v 1
1295357|NCT00787631|mal d 1
1295358|NCT00787618|Renal impairment
1295359|NCT00787605|Hypertension, diabetes mellitus, aliskiren, hydrochlorothiazide, systolic blood pressure, diastolic blood pressure, amlodipine, stage 2
1295360|NCT00787592|Burns
1295361|NCT00787592|children
1295362|NCT00787592|collagenase
1295363|NCT00787592|silver sulfadiazine
1295364|NCT00787592|Childhood burns
1295365|NCT00787579|Myopia, bifocal, children
1295366|NCT00787566|Highly emetogenic chemotherapy induced nausea and vomiting
1295367|NCT00787553|hysterectomy
1295368|NCT00787553|antibiotic prophylaxis
1295369|NCT00787553|bacterial vaginosis
1295370|NCT00787553|tinidazole
1295371|NCT00787553|cefazolin
1295372|NCT00787540|Coronary disease
1295373|NCT00787540|Psychosocial
1295374|NCT00787540|Nursing
1295375|NCT00787527|Lymphoma
1295376|NCT00787527|Non-Hodgkin's Lymphoma
1295377|NCT00787527|SAHA
1295378|NCT00787527|Vorinostat
1295379|NCT00787527|Suberoylanilide Hydroxamic Acid
1295380|NCT00787527|MSK-390
1295381|NCT00787527|CHOP
1295382|NCT00787527|Cyclophosphamide
1295383|NCT00787527|Doxorubicin
1295384|NCT00787527|AD
1295385|NCT00787527|Hydroxydaunomycin hydrochloride
1295386|NCT00787527|Cytoxan
1295387|NCT00787527|Neosar
1295388|NCT00787527|Vincristine
1295389|NCT00787527|Prednisone
1295390|NCT00787527|Untreated T-cell
1295391|NCT00787527|T-cell NHL
1295392|NCT00787527|Peripheral T-cell lymphoma
1295393|NCT00787527|PTCL
1295394|NCT00787527|CD 30
1295395|NCT00787527|Anaplastic large cell lymphoma
1295396|NCT00787527|Angioimmunoblastic T-cell lymphoma
1295397|NCT00787527|Intestinal T-cell lymphoma
1295398|NCT00787527|Subcutaneous panniculitic T-cell lymphoma
1295399|NCT00787514|ovarian cancer, folate receptor, plasma
1295400|NCT00787501|Major Depressive Disorder
1295401|NCT00787501|Depression
1295402|NCT00787501|Selective Serotonin Reuptake Inhibitors
1295403|NCT00787501|Cognitive Behavior Therapy
1295404|NCT00787501|Cognitive Therapy
1295405|NCT00787501|antidepressant medications
1295406|NCT00787488|Ovarian
1295407|NCT00787488|debulked
1295408|NCT00787488|recurrent
1295409|NCT00787488|Stage III
1295410|NCT00787488|Stage IV
1295411|NCT00787475|Diabetes
1295412|NCT00787475|Community health worker
1295413|NCT00787475|Community outreach
1295414|NCT00787462|Neuropathic
1295415|NCT00787462|Neuropathic pain
1295416|NCT00787462|Nerve pain
1295417|NCT00787462|Pain
1295418|NCT00787462|Chronic pain
1295419|NCT00787462|Pregabalin
1295420|NCT00787462|Lyrica
1295421|NCT00787462|Small fiber neuropathy
1295422|NCT00787462|Neuropathy
1295423|NCT00787436|portal hypertension
1295424|NCT00787436|Gastroesophageal
1295425|NCT00787436|Varices
1295426|NCT00787436|Liver disease
1295427|NCT00787436|cirrhosis
1295428|NCT00787423|Field Tools
1295429|NCT00787423|Drug Use
1295430|NCT00787423|Psychological Stress
1295431|NCT00787423|Ecological Momentary Assessment
1295432|NCT00787423|Global Positioning Units
1295433|NCT00787410|malignant mesothelioma
1295434|NCT00787410|IRESSA
1295435|NCT00787410|ZD1839
1295436|NCT00787397|Sleep difficulties in pediatric anxiety disorder
1295437|NCT00787397|Neural correlates of pediatric anxiety disorder
1295438|NCT00787397|Social correlates of pediatric anxiety disorder
1295439|NCT00787397|Generalized Anxiety Disorder in pediatric populations
1295440|NCT00787397|Separation Anxiety Disorder in pediatric populations
1295441|NCT00787397|Social Phobia in pediatric populations
1295442|NCT00787384|Hypereosinophilic syndrome (HES)
1295443|NCT00787384|chronic eosinophilic leukaemia (CEL)
1295444|NCT00787384|chronic idiopathic hypereosinophilia (CIH)
1295445|NCT00787384|Imatinib
1295446|NCT00787384|Response
1295447|NCT00787384|Timing to response
1295448|NCT00787371|alanine transaminase
1295449|NCT00787358|osteoporosis
1295450|NCT00787358|intertrochanteric
1295451|NCT00787358|hip fracture
1295452|NCT00787358|compression hip screw
1295453|NCT00787358|surgical fixation
1295454|NCT00787345|precaution technique during central venous catheter placement.
1295455|NCT00787332|Suspected Heparin Induced Thrombocytopenia (HIT)
1295456|NCT00787319|Ophthalmology
1295457|NCT00787319|Age-related macular degeneration
1295458|NCT00787319|outpatients
1295459|NCT00787306|chronic disease management
1295460|NCT00787306|decision aids
1295461|NCT00787306|cardiovascular risk factors
1295462|NCT00787293|Heart Failure
1295463|NCT00787293|Mitral Regurgitation
1295464|NCT00787293|Percutaneous
1295465|NCT00787293|Coronary sinus
1295466|NCT00787280|obese
1295467|NCT00787280|overweight
1295468|NCT00787280|fMRI
1295469|NCT00787280|Diet
1295470|NCT00787267|NSCLC
1295471|NCT00787267|Lung Cancer
1295472|NCT00787267|Dasatinib
1295473|NCT00787267|Genomics
1295474|NCT00787267|Genomics analysis
1295475|NCT00787267|Genomic signature
1295476|NCT00787254|Curling Ulcer
1295477|NCT00787254|Gastric Ulcer
1295478|NCT00787254|Nonsteroid anti-inflammatory drug
1295479|NCT00787254|Drug Therapy
1295480|NCT00787241|Platelets
1295481|NCT00787241|Labor
1295482|NCT00787241|Preeclampsia
1295483|NCT00787215|oral glucose tolerance test
1295484|NCT00787215|Hong Kong Chinese
1295485|NCT00787202|treatment of ulcerative colitis; CP 690 550
1295486|NCT00787189|sensorineural hearing loss
1295487|NCT00787189|tinnitus
1295488|NCT00787189|word recognition
1295489|NCT00787176|Oxytocin
1295490|NCT00787176|Labor, Obstetric
1295491|NCT00787176|Non-reassuring fetal heart rate
1295492|NCT00787176|epidural
1295493|NCT00787163|pPROM
1295494|NCT00787163|oligohydramnios
1295495|NCT00787163|amnioinfusion
1295496|NCT00787163|prematurity
1295497|NCT00787163|Early premature rupture of membranes in pregnancy
1295498|NCT00787111|Drug: Fluoxetine
1295499|NCT00787098|therapeutic mobility
1295500|NCT00787098|acute care
1295501|NCT00787098|nursing
1295502|NCT00787098|inflammatory markers
1295503|NCT00787085|Funguria
1295504|NCT00787085|Epidemiology
1295505|NCT00787085|Urinary Tract Infections
1295506|NCT00787059|Adenylyl Cyclase
1295507|NCT00787059|AC6
1295508|NCT00787059|adenovirus
1295509|NCT00787059|gene therapy
1295510|NCT00787059|congestive heart failure
1295511|NCT00787059|intracoronary
1295512|NCT00787059|nitroprusside
1295513|NCT00787033|Focal Adhesion Kinase; Advanced Non-Hematologic Malignancies
1295514|NCT00787020|Cerebrospinal Fluid
1295515|NCT00787020|Ventriculostomy
1295516|NCT00787020|Subarachnoid hemorrhage
1295517|NCT00787020|vasospasm
1295518|NCT00787020|Human Subjects
1295519|NCT00787007|healthy volunteers
1295520|NCT00787007|pharmacokinetics
1295521|NCT00786994|Actinic Keratoses
1295522|NCT00786968|mucopolysaccharidosis
1295523|NCT00786968|Hurler-Scheie
1295524|NCT00786968|Scheie
1295525|NCT00786968|laronidase
1295526|NCT00786968|spinal cord compression
1295527|NCT00786968|central nervous system
1295528|NCT00786968|enzyme replacement therapy
1295529|NCT00786968|intrathecal
1295530|NCT00786942|osteotomy
1295531|NCT00786942|knee
1295532|NCT00786942|varus deformity
1295533|NCT00786942|bone graft
1295658|NCT00786461|marsupialisation
1295534|NCT00786929|Conversion to more aggressive treatment of recurrent fluid collection
1295535|NCT00786916|pain
1295536|NCT00786916|propofol
1295537|NCT00786916|lidocaine
1295538|NCT00786916|sedation
1295539|NCT00786916|pediatric
1295540|NCT00786890|Prediabetes (IFG, IGT)
1295541|NCT00786890|Hong Kong Chinese
1295542|NCT00786890|Cardiovascular risk factors
1295543|NCT00786877|pneumonia
1295544|NCT00786864|Randomised controlled trial
1295545|NCT00786864|low back pain
1295546|NCT00786864|exercise
1295547|NCT00786864|children
1295548|NCT00786864|school-based
1295549|NCT00786864|prevalence
1295550|NCT00786864|intensity
1295551|NCT00786851|MANTLE CELL LYMPHOMA (MCL)
1295552|NCT00786851|Lenalidomide (Len)
1295553|NCT00786851|Dexamethasone (Dex)
1295554|NCT00786838|Solid tumor
1295555|NCT00786838|Advanced solid tumor
1295556|NCT00786838|Malignant tumors
1295557|NCT00786838|Sarcoma
1295558|NCT00786838|Breast tumor
1295559|NCT00786838|Ovarian tumor
1295560|NCT00786838|QT interval
1295561|NCT00786838|Trabectedin
1295562|NCT00786838|Yondelis
1295563|NCT00786838|Ecteinascidin 743
1295564|NCT00786838|ET743
1295565|NCT00786825|Type 1 diabetes
1295566|NCT00786825|Hypoglycemia unawareness
1295567|NCT00786812|Leukemia
1295568|NCT00786812|adult chronic myeloid leukemia
1295569|NCT00786812|imatinib
1295570|NCT00786812|nilotinib
1295571|NCT00786786|Any person with a spinal cord injury
1295572|NCT00786786|at least 18 years of age
1295573|NCT00786773|GERD
1295574|NCT00786773|reflux symptom
1295575|NCT00786773|heartburn
1295576|NCT00786773|acid regurgitation
1295577|NCT00786773|PPI
1295578|NCT00786773|H2RA
1295579|NCT00786773|antacid
1295580|NCT00786760|HPV
1295581|NCT00786760|Papillomavirus
1295582|NCT00786760|Infection
1295583|NCT00786760|Sexually transmitted disease
1295584|NCT00786760|STD
1295585|NCT00786747|Computer-assisted instruction
1295586|NCT00786747|Health knowledge, attitudes, practice
1295587|NCT00786747|Mass screening
1295588|NCT00786747|Patient acceptance of health care
1295589|NCT00786747|Patient education as topic
1295590|NCT00786747|Primary health care
1295591|NCT00786747|Self-efficacy
1295592|NCT00786734|pitavastatin
1295593|NCT00786734|PCI
1295594|NCT00786734|stable angina
1295595|NCT00786721|Mitochondria and Metabolic Syndrome
1295596|NCT00786708|renal
1295597|NCT00786708|kidney
1295598|NCT00786708|lipocalin
1295599|NCT00786708|urine
1295600|NCT00786708|biomarker
1295601|NCT00786708|Azotemia
1295602|NCT00786708|Renal insufficiency, chronic
1295603|NCT00786708|Renal failure, acute
1295604|NCT00786708|Hydronephrosis
1295605|NCT00786695|noncardiac chest pain
1295606|NCT00786695|gastroesophageal reflux disease
1295607|NCT00786695|diagnostic test
1295608|NCT00786695|proton pump inhibitor
1295609|NCT00786695|esomeprazole
1295610|NCT00786682|stage IV prostate cancer
1295611|NCT00786682|recurrent prostate cancer
1295612|NCT00786656|Navigation
1295613|NCT00786656|Coordination
1295614|NCT00786656|Cancer Care
1295615|NCT00786656|Patient Experience
1295616|NCT00786656|Cancer
1295617|NCT00786656|Patient Survey
1295618|NCT00786643|Gamma Interferon
1295619|NCT00786643|5-FU
1295620|NCT00786643|LV
1295621|NCT00786630|Drug treatment entry and retention
1295622|NCT00786630|Drug injection frequency
1295623|NCT00786630|HIV risk behaviors
1295624|NCT00786630|Hepatitis C risk behaviors
1295625|NCT00786591|Acute pancreatitis
1295626|NCT00786591|biological markers
1295627|NCT00786591|substance P
1295628|NCT00786591|hydrogen sulfide
1295629|NCT00786591|disease severity index
1295630|NCT00786578|training
1295631|NCT00786578|intramyocellular lipid
1295632|NCT00786578|insulin resistance
1295633|NCT00786552|recurrent/advanced thyroid cancer
1295634|NCT00786552|papillary or anaplastic thyroid cancer
1295635|NCT00786539|mitochondrial
1295636|NCT00786526|Mechanical ventilation
1295637|NCT00786526|Ventilator induced diaphragmatic dysfunction
1295638|NCT00786526|Weaning
1295639|NCT00786526|Neuromuscular diseases- Respiratory function tests
1295640|NCT00786526|Intubated patients in intensive care unit
1295641|NCT00786513|Cystic fibrosis
1295642|NCT00786513|Pseudomonas aeruginosa
1295643|NCT00786513|biofilm
1295644|NCT00786513|antibiotic susceptibility testing
1295645|NCT00786513|pediatrics
1295646|NCT00786500|Herbal medicine
1295647|NCT00786500|Type 2 diabetes
1295648|NCT00786500|Insulin sensitivity
1295649|NCT00786500|Insulin secretion
1295650|NCT00786487|insulin resistance
1295651|NCT00786487|lipid metabolism
1295652|NCT00786487|lipid infusion
1295653|NCT00786487|glycerol infusion
1295654|NCT00786487|skeletal muscle
1295655|NCT00786487|diabetes
1295656|NCT00786474|Bridging Anticoagulation
1295657|NCT00786461|silver nitrate
1295659|NCT00786448|Overactive Bladder
1295660|NCT00786422|Embolism and Thrombosis
1295661|NCT00786422|Pulmonary Embolism
1295662|NCT00786422|Embolism
1295663|NCT00786422|Venous Thrombosis
1295664|NCT00786422|Thrombosis
1295665|NCT00786422|Enzyme Inducers
1295666|NCT00786422|CYP Inducers
1295667|NCT00786422|Cohort Study
1295668|NCT00786422|Pharmacologic Actions
1295669|NCT00786422|Respiratory Tract Diseases
1295670|NCT00786422|Lung Diseases
1295671|NCT00786422|Vascular Diseases
1295672|NCT00786422|Human Immunodeficiency Virus (HIV)
1295673|NCT00786422|Neurologic disease
1295674|NCT00786422|Additional relevant MeSH terms:
1295675|NCT00786422|Fibrin Modulating Agents
1295676|NCT00786422|Anticoagulants
1295677|NCT00786422|Therapeutic Uses
1295678|NCT00786422|Hematologic Agents
1295679|NCT00786422|Enzyme Inhibitors
1295680|NCT00786422|Cardiovascular Diseases
1295681|NCT00786422|Cardiovascular Agents
1295682|NCT00786409|Lupus
1295683|NCT00786396|HIV
1295684|NCT00786396|AIDS
1295685|NCT00786396|substance abuse
1295686|NCT00786396|directly administered antiretroviral therapy
1295687|NCT00786396|adherence
1295688|NCT00786396|Substance Abuse and Dependency
1295689|NCT00786383|Phase I
1295690|NCT00786383|cancer
1295691|NCT00786383|solid tumors
1295692|NCT00786383|1121B
1295693|NCT00786383|VEGFR-2
1295694|NCT00786383|Anti-Vascular Endothelial Growth Factor Receptor 2
1295695|NCT00786370|propofol
1295696|NCT00786370|dexmedetomidine
1295697|NCT00786370|cataract
1295698|NCT00786370|respiratory
1295699|NCT00786370|blood pressure
1295700|NCT00786370|Cataract surgery
1295701|NCT00786357|shift-work
1295702|NCT00786357|sleep
1295703|NCT00786357|nurse
1295704|NCT00786357|relaxation
1295705|NCT00786344|Health Promotion: Wellness Programs
1295706|NCT00786344|Occupational Therapy
1295707|NCT00786344|Quality of Life
1295708|NCT00786344|Health
1295709|NCT00786344|Biomarkers
1295710|NCT00786331|second line treatment
1295711|NCT00786331|pemetrexed
1295712|NCT00786331|carboplatin
1295713|NCT00786318|Psychosis
1295714|NCT00786318|Agitation
1295715|NCT00786318|Delirium
1295716|NCT00786305|Nebulization
1295717|NCT00786305|ceftazidime
1295718|NCT00786305|amikacin
1295719|NCT00786305|pneumonia
1295720|NCT00786305|Pseudomonas aeruginosa
1295721|NCT00786305|mechanical ventilation
1295722|NCT00786305|Ventilator-associated pneumonia
1295723|NCT00786305|treatment
1295724|NCT00786279|atherosclerosis
1295725|NCT00786266|shift-work
1295726|NCT00786266|sleep
1295727|NCT00786266|nurse
1295728|NCT00786266|relaxation
1295729|NCT00786253|Erectile dysfunction
1295730|NCT00786253|Vardenafil
1295731|NCT00786240|Bioequivalence
1295732|NCT00786240|Therapeutic Equivalency
1295733|NCT00786214|Functional Dyspepsia
1295734|NCT00786214|Acupuncture
1295735|NCT00786214|Traditional Chinese Medicine
1295736|NCT00786201|CNTO 888
1295737|NCT00786201|Idiopathic Pulmonary Fibrosis
1295738|NCT00786201|IPF
1295739|NCT00786188|Menopause
1295740|NCT00786188|Vasomotor Symptoms
1295741|NCT00786188|Hot flash
1295742|NCT00786188|Perimenopause
1295743|NCT00786188|Nonhormonal therapies
1295744|NCT00786188|Climacteric symptoms
1295745|NCT00786188|Mesafem
1295746|NCT00786188|Low-Dose Mesylate salt of Paroxetine (LDMP)
1295747|NCT00786149|Underserved populations
1295748|NCT00786149|Homelessness
1295749|NCT00786149|Nicotine replacement therapy
1295750|NCT00786149|Counseling
1295751|NCT00786149|Cancer Prevention and control
1295752|NCT00786136|diabetes mellitus
1295753|NCT00786136|chronic kidney disease
1295754|NCT00786136|contrast induced acute kidney injury
1295755|NCT00786136|angiography
1295756|NCT00786123|irritable bowel syndrome
1295757|NCT00786123|rectal hypersensitivity
1295758|NCT00786123|probiotics
1295759|NCT00786123|melatonin
1295760|NCT00786123|brain-gut axis
1295761|NCT00786110|Sorafenib
1295762|NCT00786110|Paclitaxel
1295763|NCT00786110|Disease free survival
1295764|NCT00786084|Hiatal hernia
1295765|NCT00786084|PEH
1295766|NCT00786084|paraesophageal hernia
1295767|NCT00786084|synthetic mesh
1295768|NCT00786084|small intestine submucosa
1295769|NCT00786071|Rett syndrome.
1295770|NCT00786071|Nutritional status.
1295771|NCT00786071|Metabolic alterations.
1295772|NCT00786058|refractory pancreatic cancer
1295773|NCT00786058|gemcitabine
1295774|NCT00786058|phase III
1295775|NCT00786058|second line
1295776|NCT00786045|stroke
1295777|NCT00786045|rehabilitation
1295778|NCT00786045|walking
1295779|NCT00786032|Amyotrophic Lateral Sclerosis
1295780|NCT00786032|Brain Computer Interface (BCI)
1295781|NCT00786032|Lou Gehrig's disease
1295782|NCT00786019|Type
1295783|NCT00786019|2
1295784|NCT00786019|Diabetes
1295785|NCT00786019|Blood
1295786|NCT00786019|Vessel
1295787|NCT00786019|Function
1295788|NCT00786019|Exercise
1295789|NCT00786019|Program
1295790|NCT00786019|Intervention
1295791|NCT00786019|Vitamin
1295792|NCT00786019|C
1295793|NCT00786019|Men
1295794|NCT00786019|Women
1295795|NCT00786019|Blood vessel function
1295796|NCT00786006|pancreatic cancer
1295797|NCT00786006|gemcitabine
1295798|NCT00786006|oxaliplatin
1295799|NCT00786006|irinotecan
1295800|NCT00786006|fluorouracil
1295801|NCT00786006|Failure to gemcitabine chemotherapy
1295802|NCT00785993|Egg banking, clinical outcome
1295803|NCT00785980|quinine sulfate
1295804|NCT00785980|ciprofloxacin
1295805|NCT00785980|drug interactions
1295806|NCT00785980|cytochrome p450
1295807|NCT00785980|male
1295808|NCT00785980|female
1295809|NCT00785980|adult
1295810|NCT00785980|pharmacokinetics
1295811|NCT00785967|V(D)J recombination; RAG-1/2 recombinase function
1295812|NCT00785954|Heart Diseases
1295813|NCT00785954|Myocardial Ischemia
1295814|NCT00785954|Infarction
1295815|NCT00785954|Myocardial Infarction
1295816|NCT00785941|Tumors
1295817|NCT00785941|Antibodies, Monoclonal
1295818|NCT00785928|Arthritis
1295819|NCT00785915|AZD6765
1295820|NCT00785915|Japanese and Caucasian Healthy Volunteers
1295821|NCT00785915|Phase I study
1295822|NCT00785915|Single and multiple Ascending Dose
1295823|NCT00785915|Japanese volunteers
1295824|NCT00785889|Colorectal cancer screening
1295825|NCT00785889|optical colonoscopy
1295826|NCT00785889|water method
1295827|NCT00785889|sedation
1295828|NCT00785876|Paediatric
1295829|NCT00785876|Emergency Department
1295830|NCT00785876|Ankle
1295831|NCT00785876|Injury
1295832|NCT00785876|Low risk ankle rule
1295833|NCT00785863|hyperalgesia
1295834|NCT00785863|remifentanil
1295835|NCT00785863|ketorolac
1295836|NCT00785863|parecoxib
1295837|NCT00785863|COX-1 inhibitor
1295838|NCT00785863|COX-2 inhibitor
1295839|NCT00785837|Hydrotherapy
1295840|NCT00785837|Perinatal Care
1295841|NCT00785837|Neonatology
1295842|NCT00785824|Lactation
1295843|NCT00785824|Endocrine System Diseases
1295844|NCT00785824|Musculoskeletal System Disease
1295845|NCT00785824|Hormone
1295846|NCT00785824|Physiological Properties
1295847|NCT00785798|Relapsed Lymphomas
1295848|NCT00785798|Refractory Lymphomas
1295849|NCT00785785|Unresectable GIST
1295850|NCT00785785|metastatic GIST
1295851|NCT00785785|nilotinib
1295852|NCT00785785|AMN107
1295853|NCT00785785|imatinib
1295854|NCT00785785|STI571
1295855|NCT00785772|Gabapentin Pharmacokinetics
1295856|NCT00785759|Alzheimer's Disease
1295857|NCT00785746|elderly, balance, core, strength
1295858|NCT00785733|asthma
1295859|NCT00785707|sensorineural hearing loss
1295860|NCT00785707|cochlear implant
1295861|NCT00785668|Asthma
1295862|NCT00785668|Allergy
1295863|NCT00785668|Interleukin-4
1295864|NCT00785668|Interleukin-13
1295865|NCT00785668|IL-4
1295866|NCT00785668|IL-13
1295867|NCT00785668|Pharmacokinetics
1295868|NCT00785668|Safety
1295869|NCT00785668|Tolerability
1295870|NCT00785668|Aerovance
1295871|NCT00785668|dry powder
1295872|NCT00785629|phosphorus
1295873|NCT00785629|secondary hyperparathyroidism
1295874|NCT00785629|vascular calcification
1295875|NCT00785616|HIV
1295876|NCT00785616|Adherence
1295877|NCT00785616|MEMS
1295878|NCT00785603|Depression
1295879|NCT00785603|pain
1295880|NCT00785603|CYP2D6
1295881|NCT00785603|interactions
1295882|NCT00785603|Pupillometry
1295883|NCT00785603|Tramadol
1295884|NCT00785603|Paroxetine
1295885|NCT00785603|MR-ratio
1295886|NCT00785564|T-wave memory
1295887|NCT00785564|Sick Sinus Syndrome
1295888|NCT00785551|male
1295889|NCT00785551|female
1295890|NCT00785551|pharmacokinetics
1295891|NCT00785551|normal and impaired renal function
1295892|NCT00785538|Tumors
1295893|NCT00785538|Antibodies, Monoclonal
1295894|NCT00785525|Healthy Unrelated Stem Cell Donors
1295895|NCT00785512|nebivolol
1295896|NCT00785512|Bystolic®
1295897|NCT00785512|Hypertension
1295898|NCT00785512|blood pressure
1295899|NCT00785512|withdrawal
1295900|NCT00785499|obesity
1295901|NCT00785499|metabolic syndrome
1295902|NCT00785499|milk components
1295903|NCT00785499|casein
1295904|NCT00785499|whey
1295905|NCT00785499|children
1295906|NCT00785499|adolescent
1295907|NCT00785486|midazolam
1295908|NCT00785486|drug interactions
1295909|NCT00785486|cytochrome p450
1295910|NCT00785447|Cardiopulmonary Resuscitation
1295911|NCT00785447|Respiratory Physiology
1295912|NCT00785447|Mouth to mouth ventilation
1295913|NCT00785447|Mouth to nose ventilation
1295914|NCT00785434|MDD
1295915|NCT00785434|escitalopram
1295916|NCT00785421|heparin
1295917|NCT00785421|LMWH
1295918|NCT00785421|pancreatic cancer
1295919|NCT00785408|obesity
1295920|NCT00785408|overweight
1295921|NCT00785408|weight loss
1295922|NCT00785408|Amylin
1295923|NCT00785408|AC2307
1295924|NCT00785382|Pain, Pregabalin, Lyrica, Breast surgery
1295925|NCT00785369|skin disorders
1295926|NCT00785369|skin cancer
1295927|NCT00785369|melanoma
1295928|NCT00785369|lentigo maligna
1295929|NCT00785356|Uterine fibroids
1295930|NCT00785356|Anemia
1295931|NCT00785343|stroke
1295932|NCT00785343|acute
1295933|NCT00785343|arm
1295934|NCT00785343|robot
1295935|NCT00785343|therapy
1295936|NCT00785343|arm paresis
1295937|NCT00785330|rituximab
1295938|NCT00785330|Non-Hodgkin's lymphoma
1295939|NCT00785330|diffuse large B cell lymphoma
1295940|NCT00785330|peripheral t cell lymphoma
1295941|NCT00785330|graft-versus-host disease
1295942|NCT00785330|graft-versus-lymphoma effect
1295943|NCT00785330|allogeneic haematopoietic stem cell transplantation
1295944|NCT00785330|relapsed or primary progressive aggressive Non-Hodgkin's lymphoma
1295945|NCT00785317|Postmenopausal Hormone Replacement Therapy
1295946|NCT00785278|Wheelchair Set-Up
1295947|NCT00785278|Shoulder Joint Forces
1295948|NCT00785278|Manual Wheelchair Users
1295949|NCT00785278|Paraplegia
1295950|NCT00785278|Upper Limb Pain
1295951|NCT00785278|Secondary Injury to Spinal Cord Injury
1295952|NCT00785278|Biomechanics
1295953|NCT00785265|Live Donor Kidney Transplantation
1295954|NCT00785265|LDKT
1295955|NCT00785265|African Americans
1295956|NCT00785265|Disparity
1295957|NCT00785265|Education
1295958|NCT00785252|Catheters, Indwelling
1295959|NCT00785239|Malignant Airway Disease
1295960|NCT00785239|Benign Airway Disease
1295961|NCT00785239|Lung Cancer
1295962|NCT00785239|Emphysema
1295963|NCT00785239|Chronic Bronchitis
1295964|NCT00785239|COPD
1295965|NCT00785239|Asthma
1295966|NCT00785239|Sarcoidosis
1295967|NCT00785239|Mesothelioma
1295968|NCT00785239|CryoSpray Ablation
1295969|NCT00785239|Cryotherapy
1295970|NCT00785239|Cryospray
1295971|NCT00785239|Cryo
1295972|NCT00785213|rosiglitazone
1295973|NCT00785213|quinine sulfate
1295974|NCT00785213|drug interactions
1295975|NCT00785213|cytochrome p450
1295976|NCT00785200|MRSA
1295977|NCT00785200|Methicillin-resistant Staphylococcus aureus
1295978|NCT00785200|Chlorhexidine
1295979|NCT00785200|Asymptomatic colonization
1295980|NCT00785200|Asymptomatic colonization, MRSA
1295981|NCT00785200|Skin and soft tissue infections
1295982|NCT00785187|UVB induced skin erythema
1295983|NCT00785174|noninvasive ventilation, continuous posi
1295984|NCT00785161|Penumbra System
1295985|NCT00785161|Mechanical Thrombectomy
1295986|NCT00785161|Ischemic Stroke
1295987|NCT00785161|Intervention
1295988|NCT00785161|Neurovascular
1295989|NCT00785161|Thrombus
1295990|NCT00785161|Imaging
1295991|NCT00785161|Ischemic Penumbra
1295992|NCT00785161|Functional Outcome
1295993|NCT00785135|vision, binocular
1295994|NCT00785135|vision disparity
1295995|NCT00785135|headache
1295996|NCT00785135|dizziness
1295997|NCT00785135|anxiety
1295998|NCT00785135|neck pain
1295999|NCT00785135|learning disorders
1296000|NCT00785135|asthenopia
1296001|NCT00785135|motion sickness
1296002|NCT00785135|depth perception
1296003|NCT00785135|gait disorder
1296004|NCT00785135|diplopia
1296005|NCT00785135|photophobia
1296006|NCT00785135|agoraphobia
1296007|NCT00785135|panic disorder
1296008|NCT00785122|cancer vaccine
1296009|NCT00785109|aortic valve calcification
1296010|NCT00785109|vitamin K supplementation
1296011|NCT00785096|Perception, surgical complications, patients, nurses and physicians
1296012|NCT00785083|Asthma, adrenergic beta agonists, multiple sclerosis, pulmonary function tests, forced expiratory volume
1296013|NCT00785070|Perioperative
1296014|NCT00785070|Obstructive Sleep Apnea
1296015|NCT00785070|Screening
1296016|NCT00785070|Home Sleep Testing
1296017|NCT00785057|Hypertension
1296018|NCT00785057|Stroke
1296019|NCT00785057|Neurology
1296020|NCT00785057|JNC7
1296021|NCT00785057|2007 ESH-ESC guidelines
1296022|NCT00785057|survey
1296023|NCT00785044|Heart Failure
1296024|NCT00785044|MIBG
1296025|NCT00785044|123I-mIBG
1296026|NCT00785031|risk management
1296027|NCT00785031|Self Management
1296028|NCT00785031|Self-Efficacy
1296029|NCT00785031|Disease management
1296030|NCT00785031|nurse practitioner
1296031|NCT00785031|internet
1296032|NCT00785031|risk factors
1296033|NCT00785031|vascular diseases
1296034|NCT00785031|economic evaluation
1296035|NCT00785018|Endotoxin
1296036|NCT00785018|C1-inhibitor
1296037|NCT00785018|Inflammation
1296038|NCT00785018|Sepsis
1296039|NCT00785018|Multi organ dysfunction syndrome
1296040|NCT00785018|Complement activation
1296041|NCT00785005|Diabetes
1296042|NCT00785005|Exercise
1296043|NCT00785005|Women
1296044|NCT00785005|Research
1296045|NCT00785005|Bike
1296046|NCT00785005|Type
1296047|NCT00785005|Control
1296048|NCT00785005|Healthy
1296049|NCT00784992|NLDO
1296050|NCT00784992|DCR
1296051|NCT00784992|silicone tubes
1296052|NCT00784992|stent
1296053|NCT00784979|Renal
1296054|NCT00784979|Transplant
1296055|NCT00784979|PRA
1296056|NCT00784966|Islet transplantation
1296057|NCT00784966|Type 1 Diabetes Mellitus
1296058|NCT00784966|Kidney Transplantation
1296059|NCT00784953|Symbicort SMART
1296060|NCT00784953|budesonide
1296061|NCT00784953|formoterol
1296062|NCT00784953|ICS/LABA
1296063|NCT00784953|Asthma Control Questionnaire
1296064|NCT00784953|Not optimally controlled asthma
1296065|NCT00784927|stage I grade 1 follicular lymphoma
1296066|NCT00784927|contiguous stage II grade 1 follicular lymphoma
1296067|NCT00784927|noncontiguous stage II grade 1 follicular lymphoma
1296068|NCT00784927|stage III grade 1 follicular lymphoma
1296069|NCT00784927|stage IV grade 1 follicular lymphoma
1296070|NCT00784927|stage I grade 2 follicular lymphoma
1296071|NCT00784927|contiguous stage II grade 2 follicular lymphoma
1296072|NCT00784927|noncontiguous stage II grade 2 follicular lymphoma
1296073|NCT00784927|stage III grade 2 follicular lymphoma
1296074|NCT00784927|stage IV grade 2 follicular lymphoma
1296075|NCT00784927|stage I small lymphocytic lymphoma
1296076|NCT00784927|contiguous stage II small lymphocytic lymphoma
1296077|NCT00784927|noncontiguous stage II small lymphocytic lymphoma
1296078|NCT00784927|stage III small lymphocytic lymphoma
1296079|NCT00784927|stage IV small lymphocytic lymphoma
1296080|NCT00784927|Waldenstrom macroglobulinemia
1296081|NCT00784927|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1296082|NCT00784927|nodal marginal zone B-cell lymphoma
1296083|NCT00784927|splenic marginal zone lymphoma
1296084|NCT00784927|stage I marginal zone lymphoma
1296085|NCT00784927|contiguous stage II marginal zone lymphoma
1296086|NCT00784927|noncontiguous stage II marginal zone lymphoma
1296087|NCT00784927|stage III marginal zone lymphoma
1296088|NCT00784927|stage IV marginal zone lymphoma
1296089|NCT00784914|adult anaplastic astrocytoma
1296090|NCT00784914|adult diffuse astrocytoma
1296091|NCT00784914|adult craniopharyngioma
1296092|NCT00784914|adult choroid plexus tumor
1296093|NCT00784914|adult brain stem glioma
1296094|NCT00784914|tumors metastatic to brain
1296095|NCT00784914|recurrent adult brain tumor
1296096|NCT00784914|adult gliosarcoma
1296097|NCT00784914|adult giant cell glioblastoma
1296098|NCT00784914|adult ependymoblastoma
1296099|NCT00784914|adult medulloblastoma
1296100|NCT00784914|adult supratentorial primitive neuroectodermal tumor (PNET)
1296101|NCT00784914|adult anaplastic ependymoma
1296102|NCT00784914|adult ependymoma
1296103|NCT00784914|adult myxopapillary ependymoma
1296104|NCT00784914|adult subependymoma
1296105|NCT00784914|adult mixed glioma
1296106|NCT00784914|meningeal melanocytoma
1296107|NCT00784914|adult meningeal hemangiopericytoma
1296108|NCT00784914|adult grade I meningioma
1296109|NCT00784914|adult grade II meningioma
1296110|NCT00784914|adult grade III meningioma
1296111|NCT00784914|adult anaplastic oligodendroglioma
1296112|NCT00784914|adult oligodendroglioma
1296113|NCT00784914|adult pineoblastoma
1296114|NCT00784914|adult pineocytoma
1296115|NCT00784901|Macular Thickness Analyzed by Optical Coherence Tomography in Retinitis Pigmemtosa
1296116|NCT00784888|aromatase inhibitor
1296117|NCT00784888|quality of life
1296118|NCT00784888|safety
1296119|NCT00784888|postmenopausal breast cancer
1296120|NCT00784849|Breast cancer
1296121|NCT00784849|diagnostic
1296122|NCT00784849|lymph nodes
1296123|NCT00784836|Multiple Sclerosis - Relapsing
1296124|NCT00784810|Efficacy, tolerability, moderate/severe, oxycodone/naloxone
1296125|NCT00784810|codeine/paracetamol, chronic low back pain, osteoarthritis
1296126|NCT00784784|antiviral drugs
1296127|NCT00784784|influenza vaccines
1296128|NCT00784771|Hypnotherapy
1296129|NCT00784771|Hypnosis
1296130|NCT00784771|PTSD
1296131|NCT00784758|Asthma
1296132|NCT00784758|Lung Diseases
1296133|NCT00784758|Respiratory Tract Diseases
1296134|NCT00784745|incretin effect
1296135|NCT00784745|type 2 diabetes
1296136|NCT00784745|GLP-1
1296137|NCT00784745|GIP
1296138|NCT00784745|dexamethasone
1296139|NCT00784732|Seasonal Allergic Rhinitis
1296140|NCT00784732|Environmental Exposure Chamber
1296141|NCT00784732|nasal lavage
1296142|NCT00784719|Dry eye
1296143|NCT00784706|stroke rehabilitation
1296144|NCT00784706|perceptual deficits
1296145|NCT00784706|kinematic analysis
1296146|NCT00784693|Endometriosis
1296147|NCT00784693|pain
1296148|NCT00784693|tanezumab
1296149|NCT00784693|nerve growth factor
1296150|NCT00784693|questionnaires
1296151|NCT00784667|Colorectal neoplasm
1296152|NCT00784667|Metastasis
1296153|NCT00784615|Phenotypes of Polycystic Ovary Syndrome
1296154|NCT00784615|Cardiovascular risk factors
1296155|NCT00784615|Adiponectin
1296156|NCT00784615|C Reactive Protein
1296157|NCT00784602|prolapse
1296158|NCT00784602|pelvic organ prolapse
1296159|NCT00784589|Corticothérapy
1296160|NCT00784589|Rituximab
1296161|NCT00784589|therapeutic efficacity
1296162|NCT00784589|therapeutic tolerance
1296163|NCT00784576|Delirium
1296164|NCT00784576|Cardiac Surgery
1296165|NCT00784576|Depression
1296166|NCT00784576|Cognitive Impairment
1296167|NCT00784576|Diagnostic Criteria for Delirium
1296168|NCT00784576|Memorial Delirium Assessment Scale
1296169|NCT00784576|Delirium Index
1296170|NCT00784563|Parkinson Disease
1296171|NCT00784563|Exercise/*physiology
1296172|NCT00784563|*Physical Fitness
1296173|NCT00784563|Rehabilitation
1296174|NCT00784563|Cognition
1296175|NCT00784550|Spirometry
1296176|NCT00784550|COPD
1296177|NCT00784537|Hodgkin's lymphoma
1296178|NCT00784537|ABVD
1296179|NCT00784537|FDG-PET (18-Fluoro-deoxy-D-glucose Positron Emission Tomography)
1296180|NCT00784537|Radiotherapy
1296181|NCT00784524|stage IV breast cancer
1296182|NCT00784524|recurrent breast cancer
1296183|NCT00784524|metastatic breast cancer
1296184|NCT00784511|diabetes
1296185|NCT00784511|vitamin D
1296186|NCT00784511|African Americans
1296187|NCT00784511|overweight
1296188|NCT00784511|insulin sensitivity
1296189|NCT00784511|glucose control
1296190|NCT00784498|Procedural sedation and analgesia
1296191|NCT00784498|Emergency Department
1296192|NCT00784498|propofol versus ketamine and midazolam
1296193|NCT00784498|painful orthopedic manipulations
1296194|NCT00784485|Asthma
1296195|NCT00784485|Respiratory Tract Diseases
1296196|NCT00784485|Lung Diseases
1296197|NCT00784485|Dyspnea
1296198|NCT00784472|PCNL
1296199|NCT00784472|oxycodone
1296200|NCT00784472|morphine
1296201|NCT00784472|visceral pain
1296202|NCT00784459|Asthma
1296203|NCT00784459|Allergy
1296204|NCT00784446|AIO
1296205|NCT00784446|colorectal cancer
1296206|NCT00784446|0205
1296207|NCT00784446|Capecitabine
1296208|NCT00784446|Oxaliplatin
1296209|NCT00784446|Bevacizumab
1296210|NCT00784446|Imatinib
1296211|NCT00784433|alcohol diabetes CVD
1296212|NCT00784420|Drug Interaction, Pharmacokinetics
1296213|NCT00784407|thyroid surgery
1296214|NCT00784407|total thyroidectomy
1296215|NCT00784407|harmonic scalpel
1296216|NCT00784381|Renal failure
1296217|NCT00784381|Elderly
1296218|NCT00784381|Drug Therapy Computer-Assisted
1296219|NCT00784381|Quality of care
1296220|NCT00784381|Patients With Impaired Renal Function
1296221|NCT00784381|Inappropriateness of target drug prescribed
1296222|NCT00784368|Mycoses
1296223|NCT00784368|Candidiasis
1296224|NCT00784368|Aspergillosis
1296225|NCT00784368|Cryptococcosis
1296226|NCT00784368|Blastomycosis
1296227|NCT00784368|Histoplasmosis
1296228|NCT00784368|Neutropenia
1296229|NCT00784368|Itraconazole
1296230|NCT00784368|JK1211
1296231|NCT00784355|recurrence of idiopathic pancreatitis
1296232|NCT00784355|laparoscopic cholecystectomy
1296233|NCT00784355|etiology of pancreatitis
1296234|NCT00784342|COPD
1296235|NCT00784329|Lung Cancer
1296236|NCT00784329|Squamous Cell Lung Cancer
1296237|NCT00784329|Bronchial carcinoma in situ
1296238|NCT00784329|Central Airway Diseases
1296239|NCT00784316|Prevention
1296240|NCT00784303|Thyroid Cancer
1296241|NCT00784277|Pain medication
1296242|NCT00784277|Arthritis
1296243|NCT00784277|Joint pain
1296244|NCT00784277|Analgesia
1296245|NCT00784277|Analgesics
1296246|NCT00784277|tapentadol
1296247|NCT00784277|CG5503
1296248|NCT00784277|Nucynta
1296249|NCT00784264|Asymptomatic atherosclerosis
1296250|NCT00784264|Intima media thickness (IMT)
1296251|NCT00784264|central obesity
1296252|NCT00784264|cardiovascular disease
1296253|NCT00784251|Pain
1296254|NCT00784251|Leg pain
1296255|NCT00784251|Back pain
1296256|NCT00784251|PROMIS
1296257|NCT00784238|Schizophrenia
1296258|NCT00784238|Paliperidone Extended-release
1296259|NCT00784238|Paliperidone
1296260|NCT00784238|R076477
1296261|NCT00784225|cataract
1296262|NCT00784225|advanced macular degeneration
1296263|NCT00784212|Photosensitive Epilepsy, photic stimulation, electroencephalogram
1296264|NCT00784199|MDD
1296265|NCT00784199|Depression
1296266|NCT00784186|Pregnancy termination
1296267|NCT00784186|abortion
1296268|NCT00784186|medical abortion
1296269|NCT00784186|2nd trimester
1296270|NCT00784186|mifepristone
1296271|NCT00784186|misoprostol
1296272|NCT00784173|Syndrome
1296273|NCT00784173|Velocardiofacial
1296274|NCT00784173|Middle ear
1296275|NCT00784173|Inner ear
1296276|NCT00784173|Malformation
1296277|NCT00784147|HIV
1296278|NCT00784147|CD4
1296279|NCT00784147|experienced
1296280|NCT00784147|resistant
1296281|NCT00784147|resistance
1296282|NCT00784147|monoclonal
1296283|NCT00784147|antibody
1296284|NCT00784147|infusion
1296285|NCT00784147|ibalizumab
1296286|NCT00784147|TNX355
1296287|NCT00784147|TNX-355
1296288|NCT00784147|TMB355
1296289|NCT00784147|TMB-355
1296290|NCT00784134|intraventricular hemorrhage thrombolysis
1296291|NCT00784095|quality of life
1296292|NCT00784082|Sickle cell disease, hydroxyurea, inflammation
1296293|NCT00784043|Cochlear implant
1296294|NCT00784043|hearing loss
1296295|NCT00784030|Autosomal Dominant Polycystic Kidney Disease
1296296|NCT00784030|Polycystic Kidney Disease
1296297|NCT00784030|Water Loading
1296298|NCT00784030|Biomarkers
1296299|NCT00784017|Children with previously untreated acute lymphoblastic leukemia
1296300|NCT00784004|breathing patterns,
1296301|NCT00784004|unidirectional breathing,
1296302|NCT00784004|mask ventilation,
1296303|NCT00784004|respiratory physiology
1296304|NCT00783991|IVF
1296305|NCT00783991|PDA
1296306|NCT00783991|PC
1296307|NCT00783991|CAT
1296308|NCT00783991|COPD
1296309|NCT00783991|MDD
1296310|NCT00783991|RA
1296311|NCT00783978|Surfactant protein C
1296312|NCT00783978|Interstitial
1296313|NCT00783978|lung
1296314|NCT00783978|Children
1296315|NCT00783965|nevoid basal cell carcinoma syndrome
1296316|NCT00783965|basal cell carcinoma of the skin
1296317|NCT00783952|Mixed venous oxygen saturation
1296318|NCT00783952|Tissue oxygenation
1296319|NCT00783952|Near infrared spectroscopy
1296320|NCT00783913|Direct Current Stimulation
1296321|NCT00783913|Rehabilitation
1296322|NCT00783913|Motor Learning
1296323|NCT00783913|Stroke
1296324|NCT00783900|Prevention
1296325|NCT00783887|Cilia
1296326|NCT00783887|Axoneme
1296327|NCT00783887|Dynein
1296328|NCT00783887|Gene
1296329|NCT00783887|Ultrastructure
1296330|NCT00783887|Linkage analysis
1296331|NCT00783848|CHF
1296332|NCT00783835|Attention Deficit Hyperactivity Disorder
1296333|NCT00783835|Methylphenidate
1296334|NCT00783835|Concerta
1296335|NCT00783835|CONQoL
1296336|NCT00783822|breast neoplasms
1296337|NCT00783822|genetic counseling
1296338|NCT00783809|intracranial pressure
1296339|NCT00783809|intracranial hypertension
1296340|NCT00783809|ultrasound
1296341|NCT00783809|emergency
1296342|NCT00783809|traumatic brain injury
1296343|NCT00783809|ocular ultrasound
1296344|NCT00783796|Coronary artery disease
1296345|NCT00783796|Atherosclerosis
1296346|NCT00783796|Myocardial ischemia
1296347|NCT00783783|Psychiatric disorders
1296348|NCT00783783|Neurodevelopmental disorders
1296349|NCT00783783|Autism
1296350|NCT00783783|Risperidone
1296351|NCT00783783|Pharmacogenetics
1296352|NCT00783783|Pharmacokinetics
1296353|NCT00783770|Breastfeeding
1296354|NCT00783770|Infant
1296355|NCT00783770|Preterm
1296356|NCT00783770|Nutrition
1296357|NCT00783757|neo-adjuvant chemotherapy
1296358|NCT00783757|TOBI
1296359|NCT00783757|breast imaging
1296360|NCT00783757|optical imaging
1296361|NCT00783731|intubation
1296362|NCT00783679|Cardiac output
1296363|NCT00783679|Noninvasive cardiac output measurement
1296364|NCT00783679|Thermodilution
1296365|NCT00783653|AML
1296366|NCT00783653|FLT3
1296367|NCT00783653|acute myeloid leukemia
1296368|NCT00783653|FLT 3 inhibitor
1296369|NCT00783653|FLT3 mutated AML
1296370|NCT00783627|Endothelium
1296371|NCT00783627|progenitors
1296372|NCT00783627|stem cells
1296373|NCT00783627|sickle cell
1296374|NCT00783614|HIV
1296375|NCT00783614|Cardiovascular Disease
1296376|NCT00783614|Endothelial Dysfunction
1296377|NCT00783601|Chronic Asthma
1296378|NCT00783588|Chronic lymphocytic leukemia
1296379|NCT00783588|CLL
1296380|NCT00783588|Leukemia
1296381|NCT00783588|Leukemia, Lymphocytic, Chronic, B-Cell
1296382|NCT00783588|Leukemia, B-Cell
1296383|NCT00783588|Immune System Diseases
1296384|NCT00783588|ISF35
1296385|NCT00783588|Ad-ISF35
1296386|NCT00783588|Immunotherapy
1296387|NCT00783588|Immune therapy
1296388|NCT00783588|Active immune therapy
1296389|NCT00783575|Crohn's disease
1296390|NCT00783575|Ulcerative colitis
1296391|NCT00783575|Inflammatory bowel disease
1296392|NCT00783575|NOD2,CARD 15 mutations
1296393|NCT00783562|Low back pain
1296394|NCT00783562|Neck pain
1296395|NCT00783562|Functional disability
1296396|NCT00783562|Nursery school teachers
1296397|NCT00783562|Exercise program
1296398|NCT00783562|Prevention
1296399|NCT00783549|tolerability
1296400|NCT00783549|pharmacodynamics
1296401|NCT00783549|pharmacokinetics
1296402|NCT00783549|safety
1296403|NCT00783536|An randomized, open label, multicenter study to compare the ef
1296404|NCT00783510|Polyarticular JIA
1296405|NCT00783510|Juvenile Arthritis
1296406|NCT00783510|Juvenile Idiopathic Arthritis
1296407|NCT00783510|JIA
1296408|NCT00783510|Polyarticular-course JIA
1296409|NCT00783497|High Blood Pressure
1296410|NCT00783497|Stress
1296411|NCT00783484|First in Human (FIH), PF-03716539, PK enhancer
1296412|NCT00783445|Metabolic Cardiovascular Syndrome
1296413|NCT00783445|Metabolic Syndrome
1296414|NCT00783445|Obesity
1296415|NCT00783445|Hyperglycemia
1296416|NCT00783419|tubo-ovarian abscess, pelvic-inflammatory disease
1296417|NCT00783406|COPD
1296418|NCT00783380|Influenza vaccination
1296419|NCT00783380|Subunit
1296420|NCT00783380|Virosomal
1296421|NCT00783380|HIV/AIDS
1296422|NCT00783380|Renal Dialysis
1296423|NCT00783380|Kidney transplantation
1296424|NCT00783380|Rheumatologic diseases
1296425|NCT00783380|Immunogenicity
1296426|NCT00783380|Reactogenicity
1296427|NCT00783367|Revlimid
1296428|NCT00783367|Celgene brand of lenalidomide
1296429|NCT00783367|lenalidomide
1296430|NCT00783367|Rituxan
1296431|NCT00783367|CD20 antibody, rituximab
1296432|NCT00783367|rituximab
1296433|NCT00783367|Follicular Lymphoma
1296434|NCT00783367|Marginal Zone B-Cell Lymphoma
1296435|NCT00783367|Lymphoma, Small Lymphocytic
1296436|NCT00783367|Waldenstrom Macroglobulinemia
1296437|NCT00783367|Mantle-Cell Lymphoma
1296438|NCT00783367|Antigens, CD20
1296439|NCT00783367|refractory
1296440|NCT00783367|resistantRefractory/progressive lymphoma less than 6 months from first rituximab dose of previous rituximab-containing regimen
1296441|NCT00783367|Previously treated
1296442|NCT00783367|Treated with rituximab
1296443|NCT00783328|solid tumor
1296444|NCT00783315|Hypertension
1296445|NCT00783315|Diabetes
1296446|NCT00783315|Hypercholesterolemia
1296447|NCT00783302|CAD
1296448|NCT00783302|Visipaque
1296449|NCT00783302|CCTA
1296450|NCT00783250|COPD
1296451|NCT00783250|Respiratory Mechanics
1296452|NCT00783250|Bronchodilators
1296453|NCT00783250|COPD patients with poor reversibility
1296454|NCT00783185|psychotic disorders
1296455|NCT00783185|cannabis
1296456|NCT00783185|intervention
1296457|NCT00783172|pancreas
1296458|NCT00783172|pancreatic cancer
1296459|NCT00783172|cancer
1296460|NCT00783172|Opioid Growth Factor
1296461|NCT00783172|OGF
1296462|NCT00783172|gemcitabine
1296463|NCT00783172|chemotherapy
1296464|NCT00783159|Muscle power
1296465|NCT00783159|Frailty
1296466|NCT00783159|Exercise
1296467|NCT00783159|Vitamin D
1296468|NCT00783120|schizophrenia, negative symptoms, TMS, magnetic stimulation
1296469|NCT00783107|Gold Stage III COPD
1296470|NCT00783081|Intermittent Claudication
1296471|NCT00783081|Peripheral Arterial Disease
1296472|NCT00783068|Endotoxin
1296473|NCT00783068|GTS-21
1296474|NCT00783068|Vagal activity
1296475|NCT00783068|Autonomic balance
1296476|NCT00783055|Autonomy
1296477|NCT00783055|Older people
1296478|NCT00783055|Physically frail
1296479|NCT00783055|Nursing home
1296480|NCT00783055|Intervention study
1296481|NCT00783042|TTDE-CFR
1296482|NCT00783042|coronary artery function
1296483|NCT00783042|cardiovascular biomarkers
1296484|NCT00783042|rosuvastatin
1296485|NCT00783042|Crestor
1296486|NCT00783029|Vasodilation
1296487|NCT00783029|Vessel Reactivity
1296488|NCT00783029|Dynamic Vessel Analyzer
1296489|NCT00783029|Retina
1296490|NCT00783016|appendicitis
1296491|NCT00783016|diagnosis
1296492|NCT00783003|Tolerability
1296493|NCT00783003|Muscarinic Receptor Antagonist, Anticholinergic
1296494|NCT00783003|Safety
1296495|NCT00783003|Anticholinergic
1296496|NCT00783003|ß2 agonist
1296497|NCT00783003|Pharmacokinetics
1296498|NCT00782990|stress urinary incontinence
1296499|NCT00782990|female incontinence
1296500|NCT00782990|surgical treatment
1296501|NCT00782990|Female stress urinary incontinence
1296502|NCT00782977|Apneic oxygenation
1296503|NCT00782977|Apneic diffusion oxygenation
1296504|NCT00782964|Depression
1296505|NCT00782964|Major Depressive Disorder
1296506|NCT00782964|SSRI resistant depression
1296507|NCT00782964|strategies in depression
1296508|NCT00782925|Low back pain
1296509|NCT00782925|recurrence
1296510|NCT00782925|chronic low back pain
1296511|NCT00782925|educational program
1296512|NCT00782925|physical therapy
1296513|NCT00782925|home exercise
1296514|NCT00782925|compliance
1296515|NCT00782912|postpartum anemia, postpartum depression
1296516|NCT00782899|Schizophrenia
1296517|NCT00782899|subjective well-being
1296518|NCT00782899|depressive symptoms
1296519|NCT00782899|schizophrenia course
1296520|NCT00782886|Pathfinder
1296521|NCT00782886|Liver
1296522|NCT00782886|Resection
1296523|NCT00782886|Surgery
1296524|NCT00782886|To evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.
1296525|NCT00782886|Completeness of resection and the accuracy of the resection, as determined by preoperative predicted RLV
1296526|NCT00782873|propofol
1296527|NCT00782873|sedation
1296528|NCT00782873|safety
1296529|NCT00782873|obesity
1296530|NCT00782860|Early pregnancy failure
1296531|NCT00782860|Misoprostol
1296532|NCT00782860|Gestational sac volume
1296533|NCT00782847|diabetes mellitus
1296534|NCT00782847|diabetic nephropathy
1296535|NCT00782847|hypertension
1296536|NCT00782834|GIST
1296537|NCT00782834|Nilotinib
1296538|NCT00782821|Kidney
1296539|NCT00782821|Renal
1296540|NCT00782821|Rejection
1296541|NCT00782821|High risk
1296542|NCT00782821|Induction
1296543|NCT00782821|Immunology
1296544|NCT00782821|Transplantation
1296545|NCT00782821|B Cell
1296546|NCT00782821|Allograft
1296547|NCT00782821|Desensitization
1296548|NCT00782808|HIV DNA in Monocytes
1296549|NCT00782795|Chronic pancreatitis
1296550|NCT00782795|Insulin resistance
1296551|NCT00782756|Radiation
1296552|NCT00782756|BEVACIZUMAB
1296553|NCT00782756|AVASTIN
1296554|NCT00782756|TEMOZOLOMIDE
1296555|NCT00782756|newly diagnosed
1296556|NCT00782756|Glioblastoma
1296557|NCT00782756|GBM
1296558|NCT00782756|malignant glioma
1296559|NCT00782756|Radiotherapy
1296560|NCT00782756|08-126
1296561|NCT00782743|phenprocoumon
1296562|NCT00782743|anticoagulation
1296563|NCT00782743|acetylic salicylic acid
1296564|NCT00782743|Need for new anticoagulation treatment
1296565|NCT00782730|bladder volume measurement
1296566|NCT00782730|pregnancy
1296567|NCT00782730|bladder function
1296568|NCT00782730|Postvoid residual volume assessment
1296569|NCT00782730|Bladder volumes
1296570|NCT00782717|diabetic retinopathy
1296571|NCT00782717|cystoid macular edema;
1296572|NCT00782704|A self-administered questionnaire to collect data from patients, physicians and nurses about the severity of postoperative surgical complications.
1296573|NCT00782704|Based on this questionnaire we will develop the morbidity index
1296574|NCT00782691|FDG-PET segmentation tools
1296575|NCT00782691|Head-and-neck cancer
1296576|NCT00782691|Histological validation
1296577|NCT00782665|postoperative
1296578|NCT00782665|infection
1296579|NCT00782665|c-section
1296580|NCT00782652|myocaridal infarction
1296581|NCT00782652|right ventricular infarction
1296582|NCT00782652|cardiogenic shock
1296583|NCT00782652|RVAD
1296584|NCT00782652|Right ventricular assist device
1296585|NCT00782652|cardiac disease
1296586|NCT00782652|right ventricle
1296587|NCT00782652|cardiac shock
1296588|NCT00782652|heart dysfunction
1296589|NCT00782626|RAD001
1296590|NCT00782613|Psoriasis
1296591|NCT00782613|The primary objective of this study will be to evaluate the
1296592|NCT00782613|efficacy of topical ALT-2074 applied twice daily for 28
1296593|NCT00782613|days for treatment of chronic plaque psoriasis in adult
1296594|NCT00782613|subjects.
1296595|NCT00782613|The secondary objective will be to evaluate the safety
1296596|NCT00782613|of topical ALT-2074 applied twice daily for 28 days for
1296597|NCT00782613|treatment of chronic plaque psoriasis in adult subjects.
1296598|NCT00782613|Tertiary objectives will be to provide visual documentation
1296599|NCT00782613|of the improvement of psoriatic plaques treated with
1296600|NCT00782613|ALT-2074 using digital photography, and to determine the
1296601|NCT00782613|extent of systemic absorption of topically applied ALT-2074
1296602|NCT00782613|based on a pharmacokinetic measurement of blood
1296603|NCT00782613|concentration.
1296604|NCT00782600|Pharmacokinetics Immediate Release Oral Suspension Controlled Release Formulation
1296605|NCT00782587|Non-Muscle-Invasive Bladder Cancer
1296606|NCT00782587|Superficial Bladder Cancer
1296607|NCT00782587|recombinant human hyaluronidase
1296608|NCT00782587|rHuPH20
1296609|NCT00782587|Chemophase®
1296610|NCT00782587|Mitomycin
1296611|NCT00782574|Advanced solid tumours
1296612|NCT00782574|Poly(ADP ribose) polymerases
1296613|NCT00782574|homologous deficiency
1296614|NCT00782574|BRCA1
1296615|NCT00782561|steroid resistant focal segmental glomerulosclerosis
1296616|NCT00782561|FSGS
1296617|NCT00782561|adolescent focal segmental glomerulosclerosis
1296618|NCT00782561|focal segmental glomerulosclerosis
1296619|NCT00782548|KADIAN
1296620|NCT00782548|morphine
1296621|NCT00782548|Avinza
1296622|NCT00782548|30 mg
1296623|NCT00782548|bioequivalence
1296624|NCT00782548|fed
1296625|NCT00782483|Diagnosis
1296626|NCT00782483|Port Wine Stain
1296627|NCT00782483|PWS
1296628|NCT00782405|antidepressant action
1296629|NCT00782405|clinical psychopharmacology
1296630|NCT00782392|Nutrition
1296631|NCT00782392|Infant Formula
1296632|NCT00782379|stage III adult diffuse large cell lymphoma
1296633|NCT00782379|stage III adult diffuse mixed cell lymphoma
1296634|NCT00782379|stage III adult diffuse small cleaved cell lymphoma
1296635|NCT00782379|stage III adult Hodgkin lymphoma
1296636|NCT00782379|stage III adult lymphoblastic lymphoma
1296637|NCT00782379|stage III grade 1 follicular lymphoma
1296638|NCT00782379|stage III grade 2 follicular lymphoma
1296639|NCT00782379|stage III grade 3 follicular lymphoma
1296640|NCT00782379|stage III mantle cell lymphoma
1296641|NCT00782379|stage IV adult diffuse large cell lymphoma
1296642|NCT00782379|stage IV adult diffuse mixed cell lymphoma
1296643|NCT00782379|stage IV adult diffuse small cleaved cell lymphoma
1296644|NCT00782379|stage IV adult Hodgkin lymphoma
1296645|NCT00782379|stage IV adult lymphoblastic lymphoma
1296646|NCT00782379|stage IV grade 1 follicular lymphoma
1296647|NCT00782379|stage IV grade 2 follicular lymphoma
1296648|NCT00782379|stage IV grade 3 follicular lymphoma
1296649|NCT00782379|stage IV mantle cell lymphoma
1296650|NCT00782379|recurrent adult diffuse large cell lymphoma
1296651|NCT00782379|recurrent adult diffuse mixed cell lymphoma
1296652|NCT00782379|recurrent adult diffuse small cleaved cell lymphoma
1296653|NCT00782379|recurrent adult Hodgkin lymphoma
1296654|NCT00782379|recurrent grade 1 follicular lymphoma
1296655|NCT00782379|recurrent grade 2 follicular lymphoma
1296656|NCT00782379|recurrent grade 3 follicular lymphoma
1296657|NCT00782379|recurrent mantle cell lymphoma
1296658|NCT00782379|noncontiguous stage II adult diffuse large cell lymphoma
1296659|NCT00782379|noncontiguous stage II adult diffuse mixed cell lymphoma
1296660|NCT00782379|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1296661|NCT00782379|noncontiguous stage II adult lymphoblastic lymphoma
1296662|NCT00782379|noncontiguous stage II grade 1 follicular lymphoma
1296663|NCT00782379|noncontiguous stage II grade 2 follicular lymphoma
1296664|NCT00782379|noncontiguous stage II grade 3 follicular lymphoma
1296665|NCT00782379|noncontiguous stage II mantle cell lymphoma
1296666|NCT00782379|accelerated phase chronic myelogenous leukemia
1296667|NCT00782379|adult acute lymphoblastic leukemia in remission
1296668|NCT00782379|adult acute myeloid leukemia in remission
1296669|NCT00782379|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1296670|NCT00782379|adult acute myeloid leukemia with inv(16)(p13;q22)
1296671|NCT00782379|adult acute myeloid leukemia with t(15;17)(q22;q12)
1296672|NCT00782379|adult acute myeloid leukemia with t(16;16)(p13;q22)
1296673|NCT00782379|adult acute myeloid leukemia with t(8;21)(q22;q22)
1296674|NCT00782379|chronic myelomonocytic leukemia
1296675|NCT00782379|chronic phase chronic myelogenous leukemia
1296676|NCT00782379|recurrent adult acute myeloid leukemia
1296677|NCT00782379|refractory chronic lymphocytic leukemia
1296678|NCT00782379|relapsing chronic myelogenous leukemia
1296679|NCT00782379|secondary acute myeloid leukemia
1296680|NCT00782379|stage III chronic lymphocytic leukemia
1296681|NCT00782379|stage IV chronic lymphocytic leukemia
1296682|NCT00782379|de novo myelodysplastic syndromes
1296683|NCT00782379|previously treated myelodysplastic syndromes
1296684|NCT00782379|secondary myelodysplastic syndromes
1296685|NCT00782379|prolymphocytic leukemia
1296686|NCT00782366|predictive genomics
1296687|NCT00782366|personalized medicine
1296688|NCT00782366|personal genomics
1296689|NCT00782366|direct-to-consumer genetic testing
1296690|NCT00782366|genetic knowledge
1296691|NCT00782366|genetic attitudes
1296692|NCT00782353|HCV
1296693|NCT00782340|NOH
1296694|NCT00782340|Neurogenic Orthostatic Hypotension
1296695|NCT00782340|Orthostatic hypotension
1296696|NCT00782340|PAF
1296697|NCT00782340|Pure Autonomic Failure
1296698|NCT00782340|MSA
1296699|NCT00782340|Multiple System Atrophy
1296700|NCT00782340|Neuropathy
1296701|NCT00782340|Autonomic Failure
1296702|NCT00782340|Parkinson
1296703|NCT00782340|Dopamine Deficiency
1296704|NCT00782340|Dopamine
1296705|NCT00782340|Droxidopa
1296706|NCT00782314|asthma
1296707|NCT00782314|SMART
1296708|NCT00782314|Symbicort Turbuhaler
1296709|NCT00782314|asthma control
1296710|NCT00782301|HIV and Hepatitis co-infection
1296711|NCT00782288|digitoxin
1296712|NCT00782288|inflammatory markers
1296713|NCT00782288|cytokines
1296714|NCT00782288|gene expression
1296715|NCT00782275|RCC
1296716|NCT00782275|avastin
1296717|NCT00782275|temsirolimus
1296718|NCT00782223|hips, spine, lower limb, digital radiograph measurements, TraumaCad, digital software
1296719|NCT00782223|Measurements of orthopaedic parameters on digital X-rays using particular software
1296720|NCT00782197|osteoarthritis
1296721|NCT00782197|knee
1296722|NCT00782197|PRGF
1296723|NCT00782197|autologous plasma
1296724|NCT00782197|plasma preparations
1296725|NCT00782197|treatment
1296726|NCT00782171|Dental implants
1296727|NCT00782158|HIV
1296728|NCT00782158|Hepatitis B
1296729|NCT00782158|Coinfection
1296730|NCT00782158|Liver Fibrosis
1296731|NCT00782158|Transient Elastography
1296732|NCT00782145|psychosocial effects of cancer and its treatment
1296733|NCT00782145|recurrent childhood large cell lymphoma
1296734|NCT00782145|recurrent childhood lymphoblastic lymphoma
1296735|NCT00782145|recurrent childhood small noncleaved cell lymphoma
1296736|NCT00782145|recurrent/refractory childhood Hodgkin lymphoma
1296737|NCT00782145|accelerated phase chronic myelogenous leukemia
1296738|NCT00782145|atypical chronic myeloid leukemia, BCR-ABL negative
1296739|NCT00782145|blastic phase chronic myelogenous leukemia
1296740|NCT00782145|childhood acute lymphoblastic leukemia in remission
1296741|NCT00782145|childhood acute myeloid leukemia in remission
1296742|NCT00782145|childhood chronic myelogenous leukemia
1296743|NCT00782145|chronic myelomonocytic leukemia
1296744|NCT00782145|chronic phase chronic myelogenous leukemia
1296745|NCT00782145|juvenile myelomonocytic leukemia
1296866|NCT00781690|Chronic kidney failure
1296746|NCT00782145|recurrent childhood acute lymphoblastic leukemia
1296747|NCT00782145|recurrent childhood acute myeloid leukemia
1296748|NCT00782145|relapsing chronic myelogenous leukemia
1296749|NCT00782145|secondary acute myeloid leukemia
1296750|NCT00782145|childhood myelodysplastic syndromes
1296751|NCT00782145|primary myelofibrosis
1296752|NCT00782145|de novo myelodysplastic syndromes
1296753|NCT00782145|disseminated neuroblastoma
1296754|NCT00782145|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1296755|NCT00782145|previously treated childhood rhabdomyosarcoma
1296756|NCT00782145|previously treated myelodysplastic syndromes
1296757|NCT00782145|recurrent childhood rhabdomyosarcoma
1296758|NCT00782145|recurrent neuroblastoma
1296759|NCT00782145|recurrent ovarian germ cell tumor
1296760|NCT00782145|secondary myelodysplastic syndromes
1296761|NCT00782132|Infertility Services, HIV, pregnancy planning
1296762|NCT00782093|AMD
1296763|NCT00782080|ADHD
1296764|NCT00782080|children
1296765|NCT00782080|adolescents
1296766|NCT00782080|St. John`s Wort
1296767|NCT00782080|Valerian extract
1296768|NCT00782080|Safety
1296769|NCT00782080|Efficacy
1296770|NCT00782067|Aggressive systemic mastocytosis
1296771|NCT00782067|mast cell leukemia
1296772|NCT00782067|C-Findings
1296773|NCT00782067|tyrosine kinase inhibitor
1296774|NCT00782067|KIT mutation
1296775|NCT00782067|AHNMD
1296776|NCT00782067|Systemic
1296777|NCT00782067|Aggressive
1296778|NCT00782054|pruritus
1296779|NCT00782054|itch
1296780|NCT00782054|burn
1296781|NCT00782054|endopeptidase
1296782|NCT00782054|moisturizer
1296783|NCT00782054|randomized controlled
1296784|NCT00782028|primary care, high-risk families, maternal depression
1296785|NCT00782015|almonds
1296786|NCT00782015|heart disease
1296787|NCT00782015|vascular reactivity
1296788|NCT00782015|inflammation
1296789|NCT00782015|dyslipidemia
1296790|NCT00782015|oxidative stress
1296791|NCT00782002|Solid Tumors
1296792|NCT00782002|VEGF-A
1296793|NCT00782002|stromal cells
1296794|NCT00782002|endothelial cells
1296795|NCT00782002|malignant cells
1296796|NCT00781989|early rheumatoid arthritis
1296797|NCT00781989|biomarkers
1296798|NCT00781989|ultrasound
1296799|NCT00781963|cognitive behavior therapy
1296800|NCT00781963|insomnia
1296801|NCT00781950|PAD
1296802|NCT00781950|Peripheral Arterial Disease
1296803|NCT00781950|Diabetes
1296804|NCT00781950|Atherosclerosis
1296805|NCT00781950|Flax
1296806|NCT00781950|Flaxseeds
1296807|NCT00781950|Functional Foods
1296808|NCT00781950|Essential Fatty Acids
1296809|NCT00781950|Winnipeg
1296810|NCT00781911|Islet Cell
1296811|NCT00781911|CARCINOMA, ISLET CELL
1296812|NCT00781911|Octreotide
1296813|NCT00781911|depot octreotide acetate
1296814|NCT00781911|Insulin-Like Growth Factor (IGF) 1
1296815|NCT00781911|Metastatic, Carcinoid or Islet Cell
1296816|NCT00781911|Neuroendocrine Tumors
1296817|NCT00781898|Depot naltrexone
1296818|NCT00781898|Parolees
1296819|NCT00781898|Opioid addiction prevention
1296820|NCT00781898|Medication Treatment Alternatives
1296821|NCT00781898|Prevention of Relapse to Opioid Addiction
1296822|NCT00781872|multiple sclerosis (MS)
1296823|NCT00781872|bone marrow stromal cells
1296824|NCT00781872|stem cells
1296825|NCT00781833|Therapeutic Electric Stimulation
1296826|NCT00781833|Functional Electric Stimulation
1296827|NCT00781833|Implantable Stimulator
1296828|NCT00781833|Muscle Strength
1296829|NCT00781833|Muscle Spasticity
1296830|NCT00781820|Bifonazole
1296831|NCT00781820|Placebo
1296832|NCT00781820|Urea
1296833|NCT00781820|Nail fungus
1296834|NCT00781807|Heart-Assist-Devices
1296835|NCT00781807|Rehabilitation
1296836|NCT00781807|Outcome Assessment (Health Care)
1296837|NCT00781807|Exercise Capacity
1296838|NCT00781807|Ergometry
1296839|NCT00781807|Social Support
1296840|NCT00781807|Quality of Life
1296841|NCT00781807|Nutrition Assessment
1296842|NCT00781807|Nutrition Therapy
1296843|NCT00781807|Neuropsychological Tests
1296844|NCT00781781|Myeloid and Lymphoid malignances
1296845|NCT00781768|Bone Marrow Transplant
1296846|NCT00781768|Nausea
1296847|NCT00781768|Vomiting
1296848|NCT00781768|NK-1 antagonist
1296849|NCT00781768|Nausea and vommitting in the stem cell/marrow transplant population.
1296850|NCT00781755|smoking cessation
1296851|NCT00781755|varenicline
1296852|NCT00781755|schizophrenia
1296853|NCT00781755|serious mental illness
1296854|NCT00781755|Nicotine addiction
1296855|NCT00781755|Smoking Behavior
1296856|NCT00781742|Depression
1296857|NCT00781742|Depressive Disorder
1296858|NCT00781742|MDD
1296859|NCT00781729|Kyphosis
1296860|NCT00781729|Yoga
1296861|NCT00781729|Aging
1296862|NCT00781729|Physical performance
1296863|NCT00781729|Quality of Life
1296864|NCT00781716|ST elevation myocardial infarction
1296865|NCT00781716|Drug eluting stents
1296867|NCT00781690|Heparin
1296868|NCT00781690|Hemodialysis
1296869|NCT00781690|Biocompatibility
1296870|NCT00781677|Major Depressive Disorder
1296871|NCT00781677|Depression
1296872|NCT00781677|Anxiety
1296873|NCT00781638|Pediatric UC, Adacolumn apheresis
1296874|NCT00781625|probiotics
1296875|NCT00781625|QoL
1296876|NCT00781625|inflammation
1296877|NCT00781625|nutritional factors
1296878|NCT00781625|prophylactic aid
1296879|NCT00781625|Lactobacillus rhamnosus GR-1
1296880|NCT00781625|Lactobacillus reuteri RC-14
1296881|NCT00781625|Recurrent lower UTI in women
1296882|NCT00781599|African american
1296883|NCT00781599|smokers
1296884|NCT00781599|smoking cessation
1296885|NCT00781599|African American smokers
1296886|NCT00781586|Energy expenditure
1296887|NCT00781586|Nutritional
1296888|NCT00781586|Weight control
1296889|NCT00781573|Drug Eluting Stent
1296890|NCT00781573|Clopidogrel
1296891|NCT00781573|Optimal duration of clopidogrel post DES stent implantation
1296892|NCT00781560|Hyperlipidemia
1296893|NCT00781560|Chinese National Adult Lipid Treatment Guideline (2007)
1296894|NCT00781560|Crestor®
1296895|NCT00781547|growth hormone
1296896|NCT00781547|obesity
1296897|NCT00781547|abdominal obesity
1296898|NCT00781534|Health Supplements
1296899|NCT00781534|Ginseng
1296900|NCT00781534|Diabetes
1296901|NCT00781508|heart failure, left sided
1296902|NCT00781508|ventricular dysfunction
1296903|NCT00781508|diastolic dysfunction
1296904|NCT00781508|sildenafil
1296905|NCT00781495|insulin
1296906|NCT00781482|Positron Emission Tomography
1296907|NCT00781482|GABA receptor binding
1296908|NCT00781482|Hypnotic Drugs
1296909|NCT00781482|Eszopiclone
1296910|NCT00781482|Zolpidem
1296911|NCT00781482|[11-C] Flumazenil
1296912|NCT00781482|Molecular imaging of the brain
1296913|NCT00781469|Rheumatoid arthritis
1296914|NCT00781469|RNA
1296915|NCT00781469|Synovium
1296916|NCT00781469|Peripheral blood mononuclear cells
1296917|NCT00781456|Migraine headache
1296918|NCT00781456|menstrual
1296919|NCT00781456|oral contraceptive
1296920|NCT00781456|Menstrually-Related Migraine Headache
1296921|NCT00781443|Asthma
1296922|NCT00781417|vitamin D
1296923|NCT00781417|Chronic Kidney Disease
1296924|NCT00781417|parathyroid hormone
1296925|NCT00781417|Chronic kidney disease Stage II and III
1296926|NCT00781404|adenosine
1296927|NCT00781404|angioplasty
1296928|NCT00781404|acute myocardial infarction
1296929|NCT00781404|acute coronary syndrome with ST segment elevation
1296930|NCT00781404|infarct size
1296931|NCT00781404|rescued myocardium
1296932|NCT00781391|Systemic embolic events
1296933|NCT00781378|Thrombolytic therapy
1296934|NCT00781378|Recombinant tissue plasminogen activator
1296935|NCT00781378|Efficacy
1296936|NCT00781378|Safety
1296937|NCT00781365|Hypertension
1296938|NCT00781365|Telemonitoring
1296939|NCT00781365|Pharmacy management
1296940|NCT00781352|nitrous oxide
1296941|NCT00781352|cancer recurrence
1296942|NCT00781352|colorectal surgery
1296943|NCT00781339|Bacteriuria
1296944|NCT00781339|Catheterized
1296945|NCT00781339|Chronically Catheterized
1296946|NCT00781326|Depressive Disorder, Major
1296947|NCT00781326|Cerebrovascular Disorders
1296948|NCT00781326|Risk Factors
1296949|NCT00781326|Nimodipine
1296950|NCT00781300|Intraocular pressure
1296951|NCT00781300|Pterygium
1296952|NCT00781300|Surgery
1296953|NCT00781300|Steroids
1296954|NCT00781300|Glaucoma
1296955|NCT00781287|human immunodeficiency virus
1296956|NCT00781287|raltegravir
1296957|NCT00781287|primary HIV infection
1296958|NCT00781287|HIV-1
1296959|NCT00781261|hip
1296960|NCT00781261|collapse femoral head
1296961|NCT00781261|bisphosphonates
1296962|NCT00781261|osteonecrosis
1296963|NCT00781248|enteral feeding
1296964|NCT00781248|Subject who requires nasogastric tube
1296965|NCT00780416|Chronic Hepatitis C
1296966|NCT00780416|Protease Inhibitor
1296967|NCT00780416|Telaprevir
1296968|NCT00780416|Peginterferon Alfa-2b
1296969|NCT00780416|Ribavirin
1296970|NCT00780390|RSD
1296971|NCT00780390|SCS
1296972|NCT00780390|CRPS
1296973|NCT00780390|Complex regional pain syndrome patients before undergoing spinal cord stimulator implant and under other treatments
1296974|NCT00780377|Heart Transplant
1296975|NCT00780377|Fibrinolysis
1296976|NCT00780377|Resting conditions
1296977|NCT00780364|stroke; sour taste; cold temperature; pharyngeal swallowing
1296978|NCT00780351|vancomycin, SLEDD-f
1296979|NCT00780325|Cyclooxygenase-2
1296980|NCT00780325|Carbonic anhydrase
1296981|NCT00780325|Eicosanoids
1296982|NCT00780325|Healthy volunteers
1296983|NCT00780312|radiotherapy
1296984|NCT00780312|trismus
1296985|NCT00780312|physiotherapy
1296986|NCT00780312|lymphoedema
1296987|NCT00780312|late side effects
1296988|NCT00780312|fibrosis
1296989|NCT00780312|decreased cervical range of motion
1296990|NCT00780312|quality of life
1296991|NCT00780299|Plasma epuration
1296992|NCT00780299|Hemofiltration
1296993|NCT00780299|Cardiac arrest
1296994|NCT00780299|Shock
1296995|NCT00780299|Inflammatory mediators
1296996|NCT00778414|Bioequivalence Amoxicillin Clavulanic acid 600mg 42.9 mg per 5 mL oral suspension
1296997|NCT00778401|Bioequivalence Gabapentin tablets 800 mg fasting conditions
1296998|NCT00778388|Pseudomonas Aeruginosa
1296999|NCT00778375|Leukemia
1297000|NCT00778375|Acute Myeloid Leukemia
1297001|NCT00778375|Myelodysplastic Syndrome
1297002|NCT00778375|AML
1297003|NCT00778375|MDS
1297004|NCT00778375|Clofarabine
1297005|NCT00778375|Ara-C
1297006|NCT00778375|Cytarabine
1297007|NCT00778375|Decitabine
1297008|NCT00778362|OPSI
1297009|NCT00778362|Splenectomy
1297010|NCT00781209|irradiation
1297011|NCT00781209|stereotactic radiosurgery
1297012|NCT00781209|posterior fossa
1297013|NCT00781209|cerebellar metastases
1297014|NCT00781196|phenytoin
1297015|NCT00781196|gum hyperplasia
1297016|NCT00781196|phenytoin induced gingival overgrowth
1297017|NCT00781196|plaque index
1297018|NCT00781196|gingival overgrowth grade
1297019|NCT00781183|COPD
1297020|NCT00781183|rehabilitation
1297021|NCT00781183|walking
1297022|NCT00781170|Multiple Myeloma
1297023|NCT00781170|Plasmocytoma
1297024|NCT00781170|Stem Cell Transplantation
1297025|NCT00781157|Spinal induced hypotension in cesarean delivery
1297026|NCT00781118|Acute Myocardial Infarction (MI)
1297027|NCT00781118|ST Shift
1297028|NCT00781118|Coronary Occlusion
1297029|NCT00781118|Acute Coronary Syndrome
1297030|NCT00781105|Chronic hepatitis B
1297031|NCT00781105|Adult
1297032|NCT00781105|HBV DNA suppression
1297033|NCT00781105|Telbivudine
1297034|NCT00781092|Dry Eyes
1297035|NCT00781092|LASIK
1297036|NCT00781092|Laser Vision Correction
1297037|NCT00781079|Organization Innovation
1297038|NCT00781079|Opinion Leaders
1297039|NCT00781079|Schizophrenia
1297040|NCT00781066|POSTPARTUM HEMORRHAGE
1297041|NCT00781066|PREVENTION
1297042|NCT00781066|CORD TRACTION
1297043|NCT00781066|THIRD STAGE LABOR
1297044|NCT00781053|skin fibrosis
1297045|NCT00781053|systemic scleroderma
1297046|NCT00781053|systemic sclerosis
1297047|NCT00781053|p144
1297048|NCT00781053|orphan drug
1297049|NCT00781040|Severe sepsis in neutropenic haematological patients
1297050|NCT00781001|neuropathic pain
1297051|NCT00781001|diabetic neuropathy
1297052|NCT00781001|cannabis
1297053|NCT00781001|marijuana
1297054|NCT00780975|Aplidin
1297055|NCT00780975|Plitidepsin
1297056|NCT00780975|Prostate
1297057|NCT00780975|Cancer
1297058|NCT00780962|NAC
1297059|NCT00780962|Radiocontrast Nephropathy
1297060|NCT00780962|N-Acetycysteine
1297061|NCT00780962|RCN
1297062|NCT00780962|RCIN
1297063|NCT00780962|Creatinine
1297064|NCT00780962|Computerized Tomography
1297065|NCT00780962|CT
1297066|NCT00780962|Emergency Department
1297067|NCT00780962|ED
1297068|NCT00780962|Safety of IV N-Acetylcysteine
1297069|NCT00780949|Crohn's Disease, inflammatory bowel disease, Peyer's patches
1297070|NCT00780897|PREMATURE OVARIAN FAILURE (POF)
1297071|NCT00780897|GENETIC ANALYSIS
1297072|NCT00780897|PHYSIOPATHOLOGIC ANALYSIS
1297073|NCT00780884|acupuncture
1297074|NCT00780884|schizophrenia
1297075|NCT00780884|insomnia
1297076|NCT00780858|GnRH antagonist
1297077|NCT00780858|IUI
1297078|NCT00780845|Acute Kidney failure
1297079|NCT00780845|Clinical outcomes
1297080|NCT00780845|On-pump
1297081|NCT00780845|Coronary artery bypass grafting
1297082|NCT00780845|Morbidity
1297083|NCT00780845|Mortality
1297084|NCT00780832|overactive bladder
1297085|NCT00780832|dietary caffeine
1297086|NCT00780832|anticholinergic medication
1297087|NCT00780832|lifestyle modification
1297088|NCT00780832|incontinence
1297089|NCT00780832|urinary frequency
1297090|NCT00780806|MnB
1297091|NCT00780806|rLP2086
1297092|NCT00780806|blood collection
1297093|NCT00780806|vaccination
1297094|NCT00780793|Rheumatoid arthritis
1297095|NCT00780793|Remission
1297096|NCT00780793|Therapeutic strategy
1297097|NCT00780793|DMARDs
1297098|NCT00780793|Biological agents
1297099|NCT00780780|triamcinolone
1297100|NCT00780780|nepafenac
1297101|NCT00780780|DME
1297102|NCT00780780|edema macular
1297103|NCT00780767|angiojet
1297104|NCT00780767|massive pulmonary embolism
1297105|NCT00780767|RHEOLYTIC THROMBECTOMY
1297106|NCT00780767|patients presenting with massive pulmonary embolism
1297107|NCT00780754|prostate cancer
1297108|NCT00780754|chemoprevention
1297109|NCT00780754|dutasteride
1297110|NCT00780741|Nasolacrimal duct obstruction
1297111|NCT00780741|Simple probing
1297112|NCT00780715|Diabetes therapies
1297113|NCT00780715|Pharmacogenetics
1297114|NCT00780702|Cocaine
1297115|NCT00780702|Treatment
1297116|NCT00780702|Airpiprazole
1297117|NCT00780702|Methadone
1297118|NCT00780702|Relapse
1297119|NCT00780702|HIV
1297120|NCT00780702|Ecological Momentary Assessment (EMA)
1297121|NCT00780702|Contingency Management
1297122|NCT00780676|Dasatinib
1297123|NCT00780676|Metastatic Breast Cancer
1297124|NCT00780676|Sprycel
1297125|NCT00780676|BMS-354825
1297126|NCT00780676|Genetic testing
1297127|NCT00780676|AZD6244
1297128|NCT00780676|Selumetinib
1297129|NCT00780663|Neuroendocrine
1297130|NCT00780663|Carcinoid
1297131|NCT00780663|NET
1297132|NCT00780663|MEN-1
1297133|NCT00780663|Islet cell
1297134|NCT00780637|Heart Transplant
1297135|NCT00780637|Endothelial Function
1297136|NCT00780637|Fibrinolysis
1297137|NCT00780637|Transplant recipients at baseline
1297138|NCT00780624|RDS
1297139|NCT00780624|Infant, newborn
1297140|NCT00780624|NIPPV
1297141|NCT00780624|CPAP
1297142|NCT00780598|Acute Myeloid Leukemia
1297143|NCT00780598|AML
1297144|NCT00780598|Cancer
1297145|NCT00780598|Hematological malignancies
1297146|NCT00780598|Elderly
1297147|NCT00780598|Refractory
1297148|NCT00780598|Relapsed
1297149|NCT00780598|Blood disorder
1297150|NCT00780572|Safety Management
1297151|NCT00780572|Risk Management
1297152|NCT00780572|surveillance
1297153|NCT00780572|triggers
1297154|NCT00780559|Neuropathy
1297155|NCT00780559|diabetes
1297156|NCT00780546|tuberculosis
1297157|NCT00780546|spatial epidemiology
1297158|NCT00780546|geographic information system
1297159|NCT00780520|glutamine inflammation HSP70 sepsis
1297160|NCT00780481|Obesity
1297161|NCT00780481|Endothelial Function
1297162|NCT00780481|Fibrinolytic Balance
1297163|NCT00780481|Baseline
1297164|NCT00780468|Weight loss
1297165|NCT00780468|Diet
1297166|NCT00780468|Obesity
1297167|NCT00780455|KineSEP
1297168|NCT00780455|Rehabilitation
1297169|NCT00780455|Betaferon
1297170|NCT00780442|substance related disorders
1297171|NCT00780429|kidney
1297172|NCT00780429|transplant
1297173|NCT00780429|Mycophenolic acid
1297174|NCT00780429|Inosine monophosphate dehydrogenase
1297175|NCT00780273|subjects with edentulous mandible
1297176|NCT00780260|HIV/AIDS
1297177|NCT00780260|African Americans
1297178|NCT00780260|Women
1297179|NCT00780260|Case Management
1297180|NCT00780247|Vitamin D
1297181|NCT00780247|Sun
1297182|NCT00780247|Latitude
1297183|NCT00780247|Vitamin D status
1297184|NCT00780234|chemoprevention
1297185|NCT00780234|lung cancer
1297186|NCT00780234|pioglitazone
1297187|NCT00780221|CRP
1297188|NCT00780221|coronary artery disease
1297189|NCT00780221|polymorphisms
1297432|NCT00779259|drug interactions
1297190|NCT00780208|Attention Deficit Hyperactivity ADHD
1297191|NCT00780195|hypoglycemia
1297192|NCT00780195|African Americans
1297193|NCT00780182|Bioavailability
1297194|NCT00780156|Drug eluting stent
1297195|NCT00780156|Dual antiplatelet therapy
1297196|NCT00780156|bleeding
1297197|NCT00780156|stent thrombosis
1297198|NCT00780156|follow-up of the drug eluting stent
1297199|NCT00780143|Tumor
1297200|NCT00780143|Leukemia
1297201|NCT00780143|Plitidepsin
1297202|NCT00780143|Aplidin
1297203|NCT00780117|CURRARINO syndrome
1297204|NCT00780117|Sacrococcygeal teratoma
1297205|NCT00780117|HLXB9 (MNX1) gene
1297206|NCT00780117|Alpha foeto protein
1297207|NCT00780117|Prognosis factors
1297208|NCT00780104|Advanced myeloid leukemias
1297209|NCT00780104|AML
1297210|NCT00780104|Leukemia
1297211|NCT00780104|Relapsed myeloid leukemias
1297212|NCT00780104|Refractory myeloid leukemias
1297213|NCT00780104|MEC
1297214|NCT00780104|Rapamycin
1297215|NCT00780104|Sirolimus
1297216|NCT00780091|optimization
1297217|NCT00780091|risk scale
1297218|NCT00780091|non inferiority
1297219|NCT00780091|cluster randomization
1297220|NCT00780091|monitoring strategies
1297221|NCT00780078|Intensive care unit
1297222|NCT00780078|Extubation failure
1297223|NCT00780078|Physiotherapist
1297224|NCT00780078|Pre-extubation bedside tests
1297225|NCT00780078|Swallowing disorders
1297226|NCT00780052|Hematologic Malignancies
1297227|NCT00780052|c-myb
1297228|NCT00780052|c-myb AS ODN
1297229|NCT00780026|liver
1297230|NCT00780026|transplant
1297231|NCT00780026|blood sugar
1297232|NCT00780013|Bioequivalence metformin hydrochloride
1297233|NCT00779987|Dry eye
1297234|NCT00779987|Autologous serum
1297235|NCT00779987|Ocular Surface Disease Index
1297236|NCT00779974|Total Shoulder Arthroplasty
1297237|NCT00779974|Osteoarthritis
1297238|NCT00779961|pediatric
1297239|NCT00779961|cleft palate
1297240|NCT00779961|plastic surgery
1297241|NCT00779961|palatoplasty
1297242|NCT00779961|pharyngoplasty
1297243|NCT00779948|Femoral Neck Fracture
1297244|NCT00779948|Internal Fixation
1297245|NCT00779948|Dynamic Hip Screw
1297246|NCT00779922|Multiple Myeloma
1297247|NCT00779922|impaired renal function
1297248|NCT00779909|vitamin D
1297249|NCT00779909|gingivitis
1297250|NCT00779909|periodontal disease
1297251|NCT00779909|inflammation
1297252|NCT00779896|To evaluate therapeutic potential of tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study
1297253|NCT00779896|Stage I-IIA disease CTCL
1297254|NCT00779883|Chronic lymphocytic leukemia
1297255|NCT00779883|CLL
1297256|NCT00779883|Leukemia
1297257|NCT00779883|Leukemia, Lymphocytic, Chronic, B-Cell
1297258|NCT00779883|Leukemia, B-Cell
1297259|NCT00779883|Immune System Diseases
1297260|NCT00779883|ISF35
1297261|NCT00779883|Ad-ISF35
1297262|NCT00779883|Immunotherapy
1297263|NCT00779883|Immune therapy
1297264|NCT00779883|Active immune therapy
1297265|NCT00779870|asthma severity
1297266|NCT00779870|airway smooth muscle
1297267|NCT00779870|oxidative stress
1297268|NCT00779857|left atrial appendage
1297269|NCT00779857|laa
1297270|NCT00779857|atrial fibrillation
1297271|NCT00779857|afib
1297272|NCT00779857|af
1297273|NCT00779857|stroke
1297274|NCT00779857|tia
1297275|NCT00779844|Anesthesia
1297276|NCT00779844|Obesity
1297277|NCT00779831|Bioequivalence Pseudoephedrine hydrochloride 120 mg extended release tablets
1297278|NCT00779805|Bioequivalence Pseudoephedrine hydrochloride 120 mg ER tablets
1297279|NCT00779792|Irritant contact dermatitis
1297280|NCT00779792|experimental contact dermatitis
1297281|NCT00779792|treatment
1297282|NCT00779792|efficacy
1297283|NCT00779792|topical steroids
1297284|NCT00779792|topical immune modulators
1297285|NCT00779792|glycerol
1297286|NCT00779779|Gastroenteritis
1297287|NCT00779766|Human papillomavirus
1297288|NCT00779766|vaccine
1297289|NCT00779766|cervical cancer
1297290|NCT00779766|cervical infection
1297291|NCT00779753|Parenteral Feeding
1297292|NCT00779753|Neonate
1297293|NCT00779753|Lysine
1297294|NCT00779727|women
1297295|NCT00779727|increased
1297296|NCT00779727|risk
1297297|NCT00779714|metastatic (AJCC stage IV)
1297298|NCT00779714|first-line chemotherapy
1297299|NCT00779714|ex-vivo chemosensitivity profiling
1297300|NCT00779714|evaluation of biomarkers
1297301|NCT00779701|Hyperglycemia
1297302|NCT00779701|Glycemic control
1297303|NCT00779688|Endoscopic Retrograde Cholangiopancreatography
1297304|NCT00779688|ERCP
1297305|NCT00779688|bile duct cancer
1297306|NCT00779688|pancreatic duct cancer
1297307|NCT00779688|gall bladder
1297308|NCT00779688|pancreas
1297309|NCT00779688|duodenoscope
1297310|NCT00779688|Cellvizio
1297311|NCT00779688|endomicroscopy
1297312|NCT00779688|cholangiopancreatoscopy
1297313|NCT00779688|Biliary Tract Neoplasms (suspected)
1297314|NCT00779688|Biliary Tract Mass (suspected)
1297315|NCT00779688|Biliary Tract Stricture (suspected)
1297316|NCT00779688|Pancreatic Duct Neoplasms (suspected)
1297317|NCT00779688|Pancreatic Duct Mass (suspected)
1297318|NCT00779688|Pancreatic Duct Stricture (suspected)
1297319|NCT00779662|Rheumatic Heart Disease
1297320|NCT00779662|Streptococcus
1297321|NCT00779662|Fiji
1297322|NCT00779649|Colonoscopy,
1297323|NCT00779649|Prep
1297324|NCT00779649|MoviPrep
1297325|NCT00779649|HalfLytely
1297326|NCT00779649|The effectiveness of colonoscopy preps
1297327|NCT00778557|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL, Bioequivalence fasting conditions
1297328|NCT00778544|Bioequivalence amoxicillin-clavulanic acid 600 mg 42.9 mg per 5 mL oral suspension
1297329|NCT00778531|injectable implant
1297330|NCT00778531|nasolabial folds
1297331|NCT00778531|Correction of nasolabial folds
1297332|NCT00778518|growth hormone
1297333|NCT00778518|growth hormone deficiency
1297334|NCT00778518|GHD
1297335|NCT00778518|PEG
1297336|NCT00778518|pegylated
1297337|NCT00778518|IGF-1
1297338|NCT00778505|Anesthesia
1297339|NCT00778492|Thrombelastogram
1297340|NCT00778492|Microvascular bleeding
1297341|NCT00778492|antiplatelet medication
1297342|NCT00778492|cardiac surgery
1297343|NCT00778492|consumption of blood products
1297344|NCT00778492|preoperative platelet mapping derived from modified TEG
1297345|NCT00778492|postoperative bleeding
1297346|NCT00778466|Bioequivalence metformin hydrochloride 1000 mg tablets fed conditions
1297347|NCT00778453|stroke rehabilitation
1297348|NCT00778453|kinematic analysis
1297349|NCT00778453|upper extremity training
1297350|NCT00778453|predictors
1297351|NCT00778440|Injuries
1297352|NCT00778440|Traffic Injuries
1297353|NCT00778440|Preventive medicine
1297354|NCT00778440|Observational studies
1297355|NCT00778440|Primary care
1297356|NCT00778427|Bioequivalence metformin hydrochloride 1000 mg tablets fasting conditions
1297357|NCT00779597|self care
1297358|NCT00779597|symptom management
1297359|NCT00779597|pain
1297360|NCT00779597|cancer
1297361|NCT00779597|nurse coaching
1297362|NCT00779597|patient education
1297363|NCT00779571|Polycystic Ovary Syndrome
1297364|NCT00779571|Morbid Obesity
1297365|NCT00779571|Type 2 DM
1297366|NCT00779571|Coronary heart disease
1297367|NCT00779532|Electrocardiography
1297368|NCT00779532|Pharmacokinetics
1297369|NCT00779519|Obesity
1297370|NCT00779519|Class 1
1297371|NCT00779519|Class 2
1297372|NCT00779519|Weight Loss
1297373|NCT00779519|AgRP
1297374|NCT00779519|TTP435
1297375|NCT00779519|alphaMSH
1297376|NCT00779519|Agouti-Related Protein
1297377|NCT00779519|alpha-melanocyte stimulating hormone
1297378|NCT00779506|Acute schizophrenia
1297379|NCT00779506|PANSS
1297380|NCT00779493|irritable bowel syndrome
1297381|NCT00779493|constipation
1297382|NCT00779493|diarrhea
1297383|NCT00779493|gas
1297384|NCT00779493|bloating
1297385|NCT00779493|abdominal pain
1297386|NCT00779493|disturbance of defecation
1297387|NCT00779493|irritable colon
1297388|NCT00779480|Acute Myelogenous Leukemia
1297389|NCT00779480|Safety
1297390|NCT00779480|Dose Tolerance
1297391|NCT00779480|Pharmacokinetics/Pharmacodynamics
1297392|NCT00779480|FLT-3
1297393|NCT00779467|non narcotic
1297394|NCT00779467|epidural
1297395|NCT00779467|labor pain
1297396|NCT00779467|Non narcotic treatment of labor pain
1297397|NCT00779454|KRAS wild-type
1297398|NCT00779454|Cholangiocarcinoma
1297399|NCT00779454|Inoperable
1297400|NCT00779441|Bioequivalence zolpidem 10mg tablets
1297401|NCT00779428|This is an open-label continuing treatment protocol in patients with advanced malignancies who will receive Tanespimycin
1297402|NCT00779415|Partial Thickness
1297403|NCT00779415|Rotator Cuff
1297404|NCT00779402|cancer
1297405|NCT00779402|prostate cancer
1297406|NCT00779402|prostatectomy
1297407|NCT00779402|PSA
1297408|NCT00779389|Head and Neck cancer
1297409|NCT00779376|Bioequivalence
1297410|NCT00779363|obese,
1297411|NCT00779363|Diabetes
1297412|NCT00779350|Bioequivalence sertraline 100 mg tablets fasting conditions
1297413|NCT00779337|Epstein-Barr virus
1297414|NCT00779337|lymphoma
1297415|NCT00779337|immunotherapy
1297416|NCT00779324|traumatic brain injury
1297417|NCT00779324|irritability
1297418|NCT00779324|aggression
1297419|NCT00779324|amantadine
1297420|NCT00779324|behavior
1297421|NCT00779311|Metastatic Colorectal Cancer
1297422|NCT00779298|rye whole-meal bread
1297423|NCT00779298|white-wheat bread
1297424|NCT00779298|gastric emptying rate
1297425|NCT00779298|postprandial glucose response
1297426|NCT00779298|healthy subjects
1297427|NCT00779272|neoadjuvant chemotherapy
1297428|NCT00779272|clinically postoperative outcome
1297429|NCT00779272|liver regeneration after liver resection
1297430|NCT00779259|quinine sulfate
1297431|NCT00779259|theophylline
1297433|NCT00779259|cytochrome p450
1297434|NCT00779259|humans
1297435|NCT00779259|male
1297436|NCT00779259|adult
1297437|NCT00779246|Methicillin resistance
1297438|NCT00779246|Infection control
1297439|NCT00779246|Staphylococcus aureus
1297440|NCT00779246|Cross infection
1297441|NCT00779246|Epidemiology
1297442|NCT00779246|Chlorhexidine
1297443|NCT00779233|Bioequivalence
1297444|NCT00779207|obesity
1297445|NCT00779207|aging
1297446|NCT00779207|exercise
1297447|NCT00779207|diet
1297448|NCT00779207|weight loss
1297449|NCT00779207|physical function
1297450|NCT00779207|Obesity in the Elderly
1297451|NCT00779181|Hypertension
1297452|NCT00779181|High blood pressure
1297453|NCT00779181|Htn
1297454|NCT00779181|Addrenex
1297455|NCT00779168|recurrent prostate cancer
1297456|NCT00779168|adenocarcinoma of the prostate
1297457|NCT00779142|resistant diabetic macular edema
1297458|NCT00779103|puberty
1297459|NCT00779103|precocious puberty
1297460|NCT00779103|early puberty
1297461|NCT00779103|early onset puberty
1297462|NCT00779103|histrelin
1297463|NCT00779103|histrelin subcutaneous implant
1297464|NCT00779103|implant therapy
1297465|NCT00779077|device characteristics
1297466|NCT00779064|Atrial Fibrillation
1297467|NCT00779051|Bioequivalence Zolpidem 10mg tablets
1297468|NCT00779038|IONSYS
1297469|NCT00779038|Fentanyl Iontophoretic Transdermal System
1297470|NCT00779038|Postoperative pain
1297471|NCT00778986|heart failure
1297472|NCT00778986|remote patient monitoring
1297473|NCT00778986|telemonitoring
1297474|NCT00778986|home monitoring
1297475|NCT00778986|randomized controlled trial
1297476|NCT00778986|self care
1297477|NCT00778973|Bioequivalence sertraline 100 mg tablets under fed conditions
1297478|NCT00778947|Breast Reconstruction
1297479|NCT00778947|Halmonic Scalpel
1297480|NCT00778947|diathermy
1297481|NCT00778947|Free Tissue Transfer
1297482|NCT00778921|Aliskiren
1297483|NCT00778921|Amlodipine
1297484|NCT00778921|Non-responder to Amlodipine
1297485|NCT00778908|Nasopharyngeal carcinoma
1297486|NCT00778908|Locally advanced disease
1297487|NCT00778908|Intensity-modulated radiation therapy
1297488|NCT00778908|Accelerated hyperfractionation
1297489|NCT00778908|Concomitant boost radiation therapy
1297490|NCT00778908|Concurrent chemotherapy
1297491|NCT00778895|Flu
1297492|NCT00778895|Safety
1297493|NCT00778895|Immunogenicity
1297494|NCT00778895|Flu vaccine
1297495|NCT00778895|Influenza
1297496|NCT00778895|Virus
1297497|NCT00778882|Chronic Granulomatous Disease
1297498|NCT00778882|Retroviral Vector
1297499|NCT00778882|Gene Therapy
1297500|NCT00778843|Chronic hepatitis C
1297501|NCT00778843|Oxidative stress
1297502|NCT00778843|Antioxidant
1297503|NCT00778843|Cytokines
1297504|NCT00778843|Nutritional supplement
1297505|NCT00778830|mCRC
1297506|NCT00778804|CVD risk
1297507|NCT00778804|self monitoring
1297508|NCT00778804|Internet
1297509|NCT00778804|telemedicine
1297510|NCT00778791|Bioequivalence metformin HC1 750 mg extended-release tablets
1297511|NCT00778778|Bioequivalence cefprozil 500mg tablets fasting conditions
1297512|NCT00778765|Bioequivalence gabapentin fed conditions
1297513|NCT00778752|Multiple Myeloma
1297514|NCT00778752|Stem Cell Transplantation
1297515|NCT00778752|Revlimid
1297516|NCT00778752|Lenalidomide
1297517|NCT00778739|bioequivalence 1) CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL fed conditions
1297518|NCT00778726|Bioequivalence benazepril and hydrochlorothiazide tablets
1297519|NCT00778713|Bioequivalence
1297520|NCT00778674|Bioequivalence Benazepril HCl Hydrochlorothiazide Tablets
1297521|NCT00778661|Bioequivalence
1297522|NCT00778648|Common cold
1297523|NCT00778648|prevention
1297524|NCT00778648|dietary supplement
1297525|NCT00778609|Combined Oral Contraceptives
1297526|NCT00778609|Pelvic Pain
1297527|NCT00778609|Headache
1297528|NCT00778596|Hepatitis B
1297529|NCT00778596|Telbivudine
1297530|NCT00778596|Prednisolone
1297531|NCT00778583|Bioequivalence Nitrofurantoin capsules
1297532|NCT00778349|Bioavailability Metformin solution 100 mg/mL
1297533|NCT00778336|Peripheral Thrombosis
1297534|NCT00778336|DVT
1297535|NCT00778336|Limb Ischemia
1297536|NCT00778336|AV Access
1297537|NCT00778336|AngioJet
1297538|NCT00778336|Thrombectomy
1297539|NCT00778323|remote ischemic preconditioning
1297540|NCT00778323|cervical compression myelopathy
1297541|NCT00778323|spinal cord
1297542|NCT00778323|neuron-specific enolase
1297543|NCT00778323|s-100B
1297544|NCT00778310|Attention Deficit Disorder with Hyperactivity
1297545|NCT00778310|Attention Deficit Hyperactivity Disorder
1297546|NCT00778310|ADHD
1297547|NCT00778297|prevention
1297548|NCT00778297|influenza
1297549|NCT00778297|infection
1297550|NCT00778297|vaccine
1297551|NCT00778297|Influenza vaccine
1297552|NCT00778297|Influenza in humans
1297553|NCT00778284|Bioequivalence
1297554|NCT00778271|Bioequivalence gabapentin 400mg capsules fasting conditions
1297555|NCT00778258|Food Allergy
1297556|NCT00778258|Milk Allergy
1297557|NCT00778245|Bioequivalence cefprozil 500mg tablets fed conditions
1297558|NCT00778232|Bioequivalence Gabapentin tablets 800 mg fed conditions
1297559|NCT00778219|heart rate variability, tracheal intubation
1297560|NCT00778206|Phenylketonuria
1297561|NCT00778206|Hyperphenylalaninemia
1297562|NCT00778206|PKU
1297563|NCT00778206|Phenylalanine
1297564|NCT00778193|NSAID
1297565|NCT00778193|ulcer
1297566|NCT00778193|gastroduodenal ulcer
1297567|NCT00778193|naproxen
1297568|NCT00778193|aspirin
1297569|NCT00778193|ASA
1297570|NCT00778193|celecoxib
1297571|NCT00778193|clopidogrel
1297572|NCT00778193|healing
1297573|NCT00778193|Cyclooxygenase 2 Inhibitors
1297574|NCT00778193|Anti-Inflammatory Agents, Non-Steroidal
1297575|NCT00778193|Platelet Aggregation Inhibitors
1297576|NCT00778193|Wound Healing
1297577|NCT00778180|Bioequivalence furosemide 80 mg tablets
1297578|NCT00778141|Bioequivalecne metformin HC1 750 mg extended-release tablets
1297579|NCT00778128|CP-4126
1297580|NCT00778128|Cancer
1297581|NCT00778128|Metastatic
1297582|NCT00778128|Solid tumours
1297583|NCT00778128|Gemzitabine
1297584|NCT00778128|Gemzar
1297585|NCT00778115|Bioequivalence Loperamide HCl 2 mg and simethicone 125 mg tablets
1297586|NCT00778089|skin test
1297587|NCT00778089|ArteFill
1297588|NCT00778089|Skin test prior to administration of ArteFill® implant
1297589|NCT00778076|Knee OA, Hyaluronic acid, Gait, Pain, Synovial fluid
1297590|NCT00778063|dexmedetomidine
1297591|NCT00778063|pressure equalization tubes in the ear
1297592|NCT00778063|myringotomy
1297593|NCT00778063|sevoflurane
1297594|NCT00778050|Bioequivalence, amoxicillin 600mg fasting conditions
1297595|NCT00778037|Bioequivalence Cyclobenzaprine hydrochloride 10 mg tablet fasting conditions
1297596|NCT00778024|Bioequivalence fluoxetine HCL 40 mg capsules fasting conditions
1297597|NCT00778011|Nausea
1297598|NCT00778011|Vomiting
1297599|NCT00778011|Ondansetron
1297600|NCT00778011|Metoclopramide
1297601|NCT00778011|Randomized
1297602|NCT00778011|Double-Blind
1297603|NCT00778011|nausea and vomiting in the emergency department
1297604|NCT00777998|Multiple Myeloma
1297605|NCT00777998|Stem Cell Transplantation
1297606|NCT00777998|Thalidomide
1297607|NCT00777998|DLI
1297608|NCT00777985|Cardiovascular system
1297609|NCT00777985|Sleep
1297610|NCT00777985|Endothelial function
1297611|NCT00777985|Endothelin system
1297612|NCT00777972|Bioequivalence Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets fasting conditions
1297613|NCT00777946|Aliskiren, Amlodipine, Non-responder to aliskiren
1297614|NCT00777907|neurovascular embolization
1297615|NCT00777907|therapeutic embolization
1297616|NCT00777894|advanced adult primary liver cancer
1297617|NCT00777894|localized unresectable adult primary liver cancer
1297618|NCT00777894|adult primary hepatocellular carcinoma
1297619|NCT00777855|warfarin
1297620|NCT00777855|pharmacokinetics
1297621|NCT00777855|drug transporter
1297622|NCT00777855|healthy volunteer
1297623|NCT00777855|drug interaction
1297624|NCT00777855|rifampin
1297625|NCT00777829|Nap
1297626|NCT00777829|Pharmacology
1297627|NCT00777829|Memory
1297628|NCT00777829|Visual Learning
1297629|NCT00777829|Verbal Memory
1297630|NCT00777829|Motor Learning
1297631|NCT00777816|Rheumatoid
1297632|NCT00777816|Arthritis
1297633|NCT00777790|Meningitis
1297634|NCT00777790|Meningococcemia
1297635|NCT00777790|Neisseria meningitidis
1297636|NCT00777777|multi-vessel, therapy, surgery, CABG
1297637|NCT00777764|Xolair
1297638|NCT00777764|Asthma
1297639|NCT00777764|Skin Tests
1297640|NCT00777751|Chest Tumor
1297641|NCT00777751|Heart
1297642|NCT00777751|Lung Cancer
1297643|NCT00777751|Esophageal Cancer
1297644|NCT00777751|Thymoma
1297645|NCT00777751|Radiation dose to the heart
1297646|NCT00777751|Cardiac Enzymes
1297647|NCT00777751|Cardiac Biomarkers
1297648|NCT00777751|Radiation Therapy
1297649|NCT00777751|RT
1297650|NCT00777751|Electrocardiograms
1297651|NCT00777751|ECG
1297652|NCT00777738|Advanced Waldenström's macroglobulinemia
1297653|NCT00777738|Bortezomib
1297654|NCT00777738|Dexamethasone
1297655|NCT00777738|Safety
1297656|NCT00777738|Efficacy
1297657|NCT00777712|Wound healing
1297658|NCT00777712|diabetes
1297659|NCT00777712|inflammatory cell
1297660|NCT00777712|monocyte
1297661|NCT00777712|leukocyte
1297662|NCT00777712|macrophage
1297663|NCT00777699|Cancer
1297664|NCT00777699|Solid Tumors
1297665|NCT00777699|NSCLC
1297666|NCT00777686|Intracranial Glioblastoma
1297667|NCT00777686|Intracranial Gliosarcoma
1297668|NCT00777686|glioblastoma
1297669|NCT00777686|recurrent glioblastoma
1297670|NCT00777686|gliosarcoma
1297671|NCT00777686|brain cancer
1297672|NCT00777686|magnetic resonance spectroscopy
1297673|NCT00777686|MRS
1297674|NCT00777686|magnetic resonance imaging
1297675|NCT00777686|MRI
1297676|NCT00777686|MRI/MRS
1297677|NCT00777686|Recurrent Glioblastoma Treated with Antiangiogenic agents
1297678|NCT00777686|contrast enhanced MRI
1297679|NCT00777686|DCE-MRI
1297680|NCT00777686|diffusion-weighted MRI
1297681|NCT00777686|DSC
1297682|NCT00777686|DW-MRI
1297683|NCT00777673|Breast Cancer
1297684|NCT00777673|Triple Negative
1297685|NCT00777673|Neoadjuvant
1297686|NCT00777673|Neoadjuvant therapy
1297687|NCT00777673|ER, PR and HER2 Negative
1297688|NCT00777634|Binge Eating Disorder
1297689|NCT00777634|Eating Disorder
1297690|NCT00777595|QTc
1297691|NCT00777595|CHF 4226 HFA
1297692|NCT00777595|pMDI
1297693|NCT00777595|Carmoterol
1297694|NCT00777582|Poly (ADP ribose) polymerases
1297695|NCT00777582|Homologous Recombination Deficiency (HRD)
1297696|NCT00777582|Advanced solid tumours
1297697|NCT00777569|Smoking
1297698|NCT00777569|PREPS
1297699|NCT00777569|Harm reduction
1297700|NCT00777569|Biomarkers of tobacco exposure
1297701|NCT00777569|Compensatory smoking
1297702|NCT00777543|Bioavailability
1297703|NCT00777543|Ferulic acid
1297704|NCT00777543|Phenolic compounds
1297705|NCT00777543|Colonic metabolites
1297706|NCT00777543|Immunomodulatory effects
1297707|NCT00777543|No disease
1297708|NCT00777517|Cardiovascular Diseases
1297709|NCT00777504|angiogenesis
1297710|NCT00777504|inhibitor
1297711|NCT00777504|duration of therapy
1297712|NCT00777504|GIST
1297713|NCT00777491|stage II bladder cancer
1297714|NCT00777491|stage III bladder cancer
1297715|NCT00777491|transitional cell carcinoma of the bladder
1297716|NCT00777478|Sunitinib
1297717|NCT00777478|Capecitabine
1297718|NCT00777478|Irinotecan
1297719|NCT00777478|colorectal cancer
1297720|NCT00777465|Acute kidney injury
1297721|NCT00777465|Kidney failure
1297722|NCT00777465|Risk factors
1297723|NCT00777465|Clinical outcomes
1297724|NCT00777465|Cardiac valve surgery
1297725|NCT00777465|Coronary artery bypass grafting
1297726|NCT00777465|Morbidity
1297727|NCT00777465|Mortality
1297728|NCT00777452|quality of life
1297729|NCT00777452|localized prostate cancer
1297730|NCT00777452|FACT-P
1297731|NCT00777439|Dopamine
1297732|NCT00777439|Domperidone
1297733|NCT00777439|Gastroparesis
1297734|NCT00777439|Gastrointestinal Diseases
1297735|NCT00777439|Neurologic Manifestations
1297736|NCT00777439|Stomach Diseases
1297737|NCT00777439|Digestive System Diseases
1297738|NCT00777439|Esophagitis
1297739|NCT00777439|Esophageal Disorders
1297740|NCT00777439|Paralysis
1297741|NCT00777426|HIV positive with HAD
1297742|NCT00777413|Bioequiavlence Minocycline Tablets
1297743|NCT00777400|Kidney transplant
1297744|NCT00777400|T regulatory cells
1297745|NCT00777400|Efalizumab
1297746|NCT00777400|Rejection
1297747|NCT00777400|Safely convert renal transplant from mycophenolate mofetil and Calcineurin inhibitor to efalizumab and sirolimus
1297748|NCT00777387|human oocyte cryopreservation
1297749|NCT00777387|slow-freeze
1297750|NCT00777387|vitrification
1297751|NCT00777361|Mass balance
1297752|NCT00777361|AZD3480, Pharmacokinetics, Healthy volunteers
1297753|NCT00777322|keratoconus
1297754|NCT00777322|pellucid marginal degeneration
1297755|NCT00777322|corneal ectasia
1297756|NCT00777322|collagen cross-linking
1297757|NCT00777322|riboflavin
1297758|NCT00777322|UV light
1297759|NCT00777322|excimer laser
1297760|NCT00777322|Topography-Computer Assisted Treatment (T-Cat)
1297761|NCT00777322|Wavelight Allegretto laser
1297762|NCT00777309|NSCLC
1297763|NCT00777296|Cystic Fibrosis
1297764|NCT00777296|Respiratory Infections
1297765|NCT00777296|Pulmonary Cystic Fibrosis
1297766|NCT00777296|CFTR
1297767|NCT00776672|Bioequivalence Fosinopril Tablets
1297768|NCT00776659|An Observational Study of Indian Breast Cancer Patients Receiving Adjuvant Therapy with Aromasin
1297769|NCT00776659|Antineoplastic Hormonal Drugs
1297770|NCT00776659|Aromasin
1297771|NCT00776646|bioequivalence hydrochlorothiazide 50 mg tablet fasting conditions
1297772|NCT00776633|aspirin
1297773|NCT00776633|clopidogrel
1297774|NCT00776633|oral anticoagulation
1297775|NCT00776633|warfarin
1297776|NCT00776633|drug eluting stent
1297777|NCT00776633|phenprocoumon
1297778|NCT00776620|Bioequivalence Glimepiride Tablets
1297779|NCT00776607|LADA
1297780|NCT00776607|Latent autoimmune diabetes in adults
1297781|NCT00776607|Type 1.5
1297782|NCT00776607|Slowly progressive type 1 diabetes
1297783|NCT00776594|Androgen deprivation therapy
1297784|NCT00776594|ADT
1297785|NCT00776594|bevacizumab
1297786|NCT00776581|Combined spinal-epidural analgesia
1297787|NCT00776581|Patient-controlled analgesia
1297788|NCT00776581|Epidural analgesia
1297789|NCT00776555|Not required
1297790|NCT00776542|bioequivalence Minocycline Tablets
1297791|NCT00776529|sensorimotor training
1297792|NCT00776529|Strengthening
1297793|NCT00776529|Balance
1297794|NCT00776516|Healthy volunteer subjects
1297795|NCT00776516|CYP3A4 inducer
1297796|NCT00776516|rifampin
1297797|NCT00776516|drug interaction
1297798|NCT00776516|pharmacokinetics
1297799|NCT00776516|YM178
1297800|NCT00776516|mirabegron
1297801|NCT00776503|Epigenetic
1297802|NCT00776503|Myelodysplasia
1297803|NCT00776503|Cytarabine
1297804|NCT00776490|Bioequivalence Glimepiride Tablets
1297805|NCT00777270|episiotomy
1297806|NCT00777270|perineal lesion
1297807|NCT00777270|vaginal trauma
1297808|NCT00777257|Meningitis
1297809|NCT00777257|Meningococcemia
1297810|NCT00777257|Pertussis
1297811|NCT00777257|Neisseria meningitidis
1297812|NCT00777257|Tetanus
1297813|NCT00777257|Diphtheria
1297814|NCT00777244|mitotane
1297815|NCT00777244|adjuvant therapy
1297816|NCT00777244|disease free survival
1297817|NCT00777231|Sickle Cell
1297818|NCT00777231|Stem Cell
1297819|NCT00777231|Tolerance
1297820|NCT00777231|Bone Marrow Transplant
1297821|NCT00777231|Total Body Irradiation (TBI)
1297822|NCT00777231|Apheresis
1297823|NCT00777231|Aplastic Anemia
1297824|NCT00777231|Hemoglobinopathies
1297825|NCT00777231|Non Malignant
1297826|NCT00777218|migraine
1297827|NCT00777205|Peer Support
1297828|NCT00777205|Quality of Life
1297829|NCT00777205|Telephone
1297830|NCT00777192|colon cancer
1297831|NCT00777192|Cancers of the colon and rectum
1297832|NCT00777192|Oxaliplatin
1297833|NCT00777192|oxaliplatin chemotherapy
1297834|NCT00777192|inflammatory cytokines
1297835|NCT00777192|neurocognitive symptoms
1297836|NCT00777192|neuropsychiatric symptoms
1297837|NCT00777179|Vandetanib, NSCLC, Maintenance, Phase II
1297838|NCT00777166|oxytocin
1297839|NCT00777166|ST depression
1297840|NCT00777166|cesarean section
1297841|NCT00777166|blood loss
1297842|NCT00777153|Cancer
1297843|NCT00777153|Tumour
1297844|NCT00777153|Advanced Solid Tumour
1297845|NCT00777153|GBM
1297846|NCT00777153|Glioblastoma
1297847|NCT00777140|Stroke
1297848|NCT00777140|Ischemic Stroke
1297849|NCT00777140|Thrombolytic treatment
1297850|NCT00777140|Middle cerebral artery occlusion
1297851|NCT00777140|Deferoxamine
1297852|NCT00777140|Iron chelator
1297853|NCT00777140|Acute Ischemic Stroke treated with Intravenous Thrombolytic
1297854|NCT00777127|actinic keratosis
1297855|NCT00777127|invasive SCC
1297856|NCT00777127|in situ SCC
1297857|NCT00777127|histological classification
1297858|NCT00777127|histological progression
1297859|NCT00777127|clinical clearance
1297860|NCT00777127|cryotherapy
1297861|NCT00777114|relapsed non-Hodgkin's lymphoma
1297862|NCT00777101|HER2
1297863|NCT00777101|ErbB2
1297864|NCT00777101|metastatic
1297865|NCT00777101|neratinib
1297866|NCT00777101|lapatinib
1297867|NCT00777101|capecitabine
1297868|NCT00777101|HKI-272
1297869|NCT00777101|Tykerb
1297870|NCT00777101|Tyverb
1297871|NCT00777101|Xeloda
1297872|NCT00777088|neurovascular embolization
1297873|NCT00777088|therapeutic embolization
1297874|NCT00777075|nitrate
1297875|NCT00777075|nitric oxide
1297876|NCT00777075|asymmetric dimethylarginine
1297877|NCT00777075|blood pressure
1297878|NCT00777075|NOS
1297879|NCT00777075|IIEF
1297880|NCT00777062|alcohol
1297881|NCT00777062|cocaine
1297882|NCT00777062|addiction
1297883|NCT00777062|alcoholism
1297884|NCT00777062|substance dependence
1297885|NCT00777062|substance abuse
1297886|NCT00777036|Leukemia, Pediatric
1297887|NCT00777023|Hot Flashes
1297888|NCT00777023|Hot Flushes
1297889|NCT00777023|Postmenopausal symptoms
1297890|NCT00777023|Vasomotor symptoms
1297891|NCT00777010|memory loss
1297892|NCT00777010|mild cognitive impairment
1297893|NCT00777010|forgetfulness
1297894|NCT00776997|Gastroesophageal Reflux
1297895|NCT00776958|A Lynne Cohen Consortium Project
1297896|NCT00776958|Multi-Center Database Registry
1297897|NCT00776958|High Risk
1297898|NCT00776958|Cancer
1297899|NCT00776958|Breast
1297900|NCT00776958|BRCA1 or BRCA2 gene
1297901|NCT00776958|Ovary
1297902|NCT00776958|Questionnaire
1297903|NCT00776919|Acne Vulgaris
1297904|NCT00776919|Acne
1297905|NCT00776880|Surgical operation
1297906|NCT00776867|Pediatric
1297907|NCT00776867|solid tumors
1297908|NCT00776867|Pediatric solid tumors
1297909|NCT00776867|08-091
1297910|NCT00776841|Phase-I
1297911|NCT00776841|Hypercholesterolemia
1297912|NCT00776841|Obesity
1297913|NCT00776841|fatty liver
1297914|NCT00776841|Part A: Healthy male volunteers Part B: Mildly overweight, otherwise healthy hypercholesterolemic male volunteers
1297915|NCT00776828|cilostazol
1297916|NCT00776828|clopidogrel
1297917|NCT00776828|statin
1297918|NCT00776828|drug-eluting stent
1297919|NCT00776802|GCS-100
1297920|NCT00776802|Diffuse Large B-cell Lymphoma
1297921|NCT00776802|DLBCL
1297922|NCT00776802|Relapsed or refractory DLBCL
1297923|NCT00776802|Etoposide; Dexamethasone
1297924|NCT00776789|Skin to skin contact
1297925|NCT00776789|Salivary cortisol
1297926|NCT00776789|Breast feeding Behavior
1297927|NCT00776776|BMI > 40
1297928|NCT00776776|Obesity
1297929|NCT00776776|Adolescents
1297930|NCT00776776|Weight Loss Surgery
1297931|NCT00776737|Attention Deficit Disorder
1297932|NCT00776737|Attention Deficit Hyperactivity Disorder
1297933|NCT00776737|Computer Aided Learning
1297934|NCT00776737|Attention Deficits
1297935|NCT00776737|Healthy Volunteer
1297936|NCT00776737|HV
1297937|NCT00776724|breast ca
1297938|NCT00776724|phase III
1297939|NCT00776724|Tailored neoadjuvant chemotherapy
1297940|NCT00776724|stage II/III
1297941|NCT00776711|Healthy
1297942|NCT00776711|Avian Influenza
1297943|NCT00776711|Immunity
1297944|NCT00776711|Preventive
1297945|NCT00776711|Bird Flu
1297946|NCT00776711|Healthy Volunteer
1297947|NCT00776711|HV
1297948|NCT00776711|Influenza
1297949|NCT00776451|AMD
1297950|NCT00776438|Influenza
1297951|NCT00776438|Orthomyxoviruses
1297952|NCT00776438|Myxovirus Infection
1297953|NCT00776438|Inactivated Split-virion influenza vaccine
1297954|NCT00776438|Adults
1297955|NCT00776438|Elderly
1297965|NCT00776399|Colorectal cancer
1297966|NCT00776399|lung metastasis
1297967|NCT00776399|radiofrequency ablation
1297968|NCT00776399|metastasectomy
1297969|NCT00776399|Lung metastasis from colorectal cancer
1297970|NCT00776373|ALL
1297971|NCT00776373|Burkitt's Lymphoma
1297972|NCT00776373|Adult T-Cell leukemia/lymphoma
1297973|NCT00776373|Lymphoblastic leukemia
1297974|NCT00776373|CML in lymphoid blast crisis patients
1297975|NCT00776373|HiVAC
1297976|NCT00776373|Rapamycin
1297977|NCT00776360|oxytocin
1297978|NCT00776360|gastroparesis
1297979|NCT00776360|diabetics
1297980|NCT00776360|The effect of oxytocin on gastric emptying
1297981|NCT00776347|Dementia with Lewy bodies (DLB)
1297982|NCT00776347|FDG-PET
1297983|NCT00776334|bioequivalence Fosinopril Tablets
1297984|NCT00776321|hypercholesterolemia
1297985|NCT00776321|dyslipidemia
1297986|NCT00776321|thyroid
1297987|NCT00776321|safety
1297988|NCT00776308|molecular breast imaging
1297989|NCT00776308|breast cancer
1297990|NCT00776308|mammography
1297991|NCT00776295|Small Cell Lung Cancer
1297992|NCT00776295|SCLC
1297993|NCT00776295|Limited Stage Small Cell Lung Cancer
1297994|NCT00776282|bioequivalence loratadine 10 mg orally disintegrating
1297995|NCT00776282|tablets fed conditions
1297996|NCT00776269|Argon laser
1297997|NCT00776269|Trichiasis
1297998|NCT00776269|Radiofrequency
1297999|NCT00776269|Patients with trichiasis
1298000|NCT00776256|satiety
1298001|NCT00776256|food intake
1298002|NCT00776243|incretin
1298003|NCT00776243|GLP-1
1298004|NCT00776243|GIP
1298005|NCT00776243|intensive insulin therapy
1298006|NCT00776217|bioequivalence loratadine 10 mg orally disintegrating tablets fasting
1298007|NCT00776204|Coronary Artery Disease
1298008|NCT00776204|Drug eluting stent
1298009|NCT00776204|Percutaneous Coronary Interventions
1298010|NCT00776204|Optical Coherence Tomography
1298011|NCT00776191|Physioneal 35
1298012|NCT00776191|Physioneal 40
1298013|NCT00776191|children
1298014|NCT00776191|chronic peritoneal dialysis
1298015|NCT00776178|Survival Study
1298016|NCT00776178|Bladder Cancer
1298017|NCT00776178|Cancer Recurrence
1298018|NCT00776178|Tumor Markers/Heterogeneity
1298019|NCT00776139|Cetirizine Hydrochloride 10 mg tablet fasting conditions
1298020|NCT00776126|Breast
1298021|NCT00776126|3D Digital Mammography
1298022|NCT00776126|Digital Breast Tomosynthesis
1298023|NCT00776113|Bioequivalence Carvedilol fasting
1298024|NCT00776100|stage IV non-small cell lung cancer
1298025|NCT00776100|adenosquamous cell lung cancer
1298026|NCT00776100|squamous cell lung cancer
1298027|NCT00776100|large cell lung cancer
1298028|NCT00776100|adenocarcinoma of the lung
1298029|NCT00776100|bronchoalveolar cell lung cancer
1298030|NCT00776087|Medical costs
1298031|NCT00776087|Telemonitoring
1298032|NCT00776087|Implantable cardioverter-defibrillator
1298033|NCT00776074|Leiomyoma
1298034|NCT00776074|Uterine Fibroids
1298035|NCT00776074|Drug Therapy
1298036|NCT00776074|Uterine Neoplasms
1298037|NCT00776074|Fibroid Tumor
1298038|NCT00776035|Obesity
1298039|NCT00776035|Heart
1298040|NCT00776035|Failure
1298041|NCT00776035|PET
1298042|NCT00776035|radiation
1298043|NCT00776035|metabolism
1298158|NCT00775515|chronic
1298044|NCT00776022|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
1298045|NCT00776009|ADHD, children, subjects, laboratory classroom
1298046|NCT00775996|bioequivalence Clorazepate Tablets
1298047|NCT00775970|Obesity
1298048|NCT00775970|Weight loss maintenance
1298049|NCT00775970|Spontaneous physical activity
1298050|NCT00775970|Lipid oxydation
1298051|NCT00775970|Walking
1298052|NCT00775944|Tobacco
1298053|NCT00775944|Cigarette
1298054|NCT00775944|Smoking
1298055|NCT00775944|Counselling
1298056|NCT00775944|Nicotine Replacement Therapy
1298057|NCT00775944|Telephone
1298058|NCT00775944|Quitline
1298059|NCT00775944|Helpline
1298060|NCT00775931|osteopetrosis
1298061|NCT00775918|Bioequivalence Doxycycline monohydrate 100mg tablets fed conditions
1298062|NCT00775905|Bioequivalence amlodipine tablets fasting
1298063|NCT00775892|ACL
1298064|NCT00775892|Ligament
1298065|NCT00775879|Général anesthesia
1298066|NCT00775879|Gynecology
1298067|NCT00775866|prostate cancer, magnetic resonance imaging, guided imagery
1298068|NCT00775853|Biomarkers
1298069|NCT00775853|Catecholamines
1298070|NCT00775853|18F-Fluoro-L-dopa
1298071|NCT00775853|Fluorodopamine
1298072|NCT00775853|Parkinson's Disease
1298073|NCT00775853|Parkinson Disease
1298074|NCT00775853|PD
1298075|NCT00775840|Cardiac Failure
1298076|NCT00775840|Congestive Heart Failure
1298077|NCT00775840|Drug Therapy
1298078|NCT00775840|Hypertension
1298079|NCT00775840|Diabetes Mellitus
1298080|NCT00775827|bioequivalence fenofibrate tablets
1298081|NCT00775814|Hypertension
1298082|NCT00775814|Drug Therapy
1298083|NCT00775814|Blood Pressure
1298084|NCT00775814|Insulin, Resistant
1298085|NCT00775788|Fat Injection to Breast
1298086|NCT00775788|Fat Grafting to Breast
1298087|NCT00775762|Symptomatic Polyvascular disease
1298088|NCT00775762|Multiple recurrent cardiovascular events
1298089|NCT00775749|post operative nausea and vomiting
1298090|NCT00775749|gynecological surgery
1298091|NCT00775749|outpatient surgery
1298092|NCT00775749|nicotine patch
1298093|NCT00775749|laparoscopic surgery
1298094|NCT00775723|6sulphatoxymelatonin
1298095|NCT00775723|preterm infants
1298096|NCT00775723|melatonin is low in preterm infants at least until the age of 6 months
1298097|NCT00775697|wheezing
1298098|NCT00775697|children
1298099|NCT00775697|montelukast
1298100|NCT00775697|bronchodilators
1298101|NCT00775697|lung function
1298102|NCT00775697|Rint
1298103|NCT00775684|Exenatide
1298104|NCT00775684|Sitagliptin
1298105|NCT00775684|Glimepiride
1298106|NCT00775684|Glucagon-Like Peptide-1
1298107|NCT00775684|Impaired Fasting Glucose
1298108|NCT00775684|Type 2 Diabetes
1298109|NCT00775684|Beta-cell Function
1298110|NCT00775684|Beta-cell Secretory Capacity
1298111|NCT00775684|Glucose-potentiated arginine
1298112|NCT00775658|allergy
1298113|NCT00775658|skin testing
1298114|NCT00775658|eye drops
1298115|NCT00775658|antihistamines
1298116|NCT00775645|neurotoxicity
1298117|NCT00775645|chemotherapeutic agent toxicity
1298118|NCT00775645|fatigue
1298119|NCT00775645|neuropathy
1298120|NCT00775645|stage IA breast cancer
1298121|NCT00775645|stage IB breast cancer
1298122|NCT00775645|stage II breast cancer
1298123|NCT00775645|stage IIIA breast cancer
1298124|NCT00775645|stage IIIB breast cancer
1298125|NCT00775645|stage IIIC breast cancer
1298126|NCT00775632|Graft Versus Host Disease
1298127|NCT00775632|Alemtuzumab
1298128|NCT00775632|Campath
1298129|NCT00775632|Bone Marrow Transplants
1298130|NCT00775619|bioequivalence Carvedilol 12.5 mg tablets fed conditions
1298131|NCT00775606|AIDS, HIV
1298132|NCT00775593|recurrent adult acute myeloid leukemia
1298133|NCT00775593|adult acute basophilic leukemia
1298134|NCT00775593|adult acute eosinophilic leukemia
1298135|NCT00775593|adult erythroleukemia (M6a)
1298136|NCT00775593|adult pure erythroid leukemia (M6b)
1298137|NCT00775593|adult acute megakaryoblastic leukemia (M7)
1298138|NCT00775593|adult acute minimally differentiated myeloid leukemia (M0)
1298139|NCT00775593|adult acute monoblastic leukemia (M5a)
1298140|NCT00775593|adult acute monocytic leukemia (M5b)
1298141|NCT00775593|adult acute myeloblastic leukemia with maturation (M2)
1298142|NCT00775593|adult acute myeloblastic leukemia without maturation (M1)
1298143|NCT00775593|adult acute myelomonocytic leukemia (M4)
1298144|NCT00775593|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1298145|NCT00775593|adult acute myeloid leukemia with t(16;16)(p13;q22)
1298146|NCT00775593|adult acute myeloid leukemia with t(8;21)(q22;q22)
1298147|NCT00775593|adult acute myeloid leukemia with inv(16)(p13;q22)
1298148|NCT00775580|bioequivalence Atenolol Tablets
1298149|NCT00775567|Fructose
1298150|NCT00775567|Intolerance
1298151|NCT00775567|Adaptation
1298152|NCT00775567|Prebiotic
1298153|NCT00775567|Healthy men or women 18-40
1298154|NCT00775541|Diabetes
1298155|NCT00775541|Type 2 Diabetes
1298156|NCT00775528|Cystic Fibrosis
1298157|NCT00775528|Pancreatic Exocrine Insufficiency
1298159|NCT00775515|prostatitis
1298160|NCT00775515|prostate
1298161|NCT00775515|pain
1298162|NCT00775515|pelvic
1298163|NCT00775515|pelvis
1298164|NCT00775515|inflamation
1298165|NCT00775502|Multiple myeloma
1298166|NCT00775502|GM-2 ganglioside
1298167|NCT00775502|monoclonal antibody
1298168|NCT00775502|Potelligent design
1298169|NCT00775502|Treatment of subjects who have failed previous treatment
1298170|NCT00775489|glaucoma, steroid, nasal
1298171|NCT00775476|Systemic lupus erythematosus (SLE), an autoimmune disease
1298172|NCT00775463|Scleroderma, Diffuse
1298173|NCT00775463|Scleroderma, Limited
1298174|NCT00775463|Scleroderma, Systemic
1298175|NCT00775463|Ulcer
1298176|NCT00775463|prostacyclin
1298177|NCT00775450|Influenza
1298178|NCT00775450|Orthomyxovirus Infection
1298179|NCT00775450|Inactivated Split-virion influenza vaccine
1298180|NCT00775450|Elderly
1298181|NCT00775437|juvenile idiopathic arthritis
1298182|NCT00775437|compassionate use
1298183|NCT00775437|open label
1298184|NCT00775424|HIV infection
1298185|NCT00775424|DNA vaccine
1298186|NCT00775424|IL-12 adjuvant
1298187|NCT00775424|IL-15 adjuvant
1298188|NCT00775398|Hemostasis
1298189|NCT00775398|Thrombin-JMI
1298190|NCT00775398|Thrombin
1298191|NCT00775398|Blood Coagulation
1298192|NCT00775385|Chemotherapy, Adjuvant
1298193|NCT00775372|Bioequivalence study of clarithromycin 250mg/5mL powdder
1298194|NCT00775359|bioequivalence fenofibrate tablets
1298195|NCT00775333|Carpal Tunnel Syndrome
1298196|NCT00775333|Diabetes
1298197|NCT00775333|APB strength
1298198|NCT00775333|Sensory Function
1298199|NCT00775333|Pillar Pain
1298200|NCT00775333|Cold Intolerance
1298201|NCT00775333|Patient Satisfaction
1298202|NCT00775320|Brain scan
1298203|NCT00775307|Non-small cell lung cancer
1298204|NCT00775307|Stage I
1298205|NCT00775307|adjuvant therapy
1298206|NCT00775307|Adjuvant Drug Therapy
1298207|NCT00775281|Tachykinin receptors
1298208|NCT00775281|Protein expression
1298209|NCT00775281|Contractile proteins
1298210|NCT00775281|Inflammatory proteins
1298211|NCT00775268|18F Fluorothymidine
1298212|NCT00775268|PET/CT
1298213|NCT00775268|FLT
1298214|NCT00775268|Lymphoma
1298215|NCT00775268|FDG
1298216|NCT00775255|Bioequiavelnce clarithromycin
1298217|NCT00775242|Menopause
1298218|NCT00775242|Hormone Replacement Therapy
1298219|NCT00775242|Microspheres
1298220|NCT00775242|Progesterone
1298221|NCT00775242|Estradiol
1298222|NCT00775242|Hot flashes
1298223|NCT00775229|hair pulling
1298224|NCT00775203|Unipolar
1298225|NCT00775190|birth control pills
1298226|NCT00775190|oral contraceptives
1298227|NCT00775190|brand name
1298228|NCT00775190|generic
1298229|NCT00775190|side effects
1298230|NCT00775190|oral contraceptive side effects
1298231|NCT00775190|dysfunctional uterine bleeding
1298232|NCT00775190|pre-menstrual symptoms
1298233|NCT00775177|Bioequivalence Doxycycline monohydrate 100mg tablets fed conditions
1298234|NCT00775164|Obese children with insulin resistance
1298235|NCT00775151|Bioequivalence amlodipine 10 mg tablet under fed conditions
1298236|NCT00775138|Bronchiectasis
1298237|NCT00775138|Respiratory Infections
1298238|NCT00775138|Amikacin
1298239|NCT00775138|Genetic Diseases, Inborn
1298240|NCT00775138|Respiratory Tract Diseases
1298241|NCT00775138|Cystic Fibrosis
1298242|NCT00775138|Respiratory Tract Infections
1298243|NCT00775138|Lung Diseases
1298244|NCT00775138|Infant, Newborn, Diseases
1298245|NCT00775138|Pancreatic Diseases
1298246|NCT00775125|VX-950-TiDP24-C124
1298247|NCT00775125|VX-950-C124
1298248|NCT00775125|HCV
1298249|NCT00775125|DDI
1298250|NCT00775125|telaprevir
1298251|NCT00775125|darunavir
1298252|NCT00775125|ritonavir
1298253|NCT00775125|fosamprenavir
1298254|NCT00775125|interaction
1298255|NCT00775125|pharmacokinetics
1298256|NCT00775125|steady-state
1298257|NCT00775112|supportive care
1298258|NCT00775112|lumbar puncture
1298259|NCT00775112|childhood disease
1298260|NCT00775112|pediatric hemato-oncology
1298261|NCT00775099|Air Pollution
1298262|NCT00775099|Particles
1298263|NCT00775099|Particulate Matter
1298264|NCT00775099|Vascular function
1298265|NCT00775099|Endothelial function
1298266|NCT00775099|Thrombosis
1298267|NCT00775086|ORTHO EVRA
1298268|NCT00775086|contraception
1298269|NCT00775086|NGMN
1298270|NCT00775086|contraceptive patch
1298271|NCT00775086|bioequivalence
1298272|NCT00775086|EE
1298273|NCT00775086|norelgestromin
1298274|NCT00775086|ethinyl estradiol
1298275|NCT00775073|Liver cancer
1298276|NCT00775073|HCC
1298277|NCT00775047|depo medroxyprogesterone acetate
1298278|NCT00775047|Depo Provera
1298279|NCT00775047|contraceptive compliance
1298280|NCT00775047|pharmacists
1298281|NCT00775047|Compliance in receiving additional Depo Provera injections
1298282|NCT00775047|Satisfaction in receiving Depo Provera injections at a pharmacy compared with usual clinic
1298283|NCT00775008|weight loss, health information, e-health
1298284|NCT00774995|Engerix-B
1298285|NCT00774995|Hepatitis B
1298286|NCT00774982|Crohns Disease
1298287|NCT00774982|Pharmacokinetics
1298288|NCT00774982|Local Targeted Delivery to the Ileum
1298289|NCT00774982|Delayed Release
1298290|NCT00774982|Immunology Measurements
1298291|NCT00774982|Pharmacokinetics in Crohns Disease Patients
1298292|NCT00774943|Systemic lupus erythematosus
1298293|NCT00774943|ICOSL
1298294|NCT00774943|B7RP-1
1298295|NCT00774943|Costimulation
1298296|NCT00774930|Carcinoid tumor
1298297|NCT00774930|Somatuline Depot
1298298|NCT00774930|Lanreotide Autogel
1298299|NCT00774930|Neuroendocrine tumor
1298300|NCT00774930|NET
1298301|NCT00774930|Diarrhea
1298302|NCT00774930|Flushing
1298303|NCT00774930|Carcinoid tumour
1298304|NCT00774930|Neuroendocrine tumour
1298305|NCT00774930|Diarrhoea
1298306|NCT00774917|numen
1298307|NCT00774917|hyperplasia
1298308|NCT00774904|Type 2 Diabetes
1298309|NCT00774904|Diabetic Nephropathy
1298310|NCT00774904|Glucose Metabolism
1298311|NCT00774904|Angiotensin II Type 1 Receptor Blockers
1298312|NCT00774891|Echocardiography- exercise
1298313|NCT00774891|Echocardiography- dobutamine
1298314|NCT00774891|Wall stress
1298315|NCT00774891|Ventricular volume-left
1298316|NCT00774891|Ischemia
1298317|NCT00774891|Angina
1298318|NCT00774891|Heart diseases
1298319|NCT00774891|Stress echocardiography
1298320|NCT00774891|Ventricular volume
1298321|NCT00774891|Vascular diseases
1298322|NCT00774878|Breast cancer
1298323|NCT00774878|Breast Tumors
1298324|NCT00774878|Anti IGF-1R
1298325|NCT00774878|Hormonosensitivity
1298326|NCT00774865|Robotic
1298327|NCT00774865|CABG
1298328|NCT00774865|LITA
1298329|NCT00774865|Patency
1298330|NCT00774865|Long
1298331|NCT00774865|Term
1298332|NCT00774852|lupus
1298333|NCT00774852|systemic lupus erythematosus
1298334|NCT00774852|lupus nephritis
1298335|NCT00774852|SLE
1298336|NCT00774852|abatacept
1298337|NCT00774852|CTLA4
1298338|NCT00774852|CTLA4Ig
1298339|NCT00774852|glomerulonephritis
1298340|NCT00774839|Newly Diagnosed
1298341|NCT00774839|Colon
1298342|NCT00774839|Stage II
1298343|NCT00774839|Stage III
1298344|NCT00774826|Follicular lymphoma
1298345|NCT00774826|Rituximab
1298346|NCT00774813|Depression
1298347|NCT00774813|Mild
1298348|NCT00774813|Moderate
1298349|NCT00774813|Anxiety
1298350|NCT00774813|Kalaco Scientific, Inc.
1298351|NCT00774800|Recombinant Hyaluronidase
1298352|NCT00774800|Type 1 Diabetes Mellitus
1298353|NCT00774800|Humalog
1298354|NCT00774800|Humulin R
1298355|NCT00774800|rHuPH20
1298356|NCT00774800|Hylenex
1298357|NCT00774787|Combination treatment
1298358|NCT00774787|Imiquimod
1298359|NCT00774787|Cryotherapy
1298360|NCT00774774|Influenza, human
1298361|NCT00774774|Masks
1298362|NCT00774774|Disease Transmission, Horizontal
1298363|NCT00774761|Chronic
1298364|NCT00774761|Obstructive
1298365|NCT00774761|Pulmonary
1298366|NCT00774761|Disease
1298367|NCT00774761|COPD
1298368|NCT00774761|Pharmacodynamic
1298369|NCT00774761|Pharmacokinetic
1298370|NCT00774748|low molecular weight heparin
1298371|NCT00774748|enoxaparin
1298372|NCT00774748|Lovenox
1298373|NCT00774748|Insuflon
1298374|NCT00774748|subcutaneous catheter
1298375|NCT00774748|once or twice daily dosing of subcutaneous enoxaparin
1298376|NCT00774735|healthy volunteer
1298377|NCT00774735|darunavir
1298378|NCT00774735|lopinavir
1298379|NCT00774735|ritonavir
1298380|NCT00774735|GSK1349572
1298381|NCT00774735|integrase
1298382|NCT00774735|pharmacokinetics
1298383|NCT00774709|Heart failure
1298384|NCT00774709|Preserved ejection fraction
1298385|NCT00774709|Diastolic dysfunction
1298386|NCT00774709|Dyssynchrony
1298387|NCT00774709|Echocardiography
1298388|NCT00774709|Patients with acute heart failure clinically
1298389|NCT00774709|diagnosed
1298390|NCT00774709|BNP level > 100 ng / l or NT-proBNP > 300 ng /l
1298391|NCT00774709|Preserved left ventricular ejection fraction(LVEF
1298392|NCT00774709|≥ 45%)
1298393|NCT00774696|Bioequivalence study of clarithromycin
1298394|NCT00774683|Pilot
1298395|NCT00774683|Pharmacokinetics
1298396|NCT00774683|Raltegravir
1298397|NCT00774683|Cervicovaginal
1298398|NCT00774683|HIV
1298399|NCT00774683|Women
1298400|NCT00774657|Aortic Stenosis
1298401|NCT00774657|Valvular heart disease
1298402|NCT00774657|Heart disease
1298403|NCT00774657|Cardiovascular disease
1298404|NCT00774657|Two dimensional echocardiography
1298405|NCT00774657|Three dimensional echocardiography
1298406|NCT00774631|Meningitis
1298407|NCT00774631|Hypothermia
1298408|NCT00774631|Intensive care
1298409|NCT00774618|Rib Fracture
1298410|NCT00774618|Thoracic Injuries
1298411|NCT00774618|Flail Chest
1298412|NCT00774618|Rib Fracture Repair
1298413|NCT00774618|Rib Fracture ORIF
1298414|NCT00774618|Chronic rib fractures
1298415|NCT00774618|Non-healing rib fractures
1298416|NCT00774618|Rib Fracture Non-union
1298417|NCT00774605|percutaneous, transcutaneous, topical, varenicline, transdermal, transdermal delivery system, patch
1298418|NCT00774592|Adolescent Risk Reduction
1298419|NCT00774592|HIV/AIDS Prevention
1298420|NCT00774592|Behavioral Change
1298421|NCT00774592|HIV
1298422|NCT00774579|growth hormone
1298423|NCT00774579|growth hormone deficiency
1298424|NCT00774579|liver fat
1298425|NCT00774579|liver steatosis
1298426|NCT00774579|growth hormone replacement
1298427|NCT00774566|catheter ablation
1298428|NCT00774566|randomized
1298429|NCT00774566|cryo
1298430|NCT00774566|radiofrequency
1298431|NCT00774566|atrial fibrillation
1298432|NCT00774566|cryo-balloon
1298433|NCT00774566|PV-Isolation
1298434|NCT00774553|Type 2 diabetes
1298435|NCT00774540|Acute pain
1298436|NCT00774540|Inflammatory pain
1298437|NCT00774540|Inflammatory mediators
1298438|NCT00774540|Pain relief
1298439|NCT00774540|Microdialysis
1298440|NCT00774514|Air Pollution
1298441|NCT00774514|Nitrogen Dioxide
1298442|NCT00774514|NO2
1298443|NCT00774514|Endothelial dysfunction
1298444|NCT00774501|Anesthesia
1298445|NCT00774501|suspended ventilation
1298446|NCT00774488|Euglycemic-hyperinsulinemic clamp
1298447|NCT00774488|fat biopsies
1298448|NCT00774488|microarray analysis
1298449|NCT00774488|quantitative real time PCR
1298450|NCT00774488|overnutrition
1298451|NCT00774488|low grade-inflammation
1298452|NCT00774475|Clopidogrel therapy
1298453|NCT00774475|platelet function inhibition
1298454|NCT00774462|Myositis
1298455|NCT00774462|Anti-synthetase
1298456|NCT00774462|Anti-SRP
1298457|NCT00774462|Myasthenia gravis
1298458|NCT00774462|Rituximab
1298459|NCT00774449|lung transplantation
1298460|NCT00774449|bronchiolitis obliterans syndrome
1298461|NCT00774449|broncholaveolar lavage
1298462|NCT00774449|high-resolution computertomography
1298463|NCT00774449|quality of life
1298464|NCT00774436|focal cryotherapy
1298465|NCT00774436|low-risk prostate cancer
1298466|NCT00774423|Spinal muscular atrophies (SMA)
1298467|NCT00774423|Degeneration of the motor neurons
1298468|NCT00774423|Anterior horn of the spinal cord
1298469|NCT00774423|Riluzole
1298470|NCT00774384|Neisseria meningitidis
1298471|NCT00774384|Mucosal
1298472|NCT00774384|Vaccination
1298473|NCT00774384|Immunity
1298474|NCT00774384|T cells
1298475|NCT00774384|T regulatory cells
1298476|NCT00774371|Overweight
1298477|NCT00774371|Obese
1298478|NCT00774371|Breast cancer survivors
1298479|NCT00774371|Weight loss
1298480|NCT00774371|Physical activity
1298481|NCT00774371|Exercise
1298482|NCT00774371|Cognitive behavioral therapy
1298483|NCT00774358|Primary Immunodeficiency
1298484|NCT00774319|HNSCC
1298485|NCT00774319|neo Adjuvant
1298486|NCT00774319|Chemoradiation therapy
1298487|NCT00774319|TPF
1298488|NCT00774306|vascular risk
1298489|NCT00774306|lipid fractions
1298490|NCT00774306|lipoprotein(a)
1298491|NCT00774306|C-reactive protein
1298492|NCT00774306|subarachnoid hemorrhage
1298493|NCT00774306|antiepileptic drug
1298494|NCT00774306|randomized
1298495|NCT00774306|seizure
1298496|NCT00774306|cholesterol
1298497|NCT00774293|Homoeopathic treatment,
1298498|NCT00774293|heart surgery,
1298499|NCT00774293|randomized clinical trial
1298500|NCT00774254|Health Disparities
1298501|NCT00774254|Risk Communication
1298502|NCT00774254|Numeracy
1298503|NCT00774254|Doctor-Patient Communication
1298504|NCT00774254|Virtual Reality Technology
1298505|NCT00774254|Communication
1298506|NCT00774228|Cataract or intraocular lens placement surgery
1298507|NCT00774215|Pelvic Organ Prolapse
1298508|NCT00774215|Cystocele
1298509|NCT00774215|Rectocele
1298510|NCT00774215|Enterocele
1298511|NCT00774215|Synthetic Mesh
1298512|NCT00774215|Vaginal Mesh
1298513|NCT00774215|Transobturator
1298514|NCT00774202|Pts w/ Chronic ITP who have fail/relap after Rituxan rx
1298515|NCT00774189|Bioequivalence clarithromycin 250mg tablets fasting
1298527|NCT00774163|probiotics
1298528|NCT00774163|lactobacillus
1298529|NCT00774163|reuteri
1298530|NCT00774163|none (safety only)
1298531|NCT00774150|Neural correlates of pediatric anxiety disorder
1298532|NCT00774150|Social correlates of pediatric anxiety disorder
1298533|NCT00774150|Generalized Anxiety Disorder in pediatric populations
1298534|NCT00774150|Separation Anxiety Disorder in pediatric populations
1298535|NCT00774150|Social Phobia in pediatric populations
1298536|NCT00774137|Acute Kidney Injury
1298537|NCT00774137|IL-18
1298538|NCT00774137|NGAL
1298539|NCT00774137|Cystatin C
1298540|NCT00774137|Biomarkers
1298541|NCT00774137|Dialysis
1298542|NCT00774124|GDM, pregnancy, macrosomia
1298543|NCT00774111|healthy volunteer
1298544|NCT00774111|pharmacokinetics
1298545|NCT00774111|GSK1349572
1298546|NCT00774111|integrase
1298547|NCT00774111|etravirine
1298548|NCT00774098|all adult patients (>18 years) planned to undergo a major liver resection
1298549|NCT00774085|Schizophrenia
1298550|NCT00774085|Risperidone
1298551|NCT00774085|Risperdal Consta
1298552|NCT00774085|Propective
1298553|NCT00774085|Retrospective
1298554|NCT00774085|Mental disorders
1298555|NCT00774085|Observational
1298556|NCT00774072|subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways
1298557|NCT00774059|Breast ptosis, Breast lift
1298558|NCT00774046|Therapy-related myelodysplastic syndrome/ Therapy -related Acute myeloid leukemia
1298559|NCT00774046|Myelodysplastic syndrome
1298560|NCT00774046|Acute myeloid leukemia
1298561|NCT00774033|Keratinocytes
1298562|NCT00774033|Cell spray
1298563|NCT00774033|Deep partial thickness burns
1298564|NCT00774033|Full thickness burns
1298565|NCT00774020|Paget's Disease of Bone
1298566|NCT00774020|Serum Alkaline Phosphatase
1298567|NCT00774007|Irritable bowel syndrome, abdominal pain, abdominal bloating, immune cells, mast cells
1298568|NCT00773994|anterior palatal eminence
1298569|NCT00773994|palatal elevation above the maxillary plane
1298570|NCT00773994|anterior uvular prolapse
1298571|NCT00773994|"inverted-V present in base view."
1298572|NCT00773981|anastomotic leakage
1298573|NCT00773942|Medication therapy management
1298574|NCT00773942|Pharmacist
1298575|NCT00773942|Chronic care
1298576|NCT00773942|Medicare
1298577|NCT00773942|Medicaid
1298578|NCT00773942|Medication reconciliation
1298579|NCT00773942|Adverse drug events
1298580|NCT00773942|Drug related problems
1298581|NCT00773916|Attention Deficit Disorder
1298582|NCT00773916|Attention Deficit Disorders with Hyperactivity
1298583|NCT00773916|Hyperkinetic Syndrome
1298584|NCT00773916|Family Function
1298585|NCT00773916|Adverse Factors
1298586|NCT00773916|Parental Psychopathology
1298587|NCT00773877|RNFL thickness
1298588|NCT00773864|Healthcare employees who work in the rehabilitation center
1298589|NCT00773851|ventral hernia
1298590|NCT00773851|laparoscopy
1298591|NCT00773851|mesh
1298592|NCT00773851|recurrence
1298593|NCT00773825|Genomic imprinting
1298594|NCT00773825|Reproductive techniques, assisted
1298595|NCT00773825|Beckwith-Wiedemann syndrome
1298596|NCT00773825|Angelman syndrome
1298597|NCT00773812|Autistic Disorder
1298598|NCT00773812|Autism
1298599|NCT00773812|Mecamylamine
1298600|NCT00773812|Pervasive Developmental Disorder-Not Otherwise Specified
1298601|NCT00773799|To define activities and patient characteristics likely to lead to dissemination of resistant bacteria in rehabilitation centers and
1298602|NCT00773799|To define specific risk factors for acquisition of resistant bacteria (ESBL producers and MRSA) in rehabilitation centers.
1298603|NCT00773799|ESBL producers
1298604|NCT00773799|MRSA
1298605|NCT00773786|COPD
1298606|NCT00773786|Bronchodilator
1298607|NCT00773786|arformoterol
1298608|NCT00773786|tiotropium
1298609|NCT00773773|Biomarkers - PSA, hK2 and solubilized
1298610|NCT00773773|urokinase-receptor forms (su-PAR)
1298611|NCT00773773|08-114
1298612|NCT00773760|opioids
1298613|NCT00773760|COMT
1298614|NCT00773760|SNP
1298615|NCT00773760|analgesia
1298616|NCT00773760|postoperative pain
1298617|NCT00773747|Neoplasms, Plasma Cell
1298618|NCT00773747|Neoplasms by Histologic Type
1298619|NCT00773747|Neoplasms
1298620|NCT00773747|Hemostatic Disorders
1298621|NCT00773747|Vascular Diseases
1298622|NCT00773747|Cardiovascular Diseases
1298623|NCT00773747|Paraproteinemias
1298624|NCT00773747|Blood Protein Disorders
1298625|NCT00773747|Hematologic Diseases
1298626|NCT00773747|Hemorrhagic Disorders
1298627|NCT00773747|Lymphoproliferative Disorders
1298628|NCT00773747|Immunoproliferative Disorders
1298629|NCT00773747|Immune System Diseases
1298630|NCT00773747|Vorinostat
1298631|NCT00773747|Bortezomib
1298632|NCT00773747|Anti-Inflammatory Agents, Non-Steroidal
1298633|NCT00773747|Analgesics, Non-Narcotic
1298634|NCT00773747|Analgesics
1298635|NCT00773747|Sensory System Agents
1298636|NCT00773747|Peripheral Nervous System Agents
1298637|NCT00773747|Physiological Effects of Drugs
1298638|NCT00773747|Pharmacologic Actions
1298639|NCT00773747|Anti-Inflammatory Agents
1298640|NCT00773747|Therapeutic Uses
1298641|NCT00773747|Antirheumatic Agents
1298642|NCT00773747|Antineoplastic Agents
1298643|NCT00773747|Enzyme Inhibitors
1298644|NCT00773747|Molecular Mechanisms of Pharmacological Action
1298645|NCT00773747|Anticarcinogenic Agents
1298646|NCT00773734|moderate-to-severe plaque-type psoriasis
1298647|NCT00773708|HIV infection
1298648|NCT00773708|Discordant patient
1298649|NCT00773708|CD4 recovery
1298650|NCT00773708|intensification antiretroviral therapy
1298651|NCT00773708|raltegravir
1298652|NCT00773708|"HIV-1 infected patient classified as discordant who showed high level of CD8+HLADR+CD38+ and cell death values at the screening"
1298653|NCT00773682|osteoarthritis
1298654|NCT00773682|hands
1298655|NCT00773682|mud-packs therapy
1298656|NCT00773682|balneotherapy
1298657|NCT00773682|Osteoarthritis of the hands
1298658|NCT00773669|male breast cancer
1298659|NCT00773669|Male breast cancer patients diagnosed and/or
1298660|NCT00773669|treated at Summa Health System/Akron City Hospital
1298661|NCT00773669|from the reference year of 1995 through 2007.
1298662|NCT00773656|Radiotherapy
1298663|NCT00773656|Biologically effective dose
1298664|NCT00773656|Radiation injury
1298665|NCT00773643|to procure human temporalis muscle, subcutaneous adipose (fat), and bone tissue samples from children with craniosynostosis,
1298666|NCT00773643|to grow cells from these tissues in vitro
1298667|NCT00773643|to evaluate the osteogenic potentials of these cell types.
1298668|NCT00773617|Bulimia Nervosa
1298669|NCT00773617|Treatment Efficacy
1298670|NCT00773617|Integrative Cognitive Affective Therapy
1298671|NCT00773617|Cognitive Behavior Therapy
1298672|NCT00773604|blepharospasm
1298673|NCT00773604|Deep brain Stimulation
1298674|NCT00773604|cervical dystonia
1298675|NCT00773604|cranial dystonia
1298676|NCT00773604|generalized dystonia
1298677|NCT00773604|subthalamic nucleus
1298678|NCT00773604|DBS
1298679|NCT00773591|Sleep-related breathing disorders
1298680|NCT00773591|Snoring
1298681|NCT00773578|Children
1298682|NCT00773578|Tobacco smoke exposure
1298683|NCT00773578|Exhaled nitric oxide
1298684|NCT00773578|Nasal lavage
1298685|NCT00773578|Cytokines
1298686|NCT00773565|patients with obesity (BMI > 30 kg/m2)
1298687|NCT00773552|OAB
1298688|NCT00773552|overactive bladder
1298689|NCT00773552|urinary urge
1298690|NCT00773552|urge incontinence
1298691|NCT00773552|urge
1298692|NCT00773539|atrial fibrillation
1298693|NCT00773539|pulmonary veins
1298694|NCT00773539|ablation
1298695|NCT00773500|Medication Errors
1298696|NCT00773487|Asthma GINA 1
1298697|NCT00773487|Mild intermittant asthma
1298698|NCT00773448|Cancer
1298699|NCT00773448|Screening
1298700|NCT00773435|Upper respiratory tract infections
1298701|NCT00773435|Children
1298702|NCT00773435|Echinacea
1298703|NCT00773435|Prevention
1298704|NCT00773435|Immune modulation
1298705|NCT00773422|smoking lapse behavior
1298706|NCT00773422|smoking cessation
1298707|NCT00773422|varenicline
1298708|NCT00773422|naltrexone
1298709|NCT00773422|medication effect on smoking lapse behavior
1298710|NCT00773370|stroke
1298711|NCT00773370|exercise
1298720|NCT00773344|Solid Tumors (dose escalation/Phase 1)
1298721|NCT00773344|Breast Cancer (recommended dose phase/Phase 2)
1298722|NCT00773318|LM/SL
1298723|NCT00773318|SPECT/low-dose multislice CT
1298724|NCT00773305|seed implantation
1298725|NCT00773292|HAM/TSP
1298726|NCT00773266|Aphakia
1298727|NCT00773266|Secondary IOL-Implantation
1298728|NCT00773266|Iris-Fixated IOL
1298729|NCT00773266|Artisan
1298730|NCT00773266|Anterior Segment OCT
1298731|NCT00773266|Aphakia - secondary iris-fixated IOL position
1298732|NCT00773253|dystonia
1298733|NCT00773253|cervical dystonia
1298734|NCT00773253|Botox
1298735|NCT00773253|idiopathic primary cervical dystonia
1298736|NCT00773227|Oculopharyngeal muscular dystrophy
1298737|NCT00773227|Swallowing disorders, dysphagia
1298738|NCT00773227|Pharyngeal propulsion
1298739|NCT00773227|Upper oesophageal sphincter
1298740|NCT00773227|Cricopharyngeal muscle
1298741|NCT00773227|Autologous myoblasts
1298742|NCT00773227|Autograft
1298743|NCT00773227|Myotomy of the upper oesophageal sphincter
1298744|NCT00773227|Fibroscopy of swallowing
1298745|NCT00773227|Videofluoroscopy of swallowing
1298746|NCT00773214|Obesity
1298747|NCT00773214|Appetite
1298748|NCT00773214|Body composition
1298749|NCT00773214|Energy compensation
1298750|NCT00773201|Long QT syndrome
1298751|NCT00773201|Cardiac repolarisation
1298752|NCT00773201|Genome-wide association
1298753|NCT00773201|Electrophysiology
1298754|NCT00773201|Drugs/adverse effects
1298755|NCT00773175|pediatric
1298756|NCT00773175|hylenex
1298757|NCT00773175|subcutaneous infusion
1298758|NCT00773175|hyaluronidase
1298759|NCT00773175|rHuPH20
1298760|NCT00773175|recombinant human hyaluronidase
1298761|NCT00773149|Adult Acute Lymphocytic Leukemia
1298762|NCT00773149|Alemtuzumab
1298763|NCT00773136|Bimatoprost
1298764|NCT00773136|Eyelash lengthening
1298765|NCT00773136|Prostaglandin Analogs
1298766|NCT00773136|Cosmetics
1298767|NCT00773123|RT-View
1298768|NCT00773123|Spectral domain OCT
1298769|NCT00773123|Ganglion cell layer
1298770|NCT00773123|RNFL
1298771|NCT00773123|Visual field defect
1298772|NCT00773110|hemolysis
1298773|NCT00773110|systemic inflammatory response syndrome
1298774|NCT00773110|cardiopulmonary bypass
1298775|NCT00773110|albumin
1298776|NCT00773097|Prevention
1298777|NCT00773097|Colorectal Cancer
1298778|NCT00773084|Diastolic Heart Failure
1298779|NCT00773084|Hispanic Americans
1298780|NCT00773084|Aliskiren
1298781|NCT00773084|Spironolactone
1298782|NCT00773084|Lisinopril
1298783|NCT00773084|Diastolic Heart Failure in Hispanic Americans
1298784|NCT00773071|Cervical cancer, vulvar cancer, LM/SL, SPECT/CT
1298785|NCT00773058|acute respiratory distress syndrome
1298786|NCT00773058|glucocorticoid
1298787|NCT00773058|adrenal insufficiency
1298788|NCT00773045|pain scores
1298789|NCT00773045|critically ill patients
1298790|NCT00773045|ICU
1298791|NCT00773045|pain management
1298792|NCT00773045|pain measurement
1298793|NCT00773019|infusion pump
1298794|NCT00773019|implantable
1298795|NCT00773019|performance
1298796|NCT00773006|coronary artery disease
1298797|NCT00773006|percutaneous coronary intervention
1298798|NCT00773006|anticoagulation
1298799|NCT00772993|glaucoma
1298800|NCT00772993|myopia
1298801|NCT00772993|myopia with glaucoma
1298802|NCT00772993|normal control
1298803|NCT00772954|Clostridium difficile diarrhea
1298804|NCT00772954|Clostridium difficile toxoid vaccine
1298805|NCT00772928|Pertussis
1298806|NCT00772928|Whooping cough
1298807|NCT00772928|Diphtheria
1298808|NCT00772928|Tetanus
1298809|NCT00772928|Haemophilus influenzae
1298810|NCT00772928|Poliovirus Types 1, 2, and 3.
1298811|NCT00772915|stage I multiple myeloma
1298812|NCT00772915|stage II multiple myeloma
1298813|NCT00772915|stage III multiple myeloma
1298814|NCT00772902|HIV-1
1298815|NCT00772902|LDL
1298816|NCT00772902|HDL
1298817|NCT00772902|non-HDL cholesterol
1298818|NCT00772902|triglycerides
1298819|NCT00772902|cholesterol
1298820|NCT00772889|Elderly
1298821|NCT00772889|Vaccine
1298822|NCT00772889|Influenza
1298823|NCT00772876|P1446A-05
1298824|NCT00772876|Advanced refractory malignancies
1298825|NCT00772876|Phase I
1298826|NCT00772850|Humeral fracture; Antegrade nailing; Rotator cuff
1298827|NCT00772837|Functional Dyspepsia
1298828|NCT00772837|Helicobacter Pylori eradication
1298829|NCT00772837|Quality of Life
1298830|NCT00772837|Dyspeptic Symptoms
1298831|NCT00772824|Breast cancer
1298832|NCT00772824|Chemotherapy
1298833|NCT00772824|Epirubicin
1298834|NCT00772824|Glutamine
1298835|NCT00772824|FEC chemotherapy
1298836|NCT00772798|ovarian cancer
1298837|NCT00772798|HDAC inhibitor
1298838|NCT00772798|vorinostat
1298839|NCT00772785|opioid dependence
1298840|NCT00772785|opioid addiction
1298841|NCT00772785|buprenorphine
1298842|NCT00772785|methadone
1298843|NCT00772785|heroin
1298844|NCT00772785|implant
1298845|NCT00772785|opioid withdrawal
1298846|NCT00772785|opioid pain medication
1298847|NCT00772785|suboxone
1298848|NCT00772772|Vitamin D3 repletion
1298849|NCT00772772|levels of endotoxin
1298850|NCT00772772|intestinal permeability
1298851|NCT00772772|accelerated atherosclerosis
1298852|NCT00772759|AZD3199
1298853|NCT00772759|Japanese Healthy Volunteers
1298854|NCT00772759|Phase I study
1298855|NCT00772759|Single and Multiple Ascending Dose
1298856|NCT00772759|safety
1298857|NCT00772759|tolerability
1298858|NCT00772759|PK
1298859|NCT00772746|panic
1298860|NCT00772746|respiration
1298861|NCT00772746|anxiety
1298862|NCT00772746|exercise
1298863|NCT00772746|cognition
1298864|NCT00772733|Quality assurance
1298865|NCT00772733|rehabilitation
1298866|NCT00772733|chronic care model
1298867|NCT00772733|COPD
1298868|NCT00772707|contact lens solution
1298869|NCT00772707|OPTI-FREE RepleniSH
1298870|NCT00772707|contact lenses
1298871|NCT00772694|testicular cancer
1298872|NCT00772694|germ cell cancer
1298873|NCT00772694|sorafenib
1298874|NCT00772668|stage III grade 1 follicular lymphoma
1298875|NCT00772668|stage IV grade 1 follicular lymphoma
1298876|NCT00772668|stage III grade 2 follicular lymphoma
1298877|NCT00772668|stage IV grade 2 follicular lymphoma
1298878|NCT00772668|stage III marginal zone lymphoma
1298879|NCT00772668|stage IV marginal zone lymphoma
1298880|NCT00772655|Follicular Lymphoma
1298881|NCT00772655|First line therapy
1298882|NCT00772655|Zevalin
1298883|NCT00772655|90Yttrium-Ibritumomab Tiuxetan
1298884|NCT00772655|Yttrium
1298885|NCT00772655|Rituximab
1298886|NCT00772655|Radio-immuno therapy
1298887|NCT00772642|Cross-Sectional
1298888|NCT00772642|Plasmodium Falciparum Malaria
1298889|NCT00772642|Cord Blood
1298890|NCT00772642|Immunology
1298891|NCT00772642|Mali
1298892|NCT00772642|Malaria
1298893|NCT00772629|Menactra®
1298894|NCT00772629|Meningitis
1298895|NCT00772629|Meningococcemia
1298896|NCT00772629|Neisseria meningitidis
1298897|NCT00772616|Anesthesia
1298898|NCT00772616|Analgesia
1298899|NCT00772616|Patient-Controlled Analgesia
1298900|NCT00772616|Hyperalgesia
1298901|NCT00772603|Partial onset epilepsy
1298902|NCT00772603|Partial onset seizures
1298903|NCT00772590|HIV
1298904|NCT00772590|antiretroviral therapy intensification
1298905|NCT00772590|suboptimal CD4+ T cell response
1298906|NCT00772590|virological suppression
1298907|NCT00772590|bovine colostrum
1298908|NCT00772590|raltegravir
1298909|NCT00772577|Hypertension, Obese, aliskiren, hydrochlorothiazide, systolic blood pressure, diastolic blood pressure, ramipril, stage 2
1298910|NCT00772564|Acute ST Elevation Myocardial Infarction
1298911|NCT00772525|Visual acuity
1298912|NCT00772525|Contrast sensitivity
1298913|NCT00772525|Visual Evoked Potentials
1298914|NCT00772525|Optical Coherence Tomography
1298915|NCT00772512|PF-04802540, polysomnography, REM, cross over
1298916|NCT00772486|Chronic lymphocytic leukemia
1298917|NCT00772486|Leukemia
1298918|NCT00772486|Leukemia, Lymphocytic, Chronic, B-Cell
1298919|NCT00772486|Leukemia, B-Cell
1298920|NCT00772486|Immune System Diseases
1298921|NCT00772486|Rituximab
1298922|NCT00772486|Fludarabine
1298923|NCT00772486|Cyclophosphamide
1298924|NCT00772486|ISF35
1298925|NCT00772486|Ad-ISF35
1298926|NCT00772486|Refractory
1298927|NCT00772486|Resistant
1298928|NCT00772486|17p-
1298929|NCT00772486|del 17p
1298930|NCT00772486|17p
1298931|NCT00772486|Resistant CLL
1298932|NCT00772486|Refractory CLL
1298933|NCT00772486|17p- CLL
1298934|NCT00772486|CLL
1298935|NCT00772460|patient warming
1298936|NCT00772460|convective warming
1298937|NCT00772460|conductive warming
1298938|NCT00772460|intraoperative normothermia
1298939|NCT00772460|accidental hypothermia
1298940|NCT00772460|intraoperative hypothermia
1298941|NCT00772447|Skin Infections
1298942|NCT00772447|Complicated Bacterial Skin and Skin Structure Infection due to Gram-positive Pathogens
1298943|NCT00772421|Epilepsy
1298944|NCT00772421|Recruitment rhythm
1298945|NCT00772421|DBS
1298946|NCT00772408|pulmonary tuberculosis
1298947|NCT00772408|Toll-like receptor 2 gene polymorphisms
1298948|NCT00772408|blood lymphocyte subsets
1298949|NCT00772408|systemic symptoms
1298950|NCT00772408|pleural effusion
1298951|NCT00772395|Periprosthetic bone loss risedronate bisphosphonates
1298952|NCT00772382|Chronic Kidney Disease
1298953|NCT00772382|Dialysis
1298954|NCT00772382|Hyperphosphatemia
1298955|NCT00772382|Phosphate binder
1298956|NCT00772369|Pertussis
1298957|NCT00772369|Whooping cough
1298958|NCT00772369|Diphtheria
1298959|NCT00772369|Tetanus
1298960|NCT00772369|Haemophilus influenzae
1298961|NCT00772369|Poliovirus Types 1, 2, and 3.
1298962|NCT00772343|Diarrhea
1298963|NCT00772343|Clostridium difficile infection
1298964|NCT00772343|Clostridium difficile toxoid
1298965|NCT00772330|MIDI Arrow
1298966|NCT00772330|Glaucoma Drainage Device
1298967|NCT00772330|GDD
1298968|NCT00772330|InnFocus
1298969|NCT00772330|Glaucoma treatment
1298970|NCT00772317|Recurrent
1298971|NCT00772317|prostate cancer
1298972|NCT00772317|ebrt
1298973|NCT00772317|hifu
1298974|NCT00772304|rhinitis
1298975|NCT00772291|inguinal
1298976|NCT00772291|hernia
1298977|NCT00772291|chronic
1298978|NCT00772291|pain
1298979|NCT00772291|pregabalin
1298980|NCT00772291|chronic pain after inguinal herniorraphy
1298981|NCT00772278|carotid stenosis
1298982|NCT00772278|asymptomatic
1298983|NCT00772278|carotid stenting
1298984|NCT00772278|carotid endarterectomy
1298985|NCT00772265|Bioequivalence
1298986|NCT00772265|pharmacokinetic
1298987|NCT00772265|Pharmacodynamic
1298988|NCT00772265|Isophane insulin
1298989|NCT00772252|Liver support treatment
1298990|NCT00772239|Coagulation Management
1298991|NCT00772239|Cardiac surgery
1298992|NCT00772239|Bleeding
1298993|NCT00772239|Rotem
1298994|NCT00772226|laparoscopic cholecystectomy
1298995|NCT00772226|pain
1298996|NCT00772226|PONV
1298997|NCT00772226|music
1298998|NCT00772226|therapy
1298999|NCT00772226|fatigue after elective laparoscopic cholecystectomy
1299000|NCT00772213|multiple trauma
1299001|NCT00772213|outcome and process assessment
1299002|NCT00772187|Laparoscopic surgery (general surgery).
1299003|NCT00772174|Glucose Metabolism Disorder
1299004|NCT00772174|Dysmetabolic Syndrome
1299005|NCT00772174|Type II Diabetes
1299006|NCT00772174|Diabetes Mellitus, Lipoatrophic
1299007|NCT00772174|Dyslipidemia
1299008|NCT00772174|Drug Therapy
1299009|NCT00772161|ADHD
1299010|NCT00772161|Attention Deficit Disorder
1299011|NCT00772161|Attention Deficit an Disruptive Behavior Disorders
1299012|NCT00772161|Children
1299013|NCT00772161|Central Nervous System Stimulants
1299014|NCT00772161|Methylphenidate
1299015|NCT00772161|Pharmacokinetics
1299016|NCT00772161|Area Under Curve
1299017|NCT00772161|Therapeutic Equivalency
1299018|NCT00772161|Psychopharmacology
1299019|NCT00772148|Liver
1299020|NCT00772148|Hepatic
1299021|NCT00772148|Transplantation
1299022|NCT00772148|Immunosuppression
1299023|NCT00772148|Tacrolimus
1299024|NCT00772148|Prograf
1299025|NCT00772135|pulmonary hypertension
1299026|NCT00772135|congenital heart defects
1299027|NCT00772135|exercise
1299028|NCT00772135|phosphodiesterase inhibitors
1299029|NCT00772135|Exercise induced pulmonary arterial hypertensive response in congenital heart disease
1299030|NCT00772122|Recurrent Miscarriage
1299031|NCT00772122|G-CSF
1299032|NCT00772122|pregnancy outcome
1299033|NCT00772122|pregnancy outcome of pregnancies treated with G-CSF
1299034|NCT00772122|treatment of recurrent miscarriage
1299035|NCT00772109|Influenza
1299036|NCT00772109|Orthomyxoviruses
1299037|NCT00772109|Inactivated Split-virion influenza vaccine
1299038|NCT00772109|Fluzone®
1299039|NCT00772109|Adults
1299040|NCT00772070|Menactra®
1299041|NCT00772070|Menomune®
1299042|NCT00772070|Meningitis
1299043|NCT00772070|Meningococcemia
1299044|NCT00772070|Neisseria meningitidis
1299045|NCT00772044|OSA
1299046|NCT00772044|sleep apnea
1299047|NCT00772044|apnea
1299048|NCT00772044|AHI
1299049|NCT00772031|chronic migraine, migraine prevention, chronic headache
1299050|NCT00772018|stage 0 bladder cancer
1299051|NCT00771992|Asthma GINA 1
1299052|NCT00771979|Healthy Volunteers
1299053|NCT00771979|Relative Bioavailability
1299054|NCT00771966|patients with cancer in the prostate
1299055|NCT00771953|apricoxib
1299056|NCT00771953|docetaxel
1299057|NCT00771953|pemetrexed
1299058|NCT00771953|Stage IIIb or Stage IV
1299059|NCT00771927|Vimpat®
1299060|NCT00771927|Lacosamide
1299061|NCT00771927|LCM
1299062|NCT00771927|epilepsy
1299063|NCT00771927|epilepsies
1299064|NCT00771927|seizure
1299065|NCT00771927|partial seizure
1299066|NCT00771927|partial onset
1299067|NCT00771927|seizure disorder
1299068|NCT00771927|single seizure
1299069|NCT00771927|motor seizure
1299070|NCT00771927|convulsions
1299071|NCT00771927|add-on
1299072|NCT00771927|AED
1299073|NCT00771927|anti-epileptic
1299074|NCT00771927|anti-epileptic drug
1299075|NCT00771927|seizure control
1299076|NCT00771927|open-label
1299077|NCT00771927|post authorization
1299078|NCT00771927|PASS
1299079|NCT00771927|late stage
1299080|NCT00771927|trial
1299081|NCT00771927|study
1299082|NCT00771927|phase 4
1299083|NCT00771927|phase IV
1299084|NCT00771914|aspirin
1299085|NCT00771914|omega 3 fatty acids
1299086|NCT00771914|Lovaza
1299087|NCT00771914|myocardial infarction
1299088|NCT00771914|aspirin resistance
1299089|NCT00771914|cardiovascular disease
1299090|NCT00771901|obesity
1299091|NCT00771901|insulin resistance
1299092|NCT00771901|type II diabetes
1299093|NCT00771862|pain
1299094|NCT00771862|amputation
1299095|NCT00771862|phantom limb
1299096|NCT00771862|stump pain
1299097|NCT00771862|catheter
1299098|NCT00771862|nerve block
1299099|NCT00771862|peripheral nerve block
1299100|NCT00771862|ucsd
1299101|NCT00771862|post-amputation phantom limb or stump pain
1299102|NCT00771849|Meningitis
1299103|NCT00771849|Meningococcemia
1299104|NCT00771849|Neisseria meningitidis
1299105|NCT00771836|Stem cell transplantation
1299106|NCT00771836|Airway hyper-reactivity
1299107|NCT00771836|methacholine
1299108|NCT00771836|pediatric
1299109|NCT00771810|Ovarian Cancer
1299110|NCT00771810|Thrombocytopenia
1299111|NCT00771810|Cytopenia
1299112|NCT00771810|Chemotherapy
1299113|NCT00771797|PAOD
1299114|NCT00771797|diabetis
1299115|NCT00771797|vascular function
1299116|NCT00771797|in diabetics with PAOD
1299117|NCT00771784|Endotracheal intubation
1299118|NCT00771784|tracheostomy
1299119|NCT00771784|laryngeal mask
1299120|NCT00771771|Stroke
1299121|NCT00771771|Rehabilitation
1299122|NCT00771771|Early Supported Discharge
1299123|NCT00771771|ESD
1299124|NCT00771771|RCT
1299125|NCT00771758|Vertebral compression fracture
1299126|NCT00771758|Osteoporosis
1299127|NCT00771758|Acute pain
1299128|NCT00771758|Analgesic
1299129|NCT00771758|Oxycodone
1299130|NCT00771758|Tapentadol
1299131|NCT00771732|toe nail fungus
1299132|NCT00771719|VAP
1299133|NCT00771706|Pediatric Cough, Quality of Life
1299134|NCT00771706|Drug (including placebo)
1299135|NCT00771693|NIDDM
1299136|NCT00771693|Platelet Activation
1299137|NCT00771693|Postprandial hyperglycemia
1299138|NCT00771693|insulin
1299139|NCT00771667|Interleukin-12
1299140|NCT00771667|Inflammation
1299141|NCT00771667|Research study
1299142|NCT00771667|Ustekinumab
1299143|NCT00771667|CNTO1275
1299144|NCT00771667|Interleukin-23
1299145|NCT00771641|stage III squamous cell carcinoma of the lip and oral cavity
1299146|NCT00771641|stage IV squamous cell carcinoma of the lip and oral cavity
1299147|NCT00771641|stage II squamous cell carcinoma of the oropharynx
1299148|NCT00771641|stage II lymphoepithelioma of the oropharynx
1299149|NCT00771641|stage III squamous cell carcinoma of the oropharynx
1299150|NCT00771641|stage III lymphoepithelioma of the oropharynx
1299151|NCT00771641|stage IV squamous cell carcinoma of the oropharynx
1299152|NCT00771641|stage IV lymphoepithelioma of the oropharynx
1299153|NCT00771641|stage II squamous cell carcinoma of the hypopharynx
1299154|NCT00771641|stage III squamous cell carcinoma of the hypopharynx
1299155|NCT00771641|stage IV squamous cell carcinoma of the hypopharynx
1299156|NCT00771641|stage III squamous cell carcinoma of the larynx
1299157|NCT00771641|stage IV squamous cell carcinoma of the larynx
1299158|NCT00771628|Intubation, Flex-It, stylet, GlideScope
1299159|NCT00771615|human
1299160|NCT00771615|Avian
1299161|NCT00771615|safety
1299162|NCT00771615|vaccines
1299163|NCT00771615|influenza
1299164|NCT00771615|pandemic
1299165|NCT00771615|immunogenicity
1299166|NCT00771615|H5N1
1299167|NCT00771602|Chronic Lymphocytic Leukemia
1299168|NCT00771602|Leukemia
1299169|NCT00771602|CLL
1299170|NCT00771602|PLL
1299171|NCT00771602|SLL
1299172|NCT00771602|Rituximab
1299173|NCT00771602|Rituxan
1299174|NCT00771602|Alemtuzumab
1299175|NCT00771602|Campath
1299176|NCT00771563|Non-Small Cell Lung Cancer
1299177|NCT00771563|chemotherapy
1299178|NCT00771563|Low Molecular Weight Heparin
1299179|NCT00771537|HIV Testing
1299180|NCT00771537|Persuasion
1299181|NCT00771537|Health Communication
1299182|NCT00771537|Clinical Trials Participation
1299183|NCT00771537|Attitudes toward Health
1299184|NCT00771537|Diagnostic Tests
1299185|NCT00771537|Behavioral Research
1299186|NCT00771537|Intervention Studies
1299187|NCT00771524|Pharmacokinetics
1299188|NCT00771524|Hip replacement
1299189|NCT00771524|Ceftobiprole
1299190|NCT00771498|rifampin
1299191|NCT00771498|lopinavir
1299192|NCT00771498|drug interaction
1299193|NCT00771498|pharmacokinetic
1299194|NCT00771459|Local infiltration analgesia
1299195|NCT00771459|postoperative pain
1299196|NCT00771459|ropivacaine
1299197|NCT00771446|Hepatitis, acute
1299198|NCT00771446|Acute Hepatitis OR Chronic Hepatitis
1299199|NCT00771433|neutropenia
1299200|NCT00771433|chemotherapeutic agent toxicity
1299201|NCT00771433|recurrent breast cancer
1299202|NCT00771433|stage I breast cancer
1299203|NCT00771433|stage II breast cancer
1299204|NCT00771433|stage IIIA breast cancer
1299205|NCT00771433|stage IIIB breast cancer
1299206|NCT00771433|stage IIIC breast cancer
1299207|NCT00771433|stage IV breast cancer
1299208|NCT00771407|Ostomy creation
1299209|NCT00771407|Parastomal hernia
1299210|NCT00771394|Vesicare
1299211|NCT00771394|Solifenacin succinate
1299212|NCT00771394|Tamsulosin
1299213|NCT00771394|Overactive Bladder
1299214|NCT00771394|BPH
1299215|NCT00771381|18F-FAZA
1299216|NCT00771381|18F-FDG
1299217|NCT00771381|Positron Emission Tomography
1299218|NCT00771381|Cell Hypoxia
1299219|NCT00771303|Pregnancy
1299220|NCT00771303|Pulmonary embolism
1299221|NCT00771303|MSCT
1299222|NCT00771290|Rectal sparing
1299223|NCT00771290|Colon cancer
1299224|NCT00771277|Brain Injuries
1299225|NCT00771277|Caregivers
1299226|NCT00771277|Volunteer Workers
1299227|NCT00771277|Social Networks
1299228|NCT00771264|Overactive Bladder
1299229|NCT00771251|Rheumatoid arthritis
1299230|NCT00771251|Fully Human anti-TNFa monoclonal antibody
1299231|NCT00771251|CNTO148
1299232|NCT00771251|Golimumab
1299233|NCT00771238|pressure ulcers
1299234|NCT00771238|Therapy mattresses
1299235|NCT00771238|Incidence of pressure ulcers
1299236|NCT00771225|genital prolapse
1299237|NCT00771225|surgery
1299238|NCT00771225|fascial repair
1299239|NCT00771225|mesh
1299240|NCT00771225|prolift
1299241|NCT00771212|Pain
1299242|NCT00771212|Observational
1299243|NCT00771212|Taiwan
1299244|NCT00771199|Cancer pain
1299245|NCT00771199|Pain
1299246|NCT00771199|Fentanyl
1299247|NCT00771199|Durogesic
1299248|NCT00771199|Cancer
1299249|NCT00771199|Transdermal
1299250|NCT00771186|pediatric
1299251|NCT00771186|Laryngeal EMG
1299252|NCT00771173|Phenazopyrdine
1299253|NCT00771173|post operative bladder catheritization
1299254|NCT00771173|VAS scores
1299255|NCT00771173|Bladder pain related to indwelling foley catheters.
1299256|NCT00771173|Bladder irritaion related to indwelling foley catheters.
1299257|NCT00771147|Advanced Renal Cell Carcinoma ( RCC)
1299258|NCT00771134|Depression
1299259|NCT00771134|Bipolar I Disorder
1299260|NCT00771134|Bipolar II Disorder
1299261|NCT00771134|Placebo-controlled
1299262|NCT00771134|Double-blind
1299263|NCT00771134|Randomised controlled
1299264|NCT00771134|Multicenter
1299265|NCT00771134|Clinical study
1299266|NCT00771134|Mania
1299267|NCT00771108|NAFLD
1299268|NCT00771108|Obesity
1299269|NCT00771108|Metabolic Syndrome
1299270|NCT00771108|Nonalcoholic Fatty Liver Disease
1299271|NCT00771095|weight loss
1299272|NCT00771095|elaboration
1299273|NCT00771095|self efficacy
1299274|NCT00771082|inflammatory markers
1299275|NCT00771082|bone markers
1299276|NCT00771082|OA
1299277|NCT00771069|Hypertension
1299278|NCT00771069|Type II DM
1299279|NCT00771069|DM related complication
1299280|NCT00771069|JNC7
1299281|NCT00771069|2007 ESH-ESC guidelines
1299282|NCT00771069|survey
1299283|NCT00771056|untreated
1299284|NCT00771017|adenocarcinoma of the prostate
1299285|NCT00771017|recurrent prostate cancer
1299286|NCT00771017|stage II prostate cancer
1299287|NCT00771017|stage III prostate cancer
1299288|NCT00771017|stage I prostate cancer
1299289|NCT00771004|drug effects
1299290|NCT00771004|Type II Diabetes
1299291|NCT00771004|Angioplasty, Transluminal, Percutaneous Coronary
1299292|NCT00771004|Drug Therapy
1299293|NCT00771004|Heart
1299294|NCT00771004|physiology
1299295|NCT00771004|function
1299296|NCT00770991|Polyp, Familial Adenomatous Polyposis, Prevention
1299297|NCT00770978|ICU
1299298|NCT00770965|Plaque psoriasis, skin condition, thickening, flaking, skin disease, autoimmune disease
1299299|NCT00770952|Glucose Metabolism Disorder
1299300|NCT00770952|Dysmetabolic Syndrome
1299301|NCT00770952|Type II Diabetes
1299302|NCT00770952|Diabetes Mellitus, Lipoatrophic
1299303|NCT00770952|Dyslipidemia
1299304|NCT00770952|Drug Therapy
1299305|NCT00770939|Complete healing of chronic diabetic foot ulcers
1299306|NCT00770939|Platelet Rich Fibrin
1299307|NCT00770939|Vivostat
1299308|NCT00770939|Growth factor treatment
1299309|NCT00770939|Treatment of chronic diabetic foot ulcers
1299310|NCT00770926|risk reduction
1299311|NCT00770926|minority
1299312|NCT00770926|diabetes prevention
1299313|NCT00770926|lifestyle program
1299314|NCT00770926|behavior change
1299315|NCT00770913|reflux esophagitis
1299316|NCT00770913|rabeprazole
1299317|NCT00770913|GERD
1299318|NCT00770913|Japan
1299319|NCT00770887|Undesired fertility
1299320|NCT00770861|nebivolol
1299321|NCT00770861|Bystolic ™
1299322|NCT00770861|Hypertension
1299323|NCT00770861|Hispanic
1299324|NCT00770861|Hypertension in Hispanic patients
1299325|NCT00770848|CRPC
1299326|NCT00770835|Glucose Metabolism Disorder
1299327|NCT00770835|Dysmetabolic Syndrome
1299328|NCT00770835|Type II Diabetes
1299329|NCT00770835|Diabetes Mellitus, Lipoatrophic
1299330|NCT00770835|Dyslipidemia
1299331|NCT00770835|Drug Therapy
1299332|NCT00770822|Primary
1299333|NCT00770822|Prostate
1299334|NCT00770822|Cancer
1299335|NCT00770822|Primary T1c/T2a organ confined prostate cancer
1299336|NCT00770822|organ-confined
1299337|NCT00770796|Contrast induced nephropathy
1299338|NCT00770770|Macular edema secondary to RVO
1299339|NCT00770744|Schizophrenia
1299340|NCT00770744|Antipsychotic
1299341|NCT00770744|Olanzapine
1299342|NCT00770744|Lu 31-130
1299343|NCT00770731|Torisel
1299344|NCT00770731|Temsirolimus
1299345|NCT00770731|Hycamtin
1299346|NCT00770731|Topotecan hydrochloride
1299347|NCT00770731|Velcade
1299348|NCT00770731|Bortezomib
1299349|NCT00770731|FDG-PET Scans
1299350|NCT00770731|18F-Fluoro-2-Deoxyglucose Positron Emission Tomography
1299351|NCT00770718|intracranial hemorrhage
1299352|NCT00770718|warfarin
1299353|NCT00770718|anticoagulant
1299354|NCT00770718|Factor VII
1299355|NCT00770718|Prothrombin
1299356|NCT00770692|insomnia
1299357|NCT00770692|primary insomnia
1299358|NCT00770692|insomnia associated with psychiatric or physical disorder(s)
1299359|NCT00770666|Tobacco dependence treatment
1299360|NCT00770653|Glucose Metabolism Disorder
1299361|NCT00770653|Dysmetabolic Syndrome
1299362|NCT00770653|Type II Diabetes
1299363|NCT00770653|Diabetes Mellitus, Lipoatrophic
1299364|NCT00770653|Dyslipidemia
1299365|NCT00770653|Hyperlipidemias
1299366|NCT00770653|Drug Therapy
1299367|NCT00770640|Glucose Metabolism Disorder
1299368|NCT00770640|Dysmetabolic Syndrome
1299369|NCT00770640|Type II Diabetes
1299370|NCT00770640|Diabetes Mellitus, Lipoatrophic
1299371|NCT00770640|Dyslipidemia
1299372|NCT00770640|Drug Therapy
1299373|NCT00770627|160 children
1299374|NCT00770627|parallel group
1299375|NCT00770614|Contrast Induced Nephropathy
1299376|NCT00770601|NOMID
1299377|NCT00770601|CINCA Syndrome
1299378|NCT00770601|Canakinumab
1299379|NCT00770588|non-small cell lung cancer (NSCLC)
1299380|NCT00770588|Gefitinib
1299381|NCT00770575|Biological Markers
1299382|NCT00770575|Biochemical Markers
1299383|NCT00770575|Carotid Artery, Internal
1299384|NCT00770575|Carotid Artery, Common
1299385|NCT00770575|Marker, Surrogate
1299386|NCT00770575|Vascular Diseases
1299387|NCT00770575|Diabetes Mellitus
1299388|NCT00770575|Drug Therapy
1299389|NCT00770536|fallopian tube cancer
1299390|NCT00770536|Gynecological Malignancy
1299391|NCT00770536|primary peritoneal cancer of predominantly epithelial origin
1299392|NCT00770536|Stage II to IV ovarian cancer
1299393|NCT00770523|patients without comorbidity
1299394|NCT00770510|Primary insomnia
1299395|NCT00770497|drug effects
1299396|NCT00770497|Hypertension
1299397|NCT00770497|Vascular Resistance
1299398|NCT00770497|Drug Therapy
1299399|NCT00770497|physiopathology, vascular
1299400|NCT00770484|Exercise
1299401|NCT00770484|Propanolol
1299402|NCT00770484|Beta blockers
1299403|NCT00770471|adult glioblastoma
1299404|NCT00770471|adult gliosarcoma
1299405|NCT00770471|adult giant cell glioblastoma
1299406|NCT00770458|Down Syndrome
1299407|NCT00770445|Glucose Metabolism Disorder
1299408|NCT00770445|Dysmetabolic Syndrome
1299409|NCT00770445|Type II Diabetes
1299410|NCT00770445|Diabetes Mellitus, Lipoatrophic
1299411|NCT00770445|Dyslipidemia
1299412|NCT00770445|Drug Therapy
1299413|NCT00770432|Human Experimentation
1299414|NCT00770419|depression
1299415|NCT00770419|psychosocial effects of cancer and its treatment
1299416|NCT00770419|unspecified adult solid tumor, protocol specific
1299417|NCT00770419|acute undifferentiated leukemia
1299418|NCT00770419|adult acute lymphoblastic leukemia in remission
1299419|NCT00770419|adult acute myeloid leukemia in remission
1299420|NCT00770419|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1299421|NCT00770419|adult acute myeloid leukemia with inv(16)(p13;q22)
1299422|NCT00770419|adult acute myeloid leukemia with t(15;17)(q22;q12)
1299423|NCT00770419|adult acute myeloid leukemia with t(16;16)(p13;q22)
1299424|NCT00770419|adult acute myeloid leukemia with t(8;21)(q22;q22)
1299425|NCT00770419|atypical chronic myeloid leukemia, BCR-ABL negative
1299426|NCT00770419|chronic myelomonocytic leukemia
1299427|NCT00770419|mast cell leukemia
1299428|NCT00770419|meningeal chronic myelogenous leukemia
1299429|NCT00770419|prolymphocytic leukemia
1299430|NCT00770419|recurrent adult acute lymphoblastic leukemia
1299431|NCT00770419|recurrent adult acute myeloid leukemia
1299432|NCT00770419|recurrent adult T-cell leukemia/lymphoma
1299433|NCT00770419|refractory chronic lymphocytic leukemia
1299434|NCT00770419|refractory hairy cell leukemia
1299435|NCT00770419|relapsing chronic myelogenous leukemia
1299436|NCT00770419|secondary acute myeloid leukemia
1299437|NCT00770419|T-cell large granular lymphocyte leukemia
1299438|NCT00770419|AIDS-related diffuse large cell lymphoma
1299439|NCT00770419|AIDS-related diffuse mixed cell lymphoma
1299440|NCT00770419|AIDS-related diffuse small cleaved cell lymphoma
1299441|NCT00770419|AIDS-related immunoblastic large cell lymphoma
1299442|NCT00770419|AIDS-related lymphoblastic lymphoma
1299443|NCT00770419|AIDS-related peripheral/systemic lymphoma
1299444|NCT00770419|AIDS-related primary CNS lymphoma
1299445|NCT00770419|AIDS-related small noncleaved cell lymphoma
1299446|NCT00770419|HIV-associated Hodgkin lymphoma
1299447|NCT00770419|recurrent adult Hodgkin lymphoma
1299448|NCT00770419|anaplastic large cell lymphoma
1299449|NCT00770419|angioimmunoblastic T-cell lymphoma
1299450|NCT00770419|cutaneous B-cell non-Hodgkin lymphoma
1299451|NCT00770419|recurrent cutaneous T-cell non-Hodgkin lymphoma
1299452|NCT00770419|recurrent mycosis fungoides/Sezary syndrome
1299453|NCT00770419|adult grade III lymphomatoid granulomatosis
1299454|NCT00770419|adult nasal type extranodal NK/T-cell lymphoma
1299455|NCT00770419|Waldenstrom macroglobulinemia
1299456|NCT00770419|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1299457|NCT00770419|nodal marginal zone B-cell lymphoma
1299458|NCT00770419|splenic marginal zone lymphoma
1299459|NCT00770419|recurrent adult Burkitt lymphoma
1299460|NCT00770419|recurrent adult diffuse large cell lymphoma
1299461|NCT00770419|recurrent adult diffuse mixed cell lymphoma
1299462|NCT00770419|recurrent adult diffuse small cleaved cell lymphoma
1299463|NCT00770419|recurrent adult grade III lymphomatoid granulomatosis
1299464|NCT00770419|recurrent adult immunoblastic large cell lymphoma
1299465|NCT00770419|recurrent adult lymphoblastic lymphoma
1299466|NCT00770419|recurrent grade 1 follicular lymphoma
1299467|NCT00770419|recurrent grade 2 follicular lymphoma
1299468|NCT00770419|recurrent grade 3 follicular lymphoma
1299469|NCT00770419|recurrent mantle cell lymphoma
1299470|NCT00770419|recurrent marginal zone lymphoma
1299471|NCT00770419|recurrent small lymphocytic lymphoma
1299472|NCT00770419|intraocular lymphoma
1299473|NCT00770419|primary central nervous system non-Hodgkin lymphoma
1299474|NCT00770419|primary central nervous system Hodgkin lymphoma
1299475|NCT00770419|chronic eosinophilic leukemia
1299476|NCT00770419|chronic neutrophilic leukemia
1299477|NCT00770419|primary myelofibrosis
1299478|NCT00770419|primary systemic amyloidosis
1299479|NCT00770419|refractory multiple myeloma
1299480|NCT00770419|previously treated myelodysplastic syndromes
1299481|NCT00770419|secondary myelodysplastic syndromes
1299482|NCT00770419|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1299483|NCT00770393|squamous cell carcinoma of the pyriform sinus
1299484|NCT00770393|laryngeal preservation
1299485|NCT00770393|patients with biopsy-proven previously untreated resectable T3 with fixed cord involvement squamous cell carcinoma of the pyriform sinus
1299486|NCT00770380|smoking
1299487|NCT00770367|Cardiovascular risk
1299488|NCT00770367|biological markers
1299489|NCT00770354|Breast cancer
1299490|NCT00770328|Plasma PAI-1 level at 0, 4, 8 weeks
1299491|NCT00770328|Plasma hsCRP level at 0, 4, 8 weeks
1299492|NCT00770328|Plasma TNF-a level at 0, 4, 8 weeks
1299493|NCT00770302|DPP-4 inhibitors
1299494|NCT00770302|HBA1c
1299495|NCT00770302|Incretins
1299496|NCT00770302|Pharmacokinetics
1299497|NCT00770276|obesity WHO I-III
1299498|NCT00770276|metabolic syndrome
1299499|NCT00770276|Framingham risk score
1299500|NCT00770276|subclinical atherosclerosis
1299501|NCT00770276|endothelial dysfunction
1299502|NCT00770263|any solid tumors
1299503|NCT00770250|asthma symptoms
1299504|NCT00770250|words used by patients and physicians
1299505|NCT00770250|express asthma symptoms
1299506|NCT00770237|Smoking
1299507|NCT00770237|Nicotine
1299508|NCT00770237|Schizophrenia
1299509|NCT00770224|contiguous stage II grade 1 follicular lymphoma
1299510|NCT00770224|contiguous stage II grade 2 follicular lymphoma
1299511|NCT00770224|contiguous stage II grade 3 follicular lymphoma
1299512|NCT00770224|noncontiguous stage II grade 1 follicular lymphoma
1299513|NCT00770224|noncontiguous stage II grade 2 follicular lymphoma
1299514|NCT00770224|noncontiguous stage II grade 3 follicular lymphoma
1299515|NCT00770224|stage III grade 1 follicular lymphoma
1299516|NCT00770224|stage III grade 2 follicular lymphoma
1299517|NCT00770224|stage III grade 3 follicular lymphoma
1299518|NCT00770224|stage IV grade 1 follicular lymphoma
1299519|NCT00770224|stage IV grade 2 follicular lymphoma
1299520|NCT00770224|stage IV grade 3 follicular lymphoma
1299521|NCT00770198|liver
1299522|NCT00770198|alcohol
1299523|NCT00770198|HCV
1299524|NCT00770185|endometrial adenocarcinoma
1299525|NCT00770185|endometrial adenosquamous cell carcinoma
1299526|NCT00770185|endometrial clear cell carcinoma
1299527|NCT00770185|endometrial papillary carcinoma
1299528|NCT00770185|recurrent endometrial carcinoma
1299529|NCT00770185|stage III endometrial carcinoma
1299530|NCT00770185|stage IV endometrial carcinoma
1299531|NCT00770172|chemotherapeutic agent toxicity
1299532|NCT00770172|neutropenia
1299533|NCT00770172|unspecified adult solid tumor, protocol specific
1299534|NCT00770120|recurrent malignant mesothelioma
1299535|NCT00770120|stage II malignant mesothelioma
1299536|NCT00770120|stage III malignant mesothelioma
1299537|NCT00770120|stage IV malignant mesothelioma
1299538|NCT00770094|LASIK
1299539|NCT00770094|Laser Vision correction
1299540|NCT00770094|Myopia
1299541|NCT00770094|Myopia with astigmatism
1299542|NCT00770094|Nearsighted
1299543|NCT00770081|Type 2 diabetes
1299544|NCT00770081|vildagliptin
1299545|NCT00770068|Mood Disorders
1299546|NCT00770068|Major Depressive Disorder
1299547|NCT00770068|Bipolar Disorder
1299548|NCT00770068|Tree Pollen
1299549|NCT00770068|Ragweed Pollen
1299550|NCT00770068|Rhinitis
1299551|NCT00770068|Allergic
1299552|NCT00770068|Seasonal
1299553|NCT00770068|Allergens
1299554|NCT00770055|stage IV breast cancer
1299555|NCT00770055|recurrent breast cancer
1299556|NCT00770016|insulin sensitivity
1299557|NCT00770016|Substrate metabolism
1299558|NCT00770016|Fatty liver
1299559|NCT00770016|intramyocellular lipid
1299560|NCT00770016|intracellular signaling
1299561|NCT00770003|patients
1299562|NCT00770003|allergic rhinitis
1299563|NCT00770003|tolerability
1299564|NCT00770003|safety
1299565|NCT00770003|nasal symptoms
1299566|NCT00769990|bone metastases
1299567|NCT00769990|pain
1299568|NCT00769990|recurrent breast cancer
1299569|NCT00769990|stage IV breast cancer
1299570|NCT00769990|recurrent prostate cancer
1299571|NCT00769990|stage IV prostate cancer
1299572|NCT00769990|recurrent melanoma
1299573|NCT00769990|stage IV melanoma
1299574|NCT00769990|recurrent renal cell cancer
1299575|NCT00769990|stage IV renal cell cancer
1299576|NCT00769990|recurrent non-small cell lung cancer
1299577|NCT00769990|stage IV non-small cell lung cancer
1299578|NCT00769990|extensive stage small cell lung cancer
1299579|NCT00769990|recurrent small cell lung cancer
1299580|NCT00769964|Healthy (Dysmenorrhea)
1299581|NCT00769951|pain
1299582|NCT00769951|depression
1299583|NCT00769951|weight changes
1299584|NCT00769951|cognitive/functional effects
1299585|NCT00769951|malnutrition
1299586|NCT00769951|psychosocial effects of cancer and its treatment
1299587|NCT00769951|unspecified adult solid tumor, protocol specific
1299588|NCT00769951|hematopoietic/lymphoid cancer
1299589|NCT00769938|Atrial fibrillation
1299590|NCT00769938|Percutaneous coronary stenting
1299591|NCT00769938|Bleeding complications
1299592|NCT00769938|Triple therapy
1299593|NCT00769925|Generalized Anxiety
1299594|NCT00769925|Social Phobia
1299595|NCT00769925|Separation Anxiety
1299596|NCT00769925|Phobia
1299597|NCT00769899|AZD7325
1299598|NCT00769899|Japanese Healthy Volunteers
1299599|NCT00769899|Phase I study
1299600|NCT00769899|Single Ascending Dose
1299601|NCT00769873|anticoagulation
1299602|NCT00769873|thrombosis
1299603|NCT00769873|portal vein thrombosis
1299604|NCT00769873|splenic vein thrombosis
1299605|NCT00769873|splenectomy
1299606|NCT00769873|randomized
1299607|NCT00769873|laparoscopic splenectomy
1299608|NCT00769873|lovenox
1299609|NCT00769860|myositis
1299610|NCT00769860|IBM
1299611|NCT00769860|inclusion body myositis
1299612|NCT00769847|Endoscopic, craniosynostosis, sagittal, synostosis
1299613|NCT00769834|chronic kidney disease
1299614|NCT00769834|chronic renal insufficiency
1299615|NCT00769834|uremia
1299616|NCT00769834|disc edema
1299617|NCT00769834|papilledema
1299618|NCT00769834|idiopathic intracranial hypertension
1299619|NCT00769834|pseudotumor cerebri
1299620|NCT00769821|lymphedema
1299621|NCT00769821|perioperative/postoperative complications
1299622|NCT00769821|cancer survivor
1299623|NCT00769821|stage I breast cancer
1299624|NCT00769821|stage II breast cancer
1299625|NCT00769821|stage IIIA breast cancer
1299626|NCT00769821|stage IIIB breast cancer
1299627|NCT00769821|stage IIIC breast cancer
1299628|NCT00769821|stage IV breast cancer
1299629|NCT00769795|prostate cancer
1299630|NCT00769795|prostatic neoplasm
1299631|NCT00769795|androgen deprivation therapy
1299632|NCT00769795|insulin-like growth factor receptor I
1299633|NCT00769795|neoadjuvant
1299634|NCT00769795|prostatectomy
1299635|NCT00769782|gastrointestinal stromal tumor
1299636|NCT00769782|liver metastases
1299637|NCT00769769|Health Status
1299638|NCT00769756|Different Strategies to Fight Obesity in Families
1299639|NCT00769730|hepatocellular carcinoma
1299640|NCT00769730|hepatitis B virus
1299641|NCT00769730|transcatheter arterial chemoembolization
1299642|NCT00769717|obesity
1299643|NCT00769717|wellness
1299644|NCT00769717|cardiovascular disease prevention
1299645|NCT00769717|health at every size
1299646|NCT00769717|weight loss
1299647|NCT00769704|Melanoma
1299648|NCT00769704|OncoVEX^GM-CSF
1299649|NCT00769704|GM-CSF
1299650|NCT00769704|Stage IIIb, IIIc and IV Disease
1299651|NCT00769704|oncolytic
1299652|NCT00769704|OncoVex
1299653|NCT00769704|T-Vec
1299654|NCT00769704|talimogene laherparepvec
1299655|NCT00769691|Cardiac surgery
1299656|NCT00769691|Cerebral blood flow autoregulation
1299657|NCT00769678|Biventricular Pacing
1299658|NCT00769665|Dry Eye
1299659|NCT00769665|re-wetting drops
1299660|NCT00769652|malnutrition
1299661|NCT00769652|non-small cell lung cancer
1299662|NCT00769652|small cell lung cancer
1299663|NCT00769652|stage III prostate cancer
1299664|NCT00769652|stage IV prostate cancer
1299665|NCT00769652|pancreatic cancer
1299666|NCT00769652|weight changes
1299667|NCT00769626|Low Back Pain
1299668|NCT00769626|Clinical Practice Guidelines
1299669|NCT00769626|Spinal Manipulation
1299670|NCT00769626|Physical Therapy Techniques
1299671|NCT00769613|stage III adult Burkitt lymphoma
1299672|NCT00769613|stage III adult diffuse large cell lymphoma
1299673|NCT00769613|stage III adult diffuse mixed cell lymphoma
1299674|NCT00769613|stage III adult diffuse small cleaved cell lymphoma
1299675|NCT00769613|stage III adult Hodgkin lymphoma
1299676|NCT00769613|stage III adult immunoblastic large cell lymphoma
1299677|NCT00769613|stage III adult lymphoblastic lymphoma
1299678|NCT00769613|stage III grade 1 follicular lymphoma
1299679|NCT00769613|stage III grade 2 follicular lymphoma
1299680|NCT00769613|stage III grade 3 follicular lymphoma
1299681|NCT00769613|stage III mantle cell lymphoma
1299682|NCT00769613|stage III marginal zone lymphoma
1299683|NCT00769613|stage III small lymphocytic lymphoma
1299684|NCT00769613|stage IV adult Burkitt lymphoma
1299685|NCT00769613|stage IV adult diffuse large cell lymphoma
1299686|NCT00769613|stage IV adult diffuse mixed cell lymphoma
1299687|NCT00769613|stage IV adult diffuse small cleaved cell lymphoma
1299688|NCT00769613|stage IV adult Hodgkin lymphoma
1299689|NCT00769613|stage IV adult immunoblastic large cell lymphoma
1299690|NCT00769613|stage IV adult lymphoblastic lymphoma
1299691|NCT00769613|stage IV grade 1 follicular lymphoma
1299692|NCT00769613|stage IV grade 2 follicular lymphoma
1299693|NCT00769613|stage IV grade 3 follicular lymphoma
1299694|NCT00769613|stage IV mantle cell lymphoma
1299695|NCT00769613|stage IV marginal zone lymphoma
1299696|NCT00769613|stage IV small lymphocytic lymphoma
1299697|NCT00769613|recurrent adult Burkitt lymphoma
1299698|NCT00769613|recurrent adult diffuse large cell lymphoma
1299699|NCT00769613|recurrent adult diffuse mixed cell lymphoma
1299700|NCT00769613|recurrent adult diffuse small cleaved cell lymphoma
1299701|NCT00769613|recurrent adult Hodgkin lymphoma
1299702|NCT00769613|recurrent adult immunoblastic large cell lymphoma
1299703|NCT00769613|recurrent adult lymphoblastic lymphoma
1299704|NCT00769613|recurrent childhood large cell lymphoma
1299705|NCT00769613|recurrent childhood lymphoblastic lymphoma
1299706|NCT00769613|recurrent childhood small noncleaved cell lymphoma
1299707|NCT00769613|recurrent cutaneous T-cell non-Hodgkin lymphoma
1299708|NCT00769613|recurrent grade 1 follicular lymphoma
1299709|NCT00769613|recurrent grade 2 follicular lymphoma
1299710|NCT00769613|recurrent grade 3 follicular lymphoma
1299711|NCT00769613|recurrent mantle cell lymphoma
1299712|NCT00769613|recurrent marginal zone lymphoma
1299713|NCT00769613|recurrent small lymphocytic lymphoma
1299714|NCT00769613|recurrent/refractory childhood Hodgkin lymphoma
1299715|NCT00769613|recurrent mycosis fungoides/Sezary syndrome
1299716|NCT00769613|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1299717|NCT00769613|nodal marginal zone B-cell lymphoma
1299718|NCT00769613|splenic marginal zone lymphoma
1299719|NCT00769613|noncontiguous stage II adult Burkitt lymphoma
1299720|NCT00769613|noncontiguous stage II adult diffuse large cell lymphoma
1299721|NCT00769613|noncontiguous stage II adult diffuse mixed cell lymphoma
1299722|NCT00769613|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1299723|NCT00769613|noncontiguous stage II adult immunoblastic large cell lymphoma
1299724|NCT00769613|noncontiguous stage II adult lymphoblastic lymphoma
1299725|NCT00769613|noncontiguous stage II grade 1 follicular lymphoma
1299726|NCT00769613|noncontiguous stage II grade 2 follicular lymphoma
1299727|NCT00769613|noncontiguous stage II grade 3 follicular lymphoma
1299728|NCT00769613|noncontiguous stage II mantle cell lymphoma
1299729|NCT00769613|noncontiguous stage II marginal zone lymphoma
1299730|NCT00769613|noncontiguous stage II small lymphocytic lymphoma
1299731|NCT00769613|accelerated phase chronic myelogenous leukemia
1299732|NCT00769613|adult acute lymphoblastic leukemia in remission
1299733|NCT00769613|adult acute myeloid leukemia in remission
1299734|NCT00769613|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1299735|NCT00769613|adult acute myeloid leukemia with inv(16)(p13;q22)
1299736|NCT00769613|adult acute myeloid leukemia with t(15;17)(q22;q12)
1299737|NCT00769613|adult acute myeloid leukemia with t(16;16)(p13;q22)
1299738|NCT00769613|adult acute myeloid leukemia with t(8;21)(q22;q22)
1299739|NCT00769613|atypical chronic myeloid leukemia, BCR-ABL1 negative
1299740|NCT00769613|blastic phase chronic myelogenous leukemia
1299741|NCT00769613|childhood acute lymphoblastic leukemia in remission
1299742|NCT00769613|childhood acute myeloid leukemia in remission
1299743|NCT00769613|childhood chronic myelogenous leukemia
1299744|NCT00769613|chronic myelomonocytic leukemia
1299745|NCT00769613|chronic phase chronic myelogenous leukemia
1299746|NCT00769613|juvenile myelomonocytic leukemia
1299747|NCT00769613|recurrent adult acute lymphoblastic leukemia
1299748|NCT00769613|recurrent adult acute myeloid leukemia
1299749|NCT00769613|recurrent childhood acute lymphoblastic leukemia
1299750|NCT00769613|recurrent childhood acute myeloid leukemia
1299751|NCT00769613|refractory chronic lymphocytic leukemia
1299752|NCT00769613|refractory hairy cell leukemia
1299753|NCT00769613|relapsing chronic myelogenous leukemia
1299754|NCT00769613|secondary acute myeloid leukemia
1299755|NCT00769613|stage III chronic lymphocytic leukemia
1299756|NCT00769613|stage IV chronic lymphocytic leukemia
1299757|NCT00769613|childhood myelodysplastic syndromes
1299758|NCT00769613|chronic eosinophilic leukemia
1299759|NCT00769613|primary myelofibrosis
1299760|NCT00769613|chronic neutrophilic leukemia
1299761|NCT00769613|de novo myelodysplastic syndromes
1299762|NCT00769613|disseminated neuroblastoma
1299763|NCT00769613|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1299764|NCT00769613|high risk metastatic gestational trophoblastic tumor
1299765|NCT00769613|previously treated childhood rhabdomyosarcoma
1299766|NCT00769613|previously treated myelodysplastic syndromes
1299767|NCT00769613|recurrent Wilms tumor and other childhood kidney tumors
1299768|NCT00769613|recurrent childhood rhabdomyosarcoma
1299769|NCT00769613|recurrent neuroblastoma
1299770|NCT00769613|recurrent ovarian epithelial cancer
1299771|NCT00769613|recurrent ovarian germ cell tumor
1299772|NCT00769613|recurrent malignant testicular germ cell tumor
1299773|NCT00769613|secondary myelodysplastic syndromes
1299774|NCT00769613|stage I multiple myeloma
1299775|NCT00769613|stage II multiple myeloma
1299776|NCT00769613|stage III multiple myeloma
1299777|NCT00769613|stage II ovarian epithelial cancer
1299778|NCT00769613|stage III ovarian epithelial cancer
1299779|NCT00769613|stage IV ovarian epithelial cancer
1299780|NCT00769613|stage III malignant testicular germ cell tumor
1299781|NCT00769613|stage IIIA breast cancer
1299782|NCT00769613|stage IIIB breast cancer
1299783|NCT00769613|stage IIIC breast cancer
1299784|NCT00769613|stage IV breast cancer
1299785|NCT00769613|refractory multiple myeloma
1299786|NCT00769613|cytomegalovirus infection
1299787|NCT00769600|Recurrent Non-Small Cell Lung Cancer
1299788|NCT00769587|aggressive systemic mastocytosis
1299789|NCT00769587|smoldering systemic mastocytosis
1299790|NCT00769561|Temporomandibular disorders
1299791|NCT00769561|Biofeedback
1299792|NCT00769561|Cognitive behavioral therapy
1299793|NCT00769561|Pain
1299794|NCT00769548|adenocarcinoma of the prostate
1299795|NCT00769548|stage I prostate cancer
1299796|NCT00769548|stage IIB prostate cancer
1299797|NCT00769548|stage IIA prostate cancer
1299798|NCT00769548|stage III prostate cancer
1299799|NCT00769548|stage IV prostate cancer
1299800|NCT00769535|heat shock protein70
1299801|NCT00769535|tumor necrosis factor-alpha promoter
1299802|NCT00769535|polymorphism
1299803|NCT00769522|B-cell chronic lymphocytic leukemia
1299804|NCT00769522|stage 0 chronic lymphocytic leukemia
1299805|NCT00769522|stage I chronic lymphocytic leukemia
1299806|NCT00769522|stage II chronic lymphocytic leukemia
1299807|NCT00769522|stage III chronic lymphocytic leukemia
1299808|NCT00769522|stage IV chronic lymphocytic leukemia
1299809|NCT00769509|energy expenditure
1299810|NCT00769509|indirect calorimetry
1299811|NCT00769509|human milk
1299812|NCT00769509|preterm formula
1299813|NCT00769509|premature infant
1299814|NCT00769483|Pancreas
1299815|NCT00769483|Pancreatic Cancer
1299816|NCT00769483|Advanced cancer of the pancreas
1299817|NCT00769483|Pancreatic Adenocarcinoma
1299818|NCT00769483|MK-0646
1299819|NCT00769483|Gemcitabine
1299820|NCT00769483|Gemzar
1299821|NCT00769483|Erlotinib hydrochloride
1299822|NCT00769483|Erlotinib
1299823|NCT00769483|OSI-774
1299824|NCT00769483|Tarceva
1299825|NCT00769470|stage I breast cancer
1299826|NCT00769470|stage II breast cancer
1299827|NCT00769470|stage IIIA breast cancer
1299828|NCT00769470|stage IIIB breast cancer
1299829|NCT00769470|stage IIIC breast cancer
1299830|NCT00769470|HER2-positive breast cancer
1299831|NCT00769431|stage I prostate cancer
1299832|NCT00769431|stage IIB prostate cancer
1299833|NCT00769431|stage IIA prostate cancer
1299834|NCT00769405|recurrent colon cancer
1299835|NCT00769405|stage IV colon cancer
1299836|NCT00769405|recurrent rectal cancer
1299837|NCT00769405|stage IV rectal cancer
1299838|NCT00769405|peritoneal carcinomatosis
1299839|NCT00769392|Macular Degeneration
1299840|NCT00769392|Intravitreal injections
1299841|NCT00769392|Eye anesthesia-Topical/subconjunctival
1299842|NCT00769392|Eye-surgical procedures
1299843|NCT00769392|Ophthalmologic anesthesia methods
1299844|NCT00769327|chronic myelogenous leukemia, BCR-ABL1 positive
1299845|NCT00769327|chronic phase chronic myelogenous leukemia
1299846|NCT00769301|Symptoms
1299847|NCT00769301|pain
1299848|NCT00769301|fatigue
1299849|NCT00769301|depression
1299850|NCT00769301|sleeplessness
1299851|NCT00769301|genetic markers
1299852|NCT00769301|caregiver burden.
1299853|NCT00769275|silent ischemia
1299854|NCT00769275|type 2 diabetes mellitus
1299855|NCT00769275|screening
1299856|NCT00769275|cardiac outcome
1299857|NCT00769275|Prevalence silent myocardial ischemia
1299858|NCT00769275|Cardiac outcome in screened and not-screened subjects
1299859|NCT00769262|Premature neonates
1299860|NCT00769262|Thermoregulation
1299861|NCT00769262|Isolette
1299862|NCT00769262|Feeding status
1299863|NCT00769249|psychosocial effects of cancer and its treatment
1299982|NCT00768729|Rapamycin
1299864|NCT00769249|unspecified adult solid tumor, protocol specific
1299865|NCT00769223|radiation toxicity
1299866|NCT00769223|recurrent prostate cancer
1299867|NCT00769223|stage IIB prostate cancer
1299868|NCT00769223|stage IIA prostate cancer
1299869|NCT00769223|stage III prostate cancer
1299870|NCT00769223|stage I prostate cancer
1299871|NCT00769223|stage IV prostate cancer
1299872|NCT00769223|adenocarcinoma of the prostate
1299873|NCT00769197|optic disc cupping
1299874|NCT00769197|cerebral palsy
1299875|NCT00769197|static encephalopathy
1299876|NCT00769197|optic disc
1299877|NCT00769197|optic nerve
1299878|NCT00769197|periventricular Leukomalacia
1299879|NCT00769184|chronic plaque psoriasis
1299880|NCT00769171|Complicated Intra-Abdominal Infections
1299881|NCT00769158|Alcohol
1299882|NCT00769158|Alcoholism
1299883|NCT00769158|Alcohol Dependence
1299884|NCT00769145|Corneal neovascularization
1299885|NCT00769145|Ranibizumab
1299886|NCT00769145|Corneal transplantation
1299887|NCT00769119|bronchiectasis
1299888|NCT00769119|Phase II
1299889|NCT00769106|hepatocellular carcinoma
1299890|NCT00769106|recurrent
1299891|NCT00769106|cytokine-induced killer cell
1299892|NCT00769093|ferumoxytol
1299893|NCT00769093|diagnostic imaging
1299894|NCT00769080|PSP
1299895|NCT00769080|Standard Treatment
1299896|NCT00769080|Standard Treatment plus PSP
1299897|NCT00769067|Lung cancer
1299898|NCT00769067|advanced
1299899|NCT00769067|second or third line
1299900|NCT00769054|Postoperative pain
1299901|NCT00769054|PONV
1299902|NCT00769028|Systemic sclerosis
1299903|NCT00769028|Diffuse cutaneous systemic sclerosis
1299904|NCT00769028|Scleroderma
1299905|NCT00769028|Biological
1299906|NCT00769028|Hyperimmune caprine serum
1299907|NCT00769028|Goat Serum
1299908|NCT00769015|age-related macular degeneration
1299909|NCT00769015|depression
1299910|NCT00769015|vision loss
1299911|NCT00769002|influenza
1299912|NCT00769002|flu
1299913|NCT00769002|vaccine
1299914|NCT00769002|vaccination
1299915|NCT00769002|immune response
1299916|NCT00769002|FluShield
1299917|NCT00769002|FluMist
1299918|NCT00769002|PET-CT
1299919|NCT00769002|Healthy Volunteers
1299920|NCT00768989|Combination Therapy
1299921|NCT00768976|Participant must have participated in a clinical trial conducted by the Summa Health System Hospitals Cancer Research Program.
1299922|NCT00768976|Participant should have been registered for clinical trial participation three months prior to receiving the satisfaction survey.
1299923|NCT00768963|ranibizumab
1299924|NCT00768963|pterygium
1299925|NCT00768950|Seronegative spondyloarthropathies
1299926|NCT00768950|Endoscopic capsule examination
1299927|NCT00768950|Small bowel and colon lesions
1299928|NCT00768950|Nonsteroidal anti-inflammatory drugs
1299929|NCT00768950|Anti TNF Alpha Drugs
1299930|NCT00768937|hepatocellular carcinoma
1299931|NCT00768937|sorafenib
1299932|NCT00768937|transarterial chemoembolization
1299933|NCT00768937|tumor angiogenesis
1299934|NCT00768937|angiogenic factors
1299935|NCT00768924|Bone Void Filler
1299936|NCT00768924|Post-Harvest Iliac Crest
1299937|NCT00768924|Ability of CopiOs to fill the post-harvest iliac crest bone void created by a surgeon during spinal fusion.
1299938|NCT00768911|glioblastoma
1299939|NCT00768911|Glioblastoma multiforme (newly diagnosed)
1299940|NCT00768898|conjunctival
1299941|NCT00768898|staining
1299942|NCT00768872|activity, spinal cord stimulation, pain
1299943|NCT00768859|breast cancer
1299944|NCT00768859|HER2 positive
1299945|NCT00768859|neo-adjuvant
1299946|NCT00768859|trastuzumab
1299947|NCT00768859|paclitaxel
1299948|NCT00768859|carboplatin
1299949|NCT00768846|PCI
1299950|NCT00768846|Stent
1299951|NCT00768846|DES
1299952|NCT00768846|CAD
1299953|NCT00768833|S.pneumoniae healthy subjects
1299954|NCT00768833|Healthy subjects
1299955|NCT00768820|Velocardiofacial syndrome
1299956|NCT00768820|Williams syndrome
1299957|NCT00768820|fragile X syndrome
1299958|NCT00768820|cognitive phenotype
1299959|NCT00768820|psychiatric phenotype
1299960|NCT00768794|thrush
1299961|NCT00768781|insomnia
1299962|NCT00768781|hyperarousal
1299963|NCT00768781|mindfulness meditation
1299964|NCT00768781|complementary and alternative medicine
1299965|NCT00768781|cognitive-behavioral therapy
1299966|NCT00768768|iontophoresis
1299967|NCT00768768|terbinafine
1299968|NCT00768768|onychomycosis
1299969|NCT00768755|non-squamous NSCLC
1299970|NCT00768755|axitinib
1299971|NCT00768755|pemetrexed/cisplatin
1299972|NCT00768742|Uterine Fibroid RF Ablation
1299973|NCT00768742|Intrauterine Ultrasound
1299974|NCT00768742|VizAblate
1299975|NCT00768729|End stage renal disease
1299976|NCT00768729|Kidney transplantation
1299977|NCT00768729|Renal transplantation
1299978|NCT00768729|Kidney failure
1299979|NCT00768729|Children
1299980|NCT00768729|Adolescents
1299981|NCT00768729|Sirolimus
1299983|NCT00768729|CellCept
1299984|NCT00768729|Mycophenolate mofetil (MMF)
1299985|NCT00768729|Azathioprine
1299986|NCT00768703|Congenital diaphragmatic hernia
1299987|NCT00768703|lung-head ratio
1299988|NCT00768703|percutaneous tracheal occlusion
1299989|NCT00768703|fetal intervention
1299990|NCT00768677|binge eating behavior
1299991|NCT00768677|adolescents
1299992|NCT00768664|recurrent or metastatic squamous cell cancer of the Head and Neck; no prior systemic therapy for recurrence
1299993|NCT00768638|Chronic kidney disease
1299994|NCT00768612|Acute, Schizophrenia, Phase2a, Vabicaserin
1299995|NCT00768599|Econazole
1299996|NCT00768599|Foam
1299997|NCT00768599|Quinnova
1299998|NCT00768573|taste test
1299999|NCT00768534|Acute Otitis Media
1300000|NCT00768534|Serotype distribution
1300001|NCT00768508|Alcohol
1300002|NCT00768508|Alcohol Dependence
1300003|NCT00768508|Alcoholism
1300004|NCT00768495|revascularization
1300005|NCT00768495|claudication
1300006|NCT00768495|hyperspectral
1300007|NCT00768495|oxygenation
1300008|NCT00768495|limb ischemia
1300009|NCT00768482|opioid dependence
1300010|NCT00768482|opioid addiction
1300011|NCT00768482|buprenorphine
1300012|NCT00768482|methadone
1300013|NCT00768482|heroin
1300014|NCT00768482|implant
1300015|NCT00768482|opioid withdrawal
1300016|NCT00768482|opioid pain medication
1300017|NCT00768482|suboxone
1300018|NCT00768469|HKI-272
1300019|NCT00768469|Paclitaxel
1300020|NCT00768469|Combination
1300021|NCT00768469|Solid Tumor
1300022|NCT00768443|GERD
1300023|NCT00768443|PPI
1300024|NCT00768417|Nuts
1300025|NCT00768417|Lipids
1300026|NCT00768417|Mastication
1300027|NCT00768417|Bioaccessibility
1300028|NCT00768417|Satiety
1300029|NCT00768417|Hormones
1300030|NCT00768417|Human
1300031|NCT00768391|Tumors
1300032|NCT00768391|Lymphoma
1300033|NCT00768391|Antibodies, Monoclonal
1300034|NCT00768378|Physical Therapy (Specialty)
1300035|NCT00768378|Balance dysfunction or disorder
1300036|NCT00768378|Vestibular
1300037|NCT00768378|Rehabilitation
1300038|NCT00768365|adrenal incidentaloma
1300039|NCT00768365|cardiovascular risk
1300040|NCT00768352|Pediatric
1300041|NCT00768352|Resident
1300042|NCT00768352|Depression
1300043|NCT00768352|Screening
1300044|NCT00768352|Substance Abuse
1300045|NCT00768352|Pediatric Resident knowledge of mental health topics
1300046|NCT00768352|Pediatric Resident current practices for screening and treating mental health disorders
1300047|NCT00768352|Pediatric Resident mental health care competency
1300048|NCT00768339|antisense
1300049|NCT00768339|AEG35156
1300050|NCT00768339|lymphocytic
1300051|NCT00768339|lymphoma
1300052|NCT00768339|leukemia
1300053|NCT00768339|B-cell
1300054|NCT00768326|Schizophrenia
1300055|NCT00768326|Antipsychotic
1300056|NCT00768326|Lu 31-130
1300057|NCT00768313|scoliosis correction rod strength adolescent
1300058|NCT00768300|idiopathic pulmonary fibrosis
1300059|NCT00768300|interstitial lung disease
1300060|NCT00768300|ambrisentan
1300061|NCT00768274|Cholesterol
1300062|NCT00768274|High density lipoprotein
1300063|NCT00768274|Dyslipidemia
1300064|NCT00768274|Atherosclerosis
1300065|NCT00768274|Apolipoprotein A-I
1300066|NCT00768261|Dementia of the Alzheimer type
1300067|NCT00768248|pain
1300068|NCT00768248|phantom limb
1300069|NCT00768248|stump pain
1300070|NCT00768248|catheter
1300071|NCT00768248|nerve block
1300072|NCT00768248|peripheral nerve block
1300073|NCT00768248|NMCSD
1300074|NCT00768248|Post-Amputation Phantom Limb or Stump Pain
1300075|NCT00768235|Sedentary elderly women that had medical assignment
1300076|NCT00768222|wound healing
1300077|NCT00768209|Pharmacokinetics
1300078|NCT00768196|GERD
1300079|NCT00768196|Korea
1300080|NCT00768196|typical symptom
1300081|NCT00768196|quality of life
1300082|NCT00768196|Naturalistic
1300083|NCT00768196|epidemiological
1300084|NCT00768183|KADIAN
1300085|NCT00768183|morphine
1300086|NCT00768183|alcohol
1300087|NCT00768183|water
1300088|NCT00768183|Ethanol
1300089|NCT00768183|solution
1300090|NCT00768183|fed
1300091|NCT00768183|fasting
1300092|NCT00768157|hepatocellular carcinoma
1300093|NCT00768157|hepatitis B virus
1300094|NCT00768157|surgery
1300095|NCT00768157|anti-virus
1300096|NCT00768157|recurrence
1300097|NCT00768144|Sutent
1300098|NCT00768144|sunitinib
1300099|NCT00768118|healthy, no evidence of disease
1300100|NCT00768105|Type 2 diabetes
1300101|NCT00768079|Benralizumab
1300102|NCT00768079|MEDI-563
1300103|NCT00768079|Asthma
1300104|NCT00768066|Chronic Ischemic Left Ventricular Dysfunction
1300105|NCT00768053|EULAR-RAID
1300106|NCT00768053|active rheumatoid arthritis
1300107|NCT00768053|etanercept
1300108|NCT00768040|Diabetes
1300109|NCT00768040|Macular edema
1300110|NCT00768040|Aliskiren
1300111|NCT00768040|Diabetic retinopathy
1300112|NCT00768040|Diabetes mellitus type 1
1300113|NCT00768040|Diabetes mellitus type 2
1300114|NCT00768027|hyperspectral imaging
1300115|NCT00768027|tissue oxygenation
1300116|NCT00768027|wounds
1300117|NCT00768027|wound healing
1300118|NCT00768027|prevention
1300119|NCT00768027|hyperbaric
1300120|NCT00767988|Probiotics
1300121|NCT00767988|Spina Bifida
1300122|NCT00767988|Dietary Supplements
1300123|NCT00767988|Bacteriuria
1300124|NCT00767988|Urinary Tract Infection (UTI)
1300125|NCT00767962|recurrent primary spontaneous pneumothorax
1300126|NCT00767949|wet
1300127|NCT00767949|AMD
1300128|NCT00767923|hyperspectral imaging
1300129|NCT00767923|tissue oxygenation
1300130|NCT00767923|foot amputation
1300131|NCT00767923|critical limb ischemia
1300132|NCT00767923|tissue necrosis
1300133|NCT00767897|Dose response relationship
1300134|NCT00767897|immunity
1300135|NCT00767884|panretinal photocoagulation
1300136|NCT00767884|diabetic retinopathy
1300137|NCT00767884|optic nerve head changes
1300138|NCT00767871|Panic disorder
1300139|NCT00767871|PET
1300140|NCT00767871|Escitaopram
1300141|NCT00767858|Genetic
1300142|NCT00767858|Genetic Literacy
1300143|NCT00767858|Human Genetic Research
1300144|NCT00767858|Cultural Congruence
1300145|NCT00767858|Interview
1300146|NCT00767845|psychosocial effects of cancer and its treatment
1300147|NCT00767845|stage I prostate cancer
1300148|NCT00767845|stage II prostate cancer
1300149|NCT00767845|stage III prostate cancer
1300150|NCT00767819|progressive GIST
1300151|NCT00767819|progressive sarcoma
1300152|NCT00767767|anesthetic drugs, associative memory, fear
1300153|NCT00767754|panic disorder
1300154|NCT00767754|paroxetine
1300155|NCT00767754|PET
1300156|NCT00767741|diabetes
1300157|NCT00767741|post prandial glucose level
1300158|NCT00767741|insulin
1300159|NCT00767741|pharmacokinetics
1300160|NCT00767741|pharmacodynamics
1300161|NCT00767728|UC
1300162|NCT00767728|ulcerative colitis
1300163|NCT00767728|IBD
1300164|NCT00767728|Inflammatory Bowel Disease
1300165|NCT00767702|Genetic/Genomic Researchers
1300166|NCT00767702|Human Genetic Variation
1300167|NCT00767702|Interviews
1300168|NCT00767702|Research Design
1300169|NCT00767702|Race/Ethnicity
1300170|NCT00767702|Interview
1300171|NCT00767676|Contact sensitization
1300172|NCT00767676|Healthy Adult Volunteers
1300173|NCT00767650|Aplastic Anemia
1300174|NCT00767650|Cyclosporine
1300175|NCT00767650|Campath
1300176|NCT00767650|Neurophyschological Side Effect
1300177|NCT00767611|Infertility
1300178|NCT00767611|Sperm
1300179|NCT00767611|Embryo Development
1300180|NCT00767611|In Vitro Fertilization
1300181|NCT00767598|CYP3A5
1300182|NCT00767598|sildenafil
1300183|NCT00767598|udenafil
1300184|NCT00767598|vardenafil
1300185|NCT00767585|breast cancer
1300186|NCT00767585|aromatase inhibitors
1300187|NCT00767585|bone mineral density
1300188|NCT00767585|osteoporosis
1300189|NCT00767572|Coarctation of the aorta
1300190|NCT00767572|cross over design
1300191|NCT00767572|atorvastatin
1300192|NCT00767572|endothelial function
1300193|NCT00767559|Deep Vein Thrombosis, anticoagulants, surgery, pulmonary embolus, warfarin, fondaparinox
1300194|NCT00767546|seborrhic dermatitis
1300195|NCT00767546|parkinson's disease
1300196|NCT00767546|Parkinson disease parkinsonism and seborrhic dermatitis
1300197|NCT00767520|Advanced Estrogen Receptor Positive Breast Cancer
1300198|NCT00767494|OAG
1300199|NCT00767494|OH
1300200|NCT00767494|Open-angle glaucoma or ocular hypertension
1300201|NCT00767481|glaucoma
1300202|NCT00767481|Patients with open-angle glaucoma or ocular hypertension
1300203|NCT00767468|adult primary hepatocellular carcinoma
1300204|NCT00767468|advanced adult primary liver cancer
1300205|NCT00767468|localized unresectable adult primary liver cancer
1300206|NCT00767468|recurrent adult primary liver cancer
1300207|NCT00767455|cumulative irritation
1300208|NCT00767455|healthy adult volunteers
1300209|NCT00767429|accelerometer
1300210|NCT00767429|fall risk
1300211|NCT00767429|target group
1300212|NCT00767429|field measurements
1300213|NCT00767416|MEDI-559
1300214|NCT00767416|Respiratory Syncytial Virus
1300215|NCT00767416|RSV
1300216|NCT00767416|Pediatric
1300217|NCT00767416|Vaccine
1300218|NCT00767416|respiratory syncytial virus, RSV, pediatric, vaccine
1300219|NCT00767390|ACL Patch Placement
1300220|NCT00767377|Time to Progression
1300221|NCT00767377|Overall survival
1300222|NCT00767377|Response rate
1300223|NCT00767377|Quality of Live
1300224|NCT00767377|Toxicities
1300225|NCT00767364|Infant
1300226|NCT00767338|Infertility
1300227|NCT00767338|Pregnancy
1300228|NCT00767338|Men
1300229|NCT00767338|Palpable varicocele
1300230|NCT00767338|Abnormal semen analysis
1300231|NCT00767338|Intrauterine insemination
1300232|NCT00767338|Microsurgical varicocelectomy
1300233|NCT00767312|HIV
1300234|NCT00767312|Antiretrovial Therapy
1300235|NCT00767312|Viremia
1300236|NCT00767312|Genetic Analysis
1300237|NCT00767312|Single Copy Assay
1300238|NCT00767286|stage IIB prostate cancer
1300239|NCT00767286|stage IIA prostate cancer
1300240|NCT00767286|stage III prostate cancer
1300241|NCT00767286|stage IV prostate cancer
1300242|NCT00767260|type 2 diabetes mellitus
1300243|NCT00767260|bone marrow mononuclear cell
1300244|NCT00767260|hyperbaric oxygen therapy
1300245|NCT00767247|Arterial Hypertension
1300246|NCT00767208|type 2 diabetic subjects
1300247|NCT00767195|pulmonary edema
1300248|NCT00767195|cardiogenic
1300249|NCT00767195|non-cardiogenic
1300250|NCT00767195|mortality
1300251|NCT00767195|length of stay
1300252|NCT00767182|preeclampsia
1300253|NCT00767182|eclampsia
1300254|NCT00767182|retroplacental hematoma
1300255|NCT00767182|vascular IUGR
1300256|NCT00767182|IUFD
1300257|NCT00767182|placental volume
1300258|NCT00767169|Edentatio (Toothlessness)
1300259|NCT00767156|Sea buckthorn oil, Oral and topical treatment, Skin aging
1300260|NCT00767130|single nucleotide polymorphisms, SNP, LDL cholesterol, statin myopathy, atorvastatin, simvastatin, rosuvastatin
1300261|NCT00767117|TMC125-C197
1300262|NCT00767117|TMC125-TiDP2-C197
1300263|NCT00767117|HIV
1300264|NCT00767117|DDI
1300265|NCT00767117|Lopinavir
1300266|NCT00767117|Intelence
1300267|NCT00767117|Kaletra
1300268|NCT00767117|Ritonavir
1300269|NCT00767117|Etravirine
1300270|NCT00767117|Interaction
1300271|NCT00767117|Pharmacokinetics
1300272|NCT00767117|Steady-state
1300273|NCT00767091|Parkinson's disease
1300274|NCT00767091|Apathy
1300275|NCT00767091|Rivastigmine
1300276|NCT00767091|transdermal patch
1300277|NCT00767091|anticholinesterasic
1300278|NCT00767091|acetylcholine
1300279|NCT00767052|Healthy Volunteer
1300280|NCT00767052|Safety
1300281|NCT00767052|Tolerability
1300282|NCT00767052|Pharmacokinetics
1300283|NCT00767052|AZD1236
1300284|NCT00767039|Very Premature
1300285|NCT00767039|RDS
1300286|NCT00767039|Surfactant
1300287|NCT00767026|Epilepsy
1300288|NCT00767026|Caregiver Burden
1300289|NCT00767026|Parenting a Child with a Chronic Illness
1300290|NCT00767013|DSCT, coronary artery disease, aortic valve stenosis
1300291|NCT00766987|coronary artery disease
1300292|NCT00766987|FDG PET viability imaging
1300293|NCT00766987|morbidity and mortality
1300294|NCT00766987|revascularization
1300295|NCT00766987|resource utilization
1300296|NCT00766974|Chronic Venous Disease
1300297|NCT00766974|C3
1300298|NCT00766974|Edema
1300299|NCT00766974|Compression Garments
1300300|NCT00766974|Compression Stockings
1300301|NCT00766974|Bioimpedance
1300302|NCT00766961|Peptic ulcer bleeding uncontrolled by endoscopic therapy.
1300303|NCT00766935|Lymphedema
1300304|NCT00766935|Bioimpedance
1300305|NCT00766909|Insulin pulsatility
1300306|NCT00766909|Insulin secretion
1300307|NCT00766909|Insulin sensitivity
1300308|NCT00766909|Calcineurin inhibitor
1300309|NCT00766909|Cyclosporine
1300310|NCT00766909|Tacrolimus
1300311|NCT00766896|Stroke
1300312|NCT00766896|Cerebral Infarction
1300313|NCT00766896|Acute Coronary Syndrome
1300314|NCT00766896|Cardiovascular Diseases
1300315|NCT00766896|Vascular Diseases
1300316|NCT00766896|Platelet Activation
1300317|NCT00766896|Platelets
1300318|NCT00766896|Platelet Function Tests
1300319|NCT00766896|Aspirin
1300320|NCT00766896|Atherosclerosis
1300321|NCT00766896|Ischemia
1300322|NCT00766896|Thrombosis
1300323|NCT00766883|Allogeneic HSCT
1300324|NCT00766883|Psychosocial Distress
1300325|NCT00766883|Coping
1300326|NCT00766883|Cognitive Behavior Therapy
1300327|NCT00766883|Self Efficacy
1300328|NCT00766883|Allogeneic Stem Cell Transplant
1300329|NCT00766870|Efficacy
1300330|NCT00766870|Safety
1300331|NCT00766870|Depression
1300332|NCT00766870|Interventional
1300333|NCT00766870|Placebo
1300334|NCT00766870|Short-term
1300335|NCT00766870|Major Depressive Disorder
1300336|NCT00766870|Major Depressive Episode
1300337|NCT00766857|Exenatide
1300338|NCT00766857|Type 2 diabetes mellitus
1300339|NCT00766857|Congestive heart failure
1300340|NCT00766857|Incretin hormones
1300341|NCT00766857|GLP-1 agonist
1300342|NCT00766857|Cardiac metabolism
1300343|NCT00766857|Insulin resistance
1300344|NCT00766857|Cardiac MRI
1300345|NCT00766844|vasospasm
1300346|NCT00766844|spinal cord stimulation
1300347|NCT00766844|aneurysm
1300348|NCT00766844|subarachnoid hemorrhage
1300349|NCT00766831|Cancer pain
1300350|NCT00766831|Hydromorphone OROS
1300351|NCT00766831|Jurnista
1300352|NCT00766779|hematopoietic cell transplantation
1300353|NCT00766779|Acute Myeloid Leukemia
1300354|NCT00766779|first Complete Remission
1300355|NCT00766766|Environmental Tobacco Exposure
1300356|NCT00766753|HLA-A2 positive
1300357|NCT00766753|Malignant Gliomas
1300358|NCT00766753|Vaccine
1300359|NCT00766740|ST elevation myocardial infarction
1300360|NCT00766740|thrombectomy
1300361|NCT00766740|primary PCI
1300362|NCT00766675|Pain
1300363|NCT00766675|Fibromyalgia
1300364|NCT00766675|Ultracet
1300365|NCT00766675|Tramadol Hydrochloride
1300366|NCT00766675|Acetaminophen
1300367|NCT00766662|Malaria
1300368|NCT00766662|Intermittent Preventive Treatment
1300369|NCT00766662|EPI vaccine coverage
1300370|NCT00766662|Resistance of P. falciparum to Sulfadoxine- Pyrimethamine
1300371|NCT00766649|Age Related Macular Degeneration (AMD)
1300372|NCT00766649|Geographic Atrophy
1300373|NCT00766649|Sirolimus
1300374|NCT00766649|Age-Related Macular Degeneration
1300375|NCT00766649|AMD
1300376|NCT00766636|Adenocarcinoma of the pancreatic head
1300377|NCT00766636|Pancreaticoduodenectomy
1300378|NCT00766636|Preoperative chemotherapy
1300379|NCT00766636|Chemoradiation
1300380|NCT00766636|Resectable pancreatic cancer
1300381|NCT00766636|Surgical removal of the pancreas and duodenum
1300382|NCT00766636|External-beam radiation therapy
1300383|NCT00766636|EBRT
1300384|NCT00766636|Gemcitabine
1300385|NCT00766636|Erlotinib
1300386|NCT00766623|endothelium,
1300387|NCT00766623|postprandial
1300388|NCT00766623|microvascular
1300389|NCT00766623|macrovascular
1300390|NCT00766597|Treatment Experienced
1300391|NCT00766584|Aging
1300392|NCT00766584|Autonomic nervous system
1300393|NCT00766584|stroke
1300394|NCT00766584|Myocardiac infarction
1300395|NCT00766584|Prospective cohort
1300396|NCT00766584|Sleep apnea/hypopnea
1300397|NCT00766571|VACTERL Association
1300398|NCT00766571|VATER Association
1300399|NCT00766571|Multiple Congenital Anomalies
1300400|NCT00766571|VACTERL
1300401|NCT00766571|Congenital Defects
1300402|NCT00766571|Birth Defects
1300403|NCT00766571|Congenital Abnormalities
1300404|NCT00766558|anorexia
1300405|NCT00766558|bulimia
1300406|NCT00766558|eating disorder not otherwise specified
1300407|NCT00766519|fluid responsiveness
1300408|NCT00766519|monitoring
1300409|NCT00766519|arterial pulse pressure
1300410|NCT00766506|IONSYS
1300411|NCT00766506|Fentanyl
1300412|NCT00766506|Morphine
1300413|NCT00766506|PCA
1300414|NCT00766506|Postoperative pain
1300415|NCT00766506|Mobilization
1300416|NCT00766493|carotid artery stenosis
1300417|NCT00766493|embolic protection device
1300418|NCT00766493|distal embolic filter
1300419|NCT00766493|minimizing risks of carotid artery stenting
1300420|NCT00766480|squamous cell carcinoma of the esophagus
1300421|NCT00766480|stage IIA esophageal cancer
1300422|NCT00766480|stage IIB esophageal cancer
1300423|NCT00766480|stage IIIA esophageal cancer
1300424|NCT00766480|stage IIIB esophageal cancer
1300425|NCT00766480|stage IIIC esophageal cancer
1300426|NCT00766467|armodafinil
1300427|NCT00766467|Nuvigil
1300428|NCT00766467|fatigue
1300429|NCT00766454|breast cancer
1300430|NCT00766441|diabetes
1300431|NCT00766441|hypoglycemia
1300432|NCT00766441|ramadan
1300433|NCT00766441|fasting
1300434|NCT00766415|COPD
1300435|NCT00766415|Moderate to severe COPD
1300436|NCT00766402|Spondylitis, ankylosing
1300437|NCT00766402|Pain
1300438|NCT00766402|Ultracet
1300439|NCT00766402|Diclofenac
1300440|NCT00766402|Voltaren
1300441|NCT00766402|Tramadol/acetaminophen
1300442|NCT00766389|Glaucoma
1300443|NCT00766389|Retinal nerve fiber layer
1300444|NCT00766389|Cirrus OCT
1300445|NCT00766389|Stratus OCT
1300446|NCT00766363|Alzheimer's Disease
1300447|NCT00766363|Central Nervous System Diseases
1300448|NCT00766363|Pharmacokinetics
1300449|NCT00766363|Cognition
1300450|NCT00766350|fibromyalgia
1300451|NCT00766350|quetiapine
1300452|NCT00766350|amitriptyline
1300453|NCT00766337|wet AMD
1300454|NCT00766298|Exercise
1300455|NCT00766298|Weight Loss
1300456|NCT00766298|Physical Activity
1300457|NCT00766298|Type 2 Diabetes Mellitus
1300458|NCT00766285|Baculovirus, influenza, stem cell transplant
1300459|NCT00766272|Rehabilitation
1300460|NCT00766272|Treadmill
1300461|NCT00766272|MS
1300462|NCT00766272|Gait
1300463|NCT00766272|Robot
1300464|NCT00766259|methicillin-resistant Staphylococcus
1300465|NCT00766259|colonization
1300466|NCT00766246|Non-Small Cell Lung Cancer
1300467|NCT00766246|Advanced Non-Small Cell Lung Cancer
1300468|NCT00766246|Lung Cancer
1300469|NCT00766233|Hyperthermia
1300470|NCT00766233|superficial tumor treatment
1300471|NCT00766233|superficial tumors
1300472|NCT00766220|Colon
1300473|NCT00766220|Liver
1300474|NCT00766220|Colorectal cancer
1300475|NCT00766220|Colorectal cancer metastases to the liver
1300476|NCT00766220|Metastases to the liver
1300477|NCT00766220|Colorectal cancer mets to liver
1300478|NCT00766220|Colon cancer metastasized to liver
1300479|NCT00766220|Yttrium microspheres
1300480|NCT00766220|SIR-Spheres
1300481|NCT00766220|Yttrium-90
1300482|NCT00766220|Cetuximab
1300483|NCT00766220|C225
1300484|NCT00766220|Erbitux
1300485|NCT00766220|IMC-C225
1300486|NCT00766220|Irinotecan
1300487|NCT00766220|CPT-11
1300488|NCT00766220|Liver directed therapy
1300489|NCT00766207|Teratogens
1300490|NCT00766207|Abnormalities, Drug-Induced
1300491|NCT00766207|Contraception
1300492|NCT00766181|IV placement; Parent satisfaction level
1300493|NCT00766168|contact lens
1300494|NCT00766168|rigid gas permeable
1300495|NCT00766168|refractive index
1300496|NCT00766155|stage II rectal cancer
1300497|NCT00766155|stage III rectal cancer
1300498|NCT00766155|adenocarcinoma of the rectum
1300499|NCT00766142|adenocarcinoma of the colon
1300500|NCT00766142|recurrent colon cancer
1300501|NCT00766142|stage IV colon cancer
1300502|NCT00766142|adenocarcinoma of the rectum
1300503|NCT00766142|recurrent rectal cancer
1300504|NCT00766142|stage IV rectal cancer
1300505|NCT00766142|peritoneal carcinomatosis
1300506|NCT00766129|saphenous vein graft, TAXUS stent, Chopin stent
1300507|NCT00766116|AML
1300508|NCT00766103|Cerebral metabolism, perfusion, induced hypothermia
1300509|NCT00766064|posttraumatic stress disorder
1300510|NCT00766051|Neurophysiologically Based Occupational Therapy Intervention (NBOTI)
1300511|NCT00766051|NBOTI
1300512|NCT00766051|NICU
1300513|NCT00766051|NCCU
1300514|NCT00766051|Developmental Biology
1300515|NCT00766051|Critical Period
1300516|NCT00766051|Brain Development
1300517|NCT00766051|Sensory Integration
1300518|NCT00766051|Neurodevelopment
1300519|NCT00766051|Sensitive Period
1300520|NCT00766038|Mood disorders
1300521|NCT00766038|Cognitive disorders
1300522|NCT00766038|Fatigue
1300523|NCT00766038|Metabolic disorders
1300524|NCT00766025|Taiwanese Subjects
1300525|NCT00766025|CYP2C19
1300526|NCT00766025|Poor Metabolizers
1300527|NCT00766025|Extensive Metabolizers
1300528|NCT00766025|Taiwanese Subjects identified as CYP2C19 Poor or Extensive Metabolizers
1300529|NCT00766012|safety
1300530|NCT00766012|tolerability
1300531|NCT00766012|pharmacokinetics
1300532|NCT00766012|AZD2066
1300533|NCT00766012|Japanese
1300534|NCT00765999|Constipation
1300535|NCT00765999|Chronic Constipation
1300536|NCT00765999|Irritable Bowel Syndrome With Constipation
1300537|NCT00765999|Linaclotide
1300538|NCT00765986|18F-FAZA
1300539|NCT00765986|18F-FDG
1300540|NCT00765986|Positron Emission Tomography
1300541|NCT00765973|Other Advanced Solid Tumors
1300542|NCT00765960|Vision
1300543|NCT00765947|Essential Hypertension ( mild to moderate)
1300544|NCT00765934|Healthy
1300545|NCT00765921|glaucoma, neovascular
1300546|NCT00765921|macular edema
1300547|NCT00765921|eye enucleation
1300548|NCT00765921|antibodies, monoclonal
1300549|NCT00765921|radiation oncology
1300550|NCT00765895|idiopathic gastroparesis
1300551|NCT00765882|Constipation
1300552|NCT00765882|Chronic Constipation
1300553|NCT00765882|Linaclotide
1300554|NCT00765869|Decision support techniques
1300555|NCT00765856|Opioid tolerant
1300556|NCT00765856|Pediatric
1300557|NCT00765856|Male 6-17 years of age
1300558|NCT00765856|Female 6-17 years of age
1300559|NCT00765856|Pain
1300560|NCT00765856|Non malignant
1300561|NCT00765856|Malignant
1300562|NCT00765843|heel pain
1300563|NCT00765830|Type 2 diabetes, vildagliptin
1300564|NCT00765817|diabetes
1300565|NCT00765817|exenatide
1300566|NCT00765817|Amylin
1300567|NCT00765817|Lilly
1300568|NCT00765817|metformin
1300569|NCT00765817|pioglitazone
1300570|NCT00765817|insulin glargine
1300571|NCT00765804|Dry Eye
1300572|NCT00765804|Iontophoresis
1300573|NCT00765804|Ophthalmic Delivery
1300574|NCT00765791|head and neck cancer
1300575|NCT00765791|oral cancer
1300576|NCT00765791|oropharyngeal cancer
1300577|NCT00765791|laryngeal cancer
1300578|NCT00765791|selective neck dissection
1300579|NCT00765791|submuscular recess
1300580|NCT00765791|level 2b
1300581|NCT00765778|resistant bacteria rehabilitation centers
1300582|NCT00765765|stage IV breast cancer
1300583|NCT00765765|recurrent breast cancer
1300584|NCT00765765|male breast cancer
1300585|NCT00765752|Insomnia
1300586|NCT00765752|depression
1300587|NCT00765752|GABA
1300588|NCT00765752|magnetic resonance spectroscopy
1300589|NCT00765752|MRS
1300590|NCT00765752|Sleep
1300591|NCT00765752|antidepressant medication use
1300592|NCT00765739|muscle fibers
1300593|NCT00765739|aging
1300594|NCT00765726|hemophilia
1300595|NCT00765726|hemophilia A
1300596|NCT00765726|ReFacto
1300597|NCT00765726|Xyntha
1300598|NCT00765726|moroctocog alfa
1300599|NCT00765726|bleeding disorder
1300600|NCT00765713|Sleep apnea
1300601|NCT00765713|CPAP
1300602|NCT00765713|Ventricular arrhythmias
1300603|NCT00765713|Defibrillator therapies
1300604|NCT00765700|Sprain
1300605|NCT00765700|Strain
1300606|NCT00765700|Pain
1300607|NCT00765700|Ankle Pain
1300608|NCT00765700|Shoulder Pain
1300609|NCT00765700|Elbow Pain
1300610|NCT00765700|Tennis Elbow
1300611|NCT00765700|Knee pain
1300612|NCT00765700|Wrist Pain
1300613|NCT00765700|Hand Pain
1300614|NCT00765700|Muscle, Bone and Cartilage Disorders
1300615|NCT00765674|aliskiren
1300616|NCT00765674|antihypertensive
1300617|NCT00765674|hypertension
1300618|NCT00765674|renin inhibitor
1300619|NCT00765674|moderate-severe hypertension
1300620|NCT00765661|Kidney
1300621|NCT00765661|Transplantation
1300622|NCT00765661|Immunosuppression
1300623|NCT00765661|Tacrolimus
1300624|NCT00765661|Prograf
1300625|NCT00765648|hypertension
1300626|NCT00765648|emergency department
1300627|NCT00765648|Nicardipine
1300628|NCT00765648|Labetalol
1300629|NCT00765648|hypertensive emergency
1300630|NCT00765648|hypertensive urgency
1300631|NCT00765635|complete occlusion of the ear canal due to cerumen
1300632|NCT00765622|Urinary incontinence
1300633|NCT00765622|pelvic floor
1300634|NCT00765622|functional evaluation
1300635|NCT00765609|Paediatric
1300636|NCT00765609|Analgesic
1300637|NCT00765609|Prescribing
1300638|NCT00765609|Parents
1300639|NCT00765596|Obesity
1300640|NCT00765596|Insulin resistance
1300641|NCT00765596|Gastric tube
1300642|NCT00765596|Ghrelin
1300643|NCT00765583|Wrinkles (Nasolabial Folds)
1300644|NCT00765570|large tumors in the head & neck, lung, abdomen or pelvis
1300645|NCT00765557|To determine if laxative therapy can resolve Urge Syndrome, and if so, in which patients.
1300646|NCT00765557|To determine usefulness of KUB, an abdominal X-ray of the kidneys, ureters, and bladder.
1300647|NCT00765557|To predict the bowel activity of children with Urge Syndrome, who are most likely to respond to laxatives, with the use of the Bowel/Bladder questionnaire.
1300648|NCT00765544|MS
1300649|NCT00765544|Rehabilitation
1300650|NCT00765544|Treadmill
1300651|NCT00765544|Robot
1300652|NCT00765544|Foot-drop
1300653|NCT00765531|To determine the prevalence of genetic mutations in a population.
1300654|NCT00765531|To identify stone formers with significant family history of stones.
1300655|NCT00765531|To follow a cohort of pediatric stone formers an their families to report the long-term recurrence rats and therapeutic outcomes.
1300656|NCT00765518|Ischemic Dilated Cardiomyopathy
1300657|NCT00765518|Non-Ischemic Dilated Cardiomyopathy
1300658|NCT00765518|ixmyelocel-T
1300659|NCT00765505|Insulin Resistance
1300660|NCT00765505|Obesity
1300661|NCT00765505|Exercise Training
1300662|NCT00765505|Physical Activity
1300663|NCT00765492|Phase I
1300664|NCT00765479|stage IIB prostate cancer
1300665|NCT00765479|stage IIA prostate cancer
1300666|NCT00765466|Explore the effect of AVR118 4.0 mL, given subcutaneously on appetite
1300667|NCT00765453|Heart attack
1300668|NCT00765453|Anterior Myocardial infarction (MI)
1300669|NCT00765453|adult stem cells
1300670|NCT00765453|bone marrow progenitor cells
1300671|NCT00765453|bone marrow stem cells
1300672|NCT00765453|autologous
1300673|NCT00765453|left ventricular function
1300674|NCT00765453|intracoronary injection
1300675|NCT00765440|infection
1300676|NCT00765440|malnutrition
1300677|NCT00765440|stage I adenoid cystic carcinoma of the oral cavity
1300678|NCT00765440|stage I mucoepidermoid carcinoma of the oral cavity
1300679|NCT00765440|stage I verrucous carcinoma of the oral cavity
1300680|NCT00765440|stage II adenoid cystic carcinoma of the oral cavity
1300681|NCT00765440|stage II mucoepidermoid carcinoma of the oral cavity
1300682|NCT00765440|stage II verrucous carcinoma of the oral cavity
1300683|NCT00765440|stage III adenoid cystic carcinoma of the oral cavity
1300684|NCT00765440|stage III mucoepidermoid carcinoma of the oral cavity
1300685|NCT00765440|stage III verrucous carcinoma of the oral cavity
1300686|NCT00765440|stage IV adenoid cystic carcinoma of the oral cavity
1300687|NCT00765440|stage IV mucoepidermoid carcinoma of the oral cavity
1300688|NCT00765440|stage IV verrucous carcinoma of the oral cavity
1300689|NCT00765440|stage I squamous cell carcinoma of the larynx
1300690|NCT00765440|stage I verrucous carcinoma of the larynx
1300691|NCT00765440|stage II squamous cell carcinoma of the larynx
1300692|NCT00765440|stage II verrucous carcinoma of the larynx
1300693|NCT00765440|stage III squamous cell carcinoma of the larynx
1300694|NCT00765440|stage III verrucous carcinoma of the larynx
1300695|NCT00765440|stage IV squamous cell carcinoma of the larynx
1300696|NCT00765440|stage IV verrucous carcinoma of the larynx
1300697|NCT00765440|stage I lymphoepithelioma of the oropharynx
1300698|NCT00765440|stage I squamous cell carcinoma of the oropharynx
1300699|NCT00765440|stage II lymphoepithelioma of the oropharynx
1300700|NCT00765440|stage II squamous cell carcinoma of the oropharynx
1300701|NCT00765440|stage III lymphoepithelioma of the oropharynx
1300702|NCT00765440|stage III squamous cell carcinoma of the oropharynx
1300703|NCT00765440|stage IV lymphoepithelioma of the oropharynx
1300944|NCT00764270|atherosclerosis
1300704|NCT00765440|stage IV squamous cell carcinoma of the oropharynx
1300705|NCT00765440|stage I squamous cell carcinoma of the hypopharynx
1300706|NCT00765440|stage II squamous cell carcinoma of the hypopharynx
1300707|NCT00765440|stage III squamous cell carcinoma of the hypopharynx
1300708|NCT00765440|stage IV squamous cell carcinoma of the hypopharynx
1300709|NCT00765440|tongue cancer
1300710|NCT00765401|Abdominal Pain
1300711|NCT00765401|Cystic Fibrosis
1300712|NCT00765401|H. pylori
1300713|NCT00765401|Children
1300714|NCT00765388|urostomy, 1-piece, cross-over, randomised, preference
1300715|NCT00765375|acne
1300716|NCT00765375|Botox
1300717|NCT00765375|cosmetic treatments
1300718|NCT00765336|Spermatogenesis in Healthy Males
1300719|NCT00765323|Octreotide
1300720|NCT00765323|Sandostatin LAR
1300721|NCT00765323|Growth hormone
1300722|NCT00765323|IGF-1
1300723|NCT00765310|atherosclerosis
1300724|NCT00765310|lipoic acid
1300725|NCT00765310|thioctic acid
1300726|NCT00765310|triglycerides
1300727|NCT00765310|overweight
1300728|NCT00765310|obesity
1300729|NCT00765310|oxidative stress
1300730|NCT00765310|inflammation
1300731|NCT00765297|fall risk
1300732|NCT00765297|movement characteristics
1300733|NCT00765297|stumble detection
1300734|NCT00765297|accelerometry
1300735|NCT00765284|HDL
1300736|NCT00765284|RCT
1300737|NCT00765284|Cholesterol
1300738|NCT00765245|stage I adult diffuse large cell lymphoma
1300739|NCT00765245|contiguous stage II adult diffuse large cell lymphoma
1300740|NCT00765245|noncontiguous stage II adult diffuse large cell lymphoma
1300741|NCT00765245|stage III adult diffuse large cell lymphoma
1300742|NCT00765245|stage IV adult diffuse large cell lymphoma
1300743|NCT00765232|laparoscopic
1300744|NCT00765232|donor
1300745|NCT00765232|nephrectomy
1300746|NCT00765219|Generalized Anxiety Disorder
1300747|NCT00765219|Geriatric
1300748|NCT00765180|colonoscopy
1300749|NCT00765180|hood
1300750|NCT00765180|NBI
1300751|NCT00765141|wound debridement
1300752|NCT00765141|removed orthopedic implants
1300753|NCT00765141|removed catheters or shunts
1300754|NCT00765141|excised tonsils
1300755|NCT00765141|amputated tissue
1300756|NCT00765141|sputum, stool
1300757|NCT00765141|or other excretions.
1300758|NCT00765128|Percutaneous
1300759|NCT00765128|Nephrolithotomy
1300760|NCT00765128|Kidney stones
1300761|NCT00765102|Multiple Myelonoma
1300762|NCT00765102|Romidepsin
1300763|NCT00765102|Bortezomib
1300764|NCT00765076|Vaccine
1300765|NCT00765076|Elderly
1300766|NCT00765076|Influenza
1300767|NCT00765063|Diabetic Foot Ulcers Neuroischaemic
1300768|NCT00765050|Cellular therapy
1300769|NCT00765050|CD133+
1300770|NCT00765024|strongyloidiasis, ivermectin, albendazole
1300771|NCT00765011|Head and Neck Cancer
1300772|NCT00764998|Influenza
1300773|NCT00764998|HIV
1300774|NCT00764998|Influenza Vaccine
1300775|NCT00764998|Efficacy
1300776|NCT00764985|Syncope
1300777|NCT00764985|Pre-Syncope
1300778|NCT00764985|Fainting
1300779|NCT00764972|To evaluate the use of sorafenib added to vinorelbine chemotherapy, to find out which are the doses of two drugs can be safely combined
1300780|NCT00764933|information programme
1300781|NCT00764933|anxiety reduction
1300782|NCT00764933|multicenter trial
1300783|NCT00764933|intensive care
1300784|NCT00764933|critical care
1300785|NCT00764920|human skin
1300786|NCT00764907|T-cell childhood acute lymphoblastic leukemia
1300787|NCT00764907|B-cell childhood acute lymphoblastic leukemia
1300788|NCT00764907|untreated childhood acute lymphoblastic leukemia
1300789|NCT00764881|Oral contraceptive
1300790|NCT00764881|Sexual dysfunction
1300791|NCT00764881|Libido
1300792|NCT00764829|hematopoietic stem cell transplantation
1300793|NCT00764829|fludarabine
1300794|NCT00764829|mycophenolate mofetil
1300795|NCT00764829|mycophenolic acid
1300796|NCT00764829|biomarkers
1300797|NCT00764816|Chronic kidney disease, stages 3 and 4
1300798|NCT00764816|phosphaturia
1300799|NCT00764816|phosphorus
1300800|NCT00764816|PTH
1300801|NCT00764816|FGF23
1300802|NCT00764816|Dietary protein source
1300803|NCT00764777|Peripheral Vascular Disease
1300804|NCT00764777|Intermittent Claudication
1300805|NCT00764777|Critical limb Ischemia
1300806|NCT00764777|TASC A
1300807|NCT00764777|TASC B
1300808|NCT00764777|TASC C
1300809|NCT00764777|TASC D
1300810|NCT00764777|balloon-expandable stent
1300811|NCT00764777|Self-expanding stent
1300812|NCT00764777|TASC
1300813|NCT00764764|shoulder pain
1300814|NCT00764764|rotator cuff
1300815|NCT00764764|impingement
1300816|NCT00764764|cervical referred pain
1300817|NCT00764764|neural tension
1300818|NCT00764738|ARMD
1300819|NCT00764738|AMD
1300820|NCT00764738|exudative AMD
1300821|NCT00764712|Tight glycemia control
1300822|NCT00764712|cardiac surgery patients
1300823|NCT00764699|poor growth
1300945|NCT00764270|lipoic acid
1300824|NCT00764699|inflammatory bowel disease
1300825|NCT00764686|Exercise
1300826|NCT00764686|Education
1300827|NCT00764686|Hydrotherapy
1300828|NCT00764686|Physical Therapy Modalities
1300829|NCT00764647|family caregivers
1300830|NCT00764647|caregiver education
1300831|NCT00764647|caregiver burden
1300832|NCT00764647|caregiver hardiness
1300833|NCT00764647|caregiver depressive symptoms
1300834|NCT00764621|Gadolinium ethoxybenzyl DTPA
1300835|NCT00764621|Contrast media
1300836|NCT00764621|Outcome Assessment (Health Care)
1300837|NCT00764621|Magnetic Resonance Imaging
1300838|NCT00764621|Tomography, X-Ray Computed
1300839|NCT00764621|Liver
1300840|NCT00764595|gastrointestinal stromal tumor
1300841|NCT00764595|liver metastases
1300842|NCT00764582|Corneal penetration of levofloxacin and moxifloxacin
1300843|NCT00764569|oral tissue
1300844|NCT00764556|Glucose
1300845|NCT00764556|Insulin
1300846|NCT00764556|COPD
1300847|NCT00764556|Exacerbations
1300848|NCT00764556|Tight glycaemic control
1300849|NCT00764556|Acute hospital ward
1300850|NCT00764543|To measure 24-hour ambulatory blood pressure in children who have unilateral hydronephrosis or multicystic-dysplastic kidneys
1300851|NCT00764543|To compare these blood pressure measurements between the children who require surgical correction and those who do not need surgical correction.
1300852|NCT00763685|preoperative pain prophylaxis
1300853|NCT00763685|postoperative pain
1300854|NCT00763672|Preeclampsia
1300855|NCT00763672|Hypertension
1300856|NCT00763672|Intra uterine growth retardation
1300857|NCT00763672|Antiangiogenic factor
1300858|NCT00763672|Prevention
1300859|NCT00763646|Gastric or Gastroesophageal Junction Adenocarcinoma
1300860|NCT00763633|nausea
1300861|NCT00763633|vomiting
1300862|NCT00763633|pregnancy
1300863|NCT00763633|B6
1300864|NCT00763620|Community acquired pneumonia
1300865|NCT00763620|Nosocomial pneumonia
1300866|NCT00763620|Mini bronchoalveolar lavage
1300867|NCT00763620|Endotracheal aspirates
1300868|NCT00763620|Expectorated sputum
1300869|NCT00763607|non small cell lung cancer patients
1300870|NCT00763594|Major Depression
1300871|NCT00763594|Interpersonal Psychotherapy
1300872|NCT00763594|Brief Relational Therapy
1300873|NCT00763594|Outcome research
1300874|NCT00763581|Patient Non-Adherence
1300875|NCT00763581|Patient Non-Compliance
1300876|NCT00763581|Patient Nonadherence
1300877|NCT00763581|Patient Noncompliance
1300878|NCT00763581|Patient Refusal of Treatment
1300879|NCT00763581|Treatment Refusal
1300880|NCT00763581|Refusal of Treatment
1300881|NCT00763568|Chronic hepatitis C
1300882|NCT00763568|Viral hepatitis
1300883|NCT00763555|psoriasis
1300884|NCT00763555|spray
1300885|NCT00763555|calcitriol
1300886|NCT00763516|Pancreatic Cancer
1300887|NCT00763516|Proton radiation
1300888|NCT00763516|Chemotherapy
1300889|NCT00763516|Xeloda
1300890|NCT00763516|Gemzar
1300891|NCT00763516|Resectable
1300892|NCT00763516|Surgery
1300893|NCT00763503|psoriasis
1300894|NCT00763503|PK
1300895|NCT00763503|calcitriol
1300896|NCT00763490|umbilical cord blood
1300897|NCT00763490|stem cell transplant
1300898|NCT00763490|leukemia
1300899|NCT00763490|multiple myeloma
1300900|NCT00763490|lymphoma
1300901|NCT00763477|Cystic fibrosis
1300902|NCT00763477|Weight
1300903|NCT00763477|Appetite
1300904|NCT00763477|Ghrelin
1300905|NCT00763477|Cystic fibrosis with low BMI
1300906|NCT00764465|Healthy Subjects
1300907|NCT00764465|Pharmacokinetics study
1300908|NCT00764465|Pharmacokinetics of medications
1300909|NCT00764426|alcoholic beverages
1300910|NCT00764426|non-alcoholic beverages
1300911|NCT00764426|inflammation
1300912|NCT00764426|Serum concentration of inflammatory markers before and after intervention
1300913|NCT00764413|EDSS
1300914|NCT00764413|methylprednisolone
1300915|NCT00764413|circadian rhythms
1300916|NCT00764413|MSFC
1300917|NCT00764400|aphasia
1300918|NCT00764400|anomia
1300919|NCT00764400|speech therapy
1300920|NCT00764400|rehabilitation
1300921|NCT00764387|Neoplastic CNS lesions
1300922|NCT00764387|Contrast enhanced MRI
1300923|NCT00764387|Comparison
1300924|NCT00764374|YM443
1300925|NCT00764374|Z-338
1300926|NCT00764374|Acotiamide
1300927|NCT00764374|Rome III
1300928|NCT00764374|Signs and symptoms, digestive
1300929|NCT00764361|Diabetic
1300930|NCT00764361|Ulcer
1300931|NCT00764361|Wound
1300932|NCT00764348|Acute and Chronic Wounds
1300933|NCT00764322|menopausal symptoms
1300934|NCT00764322|recurrent breast cancer
1300935|NCT00764322|stage I breast cancer
1300936|NCT00764322|stage II breast cancer
1300937|NCT00764322|stage IIIA breast cancer
1300938|NCT00764322|stage IIIB breast cancer
1300939|NCT00764322|stage IIIC breast cancer
1300940|NCT00764322|stage IV breast cancer
1300941|NCT00764322|ductal breast carcinoma in situ
1300942|NCT00764322|breast cancer in situ
1300943|NCT00764296|acute wounds and chronic wounds
1300946|NCT00764270|thioctic acid
1300947|NCT00764270|triglycerides
1300948|NCT00764270|overweight
1300949|NCT00764270|obesity
1300950|NCT00764270|oxidative stress
1300951|NCT00764270|inflammation
1300952|NCT00764244|Diabetes
1300953|NCT00764244|Macular edema
1300954|NCT00764244|Optical Coherence tomography
1300955|NCT00764244|VitrectomyLaser therapy
1300956|NCT00764244|Intravitreal triamcinolone injection
1300957|NCT00764231|acute myeloid leukemia
1300958|NCT00764231|exercise
1300959|NCT00764231|fatigue
1300960|NCT00764231|quality of life
1300961|NCT00764231|home-based
1300962|NCT00764231|AML
1300963|NCT00764218|Obstructive sleep apnea syndrome
1300964|NCT00764218|Hypertension
1300965|NCT00764218|Cardiovascular phenotype
1300966|NCT00764205|ACS
1300967|NCT00764205|non STEMI
1300968|NCT00764205|ECG troponin
1300969|NCT00764205|iSTAT
1300970|NCT00764205|Acute coronary syndrome without ST-segment elevation
1300971|NCT00764192|hemodialysis
1300972|NCT00764192|Flow-mediated dilation
1300973|NCT00764192|nictric oxide
1300974|NCT00764192|endothelial function
1300975|NCT00764179|Neonates with intra-uterine growth delay
1300976|NCT00764166|PSA (biochemical)
1300977|NCT00764166|Progression- free Survival
1300978|NCT00764166|Clinical progress
1300979|NCT00764166|Overall survival
1300980|NCT00764166|Tolerance to the treatment
1300981|NCT00764166|Quality of Live
1300982|NCT00764153|Displaced Femoral Neck Fractures
1300983|NCT00764153|Treatment
1300984|NCT00764153|Function
1300985|NCT00764153|Pain
1300986|NCT00764153|Quality of life
1300987|NCT00764153|Complications
1300988|NCT00764153|Reoperations
1300989|NCT00764153|Internal Fixation
1300990|NCT00764153|Hemiarthroplasty
1300991|NCT00764153|Activities of Daily Living
1300992|NCT00764140|tumor growth factor
1300993|NCT00764127|adolescent
1300994|NCT00764127|obesity
1300995|NCT00764127|bariatric surgery
1300996|NCT00764127|eating
1300997|NCT00764114|Spondylodiscitis
1300998|NCT00764114|Duration treatment
1300999|NCT00764114|Antibiotic
1301000|NCT00764114|men or women more than 18 years
1301001|NCT00764114|proved bacterial spondylodiscitis
1301002|NCT00764114|patient for which is decided a treatment antibiotic
1301003|NCT00764114|the diagnosis on clinical
1301004|NCT00764114|Radiological
1301005|NCT00764114|microbiological criteria
1301006|NCT00764088|full Thickness wounds
1301007|NCT00764075|heart failure; EF<35%; NYHA II, III or IV
1301008|NCT00764062|Amoxicillin
1301009|NCT00764062|Drug resistance, microbial
1301010|NCT00764062|Streptococcus
1301011|NCT00764062|Surgery, oral
1301012|NCT00764049|Albumin dialysis
1301013|NCT00764049|Artificial liver support
1301014|NCT00764049|Acute on chronic liver failure
1301015|NCT00764036|phase I
1301016|NCT00764036|safety
1301017|NCT00764023|wound debridement
1301018|NCT00764023|removed orthopedic implants
1301019|NCT00764023|removed catheters or shunts
1301020|NCT00764023|excised tonsils, amputated tissue
1301021|NCT00764023|sputum
1301022|NCT00764023|stool
1301023|NCT00764023|other excretions.
1301024|NCT00763997|dipyrone
1301025|NCT00763997|platelet aggregation
1301026|NCT00763997|neuraxial blockage
1301027|NCT00763997|ibuprofen
1301028|NCT00763997|platelet aggregation under dipyrone compared to ibuprofen, acetaminophen and parecoxib/valdecoxib
1301029|NCT00763997|neuraxial blockage in patients receiving ibuprofen is critical in special circumstances, but traditionally not fpr dipyrone
1301030|NCT00763984|Bladder Control for Women
1301031|NCT00763984|Exercising Your Pelvic Muscles
1301032|NCT00763984|Kegel Exercises: How to Strengthen Pelvic Floor Muscles
1301033|NCT00763984|Kegel Exercises for Your Pelvic Muscles
1301034|NCT00763984|Pelvic Floor Disorders
1301035|NCT00763984|Pelvic Support Problems
1301036|NCT00763984|Pregnancy
1301037|NCT00763984|Pregnancy Childbirth and Bladder Control
1301038|NCT00763984|Urinary Incontinence
1301039|NCT00763984|Urinary Incontinence: Embarrassing but Treatable
1301040|NCT00763958|opiates
1301041|NCT00763958|HIV
1301042|NCT00763945|Acute coronary Syndrome
1301043|NCT00763945|STEMI
1301044|NCT00763945|NSTEMI
1301045|NCT00763945|Registry
1301046|NCT00763919|Patient Non-Adherence
1301047|NCT00763919|Patient Non-Compliance
1301048|NCT00763919|Patient Nonadherence
1301049|NCT00763919|Patient Noncompliance
1301050|NCT00763919|Patient Refusal of Treatment
1301051|NCT00763919|Refusal of Treatment
1301052|NCT00763919|Treatment Refusal
1301053|NCT00763906|septic shock
1301054|NCT00763906|fuzzy logic
1301055|NCT00763906|norepinephrine weaning
1301056|NCT00763893|Marfan syndrome
1301057|NCT00763893|Angiotensin II Type 1 Receptor Blockers
1301058|NCT00763893|Aortic Aneurysm, Thoracic
1301059|NCT00763880|Hematoma block
1301060|NCT00763880|Lidocaine
1301061|NCT00763880|Forearm fracture
1301062|NCT00763880|Radius fracture
1301063|NCT00763880|Ulna fracture
1301064|NCT00763880|Ketamine
1301065|NCT00763880|Midazolam
1301066|NCT00763880|Procedural sedation
1301067|NCT00763867|Heart Failure, Diastolic
1301068|NCT00763867|Decompensated Heart Failure
1301069|NCT00763867|Sildenafil
1301070|NCT00763867|Exercise Capacity
1301071|NCT00763841|Auditory hallucinations
1301072|NCT00763828|Myocardial Infarction
1301073|NCT00763828|Hypothermia, Induced
1301074|NCT00763815|hyperglycemia GLP-1 pioglitazone
1301075|NCT00763789|conscious sedation
1301076|NCT00763789|remifentanil
1301077|NCT00763789|hysteroscopic surgery
1301078|NCT00763789|anesthesia recovery period
1301079|NCT00763789|ambulatory surgery
1301080|NCT00763789|patient satisfaction
1301081|NCT00763789|length of stay
1301082|NCT00763776|Liver cirrhosis
1301083|NCT00763776|Hepatectomy
1301084|NCT00763776|Liver parenchyma transection
1301085|NCT00763776|Randomized controlled trial
1301086|NCT00763763|Imatinib mesylate
1301087|NCT00763763|Combination therapy
1301088|NCT00763763|Leukemia, Lymphocytic, Acute
1301089|NCT00763763|Philadelphia Chromosome
1301090|NCT00763763|Blast Crisis
1301091|NCT00763763|Leukemia, Myeloid, Chronic
1301092|NCT00763750|glioblastoma multiforme or anaplastic glioma
1301093|NCT00763737|congenital diaphragmatic hernia
1301094|NCT00763737|fetal surgery
1301095|NCT00763737|pulmonary hypoplasia
1301096|NCT00763737|observed/expected lung to head ratio
1301097|NCT00763737|liver position
1301098|NCT00763737|feto
1301099|NCT00763737|fetoscopic endoluminal tracheal occlusion
1301100|NCT00763737|standardized neonatal care
1301101|NCT00763711|Urinary Incontinence
1301102|NCT00763711|ISD
1301103|NCT00763698|Left heart pacing lead
1301104|NCT00763698|Cardiac resynchronization therapy (CRT)
1301105|NCT00763698|Heart failure
1301106|NCT00763698|ICD
1301107|NCT00763464|Coronary Artery Disease
1301108|NCT00763464|ischemia diagnostic
1301109|NCT00763451|hyperglycemia, GLP-1
1301110|NCT00763438|Schizophrenia
1301111|NCT00763438|Sertindole
1301112|NCT00763438|Safety study
1301113|NCT00763425|polypectomy
1301114|NCT00763425|colonic polyp
1301115|NCT00763425|colorectal polyp
1301116|NCT00763425|colorectal cancer prevention
1301117|NCT00763412|Cystic Fibrosis
1301118|NCT00763412|Diabetes
1301119|NCT00763412|Cystic Fibrosis Related Diabetes
1301120|NCT00763412|Pre-diabetes
1301121|NCT00763412|oral hypoglycemic agents
1301122|NCT00763412|Repaglinide
1301123|NCT00763412|treatment
1301124|NCT00763412|inflammatory markers
1301125|NCT00763412|Lung function
1301126|NCT00763412|nutrition
1301127|NCT00763399|probiotics
1301128|NCT00763386|Total Knee Arthroplasty
1301129|NCT00763386|Osteoarthritis
1301130|NCT00763386|Knee
1301131|NCT00763373|Lower respiratory infection
1301132|NCT00763373|Upper respiratory infection
1301133|NCT00763373|Urinary tract infection
1301134|NCT00763373|Soft tissue infection
1301135|NCT00763373|Hepatobiliary infection
1301136|NCT00763360|Cataract
1301137|NCT00763347|Glucose Metabolism Disorder
1301138|NCT00763347|Dysmetabolic Syndrome
1301139|NCT00763347|Type II Diabetes
1301140|NCT00763347|Diabetes Mellitus, Lipoatrophic
1301141|NCT00763347|Dyslipidemia
1301142|NCT00763347|Drug Therapy
1301143|NCT00763321|Effect on sleep interference by pain
1301144|NCT00763308|Weight
1301145|NCT00763308|Blood Pressure
1301146|NCT00763308|Smoking Status
1301147|NCT00763308|Cardiovascular Risk Profile
1301148|NCT00763295|latent tuberculosis
1301149|NCT00763295|HIV
1301150|NCT00763295|IFN-γ based assay
1301151|NCT00763282|Spinal cord injuries
1301152|NCT00763282|Pressure ulcers
1301153|NCT00763282|Health behavior
1301154|NCT00763282|self management
1301155|NCT00763282|Rehabilitation
1301156|NCT00763282|Outcome assessment
1301157|NCT00763282|QUERI
1301158|NCT00763282|Veterans
1301159|NCT00763243|profound bilateral hearing loss with cochlear implants
1301160|NCT00763230|Depression
1301161|NCT00763230|Treatment
1301162|NCT00763230|Transcranial direct current stimulation
1301163|NCT00763217|inflammation
1301164|NCT00763217|coagulation
1301165|NCT00763217|neuroprotection
1301166|NCT00763217|drugs
1301167|NCT00763217|clinical neurology
1301168|NCT00763217|pharmacology
1301169|NCT00763217|biological factors
1301170|NCT00763204|Plaque Type Psoriasis
1301171|NCT00763204|Topical
1301172|NCT00763178|PTSD
1301173|NCT00763152|prostate
1301174|NCT00763152|prostate bed
1301175|NCT00763152|periprostatic
1301176|NCT00763139|RA
1301177|NCT00763139|Rheumatoid Arthritis
1301178|NCT00763126|parturient
1301179|NCT00763126|epidural analgesia
1301180|NCT00763126|labor
1301181|NCT00763126|spouse
1301182|NCT00763126|Stress levels
1301183|NCT00763126|Salivary amylase
1301184|NCT00763100|Breast cancer
1301185|NCT00763100|Three dimensional versus two dimensional
1301186|NCT00763100|Breast cancer surveillance
1301187|NCT00763100|Tomosynthesis
1301188|NCT00763087|diabetes mellitus
1301189|NCT00763087|peripheral neuropathy
1301190|NCT00763087|exercise
1301191|NCT00763074|Intra-Abdominal Fat
1301192|NCT00763074|Adipokines
1301193|NCT00763074|Exercise
1301194|NCT00763074|Diet therapy
1301195|NCT00763061|Glaucoma
1301196|NCT00763035|Coronary Artery Disease
1301197|NCT00763035|Coronary Vessels
1301198|NCT00763035|Myocardial Ischemia
1301199|NCT00763035|Coronary Disease
1301200|NCT00763035|Ischemic heart disease
1301201|NCT00763035|asthma
1301202|NCT00763035|copd
1301203|NCT00763022|Glucose Metabolism Disorder
1301204|NCT00763022|Dysmetabolic Syndrome
1301205|NCT00763022|Type II Diabetes
1301206|NCT00763022|Diabetes Mellitus, Lipoatrophic
1301207|NCT00763022|Dyslipidemia
1301208|NCT00763022|Drug Therapy
1301209|NCT00762957|Glucose Metabolism Disorder
1301210|NCT00762957|Dysmetabolic Syndrome
1301211|NCT00762957|Type II Diabetes
1301212|NCT00762957|Diabetes Mellitus, Lipoatrophic
1301213|NCT00762957|Dyslipidemia
1301214|NCT00762957|Drug Therapy
1301215|NCT00762944|Patients requiring total joint reconstruction due to:
1301216|NCT00762944|Arthritis (osteo-, rheumatoid, traumatic) malignancy
1301217|NCT00762944|Ankylosis functional deformity
1301218|NCT00762944|Avascular necrosis revisions
1301219|NCT00762944|Benign neoplasms fracture
1301220|NCT00762944|Multiple operated joints
1301221|NCT00762931|bronchoconstriction
1301222|NCT00762931|neuromodulation
1301223|NCT00762931|neurostimulation
1301224|NCT00762931|vagus nerve stimulation
1301225|NCT00762931|vagal nerve stimulation
1301226|NCT00762931|nVNS
1301227|NCT00762931|VNS
1301228|NCT00762931|non invasive
1301229|NCT00762931|gammacore
1301230|NCT00762918|cystic fibrosis
1301231|NCT00762918|vitamin d
1301232|NCT00762918|inflammation
1301233|NCT00762905|cyanoacrylate
1301234|NCT00762905|LiquiBand Laparoscopic
1301235|NCT00762905|Dermabond
1301236|NCT00762905|The rate of complete dermal apposition
1301237|NCT00762905|The rate of wound infections and wound dehiscence
1301238|NCT00762905|The rate of optimal cosmesis
1301239|NCT00762892|Raltegravir
1301240|NCT00762892|Integrase inhibitor
1301241|NCT00762892|Protease inhibitor
1301242|NCT00762892|Naive patients
1301243|NCT00762892|HIV disease
1301244|NCT00762892|Lipids
1301245|NCT00762892|Treatment Naïve
1301246|NCT00762879|Juvenile Idiopathic Arthritis
1301247|NCT00762879|JIA
1301248|NCT00762879|Arthritis
1301249|NCT00762879|Osteoporosis
1301250|NCT00762879|Osteoporosis in Children
1301251|NCT00762866|Major Depressive Disorder
1301252|NCT00762866|Depression
1301253|NCT00762866|Bipolar I Disorder
1301254|NCT00762866|Bipolar II Disorder
1301255|NCT00762866|Bipolar Disorder NOS
1301256|NCT00762866|Psychotic Disorder
1301257|NCT00762866|Schizophrenia
1301258|NCT00762866|Schizoaffective Disorder
1301259|NCT00762840|Periapical lesions
1301260|NCT00762840|Apical Periodontitis
1301261|NCT00762840|endodontic procedure
1301262|NCT00762840|root canal treatment
1301263|NCT00762814|Parkinson disease
1301264|NCT00762814|Individuals
1301265|NCT00762814|frequent
1301266|NCT00762814|freezing
1301267|NCT00762814|during
1301268|NCT00762814|gait
1301269|NCT00762801|RLIP76
1301270|NCT00762801|Cancer
1301271|NCT00762801|apoptosis
1301272|NCT00762775|Bone resorption
1301273|NCT00762775|Calcium homeostasis
1301274|NCT00762775|Bone markers
1301275|NCT00762775|Calcium and Vitamin D supplementation
1301276|NCT00762775|Parathyroid hormone levels
1301277|NCT00762775|Interaction between calcium and vitamin D supplementation
1301278|NCT00762736|Glucose Metabolism Disorder
1301279|NCT00762736|Dysmetabolic Syndrome
1301280|NCT00762736|Type II Diabetes
1301281|NCT00762736|Diabetes Mellitus, Lipoatrophic
1301282|NCT00762736|Dyslipidemia
1301283|NCT00762736|Drug Therapy
1301284|NCT00762723|Degenerative Disc Disease
1301285|NCT00762723|Spinal Stenosis
1301286|NCT00762723|Spondylolisthesis
1301287|NCT00762723|ALIF
1301288|NCT00762723|fusion success
1301289|NCT00762723|Anterior Lumbar Plate
1301290|NCT00762723|fixed versus variable screw configurations
1301291|NCT00762723|Anterior Lumbar Interbody Fusion to treat spinal instability
1301292|NCT00762710|Alcohol
1301293|NCT00762710|Abuse
1301294|NCT00762710|Use
1301295|NCT00762710|Disorder
1301296|NCT00762710|Dependence
1301297|NCT00762710|Symptoms
1301298|NCT00762710|Alcoholic
1301299|NCT00762710|Alcoholism
1301300|NCT00762710|Prazosin
1301301|NCT00762710|Drug
1301302|NCT00762710|Medicine
1301303|NCT00762710|Medication
1301304|NCT00762710|Treatment
1301305|NCT00762710|Study
1301306|NCT00762710|Placebo
1301307|NCT00762710|Medical
1301308|NCT00762710|Management
1301309|NCT00762710|Craving
1301310|NCT00762710|Consumption
1301311|NCT00762710|Binge
1301312|NCT00762710|Drinking
1301313|NCT00762710|Drink
1301314|NCT00762710|Heavy
1301315|NCT00762697|diabetic, venous insufficiency
1301316|NCT00762684|Glucose Metabolism Disorder
1301317|NCT00762684|Dysmetabolic Syndrome
1301318|NCT00762684|Type II Diabetes
1301319|NCT00762684|Diabetes Mellitus, Lipoatrophic
1301320|NCT00762684|Dyslipidemia
1301321|NCT00762658|Plaque Type Psoriasis
1301322|NCT00762658|Topical
1301323|NCT00762645|IOP lowering efficacy
1301324|NCT00762645|CACG
1301325|NCT00762632|patients with c-kit+ AML
1301326|NCT00762606|Cataract
1301327|NCT00762593|urinary stress incontinence
1301328|NCT00762593|urinary stress incontinence in women
1301329|NCT00762580|rotator cuff
1301330|NCT00762580|rehabilitation
1301331|NCT00762554|analgesia
1301332|NCT00762554|cesarean section
1301333|NCT00762554|fentanyl
1301334|NCT00762554|Depodur
1301335|NCT00762554|Post-cesarean section analgesia
1301336|NCT00762541|Myopia
1301337|NCT00762541|Laser In Situ Keratomileusis
1301338|NCT00762541|Laser Therapy
1301339|NCT00762541|Laser Corneal Surgery
1301340|NCT00762541|Refractive Surgical Procedures
1301341|NCT00762541|Ophthalmologic Surgical Procedure
1301342|NCT00762541|Operative Surgical Procedures
1301343|NCT00762541|Therapeutics
1301344|NCT00762489|Temporal artery thermometry
1301345|NCT00762489|Rectal temperature
1301346|NCT00762489|Axillary temperature
1301347|NCT00762489|Newborns
1301348|NCT00762489|Temperature measurement
1301349|NCT00762476|cold, common
1301350|NCT00762476|rhinovirus
1301351|NCT00762424|Kidney stone
1301352|NCT00762424|Ureterolithiasis
1301353|NCT00762424|Tamsulosin
1301354|NCT00762424|Flowmax
1301355|NCT00762424|Emergency Department
1301356|NCT00762411|Alzheimer's Disease
1301357|NCT00762398|Major surgery, excpected blood loss, arterial line
1301358|NCT00762372|anesthesia
1301359|NCT00762372|desflurane
1301360|NCT00762359|Curling Ulcer
1301361|NCT00762359|Gastric Ulcer
1301362|NCT00762359|Aspirin
1301363|NCT00762359|Acetylsalicylic Acid
1301364|NCT00762359|Drug Therapy
1301365|NCT00762346|non small cell lung cancer
1301366|NCT00762346|NTX
1301367|NCT00762346|zometa
1301368|NCT00762320|HIV
1301369|NCT00762320|Kaletra
1301370|NCT00762320|treatment Experienced
1301371|NCT00762294|breast cancer
1301372|NCT00762294|arimidex
1301373|NCT00762294|femara
1301374|NCT00762294|bone health
1301375|NCT00762281|Hyperopia
1301376|NCT00762281|Laser In Situ Keratomileusis
1301377|NCT00762281|Laser Therapy
1301378|NCT00762281|Laser Corneal Surgery
1301379|NCT00762281|Refractive Surgical Procedures
1301380|NCT00762281|Ophthalmologic Surgical Procedure
1301381|NCT00762281|Operative Surgical Procedures
1301382|NCT00762281|Therapeutics
1301383|NCT00762268|SAMe
1301384|NCT00762268|alternative treatments
1301385|NCT00762268|bipolar disorder
1301386|NCT00762268|depression
1301387|NCT00762268|bipolar depression
1301388|NCT00762268|treatment-resistant depression
1301389|NCT00762255|recurrent glioblastoma
1301390|NCT00762255|multiple agents
1301391|NCT00762255|immunotherapy
1301392|NCT00762255|chemotherapy
1301393|NCT00762255|brain and nervous system
1301394|NCT00762242|metabolomics
1301395|NCT00762242|flow-mediated vasodilation
1301396|NCT00762229|Cholesterol
1301397|NCT00762229|Ezetimibe
1301398|NCT00762216|Cataract
1301399|NCT00762190|Glucose Metabolism Disorder
1301400|NCT00762190|Dysmetabolic Syndrome
1301401|NCT00762190|Type II Diabetes
1301402|NCT00762190|Diabetes Mellitus, Lipoatrophic
1301403|NCT00762190|Dyslipidemia
1301404|NCT00762190|Drug Therapy
1301405|NCT00762164|Hypercholesterolemia
1301406|NCT00762164|Statins
1301407|NCT00762164|Ezetimibe
1301408|NCT00762151|Dental Plaque
1301409|NCT00762138|Platelet rich plasma
1301410|NCT00762138|wounds
1301411|NCT00762138|leg ulcers
1301412|NCT00762138|pressure ulcers
1301413|NCT00762138|diabetic ulcers
1301414|NCT00762138|management of mechanically or surgically-debrided wounds
1301415|NCT00762125|Fibromyalgia Syndrome
1301416|NCT00762125|FMS
1301417|NCT00762125|Physical Therapy
1301418|NCT00762125|Psychotherapy
1301419|NCT00762125|Group Counseling
1301420|NCT00762125|Individual Counseling
1301421|NCT00762125|Chronic Pain
1301422|NCT00762112|Glucose Metabolism Disorder
1301423|NCT00762112|Dysmetabolic Syndrome
1301424|NCT00762112|Type II Diabetes
1301425|NCT00762112|Diabetes Mellitus, Lipoatrophic
1301426|NCT00762112|Dyslipidemia
1301427|NCT00762112|Drug Therapy.
1301428|NCT00762099|Arthroplasty, Hip
1301429|NCT00762099|Hip replacement
1301430|NCT00762099|Pain Management
1301431|NCT00762099|Functional Rehabilitation
1301432|NCT00762099|Anxiety
1301433|NCT00762099|Perioperative
1301434|NCT00762099|Pregabalin
1301435|NCT00762099|Arthroplasty
1301436|NCT00762086|Peripheral Arterial Disease
1301437|NCT00762086|intermittent pneumatic compression treatment
1301438|NCT00762086|Initial claudication
1301439|NCT00762073|eosinophilic esophagitis
1301440|NCT00762060|colorectal surgery
1301441|NCT00762047|Fecal Incontinence
1301442|NCT00762021|cataract
1301443|NCT00762008|biomarkers
1301444|NCT00761995|Raised IOP
1301445|NCT00761969|peripheral arterial disease
1301446|NCT00761969|secondary prevention
1301447|NCT00761969|cardiovascular /atherothrombotic events
1301448|NCT00761969|European guidelines
1301449|NCT00761969|Cardiovascular disease prevention
1301450|NCT00761956|Total Knee Arthroplasty
1301451|NCT00761956|Osteoarthritis
1301452|NCT00761956|Knee
1301453|NCT00761943|Adhesive Capsulitis
1301454|NCT00761943|Bursitis
1301455|NCT00761943|Frozen Shoulder
1301456|NCT00761904|hypertension
1301457|NCT00761904|hyperlipidemia
1301458|NCT00761904|free generic samples
1301459|NCT00761891|aspirin
1301460|NCT00761891|cyclooxygenase-1
1301461|NCT00761891|aspirin resistance
1301462|NCT00761891|aspirin nonresponse
1301463|NCT00761891|platelet
1301464|NCT00761891|Normal volunteers
1301465|NCT00761878|Skin aging
1301466|NCT00761878|Skin wrinkling
1301467|NCT00761865|Lateral Ankle Sprin
1301468|NCT00761865|Air Cast Stirrup Brace
1301469|NCT00761865|High Tide Fracture Boot
1301470|NCT00761839|wound healing
1301471|NCT00761839|self-management
1301472|NCT00761839|patient education
1301473|NCT00761826|Mixed Astigmatism
1301474|NCT00761826|Laser In Situ Keratomileusis
1301475|NCT00761826|Laser Therapy
1301476|NCT00761826|Laser Corneal Surgery
1301477|NCT00761826|Refractive Surgical Procedures
1301478|NCT00761826|Ophthalmologic Surgical Procedure
1301479|NCT00761826|Operative Surgical Procedures
1301480|NCT00761826|Therapeutics
1301481|NCT00761813|Sliding Hip Screw Fixation
1301482|NCT00761813|Cannulated Screw Fixation
1301483|NCT00761787|allograft
1301484|NCT00761787|rejection
1301485|NCT00761787|biopsy
1301486|NCT00761787|gene
1301487|NCT00761787|expression
1301488|NCT00761787|cardiology
1301489|NCT00761787|heart
1301490|NCT00761787|transplant
1301491|NCT00761774|Epilepsy
1301492|NCT00761774|Monotherapy
1301493|NCT00761774|Partial Onset Seizures
1301494|NCT00761761|Sensoril
1301495|NCT00761761|Bipolar Illness
1301496|NCT00761761|Cognitive enhancement
1301497|NCT00761748|Urostomy,
1301498|NCT00761748|2-piece,
1301499|NCT00761748|preference,
1301500|NCT00761722|Acute Myeloid Leukemia
1301501|NCT00761722|Myelodysplastic Syndromes
1301502|NCT00761722|Lymphoma
1301503|NCT00761722|Multiple Myeloma
1301504|NCT00761722|Chronic Myelomonocytic Leukemia (CMML)
1301505|NCT00761709|Open Angle Glaucoma
1301506|NCT00761709|Ocular Hypertension
1301507|NCT00761696|solid tumor malignancies
1301508|NCT00761683|Endometriosis
1301509|NCT00761657|Kidney
1301510|NCT00761657|Chronic Kidney Disease
1301511|NCT00761657|CKD
1301512|NCT00761657|Stage 3 or 4 Chronic Kidney Disease
1301513|NCT00761657|Renal
1301514|NCT00761657|Anemia
1301515|NCT00761657|Oral anemia treatment
1301516|NCT00761657|Hemoglobin levels
1301517|NCT00761657|Blood count
1301518|NCT00761657|Erythropoietin
1301519|NCT00761644|Metastatic cancer
1301520|NCT00761644|Doxil
1301521|NCT00761644|Liposomal doxorubicin
1301522|NCT00761644|Doxorubicin hydrochloride (liposomal)
1301523|NCT00761644|Avastin
1301524|NCT00761644|Bevacizumab
1301525|NCT00761644|Anti-VEGF monoclonal antibody
1301526|NCT00761644|rhuMAb-VEGF
1301527|NCT00761644|Torisel
1301528|NCT00761644|Temsirolimus
1301529|NCT00761644|CCI-779
1301530|NCT00761644|Dynamic contrast-enhanced magnetic resonance imaging
1301531|NCT00761644|DCE-MRI scan
1301532|NCT00761618|Intrapleural catheter
1301533|NCT00761618|IPC
1301534|NCT00761618|Pleurodesis
1301535|NCT00761618|PD
1301536|NCT00761618|Pleural effusion
1301537|NCT00761618|Fluid in the chest cavity
1301538|NCT00761618|Recurrent malignant pleural effusion
1301539|NCT00761618|MPE
1301540|NCT00761618|Pleural inflammatory response
1301541|NCT00761605|Schizophrenia
1301542|NCT00761605|Paliperidone
1301543|NCT00761605|Paliperidone extended-release
1301544|NCT00761605|Antipsychotics Agents
1301545|NCT00761579|Schizophrenia
1301546|NCT00761579|Paliperidone
1301547|NCT00761579|Antipsychotics Agents
1301548|NCT00761566|Elite swimmers
1301549|NCT00761566|Exercise
1301550|NCT00761566|Preconditioning
1301551|NCT00761553|The study is designed to determine the effects of food supplements and strength training.
1301552|NCT00761501|Phase I
1301553|NCT00761501|Healthy Volunteer
1301554|NCT00761488|Visual acuity,
1301555|NCT00761488|corneal and
1301556|NCT00761488|refractive
1301557|NCT00761488|cylinder
1301558|NCT00761488|following
1301559|NCT00761488|implantation of the
1301560|NCT00761488|AcrySof® Toric
1301561|NCT00761475|incisional hernia
1301562|NCT00761462|Pediatrics
1301563|NCT00761462|Safety
1301564|NCT00761462|Musculoskeletal System
1301565|NCT00761462|Neurologic Manifestations
1301566|NCT00761462|Joint Diseases
1301567|NCT00761462|Joint Deformities, Acquired
1301568|NCT00761449|MDS
1301569|NCT00761449|AML
1301570|NCT00761449|Lenalidomide
1301571|NCT00761449|monosomy 5
1301572|NCT00761449|del5q
1301573|NCT00761410|Arthroplasty
1301574|NCT00761410|Knee
1301575|NCT00761410|Replacement
1301576|NCT00761410|High Flexion
1301577|NCT00761410|PFC Sigma RP-F
1301578|NCT00761397|Oropharyngeal cancer
1301579|NCT00761397|Dysphagic
1301580|NCT00761397|Swallowing exercises
1301581|NCT00761397|Swallowing rehabilitative regimens
1301582|NCT00761397|PREPARE
1301583|NCT00761397|Patients' Radiation Expectations
1301584|NCT00761397|Prevention, Adherence, Rehabilitative Exercises
1301585|NCT00761384|B-cell lymphoma
1301586|NCT00761384|Refractory
1301587|NCT00761384|Recurrent
1301588|NCT00761384|90Y-ibritumomab
1301589|NCT00761384|Stem cells support
1301590|NCT00761384|Dosimetry study
1301591|NCT00761371|external genital and perianal warts
1301592|NCT00761358|Acotiamide
1301593|NCT00761345|pancreatic cancer
1301594|NCT00761345|locally advanced
1301595|NCT00761345|unresectable
1301596|NCT00761345|metastatic pancreatic cancer
1301597|NCT00761319|Open-angle glaucoma
1301598|NCT00761319|ocular hypertension
1301599|NCT00761306|Major Depressive Disorder
1301600|NCT00761306|Long-term
1301601|NCT00761306|Safety
1301602|NCT00761306|Open-label
1301603|NCT00761280|Anaplastic astrocytoma
1301604|NCT00761280|Glioblastoma
1301605|NCT00761280|Antisense
1301606|NCT00761280|Cancer
1301607|NCT00761280|Transforming Growth Factor beta 2
1301608|NCT00761280|Targeted therapy
1301609|NCT00761280|Brain tumor
1301610|NCT00761280|Glioma
1301611|NCT00761280|Central Nervous System (CNS)
1301612|NCT00761280|Convection Enhanced Delivery (CED)
1301613|NCT00761280|Intratumoral administration
1301614|NCT00761267|Anidulafungin
1301615|NCT00761267|pediatrics
1301616|NCT00761267|candidemia
1301617|NCT00761267|invasive candidiasis
1301618|NCT00761267|safety
1301619|NCT00761254|Domperidone
1301620|NCT00761254|Gastroparesis
1301621|NCT00761241|pancreas cancer
1301622|NCT00761241|combined modality therapy
1301623|NCT00761228|Vegetative State
1301624|NCT00761228|Minimally Conscious State
1301625|NCT00761228|Coma
1301626|NCT00761228|Traumatic Brain Injury
1301627|NCT00761215|Skin
1301628|NCT00761215|Infection
1301629|NCT00761215|Complicated Skin and Skin Structure Infection
1301630|NCT00761189|Paliperidone
1301631|NCT00761189|R076477
1301632|NCT00761189|Schizophrenia
1301633|NCT00761176|Diabetes
1301634|NCT00761176|Ulcers
1301635|NCT00761176|Wounds
1301636|NCT00761163|The purpose of this study is to identify the body's response to aerobic vs. resistance exercise
1301637|NCT00761150|Effect on sleep interference by pain
1301638|NCT00761137|sialorrhea
1301639|NCT00761137|drooling
1301640|NCT00761137|excessive salivation
1301641|NCT00761137|parkinson's disease
1301642|NCT00761124|PSA screening
1301643|NCT00761124|Prostate cancer and Latino men
1301644|NCT00761111|information booklet
1301645|NCT00761111|low back beliefs
1301646|NCT00761111|education
1301647|NCT00761111|disc hernia
1301648|NCT00761111|discectomy
1301649|NCT00761111|A common monoradicular sciatica
1301650|NCT00761111|on a slipped disc
1301651|NCT00761111|with a clinical radio
1301652|NCT00761111|agreement requiring a surgical treatment
1301653|NCT00761111|carried out
1301654|NCT00761111|one duration
1301655|NCT00761111|of evolution higher
1301656|NCT00761111|than four weeks
1301657|NCT00761111|at naive subjects
1301658|NCT00761111|of any rachidian interventional treatment
1301659|NCT00761111|after failure of an good ambulatory
1301660|NCT00761098|Cirrhosis
1301661|NCT00761098|SBP
1301662|NCT00761072|Propofol
1301663|NCT00761072|Remifentanil
1301664|NCT00761072|Total Intravenous Anesthesia
1301665|NCT00761059|analgesia
1301666|NCT00761059|infant, premature
1301667|NCT00761059|glucose
1301668|NCT00761059|nasopharyngeal suctioning
1301669|NCT00760279|Bacterial infection
1301670|NCT00760279|Azithromycin
1301671|NCT00760266|Hypertension
1301672|NCT00760266|older population
1301673|NCT00760266|aliskiren
1301674|NCT00760266|hydrochlorothiazide
1301675|NCT00760266|systolic blood pressure
1301676|NCT00760266|diastolic blood pressure
1301677|NCT00760266|amlodipine, stage 2
1301678|NCT00760253|target control infusion
1301679|NCT00760253|alfentanyl
1301680|NCT00760253|propofol
1301681|NCT00760253|BIS
1301682|NCT00760240|compliance
1301683|NCT00760240|eyedrop instillation
1301808|NCT00760656|Health outcomes in adults who survived pediatric cancer
1301684|NCT00760240|How patients with low vision due to glaucoma or retinal pathology instill eyedrops into their own eyes.
1301685|NCT00760214|Essential Hypertension
1301686|NCT00760214|Hypertension
1301687|NCT00760214|Drug Therapy
1301688|NCT00760214|Blood Pressure, High
1301689|NCT00760214|Vascular Disease
1301690|NCT00760214|Cardiovascular Disease
1301691|NCT00760201|executive
1301692|NCT00760201|administrator
1301693|NCT00760201|perceptions
1301694|NCT00760201|legal counsel
1301695|NCT00760201|end of life
1301696|NCT00760188|knee replacement
1301697|NCT00760175|Lung transplant Recipients
1301698|NCT00760175|Vaxigrip
1301699|NCT00760162|Chronic Kidney failure stage three and four
1301700|NCT00760162|Probiotics
1301701|NCT00760162|Kibow Biotics
1301702|NCT00760162|Enteric Dialysis
1301703|NCT00760162|Gut based removal uremic toxin removal
1301704|NCT00760149|tuberculosis
1301705|NCT00760149|rifampicin
1301706|NCT00760149|pharmacokinetics
1301707|NCT00760149|pharmacodynamics
1301708|NCT00760136|patellofemoral pain
1301709|NCT00760136|quadriceps contraction
1301710|NCT00761033|children undergoing intravenous placement in the pediatric emergency department
1301711|NCT00761020|Malaria
1301712|NCT00761020|Diagnosis
1301713|NCT00761020|Biomarker
1301714|NCT00761007|Irritable Bowel Syndrome
1301715|NCT00761007|Bowel disease
1301716|NCT00760994|Alcohol
1301717|NCT00760994|Alcoholic
1301718|NCT00760994|Alcoholism
1301719|NCT00760994|Post-traumatic stress disorder
1301720|NCT00760994|PTSD
1301721|NCT00760994|Experiential acceptance
1301722|NCT00760994|Mindfulness
1301723|NCT00760994|Meditation
1301724|NCT00760994|Meditate
1301725|NCT00760994|Cognitive restructuring
1301726|NCT00760994|Cognitive
1301727|NCT00760994|Behavioral
1301728|NCT00760994|Therapy
1301729|NCT00760994|Treatment
1301730|NCT00760994|Study
1301731|NCT00760994|Intervention
1301732|NCT00760968|Rheumatoid Arthritis
1301733|NCT00760968|Drug Therapy
1301734|NCT00760955|Asymmetric Diabetic Proximal Motor Neuropathy
1301735|NCT00760955|Diabetic Amyotrophy
1301736|NCT00760955|Diabetic Autonomic Neuropathy
1301737|NCT00760955|Diabetic Polyneuropathy
1301738|NCT00760955|Neuralgia, Diabetic
1301739|NCT00760955|Symmetric Diabetic Proximal Motor Neuropathy
1301740|NCT00760955|Drug Therapy
1301741|NCT00760942|Low birth weight
1301742|NCT00760942|neonates
1301743|NCT00760942|premature infants
1301744|NCT00760942|nutrition
1301745|NCT00760942|human milk fortification
1301746|NCT00760942|Infant
1301747|NCT00760916|Pulmonary Arterial Hypertension
1301748|NCT00760903|Moderate brain trauma
1301749|NCT00760890|Iron, breastfed infant
1301750|NCT00760877|MYELOGENOUS
1301751|NCT00760877|LEUKEMIA
1301752|NCT00760877|Chronic Phase
1301753|NCT00760877|CML
1301754|NCT00760864|Rheumatoid Arthritis
1301755|NCT00760864|Drug Therapy
1301756|NCT00760851|Probiotics
1301757|NCT00760851|Child, preschool
1301758|NCT00760851|Child Day Care Centers
1301759|NCT00760851|Health
1301760|NCT00760851|Immune system
1301761|NCT00760838|Inadequately controlled severe asthma
1301762|NCT00760825|cholera
1301763|NCT00760825|vibrios
1301764|NCT00760825|oral cholera vaccine
1301765|NCT00760812|Autism
1301766|NCT00760812|Autism Spectrum Disorders
1301767|NCT00760812|Pervasive Developmental Disorders
1301768|NCT00760812|Toddlers
1301769|NCT00760812|Intervention
1301770|NCT00760799|Lumbar Disc Herniation
1301771|NCT00760786|IVUS-VH
1301772|NCT00760786|Plaque characterization
1301773|NCT00760786|Omega3-fatty acid
1301774|NCT00760786|Atorvastatin
1301775|NCT00760773|Probiotic treatment
1301776|NCT00760773|Daycare attendance
1301777|NCT00760773|Pediatric
1301778|NCT00760773|Emergency department
1301779|NCT00760747|ADHD
1301780|NCT00760747|Children
1301781|NCT00760747|Stimulant
1301782|NCT00760747|Atomoxetine
1301783|NCT00760747|Adolescents
1301784|NCT00760734|Chronic traumatic brain injury
1301785|NCT00760734|Post concussion syndrome
1301786|NCT00760734|Post traumatic stress disorder
1301787|NCT00760734|Chronic post traumatic stress disorder
1301788|NCT00760721|Hepatitis B Screening
1301789|NCT00760721|Korean Americans
1301790|NCT00760708|nucleosides
1301791|NCT00760708|neurotransmitter
1301792|NCT00760708|myocardial ischemia
1301793|NCT00760708|Adenosine
1301794|NCT00760695|anorexia nervosa
1301795|NCT00760695|chronic
1301796|NCT00760695|dronabinol
1301797|NCT00760695|weight gain
1301798|NCT00760695|EDI
1301799|NCT00760682|osteoradionecrosis
1301800|NCT00760682|hyperbaric oxygen
1301801|NCT00760682|sequestrectomy
1301802|NCT00760669|Spondylitis, Ankylosing
1301803|NCT00760669|Arthritis, Rheumatoid
1301804|NCT00760669|Psoriasis
1301805|NCT00760669|Arthritis, Psoriatic
1301806|NCT00760669|Infliximab
1301807|NCT00760669|Remicade
1301809|NCT00760656|Survivors of Pediatric Cancer
1301810|NCT00760630|abnormal stress test
1301811|NCT00760630|fractional flow reserve
1301812|NCT00760630|pressure drop coefficient
1301813|NCT00760630|lesion flow coefficient
1301814|NCT00760617|Influenza
1301815|NCT00760617|Elderly
1301816|NCT00760604|Esophageal neoplasms
1301817|NCT00760604|Esophagectomy
1301818|NCT00760591|Acute kidney failure
1301819|NCT00760591|Colonoscopy
1301820|NCT00760591|Neutrophil gelatinase-associated lipocalin
1301821|NCT00760552|Hypertension
1301822|NCT00760552|Adherence
1301823|NCT00760552|Pharmacist
1301824|NCT00760552|Interdisciplinary
1301825|NCT00760552|Randomized Controlled
1301826|NCT00760552|Primary Care
1301827|NCT00760539|Glaucoma
1301828|NCT00760539|Hypertension
1301829|NCT00760526|Continuous Glucose Monitor
1301830|NCT00760513|non alcoholic fatty liver disease
1301831|NCT00760513|NAFLD
1301832|NCT00760513|fish oil
1301833|NCT00760513|intervention
1301834|NCT00760513|RCT
1301835|NCT00760513|biomarkers
1301836|NCT00760487|Cataract AcrySof Toric IOL
1301837|NCT00760487|Bilateral cataract
1301838|NCT00760474|Fibromyalgia; fMRI; pain; pregabalin; Lyrica; imaging
1301839|NCT00760435|Kawasaki disease
1301840|NCT00760435|Infliximab
1301841|NCT00760435|Remicade
1301842|NCT00760435|Pediatrics
1301843|NCT00760409|recurrent tumor
1301844|NCT00760396|healthy volunteers
1301845|NCT00760383|Total Knee Arthroplasty
1301846|NCT00760383|Osteoarthritis
1301847|NCT00760383|Muscle Metabolism
1301848|NCT00760383|Rehabilitation
1301849|NCT00760383|Physical Therapy
1301850|NCT00760370|bone marker
1301851|NCT00760370|bisphosphonate
1301852|NCT00760370|Zometa
1301853|NCT00760370|retention
1301854|NCT00760370|breast cancer
1301855|NCT00760370|multiple myeloma
1301856|NCT00760370|CTX
1301857|NCT00760370|bone specific ALP
1301858|NCT00760357|Critical Ischemia
1301859|NCT00760344|Glucose Metabolism Disorder
1301860|NCT00760344|Dysmetabolic Syndrome
1301861|NCT00760344|Type II Diabetes
1301862|NCT00760344|Diabetes Mellitus, Lipoatrophic
1301863|NCT00760344|Dyslipidemia
1301864|NCT00760344|Drug Therapy
1301865|NCT00760331|HNF1B
1301866|NCT00760331|TCF2
1301867|NCT00760331|MODY-5
1301868|NCT00760331|CAKUT
1301869|NCT00760331|Anomaly of renal development
1301870|NCT00760318|cervical dystonia, keppra, botox, spasmodic torticollis
1301871|NCT00760305|cancer pain
1301872|NCT00760305|bone metastasis
1301873|NCT00760305|patient education
1301874|NCT00760305|psychoeducational education
1301875|NCT00760305|side effects
1301876|NCT00760305|analgesics
1301877|NCT00760292|Type 2 Diabetes Mellitus
1301878|NCT00760292|Genetic Variants
1301879|NCT00760292|SNP
1301880|NCT00760292|DNA microarray
1301881|NCT00760123|Lymphedema
1301882|NCT00760123|Prevention
1301883|NCT00760123|Breast cancer
1301884|NCT00760123|Physical therapy
1301885|NCT00760110|Morning BP
1301886|NCT00760110|Clinic BP
1301887|NCT00760110|micro- and macrovascular complications
1301888|NCT00760084|Acute Myelogenous Leukemia
1301889|NCT00760084|Myelodysplastic Syndrome
1301890|NCT00760084|Dacogen
1301891|NCT00760084|Decitabine
1301892|NCT00760071|cystic fibrosis,
1301893|NCT00760071|lung disease,
1301894|NCT00760071|MRI,
1301895|NCT00760071|morphology,
1301896|NCT00760071|function
1301897|NCT00760071|morphological MRI
1301898|NCT00760071|functional MRI
1301899|NCT00760071|correlation to clinical data
1301900|NCT00760058|cataract, intraocular lens
1301901|NCT00760032|Cirrhosis
1301902|NCT00760032|Ascites
1301903|NCT00760032|Lipopolysaccharide binding protein
1301904|NCT00760032|Infections
1301905|NCT00760032|Cytokines
1301906|NCT00760032|Ciprofloxacin
1301907|NCT00760019|vascular inflammation
1301908|NCT00760019|endothelium-dependent flow-mediated blood vessel function
1301909|NCT00760006|cleft secondary palate
1301910|NCT00760006|Patients undergoing primary closure of a cleft secondary palate
1301911|NCT00759993|weight gain
1301912|NCT00759993|Obesity
1301913|NCT00759993|Psychiatry
1301914|NCT00759993|Medication
1301915|NCT00759993|Induced
1301916|NCT00759980|Thrombocytopenia
1301917|NCT00759980|Platelet transfusion
1301918|NCT00759967|Randomized
1301919|NCT00759967|Cross-Over
1301920|NCT00759967|Conventional
1301921|NCT00759967|Daily
1301922|NCT00759967|Hemodialysis
1301923|NCT00759954|bioequivalence
1301924|NCT00759954|morphine sulfate sustained release capsules
1301925|NCT00759954|KADIAN capsules
1301926|NCT00759954|200 mg
1301927|NCT00759954|applesauce
1301928|NCT00759941|Glaucoma
1301929|NCT00759928|Refractory Solid Tumors
1301930|NCT00759928|Unresectable Stage III/IV
1301931|NCT00759928|Sorafenib
1301932|NCT00759928|Erlotinib
1301933|NCT00759928|Pharmacokinetics
1301934|NCT00759915|10 mg
1301935|NCT00759915|KADIAN capsules
1301936|NCT00759915|20 mg
1301937|NCT00759915|fed conditions
1301938|NCT00759915|bioequivalence
1301939|NCT00759902|bioequivalence
1301940|NCT00759902|10 mg
1301941|NCT00759902|KADIAN capsules
1301942|NCT00759902|20 mg
1301943|NCT00759902|under fasted conditions
1301944|NCT00759889|venous leg ulcer
1301945|NCT00759876|Duchenne muscular dystrophy
1301946|NCT00759876|Nonsense mutation
1301947|NCT00759876|Premature stop codon
1301948|NCT00759876|DMD
1301949|NCT00759876|PTC124
1301950|NCT00759876|Ataluren
1301951|NCT00759850|Acute Myocardial Infarction
1301952|NCT00759850|Drug Eluting Stent
1301953|NCT00759850|Primary PCI
1301954|NCT00759824|Small cell lung carcinoma
1301955|NCT00759824|Valproic acid
1301956|NCT00759824|Adriamycin
1301957|NCT00759824|Cyclophosphamide
1301958|NCT00759824|Vindesine
1301959|NCT00759824|Second-line chemotherapy
1301960|NCT00759811|Heart Failure
1301961|NCT00759811|Myocardial Ischemia
1301962|NCT00759811|Methotrexate
1301963|NCT00759811|Inflammation
1301964|NCT00759811|Anti-Inflammatory Agents
1301965|NCT00759811|Inflammation Mediators
1301966|NCT00759798|Chronic Lymphocytic Leukemia
1301967|NCT00759798|Leukemia
1301968|NCT00759798|FCR
1301969|NCT00759798|Fludarabine
1301970|NCT00759798|Cyclophosphamide
1301971|NCT00759798|Rituximab
1301972|NCT00759772|Anorexia Nervosa
1301973|NCT00759772|Disordered Eating
1301974|NCT00759772|Osteoporosis
1301975|NCT00759772|Parathyroid Hormone
1301976|NCT00759772|Bone
1301977|NCT00759759|bioequivalence
1301978|NCT00759759|morphine sulfate sustained release capsules
1301979|NCT00759759|KADIAN capsules
1301980|NCT00759759|200 mg
1301981|NCT00759746|Weight loss maintenance
1301982|NCT00759733|pregnancy
1301983|NCT00759733|heart disease
1301984|NCT00759733|heart function testing
1301985|NCT00759733|echocardiography
1301986|NCT00759733|B-type natriuretic peptide
1301987|NCT00759733|obstetrical care
1301988|NCT00759720|Glucose Metabolism Disorder
1301989|NCT00759720|Dysmetabolic Syndrome
1301990|NCT00759720|Type II Diabetes
1301991|NCT00759720|Diabetes Mellitus, Lipoatrophic
1301992|NCT00759720|Dyslipidemia
1301993|NCT00759720|Drug Therapy
1301994|NCT00759707|saphenous vein bypass grafts
1301995|NCT00759707|flow-mediated vasodilation
1301996|NCT00759681|Arterial Surgery
1301997|NCT00759681|Open vascular Surgery
1301998|NCT00759681|Sealant
1301999|NCT00759655|hemophilia A
1302000|NCT00759655|Xyntha
1302001|NCT00759655|ReFacto
1302002|NCT00759655|moroctocog alfa
1302003|NCT00759655|bleeding disorder
1302004|NCT00759642|breast cancer
1302005|NCT00759642|hormone receptor positive
1302006|NCT00759642|HER-2 negative
1302007|NCT00759616|Knee Replacement
1302008|NCT00759603|Leukemia
1302009|NCT00759603|CLL
1302010|NCT00759603|Chronic Lymphocytic Leukemia
1302011|NCT00759603|SLL
1302012|NCT00759603|Small Lymphocytic Lymphoma
1302013|NCT00759603|Lenalidomide
1302014|NCT00759603|Revlimid
1302015|NCT00759603|Rituximab
1302016|NCT00759603|Rituxan
1302017|NCT00759551|Blood Pressure
1302018|NCT00759551|Drug Therapy
1302019|NCT00759551|Systolic Pressure
1302020|NCT00759551|Diastolic Pressure
1302021|NCT00759551|Vascular Diseases
1302022|NCT00759538|Lung Transplantation
1302023|NCT00759538|Pulmonary Rehabilitation
1302024|NCT00759538|Exercise tolerance
1302025|NCT00759538|Quality of Life
1302026|NCT00759499|study of debridement tissue for research purposes.
1302027|NCT00759499|open wound
1302028|NCT00759486|craniofacial fracture
1302029|NCT00759486|Subjects who are in the active phase of craniofacial skeletal growth, and have sustained a craniofacial fracture
1302030|NCT00759473|substance-related disorders
1302031|NCT00759460|Schizophrenia
1302032|NCT00759434|Varicose veins
1302033|NCT00759434|Chronic venous insufficiency
1302034|NCT00759434|Venous ulceration
1302035|NCT00759434|Surgery
1302036|NCT00759434|Endovenous Laser
1302037|NCT00759421|Schizophrenia
1302038|NCT00759408|primary pulmonary hypertension
1302039|NCT00759408|secondary pulmonary hypertension due to left heart failure
1302040|NCT00759408|secondary pulmonary hypertension due to other causes
1302041|NCT00759408|patients without pulmonary disease or pulmonary hypertension
1302042|NCT00759395|Anxious Major Depressive Disorder
1302043|NCT00759382|Non small cell lung carcinoma
1302044|NCT00759382|PET scan
1302045|NCT00759382|Observational study
1302046|NCT00759382|Non metastatic
1302047|NCT00759382|treated
1302048|NCT00759382|curative intent
1302049|NCT00759369|ADPKD
1302050|NCT00759356|bioavailability
1302051|NCT00759356|KADIAN
1302052|NCT00759356|200 mg
1302053|NCT00759356|morphine sulfate sustained release capsules
1302054|NCT00759356|100 mg
1302055|NCT00759356|fed conditions
1302056|NCT00759343|Kidney stones
1302057|NCT00759343|urinary stone disease
1302058|NCT00759343|urinary stones
1302059|NCT00759343|urine
1302060|NCT00759343|serum
1302061|NCT00759330|Flurbiprofen, low back pain, chronic low back pain
1302062|NCT00759317|normal controls
1302063|NCT00759304|Aging
1302064|NCT00759304|cardiovascular risk factors
1302065|NCT00759304|Autonomic nervous system
1302066|NCT00759304|stroke
1302067|NCT00759304|Myocardiac infarction
1302068|NCT00759304|Neuropsychological evaluation
1302069|NCT00759304|Prospective cohort
1302070|NCT00759291|free fatty acids
1302071|NCT00759291|insulin-mediated
1302072|NCT00759291|endothelium-dependent vasodilation
1302073|NCT00759291|metabolic syndrome
1302074|NCT00759278|pregnancy
1302075|NCT00759278|umbilical artery systolic to diastolic flow ratio
1302076|NCT00759278|middle cerebral artery peak systolic flow
1302077|NCT00759278|antihypertensive medication
1302078|NCT00759265|Muscle strength
1302079|NCT00759265|Physical activity
1302080|NCT00759265|Mobility
1302081|NCT00759265|Gait analysis
1302082|NCT00759252|diagnosis of dementia
1302083|NCT00759252|perceptions of risk
1302084|NCT00759252|dementia screening
1302085|NCT00759239|Open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension
1302086|NCT00759226|esophageal cancer
1302087|NCT00759226|Gemcitabine
1302088|NCT00759226|Cisplatin
1302089|NCT00759226|5-FU
1302090|NCT00759226|Folinic Acid
1302091|NCT00759226|inoperable esophageal cancer
1302092|NCT00759213|Discharge planning
1302093|NCT00759213|Family needs
1302094|NCT00759213|Family concerns
1302095|NCT00759213|NICU
1302096|NCT00759213|Infants
1302097|NCT00759200|Chronic hepatitis C
1302098|NCT00759200|genotype 2
1302099|NCT00759200|genotype 3
1302100|NCT00759200|albumin interferon alfa-2b
1302101|NCT00759200|alb-interferon
1302102|NCT00759174|Optic Neuropathy Acute NAION PDE5 Inhibitor
1302103|NCT00759161|Plaque Type Psoriasis
1302104|NCT00759161|Topical
1302105|NCT00759148|pink eye
1302106|NCT00759148|conjunctivitis
1302107|NCT00759148|moxifloxacin
1302108|NCT00759148|fluoroquinolone
1302109|NCT00759135|Benign Prostatic Hyperplasia
1302110|NCT00759135|BPH
1302111|NCT00759135|Enlarged Prostate
1302112|NCT00759122|mdd
1302113|NCT00759122|major depressive disorder
1302114|NCT00759122|depression
1302115|NCT00759096|bilateral implantation
1302116|NCT00759096|ReSTOR Aspheric IOL
1302117|NCT00759096|uniocular unaided distance
1302118|NCT00759096|binocular unaided distance
1302119|NCT00759096|intermediate visual acuity
1302120|NCT00759096|near visual acuity
1302121|NCT00759083|HIT
1302122|NCT00759083|HITTS
1302123|NCT00759070|Treatment Naïve
1302124|NCT00759057|Spinal Stenosis
1302125|NCT00759057|Spinal Instability
1302126|NCT00759057|Leg Pain
1302127|NCT00759018|GVHD
1302128|NCT00759018|Prochymal
1302129|NCT00759018|Graft vs Host Disease
1302130|NCT00758992|gene transfer
1302131|NCT00758966|OCD,
1302132|NCT00758966|naltrexone,
1302133|NCT00758966|fluoxetine,
1302134|NCT00758966|obsessive-compulsive disorder
1302135|NCT00758940|Clinical
1302136|NCT00758940|assessment
1302137|NCT00758940|of visual
1302138|NCT00758940|function
1302139|NCT00758940|with the Acrysof ReSTOR
1302140|NCT00758940|multifocal IOL
1302141|NCT00758927|diabetes mellitus
1302142|NCT00758927|combined hyperlipidemia
1302143|NCT00758927|OMACOR
1302144|NCT00758927|small dense LDL
1302145|NCT00758927|HDL subfraction
1302146|NCT00758914|Vitamin E
1302147|NCT00758849|NOH
1302148|NCT00758849|Orthostatic hypotension
1302149|NCT00758849|PAF
1302150|NCT00758849|MSA
1302151|NCT00758849|Shy-Drager syndrome
1302152|NCT00758849|Olivopontocerebellar atrophy
1302153|NCT00758849|Striatonigral degeneration
1302154|NCT00758849|Autonomic Failure
1302155|NCT00758849|Parkinson
1302156|NCT00758849|Fipamezole
1302157|NCT00758849|JP-1730
1302158|NCT00758823|head lice
1302159|NCT00758810|Health Education
1302160|NCT00758810|Myocardial Infarction
1302161|NCT00758810|Acute Coronary Syndrome
1302162|NCT00758810|Quality of Life
1302163|NCT00758797|metastatic melanoma
1302164|NCT00758758|Anterior Cervical Discectomy and Fusion,
1302165|NCT00758758|Degenerative Disc Disease,
1302166|NCT00758758|Cervical Spine,
1302167|NCT00758758|Herniated Disc
1302168|NCT00758745|Cataract
1302169|NCT00758745|Patients
1302170|NCT00758745|bilateral
1302171|NCT00758745|age related
1302172|NCT00758745|undergoing
1302173|NCT00758745|phacoemulsification
1302174|NCT00758732|Cancer
1302175|NCT00758732|Ovarian cancer
1302176|NCT00758732|Chemotherapy
1302177|NCT00758732|Docetaxel
1302178|NCT00758732|Carboplatin
1302179|NCT00758732|Pegylated doxorubicin
1302180|NCT00758732|Platinum sensitive
1302181|NCT00758719|Spinal Fusion
1302182|NCT00758719|DDD
1302183|NCT00758706|COPD
1302184|NCT00758693|Chronic Lymphocytic Leukemia
1302185|NCT00758693|Bendamustine
1302186|NCT00758693|Treanda
1302187|NCT00758693|Rituximab
1302188|NCT00758693|Rituxan
1302189|NCT00758667|capsular contracture
1302190|NCT00758667|capsulectomy
1302191|NCT00758667|mesna
1302192|NCT00758667|Capsular contracture after breast implant placement
1302193|NCT00758654|myocardial strain
1302194|NCT00758654|Strain-Encoded MRI
1302195|NCT00758654|dobutamine stress MRI
1302196|NCT00758654|ischemia
1302197|NCT00758654|strain rate reserve
1302198|NCT00758641|plantar fasciitis
1302199|NCT00758641|platelet rich plasma
1302200|NCT00758641|GPS
1302201|NCT00758615|Obesity
1302202|NCT00758615|Physical activity
1302203|NCT00758615|Injury Prevention
1302204|NCT00758615|Pedestrian safety
1302205|NCT00758615|Self efficacy
1302206|NCT00758615|School
1302207|NCT00758615|Walking School Bus
1302208|NCT00758615|Safe Routes to School
1302209|NCT00758589|Asthma
1302210|NCT00758576|Cataract
1302211|NCT00758550|Visual function;
1302212|NCT00758550|Refractive cylinder;
1302213|NCT00758550|AcrySof® Toric;
1302214|NCT00758550|AcrySof® Natural
1302215|NCT00758537|Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease
1302216|NCT00758524|Essential hypertension
1302217|NCT00758524|phase 2 study
1302218|NCT00758524|antihypertensive agent
1302219|NCT00758511|cortisol
1302220|NCT00758511|pain
1302221|NCT00758511|pain management
1302222|NCT00758511|preterm infants
1302223|NCT00758511|sucrose
1302224|NCT00758511|facilitated tucking
1302225|NCT00758459|COPD
1302226|NCT00758433|Adverse Events
1302227|NCT00758433|Erythema Rating
1302228|NCT00758433|Pharmacokinetics
1302229|NCT00758433|Civamide
1302230|NCT00758433|Phase 1
1302231|NCT00758433|Pain
1302232|NCT00758433|Patch
1302233|NCT00758420|Varicose Veins
1302234|NCT00758407|Fatigue, Cancer, Methylphenidate,
1302235|NCT00758381|pancreatic cancer
1302236|NCT00758381|advanced or metastatic
1302237|NCT00758381|sorafenib
1302238|NCT00758368|Parkinson's disease
1302239|NCT00758368|PD
1302240|NCT00758368|pulsatile apomorphine
1302241|NCT00758368|dyskinesia
1302242|NCT00758368|apomorphine
1302243|NCT00758368|continuous dopaminergic stimulation
1302244|NCT00758342|IOP lowering efficacy and safety of Azopt plus Travatan
1302245|NCT00758316|Malignant
1302246|NCT00758316|Pleural
1302247|NCT00758316|Effusions
1302248|NCT00758316|Thoracoscopy
1302249|NCT00758316|Catheter
1302250|NCT00758303|Triglycerides
1302251|NCT00758303|Cholesterol
1302252|NCT00758277|prevention of alcohol relapse
1302253|NCT00758264|Safety
1302254|NCT00758264|Routine infancy vaccination
1302255|NCT00758264|Meningococcal vaccine
1302256|NCT00758264|Immunogenicity
1302257|NCT00758264|Pneumococcal vaccine
1302258|NCT00758251|Schizophrenia
1302259|NCT00758251|Seroquel XR
1302260|NCT00758251|CGI
1302261|NCT00758238|hypertension
1302262|NCT00758238|self-management
1302263|NCT00758238|e-health
1302264|NCT00758225|Duchenne Muscular Dystrophy
1302265|NCT00758225|DMD
1302266|NCT00758225|Duchenne
1302267|NCT00758225|Idebenone
1302268|NCT00758212|Influenza in Humans
1302269|NCT00758212|Acquired Immune Deficiency Syndrome
1302270|NCT00758212|Immunization, Active
1302271|NCT00758186|Colorectal cancer
1302272|NCT00758186|Endoscopic stent
1302273|NCT00758186|Intestinal obstruction
1302274|NCT00758186|Laparoscopy
1302275|NCT00758173|prostate cancer
1302276|NCT00758160|Attention Deficit Disorder With Hyperactivity
1302277|NCT00758160|Methylphenidate
1302278|NCT00758160|Concerta
1302279|NCT00758147|force feedback joystick
1302280|NCT00758147|stroke
1302281|NCT00758147|haptics
1302282|NCT00758147|kinematics
1302283|NCT00758147|rehabilitation
1302284|NCT00758147|robotics
1302285|NCT00758147|Force feedback joystick in stroke rehabilitation
1302286|NCT00758108|Genotype/Phenotype Correlation
1302287|NCT00758108|Energy Homeostasis
1302288|NCT00758108|Nociception
1302289|NCT00758108|Obesity
1302290|NCT00758108|Behavior and Neurocognition
1302291|NCT00758108|WAGR Syndrome
1302292|NCT00758108|Wilm's Tumor
1302293|NCT00758108|Aniridia
1302294|NCT00758108|Mental Retardation
1302295|NCT00758108|Urogenital Abnormalities
1302296|NCT00758108|Healthy Volunteer
1302297|NCT00758082|type 1 diabetes
1302298|NCT00758082|PDA phone (Personal Digital Assistant)
1302299|NCT00758082|HbA1c
1302300|NCT00758056|endometrial cancer
1302301|NCT00758043|Genotype 1
1302302|NCT00758030|Schizophrenia
1302303|NCT00758030|Paliperidone
1302304|NCT00758017|low back pain
1302305|NCT00758017|acupuncture
1302306|NCT00758004|Cardiovascular Diseases
1302307|NCT00757991|healthy, no evidence of disease
1302308|NCT00757978|Schizophrenia
1302309|NCT00757978|negative symptoms
1302310|NCT00757978|clozapine
1302311|NCT00757965|colon cancer
1302312|NCT00757965|rectal cancer
1302313|NCT00757952|ovarian epithelial cancer
1302314|NCT00757939|Alzheimer's Disease, MRI, PET
1302315|NCT00757900|influenza, human
1302316|NCT00757887|malaria
1302317|NCT00757887|plasmodium
1302318|NCT00757887|falciparum
1302319|NCT00757887|human
1302320|NCT00757887|experimental infection
1302321|NCT00757874|Female urogenital disease
1302322|NCT00757874|skin disease
1302323|NCT00757848|cystic fibrosis
1302324|NCT00757835|24-hour IOP
1302325|NCT00757835|exfoliative glaucoma
1302326|NCT00757835|travoprost/timolol
1302327|NCT00757835|latanoprost/timolol
1302328|NCT00757835|fixed combinations
1302329|NCT00757783|HIV
1302330|NCT00757783|AIDS
1302331|NCT00757783|Immunodeficiency Virus, Human
1302332|NCT00757783|PREZISTA
1302333|NCT00757783|darunavir
1302334|NCT00757783|TMC114
1302335|NCT00757783|Protease Inhibitor
1302336|NCT00757783|Truvada
1302337|NCT00757783|Atazanavir
1302338|NCT00757783|REYATAZ
1302339|NCT00757783|HIV Infections
1302340|NCT00757783|Treatment Naïve
1302341|NCT00757770|Gastroenteritis
1302342|NCT00757757|Prostate cancer
1302343|NCT00757757|bone metastases
1302344|NCT00757757|anti-M-CSF
1302345|NCT00757757|M-CSF antibody
1302346|NCT00757757|M-CSF
1302347|NCT00757757|Prostate Cancer with bone metastases
1302348|NCT00757744|drug counseling
1302349|NCT00757744|HIV risks
1302350|NCT00757744|methadone maintenance
1302351|NCT00757744|HIV Seronegativity
1302352|NCT00757718|Sleep Disordered Breathing
1302353|NCT00757718|Obstructive Sleep Apnea
1302354|NCT00757718|Gestational Hypertension
1302355|NCT00757718|Preeclampsia
1302356|NCT00757705|Schizophrenia
1302357|NCT00757705|Paliperidone Extended-Release
1302358|NCT00757692|Vandetanib (ZD6474)
1302359|NCT00757692|Hormone
1302360|NCT00757692|Refractory
1302361|NCT00757692|Prostate Cancer
1302362|NCT00757692|Chemotherapy
1302363|NCT00757692|Naïve
1302364|NCT00757666|Pacemaker
1302365|NCT00757640|gastric cancer, surgery, prophylactic cholecystectomy
1302366|NCT00757614|AIDS-related lymphoma
1302367|NCT00757614|cutaneous lymphoma
1302368|NCT00757614|adult Hodgkin lymphoma
1302369|NCT00757614|adult non-Hodgkin lymphoma
1302370|NCT00757614|intraocular lymphoma
1302371|NCT00757614|adult T-cell leukemia/lymphoma
1302372|NCT00757614|primary central nervous system non-Hodgkin lymphoma
1302373|NCT00757614|primary central nervous system Hodgkin lymphoma
1302374|NCT00757614|noncutaneous extranodal lymphoma
1302375|NCT00757614|adult astrocytic tumors
1302376|NCT00757614|adult brain stem glioma
1302377|NCT00757614|adult choroid plexus tumor
1302378|NCT00757614|adult craniopharyngioma
1302379|NCT00757614|adult embryonal tumor
1302380|NCT00757614|adult ependymal tumors
1302381|NCT00757614|adult meningeal tumor
1302382|NCT00757614|adult oligodendroglial tumors
1302383|NCT00757614|adult pineal parenchymal tumor
1302384|NCT00757614|adult brain tumor
1302385|NCT00757614|intraocular melanoma
1302386|NCT00757614|bladder cancer
1302387|NCT00757614|clear cell sarcoma of the kidney
1302388|NCT00757614|congenital mesoblastic nephroma
1302389|NCT00757614|esophageal cancer
1302390|NCT00757614|melanoma
1302391|NCT00757614|pancreatic cancer
1302392|NCT00757614|peripheral primitive neuroectodermal tumor of the kidney
1302393|NCT00757614|renal cell carcinoma
1302394|NCT00757614|rhabdoid tumor of the kidney
1302395|NCT00757614|transitional cell cancer of the renal pelvis and ureter
1302396|NCT00757575|PNEUMONET JAPAN STUDY
1302397|NCT00757549|recurrent squamous cell carcinoma of the hypopharynx
1302398|NCT00757549|recurrent squamous cell carcinoma of the larynx
1302399|NCT00757549|recurrent squamous cell carcinoma of the oropharynx
1302400|NCT00757549|stage III squamous cell carcinoma of the hypopharynx
1302401|NCT00757549|stage III squamous cell carcinoma of the larynx
1302402|NCT00757549|stage III squamous cell carcinoma of the oropharynx
1302403|NCT00757549|stage IV squamous cell carcinoma of the hypopharynx
1302404|NCT00757549|stage IV squamous cell carcinoma of the larynx
1302405|NCT00757549|stage IV squamous cell carcinoma of the oropharynx
1302406|NCT00757536|Rhegmatogenous retinal detachment
1302407|NCT00757536|primary vitrectomy
1302408|NCT00757536|encircling band
1302409|NCT00757536|endolaser treatment
1302410|NCT00757523|Acne
1302411|NCT00757523|Acne Vulgaris
1302412|NCT00757523|Akne
1302413|NCT00757523|Akne Vulgaris
1302414|NCT00757510|Congenital Heart Disease
1302415|NCT00757497|Treatment Study
1302416|NCT00757497|Psychosis
1302417|NCT00757497|Electrical Stimulation
1302418|NCT00757497|Refractory
1302419|NCT00757497|Novel
1302420|NCT00757497|Childhood Onset Psychotic Disorders
1302421|NCT00757497|Schizophrenia
1302422|NCT00757471|Macular hole surgery
1302423|NCT00757471|membranepeeling
1302424|NCT00757471|closure rate
1302425|NCT00757471|vitreoretinal dyes
1302426|NCT00757458|Propofol
1302427|NCT00757458|Bacterial growth
1302428|NCT00757458|Fungal growth
1302429|NCT00757458|EDTA
1302430|NCT00757458|Target controlled infusion
1302431|NCT00757445|Antibiotic therapy
1302432|NCT00757445|Microbiological diagnosis
1302433|NCT00757419|Safety
1302434|NCT00757419|tolerability
1302435|NCT00757419|healthy subjects
1302436|NCT00757406|Lymphedema
1302437|NCT00757406|Bioimpedance
1302438|NCT00757393|Growth hormone
1302439|NCT00757393|Pediatrics
1302440|NCT00757393|Vitamin D
1302441|NCT00757393|Calcium
1302442|NCT00757393|Exercise
1302443|NCT00757380|epiretinal membranes
1302444|NCT00757380|vitreoretinal dyes
1302445|NCT00757380|membranepeeling
1302446|NCT00757367|Healthy subjects
1302447|NCT00757367|insulin
1302448|NCT00757367|bronchoscope
1302449|NCT00757367|serum insulin
1302450|NCT00757367|serum C-Peptide
1302451|NCT00757367|BAL fluid
1302452|NCT00757367|FDKP
1302453|NCT00757328|Bipolar depression Treatment
1302454|NCT00757315|acne keloidalis nuchae
1302455|NCT00757315|NdYag laser
1302456|NCT00757315|AKN
1302457|NCT00757315|acne keloidalis
1302458|NCT00757315|AK
1302459|NCT00757315|dermatitis papillaris capillitii
1302460|NCT00757315|folliculitis keloidalis nuchae
1302461|NCT00757315|sycosis nuchae
1302462|NCT00757315|acne keloid
1302463|NCT00757315|keloidal folliculitis
1302464|NCT00757315|lichen keloidalis nuchae
1302465|NCT00757315|folliculitis nuchae scleroticans
1302466|NCT00757315|sycosis framboesiformis
1302467|NCT00757302|breast cancer
1302468|NCT00757302|CarolIReS
1302469|NCT00757302|intraoperative gamma camera
1302470|NCT00757302|lymphoscintigraphy
1302471|NCT00757302|sentinel lymph node
1302472|NCT00757302|Hundred and ten patients with infiltrative breast cancer or ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.
1302473|NCT00757289|Tennis Elbow
1302474|NCT00757276|Copeptin
1302475|NCT00757276|Diabetes insipidus
1302476|NCT00757276|diagnostic marker
1302477|NCT00757276|Vasopressin
1302478|NCT00757276|antidiuretic hormone (ADH)
1302479|NCT00757263|ovarian epithelial cancer
1302480|NCT00757263|ovarian germ cell tumor
1302481|NCT00757263|ovarian sarcoma
1302482|NCT00757263|ovarian stromal cancer
1302483|NCT00757250|HIV
1302484|NCT00757250|AIDS
1302485|NCT00757250|Human Immunodeficiency Virus
1302486|NCT00757250|CD4+ T-lymphocytes
1302487|NCT00757250|treatment Experienced
1302488|NCT00757237|aztreonam lysine
1302489|NCT00757237|tobramycin inhalation solution
1302490|NCT00757237|tobramycin nebuliser solution
1302491|NCT00757237|cystic fibrosis
1302492|NCT00757237|pseudomonas aeruginosa
1302493|NCT00757237|lung infection
1302494|NCT00757237|CFQ-R
1302495|NCT00757237|inhaled antibiotic
1302496|NCT00757211|breast cancer
1302497|NCT00757211|male breast cancer
1302498|NCT00757198|pain, postoperative, opioid, PCA, cardiac surgery
1302499|NCT00757185|skin blood flow
1302500|NCT00757185|microcirculation
1302501|NCT00757172|adenocarcinoma of the esophagus
1302502|NCT00757172|adenocarcinoma of the gastroesophageal junction
1302503|NCT00757172|stage II esophageal cancer
1302504|NCT00757172|stage III esophageal cancer
1302505|NCT00757172|stage IV esophageal cancer
1302506|NCT00757159|Periodontal disease
1302507|NCT00757159|Hydroxyapatite
1302508|NCT00757159|Enamel matrix protein
1302509|NCT00757159|Regeneration
1302510|NCT00757159|Human
1302511|NCT00757146|chronic lung disease
1302512|NCT00757146|bronchopulmonary dysplasia
1302513|NCT00757146|inhaled nitric oxide
1302514|NCT00757146|premature infants
1302515|NCT00757120|COPD
1302516|NCT00757120|Cigarette Smoke-Induced Inflammation
1302517|NCT00757120|EMMPRIN
1302518|NCT00757120|Matrix Metalloproteinase
1302519|NCT00757107|Short femoral stem
1302520|NCT00757107|Stress shielding
1302521|NCT00757107|Stem migration
1302522|NCT00757107|Implant Survival
1302523|NCT00757107|DEXA
1302524|NCT00757107|Radiostereometric analysis
1302525|NCT00757094|Fasting
1302526|NCT00757094|Chemotherapy
1302527|NCT00757094|Cancer
1302528|NCT00757068|Non-smoking
1302529|NCT00757068|Women
1302530|NCT00757068|Pregnancy
1302531|NCT00757068|Treatment
1302532|NCT00757068|Mood
1302533|NCT00757068|Weight
1302534|NCT00757068|Supportive
1302535|NCT00757068|Adjustment
1302536|NCT00757055|Heart failure
1302537|NCT00757055|Diastolic heart failure
1302538|NCT00757055|Heart failure with preserved systolic function
1302539|NCT00757055|Heart failure with normal ejection fraction
1302540|NCT00757055|Ivabradine
1302541|NCT00757055|Diastolic dysfunction
1302542|NCT00757042|atopic dermatitis
1302543|NCT00757042|skin diseases
1302544|NCT00757042|healthy volunteer
1302545|NCT00757029|ADHD,
1302546|NCT00757029|norepinephrine transporter
1302547|NCT00757029|pharmacogenetics
1302548|NCT00757016|low back pain
1302549|NCT00757016|randomised controlled trial
1302550|NCT00757016|slow release corticosteroid
1302551|NCT00757016|injection treatment
1302552|NCT00756977|Colonoscopy
1302553|NCT00756977|screening
1302554|NCT00756964|cardiac surgery
1302555|NCT00756964|hyperuricemia
1302556|NCT00756951|SCV-07
1302557|NCT00756951|Oral Mucositis
1302558|NCT00756925|CRH
1302559|NCT00756925|cocaine
1302560|NCT00756925|functional magnetic resonance imaging
1302561|NCT00756925|gender differences
1302562|NCT00756912|ANC
1302563|NCT00756912|BMT
1302564|NCT00756912|graft versus leukemia
1302565|NCT00756912|graft vs. host disease
1302566|NCT00756912|MD2 (endotoxin binding-protein)
1302567|NCT00756912|undergo allogeneic BMT
1302568|NCT00756912|myeloablative
1302569|NCT00756912|conditioning
1302570|NCT00756912|therapy
1302571|NCT00756899|Vitamin D deficiency, insulin resistance, obesity, bone
1302572|NCT00756873|Elective tonsillectomy
1302573|NCT00756847|Solid Tumors
1302574|NCT00756847|NSCLC
1302575|NCT00756847|Ovarian Cancer
1302576|NCT00756847|Endometrial Cancer
1302577|NCT00756821|Spinal Muscular Atrophy
1302578|NCT00756821|Blood Biomarkers
1302579|NCT00756821|Urine Biomarkers
1302580|NCT00756821|Type I Spinal Muscular Atrophy
1302581|NCT00756821|Type II Spinal Muscular Atrophy
1302582|NCT00756821|Type III Spinal Muscular Atrophy
1302583|NCT00756821|Modified Hammersmith Functional Motor Scale
1302584|NCT00756821|Disease severity
1302585|NCT00756821|Biomarkers
1302586|NCT00756808|latent tuberculosis in elderly
1302587|NCT00756782|hepatocellular carcinoma
1302588|NCT00756756|G-CSF
1302589|NCT00756756|Myocardial infarction
1302590|NCT00756743|PF-04802540 multiple dose safety study
1302591|NCT00756730|lopinavir
1302592|NCT00756730|ritonavir
1302593|NCT00756730|atazanavir
1302594|NCT00756730|fosamprenavir
1302595|NCT00756730|darunavir
1302596|NCT00756730|anti-retroviral
1302597|NCT00756730|AIDS
1302598|NCT00756730|HIV
1302599|NCT00756730|LARD
1302600|NCT00756730|triglyceride
1302601|NCT00756730|protease inhibitors
1302602|NCT00756730|treatment Experienced
1302603|NCT00756717|MK-0752
1302604|NCT00756717|Tamoxifen
1302605|NCT00756717|Letroxole
1302606|NCT00756704|Smoking Cessation
1302607|NCT00756704|Emergency Medicine
1302608|NCT00756704|Emergency Nursing
1302609|NCT00756704|Effectiveness Trial
1302610|NCT00756704|Implementation
1302611|NCT00756704|Relapse prevention
1302612|NCT00756691|18F-FAZA
1302613|NCT00756691|Positron Emission Tomography
1302614|NCT00756691|Radiation dosimetry
1302615|NCT00756691|Pharmacokinetics
1302616|NCT00756665|prostate
1302617|NCT00756665|cancer
1302618|NCT00756639|small cell carcinoma of the bladder
1302619|NCT00756639|urothelial carcinoma
1302620|NCT00756639|genitourinary bladder
1302621|NCT00756639|urothelium
1302622|NCT00756639|bladder
1302623|NCT00756639|bladder cancer
1302624|NCT00756639|prophylactic cranial irradiation
1302625|NCT00756639|PCI
1302626|NCT00756639|brain metastasis
1302627|NCT00756639|genitourinary
1302628|NCT00756639|radiation
1302629|NCT00756639|TCC
1302630|NCT00756639|adenocarcinoma
1302631|NCT00756626|Bottle Weaning
1302632|NCT00756626|Bottle Feeding
1302633|NCT00756626|Overweight in toddlers
1302634|NCT00756626|Bottle use
1302635|NCT00756626|excess weight for length
1302636|NCT00756600|Infants
1302637|NCT00756600|scheduled
1302638|NCT00756600|unilateral
1302639|NCT00756600|bilateral
1302640|NCT00756600|repair
1302641|NCT00756587|Cup Feeding
1302642|NCT00756587|late Preterm
1302643|NCT00756574|N95
1302644|NCT00756574|Respirator
1302645|NCT00756574|mask
1302646|NCT00756574|influenza
1302647|NCT00756574|efficacy
1302648|NCT00756561|Fine Needle Aspiration
1302649|NCT00756561|Male Health
1302650|NCT00756561|Male Contraception
1302651|NCT00756548|colonoscopy
1302652|NCT00756548|screening
1302653|NCT00756535|Exercise Therapy
1302654|NCT00756535|Length of Stay
1302655|NCT00756535|Disability Evaluation
1302656|NCT00756522|COPD
1302657|NCT00756509|unresectable or metastatic GIST
1302658|NCT00756509|1st. line treatment
1302659|NCT00756483|Resistance
1302660|NCT00756483|Exercise
1302661|NCT00756470|Breast Cancer
1302662|NCT00756470|Inflammatory Breast Cancer
1302663|NCT00756470|IBC
1302664|NCT00756470|ErbB2 overexpression
1302665|NCT00756470|Lapatinib
1302666|NCT00756470|Paclitaxel
1302667|NCT00756470|5-Fluorouracil
1302668|NCT00756470|Epirubicin
1302669|NCT00756470|Cyclophosphamide
1302670|NCT00756470|Neoadjuvant Chemotherapy
1302671|NCT00756457|PTTD
1302672|NCT00756457|Tendinopathy
1302673|NCT00756457|Tendon Injuries
1302674|NCT00756457|Muscular Diseases
1302675|NCT00756457|Foot Diseases
1302676|NCT00756444|PK Study, Metastatic Recurrent
1302677|NCT00756405|Adults
1302678|NCT00756405|Antioxidants
1302679|NCT00756405|Inflammatory markers
1302680|NCT00756405|Diet
1302681|NCT00756405|Supplements
1302682|NCT00756392|3T MR Spectroscopy
1302683|NCT00756392|Prostate Imaging
1302684|NCT00756379|Cardiovascular disease
1302685|NCT00756379|Atherosclerosis
1302686|NCT00756379|Coronary artery disease
1302687|NCT00756379|Coronary perfusion defect
1302688|NCT00756379|Absolute coronary flow
1302689|NCT00756379|Lifestyle management
1302690|NCT00756379|Cardiovascular rehabilitation
1302691|NCT00756379|Cardiovascular dietary guidelines
1302692|NCT00756366|positron emission tomography
1302693|NCT00756366|myocardial energetics
1302694|NCT00756366|sympathetic nerve function
1302695|NCT00756353|Heroin
1302696|NCT00756353|Buprenorphine use
1302697|NCT00756327|pediatric eyes
1302698|NCT00756327|bilateral cataract
1302699|NCT00756327|IOL implantation
1302700|NCT00756327|Aqualase capsule wash
1302701|NCT00756327|posterior capsule opacification
1302702|NCT00756314|Ambulatory Care Facilities
1302703|NCT00756314|abortion care
1302704|NCT00756314|contraception
1302705|NCT00756314|counseling
1302706|NCT00756314|outpatient clinic
1302707|NCT00756288|Actinic Keratoses
1302708|NCT00756288|Blue light therapy
1302709|NCT00756288|photosensitizer
1302710|NCT00756288|Retinoid
1302711|NCT00756275|Tobacco Smoking
1302712|NCT00756275|Smoking Cessation
1302713|NCT00756275|Nicotine Dependence
1302714|NCT00756275|Tobacco Use Disorder
1302715|NCT00756262|Vancomycin Resistant enterococcal colonization
1302716|NCT00756262|Probiotics
1302717|NCT00756262|LGG
1302718|NCT00756262|Lactobacillus rhamnosus
1302719|NCT00756249|Acute ischemic stroke
1302720|NCT00756249|Erythropoietin
1302721|NCT00756249|Carbamylated
1302722|NCT00756249|Neuroprotection
1302723|NCT00755183|Meibomian Gland Dysfunction
1302724|NCT00755183|Dry Eye Syndrome
1302725|NCT00756197|Radiation Proctitis
1302726|NCT00756197|Radiation Induced Proctitis
1302727|NCT00756184|Glaucoma
1302728|NCT00756184|Adherence
1302729|NCT00756184|Teaching
1302730|NCT00756171|Cholestatic
1302731|NCT00756171|pruritus
1302732|NCT00756171|of any cause
1302733|NCT00756158|Attention Deficit Hyperactivity Disorder
1302734|NCT00756158|dopaminergic
1302735|NCT00756158|noradrenergic
1302736|NCT00756158|endophenotype
1302737|NCT00756158|molecular genetics
1302738|NCT00756158|candidate gene
1302739|NCT00756158|Family-based Association study
1302740|NCT00756145|stage V
1302741|NCT00756145|treated
1302742|NCT00756145|hemodiafiltration
1302743|NCT00756132|Breast
1302744|NCT00756132|Neoplasm
1302745|NCT00756132|Locally Advanced
1302746|NCT00756132|Stage IV
1302747|NCT00756132|Stage III
1302748|NCT00756132|Cognitive Function
1302749|NCT00756132|Cytokines
1302750|NCT00756132|Inflammatory
1302751|NCT00756132|Node positive
1302752|NCT00756106|adult glioblastoma
1302753|NCT00756106|adult giant cell glioblastoma
1302754|NCT00756106|adult gliosarcoma
1302755|NCT00756106|adult anaplastic astrocytoma
1302756|NCT00756106|adult anaplastic ependymoma
1302757|NCT00756106|adult anaplastic oligodendroglioma
1302758|NCT00756106|adult mixed glioma
1302759|NCT00756093|Dry Eye, Artificial Tears,
1302760|NCT00756067|Streptococcus pneumoniae
1302761|NCT00756067|pneumococcal vaccine
1302762|NCT00756041|Diabetic Mononeuropathy
1302763|NCT00756041|Diabetic Neuralgia
1302764|NCT00756041|Mononeuropathy, Diabetic
1302765|NCT00756041|Neuralgia, Diabetic
1302766|NCT00756041|Diabetic Polyneuropathy
1302767|NCT00756041|Drug Therapy
1302768|NCT00756028|OHSS
1302769|NCT00756028|quality of life
1302770|NCT00756028|IVF
1302771|NCT00756028|ICSI
1302772|NCT00756028|GnRH-agonist
1302773|NCT00756028|GnRH-antagonist
1302774|NCT00756015|rotator cuff
1302775|NCT00756015|post-operative immobilization protocol
1302776|NCT00756015|post-operative early motion protocol
1302777|NCT00756015|physical therapy
1302778|NCT00756015|cuff repair integrity
1302779|NCT00756015|ultrasound
1302780|NCT00756002|Chronic Insomnia
1302781|NCT00756002|DIMS (Disorders of Initiating and Maintaining Sleep)
1302782|NCT00756002|Disorders of Initiating and Maintaining Sleep
1302783|NCT00756002|Insomnia Disorder Sleep Initiation Dysfunction
1302784|NCT00756002|Transient Insomnia
1302785|NCT00756002|Drug Therapy
1302786|NCT00756002|Sleep Disorders, Intrinsic
1302787|NCT00755976|stage IV melanoma
1302788|NCT00755950|Acute
1302789|NCT00755950|Hepatitis
1302790|NCT00755950|Silymarin
1302791|NCT00755950|Global Health
1302792|NCT00755911|dental
1302793|NCT00755911|tooth
1302794|NCT00755911|implant
1302795|NCT00755911|extraction
1302796|NCT00755911|Oral
1302797|NCT00755911|Surgical
1302798|NCT00755911|Procedures
1302799|NCT00755898|cancer
1302800|NCT00755898|diagnostic test
1302801|NCT00755898|urine
1302802|NCT00755898|amantadine acetylation
1302803|NCT00755885|stage IIIA breast cancer
1302804|NCT00755885|stage IIIB breast cancer
1302805|NCT00755885|stage IIIC breast cancer
1302806|NCT00755885|stage IV breast cancer
1302807|NCT00755885|recurrent breast cancer
1302808|NCT00755885|estrogen receptor-positive breast cancer
1302809|NCT00755885|progesterone receptor-positive breast cancer
1302810|NCT00755859|IgA nephropathy
1302811|NCT00755859|steroids
1302812|NCT00755859|azathioprine
1302813|NCT00755859|chronic kidney disease progression
1302814|NCT00755859|proteinuria
1302815|NCT00755846|Diabetes Mellitus
1302816|NCT00755846|Drug Therapy
1302817|NCT00755846|Diabetes Mellitus, Type II
1302818|NCT00755846|Type 2 Diabetes Mellitus
1302819|NCT00755846|Hyperinsulinism
1302820|NCT00755846|Insulin Resistance
1302821|NCT00755807|Central Neuropathic Pain
1302822|NCT00755807|Multiple Sclerosis
1302823|NCT00755781|lung transplant
1302824|NCT00755781|lung transplant recipient
1302825|NCT00755781|bronchiolitis obliterans syndrome
1302826|NCT00755781|bronchiolitis obliterans
1302827|NCT00755781|single lung transplant
1302828|NCT00755781|double lung transplant
1302829|NCT00755781|heart-lung transplant
1302830|NCT00755781|Aerosol
1302831|NCT00755768|hemodialysis
1302832|NCT00755768|phosphate
1302833|NCT00755768|calcium phosphate product
1302834|NCT00755768|dietician
1302835|NCT00755768|dietetic advice
1302836|NCT00755742|obesity
1302837|NCT00755742|insulin resistance
1302838|NCT00755742|metabolic syndrome
1302839|NCT00755742|hepatitis C
1302840|NCT00755742|adipokine
1302841|NCT00755742|TNF
1302842|NCT00755742|leptin
1302843|NCT00755742|adiponectin
1302844|NCT00755742|fatigue
1302845|NCT00755742|mood
1302846|NCT00755742|depression
1302847|NCT00755742|exercise
1302848|NCT00755742|diet
1302849|NCT00755742|counseling
1302850|NCT00755742|behavior modification
1302851|NCT00755729|Preoperative oral carbohydrate
1302852|NCT00755729|Insulin resistance
1302853|NCT00755729|phosphatidylinositol-3-kinase
1302854|NCT00755716|nicotine patch
1302855|NCT00755716|smoking
1302856|NCT00755716|topiramate
1302857|NCT00755703|Influenza
1302858|NCT00755703|Vaccine
1302859|NCT00755703|Pandemic
1302860|NCT00755703|Avian influenza
1302861|NCT00755703|Adenovirus strain 5
1302862|NCT00755703|Vectored vaccine
1302863|NCT00755703|Intranasal
1302864|NCT00755703|Tissue-culture derived
1302865|NCT00755703|Non-replicating
1302866|NCT00755690|Chronic Kidney Disease
1302867|NCT00755690|CKD
1302868|NCT00755690|Diet
1302869|NCT00755690|Dietary Phosphate
1302870|NCT00755690|Mineral Metabolism
1302871|NCT00755690|FGF-23
1302872|NCT00755664|homocysteine
1302873|NCT00755664|folate acid,
1302874|NCT00755664|vitamin B
1302875|NCT00755664|random controlled trail
1302876|NCT00755651|Menorrhagia
1302877|NCT00755651|Uterine fibroids
1302878|NCT00755651|Endometrial polyps
1302879|NCT00755651|Endometrial cancer
1302880|NCT00755599|Papanicolaou Smear
1302881|NCT00755599|Vaginitis
1302882|NCT00755599|Patient Satisfaction
1302883|NCT00755586|Brachial plexus
1302884|NCT00755586|Muscle denervation
1302885|NCT00755586|Stem cell transplantation
1302886|NCT00755586|Bone marrow cells
1302887|NCT00755586|Satellite cells
1302888|NCT00755586|Fibrosis
1302889|NCT00755573|Pain
1302890|NCT00755573|Neuropathic pain
1302891|NCT00755560|Toxocara
1302892|NCT00755560|Pediatrics
1302893|NCT00755560|Albendazole
1302894|NCT00755560|eosinophilia
1302895|NCT00755560|parasitology
1302896|NCT00755560|pediatric clinical pharmacology
1302897|NCT00755547|Childhood
1302898|NCT00755547|insulin sensitivity
1302899|NCT00755547|steatosis, spectroscopy
1302900|NCT00755534|Metastatic colorectal cancer
1302901|NCT00755534|Second line
1302902|NCT00755534|Irinotecan
1302903|NCT00755534|Cetuximab (Erbitux)
1302904|NCT00755534|Capecitabine (Xeloda)
1302905|NCT00755521|Fibromyalgia
1302906|NCT00755521|tenderness
1302907|NCT00755521|widespread pain
1302908|NCT00755521|comrbidity
1302909|NCT00755508|Chronic Insomnia
1302910|NCT00755508|DIMS (Disorders of Initiating and Maintaining Sleep)
1302911|NCT00755508|Disorders of Initiating and Maintaining Sleep
1302912|NCT00755508|Insomnia Disorder Sleep Initiation Dysfunction
1302913|NCT00755508|Transient Insomnia
1302914|NCT00755508|Drug Therapy
1302915|NCT00755508|Sleep Disorders, Intrinsic
1302916|NCT00755495|Chronic Insomnia
1302917|NCT00755495|DIMS (Disorders of Initiating and Maintaining Sleep)
1302918|NCT00755495|Disorders of Initiating and Maintaining Sleep
1302919|NCT00755495|Insomnia Disorder Sleep Initiation Dysfunction
1302920|NCT00755495|Transient Insomnia
1302921|NCT00755495|Drug Therapy
1302922|NCT00755495|Sleep Disorders, Intrinsic
1302923|NCT00755482|Osteoarthritis
1302924|NCT00755482|Clinical trial
1302925|NCT00755482|Aquamin F
1302926|NCT00755482|NSAID
1302927|NCT00755469|Reperfusion injury
1302928|NCT00755469|Post-Conditioning
1302929|NCT00755469|Infarct size
1302930|NCT00755456|Peritoneal dialysis
1302931|NCT00755456|L-carnitine
1302932|NCT00755456|Insulin resistance
1302933|NCT00755456|Glucose homeostasis
1302934|NCT00755456|Dyslipidemia
1302935|NCT00755430|autism spectrum disorders (ASD)
1302936|NCT00755430|structural and functional connectivity
1302937|NCT00755430|diffusion spectrum imaging (DSI)
1302938|NCT00755430|functional magnetic resonance imaging (fMRI)
1302939|NCT00755430|siblings
1302940|NCT00755430|repeated follow-up measurement
1302941|NCT00755417|Hot flashes
1302942|NCT00755417|Hot flushes
1302943|NCT00755417|Postmenopausal symptoms
1302944|NCT00755417|Vasomotor symptoms
1302945|NCT00755404|Peritoneal dialysis
1302946|NCT00755404|L-carnitine
1302947|NCT00755404|Diabetes
1302948|NCT00755404|Glucose homeostasis
1302949|NCT00755404|Dyslipidemia
1302950|NCT00755391|BN and subthreshold BN
1302951|NCT00755378|Phase I
1302952|NCT00755365|pelvic fractures
1302953|NCT00755365|angioembolism
1302954|NCT00755365|Treatment at Hershey Medical Center
1302955|NCT00755365|Angioembolization in Operating Room
1302956|NCT00755339|Repetitive TMS (rTMS)
1302957|NCT00755339|Magnetoencephalogram
1302958|NCT00755339|Transcranial Magnetic Stimulation (TMS)
1302959|NCT00755339|Tourette Syndrome
1302960|NCT00755339|Tic Disorder
1302961|NCT00755339|Tourete Syndrome
1302962|NCT00755326|OA
1302963|NCT00755313|cognitive/functional effects
1302964|NCT00755313|fatigue
1302965|NCT00755313|long-term effects secondary to cancer therapy in adults
1302966|NCT00755313|psychosocial effects of cancer and its treatment
1302967|NCT00755313|chemotherapeutic agent toxicity
1302968|NCT00755313|neurotoxicity
1302969|NCT00755313|stage IA breast cancer
1302970|NCT00755313|stage IB breast cancer
1302971|NCT00755313|stage II breast cancer
1302972|NCT00755313|stage IIIA breast cancer
1302973|NCT00755313|stage IIIB breast cancer
1302974|NCT00755313|stage IIIC breast cancer
1302975|NCT00755313|estrogen receptor-negative breast cancer
1302976|NCT00755313|estrogen receptor-positive breast cancer
1302977|NCT00755313|progesterone receptor-negative breast cancer
1302978|NCT00755313|progesterone receptor-positive breast cancer
1302979|NCT00755300|Total knee replacement
1302980|NCT00755300|esophageal echocardiography
1302981|NCT00755274|Influenza
1302982|NCT00755274|Orthomyxoviruses
1302983|NCT00755274|Orthomyxoviridae Infections
1302984|NCT00755274|Influenza vaccine
1302985|NCT00755261|STS
1302986|NCT00755248|Coronary Artery Bypass Grafting (CABG)
1302987|NCT00755248|outcome
1302988|NCT00755248|saphenous graft patency
1302989|NCT00755248|biochemical factors
1302990|NCT00755248|genomics
1302991|NCT00755235|Depression
1302992|NCT00755235|Primary care
1302993|NCT00755235|Effectiveness
1302994|NCT00755235|Care management
1302995|NCT00755222|Peyronie's disease
1302996|NCT00755222|penile plaque
1302997|NCT00755222|penile curvature
1302998|NCT00755209|Traumatic brain injury (TBI)
1302999|NCT00755209|Adults
1303000|NCT00755209|Moderately severe TBI
1303001|NCT00755209|Delayed traumatic intracranial haemorrhage
1303002|NCT00755209|Expanding traumatic intracranial haemorrhage
1303003|NCT00755209|Progressive intracranial haemorrhage (PIH)
1303004|NCT00755209|Antifibrinolytic agent
1303005|NCT00755209|Tranexamic acid (TXA)
1303006|NCT00755209|Randomised, placebo-controlled trial
1303007|NCT00755209|Human
1303008|NCT00755196|Plaque Type Psoriasis
1303009|NCT00755196|Topical
1303010|NCT00755170|Vinorelbine
1303011|NCT00755170|Bevacizumab
1303012|NCT00755170|Chemotherapy
1303013|NCT00755157|Cancer
1303014|NCT00755157|SCLC
1303015|NCT00755157|Docetaxel
1303016|NCT00755157|Bevacizumab
1303017|NCT00755157|Chemotherapy
1303018|NCT00755131|Cardiac Rehabilitation
1303019|NCT00755131|High Mobility Group Box proteins
1303020|NCT00755131|Inflammatory markers
1303021|NCT00755131|Cardiopulmonary Functional Capacity
1303022|NCT00755131|Maximal Oxygen Consumption
1303023|NCT00755131|Echocardiography
1303024|NCT00755131|Left Ventricular Ejection Fraction
1303025|NCT00755131|Left Ventricular Chambers Dilation
1303026|NCT00755131|Left Ventricular Remodeling
1303027|NCT00755131|Left Atrium Remodeling
1303028|NCT00755131|Cardiac Remodeling
1303029|NCT00755131|Exercise Training
1303030|NCT00755118|Metastatic colorectal cancer
1303031|NCT00755118|Second line
1303032|NCT00755118|Irinotecan
1303033|NCT00755118|Cetuximab
1303034|NCT00755118|Bevacizumab
1303035|NCT00755105|body iron excretion
1303036|NCT00755105|Iron isotopes
1303037|NCT00755092|Doula
1303038|NCT00755092|Psychological care
1303039|NCT00755092|Labor analgesia
1303040|NCT00755079|spinal cord injury
1303041|NCT00755079|beta-2 agonist
1303139|NCT00754897|Neurologic Examination
1303042|NCT00755079|respiratory muscle strength
1303043|NCT00755079|pulmonary function test
1303044|NCT00755053|Clotrimazole
1303045|NCT00755053|Ovule
1303046|NCT00755053|Tablet
1303047|NCT00755053|Vulvovaginal candidiasis
1303048|NCT00755053|Non-inferiority
1303049|NCT00755040|graft versus host disease
1303050|NCT00755040|stage III adult Burkitt lymphoma
1303051|NCT00755040|stage III adult diffuse large cell lymphoma
1303052|NCT00755040|stage III adult diffuse mixed cell lymphoma
1303053|NCT00755040|stage III adult diffuse small cleaved cell lymphoma
1303054|NCT00755040|stage III adult Hodgkin lymphoma
1303055|NCT00755040|stage III adult immunoblastic large cell lymphoma
1303056|NCT00755040|stage III adult lymphoblastic lymphoma
1303057|NCT00755040|stage III grade 1 follicular lymphoma
1303058|NCT00755040|stage III grade 2 follicular lymphoma
1303059|NCT00755040|stage III grade 3 follicular lymphoma
1303060|NCT00755040|stage III mantle cell lymphoma
1303061|NCT00755040|stage III marginal zone lymphoma
1303062|NCT00755040|stage III small lymphocytic lymphoma
1303063|NCT00755040|stage IV adult Burkitt lymphoma
1303064|NCT00755040|stage IV adult diffuse large cell lymphoma
1303065|NCT00755040|stage IV adult diffuse mixed cell lymphoma
1303066|NCT00755040|stage IV adult diffuse small cleaved cell lymphoma
1303067|NCT00755040|stage IV adult Hodgkin lymphoma
1303068|NCT00755040|stage IV adult immunoblastic large cell lymphoma
1303069|NCT00755040|stage IV adult lymphoblastic lymphoma
1303070|NCT00755040|stage IV grade 1 follicular lymphoma
1303071|NCT00755040|stage IV grade 2 follicular lymphoma
1303072|NCT00755040|stage IV grade 3 follicular lymphoma
1303073|NCT00755040|stage IV mantle cell lymphoma
1303074|NCT00755040|stage IV marginal zone lymphoma
1303075|NCT00755040|stage IV small lymphocytic lymphoma
1303076|NCT00755040|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1303077|NCT00755040|nodal marginal zone B-cell lymphoma
1303078|NCT00755040|splenic marginal zone lymphoma
1303079|NCT00755040|noncontiguous stage II adult Burkitt lymphoma
1303080|NCT00755040|noncontiguous stage II adult diffuse large cell lymphoma
1303081|NCT00755040|noncontiguous stage II adult diffuse mixed cell lymphoma
1303082|NCT00755040|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1303083|NCT00755040|noncontiguous stage II adult immunoblastic large cell lymphoma
1303084|NCT00755040|noncontiguous stage II adult lymphoblastic lymphoma
1303085|NCT00755040|noncontiguous stage II grade 1 follicular lymphoma
1303086|NCT00755040|noncontiguous stage II grade 2 follicular lymphoma
1303087|NCT00755040|noncontiguous stage II grade 3 follicular lymphoma
1303088|NCT00755040|noncontiguous stage II mantle cell lymphoma
1303089|NCT00755040|noncontiguous stage II marginal zone lymphoma
1303090|NCT00755040|noncontiguous stage II small lymphocytic lymphoma
1303091|NCT00755040|accelerated phase chronic myelogenous leukemia
1303092|NCT00755040|adult acute lymphoblastic leukemia in remission
1303093|NCT00755040|adult acute myeloid leukemia in remission
1303094|NCT00755040|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1303095|NCT00755040|adult acute myeloid leukemia with inv(16)(p13;q22)
1303096|NCT00755040|adult acute myeloid leukemia with t(15;17)(q22;q12)
1303097|NCT00755040|adult acute myeloid leukemia with t(16;16)(p13;q22)
1303098|NCT00755040|adult acute myeloid leukemia with t(8;21)(q22;q22)
1303099|NCT00755040|atypical chronic myeloid leukemia, BCR-ABL negative
1303100|NCT00755040|blastic phase chronic myelogenous leukemia
1303101|NCT00755040|chronic myelomonocytic leukemia
1303102|NCT00755040|chronic phase chronic myelogenous leukemia
1303103|NCT00755040|secondary acute myeloid leukemia
1303104|NCT00755040|stage III chronic lymphocytic leukemia
1303105|NCT00755040|stage IV chronic lymphocytic leukemia
1303106|NCT00755040|chronic eosinophilic leukemia
1303107|NCT00755040|primary myelofibrosis
1303108|NCT00755040|chronic neutrophilic leukemia
1303109|NCT00755040|de novo myelodysplastic syndromes
1303110|NCT00755040|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1303111|NCT00755040|previously treated myelodysplastic syndromes
1303112|NCT00755040|secondary myelodysplastic syndromes
1303113|NCT00755040|stage I multiple myeloma
1303114|NCT00755040|stage II multiple myeloma
1303115|NCT00755040|stage III multiple myeloma
1303116|NCT00755027|Parkinson's disease
1303117|NCT00755027|Apathy
1303118|NCT00755027|Rasagiline
1303119|NCT00755001|Total Hip Replacement
1303120|NCT00754949|Blepharoconjunctivitis,
1303121|NCT00754949|Ophthalmology
1303122|NCT00754936|Depression
1303123|NCT00754923|recurrent non-small cell lung cancer
1303124|NCT00754923|stage IIIB non-small cell lung cancer
1303125|NCT00754923|stage IV non-small cell lung cancer
1303126|NCT00754923|adenocarcinoma of the lung
1303127|NCT00754923|bronchoalveolar cell lung cancer
1303128|NCT00754923|large cell lung cancer
1303129|NCT00754910|stage I non-small cell lung cancer
1303130|NCT00754910|stage II non-small cell lung cancer
1303131|NCT00754910|stage IIIA non-small cell lung cancer
1303132|NCT00754910|stage IIIB non-small cell lung cancer
1303133|NCT00754910|stage IV non-small cell lung cancer
1303134|NCT00754910|recurrent non-small cell lung cancer
1303135|NCT00754897|Phone Interview
1303136|NCT00754897|Anesthesia
1303137|NCT00754897|Siblings
1303138|NCT00754897|Inguinal Hernia
1303140|NCT00754897|Developmental Delay Disorders
1303141|NCT00754884|salmon calcitonin
1303142|NCT00754884|endorphins
1303143|NCT00754884|treatment
1303144|NCT00754884|fibromyalgia
1303145|NCT00754858|extensive stage small cell lung cancer
1303146|NCT00754845|stage I breast cancer
1303147|NCT00754845|stage II breast cancer
1303148|NCT00754845|stage IIIA breast cancer
1303149|NCT00754845|stage IIIB breast cancer
1303150|NCT00754845|stage IIIC breast cancer
1303151|NCT00754832|Multiple sclerosis
1303152|NCT00754832|fatigue
1303153|NCT00754832|ginseng
1303154|NCT00754806|HALS
1303155|NCT00754806|open splenectomy
1303156|NCT00754806|splenomegaly
1303157|NCT00754806|HALS as a hybrid approach of pure laparoscopy and open surgery has some definite advantages over open surgery
1303158|NCT00754806|In the HALS group, incision length is significantly shorter
1303159|NCT00754806|In the HALS group, postoperative pain is less than with open surgery
1303160|NCT00754806|In the HALS group, postoperative hospital stay is shorter than with open surgery
1303161|NCT00754780|NF1
1303162|NCT00754780|plexiform neurofibroma
1303163|NCT00754767|neurotoxicity
1303164|NCT00754767|chemotherapeutic agent toxicity
1303165|NCT00754767|stage IV breast cancer
1303166|NCT00754767|recurrent breast cancer
1303167|NCT00754754|brain
1303168|NCT00754754|surgery
1303169|NCT00754754|retraction
1303170|NCT00754754|injury
1303171|NCT00754754|monitoring
1303172|NCT00754741|medication adherence
1303173|NCT00754741|motivational interviewing
1303174|NCT00754715|Multiple dosing study,
1303175|NCT00754715|safety
1303176|NCT00754702|Vinorelbine metronomic-lapatinib
1303177|NCT00754702|Chemotherapy
1303178|NCT00754702|Targeted therapy
1303179|NCT00754689|Rimonabant/metformin combination
1303180|NCT00754663|exercise
1303181|NCT00754663|implantable cardioverter-defibrillator
1303182|NCT00754663|arrhythmia
1303186|NCT00754546|exercise;
1303187|NCT00754546|treadmill;
1303188|NCT00754546|cycle ergometer;
1303189|NCT00754546|breathlessness;
1303190|NCT00754546|leg discomfort
1303191|NCT00754533|cardiac rehabilitation
1303192|NCT00754533|coronary heart disease
1303193|NCT00754533|interval training
1303194|NCT00754533|continuous training
1303195|NCT00754533|ventilatory threshold
1303196|NCT00754481|Paediatrics
1303197|NCT00754468|Barrett's Esophagus
1303198|NCT00754468|Esophageal Cancer
1303199|NCT00754468|Esophageal Dysplasia
1303200|NCT00754468|Low Grade Dysplasia
1303201|NCT00754468|High Grade Dysplasia
1303202|NCT00754442|hyperparathyroidism
1303203|NCT00754442|parathyroid
1303204|NCT00754442|vitamin D
1303205|NCT00754442|vitamin D deficiency
1303206|NCT00754416|Shoulder Replacement
1303207|NCT00754403|Glucose Metabolism Disorder
1303208|NCT00754403|Dysmetabolic Syndrome
1303209|NCT00754403|Type II Diabetes
1303210|NCT00754403|Diabetes Mellitus, Lipoatrophic
1303211|NCT00754403|Dyslipidemia
1303212|NCT00754403|Drug Therapy
1303213|NCT00754390|dietary zinc absorption
1303214|NCT00754390|dietary phytic acid
1303215|NCT00754390|dietary calcium
1303216|NCT00754377|Education
1303217|NCT00754377|Program Evaluation
1303218|NCT00754377|Quality of Health Care
1303219|NCT00754377|Medical Residents
1303220|NCT00754351|docetaxel
1303221|NCT00754351|gemcitabine
1303222|NCT00754351|bevacizumab
1303223|NCT00754351|chemotherapy
1303224|NCT00754338|comfort
1303225|NCT00754338|wetability
1303226|NCT00754338|protein deposit
1303227|NCT00754338|lipid deposit
1303228|NCT00754312|breast cancer
1303229|NCT00754299|nonunion/malunion osseous fractures
1303230|NCT00754299|nicotine dependent
1303231|NCT00754299|chronic osseous infection
1303232|NCT00754299|infected osseous nonunions
1303233|NCT00754299|Fracture nonunion or infection
1303234|NCT00754286|Aromatherapy
1303235|NCT00754247|Keloid
1303236|NCT00754247|Hypertrophic scar
1303237|NCT00754247|Hydrocortisone, silicone, vitamin E lotion
1303238|NCT00754247|HSE
1303239|NCT00754247|Onion extract gel
1303240|NCT00754247|OE
1303241|NCT00754247|Cetearyl alcohol lotion
1303242|NCT00754247|CEA
1303243|NCT00754234|iron absorption
1303244|NCT00754234|iron requirements
1303245|NCT00754234|dietary guidelines
1303246|NCT00754234|MyPyramid
1303247|NCT00754221|Phase 3, safety study, [S,S]-Reboxetine, Fibromyalgia
1303248|NCT00754208|Attention Deficit Hyperactivity Disorder
1303249|NCT00754208|Stimulant Treatment
1303250|NCT00754208|Young Children
1303251|NCT00754195|Thoracotomy
1303252|NCT00754182|thyroidectomy
1303253|NCT00754182|surgery
1303254|NCT00754182|synthetic glue
1303255|NCT00754182|subcuticular suture
1303256|NCT00754169|Traumatic Brain Injury
1303257|NCT00754169|Brain Imaging
1303258|NCT00754169|Brain Plasticity
1303259|NCT00754169|Neuroplasticity
1303260|NCT00754169|Neuropsychological Testing
1303261|NCT00754169|Head Injury
1303262|NCT00754169|Healthy Volunteer
1303263|NCT00754156|Closure, Wounds
1303264|NCT00754143|Type 1 or Type 2 diabetes
1303265|NCT00754143|proteinuria
1303266|NCT00754117|diffuse large b cell lymphoma
1303267|NCT00754117|newly diagnosed
1303268|NCT00754078|tomotherapy
1303269|NCT00754065|Oral contraceptive
1303270|NCT00754065|Estradiol valerate and dienogest
1303271|NCT00754065|EV/DNG
1303272|NCT00754065|comparative tolerability
1303273|NCT00754052|Pediatric
1303274|NCT00754052|Down syndrome
1303275|NCT00754052|Downs
1303276|NCT00754052|Cognitive Dysfunction of Down syndrome
1303277|NCT00754039|Mixed hyperlipidemia
1303278|NCT00754026|Shoulder surgery
1303279|NCT00754013|pediatric
1303280|NCT00754013|Down syndrome
1303281|NCT00754013|cognitive dysfunction
1303282|NCT00754013|Downs
1303283|NCT00754013|Aricept
1303284|NCT00754013|children with Down syndrome
1303285|NCT00753987|Cystic Fibrosis
1303286|NCT00753987|Hypertonic Saline
1303287|NCT00753987|Infants
1303288|NCT00753961|Shiftworkers
1303289|NCT00753961|volunteers
1303290|NCT00753948|Tetraplegia
1303291|NCT00753948|Mild asthma
1303292|NCT00753948|Exhaled Nitric Oxide
1303293|NCT00753948|NOS inhibitor
1303294|NCT00753948|Spinal cord injury
1303295|NCT00753948|Pulmonary Function
1303296|NCT00753935|aspirin
1303297|NCT00753935|aspirin resistance
1303298|NCT00753935|aspirin nonresponse
1303299|NCT00753935|cyclooxygenase
1303300|NCT00753935|thromboxane
1303301|NCT00753935|oxidative stress
1303302|NCT00753922|Breast Reconstruction
1303303|NCT00753922|Breast Augmentation
1303304|NCT00753922|Revision
1303305|NCT00753922|Silicone breast implants
1303306|NCT00753922|Round low-bleed
1303307|NCT00753909|Non Small Cell Lung Cancer
1303308|NCT00753909|Paclitaxel
1303309|NCT00753909|Carboplatin
1303310|NCT00753909|Bevacizumab
1303311|NCT00753896|Amylin
1303312|NCT00753896|Lilly
1303313|NCT00753896|exenatide once weekly
1303314|NCT00753896|thiazolidinedione
1303315|NCT00753896|metformin
1303316|NCT00753870|current
1303317|NCT00753870|no health problems
1303318|NCT00753870|no daily cough from smoking
1303319|NCT00753857|risk communication
1303320|NCT00753857|probability sample by random digit dialing
1303321|NCT00753844|peptide vaccine
1303322|NCT00753844|URLC10
1303323|NCT00753831|Blepharoptosis
1303324|NCT00753831|Ophthalmoplegia
1303325|NCT00753831|Blepharospasm
1303326|NCT00753818|infant formula
1303327|NCT00753818|visual development
1303328|NCT00753805|mare's milk
1303329|NCT00753805|atopic dermatitis
1303330|NCT00753805|endogenous eczema
1303331|NCT00753805|SCORAD
1303332|NCT00753805|Bifidobacteria
1303333|NCT00753792|multiple sclerosis
1303334|NCT00753792|relapse
1303335|NCT00753792|methylprednisolone
1303336|NCT00753766|A1c
1303337|NCT00753766|Blood Glucose Management
1303338|NCT00753766|Blood Pressure
1303339|NCT00753766|Case Management
1303340|NCT00753766|Diabetes Mellitus
1303341|NCT00753766|Intervention study
1303342|NCT00753766|Multifactorial
1303343|NCT00753766|Peri-operative complications
1303344|NCT00753766|Pre-operative
1303345|NCT00753753|stent thrombosis
1303346|NCT00753753|clopidogrel
1303347|NCT00753753|aspirin
1303348|NCT00753753|bleeding
1303349|NCT00753753|coronary
1303350|NCT00753753|angioplasty
1303351|NCT00753740|Cancer
1303352|NCT00753740|Neoplasms
1303353|NCT00753740|Solid Tumor
1303354|NCT00753740|Ovarian Cancer
1303355|NCT00753740|Solid Malignancies
1303356|NCT00753727|soft tissue
1303357|NCT00753727|Sarcoma
1303358|NCT00753727|Sunitinib
1303359|NCT00753727|neoadjuvant
1303360|NCT00753727|radiotherapy
1303361|NCT00753714|ZD6474
1303362|NCT00753714|VANDETANIB
1303363|NCT00753714|ZACTIMA
1303364|NCT00753714|ADVANCED
1303365|NCT00753714|NSCLC
1303366|NCT00753714|LUNG CANCER
1303367|NCT00753714|ELDERLY PATIENTS
1303368|NCT00753714|GEMCITABINE
1303369|NCT00753714|PHASE II
1303370|NCT00753714|RANDOMIZED
1303371|NCT00753714|DOUBLE-BLIND
1303372|NCT00753714|histologically or cytologically-confirmed advanced (stage IIIB with supraclavicular lymph node metastases or pleural effusion or stage IV) NSCLC
1303373|NCT00753688|metastatic soft-tissue sarcoma
1303374|NCT00753688|pazopanib
1303375|NCT00753688|Soft Tissue Sarcoma
1303376|NCT00753688|placebo
1303377|NCT00753675|Intrahepatic
1303378|NCT00753675|Cholangiocarcinoma
1303379|NCT00753675|Vandetanib
1303380|NCT00753675|Zactima
1303381|NCT00753675|Advanced
1303382|NCT00753675|Biliary
1303383|NCT00753675|Tract
1303384|NCT00753675|Gallbladder
1303385|NCT00753675|Extrahepatic Bile Duct
1303386|NCT00753675|Intrahepatic Cholangiocarcinoma
1303387|NCT00753675|Ampullary Carcinoma
1303388|NCT00753662|TMS AD H2 coil
1303389|NCT00753649|Infant
1303390|NCT00753649|First nation
1303391|NCT00753649|Aboriginal
1303392|NCT00753649|Canada
1303393|NCT00753636|Parkinson's disease
1303394|NCT00753636|Isradipine
1303395|NCT00753636|Neuroprotection
1303396|NCT00753623|Pain
1303397|NCT00753623|Neuropathic pain
1303398|NCT00753623|Pain scores
1303399|NCT00753610|EPC
1303400|NCT00753610|CCRT
1303401|NCT00753610|Cervical cancer
1303402|NCT00753597|B cell depletion
1303403|NCT00753597|steroidogenesis
1303404|NCT00753571|Amyotrophic Lateral Sclerosis
1303405|NCT00753571|Cistanche Total Glycosides
1303406|NCT00753571|Randomized Control Trial Study
1303407|NCT00753545|Serous,
1303408|NCT00753545|Ovarian cancer,
1303409|NCT00753545|PARP,
1303410|NCT00753545|BRCA1,
1303411|NCT00753545|BRCA2,
1303412|NCT00753545|Poly(ADP ribose) polymerases,
1303413|NCT00753545|Platinum sensitive,
1303414|NCT00753545|Homologous Recombination Deficiency (HRD)
1303415|NCT00753532|Carotid artery stenoses
1303416|NCT00753532|Brain ischaemia
1303417|NCT00753532|stroke
1303418|NCT00753532|Lipid abnormalities
1303419|NCT00753532|Fatty Liver
1303420|NCT00753519|Parkinson's Disease
1303421|NCT00753519|Brain Stimulation
1303422|NCT00753519|Motor Cortex
1303423|NCT00753519|Bradykinesia
1303424|NCT00753519|Parkinson Disease
1303425|NCT00753519|PD
1303426|NCT00753480|EOC
1303427|NCT00753480|PPC
1303428|NCT00753480|FTC
1303429|NCT00753467|HBV
1303430|NCT00753467|Treatment
1303431|NCT00753467|Interferon-gamma
1303432|NCT00753467|combination
1303433|NCT00753467|Hepsera
1303434|NCT00753467|Actimmune
1303435|NCT00753467|HBV DNA
1303436|NCT00753454|Rheumatoid Arthritis
1303437|NCT00753454|Joint Disease
1303438|NCT00753454|Arthritis
1303439|NCT00753454|Certolizumab pegol
1303440|NCT00753454|Cimzia
1303441|NCT00753441|Pancreatic cancer
1303442|NCT00753441|Bile duct obstruction
1303443|NCT00753441|Stent
1303444|NCT00753441|Bypass
1303445|NCT00753428|HIV-free survival
1303446|NCT00753428|Community based evaluation
1303447|NCT00753428|Pregnancy
1303448|NCT00753428|Under 2 child survival
1303449|NCT00753428|PMTCT
1303450|NCT00753428|Pediatric HIV infection
1303451|NCT00753428|HAART
1303452|NCT00753428|Routine ART
1303453|NCT00753428|HIV Seronegativity
1303454|NCT00753415|Urinary Bladder Neoplasms
1303455|NCT00753415|Breast Neoplasms
1303456|NCT00753415|Renal Cell carcinoma
1303457|NCT00753415|Melanoma
1303458|NCT00753415|Prostatic Neoplasms
1303459|NCT00753415|Colonic Neoplasms
1303460|NCT00753415|Urologic Neoplasms
1303461|NCT00753415|Urogenital Neoplasms
1303462|NCT00753415|Urinary Bladder Diseases
1303463|NCT00753415|Urologic Diseases
1303464|NCT00753415|Breast Diseases
1303465|NCT00753415|Skin Diseases
1303466|NCT00753415|Neoplasms
1303467|NCT00753415|Glandular and Epithelial Neoplasms by Histologic Type
1303468|NCT00753415|Adenocarcinoma
1303469|NCT00753415|Kidney Neoplasms
1303470|NCT00753415|Kidney Diseases
1303471|NCT00753415|Neuroendocrine Tumors
1303472|NCT00753415|Neuroectodermal Tumors
1303473|NCT00753415|Neoplasms, Germ Cell and Embryonal
1303474|NCT00753415|Neoplasms, Nerve Tissue
1303475|NCT00753415|Nevi and Melanomas
1303476|NCT00753415|Genital Neoplasms
1303477|NCT00753415|Male Genital Diseases
1303478|NCT00753415|Male, Prostatic Diseases
1303479|NCT00753415|Colorectal Neoplasms
1303480|NCT00753415|Intestinal Neoplasms
1303481|NCT00753389|Postoperative residual curarization,
1303482|NCT00753389|muscle relaxants,
1303483|NCT00753389|morbidity mortality
1303484|NCT00753363|Glucose Metabolism
1303485|NCT00753350|obesity
1303486|NCT00753324|PMTCT
1303487|NCT00753324|HAART
1303488|NCT00753324|Pregnancy
1303489|NCT00753324|HIV Infection
1303490|NCT00753324|HIV Transmission
1303491|NCT00753324|HIV Seronegativity
1303492|NCT00753311|migraine
1303493|NCT00753311|rizatriptan
1303494|NCT00753311|unilateral trigeminal autonomic symptoms
1303495|NCT00753311|Migraine with or without aura
1303496|NCT00753272|Efficacy
1303497|NCT00753272|Influenza Vaccines
1303498|NCT00753272|Influenza
1303499|NCT00753272|Vaccine
1303500|NCT00753272|Elderly
1303501|NCT00753259|atrial fibrillation
1303502|NCT00753259|disease management program
1303503|NCT00753259|integrated chronic care program
1303504|NCT00753259|guideline
1303505|NCT00753259|stroke
1303506|NCT00753259|heart failure
1303507|NCT00753259|quality of life
1303508|NCT00753259|costs
1303509|NCT00753246|glioblastoma multiforma
1303510|NCT00753233|Hypertrophic Cardiomyopathy
1303511|NCT00753233|Children
1303512|NCT00753233|Sudden Death
1303513|NCT00753233|Arrhythmias
1303514|NCT00753233|Electrophysiology Study
1303515|NCT00753220|Metastatic
1303516|NCT00753220|Androgen
1303517|NCT00753220|Independent
1303518|NCT00753220|Prostate Cancer
1303519|NCT00753220|(AIPC),
1303520|NCT00753220|Hormone-refractory
1303521|NCT00753220|(HRPC),
1303522|NCT00753220|cryotherapy,
1303523|NCT00753220|dendritic cell,
1303524|NCT00753220|immunotherapy
1303525|NCT00753220|Chemo-naïve
1303526|NCT00753220|lymph nodes
1303527|NCT00753220|bone
1303528|NCT00753207|stage IV breast cancer
1303529|NCT00753207|recurrent breast cancer
1303530|NCT00753194|hearing
1303531|NCT00753194|newborn
1303532|NCT00753194|otoacoustic emissions
1303533|NCT00753168|glaucoma, open angle, ocular hypertension, beta blocker, beta adrenergic, intraocular pressure
1303534|NCT00753155|HRQoL;
1303535|NCT00753155|exercise
1303536|NCT00753155|capacity
1303537|NCT00753142|Hyperglycemia
1303538|NCT00753129|Prone position
1303539|NCT00753129|ALI/ARDS
1303540|NCT00753129|Head elevation
1303541|NCT00753103|Infliximab
1303542|NCT00753103|Vasculitis
1303543|NCT00753103|antitnf monoclonal antibody
1303544|NCT00753064|Red Scorpion envenomation
1303545|NCT00753064|Composite clinical scoring system
1303546|NCT00753064|AScVS
1303547|NCT00753064|Prazosin
1303548|NCT00753064|Superiority
1303549|NCT00753051|clozapine-resistant schizophrenics
1303550|NCT00753051|haloperidol augmenting clozapine
1303551|NCT00753051|electroconvulsive therapy augmenting clozapine
1303552|NCT00753038|carcinoma
1303553|NCT00753038|squamous cell
1303554|NCT00753038|head
1303555|NCT00753038|neck
1303556|NCT00753038|REOLYSIN
1303557|NCT00753038|chemotherapy
1303558|NCT00753038|Carboplatin
1303559|NCT00753038|Paclitaxel
1303560|NCT00753025|lower extremity ischemia
1303561|NCT00753025|Bone marrow
1303562|NCT00753025|Progenitor cells
1303563|NCT00753025|Neoangiogenesis
1303564|NCT00753012|cardiovascular testing
1303565|NCT00753012|home blood pressure monitoring
1303566|NCT00753012|office home blood pressure monitoring
1303567|NCT00753012|cardiopulmonary exercise testing
1303568|NCT00753012|transthoracic echocardiography
1303569|NCT00753012|Lisdexamfetamine
1303570|NCT00753012|Vyvanse
1303571|NCT00753012|normotensive and hypertensive adults with ADHD
1303572|NCT00753012|ADHD medication.
1303573|NCT00752999|SLE
1303574|NCT00752999|Lupus
1303575|NCT00752986|ZD6474
1303576|NCT00752986|Vandetanib
1303577|NCT00752986|Zactima
1303578|NCT00752986|Fulvestrant
1303579|NCT00752986|Faslodex
1303580|NCT00752986|Breast Cancer
1303581|NCT00752986|Advanced, Metastatic
1303582|NCT00752986|Hormone Receptor Positive
1303583|NCT00752986|Post-Menopausal Patients
1303584|NCT00752986|post-menopausal women with hormone receptor positive advanced breast cancer
1303585|NCT00752973|Head Lice
1303586|NCT00752960|single nucleotide polymorphism, SNP, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, metabolic syndrome
1303587|NCT00752934|nursing homes
1303588|NCT00752934|children
1303589|NCT00752934|ages 1-18 years
1303590|NCT00752934|spastic quadriplegia
1303591|NCT00752921|Etoricoxib, Fasting Headache, Headache, Yom Kippur
1303592|NCT00752895|stage I chronic lymphocytic leukemia
1303593|NCT00752895|stage II chronic lymphocytic leukemia
1303594|NCT00752895|stage III chronic lymphocytic leukemia
1303595|NCT00752895|stage IV chronic lymphocytic leukemia
1303596|NCT00752882|Ceftazidime
1303597|NCT00752882|Pharmacokinetics
1303598|NCT00752882|Pseudomonas
1303599|NCT00752882|aeruginosa
1303600|NCT00752882|Meningitis
1303601|NCT00752882|Patients
1303602|NCT00752882|hospitalised
1303603|NCT00752882|cerebrolesion
1303604|NCT00752882|acquired
1303605|NCT00752882|pneumopathy
1303606|NCT00752882|mechanic
1303607|NCT00752882|ventilation
1303608|NCT00752869|low testosterone
1303609|NCT00752856|HIV treatment
1303610|NCT00752856|Treatment-naive
1303611|NCT00752856|Adult
1303612|NCT00752843|mifepristone
1303613|NCT00752843|CORLUX
1303614|NCT00752843|fluvastatin
1303615|NCT00752843|Lescol
1303616|NCT00752843|drug-drug interaction
1303617|NCT00752843|DDI
1303618|NCT00752843|pharmacokinetics
1303619|NCT00752830|AZD0328
1303620|NCT00752830|Food Effect
1303621|NCT00752817|Virtual Reality
1303622|NCT00752817|Simulator
1303623|NCT00752817|Proficiency
1303624|NCT00752817|Laparoscopic
1303625|NCT00752817|Colectomy
1303626|NCT00752817|Education
1303627|NCT00752817|Surgical Training
1303628|NCT00752804|ICU patients with acute renal failure after cardiac surgery
1303629|NCT00752791|Anemia
1303630|NCT00752791|Drug Therapy
1303631|NCT00752791|Peritoneal Dialysis.
1303632|NCT00752778|MRI, PET scan
1303633|NCT00752765|knee osteoarthritis
1303634|NCT00752765|bariatric surgery
1303635|NCT00752765|weight loss
1303636|NCT00752765|knee pain
1303637|NCT00752752|Marathon Running
1303638|NCT00752752|Cardiac Ischemia
1303639|NCT00752752|Magnetic Resonance Imaging
1303640|NCT00752739|adenocarcinoma of the prostate
1303641|NCT00752739|stage I prostate cancer
1303642|NCT00752739|stage II prostate cancer
1303643|NCT00752739|stage III prostate cancer
1303644|NCT00752739|stage IV prostate cancer
1303645|NCT00752726|overweight, orlistat, body composition
1303646|NCT00752713|AMI,
1303647|NCT00752713|Reperfusion
1303648|NCT00752713|successful
1303649|NCT00752700|Patients
1303650|NCT00752700|radically
1303651|NCT00752700|treated
1303652|NCT00752687|Phase 1
1303653|NCT00752674|Low back pain
1303654|NCT00752674|physical therapy
1303655|NCT00752674|pain
1303656|NCT00752661|osteoarthritis
1303657|NCT00752661|low back pain
1303658|NCT00752661|oral drug
1303659|NCT00752661|tramadol
1303660|NCT00752648|TMC435350-TiDP16-C106
1303661|NCT00752648|TMC435350-C106
1303662|NCT00752648|Bioavailability
1303663|NCT00752648|Pharmacokinetics
1303664|NCT00752635|TriCilest
1303665|NCT00752635|acne vulgaris
1303666|NCT00752609|Anemia
1303667|NCT00752609|Drug Therapy
1303668|NCT00752609|Hemodialysis
1303669|NCT00752609|Kidney Failure
1303670|NCT00752596|patients
1303671|NCT00752596|with ICD
1303672|NCT00752583|Chronic renal insufficiency (patients under dialysis)
1303673|NCT00752570|Metastatic Colorectal Cancer
1303674|NCT00752570|colorectal cancer
1303675|NCT00752570|colon cancer
1303676|NCT00752557|Bone mineral density
1303677|NCT00752557|bone morphogenetic protein
1303678|NCT00752557|osteoporosis
1303679|NCT00752544|TMC435350
1303680|NCT00752544|HCV
1303681|NCT00752544|Hepatitis C
1303682|NCT00752544|TMC435350-TiDP16-C109
1303683|NCT00752544|TMC435350-C109
1303684|NCT00752531|Chronic Obstructive Pulmonary Disease
1303685|NCT00752531|COPD
1303686|NCT00752518|bolus
1303687|NCT00752518|intravenous
1303688|NCT00752518|proteasome inhibitor
1303689|NCT00752518|multiple myeloma
1303690|NCT00752518|refractory
1303691|NCT00752518|relapse
1303692|NCT00752505|Fibromyalgia
1303693|NCT00752492|Isocapnic hyperpnoea
1303694|NCT00752492|obesity
1303695|NCT00752492|isoflurane
1303696|NCT00752492|Recovery of obese patient from isoflurane anesthesia
1303697|NCT00752479|living
1303698|NCT00752479|related
1303699|NCT00752466|Healthy volunteers
1303700|NCT00752466|drug interaction
1303701|NCT00752466|Flunarizine
1303702|NCT00752466|Topiramate
1303703|NCT00752466|Migraine
1303704|NCT00752453|ICU
1303705|NCT00752453|patients
1303706|NCT00752453|lactate
1303707|NCT00752453|acidosis
1303708|NCT00752440|Diabetes Mellitus
1303709|NCT00752440|Autonomic Neuropathy
1303710|NCT00752440|Inspiratory Muscle training
1303711|NCT00752427|Schizophrenia: paliperidone
1303712|NCT00752414|COPD
1303713|NCT00752414|Patients
1303714|NCT00752401|Vitamin D
1303715|NCT00752401|Cholecalciferol
1303716|NCT00752401|Vitamin D3
1303717|NCT00752401|25-hydroxyvitamin D3
1303718|NCT00752401|Immunomodulation
1303719|NCT00752401|Vitamin D deficiency
1303720|NCT00752401|Kidney transplantation
1303721|NCT00752401|Renal transplantation
1303722|NCT00752401|Graft function
1303723|NCT00752401|Acute rejection
1303724|NCT00752401|Renal osteodystrophy
1303725|NCT00752401|Posttransplant bone loss
1303726|NCT00752375|pyelonephritis
1303727|NCT00752375|pediatric pyelonephritis
1303728|NCT00752375|vesicoureteral reflux
1303729|NCT00752375|DMSA scan
1303730|NCT00752362|Supralimus®,
1303731|NCT00752362|Infinnium®,
1303732|NCT00752362|Matrix®,
1303733|NCT00752362|Restenosis
1303734|NCT00752362|Percutaneous
1303735|NCT00752362|Revascularization
1303736|NCT00752362|Techniques
1303737|NCT00752362|Metallic
1303738|NCT00752362|Platform
1303739|NCT00752362|Agents
1303740|NCT00752362|Antiproliferative
1303741|NCT00752362|Properties
1303742|NCT00752349|Videofluoroscopic
1303743|NCT00752349|swallowing
1303744|NCT00752349|study
1303745|NCT00752349|(VFSS)
1303746|NCT00752349|ultrasound
1303747|NCT00752336|HRQoL
1303748|NCT00752336|exercise capacity
1303749|NCT00752323|adult giant cell glioblastoma
1303750|NCT00752323|adult glioblastoma
1303751|NCT00752323|adult gliosarcoma
1303752|NCT00752323|recurrent adult brain tumor
1303753|NCT00752310|TMC114-TiDP29-C169
1303754|NCT00752310|TMC114-C169
1303755|NCT00752310|Darunavir (suspension formulation)
1303756|NCT00752297|Botulinum Toxin Type A
1303757|NCT00752297|Botulinum Toxin
1303758|NCT00752297|Glabellar Rhytides
1303759|NCT00752297|Rhytides
1303760|NCT00752297|Frown Lines
1303761|NCT00752297|Neuromuscular Agents
1303762|NCT00752297|Neurotoxin
1303763|NCT00752297|Forehead
1303764|NCT00752297|Eyebrow
1303765|NCT00752297|Wrinkle
1303766|NCT00752284|coronectomy
1303767|NCT00752284|neurosensory deficit
1303768|NCT00752284|third molar surgery
1303769|NCT00752271|Arthroscopic
1303770|NCT00752258|Botulinum Toxin Type A
1303771|NCT00752258|Botulinum Toxin
1303772|NCT00752258|Glabellar Rhytides
1303773|NCT00752258|Rhytides
1303774|NCT00752258|Frown Lines
1303775|NCT00752258|Neuromuscular Agents
1303776|NCT00752258|Neurotoxin
1303777|NCT00752258|Forehead
1303778|NCT00752258|Eyebrow
1303779|NCT00752258|Wrinkle
1303780|NCT00752258|Frown Lines Between the Eyebrows
1303781|NCT00752245|ICU patients with acute renal failure with sepsis/multi-organ failure
1303782|NCT00752232|Phase IIa
1303783|NCT00752232|multiple ascending dose study of ACC-001
1303784|NCT00752206|AZD0530
1303785|NCT00752206|Saracatinib
1303786|NCT00752206|Osteosarcoma
1303787|NCT00752206|Recurrent
1303788|NCT00752206|Localized
1303789|NCT00752206|to the Lung
1303790|NCT00752180|pharmacokinetics
1303791|NCT00752180|pharmacodynamics
1303792|NCT00752180|type 1 diabetics
1303793|NCT00752180|recombinant human insulin
1303794|NCT00752167|exercise induced bronchospasm
1303795|NCT00752167|asthma
1303796|NCT00752167|athlete
1303797|NCT00752167|sports
1303798|NCT00752167|eucapnic voluntary hyperventilation
1303799|NCT00752167|albuterol
1303800|NCT00752154|Subjects
1303801|NCT00752154|active
1303802|NCT00752154|Rheumatoid
1303803|NCT00752154|Arthritis
1303804|NCT00752154|revised
1303805|NCT00752154|American
1303806|NCT00752154|College
1303807|NCT00752154|Rheumatology
1303808|NCT00752154|Criteria
1303809|NCT00752128|Drug Eluting Stent
1303810|NCT00752128|Interventional Cardiology
1303811|NCT00752128|Percutaneous Coronary Intervention
1303812|NCT00752115|non-small cell lung cancer
1303813|NCT00752115|previously untreated
1303814|NCT00752102|Secondary Hyperparathryoidism
1303815|NCT00752102|Chronic Kidney Disease
1303816|NCT00752102|Vitamin D
1303817|NCT00752102|Coronary Calcification
1303818|NCT00752102|Bone metabolism
1303819|NCT00752089|enamel fluoride uptake
1303820|NCT00752089|erosion
1303821|NCT00752089|enamel remineralization
1303822|NCT00752076|EGFR mutation
1303823|NCT00752076|NSCLC cell line
1303824|NCT00752076|Malignant pleural effusion
1303825|NCT00752063|Sorafenib
1303826|NCT00752063|Capecitabine
1303827|NCT00752063|Oxaliplatin
1303828|NCT00752063|Advanced Hepatocellular Carcinoma
1303829|NCT00752063|Metastatic Hepatocellular Carcinoma
1303830|NCT00752050|Botulinum Toxin Type A
1303831|NCT00752050|Botulinum Toxin
1303832|NCT00752050|Glabellar Rhytides
1303833|NCT00752050|Rhytides
1303834|NCT00752050|Frown Lines
1303835|NCT00752050|Neuromuscular Agents
1303836|NCT00752050|Neurotoxin
1303837|NCT00752050|Forehead
1303838|NCT00752050|Eyebrow
1303839|NCT00752050|Wrinkle
1303840|NCT00752037|HIV
1303841|NCT00752037|Protease Inhibitor
1303842|NCT00752037|Integrase Inhibitor
1303843|NCT00752037|Treatment Experienced
1303844|NCT00752037|Naive
1303845|NCT00752024|HICH
1303846|NCT00752024|Suction drainages
1303847|NCT00752024|TTAC
1303848|NCT00752011|Cancer
1303849|NCT00752011|Solid Tumors
1303850|NCT00752011|Advanced Cancer
1303851|NCT00752011|Carboplatin
1303852|NCT00752011|Paraplatin
1303853|NCT00752011|TAS-106
1303854|NCT00752011|Antitumor Activity
1303855|NCT00752011|Biomarkers
1303856|NCT00751998|biliary
1303857|NCT00751998|ERCP
1303858|NCT00751998|cholangioscopy
1303859|NCT00751998|pancreatic
1303860|NCT00751985|Heavy drinking
1303861|NCT00751985|Ultra-brief intervention
1303862|NCT00751985|Brief intervention
1303863|NCT00751985|Alcohol prevention
1303864|NCT00751985|Randomized trial
1303865|NCT00751985|Personal normative feedback
1303866|NCT00751985|Self-help material
1303867|NCT00751985|Web-based
1303868|NCT00751985|Intervention Studies
1303869|NCT00751985|prevention & control
1303870|NCT00751959|Continuous positive airway pressure (CPAP)
1303871|NCT00751959|extremely preterm infant
1303872|NCT00751959|Idiopathic respiratory distress syndrome (IRDS)
1303873|NCT00751959|Surfactant
1303874|NCT00751946|Posttraumatic Stress Disorder
1303875|NCT00751946|PTSD
1303876|NCT00751946|psychotherapy
1303877|NCT00751946|adolescents
1303878|NCT00751946|clinical trial
1303879|NCT00751933|Ulcerative colitis
1303880|NCT00751933|Vaccines
1303881|NCT00751933|Oats
1303882|NCT00751920|Magnetic Resonance Imaging
1303883|NCT00751920|Pediatrics
1303884|NCT00751920|Multi-Detector Computed Tomography
1303885|NCT00751920|Computed Tomography
1303886|NCT00751920|Detection
1303887|NCT00751907|Cerebral blood flow
1303888|NCT00751894|Children
1303889|NCT00751894|cancer
1303890|NCT00751894|Bone marrow transplantation
1303891|NCT00751894|Stem cell mobilization
1303892|NCT00751894|G-CSF
1303893|NCT00751894|Children with solid malignancies
1303894|NCT00751881|relapsing multiple sclerosis
1303895|NCT00751868|breast cancer
1303896|NCT00751842|Diabetes
1303897|NCT00751842|Juvenile Diabetes
1303898|NCT00751842|Diabetes type 1
1303899|NCT00751842|Autoimmune Diabetes
1303900|NCT00751842|Insulin dependent Diabetes
1303901|NCT00751842|Type 1 diabetes
1303902|NCT00751842|Type 1 diabetes mellitus
1303903|NCT00751842|Diamyd
1303904|NCT00751842|rhGAD65
1303905|NCT00751842|GAD
1303906|NCT00751842|GAD-alum
1303907|NCT00751816|musculoskeletal complications
1303908|NCT00751816|stage I squamous cell carcinoma of the hypopharynx
1303909|NCT00751816|stage II squamous cell carcinoma of the hypopharynx
1303910|NCT00751816|stage III squamous cell carcinoma of the hypopharynx
1303911|NCT00751816|stage IV squamous cell carcinoma of the hypopharynx
1303912|NCT00751816|stage I squamous cell carcinoma of the larynx
1303913|NCT00751816|stage I verrucous carcinoma of the larynx
1303914|NCT00751816|stage II squamous cell carcinoma of the larynx
1303915|NCT00751816|stage II verrucous carcinoma of the larynx
1303916|NCT00751816|stage III squamous cell carcinoma of the larynx
1303917|NCT00751816|stage III verrucous carcinoma of the larynx
1303918|NCT00751816|stage IV squamous cell carcinoma of the larynx
1303919|NCT00751816|stage IV verrucous carcinoma of the larynx
1303920|NCT00751816|stage I adenoid cystic carcinoma of the oral cavity
1303921|NCT00751816|stage I mucoepidermoid carcinoma of the oral cavity
1303922|NCT00751816|stage I verrucous carcinoma of the oral cavity
1303923|NCT00751816|stage II adenoid cystic carcinoma of the oral cavity
1303924|NCT00751816|stage II mucoepidermoid carcinoma of the oral cavity
1303925|NCT00751816|stage II verrucous carcinoma of the oral cavity
1303926|NCT00751816|stage III adenoid cystic carcinoma of the oral cavity
1303927|NCT00751816|stage III mucoepidermoid carcinoma of the oral cavity
1303928|NCT00751816|stage III verrucous carcinoma of the oral cavity
1303929|NCT00751816|stage IV adenoid cystic carcinoma of the oral cavity
1304141|NCT00751023|Addiction
1303930|NCT00751816|stage IV mucoepidermoid carcinoma of the oral cavity
1303931|NCT00751816|stage IV verrucous carcinoma of the oral cavity
1303932|NCT00751816|stage I squamous cell carcinoma of the lip and oral cavity
1303933|NCT00751816|stage II squamous cell carcinoma of the lip and oral cavity
1303934|NCT00751816|stage III squamous cell carcinoma of the lip and oral cavity
1303935|NCT00751816|stage IV squamous cell carcinoma of the lip and oral cavity
1303936|NCT00751816|stage I basal cell carcinoma of the lip
1303937|NCT00751816|stage II basal cell carcinoma of the lip
1303938|NCT00751816|stage III basal cell carcinoma of the lip
1303939|NCT00751816|stage IV basal cell carcinoma of the lip
1303940|NCT00751816|stage I lymphoepithelioma of the nasopharynx
1303941|NCT00751816|stage I squamous cell carcinoma of the nasopharynx
1303942|NCT00751816|stage II lymphoepithelioma of the nasopharynx
1303943|NCT00751816|stage II squamous cell carcinoma of the nasopharynx
1303944|NCT00751816|stage III lymphoepithelioma of the nasopharynx
1303945|NCT00751816|stage III squamous cell carcinoma of the nasopharynx
1303946|NCT00751816|stage IV lymphoepithelioma of the nasopharynx
1303947|NCT00751816|stage IV squamous cell carcinoma of the nasopharynx
1303948|NCT00751816|stage I lymphoepithelioma of the oropharynx
1303949|NCT00751816|stage I squamous cell carcinoma of the oropharynx
1303950|NCT00751816|stage II lymphoepithelioma of the oropharynx
1303951|NCT00751816|stage II squamous cell carcinoma of the oropharynx
1303952|NCT00751816|stage III lymphoepithelioma of the oropharynx
1303953|NCT00751816|stage III squamous cell carcinoma of the oropharynx
1303954|NCT00751816|stage IV lymphoepithelioma of the oropharynx
1303955|NCT00751816|stage IV squamous cell carcinoma of the oropharynx
1303956|NCT00751816|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1303957|NCT00751816|stage I inverted papilloma of the paranasal sinus and nasal cavity
1303958|NCT00751816|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1303959|NCT00751816|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1303960|NCT00751816|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1303961|NCT00751816|stage II inverted papilloma of the paranasal sinus and nasal cavity
1303962|NCT00751816|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1303963|NCT00751816|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1303964|NCT00751816|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1303965|NCT00751816|stage III inverted papilloma of the paranasal sinus and nasal cavity
1303966|NCT00751816|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1303967|NCT00751816|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1303968|NCT00751816|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1303969|NCT00751816|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1303970|NCT00751816|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1303971|NCT00751816|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1303972|NCT00751816|high-grade salivary gland mucoepidermoid carcinoma
1303973|NCT00751816|low-grade salivary gland mucoepidermoid carcinoma
1303974|NCT00751816|salivary gland acinic cell tumor
1303975|NCT00751816|salivary gland adenocarcinoma
1303976|NCT00751816|salivary gland adenoid cystic carcinoma
1303977|NCT00751816|salivary gland anaplastic carcinoma
1303978|NCT00751816|salivary gland malignant mixed cell type tumor
1303979|NCT00751816|salivary gland poorly differentiated carcinoma
1303980|NCT00751816|salivary gland squamous cell carcinoma
1303981|NCT00751816|stage I salivary gland cancer
1303982|NCT00751816|stage II salivary gland cancer
1303983|NCT00751816|stage III salivary gland cancer
1303984|NCT00751816|stage IV salivary gland cancer
1303985|NCT00751790|triptorelin, 6-month formulation, advanced prostate cancer
1303986|NCT00751712|Aortic Arch
1303987|NCT00751699|Pharmacokinetics
1303988|NCT00751686|Gastroenteritis
1303989|NCT00751686|Burden
1303990|NCT00751686|Rotavirus
1303991|NCT00751686|< 5 years
1303992|NCT00751686|Greece
1303993|NCT00751686|Children
1303994|NCT00751660|small cell lung cancer
1303995|NCT00751660|non-small cell lung cancer
1303996|NCT00751660|tobacco use disorder
1303997|NCT00751647|CF
1303998|NCT00751634|subarachnoid hemorrhage
1303999|NCT00751634|intracerebral hemorrhage
1304000|NCT00751634|fever
1304001|NCT00751621|Immune globulin subcutaneous
1304002|NCT00751621|SCIG
1304003|NCT00751621|primary immunodeficiency
1304004|NCT00751621|PID
1304005|NCT00751608|Familial hypercholesterolemia, endothelial function, venous occlusion plethysmography, forearm blood flow, ApoAI-mimetic, endothelial dependent vasodilation
1304006|NCT00751595|HIV
1304007|NCT00751595|Tat protein
1304008|NCT00751595|Therapeutic vaccine
1304009|NCT00751595|HAART
1304010|NCT00751595|HIV Therapeutic Vaccine
1304011|NCT00751595|Treatment Experienced
1304012|NCT00751582|nutrition
1304013|NCT00751582|education
1304014|NCT00751582|supplementation
1304015|NCT00751569|umbilical cord blood
1304016|NCT00751556|Naproxen Sodium
1304017|NCT00751556|Bioavailability
1304018|NCT00751543|To evaluate the longitudinal change of tumor perfusion in the course of radiation therapy in adenocarcinoma and squamous cell carcinoma using perfusion MDCT
1304142|NCT00751023|Craving
1304143|NCT00751023|Cognitive
1304144|NCT00751010|Vulvar pain
1304019|NCT00751543|Comparison between adenocarcinoma and squamous cell carcinoma will be evaluated according to the derived perfusion parameter obtained from perfusion MDCT
1304020|NCT00751530|HIV
1304021|NCT00751530|AIDS
1304022|NCT00751530|raltegravir
1304023|NCT00751530|BRAVO
1304024|NCT00751530|protease inhibitor
1304025|NCT00751530|treatment Experienced
1304026|NCT00751517|Vasculitis
1304027|NCT00751517|Cyclophosphamide
1304028|NCT00751517|Methotrexate
1304029|NCT00751517|Systemic Necrotizing Vasculitides
1304030|NCT00751504|Quetiapine
1304031|NCT00751504|Psychotic depression
1304032|NCT00751491|Stable angina
1304033|NCT00751491|Percutaneous Coronary Intervention
1304034|NCT00751491|Myonecrosis
1304035|NCT00751478|ALO-01
1304036|NCT00751478|morphine
1304037|NCT00751478|Determination of the relative pharmacodynamic effects
1304038|NCT00751478|(including drug-liking), pharmacokinetics, and safety of
1304039|NCT00751478|ALO-01 when administered whole or crushed and compared to
1304040|NCT00751478|equivalent doses of immediate release morphine and placebo
1304041|NCT00751465|Social Anxiety Disorder
1304042|NCT00751465|Social Phobia
1304043|NCT00751465|Fear of blushing
1304044|NCT00751465|attention
1304045|NCT00751465|attention training
1304046|NCT00751465|cognitive behavior therapy
1304047|NCT00751452|Children
1304048|NCT00751452|Allogeneic bone marrow transplantation
1304049|NCT00751452|Intestinal damage
1304050|NCT00751452|Citrulline
1304051|NCT00751452|Graft versus Host Disease
1304052|NCT00751452|0 to 18 years old
1304053|NCT00751439|Oximeter
1304054|NCT00751439|Arterial blood gas
1304055|NCT00751439|comparison
1304056|NCT00751426|Interferon-alpha
1304057|NCT00751426|hepatitis c
1304058|NCT00751426|Drug addiction
1304059|NCT00751426|methadone
1304060|NCT00751426|psychiatric disorder
1304061|NCT00751426|Safety and efficacy of Interferon-alpha i patients with a psychiatric disorder.
1304062|NCT00751400|Non-prescription
1304063|NCT00751361|Rheopheresis
1304064|NCT00751361|Dry Age Related Macular Degeneration
1304065|NCT00751361|AMD
1304066|NCT00751361|apheresis
1304067|NCT00751361|microcirculation
1304068|NCT00751348|second year of life
1304069|NCT00751348|one-dose schedule
1304070|NCT00751348|varicella
1304071|NCT00751348|rubella
1304072|NCT00751348|measles
1304073|NCT00751348|mumps
1304074|NCT00751335|Obstructive Sleep Apnea
1304075|NCT00751335|Humidification
1304076|NCT00751335|Continuous Positive Airway Pressure
1304077|NCT00751322|Pulmonary
1304078|NCT00751322|Protein
1304079|NCT00751309|allograft
1304080|NCT00751309|rejection
1304081|NCT00751309|biopsy
1304082|NCT00751309|gene
1304083|NCT00751309|expression
1304084|NCT00751309|pulmonary
1304085|NCT00751309|lung
1304086|NCT00751309|transplant
1304087|NCT00751296|Lenalidomide
1304088|NCT00751296|immunomodulatory drug (IMiD®)
1304089|NCT00751296|Thalidomide analogues
1304090|NCT00751270|Immunotherapy
1304091|NCT00751270|Gene therapy
1304092|NCT00751270|Tumor Vaccine
1304093|NCT00751270|Cytotoxicity
1304094|NCT00751270|Radiation
1304095|NCT00751257|Nicotine
1304096|NCT00751257|N-acetylcysteine
1304097|NCT00751257|smoking reduction
1304098|NCT00751244|women
1304099|NCT00751244|posttraumatic stress disorder
1304100|NCT00751244|PTSD
1304101|NCT00751244|psychotherapy
1304102|NCT00751244|clinical trial
1304103|NCT00751244|emotion regulation
1304104|NCT00751231|PCI
1304105|NCT00751231|percutaneous coronary intervention
1304106|NCT00751205|Peripheral Neuropathy
1304107|NCT00751205|Prostate Carcinoma
1304108|NCT00751205|Ovarian Carcinoma
1304109|NCT00751192|Men who have sex with men
1304110|NCT00751192|Peru
1304111|NCT00751192|HIV testing
1304112|NCT00751192|video
1304113|NCT00751192|online
1304114|NCT00751192|Internet
1304115|NCT00751192|HIV Seronegativity
1304116|NCT00751153|drug substitution
1304117|NCT00751153|Raltegravir
1304118|NCT00751153|Atazanavir
1304119|NCT00751153|treatment Experienced
1304120|NCT00751140|surgical candidates
1304121|NCT00751140|upper urinary tract
1304122|NCT00751140|urothelial carcinoma
1304123|NCT00751140|lymph node dissection
1304124|NCT00751127|open angle glaucoma
1304125|NCT00751127|ocular hypertension
1304126|NCT00751101|palmar-plantar erythrodysesthesia
1304127|NCT00751101|chemotherapeutic agent toxicity
1304128|NCT00751101|stage IV breast cancer
1304129|NCT00751101|recurrent breast cancer
1304130|NCT00751088|single-incision
1304131|NCT00751088|sling
1304132|NCT00751088|stress incontinence
1304133|NCT00751088|surgery
1304134|NCT00751088|treatment
1304135|NCT00751088|Female urinary stress incontinence
1304136|NCT00751062|open angle glaucoma ocular hypertension
1304137|NCT00751049|open angle glaucoma ocular hypertension
1304138|NCT00751036|GIST
1304139|NCT00751023|Methamphetamine
1304140|NCT00751023|Modafinil
1304145|NCT00751010|Vulvodynia
1304146|NCT00751010|Interstitial cystitis
1304147|NCT00750971|ASSIST
1304148|NCT00750971|SLE
1304149|NCT00750971|Stem Cell Transplantation
1304150|NCT00750971|Tolerance
1304151|NCT00750958|cardiac rhythm changes
1304152|NCT00750945|Parkinson's disease
1304153|NCT00750945|Cueing training
1304154|NCT00750945|Treadmill training
1304155|NCT00750945|Music
1304156|NCT00750893|Gastroenteritis
1304157|NCT00750867|multiple system atrophy, MSA,
1304158|NCT00750867|intravenous immunoglobulin, IVIg
1304159|NCT00750854|arthritis
1304160|NCT00750854|osteoarthritis
1304161|NCT00750854|fibromyalgia
1304162|NCT00750854|connective tissue disorder
1304163|NCT00750841|advanced cancer
1304164|NCT00750841|metastatic
1304165|NCT00750841|rifampicin
1304166|NCT00750841|pharmacokinetics
1304167|NCT00750841|Phase I
1304168|NCT00750841|Advanced solid tumours
1304169|NCT00750828|Saliva
1304170|NCT00750828|Sjögren's Syndrome
1304171|NCT00750828|GCF
1304172|NCT00750828|Oral Mucosal Wetness
1304173|NCT00750815|B Cell
1304174|NCT00750815|hematologic malignancy
1304175|NCT00750815|plasma
1304176|NCT00750815|bone marrow
1304177|NCT00750802|Phase I
1304178|NCT00750776|Quality assurance
1304179|NCT00750776|medical treatment
1304180|NCT00750776|Patient satisfaction
1304181|NCT00750763|Mucosal inflammation
1304182|NCT00750763|Fleet
1304183|NCT00750763|Picoprep
1304184|NCT00750763|Colonlytely
1304185|NCT00750763|Colonoscopy
1304186|NCT00750763|tolerability
1304187|NCT00750763|efficacy
1304188|NCT00750737|Hematologic Malignancies
1304189|NCT00750737|Blood Cancer
1304190|NCT00750737|Lymphatic Cancer
1304191|NCT00750737|Amphotericin B Lipid Complex
1304192|NCT00750737|Amphotericin B
1304193|NCT00750737|ABLC
1304194|NCT00750737|Fungizone
1304195|NCT00750737|Noxafil
1304196|NCT00750737|SCH56592
1304197|NCT00750737|Posaconazole
1304198|NCT00750737|Invasive fungal infections
1304199|NCT00750737|IFI
1304200|NCT00750737|Hematopoietic Stem Cell Transplant
1304201|NCT00750737|HSCT
1304202|NCT00750737|Bone Marrow Transplant
1304203|NCT00750737|Allogeneic hematopoietic stem cell transplant
1304204|NCT00750724|Hyaluronic acid,
1304205|NCT00750724|OA knee,
1304206|NCT00750724|MRI
1304207|NCT00750698|lung cancer
1304208|NCT00750698|non small cell lung cancer
1304209|NCT00750685|Primary Breast Reconstruction
1304210|NCT00750672|Endometrial neoplasia
1304211|NCT00750672|Follow-up care
1304212|NCT00750672|survivorship
1304213|NCT00750672|Primary care provider
1304214|NCT00750659|Chronic myeloid leukemia
1304215|NCT00750659|Ph+ acute lymphoblastic leukemia
1304216|NCT00750659|stem cell transplantation
1304217|NCT00750659|nilotinib
1304218|NCT00750646|compliance
1304219|NCT00750646|eye drop administration
1304220|NCT00750646|MEMS
1304221|NCT00750646|adherence
1304222|NCT00750633|swimmer's ear
1304223|NCT00750633|ear drops
1304224|NCT00750633|ear infection
1304225|NCT00750633|ear pain
1304226|NCT00750633|ear inflammation
1304227|NCT00750620|mild, moderate, and severe renal impaired subjects
1304228|NCT00750620|normal renal function subjects
1304229|NCT00750620|Glomerular filtration rate (GFR)
1304230|NCT00750620|Modification of Diet in Renal Disease (MDRD) formula
1304231|NCT00750620|YM178
1304232|NCT00750620|pharmacokinetics
1304233|NCT00750594|Children
1304234|NCT00750594|Migraine headaches
1304235|NCT00750581|Patent Ductus Arteriosus
1304236|NCT00750568|Bronchial asthma
1304237|NCT00750568|Asthma, bronchial
1304238|NCT00750568|Status Asthmaticus
1304239|NCT00750568|Terbutaline sulfate
1304240|NCT00750555|squamous cell cancer of head and neck
1304241|NCT00750555|SCCHN
1304242|NCT00750529|sleep
1304243|NCT00750529|Alzheimer
1304244|NCT00750529|old patients
1304245|NCT00750516|Lactic acid
1304246|NCT00750516|hypotension
1304247|NCT00750516|sepsis
1304248|NCT00750503|tobacco cessation
1304249|NCT00750503|behavioral therapy
1304250|NCT00750503|pharmacotherapy
1304251|NCT00750503|workplace
1304252|NCT00750503|oral cancer screening
1304253|NCT00750503|Tobacco Quit rates
1304254|NCT00750477|osteoarthritis
1304255|NCT00750477|arthritis
1304256|NCT00750477|knee
1304257|NCT00750477|eggshell
1304258|NCT00750477|membrane
1304259|NCT00750477|OPTION
1304260|NCT00750451|fertilization in vitro
1304261|NCT00750451|assisted reproduction
1304262|NCT00750451|recurrent implantation failure
1304263|NCT00750451|low molecular weight heparin
1304264|NCT00750451|heparin
1304265|NCT00750451|luteal phase
1304266|NCT00750438|Obesity
1304267|NCT00750438|Short chain fatty acids
1304268|NCT00750438|Appetite
1304269|NCT00750438|Body weight
1304270|NCT00750438|Insulin sensitivity
1304271|NCT00750438|Propionate
1304272|NCT00750438|Propionate ester
1304273|NCT00750425|advanced cancer,
1304274|NCT00750425|metastatic
1304275|NCT00750425|ketoconazole
1304276|NCT00750425|pharmacokinetics
1304277|NCT00750425|Phase I
1304278|NCT00750412|TeenScreen
1304279|NCT00750412|Mental Health
1304280|NCT00750412|Adolescent Mental Health
1304281|NCT00750412|Social Work
1304282|NCT00750399|radiation
1304283|NCT00750399|retinopathy
1304284|NCT00750399|ranibizumab
1304285|NCT00750399|melanoma
1304286|NCT00750399|choroid
1304287|NCT00750386|Cancer
1304288|NCT00750386|Ovarian cancer
1304289|NCT00750386|Dose-dense chemotherapy
1304290|NCT00750373|Endocarditis
1304291|NCT00750360|Influenza
1304292|NCT00750360|Korea
1304293|NCT00750360|FluarixTM
1304294|NCT00750347|pain,
1304295|NCT00750347|analgesia
1304296|NCT00750347|Healthy volunteers
1304297|NCT00750334|Oral Clofarabine,
1304298|NCT00750334|relapsed/refractory MDS,
1304299|NCT00750334|Myelodysplastic
1304300|NCT00750295|Chronic kidney disease,
1304301|NCT00750295|hemodialysis,
1304302|NCT00750295|serum phosphorus,
1304303|NCT00750295|phosphate binders
1304304|NCT00750282|Alzheimer Disease
1304305|NCT00750282|Amyloid beta-Protein
1304306|NCT00750269|stage I non-small cell lung cancer
1304307|NCT00750256|Safety
1304308|NCT00750256|pharmacokinetics
1304309|NCT00750256|tolerability
1304310|NCT00750230|arthritis
1304311|NCT00750230|osteoarthritis
1304312|NCT00750230|fibromyalgia
1304313|NCT00750230|connective tissue disorder
1304314|NCT00750217|transfer methadone buprenorphine patch heroin addiction
1304315|NCT00750204|Acute Lung Injury
1304316|NCT00750204|ALI
1304317|NCT00750204|Acute Respiratory Distress Syndrome
1304318|NCT00750204|Mechanical Ventilation
1304319|NCT00750204|Sedation
1304320|NCT00750204|Critical Illness
1304321|NCT00750204|Ventilator Induced Lung Injury
1304322|NCT00750204|VILI
1304323|NCT00750204|Cytokines
1304324|NCT00750204|Protective Ventilation
1304325|NCT00750204|Airway Pressure Release Ventilation
1304326|NCT00750204|APRV
1304327|NCT00750204|Breathing Comfort
1304328|NCT00750204|Dyssynchrony
1304329|NCT00750204|Asynchrony
1304330|NCT00750191|Lower Back Pain
1304331|NCT00750165|Obstructive Sleep Apnea
1304332|NCT00750165|Humidification
1304333|NCT00750165|Continuous Positive Airway Pressure
1304334|NCT00750152|tinea cruris
1304335|NCT00750152|jock itch
1304336|NCT00750139|Tinea Pedis
1304337|NCT00750139|Athlete's foot
1304338|NCT00750126|Allograft
1304339|NCT00750126|Children
1304340|NCT00750126|malignancy
1304341|NCT00750126|Reduced Intensity Conditioning
1304342|NCT00750126|Fludarabin
1304343|NCT00750126|Busulfex
1304344|NCT00750126|Thymoglobulin
1304345|NCT00750100|infertility
1304346|NCT00750100|IVF
1304347|NCT00750100|hCG
1304348|NCT00750100|primary infertility
1304349|NCT00750100|secondary infertility
1304350|NCT00750100|patients requiring in-vitro fertilisation
1304351|NCT00750087|Schizophrenia
1304352|NCT00750074|mechanical ventilation
1304353|NCT00750061|Spinal Cord Injury
1304354|NCT00750048|pain,
1304355|NCT00750048|sensitization,
1304356|NCT00750048|analgesia
1304357|NCT00750035|Total hysterectomy
1304358|NCT00750035|subtotal hysterectomy
1304359|NCT00750035|urinary function
1304360|NCT00750035|bowel function
1304361|NCT00750035|sexual function
1304362|NCT00750035|Quality of life
1304363|NCT00750035|Psychological function
1304364|NCT00750009|unspecified adult solid tumor, protocol specific
1304365|NCT00750009|accelerated phase chronic myelogenous leukemia
1304366|NCT00750009|acute undifferentiated leukemia
1304367|NCT00750009|adult acute lymphoblastic leukemia in remission
1304368|NCT00750009|adult acute myeloid leukemia in remission
1304369|NCT00750009|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1304370|NCT00750009|adult acute myeloid leukemia with inv(16)(p13;q22)
1304371|NCT00750009|adult acute myeloid leukemia with t(15;17)(q22;q12)
1304372|NCT00750009|adult acute myeloid leukemia with t(16;16)(p13;q22)
1304373|NCT00750009|adult acute myeloid leukemia with t(8;21)(q22;q22)
1304374|NCT00750009|atypical chronic myeloid leukemia, BCR-ABL1 negative
1304375|NCT00750009|blastic phase chronic myelogenous leukemia
1304376|NCT00750009|childhood acute lymphoblastic leukemia in remission
1304377|NCT00750009|childhood acute myeloid leukemia in remission
1304378|NCT00750009|childhood chronic myelogenous leukemia
1304379|NCT00750009|chronic myelomonocytic leukemia
1304380|NCT00750009|chronic phase chronic myelogenous leukemia
1304381|NCT00750009|juvenile myelomonocytic leukemia
1304382|NCT00750009|mast cell leukemia
1304383|NCT00750009|meningeal chronic myelogenous leukemia
1304384|NCT00750009|progressive hairy cell leukemia, initial treatment
1304385|NCT00750009|prolymphocytic leukemia
1304386|NCT00750009|recurrent adult acute lymphoblastic leukemia
1304387|NCT00750009|recurrent adult acute myeloid leukemia
1304388|NCT00750009|recurrent adult T-cell leukemia/lymphoma
1304389|NCT00750009|recurrent childhood acute lymphoblastic leukemia
1304390|NCT00750009|recurrent childhood acute myeloid leukemia
1304391|NCT00750009|refractory chronic lymphocytic leukemia
1304392|NCT00750009|refractory hairy cell leukemia
1304393|NCT00750009|relapsing chronic myelogenous leukemia
1304394|NCT00750009|secondary acute myeloid leukemia
1304395|NCT00750009|stage 0 chronic lymphocytic leukemia
1304396|NCT00750009|stage I adult T-cell leukemia/lymphoma
1304397|NCT00750009|stage I chronic lymphocytic leukemia
1304398|NCT00750009|stage II adult T-cell leukemia/lymphoma
1304399|NCT00750009|stage II chronic lymphocytic leukemia
1304400|NCT00750009|stage III adult T-cell leukemia/lymphoma
1304401|NCT00750009|stage III chronic lymphocytic leukemia
1304402|NCT00750009|stage IV adult T-cell leukemia/lymphoma
1304403|NCT00750009|stage IV chronic lymphocytic leukemia
1304404|NCT00750009|T-cell large granular lymphocyte leukemia
1304405|NCT00750009|untreated adult acute lymphoblastic leukemia
1304406|NCT00750009|untreated adult acute myeloid leukemia
1304407|NCT00750009|untreated childhood acute lymphoblastic leukemia
1304408|NCT00750009|untreated childhood acute myeloid leukemia and other myeloid malignancies
1304409|NCT00750009|untreated hairy cell leukemia
1304410|NCT00750009|AIDS-related diffuse large cell lymphoma
1304411|NCT00750009|AIDS-related diffuse mixed cell lymphoma
1304412|NCT00750009|AIDS-related diffuse small cleaved cell lymphoma
1304413|NCT00750009|AIDS-related immunoblastic large cell lymphoma
1304414|NCT00750009|AIDS-related lymphoblastic lymphoma
1304415|NCT00750009|AIDS-related peripheral/systemic lymphoma
1304416|NCT00750009|AIDS-related primary CNS lymphoma
1304417|NCT00750009|AIDS-related small noncleaved cell lymphoma
1304418|NCT00750009|HIV-associated Hodgkin lymphoma
1304419|NCT00750009|recurrent adult Hodgkin lymphoma
1304420|NCT00750009|recurrent/refractory childhood Hodgkin lymphoma
1304421|NCT00750009|stage I adult Hodgkin lymphoma
1304422|NCT00750009|stage I childhood Hodgkin lymphoma
1304423|NCT00750009|stage II adult Hodgkin lymphoma
1304424|NCT00750009|stage II childhood Hodgkin lymphoma
1304425|NCT00750009|stage III adult Hodgkin lymphoma
1304426|NCT00750009|stage III childhood Hodgkin lymphoma
1304427|NCT00750009|stage IV adult Hodgkin lymphoma
1304428|NCT00750009|stage IV childhood Hodgkin lymphoma
1304429|NCT00750009|anaplastic large cell lymphoma
1304430|NCT00750009|angioimmunoblastic T-cell lymphoma
1304431|NCT00750009|cutaneous B-cell non-Hodgkin lymphoma
1304432|NCT00750009|recurrent cutaneous T-cell non-Hodgkin lymphoma
1304433|NCT00750009|stage I cutaneous T-cell non-Hodgkin lymphoma
1304434|NCT00750009|stage II cutaneous T-cell non-Hodgkin lymphoma
1304435|NCT00750009|stage III cutaneous T-cell non-Hodgkin lymphoma
1304436|NCT00750009|stage IV cutaneous T-cell non-Hodgkin lymphoma
1304437|NCT00750009|recurrent mycosis fungoides/Sezary syndrome
1304438|NCT00750009|stage I mycosis fungoides/Sezary syndrome
1304439|NCT00750009|stage II mycosis fungoides/Sezary syndrome
1304440|NCT00750009|stage III mycosis fungoides/Sezary syndrome
1304441|NCT00750009|stage IV mycosis fungoides/Sezary syndrome
1304442|NCT00750009|adult grade III lymphomatoid granulomatosis
1304443|NCT00750009|adult nasal type extranodal NK/T-cell lymphoma
1304444|NCT00750009|Waldenstrom macroglobulinemia
1304445|NCT00750009|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1304446|NCT00750009|nodal marginal zone B-cell lymphoma
1304447|NCT00750009|splenic marginal zone lymphoma
1304448|NCT00750009|contiguous stage II adult Burkitt lymphoma
1304449|NCT00750009|contiguous stage II adult diffuse large cell lymphoma
1304450|NCT00750009|contiguous stage II adult diffuse mixed cell lymphoma
1304451|NCT00750009|contiguous stage II adult diffuse small cleaved cell lymphoma
1304452|NCT00750009|contiguous stage II adult immunoblastic large cell lymphoma
1304453|NCT00750009|contiguous stage II adult lymphoblastic lymphoma
1304454|NCT00750009|contiguous stage II grade 1 follicular lymphoma
1304455|NCT00750009|contiguous stage II grade 2 follicular lymphoma
1304456|NCT00750009|contiguous stage II grade 3 follicular lymphoma
1304457|NCT00750009|contiguous stage II mantle cell lymphoma
1304458|NCT00750009|contiguous stage II marginal zone lymphoma
1304459|NCT00750009|contiguous stage II small lymphocytic lymphoma
1304460|NCT00750009|stage I adult Burkitt lymphoma
1304461|NCT00750009|stage I adult diffuse large cell lymphoma
1304462|NCT00750009|stage I adult diffuse mixed cell lymphoma
1304463|NCT00750009|stage I adult diffuse small cleaved cell lymphoma
1304464|NCT00750009|stage I adult immunoblastic large cell lymphoma
1304465|NCT00750009|stage I adult lymphoblastic lymphoma
1304466|NCT00750009|stage I grade 1 follicular lymphoma
1304467|NCT00750009|stage I grade 2 follicular lymphoma
1304468|NCT00750009|stage I grade 3 follicular lymphoma
1304469|NCT00750009|stage I mantle cell lymphoma
1304470|NCT00750009|stage I marginal zone lymphoma
1304471|NCT00750009|stage I small lymphocytic lymphoma
1304472|NCT00750009|noncontiguous stage II adult Burkitt lymphoma
1304473|NCT00750009|noncontiguous stage II adult diffuse large cell lymphoma
1304474|NCT00750009|noncontiguous stage II adult diffuse mixed cell lymphoma
1304475|NCT00750009|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1304476|NCT00750009|noncontiguous stage II adult immunoblastic large cell lymphoma
1304477|NCT00750009|noncontiguous stage II adult lymphoblastic lymphoma
1304478|NCT00750009|noncontiguous stage II grade 1 follicular lymphoma
1304479|NCT00750009|noncontiguous stage II grade 2 follicular lymphoma
1304480|NCT00750009|noncontiguous stage II grade 3 follicular lymphoma
1304481|NCT00750009|noncontiguous stage II mantle cell lymphoma
1304482|NCT00750009|noncontiguous stage II marginal zone lymphoma
1304483|NCT00750009|noncontiguous stage II small lymphocytic lymphoma
1304484|NCT00750009|stage I childhood large cell lymphoma
1304485|NCT00750009|stage I childhood lymphoblastic lymphoma
1304486|NCT00750009|stage I childhood small noncleaved cell lymphoma
1304487|NCT00750009|stage II childhood large cell lymphoma
1304488|NCT00750009|stage II childhood lymphoblastic lymphoma
1304489|NCT00750009|stage II childhood small noncleaved cell lymphoma
1304490|NCT00750009|stage III adult Burkitt lymphoma
1304491|NCT00750009|stage III adult diffuse large cell lymphoma
1304492|NCT00750009|stage III adult diffuse mixed cell lymphoma
1304493|NCT00750009|stage III adult diffuse small cleaved cell lymphoma
1304494|NCT00750009|stage III adult immunoblastic large cell lymphoma
1304495|NCT00750009|stage III adult lymphoblastic lymphoma
1304496|NCT00750009|stage III childhood large cell lymphoma
1304497|NCT00750009|stage III childhood lymphoblastic lymphoma
1304498|NCT00750009|stage III childhood small noncleaved cell lymphoma
1304499|NCT00750009|stage III grade 1 follicular lymphoma
1304500|NCT00750009|stage III grade 2 follicular lymphoma
1304501|NCT00750009|stage III grade 3 follicular lymphoma
1304502|NCT00750009|stage III mantle cell lymphoma
1304503|NCT00750009|stage III marginal zone lymphoma
1304504|NCT00750009|stage III small lymphocytic lymphoma
1304505|NCT00750009|stage IV adult Burkitt lymphoma
1304506|NCT00750009|stage IV adult diffuse large cell lymphoma
1304507|NCT00750009|stage IV adult diffuse mixed cell lymphoma
1304508|NCT00750009|stage IV adult diffuse small cleaved cell lymphoma
1304509|NCT00750009|stage IV adult immunoblastic large cell lymphoma
1304510|NCT00750009|stage IV adult lymphoblastic lymphoma
1304511|NCT00750009|stage IV childhood large cell lymphoma
1304512|NCT00750009|stage IV childhood lymphoblastic lymphoma
1304513|NCT00750009|stage IV childhood small noncleaved cell lymphoma
1304514|NCT00750009|stage IV grade 1 follicular lymphoma
1304515|NCT00750009|stage IV grade 2 follicular lymphoma
1304516|NCT00750009|stage IV grade 3 follicular lymphoma
1304517|NCT00750009|stage IV mantle cell lymphoma
1304518|NCT00750009|stage IV marginal zone lymphoma
1304519|NCT00750009|stage IV small lymphocytic lymphoma
1304520|NCT00750009|recurrent adult Burkitt lymphoma
1304521|NCT00750009|recurrent adult diffuse large cell lymphoma
1304522|NCT00750009|recurrent adult diffuse mixed cell lymphoma
1304523|NCT00750009|recurrent adult diffuse small cleaved cell lymphoma
1304524|NCT00750009|recurrent adult grade III lymphomatoid granulomatosis
1304525|NCT00750009|recurrent adult immunoblastic large cell lymphoma
1304526|NCT00750009|recurrent adult lymphoblastic lymphoma
1304527|NCT00750009|recurrent childhood grade III lymphomatoid granulomatosis
1304528|NCT00750009|recurrent childhood large cell lymphoma
1304529|NCT00750009|recurrent childhood lymphoblastic lymphoma
1304530|NCT00750009|recurrent childhood small noncleaved cell lymphoma
1304531|NCT00750009|recurrent grade 1 follicular lymphoma
1304532|NCT00750009|recurrent grade 2 follicular lymphoma
1304533|NCT00750009|recurrent grade 3 follicular lymphoma
1304534|NCT00750009|recurrent mantle cell lymphoma
1304535|NCT00750009|recurrent marginal zone lymphoma
1304536|NCT00750009|recurrent small lymphocytic lymphoma
1304537|NCT00750009|Burkitt lymphoma
1304538|NCT00750009|childhood diffuse large cell lymphoma
1304539|NCT00750009|childhood grade III lymphomatoid granulomatosis
1304540|NCT00750009|childhood immunoblastic large cell lymphoma
1304541|NCT00750009|childhood nasal type extranodal NK/T-cell lymphoma
1304542|NCT00750009|intraocular lymphoma
1304543|NCT00750009|primary central nervous system non-Hodgkin lymphoma
1304544|NCT00750009|primary central nervous system Hodgkin lymphoma
1304545|NCT00750009|post-transplant lymphoproliferative disorder
1304546|NCT00750009|chronic eosinophilic leukemia
1304547|NCT00750009|chronic neutrophilic leukemia
1304548|NCT00750009|primary myelofibrosis
1304549|NCT00750009|essential thrombocythemia
1304550|NCT00750009|polycythemia vera
1304551|NCT00750009|extramedullary plasmacytoma
1304552|NCT00750009|isolated plasmacytoma of bone
1304553|NCT00750009|stage I multiple myeloma
1304554|NCT00750009|stage II multiple myeloma
1304555|NCT00750009|stage III multiple myeloma
1304556|NCT00750009|primary systemic amyloidosis
1304557|NCT00750009|refractory multiple myeloma
1304558|NCT00750009|de novo myelodysplastic syndromes
1304559|NCT00750009|previously treated myelodysplastic syndromes
1304560|NCT00750009|secondary myelodysplastic syndromes
1304561|NCT00750009|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1304562|NCT00750009|childhood myelodysplastic syndromes
1304563|NCT00750009|recurrent childhood anaplastic large cell lymphoma
1304564|NCT00750009|stage I childhood anaplastic large cell lymphoma
1304565|NCT00750009|stage II childhood anaplastic large cell lymphoma
1304566|NCT00750009|stage III childhood anaplastic large cell lymphoma
1304567|NCT00750009|stage IV childhood anaplastic large cell lymphoma
1304568|NCT00749970|schizophrenia
1304569|NCT00749970|subjective well-being
1304570|NCT00749970|psychometric validation
1304571|NCT00749957|AAV
1304572|NCT00749957|adeno-associated virus
1304573|NCT00749957|RPE65
1304574|NCT00749957|Leber congenital amaurosis
1304575|NCT00749957|LCA
1304576|NCT00749957|gene therapy
1304577|NCT00749957|human gene transfer
1304578|NCT00749944|nicotine withdrawal, smoking cessation, varenicline
1304579|NCT00749931|IDC, DCIS, ILC
1304580|NCT00749918|vitamin D
1304581|NCT00749918|Cholecalciferol
1304582|NCT00749918|Insulin sensitivity
1304583|NCT00749918|MinMod Millennium
1304584|NCT00749918|FSIGT
1304585|NCT00749918|modified frequently sampled IV glucose tolerance test
1304586|NCT00749892|Transitional Cell Carcinoma
1304587|NCT00749892|Bladder Cancer
1304588|NCT00749892|Urothelial Cancer
1304589|NCT00749892|Erlotinib Hydrochloride
1304590|NCT00749892|Tarceva
1304591|NCT00749892|OSI-774
1304592|NCT00749892|TCC
1304593|NCT00749879|PK
1304594|NCT00749879|Pharmacokinetics
1304595|NCT00749866|Nebulised antibiotics
1304596|NCT00749866|Non cystic fibrosis bronchiectasis
1304597|NCT00749866|Bacterial Load
1304598|NCT00749866|Inflammation
1304599|NCT00749866|Quality of Life
1304600|NCT00749866|Side Effects
1304601|NCT00749853|ovarian stimulation
1304602|NCT00749853|FSH
1304603|NCT00749853|genotyping
1304604|NCT00749853|polymorphism
1304605|NCT00749840|Acquired Immune Deficiency Syndrome
1304606|NCT00749840|Human Immunodeficiency Virus
1304607|NCT00749840|Questionnaire
1304608|NCT00749840|AIDS
1304609|NCT00749840|HIV
1304610|NCT00749840|Highly Active Antiretroviral Therapy
1304611|NCT00749840|HAART
1304612|NCT00749840|Steps of HIV Care
1304613|NCT00749840|CDC
1304614|NCT00749827|Contrast Induced Nephropathy, fluid prophylaxis
1304615|NCT00749814|sleep patterns in children in the night prior to surgery and post surgery.
1304616|NCT00749814|the influence of melatonin on sleep patterns
1304617|NCT00749801|drug naive
1304618|NCT00749801|Dyslipidemic
1304619|NCT00749801|nattokinase
1304620|NCT00749801|fibrinolytic
1304621|NCT00749775|Eplerenone
1304622|NCT00749775|Selara
1304623|NCT00749775|Hypertension
1304624|NCT00749775|Good post-marketing study Practice
1304625|NCT00749775|Drug use Investigation
1304626|NCT00749775|Regulatory Post Marketing Commitment Plan
1304627|NCT00749775|ESSENCE
1304628|NCT00749762|DURING
1304629|NCT00749762|PRONE
1304630|NCT00749762|SUPINE
1304631|NCT00749762|POSITIONING
1304632|NCT00749749|Abdominal Hysterectomy
1304633|NCT00749749|Postoperative pain
1304634|NCT00749736|vitamin D
1304635|NCT00749736|determine
1304636|NCT00749736|normal
1304637|NCT00749736|intrapatient
1304638|NCT00749736|interpatient
1304639|NCT00749736|variability
1304640|NCT00749736|measures
1304641|NCT00749736|immune system
1304642|NCT00749723|brain tumor
1304643|NCT00749723|relapse
1304644|NCT00749723|children
1304645|NCT00749723|etoposide
1304646|NCT00749723|intraventricular
1304647|NCT00749723|temozolomide
1304648|NCT00749710|femoral neck fractures
1304649|NCT00749710|pertrochanteric fractures
1304650|NCT00749710|antiaggregant therapy
1304651|NCT00749710|clopidogrel
1304652|NCT00749710|plavix
1304653|NCT00749697|radioiodine
1304654|NCT00749697|differentiated thyroid cancers
1304655|NCT00749697|dosimetry
1304656|NCT00749697|metastases
1304657|NCT00749684|interferon-alpha
1304658|NCT00749658|Tobacco
1304659|NCT00749658|Nicotine
1304660|NCT00749658|Smoking
1304661|NCT00749658|Varenicline
1304662|NCT00749658|Bupropion
1304663|NCT00749658|Human laboratory study
1304664|NCT00749658|Stress tolerance
1304665|NCT00749658|Startle response
1304666|NCT00749658|Cognitive assessment
1304667|NCT00749658|Progressive ratio
1304668|NCT00749658|Motivation
1304669|NCT00749645|Arthritis, Rheumatoid, Andrographolides treatment, Efficacy.
1304670|NCT00749632|urinary incontinence, urge
1304671|NCT00749632|urinary urge incontinence
1304672|NCT00749632|urge incontinence
1304673|NCT00749632|over active bladder
1304674|NCT00749619|Tunneled Cuffed Catheter
1304675|NCT00749619|Catheter Lock Solution
1304676|NCT00749619|Catheter Related Bacteremia
1304677|NCT00749606|Obesity
1304678|NCT00749606|Metabolic syndrome
1304679|NCT00749606|Weight loss
1304680|NCT00749606|Diabetes prevention
1304681|NCT00749593|Congenital Adrenal Hyperplasia
1304682|NCT00749593|Quality of Life
1304683|NCT00749593|Genotype
1304684|NCT00749593|Metabolic outcomes
1304685|NCT00749580|Safety
1304686|NCT00749567|NSCLC
1304687|NCT00749567|TKI's
1304688|NCT00749567|Anti-VEGF
1304689|NCT00749554|Cooled Radiofrequency
1304690|NCT00749554|Disc biacuplasty
1304691|NCT00749554|TransDiscal system
1304692|NCT00749554|Discogenic pain
1304693|NCT00749541|vitamin d coronary catheterization
1304694|NCT00749528|Wheezing
1304695|NCT00749528|Hair trace elements
1304696|NCT00749528|Hair toxic metals
1304697|NCT00749528|Oxidative stress
1304698|NCT00749515|Thalassemia
1304699|NCT00749515|Iron
1304700|NCT00749515|Chelation
1304701|NCT00749502|Neoplasms
1304702|NCT00749502|Ovarian neoplasms
1304703|NCT00749502|Prostatic neoplasms
1304704|NCT00749502|Endocrine gland neoplasms
1304705|NCT00749502|Ovarian diseases
1304706|NCT00749502|Adnexal diseases
1304707|NCT00749502|Genital diseases, female
1304708|NCT00749502|Genital diseases, male
1304709|NCT00749502|Genital neoplasms, female
1304710|NCT00749502|Urogenital neoplasms
1304711|NCT00749502|Endocrine system diseases
1304712|NCT00749502|Gonadal disorders
1304713|NCT00749502|Genital neoplasms, male
1304714|NCT00749502|Prostatic diseases
1304715|NCT00749489|Pain
1304716|NCT00749489|Hip Fractures
1304717|NCT00749489|Femoral Fractures
1304718|NCT00749489|Analgesics
1304719|NCT00749489|Opioid
1304720|NCT00749489|Nerve Block
1304721|NCT00749489|Geriatric
1304722|NCT00749489|Nerve Stimulation
1304723|NCT00749463|nicotine dependence, smoking cessation, NRT
1304724|NCT00749450|stage II colon cancer
1304725|NCT00749450|stage III colon cancer
1304726|NCT00749450|stage II rectal cancer
1304727|NCT00749450|stage III rectal cancer
1304728|NCT00749437|stage I breast cancer
1304729|NCT00749437|stage II breast cancer
1304730|NCT00749437|ductal breast carcinoma in situ
1304731|NCT00749437|invasive ductal breast carcinoma
1304732|NCT00749437|medullary ductal breast carcinoma with lymphocytic infiltrate
1304733|NCT00749437|papillary ductal breast carcinoma
1304734|NCT00749437|tubular ductal breast carcinoma
1304735|NCT00749437|mucinous ductal breast carcinoma
1304736|NCT00749437|breast cancer in situ
1304737|NCT00749411|COPD
1304738|NCT00749411|long-acting beta agonist
1304739|NCT00749411|Emphysema
1304740|NCT00749411|Chronic Bronchitis
1304741|NCT00749411|Chronic Obstructive Pulmonary Disease (COPD)
1304742|NCT00749411|bronchodilator
1304743|NCT00749411|long acting muscarinic antagonist
1304744|NCT00749359|healthy volunteers
1304745|NCT00749359|paroxetine
1304746|NCT00749346|TTFields
1304747|NCT00749346|NSCLC
1304748|NCT00749346|Alimta
1304749|NCT00749346|Pemetrexed
1304750|NCT00749333|Healthy Volunteer
1304751|NCT00749333|Safety
1304752|NCT00749333|Tolerability
1304753|NCT00749333|AZD8566
1304754|NCT00749333|study
1304755|NCT00749320|MRI
1304756|NCT00749320|Sunitinib
1304757|NCT00749320|Pazopanib
1304758|NCT00749307|Heart rate variability
1304759|NCT00749307|Docosahexaenoic acid
1304760|NCT00749307|DHA
1304761|NCT00749307|Long chain fatty acids
1304762|NCT00749307|Long chain polyunsaturated fatty acids
1304763|NCT00749307|Algal fatty acids
1304764|NCT00749307|Schizochytrium
1304765|NCT00749307|Omega 3
1304766|NCT00749307|Death, Sudden, Cardiac
1304767|NCT00749307|Arrhythmias, Cardiac
1304768|NCT00749281|atherosclerosis
1304769|NCT00749281|ngal
1304770|NCT00749281|coronary artery disease
1304771|NCT00749268|hernia
1304772|NCT00749255|Breast Cancer
1304773|NCT00749255|Digital archiver software
1304774|NCT00749242|Traumatic vertebral fracture
1304775|NCT00749242|Vertebroplasty
1304776|NCT00749242|Balloon kyphoplasty
1304777|NCT00749242|Bohler bracing
1304778|NCT00749229|Traumatic vertebral fracture
1304779|NCT00749229|Balloon Kyphoplasty
1304780|NCT00749229|type A3.2, or A3.3 or B1 or C1 in the MAGERL CLASSIFICATION
1304781|NCT00749203|Stress Disorders, Post-Traumatic
1304782|NCT00749203|PTSD
1304783|NCT00749203|anxiety disorder
1304784|NCT00749203|ketamine
1304785|NCT00749203|depression
1304786|NCT00749203|depressed mood
1304787|NCT00749177|traditional healing
1304788|NCT00749177|anxiety
1304789|NCT00749177|depression
1304790|NCT00749177|aboriginal
1304791|NCT00749177|children
1304792|NCT00749177|youth
1304793|NCT00749164|Mesenchymal stem cells
1304794|NCT00749164|Umbilical cord
1304795|NCT00749164|graft-vs-host disease
1304796|NCT00749164|Steroid resistant
1304797|NCT00749151|smoking cessation
1304798|NCT00749151|telephone help line
1304799|NCT00749138|hepatitis C, tamoxifen
1304800|NCT00749125|Emotional Circuitry
1304801|NCT00749125|fMRI
1304802|NCT00749112|Idiopathic Thrombocytopenic Purpura
1304803|NCT00749112|Anemia
1304804|NCT00749112|Hemolytic
1304805|NCT00749112|Autoimmune
1304806|NCT00749112|Alemtuzumab
1304807|NCT00749112|Rituximab
1304808|NCT00749086|Osteoporosis
1304809|NCT00749086|Non-traumatic vertebral fracture
1304810|NCT00749086|Vertebral compression
1304811|NCT00749086|Balloon kyphoplasty
1304812|NCT00749086|Vertebroplasty
1304813|NCT00749073|Spinal Stenosis
1304814|NCT00749073|Lumbar Spinal Stenosis
1304815|NCT00749073|Laminotomy
1304816|NCT00749073|Laminectomy
1304817|NCT00749073|Spine Surgery
1304818|NCT00749060|osteoporosis
1304819|NCT00749060|non-traumatic vertebral fracture
1304820|NCT00749060|vertebral compression
1304821|NCT00749060|Balloon kyphoplasty
1304822|NCT00749060|vertebroplasty
1304823|NCT00749047|Pioglitazone
1304824|NCT00749047|Open study
1304825|NCT00749047|Proteinuria
1304826|NCT00749047|Glomerular selectivity indices
1304827|NCT00749034|Safety
1304828|NCT00749034|Immunogenicity
1304829|NCT00749034|Tuberculosis
1304830|NCT00749034|Vaccination
1304831|NCT00749034|Vaccination against tuberculosis
1304832|NCT00749034|Safety and immunogenicity of VPM1002 in comparison with BCG
1304833|NCT00749021|choroidal neovascularization
1304834|NCT00749021|vascularized
1304835|NCT00749008|Cerebral palsy
1304836|NCT00749008|Generalized movements
1304837|NCT00749008|Fidgety movements
1304838|NCT00749008|Prechtl
1304839|NCT00748982|AZD1305
1304840|NCT00748982|anti-arrhythmics
1304841|NCT00748982|safety
1304842|NCT00748969|MPS I
1304843|NCT00748969|MPS II
1304844|NCT00748969|MPS VI
1304845|NCT00748969|growth hormone
1304846|NCT00748969|short stature
1304847|NCT00748956|Mood Disorder
1304848|NCT00748956|Anxiety Disorders
1304849|NCT00748943|chlorine
1304850|NCT00748943|dioxide
1304851|NCT00748943|mouthwash
1304852|NCT00748943|halitosis
1304853|NCT00748943|bacteria
1304854|NCT00748943|saliva
1304855|NCT00748904|cirrhosis of liver and progressive renal failure
1304856|NCT00748891|Cancer
1304857|NCT00748891|tumour
1304858|NCT00748891|advanced sold tumour
1304859|NCT00748891|imaging
1304860|NCT00748891|DCE-CT Scan
1304861|NCT00748891|DCE-MRI scan
1304862|NCT00748891|Cediranib
1304863|NCT00748891|Recentin
1304864|NCT00748878|To better understand platelet function during ECMO
1304865|NCT00748865|Dry Eye
1304866|NCT00748865|Artificial Tears
1304867|NCT00748839|HIT
1304868|NCT00748839|Heparin-induced thrombocytopenia
1304869|NCT00748839|heparin treatment
1304870|NCT00748839|venous thrombosis
1304871|NCT00748839|arterial thrombosis
1304872|NCT00748839|predictive clinical score
1304873|NCT00748839|biological test
1304874|NCT00748839|anti-H-PF4 antibodies
1304875|NCT00748813|Influenza vaccine
1304876|NCT00748800|HIV prevention
1304877|NCT00748800|HIV seronegativity
1304878|NCT00748774|Primary Brain Tumor
1304879|NCT00748774|Caregivers
1304880|NCT00748774|Symptom Severity
1304881|NCT00748774|Questionnaire
1304882|NCT00748774|M.D. Anderson Symptom Inventory-Brain Tumor
1304883|NCT00748774|MDASI-BT
1304884|NCT00748761|Obsessive-Compulsive Disorder
1304885|NCT00748761|OCD
1304886|NCT00748761|Cognitive-Behavioral Therapy
1304887|NCT00748761|CBT
1304888|NCT00748761|MRSI
1304889|NCT00748761|Glutamate
1304890|NCT00748735|cardiac resynchronization therapy
1304891|NCT00748735|echocardiography
1304892|NCT00748735|heart failure
1304893|NCT00748735|left ventricular function
1304894|NCT00748735|pacing
1304895|NCT00748735|myocardial deformation imaging
1304896|NCT00748735|Optimal Definition of Left Ventricular Lead Position in Cardiac Resynchronization Therapy
1304897|NCT00748722|Breast reconstruction
1304898|NCT00748722|Perforator flaps
1304899|NCT00748722|CT Angiography
1304900|NCT00748696|sarcopenia
1304901|NCT00748696|elderly
1304902|NCT00748696|resistance training
1304903|NCT00748696|oral nutritional supplement
1304904|NCT00748683|elderly
1304905|NCT00748683|longterm care
1304906|NCT00748644|Wegener's granulomatosis,
1304907|NCT00748644|microscopic polyangiitis,
1304908|NCT00748644|ANCA-associated vasculitis,
1304909|NCT00748644|rituximab,
1304910|NCT00748644|azathioprine
1304911|NCT00748631|Vertebral fracture
1304912|NCT00748631|Vertebral compression fracture
1304913|NCT00748631|Multiple Myeloma Bone marrow diseases
1304914|NCT00748631|Vertebral metastases
1304915|NCT00748631|Balloon Kyphoplasty
1304916|NCT00748618|Kidney transplantation (KTX)
1304917|NCT00748618|Vitamin D deficiency
1304918|NCT00748618|Cardiovascular Disease (CVD)
1304919|NCT00748618|Vascular risk
1304920|NCT00748618|Parathyroid hormone (PTH)
1304921|NCT00748618|Carotid intima media thickness (CIMT)
1304922|NCT00748618|Insulin resistance (IR)
1304923|NCT00748605|Obesity
1304924|NCT00748592|Insomnia, Primary Insomnia, Chronic Insomnia, DIMS (Disorders of Initiating and Maintaining Sleep), Disorders of Initiating and Maintaining Sleep
1304925|NCT00748566|Ziprasidone
1304926|NCT00748566|metabolic syndrome
1304927|NCT00748566|risk factors
1304928|NCT00748566|schizophrenia
1304929|NCT00748566|psychotic disorders.
1304930|NCT00748540|sensorineural hearing loss
1304931|NCT00748540|conductive hearing loss
1304932|NCT00748540|mixed hearing loss
1304933|NCT00748527|fallopian tube cancer
1304934|NCT00748527|stage III ovarian epithelial cancer
1304935|NCT00748527|stage IV ovarian epithelial cancer
1304936|NCT00748527|recurrent ovarian epithelial cancer
1304937|NCT00748527|peritoneal cavity cancer
1304938|NCT00748514|capsular incision
1304939|NCT00748514|biochemical recurrence
1304940|NCT00748514|radical perineal prostatectomy
1304941|NCT00748501|Amyotrophic Lateral Sclerosis,
1304942|NCT00748501|ALS,
1304943|NCT00748501|Lou Gehrig's Disease
1304944|NCT00748488|Parkinson
1304945|NCT00748488|Physical Therapy
1304946|NCT00748488|Physical Activity
1304947|NCT00748462|Acne scar, Wrinkle, Pigmentation, Fractional CO2 laser
1304948|NCT00748449|Colorectal advanced adenoma
1304949|NCT00748449|Colorectal cancer polypectomy (endoscopic)
1304950|NCT00748449|Colectomy
1304951|NCT00748449|Colonoscopy with anaesthesia
1304952|NCT00748449|CT-colonography
1304953|NCT00748436|Obese females
1304954|NCT00748436|Weight loss
1304955|NCT00748436|Betahistine
1304956|NCT00748423|Inhaled drug
1304957|NCT00748423|Acute lung injury
1304958|NCT00748423|Nitric oxide
1304959|NCT00748423|Sickle cell
1304960|NCT00748410|CD11b
1304961|NCT00748410|Ulcerative colitis
1304962|NCT00748410|99mTc-HMPAO-labelled leukocyte scintigraphy
1304963|NCT00748384|HMP, CNV, AMD, PHP, HPHP, foresee
1304964|NCT00748371|platelet aggregation
1304965|NCT00748371|granule secretion
1304966|NCT00748371|thromboxane production
1304967|NCT00748371|prostacyclin production
1304968|NCT00748358|metastatic prostate carcinoma
1304969|NCT00748358|sunitinib [Substance Name]
1304970|NCT00748358|Clinical Trial, Phase II [Publication Type]
1304971|NCT00748345|Caspofungin,
1304972|NCT00748345|burn patients,
1304973|NCT00748345|pharmacokinetics,
1304974|NCT00748345|optimal dose,
1304975|NCT00748345|antifungal treatment
1304976|NCT00748319|Receptors KIR
1304977|NCT00748319|Polymerase chain reaction
1304978|NCT00748319|Diagnosis
1304979|NCT00748319|Lymphoma T-cell cutaneous
1304980|NCT00748319|Mycosis fungicides
1304981|NCT00748319|Sezary syndrome
1304982|NCT00748319|Differential diagnosis from dermatitis
1304983|NCT00748306|challenge
1304984|NCT00748306|early asthmatic response
1304985|NCT00748306|mild asthmatics
1304986|NCT00748306|Allergen
1304987|NCT00748306|methacholine
1304988|NCT00748293|Colonoscopy
1304989|NCT00748293|Colon cleansing
1304990|NCT00748293|Low-reside diet
1304991|NCT00748293|Compliance
1304992|NCT00748293|PEG-ELS
1304993|NCT00748280|Endodontics
1304994|NCT00748280|CEM cement
1304995|NCT00748280|Calcium enriched mixture
1304996|NCT00748280|MTA
1304997|NCT00748280|Root Canal Therapy
1304998|NCT00748280|Pain
1304999|NCT00748280|Pulpotomy
1305000|NCT00748280|Human
1305001|NCT00748280|Permanent
1305002|NCT00748280|Molar teeth
1305003|NCT00748267|anxiety disorder
1305004|NCT00748267|pain
1305005|NCT00748267|nausea and vomiting
1305006|NCT00748267|breast cancer
1305007|NCT00748254|Rheumatoid arthritis
1305008|NCT00748215|diarrhea
1305009|NCT00748215|chemotherapeutic agent toxicity
1305010|NCT00748215|recurrent colon cancer
1305011|NCT00748215|recurrent rectal cancer
1305012|NCT00748215|stage IV colon cancer
1305013|NCT00748215|stage IV rectal cancer
1305014|NCT00748202|Hereditary angioedema
1305015|NCT00748202|C1-Esterase inhibitor
1305016|NCT00748202|intravenous
1305017|NCT00748202|subcutaneous
1305018|NCT00748202|pharmacokinetic
1305019|NCT00748189|Safety
1305020|NCT00748189|Untreated
1305021|NCT00748189|Efficacy
1305022|NCT00748189|Chronic Lymphocytic Leukemia
1305023|NCT00748189|Chronic Lymphocytic Leukemia (CLL), untreated
1305024|NCT00748189|Ofatumumab
1305025|NCT00748189|Oncology
1305026|NCT00748163|stage IV non-small cell lung cancer
1305027|NCT00748150|flu
1305028|NCT00748150|influenza
1305029|NCT00748150|influenza vaccine antigen
1305030|NCT00748150|immunogenicity
1305031|NCT00748150|antibody response
1305032|NCT00748150|intra muscular
1305033|NCT00748150|elderly
1305034|NCT00748150|non-elderly
1305035|NCT00748137|Type 1 Diabetes
1305036|NCT00748137|Youth
1305037|NCT00748137|Insulin dose
1305038|NCT00748111|Sudden death
1305039|NCT00748111|Out of hospital cardiac arrest
1305040|NCT00748111|Acute myocardial infarction
1305041|NCT00748111|Acute coronary syndrome
1305042|NCT00748098|PSG
1305043|NCT00748098|Restless Legs Syndrome
1305044|NCT00748098|gabapentin enacarbil
1305045|NCT00748098|XP13512
1305046|NCT00748098|GSK1838262
1305047|NCT00748098|sleep disturbance
1305048|NCT00748098|RLS
1305049|NCT00748098|polysomnography
1305050|NCT00748085|Malignant Airway Disease
1305051|NCT00748085|Lung Cancer
1305052|NCT00748085|Inoperable Lung Cancer
1305053|NCT00748085|Mesothelioma
1305054|NCT00748085|Endoluminal Tumor
1305055|NCT00748072|Vasopressin
1305056|NCT00748072|bleeding
1305057|NCT00748072|biopsy
1305058|NCT00748072|ultrasonography
1305059|NCT00748059|autonomic nervous system diseases
1305060|NCT00748059|blood pressure
1305061|NCT00748059|congenital
1305062|NCT00748059|orthostasis
1305063|NCT00748059|catecholamines
1305064|NCT00748046|Biodistribution
1305065|NCT00748046|Radiation dosimetry
1305066|NCT00748046|Pharmacokinetics
1305067|NCT00748046|Safety
1305068|NCT00748007|Down syndrome, cholinesterase inhibitor, Rivastigmine
1305069|NCT00747994|Paget's disease of bone
1305070|NCT00747994|Relatives
1305071|NCT00747994|Mutations screening
1305072|NCT00747994|Haplotypes analysis
1305073|NCT00747994|Linkage analysis
1305074|NCT00747994|< 55 years
1305075|NCT00747994|4 > or = WAFFECTED Bones
1305076|NCT00747994|bone deformity
1305077|NCT00747981|CT Scan
1305078|NCT00747981|Endoscopy
1305079|NCT00747981|Aspiration
1305080|NCT00747981|Foreign Bodies
1305081|NCT00747955|Human Performance
1305082|NCT00747955|Physical Disability
1305083|NCT00747955|Functional Outcome Measures
1305084|NCT00747955|Health Volunteer
1305085|NCT00747955|HV
1305086|NCT00747942|overweight
1305087|NCT00747942|physical inactivity
1305088|NCT00747942|physical fitness
1305089|NCT00747942|lifestyle change
1305090|NCT00747929|Obesity
1305091|NCT00747916|Parietal pleura
1305092|NCT00747916|Neoplasms
1305093|NCT00747916|Pleural Surface
1305094|NCT00747916|Pleural Neoplasms
1305095|NCT00747916|Lung Cancer
1305096|NCT00747903|basal cell carcinoma of the skin
1305097|NCT00747903|recurrent skin cancer
1305098|NCT00747877|stage II multiple myeloma
1305099|NCT00747877|stage III multiple myeloma
1305100|NCT00747877|refractory multiple myeloma
1305101|NCT00747877|stage I multiple myeloma
1305102|NCT00747864|Gestational Age
1305103|NCT00747864|Urine
1305104|NCT00747864|Concentration
1305105|NCT00747864|of S100B
1305106|NCT00747851|protein
1305107|NCT00747851|synthesis
1305108|NCT00747851|response
1305109|NCT00747851|PAF-stimulated
1305110|NCT00747851|PMNs
1305111|NCT00747851|collected
1305112|NCT00747838|Afib
1305113|NCT00747838|Atrial Fibrillation
1305114|NCT00747838|Maze
1305115|NCT00747838|Mini-Maze
1305116|NCT00747825|cancer
1305117|NCT00747825|oncology
1305118|NCT00747825|melanoma
1305119|NCT00747825|tumor
1305120|NCT00747812|Headache
1305121|NCT00747812|Migraine
1305122|NCT00747812|Refractory
1305123|NCT00747812|Chronic
1305124|NCT00747812|Pain
1305125|NCT00747799|recurrent or metastatic Nasopharyngeal Neoplasms
1305126|NCT00747773|Lung Cancer
1305127|NCT00747773|CryoPsray Ablation
1305128|NCT00747773|CSA therapy
1305129|NCT00747773|CSA treatment
1305130|NCT00747773|Lobectomy
1305131|NCT00747773|lung resection
1305132|NCT00747760|TSH Receptor, resistance TSH, Hyperthyrortropinemia
1305133|NCT00747747|Sinusitis
1305134|NCT00747734|Neuropilin-1
1305135|NCT00747734|NRP1
1305136|NCT00747734|anti-NRP1
1305137|NCT00747734|anti-angiogenic
1305138|NCT00747708|heart failure
1305139|NCT00747708|coronary heart disease
1305140|NCT00747708|adult stem cells
1305141|NCT00747708|bone marrow progenitor cells
1305142|NCT00747708|bone marrow stem cells
1305143|NCT00747708|autologous
1305144|NCT00747708|granulocyte-colony stimulating factor
1305145|NCT00747708|left ventricular function
1305146|NCT00747708|intracoronary injection
1305147|NCT00747708|intramyocardial injection
1305148|NCT00747695|Pediatric Pharmacokinetics
1305149|NCT00747695|Pediatric Pharmacodynamics
1305150|NCT00747695|Rabeprazole
1305151|NCT00747695|Pediatric GERD
1305152|NCT00747695|Aciphex
1305153|NCT00747682|Cerebral Perfusion,
1305154|NCT00747682|Oxygenation,
1305155|NCT00747682|Electrical
1305156|NCT00747682|Activity
1305157|NCT00747656|Electrocardiography
1305158|NCT00747656|Emergency medical services
1305159|NCT00747656|Emergency medicine
1305160|NCT00747656|Health services
1305161|NCT00747656|Cost effectiveness
1305162|NCT00747643|tobacco
1305163|NCT00747643|nicotine
1305164|NCT00747643|smoking
1305165|NCT00747643|reward
1305166|NCT00747643|reinforcement
1305167|NCT00747643|craving
1305168|NCT00747643|cues
1305169|NCT00747643|conditioned stimuli
1305170|NCT00747643|cue reactivity
1305171|NCT00747630|Fetal Alcohol Syndrome
1305172|NCT00747630|Teen pregnancy
1305173|NCT00747617|polycystic ovary syndrome
1305174|NCT00747617|androgens
1305175|NCT00747617|ovary
1305176|NCT00747617|LH
1305177|NCT00747604|Growth Hormone (GH) Insensitivity Syndrome
1305178|NCT00747604|Insulin-like Growth Factor Deficiency (IGFD)
1305179|NCT00747604|Short Stature
1305180|NCT00747604|Insulin-like Growth Factor (IGF-1)
1305181|NCT00747604|Growth
1305182|NCT00747591|urine
1305183|NCT00747591|concentration
1305184|NCT00747591|of S100B
1305185|NCT00747578|ankylosing spondylitis (AS), costs,
1305186|NCT00747578|rheumatoid arthritis (RA),
1305187|NCT00747578|systemic lupus erythematosus (SLE),
1305188|NCT00747578|health-related
1305189|NCT00747578|quality of life (HRQOL)
1305190|NCT00747578|compare
1305191|NCT00747578|utility
1305192|NCT00747578|patients
1305193|NCT00747565|cataract, tecnis, multifocal, intraocular lens
1305194|NCT00747552|IAP measurements
1305195|NCT00747552|Abdominal compartment syndrome
1305196|NCT00747552|NICU patients
1305197|NCT00747552|Intra-abdominal Hypertension
1305198|NCT00747539|Hepatitis C Virus
1305199|NCT00747539|HCV
1305200|NCT00747539|Human Immunodeficiency Virus
1305201|NCT00747539|Coinfection
1305202|NCT00747526|Gastroesophageal Reflux Disease (GERD)
1305203|NCT00747526|Pediatrics
1305204|NCT00747526|Pharmacokinetics
1305205|NCT00747526|Pharmacodynamics
1305206|NCT00747526|Rabeprazole
1305207|NCT00747526|GERD
1305208|NCT00747526|Aciphex
1305209|NCT00747513|school
1305210|NCT00747513|prevention
1305211|NCT00747513|overweight
1305212|NCT00747513|children
1305213|NCT00747513|diet
1305214|NCT00747513|physical activity
1305215|NCT00747513|fitness
1305216|NCT00747487|Leber
1305217|NCT00747487|LHON
1305218|NCT00747487|Leber's Hereditary Optic Neuropathy
1305219|NCT00747487|Idebenone
1305220|NCT00747461|Benign Airway Disease
1305221|NCT00747461|Airway Injury
1305222|NCT00747461|Sarcoidosis
1305223|NCT00747461|Wegener's Granulomatosis
1305224|NCT00747461|Rhinoscleroma
1305225|NCT00747461|Recurrent Respiratory Papillomatosis(RRP)
1305226|NCT00747448|Barrett's Esophagus
1305227|NCT00747448|High Grade Dysplasia
1305228|NCT00747448|Low Grade Dysplasia
1305229|NCT00747448|Squamous Dysplasia
1305230|NCT00747448|Esophageal Cancer
1305231|NCT00747448|CryoSpray Ablation
1305232|NCT00747448|Cryotherapy
1305233|NCT00747448|Cryospray
1305234|NCT00747435|sensorineural hearing loss
1305235|NCT00747435|ski slope audiogram
1305236|NCT00747435|electric acoustic stimulation
1305237|NCT00747409|postprandial glucose, diastolic function, analogue insulins
1305238|NCT00747396|Romania,
1305239|NCT00747396|children,
1305240|NCT00747396|foster care,
1305241|NCT00747396|institutionalization,
1305242|NCT00747396|brain function,
1305243|NCT00747396|MRI,
1305244|NCT00747396|attachment,
1305245|NCT00747396|language,
1305246|NCT00747396|growth,
1305247|NCT00747396|IQ,
1305248|NCT00747396|psychiatric symptomatology
1305249|NCT00747396|early intervention
1305250|NCT00747383|Diabetes Mellitus
1305251|NCT00747383|GLP1
1305252|NCT00747383|DPP4
1305253|NCT00747370|stress urinary incontinence
1305254|NCT00747370|Tension free vaginal tape
1305255|NCT00747370|tension free vaginal tape obturator
1305256|NCT00747370|genital prolapse
1305257|NCT00747344|Psoriasis
1305258|NCT00747344|Psoriatic Arthritis
1305259|NCT00747344|Ustekinumab
1305260|NCT00747344|CNTO 1275
1305261|NCT00747331|Cardiopulmonary bypass
1305262|NCT00747331|Lactic acidosis
1305263|NCT00747331|Oxygen delivery
1305264|NCT00747331|Acute renal failure
1305265|NCT00747331|outcome
1305266|NCT00747331|cardiac
1305267|NCT00747331|surgery
1305268|NCT00747318|Moderate to Severe
1305269|NCT00747305|stage IV renal cell cancer
1305270|NCT00747305|clear cell renal cell carcinoma
1305271|NCT00747305|recurrent renal cell cancer
1305272|NCT00747292|laparoscopic
1305273|NCT00747292|colon
1305274|NCT00747292|analgesia
1305275|NCT00747292|fluid optimised
1305276|NCT00747253|laser interstitial thermal therapy
1305277|NCT00747253|laser therapy
1305278|NCT00747253|thermal therapy
1305279|NCT00747253|brain tumors
1305280|NCT00747253|recurrent brain tumor
1305281|NCT00747253|progressive brain tumor
1305282|NCT00747253|glioblastoma multiforme tumor
1305283|NCT00747240|Ile198Thr
1305284|NCT00747240|Ala379Val
1305285|NCT00747240|variants
1305286|NCT00747240|PAF-AH
1305287|NCT00747227|cataract
1305288|NCT00747227|monofocal
1305289|NCT00747227|intraocular lens
1305290|NCT00747227|acrylic
1305291|NCT00747214|Rheumatoid Arthritis
1305292|NCT00747214|RA
1305293|NCT00747214|DMARD
1305294|NCT00747214|CRP
1305295|NCT00747201|Replicating Effective Programs
1305296|NCT00747201|Care Management
1305297|NCT00747201|Implementation
1305298|NCT00747201|Intervention
1305299|NCT00747188|Problem-based learning (PBL)
1305300|NCT00747188|lecture
1305301|NCT00747188|nursing
1305302|NCT00747188|education
1305303|NCT00747188|none of students had any prior exposure to PBL
1305304|NCT00747175|Type 2 diabetes
1305305|NCT00747162|Compartment Syndrome
1305306|NCT00747162|Muscle Oxygenation
1305307|NCT00747162|Skin Pigmentation
1305308|NCT00747149|diabetes
1305309|NCT00747149|type 2
1305310|NCT00747136|Barrett's
1305311|NCT00747136|Dysplasia
1305312|NCT00747136|esophageal cancer
1305313|NCT00747136|Patients
1305314|NCT00747110|5-ASA
1305315|NCT00747110|mesalamine
1305316|NCT00747110|mesalazine
1305317|NCT00747110|budesonide
1305318|NCT00747110|ulcerative colitis
1305319|NCT00747084|unsedated colonoscopy
1305320|NCT00747071|Clostridium difficile
1305321|NCT00747071|diarrhea
1305322|NCT00747071|colostrum
1305323|NCT00747058|phase 1, human study, healthy volunteers
1305324|NCT00747045|Chronic Thromboembolic Pulmonary Hypertension
1305325|NCT00747045|Lung Injury
1305326|NCT00747045|Ventilation Strategies
1305327|NCT00746993|Contraception
1305328|NCT00746993|Counseling
1305329|NCT00746980|alopecia
1305330|NCT00746980|areata
1305331|NCT00746980|universalis
1305332|NCT00746980|severe
1305333|NCT00746980|ophiasis
1305334|NCT00746980|variants
1305335|NCT00746954|buspirone
1305336|NCT00746954|acetazolamide
1305337|NCT00746941|PML
1305338|NCT00746941|Human Polyomavirus JC
1305339|NCT00746941|HIV
1305340|NCT00746941|Central Nervous System Disease
1305341|NCT00746941|Mefloquine
1305342|NCT00746941|JC Virus
1305343|NCT00746928|Blood pressure
1305344|NCT00746928|Hypertension
1305345|NCT00746928|sympathetic control
1305346|NCT00746928|chemosensitivity
1305347|NCT00746928|baroreflex
1305348|NCT00746915|Patients undergoing elective pain relief treatment of lumbar epidural steroid injection under fluoroscopy
1305349|NCT00746902|Refractory hypertension
1305350|NCT00746902|Obstructive sleep apnea syndrome
1305351|NCT00746902|Obesity
1305352|NCT00746902|Leptinemia
1305353|NCT00746902|RHOOSAS study
1305354|NCT00746889|osteoarthritis
1305355|NCT00746889|knee
1305356|NCT00746889|corticosteroids
1305357|NCT00746889|ultrasound
1305358|NCT00746876|Hip
1305359|NCT00746876|Fracture
1305360|NCT00746876|Femoral neck
1305361|NCT00746876|Hemiarthroplasty
1305362|NCT00746876|Bipolar
1305363|NCT00746876|Unipolar
1305364|NCT00746876|Displaced femoral neck fractures
1305365|NCT00746863|mid-urethral sling
1305366|NCT00746863|pubovaginal sling
1305367|NCT00746863|postoperative pain
1305368|NCT00746863|visual analog scale
1305369|NCT00746863|suprapubic approach
1305370|NCT00746863|SPARC sling
1305371|NCT00746850|acute cholecystitis
1305372|NCT00746850|laparoscopic cholecystectomy
1305373|NCT00746850|conversion rate
1305374|NCT00746850|morbidity
1305375|NCT00746850|mortality
1305376|NCT00746850|postoperative pain
1305377|NCT00746850|hospital stay
1305378|NCT00746837|AZD5672
1305379|NCT00746824|Obesity
1305380|NCT00746824|weight loss
1305381|NCT00746824|7TM Pharma
1305382|NCT00746824|TM30339
1305383|NCT00746824|Y4 receptor antagonist
1305384|NCT00746811|cholesterol
1305385|NCT00746811|hypercholesterolemia
1305386|NCT00746811|omega 3
1305387|NCT00746798|West Nile Fever
1305388|NCT00746798|ChimeriVax
1305389|NCT00746798|West Nile Virus Vaccine
1305390|NCT00746785|Olanzapine
1305391|NCT00746772|antioxidant
1305392|NCT00746772|oral lichen planus
1305393|NCT00746772|treatment
1305394|NCT00746772|purslane
1305395|NCT00746759|Lung Cancer
1305396|NCT00746759|Smoker
1305397|NCT00746759|Former Smoker
1305398|NCT00746759|Gene Expression
1305399|NCT00746759|Bronchoscopy
1305400|NCT00746746|Advanced Melanoma
1305401|NCT00746733|Drug
1305402|NCT00746733|Interaction
1305403|NCT00746733|Study
1305404|NCT00746720|hip replacement
1305405|NCT00746720|osteoarthritis
1305406|NCT00746720|etoricoxib
1305407|NCT00746720|pain
1305408|NCT00746720|cerebrospinal fluid
1305409|NCT00746720|pharmacokinetics
1305410|NCT00746707|adhesive glue, perineal tear, suture
1305411|NCT00746668|Reading
1305412|NCT00746668|Macular Degeneration
1305413|NCT00746668|Rehabilitation
1305414|NCT00746668|Vision, Low
1305415|NCT00746655|Hepatocellular
1305416|NCT00746642|glucose measurements
1305417|NCT00746616|Total Hip Arthroplasty,
1305418|NCT00746616|Acetabular Cup,
1305419|NCT00746616|Hip Resurfacing
1305420|NCT00746616|Young,
1305421|NCT00746616|active
1305422|NCT00746616|patients
1305423|NCT00746590|hepatocellular carcinoma
1305424|NCT00746590|liver cancer
1305425|NCT00746590|Prolarix
1305426|NCT00746590|tretazicar
1305427|NCT00746590|caricotamide
1305428|NCT00746590|Phase 2
1305429|NCT00746590|tumor
1305430|NCT00746590|chemotherapy
1305431|NCT00746564|Implantable Cardiac Monitor
1305432|NCT00746564|Arrhythmias
1305433|NCT00746564|Atrial Fibrillation
1305434|NCT00746551|iron deficiency anemia
1305435|NCT00746551|pregnancy
1305436|NCT00746551|third trimester
1305437|NCT00746551|intravenous iron
1305438|NCT00746551|efficacy
1305439|NCT00746551|a randomized trial
1305440|NCT00746551|Female
1305441|NCT00746551|Ferric Compounds/therapeutic use*
1305442|NCT00746551|Infusions, Intravenous
1305443|NCT00746551|Hematologic/therapy*
1305444|NCT00746538|Hilar cholangiocarcinoma
1305445|NCT00746538|biliary stent
1305446|NCT00746538|plastic stent
1305447|NCT00746538|metallic stent
1305448|NCT00746538|quality of life
1305449|NCT00746525|stroke
1305450|NCT00746525|motor learning
1305451|NCT00746525|rehabilitation of upper extremity
1305452|NCT00746525|functional electrical stimulation
1305453|NCT00746525|FES
1305454|NCT00746525|brain computer interface
1305455|NCT00746525|BCI
1305456|NCT00746525|coordination
1305457|NCT00746525|motor control
1305458|NCT00746460|primary prevention
1305459|NCT00746460|patient knowledge
1305460|NCT00746460|nurse
1305461|NCT00746460|exercise
1305462|NCT00746460|smoking cessation
1305463|NCT00746460|weight loss
1305464|NCT00746447|maintenance
1305465|NCT00746447|5-ASA
1305466|NCT00746447|mesalamine
1305467|NCT00746447|mesalazine
1305468|NCT00746447|ulcerative colitis
1305469|NCT00746434|Mild plaque psoriasis,
1305470|NCT00746434|Moderate plaque psoriasis,
1305471|NCT00746434|0.5% Roflumilast cream
1305472|NCT00746421|Cognition
1305473|NCT00746421|attention
1305474|NCT00746421|bipolar
1305475|NCT00746421|disability
1305476|NCT00746408|Internet
1305477|NCT00746408|Information supply
1305478|NCT00746408|Tailoring
1305479|NCT00746408|Patient empowerment
1305480|NCT00746408|Headaches
1305481|NCT00746408|Consumer Health Information
1305482|NCT00746408|Information Services
1305483|NCT00746408|Information Storage and Retrieval
1305484|NCT00746408|Information Systems
1305485|NCT00746395|capsule
1305486|NCT00746395|endoscopy
1305487|NCT00746395|prokinetic
1305488|NCT00746395|lubiprostone
1305489|NCT00746395|Normal
1305490|NCT00746395|volunteers
1305491|NCT00746382|Mild atopic dermatitis, Roflumilast cream 0.5%
1305492|NCT00746369|HIV
1305493|NCT00746369|Prevention
1305494|NCT00746369|Adolescents
1305495|NCT00746369|HIV Seronegativity
1305496|NCT00746356|heart failure
1305497|NCT00746356|cardiac resynchronization therapy
1305498|NCT00746356|autocapture
1305499|NCT00746356|Current RF
1305500|NCT00746356|Promote RF
1305501|NCT00746343|Bipolar I Disorder
1305502|NCT00746343|Medical Risks
1305503|NCT00746343|Integrated Risk Reduction Intervention
1305504|NCT00746343|Currently in Remission
1305505|NCT00746343|BMI
1305506|NCT00746330|Asthma
1305507|NCT00746330|Children
1305508|NCT00746330|Persistent asthma
1305509|NCT00746304|botulinum
1305510|NCT00746304|esotropia
1305511|NCT00746278|Ovarian Cysts
1305512|NCT00746278|Electrocoagulation
1305513|NCT00746278|Ovarian Function Tests
1305514|NCT00746278|Laparoscopy
1305515|NCT00746265|behavioral interventions for weight loss
1305516|NCT00746252|bipolar
1305517|NCT00746252|children
1305518|NCT00746252|antipsychotic
1305519|NCT00746252|side effect
1305520|NCT00746239|insomnia
1305521|NCT00746239|sleep difficulty
1305522|NCT00746239|panic disorder
1305523|NCT00746239|nocturnal panic attacks
1305524|NCT00746239|anxiety
1305525|NCT00746226|birch pollen
1305526|NCT00746213|Thoracotomy
1305527|NCT00746213|Chronic Pain
1305528|NCT00746200|chronic constipation
1305529|NCT00746200|electroacupuncture
1305530|NCT00746200|randomized controlled trial
1305531|NCT00746174|insulin sensitivity
1305532|NCT00746174|magnetic resonance spectroscopy (MRS)
1305533|NCT00746174|lipotoxicity
1305534|NCT00746174|lipid oxidation
1305535|NCT00746174|thiazolidinediones
1305536|NCT00746174|intracellular
1305537|NCT00746174|triglyceride
1305538|NCT00746174|content
1305539|NCT00746161|total gastrectomy
1305540|NCT00746161|double tract reconstruction
1305541|NCT00746161|gastric cancer
1305542|NCT00746161|Total gastrectomy in patients with gastric cancer
1305543|NCT00746148|Polycystic Ovary Syndrome
1305544|NCT00746148|Reflexology
1305545|NCT00746148|Complementary and Alternative Medicine
1305546|NCT00746148|Endocrinopathy
1305547|NCT00746148|Oligo
1305548|NCT00746148|Amenorrhoea
1305549|NCT00746135|Heart failure (NYHA class III and IV)
1305550|NCT00746135|Ventricular Dyssynchrony
1305551|NCT00746109|randomized
1305552|NCT00746109|clinical trial
1305553|NCT00746109|ultrasound
1305554|NCT00746109|prospective
1305555|NCT00746109|abscess
1305556|NCT00746109|packing
1305557|NCT00746109|incision and drainage
1305558|NCT00746109|superficial soft tissue infection
1305559|NCT00746083|pediatric
1305560|NCT00746083|obesity
1305561|NCT00746083|African American
1305562|NCT00746083|adolescents
1305563|NCT00746083|intervention
1305564|NCT00746083|home-based
1305565|NCT00746083|community-based
1305566|NCT00746070|cardiovascular disease, endothelium function, aldosterone
1305567|NCT00746057|Renal graft
1305568|NCT00746057|chronic rejection
1305569|NCT00746057|tolerance
1305570|NCT00746057|DNA chip
1305571|NCT00746057|biopsy
1305572|NCT00746044|Healthy
1305573|NCT00746031|MTI
1305574|NCT00746031|Fibroids
1305575|NCT00746031|Novel
1305576|NCT00746031|MR imaging
1305577|NCT00746031|techniques
1305578|NCT00746018|ovary
1305579|NCT00746018|uterus
1305580|NCT00746018|cervix
1305581|NCT00746018|08-092
1305582|NCT00746005|mild cognitive impairment
1305583|NCT00745992|Voriconazole
1305584|NCT00745992|Antifungal Agents
1305585|NCT00745992|Invasive fungal infections
1305586|NCT00745992|Therapeutic drug monitoring
1305587|NCT00745992|CYP Genetic polymorphism
1305588|NCT00745966|Bipolar
1305589|NCT00745966|atypical antipsychotics
1305590|NCT00745966|quality of life
1305591|NCT00745966|observational
1305592|NCT00745953|Metabolic syndrome
1305593|NCT00745953|Lipotoxicity
1305594|NCT00745953|Insulin sensitivity
1305595|NCT00745953|Myocardial triglyceride levels
1305596|NCT00745953|Hepatic triglyceride levels
1305597|NCT00745953|Magnetic resonance spectroscopy
1305598|NCT00745940|Mindfulness-Based Cognitive Therapy
1305599|NCT00745940|MBCT
1305600|NCT00745940|Depression
1305601|NCT00745940|Traumatic Brain Injury
1305602|NCT00745940|TBI
1305603|NCT00745927|Colorectal neoplasm
1305604|NCT00745927|Colorectal cancer
1305605|NCT00745927|Screening colonoscopy
1305606|NCT00745927|CO2 insufflations
1305607|NCT00745927|Colonoscopy
1305608|NCT00745914|PPAR-gamma, diabetic, kidney disease, atherosclerosis
1305609|NCT00745901|contraception
1305610|NCT00745901|bleeding
1305611|NCT00745901|cycle control
1305612|NCT00745888|oxidative stress
1305613|NCT00745888|intensive care
1305614|NCT00745888|Postoperative intensive care
1305615|NCT00745875|NSCLC
1305616|NCT00745875|Phase II
1305617|NCT00745875|ZD4054
1305618|NCT00745875|Pemetrexed
1305619|NCT00745875|Lung Cancer
1305620|NCT00745862|Skin
1305621|NCT00745849|non-allergic rhinitis, laryngopharyngeal reflux
1305622|NCT00745095|Safety
1305623|NCT00745095|Efficacy
1305624|NCT00745095|Colonoscopy
1305625|NCT00745095|PIEE
1305626|NCT00745095|MoviPrep
1305627|NCT00745095|Neostigmine
1305628|NCT00745095|Glycopyrrolate
1305629|NCT00745069|Tapentadol
1305630|NCT00745069|Osteoarthritis
1305631|NCT00745069|Analgesia
1305632|NCT00745069|Chronic pain
1305633|NCT00745056|Cognition
1305634|NCT00745056|Memory
1305635|NCT00745056|Hormone Therapy
1305636|NCT00745056|HT
1305637|NCT00745043|COPD
1305638|NCT00745043|Betablockers
1305639|NCT00745043|bronchodilator
1305640|NCT00745043|exercise capacity
1305641|NCT00745043|methacholine challenge
1305642|NCT00745030|Parkinson's disease
1305643|NCT00745030|Multiple Systems Atrophy
1305644|NCT00745030|Lewy Body Dementia
1305645|NCT00745017|recurrent depression
1305646|NCT00745017|major depressive disorder
1305647|NCT00745017|interpersonal therapy
1305648|NCT00745017|cognitive behavioral therapy
1305649|NCT00745017|antidepressant therapies
1305650|NCT00745017|outome predictors
1305651|NCT00745017|personality dimensions
1305652|NCT00745004|IBS D
1305653|NCT00744978|Efficacy
1305654|NCT00744978|Safety
1305655|NCT00744978|Pharmacokinetics
1305656|NCT00744978|Alzheimer's disease
1305657|NCT00744952|Large-vessel vasculitis
1305658|NCT00744939|Gadolinium
1305659|NCT00744939|NSF
1305660|NCT00744939|Renal Impairment
1305661|NCT00744939|chemically induced
1305662|NCT00744939|adverse effects
1305663|NCT00744939|Contrast Media
1305664|NCT00744939|complications
1305665|NCT00744913|Pregnancy
1305666|NCT00744913|Women
1305667|NCT00744913|Nicotine replacement therapy
1305668|NCT00744913|Smoking cessation
1305669|NCT00745836|insulin sensitivity
1305670|NCT00745823|HIV Infections
1305671|NCT00745823|Treatment Naïve
1305672|NCT00745810|cardiopulmonary bypass
1305673|NCT00745810|oxidative injuries
1305674|NCT00745797|nonsmall cell lung cancer
1305675|NCT00745797|brain metastasis
1305676|NCT00745797|prophylactic cranial irradiation
1305677|NCT00745784|Young Bereaved Spouses
1305678|NCT00745771|pharmacokinetics
1305679|NCT00745771|of Diractin®
1305680|NCT00745771|safety
1305681|NCT00745771|efficacy
1305682|NCT00745771|exercise
1305683|NCT00745758|SAH, vasospasm, ADMA
1305684|NCT00745732|Non-Small Cell Lung Cancer
1305685|NCT00745732|Lung Cancer
1305686|NCT00745732|NSCLC
1305687|NCT00745732|ZD6474
1305688|NCT00745732|ZACTIMA
1305689|NCT00745732|Vandetanib
1305690|NCT00745732|Inoperable NSCLC
1305691|NCT00745732|Unresectable NSCLC
1305692|NCT00745732|Radiation Therapy
1305693|NCT00745732|Palliative radiation therapy
1305694|NCT00745732|Angiogenesis
1305695|NCT00745719|parathyroidectomy
1305696|NCT00745719|cardiovascular
1305697|NCT00745719|bone
1305698|NCT00745719|endstage renal disease
1305699|NCT00745693|Endothelin
1305700|NCT00745693|Air pollution
1305701|NCT00745693|Diesel exhaust
1305702|NCT00745693|Vascular function
1305703|NCT00745693|exposure
1305704|NCT00745680|Left ventricular remodeling, acute myocardial infarction
1305705|NCT00745667|laparoscopic
1305706|NCT00745667|peptic ulcer
1305707|NCT00745654|Lung Transplantation
1305708|NCT00745654|Chronic pain
1305709|NCT00745654|Thoracotomy
1305710|NCT00745641|radiation injury
1305711|NCT00745641|computed tomography
1305712|NCT00745641|reactive oxygen species
1305713|NCT00745641|free radicals
1305714|NCT00745628|coronary heart disease
1305715|NCT00745628|secondary prevention
1305716|NCT00745602|direct current cardioversion, cerebral blood flow
1305717|NCT00745589|vascular,
1305718|NCT00745589|valvular calcification,
1305719|NCT00745589|phosphate binder,
1305720|NCT00745589|sevelamer,
1305721|NCT00745589|endstage renal disease
1305722|NCT00745589|peritoneal dialysis
1305723|NCT00745563|infertility
1305724|NCT00745563|insemination
1305725|NCT00745563|slow release
1305726|NCT00745550|SB1518
1305727|NCT00745550|Chronic Idiopathic Myelofibrosis
1305728|NCT00745550|Myeloproliferative disorders
1305729|NCT00745550|Polycythemia Vera
1305730|NCT00745550|Essential Thrombocythemia
1305731|NCT00745550|JAK2 inhibitor
1305732|NCT00745537|postpartum major depression
1305733|NCT00745537|adolescent mothers
1305734|NCT00745537|telephone depression care management
1305735|NCT00745537|barriers to depression care
1305736|NCT00745524|Attention-deficit hyperactivity disorder
1305737|NCT00745524|adolescent
1305738|NCT00745524|adult
1305739|NCT00745524|high risk population
1305740|NCT00745524|functional impairment
1305741|NCT00745524|quality of life
1305742|NCT00745511|AMD
1305743|NCT00745511|Avastin
1305744|NCT00745511|ORA102
1305745|NCT00745511|macular degeneration
1305746|NCT00745511|neo-vascular age related macular degeneration (AMD)
1305747|NCT00745498|Proliferative diabetic retinopathy
1305748|NCT00745498|vitrectomy
1305749|NCT00745498|bevacizumab
1305750|NCT00745498|vitreous hemorrhage
1305751|NCT00745485|Osteoporosis
1305752|NCT00745485|zoledronic acid
1305753|NCT00745485|postmenopausal women
1305754|NCT00745472|AEP
1305755|NCT00745472|experimental pain
1305756|NCT00745472|healthy volunteers
1305757|NCT00745459|Patients
1305758|NCT00745459|undergoing
1305759|NCT00745459|gastric
1305760|NCT00745459|endoscopy
1305761|NCT00745446|Air pollution
1305762|NCT00745446|Diesel exhaust
1305763|NCT00745446|Endothelial function
1305764|NCT00745446|Vascular function
1305765|NCT00745446|Particle trap
1305766|NCT00745446|Thrombosis
1305767|NCT00745446|effects
1305768|NCT00745446|inhalation
1305769|NCT00745420|Sickle Cell Disease
1305770|NCT00745420|Sickle Cell Anemia
1305771|NCT00745407|adipocytokines
1305772|NCT00745407|insulin sensitivity
1305773|NCT00745407|hypertriglyceridemic patients
1305774|NCT00745394|NIRS
1305775|NCT00745394|bypass
1305776|NCT00745394|cardiopulmonary
1305777|NCT00745394|CPB
1305778|NCT00745394|monitoring
1305779|NCT00745394|system
1305780|NCT00745381|PANCREAS
1305781|NCT00745381|STOMACH
1305782|NCT00745381|Questionnaire
1305783|NCT00745381|08-105
1305784|NCT00745368|HIV
1305785|NCT00745368|Raltegravir
1305786|NCT00745368|pharmacokinetics
1305787|NCT00745368|Treatment Experienced
1305788|NCT00745355|Quality of Life
1305789|NCT00745355|Questionnaires
1305790|NCT00745355|08-076
1305791|NCT00745342|type 1 diabetes
1305792|NCT00745342|glycemic control
1305793|NCT00745342|family conflict
1305794|NCT00745342|quality of life
1305795|NCT00745342|parental involvement
1305796|NCT00745316|Heart Failure
1305797|NCT00745316|Renal Insufficiency
1305798|NCT00745316|Congestive Heart Failure
1305799|NCT00745303|Tai Chi Chuan; Lipid; Cytokine
1305800|NCT00745290|Total knee arthroplasty
1305801|NCT00745290|Pain
1305802|NCT00745290|Analgesia
1305803|NCT00745277|carbidopa
1305804|NCT00745277|levodopa
1305805|NCT00745277|Parkinson's disease
1305806|NCT00745264|heat
1305807|NCT00745264|exercise
1305808|NCT00745251|Sleep apnea; obesity
1305809|NCT00745238|endothelial function
1305810|NCT00745238|peripheral arterial tone
1305811|NCT00745238|systemic inflammation
1305812|NCT00745238|oxidative stress
1305813|NCT00745238|respiratory and peripheral muscular function
1305814|NCT00745225|peritoneal dialysis, cardiovascular, PPAR-gamma
1305815|NCT00745212|venous thromboembolism diseases
1305816|NCT00745212|placental vascular pathologies
1305817|NCT00745212|antithrombotic treatment
1305818|NCT00745212|symptomatic thromboembolic events
1305819|NCT00745212|pregnant women
1305820|NCT00745212|score
1305821|NCT00745212|therapeutic strategies
1305822|NCT00745212|heparin
1305823|NCT00745212|aspirin
1305824|NCT00745212|pregnancy pathology
1305825|NCT00745199|End Stage Renal Disease
1305826|NCT00745199|Cromolyn Sodium
1305827|NCT00745199|Pruritus
1305828|NCT00745199|Tryptase
1305829|NCT00745160|Questionaires
1305830|NCT00745147|constipation
1305831|NCT00745147|traditional Chinese medicine
1305832|NCT00745147|Chinese herbal formula
1305833|NCT00745147|lactulose
1305834|NCT00745147|cost-effective
1305835|NCT00745147|long-term care
1305836|NCT00745134|Rectum
1305837|NCT00745134|Rectal Cancer
1305838|NCT00745134|Colon Cancer
1305839|NCT00745134|Curcumin
1305840|NCT00745134|Diferuloylmethane
1305841|NCT00745134|Capecitabine
1305842|NCT00745134|Radiation Therapy
1305843|NCT00745134|RT
1305844|NCT00745134|XRT
1305845|NCT00745134|Surgery for Rectal Cancer
1305846|NCT00744900|Pemetrexed, Non-Small Cell Lung Cancer, brain metastasis
1305847|NCT00744887|TMC114-TiDP3-C181
1305848|NCT00744887|TMC114-C181, health volunteers, Darunavir, ritonavir oral solution
1305849|NCT00744874|atrial fibrillation
1305850|NCT00744861|Lumbar Fusion
1305851|NCT00744861|exospine
1305852|NCT00744861|Exo-Spine
1305853|NCT00744848|hemorrhoids
1305854|NCT00744835|atrial fibrillation
1305855|NCT00744822|Lung Transplantation
1305856|NCT00744822|Infections
1305857|NCT00744822|Graft Rejection
1305858|NCT00744809|TMC278-C152
1305859|NCT00744809|TMC278-TiDP6-C152
1305860|NCT00744809|Healthy Volunteers
1305861|NCT00744809|QT/QTc interval
1305862|NCT00744796|Endothelial Dystrophy
1305863|NCT00744796|Fuchs' Endothelial Corneal Dystrophy
1305864|NCT00744770|TMC278-TiDP6-C121
1305865|NCT00744770|TMC278-C121
1305866|NCT00744770|open-label
1305867|NCT00744770|drug-drug interaction
1305868|NCT00744770|methadone
1305869|NCT00744770|TMC278
1305870|NCT00744757|5-aza-2'-deoxycytidine
1305871|NCT00744757|decitabine
1305872|NCT00744757|dacogen
1305873|NCT00744757|Myelodysplastic Syndrome
1305874|NCT00744744|stage 0 bladder cancer
1305875|NCT00744731|Partial-onset Seizures
1305876|NCT00744731|Simple Partial Seizures
1305877|NCT00744731|Complex Partial Seizures
1305878|NCT00744705|Retinal nerve fiber layer
1305879|NCT00744705|Glaucoma
1305880|NCT00744705|Myopia
1305881|NCT00744692|Immunodeficiencies
1305882|NCT00744692|Congenital Marrow Failures
1305883|NCT00744692|Hemoglobinopathies
1305884|NCT00744692|Inborn Errors of Metabolism
1305885|NCT00744692|SCIDS
1305886|NCT00744692|Wiskott Aldrich
1305887|NCT00744692|FEL
1305888|NCT00744692|HLH
1305889|NCT00744692|IPEX
1305890|NCT00744692|LAD
1305891|NCT00744692|Sickle Cell
1305892|NCT00744692|Thalassemia
1305893|NCT00744692|Omenn's Syndrome
1305894|NCT00744692|Hurler's Syndrome
1305895|NCT00744692|MLD
1305896|NCT00744692|ALD
1305897|NCT00744692|Sanfilippo
1305898|NCT00744692|Krabbe
1305899|NCT00744692|Hunter's syndrome
1305900|NCT00744692|TaySachs
1305901|NCT00744692|Diamond Blackfan Anemia
1305902|NCT00744692|transplant
1305903|NCT00744692|MPS
1305904|NCT00744692|Gaucher
1305905|NCT00744679|MS
1305906|NCT00744679|Multiple Sclerosis
1305907|NCT00744666|Intravitreal triamcinolone acetonide
1305908|NCT00744666|Side-effects
1305909|NCT00744666|Ocular hypertension
1305910|NCT00744666|Glaucoma
1305911|NCT00744666|Prevention
1305912|NCT00744666|Vitreoretinal diseases requiring IVTA for treatment
1305913|NCT00744653|Breast Cancer
1305914|NCT00744653|Recurrence
1305915|NCT00744640|advanced pancreatic cancer
1305916|NCT00744640|palliative chemotherapy
1305917|NCT00744640|first-line therapy
1305918|NCT00744640|capecitabine
1305919|NCT00744640|oxaliplatin
1305920|NCT00744640|gemcitabine
1305921|NCT00744640|dose-finding study
1305922|NCT00744640|Phase II
1305923|NCT00744627|Generalized Anxiety Disorder
1305924|NCT00744627|Anxiety Disorders
1305925|NCT00744627|Drug Therapy
1305926|NCT00744614|PC02
1305927|NCT00744614|Respiratory Rate
1305928|NCT00744614|Arterial blood gas
1305929|NCT00744614|Intubation
1305930|NCT00744614|Capnography
1305931|NCT00744601|impulsivity
1305932|NCT00744601|cocaine dependence
1305933|NCT00744601|relapse
1305934|NCT00744601|neuroimaging
1305935|NCT00744601|functional magnetic resonance imaging (fMRI)
1305936|NCT00744601|single photon emission computed tomography (SPECT)
1305937|NCT00744588|substance abuse
1305938|NCT00744588|alcohol dependence
1305939|NCT00744588|hypothalamic-pituitary-adrenal (HPA) system
1305940|NCT00744588|cosyntropin
1305941|NCT00744588|corticotropin-releasing Hormone (CRH)
1305942|NCT00744588|pituitary-adrenal system
1305943|NCT00744588|stress
1305944|NCT00744588|trauma
1305945|NCT00744588|neurosteroids
1305946|NCT00744588|cortisol
1305947|NCT00744588|relapse
1305948|NCT00744575|back pain
1305949|NCT00744575|eeg
1305950|NCT00744575|chronic pain
1305951|NCT00744562|Phase 1,
1305952|NCT00744562|dose escalation,
1305953|NCT00744562|histologically
1305954|NCT00744562|confirmed
1305955|NCT00744562|malignancy
1305956|NCT00744562|metastatic
1305957|NCT00744549|Male Urogenital Diseases
1305958|NCT00744549|Antioxidants
1305959|NCT00744549|Vitamin E
1305960|NCT00744549|Vitamin D
1305961|NCT00744549|Lycopene
1305962|NCT00744549|Selenium
1305963|NCT00744536|Myelodysplastic syndrome
1305964|NCT00744536|Chronic myelomonocytic leukemia
1305965|NCT00744536|High intermediate risk and high risk IPSS score
1305966|NCT00744536|Angiogenesis
1305967|NCT00744536|Metronomic chemotherapy
1305968|NCT00744536|Myelodysplastic Myeloproliferative Diseases
1305969|NCT00744523|carotid artery stenting
1305970|NCT00744523|stroke
1305971|NCT00744523|cerebral protection
1305972|NCT00744523|high surgical risk
1305973|NCT00744510|Polycystic Ovary Syndrome
1305974|NCT00744510|Reflexology
1305975|NCT00744510|Complementary and Alternative Medicine
1305976|NCT00744510|Endocrinopathy
1305977|NCT00744510|Oligo
1305978|NCT00744510|Amenorrhoea
1305979|NCT00744484|Chronic Obstructive Pulmonary Disease
1305980|NCT00744484|COPD
1305981|NCT00744484|Physical group training
1305982|NCT00744484|Water exercise
1305983|NCT00744484|Cardiorespiratory fitness
1305984|NCT00744484|Functional exercise capacity
1305985|NCT00744484|Health related quality of life
1305986|NCT00744471|monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth OA
1305987|NCT00744458|Primary Health care in rural Africa
1305988|NCT00744458|Chronic non-communicable diseases
1305989|NCT00744458|Patient Compliance
1305990|NCT00744458|Treatment adherence
1305991|NCT00744445|hemodialysis
1305992|NCT00744445|erythropoietin
1305993|NCT00744419|GERD
1305994|NCT00744419|pharmacokinetics
1305995|NCT00744419|pantoprazole
1305996|NCT00744419|neonates
1305997|NCT00744419|infants
1305998|NCT00744406|recurrent depression
1305999|NCT00744406|major depressive disorder
1306000|NCT00744406|interpersonal therapy
1306001|NCT00744406|cognitive behavioral therapy
1306002|NCT00744406|antidepressant treatment
1306003|NCT00744406|outcome predictors
1306004|NCT00744406|personality dimensions
1306005|NCT00744393|sleep
1306006|NCT00744393|critically ill
1306007|NCT00744393|mechanical ventilation
1306008|NCT00744380|Analgesia
1306009|NCT00744380|Mechanical ventilation
1306010|NCT00744354|refractory multiple myeloma
1306011|NCT00744354|stage I multiple myeloma
1306012|NCT00744354|stage II multiple myeloma
1306013|NCT00744354|stage III multiple myeloma
1306014|NCT00744341|SLV320; Acute Decompensated Heart Failure (ADHF); chronic heart failure; renal failure; I.V. doses; hospitalization
1306015|NCT00744328|Postpartum depression
1306016|NCT00744328|estradiol
1306017|NCT00744328|Postpartum major depressive disorder
1306018|NCT00744315|myocardial revascularization
1306019|NCT00744315|myocardial ischemia
1306020|NCT00744315|genetics, medical
1306021|NCT00744315|Angiogenesis Inducing Agents
1306022|NCT00744302|Dialysate calcium
1306023|NCT00744302|Mineral metabolism
1306024|NCT00744302|Parathyroid hormone
1306025|NCT00744302|Calcification
1306026|NCT00744302|Cardiovascular disease
1306027|NCT00744302|Haemodialysis
1306028|NCT00744289|Hepatitis B
1306029|NCT00744289|People who inject drugs
1306030|NCT00744289|Financial incentive
1306031|NCT00744289|Vaccine completion
1306032|NCT00744276|fibrocystic breast disease
1306033|NCT00744276|fibrocystic disease of breast
1306034|NCT00744276|breast pain
1306035|NCT00744276|mastalgia
1306036|NCT00744276|cyclic mastalgia
1306037|NCT00744276|cystic breast disease
1306038|NCT00744250|Exocrine Pancreatic Insufficiency
1306039|NCT00744250|Chronic Pancreatitis
1306040|NCT00744250|Cystic fibrosis
1306041|NCT00744250|Pancrelipase
1306042|NCT00744250|Pancrecarb
1306043|NCT00744250|Intraduodenal aspiration
1306044|NCT00744250|Bioavailability
1306045|NCT00744237|nebivolol
1306046|NCT00744237|Bystolic ™
1306047|NCT00744237|Hypertension
1306048|NCT00744237|Diabetes
1306049|NCT00744198|Autologous
1306050|NCT00744198|Biological
1306051|NCT00744198|Mesh
1306052|NCT00744198|Polypropylene
1306053|NCT00744198|Sling
1306054|NCT00744198|Synthetic
1306055|NCT00744198|Stress incontinence
1306056|NCT00744198|Surgery
1306057|NCT00744198|TOT
1306058|NCT00744198|Treatment
1306059|NCT00744185|infantile capillary hemangiomas
1306060|NCT00744185|propranolol
1306061|NCT00744185|ultrasonography
1306062|NCT00744172|hysterectomy
1306063|NCT00744172|vaginal
1306064|NCT00744172|laparoscopy
1306065|NCT00744172|abdominal
1306066|NCT00744172|complication
1306067|NCT00744172|quality of life
1306068|NCT00744172|cost-effectiveness
1306069|NCT00744172|Morbidity of three types of hysterectomy
1306070|NCT00744159|colon cancer
1306071|NCT00744159|laparoscopic colorectal surgery
1306072|NCT00744159|cellular immunity
1306073|NCT00744159|HLA-DR expression on monocyte
1306074|NCT00744133|Plasmodium falciparum, NF54, Anopheles stephensi, mosquito, malaria
1306075|NCT00744120|cancer
1306076|NCT00744107|Ischemic coronary artery disease in native coronary arteries
1306077|NCT00744107|Single stent
1306078|NCT00744107|RVD 2.5- 4.0mm
1306079|NCT00744107|Lesion length up to 26mm
1306080|NCT00744107|de novo or previously unstented lesions
1306081|NCT00744094|resistance training
1306082|NCT00744094|protein supplementation
1306083|NCT00744094|hypertrophy
1306084|NCT00744068|Stimulant
1306085|NCT00744068|Drug treatment
1306086|NCT00744068|Continuing care
1306087|NCT00744068|Telephone support
1306088|NCT00744068|Aftercare
1306089|NCT00744055|alcohol dependence
1306090|NCT00744055|post traumatic stress disorder
1306091|NCT00744055|treatment
1306092|NCT00744055|prazosin
1306093|NCT00744042|Hypophosphatasia
1306094|NCT00744042|HPP
1306095|NCT00744042|Bone Disease
1306096|NCT00744042|Soft Bones
1306097|NCT00744042|Low Alkaline Phosphatase
1306098|NCT00744042|genetic metabolic disorder
1306099|NCT00744042|alkaline phosphatase
1306100|NCT00744042|tissue non-specific alkaline phosphatase
1306101|NCT00744042|rickets
1306102|NCT00744042|osteomalacia
1306103|NCT00744029|prehospital delays
1306104|NCT00744029|intervention
1306105|NCT00744029|population-based
1306106|NCT00744029|stroke
1306107|NCT00744016|UC
1306108|NCT00744016|Ulcerative colitis
1306109|NCT00744016|IBD
1306110|NCT00744016|Inflammatory bowel disease
1306111|NCT00743990|Cough symptoms
1306112|NCT00743990|Cold symptoms
1306113|NCT00743990|Congestion
1306114|NCT00743990|Children
1306115|NCT00743990|URI
1306116|NCT00743990|Alternative cough symptom treatment
1306117|NCT00743951|patient decision aids
1306118|NCT00743951|patient preferences
1306119|NCT00743951|osteoarthritis
1306120|NCT00743951|joint replacement
1306121|NCT00743951|waiting times
1306122|NCT00743925|Unstable Angina
1306123|NCT00743925|STEMI
1306124|NCT00743925|NSTEMI
1306125|NCT00743925|ACS
1306126|NCT00743925|Acute Coronary Syndrome
1306127|NCT00743925|C14.280.647.124
1306128|NCT00743925|C14.280.647.500
1306129|NCT00743912|rifaximin
1306130|NCT00743912|midazolam
1306131|NCT00743912|pharmacokinetics
1306132|NCT00743899|Angioplasty, Transluminal, Percutaneous Coronary
1306133|NCT00743899|Everolimus-eluting stent
1306134|NCT00743873|medial retinaculum tear s/p patella dislocation
1306135|NCT00743860|darapladib
1306136|NCT00743860|pharmacokinetics
1306137|NCT00743860|metabolite
1306138|NCT00743860|SB-480848
1306139|NCT00743847|schizophrenia, treatment, cognition
1306140|NCT00743808|hypertension
1306141|NCT00743808|diabetes
1306142|NCT00743808|quality improvement
1306143|NCT00743808|blood pressure
1306144|NCT00743795|Hepatitis C
1306145|NCT00743795|HCV
1306146|NCT00743795|Rapid Virologic Response
1306147|NCT00743795|Sustained Virologic Response
1306148|NCT00743795|HCV RNA
1306149|NCT00743795|Polymerase inhibitor
1306150|NCT00743795|GS-9190
1306151|NCT00743782|Hypoparathyroidism
1306152|NCT00743782|Parathyroid Hormone 1-34
1306153|NCT00743769|Myocardial Infarction
1306154|NCT00743769|Myocardial Ischemia
1306155|NCT00743769|Myocardial Diseases
1306156|NCT00743769|Infarction
1306157|NCT00743756|obesity
1306158|NCT00743756|diabetes
1306159|NCT00743756|endothelial function
1306160|NCT00743756|insulin sensitivity
1306161|NCT00743743|dementia
1306162|NCT00743743|Alzheimer disease
1306163|NCT00743743|cognition
1306164|NCT00743743|function
1306165|NCT00743743|behavior
1306166|NCT00743743|treatment
1306167|NCT00743730|developmental delay
1306168|NCT00743730|cognitive impairment
1306169|NCT00743730|pain control
1306170|NCT00743730|post operative pain
1306171|NCT00743730|opioid
1306172|NCT00743730|pain assessment
1306173|NCT00743730|Parent Nurse controlled Analgesic
1306174|NCT00743730|patient controlled analgesic
1306175|NCT00743730|children
1306176|NCT00743730|pain
1306177|NCT00743730|analgesic
1306178|NCT00743730|safety
1306179|NCT00743730|parent satisfaction
1306180|NCT00743730|nurse satisfaction
1306181|NCT00743730|Pediatric
1306182|NCT00743717|total knee arthroplasty
1306183|NCT00743717|osteoarthritis
1306184|NCT00743717|ceramic bearing
1306185|NCT00743717|zirconia
1306186|NCT00743691|Ethiopia
1306187|NCT00743691|Community
1306188|NCT00743691|Community based
1306189|NCT00743691|Health extension Worker
1306190|NCT00743691|Health Extension Program
1306191|NCT00743678|Colorectal Cancer
1306192|NCT00743678|Unresectable liver metastasis
1306193|NCT00743678|FOLFOX6
1306194|NCT00743678|Cetuximab
1306195|NCT00743678|Neoadjuvant therapy
1306196|NCT00743665|Youth
1306197|NCT00743665|consensus
1306198|NCT00743665|criteria
1306199|NCT00743665|CVS
1306200|NCT00743652|13 valent Pneumococcal Conjugate Vaccine
1306201|NCT00743652|Antibody Response
1306202|NCT00743652|safety
1306203|NCT00743652|Alaskan Native Children
1306204|NCT00743639|Cardiomyopathy
1306205|NCT00743639|stem cell
1306206|NCT00743639|cardiac failure
1306207|NCT00743626|Pap test
1306208|NCT00743626|HPV
1306209|NCT00743626|Healthy patients screened for cervical cancer tests.
1306210|NCT00743613|Erectile Dysfunction
1306211|NCT00743613|ED
1306212|NCT00743613|Peripheral Arterial Disease
1306213|NCT00743613|PAD
1306214|NCT00743613|Ankle-Brachial Index
1306215|NCT00743613|ABI
1306216|NCT00743600|ultrasound
1306217|NCT00743600|rotator cuff
1306218|NCT00743561|MSA
1306219|NCT00743561|sleep apnea
1306220|NCT00743561|ambulatory polygraphy
1306221|NCT00743561|polysomnography
1306222|NCT00743548|interdental self-care aids
1306223|NCT00743548|plaque
1306224|NCT00743548|bleeding gums
1306225|NCT00743535|Cystocele
1306226|NCT00743535|Mesh
1306227|NCT00743535|Prolapse
1306228|NCT00743535|Sling
1306229|NCT00743535|Stress incontinence
1306230|NCT00743535|Surgery
1306231|NCT00743535|TOT
1306232|NCT00743535|TVT
1306233|NCT00743535|Treatment
1306234|NCT00743522|Reducing shocks
1306235|NCT00743509|sarcoma
1306236|NCT00743509|Cyclophosphamide
1306237|NCT00743509|Sirolimus
1306238|NCT00743509|Progressive or recurrent, advanced (unresectable or metastatic) high-grade osteosarcoma, Ewing's or soft tissue sarcoma previously treated with chemotherapy.
1306239|NCT00743483|cystic fibrosis
1306240|NCT00743483|pancreatic insufficiency
1306241|NCT00743483|bucelipase alfa
1306242|NCT00743483|bile salt stimulating lipase
1306243|NCT00743483|BSSL
1306244|NCT00743483|coefficient of fat absorption
1306245|NCT00743470|HIV co-infected with tuberculosis
1306246|NCT00743457|Possible VPS failure with symptom such as headache
1306247|NCT00743457|vomiting
1306248|NCT00743457|lethargy
1306249|NCT00743457|VPS failure
1306250|NCT00743444|GERD
1306251|NCT00743444|transient lower esophageal sphincter relaxations (TLESRs)
1306252|NCT00743444|reflux
1306253|NCT00743405|M1 receptor agonist
1306254|NCT00743405|schizophrenia
1306255|NCT00743405|GSK1034702
1306256|NCT00743405|safety
1306257|NCT00743405|pharmacokinetics
1306258|NCT00743379|Phase 1/2
1306259|NCT00743379|Advanced Solid Tumors
1306260|NCT00743379|Hypoxia
1306261|NCT00743379|Prodrug
1306262|NCT00743379|Dose-Escalation
1306263|NCT00743379|Evofosfamide
1306264|NCT00743366|quetiapine
1306265|NCT00743366|smoked marijuana
1306266|NCT00743366|marijuana use
1306267|NCT00743353|laryngeal
1306268|NCT00743353|squamous cell
1306269|NCT00743353|anaplastic astrocytoma
1306270|NCT00743353|oligodendroglioma
1306271|NCT00743353|glioblastoma multiforme
1306272|NCT00743340|HIV-1 infection
1306273|NCT00743340|emtricitabine
1306274|NCT00743340|pediatrics
1306275|NCT00743340|pediatric patients
1306276|NCT00743327|hormone therapy
1306277|NCT00743314|lymphedema
1306278|NCT00743314|stage I breast cancer
1306279|NCT00743314|stage II breast cancer
1306280|NCT00743301|CVD
1306281|NCT00743301|Palm olein
1306282|NCT00743301|Olive oil
1306283|NCT00743301|Lard
1306284|NCT00743301|healthy men
1306285|NCT00743301|metabolic syndrome
1306286|NCT00743301|Risk of cardiovascular disease and metabolic syndrome
1306287|NCT00743288|stage I multiple myeloma
1306288|NCT00743288|stage II multiple myeloma
1306289|NCT00743288|stage III multiple myeloma
1306290|NCT00743288|refractory multiple myeloma
1306291|NCT00743275|Influenza
1306292|NCT00743262|laryngectomy
1306293|NCT00743262|larynx cancer
1306294|NCT00743249|Dry eye
1306295|NCT00743249|Tear duct
1306296|NCT00743249|Punctal plug
1306297|NCT00743236|perioperative/postoperative complications
1306298|NCT00743236|urinary complications
1306299|NCT00743236|long-term effects secondary to cancer therapy in adults
1306300|NCT00743236|stage I renal cell cancer
1306301|NCT00743223|temporomandibular disorder
1306302|NCT00743223|orofacial pain
1306303|NCT00743223|posture of the head
1306304|NCT00743210|pregnancy
1306305|NCT00743210|obesity
1306306|NCT00743210|asymmetric dimethylarginine
1306307|NCT00743210|L-arginine
1306308|NCT00743210|L-citrulline
1306309|NCT00743197|coronary artery disease (CAD)
1306310|NCT00743197|chest pain
1306311|NCT00743197|myocardial ischemia
1306312|NCT00743197|endothelial function
1306313|NCT00743184|BPH
1306314|NCT00743184|LUTS
1306315|NCT00743184|Lower urinary tract symptoms (LUTS)
1306316|NCT00743171|Lung transplantation
1306317|NCT00743171|Home spirometry
1306318|NCT00743171|non-adherence
1306319|NCT00743171|outcomes
1306320|NCT00743171|bronchiolitis obliterans
1306321|NCT00743158|ztr
1306322|NCT00743158|transfer impedance
1306323|NCT00743158|cystic fibrosis
1306324|NCT00743158|pulmonary function test
1306325|NCT00743158|pft
1306326|NCT00743145|naltrexone
1306327|NCT00743145|smoked marijuana
1306328|NCT00743145|marijuana use
1306329|NCT00743132|evaluation
1306330|NCT00743132|incidence
1306331|NCT00743132|liver surgery
1306332|NCT00743132|resection
1306333|NCT00743132|impact
1306334|NCT00743132|postoperative
1306335|NCT00743132|mortality
1306336|NCT00743119|oral thc
1306337|NCT00743119|smoked marijuana
1306338|NCT00743119|pain
1306339|NCT00743119|analgesic effects
1306340|NCT00743106|nephrectomy
1306341|NCT00743106|fenoldopam
1306342|NCT00743106|atrophic minimally functioning kidney
1306343|NCT00743093|acetaminophen
1306344|NCT00743093|protein adducts
1306345|NCT00743093|drug safety
1306346|NCT00743093|alanine aminotransferase
1306347|NCT00743093|Alanine Amino Transferase
1306348|NCT00743080|laparoscopy
1306349|NCT00743080|myomectomy
1306350|NCT00743080|myomas
1306351|NCT00743080|morcellator
1306352|NCT00743080|supracervical hysterectomy
1306353|NCT00743080|surgery
1306354|NCT00743080|symptomatic uterine myomas
1306355|NCT00743067|XL880
1306356|NCT00743067|MET inhibitor
1306357|NCT00743067|GSK1363089
1306358|NCT00743067|Solid Tumors
1306359|NCT00743067|c-Met
1306360|NCT00743054|Carcinoma, Renal Cell
1306361|NCT00743054|MicroRNAs
1306362|NCT00743041|PTSD, EFT, depression, anxiety, telephone
1306363|NCT00743028|Other hematological and non-hematological malignancies
1306364|NCT00743002|TT223
1306365|NCT00742989|osteopathic
1306366|NCT00742989|lymphatic
1306367|NCT00742989|treatment
1306368|NCT00742989|OLT
1306369|NCT00742989|normal
1306370|NCT00742976|Weight gain in insulin treated type 2 diabetes
1306371|NCT00742976|extracellular volume
1306372|NCT00742976|insulin treatment
1306373|NCT00742976|sodium retention
1306374|NCT00742963|TH-302
1306375|NCT00742963|Advanced Soft Tissue Sarcoma
1306376|NCT00742963|Doxorubicin
1306377|NCT00742963|Phase 1/2
1306378|NCT00742950|Corneal incision
1306379|NCT00742950|Cataract surgery
1306380|NCT00742950|Phacoemulsification
1306381|NCT00742950|Surgically induced astigmatism
1306382|NCT00742950|Corneal Topography
1306383|NCT00742937|Hypovitaminosis A
1306384|NCT00742924|metastatic osteosarcoma
1306385|NCT00742911|Solid Tumors, Liver
1306386|NCT00742898|Quasi-experimental design
1306387|NCT00742898|Non-targeted opt-out rapid HIV screening
1306388|NCT00742898|Diagnostic rapid HIV testing
1306389|NCT00742898|Emergency department
1306390|NCT00742898|Effectiveness
1306391|NCT00742898|Efficiency
1306392|NCT00742898|Health services research
1306393|NCT00742898|Program evaluation
1306394|NCT00742898|Effectiveness and efficiency of non-targeted rapid HIV screening in the ED
1306395|NCT00742885|Immunogenicity
1306396|NCT00742885|Safety
1306397|NCT00742885|Pandemic Influenza
1306398|NCT00742872|Mosapride
1306399|NCT00742872|Irritable Bowel Syndrome
1306400|NCT00742872|Constipation
1306401|NCT00742859|Atrial Fibrillation
1306402|NCT00742859|Betrixaban
1306403|NCT00742859|Factor Xa inhibitor
1306404|NCT00742859|Warfarin
1306405|NCT00742846|Adhesive Capsulitis
1306406|NCT00742846|Subacromial injection
1306407|NCT00742846|Intraarticular injection
1306408|NCT00742833|Overactive bladder
1306409|NCT00742833|Frequency
1306410|NCT00742833|Micturition
1306411|NCT00742833|Urgency
1306412|NCT00742833|Urge urinary incontinence
1306413|NCT00742833|β3-agonist
1306414|NCT00742820|bioequivalence
1306415|NCT00742807|sensation
1306416|NCT00742807|relief
1306417|NCT00742807|during
1306418|NCT00742807|surgery
1306419|NCT00742781|Crohn's
1306420|NCT00742781|vitamin D
1306421|NCT00742768|absorption
1306422|NCT00742768|encapsulation
1306423|NCT00742768|menaquinone
1306424|NCT00742768|Bio-availability
1306425|NCT00742755|Follow-up of breast abnormalities
1306426|NCT00742755|Korean American immigrants
1306427|NCT00742742|Walnut
1306428|NCT00742742|Lipids
1306429|NCT00742742|Blood Glucose
1306430|NCT00742729|Colorectal cancer screening
1306431|NCT00742729|Fecal occult blood test
1306432|NCT00742729|Endoscopies
1306433|NCT00742729|Filipino American immigrants
1306434|NCT00742729|Community based organizations and churches
1306435|NCT00742716|Parathyroid Diseases
1306436|NCT00742716|Renal Insufficiency
1306437|NCT00742716|Kidney Failure, Chronic
1306438|NCT00742716|Hyperparathyroidism, Secondary
1306439|NCT00742716|Vitamin D
1306440|NCT00742716|Hyperparathyroidism
1306441|NCT00742716|Renal Insufficiency, Chronic
1306442|NCT00742716|Kidney Diseases
1306443|NCT00742716|Kidney Failure
1306444|NCT00742690|cirrhosis
1306445|NCT00742690|type 1 hepatorenal syndrome
1306446|NCT00742690|terlipressin
1306447|NCT00742690|albumin
1306448|NCT00742690|effective circulating volume
1306449|NCT00742690|Patients
1306450|NCT00742690|with
1306451|NCT00742677|female reproductive cancer
1306452|NCT00742664|Prader-Willi Syndrome
1306453|NCT00742664|Compulsive behavior
1306454|NCT00742664|Hoarding
1306455|NCT00742664|Obsessive-compulsive disorder
1306456|NCT00742664|Children
1306457|NCT00742664|Treatment
1306458|NCT00742664|genetically
1306459|NCT00742664|confirmed
1306460|NCT00742664|diagnosis
1306461|NCT00742638|CCMD-3,
1306462|NCT00742638|CRF,
1306463|NCT00742638|EPS,
1306464|NCT00742638|GCP,
1306465|NCT00742638|ICH,
1306466|NCT00742638|ITT,
1306467|NCT00742638|LOCF,
1306468|NCT00742638|MADRS,
1306469|NCT00742638|PANSS,
1306470|NCT00742638|YMRS.
1306471|NCT00742638|Acute
1306472|NCT00742638|manic
1306473|NCT00742638|patients
1306474|NCT00742638|with
1306475|NCT00742638|bipolar
1306476|NCT00742638|disorder
1306477|NCT00742612|Carotid Endarterectomy
1306478|NCT00742612|von Willebrand Factor
1306479|NCT00742612|Microembolic Signal
1306480|NCT00742599|Stomach Diseases
1306481|NCT00742586|Gene Expression Changes in Blood Cells
1306482|NCT00742586|RNA
1306483|NCT00742586|Pure Autonomic Failure
1306484|NCT00742586|Multiply System Atrophy
1306485|NCT00742586|Parkinson's Plus
1306486|NCT00742573|Major Depressive Disorder
1306487|NCT00742573|Mood Disorders
1306488|NCT00742573|Hispanic
1306489|NCT00742560|Multiple Myeloma
1306490|NCT00742547|prevention
1306491|NCT00742547|health services research
1306492|NCT00742534|Bronchopulmonary Dysplasia
1306493|NCT00742534|Prematurity
1306494|NCT00742534|Lung Disease
1306495|NCT00742534|preterm infants
1306496|NCT00742521|cortisol
1306497|NCT00742521|catecholamines
1306498|NCT00742521|Type 1 DM
1306499|NCT00742508|carvedilol phosphate
1306500|NCT00742508|ß-blocker
1306501|NCT00742508|SK&F-105517-D
1306502|NCT00742508|Chronic heart failure(CHF)
1306503|NCT00742469|TD
1306504|NCT00742469|traveller's diarrhea
1306505|NCT00742469|campylobacter
1306506|NCT00742469|shigella
1306507|NCT00742469|salmonella
1306508|NCT00742469|E. coli
1306509|NCT00742469|diarrhea
1306510|NCT00742456|Microcirculation
1306511|NCT00742456|Insulin
1306512|NCT00742456|Hypertension
1306513|NCT00742456|Obesity
1306514|NCT00742443|Scar Revision
1306515|NCT00742430|aspirin resistance
1306516|NCT00742430|coronary artery disease
1306517|NCT00742430|clopidogrel resistance
1306518|NCT00742430|major adverse cardiac events
1306519|NCT00742430|multiplate platelet function analyser
1306520|NCT00742430|percutaneous coronary intervention
1306521|NCT00742417|Alzheimer's
1306522|NCT00742417|Dementia
1306523|NCT00742417|Senile
1306524|NCT00742417|Loss of cognitive abilities
1306525|NCT00742417|Old age
1306526|NCT00742417|Elderly
1306527|NCT00742417|Aging
1306528|NCT00742417|Albumin
1306529|NCT00742417|Caregiver
1306530|NCT00742417|amyloid
1306531|NCT00742417|beta amyloid
1306532|NCT00742417|Central Nervous System Diseases
1306533|NCT00742417|Brain Disease
1306534|NCT00742417|Mental Disorders
1306535|NCT00742417|Plasma Exchange
1306536|NCT00742404|stage I multiple myeloma
1306537|NCT00742404|stage II multiple myeloma
1306538|NCT00742404|stage III multiple myeloma
1306539|NCT00742391|Peplin
1306540|NCT00742391|Actinic keratosis
1306541|NCT00742391|PEP005
1306542|NCT00742378|Glaucoma
1306543|NCT00742378|Retinal nerve fiber layer
1306544|NCT00742378|Cirrus OCT
1306545|NCT00742365|Seasonal Affective Disorder
1306546|NCT00742365|Light Therapy
1306547|NCT00742365|Seasonal Depression
1306548|NCT00742365|Psychiatric Disorder
1306549|NCT00742365|Bright Light
1306550|NCT00742365|Major Depressive Disorder
1306551|NCT00742365|Bipolar Disorder
1306552|NCT00742339|cirrhosis
1306553|NCT00742339|hepatorenal syndrome
1306554|NCT00742339|terlipressin
1306555|NCT00742339|midodrine
1306556|NCT00742339|octreotide
1306557|NCT00742339|human albumin
1306558|NCT00742339|effective circulating volume
1306559|NCT00742339|The criteria which will be used for the diagnosis of HRS will be the criteria which were recently published by the International Ascites Club
1306560|NCT00742339|Patients with cirrhosis and type 2 HRS only with serum creatinine value > 2.5 mg/dl
1306561|NCT00742339|All patients with cirrhosis and type 1 HRS
1306562|NCT00742326|HIV
1306563|NCT00742326|Hepatitis C
1306564|NCT00742326|Liver Disease
1306565|NCT00742326|Fatty Liver
1306566|NCT00742326|Steatosis
1306567|NCT00742313|Endoscopic
1306568|NCT00742313|saphenous
1306569|NCT00742313|vein
1306570|NCT00742313|harvest
1306571|NCT00742300|ASCT
1306572|NCT00742300|Tolerance induction
1306573|NCT00742300|SLE
1306574|NCT00742300|Transplantation
1306575|NCT00742300|Autoimmune diseases
1306576|NCT00742287|smoking
1306577|NCT00742287|oligomeric proanthocyanidins
1306578|NCT00742287|polyphenols
1306579|NCT00742287|supplementation
1306580|NCT00742287|vascular function
1306581|NCT00742287|oxidative stress
1306582|NCT00742287|inflammation
1306583|NCT00742261|Pharmacokinetics
1306584|NCT00742261|Safety
1306585|NCT00742261|MET
1306586|NCT00742261|Bioavailability
1306587|NCT00742261|Patients
1306588|NCT00742261|GSK1363089A
1306589|NCT00742261|GSK1363089G
1306590|NCT00742261|GSK1363089
1306591|NCT00742261|Relative
1306592|NCT00742248|COPD
1306593|NCT00742222|Electronic brachytherapy registry
1306594|NCT00742222|Multi-society registry
1306595|NCT00742222|Breast cancer registry
1306596|NCT00742209|migraine
1306597|NCT00742209|prophylaxis
1306598|NCT00742209|prevention
1306599|NCT00742196|Parapapillary atrophy
1306600|NCT00742196|Retinal nerve fiber layer thickness
1306601|NCT00742196|Glaucoma
1306602|NCT00742196|Cirrus OCT
1306603|NCT00742170|opioid dependence
1306604|NCT00742170|opioid detoxification
1306605|NCT00742170|electroacupuncture
1306606|NCT00742170|adjunctive treatment
1306607|NCT00742170|alternative/complementary medicine
1306608|NCT00742157|Growth Hormone
1306609|NCT00742157|TPN
1306610|NCT00742157|Total Parenteral Nutrition
1306611|NCT00742157|Glutamine
1306612|NCT00742157|Short Bowel Syndrome
1306613|NCT00742157|Increase in absorption of small bowel.
1306614|NCT00742144|CD20 positive
1306615|NCT00742144|Chronic lymphocytic leukemia
1306616|NCT00742144|Follicular lymphoma
1306617|NCT00742144|GSK1841157
1306618|NCT00742144|Japanese patient
1306619|NCT00742144|Ofatumumab
1306620|NCT00742131|MET inhibitor
1306621|NCT00742131|c-Met
1306622|NCT00742131|XL880
1306623|NCT00742131|GSK1363089
1306624|NCT00742131|Solid Tumors
1306625|NCT00742105|PI3K
1306626|NCT00742105|mTOR
1306627|NCT00742105|Advanced solid tumor
1306628|NCT00742105|Adult
1306629|NCT00742079|Paranoid Schizophrenia
1306630|NCT00742079|Paranoid Delusions
1306631|NCT00742079|CBT
1306632|NCT00742079|D-Cycloserine
1306633|NCT00742066|Hypertension
1306634|NCT00742066|Insulin resistance
1306635|NCT00742066|Microcirculation
1306636|NCT00742066|Angiotensin II receptor blocker
1306637|NCT00742053|ECG PICC
1306638|NCT00742053|Patients undergoing PICC placement
1306639|NCT00742040|up-titration
1306640|NCT00742040|captopril
1306641|NCT00742040|pediatric
1306642|NCT00742040|cardiac patients
1306643|NCT00742027|Classical Hodgkin Lymphoma
1306644|NCT00742027|Classical Hodgkin's Lymphoma
1306645|NCT00742027|Hodgkin Lymphoma
1306646|NCT00742027|Hodgkin's Lymphoma
1306647|NCT00742027|Nodular sclerosing
1306648|NCT00742027|Mixed-cellularity
1306649|NCT00742027|Lymphocyte-rich
1306650|NCT00742027|Lymphocyte depleted
1306651|NCT00742027|HL
1306652|NCT00742027|Classical HL
1306653|NCT00742027|Refractory Hodgkin's Lymphoma
1306654|NCT00742027|Refractory Hodgkin Lymphoma
1306655|NCT00742027|Refractory HL
1306656|NCT00742014|Pulmonary arterial hypertension
1306657|NCT00742014|Pediatrics
1306658|NCT00742014|Sildenafil
1306659|NCT00742014|Catheterization
1306660|NCT00742014|Right ventricular contractility
1306661|NCT00742001|red blood cells
1306662|NCT00742001|transfusion
1306663|NCT00742001|recovery
1306664|NCT00742001|feasibility
1306665|NCT00742001|white blood cell inactivation
1306666|NCT00741988|Non-Small Cell Lung Cancer
1306667|NCT00741988|Advanced Disease
1306668|NCT00741988|Untreated
1306669|NCT00741988|Ixabepilone
1306670|NCT00741988|Carboplatin
1306671|NCT00741988|Bevacizumab
1306672|NCT00741975|HIV prevention
1306673|NCT00741949|Respiratory failure
1306674|NCT00741949|Target Controlled Infusion
1306675|NCT00741949|TCI
1306676|NCT00741949|Propofol
1306677|NCT00741949|Noninvasive ventilation
1306678|NCT00741949|Broncho-alveolar lavage
1306679|NCT00741936|Functional Constipation
1306680|NCT00741936|Chinese Herbal Medicine
1306681|NCT00741936|MaZiRenWan
1306682|NCT00741936|Hemp Seed Pill
1306683|NCT00741936|Traditional Chinese Medicine
1306684|NCT00741936|Herbal Medicine
1306685|NCT00741923|beans
1306686|NCT00741923|pulses
1306687|NCT00741923|satiety
1306688|NCT00741923|appetite
1306689|NCT00741923|obesity
1306690|NCT00741923|overweight
1306691|NCT00741923|diabetes
1306692|NCT00741923|metabolic syndrome
1306693|NCT00741923|hypertension
1306694|NCT00741923|blood glucose
1306695|NCT00741923|insulin
1306696|NCT00741923|cholesterol
1306697|NCT00741923|HDL
1306698|NCT00741923|LDL
1306699|NCT00741923|leptin
1306700|NCT00741923|GLP-1
1306701|NCT00741923|adiponectin
1306702|NCT00741923|Peptide YY
1306703|NCT00741923|diet
1306704|NCT00741910|Crohn's Disease
1306705|NCT00741910|TNF-alpha inhibitor
1306706|NCT00741910|MAP Kinase inhibitor
1306707|NCT00741910|CNI-1493
1306708|NCT00741871|Lymphoid malignancies
1306709|NCT00741871|Hodgkin's Lymphoma
1306710|NCT00741871|Diffuse large B cell lymphoma
1306711|NCT00741858|Chiari malformation;
1306712|NCT00741858|Duraplasty;
1306713|NCT00741858|Posterior fossa decompression;
1306714|NCT00741858|Duragen;
1306715|NCT00741858|Duraguard
1306716|NCT00741832|chronic obstructive pulmonary disease
1306717|NCT00741832|dynamic hyperinflation
1306718|NCT00741832|dyspnea
1306719|NCT00741832|recovery
1306720|NCT00741832|positive expiratory pressure
1306721|NCT00741832|exercise
1306722|NCT00741819|pulmonary arterial hypertension
1306723|NCT00741819|PAH
1306724|NCT00741819|treprostinil sodium
1306725|NCT00741819|inhalation
1306726|NCT00741819|ventavis
1306727|NCT00741819|iloprost
1306728|NCT00741806|vaccination
1306729|NCT00741806|avian
1306730|NCT00741793|Rheumatoid arthritis; psoriatic arthritis; axial spondyloarthritis
1306731|NCT00741793|Remicade®
1306732|NCT00741793|Simponi®
1306733|NCT00741793|Simponi® I.V
1306734|NCT00741793|Stelara®
1306735|NCT00741793|Registry
1306736|NCT00741793|BioTRAC
1306737|NCT00741767|Chronic Obstructive Pulmonary Disease
1306738|NCT00741767|COPD
1306739|NCT00741767|Sleep
1306740|NCT00741767|Sleep quality
1306741|NCT00741767|Lung hyperinflation
1306742|NCT00741754|salivary flow
1306743|NCT00741754|oral neoplasm
1306744|NCT00741754|calcium hydroxide
1306745|NCT00741754|sodium dodecylsulphate
1306746|NCT00741754|radiotherapy.
1306747|NCT00741741|TMC278-C150
1306748|NCT00741741|TMC278-TiDP15-C150
1306749|NCT00741741|HIV-1 infected patients
1306750|NCT00741741|Intramuscular or subcutaneous injection
1306751|NCT00741741|Nanosuspension
1306752|NCT00741741|Therapy
1306753|NCT00741741|Prevention
1306754|NCT00741741|Healthy volunteers
1306755|NCT00741741|HIV Infections
1306756|NCT00741728|epidemiology
1306757|NCT00741728|risk factors
1306758|NCT00741728|heart rate
1306759|NCT00741728|baroreflex sensitivity
1306760|NCT00741728|sudden death
1306761|NCT00741715|primary hypercholesterolemia
1306762|NCT00741702|Hypertension
1306763|NCT00741702|Type 2 diabetes
1306764|NCT00741702|First Nations populations
1306765|NCT00741689|Japanese
1306766|NCT00741689|healthy
1306767|NCT00741689|volunteers
1306768|NCT00741663|cirrhosis
1306769|NCT00741663|ascites
1306770|NCT00741663|diuretic therapy
1306771|NCT00741663|potassium canrenoate
1306772|NCT00741663|furosemide
1306773|NCT00741663|hyperkalemia
1306774|NCT00741663|plasma renin activity
1306775|NCT00741663|nitric oxide
1306776|NCT00741663|serum sodium concentration
1306777|NCT00741663|refractory ascites
1306778|NCT00741663|Nonazotemic patients with cirrhosis and moderate ascites
1306779|NCT00741650|Musculoskeletal pain
1306780|NCT00741650|Brief cognitive intervention
1306781|NCT00741650|Cognitive behavior therapy
1306782|NCT00741650|Intervention Study
1306783|NCT00741650|Health prevention
1306784|NCT00741650|workplace intervention
1306785|NCT00741637|Vibrio Cholerae
1306786|NCT00741637|Diarrhea
1306787|NCT00741637|Live oral Vaccines
1306788|NCT00741637|Immunogenicity
1306789|NCT00741637|Safety
1306790|NCT00741637|HIV
1306791|NCT00741624|refractive surgery
1306792|NCT00741585|Ambulatory blood pressure monitoring
1306793|NCT00741585|Chronotherapy
1306794|NCT00741585|Circadian
1306795|NCT00741585|Non-dipper
1306796|NCT00741585|Type 2 diabetes
1306797|NCT00741585|Resistant hypertension
1306798|NCT00741585|Total mortality
1306799|NCT00741572|sarcoidosis
1306800|NCT00741572|fibrosis
1306801|NCT00741572|oxidative stress
1306802|NCT00741572|inflammation
1306803|NCT00741572|triggers
1306804|NCT00741572|individual sensitivity
1306805|NCT00741559|epilepsy
1306806|NCT00741559|pediatrics
1306807|NCT00741559|magnetoencephalography
1306808|NCT00741559|electroencephalography
1306809|NCT00741559|positron emission tomography
1306810|NCT00741546|Vitamin D
1306811|NCT00741546|malnutrition
1306812|NCT00741546|cardiac surgery
1306813|NCT00741546|study
1306814|NCT00741546|emphasize
1306815|NCT00741546|importance
1306816|NCT00741546|significant
1306817|NCT00741546|high risk patient
1306818|NCT00741520|Obstructive Sleep Apnea
1306819|NCT00741520|Blood Pressure
1306820|NCT00741520|PreHypertension
1306821|NCT00741520|Masked Hypertension
1306822|NCT00741507|Anesthetics
1306823|NCT00741507|Sedatives
1306824|NCT00741507|Analgesics
1306825|NCT00741494|infertility
1306826|NCT00741494|ICSI
1306827|NCT00741494|hyaluronan binding
1306828|NCT00741494|sperm
1306829|NCT00741494|sperm selection
1306830|NCT00741494|male factor
1306831|NCT00741494|hyaluronan
1306832|NCT00741494|sperm maturity
1306833|NCT00741494|clinical pregnancy rates
1306834|NCT00741494|hyaluronan binding assay
1306835|NCT00741494|HBA
1306836|NCT00741494|PICSI
1306837|NCT00741481|metastatic colorectal cancer
1306838|NCT00741481|fdg pet
1306839|NCT00741481|response evaluation
1306840|NCT00741468|Drug-drug interactions
1306841|NCT00741468|DDI
1306842|NCT00741455|Non-myeloablative transplant
1306843|NCT00741455|Chronic Myelogenous Leukemia
1306844|NCT00741455|Acute Myelogenous Leukemia
1306845|NCT00741455|Acute Lymphoblastic Leukemia
1306846|NCT00741455|Multiple Myeloma
1306847|NCT00741455|Non-Hodgkin's Lymphoma
1306848|NCT00741455|Myelodysplastic syndrome
1306849|NCT00741455|Chronic Lymphocytic Leukemia
1306850|NCT00741455|Hodgkin's Disease
1306851|NCT00741416|Heart Disease
1306852|NCT00741416|Biorepository
1306853|NCT00741416|Biobank
1306854|NCT00741403|Phase I
1306855|NCT00741403|malignancies
1306856|NCT00741403|refractory
1306857|NCT00741403|relapsed
1306858|NCT00741390|Diabetes
1306859|NCT00741390|Lancets
1306860|NCT00741390|Pain
1306861|NCT00741377|Multiple myeloma
1306862|NCT00741377|bone disease
1306863|NCT00741377|antibody
1306864|NCT00741364|vitamin D
1306865|NCT00741364|prostate cancer
1306866|NCT00741364|prostatectomy
1306867|NCT00741364|pathology
1306868|NCT00741364|immunohistochemistry
1306869|NCT00741351|Anesthesia
1306870|NCT00741351|Craniotomy
1306871|NCT00741351|Neurosurgery
1306872|NCT00741338|MPS I, Mucopolysaccharidosis, Hurler syndrome
1306873|NCT00741312|pregnancy
1306874|NCT00741312|preeclampsia
1306875|NCT00741312|exercise
1306876|NCT00741299|bipolar affective disorder, Smoking
1306877|NCT00741286|Cerebral infarction
1306878|NCT00741286|Cilostazol
1306879|NCT00741286|Aspirin
1306880|NCT00741286|Transcranial Doppler
1306881|NCT00741286|Pulsatile Index
1306882|NCT00741260|solid tumor
1306883|NCT00741260|erbB2+ breast cancer
1306884|NCT00741260|prior Herceptin
1306885|NCT00741260|metastatic
1306886|NCT00741247|staging
1306887|NCT00741247|Endobronchial ultrasound
1306888|NCT00741247|Endoscopic ultrasound
1306889|NCT00741234|SB939
1306890|NCT00741234|Myelodysplastic Syndrome
1306891|NCT00741234|Combination with azacitidine
1306892|NCT00741234|Solid malignancies
1306893|NCT00741234|Hematologic malignancies
1306894|NCT00741234|HDAC inhibitor
1306895|NCT00741234|Refractory to standard therapy
1306896|NCT00741221|Cancer
1306897|NCT00741221|NSCLC
1306898|NCT00741221|Docetaxel
1306899|NCT00741221|Bevacizumab
1306900|NCT00741208|asthma
1306901|NCT00741208|soy isoflavone
1306902|NCT00741208|genistein
1306903|NCT00741208|soy
1306904|NCT00741195|Cancer
1306905|NCT00741195|NSCLC
1306906|NCT00741195|Docetaxel
1306907|NCT00741195|Bevacizumab
1306908|NCT00741182|Fracture
1306909|NCT00741182|Osteoporosis
1306910|NCT00741182|Forsteo
1306911|NCT00741182|Teriparatide
1306912|NCT00741182|Fracture healing
1306913|NCT00741169|TMC435350-TiDP16-C105
1306914|NCT00741169|TMC435350-C105
1306915|NCT00741169|Hepatitis C
1306916|NCT00741169|HCV
1306917|NCT00741169|Rifampin
1306918|NCT00741156|pediatric
1306919|NCT00741156|hypertension
1306920|NCT00741156|congestive cardiomyopathy
1306921|NCT00741156|angiotensin-converting enzyme inhibitor
1306922|NCT00741156|cardiac catheterization
1306923|NCT00741143|Food Fortification
1306924|NCT00741143|Iron deficiency
1306925|NCT00741143|NaFeEdta
1306926|NCT00741143|Iron deficiency anemia
1306927|NCT00741143|Cognition
1306928|NCT00741130|retinal nerve fiber layer
1306929|NCT00741130|optic nerve head
1306930|NCT00741130|Cirrus OCT
1306931|NCT00741117|Pulse Oximetry
1306932|NCT00741117|Blood Gas Analysis
1306933|NCT00741117|Liver Disease
1306934|NCT00741117|Hyperbilirubinemia
1306935|NCT00741091|Cerebrovascular Disease
1306936|NCT00741091|Carotid Stent
1306937|NCT00741091|Stent
1306938|NCT00741091|Carotid Endarterectomy (CEA)
1306939|NCT00741078|endothelial
1306940|NCT00741078|function
1306941|NCT00741078|insulin
1306942|NCT00741078|sensitivity
1306943|NCT00741065|Coronary Artery Bypass Grafting
1306944|NCT00741065|Myocardial Regeneration
1306945|NCT00741052|V. cholerae,
1306946|NCT00741052|ciprofloxacin,
1306947|NCT00741052|azithromycin,
1306948|NCT00741052|randomized
1306949|NCT00741039|Breast
1306950|NCT00741039|Lung
1306951|NCT00741039|Prostate
1306952|NCT00741039|Vaccine
1306953|NCT00741026|Insulin Resistance
1306954|NCT00741026|Diabetes mellitus
1306955|NCT00741026|Antipsychotic
1306956|NCT00741013|randomized
1306957|NCT00741013|positron emission tomography
1306958|NCT00741013|lung inflammation
1306959|NCT00741013|lovastatin
1306960|NCT00741013|recombinant human activated protein C
1306961|NCT00741013|endotoxin
1306962|NCT00741013|fluorodeoxyglucose
1306963|NCT00740987|Mechanical device
1306964|NCT00740987|Intermittent pneumatic compression
1306965|NCT00740987|Venous thromboembolism prophylaxis
1306966|NCT00740987|Intensive care unit
1306967|NCT00740987|Hospitalization
1306968|NCT00740987|Intensive
1306969|NCT00740987|Care
1306970|NCT00740987|Unit
1306971|NCT00740961|psychosocial effects of cancer and its treatment
1306972|NCT00740961|cognitive/functional effects
1306973|NCT00740961|breast cancer
1306974|NCT00740961|colon cancer
1306975|NCT00740948|Sjogren's disease
1306976|NCT00740948|Rituximab
1306977|NCT00740948|Treatment
1306978|NCT00740948|anti CD20
1306979|NCT00740935|prevention
1306980|NCT00740935|rotavirus vaccine
1306981|NCT00740935|gastroenteritis
1306982|NCT00740935|systematic vaccination
1306983|NCT00740935|infants
1306984|NCT00740935|aged 6 to 12 weeks
1306985|NCT00740922|Becaplermin gel
1306986|NCT00740922|Target Ulcer
1306987|NCT00740922|Retrospective Studies
1306988|NCT00740922|Diabetic Foot
1306989|NCT00740922|Neoplasms
1306990|NCT00740922|Long-Term Safety
1306991|NCT00740922|Topical Administration
1306992|NCT00740909|Trich
1306993|NCT00740909|Hair Pulling
1306994|NCT00740909|Cognitive Behavioral Therapy
1306995|NCT00740909|Behavioral Therapy
1306996|NCT00740896|Cigarette Smoking
1306997|NCT00740896|Airway dendritic cells
1306998|NCT00740883|venous thromboembolism
1306999|NCT00740883|warfarin
1307000|NCT00740883|duration of anticoagulation
1307001|NCT00740883|recurrent venous thromboembolism
1307002|NCT00740883|anticoagulant-related bleeding
1307003|NCT00740870|RVOT
1307004|NCT00740870|Dysfunctional
1307005|NCT00740870|conduit
1307006|NCT00740870|Indications
1307007|NCT00740870|Invasive
1307008|NCT00740870|intervention
1307009|NCT00740870|Tetralogy of Fallot
1307010|NCT00740870|Right Ventricular Outflow Tract
1307011|NCT00740857|Dental pain analgesia
1307012|NCT00740844|Intermittent pneumatic compression
1307013|NCT00740844|Hospitalization
1307014|NCT00740844|Intensive care unit
1307015|NCT00740844|High bleeding risk
1307016|NCT00740844|Venous thromboembolism prophylaxis
1307017|NCT00740831|Uterine Myomas
1307018|NCT00740779|prostatitis, chronic pelvic pain
1307019|NCT00740766|Perinatal Outcomes
1307020|NCT00740766|Obesity
1307021|NCT00740766|Pregnant women
1307022|NCT00740753|liver tumor
1307023|NCT00740753|cancer
1307024|NCT00740753|hepatoma
1307025|NCT00740753|yttrium
1307026|NCT00740740|Aneurysm
1307027|NCT00740740|Rupture
1307028|NCT00740727|Disaster
1307029|NCT00740727|Mass casualty incident
1307030|NCT00740727|Prehospital
1307031|NCT00740727|Rehydration
1307032|NCT00740727|Intravascular access
1307033|NCT00740714|Parkinson disease
1307034|NCT00740714|PD
1307035|NCT00740714|Coenzyme Q10
1307036|NCT00740714|CoQ
1307037|NCT00740701|TMS
1307038|NCT00740701|fMRI
1307039|NCT00740701|verbal working memory
1307040|NCT00740701|classical conditioning
1307041|NCT00740701|eyeblink
1307042|NCT00740701|classical eyeblink conditioning
1307043|NCT00740701|Healthy subjects
1307044|NCT00740701|Memory
1307045|NCT00740675|adverse drug events
1307046|NCT00740675|outpatient
1307047|NCT00740662|morbid obesity
1307048|NCT00740662|small bowel
1307049|NCT00740662|gastric bypass
1307050|NCT00740662|weight loss
1307051|NCT00740636|TEMOZOLOMIDE
1307052|NCT00740636|Lung
1307053|NCT00740623|Partial Onset Seizures
1307054|NCT00740623|Simple Partial Seizures
1307055|NCT00740623|Complex Partial Seizures
1307056|NCT00740597|recurrent adult soft tissue sarcoma
1307057|NCT00740597|stage I adult soft tissue sarcoma
1307058|NCT00740597|stage II adult soft tissue sarcoma
1307059|NCT00740597|stage III adult soft tissue sarcoma
1307060|NCT00740597|adult alveolar soft-part sarcoma
1307061|NCT00740597|adult epithelioid sarcoma
1307062|NCT00740597|adult extraskeletal chondrosarcoma
1307063|NCT00740597|adult extraskeletal osteosarcoma
1307064|NCT00740597|adult fibrosarcoma
1307065|NCT00740597|adult malignant fibrous histiocytoma
1307066|NCT00740597|adult malignant hemangiopericytoma
1307067|NCT00740597|adult malignant mesenchymoma
1307068|NCT00740597|adult neurofibrosarcoma
1307069|NCT00740597|adult rhabdomyosarcoma
1307070|NCT00740597|dermatofibrosarcoma protuberans
1307071|NCT00740584|Prevention
1307072|NCT00740571|neuralgia
1307073|NCT00740571|off-label
1307074|NCT00740571|cancer
1307075|NCT00740558|HRV
1307076|NCT00740558|Activator
1307077|NCT00740558|Chiropractic
1307078|NCT00740558|VLF
1307079|NCT00740558|HF
1307080|NCT00740558|LF
1307081|NCT00740558|LF/HF
1307082|NCT00740532|EGFR, HER-2, HER-3, MET, KRAS
1307083|NCT00740506|Behavioral
1307084|NCT00740506|Environmental
1307085|NCT00740506|Delivery
1307086|NCT00740506|Pregnancy
1307087|NCT00740493|recurrent venous thromboembolism
1307088|NCT00740493|idiopathic deep vein thrombosis
1307089|NCT00740493|optimal duration of anticoagulation
1307090|NCT00740480|Evaluation
1307091|NCT00740480|ENTact™
1307092|NCT00740480|Septal
1307093|NCT00740480|Staple
1307094|NCT00740480|System
1307095|NCT00740480|tissue
1307096|NCT00740480|approximation
1307097|NCT00740480|during
1307098|NCT00740480|septoplasties
1307099|NCT00740467|graft versus host disease
1307100|NCT00740467|adult acute myeloid leukemia in remission
1307101|NCT00740467|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1307102|NCT00740467|adult acute myeloid leukemia with inv(16)(p13;q22)
1307103|NCT00740467|adult acute myeloid leukemia with t(15;17)(q22;q12)
1307104|NCT00740467|adult acute myeloid leukemia with t(16;16)(p13;q22)
1307105|NCT00740467|adult acute myeloid leukemia with t(8;21)(q22;q22)
1307106|NCT00740467|recurrent adult acute myeloid leukemia
1307107|NCT00740467|adult acute lymphoblastic leukemia in remission
1307108|NCT00740467|recurrent adult acute lymphoblastic leukemia
1307109|NCT00740467|accelerated phase chronic myelogenous leukemia
1307110|NCT00740467|chronic phase chronic myelogenous leukemia
1307111|NCT00740467|refractory multiple myeloma
1307112|NCT00740467|relapsing chronic myelogenous leukemia
1307113|NCT00740467|recurrent adult Hodgkin lymphoma
1307114|NCT00740467|adult nasal type extranodal NK/T-cell lymphoma
1307115|NCT00740467|anaplastic large cell lymphoma
1307116|NCT00740467|angioimmunoblastic T-cell lymphoma
1307117|NCT00740467|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1307118|NCT00740467|nodal marginal zone B-cell lymphoma
1307119|NCT00740467|recurrent adult Burkitt lymphoma
1307120|NCT00740467|recurrent adult diffuse large cell lymphoma
1307121|NCT00740467|recurrent adult diffuse mixed cell lymphoma
1307122|NCT00740467|recurrent adult diffuse small cleaved cell lymphoma
1307123|NCT00740467|recurrent adult grade III lymphomatoid granulomatosis
1307124|NCT00740467|recurrent adult immunoblastic large cell lymphoma
1307125|NCT00740467|recurrent adult lymphoblastic lymphoma
1307126|NCT00740467|recurrent adult T-cell leukemia/lymphoma
1307127|NCT00740467|recurrent cutaneous T-cell non-Hodgkin lymphoma
1307128|NCT00740467|recurrent grade 1 follicular lymphoma
1307129|NCT00740467|recurrent grade 2 follicular lymphoma
1307130|NCT00740467|recurrent grade 3 follicular lymphoma
1307131|NCT00740467|recurrent grade I lymphomatoid granulomatosis
1307132|NCT00740467|recurrent grade II lymphomatoid granulomatosis
1307133|NCT00740467|recurrent mantle cell lymphoma
1307134|NCT00740467|recurrent marginal zone lymphoma
1307135|NCT00740467|recurrent small lymphocytic lymphoma
1307136|NCT00740467|splenic marginal zone lymphoma
1307137|NCT00740467|refractory chronic lymphocytic leukemia
1307138|NCT00740454|pregnancy
1307139|NCT00740454|postpartum
1307140|NCT00740454|deep vein thrombosis
1307141|NCT00740454|venous thromboembolism
1307142|NCT00740454|diagnosis
1307143|NCT00740454|compression ultrasonography
1307144|NCT00740441|renal cell carcinoma
1307145|NCT00740441|rcc
1307146|NCT00740441|kidney cancer
1307147|NCT00740428|Pelvic floor,
1307148|NCT00740428|muscular dysfunction,
1307149|NCT00740428|urinary incontinence
1307150|NCT00740415|contiguous stage II mantle cell lymphoma
1307151|NCT00740415|noncontiguous stage II mantle cell lymphoma
1307152|NCT00740415|stage III mantle cell lymphoma
1307153|NCT00740415|stage IV mantle cell lymphoma
1307154|NCT00740389|TMC125-C187
1307155|NCT00740389|TMC125-TiDP2-C187
1307156|NCT00740389|HIV
1307157|NCT00740389|AIDS
1307158|NCT00740389|Fungal Infection
1307159|NCT00740389|Pharmacokinetics
1307160|NCT00740376|osteoarthritis
1307161|NCT00740363|renal transplantation
1307162|NCT00740363|diabetes
1307163|NCT00740363|glucose intolerance
1307164|NCT00740363|impaired glucose tolerance
1307165|NCT00740337|Chronic Obstructive Pulmonary Disease
1307166|NCT00740337|COPD
1307167|NCT00740337|Emphysema
1307168|NCT00740337|Natural Killer T-cell
1307169|NCT00740337|Interleukin-13
1307170|NCT00740337|Innate Immune Signaling
1307171|NCT00740324|During
1307172|NCT00740324|Endoscopy
1307173|NCT00740324|Gastric
1307174|NCT00740324|Peristalsis
1307175|NCT00740311|Prevention of the reduction of the alveolar crest
1307176|NCT00740298|infants
1307177|NCT00740298|undergoing
1307178|NCT00740298|vaccinations
1307179|NCT00740285|scleroderma
1307180|NCT00740285|scleroderma - limited or diffuse types
1307181|NCT00740285|lidocaine
1307182|NCT00740285|effectiveness
1307183|NCT00740272|brady-tachy syndrome
1307184|NCT00740272|AF ablation
1307185|NCT00740259|flunarizine
1307186|NCT00740259|schizophrenia
1307187|NCT00740259|antipsychotic
1307188|NCT00740233|fibromyalgia
1307189|NCT00740233|irritable bowel syndrome
1307190|NCT00740233|interstitial cystitis
1307191|NCT00740233|chronic fatigue syndrome
1307192|NCT00740233|vulvodynia
1307193|NCT00740233|chronic stress
1307194|NCT00740233|chronic pain
1307195|NCT00740233|stress-related conditions
1307196|NCT00740233|functional GI disorders
1307197|NCT00740220|hypoxemia
1307198|NCT00740220|anoxia
1307199|NCT00740220|oxygen
1307200|NCT00740220|dyspnea
1307201|NCT00740220|pulmonary disease
1307202|NCT00740220|chronic obstructive
1307203|NCT00740194|Physiology
1307204|NCT00740194|males
1307205|NCT00740181|myelodysplasia
1307206|NCT00740181|refractory leukemia
1307207|NCT00740181|acute leukemia
1307208|NCT00740168|bevacizumab
1307209|NCT00740168|cancer
1307210|NCT00740155|Dengue virus
1307211|NCT00740155|Dengue fever
1307212|NCT00740155|Dengue hemorrhagic fever
1307213|NCT00740155|Dengue diseases
1307214|NCT00740142|L ornithine L aspartate
1307215|NCT00740142|Lactulose
1307216|NCT00740142|Hepatic encephalopathy
1307217|NCT00740142|LOLA
1307218|NCT00740129|Paget's Disease
1307219|NCT00740129|Zoledronic acid
1307220|NCT00740129|Reclast®/Aclasta®
1307221|NCT00740129|infusion
1307222|NCT00740129|re-treatment
1307223|NCT00740129|re-lapse
1307224|NCT00740116|Tumor of ovary
1307225|NCT00740116|Surgical blood loss
1307226|NCT00740116|Postoperative blood loss
1307227|NCT00740116|Preventive therapy
1307228|NCT00740116|Thromboembolism
1307229|NCT00740103|Semapimod
1307230|NCT00740103|Crohn's Disease
1307231|NCT00740103|TNF-alpha inhibitor
1307232|NCT00740103|MAP Kinase inhibitor
1307233|NCT00740103|CNI-1493
1307234|NCT00740090|Malaria
1307235|NCT00740090|Reactogenicity, Safety, Immunogenicity
1307236|NCT00740090|Maleria Endemic
1307237|NCT00740090|Plasmodium Falciparum
1307238|NCT00740090|Dose Escalating
1307239|NCT00740077|cranberry
1307240|NCT00740077|flavonoid
1307241|NCT00740077|phenolic acid
1307242|NCT00740077|phytochemical
1307243|NCT00740077|bioavailability
1307244|NCT00740064|HIV infections
1307245|NCT00740038|Stress Management
1307246|NCT00740038|Quality of Life
1307247|NCT00740038|Exercise
1307248|NCT00740038|Cancer
1307249|NCT00740038|Chemotherapy
1307250|NCT00740025|QD dose
1307251|NCT00740025|BID dosing
1307252|NCT00740025|peak estradiol
1307253|NCT00740025|oocytes
1307254|NCT00740025|implantation rate
1307255|NCT00740025|pregnancy rate
1307256|NCT00740012|Nocturnal glucose profiles
1307257|NCT00740012|continuous glucose profiles
1307258|NCT00739999|heterozygous familial hypercholesterolemia (HeFH); atorvastatin; pediatric
1307259|NCT00739986|Crohn's Disease
1307260|NCT00739986|TNF-alpha
1307261|NCT00739986|IL-6
1307262|NCT00739986|MAP Kinase
1307263|NCT00739986|CNI-1493
1307264|NCT00739973|Hypertension, Aliskiren, Amlodipine
1307265|NCT00739947|Observational
1307266|NCT00739947|rotator cuff tear
1307267|NCT00739947|arthroscopic
1307268|NCT00739947|surgical
1307269|NCT00739947|outcome study
1307270|NCT00739934|Open-Label
1307271|NCT00739934|Pharmacokinetics
1307272|NCT00739934|Intravenous to oral switch
1307273|NCT00739934|Safety
1307274|NCT00739934|Voriconazole
1307275|NCT00739934|Immunocompromise
1307276|NCT00739934|Children
1307277|NCT00739934|High Risk For Systemic Fungal Infection.
1307278|NCT00739921|PCR Analysis
1307279|NCT00739921|Allergic fungal sinusitis
1307280|NCT00739921|Chronic rhinosinusitis
1307281|NCT00739921|Nasal Polyps
1307282|NCT00739908|MDD
1307283|NCT00739895|athletes
1307284|NCT00739882|Efalizumab,
1307285|NCT00739882|Chronic plaque psoriasis
1307286|NCT00739882|moderate to severe
1307287|NCT00739882|involving
1307288|NCT00739882|hands
1307289|NCT00739882|feet
1307290|NCT00739869|Silent Infarcts
1307291|NCT00739869|Magnetic Resonance Imaging
1307292|NCT00739869|MRI
1307293|NCT00739869|Subclinical Cerebrovascular Disease
1307294|NCT00739869|White Matter Grade Abnormalities
1307295|NCT00739869|Total Brain Volume
1307296|NCT00739869|Ventricular and Hippocampal Volume
1307297|NCT00739869|Subclinical Vascular Abnormalities
1307298|NCT00739869|Cerebrovascular Disease
1307299|NCT00739869|CVD
1307300|NCT00739869|Subclinical CVD
1307301|NCT00739856|posttraumatic stress disorder
1307302|NCT00739856|electroconvulsive therapy
1307303|NCT00739856|medication refractoriness
1307304|NCT00739843|Dementia,
1307305|NCT00739843|Cognitive Disorders,
1307306|NCT00739843|Hemodialysis
1307307|NCT00739791|adenocarcinoma of the prostate
1307308|NCT00739791|stage I prostate cancer
1307309|NCT00739791|stage IIB prostate cancer
1307310|NCT00739791|stage IIA prostate cancer
1307311|NCT00739765|Trauma
1307312|NCT00739765|Psychotherapy
1307313|NCT00739765|Anxiety
1307314|NCT00739752|Attitude to Health
1307315|NCT00739752|Communication
1307316|NCT00739752|Intervention Studies
1307317|NCT00739752|Health Promotion
1307318|NCT00739752|Psychology, Medical
1307319|NCT00739752|Sexual Behavior
1307320|NCT00739752|Behavioral Research
1307321|NCT00739752|Vaccination
1307322|NCT00739713|dry eye
1307323|NCT00739713|sea buckthorn
1307324|NCT00739713|Hippophaë
1307325|NCT00739700|hemodynamics
1307326|NCT00739700|blood pressure
1307327|NCT00739700|blood pressure monitors
1307328|NCT00739687|Chronic Heart Failure
1307329|NCT00739661|Systemic Hedgehog
1307330|NCT00739661|Hedgehog Pathway Inhibitor
1307331|NCT00739648|COPD
1307332|NCT00739648|Patients
1307333|NCT00739622|TMC278-TiDP6-C136
1307334|NCT00739622|TMC278-C136
1307335|NCT00739622|Healthy Volunteer
1307336|NCT00739596|Hypertension
1307337|NCT00739596|African American
1307338|NCT00739596|aliskiren
1307339|NCT00739596|hydrochlorothiazide
1307340|NCT00739596|systolic blood pressure
1307341|NCT00739596|diastolic blood pressure
1307342|NCT00739596|amlodipine
1307343|NCT00739596|stage 2
1307344|NCT00739583|Skin preparation
1307345|NCT00739583|Skin marking
1307346|NCT00739583|site marking
1307347|NCT00739583|Site identification
1307348|NCT00739570|Activator
1307349|NCT00739570|EMG
1307350|NCT00739570|Thermography
1307351|NCT00739570|Diagnostic
1307352|NCT00739570|X-Rays
1307353|NCT00739557|elective TAAA repair
1307354|NCT00739544|Reference Values
1307355|NCT00739544|Sensory Thresholds
1307356|NCT00739544|Pain Threshold
1307357|NCT00739544|Breast Neoplasms
1307358|NCT00739531|Asthma
1307359|NCT00739531|nitric oxide
1307360|NCT00739531|eNO
1307361|NCT00739531|FENO
1307362|NCT00739531|Apieron INSIGHT
1307363|NCT00739531|Aerocrine NIOX
1307364|NCT00739518|Neurological
1307365|NCT00739518|MRI
1307366|NCT00739505|Hypophosphatasia
1307367|NCT00739505|Bone Disease
1307368|NCT00739505|Soft Bones
1307369|NCT00739505|Low Alkaline Phosphatase
1307370|NCT00739505|genetic metabolic disorder
1307371|NCT00739505|alkaline phosphatase
1307372|NCT00739505|tissue non-specific alkaline phosphatase
1307373|NCT00739505|rickets
1307374|NCT00739505|osteomalacia
1307375|NCT00739492|weight loss, obesity, financial incentives
1307376|NCT00739479|Metabolic Syndrome
1307377|NCT00739479|METS
1307378|NCT00739479|Obesity
1307379|NCT00739479|Partially Hydrolyzed Whey Protein
1307380|NCT00739479|Partially Hydrolyzed Gelatin
1307381|NCT00739479|PHWP
1307382|NCT00739479|PHG
1307383|NCT00739479|Weight Loss
1307384|NCT00739466|Liposomal Alendronate
1307385|NCT00739466|Percutaneous coronary intervention
1307386|NCT00739466|Coronary stenting
1307387|NCT00739466|de novo stenotic lesions
1307388|NCT00739466|Native coronary arteries
1307389|NCT00739466|Restenosis
1307390|NCT00739466|Bare metal stent
1307391|NCT00739466|Presillion CoCr coronary stent
1307392|NCT00739453|Advanced cancer
1307393|NCT00739453|Non-small cell lung cancer
1307394|NCT00739453|Pancreatic cancer
1307395|NCT00739453|Colorectal cancer
1307396|NCT00739453|Prostate cancer
1307397|NCT00739414|Histone Deacetylases
1307398|NCT00739414|HDAC inhibitor
1307399|NCT00739414|LBH589
1307400|NCT00739414|Advanced solid tumor
1307401|NCT00739414|Adult
1307402|NCT00739401|AAA
1307403|NCT00739401|Aneurysm
1307404|NCT00739401|Suprarenal
1307405|NCT00739401|Proximal
1307406|NCT00739401|Cuff
1307407|NCT00739401|Extension
1307408|NCT00739401|Endograft
1307409|NCT00739401|Endovascular repair
1307410|NCT00739401|EVAR
1307411|NCT00739401|Endoleak
1307412|NCT00739401|Type I
1307413|NCT00739388|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1307414|NCT00739388|adult acute myeloid leukemia with inv(16)(p13;q22)
1307415|NCT00739388|adult acute myeloid leukemia with t(16;16)(p13;q22)
1307416|NCT00739388|adult acute myeloid leukemia with t(8;21)(q22;q22)
1307417|NCT00739388|secondary acute myeloid leukemia
1307418|NCT00739388|untreated adult acute myeloid leukemia
1307419|NCT00739388|adult acute myeloblastic leukemia without maturation (M1)
1307420|NCT00739388|adult acute myeloblastic leukemia with maturation (M2)
1307421|NCT00739388|adult acute myelomonocytic leukemia (M4)
1307422|NCT00739388|adult acute monoblastic leukemia (M5a)
1307423|NCT00739388|adult acute monocytic leukemia (M5b)
1307424|NCT00739388|adult erythroleukemia (M6a)
1307425|NCT00739388|adult pure erythroid leukemia (M6b)
1307426|NCT00739388|adult acute megakaryoblastic leukemia (M7)
1307427|NCT00739375|Influence
1307428|NCT00739375|of av access
1307429|NCT00739375|flow
1307430|NCT00739375|development
1307431|NCT00739362|Behavioral Weight Loss Treatment
1307432|NCT00739362|Obesity
1307433|NCT00739362|Appetite Control
1307434|NCT00739362|Weight Loss
1307435|NCT00739362|Transcranial Direct Current Stimulation (TDCS)
1307436|NCT00739349|Dry Eye
1307437|NCT00739349|Cyclosporine
1307438|NCT00739336|diabetes mellitus
1307439|NCT00739336|obesity
1307440|NCT00739336|prevention
1307441|NCT00739310|High Frequency Chest Wall Oscillation
1307442|NCT00739310|Cerebral Palsy
1307443|NCT00739310|Restrictive lung disease
1307444|NCT00739297|Chronic asthma
1307445|NCT00739284|preferred
1307446|NCT00739284|procedure
1307447|NCT00739284|drainage
1307448|NCT00739284|obstructed
1307449|NCT00739284|kidney
1307450|NCT00739284|stone
1307451|NCT00739258|HIV-infected person
1307452|NCT00739258|Entamoeba
1307453|NCT00739258|Cryptosporidium
1307454|NCT00739258|Giardia
1307455|NCT00739258|ELISA
1307456|NCT00739258|PCR
1307457|NCT00739258|IDU
1307458|NCT00739258|Gonorrhea
1307459|NCT00739258|Chlamydial trachomatis
1307460|NCT00739258|Syphilis
1307461|NCT00739258|Genital warts
1307462|NCT00739258|Herpes simplex virus
1307463|NCT00738179|Continuous Positive Airway Pressure (CPAP)
1307464|NCT00738179|Obstructive Sleep Apnea (OSA)
1307465|NCT00738179|Cardiovascular (CV)
1307466|NCT00738179|Cardiovascular Disease
1307467|NCT00738179|Clinical Trial
1307468|NCT00738166|diet, organic, health
1307469|NCT00738166|healthy people
1307470|NCT00738140|insulin sensitivity
1307471|NCT00738140|Diabetes Prevention Program
1307472|NCT00738140|lifestyle intervention
1307473|NCT00738127|Acute trans-scaphoid perilunate dislocations
1307474|NCT00738127|Open reduction and internal fixation
1307475|NCT00738127|Kirschner-wire
1307476|NCT00738127|Range of motion
1307477|NCT00738114|non-cardiac
1307478|NCT00738114|surgery
1307479|NCT00738114|mortality
1307480|NCT00738114|morbidity
1307481|NCT00738114|perioperative
1307482|NCT00738114|period
1307483|NCT00738101|Omega-3
1307484|NCT00738101|Omegaven
1307485|NCT00738101|Cholestasis
1307486|NCT00738101|Liver damage
1307487|NCT00738088|Sulphonylurea
1307488|NCT00738088|Pharmacogenetics
1307489|NCT00738062|NOH
1307490|NCT00738062|Neurogenic Orthostatic Hypotension
1307491|NCT00738062|Orthostatic hypotension
1307492|NCT00738062|PAF
1307493|NCT00738062|Pure Autonomic Failure
1307494|NCT00738062|MSA
1307495|NCT00738062|Multiple System Atrophy
1307496|NCT00738062|Neuropathy
1307497|NCT00738062|Autonomic Failure
1307498|NCT00738062|Parkinson
1307499|NCT00738062|Dopamine Deficiency
1307500|NCT00738062|Dopamine
1307501|NCT00738062|Droxidopa
1307502|NCT00738049|atherosclerosis
1307503|NCT00738049|coronary artery disease
1307504|NCT00738049|myocardial perfusion defect
1307505|NCT00738049|endothelial dysfunction
1307506|NCT00738049|endothelin receptor blockade
1307507|NCT00738036|Analgesics
1307508|NCT00738036|Opioid
1307509|NCT00738036|Opioid maintenance therapy
1307510|NCT00738036|Acute pain
1307511|NCT00738023|diabetes,
1307512|NCT00738023|hypertension,
1307513|NCT00738023|free-fatty acids
1307514|NCT00738010|NMES
1307515|NCT00738010|ACL
1307516|NCT00738010|Atrophy Prevention
1307517|NCT00738010|Accelerated Recovery
1307518|NCT00738010|Knee Surgery
1307519|NCT00739232|Safety and tolerability of HSD-016
1307520|NCT00739219|Asthma
1307521|NCT00739219|inflammation
1307522|NCT00739219|nitric oxide
1307523|NCT00739219|eNO
1307524|NCT00739219|FENO
1307525|NCT00739206|uncomplicated
1307526|NCT00739206|severe
1307527|NCT00739206|treatment
1307528|NCT00739206|Plasmodium Falciparum
1307529|NCT00739193|Blood Pressure
1307530|NCT00739180|Childhood obesity
1307531|NCT00739180|Abdominal obesity
1307532|NCT00739180|Visceral fat
1307533|NCT00739180|Insulin resistance
1307534|NCT00739180|Liver fat
1307535|NCT00739180|Skeletal muscle lipid
1307536|NCT00739180|Fitness
1307537|NCT00739167|adult primary hepatocellular carcinoma
1307538|NCT00739167|advanced adult primary liver cancer
1307539|NCT00739167|liver metastases
1307540|NCT00739167|recurrent adult primary liver cancer
1307541|NCT00739154|glaucoma
1307542|NCT00739154|Phenytoin
1307543|NCT00739154|retinal nerve fiber layer
1307544|NCT00739154|corrected pattern standard deviation
1307545|NCT00739154|visual acuity
1307546|NCT00739154|optic disc cupping
1307547|NCT00739141|CYCLOPHOSPHAMIDE (CYTOXAN)
1307548|NCT00739141|CYCLOSPORINE A
1307549|NCT00739141|FLUDARABINE
1307550|NCT00739141|G-CSF
1307551|NCT00739141|MYCOPHENOLATE MOFETIL (MMF)
1307552|NCT00739141|THI0TEPA
1307553|NCT00739141|UMBILICAL CORD BLOOD (UCB)
1307554|NCT00739141|08-087
1307555|NCT00739128|celiac disease
1307556|NCT00739128|hepatitis B vaccine
1307557|NCT00739115|Respiratory
1307558|NCT00739115|Distress
1307559|NCT00739115|Prematurity
1307560|NCT00739115|Heliox
1307561|NCT00739115|CPAP
1307562|NCT00739102|Superficial Femoral Artery
1307563|NCT00739102|Nitinol Self-Expandable Stent System
1307564|NCT00739089|hemodynamics
1307565|NCT00739089|oxygen
1307566|NCT00739089|renal dialysis
1307567|NCT00739089|shock
1307568|NCT00739089|sepsis
1307569|NCT00739089|hypotension
1307570|NCT00739089|lactic acidosis
1307571|NCT00739063|Breast cancer
1307572|NCT00739063|Carcinoma of the breast
1307573|NCT00739063|Stage IV
1307574|NCT00739063|Triple receptor-negative
1307575|NCT00739063|Triple receptor-negative breast cancer
1307576|NCT00739063|Metastatic triple receptor-negative breast cancer
1307577|NCT00739063|Epidermal growth factor receptor
1307578|NCT00739063|EGFR
1307579|NCT00739063|EGFR-overexpressing
1307580|NCT00739063|GFR inhibitor erlotinib
1307581|NCT00739063|Erlotinib hydrochloride
1307582|NCT00739063|Erlotinib
1307583|NCT00739063|Tarceva
1307584|NCT00739063|OSI-774
1307585|NCT00739024|Migraine
1307586|NCT00739024|Headache
1307587|NCT00738998|Breast Cancer
1307588|NCT00738998|Aromatase Inhibitors
1307589|NCT00738998|Symptom Assessment
1307590|NCT00738998|Questionnaire
1307591|NCT00738998|Survey
1307592|NCT00738998|Phone Call
1307593|NCT00738998|Arimidex
1307594|NCT00738998|Anastrozole
1307595|NCT00738959|AZD0328
1307596|NCT00738959|Japanese
1307597|NCT00738959|Caucasian
1307598|NCT00738959|pharmacokinetics
1307599|NCT00738959|safety
1307600|NCT00738959|tolerability
1307601|NCT00738946|Intermittent Preventive treatment
1307602|NCT00738946|insecticide treated bednets
1307603|NCT00738946|malaria
1307604|NCT00738933|Atherosclerosis
1307605|NCT00738933|Plant sterols
1307606|NCT00738933|Plant stanols
1307607|NCT00738933|Aortic valve
1307608|NCT00738907|Type 1 diabetes
1307618|NCT00738868|recurrent squamous cell carcinoma of the hypopharynx
1307619|NCT00738868|stage III squamous cell carcinoma of the hypopharynx
1307620|NCT00738868|stage III squamous cell carcinoma of the larynx
1307621|NCT00738868|stage III verrucous carcinoma of the larynx
1307622|NCT00738868|recurrent squamous cell carcinoma of the larynx
1307623|NCT00738868|recurrent verrucous carcinoma of the larynx
1307624|NCT00738868|recurrent squamous cell carcinoma of the lip and oral cavity
1307625|NCT00738868|stage III squamous cell carcinoma of the lip and oral cavity
1307626|NCT00738868|recurrent verrucous carcinoma of the oral cavity
1307627|NCT00738868|stage III verrucous carcinoma of the oral cavity
1307628|NCT00738868|recurrent squamous cell carcinoma of the nasopharynx
1307629|NCT00738868|stage III squamous cell carcinoma of the nasopharynx
1307630|NCT00738868|recurrent squamous cell carcinoma of the oropharynx
1307631|NCT00738868|stage III squamous cell carcinoma of the oropharynx
1307632|NCT00738868|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1307633|NCT00738868|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1307634|NCT00738868|recurrent salivary gland cancer
1307635|NCT00738868|salivary gland squamous cell carcinoma
1307636|NCT00738868|stage III salivary gland cancer
1307637|NCT00738855|Adhesions
1307638|NCT00738855|Oral contrast
1307639|NCT00738855|Exploration
1307640|NCT00738842|Uric
1307641|NCT00738842|Acid
1307642|NCT00738842|Level
1307643|NCT00738829|CLL
1307644|NCT00738829|untreated
1307645|NCT00738829|immune therapy
1307646|NCT00738829|dose escalation
1307647|NCT00738829|maximum tolerated dose
1307648|NCT00738829|maintenance therapy
1307649|NCT00738829|Lenalidomide
1307650|NCT00738829|Rituximab
1307651|NCT00738829|Fludarabine
1307652|NCT00738816|Medication review
1307653|NCT00738816|Patient
1307654|NCT00738816|Safety
1307655|NCT00738816|Drug
1307656|NCT00738816|Prescriptions
1307657|NCT00738816|Drug-use
1307658|NCT00738803|leg length
1307659|NCT00738803|hip arthroplasty
1307660|NCT00738803|offset
1307661|NCT00738790|rectal cancer
1307662|NCT00738790|preoperative radiotherapy and local excision
1307663|NCT00738777|pre-operative
1307664|NCT00738777|endocrine treatment
1307665|NCT00738777|drug resistance
1307666|NCT00738764|cancer
1307667|NCT00738764|antibody
1307668|NCT00738764|Phase 1 Clinical Trial
1307669|NCT00738751|NSCLC
1307670|NCT00738751|Metastatic
1307671|NCT00738751|erlotinib
1307672|NCT00738751|aerodigestive tract cancers
1307673|NCT00738751|non-small cell lung cancer
1307674|NCT00738751|H&N cancer
1307675|NCT00738738|Generalized Anxiety Disorder Elderly
1307676|NCT00738725|High risk plaque
1307677|NCT00738725|High-risk plaque
1307678|NCT00738725|Vulnerable plaque
1307679|NCT00738725|Atherosclerotic Disease
1307680|NCT00738725|Heart Disease
1307681|NCT00738725|Stroke
1307682|NCT00738712|Vascular MRI
1307683|NCT00738712|Abdominal MRI
1307684|NCT00738712|Pelvic MRI
1307685|NCT00738712|Breast MRI
1307686|NCT00738712|Magnetic Resonance Imaging (MRI)
1307687|NCT00738699|ovarian cancer
1307688|NCT00738699|relapsed ovarian cancer
1307689|NCT00738699|refractory ovarian cancer
1307690|NCT00738686|coronary artery disease
1307691|NCT00738686|drug-eluting stent
1307692|NCT00738686|percutaneous coronary intervention
1307693|NCT00738686|major adverse cardiac event
1307694|NCT00738686|in-stent restenosis
1307695|NCT00738686|stent thrombosis
1307696|NCT00738673|Hormone refractory prostate cancer
1307697|NCT00738673|Agonist treatment failure
1307698|NCT00738660|type1 DM
1307699|NCT00738660|microalbuminuria
1307700|NCT00738660|nephropathy
1307701|NCT00738660|albumin excretion rate
1307702|NCT00738660|dual blockade
1307703|NCT00738660|ACEI
1307704|NCT00738660|ARB
1307705|NCT00738647|Filling materials
1307706|NCT00738647|Restorative materials
1307707|NCT00738647|clinical trial
1307708|NCT00738647|Resin based composite
1307709|NCT00738634|Depression
1307710|NCT00738634|Motor Activity
1307711|NCT00738634|Adolescent
1307712|NCT00738621|PONV
1307713|NCT00738621|breast surgery
1307714|NCT00738621|prevention
1307715|NCT00738621|antiemetics
1307716|NCT00738608|morphine
1307717|NCT00738608|consumption
1307718|NCT00738608|postoperative
1307719|NCT00738608|pain
1307720|NCT00738608|Pain during 24h postoperative
1307721|NCT00738608|Morphine consumption in 24h postoperative
1307722|NCT00738595|Smoking Cessation
1307723|NCT00738569|Chronic inflammation
1307724|NCT00738569|memory cells
1307725|NCT00738569|activated t-lymphocytes
1307726|NCT00738543|Antiseptics
1307727|NCT00738543|Administration, cutaneous
1307728|NCT00738543|Iodophors
1307729|NCT00738543|Chlorine compounds
1307730|NCT00738543|Anti-infecting agents, local
1307731|NCT00738517|heart failure
1307732|NCT00738517|coronary heart disease
1307733|NCT00738517|autoantibodies
1307734|NCT00738517|immunoadsorption
1307735|NCT00738517|immunoglobulin substitution
1307736|NCT00738504|Intensive insulin therapy
1307737|NCT00738504|Carbohydrate restrictive strategy
1307738|NCT00738504|RIFLE Criteria
1307739|NCT00738504|Acute Kidney Injury
1307740|NCT00738504|Critically ill patients
1307741|NCT00738504|Acute
1307742|NCT00738491|Angina pectoris
1307743|NCT00738491|Exercise capacity
1307744|NCT00738491|Myocardial ischaemia
1307745|NCT00738491|Air pollution
1307746|NCT00738478|distal gastrectomy
1307747|NCT00738478|quality of life
1307748|NCT00738452|recurrent non-small cell lung cancer
1307749|NCT00738452|stage II non-small cell lung cancer
1307750|NCT00738452|stage IIIA non-small cell lung cancer
1307751|NCT00738452|stage IIIB non-small cell lung cancer
1307752|NCT00738439|scoliosis
1307753|NCT00738439|kyphosis
1307754|NCT00738439|treatment outcomes
1307755|NCT00738439|spinal deformity
1307756|NCT00738426|non-invasive body contouring of waists hips and thighs
1307757|NCT00738413|Iron chelation
1307758|NCT00738413|Iron balance
1307759|NCT00738413|Secondary iron overload
1307760|NCT00738413|deferoxamine
1307761|NCT00738413|deferasirox
1307762|NCT00738400|Vardenafil
1307763|NCT00738400|Erectile Dysfunction
1307764|NCT00738400|Double-blind study
1307765|NCT00738387|Tumor vascular disrupting agent
1307766|NCT00738387|VDA
1307767|NCT00738387|ASA404
1307768|NCT00738387|non-small cell lung cancer
1307769|NCT00738387|NSCLC
1307770|NCT00738361|ciliary body and choroid melanoma, medium/large size
1307771|NCT00738361|iris melanoma
1307772|NCT00738361|metastatic intraocular melanoma
1307773|NCT00738361|recurrent intraocular melanoma
1307774|NCT00738361|extraocular extension melanoma
1307775|NCT00738348|surgery
1307776|NCT00738335|stage IV non-small cell lung cancer
1307777|NCT00738335|tumors metastatic to brain
1307778|NCT00738335|recurrent non-small cell lung cancer
1307779|NCT00738322|AZD1305
1307780|NCT00738322|safety
1307781|NCT00738322|pharmacokinetics
1307782|NCT00738322|single ascending doses
1307783|NCT00738322|Japanese
1307784|NCT00738322|male
1307785|NCT00738309|Treatment Outcomes
1307786|NCT00738309|Spinal Deformity
1307787|NCT00738309|Scheuermann's Kyphosis
1307788|NCT00738283|Zinc
1307789|NCT00738283|Copper
1307790|NCT00738283|Neonate
1307791|NCT00738257|Renal
1307792|NCT00738257|transplant,
1307793|NCT00738257|pamidronate,
1307794|NCT00738257|ciclosporin,
1307795|NCT00738257|Ciclosporin A,
1307796|NCT00738257|steroids,
1307797|NCT00738257|bone mineral density,
1307798|NCT00738257|fracture rates
1307799|NCT00738257|immunosuppressive
1307800|NCT00738257|regimen
1307801|NCT00738244|hearing aid algorithm
1307802|NCT00738244|wind-noise suppression
1307803|NCT00738231|risk factors; coronary arterial hearth disease
1307804|NCT00738218|Coronary Artery Disease
1307805|NCT00738218|Computed Tomography
1307806|NCT00738218|Angiography
1307807|NCT00738205|Electronic device
1307808|NCT00738205|Growth hormone treatment
1307809|NCT00738192|Postoperative analgesia
1307810|NCT00738192|Opioids
1307811|NCT00738192|Laparoscopic surgery
1307812|NCT00737997|Pediatrics
1307813|NCT00737997|Scoliosis
1307814|NCT00737997|Morphine
1307815|NCT00737997|Surgery
1307816|NCT00737997|Analgesia
1307817|NCT00737984|Infertility
1307818|NCT00737984|Clinical pregnancy rate
1307819|NCT00737971|avastin
1307820|NCT00737971|bevacizumab
1307821|NCT00737971|triamcinolone
1307822|NCT00737971|diabetic macular edema
1307823|NCT00737971|macular edema
1307824|NCT00737971|intravitreal injection
1307825|NCT00737958|Angina pectoris
1307826|NCT00737958|Air pollution
1307827|NCT00737958|Diesel exhaust
1307828|NCT00737958|Myocardial ischaemia
1307829|NCT00737958|Exercise capacity
1307830|NCT00737919|Cholesterol
1307831|NCT00737919|Plant sterols
1307832|NCT00737919|Atherosclerotic carotid plaques
1307833|NCT00737906|Chronic rhinitis
1307834|NCT00737906|Nasal Obstruction
1307835|NCT00737906|Nasal Obstruction Symptoms
1307836|NCT00737906|Failed Medical Management for Nasal Obstruction
1307837|NCT00737906|Inflammation of the nasal mucosa
1307838|NCT00737906|Pediatric Turbinate reduction
1307839|NCT00737906|Coblation
1307840|NCT00737906|Arthrocare
1307841|NCT00737906|ENT
1307842|NCT00737906|Failed Medical Management for Chronic Sinusitis
1307843|NCT00737906|Turbinate
1307844|NCT00737906|Inferior Turbinate Hypertrophy
1307845|NCT00737906|Bilateral Inferior Turbinate Hypertrophy
1307846|NCT00737906|Turbinate Hypertrophy
1307847|NCT00737906|Inferior Turbinate
1307848|NCT00737906|Bilateral Inferior Turbinate
1307849|NCT00737893|Erythropoietin
1307850|NCT00737893|Radical Prostatectomy
1307851|NCT00737893|Erectile Dysfunction
1307852|NCT00737893|Prostate Cancer
1307853|NCT00737880|Pancreas Clinical, Donor
1307854|NCT00737880|Pancreas Clinical, Preservation Solutions
1307855|NCT00737880|Organ Preservation and Procurement, Surgery
1307856|NCT00737880|Organ Procurement, Ischemia reperfusion Injury
1307857|NCT00737880|Organ Preservation and Procurement
1307858|NCT00737867|lung cancer
1307859|NCT00737867|chemotherapy
1307860|NCT00737867|vinorelbine
1307861|NCT00737867|gemcitabine
1307862|NCT00737867|carboplatin
1307863|NCT00737867|advanced lung cancer
1307864|NCT00737867|non-small cell lung cancer
1307865|NCT00737854|OLP
1307866|NCT00737854|Free Soft Tissue Graft
1307867|NCT00737854|Treatment
1307868|NCT00737841|stress
1307869|NCT00737841|brain-gut interactions
1307870|NCT00737841|visceral perception
1307871|NCT00737841|gastrointestinal motility
1307872|NCT00737841|emotion
1307873|NCT00737828|Cardiopulmonary exercise test
1307874|NCT00737828|CPX
1307875|NCT00737828|CPEX
1307876|NCT00737828|surgical outcome
1307877|NCT00737828|colorectal surgery
1307878|NCT00737828|risk stratification
1307879|NCT00737815|Randomized Controlled Trial
1307880|NCT00737815|Magnesium
1307881|NCT00737815|Diabetes Mellitus, Type 2
1307882|NCT00737815|Inflammation
1307883|NCT00737802|GERD
1307884|NCT00737802|Heartburn
1307885|NCT00737802|Esophageal reflux
1307886|NCT00737802|Barretts esophagus
1307887|NCT00737802|Normal subjects
1307888|NCT00737763|efalizumab
1307889|NCT00737763|Raptiva
1307890|NCT00737763|Diabetes
1307891|NCT00737763|Type 1 Diabetes Mellitus
1307892|NCT00737750|Neuromuscular electrical stimulation (NMES)
1307893|NCT00737750|Knee Surgery
1307894|NCT00737750|Anterior cruciate ligament
1307895|NCT00737750|Atrophy Prevention
1307896|NCT00737750|Accelerated Recovery
1307897|NCT00737737|Analgesia
1307898|NCT00737737|Chronic Pain
1307899|NCT00737737|Neuroendocrine Axis
1307900|NCT00737737|Degenerative Diseases
1307901|NCT00737724|Enzyme-Linked ImmunoSpot
1307902|NCT00737724|Deferred treatment
1307903|NCT00737724|Immune Recovery Inflammatory Syndrome
1307904|NCT00737698|COPD
1307905|NCT00737698|exercise
1307906|NCT00737698|repetitive magnetic stimulation
1307907|NCT00737698|quadriceps strength
1307908|NCT00737685|Pediatric
1307909|NCT00737685|UBMT
1307910|NCT00737685|Severe
1307911|NCT00737672|Hemodialysis
1307912|NCT00737672|Stent Graft
1307913|NCT00737672|Venous Anastomosis
1307914|NCT00737672|Arteriovenous Grafts
1307915|NCT00737659|Renal Transplant
1307916|NCT00737659|Renal
1307917|NCT00737659|Transplant
1307918|NCT00737659|MMF
1307919|NCT00737659|MPA
1307920|NCT00737659|Recipients
1307921|NCT00737646|Cancer
1307922|NCT00737646|Colorectal cancer
1307923|NCT00737646|Patient education
1307924|NCT00737646|Physician education
1307925|NCT00737633|Diabetes
1307926|NCT00737633|Type 2 Diabetes
1307927|NCT00737633|Diabetes Mellitus
1307928|NCT00737633|Metabolic Diseases
1307929|NCT00737633|Glucose Metabolism Disorders
1307930|NCT00737633|Glycemic Control
1307931|NCT00737620|Renal Failure, End Stage
1307932|NCT00737620|Blood Vessel Grafting
1307933|NCT00737620|Hemodialysis
1307934|NCT00737620|Surgical Arteriovenous Shunt
1307935|NCT00737607|outcome
1307936|NCT00737607|surgery
1307937|NCT00737607|lumbar spinal stenosis
1307938|NCT00737607|minimally invasive
1307939|NCT00737581|Subject's
1307940|NCT00737581|response
1307941|NCT00737581|changes
1307942|NCT00737581|in spinal
1307943|NCT00737581|cord
1307944|NCT00737581|stimulation
1307945|NCT00737581|during
1307946|NCT00737581|postural
1307947|NCT00737568|Tenofovir DF
1307948|NCT00737568|Emtricitabine
1307949|NCT00737568|Chronic hepatitis B
1307950|NCT00737568|Combination therapy
1307951|NCT00737555|Solid tumour
1307952|NCT00737555|Solid tumor
1307953|NCT00737555|Pharmacokinetic
1307954|NCT00737555|Interaction
1307955|NCT00737555|dose escalation
1307956|NCT00737555|cancer
1307957|NCT00737555|paclitaxel
1307958|NCT00737542|management
1307959|NCT00737542|post
1307960|NCT00737529|Mantle Cell Lymphoma
1307961|NCT00737529|Non-Hodgkin's Lymphoma
1307962|NCT00737529|CC-5013
1307963|NCT00737529|Revlimid
1307964|NCT00737529|Lenalidomide
1307965|NCT00737516|Registry
1307966|NCT00737516|Unrelated Umbilical Cord Blood donor
1307967|NCT00737516|Hematopoietic Reconstitution
1307968|NCT00737516|Center for Cord Blood
1307969|NCT00737516|Bone Marrow Transplantation
1307970|NCT00737503|vaccine effectiveness, rotavirus, diarrhoea, Bangladesh
1307971|NCT00737451|urticaria
1307972|NCT00737451|goiter
1307973|NCT00737438|BEVACIZUMAB (AVASTIN)
1307974|NCT00737438|CAPECITABINE (ORAL)
1307975|NCT00737438|CISPLATIN
1307976|NCT00737438|EPIRUBICIN
1307977|NCT00737438|IRINOTECAN (CPT-11) CAMPTOSAR
1307978|NCT00737438|TAXOTERE (DOCETAXEL)
1307979|NCT00737438|ESOPHAGUS
1307980|NCT00737438|STOMACH
1307981|NCT00737438|08-081
1307982|NCT00737425|laparoscopic-assisted surgery
1307983|NCT00737425|abdominal
1307984|NCT00737425|pain relief
1307985|NCT00737425|wound healing
1307986|NCT00737425|low intensity ultrasound
1307987|NCT00737412|Bio-K+CL1285
1307988|NCT00737412|Probiotics
1307989|NCT00737412|Traveler's Diarrhea
1307990|NCT00737412|Lactobacillus Acidophilus
1307991|NCT00737412|Lactobacillus Casei
1307992|NCT00737399|depression
1307993|NCT00737399|anxiety
1307994|NCT00737399|pain
1307995|NCT00737399|insomnia
1307996|NCT00737399|cancer
1307997|NCT00737399|cholangiocarcinoma
1307998|NCT00737399|EFT (Emotional Freedom Techniques)
1307999|NCT00737386|Leishmania tropica
1308000|NCT00737386|Hyrax
1308001|NCT00737386|Sandfly
1308002|NCT00737347|type 2 diabetes
1308003|NCT00737347|obesity
1308004|NCT00737347|weight gain
1308005|NCT00737347|thiazolidinediones
1308006|NCT00737334|Carotid stenosis
1308007|NCT00737334|EEGo
1308008|NCT00737334|nonlinear EEG
1308009|NCT00737334|BIS
1308010|NCT00737334|cerebral oximetry
1308011|NCT00737334|FORE-SIGHT cerebral oximeter
1308012|NCT00737334|cerebral monitoring
1308013|NCT00737334|arterial jugular venous lactate difference
1308014|NCT00737334|cerebral ischemia
1308015|NCT00737334|carotid endarterectomy
1308016|NCT00737321|Impact of ischemia
1308017|NCT00737321|Impact of stress and
1308018|NCT00737321|Identify patterns of gene expression
1308019|NCT00737308|crowns
1308020|NCT00737308|ceramics
1308021|NCT00737295|Biliary
1308022|NCT00737295|Dyskinesia
1308023|NCT00737295|Gallbladder
1308024|NCT00737295|Cholecystitis
1308025|NCT00737282|Uterine Fibroids
1308026|NCT00737269|Complicated Skin and Soft-Tissue Infection
1308027|NCT00737269|Skin Infection
1308028|NCT00737269|Skin Infection Registry
1308029|NCT00737269|cSSTI Registry
1308030|NCT00737243|Carcinoma of Unknown Primary Site
1308031|NCT00737243|Molecular profiling assay
1308032|NCT00737243|Bevacizumab
1308033|NCT00737243|Erlotinib
1308034|NCT00737243|Paclitaxel
1308035|NCT00737243|Carboplatin
1308036|NCT00737230|long-term effects secondary to cancer therapy in adults
1308037|NCT00737230|long-term effects secondary to cancer therapy in children
1308038|NCT00737230|gastrointestinal complications
1308039|NCT00737230|radiation toxicity
1308040|NCT00737230|prostate cancer
1308041|NCT00737230|bladder cancer
1308042|NCT00737230|vulvar cancer
1308043|NCT00737230|vaginal cancer
1308044|NCT00737230|cervical cancer
1308045|NCT00737230|endometrial cancer
1308046|NCT00737230|anal cancer
1308047|NCT00737230|rectal cancer
1308048|NCT00737230|malignant testicular germ cell tumor
1308049|NCT00737204|HIV
1308050|NCT00737204|AIDS
1308051|NCT00737204|Armodafinil
1308052|NCT00737204|Depression
1308053|NCT00737191|unspecified adult solid tumor, protocol specific
1308054|NCT00737191|hematopoietic/lymphoid cancer
1308055|NCT00737191|pain
1308056|NCT00737178|IUD
1308057|NCT00737178|Intrauterine device
1308058|NCT00737178|Intrauterine contraception
1308059|NCT00737178|Medication abortion
1308060|NCT00737178|Medical abortion
1308061|NCT00737165|Suicide, Prevention
1308062|NCT00737165|Community
1308063|NCT00737152|RAS 130
1308064|NCT00737152|Exercise
1308065|NCT00737152|Diabetes Mellitus
1308066|NCT00737152|Type II Diabetes
1308067|NCT00737152|Diabetes
1308068|NCT00737152|Aerobic
1308069|NCT00737139|Hip
1308070|NCT00737139|Knee
1308071|NCT00737139|Arthroplasty
1308072|NCT00737139|Epinephrine
1308073|NCT00737139|Hemostasis
1308074|NCT00737126|Diabetic nephropathies
1308075|NCT00737126|Hyperhomocysteinemia
1308076|NCT00737126|Folic acid
1308077|NCT00737126|Endothelial dysfunction
1308078|NCT00737113|allogeneic stem cell transplantation
1308079|NCT00737113|Engrafted
1308080|NCT00737113|subjects
1308081|NCT00737087|total shoulder replacement
1308082|NCT00737087|rotator cuff
1308083|NCT00737087|osteoarthritis
1308084|NCT00737087|rheumatoid arthritis
1308085|NCT00737087|Delta Extend
1308086|NCT00737074|Fibrovascular proliferation
1308087|NCT00737074|Internal limiting membrane peeling
1308088|NCT00737074|Macular detachment
1308089|NCT00737074|Macular hole
1308090|NCT00737074|Proliferative diabetic retinopathy.
1308091|NCT00737061|Female
1308092|NCT00737061|Sterilization
1308093|NCT00737048|Pain
1308094|NCT00737048|Tooth extraction
1308095|NCT00737048|Oral surgery
1308096|NCT00737048|Postoperative pain
1308097|NCT00737048|JNS013
1308098|NCT00737048|Tramadol hydrochloride
1308099|NCT00737048|Acetaminophen
1308100|NCT00737035|Intimate Partner Homicide
1308101|NCT00737035|Parental Homicide
1308102|NCT00737035|Guardians of Child Survivors of Parental Homicide
1308103|NCT00737035|Post-Traumatic Stress Disorder
1308104|NCT00737035|Uxoricide Project
1308105|NCT00737022|Diabetic vitrectomy
1308106|NCT00737022|Epiretinal membrane (ERM)
1308107|NCT00737022|Macular appearance
1308108|NCT00737022|Optical coherence tomography (OCT)
1308109|NCT00737022|Visual function
1308110|NCT00737009|Breast cancer
1308111|NCT00737009|adherence
1308112|NCT00737009|anastrozole
1308113|NCT00737009|post-menopausal women
1308114|NCT00736996|Metabolic Syndrome
1308115|NCT00736996|Mild Cognitive Impairment
1308116|NCT00736996|Insulin Resistance
1308117|NCT00736996|Endurance Exercise
1308118|NCT00736983|Perianal fistulas
1308119|NCT00736983|Crohn's disease
1308120|NCT00736970|ridaforolimus
1308121|NCT00736970|deforolimus
1308122|NCT00736970|AP23573
1308123|NCT00736970|breast cancer
1308124|NCT00736957|Chronic Pain
1308125|NCT00736957|Acetaminophen
1308126|NCT00736957|Tramadol
1308127|NCT00736957|JNS013
1308128|NCT00736931|Brivaracetam
1308129|NCT00736931|Cognitive neurophysiological tests (CNT)
1308130|NCT00736931|Neuropsychological assessments
1308131|NCT00736918|Suicide Attempt
1308132|NCT00736905|TMC278-TiDP6-C130
1308133|NCT00736905|TMC278-C130
1308134|NCT00736905|healthy volunteer
1308135|NCT00736905|hepatic impairment
1308136|NCT00736905|HIV Infections
1308137|NCT00736892|Acute lung injury
1308138|NCT00736892|Acute respiratory distress syndrome
1308139|NCT00736892|Mechanical ventilation
1308140|NCT00736892|Prognosis
1308141|NCT00736892|Definitions
1308142|NCT00736879|Diabetes Mellitus, Type 2
1308143|NCT00736879|Diabetes Mellitus
1308144|NCT00736879|Endocrine System Diseases
1308145|NCT00736879|Glucose Metabolism Disorders
1308146|NCT00736879|Metabolic Diseases
1308147|NCT00736866|acetylcysteine
1308148|NCT00736866|contrast-induced nephropathy
1308149|NCT00736866|angiography
1308150|NCT00736866|angioplasty with or without Stent
1308151|NCT00736853|Chronic pain
1308152|NCT00736853|Acetoaminophen
1308153|NCT00736853|Tramadol
1308154|NCT00736853|Osteoarthritis of the knee
1308155|NCT00736853|Low back pain
1308156|NCT00736840|Methacetin
1308157|NCT00736840|Breath
1308158|NCT00736840|Test
1308159|NCT00736840|Cirrhosis
1308160|NCT00736827|BK virus
1308161|NCT00736827|acute renal failure
1308162|NCT00736827|hemodiafiltration
1308163|NCT00736827|humans
1308164|NCT00736827|patients
1308165|NCT00736827|polytrauma
1308166|NCT00736827|surgery
1308167|NCT00736827|complement
1308168|NCT00736827|inflammation
1308169|NCT00736827|inflammatory response
1308170|NCT00736827|biomarkers
1308171|NCT00736827|cytokines
1308172|NCT00736827|cell surface markers
1308173|NCT00736827|functional polymorphisms
1308174|NCT00736827|infections
1308175|NCT00736827|systemic inflammatory response syndrome
1308176|NCT00736827|SIRS
1308177|NCT00736827|sepsis
1308178|NCT00736827|severe sepsis
1308179|NCT00736827|shock
1308180|NCT00736827|organ dysfunctions
1308181|NCT00736827|SOFA
1308182|NCT00736827|severity of disease
1308183|NCT00736827|APACHEII
1308184|NCT00736827|SAPSII
1308185|NCT00736827|SPAPS3
1308186|NCT00736827|length of stay
1308187|NCT00736827|outcome
1308188|NCT00736827|mortality
1308189|NCT00736814|stage IIIB non-small cell lung cancer
1308190|NCT00736814|stage IV non-small cell lung cancer
1308191|NCT00736801|Airway hyperresponsiveness
1308192|NCT00736788|AZD1704,
1308193|NCT00736788|Japanese
1308194|NCT00736788|Healthy
1308195|NCT00736788|Volunteers,
1308196|NCT00736788|Phase I study,
1308197|NCT00736788|Single Ascending Dose
1308198|NCT00736788|Safety,
1308199|NCT00736788|Tolerability
1308200|NCT00736788|Pharmacokinetics
1308201|NCT00736775|AD
1308202|NCT00736775|Alzheimer's
1308203|NCT00736775|Alzheimers
1308204|NCT00736762|Global postural re-education
1308205|NCT00736762|Balance
1308206|NCT00736762|Physical therapy
1308207|NCT00736762|older people
1308208|NCT00736723|NT-proBNP
1308209|NCT00736723|myocardial dysfunction
1308210|NCT00736723|humans
1308211|NCT00736723|patients
1308212|NCT00736723|polytrauma
1308213|NCT00736723|complement
1308214|NCT00736723|inflammation
1308215|NCT00736723|inflammatory response
1308216|NCT00736723|biomarkers
1308217|NCT00736723|cytokines
1308218|NCT00736723|cell surface markers
1308219|NCT00736723|functional polymorphisms
1308220|NCT00736723|infections
1308221|NCT00736723|systemic inflammatory response syndrome
1308222|NCT00736723|SIRS
1308223|NCT00736723|sepsis
1308224|NCT00736723|severe sepsis
1308225|NCT00736723|shock
1308226|NCT00736723|organ dysfunctions
1308227|NCT00736723|SOFA
1308228|NCT00736723|severity of disease
1308229|NCT00736723|APACHEII
1308230|NCT00736723|SAPSII
1308231|NCT00736723|SPAPS3
1308232|NCT00736723|length of stay
1308233|NCT00736723|outcome
1308234|NCT00736723|mortality
1308235|NCT00736710|Repetitive Transcranial Magnetic Stimulation
1308236|NCT00736710|Cigarette smoking
1308237|NCT00736710|Schizophrenia
1308238|NCT00736710|Randomized
1308239|NCT00736710|Double-blind
1308240|NCT00736710|Placebo-controlled
1308241|NCT00736710|longitudinal
1308242|NCT00736710|nicotine patch
1308243|NCT00736684|Femoral fractures [MeSH]
1308244|NCT00736684|hip fractures [MeSH]
1308245|NCT00736684|trochanteric fractures (femoral neck fractures [MeSH])
1308246|NCT00736684|intramedullary nailing (fracture fixation, intramedullary [MeSH])
1308247|NCT00736684|complex femoral fractures
1308248|NCT00736684|femoral nail
1308249|NCT00736684|surgical treatment (surgical procedures, operative [MeSH])
1308250|NCT00736684|complications
1308251|NCT00736658|Japanese
1308252|NCT00736658|MAD
1308253|NCT00736658|Multiple ascending dose
1308254|NCT00736658|Chronic pain
1308255|NCT00736645|adenocarcinoma of the prostate
1308256|NCT00736645|stage I prostate cancer
1308257|NCT00736645|stage II prostate cancer
1308258|NCT00736632|Vitamin D
1308259|NCT00736632|Insulin Resistance
1308260|NCT00736632|Type 2 Diabetes Mellitus
1308261|NCT00736632|Cardiovascular Disease
1308262|NCT00736619|MAB C225(CETUXIMAB)(ANTI-EGFR)
1308263|NCT00736619|TAXOL (PACLITAXEL)
1308264|NCT00736619|Radiation Therapy
1308265|NCT00736619|08-084
1308266|NCT00736606|simvastatin
1308267|NCT00736606|AZD5672
1308268|NCT00736593|Wound
1308269|NCT00736593|Healing
1308270|NCT00736580|Cesarean delivery
1308271|NCT00736580|Surgical Needles
1308272|NCT00736580|blunt-tip needles
1308273|NCT00736580|surgical glove perforation
1308274|NCT00736567|Diarrhea
1308275|NCT00736567|Diagnostic
1308276|NCT00736567|Pediatric
1308277|NCT00736554|Staphylococcus aureus
1308278|NCT00736554|CA-MRSA
1308279|NCT00736554|skin and soft tissue infections
1308280|NCT00736554|resistance
1308281|NCT00736554|emergency department
1308282|NCT00736541|ARF
1308283|NCT00736541|OLT
1308284|NCT00736541|NAC
1308285|NCT00736541|I/R injury
1308286|NCT00736528|safety, tolerability, pharmacokinetics, cognition
1308287|NCT00736515|combination therapy,monotherapy,gliclazide MR,insulin,CGMS
1308288|NCT00736489|Asthma
1308289|NCT00736489|airway obstruction
1308290|NCT00736489|beta2-agonist
1308291|NCT00736489|efficacy
1308292|NCT00736489|inhalation
1308293|NCT00736476|helicobacter pylori infection
1308294|NCT00736476|vaccination
1308295|NCT00736476|adults
1308296|NCT00736463|HDL cholesterol
1308297|NCT00736463|statin
1308298|NCT00736463|inflammation
1308299|NCT00736463|atherosclerosis
1308300|NCT00736463|prevention
1308301|NCT00736463|patients with low baseline HDL cholesterol
1308302|NCT00736437|UV-induced
1308303|NCT00736437|Herpes labialis
1308304|NCT00736437|time to healing
1308305|NCT00736424|Epilepsy
1308306|NCT00736424|SUDEP
1308307|NCT00736424|DBS
1308308|NCT00736411|infertility
1308309|NCT00736411|IVF
1308310|NCT00736411|acupuncture
1308311|NCT00736385|nonalcoholic fatty liver disease
1308312|NCT00736372|cancer
1308313|NCT00736372|metastatic cancer
1308314|NCT00736372|advanced or metastatic cancer
1308315|NCT00736346|Panic Disorder
1308316|NCT00736346|anxiety
1308317|NCT00736346|chest pain
1308318|NCT00736346|emergency department
1308319|NCT00736346|cognitive-behavioral treatment
1308320|NCT00736320|Hodgkin Lymphoma
1308321|NCT00736320|early stage
1308322|NCT00736320|PET
1308323|NCT00736307|limbal stem cell deficiency
1308324|NCT00736294|Catheter Ablation, Radiofrequency
1308325|NCT00736294|Angiotensin-Converting Enzyme Inhibitors
1308326|NCT00736281|Sublingual Immunotherapy for Food Allergy
1308327|NCT00736281|Food Drops for Food Allergy
1308328|NCT00736268|Lung Disease
1308329|NCT00736268|Chronic Bronchitis
1308330|NCT00736268|Emphysema
1308331|NCT00736268|Caregiver stress
1308332|NCT00736268|COPD
1308333|NCT00736268|Chronic Obstructive Pulmonary Disease
1308334|NCT00736255|ADHD
1308335|NCT00736255|Smoking
1308336|NCT00736242|HIV
1308337|NCT00736229|hyperglycemia
1308338|NCT00736229|acute coronary syndromes
1308339|NCT00736229|myocardial infarction
1308340|NCT00736216|cervical cancer
1308341|NCT00736216|human papilloma virus infection
1308342|NCT00736203|fMRI
1308343|NCT00736203|non-smokers
1308344|NCT00736190|Hepatitis B
1308345|NCT00736190|Hepatitis
1308346|NCT00736190|Tenofovir disoproxil fumarate
1308347|NCT00736190|Tenofovir DF
1308348|NCT00736190|Asian-American
1308349|NCT00736177|IVF
1308350|NCT00736177|blastocyst transfer
1308351|NCT00736177|endometrium
1308352|NCT00736177|embryo cryopreservation
1308353|NCT00736164|stage I prostate cancer
1308354|NCT00736164|stage II prostate cancer
1308355|NCT00736164|adenocarcinoma of the prostate
1308356|NCT00736125|postoperative cognitive dysfunction
1308357|NCT00736125|total knee arthroplasty
1308358|NCT00736125|cerebral emboli
1308359|NCT00736125|carbon dioxide lavage
1308360|NCT00736125|pulsatile saline lavage
1308361|NCT00736112|Food Allergy in Children
1308362|NCT00736112|Otitis Media with Effusion (OME)
1308363|NCT00736112|Recurrent Middle Ear Infections
1308364|NCT00736112|Middle Ear Fluid
1308365|NCT00736112|Food Allergy and Otitis Media with Effusion
1308366|NCT00736112|Recurrent middle ear fluid in children <4 years old
1308367|NCT00736112|Chronic ear infections in children <4 years old
1308368|NCT00736086|femoral artery
1308369|NCT00736086|post-percutaneous cardiac catheterization
1308370|NCT00736086|post-percutaneous peripheral vascular catheterization
1308371|NCT00736086|post-percutaneous diagnostic catheterization
1308372|NCT00736086|early ambulation
1308373|NCT00736086|vascular closure
1308374|NCT00736073|pancreatitis
1308375|NCT00736060|Fever
1308376|NCT00736060|Blood cultures
1308377|NCT00736047|Smokers
1308378|NCT00736047|smoking cessation
1308379|NCT00736047|vaccine
1308380|NCT00736047|antibodies
1308381|NCT00736047|anti-nicotine
1308382|NCT00736034|Age Associated Memory Impairment
1308383|NCT00736021|PTSD
1308384|NCT00736021|Pharmacological Treatment
1308385|NCT00736021|SSRI
1308386|NCT00736021|Escitalopram
1308387|NCT00736021|Anxiety Disorders
1308388|NCT00736008|Factor V Leiden
1308389|NCT00736008|Prothrombin Mutation
1308390|NCT00736008|Hypercoagulability
1308391|NCT00736008|Pediatrics
1308392|NCT00735969|Non-Responder
1308393|NCT00735969|Relapser
1308394|NCT00735969|High Dose Ribavirin
1308395|NCT00735969|Peginterferon
1308396|NCT00735969|Chronic Hepatitis C
1308397|NCT00735956|Screening
1308398|NCT00735956|Brief Intervention
1308399|NCT00735943|Pegaptanib
1308400|NCT00735943|macular degeneration
1308401|NCT00735943|vascular endothelial growth factor
1308402|NCT00735904|AG-013736
1308403|NCT00735904|axitinib
1308404|NCT00735904|cisplatin
1308405|NCT00735904|gemcitabine
1308406|NCT00735904|NSCLC
1308407|NCT00735904|squamous cell
1308408|NCT00735904|lung cancer
1308409|NCT00735891|Stage IIIB non small cell lung cancer
1308410|NCT00735891|Stage IV non small cell lung cancer
1308411|NCT00735878|Lung Cancer
1308412|NCT00735878|Advanced Lung Cancer
1308413|NCT00735878|NSCLC
1308414|NCT00735865|Dry Eye Syndrome
1308415|NCT00735865|Punctal Occlusion
1308416|NCT00735865|Punctal Plugs
1308417|NCT00735865|Tear Drainage duct blockage
1308418|NCT00735852|endometriosis
1308419|NCT00735852|chronic cyclical pelvic pain
1308420|NCT00735826|resectable
1308421|NCT00735826|stage I-III
1308422|NCT00735826|NSCLC
1308423|NCT00735826|non-small cell lung cancer
1308424|NCT00735826|vorinostat
1308425|NCT00735826|proof of principle
1308426|NCT00735826|resectable stage I to III NSCLC
1308427|NCT00735813|Catheterization, Central
1308428|NCT00735813|Catheterization, Peripheral
1308429|NCT00735813|Infection
1308430|NCT00735813|Methods
1308431|NCT00735813|Sepsis
1308432|NCT00735813|Microscopy, Electron, Scanning
1308433|NCT00735813|Sonication
1308434|NCT00735813|Taurolidine
1308435|NCT00735813|Catheters, Indwelling
1308436|NCT00735813|Pediatrics
1308437|NCT00735800|Dementia
1308438|NCT00735800|Caregivers
1308439|NCT00735800|Alzheimer's disease
1308440|NCT00735774|Healthy volunteer study
1308441|NCT00735748|Patients who will undergo a general anesthesia for a procedure in short stay
1308442|NCT00735735|low back pain
1308443|NCT00735735|chronic
1308444|NCT00735735|Substance P
1308445|NCT00735722|AF
1308446|NCT00735722|CAD
1308447|NCT00735709|Depression
1308448|NCT00735709|Depressive Disorder
1308449|NCT00735709|Mood Disorder
1308450|NCT00735709|Mental Disorder
1308451|NCT00735709|Melancholia, Involutional
1308452|NCT00735709|Paraphrenia, Involutional
1308453|NCT00735709|Drug Therapy
1308454|NCT00735696|Non Small Cell Lung Cancer
1308455|NCT00735696|Lung
1308456|NCT00735696|NSCLC
1308457|NCT00735683|Weight loss
1308458|NCT00735683|Weight-loss drugs
1308459|NCT00735683|Obesity
1308460|NCT00735683|Overweight
1308461|NCT00735683|Body weight
1308462|NCT00735683|Diet
1308463|NCT00735683|Metabolic Disorder
1308464|NCT00735683|Nutrition Disorder
1308465|NCT00735670|SCI
1308466|NCT00735657|Efficiency
1308467|NCT00735657|Pars
1308468|NCT00735657|Plana
1308469|NCT00735657|Vitrectomy
1308470|NCT00735644|Japanese encephalitis, Hepatitis A, Inactivated Mouse-Brain
1308471|NCT00735631|Patients entering the post-operative cardiac intensive care unit following coronary artery reconstruction surgery.
1308472|NCT00735618|Advanced Cancer
1308473|NCT00735618|Cancer Patients
1308474|NCT00735618|Relaxation Therapy
1308475|NCT00735618|Relaxation and Heart Rate Variability
1308476|NCT00735618|Guided Relaxation
1308477|NCT00735618|HRV
1308478|NCT00735618|Stress, Anxiety, and Panic Disorder
1308479|NCT00735605|obstructed defecation
1308480|NCT00735605|constipation
1308481|NCT00735605|puborectalis
1308482|NCT00735592|X rays findings
1308483|NCT00735579|major abdominal surgery
1308484|NCT00735579|coagulation
1308485|NCT00735579|extracellular matrix proteins
1308486|NCT00735579|wound healing after major abdominal surgery
1308487|NCT00735566|gastric cancer
1308488|NCT00735566|antiangiogenic factors
1308489|NCT00735566|TNM stage
1308490|NCT00735553|Uterine Fibroids
1308491|NCT00735527|seizures
1308492|NCT00735527|status epilepticus
1308493|NCT00735527|lorazepam
1308494|NCT00735527|intra-nasal
1308495|NCT00735514|radiation toxicity
1308496|NCT00735514|sexuality and reproductive issues
1308497|NCT00735514|stage I endometrial carcinoma
1308498|NCT00735514|stage II endometrial carcinoma
1308499|NCT00735514|stage IB cervical cancer
1308500|NCT00735514|stage IIA cervical cancer
1308501|NCT00735514|stage IIB cervical cancer
1308502|NCT00735514|stage III cervical cancer
1308503|NCT00735488|Thalassemia
1308504|NCT00735488|Sickle cell anemia
1308505|NCT00735488|Carrier detection
1308506|NCT00735488|Prenatal Diagnosis
1308507|NCT00735488|Genetic counseling
1308508|NCT00735462|external genital warts
1308509|NCT00735462|perianal warts
1308510|NCT00735462|condylomata acuminata
1308511|NCT00735462|human papilloma virus
1308512|NCT00735462|HPV types 6 and 11
1308513|NCT00735436|Malignant glioma
1308514|NCT00735436|Glioblastoma multiforme
1308515|NCT00735436|GBM
1308516|NCT00735436|Gliosarcoma
1308517|NCT00735436|Gliadel
1308518|NCT00735436|Carmustine
1308519|NCT00735436|Irinotecan
1308520|NCT00735436|CPT-11
1308521|NCT00735436|Camptosar
1308522|NCT00735436|Avastin
1308523|NCT00735436|Bevacizumab
1308532|NCT00735410|Influenza vaccine
1308533|NCT00735410|Seasonal
1308534|NCT00735410|Split
1308535|NCT00735397|Partial onset seizures
1308536|NCT00735384|sepsis
1308537|NCT00735384|critical illness
1308538|NCT00735384|muscle, skeletal
1308539|NCT00735384|myopathy
1308540|NCT00735384|isometric contraction
1308541|NCT00735384|intensive care units
1308542|NCT00735384|torque
1308543|NCT00735384|muscular atrophy
1308544|NCT00735384|malignant hyperthermia
1308545|NCT00735384|skin resistance
1308546|NCT00735358|gastric variceal bleeding
1308547|NCT00735358|cyanoacrylate
1308548|NCT00735358|rebleeding
1308549|NCT00735358|complication
1308550|NCT00735358|survival
1308551|NCT00735358|acute gastric variceal bleeding
1308552|NCT00735345|Esophageal cancer
1308553|NCT00735345|Pre-operative
1308554|NCT00735345|Chemo-immunotherapy
1308555|NCT00735345|Radiochemo-immunotherapy
1308556|NCT00735345|EGFR
1308557|NCT00735345|Radiosensitivity
1308558|NCT00735345|Resection
1308559|NCT00735332|Melanoma
1308560|NCT00735332|Metastatic Melanoma
1308561|NCT00735332|Phase II
1308562|NCT00735332|Skin Cancer
1308563|NCT00735319|Neonatal Jaundice
1308564|NCT00735319|Physiological Neonatal Jaundice
1308565|NCT00735319|Neonatal Hyperbilirubinemia
1308566|NCT00735319|Transcutaneous Bilirubinometer
1308567|NCT00735306|Locally advanced
1308568|NCT00735306|Unresectable
1308569|NCT00735293|hyperhidrosis
1308570|NCT00735293|bromidrosis
1308571|NCT00735293|bromhidrosis
1308572|NCT00735293|osmidrosis
1308573|NCT00735293|hircismus
1308574|NCT00735293|excessive
1308575|NCT00735293|underarm
1308576|NCT00735293|sweat
1308577|NCT00735293|perspiration
1308578|NCT00735293|Body Odor
1308579|NCT00735280|Coronary artery disease, stent, heparin
1308580|NCT00735267|Generalized Anxiety Disorder
1308581|NCT00735254|post
1308582|NCT00735254|surgical
1308583|NCT00735241|colon cancer
1308584|NCT00735241|colorectal cancer
1308585|NCT00735241|liver metastases
1308586|NCT00735241|SIR-Spheres Microspheres
1308587|NCT00735241|yttrium-90
1308588|NCT00735241|FOLFOX
1308589|NCT00735241|Bevacizumab
1308590|NCT00735241|chemo-radiation
1308591|NCT00735228|surgery
1308592|NCT00735228|artificial pancreas
1308593|NCT00735228|tight glycemic control
1308594|NCT00735228|Liver
1308595|NCT00735215|Breast cancer,
1308596|NCT00735215|fulvestrant,
1308597|NCT00735215|postmenopausal,
1308598|NCT00735215|women
1308599|NCT00735215|locally advanced,
1308600|NCT00735215|hormone receptor-positive.
1308601|NCT00735189|warfarin
1308602|NCT00735189|anticoagulation
1308603|NCT00735189|anticoagulation clinics
1308604|NCT00735176|Radiculopathy, cervical
1308605|NCT00735176|Nerve Root Compression
1308606|NCT00735176|Disc, intervertebral
1308607|NCT00735176|Intervertebral Disk Displacement
1308608|NCT00735176|Spondylosis
1308609|NCT00735176|Spinal Osteophytosis
1308610|NCT00735176|Arthroplasty, replacement
1308611|NCT00735176|Diskectomy
1308612|NCT00735176|Spinal Fusion
1308613|NCT00735163|algorithm
1308614|NCT00735163|tight glycemic control
1308615|NCT00735163|glucose control
1308616|NCT00735163|intensive care
1308617|NCT00735163|insulin
1308618|NCT00735163|ICU
1308619|NCT00735150|Breast
1308620|NCT00735150|Ovary
1308621|NCT00735150|Mutation carrier
1308622|NCT00735137|Twins
1308623|NCT00735137|Short cervix
1308624|NCT00735137|Preterm birth
1308625|NCT00735137|Vaginal pessary
1308626|NCT00735124|analgesia requirement and post operative pain
1308627|NCT00735111|QOL
1308628|NCT00735111|Quality of Life
1308629|NCT00735111|KPS
1308630|NCT00735111|Karnofsky Performance Status
1308631|NCT00735111|Cancer
1308632|NCT00735098|Knee Osteoarthritis
1308633|NCT00735098|arthritis
1308634|NCT00735085|Brain Injury
1308635|NCT00735072|HIV infection
1308636|NCT00735072|T cell activation
1308637|NCT00735072|Antiretroviral Therapy
1308638|NCT00735072|CCR5
1308639|NCT00735072|Maraviroc
1308640|NCT00735059|dialysis membrane
1308641|NCT00735059|Polynephron
1308642|NCT00735059|Elisio H
1308643|NCT00735059|Polyethersulfone
1308644|NCT00735059|Diapes
1308645|NCT00735059|PES-DS
1308646|NCT00735059|online post-dilution hemodiafiltration
1308647|NCT00735059|hemodialysis
1308648|NCT00735059|protein-bound toxins
1308649|NCT00735059|beta-2-microglobulin
1308650|NCT00735059|hemodialysis patients
1308651|NCT00735046|Early dementia in Alzheimer's disease (MMSE ≥ 21)
1308652|NCT00735033|Physical therapy
1308653|NCT00735033|Physical therapy modalities
1308654|NCT00735033|Cerebral Vascular Accident (CVA)
1308655|NCT00735020|influenza
1308656|NCT00735020|vaccine
1308657|NCT00735020|adjuvants
1308658|NCT00735020|flu
1308659|NCT00735007|Multiple Sclerosis
1308660|NCT00734968|Urinary tract infection (UTI)
1308661|NCT00734968|suburethral sling
1308662|NCT00734968|Prevention
1308663|NCT00734968|Nitrofurantoin
1308664|NCT00734968|Prophylaxis
1308665|NCT00734955|Partial Mastectomy
1308666|NCT00734955|Lumpectomy
1308667|NCT00734955|Mastectomy
1308668|NCT00734942|young carers
1308669|NCT00734942|family support
1308670|NCT00734942|children (up to the age of 18) of chronically ill parents
1308671|NCT00734929|PONV
1308672|NCT00734929|nausea
1308673|NCT00734929|emesis
1308674|NCT00734929|antiemetics
1308675|NCT00734929|aprepitant
1308676|NCT00734929|ondansetron
1308677|NCT00734929|dexamethasone
1308678|NCT00734916|total parenteral nutrition
1308679|NCT00734916|infections
1308680|NCT00734916|Infectious complications related to parenteral nutrition
1308681|NCT00734903|Women
1308682|NCT00734903|Substance Use Disorders
1308683|NCT00734903|Treatment Efficacy
1308684|NCT00734903|Women's Health
1308685|NCT00734903|Outcome Assessment (Health Care)
1308686|NCT00734890|unspecified adult solid tumor, protocol specific
1308687|NCT00734890|AIDS-related diffuse large cell lymphoma
1308688|NCT00734890|AIDS-related diffuse mixed cell lymphoma
1308689|NCT00734890|AIDS-related diffuse small cleaved cell lymphoma
1308690|NCT00734890|AIDS-related immunoblastic large cell lymphoma
1308691|NCT00734890|AIDS-related lymphoblastic lymphoma
1308918|NCT00734331|cholinergic tone
1308692|NCT00734890|AIDS-related peripheral/systemic lymphoma
1308693|NCT00734890|AIDS-related small noncleaved cell lymphoma
1308694|NCT00734890|HIV-associated Hodgkin lymphoma
1308695|NCT00734890|recurrent adult Burkitt lymphoma
1308696|NCT00734890|recurrent adult diffuse large cell lymphoma
1308697|NCT00734890|recurrent adult diffuse mixed cell lymphoma
1308698|NCT00734890|recurrent adult diffuse small cleaved cell lymphoma
1308699|NCT00734890|recurrent adult grade III lymphomatoid granulomatosis
1308700|NCT00734890|recurrent adult Hodgkin lymphoma
1308701|NCT00734890|recurrent adult immunoblastic large cell lymphoma
1308702|NCT00734890|recurrent adult lymphoblastic lymphoma
1308703|NCT00734890|recurrent adult T-cell leukemia/lymphoma
1308704|NCT00734890|recurrent cutaneous T-cell non-Hodgkin lymphoma
1308705|NCT00734890|recurrent grade 1 follicular lymphoma
1308706|NCT00734890|recurrent grade 2 follicular lymphoma
1308707|NCT00734890|recurrent grade 3 follicular lymphoma
1308708|NCT00734890|recurrent mantle cell lymphoma
1308709|NCT00734890|recurrent marginal zone lymphoma
1308710|NCT00734890|recurrent small lymphocytic lymphoma
1308711|NCT00734890|anaplastic large cell lymphoma
1308712|NCT00734890|angioimmunoblastic T-cell lymphoma
1308713|NCT00734890|recurrent mycosis fungoides/Sezary syndrome
1308714|NCT00734890|adult nasal type extranodal NK/T-cell lymphoma
1308715|NCT00734890|Waldenström macroglobulinemia
1308716|NCT00734890|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1308717|NCT00734890|nodal marginal zone B-cell lymphoma
1308718|NCT00734890|splenic marginal zone lymphoma
1308719|NCT00734890|intraocular lymphoma
1308720|NCT00734890|post-transplant lymphoproliferative disorder
1308721|NCT00734890|cutaneous B-cell non-Hodgkin lymphoma
1308722|NCT00734890|small intestine lymphoma
1308723|NCT00734890|adenocarcinoma of the lung
1308724|NCT00734890|bronchoalveolar cell lung cancer
1308725|NCT00734890|large cell lung cancer
1308726|NCT00734890|adenosquamous cell lung cancer
1308727|NCT00734890|recurrent non-small cell lung cancer
1308728|NCT00734890|stage IIIA non-small cell lung cancer
1308729|NCT00734890|stage IIIB non-small cell lung cancer
1308730|NCT00734890|stage IV non-small cell lung cancer
1308731|NCT00734890|stage III adult Burkitt lymphoma
1308732|NCT00734890|stage III adult diffuse large cell lymphoma
1308733|NCT00734890|stage III adult diffuse mixed cell lymphoma
1308734|NCT00734890|stage III adult diffuse small cleaved cell lymphoma
1308735|NCT00734890|stage III adult Hodgkin lymphoma
1308736|NCT00734890|stage III adult immunoblastic large cell lymphoma
1308737|NCT00734890|stage III adult lymphoblastic lymphoma
1308738|NCT00734890|stage III adult T-cell leukemia/lymphoma
1308739|NCT00734890|stage III cutaneous T-cell non-Hodgkin lymphoma
1308740|NCT00734890|stage III grade 1 follicular lymphoma
1308741|NCT00734890|stage III grade 2 follicular lymphoma
1308742|NCT00734890|stage III grade 3 follicular lymphoma
1308743|NCT00734890|stage III mantle cell lymphoma
1308744|NCT00734890|stage III marginal zone lymphoma
1308745|NCT00734890|stage III mycosis fungoides/Sezary syndrome
1308746|NCT00734890|stage III small lymphocytic lymphoma
1308747|NCT00734890|stage IV adult Burkitt lymphoma
1308748|NCT00734890|stage IV adult diffuse large cell lymphoma
1308749|NCT00734890|stage IV adult diffuse mixed cell lymphoma
1308750|NCT00734890|stage IV adult diffuse small cleaved cell lymphoma
1308751|NCT00734890|stage IV adult Hodgkin lymphoma
1308752|NCT00734890|stage IV adult immunoblastic large cell lymphoma
1308753|NCT00734890|stage IV adult lymphoblastic lymphoma
1308754|NCT00734890|stage IV adult T-cell leukemia/lymphoma
1308755|NCT00734890|stage IV cutaneous T-cell non-Hodgkin lymphoma
1308756|NCT00734890|stage IV grade 1 follicular lymphoma
1308757|NCT00734890|stage IV grade 2 follicular lymphoma
1308758|NCT00734890|stage IV grade 3 follicular lymphoma
1308759|NCT00734890|stage IV mantle cell lymphoma
1308760|NCT00734890|stage IV marginal zone lymphoma
1308761|NCT00734890|stage IV mycosis fungoides/Sezary syndrome
1308762|NCT00734890|stage IV small lymphocytic lymphoma
1308763|NCT00734864|Dasatinib
1308764|NCT00734864|Sprycel
1308765|NCT00734864|Temozolomide
1308766|NCT00734864|Temodar
1308767|NCT00734864|Recurrent Malignant Glioma
1308768|NCT00734864|Malignant Glioma
1308769|NCT00734864|glioblastoma multiforme
1308770|NCT00734864|gliosarcoma
1308771|NCT00734864|anaplastic astrocytoma
1308772|NCT00734864|anaplastic oligodendroglioma
1308773|NCT00734864|anaplastic mixed glioma
1308774|NCT00734864|glioma
1308775|NCT00734851|prostate cancer
1308776|NCT00734851|sunitinib
1308777|NCT00734851|docetaxel
1308778|NCT00734851|PSA
1308779|NCT00734851|radiation
1308780|NCT00734851|PSA recurrence
1308781|NCT00734851|No metastatic disease
1308782|NCT00734838|Breast Cancer
1308783|NCT00734838|Breast Biopsy
1308784|NCT00734838|Reduction mammoplasty
1308785|NCT00734825|Appendicitis
1308786|NCT00734825|IV Contrast
1308787|NCT00734825|Oral Contrast
1308788|NCT00734825|CT scan
1308789|NCT00734812|Hysterectomy
1308790|NCT00734812|Laparoscopic
1308791|NCT00734799|Posttraumatic Stress Disorder
1308792|NCT00734799|Insomnia,
1308793|NCT00734799|Imagery Rehearsal Therapy,
1308794|NCT00734799|IRT,
1308795|NCT00734799|Cognitive Behavioral Therapy for Insomnia,
1308796|NCT00734799|CBTI.
1308797|NCT00734786|gonyautoxin
1308798|NCT00734773|neurotoxicity
1308799|NCT00734773|primary central nervous system non-Hodgkin lymphoma
1308800|NCT00734773|primary central nervous system Hodgkin lymphoma
1308801|NCT00734760|patient education
1308802|NCT00734760|acute coronary syndrome
1308803|NCT00734760|prehospital delay to treatment
1308804|NCT00734747|GERD
1308805|NCT00734747|Gastroesophageal Reflux
1308806|NCT00734747|Fundoplication
1308807|NCT00734747|Endoluminal
1308808|NCT00734747|Gastroesophageal Flap Valve
1308809|NCT00734734|Prophylaxis of Influenza
1308810|NCT00734734|Influenza Vaccines
1308811|NCT00734734|MF59C.1
1308812|NCT00734721|intravitreal injection
1308813|NCT00734695|BURN
1308814|NCT00734695|EYE
1308815|NCT00734695|VITAMIN C
1308816|NCT00734695|ASCORBIC ACID
1308817|NCT00734682|Glioblastoma
1308818|NCT00734682|Gliosarcoma
1308819|NCT00734682|Anaplastic Astrocytoma
1308820|NCT00734682|Anaplastic Oligodendroglioma
1308821|NCT00734682|Anaplastic Mixed Oligoastrocytoma
1308822|NCT00734682|Malignant Astrocytoma NOS
1308823|NCT00734682|Nanoliposomal CPT-11
1308824|NCT00734682|liposomal irinotecan
1308825|NCT00734669|Diabetes
1308826|NCT00734669|Hypoglycemia
1308827|NCT00734656|steroid 5Alpha Reductase
1308828|NCT00734656|dutasteride
1308829|NCT00734656|neuroactive steroid
1308830|NCT00734643|Hypoplastic Left Heart Syndrome
1308831|NCT00734643|Family coping
1308832|NCT00734643|Complex Congenital Heart Disease
1308833|NCT00734630|nebivolol
1308834|NCT00734630|Bystolic ™
1308835|NCT00734630|lisinopril
1308836|NCT00734630|losartan
1308837|NCT00734630|Hypertension
1308838|NCT00734617|Cigarette
1308839|NCT00734617|Nicotine
1308840|NCT00734591|Observational Study Exubera
1308841|NCT00734565|vaccine
1308842|NCT00734565|prevention
1308843|NCT00734565|haemophilus influenzae type b
1308844|NCT00734565|children
1308845|NCT00734552|Continuous Ambulatory Peritoneal Dialysis
1308846|NCT00734552|α-Keto Acid
1308847|NCT00734552|Low Protein Diet
1308848|NCT00734552|Residual Renal Function
1308849|NCT00734539|Candida
1308850|NCT00734539|Neonate
1308851|NCT00734539|Fluconazole
1308852|NCT00734539|Prophylaxis
1308853|NCT00734539|Colonization
1308854|NCT00734539|Resistance
1308855|NCT00734526|Glioblastoma
1308856|NCT00734526|Gliosarcoma
1308857|NCT00734526|Brain Cancer
1308858|NCT00734526|Sorafenib
1308859|NCT00734526|Temozolomide
1308860|NCT00734526|Radiation
1308861|NCT00734526|Radiotherapy
1308862|NCT00734526|XRT
1308863|NCT00734513|GI Cancer
1308864|NCT00734513|Emotional Disclosure
1308865|NCT00734513|Behavioral Intervention
1308866|NCT00734513|Partner
1308867|NCT00734513|Couples
1308868|NCT00734487|Spectral Domain Optical Coherence Tomography
1308869|NCT00734487|Optical Coherence Tomography
1308870|NCT00734487|AREDS2
1308871|NCT00734487|AMD
1308872|NCT00734487|Age-related macular degeneration
1308873|NCT00734487|Drusen
1308874|NCT00734474|Diabetes, type 2 diabetes
1308875|NCT00734461|Non-physically dependent subjects
1308876|NCT00734461|history of opioid abuse
1308877|NCT00734448|gestational diabetes mellitus
1308878|NCT00734448|carbohydrate intolerance
1308879|NCT00734448|myo-inositol
1308880|NCT00734448|insulin resistance
1308881|NCT00734435|schizophrenia
1308882|NCT00734435|schizophreniform
1308883|NCT00734435|schizoaffective disorder
1308884|NCT00734435|Zyprexa
1308885|NCT00734435|olanzapine
1308886|NCT00734422|Phobic Disorders (Fear of Flying)
1308887|NCT00734422|Virtual Reality Exposure Therapy
1308888|NCT00734422|Fear extinction
1308889|NCT00734422|Yohimbine
1308890|NCT00734409|Mechanical ventilation
1308891|NCT00734409|Human
1308892|NCT00734409|conscious sedation
1308893|NCT00734409|bispectral index
1308894|NCT00734409|monitoring
1308895|NCT00734409|critical care
1308896|NCT00734409|propofol
1308897|NCT00734396|Mesenchymal stem cells
1308898|NCT00734396|Allograft rejection
1308899|NCT00734396|Subclinical rejection
1308900|NCT00734383|coronary artery bypass surgery
1308901|NCT00734383|coronary artery bypass grafting
1308902|NCT00734383|cardiopulmonary bypass
1308903|NCT00734383|diabetes
1308904|NCT00734383|myocardial injury markers,
1308905|NCT00734383|sex differences
1308906|NCT00734383|cardiac anesthesia
1308907|NCT00734383|inhalational anesthetics
1308908|NCT00734370|Panic Disorder and Agoraphobia
1308909|NCT00734370|Virtual Reality Exposure Therapy
1308910|NCT00734357|contrast
1308911|NCT00734357|ct
1308912|NCT00734357|cat scan
1308913|NCT00734357|kidney
1308914|NCT00734357|nephrotoxicity
1308915|NCT00734357|Computerized Emission Tomography
1308916|NCT00734331|inflammatory bowel disease
1308917|NCT00734331|micro RNA
1308919|NCT00734331|inflammation
1308920|NCT00734318|Severe asthma
1308921|NCT00734318|Fluticasone
1308922|NCT00734318|Formoterol
1308923|NCT00734305|cancer, solid tumors, oncology, Phase I, ErbB3, HER3
1308924|NCT00734305|(erbB-3, HER-3)
1308925|NCT00734292|Asthma
1308926|NCT00734292|Asthma Mild to Moderate
1308927|NCT00734279|Puberty
1308928|NCT00734279|Delayed
1308929|NCT00734279|Early
1308930|NCT00734279|Precocious
1308931|NCT00734279|Peripubertal
1308932|NCT00734279|Gonadotropin
1308933|NCT00734279|FSH
1308934|NCT00734279|LH
1308935|NCT00734266|COPD
1308936|NCT00734266|CPB
1308937|NCT00734266|Leukotrienes
1308938|NCT00734253|Nephropathy
1308939|NCT00734253|Kidney Disease
1308940|NCT00734253|Diabetes
1308941|NCT00734253|Pyridoxamine
1308942|NCT00734253|Pyridorin
1308943|NCT00734253|NephroGenex
1308944|NCT00734253|PYR-210
1308945|NCT00734227|Survival and control of hemorrhage
1308946|NCT00734214|Parenteral Fluids
1308947|NCT00734214|Isotonic
1308948|NCT00734214|Hypotonic
1308949|NCT00734214|Pediatric
1308950|NCT00734214|Fluid overload
1308951|NCT00734201|Study effects on blood pressure and weight in obese subjects
1308952|NCT00734175|Vaccine
1308953|NCT00734175|Influenza
1308954|NCT00734162|tenofovir
1308955|NCT00734162|adolescents
1308956|NCT00734162|chronic hepatitis B
1308957|NCT00734149|Multiple myeloma
1308958|NCT00734136|Angiogenic Factors
1308959|NCT00734136|Hepatorenal Syndrome
1308960|NCT00734136|Liver Disease
1308961|NCT00734136|Renal Failure
1308962|NCT00734136|Liver Cirrhosis
1308963|NCT00734136|Ascites
1308964|NCT00734123|Atherosclerosis
1308965|NCT00734123|Cardiovascular Prevention
1308966|NCT00734123|Carotid Intima-Media Thickness
1308967|NCT00734123|Ankle-Brachial Index
1308968|NCT00734110|Arthroplasty, Replacement, Knee, P.F.C. Sigma RPF, Sigma RP
1308969|NCT00734097|heartburn
1308970|NCT00734097|reflux
1308971|NCT00734097|proton
1308972|NCT00734097|pump
1308973|NCT00734097|inhibitor
1308974|NCT00734084|Arthroplasty
1308975|NCT00734084|Knee
1308976|NCT00734084|UKA
1308977|NCT00734084|Partial
1308978|NCT00734084|Preservation
1308979|NCT00734071|Generalized Anxiety Disorder
1308980|NCT00734071|Mood Disorder
1308981|NCT00734071|Affective Disorder
1308982|NCT00734071|Anxiety Disorder
1308983|NCT00734071|Drug Therapy
1308984|NCT00734058|Ablation
1308985|NCT00734058|AF
1308986|NCT00734058|Atrial Fibrillation
1308987|NCT00734058|Cardiac
1308988|NCT00734058|Endocardial
1308989|NCT00734058|Endocardium
1308990|NCT00734058|EP
1308991|NCT00734058|Electrophysiology
1308992|NCT00734058|Epicardial
1308993|NCT00734058|Epicardium
1308994|NCT00734058|Heart
1308995|NCT00734058|Interventional
1308996|NCT00734058|Lesion
1308997|NCT00734058|PVI
1308998|NCT00734058|Pulmonary Vein
1308999|NCT00734058|MAZE
1309000|NCT00734058|Surgery
1309001|NCT00734058|Surgical
1309002|NCT00734058|Treatment
1309003|NCT00734058|Patients with persistent AF with 3 months duration
1309004|NCT00734058|Requiring concomitant open heart surgery
1309005|NCT00734045|Congestive Heart Failure (CHF)
1309006|NCT00734045|NT-proBNP
1309007|NCT00734032|SB-480848
1309008|NCT00734032|Dyslipidaemia
1309009|NCT00734019|Arthroplasty, Replacement, Knee, TKR, PFC Sigma
1309010|NCT00734006|Cortico-cortical
1309011|NCT00734006|connectivity
1309012|NCT00734006|Transcranial
1309013|NCT00734006|Magnetic
1309014|NCT00734006|Stimulation
1309015|NCT00733993|substance abuse
1309016|NCT00733993|cocaine
1309017|NCT00733993|caffeine
1309018|NCT00733993|impulsivity
1309019|NCT00733980|Depressive Disorder, Major
1309020|NCT00733967|Methamphetamine
1309021|NCT00733967|Chantix
1309022|NCT00733967|Varenicline
1309023|NCT00733941|Exercise test
1309024|NCT00733941|Running
1309025|NCT00733941|Arterial diameter
1309026|NCT00733941|Monitoring, physiologic
1309027|NCT00733941|Oxygen Consumption
1309028|NCT00733928|Arthroplasty,
1309029|NCT00733928|Replacement,
1309030|NCT00733928|Knee,
1309031|NCT00733928|P.F.C.
1309032|NCT00733928|Sigma
1309033|NCT00733928|all-polyethylene
1309034|NCT00733915|Arthroplasty, knee, TKA, TKR, Duofix, Porocoat, LCS
1309035|NCT00733902|monoclonal antibody
1309036|NCT00733902|RN624
1309037|NCT00733902|PF-04383119
1309038|NCT00733902|nerve growth factor
1309039|NCT00733902|anti-nerve growth factor
1309040|NCT00733902|OA
1309041|NCT00733902|pain
1309042|NCT00733889|esophageal carcinoma
1309043|NCT00733889|cetuximab
1309044|NCT00733889|docetaxel
1309045|NCT00733889|cisplatin
1309046|NCT00733889|5-fluorouracil
1309047|NCT00733876|Acute Renal Failure Cardiac Surgery Stem Cell
1309048|NCT00733863|Active immunization
1309049|NCT00733863|Alzheimer disease
1309050|NCT00733863|Antibody
1309051|NCT00733863|Central Nervous System Diseases
1309052|NCT00733863|Neurodegenerative diseases
1309053|NCT00733863|Vaccine
1309054|NCT00733824|Plerixafor
1309055|NCT00733824|Lymphoma
1309056|NCT00733824|Hematopoietic Stem Cell Mobilization
1309057|NCT00733824|Transplantation, Autologous
1309058|NCT00733824|Receptors, CXCR4
1309059|NCT00733811|thalassemia major
1309060|NCT00733811|chelation treatment
1309061|NCT00733811|secondary hemochromatosis
1309062|NCT00733798|Melanoma
1309063|NCT00733798|Malignant melanoma
1309064|NCT00733798|metastatic melanoma
1309065|NCT00733798|Phase 1
1309066|NCT00733798|Phase 2
1309067|NCT00733785|Rosiglitazone XR
1309068|NCT00733785|Pharmacokinetics
1309069|NCT00733785|Strength Equivalence.
1309070|NCT00733785|Alzheimers Disease
1309071|NCT00733785|Repeat dose
1309072|NCT00733785|Dose proportionality
1309073|NCT00733772|flaxseed
1309074|NCT00733772|lignans
1309075|NCT00733772|alpha-Linolenic Acid
1309076|NCT00733772|LDL Cholesterol
1309077|NCT00733746|adenocarcinoma of the pancreas
1309078|NCT00733746|stage I pancreatic cancer
1309079|NCT00733746|stage II pancreatic cancer
1309080|NCT00733733|kidney
1309081|NCT00733733|transplantation
1309082|NCT00733733|non-heart-beating donor
1309083|NCT00733733|delayed graft function
1309084|NCT00733733|Antithymocyte globulin
1309085|NCT00733733|ischemia-reperfusion damage
1309086|NCT00733707|adherence
1309087|NCT00733707|oral contraceptive pills
1309088|NCT00733707|contraception
1309089|NCT00733707|text messaging
1309090|NCT00733694|Arthroplasty, Replacement, Knee,LCS
1309091|NCT00733681|Arthroplasty, Replacement, Knee
1309092|NCT00733681|Prosthesis Failure
1309093|NCT00733681|Revision surgery
1309094|NCT00733668|considered
1309095|NCT00733668|entry
1309096|NCT00733668|into
1309097|NCT00733668|the study
1309098|NCT00733668|SSRI
1309099|NCT00733668|Seroquel
1309100|NCT00733668|Quetiapine
1309101|NCT00733668|fumarate
1309102|NCT00733668|antipsychotic
1309103|NCT00733642|antibody amyloid Alzheimer's Disease AD
1309104|NCT00733616|advanced gastric adenocarcinoma
1309105|NCT00733616|docetaxel
1309106|NCT00733616|oxaliplatin
1309107|NCT00733616|capecitabine
1309108|NCT00733616|intermediate general status
1309109|NCT00733603|Interstitial Cystitis
1309110|NCT00733603|IC
1309111|NCT00733603|Painful Bladder Syndrome
1309112|NCT00733603|PBS
1309113|NCT00733603|Bladder Pain
1309114|NCT00733603|Pelvic Pain
1309115|NCT00733590|defibrillator, implanted
1309116|NCT00733590|genomics
1309117|NCT00733590|electrocardiography
1309118|NCT00733590|electrophysiological study
1309119|NCT00733590|proteomics
1309120|NCT00733577|diabetes
1309121|NCT00733577|pharmacodynamics
1309122|NCT00733577|safety
1309123|NCT00733577|pharmacokinetics
1309124|NCT00733564|Local anesthetic
1309125|NCT00733564|Propofol
1309126|NCT00733564|Sevoflurane
1309127|NCT00733551|motilin
1309128|NCT00733551|gastric emptying
1309129|NCT00733551|GSK962040
1309130|NCT00733551|oral dose
1309131|NCT00733538|stage I multiple myeloma
1309132|NCT00733525|Bulimia Nervosa
1309133|NCT00733512|ReSTOR Aspheric +4 IOL
1309134|NCT00733499|Arthroplasty, replacement, Knee, LCS Duofix, Porocoat
1309135|NCT00733486|Arthroplasty, Replacement, Knee, LCS Complete APG (MeSH);
1309136|NCT00733473|Wheezing
1309137|NCT00733473|Acute asthma
1309138|NCT00733473|Children
1309139|NCT00733460|BFPET
1309140|NCT00733460|Coronary Artery Disease
1309141|NCT00733460|Myocardial Perfusion Imaging
1309142|NCT00733460|Radiation Dosimetry
1309143|NCT00733447|Biventricular failure
1309144|NCT00733434|Microsurgery
1309145|NCT00733434|Head and neck
1309146|NCT00733434|Prostaglandin E1
1309147|NCT00733434|Thrombosis
1309148|NCT00733434|Complication
1309149|NCT00733421|Day surgery
1309150|NCT00733421|Hallux Valgus
1309151|NCT00733421|Pain
1309152|NCT00733421|Analgesics
1309153|NCT00733395|Muscle pain
1309154|NCT00733382|migraine
1309155|NCT00733382|dexamethasone
1309156|NCT00733382|dihydroergotamine
1309157|NCT00733369|Arthroplasty
1309158|NCT00733369|Replacement
1309159|NCT00733369|Knee
1309160|NCT00733369|PFC Sigma RPF
1309161|NCT00733369|PFC Sigma RP
1309162|NCT00733356|Attention Deficit Hyperactivity Disorder
1309163|NCT00733356|ADHD
1309164|NCT00733356|ADD
1309165|NCT00733356|reading
1309166|NCT00733356|brain hemodynamics
1309167|NCT00733356|brain imaging
1309168|NCT00733356|attention
1309169|NCT00733356|Near-Infrared Spectroscopy
1309170|NCT00733356|NIRS
1309171|NCT00733356|MSIT
1309172|NCT00733343|heart failure
1309173|NCT00733343|sleep disordered breathing
1309174|NCT00733343|sleep apnea
1309175|NCT00733343|left ventricular systolic dysfunction
1309176|NCT00733343|SBAS
1309177|NCT00733343|HF
1309178|NCT00733330|Arthroplasty, Knee, TKA, TKR, CAS, minimally invasive
1309179|NCT00733317|Wheezing
1309180|NCT00733317|Acute asthma
1309181|NCT00733317|Children
1309182|NCT00733317|Budesonide
1309183|NCT00733317|Emergency room
1309184|NCT00733304|vascular endothelial growth factor (VEGF)
1309185|NCT00733304|choroidal neovascularization (CNV)
1309186|NCT00733304|age-related macular degeneration (AMD)
1309187|NCT00733304|pazopanib
1309188|NCT00733304|angiogenesis
1309189|NCT00733291|Daily disposable contact lenses
1309190|NCT00733291|Multi-purpose disinfecting solutions
1309191|NCT00733278|Postpartum contraception
1309192|NCT00733278|Copper IUD
1309193|NCT00733265|Renal Impairment
1309194|NCT00733252|non-small cell lung cancer
1309195|NCT00733252|small cell lung cancer
1309196|NCT00733252|benign respiratory tract neoplasm
1309197|NCT00733252|lung papilloma
1309198|NCT00733252|recurrent respiratory papillomatosis
1309199|NCT00733252|squamous lung dysplasia
1309200|NCT00733252|malignant mesothelioma
1309201|NCT00733252|pulmonary carcinoid tumor
1309202|NCT00733252|lung metastases
1309203|NCT00733239|methadone
1309204|NCT00733239|opioid dependence
1309205|NCT00733239|opioid
1309206|NCT00733226|wheezing
1309207|NCT00733226|asthma
1309208|NCT00733226|childhood
1309209|NCT00733226|OM-85 BV
1309210|NCT00733226|Broncho-Vaxom
1309211|NCT00733213|Prostate Cancer, Treatment alternatives, Metastasis
1309212|NCT00733200|Minor Liver Resection
1309213|NCT00733200|Major Liver Resection
1309214|NCT00733200|Hilar
1309215|NCT00733174|IGT
1309216|NCT00733161|passive leg exercise
1309217|NCT00733161|congestive heart failure
1309218|NCT00733161|endothelium-derived factors
1309219|NCT00733161|elderly
1309220|NCT00733148|glucose, interstitial, intensive care
1309221|NCT00733135|peripheral vascular disease
1309222|NCT00733135|atherectomy
1309223|NCT00733135|atherosclerosis
1309224|NCT00733135|calcified lesions
1309225|NCT00733109|CIN2
1309226|NCT00733109|management
1309227|NCT00733096|radiculopathy
1309228|NCT00733096|sciatica
1309229|NCT00733096|low back pain
1309230|NCT00733083|tonsillectomy
1309231|NCT00733083|paediatric
1309232|NCT00733083|pain
1309233|NCT00733083|child
1309234|NCT00733083|opiates
1309235|NCT00733083|pre-emptive
1309236|NCT00733083|oxycodone
1309237|NCT00733083|morphine
1309238|NCT00733083|dexamethasone
1309239|NCT00733070|CTO
1309240|NCT00733070|Chronic Total Occlusion
1309241|NCT00733070|Revascularization
1309242|NCT00733057|Minocycline
1309243|NCT00733057|Schizophrenia
1309244|NCT00733057|Negative symptoms
1309245|NCT00733057|Cognitive
1309246|NCT00733044|Objective tinnitus
1309247|NCT00733044|Tinnitus
1309248|NCT00733044|RCT
1309249|NCT00733044|Specialised treatment
1309250|NCT00733044|Usual care
1309251|NCT00733044|Cost-effectiveness
1309252|NCT00733031|Phase I,
1309253|NCT00733031|cancer,
1309254|NCT00733031|solid tumors,
1309255|NCT00733031|advanced solid malignancies,
1309256|NCT00733031|dose escalation,
1309257|NCT00733031|combination treatment,
1309258|NCT00733031|TRK inhibitor
1309259|NCT00733018|Nutrigenomics
1309260|NCT00733018|Gene Expression
1309261|NCT00733018|Diet, Carbohydrate-Restricted
1309262|NCT00733018|Life Style
1309263|NCT00733018|Health Behavior
1309264|NCT00732992|Solid tumor
1309265|NCT00732992|malignancy
1309266|NCT00732992|sunitinib
1309267|NCT00732992|pemetrexed
1309268|NCT00732992|phase 1
1309269|NCT00732992|neoplasms
1309270|NCT00732979|Elective
1309271|NCT00732979|hepatic
1309272|NCT00732979|resection
1309273|NCT00732979|due to any
1309274|NCT00732979|reason.
1309275|NCT00732966|cyp2c9
1309276|NCT00732966|losartan
1309277|NCT00732966|pharmacogenetics
1309278|NCT00732966|pharmacokinetics
1309279|NCT00732966|pharmacodynamics
1309280|NCT00732953|patients with coronary artery disease
1309281|NCT00732953|percutaneous coronary intervention
1309282|NCT00732953|stent implantation
1309283|NCT00732953|paclitaxel eluting balloon
1309284|NCT00732953|angiographic follow-up
1309285|NCT00732953|clinical follow-up
1309286|NCT00732940|SLE
1309287|NCT00732940|Lupus
1309288|NCT00732940|Systemic Lupus Erythematosus
1309289|NCT00732940|Antibodies
1309290|NCT00732940|Autoimmune Diseases
1309291|NCT00732940|Belimumab
1309292|NCT00732927|thrombosis, vein, retina
1309293|NCT00732914|Renal Cell Carcinoma
1309294|NCT00732914|Sunitinib
1309295|NCT00732914|Sorafenib
1309296|NCT00732914|Sequential
1309297|NCT00732901|substance abuse
1309298|NCT00732901|cocaine
1309299|NCT00732901|impulsivity
1309300|NCT00732901|serotonin
1309301|NCT00732901|Remeron
1309302|NCT00732901|Mirtzapine
1309303|NCT00732901|Lexapro
1309304|NCT00732901|Escatilopram
1309305|NCT00732888|Pharmacokinetics
1309306|NCT00732888|Healthy volunteers
1309307|NCT00732888|No condition
1309308|NCT00732888|Pharmacokinetics study
1309309|NCT00732862|Type 2 diabetes
1309310|NCT00732862|intensive therapy
1309311|NCT00732849|immunonutrition
1309312|NCT00732849|surgical patients
1309313|NCT00732849|postoperative period
1309314|NCT00732836|Liver Cancer
1309315|NCT00732836|Solid Cancer
1309316|NCT00732836|Abraxane
1309317|NCT00732836|nab paclitaxel
1309318|NCT00732836|HAI abraxane
1309319|NCT00732836|HAI
1309320|NCT00732836|hepatic arterial infusion
1309321|NCT00732836|hepatic metastases
1309322|NCT00732797|Dizziness
1309323|NCT00732797|Self-management
1309324|NCT00732797|booklet-based
1309325|NCT00732797|vestibular rehabilitation
1309326|NCT00732784|Pharmacokinetics
1309327|NCT00732784|Healthy volunteers
1309328|NCT00732784|No condition
1309329|NCT00732784|Pharmacokinetics study
1309330|NCT00732771|primary hyperaldosteronism
1309331|NCT00732771|hypokalemia
1309332|NCT00732771|hypertension
1309333|NCT00732771|aldosterone synthase inhibitor
1309334|NCT00732758|Vitamin D Deficiency
1309335|NCT00732758|Vitamin D Insufficiency
1309336|NCT00732758|Child
1309337|NCT00732758|Adolescent
1309338|NCT00732758|African American
1309339|NCT00732758|Caucasian
1309340|NCT00732758|Definition
1309341|NCT00732758|Preadolescent
1309342|NCT00732745|adenocarcinoma of the esophagus
1309343|NCT00732745|adenocarcinoma of the gastroesophageal junction
1309344|NCT00732745|squamous cell carcinoma of the esophagus
1309345|NCT00732745|stage III esophageal cancer
1309346|NCT00732745|stage IV esophageal cancer
1309347|NCT00732745|recurrent esophageal cancer
1309348|NCT00732732|diarrhea
1309349|NCT00732732|Plantain
1309350|NCT00732732|Green banana
1309351|NCT00732732|Infants
1309352|NCT00732732|Children
1309353|NCT00732706|FNB
1309354|NCT00732706|Femoral Nerve
1309355|NCT00732706|Sartorius Twitch
1309356|NCT00732706|Quadriceps Twitch
1309357|NCT00732706|Analgesia
1309358|NCT00732706|Anesthesia
1309359|NCT00732693|Premature ovarian failure
1309360|NCT00732693|Sex hormone replacement
1309361|NCT00732693|HRT
1309362|NCT00732693|Blood pressure
1309363|NCT00732693|Bone mineral density
1309364|NCT00732693|Bone metabolism
1309365|NCT00732693|Uterine function
1309366|NCT00732680|Empty nose syndrome
1309367|NCT00732680|Over resection of turbinate
1309368|NCT00732680|Atrophic rhinitis
1309369|NCT00732654|Food Allergy
1309370|NCT00732654|Oral Immunotherapy
1309371|NCT00732654|Immunoglobulin E
1309372|NCT00732615|Hypoparathyroidism
1309373|NCT00732602|Glucagon
1309374|NCT00732602|Glucose-dependent Insulinotropic Polypeptide
1309375|NCT00732602|Glucagon-Like peptide 2
1309376|NCT00732589|suprascapular nerve block
1309377|NCT00732589|shoulder pain
1309378|NCT00732589|hemiplegia
1309379|NCT00732576|Cardiovascular
1309380|NCT00732576|Calcification
1309381|NCT00732563|stage I non-small cell lung cancer
1309382|NCT00732563|stage II non-small cell lung cancer
1309383|NCT00732550|cholelithiasis
1309384|NCT00732550|cholecystitis
1309385|NCT00732537|Hypoxia
1309386|NCT00732537|Respiratory failure
1309387|NCT00732537|Infant, term
1309388|NCT00732537|Nitric oxide
1309389|NCT00732524|Hyperglycemia
1309390|NCT00732524|Glucose toxicity
1309391|NCT00732524|Glargine
1309392|NCT00732524|Glipizide
1309393|NCT00732511|Endothelial dysfunction
1309394|NCT00732511|Blood vessel stiffness
1309395|NCT00732511|Nitric oxide
1309396|NCT00732511|Oxidative stress
1309397|NCT00732498|contiguous stage II grade 1 follicular lymphoma
1309398|NCT00732498|contiguous stage II grade 2 follicular lymphoma
1309399|NCT00732498|contiguous stage II grade 3 follicular lymphoma
1309400|NCT00732498|noncontiguous stage II grade 1 follicular lymphoma
1309401|NCT00732498|noncontiguous stage II grade 2 follicular lymphoma
1309402|NCT00732498|noncontiguous stage II grade 3 follicular lymphoma
1309403|NCT00732498|recurrent grade 1 follicular lymphoma
1309404|NCT00732498|recurrent grade 2 follicular lymphoma
1309405|NCT00732498|recurrent grade 3 follicular lymphoma
1309406|NCT00732498|stage III grade 1 follicular lymphoma
1309407|NCT00732498|stage III grade 2 follicular lymphoma
1309408|NCT00732498|stage III grade 3 follicular lymphoma
1309409|NCT00732498|stage IV grade 1 follicular lymphoma
1309410|NCT00732498|stage IV grade 2 follicular lymphoma
1309411|NCT00732498|stage IV grade 3 follicular lymphoma
1309412|NCT00732485|Burn injury
1309413|NCT00732485|Fenofibrate
1309414|NCT00732485|Insulin resistance
1309415|NCT00732485|Mitochondrial function
1309416|NCT00732485|Fat oxidation
1309417|NCT00732485|PPAR
1309418|NCT00732485|Protein
1309419|NCT00732485|Glucose
1309420|NCT00732485|Wound
1309421|NCT00732472|Chronic Obstructive Pulmonary Disease (COPD)
1309422|NCT00732472|Magnesium stearate
1309423|NCT00732472|GSK573719
1309424|NCT00732459|myocardial protection
1309425|NCT00732459|cardiac surgery
1309426|NCT00732459|heart valve replacement
1309427|NCT00732446|moxifloxacin
1309428|NCT00732446|dexamethasone
1309429|NCT00732446|ocular inflammation
1309430|NCT00732446|ocular infection
1309431|NCT00732420|pazopanib
1309432|NCT00732420|Phase I
1309433|NCT00732420|topotecan
1309434|NCT00732420|Advanced Solid Tumors
1309435|NCT00732407|aliskiren
1309436|NCT00732407|arteial stiffness
1309437|NCT00732407|platelet function
1309438|NCT00732407|diabetes mellitus
1309439|NCT00732355|syphilis
1309440|NCT00732342|Alcohol Abuse
1309441|NCT00732342|Contingency Management
1309442|NCT00732342|Treatment Duration
1309443|NCT00732316|accelerated phase chronic myelogenous leukemia
1309444|NCT00732316|adult acute lymphoblastic leukemia in remission
1309445|NCT00732316|adult acute myeloid leukemia in remission
1309446|NCT00732316|acute undifferentiated leukemia
1309447|NCT00732316|blastic phase chronic myelogenous leukemia
1309448|NCT00732316|childhood acute lymphoblastic leukemia in remission
1309449|NCT00732316|childhood acute myeloid leukemia in remission
1309450|NCT00732316|childhood chronic myelogenous leukemia
1309451|NCT00732316|childhood myelodysplastic syndromes
1309452|NCT00732316|chronic phase chronic myelogenous leukemia
1309453|NCT00732316|chronic myelomonocytic leukemia
1309454|NCT00732316|de novo myelodysplastic syndromes
1309455|NCT00732316|previously treated myelodysplastic syndromes
1309456|NCT00732316|recurrent childhood acute lymphoblastic leukemia
1309457|NCT00732316|recurrent childhood acute myeloid leukemia
1309458|NCT00732316|recurrent adult acute lymphoblastic leukemia
1309459|NCT00732316|recurrent adult acute myeloid leukemia
1309460|NCT00732316|refractory anemia with excess blasts
1309461|NCT00732316|refractory anemia with excess blasts in transformation
1309462|NCT00732316|relapsing chronic myelogenous leukemia
1309463|NCT00732316|secondary myelodysplastic syndromes
1309464|NCT00732290|Healthy volunteer
1309465|NCT00732290|Pharmacokinetic
1309466|NCT00732290|pharmacodynamic
1309467|NCT00732290|Polymorphism, Genetic
1309468|NCT00732277|sepsis
1309469|NCT00732277|septicaemia
1309470|NCT00732277|septicemia
1309471|NCT00732277|paediatric
1309472|NCT00732277|pediatric
1309473|NCT00732277|children
1309474|NCT00732251|Bipolar Disorder
1309475|NCT00732251|Stable Bipolar Disorder
1309476|NCT00732251|Mania
1309477|NCT00732251|Mixed mania
1309478|NCT00732251|Allopurinol
1309479|NCT00732238|Spinal Cord Injury
1309480|NCT00732238|Urinary Tract Infection
1309481|NCT00732238|Catheter Dependent
1309482|NCT00732225|DisCoVisc OVD
1309483|NCT00732225|Ophthalmic Viscosurgical Device
1309484|NCT00732212|UGI Bleeding
1309485|NCT00732212|Ulcer or variceal hemorrhage
1309486|NCT00732212|Stigmata of recent hemorrhage
1309487|NCT00732212|Endoscopy
1309488|NCT00732212|Randomized Controlled Trial
1309489|NCT00732212|Non-variceal UGI hemorrhage
1309490|NCT00732212|Variceal hemorrhage
1309491|NCT00732199|Sleep apnea syndromes
1309492|NCT00732199|central apnea
1309493|NCT00732199|hypoxia
1309494|NCT00732199|aging
1309495|NCT00732173|stage I endometrial carcinoma
1309496|NCT00732173|stage II endometrial carcinoma
1309497|NCT00732160|Glucose
1309498|NCT00732160|Insulin
1309499|NCT00732147|triglycerides
1309500|NCT00732147|endogenous
1309501|NCT00732147|glucose
1309502|NCT00732147|production
1309503|NCT00732121|Type 2 Diabetes
1309504|NCT00732108|migraine
1309505|NCT00732108|headache
1309506|NCT00732108|dizziness
1309507|NCT00732108|vertigo
1309508|NCT00732108|topiramate
1309509|NCT00732108|Topamax
1309510|NCT00732095|Self-change
1309511|NCT00732095|Natural recovery
1309512|NCT00732095|Alcohol Drinking
1309513|NCT00732095|Mechanisms of Change
1309514|NCT00732095|Advertisements
1309515|NCT00732082|LAG-3 and gemcitabine treatment for advanced pancreas cancer
1309516|NCT00732069|hemodialysis
1309517|NCT00732069|oxidative stress
1309518|NCT00732069|inflammation
1309519|NCT00732069|kallikrein-kinin
1309520|NCT00732069|angiotensin receptor blockade
1309521|NCT00732069|angiotensin converting enzyme inhibition
1309522|NCT00732069|RAAS
1309523|NCT00732069|fibrinolysis
1309524|NCT00732069|endothelial dysfunction
1309525|NCT00732056|Metastatic Breast Cancer
1309526|NCT00732056|Recurrent Breast Cancer
1309527|NCT00732043|prostate cancer
1309528|NCT00732043|prostate-specific antigen
1309529|NCT00732043|PSA
1309530|NCT00732043|pomegranate
1309531|NCT00732030|Toric IOL
1309532|NCT00732017|Sprain
1309533|NCT00732017|Electric stimulation
1309534|NCT00732017|Physical trauma
1309535|NCT00732017|Inflammation
1309536|NCT00731991|Muscle
1309537|NCT00731978|Near-Infrared Spectroscopy
1309538|NCT00731978|Intraoperative Care
1309539|NCT00731965|Arthritis, Juvenile Rheumatoid
1309540|NCT00731965|Measles-Mumps-Rubella Vaccine
1309541|NCT00731965|Serology
1309542|NCT00731965|Lymphocytes
1309543|NCT00731952|surgically resectable
1309544|NCT00731939|Erectile Dysfunction
1309545|NCT00731939|Penile implant
1309546|NCT00731939|Titan
1309547|NCT00731913|Surgical wounds
1309548|NCT00731913|Sutures
1309549|NCT00731900|pharmacogenetic
1309550|NCT00731900|study
1309551|NCT00731900|Topirmate
1309552|NCT00731900|induced
1309553|NCT00731887|Burn injury
1309554|NCT00731887|Burn recovery
1309555|NCT00731874|Kidney transplantation
1309556|NCT00731874|Immunosuppression
1309557|NCT00731874|Minimization
1309558|NCT00731874|Tacrolimus
1309559|NCT00731874|Prograf
1309560|NCT00731874|Thymoglobulin
1309561|NCT00731848|prostate cancer
1309562|NCT00731848|prostate-specific antigens
1309563|NCT00731848|PSA
1309564|NCT00731835|Vascular
1309565|NCT00731822|Chronic Obstructive Pulmonary Disease
1309566|NCT00731822|Novel Dry Powder Inhaler
1309567|NCT00731822|Chronic Obstructive Pulmonary Disease (COPD)
1309568|NCT00731822|GW685698/GW642444
1309569|NCT00731809|Crohn's disease
1309570|NCT00731796|Stroke
1309571|NCT00731796|Retrochiasmatic
1309572|NCT00731796|Vision
1309573|NCT00731796|VFD
1309574|NCT00731783|Abscesses
1309575|NCT00731783|Furunculosis
1309576|NCT00731783|Staphylococcus aureus colonization
1309577|NCT00731783|Staphylococcal Skin Infections
1309578|NCT00731783|MRSA
1309579|NCT00731770|COPD
1309580|NCT00731770|sleep
1309581|NCT00731770|daytime somnolence
1309582|NCT00731718|Head Lice
1309583|NCT00731692|FTY720, primary progressive multiple sclerosis,PPMS
1309584|NCT00731679|IBS
1309585|NCT00731679|Abdominal pain
1309586|NCT00731679|Bloating
1309587|NCT00731679|Diarrhea
1309588|NCT00731679|Rifaximin
1309589|NCT00731666|penile length
1309590|NCT00731666|IPP
1309591|NCT00731666|Erectile dysfunction
1309592|NCT00731653|depression
1309593|NCT00731653|combination
1309594|NCT00731640|AcrySof
1309595|NCT00731640|ReSTOR
1309596|NCT00731640|Multifocal
1309597|NCT00731640|Intraocular Lens
1309598|NCT00731627|intracranial aneurysm
1309599|NCT00731614|cognitive therapy
1309600|NCT00731614|mirror training
1309601|NCT00731614|nondirective therapy
1309602|NCT00731614|veterans
1309603|NCT00731614|amputees
1309604|NCT00731601|shock
1309605|NCT00731601|peptic ulcer bleeding
1309606|NCT00731601|rebleeding
1309607|NCT00731575|asthma
1309608|NCT00731575|child
1309609|NCT00731575|pathogenesis
1309610|NCT00731575|rhinovirus
1309611|NCT00731575|prednisolone
1309612|NCT00731575|Prevention
1309613|NCT00731575|pediatric
1309614|NCT00731562|food, varenicline, pharmacokinetics, bioavailability
1309615|NCT00731549|Aripiprazole
1309616|NCT00731549|IM Depot
1309617|NCT00731549|Schizophrenia
1309618|NCT00731549|Intramuscular
1309619|NCT00731536|Hepatosplenic T-cell Lymphoma
1309620|NCT00731536|Remicade
1309621|NCT00731536|Infliximab
1309622|NCT00731536|Dutch national database of pathology
1309623|NCT00731536|PALGA
1309624|NCT00731536|Autoimmune disease
1309625|NCT00731536|Non-Hodgkin lymphoma
1309626|NCT00731523|FTY720, Pharmacokinetics, Renal insufficiency
1309627|NCT00731510|Acute mountain sickness
1309628|NCT00731510|Body composition,Hypoxia
1309629|NCT00731510|Carbohydrate supplementation
1309630|NCT00731510|Expedition,
1309631|NCT00731510|Hydration,
1309632|NCT00731510|Hypoxia
1309633|NCT00731510|Performance
1309634|NCT00731497|SODIS
1309635|NCT00731497|Drinking Water
1309636|NCT00731497|Disinfection
1309637|NCT00731497|Intervention Trial
1309638|NCT00731484|Dry Eye Disease
1309639|NCT00731484|Tear Osmolarity
1309640|NCT00731484|Tear Osmolality
1309641|NCT00731458|OCT;
1309642|NCT00731458|Cirrus;
1309643|NCT00731458|Stratus;
1309644|NCT00731458|macular thickness
1309645|NCT00731445|Z-208
1309646|NCT00731432|gingivitis, diabetes mellitus, herbal, oral inflammation
1309647|NCT00731419|biliary
1309648|NCT00731419|obstruction
1309649|NCT00731419|malignant
1309650|NCT00731419|stent
1309651|NCT00731419|palliation
1309652|NCT00731393|Thiomersal-free influenza split vaccine 2003/2004
1309653|NCT00731393|Influsplit SSW®/Fluarix™ 2003/2004
1309654|NCT00731393|Influenza
1309655|NCT00731380|Abraxane
1309656|NCT00731380|Head and Neck Cancer
1309657|NCT00731380|Determine
1309658|NCT00731380|Maximum
1309659|NCT00731380|Tolerated dose
1309660|NCT00731380|ABI-007
1309661|NCT00731380|Combination
1309662|NCT00731380|Cisplatin
1309663|NCT00731380|5-Fluorouracil
1309664|NCT00731380|Patients
1309665|NCT00731354|lipoplasty
1309666|NCT00731354|liposuction
1309667|NCT00731354|VASER
1309668|NCT00731354|body contouring
1309669|NCT00731354|body sculpting
1309670|NCT00731354|Any patient
1309671|NCT00731354|expressing
1309672|NCT00731354|interest
1309673|NCT00731354|in elective surgery
1309674|NCT00731341|Uterine fibroids
1309675|NCT00731341|Leiomyoma
1309676|NCT00731341|Menorrhagia
1309677|NCT00731341|Hysteroscopic cryoablation
1309678|NCT00731341|Minimally invasive
1309679|NCT00731328|refractory anemia
1309680|NCT00731328|refractory anemia with ringed sideroblasts
1309681|NCT00731328|refractory cytopenia with multilineage dysplasia
1309682|NCT00731328|childhood myelodysplastic syndromes
1309683|NCT00731328|de novo myelodysplastic syndromes
1309684|NCT00731328|previously treated myelodysplastic syndromes
1309685|NCT00731328|secondary myelodysplastic syndromes
1309686|NCT00731328|aplastic anemia
1309687|NCT00731328|paroxysmal nocturnal hemoglobinuria
1309688|NCT00731315|UTI
1309689|NCT00731315|Kiosk
1309690|NCT00731315|Computer Assisted Care
1309691|NCT00731315|cystitis
1309692|NCT00731289|Osteoarthritis
1309693|NCT00731289|Knee
1309694|NCT00731289|Hyaluronan
1309695|NCT00731289|Gait Analysis
1309696|NCT00731276|unspecified adult solid tumor, protocol specific
1309697|NCT00731263|Cancer
1309698|NCT00731263|Advance solid tumours
1309699|NCT00731263|Dose Escalation
1309700|NCT00731263|Preliminary efficacy
1309701|NCT00731263|AZD8055
1309702|NCT00731263|Tor kinase inhibitor
1309703|NCT00731263|Oral administration
1309704|NCT00731250|Capsaicin challenge
1309705|NCT00731237|Drug Eluting Stent
1309706|NCT00731237|Percutaneous Coronary Intervention
1309707|NCT00731237|Everolimus
1309708|NCT00731224|Alzheimer's disease, rivastigmine, patch
1309709|NCT00731211|Renal Cell Carcinoma
1309710|NCT00731211|Metastatic
1309711|NCT00731211|Pazopanib
1309712|NCT00731211|Previously-treated
1309713|NCT00731198|ERCP
1309714|NCT00731198|Drotaverine hydrochloride
1309715|NCT00731198|Hyoscine-N-butylbromide
1309716|NCT00731185|functional
1309717|NCT00731185|endoscopic
1309718|NCT00731185|sinus
1309719|NCT00731185|surgery
1309720|NCT00731172|crohns disease
1309721|NCT00731146|Interscalene Brachial Plexus Block
1309722|NCT00731146|Regional Anesthesia
1309723|NCT00731146|Ultrasound guided peripheral nerve block
1309724|NCT00731146|Minimum Effective Anesthetic Volume
1309725|NCT00731146|Nerve Stimulator guided peripheral nerve block
1309726|NCT00731133|disulfiram
1309727|NCT00731133|methamphetamine dependence
1309728|NCT00731133|open label
1309729|NCT00731120|Generalized Anxiety Disorder
1309730|NCT00731120|Mood Disorder
1309731|NCT00731120|Affective Disorder
1309732|NCT00731120|Anxiety Disorder
1309733|NCT00731120|Drug Therapy
1309734|NCT00731107|Veress Needle
1309735|NCT00731107|XCEL bladeless trocar
1309736|NCT00731107|Laparoscopic entry techniques
1309737|NCT00731094|overweight
1309738|NCT00731094|sedentary lifestyle
1309739|NCT00731094|exercise
1309740|NCT00731094|primary health care
1309741|NCT00731094|controlled clinical trials, randomized
1309742|NCT00731068|Achilles tendon
1309743|NCT00731042|Skin health
1309744|NCT00731029|Influenza
1309745|NCT00731029|Thiomersal-free influenza split vaccine 2002/2003
1309746|NCT00731029|Influsplit SSW®/Fluarix™ 2002/2003
1309747|NCT00731003|serotonin
1309748|NCT00731003|gut permeability
1309749|NCT00731003|visceral sensitivity
1309750|NCT00731003|irritable bowel syndrome
1309751|NCT00730990|Positron Emission Tomography study in healthy volunteers for ligand qualification and receptor occupancy determination.
1309752|NCT00730964|Surveillance
1309753|NCT00730964|Optison
1309754|NCT00730964|Perflutren
1309755|NCT00730964|Echocardiography
1309756|NCT00730964|Subjects receive Optison during enhanced echocardiography
1309757|NCT00730938|fibrin
1309758|NCT00730938|endophthalmitis
1309759|NCT00730938|cataract extraction
1309760|NCT00730938|Lens
1309761|NCT00730938|implantation,
1309762|NCT00730938|intraocular
1309763|NCT00730886|Uterine Fibroids
1309764|NCT00730886|Unexplained Infertility
1309765|NCT00730886|MRgFUS
1309766|NCT00730886|ExAblate
1309767|NCT00730886|Focused Ultrasound
1309768|NCT00730886|Myomectomy
1309769|NCT00730860|radiofrequency ablation
1309770|NCT00730860|Cancer of Liver
1309771|NCT00730860|postoperative
1309772|NCT00730860|transhepatic arterial chemoembolization
1309773|NCT00730860|prospective
1309774|NCT00730847|PMS
1309775|NCT00730847|Post-marketing surveillance
1309776|NCT00730847|Safety
1309777|NCT00730847|Prescribing Information
1309778|NCT00730847|Philippines
1309779|NCT00730847|HPV
1309780|NCT00730847|Human papillomavirus
1309781|NCT00730834|tinnitus
1309782|NCT00730834|ringing in the ears
1309783|NCT00730834|buzzing
1309784|NCT00730834|static
1309785|NCT00730834|hyperacusis
1309786|NCT00730834|loudness discomfort
1309787|NCT00730834|Clinically
1309788|NCT00730834|significant
1309789|NCT00730834|discomfort
1309790|NCT00730808|Enteral nutritional regimen prior to surgery
1309791|NCT00730795|Tuberculosis vaccine
1309792|NCT00730769|Valganciclovir
1309793|NCT00730769|Ganciclovir
1309794|NCT00730769|Pharmacokinetics
1309795|NCT00730769|Solid organ transplantation
1309796|NCT00730769|Transplant
1309797|NCT00730756|Adolescents
1309798|NCT00730756|Irritant(non-allergic)rhinitis
1309799|NCT00730756|Adults
1309800|NCT00730756|GW685698
1309801|NCT00730756|Air Pollution
1309802|NCT00730730|Iliac Artery, Peripheral Vascular Disease (PVD)
1309803|NCT00730704|Human Papilloma Virus vaccines
1309804|NCT00730704|HPV
1309805|NCT00730704|Gardasil
1309806|NCT00730704|Post partum
1309807|NCT00730691|Generalized Anxiety Disorder
1309808|NCT00730691|Mood Disorder
1309809|NCT00730691|Affective Disorder
1309810|NCT00730691|Anxiety Disorder
1309811|NCT00730691|Drug Therapy
1309812|NCT00730678|Metabolism
1309813|NCT00730678|Pharmacogenetic testing
1309814|NCT00730665|PPI partial responders with non-erosive GERD.
1309815|NCT00730652|Medarex Inc.
1309816|NCT00730626|Probiotics
1309817|NCT00730626|Immunity
1309818|NCT00730626|Immune response
1309819|NCT00730626|Intestinal microflora
1309820|NCT00730626|Blood lipids
1309821|NCT00730626|Phagocytosis activity
1309822|NCT00730613|adult anaplastic astrocytoma
1309823|NCT00730613|adult diffuse astrocytoma
1309824|NCT00730613|adult pilocytic astrocytoma
1309825|NCT00730613|adult subependymal giant cell astrocytoma
1309826|NCT00730613|adult anaplastic ependymoma
1309827|NCT00730613|adult ependymoma
1309828|NCT00730613|adult myxopapillary ependymoma
1309829|NCT00730613|adult subependymoma
1309830|NCT00730613|adult anaplastic oligodendroglioma
1309831|NCT00730613|adult oligodendroglioma
1309832|NCT00730613|adult brain stem glioma
1309833|NCT00730613|adult giant cell glioblastoma
1309834|NCT00730613|adult glioblastoma
1309835|NCT00730613|recurrent adult brain tumor
1309836|NCT00730613|adult gliosarcoma
1309837|NCT00730613|adult mixed glioma
1309838|NCT00730613|adult pineal gland astrocytoma
1309839|NCT00730600|Thai Traditional massage
1309840|NCT00730600|Bone Formation
1309841|NCT00730600|Bone Resorption
1309842|NCT00730587|Nutrition
1309843|NCT00730587|Body Fat
1309844|NCT00730587|Infant
1309845|NCT00730587|Healthy Babies
1309846|NCT00730561|nerve conduction velocity
1309847|NCT00730561|hematopoietic stem cell transplantation
1309848|NCT00730535|Overactive bladder, Tolterodine,Symptoms Relapse, Predictor
1309849|NCT00730522|Methamphetamine
1309850|NCT00730522|Dependency
1309851|NCT00730522|Addiction
1309852|NCT00730522|vigabatrin
1309853|NCT00730509|cystic fibrosis
1309854|NCT00730509|folate
1309855|NCT00730509|vitamin B12
1309856|NCT00730496|Embryo culture supernatant
1309857|NCT00730496|injection
1309858|NCT00730496|embryo transfer
1309859|NCT00730496|embryo implantation rate
1309860|NCT00730483|liver metastases
1309861|NCT00730483|metastatic gastrointestinal carcinoid tumor
1309862|NCT00730483|regional gastrointestinal carcinoid tumor
1309863|NCT00730483|islet cell carcinoma
1309864|NCT00730483|gastrinoma
1309865|NCT00730483|insulinoma
1309866|NCT00730483|glucagonoma
1309867|NCT00730483|pancreatic polypeptide tumor
1309868|NCT00730483|somatostatinoma
1309869|NCT00730470|Human Epidermal Growth Factor Receptor 3
1309870|NCT00730470|HER3
1309871|NCT00730470|Heregulin
1309872|NCT00730470|erb B3
1309873|NCT00730470|Solid Tumors
1309874|NCT00730470|Phase I Clinical Study
1309875|NCT00730457|influenza
1309876|NCT00730457|recombinant
1309877|NCT00730457|hemagglutinin
1309878|NCT00730457|vaccine
1309879|NCT00730444|Neuroblastoma
1309880|NCT00730444|Nuclear medicine
1309881|NCT00730444|Diagnostic scintigraphy
1309882|NCT00730444|Known and suspected neuroblastoma
1309883|NCT00730431|Hepatitis C, healthy volunteers
1309884|NCT00730418|Benign Prostatic Hyperplasia
1309885|NCT00730418|alpha Adrenergic Blockers
1309886|NCT00730418|alpha-1 Adrenergic Receptor
1309887|NCT00730405|Distal, Subungual onychomycosis
1309888|NCT00730405|onychomycosis
1309889|NCT00730405|nail fungus
1309890|NCT00730405|Toenail fungus
1309891|NCT00730392|Type 1 diabetes, Etanercept, honeymoon period
1309892|NCT00730366|Malaria
1309893|NCT00730366|Pregnancy
1309894|NCT00730366|Intermittent Preventive Treatment
1309895|NCT00730340|Tonsillectomy, tonsillar fossa, wound closure
1309896|NCT00730314|unrelated
1309897|NCT00730314|BMT
1309898|NCT00730314|HSCT
1309899|NCT00730314|bone marrow transplantation
1309900|NCT00730314|sickle cell disease
1309901|NCT00730314|thalassemia
1309902|NCT00730314|CGD
1309903|NCT00730314|HLH
1309904|NCT00730314|Blackfan-Diamond anemia
1309905|NCT00730314|Hurler
1309906|NCT00730314|leukodystrophy
1309907|NCT00730314|LAD I
1309908|NCT00730314|Genetic diseases
1309909|NCT00730314|Red blood cell defects
1309910|NCT00730314|Leukocyte defects and immune deficiencies
1309911|NCT00730314|Hereditary Lymphohistiocytosis
1309912|NCT00730314|chronic granulomatous disease
1309913|NCT00730314|Wiskott-Aldrich syndrome
1309914|NCT00730314|Chediak Higashi syndrome
1309915|NCT00730314|CD40 ligand deficiency
1309916|NCT00730314|Hyper IgM syndrome
1309917|NCT00730314|leucocytes adhesion defect type 1
1309918|NCT00730314|Osteopetrosis
1309919|NCT00730314|congenital neutropenia
1309920|NCT00730314|X-linked lymphoproliferative disease
1309921|NCT00730314|Platelets defects
1309922|NCT00730314|Congenital amegakaryocytic thrombocytopenia
1309923|NCT00730314|Metabolic and storage disorders
1309924|NCT00730314|Hurler disease
1309925|NCT00730314|leukodystrophies
1309926|NCT00730314|Niemann-Pick disease
1309927|NCT00730314|Fucosidosis
1309928|NCT00730314|Stem cell defects
1309929|NCT00730314|reticular agenesis
1309930|NCT00730301|Emphysema
1309931|NCT00730301|Chronic obstructive pulmonary disease
1309932|NCT00730301|Lung volume reduction
1309933|NCT00730301|Lung function
1309934|NCT00730288|Dengue
1309935|NCT00730288|Dengue fever
1309936|NCT00730288|Dengue hemorrhagic fever
1309937|NCT00730288|Dengue virus
1309938|NCT00730262|Glioblastoma Multiforme (GBM)
1309939|NCT00730262|Phase II
1309940|NCT00730262|Brain Cancer
1309941|NCT00730249|ADHD
1309942|NCT00730249|Attention Deficit Hyperactivity Disorder
1309943|NCT00730249|adult
1309944|NCT00730249|methylphenidate hydrochloride
1309945|NCT00730249|Medikinet retard
1309946|NCT00730249|controlled clinical trial
1309947|NCT00730249|safety
1309948|NCT00730249|randomized, double-blind, placebo-controlled trial
1309949|NCT00730249|treatment
1309950|NCT00730249|central nervous system stimulants
1309951|NCT00730249|therapeutic uses
1309952|NCT00730223|Nevirapine
1309953|NCT00730223|Efavirenz
1309954|NCT00730223|pharmacokinetics
1309955|NCT00730223|healthy
1309956|NCT00730223|CYP2B6
1309957|NCT00730223|HIV/AIDS
1309958|NCT00730210|Hypoparathyroidism
1309959|NCT00730210|HypoPTH
1309960|NCT00730210|PTH
1309961|NCT00730184|acid-base
1309962|NCT00730184|potassium
1309963|NCT00730184|acidosis
1309964|NCT00730184|osteoporosis
1309965|NCT00730184|sarcopenia
1309966|NCT00730184|calcium absorption
1309967|NCT00730184|dietary protein
1309968|NCT00730145|pharmacokinetics, PD-0332334, hemodialysis, renal dialysis
1309969|NCT00730119|Non-invasive Blood Pressure (NIBP)
1309970|NCT00730119|GE Monitor
1309971|NCT00730119|Temperature
1309972|NCT00730119|SpO2
1309973|NCT00730119|Respiration, ECG
1309974|NCT00730106|Gastroesophageal reflux disease
1309975|NCT00730106|Alarm symptoms
1309976|NCT00730106|Gastrointestinal endoscopy
1309977|NCT00730093|Vitamin B12 absorption
1309978|NCT00730093|Pregnancy
1309979|NCT00730080|phenylketonuria
1309980|NCT00730080|sapropterin
1309981|NCT00730080|Kuvan
1309982|NCT00730080|cognition
1309983|NCT00730080|executive abilities
1309984|NCT00730080|brain
1309985|NCT00730067|COPD
1309986|NCT00730067|Pulmonary hypertension
1309987|NCT00730067|Sildenafil
1309988|NCT00730067|NT-pro BNP
1309989|NCT00730067|apelin
1309990|NCT00730054|Remifentanil
1309991|NCT00730054|clonidine
1309992|NCT00730054|acute pain
1309993|NCT00730054|respiration
1309994|NCT00730054|sedation
1309995|NCT00730054|cognitive function
1309996|NCT00730041|obstructive sleep apnea
1309997|NCT00730041|continuous positive air pressure
1309998|NCT00730028|Methicillin-resistant Staphylococcus aureus (MRSA), cellulitis, abscess, children, elderly
1309999|NCT00730002|Lupus
1310000|NCT00729989|Meconium Aspiration
1310001|NCT00729989|Respiratory Distress
1310002|NCT00729989|Meconium Stained Amniotic Fluid
1310003|NCT00729976|Ibuprofen
1310004|NCT00729976|Suppository
1310005|NCT00729976|febrile children
1310006|NCT00729937|Methicillin, Staphylococcus aureus, MRSA
1310007|NCT00729924|Raltegravir
1310008|NCT00729924|CSF
1310009|NCT00729924|ABCB1 SNP
1310010|NCT00729924|HIV/AIDS
1310011|NCT00729911|Atrial fibrillation Ablation
1310012|NCT00729885|Vertigo
1310013|NCT00729885|Benign Paroxysmal Positional Vertigo
1310014|NCT00729885|BPPV
1310015|NCT00729885|Positional Vertigo
1310016|NCT00729872|AG011
1310017|NCT00729872|Ulcerative Colitis
1310018|NCT00729872|human Interleukin-10
1310019|NCT00729859|HDL
1310020|NCT00729859|Insulin sensitivity
1310021|NCT00729859|testosterone
1310022|NCT00729859|estradiol
1310023|NCT00729859|cholesterol
1310024|NCT00729846|choroidal neovascularization
1310025|NCT00729846|macular degeneration
1310026|NCT00729846|macular edema
1310027|NCT00729846|intravitreal bevacizumab
1310028|NCT00729846|vegf
1310029|NCT00729846|verteporfin PDT
1310030|NCT00729820|PERSONALITY
1310031|NCT00729820|COGNITIVE PERFORMANCE
1310032|NCT00729820|the practical usefulness (validity) of processing speed, accuracy of performance and personality measures in predicting impulsive behavior
1310033|NCT00729807|recurrent melanoma
1310034|NCT00729794|Vasopressin
1310035|NCT00729794|Epinephrine
1310036|NCT00729794|Adrenal Cortex Hormones
1310037|NCT00729794|Heart Arrest
1310038|NCT00729781|nasal obstruction
1310039|NCT00729781|airway resistance
1310040|NCT00729781|soft tissue collapse
1310041|NCT00729781|cosmetic contour deformity
1310044|NCT00729755|Creatine
1310045|NCT00729755|Augmentation
1310046|NCT00729755|Major Depressive Disorder
1310047|NCT00729755|Efficacy
1310048|NCT00729755|Brain Energy Metabolism
1310049|NCT00729729|Comparative
1310050|NCT00729729|bioavailability
1310051|NCT00729729|of PCA
1310052|NCT00729729|formulations
1310053|NCT00729716|Microfracture
1310054|NCT00729716|Cartilage repair
1310055|NCT00729716|Autologous chondrocyte implantation
1310056|NCT00729703|ICD
1310057|NCT00729703|Minimized
1310058|NCT00729703|ventricular
1310059|NCT00729703|pacing
1310060|NCT00729703|indication
1310061|NCT00729703|Clinical outcome
1310062|NCT00729703|Inappropriate shock
1310063|NCT00729690|Pregabalin
1310064|NCT00729690|CSF
1310065|NCT00729690|Neurotransmitter
1310066|NCT00729677|nausea and vomiting
1310067|NCT00729677|colon cancer
1310068|NCT00729677|rectal cancer
1310069|NCT00729638|relapsed multiple myeloma
1310070|NCT00729638|refractory multiple myeloma
1310071|NCT00729638|RAD001
1310072|NCT00729638|lenalidomide
1310073|NCT00729625|stroke, rehabilitation, robotics
1310074|NCT00729612|stage IIIB non-small cell lung cancer
1310075|NCT00729612|stage IV non-small cell lung cancer
1310076|NCT00729612|recurrent non-small cell lung cancer
1310077|NCT00729612|squamous cell lung cancer
1310078|NCT00729573|Microbicide
1310079|NCT00729573|HIV Seronegativity
1310080|NCT00729573|Bone Mineral Density
1310081|NCT00729560|PCOS
1310082|NCT00729547|Depression
1310083|NCT00729547|Biofeedback
1310084|NCT00729547|Psychophysiology
1310085|NCT00729534|Perception
1310086|NCT00729534|Focus Group
1310087|NCT00729534|Perception of Clinical Research Participation
1310088|NCT00729521|Fall injury hospitalization
1310089|NCT00729521|Fall injury emergency department visit
1310090|NCT00729521|Fall injury death
1310091|NCT00729508|Cat allergy
1310092|NCT00729508|Immunotherapy
1310093|NCT00729508|Cat-PAD
1310094|NCT00729508|Environmental Exposure Chamber
1310095|NCT00729495|Phase I,
1310096|NCT00729495|Healthy
1310097|NCT00729495|Volunteer
1310098|NCT00729495|Study
1310099|NCT00729482|RAD001 (everolimus)
1310100|NCT00729482|second-line treatment
1310101|NCT00729482|advanced gastric cancer
1310102|NCT00729469|Vulvar and vaginal atrophy in postmenopausal women
1310103|NCT00729469|Menopausal symptoms
1310104|NCT00729469|Vaginal atrophy
1310105|NCT00729469|Urogenital atrophy
1310106|NCT00729456|Diabetes
1310107|NCT00729456|Education
1310108|NCT00729456|Ulcer
1310109|NCT00729456|Foot
1310110|NCT00729456|Behaviour
1310111|NCT00729443|Single dose
1310112|NCT00729443|Phase 1
1310113|NCT00729443|Safety of AZD3241
1310114|NCT00729443|tolerability of AZD3241
1310115|NCT00729430|Heart Attack
1310116|NCT00729430|Sudden Cardiac Death
1310117|NCT00729430|Peri-infarct Zone
1310118|NCT00729430|Omega-3 Fatty Acids
1310119|NCT00729430|Biological Markers
1310120|NCT00729430|Cytogenetic Analysis
1310121|NCT00729430|Cardiac Arrest
1310122|NCT00729417|incontinence
1310123|NCT00729417|obstetric risk factors
1310124|NCT00729417|women
1310125|NCT00729417|of age 18
1310126|NCT00729417|above
1310127|NCT00729404|Female Contraception
1310128|NCT00729404|Ovulation Inhibition
1310129|NCT00729391|HIV
1310130|NCT00729391|Sexual Risk
1310131|NCT00729391|Substance Abuse
1310132|NCT00729391|Victimization
1310133|NCT00729391|Violence
1310134|NCT00729391|Voluntary Counseling and Testing (VCT)
1310135|NCT00729365|Urine albumin excretion rates
1310136|NCT00729365|Nighttime and daytime blood pressure
1310137|NCT00729365|Endothelial Dysfunction
1310138|NCT00729352|NQO1, ozone, airway mucociliary clearance.
1310139|NCT00729339|Gastroesophageal reflux disease
1310140|NCT00729339|Mosapride
1310141|NCT00729339|Lansoprazole
1310142|NCT00729326|diabetes
1310143|NCT00729326|exenatide
1310144|NCT00729326|sitagliptin
1310145|NCT00729326|Amylin
1310146|NCT00729326|Lilly
1310147|NCT00729326|metformin
1310148|NCT00729326|thiazolidinedione
1310149|NCT00729313|Treatment
1310150|NCT00729300|cocaine
1310151|NCT00729300|disulfiram
1310152|NCT00729300|antabuse
1310153|NCT00729300|addiction
1310154|NCT00729300|stimulant
1310155|NCT00729287|stage 0 bladder cancer
1310156|NCT00729287|stage I bladder cancer
1310157|NCT00729287|transitional cell carcinoma of the bladder
1310158|NCT00729261|mechanical ventilation
1310159|NCT00729261|extubation
1310160|NCT00729261|outcomes
1310161|NCT00729261|brain injury
1310162|NCT00729248|Transplants
1310163|NCT00729248|Kidney Transplantation
1310164|NCT00729248|Immunosuppression
1310165|NCT00729248|Assay
1310166|NCT00729248|Graft Rejection
1310167|NCT00729235|Slow VT, CRT-D, ATP therapy
1310168|NCT00729235|Incidence
1310169|NCT00729235|of slow VTs
1310170|NCT00729235|in CRT-D patients
1310171|NCT00729235|Clinical
1310172|NCT00729235|relevance
1310173|NCT00729235|treatment
1310174|NCT00729235|VTs
1310175|NCT00729235|during
1310176|NCT00729235|2-years
1310177|NCT00729235|follow-up
1310178|NCT00729196|Obesity
1310179|NCT00729196|Type 2 Diabetes
1310180|NCT00729196|Glycemic Load
1310181|NCT00729196|Weight Loss
1310182|NCT00729196|Glycated Hemoglobin
1310183|NCT00729170|Milk
1310184|NCT00729170|Calcium
1310185|NCT00729170|Weight loss
1310186|NCT00729170|Bone density
1310187|NCT00729170|Appetite
1310188|NCT00729144|fecal incontinence
1310189|NCT00729144|bowel incontinence
1310190|NCT00729144|pelvic floor disorder
1310191|NCT00729131|Ozone, TNF, TNF promoter polymorphism, airway hyperresponsiveness.
1310192|NCT00729118|stage I multiple myeloma
1310193|NCT00729118|stage II multiple myeloma
1310194|NCT00729118|stage III multiple myeloma
1310195|NCT00729118|refractory multiple myeloma
1310196|NCT00729092|PET SCAN
1310197|NCT00729092|PAIN LEVELS
1310198|NCT00729079|Diabetes Prevention
1310199|NCT00729079|Pre-Diabetes
1310200|NCT00729079|Exercise
1310201|NCT00729079|Fat Intake
1310202|NCT00729079|Fasting blood sugar
1310203|NCT00729079|tobacco cessation
1310204|NCT00729053|renal
1310205|NCT00729053|cell
1310206|NCT00729053|renal carcinoma
1310207|NCT00729053|metastatic
1310208|NCT00729053|recurrent
1310209|NCT00729053|treatment naive
1310210|NCT00729040|heart
1310211|NCT00729040|weight
1310212|NCT00729040|Overweight
1310213|NCT00729040|bmi
1310214|NCT00729040|diabetes
1310215|NCT00729040|type 2
1310216|NCT00729040|diabetic
1310217|NCT00729040|walk
1310218|NCT00729040|walk*
1310219|NCT00729040|diab*
1310220|NCT00729040|obese
1310221|NCT00729040|exercise
1310222|NCT00729040|activity
1310223|NCT00729040|coronary
1310224|NCT00729040|pedometer
1310225|NCT00729027|hypercholesterolemia
1310226|NCT00729014|herbal nephropathy
1310227|NCT00729014|Chinese herbal nephropathy
1310228|NCT00729014|nephrotoxicity
1310229|NCT00729014|renal disease
1310230|NCT00729014|adverse drug reaction
1310231|NCT00729014|Chinese herbal medicine
1310232|NCT00729001|Rotavirus Gastroenteritis
1310233|NCT00729001|Human rotavirus vaccine
1310234|NCT00728988|Asia Lipitor Pre-treatment in Acute Coronary Syndrome
1310235|NCT00728975|constipation
1310236|NCT00728975|cancer
1310237|NCT00728975|palliative care
1310238|NCT00728975|terminal
1310239|NCT00728975|bowel
1310240|NCT00728962|dental implants
1310241|NCT00728962|Osseotite Certain Prevail
1310242|NCT00728962|multicenter
1310243|NCT00728962|observational
1310244|NCT00728962|clinical study
1310245|NCT00728962|partial edentulism
1310246|NCT00728962|single stage
1310247|NCT00728962|immediate occlusal loading
1310248|NCT00728962|crestal bone level
1310249|NCT00728962|short fixed bridge
1310250|NCT00728949|breast cancer
1310251|NCT00728949|Postmenopausal
1310252|NCT00728949|Hormones
1310253|NCT00728949|Antiestrogen
1310254|NCT00728936|Hepatitis C
1310255|NCT00728936|unresponsive to pegylated interferon and ribavirin therapy
1310256|NCT00728936|HCV
1310257|NCT00728923|OCD
1310258|NCT00728910|Low HDL cholesterol
1310259|NCT00728910|High triglycerides
1310260|NCT00728910|niacin
1310261|NCT00728910|fibrate
1310262|NCT00728897|Healthy volunteer
1310263|NCT00728897|relative bioavailability.
1310264|NCT00728884|dental implants
1310265|NCT00728884|Certain Prevail
1310266|NCT00728884|multicenter
1310267|NCT00728884|clinical study
1310268|NCT00728884|partial edentulism
1310269|NCT00728884|total edentulism
1310270|NCT00728884|platform switching
1310271|NCT00728884|single stage
1310272|NCT00728884|early loading
1310273|NCT00728884|crestal bone level
1310274|NCT00728884|single tooth replacements
1310275|NCT00728884|short or long fixed bridges
1310276|NCT00728884|overdenture
1310277|NCT00728884|fixed denture
1310278|NCT00728871|cervical cancer, HPV, immunity
1310279|NCT00728858|Hypertension
1310280|NCT00728858|SNP
1310281|NCT00728858|Nifedipine
1310282|NCT00728858|Barnidipine
1310283|NCT00728845|adenocarcinoma of the lung
1310284|NCT00728845|large cell lung cancer
1310285|NCT00728845|recurrent non-small cell lung cancer
1310286|NCT00728845|stage IIIB non-small cell lung cancer
1310287|NCT00728845|stage IV non-small cell lung cancer
1310288|NCT00728832|extended release epidural morphine
1310289|NCT00728832|morphine
1310290|NCT00728832|thoracic epidural
1310291|NCT00728832|pharmacokinetics
1310292|NCT00728832|pharmacodynamics
1310293|NCT00728832|postoperative pain
1310294|NCT00728832|upper abdominal surgery
1310295|NCT00728819|Inpatients
1310296|NCT00728819|Requiring
1310297|NCT00728819|DL PICC
1310298|NCT00728819|Access
1310299|NCT00728819|Medications
1310300|NCT00728819|Blood
1310301|NCT00728806|Continuous Ambulatory Peritoneal Dialysis
1310302|NCT00728806|Ultrafiltration failure
1310303|NCT00728806|Biomarker
1310304|NCT00728806|Proteomics
1310305|NCT00728793|Advanced Solid Tumors
1310306|NCT00728793|EGFR
1310307|NCT00728793|HDAC
1310308|NCT00728793|Her2
1310309|NCT00728793|Open-Label
1310310|NCT00728793|Dose-Escalation
1310311|NCT00728780|Adverse events
1310312|NCT00728780|Pharmacokinetic variables
1310313|NCT00728767|Heavy drinking
1310314|NCT00728767|Brief intervention
1310315|NCT00728767|Alcohol prevention
1310316|NCT00728767|Randomized trial
1310317|NCT00728767|Motivational interviewing
1310318|NCT00728767|Intervention Studies
1310319|NCT00728767|prevention & control
1310320|NCT00728754|dental implants
1310321|NCT00728754|Osseotite Certain Prevail
1310322|NCT00728754|Lateralized
1310323|NCT00728754|non-lateralized
1310324|NCT00728754|Osseotite Certain
1310325|NCT00728754|multicenter
1310326|NCT00728754|randomized
1310327|NCT00728754|clinical study
1310328|NCT00728754|partial edentulism
1310329|NCT00728754|single stage
1310330|NCT00728754|early loading
1310331|NCT00728754|crestal bone level
1310332|NCT00728754|short fixed bridge
1310333|NCT00728741|Neural Networks
1310334|NCT00728741|Cortical Activation
1310335|NCT00728741|Strategy
1310336|NCT00728741|fMRI
1310337|NCT00728741|Healthy Volunteer
1310338|NCT00728741|HV
1310339|NCT00728728|pregnenolone
1310340|NCT00728728|schizophrenia
1310341|NCT00728728|cognitive
1310342|NCT00728728|positive symptom
1310343|NCT00728728|negative symptom
1310344|NCT00728728|placebo control
1310345|NCT00728715|Budesonide
1310346|NCT00728715|Formoterol
1310347|NCT00728715|Non cystic fibrosis bronchiectasis
1310348|NCT00726986|extensive stage small cell lung cancer
1310349|NCT00726973|Macular edema
1310350|NCT00726960|Heroin abuse
1310351|NCT00726960|Opioids
1310352|NCT00726960|Opiates
1310353|NCT00726960|Substance abuse
1310354|NCT00726960|Addiction
1310355|NCT00726934|Neutropenic Diet
1310356|NCT00726934|Food Safety Guidelines
1310357|NCT00726934|child
1310358|NCT00726934|cancer
1310359|NCT00726908|Obesity
1310360|NCT00726908|diet
1310361|NCT00726908|carbohydrate
1310362|NCT00726908|insulin
1310363|NCT00726895|Bioavailability
1310364|NCT00726882|HCV Infection
1310365|NCT00726869|Patients After One to three Prior Therapies
1310366|NCT00726843|Headache
1310367|NCT00726843|Complementary and Alternative Medicine
1310368|NCT00726843|Pediatric
1310369|NCT00726843|Yoga
1310370|NCT00726830|pain
1310371|NCT00726830|unspecified adult solid tumor, protocol specific
1310372|NCT00726830|accelerated phase chronic myelogenous leukemia
1310373|NCT00726830|acute undifferentiated leukemia
1310374|NCT00726830|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1310375|NCT00726830|adult acute myeloid leukemia with inv(16)(p13;q22)
1310376|NCT00726830|adult acute myeloid leukemia with t(15;17)(q22;q12)
1310377|NCT00726830|adult acute myeloid leukemia with t(16;16)(p13;q22)
1310378|NCT00726830|adult acute myeloid leukemia with t(8;21)(q22;q22)
1310379|NCT00726830|atypical chronic myeloid leukemia, BCR-ABL1 negative
1310710|NCT00727948|Angiogenesis
1310380|NCT00726830|blastic phase chronic myelogenous leukemia
1310381|NCT00726830|chronic myelomonocytic leukemia
1310382|NCT00726830|chronic phase chronic myelogenous leukemia
1310383|NCT00726830|mast cell leukemia
1310384|NCT00726830|meningeal chronic myelogenous leukemia
1310385|NCT00726830|progressive hairy cell leukemia, initial treatment
1310386|NCT00726830|prolymphocytic leukemia
1310387|NCT00726830|recurrent adult acute lymphoblastic leukemia
1310388|NCT00726830|recurrent adult acute myeloid leukemia
1310389|NCT00726830|recurrent adult T-cell leukemia/lymphoma
1310390|NCT00726830|refractory chronic lymphocytic leukemia
1310391|NCT00726830|refractory hairy cell leukemia
1310392|NCT00726830|relapsing chronic myelogenous leukemia
1310393|NCT00726830|secondary acute myeloid leukemia
1310394|NCT00726830|stage III adult T-cell leukemia/lymphoma
1310395|NCT00726830|stage III chronic lymphocytic leukemia
1310396|NCT00726830|stage IV adult T-cell leukemia/lymphoma
1310397|NCT00726830|stage IV chronic lymphocytic leukemia
1310398|NCT00726830|T-cell large granular lymphocyte leukemia
1310399|NCT00726830|untreated adult acute lymphoblastic leukemia
1310400|NCT00726830|untreated adult acute myeloid leukemia
1310401|NCT00726830|untreated hairy cell leukemia
1310402|NCT00726830|adult grade III lymphomatoid granulomatosis
1310403|NCT00726830|adult nasal type extranodal NK/T-cell lymphoma
1310404|NCT00726830|AIDS-related diffuse large cell lymphoma
1310405|NCT00726830|AIDS-related diffuse mixed cell lymphoma
1310406|NCT00726830|AIDS-related diffuse small cleaved cell lymphoma
1310407|NCT00726830|AIDS-related immunoblastic large cell lymphoma
1310408|NCT00726830|AIDS-related peripheral/systemic lymphoma
1310409|NCT00726830|AIDS-related primary CNS lymphoma
1310410|NCT00726830|AIDS-related small noncleaved cell lymphoma
1310411|NCT00726830|AIDS-related lymphoblastic lymphoma
1310412|NCT00726830|anaplastic large cell lymphoma
1310413|NCT00726830|angioimmunoblastic T-cell lymphoma
1310414|NCT00726830|splenic marginal zone lymphoma
1310415|NCT00726830|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1310416|NCT00726830|nodal marginal zone B-cell lymphoma
1310417|NCT00726830|stage III adult Burkitt lymphoma
1310418|NCT00726830|stage III adult diffuse large cell lymphoma
1310419|NCT00726830|stage III adult diffuse mixed cell lymphoma
1310420|NCT00726830|stage III adult diffuse small cleaved cell lymphoma
1310421|NCT00726830|stage III adult Hodgkin lymphoma
1310422|NCT00726830|stage III adult immunoblastic large cell lymphoma
1310423|NCT00726830|stage III adult lymphoblastic lymphoma
1310424|NCT00726830|stage III cutaneous T-cell non-Hodgkin lymphoma
1310425|NCT00726830|stage III mycosis fungoides/Sezary syndrome
1310426|NCT00726830|stage III grade 1 follicular lymphoma
1310427|NCT00726830|stage III grade 2 follicular lymphoma
1310428|NCT00726830|stage III grade 3 follicular lymphoma
1310429|NCT00726830|stage III mantle cell lymphoma
1310430|NCT00726830|stage III marginal zone lymphoma
1310431|NCT00726830|stage III small lymphocytic lymphoma
1310432|NCT00726830|stage IV adult Burkitt lymphoma
1310433|NCT00726830|stage IV adult diffuse large cell lymphoma
1310434|NCT00726830|stage IV adult diffuse mixed cell lymphoma
1310435|NCT00726830|stage IV adult diffuse small cleaved cell lymphoma
1310436|NCT00726830|stage IV adult Hodgkin lymphoma
1310437|NCT00726830|stage IV adult immunoblastic large cell lymphoma
1310438|NCT00726830|stage IV adult lymphoblastic lymphoma
1310439|NCT00726830|stage IV cutaneous T-cell non-Hodgkin lymphoma
1310440|NCT00726830|stage IV mycosis fungoides/Sezary syndrome
1310441|NCT00726830|stage IV grade 1 follicular lymphoma
1310442|NCT00726830|stage IV grade 2 follicular lymphoma
1310443|NCT00726830|stage IV grade 3 follicular lymphoma
1310444|NCT00726830|stage IV mantle cell lymphoma
1310445|NCT00726830|stage IV marginal zone lymphoma
1310446|NCT00726830|stage IV small lymphocytic lymphoma
1310447|NCT00726830|HIV-associated Hodgkin lymphoma
1310448|NCT00726830|recurrent adult Hodgkin lymphoma
1310449|NCT00726830|recurrent adult Burkitt lymphoma
1310450|NCT00726830|recurrent adult diffuse large cell lymphoma
1310451|NCT00726830|recurrent adult diffuse mixed cell lymphoma
1310452|NCT00726830|recurrent adult diffuse small cleaved cell lymphoma
1310453|NCT00726830|recurrent adult grade III lymphomatoid granulomatosis
1310454|NCT00726830|recurrent adult immunoblastic large cell lymphoma
1310455|NCT00726830|recurrent adult lymphoblastic lymphoma
1310456|NCT00726830|recurrent cutaneous T-cell non-Hodgkin lymphoma
1310457|NCT00726830|recurrent mycosis fungoides/Sezary syndrome
1310458|NCT00726830|recurrent grade 1 follicular lymphoma
1310459|NCT00726830|recurrent grade 2 follicular lymphoma
1310460|NCT00726830|recurrent grade 3 follicular lymphoma
1310461|NCT00726830|recurrent mantle cell lymphoma
1310462|NCT00726830|recurrent marginal zone lymphoma
1310463|NCT00726830|recurrent small lymphocytic lymphoma
1310464|NCT00726830|intraocular lymphoma
1310465|NCT00726830|primary central nervous system non-Hodgkin lymphoma
1310466|NCT00726830|primary central nervous system Hodgkin lymphoma
1310467|NCT00726830|post-transplant lymphoproliferative disorder
1310468|NCT00726830|chronic eosinophilic leukemia
1310469|NCT00726830|chronic neutrophilic leukemia
1310470|NCT00726830|primary myelofibrosis
1310471|NCT00726830|essential thrombocythemia
1310472|NCT00726830|polycythemia vera
1310473|NCT00726830|extramedullary plasmacytoma
1310474|NCT00726830|isolated plasmacytoma of bone
1310475|NCT00726830|monoclonal gammopathy of undetermined significance
1310476|NCT00726830|stage II multiple myeloma
1310477|NCT00726830|stage III multiple myeloma
1310478|NCT00726830|primary systemic amyloidosis
1310479|NCT00726830|refractory multiple myeloma
1310480|NCT00726830|de novo myelodysplastic syndromes
1310481|NCT00726830|previously treated myelodysplastic syndromes
1310482|NCT00726830|secondary myelodysplastic syndromes
1310483|NCT00726830|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1310484|NCT00726830|cutaneous B-cell non-Hodgkin lymphoma
1310485|NCT00726830|Waldenström macroglobulinemia
1310486|NCT00728689|Orthopoxviral
1310487|NCT00728689|Smallpox
1310488|NCT00728689|Monkey pox
1310489|NCT00728676|PKU,
1310490|NCT00728676|Phe,
1310491|NCT00728676|PAH,
1310492|NCT00728676|Kuvan,
1310493|NCT00728676|Trp,
1310494|NCT00728676|Tyr
1310495|NCT00728663|adenocarcinoma of the prostate
1310496|NCT00728663|recurrent prostate cancer
1310497|NCT00728663|stage IV prostate cancer
1310498|NCT00728650|hepatocellular carcinoma
1310499|NCT00728650|colorectal carcinoma metastatic to liver
1310500|NCT00728650|primary liver cancer
1310501|NCT00728637|Prevention
1310502|NCT00728624|Antibiotic susceptibility; beta lactamase; ESBLs
1310503|NCT00728598|Proliferative diabetic retinopathy
1310504|NCT00728598|Angiogenesis
1310505|NCT00728598|Vitreous levels
1310506|NCT00728598|Vascular endothelial growth factor
1310507|NCT00728598|Fractalkine
1310508|NCT00728598|Growth factor
1310509|NCT00728585|mucositis
1310510|NCT00728585|graft versus host disease
1310511|NCT00728585|recurrent childhood large cell lymphoma
1310512|NCT00728585|recurrent childhood lymphoblastic lymphoma
1310513|NCT00728585|recurrent childhood small noncleaved cell lymphoma
1310514|NCT00728585|recurrent/refractory childhood Hodgkin lymphoma
1310515|NCT00728585|accelerated phase chronic myelogenous leukemia
1310516|NCT00728585|blastic phase chronic myelogenous leukemia
1310517|NCT00728585|childhood acute lymphoblastic leukemia in remission
1310518|NCT00728585|childhood acute myeloid leukemia in remission
1310519|NCT00728585|childhood chronic myelogenous leukemia
1310520|NCT00728585|chronic phase chronic myelogenous leukemia
1310521|NCT00728585|juvenile myelomonocytic leukemia
1310522|NCT00728585|recurrent childhood acute lymphoblastic leukemia
1310523|NCT00728585|recurrent childhood acute myeloid leukemia
1310524|NCT00728585|secondary acute myeloid leukemia
1310525|NCT00728585|childhood myelodysplastic syndromes
1310526|NCT00728585|de novo myelodysplastic syndromes
1310527|NCT00728585|disseminated neuroblastoma
1310528|NCT00728585|previously treated childhood rhabdomyosarcoma
1310529|NCT00728585|previously treated myelodysplastic syndromes
1310530|NCT00728585|recurrent Wilms tumor and other childhood kidney tumors
1310531|NCT00728585|recurrent childhood rhabdomyosarcoma
1310532|NCT00728585|recurrent neuroblastoma
1310533|NCT00728585|recurrent malignant testicular germ cell tumor
1310534|NCT00728585|secondary myelodysplastic syndromes
1310535|NCT00728585|stage I multiple myeloma
1310536|NCT00728585|stage II multiple myeloma
1310537|NCT00728585|stage III multiple myeloma
1310538|NCT00728585|refractory multiple myeloma
1310539|NCT00728585|stage I ovarian epithelial cancer
1310540|NCT00728585|stage II ovarian epithelial cancer
1310541|NCT00728585|stage III ovarian epithelial cancer
1310542|NCT00728585|stage IV ovarian epithelial cancer
1310543|NCT00728585|recurrent ovarian epithelial cancer
1310544|NCT00728585|recurrent ovarian germ cell tumor
1310545|NCT00728585|stage IIIA breast cancer
1310546|NCT00728585|stage IIIB breast cancer
1310547|NCT00728585|stage IIIC breast cancer
1310548|NCT00728585|stage IV breast cancer
1310549|NCT00728585|recurrent breast cancer
1310550|NCT00728559|laparoscopy
1310551|NCT00728559|preemptive
1310552|NCT00728559|postoperative
1310553|NCT00728559|pain
1310554|NCT00728559|trocar
1310555|NCT00728559|site
1310556|NCT00728546|tuberculosis
1310557|NCT00728546|isoniazid
1310558|NCT00728546|Arylamine N-acetyl transferase
1310559|NCT00728546|genotyping
1310560|NCT00728546|hepatotoxicity
1310561|NCT00728546|pharmacogenetics
1310562|NCT00728533|Prostate Cancer requiring Androgen Ablation Therapy
1310563|NCT00728520|Leukemia
1310564|NCT00728520|Azacitidine
1310565|NCT00728520|Untreated
1310566|NCT00728520|Elderly
1310567|NCT00728507|Tuberculosis
1310568|NCT00728507|Moxifloxacin
1310569|NCT00728507|Rifapentine
1310570|NCT00728468|Phase 1
1310571|NCT00728468|PF-00299804
1310572|NCT00728468|Dextromethorphan
1310573|NCT00728468|CYP2D6 Inhibition
1310574|NCT00728468|Cancer Patients
1310575|NCT00728442|Clinical practice guidelines
1310576|NCT00728442|Guideline adherence
1310577|NCT00728442|Clinical decision support systems
1310578|NCT00728442|Randomized controlled trial
1310579|NCT00728442|Intervention study
1310580|NCT00728429|cardiac toxicity
1310581|NCT00728429|chemotherapeutic agent toxicity
1310582|NCT00728429|unspecified adult solid tumor, protocol specific
1310583|NCT00728390|advanced cancer refractory advanced non-small cell lung cancer
1310584|NCT00728377|gestational diabetes
1310585|NCT00728377|physical activity
1310586|NCT00728377|behavior change
1310587|NCT00728377|glucose tolerance
1310588|NCT00728377|pregnancy
1310589|NCT00728364|Anderson Fabry disease
1310590|NCT00728364|chronic kidney disease
1310591|NCT00728364|prevalence
1310592|NCT00728351|Type 2 diabetes, vildagliptin
1310593|NCT00728338|docosahexenoic acid (DHA)
1310594|NCT00728338|dietary supplement
1310595|NCT00728338|n-3 polyunsaturated fatty acid
1310596|NCT00728338|cardiovascular disease
1310597|NCT00728325|PTSD
1310598|NCT00728325|Vocational Rehabilitation
1310599|NCT00728325|Supported Employment
1310600|NCT00728312|Methamphetamine
1310601|NCT00728312|Therapeutics
1310602|NCT00728312|Psychopharmacology
1310603|NCT00728312|Amphetamine
1310604|NCT00728299|Coronary artery disease, carotid intima-media thickness
1310605|NCT00728286|Type 2 Diabetes Mellitus
1310606|NCT00728286|Acute Coronary Syndrome
1310607|NCT00728286|Platelet dependent thrombogenicity
1310608|NCT00728273|Efficacy
1310609|NCT00728273|Vietnam
1310610|NCT00728273|school children
1310611|NCT00728273|anemia
1310612|NCT00728273|fortification
1310613|NCT00728273|micronutrient
1310614|NCT00728260|Meningitis
1310615|NCT00728260|Meningococcal disease
1310616|NCT00728260|Menactra vaccine
1310617|NCT00728247|Cervical Spine
1310618|NCT00728247|Kinematics
1310619|NCT00728247|Manipulation
1310620|NCT00728247|Biomechanics
1310621|NCT00728234|aEEG
1310622|NCT00728234|preterm infants
1310623|NCT00728234|predictive value
1310624|NCT00728234|outcome
1310625|NCT00728221|Ginseng
1310626|NCT00728221|Korean Red Ginseng
1310627|NCT00728221|Ginsenoside
1310628|NCT00728221|Flow Mediated Dilation
1310629|NCT00728221|Endothelial Function
1310630|NCT00728221|Hypertension
1310631|NCT00728208|Young
1310632|NCT00728208|Elderly
1310633|NCT00728208|Randomised
1310634|NCT00728208|GSK372475
1310635|NCT00728195|Schizophrenia
1310636|NCT00728195|Central Nervous System
1310637|NCT00728195|JNJ-37822681
1310638|NCT00728182|Stroke
1310639|NCT00728182|Vascular cognitive impairment
1310640|NCT00728182|Coiling
1310641|NCT00728182|Endovascular repair
1310642|NCT00728182|Brain aneurysm
1310643|NCT00728182|NA-1
1310644|NCT00728169|Asthma
1310645|NCT00728169|Focus Group
1310646|NCT00728169|Community Based Participatory Research
1310647|NCT00728156|Type 2 Diabetes mellitus
1310648|NCT00728156|Coronary artery disease
1310649|NCT00728156|Platelet dependent thrombogenicity
1310650|NCT00728156|Aspirin
1310651|NCT00728156|Clopidogrel
1310652|NCT00728156|Badimon Chamber
1310653|NCT00728130|carcinoma
1310654|NCT00728130|upper
1310655|NCT00728130|aerodigestive
1310656|NCT00728130|tract
1310657|NCT00728130|submandibular
1310658|NCT00728130|gland
1310659|NCT00728117|indomethacin
1310660|NCT00728117|ibuprofen
1310661|NCT00728117|preterm infant
1310662|NCT00728104|Learn
1310663|NCT00728104|L-Carnitine
1310664|NCT00728104|Co-enzyme Q10
1310665|NCT00728104|Effective
1310666|NCT00728104|These supplements
1310667|NCT00728104|Compared
1310668|NCT00728104|Standard
1310669|NCT00728091|aquaretic
1310670|NCT00728091|SIADH
1310671|NCT00728078|hepatocellular carcinoma
1310672|NCT00728078|liver cancer
1310673|NCT00728078|radiofrequency ablation
1310674|NCT00728078|thalidomide
1310675|NCT00728052|single
1310676|NCT00728052|Tolerability
1310677|NCT00728052|dose escalation
1310678|NCT00728052|Pharmacodynamics
1310679|NCT00728052|GSK598809
1310680|NCT00728052|placebo
1310681|NCT00728052|Safety
1310682|NCT00728052|Smokers
1310683|NCT00728052|Pharmacokinetics
1310684|NCT00728039|Youth
1310685|NCT00728039|Consensus
1310686|NCT00728039|Criteria
1310687|NCT00728039|CVS
1310688|NCT00728026|Chart must reveal the following procedures:
1310689|NCT00728026|Heart rate variability,
1310690|NCT00728026|Deep Breathing Test,
1310691|NCT00728026|Valsalva maneuver,
1310692|NCT00728026|Table test,
1310693|NCT00728026|Thermoregulatory Sweat Testing,
1310694|NCT00728026|Quantitative Sudomotor Axon Reflex Test (QSART),
1310695|NCT00728026|Vital signs,
1310696|NCT00728026|postural changes in heart rate and blood pressure,
1310697|NCT00728026|composite autonomic score
1310698|NCT00728013|Acute coronary syndrome
1310699|NCT00728013|intensive lipid-lowering
1310700|NCT00728013|statins
1310701|NCT00728000|Pancreatic Cancer
1310702|NCT00727987|Rheumatoid arthritis
1310703|NCT00727987|Fully Human anti-TNFa monoclonal antibody
1310704|NCT00727987|CNTO148
1310705|NCT00727987|Golimumab
1310706|NCT00727974|Genome Wide Scan (GWS)
1310707|NCT00727974|Mitochondrial scan
1310708|NCT00727974|Family trios
1310709|NCT00727948|Breast cancer
1310711|NCT00727948|Aspirin
1310712|NCT00727948|Tamoxifen
1310713|NCT00727935|Women
1310714|NCT00727935|parturients
1310715|NCT00727935|with
1310716|NCT00727935|realization
1310717|NCT00727935|episiotomy
1310718|NCT00727922|Neuropathy
1310719|NCT00727922|Oxaliplatin
1310720|NCT00727922|Mangafodipir
1310721|NCT00727909|Hearing loss
1310722|NCT00727909|Hearing Aids
1310723|NCT00727909|Speech Perception
1310724|NCT00727909|Persons with Hearing Impairment
1310725|NCT00727896|Life style modification,
1310726|NCT00727896|Type 2 diabetes,
1310727|NCT00727896|SMS,
1310728|NCT00727896|Patient adherence
1310729|NCT00727883|Breast Cancer
1310730|NCT00727883|Adjuvant TAM
1310731|NCT00727883|post-menopausal
1310732|NCT00727883|women
1310733|NCT00727870|Shave Biopsy management
1310734|NCT00727870|"Biopsy/adverse effects[Mesh]"
1310735|NCT00727870|"Biopsy/complications[Mesh])"
1310736|NCT00727857|Glucose Metabolism Disorder
1310737|NCT00727857|Dysmetabolic Syndrome
1310738|NCT00727857|Type II Diabetes
1310739|NCT00727857|Diabetes Mellitus, Lipoatrophic
1310740|NCT00727857|Dyslipidemia
1310741|NCT00727857|Drug Therapy
1310742|NCT00727844|XDR-TB
1310743|NCT00727844|Linezolid
1310744|NCT00727844|Drug Resistance
1310745|NCT00727844|Computed Tomography
1310746|NCT00727844|Pharmacokinetics
1310747|NCT00727844|Tuberculosis
1310748|NCT00727844|Drug Resistance Tuberculosis
1310749|NCT00727844|MDR-TB
1310750|NCT00727831|neurotoxicity
1310751|NCT00727831|chemotherapeutic agent toxicity
1310752|NCT00727831|mucositis
1310753|NCT00727831|primary central nervous system non-Hodgkin lymphoma
1310754|NCT00727831|contiguous stage II adult diffuse large cell lymphoma
1310755|NCT00727831|noncontiguous stage II adult diffuse large cell lymphoma
1310756|NCT00727831|stage I adult diffuse large cell lymphoma
1310757|NCT00727831|stage III adult diffuse large cell lymphoma
1310758|NCT00727831|stage IV adult diffuse large cell lymphoma
1310759|NCT00726817|butyrate, visceral perception, compliance
1310760|NCT00726791|chronic pain
1310761|NCT00726791|pain disorder
1310762|NCT00726778|race/ethnicity
1310763|NCT00726778|insulin senistivity
1310764|NCT00726778|genetic admixture
1310765|NCT00726778|type 2 diabetes
1310766|NCT00726778|obesity
1310767|NCT00726778|body composition
1310768|NCT00726778|Insulin dynamics
1310769|NCT00726778|Racial/ethnic differences
1310770|NCT00726752|solid tumor
1310771|NCT00726752|Axitinib
1310772|NCT00726752|Pharmacokinetics
1310773|NCT00726752|Phase 1
1310774|NCT00726739|recurrent melanoma
1310775|NCT00726713|Metanx
1310776|NCT00726713|diabetes
1310777|NCT00726713|neuropathy
1310778|NCT00726713|folic acid
1310779|NCT00726713|folate
1310780|NCT00726713|L-methylfolate
1310781|NCT00726713|vitamin B6
1310782|NCT00726713|Pyridoxal 5'-phosphate
1310783|NCT00726713|vitamin B12
1310784|NCT00726713|methylcobalamin
1310785|NCT00726700|stage III grade 3 follicular lymphoma
1310786|NCT00726700|stage I adult lymphoblastic lymphoma
1310787|NCT00726700|stage III adult lymphoblastic lymphoma
1310788|NCT00726700|stage IV adult lymphoblastic lymphoma
1310789|NCT00726700|contiguous stage II adult lymphoblastic lymphoma
1310790|NCT00726700|noncontiguous stage II adult lymphoblastic lymphoma
1310791|NCT00726700|anaplastic large cell lymphoma
1310792|NCT00726700|stage III adult diffuse large cell lymphoma
1310793|NCT00726700|stage I adult diffuse large cell lymphoma
1310794|NCT00726700|stage IV adult diffuse large cell lymphoma
1310795|NCT00726700|contiguous stage II adult diffuse large cell lymphoma
1310796|NCT00726700|contiguous stage II adult immunoblastic large cell lymphoma
1310797|NCT00726700|noncontiguous stage II adult diffuse large cell lymphoma
1310798|NCT00726700|noncontiguous stage II adult immunoblastic large cell lymphoma
1310799|NCT00726700|stage III adult immunoblastic large cell lymphoma
1310800|NCT00726700|stage I adult immunoblastic large cell lymphoma
1310801|NCT00726700|stage IV adult immunoblastic large cell lymphoma
1310802|NCT00726700|stage III adult Burkitt lymphoma
1310803|NCT00726700|stage IV adult Burkitt lymphoma
1310804|NCT00726700|stage III mantle cell lymphoma
1310805|NCT00726700|stage I mantle cell lymphoma
1310806|NCT00726700|contiguous stage II mantle cell lymphoma
1310807|NCT00726700|noncontiguous stage II mantle cell lymphoma
1310808|NCT00726700|stage I adult Burkitt lymphoma
1310809|NCT00726700|contiguous stage II adult Burkitt lymphoma
1310810|NCT00726700|noncontiguous stage II adult Burkitt lymphoma
1310811|NCT00726700|stage III marginal zone lymphoma
1310812|NCT00726700|stage IV marginal zone lymphoma
1310813|NCT00726700|stage I marginal zone lymphoma
1310814|NCT00726700|contiguous stage II marginal zone lymphoma
1310815|NCT00726700|noncontiguous stage II marginal zone lymphoma
1310816|NCT00727792|participants
1310817|NCT00727792|scheduled
1310818|NCT00727792|clinically
1310819|NCT00727792|ordered
1310820|NCT00727792|MRI
1310821|NCT00727779|diabetes, metabolic syndrome, type 2 diabetes
1310822|NCT00727766|Clofarabine
1310823|NCT00727766|Clolar
1310824|NCT00727766|AML
1310825|NCT00727766|Consolidation
1310826|NCT00727753|Macular Degeneration
1310827|NCT00727753|Age-Related Maculopathies
1310828|NCT00727740|Cholangiopancreatography, Endoscopic Retrograde
1310829|NCT00727740|Pancreatitis
1310830|NCT00727740|Indomethacin
1310831|NCT00727727|Piribedil (trade name: Clarium)
1310832|NCT00727727|non-ergot dopamine agonist
1310833|NCT00727727|Morbus Parkinson
1310834|NCT00727727|Tolerability
1310835|NCT00727727|Efficacy
1310836|NCT00727727|Post Marketing Surveillance
1310837|NCT00727714|Cement dust exposure
1310838|NCT00727714|Cross-shift study
1310839|NCT00727714|Lung function indices
1310840|NCT00727714|Exhaled nitric oxide
1310841|NCT00727714|Serum inflammatory markers
1310842|NCT00727701|varicose ulcer
1310843|NCT00727701|veteran
1310844|NCT00727701|recurrence
1310845|NCT00727701|aftercare
1310846|NCT00727675|chronic pain
1310847|NCT00727675|opioid dependence
1310848|NCT00727675|Cognitive Behavioral Therapy (CBT)
1310849|NCT00727662|Breast Cancer
1310850|NCT00727662|Fatigue
1310851|NCT00727662|Proinflammatory Cytokines
1310852|NCT00727662|Physical functioning
1310853|NCT00727662|Quality of life
1310854|NCT00727649|fecal incontinence
1310855|NCT00727649|adults
1310856|NCT00727649|diarrhea
1310857|NCT00727636|inflammatory bowel disease (IBD)
1310858|NCT00727636|immunogenicity
1310859|NCT00727636|safety
1310860|NCT00727636|HPV
1310861|NCT00727636|Gardasil
1310862|NCT00727636|vaccine
1310863|NCT00727623|acute coronary syndrome
1310864|NCT00727623|myocardial infarction
1310865|NCT00727623|predictors of mortality
1310866|NCT00727623|reperfusion therapy
1310867|NCT00727610|Adverse drug event
1310868|NCT00727610|harm
1310869|NCT00727610|patient safety
1310870|NCT00727610|clinical decision support
1310871|NCT00727610|Adverse drug related event
1310872|NCT00727584|spinal cord compression
1310873|NCT00727584|unspecified adult solid tumor, protocol specific
1310874|NCT00727571|Anemia
1310875|NCT00727571|Chronic Kidney Disease
1310876|NCT00727571|Quality of Life
1310877|NCT00727571|CKD
1310878|NCT00727571|Chronic Renal Insufficiency
1310879|NCT00727558|refractive error
1310880|NCT00727532|clear cell renal cell carcinoma
1310881|NCT00727532|hereditary clear cell renal cell carcinoma
1310882|NCT00727532|recurrent renal cell cancer
1310883|NCT00727532|stage I renal cell cancer
1310884|NCT00727532|stage II renal cell cancer
1310885|NCT00727532|stage III renal cell cancer
1310886|NCT00727532|stage IV renal cell cancer
1310887|NCT00727519|Hemodialysis
1310888|NCT00727519|Nephrology
1310889|NCT00727519|Pomegranate Juice
1310890|NCT00727519|Israel
1310891|NCT00727493|osteoporosis,
1310892|NCT00727493|bisphosphonate
1310893|NCT00727493|therapy
1310894|NCT00727493|dental implant
1310895|NCT00727480|vascularity
1310896|NCT00727480|fingertips
1310897|NCT00727467|auditory cueing device
1310898|NCT00727467|Parkinson's disease
1310899|NCT00727467|freezing
1310900|NCT00727467|gait
1310901|NCT00727467|mobility
1310902|NCT00727454|Obstructive sleep apnea
1310903|NCT00727454|CPAP
1310904|NCT00727454|Heart remodeling
1310905|NCT00727454|Cardiovascular disease
1310906|NCT00727454|MRI
1310907|NCT00727441|adenocarcinoma of the pancreas
1310908|NCT00727441|stage I pancreatic cancer
1310909|NCT00727441|stage II pancreatic cancer
1310910|NCT00727428|FluLaval® TF
1310911|NCT00727428|Safety
1310912|NCT00727428|Immunogenicity
1310913|NCT00727428|Influenza
1310914|NCT00727415|advanced or progressive chronic lymphocytic leukemia
1310915|NCT00727415|Lenalidomide
1310916|NCT00727415|Fludarabine
1310917|NCT00727389|Prevention
1310918|NCT00727389|Quality of Health Care
1310919|NCT00727389|Health Care Evaluation Mechanisms
1310920|NCT00727376|esophageal
1310921|NCT00727376|stenting
1310922|NCT00727363|probiotics
1310923|NCT00727363|lactobacillus reuteri
1310924|NCT00727363|preterm infants
1310925|NCT00727363|nosocomial infection
1310926|NCT00727363|necrotizing enterocolitis
1310927|NCT00727350|NSCLC
1310928|NCT00727350|Novalis
1310929|NCT00727350|Stereotactic
1310930|NCT00727350|SBRT
1310931|NCT00727350|T1, T2 or T3NO NSCLC
1310932|NCT00727337|auditory perception
1310933|NCT00727337|rehabilitation of hearing impaired
1310934|NCT00727324|Ulcerative Colitis
1310935|NCT00727324|UC
1310936|NCT00727324|moderate
1310937|NCT00727324|severe
1310938|NCT00727324|LPS
1310939|NCT00727324|Alkaline Phosphatase
1310940|NCT00727324|AP
1310941|NCT00727324|BIAP
1310942|NCT00727324|Mucositis
1310943|NCT00727285|Cystic Fibrosis
1310944|NCT00727285|pulmonary exacerbation
1310945|NCT00727285|gene expression
1310946|NCT00727285|biomarker
1310947|NCT00727285|inflammation
1310948|NCT00727285|CF pulmonary exacerbation
1310949|NCT00727272|Bioavailability
1310950|NCT00727246|Traumatic Brain Injury
1310951|NCT00727246|FMRI
1310952|NCT00727246|Memory
1310953|NCT00727246|Cognition
1310954|NCT00727246|Neuropsychology
1310955|NCT00727233|Neuroblastosis Type I
1310956|NCT00727233|Plexiform Neurofibromas
1310957|NCT00727233|Angiogenesis Inhibitor
1310958|NCT00727233|Kinase Inhibitor
1310959|NCT00727233|Neurofibromatosis Type 1
1310960|NCT00727233|NF1
1310961|NCT00727233|Plexiform Neurofibroma
1310962|NCT00727220|type 1 diabetes
1310963|NCT00727220|continuous glucose sensor monitoring
1310964|NCT00727207|recurrent mantle cell lymphoma
1310965|NCT00727207|contiguous stage II mantle cell lymphoma
1310966|NCT00727207|noncontiguous stage II mantle cell lymphoma
1310967|NCT00727207|stage I mantle cell lymphoma
1310968|NCT00727207|stage III mantle cell lymphoma
1310969|NCT00727207|stage IV mantle cell lymphoma
1310970|NCT00727181|aortic valve
1310971|NCT00727181|heart valve
1310972|NCT00727181|tissue valve
1310973|NCT00727181|bioprosthesis
1310974|NCT00727181|valve disorder
1310975|NCT00727181|valve disease
1310976|NCT00727181|cardiac surgery
1310977|NCT00727181|aortic valve stenosis
1310978|NCT00727181|aortic valve regurgitation
1310979|NCT00727168|prevalence study
1310980|NCT00727168|glaucoma
1310981|NCT00727142|NPH
1310982|NCT00727142|Hydrocephalus
1310983|NCT00727142|Shunt
1310984|NCT00727129|vasomotor symptoms
1310985|NCT00727129|estrogen
1310986|NCT00727129|estradiol
1310987|NCT00727129|hot flashes
1310988|NCT00727103|Varenicline
1310989|NCT00727103|Smoking cessation
1310990|NCT00727103|Schizophrenia
1310991|NCT00727103|Schizoaffective disorder
1310992|NCT00727103|Alcohol dependence
1310993|NCT00727103|Nicotine dependence
1310994|NCT00727064|Healthy Subjects
1310995|NCT00727051|invasive coronary angiography
1310996|NCT00727051|multidetector coronary CTA
1310997|NCT00727051|coronary artery disease
1310998|NCT00727051|detecting coronary artery disease
1310999|NCT00727038|glaucoma
1311000|NCT00727038|neovascular glaucoma
1311001|NCT00727038|new onset glaucoma
1311002|NCT00727038|retinal ischemia
1311003|NCT00727038|central retinal vein occlusion
1311004|NCT00727038|proliferative diabetic retinopathy
1311005|NCT00727038|ocular ischemic syndrome
1311006|NCT00727038|carotid stenosis
1311007|NCT00727038|vascular endothelial growth factor
1311008|NCT00727038|neovascular
1311009|NCT00727025|skin closure devices
1311010|NCT00727025|linear scars
1311011|NCT00727012|mitral valve
1311012|NCT00727012|heart valve
1311013|NCT00727012|valve repair
1311014|NCT00727012|valve disorder
1311015|NCT00727012|valve disease
1311016|NCT00727012|cardiac surgery
1311017|NCT00726999|Gabapentin
1311018|NCT00726999|Pediatric Spinal Fusion
1311019|NCT00726999|Narcotic Use
1311020|NCT00726687|Cancer
1311021|NCT00726687|Indibulin
1311022|NCT00726687|Capecitabine
1311023|NCT00726687|Xeloda
1311024|NCT00726674|Diabetes HbA1C
1311025|NCT00726661|Metastatic Breast Cancer
1311026|NCT00726661|Locally Recurrent Breast Cancer
1311027|NCT00726661|Avastin
1311028|NCT00726648|CDP323
1311029|NCT00726648|Relapsing multiple sclerosis
1311030|NCT00726648|Blood biomarkers
1311031|NCT00726622|rectal cancer
1311032|NCT00726622|adenocarcinoma of the rectum
1311033|NCT00726596|recurrent prostate cancer
1311034|NCT00726596|stage IV prostate cancer
1311035|NCT00726596|Prostate-Specific Antigen
1311036|NCT00726583|Cancer
1311037|NCT00726583|Solid Tumors
1311038|NCT00726583|Carcinoma
1311039|NCT00726583|PI-3K
1311040|NCT00726583|PI3 kinase
1311041|NCT00726583|PI3K
1311042|NCT00726570|Disorders, Blood coagulation
1311043|NCT00726570|Deep Vein Thrombosis
1311044|NCT00726570|Perioperative Care
1311045|NCT00726570|Digestive System Surgical Procedures
1311046|NCT00726544|thrombocytopenia
1311047|NCT00726544|microangiopathic hemolytic anemia
1311048|NCT00726544|von Willebrand Factor
1311049|NCT00726544|ADAMTS13
1311050|NCT00726531|Falls prevention
1311051|NCT00726531|Exercise promotion
1311052|NCT00726531|Older people
1311053|NCT00726466|Age Related Macular Degeneration
1311054|NCT00726466|AMD
1311055|NCT00726466|CNV
1311056|NCT00726453|TARGET VESSEL REVASCULARIZATION (TVR)
1311057|NCT00726453|MYOCARDIAL INFARCTION (MI)
1311058|NCT00726453|TARGET VESSEL FAILURE (TVF)
1311059|NCT00726453|TARGET LESION REVASCULARIZATION (TLR)
1311060|NCT00726453|TARGET LESION FAILURE (TLF)
1311061|NCT00726453|STENT THROMBOSIS
1311062|NCT00726453|RESTENOTIC LESION
1311063|NCT00726453|PERCUTANEOUS CORONARY INTERVENTION (PCI)
1311064|NCT00726440|Type 1 Diabetes
1311065|NCT00726440|Real Time Continuous Glucose Monitoring System
1311066|NCT00726440|HbA1c
1311067|NCT00726440|Navigator®
1311068|NCT00726427|pharmacokinetics
1311069|NCT00726427|pharmacodynamics
1311070|NCT00726427|AZD1656
1311071|NCT00726427|safety
1311072|NCT00726427|tolerability
1311073|NCT00726427|Healthy Volunteers
1311074|NCT00726414|Bioavailability
1311075|NCT00726401|Allergies
1311076|NCT00726401|Nasal
1311077|NCT00726401|Congestion
1311078|NCT00726401|Sneezing
1311079|NCT00726401|Pruritus
1311080|NCT00726401|Teary
1311081|NCT00726401|Eyes
1311082|NCT00726388|safety
1311083|NCT00726388|diclofenac
1311084|NCT00726388|pain, postoperative
1311085|NCT00726375|(GVHD)
1311086|NCT00726362|Statin
1311087|NCT00726362|LDL-C
1311088|NCT00726336|healthy volunteer
1311089|NCT00726336|pharmacokinetics
1311090|NCT00726336|GSK1349572
1311091|NCT00726336|integrase
1311092|NCT00726323|c-Met
1311093|NCT00726323|Papillary Renal Cell Carcinoma(PRC)
1311094|NCT00726323|Sporadic papillary renal cell carcinoma,
1311095|NCT00726323|Clear cell renal carcinoma
1311096|NCT00726323|Hereditary papillary renal cell carcinoma,
1311097|NCT00726310|Spondylolisthesis
1311098|NCT00726310|Instability
1311099|NCT00726284|HNP
1311100|NCT00726271|obesity
1311101|NCT00726271|appetite set point
1311102|NCT00726219|Major
1311103|NCT00726219|knee
1311104|NCT00726219|surgery
1311105|NCT00726180|Breast cancer
1311106|NCT00726180|Women
1311107|NCT00726180|w/Her2
1311108|NCT00726180|positive
1311109|NCT00726180|ERnegative
1311110|NCT00726180|not metastasized
1311111|NCT00726167|Ventilator associated Pneumonia
1311112|NCT00726167|mechanically ventilated
1311113|NCT00726167|procalcitonin
1311114|NCT00726167|pneumonia scores
1311115|NCT00726154|Bipolar Disorder
1311116|NCT00726154|Circadian Rhythm
1311117|NCT00726154|Moderators
1311118|NCT00726154|Lithium
1311119|NCT00726154|Quetiapine
1311120|NCT00726141|Brief Intervention
1311121|NCT00726141|Smoking Cessation
1311122|NCT00726141|Motivational Interviewing
1311123|NCT00726141|Expert System
1311124|NCT00726141|Readiness to Change
1311125|NCT00726141|Hormonal Contraceptive
1311126|NCT00726141|Adolescents
1311127|NCT00726128|DDD
1311128|NCT00726102|Zinc nutrition
1311129|NCT00726102|Growth
1311130|NCT00726102|Development
1311131|NCT00726102|China
1311132|NCT00726102|Infants
1311133|NCT00726102|Toddlers
1311134|NCT00726076|Epilepsy
1311135|NCT00726076|Medication
1311136|NCT00726076|Stress
1311137|NCT00726076|Sleep
1311138|NCT00726076|Lifestyle Management
1311139|NCT00726063|dental implants
1311140|NCT00726063|Nanotite implant
1311141|NCT00726063|Osseotite implants
1311142|NCT00726063|multicenter
1311143|NCT00726063|randomized
1311144|NCT00726063|clinical study
1311145|NCT00726063|partial edentulism
1311146|NCT00726063|prosthesis
1311147|NCT00726050|Theta Burst Stimulation
1311148|NCT00726050|Somatosensory Stimulation
1311149|NCT00726050|Somatosensory Cortex
1311150|NCT00726050|Tactile Discrimination
1311151|NCT00726050|Healthy Volunteer
1311152|NCT00726050|HV
1311153|NCT00726037|Denileukin diftitox
1311154|NCT00726037|Metastatic Pancreatic Cancer
1311155|NCT00726037|Ontak
1311156|NCT00726037|Regulatory T-cell
1311157|NCT00726011|due
1311158|NCT00726011|cancer treatment
1311159|NCT00725998|Cochlear Implantation.
1311160|NCT00725998|Cochlear nerve.
1311161|NCT00725998|Child.
1311162|NCT00725998|study
1311163|NCT00725998|ECAP
1311164|NCT00725998|During
1311165|NCT00725998|First year
1311166|NCT00725985|Clinically Isolated Syndrome (CIS)
1311167|NCT00725985|Early MS
1311168|NCT00725985|Multiple Sclerosis
1311169|NCT00725972|Improve
1311170|NCT00725972|Patient care
1311171|NCT00725972|Applying
1311172|NCT00725972|Systematic
1311173|NCT00725972|Fashion
1311174|NCT00725972|Proven
1311175|NCT00725972|Resuscitation
1311176|NCT00725972|Algorithms
1311177|NCT00725972|High risk
1311178|NCT00725972|Surgical
1311179|NCT00725959|HIV Prevention
1311180|NCT00725959|Social Networking
1311181|NCT00725959|Technology Based Intervention
1311182|NCT00725920|PTSD,
1311183|NCT00725920|posttraumatic
1311184|NCT00725920|stress
1311185|NCT00725920|disorder,
1311186|NCT00725920|randomization,
1311187|NCT00725920|placebo,
1311188|NCT00725920|controlled
1311189|NCT00725907|PRP
1311190|NCT00725907|ATFL
1311191|NCT00725881|PAD
1311192|NCT00725881|Peripheral arterial disease
1311193|NCT00725881|Peripheral artery disease
1311194|NCT00725881|Intermittent claudication
1311195|NCT00725881|IC
1311196|NCT00725881|atherosclerosis
1311197|NCT00725881|leg pain
1311198|NCT00725881|walking pain
1311199|NCT00725868|Major adverse
1311200|NCT00725855|Schizophrenia
1311201|NCT00725855|P50 Sensory Gating
1311202|NCT00725855|Mismatched Negativity
1311203|NCT00725829|coagulation
1311204|NCT00725829|cholesterol
1311205|NCT00725829|acute ischemia
1311206|NCT00725829|fibrin clot
1311207|NCT00725803|Hepatitis C
1311208|NCT00725803|HCV
1311209|NCT00725803|Fibrosis
1311210|NCT00725803|Apoptosis
1311211|NCT00725803|GS-9450
1311212|NCT00725790|Erectile Dysfunction
1311213|NCT00725790|Spinal Cord Injury
1311214|NCT00725764|VEGFR2
1311215|NCT00725764|XL880
1311216|NCT00725764|foretinib
1311217|NCT00725764|Squamous Cell Cancer of the Head and Neck
1311218|NCT00725764|MET
1311219|NCT00725764|GSK1363089
1311220|NCT00725738|Myocardial
1311221|NCT00725738|Infarction,
1311222|NCT00725738|Stem
1311223|NCT00725738|Cell
1311224|NCT00725738|Therapy
1311225|NCT00725712|c-Met
1311226|NCT00725712|Metastatic Gastric Carcinoma
1311227|NCT00725712|adenocarcinoma
1311228|NCT00725712|Gastric cancer
1311229|NCT00725712|GSK1363089
1311230|NCT00725712|XL880
1311231|NCT00725712|MET inhibitor
1311232|NCT00725686|"Choroidal Neovascularization (CNV) WET AMD"
1311233|NCT00725673|COPD
1311234|NCT00725673|Osteoporosis
1311235|NCT00725673|BMD
1311236|NCT00725673|DEXA-scan
1311237|NCT00725660|pre eclampsia
1311238|NCT00725660|doppler
1311239|NCT00725660|uterine
1311240|NCT00725660|arteries
1311241|NCT00725660|angiogenic
1311242|NCT00725660|factors
1311243|NCT00725647|N terminal B type natriuretic peptide
1311244|NCT00725647|echocardiography
1311245|NCT00725647|diagnosis
1311246|NCT00725647|atrial natriuretic peptides
1311247|NCT00725647|preterm infant
1311248|NCT00725634|Neoplasms,
1311249|NCT00725634|Lymphoma,
1311250|NCT00725634|Multiple Myeloma,
1311251|NCT00725634|Neoplasms, Plasma Cell,
1311252|NCT00725634|Neoplasms by Histologic Type,
1311253|NCT00725634|Lymphoproliferative Disorders,
1311254|NCT00725634|Lymphatic Diseases, Immunoproliferative Disorders
1311255|NCT00725634|Immune System Diseases Hemostatic Disorders
1311256|NCT00725634|Vascular Diseases
1311257|NCT00725634|Cardiovascular Diseases
1311258|NCT00725634|Paraproteinemias
1311259|NCT00725634|Blood Protein Disorders
1311260|NCT00725634|Hematologic Diseases
1311261|NCT00725634|Hemorrhagic Disorders
1311262|NCT00725634|Erlotinib
1311263|NCT00725634|Protein Kinase Inhibitors
1311264|NCT00725634|Enzyme Inhibitors,
1311265|NCT00725634|Molecular Mechanisms of Pharmacological Action
1311266|NCT00725634|Pharmacologic Actions
1311267|NCT00725608|Suboxone
1311268|NCT00725608|Subutex
1311269|NCT00725608|Buprenorphine
1311270|NCT00725608|Naloxone
1311271|NCT00725595|Cheyne Stocks respiration
1311272|NCT00725595|heart failure
1311273|NCT00725595|sleep apnea
1311274|NCT00725595|ventilator
1311275|NCT00725569|Caesarian Section
1311276|NCT00725569|Homeopathy
1311277|NCT00725569|Pain
1311278|NCT00725569|Analgesia
1311279|NCT00725556|Autism
1311280|NCT00725556|Asperger Syndrome
1311281|NCT00725530|Lens deposits
1311282|NCT00725530|Soft contact lens wearers
1311283|NCT00725517|Icodextrin
1311284|NCT00725517|ultrafiltration
1311285|NCT00725517|creatinine clearance
1311286|NCT00725517|urea nitrogen clearance
1311287|NCT00725491|Reproductive
1311288|NCT00725491|techniques
1311289|NCT00725491|assisted
1311290|NCT00725478|Piribedil (trade name: CLARIUM)
1311291|NCT00725478|non-ergot dopamine agonist
1311292|NCT00725478|Morbus Parkinson
1311293|NCT00725478|Tolerability
1311294|NCT00725478|Efficacy
1311295|NCT00725478|Post Marketing Surveillance
1311296|NCT00725465|laparoscopy
1311297|NCT00725465|CO2 colonoscopy
1311298|NCT00725465|intraoperative CO2 colonoscopy
1311299|NCT00725465|combined Lap-CO2 procedure
1311300|NCT00725465|to evaluate simultaneous CO2 laparoscopy and colonoscopy safety and physiologic effects on patients from the additional CO2 insufflation
1311301|NCT00725426|healthy subjects
1311302|NCT00725400|Colorectal Cancer
1311303|NCT00725400|Erbitux
1311304|NCT00725400|Cetuximab
1311305|NCT00725400|Surgery
1311306|NCT00725400|Radiation
1311307|NCT00725348|Psoriasis
1311308|NCT00725335|ischemia
1311309|NCT00725335|liver cancer
1311310|NCT00725335|radical excision
1311311|NCT00725335|prognosis
1311312|NCT00725309|Chronic Obstructive Pulmonary Disease
1311313|NCT00725309|COPD
1311314|NCT00725309|Elastin
1311315|NCT00725309|ELN
1311316|NCT00725283|Leukemia
1311317|NCT00725283|ASCI
1311318|NCT00725283|Complete remission
1311319|NCT00725283|Immunotherapy
1311320|NCT00725283|adult
1311321|NCT00725283|Acute Myeloid Leukemia
1311322|NCT00725283|Tumor antigen
1311323|NCT00725283|WT1
1311324|NCT00725244|Radiation Injuries
1311325|NCT00725244|Telangiectasis
1311326|NCT00725244|Bipolar Eletrocoagulation
1311327|NCT00725244|Argon Plasma Coagulation
1311328|NCT00725231|T cell lymphoma
1311329|NCT00725218|NSAIDs
1311330|NCT00725218|Postoperative pain
1311331|NCT00725218|Analgesia
1311332|NCT00725218|Abortion
1311333|NCT00725192|PTSD
1311334|NCT00725192|Posttraumatic Stress Disorder
1311335|NCT00725192|Physical Assault
1311336|NCT00725192|Physical Abuse
1311337|NCT00725192|Sexual Assault
1311338|NCT00725192|Sexual Abuse
1311339|NCT00725192|Interpersonal Assault
1311340|NCT00725192|Cognitive Processing Therapy
1311341|NCT00725192|Sleep Impairment
1311342|NCT00725192|Insomnia
1311343|NCT00725192|Hypnosis
1311344|NCT00725179|acetaminophen toxicity
1311345|NCT00725179|n-acetylcysteine
1311346|NCT00725179|liver toxicity
1311347|NCT00725166|Aging
1311348|NCT00725166|Biopsy
1311349|NCT00725166|Skeletal muscle
1311350|NCT00725166|Molecular biology
1311351|NCT00725166|Genetic markers
1311352|NCT00725166|Gene expression regulation
1311353|NCT00725166|Young and old men
1311354|NCT00725166|Healthy volunteers
1311355|NCT00725153|Contact lens deposits
1311356|NCT00725153|Soft contact lenses
1311357|NCT00725153|Myopia
1311358|NCT00725140|Migraine
1311359|NCT00725140|Early intervention
1311360|NCT00725140|Primary Care
1311361|NCT00725140|Almotriptan
1311362|NCT00725127|Aspirin
1311363|NCT00725127|Chronotherapy
1311364|NCT00725127|Primary prevention
1311365|NCT00725127|Impaired fasting glucose
1311366|NCT00725127|Type 2 diabetes
1311367|NCT00725127|Total mortality
1311368|NCT00725127|Myocardial infarction
1311369|NCT00725127|Stroke
1311370|NCT00725127|Angina pectoris
1311371|NCT00725127|Chronic kidney disease
1311372|NCT00725114|due
1311373|NCT00725114|cancer
1311374|NCT00725114|treatment
1311375|NCT00725088|ST-Elevated Myocardial Infarction
1311376|NCT00725088|Exercise Training
1311377|NCT00725088|Rehabilitation
1311378|NCT00725075|Negative symptoms
1311379|NCT00725075|Glycine Uptake inhibitor
1311380|NCT00725075|Add-on treatment
1311381|NCT00725075|Second Generation Antipsychotic
1311382|NCT00725062|graft versus host disease
1311383|NCT00725062|adult acute lymphoblastic leukemia in remission
1311384|NCT00725062|adult acute myeloid leukemia in remission
1311385|NCT00725062|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1311386|NCT00725062|adult acute myeloid leukemia with inv(16)(p13;q22)
1311387|NCT00725062|adult acute myeloid leukemia with t(15;17)(q22;q12)
1311388|NCT00725062|adult acute myeloid leukemia with t(16;16)(p13;q22)
1311389|NCT00725062|adult acute myeloid leukemia with t(8;21)(q22;q22)
1311390|NCT00725062|chronic phase chronic myelogenous leukemia
1311391|NCT00725062|accelerated phase chronic myelogenous leukemia
1311392|NCT00725062|relapsing chronic myelogenous leukemia
1311393|NCT00725062|de novo myelodysplastic syndromes
1311394|NCT00725062|previously treated myelodysplastic syndromes
1311395|NCT00725062|secondary myelodysplastic syndromes
1311396|NCT00725062|stage I multiple myeloma
1311397|NCT00725062|stage II multiple myeloma
1311398|NCT00725062|stage III multiple myeloma
1311399|NCT00725062|refractory multiple myeloma
1311400|NCT00725062|stage III adult Burkitt lymphoma
1311401|NCT00725062|stage III adult diffuse large cell lymphoma
1311402|NCT00725062|stage III adult diffuse mixed cell lymphoma
1311403|NCT00725062|stage III adult diffuse small cleaved cell lymphoma
1311404|NCT00725062|stage III adult immunoblastic large cell lymphoma
1311405|NCT00725062|stage III adult lymphoblastic lymphoma
1311406|NCT00725062|stage III grade 1 follicular lymphoma
1311407|NCT00725062|stage III grade 2 follicular lymphoma
1311408|NCT00725062|stage III grade 3 follicular lymphoma
1311409|NCT00725062|stage III mantle cell lymphoma
1311410|NCT00725062|stage III marginal zone lymphoma
1311411|NCT00725062|stage III small lymphocytic lymphoma
1311412|NCT00725062|stage IV adult Burkitt lymphoma
1311413|NCT00725062|stage IV adult diffuse large cell lymphoma
1311414|NCT00725062|stage IV adult diffuse mixed cell lymphoma
1311415|NCT00725062|stage IV adult diffuse small cleaved cell lymphoma
1311416|NCT00725062|stage IV adult immunoblastic large cell lymphoma
1311417|NCT00725062|stage IV adult lymphoblastic lymphoma
1311418|NCT00725062|stage IV grade 1 follicular lymphoma
1311419|NCT00725062|stage IV grade 2 follicular lymphoma
1311420|NCT00725062|stage IV grade 3 follicular lymphoma
1311421|NCT00725062|stage IV mantle cell lymphoma
1311422|NCT00725062|stage IV marginal zone lymphoma
1311423|NCT00725062|stage IV small lymphocytic lymphoma
1311424|NCT00725062|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1311425|NCT00725062|nodal marginal zone B-cell lymphoma
1311426|NCT00725062|splenic marginal zone lymphoma
1311427|NCT00725062|recurrent adult acute lymphoblastic leukemia
1311428|NCT00725062|recurrent childhood acute myeloid leukemia
1311429|NCT00725062|recurrent adult Burkitt lymphoma
1311430|NCT00725062|recurrent adult diffuse large cell lymphoma
1311431|NCT00725062|recurrent adult diffuse mixed cell lymphoma
1311432|NCT00725062|recurrent adult diffuse small cleaved cell lymphoma
1311433|NCT00725062|recurrent adult immunoblastic large cell lymphoma
1311434|NCT00725062|recurrent adult lymphoblastic lymphoma
1311435|NCT00725062|recurrent grade 1 follicular lymphoma
1311436|NCT00725062|recurrent grade 2 follicular lymphoma
1311437|NCT00725062|recurrent grade 3 follicular lymphoma
1311438|NCT00725062|recurrent mantle cell lymphoma
1311439|NCT00725062|recurrent marginal zone lymphoma
1311440|NCT00725062|recurrent small lymphocytic lymphoma
1311441|NCT00725049|dental implants
1311442|NCT00725049|Nanotite Certain implant
1311443|NCT00725049|Osseotite
1311444|NCT00725049|multicenter
1311445|NCT00725049|randomized
1311446|NCT00725049|clinical study
1311447|NCT00725049|partial edentulism
1311448|NCT00725049|crestal bone level
1311449|NCT00725049|short fixed bridge
1311450|NCT00725049|cost analysis
1311451|NCT00725023|Pain, chronic pain, tennis elbow, lateral epicondylitis
1311452|NCT00724997|live attenuated flu vaccines
1311453|NCT00724997|Influenza A (H1N1)
1311454|NCT00724997|intranasally application
1311455|NCT00724997|replication-deficient influenza virus
1311456|NCT00724984|PCI-24781
1311457|NCT00724984|Lymphoma
1311458|NCT00724984|Hodgkin Disease
1311459|NCT00724984|Lymphoma, Non-Hodgkin
1311460|NCT00724984|Lymphoma, Large B-Cell, Diffuse
1311461|NCT00724984|Lymphoma, Follicular
1311462|NCT00724984|Lymphoma, B-Cell, Marginal Zone
1311463|NCT00724984|Leukemia, Lymphocytic, Chronic, B-Cell
1311464|NCT00724984|Lymphoma, Mantle Cell
1311465|NCT00724984|Lymphoma, T-Cell, Cutaneous
1311466|NCT00724984|Lymphoma, T-Cell, Peripheral
1311467|NCT00724971|B-cell Non-Hodgkin's Lymphoma
1311468|NCT00724971|NHL
1311469|NCT00724919|ESBL
1311470|NCT00724906|Essential Tremor
1311471|NCT00724906|Parkinsonian Tremor
1311472|NCT00724906|Parkinson Disease
1311473|NCT00724906|Upper Extremity Tremor with duration of less than 2 years
1311474|NCT00724906|Diagnosis
1311475|NCT00724906|Subjects
1311476|NCT00724906|Upper
1311477|NCT00724906|Extremity
1311478|NCT00724906|Tremor
1311479|NCT00724906|Less
1311480|NCT00724906|Than 2 years
1311481|NCT00724880|coronary artery bypass grafting
1311482|NCT00724880|clopidogrel
1311483|NCT00724880|post-operative bleeding
1311484|NCT00724867|Systemic Lupus Erythematosus
1311485|NCT00724867|Belimumab
1311486|NCT00724867|SLE
1311487|NCT00724867|Antibodies
1311488|NCT00724867|Lupus
1311489|NCT00724867|Autoimmune Diseases
1311490|NCT00724828|Bacterial otitis media
1311491|NCT00724828|pneumoniae
1311492|NCT00724828|sepsis
1311493|NCT00724828|bacteremia
1311494|NCT00724828|meningitis
1311495|NCT00724828|Streptococcus pneumoniae carriage rate
1311496|NCT00724802|babies with canavan disease
1311497|NCT00724789|Neonatal outcome
1311498|NCT00724789|Congenital malformations
1311499|NCT00724789|In-Vitro fertilization
1311500|NCT00724789|Controlled ovarian stimulation
1311501|NCT00724789|Follow-up
1311502|NCT00724776|Chronic hepatitis C, Albinterferon alfa 2b, phase I, Japan
1311503|NCT00724763|acupuncture, high blood pressure, HRV
1311504|NCT00724724|Stroke
1311505|NCT00724724|Transient Ischemic Attack
1311506|NCT00724711|HIV
1311507|NCT00724711|HIV 1
1311508|NCT00724685|Ropivacaine
1311509|NCT00724685|elastomeric pump
1311510|NCT00724685|patient controlled analgesia
1311511|NCT00724685|morphine consumption
1311512|NCT00724659|Arthrogram
1311513|NCT00724659|Contrast
1311514|NCT00724659|Joint
1311515|NCT00724659|Ultrasound
1311516|NCT00724646|parents
1311517|NCT00724646|medically fragile
1311518|NCT00724646|death
1311519|NCT00724646|end-of-life care
1311520|NCT00724646|surveys
1311521|NCT00724633|dialysate
1311522|NCT00724633|sodium
1311523|NCT00724633|hemodialysis
1311524|NCT00724633|blood pressure
1311525|NCT00724633|thirst
1311526|NCT00724633|intradialytic symptoms
1311527|NCT00724633|interdialytic weight gain
1311528|NCT00724633|extracellular fluid balance
1311529|NCT00724633|mechanisms
1311530|NCT00724607|Concussion, traumatic brain injury
1311531|NCT00724607|Screening
1311532|NCT00724607|neuroimaging
1311533|NCT00724607|Posttraumatic stress disorder
1311534|NCT00724594|chorioamnionitis
1311535|NCT00724594|maternal chorioamnionitis
1311536|NCT00724594|neonatal white matter injury
1311537|NCT00724594|N-acetylcysteine
1311538|NCT00724594|NAC
1311539|NCT00724594|anti-oxidant treatment
1311540|NCT00724581|Atrial fibrillation, amiodarone
1311541|NCT00724568|Newly Diagnosed Multiple Myeloma
1311542|NCT00724555|stroke
1311543|NCT00724555|tissue plasminogen activator
1311544|NCT00724555|tPA
1311545|NCT00724529|Crohn's Disease
1311546|NCT00724529|Ankylosing Spondylitis
1311547|NCT00724516|Mammogram
1311548|NCT00724516|Biopsy
1311549|NCT00724516|Needle
1311550|NCT00724516|Wire
1311551|NCT00724516|Localization
1311552|NCT00724516|Compression
1311553|NCT00724516|Paddle
1311554|NCT00724503|colon cancer
1311555|NCT00724503|Colorectal carcinoma
1311556|NCT00724503|liver metastases
1311557|NCT00724503|SIR-Spheres microspheres
1311558|NCT00724503|yttrium-90
1311559|NCT00724503|FOLFOX
1311560|NCT00724503|bevacizumab
1311561|NCT00724503|metastatic colorectal cancer
1311562|NCT00724490|Deep Brain Stimulation
1311563|NCT00724490|Obsessive Compulsive Disorder
1311564|NCT00724490|Nucleus Accumbens
1311565|NCT00724438|Contraception
1311566|NCT00724438|Implanon
1311567|NCT00724438|Obesity
1311568|NCT00724438|Blood spots
1311569|NCT00724438|Implant
1311570|NCT00724438|Pharmacokinetics
1311571|NCT00724412|Dry Eye
1311572|NCT00724412|Corneal Staining
1311573|NCT00724360|relapsed/refractory
1311574|NCT00724360|HER2
1311575|NCT00724360|positive
1311576|NCT00724360|B-ALL
1311577|NCT00724360|trastuzumab
1311578|NCT00724347|Auditory Perception
1311579|NCT00724347|Hearing Loss
1311580|NCT00724347|Presbycusis
1311581|NCT00724347|Perceptual Learning
1311582|NCT00724347|Hearing Prosthesis
1311583|NCT00724347|Speech Discrimination
1311584|NCT00724347|Delayed Treatment
1311585|NCT00724334|myelofibrosis
1311586|NCT00724321|iloprost
1311587|NCT00724321|hypoxic
1311588|NCT00724321|pulmonary
1311589|NCT00724321|vasoconstriction
1311590|NCT00724321|altitude
1311591|NCT00724308|Smoking
1311592|NCT00724308|Smoking Cessation
1311593|NCT00724308|Tobacco
1311594|NCT00724308|Mental Health
1311595|NCT00724282|sleep
1311596|NCT00724282|eszopiclone
1311597|NCT00724282|insulin secretion
1311598|NCT00724282|insulin action
1311599|NCT00724282|glucose tolerance
1311600|NCT00724269|Contact lens wear
1311601|NCT00724269|multi-purpose solution
1311602|NCT00724269|corneal staining
1311603|NCT00724256|Pyelonephritis.
1311604|NCT00724256|Urinary Tract Infections.
1311605|NCT00724256|Children.
1311606|NCT00724256|Randomised controlled trial.
1311607|NCT00724256|Therapy.
1311608|NCT00724256|Ceftibuten.
1311609|NCT00724204|probiotics
1311610|NCT00724204|safety
1311611|NCT00724204|fecal microbiota
1311612|NCT00724204|infections
1311613|NCT00724178|Pediatric HIV infection, bone mineral content, bone mineral density, Vitamin D, calcium Dual x-ray absorptiometry
1311614|NCT00724165|physical activity
1311615|NCT00724165|Latinas
1311616|NCT00724152|coping skills
1311617|NCT00724152|psychology
1311618|NCT00724152|audiology
1311619|NCT00724152|veterans
1311620|NCT00724152|tinnitus
1311621|NCT00724152|adult
1311622|NCT00724152|intervention studies
1311623|NCT00724152|tinnitus, noise induced
1311624|NCT00724152|noise
1311625|NCT00724152|auditory perception
1311626|NCT00724126|Diarrhea
1311627|NCT00724126|Rifaximin
1311628|NCT00724126|IBS
1311629|NCT00724126|Abdominal pain
1311630|NCT00724126|Bloating
1311631|NCT00724113|Shoulder capsulitis
1311632|NCT00724113|ARTHRO distension
1311633|NCT00724113|Mobilisation
1311634|NCT00724113|Randomised clinical trial
1311635|NCT00724100|Malignancy
1311636|NCT00724100|Solid tumor
1311637|NCT00724100|Tubulin inhibitor
1311638|NCT00724087|short sleep duration
1311639|NCT00724087|energy expenditure
1311640|NCT00724087|insulin secretion
1311641|NCT00724087|insulin action
1311642|NCT00724087|lipid turnover
1311643|NCT00724087|free fatty acids
1311644|NCT00724074|Arthritis of the knee
1311645|NCT00724074|Knee replacement
1311646|NCT00724074|Osteoarthritis, knee
1311647|NCT00724074|Arthroplasty, knee
1311648|NCT00724061|recurrent mycosis fungoides/Sezary syndrome
1311649|NCT00724061|stage I mycosis fungoides/Sezary syndrome
1311650|NCT00724061|stage II mycosis fungoides/Sezary syndrome
1311651|NCT00724061|stage III mycosis fungoides/Sezary syndrome
1311652|NCT00724061|stage IV mycosis fungoides/Sezary syndrome
1311653|NCT00724061|recurrent cutaneous T-cell non-Hodgkin lymphoma
1311654|NCT00724061|stage I cutaneous T-cell non-Hodgkin lymphoma
1311655|NCT00724061|stage II cutaneous T-cell non-Hodgkin lymphoma
1311656|NCT00724061|stage III cutaneous T-cell non-Hodgkin lymphoma
1311657|NCT00724061|stage IV cutaneous T-cell non-Hodgkin lymphoma
1311658|NCT00724048|Huntington Disease
1311659|NCT00724035|Anesthesia
1311660|NCT00724035|Upper extremity
1311661|NCT00724035|Nerve block
1311662|NCT00724035|Ultrasound
1311663|NCT00724035|Brachial plexus
1311664|NCT00724022|Kidney transplant status
1311665|NCT00724022|Steroid free
1311666|NCT00724022|Reduced
1311667|NCT00724022|Calcineurin
1311668|NCT00724022|Inhibitor
1311669|NCT00724022|Immunosuppression
1311670|NCT00723970|Major Depressive Disorder
1311671|NCT00723970|Insomnia
1311672|NCT00723970|Hot Flashes
1311673|NCT00723970|Menopause
1311674|NCT00723970|Quetiapine
1311675|NCT00723944|dental implants
1311676|NCT00723944|Osseotite Certain Prevail
1311677|NCT00723944|Lateralized
1311678|NCT00723944|non-lateralized
1311679|NCT00723944|Osseotite Certain
1311680|NCT00723944|multicenter
1311681|NCT00723944|randomized
1311682|NCT00723944|clinical study
1311683|NCT00723944|partial edentulism
1311684|NCT00723944|single stage
1311685|NCT00723944|early loading
1311686|NCT00723944|crestal bone level
1311687|NCT00723944|short fixed bridge
1311688|NCT00723918|HIV-associated neuropathy
1311689|NCT00723918|HIV
1311690|NCT00723918|AIDS
1311691|NCT00723918|cannabinoid
1311692|NCT00723918|Cannabis
1311693|NCT00723918|methadone
1311694|NCT00723918|distal sensory polyneuropathy
1311695|NCT00723918|polyneuropathy
1311696|NCT00723905|Crohn's Disease, Rheumatoid Arthritis
1311697|NCT00723866|Botulinum toxin, Spasticity, Stroke, Rehabilitation.
1311698|NCT00723853|Obesity
1311699|NCT00723853|Type 2 diabetes
1311700|NCT00723853|African American children
1311701|NCT00723853|African American youth
1311702|NCT00723853|Community based
1311703|NCT00723853|Family oriented
1311704|NCT00723853|Obesity & Risk of type 2 diabetes
1311705|NCT00723840|EuroQOL (EQ-5D)
1311706|NCT00722800|YAZ
1311707|NCT00722800|oral contraceptive
1311708|NCT00722800|hidradenitis suppurativa
1311709|NCT00722774|Vaccine
1311710|NCT00722774|Influenza
1311711|NCT00722761|YAZ
1311712|NCT00722761|oral contraceptive
1311713|NCT00722761|Acne vulgaris
1311714|NCT00723814|normal
1311715|NCT00723801|Marfan syndrome
1311716|NCT00723801|Losartan
1311717|NCT00723801|Atenolol
1311718|NCT00723801|Diastolic Function
1311719|NCT00723801|Aortic Stiffness
1311720|NCT00723788|Appendicitis
1311721|NCT00723788|Children
1311722|NCT00723788|Magnetic Resonance Imaging
1311723|NCT00723775|KALETRA
1311724|NCT00723775|GSK706769
1311725|NCT00723775|HIV
1311726|NCT00723775|healthy volunteers
1311727|NCT00723762|Valproic acid
1311728|NCT00723762|Urea cycle
1311729|NCT00723762|Ornithine
1311730|NCT00723762|Valproate
1311731|NCT00723762|Side effect
1311732|NCT00723749|Suboxone
1311733|NCT00723749|Subutex
1311734|NCT00723749|Buprenorphine
1311735|NCT00723749|Naloxone
1311736|NCT00723697|Subutex
1311737|NCT00723684|ADHD
1311738|NCT00723684|Children
1311739|NCT00723684|EEG-Neurofeedback
1311740|NCT00723658|Waldenström macroglobulinemia
1311741|NCT00723619|asthma
1311742|NCT00723619|spirometry
1311743|NCT00723619|FENO
1311744|NCT00723619|normal values for spirometry in childhood
1311745|NCT00723619|normal values for FENO in childhood
1311746|NCT00723606|Intramuscular ziprasidone, agitation, efficacy and safety
1311747|NCT00723593|Graft-Versus-Host Disease
1311748|NCT00723593|Gastrointestinal
1311749|NCT00723593|Apoptotic Assay
1311750|NCT00723593|Serum Proteomic Pattern Analysis
1311751|NCT00723593|Mucosal Biopsy
1311752|NCT00723593|Graft Versus Host Disease
1311753|NCT00723593|GVHD
1311754|NCT00723580|Kabuki Syndrome
1311755|NCT00723580|Actigraphy
1311756|NCT00723580|Treatment Response Measurement
1311757|NCT00723567|Spectrin Gene
1311758|NCT00723567|Hereditary Elliptocytosis (HE)
1311759|NCT00723567|Hereditary Pyropoikilocytosis (HPP)
1311760|NCT00723567|Genetics
1311761|NCT00723554|pulmonary arterial hypertension
1311762|NCT00723554|inhaled therapy
1311763|NCT00723554|power disc-15
1311764|NCT00723528|Psoriasis
1311765|NCT00723528|Ustekinumab
1311766|NCT00723528|CNTO 1275
1311767|NCT00723515|White spot lesion
1311768|NCT00723515|Tooth remineralization
1311769|NCT00723515|Fluoride varnishes
1311770|NCT00723502|Helicobacter pylori
1311771|NCT00723502|Eradication
1311772|NCT00723502|Dyspepsia
1311773|NCT00723489|Yellow Fever Vaccine
1311774|NCT00723489|Scarification Method
1311775|NCT00723489|Atopic Dermatitis
1311776|NCT00723489|IgG antibodies
1311777|NCT00723476|Quality of Life
1311778|NCT00723476|Adolescent
1311779|NCT00723476|Advance Care Planning
1311780|NCT00723476|Palliative Care
1311781|NCT00723476|End-of-Life Care
1311782|NCT00723476|HIV/AIDS
1311783|NCT00723476|Psychological Adjustment
1311784|NCT00723450|Bipolar I pediatric lamictal adolescent
1311785|NCT00723437|nail, psoriasis, NAPSI,acitretin
1311786|NCT00723424|AZD5672
1311787|NCT00723424|digoxin
1311788|NCT00723411|Diabetes
1311789|NCT00723411|Juvenile Diabetes
1311790|NCT00723411|Diabetes type 1
1311791|NCT00723411|Autoimmune Diabetes
1311792|NCT00723411|Insulin dependent Diabetes
1311793|NCT00723411|Type 1 diabetes
1311794|NCT00723411|Type 1 diabetes mellitus
1311795|NCT00723411|Diamyd
1311796|NCT00723411|rhGAD65
1311797|NCT00723411|GAD
1311798|NCT00723411|GAD-alum
1311799|NCT00723398|omega-3 fatty acids
1311800|NCT00723398|antiestrogens
1311801|NCT00723398|breast cancer prevention
1311802|NCT00723398|breast density
1311803|NCT00723398|biomarkers of mammary carcinogenesis
1311804|NCT00723385|cholesterol
1311805|NCT00723385|LDL-cholesterol
1311806|NCT00723385|cholecalciferol
1311807|NCT00723385|lipids
1311808|NCT00723385|C-reactive protein
1311809|NCT00723359|Multiple Myeloma
1311810|NCT00723359|Refractory
1311811|NCT00723359|Relapsed
1311812|NCT00723346|Relapse
1311813|NCT00723346|Lymphoma lymphoblastic
1311814|NCT00723333|Bone Marrow Transplant
1311815|NCT00723333|Myelofibrosis
1311816|NCT00723333|Stem Cell Transplant
1311817|NCT00723333|Allogenic Transplant
1311818|NCT00723320|Atherosclerosis
1311819|NCT00723320|Atorvastatin
1311820|NCT00723320|Therapeutic lifestyle change
1311821|NCT00723320|CIMT
1311822|NCT00723320|ABI
1311823|NCT00723320|PWV
1311824|NCT00723307|No diabetes mellitus
1311825|NCT00723307|Elevated waist circumference
1311826|NCT00723294|invasive ductal breast carcinoma
1311827|NCT00723294|male breast cancer
1311828|NCT00723294|stage IA breast cancer
1311829|NCT00723294|stage IB breast cancer
1311830|NCT00723294|stage II breast cancer
1311831|NCT00723281|transplant coronary artery disease
1311832|NCT00723281|CT angiography
1311833|NCT00723281|conventional angiography
1311834|NCT00723281|intravascular ultrasound
1311835|NCT00723281|Heart transplant patients with known transplant coronary artery disease
1311836|NCT00723268|Oral ulcers
1311837|NCT00723216|Prevention
1311838|NCT00723216|venous thromboembolism
1311839|NCT00723216|curative surgery
1311840|NCT00723203|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
1311841|NCT00723203|recurrent adult acute lymphoblastic leukemia
1311842|NCT00723203|recurrent adult acute myeloid leukemia
1311843|NCT00723190|CLONICEL
1311844|NCT00723190|Attention Deficit Hyperactivity Disorder
1311845|NCT00723190|clonidine HCl sustained release
1311846|NCT00723177|opioid withdrawal, analgesia
1311847|NCT00723164|Sevoflurane induction
1311848|NCT00723164|Premedication
1311849|NCT00723164|laryngeal mask airway
1311850|NCT00723164|Anesthesia, inhalation [E03.155.197.197]
1311851|NCT00723125|Breast Cancer
1311852|NCT00723112|Myelodysplastic Syndrome
1311853|NCT00723112|Erythropoiesis
1311854|NCT00723112|Ineffective Hematopoiesis
1311855|NCT00723112|Erythroid Progenitors
1311856|NCT00723112|Dyserythropoiesis
1311857|NCT00723086|docetaxel, prednisolone, drug combination
1311858|NCT00723073|micafungin, caspofungin, febrile neutropenia
1311859|NCT00723047|Patients
1311860|NCT00723047|CD complicated
1311861|NCT00723047|least
1311862|NCT00723047|One perianal fistula
1311863|NCT00723047|Draining
1311864|NCT00723047|2 months duration
1311865|NCT00723021|Bronchodilator
1311866|NCT00723008|anxiety
1311867|NCT00723008|insomnia
1311868|NCT00723008|pain
1311869|NCT00723008|Alpha Stim
1311870|NCT00723008|Cranial electrotherapy stimulation
1311871|NCT00722995|Morbid obesity
1311872|NCT00722995|Sleeve gastrectomy
1311873|NCT00722995|Gastric bypass
1311874|NCT00722995|Complications
1311875|NCT00722995|Efficacity
1311876|NCT00722995|Safety
1311877|NCT00722995|Compare
1311878|NCT00722982|coxarthrosis
1311879|NCT00722982|hip
1311880|NCT00722982|RSA
1311881|NCT00722982|DXA
1311882|NCT00722982|C-stem AMT
1311883|NCT00722982|Marathon
1311884|NCT00722969|non-small cell lung cancer
1311885|NCT00722969|erlotinib
1311886|NCT00722969|sorafenib
1311887|NCT00722956|atorvastatin
1311888|NCT00722956|AZD5672
1311889|NCT00722943|infant
1311890|NCT00722943|premature
1311891|NCT00722943|message
1311892|NCT00722943|therapy
1311893|NCT00722943|NICU
1311894|NCT00722943|neonatal intensive care unit
1311895|NCT00722943|cortisol level
1311896|NCT00722943|stress
1311897|NCT00722943|postnatal
1311898|NCT00722943|weight gain
1311899|NCT00722943|DMT
1311900|NCT00722943|Development Message Therapy
1311901|NCT00722943|growth
1311902|NCT00722930|Follicular Lymphoma
1311903|NCT00722930|High-risk FLIPI
1311904|NCT00722930|R-CHOP
1311905|NCT00722930|GOTEL
1311906|NCT00722930|Partial
1311907|NCT00722930|Complete
1311908|NCT00722930|Response
1311909|NCT00722930|Induction
1311910|NCT00722930|Chemotherapy
1311911|NCT00722917|Glucose Metabolism Disorder
1311912|NCT00722917|Dysmetabolic Syndrome
1311913|NCT00722917|Type II Diabetes
1311914|NCT00722917|Diabetes Mellitus, Lipoatrophic
1311915|NCT00722917|Dyslipidemia
1311916|NCT00722917|Drug Therapy
1311917|NCT00722904|post-intervention surveillance of aortic coarctation
1311918|NCT00722904|MRA and 2D phase contrast imaging
1311919|NCT00722904|4D Flow velocity mapping
1311920|NCT00722904|Patients undergoing routine post-intervention surveillance of aortic coarctation
1311921|NCT00722904|Healthy volunteers
1311922|NCT00722891|Eye Diseases
1311923|NCT00722878|Primary Ciliary Dyskinesia
1311924|NCT00722865|Avastin
1311925|NCT00722865|bevacizumab
1311926|NCT00722865|ABVD
1311927|NCT00722865|angiogenesis
1311928|NCT00722865|antiangiogenic
1311929|NCT00722865|Hodgkin
1311930|NCT00722839|cytomegalovirus infection
1311931|NCT00722826|Pulmonary Regurgitation
1311932|NCT00722826|Tetralogy of Fallot
1311933|NCT00722748|Genebank
1311934|NCT00722748|Gene registry
1311935|NCT00722748|Cardiac Arrythmia Disease
1311936|NCT00722735|uncomplicated Urinary Tract Infection in Women
1311937|NCT00722735|Antibacterial Chemotherapy
1311938|NCT00722735|Proof-of-Concept
1311939|NCT00722709|Pain
1311940|NCT00722709|Fatigue
1311941|NCT00722709|Colon
1311942|NCT00722709|Surgery
1311943|NCT00722709|ERAS
1311944|NCT00722709|Fastrack
1311945|NCT00722709|Local anaesthetic
1311946|NCT00722709|Peritoneum
1311947|NCT00722709|Metabolic
1311948|NCT00722709|Endocrine
1311949|NCT00722709|Post surgical metabolic response
1311950|NCT00722709|Complications
1311951|NCT00722709|Time to passage of flatus
1311952|NCT00722709|Time to passage of stool
1311953|NCT00722709|Time to discharge from facility
1311954|NCT00722709|Re-admission rate
1311955|NCT00722696|Metabolism
1311956|NCT00722696|Muscles
1311957|NCT00722696|Exercise
1311958|NCT00722670|risk reduction
1311959|NCT00722670|prevention
1311960|NCT00722670|HIV prevention
1311961|NCT00722657|asthma
1311962|NCT00722657|epidemiology
1311963|NCT00722644|HIV
1311964|NCT00722644|Medication Adherence
1311965|NCT00722644|Stress Management
1311966|NCT00722644|CD4/Viral Loads
1311967|NCT00722644|Cognitive Behavioral Treatment
1311968|NCT00722618|Infertility
1311969|NCT00722605|lung
1311970|NCT00722605|esophageal
1311971|NCT00722605|cone beam ct scan
1311972|NCT00722592|cancer
1311973|NCT00722592|ovarian
1311974|NCT00722592|platinum-resistant
1311975|NCT00722592|Phase II
1311976|NCT00722592|EC145
1311977|NCT00722592|EC20
1311978|NCT00722579|Coronary Artery Disease
1311979|NCT00722553|Transitional Cell Carcinoma of the Urinary Bladder
1311980|NCT00722553|Transitional Cell Carcinoma
1311981|NCT00722553|Bladder Cancer
1311982|NCT00722553|Urinary Bladder Cancer
1311983|NCT00722553|Bladder
1311984|NCT00722553|Carcinoma
1311985|NCT00722553|Urinary
1311986|NCT00722553|Metastatic
1311987|NCT00722553|Relapsed
1311988|NCT00722527|Primary Familial and Congenital Polycythemia
1311989|NCT00722527|Polycythemia
1311990|NCT00722527|Molecular Biology
1311991|NCT00722527|Genetics
1311992|NCT00722527|Erythropoiesis
1311993|NCT00722527|EPOR mutation
1311994|NCT00722527|Thrombocytosis
1311995|NCT00722527|Hypoxia
1311996|NCT00722475|recurrent miscarriage
1311997|NCT00722475|immunology
1311998|NCT00722475|intravenous immunoglobulin
1311999|NCT00722475|miscarriage
1312000|NCT00722462|Infertility
1312001|NCT00722462|IVF
1312002|NCT00722462|Acupuncture
1312003|NCT00722436|antifibrinolytic, tranexamic acid
1312004|NCT00722423|Hepatitis C
1312005|NCT00722423|integrated care
1312006|NCT00722423|alpha interferon
1312007|NCT00722423|mental health
1312008|NCT00722410|Carbapenem
1312009|NCT00722410|resistant
1312010|NCT00722410|Klebsiella pneumoniae
1312011|NCT00722410|Carpapenemases
1312012|NCT00722410|Probiotics
1312013|NCT00722410|VSL3
1312014|NCT00722397|genetics, pediatrics
1312015|NCT00722384|AMD
1312016|NCT00722384|Macular Degeneration
1312017|NCT00722384|Opko Health
1312018|NCT00722384|Acuity Pharmaceuticals
1312019|NCT00722384|bevasiranib
1312020|NCT00722384|Cand5
1312021|NCT00722384|Age-Related
1312022|NCT00722345|Obesity
1312023|NCT00722345|Physical activity
1312024|NCT00722345|Adolescents
1312025|NCT00722345|Exercise counseling intervention
1312026|NCT00722332|HBIG (Hepatitis B Immune Globulin)
1312027|NCT00722332|Chronic Hepatitis B Recurrence
1312028|NCT00722332|Liver Transplant
1312029|NCT00722319|oral anticoagulation
1312030|NCT00722319|warfarin
1312031|NCT00722319|percutaneous coronary intervention
1312032|NCT00722319|stent
1312033|NCT00722319|antiplatelet agents
1312034|NCT00722306|non-restorative
1312035|NCT00722306|sleep
1312036|NCT00722293|Solid tumors
1312037|NCT00722293|Cancer
1312038|NCT00722293|Neoplasms, Ovarian
1312039|NCT00722293|doxorubicin
1312040|NCT00722293|epirubicin
1312041|NCT00722293|anti-angiogenesis
1312042|NCT00722293|pharmacodynamics
1312043|NCT00722293|pazopanib (GW786034)
1312044|NCT00722293|pharmacokinetics
1312045|NCT00722293|Soft Tissue
1312046|NCT00722293|Sarcoma
1312047|NCT00722280|Amputation, upper limb, composite tissue, immunosuppression
1312048|NCT00722267|severe COPD
1312049|NCT00722267|COPD symptoms
1312050|NCT00722267|variability of symptoms
1312051|NCT00722267|patient's perception
1312052|NCT00722254|Myeloproliferative Disorder
1312053|NCT00722254|Primary Myelofibrosis
1312054|NCT00722254|Primary Pulmonary Hypertension
1312055|NCT00722254|Secondary Myelofibrosis
1312056|NCT00722254|Pulmonary Arterial Hypertension
1312057|NCT00722254|Flolan
1312058|NCT00722254|Clonality
1312059|NCT00722254|CD34+ cells
1312060|NCT00722254|Hematologic abnormalities
1312061|NCT00722241|Continuous Glucose Monitoring
1312062|NCT00722241|Interstitial Fluid
1312063|NCT00722241|Diabetes Mellitus
1312064|NCT00722215|Endothelin antagonist
1312065|NCT00722215|Chronic kidney disease
1312066|NCT00722215|Proteinuria
1312067|NCT00722215|Cardiovascular disease
1312068|NCT00722215|Blood pressure
1312069|NCT00722215|Arterial stiffness
1312070|NCT00722215|Endothelial function
1312071|NCT00722189|Mycoses
1312072|NCT00722176|Schizophrenia
1312073|NCT00722163|Cognitive Behavioural therapy
1312074|NCT00722163|Psychosis
1312075|NCT00722150|Artesunate
1312076|NCT00722150|Plasmodium Falciparum
1312077|NCT00722150|Cambodia
1312078|NCT00722124|tobacco use
1312079|NCT00722124|cigarettes
1312080|NCT00722124|smokers
1312081|NCT00722111|tongue
1312082|NCT00722111|pressure
1312083|NCT00722098|Melanoma
1312084|NCT00722098|Dendritic Cell
1312085|NCT00722098|Vaccine
1312086|NCT00722098|Immunotherapy
1312087|NCT00722098|Cyclophosphamide
1312088|NCT00722085|Amniotic Fluid Sludge
1312089|NCT00722085|Cerclage
1312090|NCT00722085|Ultrasound
1312091|NCT00722085|Preterm Delivery
1312092|NCT00722085|Neonatal
1312093|NCT00722072|male breast cancer
1312094|NCT00722072|stage IIIA breast cancer
1312095|NCT00722072|stage IIIB breast cancer
1312096|NCT00722072|stage IIIC breast cancer
1312097|NCT00722072|stage IV breast cancer
1312098|NCT00722072|recurrent breast cancer
1312099|NCT00722046|Alzheimer's disease
1312100|NCT00722046|antibody
1312101|NCT00722046|amyloid
1312102|NCT00722033|preterm
1312103|NCT00722033|aEEG
1312104|NCT00722033|apneas
1312105|NCT00722033|surfactant
1312106|NCT00722033|indomethacin
1312107|NCT00722033|aminophyline
1312108|NCT00722020|Asthma
1312109|NCT00722020|Bronchial Disease
1312110|NCT00722020|Status Asthmaticus
1312111|NCT00722020|High Frequency Chest Wall Oscillation
1312112|NCT00722020|the Vest
1312113|NCT00722020|HFCWO
1312114|NCT00722007|hip resurfacing
1312115|NCT00722007|osteoarthritis
1312116|NCT00722007|avascular necrosis
1312117|NCT00722007|rheumatoid arthritis
1312118|NCT00721994|hip resurfacing
1312119|NCT00721994|osteoarthritis
1312120|NCT00721994|avascular necrosis
1312121|NCT00721994|rheumatoid arthritis
1312122|NCT00721981|patient preference
1312123|NCT00721981|oncology
1312124|NCT00721981|chemotherapy
1312125|NCT00721981|NSCLC
1312126|NCT00721968|Open angle
1312127|NCT00721968|Glaucoma
1312128|NCT00721968|Cataract
1312129|NCT00721968|Surgery
1312130|NCT00721955|Bipolar 1 disorder,
1312131|NCT00721955|agitation,
1312132|NCT00721955|acute,
1312133|NCT00721955|treatment
1312134|NCT00721929|adrenal glands, adrenal masses
1312135|NCT00721890|chemoprevention
1312136|NCT00721890|green tea
1312137|NCT00721890|relapse free-survival
1312138|NCT00721890|proteases
1312139|NCT00721864|Paroxysmal Nocturnal Hemoglobinuria
1312140|NCT00721864|PIG-A Mutation
1312141|NCT00721864|Prion Protein
1312142|NCT00721864|Hematopoietic stem cells
1312143|NCT00721864|Clonal disorder
1312144|NCT00721838|adolescent obesity
1312145|NCT00721838|eating behavior
1312146|NCT00721838|dietary intake
1312147|NCT00721825|Stroke
1312148|NCT00721825|Cerebral infarct
1312149|NCT00721825|Rehabilitation
1312150|NCT00721825|Double blind Randomized
1312151|NCT00721825|Placebo controlled
1312152|NCT00721825|Traditional Chinese Medicine
1312153|NCT00721825|Neuroaid
1312154|NCT00721812|pharmacokinetics
1312155|NCT00721812|Phase 1
1312156|NCT00721812|first time in humans
1312157|NCT00721812|IBD
1312158|NCT00721812|safety
1312159|NCT00721812|human volunteers
1312160|NCT00721799|Positron-Emission Tomography
1312161|NCT00721786|Smoking cessation
1312162|NCT00721786|Cigarette smoking
1312163|NCT00721786|Tobacco smoking
1312164|NCT00721786|Internet interventions
1312165|NCT00721786|Spanish-speaking
1312166|NCT00721773|Continuous Ambulatory Peritoneal Dialysis
1312167|NCT00721773|Angiotensin-converting Enzyme Inhibitor
1312168|NCT00721773|Angiotensin II Receptor Blocker
1312169|NCT00721773|Renin angiotensin system inhibitor
1312170|NCT00721773|Residual Renal Function
1312171|NCT00721760|Hip fractures
1312172|NCT00721760|Heparin Low-Molecular-Weight
1312173|NCT00721760|Randomized Controlled Trial
1312174|NCT00721747|breast cancer patients her2 negative pathological responses
1312175|NCT00721734|Myeloma
1312176|NCT00721734|Renal Insufficiency
1312177|NCT00721734|Proteasome
1312178|NCT00721734|Hematological
1312179|NCT00721734|carfilzomib
1312180|NCT00721734|PR-171
1312181|NCT00721721|Dietary Sodium
1312182|NCT00721721|Dietary Potassium
1312183|NCT00721721|Genes
1312184|NCT00721721|Genomics
1312185|NCT00721708|histidine dipeptides
1312186|NCT00721708|carnosine
1312187|NCT00721708|anserine
1312188|NCT00721695|Cataract
1312189|NCT00721695|Cataract Extraction
1312190|NCT00721695|Lens Implantation
1312191|NCT00721695|Phacoemulsification
1312192|NCT00721682|Pediatry
1312193|NCT00721682|Ill-treatment
1312194|NCT00721682|Pain
1312195|NCT00721682|maltreated children
1312196|NCT00721669|solid tumor
1312197|NCT00721656|Dry eye syndromes
1312198|NCT00721656|Corneal diseases
1312199|NCT00721656|Conjunctival Diseases
1312200|NCT00721643|Angelica keiskei
1312201|NCT00721643|absorption kinetics
1312202|NCT00721643|quercetin
1312203|NCT00721630|CAPECITABINE
1312204|NCT00721630|LAPATINIB
1312205|NCT00721604|shock
1312206|NCT00721604|fluid responsiveness
1312207|NCT00721604|volume expansion
1312208|NCT00721591|Recurrent Pregnancy Loss
1312209|NCT00721591|Habitual abortion
1312210|NCT00721591|Fetal demise
1312211|NCT00721591|Antiphospholipid antibodies
1312212|NCT00721591|Inherited thrombophilia
1312213|NCT00721578|Observational study
1312214|NCT00721578|Effectiveness
1312215|NCT00721578|Safety
1312216|NCT00721578|Tolerability
1312217|NCT00721578|Systemic Fungal Infection
1312218|NCT00721565|Breast Cancer
1312219|NCT00721565|Exercise
1312220|NCT00721565|Social Cognitive Theory
1312221|NCT00721565|Adherence
1312222|NCT00721565|Symptoms
1312223|NCT00721565|Body Composition
1312224|NCT00721552|beta-cell function
1312225|NCT00721552|glucocorticoid-induced diabetes
1312226|NCT00721552|glucocorticoid
1312227|NCT00721552|DPP-4 inhibitors
1312228|NCT00721552|sitagliptin
1312229|NCT00721552|diabetes mellitus
1312230|NCT00721552|steroid diabetes
1312231|NCT00721552|insulin resistance
1312232|NCT00721552|insulin sensitivity
1312233|NCT00721526|alcohol dependence
1312234|NCT00721526|alcoholism
1312235|NCT00721526|anxiety disorder
1312236|NCT00721526|pharmacotherapy
1312237|NCT00721526|disulfiram
1312238|NCT00721526|lorazepam
1312239|NCT00721513|stage III squamous cell carcinoma of the oropharynx
1312240|NCT00721513|stage IV squamous cell carcinoma of the oropharynx
1312241|NCT00721513|stage III squamous cell carcinoma of the hypopharynx
1312242|NCT00721513|stage IV squamous cell carcinoma of the hypopharynx
1312243|NCT00721513|stage III squamous cell carcinoma of the larynx
1312244|NCT00721513|stage III verrucous carcinoma of the larynx
1312245|NCT00721513|stage IV squamous cell carcinoma of the larynx
1312246|NCT00721513|stage IV verrucous carcinoma of the larynx
1312247|NCT00721487|C. albicans
1312248|NCT00721487|fluconazole
1312249|NCT00721461|Assess
1312250|NCT00721461|Tolerability
1312251|NCT00721461|MedPulser DDS device
1312252|NCT00721448|Pharmacokinetics
1312253|NCT00721422|Pharmacokinetics of PD 0332334 in subjects with renal insufficiency
1312254|NCT00721409|hormone-receptor positive advanced breast cancer
1312255|NCT00721396|Meningococcal disease,
1312256|NCT00721396|Neisseria meningitidis serogroup B,
1312257|NCT00721396|Prevention,
1312258|NCT00721396|Vaccination,
1312259|NCT00721396|Infants
1312260|NCT00721383|caregiving, Alzheimer's disease, physical activity
1312261|NCT00721370|sentinel lymph node mapping
1312262|NCT00721370|breast cancer
1312263|NCT00721370|near infrared imaging
1312264|NCT00721357|muscles
1312265|NCT00721357|work
1312266|NCT00721357|Magnetic Resonance Imaging
1312267|NCT00721357|control groups
1312268|NCT00721344|Healthy males and females
1312269|NCT00721331|CombinatoRx
1312270|NCT00721331|Atopic
1312271|NCT00721331|Dermatitis
1312272|NCT00721331|Topical
1312273|NCT00721331|CRx-197
1312274|NCT00721331|Normal Healthy Volunteers
1312275|NCT00721318|chronic widespread pain
1312276|NCT00721318|fibromyalgia
1312277|NCT00721318|rheumatoid arthritis
1312278|NCT00721318|Estonia
1312279|NCT00721305|Type 1 human immunodeficiency virus infection
1312280|NCT00721305|Lovastatin
1312281|NCT00721305|Adaptive Immunity
1312282|NCT00721305|Cellular cholesterol
1312283|NCT00721305|Rho GTPases
1312284|NCT00721305|Lymphocyte function-associated antigen-1
1312285|NCT00721253|ReSTOR
1312286|NCT00721240|responder
1312287|NCT00721240|leucotriene antagonist
1312288|NCT00721214|Myelodysplastic Syndrome
1312289|NCT00721214|5-azacytidine
1312290|NCT00721214|allogeneic stem cell transplantation
1312291|NCT00721201|subclinical Cushing's
1312292|NCT00721175|biliary stent
1312293|NCT00721175|plastic stent
1312294|NCT00721175|metallic stent
1312295|NCT00721175|Complex hilar cholangiocarcinoma (Bismuth type II,III,IV)
1312296|NCT00721162|Ovarian Cancer,
1312297|NCT00721162|Fallopian Tube Cancer
1312298|NCT00721162|Primary Peritoneal Carcinoma
1312299|NCT00721149|Atrial Fibrillation
1312300|NCT00721149|Paroxysmal Atrial Fibrillation
1312301|NCT00721149|Ablation
1312302|NCT00721149|Non-randomized
1312303|NCT00721136|bleeding
1312304|NCT00721136|anticoagulation
1312305|NCT00721136|pacemaker
1312306|NCT00721136|implantable cardioverter-defibrillator
1312307|NCT00721136|"patients undergoing implantation of a pacemaker or defibrillator (ICD)"
1312308|NCT00721110|pain control
1312309|NCT00721110|nausea
1312310|NCT00721110|surgery recovery
1312311|NCT00721097|Severe asthma
1312312|NCT00721097|exacerbation
1312313|NCT00721097|predictive factors
1312314|NCT00721097|Severe
1312315|NCT00721084|short sleep duration
1312316|NCT00721084|maximal aerobic capacity
1312317|NCT00721084|body fat
1312318|NCT00721084|visceral adiposity
1312319|NCT00721084|activity-related energy expenditure
1312320|NCT00721084|energy metabolism
1312321|NCT00721071|Pediatrics
1312322|NCT00721071|Cystic Fibrosis
1312323|NCT00721071|Hypertonic Saline
1312324|NCT00721071|Induced Sputum
1312325|NCT00721071|Expectorated Sputum
1312326|NCT00721058|Eligible
1312327|NCT00721058|Operable
1312328|NCT00721058|Disease
1312329|NCT00721058|Conserving
1312330|NCT00721058|Therapy
1312331|NCT00721058|Visible mass on mammography
1312332|NCT00721058|Ultrasound > 0.5 cm
1312333|NCT00721058|Histologically
1312334|NCT00721058|Proven
1312335|NCT00721045|Heart Failure
1312336|NCT00721045|Congestive Heart Failure
1312337|NCT00721032|Ventricular tachycardia (VT)
1312338|NCT00721032|Implantable cardioverter-defibrillator (ICD)
1312339|NCT00721032|Ablation
1312340|NCT00721032|Cardiomyopathy
1312341|NCT00721032|Electrophysiology study
1312342|NCT00721019|short sleep duration
1312343|NCT00721019|glucose clamp technique
1312344|NCT00721019|insulin secretion
1312345|NCT00721019|insulin action
1312346|NCT00721019|lipid turnover
1312347|NCT00721019|free fatty acids
1312348|NCT00721006|peripheral artery disease
1312349|NCT00721006|peripheral vascular disease
1312350|NCT00721006|PAD
1312351|NCT00721006|PVD
1312352|NCT00720993|Colorectal cancer screening
1312353|NCT00720993|Gene expression
1312354|NCT00720993|RTPCR
1312355|NCT00720980|granuloma annulare, ROM
1312356|NCT00720967|Renal dysfunction
1312357|NCT00720967|Hemodialysis
1312358|NCT00720967|Modified ultrafiltration
1312359|NCT00720967|Open heart surgery
1312360|NCT00720954|Thoracoscopy
1312361|NCT00720954|Pleural needle biopsy
1312362|NCT00720954|Malignant pleural diseases
1312363|NCT00720954|Mesothelioma
1312364|NCT00720954|Diagnosis
1312365|NCT00720954|Pleurisy tuberculosis
1312366|NCT00720954|Patients with pleural diseases and pleural effusion should have been included in the study.
1312367|NCT00720941|SUTENT
1312368|NCT00720941|Locally advanced and/or metastatic renal cell carcinoma
1312369|NCT00720941|Pazopanib
1312370|NCT00720941|Sunitinib
1312371|NCT00720941|GW786034
1312372|NCT00720941|Renal cell carcinoma
1312373|NCT00720928|Behcet's disease
1312374|NCT00720928|posterior uveitis
1312375|NCT00720928|flucinolone acetonide
1312376|NCT00720928|RETISERT
1312377|NCT00720915|unprovoked deep vein thrombosis
1312378|NCT00720915|unprovoked pulmonary embolism
1312379|NCT00720915|anticoagulant therapy
1312380|NCT00720889|short sleep duration
1312381|NCT00720889|glucose clamp technique
1312382|NCT00720889|insulin secretion
1312383|NCT00720889|insulin action
1312384|NCT00720889|lipid turnover
1312385|NCT00720889|free fatty acids
1312386|NCT00720876|contiguous stage II grade 1 follicular lymphoma
1312387|NCT00720876|contiguous stage II grade 2 follicular lymphoma
1312388|NCT00720876|contiguous stage II grade 3 follicular lymphoma
1312389|NCT00720876|noncontiguous stage II grade 1 follicular lymphoma
1312390|NCT00720876|noncontiguous stage II grade 2 follicular lymphoma
1312391|NCT00720876|noncontiguous stage II grade 3 follicular lymphoma
1312392|NCT00720876|recurrent grade 1 follicular lymphoma
1312393|NCT00720876|recurrent grade 2 follicular lymphoma
1312394|NCT00720876|recurrent grade 3 follicular lymphoma
1312395|NCT00720876|stage I grade 1 follicular lymphoma
1312396|NCT00720876|stage I grade 2 follicular lymphoma
1312397|NCT00720876|stage I grade 3 follicular lymphoma
1312398|NCT00720876|stage III grade 1 follicular lymphoma
1312399|NCT00720876|stage III grade 2 follicular lymphoma
1312400|NCT00720876|stage III grade 3 follicular lymphoma
1312401|NCT00720876|stage IV grade 1 follicular lymphoma
1312402|NCT00720876|stage IV grade 2 follicular lymphoma
1312403|NCT00720876|stage IV grade 3 follicular lymphoma
1312404|NCT00720876|contiguous stage II marginal zone lymphoma
1312405|NCT00720876|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1312406|NCT00720876|nodal marginal zone B-cell lymphoma
1312407|NCT00720876|noncontiguous stage II marginal zone lymphoma
1312408|NCT00720876|recurrent marginal zone lymphoma
1312409|NCT00720876|splenic marginal zone lymphoma
1312410|NCT00720876|stage I marginal zone lymphoma
1312411|NCT00720876|stage III marginal zone lymphoma
1312412|NCT00720876|stage IV marginal zone lymphoma
1312413|NCT00720876|contiguous stage II mantle cell lymphoma
1312414|NCT00720876|noncontiguous stage II mantle cell lymphoma
1312415|NCT00720876|recurrent mantle cell lymphoma
1312416|NCT00720876|stage I mantle cell lymphoma
1312417|NCT00720876|stage III mantle cell lymphoma
1312418|NCT00720876|stage IV mantle cell lymphoma
1312419|NCT00720850|MDS
1312420|NCT00720850|AML
1312421|NCT00720850|Lenalidomide
1312422|NCT00720850|monosomy 5
1312423|NCT00720850|monosomy del5q
1312424|NCT00720837|Brain Tumor
1312425|NCT00720837|Brain Cancer
1312426|NCT00720837|MR-guided laser thermal ablation of brain tumors
1312427|NCT00720837|Visualase® Thermal Therapy System
1312428|NCT00720837|Magnetic Resonance Thermal Imaging
1312429|NCT00720837|MRTI
1312430|NCT00720837|Visualase Cooled Laser Application System
1312431|NCT00720837|Laser Interstitial Thermal Therapy
1312432|NCT00720837|LITT
1312433|NCT00720824|Immunizations
1312434|NCT00720824|Children
1312435|NCT00720824|Injections
1312436|NCT00720824|aged 4-6 Years
1312437|NCT00720824|Hypnosis
1312438|NCT00720811|Malaria ACT
1312439|NCT00720811|Rapid
1312440|NCT00720811|Diagnosis
1312441|NCT00720811|Community
1312442|NCT00720811|health
1312443|NCT00720811|worker
1312444|NCT00720811|Artemesinin
1312445|NCT00720811|based
1312446|NCT00720811|Combination
1312447|NCT00720811|Therapy
1312448|NCT00720811|Anti Malarial
1312449|NCT00720811|Treatment
1312450|NCT00720811|antibiotics
1312451|NCT00720785|Metastatic Solid Tumor
1312452|NCT00720785|Chronic Myelogenous Leukemia (CML)
1312453|NCT00720785|Small Lymphocytic Lymphoma (SLL)
1312454|NCT00720785|Tumor Cytotoxicity
1312455|NCT00720785|Chronic Lymphocytic Leukemia (CLL)
1312456|NCT00720785|Lung Cancer
1312457|NCT00720785|Prostate Cancer
1312458|NCT00720785|Colon Cancer
1312459|NCT00720785|Kidney Cancer
1312460|NCT00720785|Pancreatic Cancer
1312461|NCT00720785|Leukemia
1312462|NCT00720785|Chronic Myelogenous Leukemia
1312463|NCT00720785|CML
1312464|NCT00720785|Small Lymphocytic Lymphoma
1312465|NCT00720785|SLL
1312466|NCT00720785|Chronic Lymphocytic Leukemia
1312467|NCT00720785|CLL
1312468|NCT00720772|coronary calcification
1312469|NCT00720772|vascular calcification
1312470|NCT00720772|sodium thiosulfate
1312471|NCT00720759|stroke
1312472|NCT00720759|hemiparesis
1312473|NCT00720759|randomized controlled trial
1312474|NCT00720759|d-cycloserine
1312475|NCT00720759|distributed practice
1312476|NCT00720759|constraint induced movement therapy
1312477|NCT00720733|HIV
1312478|NCT00720733|Mood
1312479|NCT00720733|Emotion
1312480|NCT00720733|Coping
1312481|NCT00720733|Aids
1312482|NCT00720733|Affect
1312483|NCT00720733|Adults
1312484|NCT00720733|Diagnosed
1312485|NCT00720707|Coronally advanced flap
1312486|NCT00720707|gingival recession
1312487|NCT00720707|enamel matrix protein
1312488|NCT00720707|acellular dermal matrix
1312489|NCT00720707|root coverage
1312490|NCT00720668|hepatitis B
1312491|NCT00720668|hepatocellular carcinoma
1312492|NCT00720668|radiofrequency ablation
1312493|NCT00720668|reactivation
1312494|NCT00720655|coronary heart disease
1312495|NCT00720629|graft versus host disease
1312496|NCT00720629|GVHD
1312497|NCT00720629|allogeneic transplant
1312498|NCT00720629|GVHD prevention
1312499|NCT00720629|unrelated donors
1312500|NCT00720629|mismatched unrelated donors
1312501|NCT00720629|hematological malignancies
1312502|NCT00720629|Leukemia
1312503|NCT00720629|Lymphoma
1312504|NCT00720629|Myelodysplastic Syndrome
1312505|NCT00720629|Myelofibrosis
1312506|NCT00720629|Aplastic Anemia
1312507|NCT00720629|Multiple Myeloma
1312508|NCT00720616|Growth hormone
1312509|NCT00720616|Metabolic syndrome
1312510|NCT00720616|Insulin sensitivity
1312511|NCT00720603|Autologous Stem Cell Transplant
1312512|NCT00720577|Peripheral Arterial Disease
1312513|NCT00720577|PAD
1312514|NCT00720577|Lower extremity peripheral arterial atherosclerotic plaque
1312515|NCT00720577|RNA Expression
1312516|NCT00720577|Lipid Biomarkers
1312517|NCT00720564|adult glioblastoma
1312518|NCT00720564|adult anaplastic astrocytoma
1312519|NCT00720564|adult anaplastic oligodendroglioma
1312520|NCT00720564|adult gliosarcoma
1312521|NCT00720564|adult mixed glioma
1312522|NCT00720551|STISIM
1312523|NCT00720551|Alcohol
1312524|NCT00720538|Inflammatory bowel diseases.
1312525|NCT00720538|Crohn disease.
1312526|NCT00720538|Ulcerative, colitis.
1312527|NCT00720538|Randomised controlled trial.
1312528|NCT00720538|Therapy.
1312529|NCT00720538|Thalidomide.
1312530|NCT00720538|Children.
1312531|NCT00720525|arterial stiffness
1312532|NCT00720525|arterial wave reflections
1312533|NCT00720525|diastolic heart failure
1312534|NCT00720512|adenocarcinoma of the colon
1312535|NCT00720512|adenocarcinoma of the rectum
1312536|NCT00720512|recurrent colon cancer
1312537|NCT00720512|recurrent rectal cancer
1312538|NCT00720512|stage IV colon cancer
1312539|NCT00720512|stage IV rectal cancer
1312540|NCT00720512|stage III rectal cancer
1312541|NCT00720512|stage III colon cancer
1312542|NCT00720473|Bipolar depression
1312543|NCT00720473|Elderly
1312544|NCT00720473|Lamotrigine
1312545|NCT00720473|Brain energy metabolism
1312546|NCT00720460|Magnetic Resonance Imaging
1312547|NCT00720460|Minimally Invasive Therapy
1312548|NCT00720460|Heart Catheterization
1312549|NCT00720460|Healthy Volunteers
1312550|NCT00720460|Gadolinium Contrast
1312551|NCT00720460|Healthy Volunteer
1312552|NCT00720460|HV
1312553|NCT00720447|stage III mantle cell lymphoma
1312554|NCT00720447|stage IV mantle cell lymphoma
1312555|NCT00720421|Phase I
1312556|NCT00720421|pharmacodynamic study
1312557|NCT00720408|Immunosuppressant
1312558|NCT00720408|Graft loss
1312559|NCT00720408|Combination drug therapy
1312560|NCT00720408|Randomized controlled trial
1312561|NCT00720408|Open level method
1312562|NCT00720395|Psychiatry
1312563|NCT00720395|Pregnancy
1312564|NCT00720369|Bipolar depression
1312565|NCT00720369|elderly
1312566|NCT00720369|Coenzyme Q10
1312567|NCT00720369|Magnetic resonance spectroscopy
1312568|NCT00720356|adult glioblastoma
1312569|NCT00720356|adult gliosarcoma
1312570|NCT00720330|Inguinal Herniorrhaphy
1312571|NCT00720330|Pain assessment
1312572|NCT00720330|Outcomes
1312573|NCT00720317|Diabetic Retinopathy
1312574|NCT00720317|Sickle Cell Trait
1312575|NCT00720317|Vision Loss
1312576|NCT00720317|Eye disease
1312577|NCT00720304|stage III squamous cell carcinoma of the hypopharynx
1312578|NCT00720304|stage IV squamous cell carcinoma of the hypopharynx
1312579|NCT00720304|stage III squamous cell carcinoma of the larynx
1312580|NCT00720304|stage III verrucous carcinoma of the larynx
1312581|NCT00720304|stage IV squamous cell carcinoma of the larynx
1312582|NCT00720304|stage IV verrucous carcinoma of the larynx
1312583|NCT00720304|stage III squamous cell carcinoma of the lip and oral cavity
1312584|NCT00720304|stage IV squamous cell carcinoma of the lip and oral cavity
1312585|NCT00720304|stage III verrucous carcinoma of the oral cavity
1312586|NCT00720304|stage IV verrucous carcinoma of the oral cavity
1312587|NCT00720304|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1312588|NCT00720304|stage III squamous cell carcinoma of the nasopharynx
1312589|NCT00720304|stage IV squamous cell carcinoma of the nasopharynx
1312590|NCT00720304|stage III squamous cell carcinoma of the oropharynx
1312591|NCT00720304|stage IV squamous cell carcinoma of the oropharynx
1312592|NCT00720291|Metronidazole
1312593|NCT00720291|BV
1312594|NCT00720291|Pregnancy
1312595|NCT00720265|Organ Transplantation
1312596|NCT00720265|Tacrolimus
1312597|NCT00720265|Prograf
1312598|NCT00720265|FK506MR
1312599|NCT00720226|COPD
1312600|NCT00720226|emphysema
1312601|NCT00720226|angiotensin receptor blocker
1312602|NCT00720200|Communication
1312603|NCT00720200|Intensive Care Units
1312604|NCT00720200|Palliative Care
1312605|NCT00720200|End-of-Life Issues
1312606|NCT00720200|Talking with Your Doctor
1312607|NCT00720200|Coping with Chronic Illness
1312608|NCT00720161|metformin, spina bifida, duchenne, insulin resistance
1312609|NCT00720148|Solid tumors
1312610|NCT00720122|Bone density
1312611|NCT00720122|Bone turnover markers
1312612|NCT00720122|rhIGF-1
1312613|NCT00720122|Bone structure
1312614|NCT00720122|Anorexia nervosa
1312615|NCT00720096|Persistent Ovarian Cancer
1312616|NCT00720096|Genomic directed salvage chemotherapy
1312617|NCT00720096|Genomic Microarray
1312618|NCT00720083|stage III squamous cell carcinoma of the hypopharynx
1312619|NCT00720083|stage IV squamous cell carcinoma of the hypopharynx
1312620|NCT00720083|stage III squamous cell carcinoma of the larynx
1312621|NCT00720083|stage IV squamous cell carcinoma of the larynx
1312622|NCT00720083|stage III verrucous carcinoma of the oral cavity
1312623|NCT00720083|stage IV verrucous carcinoma of the oral cavity
1312624|NCT00720083|stage III squamous cell carcinoma of the oropharynx
1312625|NCT00720083|stage IV squamous cell carcinoma of the oropharynx
1312626|NCT00720070|stage I squamous cell carcinoma of the oropharynx
1312627|NCT00720070|stage II squamous cell carcinoma of the oropharynx
1312628|NCT00720070|stage III squamous cell carcinoma of the oropharynx
1312629|NCT00720070|stage I squamous cell carcinoma of the larynx
1312630|NCT00720070|stage I verrucous carcinoma of the larynx
1312631|NCT00720070|stage II squamous cell carcinoma of the larynx
1312632|NCT00720070|stage II verrucous carcinoma of the larynx
1312633|NCT00720070|stage III squamous cell carcinoma of the larynx
1312634|NCT00720070|stage III verrucous carcinoma of the larynx
1312635|NCT00720070|stage I squamous cell carcinoma of the lip and oral cavity
1312636|NCT00720070|stage I verrucous carcinoma of the oral cavity
1312637|NCT00720070|stage II squamous cell carcinoma of the lip and oral cavity
1312638|NCT00720070|stage II verrucous carcinoma of the oral cavity
1312639|NCT00720070|stage III squamous cell carcinoma of the lip and oral cavity
1312640|NCT00720070|stage III verrucous carcinoma of the oral cavity
1312641|NCT00720070|stage I squamous cell carcinoma of the hypopharynx
1312642|NCT00720070|stage II squamous cell carcinoma of the hypopharynx
1312643|NCT00720070|stage III squamous cell carcinoma of the hypopharynx
1312644|NCT00720070|tongue cancer
1312645|NCT00720057|Dental Pain
1312646|NCT00720057|Analgesia
1312647|NCT00720031|Melanoma,
1312648|NCT00720031|Melan-A tumor reactive T cell clones,
1312649|NCT00720031|immunotherapy
1312650|NCT00720031|HLA-A2 melanoma patients with
1312651|NCT00720031|either loco-regional or lymphnode metastasis
1312652|NCT00720031|transit nodules not surgically resectable
1312653|NCT00720031|-measurable cutaneous or visceral metastasis .
1312654|NCT00720031|Patients' tumor express Melan-A/MART-1 antigen.
1312655|NCT00720005|Cataract
1312656|NCT00720005|cataract extraction
1312657|NCT00720005|intraocular lens
1312658|NCT00720005|age related
1312659|NCT00719992|Exercise tolerance test
1312660|NCT00719992|HS-CRP
1312661|NCT00719992|Coronary angiography
1312662|NCT00719992|Patients
1312663|NCT00719979|Major Depressive Disorder
1312664|NCT00719979|Cognitive Behavior Therapy
1312665|NCT00719979|Technology Assisted
1312666|NCT00719979|Internet
1312667|NCT00719979|Primary Care
1312668|NCT00719966|stage IA breast cancer
1312669|NCT00719966|stage IB breast cancer
1312670|NCT00719966|stage II breast cancer
1312671|NCT00719966|stage IIIA breast cancer
1312672|NCT00719966|stage IIIB breast cancer
1312673|NCT00719966|stage IIIC breast cancer
1312674|NCT00719966|stage IV breast cancer
1312675|NCT00719966|ductal breast carcinoma in situ
1312676|NCT00719953|Cognitex
1312677|NCT00719953|subjects
1312678|NCT00719940|tinnitus, cognitive behavioral therapy, CBT
1312679|NCT00719927|Social Support
1312680|NCT00719914|eptifibatide
1312681|NCT00719914|Integrilin
1312682|NCT00719914|ST-Elevation Myocardial Infarction
1312683|NCT00719914|Acute Myocardial Infarction
1312684|NCT00719849|chronic myelogenous leukemia
1312685|NCT00719849|acute lymphoblastic leukemia
1312686|NCT00719849|acute myeloid leukemia
1312687|NCT00719849|atypical chronic myeloid leukemia
1312688|NCT00719849|chronic myelomonocytic leukemia
1312689|NCT00719849|anaplastic large cell lymphoma
1312690|NCT00719849|splenic marginal zone lymphoma
1312691|NCT00719849|nodal marginal zone B-cell lymphoma
1312692|NCT00719849|recurrent adult Hodgkin lymphoma
1312693|NCT00719849|recurrent adult diffuse large cell lymphoma
1312694|NCT00719849|recurrent adult immunoblastic large cell lymphoma
1312695|NCT00719849|recurrent childhood large cell lymphoma
1312696|NCT00719849|recurrent mycosis fungoides/Sezary syndrome
1312697|NCT00719849|recurrent grade 1 follicular lymphoma
1312698|NCT00719849|recurrent grade 2 follicular lymphoma
1312699|NCT00719849|recurrent grade 3 follicular lymphoma
1312700|NCT00719849|recurrent mantle cell lymphoma
1312701|NCT00719849|recurrent marginal zone lymphoma
1312702|NCT00719849|recurrent small lymphocytic lymphoma
1312703|NCT00719849|recurrent/refractory childhood Hodgkin lymphoma
1312704|NCT00719849|childhood diffuse large cell lymphoma
1312705|NCT00719849|childhood immunoblastic large cell lymphoma
1312706|NCT00719849|refractory multiple myeloma
1312707|NCT00719849|de novo myelodysplastic syndromes
1312708|NCT00719849|previously treated myelodysplastic syndromes
1312709|NCT00719849|secondary myelodysplastic syndromes
1312710|NCT00719849|myelodysplastic/myeloproliferative disease
1312711|NCT00719849|childhood myelodysplastic syndromes
1312712|NCT00719849|recurrent childhood anaplastic large cell lymphoma
1312713|NCT00719849|refractory anemia
1312714|NCT00719849|refractory anemia with excess blasts
1312715|NCT00719849|refractory anemia with ringed sideroblasts
1312716|NCT00719849|refractory cytopenia with multilineage dysplasia
1312717|NCT00719849|stage III adult diffuse large cell lymphoma
1312718|NCT00719849|stage IV adult diffuse large cell lymphoma
1312719|NCT00719849|stage III adult immunoblastic large cell lymphoma
1312720|NCT00719849|stage IV adult immunoblastic large cell lymphoma
1312721|NCT00719849|stage III childhood anaplastic large cell lymphoma
1312722|NCT00719849|stage III childhood large cell lymphoma
1312723|NCT00719849|stage IV childhood anaplastic large cell lymphoma
1312724|NCT00719849|stage IV childhood large cell lymphoma
1312725|NCT00719849|stage III adult Hodgkin lymphoma
1312726|NCT00719849|stage III childhood Hodgkin lymphoma
1312727|NCT00719849|stage IV adult Hodgkin lymphoma
1312728|NCT00719849|stage IV childhood Hodgkin lymphoma
1312729|NCT00719849|stage II multiple myeloma
1312730|NCT00719849|stage III multiple myeloma
1312731|NCT00719849|stage III chronic lymphocytic leukemia
1312732|NCT00719849|stage IV chronic lymphocytic leukemia
1312733|NCT00719849|stage III small lymphocytic lymphoma
1312734|NCT00719849|stage IV small lymphocytic lymphoma
1312735|NCT00719849|stage III marginal zone lymphoma
1312736|NCT00719849|stage IV marginal zone lymphoma
1312737|NCT00719849|stage III grade 1 follicular lymphoma
1312738|NCT00719849|stage III grade 2 follicular lymphoma
1312739|NCT00719849|stage III grade 3 follicular lymphoma
1312740|NCT00719849|stage IV grade 1 follicular lymphoma
1312741|NCT00719849|stage IV grade 2 follicular lymphoma
1312742|NCT00719849|stage IV grade 3 follicular lymphoma
1312743|NCT00719849|Waldenstrom macroglobulinemia
1312744|NCT00719849|stage III mantle cell lymphoma
1312745|NCT00719849|stage IV mantle cell lymphoma
1312746|NCT00719849|stage III mycosis fungoides/Sezary syndrome
1312747|NCT00719849|stage IV mycosis fungoides/Sezary syndrome
1312748|NCT00719849|juvenile myelomonocytic leukemia
1312749|NCT00719849|chronic eosinophilic leukemia
1312750|NCT00719849|chronic idiopathic myelofibrosis
1312751|NCT00719849|chronic neutrophilic leukemia
1312752|NCT00719849|essential thrombocythemia
1312753|NCT00719849|polycythemia vera
1312754|NCT00719836|SB1518
1312755|NCT00719836|Chronic Idiopathic Myelofibrosis
1312756|NCT00719836|JAK2 Inhibitor
1312757|NCT00719823|Maraviroc Compassionate Use
1312758|NCT00719810|complicated
1312759|NCT00719810|skin
1312760|NCT00719797|stage IV rectal cancer
1312761|NCT00719797|stage IV colon cancer
1312762|NCT00719797|stage III rectal cancer
1312763|NCT00719797|stage III colon cancer
1312764|NCT00719784|Respiratory
1312765|NCT00719784|Pulmonary
1312766|NCT00719784|Thoracic
1312767|NCT00719784|Chest
1312768|NCT00719784|Lung
1312769|NCT00719771|Osteoarthritis
1312770|NCT00719771|Glenohumeral joint
1312771|NCT00719771|Glenoid
1312772|NCT00719771|Shoulder arthroplasty
1312773|NCT00719758|TRK-100STP,
1312774|NCT00719758|beraprost sodium,
1312775|NCT00719758|Careload LA
1312776|NCT00719758|AST-120
1312777|NCT00719758|Spherical carbon adsorbent
1312778|NCT00719758|Drug-drug interaction
1312779|NCT00719745|Organ transplantation
1312780|NCT00719745|Tacrolimus
1312781|NCT00719745|Prograf
1312782|NCT00719745|MR4
1312783|NCT00719732|ReSTOR Aspheric +3 IOL
1312790|NCT00719706|Bipolar disorder
1312791|NCT00719706|Bipolar depression
1312792|NCT00719706|Natural substances
1312793|NCT00719706|Depression
1312794|NCT00719693|Food effect, phase I
1312795|NCT00719693|adverse events
1312796|NCT00719680|CVID
1312797|NCT00719680|XLA
1312798|NCT00719667|OPCAB
1312799|NCT00719667|coronary
1312800|NCT00719667|bypass
1312801|NCT00719667|grafting
1312802|NCT00719667|off pump
1312803|NCT00719654|Preeclampsia
1312804|NCT00719654|Proteome
1312805|NCT00719654|Pregnancy
1312806|NCT00719641|Colonoscopy
1312807|NCT00719641|Looping
1312808|NCT00719641|Prevent Looping
1312809|NCT00719641|Colon Cancer Screening
1312810|NCT00719641|Segmental Stiffening Wire
1312811|NCT00719628|Postoperative
1312812|NCT00719628|Cognitive
1312813|NCT00719628|Dysfunction
1312814|NCT00719615|Thyroid Cancer
1312815|NCT00719615|Thyroid Nodules
1312816|NCT00719615|Vitamin D
1312817|NCT00719602|Coinfection
1312818|NCT00719589|Voiding Dysfunction
1312819|NCT00719589|Interstim
1312820|NCT00719576|Cartilage legions,
1312821|NCT00719576|symptomatic focal cartilage defects,
1312822|NCT00719576|microfracture,
1312823|NCT00719576|MACI,
1312824|NCT00719576|autologous chondrocyte
1312825|NCT00719563|fatigue
1312826|NCT00719563|unspecified adult solid tumor, protocol specific
1312827|NCT00719563|accelerated phase chronic myelogenous leukemia
1312828|NCT00719563|acute undifferentiated leukemia
1312829|NCT00719563|adult acute lymphoblastic leukemia in remission
1312830|NCT00719563|adult acute myeloid leukemia in remission
1312831|NCT00719563|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1312832|NCT00719563|adult acute myeloid leukemia with inv(16)(p13;q22)
1312833|NCT00719563|adult acute myeloid leukemia with t(15;17)(q22;q12)
1312834|NCT00719563|adult acute myeloid leukemia with t(16;16)(p13;q22)
1312835|NCT00719563|adult acute myeloid leukemia with t(8;21)(q22;q22)
1312836|NCT00719563|atypical chronic myeloid leukemia, BCR-ABL1 negative
1312837|NCT00719563|blastic phase chronic myelogenous leukemia
1312838|NCT00719563|chronic myelomonocytic leukemia
1312839|NCT00719563|chronic phase chronic myelogenous leukemia
1312840|NCT00719563|mast cell leukemia
1312841|NCT00719563|progressive hairy cell leukemia, initial treatment
1312842|NCT00719563|prolymphocytic leukemia
1312843|NCT00719563|recurrent adult acute lymphoblastic leukemia
1312844|NCT00719563|recurrent adult acute myeloid leukemia
1312845|NCT00719563|recurrent adult T-cell leukemia/lymphoma
1312846|NCT00719563|refractory chronic lymphocytic leukemia
1312847|NCT00719563|refractory hairy cell leukemia
1312848|NCT00719563|relapsing chronic myelogenous leukemia
1312849|NCT00719563|secondary acute myeloid leukemia
1312850|NCT00719563|stage 0 chronic lymphocytic leukemia
1312851|NCT00719563|stage I adult T-cell leukemia/lymphoma
1312852|NCT00719563|stage I chronic lymphocytic leukemia
1312853|NCT00719563|stage II adult T-cell leukemia/lymphoma
1312854|NCT00719563|stage II chronic lymphocytic leukemia
1312855|NCT00719563|stage III adult T-cell leukemia/lymphoma
1312856|NCT00719563|stage III chronic lymphocytic leukemia
1312857|NCT00719563|stage IV adult T-cell leukemia/lymphoma
1312858|NCT00719563|stage IV chronic lymphocytic leukemia
1312859|NCT00719563|T-cell large granular lymphocyte leukemia
1312860|NCT00719563|untreated adult acute lymphoblastic leukemia
1312861|NCT00719563|recurrent adult Hodgkin lymphoma
1312862|NCT00719563|stage I adult Hodgkin lymphoma
1312863|NCT00719563|stage II adult Hodgkin lymphoma
1312864|NCT00719563|stage III adult Hodgkin lymphoma
1312865|NCT00719563|stage IV adult Hodgkin lymphoma
1312866|NCT00719563|anaplastic large cell lymphoma
1312867|NCT00719563|angioimmunoblastic T-cell lymphoma
1312868|NCT00719563|cutaneous B-cell non-Hodgkin lymphoma
1312869|NCT00719563|recurrent cutaneous T-cell non-Hodgkin lymphoma
1312870|NCT00719563|stage I cutaneous T-cell non-Hodgkin lymphoma
1312871|NCT00719563|stage II cutaneous T-cell non-Hodgkin lymphoma
1312872|NCT00719563|stage III cutaneous T-cell non-Hodgkin lymphoma
1312873|NCT00719563|stage IV cutaneous T-cell non-Hodgkin lymphoma
1312874|NCT00719563|recurrent mycosis fungoides/Sezary syndrome
1312875|NCT00719563|stage I mycosis fungoides/Sezary syndrome
1312876|NCT00719563|stage II mycosis fungoides/Sezary syndrome
1312877|NCT00719563|stage III mycosis fungoides/Sezary syndrome
1312878|NCT00719563|stage IV mycosis fungoides/Sezary syndrome
1312879|NCT00719563|adult grade III lymphomatoid granulomatosis
1312880|NCT00719563|adult nasal type extranodal NK/T-cell lymphoma
1312881|NCT00719563|Waldenström macroglobulinemia
1312882|NCT00719563|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1312883|NCT00719563|nodal marginal zone B-cell lymphoma
1312884|NCT00719563|splenic marginal zone lymphoma
1312885|NCT00719563|contiguous stage II adult Burkitt lymphoma
1312886|NCT00719563|contiguous stage II adult diffuse large cell lymphoma
1312887|NCT00719563|contiguous stage II adult diffuse mixed cell lymphoma
1312888|NCT00719563|contiguous stage II adult diffuse small cleaved cell lymphoma
1312889|NCT00719563|contiguous stage II adult immunoblastic large cell lymphoma
1312890|NCT00719563|contiguous stage II adult lymphoblastic lymphoma
1312891|NCT00719563|contiguous stage II grade 1 follicular lymphoma
1312892|NCT00719563|contiguous stage II grade 2 follicular lymphoma
1312893|NCT00719563|contiguous stage II grade 3 follicular lymphoma
1312894|NCT00719563|contiguous stage II mantle cell lymphoma
1312895|NCT00719563|contiguous stage II marginal zone lymphoma
1312896|NCT00719563|contiguous stage II small lymphocytic lymphoma
1312897|NCT00719563|stage I adult Burkitt lymphoma
1312898|NCT00719563|stage I adult diffuse large cell lymphoma
1312899|NCT00719563|stage I adult diffuse mixed cell lymphoma
1312900|NCT00719563|stage I adult diffuse small cleaved cell lymphoma
1312901|NCT00719563|stage I adult immunoblastic large cell lymphoma
1312902|NCT00719563|stage I adult lymphoblastic lymphoma
1312903|NCT00719563|stage I grade 1 follicular lymphoma
1312904|NCT00719563|stage I grade 2 follicular lymphoma
1312905|NCT00719563|stage I grade 3 follicular lymphoma
1312906|NCT00719563|stage I mantle cell lymphoma
1312907|NCT00719563|stage I marginal zone lymphoma
1312908|NCT00719563|stage I small lymphocytic lymphoma
1312909|NCT00719563|noncontiguous stage II adult Burkitt lymphoma
1312910|NCT00719563|noncontiguous stage II adult diffuse large cell lymphoma
1312911|NCT00719563|noncontiguous stage II adult diffuse mixed cell lymphoma
1312912|NCT00719563|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1312913|NCT00719563|noncontiguous stage II adult immunoblastic large cell lymphoma
1312914|NCT00719563|noncontiguous stage II adult lymphoblastic lymphoma
1312915|NCT00719563|noncontiguous stage II grade 1 follicular lymphoma
1312916|NCT00719563|noncontiguous stage II grade 2 follicular lymphoma
1312917|NCT00719563|noncontiguous stage II grade 3 follicular lymphoma
1312918|NCT00719563|noncontiguous stage II mantle cell lymphoma
1312919|NCT00719563|noncontiguous stage II marginal zone lymphoma
1312920|NCT00719563|noncontiguous stage II small lymphocytic lymphoma
1312921|NCT00719563|stage III adult Burkitt lymphoma
1312922|NCT00719563|stage III adult diffuse large cell lymphoma
1312923|NCT00719563|stage III adult diffuse mixed cell lymphoma
1312924|NCT00719563|stage III adult diffuse small cleaved cell lymphoma
1312925|NCT00719563|stage III adult immunoblastic large cell lymphoma
1312926|NCT00719563|stage III adult lymphoblastic lymphoma
1312927|NCT00719563|stage III grade 1 follicular lymphoma
1312928|NCT00719563|stage III grade 2 follicular lymphoma
1312929|NCT00719563|stage III grade 3 follicular lymphoma
1312930|NCT00719563|stage III mantle cell lymphoma
1312931|NCT00719563|stage III marginal zone lymphoma
1312932|NCT00719563|stage III small lymphocytic lymphoma
1312933|NCT00719563|stage IV adult Burkitt lymphoma
1312934|NCT00719563|stage IV adult diffuse large cell lymphoma
1312935|NCT00719563|stage IV adult diffuse mixed cell lymphoma
1312936|NCT00719563|stage IV adult diffuse small cleaved cell lymphoma
1312937|NCT00719563|stage IV adult immunoblastic large cell lymphoma
1312938|NCT00719563|stage IV adult lymphoblastic lymphoma
1312939|NCT00719563|stage IV grade 1 follicular lymphoma
1312940|NCT00719563|stage IV grade 2 follicular lymphoma
1312941|NCT00719563|stage IV grade 3 follicular lymphoma
1312942|NCT00719563|stage IV mantle cell lymphoma
1312943|NCT00719563|stage IV marginal zone lymphoma
1312944|NCT00719563|stage IV small lymphocytic lymphoma
1312945|NCT00719563|recurrent adult Burkitt lymphoma
1312946|NCT00719563|recurrent adult diffuse large cell lymphoma
1312947|NCT00719563|recurrent adult diffuse mixed cell lymphoma
1312948|NCT00719563|recurrent adult diffuse small cleaved cell lymphoma
1312949|NCT00719563|recurrent adult grade III lymphomatoid granulomatosis
1312950|NCT00719563|recurrent adult immunoblastic large cell lymphoma
1312951|NCT00719563|recurrent adult lymphoblastic lymphoma
1312952|NCT00719563|recurrent grade 1 follicular lymphoma
1312953|NCT00719563|recurrent grade 2 follicular lymphoma
1312954|NCT00719563|recurrent grade 3 follicular lymphoma
1312955|NCT00719563|recurrent mantle cell lymphoma
1312956|NCT00719563|recurrent marginal zone lymphoma
1313080|NCT00719082|Posturography
1312957|NCT00719563|recurrent small lymphocytic lymphoma
1312958|NCT00719563|intraocular lymphoma
1312959|NCT00719563|post-transplant lymphoproliferative disorder
1312960|NCT00719563|chronic eosinophilic leukemia
1312961|NCT00719563|chronic neutrophilic leukemia
1312962|NCT00719563|primary myelofibrosis
1312963|NCT00719563|essential thrombocythemia
1312964|NCT00719563|polycythemia vera
1312965|NCT00719563|extramedullary plasmacytoma
1312966|NCT00719563|isolated plasmacytoma of bone
1312967|NCT00719563|monoclonal gammopathy of undetermined significance
1312968|NCT00719563|stage I multiple myeloma
1312969|NCT00719563|stage II multiple myeloma
1312970|NCT00719563|stage III multiple myeloma
1312971|NCT00719563|primary systemic amyloidosis
1312972|NCT00719563|refractory multiple myeloma
1312973|NCT00719563|de novo myelodysplastic syndromes
1312974|NCT00719563|previously treated myelodysplastic syndromes
1312975|NCT00719563|secondary myelodysplastic syndromes
1312976|NCT00719563|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1312977|NCT00719550|Locally Advanced
1312978|NCT00719550|Metastatic
1312979|NCT00719537|preeclampsia
1312980|NCT00719537|progesterone
1312981|NCT00719537|aspirin
1312982|NCT00719537|prevent
1312983|NCT00719537|soluble fms-like tyrosine kinase (sFlt-1)
1312984|NCT00719537|Placental Growth Factor (PlGF)
1312985|NCT00719537|risk
1312986|NCT00719524|Neoplasms
1312987|NCT00719524|Antineoplastic Combined Chemotherapy Protocol
1312988|NCT00719511|Rhinoconjunctivitis
1312989|NCT00719511|Allergic
1312990|NCT00719498|Epo-alpha
1312991|NCT00719498|Cardiac arrest
1312992|NCT00719498|Mild hypothermia
1312993|NCT00719485|lumbar decompression
1312994|NCT00719472|Follicular NHL
1312995|NCT00719472|NHL
1312996|NCT00719472|Large B-Cell NHL
1312997|NCT00719446|Acute Lung Injury
1312998|NCT00719433|stroke
1312999|NCT00719433|chronic
1313000|NCT00719433|rehabilitation
1313001|NCT00719433|robot therapy
1313002|NCT00719433|arm therapy
1313003|NCT00719420|Randomized clinical trial
1313004|NCT00719420|Helicobacter pylori
1313005|NCT00719420|clarithromycin
1313006|NCT00719420|metronidazole
1313007|NCT00719420|amoxicillin
1313008|NCT00719420|proton pump inhibitor
1313009|NCT00719420|Colombia
1313010|NCT00719407|birth asphyxia
1313011|NCT00719407|neonatal encephalopathy
1313012|NCT00719407|hypoxic-ischemic encephalopathy
1313013|NCT00719407|neuroprotection
1313014|NCT00719407|neonate
1313015|NCT00719394|alzheimer Disease
1313016|NCT00719368|Groin hernia
1313017|NCT00719368|pain
1313018|NCT00719368|chronic
1313019|NCT00719368|quantitative sensory testing
1313020|NCT00719368|Persistent postoperative pain
1313021|NCT00719342|Retinal vessel diameter
1313022|NCT00719342|Flicker-induced vasodilatation
1313023|NCT00719342|Optic nerve head blood flow
1313024|NCT00719342|Ocular Physiology
1313025|NCT00719342|Regional Blood Flow
1313026|NCT00719329|chlorhexidine
1313027|NCT00719329|umbilical cord
1313028|NCT00719316|Renin inhibitor
1313029|NCT00719316|Patients
1313030|NCT00719316|ACE inhibitor or ARB
1313031|NCT00719316|Chronic Kidney Disease
1313032|NCT00719316|Hypertension
1313033|NCT00719290|Primary Angle Closure Glaucoma
1313034|NCT00719290|Phacoemulsification
1313035|NCT00719290|Goniosynechialysis
1313036|NCT00719290|Outflow facility
1313037|NCT00719277|cardiac arrhythmia
1313038|NCT00719277|syncope
1313039|NCT00719277|ECG
1313040|NCT00719277|implantable ECG monitor
1313041|NCT00719277|ILR
1313042|NCT00719264|Renal cell carcinoma
1313043|NCT00719264|Adults
1313044|NCT00719264|Bevacizumab
1313045|NCT00719264|RAD001
1313046|NCT00719264|Everolimus
1313047|NCT00719264|Interferon
1313048|NCT00719264|Clear
1313049|NCT00719264|Roferon
1313050|NCT00719264|Avastin
1313051|NCT00719264|Nephrectomy
1313052|NCT00719264|newly diagnosed
1313053|NCT00719251|Complications of Diabetes Mellitus
1313054|NCT00719251|Electric stimulation
1313055|NCT00719251|Low-Level Laser Therapy
1313056|NCT00719199|Colorectal cancer
1313057|NCT00719199|metastatic cancer
1313058|NCT00719199|prior therapy
1313059|NCT00719199|1b
1313060|NCT00719186|Polycystic Ovary Syndrome
1313061|NCT00719186|Infertility
1313062|NCT00719186|Pregnancy
1313063|NCT00719186|Women
1313064|NCT00719173|nausea and vomiting
1313065|NCT00719173|breast cancer
1313066|NCT00719160|Gastric acid
1313067|NCT00719160|Dietary protein
1313068|NCT00719160|Calcium
1313069|NCT00719160|Intestinal absorption
1313070|NCT00719160|Calcium sensing receptor
1313071|NCT00719108|Diabetes, Healthy Volunteers
1313072|NCT00719095|prescription opioid
1313073|NCT00719095|opioid detoxification
1313074|NCT00719095|buprenorphine
1313075|NCT00719095|naltrexone
1313076|NCT00719095|community reinforcement approach
1313077|NCT00719095|prescription opioid abuse
1313078|NCT00719082|Human Stability
1313079|NCT00719082|Geriatric
1313081|NCT00719069|healthy subjects who smoke
1313082|NCT00719069|healthy subjects
1313083|NCT00719056|teicoplanin
1313084|NCT00719056|prophylaxis
1313085|NCT00719056|arthroplasty
1313086|NCT00719056|surgical site infections
1313087|NCT00719043|Influenza
1313088|NCT00719043|H5N1
1313089|NCT00719043|Avian
1313090|NCT00719043|Vaccines
1313091|NCT00719043|Safety
1313092|NCT00719043|Immunogenicity
1313093|NCT00719043|Pandemic
1313094|NCT00719043|Human
1313095|NCT00719017|Brachytherapy
1313096|NCT00719017|Early stage edometrial cancer
1313097|NCT00719017|Quality of life
1313098|NCT00719017|Recurrence
1313099|NCT00719017|Treatment
1313100|NCT00719017|Vaginectomy
1313101|NCT00719004|Anatomy
1313102|NCT00719004|Foot
1313103|NCT00719004|Sonography
1313104|NCT00719004|Medical
1313105|NCT00718991|CLI
1313106|NCT00718991|excimer laser
1313107|NCT00718991|debulking
1313108|NCT00718978|bioengineered
1313109|NCT00718978|ski
1313110|NCT00718978|keratinocytes
1313111|NCT00718978|fibroblasts
1313112|NCT00718978|skin
1313113|NCT00718978|culture
1313114|NCT00718978|autologous
1313115|NCT00718978|CSS
1313116|NCT00718978|full-thickness loss of substance from:
1313117|NCT00718978|burns
1313118|NCT00718978|ulcers
1313119|NCT00718978|giant nevi
1313120|NCT00718978|cicatricial outcomes
1313121|NCT00718965|Primary hypercholesterolemia
1313122|NCT00718952|Pulmonary Hypertension
1313123|NCT00718939|Diastolic Heart Failure
1313124|NCT00718939|Cardiac dysfunction
1313125|NCT00718939|Heart Failure
1313126|NCT00718926|dry eye
1313127|NCT00718926|Thiol redox
1313128|NCT00718926|Oxidative stress
1313129|NCT00718913|Adjuvant Gastric Cancer
1313130|NCT00718913|Adjuvant chemotherapy
1313131|NCT00718913|Adjuvant chemo-radiation
1313132|NCT00718913|Capecitabine
1313133|NCT00718874|obesity, puberty, diabetes,insulin dynamics
1313134|NCT00718861|Osteoporosis
1313135|NCT00718861|zoledronic acid
1313136|NCT00718861|post-menopausal
1313137|NCT00718848|hemodialysis
1313138|NCT00718848|left ventricular hypertrophy
1313139|NCT00718848|left ventricular systolic function
1313140|NCT00718835|smoking cessation
1313141|NCT00718835|behavioral treatment
1313142|NCT00718835|contingency management
1313143|NCT00718835|opioid maintenance
1313144|NCT00718835|methadone
1313145|NCT00718835|buprenorphine
1313146|NCT00718822|clinical outcome
1313147|NCT00718822|ICSI cycles
1313148|NCT00718822|low oxygen
1313149|NCT00718822|poor responders
1313150|NCT00718822|pregnancy rate
1313151|NCT00718822|prospective randomized study
1313152|NCT00718796|cardiovascular disease
1313153|NCT00718796|naturopathic medicine
1313154|NCT00718796|natural health products
1313155|NCT00718796|lifestyle intervention
1313156|NCT00718796|dietary advice
1313157|NCT00718796|coronary heart disease
1313158|NCT00718770|Not respond
1313159|NCT00718770|Radioactive iodine
1313160|NCT00718770|Therapy
1313161|NCT00718770|Shows signs
1313162|NCT00718770|Aggressive behavior
1313163|NCT00718744|Allergen-extract
1313164|NCT00718744|Standardization
1313165|NCT00718731|Alzheimer Disease
1313166|NCT00718718|Arthritis, Rheumatoid
1313167|NCT00718718|Rheumatoid Arthritis
1313168|NCT00718718|Active Rheumatoid Arthritis
1313169|NCT00718718|CNTO 136
1313170|NCT00718718|Interleukin-6
1313171|NCT00718718|Anti-interleukin-6 monoclonal antibody
1313172|NCT00718718|Methotrexate
1313173|NCT00718718|Placebo
1313174|NCT00718705|Prematurity
1313175|NCT00718705|Ureaplasma spp
1313176|NCT00718705|Mycoplasma Hominis
1313177|NCT00718705|Amniotic fluid
1313178|NCT00718705|Josamycine
1313179|NCT00718692|Idiopathic
1313180|NCT00718692|ITP
1313181|NCT00718666|Safety
1313182|NCT00718666|Vaccines, conjugate
1313183|NCT00718666|Immunogenicity
1313184|NCT00718666|Meningococcal vaccine
1313185|NCT00718666|Booster vaccination
1313186|NCT00718666|Primary vaccination
1313187|NCT00718666|Neisseria meningitides
1313188|NCT00718666|Toddlers
1313189|NCT00718666|Humans
1313190|NCT00718666|Meningococcal disease
1313191|NCT00718653|Macular pigment, lutein, green tea extract, antioxidant
1313192|NCT00718640|Multiple Myeloma
1313193|NCT00718640|Velcade
1313194|NCT00718640|Bortezomib
1313195|NCT00718640|Dexamethasone
1313196|NCT00718627|Urea cycle Disorders
1313197|NCT00718627|Carbamoylphosphate synthetase I deficiency
1313198|NCT00718627|Ornithine transcarbamoylase deficiency
1313199|NCT00718627|Argininosuccinate synthase deficiency
1313200|NCT00718627|Citrullinemia
1313201|NCT00718627|newborns
1313202|NCT00718627|infants
1313203|NCT00718627|liver cell transplantation
1313204|NCT00718627|liver cell infusion
1313205|NCT00718614|Choroidal blood flow
1313206|NCT00718614|Laser Doppler flowmetry
1313207|NCT00718614|Diabetic Retinopathy
1313208|NCT00718614|Diabetic Neuropathy
1313209|NCT00718601|Myeloma
1313210|NCT00718601|Multiple Myeloma
1313211|NCT00718601|Relapsed Multiple Myeloma
1313212|NCT00718601|Refractory Multiple Myeloma
1313213|NCT00718601|Relapsed or Refractory Multiple Myeloma
1313214|NCT00718588|RA
1313215|NCT00718575|Liver Disease
1313216|NCT00718575|Transplantation
1313217|NCT00718562|nilotinib
1313218|NCT00718562|AMN107
1313219|NCT00718562|Sunitinib
1313220|NCT00718562|Sunitinib malate
1313221|NCT00718562|Imatinib
1313222|NCT00718562|Imatinib mesylate
1313223|NCT00718562|Tyrosine
1313224|NCT00718536|Atazanavir
1313225|NCT00718536|Raltegravir
1313226|NCT00718536|once-daily
1313227|NCT00718536|pharmacokinetics
1313228|NCT00718536|HIV
1313229|NCT00718497|Amyotrophic Lateral Sclerosis
1313230|NCT00718497|Cerebrospinal Fluid
1313231|NCT00718497|Neurodegenerative Disease
1313232|NCT00718497|Motor Neuron Disease
1313233|NCT00718497|Autonomic Nervous System
1313234|NCT00718497|Neurodegenerative Diseases
1313235|NCT00718497|Movement Disorders
1313236|NCT00718484|Sarcoma
1313237|NCT00718484|Soft Tissue Sarcoma
1313238|NCT00718484|Doxorubicin
1313239|NCT00718484|anthracyclin
1313240|NCT00718484|Palifosfamide
1313241|NCT00718484|IFOS
1313242|NCT00718471|STEMI
1313243|NCT00718471|Primary PCI
1313244|NCT00718471|Anticoagulation
1313245|NCT00718458|Amyotrophic Lateral Sclerosis
1313246|NCT00718458|Cerebrospinal Fluid
1313247|NCT00718458|Neurodegenerative Disease
1313248|NCT00718458|Motor Neuron Disease
1313249|NCT00718458|Autonomic Nervous System
1313250|NCT00718458|Neurodegenerative Diseases
1313251|NCT00718458|Movement Disorders
1313252|NCT00718445|Amyotrophic Lateral Sclerosis
1313253|NCT00718445|Cerebrospinal Fluid
1313254|NCT00718445|Neurodegenerative Disease
1313255|NCT00718445|Motor Neuron Disease
1313256|NCT00718445|Autonomic Nervous System
1313257|NCT00718445|Neurodegenerative Diseases
1313258|NCT00718445|Movement Disorders
1313259|NCT00718432|Frailty
1313260|NCT00718432|Osteoporosis
1313261|NCT00718432|Depression
1313262|NCT00718419|Waldenstrom's Macroglobulinemia
1313263|NCT00718419|Multiple Myeloma
1313264|NCT00718406|Acute coronary syndrome
1313265|NCT00718406|Chest pain
1313266|NCT00718406|Betablockers
1313267|NCT00718406|Morphine
1313268|NCT00718406|Prehospital phase
1313269|NCT00718393|Amyotrophic Lateral Sclerosis
1313270|NCT00718393|Cerebrospinal Fluid
1313271|NCT00718393|Neurodegenerative Disease
1313272|NCT00718393|Motor Neuron Disease
1313273|NCT00718393|Autonomic Nervous System
1313274|NCT00718393|Neurodegenerative Diseases
1313275|NCT00718393|Movement Disorders
1313276|NCT00718354|Bleeding events
1313277|NCT00718341|Fragile X Syndrome, adults, efficacy
1313278|NCT00718328|Intracerebral
1313279|NCT00718328|Hemorrhage
1313280|NCT00718328|Edema
1313281|NCT00718328|Statins
1313282|NCT00718302|Ankle Fractures
1313283|NCT00718302|Displaced Lateral Malleolus Fractures
1313284|NCT00718302|Antiglide Plating
1313285|NCT00718302|Lateral Plating
1313286|NCT00718289|Citric acid
1313287|NCT00718289|citrate
1313288|NCT00718289|acetic acid
1313289|NCT00718289|acetate
1313290|NCT00718289|haemodialysis
1313291|NCT00718289|calcium
1313292|NCT00718289|hypotension
1313293|NCT00718289|haemodynamics
1313294|NCT00718289|Dialysate for Haemodialysis
1313295|NCT00718276|Healthy postmenopausal women
1313296|NCT00718250|Acute myeloid leukaemia
1313297|NCT00718250|Cancer vaccines
1313298|NCT00718250|Immunotherapy
1313299|NCT00718237|Gastroenteritis
1313300|NCT00718237|Rotavirus
1313301|NCT00718224|Knee surgery
1313302|NCT00718224|VTE prevention
1313303|NCT00718198|Inpatient
1313304|NCT00718198|Computer Physician Order Entry
1313305|NCT00718198|Diabetes Mellitus
1313306|NCT00718185|Sildenafil
1313307|NCT00718185|Pediatrics
1313308|NCT00718172|Ribavirin Pretreatment
1313309|NCT00718172|Gene Expression
1313310|NCT00718172|Peginterferon
1313311|NCT00718172|Hepatitis C
1313312|NCT00718172|Liver Biopsy
1313313|NCT00718172|HCV
1313314|NCT00718159|Acute Myeloid Leukemia
1313315|NCT00718159|Myeloid Leukemia
1313316|NCT00718159|Relapsed
1313317|NCT00718159|Refractory
1313318|NCT00718146|Influenza
1313319|NCT00718146|Orthomyxoviridae Infections
1313320|NCT00718146|Orthomyxoviruses
1313321|NCT00718146|Split-virion influenza vaccine
1313322|NCT00718133|Asthma
1313323|NCT00718133|Allergy
1313324|NCT00718133|Respiratory
1313325|NCT00718133|Pollution
1313326|NCT00718133|Children
1313327|NCT00718133|Air pollution
1313328|NCT00718120|Fluviral
1313329|NCT00718120|Influenza
1313330|NCT00718107|Amyotrophic Lateral Sclerosis
1313331|NCT00718107|Cerebrospinal Fluid
1313332|NCT00718107|Neurodegenerative Disease
1313333|NCT00718107|Motor Neuron Disease
1313334|NCT00718107|Autonomic Nervous System
1313335|NCT00718107|Neurodegenerative Diseases
1313336|NCT00718107|Movement Disorders
1313337|NCT00718107|Quality of Life
1313338|NCT00718094|Ulcerative colitis
1313339|NCT00718094|EGCG
1313340|NCT00718094|Green tea polyphenols
1313341|NCT00718094|Inflammatory bowel disease
1313342|NCT00718094|Colitis
1313343|NCT00718094|IBD
1313344|NCT00718094|Green tea
1313345|NCT00718068|Potassium chloride
1313346|NCT00718068|Preparations, Pharmaceutical
1313347|NCT00718068|Hypokalemia
1313348|NCT00718068|Critical Care
1313349|NCT00718068|Adult
1313350|NCT00718068|Randomized Controlled Trial
1313351|NCT00718055|MRI
1313352|NCT00718055|liverspecific
1313353|NCT00718055|contrast
1313354|NCT00718055|colorectal
1313355|NCT00718055|metastases
1313356|NCT00718042|healthy donors
1313357|NCT00718029|Human Immunodeficiency Virus
1313358|NCT00718029|Cerebrospinal Fluid
1313359|NCT00718029|Raltegravir
1313360|NCT00718029|Drug Concentrations
1313361|NCT00718016|Amyotrophic Lateral Sclerosis
1313362|NCT00718016|Cerebrospinal Fluid
1313363|NCT00718016|Neurodegenerative Disease
1313364|NCT00718016|Motor Neuron Disease
1313365|NCT00718016|Autonomic Nervous System
1313366|NCT00718016|Neurodegenerative Diseases
1313367|NCT00718016|Movement Disorders
1313368|NCT00718003|Amyotrophic Lateral Sclerosis
1313369|NCT00718003|Cerebrospinal Fluid
1313370|NCT00718003|Neurodegenerative Disease
1313371|NCT00718003|Motor Neuron Disease
1313372|NCT00718003|Autonomic Nervous System
1313373|NCT00718003|Neurodegenerative Diseases
1313374|NCT00718003|Movement Disorders
1313375|NCT00717990|Colorectal cancer
1313376|NCT00717990|Bevacizumab
1313377|NCT00717990|XELIRI
1313378|NCT00717951|advanced breast cancer
1313379|NCT00717951|docetaxol
1313380|NCT00717951|capecitabine
1313381|NCT00717951|cisplatin
1313382|NCT00717925|B-cell Non-Hodgkin's Lymphoma
1313383|NCT00717925|NHL
1313384|NCT00717912|BLOOD GLUCOSE
1313385|NCT00717912|glycemic index
1313386|NCT00717912|rates of digestion and absorption of food
1313387|NCT00717899|Asthma
1313388|NCT00717899|Allergy
1313389|NCT00717899|Respiratory
1313390|NCT00717899|Pollution
1313391|NCT00717899|Children
1313392|NCT00717899|Air pollution
1313393|NCT00717886|Breast
1313394|NCT00717886|Lymph Nodes
1313395|NCT00717873|Mucus Clearance
1313396|NCT00717873|Secretion Clearance
1313397|NCT00717873|HFCWO
1313398|NCT00717808|Tranilast
1313399|NCT00717808|Rheumatoid Arthritis
1313400|NCT00717808|Pharmacokinetics
1313401|NCT00717808|Methotrexate
1313402|NCT00717795|Survivor
1313403|NCT00717795|Physical Activity
1313404|NCT00717795|NED
1313405|NCT00717795|08-067
1313406|NCT00717782|botulinum toxin
1313407|NCT00717782|thrombosed external haemorrhoids
1313408|NCT00717782|pain
1313409|NCT00717769|Atopic Dermatitis
1313410|NCT00717756|liver cancer, second line
1313411|NCT00717743|RCC
1313412|NCT00717743|patients
1313413|NCT00717743|scheduled
1313414|NCT00717743|nephrectomy
1313415|NCT00717730|Nutrition
1313416|NCT00717730|Children
1313417|NCT00717730|Folate
1313418|NCT00717730|Vitamin B12
1313419|NCT00717730|India
1313420|NCT00717730|Homocysteine
1313421|NCT00717730|Methyl Malonic Acid
1313422|NCT00717717|Cancer Survivor
1313423|NCT00717717|Physical Activity
1313424|NCT00717717|Health Behavior
1313425|NCT00717717|Psychosocial Well-being
1313426|NCT00717717|Coaching
1313427|NCT00717717|Long Term
1313428|NCT00717717|Consequences
1313429|NCT00717717|Chemotherapy
1313430|NCT00717717|Motivation
1313431|NCT00717704|Malignant solid tumor
1313432|NCT00717704|Phase 1
1313433|NCT00717704|Dose escalation
1313434|NCT00717704|Metastatic or locally advanced/unresectable
1313435|NCT00717704|Disease progression through standard therapy
1313436|NCT00717691|Hallux Limitus
1313437|NCT00717691|Dynamic Splinting
1313438|NCT00717691|Dynasplint
1313439|NCT00717678|Immunosuppressant
1313440|NCT00717678|Combination drug therapy
1313441|NCT00717678|Graft loss
1313442|NCT00717678|Randomized controlled trial
1313443|NCT00717678|Open level method
1313444|NCT00717665|Hypertension
1313445|NCT00717665|Telemanagement
1313446|NCT00717665|Home blood pressure monitoring
1313447|NCT00717665|Self care
1313448|NCT00717639|diagnostic accuracy
1313449|NCT00717639|magnetic resonance angiography
1313450|NCT00717639|steady state
1313451|NCT00717639|digital subtraction angiography
1313452|NCT00717639|peripheral arteries
1313453|NCT00717626|Hemophilia
1313454|NCT00717626|Prophylaxis
1313455|NCT00717626|Youth
1313456|NCT00717626|Young Adults
1313457|NCT00717626|Feasibility
1313458|NCT00717600|bacteriuria
1313459|NCT00717600|urinary tract infection
1313460|NCT00717600|probiotics
1313461|NCT00717600|lactobacillus
1313462|NCT00717600|vagina
1313463|NCT00717600|bladder
1313464|NCT00717600|neurogenic bladder
1313465|NCT00717600|spina bifida
1313466|NCT00717600|myelomeningocele
1313467|NCT00717600|neuropathic bladder
1313468|NCT00717587|stage IV renal cell cancer
1313469|NCT00717587|recurrent renal cell cancer
1313470|NCT00717574|depth of sedation
1313471|NCT00717574|nitrous oxide
1313472|NCT00717574|general anesthesia
1313473|NCT00717574|anesthesia indices
1313474|NCT00717561|CAP
1313475|NCT00717561|Community-acquired pneumonia
1313476|NCT00717548|Somatic Complaints
1313477|NCT00717535|health status unknown
1313478|NCT00717522|Soft Tissue Sarcoma
1313479|NCT00717522|CC-4047
1313480|NCT00717522|Pomalidomide
1313481|NCT00717509|schizophrenia
1313482|NCT00717509|metabolic side effect
1313483|NCT00717509|clozapine
1313484|NCT00717509|genetic polymorphism
1313485|NCT00717496|Breastfeeding
1313486|NCT00717496|Telephone Support
1313487|NCT00717496|Latino
1313488|NCT00717470|Kidney
1313489|NCT00717470|Transplant
1313490|NCT00717470|Immunosuppression
1313491|NCT00717470|Advagraf
1313492|NCT00717470|Prograf
1313493|NCT00717470|FK506
1313494|NCT00717444|Substance Abuse
1313495|NCT00717444|HIV
1313496|NCT00717444|Contingency Management
1313497|NCT00717444|Physical Activity
1313498|NCT00717431|Deep Brain Stimulation
1313499|NCT00717431|Seizures
1313500|NCT00717431|Epilepsy
1313501|NCT00717392|ADHD
1313502|NCT00717392|ASD
1313503|NCT00717379|Organ Transplantation
1313504|NCT00717379|Tacrolimus
1313505|NCT00717379|Prograf
1313506|NCT00717379|Kidney
1313507|NCT00717379|Immunosuppression
1313508|NCT00717340|tivozanib
1313509|NCT00717340|AV-951
1313510|NCT00717327|MRL
1313511|NCT00717327|Adolescents
1313512|NCT00717327|Health Literacy
1313513|NCT00717301|TBI, traumatic brain injury, S100B, head CT scan
1313514|NCT00717288|diabetes
1313515|NCT00717288|hyperglycemia
1313516|NCT00717288|open heart surgery
1313517|NCT00717288|cardiothoracic surgery
1313518|NCT00717288|detemir
1313519|NCT00717288|insulin infusion
1313520|NCT00717288|intravenous insulin
1313521|NCT00717275|Brain Metastases
1313522|NCT00717275|Temozolomide
1313523|NCT00717275|Temodar
1313524|NCT00717275|TMZ
1313525|NCT00717275|Stereotactic Radiosurgery
1313526|NCT00717275|SRS
1313527|NCT00717236|Certolizumab pegol
1313528|NCT00717236|Cimzia
1313529|NCT00717236|Rheumatoid Arthritis
1313530|NCT00717236|Joint Disease
1313531|NCT00717236|Chronic Arthritis
1313532|NCT00717223|Diabetes
1313533|NCT00717223|Type 1 diabetes mellitus
1313534|NCT00717223|Type 2 diabetes mellitus
1313535|NCT00717223|Literacy
1313536|NCT00717223|Glycemic control
1313537|NCT00717210|1p/19q loss
1313538|NCT00717210|MGMT
1313539|NCT00717210|prognostic factors
1313540|NCT00717210|PCV
1313541|NCT00717210|temozolomide
1313542|NCT00717197|HGG
1313543|NCT00717197|anaplastic astrocytoma
1313544|NCT00717197|anaplastic oligodendroglioma
1313545|NCT00717197|anaplastic mixed glioma
1313546|NCT00717197|glioblastoma multiforme
1313547|NCT00717197|GBM
1313548|NCT00717197|Xeloda
1313549|NCT00717197|capecitabine
1313550|NCT00717171|electrical stimulation
1313551|NCT00717171|pain
1313552|NCT00717171|medication
1313553|NCT00717171|edema
1313554|NCT00717171|interferential
1313555|NCT00717171|neuromuscular
1313556|NCT00717171|high voltage pulsed current
1313557|NCT00717171|knee
1313558|NCT00717158|Health Behavior
1313559|NCT00717158|Lifestyle
1313560|NCT00717158|health care costs
1313561|NCT00717158|quality of life
1313562|NCT00717145|bioequivalence
1313563|NCT00717132|weight
1313564|NCT00717132|cost effectiveness
1313565|NCT00717132|obesity
1313566|NCT00717132|family based behavioral treatment
1313567|NCT00717119|GI
1313568|NCT00717119|NSAID
1313569|NCT00717119|Complications
1313570|NCT00717119|Treated
1313571|NCT00717119|Patients
1313572|NCT00717106|ILR
1313573|NCT00717106|ECG monitoring
1313574|NCT00717106|cardiac arrhythmia
1313575|NCT00717106|syncope
1313576|NCT00717106|presyncope
1313577|NCT00717106|fainting
1313578|NCT00717080|Retinitis Pigmentosa
1313579|NCT00717080|Cataract
1313580|NCT00717067|maraviroc, pharmacokinetics, renal impairment
1313581|NCT00717054|postoperative nausea and vomiting
1313582|NCT00717041|Depression
1313583|NCT00717041|Anxiety
1313584|NCT00717041|Cognitive Impairment
1313585|NCT00717041|Emergency medicine
1313586|NCT00717041|prehospital care
1313587|NCT00717028|Cerebral palsy
1313588|NCT00717028|Dysphagia
1313589|NCT00717028|Deglutition
1313590|NCT00717028|Endoscopy
1313591|NCT00717015|Hormone Receptor Positive Breast Cancer
1313592|NCT00716989|Cutaneous immune system
1313593|NCT00716989|innate immunity
1313594|NCT00716989|tuberculin skin tests
1313595|NCT00716989|intradermal vaccination
1313596|NCT00716989|pathophysiology
1313597|NCT00716989|Healthy subjects
1313598|NCT00716989|Immunosuppressed patients
1313599|NCT00716976|ototoxicity
1313600|NCT00716976|childhood central nervous system germ cell tumor
1313601|NCT00716976|childhood extracranial germ cell tumor
1313602|NCT00716976|childhood extragonadal germ cell tumor
1313603|NCT00716976|childhood malignant testicular germ cell tumor
1313604|NCT00716976|childhood malignant ovarian germ cell tumor
1313605|NCT00716976|childhood teratoma
1313606|NCT00716976|childhood medulloblastoma
1313607|NCT00716976|disseminated neuroblastoma
1313608|NCT00716976|regional neuroblastoma
1313609|NCT00716976|localized resectable neuroblastoma
1313610|NCT00716976|localized unresectable neuroblastoma
1313611|NCT00716976|stage 4S neuroblastoma
1313612|NCT00716976|localized osteosarcoma
1313613|NCT00716976|metastatic osteosarcoma
1313614|NCT00716976|childhood hepatoblastoma
1313615|NCT00716976|stage I childhood liver cancer
1313616|NCT00716976|stage II childhood liver cancer
1313617|NCT00716976|stage III childhood liver cancer
1313618|NCT00716976|stage IV childhood liver cancer
1313619|NCT00716963|late allergic response
1313620|NCT00716963|fluticasone propionate
1313621|NCT00716937|pilonidal sinus
1313622|NCT00716937|karydakis
1313623|NCT00716937|laying open
1313624|NCT00716911|cytomegalovirus infection
1313625|NCT00716911|accelerated phase chronic myelogenous leukemia
1313626|NCT00716911|atypical chronic myeloid leukemia, BCR-ABL negative
1313627|NCT00716911|blastic phase chronic myelogenous leukemia
1313628|NCT00716911|chronic myelomonocytic leukemia
1313629|NCT00716911|chronic phase chronic myelogenous leukemia
1313630|NCT00716911|recurrent adult acute lymphoblastic leukemia
1313631|NCT00716911|recurrent adult acute myeloid leukemia
1313632|NCT00716911|refractory chronic lymphocytic leukemia
1313633|NCT00716911|refractory hairy cell leukemia
1313634|NCT00716911|relapsing chronic myelogenous leukemia
1313635|NCT00716911|secondary acute myeloid leukemia
1313636|NCT00716911|stage III chronic lymphocytic leukemia
1313637|NCT00716911|stage IV chronic lymphocytic leukemia
1313638|NCT00716911|splenic marginal zone lymphoma
1313639|NCT00716911|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1313640|NCT00716911|nodal marginal zone B-cell lymphoma
1313641|NCT00716911|stage III adult Burkitt lymphoma
1313642|NCT00716911|stage III adult diffuse large cell lymphoma
1313643|NCT00716911|stage III adult diffuse mixed cell lymphoma
1313644|NCT00716911|stage III adult diffuse small cleaved cell lymphoma
1313645|NCT00716911|stage III adult immunoblastic large cell lymphoma
1313646|NCT00716911|stage III adult lymphoblastic lymphoma
1313647|NCT00716911|stage III grade 1 follicular lymphoma
1313648|NCT00716911|stage III grade 2 follicular lymphoma
1313649|NCT00716911|stage III grade 3 follicular lymphoma
1313650|NCT00716911|stage III mantle cell lymphoma
1313651|NCT00716911|stage III marginal zone lymphoma
1313652|NCT00716911|stage III small lymphocytic lymphoma
1313653|NCT00716911|stage IV adult Burkitt lymphoma
1313654|NCT00716911|stage IV adult diffuse large cell lymphoma
1313655|NCT00716911|stage IV adult diffuse mixed cell lymphoma
1313656|NCT00716911|stage IV adult diffuse small cleaved cell lymphoma
1313657|NCT00716911|stage IV adult immunoblastic large cell lymphoma
1313658|NCT00716911|stage IV adult lymphoblastic lymphoma
1313659|NCT00716911|stage IV grade 1 follicular lymphoma
1313660|NCT00716911|stage IV grade 2 follicular lymphoma
1313661|NCT00716911|stage IV grade 3 follicular lymphoma
1313662|NCT00716911|stage IV mantle cell lymphoma
1313663|NCT00716911|stage IV marginal zone lymphoma
1313664|NCT00716911|stage IV small lymphocytic lymphoma
1313665|NCT00716911|recurrent adult Hodgkin lymphoma
1313666|NCT00716911|recurrent adult Burkitt lymphoma
1313667|NCT00716911|recurrent adult diffuse large cell lymphoma
1313668|NCT00716911|recurrent adult diffuse mixed cell lymphoma
1313669|NCT00716911|recurrent adult diffuse small cleaved cell lymphoma
1313670|NCT00716911|recurrent adult immunoblastic large cell lymphoma
1313671|NCT00716911|recurrent adult lymphoblastic lymphoma
1313672|NCT00716911|recurrent cutaneous T-cell non-Hodgkin lymphoma
1313673|NCT00716911|recurrent mycosis fungoides/Sezary syndrome
1313674|NCT00716911|recurrent grade 1 follicular lymphoma
1313675|NCT00716911|recurrent grade 2 follicular lymphoma
1313676|NCT00716911|recurrent grade 3 follicular lymphoma
1313677|NCT00716911|recurrent mantle cell lymphoma
1313678|NCT00716911|recurrent marginal zone lymphoma
1313679|NCT00716911|recurrent small lymphocytic lymphoma
1313680|NCT00716911|chronic eosinophilic leukemia
1313681|NCT00716911|chronic neutrophilic leukemia
1313682|NCT00716911|primary myelofibrosis
1313683|NCT00716911|stage II multiple myeloma
1313684|NCT00716911|stage III multiple myeloma
1313685|NCT00716911|refractory multiple myeloma
1313686|NCT00716911|de novo myelodysplastic syndromes
1313687|NCT00716911|previously treated myelodysplastic syndromes
1313688|NCT00716911|secondary myelodysplastic syndromes
1313689|NCT00716911|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1313690|NCT00716911|stage I multiple myeloma
1313691|NCT00716898|Condition
1313692|NCT00716898|Cancer
1313693|NCT00716898|Patients
1313694|NCT00716898|Thrombosis
1313695|NCT00716898|Unstable
1313696|NCT00716898|Angina
1313697|NCT00716898|Pectoris
1313698|NCT00716885|Heart failure
1313699|NCT00716885|Oxidative stress
1313700|NCT00716885|Endothelial Progenitor Cells
1313701|NCT00716885|White blood cells
1313702|NCT00716872|cancer
1313703|NCT00716872|sleep
1313704|NCT00716872|insomnia
1313705|NCT00716872|Internet
1313706|NCT00716872|SHUTi
1313707|NCT00716833|pain
1313708|NCT00716833|coxibe
1313709|NCT00716833|preemptive
1313710|NCT00716833|abdominothoracic
1313711|NCT00716833|sensibilisation
1313712|NCT00716833|Analgesia
1313713|NCT00716807|BMS
1313714|NCT00716807|TMD
1313715|NCT00716794|Prostate cancer
1313716|NCT00716794|HE3235
1313717|NCT00716794|Apoptone
1313718|NCT00716781|Group B streptococcus
1313719|NCT00716781|Sepsis
1313720|NCT00716781|Infants
1313721|NCT00716781|Diagnosis
1313722|NCT00716781|Physical examination
1313723|NCT00716781|Laboratory tests
1313724|NCT00716768|Laparoscopic
1313725|NCT00716768|Inguinal Hernia
1313726|NCT00716768|Infants
1313727|NCT00716755|Positron emission tomography
1313728|NCT00716755|antipsychotics
1313729|NCT00716755|risperidone
1313730|NCT00716755|olanzapine
1313731|NCT00716755|Dopamine
1313732|NCT00716755|D2 receptor
1313733|NCT00716755|elderly
1313734|NCT00716755|schizophrenia
1313735|NCT00716755|schizoaffective disorder
1313736|NCT00716755|schizophreniform disorder
1313737|NCT00716755|delusional disorder
1313738|NCT00716755|psychotic disorder NOS
1313739|NCT00716729|Questionnaire
1313740|NCT00716729|Hip
1313741|NCT00716729|Groin
1313742|NCT00716729|Disability
1313743|NCT00716729|Strength
1313744|NCT00716729|To develop two new outcome measures for patients with hip and groin disability
1313745|NCT00716716|Hemophilia B severe, previously treated patients
1313746|NCT00716703|Appendicitis
1313747|NCT00716703|Computed tomography
1313748|NCT00716703|pediatric
1313749|NCT00716703|child
1313750|NCT00716703|sensitivity
1313751|NCT00716703|specificity
1313752|NCT00716703|contrast administration route
1313753|NCT00716703|time factors
1313754|NCT00716690|Stem cell transplantation
1313755|NCT00716690|GVHD
1313756|NCT00716677|difficult asthma
1313757|NCT00716677|respiratory inductance plethysmography
1313758|NCT00716664|cystic fibrosis
1313759|NCT00716664|musculoskeletal
1313760|NCT00716664|exercise capacity
1313761|NCT00716664|posture
1313762|NCT00716664|lung function
1313763|NCT00716664|physical functioning
1313764|NCT00716612|Coenzyme Q 10
1313765|NCT00716612|Statin
1313766|NCT00716612|Myalgia
1313767|NCT00716599|malaria
1313768|NCT00716599|diagnosis
1313769|NCT00716599|rapid diagnostic test
1313770|NCT00716599|rapid diagnostic tests
1313771|NCT00716599|fever case management
1313772|NCT00716599|training
1313773|NCT00716599|fever case management in malaria-endemic areas
1313777|NCT00716521|mobile actigraphy inpatient polysomnography actigraphy ambien
1313778|NCT00716508|Patella tendon rupute, suture anchors, repair patella tendon
1313779|NCT00716482|breast
1313780|NCT00716482|lesion
1313781|NCT00716482|ultrasound
1313782|NCT00716482|BI-RADS
1313783|NCT00716482|malignancy
1313784|NCT00716482|women
1313785|NCT00716469|Neurofibroma
1313786|NCT00716469|Plexiform
1313787|NCT00716469|NF1
1313788|NCT00716469|Photo dynamic therapy
1313789|NCT00716456|MAB C225(CETUXIMAB)(ANTI-EGFR)
1313790|NCT00716456|OSI-774, TARCEVA (ERLOTINIB)
1313791|NCT00716456|Lung
1313792|NCT00716456|Adenocarcinoma
1313793|NCT00716456|Lung cancer
1313794|NCT00716443|Nasolabial folds
1313795|NCT00716443|wrinkles
1313796|NCT00716443|topical anesthetic
1313797|NCT00716430|acute coronary syndromes
1313798|NCT00716430|quality improvement
1313799|NCT00716404|FlowMedica
1313800|NCT00716404|Benephit
1313801|NCT00716404|TRT
1313802|NCT00716404|Patients
1313803|NCT00716404|Components
1313804|NCT00716404|Benephit Infusion System
1313805|NCT00716404|Planned
1313806|NCT00716404|To be used
1313807|NCT00716391|Head and Neck Cancer
1313808|NCT00716378|Simulated Driving
1313809|NCT00716378|Risky Driving Behavior
1313810|NCT00716378|Social Influences
1313811|NCT00716365|angiography
1313812|NCT00716365|hemostasis
1313813|NCT00716365|femoral artery
1313814|NCT00716365|duplex
1313815|NCT00716352|non-ST elevation acute coronary syndrome
1313816|NCT00716352|educational intervention
1313817|NCT00716352|evidence based practice
1313818|NCT00716352|guidelines
1313819|NCT00716339|pseudophakic accommodation
1313820|NCT00716326|Transcutaneous Electrical Nerve Stimulation
1313821|NCT00716326|Chronic pain
1313822|NCT00716326|Neuropathic pain
1313823|NCT00716326|Short-term efficacy
1313824|NCT00716326|Long-term efficacy
1313825|NCT00716300|obesity
1313826|NCT00716300|CVD
1313827|NCT00716300|HDL kinetics
1313828|NCT00716300|Anti-inflammatory and anti-oxidation studies
1313829|NCT00716300|30 subjects recruited (15 MetS and 15 lean controls)
1313830|NCT00716261|Parkinson's disease
1313831|NCT00716261|Audio feedback
1313832|NCT00716261|postural control
1313833|NCT00716235|ADHD
1313834|NCT00716235|ASD
1313835|NCT00716235|PDD
1313836|NCT00716235|DCD
1313837|NCT00716235|Executive Functions
1313838|NCT00716196|thin prep
1313839|NCT00716196|EUS
1313840|NCT00716183|mastitis
1313841|NCT00716183|Staphylococcus
1313842|NCT00716183|Streptococcus
1313843|NCT00716183|lactation
1313844|NCT00716183|breastfeeding
1313845|NCT00716170|Diabetes Mellitus
1313846|NCT00716170|Glucagon
1313847|NCT00716170|Insulin
1313848|NCT00716170|Incretin hormones
1313849|NCT00716170|Glucose-dependent insulinotropic polypeptide
1313850|NCT00716170|Glucagon-like peptide-1
1313851|NCT00716170|Glucagon-like peptide-2
1313852|NCT00716144|Psoriasis
1313853|NCT00716131|Amyotrophic Lateral Sclerosis
1313854|NCT00716131|Cerebrospinal Fluid
1313855|NCT00716131|Neurodegenerative Disease
1313856|NCT00716131|Motor Neuron Disease
1313857|NCT00716131|Autonomic Nervous System
1313858|NCT00716131|Neurodegenerative Diseases
1313859|NCT00716131|Movement Disorders
1313860|NCT00716118|Oocyte Cryopreservation
1313861|NCT00716118|Slow-Freeze
1313862|NCT00716118|Egg Freezing
1313863|NCT00716118|Meiotic Spindle
1313864|NCT00716118|Mitochondria
1313865|NCT00716118|Human Oocytes Freezing.
1313866|NCT00716105|Infant formula
1313867|NCT00716105|Protein metabolism
1313868|NCT00716079|Cerebral Hemorrhage
1313869|NCT00716079|Stroke
1313870|NCT00716079|antihypertensive drugs
1313871|NCT00716079|blood pressure
1313872|NCT00716079|disability
1313873|NCT00716079|clinical trial
1313874|NCT00716079|outcomes
1313875|NCT00716053|emphysema
1313876|NCT00716053|chronic obstructive pulmonary disease
1313877|NCT00716053|COPD
1313878|NCT00716053|lung volume reduction
1313879|NCT00716053|LVRS
1313880|NCT00716053|BLVR
1313881|NCT00716053|Aeris
1313882|NCT00716040|AIDS treatment
1313883|NCT00716040|HAART adherence
1313884|NCT00716040|intervention
1313885|NCT00716014|Pachyonychia Congenita
1313886|NCT00716014|siRNA
1313887|NCT00716001|patients with chronic renal failure undergoing elective percutaneous coronary intervention
1313888|NCT00715988|Methadone
1313889|NCT00715988|analgesia
1313890|NCT00715988|newborns
1313891|NCT00715988|QT prolongation
1313892|NCT00715988|Young Infants
1313893|NCT00715975|clobetasol
1313894|NCT00715975|halobetasol
1313895|NCT00715975|psoriasis
1313896|NCT00715975|evaluating the efficacy and tolerability of the drug Halobetasol propionate
1313897|NCT00715962|Hospitalization
1313898|NCT00715962|Aged
1313899|NCT00715949|traumatic brain injury
1313900|NCT00715949|pediatric
1313901|NCT00715949|neurocognitive
1313902|NCT00715949|concussion
1313906|NCT00715923|informed consent document
1313907|NCT00715923|ethics
1313908|NCT00715910|Meningococcal vaccine
1313909|NCT00715910|Booster vaccination
1313910|NCT00715910|Immunogenicity
1313911|NCT00715910|Meningococcal disease
1313912|NCT00715910|Safety
1313913|NCT00715897|chronic neurological deficient due to stroke
1313914|NCT00715884|Atherosclerosis
1313915|NCT00715884|de novo native coronary lesion
1313916|NCT00715871|smoking
1313917|NCT00715871|smoke cessation
1313918|NCT00715871|stop smoking
1313919|NCT00715871|quit smoking
1313920|NCT00715871|nicotine replacement therapy
1313921|NCT00715871|Smoke Break
1313922|NCT00715871|liquid cigarette
1313923|NCT00715871|liquid nicotine cigarette
1313924|NCT00715858|Alzheimer's disease
1313925|NCT00715858|dementia
1313926|NCT00715858|inflammation
1313927|NCT00715858|cytokine
1313928|NCT00715858|biomarker
1313929|NCT00715858|cerebrospinal fluid
1313930|NCT00715858|serum
1313931|NCT00715858|doxycycline
1313932|NCT00715858|rifampin
1313933|NCT00715845|cardiovascular disease
1313934|NCT00715845|embolism
1313935|NCT00715845|microemboli
1313936|NCT00715845|cognitive decline
1313937|NCT00715845|mitral valve repair
1313938|NCT00715845|cerebral microemboli
1313939|NCT00715845|coronary artery bypass graft
1313940|NCT00715845|CABG
1313941|NCT00715845|transcranial doppler
1313942|NCT00715845|transesophageal echocardiogram
1313943|NCT00715845|magnetic resonance imaging
1313944|NCT00715845|carbon dioxide
1313945|NCT00715832|Breast cancer
1313946|NCT00715832|Dendritic cell vaccine
1313947|NCT00715832|OFA/iLRP
1313948|NCT00715832|Patients
1313949|NCT00715832|Line
1313950|NCT00715832|Chemotherapy
1313951|NCT00715832|Setting
1313952|NCT00715832|Four different lines
1313953|NCT00715806|claustrophobia
1313954|NCT00715806|magnetic resonance imaging
1313955|NCT00715806|MRI
1313956|NCT00715806|anxiety
1313957|NCT00715806|open design
1313958|NCT00715806|severely anxious patients
1313959|NCT00715793|Decitabine
1313960|NCT00715793|Temozolomide
1313961|NCT00715793|Metastatic
1313962|NCT00715793|Melanoma
1313963|NCT00715793|Non-resectable
1313964|NCT00715793|Stage IIIB melanoma
1313965|NCT00715793|stage IV melanoma
1313966|NCT00715793|TMZ
1313967|NCT00715793|DTIC
1313968|NCT00715793|promoter methylation
1313969|NCT00715793|skin cancer
1313970|NCT00715793|chemotherapy
1313971|NCT00715767|BLS training
1313972|NCT00715767|CPR
1313973|NCT00715767|post graduate education
1313974|NCT00715767|resource-limited settings
1313975|NCT00715767|medical education
1313976|NCT00715767|CPR retention
1313977|NCT00715767|cultural barriers
1313978|NCT00715741|atelectasis
1313979|NCT00715741|oxygen
1313980|NCT00715741|saturation
1313981|NCT00715728|Plastic surgery
1313982|NCT00715728|Warming
1313983|NCT00715728|Core temperature
1313984|NCT00715728|Bair Hugger
1313985|NCT00715728|Hot Dog heating system
1313986|NCT00715715|Hepatitis B e Antigen
1313987|NCT00715715|HBeAg-positive chronic hepatitis B
1313988|NCT00715702|AZD5672
1313989|NCT00715676|Osteoporosis
1313990|NCT00715676|2-methylene-19-nor-(20S)-1a, 25-dihydroxyvitamin D3
1313991|NCT00715676|Vitamin D
1313992|NCT00715676|Bone Density Conservation Agents
1313993|NCT00715676|Bone Regeneration
1313994|NCT00715650|Rehabilitation, Vocational
1313995|NCT00715650|Compensation and Redress
1313996|NCT00715650|disability evaluation
1313997|NCT00715637|AML
1313998|NCT00715637|Leukemia
1313999|NCT00715637|MDS
1314000|NCT00715637|Amonafide
1314001|NCT00715637|Cytarabine
1314002|NCT00715637|Daunorubicin
1314003|NCT00715637|Lymphatic disorders
1314004|NCT00715624|hyperglycemia, GLP-1, metformin, insulin
1314005|NCT00715611|pemetrexed
1314006|NCT00715611|cisplatin
1314007|NCT00715611|IMRT
1314008|NCT00715611|PLEURA
1314009|NCT00715611|Malignant
1314010|NCT00715611|08-053
1314011|NCT00715598|Pain Assessment
1314012|NCT00715598|Measurement
1314013|NCT00715585|diabetes
1314014|NCT00715585|education
1314015|NCT00715585|health literacy
1314016|NCT00715572|hypothyroidism, treatment, thyroxine, triiodothyronine
1314017|NCT00715559|Major depressive disorder, depression
1314018|NCT00715559|neurotrophic
1314019|NCT00715559|brain-derived neurotrophic factor
1314020|NCT00715559|antidepressant
1314021|NCT00715559|cysteamine
1314022|NCT00715546|Adipose-derived stem cell
1314023|NCT00715546|Lipodystrophy
1314024|NCT00715533|acute (< 24 hours) stroke
1314025|NCT00715533|stroke
1314026|NCT00715533|TIA
1314027|NCT00715533|MRI
1314028|NCT00715533|imaging
1314029|NCT00715533|acute
1314030|NCT00715520|Transcranial Magnetic Stimulation
1314031|NCT00715520|Rehabilitation
1314032|NCT00715520|Stroke
1314033|NCT00715520|Plasticity
1314034|NCT00715507|decision making
1314035|NCT00715507|graphic display
1314036|NCT00715494|brain injuries, dementia, myopathies, muscle disorders
1314037|NCT00715481|Type 2 diabetes
1314038|NCT00715481|Cardiovascular disease
1314039|NCT00715481|Diabetic Nephropathy
1314040|NCT00715481|Glomerular filtration rate
1314041|NCT00715481|Albuminuria
1314042|NCT00715455|CAD
1314043|NCT00715455|PCI
1314044|NCT00715455|ANTICOAGULANT
1314045|NCT00715442|Kidney
1314046|NCT00715442|Renal Cell Carcinoma
1314047|NCT00715442|RCC
1314048|NCT00715442|Sutent
1314049|NCT00715442|Sunitinib malate
1314050|NCT00715442|Clear cell
1314051|NCT00715442|SU011248
1314052|NCT00715442|Nephrectomy
1314053|NCT00715442|Surgical removal of kidney
1314054|NCT00715442|Cytoreductive nephrectomy
1314055|NCT00715429|leg cramps
1314056|NCT00715429|vitamin D deficiency
1314057|NCT00715416|peripheral vascular diseases
1314058|NCT00715416|Intermittent Claudication
1314059|NCT00715416|Angioplasty
1314060|NCT00715390|Children
1314061|NCT00715390|Cardiac Arrhythmia
1314062|NCT00715390|General Anesthesia
1314063|NCT00715377|benztropine
1314064|NCT00715377|Anticholinergic antiparkinsonian agents
1314065|NCT00715377|antipsychotics
1314066|NCT00715377|elderly population
1314067|NCT00715377|side-effects
1314068|NCT00715338|Exhaled Breath Condensate
1314069|NCT00715338|elective surgery
1314070|NCT00715338|mechanical ventilation
1314071|NCT00715338|Isofurans
1314072|NCT00715338|thrombomodulin
1314073|NCT00715338|requiring
1314074|NCT00715338|mechanical
1314075|NCT00715338|ventilation
1314076|NCT00715325|colonoscopy
1314077|NCT00715325|disposable
1314078|NCT00715325|single use
1314079|NCT00715312|Inflammation
1314080|NCT00715312|LDL
1314081|NCT00715312|Oleic acid
1314082|NCT00715312|Palmitic acid
1314083|NCT00715312|trans fatty acid
1314084|NCT00715312|C-reactive protein
1314085|NCT00715286|epithelial ovarian cancer
1314086|NCT00715286|neoadjuvant chemotherapy
1314087|NCT00715286|randomized study
1314088|NCT00715273|Magnetic Resonance Imaging
1314089|NCT00715273|Atherosclerotic Plaque
1314090|NCT00715273|Lipid Lowering Therapy
1314091|NCT00715247|Myeloproliferative Disorders
1314092|NCT00715247|Hematological Malignancies
1314093|NCT00715247|Polycythemia Vera
1314094|NCT00715247|Essential Thrombocythemia
1314095|NCT00715247|Myelofibrosis
1314096|NCT00715247|Genetics
1314097|NCT00715247|Chronic Leukemia
1314098|NCT00715234|adolescent reminder/recall
1314099|NCT00715234|adolescent vaccines
1314100|NCT00715234|Tdap
1314101|NCT00715234|Meningococcal
1314102|NCT00715234|HPV
1314103|NCT00715234|Reminder cards
1314104|NCT00715234|Recall messages
1314105|NCT00715234|vaccine
1314106|NCT00715234|conjugate
1314107|NCT00715221|Diabetes
1314108|NCT00715195|Cognitive behavioral
1314109|NCT00715195|Long-term study
1314110|NCT00715195|Education
1314111|NCT00715182|Renal Cell Cancer
1314112|NCT00715156|allergy, peach, birch
1314113|NCT00715156|recombinants allergens diagnosis
1314114|NCT00715156|OAS
1314115|NCT00715156|LTP
1314116|NCT00715156|systemic reactions
1314117|NCT00715156|subjects with severe reaction to other fruits
1314118|NCT00715143|hip
1314119|NCT00715143|replacement
1314120|NCT00715143|ceramic
1314121|NCT00715143|orthopaedic
1314122|NCT00715143|joint
1314123|NCT00715143|degenerative
1314124|NCT00715143|non-inflammatory
1314125|NCT00715143|osteoarthritis
1314126|NCT00715143|avascular necrosis
1314127|NCT00715143|congenital hip dysplasia
1314128|NCT00715143|traumatic arthritis
1314129|NCT00715130|Energy
1314130|NCT00715130|Obesity
1314131|NCT00715130|Energy Balance
1314132|NCT00715130|Physical Activity
1314133|NCT00715130|Dietary Intake
1314134|NCT00715130|Overweight
1314135|NCT00715130|Sedentary
1314136|NCT00715130|Worksite
1314137|NCT00715130|Body Mass Index
1314138|NCT00715130|Weight Maintenance
1314139|NCT00715117|children
1314140|NCT00715117|pediatric
1314141|NCT00715117|Crohn's Disease
1314142|NCT00715117|naltrexone
1314143|NCT00715117|LDN
1314144|NCT00715117|IBD
1314145|NCT00715117|Inflammatory bowel disease
1314146|NCT00715091|NSAIDS
1314147|NCT00715091|ankylosing spondylitis
1314148|NCT00715091|SpA
1314149|NCT00715091|Spondyloarthritis
1314150|NCT00715091|radiographic changes
1314151|NCT00715078|prostate cancer
1314152|NCT00715078|prostate
1314153|NCT00715078|immune therapy
1314154|NCT00715078|immunotherapy
1314155|NCT00715078|vaccine
1314156|NCT00715078|dendritic cells
1314157|NCT00715078|antigen-presenting cells
1314158|NCT00715078|antigen presenting cells
1314159|NCT00715078|cancer vaccine
1314160|NCT00715078|prostate specific antigen (PSA)
1314161|NCT00715078|prostatic adenocarcinoma
1314162|NCT00715065|syncope
1314163|NCT00715065|faint
1314164|NCT00715065|blood
1314165|NCT00715065|blood injury phobia
1314166|NCT00715065|phobia
1314167|NCT00715052|neurologic deficiency due traumatic brain injury
1314168|NCT00715039|generalized anxiety disorder
1314169|NCT00715039|onset of efficacy
1314170|NCT00715039|Daily Assessment of Symptoms-Anxiety (DAS-A)
1314171|NCT00715039|Methods
1314172|NCT00715026|Arthritis
1314173|NCT00715026|Total Hip
1314174|NCT00715026|Ceramic
1314175|NCT00715026|Hip Replacement
1314176|NCT00715026|Total Hip Arthroplasty (THA)
1314177|NCT00715026|Joint Disease
1314178|NCT00715013|recurrent Glioblastoma
1314179|NCT00715000|Preterm babies hydration
1314180|NCT00715000|Oral rehydration solution
1314181|NCT00715000|Continuous gastric drip
1314182|NCT00715000|Fluid therapy
1314183|NCT00715000|Premature babies comfort
1314184|NCT00715000|Infant care
1314185|NCT00715000|Technical challenge for the nurses/doctors in charge
1314186|NCT00714987|ARDS
1314187|NCT00714987|Mechanical ventilation
1314188|NCT00714987|PEEP with low level
1314189|NCT00714987|PEEP with high level
1314190|NCT00714987|EVLW
1314191|NCT00714987|Picco® system
1314192|NCT00714987|PaO2/FiO2 ratio
1314193|NCT00714974|Neuromuscular blocking agents
1314194|NCT00714974|Bispectral analysis
1314195|NCT00714948|Bladder
1314196|NCT00714948|Urinary
1314197|NCT00714948|SORAFENIB
1314198|NCT00714948|CISPLATIN
1314199|NCT00714948|GEMCITABINE
1314200|NCT00714935|Risk Factors
1314201|NCT00714935|Risk Reduction Behavior
1314202|NCT00714935|Counseling
1314203|NCT00714909|Breast cancer
1314204|NCT00714909|Catheter related thrombosis
1314205|NCT00714909|Diagnosis
1314206|NCT00714909|Echography doppler
1314207|NCT00714909|Risk factors
1314208|NCT00714896|smoking cessation
1314209|NCT00714896|nicotine dependence
1314210|NCT00714896|stage-based intervention
1314211|NCT00714896|nicotine replacement medications
1314212|NCT00714896|counseling
1314213|NCT00714896|substance abuse treatment
1314214|NCT00714883|drug-eluting stents
1314215|NCT00714883|Percutaneous coronary intervention (PCI)
1314216|NCT00714870|BMI
1314217|NCT00714870|Quality of life
1314218|NCT00714857|ICU patients
1314219|NCT00714857|Dexmedetomidine
1314220|NCT00714857|Sedation
1314221|NCT00714857|Judged
1314222|NCT00714857|Attending
1314223|NCT00714857|Physician
1314224|NCT00714844|insulin therapy
1314225|NCT00714844|insulin detemir
1314226|NCT00714844|waist circumference
1314227|NCT00714831|Physical activity promotion
1314228|NCT00714831|Primary health care
1314229|NCT00714831|Adherence
1314230|NCT00714818|Schizophrenia
1314231|NCT00714818|Bipolar Disorder
1314232|NCT00714818|Schizoaffective disorder
1314233|NCT00714818|Genetic Counseling
1314234|NCT00714818|Risk perception
1314235|NCT00714818|Stigma
1314236|NCT00714818|Control
1314237|NCT00714818|Knowledge
1314238|NCT00714818|family members
1314239|NCT00714818|Sibling parent or child with schizophrenia
1314240|NCT00714818|Sibling parent or child with bipolar disorder
1314241|NCT00714818|Sibling parent or child with schizoaffective disorder
1314242|NCT00714805|Amyotrophic Lateral Sclerosis
1314243|NCT00714805|Gastric Motility
1314244|NCT00714805|Autonomic Nervous System
1314245|NCT00714805|Neurodegenerative Diseases
1314246|NCT00714805|Movement Disorders
1314247|NCT00714805|Gastrointestinal Motility
1314248|NCT00714779|Major depressive Disorder
1314249|NCT00714779|fluoxetine
1314250|NCT00714779|short-term psychodynamic psychotherapy
1314251|NCT00714779|PET
1314252|NCT00714753|stage I prostate cancer
1314253|NCT00714753|stage II prostate cancer
1314254|NCT00714753|adenocarcinoma of the prostate
1314255|NCT00714740|apnea, sleep, altitude, hypoxia
1314256|NCT00714727|migraine
1314257|NCT00714727|headache
1314258|NCT00714727|acupuncture
1314259|NCT00714714|acne
1314260|NCT00714714|irritation
1314261|NCT00714714|objective sensory methods
1314262|NCT00714688|Adult
1314263|NCT00714688|ADHD
1314264|NCT00714688|Concerta
1314265|NCT00714675|citrulline
1314266|NCT00714675|protein-energy malnutrition
1314267|NCT00714675|aged
1314268|NCT00714675|protein biosynthesis
1314269|NCT00714675|amino acid
1314270|NCT00714662|high flux hemodialysis
1314271|NCT00714649|Head and Neck Squamous Cell Carcinoma treated with surgery
1314272|NCT00714649|and/or radiotherapy
1314273|NCT00714636|Amyotrophic Lateral Sclerosis
1314274|NCT00714636|Cerebrospinal Fluid
1314275|NCT00714636|Neurodegenerative Disease
1314276|NCT00714636|Motor Neuron Disease
1314277|NCT00714636|Autonomic Nervous System
1314278|NCT00714636|Neurodegenerative Diseases
1314279|NCT00714636|Movement Disorders
1314280|NCT00714623|Coronary Artery Disease
1314281|NCT00714623|Coronary Restenosis
1314282|NCT00714623|Coronary Thrombosis
1314283|NCT00714623|Drug-Eluting Stents
1314284|NCT00714623|Angioplasty, Transluminal, Percutaneous Coronary
1314285|NCT00714610|Serum metal ion concentration
1314286|NCT00714597|Venous thrombosis
1314287|NCT00714597|Primary prevention
1314288|NCT00714584|Infusions, Intravenous
1314289|NCT00714584|Safety
1314290|NCT00714584|Pharmacokinetics
1314291|NCT00714584|Naltrexone
1314292|NCT00714584|Administration, Oral
1314293|NCT00714571|cognitive rehabilitation
1314294|NCT00714571|explicit memory training
1314295|NCT00714571|mild cognitive impairment
1314296|NCT00714571|Alzheimer's disease
1314297|NCT00714571|traumatic brain injury
1314298|NCT00714571|veterans
1314299|NCT00714558|Pharmacokinetics
1314300|NCT00714558|Administration, Oral
1314301|NCT00714558|Naltrexone
1314302|NCT00714558|Biological Availability
1314303|NCT00714558|Infusions, Intravenous
1314304|NCT00714558|Fentanyl
1314305|NCT00714558|Safety
1314306|NCT00714558|Naloxone
1314307|NCT00714545|Coronary Artery Disease
1314308|NCT00714545|Coronary Restenosis
1314309|NCT00714545|Brachytherapy
1314310|NCT00714532|smoking cessation
1314311|NCT00714532|Asian American
1314312|NCT00714532|Chinese American
1314313|NCT00714532|smoking reduction
1314314|NCT00714532|stage-based intervention
1314315|NCT00714532|expert system
1314316|NCT00714532|nicotine replacement
1314317|NCT00714532|counseling
1314318|NCT00714519|Xenaderm
1314319|NCT00714519|partial
1314320|NCT00714519|thickness
1314321|NCT00714519|wounds
1314322|NCT00714519|Nursing Homes
1314323|NCT00714506|obesity
1314324|NCT00714506|physical activity
1314325|NCT00714506|older adults
1314326|NCT00714506|functional disability
1314327|NCT00714493|rheumatoid arthritis
1314328|NCT00714493|remicade
1314329|NCT00714493|infliximab
1314330|NCT00714493|Centocor
1314331|NCT00714493|etanercept
1314332|NCT00714493|enbrel
1314333|NCT00714493|adalimumab
1314334|NCT00714493|humira
1314335|NCT00714493|restart
1314336|NCT00714493|swollen joints
1314337|NCT00714493|tender joints.
1314338|NCT00714480|Thymoglobulin
1314339|NCT00714480|Renal Transplant
1314340|NCT00714480|Kidney Transplant
1314341|NCT00714480|Immunosuppression
1314342|NCT00714480|Induction therapy
1314343|NCT00714467|smoking cessation
1314344|NCT00714467|Asian
1314345|NCT00714467|Chinese American
1314346|NCT00714467|family support
1314347|NCT00714467|social support
1314348|NCT00714467|stage-based intervention
1314349|NCT00714441|Diabetes Type 2
1314350|NCT00714441|Distress
1314351|NCT00714441|Problem Solving Therapy
1314352|NCT00714441|Computer Automated Self-Management (CASM)
1314353|NCT00714428|Traumatic Brain Injury
1314354|NCT00714428|Quality of Life
1314355|NCT00714402|UTI
1314356|NCT00714389|Urogynecology
1314357|NCT00714376|Prostate cancer
1314358|NCT00714376|High-risk prostate cancer
1314359|NCT00714376|Radical prostatectomy
1314360|NCT00714376|Early rising PSA
1314361|NCT00714376|Taxotere
1314362|NCT00714376|Docetaxel
1314363|NCT00714350|Information Display
1314364|NCT00714350|situational awareness
1314365|NCT00714350|Create intuitive visualization
1314366|NCT00714337|Formulation
1314367|NCT00714337|pharmacokinetics
1314368|NCT00714324|Nutrition
1314369|NCT00714324|Screening
1314370|NCT00714311|borderline personality disorder
1314371|NCT00714311|randomized controlled trial
1314372|NCT00714311|Transference-Focused Psychotherapy
1314373|NCT00714311|treatment by experienced community psychotherapists
1314374|NCT00714298|biological markers
1314375|NCT00714298|emergency service hospital
1314376|NCT00714298|heart fatty acid binding protein
1314377|NCT00714298|ischemia modified albumin
1314378|NCT00714285|Primary study
1314379|NCT00714285|immunogenicity
1314380|NCT00714285|safety
1314381|NCT00714259|Low Grade B Cell Malignancies
1314382|NCT00714259|nonmyeloablative transplant
1314383|NCT00714259|allogeneic
1314384|NCT00714246|advanced non small cell lung cancer
1314385|NCT00714233|Polycystic Ovary Syndrome
1314386|NCT00714233|Overweight Adolescent Girls
1314387|NCT00714233|Irregular Menstrual Cycles
1314388|NCT00714220|Amyotrophic Lateral Sclerosis
1314389|NCT00714220|Gastric Motility
1314390|NCT00714220|Autonomic Nervous System
1314391|NCT00714220|Neurodegenerative Diseases
1314392|NCT00714220|Movement Disorders
1314393|NCT00714220|Substrate Utilization
1314394|NCT00714207|adolescents
1314395|NCT00714207|smoking
1314396|NCT00714207|smoking cessation
1314397|NCT00714207|tobacco use
1314398|NCT00714194|sedation
1314399|NCT00714194|delirium
1314400|NCT00714194|sleep
1314401|NCT00714194|sedation withdrawal
1314402|NCT00714194|ICU patients
1314403|NCT00714181|unspecified adult solid tumor, protocol specific
1314404|NCT00714168|Weight Loss
1314405|NCT00714168|Weight Control
1314406|NCT00714155|Colpocleisis
1314407|NCT00714142|Renal blood flow
1314408|NCT00714142|PET imaging
1314409|NCT00714129|Steatosis
1314410|NCT00714129|Diabetes
1314411|NCT00714116|safety
1314412|NCT00714116|pharmacokinetics
1314413|NCT00714103|Leukemia
1314414|NCT00714103|Chronic Lymphocytic Leukemia
1314415|NCT00714103|CLL
1314416|NCT00714103|8-Chloro-Adenosine
1314417|NCT00714103|purine analogues
1314418|NCT00714103|Cancer
1314419|NCT00714090|repetitive Transcranial Magnetic Stimulation (rTMS)
1314420|NCT00714090|Major depressive disorders
1314421|NCT00714090|Depression
1314422|NCT00714090|Venlafaxine
1314423|NCT00714077|rectal cancer
1314424|NCT00714077|concurrent chemoradiotherapy
1314425|NCT00714077|adjuvant therapy
1314426|NCT00714077|phase III study
1314427|NCT00714038|Quality development project
1314428|NCT00714038|primary care nurses
1314429|NCT00714038|asthma
1314430|NCT00714038|patient compliance
1314431|NCT00714038|follow-up
1314432|NCT00714025|RAD001
1314433|NCT00714025|TCC
1314434|NCT00714025|Palliative treatment
1314435|NCT00714025|advance or metastatic TCC
1314436|NCT00714025|Failure after Platinum-based chemotherapy
1314437|NCT00714012|Display development
1314438|NCT00714012|Intuitive display use
1314439|NCT00714012|visualizations are intuitive
1314440|NCT00713999|Sexually transmitted infections
1314441|NCT00713999|Urogenital schistosomiasis
1314442|NCT00713999|Schistosoma haematobium
1314443|NCT00713999|Reproductive health
1314444|NCT00713999|Pelvic examination
1314445|NCT00713999|Ultrasonography
1314446|NCT00713999|Questionnaire
1314447|NCT00713999|Madagascar
1314448|NCT00713986|Pain
1314449|NCT00713986|Newborn Infant
1314450|NCT00713986|Analgesia
1314451|NCT00713960|Quality development project
1314452|NCT00713960|primary care nurses
1314453|NCT00713960|cardiovascular disease
1314454|NCT00713960|secondary prevention
1314455|NCT00713960|follow-up
1314456|NCT00713947|Gastric lesions induced by low dose of aspirin
1314457|NCT00713947|Helicobacter pylori
1314458|NCT00713934|Autologous Bone marrow stem cells
1314459|NCT00713934|Cirrhosis
1314460|NCT00713921|Female
1314461|NCT00713921|Diabetics
1314462|NCT00713921|Stroke
1314463|NCT00713908|Voiding dysfunction following TVT placement
1314464|NCT00713895|smoking cessation
1314465|NCT00713895|randomized trial
1314466|NCT00713895|Asian
1314467|NCT00713895|Chinese American
1314468|NCT00713895|stages of change
1314469|NCT00713882|Survivors
1314470|NCT00713882|Quality of Life
1314471|NCT00713869|Oocyte cryopreservation
1314472|NCT00713869|Slow freeze
1314473|NCT00713843|Neck Pain
1314474|NCT00713843|Manuel Therapy Utrecht
1314475|NCT00713843|Physiotherapy
1314476|NCT00713830|hyperglycemia, GLP-1
1314477|NCT00713817|Pain
1314478|NCT00713817|Peripheral Neuropathy
1314479|NCT00713804|Schizophrenia
1314480|NCT00713804|Bipolar Disorder
1314481|NCT00713804|Schizoaffective disorder
1314482|NCT00713804|Genetic Counseling
1314483|NCT00713804|Risk perception
1314484|NCT00713804|Stigma
1314485|NCT00713804|Control
1314486|NCT00713804|Knowledge
1314487|NCT00713791|Healthy Volunteers
1314488|NCT00713791|ZD4054
1314489|NCT00713778|Ovarian Cysts
1314490|NCT00713778|Electrocoagulation
1314491|NCT00713778|Ovarian Function Tests
1314492|NCT00713778|Laparoscopy
1314493|NCT00713765|Healthy volunteers
1314494|NCT00713752|HIV-negative
1314495|NCT00713739|kidney stones
1314496|NCT00713739|ureteral stones
1314497|NCT00713739|medical expulsion therapy
1314498|NCT00713726|Pain
1314499|NCT00713726|Analgesia
1314500|NCT00713726|Newborn Infant
1314501|NCT00713726|Opioids
1314502|NCT00713726|Side-effects
1314503|NCT00713726|Intensive care
1314504|NCT00713726|Postoperative
1314505|NCT00713713|Respiratory Distress Syndrome, Adult
1314506|NCT00713713|Tidal volume
1314507|NCT00713713|cardiac output
1314508|NCT00713713|Respiration, Artificial
1314509|NCT00713713|Protective ventilation
1314510|NCT00713700|patent ductus arteriosus
1314511|NCT00713700|PDA
1314512|NCT00713687|photodynamic therapy
1314513|NCT00713687|PDT
1314514|NCT00713687|gemcitabine
1314515|NCT00713687|oxaliplatin
1314516|NCT00713687|cholangiocarcinoma
1314517|NCT00713674|Methicillin resistance
1314518|NCT00713661|Colorectal Anastomosis
1314519|NCT00713661|Colorectal Resection
1314520|NCT00713661|Tachosil
1314521|NCT00713635|Congenital Heart Disease
1314522|NCT00713622|Partial
1314523|NCT00713622|onset
1314524|NCT00713622|seizures
1314525|NCT00713609|Acne
1314526|NCT00713609|Acne Vulgaris
1314527|NCT00713609|Pimples
1314528|NCT00713596|Nasal Surgery
1314529|NCT00713596|Septorhinoplasty
1314530|NCT00713596|fibrin glue
1314531|NCT00713596|fibrinogen
1314532|NCT00713596|Swelling
1314533|NCT00713596|fibrin
1314534|NCT00713596|tisseel
1314535|NCT00713583|Cocaine, levodopa, contingency management
1314536|NCT00713570|intellectual functioning
1314537|NCT00713570|memory,visual-spatial and perceptual functions
1314538|NCT00713570|cognitive abilities
1314539|NCT00713570|COMT
1314540|NCT00713570|BDNF
1314541|NCT00713570|neuron biological systemic pathway candidate genes
1314542|NCT00713570|Chinese
1314543|NCT00713570|Taiwan
1314544|NCT00713570|Healthy subjects
1314545|NCT00713557|coronary angioplasty
1314546|NCT00713544|Rheumatoid Arthritis
1314547|NCT00713544|RA
1314548|NCT00713544|AZD5672
1314549|NCT00713531|HIV-negative
1314550|NCT00713531|male and female clients
1314551|NCT00713531|ages 18-50 years
1314552|NCT00713531|seeking HIV counseling
1314553|NCT00713531|testing at TRCARC
1314554|NCT00713518|AMD Age Related Macular Degeneration Choroidal Neovascularization Monet
1314555|NCT00713505|psychosocial effects of cancer and its treatment
1314556|NCT00713505|long-term effects secondary to cancer therapy in children
1314557|NCT00713505|cancer survivor
1314558|NCT00713505|cognitive/functional effects
1314559|NCT00713505|childhood acute lymphoblastic leukemia
1314560|NCT00713505|childhood acute myeloid leukemia in remission
1314561|NCT00713505|childhood anaplastic large cell lymphoma
1314562|NCT00713505|childhood large cell lymphoma
1314563|NCT00713505|childhood lymphoblastic lymphoma
1314564|NCT00713505|childhood small noncleaved cell lymphoma
1314565|NCT00713505|childhood nasal type extranodal NK/T-cell lymphoma
1314566|NCT00713505|childhood grade III lymphomatoid granulomatosis
1314567|NCT00713505|childhood chronic myelogenous leukemia
1314568|NCT00713492|Alcohol
1314569|NCT00713492|Self -Administration
1314570|NCT00713492|Intoxication
1314571|NCT00713492|Healthy Volunteer
1314572|NCT00713492|HV
1314573|NCT00713479|methamphetamine
1314574|NCT00713479|varenicline
1314575|NCT00713479|Chantix
1314576|NCT00713479|stimulant
1314577|NCT00713479|crystal meth
1314578|NCT00713466|CLIPP cases
1314579|NCT00713466|Pediatric clerkship
1314580|NCT00713466|Standardizing
1314581|NCT00713466|Students' exposure
1314582|NCT00713466|Essential
1314583|NCT00713466|Enhancing
1314584|NCT00713466|Experience
1314585|NCT00713453|Pompe disease
1314586|NCT00713453|muscle
1314587|NCT00713453|enzyme replacement therapy
1314588|NCT00713440|Incretin Effect
1314589|NCT00713440|Steroids
1314590|NCT00713440|Glucagon-Like Peptide 1
1314591|NCT00713440|Gastric Inhibitory Peptide
1314592|NCT00713440|Glucose-dependent Insulinotropic Polypeptide
1314593|NCT00713440|Insulin
1314594|NCT00713440|C-peptide
1314595|NCT00713440|Glucagon
1314596|NCT00713427|Biliary
1314597|NCT00713427|Strictures
1314598|NCT00713427|Malignant
1314599|NCT00713427|Neoplasm
1314600|NCT00713427|Palliation
1314601|NCT00713414|Spasmodic Dysphonia
1314602|NCT00713414|Dystonia
1314603|NCT00713414|Basal Ganglia
1314604|NCT00713414|PET Imaging
1314605|NCT00713414|fMRI
1314606|NCT00713414|Voice Disorder
1314607|NCT00713414|Healthy Volunteer
1314608|NCT00713414|HV
1314609|NCT00713375|Autonomic Nervous System
1314610|NCT00713375|Subarachnoid Hemorrhage
1314611|NCT00713375|Intracranial Hemorrhages
1314612|NCT00713375|Cerebral Hemorrhage
1314613|NCT00713362|Aspiration, chest tube, pneumothorax, thoracoscopic surgery
1314614|NCT00713349|White
1314615|NCT00713349|Petrolatum
1314616|NCT00713349|Xenaderm
1314617|NCT00713349|Vehicle
1314618|NCT00713349|Partial thickness wounds
1314619|NCT00713349|Healing
1314620|NCT00713349|Cryo-surgery
1314621|NCT00713336|ZD4054
1314622|NCT00713336|Healthy Volunteers
1314623|NCT00713336|QT interval
1314624|NCT00713323|Pain
1314625|NCT00713323|Peripheral Neuropathy
1314626|NCT00713297|medication errors
1314627|NCT00713297|computerized physician order entry
1314628|NCT00713297|pharmaceutical care
1314629|NCT00713297|chemotherapeutic agents
1314630|NCT00713297|reengineering
1314631|NCT00713284|Kidney transplantation
1314632|NCT00713284|Sirolimus
1314633|NCT00713284|Immunosuppression
1314634|NCT00713284|Tacrolimus
1314635|NCT00713271|Healthy male
1314636|NCT00713271|tolerability
1314637|NCT00713271|safety
1314638|NCT00713271|inhalation
1314639|NCT00713258|Postmenopausal women
1314640|NCT00713258|Back pain
1314641|NCT00713258|Osteoporosis related fracture
1314642|NCT00713245|Pompe disease
1314643|NCT00713245|late onset
1314644|NCT00713232|naming test
1314645|NCT00713219|IMRT
1314646|NCT00713219|cetuximab
1314647|NCT00713219|docetaxel
1314648|NCT00713206|Dental implants, maxilla, sinus lift, augmentation
1314649|NCT00713193|Idiopathic TTP
1314650|NCT00713193|Treatment
1314651|NCT00713193|Exacerbation
1314652|NCT00713193|Relapse
1314653|NCT00713193|Plasma Exchange
1314654|NCT00713167|Grape Seed Extract
1314655|NCT00713167|Hyperlipidemia
1314656|NCT00713154|Radiotherapy
1314657|NCT00713154|induced
1314658|NCT00713128|nausea vomiting colorectal cancer
1314659|NCT00713115|laparoscopy, needlescopy, adrenalectomy
1314660|NCT00713102|in-flight emergency
1314661|NCT00713089|Eczema
1314662|NCT00713089|Asthma
1314663|NCT00713089|Allergic rhinitis
1314664|NCT00713089|Singapore
1314665|NCT00713089|Indonesia
1314666|NCT00713089|Gastrointestinal Flora
1314667|NCT00713076|multi-purpose solution
1314668|NCT00713076|contact lens wearers
1314669|NCT00713076|Contact lense wearers
1314670|NCT00713063|smoking cessation
1314671|NCT00713063|exercise
1314672|NCT00713063|physical activity
1314673|NCT00713063|health education
1314674|NCT00713050|stroke
1314675|NCT00713050|aphasia
1314676|NCT00713050|imitation
1314677|NCT00713050|mirror neuron
1314678|NCT00713037|fluoromisonidazole
1314679|NCT00713037|PET scan
1314680|NCT00713037|Hypoxia-PET
1314681|NCT00713037|IMPT
1314682|NCT00713024|Pain; Functional neuroimaging; Neuropathy; Thermal sensation
1314683|NCT00713011|Adalat XL
1314684|NCT00713011|Diltiazem
1314685|NCT00713011|Tiazac XC
1314686|NCT00713011|Proteinuria
1314687|NCT00712998|radiation injuries
1314688|NCT00712998|free radicals
1314689|NCT00712998|reactive oxygen species
1314690|NCT00712998|radiation injury from X-ray computed tomography
1314691|NCT00712998|free radical production
1314692|NCT00712998|blood reactive oxygen species level
1314693|NCT00712985|Breast cancer
1314694|NCT00712985|aromatase inhibitors
1314695|NCT00712972|knee injection
1314696|NCT00712972|parapatellar
1314697|NCT00712959|Pertussis
1314698|NCT00712959|Tetanus
1314699|NCT00712959|Diphtheria
1314700|NCT00712959|Acellular pertussis
1314701|NCT00712959|ADACEL®,
1314702|NCT00712959|Tdap vaccine
1314703|NCT00712933|SLE
1314704|NCT00712933|Belimumab
1314705|NCT00712933|Antibodies
1314706|NCT00712933|Systemic Lupus Erythematosus
1314707|NCT00712933|Lupus
1314708|NCT00712933|Autoimmune Diseases
1314709|NCT00712907|vitamin C
1314710|NCT00712907|retinal blood flow
1314711|NCT00712907|intraocular pressure
1314712|NCT00712907|retinal vessel diameter
1314713|NCT00712894|Acute myocardial infarction
1314714|NCT00712894|Percutaneous coronary intervention
1314715|NCT00712894|No-reflow phenomenon
1314716|NCT00712894|Vasodilator agents
1314717|NCT00712855|Liver Cancer
1314718|NCT00712842|Diabetes
1314719|NCT00712842|ocular blood flow
1314720|NCT00712829|Prostate cancer
1314721|NCT00712829|Imaging
1314722|NCT00712816|osteoarthritis
1314723|NCT00712816|total knee arthroplasty
1314724|NCT00712816|cryotherapy
1314725|NCT00712790|First line treatment for Hepatocellular Carcinoma
1314726|NCT00712777|Brimonidine
1314727|NCT00712777|alpha 2 receptor polymorphism
1314728|NCT00712777|Intraocular Pressure
1314729|NCT00712764|Adenosine
1314730|NCT00712764|Choroidal blood flow
1314731|NCT00712764|Suction cup
1314732|NCT00712751|Rectum
1314733|NCT00712751|Quality of Life
1314734|NCT00712751|Sexual Health
1314735|NCT00712751|08-073
1314736|NCT00712738|Nifedipine
1314737|NCT00712738|Thalassemia
1314738|NCT00712738|Hemochromatosis
1314739|NCT00712738|Iron Overload
1314740|NCT00712738|Iron Excretion
1314741|NCT00712712|bone metastases
1314742|NCT00712712|unspecified adult solid tumor, protocol specific
1314743|NCT00712712|pain
1314744|NCT00712699|Preschool
1314745|NCT00712699|Children
1314746|NCT00712699|ADHD
1314747|NCT00712699|Medication
1314748|NCT00712699|Controlled Study
1314749|NCT00712699|Placebo
1314750|NCT00712699|Mixed Amphetamine Salts
1314751|NCT00712673|hyperglycemia, GLP-1, metformin
1314752|NCT00712660|prevention
1314753|NCT00712660|relapse
1314754|NCT00712660|schizophrenia
1314755|NCT00712634|cytomegalovirus infection
1314756|NCT00712621|Genetics Home Reference related topics
1314757|NCT00712621|breast cancer
1314758|NCT00712621|breast cancer related to depression
1314759|NCT00712621|Condition
1314760|NCT00712621|Stage I-IV Carcinoma of Breast
1314761|NCT00712608|Term
1314762|NCT00712608|Infant
1314763|NCT00712608|Formula
1314764|NCT00712595|Uterine fibroids
1314765|NCT00712595|mifepristone
1314766|NCT00712595|antiprogestins
1314767|NCT00712582|Non-Hodgkin
1314768|NCT00712582|Lymphoma
1314769|NCT00712582|Rituximab
1314770|NCT00712582|Cyclophosphamide
1314771|NCT00712582|Doxorubicin
1314772|NCT00712582|Vincristine
1314773|NCT00712582|ifosfamide
1314774|NCT00712582|etoposide
1314775|NCT00712582|carboplatin
1314776|NCT00712582|stem cell transplant
1314777|NCT00712582|08-026
1314778|NCT00712569|Communication
1314779|NCT00712569|Internet
1314780|NCT00712569|Physician
1314781|NCT00712569|Patient
1314782|NCT00712569|08-079
1314783|NCT00712556|stage III adult Burkitt lymphoma
1314784|NCT00712556|stage III adult diffuse large cell lymphoma
1314785|NCT00712556|stage III adult diffuse mixed cell lymphoma
1314786|NCT00712556|stage III adult diffuse small cleaved cell lymphoma
1314787|NCT00712556|stage III adult immunoblastic large cell lymphoma
1314788|NCT00712556|stage III adult lymphoblastic lymphoma
1314789|NCT00712556|stage III grade 1 follicular lymphoma
1314790|NCT00712556|stage III grade 2 follicular lymphoma
1314791|NCT00712556|stage III grade 3 follicular lymphoma
1314792|NCT00712556|stage III mantle cell lymphoma
1314793|NCT00712556|stage III marginal zone lymphoma
1314794|NCT00712556|stage III small lymphocytic lymphoma
1314795|NCT00712556|stage IV adult Burkitt lymphoma
1314796|NCT00712556|stage IV adult diffuse large cell lymphoma
1314797|NCT00712556|stage IV adult diffuse mixed cell lymphoma
1314798|NCT00712556|stage IV adult diffuse small cleaved cell lymphoma
1314799|NCT00712556|stage IV adult immunoblastic large cell lymphoma
1314800|NCT00712556|stage IV adult lymphoblastic lymphoma
1314801|NCT00712556|stage IV grade 1 follicular lymphoma
1314802|NCT00712556|stage IV grade 2 follicular lymphoma
1314803|NCT00712556|stage IV grade 3 follicular lymphoma
1314804|NCT00712556|stage IV mantle cell lymphoma
1314805|NCT00712556|stage IV marginal zone lymphoma
1314806|NCT00712556|stage IV small lymphocytic lymphoma
1314807|NCT00712556|recurrent adult Burkitt lymphoma
1314808|NCT00712556|recurrent adult diffuse large cell lymphoma
1314809|NCT00712556|recurrent adult diffuse mixed cell lymphoma
1314810|NCT00712556|recurrent adult diffuse small cleaved cell lymphoma
1314811|NCT00712556|recurrent adult immunoblastic large cell lymphoma
1314812|NCT00712556|recurrent adult lymphoblastic lymphoma
1314813|NCT00712556|recurrent childhood large cell lymphoma
1314814|NCT00712556|recurrent childhood lymphoblastic lymphoma
1314815|NCT00712556|recurrent childhood small noncleaved cell lymphoma
1314816|NCT00712556|recurrent cutaneous T-cell non-Hodgkin lymphoma
1314817|NCT00712556|recurrent grade 1 follicular lymphoma
1314818|NCT00712556|recurrent grade 2 follicular lymphoma
1314819|NCT00712556|recurrent grade 3 follicular lymphoma
1314820|NCT00712556|recurrent mantle cell lymphoma
1314821|NCT00712556|recurrent marginal zone lymphoma
1314822|NCT00712556|recurrent small lymphocytic lymphoma
1314823|NCT00712556|recurrent mycosis fungoides/Sezary syndrome
1314824|NCT00712556|nodal marginal zone B-cell lymphoma
1314825|NCT00712556|splenic marginal zone lymphoma
1314826|NCT00712556|NC stage II adult immunoblastic large cell lymphoma
1314827|NCT00712556|NC stage II adult lymphoblastic lymphoma
1314828|NCT00712556|NC stage II grade 1 follicular lymphoma
1314829|NCT00712556|NC stage II grade 2 follicular lymphoma
1314830|NCT00712556|NC stage II grade 3 follicular lymphoma
1314831|NCT00712556|NC stage II mantle cell lymphoma
1314832|NCT00712556|NC stage II marginal zone lymphoma
1314833|NCT00712556|NC stage II small lymphocytic lymphoma
1314834|NCT00712543|constipation
1314835|NCT00712543|laxative
1314836|NCT00712543|lactulose
1314837|NCT00712543|Kristalose®
1314838|NCT00712530|HIV
1314839|NCT00712530|Vaccine
1314840|NCT00712530|Immune Therapy
1314841|NCT00712530|DermaVir
1314842|NCT00712517|postoperative pain
1314843|NCT00712517|Piritramid
1314844|NCT00712517|propofol
1314845|NCT00712517|sevoflurane
1314846|NCT00712517|varicose vein
1314847|NCT00712517|Anesthesia
1314848|NCT00712504|advanced solid tumors, non small cell lung cancer, pulmonary neoplasms, sunitinib (SUTENT), docetaxel (Taxotere), Angiogenesis Inhibitors
1314849|NCT00712491|wet AMD
1314850|NCT00712491|CNV
1314851|NCT00712465|Atrial fibrillation
1314852|NCT00712465|interaction
1314853|NCT00712465|pharmacokinetic
1314854|NCT00712452|fertility
1314855|NCT00712452|chemotherapy
1314856|NCT00712439|DPN,
1314857|NCT00712439|Diabetic
1314858|NCT00712439|Peripheral
1314859|NCT00712439|Neuropathy
1314860|NCT00712439|Painful
1314861|NCT00712426|Huntington's disease
1314862|NCT00712426|Creatine
1314863|NCT00712426|Mitochondrial Dysfunction
1314864|NCT00712426|Total Functional Capacity
1314865|NCT00712426|UHDRS
1314866|NCT00712413|Helicobacter pylori infection
1314867|NCT00712413|Quadruple therapy
1314868|NCT00712413|Safety
1314869|NCT00712413|Efficacy
1314870|NCT00712413|Tolerability
1314871|NCT00712413|BID dosing
1314872|NCT00712400|Latanoprost
1314873|NCT00712400|Choroidal Blood Flow
1314874|NCT00712400|Intraocular Pressure
1314875|NCT00712374|Malaria
1314876|NCT00712374|All causes mortality
1314877|NCT00712374|Cost effectiveness
1314878|NCT00712361|Invasive
1314879|NCT00712361|Non-Invasive
1314880|NCT00712361|Peripheral blood parameters
1314881|NCT00712361|Finger mounted device
1314882|NCT00712361|Blood tissue
1314883|NCT00712361|Tissue color distribution
1314884|NCT00712361|Accuracy
1314885|NCT00712361|Tissue pigmentation
1314886|NCT00712361|pH
1314887|NCT00712361|Hemoglobin
1314888|NCT00712361|Hematocrit
1314889|NCT00712361|SpO2
1314890|NCT00712361|Blood pressure
1314891|NCT00712361|Pulse
1314892|NCT00712361|CO2
1314893|NCT00712348|Gaucher disease
1314894|NCT00712348|imiglucerase
1314895|NCT00712348|glucocerebrosidase
1314896|NCT00712348|enzyme replacement therapy
1314897|NCT00712348|lysosomal storage disorder
1314898|NCT00712335|asthmatics
1314899|NCT00712335|smokers
1314900|NCT00712335|inhaled corticosteroids
1314901|NCT00712335|leukotriene receptor antagonists
1314902|NCT00712322|Pediatric, Children, Urodynamics, Oral Suspension, Overactive bladder, Dose-finding, Neurogenic Detrusor Overactivity, Meningomyelocele, Spinal cord injury
1314903|NCT00712309|atherosclerotic
1314904|NCT00712309|lesions
1314905|NCT00712296|Asthma
1314906|NCT00712296|alternative medicine
1314907|NCT00712296|complementary medicine
1314908|NCT00712296|herbal therapy
1314909|NCT00712283|fitness to drive
1314910|NCT00712283|operate machines
1314911|NCT00712283|To determine the fitness to drive and operate machines.
1314912|NCT00712270|Schizophrenia
1314913|NCT00712270|Antipsychotic drug treatment response
1314914|NCT00712270|Risperidone
1314915|NCT00712270|Aripiprazole
1314916|NCT00712270|Fallypride
1314917|NCT00712270|Positron emission tomography
1314918|NCT00712270|Magnetic Resonance Imaging
1314919|NCT00712270|Dopamine D2 Receptors
1314920|NCT00712257|treatment of superficial femoral artery instent restenosis
1314921|NCT00712244|Discovisc
1314922|NCT00712244|Ophthalmic Viscosurgical Device
1314923|NCT00712231|pseudophakic
1314924|NCT00712231|anterior chamber depth
1314925|NCT00712231|Pentacam
1314926|NCT00712218|Ovarian cancer, FIGO stage IIB-IV
1314927|NCT00712205|Asthma
1314928|NCT00712205|Vitamin D
1314929|NCT00712192|coronary artery bypass grafting
1314930|NCT00712192|endoscopic vein harvest
1314931|NCT00712192|saphenous vein
1314932|NCT00712192|endothelial cells
1314933|NCT00712192|eNOS
1314934|NCT00712192|ET-1
1314935|NCT00712179|Stroke
1314936|NCT00712179|walking
1314937|NCT00712179|Treadmill
1314938|NCT00712179|body weight support system
1314939|NCT00712166|cystic fibrosis
1314940|NCT00712166|pseudomonas aeruginosa
1314941|NCT00712166|lung infection
1314942|NCT00712166|CFQ-R
1314943|NCT00712166|inhaled antibiotic
1314944|NCT00712166|aztreonam lysine
1314945|NCT00712153|multislice computed tomography
1314946|NCT00712153|coronary artery bypass grafting
1314947|NCT00712153|Patients
1314948|NCT00712153|underwent
1314949|NCT00712153|surgeries
1314950|NCT00712140|stage IA breast cancer
1314951|NCT00712140|stage IB breast cancer
1314952|NCT00712140|stage II breast cancer
1314953|NCT00712140|stage IIIA breast cancer
1314954|NCT00712140|HER2-positive breast cancer
1314955|NCT00712127|Body Fat
1314956|NCT00712127|Exercise
1314957|NCT00712127|Metabolic syndrome
1314958|NCT00712127|Obesity
1314959|NCT00712127|Nutrition
1314960|NCT00712127|Physical Activity
1314961|NCT00712127|Weight Loss
1314962|NCT00712114|phase I
1314963|NCT00712114|safety
1314964|NCT00712114|tolerance
1314965|NCT00712114|rheumatoid arthritis
1314966|NCT00712114|pharmacokinetics
1314967|NCT00712114|methotrexate
1314968|NCT00712114|anti-inflammatory
1314969|NCT00712101|infarction
1314970|NCT00712101|intervention
1314971|NCT00712101|stent
1314972|NCT00712101|abciximab
1314973|NCT00712101|platelets
1314974|NCT00712088|HIV
1314975|NCT00712088|Unsafe Sex
1314976|NCT00712088|High Risk Sex
1314977|NCT00712088|HIV Prevention
1314978|NCT00712088|African-American
1314979|NCT00712088|gay
1314980|NCT00712088|bisexual
1314981|NCT00712088|intervention trial
1314982|NCT00712075|Cognitive Behavioral Therapy
1314983|NCT00712075|Social Skills Training
1314984|NCT00712075|Experience Sampling Method
1314985|NCT00712075|Computer-assisted therapy
1314986|NCT00712075|schizophrenia
1314987|NCT00712062|PCNSL
1314988|NCT00712062|Pemetrexed
1314989|NCT00712062|Alimta
1314990|NCT00712062|Recurrent
1314991|NCT00712062|Progressive
1314992|NCT00712049|intima-media-thickness
1314993|NCT00712049|dyslipidemia
1314994|NCT00712049|progression of atherosclerosis
1314995|NCT00712049|peripheral artery disease
1314996|NCT00712049|major cardiovascular events
1314997|NCT00712036|Heroin dependence
1314998|NCT00712036|Interim Methadone Treatment
1314999|NCT00712036|Counseling
1315000|NCT00712023|Hypothermia
1315001|NCT00712023|Vascular surgery
1315002|NCT00712023|Forced-air warming mattress
1315003|NCT00712023|Circulating-water mattress
1315004|NCT00712010|Glucose
1315005|NCT00712010|Insulin
1315006|NCT00711997|H19 gene, plasmid, diphtheria toxin, pancreatic cancer
1315007|NCT00711984|renal artery stenosis
1315008|NCT00711984|stent
1315009|NCT00711984|comparison of treatments
1315010|NCT00711984|progression
1315011|NCT00711984|atherosclerosis
1315012|NCT00711984|peripheral artery disease
1315013|NCT00711984|major cardiovascular events
1315014|NCT00711958|Chemotherapy associated anemia in cancer patients
1315015|NCT00711945|Crohn's disease
1315016|NCT00711945|Relapse
1315017|NCT00711945|outcomes
1315018|NCT00711945|growth
1315019|NCT00711932|Ovarian Cancer
1315020|NCT00711932|TRA-8
1315021|NCT00711932|Monoclonal Antibody
1315022|NCT00711932|Tissue Slice Technology
1315023|NCT00711906|Malaria
1315024|NCT00711906|Pregnancy
1315025|NCT00711906|HIV
1315026|NCT00711906|Intermittent Preventive Treatment
1315027|NCT00711906|Safety
1315028|NCT00711906|Efficacy
1315029|NCT00711880|Pain
1315030|NCT00711880|Peripheral Neuropathy
1315031|NCT00711854|Staphylococcal infection
1315032|NCT00711841|HELLP syndrome
1315033|NCT00711841|dexamethasone
1315034|NCT00711841|postpartum period
1315035|NCT00711841|class I HELLP syndrome
1315036|NCT00711815|Women of the state of Alabama
1315037|NCT00711815|CIN 1
1315038|NCT00711815|negative biopsy
1315039|NCT00711815|normal colposcopy
1315040|NCT00711815|HPV
1315041|NCT00711802|Complicated
1315042|NCT00711802|Skin
1315043|NCT00711802|Structure
1315044|NCT00711789|Acute renal failure
1315045|NCT00711789|Septic shock
1315046|NCT00711789|angiotensin II
1315047|NCT00711789|neutrophil gelatinase associated lipocalin (NGAL)
1315048|NCT00711789|cystatin C
1315049|NCT00711776|Aciclovir cream 5%
1315050|NCT00711776|Volunteer
1315051|NCT00711776|Japanese
1315052|NCT00711776|Male
1315053|NCT00711776|Bioequivalence
1315054|NCT00711763|Preterm Infant
1315055|NCT00711763|Parenteral nutrition cycling
1315056|NCT00711763|TPN cycling
1315057|NCT00711763|Hypercalcuria
1315058|NCT00711750|underwent
1315059|NCT00711750|specific
1315060|NCT00711750|creation
1315061|NCT00711750|hospital
1315062|NCT00711750|November 2003
1315063|NCT00711750|October 2005
1315064|NCT00711737|metabolic parameters
1315065|NCT00711737|escitalopram
1315066|NCT00711737|metabolic syndrome
1315067|NCT00711737|antidepressant
1315068|NCT00711724|Attention Deficit Hyperactivity Disorder (ADHD)
1315069|NCT00711724|Adolescent
1315070|NCT00711711|Physical Therapy - Therapeutics - Edema
1315071|NCT00711711|Arthroplasty replacement knee
1315072|NCT00711711|Treatment outcome
1315073|NCT00711685|Topical vancomycin
1315074|NCT00711685|mediastinitis
1315075|NCT00711685|coronary
1315076|NCT00711685|artery
1315077|NCT00711685|bypass
1315078|NCT00711685|graft
1315079|NCT00711685|Patients
1315080|NCT00711672|Personal Communication
1315081|NCT00711672|Doctor Patient Relations
1315082|NCT00711672|Narrative Medicine
1315083|NCT00711659|Physical exam
1315084|NCT00711659|Pediatric clerkship
1315085|NCT00711659|Medical students
1315086|NCT00711646|Spasticity
1315087|NCT00711646|Multiple Sclerosis
1315088|NCT00711633|Premature birth,
1315089|NCT00711633|infant,
1315090|NCT00711633|infant formula,
1315091|NCT00711633|bacterial colonization,
1315092|NCT00711633|Bifidobacterium,
1315093|NCT00711633|calprotectin
1315094|NCT00711620|sepsis
1315095|NCT00711620|Immunotherapy
1315096|NCT00711620|Thymosin
1315097|NCT00711607|pharmacokinetics (PK)
1315098|NCT00711607|combined oral contraceptive
1315099|NCT00711607|nomegestrol acetate
1315100|NCT00711607|estradiol
1315101|NCT00711607|NOMAC
1315102|NCT00711607|E2
1315103|NCT00711607|NOMAC-E2
1315104|NCT00711607|pharmacokinetics
1315105|NCT00711581|Cholecystectomy
1315106|NCT00711581|Cholecystectomy, Laparoscopic
1315107|NCT00711581|Laparoscopy
1315108|NCT00711568|depression
1315109|NCT00711568|magnetic stimulation
1315110|NCT00711555|nausea
1315111|NCT00711555|vomiting
1315112|NCT00711555|multiple days
1315113|NCT00711555|chemotherapy
1315114|NCT00711555|serotonin receptor antagonist
1315115|NCT00711555|quality of life
1315116|NCT00711555|therapy
1315117|NCT00711555|corticosteroids
1315118|NCT00711555|aprepitant
1315119|NCT00711555|rescue therapy
1315120|NCT00711542|intracoronary progenitor cell therapy
1315121|NCT00711542|NSTEMI
1315122|NCT00711542|coronary flow reserve
1315123|NCT00711542|randomized doubleblind Placebo-controlled trial
1315124|NCT00711529|hot flashes
1315125|NCT00711529|breast cancer
1315126|NCT00711529|Hypnotherapy
1315127|NCT00711529|Quality of Life
1315128|NCT00711529|Gabapentin
1315129|NCT00711503|endogenous insulin production
1315130|NCT00711503|C-peptide level
1315131|NCT00711503|insulin requirement
1315132|NCT00711490|Diabetic Macular Edema
1315133|NCT00711490|Diabetic Retinopathy
1315134|NCT00711490|Rapamycin
1315135|NCT00711490|Sirolimus
1315136|NCT00711490|Diabetes
1315137|NCT00711477|obesity
1315138|NCT00711477|overweight
1315139|NCT00711477|magnetic resonance imaging
1315140|NCT00711477|naltrexone
1315141|NCT00711477|bupropion
1315142|NCT00711464|cognition, pharmacology, memory, attention
1315143|NCT00711451|systemic vascular resistance
1315144|NCT00711451|pregnancy
1315145|NCT00711451|scheduled cesarean delivery
1315146|NCT00711451|syncytiotrophoblast apoptosis
1315147|NCT00711451|continuous wave Doppler
1315148|NCT00711438|Breathlessness
1315149|NCT00711438|Dyspnoea
1315150|NCT00711438|Dyspnea
1315151|NCT00711438|Palliative care
1315152|NCT00711438|RCT
1315153|NCT00711438|Randomised controlled trial
1315154|NCT00711438|COPD
1315155|NCT00711438|Chronic respiratory disease
1315156|NCT00711425|Jaw, Edentulous, Partially (posterior mandible)
1315157|NCT00711412|adenocarcinoma of the esophagus
1315158|NCT00711412|stage I esophageal cancer
1315159|NCT00711412|stage II esophageal cancer
1315160|NCT00711412|stage III esophageal cancer
1315161|NCT00711412|stage IV esophageal cancer
1315162|NCT00711399|Respiratory sounds
1315163|NCT00711399|Wheeze
1315164|NCT00711399|Cough
1315165|NCT00711386|GSK706769,
1315166|NCT00711386|CCR5
1315167|NCT00711386|Healthy volunteers
1315168|NCT00711373|VCA
1315169|NCT00711373|composite tissue allotransplantation
1315170|NCT00711373|amputation
1315171|NCT00711373|Hand
1315172|NCT00711360|heart failure
1315173|NCT00711360|implantable cardioverter-defibrillator
1315174|NCT00711360|intrathoracic impedance
1315175|NCT00711360|cardiac resynchronization therapy
1315176|NCT00711360|home monitoring
1315177|NCT00711347|Discovisc
1315178|NCT00711347|Ophthalmic Visco Surgical Device
1315179|NCT00711321|Alzheimer
1315180|NCT00711321|Morbus Alzheimer
1315181|NCT00711321|Vaccine
1315182|NCT00711321|Alzheimer Vaccine
1315183|NCT00711321|A-beta immunotherapy
1315184|NCT00711308|pulmonary embolism
1315185|NCT00711308|low molecular weight heparin
1315186|NCT00711308|vitamin K antagonist
1315187|NCT00711308|Longterm
1315188|NCT00711295|Influenza (Pandemic)
1315189|NCT00711282|Replacement of non-restorable single tooth/teeth
1315190|NCT00711256|Sunscreen
1315191|NCT00711256|Application
1315192|NCT00711256|Vitamin D
1315193|NCT00711256|Sun protection factor
1315194|NCT00711256|Clothing
1315195|NCT00711243|unspecified adult solid tumor, protocol specific
1315196|NCT00711243|adenocarcinoma of the stomach
1315197|NCT00711243|stage III gastric cancer
1315198|NCT00711243|stage IV gastric cancer
1315199|NCT00711230|HIV
1315200|NCT00711230|Vaccine
1315201|NCT00711230|Immune Therapy
1315202|NCT00711230|DermaVir
1315203|NCT00711204|Severe
1315204|NCT00711204|Alzheimer's Disease
1315205|NCT00711191|pancreas cancer; cancer of the pancreas; gemcitabine; chemotherapy; monoclonal antibody; immunotherapy; CD40
1315206|NCT00711165|Asthma
1315207|NCT00711165|Nitric Oxide
1315208|NCT00711165|Exhaled Breath Condensate
1315209|NCT00711165|Methacholine Challenge
1315210|NCT00711152|diabetes
1315211|NCT00711152|protocol-driven structured care
1315212|NCT00711152|web-based
1315213|NCT00711152|joint asia diabetes evaluation
1315214|NCT00711139|Alzheimer
1315215|NCT00711139|Morbus Alzheimer
1315216|NCT00711139|Alzheimer Vaccine
1315217|NCT00711139|Vaccine
1315218|NCT00711139|AD
1315219|NCT00711139|A-beta immunotherapy
1315220|NCT00711126|intravenous,
1315221|NCT00711126|tolerability
1315222|NCT00711126|pharmacokinetics,
1315223|NCT00711126|oral,
1315224|NCT00711126|pharmacodynamics,
1315225|NCT00711126|safety,
1315226|NCT00711126|GW642444,
1315227|NCT00711126|inhaled,
1315228|NCT00711113|Jaw, Edentulous, Partially (posterior maxilla)
1315229|NCT00711100|Substitution for cigarettes
1315230|NCT00711100|Oral tobacco products
1315231|NCT00711087|Spinal Cord Injury
1315232|NCT00711087|Bladder
1315233|NCT00711087|Botulinum toxin (BOTOX-A
1315234|NCT00711087|Detrusor External Sphincter Dyssynergia
1315235|NCT00711074|pharmacokinetics
1315236|NCT00711074|mass balance
1315237|NCT00711074|radiolabel
1315238|NCT00711074|AZD5672
1315239|NCT00711048|GERD
1315240|NCT00711048|healthy volunteer
1315241|NCT00711048|esophagus
1315242|NCT00711048|pain
1315243|NCT00711035|CMV
1315244|NCT00711035|Adenovirus
1315245|NCT00711035|EBV
1315246|NCT00711035|non-myeloablative transplants
1315247|NCT00711035|Prior allogeneic hematopoietic stem cell transplant
1315248|NCT00711022|Jaw, Edentulous (maxilla, with poor bone quality and quantity)
1315249|NCT00711009|Human Immunodeficiency Virus infection
1315250|NCT00710996|AcrySof IQ IOL
1315251|NCT00710983|Mortality
1315252|NCT00710983|Morbidity
1315253|NCT00710983|Growth
1315254|NCT00710983|Immunology
1315255|NCT00710970|Urinary Bladder Neoplasms
1315256|NCT00710970|Previous Chemotherapy
1315257|NCT00710970|Tamoxifen
1315258|NCT00710970|Anti-tumor activity
1315259|NCT00710957|Vitamin D
1315260|NCT00710957|Physical Function
1315261|NCT00710957|Falls
1315262|NCT00710957|Aging
1315263|NCT00710957|CHS
1315264|NCT00710944|Jaw, Edentulous, Partially (missing/extracted/avulsed teeth in the maxilla within zone 15(4)-25(13))
1315265|NCT00710931|Bilateral Cataract
1315266|NCT00710931|IOL
1315267|NCT00710931|ReSTOR
1315268|NCT00710931|Aspheric
1315269|NCT00710905|Cataract IOL ReSTOR Aspheric
1315270|NCT00710905|Bilateral cataract
1315271|NCT00710892|suicide gene-modified allodepleted donor lymphocytes
1315272|NCT00710892|given to recipients of haploidentical stem cell transplants
1315273|NCT00710892|Stage III
1315274|NCT00710892|Stage IV
1315275|NCT00710892|Myelodysplastic syndrome
1315276|NCT00710892|AML after first relapse
1315277|NCT00710892|primary refractory disease
1315278|NCT00710892|CML
1315279|NCT00710892|Hemophagocytic lymphohistiocytosis (HLH)
1315280|NCT00710892|familial hemophagocytic lymphohistiocytosis (FLH)
1315281|NCT00710892|viral-associated hemophagocytic syndrome (VAHS)
1315282|NCT00710892|Severe chronic active Epstein Barr virus infection (SCAEBV)
1315283|NCT00710892|T or NK cell malignancy
1315284|NCT00710892|X-linked lymphoproliferative disease (XLP)
1315285|NCT00710879|Efficacy
1315286|NCT00710866|Influenza Vaccines
1315287|NCT00710866|Infant
1315288|NCT00710866|Dose-Response Relationship, Immunologic
1315289|NCT00710853|Geriatric
1315290|NCT00710853|Qi gong
1315291|NCT00710853|Yoga
1315292|NCT00710853|Tai chi
1315293|NCT00710853|Geriatric Assessment
1315294|NCT00710840|Knee Replacement
1315295|NCT00710840|Knee OA
1315296|NCT00710840|OA
1315297|NCT00710827|NEBIDO,
1315298|NCT00710827|Hypogonadism,
1315299|NCT00710827|Symptomatic late onset,
1315300|NCT00710827|Testosterone deficiency
1315301|NCT00710814|Roux-en-Y gastric bypass
1315302|NCT00710814|Leptin
1315303|NCT00710814|Bariatric surgery
1315304|NCT00710814|Overweight after Roux-en-Y gastric bypass surgery
1315305|NCT00710801|Hepatitis C Virus
1315306|NCT00710801|HCV
1315307|NCT00710801|Liver Transplant
1315308|NCT00710801|Cyclosporine
1315309|NCT00710801|Tacrolimus
1315310|NCT00710801|Myfortic
1315311|NCT00710788|QT interval
1315312|NCT00710788|QT dispersion
1315313|NCT00710788|arrhythmias
1315314|NCT00710788|death
1315315|NCT00710788|TC score
1315316|NCT00710775|Aortic valve stenosis
1315317|NCT00710775|Heart surgery
1315318|NCT00710775|Endovascular techniques
1315319|NCT00710749|Lower urinary tract symptoms leading to lower flow rates
1315320|NCT00710697|Bladder Cancer
1315321|NCT00710697|Breast Cancer
1315322|NCT00710697|Colorectal Cancer
1315323|NCT00710697|Gastrointestinal Neoplasm
1315324|NCT00710697|Head and Neck Cancer
1315325|NCT00710697|Lung Cancer
1315326|NCT00710697|Ovarian Cancer
1315327|NCT00710697|Pancreatic Cancer
1315328|NCT00710697|Prostrate Cancer
1315329|NCT00710684|Alzheimer's disease cognition SB-742457
1315330|NCT00710671|HIV positive
1315331|NCT00710671|YMSM
1315332|NCT00710671|risk factors
1315333|NCT00710671|coping
1315334|NCT00710671|identity development
1315335|NCT00710671|psychosocial needs
1315336|NCT00710658|Internet support
1315337|NCT00710658|Tailored information
1315338|NCT00710658|Self-management
1315339|NCT00710658|Quality of life
1315340|NCT00710658|Online messaging
1315341|NCT00710658|Online discussion groups
1315342|NCT00710645|Multiple Sclerosis
1315343|NCT00710645|Spasticity
1315344|NCT00710632|cachexia
1315345|NCT00710632|lung cancer
1315346|NCT00710632|gastrointestinal cancer
1315347|NCT00710632|unspecified adult solid tumor, protocol specific
1315348|NCT00710632|hematopoietic/lymphoid cancer
1315349|NCT00710606|contraceptive ring
1315350|NCT00710606|obesity
1315351|NCT00710606|pharmacokinetics
1315352|NCT00710606|pharmacodynamics
1315353|NCT00710606|Pharmacokinetics of the contraceptive ring in obese women.
1315354|NCT00710593|Highly-active antiretroviral therapy
1315355|NCT00710593|Human papillomavirus
1315356|NCT00710593|HPV vaccine
1315357|NCT00710567|Heart Failure
1315358|NCT00710567|LVAS
1315359|NCT00710567|LVAD
1315360|NCT00710567|Rotary Pump
1315361|NCT00710554|Pain
1315362|NCT00710554|Peripheral Neuropathy
1315363|NCT00710554|Allodynia
1315364|NCT00710541|non invasive ventilation
1315365|NCT00710541|COPD
1315366|NCT00710541|hypercapnia
1315367|NCT00710541|GOLD stage IV
1315368|NCT00710528|CLL
1315369|NCT00710528|NHL
1315370|NCT00710528|AML
1315371|NCT00710528|MM
1315372|NCT00710528|Phosphatidylinositol 3-kinase
1315373|NCT00710515|Melanoma
1315374|NCT00710515|Phase I
1315375|NCT00710515|AZD6244
1315376|NCT00710502|Transvaginal
1315377|NCT00710502|NOTES
1315378|NCT00710502|Cholecystectomy
1315379|NCT00710502|Laparoscopic
1315380|NCT00710489|Acne
1315381|NCT00710489|Actinic Keratosis
1315382|NCT00710489|Dysplastic Nevi
1315383|NCT00710489|Eczema
1315384|NCT00710489|Psoriasis
1315385|NCT00710489|Vitiligo
1315386|NCT00710489|Skin Cancer
1315387|NCT00710489|Rosacea
1315388|NCT00710489|Leg or Foot Ulcers
1315389|NCT00710489|Atopic Dermatosis
1315390|NCT00710463|COPD
1315391|NCT00710463|non invasive ventilation
1315392|NCT00710463|pulmonary rehabilitation
1315393|NCT00710450|IL13
1315394|NCT00710450|leukotriene
1315395|NCT00710450|histamine
1315396|NCT00710450|IL4
1315397|NCT00710450|Must be allergic asthma or allergic rhinitis
1315398|NCT00710437|Dexmedetomidine
1315399|NCT00710437|Carotid Endarterectomy
1315400|NCT00710437|Electroencephalogram
1315401|NCT00710424|Pain
1315402|NCT00710424|diabetic neuropathy
1315403|NCT00710411|humans
1315404|NCT00710411|patients
1315405|NCT00710411|polytrauma
1315406|NCT00710411|complement
1315407|NCT00710411|inflammation
1315408|NCT00710411|inflammatory response
1315409|NCT00710411|biomarkers
1315410|NCT00710411|cytokines
1315411|NCT00710411|cell surface markers
1315412|NCT00710411|apoptosis
1315413|NCT00710411|NF-kappaB
1315414|NCT00710411|functional polymorphisms
1315415|NCT00710411|mesenchymal stem cell
1315416|NCT00710411|severity of injury
1315417|NCT00710411|ISS
1315418|NCT00710411|infections
1315419|NCT00710411|systemic inflammatory response syndrome
1315420|NCT00710411|SIRS
1315421|NCT00710411|sepsis
1315422|NCT00710411|severe sepsis
1315423|NCT00710411|shock
1315424|NCT00710411|organ dysfunctions
1315425|NCT00710411|SOFA
1315426|NCT00710411|severity of disease
1315427|NCT00710411|APACHEII
1315428|NCT00710411|SAPSII
1315429|NCT00710411|SPAPS3
1315430|NCT00710411|length of stay
1315431|NCT00710411|wound healing
1315432|NCT00710411|outcome
1315433|NCT00710411|mortality
1315434|NCT00710398|Dairy Products
1315435|NCT00710398|Dietary Protein
1315436|NCT00710398|Body Composition
1315437|NCT00710398|Fat mass loss
1315438|NCT00710398|Lean mass gain
1315439|NCT00710398|Pre-menopausal Women
1315440|NCT00710359|Cobalamin deficiency
1315441|NCT00710359|Infant
1315442|NCT00710359|Nutrition
1315443|NCT00710359|Cobalamin supplementation
1315444|NCT00710359|Feeding problems
1315445|NCT00710359|Gastrointestinal symptoms
1315446|NCT00710346|Leiomyoma
1315447|NCT00710346|Uterus
1315448|NCT00710346|Fibroids
1315449|NCT00710346|Surgical
1315450|NCT00710320|Children core temperature,
1315451|NCT00710320|Pediatric surgery,
1315452|NCT00710320|Anesthesia induction
1315453|NCT00710294|Refractory Hypertension
1315454|NCT00710294|High Blood Pressure
1315455|NCT00710294|Uncontrolled Blood Pressure
1315456|NCT00710281|Intracranial Aneurysm
1315457|NCT00710281|Subarachnoid arterial aneurysm
1315458|NCT00710281|Aneurysm
1315459|NCT00710281|Brain Aneurysm
1315460|NCT00710281|Cerebral Aneurysm
1315461|NCT00710281|Wall Shear Stress(WSS)
1315462|NCT00710281|Hemodynamic Stress
1315463|NCT00710281|Subarachnoid Hemorrhage(SAH)
1315464|NCT00710268|Bevacizumab
1315465|NCT00710268|Poly(ADP ribose) polymerases
1315466|NCT00710268|Metastatic Solid Tumours
1315467|NCT00710268|PARP inhibitor
1315468|NCT00710255|Asthma
1315469|NCT00710255|Exercise induced bronchospasm
1315470|NCT00710255|Hyperpnea induced bronchospasm
1315471|NCT00710255|leukotrienes
1315472|NCT00710255|adenosine
1315473|NCT00710255|exhaled breath condensate
1315474|NCT00710242|prolonged labor
1315475|NCT00710229|age related macular degeneration
1315476|NCT00710229|Ranibizumab-Lucentis
1315477|NCT00710229|Bevacizumab-Avastin
1315478|NCT00710216|Viral kinetics
1315479|NCT00710216|Viral dynamics
1315480|NCT00710216|Telbivudine
1315481|NCT00710216|Lamivudine
1315482|NCT00710203|Dermatosis Papulosa Nigra
1315483|NCT00710203|seborrheic keratoses
1315484|NCT00710190|Drug Resistant Hypertension
1315485|NCT00710190|Refractory Hypertension
1315486|NCT00710190|High Blood Pressure
1315487|NCT00710190|Baroreflex Hypertension Therapy
1315488|NCT00710177|PPHN
1315489|NCT00710177|PTGS1
1315490|NCT00710177|NSAID
1315491|NCT00710151|neurotoxicity
1315492|NCT00710151|cognition in survivors
1315493|NCT00710151|diagnostic imaging
1315494|NCT00710138|Cobalamin deficiency
1315495|NCT00710138|Infant
1315496|NCT00710138|Nutrition
1315497|NCT00710138|Cobalamin supplementation
1315498|NCT00710138|Neurodevelopment
1315499|NCT00710138|Neurological symptoms
1315500|NCT00710112|CLD
1315501|NCT00710112|VLBW infants
1315502|NCT00710112|Toll like Receptors
1315503|NCT00710112|Biomarkers
1315504|NCT00710099|iontophoresis
1315505|NCT00710099|cutaneous microcirculation
1315506|NCT00710099|sildenafil
1315507|NCT00710099|Healthy volunteers
1315508|NCT00710086|Remifentanil
1315509|NCT00710086|Patient-controlled analgesia
1315510|NCT00710086|Intravenous analgesia
1315511|NCT00710073|Chronic pelvic pain syndrome
1315512|NCT00710073|Neuromodulation
1315513|NCT00710060|HIV
1315514|NCT00710060|Popular Opinion Leader
1315515|NCT00710060|POL
1315516|NCT00710060|Behavioral Intervention
1315517|NCT00710060|STD
1315518|NCT00710060|STI
1315519|NCT00710060|Community
1315520|NCT00710060|Prevention
1315521|NCT00710060|International
1315522|NCT00710060|Global
1315523|NCT00710047|ZD4054
1315524|NCT00710047|Zibotentan
1315525|NCT00710047|Healthy Volunteers
1315526|NCT00710034|Oral Tobacco Products
1315527|NCT00710034|Snus
1315528|NCT00710034|Smoking Substitution
1315529|NCT00710034|Harm Reduction
1315530|NCT00710034|Biomarkers of Tobacco Exposure
1315531|NCT00710021|Systemic lupus erythematosus
1315532|NCT00710021|SLE
1315533|NCT00710021|Vitamin D3
1315534|NCT00710021|Vitamin D deficiency
1315535|NCT00710021|IFN alpha expression
1315536|NCT00710008|type 2 diabetes,
1315537|NCT00710008|exercise training,
1315538|NCT00710008|ATP-synthesis,
1315539|NCT00710008|intramyocellular lipids,
1315540|NCT00710008|hepatocellular lipids
1315541|NCT00710008|first degree relatives of
1315542|NCT00710008|patients
1315543|NCT00709982|Norgestimate
1315544|NCT00709982|Contraceptives, Oral
1315545|NCT00709982|Ortho-Cyclen
1315546|NCT00709982|Folic Acid
1315547|NCT00709982|Ethinyl Estradiol
1315548|NCT00709969|Malaria
1315549|NCT00709969|co-artemether
1315550|NCT00709969|auditory
1315551|NCT00709969|Plasmodium falciparum
1315552|NCT00709969|marsh fever
1315553|NCT00709969|remittent fever
1315554|NCT00709969|artemether
1315555|NCT00709969|artemisinins
1315556|NCT00709969|lumefantrine
1315557|NCT00709969|child
1315558|NCT00709969|infant
1315559|NCT00709969|Africa
1315560|NCT00709956|Ventavis
1315561|NCT00709956|iloprost
1315562|NCT00709956|inhaled treatment
1315563|NCT00709956|pulmonary arterial hypertension
1315564|NCT00709904|venous thromboprophylaxis
1315565|NCT00709904|primary prevention
1315566|NCT00709904|orthopedic surgery
1315567|NCT00709878|skin rash, lapatinib, cetuximab, erlotinib, panitumumab
1315568|NCT00709865|renal insufficiency
1315569|NCT00709865|diuretic
1315570|NCT00709865|congestive heart failure
1315571|NCT00709865|acute decompensated heart failure
1315572|NCT00709852|Patients referred for a contrast-enhanced MRI of the CNS
1315573|NCT00709852|CNS Imaging
1315574|NCT00709839|glucocorticoid
1315575|NCT00709839|hydrocortisone
1315576|NCT00709839|carbohydrate metabolism
1315577|NCT00709839|appetite-regulatory hormones
1315578|NCT00709813|Symptom management
1315579|NCT00709813|Cancer
1315580|NCT00709813|Patient-centered care
1315581|NCT00709800|Pandemic Influenza
1315582|NCT00709800|Avian Influenza
1315583|NCT00709800|DNA Vaccines
1315584|NCT00709800|Antibody
1315585|NCT00709800|T Cells
1315586|NCT00709800|HA/NP/M2
1315587|NCT00709787|Epidemiology, hypertension, risk factors, coronary heart disease, patient management, compliance with medication
1315588|NCT00708760|web based learning
1315589|NCT00708760|moderate sedation
1315590|NCT00708747|Immunoglobulins
1315591|NCT00708747|inhibitor proteins
1315592|NCT00708747|human albumin
1315593|NCT00708747|systemic inflammatory response syndrome
1315594|NCT00708747|interleukins
1315595|NCT00708747|standardized serum-protein solution
1315596|NCT00708734|exercise
1315597|NCT00708721|hypomethylating therapy
1315598|NCT00708721|CML
1315599|NCT00708721|myelodysplastic syndromes
1315600|NCT00708708|Plaque-type psoriasis
1315601|NCT00708695|nurse
1315602|NCT00708695|home visits
1315603|NCT00708695|pregnancy
1315604|NCT00708695|welfare
1315605|NCT00708695|child development
1315606|NCT00708695|Child Rearing
1315607|NCT00708695|Reproductive Behavior
1315608|NCT00708695|Risk Reduction Behavior
1315609|NCT00708656|IBD
1315610|NCT00708656|Colitis
1315611|NCT00708656|UC
1315612|NCT00709761|Erbb2
1315613|NCT00709761|ABRAXANE
1315614|NCT00709761|MBC
1315615|NCT00709761|first or second line therapy
1315616|NCT00709761|Metastatic Breast Cancer
1315617|NCT00709761|TYKERB
1315618|NCT00709748|Transcutaneous electrical nerve stimulation
1315619|NCT00709748|TENS
1315620|NCT00709748|Empi
1315621|NCT00709748|Electrotherapy
1315622|NCT00709748|Back pain
1315623|NCT00709748|Lower back pain
1315624|NCT00709748|Chronic lower back pain
1315625|NCT00709735|stress disorders
1315626|NCT00709735|post-traumatic
1315627|NCT00709735|memory
1315628|NCT00709735|propranolol
1315629|NCT00709735|psychophysiology
1315630|NCT00709722|Lupus nephritis
1315631|NCT00709722|Deoxyspergualin
1315632|NCT00709722|Immunosuppression
1315633|NCT00709709|stenosis
1315634|NCT00709709|coronaropathy
1315635|NCT00709709|stent
1315636|NCT00709709|bypass surgery
1315637|NCT00709709|suspect
1315638|NCT00709709|known
1315639|NCT00709696|Tobacco
1315640|NCT00709696|nicotine
1315641|NCT00709696|smoking
1315642|NCT00709696|varenicline
1315643|NCT00709696|human laboratory study
1315644|NCT00709696|stress tolerance
1315645|NCT00709696|startle response
1315646|NCT00709696|cognitive assessment
1315647|NCT00709696|progressive ratio
1315648|NCT00709670|MSCT
1315649|NCT00709670|Echocardiography
1315650|NCT00709670|Coronarography
1315651|NCT00709670|Acute coronary syndrome without ST segment elevation
1315652|NCT00709670|normal ECG
1315653|NCT00709670|normal troponin
1315654|NCT00709670|Acute
1315655|NCT00709657|Age-related macular degeneration
1315656|NCT00709657|anti-VEGF
1315657|NCT00709644|Ortho Tri-Cyclen Lo
1315658|NCT00709644|Contraceptives, Oral
1315659|NCT00709644|Norgestimate
1315660|NCT00709644|Ethinyl Estradiol
1315661|NCT00709644|Folic Acid
1315662|NCT00709644|Female Contraception
1315663|NCT00709631|Malignant transformation of leg ulcer
1315664|NCT00709631|MARJOLIN's ulcer
1315665|NCT00709631|Biopsy
1315666|NCT00709631|Leg ulcer
1315667|NCT00709631|Chronic wound
1315668|NCT00709631|Squamous cell carcinoma
1315669|NCT00709631|Basal cell carcinoma
1315670|NCT00709618|Erbb2
1315671|NCT00709618|MBC
1315672|NCT00709618|First or Second line therapy
1315673|NCT00709618|Metastatic Breast Cancer
1315674|NCT00709618|Vinorelbine
1315675|NCT00709618|Tykerb
1315676|NCT00709605|HIV Negative
1315677|NCT00709605|Healthy
1315678|NCT00709605|Immunity
1315679|NCT00709605|Preventive
1315680|NCT00709605|Virus
1315681|NCT00709605|Healthy Volunteer
1315682|NCT00709605|HV
1315683|NCT00709592|total body irradiation
1315684|NCT00709592|Allogeneic Peripheral Blood Stem Cell Transplantation
1315685|NCT00709592|thymoglobulin
1315686|NCT00709579|Patients needing an oral corticotherapy
1315942|NCT00708422|TFBUT
1315687|NCT00709579|Patients needing a topical corticotherapy
1315688|NCT00709579|Corticotherapy
1315689|NCT00709566|Hip
1315690|NCT00709566|osteoarthritis
1315691|NCT00709566|exercise
1315692|NCT00709566|manual therapy
1315693|NCT00709553|ZD4054
1315694|NCT00709553|Healthy Volunteers
1315695|NCT00709527|AMD
1315696|NCT00709514|Oneness
1315697|NCT00709514|DCB-WH1
1315698|NCT00709514|DCB-WH1-CP001
1315699|NCT00709514|chronic
1315700|NCT00709514|diabetic
1315701|NCT00709514|foot ulcers
1315702|NCT00709514|topical ointment
1315703|NCT00709501|weight loss
1315704|NCT00709501|obesity
1315705|NCT00709501|overweight
1315706|NCT00709488|Litx™ BPH System
1315707|NCT00709488|LS11
1315708|NCT00709488|Talaporfin sodium
1315709|NCT00709462|Breast cancer
1315710|NCT00709462|Colorectal cancer
1315711|NCT00709462|Pancreatic cancer
1315712|NCT00709462|Bladder cancer
1315713|NCT00709462|Ovarian cancer
1315714|NCT00709462|Metastatic cancer
1315715|NCT00709462|Locally advanced cancer
1315716|NCT00709462|Cancer Vaccine
1315717|NCT00709462|Vaccine
1315718|NCT00709449|Age-related macular degeneration
1315719|NCT00709449|Glaucoma
1315720|NCT00709436|orthopedic
1315721|NCT00709436|ketamine
1315722|NCT00709436|pain
1315723|NCT00709410|Cholera, Diarrhea, Vaccination, Vaccines
1315724|NCT00709397|HIV-1
1315725|NCT00709397|drug resistance
1315726|NCT00709397|raltegravir
1315727|NCT00709397|integrase inhibitor
1315728|NCT00709371|obesity
1315729|NCT00709371|zonisamide
1315730|NCT00709371|bupropion
1315731|NCT00709358|bacteria
1315732|NCT00709358|fungi
1315733|NCT00709358|real time PCR
1315734|NCT00709358|adequate antimicrobial therapy
1315735|NCT00709358|microbial DNA
1315736|NCT00709358|microbial diagnosis
1315737|NCT00709345|Antipsychotic Medications
1315738|NCT00709345|Behavioral Interventions
1315739|NCT00709332|Norgestimate
1315740|NCT00709332|Folic Acid
1315741|NCT00709332|Ortho-Cyclen
1315742|NCT00709332|Female contraception
1315743|NCT00709332|Ethinyl Estradiol
1315744|NCT00709332|Drug Interactions
1315745|NCT00709332|Pharmacokinetics
1315746|NCT00709332|Contraceptives, Oral
1315747|NCT00709319|Diabetic retinopathy
1315748|NCT00709319|Diabetic macular edema
1315749|NCT00709319|dme
1315750|NCT00709319|vitrectomy
1315751|NCT00709293|Ischemia Reperfusion Injury
1315752|NCT00709293|Pediatric Heart Transplant
1315753|NCT00709293|ATG
1315754|NCT00709293|Induction Therapy
1315755|NCT00709280|Cystic Fibrosis
1315756|NCT00709280|hypertonic saline
1315757|NCT00709280|inhaled saline
1315758|NCT00709267|Folic Acid
1315759|NCT00709267|Chemistry, Analytical
1315760|NCT00709267|Administration, Oral
1315761|NCT00709267|Infusions, Intravenous
1315762|NCT00709267|Biological Availability
1315763|NCT00709267|Safety
1315764|NCT00709254|AeroLEF
1315765|NCT00709254|fentanyl
1315766|NCT00709254|pharmacokinetics
1315767|NCT00709254|liposome
1315768|NCT00709254|encapsulated
1315769|NCT00709241|Heart failure
1315770|NCT00709241|Psychosocial factors
1315771|NCT00709241|Depression
1315772|NCT00709241|Patient compliance
1315773|NCT00709215|refractory TdT-positive leukemia
1315774|NCT00709215|ALL
1315775|NCT00709215|AML
1315776|NCT00709215|blastic CML
1315777|NCT00709189|Pharmacokinetics
1315778|NCT00709189|Ethinyl Estradiol
1315779|NCT00709189|Drug Interactions
1315780|NCT00709189|Norgestimate
1315781|NCT00709189|Contraceptives, Oral
1315782|NCT00709189|Ortho-Cyclen
1315783|NCT00709189|Folic Acid
1315784|NCT00709176|Quality of Life
1315785|NCT00709176|Randomized Clinical Trial
1315786|NCT00709176|Advanced Cancer
1315787|NCT00709176|Breast Cancer
1315788|NCT00709176|Colorectal Cancer
1315789|NCT00709176|Lung Cancer
1315790|NCT00709176|Prostate Cancer
1315791|NCT00709176|Family caregiver
1315792|NCT00709176|cancer survivorship
1315793|NCT00709176|coping
1315794|NCT00709176|communication
1315795|NCT00709176|uncertainty
1315796|NCT00709176|support
1315797|NCT00709176|depression
1315798|NCT00709176|self-efficacy
1315799|NCT00709176|benefits of illness
1315800|NCT00709176|Caregivers
1315801|NCT00709163|Pediatric
1315802|NCT00709163|Dilated Cardiomyopathy
1315803|NCT00709163|Nesiritide
1315804|NCT00709150|Major Depression
1315805|NCT00709150|Diabetes
1315806|NCT00709150|Hispanics
1315807|NCT00709150|Collaborative Depression Care Management
1315808|NCT00709137|resistant hypertensions
1315809|NCT00709137|spironolactone
1315810|NCT00709137|amiloride
1315811|NCT00709137|ambulatory blood pressure monitoring
1315812|NCT00709124|Respiration, Artificial
1315813|NCT00709124|Critical Illness
1315814|NCT00709124|Intensive Care Units
1315943|NCT00708422|Glaucoma
1315815|NCT00709124|Electric Stimulation Therapy
1315816|NCT00709124|Muscle Weakness
1315817|NCT00709124|Paresis
1315818|NCT00709124|Mechanically
1315819|NCT00709124|Ventilated
1315820|NCT00709124|Patients
1315821|NCT00709124|Admitted
1315822|NCT00709124|Medical
1315823|NCT00709111|CCR5 antagonist
1315824|NCT00709111|CD4 T-cell count
1315825|NCT00709111|immune activation
1315826|NCT00709111|treatment experienced
1315827|NCT00709098|pulmonary arterial hypertension
1315828|NCT00709098|inhaled treatment
1315829|NCT00709098|inhalation solution
1315830|NCT00709098|iloprost
1315831|NCT00709098|Ventavis
1315832|NCT00709085|single nucleotide polymorphism
1315833|NCT00709072|stuttering
1315834|NCT00709072|relapse
1315835|NCT00709072|Lidcombe Program
1315836|NCT00709072|Preschool children
1315837|NCT00709059|hepatitis C
1315838|NCT00709046|Endoscopic treatment
1315839|NCT00709046|Peptic ulcer
1315840|NCT00709046|Bleeding
1315841|NCT00709046|Thermocoagulation
1315842|NCT00709046|Proton pump inhibitors
1315843|NCT00709033|refractory
1315844|NCT00709033|relapsed
1315845|NCT00709033|low
1315846|NCT00709033|intermediate-grade
1315847|NCT00709033|Non-Hodgkin lymphoma
1315848|NCT00709033|Chronic Lymphocytic Leukemia
1315849|NCT00709020|cancer survivor
1315850|NCT00709020|breast cancer
1315851|NCT00708981|Diabetic Nephropathy
1315852|NCT00708968|randomized clinical trial
1315853|NCT00708968|coping
1315854|NCT00708968|quality of life
1315855|NCT00708968|family
1315856|NCT00708968|family caregiver
1315857|NCT00708968|cancer survivorship
1315858|NCT00708968|communication
1315859|NCT00708968|uncertainty
1315860|NCT00708968|support
1315861|NCT00708968|family education
1315862|NCT00708968|Caregivers
1315863|NCT00708955|Evaluation and Treatment
1315864|NCT00708955|Eye Diseases
1315865|NCT00708942|Cervical intraepithelial neoplasia (CIN)
1315866|NCT00708929|Age-related macular degeneration
1315867|NCT00708929|Complement factor H
1315868|NCT00708929|Choroidal blood flow
1315869|NCT00708916|Cutaneous lupus
1315870|NCT00708916|Intervention
1315871|NCT00708916|Discoid lupus
1315872|NCT00708916|Phosphodiesterase 5 inhibitor
1315873|NCT00708903|Thorough QTc study
1315874|NCT00708890|Substance use disorders
1315875|NCT00708890|Self-help groups
1315876|NCT00708890|Twelve Step groups
1315877|NCT00708877|cancer
1315878|NCT00708877|cholangiocarcinoma
1315879|NCT00708851|psoriasis
1315880|NCT00708812|Non-small Cell Lung Cancer
1315881|NCT00708812|Endostar
1315882|NCT00708812|Paclitaxel
1315883|NCT00708812|Carboplatin
1315884|NCT00708630|yellow fever vaccine
1315885|NCT00708630|patient information
1315886|NCT00708630|symptom reports
1315887|NCT00708630|patient satisfaction
1315888|NCT00708617|Liver fibrosis
1315889|NCT00708617|Alcoholic liver disease
1315890|NCT00708617|Non invasive diagnostic methods
1315891|NCT00708617|Transient elastography
1315892|NCT00708617|Fibrotest
1315893|NCT00708604|Diabetes Mellitus
1315894|NCT00708604|Kidney Transplantation
1315895|NCT00708604|Islet Transplantation
1315896|NCT00708604|Sirolimus/Tacrolimus/MMF-based Immunosuppressive Regimen
1315897|NCT00708565|To study the effects of iloprost on hypoxic pulmonary vasoconstriction at high altitude
1315898|NCT00708552|Alzheimer's disease
1315899|NCT00708552|Cognition
1315900|NCT00708552|SB-742457
1315901|NCT00708526|hypercapnia
1315902|NCT00708526|hyperpnoea
1315903|NCT00708526|accelerated recovery
1315904|NCT00708513|Cell Saver
1315905|NCT00708513|Liver Tumors
1315906|NCT00708513|Liver Cancer
1315907|NCT00708513|Surgical Oncology
1315908|NCT00708513|Whipple
1315909|NCT00708513|Blood Transfusion
1315910|NCT00708513|Blood salvage
1315911|NCT00708513|cancer surgery
1315912|NCT00708513|blood loss
1315913|NCT00708500|Treatment failure
1315914|NCT00708487|in vitro fertilization
1315915|NCT00708487|oxygen concentration
1315916|NCT00708487|blastocyst
1315917|NCT00708487|live birth
1315918|NCT00708487|embryo
1315919|NCT00708474|Bone graft
1315920|NCT00708474|Bone void filler
1315921|NCT00708474|Bone plug
1315922|NCT00708474|OsseoFit™
1315923|NCT00708474|knee
1315924|NCT00708474|bone graft sites in the knee
1315925|NCT00708461|obesity
1315926|NCT00708461|obesity prevention
1315927|NCT00708461|worksite
1315928|NCT00708461|environment
1315929|NCT00708461|intervention
1315930|NCT00708448|NSCLC
1315931|NCT00708435|Anticoagulant reversal
1315932|NCT00708435|Prothrombin
1315933|NCT00708435|Complex
1315934|NCT00708435|Concentrate
1315935|NCT00708435|Coagulopathy
1315936|NCT00708435|induced by
1315937|NCT00708435|coumarin
1315938|NCT00708435|derivatives
1315939|NCT00708435|Kcentra
1315940|NCT00708422|Ocular surface health
1315941|NCT00708422|OSDI
1315944|NCT00708422|Ocular hypertension
1315945|NCT00708422|Corneal staining
1315946|NCT00708409|Ross operation
1315947|NCT00708409|autograft procedure
1315948|NCT00708409|pulmonary homograft
1315949|NCT00708409|root replacement technique
1315950|NCT00708409|subcoronary implantation technique
1315951|NCT00708396|Patients
1315952|NCT00708396|suffer
1315953|NCT00708396|from
1315954|NCT00708383|embryo development
1315955|NCT00708383|embryo quality
1315956|NCT00708383|implantation
1315957|NCT00708383|IVF/ICSI outcome
1315958|NCT00708383|multiple pregnancy
1315959|NCT00708370|Interventional
1315960|NCT00708370|Non-drug
1315961|NCT00708370|Disease Management Program
1315962|NCT00708370|Cardiovascular Risk Control
1315963|NCT00708370|Dyslipidemias
1315964|NCT00708370|Primary Care Centers
1315965|NCT00708357|eNOS Gene Polymorphism
1315966|NCT00708357|ocular blood flow
1315967|NCT00708331|Cataract
1315968|NCT00708331|Extraction
1315969|NCT00708331|Intraocular Lens
1315970|NCT00708331|Hydrophilic Acrylic
1315971|NCT00708318|AeroLEF
1315972|NCT00708318|fentanyl
1315973|NCT00708318|pharmacokinetic
1315974|NCT00708318|liposome
1315975|NCT00708318|encapsulated
1315976|NCT00708305|toothpaste
1315977|NCT00708305|plaque fluid
1315978|NCT00708305|fluoride
1315979|NCT00708292|AUY922
1315980|NCT00708292|Multiple Myeloma
1315981|NCT00708292|HSP90 inhibitors
1315982|NCT00708292|Phase I/II
1315983|NCT00708279|angina pectoris, osteopathic manipulation
1315984|NCT00708266|Obesity
1315985|NCT00708266|Diabetes
1315986|NCT00708266|Non-esterified fatty acids
1315987|NCT00708266|Cytokines
1315988|NCT00708266|Inflammation
1315989|NCT00708266|Subcutaneous fat
1315990|NCT00708266|Adipose tissue
1315991|NCT00708253|balloon assisted enteroscopy
1315992|NCT00708253|single balloon enteroscopy
1315993|NCT00708253|double balloon enteroscopy
1315994|NCT00708253|insertion depth
1315995|NCT00708227|Asthma
1315996|NCT00708227|Pharmacogenetics
1315997|NCT00708227|Salmeterol
1315998|NCT00708227|African American
1315999|NCT00708227|White
1316000|NCT00708201|ileus
1316001|NCT00708201|POI
1316002|NCT00708188|Stroke, ischemic, etiology, TOAST, CT, multidetector
1316003|NCT00708175|Glucose Metabolism Disorder
1316004|NCT00708175|Dysmetabolic Syndrome
1316005|NCT00708175|Type II Diabetes
1316006|NCT00708175|Diabetes Mellitus
1316007|NCT00708175|Lipoatrophic
1316008|NCT00708175|Postmenopausal
1316009|NCT00708162|HIV
1316010|NCT00708162|HIV I
1316011|NCT00708162|Treatment Experienced
1316012|NCT00708149|lansoprazole, weaning,stress ulcer prophylaxis
1316013|NCT00708136|Falls
1316014|NCT00708136|elderly
1316015|NCT00708136|Balance
1316016|NCT00708136|speed of stepping
1316017|NCT00708136|Stability
1316018|NCT00708136|ELDERLY FALLERS
1316019|NCT00708123|remineralization
1316020|NCT00708123|enamel
1316021|NCT00708123|fluoride
1316022|NCT00708123|caries
1316023|NCT00708123|in situ
1316024|NCT00708110|dose-ranging study
1316025|NCT00708110|phase IIa
1316026|NCT00708110|integrase inhibitor
1316027|NCT00708110|HIV-1 infection
1316028|NCT00708097|fluoride
1316029|NCT00708097|in situ
1316030|NCT00708097|remineralization
1316031|NCT00708097|enamel
1316032|NCT00708097|caries
1316033|NCT00708084|Rabies post-exposure prophylaxis
1316034|NCT00708084|Monoclonal antibody
1316035|NCT00708058|Implanted cardiac defibrillators
1316036|NCT00708058|Congestive Heart Failure
1316037|NCT00708058|Emergency Department
1316038|NCT00708045|Breast Cancer
1316039|NCT00708019|cancer pain
1316040|NCT00708019|bone metastasis
1316041|NCT00708019|psychoeducational intervention
1316042|NCT00708019|nurse coaching
1316043|NCT00708019|patient education
1316044|NCT00708019|breast cancer
1316045|NCT00707993|Glucose Metabolism Disorder
1316046|NCT00707993|Dysmetabolic Syndrome
1316047|NCT00707993|Type II Diabetes
1316048|NCT00707993|Diabetes Mellitus
1316049|NCT00707993|Lipoatrophic
1316050|NCT00707993|Dyslipidemia
1316051|NCT00707993|Drug Therapy
1316052|NCT00707980|Major Depressive Disorder
1316053|NCT00707980|Depression
1316054|NCT00707980|Melancholia
1316055|NCT00707980|Mood Disorder
1316056|NCT00707980|Dysthymic Disorder
1316057|NCT00707980|Drug Therapy
1316058|NCT00707967|Tuberculosis vaccine
1316059|NCT00707954|Diabetes
1316060|NCT00707954|TA-7284
1316061|NCT00707941|Influenza like illness
1316062|NCT00707941|Pneumonia
1316063|NCT00707941|Bronchiolitis
1316064|NCT00707941|Upper respiratory tract illness
1316065|NCT00707941|Otitis media
1316066|NCT00707941|Viral shedding
1316067|NCT00707941|Nasopharyngeal wash
1316068|NCT00707941|Viral culture
1316069|NCT00707941|PCR
1316070|NCT00707928|retained placenta
1316071|NCT00707915|aged
1316072|NCT00707915|benzodiazepines
1316073|NCT00707915|hypnotics
1316074|NCT00707915|cognition
1316075|NCT00707915|posture
1316076|NCT00707902|Sore throats,
1316077|NCT00707902|Pharyngitis
1316078|NCT00707902|Acute
1316079|NCT00707876|Peripheral arterial disease (PAD); Magnetic Resonance Angiography (MRA); Magnetic Resonance Imaging (MRI), imaging agent or biomarker
1316080|NCT00707863|Escitalopram
1316081|NCT00707863|Lexapro
1316082|NCT00707863|fMRI
1316083|NCT00707863|pictures
1316084|NCT00707850|Hepatitis C
1316085|NCT00707850|Thalassemia
1316086|NCT00707850|Pegasys
1316087|NCT00707850|Ribavirin
1316088|NCT00707824|pruritus
1316089|NCT00707824|epidural morphine
1316090|NCT00707811|Dyspnea
1316091|NCT00707811|Shortness of Breath
1316092|NCT00707811|Trouble Breathing
1316093|NCT00707811|ST2
1316094|NCT00707811|IL-33
1316095|NCT00707798|Young adults
1316096|NCT00707798|Pneumococcal vaccine,
1316097|NCT00707798|Streptococcus pneumoniae,
1316098|NCT00707785|vitamin A
1316099|NCT00707785|Treatment
1316100|NCT00707785|neonates
1316101|NCT00707785|newborn
1316102|NCT00707785|sepsis
1316103|NCT00707785|necrotizing enterocolitis
1316104|NCT00707785|meningitis
1316105|NCT00707785|pneumonia
1316106|NCT00707772|Hepatitis C
1316107|NCT00707772|Hemophilia
1316108|NCT00707772|Pegasys
1316109|NCT00707772|Ribavirin
1316110|NCT00707759|Pediatric renal transplantation,Bone metabolism (DXA-pQCT)
1316111|NCT00707759|mRNAFOXP3/IL-17,Steroid withdrawal
1316112|NCT00707746|statin intolerant
1316113|NCT00707746|hypercholesterolemia
1316114|NCT00707707|breast cancer
1316115|NCT00707707|triple negative
1316116|NCT00707707|metastatic
1316117|NCT00707694|95 years of age and older
1316118|NCT00707681|microbio, MS-20, Hepatoma, Advanced Hepatocellular Carcinoma
1316119|NCT00707668|Diabetes
1316120|NCT00707668|metabolic syndrome
1316121|NCT00707668|dyslipidemia
1316122|NCT00707668|osteoporosis
1316123|NCT00707642|West Nile Virus
1316124|NCT00707642|West Nile Vaccine
1316125|NCT00707642|West Nile virus disease
1316126|NCT00707642|Hawaii Biotech
1316127|NCT00707629|type 1 diabetes
1316128|NCT00707629|neurocognitive measures
1316129|NCT00707629|behavioral measures
1316130|NCT00707603|Insulin resistance
1316131|NCT00707603|Liver fat
1316132|NCT00707603|Muscle fat
1316133|NCT00707603|Abdominal fat
1316134|NCT00707603|Cytokines
1316135|NCT00707577|Worksite Wellness
1316136|NCT00707577|Weight loss and maintenance
1316137|NCT00707577|Physical Activity
1316138|NCT00707577|Health and Fitness interventions
1316139|NCT00707577|Healthy eating
1316140|NCT00707577|Weight loss
1316141|NCT00707577|Maintenance programs
1316142|NCT00707564|hemostasis
1316143|NCT00707564|tooth extractions
1316144|NCT00707551|AZD1305
1316145|NCT00707551|Verapamil
1316146|NCT00707551|Ketoconazole
1316147|NCT00707551|pharmacokinetics
1316148|NCT00707525|aneuploidies, natural cycle, stimulated cycle, preimplantation genetic diagnosis
1316149|NCT00707486|Hemostasis, tooth extractions, third molar
1316150|NCT00707473|Carcinoma of Paranasal Sinuses
1316151|NCT00707473|Paranasal Sinuses
1316152|NCT00707473|Nasal Sinuses
1316153|NCT00707473|Nasal Cavity
1316154|NCT00707473|Squamous Cell Carcinoma
1316155|NCT00707473|Undifferentiated Carcinoma
1316156|NCT00707473|Poorly Differentiated Carcinoma
1316157|NCT00707473|Docetaxel
1316158|NCT00707473|5-Fluorouracil
1316159|NCT00707473|Cisplatin
1316160|NCT00707473|Platinol®
1316161|NCT00707473|Platinol®-AQ
1316162|NCT00707460|Diabetes
1316163|NCT00707460|Cardiovascular
1316164|NCT00707460|Obesity
1316165|NCT00707460|First.Nation
1316166|NCT00707460|Aboriginal (Health)
1316167|NCT00707460|Dietary
1316168|NCT00707460|Intervention
1316169|NCT00707460|Nutrition
1316170|NCT00707460|Traditional (Diet)
1316171|NCT00707460|Sandy Lake (Health & Diabetes Project)
1316172|NCT00707460|(High) protein
1316173|NCT00707460|(High) fibre (er)
1316174|NCT00707460|(Low) carbohydrate
1316175|NCT00707447|diabetes-prevention
1316176|NCT00707447|lifestyle modification
1316177|NCT00707447|behavior therapy
1316178|NCT00707447|self-management
1316179|NCT00707434|Continuous Glucose Monitor
1316180|NCT00707434|Medtronic Guardian
1316181|NCT00707434|Guardian® blood-sugar monitoring device
1316182|NCT00707434|Glucose Monitoring
1316183|NCT00707434|Critically Ill
1316184|NCT00707434|ICU
1316185|NCT00707434|Intensive Care Unit
1316186|NCT00707434|Glycemic Excursions
1316187|NCT00707434|Glucose Control
1316188|NCT00707434|Glucose Testing
1316189|NCT00707434|Hyperglycemia
1316190|NCT00707434|Hypoglycemia
1316191|NCT00707434|Insulin Infusion
1316192|NCT00707382|Pharmacogenetics
1316193|NCT00707382|Compliance
1316194|NCT00707382|Antipsychotic drugs
1316195|NCT00707382|Schizophrenia
1316196|NCT00707369|Periodontitis
1316197|NCT00707369|Mechanical Debridement
1316198|NCT00707369|Antibiotics
1316199|NCT00707369|Attachment loss
1316200|NCT00707369|Randomized controlled trial
1316201|NCT00707356|Prostatic disease
1316202|NCT00707356|genital neoplasm, male
1316203|NCT00707356|Urogenital neoplasm
1316204|NCT00707356|Genital disease
1316205|NCT00707356|male
1316206|NCT00707356|Male urogenital disease
1316207|NCT00707356|Neoplasms
1316208|NCT00707356|Neoplasm by site
1316209|NCT00707356|prostatic neoplasm
1316210|NCT00707356|Carcinoma
1316211|NCT00707330|oxidative stress
1316212|NCT00707330|8-oxo-deoxyguanine
1316213|NCT00707330|8-oxodG
1316214|NCT00707330|clarithromycin
1316215|NCT00707330|malondialdehyde
1316216|NCT00707330|mda
1316217|NCT00707330|vitamine C
1316218|NCT00707330|ascorbic acid
1316219|NCT00707317|M. tuberculosis
1316220|NCT00707317|latent tuberculosis infection
1316221|NCT00707317|Quantiferon assay
1316222|NCT00707317|ELISPOT assay
1316223|NCT00707317|tuberculin skin test
1316224|NCT00707317|immunocompromised patients
1316225|NCT00707304|Non Small Cell Lung Cancer
1316226|NCT00707304|Talactoferrin
1316227|NCT00707304|Dendritic Cell Recruiter and Activator
1316228|NCT00707304|Immunomodulatory agent
1316229|NCT00707291|contact lens
1316230|NCT00707291|normal
1316231|NCT00707252|Non-small cell lung cancer
1316232|NCT00707252|Erlotinib
1316233|NCT00707252|Polyphenon E
1316234|NCT00707252|Tarceva
1316235|NCT00707252|Advanced Non-small Cell Lung Cancer Stage IIIb or IV
1316236|NCT00707239|Hospital-acquired pneumonia
1316237|NCT00707239|Ventilator-associated pneumonia
1316238|NCT00707226|Laser Doppler flowmetry
1316239|NCT00707226|Choroidal blood flow
1316240|NCT00707226|Fundus pulsation amplitude
1316241|NCT00707226|Intraocular Pressure
1316242|NCT00707200|severe malarial anemia (SMA)
1316243|NCT00707200|cerebral malarial (CM)
1316244|NCT00707200|lactic acidosis
1316245|NCT00707200|hyperparasitemia
1316246|NCT00707200|respiratory distress
1316247|NCT00707200|hypoxia
1316248|NCT00707200|death
1316249|NCT00707200|transfusion
1316250|NCT00707187|systemic sclerosis
1316251|NCT00707187|scleroderma
1316252|NCT00707187|raynaud phenomenon
1316253|NCT00707174|Lentigo Maligna
1316254|NCT00707148|pertussis, diptheria, tetanus, vaccine, Tdap
1316255|NCT00707122|serum albumin, severe sepsis, septic shock, fluid therapy, hypoalbuminemia, critically ill
1316256|NCT00707083|untreated childhood acute lymphoblastic leukemia
1316257|NCT00707083|childhood acute lymphoblastic leukemia in remission
1316258|NCT00707083|B-cell childhood acute lymphoblastic leukemia
1316259|NCT00707083|T-cell childhood acute lymphoblastic leukemia
1316260|NCT00707070|psoriasis
1316261|NCT00707070|acitretin
1316262|NCT00707070|efalizumab
1316263|NCT00707031|hyperglycemia, GLP-1, metformin
1316264|NCT00707005|antibiotic susceptibility
1316265|NCT00707005|bacterial flora
1316266|NCT00707005|fluoroquinolone
1316267|NCT00707005|LASIK
1316268|NCT00707005|refractive surgery
1316269|NCT00706992|MART-1 Peptide
1316270|NCT00706992|Melanoma
1316271|NCT00706992|Adjuvant Therapy
1316272|NCT00706992|Gene Therapy
1316273|NCT00706992|T Cell Persistence
1316274|NCT00706979|smoking
1316275|NCT00706979|smoking cessation
1316276|NCT00706979|nicotine replacement therapy
1316277|NCT00706966|adenocarcinoma of the prostate
1316278|NCT00706966|stage IIB prostate cancer
1316279|NCT00706966|stage IIA prostate cancer
1316280|NCT00706966|benign prostatic hyperplasia
1316281|NCT00706953|pegylated liposomal doxorubicin
1316282|NCT00706953|VELCADE
1316283|NCT00706953|DOXIL
1316284|NCT00706953|relapsed
1316285|NCT00706953|Multiple Myeloma
1316286|NCT00706940|dry eye
1316287|NCT00706940|Optical coherence tomography
1316288|NCT00706927|xalacom
1316289|NCT00706927|combigan
1316290|NCT00706927|ocular blood flow
1316291|NCT00706914|Airflow Obstruction, Chronic
1316292|NCT00706914|Chronic Airflow Obstruction
1316293|NCT00706914|Chronic Obstructive Pulmonary Disease
1316294|NCT00706914|Chronic Obstructive Airway Disease
1316295|NCT00706914|Chronic Obstructive Lung Disease
1316296|NCT00706914|COPD
1316297|NCT00706914|COAD
1316298|NCT00706901|MI
1316299|NCT00706901|IHMD
1316300|NCT00706888|Reduction of cardiovascular factor of risk
1316301|NCT00706875|GTD survivors
1316302|NCT00706875|questionnaires
1316303|NCT00706875|GTD
1316304|NCT00706862|Non small cell lung cancer
1316305|NCT00706862|Talactoferrin
1316306|NCT00706862|Dendritic cell recruiter and activator
1316307|NCT00706862|DCRA
1316308|NCT00706862|Immunomodulatory agent
1316309|NCT00706862|Lactoferrin
1316310|NCT00706849|familial hypercholesterolemia
1316311|NCT00706836|anxiety
1316312|NCT00706836|functional magnetic resonance imaging
1316313|NCT00706836|fMRI
1316314|NCT00706836|pregabalin
1316315|NCT00706836|Lyrica
1316316|NCT00706823|Endotracheal Intubation
1316317|NCT00706823|Supraglottic Airway
1316318|NCT00706810|Cancer
1316319|NCT00706810|Brain cancer
1316320|NCT00706810|Meningioma
1316321|NCT00706797|Moderate Rheumatoid Arthritis
1316322|NCT00706784|Healthy women 18-40 years of age
1316323|NCT00706771|sodium bicarbonate
1316324|NCT00706771|serum neutrophil gelatinase associated lipocalin
1316325|NCT00706771|renal impairment
1316326|NCT00706771|renal failure
1316327|NCT00706771|systemic inflammatory response syndrome
1316328|NCT00706771|defined
1316329|NCT00706771|by serum NGAL ≥ 100 ng/ml.
1316330|NCT00706758|Irritable bowel syndrome
1316331|NCT00706758|Patient education
1316332|NCT00706745|atherosclerosis
1316333|NCT00706745|dietary supplements
1316334|NCT00706745|randomised controlled trial
1316335|NCT00706745|arterial stiffness
1316336|NCT00706745|linoleic acid
1316337|NCT00706732|Influenza
1316338|NCT00706732|Flu
1316339|NCT00706732|A/Wyoming/03/2003
1316340|NCT00706732|Alphavirus
1316341|NCT00706719|Adult Onset Idiopathic Hypothalamic Hypogonadism (AIHH)
1316342|NCT00706719|Secondary hypogonadism
1316343|NCT00706719|Semen volume
1316344|NCT00706719|Sperm count
1316345|NCT00706719|Sperm motility
1316346|NCT00706706|sunitinib Phase IV metastatic renal cell carcinoma Chinese
1316347|NCT00706693|hypoglycemia
1316348|NCT00706693|treatment
1316349|NCT00706693|glucose
1316350|NCT00706693|sucrose
1316351|NCT00706693|fructose
1316352|NCT00706654|Aripiprazole
1316353|NCT00706654|Intramuscular (IM) depot
1316354|NCT00706654|Schizophrenia
1316355|NCT00706615|stage IV breast cancer
1316356|NCT00706615|recurrent breast cancer
1316357|NCT00706602|COPD
1316358|NCT00706602|prognosis
1316359|NCT00706602|prediction rule
1316360|NCT00706602|health-related quality of life
1316361|NCT00706602|risk factors
1316362|NCT00706602|derivation
1316363|NCT00706602|validation
1316364|NCT00706602|exacerbation
1316365|NCT00706602|mortality
1316366|NCT00706602|primary care
1316367|NCT00706602|treatment
1316368|NCT00706602|decision making
1316369|NCT00706589|Chronic Motor Tic disorder
1316370|NCT00706589|Chronic Phonic Tic disorder
1316371|NCT00706589|Tourette's disorder
1316372|NCT00706589|Aripiprazole
1316373|NCT00706589|Abilify
1316374|NCT00706589|Children
1316375|NCT00706589|Adolescent
1316376|NCT00706576|Hepatocellular cancer
1316377|NCT00706576|HCC
1316378|NCT00706576|Opioid growth factor
1316379|NCT00706576|OGF
1316380|NCT00706576|Cirrhosis
1316381|NCT00706550|pneumococcal polysaccharide vaccine
1316382|NCT00706537|Pharmacokinetic safety NASH patients
1316383|NCT00706511|OSA
1316384|NCT00706511|Diabetes
1316385|NCT00706511|Metabolism
1316386|NCT00706511|Gender
1316387|NCT00706485|Y-90 plaque applicator
1316388|NCT00706485|dural brachytherapy
1316389|NCT00706446|Asthma
1316390|NCT00706446|Pharmacogenetics
1316391|NCT00706446|Beta agonists
1316392|NCT00706446|salmeterol
1316393|NCT00706446|formoterol
1316394|NCT00706446|tiotropium
1316395|NCT00706446|beta adrenergic receptor
1316396|NCT00706446|single nucleotide polymorphism
1316397|NCT00706433|Photodynamic Therapy
1316398|NCT00706420|Diabetes Mellitus
1316399|NCT00706420|Islet Transplantation Alone
1316400|NCT00706420|Glucocorticoid-free Immunosuppressive Regimen
1316401|NCT00706394|Powerlink
1316402|NCT00706394|34mm
1316403|NCT00706394|Abdominal Aortic Aneurysm
1316404|NCT00706394|EVAR
1316405|NCT00706381|Deiodinase
1316406|NCT00706381|Bile Acids
1316407|NCT00706381|Cholecystokinin
1316408|NCT00706381|Thyroid Hormones
1316409|NCT00706381|Energy Expenditure
1316410|NCT00706381|Health Volunteer
1316411|NCT00706381|HV
1316412|NCT00706368|Sexually transmitted infections
1316413|NCT00706368|Acceptability
1316414|NCT00706368|Adolescent vaginitis
1316415|NCT00706342|Adult Refractory Immune Thrombocytopenic Purpura (ITP)
1316416|NCT00706329|Minimally invasive surgery
1316417|NCT00706329|Umbilical hernia
1316418|NCT00706329|Infant
1316419|NCT00706316|Nasopharygneal Cancer
1316420|NCT00706316|Epstein Barr Virus
1316421|NCT00706316|(EBV)-Specific Cytotoxic T-Lymphocytes
1316422|NCT00706316|Recurrent
1316423|NCT00706316|Metastatic
1316424|NCT00706316|EBV-Positive Nasopharygneal Cancer
1316425|NCT00706303|COPD
1316426|NCT00706303|self management
1316427|NCT00706290|anxiety
1316428|NCT00706290|depression
1316429|NCT00706290|quality of life
1316430|NCT00706290|psychosocial effects of cancer and its treatment
1316431|NCT00706290|advanced cancer
1316432|NCT00706290|metastatic cancer
1316433|NCT00706290|stage IV cancer
1316434|NCT00706290|cognitive behavioral therapy
1316435|NCT00706277|forced vital capacity
1316436|NCT00706277|forced expired volume in 1 s
1316437|NCT00706264|Short cervix
1316438|NCT00706264|preterm birth
1316439|NCT00706264|arabin pessary
1316440|NCT00706238|metastatic,
1316441|NCT00706238|Melanoma,
1316442|NCT00706238|Antigen-Specific Cancer Immunotherapeutic,
1316443|NCT00706238|ASCI
1316444|NCT00706238|MAGE-A3
1316445|NCT00706238|tumor antigen,
1316446|NCT00706199|bone marrow
1316447|NCT00706199|volunteers
1316448|NCT00706199|antigen expression
1316449|NCT00706186|Mild Alzheimer's
1316450|NCT00706186|Disease
1316451|NCT00706173|Post-traumatic stress disorder
1316452|NCT00706173|PTSD
1316453|NCT00706173|Cortisol
1316454|NCT00706173|hydrocortisone
1316455|NCT00706173|pharmacological treatment
1316456|NCT00706160|Epilepsy
1316457|NCT00706160|Language
1316458|NCT00706160|fMRI
1316459|NCT00706160|Magnetoencephalogram
1316460|NCT00706160|Temporal Lobe Epilepsy
1316461|NCT00706160|Partial Epilepsy
1316462|NCT00706160|Healthy Volunteer
1316463|NCT00706160|HV
1316464|NCT00706147|Hereditary ALS
1316465|NCT00706147|Hereditary neurological disease
1316466|NCT00706147|Lou Gehrig's Disease
1316467|NCT00706147|Motor Neuron Disease
1316468|NCT00706147|Amyotrophic Lateral Sclerosis (ALS)
1316469|NCT00706147|Familial ALS
1316470|NCT00706147|Neuromuscular disease
1316471|NCT00706147|SOD1 mutation
1316472|NCT00706147|Superoxide dismutase
1316473|NCT00706147|SOD1 positive ALS
1316474|NCT00706147|inherited ALS
1316475|NCT00706134|Hypertension
1316476|NCT00706134|≥ 65 years
1316477|NCT00706134|aliskiren
1316478|NCT00706134|placebo
1316479|NCT00706134|light meal
1316480|NCT00706121|colon cancer
1316481|NCT00706121|rectal cancer
1316482|NCT00706121|adenomatous polyp
1316483|NCT00706095|Cancer
1316484|NCT00706095|advanced solid tumors
1316485|NCT00706069|Metastatic Breast Cancer
1316486|NCT00706069|Vinorelbine oral
1316487|NCT00706069|Capecitabine
1316488|NCT00706043|Low back pain
1316489|NCT00706030|Metastatic breast cancer
1316490|NCT00706004|constipation
1316491|NCT00706004|cystic fibrosis
1316492|NCT00706004|lubiprostone
1316493|NCT00706004|Constipation in adults with cystic fibrosis
1316494|NCT00705978|Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis
1316495|NCT00705965|Coronary artery disease
1316496|NCT00705965|depression
1316497|NCT00705965|psychotherapy
1316498|NCT00705965|randomized controlled trial
1316499|NCT00705952|No diabetes medications
1316500|NCT00705952|New onset
1316501|NCT00705939|Gaucher Disease
1316502|NCT00705939|Enzyme replacement therapy
1316503|NCT00705926|Acute Infection
1316504|NCT00705926|HIV
1316505|NCT00705926|HAART
1316506|NCT00705926|Treatment Naive
1316507|NCT00705913|aortic valve
1316508|NCT00705913|heart valve
1316509|NCT00705913|valve replacement
1316510|NCT00705913|valve disease
1316511|NCT00705900|psoriasis
1316512|NCT00705887|Ultraviolet Rays
1316513|NCT00705887|Motivation
1316514|NCT00705887|Health Education
1316515|NCT00705887|Randomized Controlled Trial
1316516|NCT00705887|Health Knowledge, Attitudes, Practice
1316517|NCT00705874|cancer
1316518|NCT00705874|advanced cancer
1316519|NCT00705874|solid tumors
1316520|NCT00705874|lymphoma
1316521|NCT00705874|CGC-11047
1316522|NCT00705861|Erectile dysfunction
1316523|NCT00705861|Diabetes Mellitus
1316524|NCT00705861|SK3530
1316525|NCT00705848|trachea
1316526|NCT00705848|malacia
1316527|NCT00705848|stenosis
1316528|NCT00705835|Prostate
1316529|NCT00705835|ALHYDROGEL
1316530|NCT00705835|RS-PSMA
1316531|NCT00705809|Epidemiology
1316532|NCT00705809|Peripheral T-Cell Lymphoma
1316533|NCT00705796|Hypogonadism
1316534|NCT00705796|Spermatogenesis
1316535|NCT00705796|Quality of Life
1316536|NCT00705783|Aripiprazole
1316537|NCT00705783|Intramuscular (IM) depot
1316538|NCT00705783|Schizophrenia
1316539|NCT00705770|Open-Angle Glaucoma
1316540|NCT00705770|Intraocular Pressure
1316541|NCT00705770|Anecortave Acetate
1316542|NCT00705757|periocular skin pigmentation
1316543|NCT00705757|Lumigan
1316544|NCT00705757|Travatan
1316545|NCT00705757|Xalatan
1316546|NCT00705757|latanoprost
1316547|NCT00705757|bimatoprost
1316548|NCT00705757|travoprost
1316549|NCT00705731|Colorectal cancer (CRC)
1316550|NCT00705731|Colorectal cancer screening
1316551|NCT00705731|Colonoscopy
1316552|NCT00705731|Fecal occult blood test (FOBT)
1316553|NCT00705731|Cost-effectiveness
1316554|NCT00705718|Endurant Stent Graft System
1316555|NCT00705718|Abdominal Aortic Aneurysms
1316556|NCT00705718|Endovascular Treatment
1316557|NCT00705705|High-Risk Behavior
1316558|NCT00705705|Men Who Have Sex With Men
1316559|NCT00705705|HIV Seronegativity
1316560|NCT00705692|Tetanus
1316561|NCT00705692|Vaccines
1316562|NCT00705692|Renal Dialysis
1316563|NCT00705692|Levamisole
1316564|NCT00705679|Microbicide
1316565|NCT00705679|HIV Seronegativity
1316566|NCT00705653|cancer
1316567|NCT00705653|advanced cancer
1316568|NCT00705653|solid tumors
1316569|NCT00705653|CGC-11047
1316570|NCT00705653|PG-11047
1316571|NCT00705640|stage II melanoma
1316572|NCT00705640|stage III melanoma
1316573|NCT00705640|stage IV melanoma
1316574|NCT00705640|ciliary body and choroid melanoma, medium/large size
1316575|NCT00705640|ciliary body and choroid melanoma, small size
1316576|NCT00705640|conjunctival melanoma
1316577|NCT00705640|extraocular extension melanoma
1316578|NCT00705640|iris melanoma
1316579|NCT00705640|metastatic intraocular melanoma
1316580|NCT00705640|recurrent intraocular melanoma
1316581|NCT00705627|nasopharyngeal carcinoma
1316582|NCT00705627|neoadjuvant chemotherapy
1316583|NCT00705627|concurrent chemotherapy
1316584|NCT00705627|randomized controlled clinical trials
1316585|NCT00705601|Nonrestorative Sleep, Restorative Sleep Questionnaire Refinement
1316586|NCT00705575|Essential Hypertension
1316587|NCT00705575|Stage II
1316588|NCT00705549|Advanced
1316589|NCT00705549|NSCLC
1316590|NCT00705549|ERCC1
1316591|NCT00705549|RRM1
1316592|NCT00705549|BCRA1
1316593|NCT00705549|Alimta
1316594|NCT00705549|Gemcitabine
1316595|NCT00705536|rHuPH20
1316596|NCT00705536|Hyaluronidase
1316597|NCT00705536|Insulin
1316598|NCT00705523|alcohol
1316599|NCT00705523|treatment
1316600|NCT00705523|nicotinic acetylcholine receptors
1316601|NCT00705523|pharmacotherapy
1316602|NCT00705523|outpatient
1316603|NCT00705510|Cyclosporine
1316604|NCT00705510|Unstable tear film
1316605|NCT00705510|Meibomian gland
1316606|NCT00705510|Meibomian gland dysfunction
1316607|NCT00705497|Radiofrequency tumor ablation
1316608|NCT00705497|RFA
1316609|NCT00705458|stress myocardial perfusion imaging
1316610|NCT00705458|coronary computed tomography angiography
1316611|NCT00705445|Malnutrition
1316612|NCT00705445|Diarrhea
1316613|NCT00705445|Pneumonia
1316614|NCT00705445|Growth
1316615|NCT00705445|Zinc Supplements
1316616|NCT00705445|Microbiome
1316617|NCT00705419|Treatment Experienced
1316618|NCT00705354|Sinusitis
1316619|NCT00705354|Chronic Sinusitis
1316620|NCT00705354|Nasal Surgery
1316621|NCT00705354|Functional Endoscopic Sinus Surgery (FESS)
1316622|NCT00705354|Enoscopic Sinus Surgery (ESS)
1316623|NCT00705341|Normal Controls
1316624|NCT00705328|low-income families
1316625|NCT00705328|children
1316626|NCT00705328|recreation
1316627|NCT00705328|family healthy lifestyle
1316628|NCT00705328|linkages to community resources
1316629|NCT00705328|Families with low incomes
1316630|NCT00705328|working poor
1316631|NCT00705328|welfare recipients
1316632|NCT00705315|breast cancer
1316633|NCT00705315|chemotherapy
1316634|NCT00705315|biological therapy
1316635|NCT00705302|Chronic Obstructive Pulmonary Disease
1316636|NCT00705302|Outpatient
1316637|NCT00705302|Patient education
1316638|NCT00705302|Pulmonary rehabilitation
1316639|NCT00705302|Self-management
1316640|NCT00705250|Bendamustine HCL
1316641|NCT00705237|sinusitis
1316642|NCT00705185|Major Depressive Disorder
1316643|NCT00705185|Blood Test
1316644|NCT00705159|Blepharokeratoconjunctivitis
1316645|NCT00705146|Osteoarthritis, carpometacarpal joint
1316646|NCT00705146|Thumb splints
1316647|NCT00705146|AUSCAN-HI 3.1
1316648|NCT00705146|Grip and pinch strength
1316649|NCT00705133|pulmonary hypertension
1316650|NCT00705133|pulmonary fibrosis
1316651|NCT00705133|interstitial lung disease
1316652|NCT00705120|Osteogenesis Imperfecta
1316653|NCT00705120|Bone Marrow Cell Transplantation
1316654|NCT00705120|Mesenchymal Stem Cells
1316655|NCT00705120|Stem Cell Transplantation, Mesenchymal
1316656|NCT00705094|cardiovascular risk factors
1316657|NCT00705094|cardiac function
1316658|NCT00705094|VO2peak
1316659|NCT00705094|Chemotherapy
1316660|NCT00705055|Anthropometry
1316661|NCT00705055|face recognition
1316662|NCT00705055|genetic disease
1316663|NCT00705055|newborn infant
1316664|NCT00705016|Randomized treatment
1316665|NCT00705016|open-label
1316666|NCT00705016|controlled
1316667|NCT00705016|recurrent
1316668|NCT00705016|metastatic
1316669|NCT00705016|SCCHN
1316670|NCT00705016|suitable
1316671|NCT00705016|for local therapy
1316672|NCT00705003|depression
1316673|NCT00704990|Attention Deficit Disorder
1316674|NCT00704990|Pediatrics
1316675|NCT00704990|Attention
1316676|NCT00704990|Impulsivity
1316677|NCT00704990|Complementary Therapies
1316678|NCT00704938|recurrent renal cell cancer
1316679|NCT00704938|stage IV renal cell cancer
1316680|NCT00704938|recurrent melanoma
1316681|NCT00704938|stage IV melanoma
1316682|NCT00704938|unspecified adult solid tumor, protocol specific
1316683|NCT00704925|Lambert Eaton Myasthenic Syndrome
1316684|NCT00704925|3,4 DAP
1316685|NCT00704925|3,4 Diaminopyridine
1316686|NCT00704912|Polycystic Ovary Syndrome
1316687|NCT00704886|dementia
1316688|NCT00704860|healthy volunteers treatment resistant major depression hippocampus atrophy MRI serotonin genotyping
1316689|NCT00704847|Osteoarthritis, oral salmon calcitonin, treatment, efficacy,
1316690|NCT00704847|tolerability
1316691|NCT00704834|Multiple Sclerosis
1316692|NCT00704834|Relapsing Remitting Multiple Sclerosis
1316693|NCT00704834|Chronic Progressive Multiple Sclerosis
1316694|NCT00704834|Clinically Isolated Syndrome
1316695|NCT00704834|Normal Controls
1316696|NCT00704834|Blood Draw
1316697|NCT00704821|Cancer
1316698|NCT00704821|PTC299
1316699|NCT00704821|VEGF
1316700|NCT00704821|Angiogenesis
1316701|NCT00704821|Post-transcriptional control
1316702|NCT00704821|Docetaxel
1316703|NCT00704743|Colles fracture treatment
1316704|NCT00704743|Displaced fracture of distal radius
1316705|NCT00704743|distal radius fracture treatment
1316706|NCT00704743|RCT
1316707|NCT00704743|Emergency Department
1316708|NCT00704743|cast
1316709|NCT00704743|splint
1316710|NCT00704743|treatment
1316711|NCT00704730|Medullary Thyroid Cancer
1316712|NCT00704730|MTC
1316713|NCT00704704|high risk MDS
1316714|NCT00704704|IPSS
1316715|NCT00704704|5-AZA-Cytidine
1316716|NCT00704704|Thalidomide
1316717|NCT00704704|response rate
1316718|NCT00704704|cytogenetic response
1316719|NCT00704704|QOL questionaries
1316720|NCT00704704|INT-2 or High risk MDS
1316721|NCT00704678|Chronic Kidney Disease
1316722|NCT00704678|hemodialysis
1316723|NCT00704678|hyperphosphatemia
1316724|NCT00704678|Asian
1316725|NCT00704678|patients
1316726|NCT00704665|Diffuse Scleroderma
1316727|NCT00704665|Skin score
1316728|NCT00704639|Head and Neck
1316729|NCT00704639|Cetuximab
1316730|NCT00704639|Carboplatin
1316731|NCT00704639|Radiotherapy
1316732|NCT00704626|Multiple Sclerosis
1316733|NCT00704626|Autoimmune disease
1316734|NCT00704626|Inflammatory disease
1316735|NCT00704626|Myasthenia Gravis
1316736|NCT00704626|Transverse Myelitis
1316737|NCT00704600|Locally advanced rectal cancer
1316738|NCT00704600|nelfinavir
1316739|NCT00704600|radiosensitivity
1316740|NCT00704600|chemoradiation
1316741|NCT00704587|cancer occurence
1316742|NCT00704587|cancer recurrence
1316743|NCT00704587|neo-adjuvant treatment response measurement
1316744|NCT00704561|Acute Myocardial Infarction
1316745|NCT00704561|Percutaneous Coronary Interventions
1316746|NCT00704561|Optical Coherence Tomography
1316747|NCT00704561|Thrombus
1316748|NCT00704509|Schizophrenia
1316749|NCT00704509|Antipsychotic
1316750|NCT00704509|Bifeprunox
1316751|NCT00704496|Sleep, Pseudoephedrine
1316752|NCT00704483|Chronic Kidney Disease
1316753|NCT00704483|hemodialysis
1316754|NCT00704483|hyperphosphatemia
1316755|NCT00704483|hemodiafiltration
1316756|NCT00704470|Patient Simulation
1316757|NCT00704470|Education, Medical, Continuing
1316758|NCT00704470|Education, Medical, Graduate
1316759|NCT00704470|Stress
1316760|NCT00704457|Interstitial Cystitis
1316761|NCT00704457|IC
1316762|NCT00704457|Sacral Nerve Stimulation
1316763|NCT00704431|SB-480848
1316764|NCT00704431|darapladib
1316765|NCT00704431|tolerability
1316766|NCT00704418|Cataract extraction
1316767|NCT00704418|intraocular lens implantation
1316768|NCT00704405|hepatitis C
1316769|NCT00704392|Solid tumors
1316770|NCT00704392|NSCLC
1316771|NCT00704379|traumatic brain injury
1316772|NCT00704379|TBI
1316773|NCT00704379|mood disorders
1316774|NCT00704379|anxiety disorders
1316775|NCT00704379|community reintegration
1316776|NCT00704379|executive function
1316777|NCT00704379|sertraline
1316778|NCT00704379|diffusion tensor imaging
1316779|NCT00704366|Advanced carcinoma
1316780|NCT00704327|Cognitive Functions
1316781|NCT00704327|Brain Ischemia
1316782|NCT00704327|Cerebral Atrophy
1316783|NCT00704327|Dementia
1316784|NCT00704327|Intracranial atherosclerosis
1316785|NCT00704327|Memory impairment
1316786|NCT00704314|Insulin resistance
1316787|NCT00704314|Statins
1316788|NCT00704314|Muscle and liver triglycerides
1316789|NCT00704301|Delirium
1316790|NCT00704301|Confusion
1316791|NCT00704288|GBM
1316792|NCT00704288|Malignant gliomas
1316793|NCT00704275|dry eye
1316794|NCT00704249|HIV infection
1316795|NCT00704249|nevirapine
1316796|NCT00704249|Treatment Experienced
1316797|NCT00704236|Traditional Chinese Treatment
1316798|NCT00704210|Low Back Pain
1316799|NCT00704171|Elective pulmonary resection via open thoracotomy.
1316800|NCT00704158|CR011-vcMMAE
1316801|NCT00704158|locally advanced breast cancer
1316802|NCT00704158|metastatic breast cancer
1316803|NCT00704158|breast cancer
1316804|NCT00704158|CuraGen
1316805|NCT00704145|Drug Eluting Stents
1316806|NCT00704145|Percutaneous Coronary Interventions
1316807|NCT00704145|Optical Coherence Tomography
1316808|NCT00704119|Rhudex
1316809|NCT00704119|pharmacokinetic study
1316810|NCT00704106|Hepatitis B
1316811|NCT00704106|HBV
1316812|NCT00704106|Treatment
1316813|NCT00704093|pacing
1316814|NCT00704093|perfusion
1316815|NCT00704093|oxidative metabolism
1316816|NCT00704093|efficiency
1316817|NCT00704080|GBM
1316818|NCT00704080|Anaplastic glioma
1316819|NCT00704067|vocational rehabilitation
1316820|NCT00704067|supported employment
1316821|NCT00704067|cognitive training
1316822|NCT00704067|cognitive remediation
1316823|NCT00704067|cognitive rehabilitation
1316824|NCT00704067|veterans
1316825|NCT00704054|Pediatric
1316826|NCT00704054|Solid Tumor
1316827|NCT00704054|CNS Tumor
1316828|NCT00704054|Lymphoma
1316829|NCT00704015|Smoking cessation
1316830|NCT00704015|Acute injury
1316831|NCT00704015|Musculoskeletal
1316832|NCT00704015|Postoperative complications
1316833|NCT00704002|neck fracture of the fifth metacarpal
1316834|NCT00704002|displacement
1316835|NCT00704002|antegrade intramedullary splinting
1316836|NCT00704002|conservative treatment
1316837|NCT00703989|hyperglycemia
1316838|NCT00703989|diabetic complications
1316839|NCT00703989|advanced glycation endproducts
1316840|NCT00703989|hexosamine pathway
1316841|NCT00703989|prostacyclin synthase
1316842|NCT00703989|reactive oxygen species
1316843|NCT00703976|head and neck cancers
1316844|NCT00703963|International normalized ratio (INR)
1316845|NCT00703950|Sucking patterns
1316846|NCT00703950|preterm infants
1316847|NCT00703950|breastfeeding
1316848|NCT00703924|cutaneous leishmaniasis topical treatment safety efficacy
1316849|NCT00703898|HIV
1316850|NCT00703898|nevirapine
1316851|NCT00703898|durability
1316852|NCT00703898|AIDS
1316853|NCT00703898|Treatment Naïve
1316854|NCT00703885|functional magnetic resonance imaging
1316855|NCT00703885|fMRI
1316856|NCT00703885|alprazolam
1316857|NCT00703885|anxiety disorders
1316858|NCT00703872|Chronic Hepatitis C
1316859|NCT00703872|Naive
1316860|NCT00703872|Nonresponders
1316861|NCT00703872|Interferon
1316862|NCT00703872|Patients with Chronic Hepatitis C
1316863|NCT00703859|Radiotherapy plus temozolomide plus DCA
1316864|NCT00703859|PK profile of DCA
1316865|NCT00703859|MGMT promoter methylation status
1316866|NCT00703859|Newly diagnosed Glioblastoma multiform tumours
1316867|NCT00703846|Phase 4
1316868|NCT00703846|Seborrheic
1316869|NCT00703846|Ketoconazole
1316870|NCT00703846|Dermatitis
1316871|NCT00703794|ev3 Neurovascular
1316872|NCT00703794|aneurysms
1316873|NCT00703794|cerebrovascular
1316874|NCT00703794|endovascular
1316875|NCT00703794|neurovascular therapies
1316876|NCT00703794|RACER
1316877|NCT00703794|AXIUM
1316878|NCT00703794|The AXIUM Progressive Coil System
1316879|NCT00703794|ev3
1316880|NCT00703794|MTI
1316881|NCT00703794|Micro Therapeutics
1316882|NCT00703794|FX detachable coil system
1316883|NCT00703794|K060747
1316884|NCT00703794|brain diseases
1316885|NCT00703781|Cataract extraction with intraocular lens implantation
1316886|NCT00703768|Quality of Life
1316887|NCT00703768|Androgen Deprivation Therapy
1316888|NCT00703768|Goserelin
1316889|NCT00703755|Diabetes
1316890|NCT00703755|Hypertriglyceridaemia
1316891|NCT00703755|Metabolic Syndrome
1316892|NCT00703716|mini-invasive
1316893|NCT00703716|dynamic screw-plate
1316894|NCT00703716|Surfix
1316895|NCT00703716|Lock-screw
1316896|NCT00703703|Heart rate, overactive bladder
1316897|NCT00703677|progressive supranuclear palsy
1316898|NCT00703677|corticobasal degeneration
1316899|NCT00703677|PSP
1316900|NCT00703677|CBD
1316901|NCT00703677|lithium
1316902|NCT00703677|tau
1316903|NCT00703651|Influenza
1316904|NCT00703651|Orthomyxoviridae Infection
1316905|NCT00703651|Inactivated, Split-virion influenza vaccine
1316906|NCT00703651|Intradermal injection
1316907|NCT00703651|Adults.
1316908|NCT00703612|Diabetes Mellitus
1316909|NCT00703612|Adipose-derived stem cells
1316910|NCT00703612|Adipose stromal vascular fraction
1316911|NCT00703612|Autologous
1316912|NCT00703612|Hyperglycemia
1316913|NCT00703599|Diabetes Mellitus
1316914|NCT00703599|Adipose-derived stem cells
1316915|NCT00703599|Adipose stromal vascular fraction
1316916|NCT00703599|Autologous
1316917|NCT00703599|Insulin-dependence
1316918|NCT00703586|Maraviroc
1316919|NCT00703586|Treatment Experienced
1316920|NCT00703573|Atopic Dermatitis
1316921|NCT00703560|HCV
1316922|NCT00703560|Genotype 1
1316923|NCT00703560|HIV co-infection
1316924|NCT00703560|viral kinetics
1316925|NCT00703560|HCV quasi-species
1316926|NCT00703560|Hepatitis C genotype 1
1316927|NCT00703560|HIV Infections
1316928|NCT00703547|Depression
1316929|NCT00703534|GERD
1316930|NCT00703534|Acid Reflux
1316931|NCT00703534|Heartburn
1316932|NCT00703534|Regurgitation
1316933|NCT00703534|non-acid reflux
1316934|NCT00703534|PRO measures
1316935|NCT00703521|rabies vaccination
1316936|NCT00703521|pre-exposure prophylaxis
1316937|NCT00703521|rabies virus neutralizing antibody
1316938|NCT00703521|Antibody response
1316939|NCT00703521|immunologic memory of rabies vaccination
1316940|NCT00703521|Safety of rabies vaccination administered in pre-exposure regimens both intramuscular and intradermal routes
1316941|NCT00703508|PCOS
1316942|NCT00703495|traumatic
1316943|NCT00703495|brain injury
1316944|NCT00703495|brain regional oxygen saturation (rSO2)
1316945|NCT00703495|brain tissue oxygenation (PbtO2)
1316946|NCT00703495|cerebral perfusion pressure (CPP)
1316947|NCT00703482|Ventricular diastolic Function
1316948|NCT00703482|Diabetes
1316949|NCT00703469|Hep C
1316950|NCT00703456|Functional ankle instability
1316951|NCT00703456|Balance training
1316952|NCT00703443|Genetics
1316953|NCT00703443|Dilated Cardiomyopathy
1316954|NCT00703443|Hypertrophic Cardiomyopathy
1316955|NCT00703443|Mitochondrial Cardiomyopathy
1316956|NCT00703443|Noncompaction Cardiomyopathy
1316957|NCT00703443|Restrictive Cardiomyopathy
1316958|NCT00703443|Heart Failure
1316959|NCT00703430|Alzheimer's disease, agitation, aggression, dementia
1316960|NCT00703417|osteoporosis
1316961|NCT00703417|diabetes
1316962|NCT00703404|Anti-Retroviral Therapy
1316963|NCT00703404|HIV
1316964|NCT00703404|Virologic Response
1316965|NCT00703404|Treatment Naïve
1316966|NCT00703391|Chronic
1316967|NCT00703391|obstructive
1316968|NCT00703391|pulmonary
1316969|NCT00703391|lung
1316970|NCT00703391|respiratory disease
1316971|NCT00703391|tolerability
1316972|NCT00703391|placebo-controlled
1316973|NCT00703391|pharmacokinetics
1316974|NCT00703391|COPD
1316975|NCT00703365|Hepatocellular Carcinoma (HCC)
1316976|NCT00703352|Transposition of the great arteries.
1316977|NCT00703352|Transposition of the great vessels.
1316978|NCT00703352|Mustard.
1316979|NCT00703352|Senning.
1316980|NCT00703339|fibrosis, pulmonary
1316981|NCT00703339|hypertension, pulmonary
1316982|NCT00703339|exercise, aerobic
1316983|NCT00703326|Metastatic breast cancer
1316984|NCT00703326|HER2 negative breast cancer
1316985|NCT00703326|locally recurrent breast cancer
1316986|NCT00703313|Study drug concentration in human tears
1316987|NCT00703274|ischemic stroke
1316988|NCT00703274|stroke
1316989|NCT00703274|cerebrovascular stroke
1316990|NCT00703274|cerebrovascular accident
1316991|NCT00703274|CVA
1316992|NCT00703274|community health services
1316993|NCT00703274|community health workers
1316994|NCT00703274|navigators
1316995|NCT00703274|health education
1316996|NCT00703274|barriers to care
1316997|NCT00703274|healthcare access
1316998|NCT00703274|healthcare disparities
1316999|NCT00703248|Human Immunodeficiency Virus (HIV)
1317000|NCT00703248|complementary therapies
1317001|NCT00703222|high-risk neuroblastoma
1317002|NCT00703222|single autologous stem cell rescue
1317003|NCT00703209|symptomatic diabetic neuropathy
1317004|NCT00703209|diabetes
1317005|NCT00703209|burning feet
1317006|NCT00703209|Diabetic Neuropathy
1317007|NCT00703209|Loss of sensation in the foot
1317008|NCT00703209|Neuropathy
1317009|NCT00703209|Painful Diabetic Neuropathy
1317010|NCT00703196|cervical cancer
1317011|NCT00703196|human papilloma virus infection
1317012|NCT00703196|low-grade squamous intraepithelial lesion
1317013|NCT00703196|high-grade squamous intraepithelial lesion
1317014|NCT00703196|atypical squamous cells of undetermined significance
1317015|NCT00703196|cervical intraepithelial neoplasia grade 1
1317016|NCT00703196|cervical intraepithelial neoplasia grade 2
1317017|NCT00703196|cervical intraepithelial neoplasia grade 3
1317018|NCT00703144|Pharmacokinetics
1317019|NCT00703144|piperacillin/tazobactam.
1317020|NCT00703144|Septic patients
1317021|NCT00703144|oliguric renal failure
1317022|NCT00703144|continuous veno-venous hemodiafiltration.
1317023|NCT00703131|fistula
1317024|NCT00703131|anal fistula
1317025|NCT00703118|Hepatitis C, Chronic
1317026|NCT00703118|Telaprevir
1317027|NCT00703118|Peg-IFN-alfa-2a
1317028|NCT00703118|Ribavirin
1317029|NCT00703105|ovarian cancer
1317030|NCT00703105|Tregs
1317031|NCT00703105|vaccine
1317032|NCT00703105|Recurrent Ovarian Cancer
1317033|NCT00703079|Acromegaly
1317034|NCT00703079|GH
1317035|NCT00703079|IGF-I
1317036|NCT00703079|Octreotide-LAR
1317037|NCT00703079|Lanreotide
1317038|NCT00703079|Transsphenoidal surgery
1317039|NCT00703066|Malaria
1317040|NCT00703066|Vaccine
1317041|NCT00703066|GMZ2
1317042|NCT00703066|Safety
1317043|NCT00703066|African
1317044|NCT00703066|immunogenicity
1317045|NCT00703053|influenza, H5N1, vaccine, avian influenza, parent protocol
1317046|NCT00703040|Care engagement
1317047|NCT00703040|Linkage to care
1317048|NCT00703040|HIV Infections
1317049|NCT00703027|diabetes mellitus
1317050|NCT00703027|care decision
1317051|NCT00703027|data mining
1317052|NCT00703014|Neonatal outcome
1317053|NCT00703014|Congenital malformations
1317054|NCT00703014|In-Vitro fertilization
1317055|NCT00703014|Controlled ovarian stimulation
1317056|NCT00703014|Follow-up
1317062|NCT00702975|phase II
1317063|NCT00702975|NSCLC
1317064|NCT00702975|bevacizumab
1317065|NCT00702975|erlotinib
1317066|NCT00702975|metastatic NSCLC
1317067|NCT00702962|lung cancer
1317068|NCT00702962|small cell lung cancer
1317069|NCT00702949|breast cancer
1317070|NCT00702949|hot flashes
1317071|NCT00702923|Stage D0 Prostate Cancer
1317072|NCT00702923|Rising PSA
1317073|NCT00702923|Casodex
1317074|NCT00702923|Tremelimumab
1317075|NCT00702910|Asthma patients
1317076|NCT00702910|Magnesium stearate
1317077|NCT00702910|Tolerability
1317078|NCT00702910|Safety
1317079|NCT00702910|Lactose
1317080|NCT00702910|GW642444M
1317081|NCT00702910|Pharmacodynamics
1317082|NCT00702910|Efficacy
1317083|NCT00702910|Pharmacokinetics
1317084|NCT00702884|recurrent esophageal cancer
1317085|NCT00702884|stage IIIA esophageal cancer
1317086|NCT00702884|stage IIIB esophageal cancer
1317087|NCT00702884|stage IIIC esophageal cancer
1317088|NCT00702884|stage IV esophageal cancer
1317089|NCT00702871|Ventilator Associated Pneumonia
1317090|NCT00702871|antimicrobial susceptibility pattern
1317091|NCT00702871|stress ulcer prophylaxis
1317092|NCT00702858|Breast Cancer
1317093|NCT00702858|Joint Pain
1317094|NCT00702858|Aromatase Inhibitors
1317095|NCT00702845|In vitro fertilization
1317096|NCT00702845|Pharmacological effects of drugs
1317097|NCT00702845|Hormones
1317098|NCT00702845|Hormone Substitutes and Hormone Antagonists
1317099|NCT00702845|Pharmacological Actions
1317100|NCT00702845|Randomized
1317101|NCT00702845|Multi-center
1317102|NCT00702845|Multi-national
1317103|NCT00702845|Double-blind
1317104|NCT00702845|Active-controlled
1317105|NCT00702845|Equivalence
1317106|NCT00702832|Vestibular rehabilitation
1317107|NCT00702832|acute vestibular injury
1317108|NCT00702832|Dizziness
1317109|NCT00702832|Nausea
1317110|NCT00702832|Nystagmus
1317111|NCT00702832|Daily life activities
1317112|NCT00702832|Balance
1317113|NCT00702832|physiotherapy
1317114|NCT00702819|Pan-Vascular Endothelial Growth Factor Blockade
1317115|NCT00702819|Safety
1317116|NCT00702806|Pharmacological effects of drugs
1317117|NCT00702806|Hormones
1317118|NCT00702806|Hormone substitutes and Hormone Antagonists
1317119|NCT00702806|Pharmacological Actions
1317120|NCT00702806|Randomized
1317121|NCT00702806|Multi-center
1317122|NCT00702806|Multi-national
1317123|NCT00702793|Smoking cessation
1317124|NCT00702793|schizophrenia
1317125|NCT00702793|schizoaffective
1317126|NCT00702793|psychosis
1317127|NCT00702793|varenicline
1317128|NCT00702793|champix
1317129|NCT00702793|chantix
1317130|NCT00702793|nicotine dependence
1317131|NCT00702780|Alzheimer's disease
1317132|NCT00702780|escitalopram
1317133|NCT00702780|MRI
1317134|NCT00702767|This study was completed in October 2006
1317135|NCT00702741|Knee
1317136|NCT00702741|Meniscus
1317137|NCT00702741|Meniscectomy
1317138|NCT00702741|Mesenchymal Stem Cells
1317139|NCT00702741|MSCs
1317140|NCT00702741|Adult Human Stem Cells
1317141|NCT00702741|Osiris
1317142|NCT00702741|Chondrogen
1317143|NCT00702728|Contrast induced nephropathy
1317144|NCT00702728|Furosemide
1317145|NCT00702728|Percutaneous coronary interventions
1317146|NCT00702728|Saline hydration
1317147|NCT00702702|Uterine fibroids
1317148|NCT00702702|Anemia
1317149|NCT00702689|Skin Sclerosis
1317150|NCT00702689|Graft Versus Host Disease
1317151|NCT00702676|Healthy Volunteers
1317152|NCT00702663|Hepatitis B
1317153|NCT00702663|Hepatitis B vaccination
1317154|NCT00702663|booster effect
1317155|NCT00702663|Taiwan
1317156|NCT00702663|young adults
1317157|NCT00702637|Traumatic Brain Injury
1317158|NCT00702637|Fatigue
1317159|NCT00702637|Modafinil
1317160|NCT00702637|Somnolence
1317161|NCT00702624|Neonatal outcome
1317162|NCT00702624|Congenital malformations
1317163|NCT00702624|In-Vitro fertilization
1317164|NCT00702624|Controlled ovarian stimulation
1317165|NCT00702624|Follow-up
1317166|NCT00702611|Ulcerative Colitis
1317167|NCT00702611|Inflammatory Bowel disease
1317168|NCT00702611|Steroid dependent
1317169|NCT00702611|Adacolumn
1317170|NCT00702611|Apheresis
1317171|NCT00702611|Granulocyte Monocyte apheresis
1317172|NCT00702611|GMA apheresis
1317173|NCT00702611|Granulocytapheresis
1317174|NCT00702598|Depression
1317175|NCT00702598|occupational function
1317176|NCT00702598|rating scales
1317177|NCT00702598|RCT
1317178|NCT00702598|cognitive behaviour therapy
1317179|NCT00702598|CBT
1317180|NCT00702598|escitalopram
1317181|NCT00702598|antidepressants
1317182|NCT00702585|Ovulation Induction
1317183|NCT00702585|Pharmacological effects of drugs
1317184|NCT00702585|Hormones
1317185|NCT00702585|Hormone substitutes and Hormone Antagonists
1317186|NCT00702585|Pharmacological Actions
1317187|NCT00702585|Randomized
1317188|NCT00702585|Multi-center
1317189|NCT00702585|Multi-national
1317190|NCT00702572|Phase I
1317191|NCT00702572|Advanced non-small cell lung cancer
1317192|NCT00702546|In-vitro fertilization
1317193|NCT00702546|Controlled Ovarian Stimulation
1317194|NCT00702546|Cumulative pregnancy data
1317195|NCT00702546|Follow-up
1317196|NCT00702533|Hyper/Hyposecretion
1317197|NCT00702533|Gastric Analysis
1317198|NCT00702533|Gastric pH
1317199|NCT00702533|SmartPill
1317200|NCT00702533|ph Monitoring
1317201|NCT00702533|Gastric Secretion
1317202|NCT00702533|Gastric Acid Output
1317203|NCT00702533|Healthy Volunteer
1317204|NCT00702533|HV
1317205|NCT00702520|Neonatal outcome
1317206|NCT00702520|Congenital malformations
1317207|NCT00702520|In-Vitro fertilization
1317208|NCT00702520|Controlled ovarian stimulation
1317209|NCT00702520|Follow-up
1317210|NCT00702507|Diaper dermatitis complicated by candidiasis
1317211|NCT00702494|placental growth factor
1317212|NCT00702494|monoclonal antibody
1317213|NCT00702494|Phase I
1317214|NCT00702494|solid tumors
1317215|NCT00702494|Patients with solid tumors
1317216|NCT00702481|Head and Neck Squamous Cell Cancer
1317217|NCT00702481|Chemoradiation
1317218|NCT00702481|EGFR monoclonal antibody
1317219|NCT00702468|Spasticity
1317220|NCT00702468|Multiple Sclerosis
1317221|NCT00702455|Weight loss maintenance.
1317222|NCT00702455|Interactive phone and mail-based intervention.
1317223|NCT00702442|Nausea, Vomiting
1317224|NCT00702442|Vomiting episodes
1317225|NCT00702416|Analgesia, Patient-controlled
1317226|NCT00702416|Anesthesia, Regional
1317227|NCT00702416|Ultrasound
1317228|NCT00702416|Postoperative Pain
1317229|NCT00702416|Brachial Plexus
1317230|NCT00702364|Attention
1317231|NCT00702364|Traumatic Brain INjury
1317232|NCT00702364|Atomoxetine
1317233|NCT00702364|Strattera
1317234|NCT00702351|Infertility
1317235|NCT00702351|Pharmacological effects of drugs
1317236|NCT00702351|Drug therapy
1317237|NCT00702351|Hormones
1317238|NCT00702351|GnRH agonist
1317239|NCT00702351|RecFSH
1317240|NCT00702351|Corifollitropin alfa
1317241|NCT00702351|Open-label
1317242|NCT00702338|Neonatal outcome
1317243|NCT00702338|Congenital malformations
1317244|NCT00702338|Ovulation Induction
1317245|NCT00702338|Follow-up
1317246|NCT00702325|Asthma
1317247|NCT00702312|Blood pressure
1317248|NCT00702299|stage III ovarian epithelial cancer
1317249|NCT00702299|recurrent ovarian epithelial cancer
1317250|NCT00702299|peritoneal cavity cancer
1317251|NCT00702299|fallopian tube cancer
1317252|NCT00702286|Surface acoustic ultrasound
1317253|NCT00702286|biofilm formation
1317254|NCT00702286|percoutaneous nephrostomy tube
1317255|NCT00702286|Patients requiring per coetaneous drainage due to urinary
1317256|NCT00702286|tract obstruction
1317257|NCT00702286|To evaluate the efficacy of surface acoustic wave in
1317258|NCT00702286|reducing pain and improving drainage
1317259|NCT00702273|In-vitro fertilization
1317260|NCT00702273|Controlled Ovarian Stimulation
1317261|NCT00702273|Cumulative pregnancy data
1317262|NCT00702273|Follow-up
1317263|NCT00702247|Multiple Myeloma - Nonmyeloablative transplantation - Autologous Transplant - Graft versus myeloma
1317264|NCT00702247|Newly diagnosed multiple myeloma
1317265|NCT00702247|Tandem Auto-Allo Transplant
1317266|NCT00702247|Overall survival
1317267|NCT00702247|Event free survival
1317268|NCT00702247|Disease response
1317269|NCT00702234|Neonatal outcome
1317270|NCT00702234|Congenital malformations
1317271|NCT00702234|In-Vitro fertilization
1317272|NCT00702234|Controlled ovarian stimulation
1317273|NCT00702234|Follow-up
1317274|NCT00702221|high blood pressure
1317275|NCT00702221|vaccines
1317276|NCT00702208|cervical cytology
1317277|NCT00702208|Pap smear
1317278|NCT00702208|self-sampling
1317279|NCT00702208|abnormal
1317280|NCT00702208|normal
1317281|NCT00702195|Neonatal outcome
1317282|NCT00702195|Congenital malformations
1317283|NCT00702195|In-Vitro Fertilization
1317284|NCT00702195|Controlled ovarian stimulation
1317285|NCT00702195|Follow-up
1317286|NCT00702195|Ovulation Induction
1317287|NCT00702195|Neonates
1317288|NCT00702182|Lung Cancer
1317289|NCT00702182|Vinorelbine
1317290|NCT00702182|Erlotinib
1317291|NCT00702182|Phase 1
1317292|NCT00702169|high frequency ventilation monitoring
1317293|NCT00702169|lung disease
1317294|NCT00702169|Respiratory distress syndrome
1317295|NCT00702169|lung barotrauma
1317296|NCT00702169|mechanical ventilation
1317297|NCT00702169|endotracheal tube displacement
1317298|NCT00702169|endotracheal tube occlusion
1317299|NCT00702169|one lung intubation
1317300|NCT00702156|Heart Failure
1317301|NCT00702156|Chronic Obstructive Pulmonary Disease
1317302|NCT00702156|Beta-blockers
1317303|NCT00702156|Pulmonary Function
1317304|NCT00702130|Ventilator Associated Pneumonia
1317305|NCT00702104|prostate cancer
1317306|NCT00702078|COPD
1317307|NCT00702078|home-based treatment
1317308|NCT00702078|early intervention
1317309|NCT00702065|Multiple Sclerosis Quality of life
1317310|NCT00702052|Mantle Cell Lymphoma
1317311|NCT00702052|Lymphoma
1317312|NCT00702052|B-Cell Lymphoma
1317313|NCT00702052|Mantle Zone Lymphoma
1317314|NCT00702052|Refractory Lymphoma
1317315|NCT00702052|Aggressive Lymphoma
1317316|NCT00702052|PILLAR-1
1317317|NCT00702026|Irritable Bowel Syndrome
1317318|NCT00702026|Hypersensitivity
1317319|NCT00702026|Probiotics
1317320|NCT00702026|Multispecies
1317321|NCT00702013|P-glycoprotein
1317322|NCT00702013|lymphocyte
1317323|NCT00702013|HIV
1317324|NCT00702013|children
1317325|NCT00702013|ontogenesis
1317326|NCT00702013|Ontogenesis P-gp in human lymphocytes
1317327|NCT00702013|Study of the influence of HIV infection
1317328|NCT00702013|Antiretroviral treatments on P-gp activity
1317329|NCT00702013|Expression in human lymphocytes
1317330|NCT00702000|ICU acquired paresis
1317331|NCT00701987|Cutaneous Metastatic Melanoma
1317332|NCT00701974|Non-inferiority based on efficiency
1317333|NCT00701961|Mefloquine-artesunate
1317334|NCT00701961|Malaria
1317335|NCT00701961|Pregnancy
1317336|NCT00701961|Pharmacokinetics
1317337|NCT00701961|Sub-Saharan Africa
1317338|NCT00701961|P falciparum malaria infection in pregnancy
1317339|NCT00701948|Late onset neonatal sepsis
1317340|NCT00701948|Nosocomial bacterial infection
1317341|NCT00701948|Inflammatory markers
1317342|NCT00701948|multiplex dosage
1317343|NCT00701935|diabetes mellitus
1317344|NCT00701935|Amylin
1317345|NCT00701935|Lilly
1317346|NCT00701922|lung transplantation
1317347|NCT00701922|Bronchiolitis Obliterans
1317348|NCT00701922|Epstein-Barr Virus Infections
1317349|NCT00701922|Paramyxoviridae Infections
1317350|NCT00701922|Herpesviridae
1317351|NCT00701909|wound care
1317352|NCT00701909|procedural pain intensity
1317353|NCT00701909|procedural hyperalgesia
1317354|NCT00701909|wound care pain intensity
1317355|NCT00701909|wound care hyperalgesia
1317356|NCT00701909|Wound care pain quality
1317357|NCT00701909|Level of drowsiness
1317358|NCT00701909|level of nausea
1317359|NCT00701909|Level of vomiting
1317360|NCT00701909|Level of hallucinations
1317361|NCT00701909|Level of dysphoria
1317362|NCT00701896|HIV
1317363|NCT00701896|Positive
1317364|NCT00701896|Smokers
1317365|NCT00701896|Varenicline
1317366|NCT00701883|Cholesterol
1317367|NCT00701883|Hyperlipidemia
1317368|NCT00701883|HDL
1317369|NCT00701883|LDL
1317370|NCT00701883|Triglycerides
1317371|NCT00701883|Dyslipidemia
1317372|NCT00701870|NSCLC
1317373|NCT00701870|Chemotherapy induced neutropenia
1317374|NCT00701870|CIN
1317375|NCT00701857|stage III esophageal cancer
1317376|NCT00701857|stage IV esophageal cancer
1317377|NCT00701844|Aplastic Anemia
1317378|NCT00701844|Lymphatic Diseases
1317379|NCT00701844|Leukemia
1317380|NCT00701844|Leukemia, Lymphoid
1317381|NCT00701844|Immunoproliferative Disorders
1317382|NCT00701844|Precursor Cell Lymphoblastic Leukemia-Lymphoma
1317383|NCT00701844|Anemia
1317384|NCT00701844|Quality of Life
1317385|NCT00701844|Lymphoproliferative Disorders
1317386|NCT00701844|Lymphoma
1317387|NCT00701844|Multiple Myeloma
1317388|NCT00701805|Secondary hyperparathyroidism
1317389|NCT00701805|Hemodialysis
1317390|NCT00701805|paricalcitol
1317391|NCT00701792|cirrhosis transplantation
1317392|NCT00701779|Benign Prostatic Hyperplasia
1317393|NCT00701779|Dutasteride
1317394|NCT00701779|Tamsulosin
1317395|NCT00701753|Pharmacogenetic
1317396|NCT00701753|DNA
1317397|NCT00701753|RNA
1317398|NCT00701753|Antipsychotic
1317399|NCT00701753|Olanzapine
1317400|NCT00701753|Risperidone
1317401|NCT00701753|Quetiapine
1317402|NCT00701753|Personalized medicine
1317403|NCT00701740|photoaging
1317404|NCT00701740|isotretinoin
1317405|NCT00701740|profilometry
1317406|NCT00701740|digital analysis
1317407|NCT00701727|metabolic diseases
1317408|NCT00701727|metabolic disorder
1317409|NCT00701727|dyslipidemias
1317410|NCT00701727|lipid metabolism disorders
1317411|NCT00701714|Treatment
1317412|NCT00701714|associated
1317413|NCT00701714|with CRI
1317414|NCT00701688|Mucositis, Oral
1317415|NCT00701688|Hematopoietic Stem Cell Transplantation
1317416|NCT00701688|Allogeneic Transplantation
1317417|NCT00701688|Pharmacokinetics
1317418|NCT00701688|Maximum Tolerated Dose
1317419|NCT00701675|sertraline
1317420|NCT00701675|pharmacotherapy
1317421|NCT00701675|geriatric
1317422|NCT00701649|mild essential hypertension
1317423|NCT00701649|moderate essential hypertension
1317424|NCT00701636|Daptomycin
1317425|NCT00701636|Antibiotic Prophylaxis
1317426|NCT00701636|Pharmacokinetics
1317427|NCT00701636|Surgical Wound Infection
1317428|NCT00701636|Staphylococcus aureus
1317429|NCT00701636|Cardiopulmonary Bypass Surgery
1317430|NCT00701623|The intention of this work is to verify the effectiveness and safety of sodium heparin in the treatment of burns of the skin.
1317431|NCT00701610|Von Willebramd Factor (VWF)
1317432|NCT00701610|All infants born in our hospital since August 2007 ill august 2009 will enter.
1317433|NCT00701610|Therombocytopenia, maternal aspirin will be excluded
1317434|NCT00701597|ocular blood flow dysregulation, glaucoma, endothelin-1
1317435|NCT00701584|Phytoestrogens
1317436|NCT00701584|Isoflavones
1317437|NCT00701584|Lignans
1317438|NCT00701584|Breast cancer survival
1317439|NCT00701584|breast cancer recurrence
1317440|NCT00701571|Virtual Reality
1317441|NCT00701571|Oncology
1317442|NCT00701571|Lumbar puncture
1317443|NCT00701545|von Willebrand disease
1317444|NCT00701545|VWD, Humate-P®
1317445|NCT00701545|Infusion volume reduced
1317446|NCT00701545|ivr
1317447|NCT00701532|Cocaine
1317448|NCT00701532|Substance abuse
1317449|NCT00701532|Addiction
1317450|NCT00701532|Dependence
1317451|NCT00701532|Modafinil
1317452|NCT00701532|Brain imaging
1317453|NCT00701519|CHF,
1317454|NCT00701519|Sleep apnea,
1317455|NCT00701519|Obstructive sleep apnea,
1317456|NCT00701519|Heart failure
1317457|NCT00701506|Knee
1317458|NCT00701506|Osteoarthritis
1317459|NCT00701506|Treatment
1317460|NCT00701506|Electrostimulation
1317461|NCT00701493|Topiramate
1317462|NCT00701493|Topiramate oral liquid
1317463|NCT00701493|TOPAMAX Sprinkle capsule
1317464|NCT00701493|topiramate capsules
1317465|NCT00701480|acne
1317466|NCT00701480|skin cleanser
1317467|NCT00701480|Hibiscus sabdariffa
1317468|NCT00701480|Roselle
1317469|NCT00701480|safety
1317470|NCT00701480|efficacy
1317471|NCT00701467|ICD
1317472|NCT00701467|ICD implanted patients
1317473|NCT00701454|Thai-muslim
1317474|NCT00701454|Thai-HALAL
1317475|NCT00701454|Diabetes
1317476|NCT00701454|Hypertension
1317477|NCT00701454|Hyperlipidemia
1317478|NCT00701454|Metabolic syndrome
1317479|NCT00701441|sleep apnea,
1317480|NCT00701441|oxidative stress
1317481|NCT00701428|Hypertension
1317482|NCT00701428|Sleep Apnea
1317483|NCT00701428|Angiotensin II antagonist
1317484|NCT00701428|CPAP
1317485|NCT00701415|α-GAL, α-Galactosidase-A, r-hαGAL
1317486|NCT00701402|time to lipid-lowering drug implementation
1317487|NCT00701402|dyslipidemic patients
1317488|NCT00701376|Gastric Bypass surgery
1317489|NCT00701376|Hepatic disease
1317490|NCT00701376|Hepatic function
1317491|NCT00701350|Pregnancy
1317492|NCT00701350|Intra-amniotic Infection
1317493|NCT00701350|Preterm Birth
1317494|NCT00701350|Preterm Premature Rupture of Membranes
1317495|NCT00701337|Estrogen Replacement Therapy
1317496|NCT00701337|menopausal women
1317497|NCT00701311|Prostatitis
1317498|NCT00701311|Pelvic pain
1317499|NCT00701285|heart failure
1317500|NCT00701285|pitavastatin
1317501|NCT00701285|pravastatin
1317502|NCT00701285|statin
1317503|NCT00701259|Frequent heartburn, proton pump inhibitor, lansoprazole
1317504|NCT00701259|Treatment of
1317505|NCT00701259|over 14 days
1317506|NCT00701246|Anemia
1317507|NCT00701246|Iron deficiency anemia
1317508|NCT00701246|Infants
1317509|NCT00701246|Children
1317510|NCT00701246|Clinical trials
1317511|NCT00701246|Ferrous sulfate
1317512|NCT00701246|Folic acid
1317513|NCT00701246|Daycare centers
1317514|NCT00701246|Anaemia in children
1317515|NCT00701246|born at term
1317516|NCT00701246|non-twins
1317517|NCT00701246|with parental approval for participation in the study
1317518|NCT00701246|growth
1317519|NCT00701220|Cardiovascular Disease
1317520|NCT00701220|Cardiomyopathy
1317521|NCT00701220|Heart Disease
1317522|NCT00701220|Myocardial Disease
1317523|NCT00701220|Myocardial Ischemia
1317524|NCT00701207|To determine if nicotine treatment reduces lung inflammation
1317525|NCT00701194|placement instability
1317526|NCT00701194|disruptive behavior disorders
1317527|NCT00701194|school readiness
1317528|NCT00701194|developmental delays
1317529|NCT00701194|cortisol
1317530|NCT00701194|executive functioning
1317531|NCT00701194|therapeutic foster care
1317532|NCT00701194|prevention
1317533|NCT00701194|early intervention
1317534|NCT00701181|Phase II
1317535|NCT00701181|Prospective
1317536|NCT00701181|Randomized
1317537|NCT00701181|Diabetic Macular Edema
1317538|NCT00701181|PF-04523655
1317539|NCT00701181|Laser
1317540|NCT00701129|Glycogenesis 2
1317541|NCT00701129|Acid
1317542|NCT00701129|Maltase
1317543|NCT00701129|Deficiency
1317544|NCT00701090|Type 2 Diabetes Mellitus
1317545|NCT00701090|Non Insulin Dependent
1317546|NCT00701077|Brugada syndrome
1317547|NCT00701077|Electrophysiological study
1317548|NCT00701077|Ion channel blockade
1317549|NCT00701064|posttraumatic stress disorder
1317550|NCT00701064|phototherapy
1317551|NCT00701064|anxiety
1317552|NCT00701064|depression
1317553|NCT00701064|sleep
1317554|NCT00701064|negative ion generator
1317555|NCT00701038|Sleep apnea,
1317556|NCT00701038|obstructive sleep apnea,
1317557|NCT00701038|heart failure,
1317558|NCT00701038|CHF
1317559|NCT00701025|inflammation in asthmatic and non-asthmatic participants
1317560|NCT00701012|low or high ligation
1317561|NCT00700986|Electroretinography
1317562|NCT00700986|Rheumatoid Arthritis
1317563|NCT00700986|Anti-TNF
1317564|NCT00700986|Disease Modifying Anti-Rheumatic Drugs (DMARD)
1317565|NCT00700973|anger
1317566|NCT00700973|psychotherapy, brief
1317567|NCT00700973|diagnosis, dual
1317568|NCT00700947|Heart Disease
1317569|NCT00700947|Mitral Regurgitation
1317570|NCT00700947|Heart Valve Disease
1317571|NCT00700947|Mitral Valve Insufficiency
1317572|NCT00700947|Heart Surgery
1317573|NCT00700947|Heart Valve Surgery
1317574|NCT00700934|FEV1
1317575|NCT00700934|mortality
1317576|NCT00700934|Quality of life
1317577|NCT00700908|type 2 diabetes
1317578|NCT00700908|telephone intervention
1317579|NCT00700908|automated
1317580|NCT00700882|stage IV melanoma
1317581|NCT00700882|acral lentiginous malignant melanoma
1317582|NCT00700882|mucosal melanoma
1317583|NCT00700882|recurrent melanoma
1317584|NCT00700882|stage IIIA melanoma
1317585|NCT00700882|stage IIIB melanoma
1317586|NCT00700882|stage IIIC melanoma
1317587|NCT00700869|Altered level of consciousness
1317588|NCT00700869|Tracheal tube withdrawal
1317589|NCT00700869|Respiration
1317590|NCT00700869|Artificial Respiration
1317591|NCT00700869|Physiology
1317592|NCT00700856|diabetes
1317593|NCT00700856|cardiovascular disease
1317594|NCT00700856|pioglitazone
1317595|NCT00700856|sulphonylurea
1317596|NCT00700856|metformin monotherapy
1317597|NCT00700856|hypoglycemic therapy
1317598|NCT00700843|bariatric surgery
1317599|NCT00700843|long term follow up
1317600|NCT00700843|gastric partitioning surgery
1317601|NCT00700843|Roux-en-Y gastric bypass surgery
1317602|NCT00700843|obesity
1317603|NCT00700804|Calcium retention
1317604|NCT00700804|dietary protein
1317605|NCT00700804|dietary calcium
1317606|NCT00700791|Single and bilateral body contouring surgical sites.
1317607|NCT00700778|breast cancer
1317608|NCT00700778|BRCA1 mutation carrier
1317609|NCT00700739|Cervical
1317610|NCT00700739|Disc
1317611|NCT00700739|Arthroplasty
1317612|NCT00700739|Spinal
1317613|NCT00700726|blood test
1317614|NCT00700726|asthma
1317615|NCT00700726|skin test
1317616|NCT00700713|Meningitis
1317617|NCT00700713|Meningococcemia
1317618|NCT00700713|Neisseria meningitidis
1317619|NCT00700713|Menactra®
1317620|NCT00700700|Congestive Heart Failure
1317621|NCT00700700|Cardiac Resynchronization Therapy
1317622|NCT00700700|Dyspnea
1317623|NCT00700700|Exercise Tolerance
1317624|NCT00700687|cardiovascular prophylactic therapy
1317625|NCT00700674|EEG entropy
1317626|NCT00700674|Elderly
1317627|NCT00700674|Decreases
1317628|NCT00700674|POCD
1317629|NCT00700674|Use of EEG entropy
1317630|NCT00700674|Geriatric
1317631|NCT00700635|Meningitis; Meningococcal infection, Neisseria meningitidis
1317632|NCT00700609|Depression
1317633|NCT00700609|Family Therapy
1317634|NCT00700609|Adolescents
1317635|NCT00700596|Salvia
1317636|NCT00700596|SA
1317637|NCT00700596|Salvinorin
1317638|NCT00700596|Psychotomimetic Effects
1317639|NCT00700583|nocturia
1317640|NCT00700583|bladder
1317641|NCT00700583|urination disorders
1317642|NCT00700583|hydrochlorothiazide
1317643|NCT00700583|terazosin
1317644|NCT00700557|Antibiotic Associated Diarrhea
1317645|NCT00700557|probiotics
1317646|NCT00700557|treatment
1317647|NCT00700544|AML
1317648|NCT00700544|elderly patients
1317649|NCT00700544|Treatment outcome
1317650|NCT00700531|Hemodialysis
1317651|NCT00700531|Multiple myeloma
1317652|NCT00700531|Cast nephropathy
1317653|NCT00700531|Kidney failure
1317654|NCT00700518|Raynaud's Syndrome
1317655|NCT00700518|Raynaud's Disease
1317656|NCT00700518|RP
1317657|NCT00700505|Benign Prostatic Hyperplasia
1317658|NCT00700505|BPH
1317659|NCT00700505|Benign Prostatic Hypertrophy
1317660|NCT00700505|Urinary Retention
1317661|NCT00700505|Shy Bladder
1317662|NCT00700505|Urinary Hesitancy
1317663|NCT00700505|Bashful Bladder
1317664|NCT00700505|Paruresis
1317665|NCT00700492|subfertility
1317666|NCT00700492|pregnancy rate
1317667|NCT00700492|miscarriage
1317668|NCT00700479|vascular endothelium
1317669|NCT00700479|nitric oxide
1317670|NCT00700479|aldosterone
1317671|NCT00700479|vascular biology
1317672|NCT00700466|Outcome assessment, patients;
1317673|NCT00700466|autonomic nervous system;
1317674|NCT00700466|perioperative care;
1317675|NCT00700466|adrenergic beta antagonist
1317676|NCT00700466|Autonomic regulation
1317677|NCT00700466|Perioperative beta-blockade
1317678|NCT00700466|outcome
1317679|NCT00700440|Radiotherapy
1317680|NCT00700440|chemotherapy
1317681|NCT00700440|Drug Targeting
1317682|NCT00700440|loco-regionally advanced nasopharyngeal carcinoma
1317683|NCT00700440|Safety.
1317684|NCT00700440|efficacy
1317685|NCT00700427|ADHD
1317686|NCT00700427|Adult
1317687|NCT00700427|long term
1317688|NCT00700427|maintenance of response
1317689|NCT00700427|Attention Deficit Hyperactivity Disorder
1317690|NCT00700388|Chronic bronchitis
1317691|NCT00700388|COPD
1317692|NCT00700388|Bronchiectasis
1317693|NCT00700375|Patients undergoing an emergent coronary procedure
1317694|NCT00700362|Complications
1317695|NCT00700362|Hyperglycemia
1317696|NCT00700362|Insulin infusion
1317697|NCT00700349|depression
1317698|NCT00700349|stress
1317699|NCT00700349|microcredit
1317700|NCT00700349|poverty
1317701|NCT00700349|South Africa
1317702|NCT00700336|malignant pleural mesothelioma
1317703|NCT00700336|solid tumors
1317704|NCT00700323|ADHD
1317705|NCT00700323|ADHD diagnosed children
1317706|NCT00700310|Partial onset seizures
1317707|NCT00700310|E2007
1317708|NCT00700310|perampanel
1317709|NCT00700310|refractory partial seizures
1317710|NCT00700310|adjunctive therapy
1317711|NCT00700310|seizure frequency
1317712|NCT00700310|reduction in seizure frequency
1317713|NCT00700310|safety
1317714|NCT00700310|concomitant AED(s)
1317715|NCT00700297|Oral aphthosis
1317716|NCT00700297|Genital aphthosis
1317717|NCT00700297|Psuedofolliculitis
1317718|NCT00700297|Erythem nodusom
1317719|NCT00700297|Joint manifestations
1317720|NCT00700297|Colchicine
1317721|NCT00700284|HIV-I
1317722|NCT00700284|Reverse transcriptase inhibitors
1317723|NCT00700284|HIV Seronegativity
1317724|NCT00700271|Hypertension
1317725|NCT00700271|ambulatory blood pressure monitoring
1317726|NCT00700245|Obese
1317727|NCT00700245|Adults
1317728|NCT00700232|genetics
1317729|NCT00700232|gene expression
1317730|NCT00700232|MDR3
1317731|NCT00700232|estrogens
1317732|NCT00700232|cholestasis
1317733|NCT00700232|pregnancy
1317734|NCT00700232|controls
1317735|NCT00700219|Preterm Labor
1317736|NCT00700219|Preterm Birth
1317737|NCT00700219|Intra-amniotic Infection
1317738|NCT00700219|Pregnancy
1317739|NCT00700219|Women
1317740|NCT00700206|Hematology
1317741|NCT00700206|MDS
1317742|NCT00700206|Myelodysplastic Syndrome
1317743|NCT00700206|Low Risk MDS
1317744|NCT00700206|Intermediate-1 risk MDS
1317745|NCT00700206|Int-1 risk MDS
1317746|NCT00700206|Telintra
1317747|NCT00700206|ezatiostat hydrochloride
1317748|NCT00700206|ezatiostat
1317749|NCT00700206|TLK199
1317750|NCT00700206|Glutathione
1317751|NCT00700206|Glutathione analog
1317752|NCT00700206|Glutathione Transferase
1317753|NCT00700206|Glutathione Transferase inhibitor
1317754|NCT00700206|Glutathione Transferase P1-1 inhibitor
1317755|NCT00700206|GSTp1-1 inhibitor
1317756|NCT00700206|Apoptosis
1317757|NCT00700206|Differentiation
1317758|NCT00700206|Enzyme inhibitor
1317759|NCT00700167|ANTIGENBEARING DENDRITIC CELLS
1317760|NCT00700167|98-098
1317761|NCT00700154|Vascular Surgery
1317762|NCT00700154|Complications
1317763|NCT00700154|Hyperglycemia
1317764|NCT00700154|Insulin infusion
1317765|NCT00700154|Diabetic ulcers
1317766|NCT00700154|Infection
1317767|NCT00700141|Tachosil
1317768|NCT00700141|thyroid
1317769|NCT00700141|parathyroid
1317770|NCT00700141|fleece-bound hemostasispathologic processes
1317771|NCT00700141|hemorrhage
1317772|NCT00700141|thyroid surgery
1317773|NCT00700128|headaches
1317774|NCT00700128|migraines
1317775|NCT00700128|breakthrough bleeding
1317776|NCT00700128|breakthrough spotting
1317777|NCT00700128|menstrually associated migraines
1317778|NCT00700128|breakthrough bleeding or breakthrough spotting
1317779|NCT00700115|HAART
1317780|NCT00700115|lopinavir/ritonavir
1317781|NCT00700115|raltegravir
1317782|NCT00700115|HIV/AIDS patients on HAART
1317783|NCT00700115|Treatment Experienced
1317784|NCT00700089|Attempted suicide
1317785|NCT00700089|Assertive intervention
1317786|NCT00700089|Prevention
1317787|NCT00700089|Treatment
1317791|NCT00700063|Peplin
1317792|NCT00700063|Actinic keratosis
1317793|NCT00700063|PEP005
1317794|NCT00700050|Cystic Fibrosis
1317795|NCT00700050|Sex hormones
1317796|NCT00700050|Pseudomonas aeruginosa
1317797|NCT00700050|Paediatrics
1317798|NCT00700024|Body composition
1317799|NCT00700024|Physical activity
1317800|NCT00700024|Metabolic syndrome
1317801|NCT00700011|Myelodysplastic Syndromes
1317802|NCT00699998|ACS
1317803|NCT00699985|Psychological Symptoms
1317804|NCT00699985|Behcet's Disease
1317805|NCT00699972|E2007
1317806|NCT00699972|perampanel
1317807|NCT00699972|refractory partial seizures
1317808|NCT00699972|adjunctive therapy
1317809|NCT00699972|seizure frequency
1317810|NCT00699972|partial onset seizures
1317811|NCT00699972|reduction in seizure frequency
1317812|NCT00699972|safety
1317813|NCT00699972|concomitant AED(s)
1317814|NCT00699959|Coronary patients
1317815|NCT00699959|heart failure
1317816|NCT00699959|dyslipidemia
1317817|NCT00699946|delirium, atypical antipsychotics, olanzapine, orthopedic
1317818|NCT00699933|acute pancreatitis
1317819|NCT00699933|interventional therapy
1317820|NCT00699933|CT-guided drainage therapy
1317821|NCT00699933|percutaneous necrosectomy
1317822|NCT00699933|Comparison of different diagnostic procedures: MRI, CT, Ultrasound
1317823|NCT00699933|Evaluation of interventional therapy including percutaneous drainage techniques und necrosectomies
1317824|NCT00699907|ovarian epithelial cancer
1317825|NCT00699894|PONV
1317826|NCT00699894|prevention of postoperative nausea and vomiting
1317827|NCT00699894|aprepitant
1317828|NCT00699894|ondansetron
1317829|NCT00699894|orthognathic surgery
1317830|NCT00699881|Time to Progression
1317831|NCT00699881|Toxicity
1317832|NCT00699881|Overall survival
1317833|NCT00699881|Response rate
1317834|NCT00699881|Quality of live
1317835|NCT00699855|Growth Hormon Deficiency and
1317836|NCT00699855|Turner Syndrome in pre-pubertal children
1317837|NCT00699855|Long term follow-up of predictive markers
1317838|NCT00699842|Myelodysplastic Syndrome
1317839|NCT00699842|MDS
1317840|NCT00699842|Low to Intermediate-1 MDS
1317841|NCT00699842|Non-deletion 5q
1317842|NCT00699842|Lenalidomide
1317843|NCT00699790|Diabetes
1317844|NCT00699790|NOS
1317845|NCT00699764|Herpes simplex candidate vaccine
1317846|NCT00699764|Herpes simplex
1317847|NCT00699751|Hormone Refractory Prostate Cancer
1317848|NCT00699751|Bone Metastases
1317849|NCT00699751|Radium-223
1317850|NCT00699738|Healthy women during pregnancy and in the postpartum period
1317851|NCT00699725|Compliance
1317852|NCT00699725|gastroprotector therapy
1317853|NCT00699725|NSAID
1317854|NCT00699725|risk factors
1317855|NCT00699712|ADHF
1317856|NCT00699712|AHF
1317857|NCT00699712|HF
1317858|NCT00699699|Chronic Obstructive Pulmonary Disease (COPD)
1317859|NCT00699686|Diabetes
1317860|NCT00699686|Insulin
1317861|NCT00699686|Endothelium
1317862|NCT00699686|Cardiovascular disease
1317863|NCT00699686|Stem cells
1317864|NCT00699673|Brain natriuretic peptide
1317865|NCT00699673|EuroScore
1317866|NCT00699673|Cardiac surgery
1317867|NCT00699673|Cardiopulmonary bypass
1317868|NCT00699673|Coronary artery disease
1317869|NCT00699673|Valvular disease
1317870|NCT00699673|Risk stratification in cardiac surgery
1317871|NCT00699660|Disability Examination
1317872|NCT00699660|Clinician Administered PTSD Scale
1317873|NCT00699660|Quality of Care
1317874|NCT00699634|Neuropathic
1317875|NCT00699634|Pain
1317876|NCT00699634|Phantom
1317877|NCT00699634|Limb
1317878|NCT00699621|Intracerebral hemorrhage
1317879|NCT00699621|Hematoma enlargement
1317880|NCT00699621|Antiplatelet agent
1317881|NCT00699621|Platelet transfusion
1317882|NCT00699621|Outcome
1317883|NCT00699608|Zopiclone
1317884|NCT00699608|Hypnotic
1317885|NCT00699608|Residual effects
1317886|NCT00699608|Eszopiclone
1317887|NCT00699582|E2007 (perampanel)
1317888|NCT00699582|refractory partial seizures
1317889|NCT00699582|adjunctive therapy
1317890|NCT00699582|seizure frequency
1317891|NCT00699582|reduction in seizure frequency
1317892|NCT00699582|partial onset seizures
1317893|NCT00699582|safety
1317894|NCT00699582|concomitant AED(s)
1317895|NCT00699569|hyperimmune colostrum
1317896|NCT00699569|mucositis
1317897|NCT00699556|alcohol
1317898|NCT00699556|nicotine
1317899|NCT00699556|smoking cessation
1317900|NCT00699556|smoking cessation medications
1317901|NCT00699530|Prolactin
1317902|NCT00699530|Insulin resistance
1317903|NCT00699530|Glucose tolerance
1317904|NCT00699530|Body Composition
1317905|NCT00699530|Substrate metabolism
1317906|NCT00699517|tubulin modulator
1317907|NCT00699517|endothelium
1317908|NCT00699517|combretastatin
1317909|NCT00699517|cisplatin
1317910|NCT00699504|ECG
1317911|NCT00699504|QT
1317912|NCT00699504|Effect of study drug on healthy volunteers
1317913|NCT00699478|vitamin B12 deficiency
1317914|NCT00699478|post total gastrectomy
1317915|NCT00699478|stomach cancer
1317916|NCT00699465|Thromboprophylaxis
1317917|NCT00699465|Prevention of venous thromboembolism after ICH
1317918|NCT00699465|Enoxaparin
1317919|NCT00699465|Intermittent pneumatic compression
1317920|NCT00699452|aortic stenosis
1317921|NCT00699452|valve
1317922|NCT00699452|candesartan
1317923|NCT00699439|Medical Informatics
1317924|NCT00699439|Asthma
1317925|NCT00699439|Emergency Service, Hospital
1317926|NCT00699439|Bayesian Method
1317927|NCT00699387|Chagas disease
1317928|NCT00699387|Pediatrics
1317929|NCT00699387|benznidazole
1317930|NCT00699387|population pharmacokinetics
1317931|NCT00699387|neglected diseases
1317932|NCT00699387|parasitology
1317933|NCT00699387|pediatric clinical pharmacology
1317934|NCT00699374|sunitinib
1317935|NCT00699374|phase 3
1317936|NCT00699374|randomized
1317937|NCT00699374|hepatocellular
1317938|NCT00699374|liver
1317939|NCT00699361|Pantoprazole
1317940|NCT00699361|congestive heart failure
1317941|NCT00699335|pain
1317942|NCT00699335|fentanyl
1317943|NCT00699335|transdermal patch
1317944|NCT00699322|glucose variability
1317945|NCT00699322|oxidative stress
1317946|NCT00699322|sitagliptin
1317947|NCT00699322|glimepiride
1317953|NCT00699296|LBH589
1317954|NCT00699296|HDAC inhibitor
1317955|NCT00699296|cutaneous T-ceII lymphoma
1317956|NCT00699296|adult T-cell leukemia
1317957|NCT00699283|Epilepsy; Monotherapy
1317958|NCT00699283|Partial Onset Seizures
1317959|NCT00699283|Adults and Adolescents
1317967|NCT00699244|forearm
1317968|NCT00699244|hand
1317969|NCT00699244|elbow
1317970|NCT00699244|wrist
1317971|NCT00699244|brachial plexus
1317972|NCT00699244|infraclavicular block
1317973|NCT00699231|Hepatitis B
1317974|NCT00699231|Engerix™-B
1317975|NCT00699231|Recombinant hepatitis B vaccine
1317976|NCT00699231|Adjuvant
1317977|NCT00699218|Bipolar
1317978|NCT00699218|Depression
1317979|NCT00699218|TMS
1317980|NCT00699218|repetitive Transcranial Magnetic Stimulation
1317981|NCT00699218|treatment
1317982|NCT00699218|Efficacy
1317983|NCT00699218|Safety
1317984|NCT00699192|Blood pressure
1317985|NCT00699192|hypertension
1317986|NCT00699192|elderly
1317987|NCT00699166|IBS
1317988|NCT00699166|Diarrhea
1317989|NCT00699166|gastrointestinal functional disorder
1317990|NCT00699166|IBS-D
1317991|NCT00699127|anxiety
1317992|NCT00699127|parents
1317993|NCT00699127|NICU
1317994|NCT00699127|prematurity
1317995|NCT00699127|Anxiety of parents to NICU infants
1317996|NCT00699114|Pain
1317997|NCT00699114|Analgesics
1317998|NCT00699114|Molar
1317999|NCT00699114|Third
1318000|NCT00699114|Acetaminophen
1318001|NCT00699114|Paracetamol
1318002|NCT00699114|Ibuprofen
1318003|NCT00699114|Codeine
1318004|NCT00699114|Placebo
1318005|NCT00699101|Breast Cancer
1318006|NCT00699101|Conture®
1318007|NCT00699101|Brachytherapy
1318012|NCT00699062|antileukotriene
1318013|NCT00699062|small airway
1318014|NCT00699062|airway remodeling
1318015|NCT00699062|HRCT
1318016|NCT00699049|Alpha blocker
1318017|NCT00699049|Tamsulosin
1318018|NCT00699049|Solifenacin
1318019|NCT00699049|Overactive Bladder
1318020|NCT00699049|Urgency incontinence
1318021|NCT00699036|nonalcoholic steatohepatitis (NASH)
1318022|NCT00699036|fatty liver
1318023|NCT00699036|insulin resistance
1318024|NCT00699023|postprandial lipemia
1318025|NCT00699023|type 2 diabetes
1318026|NCT00699023|ezetimibe
1318027|NCT00699023|hypercholesterolemia
1318028|NCT00699010|Abuse Liability
1318029|NCT00699010|Abuse Prevention
1318030|NCT00699010|Abuse Resistance
1318031|NCT00699010|Abuse Deterrence
1318044|NCT00698984|Soy Isoflavones, Bone Mineral Density, Bone Mineral Content, postmenopausal Women, Bone Markers, Bone Health, Phytoestrogens
1318045|NCT00698958|Respiratory insufficiency
1318046|NCT00698958|Hypercapnic chronic respiratory failure secondary to neuromuscular diseases or alterations of thoracic cage
1318047|NCT00698932|DPP-4 inhibitors
1318048|NCT00698932|HBA1c
1318049|NCT00698932|Incretins
1318050|NCT00698919|Bacterial DNA
1318051|NCT00698919|Systemic inflammatory response syndrome
1318052|NCT00698919|Infection
1318053|NCT00698919|Intensive Care Unit
1318054|NCT00698906|Hepatitis B
1318055|NCT00698906|HBV-MPL
1318056|NCT00698906|Recombinant Hepatitis B vaccine
1318057|NCT00698893|Herpes simplex
1318058|NCT00698893|Herpes simplex candidate (gD) vaccine
1318059|NCT00698880|Portal vein embolization
1318060|NCT00698880|Hepatic vein embolization
1318061|NCT00698880|Liver regeneration
1318062|NCT00698867|Total Elbow Arthroplasty
1318063|NCT00698867|Total Elbow Replacement
1318064|NCT00698867|Osteoarthritis
1318065|NCT00698867|Elbow arthritis
1318069|NCT00698828|Cachexia, COPD, Chronic Obstructive Pulmonary Disease
1318070|NCT00698763|An ischaemic cerebrovascular event (stroke or TIA)
1318076|NCT00698737|Opioid
1318077|NCT00698737|Cocaine
1318078|NCT00698711|Prostate cancer
1318079|NCT00698711|MUC-2-KLH
1318080|NCT00698711|QS 21
1318081|NCT00698698|tear proteins
1318082|NCT00698698|diabetic retinopathy
1318083|NCT00698698|HPLC
1318084|NCT00698698|Mass spectroscopy
1318085|NCT00698685|Allogeneic Hematopoietic Cell Transplantation
1318086|NCT00698685|Preparative Regimen
1318087|NCT00698685|Pentostatin
1318088|NCT00698685|Alemtuzumab
1318089|NCT00698685|Hodgkin Disease and Lymphoma, non-Hodgkin
1318090|NCT00698685|leukemia, myeloid, acute
1318091|NCT00698685|leukemia, lymphocytic, acute
1318092|NCT00698685|leukemia, myeloid, chronic
1318093|NCT00698685|leukemia, lymphocytic, chronic
1318094|NCT00698685|Multiple Myeloma
1318095|NCT00698685|Myelodysplastic Syndromes
1318096|NCT00698685|Carcinoma, Renal Cell
1318097|NCT00698672|RSA
1318098|NCT00698646|Systolic blood pressure
1318099|NCT00698646|Diastolic blood pressure
1318100|NCT00698646|Valsartan
1318101|NCT00698646|Hydrochlorothiazide
1318103|NCT00698607|Everolimus
1318104|NCT00698607|Sirolimus
1318105|NCT00698607|drug eluting stent
1318106|NCT00698607|Clopidogrel
1318107|NCT00698581|Epilepsy; Monotherapy
1318108|NCT00698581|Partial Onset Seizures
1318109|NCT00698581|Adults and Adolescents
1318110|NCT00698568|Herpes simplex, Herpes simplex candidate vaccine
1318111|NCT00698555|Hepatitis B
1318112|NCT00698555|HBV-MPL
1318113|NCT00698555|Recombinant hepatitis B vaccine
1318114|NCT00698542|PSST
1318115|NCT00698542|sepsis
1318116|NCT00698542|Neuro Care Unit
1318117|NCT00698542|Surviving Sepsis Campaign
1318118|NCT00698542|SSC
1318119|NCT00698529|Technology Transfer
1318120|NCT00698529|HIV Seronegativity
1318121|NCT00698516|Bevacizumab
1318122|NCT00698516|Small Cell Lung Cancer (SCLC)
1318123|NCT00698516|Topotecan
1318127|NCT00698490|Herpes simplex
1318128|NCT00698490|Herpes simplex candidate vaccine
1318129|NCT00698464|Pasireotide
1318130|NCT00698464|PK profile,
1318131|NCT00698464|Single dose
1318132|NCT00698464|Pasireotide subcutaneous injection
1318133|NCT00698464|Safety
1318134|NCT00698464|Mild hepatic impaired patients
1318135|NCT00698464|Moderate hepatic impaired patients
1318136|NCT00698464|Severe hepatic impaired patients
1318137|NCT00698451|Ovarian cancer
1318138|NCT00698451|fallopian tube cancer
1318139|NCT00698451|primary peritoneal cancer
1318140|NCT00698451|DOXIL
1318141|NCT00698451|carboplatin
1318142|NCT00698451|bevacizumab
1318143|NCT00698438|At least 18 years of age
1318144|NCT00698438|Open-angle glaucoma
1318145|NCT00698425|Iontophoresis
1318146|NCT00698425|Ophthalmology
1318147|NCT00698412|Knee osteoarthritis
1318148|NCT00698412|Daily cane use
1318149|NCT00698412|Pain
1318150|NCT00698412|Function
1318151|NCT00698412|Quality of life
1318152|NCT00698412|Energy consumption during the gait
1318153|NCT00698399|liver
1318154|NCT00698399|transplant
1318155|NCT00698399|TMAO
1318156|NCT00698399|NGAL
1318157|NCT00698399|cystatin-C
1318158|NCT00698399|Ischemia Reperfusion Injury
1318159|NCT00698399|Liver Transplant
1318160|NCT00698399|LTx
1318161|NCT00698399|allantion
1318162|NCT00698386|Micronutrient Zinc
1318163|NCT00698386|Category I PTB
1318164|NCT00698386|RNTCP
1318165|NCT00698386|DOTS
1318166|NCT00698386|Sputum smear conversion
1318167|NCT00698386|Reduced relapse
1318168|NCT00698386|Immunopathogenesis
1318169|NCT00698386|Category-I
1318170|NCT00698373|Fluorine-18-α-methyltyrosine,
1318171|NCT00698373|Positron emission tomography,
1318172|NCT00698373|Fluorine-18-fluorodeoxyglucose,
1318173|NCT00698373|Lung cancer,
1318174|NCT00698360|chronic kidney disease
1318175|NCT00698360|melatonin
1318176|NCT00698360|erythropoietin
1318177|NCT00698360|circadian rhythm
1318181|NCT00698334|HIV infection
1318182|NCT00698334|Acquired immunodeficiency syndrome
1318183|NCT00698334|Tuberculosis
1318184|NCT00698321|HIV/STD Prevention
1318185|NCT00698321|HIV Seronegativity
1318186|NCT00698295|schizophrenia
1318187|NCT00698295|atypical antipsychotics
1318188|NCT00698295|EEG
1318189|NCT00698243|OSI-027
1318190|NCT00698243|Solid tumor
1318191|NCT00698243|Lymphoma
1318192|NCT00698204|Mucositis
1318193|NCT00698204|Head and Neck Cancer
1318194|NCT00698204|Head and Neck Neoplasms
1318195|NCT00698204|Stomatitis
1318196|NCT00698191|Lupus Erythematosus,Systemic
1318197|NCT00698191|Lupus Nephritis
1318198|NCT00698191|Mesenchymal Stem Cells
1318199|NCT00698191|Transplantation
1318200|NCT00698178|Gastroesophageal reflux disease
1318201|NCT00698178|Waist circumference
1318202|NCT00698178|Body mass index
1318203|NCT00698178|Obesity
1318204|NCT00698152|Total Hip Arthroplasty
1318205|NCT00698152|Total Hip Replacement
1318206|NCT00698152|Hip Arthritis
1318207|NCT00698152|Polyethylene
1318208|NCT00698139|heart failure
1318209|NCT00698139|chronotropic incompetence
1318210|NCT00698113|anxiety
1318211|NCT00698113|depression
1318212|NCT00698113|stress
1318213|NCT00698113|cancer symptoms
1318214|NCT00698113|pediatric cancer
1318215|NCT00698113|massage
1318216|NCT00698113|parent delivered massage
1318217|NCT00698100|DNA
1318218|NCT00698100|HU & MOUSE
1318219|NCT00698100|TYROSINASE
1318220|NCT00698087|Hepatitis B
1318221|NCT00698087|Engerix™-B
1318222|NCT00698087|Adjuvanted recombinant hepatitis B vaccine
1318223|NCT00698061|Hepatitis B
1318224|NCT00698061|Adjuvanted vaccine
1318225|NCT00698048|Sepsis
1318226|NCT00698048|Septic Shock
1318227|NCT00698048|Vasopressin
1318228|NCT00698048|Copeptin
1318229|NCT00698048|Paediatrics
1318230|NCT00698035|Vaginal Testosterone Cream
1318231|NCT00698035|ESTRING
1318232|NCT00698022|healthy
1318233|NCT00698022|weight gain
1318234|NCT00698022|anti-psychotic
1318235|NCT00698022|risperidone
1318236|NCT00698022|mifepristone
1318237|NCT00698022|mitigation
1318238|NCT00698022|weight loss
1318239|NCT00698009|Neuroblastoma
1318240|NCT00698009|Natural Killer Cell
1318241|NCT00698009|NK Cell Infusion
1318242|NCT00698009|Haploidentical Natural Killer (NK) Cells
1318243|NCT00698009|Fludarabine
1318244|NCT00698009|Fludarabine Phosphate
1318245|NCT00698009|Fludara
1318246|NCT00698009|Cyclophosphamide
1318247|NCT00698009|Cytoxan
1318248|NCT00698009|Neosar
1318249|NCT00698009|Interleukin-2
1318250|NCT00698009|IL-2
1318251|NCT00698009|Proleukin
1318252|NCT00698009|Mesna
1318253|NCT00698009|Mesnex
1318254|NCT00698009|Infusion of NK cells
1318255|NCT00698009|Pediatric NK Cell Infusion
1318256|NCT00698009|Pediatric Neuroblastoma
1318257|NCT00698009|Pediatric NK
1318258|NCT00698009|Pediatric
1318259|NCT00697983|Osteoporosis
1318260|NCT00697983|ATP
1318261|NCT00697983|Purinergic receptors
1318262|NCT00697983|Bone mineral density
1318263|NCT00697983|Single nucleotide polymorphism
1318264|NCT00697970|Hepatitis B
1318265|NCT00697970|Engerix™-B
1318266|NCT00697970|Recombinant Hepatitis B vaccine
1318267|NCT00697970|Adjuvant
1318268|NCT00697957|acceleration
1318269|NCT00697957|bone density
1318270|NCT00697957|cardiovascular diseases
1318271|NCT00697957|exercise
1318272|NCT00697957|female
1318273|NCT00697957|fragility fractures
1318274|NCT00697957|impact intensity
1318275|NCT00697957|intervention studies
1318276|NCT00697957|osteoporosis
1318277|NCT00697957|premenopause
1318278|NCT00697944|FUNGAL INFECTION
1318279|NCT00697944|SEPSIS
1318280|NCT00697944|INTENSIVE CARE
1318281|NCT00697944|AMBISOME
1318282|NCT00697944|PREEMPTIVE TREATMENT
1318283|NCT00697944|Sepsis with candida colonisation
1318284|NCT00697931|Hepatitis B
1318285|NCT00697931|Engerix™-B
1318286|NCT00697931|Recombinant Hepatitis B vaccine
1318287|NCT00697931|Adjuvant
1318288|NCT00697918|Partial onset seizure
1318289|NCT00697918|Adjunctive therapy
1318290|NCT00697905|nasopharyngeal carcinoma
1318291|NCT00697905|Gemcitabine-Carboplatin
1318292|NCT00697892|Human Immunodeficiency Virus
1318293|NCT00697892|Drug Interactions
1318294|NCT00697879|tumour
1318295|NCT00697879|Solid tumour
1318296|NCT00697879|histone deacetylase inhibitor
1318297|NCT00697879|dose escalation
1318298|NCT00697879|cancer
1318299|NCT00697866|Adjuvanted hepatitis B vaccine
1318300|NCT00697866|Hepatitis B
1318301|NCT00697866|Recombinant hepatitis B vaccine
1318302|NCT00697853|Hepatitis B
1318303|NCT00697853|Adjuvanted hepatitis B vaccine
1318304|NCT00697853|Recombinant hepatitis B vaccine
1318305|NCT00697840|Hepatitis B
1318306|NCT00697840|Engerix™-B
1318307|NCT00697840|Recombinant hepatitis B vaccine
1318308|NCT00697840|Adjuvant
1318309|NCT00697814|Hypogonadotropic hypogonadism
1318310|NCT00697814|Prolactinoma
1318311|NCT00697788|pediatric
1318312|NCT00697788|burn
1318313|NCT00697788|sedation
1318314|NCT00697775|Hepatitis B
1318315|NCT00697775|Recombinant hepatitis B vaccine
1318316|NCT00697775|Adjuvant
1318317|NCT00697762|Partial onset seizure
1318318|NCT00697762|Adjunctive therapy
1318319|NCT00697749|Recombinant hepatitis B vaccine
1318320|NCT00697749|Adjuvanted hepatitis B vaccine
1318321|NCT00697749|Hepatitis B
1318322|NCT00697736|Systemic Scleroderma
1318323|NCT00697736|Echocardiography
1318324|NCT00697723|Coronary artery bypass graft
1318325|NCT00697723|Intra-aortic balloon pump
1318326|NCT00697723|transit-time flowmetry
1318327|NCT00697710|Atopic Dermatitis
1318328|NCT00697697|asthmatic children
1318333|NCT00697671|NK cell infusion
1318334|NCT00697671|Immunotherapy
1318335|NCT00697671|hematologic malignancy
1318336|NCT00697671|Miltenyi Biotec device
1318337|NCT00697671|haploidentical donor
1318338|NCT00697658|Paliperidone ER
1318339|NCT00697658|Schizophrenia
1318340|NCT00697645|Stroke,
1318341|NCT00697645|Cerebrovascular disease,
1318342|NCT00697645|Transcranial magnetic stimulation,
1318343|NCT00697645|rehabilitation
1318344|NCT00697632|MET
1318345|NCT00697632|AXL
1318346|NCT00697632|VEGFR
1318347|NCT00697632|NSCLC
1318348|NCT00697632|HNSCC (Head and neck squamous cell carcinoma)
1318349|NCT00697632|Tumor
1318350|NCT00697632|Safety
1318351|NCT00697632|Phase 1
1318352|NCT00697632|Solid tumor
1318353|NCT00697606|Seprafilm®
1318354|NCT00697606|cesarean
1318355|NCT00697606|adhesions
1318356|NCT00697606|primary
1318357|NCT00697606|repeat
1318358|NCT00697593|Efalizumab
1318359|NCT00697593|Chronic Plaque Psoriasis
1318360|NCT00697593|Transition from systemic therapies on to Efalizumab
1318361|NCT00697580|Obesity
1318362|NCT00697580|Type 2 Diabetes
1318363|NCT00697580|Cardiovascular risk
1318364|NCT00697580|Cancer
1318365|NCT00697580|Latino
1318366|NCT00697580|Adolescents
1318367|NCT00697580|Strength Training
1318368|NCT00697580|Circuit Training
1318369|NCT00697580|Nutrition
1318370|NCT00697567|Herpes simplex
1318371|NCT00697567|Herpes simplex vaccine
1318372|NCT00697554|Hepatitis B
1318373|NCT00697554|Adjuvanted hepatitis B vaccine
1318374|NCT00697541|erythematous rosacea
1318375|NCT00697541|facial gel
1318376|NCT00697541|brimonidine
1318377|NCT00697541|ophthalmic solution
1318378|NCT00697528|Graves
1318379|NCT00697528|Color Doppler Imaging
1318380|NCT00697528|Graves' Ophthalmopathy
1318381|NCT00697528|Orbital Venous Flow
1318382|NCT00697489|Pelvic organ prolapse
1318383|NCT00697489|Urinary incontinence
1318384|NCT00697489|Mesh
1318385|NCT00697476|second line chemotherapy
1318386|NCT00697463|Teriparatide
1318387|NCT00697463|Forteo
1318388|NCT00697463|Osteopenia
1318389|NCT00697463|Osteoporosis
1318390|NCT00697463|Fracture
1318391|NCT00697463|Low Bone Density
1318392|NCT00697463|Premenopausal women
1318393|NCT00697411|Aicardi syndrome
1318394|NCT00697411|Microphthalmia with linear skin defects (MLS) syndrome
1318395|NCT00697411|X-linked disorders
1318396|NCT00697372|Angioplasty, Transluminal, Percutaneous Coronary
1318397|NCT00697372|Drug-Eluting Stents
1318398|NCT00697359|Atrial fibrillation
1318399|NCT00697359|Monitoring
1318400|NCT00697359|Pulmonary vein isolation
1318401|NCT00697359|Implantable loop recorder
1318402|NCT00697346|Drug therapy
1318403|NCT00697333|NSCLC
1318404|NCT00697333|FDG-PET
1318405|NCT00697333|Radiotherapy
1318406|NCT00697333|planning
1318407|NCT00697333|target volumes
1318408|NCT00697307|bioequivalence
1318409|NCT00697307|contraception
1318410|NCT00697307|contraceptive patch
1318411|NCT00697307|ORTHO EVRA
1318412|NCT00697307|norelgestromin
1318413|NCT00697307|NGMN
1318414|NCT00697307|ethinyl estradiol
1318415|NCT00697307|EE
1318416|NCT00697294|Vitamin D deficiency
1318417|NCT00697294|Infants
1318418|NCT00697294|Breast feeding
1318419|NCT00697281|allergic rhinitis
1318420|NCT00697281|human
1318421|NCT00697281|clinical trial
1318422|NCT00697281|efficacy
1318423|NCT00697281|safety
1318424|NCT00697281|challenge test
1318425|NCT00697268|Depression
1318426|NCT00697268|Depression Treatment
1318427|NCT00697268|Unipolar Depression
1318428|NCT00697268|Citalopram
1318429|NCT00697268|Serotonin
1318430|NCT00697268|Major Depression
1318431|NCT00697268|Healthy Volunteer
1318432|NCT00697268|HV
1318433|NCT00697255|Pharmacological effects of drugs
1318434|NCT00697255|Hormones
1318435|NCT00697255|Hormone Substitutes and Hormone Antagonists
1318436|NCT00697255|Pharmacological Actions
1318437|NCT00697255|Monofollicular growth
1318438|NCT00697255|Randomized
1318439|NCT00697255|Open-label
1318440|NCT00697255|Active-controlled
1318441|NCT00697242|Hepatitis B
1318442|NCT00697242|Engerix™-B
1318443|NCT00697242|Recombinant Hepatitis B vaccine
1318444|NCT00697229|Hepatitis B
1318445|NCT00697229|Engerix™-B
1318446|NCT00697229|Recombinant hepatitis B vaccine
1318447|NCT00697216|Hepatitis B
1318448|NCT00697216|Recombinant hepatitis B vaccine
1318449|NCT00697216|Adjuvanted hepatitis B vaccine
1318450|NCT00697177|Gastro-oesophageal reflux
1318451|NCT00697177|24 hour oesophageal pH monitoring
1318452|NCT00697177|Physiotherapy Airway clearance techniques
1318453|NCT00697177|Exercise
1318454|NCT00697164|Malaria
1318455|NCT00697164|Treatment
1318456|NCT00697164|Adjunctive
1318457|NCT00697164|Erythropoietin
1318458|NCT00697164|Survival
1318459|NCT00697151|cerebrovascular diseases
1318460|NCT00697151|ischemic stroke
1318461|NCT00697151|patent foramen ovale
1318462|NCT00697151|warfarin
1318463|NCT00697151|aspirin
1318464|NCT00697151|transesophageal echocardiography
1318465|NCT00697138|Cocaine
1318466|NCT00697138|Dependence
1318467|NCT00697138|Pharmacotherapies
1318468|NCT00697125|Hepatitis B
1318469|NCT00697125|Engerix™-B
1318470|NCT00697125|Recombinant hepatitis B vaccine
1318471|NCT00697099|VTE prevention
1318472|NCT00697099|Total Hip Replacement
1318473|NCT00697099|Heparin Low-Molecular-Weight
1318474|NCT00697086|Heart disease
1318475|NCT00697073|Friedreich's Ataxia
1318476|NCT00697073|Idebenone
1318477|NCT00697073|ICARS
1318478|NCT00697060|Metastatic
1318479|NCT00697060|Previously treated
1318489|NCT00697021|Thromboelastography
1318490|NCT00697021|Aspirin
1318491|NCT00697021|Clopidogrel
1318492|NCT00697021|Plavix
1318493|NCT00697021|Resistance
1318494|NCT00697021|Platelet
1318495|NCT00697021|Coronary Stenting
1318496|NCT00697021|Bare Metal Stent
1318497|NCT00697021|Dual antiplatelet therapy
1318498|NCT00697021|Overreactivity
1318499|NCT00697021|Primary Coronary Intervention
1318500|NCT00697008|GERD
1318501|NCT00697008|CLINICAL GUIDELINE
1318502|NCT00697008|Symptoms
1318503|NCT00697008|clinical outcome
1318504|NCT00696982|Arterial stiffness
1318505|NCT00696982|Augmentation index
1318506|NCT00696982|diabetes mellitus
1318507|NCT00696956|local drug delivery
1318508|NCT00696956|balloon angioplasty
1318509|NCT00696956|safety and tolerance of paclitaxel coated PTA balloons
1318510|NCT00696956|in inhibiting restenosis of below the knee arteries
1318511|NCT00696956|Efficacy of paclitaxel coated PTA balloons
1318512|NCT00696956|in inhibiting restenosis of below the knee arteries (late lumen loss)
1318513|NCT00696943|cell death
1318514|NCT00696943|PET imaging
1318515|NCT00696943|brain metastases
1318516|NCT00696943|stereotactic radiosurgery
1318517|NCT00696930|Malignant Carcinoid Tumors
1318518|NCT00696917|Hepatitis B
1318519|NCT00696917|Adjuvanted Hepatitis B vaccine
1318520|NCT00696917|Recombinant Hepatitis B vaccine
1318521|NCT00696891|Adjuvanted hepatitis B vaccine, hepatitis B, Engerix™-B
1318522|NCT00696878|Infertility
1318523|NCT00696878|Pharmacological effects of drugs
1318524|NCT00696878|Hormones, Hormone Substitutes and Hormone Antagonists
1318525|NCT00696878|Pharmacological Actions
1318526|NCT00696878|Multi-center
1318527|NCT00696865|Safety
1318528|NCT00696865|Tolerability
1318529|NCT00696865|Phase I
1318530|NCT00696852|Mindfulness
1318531|NCT00696852|Meditation
1318532|NCT00696852|Yoga
1318533|NCT00696852|Inflammatory Markers
1318534|NCT00696839|Behavior Therapy
1318535|NCT00696839|Anti-Retroviral Agents
1318536|NCT00696839|Relaxation
1318537|NCT00696839|Clinical Nursing Research
1318538|NCT00696839|Complementary Therapies
1318539|NCT00696813|Registry
1318540|NCT00696813|Healthcare Utilization
1318541|NCT00696813|Outcome
1318542|NCT00696813|Safety
1318543|NCT00696813|Efficacy
1318544|NCT00696813|Cost-effectiveness
1318545|NCT00696813|Paliperidone ER
1318546|NCT00696813|Invega®
1318547|NCT00696813|Oral antipsychotics
1318548|NCT00696800|Infertility
1318549|NCT00696800|Pharmacological effect of drugs
1318550|NCT00696800|Hormones
1318551|NCT00696800|Hormone substitutes and hormone antagonists
1318552|NCT00696800|Pharmacological actions
1318553|NCT00696800|Randomized
1318554|NCT00696800|Multi-center
1318555|NCT00696800|Multi-national
1318556|NCT00696800|Double-blind
1318557|NCT00696800|Active-controlled
1318558|NCT00696800|Non-inferiority
1318559|NCT00696761|LUTS
1318560|NCT00696761|BPH
1318561|NCT00696761|bladder outlet obstruction
1318562|NCT00696761|bladder contractility
1318563|NCT00696748|metabolic syndrome
1318564|NCT00696748|hypogonadism
1318565|NCT00696748|testosterone undecanoate
1318566|NCT00696735|Phase III study patients with follicular lymphoma
1318567|NCT00696709|Herpes Zoster (Shingles)
1318568|NCT00696696|Pancreatic adenocarcinoma
1318569|NCT00696696|metastatic
1318570|NCT00696696|EGRF inhibitor
1318571|NCT00696696|targeted therapy
1318572|NCT00696696|combined cancer therapy
1318573|NCT00696696|kinase inhibitor
1318574|NCT00696696|VEGF-R inhibitor
1318575|NCT00696683|scorpion
1318576|NCT00696683|sting
1318577|NCT00696683|envenomation
1318578|NCT00696683|antivenom
1318579|NCT00696631|Heart disease
1318580|NCT00696631|morbidity
1318581|NCT00696618|HIV prevention
1318582|NCT00696618|MSM
1318583|NCT00696618|Enema
1318584|NCT00696618|HIV Seronegativity
1318585|NCT00696605|Hypoosmolality
1318586|NCT00696605|Hyperosmolality
1318587|NCT00696605|Copeptin
1318588|NCT00696605|Vasopressin
1318589|NCT00696592|Age-Related Macular Degeneration
1318590|NCT00696592|Choroidal Neovascularization
1318591|NCT00696592|Bevacizumab
1318592|NCT00696592|Photodynamic Therapy
1318593|NCT00696579|BCG
1318594|NCT00696579|Gemcitabine
1318595|NCT00696579|Intravesical
1318596|NCT00696579|Therapy
1318597|NCT00696579|Superficial
1318598|NCT00696579|Transitional
1318599|NCT00696579|Cell carcinoma
1318600|NCT00696566|Thrombosis
1318601|NCT00696566|Platelet aggregation inhibitor
1318602|NCT00696566|Blood platelets
1318603|NCT00696566|P2 receptor
1318604|NCT00696566|Cytochrome P450
1318605|NCT00696540|Bronchiolitis, respiratory distress, hypertonic saline
1318606|NCT00696527|Infiltrative breast cancer-Clinical practice
1318607|NCT00696527|Women with infiltrative breast cancer
1318608|NCT00696514|fracture
1318609|NCT00696514|cognition
1318610|NCT00696501|Neuromuscular mapping
1318611|NCT00696501|Spinal surgery
1318612|NCT00696501|Neurodiagnostics
1318613|NCT00696501|Segmental root innervation
1318614|NCT00696501|Dermatomal innervation
1318615|NCT00696501|Myotomal innervation
1318616|NCT00696501|Nerve roots
1318617|NCT00696501|Sensory
1318618|NCT00696501|Signs and Symptoms
1318619|NCT00696462|forced-air warming
1318620|NCT00696462|Bair Hugger
1318621|NCT00696462|cesarean section
1318622|NCT00696462|postoperative infection
1318623|NCT00696462|surgical site infections
1318624|NCT00696436|Essential Hypertension
1318625|NCT00696436|Cardiovascular Disease
1318626|NCT00696436|High Blood Pressure
1318627|NCT00696436|Drug Therapy
1318628|NCT00696423|Infanrix/Hib
1318629|NCT00696423|Chinese children
1318630|NCT00696410|Heart Failure
1318631|NCT00696410|Cardiomyopathy
1318632|NCT00696410|Remodeling
1318633|NCT00696410|Antioxidant
1318634|NCT00696410|Zinc
1318635|NCT00696410|Copper
1318636|NCT00696384|Essential Hypertension
1318637|NCT00696384|Cardiovascular Disease
1318638|NCT00696384|High Blood Pressure
1318639|NCT00696384|Drug Therapy
1318640|NCT00696371|Neuroinflammation
1318641|NCT00696371|PBR28
1318642|NCT00696371|PET Imaging
1318643|NCT00696371|Health Volunteer
1318644|NCT00696371|HV
1318645|NCT00696358|Vitiligo
1318646|NCT00696345|colorectal cancer
1318647|NCT00696345|screening
1318648|NCT00696345|biomarker
1318649|NCT00696345|plasma
1318650|NCT00696345|blood
1318651|NCT00696332|ALS
1318652|NCT00696319|Rupture of the anterior cruciate ligament of the knee
1318653|NCT00696306|Acute Ischemic Stroke
1318654|NCT00696306|Stroke
1318655|NCT00696306|MRI
1318656|NCT00696306|DTI
1318657|NCT00696306|Diffusion Tensor Imaging
1318658|NCT00696306|SWI
1318659|NCT00696306|Susceptibility Weighted Imaging
1318660|NCT00696306|Outcome
1318661|NCT00696306|Axonal Injury
1318662|NCT00696280|nausea
1318663|NCT00696280|vomiting
1318664|NCT00696280|Carboplatin
1318665|NCT00696280|cancer
1318666|NCT00696280|delayed emesis following treatment with carboplatin
1318667|NCT00696241|Essential Hypertension
1318668|NCT00696241|Cardiovascular Disease
1318669|NCT00696241|High Blood Pressure
1318670|NCT00696241|Drug Therapy
1318671|NCT00696215|Parkinson's disease
1318672|NCT00696215|rasagiline
1318673|NCT00696215|cognition
1318674|NCT00696215|MAO-B
1318675|NCT00696202|Mirena
1318676|NCT00696202|Levonorgestrel
1318677|NCT00696202|Intrauterine device
1318678|NCT00696202|Efficacy
1318679|NCT00696202|Tolerability
1318680|NCT00696202|First year of use
1318807|NCT00695669|Avian
1318681|NCT00696189|Post operative visual loss (POVL)
1318682|NCT00696189|Intraocular pressure (IOP)
1318683|NCT00696189|Nitrous oxide
1318684|NCT00696176|STAT 3 DECOY
1318685|NCT00696150|ultrasound
1318686|NCT00696150|hip
1318687|NCT00696150|pain
1318688|NCT00696124|lower leg ischemia
1318689|NCT00696124|peripheral artery disease
1318690|NCT00696111|PCOS
1318691|NCT00696111|OSA
1318692|NCT00696111|Metabolism
1318693|NCT00696111|Diabetes
1318694|NCT00696085|fetal alcohol exposure
1318695|NCT00696085|blood markers of alcohol use
1318696|NCT00696085|brief intervention
1318697|NCT00696059|Rheumatoid arthritis
1318698|NCT00696059|Computed tomography
1318699|NCT00696059|Magnetic resonance imaging
1318700|NCT00696059|Radiography
1318701|NCT00696059|Tumor necrosis factor alpha antagonists
1318702|NCT00696046|CORD BLOOD CELLS
1318703|NCT00696046|INTRA BONE MARROW INJECTION
1318704|NCT00696046|ENGRAFTMENT
1318705|NCT00696046|transplants
1318706|NCT00696033|Benzodiazepines
1318707|NCT00696033|Lorazepam
1318708|NCT00696033|Diazepam
1318709|NCT00696033|Memory
1318710|NCT00696033|Perceptual priming
1318711|NCT00696033|Functional brain imaging
1318712|NCT00696033|FMRI
1318713|NCT00696007|Upper GU Tract Transitional Cell Carinoma
1318714|NCT00696007|Nephroureterectomy
1318715|NCT00696007|Chemotherapy
1318716|NCT00696007|Gemcitabine
1318717|NCT00696007|Cisplatin
1318718|NCT00695981|Rotator cuff
1318719|NCT00695981|Arthroscopic surgery
1318720|NCT00695981|Open surgery
1318721|NCT00695981|Physiotherapy
1318722|NCT00695981|Physical therapy
1318723|NCT00695981|Effectiveness
1318724|NCT00695981|RCT
1318725|NCT00695981|cost-effectiveness
1318726|NCT00695955|Essential Hypertension
1318727|NCT00695955|Cardiovascular Disease
1318728|NCT00695955|High Blood Pressure
1318729|NCT00695955|Drug Therapy
1318730|NCT00695942|preeclampsia
1318731|NCT00695942|eclampsia
1318732|NCT00695942|retroplacental hematoma
1318733|NCT00695942|vascular IUGR
1318734|NCT00695942|IUFD
1318735|NCT00695942|VTE
1318736|NCT00695929|cardiac surgery with cardiopulmonary bypass
1318737|NCT00695903|Gram-positive bacterial infections
1318738|NCT00695903|Staph Aureus
1318739|NCT00695903|Bacteremia
1318740|NCT00695903|MRSA
1318741|NCT00695903|Infective Endocarditis
1318742|NCT00695903|Right-sided Infective endocarditis
1318743|NCT00695903|SABIE
1318744|NCT00695903|SAIE
1318745|NCT00695903|RIE
1318746|NCT00695890|Pupillometry
1318747|NCT00695890|Sevoflorane
1318748|NCT00695890|Propofol
1318749|NCT00695877|HIV Seronegativity
1318750|NCT00695877|HIV Preventive Vaccine
1318751|NCT00695851|PCK3145
1318752|NCT00695851|Prostate
1318753|NCT00695838|GERD symptoms- Waist circumference
1318754|NCT00695838|Patients with symptomatic GERD
1318755|NCT00695812|Neurodevelopmental disorders
1318756|NCT00695812|Autism Spectrum Disorders
1318757|NCT00695812|Broader autism phenotype
1318758|NCT00695812|Siblings
1318759|NCT00695812|Cognitive language and social emotional development
1318760|NCT00695812|to identify siblings who manifest any autism or broader autism phenotype characteristics
1318761|NCT00695799|Propofol
1318762|NCT00695799|Anesthesia care provider
1318763|NCT00695799|Pollution
1318764|NCT00695799|Operating room
1318765|NCT00695799|Environment
1318766|NCT00695786|Non-Hodgkin's Lymphoma
1318767|NCT00695786|Lymphoma
1318768|NCT00695786|Lenalidomide
1318769|NCT00695786|Revlimid
1318770|NCT00695786|Rituximab
1318771|NCT00695786|Rituxan
1318772|NCT00695773|Prostate Cancer Surgery
1318773|NCT00695773|Laparoscopic surgery for Prostate Cancer
1318774|NCT00695773|Prostatectomy
1318775|NCT00695773|Urologic Surgical Procedures
1318776|NCT00695747|Glaucoma
1318777|NCT00695747|Cataracts
1318778|NCT00695747|Phacoemulsification(IOL)
1318779|NCT00695747|Trabeculectomy
1318780|NCT00695734|hemodialysis
1318781|NCT00695734|end stage renal failure
1318782|NCT00695734|tuberculosis
1318783|NCT00695734|latent tuberculosis infection
1318784|NCT00695734|Patients under hemodialysis for end stage renal failure
1318785|NCT00695708|schizophrenia
1318786|NCT00695708|neuroplasticity
1318787|NCT00695708|sensory gating
1318788|NCT00695708|cognitive impairment
1318789|NCT00695708|MEG
1318790|NCT00695708|Disorders with Psychotic Features
1318791|NCT00695695|Parents
1318792|NCT00695695|Down Syndrome
1318793|NCT00695695|Hope
1318794|NCT00695695|Uncertainty
1318795|NCT00695695|Adaptation
1318796|NCT00695695|DS
1318797|NCT00695695|Survey
1318798|NCT00695682|Remicade
1318799|NCT00695682|Infliximab
1318800|NCT00695682|CSME
1318801|NCT00695682|BDR
1318802|NCT00695682|CNV
1318803|NCT00695682|AMD
1318804|NCT00695669|H5N1
1318805|NCT00695669|immunogenicity
1318806|NCT00695669|influenza
1318808|NCT00695669|pandemic
1318809|NCT00695669|vaccines
1318810|NCT00695669|human
1318811|NCT00695669|safety
1318812|NCT00695656|Hypertension
1318813|NCT00695656|general practitioner consultation
1318814|NCT00695656|Patients with hypertension
1318815|NCT00695630|conscious sedation
1318816|NCT00695630|dental anxiety/drug therapy
1318817|NCT00695630|behavior/drug effects
1318818|NCT00695617|MARS treatment
1318819|NCT00695617|Citrate anticoagulation
1318820|NCT00695604|Acute asthma
1318821|NCT00695604|fluticasone
1318822|NCT00695604|inhaled corticosteroids
1318823|NCT00695591|Home sleep testing neuromuscular disease
1318824|NCT00695591|Neuromuscular disease patients with FEV1<50% of predicted
1318825|NCT00695552|Major depression, exercise
1318826|NCT00695539|Rosuvastatin
1318827|NCT00695539|hypercholesterolaemia
1318828|NCT00695526|cranberry
1318829|NCT00695526|total to HDL cholesterol ratio
1318830|NCT00695526|type 2 diabetes
1318831|NCT00695513|Food supplement
1318832|NCT00695513|Haemodialysis
1318833|NCT00695500|Varenicline
1318834|NCT00695500|Alcohol
1318835|NCT00695500|Alcohol Use
1318836|NCT00695487|Anesthesia
1318837|NCT00695487|THC
1318838|NCT00695487|Postoperative Nausea
1318839|NCT00695474|Hypovitaminosis D
1318840|NCT00695474|Type 2 diabetes
1318841|NCT00695474|Glycemic control
1318842|NCT00695474|Inflammation
1318843|NCT00695474|Blood pressure
1318844|NCT00695461|Colorectal surgery
1318845|NCT00695461|Probiotics
1318846|NCT00695461|Lactobacillus
1318847|NCT00695461|Bacterial translocation
1318848|NCT00695461|Postoperative complications
1318849|NCT00695461|Inflammatory reaction
1318850|NCT00695448|Phosphoinositide 3-kinase inhibitor
1318851|NCT00695448|solid tumors
1318852|NCT00695435|normal volunteers
1318853|NCT00695435|anti-infective
1318854|NCT00695435|tobramycin
1318855|NCT00695422|high-grade squamous intraepithelial lesion
1318856|NCT00695422|low-grade squamous intraepithelial lesion
1318857|NCT00695422|human papilloma virus infection
1318858|NCT00695422|AIDS-related diffuse large cell lymphoma
1318859|NCT00695422|AIDS-related diffuse mixed cell lymphoma
1318860|NCT00695422|AIDS-related diffuse small cleaved cell lymphoma
1318861|NCT00695422|AIDS-related immunoblastic large cell lymphoma
1318862|NCT00695422|AIDS-related Kaposi sarcoma
1318863|NCT00695422|AIDS-related lymphoblastic lymphoma
1318864|NCT00695422|AIDS-related malignancies
1318865|NCT00695422|AIDS-related peripheral/systemic lymphoma
1318866|NCT00695422|AIDS-related primary CNS lymphoma
1318867|NCT00695422|AIDS-related small noncleaved cell lymphoma
1318868|NCT00695422|multicentric Castleman disease
1318869|NCT00695422|HIV Infections
1318870|NCT00695409|recurrent mantle cell lymphoma
1318871|NCT00695409|stage III mantle cell lymphoma
1318872|NCT00695409|stage IV mantle cell lymphoma
1318873|NCT00695409|recurrent adult diffuse large cell lymphoma
1318874|NCT00695409|stage III adult diffuse large cell lymphoma
1318875|NCT00695409|stage IV adult diffuse large cell lymphoma
1318876|NCT00695409|recurrent grade 1 follicular lymphoma
1318877|NCT00695409|recurrent grade 2 follicular lymphoma
1318878|NCT00695409|recurrent grade 3 follicular lymphoma
1318879|NCT00695409|stage III grade 1 follicular lymphoma
1318880|NCT00695409|stage III grade 2 follicular lymphoma
1318881|NCT00695409|stage III grade 3 follicular lymphoma
1318882|NCT00695409|stage IV grade 1 follicular lymphoma
1318883|NCT00695409|stage IV grade 2 follicular lymphoma
1318884|NCT00695409|stage IV grade 3 follicular lymphoma
1318885|NCT00695409|stage III adult immunoblastic large cell lymphoma
1318886|NCT00695409|stage IV adult immunoblastic large cell lymphoma
1318887|NCT00695409|recurrent adult immunoblastic large cell lymphoma
1318888|NCT00695396|MDS
1318889|NCT00695396|Myelodysplastic syndromes
1318890|NCT00695396|Anemia
1318891|NCT00695396|Epoetin alfa
1318892|NCT00695396|EPO
1318893|NCT00695383|Exercise therapy
1318894|NCT00695383|Physiotherapy
1318895|NCT00695383|Critical illness
1318896|NCT00695383|Intensive care
1318897|NCT00695383|Muscle weakness
1318898|NCT00695383|Mechanical ventilation
1318899|NCT00695370|Children
1318900|NCT00695370|cancer
1318901|NCT00695370|Bone marrow transplantation
1318902|NCT00695370|Mobilization
1318903|NCT00695370|G-CSF
1318904|NCT00695370|Children with solid malignancies
1318905|NCT00695357|Asthma treatment
1318906|NCT00695357|GINA 2006
1318907|NCT00695357|patient perception
1318908|NCT00695344|Effect of everolimus in graft vascular cardiac illness
1318909|NCT00695331|Labor Augmentation
1318910|NCT00695331|Misoprostol
1318911|NCT00695331|Oxytocin
1318912|NCT00695318|AMD
1318913|NCT00695318|Age-Related Macular Degeneration
1318914|NCT00695318|Geographic Atrophy
1318915|NCT00695318|GA
1318916|NCT00695305|rilapladib,
1318917|NCT00695305|Lp-PLA2,
1318918|NCT00695305|atherosclerosis
1318919|NCT00695305|SB-659032,
1318920|NCT00695305|FDG-PET,
1318921|NCT00695292|Small Cell Lung Cancer
1318922|NCT00695292|Extensive Stage
1318923|NCT00695292|irinotecan
1318924|NCT00695292|carboplatin
1318925|NCT00695292|sunitinib
1318926|NCT00695279|Gene therapy
1318927|NCT00695253|AAA
1318928|NCT00695240|Continuous bupivacaine infusion
1318929|NCT00695240|Analgesia
1318930|NCT00695227|laryngopharyngeal reflux
1318931|NCT00695227|extraesophageal reflux symptoms
1318932|NCT00695214|Obstructive Sleep Apnea
1318933|NCT00695214|Propofol
1318934|NCT00695214|Sleep Endoscopy
1318935|NCT00695201|DEXAMETHASONE
1318936|NCT00695201|FLOXURIDINE
1318937|NCT00695201|IRINOTECAN (CPT-11) CAMPTOSAR
1318938|NCT00695201|OXALIPLATIN
1318939|NCT00695188|rheumatoid arthritis
1318940|NCT00695188|MTX polyglutamates
1318941|NCT00695188|clinical outcome
1318942|NCT00695175|Hypertension
1318943|NCT00695175|Private cardiology consultation
1318944|NCT00695175|Patients with hypertension
1318945|NCT00695162|noise
1318946|NCT00695162|speech intelligibility
1318947|NCT00695162|cognition
1318948|NCT00695149|Spinal cord Injury
1318949|NCT00695149|Central nervous system
1318950|NCT00695149|Regeneration
1318951|NCT00695149|Bone marrow stromal cells
1318952|NCT00695149|Transplantation
1318953|NCT00695136|Autism
1318954|NCT00695136|Cognitive Disorder
1318955|NCT00695136|Sleep
1318956|NCT00695136|Autism Spectrum Disorder
1318957|NCT00695136|ASD
1318958|NCT00695123|Bone Marrow Transplant
1318959|NCT00695123|Sickle Cell Disease
1318960|NCT00695123|G-CSF
1318961|NCT00695123|Apheresis
1318962|NCT00695123|SD
1318963|NCT00695123|Healthy Volunteer
1318964|NCT00695123|HV
1318965|NCT00695110|testosterone
1318966|NCT00695110|male hypogonadism
1318967|NCT00695110|low testosterone
1318968|NCT00695097|Rituximab
1318969|NCT00695097|Renal Transplant Rejection
1318970|NCT00695097|B cells
1318971|NCT00695097|Patients with biopsy proven acute rejection cellular infiltrate, B cells
1318972|NCT00695084|multiple sclerosis
1318973|NCT00695071|Healthy Volunteers
1318974|NCT00695058|Stress incontinence
1318975|NCT00695058|urge incontinence
1318976|NCT00695058|overactive bladder syndrome
1318977|NCT00695058|vibration
1318978|NCT00695058|nerve stimulation
1318979|NCT00695045|Pain, Postoperative
1318980|NCT00695045|Arthroplasty, Replacement, Knee
1318981|NCT00695045|Morphine
1318982|NCT00695045|Injections, Intrathecal
1318983|NCT00695032|renal toxicity
1318984|NCT00695032|chemotherapeutic agent toxicity
1318985|NCT00695032|unspecified adult solid tumor, protocol specific
1318986|NCT00695019|Prevention of Relapse
1318987|NCT00695019|HCV genotype 1b
1318988|NCT00695019|Recurrence
1318989|NCT00695006|manual therapy, cervical traction, cervical radiculopathy
1318990|NCT00694993|first time in human
1318991|NCT00694993|Allergic rhinitis,
1318992|NCT00694980|UC
1318993|NCT00694980|Ulcerative Colitis
1318994|NCT00694967|short cervix, cervical funneling, spontaneous preterm birth, cerclage, progesterone
1318995|NCT00694954|Iron deficiency anemia
1318996|NCT00694954|Wireless capsule endoscopy
1318997|NCT00694954|Obscure-occult gastrointestinal bleeding
1318998|NCT00694941|ONO-2506PO
1318999|NCT00694941|Amyotrophic Lateral Sclerosis
1319000|NCT00694941|ALS
1319001|NCT00694915|STCC (Superficial Transitional Cell Carcinoma)
1319002|NCT00694902|Healthy Volunteers
1319003|NCT00694889|Psychosis
1319004|NCT00694889|First Episode
1319005|NCT00694889|Schizophrenia
1319006|NCT00694889|Cognitive Remediation
1319007|NCT00694876|Health Literacy
1319008|NCT00694876|Patient Nonadherence
1319009|NCT00694876|Patient Noncompliance
1319010|NCT00694876|Follow Up
1319011|NCT00694876|India
1319012|NCT00694876|Glaucoma
1319013|NCT00694863|high risk for ESRD
1319014|NCT00694863|immunosuppressive treatment
1319015|NCT00694863|membranous nephropathy
1319016|NCT00694863|ACTH
1319017|NCT00694850|Interstitial lung disease associated pulmonary hypertension
1319018|NCT00694837|glioblastoma
1319019|NCT00694837|nelfinavir
1319020|NCT00694837|functional imaging
1319021|NCT00694837|AKT pathway
1319022|NCT00694824|Coronary artery calcification
1319023|NCT00694824|calcium score
1319024|NCT00694824|(TGF) b1,
1319025|NCT00694824|fetuin A
1319026|NCT00694824|osteoprotegerin (OPG)
1319027|NCT00694824|fibroblast growth factor (FGF) 23,
1319028|NCT00694824|matrix gla protein (MGP)
1319029|NCT00694824|hemodialysis patients
1319030|NCT00694811|Obesity
1319031|NCT00694811|Weight loss
1319032|NCT00694811|Diet
1319033|NCT00694811|Very-low-energy diet
1319034|NCT00694811|Predictive factors
1319035|NCT00694811|Re-feeding
1319036|NCT00694798|STCC
1319037|NCT00694798|Superficial Transitional Cell Carcinoma- BCG refractor
1319038|NCT00694772|Obstructive sleep apnea
1319039|NCT00694772|OSA
1319040|NCT00694772|Apnea hypopnea index
1319041|NCT00694772|AHI
1319042|NCT00694772|Coblation
1319043|NCT00694772|Electrocautery
1319044|NCT00694772|Tonsillectomy
1319045|NCT00694772|Tonsillotomy
1319046|NCT00694759|Polycystic ovary syndrome
1319047|NCT00694759|insulin
1319048|NCT00694759|PCOS
1319049|NCT00694759|cortisol regulation
1319050|NCT00694759|regulation
1319051|NCT00694746|ALT
1319052|NCT00694746|Non-Alcoholic Fatty Liver Disease
1319053|NCT00694746|Adolescents
1319054|NCT00694746|Overweight
1319055|NCT00694746|Treatment
1319056|NCT00694733|Obesity
1319057|NCT00694733|Menopausal Syndrome
1319058|NCT00694733|Cortisol
1319059|NCT00694720|Cheyne-stokes breathing
1319060|NCT00694694|Malaria
1319061|NCT00694694|Africa
1319062|NCT00694694|Child
1319063|NCT00694681|Telephonic care management
1319064|NCT00694668|Deliberate Self-Harm
1319065|NCT00694668|Self-Injurious Behaviour
1319066|NCT00694668|Suicidal Behaviour
1319067|NCT00694668|Cognitive behavioural therapy
1319068|NCT00694668|Mindfulness Based cognitive therapy
1319069|NCT00694655|Yellow Fever
1319070|NCT00694655|Vaccine
1319071|NCT00694655|Immunity
1319072|NCT00694655|yellow fever vaccine
1319073|NCT00694655|CD8 T cell responses
1319074|NCT00694642|Refractory angina
1319075|NCT00694629|pulmonary tuberculosis
1319076|NCT00694629|treatment
1319077|NCT00694616|Obstructive sleep apnea
1319078|NCT00694616|Metabolic syndrome
1319079|NCT00694616|Insulin resistance
1319080|NCT00694616|Hypertension
1319081|NCT00694616|Dyslipidemia
1319082|NCT00694616|Continuous positive airway pressure (CPAP)
1319083|NCT00694603|cetuximab
1319084|NCT00694603|tyrosine kinase inhibitor
1319085|NCT00694590|AMD3100
1319086|NCT00694590|Rituximab
1319087|NCT00694590|Chronic Lymphocytic Leukemia
1319088|NCT00694590|CLL
1319089|NCT00694590|Small Lymphocytic Lymphoma
1319090|NCT00694590|SLL
1319091|NCT00694577|non-invasive breast cancer
1319092|NCT00694577|early invasive breast cancer
1319093|NCT00694577|radiation
1319094|NCT00694577|PBI
1319095|NCT00694564|abdominal pain
1319096|NCT00694564|children
1319097|NCT00694551|vaccine
1319098|NCT00694551|PSMA
1319099|NCT00694551|TARP
1319100|NCT00694551|immunology
1319101|NCT00694551|PSA
1319102|NCT00694538|Interferential laser therapy
1319103|NCT00694525|21OHD
1319104|NCT00694525|21-hydroxylase deficiency
1319105|NCT00694525|CAH
1319106|NCT00694499|Morbidity
1319107|NCT00694499|Mortality
1319108|NCT00694486|otitis
1319109|NCT00694486|Eustachian tube function
1319110|NCT00694486|Normal middle ear status
1319111|NCT00694473|hyperglycemia
1319112|NCT00694473|hypoglycemia
1319113|NCT00694473|insulin
1319114|NCT00694473|critical illness
1319115|NCT00694473|intensive insulin therapy
1319116|NCT00694473|continuous glucose monitoring
1319117|NCT00694473|CGM
1319118|NCT00694473|interstitial fluid glucose
1319119|NCT00694473|intensive care unit
1319120|NCT00694473|Blood glucose
1319121|NCT00694460|rabies vaccination
1319122|NCT00694460|pre-exposure prophylaxis
1319123|NCT00694460|rabies virus neutralizing antibody
1319124|NCT00694434|Cryopreservation
1319125|NCT00694434|Frozen embryo transfer
1319126|NCT00694434|Graduated Embryo Score
1319127|NCT00694421|otitis
1319128|NCT00694421|Eustachian tube
1319129|NCT00694421|virus
1319130|NCT00694421|Middle ear disease
1319131|NCT00694408|End stage liver disease
1319132|NCT00694408|Paediatric liver transplantation
1319133|NCT00694408|Steroid free immunosuppression
1319134|NCT00694395|Qualitative study
1319135|NCT00694395|stroke
1319136|NCT00694395|20 patients, Family or caregivers
1319137|NCT00694395|acute ischemic stroke
1319138|NCT00694395|delayed to receive thrombolytic therapy.
1319139|NCT00694382|chemotherapy
1319140|NCT00694369|Postoperative Dental Pain
1319141|NCT00694343|Cesarean section
1319142|NCT00694343|spinal anesthesia
1319143|NCT00694343|hypotension
1319147|NCT00694304|Major Depressive Disorder
1319148|NCT00694304|Long-term
1319149|NCT00694304|Safety
1319150|NCT00694304|Open-label
1319151|NCT00694291|Rising PSA
1319152|NCT00694265|Carpal Tunnel Syndrome
1319153|NCT00694265|Median Nerve
1319154|NCT00694265|Ultrasonography
1319155|NCT00694265|Prospective cohort study
1319156|NCT00694252|Breast cancer
1319157|NCT00694252|Tykerb
1319158|NCT00694252|CTCs
1319159|NCT00694239|hypertension
1319160|NCT00694239|compliance
1319161|NCT00694226|Adolescent
1319162|NCT00694226|Substance use
1319163|NCT00694226|Brief intervention
1319164|NCT00694226|Child psychiatry
1319165|NCT00694213|Pandemic Influenza
1319166|NCT00694213|Avian Influenza
1319167|NCT00694213|DNA Vaccines
1319168|NCT00694213|Antibody
1319169|NCT00694213|T Cells
1319170|NCT00694213|HA/NP/M2
1319171|NCT00694213|Biojector
1319172|NCT00694200|breast cancer
1319173|NCT00694200|chemotherapy
1319174|NCT00694200|anti-angiogenesis therapy
1319175|NCT00694174|Procedural Pain in Newborn Infants
1319176|NCT00694174|newborn infant
1319177|NCT00694174|acute procedural pain
1319178|NCT00694174|skin blood flow changes
1319179|NCT00694174|sucrose analgesia
1319180|NCT00694174|laser doppler imager
1319181|NCT00694174|neonatal infant pain scale
1319182|NCT00694161|Transthyretin
1319183|NCT00694161|TTR
1319184|NCT00694161|ATTR
1319185|NCT00694161|TTR amyloidosis
1319186|NCT00694161|cardiomyopathy
1319187|NCT00694161|V122I
1319188|NCT00694161|wild-type TTR
1319189|NCT00694161|SSA
1319190|NCT00694161|Patients with V122I or wild-type TTR amyloid cardiomyopathy
1319191|NCT00694148|Treatment of glabellar frown lines
1319192|NCT00694135|Iontophoresis
1319193|NCT00694135|Non-Infectious Acute Anterior Segment Uveitis
1319194|NCT00694135|Ophthalmology
1319195|NCT00694122|glucose
1319196|NCT00694122|cortisol
1319197|NCT00694122|growth hormone
1319198|NCT00694122|glucagon
1319199|NCT00694122|insulin
1319200|NCT00694109|Familial Hypercholesterolemia
1319201|NCT00694109|FH
1319202|NCT00694109|Heterozygous Familial Hypercholesterolemia
1319203|NCT00694109|HeFH
1319204|NCT00694109|Homozygous Familial Hypercholesterolemia
1319205|NCT00694109|HoFH
1319206|NCT00694057|Type 2 Diabetes Mellitus
1319207|NCT00694057|Metformin
1319208|NCT00694057|HbA1c
1319209|NCT00694044|Safety, Tolerability, Pharmacokinetics, Cognition
1319210|NCT00694031|Mortality
1319211|NCT00694031|Convective therapies
1319212|NCT00694031|On-line Hemodiafiltration
1319213|NCT00694031|Dialysis Adequacy
1319214|NCT00694031|Age 18 or older
1319215|NCT00694031|Undergoing hemodialysis
1319216|NCT00694018|randomized trial
1319217|NCT00694018|walking
1319218|NCT00694005|stent
1319219|NCT00694005|bifurcation
1319220|NCT00694005|balloon angioplasty
1319221|NCT00693966|HPV, Vaccine
1319222|NCT00693953|Evoked Potentials
1319223|NCT00693953|Evoked Potentials, Auditory
1319224|NCT00693953|Evoked Potentials, Visual
1319225|NCT00693953|Electroencephalography
1319226|NCT00693953|Brain Mapping
1319227|NCT00693940|Peripheral Arterial Disease
1319228|NCT00693940|PAD
1319229|NCT00693927|Hematopoietic cell transplantation
1319230|NCT00693927|Allogeneic
1319231|NCT00693927|Nonmyeloablative
1319232|NCT00693927|CD8-depletion
1319233|NCT00693927|PBSC
1319234|NCT00693927|GVHD
1319235|NCT00693927|Hematological malignancies and renal cell carcinoma
1319236|NCT00693914|Brain Tumor
1319237|NCT00693914|Cognitive Late Effects
1319238|NCT00693914|Radiation Therapy
1319239|NCT00693914|Working Memory
1319240|NCT00693888|dementia
1319241|NCT00693888|system of care
1319242|NCT00693888|level of care
1319243|NCT00693888|interventional study
1319244|NCT00693888|evaluation
1319245|NCT00693888|dementia diagnostic
1319246|NCT00693888|Evaluation of the care study
1319247|NCT00693875|incidence
1319248|NCT00693875|awareness
1319249|NCT00693875|general anesthesia
1319250|NCT00693875|relevant factor
1319251|NCT00693875|the incidence of intra-operative awareness in China
1319252|NCT00693875|the relevant factors
1319253|NCT00693862|Focus of the study is pharmacokinetics of the study drug
1319254|NCT00693849|depression
1319255|NCT00693849|CNS
1319256|NCT00693849|iSPOT
1319257|NCT00693849|MDD
1319258|NCT00693836|stage I non-small cell lung cancer
1319259|NCT00693836|stage II non-small cell lung cancer
1319260|NCT00693836|stage IIIA non-small cell lung cancer
1319261|NCT00693836|stage IIIB non-small cell lung cancer
1319262|NCT00693836|stage IV non-small cell lung cancer
1319263|NCT00693836|recurrent non-small cell lung cancer
1319264|NCT00693836|extensive stage small cell lung cancer
1319265|NCT00693836|limited stage small cell lung cancer
1319266|NCT00693836|recurrent small cell lung cancer
1319267|NCT00693823|atherosclerosis
1319268|NCT00693823|stent
1319269|NCT00693823|angioplasty
1319270|NCT00693823|covered stent
1319271|NCT00693797|ventricular hypertrophy
1319272|NCT00693797|collagen
1319273|NCT00693797|aortic stenosis
1319274|NCT00693784|Intervertebral Disk
1319275|NCT00693784|chronic low back pain
1319276|NCT00693784|internal disc disruption
1319277|NCT00693784|degenerative disc disease
1319278|NCT00693758|MRI
1319279|NCT00693758|coronary reactivity
1319280|NCT00693758|coronary physiology
1319281|NCT00693745|Acutely
1319282|NCT00693719|recurrent breast cancer
1319283|NCT00693719|stage IIIA breast cancer
1319284|NCT00693719|stage IIIB breast cancer
1319285|NCT00693719|stage IIIC breast cancer
1319286|NCT00693719|stage IV breast cancer
1319287|NCT00693706|cell culture
1319288|NCT00693706|Safety
1319289|NCT00693706|Influenza
1319290|NCT00693706|Humans
1319291|NCT00693706|Adults
1319292|NCT00693706|Immunogenicity
1319293|NCT00693706|Influenza vaccine
1319294|NCT00693706|Vaccine
1319295|NCT00693680|depression
1319296|NCT00693680|antidepressant treatment
1319297|NCT00693680|zinc
1319298|NCT00693680|placebo
1319299|NCT00693667|osteoporosis
1319300|NCT00693667|postmenopausal women
1319301|NCT00693667|botanical drug
1319302|NCT00693654|Uremic Pruritis
1319303|NCT00693641|Jellyfish
1319304|NCT00693641|Cyanea sp
1319305|NCT00693641|Safe Sea
1319306|NCT00693641|Prevention
1319307|NCT00693641|treatment
1319308|NCT00693641|Pain relief
1319309|NCT00693641|Prevention of pain
1319310|NCT00693628|volume
1319311|NCT00693628|healing
1319312|NCT00693628|shrinker
1319313|NCT00693628|transtibial amputation
1319314|NCT00693628|individuals who have undergone transtibial amputation
1319315|NCT00693615|HPV, Vaccine
1319316|NCT00693589|endothelial function
1319317|NCT00693589|flow mediated dilatation
1319318|NCT00693589|rosuvastatin
1319319|NCT00693589|folic acid
1319320|NCT00693589|B vitamins
1319321|NCT00693576|renal transplant
1319322|NCT00693576|panel reactive antibody
1319323|NCT00693576|sensitization
1319324|NCT00693576|simvastatin
1319325|NCT00693576|immunological
1319326|NCT00693563|Spinal Cord Injury
1319327|NCT00693550|lip and oral cavity squamous cell carcinoma
1319328|NCT00693550|oropharyngeal squamous cell carcinoma
1319329|NCT00693524|liver allograft transplantation
1319330|NCT00693524|sequential therapy
1319331|NCT00693524|tacrolimus
1319332|NCT00693511|obesity
1319333|NCT00693511|adolescents
1319334|NCT00693511|adiposity
1319335|NCT00693511|insulin sensitivity
1319336|NCT00693511|type 2 diabetes
1319337|NCT00693511|Latino
1319338|NCT00693511|circuit training
1319339|NCT00693511|physical activity
1319340|NCT00693511|motivational interviewing
1319341|NCT00693498|pediatrics
1319342|NCT00693498|congenital heart disease
1319343|NCT00693472|Antipsychotic Agents
1319344|NCT00693459|Hemorrhoids
1319345|NCT00693446|Pancreas-kidney allograft
1319346|NCT00693446|tacrolimus
1319347|NCT00693446|sirolimus
1319348|NCT00693446|Pancreas-kidney allograft recipients
1319349|NCT00693381|Transplantation
1319350|NCT00693381|Graft Rejection
1319351|NCT00693381|Renal Transplantation
1319352|NCT00693355|gut health
1319353|NCT00693342|stage IA primary peritoneal cavity cancer
1319354|NCT00693342|stage IB primary peritoneal cavity cancer
1319355|NCT00693342|stage IC primary peritoneal cavity cancer
1319356|NCT00693342|stage IIA primary peritoneal cavity cancer
1319357|NCT00693342|stage IIB primary peritoneal cavity cancer
1319358|NCT00693342|stage IIC primary peritoneal cavity cancer
1319359|NCT00693342|stage IIIA primary peritoneal cavity cancer
1319360|NCT00693342|stage IIIB primary peritoneal cavity cancer
1319361|NCT00693342|stage IIIC primary peritoneal cavity cancer
1319362|NCT00693342|stage IV primary peritoneal cavity cancer
1319363|NCT00693342|stage IA fallopian tube cancer
1319364|NCT00693342|stage IB fallopian tube cancer
1319365|NCT00693342|stage IC fallopian tube cancer
1319366|NCT00693342|stage IIA fallopian tube cancer
1319367|NCT00693342|stage IIB fallopian tube cancer
1319368|NCT00693342|stage IIC fallopian tube cancer
1319369|NCT00693342|stage IIIA fallopian tube cancer
1319370|NCT00693342|stage IIIB fallopian tube cancer
1319371|NCT00693342|stage IIIC fallopian tube cancer
1319372|NCT00693342|stage IV fallopian tube cancer
1319373|NCT00693342|stage IA ovarian epithelial cancer
1319374|NCT00693342|stage IB ovarian epithelial cancer
1319375|NCT00693342|stage IC ovarian epithelial cancer
1319376|NCT00693342|stage IIA ovarian epithelial cancer
1319377|NCT00693342|stage IIB ovarian epithelial cancer
1319378|NCT00693342|stage IIC ovarian epithelial cancer
1319379|NCT00693342|stage IIIA ovarian epithelial cancer
1319380|NCT00693342|stage IIIB ovarian epithelial cancer
1319381|NCT00693342|stage IIIC ovarian epithelial cancer
1319382|NCT00693342|stage IV ovarian epithelial cancer
1319383|NCT00693329|Contrast Induced Nephrophathy (CIN)
1319384|NCT00693329|Kidney
1319385|NCT00693329|NGAL
1319386|NCT00693316|Healthy volunteer study
1319387|NCT00693303|single subject
1319388|NCT00693303|quantitative
1319389|NCT00693290|Colonoscopy
1319390|NCT00693290|Colorectal screening
1319391|NCT00693290|Colon preparation
1319392|NCT00693277|none - entry made in error
1319393|NCT00693264|Human Volunteers
1319394|NCT00693264|Hoodia
1319395|NCT00693264|Safety
1319396|NCT00693251|stent
1319397|NCT00693251|bifurcation
1319398|NCT00693251|coronary artery stenosis
1319399|NCT00693251|balloon angioplasty
1319400|NCT00693238|Prostate Cancer
1319401|NCT00693238|Proton Radiation
1319402|NCT00693225|Erosive Esophagitis
1319403|NCT00693225|Reflux Esophagitis
1319404|NCT00693225|Gastroesophageal reflux disease
1319405|NCT00693225|GERD
1319406|NCT00693225|proton pump inhibitor
1319407|NCT00693225|omeprazole/sodium bicarbonate
1319408|NCT00693212|ADHD
1319409|NCT00693212|Adult
1319410|NCT00693212|crossover
1319411|NCT00693212|randomized
1319412|NCT00693212|Long-term
1319413|NCT00693212|Open-label
1319414|NCT00693212|methylphenidate
1319415|NCT00693212|Social adjustment
1319416|NCT00693199|Amlodipine
1319417|NCT00693199|Terazosin
1319418|NCT00693199|Lower Urinary Tract Symptoms (LUTS)
1319419|NCT00693199|Essential hypertension
1319420|NCT00693199|International Prostate Symptom Score (IPSS)
1319421|NCT00693199|Quality Of Life (QOL)
1319422|NCT00693173|anal
1319423|NCT00693173|cancer
1319424|NCT00693173|rectal
1319425|NCT00693173|IMRT
1319426|NCT00693173|genital
1319427|NCT00693173|sparing
1319428|NCT00693173|drop
1319429|NCT00693173|technique
1319430|NCT00693160|healthy volunteers
1319431|NCT00693160|analgesia
1319432|NCT00693160|pain
1319433|NCT00693160|Healthy subjects
1319434|NCT00693147|Goiter [C19.874.283]
1319435|NCT00693147|Thyroid Neoplasms [C19.874.788]
1319436|NCT00693121|Traumatic Brain Injury
1319437|NCT00693121|Posttraumatic Confusional State
1319438|NCT00693121|Delirium
1319439|NCT00693121|Amantadine
1319440|NCT00693121|Clinical trial
1319441|NCT00693108|Poor
1319442|NCT00693108|Response
1319443|NCT00693108|Ovarian
1319444|NCT00693108|Stimulation
1319445|NCT00693108|IVF
1319446|NCT00693108|Patients
1319447|NCT00693095|Grade IV Glioblastoma Multiforme
1319448|NCT00693095|Newly-diagnosed
1319449|NCT00693095|CMV positive
1319450|NCT00693082|PCOS
1319451|NCT00693082|flaxseed
1319452|NCT00693069|angioplasty
1319453|NCT00693069|clopidogrel
1319454|NCT00693069|coronary artery disease
1319455|NCT00693069|platelets
1319456|NCT00693069|Percutaneous coronary intervention
1319457|NCT00693056|Erectile Dysfunctions
1319458|NCT00693056|ED
1319459|NCT00693043|Pain control
1319460|NCT00693030|Coronary Artery Disease
1319461|NCT00693030|Percutaneous Coronary Interventions
1319462|NCT00693030|Drug-Eluting stents
1319463|NCT00693030|Optical Coherence Tomography
1319464|NCT00693030|Thrombosis
1319465|NCT00693030|Long lesions in native vessel requiring stents in overlap
1319466|NCT00692991|Microvascular Obstruction
1319467|NCT00692991|Cardiac MRI
1319468|NCT00692991|Alcohol Ablation
1319469|NCT00692991|Diagnostic PCI
1319470|NCT00692978|Monodisperse aerosols
1319471|NCT00692978|Healthy Volunteers
1319472|NCT00692978|Asthmatics
1319473|NCT00692978|Pharmacokinetics
1319474|NCT00692978|Randomized
1319475|NCT00692965|HIV
1319476|NCT00692965|Sleep Quality
1319477|NCT00692965|Sleep apnea
1319478|NCT00692965|Berlin Questionnaire
1319479|NCT00692965|Pittsburgh Sleep Quality Index
1319480|NCT00692952|contraceptive efficacy
1319483|NCT00692926|ALDHbr
1319484|NCT00692926|Umbilical Cord Blood
1319485|NCT00692926|Transplantation
1319486|NCT00692926|Hematological malignancy
1319487|NCT00692926|MDS
1319488|NCT00692926|severe aplastic anemia
1319489|NCT00692926|inborn error of metabolism
1319490|NCT00692926|congenital marrow failure or congenital immunodeficiency syndrome
1319491|NCT00692926|Hurler's Disease
1319492|NCT00692926|Tay Sach's
1319493|NCT00692926|PMD
1319494|NCT00692926|Hunter's Syndrome
1319495|NCT00692926|Krabbe
1319496|NCT00692926|MLD
1319497|NCT00692926|ALD
1319498|NCT00692926|ALL
1319499|NCT00692926|AML
1319500|NCT00692887|AMD
1319501|NCT00692874|Quality of Life
1319502|NCT00692861|Celiac Disease
1319503|NCT00692861|Ataxia
1319504|NCT00692861|Adults
1319505|NCT00692861|Health Volunteer
1319506|NCT00692861|HV
1319507|NCT00692848|Procalcitonin
1319508|NCT00692848|Antibiotic
1319509|NCT00692848|Fever without source
1319510|NCT00692848|Fever without focus
1319511|NCT00692848|bacteremia
1319512|NCT00692848|Urinary tract infection
1319513|NCT00692835|Goiter [C19.874.283]
1319514|NCT00692835|Thyroid Neoplasms [C19.874.788]
1319515|NCT00692822|Neisseria gonorrheae
1319516|NCT00692822|Antimicrobial Susceptibility
1319517|NCT00692822|Quinolone Resistance
1319518|NCT00692822|Sexually transmitted diseases
1319519|NCT00692809|Latent tuberculosis infection
1319520|NCT00692809|Human immunodeficiency virus
1319521|NCT00692809|Tuberculosis
1319522|NCT00692809|Natural Killer T Cells
1319523|NCT00692809|Invariant Natural Killer T Cells
1319524|NCT00692809|Regulatory T cells
1319525|NCT00692809|Interferon-gamma
1319526|NCT00692796|Pulmonary fibrosis
1319527|NCT00692796|Pulmonary rehabilitation
1319528|NCT00692796|Dyspnea
1319529|NCT00692796|Quality of life
1319530|NCT00692783|candida
1319531|NCT00692783|dubliniensis
1319532|NCT00692783|candidiasis
1319533|NCT00692783|HIV
1319534|NCT00692783|AIDS
1319535|NCT00692783|azole resistance.
1319536|NCT00692770|Hepatocellular carcinoma
1319537|NCT00692770|Sorafenib
1319538|NCT00692770|Adjuvant
1319539|NCT00692770|Surgical resection
1319540|NCT00692770|Ablation
1319541|NCT00692770|Nexavar
1319542|NCT00692770|Adjuvant therapy
1319543|NCT00692770|Liver cancer
1319544|NCT00692770|HCC
1319545|NCT00692770|STORM
1319546|NCT00692757|Hypochlorous Acid
1319547|NCT00692757|Colony forming units
1319548|NCT00692757|surgical site infection
1319549|NCT00692757|nosocomial infection
1319550|NCT00692757|bacterial bioburden
1319551|NCT00692757|wound healing
1319552|NCT00692744|Subarachnoid hemorrhage
1319553|NCT00692744|Cerebral aneurysm
1319554|NCT00692744|Elderly
1319555|NCT00692731|green tea,
1319556|NCT00692731|polyphenols,
1319557|NCT00692731|weight loss,
1319558|NCT00692731|body fat
1319559|NCT00691743|Upper GI Symptoms
1319560|NCT00691743|GERD
1319561|NCT00691743|NSAIDs
1319562|NCT00691717|Anecortave acetate
1319563|NCT00691717|Open-angle glaucoma
1319564|NCT00691717|IOP
1319565|NCT00691717|OHT
1319566|NCT00691704|Multiple Myeloma
1319567|NCT00691691|Liver malignancy
1319568|NCT00691691|Stereotactic Body Radiation Therapy
1319569|NCT00691691|Efficacy of SBRT in liver tumors
1319570|NCT00691691|Hepatic toxicity with SBRT
1319571|NCT00691678|breast cancer
1319572|NCT00691678|aromatase inhibitor
1319573|NCT00691678|supportive care
1319574|NCT00691665|Rhinitis
1319575|NCT00691665|Seasonal Allergic Rhinitis
1319576|NCT00691665|allergies
1319577|NCT00691652|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1319578|NCT00691652|nodal marginal zone B-cell lymphoma
1319579|NCT00691652|splenic marginal zone lymphoma
1319580|NCT00691652|recurrent adult Burkitt lymphoma
1319581|NCT00691652|recurrent adult diffuse large cell lymphoma
1319582|NCT00691652|recurrent adult diffuse mixed cell lymphoma
1319583|NCT00691652|recurrent adult diffuse small cleaved cell lymphoma
1319584|NCT00691652|recurrent adult grade III lymphomatoid granulomatosis
1319585|NCT00691652|recurrent adult immunoblastic large cell lymphoma
1319586|NCT00691652|recurrent adult lymphoblastic lymphoma
1319587|NCT00691652|recurrent grade 1 follicular lymphoma
1319588|NCT00691652|recurrent grade 2 follicular lymphoma
1319589|NCT00691652|recurrent grade 3 follicular lymphoma
1319590|NCT00691652|recurrent mantle cell lymphoma
1319591|NCT00691652|recurrent marginal zone lymphoma
1319592|NCT00691652|recurrent small lymphocytic lymphoma
1319593|NCT00691652|cutaneous B-cell non-Hodgkin lymphoma
1319594|NCT00691639|Open-angle glaucoma
1319595|NCT00691639|IOP
1319596|NCT00691626|posttraumatic stress
1319597|NCT00691626|nightmares
1319598|NCT00691626|sleep
1319599|NCT00691626|psychotherapy
1319600|NCT00691626|imagery rehearsal
1319601|NCT00691626|insomnia
1319602|NCT00691626|behavioral treatment
1319603|NCT00691626|veterans
1319604|NCT00691626|Operation Iraqi Freedom
1319605|NCT00691626|Operation Enduring Freedom
1319606|NCT00691613|Apoptosis
1319607|NCT00691613|Annexin
1319608|NCT00691613|Hypoxia
1319609|NCT00691613|Ischemia-Reperfusion Injury
1319610|NCT00691600|abscess
1319611|NCT00691600|Abscesses in the pediatric emergency population
1319612|NCT00691587|mechanical ventilation
1319613|NCT00691587|mechanically ventilated
1319614|NCT00691587|Pseudomonas aeruginosa
1319615|NCT00691587|ventilator associated pneumonia
1319616|NCT00691574|Smith-Magenis Syndrome
1319617|NCT00691574|melatonin
1319618|NCT00691574|circadian rhythm
1319619|NCT00691574|sleep
1319620|NCT00691561|HIV Prevention
1319621|NCT00691561|African American
1319622|NCT00691561|Black
1319623|NCT00691561|gay
1319624|NCT00691561|Men who have sex men
1319625|NCT00691561|HIV Seronegativity
1319626|NCT00691548|Stage IV cancer
1319627|NCT00691522|PERITUMORAL BRAIN EDEMA
1319628|NCT00691522|PRIMARY MALIGNANT BRAIN TUMORS
1319629|NCT00691522|METASTATIC BRAIN TUMORS
1319630|NCT00691509|breast cancer
1319631|NCT00691496|HIV Prevention
1319632|NCT00691496|African-American
1319633|NCT00691496|gay
1319634|NCT00691496|bisexual
1319635|NCT00691496|intervention trial
1319636|NCT00691496|HIV Seronegativity
1319637|NCT00691483|smoking cessation
1319638|NCT00691483|smoking treatment
1319639|NCT00691483|patient self-selected quit date
1319640|NCT00692705|Alzheimer´s Disease
1319641|NCT00692705|amyloid deposits
1319642|NCT00692705|Positron Emission Tomography
1319643|NCT00692705|phase I
1319644|NCT00692653|Localized prostate cancer
1319645|NCT00692653|Treatment decision making
1319646|NCT00692653|Tailored decision aid
1319647|NCT00692640|Cancer
1319648|NCT00692640|Solid Tumors
1319649|NCT00692640|NSCLC
1319650|NCT00692627|Falciparum
1319651|NCT00692627|malaria
1319652|NCT00692627|volume
1319653|NCT00692627|haemodynamics
1319654|NCT00692601|Acute Exercise protocol
1319655|NCT00692601|Crossover design
1319656|NCT00692601|Oxygen consumption (VO2)
1319657|NCT00692601|Respiratory Exchange Ratio (RER)
1319658|NCT00692601|Adrenergic System Agonism
1319659|NCT00692601|Capsiate Natura
1319660|NCT00692601|Young
1319661|NCT00692601|Male
1319662|NCT00692588|Alzheimer's Disease
1319663|NCT00692588|Magnetic Resonance Imaging
1319664|NCT00692588|Magnetic Resonance Spectroscopy
1319665|NCT00692588|Diffusion Tensor Imaging
1319666|NCT00692588|Susceptibility Weighted Imaging
1319667|NCT00692588|Doxycycline
1319668|NCT00692588|Rifampicin
1319669|NCT00692575|Brain Injuries, Traumatic
1319670|NCT00692575|Caregivers
1319671|NCT00692562|Islets of Langerhans Transplantation
1319672|NCT00692562|Kidney Transplantation
1319673|NCT00692562|Type 1 Diabetes Mellitus
1319674|NCT00692562|alemtuzumab
1319675|NCT00692549|ultrasound
1319676|NCT00692549|iv access
1319677|NCT00692549|Patients with difficult iv access in emergency departments.
1319678|NCT00692536|Obesity
1319679|NCT00692536|Postmenopausal
1319680|NCT00692536|Diet intervention
1319681|NCT00692523|Stroke
1319682|NCT00692523|rehabilitation
1319683|NCT00692523|Nintendo Wii
1319684|NCT00692510|AZD3480
1319685|NCT00692510|Cocktail
1319686|NCT00692510|caffeine
1319687|NCT00692510|bupropion
1319688|NCT00692510|omeprazole
1319689|NCT00692510|midazolam
1319690|NCT00692510|rosiglitazone
1319691|NCT00692510|metabolism
1319692|NCT00692510|Drug Drug Interaction
1319693|NCT00692497|One-Stop
1319694|NCT00692497|Public Health Research
1319695|NCT00692497|Delivery of Health Care/*standards
1319696|NCT00692497|Evaluation Studies
1319697|NCT00692497|Referral
1319698|NCT00692497|Surgery, Outpatient
1319699|NCT00692497|Surgery, Day
1319700|NCT00692497|Telemedicine
1319701|NCT00692484|Antimicrobial
1319702|NCT00692484|Antisepsis
1319703|NCT00692484|Topical antisepsis
1319704|NCT00692471|Sleep
1319705|NCT00692471|Orthostatic tachycardia
1319706|NCT00692471|POTS
1319707|NCT00692445|depression
1319708|NCT00692432|Macrophage Migration Inhibitory Factor
1319709|NCT00692432|MIF
1319710|NCT00692432|Cardiopulmonary bypass
1319711|NCT00692432|CPB
1319712|NCT00692432|inflammation
1319713|NCT00692432|inflammatory marker
1319714|NCT00692432|myocardial depression
1319715|NCT00692432|myocardial depressant factor
1319716|NCT00692419|pain
1319717|NCT00692419|sexual dysfunction
1319718|NCT00692419|depression
1319719|NCT00692419|symptoms
1319720|NCT00692380|gated IMRT
1319721|NCT00692367|Body fat
1319722|NCT00692367|Exercise
1319723|NCT00692367|Fatty acids
1319724|NCT00692367|Impaired glucose tolerance
1319725|NCT00692367|Insulin resistance
1319726|NCT00692367|Insulin Sensitivity
1319727|NCT00692367|Metabolic syndrome
1319728|NCT00692367|Obesity
1319729|NCT00692367|Physical activity
1319730|NCT00692367|Weight Loss
1319731|NCT00692354|Advanced
1319732|NCT00692354|Solid
1319733|NCT00692354|Tumour
1319734|NCT00692354|Tumor
1319735|NCT00692354|Oral
1319736|NCT00692341|hepatic impairment
1319737|NCT00692328|fatigue; TMS; MEP
1319738|NCT00692315|glutathione
1319739|NCT00692315|methionine
1319740|NCT00692315|folinic acid
1319741|NCT00692315|redox
1319742|NCT00692315|oxidative stress
1319743|NCT00692315|behavior
1319744|NCT00692302|Suicide Attempts
1319745|NCT00692302|Adolescents
1319746|NCT00692302|Suicidal
1319747|NCT00692302|Adolescent Suicide Attempters
1319748|NCT00692289|Quality of Life
1319749|NCT00692263|Healthy subjects
1319750|NCT00692250|Familial Hypercholesterolemia
1319751|NCT00692237|Type 2 diabetes mellitus
1319752|NCT00692237|Endothelial dysfunction
1319753|NCT00692237|Sildenafil
1319754|NCT00692224|neonatal jaundice
1319755|NCT00692224|zinc
1319756|NCT00692224|hyperbilirubinemia
1319757|NCT00692224|enterohepatic circulation
1319758|NCT00692224|bilirubin
1319759|NCT00692211|screening
1319760|NCT00692198|COPD
1319761|NCT00692185|Anorexia Nervosa
1319762|NCT00692172|psoriasis
1319763|NCT00692172|alefacept
1319764|NCT00692172|intramuscular
1319765|NCT00692159|TRC102
1319766|NCT00692159|Methoxyamine HCL
1319767|NCT00692159|Pemetrexed
1319768|NCT00692159|Alimta
1319769|NCT00692159|Tracon
1319770|NCT00692159|Phase 1
1319771|NCT00692159|Cancer
1319772|NCT00692159|BER
1319773|NCT00692159|Base Excision Repair
1319774|NCT00692159|Small Molecule
1319775|NCT00692159|Anti-folate
1319776|NCT00692159|Solid Tumor
1319777|NCT00692159|Neoplastic Processes
1319778|NCT00692159|Pathologic Processes
1319779|NCT00692159|Pathological Conditions, Signs and Symptoms
1319780|NCT00692146|Proof of Mechanism
1319781|NCT00692146|Capsaicin evoked pain
1319782|NCT00692133|schizophrenia
1319783|NCT00692133|bipolar disorder
1319784|NCT00692133|antipsychotic treatment
1319785|NCT00692133|patients´preferences
1319786|NCT00692107|Radiotherapy
1319787|NCT00692107|Dose
1319788|NCT00692094|melatonin
1319789|NCT00692094|circadian rhythms
1319790|NCT00692094|sleep
1319791|NCT00692081|adolescents
1319792|NCT00692081|borderline intellectual functioning
1319793|NCT00692081|social competence training
1319794|NCT00692081|vocational training
1319795|NCT00692081|group intervention
1319796|NCT00692081|cognitive behavioral therapy
1319797|NCT00692081|Adolescents with borderline intellectual functioning
1319798|NCT00692068|residual renal function
1319799|NCT00692068|oxidative stress
1319800|NCT00692068|carbonyl stress
1319801|NCT00692068|peritoneal dialysis
1319802|NCT00692042|Safety
1319803|NCT00692042|tolerability
1319804|NCT00692029|Normal
1319805|NCT00692029|Healthy Volunteers
1319806|NCT00692016|Naproxen Sodium
1319807|NCT00691990|Goiter [C19.874.283]
1319808|NCT00691990|Thyroid Neoplasms [C19.874.788]
1319809|NCT00691977|Radiation Therapy
1319810|NCT00691938|LBH589
1319811|NCT00691938|Decitabine
1319812|NCT00691938|panobinostat
1319813|NCT00691938|histone deacetylase
1319814|NCT00691938|methylation
1319815|NCT00691938|hypomethylation
1319816|NCT00691925|refractive surgery
1319817|NCT00691886|sedation
1319818|NCT00691873|Allergic
1319819|NCT00691873|Asthma
1319820|NCT00691873|Immunotherapy
1319821|NCT00691860|Parastomal hernias
1319822|NCT00691860|Tolerance of lightweight meshes
1319823|NCT00691860|Paracolostomy hernias
1319824|NCT00691860|Peristomal hernias
1319825|NCT00691847|Refractive surgery
1319826|NCT00691834|Magnetic resonance Imaging
1319827|NCT00691821|Negative-Pressure Wound Therapy
1319828|NCT00691821|Bandages
1319829|NCT00691821|Community Health Services
1319830|NCT00691795|Analgesia
1319831|NCT00691795|Epidural
1319832|NCT00691795|Pregnancy
1319833|NCT00691795|Labor
1319834|NCT00691795|Clonidine
1319835|NCT00691795|Fentanyl
1319836|NCT00691795|Bupivacaine
1319837|NCT00691795|Childbirth
1319838|NCT00691782|African American females between the ages of 21 and 60
1319839|NCT00691769|alopecia
1319840|NCT00691769|lupus
1319841|NCT00691756|renal failure
1319842|NCT00691756|thoracoabdominal aortic aneurysm repair
1319843|NCT00691756|cold crystalloid
1319844|NCT00691756|cold blood
1319845|NCT00691756|renal perfusion
1319846|NCT00691470|Anticoagulation
1319847|NCT00691470|Vitamin K-dependent clotting factor inhibitor
1319848|NCT00691470|Coumadin
1319849|NCT00691470|Warfarin
1319850|NCT00691470|Atrial fibrillation
1319851|NCT00691470|Prosthetic heart valve
1319852|NCT00691470|Venous thromboembolic disease
1319853|NCT00691470|Myocardial infarction or cardiomyopathy
1319854|NCT00691470|Patients with one or more of the following indications for chronic warfarin anticoagulation:
1319855|NCT00691470|Atrial fibrillation (paroxysmal, persistent or permanent, not due to a reversible cause, documented by ECG) or atrial flutter;
1319856|NCT00691470|A prosthetic heart valve in the aortic or mitral position that requires chronic anticoagulation;
1319857|NCT00691470|A history of venous thromboembolic disease (DVT and/or PE) requiring long term anticoagulation (> 6 months);
1319858|NCT00691470|A history of myocardial infarction or cardiomyopathy requiring anticoagulation.
1319859|NCT00691470|Currently receiving chronic warfarin therapy for another indication not listed, with Sponsor approval.
1319860|NCT00691457|Contact lens
1319861|NCT00691457|solution
1319862|NCT00691457|confocal microscope
1319863|NCT00691444|melatonin
1319864|NCT00691444|circadian rhythms
1319865|NCT00691444|sleep
1319866|NCT00691418|perinatal
1319867|NCT00691418|premature
1319868|NCT00691418|pregnancy
1319869|NCT00691418|gestation
1319870|NCT00691405|Arformoterol
1319871|NCT00691405|(R,R)-formoterol
1319872|NCT00691392|Multi-Drug Resistant Tuberculosis
1319873|NCT00691392|Extensively Drug Resistant Tuberculosis
1319874|NCT00691392|MDR TB
1319875|NCT00691392|XDR TB
1319876|NCT00691392|MDR
1319877|NCT00691392|XDR
1319878|NCT00691379|Breast cancer
1319879|NCT00691379|Triple negative
1319880|NCT00691379|Chemotherapy
1319881|NCT00691379|Anti-angiogenesis therapy
1319882|NCT00691353|Bipolar Disorder
1319883|NCT00691353|antipsychotics
1319884|NCT00691353|social functioning
1319885|NCT00691353|mood stabilizers
1319886|NCT00691353|Bipolar Disorder Type I
1319887|NCT00691353|atypical antipsychotics
1319888|NCT00691353|monotherapy
1319889|NCT00691353|cotherapy
1319890|NCT00691340|POAG
1319891|NCT00691340|Alzheimer's disease
1319892|NCT00691340|cellular proteome
1319893|NCT00691340|human leucocytes
1319894|NCT00691340|vasospasm
1319895|NCT00691340|Healthy subjects
1319896|NCT00691327|Revision of augmentation or reconstruction
1319897|NCT00691314|Stroke
1319898|NCT00691314|Transietn Ischemic Attack
1319899|NCT00691314|Stents
1319900|NCT00691314|Stenosis
1319901|NCT00691301|cervical squamous cell carcinoma
1319902|NCT00691301|recurrent cervical cancer
1319903|NCT00691301|stage III cervical cancer
1319904|NCT00691301|stage IVA cervical cancer
1319905|NCT00691301|stage IVB cervical cancer
1319906|NCT00691288|omega-3 fatty acid
1319907|NCT00691288|hypertriglyceridemia
1319908|NCT00691288|HIV
1319909|NCT00691288|pediatric
1319910|NCT00691288|HAART
1319911|NCT00691275|dehydration
1319912|NCT00691275|acute gastroenteritis
1319913|NCT00691275|ondansetron
1319914|NCT00691275|rehydration
1319915|NCT00691262|Atopic dermatitis
1319916|NCT00691262|Prograf
1319917|NCT00691262|Tacrolimus
1319918|NCT00691262|FK506
1319919|NCT00691262|Tacrolimus ointment
1319920|NCT00691249|Diabetes
1319921|NCT00691249|Diet
1319922|NCT00691249|Fiber
1319923|NCT00691236|osteosarcoma
1319924|NCT00691236|zoledronic acid
1319925|NCT00691236|bisphosphonates
1319926|NCT00691236|adjuvant to chemotherapy
1319927|NCT00691223|Focal dermal hypoplasia
1319928|NCT00691223|Goltz syndrome
1319929|NCT00691223|X linked disorders
1319930|NCT00691223|PORCN
1319931|NCT00691223|Wnt signaling
1319932|NCT00691210|Hodgkin's Disease
1319933|NCT00691210|Non-Hodgkin's Lymphoma
1319934|NCT00691184|Onychomycosis, Toenail fungal infection, Terbinafine HCl, Pharmacokinetics
1319935|NCT00691171|gastroesophageal reflux disease
1319936|NCT00691171|GERD
1319937|NCT00691171|nonsteroidal anti-inflammatory drugs
1319938|NCT00691171|peptic ulcer
1319939|NCT00691171|Diagnosed GERD
1319940|NCT00691171|Atypical GERD symptoms
1319941|NCT00691171|chronic NSAID therapy
1319942|NCT00691171|Risk for ulcer
1319943|NCT00691145|Atopic dermatitis
1319944|NCT00691145|Tacrolimus ointment
1319945|NCT00691132|non-small cell lung cancer
1319946|NCT00691132|small cell lung cancer
1319947|NCT00691132|tobacco use disorder
1319948|NCT00691119|breast cancer
1319949|NCT00691119|radiation
1319950|NCT00691119|Relaxation and Visualization Therapy
1319951|NCT00691119|relaxation
1319952|NCT00691119|visualization
1319953|NCT00691119|RVT
1319954|NCT00691119|complementary and alternative medicine
1319955|NCT00691119|CAM
1319956|NCT00691119|alternative medicine
1319957|NCT00691093|observational
1319958|NCT00691080|Melatonin
1319959|NCT00691080|Sleep
1319960|NCT00691080|Autism
1319961|NCT00691080|ASD
1319962|NCT00691080|Sleep problems in children with autism spectrum disorder
1319963|NCT00691054|recurrent pancreatic cancer
1319964|NCT00691054|stage III pancreatic cancer
1319965|NCT00691054|stage IV pancreatic cancer
1319966|NCT00691041|HIV Prevention
1319967|NCT00691041|Men who have sex with men
1319968|NCT00691041|African American
1319969|NCT00691041|Unprotected sex
1319970|NCT00691041|HIV Seronegativity
1319971|NCT00691028|Rheumatoid Arthritis
1319972|NCT00691028|RA
1319973|NCT00691028|Infliximab
1319974|NCT00691028|TA-650
1319975|NCT00691028|Remicade
1319976|NCT00691015|stage III adult Burkitt lymphoma
1319977|NCT00691015|stage III adult diffuse large cell lymphoma
1319978|NCT00691015|stage III adult diffuse mixed cell lymphoma
1319979|NCT00691015|stage III adult diffuse small cleaved cell lymphoma
1319980|NCT00691015|stage III adult Hodgkin lymphoma
1319981|NCT00691015|stage III adult immunoblastic large cell lymphoma
1319982|NCT00691015|stage III adult lymphoblastic lymphoma
1319983|NCT00691015|stage III grade 1 follicular lymphoma
1319984|NCT00691015|stage III grade 2 follicular lymphoma
1319985|NCT00691015|stage III grade 3 follicular lymphoma
1319986|NCT00691015|stage III mantle cell lymphoma
1319987|NCT00691015|stage III marginal zone lymphoma
1319988|NCT00691015|stage III small lymphocytic lymphoma
1319989|NCT00691015|stage IV adult Burkitt lymphoma
1319990|NCT00691015|stage IV adult diffuse large cell lymphoma
1319991|NCT00691015|stage IV adult diffuse mixed cell lymphoma
1319992|NCT00691015|stage IV adult diffuse small cleaved cell lymphoma
1319993|NCT00691015|stage IV adult Hodgkin lymphoma
1319994|NCT00691015|stage IV adult immunoblastic large cell lymphoma
1319995|NCT00691015|stage IV adult lymphoblastic lymphoma
1319996|NCT00691015|stage IV grade 1 follicular lymphoma
1319997|NCT00691015|stage IV grade 2 follicular lymphoma
1319998|NCT00691015|stage IV grade 3 follicular lymphoma
1319999|NCT00691015|stage IV mantle cell lymphoma
1320000|NCT00691015|stage IV marginal zone lymphoma
1320001|NCT00691015|stage IV small lymphocytic lymphoma
1320002|NCT00691015|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1320003|NCT00691015|nodal marginal zone B-cell lymphoma
1320004|NCT00691015|splenic marginal zone lymphoma
1320005|NCT00691015|noncontiguous stage II adult Burkitt lymphoma
1320006|NCT00691015|noncontiguous stage II adult diffuse large cell lymphoma
1320007|NCT00691015|noncontiguous stage II adult diffuse mixed cell lymphoma
1320008|NCT00691015|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1320009|NCT00691015|noncontiguous stage II adult immunoblastic large cell lymphoma
1320010|NCT00691015|noncontiguous stage II adult lymphoblastic lymphoma
1320011|NCT00691015|noncontiguous stage II grade 1 follicular lymphoma
1320012|NCT00691015|noncontiguous stage II grade 2 follicular lymphoma
1320013|NCT00691015|noncontiguous stage II grade 3 follicular lymphoma
1320014|NCT00691015|noncontiguous stage II mantle cell lymphoma
1320015|NCT00691015|noncontiguous stage II marginal zone lymphoma
1320016|NCT00691015|noncontiguous stage II small lymphocytic lymphoma
1320017|NCT00691015|accelerated phase chronic myelogenous leukemia
1320018|NCT00691015|adult acute lymphoblastic leukemia in remission
1320019|NCT00691015|adult acute myeloid leukemia in remission
1320020|NCT00691015|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1320021|NCT00691015|adult acute myeloid leukemia with inv(16)(p13;q22)
1320022|NCT00691015|adult acute myeloid leukemia with t(15;17)(q22;q12)
1320023|NCT00691015|adult acute myeloid leukemia with t(16;16)(p13;q22)
1320024|NCT00691015|adult acute myeloid leukemia with t(8;21)(q22;q22)
1320025|NCT00691015|chronic phase chronic myelogenous leukemia
1320026|NCT00691015|recurrent adult acute lymphoblastic leukemia
1320027|NCT00691015|recurrent adult acute myeloid leukemia
1320028|NCT00691015|secondary acute myeloid leukemia
1320029|NCT00691015|stage III chronic lymphocytic leukemia
1320030|NCT00691015|stage IV chronic lymphocytic leukemia
1320031|NCT00691015|de novo myelodysplastic syndromes
1320032|NCT00691015|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1320033|NCT00691015|previously treated myelodysplastic syndromes
1320034|NCT00691015|secondary myelodysplastic syndromes
1320035|NCT00691015|stage I multiple myeloma
1320036|NCT00691015|stage II multiple myeloma
1320037|NCT00691015|stage III multiple myeloma
1320038|NCT00691015|primary myelofibrosis
1320039|NCT00691015|atypical chronic myeloid leukemia, BCR-ABL negative
1320040|NCT00691015|chronic eosinophilic leukemia
1320041|NCT00691015|chronic myelomonocytic leukemia
1320042|NCT00691015|chronic neutrophilic leukemia
1320043|NCT00690989|Headache
1320044|NCT00690989|Adherence
1320045|NCT00690989|Followup
1320046|NCT00690976|HIV Seronegativity
1320047|NCT00690976|HIV risk behavior
1320048|NCT00690976|Unprotected sex
1320049|NCT00690976|men who have sex with men
1320050|NCT00690976|gay
1320051|NCT00690976|Latino
1320052|NCT00690976|Unsafe Sex
1320053|NCT00690963|Radiotherapy
1320054|NCT00690963|Intensity-Modulated
1320055|NCT00690963|Dose Fractionation
1320056|NCT00690950|BPH
1320182|NCT00690430|neuroendocrine
1320057|NCT00690937|hypercholesterolemia, bile acid sequestrant, LDL-cholesterol
1320058|NCT00690924|lung cancer
1320059|NCT00690924|tobacco use disorder
1320060|NCT00690924|squamous lung dysplasia
1320061|NCT00690885|chronic cough
1320062|NCT00690885|COPD
1320063|NCT00690885|IPF
1320064|NCT00690885|interferon alpha
1320065|NCT00690872|recurrent lymphoepithelioma of the nasopharynx
1320066|NCT00690872|recurrent squamous cell carcinoma of the nasopharynx
1320067|NCT00690872|stage IV lymphoepithelioma of the nasopharynx
1320068|NCT00690872|stage IV squamous cell carcinoma of the nasopharynx
1320069|NCT00690859|Bipolar disorders
1320070|NCT00690859|Predictors of recurrence
1320071|NCT00690820|Cystic Fibrosis
1320072|NCT00690820|Pancreatic Exocrine Insufficiency
1320073|NCT00690807|eczema
1320074|NCT00690781|casein
1320075|NCT00690781|milk soluble proteins
1320076|NCT00690781|protein feeding pattern
1320077|NCT00690781|overweight
1320078|NCT00690781|obesity
1320079|NCT00690781|energy restriction
1320080|NCT00690781|protein metabolism
1320081|NCT00690781|lean body mass
1320082|NCT00690781|body composition
1320083|NCT00690781|nitrogen balance
1320084|NCT00690781|protein synthesis
1320085|NCT00690781|proteolysis
1320086|NCT00690781|spread
1320087|NCT00690781|pulse
1320088|NCT00690768|Diabetic Retinopathy
1320089|NCT00690768|Retinal detachment
1320090|NCT00690768|Vitreous Hemorrhage
1320091|NCT00690768|Bevacizumab
1320092|NCT00690768|preoperative
1320093|NCT00690768|pars plana vitrectomy
1320094|NCT00690755|Diabetic
1320095|NCT00690716|Nasal CO2
1320096|NCT00690716|Phase II
1320097|NCT00690716|Adaptive
1320098|NCT00690716|Randomized
1320099|NCT00690716|Double-Blind
1320100|NCT00690716|Placebo-Controlled
1320101|NCT00690716|Multiple-Dose
1320102|NCT00690716|Multi-center
1320103|NCT00690716|Safety
1320104|NCT00690716|Efficacy
1320105|NCT00690716|Mild Headache
1320106|NCT00690716|Migraineur
1320107|NCT00690703|non small cell lung cancer
1320108|NCT00690703|pulmonary metastases
1320109|NCT00690703|radiofrequency ablation
1320110|NCT00690690|HIV Seronegativity
1320111|NCT00690690|HIV risk behavior
1320112|NCT00690690|Unprotected sex
1320113|NCT00690690|men who have sex with men
1320114|NCT00690690|gay
1320115|NCT00690690|Latino
1320116|NCT00690690|unsafe sex
1320117|NCT00690690|high risk sex
1320118|NCT00690677|LBH589
1320119|NCT00690677|Metastatic Colorectal Cancer
1320120|NCT00690677|Refractory Colorectal Cancer
1320121|NCT00690664|Hair characteristics
1320122|NCT00690651|ankle
1320123|NCT00690651|fracture
1320124|NCT00690651|mobilisation
1320125|NCT00690651|bed rest
1320126|NCT00690651|internal fixation
1320127|NCT00690638|dutogliptin
1320128|NCT00690638|PHX1149
1320129|NCT00690638|DPP4 inhibitor
1320130|NCT00690625|Myofacial pain
1320131|NCT00690625|Omega 3 fatty acids
1320132|NCT00690612|pediatric
1320133|NCT00690612|renal disease
1320134|NCT00690612|high blood pressure
1320135|NCT00690599|Patient satisfaction
1320136|NCT00690599|Dentist-Patient relations
1320137|NCT00690599|Answering services
1320138|NCT00690586|Nephrotic syndrome
1320139|NCT00690586|Underfill and overfill theory
1320140|NCT00690586|Steroid resistance
1320141|NCT00690586|Urine proteomics
1320142|NCT00690586|AVP
1320143|NCT00690586|ANP
1320144|NCT00690586|Angiotensin II
1320145|NCT00690586|Renin and Aldosterone
1320146|NCT00690573|Juvenile Rheumatoid Arthritis
1320147|NCT00690560|contiguous stage II adult diffuse large cell lymphoma
1320148|NCT00690560|noncontiguous stage II adult diffuse large cell lymphoma
1320149|NCT00690560|stage I adult diffuse large cell lymphoma
1320150|NCT00690560|stage III adult diffuse large cell lymphoma
1320151|NCT00690560|stage IV adult diffuse large cell lymphoma
1320152|NCT00690547|Functionality
1320153|NCT00690547|Deliberately
1320154|NCT00690547|Activated
1320155|NCT00690547|Quadriceps
1320156|NCT00690547|Femoris
1320157|NCT00690547|During
1320158|NCT00690547|After
1320159|NCT00690547|Active
1320160|NCT00690547|Extension
1320161|NCT00690534|sarcopenia
1320162|NCT00690534|aging
1320163|NCT00690534|muscle metabolism
1320164|NCT00690521|congestive heart failure
1320165|NCT00690521|diuretics
1320166|NCT00690521|combination
1320167|NCT00690508|Intubation, Trachea, Sternum,
1320168|NCT00690508|Tube tip, Tube placement, Tube tip palpation,
1320169|NCT00690508|Validate
1320170|NCT00690508|use
1320171|NCT00690508|SSTTP
1320172|NCT00690508|corrrect
1320173|NCT00690508|placement
1320174|NCT00690495|Anesthesia
1320175|NCT00690495|Induction
1320176|NCT00690495|Pain
1320177|NCT00690482|COPD
1320178|NCT00690456|Randomized Controlled Trial
1320179|NCT00690456|Metformin
1320180|NCT00690443|Hyperlipidemia
1320181|NCT00690430|Carcinoid
1320183|NCT00690430|gastroenteropancreatic
1320184|NCT00690430|somatostatin analogue
1320185|NCT00690430|Symptomatic Refractory Resistant Carcinoid Disease
1320186|NCT00690404|formulation
1320187|NCT00690404|pharmacokinetic
1320188|NCT00690404|crossover formulation
1320189|NCT00690404|food effect
1320190|NCT00690404|oral solution
1320191|NCT00690404|healthy volunteers
1320192|NCT00690391|surgery
1320193|NCT00690391|prognostic
1320194|NCT00690391|palliation
1320195|NCT00690365|Switching
1320196|NCT00690365|Quetiapine
1320197|NCT00690365|schizophrenia
1320198|NCT00690365|unsuccessfully treated
1320199|NCT00690365|antipsychotics
1320200|NCT00690352|Specialized Substance Abuse Supervision
1320201|NCT00690352|SSAS
1320202|NCT00690352|substance use disorder
1320203|NCT00690352|felony drug offender
1320204|NCT00690352|probation
1320205|NCT00690352|parole
1320206|NCT00690352|cognitive behavioral therapy
1320207|NCT00690352|CBT
1320208|NCT00690326|physical activity
1320209|NCT00690326|Diabetes mellitus
1320210|NCT00690326|Behavioral change communication
1320211|NCT00690326|Household physical activity
1320212|NCT00690313|Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis
1320213|NCT00690300|adenocarcinoma of the pancreas
1320214|NCT00690300|pancreatic cancer
1320215|NCT00690300|pancreas carcinoma
1320216|NCT00690300|advanced pancreatic cancer
1320217|NCT00690300|metastatic pancreatic cancer
1320218|NCT00690300|second line
1320219|NCT00690300|palliative
1320220|NCT00690300|Oxaliplatin
1320221|NCT00690300|Docetaxel
1320222|NCT00690300|Taxotere
1320223|NCT00690300|Eloxatin
1320224|NCT00690300|Cancer of pancreas
1320225|NCT00690300|Pancreas cancer
1320226|NCT00690287|Type 2 diabetes
1320227|NCT00690274|schizophrenia
1320228|NCT00690274|cognitive deficients
1320229|NCT00690274|cognitive enhancing
1320230|NCT00690274|antipsychotics
1320231|NCT00690261|tumor associated macrophage
1320232|NCT00690261|lung cancer
1320233|NCT00690261|outcome
1320234|NCT00690248|Acute mania
1320235|NCT00690248|Bipolar disorder
1320236|NCT00690248|depressive symptoms
1320237|NCT00690248|mixed mania
1320238|NCT00690235|Schizophrenia
1320239|NCT00690235|Schizoaffective
1320240|NCT00690235|Olanzapine
1320241|NCT00690235|Zyprexa
1320242|NCT00690235|Clozapine
1320243|NCT00690235|Clozaril
1320244|NCT00690235|Pramlintide
1320245|NCT00690235|Diabetes
1320246|NCT00690235|Weight Gain
1320247|NCT00690235|Obesity
1320248|NCT00690235|Metabolic Syndrome
1320249|NCT00690222|cataract surgery
1320250|NCT00690222|phacoemulsification
1320251|NCT00690222|pupil
1320252|NCT00690222|dilation
1320253|NCT00690222|mydriasis
1320254|NCT00690222|intracameral
1320255|NCT00690222|topical
1320256|NCT00690222|pseudoexfoliation syndrome
1320257|NCT00690209|Chronic ischemic cardiomyopathy with residual viability
1320258|NCT00690209|surgical coronary revascularization
1320259|NCT00690209|stem cell therapy
1320260|NCT00690209|Chronic ischemic heart disease
1320261|NCT00690209|severe impairment of global contractility left ventricular dilation
1320262|NCT00690209|residual viability
1320263|NCT00690183|physical activity
1320264|NCT00690183|stem cells
1320265|NCT00690183|lifestyle
1320266|NCT00690170|ketamine
1320267|NCT00690170|nicotine
1320268|NCT00690170|schizophrenia
1320269|NCT00690170|cognitive deficits
1320270|NCT00690170|P300 oddball paradigm
1320271|NCT00690170|Mismatch Negativity
1320272|NCT00690170|P50 gating
1320273|NCT00690157|heart failure, prognosis, markers,heart transplantation
1320274|NCT00690144|simulation
1320275|NCT00690144|medical education
1320276|NCT00690144|performance of clinical reasoning and skills
1320277|NCT00690131|Smoking cessation, severe mental illness, behavioral treatment
1320278|NCT00690118|amyotrophic lateral sclerosis
1320279|NCT00690118|survival time
1320280|NCT00690118|ALS functioning Rating Scale
1320281|NCT00690118|quality of life
1320282|NCT00690118|non-invasive ventilation
1320283|NCT00690118|clinical tolerability
1320284|NCT00690118|survival
1320285|NCT00690105|Dermatitis, Atopic
1320286|NCT00690105|Dermatologic Agents
1320287|NCT00690105|Topical Drug Administration
1320288|NCT00690105|Tacrolimus
1320289|NCT00690105|Calcineurin
1320290|NCT00690105|Corticosteroid
1320291|NCT00690105|Fluticasone propionate
1320292|NCT00690105|Face
1320293|NCT00690092|Coccidioidin
1320294|NCT00690092|Coccidioidin SD
1320295|NCT00690092|Spherule-derived coccidioidin
1320296|NCT00690092|Coccidioidomycosis
1320297|NCT00690092|Valley Fever
1320298|NCT00690092|Coccidioides immitis
1320299|NCT00690079|MAD
1320300|NCT00690079|Multiple ascending dose
1320301|NCT00690079|Chronic pain
1320302|NCT00690079|pain
1320303|NCT00690066|T1DM
1320304|NCT00690066|Type 1 Diabetes Mellitus
1320305|NCT00690066|Type 1 Diabetes
1320306|NCT00690066|Diabetes Mellitus, Insulin-Dependent
1320307|NCT00690066|Juvenile Diabetes
1320308|NCT00690066|Adult Human Stem Cells
1320309|NCT00690066|Mesenchymal Stem Cells
1320310|NCT00690066|MSCs
1320311|NCT00690066|Insulin
1320312|NCT00690066|Osiris
1320313|NCT00690066|Prochymal
1320314|NCT00690053|Toxicity
1320315|NCT00690053|PET
1320316|NCT00690053|HX-4
1320317|NCT00690053|cancer
1320318|NCT00690040|Induction of labor
1320319|NCT00690040|Ripening
1320320|NCT00690040|Single balloon catheter
1320321|NCT00690040|Double balloon catheter
1320322|NCT00690014|OAT
1320323|NCT00690014|GFR
1320324|NCT00690014|renal function
1320325|NCT00690014|PAH
1320326|NCT00690001|HIV-1 infection
1320327|NCT00690001|Treatment Experienced
1320328|NCT00689988|Down syndrome
1320329|NCT00689988|communication AIDS for disabled
1320330|NCT00689988|language development disorders
1320331|NCT00689988|vocabulary
1320332|NCT00689988|gestures
1320333|NCT00689988|language tests
1320334|NCT00689988|child
1320335|NCT00689975|stage IA breast cancer
1320336|NCT00689975|stage IB breast cancer
1320337|NCT00689975|stage II breast cancer
1320338|NCT00689975|stage IIIA breast cancer
1320339|NCT00689975|stage IIIB breast cancer
1320340|NCT00689975|stage IIIC breast cancer
1320341|NCT00689962|Lisfranc
1320342|NCT00689962|fracture
1320343|NCT00689962|dislocation
1320344|NCT00689962|bioabsorbable
1320345|NCT00689949|folic acid
1320346|NCT00689949|folate
1320347|NCT00689949|p-aminobenzoylglutamate
1320348|NCT00689949|formiminoglutamate
1320349|NCT00689949|homocysteine
1320350|NCT00689949|experimental validation of a new biomarker
1320351|NCT00689936|newly diagnosed multiple myeloma
1320352|NCT00689936|Lenalidomide
1320353|NCT00689936|Revlimid
1320354|NCT00689936|phase III
1320355|NCT00689910|pharmacokinetics
1320356|NCT00689910|pregnancy
1320357|NCT00689910|Raltegravir
1320358|NCT00689910|HIV
1320359|NCT00689910|antiretroviral
1320360|NCT00689910|Treatment of HIV in pregnant women with Raltegravir
1320361|NCT00689897|Primary Dysmenorrhea
1320362|NCT00689897|Deqi
1320363|NCT00689897|acupuncture
1320364|NCT00689897|psychology
1320365|NCT00689858|Healthy volunteers
1320366|NCT00689845|contiguous stage II adult diffuse large cell lymphoma
1320367|NCT00689845|noncontiguous stage II adult diffuse large cell lymphoma
1320368|NCT00689845|stage I adult diffuse large cell lymphoma
1320369|NCT00689845|stage III adult diffuse large cell lymphoma
1320370|NCT00689845|stage IV adult diffuse large cell lymphoma
1320371|NCT00689832|Dermatitis, Atopic
1320372|NCT00689832|Dermatologic Agents
1320373|NCT00689832|Topical Drug Administration
1320374|NCT00689832|Tacrolimus
1320375|NCT00689832|Calcineurin
1320376|NCT00689832|Corticosteroid
1320377|NCT00689832|Fluticasone propionate
1320378|NCT00689832|Child
1320379|NCT00689819|Hypertension
1320380|NCT00689819|High blood pressure
1320381|NCT00689819|Pre-clinical cardiac dysfunction
1320382|NCT00689806|Asthma
1320383|NCT00689793|Fatigue
1320384|NCT00689793|Blood donation
1320385|NCT00689793|Iron deficiency
1320386|NCT00689793|Ferrous sulphate
1320387|NCT00689793|Donation
1320388|NCT00689793|Donors
1320389|NCT00689793|Iron
1320390|NCT00689793|Ferritin
1320391|NCT00689793|Hemoglobin
1320392|NCT00689793|Anemia
1320393|NCT00689793|Anaemia
1320394|NCT00689793|Haemoglobin
1320395|NCT00689793|Don
1320396|NCT00689793|Women blood donors
1320397|NCT00689780|Pain
1320398|NCT00689780|safety
1320399|NCT00689780|chronic low back pain
1320400|NCT00689767|drug eluting stent
1320401|NCT00689754|gastrointestinal hemorrhage
1320402|NCT00689754|gastrointestinal intubation
1320403|NCT00689754|endoscopy
1320404|NCT00689741|HPV
1320405|NCT00689741|vaccine
1320406|NCT00689715|Cystic tumor
1320407|NCT00689715|Pancreas
1320408|NCT00689715|EUS
1320409|NCT00689702|cetuximab
1320410|NCT00689702|capecitabine
1320411|NCT00689702|radiotherapy
1320412|NCT00689702|rectal cancer
1320413|NCT00689676|expressive language
1320414|NCT00689676|cognition
1320415|NCT00689676|early development
1320416|NCT00689676|very low birt weight
1320417|NCT00689676|prematurity
1320418|NCT00689663|cholecystectomy
1320419|NCT00689637|AZD3480
1320420|NCT00689637|Warfarin
1320421|NCT00689637|Drug interaction
1320422|NCT00689624|Colorectal Cancer
1320423|NCT00689624|Cetuximab
1320424|NCT00689624|FOLFOXIRI
1320425|NCT00689611|Acute coronary syndrome
1320426|NCT00689611|Myocardial infarction
1320427|NCT00689611|Smoking cessation
1320428|NCT00689611|Zyban
1320429|NCT00689611|Secondary intervention post-ACS
1320430|NCT00689598|Atrial fibrillation, spironolactone
1320431|NCT00689585|Complex Regional Pain Syndrome
1320687|NCT00688805|Drug Cues
1320432|NCT00689585|Reflex Sympathetic Dystrophy
1320433|NCT00689585|RSD
1320434|NCT00689585|Chronic Pain
1320435|NCT00689585|Ethosuximide
1320436|NCT00689585|Zarontin
1320437|NCT00689585|Anticonvulsant
1320438|NCT00689572|cocaine dependence
1320439|NCT00689572|cocaine abuse
1320440|NCT00689572|cocaine
1320441|NCT00689572|crack
1320442|NCT00689559|Alzheimer's disease
1320443|NCT00689559|AZD3480
1320444|NCT00689559|Aripiprazole
1320445|NCT00689533|VEPTR
1320446|NCT00689533|TIS
1320447|NCT00689533|scoliosis
1320448|NCT00689533|juvenile
1320449|NCT00689520|Venous thromboembolism
1320450|NCT00689520|low molecular weight heparin
1320451|NCT00689520|Vitamin K antagonist
1320452|NCT00689520|Longterm
1320453|NCT00689507|Multiple Myeloma
1320454|NCT00689507|Relapsed
1320455|NCT00689507|Refractory
1320456|NCT00689507|Bortezomib
1320457|NCT00689507|Velcade
1320458|NCT00689494|Nanopaz device
1320459|NCT00689494|Blood progesterone measure in using the device
1320460|NCT00689494|Delivery progesterone
1320461|NCT00689494|Progesterone levonorgestrel
1320462|NCT00689481|Plaque-type Psoriasis
1320463|NCT00689481|psoriasis
1320464|NCT00689468|Otitis media
1320465|NCT00689468|Echinacea
1320466|NCT00689468|Osteopathic Medicine
1320467|NCT00689455|Metabolic Syndrome
1320468|NCT00689455|Lipids
1320469|NCT00689455|Waist Circumference
1320470|NCT00689429|Pilon Fractures
1320471|NCT00689416|imaging biomarkers
1320472|NCT00689416|MRI
1320473|NCT00689416|FDG-PET/CT scanning
1320474|NCT00689416|Crestor
1320475|NCT00689403|AZD1305
1320476|NCT00689403|pharmacokinetics
1320477|NCT00689403|Properties of different ER formulations
1320478|NCT00689377|Peripheral Arterial Disease (PAD)
1320479|NCT00689377|Cardiovascular Disease (CVD)
1320480|NCT00689377|Atherosclerotic cardiovascular disease
1320481|NCT00689377|Atherosclerosis
1320482|NCT00689377|Primary CVD prevention
1320483|NCT00689364|Cohort Study
1320484|NCT00689364|Colorectal Cancer
1320485|NCT00689364|Traditional Chinese Medicine
1320486|NCT00689364|Risk of recurrence and metastasis
1320487|NCT00689351|Prevention
1320488|NCT00689351|against
1320489|NCT00689351|pneumococcal
1320490|NCT00689351|disease
1320491|NCT00689351|Vaccine
1320492|NCT00689338|Candida
1320493|NCT00689338|Candidemia
1320494|NCT00689338|Systemic Candidiasis
1320495|NCT00689338|ICU
1320496|NCT00689338|Intensive Care Unit
1320497|NCT00689338|Critical Care Unit
1320498|NCT00689338|Anidulafungin
1320499|NCT00689338|Ecalta
1320500|NCT00689338|Eraxis
1320501|NCT00689338|Fluconazole
1320502|NCT00689338|Voriconazole
1320503|NCT00689325|Schizophrenia
1320504|NCT00689325|remission
1320505|NCT00689325|subjective well-being and effectiveness
1320506|NCT00689325|Quality of Life
1320507|NCT00689312|Gastroenteritis
1320508|NCT00689312|Pediatrics
1320509|NCT00689312|Rehydration therapy
1320510|NCT00689299|Sublingual Immunotherapy (SLIT)
1320511|NCT00689299|Non-seasonal allergic rhinitis
1320512|NCT00689299|Immunotherapy
1320513|NCT00689299|Allergic rhinitis
1320514|NCT00689299|Cat
1320515|NCT00689299|Perennial allergy
1320516|NCT00689299|Non-seasonal allergy
1320517|NCT00689286|Knee Osteoarthritis
1320518|NCT00689286|Neuromuscular stimulator
1320519|NCT00689273|PF-04136309 CCR2 osteoarthritic pain knee, phase 2 placebo multicenter double-blind placebo-controlled
1320520|NCT00689247|AZD1305
1320521|NCT00689247|ADME
1320522|NCT00689247|pharmacokinetic
1320523|NCT00689247|Absorption
1320524|NCT00689247|distribution
1320525|NCT00689247|metabolism
1320526|NCT00689247|excretion
1320527|NCT00689221|newly diagnosed Glioblastoma (WHO Grade IV)
1320528|NCT00689221|Cilengitide
1320529|NCT00689221|Temozolomide
1320530|NCT00689221|Radiotherapy
1320531|NCT00689208|Clamp
1320532|NCT00689195|Curcumin
1320533|NCT00689195|Ashwagandha
1320534|NCT00689195|osteosarcoma
1320535|NCT00689195|Pharmacokinetics of curcumin and ashwagandha formulation
1320536|NCT00689195|response
1320537|NCT00689182|iron reduction
1320538|NCT00689182|iron overload
1320539|NCT00689182|phlebotomy
1320540|NCT00689182|hematopoietic stem cell transplant
1320541|NCT00689169|Lymphoma
1320542|NCT00689169|Lymphoma Diffuse
1320543|NCT00689169|B-Cell lymphoma
1320544|NCT00689169|Aggressive lymphoma
1320545|NCT00689156|Epirubicin
1320546|NCT00689156|docetaxel
1320547|NCT00689156|Adjuvant chemotherapy
1320548|NCT00689156|DNA Topoisomerases, Type II
1320549|NCT00689130|Analgesia
1320550|NCT00689130|Bispectral Index
1320551|NCT00689130|BIS Variability
1320552|NCT00689130|Electroencephalography
1320553|NCT00689130|Electromyography
1320554|NCT00689130|Monitoring, Intraoperative
1320555|NCT00689130|Movement
1320556|NCT00689130|Pain, Postoperative
1320557|NCT00689130|Somatic Events
1320558|NCT00689130|Patients under general anesthesia undergoing a moderately painful procedure.
1320559|NCT00689117|Acne Vulgaris
1320560|NCT00689117|Acne
1320561|NCT00689104|Overactive bladder (OAB)
1320562|NCT00689104|Frequency
1320563|NCT00689104|Micturition
1320564|NCT00689104|Urgency
1320565|NCT00689104|Urinary incontinence
1320566|NCT00689104|Urinary urge incontinence
1320567|NCT00689104|YM178
1320568|NCT00689091|Awareness
1320569|NCT00689091|BIS Monitor
1320570|NCT00689091|electronic alerts
1320571|NCT00689091|minimum
1320572|NCT00689091|alveolar
1320573|NCT00689091|concentration
1320574|NCT00689078|Allergic conjunctivitis
1320575|NCT00689065|siRNA
1320576|NCT00689065|RNA interference (RNAi)
1320577|NCT00689065|Cyclodextrin
1320578|NCT00689065|Cancer
1320579|NCT00689065|Neoplasms
1320580|NCT00689065|Solid Tumor
1320581|NCT00689065|Ovarian Cancer
1320582|NCT00689065|Lung Cancer
1320583|NCT00689065|Non Small Cell Lung Cancer
1320584|NCT00689065|Pancreatic Cancer
1320585|NCT00689065|Breast Cancer
1320586|NCT00689065|Colon Cancer
1320587|NCT00689065|Endometrial Cancer
1320588|NCT00689065|Kidney (Renal Cell) Cancer
1320589|NCT00689065|Melanoma
1320590|NCT00689065|Prostate Cancer
1320591|NCT00689065|Skin Cancer
1320592|NCT00689065|Thyroid Cancer
1320593|NCT00689065|Solid Malignancies
1320594|NCT00689039|AZD1305
1320595|NCT00689039|safety
1320596|NCT00689039|pharmacokinetics
1320597|NCT00689039|multiple ascending doses
1320598|NCT00689039|Safety and pharmacokinetics
1320599|NCT00689026|Colonoscopy
1320600|NCT00689026|Diabetes Mellitus, Type 1
1320601|NCT00689026|Diabetes Mellitus, Type 2
1320602|NCT00689026|Cleansing
1320603|NCT00689026|Preparation
1320604|NCT00689026|PEG
1320605|NCT00689026|Quality
1320606|NCT00689013|Herpes Zoster
1320607|NCT00689013|Prevention & control
1320608|NCT00689013|Pharmacists
1320609|NCT00689013|Pharmacy
1320610|NCT00689013|Pharmacies
1320611|NCT00689013|Aged
1320612|NCT00689013|Immunization
1320613|NCT00689013|Vaccination
1320614|NCT00689000|Leukemia
1320615|NCT00689000|AML
1320616|NCT00689000|MDS
1320617|NCT00689000|MM
1320618|NCT00689000|Acute Myeloid Leukemia
1320619|NCT00689000|Myelodysplastic Syndrome
1320620|NCT00689000|Multiple Myeloma
1320621|NCT00689000|Cancer
1320622|NCT00689000|Hematological malignancies
1320623|NCT00689000|Elderly
1320624|NCT00689000|Refractory
1320625|NCT00689000|Blood
1320626|NCT00688974|type 2 diabetes
1320627|NCT00688974|obesity
1320628|NCT00688974|gastric bypass
1320629|NCT00688974|adjustable gastric banding
1320630|NCT00688974|BMI > 35.
1320631|NCT00688974|obesity for more than 5 years
1320632|NCT00688961|omega-3 fatty acids
1320633|NCT00688961|aspirin
1320634|NCT00688961|platelet aggregation
1320635|NCT00688961|Healthy volunteers; no disease
1320636|NCT00688948|pilot clinical trial
1320637|NCT00688935|melatonin
1320638|NCT00688935|circadian rhythms
1320639|NCT00688935|sleep
1320640|NCT00688935|sleep disorders
1320641|NCT00688909|breast cancer
1320642|NCT00688909|adjuvant treatment in post menopausal women
1320643|NCT00688909|letrozole
1320644|NCT00688909|arthralgia-myalgia
1320645|NCT00688883|Fludarabine
1320646|NCT00688883|Purine analog
1320647|NCT00688883|Indolent lymphoma
1320648|NCT00688870|Prevention against pneumococcal disease
1320649|NCT00688844|PKU
1320650|NCT00688844|Phenylketonuria
1320651|NCT00688844|BH4
1320652|NCT00688844|Kuvan
1320653|NCT00688844|Tetrahydrobiopterin
1320654|NCT00688844|Sapropterin Dihydrochloride
1320655|NCT00688844|Nutrition
1320656|NCT00688844|PHE
1320657|NCT00688844|Phenylalanine
1320658|NCT00688844|PAH
1320659|NCT00688844|Phenylalanine hydroxylase
1320660|NCT00688844|Neurotransmitters
1320661|NCT00688844|Serotonin
1320662|NCT00688844|Catecholamines
1320663|NCT00688844|Diet
1320664|NCT00688844|Body Fat
1320665|NCT00688844|Bone Density
1320666|NCT00688831|AZD1305
1320667|NCT00688831|SAD
1320668|NCT00688831|safety
1320669|NCT00688831|pharmcokinetics
1320670|NCT00688831|Safety and tolerability
1320671|NCT00688818|Co-morbid depressive and anxiety disorders
1320672|NCT00688818|Quetiapine
1320673|NCT00688818|Randomized
1320674|NCT00688818|Placebo-controlled
1320675|NCT00688818|Double-blind
1320676|NCT00688818|Major depressive disorder
1320677|NCT00688818|Dysthymic disorder
1320678|NCT00688818|Anxiety disorders
1320679|NCT00688818|Generalized anxiety disorder
1320680|NCT00688818|Social anxiety disorder
1320681|NCT00688818|Panic disorder
1320682|NCT00688818|Post-traumatic stress disorder
1320683|NCT00688805|Propanolol
1320684|NCT00688805|Substance Abuse
1320685|NCT00688805|Craving
1320686|NCT00688805|Imagery
1320688|NCT00688805|Cocaine
1320689|NCT00688792|Asthma
1320690|NCT00688792|Children
1320691|NCT00688792|Adherence
1320692|NCT00688792|Maternal factors
1320693|NCT00688779|Healthy male
1320694|NCT00688779|allergic rhinitis
1320695|NCT00688779|tolerability
1320696|NCT00688779|safety
1320697|NCT00688779|intranasally
1320698|NCT00688779|Healthy subjects
1320699|NCT00688766|GIST
1320700|NCT00688766|Metastatic and/or Unresectable Gastrointestinal Stromal
1320701|NCT00688753|renal cell carcinoma
1320702|NCT00688753|non clear cell carcinoma
1320703|NCT00688753|papillary cell renal carcinoma
1320704|NCT00688753|adults
1320705|NCT00688753|everolimus
1320706|NCT00688740|adjuvant treatment
1320707|NCT00688727|non epileptic seizures
1320708|NCT00688727|cognitive behavioural therapy
1320709|NCT00688727|dissociative disorders
1320710|NCT00688727|Seizure disorders
1320711|NCT00688727|randomised controlled trial
1320712|NCT00688714|Antiplatelet
1320713|NCT00688701|hyperglycemia, GLP-1
1320714|NCT00688688|Overactive Bladder
1320715|NCT00688688|Frequency
1320716|NCT00688688|Micturition
1320717|NCT00688688|Urgency
1320718|NCT00688688|Urinary incontinence
1320719|NCT00688688|Urinary urge incontinence
1320720|NCT00688675|GERD
1320721|NCT00688675|Pharmacoepidemiology
1320722|NCT00688662|Sphincter of Oddi Dysfunction
1320723|NCT00688662|Pancreatitis
1320724|NCT00688662|Sphincterotomy
1320725|NCT00688623|Neuroendocrine tumors
1320726|NCT00688623|non-functioning neuroendocrine tumors carcinoids
1320727|NCT00688623|non-functioning carcinoids
1320728|NCT00688623|adults
1320729|NCT00688623|everolimus
1320730|NCT00688610|primary care
1320731|NCT00688610|procalcitonin
1320732|NCT00688610|antibiotic prescription
1320733|NCT00688597|Pompe Disease
1320734|NCT00688584|problem drinking
1320735|NCT00688584|randomized control trial
1320736|NCT00688584|Pamphlet-based personalized alcohol feedback (PAF)
1320737|NCT00688571|Pulmonary Valve
1320738|NCT00688571|Congenital Heart Disease
1320739|NCT00688545|Celecoxib
1320740|NCT00688545|COX-2
1320741|NCT00688545|NSAIDs
1320742|NCT00688545|observational study
1320743|NCT00688545|noninterventional study
1320744|NCT00688545|cohort study
1320745|NCT00688545|registry
1320746|NCT00688545|epidemiologic study
1320747|NCT00688545|pediatrics
1320748|NCT00688545|rheumatology
1320749|NCT00688545|phase iv study
1320750|NCT00688532|Prostate cancer
1320751|NCT00688532|pharmacoepidemiology study
1320752|NCT00688519|Plaque-type Psoriasis
1320753|NCT00688519|Psoriasis
1320754|NCT00688506|Chronic pelvic pain syndrome
1320755|NCT00688506|Neuromodulation
1320756|NCT00688506|Brain effects
1320757|NCT00688506|Neuroimaging
1320758|NCT00688493|QT
1320759|NCT00688493|Healthy volunteers
1320760|NCT00688480|CKD
1320761|NCT00688480|LVH
1320762|NCT00688480|Echo LVH
1320763|NCT00688480|Chronic Stage 3
1320764|NCT00688467|Neutrophilic Asthma
1320765|NCT00688454|Hyperlipidemia
1320766|NCT00688454|Rosuvastatin
1320767|NCT00688454|Efficacy
1320768|NCT00688454|tolerability
1320769|NCT00688454|CRESTOR therapy
1320770|NCT00688441|Randomized
1320771|NCT00688441|Double-Blind
1320772|NCT00688441|Multi-Center
1320773|NCT00688441|Placebo-Controlled
1320774|NCT00688441|Phase II
1320775|NCT00688441|Nasal Carbon Dioxide
1320776|NCT00688441|Carbon Dioxide
1320777|NCT00688441|Efficacy
1320778|NCT00688441|Safety
1320779|NCT00688441|Total Nasal Symptom Score
1320780|NCT00688441|RQLQ
1320781|NCT00688428|esomeprazole
1320782|NCT00688428|upper gi symptoms
1320783|NCT00688428|low dose Aspirin treatment
1320784|NCT00688402|Reflux Inhibitor
1320785|NCT00688402|GERD
1320786|NCT00688402|formulations
1320787|NCT00688389|Dengue fever, CLEC5A, Mannose receptor, DC-SIGN, NALP,
1320788|NCT00688389|decoy receptor 3 (DcR3), Toll-like receptors(TLRs),
1320789|NCT00688389|(Nod)-like receptors (NLRs)
1320790|NCT00688376|Attention
1320791|NCT00688376|cancer
1320792|NCT00688376|chemotherapy
1320793|NCT00688376|donepezil
1320794|NCT00688376|acetylcholinesterase
1320795|NCT00688376|inhibitor
1320796|NCT00688363|Diabetes control
1320797|NCT00688363|glycated haemoglobin
1320798|NCT00688363|blood-glucose-self-monitoring
1320799|NCT00688363|type 2-diabetes
1320800|NCT00688363|conventional insulin therapy
1320801|NCT00688350|Hypertension
1320802|NCT00688350|Aging
1320803|NCT00688350|Medication adherence
1320804|NCT00688350|Medication compliance
1320805|NCT00688337|Breast cancer
1320806|NCT00688337|lymph nodes
1320807|NCT00688337|gene-expression
1320808|NCT00688337|oncotype
1320809|NCT00688337|Age over 18
1320810|NCT00688337|Newly diagnosed breast cancer prior to surgery or treatment.
1320811|NCT00688337|No evidence of clinical nodal disease
1320812|NCT00688324|schizophrenia
1320813|NCT00688324|schizoaffective disorder
1320814|NCT00688324|glutamate
1320815|NCT00688324|NMDA receptor
1320816|NCT00688324|magnetic resonance spectroscopy
1320817|NCT00688324|acamprosate
1320818|NCT00688311|HIV
1320819|NCT00688311|synbiotic
1320820|NCT00688311|probiotic
1320821|NCT00688311|immune activation
1320822|NCT00688311|blood CD4 count
1320823|NCT00688311|bacterial translocation
1320824|NCT00688311|Human Immunodeficiency Virus
1320825|NCT00688285|chronic kidney disease
1320826|NCT00688285|clinical alerts
1320827|NCT00688285|late referral
1320828|NCT00688285|electronic medical record
1320829|NCT00688285|Computerized clinical decision support systems (CDSS)
1320830|NCT00688272|Safety
1320831|NCT00688272|Photoirritant
1320832|NCT00688272|Placebo control
1320833|NCT00688272|Photosensitivity
1320834|NCT00688272|Ciprofloxacin
1320835|NCT00688272|Eltrombopag
1320836|NCT00688259|clinical trials
1320837|NCT00688259|psychotherapy
1320838|NCT00688246|osteoporosis
1320839|NCT00688246|breast cancer
1320840|NCT00688233|Seifi's Functional, Class II/1, Mandibular Retrognathism
1320841|NCT00688220|Arthritis
1320842|NCT00688220|Carpel tunnel syndrome
1320843|NCT00688220|Epicondylitis
1320844|NCT00688207|PPAR agonist,
1320845|NCT00688207|Rosiglitazone XR,
1320846|NCT00688207|BRL-049653.
1320847|NCT00688207|Alzheimer's disease,
1320848|NCT00688194|stage IV breast cancer
1320849|NCT00688194|recurrent breast cancer
1320850|NCT00688168|Multiple Myeloma
1320851|NCT00688168|Phone Call
1320852|NCT00688168|Treatment Naive
1320853|NCT00688168|Inflammatory Cytokines
1320854|NCT00688168|Questionnaire
1320855|NCT00688168|Survey
1320856|NCT00688168|Interactive Voice Response
1320857|NCT00688168|Symptom Production
1320858|NCT00688168|Pain
1320859|NCT00688168|IVR
1320860|NCT00688168|MM
1320861|NCT00688129|school readiness
1320862|NCT00688129|foster care
1320863|NCT00688129|maltreatment
1320864|NCT00688129|literacy
1320865|NCT00688129|social emotional skills
1320866|NCT00688129|self regulation
1320867|NCT00688129|caregiver involvement
1320868|NCT00688116|metastatic cancer
1320869|NCT00688116|solid tumor
1320870|NCT00688116|histologically or cytologically confirmed non-hematological malignancy that is metastatic or unresectable
1320871|NCT00688116|STA-9090
1320872|NCT00688116|ganetespib
1320873|NCT00688090|Immunotherapy, Melanoma, Cancer Vaccine
1320874|NCT00688077|Fibroblast growth factor - 23
1320875|NCT00688077|Calcitonin
1320876|NCT00688064|Acne
1320877|NCT00688051|Cystic Fibrosis
1320878|NCT00688051|Adherence to treatment
1320879|NCT00688038|Advanced Cancer
1320880|NCT00688038|Bone Metastases
1320881|NCT00688038|Laser Ablation
1320882|NCT00688038|Magnetic Resonance Thermal Imaging
1320883|NCT00688038|Laser Induced Thermal Therapy
1320884|NCT00688038|MRTI
1320885|NCT00688038|LITT
1320886|NCT00688012|antisense
1320887|NCT00688012|microRna antagonist
1320888|NCT00688012|anti-miR-122
1320889|NCT00688012|Safety in healthy volunteers
1320890|NCT00688012|Hepatitis C
1320891|NCT00687999|Chronic hepatitis C
1320892|NCT00687999|diabetes
1320893|NCT00687999|Insulin resistance
1320894|NCT00687999|combination therapy
1320895|NCT00687986|surgery
1320896|NCT00687986|stereotactic radiotherapy
1320897|NCT00687986|tumor control
1320898|NCT00687986|quality of life
1320899|NCT00687960|Diabetes
1320900|NCT00687960|Diet
1320901|NCT00687960|Fiber
1320902|NCT00687960|Age
1320903|NCT00687947|FHM
1320904|NCT00687947|MA
1320905|NCT00687947|healthy controls
1320906|NCT00687947|CGRP
1320907|NCT00687934|metastatic cancer
1320908|NCT00687934|solid tumor
1320909|NCT00687934|histologically or cytologically confirmed non-hematological
1320910|NCT00687934|malignancy that is metastatic or unresectable for which no
1320911|NCT00687934|standard therapy exists
1320912|NCT00687934|STA-9090
1320913|NCT00687934|ganetespib
1320914|NCT00687921|Knee trauma
1320915|NCT00687921|MRI
1320916|NCT00687921|arthroscopy
1320917|NCT00687921|Patients over the age of 18 who had knee trauma intent to or had MRI assessment scheduled for arthroscopy
1320918|NCT00687908|Acne
1320919|NCT00687895|malaria microscopy primary health care children
1320920|NCT00687882|Venous Thromboembolism
1320921|NCT00687882|Postthrombotic Syndrome
1320922|NCT00687882|Antithrombotic Therapy
1320923|NCT00687882|Duration of Therapy
1320924|NCT00687882|Children
1320925|NCT00687869|stroke
1320926|NCT00687869|rehabilitation
1320927|NCT00687869|patient care management
1320928|NCT00687869|patient participation
1320929|NCT00687856|Left Ventricular Assist Device
1320930|NCT00687843|Gastric Cancer
1320931|NCT00687843|TS-1
1320932|NCT00687843|PSK
1320933|NCT00687843|Relapse-free survival
1320934|NCT00687830|Afternoon colonoscopy
1320935|NCT00687830|Morning
1320936|NCT00687830|Evening
1320937|NCT00687830|Bowel Preparation
1320938|NCT00687830|Efficacy
1320939|NCT00687830|Satisfaction
1320940|NCT00687817|NSCLC
1320941|NCT00687804|DME
1320942|NCT00687804|Diabetic
1320943|NCT00687804|macula
1320944|NCT00687804|edema
1320945|NCT00687804|ranibizumab
1320946|NCT00687804|RESTORE
1320947|NCT00687791|patients with cataract and glaucoma
1320948|NCT00687791|ologen
1320949|NCT00687791|oculusgen
1320950|NCT00687791|collagen matrix
1320951|NCT00687791|Phacotrabeculectomy
1320952|NCT00687791|Aeon Astron
1320953|NCT00687791|trabeculectomy
1320954|NCT00687791|tissue engineering
1320955|NCT00687791|mitomycin-C
1320956|NCT00687778|C11-Acetate
1320957|NCT00687778|FDG
1320958|NCT00687778|sarcoma
1320959|NCT00687778|Measurement of C11-Acetate uptake in tumors which are often non-FDG avid.
1320960|NCT00687778|Soft tissue sarcomas
1320961|NCT00687778|well-differentiated thyroid cancer
1320962|NCT00687778|well-differentiated and bronchoalveolar lung cancer
1320963|NCT00687778|indolent lymphomas, neuroendocrine tumors
1320964|NCT00687778|GIST
1320965|NCT00687778|uterine malignancies
1320966|NCT00687778|mucin-producing cancer
1320967|NCT00687778|teratoma, hepatoma
1320968|NCT00687778|HCC
1320969|NCT00687778|lobular breast carcinoma
1320970|NCT00687765|patients with newly diagnosed glioblastoma
1320971|NCT00687752|fetal deglutition
1320972|NCT00687752|larynx
1320973|NCT00687752|fetal CNS pathology
1320974|NCT00687752|sonography
1320975|NCT00687752|hydramnios
1320976|NCT00687739|hormone therapy
1320977|NCT00687739|obesity
1320978|NCT00687739|postmenopause
1320979|NCT00687739|disease /disorder proneness /risk
1320980|NCT00687739|insulin sensitivity /resistance
1320981|NCT00687739|metabolic syndrome
1320982|NCT00687739|women's health
1320983|NCT00687726|osteoarthritis
1320984|NCT00687726|knee
1320985|NCT00687726|exercise
1320986|NCT00687726|balance
1320987|NCT00687700|propranolol
1320988|NCT00687700|B2-agonist,
1320989|NCT00687700|B-antagonist,
1320990|NCT00687687|Patients must have advanced (stage III or IV), persistent or recurrent uterine carcinosarcoma with documented disease progression.
1320991|NCT00687674|refractory multiple myeloma
1320992|NCT00687661|Chronic Kidney Failure
1320993|NCT00687661|Vascular Calcification
1320994|NCT00687661|Bisphosphonates
1320995|NCT00687648|stage IV breast cancer
1320996|NCT00687648|recurrent breast cancer
1320997|NCT00687648|HER2-negative breast cancer
1320998|NCT00687648|estrogen receptor-positive breast cancer
1320999|NCT00687648|progesterone receptor-positive breast cancer
1321000|NCT00687622|GSK1120212
1321001|NCT00687622|Oncology
1321002|NCT00687622|melanoma
1321003|NCT00687622|MEK inhibitor
1321004|NCT00687622|solid tumors
1321005|NCT00687622|First Time in Human
1321006|NCT00687609|Attention Deficit Hyperactivity Disorder with Cannabis Abuse
1321007|NCT00687609|Marihuana Abuse
1321008|NCT00687609|Comorbid Cannabis Abuse
1321009|NCT00687583|pediatrics
1321010|NCT00687583|anesthesia
1321011|NCT00687583|head movements
1321012|NCT00687583|endotracheal tube
1321013|NCT00687570|patients with rectal cancer undergoing surgery
1321014|NCT00687570|Bowel purity degree
1321015|NCT00687570|Bowel preparation
1321016|NCT00687570|Rectal cancer
1321017|NCT00687570|Nutritional status
1321018|NCT00687570|complications with traditional bowel preparation
1321019|NCT00687570|Complications
1321020|NCT00687570|Physiological status
1321021|NCT00687544|HIV
1321022|NCT00687492|hypercholesterolemia
1321023|NCT00687492|NCEP ATP III guidelines
1321024|NCT00687492|survey
1321025|NCT00687479|insulin sensitivity
1321026|NCT00687479|insulin secretion
1321027|NCT00687479|infant outcome
1321028|NCT00687466|Cystic Fibrosis
1321029|NCT00687466|Glucose Intolerance
1321030|NCT00687453|Glargine
1321031|NCT00687453|Type 2 diabetes
1321032|NCT00687453|Basal insulin
1321033|NCT00687414|gene expression
1321034|NCT00687414|gene sequencing
1321035|NCT00687414|gene encoding
1321036|NCT00687414|MPD
1321037|NCT00687414|MDS
1321038|NCT00687414|AML
1321039|NCT00687414|mDia
1321040|NCT00687388|Cyclooxygenase 2 Inhibitors
1321041|NCT00687388|Alpha Blockers
1321042|NCT00687388|Treatment Outcome
1321043|NCT00687375|Inguinal
1321044|NCT00687375|Groin hernia
1321045|NCT00687375|TAPP
1321046|NCT00687375|TEP
1321047|NCT00687375|Comparing
1321048|NCT00687375|Two
1321049|NCT00687375|Techniques
1321050|NCT00687349|End-of-Life issues
1321051|NCT00687349|Talking with your doctor
1321052|NCT00687349|Coping with chronic illness
1321053|NCT00687336|Helicobacter pylori
1321054|NCT00687336|Treatment
1321055|NCT00687336|Upper gastrointestinal bleeding
1321056|NCT00687310|Asthma education
1321057|NCT00687310|satisfaction adherence
1321058|NCT00687310|Quality of Life
1321059|NCT00687310|PIKO meter cluster
1321060|NCT00687310|Symbicort® Turbuhaler®
1321061|NCT00687297|Stage IIIB Non Small Cell Lung Cancer
1321062|NCT00687297|Stage IV Non Small Cell Lung Cancer
1321063|NCT00687297|Vandetanib
1321064|NCT00687297|Docetaxel plus carboplatin
1321065|NCT00687258|Anemia
1321066|NCT00687258|Oxidative Stress
1321067|NCT00687258|Erythropoietin
1321068|NCT00687258|dialyser membrane
1321069|NCT00687258|Vitamin E
1321070|NCT00687258|Erythropoietin responsiveness
1321071|NCT00687258|Erythropoietin resistance
1321072|NCT00687258|hemodialysis
1321073|NCT00687245|children
1321074|NCT00687245|reflux
1321075|NCT00687245|GERD
1321076|NCT00687245|pediatric
1321077|NCT00687232|Phase I
1321078|NCT00687232|Japan
1321079|NCT00687232|Japanese
1321080|NCT00687232|inhalation
1321081|NCT00687219|hepatitis C
1321082|NCT00687193|Phase 2 monotherapy in Japan
1321083|NCT00686192|Obesity
1321084|NCT00686192|Calcium carbonate
1321085|NCT00686192|Dietary Supplements
1321086|NCT00686192|Lipolysis
1321087|NCT00686179|TQT
1321088|NCT00686179|ECG
1321089|NCT00686179|QT
1321090|NCT00686179|QTc
1321091|NCT00686179|AZD3480
1321092|NCT00686179|ECG(QTc effects)
1321093|NCT00686166|adenocarcinoma of the rectum
1321094|NCT00686166|stage IIA rectal cancer
1321095|NCT00686166|stage IIB rectal cancer
1321096|NCT00686166|stage IIC rectal cancer
1321097|NCT00686166|stage IIIA rectal cancer
1321098|NCT00686166|stage IIIB rectal cancer
1321099|NCT00686166|stage IIIC rectal cancer
1321100|NCT00686140|Schizophrenia
1321101|NCT00686140|clinical trial
1321102|NCT00686140|risperidone
1321103|NCT00686140|immune
1321104|NCT00686140|celecoxib
1321105|NCT00686127|breast cancer
1321106|NCT00686127|neuropathic pain
1321107|NCT00686127|topical lidocaine
1321108|NCT00686127|postmastectomy pain
1321109|NCT00686127|breast symptoms
1321110|NCT00686127|breast pain
1321111|NCT00686114|Esophageal cancer
1321112|NCT00686114|chemoradiation
1321113|NCT00686114|radiosensitivity
1321114|NCT00686114|EGFR inhibition
1321115|NCT00686101|Perception of risk
1321116|NCT00686101|Smoking risks
1321117|NCT00686101|Smoking consequences
1321118|NCT00686101|Quitting smoking
1321119|NCT00686101|Motivation to quit smoking
1321120|NCT00686101|Schizophrenia
1321121|NCT00686088|prostate cancer
1321122|NCT00686088|locally recurrent
1321123|NCT00686088|PRX302
1321124|NCT00686075|Respiratory Syncytial Virus (RSV)
1321125|NCT00686075|Parainfluenza Virus Type 3 (PIV3)
1321126|NCT00686075|MEDI-534
1321127|NCT00686062|Prenatal testing
1321128|NCT00686062|Amniocentesis
1321129|NCT00686062|Decision making
1321130|NCT00686062|Down syndrome
1321131|NCT00686049|HIV Treatment Readiness Measure (HTRM)
1321132|NCT00686049|Highly Active Antiretroviral Treatment (HAART)
1321133|NCT00686049|Adherence
1321134|NCT00686049|Treatment readiness
1321135|NCT00686049|HIV
1321136|NCT00686036|prostate cancer
1321137|NCT00686036|hormone treatment
1321138|NCT00686023|pertrochanteric femur fracture
1321139|NCT00686023|DHS
1321140|NCT00686023|IMN
1321141|NCT00686010|CETP Inhibitor
1321142|NCT00686010|HDL-C
1321143|NCT00686010|LDL-C
1321144|NCT00686010|Apolipoprotein
1321145|NCT00685997|Malignant lymphoma
1321146|NCT00685997|Hodgkin's disease
1321147|NCT00685997|Non-Hodgkin's lymphoma
1321148|NCT00685997|Imaging
1321149|NCT00685997|Whole-Body MRI
1321150|NCT00685997|CT
1321151|NCT00685997|Radiation
1321152|NCT00685984|Type 2 diabetes
1321153|NCT00685984|silent myocardial ischemia
1321154|NCT00685984|endothelial function
1321155|NCT00685971|Cystic Fibrosis
1321156|NCT00685971|Vitamin D deficiency
1321157|NCT00685958|Blood thinner
1321158|NCT00685958|enoxaparin
1321159|NCT00685958|hip fracture surgery
1321160|NCT00685958|bleeding
1321161|NCT00685958|thromboembolism
1321162|NCT00685945|Bradykinin
1321163|NCT00685945|Obesity
1321164|NCT00685945|Nitric Oxide Donor
1321165|NCT00685945|tissue type plasminogen activator
1321166|NCT00685945|isosorbide dinitrate
1321167|NCT00685945|phosphodiesterase inhibitor
1321168|NCT00685945|Renin-Angiotensin Aldosterone System
1321169|NCT00685945|Fibrinolysis
1321170|NCT00685945|Angiotensin converting enzyme
1321171|NCT00685932|Cesarean section
1321172|NCT00685932|Postpartum pain
1321173|NCT00685932|Post-cesarean pain
1321174|NCT00685932|Surgical retractor
1321175|NCT00685932|Elastic retractor
1321176|NCT00687180|Prednisolone dosage
1321177|NCT00687167|Therapeutic Equivalency
1321178|NCT00687154|DME
1321179|NCT00687154|Laser
1321180|NCT00687154|macular edema
1321181|NCT00687154|retinopathy
1321182|NCT00687154|scatter photocoagulation
1321183|NCT00687141|Safety
1321184|NCT00687141|tolerability
1321185|NCT00687141|AZD0328
1321186|NCT00687128|Insulin resistance
1321187|NCT00687128|Metabolic syndrome
1321188|NCT00687128|Aerobic exercise
1321189|NCT00687128|Exercise behavior
1321190|NCT00687115|24 Hour Energy Expenditure
1321191|NCT00687115|Respiratory Chamber
1321192|NCT00687115|Obesity
1321193|NCT00687115|Weight Loss
1321194|NCT00687115|Overfeeding
1321195|NCT00687102|breast cancer
1321196|NCT00687102|Tamoxifen
1321197|NCT00687102|Raloxifene
1321198|NCT00687102|hormone therapy
1321199|NCT00687089|Opiates
1321200|NCT00687089|Subutex
1321201|NCT00687089|Buprenorphine
1321202|NCT00687089|Patients who addicted to opiates
1321203|NCT00687076|Endovascular Intervention
1321204|NCT00687076|MRI
1321205|NCT00687076|Ultrasound
1321206|NCT00687076|Cholesterol Medications
1321207|NCT00687076|High Cholesterol
1321208|NCT00687076|Peripheral Arterial disease
1321209|NCT00687076|Claudication
1321210|NCT00687076|Leg Pain
1321211|NCT00687076|Niaspan
1321212|NCT00687076|Extended Release Niacin
1321213|NCT00687076|Zetia
1321214|NCT00687076|Ezetimibe
1321215|NCT00687076|Simvastatin
1321216|NCT00687076|Zocor
1321217|NCT00687076|Atorvastatin
1321218|NCT00687076|Lipitor
1321219|NCT00687050|end-stage renal disease
1321220|NCT00687050|chronic kidney disease
1321221|NCT00687037|oral hygiene
1321222|NCT00687024|Epilepsy
1321223|NCT00687024|Magnetic Resonance Imaging
1321224|NCT00687024|Magnetoencephalography
1321225|NCT00687011|Antiemetic
1321226|NCT00686998|Schizophrenia
1321227|NCT00686985|Docetaxel
1321228|NCT00686985|Carboplatin
1321229|NCT00686985|chemotherapy
1321230|NCT00686985|relapse SCLC
1321231|NCT00686972|Bariatric Surgery
1321232|NCT00686972|Glucose Regulation
1321233|NCT00686972|Cardiac Function
1321234|NCT00686972|Body Composition
1321235|NCT00686946|Severe mental illness
1321236|NCT00686946|Antipsychotic medications
1321237|NCT00686946|Pregnancy
1321238|NCT00686946|Evidence-based guidelines
1321239|NCT00686946|Maternal and infant health and wellbeing
1321240|NCT00686933|Attention-Deficit/Hyperactivity Disorder
1321241|NCT00686907|melatonin, circadian rhythms, sleep
1321242|NCT00686881|hepatitis C
1321243|NCT00686868|GSK1841157;
1321244|NCT00686868|rheumatoid arthritis,
1321245|NCT00686868|B-cell depletion
1321246|NCT00686868|anti-CD20 monoclonal antibody,
1321247|NCT00686855|tacrolimus
1321248|NCT00686855|dexamethasone
1321249|NCT00686855|oral rinse
1321250|NCT00686842|HIV infection
1321251|NCT00686842|AIDS-related Kaposi sarcoma
1321252|NCT00686842|recurrent Kaposi sarcoma
1321253|NCT00686842|Treatment Experienced
1321254|NCT00686829|HIV
1321255|NCT00686829|Treatment Experienced
1321256|NCT00686816|pre-diabetic
1321257|NCT00686816|obese
1321258|NCT00686803|hypertension
1321259|NCT00686803|controlled hypertension
1321260|NCT00686803|hypertensives
1321261|NCT00686790|Hepatitis D
1321262|NCT00686790|Hepatitis B
1321263|NCT00686777|hepatitis C
1321264|NCT00686764|trans-femoral amputation
1321265|NCT00686738|osteosarcoma
1321266|NCT00686738|transforming growth factor-beta 1
1321267|NCT00686738|nuclear factor-kappa B
1321268|NCT00686738|positron emission tomography/computed tomography
1321269|NCT00686738|magnetic resonance spectroscopy
1321270|NCT00686738|predicting response to neoadjuvant chemotherapy
1321271|NCT00686712|Glargine
1321272|NCT00686712|Type 2 diabetes
1321273|NCT00686712|Basal insulin
1321274|NCT00686699|Anti-Dyskinesia Agents
1321275|NCT00686699|Antipsychotic Agents
1321276|NCT00686673|DECISION AIDS
1321277|NCT00686660|copd
1321278|NCT00686660|rehabilitation
1321279|NCT00686660|quality of life
1321280|NCT00686660|inflammation
1321281|NCT00686647|Coronary Angioplasty
1321282|NCT00686647|Coronary Stents
1321283|NCT00686647|Scoring Balloons
1321284|NCT00686647|Coronary Artery Bifurcation Lesions
1321285|NCT00686634|sitagliptin
1321286|NCT00686634|type 2 diabetes
1321287|NCT00686634|combination therapy
1321288|NCT00686608|Obesity
1321289|NCT00686556|recurrent adult acute lymphoblastic leukemia
1321290|NCT00686556|recurrent childhood acute lymphoblastic leukemia
1321291|NCT00686556|recurrent adult acute myeloid leukemia
1321292|NCT00686556|recurrent childhood acute myeloid leukemia
1321293|NCT00686556|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1321294|NCT00686556|adult acute myeloid leukemia with inv(16)(p13;q22)
1321295|NCT00686556|adult acute myeloid leukemia with t(15;17)(q22;q12)
1321296|NCT00686556|adult acute myeloid leukemia with t(16;16)(p13;q22)
1321297|NCT00686556|adult acute myeloid leukemia with t(8;21)(q22;q22)
1321298|NCT00686556|ALL
1321299|NCT00686556|MDS
1321300|NCT00686543|Antifungal Agents
1321301|NCT00686543|Anti-Infective Agents
1321302|NCT00686530|Fetal Death
1321303|NCT00686530|Magnetic Resonance Imaging
1321304|NCT00686530|Autopsy
1321305|NCT00686530|Telencephalon
1321306|NCT00686530|Pyramidal Tracts
1321307|NCT00686504|Pain
1321308|NCT00686504|PET
1321309|NCT00686504|Phase 1
1321310|NCT00686504|Analgesia
1321311|NCT00686504|Positron Emission Tomography
1321312|NCT00686504|mGlu5 receptor
1321313|NCT00686504|Dose finding
1321314|NCT00686504|Analgesia/Pain
1321315|NCT00686491|Asthma
1321316|NCT00686491|Environment
1321317|NCT00686491|Type of sport
1321318|NCT00686491|Cardiovascular disease
1321319|NCT00686491|Athletes
1321320|NCT00686478|burn
1321321|NCT00686478|hypertrophic scar
1321322|NCT00686478|fibroproliferative disorder
1321323|NCT00686465|recurrent cancer
1321324|NCT00686465|PET/CT
1321325|NCT00686465|FDG
1321326|NCT00686465|planned management
1321327|NCT00686465|actual treatment
1321328|NCT00686452|Asthma
1321329|NCT00686452|Airway hyperresponsiveness
1321330|NCT00686452|Swimmers
1321331|NCT00686452|Airway inflammation
1321332|NCT00686452|Airway remodelling
1321333|NCT00686439|osteoarthritis
1321334|NCT00686439|adalimumab
1321335|NCT00686439|mri
1321336|NCT00686426|Obesity
1321337|NCT00686426|Weight gain
1321338|NCT00686426|regain
1321339|NCT00686426|dairy
1321340|NCT00686426|calcium
1321341|NCT00686413|PET
1321342|NCT00686413|AZD3480
1321343|NCT00686413|PET examination
1321344|NCT00686400|schizophrenia
1321345|NCT00686400|first-episode
1321346|NCT00686400|infection
1321347|NCT00686400|Toxoplasma gondii
1321348|NCT00686400|levels of IgG antibodies to TG
1321349|NCT00686387|Tissue Bank
1321350|NCT00686387|Glioblastoma Multiforme
1321351|NCT00686387|NAT2
1321352|NCT00686387|EGFR
1321353|NCT00686387|MGMT
1321354|NCT00686387|Brain and Spinal TumorGliomas
1321355|NCT00686374|Crohn's Disease
1321356|NCT00686374|adalimumab
1321357|NCT00686361|Cystic Fibrosis
1321358|NCT00686361|choline nutrition
1321359|NCT00686361|choline and methyl metabolism
1321360|NCT00686361|CF and oxidative stress
1321361|NCT00686348|acromegaly
1321362|NCT00686335|asthma
1321363|NCT00686335|nocturnal asthma
1321364|NCT00686335|glucocorticoid dependent persistent asthma
1321365|NCT00686335|signs and symptoms
1321366|NCT00686335|lung function
1321367|NCT00686335|prednisone
1321368|NCT00686322|chemotherapy
1321369|NCT00686322|radiotherapy
1321370|NCT00686322|lung cancer
1321371|NCT00686309|exhaled NO
1321372|NCT00686309|off line
1321373|NCT00686309|on line
1321374|NCT00686309|comparison
1321375|NCT00686309|Bland altman method
1321376|NCT00686296|soft tissue abscess requiring incision and drainage
1321377|NCT00686283|Adolescents
1321378|NCT00686283|Diabetes
1321379|NCT00686283|Exercise
1321380|NCT00686270|HIV-1 infection
1321381|NCT00686270|NRTI resistance
1321382|NCT00686270|M184V mutation
1321383|NCT00686270|reverse transcriptase
1321384|NCT00686270|apricitabine
1321385|NCT00686270|drug resistance
1321386|NCT00686270|safety and tolerability
1321387|NCT00686270|therapy failure
1321388|NCT00686270|Treatment Experienced
1321389|NCT00686257|acute respiratory insufficiency
1321390|NCT00686257|noninvasive ventilation
1321391|NCT00686257|oronasal face mask
1321392|NCT00686257|total face mask
1321393|NCT00686244|metabolic syndrome
1321394|NCT00686244|physical activity
1321395|NCT00686244|overweight
1321396|NCT00686244|malnutrition
1321397|NCT00686244|prevention
1321398|NCT00686231|To determine if topical nitroglycerin acts to vasodilate the radial artery by a direct local action, or by systemic vasodilation
1321399|NCT00686231|To determine if topical nitroglycerin dilates the radial artery in the presence of local anesthetic agents used in cardiac catheterization
1321400|NCT00686218|chronic phase chronic myelogenous leukemia
1321401|NCT00686205|healthy donors
1321402|NCT00686205|HIV positives
1321403|NCT00685919|Dopamine
1321404|NCT00685919|Natriuresis
1321405|NCT00685919|Catecholamines
1321406|NCT00685906|oral contraceptive
1321407|NCT00685906|birth control
1321408|NCT00685906|Healthy volunteers
1321409|NCT00685893|End-of-life issues
1321410|NCT00685893|Talking with your doctor
1321411|NCT00685893|Coping with chronic illness
1321412|NCT00685880|thumb carpo metacarpal joint osteoarthritis
1321413|NCT00685880|prolotherapy
1321414|NCT00685880|intra articular steroid
1321415|NCT00685880|hand therapy
1321416|NCT00685867|Staphylococcus aureus
1321417|NCT00685867|Resistance
1321418|NCT00685867|Prevention
1321419|NCT00685854|Macular Telangiectasia
1321420|NCT00685854|Vascular Endothelial Growth Factor
1321421|NCT00685854|Ranibizumab
1321422|NCT00685841|Chronic obstructive pulmonary disease
1321423|NCT00685828|gastrointestinal stromal tumor
1321424|NCT00685815|IV Iron
1321425|NCT00685815|Restless Legs Syndrome
1321426|NCT00685815|RLS
1321427|NCT00685815|Iron
1321428|NCT00685789|Bell's palsy，deqi，acupuncture, neuropsychology
1321429|NCT00685776|CHD/CHD risk-equivalent disease
1321430|NCT00685776|Coronary Heart Disease (CHD)
1321431|NCT00685763|Pancreatic cancer
1321432|NCT00685763|Unresectable
1321433|NCT00685763|Proton radiation
1321434|NCT00685763|Chemotherapy
1321435|NCT00685750|tumor antigen
1321436|NCT00685750|biomarkers
1321437|NCT00685737|Hyperlipidemia
1321438|NCT00685724|pathological gambling
1321439|NCT00685724|cognitive-behavioral therapy
1321440|NCT00685724|motivational enhancement therapy
1321441|NCT00685711|Cat allergy
1321442|NCT00685711|Immunotherapy
1321443|NCT00685711|Cat-PAD
1321444|NCT00685698|Diabetic Foot Infections, DFI, Nemonoxacin
1321445|NCT00685685|Therapeutic Equivalency
1321446|NCT00685672|labor analgesia
1321447|NCT00685672|fentanyl
1321448|NCT00685672|epinephrine
1321449|NCT00685659|cocaine dependence
1321450|NCT00685659|treatment
1321451|NCT00685659|continuing care
1321452|NCT00685659|outcomes
1321453|NCT00685659|incentives
1321454|NCT00685659|adaptive
1321455|NCT00685646|bone metastases
1321456|NCT00685646|stage IV prostate cancer
1321457|NCT00685633|stage I prostate cancer
1321458|NCT00685633|stage II prostate cancer
1321459|NCT00685633|stage III prostate cancer
1321460|NCT00685633|recurrent prostate cancer
1321461|NCT00685607|Pilot Study
1321462|NCT00685607|Outcome Measures
1321463|NCT00685594|diabetes
1321464|NCT00685594|vitamin D
1321465|NCT00685594|cholecalciferol
1321466|NCT00685594|glucose tolerance
1321467|NCT00685581|TFA
1321468|NCT00685581|SFA
1321469|NCT00685581|Clinical trial
1321470|NCT00685581|fat milk
1321471|NCT00685568|colon cancer
1321472|NCT00685568|rectal cancer
1321473|NCT00685568|familial adenomatous polyposis
1321474|NCT00685555|Screen time
1321475|NCT00685555|Fruits and Vegetable Consumption
1321476|NCT00685555|Physical Activity
1321477|NCT00685555|Obesity
1321478|NCT00685555|Overweight
1321479|NCT00685542|diacerein
1321480|NCT00685542|osteoarthritis
1321481|NCT00685542|hand
1321482|NCT00685529|COPD
1321483|NCT00685529|Arformoterol
1321484|NCT00685529|formoterol
1321485|NCT00685516|adenocarcinoma of the prostate
1321486|NCT00685516|recurrent prostate cancer
1321487|NCT00685516|stage I prostate cancer
1321488|NCT00685516|stage II prostate cancer
1321489|NCT00685516|stage III prostate cancer
1321490|NCT00685516|stage IV prostate cancer
1321491|NCT00685503|Macular Telangiectasia
1321492|NCT00685503|Vascular Endothelial Growth Factor
1321493|NCT00685503|Ranibizumab
1321494|NCT00685503|Neovascularization
1321495|NCT00685490|branch retinal vein occlusion
1321496|NCT00685490|internal limiting membrane
1321497|NCT00685490|macular edema
1321498|NCT00685490|vitrectomy
1321499|NCT00685477|CCK infusion
1321500|NCT00685477|Gallbladder ejection fraction
1321501|NCT00685477|Normal volunteers
1321502|NCT00685464|Abciximab
1321503|NCT00685464|Reo-Pro
1321504|NCT00685464|Intracoronary
1321505|NCT00685464|PCI
1321506|NCT00685451|cognitive behavior therapy
1321507|NCT00685451|addiction
1321508|NCT00685451|PTSD
1321509|NCT00685438|Environmental Medicine
1321510|NCT00685438|Altitude
1321511|NCT00685438|Ultraviolet Rays
1321512|NCT00685438|Antioxidants
1321513|NCT00685438|Oxidative Stress
1321514|NCT00685438|Erythema
1321515|NCT00685425|Asthma
1321516|NCT00685425|Exercised induced bronchoconstriction
1321517|NCT00685412|CIN 2 or 3
1321518|NCT00685412|cervical cancer
1321519|NCT00685399|Uveitis,
1321520|NCT00685399|eye,
1321521|NCT00685399|IL-17,
1321522|NCT00685399|IL-17A,
1321523|NCT00685399|IL17,
1321524|NCT00685399|AIN457,
1321525|NCT00685399|Vogt-Koyanagi-Harada,
1321526|NCT00685399|Behcet's,
1321527|NCT00685399|Behcet,
1321528|NCT00685399|Sympathetic ophthalmia,
1321529|NCT00685399|Multifocal choroiditis,
1321530|NCT00685399|Birdshot,
1321531|NCT00685399|HLA-B27,
1321532|NCT00685399|Birdshot retinochoroiditis,
1321533|NCT00685399|Retinal vasculitis,
1321534|NCT00685399|Sarcoidosis,
1321535|NCT00685399|Intermediate uveitis,
1321536|NCT00685399|Panuveitis,
1321537|NCT00685399|Posterior uveitis
1321538|NCT00685386|endoscopic retrograde cholangiopancreatography
1321539|NCT00685386|carbon dioxide
1321540|NCT00685386|randomized controlled clinical trial
1321541|NCT00685373|Cryopyrin-associated periodic syndromes (CAPS):
1321542|NCT00685373|Familial Cold Autoinflammatory Syndrome (FCAS),
1321543|NCT00685373|Muckle-Wells Syndrome (MWS),
1321544|NCT00685373|MWS with overlapping symptoms of Neonatal Onset Multisystem Inflammatory Disease (NOMID) or Neonatal Onset Multisystem Inflammatory Disease (NOMID),
1321545|NCT00685373|children,
1321546|NCT00685373|systemic autoinflammatory disease,
1321547|NCT00685373|CIAS-1 gene,
1321548|NCT00685373|NALP-3,
1321549|NCT00685373|ACZ885,
1321550|NCT00685373|human monoclonal anti-human interleukin-1beta (IL-1beta),
1321551|NCT00685373|antibody,
1321552|NCT00685373|autosomal dominant,
1321553|NCT00685373|familial autoinflammatory syndrome
1321554|NCT00685360|Tuberculosis
1321555|NCT00685360|Pulmonary
1321556|NCT00685360|Multidrug resistant
1321557|NCT00685360|Antitubercular Agents
1321558|NCT00685360|OPC 67683
1321559|NCT00685347|Asthma
1321560|NCT00685347|Exercised induced bronchoconstriction
1321561|NCT00685334|Atypical Antipsychotics
1321562|NCT00685334|Anorexia Nervosa
1321563|NCT00685321|schizophrenia
1321564|NCT00685321|TMS
1321565|NCT00685321|brain stimulation
1321566|NCT00685321|negative symptoms
1321567|NCT00685321|clinical improvement
1321568|NCT00685321|cognitive improvement
1321569|NCT00685308|Atherosclerosis
1321570|NCT00685308|Intracranial artery
1321571|NCT00685308|Angioplasty
1321572|NCT00685308|Stent
1321573|NCT00685295|Emergency Department
1321574|NCT00685295|acute
1321575|NCT00685269|Obstructive Sleep Apnea Syndrome
1321576|NCT00685269|OSAS
1321577|NCT00685256|breast cancer
1321578|NCT00685256|hereditary breast/ovarian cancer (BRCA1, BRCA2)
1321579|NCT00685243|Fraxel
1321580|NCT00685243|Pulsed dye laser
1321581|NCT00685243|Surgical scars
1321582|NCT00685230|scorpion sting
1321583|NCT00685230|envenomation
1321584|NCT00685230|alacramyn
1321585|NCT00685191|Raltegravir
1321586|NCT00685191|HIV
1321587|NCT00685191|dynamics
1321588|NCT00685191|viral load
1321589|NCT00685191|Treatment Experienced
1321590|NCT00685178|addiction
1321591|NCT00685178|drug dependence
1321592|NCT00685178|stimulant
1321593|NCT00685139|Therapeutic Equivalency
1321594|NCT00685126|RAD
1321595|NCT00685126|Reactive Airways Disease
1321596|NCT00685126|Levalbuterol
1321597|NCT00685126|Racemic albuterol
1321598|NCT00685100|IVTA; CNV; age-related macular degeneration; PDT
1321599|NCT00685087|To define the natural history and the clinical, laboratory and histomorphometric features of chronic pancreatitis (CP).
1321600|NCT00685087|To identify clinical and laboratory parameters that correlate with the pathophysiologic state in patients with CP.
1321601|NCT00685087|To quantify the behavioral abnormalities associated with CP.
1321602|NCT00685087|To determine psychological and behavioral correlates of CP disease progression and outcomes.
1321603|NCT00685074|Motivational Interview
1321604|NCT00685074|Computer based intervention
1321605|NCT00685074|Substance abuse
1321606|NCT00685074|post-partum
1321607|NCT00685061|Adult, primary deceased donor kidney transplant recipients
1321608|NCT00685048|Gambling
1321609|NCT00685048|Brief Therapies
1321610|NCT00685048|Substance Abuse
1321611|NCT00685035|high frequency chest wall oscillation, cystic fibrosis
1321612|NCT00685022|Asthma
1321613|NCT00685022|Racemic albuterol
1321614|NCT00685009|Cognition
1321615|NCT00685009|Memory
1321616|NCT00685009|Hormone Therapy
1321617|NCT00684983|IGF-1R
1321618|NCT00684983|IMC-A12
1321619|NCT00684970|CRPC
1321620|NCT00684970|HRPC
1321621|NCT00684970|metastatic prostate cancer
1321622|NCT00684931|Attention
1321623|NCT00684931|Deficit
1321624|NCT00684931|Disorder
1321625|NCT00684931|Hyperactivity
1321626|NCT00684931|cerebellum
1321627|NCT00684931|alteration
1321628|NCT00684931|fronto-cerebello-frontal loops
1321629|NCT00684918|AML, obatoclax
1321630|NCT00684905|adenocarcinoma of the prostate
1321631|NCT00684905|recurrent prostate cancer
1321632|NCT00684905|stage I prostate cancer
1321633|NCT00684905|stage II prostate cancer
1321634|NCT00684905|stage III prostate cancer
1321635|NCT00684892|Emphysema
1321636|NCT00684892|Endobronchial Lung Volume Reduction
1321637|NCT00684879|Hereditary Hemorrhagic Telangiectasia
1321638|NCT00684879|Health Belief Model
1321639|NCT00684879|Illness Perceptions
1321640|NCT00684879|Screening
1321641|NCT00684879|HHT
1321642|NCT00684866|Asthma
1321643|NCT00684866|Levalbuterol
1321644|NCT00684866|Racemic Albuterol
1321645|NCT00684853|AMD
1321646|NCT00684853|PDT
1321647|NCT00684853|Avastin
1321648|NCT00684853|Bevacizumab
1321649|NCT00684853|Full fluence
1321650|NCT00684853|exudative
1321651|NCT00684853|CNV
1321652|NCT00684853|Drusen
1321653|NCT00684853|ARMD
1321654|NCT00684853|Vetaporfin
1321655|NCT00684853|efficacy
1321656|NCT00684853|treatment
1321657|NCT00684840|Behavioral Economics
1321658|NCT00684840|Drug self administration
1321659|NCT00684840|Opioid
1321660|NCT00684827|Asthma
1321661|NCT00684827|Racemic albuterol
1321662|NCT00684814|equivalency
1321663|NCT00684814|Therapeutic equivalency
1321664|NCT00684801|recurrent non-small cell lung cancer
1321665|NCT00684801|recurrent small cell lung cancer
1321666|NCT00684801|stage IIIA non-small cell lung cancer
1321667|NCT00684801|stage IIIB non-small cell lung cancer
1321668|NCT00684801|stage IV non-small cell lung cancer
1321669|NCT00684801|extensive stage small cell lung cancer
1321670|NCT00684801|recurrent pancreatic cancer
1321671|NCT00684801|stage III pancreatic cancer
1321672|NCT00684801|stage IV pancreatic cancer
1321673|NCT00684801|recurrent ovarian epithelial cancer
1321674|NCT00684801|recurrent ovarian germ cell tumor
1321675|NCT00684801|stage III ovarian epithelial cancer
1321676|NCT00684801|stage III ovarian germ cell tumor
1321677|NCT00684801|stage IV ovarian epithelial cancer
1321678|NCT00684801|stage IV ovarian germ cell tumor
1321679|NCT00684801|recurrent colon cancer
1321680|NCT00684801|stage III colon cancer
1321681|NCT00684801|stage IV colon cancer
1321682|NCT00684801|recurrent rectal cancer
1321683|NCT00684801|stage III rectal cancer
1321684|NCT00684801|stage IV rectal cancer
1321685|NCT00684788|opiate dependence
1321686|NCT00684788|naltrexone
1321687|NCT00684788|reinforcement
1321688|NCT00684788|behavior therapy
1321689|NCT00684788|cocaine dependence
1321690|NCT00684788|risk reduction behavior
1321691|NCT00684749|Mentor BodyLogic TM System
1321692|NCT00684749|Breast augmentation
1321693|NCT00684749|Breast implant choice
1321694|NCT00684749|Reoperation rates
1321695|NCT00684736|septic shock
1321696|NCT00684736|shock
1321697|NCT00684736|serotonin
1321698|NCT00684736|kynurenine
1321699|NCT00684736|tryptophan
1321700|NCT00684723|Therapeutic Equivalency
1321701|NCT00684710|Alzheimer Disease
1321702|NCT00684697|premature infants iron neurodevelopment
1321703|NCT00684684|Bronchoscopy
1321704|NCT00684684|Clinically indicated for routine diagnostic bronchoscopy
1321705|NCT00684671|Immune memory
1321706|NCT00684671|Combined hepatitis A and B vaccine
1321707|NCT00684671|> 41 years old
1321708|NCT00684658|Type 1 Diabetes
1321709|NCT00684658|Children and Teenagers
1321710|NCT00684658|Coping with Chronic Illness
1321711|NCT00684658|Adolescence
1321712|NCT00684658|Internet psychosocial program
1321713|NCT00684658|Coping Skills Training
1321714|NCT00684645|Safety and tolerability of SUTENT® in patients with metastatic or advanced renal cell carcinoma after failure of cytokines in real-life setting.
1321715|NCT00684632|Pain, cancer
1321716|NCT00684606|Induction of Labor
1321717|NCT00684606|Low Bishop Score
1321718|NCT00684606|Transcervical Foley Catheter.
1321719|NCT00684606|IV Oxytocin
1321720|NCT00684580|St. Jude Alumni
1321721|NCT00684580|St. Jude Life Participants
1321722|NCT00684554|Heroin Dependence
1321723|NCT00684554|Opioid Dependence
1321724|NCT00684554|Primary Care
1321725|NCT00684554|Buprenorphine
1321726|NCT00684541|Social Anxiety
1321727|NCT00684541|Information Processing
1321728|NCT00684541|Interpretation
1321729|NCT00684528|DM 2
1321730|NCT00684528|Metformin
1321731|NCT00684528|Januvia
1321732|NCT00684528|Community setting
1321733|NCT00684528|newly diagnosed diadetics, or diabetes patients not treated during the last year
1321734|NCT00684502|Safety
1321735|NCT00684502|tolerability
1321736|NCT00684502|AZD2066
1321737|NCT00684502|Pain conditions
1321738|NCT00684489|hypertension
1321739|NCT00684489|renin-guided therapeutics
1321740|NCT00684463|Antiemetic
1321741|NCT00684450|titration of protamine
1321742|NCT00684450|exact dose
1321743|NCT00684450|protamine
1321744|NCT00684450|neutralize heparin
1321745|NCT00684437|Health Literacy
1321746|NCT00684437|Smoking Risk
1321747|NCT00684437|Focus Group
1321748|NCT00684437|Questionnaire
1321749|NCT00684437|Survey
1321750|NCT00684411|T NHL
1321751|NCT00684411|Gleevec
1321752|NCT00684411|imatinib mesylate
1321753|NCT00684398|Neurofibromatosis Type 1
1321754|NCT00684398|Quality of Life
1321755|NCT00684398|Adaptation
1321756|NCT00684398|Stress and Coping Model
1321757|NCT00684398|NF1
1321758|NCT00684398|Survey
1321759|NCT00684359|Patients having PCI with a drug eluting stent
1321760|NCT00684346|18FDG-PET imaging
1321761|NCT00684346|airway inflammation
1321762|NCT00684346|cystic fibrosis
1321763|NCT00684346|pediatric
1321764|NCT00684346|pulmonary exacerbation
1321765|NCT00684333|painless Injections
1321766|NCT00684333|Subcutaneous Injections
1321767|NCT00684333|Subcutaneous Injections to healthy volunteers
1321768|NCT00684320|Social Anxiety Disorder
1321769|NCT00684320|Information Processing
1321770|NCT00684320|Attention Bias
1321771|NCT00684307|Anticoagulant Treatment
1321772|NCT00684307|Risk Factors For Stroke
1321773|NCT00684294|cancer
1321774|NCT00684294|oncology
1321775|NCT00684294|solid tumor
1321776|NCT00684268|silibinin
1321777|NCT00684268|chronic hepatitis C
1321778|NCT00684268|peginterferon
1321779|NCT00684268|ribavirin
1321780|NCT00684268|nonresponders
1321781|NCT00684268|efficacy of iv. silibinin
1321782|NCT00684268|safety
1321783|NCT00684255|Autoimmune Disease
1321784|NCT00684255|Reduced Intensity Transplant
1321785|NCT00684242|Advanced Cancer
1321786|NCT00684242|Refractory Cancer Pain
1321787|NCT00684242|Lenalidomide
1321788|NCT00684242|Revlimid
1321789|NCT00684242|CC-5103
1321790|NCT00684229|Anesthesia; regional
1321791|NCT00684229|Cancer recurrence
1321792|NCT00684229|Anesthesia; inhalational
1321793|NCT00684229|Analgesia; opioid
1321794|NCT00684216|metastatic
1321795|NCT00684216|ER positive
1321796|NCT00684216|PD during/after first line hormonal treatment
1321797|NCT00684190|Reflux Inhibitor
1321798|NCT00684190|GERD
1321799|NCT00684190|PPI Interaction
1321800|NCT00684177|infection
1321801|NCT00684177|retapamulin
1321802|NCT00684177|secondarily-infected traumatic lesions
1321803|NCT00684177|placebo
1321804|NCT00684164|Euvolemic Hyponatremia
1321805|NCT00684164|Hypervolemic Hyponatremia
1321806|NCT00684164|Neurological injury
1321807|NCT00684151|Lipid-lowering
1321808|NCT00684138|cataract
1321809|NCT00684138|cataract surgery
1321810|NCT00684138|IOL
1321811|NCT00684138|intraocular lens
1321812|NCT00684138|ReSTOR
1321813|NCT00684138|Replacement of cataract
1321814|NCT00684125|late cardiac tamponade
1321815|NCT00684112|pediatrics
1321816|NCT00684112|Scoliosis
1321817|NCT00684112|Gabapentin
1321818|NCT00684099|NSCLC
1321819|NCT00684099|Pemetrexed
1321820|NCT00684099|Docetaxel
1321821|NCT00684073|Suboxone
1321822|NCT00684073|Subutex
1321823|NCT00684073|Buprenorphine
1321824|NCT00684073|Naloxone
1321825|NCT00684060|Acute Myocardial Infarction
1321826|NCT00684060|Global Left Ventricular Ejection Fraction
1321827|NCT00684060|Regional Left Ventricular Ejection Fraction
1321828|NCT00684060|Left Ventricular Mass
1321829|NCT00684060|Infarct Size
1321830|NCT00684060|End Systolic Volume
1321831|NCT00684060|End Diastolic Volume
1321832|NCT00684047|Fibrin Sealant
1321833|NCT00684047|Hemostasis
1321834|NCT00684047|Peripheral Vascular Surgery
1321835|NCT00684034|Redox state in the course of chronic renal insufficiency and hemodialysis.
1321836|NCT00684021|Acute Myocardial Infarction
1321837|NCT00684021|Global Left Ventricular Ejection Fraction
1321838|NCT00684021|Regional Left Ventricular Ejection Fraction
1321839|NCT00684021|Left Ventricular Mass
1321840|NCT00684021|Infarct Size
1321841|NCT00684021|End Systolic Volume
1321842|NCT00684021|End Diastolic Volume
1321843|NCT00684008|interleukin-7
1321844|NCT00684008|immune based therapies
1321845|NCT00684008|graft vs host disease
1321846|NCT00684008|immune reconstitution
1321847|NCT00684008|infection
1321848|NCT00684008|lymphopenia
1321849|NCT00684008|hematopoetic stem cell transplantation
1321850|NCT00684008|bone marrow transplantation
1321851|NCT00684008|peripheral blood stem cell transplant
1321852|NCT00684008|immunosuppression
1321853|NCT00683995|Pain, Cancer
1321854|NCT00683982|nitazoxanide
1321855|NCT00683982|Probiotics
1321856|NCT00683982|Diarrhea
1321857|NCT00683982|Rotavirus
1321858|NCT00683982|Children
1321859|NCT00683943|Spinocerebellar Ataxia
1321860|NCT00683943|Lithium
1321861|NCT00683917|Uterine fibroids
1321862|NCT00683917|Fibroids
1321863|NCT00683891|FOCUS
1321864|NCT00683891|Weight gain
1321865|NCT00683891|Sialorrhea
1321866|NCT00683891|Treatment refractory schizophrenia
1321867|NCT00683891|FazaClo
1321868|NCT00683891|Treatment resistant schizophrenia
1321869|NCT00683891|clozapine
1321870|NCT00683891|Hypersalivation
1321871|NCT00683865|Antibiotic treatment
1321872|NCT00683865|Pelvic infection
1321873|NCT00683865|Interventional study
1321874|NCT00683865|Female
1321875|NCT00683852|Depression
1321876|NCT00683839|Tobacco
1321877|NCT00683839|Smoking
1321878|NCT00683839|Smokeless
1321879|NCT00683839|Cessation
1321880|NCT00683839|Public health clinic
1321881|NCT00683839|Dental patients
1321882|NCT00683839|5 As
1321883|NCT00683839|NRT
1321884|NCT00683839|Tobacco Quit Line
1321885|NCT00683839|Smokeless tobacco
1321886|NCT00683826|Leucine
1321887|NCT00683826|Weight Loss
1321888|NCT00683813|cardiac rehabilitation
1321889|NCT00683813|telehealth
1321890|NCT00683813|Internet
1321891|NCT00683800|Menopause
1321892|NCT00683800|Hot Flush
1321893|NCT00683800|Hot Flash
1321894|NCT00683800|Desvenlafaxine succinate Sustained Release
1321895|NCT00683787|recurrent gastric cancer
1321896|NCT00683787|stage IV gastric cancer
1321897|NCT00683787|adenocarcinoma of the stomach
1321898|NCT00683761|High grade recurrent glioma
1321899|NCT00683761|Phase 2
1321900|NCT00683761|Phase 1
1321901|NCT00683761|Multi-center
1321902|NCT00683761|Open label
1321903|NCT00683761|Multiple dose
1321904|NCT00683761|Brain Cancer
1321905|NCT00683761|Brain Tumor
1321906|NCT00683761|GBM
1321907|NCT00683761|glioma
1321908|NCT00683761|glioblastoma
1321909|NCT00683761|astrocytoma
1321910|NCT00683761|oligodendroglioma
1321911|NCT00683761|131I-TM601
1321912|NCT00683761|TM601
1321913|NCT00683748|Transplantation
1321914|NCT00683748|Immunological monitoring
1321915|NCT00683748|Immunological risk
1321916|NCT00683748|T cell reactivity
1321917|NCT00683748|Cellular immunity
1321918|NCT00683735|Incretin, DPP-4, metformin, sitagliptin, insulin secretion
1321919|NCT00683722|COPD
1321920|NCT00683722|Airflow Obstruction, Chronic
1321921|NCT00683722|Chronic Airflow Obstruction
1321922|NCT00683722|Chronic Obstructive Airway Disease
1321923|NCT00683722|Chronic Obstructive Lung Disease
1321924|NCT00683722|Chronic Obstructive Pulmonary Disease
1321925|NCT00683722|Pulmonary Emphysema
1321926|NCT00683722|Chronic Bronchitis
1321927|NCT00683722|Mesenchymal Stem Cells
1321928|NCT00683722|MSCs
1321929|NCT00683722|Adult Human Stem Cells
1321930|NCT00683722|Osiris
1321931|NCT00683722|Prochymal
1321932|NCT00683709|Bipolar and Schizoaffective Disorder
1321933|NCT00683709|Clozapine
1321934|NCT00683709|Metabolic Side Effects
1321935|NCT00683709|Diet & Exercise
1321936|NCT00683709|BMI
1321937|NCT00683696|Cardiac Resynchronization Therapy
1321938|NCT00683696|Heart Failure
1321939|NCT00683696|Ventricular Dyssynchrony
1321940|NCT00683696|Mechanical Dyssynchrony
1321941|NCT00683696|Intraventricular Dyssynchrony
1321942|NCT00683696|Echocardiography
1321943|NCT00683696|Normal QRS
1321944|NCT00683696|Heart Disease
1321945|NCT00683696|EchoCRT
1321946|NCT00683683|cardiac arrest, hypothermia, knowledge translation
1321947|NCT00683631|liver cancer
1321948|NCT00683631|liver tumor
1321949|NCT00683631|HCC
1321950|NCT00683631|hepatocellular carcinoma
1321951|NCT00683631|hepatoma
1321952|NCT00683618|HMG-CoA
1321953|NCT00683618|LDL-C
1321954|NCT00683618|CHD
1321955|NCT00683579|HAART
1321956|NCT00683579|DHHS guidelines
1321957|NCT00683579|Treatment Naive
1321958|NCT00683566|parkinson
1321959|NCT00683553|Acute Renal Failure
1321960|NCT00683553|Acute Kidney Injury
1321961|NCT00683540|implementation
1321962|NCT00683540|evaluation
1321963|NCT00683540|research methodology
1321964|NCT00683540|intervention
1321965|NCT00683527|Iron supplementation
1321966|NCT00683527|Timing
1321967|NCT00683527|Serum ferritin
1321968|NCT00683527|Very low birth weight infants
1321969|NCT00683514|Untreated locally advanced inoperable stage IIIA or stage IIIB NSCLC amenable to radical radiotherapy to a dose of 66 Gy
1321970|NCT00683501|ocular hypertension
1321971|NCT00683501|elevated IOP
1321972|NCT00683501|glaucoma
1321973|NCT00683501|neuroprotection
1321974|NCT00683488|Substance Abuse
1321975|NCT00683488|Adolescent community reinforcement approach
1321976|NCT00683488|Adolescent Risk Behavior Assessment
1321977|NCT00683488|Child and Adolescent Services Assessment
1321978|NCT00683488|Cognitive behavioral therapy
1321979|NCT00683488|Cognitive Therapy Rating Scale
1321980|NCT00683488|Individual behavior therapy
1321981|NCT00683488|Individual cognitive problem solving
1321982|NCT00683488|Motivational enhancement therapy
1321983|NCT00683488|HIV-Positive Youth With Substance Abuse
1321984|NCT00683488|Complementary Therapies
1321985|NCT00683475|Prostate Cancer
1321986|NCT00683449|Asthma
1321987|NCT00683449|Dose-Escalation
1321988|NCT00683449|Controlled
1321989|NCT00683449|MN-221
1321990|NCT00683436|insomnia
1321991|NCT00683397|assess
1321992|NCT00683397|prevalence
1321993|NCT00683397|thrombophilia
1321994|NCT00683397|common
1321995|NCT00683397|VTE
1321996|NCT00683397|risk factors
1321997|NCT00683397|patients
1321998|NCT00683384|Arthritis
1321999|NCT00683384|psoriatic
1322000|NCT00683371|Chronic Rhinosinusitis
1322001|NCT00683371|Sinus Disease
1322002|NCT00683371|Allergy
1322003|NCT00683371|Maxillary Sinus
1322004|NCT00683371|Microarray
1322005|NCT00683358|cancer
1322006|NCT00683358|pancreas
1322007|NCT00683358|advanced
1322008|NCT00683358|peptide
1322009|NCT00683358|vaccination
1322010|NCT00683358|VEGFR1
1322011|NCT00683358|HLA
1322012|NCT00683358|gemcitabine
1322013|NCT00683358|IFA
1322014|NCT00683358|Cancer of Pancreas
1322015|NCT00683358|Neoplasms, Pancreatic
1322016|NCT00683358|Pancreas Cancer
1322017|NCT00683332|Observational study
1322018|NCT00683332|Tigecycline
1322019|NCT00683332|infection
1322020|NCT00683332|skin
1322021|NCT00683332|abdominal
1322022|NCT00683319|long-term effects secondary to cancer therapy in children
1322023|NCT00683319|cognitive/functional effects
1322024|NCT00683319|ototoxicity
1322025|NCT00683319|childhood infratentorial ependymoma
1322026|NCT00683319|childhood supratentorial ependymoma
1322027|NCT00683293|Laparoscopic Hysterectomy
1322028|NCT00683293|Robot-assisted Laparoscopic Hysterectomy
1322029|NCT00683293|Robot-assisted Surgery
1322030|NCT00683280|Contingency Management
1322031|NCT00683280|Cigarette Smoking Cessation
1322032|NCT00683280|varenicline
1322033|NCT00683267|THA, Total hip arthroplasty, total hip replacement
1322034|NCT00683254|nasal obstruction
1322035|NCT00683254|nasal stent
1322036|NCT00683241|Vaccine
1322037|NCT00683241|Ovarian
1322038|NCT00683241|Peritoneal
1322039|NCT00683228|Second hand Smoke
1322040|NCT00683202|Assisted reproduction
1322041|NCT00683202|Ovarian response
1322042|NCT00683202|Uteroplacental hemodynamics
1322043|NCT00683202|Doppler ultrasonography
1322044|NCT00683202|Implantation rate
1322045|NCT00683202|Pregnancy rate
1322046|NCT00683202|Live birth rate
1322047|NCT00683189|MLD
1322048|NCT00683176|Diabetic Macular Edema
1322049|NCT00683176|OCT
1322050|NCT00683163|Combination of PTH and ibandronate
1322051|NCT00683163|Bone marker formation
1322052|NCT00683163|Postmenopausal
1322053|NCT00683163|Trabecular spine BMD
1322054|NCT00683150|Endothelial Function
1322055|NCT00683150|Abdominal Surgery
1322056|NCT00683150|Thoracic Surgery
1322057|NCT00683150|Vendy's-DTM Machine
1322058|NCT00683150|Digital Thermal Monitoring
1322059|NCT00683150|DTM
1322060|NCT00683124|Marfan Syndrome
1322061|NCT00683124|Losartan
1322062|NCT00683124|Nebivolol
1322063|NCT00683124|Transforming Growth Factor Beta
1322064|NCT00683124|Aortic Root Dilation
1322065|NCT00683111|acute coronary syndrome
1322066|NCT00683111|acute myocardial infarction
1322067|NCT00683111|aspirin
1322068|NCT00683111|clopidogrel
1322069|NCT00683111|heparin
1322070|NCT00683111|thrombolytic
1322071|NCT00683111|famotidine
1322072|NCT00683111|esomeprazole
1322073|NCT00683098|recurrent hernia
1322074|NCT00683098|endoscopic total extraperitoneal repair
1322075|NCT00683098|inguinal pain
1322076|NCT00683098|questionnaire
1322077|NCT00683085|cancer
1322078|NCT00683085|pancreas
1322079|NCT00683085|advanced
1322080|NCT00683085|peptide
1322081|NCT00683085|vaccination
1322082|NCT00683085|VEGFR1
1322083|NCT00683085|HLA
1322084|NCT00683085|gemcitabine
1322085|NCT00683085|IFA
1322086|NCT00683085|Cancer of Pancreas
1322087|NCT00683085|Neoplasms, Pancreas
1322088|NCT00683085|Pancreas Cancer
1322089|NCT00683072|Ventilator
1322090|NCT00683072|patient-ventilator asynchrony
1322091|NCT00683046|Relapsed or refractory acute myelogenous or lymphoid leukemia.
1322092|NCT00683046|Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.Chronic myelogenous leukemia in accelerated phase or blast-crisis.
1322093|NCT00683046|Chronic myelogenous leukemia in chronic phase
1322094|NCT00683046|Chronic myelogenous leukemia in accelerated phase or blast-crisis
1322095|NCT00683046|Recurrent or refractory malignant lymphoma or Hodgkin's disease.
1322096|NCT00683046|Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
1322097|NCT00683046|Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.
1322098|NCT00683046|Severe aplastic anemia after failure of immunosuppressive therapy.
1322099|NCT00683046|Myelodysplastic syndromes (including PNH)
1322100|NCT00683046|Multiple myeloma at high risk for disease recurrence.
1322101|NCT00683033|Contingency Management
1322102|NCT00683033|Cigarette Smoking Cessation
1322103|NCT00683033|Substance Abusers
1322104|NCT00683020|Chronic Diseases
1322105|NCT00683020|Diabetes
1322106|NCT00683020|Vulnerable population
1322107|NCT00683020|Urban populations
1322108|NCT00683020|Disease Management
1322109|NCT00683020|Health Information Technology
1322110|NCT00683020|Safety
1322111|NCT00683020|Health Literacy
1322112|NCT00683020|Level of English Proficiency
1322113|NCT00683007|TE echo
1322114|NCT00683007|hemodilution
1322115|NCT00683007|hypertonic
1322116|NCT00683007|saline
1322117|NCT00683007|Arterial Pressure Cardiac Output
1322118|NCT00682994|Advanced Cancer
1322119|NCT00682994|Family Member
1322120|NCT00682994|Palliative Care
1322121|NCT00682994|Decision Making
1322122|NCT00682994|Information Disclosure
1322123|NCT00682994|Interview
1322124|NCT00682994|Survey
1322125|NCT00682994|Questionnaire
1322126|NCT00682981|ES-SCLC
1322127|NCT00682981|Obatoclax
1322128|NCT00682968|patient non-adherence
1322129|NCT00682968|antihypertensive agents
1322130|NCT00682968|hypertension
1322131|NCT00682955|Diarrhea
1322132|NCT00682955|Zinc Sulphate
1322133|NCT00682955|Efficacy
1322134|NCT00682929|cannabis
1322135|NCT00682929|marijuana
1322136|NCT00682929|Multiple Sclerosis
1322137|NCT00682929|spasticity
1322138|NCT00682916|Obesity
1322139|NCT00682916|Diabetes
1322140|NCT00682916|Soluble Fiber
1322141|NCT00682916|Overweight
1322142|NCT00682903|glucose
1322143|NCT00682903|diabetes
1322144|NCT00682903|glycemia
1322145|NCT00682877|gastroparesis
1322146|NCT00682877|Digestive
1322147|NCT00682877|Gastrointestinal
1322148|NCT00682877|Stomach
1322149|NCT00682877|Motility
1322150|NCT00682877|Non-Invasive
1322151|NCT00682877|Capsule
1322152|NCT00682877|GI
1322153|NCT00682877|Device
1322154|NCT00682877|Digestive System Diseases
1322155|NCT00682838|Treatment compliance
1322156|NCT00682838|Self-management
1322157|NCT00682838|Telemedicine
1322158|NCT00682825|Anesthesia
1322159|NCT00682825|Awareness
1322160|NCT00682825|Bispectral
1322161|NCT00682825|BIS
1322162|NCT00682825|Recall
1322163|NCT00682799|RC
1322164|NCT00682799|RIC
1322165|NCT00682799|MDS
1322166|NCT00682799|SCT
1322167|NCT00682786|rectal
1322168|NCT00682786|rectum
1322169|NCT00682786|cancer
1322170|NCT00682786|carcinoma
1322171|NCT00682760|Botulinum Toxin Type A
1322172|NCT00682760|Blepharospasm
1322173|NCT00682747|xerostomia
1322174|NCT00682747|hyperbaric oxygenation
1322175|NCT00682747|radiotherapy
1322176|NCT00682721|Bacterial Vaginosis
1322177|NCT00682721|Herpes Simplex Virus Type II
1322178|NCT00682708|malnutrition
1322179|NCT00682708|ready to use food
1322180|NCT00682708|Niger
1322181|NCT00682695|stroke
1322182|NCT00682695|brain attack
1322183|NCT00682695|hemorrhagic stroke
1322184|NCT00682695|risk factors
1322185|NCT00682682|Pain distraction
1322186|NCT00682682|Analgesic interventions
1322187|NCT00682682|Burn patients
1322188|NCT00682669|Asthma
1322189|NCT00682669|Mindfulness-based stress reduction
1322190|NCT00682669|Peak expiratory flow rate
1322191|NCT00682669|Spirometry
1322192|NCT00682669|Quality of life
1322193|NCT00682656|cutaneous leishmaniasis
1322194|NCT00682656|azithromycin
1322195|NCT00682656|N- methyl glucamine
1322196|NCT00682643|Perennial Allergic Rhinitis
1322197|NCT00682643|fluticasone furoate
1322198|NCT00682643|ocular safety
1322199|NCT00682630|Malaria
1322200|NCT00682630|anti-malarial
1322201|NCT00682630|pyronaridine
1322202|NCT00682630|ACT
1322203|NCT00682617|hip
1322204|NCT00682617|osteoarthritis
1322205|NCT00682617|exercise
1322206|NCT00682617|disability
1322207|NCT00682617|physical function
1322208|NCT00682604|Family Health Program; Food consumption; Nutritional status
1322209|NCT00682591|hepatitis C
1322210|NCT00682591|drug substitution
1322211|NCT00682591|neurocognitive
1322212|NCT00682591|patients with stable drug substitution therapy
1322213|NCT00682591|patients with interferon-based antiviral therapy
1322214|NCT00682578|falciparum malaria
1322215|NCT00682578|vivax malaria
1322216|NCT00682578|dihydroartemisinin-piperaquine
1322217|NCT00682539|diabetic retinopathy
1322218|NCT00682539|macular edema
1322219|NCT00682539|intravitreal Avastin/ Triamcinolone / Lucentis
1322220|NCT00682526|EMS patients with intention to treat with coronary reperfusion therapy (PCI or thrombolytics) based on their initial presentation
1322221|NCT00682513|dystonia
1322222|NCT00682513|parkinsonism
1322223|NCT00682513|rapid-onset dystonia-parkinsonism
1322224|NCT00682513|RDP
1322225|NCT00682513|Alternating Hemiplegia of Childhood
1322226|NCT00682513|AHC
1322227|NCT00682500|Pneumonia
1322228|NCT00682500|Aspiration
1322229|NCT00682500|Drowning
1322230|NCT00682500|inhalation
1322231|NCT00682487|Myocardial infarction
1322232|NCT00682487|Stress
1322233|NCT00682487|Hair Cortisol
1322234|NCT00682474|Cigarette smoking
1322235|NCT00682474|Nicotine dependence
1322236|NCT00682474|Adolescents
1322237|NCT00682474|Youth
1322238|NCT00682474|School health
1322239|NCT00682474|Randomized controlled trial
1322240|NCT00682461|Nicotine Tolerability NRT
1322241|NCT00682448|Olanzapine
1322242|NCT00682448|Zyprexa
1322243|NCT00682448|Weight Gain
1322244|NCT00682448|Antipsychotics
1322245|NCT00682448|Metformin
1322246|NCT00682448|Glucophage
1322247|NCT00682448|Bipolar Disorder
1322248|NCT00682448|Schizophrenia
1322249|NCT00682448|Depression
1322250|NCT00682448|Diabetes
1322251|NCT00682448|Side effects
1322252|NCT00682448|Metabolic complications
1322253|NCT00682448|Prevention
1322254|NCT00682448|Treatment
1322255|NCT00682448|Metabolic side effects of olanzapine
1322256|NCT00682435|Nonedlerly patients with acute moderate to severe pain
1322257|NCT00682422|pediatrics, overweight, obese, behavioral intervention
1322258|NCT00682383|Advanced NSCLC
1322259|NCT00682383|Lung Cancer
1322260|NCT00682383|Mount Sinai Medical Center CCOP
1322261|NCT00682357|Osteoarthritis, intra articular steroids
1322262|NCT00682318|Fish oil
1322263|NCT00682318|red wine
1322264|NCT00682318|alcohol
1322265|NCT00682318|oxidative stress
1322266|NCT00682318|Healthy volunteers
1322267|NCT00682305|Acute Lymphoblastic Leukemia
1322268|NCT00682305|Hematopoeitic Stem Cell Transplantation
1322269|NCT00682292|Renal transplantation
1322270|NCT00682292|Immunisation
1322271|NCT00682292|Acute rejection
1322272|NCT00682292|Induction therapy
1322273|NCT00682292|Thymoglobulin
1322274|NCT00682292|Daclizumab
1322275|NCT00682292|Rejection in sensitized renal transplant recipients
1322276|NCT00682279|lapatinib
1322277|NCT00682279|GW572016
1322278|NCT00682279|topotecan
1322279|NCT00682279|oral topotecan
1322280|NCT00682279|SK&F-104864
1322281|NCT00682279|EGFR
1322282|NCT00682279|ErbB1
1322283|NCT00682279|HER-2/neu
1322284|NCT00682279|ErbB2
1322285|NCT00682279|BCRP
1322286|NCT00682266|Adolescent
1322287|NCT00682266|Overweight
1322288|NCT00682266|Exercise
1322289|NCT00682266|multidisciplinary approach
1322290|NCT00682266|Oxygen uptake
1322291|NCT00682266|Flow mediated dilatation
1322292|NCT00682266|Cardiovascular Risk Factors
1322293|NCT00682253|SPECT/CT
1322294|NCT00682253|MRI
1322295|NCT00682253|Breast neoplasms
1322296|NCT00682240|retinal morphology
1322297|NCT00682240|laser treatment
1322298|NCT00682240|pascal laser
1322299|NCT00682240|HD-OCT
1322300|NCT00682227|Epitope peptide, CTL, Esophageal cancer, Vaccination
1322301|NCT00682214|25(OH)D, muscle strength
1322302|NCT00682201|Pregnancy
1322303|NCT00682201|Blood pressure
1322304|NCT00682201|Cardiac output
1322305|NCT00682188|Overweight
1322306|NCT00682188|Obesity
1322307|NCT00682188|Adolescents
1322308|NCT00682188|Youth
1322309|NCT00682188|School health
1322310|NCT00682188|Randomized controlled trial
1322311|NCT00682188|Intervention study
1322312|NCT00682175|Congestive Heart Failure
1322313|NCT00682162|acupuncture
1322314|NCT00682162|randomised controlled trial
1322315|NCT00682162|placebo
1322316|NCT00682162|sham laser
1322317|NCT00682162|vasomotor rhinitis
1322318|NCT00682149|Oxidative stress
1322319|NCT00682149|malondialdehyde
1322320|NCT00682149|glutathione
1322321|NCT00682149|diabetes
1322322|NCT00682149|polyphenol containing antioxidants
1322323|NCT00682149|diet rich in vegetables
1322324|NCT00682149|weekly aerobic exercise
1322325|NCT00682136|postoperative analgesia
1322326|NCT00682136|abdominal surgery
1322327|NCT00682136|ropivacaine
1322328|NCT00682136|local anaesthesia
1322329|NCT00682136|tap block
1322330|NCT00682136|pain management
1322331|NCT00682123|19-norandrostenedione
1322332|NCT00682123|steroids
1322333|NCT00682123|drugs in sport
1322334|NCT00682123|World Anti-Doping Agency
1322335|NCT00682110|End-stage liver disease
1322336|NCT00682110|Hemodynamic measurements
1322337|NCT00682110|Hyperdynamic circulation
1322338|NCT00682110|Pulmonary artery catheter
1322339|NCT00682110|Cardiac output
1322340|NCT00682084|Cushing's syndrome
1322341|NCT00682084|Glucose tolerance
1322342|NCT00682084|Insulin sensitivity
1322343|NCT00682084|Substrate metabolism
1322344|NCT00682084|Body composition
1322345|NCT00682071|Ultrasound-guided
1322346|NCT00682071|embryo transfer
1322347|NCT00682071|in-vitro fertilization
1322348|NCT00682058|body composition
1322349|NCT00682058|weight loss
1322350|NCT00682058|fat
1322351|NCT00682058|fat distribution
1322352|NCT00682058|fat free mass
1322353|NCT00682058|organ
1322354|NCT00682058|resting energy expenditure
1322355|NCT00682045|tuberculosis
1322356|NCT00682045|transplantation
1322357|NCT00682032|NSCLC
1322358|NCT00682019|Erectile Dysfunction
1322359|NCT00682019|Vardenafil
1322360|NCT00682006|Omphalitis
1322361|NCT00682006|4% Chlorhexidine
1322362|NCT00682006|Newborns
1322363|NCT00681993|cosmetic
1322364|NCT00681993|effect
1322365|NCT00681993|breast
1322366|NCT00681993|irradiation
1322367|NCT00681993|concurrent
1322368|NCT00681993|chemotherapy
1322369|NCT00681993|potential acute
1322370|NCT00681993|late skin
1322371|NCT00681993|subcutaneous toxicities
1322372|NCT00681980|TSP/HAM, HTLV-1, treatment
1322373|NCT00681967|squamous cell cancer of the head & neck
1322374|NCT00681967|Gefitinib
1322375|NCT00681967|IRESSA
1322376|NCT00681967|EGFR Inhibitor
1322377|NCT00681967|EGFR-tyrosine kinase inhibitor
1322378|NCT00681967|Subjects with histologically proven squamous cell cancer of the head & neck
1322379|NCT00681967|Cohort 1:qualifying for postoperative radiotherapy
1322380|NCT00681967|(pT3, pT4, pN2b, pN2c, pN3).
1322381|NCT00681967|Cohort 2:qualifying for definite chemoradiotherapy
1322382|NCT00681967|(Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N;
1322383|NCT00681967|Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity,
1322384|NCT00681967|glottic and supraglottic larynx; Any TN1-3, T3-4 any N;
1322385|NCT00681967|Hypopharynx: T1N1-3, T2-4 and N)
1322386|NCT00681954|TRALI
1322387|NCT00681954|Randomized Autologous Transfusion
1322388|NCT00681954|Intra-Operative Testing of Pulmonary Function
1322389|NCT00681928|stage I breast cancer
1322390|NCT00681928|stage II breast cancer
1322391|NCT00681928|stage IIIA breast cancer
1322392|NCT00681928|stage IIIB breast cancer
1322393|NCT00681928|stage IIIC breast cancer
1322394|NCT00681915|Phase I
1322395|NCT00681915|Pharmacokinetics
1322396|NCT00681902|Pediatric
1322397|NCT00681902|Pain
1322398|NCT00681902|Needle
1322399|NCT00681902|Emergency
1322400|NCT00681902|Phlebotomy
1322401|NCT00681902|Intravenous
1322402|NCT00681902|Lidocaine
1322403|NCT00681902|Local
1322404|NCT00681902|Anesthesia
1322405|NCT00681876|Metastatic colorectal cancer
1322406|NCT00681876|Second line
1322407|NCT00681876|Irinotecan
1322408|NCT00681876|Erbitux (Cetuximab)
1322409|NCT00681876|Avastin (Bevacizumab)
1322410|NCT00681850|Diabetes
1322411|NCT00681850|Benchmarking
1322412|NCT00681850|quality of patient care
1322413|NCT00681850|Diabetic Population
1322414|NCT00681837|gastroesophageal reflux
1322415|NCT00681837|prevalence
1322416|NCT00681837|childhood
1322417|NCT00681837|France
1322418|NCT00681811|Metazyme
1322419|NCT00681811|Late Infantile Metachromatic Leukodystrophy
1322420|NCT00681798|pancreatic cancer
1322421|NCT00681798|pancreatic adenocarcinoma
1322422|NCT00681798|pancreas cancer
1322423|NCT00681798|dose escalation study
1322424|NCT00681798|locally advanced unresectable pancreatic adenocarcinoma
1322425|NCT00681798|Zactima
1322426|NCT00681798|Vandetanib
1322427|NCT00681798|ZD6474
1322428|NCT00681785|thrombophylaxis and transurethral surgery
1322429|NCT00681772|Erectile Dysfunction
1322430|NCT00681772|Vardenafil
1322431|NCT00681759|Low Dose Aspirin (LDA)
1322432|NCT00681759|Cardiovascular disease
1322433|NCT00681759|Low Dose Aspirin (LDA) use in in subjects with cardiovascular risk or disease
1322434|NCT00681746|Anxiety
1322435|NCT00681746|GABA receptors
1322436|NCT00681746|Positron Emission Tomography
1322437|NCT00681746|PET
1322438|NCT00681746|phase I
1322439|NCT00681733|NASH Pentoxifylline Pioglitazone
1322440|NCT00681720|Anxiety
1322441|NCT00681720|GABA receptors
1322442|NCT00681720|Positron Emission Tomography
1322443|NCT00681720|PET
1322444|NCT00681720|phase I
1322445|NCT00681707|Hypertension
1322446|NCT00681707|Post stroke
1322447|NCT00681707|JNC7
1322448|NCT00681707|2007 ESH-ESC guidelines
1322449|NCT00681707|survey
1322450|NCT00681694|brachytherapy
1322451|NCT00681694|radioactive seed implants
1322452|NCT00681681|stroke
1322453|NCT00681681|vascular marker
1322454|NCT00681681|stroke risk
1322455|NCT00681681|risk factors
1322456|NCT00681681|sex differences
1322457|NCT00681668|Postpartum Depression
1322458|NCT00681668|Quetiapine
1322459|NCT00681668|Psychotic Symptoms
1322460|NCT00681642|Corneal epithelial wound
1322461|NCT00681642|Human autoserum
1322462|NCT00681642|Cord blood
1322463|NCT00681629|Schizophrenia
1322464|NCT00681629|Integrated Care
1322465|NCT00681629|Quetiapine
1322466|NCT00681616|Anterior compartment syndrome
1322467|NCT00681616|Tibia
1322468|NCT00681616|Trauma
1322469|NCT00681616|Blood circulation
1322470|NCT00681616|Nerve compression syndromes
1322471|NCT00681603|corneal neovascularization
1322472|NCT00681603|lipid keratopathy
1322473|NCT00681603|penetrating keratopathy
1322474|NCT00681603|bevacizumab
1322475|NCT00681603|Avastin
1322476|NCT00681603|subconjunctival injection
1322477|NCT00681590|vitamin D
1322478|NCT00681590|deficiency
1322479|NCT00681590|elderly
1322480|NCT00681577|Peptide Vaccine
1322481|NCT00681577|URLC10
1322482|NCT00681577|KOC1
1322483|NCT00681577|VEGFR1
1322484|NCT00681577|VEGFR2
1322485|NCT00681564|Periodontitis
1322486|NCT00681564|Oral health
1322487|NCT00681564|Cardiovascular disease
1322488|NCT00681551|Detection of brain metastasis by MRI
1322489|NCT00681551|Magnevist
1322490|NCT00681551|Brain metastasis
1322491|NCT00681551|Meglumine gadopentetate
1322492|NCT00681538|Spasticity
1322493|NCT00681538|Multiple Sclerosis
1322494|NCT00681512|NSCLC
1322495|NCT00681512|lung cancer
1322496|NCT00681512|non small cell lung cancer
1322497|NCT00681512|lung carcinoma
1322498|NCT00681499|Quality of Life
1322499|NCT00681499|Liver Neoplasms
1322500|NCT00681499|Surgical procedures, Operative
1322501|NCT00681486|Ghrelin
1322502|NCT00681486|Nutrition
1322503|NCT00681486|Cancer patients
1322504|NCT00681486|Survival
1322505|NCT00681473|proton radiation therapy
1322506|NCT00681473|photon radiation therapy
1322507|NCT00681460|gestational diabetes
1322508|NCT00681460|birth weight
1322509|NCT00681460|fetal growth
1322510|NCT00681460|insulin resistance
1322511|NCT00681460|oxidative stress
1322512|NCT00681460|inflammatory reaction
1322513|NCT00681460|Fetal Development
1322514|NCT00681447|lumbar disc herniation
1322515|NCT00681447|discogenic pain
1322516|NCT00681447|lumbar interlaminar epidural
1322517|NCT00681447|injections
1322518|NCT00681434|stroke
1322519|NCT00681434|upper extremity
1322520|NCT00681434|hemiparesis
1322521|NCT00681421|Peptide Vaccine
1322522|NCT00681421|URLC10
1322523|NCT00681421|VEGFR1
1322524|NCT00681421|VEGFR2
1322525|NCT00681408|Steatohepatitis
1322526|NCT00681408|NASH
1322527|NCT00681408|NAFLD
1322528|NCT00681408|omega 3 fatty acids
1322529|NCT00681408|Exercise conditioning
1322530|NCT00681382|Asthma
1322531|NCT00681382|use of asthma medication
1322532|NCT00681382|asthma control
1322533|NCT00681382|telephone survey
1322534|NCT00681382|patient's perception
1322535|NCT00681369|breast cancer
1322536|NCT00681369|fulvestrant
1322537|NCT00681369|longitudinal study
1322538|NCT00681369|France
1322539|NCT00681356|TKA
1322540|NCT00681356|Total knee arthroplasty
1322541|NCT00681356|Total knee replacement
1322542|NCT00681356|Knee surgery
1322543|NCT00681343|Randomized
1322544|NCT00681343|study
1322545|NCT00681343|effectiveness/toxicity
1322546|NCT00681343|induction therapy
1322547|NCT00681343|recipients
1322548|NCT00681330|Peptide Vaccine
1322549|NCT00681330|URLC10
1322550|NCT00681330|TTK
1322551|NCT00681330|KOC1
1322552|NCT00681317|Phase I
1322553|NCT00681317|Pharmacokinetics
1322554|NCT00681304|Resected Breast Cancer
1322555|NCT00681304|Breast Cancer
1322556|NCT00681291|surgical mesh
1322557|NCT00681291|inguinal hernia repair
1322558|NCT00681291|chronic groin pain
1322559|NCT00681278|Hypertension
1322560|NCT00681278|Type II DM
1322561|NCT00681278|JNC7
1322562|NCT00681278|2007 ESH-ESC guidelines
1322563|NCT00681278|survey
1322564|NCT00681265|ocular lubricants
1322565|NCT00681252|Peptide Vaccine
1322566|NCT00681252|URLC10
1322567|NCT00681252|VEGFR1
1322568|NCT00681252|VEGFR2
1322569|NCT00681239|childhood
1322570|NCT00681239|epilepsy
1322571|NCT00681239|intractable
1322572|NCT00681239|seizures
1322573|NCT00681239|Atkins
1322574|NCT00681239|ketogenic
1322575|NCT00681226|peripheral arterial disease
1322576|NCT00681226|angiotensin converting enzyme inhibitors
1322577|NCT00681226|exercise
1322578|NCT00681200|Blood Pressure Reduction
1322579|NCT00681200|Stress Reactivity and Recovery
1322580|NCT00681200|Meditation
1322581|NCT00681200|Transcendental Meditation
1322582|NCT00681200|Stress Reduction
1322583|NCT00681200|Stress Management
1322584|NCT00681174|Care, Postoperative
1322585|NCT00681174|Analgesia
1322586|NCT00681174|Analgesics, Opioid
1322587|NCT00681174|Morphine
1322588|NCT00681174|Remifentanil
1322589|NCT00681174|Oxycodone
1322590|NCT00681174|Anesthesia, Regional
1322591|NCT00681174|Anesthesia, Intravenous
1322592|NCT00681174|Preanesthetic Medication
1322593|NCT00681174|Analgesia, Patient-Controlled
1322594|NCT00681161|obstructive sleep apnea
1322595|NCT00681161|OSA
1322596|NCT00681161|diabetes
1322597|NCT00681161|pre-diabetic condition
1322598|NCT00681161|obesity
1322599|NCT00681161|blood glucose
1322600|NCT00681161|continuous positive airway pressure
1322601|NCT00681161|CPAP
1322602|NCT00681148|Prostate specific antigen (PSA)
1322603|NCT00681148|Prostate cancer
1322604|NCT00681148|Lower urinary tract symptoms
1322605|NCT00681148|Radioactive seed implantation
1322606|NCT00681135|orthodontics
1322607|NCT00681135|toothbrush
1322608|NCT00681135|interdental brush
1322609|NCT00681135|oral hygiene
1322610|NCT00681122|Breast Cancer
1322611|NCT00681122|hormone therapy
1322612|NCT00681122|aromatase inhibitor
1322613|NCT00680342|hepatitis C
1322614|NCT00680329|Adherence
1322615|NCT00680329|Compliance
1322616|NCT00680329|Glaucoma
1322617|NCT00680329|Ocular Hypertension
1322618|NCT00680316|Pulmozyme
1322619|NCT00680316|CF
1322620|NCT00680303|Early Stuttering
1322621|NCT00680303|Lidcombe Program
1322622|NCT00680303|Stuttering Treatment
1322623|NCT00680303|Efficiency
1322624|NCT00680303|Efficacy
1322625|NCT00680303|Service Delivery
1322626|NCT00680303|Models of intervention
1322627|NCT00680290|exercise, quality of life, cpx
1322628|NCT00680277|spirulina
1322629|NCT00680277|carotenoids
1322630|NCT00680264|Treatment Outcomes
1322631|NCT00680264|Scoliosis
1322632|NCT00680264|Cerebral Palsy
1322633|NCT00679211|HER2-positive breast cancer
1322634|NCT00679211|HER2
1322635|NCT00679211|MBC
1322636|NCT00679211|Trastuzumab emtansine
1322637|NCT00679198|osteoporosis
1322638|NCT00679198|fracture
1322639|NCT00679198|communication
1322640|NCT00679198|prescription medication
1322641|NCT00679185|fatigue
1322642|NCT00679185|stage I breast cancer
1322643|NCT00679185|stage II breast cancer
1322644|NCT00679185|stage IIIA breast cancer
1322645|NCT00679185|stage IIIB breast cancer
1322646|NCT00679185|stage IIIC breast cancer
1322647|NCT00679185|lymphedema
1322648|NCT00679133|c-Met
1322649|NCT00679133|VEGFR
1322650|NCT00679133|Ron
1322651|NCT00679133|Cancer
1322652|NCT00679133|Tumor
1322653|NCT00679133|Safety
1322654|NCT00679133|Phase 1
1322655|NCT00679120|Unicompartmental osteoarthrosis
1322656|NCT00679120|RSA
1322657|NCT00679120|Bone-remodelling
1322658|NCT00679107|Degenerative Disc Disease
1322659|NCT00679068|respiratory mechanics
1322660|NCT00679068|bosentan
1322661|NCT00679068|exercise capacity
1322662|NCT00679042|Diabetes Mellitus Type 1
1322663|NCT00679042|Type 1 Diabetes Mellitus
1322664|NCT00679042|Islets of Langerhans Transplantation
1322665|NCT00679042|Allogeneic Islet transplantation
1322666|NCT00681096|Low back pain in nurses
1322667|NCT00681083|Obstructive Sleep Apnea
1322668|NCT00681083|Humidification
1322669|NCT00681083|Continuous Positive Airway Pressure
1322670|NCT00681070|laceration
1322671|NCT00681070|wound management
1322672|NCT00681070|absorbable sutures
1322673|NCT00681070|cosmetic outcomes
1322674|NCT00681044|monoclonal immunoglobulin deposition disease
1322675|NCT00681044|light chain deposition disease
1322676|NCT00681018|premature
1322677|NCT00681018|infants
1322678|NCT00681005|PPI test
1322679|NCT00681005|gastroesophageal reflux disease
1322680|NCT00681005|CYP2C19
1322681|NCT00681005|rabeprazole
1322682|NCT00681005|pantoprazole
1322683|NCT00680992|Giant Cell Tumor of Bone
1322684|NCT00680979|Prevention
1322685|NCT00680979|Obesity
1322686|NCT00680979|Binge Eating
1322687|NCT00680979|Adolescents
1322688|NCT00680979|Overweight
1322689|NCT00680979|Weight Gain
1322690|NCT00680966|Treatment efficacy
1322691|NCT00680966|Family therapy
1322692|NCT00680966|Teens
1322693|NCT00680966|Substance abuse
1322694|NCT00680966|Substance dependence
1322695|NCT00680940|NSCLC
1322696|NCT00680927|Atrial Fibrillation
1322697|NCT00680927|Risk of cardiac arrhythmias
1322698|NCT00680927|Loop recorder
1322699|NCT00680914|Streptococcus pneumoniae
1322700|NCT00680914|pneumococcal conjugate vaccine
1322701|NCT00680901|unresectable
1322702|NCT00680901|HER2
1322703|NCT00680901|TYVERB
1322704|NCT00680901|ErbB2
1322705|NCT00680901|TYKERB
1322706|NCT00680901|capecitabine
1322707|NCT00680901|CapeOx
1322708|NCT00680901|gastric/esophageal cancer
1322709|NCT00680901|GE junction
1322710|NCT00680901|metastatic
1322711|NCT00680901|lapatinib
1322712|NCT00680901|oxaliplatin
1322713|NCT00680888|Psychosis
1322714|NCT00680888|adolescents
1322715|NCT00680888|adherence
1322716|NCT00680888|quetiapine
1322717|NCT00680875|School Based Services
1322718|NCT00680875|Prevention
1322719|NCT00680875|Children
1322720|NCT00680862|HIV
1322721|NCT00680862|screening
1322722|NCT00680849|Type 2 Diabetes Mellitus
1322723|NCT00680849|Coronary Disease
1322724|NCT00680836|Irritable Bowel Syndrome
1322725|NCT00680836|Diarrhea
1322726|NCT00680836|Gulf War
1322727|NCT00680836|Veterans
1322728|NCT00680836|Small intestinal bacterial overgrowth (SIBO)
1322729|NCT00680823|Headache
1322730|NCT00680823|Migraine
1322731|NCT00680823|Ropivacaine
1322732|NCT00680797|Aging
1322733|NCT00680797|Hormones
1322734|NCT00680797|Insulin resistance
1322735|NCT00680784|sprain
1322736|NCT00680784|ankle
1322737|NCT00680784|pain
1322738|NCT00680771|Primary Insomnia
1322739|NCT00680771|Insomnia
1322740|NCT00680771|Good Sleepers
1322741|NCT00680771|Hep B
1322742|NCT00680771|Vaccine
1322743|NCT00680758|male breast cancer
1322744|NCT00680758|stage IV breast cancer
1322745|NCT00680745|Dapagliflozin
1322746|NCT00680745|efficacy
1322747|NCT00680745|safety
1322748|NCT00680745|sulphonylurea
1322749|NCT00680745|Type 2 diabetes
1322750|NCT00680732|Malaria
1322751|NCT00680732|Pregnancy
1322752|NCT00680732|Prevention
1322753|NCT00680732|Chloroquine
1322754|NCT00680732|Sulphadoxine pyrimethamine
1322755|NCT00680732|Maternal anaemia
1322756|NCT00680732|Birth weight
1322757|NCT00680732|Foetal anaemia
1322758|NCT00680719|substance abuse
1322759|NCT00680719|HIV risk
1322760|NCT00680719|Behavior and Mental Disorders
1322761|NCT00680719|HIV Seronegativity
1322762|NCT00680693|IBS, functional gastrointestinal disease
1322763|NCT00680680|Urinary retention secondary to benign prostatic hyperplasia
1322764|NCT00680667|ductal breast carcinoma
1322765|NCT00680667|stage I breast cancer
1322766|NCT00680667|stage II breast cancer
1322767|NCT00680667|stage IIIA breast cancer
1322768|NCT00680667|stage IIIB breast cancer
1322769|NCT00680667|stage IIIC breast cancer
1322770|NCT00680667|estrogen receptor-negative breast cancer
1322771|NCT00680667|progesterone receptor-negative breast cancer
1322772|NCT00680654|Pulmonary hypertension
1322773|NCT00680641|COPD
1322774|NCT00680641|Emphysema
1322775|NCT00680641|Simvastatin
1322776|NCT00680628|Pulmonary Embolism
1322777|NCT00680628|Tenecteplase
1322778|NCT00680628|Enoxaparin
1322779|NCT00680628|Thrombosis
1322780|NCT00680628|Fibrinolytics
1322781|NCT00680615|Smokeless tobacco
1322782|NCT00680602|behavior therapy
1322783|NCT00680602|group therapy
1322784|NCT00680602|psychopharmacology
1322785|NCT00680589|TYRP2 DNA Vaccine
1322786|NCT00680576|adolescent substance abuse
1322787|NCT00680550|Atrial Fibrillation
1322788|NCT00680550|Risk of cardiac Arrhythmias
1322789|NCT00680550|Loop recorder
1322790|NCT00680537|physical therapy program
1322791|NCT00680524|telephone-based intervention for PTSD
1322792|NCT00680511|methamphetamine abuse
1322793|NCT00680498|Age-Related Macular Degeneration
1322794|NCT00680498|Ranibizumab
1322795|NCT00680498|Lucentis
1322796|NCT00680498|Photodynamic Therapy
1322797|NCT00680498|Verteporfin
1322798|NCT00680498|Visudyne
1322799|NCT00680485|GSK580416
1322800|NCT00680485|ketoconazole interaction
1322801|NCT00680485|pleuromutilin
1322802|NCT00680485|oral dose
1322803|NCT00680472|Shoulder pain
1322804|NCT00680472|Pain
1322805|NCT00680472|Ketoprofen
1322806|NCT00680472|Topical Patch
1322807|NCT00680459|central line infection
1322808|NCT00680459|70% ethanol
1322809|NCT00680459|Sepsis
1322810|NCT00680446|Primary Immune Deficiency
1322811|NCT00680446|Subcutaneous
1322812|NCT00680446|Immunoglobulin G
1322813|NCT00680420|pancreas cancer
1322814|NCT00680420|pancreas cyst
1322815|NCT00680420|DNA microarray
1322816|NCT00680407|NASH
1322817|NCT00680407|non-alcoholic steatohepatitis
1322818|NCT00680394|abortion
1322819|NCT00680394|medical abortion
1322820|NCT00680394|mifepristone
1322821|NCT00680394|misoprostol
1322822|NCT00680381|adolescent substance abuse
1322823|NCT00680368|Feasibility
1322824|NCT00680368|Supervision
1322825|NCT00680368|Assessing
1322826|NCT00680355|golden rice carotenoids
1322827|NCT00680355|healthy volunteers
1322828|NCT00680355|retinol equivalence
1322829|NCT00680238|Pregnancy
1322830|NCT00680238|implantation
1322831|NCT00680238|miscarriage
1322832|NCT00680238|sHLA-G
1322833|NCT00680225|Choroidal melanoma
1322834|NCT00680225|Lucentis
1322835|NCT00680225|TTT-ICG
1322836|NCT00680212|dietary beta-carotene
1322837|NCT00680212|vitamin A status
1322838|NCT00680212|intrinsically labeled plant foods
1322839|NCT00680199|Insomnia
1322840|NCT00680199|Primary Insomnia
1322841|NCT00680199|Good Sleepers
1322842|NCT00680199|ERP
1322843|NCT00680173|Chronic Hepatitis C
1322844|NCT00680173|Single nucleotide polymorphisms
1322845|NCT00680173|Sustained virological response
1322846|NCT00680173|Peginterferon
1322847|NCT00680173|Ribavirin
1322848|NCT00680160|Onychomycosis
1322849|NCT00680160|Fungal Nail
1322850|NCT00680147|HPV
1322851|NCT00680147|Gardasil
1322852|NCT00680147|African-American
1322853|NCT00680147|adolescent
1322854|NCT00680147|health behavior
1322855|NCT00680147|sexually transmitted infections
1322856|NCT00680147|This will enroll 300 mothers of teenage girls and boys to identify barriers to HPV vaccination among low-income, African-American teens.
1322857|NCT00680134|Onychomycosis
1322858|NCT00680134|Fungal Nail
1322859|NCT00680121|Alcoholism
1322860|NCT00680121|Benfotiamine
1322861|NCT00680121|Thiamine
1322862|NCT00680095|Onychomycosis
1322863|NCT00680095|Fungal Nail
1322864|NCT00680082|statins
1322865|NCT00680082|rosuvastatin
1322866|NCT00680082|cross sectional study
1322867|NCT00680082|France
1322868|NCT00680082|CV risk factors
1322869|NCT00680069|avian influenza,H5N1,Influenza,parent protocol
1322870|NCT00680056|Pulmonary Disease, Chronic Obstructive
1322871|NCT00680056|Tiotropium
1322872|NCT00680056|Formoterol
1322873|NCT00680056|Bronchodilator Agents
1322874|NCT00680056|Exercise Tolerance
1322875|NCT00680056|Randomized Controlled Trial [Publication Type]
1322876|NCT00680056|COPD
1322877|NCT00680043|anemia
1322878|NCT00680043|chronic kidney disease
1322879|NCT00680043|CKD
1322880|NCT00680043|chronic renal failure
1322881|NCT00680043|CRF
1322882|NCT00680043|erythropoietin
1322883|NCT00680043|EPO
1322884|NCT00680043|erythropoiesis stimulating agent
1322885|NCT00680043|ESA
1322886|NCT00680043|Hematide™
1322887|NCT00680043|hemoglobin
1322888|NCT00680043|Hb
1322889|NCT00680043|Hgb
1322890|NCT00680043|Omontys
1322891|NCT00680043|peginesatide
1322892|NCT00680043|red blood cell
1322893|NCT00680043|red blood cell production
1322894|NCT00680030|impedance
1322895|NCT00680030|manometry
1322896|NCT00680030|motility disorders
1322897|NCT00680030|ineffective motility
1322898|NCT00680030|diffuse esophageal spasms
1322899|NCT00680030|achlasia-like dysmotility
1322900|NCT00680017|Dyslipidemia
1322901|NCT00680017|Kidney Disease
1322902|NCT00680004|Dynamic CTA
1322903|NCT00680004|follow-up
1322904|NCT00680004|EVAR
1322905|NCT00679991|arteriovenous fistula
1322906|NCT00679991|AVF
1322907|NCT00679991|hemodialysis
1322908|NCT00679991|vascular access
1322909|NCT00679991|PRT 201
1322910|NCT00679991|dose escalation
1322911|NCT00679991|dialysis
1322912|NCT00679991|fistula
1322913|NCT00679991|access
1322914|NCT00679991|vonapanitase
1322915|NCT00679991|kidney
1322916|NCT00679991|renal
1322917|NCT00679978|osteoporosis
1322918|NCT00679978|glucocorticoid
1322919|NCT00679978|bone mineral density
1322920|NCT00679978|osteonecrosis of the femoral head
1322921|NCT00679965|Onychomycosis
1322922|NCT00679965|Fungal Nail
1322923|NCT00679952|Pancreatic fistula
1322924|NCT00679952|Pancreatic duct stent
1322925|NCT00679952|Closed suction drainage
1322926|NCT00679939|Type 2 diabetes mellitus
1322927|NCT00679939|bone
1322928|NCT00679939|x-ray absorptiometry
1322929|NCT00679939|bone biomarkers
1322930|NCT00679939|dual-energy
1322931|NCT00679939|bone mineral density
1322932|NCT00679926|HIV
1322933|NCT00679926|AIDS
1322934|NCT00679926|HIV/AIDS
1322935|NCT00679926|Treatment Naive
1322936|NCT00679913|Pancreatic cancer
1322937|NCT00679913|Pancreaticoduodenectomy
1322938|NCT00679913|Extended lymphadenectomy
1322939|NCT00679900|Primary Insomnia
1322940|NCT00679900|Sleep Maintenance Difficulties
1322941|NCT00679887|chiropractic
1322942|NCT00679887|myofascial trigger points
1322943|NCT00679887|ischemic compression
1322944|NCT00679887|shoulder pain
1322945|NCT00679874|Cardiovascular Magnetic Resonance Imaging
1322946|NCT00679874|Cardiotoxicity
1322947|NCT00679874|Anthracyclines
1322948|NCT00679874|Trastuzumab
1322949|NCT00679874|Breast cancer
1322950|NCT00679874|Toxicity
1322951|NCT00679861|primary medical care
1322952|NCT00679861|computer expert system
1322953|NCT00679861|motivational interviewing
1322954|NCT00679861|health behavior change counselling
1322955|NCT00679861|stages of change
1322956|NCT00679848|Weight Loss
1322957|NCT00679848|Transoral Suturing
1322958|NCT00679848|Experimental
1322959|NCT00679822|OSA
1322960|NCT00679822|sleep apnea
1322961|NCT00679822|heart failure
1322962|NCT00679822|CHF
1322963|NCT00679822|heart clinic
1322964|NCT00679822|clinic
1322965|NCT00679822|obstructive sleep apnea
1322966|NCT00679809|Resident
1322967|NCT00679809|Safety
1322968|NCT00679809|Fatigue
1322969|NCT00679809|Continuity
1322970|NCT00679809|ICU
1322971|NCT00679796|varicella
1322972|NCT00679796|case-control
1322973|NCT00679783|Breast cancer
1322974|NCT00679783|Ovarian cancer
1322975|NCT00679783|BRCA
1322976|NCT00679783|Triple negative
1322977|NCT00679783|Poly(ADP ribose) polymerases
1322978|NCT00679783|Known BRCA or Recurrent High Grade Serious/ Undifferentiated Tubo- Ovarian Carcinoma
1322979|NCT00679783|Known BRCA or Triple Negative Breast Cancer
1322980|NCT00679770|Onychomycosis
1322981|NCT00679770|Fungal Nail
1322982|NCT00679757|Sleep apnea
1322983|NCT00679757|Obstructive sleep apnea
1322984|NCT00679757|Wound healing
1322985|NCT00679757|Non-healing wounds
1322986|NCT00679744|Tay-Sachs disease.
1322987|NCT00679744|Sandhoff disease.
1322988|NCT00679744|GM2 Gangliosidosis.
1322989|NCT00679744|β-hexosaminidase deficiency.
1322990|NCT00679744|Hexosaminidase
1322991|NCT00679744|Phase I clinical trial.
1322992|NCT00679731|Psoriasis
1322993|NCT00679705|Hemodynamics and arterial function of healthy females
1322994|NCT00679692|GH,IGF-1, IGFBP-3
1322995|NCT00679679|Polycystic ovary syndrome
1322996|NCT00679679|Treatment
1322997|NCT00679679|Metformin
1322998|NCT00679666|keratoconus
1322999|NCT00679666|ectasia
1323000|NCT00679666|cross-linking
1323001|NCT00679666|riboflavin
1323002|NCT00679666|UVA light
1323003|NCT00679666|cornea
1323004|NCT00679640|candesartan
1323005|NCT00679640|heart failure
1323006|NCT00679640|cohort study
1323007|NCT00679640|France
1323008|NCT00679627|Alzheimer's Disease
1323009|NCT00679627|Galantamine
1323010|NCT00679627|Dementia, Alzheimer type
1323011|NCT00679627|Memory loss
1323012|NCT00679614|Tramacet
1323013|NCT00679614|naloxone
1323014|NCT00679614|morphine
1323015|NCT00679614|analgesia
1323016|NCT00679614|elderly
1323017|NCT00679614|elderly patients
1323018|NCT00679601|Onychomycosis
1323019|NCT00679601|Fungal Nail
1323020|NCT00679588|Digestive System Surgical Procedure
1323021|NCT00679588|Urologic Surgical Procedure
1323022|NCT00679588|Prevention of venous thromboembolism
1323023|NCT00679588|Abdominal surgery
1323024|NCT00679575|statins
1323025|NCT00679575|myocardial infarction
1323026|NCT00679575|case-referent study
1323027|NCT00679575|France
1323028|NCT00679549|Heart Failure
1323029|NCT00679549|Obstructive Sleep Apnea
1323030|NCT00679549|OSA
1323031|NCT00679549|CHF
1323032|NCT00679549|Sleep apnea
1323033|NCT00679549|CHD
1323034|NCT00679536|Reduced Toxicity
1323035|NCT00679536|Toxicity
1323036|NCT00679536|Event Free Survival
1323037|NCT00679536|Graft vs Host Disease
1323038|NCT00679523|Onychomycosis
1323039|NCT00679523|Fungal Nail
1323040|NCT00679510|Rheumatoid Arthritis
1323041|NCT00679510|Rosuvastatin
1323042|NCT00679510|Cardiovascular
1323043|NCT00679510|Intima media thickness
1323044|NCT00679497|Low risk HIV infection
1323045|NCT00679497|HIV Seronegativity
1323046|NCT00679497|HIV Preventive Vaccine
1323047|NCT00679471|pre-term infants
1323048|NCT00679471|full-term infants
1323049|NCT00679471|MRI
1323050|NCT00679471|brain structure development
1323051|NCT00679471|pre term
1323052|NCT00679471|full term
1323053|NCT00679458|analgesia
1323054|NCT00679458|pain
1323055|NCT00679458|buprenorphine
1323056|NCT00679458|opioid
1323057|NCT00679458|naloxone
1323058|NCT00679445|Macular
1323059|NCT00679445|Degeneration
1323060|NCT00679445|AMD
1323061|NCT00679445|Wet Age-related macular degeneration
1323062|NCT00679432|Ulcerative colitis
1323063|NCT00679406|Chronic Insomnia lasting more than 1 month
1323064|NCT00679393|Calcaneus
1323065|NCT00679393|Intra-articular fracture
1323066|NCT00679393|open reduction internal fixation
1323067|NCT00679393|primary subtalar fusion
1323068|NCT00679380|Ulcerative colitis
1323069|NCT00679367|primary systemic amyloidosis
1323070|NCT00679341|HER2-positive breast cancer
1323071|NCT00679341|HER2
1323072|NCT00679341|Herceptin
1323073|NCT00679341|Taxotere
1323074|NCT00679341|MBC
1323075|NCT00679341|Breast cancer
1323076|NCT00679341|TDM1
1323077|NCT00679341|TDM-1
1323078|NCT00679341|HER2-positive
1323079|NCT00679341|HER2+
1323080|NCT00679341|HER2 positive breast cancer
1323081|NCT00679341|HER2+ breast cancer
1323082|NCT00679341|Armed Herceptin
1323083|NCT00679341|Trastuzumab emtansine
1323084|NCT00679341|Trastuzumab DM1
1323085|NCT00679315|female voiding dysfunction
1323086|NCT00679315|alpha adrenoreceptor antagonists
1323087|NCT00679315|IPSS or American Urological Association symptom index
1323088|NCT00679302|skin abscess
1323089|NCT00679302|CA-MRSA
1323090|NCT00679289|KW2871
1323091|NCT00679289|ecromeximab
1323092|NCT00679289|anti-ganglioside
1323093|NCT00679289|antibody
1323094|NCT00679289|interferon alpha
1323095|NCT00679289|Metastatic melanoma
1323096|NCT00679276|vaginal prolapse
1323097|NCT00679263|asthma
1323098|NCT00679263|randomized
1323099|NCT00679263|placebo controlled
1323100|NCT00679263|dose escalation
1323101|NCT00679263|safety
1323102|NCT00679263|efficacy
1323103|NCT00679263|single blind
1323104|NCT00679263|MN-221
1323105|NCT00679250|allergic rhinitis
1323106|NCT00679250|levocetirizine
1323107|NCT00679250|nasal provocation testing
1323108|NCT00679250|nasal allergen challenge
1323109|NCT00679250|nasal adenosine monophosphate challenge
1323110|NCT00679224|Pulmonary Arterial Hypertesion
1323111|NCT00679224|observational safety
1323112|NCT00679003|Crohn's disease
1323113|NCT00679003|Ulcerative colitis
1323114|NCT00679003|Inflammatory bowel disease
1323115|NCT00679003|Illness behavior
1323116|NCT00679003|Cognitive behavioral therapy
1323117|NCT00678990|Islets of Langerhans
1323118|NCT00678990|islets
1323119|NCT00678990|heparin
1323120|NCT00678977|pharmacokinetics
1323121|NCT00678977|cisplatin
1323122|NCT00678977|pazopanib (GW786034)
1323123|NCT00678977|Solid tumors
1323124|NCT00678977|anti-angiogenesis
1323125|NCT00678977|gemcitabine
1323126|NCT00678964|NSCLC
1323127|NCT00678964|Elderly patients
1323128|NCT00678938|smoking reduction
1323129|NCT00678938|smoking cessation
1323130|NCT00678938|stages of change
1323131|NCT00678938|expert system interventions
1323132|NCT00678912|mechanical ventilation
1323133|NCT00678912|automated weaning
1323134|NCT00678912|children
1323135|NCT00678899|High frequency severe to profound
1323136|NCT00678886|Type 1 diabetes
1323137|NCT00678886|new onset type 1 diabetes
1323138|NCT00678886|T1DM
1323139|NCT00678886|Type l diabetes
1323140|NCT00678886|juvenile diabetes
1323141|NCT00678873|Single Incision
1323142|NCT00678873|Single Access
1323143|NCT00678873|Surgery
1323144|NCT00678873|Cholecystectomy
1323145|NCT00678860|Questionnaire
1323146|NCT00678860|Computer Assisted Interface
1323147|NCT00678860|Quality of Life
1323148|NCT00678860|Dry Eye
1323149|NCT00678860|Ocular Surface Disease
1323150|NCT00678860|Healthy Volunteer
1323151|NCT00678860|HV
1323152|NCT00678847|bio-electrical stimulation therapy
1323153|NCT00678847|chronic venous ulcers
1323154|NCT00678847|microcurrent
1323155|NCT00678847|chronic wounds
1323156|NCT00678847|complete healing
1323157|NCT00678821|Exercise
1323158|NCT00678821|Pulmonary Hypertension
1323159|NCT00678821|Pulmonary Rehabilitation
1323160|NCT00678821|Interstitial Lung Disease
1323161|NCT00678795|Detrusor overactivity
1323162|NCT00678795|Multiple Sclerosis
1323163|NCT00678782|knee
1323164|NCT00678782|synovitis
1323165|NCT00678782|arthritis
1323166|NCT00678782|rheumatoid arthritis
1323167|NCT00678782|psoriatic arthritis
1323168|NCT00678782|spondyloarthropathies
1323169|NCT00678782|intraarticular
1323170|NCT00678782|etanercept
1323171|NCT00678756|Psoriasis vulgaris,
1323172|NCT00678756|vitamin D, UVB-phototherapy, ketokonazol,
1323173|NCT00678756|Optical Coherence Tomography,
1323174|NCT00678756|local PASI, Nizoral
1323175|NCT00678743|cholesterol
1323176|NCT00678743|dyslipidemia
1323177|NCT00678743|omega 3
1323182|NCT00678717|abdominal
1323183|NCT00678717|Pelvic
1323184|NCT00678717|Pain
1323185|NCT00678717|SCS
1323186|NCT00678717|Healthy and Chronic Visceral Pain patients
1323187|NCT00678717|Chronic Visceral Pain and spinal cord stimulator
1323188|NCT00678704|Vardenafil
1323189|NCT00678704|PDE5 inhibitor
1323190|NCT00678704|Erectile Dysfunction
1323191|NCT00678704|Diabetes Mellitus
1323192|NCT00678704|Sexual Dysfunction
1323193|NCT00678691|fibromyalgia
1323194|NCT00678691|fatigue
1323195|NCT00678678|Physiotherapy
1323196|NCT00678678|Breathing exercises
1323197|NCT00678678|Bariatric Surgery
1323198|NCT00678678|Laparoscopy
1323199|NCT00678665|ecg
1323200|NCT00678665|TSA2000
1323201|NCT00678665|Heart rate variability
1323202|NCT00678665|wavelets
1323203|NCT00678652|Meningococcal vaccine
1323204|NCT00678652|Neisseria meningitidis
1323205|NCT00678639|ACS
1323206|NCT00678639|Acute Coronary Syndrome
1323207|NCT00678639|Chest pain
1323208|NCT00678639|Cardiac MRI
1323209|NCT00678639|CMR
1323210|NCT00678639|Risk Stratification
1323211|NCT00678639|Emergency Department
1323212|NCT00678626|Key words: Docetaxel; breast cancer; breast diseases; breast neoplasms; antineoplastic agents; neoplasms;HER-2 negative; Stage IIIB or IV breast cancer.
1323213|NCT00678613|probiotics
1323214|NCT00678613|cirrhosis
1323215|NCT00678613|prophylaxis
1323216|NCT00678613|cirrhotic
1323217|NCT00678613|patients
1323218|NCT00678613|with
1323219|NCT00678613|ascites
1323220|NCT00678613|using
1323221|NCT00678600|Informatics
1323222|NCT00678600|Alerts
1323223|NCT00678600|Toxicity
1323224|NCT00678600|Virologic failure
1323225|NCT00678600|Suboptimal follow up
1323226|NCT00678587|elective invasive procedure.
1323227|NCT00678587|platelet transfusion
1323228|NCT00678587|chronic liver disease-related thrombocytopenia
1323229|NCT00678587|platelets
1323230|NCT00678587|thrombopoietin
1323231|NCT00678574|hormones
1323232|NCT00678574|menses
1323233|NCT00678574|PMS
1323234|NCT00678574|PMDD
1323235|NCT00678561|chronic plaque psoriasis, topical treatment
1323236|NCT00678535|1st line treatment for Gastric Cancer
1323237|NCT00678535|Cetuximab
1323238|NCT00678535|Capecitabine
1323239|NCT00678535|Xeloda
1323240|NCT00678535|Cisplatin
1323241|NCT00678535|Progression-free survival
1323242|NCT00678522|Atorvastatin
1323243|NCT00678522|Renal function
1323244|NCT00678522|Hemodynamics
1323245|NCT00678522|Diabetes type II
1323246|NCT00678522|sodium excretion
1323247|NCT00678509|HLA-A*2402
1323248|NCT00678509|Peptide Vaccine
1323249|NCT00678509|TTK
1323250|NCT00678496|CBT-software
1323251|NCT00678496|Computerised Cognitive Behavioural Therapy
1323252|NCT00678496|CCBT
1323253|NCT00678496|Cognitive Therapy
1323254|NCT00678496|Therapy, Computer-Assisted
1323255|NCT00678496|Depression
1323256|NCT00678496|Multiple Sclerosis
1323257|NCT00678483|Cholesterol
1323258|NCT00678483|HDL
1323259|NCT00678483|triglycerides
1323260|NCT00678483|insulin
1323261|NCT00678483|blood glucose
1323262|NCT00678457|alcohol dependence
1323263|NCT00678457|alcohol abuse
1323264|NCT00678457|drinking
1323265|NCT00678457|alcohol
1323266|NCT00678444|Anxiety
1323267|NCT00678444|Satisfaction
1323268|NCT00678444|Incomplete bladder emptying
1323269|NCT00678444|Clean Intermittent Self-catheterization
1323270|NCT00678444|Prolapse/incontinence surgery
1323271|NCT00678431|Alzheimer's Disease
1323272|NCT00678431|Dementia
1323273|NCT00678431|Nutritional Supplement
1323274|NCT00678431|Resveratrol
1323275|NCT00678418|Addiction
1323276|NCT00678418|Opiate dependence
1323277|NCT00678418|Inpatient detoxification
1323278|NCT00678418|opioid dependence
1323279|NCT00678418|heroin dependence
1323280|NCT00678405|Breathlessness
1323281|NCT00678405|Dyspnoea
1323282|NCT00678405|Dyspnea
1323283|NCT00678405|Palliative care
1323284|NCT00678405|RCT
1323285|NCT00678405|Randomised controlled trial
1323286|NCT00678405|Lung cancer
1323287|NCT00678405|COPD
1323288|NCT00678405|Heart failure
1323289|NCT00678405|Chronic respiratory disease
1323290|NCT00678392|Axitinib in Second Line Treatment of Patients With Metastatic Renal Cell Cancer
1323291|NCT00678379|Tonsillectomy
1323292|NCT00678379|Postoperative Pain
1323293|NCT00678379|Clonidine
1323294|NCT00678379|Anesthetics, Local
1323295|NCT00678366|laparoscopy
1323296|NCT00678366|carbon dioxide
1323297|NCT00678366|oxygen
1323298|NCT00678366|pain
1323299|NCT00678366|inflammation
1323300|NCT00678353|Degenerative disc disease
1323301|NCT00678340|Randomized Controlled Trial
1323302|NCT00678340|Single-Blind Study
1323303|NCT00678340|Catheter Ablation
1323304|NCT00678327|stage III adult Hodgkin lymphoma
1323305|NCT00678327|stage IV adult Hodgkin lymphoma
1323306|NCT00678327|adult nodular sclerosis Hodgkin lymphoma
1323307|NCT00678327|adult lymphocyte depletion Hodgkin lymphoma
1323308|NCT00678327|adult lymphocyte predominant Hodgkin lymphoma
1323309|NCT00678327|adult mixed cellularity Hodgkin lymphoma
1323310|NCT00678327|stage II adult Hodgkin lymphoma
1323311|NCT00678314|Anesthetics
1323312|NCT00678314|Local
1323313|NCT00678314|ropivacaine
1323314|NCT00678314|Surgery
1323315|NCT00678314|Hand
1323316|NCT00678314|carpel tunnel
1323317|NCT00678314|Carpal tunnel surgery
1323318|NCT00678301|pneumococcal conjugate vaccine
1323319|NCT00678301|Streptococcus pneumoniae
1323320|NCT00678288|Renal Cell Cancer
1323321|NCT00678288|Interferon
1323322|NCT00678275|Hematopoietic Stem Cell Transplantation
1323323|NCT00678262|pain
1323324|NCT00678262|ECG
1323325|NCT00678262|Heart rate variability
1323326|NCT00678262|wavelets
1323327|NCT00678249|Hemodialysis
1323328|NCT00678249|Vascular Prosthesis
1323329|NCT00678249|stenoses
1323330|NCT00678249|grafts
1323331|NCT00678236|RSA
1323332|NCT00678236|Gonarthritis
1323333|NCT00678236|Bone Cement
1323334|NCT00678210|dose response; PASI 75 response endpoint; subjects with moderate to severe chronic plaque psoriasis
1323335|NCT00678197|Quality of care
1323336|NCT00678197|Access to care
1323337|NCT00678197|Health Outcomes
1323338|NCT00678184|Atorvastatin
1323339|NCT00678184|healthy
1323340|NCT00678184|sodium excretion
1323341|NCT00678184|hemodynamics
1323342|NCT00678184|tubular function
1323343|NCT00678171|Degenerative Disc Disease
1323344|NCT00678158|High Does Single Fraction IGRT
1323345|NCT00678158|Bone
1323346|NCT00678158|Lymph Nodes
1323347|NCT00678158|Soft Tissue
1323348|NCT00678145|Diabetes
1323349|NCT00678145|Hypoglycemia
1323350|NCT00678145|HAAF
1323351|NCT00678145|Counterregulation
1323352|NCT00678132|PARP Inhibitor
1323353|NCT00678132|Combination Study
1323354|NCT00678132|Chemotherapy
1323355|NCT00678132|Advanced Cancer
1323356|NCT00678132|Neoplasms
1323357|NCT00678132|Cancer
1323358|NCT00678132|Solid Tumor
1323359|NCT00678119|Kidney cancer
1323360|NCT00678119|Renal cancer
1323361|NCT00678119|Renal Cell Carcinoma
1323362|NCT00678106|dalbavancin adolescent subjects
1323363|NCT00678093|Low back pain
1323364|NCT00678093|Manual therapy
1323365|NCT00678093|Mulligan snag
1323366|NCT00678080|Type 2 diabetes mellitus
1323367|NCT00678080|Pregnancy
1323368|NCT00678080|Metformin
1323369|NCT00678080|Insulin
1323370|NCT00678080|Pregnant women
1323371|NCT00678067|Hypercholesterolemic children
1323372|NCT00678067|Docosahexaenoic acid
1323373|NCT00678067|Eicosapentaenoic acid
1323374|NCT00678067|Blood lipid profile
1323375|NCT00678041|urinary catheterization
1323376|NCT00678041|urinary tract infection
1323377|NCT00678041|urinary incontinence
1323378|NCT00678041|pelvic floor prolapse
1323379|NCT00678041|antibiotics
1323380|NCT00678028|MBL, UTI
1323381|NCT00678015|NDGA
1323382|NCT00678015|Prostate Cancer
1323383|NCT00678002|solid organ transplant
1323384|NCT00677989|perforated appendicitis
1323385|NCT00677989|laparoscopic appendectomy
1323386|NCT00677989|open appendectomy
1323387|NCT00677989|cytokines
1323388|NCT00677989|free radicals
1323389|NCT00677989|oxidized proteins
1323390|NCT00677976|fMRI
1323391|NCT00677976|IBS
1323392|NCT00677976|Brain Activation
1323393|NCT00677963|carotid
1323394|NCT00677963|atherosclerosis
1323395|NCT00677963|arteriosclerosis
1323396|NCT00677963|plaque
1323397|NCT00677963|neovascularization
1323398|NCT00677963|carotid endarterectomy
1323399|NCT00677950|Degenerative Disc Disease
1323400|NCT00677937|diabetes mellitus
1323401|NCT00677937|prevention
1323402|NCT00677937|education
1323403|NCT00677937|impaired glucose tolerance
1323404|NCT00677937|multi-ethnic
1323405|NCT00677924|Colorectal Neoplasms
1323406|NCT00677924|Colorectal Tumors
1323407|NCT00677924|Colorectal Carcinoma
1323408|NCT00677911|Chronic pain
1323409|NCT00677911|Interleukin-6
1323410|NCT00677911|pain catastrophizing
1323411|NCT00677911|cytokines
1323412|NCT00677911|cortisol
1323413|NCT00677898|Patient-Centered Care
1323414|NCT00677898|Adverse effects
1323415|NCT00677898|Antipsychotics
1323416|NCT00677885|Alzheimer Disease
1323417|NCT00677885|Parkinson's Disease
1323418|NCT00677885|Frontotemporal Dementia
1323419|NCT00677885|PET Imaging
1323420|NCT00677885|AD
1323421|NCT00677885|Parkinson Disease
1323422|NCT00677885|PD
1323423|NCT00677872|Moderate to severe COPD and coincident pulmonary hypertension
1323424|NCT00677859|Leukemia
1323425|NCT00677859|Graft vs. Host Disease
1323426|NCT00677859|Hematopoietic Stem Cell Transplant
1323427|NCT00677859|Bone Marrow Transplant
1323428|NCT00677859|Myelodysplasia
1323429|NCT00677846|contrast agent ultrasound, vein thrombosis, vascularization
1323430|NCT00677833|P. Falciparum Malaria
1323431|NCT00677833|drug treatment
1323432|NCT00677833|clinical trial
1323433|NCT00677820|Influenza
1323434|NCT00677820|FluMist
1323435|NCT00677820|vaccine
1323436|NCT00677820|prevention
1323437|NCT00677820|trivalent
1323438|NCT00677807|COPD
1323439|NCT00677807|adults
1323440|NCT00677807|β2-agonist
1323441|NCT00677807|indacaterol
1323442|NCT00677794|Video Capsule Endoscopy
1323443|NCT00677794|Small Bowel
1323444|NCT00677768|Biomarkers
1323445|NCT00677768|Plasma
1323446|NCT00677768|Cerebrospinal Fluid
1323447|NCT00677768|DNA
1323448|NCT00677768|Serum
1323449|NCT00677755|Medical abortion
1323450|NCT00677755|emergency contraception
1323451|NCT00677755|mifepristone
1323452|NCT00677742|oral contraception
1323453|NCT00677742|hormonal contraception
1323454|NCT00677742|contraceptive behavior
1323455|NCT00677742|patient compliance
1323456|NCT00677729|bronchiolitis
1323457|NCT00677729|hypertonic saline
1323458|NCT00677729|infants
1323459|NCT00677716|glioblastoma multiforme
1323460|NCT00677716|GBM
1323461|NCT00677716|brain cancer
1323462|NCT00677716|Cotara
1323463|NCT00677716|radioactive isotope
1323464|NCT00677716|monoclonal antibody
1323465|NCT00677716|Glioblastoma multiforme at first relapse
1323466|NCT00677703|birth control pills
1323467|NCT00677703|contraception
1323468|NCT00677703|continuation
1323469|NCT00677703|text messaging
1323470|NCT00677703|contraceptive continuation
1323471|NCT00677703|contraceptive knowledge
1323472|NCT00677690|COPD
1323473|NCT00677677|Lung transplant
1323474|NCT00677677|Liver transplant
1323475|NCT00677677|Kidney transplant
1323476|NCT00677677|Pancreas transplant
1323477|NCT00677677|HPV
1323478|NCT00677677|Human Papillomavirus Quadrivalent Vaccine
1323479|NCT00677664|diabetic retinopathy
1323480|NCT00677664|panretinal photocoagulation
1323481|NCT00677664|copaxone
1323482|NCT00677664|nerve fiber layer thickness
1323483|NCT00677664|retinal function
1323484|NCT00677651|adipose
1323485|NCT00677651|lean
1323486|NCT00677651|obese
1323487|NCT00677651|overweight
1323488|NCT00677651|healthy
1323489|NCT00677625|Liver
1323490|NCT00677625|Transplant
1323491|NCT00677612|HLA-A*0201
1323492|NCT00677612|Peptide Vaccine
1323493|NCT00677612|VEGFR1
1323494|NCT00677612|VEGFR2
1323495|NCT00677599|Cardiovascular disease
1323496|NCT00677599|type 2 diabetes
1323497|NCT00677599|flavonoids
1323498|NCT00677599|cocoa
1323499|NCT00677599|soy
1323500|NCT00677599|epicatechin
1323501|NCT00677599|postmenopausal
1323502|NCT00677599|carotid intima media thickness
1323503|NCT00677599|plaque volume
1323504|NCT00677586|colorectal neoplasms
1323505|NCT00677586|liver metastasis
1323506|NCT00677586|surgery
1323507|NCT00677573|ART
1323508|NCT00677573|poor responder
1323509|NCT00677573|GnRH antagonist
1323510|NCT00677573|Gonadotropins
1323511|NCT00677560|resistance
1323512|NCT00677560|reactance
1323513|NCT00677560|inflammation
1323514|NCT00677547|Kidney
1323515|NCT00677547|Influenza vaccine
1323516|NCT00677547|CMI
1323517|NCT00677534|Endstage renal disease
1323518|NCT00677534|Vitamin D
1323519|NCT00677534|Monocyte function
1323520|NCT00677508|Constipation
1323521|NCT00677508|Fecal incontinence
1323522|NCT00677508|Quality of life
1323523|NCT00677508|Health related quality of life
1323524|NCT00677495|Gluten-free diet
1323525|NCT00677495|Celiac Disease
1323526|NCT00677495|Genetic predisposition
1323527|NCT00677495|Phage display library
1323528|NCT00677495|Autoimmune diseases
1323529|NCT00677482|liver transplant
1323530|NCT00677482|lung transplant
1323531|NCT00677482|kidney transplant
1323532|NCT00677482|heart transplant
1323533|NCT00677482|CMV microRNA
1323534|NCT00677469|Hyperthyroidism
1323535|NCT00677469|Cholestyramine
1323536|NCT00677456|Gastric Cancer
1323537|NCT00677456|total gastrectomy
1323538|NCT00677456|reconstruction
1323539|NCT00677456|life quality
1323540|NCT00677443|metastatic colorectal cancer
1323541|NCT00677443|S-1
1323542|NCT00677443|Capecitabine
1323543|NCT00677443|Oxaliplatin
1323544|NCT00677443|non-inferiority study
1323545|NCT00677430|Breast Cancer
1323546|NCT00677430|Breast Reconstruction
1323547|NCT00677430|Digital Imaging
1323548|NCT00677430|Questionnaire
1323549|NCT00677430|Survey
1323550|NCT00677404|Peripheral vascular diseases
1323551|NCT00677404|chronic lower limb ischemia
1323552|NCT00677391|Obesity
1323553|NCT00677378|TRPV1
1323554|NCT00677378|Nerve growth factor
1323555|NCT00677378|Capsaicin
1323556|NCT00677378|TrkA
1323557|NCT00677378|Retrosternal pain
1323558|NCT00677378|Epigastric pain
1323559|NCT00677378|Esophagitis
1323560|NCT00677378|Gastrointestinal symptoms
1323561|NCT00677352|Panic Disorder
1323562|NCT00677339|Tuberculosis
1323563|NCT00677339|Adjunctive therapy
1323564|NCT00677339|L-arginine
1323565|NCT00677339|Nitric oxide
1323566|NCT00677339|Vitamin D
1323567|NCT00677326|HLA-A*0201
1323568|NCT00677326|Peptide Vaccine
1323569|NCT00677326|VEGFR1
1323570|NCT00677326|VEGFR2
1323571|NCT00677313|metreleptin
1323572|NCT00677313|leptin
1323573|NCT00677313|Amylin
1323574|NCT00677313|diabetes mellitus
1323575|NCT00677313|hypertriglyceridemia
1323576|NCT00677313|lipodystrophy
1323577|NCT00677300|HIV
1323578|NCT00677300|Treatment Naive
1323579|NCT00677287|HLA-A*2402
1323580|NCT00677287|Peptide Vaccine
1323581|NCT00677287|RNF43
1323582|NCT00677287|TOMM34
1323583|NCT00677287|VEGFR1
1323584|NCT00677287|VEGFR2
1323585|NCT00677274|Epidural analgesia
1323586|NCT00677274|Patient-controlled analgesia
1323587|NCT00677261|Knee
1323588|NCT00677261|Arthroplasty
1323589|NCT00677261|Sciatic
1323590|NCT00677261|Nerve
1323591|NCT00677261|Block
1323592|NCT00677261|Regional
1323593|NCT00677261|Anesthesia
1323594|NCT00677261|Infiltration
1323595|NCT00677261|Local Anesthetic
1323596|NCT00677261|Analgesia
1323597|NCT00677248|Eprotirome
1323598|NCT00677248|KB2115
1323599|NCT00677248|dyslipidemia
1323600|NCT00677248|hypercholesterolemia
1323601|NCT00677248|hypertriglyceridemia
1323602|NCT00677235|Hemodialysis
1323603|NCT00677235|Vascular Prosthesis
1323604|NCT00677235|Stenosis
1323605|NCT00677235|End-stage Renal Disease (ESRD)
1323606|NCT00677222|Acute Myocardial Infarction, Heart Attack
1323607|NCT00677209|house dust mite
1323608|NCT00677209|asthma
1323609|NCT00677209|autovaccine
1323610|NCT00677209|allergy
1323611|NCT00677196|PNL
1323612|NCT00677196|Lithoclast
1323613|NCT00677196|Stonebreaker
1323614|NCT00677196|efficiency stone fragmentation
1323615|NCT00677183|NASH
1323616|NCT00677183|Biomarker
1323617|NCT00677157|Fatigue
1323618|NCT00677157|Fibromyalgia
1323619|NCT00677157|Pain
1323620|NCT00677157|Complex Regional Pain Syndrome
1323621|NCT00677157|Reflex Sympathetic Dystrophy
1323622|NCT00677157|CPRS
1323623|NCT00677157|RSD
1323624|NCT00677144|Colorectal Neoplasm
1323625|NCT00677144|S-1
1323626|NCT00677144|Capecitabine
1323627|NCT00677144|Oxaliplatin
1323628|NCT00677131|pediatrics
1323629|NCT00677131|antibiotics
1323630|NCT00677131|patient education
1323631|NCT00677118|Nasopharyngeal carcinoma
1323632|NCT00677118|Concurrent chemoradiotherapy
1323633|NCT00677118|Adjuvant chemotherapy
1323634|NCT00677118|Clinical trial
1323635|NCT00677105|Lymphoma
1323636|NCT00677105|Neoplasms
1323637|NCT00677105|Solid Tumors
1323638|NCT00677105|Advanced Cancer
1323639|NCT00677092|Treatment
1323640|NCT00677092|Chronic kidney disease
1323641|NCT00677092|Fibrosing disorders
1323642|NCT00677092|Imatinib mesylate
1323643|NCT00677079|BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
1323644|NCT00677079|BRCA-1
1323645|NCT00677079|BRCA-2
1323646|NCT00677066|bronchiolitis
1323647|NCT00677066|oxygen
1323648|NCT00677066|children
1323649|NCT00677053|Unstable Angina
1323650|NCT00677053|Myocardial Infarction
1323651|NCT00677053|Thrombolysis
1323652|NCT00677053|Anticoagulant
1323653|NCT00677053|Acute Coronary Syndrome
1323654|NCT00677027|Beta-glucan
1323655|NCT00677027|immune system
1323656|NCT00677027|Healthy subjects
1323657|NCT00677014|Heart Failure
1323658|NCT00677014|HF
1323659|NCT00677014|Cardiac Resynchronization Therapy
1323660|NCT00677014|CRT
1323661|NCT00677014|Optimization
1323662|NCT00677014|SmartDelay
1323663|NCT00677014|Echocardiography
1323664|NCT00677014|AV Delay
1323665|NCT00677001|Solid tumors
1323666|NCT00677001|solid malignancies
1323667|NCT00677001|neoplasms
1323668|NCT00677001|refractory solid tumors
1323669|NCT00677001|advanced solid tumors
1323670|NCT00676988|Luminal Crohn's Disease
1323671|NCT00676988|Infliximab
1323672|NCT00676975|Irritable Bowel disease
1323673|NCT00676975|Traditional Chinese Medicine
1323674|NCT00676962|Implementation
1323675|NCT00676962|facilitation
1323676|NCT00676962|psychotherapy
1323677|NCT00676962|training
1323678|NCT00676949|epitope peptide
1323679|NCT00676949|cyclophosphamide
1323680|NCT00676949|interleukin-2
1323681|NCT00676936|Cancer
1323682|NCT00676936|pain
1323683|NCT00676936|corticosteroids
1323684|NCT00676936|palliative
1323685|NCT00676936|supportive care
1323686|NCT00676936|Cancer patients with pain
1323687|NCT00676910|Advanced Cancer
1323688|NCT00676910|Malignancies
1323689|NCT00676910|Neoplasms
1323690|NCT00676910|Incurable Solid Cancers
1323691|NCT00676897|statin, sepsis, septic shock, simvastatin
1323692|NCT00676884|atopic eczema
1323693|NCT00676884|atopic dermatitis
1323694|NCT00676884|allergy
1323695|NCT00676858|Embolism
1323696|NCT00676858|Argon
1323697|NCT00676845|Arterial stiffness
1323698|NCT00676845|Vascular protection
1323699|NCT00676832|colitis
1323700|NCT00676832|ulcerative
1323701|NCT00676832|moderate
1323702|NCT00676832|severe
1323703|NCT00676806|Umbilical cord blood transplantation
1323704|NCT00676806|full ablation conditioning
1323705|NCT00676806|reduced intensity conditioning
1323706|NCT00676793|breast cancer
1323707|NCT00676793|EGCG
1323708|NCT00676793|Polyphenon E
1323709|NCT00676793|c-Met
1323710|NCT00676793|VEGF
1323711|NCT00676793|HGF
1323712|NCT00676780|EGCG
1323713|NCT00676780|polyphenols
1323714|NCT00676780|biomarkers
1323715|NCT00676780|prostate specific antigen
1323716|NCT00676767|Aging
1323717|NCT00676767|Diabetes
1323718|NCT00676767|Diet
1323719|NCT00676767|Fiber
1323720|NCT00676754|Multidrug-Resistant Tuberculosis, tuberculosis, Peru
1323721|NCT00676728|Advanced or Refractory Leukemia
1323722|NCT00676728|Myelodysplastic Syndromes
1323723|NCT00676728|JNJ 26481585
1323724|NCT00676728|Histone-Deacetylase Inhibitor
1323725|NCT00676728|Advanced Leukemia
1323726|NCT00676728|Refractory Leukemia
1323727|NCT00676702|Pancrelipase
1323728|NCT00676702|PANCREASE MT
1323729|NCT00676702|Cross-Over Studies
1323730|NCT00676702|Duodenum
1323731|NCT00676702|Intestine, Small
1323732|NCT00676702|Lipase
1323733|NCT00676702|Amylases
1323734|NCT00676702|Peptide Hydrolases
1323735|NCT00676702|Intubation
1323736|NCT00676702|Safety
1323737|NCT00676702|Capsules
1323738|NCT00676689|Pulmonic
1323739|NCT00676689|Regurgitation
1323740|NCT00676689|Pulmonary Valve Conduit
1323741|NCT00676689|Stenosis
1323742|NCT00676689|Congenital Heart Defect
1323743|NCT00676676|Depression
1323744|NCT00676676|Major Depressive Disorder
1323745|NCT00676663|Breast Neoplasms
1323746|NCT00676663|Breast Tumor
1323747|NCT00676663|Mammary Neoplasms
1323748|NCT00676650|Docetaxel-refractory mCRPC
1323749|NCT00676650|Second-line treatment with sunitinib and prednisone
1323750|NCT00676637|Adherence
1323751|NCT00676637|Compliance
1323752|NCT00676637|Glaucoma
1323753|NCT00676637|Ocular Hypertension
1323754|NCT00676624|uveitis
1323755|NCT00676624|vitrectomy
1323756|NCT00676624|infection
1323757|NCT00676624|severe
1323758|NCT00676611|Acetabular Fractures
1323759|NCT00676598|therapeutic hypothermia
1323760|NCT00676585|Cardiac Arrest, Shock, Steroids
1323761|NCT00676572|severe asthma
1323762|NCT00676572|corticosteroid insensitivity
1323763|NCT00676559|Diabetic
1323764|NCT00676559|Macular
1323765|NCT00676559|Edema
1323766|NCT00676559|DME
1323767|NCT00676559|Clinically Significant Macular Edema (CSME)
1323768|NCT00676533|Cipro
1323769|NCT00676533|Urinary Tract Infection
1323770|NCT00676520|Angioplasty
1323771|NCT00676520|Coronary Restenosis
1323772|NCT00676520|Coronary Artery Disease
1323773|NCT00676520|Coronary Artery Restenosis
1323774|NCT00676520|Coronary Artery Stenosis
1323775|NCT00676520|Total Artery Occlusion
1323776|NCT00676520|Stents
1323777|NCT00676520|Stent Thrombosis
1323778|NCT00676520|Total Coronary Occlusion
1323779|NCT00676520|Vascular Disease
1323780|NCT00676520|Myocardial Ischemia
1323781|NCT00676507|Gene therapy
1323782|NCT00676507|Flow cytometry
1323783|NCT00676507|Immunoenzyme technique
1323784|NCT00676507|Laboratory biomarker analysis
1323785|NCT00676507|Quality-of-life-assessment
1323786|NCT00676507|Tumor cell-derivative vaccine therapy
1323787|NCT00676481|Patient Education
1323788|NCT00676481|Emergency Medicine
1323789|NCT00676481|HIV Prevention
1323790|NCT00676481|HIV Seronegativity
1323791|NCT00676468|Asthma
1323792|NCT00676468|Inflammation
1323793|NCT00676468|Airway
1323794|NCT00676468|Fish Oil
1323795|NCT00676468|Singulair
1323796|NCT00676455|CT Software
1323797|NCT00676455|MeVis™
1323798|NCT00676455|Metastatic pulmonary and hepatic lesion growth
1323799|NCT00676416|General anesthesia
1323800|NCT00676416|Propofol
1323801|NCT00676416|Immunity
1323802|NCT00676416|Alveolar Macrophages
1323803|NCT00676403|pregabalin, RLS, efficacy, safety
1323804|NCT00676390|Heart Failure
1323805|NCT00676377|Neostigmine, Post Operative, Ileus
1323806|NCT00676364|pediatric patients
1323807|NCT00676364|pain
1323808|NCT00676364|anxiety
1323809|NCT00676364|topical anesthetic
1323810|NCT00676364|randomized control trial
1323811|NCT00676338|Amylin
1323812|NCT00676338|Lilly
1323813|NCT00676338|exenatide once weekly
1323814|NCT00676338|Byetta
1323815|NCT00676338|Januvia
1323816|NCT00676338|sitagliptin
1323817|NCT00676338|thiazolidinedione
1323818|NCT00676325|anterior vaginal prolapse
1323819|NCT00676325|traditional treatment
1323820|NCT00676325|mesh, graft
1323821|NCT00676325|NAZCA TC™ POP REPAIR SYSTEM
1323822|NCT00676325|colporrhaphy
1323823|NCT00676312|Osteoporosis
1323824|NCT00676312|parathyroid hormone
1323825|NCT00676312|pharmacodynamic
1323826|NCT00676312|pharmacokinetic
1323827|NCT00676299|Advanced Solid Cancers
1323828|NCT00676299|Refractory Solid Cancers
1323829|NCT00676299|Protein Kinase Inhibitors
1323830|NCT00676299|Phase 1 Study
1323831|NCT00676299|Oral Chemotherapy
1323832|NCT00676286|Prostate cancer active surveillance
1323833|NCT00676286|3 Tesla MR biological imaging in prostate cancer
1323834|NCT00676286|tumor gene re-arrangements in prostate cancer
1323835|NCT00676260|Glucose Metabolism Disorder
1323836|NCT00676260|Dysmetabolic Syndrome
1323837|NCT00676260|Type II Diabetes
1323838|NCT00676260|Diabetes Mellitus
1323839|NCT00676260|Lipoatrophic
1323840|NCT00676260|Dyslipidemia
1323841|NCT00676260|Drug Therapy
1323842|NCT00676247|Ultrasonography
1323843|NCT00676247|Doppler
1323844|NCT00676247|Hemodynamics
1323845|NCT00676247|Neurobehavioral development
1323846|NCT00676234|erythropoietin
1323847|NCT00676221|Renal transplant recipient
1323848|NCT00676221|Immunosuppression
1323849|NCT00676221|Gastro-intestinal symptoms
1323850|NCT00676221|Quality of life
1323851|NCT00676221|Cellcept
1323852|NCT00676221|Myfortic
1323853|NCT00676221|Kidney transplant patients.
1323854|NCT00676208|Shared Medical Appointments
1323855|NCT00676208|Diabetes
1323856|NCT00676208|Education
1323857|NCT00676195|N-Acetyl Cysteine
1323858|NCT00676169|Pseudomonas aeruginosa
1323859|NCT00676169|EPIC
1323860|NCT00676156|multiple sclerosis
1323861|NCT00676156|lipoic acid
1323862|NCT00676156|LA
1323863|NCT00676156|pharmacokinetics
1323864|NCT00676156|immunological effects
1323865|NCT00676143|antibody
1323866|NCT00676143|immunotherapy
1323867|NCT00676130|Cellulitis
1323868|NCT00676130|Bactrim
1323869|NCT00676130|Trimethoprim Sulfamethoxazole
1323870|NCT00676130|MRSA
1323871|NCT00676130|Methicillin-resistant Staphylococcus aureus
1323872|NCT00676117|male
1323873|NCT00676117|Japan
1323874|NCT00676117|Japanese
1323875|NCT00676117|Healthy volunteers
1323876|NCT00676104|Traumatic Brain Injury
1323877|NCT00676104|Trauma
1323878|NCT00676104|Hypothermia
1323879|NCT00676091|Pneumococcal conjugate vaccine
1323880|NCT00676065|Contraception
1323881|NCT00676065|Thromboembolism
1323882|NCT00676065|Breast Cancer
1323883|NCT00676052|COPD
1323884|NCT00676052|Multicenter
1323885|NCT00676052|GSK233705B
1323886|NCT00676052|double-blind
1323887|NCT00676052|Chronic Obstructive Pulmonary Disease (COPD)
1323888|NCT00676052|randomized
1323889|NCT00676039|Therapeutic Equivalency
1323890|NCT00676039|Human Experimentation
1323891|NCT00676039|Bioequivalence
1323892|NCT00676039|Brand name
1323893|NCT00676039|Generic
1323894|NCT00676039|Antidepressant
1323895|NCT00676039|Healthy volunteers
1323896|NCT00676026|menses
1323897|NCT00676026|women
1323898|NCT00676026|healthy controls
1323899|NCT00676026|Healthy females with regular menstrual cycles
1323900|NCT00676013|Burns
1323901|NCT00676013|Skin grafting
1323902|NCT00676013|AlloDerm
1323903|NCT00676013|Integra
1323904|NCT00676013|Homograft
1323905|NCT00676013|Autograft
1323906|NCT00676013|Burn Scar
1323907|NCT00675987|Impaired Fasting Glucose FPG >100-<126 mg/dL
1323908|NCT00675974|Burn
1323909|NCT00675974|Scar
1323910|NCT00675974|Pressure garments
1323911|NCT00675974|Wound healing
1323912|NCT00675974|Burn Injury
1323913|NCT00675961|Tomsk
1323914|NCT00675961|TB-Alcohol
1323915|NCT00675961|Alcohol and co-occurring disease
1323916|NCT00675961|Brief counseling intervention
1323917|NCT00675961|Naltrexone
1323918|NCT00675948|Palliative Care
1323919|NCT00675948|Pain
1323920|NCT00675948|Cancer
1323921|NCT00675935|Patient falls
1323922|NCT00675935|fall risk
1323923|NCT00675935|fall prevention
1323924|NCT00675922|Burn
1323925|NCT00675922|Wounds
1323926|NCT00675922|Wound infection
1323927|NCT00675922|Topical antimicrobials
1323928|NCT00675922|Cerium
1323929|NCT00675922|Dakins
1323930|NCT00675922|Sulfamylon Soaks
1323931|NCT00675922|Silver Nitrate
1323932|NCT00675909|Sedation
1323933|NCT00675909|Anxiety
1323934|NCT00675909|Minor procedures
1323935|NCT00675909|Emergency Department
1323936|NCT00675896|major depression with comorbid fibromyalgia.
1323937|NCT00675870|Acute Promyelocytic Leukemia
1323938|NCT00675870|Cancer
1323939|NCT00675870|Leukemia
1323940|NCT00675870|APL
1323941|NCT00675870|ATRA
1323942|NCT00675870|Tretinoid
1323943|NCT00675870|Vesanoid
1323944|NCT00675870|Retinoic Acid Receptor Alpha
1323945|NCT00675870|All Trans Retinoic Acid
1323946|NCT00675870|Arsenic Trioxide
1323947|NCT00675870|Trisenox
1323948|NCT00675870|Retinoid
1323949|NCT00675870|Relapsed or Refractory Acute Promyelocytic Leukemia
1323950|NCT00675857|Type II diabetes
1323951|NCT00675857|Metabolic syndrome
1323952|NCT00675844|Extension study
1323953|NCT00675844|HIV-1 infection
1323954|NCT00675844|Treatment Naive
1323955|NCT00675831|CD25+
1323956|NCT00675831|Tregs
1323957|NCT00675831|DLI
1323958|NCT00675831|Donor lymphocyte infusion
1323959|NCT00675818|acute kidney injury
1323960|NCT00675818|renal replacement therapy
1323961|NCT00675818|critical care unit
1323962|NCT00675818|hemodialysis
1323963|NCT00675818|hemofiltration
1323964|NCT00675805|intravenous immunoglobulin
1323965|NCT00675805|IVIG
1323966|NCT00675805|adverse reactions
1323967|NCT00675779|endometriosis
1323968|NCT00675779|atorvastatin
1323969|NCT00675779|oral
1323970|NCT00675779|contraception
1323971|NCT00675779|pain
1323972|NCT00675779|relief
1323973|NCT00675779|pelvic pain in women with endometriosis
1323974|NCT00675753|Genes
1323975|NCT00675753|Ethnology
1323976|NCT00675753|Cytokines
1323977|NCT00675753|prematurity
1323978|NCT00675727|Melanoma
1323979|NCT00675727|Mycobacterium w
1323980|NCT00675714|anabolic agents
1323981|NCT00675714|exercise
1323982|NCT00675701|To determine whether lixivaptan administration at supratherapeutic or therapeutic doses results in the prolongation of the QTc interval.
1323983|NCT00675688|Menopause
1323984|NCT00675675|Tourette Syndrome
1323985|NCT00675675|Chronic Tic Disorder
1323986|NCT00675675|Tics
1323987|NCT00675675|Behavior Therapy
1323988|NCT00675675|Habit Reversal Training
1323989|NCT00675675|Child
1323990|NCT00675675|Adolescent
1323991|NCT00675675|Neuroimaging
1323992|NCT00675662|Obesity
1323993|NCT00675662|overweight
1323994|NCT00675662|BMI
1323995|NCT00675662|ifestyle
1323996|NCT00675662|diet
1323997|NCT00675662|nutrition
1323998|NCT00675662|physical activity
1323999|NCT00675662|pre-school
1324000|NCT00675662|toddlers
1324001|NCT00675662|children
1324002|NCT00675662|Prevention of overweight and obesity in pre-school children
1324003|NCT00675649|Injections
1324004|NCT00675649|Severe, persistent asthma
1324005|NCT00675636|colon cancer
1324006|NCT00675636|hereditary non-polyposis colon cancer
1324007|NCT00675636|rectal cancer
1324008|NCT00675636|familial adenomatous polyposis
1324009|NCT00675623|Alzheimer's disease, clinical trial, memory loss, mitochondria,
1324010|NCT00675623|investigational drug, neurodegenerative disease, dementia
1324011|NCT00675610|communication
1324012|NCT00675610|HIV/AIDS
1324013|NCT00675610|Treatment Experienced
1324014|NCT00675597|Bevacizumab (Avastin)
1324015|NCT00675597|Taxotere (Docetaxel)
1324016|NCT00675597|Vinorelbine Tartrate (Navelbine)
1324017|NCT00675597|07-178
1324018|NCT00675558|Obesity
1324019|NCT00675558|morbid obesity
1324020|NCT00675558|bariatric surgery
1324021|NCT00675532|Opioids, vivitrol, naltrexone, primary care
1324022|NCT00675519|problem drinkers
1324023|NCT00675506|Growth Hormone Releasing Hormone
1324024|NCT00675506|Growth Hormone Pulse
1324025|NCT00675506|Visceral Adipose Tissue
1324026|NCT00675506|Carotid Intima-Media Thickness
1324027|NCT00675480|myocardial infarction, thrombectomy, salvage index
1324028|NCT00675467|Pediatric Cancer
1324029|NCT00675467|Focus Group
1324030|NCT00675467|Pediatric cancer patients
1324031|NCT00675467|Parents of Pediatric cancer patients
1324032|NCT00675467|Pediatric Palliative Care Program
1324033|NCT00675454|COPD
1324034|NCT00675454|Lung Volume Reduction Surgery
1324035|NCT00675454|Lung Transplant
1324036|NCT00675454|Quality of Life
1324037|NCT00675441|Chronic Graft-versus-Host Disease
1324038|NCT00675441|cGVHD
1324039|NCT00675441|GVHD
1324040|NCT00675441|Lenalidomide
1324041|NCT00675441|Revlimid
1324042|NCT00675441|CC-5013
1324043|NCT00675441|Stem Cell Transplant
1324044|NCT00675441|Allogeneic hematopoietic stem cell transplantation
1324045|NCT00675441|Allogeneic HSCT
1324046|NCT00675441|HSCT
1324047|NCT00675441|Post-Transplant Prophylactic Immunosuppressive Therapy
1324048|NCT00675441|Steroids
1324049|NCT00675441|Standard-of-care steroid treatment
1324050|NCT00675441|Corticosteroids
1324051|NCT00675441|Prednisone
1324052|NCT00675441|Medrol
1324053|NCT00675428|Relapsed or refractory Multiple Myeloma
1324054|NCT00675415|Hypoxemia
1324055|NCT00675415|Capnography
1324056|NCT00675415|Apnea
1324057|NCT00675415|Sedation
1324058|NCT00675415|ERCP
1324059|NCT00675415|EUS
1324060|NCT00675389|HIV
1324061|NCT00675389|AIDS
1324062|NCT00675389|Community Health Workers
1324063|NCT00675389|Mobile Phones
1324064|NCT00675389|Adherence
1324065|NCT00675389|Antiretroviral Therapy
1324066|NCT00675376|COPD
1324067|NCT00675376|Lung Transplant
1324068|NCT00675376|Quality of Life
1324069|NCT00675376|End Stage Lung Disease
1324070|NCT00675363|ICU
1324071|NCT00675363|Sedation strategies
1324072|NCT00675363|Daily sedative interruption
1324073|NCT00675363|Sedation protocols
1324074|NCT00675363|Mechanical Ventilation
1324075|NCT00675363|Sedation
1324076|NCT00675350|Omacetaxine
1324077|NCT00675350|Homoharringtonine
1324078|NCT00675350|HHT
1324079|NCT00675350|Solid and hematologic malignant tumors
1324080|NCT00675337|iron stores
1324081|NCT00675337|anemia
1324082|NCT00675337|iron deficiency
1324083|NCT00675337|infancy
1324084|NCT00675337|placental transfusion
1324085|NCT00675337|iron deficiency in infancy
1324086|NCT00675337|anemia in infancy
1324087|NCT00675337|placement of neonate
1324088|NCT00675324|Colonoscopy
1324089|NCT00675324|Bowel preparation
1324090|NCT00675324|Salt and electrolyte balance
1324091|NCT00675324|Patients undergoing colonoscopy
1324092|NCT00675324|Complication with traditional bowel preparation
1324093|NCT00675324|Bowel purity degree without traditional bowel preparation
1324094|NCT00675311|Remote monitoring
1324095|NCT00675311|Type 1 Diabetes
1324096|NCT00675311|Type 2 diabetes
1324097|NCT00675298|Prostatitis
1324098|NCT00675298|Cystitis, Interstitial
1324099|NCT00675298|Urinary Bladder, Overactive
1324100|NCT00675298|Chronic pelvic pain syndrome
1324101|NCT00675298|Painful bladder syndrome
1324102|NCT00675298|Urgency
1324103|NCT00675298|Frequency
1324104|NCT00675285|airway inflammation
1324105|NCT00675285|childhood asthma
1324106|NCT00675285|fractional exhaled nitric oxide
1324107|NCT00675285|leukotriene receptor antagonists
1324108|NCT00675285|lung function
1324109|NCT00675272|brain death
1324110|NCT00675272|subarachnoid hemorrhage
1324111|NCT00675272|traumatic brain injury
1324112|NCT00675272|brain injury
1324113|NCT00675272|intracerebral hemorrhage
1324114|NCT00675272|organ donation
1324115|NCT00675259|stage II breast cancer
1324116|NCT00675259|stage IIIA breast cancer
1324117|NCT00675259|stage IIIB breast cancer
1324118|NCT00675259|stage IIIC breast cancer
1324119|NCT00675246|corticoid therapy
1324120|NCT00675246|fetal lung maturation
1324121|NCT00675246|late preterm
1324122|NCT00675246|respiratory distress syndrome
1324123|NCT00675246|neonatal death
1324124|NCT00675233|recurrent squamous cell carcinoma of the larynx
1324125|NCT00675233|stage I squamous cell carcinoma of the larynx
1324126|NCT00675233|stage III squamous cell carcinoma of the larynx
1324127|NCT00675233|stage IV squamous cell carcinoma of the larynx
1324128|NCT00675233|stage 0 laryngeal cancer
1324129|NCT00675207|glaucoma
1324130|NCT00675207|ocular hypertension
1324131|NCT00675207|adjunctive treatment
1324132|NCT00675207|prostaglandin
1324133|NCT00675207|prostaglandin analog
1324134|NCT00675207|brimonidine
1324135|NCT00675207|dorzolamide
1324136|NCT00675207|brinzolamide
1324137|NCT00675207|alpha agonist
1324138|NCT00675207|carbonic anhydrase inhibitor
1324139|NCT00675207|intraocular pressure
1324140|NCT00675194|cisplatin
1324141|NCT00675194|capecitabine
1324142|NCT00675194|gastric
1324143|NCT00675194|irinotecan
1324144|NCT00675194|metastatic
1324145|NCT00675194|chemotherapy
1324146|NCT00675181|melatonin
1324147|NCT00675181|skin blood flow
1324148|NCT00675181|choroidal blood flow
1324149|NCT00675181|vasospastic subjects
1324150|NCT00675181|normal subjects
1324151|NCT00675168|Lung Cancer
1324152|NCT00675168|PET/CT
1324153|NCT00675168|Diagnosis
1324154|NCT00675155|Apoplexy
1324155|NCT00675155|Cerebral Stroke
1324156|NCT00675155|Cerebrovascular Accident
1324157|NCT00675155|Cerebrovascular Accident, Acute
1324158|NCT00675155|Cerebrovascular Apoplexy
1324159|NCT00675155|Cerebrovascular Stroke
1324160|NCT00675142|Infertility
1324161|NCT00675142|Intra-uterine insemination
1324162|NCT00675142|ovarian stimulation
1324163|NCT00675116|safety,
1324164|NCT00675116|healthy volunteers,
1324165|NCT00675116|GW823296,
1324166|NCT00675116|pharmacokinetics
1324167|NCT00675103|Gout
1324168|NCT00675103|Gouty Arthritis
1324169|NCT00675103|Anti-Gout preparations
1324170|NCT00675090|Alzheimers Disease
1324171|NCT00675077|Akinetic-Rigid Variant of Huntington Disease
1324172|NCT00675077|Chorea, Chronic Progressive Hereditary (Huntington)
1324173|NCT00675077|Chronic Progressive Hereditary Chorea (Huntington)
1324174|NCT00675077|Huntington Chorea
1324175|NCT00675077|Huntington Chronic Progressive Hereditary Chorea
1324176|NCT00675077|Huntington Disease, Akinetic-Rigid Variant
1324177|NCT00675077|Huntington Disease, Juvenile
1324178|NCT00675077|Huntington Disease, Juvenile-Onset
1324179|NCT00675064|pharmacokinetics,
1324180|NCT00675064|safety
1324181|NCT00675064|single ascending dose,
1324182|NCT00675064|Healthy volunteers,
1324183|NCT00675051|To determine if there is a trans-pulmonary gradient in the levels of EMPs in patients with PH
1324184|NCT00675051|To determine if the EMPs measured at the pulmonary capillary wedge position correlates even more strongly with the severity of PH than the circulating levels
1324185|NCT00675051|To determine if PH therapy with ET-1 receptor blocker will modify EMPs levels
1324186|NCT00675012|NGR-hTNF
1324187|NCT00675012|Capecitabine
1324188|NCT00675012|Oxaliplatin
1324189|NCT00675012|Colon cancer
1324190|NCT00674999|Burn
1324191|NCT00674999|Partial thickness burn
1324192|NCT00674960|Brain Atrophy, Circumscribed Lobar
1324193|NCT00674960|Circumscribed Lobar Atrophy of the Brain
1324194|NCT00674960|Lobar Atrophy (Brain)
1324195|NCT00674960|Pick Disease
1324196|NCT00674960|Pick's Disease
1324197|NCT00674960|Picks Disease of Brain
1324198|NCT00674947|Relapsed
1324199|NCT00674947|Refractory
1324200|NCT00674934|MS (Multiple Sclerosis)
1324201|NCT00674934|Multiple Sclerosis, Acute Fulminating
1324202|NCT00674934|Sclerosis, Disseminated
1324203|NCT00674921|Opportunistic Infections
1324204|NCT00674921|AIDS
1324205|NCT00674921|HIV
1324206|NCT00674921|Treatment Experienced
1324207|NCT00674908|Vaccine
1324208|NCT00674908|Prevention
1324209|NCT00674908|Diphtheria
1324210|NCT00674908|Tetanus
1324211|NCT00674908|Pertussis
1324212|NCT00674908|Hepatitis B
1324213|NCT00674908|Haemophilus influenzae type b
1324214|NCT00674908|Vaccine interchangeability
1324215|NCT00674908|Single vs mixed sequence
1324216|NCT00674908|Healthy infants
1324217|NCT00674895|Idiopathic Parkinson's Disease
1324218|NCT00674895|Lewy Body Parkinson's Disease
1324219|NCT00674895|Paralysis Agitans
1324220|NCT00674895|Parkinson's Disease, Idiopathic
1324221|NCT00674895|Parkinson's Disease, Lewy Body
1324222|NCT00674895|Primary Parkinsonism
1324223|NCT00674882|Hematopoietic stem cell transplant
1324224|NCT00674882|Follow-up studies
1324225|NCT00674882|Outcomes research
1324226|NCT00674882|Data collection
1324227|NCT00674869|sealant
1324228|NCT00674869|pit
1324229|NCT00674869|child
1324230|NCT00674869|over
1324231|NCT00674869|6 years old
1324232|NCT00674869|least
1324233|NCT00674843|MYOTONIC DYSTROPHY
1324234|NCT00674843|MYOPATHIES
1324235|NCT00674843|Distal Myopathies
1324236|NCT00674843|Muscular Dystrophy, Duchenne
1324237|NCT00674843|Phosphorylase Deficiency (McArdle Disease)
1324238|NCT00674817|salbutamol,
1324239|NCT00674817|Chronic Obstructive Pulmonary Disease (COPD)
1324240|NCT00674817|GSK961081 muscarinic receptor antagonist,
1324241|NCT00674817|COPD
1324242|NCT00674817|ipratropium bromide,
1324243|NCT00674817|Asthma
1324244|NCT00674817|ß2-adrenergic agonist,
1324245|NCT00674804|Communicating a Diagnosis
1324246|NCT00674804|Cancer Diagnosis
1324247|NCT00674804|Recurrence of Cancer
1324248|NCT00674804|Initial Cancer Diagnosis
1324249|NCT00674791|Immunotherapeutic vaccine
1324250|NCT00674791|breast cancer
1324251|NCT00674791|TxN2-3M0 breast cancer
1324252|NCT00674791|metastatic breast cancer
1324253|NCT00674791|immunotherapy
1324254|NCT00674791|antigen
1324255|NCT00674791|Histologically confirmed, TxN2-3M0 or metastatic breast cancer
1324256|NCT00674778|Radial
1324257|NCT00674778|Femoral
1324258|NCT00674778|artery
1324259|NCT00674778|Invasive cardiology safety
1324260|NCT00674739|external genital warts
1324261|NCT00674739|perianal warts
1324262|NCT00674739|condylomata acuminata
1324263|NCT00674739|venereal warts
1324264|NCT00674739|HPV types 6 and 11
1324265|NCT00674726|appendicitis
1324266|NCT00674726|gastroenteritis
1324267|NCT00674726|temperature
1324268|NCT00674726|fever
1324269|NCT00674726|acute abdomen
1324270|NCT00674726|Axilo-rectal temperature in appendicitis
1324271|NCT00674726|Axilo-rectal temperature in gastroenteritis
1324272|NCT00674713|Patients undergoing laparoscopic cholecystectomy for cholelithiasis
1324273|NCT00674700|House dust mites allergy
1324274|NCT00674674|topotecan
1324275|NCT00674674|pharmacokinetics
1324276|NCT00674674|neoplastic
1324277|NCT00674674|meningitis
1324278|NCT00674661|ectasia
1324279|NCT00674661|cross-linking
1324280|NCT00674661|crosslinking
1324281|NCT00674661|cornea
1324282|NCT00674661|riboflavin
1324283|NCT00674661|UVA
1324284|NCT00674648|Multiple Diseases
1324285|NCT00674648|Hematopoietic System
1324286|NCT00674648|CMV-PP65 PROTEIN SPECIFIC T CELLS
1324287|NCT00674635|adaptive study,
1324288|NCT00674635|DAS28,
1324289|NCT00674635|monoclonal antibody
1324290|NCT00674635|GSK315234A;
1324291|NCT00674635|rheumatoid arthritis,
1324292|NCT00674622|Lateral epicondylitis
1324293|NCT00674622|Tennis elbow
1324294|NCT00674622|Prolotherapy
1324295|NCT00674609|Palliative Care
1324296|NCT00674609|Pain
1324297|NCT00674609|Cancer
1324298|NCT00674596|PTX3, ramipril, endothelial dysfunction
1324299|NCT00674596|1- Diabetic proteinuria
1324300|NCT00674596|2- The aim of this study was to find out whether the
1324301|NCT00674596|beneficial effects of RAS blockage in diabetic
1324302|NCT00674596|proteinuria has any relation with the alteration
1324303|NCT00674596|of PTX3 levels.
1324304|NCT00674583|Conjugate vaccine
1324305|NCT00674583|Meningococcal disease
1324306|NCT00674583|Immunogenicity
1324307|NCT00674583|Meningococcal vaccine
1324308|NCT00674583|Safety
1324309|NCT00674570|Stress Disorders, Posttraumatic
1324310|NCT00674570|Hydrocortisone
1324311|NCT00674570|Cycloserine
1324312|NCT00674570|Extinction, Psychological
1324313|NCT00674570|PTSD
1324314|NCT00674570|San Francisco
1324315|NCT00674557|recurrent breast cancer
1324316|NCT00674557|stage IIIA breast cancer
1324317|NCT00674557|stage IIIB breast cancer
1324318|NCT00674557|stage IIIC breast cancer
1324319|NCT00674557|stage IV breast cancer
1324320|NCT00674557|HER2-negative breast cancer
1324321|NCT00674557|estrogen receptor-positive breast cancer
1324322|NCT00674557|progesterone receptor-positive breast cancer
1324323|NCT00674544|childhood
1324324|NCT00674544|children
1324325|NCT00674544|obesity
1324326|NCT00674544|physical activity
1324327|NCT00674544|nutrition
1324328|NCT00674544|fitness
1324329|NCT00674544|family
1324330|NCT00674531|Arteriosclerosis
1324331|NCT00674531|Arterial Occlusive Diseases
1324332|NCT00674531|Enterovirus
1324333|NCT00674531|Artery resection
1324334|NCT00674518|Health Promotion
1324335|NCT00674518|Health Behavior Change
1324336|NCT00674518|Physical Activity
1324337|NCT00674518|Dietary Change
1324338|NCT00674518|Weight Loss
1324339|NCT00674518|Obesity
1324340|NCT00674479|Advanced Hematologic Malignancies
1324341|NCT00674479|Cancer
1324342|NCT00674479|Blood
1324343|NCT00674479|Bone marrow
1324344|NCT00674479|Lymph nodes
1324345|NCT00674479|JAK kinase inhibitor INCB018424 phosphate
1324346|NCT00674479|Acute Myeloid Leukemia
1324347|NCT00674479|AML
1324348|NCT00674479|Acute Lymphocytic leukemia
1324349|NCT00674479|ALL
1324350|NCT00674479|Myelodysplastic Syndrome
1324351|NCT00674479|MDS
1324352|NCT00674479|Chronic myelogenous leukemia - Blast Crisis
1324353|NCT00674479|CML
1324354|NCT00674479|INCB018424
1324355|NCT00674466|GLP-1, incretin, type 2 diabetes
1324356|NCT00674453|Osteoporosis
1324357|NCT00674453|lasofoxifene
1324358|NCT00674453|bone density
1324359|NCT00674453|bone markers
1324360|NCT00674440|Congenital Hyperinsulinism
1324361|NCT00674440|Hyperinsulinism
1324362|NCT00674440|Persistent Hyperinsulinemic Hypoglycemia of Infancy
1324363|NCT00674440|CHI
1324364|NCT00674440|PHHI
1324365|NCT00674440|F-DOPA
1324366|NCT00674440|L-fluoro-dihydroxyphenylalanine
1324367|NCT00674427|AML
1324368|NCT00674427|ALL
1324369|NCT00674427|MDS
1324370|NCT00674427|CLL
1324371|NCT00674427|Multiple Myeloma
1324372|NCT00674414|stage IA breast cancer
1324373|NCT00674414|stage IB breast cancer
1324374|NCT00674414|stage II breast cancer
1324375|NCT00674414|stage IIIA breast cancer
1324376|NCT00674414|HER2-positive breast cancer
1324377|NCT00674388|Children
1324378|NCT00674388|Anesthesia
1324379|NCT00674388|Surgery
1324380|NCT00674388|Complication
1324381|NCT00674375|Chest Pain
1324382|NCT00674375|Acute Myocardial Infarction
1324383|NCT00674375|Patient Safety
1324384|NCT00674375|Misdiagnosis
1324385|NCT00674362|Rheumatoid Arthritis
1324386|NCT00674362|Moderate to Low Disease activity
1324387|NCT00674362|Certolizumab pegol
1324388|NCT00674336|Norovirus
1324389|NCT00674336|Gastroenteritis
1324390|NCT00674336|Clinical Trial
1324391|NCT00674336|Stomach flu
1324392|NCT00674336|Oysters
1324393|NCT00674336|Shellfish
1324394|NCT00674336|high hydrostatic pressures
1324395|NCT00674323|Polypoidal choroidal vasculopathy
1324396|NCT00674323|PCV
1324397|NCT00674323|Age-related macular degeneration (AMD) variant
1324398|NCT00674323|vision
1324399|NCT00674323|polyps
1324400|NCT00674323|indocyanine green angiography
1324401|NCT00674323|verteporfin
1324402|NCT00674323|ranibizumab
1324403|NCT00674323|photodynamic therapy
1324404|NCT00674297|Persistently Antiphospholipid Antibody Positive Patients
1324405|NCT00674271|Diabetes Mellitus, Type 2
1324406|NCT00674271|Mannose-Binding lectin
1324407|NCT00674271|Toll-Like Receptors
1324408|NCT00674271|Atherosclerosis
1324409|NCT00674271|Carotid Arteries
1324410|NCT00674271|Diabetes Complications
1324411|NCT00674271|Diabetic Angiopathies
1324412|NCT00674258|HLA-A*2402
1324413|NCT00674258|Peptide Vaccine
1324414|NCT00674258|URLC10
1324415|NCT00674258|TTK
1324416|NCT00674258|KOC1
1324417|NCT00674245|heartburn
1324418|NCT00674245|acid reflux
1324419|NCT00674245|GERD
1324420|NCT00674245|spectrum analysis
1324421|NCT00674245|electroencephalogram
1324422|NCT00674245|esophagitis
1324423|NCT00674245|peptic
1324424|NCT00674232|incomplete abortion
1324425|NCT00674232|spontaneous miscarriage
1324426|NCT00674219|GAD
1324427|NCT00674206|Metastatic breast cancer
1324428|NCT00674154|Vitamin D
1324429|NCT00674154|Primary hyperparathyroidism
1324430|NCT00674154|hypercalcemia
1324431|NCT00674141|Multiple Sclerosis, relapsing remitting, Dexamethasone
1324432|NCT00674128|pacemaker
1324433|NCT00674128|cardioverter-defibrillator
1324434|NCT00674128|ICD
1324435|NCT00674128|cardiac resynchronization device
1324436|NCT00674128|cyanoacrylate
1324437|NCT00674128|suture
1324438|NCT00674128|Dermabond
1324439|NCT00674128|Vicryl
1324440|NCT00674102|Vascular disrupting agent
1324441|NCT00674102|Non-small cell lung cancer
1324442|NCT00674089|IMR
1324443|NCT00674089|Newborn Mortality
1324444|NCT00674089|Vitamin A Effectiveness
1324445|NCT00674089|Premature Mortality
1324446|NCT00674089|Mortality
1324447|NCT00674063|Chronic Plaque Psoriasis
1324448|NCT00674063|Alefacept
1324449|NCT00674050|Healthy Males or Females subjects
1324450|NCT00674037|recruitment
1324451|NCT00674037|physicians participating in the recruitment of patients
1324452|NCT00674024|Pazopanib
1324453|NCT00674024|Tyrosine Kinase Inhibitor
1324454|NCT00674024|Advanced Cancer
1324455|NCT00674024|Pharmacokinetics
1324456|NCT00674024|Cancer
1324457|NCT00674024|Solid Tumor
1324458|NCT00674024|Lymphoma
1324459|NCT00674011|hypertension
1324460|NCT00674011|bevacizumab
1324461|NCT00674011|metastatic breast cancer
1324462|NCT00673998|Isokinetic
1324463|NCT00673998|Fatigue
1324464|NCT00673998|Strength
1324465|NCT00673998|Older
1324466|NCT00673985|SFA, Edwards, Popliteal, LifeStent, PTA, Nitinol
1324467|NCT00673972|Functional dyspepsia
1324468|NCT00673972|Gastric emptying
1324469|NCT00673972|Helicobacter pylori
1324470|NCT00673972|Lansoprazole
1324471|NCT00673972|Epigastric pain syndrome
1324472|NCT00673972|Postprandial distress syndrome
1324473|NCT00673959|Dry eye
1324474|NCT00673959|artificial tears
1324475|NCT00673946|bronchiolitis
1324476|NCT00673946|hospitalization
1324477|NCT00673946|oximetry
1324478|NCT00673946|pediatrics
1324479|NCT00673920|RA
1324480|NCT00673907|Wood smoke
1324481|NCT00673907|Health effects
1324482|NCT00673907|Human
1324483|NCT00673907|Airway inflammation
1324484|NCT00673907|Cardiovascular effects
1324485|NCT00673855|Dry eye
1324486|NCT00673855|Artificial tear
1324487|NCT00673842|Noninvasive assessment
1324488|NCT00673842|Holter
1324489|NCT00673829|Breast Cancer
1324490|NCT00673829|T cells
1324491|NCT00673829|Gene Transfer
1324492|NCT00673816|Von Hippel Lindau
1324493|NCT00673816|Sunitinib Malate
1324494|NCT00673816|Sutent
1324495|NCT00673816|Von Hippel-Lindau Syndrome
1324496|NCT00673816|VHL
1324497|NCT00673803|posterior capsule opacification
1324498|NCT00673803|micro incision
1324499|NCT00673803|sharp optic edge
1324500|NCT00673790|nebivolol
1324501|NCT00673790|BYSTOLIC ™
1324502|NCT00673790|hydrochlorothiazide
1324503|NCT00673790|lisinopril
1324504|NCT00673790|Prinivil (TM)
1324505|NCT00673790|Zestril (TM)
1324506|NCT00673790|losartan
1324507|NCT00673790|Cozaar (TM)
1324508|NCT00673790|Impaired Fasting Glucose
1324509|NCT00673790|Impaired Glucose Tolerance
1324510|NCT00673790|hypertension
1324511|NCT00673777|HLA-A*0201
1324512|NCT00673777|Peptide Vaccine
1324513|NCT00673777|URLC10
1324514|NCT00673777|VEGFR1
1324515|NCT00673777|VEGFR2
1324516|NCT00673751|mesenteric blood flow
1324517|NCT00673751|GLP-2
1324518|NCT00673751|short bowel syndrome
1324519|NCT00673751|Glucagon-Like Peptide 2
1324520|NCT00673738|Lung
1324521|NCT00673738|Thoracic
1324522|NCT00673738|Immunotherapy
1324523|NCT00673738|Radiotherapy
1324524|NCT00673738|LA - NSCLC
1324525|NCT00673738|Non-Small Cell Lung Cancer
1324526|NCT00673725|Atopic Dermatitis
1324527|NCT00673712|Coronary Artery Bypass Graft Surgery
1324528|NCT00673712|Pneumonia
1324529|NCT00673712|Surgical Site Infection
1324530|NCT00673699|NBI
1324531|NCT00673699|gastroscopy
1324532|NCT00673699|biopsy
1324533|NCT00673699|intestinal metaplasia
1324534|NCT00673686|Oral contraceptive
1324535|NCT00673686|Ovulation
1324536|NCT00673686|Missing pills
1324537|NCT00673686|Intake compliance
1324538|NCT00673686|Cycle control
1324539|NCT00673660|Statins
1324540|NCT00673660|Compliance
1324541|NCT00673660|Dyslipidemia
1324542|NCT00673647|cannabis
1324543|NCT00673647|dependence
1324544|NCT00673647|marijuana
1324545|NCT00673647|CBT
1324546|NCT00673647|efficacy of CBT for cannabis use disorders
1324547|NCT00673634|preoxygenation
1324548|NCT00673634|method
1324549|NCT00673634|efficiency
1324550|NCT00673634|obesity
1324551|NCT00673634|BiPAP
1324552|NCT00673634|FeO2
1324553|NCT00673621|Asthmatics and non-asthmatic male and female subjects
1324554|NCT00673608|Haemoglobinopathies,
1324555|NCT00673608|Myelodysplastic Syndromes,
1324556|NCT00673608|Transfusional iron overload,
1324557|NCT00673608|cardiac iron load
1324558|NCT00673595|smoking
1324559|NCT00673595|varenicline
1324560|NCT00673595|flow-mediated dilation
1324561|NCT00673595|blood pressure
1324562|NCT00673595|baroreflex
1324563|NCT00673582|Statins
1324564|NCT00673582|Intima Media Thickness
1324565|NCT00673582|Plaque Area
1324566|NCT00673569|recurrent non-small cell lung cancer
1324567|NCT00673569|stage IV non-small cell lung cancer
1324568|NCT00673569|stage IIIA non-small cell lung cancer
1324569|NCT00673569|stage IIIB non-small cell lung cancer
1324570|NCT00673556|Chronic Plaque Psoriasis
1324571|NCT00673556|Alefacept
1324572|NCT00673543|Corticosteroids
1324573|NCT00673543|Pregnancy
1324574|NCT00673543|Glucose control
1324575|NCT00673530|Hospital malnutrition
1324576|NCT00673530|Nutritional Status
1324577|NCT00673530|Nutrition Assessment
1324578|NCT00673530|Enteral Nutrition
1324579|NCT00673530|Parenteral Nutrition
1324580|NCT00673530|Severity of illness index
1324581|NCT00673530|cost analysis
1324582|NCT00673517|Acute respiratory distress syndrome
1324583|NCT00673517|Ventilator induced lung injury
1324584|NCT00673517|High frequency oscillation
1324585|NCT00673517|Lung protective ventilation
1324586|NCT00673517|Biomarkers
1324587|NCT00673517|Biotrauma
1324588|NCT00673504|cancer
1324589|NCT00673504|pancreatic cancer
1324590|NCT00673504|gemcitabine
1324591|NCT00673504|sunitinib
1324592|NCT00673504|Phase 2
1324593|NCT00673491|Critical Pathways
1324594|NCT00673491|Stroke
1324595|NCT00673491|Randomized Controlled Trial
1324596|NCT00673491|Effectiveness
1324597|NCT00673439|heparin-induced thrombocytopenia
1324598|NCT00673439|thrombocytopenia
1324599|NCT00673439|HIT
1324600|NCT00673439|thrombosis
1324601|NCT00673439|blood clot
1324602|NCT00673439|blood thinner
1324603|NCT00673439|anticoagulant
1324604|NCT00673439|heparin
1324605|NCT00673439|warfarin
1324606|NCT00673439|fondaparinux
1324607|NCT00673439|Arixtra
1324608|NCT00673426|enoxaparin
1324609|NCT00673426|chronic renal disease
1324610|NCT00673426|Anticoagulant activity of enoxaparin sodic
1324611|NCT00673413|Perception
1324612|NCT00673413|Emotions
1324613|NCT00673413|Adaptation
1324614|NCT00673413|Estomia
1324615|NCT00673400|Obstructed defecation syndrome
1324616|NCT00673400|ODS
1324617|NCT00673400|Rectocele
1324618|NCT00673400|Intussusception
1324619|NCT00673400|STARR
1324620|NCT00673387|overweight
1324621|NCT00673387|obesity
1324622|NCT00673387|pramlintide
1324623|NCT00673387|metreleptin
1324624|NCT00673387|Amylin
1324625|NCT00673374|emergency
1324626|NCT00673374|acute
1324627|NCT00673374|nontraumatic
1324628|NCT00673374|abdominal pain
1324629|NCT00673374|tenderness
1324630|NCT00673374|CT scan
1324631|NCT00673374|radiation
1324632|NCT00673374|diagnosis
1324633|NCT00673348|Mycoses
1324634|NCT00673348|Voriconazole
1324635|NCT00673335|breast cancer
1324636|NCT00673335|hereditary breast/ovarian cancer (BRCA1, BRCA2)
1324637|NCT00673335|BRCA1 mutation carrier
1324638|NCT00673335|BRCA2 mutation carrier
1324639|NCT00673322|Colorectal Cancer
1324640|NCT00673322|T cells
1324641|NCT00673322|Gene Transfer
1324642|NCT00673309|burns
1324643|NCT00673296|Bevacizumab
1324644|NCT00673296|Diabetic premacular hemorrhage
1324645|NCT00673296|Intravitreal gas
1324646|NCT00673283|lung cancer
1324647|NCT00673283|nodules
1324648|NCT00673283|radiography
1324649|NCT00673283|CT
1324650|NCT00673283|Stereoscopy
1324651|NCT00673257|unspecified childhood solid tumor, protocol specific
1324652|NCT00673244|Renal Replacement Therapy
1324653|NCT00673244|Dialysis
1324654|NCT00673231|Dapagliflozin
1324655|NCT00673231|efficacy
1324656|NCT00673231|safety
1324657|NCT00673231|add on to insulin
1324658|NCT00673231|Oral AntiDiabetic
1324659|NCT00673231|Type 2 diabetes
1324660|NCT00673218|IL13
1324661|NCT00673218|Cytokines
1324662|NCT00673218|Basophil stimulation
1324663|NCT00673205|androgen antagonists
1324664|NCT00673205|prostate neoplasms
1324665|NCT00673179|Doxorubicin
1324666|NCT00673179|AD
1324667|NCT00673179|Hydroxydaunomycin hydrochloride
1324668|NCT00673179|Cisplatin
1324669|NCT00673179|Paraplatin®
1324670|NCT00673179|Methotrexate
1324671|NCT00673179|Ifosfamide
1324672|NCT00673179|Osteosarcoma
1324673|NCT00673179|Sargramostim
1324674|NCT00673179|Leukine™
1324675|NCT00673179|Leucovorin
1324676|NCT00673179|Gemcitabine
1324677|NCT00673179|Gemzar
1324678|NCT00673179|Gemcitabine Hydrochloride
1324679|NCT00673179|GM-CSF
1324680|NCT00673179|Questionnaire
1324681|NCT00673179|Survey
1324682|NCT00673166|Staff motivation
1324683|NCT00673166|Hospital mortality
1324684|NCT00673166|Perception of quality of care
1324685|NCT00673140|ALS (Amyotrophic Lateral Sclerosis)
1324686|NCT00673140|Amyotrophic Lateral Sclerosis With Dementia
1324687|NCT00673140|Amyotrophic Lateral Sclerosis, Guam Form
1324688|NCT00673140|Dementia With Amyotrophic Lateral Sclerosis
1324689|NCT00673140|Gehrig's Disease
1324690|NCT00673140|Guam Form of Amyotrophic Lateral Sclerosis
1324691|NCT00673140|Lou Gehrig Disease
1324692|NCT00673127|hormone refractory
1324693|NCT00673127|KHAD
1324694|NCT00673127|ketoconazole
1324695|NCT00673127|dutasteride
1324696|NCT00673127|hydrocortisone
1324697|NCT00673114|Haplo/cord
1324698|NCT00673114|hematologic malignancy
1324699|NCT00673114|MDS
1324700|NCT00673114|Aplastic Anemia
1324701|NCT00673114|AML
1324702|NCT00673114|ALL
1324703|NCT00673114|CML
1324704|NCT00673101|liver fibrosis, cirrhosis
1324705|NCT00673101|FibroScan
1324706|NCT00673101|transient elastography
1324707|NCT00673101|elastometry
1324708|NCT00673101|methotrexate
1324709|NCT00673101|non invasive blood markers
1324710|NCT00673101|FibroTest
1324711|NCT00673101|treatment
1324712|NCT00673075|carvedilol
1324713|NCT00673075|Coreg (TM)
1324714|NCT00673075|hypertension
1324715|NCT00673075|blood pressure
1324716|NCT00673075|coronary artery disease
1324717|NCT00673075|Nebivolol
1324718|NCT00673075|BYSTOLIC (TM)
1324719|NCT00673049|IGR-1R
1324720|NCT00673049|Non small cell lung cancer
1324721|NCT00673049|CP-751
1324722|NCT00673049|871
1324723|NCT00673049|Figitumumab
1324724|NCT00673036|Coronary syndrome
1324725|NCT00673036|Myocardial infarction
1324726|NCT00673036|French registry
1324727|NCT00673010|124-IODINE
1324728|NCT00673010|I-131 METAIODOBENZ SULF (MIBG)
1324729|NCT00673010|Thyroid
1324730|NCT00673010|Parathyroid
1324731|NCT00672997|Glaucoma
1324732|NCT00672997|Hypertension
1324733|NCT00672984|QT/QTc
1324734|NCT00672958|Major Depressive Disorder
1324735|NCT00672958|Depression
1324736|NCT00672958|Drug Therapy
1324737|NCT00672958|Major Depressive Episode
1324738|NCT00672932|raltegravir
1324739|NCT00672932|central nervous system (CNS)
1324740|NCT00672932|HIV-1
1324741|NCT00672932|AIDS
1324742|NCT00672932|cerebrospinal fluid (CSF)
1324743|NCT00672932|immunoactivation
1324744|NCT00672932|antiretroviral therapy
1324745|NCT00672932|suppression
1324746|NCT00672919|Glucose Metabolism Disorder
1324747|NCT00672919|Dysmetabolic Syndrome
1324748|NCT00672919|Type II Diabetes
1324749|NCT00672919|Diabetes Mellitus, Lipoatrophic
1324750|NCT00672919|Dyslipidemia
1324751|NCT00672919|Drug Therapy
1324752|NCT00672906|anorexia nervosa
1324753|NCT00672906|group parent training
1324754|NCT00672906|caregiver burden
1324755|NCT00672906|eating disorders
1324756|NCT00672906|treatment
1324757|NCT00672893|central airway stenosis, lung sounds, airway obstruction, bronchial obstruction, bronchoscopic treatment
1324758|NCT00672880|Chronic low back pain accompanied by depression
1324759|NCT00672854|parenteral nutrition
1324760|NCT00672854|lipid emulsion
1324761|NCT00672854|nosocomial infection
1324762|NCT00672854|mortality
1324763|NCT00672854|endothelial function
1324764|NCT00672854|inflammatory markers
1324765|NCT00672854|oxidative stress
1324766|NCT00672854|immune function
1324767|NCT00672854|autonomic nervous system
1324768|NCT00672854|insulin sensitivity
1324769|NCT00672854|carbohydrate metabolism
1324770|NCT00672841|candidemia
1324771|NCT00672841|invasive candidiasis
1324772|NCT00672841|preemptive antifungal therapy
1324773|NCT00672841|surveillance
1324774|NCT00672841|β-D-Glucan (BDG)
1324775|NCT00672828|colon cancer
1324776|NCT00672828|rectal cancer
1324777|NCT00672815|coordinated school health
1324778|NCT00672815|school health policy evaluation
1324779|NCT00672815|physical activity
1324780|NCT00672802|Chronic Obstructive Pulmonary Disease
1324781|NCT00672802|COPD
1324782|NCT00672802|Insomnia
1324783|NCT00672802|Drug Therapy
1324784|NCT00672789|Sickle cell anemia
1324785|NCT00672789|Children
1324786|NCT00672789|Hydroxyurea
1324787|NCT00672789|Treatment Adherence
1324788|NCT00672776|hippocampus
1324789|NCT00672776|paroxetine
1324790|NCT00672776|stress
1324791|NCT00672776|PTSD
1324792|NCT00672763|Crohn's Disease
1324793|NCT00672763|Inflammatory Bowel Disease
1324794|NCT00672763|Vitamin D
1324795|NCT00672763|Randomised
1324796|NCT00672763|Placebo
1324797|NCT00672750|laparoscopic
1324798|NCT00672750|myomectomy
1324799|NCT00672750|menorrhagia
1324800|NCT00672750|pelvic pain
1324801|NCT00672724|Insomnia
1324802|NCT00672724|Sleep Disorder
1324803|NCT00672724|Drug Therapy
1324804|NCT00672711|Complex Regional Pain Syndrome
1324805|NCT00672711|Chronic Post-surgical Pain
1324806|NCT00672711|Genetic susceptibility
1324807|NCT00672711|COMT
1324808|NCT00672698|SURGICAL RISK
1324809|NCT00672698|ELDERLY
1324810|NCT00672698|MAJOR SURGERY
1324811|NCT00672698|P-POSSUM
1324812|NCT00672698|SAPS II
1324813|NCT00672685|Cognitive decline
1324814|NCT00672685|omega-3 fatty acids
1324815|NCT00672685|nutrition
1324816|NCT00672685|physical exercise
1324817|NCT00672685|cognitive training
1324818|NCT00672685|social activities
1324819|NCT00672685|frailty
1324820|NCT00672672|Wound healing of surgical site treated with autologous platlet gel
1324821|NCT00672659|Lost of interest, Depressed Mood
1324822|NCT00672646|Analgesic effect
1324823|NCT00672633|Omega 3 Fatty Acids
1324824|NCT00672633|Triglycerides
1324825|NCT00672633|Lovaza
1324826|NCT00672633|Trial
1324827|NCT00672620|Major Depressive Disorder
1324828|NCT00672620|Depression
1324829|NCT00672620|Drug Therapy
1324830|NCT00672620|Major Depressive Episode
1324831|NCT00672607|premenstual syndrome, PMS, clinical trial
1324832|NCT00672581|Hepatic Impairment
1324833|NCT00672568|Rotator cuff, Shoulder, Arthroscopic shoulder surgery
1324834|NCT00672555|pilonidal sinus
1324835|NCT00672555|recurrence
1324836|NCT00672555|Limberg flap
1324837|NCT00672542|melanoma
1324838|NCT00672542|dendritic cell
1324839|NCT00672542|immunoproteasome
1324840|NCT00672542|vaccine
1324841|NCT00672529|Childhood Asthma
1324842|NCT00672529|Inhaled Corticosteroids
1324843|NCT00672529|Alternative Medicine
1324844|NCT00672529|Vitamins, minerals, and fish oil as Add-on Treatment
1324845|NCT00672516|hemorrhage
1324846|NCT00672516|cardiopulmonary bypass
1324847|NCT00672516|blood component transfusion
1324848|NCT00672516|hemostasis, surgical
1324849|NCT00672503|indwelling urinary catheters
1324850|NCT00672503|urinary tract infections
1324851|NCT00672503|foley-catheter related infections
1324852|NCT00672503|hospital acquired CA-UTI
1324853|NCT00672490|Acute Mania
1324854|NCT00672490|Bipolar Disorder
1324855|NCT00672490|Quetiapine Fumarate
1324856|NCT00672490|Lithium
1324857|NCT00672477|opioid-induced constipation
1324858|NCT00672464|Schizophrenia
1324859|NCT00672464|Schizoaffective
1324860|NCT00672464|Cardiovascular
1324861|NCT00672464|Olanzapine
1324862|NCT00672464|Metformin
1324863|NCT00672464|Simvastatin
1324864|NCT00672451|diabetic kidney disease
1324865|NCT00672451|albuminuria
1324866|NCT00672412|Treatment Experienced
1324867|NCT00672399|Amylin
1324868|NCT00672399|Eli Lilly
1324869|NCT00672399|exenatide
1324870|NCT00672399|moxifloxacin
1324871|NCT00672386|Diabetes
1324872|NCT00672386|Type 2 Diabetes
1324873|NCT00672386|Adult-Onset Diabetes Mellitus
1324874|NCT00672386|Metabolic Syndrome
1324875|NCT00672386|HbA1c
1324876|NCT00672386|Body Weight
1324877|NCT00672386|Metformin
1324878|NCT00672373|Tardive Dyskinesia
1324879|NCT00672373|Schizophrenia
1324880|NCT00672373|Extract of Gingko Biloba
1324881|NCT00672360|Autism Spectrum Disorder
1324882|NCT00672347|caudal anesthesia, clonidine, morphine, bupivacaine
1324883|NCT00672334|Cardiac surgery
1324884|NCT00672334|Cardiopulmonary bypass
1324885|NCT00672334|Oxidative stress
1324886|NCT00672334|Acute renal dysfunction
1324887|NCT00672334|Sodium bicarbonate
1324888|NCT00672321|recurrent melanoma
1324889|NCT00672321|stage IB melanoma
1324890|NCT00672321|stage II melanoma
1324891|NCT00672321|stage IIIA melanoma
1324892|NCT00672308|Cholera, benefiber, ORS
1324893|NCT00672295|Ovarian Cancer
1324894|NCT00672295|Peritoneal Cancer
1324895|NCT00672295|Tubal Cancer
1324896|NCT00672295|Fallopian Tube Cancer
1324897|NCT00672295|Dasatinib
1324898|NCT00672295|Sprycel
1324899|NCT00672295|Paclitaxel
1324900|NCT00672295|Taxol
1324901|NCT00672295|Carboplatin
1324902|NCT00672295|Paraplatin
1324903|NCT00672282|androgen antagonists
1324904|NCT00672282|prostate neoplasms
1324905|NCT00672269|carcinoid
1324906|NCT00672269|family members
1324907|NCT00672269|familial
1324908|NCT00672269|tumors
1324909|NCT00672269|cancer
1324910|NCT00672256|Smoking
1324911|NCT00672256|fMRI
1324912|NCT00672243|GBM
1324913|NCT00672243|Brain tumor
1324914|NCT00672243|Erlotinib
1324915|NCT00672243|Sirolimus
1324916|NCT00672243|Glioblastoma multiforme
1324917|NCT00672243|Glioblastoma
1324918|NCT00672243|Gliosarcoma3
1324919|NCT00672243|Tarceva
1324920|NCT00672243|Rapamune
1324921|NCT00672230|Lactation
1324922|NCT00672230|Breast milk
1324923|NCT00672230|Lutein
1324924|NCT00672230|Lutein supplement
1324925|NCT00672217|Breast cancer survivors, insomnia, quality of life
1324926|NCT00672204|Islet transplant
1324927|NCT00672204|Diabetes Mellitus
1324928|NCT00672204|Hypoglycemia
1324929|NCT00672191|HIV
1324930|NCT00672191|Human immunodeficiency virus
1324931|NCT00672191|Immunodeficiency Virus, Human
1324932|NCT00672191|HIV-1
1324933|NCT00672191|ART
1324934|NCT00672191|antiretroviral therapy
1324935|NCT00672191|HAART
1324936|NCT00672191|highly active retroviral therapy
1324937|NCT00672191|cluster of differentiation CD 4+ T cell counts
1324938|NCT00672191|HIV-1 Subjects successfully ART treated
1324939|NCT00672191|Treatment Experienced
1324940|NCT00672178|RCC
1324941|NCT00672178|metastatic
1324942|NCT00672178|sorafenib
1324943|NCT00672165|MAB HUM 195 ACTINIUM-225 LABELED
1324944|NCT00672165|HEMATOPOIETIC SYSTEM
1324945|NCT00672165|02-017
1324946|NCT00672152|Autologous transplantation
1324947|NCT00672152|Allogeneic transplantation
1324948|NCT00672139|Opioid-Induced Constipation
1324949|NCT00672100|Peripheral Nerve Infusion,
1324950|NCT00672100|continuous brachial plexus block,
1324951|NCT00672100|post-operative pain
1324952|NCT00672100|diaphragmatic paresis
1324953|NCT00672087|Chronic Prostatitis with Chronic Pelvic Pain Syndrome
1324954|NCT00672087|Chronic Bacterial Prostatitis
1324955|NCT00672087|Asymptomatic Inflammatory Prostatitis
1324956|NCT00672087|Painful Bladder Syndrome
1324957|NCT00672087|Cystitis, Interstitial
1324958|NCT00672074|Postoperative Ileus
1324959|NCT00672061|Sleep Apnea, Obstructive
1324960|NCT00672061|Insomnia
1324961|NCT00672061|Drug Therapy
1324962|NCT00672048|glaucoma
1324963|NCT00672048|optometrists
1324964|NCT00672035|LT
1324965|NCT00672035|Healthy Adults
1324966|NCT00672035|Dose Ranging
1324967|NCT00672035|Patch
1324968|NCT00672035|Vaccine
1324969|NCT00672009|prostate cancer
1324970|NCT00672009|radical prostatectomy
1324971|NCT00672009|ixabepilone
1324972|NCT00671970|Glioblastoma
1324973|NCT00671970|Gliosarcoma
1324974|NCT00671970|Recurrent MG
1324975|NCT00671970|Malignant glioma
1324976|NCT00671970|Glioma
1324977|NCT00671970|Glioblastoma multiforme (GBM)
1324978|NCT00671970|GBM
1324979|NCT00671970|Brain tumor
1324980|NCT00671970|Anaplastic astrocytoma
1324981|NCT00671970|Anaplastic oligodendroglioma
1324982|NCT00671970|Anaplastic oligoastrocytoma
1324983|NCT00671970|Bevacizumab
1324984|NCT00671970|Avastin
1324985|NCT00671970|Erlotinib
1324986|NCT00671970|Tarceva
1324987|NCT00671957|Obesity
1324988|NCT00671957|Bariatric
1324989|NCT00671957|Surgery
1324990|NCT00671957|Activity
1324991|NCT00671944|protein
1324992|NCT00671944|calcium
1324993|NCT00671944|parathyroid hormone
1324994|NCT00671944|bone markers
1324995|NCT00671944|calcium kinetics
1324996|NCT00671944|absorption
1324997|NCT00671931|dexmedetomidine
1324998|NCT00671931|neuromonitoring
1324999|NCT00671931|spine procedures
1325000|NCT00671931|safe dose
1325001|NCT00671931|1- safe dose of dexmedetomidine when used in total intravenous anesthesia for procedures require neuromonitoring
1325002|NCT00671931|2- safe dose of propofol when uses in comination with dexmedetomidine in neuromontoring
1325003|NCT00671931|3effect of dexmedetomidine on somatosensory evoked potential and motor evoked potentials
1325004|NCT00671918|breast cancer
1325005|NCT00671918|lymph nodes
1325006|NCT00671918|melanoma
1325007|NCT00671918|surgery
1325008|NCT00671905|atrial fibrillation
1325009|NCT00671905|PV isolation
1325010|NCT00671905|ablation
1325011|NCT00671905|ganglionic plexi
1325012|NCT00671905|parasympathetic denervation
1325013|NCT00671892|LPS endotoxin
1325014|NCT00671892|asthma
1325015|NCT00671866|OP
1325016|NCT00671866|Pesticides
1325017|NCT00671866|Long-Term Low Level Exposure
1325018|NCT00671866|Occupational Health
1325019|NCT00671866|Neurobehavioral Effects
1325020|NCT00671853|Bipolar Disorder
1325021|NCT00671853|Anxiety
1325022|NCT00671853|Anxiety Disorders
1325023|NCT00671853|Substance Use Disorders
1325024|NCT00671827|Gynecologic Cancer
1325025|NCT00671827|Cervical Cancer
1325026|NCT00671827|Endometrial Cancer
1325027|NCT00671827|Fallopian Tube Cancer
1325028|NCT00671827|Ovarian Cancer
1325029|NCT00671827|Uterine Cancer
1325030|NCT00671827|Vaginal Cancer
1325031|NCT00671827|Vulvar Cancer
1325032|NCT00671827|Questionnaire
1325033|NCT00671827|Survey
1325034|NCT00671827|Robot-Assisted Surgery
1325035|NCT00671814|antibiotic
1325036|NCT00671801|Malignant Gliomas
1325037|NCT00671801|Glioblastoma Multiforme
1325038|NCT00671801|Gliosarcoma
1325039|NCT00671801|Anaplastic Astrocytoma
1325040|NCT00671801|Anaplastic Oligodendroglioma
1325041|NCT00671801|Anaplastic Oligoastrocytoma
1325042|NCT00671801|Camptosar
1325043|NCT00671801|Irinotecan
1325044|NCT00671801|CPT-11
1325045|NCT00671801|Lenalidomide
1325046|NCT00671801|Revlimid
1325047|NCT00671801|CC-5013
1325048|NCT00671775|Bariatric Surgery
1325049|NCT00671775|Obesity
1325050|NCT00671775|Cognitive Function
1325051|NCT00671736|cystic fibrosis
1325052|NCT00671736|Moli1901
1325053|NCT00671736|Lancovutide
1325054|NCT00671736|2622U90
1325055|NCT00671736|duramycin
1325056|NCT00671736|lung
1325057|NCT00671723|Atelectasis
1325058|NCT00671710|malignant glial brain tumors
1325059|NCT00671697|MDS
1325060|NCT00671697|hypomethylating agent
1325061|NCT00671697|oxidative stress
1325062|NCT00671684|Hirschsprung's disease
1325063|NCT00671684|Constipation
1325064|NCT00671684|Endoscopy, digestive system
1325065|NCT00671684|Diagnosis
1325066|NCT00671684|Colonoscopy
1325067|NCT00671658|Lymphoma
1325068|NCT00671658|HYPER-CVAD
1325069|NCT00671658|Leukemia
1325070|NCT00671658|Acute Lymphoblastic Leukemia
1325071|NCT00671658|ALL
1325072|NCT00671658|Remission Duration
1325073|NCT00671658|Chemotherapy
1325074|NCT00671658|Asparaginase
1325075|NCT00671658|Cyclophosphamide
1325076|NCT00671658|Cytarabine
1325077|NCT00671658|Dexamethasone
1325078|NCT00671658|Doxorubicin
1325079|NCT00671658|Leukine
1325080|NCT00671658|Methotrexate
1325081|NCT00671658|Rituximab
1325082|NCT00671658|Vincristine
1325083|NCT00671645|pilot study
1325084|NCT00671645|rectal
1325085|NCT00671645|carcinoma
1325086|NCT00671645|phase II
1325087|NCT00671645|preoperative
1325088|NCT00671645|RadioChemo
1325089|NCT00671645|molecular
1325090|NCT00671645|target
1325091|NCT00671645|therapy
1325092|NCT00671645|T3
1325093|NCT00671645|ABCSG
1325094|NCT00671645|TAKO
1325095|NCT00671645|R04
1325096|NCT00671645|08
1325097|NCT00671632|Addiction
1325098|NCT00671619|opthalmology
1325099|NCT00671619|antibody fragment
1325100|NCT00671619|TNF alpha
1325101|NCT00671606|Endometrial Cancer
1325102|NCT00671606|Lymphatic Mapping
1325103|NCT00671606|Sentinel Node Identification
1325104|NCT00671606|Lymph Node
1325105|NCT00671606|Intraoperative lymphatic mapping
1325106|NCT00671606|Total hysterectomy
1325107|NCT00671606|Bilateral salpingooophorectomy
1325108|NCT00671606|Lymph node staging
1325109|NCT00671606|Laparotomy
1325110|NCT00671606|Laparoscopy
1325111|NCT00671593|Allergy
1325112|NCT00671593|Asthma
1325113|NCT00671593|healthy
1325114|NCT00671593|Normal
1325115|NCT00671580|Skin Infections
1325116|NCT00671580|Complicated Skin and Skin Structure Infections
1325117|NCT00671567|Sleep Disorder
1325118|NCT00671567|Insomnia
1325119|NCT00671554|Melanoma
1325120|NCT00671554|Dendritic cells
1325121|NCT00671554|Cell therapy
1325122|NCT00671554|BCG vaccine
1325123|NCT00671528|Impetiginous
1325124|NCT00671515|Depressive Disorder, Major
1325125|NCT00671515|Metabolic Syndrome X
1325126|NCT00671515|pioglitazone
1325127|NCT00671489|Patients
1325128|NCT00671489|high-energy
1325129|NCT00671489|admitted
1325130|NCT00671489|intensive care unit
1325131|NCT00671489|motor vehicle accident
1325132|NCT00671489|falling from height
1325133|NCT00671489|other accident
1325134|NCT00671476|ductal breast carcinoma in situ
1325135|NCT00671463|Pancreas surgery
1325136|NCT00671463|Pancreatic adenocarcinoma
1325137|NCT00671463|Pancreatic neuroendocrine tumor
1325138|NCT00671463|Pancreatic duct stenting
1325139|NCT00671437|squamous cell carcinoma of the head and neck
1325140|NCT00671424|Interaction,
1325141|NCT00671424|Diabetes,
1325142|NCT00671424|healthy male subjects
1325143|NCT00671424|GSK189075,
1325144|NCT00671424|Diuretics,
1325145|NCT00671411|Ultrasound
1325146|NCT00671411|07-165
1325147|NCT00671398|Insomnia
1325148|NCT00671398|Sleep Disorder
1325149|NCT00671398|Drug Therapy
1325150|NCT00671385|screening
1325151|NCT00671385|compositional analysis
1325152|NCT00671385|metabolism
1325153|NCT00671385|breast
1325154|NCT00671385|breast cyst
1325155|NCT00671385|breast infection
1325156|NCT00671385|breast inflammation
1325157|NCT00671385|lipoma
1325158|NCT00671385|benign growth
1325159|NCT00671385|Women without a diagnosis for a region of interest in the breast
1325160|NCT00671372|CRC
1325161|NCT00671372|Metastatic CRC
1325162|NCT00671372|APO2L/TRAIL
1325163|NCT00671359|Food effects
1325164|NCT00671346|Cancer
1325165|NCT00671346|Coronary artery disease
1325166|NCT00671346|Myocardial infarction
1325167|NCT00671346|Cerebrovascular stroke
1325168|NCT00671346|Homocysteine
1325169|NCT00671346|Vitamin B Complex
1325170|NCT00671346|Folic acid
1325171|NCT00671346|Vitamin B12
1325172|NCT00671346|Vitamin B6
1325173|NCT00671346|Pyridoxal phosphate
1325174|NCT00671346|Osteoporotic fractures
1325175|NCT00671346|Diabetes
1325176|NCT00671333|Randomized
1325177|NCT00671333|Prospective
1325178|NCT00671333|Procedure / Surgery
1325179|NCT00671320|acute ankle sprain, acute pain, South America
1325180|NCT00671307|Gelsolin
1325181|NCT00671307|Trauma
1325182|NCT00671307|Pneumonia
1325183|NCT00671307|Peritonitis
1325184|NCT00671307|Burn
1325185|NCT00671307|Infection
1325186|NCT00671307|Sepsis
1325187|NCT00671307|Systemic Inflammatory Response Syndrome
1325188|NCT00671294|Insomnia
1325189|NCT00671281|FESS
1325190|NCT00671281|Tranexamic acid
1325191|NCT00671281|Hemostasis
1325192|NCT00671281|Visualization
1325193|NCT00671268|Grass pollen allergy
1325194|NCT00671268|specific immunotherapy
1325195|NCT00671255|Chronic Insomnia
1325196|NCT00671255|Drug Therapy
1325197|NCT00671255|Elderly
1325198|NCT00671242|Fluorine-18-α-methyltyrosine,
1325199|NCT00671242|Positron emission tomography,
1325200|NCT00671242|Fluorine-18-fluorodeoxyglucose,
1325201|NCT00671242|Lung cancer,
1325202|NCT00671242|Angiogenesis
1325203|NCT00671242|The median VEGF rate was 45% (range, 10-78%).
1325204|NCT00671242|High expression was seen in 30 patients (81%, 30/37).
1325205|NCT00671242|VEGF expression was statistically associated with progressively growing microvessel count.
1325206|NCT00671229|Healthy
1325207|NCT00671229|Asthma
1325208|NCT00671229|Nitric Oxide
1325209|NCT00671216|safety
1325210|NCT00671216|pharmacodynamics
1325211|NCT00671216|Muscarinic Receptor Antagonist
1325212|NCT00671216|tolerability
1325213|NCT00671216|healthy subjects
1325214|NCT00671216|GS642444
1325215|NCT00671216|GSK233705
1325216|NCT00671216|Anticholinergic
1325217|NCT00671216|ß2 agonist
1325218|NCT00671216|pharmacokinetics
1325219|NCT00671203|Tissue oximetry
1325220|NCT00671203|Ischemia
1325221|NCT00671203|Aortic Aneurysm Repair
1325222|NCT00671203|Aortic Stent
1325223|NCT00671203|Vascular Stent
1325224|NCT00671203|Aortic graft
1325225|NCT00671203|Vascular graft
1325226|NCT00671190|Sleep Disorder
1325227|NCT00671190|Circadian Rhythm Sleep Disorder
1325228|NCT00671190|Drug Therapy
1325229|NCT00671177|colonoscopy
1325230|NCT00671177|diagnostic techniques
1325231|NCT00671177|digestive system
1325232|NCT00671177|endoscopy
1325233|NCT00671177|gastrointestinal
1325234|NCT00671151|COPD exacerbation
1325235|NCT00671151|histone
1325236|NCT00671151|steroid resistance
1325237|NCT00671151|inflammation
1325238|NCT00671151|theophylline
1325239|NCT00671138|Celiac disease
1325240|NCT00671138|Parasitic infections
1325241|NCT00671138|necator americanus
1325242|NCT00671138|Immunity
1325243|NCT00671125|Sleep Disorder
1325244|NCT00671125|Insomnia
1325245|NCT00671125|Drug Therapy
1325246|NCT00671112|recurrent grade 1 follicular lymphoma
1325247|NCT00671112|recurrent grade 2 follicular lymphoma
1325248|NCT00671112|recurrent grade 3 follicular lymphoma
1325249|NCT00671112|recurrent mantle cell lymphoma
1325555|NCT00670527|Prostate cancer
1325250|NCT00671112|recurrent marginal zone lymphoma
1325251|NCT00671112|recurrent small lymphocytic lymphoma
1325252|NCT00671112|Waldenstrom's macroglobulinemia
1325253|NCT00671112|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1325254|NCT00671112|nodal marginal zone B-cell lymphoma
1325255|NCT00671112|splenic marginal zone lymphoma
1325256|NCT00671112|refractory hairy cell leukemia
1325257|NCT00671112|B-cell chronic lymphocytic leukemia
1325258|NCT00671112|refractory chronic lymphocytic leukemia
1325259|NCT00671112|hairy cell leukemia
1325260|NCT00671112|cutaneous B and T cell lymphoma
1325261|NCT00671112|transformed lymphoma
1325262|NCT00671112|transformed B and T cell cutaneous lymphoma
1325263|NCT00671112|relapsed or refractory diffuse large B cell lymphoma
1325264|NCT00671112|extranodal T cell lymphomas
1325265|NCT00671112|anaplastic large cell lymphoma
1325266|NCT00671112|angioimmunoblastic T cell lymphoma
1325267|NCT00671112|PTCL-NOS
1325268|NCT00671112|nasal or disseminated extranodal T/NK lymphoma
1325269|NCT00671112|enteropathy-associated T cell lymphoma
1325270|NCT00671112|hepatosplenic gamma/delta T cell lymphoma
1325271|NCT00671112|subcutaneous panniculitis-like T cell lymphoma
1325272|NCT00671112|T-prolymphocytic leukemia
1325273|NCT00671112|adult T-cell leukemia/lymphoma
1325274|NCT00671112|large granular lymphocytic leukemia
1325275|NCT00671112|aggressive NK leukemia
1325276|NCT00671099|Patients
1325277|NCT00671099|with high-energy
1325278|NCT00671099|admitted
1325279|NCT00671099|intensive care unit
1325280|NCT00671099|motor vehicle accident
1325281|NCT00671099|falling from height
1325282|NCT00671099|other accident
1325283|NCT00671086|Chronic Insomnia
1325284|NCT00671086|DIMS (Disorders of Initiating and Maintaining Sleep)
1325285|NCT00671086|Disorders of Initiating and Maintaining Sleep
1325286|NCT00671086|Insomnia Disorder Sleep Initiation Dysfunction
1325287|NCT00671086|Transient Insomnia
1325288|NCT00671086|Drug Therapy
1325289|NCT00671086|Sleep Disorders, Intrinsic
1325290|NCT00671073|Airflow Obstruction, Chronic
1325291|NCT00671073|Chronic Airflow Obstruction
1325292|NCT00671073|Chronic Obstructive Pulmonary Disease
1325293|NCT00671073|Chronic Obstructive Airway Disease
1325294|NCT00671073|Chronic Obstructive Lung Disease
1325295|NCT00671073|COPD
1325296|NCT00671073|COAD
1325297|NCT00671060|intrauterine fetal death
1325298|NCT00671060|misoprostol
1325299|NCT00671047|Autoimmune Diseases
1325300|NCT00671047|Lupus
1325301|NCT00671021|platelet aggregation
1325302|NCT00671021|aspirin
1325303|NCT00670995|Tobacco use among middle and junior high school students remains a concern among health educators.
1325304|NCT00670995|The use of tobacco prevention programs and their integration into school-based curricula has been lacking due to a number of factors.
1325305|NCT00670982|HER2 positive
1325306|NCT00670982|bevacizumab
1325307|NCT00670982|vinorelbine
1325308|NCT00670982|trastuzumab
1325309|NCT00670969|Obesity
1325310|NCT00670956|prenatal steroids
1325311|NCT00670956|hydrops
1325312|NCT00670956|congenital cystic adenomatoid malformation of the lung
1325313|NCT00670956|prenatal intervention
1325314|NCT00670956|betamethasone
1325315|NCT00670956|prenatal diagnosis
1325316|NCT00670943|Clopidogrel discontinuation
1325317|NCT00670943|Platelet aggregation
1325318|NCT00670930|Asthma, adults, anti-immunoglobulin E ( IgE), omalizumab, airway inflammation, airway remodeling, allergy
1325319|NCT00670917|pain
1325320|NCT00670917|unspecified adult solid tumor, protocol specific
1325321|NCT00670917|accelerated phase chronic myelogenous leukemia
1325322|NCT00670917|acute undifferentiated leukemia
1325323|NCT00670917|adult acute lymphoblastic leukemia in remission
1325324|NCT00670917|adult acute myeloid leukemia in remission
1325325|NCT00670917|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1325326|NCT00670917|adult acute myeloid leukemia with inv(16)(p13;q22)
1325327|NCT00670917|adult acute myeloid leukemia with t(15;17)(q22;q12)
1325328|NCT00670917|adult acute myeloid leukemia with t(16;16)(p13;q22)
1325329|NCT00670917|adult acute myeloid leukemia with t(8;21)(q22;q22)
1325330|NCT00670917|atypical chronic myeloid leukemia, BCR-ABL negative
1325331|NCT00670917|blastic phase chronic myelogenous leukemia
1325332|NCT00670917|chronic myelomonocytic leukemia
1325333|NCT00670917|chronic phase chronic myelogenous leukemia
1325334|NCT00670917|mast cell leukemia
1325335|NCT00670917|meningeal chronic myelogenous leukemia
1325336|NCT00670917|progressive hairy cell leukemia, initial treatment
1325337|NCT00670917|prolymphocytic leukemia
1325338|NCT00670917|recurrent adult acute lymphoblastic leukemia
1325339|NCT00670917|recurrent adult acute myeloid leukemia
1325340|NCT00670917|recurrent adult T-cell leukemia/lymphoma
1325341|NCT00670917|refractory chronic lymphocytic leukemia
1325342|NCT00670917|refractory hairy cell leukemia
1325343|NCT00670917|relapsing chronic myelogenous leukemia
1325344|NCT00670917|secondary acute myeloid leukemia
1325345|NCT00670917|stage 0 chronic lymphocytic leukemia
1325346|NCT00670917|stage I adult T-cell leukemia/lymphoma
1325347|NCT00670917|stage I chronic lymphocytic leukemia
1325348|NCT00670917|stage II adult T-cell leukemia/lymphoma
1325349|NCT00670917|stage II chronic lymphocytic leukemia
1325797|NCT00669422|Chemotherapy
1325350|NCT00670917|stage III adult T-cell leukemia/lymphoma
1325351|NCT00670917|stage III chronic lymphocytic leukemia
1325352|NCT00670917|stage IV adult T-cell leukemia/lymphoma
1325353|NCT00670917|stage IV chronic lymphocytic leukemia
1325354|NCT00670917|T-cell large granular lymphocyte leukemia
1325355|NCT00670917|untreated adult acute lymphoblastic leukemia
1325356|NCT00670917|untreated adult acute myeloid leukemia
1325357|NCT00670917|untreated hairy cell leukemia
1325358|NCT00670917|recurrent adult Hodgkin lymphoma
1325359|NCT00670917|stage I adult Hodgkin lymphoma
1325360|NCT00670917|stage II adult Hodgkin lymphoma
1325361|NCT00670917|stage III adult Hodgkin lymphoma
1325362|NCT00670917|stage IV adult Hodgkin lymphoma
1325363|NCT00670917|anaplastic large cell lymphoma
1325364|NCT00670917|angioimmunoblastic T-cell lymphoma
1325365|NCT00670917|cutaneous B-cell non-Hodgkin lymphoma
1325366|NCT00670917|recurrent cutaneous T-cell non-Hodgkin lymphoma
1325367|NCT00670917|stage I cutaneous T-cell non-Hodgkin lymphoma
1325368|NCT00670917|stage II cutaneous T-cell non-Hodgkin lymphoma
1325369|NCT00670917|stage III cutaneous T-cell non-Hodgkin lymphoma
1325370|NCT00670917|stage IV cutaneous T-cell non-Hodgkin lymphoma
1325371|NCT00670917|recurrent mycosis fungoides/Sezary syndrome
1325372|NCT00670917|stage I mycosis fungoides/Sezary syndrome
1325373|NCT00670917|stage II mycosis fungoides/Sezary syndrome
1325374|NCT00670917|stage III mycosis fungoides/Sezary syndrome
1325375|NCT00670917|stage IV mycosis fungoides/Sezary syndrome
1325376|NCT00670917|adult grade III lymphomatoid granulomatosis
1325377|NCT00670917|adult nasal type extranodal NK/T-cell lymphoma
1325378|NCT00670917|Waldenstrom macroglobulinemia
1325379|NCT00670917|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1325380|NCT00670917|nodal marginal zone B-cell lymphoma
1325381|NCT00670917|splenic marginal zone lymphoma
1325382|NCT00670917|contiguous stage II adult Burkitt lymphoma
1325383|NCT00670917|contiguous stage II adult diffuse large cell lymphoma
1325384|NCT00670917|contiguous stage II adult diffuse mixed cell lymphoma
1325385|NCT00670917|contiguous stage II adult diffuse small cleaved cell lymphoma
1325386|NCT00670917|contiguous stage II adult immunoblastic large cell lymphoma
1325387|NCT00670917|contiguous stage II adult lymphoblastic lymphoma
1325388|NCT00670917|contiguous stage II grade 1 follicular lymphoma
1325389|NCT00670917|contiguous stage II grade 2 follicular lymphoma
1325390|NCT00670917|contiguous stage II grade 3 follicular lymphoma
1325391|NCT00670917|contiguous stage II mantle cell lymphoma
1325392|NCT00670917|contiguous stage II marginal zone lymphoma
1325393|NCT00670917|stage I adult Burkitt lymphoma
1325394|NCT00670917|stage I adult diffuse large cell lymphoma
1325395|NCT00670917|stage I adult diffuse mixed cell lymphoma
1325396|NCT00670917|stage I adult diffuse small cleaved cell lymphoma
1325397|NCT00670917|stage I adult immunoblastic large cell lymphoma
1325398|NCT00670917|stage I adult lymphoblastic lymphoma
1325399|NCT00670917|stage I grade 1 follicular lymphoma
1325400|NCT00670917|stage I grade 2 follicular lymphoma
1325401|NCT00670917|stage I grade 3 follicular lymphoma
1325402|NCT00670917|stage I mantle cell lymphoma
1325403|NCT00670917|stage I marginal zone lymphoma
1325404|NCT00670917|stage I small lymphocytic lymphoma
1325405|NCT00670917|noncontiguous stage II adult Burkitt lymphoma
1325406|NCT00670917|noncontiguous stage II adult diffuse large cell lymphoma
1325407|NCT00670917|noncontiguous stage II adult diffuse mixed cell lymphoma
1325408|NCT00670917|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1325409|NCT00670917|noncontiguous stage II adult immunoblastic large cell lymphoma
1325410|NCT00670917|noncontiguous stage II adult lymphoblastic lymphoma
1325411|NCT00670917|noncontiguous stage II grade 1 follicular lymphoma
1325412|NCT00670917|noncontiguous stage II grade 2 follicular lymphoma
1325413|NCT00670917|noncontiguous stage II grade 3 follicular lymphoma
1325414|NCT00670917|noncontiguous stage II mantle cell lymphoma
1325415|NCT00670917|noncontiguous stage II marginal zone lymphoma
1325416|NCT00670917|noncontiguous stage II small lymphocytic lymphoma
1325417|NCT00670917|stage III adult Burkitt lymphoma
1325418|NCT00670917|stage III adult diffuse large cell lymphoma
1325419|NCT00670917|stage III adult diffuse mixed cell lymphoma
1325420|NCT00670917|stage III adult diffuse small cleaved cell lymphoma
1325421|NCT00670917|stage III adult immunoblastic large cell lymphoma
1325422|NCT00670917|stage III adult lymphoblastic lymphoma
1325423|NCT00670917|stage III grade 1 follicular lymphoma
1325424|NCT00670917|stage III grade 2 follicular lymphoma
1325425|NCT00670917|stage III grade 3 follicular lymphoma
1325426|NCT00670917|stage III mantle cell lymphoma
1325427|NCT00670917|stage III marginal zone lymphoma
1325428|NCT00670917|stage III small lymphocytic lymphoma
1325429|NCT00670917|stage IV adult Burkitt lymphoma
1325430|NCT00670917|stage IV adult diffuse large cell lymphoma
1325431|NCT00670917|stage IV adult diffuse mixed cell lymphoma
1325432|NCT00670917|stage IV adult diffuse small cleaved cell lymphoma
1325433|NCT00670917|stage IV adult immunoblastic large cell lymphoma
1325434|NCT00670917|stage IV adult lymphoblastic lymphoma
1325435|NCT00670917|stage IV grade 1 follicular lymphoma
1325436|NCT00670917|stage IV grade 2 follicular lymphoma
1325437|NCT00670917|stage IV grade 3 follicular lymphoma
1325438|NCT00670917|stage IV mantle cell lymphoma
1325439|NCT00670917|stage IV marginal zone lymphoma
1325798|NCT00669422|Recurrent
1325440|NCT00670917|stage IV small lymphocytic lymphoma
1325441|NCT00670917|recurrent adult Burkitt lymphoma
1325442|NCT00670917|recurrent adult diffuse large cell lymphoma
1325443|NCT00670917|recurrent adult diffuse mixed cell lymphoma
1325444|NCT00670917|recurrent adult diffuse small cleaved cell lymphoma
1325445|NCT00670917|recurrent adult grade III lymphomatoid granulomatosis
1325446|NCT00670917|recurrent adult immunoblastic large cell lymphoma
1325447|NCT00670917|recurrent adult lymphoblastic lymphoma
1325448|NCT00670917|recurrent grade 1 follicular lymphoma
1325449|NCT00670917|recurrent grade 2 follicular lymphoma
1325450|NCT00670917|recurrent grade 3 follicular lymphoma
1325451|NCT00670917|recurrent mantle cell lymphoma
1325452|NCT00670917|recurrent marginal zone lymphoma
1325453|NCT00670917|recurrent small lymphocytic lymphoma
1325454|NCT00670917|intraocular lymphoma
1325455|NCT00670917|primary central nervous system non-Hodgkin lymphoma
1325456|NCT00670917|primary central nervous system Hodgkin lymphoma
1325457|NCT00670917|post-transplant lymphoproliferative disorder
1325458|NCT00670917|chronic eosinophilic leukemia
1325459|NCT00670917|chronic neutrophilic leukemia
1325460|NCT00670917|primary myelofibrosis
1325461|NCT00670917|essential thrombocythemia
1325462|NCT00670917|polycythemia vera
1325463|NCT00670917|extramedullary plasmacytoma
1325464|NCT00670917|isolated plasmacytoma of bone
1325465|NCT00670917|monoclonal gammopathy of undetermined significance
1325466|NCT00670917|stage I multiple myeloma
1325467|NCT00670917|stage II multiple myeloma
1325468|NCT00670917|stage III multiple myeloma
1325469|NCT00670917|primary systemic amyloidosis
1325470|NCT00670917|refractory multiple myeloma
1325471|NCT00670917|de novo myelodysplastic syndromes
1325472|NCT00670917|previously treated myelodysplastic syndromes
1325473|NCT00670917|secondary myelodysplastic syndromes
1325474|NCT00670917|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1325475|NCT00670904|Smoking cessation
1325476|NCT00670904|Pharmacist-delivered
1325477|NCT00670865|Hospitalization
1325478|NCT00670865|Continuity of care
1325479|NCT00670865|Discharge summary
1325480|NCT00670865|Quality improvement
1325481|NCT00670865|Medical records systems
1325482|NCT00670865|Hospital information systems
1325483|NCT00670852|Glenoid component
1325484|NCT00670852|radiolucent lines
1325485|NCT00670852|Glenoid loosening
1325486|NCT00670852|glenohumeral arthritis
1325487|NCT00670852|autologous bone graft
1325488|NCT00670839|Hepatitis B vaccination
1325489|NCT00670839|GenHevac-B Pasteur
1325490|NCT00670839|HIV infection
1325491|NCT00670826|Patient warming
1325492|NCT00670813|Depression
1325493|NCT00670813|(total) sleep deprivation
1325494|NCT00670813|Modafinil
1325495|NCT00670813|polysomnography sleep
1325496|NCT00670800|Polycystic Ovary Syndrome
1325497|NCT00670800|Insulin resistance
1325498|NCT00670800|Metformin
1325499|NCT00670800|Brain function
1325500|NCT00670787|Hypertension
1325501|NCT00670787|combination pill
1325502|NCT00670787|compliance
1325503|NCT00670774|Kidney
1325504|NCT00670774|Transplant
1325505|NCT00670774|donor
1325506|NCT00670761|misoprostol
1325507|NCT00670761|incomplete abortion
1325508|NCT00670761|sublingual
1325509|NCT00670761|postabortion care
1325510|NCT00670761|MVA
1325511|NCT00670748|Metastatic Cancer
1325512|NCT00670748|Gene Therapy
1325513|NCT00670748|Immunotherapy
1325514|NCT00670748|Tumor Regression
1325515|NCT00670748|Metastatic Melanoma
1325516|NCT00670748|Metastatic Renal Cell Cancer
1325517|NCT00670735|Pediatric Hydrocephalus
1325518|NCT00670709|encephalography
1325519|NCT00670709|quantitative
1325520|NCT00670709|biomarkers
1325521|NCT00670696|Topical anesthesia
1325522|NCT00670696|Rapydan
1325523|NCT00670696|Topical anaesthesia for venous cannulation
1325524|NCT00670657|candidemia
1325525|NCT00670657|invasive candidiasis
1325526|NCT00670657|Ambisome
1325527|NCT00670657|liposomal amphotericin B
1325528|NCT00670644|male breast cancer
1325529|NCT00670644|recurrent breast cancer
1325530|NCT00670644|stage I breast cancer
1325531|NCT00670644|stage II breast cancer
1325532|NCT00670644|stage IIIA breast cancer
1325533|NCT00670644|stage IIIB breast cancer
1325534|NCT00670644|stage IIIC breast cancer
1325535|NCT00670644|stage IV breast cancer
1325536|NCT00670631|Multiple Myeloma
1325537|NCT00670631|myeloma
1325538|NCT00670605|unspecified adult solid tumor, protocol specific
1325539|NCT00670605|unspecified childhood solid tumor, protocol specific
1325540|NCT00670592|HCD122
1325541|NCT00670592|CD40
1325542|NCT00670592|NHL
1325543|NCT00670592|HL
1325544|NCT00670579|TIVAD
1325545|NCT00670579|complications
1325546|NCT00670579|nursing
1325547|NCT00670579|cystic fibrosis
1325548|NCT00670579|implanted
1325549|NCT00670553|Prostate,
1325550|NCT00670553|Head & Neck,
1325551|NCT00670553|Esophageal
1325552|NCT00670540|pulmonary embolism
1325553|NCT00670540|duplex ultrasound examination
1325554|NCT00670540|recurrence
1325556|NCT00670527|[18F] Fluorocholine PET/CT
1325557|NCT00670527|FCH
1325558|NCT00670527|lymph node metastasis
1325559|NCT00670527|staging
1325560|NCT00670527|sensitivity
1325561|NCT00670527|specificity
1325562|NCT00670527|PROPET
1325563|NCT00670514|RCT
1325564|NCT00670514|tobacco
1325565|NCT00670514|treatment intensity
1325566|NCT00670514|dentistry
1325567|NCT00670514|follow-up
1325568|NCT00670514|Smoking cessation
1325569|NCT00670514|Cost effectiveness
1325570|NCT00670475|osteoarthritis
1325571|NCT00670475|Knee
1325572|NCT00670475|virgin olive oil
1325573|NCT00670475|piroxicam
1325574|NCT00670475|Topical
1325575|NCT00670462|obesity, weight loss, treatment
1325576|NCT00670449|FTY720
1325577|NCT00670449|multiple sclerosis
1325578|NCT00670449|MS
1325579|NCT00670423|Tacrolimus
1325580|NCT00670423|Sirolimus
1325581|NCT00670423|Bortezomib
1325582|NCT00670423|Acute Graft Versus Host Disease
1325583|NCT00670423|Allogeneic Peripheral Blood Stem Cell Transplantation
1325584|NCT00670410|Neuroblastoma
1325585|NCT00670410|Autologous Transplant
1325586|NCT00670410|Allogeneic Transplant
1325587|NCT00670410|Immunotherapy
1325588|NCT00670397|stage I squamous cell carcinoma of the lip and oral cavity
1325589|NCT00670397|recurrent squamous cell carcinoma of the lip and oral cavity
1325590|NCT00670397|stage 0 lip and oral cavity cancer
1325591|NCT00670384|SLIT
1325592|NCT00670384|Immunotherapy
1325593|NCT00670384|Short ragweed
1325594|NCT00670384|SAR
1325595|NCT00670384|Seasonal allergic rhinitis
1325596|NCT00670371|Caregiver burden
1325597|NCT00670358|contiguous stage II adult diffuse large cell lymphoma
1325598|NCT00670358|noncontiguous stage II adult diffuse large cell lymphoma
1325599|NCT00670358|stage III adult diffuse large cell lymphoma
1325600|NCT00670358|stage IV adult diffuse large cell lymphoma
1325601|NCT00670358|contiguous stage II grade 3 follicular lymphoma
1325602|NCT00670358|noncontiguous stage II grade 3 follicular lymphoma
1325603|NCT00670358|stage III grade 3 follicular lymphoma
1325604|NCT00670358|stage IV grade 3 follicular lymphoma
1325605|NCT00670345|tranexamic acid
1325606|NCT00670345|prostatectomy
1325607|NCT00670345|surgery
1325608|NCT00670332|coronary artery disease
1325609|NCT00670332|echocardiography
1325610|NCT00670332|cardiac imaging
1325611|NCT00670332|heart disease
1325612|NCT00670332|ultrasound contrast agent
1325613|NCT00670332|prognosis
1325614|NCT00670306|Cetrorelix
1325615|NCT00670306|BPH
1325616|NCT00670293|Anorexia Nervosa
1325617|NCT00670293|PET Imaging
1325618|NCT00670293|Dopamine
1325619|NCT00670280|Neonatal Intensive Care Units
1325620|NCT00670280|Infant Morbidity
1325621|NCT00670280|Low Birth Weight
1325622|NCT00670280|Low Income Populations
1325623|NCT00670280|MCH Research
1325624|NCT00670280|Respiratory Illnesses
1325625|NCT00670280|Substance Exposed Infants
1325626|NCT00670280|Counseling
1325627|NCT00670267|Asthma
1325628|NCT00670267|hyperresponsiveness
1325629|NCT00670254|Sepsis
1325630|NCT00670254|Septic
1325631|NCT00670254|Shock
1325632|NCT00670254|Glucocorticoids
1325633|NCT00670254|Hydrocortisone
1325634|NCT00670215|Prevention of infectious complications
1325635|NCT00670215|transrectal needle biopsies of the prostate
1325636|NCT00670215|TRNBP
1325637|NCT00670202|Patients scheduled for elective carotid endarterectomy
1325638|NCT00670163|Men Who Have Sex With Men
1325639|NCT00670111|Heart failure
1325640|NCT00670111|exercise capacity
1325641|NCT00670111|ejection fraction
1325642|NCT00670111|Heart failure normal ejection fraction
1325643|NCT00670059|Single embryo transfer/ aneuploidy screening
1325644|NCT00670046|recurrent prostate cancer
1325645|NCT00670046|stage I prostate cancer
1325646|NCT00670046|stage IIB prostate cancer
1325647|NCT00670046|stage IIA prostate cancer
1325648|NCT00670046|stage III prostate cancer
1325649|NCT00670046|stage IV prostate cancer
1325650|NCT00670033|IOP
1325651|NCT00670033|Open-angle glaucoma
1325652|NCT00670033|Ocular Hypertension
1325653|NCT00670020|Women undergoing Cesarean section after the onset of labor
1325654|NCT00670007|Alpha1-proteinase inhibitor deficiency
1325655|NCT00670007|Chronic augmentation and maintenance therapy
1325656|NCT00670007|Emphysema
1325657|NCT00670007|Emphysema due to Alpha 1-proteinase inhibitor deficiency
1325658|NCT00669994|UTI
1325659|NCT00669994|Urinary Tract Infection
1325660|NCT00669981|PTSD
1325661|NCT00669981|Relationship Distress
1325662|NCT00669981|Couple Therapy
1325663|NCT00669968|PET myocardial perfusion imaging
1325664|NCT00669968|Cardiac PET
1325665|NCT00669968|Rubidium
1325666|NCT00669968|Coronary Artery CT Angiogram
1325667|NCT00669968|Coronary Flow Reserve
1325668|NCT00669968|Adenosine stress test
1325669|NCT00669955|H. Pylori
1325670|NCT00669955|Quadruple therapy
1325671|NCT00669955|Eradication rate
1325672|NCT00669955|Multinational trial
1325673|NCT00669955|Resistance to antibiotics
1325674|NCT00669955|Subjects with confirmed Helicobacter Pylori infection
1325675|NCT00669942|Rheumatoid Arthritis
1325676|NCT00669929|Cost effectiveness analysis of rotavirus vaccination
1325677|NCT00669916|Plaque psoriasis
1325678|NCT00669890|AML
1325679|NCT00669890|JMML
1325680|NCT00669890|MDS
1325681|NCT00669890|Allogenic Atem Cell Transplant
1325682|NCT00669890|Gemtuzumab Ozogamicin
1325683|NCT00669877|Burkitt's Lymphoma
1325684|NCT00669877|Burkitt's Like Lymphoma
1325685|NCT00669877|Leukemia
1325686|NCT00669877|Hyper-CVAD
1325687|NCT00669877|Rituximab
1325688|NCT00669877|Methotrexate
1325689|NCT00669877|Cytarabine
1325690|NCT00669851|coronary artery disease
1325691|NCT00669851|echocardiography
1325692|NCT00669851|cardiac imaging
1325693|NCT00669851|heart disease
1325694|NCT00669851|ultrasound contrast agent
1325695|NCT00669851|myocardial contrast enhancement
1325696|NCT00669851|myocardial perfusion
1325697|NCT00669838|Anesthesia, Local
1325698|NCT00669838|Lidocaine
1325699|NCT00669838|Dental care
1325700|NCT00669838|Arrhythmias, Cardiac
1325701|NCT00669838|Anxiety
1325702|NCT00669825|Celiac Disease
1325703|NCT00669812|small intestine lymphoma
1325704|NCT00669812|stage I adult T-cell leukemia/lymphoma
1325705|NCT00669812|stage II adult T-cell leukemia/lymphoma
1325706|NCT00669812|stage III adult T-cell leukemia/lymphoma
1325707|NCT00669812|stage IV adult T-cell leukemia/lymphoma
1325708|NCT00669786|Ongoing Pregnancy Rate
1325709|NCT00669760|cystic fibrosis
1325710|NCT00669760|Staphylococcus aureus
1325711|NCT00669760|persistent colonization-infection
1325712|NCT00669760|clinical status
1325713|NCT00669760|lung function
1325714|NCT00669747|Ductal Carcinoma In Situ
1325715|NCT00669747|DCIS
1325716|NCT00669747|Breast Cancer
1325717|NCT00669747|Carboplatin
1325718|NCT00669747|Intraductal
1325719|NCT00669721|osteoprotegerin
1325720|NCT00669721|RANKL
1325721|NCT00669721|heparin
1325722|NCT00669721|hemodialysis
1325723|NCT00669721|anticoagulation
1325724|NCT00669721|vascular calcification
1325725|NCT00669708|dry skin
1325726|NCT00669708|cooling
1325727|NCT00669708|itch
1325728|NCT00669695|statins
1325729|NCT00669695|cardiovascular risk
1325730|NCT00669695|Obstructive sleep apnea syndrome (OSAS) patients
1325731|NCT00669643|Leprosy
1325732|NCT00669643|Communicable Diseases
1325733|NCT00669643|Skin Diseases
1325734|NCT00669643|Multidrug Therapy
1325735|NCT00669643|MDT
1325736|NCT00669643|Uniform Multidrug Therapy
1325737|NCT00669643|U-MDT
1325738|NCT00669630|Community-based Participatory Research (CBPR)
1325739|NCT00669630|Vulnerable population
1325740|NCT00669630|High-risk population
1325741|NCT00669630|African-Americans
1325742|NCT00669630|Health Disparities
1325743|NCT00669630|Clinical Trial
1325744|NCT00669617|chronic obstructive pulmonary disease
1325745|NCT00669617|COPD
1325746|NCT00669617|indacaterol
1325747|NCT00669617|adults
1325748|NCT00669604|Mother to child transmission of HIV
1325749|NCT00669604|HIV infected children
1325750|NCT00669591|breast cancer
1325751|NCT00669591|docetaxel chemotherapy
1325752|NCT00669591|bavituximab
1325753|NCT00669591|monoclonal antibody
1325754|NCT00669578|secondary myelofibrosis
1325755|NCT00669578|polycythemia vera
1325756|NCT00669578|essential thrombocythemia
1325757|NCT00669578|primary myelofibrosis
1325758|NCT00669565|Locally Advanced or Metastatic Breast Cancer
1325759|NCT00669539|Amblyopia associated with strabismus
1325760|NCT00669539|Refractive error
1325761|NCT00669526|anxiety
1325762|NCT00669526|depression
1325763|NCT00669526|Major Depressive Disorder
1325764|NCT00669526|child
1325765|NCT00669526|adolescent
1325766|NCT00669526|CBT
1325767|NCT00669526|Cognitive-Behavioral Therapy
1325768|NCT00669526|primary care
1325769|NCT00669513|partial sleep deprivation
1325770|NCT00669513|endothelial dysfunction
1325771|NCT00669513|sympathetic activity
1325772|NCT00669513|inflammation
1325773|NCT00669500|dietary intake
1325774|NCT00669500|genetic predisposition
1325775|NCT00669500|body composition
1325776|NCT00669487|HIV/AIDS patients
1325777|NCT00669461|Constipation
1325778|NCT00669461|Parkinson's Disease
1325779|NCT00669448|Multiple chemical sensitivities
1325780|NCT00669448|MCS
1325781|NCT00669448|Mindfulness-based cognitive therapy
1325782|NCT00669448|MBCT
1325783|NCT00669448|Behavioural intervention
1325784|NCT00669448|Stress
1325785|NCT00669448|Illness perceptions
1325786|NCT00669448|Pilot trial
1325787|NCT00669435|Essential hypertension
1325788|NCT00669435|Liver steatosis
1325789|NCT00669422|Ovarian Cancer
1325790|NCT00669422|Fallopian Tube Cancer
1325791|NCT00669422|Peritoneal Cancer
1325792|NCT00669422|Uterine Neoplasms
1325793|NCT00669422|Vulvar Cancer
1325794|NCT00669422|Endometrial Cancer
1325795|NCT00669422|Cervical Cancer
1325796|NCT00669422|Assay
1325799|NCT00669422|Refractory
1325800|NCT00669422|Persistent
1325801|NCT00669422|Chemoresponse
1325802|NCT00669422|Sensitivity
1325803|NCT00669422|Precision Therapeutics
1325804|NCT00669422|ChemoFx
1325805|NCT00669409|monoclonal antibody
1325806|NCT00669396|contraception
1325807|NCT00669396|emergency contraception
1325808|NCT00669396|pregnancy prevention after unprotected intercourse
1325809|NCT00669383|premature delivery
1325810|NCT00669383|respiratory distress syndrome
1325811|NCT00669370|advanced gastric cancer
1325812|NCT00669370|adenocarcinoma
1325813|NCT00669357|End stage heart disease
1325814|NCT00669344|cognition
1325815|NCT00669344|stroke
1325816|NCT00669344|VCI
1325817|NCT00669344|VCIND
1325818|NCT00669344|Cognitive Impairment, No Dementia
1325819|NCT00669331|randomized clinical trial
1325820|NCT00669331|mannitol
1325821|NCT00669331|mucoactive
1325822|NCT00669318|refractory chronic lymphocytic leukemia
1325823|NCT00669318|recurrent small lymphocytic lymphoma
1325824|NCT00669318|B-cell chronic lymphocytic leukemia
1325825|NCT00669305|Genetics
1325826|NCT00669305|Blood cells
1325827|NCT00669305|Vector-mediated gene transfer
1325828|NCT00669305|Bone marrow
1325829|NCT00669305|CD34 cells
1325830|NCT00669292|esophageal cancer
1325831|NCT00669292|peptide
1325832|NCT00669292|URLC10
1325833|NCT00669292|TTK
1325834|NCT00669292|CpG7909
1325835|NCT00669214|Raptiva
1325836|NCT00669214|Moderate plaque psoriasis
1325837|NCT00669214|Severe plaque psoriasis
1325838|NCT00669214|Scalp
1325839|NCT00669201|cartilage
1325840|NCT00669201|osteoarthritis
1325841|NCT00669201|T2 mapping
1325842|NCT00669201|MRI
1325843|NCT00669201|Wrist
1325844|NCT00669188|Patient Provider Interaction
1325845|NCT00669188|Physician Training
1325846|NCT00669188|Patient Provider Training
1325847|NCT00669175|Naloxone
1325848|NCT00669175|Neonate
1325849|NCT00669175|Pain
1325850|NCT00669149|ptca
1325851|NCT00669149|antiaggregant therapy
1325852|NCT00669149|anticoagulant therapy
1325853|NCT00669136|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
1325854|NCT00669136|AFP Immunization
1325855|NCT00669123|Chondroitin sulphate
1325856|NCT00669123|Knee osteoarthritis
1325857|NCT00669123|Psoriasis
1325858|NCT00669110|MDD
1325859|NCT00669110|Depression
1325860|NCT00669110|Pediatrics
1325861|NCT00669110|Major Depressive Disorder
1325862|NCT00669097|ADME
1325863|NCT00669097|TKI258
1325864|NCT00669097|RTKs inhibitor
1325865|NCT00669097|PDGRF inhibitor
1325866|NCT00669097|VEGFER inhibitor
1325867|NCT00669084|Innate Immunity
1325868|NCT00669084|Malaria
1325869|NCT00669084|Plasmodium
1325870|NCT00669084|Hemoglobinopathy
1325871|NCT00669084|G6PD Deficiency
1325872|NCT00669058|hygiene
1325873|NCT00669045|TNKase
1325874|NCT00669045|AMI
1325875|NCT00669006|neuropathic pain
1325876|NCT00669006|database
1325877|NCT00669006|prospective
1325878|NCT00669006|national
1325879|NCT00668980|Down syndrome
1325880|NCT00668980|symbolic representation
1325881|NCT00668980|gestures
1325882|NCT00668980|expressive language development
1325883|NCT00668967|Cardiovascular Diseases
1325884|NCT00668967|Hypertension
1325885|NCT00668954|Diabetes
1325886|NCT00668954|Pomegranate
1325887|NCT00668954|Biomarkers
1325888|NCT00668954|Antioxidant
1325889|NCT00668941|Bone Density
1325890|NCT00668941|Bone Turnover
1325891|NCT00668941|Histomorphometry
1325892|NCT00668902|CYP2C19
1325893|NCT00668902|Pantoprazole
1325894|NCT00668902|Genotype
1325895|NCT00668902|Pharmacokinetics
1325896|NCT00668902|Metabolism
1325897|NCT00668889|Hygiene
1325898|NCT00668876|immunonutrition
1325899|NCT00668876|pancreaticoduodenectomy
1325900|NCT00668876|Th1
1325901|NCT00668876|Th2
1325902|NCT00668876|Th17
1325903|NCT00668837|Paliperidone
1325904|NCT00668837|schizophrenia
1325905|NCT00668824|Congenital Heart Disease (CHD)
1325906|NCT00668811|thyroid cancer
1325907|NCT00668811|metastatic thyroid cancer
1325908|NCT00668811|differentiated thyroid cancer
1325909|NCT00668811|papillary thyroid cancer
1325910|NCT00668811|follicular thyroid cancer
1325911|NCT00668811|Histologically confirmed
1325912|NCT00668811|metastatic stage 2,stage 3, or stage 4 differentiated thyroid cancer
1325913|NCT00668798|cytomegalovirus breast milk preterm infants transmission
1325914|NCT00668798|transmission of CMV via thawed frozen breast milk
1325915|NCT00668785|Ranibizumab
1325916|NCT00668785|Proliferative Diabetic Retinopathy
1325917|NCT00668785|Macular Edema following Panretinal Photocoagulation
1325918|NCT00668785|Safety and Efficacy
1325919|NCT00668785|Intravitreal Injection
1325920|NCT00668759|atrial fibrillation
1325921|NCT00668759|atrial fib
1325922|NCT00668759|AF
1325923|NCT00668746|chronic periodontitis, antibiotic resistance
1325924|NCT00668733|Actinic keratoses
1325925|NCT00668733|Dermatologic disease
1325926|NCT00668720|tinnitus
1325927|NCT00668720|transcranial magnetic stimulation
1325928|NCT00668707|melatonin
1325929|NCT00668707|natural health product (NHP)
1325930|NCT00668707|lung cancer
1325931|NCT00668707|complementary and alternative medicine (CAM)
1325932|NCT00668707|randomized clinical trial
1325933|NCT00668694|Psychosocial stimulation in addition to iron supplementation will improve mental and psychomotor development, language, behavior and growth of IDA infants.
1325934|NCT00668694|With the addition of stimulation IDA infants will catch up to the non-anemic infants.
1325935|NCT00668681|Abdominal Aortic Aneurysm
1325936|NCT00668655|Rosacea, metronidazole
1325937|NCT00668629|Hygiene
1325938|NCT00668616|breast cancer with 1-3 afflicted axillary lymph nodes
1325939|NCT00668603|Postmenopausal vasomotor symptoms
1325940|NCT00668603|Hot flush
1325941|NCT00668603|Vascular function
1325942|NCT00668603|Cardiac function
1325943|NCT00668603|Cardiovascular risk factor
1325944|NCT00668590|Diabetes
1325945|NCT00668577|Hygiene
1325946|NCT00668564|Inborn errors of metabolism
1325947|NCT00668564|Sphingolipidoses
1325948|NCT00668564|Recessive Leukodystrophies- GLD, Krabbe disease, MLD
1325949|NCT00668564|Peroxisomal Disorders
1325950|NCT00668564|Wolman syndrome
1325951|NCT00668564|Niemann-Pick B patients
1325952|NCT00668564|Niemann-Pick C subtype 2
1325953|NCT00668551|Parkinson disease
1325954|NCT00668551|Telemedicine
1325955|NCT00668538|Miconazole
1325956|NCT00668538|CYP1A2
1325957|NCT00668538|CYP3A4
1325958|NCT00668538|Women
1325959|NCT00668538|Healthy Subjects
1325960|NCT00668525|Depression
1325961|NCT00668525|Major Depressive Disorder
1325962|NCT00668525|Escitalopram
1325963|NCT00668512|metastatic cutaneous melanoma
1325964|NCT00668512|alpha-gal glycolipids
1325965|NCT00668486|Hygiene
1325966|NCT00668473|systemic sclerosis angiogenesis
1325967|NCT00668460|hygiene
1325968|NCT00668447|bone density
1325969|NCT00668447|bone loss
1325970|NCT00668447|postmenopausal
1325971|NCT00668434|Back Pain
1325972|NCT00668434|Leg Pain
1325973|NCT00668421|Myelofibrosis
1325974|NCT00668421|Essential Thrombocythemia
1325975|NCT00668421|Polycythemia Vera
1325976|NCT00668421|JAK2 V617F Mutation
1325977|NCT00668421|Lestaurtinib
1325978|NCT00668408|OTLT
1325979|NCT00668408|COPD
1325980|NCT00668408|CHRONIC HYPOXEMIA
1325981|NCT00668408|CHF
1325982|NCT00668395|CYP2B6
1325983|NCT00668395|Efavirenz
1325984|NCT00668395|Pharmacokinetics
1325985|NCT00668395|Pharmacogenetics
1325986|NCT00668395|Drug-Interactions
1325987|NCT00668382|Cancerous solid tumors
1325988|NCT00668382|Alpha-Gal Glycosphingolipids
1325989|NCT00668369|Liver Transplantation
1325990|NCT00668369|Tolerance
1325991|NCT00668369|Hepatitis C virus infection
1325992|NCT00668369|Immune responses
1325993|NCT00668369|Allograft tolerance
1325994|NCT00668369|Immunosuppression weaning
1325995|NCT00668369|Immunosuppression minimization
1325996|NCT00668356|HIV disease in children
1325997|NCT00668356|HIV
1325998|NCT00668356|children
1325999|NCT00668356|didanosine
1326000|NCT00668356|bioequivalence
1326001|NCT00668356|pharmacokinetics
1326002|NCT00668356|treatment experienced
1326003|NCT00668343|edss attack
1326004|NCT00668330|Bone mineral density
1326005|NCT00668330|ibandronate
1326006|NCT00668330|alfacalcidol
1326007|NCT00668317|Hyper-responsiveness, reflux cough
1326008|NCT00668304|Sinusitis
1326009|NCT00668291|Endocrinology, CARNEY Complex,
1326010|NCT00668291|primary pigmented nodular adrenocortical disease (PPNAD),
1326011|NCT00668291|PRKAR1A
1326012|NCT00668278|Supraglottic airway
1326013|NCT00668278|I-gel
1326014|NCT00668278|Laryngeal mask
1326015|NCT00668278|Controlled ventilation
1326016|NCT00668278|Peak airway pressure
1326017|NCT00668278|Seal pressure
1326018|NCT00668278|Anaesthesia
1326019|NCT00668278|Surgery
1326020|NCT00668265|Generalized Anxiety Disorder
1326021|NCT00668265|Opiate Dependence
1326022|NCT00668265|Methadone-Maintenance
1326023|NCT00668265|Drug Addiction Treatment
1326024|NCT00668252|endothelial progenitor cells
1326025|NCT00668252|estrogen
1326026|NCT00668252|menopause
1326027|NCT00668252|cardiovascular risk
1326028|NCT00668239|diffuse macular oedema
1326029|NCT00668239|type 2 diabetes mellitus
1326030|NCT00668239|laser therapy
1326031|NCT00668226|Hygiene
1326032|NCT00668213|Macular Degeneration
1326033|NCT00668200|Paget's
1326034|NCT00668200|hypocalcemia
1326035|NCT00668200|zoledronic acid
1326036|NCT00668200|serum calcium
1326037|NCT00668187|Tay-Sachs disease
1326038|NCT00668187|Sandhoff disease
1326039|NCT00668187|Late Onset Tay-Sachs disease
1326040|NCT00668187|LOTS
1326041|NCT00668187|hexosaminidase A deficiency
1326042|NCT00668187|hexosaminidase A and B deficiency
1326043|NCT00668187|infantile Tay-Sachs disease
1326044|NCT00668187|adult-onset Tay-Sachs disease
1326045|NCT00668187|prospective
1326046|NCT00668187|natural history
1326047|NCT00668187|GM1 gangliosidosis
1326048|NCT00668187|gangliosidoses
1326049|NCT00668187|β-galactosidase
1326050|NCT00668187|β-galactosidase deficiency
1326051|NCT00668187|hexosaminidase
1326052|NCT00668187|hexosaminidase deficiency
1326053|NCT00668187|Tay-Sachs
1326054|NCT00668187|Sandhoff
1326055|NCT00668187|juvenile Tay-Sachs
1326056|NCT00668187|juvenile Tay-Sachs disease
1326057|NCT00668187|late onset Tay-Sachs
1326058|NCT00668187|juvenile Sandhoff
1326059|NCT00668187|juvenile Sandhoff disease
1326060|NCT00668187|GM2 gangliosidosis
1326061|NCT00668148|Sarcoma
1326062|NCT00668148|Ewing's sarcoma / peripheral neuroectodermal tumor (PNET);
1326063|NCT00668148|rhabdomyosarcoma;
1326064|NCT00668148|leiomyosarcoma;
1326065|NCT00668148|adipocytic sarcoma
1326066|NCT00668148|synovial sarcoma
1326067|NCT00668135|Erectile Dysfunction
1326068|NCT00668135|Vardenafil
1326069|NCT00668109|Erectile Dysfunction
1326070|NCT00668109|Diabetes mellitus
1326071|NCT00668109|Hypertension
1326072|NCT00668109|Hyperlipidemia
1326073|NCT00668109|Vardenafil
1326074|NCT00668096|Erectile Dysfunction
1326075|NCT00668096|PDE5 inhibitors
1326076|NCT00668083|second line
1326077|NCT00668083|Prostate Cancer
1326078|NCT00668083|bicalutamide
1326079|NCT00668083|biochemical relapse/progression in patients with Prostate Cancer treated with bicalutamide 150mg
1326080|NCT00668070|NASH
1326081|NCT00668070|Chronic liver disease
1326082|NCT00668057|Male Erectile Dysfunction
1326083|NCT00668044|Ciprofloxacin regimen in compromised patients
1326084|NCT00668044|Ciprofloxacin
1326085|NCT00668044|Burned patients
1326086|NCT00668031|Transfusion requirements
1326087|NCT00668031|Hip replacement surgery
1326088|NCT00668031|Prevention of blood loss
1326089|NCT00668031|Bloodloss
1326090|NCT00668018|Male Erectile Dysfunction
1326091|NCT00668018|Vardenafil
1326092|NCT00668005|Erectile Dysfunction
1326093|NCT00668005|Arterial hypertension
1326094|NCT00668005|Vardenafil
1326095|NCT00667992|Asthma hyperreactivity
1326096|NCT00667979|Erectile Dysfunction
1326097|NCT00667979|Vardenafil
1326098|NCT00667966|Spinal cord injury
1326099|NCT00667966|Urodynamic
1326100|NCT00667966|Erectile dysfunction
1326101|NCT00667966|Vardenafil
1326102|NCT00667953|Temzolomide
1326103|NCT00667953|Gleevec
1326104|NCT00667953|Melanoma
1326105|NCT00667953|Advanced melanoma
1326106|NCT00667953|Phase II
1326107|NCT00667940|Medical education
1326108|NCT00667940|faculty development
1326109|NCT00667940|rater training
1326110|NCT00667940|clinical competence
1326111|NCT00667940|assessment
1326112|NCT00667927|Autologous bone marrow transplant
1326113|NCT00667927|gene marking
1326114|NCT00667914|Hip-unit
1326115|NCT00667914|Geriatric care
1326116|NCT00667914|Mobility
1326117|NCT00667914|Site of residence
1326118|NCT00667901|stage III melanoma
1326119|NCT00667901|stage IV melanoma
1326120|NCT00667888|Prostate Cancer
1326121|NCT00667888|Radiation
1326122|NCT00667888|Radiotherapy
1326123|NCT00667888|Intensity Modulated Radiotherapy
1326124|NCT00667888|IMRT
1326125|NCT00667888|Hypofractionated Intensity Modulated Radiotherapy
1326126|NCT00667888|HIMRT
1326127|NCT00667875|Alcohol Dependence
1326128|NCT00667875|Alcoholism
1326129|NCT00667875|Naltrexone
1326130|NCT00667875|Aripiprazole
1326131|NCT00667875|Substance Abuse
1326132|NCT00667862|Prostate
1326133|NCT00667862|Cancer
1326134|NCT00667862|Adenocarcinoma
1326135|NCT00667862|Prostate-Specific Antigen
1326136|NCT00667862|metastatic
1326137|NCT00667862|male
1326138|NCT00667862|HRPC
1326139|NCT00667862|DACi
1326140|NCT00667849|Tibia
1326141|NCT00667836|Neurofibromatosis Type 1
1326142|NCT00667836|NF1
1326143|NCT00667836|Spinal Anomalies
1326144|NCT00667823|SERAPHIN
1326145|NCT00667823|Pulmonary Arterial Hypertension
1326146|NCT00667823|ACT-064992
1326147|NCT00667810|antibody
1326148|NCT00667810|immunotherapy
1326149|NCT00667797|Asthma
1326150|NCT00667797|COPD
1326151|NCT00667797|chronic emphysema
1326152|NCT00667797|chronic bronchitis
1326153|NCT00667784|pediatric stem cell donor
1326154|NCT00667784|emotional sequelae
1326155|NCT00667784|physical sequelae
1326156|NCT00667784|psychological consequences of minor donation
1326157|NCT00667784|Bone Marrow Transplantation
1326158|NCT00667784|Questionnaire
1326159|NCT00667784|Survey
1326160|NCT00667784|Sibling Donor
1326161|NCT00667784|Stem Cell Transplant
1326162|NCT00667784|Well-Being
1326163|NCT00667771|Alcohol
1326164|NCT00667771|Naltrexone
1326165|NCT00667771|fMRI
1326166|NCT00667771|Alcoholism
1326167|NCT00667771|Alcoholics
1326168|NCT00667771|Alcohol Dependence
1326169|NCT00667745|Lithium
1326170|NCT00667745|Symptoms
1326171|NCT00667745|Medication Changes
1326172|NCT00667732|diabetes
1326173|NCT00667732|insulin
1326174|NCT00667732|byetta
1326175|NCT00667732|glucose
1326176|NCT00667732|blood sugar
1326177|NCT00667732|metformin
1326178|NCT00667732|A1c
1326179|NCT00667719|essential hypertension
1326180|NCT00667719|high blood pressure
1326181|NCT00667693|intubation
1326182|NCT00667693|obese
1326183|NCT00667680|tDCS, major depression
1326184|NCT00667667|whole body vibration
1326185|NCT00667667|exercise
1326186|NCT00667667|postmenopausal
1326187|NCT00667667|BMD
1326188|NCT00667667|bone
1326189|NCT00667667|elderly females
1326190|NCT00667667|Caucasian race
1326191|NCT00667654|Osteoarthritis, Knee
1326192|NCT00667641|unspecified adult solid tumor, protocol specific
1326193|NCT00667641|recurrent breast cancer
1326194|NCT00667641|stage IV breast cancer
1326195|NCT00667641|recurrent prostate cancer
1326196|NCT00667641|stage IV prostate cancer
1326197|NCT00667641|recurrent colon cancer
1326198|NCT00667641|stage IV colon cancer
1326199|NCT00667641|recurrent pancreatic cancer
1326200|NCT00667641|stage IV pancreatic cancer
1326201|NCT00667641|recurrent ovarian epithelial cancer
1326202|NCT00667641|stage IV ovarian epithelial cancer
1326203|NCT00667641|recurrent ovarian germ cell tumor
1326204|NCT00667641|stage IV ovarian germ cell tumor
1326205|NCT00667641|recurrent non-small cell lung cancer
1326206|NCT00667641|stage IV non-small cell lung cancer
1326207|NCT00667641|recurrent melanoma
1326208|NCT00667641|stage IV melanoma
1326209|NCT00667641|stage IV papillary thyroid cancer
1326210|NCT00667641|recurrent thyroid cancer
1326211|NCT00667615|vorinostat
1326212|NCT00667615|rituximab
1326213|NCT00667615|cyclophosphamide
1326214|NCT00667615|etoposide
1326215|NCT00667615|prednisone
1326216|NCT00667615|Quality of life
1326217|NCT00667615|08-045
1326218|NCT00667602|Meningococcal
1326219|NCT00667602|ACWY
1326220|NCT00667602|Conjugate Vaccine
1326221|NCT00667602|Meningitis
1326222|NCT00667602|Toddlers
1326223|NCT00667602|Infants
1326224|NCT00667602|Concomitant Vaccination
1326225|NCT00667589|sorafenib
1326226|NCT00667589|rash
1326227|NCT00667589|hand foot skin reaction
1326228|NCT00667576|chronic kidney disease
1326229|NCT00667576|secondary hyperparathyroidism
1326230|NCT00667576|hemodialysis
1326231|NCT00667576|paricalcitol
1326232|NCT00667576|maxacalcitol
1326233|NCT00667563|human papilloma virus infection
1326234|NCT00667563|cervical cancer
1326235|NCT00667563|cervical intraepithelial neoplasia
1326236|NCT00667563|HIV infection
1326237|NCT00667550|Lower urinary tract symptoms
1326238|NCT00667550|Colorectal disorders
1326239|NCT00667550|Urinary incontinence
1326240|NCT00667550|Fecal incontinence
1326241|NCT00667550|Voiding dysfunction
1326242|NCT00667550|Urgency frequency
1326243|NCT00667550|Sexual dysfunction
1326244|NCT00667550|Colorectal malignancies
1326245|NCT00667550|Inflammatory bowel disease
1326246|NCT00667524|Eosinophilic Esophagitis
1326247|NCT00667524|Dysphagia
1326248|NCT00667524|Esophageal bougienage
1326249|NCT00667524|Esophageal Dilation
1326250|NCT00667511|ESRD
1326251|NCT00667511|End Stage Renal Disease
1326252|NCT00667511|Daily Hemodialysis
1326253|NCT00667511|Nocturnal Hemodialysis
1326254|NCT00667511|Hemodialysis
1326255|NCT00667511|Kidney Failure
1326256|NCT00667511|Kidney Disease
1326257|NCT00667498|Pediatric Obesity
1326258|NCT00667498|Insulin Resistance
1326259|NCT00667498|Hyperinsulinemia
1326260|NCT00667498|Metformin
1326261|NCT00667498|Glucose Tolerance
1326262|NCT00667498|Microalbuminuria
1326263|NCT00667498|Adolescents
1326264|NCT00667498|Visceral Fat
1326265|NCT00667472|port wine stain birthmarks
1326266|NCT00667459|Cervical Disc
1326267|NCT00667446|GnRH analog
1326268|NCT00667446|Luteinizing hormone (LH)
1326269|NCT00667446|Gonadotrophin-releasing hormone agonist(GnRHa)
1326270|NCT00667446|Suppression of LH
1326271|NCT00667446|Gonadotrophin-releasing hormone (GnRH)
1326272|NCT00667446|CPP
1326273|NCT00667446|Leuprolide acetate
1326274|NCT00667446|Central Precocious Puberty
1326275|NCT00667446|Depot formulation
1326276|NCT00667446|Lupron
1326277|NCT00667446|Tanner staging
1326278|NCT00667446|Pediatrics
1326279|NCT00667433|HIV
1326280|NCT00667433|African American
1326281|NCT00667433|treatment naïve
1326282|NCT00667420|gastric
1326283|NCT00667420|esophageal
1326284|NCT00667420|panitumumab
1326285|NCT00667407|Asthma
1326286|NCT00667394|Brain Tumor
1326287|NCT00667394|Chemotherapy
1326288|NCT00667394|Radiation
1326289|NCT00667394|Anti-Angiogenesis
1326290|NCT00667394|Glioblastoma
1326291|NCT00667394|Glioma
1326292|NCT00667381|Ultrasound guidance
1326293|NCT00667381|Vascular access
1326294|NCT00667381|Vascular complications
1326295|NCT00667368|bacterial vaginosis, women, chlamydia, gonorrhea, mentronidazole, vaginal, children
1326296|NCT00667355|Ankylosing Spondylitis
1326297|NCT00667329|Waldenstrom's Macroglobulinemia
1326298|NCT00667329|Lymphoma
1326299|NCT00667329|2CdA
1326300|NCT00667329|Cladribine
1326301|NCT00667329|Leustatin
1326302|NCT00667329|Cyclophosphamide
1326303|NCT00667329|Cytoxan
1326304|NCT00667329|Neosar
1326305|NCT00667329|Rituxan
1326306|NCT00667329|Rituximab
1326307|NCT00667316|low back pain
1326308|NCT00667316|workers
1326309|NCT00667316|disability
1326310|NCT00667316|sick leave
1326311|NCT00667303|Hematopoietic stem cell transplant
1326312|NCT00667290|functional ability
1326313|NCT00667290|gait
1326314|NCT00667290|musculoskeletal disorder therapy
1326315|NCT00667290|peripheral blood vessel disorder
1326316|NCT00667277|Myelofibrosis
1326317|NCT00667277|Idiopathic
1326318|NCT00667277|Bevacizumab
1326319|NCT00667277|Avastin
1326320|NCT00667277|bone marrow fibrosis
1326321|NCT00667277|bone marrow angiogenesis
1326322|NCT00667277|JAK2
1326323|NCT00667264|pain
1326324|NCT00667264|phantom limb
1326325|NCT00667264|stump pain
1326326|NCT00667264|catheter
1326327|NCT00667264|nerve block
1326328|NCT00667264|peripheral nerve block
1326329|NCT00667264|ucsd
1326330|NCT00667264|Post-amputation phantom limb or stump pain
1326331|NCT00667251|recurrent breast cancer
1326332|NCT00667251|HER2-positive breast cancer
1326333|NCT00667251|stage IV breast cancer
1326334|NCT00667212|anger
1326335|NCT00667212|intermittent
1326336|NCT00667212|explosive
1326337|NCT00667199|Hormone Refractory Prostate Cancer
1326338|NCT00667199|Bone Metastases
1326339|NCT00667199|Radium-223
1326340|NCT00667199|Palliation of bone pain
1326341|NCT00667186|HIV
1326342|NCT00667186|Prevention
1326343|NCT00667186|Public Health
1326344|NCT00667186|Screening
1326345|NCT00667160|Mild Atopic Dermatitis
1326346|NCT00667160|Protopic
1326347|NCT00667160|Pediatric
1326348|NCT00667134|systemic sclerosis autoantibodies
1326349|NCT00667121|psychosocial effects of cancer and its treatment
1326350|NCT00667121|breast cancer
1326351|NCT00667121|hot flashes
1326352|NCT00667121|depression
1326353|NCT00667095|OAB
1326354|NCT00667095|Over Active Bladder
1326355|NCT00667095|overactive bladder
1326356|NCT00667095|Urinary Urge Incontinence
1326357|NCT00667095|Urinary Incontinence
1326358|NCT00667095|Botox
1326359|NCT00667095|DMSO
1326360|NCT00667095|bladder instillation
1326361|NCT00667095|instillation
1326362|NCT00667095|detrusor hyperreflexia
1326363|NCT00667095|urge incontinence
1326364|NCT00667082|Non small Cell Lung Cancer
1326365|NCT00667082|Pancreatic Cancer
1326366|NCT00667082|Melanoma
1326367|NCT00667082|Lymphoma
1326368|NCT00667082|Multiple Myeloma
1326369|NCT00667069|adenocarcinoma of the prostate
1326370|NCT00667069|stage III prostate cancer
1326371|NCT00667069|stage IV prostate cancer
1326372|NCT00667056|Chronic Allergic Contact Dermatitis
1326373|NCT00667056|Protopic
1326374|NCT00667043|therapeutic hypothermia
1326375|NCT00667043|cardiac arrest
1326376|NCT00667043|sedation
1326377|NCT00667043|remifentanil
1326378|NCT00667043|propofol
1326379|NCT00667043|fentanyl
1326380|NCT00667043|midazolam
1326381|NCT00667030|Inflammation
1326382|NCT00667030|Aging
1326383|NCT00667030|Metabolism
1326384|NCT00667030|Exercise
1326385|NCT00667017|recurrent mycosis fungoides/Sezary syndrome
1326386|NCT00667017|recurrent cutaneous T-cell non-Hodgkin lymphoma
1326387|NCT00666991|ovarian cancer
1326388|NCT00666991|Mullerian tumors
1326389|NCT00666991|peritoneal cavity carcinoma
1326390|NCT00666991|gastrointestinal tract tumor
1326391|NCT00666991|GI tract tumor
1326392|NCT00666991|pancreatic cancer
1326393|NCT00666991|colon cancer
1326394|NCT00666978|bladder cancer
1326395|NCT00666978|cervical cancer
1326396|NCT00666978|esophageal cancer
1326397|NCT00666978|gastric cancer
1326398|NCT00666978|renal cell carcinoma
1326399|NCT00666978|adult primary liver cancer
1326400|NCT00666978|non-small cell lung cancer
1326401|NCT00666978|small cell lung cancer
1326402|NCT00666978|pancreatic cancer
1326403|NCT00666978|hypopharyngeal cancer
1326404|NCT00666978|laryngeal cancer
1326405|NCT00666978|lip and oral cavity cancer
1326406|NCT00666978|nasopharyngeal cancer
1326407|NCT00666978|oropharyngeal cancer
1326408|NCT00666978|paranasal sinus and nasal cavity cancer
1326409|NCT00666978|adult acute myeloid leukemia
1326410|NCT00666978|tobacco use disorder
1326411|NCT00666965|SPM 962
1326412|NCT00666965|rotigotine
1326413|NCT00666965|Idiopathic Restless Legs Syndrome
1326414|NCT00666965|RLS
1326415|NCT00666926|Pancreatic Neoplasm
1326416|NCT00666926|Head and Neck neoplasm
1326417|NCT00666926|Prostatic neoplasms; Focal Adhesion Kinase
1326418|NCT00666926|Phase 1
1326419|NCT00666926|Pharmacodynamics
1326420|NCT00666926|FDG-PET
1326421|NCT00666913|breast cancer in situ
1326422|NCT00666913|stage I breast cancer
1326423|NCT00666913|stage II breast cancer
1326424|NCT00666913|stage IIIA breast cancer
1326425|NCT00666913|stage IIIB breast cancer
1326426|NCT00666913|stage IIIC breast cancer
1326427|NCT00666913|hot flashes
1326428|NCT00666887|Multiple Sclerosis
1326429|NCT00666887|Clinically Isolated Syndrome
1326430|NCT00666887|Minocycline
1326431|NCT00666887|Placebo
1326432|NCT00666874|Obesity, lifestyle, vascular inflammation
1326433|NCT00666848|Metabolic syndrome
1326434|NCT00666848|Hypertension
1326435|NCT00666848|Sitagliptin
1326436|NCT00666848|Enalapril
1326437|NCT00666835|Treatment of anemia in hemodialysis patients
1326438|NCT00666822|stage I breast cancer
1326439|NCT00666822|stage II breast cancer
1326440|NCT00666822|stage IIIA breast cancer
1326441|NCT00666809|Vardenafil,
1326442|NCT00666809|Tinnitus
1326443|NCT00666757|Severe Depressive Episode
1326444|NCT00666744|exercise
1326445|NCT00666744|frequency
1326446|NCT00666744|duration
1326447|NCT00666731|male breast cancer
1326448|NCT00666731|breast cancer
1326449|NCT00666731|ductal breast carcinoma in situ
1326450|NCT00666731|lobular breast carcinoma in situ
1326451|NCT00666731|atypical ductal breast hyperplasia
1326452|NCT00666705|maraviroc
1326453|NCT00666705|raltegravir
1326454|NCT00666705|drug interaction study
1326455|NCT00666705|healthy volunteers
1326456|NCT00666692|cancer
1326457|NCT00666692|carcinoma
1326458|NCT00666692|monoclonal antibody therapy
1326459|NCT00666692|anti-angiogenesis
1326460|NCT00666666|prostate Cancer
1326461|NCT00666666|adenocarcinoma of the prostate
1326462|NCT00666666|stage IV prostate cancer
1326463|NCT00666666|newly diagnosed stage IV prostate cancer
1326464|NCT00666653|Parkinson's disease
1326465|NCT00666653|Dopamine Agonist
1326466|NCT00666653|Levodopa
1326467|NCT00666653|Pharmacokinetics
1326468|NCT00666653|Dyskinesia
1326469|NCT00666640|Osteoporosis
1326470|NCT00666640|Fracture
1326471|NCT00666640|DXA
1326472|NCT00666640|Dual energy x-ray absorptiometry
1326473|NCT00666640|Computed tomography
1326474|NCT00666640|3D DXA
1326475|NCT00666627|Osteoporosis
1326476|NCT00666627|Post-menopausal osteoporosis
1326477|NCT00666627|Bisphosphonates
1326478|NCT00666627|Alendronate
1326479|NCT00666627|Ibandronate
1326480|NCT00666627|Risedronate
1326481|NCT00666614|Sleep
1326482|NCT00666614|Fatigue
1326483|NCT00666614|High Dose Chemotherapy
1326484|NCT00666601|Microdialysis
1326485|NCT00666601|Antibiotic
1326486|NCT00666601|Healthy subjects
1326487|NCT00666549|Myeloproliferative Disease
1326488|NCT00666549|Myelofibrosis
1326489|NCT00666549|Idiopathic Myelofibrosis
1326490|NCT00666549|Essential Thrombocythemia
1326491|NCT00666549|Polycythemia Vera
1326492|NCT00666536|Hypertension
1326493|NCT00666536|adults
1326494|NCT00666536|Valsartan + Amlodipine
1326495|NCT00666536|Angiotensin Receptor Blockers
1326496|NCT00666523|osteoarthritis, knee or hip
1326497|NCT00666510|nitric oxide
1326498|NCT00666510|bronchospasm
1326499|NCT00666510|anesthesia
1326500|NCT00666510|induced sputum
1326501|NCT00666510|asthma
1326502|NCT00666497|Acute Myeloid Leukemia
1326503|NCT00666497|Myelodysplastic Syndrome
1326504|NCT00666497|Azacitidine
1326505|NCT00666497|Vidaza
1326506|NCT00666497|MGCD0103
1326507|NCT00666497|Histone deacetylase inhibitor
1326508|NCT00666497|DNA methyltransferase inhibitor
1326509|NCT00666497|Epigenetic Therapy
1326510|NCT00666484|neurotoxicity
1326511|NCT00666484|stage I adult Hodgkin lymphoma
1326512|NCT00666484|stage II adult Hodgkin lymphoma
1326513|NCT00666484|stage III adult Hodgkin lymphoma
1326514|NCT00666484|stage IV adult Hodgkin lymphoma
1326515|NCT00666484|adult lymphocyte depletion Hodgkin lymphoma
1326516|NCT00666484|adult lymphocyte predominant Hodgkin lymphoma
1326517|NCT00666484|adult mixed cellularity Hodgkin lymphoma
1326518|NCT00666484|adult nodular sclerosis Hodgkin lymphoma
1326519|NCT00666471|epistaxis
1326520|NCT00666471|Epistaxis refractory to emergency physician treatment
1326521|NCT00666458|Type 2 diabetes
1326522|NCT00666458|metformin
1326523|NCT00666445|Alzheimer's Disease
1326524|NCT00666445|Diagnosis
1326525|NCT00666445|Neuronal function
1326526|NCT00666445|Cognitive Impairment
1326527|NCT00666445|Magnetoencephalography
1326528|NCT00666432|schizophrenia
1326529|NCT00666432|bipolar
1326530|NCT00666432|eye movements
1326531|NCT00666432|phenotype
1326532|NCT00666432|biochemical
1326533|NCT00666432|relatives
1326534|NCT00666419|nonspecific low back pain
1326535|NCT00666419|schoolchildren
1326536|NCT00666419|prevalence
1326537|NCT00666393|IONSYS™
1326538|NCT00666393|Pain, Postoperative
1326539|NCT00666393|Analgesia, Patient-Controlled
1326540|NCT00666393|Opioids
1326541|NCT00666393|Pediatrics
1326542|NCT00666380|Malaria
1326543|NCT00666380|Vaccine
1326544|NCT00666380|MSP-1 (merozoite surface protein-1)
1326545|NCT00666380|Phase 1
1326546|NCT00666367|COPD
1326547|NCT00666354|Nail Psoriasis
1326548|NCT00666354|Psoriasis
1326549|NCT00666354|Fingernail Psoriasis
1326550|NCT00666354|Methotrexate
1326551|NCT00666328|Hypertension
1326552|NCT00666328|Hemorrhage
1326553|NCT00666328|Intracranial Pressure
1326554|NCT00666328|Antihypertensive Agent
1326555|NCT00666328|Calcium Channel Blocker
1326556|NCT00666315|Consecutive euthyroid patients with multinodular goiter for whom a total Thyroidectomy under general anesthesia is indicated
1326557|NCT00666302|Atopic Dermatitis
1326558|NCT00666302|Protopic
1326559|NCT00666302|Elidel
1326560|NCT00666289|polycythemia vera
1326561|NCT00666289|essential thrombocythemia
1326562|NCT00666289|idiopathic myelofibrosis
1326563|NCT00666289|family clusters
1326564|NCT00666250|blood pressure
1326565|NCT00666250|dyslipidemia
1326566|NCT00666250|hyperglycemia
1326567|NCT00666237|Glaucoma
1326568|NCT00666237|Tube shunt surgery
1326569|NCT00666237|Trabeculectomy
1326570|NCT00666224|Clinically Definite Multiple Sclerosis
1326571|NCT00666224|Clinically Isolated Syndrome
1326572|NCT00666224|Multiple Sclerosis
1326573|NCT00666211|pain
1326574|NCT00666211|unspecified adult solid tumor, protocol specific
1326575|NCT00666211|accelerated phase chronic myelogenous leukemia
1326576|NCT00666211|acute undifferentiated leukemia
1326577|NCT00666211|adult acute lymphoblastic leukemia in remission
1326578|NCT00666211|adult acute myeloid leukemia in remission
1326579|NCT00666211|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1326580|NCT00666211|adult acute myeloid leukemia with inv(16)(p13;q22)
1326581|NCT00666211|adult acute myeloid leukemia with t(15;17)(q22;q12)
1326582|NCT00666211|adult acute myeloid leukemia with t(16;16)(p13;q22)
1326583|NCT00666211|adult acute myeloid leukemia with t(8;21)(q22;q22)
1326584|NCT00666211|atypical chronic myeloid leukemia, BCR-ABL negative
1326585|NCT00666211|blastic phase chronic myelogenous leukemia
1326586|NCT00666211|chronic myelomonocytic leukemia
1326587|NCT00666211|chronic phase chronic myelogenous leukemia
1326588|NCT00666211|mast cell leukemia
1326589|NCT00666211|meningeal chronic myelogenous leukemia
1326590|NCT00666211|progressive hairy cell leukemia, initial treatment
1326591|NCT00666211|prolymphocytic leukemia
1326592|NCT00666211|recurrent adult acute lymphoblastic leukemia
1326593|NCT00666211|recurrent adult acute myeloid leukemia
1326594|NCT00666211|recurrent adult T-cell leukemia/lymphoma
1326595|NCT00666211|refractory chronic lymphocytic leukemia
1326596|NCT00666211|refractory hairy cell leukemia
1326597|NCT00666211|relapsing chronic myelogenous leukemia
1326598|NCT00666211|secondary acute myeloid leukemia
1326599|NCT00666211|stage I adult T-cell leukemia/lymphoma
1326600|NCT00666211|stage I chronic lymphocytic leukemia
1326601|NCT00666211|stage II adult T-cell leukemia/lymphoma
1326602|NCT00666211|stage II chronic lymphocytic leukemia
1326603|NCT00666211|stage III adult T-cell leukemia/lymphoma
1326604|NCT00666211|stage III chronic lymphocytic leukemia
1326605|NCT00666211|stage IV adult T-cell leukemia/lymphoma
1326606|NCT00666211|stage IV chronic lymphocytic leukemia
1326607|NCT00666211|T-cell large granular lymphocyte leukemia
1326608|NCT00666211|stage I adult Hodgkin lymphoma
1326609|NCT00666211|stage II adult Hodgkin lymphoma
1326610|NCT00666211|stage III adult Hodgkin lymphoma
1326611|NCT00666211|stage IV adult Hodgkin lymphoma
1326612|NCT00666211|anaplastic large cell lymphoma
1326613|NCT00666211|angioimmunoblastic T-cell lymphoma
1326614|NCT00666211|cutaneous B-cell non-Hodgkin lymphoma
1326615|NCT00666211|recurrent cutaneous T-cell non-Hodgkin lymphoma
1326616|NCT00666211|stage I cutaneous T-cell non-Hodgkin lymphoma
1326617|NCT00666211|stage II cutaneous T-cell non-Hodgkin lymphoma
1326618|NCT00666211|stage III cutaneous T-cell non-Hodgkin lymphoma
1326619|NCT00666211|stage IV cutaneous T-cell non-Hodgkin lymphoma
1326620|NCT00666211|recurrent mycosis fungoides/Sezary syndrome
1326621|NCT00666211|stage I mycosis fungoides/Sezary syndrome
1326622|NCT00666211|stage II mycosis fungoides/Sezary syndrome
1326623|NCT00666211|stage III mycosis fungoides/Sezary syndrome
1326624|NCT00666211|stage IV mycosis fungoides/Sezary syndrome
1326625|NCT00666211|adult grade III lymphomatoid granulomatosis
1326626|NCT00666211|adult nasal type extranodal NK/T-cell lymphoma
1326627|NCT00666211|Waldenstrom macroglobulinemia
1326628|NCT00666211|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1326629|NCT00666211|nodal marginal zone B-cell lymphoma
1326630|NCT00666211|splenic marginal zone lymphoma
1326631|NCT00666211|contiguous stage II adult Burkitt lymphoma
1326632|NCT00666211|contiguous stage II adult diffuse large cell lymphoma
1326633|NCT00666211|contiguous stage II adult diffuse mixed cell lymphoma
1326634|NCT00666211|contiguous stage II adult diffuse small cleaved cell lymphoma
1326635|NCT00666211|contiguous stage II adult immunoblastic large cell lymphoma
1326636|NCT00666211|contiguous stage II adult lymphoblastic lymphoma
1326637|NCT00666211|contiguous stage II grade 1 follicular lymphoma
1326638|NCT00666211|contiguous stage II grade 2 follicular lymphoma
1326639|NCT00666211|contiguous stage II grade 3 follicular lymphoma
1326640|NCT00666211|contiguous stage II mantle cell lymphoma
1326641|NCT00666211|contiguous stage II marginal zone lymphoma
1326642|NCT00666211|stage I adult Burkitt lymphoma
1326643|NCT00666211|stage I adult diffuse large cell lymphoma
1326644|NCT00666211|stage I adult diffuse mixed cell lymphoma
1326645|NCT00666211|stage I adult diffuse small cleaved cell lymphoma
1326646|NCT00666211|stage I adult immunoblastic large cell lymphoma
1326647|NCT00666211|stage I adult lymphoblastic lymphoma
1326648|NCT00666211|stage I grade 1 follicular lymphoma
1326649|NCT00666211|stage I grade 2 follicular lymphoma
1326650|NCT00666211|stage I grade 3 follicular lymphoma
1326651|NCT00666211|stage I mantle cell lymphoma
1326652|NCT00666211|stage I marginal zone lymphoma
1326653|NCT00666211|stage I small lymphocytic lymphoma
1326654|NCT00666211|noncontiguous stage II adult Burkitt lymphoma
1326655|NCT00666211|noncontiguous stage II adult diffuse large cell lymphoma
1326656|NCT00666211|noncontiguous stage II adult diffuse mixed cell lymphoma
1326657|NCT00666211|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1326658|NCT00666211|noncontiguous stage II adult immunoblastic large cell lymphoma
1326659|NCT00666211|noncontiguous stage II adult lymphoblastic lymphoma
1326660|NCT00666211|noncontiguous stage II grade 1 follicular lymphoma
1326661|NCT00666211|noncontiguous stage II grade 2 follicular lymphoma
1326662|NCT00666211|noncontiguous stage II grade 3 follicular lymphoma
1326663|NCT00666211|noncontiguous stage II mantle cell lymphoma
1326664|NCT00666211|noncontiguous stage II marginal zone lymphoma
1326665|NCT00666211|noncontiguous stage II small lymphocytic lymphoma
1326666|NCT00666211|stage III adult Burkitt lymphoma
1326667|NCT00666211|stage III adult diffuse large cell lymphoma
1326668|NCT00666211|stage III adult diffuse mixed cell lymphoma
1326669|NCT00666211|stage III adult diffuse small cleaved cell lymphoma
1326670|NCT00666211|stage III adult immunoblastic large cell lymphoma
1326671|NCT00666211|stage III adult lymphoblastic lymphoma
1326672|NCT00666211|stage III grade 1 follicular lymphoma
1326673|NCT00666211|stage III grade 2 follicular lymphoma
1326674|NCT00666211|stage III grade 3 follicular lymphoma
1326675|NCT00666211|stage III mantle cell lymphoma
1326676|NCT00666211|stage III marginal zone lymphoma
1326677|NCT00666211|stage III small lymphocytic lymphoma
1326678|NCT00666211|stage IV adult Burkitt lymphoma
1326679|NCT00666211|stage IV adult diffuse large cell lymphoma
1326680|NCT00666211|stage IV adult diffuse mixed cell lymphoma
1326681|NCT00666211|stage IV adult diffuse small cleaved cell lymphoma
1326682|NCT00666211|stage IV adult immunoblastic large cell lymphoma
1326683|NCT00666211|stage IV adult lymphoblastic lymphoma
1326684|NCT00666211|stage IV grade 1 follicular lymphoma
1326685|NCT00666211|stage IV grade 2 follicular lymphoma
1326686|NCT00666211|stage IV grade 3 follicular lymphoma
1326687|NCT00666211|stage IV mantle cell lymphoma
1326688|NCT00666211|stage IV marginal zone lymphoma
1326689|NCT00666211|stage IV small lymphocytic lymphoma
1326690|NCT00666211|recurrent adult Burkitt lymphoma
1326691|NCT00666211|recurrent adult diffuse large cell lymphoma
1326692|NCT00666211|recurrent adult diffuse mixed cell lymphoma
1326693|NCT00666211|recurrent adult diffuse small cleaved cell lymphoma
1326694|NCT00666211|recurrent adult grade III lymphomatoid granulomatosis
1326695|NCT00666211|recurrent adult immunoblastic large cell lymphoma
1326696|NCT00666211|recurrent adult lymphoblastic lymphoma
1326697|NCT00666211|recurrent grade 1 follicular lymphoma
1326698|NCT00666211|recurrent grade 2 follicular lymphoma
1326699|NCT00666211|recurrent grade 3 follicular lymphoma
1326700|NCT00666211|recurrent mantle cell lymphoma
1326701|NCT00666211|recurrent marginal zone lymphoma
1326702|NCT00666211|recurrent small lymphocytic lymphoma
1326703|NCT00666211|intraocular lymphoma
1326704|NCT00666211|primary central nervous system non-Hodgkin lymphoma
1326705|NCT00666211|primary central nervous system Hodgkin lymphoma
1326706|NCT00666211|post-transplant lymphoproliferative disorder
1326707|NCT00666211|chronic eosinophilic leukemia
1326708|NCT00666211|chronic neutrophilic leukemia
1326709|NCT00666211|primary myelofibrosis
1326710|NCT00666211|essential thrombocythemia
1326711|NCT00666211|polycythemia vera
1326712|NCT00666211|extramedullary plasmacytoma
1326713|NCT00666211|isolated plasmacytoma of bone
1326714|NCT00666211|monoclonal gammopathy of undetermined significance
1326715|NCT00666211|stage I multiple myeloma
1326716|NCT00666211|stage II multiple myeloma
1326717|NCT00666211|stage III multiple myeloma
1326718|NCT00666211|primary systemic amyloidosis
1326719|NCT00666211|refractory multiple myeloma
1326720|NCT00666211|de novo myelodysplastic syndromes
1326721|NCT00666211|previously treated myelodysplastic syndromes
1326722|NCT00666211|secondary myelodysplastic syndromes
1326723|NCT00666211|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1326724|NCT00666211|recurrent adult Hodgkin lymphoma
1326725|NCT00666185|Micafungin
1326726|NCT00666185|Esophageal Candidiasis
1326727|NCT00666185|Fluconazole
1326728|NCT00666172|Women's Health
1326729|NCT00666172|Obesity
1326730|NCT00666172|Metabolic Syndrome
1326731|NCT00666172|Arterial Function
1326732|NCT00666172|Lipoproteins
1326733|NCT00666172|Overweight
1326734|NCT00666159|Atopic Dermatitis
1326735|NCT00666159|Protopic
1326736|NCT00666159|Pediatric
1326737|NCT00666146|Schizophrenia
1326738|NCT00666146|Genetics
1326739|NCT00666146|Eyetracking
1326740|NCT00666133|Preeclampsia
1326741|NCT00666133|Eclampsia
1326742|NCT00666133|Magnesium Sulfate
1326743|NCT00666107|HPV
1326744|NCT00666107|HIV
1326745|NCT00666107|Gardasil
1326746|NCT00666107|Vaccine
1326747|NCT00666094|Type 2-diabetes
1326748|NCT00666094|exercise therapy
1326749|NCT00666094|RCT
1326750|NCT00666094|Norway
1326751|NCT00666081|Pazopanib, paclitaxel, carboplatin
1326752|NCT00666068|Patients with hypopituitarism
1326753|NCT00666055|Sex
1326754|NCT00666055|Aging
1326755|NCT00666055|Antiretroviral
1326756|NCT00666055|Pharmacokinetics
1326757|NCT00666055|post-menopausal women with HIV infection
1326758|NCT00666055|pre-menopausal women with HIV infection
1326759|NCT00666029|metabolic syndrome
1326760|NCT00666029|Volunteers recruited from the community
1326761|NCT00666016|non alcoholic steatohepatitis nash hepatoprotective hepatoprotection ALT AST new drug candidate interventional study TRO19622 Trophos cholest-4-en-3-one oxime
1326762|NCT00666003|Hemodynamics
1326763|NCT00665977|Obstructive Sleep Apnea
1326764|NCT00665977|Nasal Congestion
1326765|NCT00665977|Sinus congestion
1326766|NCT00665964|osteoarthritis
1326767|NCT00665964|knee
1326768|NCT00665964|total knee arthroplasty
1326769|NCT00665964|gonarthrrsis
1326770|NCT00665964|polyethylene
1326771|NCT00665964|posterior stabilized
1326772|NCT00665951|pediatric
1326773|NCT00665951|pharmacokinetics
1326774|NCT00665951|HIV infection
1326775|NCT00665938|Physical development
1326776|NCT00665899|breast cancer
1326777|NCT00665899|couples
1326778|NCT00665899|cognitive behavioral therapy
1326779|NCT00665899|Women with early stage breast cancer and their partners.
1326780|NCT00665886|Peripheral venous catheter
1326781|NCT00665886|Catheter-related complication
1326782|NCT00665886|Bacterial Colonization
1326783|NCT00665886|Dwell time
1326784|NCT00665886|Closed system
1326785|NCT00665886|Costs
1326786|NCT00665886|Polyurethane
1326787|NCT00665886|Teflon
1326788|NCT00665873|Totally Implantable Venous Access Devices
1326789|NCT00665873|Infections
1326790|NCT00665873|Chemotherapy
1326791|NCT00665873|Valuated infections TIVAD
1326792|NCT00665860|Osteoporosis
1326793|NCT00665860|Soy isoflavones
1326794|NCT00665860|Postmenopausal women
1326795|NCT00665860|Safety
1326796|NCT00665860|Efficacy
1326797|NCT00665860|Effective dosage
1326798|NCT00665847|HIV-1
1326799|NCT00665847|TMC125-TiDP35-C213
1326800|NCT00665847|TMC125-C213
1326801|NCT00665821|nonspecific low back pain
1326802|NCT00665821|disability
1326803|NCT00665821|sick leave
1326804|NCT00665821|catastrophizing
1326805|NCT00665821|workers
1326806|NCT00665795|Dysthyroid Optic Neuropathy
1326807|NCT00665795|multidetector computed tomography
1326808|NCT00665795|color doppler
1326809|NCT00665795|Grave´s Orbitopathy
1326810|NCT00665795|Grave´s Disease
1326811|NCT00665795|morphometric analysis
1326812|NCT00665782|anxiety disorder
1326813|NCT00665782|depression
1326814|NCT00665782|psychosocial effects of cancer and its treatment
1326815|NCT00665782|ductal breast carcinoma in situ
1326816|NCT00665782|breast cancer in situ
1326817|NCT00665782|stage I breast cancer
1326818|NCT00665782|stage II breast cancer
1326819|NCT00665782|stage IIIA breast cancer
1326820|NCT00665782|stage IIIB breast cancer
1326821|NCT00665782|stage IIIC breast cancer
1326822|NCT00665769|hypercapnia
1326823|NCT00665769|normocapnia
1326824|NCT00665769|chronic lung disease
1326825|NCT00665769|periventricular leukomalacia
1326826|NCT00665769|intraventricular hemorrhage
1326827|NCT00665769|hypotension
1326828|NCT00665769|cerebral autoregulation
1326829|NCT00665769|heart rate variability
1326830|NCT00665769|autonomic nervous system
1326831|NCT00665769|detrended fluctuation analysis
1326832|NCT00665756|Glaucoma
1326833|NCT00665756|Drainage implant
1326834|NCT00665756|Ahmed valve
1326835|NCT00665756|Second trabeculectomy
1326836|NCT00665717|interaction
1326837|NCT00665717|statins
1326838|NCT00665717|pharmacokinetics
1326839|NCT00665704|Smoking Cessation
1326840|NCT00665704|Internet
1326841|NCT00665704|Intervention Studies
1326842|NCT00665704|Health Services Accessibility
1326843|NCT00665691|All Malignancies
1326844|NCT00665652|Neuropathy
1326845|NCT00665652|Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
1326846|NCT00665652|MGUS
1326847|NCT00665639|Micafungin
1326848|NCT00665639|Esophageal Candidiasis
1326849|NCT00665639|caspofungin
1326850|NCT00665613|warfarin use
1326851|NCT00665600|COPD
1326852|NCT00665600|Chronic Bronchitis
1326853|NCT00665600|Chronic Emphysema
1326854|NCT00665587|Atrial fibrillation
1326855|NCT00665587|Maze procedure
1326856|NCT00665587|Mid-term results
1326857|NCT00665587|Long-term results
1326858|NCT00665587|Surgical ablation
1326863|NCT00665548|Knee Osteoarthritis
1326864|NCT00665548|magnetic resonance imaging
1326865|NCT00665548|x rays
1326866|NCT00665535|Pressure ulcers
1326867|NCT00665535|Nursing facilities
1326868|NCT00665535|Elderly
1326869|NCT00665535|At risk for pressure ulcers
1326870|NCT00665522|Pain
1326871|NCT00665522|Postoperative Analgesia
1326872|NCT00665522|Patient-Controlled Opioids
1326873|NCT00665509|Influenza
1326874|NCT00665509|Vaccine
1326875|NCT00665509|CHMP criteria
1326876|NCT00665496|Erectile Dysfunction
1326877|NCT00665496|Vardenafil
1326878|NCT00665496|Onset of action
1326879|NCT00665470|Malignant Melanoma
1326880|NCT00665470|HLA-A2
1326881|NCT00665470|Immunotherapy
1326882|NCT00665470|Clinical Response
1326883|NCT00665470|Skin Cancer
1326884|NCT00665457|stage II breast cancer
1326885|NCT00665457|stage IIIA breast cancer
1326886|NCT00665457|stage IIIB breast cancer
1326887|NCT00665457|stage IIIC breast cancer
1326888|NCT00665444|bipolar disorder
1326889|NCT00665444|sedation
1326890|NCT00665444|overweight
1326891|NCT00665444|Abilify
1326892|NCT00665444|medication
1326893|NCT00665418|Anesthesia
1326894|NCT00665418|children
1326895|NCT00665418|Larynx
1326896|NCT00665405|Delivery, obstetric
1326897|NCT00665405|Atelectasis
1326898|NCT00665392|stage III squamous cell carcinoma of the oropharynx
1326899|NCT00665392|stage IV squamous cell carcinoma of the oropharynx
1326900|NCT00665392|tongue cancer
1326901|NCT00665379|leg lymphedema
1326902|NCT00665379|volume measurement
1326903|NCT00665379|compression therapy
1326904|NCT00665379|interface pressure
1326905|NCT00665379|static stiffness index (SSI)
1326906|NCT00665379|volume change
1326907|NCT00665353|HIV
1326908|NCT00665353|HCV
1326909|NCT00665340|Erectile Dysfunction
1326910|NCT00665340|Vardenafil
1326911|NCT00665327|Community Acquired Pneumonia
1326912|NCT00665327|Pneumonia,
1326913|NCT00665327|CAP
1326914|NCT00665314|Mobilisation stem cells
1326915|NCT00665314|G-CSF Mobilisation Regimen
1326916|NCT00665314|Lymphoma
1326917|NCT00665314|Multiple Myeloma
1326918|NCT00665314|Adult patients with lymphoma (Non Hodgkin's Lymphoma, Hodgkin's Disease) or Multiple Myeloma who previously failed Stem Cell Collections or Collection attempts.
1326919|NCT00665301|Non-invasive Cardiac Output
1326920|NCT00665288|cardiac arrest
1326921|NCT00665288|heart arrest
1326922|NCT00665288|CPR
1326923|NCT00665288|resuscitation
1326924|NCT00665288|bystander CPR
1326925|NCT00665275|complementary
1326926|NCT00665275|alternative
1326927|NCT00665275|medicine
1326928|NCT00665262|analgesia
1326929|NCT00665262|hip arthroplasty
1326930|NCT00665262|knee arthroplasty
1326931|NCT00665249|problem drinking
1326932|NCT00665249|heavy drinking
1326933|NCT00665249|Alcohol
1326934|NCT00665249|moderation
1326935|NCT00665249|motivational interviewing
1326936|NCT00665236|Migraine
1326937|NCT00665223|Huntington's Disease
1326938|NCT00665210|hip arthritis
1326939|NCT00665210|implant sizing
1326940|NCT00665197|Esophageal cancer
1326941|NCT00665197|Brachytherapy
1326942|NCT00665197|Radiotherapy
1326943|NCT00665197|Palliation
1326944|NCT00665197|Dysphagia
1326945|NCT00665184|Hypokinesia
1326946|NCT00665184|Gait
1326947|NCT00665184|Quality of life
1326948|NCT00665184|Dopamine replacement
1326949|NCT00665184|Resistance training
1326950|NCT00665171|Polycystic ovary syndrome
1326951|NCT00665171|Single nucleotide polymorphism
1326952|NCT00665171|Whole genome analysis
1326953|NCT00665171|Multigenerational family study
1326954|NCT00665158|Abdominal obesity, exercise, behaviour modification
1326955|NCT00665145|Diabetes Mellitus, Type 1
1326956|NCT00665145|Diabetes Mellitus, Type 2
1326957|NCT00665145|Diabetic Polyneuropathy
1326958|NCT00665145|Stem Cells
1326959|NCT00665132|wrist
1326960|NCT00665132|hand
1326961|NCT00665132|pain
1326962|NCT00665132|failed CTR
1326963|NCT00665132|carpal tunnel syndrome
1326964|NCT00665132|CTS
1326965|NCT00665132|CTR
1326966|NCT00665132|carpel tunnel release
1326967|NCT00665132|Peripheral nerve
1326968|NCT00665132|Median nerve
1326969|NCT00665119|Respiratory Insufficiency
1326970|NCT00665119|Respiration, Artificial
1326971|NCT00665119|Remifentanil
1326972|NCT00665119|Respiratory Mechanics
1326973|NCT00665119|Work of Breathing
1326974|NCT00665106|Diabetic macular edema
1326975|NCT00665106|Diabetes
1326976|NCT00665106|Diabetic retinopathy
1326977|NCT00665067|Myeloproliferative Disease
1326978|NCT00665067|Myelofibrosis
1326979|NCT00665067|Idiopathic Myelofibrosis
1326980|NCT00665067|Essential Thrombocythemia
1326981|NCT00665067|Polycythemia Vera
1326982|NCT00665067|Biomarkers
1326983|NCT00665067|Philadelphia Chromosome Negative
1326984|NCT00665067|Clonal Hematopoietic malignancies
1326985|NCT00665054|Vardenafil
1326986|NCT00665054|Erectile dysfunction
1326987|NCT00665054|SSES-E (sexual self-efficacy scale - erectile function)
1326988|NCT00665028|Anesthesia
1326989|NCT00665028|Postoperative myocardial ischemia
1326990|NCT00665028|ST monitoring
1326991|NCT00665015|pleural effusion
1326992|NCT00665015|coronary artery bypass
1326993|NCT00665015|heart valve replacement
1326994|NCT00665002|Myeloid
1326995|NCT00665002|Monocytic
1326996|NCT00665002|Hematopoietic
1326997|NCT00665002|Neoplasms
1326998|NCT00665002|Acute Myelogenous Leukemia
1326999|NCT00665002|AML
1327000|NCT00665002|Myelodysplastic Syndrome
1327001|NCT00665002|MDS
1327002|NCT00664989|Hemiarthroplasty Stemmed Resurfacing Conventional Shoulder
1327003|NCT00664976|bipolar depression
1327004|NCT00664976|Electroconvulsive therapy
1327005|NCT00664963|Arterial Occlusive Diseases
1327006|NCT00664963|Peripheral Vascular Diseases
1327007|NCT00664963|Drug eluting stent
1327008|NCT00664963|Restenosis
1327009|NCT00664963|Below the knee
1327010|NCT00664963|Intervention
1327011|NCT00664950|intertrochanteric hip fracture fixation
1327012|NCT00664950|interTAN IM Nail
1327013|NCT00664950|sliding hip screw
1327014|NCT00664924|ICU
1327015|NCT00664898|anti-CD40
1327016|NCT00664898|Myeloma
1327017|NCT00664885|non-psychiatric
1327018|NCT00664885|clinics
1327019|NCT00664872|case manager
1327020|NCT00664872|suicide
1327021|NCT00664872|attempt
1327022|NCT00664872|effectiveness
1327023|NCT00664859|LCP-AtorFen
1327024|NCT00664859|Non-HDL cholesterol
1327025|NCT00664859|Triglycerides
1327026|NCT00664859|HDL cholesterol
1327027|NCT00664859|LDL cholesterol
1327028|NCT00664859|Atorvastatin
1327029|NCT00664859|Fenofibrate
1327030|NCT00664846|Stroke
1327031|NCT00664846|Prevention Therapy
1327032|NCT00664833|Erectile dysfunction
1327033|NCT00664833|Phosphodiesterase Type 5 Inhibitors
1327034|NCT00664833|Patient education
1327035|NCT00664833|Impotence
1327036|NCT00664833|Vardenafil
1327037|NCT00664820|Rheumatoid Arthritics
1327038|NCT00664820|probiotics
1327039|NCT00664820|Lactobacillus
1327040|NCT00664781|stage IIIA breast cancer
1327041|NCT00664781|stage IIIB breast cancer
1327042|NCT00664781|stage IIIC breast cancer
1327043|NCT00664781|stage IV breast cancer
1327044|NCT00664781|recurrent breast cancer
1327045|NCT00664781|stage IV ovarian epithelial cancer
1327046|NCT00664781|recurrent ovarian germ cell tumor
1327047|NCT00664781|stage IV ovarian germ cell tumor
1327048|NCT00664781|ovarian stromal cancer
1327049|NCT00664781|ovarian sarcoma
1327050|NCT00664781|BRCA1 mutation carrier
1327051|NCT00664781|BRCA2 mutation carrier
1327052|NCT00664781|stage IIIA ovarian epithelial cancer
1327053|NCT00664781|stage IIIA ovarian germ cell tumor
1327054|NCT00664781|stage IIIB ovarian epithelial cancer
1327055|NCT00664781|stage IIIB ovarian germ cell tumor
1327056|NCT00664781|stage IIIC ovarian epithelial cancer
1327057|NCT00664781|stage IIIC ovarian germ cell tumor
1327058|NCT00664781|ovarian papillary serous carcinoma
1327059|NCT00664768|hypoallergenicity
1327060|NCT00664768|Cow Milk Allergy
1327061|NCT00664768|DBPCFC
1327062|NCT00664768|Stool microflora
1327063|NCT00664768|Stool characteristics
1327064|NCT00664755|Menstrual Cycle effects
1327065|NCT00664755|Cue Reactivity
1327066|NCT00664755|Smoking Cessation
1327067|NCT00664755|Impulsivity
1327068|NCT00664742|Metabolic syndrome,dyslipidemia,fluvastatin extended release
1327069|NCT00664729|Abdominal
1327070|NCT00664729|obesity
1327071|NCT00664729|exercise
1327072|NCT00664729|intensity
1327073|NCT00664729|weight loss
1327074|NCT00664729|women
1327075|NCT00664716|Rheumatoid Arthritis
1327076|NCT00664716|RA
1327077|NCT00664716|DMARD inadequate response
1327078|NCT00664716|Methotrexate
1327079|NCT00664703|Dopamine Uptake Inhibitors
1327080|NCT00664703|Dopamine
1327081|NCT00664703|Methylphenidate
1327082|NCT00664703|Mental Disorders Diagnosed in Childhood
1327083|NCT00664703|Neurologic Manifestations
1327084|NCT00664703|Attention Deficit and Disruptive Behavior Disorders
1327085|NCT00664703|Hyperkinesis
1327086|NCT00664703|Dyskinesias
1327087|NCT00664690|shoulder surgery
1327088|NCT00664690|analgesia
1327089|NCT00664677|Adult
1327090|NCT00664677|Leukemia
1327091|NCT00664677|Terameprocol
1327092|NCT00664677|Survivin
1327093|NCT00664677|AML
1327094|NCT00664677|ALL
1327095|NCT00664677|ATL
1327096|NCT00664677|CML
1327097|NCT00664677|CLL
1327098|NCT00664677|CMML
1327099|NCT00664677|MDS
1327100|NCT00664664|insomnia
1327101|NCT00664664|sleep maintenance insomnia
1327102|NCT00664664|sleep quality
1327103|NCT00664664|non-restorative sleep
1327104|NCT00664664|multiple awakenings
1327105|NCT00664651|joint contracture
1327106|NCT00664651|total knee arthroplasty
1327107|NCT00664612|Cervical Spine
1327108|NCT00664599|Ocular lesions, Visual Acuity, Retinal Vasculitis
1327109|NCT00664586|Terameprocol (EM-1421)
1327110|NCT00664586|Phase 1
1327111|NCT00664586|Infusion
1327112|NCT00664586|Refractory Solid Tumors
1327113|NCT00664586|Lymphoma
1327114|NCT00664586|Maximum Tolerated Dose
1327115|NCT00664586|Tumor Response
1327116|NCT00664586|Tumor Markers
1327117|NCT00664586|Pharmacokinetics
1327118|NCT00664573|Safety
1327119|NCT00664573|Rheumatoid Arthritis
1327120|NCT00664573|Baminercept alfa
1327121|NCT00664573|Methotrexate
1327122|NCT00664573|BG9924
1327123|NCT00664573|Efficacy
1327124|NCT00664547|obesity, exercise, diet, insulin resistance
1327125|NCT00664508|Arthroplasty
1327126|NCT00664508|Hip Replacement
1327127|NCT00664508|motion analysis
1327128|NCT00664495|Obesity, exercise, diet, insulin resistance
1327129|NCT00664456|stage IIB prostate cancer
1327130|NCT00664456|stage IIA prostate cancer
1327131|NCT00664456|stage I prostate cancer
1327132|NCT00664443|cardiac arrest
1327133|NCT00664443|CPR
1327134|NCT00664443|resuscitation
1327135|NCT00664443|bystander CPR
1327136|NCT00664443|dispatch-assisted CPR
1327137|NCT00664430|Dialysis
1327138|NCT00664430|Calcitriol Resistant
1327139|NCT00664430|Secondary Hyperparathyroidism
1327140|NCT00664417|Influenza
1327141|NCT00664417|A/H5N1
1327142|NCT00664417|Orthomyxoviridae Infections
1327143|NCT00664417|Influenza Pandemics
1327144|NCT00664404|Smoking
1327145|NCT00664404|Smoking Cessation
1327146|NCT00664404|Nicotine Withdrawal
1327147|NCT00664404|Nicotine Dependence
1327148|NCT00664404|Neuroregulatory Effects
1327149|NCT00664404|Magnetic Resonance Imaging
1327150|NCT00664404|MRI
1327151|NCT00664378|Multiple myeloma, relapsed, refractory
1327152|NCT00664365|Premature ejaculation.
1327153|NCT00664365|FTIH,
1327154|NCT00664365|GSK958108,
1327155|NCT00664365|5HT1a antagonist,
1327156|NCT00664352|Double blind
1327157|NCT00664352|Placebo controlled
1327158|NCT00664352|wound healing
1327159|NCT00664339|Heart failure,
1327160|NCT00664339|infection,
1327161|NCT00664339|immune system,
1327162|NCT00664339|atherosclerosis
1327163|NCT00664326|Renal Cell Carcinoma
1327164|NCT00664313|Linezolid
1327165|NCT00664313|Zyvox
1327166|NCT00664313|Peripheral Neuropathy
1327167|NCT00664313|Optic Neuropathy
1327168|NCT00664313|Anemia
1327169|NCT00664313|Thrombocytopenia
1327170|NCT00664300|Gilles de la Tourette's syndrome
1327171|NCT00664300|Facial expression recognition of emotion
1327172|NCT00664300|Frequency levels
1327173|NCT00664300|Automatic and voluntary information treatment
1327174|NCT00664300|Patient with Gilles de la Tourette's syndrome
1327175|NCT00664261|tobacco use disorder
1327176|NCT00664235|Pressure Ulcers
1327177|NCT00664235|Tissue Injury
1327178|NCT00664222|heart failure
1327179|NCT00664222|insulin resistance
1327180|NCT00664222|inflammatory cytokine
1327181|NCT00664222|spironolactone
1327182|NCT00664222|furosemide
1327183|NCT00664209|Parkinson's disease
1327184|NCT00664209|levodopa
1327185|NCT00664209|Helicobacter pylori
1327186|NCT00664196|Prostate Cancer
1327187|NCT00664196|T cells
1327188|NCT00664196|Gene Transfer
1327189|NCT00664183|diabetic retinopathy
1327190|NCT00664157|Idiopathic Parkinson's disease
1327191|NCT00664157|L-Dopa
1327192|NCT00664157|Deep Brain stimulation
1327193|NCT00664157|Facial expression recognition of emotion
1327194|NCT00664157|Frequency levels
1327195|NCT00664157|Automatic and voluntary information treatment
1327196|NCT00664157|Patient with an Idiopathic Parkinson's disease
1327197|NCT00664131|Acute Lymphoblastic Leukemia
1327198|NCT00664131|ALL survivors
1327199|NCT00664131|ALL neurologic symptoms
1327200|NCT00664131|ALL neurologic disability
1327201|NCT00664131|ALL late effects
1327202|NCT00664118|Doula
1327203|NCT00664118|Patient-controlled epidural analgesia
1327204|NCT00664118|Neuraxial analgesia
1327205|NCT00664118|Labor analgesia
1327206|NCT00664105|stage IIIA non-small cell lung cancer
1327207|NCT00664105|stage IIIB non-small cell lung cancer
1327208|NCT00664092|Substance Abuse
1327209|NCT00664092|Ex-Offenders
1327210|NCT00664092|Substance Abuse Recovery
1327211|NCT00664079|Thyroid Deficiency
1327212|NCT00664079|Thyroid Stimulating Hormone
1327213|NCT00664053|bone mineral density
1327214|NCT00664053|bone turnover markers
1327215|NCT00664053|strength
1327216|NCT00664053|balance
1327217|NCT00664014|hyponatremia
1327218|NCT00664014|Non-acute and non hypovolemic hyponatremia
1327219|NCT00663988|face transplantation
1327220|NCT00663975|cystic fibrosis
1327221|NCT00663975|pancreatic insufficiency
1327222|NCT00663975|pancreatic enzymes
1327223|NCT00663975|pediatrics
1327224|NCT00663962|Thoracotomy
1327225|NCT00663962|Post-surgical
1327226|NCT00663962|Pregabalin
1327227|NCT00663949|diabetes
1327228|NCT00663949|proteinuria
1327229|NCT00663949|pentoxifylline
1327230|NCT00663936|Alzheimer's Disease
1327231|NCT00663936|Alzheimer's
1327232|NCT00663923|Excimer Laser
1327233|NCT00663923|photorefractive keratectomy
1327234|NCT00663923|astigmatism
1327235|NCT00663910|basal cell carcinoma of the skin
1327236|NCT00663910|squamous cell carcinoma of the skin
1327237|NCT00663910|recurrent skin cancer
1327238|NCT00663897|functional dyspepsia
1327239|NCT00663897|epigastric pain syndrome
1327240|NCT00663897|postprandial distress syndrome
1327241|NCT00663897|proton pump inhibitor
1327242|NCT00663897|5 HT-4 receptor agonist
1327243|NCT00663884|diabetes mellitus, Type 2
1327244|NCT00663884|mitiglinide
1327245|NCT00663871|Fish Oil
1327246|NCT00663871|Omega-3 fatty acids
1327247|NCT00663871|Affect
1327248|NCT00663871|Depression
1327249|NCT00663871|Anger
1327250|NCT00663871|Nutrition
1327251|NCT00663871|Impulsivity
1327252|NCT00663871|Aggression
1327253|NCT00663871|Cognition
1327254|NCT00663871|Behavior
1327255|NCT00663845|Male Erectile Dysfunction
1327256|NCT00663845|Dyslipidemia
1327257|NCT00663845|Vardenafil
1327258|NCT00663832|Male
1327259|NCT00663832|Prostate
1327260|NCT00663832|Cancer
1327261|NCT00663832|HRPC
1327262|NCT00663832|DACi
1327263|NCT00663819|Low anterior colon resection
1327264|NCT00663819|Proctectomy
1327265|NCT00663819|Proctocolectomy
1327266|NCT00663819|Anastomosis
1327267|NCT00663819|Rectal Cancer
1327268|NCT00663819|Ileostomy
1327269|NCT00663806|UTI
1327270|NCT00663793|Male Contraception
1327271|NCT00663793|Hypogonadism
1327272|NCT00663793|Testosterone
1327273|NCT00663780|pharmacogenomics
1327274|NCT00663780|polymorphisms
1327275|NCT00663780|wound healing
1327276|NCT00663754|Body Image
1327277|NCT00663741|Unresectable / recurrent gastric cancer
1327278|NCT00663741|Sorafenib
1327279|NCT00663741|S-1
1327280|NCT00663741|Gastric
1327281|NCT00663741|Cisplatin
1327282|NCT00663741|CDDP
1327283|NCT00663728|Erectile Dysfunction
1327284|NCT00663728|Vardenafil
1327285|NCT00663715|Sciatic Nerve
1327286|NCT00663715|Peripheral Nerve Block
1327287|NCT00663715|Lower extremity surgery
1327288|NCT00663715|Local Anesthesia
1327289|NCT00663715|Ultrasound guided nerve blocks
1327290|NCT00663689|erlotinib
1327291|NCT00663650|Basal Cell Carcinoma
1327292|NCT00663650|BCC
1327293|NCT00663650|Periocular BCC
1327294|NCT00663650|Frozen Section Control
1327295|NCT00663650|Permanent Section Control
1327296|NCT00663650|Recurrence Rates
1327297|NCT00663637|endotracheal tube obstruction, occlusion
1327298|NCT00663637|mechanical ventilation, complication
1327299|NCT00663637|work of breathing
1327300|NCT00663637|airway resistance
1327301|NCT00663637|secretions
1327302|NCT00663637|pneumonia, ventilator associated
1327303|NCT00663637|biofilms
1327304|NCT00663637|endotracheal tube
1327305|NCT00663611|Immune Function
1327306|NCT00663611|Metabolism
1327307|NCT00663611|Pulsatile Growth Hormone
1327308|NCT00663598|Erectile Dysfunction
1327309|NCT00663598|Vardenafil
1327310|NCT00663585|Migraine
1327311|NCT00663585|Headache
1327312|NCT00663585|Vipassana
1327313|NCT00663585|Meditation
1327314|NCT00663585|Intensive
1327315|NCT00663572|Newborn
1327316|NCT00663572|nutrition
1327317|NCT00663572|genetic
1327318|NCT00663572|feeding behaviour
1327319|NCT00663572|psychomotor development
1327320|NCT00663572|long-term effects
1327321|NCT00663572|nutritional imprinting.
1327322|NCT00663559|renal
1327323|NCT00663559|Sunitinib
1327324|NCT00663559|Unresectable and/or metastatic renal cell cancer
1327325|NCT00663546|Malaria
1327326|NCT00663546|Plasmodium
1327327|NCT00663546|Hemoglobin E
1327328|NCT00663546|Alpha-thalssemia
1327329|NCT00663546|G6PD Deficiency
1327330|NCT00663533|Vasectomy
1327331|NCT00663533|Contraception
1327332|NCT00663520|Cardiac disease
1327333|NCT00663520|vascular dysfunction
1327334|NCT00663520|women
1327335|NCT00663520|chest pain
1327336|NCT00663520|echocardiography
1327337|NCT00663507|Sickle Cell Disease
1327338|NCT00663507|Immunosuppression
1327339|NCT00663507|Organ & Tissue Transplantation
1327340|NCT00663507|Transplantation Immunology
1327341|NCT00663494|heart failure
1327342|NCT00663494|MMP
1327343|NCT00663494|coronary sinus
1327344|NCT00663481|CoFactor
1327345|NCT00663481|ANX-510
1327346|NCT00663468|determine changes in patient pain level
1327347|NCT00663468|determine changes in patient functionality
1327348|NCT00663468|determine changes in patient life quality
1327349|NCT00663455|kidney transplant recipients
1327350|NCT00663455|children and adolescents with kidney transplants
1327351|NCT00663442|ADHD
1327352|NCT00663442|side effects
1327353|NCT00663442|sleep
1327354|NCT00663442|dopamine
1327355|NCT00663442|pharmacogenetics
1327356|NCT00663403|daptomycin
1327357|NCT00663403|pharmacokinetics
1327358|NCT00663403|renal replacement therapy
1327359|NCT00663403|critical illness
1327360|NCT00663403|intensive care units
1327361|NCT00663377|Heart Failure
1327362|NCT00663377|Insulin Resistance
1327363|NCT00663377|Losartan
1327364|NCT00663377|ACE inhibitor
1327365|NCT00663377|Inflammatory cytokine
1327366|NCT00663364|dry skin
1327367|NCT00663351|Arthritis
1327368|NCT00663351|Osteoarthritis
1327369|NCT00663351|Traumatic Arthritis
1327370|NCT00663351|Degenerative Joint Disease
1327371|NCT00663351|Avascular Necrosis
1327372|NCT00663338|Stroke
1327373|NCT00663338|Hemispatial neglect
1327374|NCT00663338|Unilateral neglect
1327375|NCT00663338|Spatial neglect
1327376|NCT00663338|Motor
1327377|NCT00663338|Weakness
1327378|NCT00663312|Idiopathic Parkinson's disease
1327379|NCT00663312|Deep Brain stimulation
1327380|NCT00663312|Hepatic glucose production
1327381|NCT00663312|Insulin
1327382|NCT00663312|Weight gain
1327383|NCT00663312|Patient with an Idiopathic Parkinson's disease
1327384|NCT00663299|Intracranial aneurysm
1327385|NCT00663247|Diverticular disease
1327386|NCT00663247|Inflammation
1327387|NCT00663247|Mesalazine
1327388|NCT00663234|Treatment Experienced
1327389|NCT00663221|Osteoporosis prevention
1327390|NCT00663195|heart failure
1327391|NCT00663195|fibrosis
1327392|NCT00663195|MMP
1327393|NCT00663195|spironolactone
1327394|NCT00663195|furosemide
1327395|NCT00663182|Entecavir
1327396|NCT00663182|cirrhosis
1327397|NCT00663182|anti-viral
1327398|NCT00663182|therapy
1327399|NCT00663169|Arthritis Gouty
1327400|NCT00663169|ACZ885
1327401|NCT00663169|IL1B protein
1327402|NCT00663169|Pain
1327403|NCT00663156|lipoaugmentation
1327404|NCT00663156|breast augmentation
1327405|NCT00663156|fat grafting
1327406|NCT00663156|liposuction
1327407|NCT00663156|lipoinfiltration
1327408|NCT00663156|Spear
1327409|NCT00663156|breast implants
1327410|NCT00663156|ASERF
1327411|NCT00663156|Lipivage
1327412|NCT00663156|Baker
1327413|NCT00663156|harvest
1327414|NCT00663156|autologous
1327415|NCT00663156|Georgetown
1327416|NCT00663143|investigate
1327417|NCT00663143|TZD exposure
1327418|NCT00663143|in vitro
1327419|NCT00663143|alters
1327420|NCT00663143|bone
1327421|NCT00663143|formation
1327422|NCT00663143|differentiation
1327423|NCT00663143|capacity
1327424|NCT00663143|bone marrow
1327425|NCT00663143|stromal cells
1327426|NCT00663130|Erectile Dysfunction
1327427|NCT00663130|Vardenafil
1327428|NCT00663117|naltrexone
1327429|NCT00663117|LDN
1327430|NCT00663117|IBD
1327431|NCT00663117|Inflammatory bowel disease
1327432|NCT00663104|early menopause
1327433|NCT00663104|exercise
1327434|NCT00663104|phytoestrogen
1327435|NCT00663104|bone
1327436|NCT00663104|CHD-risk factors
1327437|NCT00663091|WPP-201
1327438|NCT00663078|Cognitive Behavioral Therapy
1327439|NCT00663078|expert patient programme
1327440|NCT00663078|deprived population
1327441|NCT00663078|women
1327442|NCT00663065|Healthy subjects over 65
1327443|NCT00663065|healthy subjects
1327444|NCT00663052|Enbrel
1327445|NCT00663052|Psoriasis
1327446|NCT00663052|Topical Psoriasis
1327447|NCT00663052|Wyeth Psoriasis
1327448|NCT00663052|Active Psoriasis
1327449|NCT00663039|Schizophrenia
1327450|NCT00663039|Eye movements
1327451|NCT00663039|phenotype
1327452|NCT00663039|biochemical
1327453|NCT00663039|relatives
1327454|NCT00663026|antibody
1327455|NCT00663026|immunotherapy
1327456|NCT00663013|burn
1327457|NCT00663013|pain
1327458|NCT00663013|anxiety
1327459|NCT00663000|acromegaly
1327460|NCT00663000|diabetes
1327461|NCT00663000|insulin resistance
1327462|NCT00663000|impaired glucose tolerance
1327463|NCT00662987|tonsillectomy
1327464|NCT00662987|antibiotics
1327465|NCT00662961|Plastic Surgery
1327466|NCT00662948|Folicular Lymphoma
1327467|NCT00662948|Consolidation
1327468|NCT00662948|Maintenance
1327469|NCT00662935|deep brain stimulation
1327470|NCT00662935|cluster headache
1327471|NCT00662935|hypothalamus
1327472|NCT00662922|critical illness
1327473|NCT00662922|hypoglycemia
1327474|NCT00662922|neurocognitive dysfunction
1327475|NCT00662922|intensive insulin therapy
1327476|NCT00662909|Overactive bladder (OAB)
1327477|NCT00662909|Frequency
1327478|NCT00662909|Micturition
1327479|NCT00662909|Urgency
1327480|NCT00662909|Urinary incontinence
1327481|NCT00662909|Urinary urge incontinence
1327482|NCT00662909|YM178
1327483|NCT00662883|ketamine
1327484|NCT00662883|corticosteroid
1327485|NCT00662883|intranasal
1327486|NCT00662883|phase I
1327487|NCT00662883|Healthy volunteers
1327488|NCT00662870|DAPTACEL
1327489|NCT00662870|Diphtheria
1327490|NCT00662870|Tetanus
1327491|NCT00662870|Whooping Cough
1327492|NCT00662870|Polio
1327493|NCT00662870|Haemophilus influenzae type b
1327494|NCT00662870|Pertussis
1327495|NCT00662857|Diabetic adult male, diabetic adult female
1327496|NCT00662844|Vitamin D insufficiency,vitamin D3 treatment,young women
1327497|NCT00662831|Diabetic Foot Ulcers Neuroischaemic
1327498|NCT00662805|pharmacovigilance
1327499|NCT00662805|COPD
1327500|NCT00662779|asthma
1327501|NCT00662779|exercise induced bronchospasm
1327502|NCT00662779|prevention
1327503|NCT00662779|EIB
1327504|NCT00662779|children
1327505|NCT00662766|Black currant
1327506|NCT00662766|Berry seed
1327507|NCT00662766|Press residue
1327508|NCT00662766|Tocopherol
1327509|NCT00662766|Fatty acids
1327510|NCT00662766|Fiber
1327511|NCT00662766|Total phenols
1327512|NCT00662766|TEAC
1327513|NCT00662766|Comet assay
1327514|NCT00662766|Dihydroxybenzoic acid
1327515|NCT00662753|hypertension
1327516|NCT00662753|home blood pressure monitoring
1327517|NCT00662753|nurse telephone follow up
1327518|NCT00662753|medically underserved populations
1327519|NCT00662727|Extracorporeal Shockwave Therapy
1327520|NCT00662727|Myocardial Ischemia
1327521|NCT00662727|Refractory Angina
1327522|NCT00662701|Atrial Fibrillation
1327523|NCT00662688|thromboembolism
1327524|NCT00662688|chemotherapeutic agent toxicity
1327525|NCT00662688|adenocarcinoma of the pancreas
1327526|NCT00662688|stage IV pancreatic cancer
1327527|NCT00662688|recurrent pancreatic cancer
1327528|NCT00662675|Exocrine pancreatic insufficiency
1327529|NCT00662675|Steatorrhea
1327530|NCT00662675|Malabsorption syndromes
1327531|NCT00662675|Cystic fibrosis
1327532|NCT00662675|Pediatrics
1327533|NCT00662675|Adult
1327534|NCT00662675|Pancrelipase
1327535|NCT00662662|Oropharyngeal Cancer
1327536|NCT00662662|Non-Oropharyngeal Cancer
1327537|NCT00662662|Head and Neck Cancer
1327538|NCT00662662|Squamous Cell Carcinoma
1327539|NCT00662662|Squamous cell carcinoma of the head and neck
1327540|NCT00662662|SCCHN
1327541|NCT00662662|HPV-16
1327542|NCT00662662|Questionnaire
1327543|NCT00662662|Sexual Behavior
1327544|NCT00662662|Survey
1327545|NCT00662649|Multiple sclerosis.
1327546|NCT00662649|Relapse-remitting
1327547|NCT00662649|Fingolimod
1327548|NCT00662623|Chronic Obstructive Sleep Apnea
1327549|NCT00662623|Sleep Apnea
1327550|NCT00662623|Sleep Apnea Treatment
1327551|NCT00662597|Tumor vascular disrupting agent
1327552|NCT00662597|VDA
1327553|NCT00662597|ASA404
1327554|NCT00662597|non-small cell lung cancer
1327555|NCT00662597|NSCLC
1327556|NCT00662584|repetitive magnetic transcranial stimulation (rTMS)
1327557|NCT00662584|functional magnetic resonance imaging (fMRI)
1327558|NCT00662571|nucleotide polymorphisms
1327559|NCT00662571|disequilibrium haplotype
1327560|NCT00662571|acamprosate
1327561|NCT00662571|differentiate
1327562|NCT00662571|pharmacogenomic
1327563|NCT00662571|effective individualized treatment
1327564|NCT00662571|alcohol dependent
1327565|NCT00662571|N-methyl-D-aspartate receptor (NMDA)
1327566|NCT00662571|metabotropic glutamate receptor
1327567|NCT00662571|decreasing craving
1327568|NCT00662571|abstinence maintenance
1327569|NCT00662558|Chronic low back pain
1327570|NCT00662545|HIV
1327571|NCT00662545|Hepatitis B
1327572|NCT00662545|treatment experienced
1327573|NCT00662532|Peri-implantitis; antibiotic
1327574|NCT00662493|knee pain
1327575|NCT00662493|exercise
1327576|NCT00662493|rehabilitation
1327577|NCT00662480|population
1327578|NCT00662480|screening
1327579|NCT00662480|abdominal aortic aneurysms
1327580|NCT00662480|peripheral arterial disease
1327581|NCT00662480|hypertension
1327582|NCT00662480|Prevention
1327583|NCT00662467|Myocardial Infarction
1327584|NCT00662467|Hemorrhage
1327585|NCT00662467|Thromboembolism
1327586|NCT00662467|Clopidogrel
1327587|NCT00662467|Aspirin
1327588|NCT00662467|Warfarin
1327589|NCT00662454|contraceptive
1327590|NCT00662454|efficacy
1327591|NCT00662454|body weight
1327592|NCT00662441|Erectile Dysfunction
1327593|NCT00662441|Vardenafil
1327594|NCT00662428|cost-benefit analysis
1327595|NCT00662428|practice guideline
1327596|NCT00662428|inpatients
1327597|NCT00662415|phantom limb pain
1327598|NCT00662415|fMRI
1327599|NCT00662415|mirror therapy
1327600|NCT00662402|K Grant
1327601|NCT00662402|Career Advancement
1327602|NCT00662402|Award
1327603|NCT00662402|Consultation
1327604|NCT00662402|Application
1327605|NCT00662402|K
1327606|NCT00662402|The NIH priority score of the reviewed proposal.
1327607|NCT00662402|Percent of subjects who obtain funding for proposal.
1327608|NCT00662402|Percent of subjects who submit proposals for funding.
1327609|NCT00662389|skin laxity, wrinkles, rhytids
1327610|NCT00662363|constipation
1327611|NCT00662363|opioid
1327612|NCT00662363|rehabilitation
1327613|NCT00662363|post-operative
1327614|NCT00662363|orthopedic
1327615|NCT00662350|BPH
1327616|NCT00662337|Bioequivalence, diphenhydramine hydrochloride
1327617|NCT00662298|severe asthma
1327618|NCT00662298|prednisolone pharmacokinetics
1327619|NCT00662298|anti-inflammatory effects
1327620|NCT00662285|iron status
1327621|NCT00662285|blood donors
1327622|NCT00662272|Flu
1327623|NCT00662272|Influenza vaccine
1327624|NCT00662272|Adjuvant
1327625|NCT00662272|Safety of an adjuvanted vaccine
1327626|NCT00662272|Immune response to an adjuvanted vaccine
1327627|NCT00662259|Anxiety disorders
1327628|NCT00662259|Generalized anxiety
1327629|NCT00662233|alveolar childhood rhabdomyosarcoma
1327630|NCT00662233|previously treated childhood rhabdomyosarcoma
1327631|NCT00662233|previously untreated childhood rhabdomyosarcoma
1327632|NCT00662233|recurrent childhood rhabdomyosarcoma
1327633|NCT00662233|nonmetastatic childhood soft tissue sarcoma
1327634|NCT00662233|recurrent childhood soft tissue sarcoma
1327635|NCT00662233|childhood desmoplastic small round cell tumor
1327636|NCT00662233|ovarian sarcoma
1327637|NCT00662233|stage II uterine sarcoma
1327638|NCT00662233|stage III uterine sarcoma
1327639|NCT00662233|embryonal childhood rhabdomyosarcoma
1327640|NCT00662220|chronic
1327641|NCT00662220|hepatitis C
1327642|NCT00662220|ribavirin
1327643|NCT00662220|SVR
1327644|NCT00662220|genotype one
1327645|NCT00662220|genotype four
1327646|NCT00662207|electric stimulation
1327647|NCT00662207|urethral obstruction
1327648|NCT00662207|urodynamics
1327649|NCT00662207|urology
1327650|NCT00662194|HIV
1327651|NCT00662194|HBV
1327652|NCT00662194|HCV
1327653|NCT00662194|co-infection
1327654|NCT00662194|innate immunity
1327655|NCT00662181|growth hormone
1327656|NCT00662181|quality of life
1327657|NCT00662181|fat redistribution
1327658|NCT00662181|sugar metabolism
1327659|NCT00662181|fat metabolism
1327660|NCT00662181|cytokines
1327661|NCT00662168|carcinoid
1327662|NCT00662168|familial
1327663|NCT00662168|Collect and describe information about the medical and environmental factors associated with each cases of carcinoid carcinoma
1327664|NCT00662168|Develop a genogram representing the family cancer history of cases of Carcinoid.
1327665|NCT00662155|Primary Insomnia
1327666|NCT00662155|Cognitive Behavioral Therapy
1327667|NCT00662155|Insomnia
1327668|NCT00662155|Sleep
1327669|NCT00662155|Zolpidem
1327670|NCT00662155|Ambien
1327671|NCT00662155|CBT
1327672|NCT00662155|CBT-I
1327673|NCT00662142|DHA
1327674|NCT00662142|fMRI
1327675|NCT00662129|stage IV breast cancer
1327676|NCT00662129|male breast cancer
1327677|NCT00662129|recurrent breast cancer
1327678|NCT00662116|diastolic heart failure
1327679|NCT00662103|fatigue
1327680|NCT00662103|long-term effects secondary to cancer therapy in adults
1327681|NCT00662103|psychosocial effects of cancer and its treatment
1327682|NCT00662103|cancer survivor
1327683|NCT00662103|stage IA breast cancer
1327684|NCT00662103|stage IB breast cancer
1327685|NCT00662103|stage II breast cancer
1327686|NCT00662103|stage IIIA breast cancer
1327687|NCT00662103|stage IIIB breast cancer
1327688|NCT00662103|stage IIIC breast cancer
1327689|NCT00662103|breast cancer in situ
1327690|NCT00662090|MDS
1327691|NCT00662090|JMML
1327692|NCT00662090|EWOG-MDS
1327693|NCT00662090|Myelodysplastic Syndromes (MDS)
1327694|NCT00662090|Juvenile Myelomonocytic Leukemia (JMML)
1327695|NCT00662077|osteoporosis
1327696|NCT00662077|bifosfonates
1327697|NCT00662077|ibandronate
1327698|NCT00662064|Lower urinary tract
1327699|NCT00662064|Physiology
1327700|NCT00662064|Pathology
1327701|NCT00662064|Immunohistochemistry
1327702|NCT00662064|Urinary bladder
1327703|NCT00662051|Asthma
1327704|NCT00662051|Exhaled Nitric Oxide
1327705|NCT00662051|Asthma Control Test
1327706|NCT00662038|idiopathic
1327707|NCT00662038|pulmonary
1327708|NCT00662038|fibrosis
1327709|NCT00662012|Leishmaniasis
1327710|NCT00662012|Sodium stibogluconate
1327711|NCT00662012|Pentostam
1327712|NCT00662012|sand fly
1327713|NCT00661999|unspecified adult solid tumor, protocol specific
1327714|NCT00661999|monoclonal gammopathy of undetermined significance
1327715|NCT00661999|extramedullary plasmacytoma
1327716|NCT00661999|isolated plasmacytoma of bone
1327717|NCT00661999|refractory multiple myeloma
1327718|NCT00661999|stage I multiple myeloma
1327719|NCT00661999|stage II multiple myeloma
1327720|NCT00661999|stage III multiple myeloma
1327721|NCT00661999|primary systemic amyloidosis
1327722|NCT00661999|Waldenstrom macroglobulinemia
1327723|NCT00661999|post-transplant lymphoproliferative disorder
1327724|NCT00661999|stage I adult T-cell leukemia/lymphoma
1327725|NCT00661999|stage II adult T-cell leukemia/lymphoma
1327726|NCT00661999|stage III adult T-cell leukemia/lymphoma
1327727|NCT00661999|stage IV adult T-cell leukemia/lymphoma
1327728|NCT00661999|recurrent adult T-cell leukemia/lymphoma
1327729|NCT00661999|angioimmunoblastic T-cell lymphoma
1327730|NCT00661999|anaplastic large cell lymphoma
1327731|NCT00661999|stage I cutaneous T-cell non-Hodgkin lymphoma
1327732|NCT00661999|stage II cutaneous T-cell non-Hodgkin lymphoma
1327733|NCT00661999|stage III cutaneous T-cell non-Hodgkin lymphoma
1327734|NCT00661999|stage IV cutaneous T-cell non-Hodgkin lymphoma
1327735|NCT00661999|recurrent cutaneous T-cell non-Hodgkin lymphoma
1327736|NCT00661999|stage I mycosis fungoides/Sezary syndrome
1327737|NCT00661999|stage II mycosis fungoides/Sezary syndrome
1327738|NCT00661999|stage III mycosis fungoides/Sezary syndrome
1327739|NCT00661999|stage IV mycosis fungoides/Sezary syndrome
1327740|NCT00661999|recurrent mycosis fungoides/Sezary syndrome
1327741|NCT00661999|stage I adult Hodgkin lymphoma
1327742|NCT00661999|stage II adult Hodgkin lymphoma
1327743|NCT00661999|stage III adult Hodgkin lymphoma
1327744|NCT00661999|stage IV adult Hodgkin lymphoma
1327745|NCT00661999|recurrent adult Hodgkin lymphoma
1327746|NCT00661999|recurrent adult grade III lymphomatoid granulomatosis
1327747|NCT00661999|stage I adult Burkitt lymphoma
1327748|NCT00661999|stage III adult Burkitt lymphoma
1327749|NCT00661999|stage IV adult Burkitt lymphoma
1327750|NCT00661999|noncontiguous stage II adult Burkitt lymphoma
1327751|NCT00661999|noncontiguous stage II adult diffuse large cell lymphoma
1327752|NCT00661999|noncontiguous stage II adult diffuse mixed cell lymphoma
1327753|NCT00661999|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1327754|NCT00661999|noncontiguous stage II adult immunoblastic large cell lymphoma
1327755|NCT00661999|noncontiguous stage II adult lymphoblastic lymphoma
1327756|NCT00661999|noncontiguous stage II grade 1 follicular lymphoma
1327757|NCT00661999|noncontiguous stage II grade 2 follicular lymphoma
1327758|NCT00661999|noncontiguous stage II grade 3 follicular lymphoma
1327759|NCT00661999|noncontiguous stage II mantle cell lymphoma
1327760|NCT00661999|noncontiguous stage II marginal zone lymphoma
1327761|NCT00661999|noncontiguous stage II small lymphocytic lymphoma
1327762|NCT00661999|contiguous stage II adult Burkitt lymphoma
1327861|NCT00661921|metformin
1327763|NCT00661999|contiguous stage II adult diffuse large cell lymphoma
1327764|NCT00661999|contiguous stage II adult diffuse mixed cell lymphoma
1327765|NCT00661999|contiguous stage II adult diffuse small cleaved cell lymphoma
1327766|NCT00661999|contiguous stage II adult immunoblastic large cell lymphoma
1327767|NCT00661999|contiguous stage II adult lymphoblastic lymphoma
1327768|NCT00661999|contiguous stage II grade 1 follicular lymphoma
1327769|NCT00661999|contiguous stage II grade 2 follicular lymphoma
1327770|NCT00661999|contiguous stage II grade 3 follicular lymphoma
1327771|NCT00661999|contiguous stage II mantle cell lymphoma
1327772|NCT00661999|contiguous stage II marginal zone lymphoma
1327773|NCT00661999|contiguous stage II small lymphocytic lymphoma
1327774|NCT00661999|stage I adult diffuse large cell lymphoma
1327775|NCT00661999|stage I adult diffuse mixed cell lymphoma
1327776|NCT00661999|stage I adult diffuse small cleaved cell lymphoma
1327777|NCT00661999|stage III adult diffuse large cell lymphoma
1327778|NCT00661999|stage III adult diffuse mixed cell lymphoma
1327779|NCT00661999|stage III adult diffuse small cleaved cell lymphoma
1327780|NCT00661999|stage IV adult diffuse large cell lymphoma
1327781|NCT00661999|stage IV adult diffuse mixed cell lymphoma
1327782|NCT00661999|stage IV adult diffuse small cleaved cell lymphoma
1327783|NCT00661999|stage I adult immunoblastic large cell lymphoma
1327784|NCT00661999|stage III adult immunoblastic large cell lymphoma
1327785|NCT00661999|stage IV adult immunoblastic large cell lymphoma
1327786|NCT00661999|stage I adult lymphoblastic lymphoma
1327787|NCT00661999|stage III adult lymphoblastic lymphoma
1327788|NCT00661999|stage IV adult lymphoblastic lymphoma
1327789|NCT00661999|stage I grade 1 follicular lymphoma
1327790|NCT00661999|stage I grade 2 follicular lymphoma
1327791|NCT00661999|stage I grade 3 follicular lymphoma
1327792|NCT00661999|stage III grade 1 follicular lymphoma
1327793|NCT00661999|stage III grade 2 follicular lymphoma
1327794|NCT00661999|stage III grade 3 follicular lymphoma
1327795|NCT00661999|stage IV grade 1 follicular lymphoma
1327796|NCT00661999|stage IV grade 2 follicular lymphoma
1327797|NCT00661999|stage IV grade 3 follicular lymphoma
1327798|NCT00661999|stage I mantle cell lymphoma
1327799|NCT00661999|stage I marginal zone lymphoma
1327800|NCT00661999|stage III mantle cell lymphoma
1327801|NCT00661999|stage III marginal zone lymphoma
1327802|NCT00661999|stage IV mantle cell lymphoma
1327803|NCT00661999|stage IV marginal zone lymphoma
1327804|NCT00661999|stage I small lymphocytic lymphoma
1327805|NCT00661999|stage III small lymphocytic lymphoma
1327806|NCT00661999|stage IV small lymphocytic lymphoma
1327807|NCT00661999|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1327808|NCT00661999|nodal marginal zone B-cell lymphoma
1327809|NCT00661999|splenic marginal zone lymphoma
1327810|NCT00661999|recurrent adult Burkitt lymphoma
1327811|NCT00661999|recurrent adult diffuse large cell lymphoma
1327812|NCT00661999|recurrent adult diffuse mixed cell lymphoma
1327813|NCT00661999|recurrent adult diffuse small cleaved cell lymphoma
1327814|NCT00661999|recurrent adult immunoblastic large cell lymphoma
1327815|NCT00661999|recurrent adult lymphoblastic lymphoma
1327816|NCT00661999|recurrent grade 1 follicular lymphoma
1327817|NCT00661999|recurrent grade 2 follicular lymphoma
1327818|NCT00661999|recurrent grade 3 follicular lymphoma
1327819|NCT00661999|recurrent mantle cell lymphoma
1327820|NCT00661999|recurrent marginal zone lymphoma
1327821|NCT00661999|recurrent small lymphocytic lymphoma
1327822|NCT00661999|adult acute lymphoblastic leukemia in remission
1327823|NCT00661999|recurrent adult acute lymphoblastic leukemia
1327824|NCT00661999|untreated adult acute lymphoblastic leukemia
1327825|NCT00661999|stage I chronic lymphocytic leukemia
1327826|NCT00661999|stage II chronic lymphocytic leukemia
1327827|NCT00661999|stage III chronic lymphocytic leukemia
1327828|NCT00661999|stage IV chronic lymphocytic leukemia
1327829|NCT00661999|refractory chronic lymphocytic leukemia
1327830|NCT00661999|refractory hairy cell leukemia
1327831|NCT00661999|progressive hairy cell leukemia, initial treatment
1327832|NCT00661999|prolymphocytic leukemia
1327833|NCT00661999|anemia
1327834|NCT00661999|T-cell large granular lymphocyte leukemia
1327835|NCT00661999|acute undifferentiated leukemia
1327836|NCT00661999|mast cell leukemia
1327837|NCT00661999|adult nasal type extranodal NK/T-cell lymphoma
1327838|NCT00661999|untreated hairy cell leukemia
1327839|NCT00661973|asthma
1327840|NCT00661973|airway smooth muscle
1327841|NCT00661973|inhaled corticosteroids
1327842|NCT00661960|HIV Positive
1327843|NCT00661960|AIDS
1327844|NCT00661960|Antiretroviral Therapy
1327845|NCT00661960|Gastrointestinal-Associated Lymphoid Tissue
1327846|NCT00661960|Immune Reconstitution
1327847|NCT00661960|treatment experienced
1327848|NCT00661947|fructose
1327849|NCT00661947|sucrose
1327850|NCT00661947|high fructose corn syrup
1327851|NCT00661947|serum uric acid
1327852|NCT00661947|lactate
1327853|NCT00661947|glucose
1327854|NCT00661947|triglycerides
1327855|NCT00661947|Bioavailability of fructose from two formulations
1327856|NCT00661934|Subject undergoing Dialysis and Subject suffering from Cardiac Malfunction
1327857|NCT00661921|Type 2 Diabetes Mellitus
1327858|NCT00661921|AMG 108
1327859|NCT00661921|HbA1C
1327860|NCT00661921|glucose
1327862|NCT00661921|sulfonylurea
1327863|NCT00661921|IL-1 Inhibitor
1327864|NCT00661921|biologic
1327865|NCT00661921|subcutaneous injection
1327866|NCT00661895|African American
1327867|NCT00661882|adenocarcinoma of the pancreas
1327868|NCT00661882|recurrent pancreatic cancer
1327869|NCT00661882|stage I pancreatic cancer
1327870|NCT00661882|stage II pancreatic cancer
1327871|NCT00661882|stage III pancreatic cancer
1327872|NCT00661856|Soy Isoflavones, Bone Mineral Density, Post menopausal women
1327873|NCT00661843|insomnia
1327874|NCT00661843|geriatric
1327875|NCT00661843|yoga
1327876|NCT00661843|sleep
1327877|NCT00661843|electrocardiogram
1327878|NCT00661830|advanced
1327879|NCT00661830|metastatic
1327880|NCT00661830|biliary
1327881|NCT00661830|tract
1327882|NCT00661817|Exercise
1327883|NCT00661817|Physical Fitness
1327884|NCT00661817|Patient Compliance
1327885|NCT00661817|Health Behavior
1327886|NCT00661791|preterm infants
1327887|NCT00661791|massage
1327888|NCT00661791|physical activity
1327889|NCT00661791|weight gain
1327890|NCT00661791|length of hospital stay
1327891|NCT00661791|NICU
1327892|NCT00661765|varenicline bioavailability transdermal smoking cessation
1327893|NCT00661739|palliative
1327894|NCT00661739|Breast cancer
1327895|NCT00661739|metastatic
1327896|NCT00661739|Bendamustine
1327897|NCT00661739|phase I
1327898|NCT00661726|Thalassemia Intermedia
1327899|NCT00661713|Meningococcal disease
1327900|NCT00661713|Neisseria meningitidis serogroup B
1327901|NCT00661713|prevention
1327902|NCT00661713|vaccination
1327903|NCT00661713|adolescents
1327904|NCT00661700|Erectile Dysfunction
1327905|NCT00661700|Quality of Life
1327906|NCT00661674|Palonosetron
1327907|NCT00661674|Hydroxyzine
1327908|NCT00661674|Acute opioid withdrawal
1327909|NCT00661661|Long term open label study in Japan
1327910|NCT00661661|CP-690
1327911|NCT00661661|550
1327912|NCT00661661|tofacitinib
1327913|NCT00661648|surgery
1327914|NCT00661635|Laparoscopic Cholecystectomy Surgery, Acute Pain, Perioperative Pain
1327915|NCT00661609|Anti-mitotic
1327916|NCT00661609|Eg5 Inhibitor
1327917|NCT00661609|Kinesin Spindle Protein Inhibitor
1327918|NCT00661609|Urothelial Cancer
1327919|NCT00661609|Bladder Cancer
1327920|NCT00661609|Renal Pelvis Cancer
1327921|NCT00661609|Urethra Cancer
1327922|NCT00661609|Ureter Cancer
1327923|NCT00661609|Recurrent
1327924|NCT00661609|Advanced
1327925|NCT00661609|Stage IV
1327926|NCT00661596|Erectile Dysfunction
1327927|NCT00661596|Vardenafil
1327928|NCT00661583|trabeculectomy
1327929|NCT00661583|glaucoma
1327930|NCT00661583|ranibizumab
1327931|NCT00661570|laryngectomy
1327932|NCT00661570|larynx cancer
1327933|NCT00661557|Booster vaccination
1327934|NCT00661557|Meningococcal vaccine
1327935|NCT00661557|Meningococcal disease
1327936|NCT00661557|Safety
1327937|NCT00661557|immunogenicity
1327938|NCT00661544|Multiple Myeloma
1327939|NCT00661544|Ascorbic Acid
1327940|NCT00661544|Vitamin C
1327941|NCT00661544|Arsenic Trioxide
1327942|NCT00661544|Trisenox
1327943|NCT00661544|Melphalan
1327944|NCT00661544|Autologous Stem Cell Transplant
1327945|NCT00661544|Stem Cell Transplantation
1327946|NCT00661531|Breast cancer
1327947|NCT00661531|Metastatic breast cancer
1327948|NCT00661531|ER positive breast cancer
1327949|NCT00661531|Hormonal therapy
1327950|NCT00661492|Androgen-independent prostate cancer(AIPC)
1327951|NCT00661466|Gastrointestinal surgery
1327952|NCT00661466|Post operative pain
1327953|NCT00661453|Spinal Muscular Atrophy
1327954|NCT00661453|SMA
1327955|NCT00661453|Valproic Acid
1327956|NCT00661427|Head and Neck cancer
1327957|NCT00661427|Cetuximab
1327958|NCT00661414|Cancer
1327959|NCT00661414|Solid tumors
1327960|NCT00661401|gammaglobulin
1327961|NCT00661401|subcutaneous infusion
1327962|NCT00661401|specific antibodies
1327963|NCT00661401|primary antibody deficiency
1327964|NCT00661375|BAY 43-9006
1327965|NCT00661375|Phase II
1327966|NCT00661375|Renal cell carcinoma
1327967|NCT00661375|Response rate
1327968|NCT00661362|DPP-4 inhibitors
1327969|NCT00661362|HbA1c
1327970|NCT00661362|Incretins
1327971|NCT00661349|Kaletra
1327972|NCT00661349|Nevirapina
1327973|NCT00661349|HCV chronic infection
1327974|NCT00661349|Fibroscan
1327975|NCT00661349|hepatic fibrosis
1327976|NCT00661349|treatment experienced
1327977|NCT00661336|stage III melanoma
1327978|NCT00661336|recurrent melanoma
1327979|NCT00661310|re-admissions
1327980|NCT00661310|medicines
1327981|NCT00661310|management
1327982|NCT00661310|patients
1327983|NCT00661310|80 years and older
1327984|NCT00661310|acute
1327985|NCT00661310|admissions
1327986|NCT00661310|hospital
1327987|NCT00661297|Erectile Dysfunction
1327988|NCT00661297|Vardenafil
1327989|NCT00661271|mindfulness
1327990|NCT00661271|meditation
1327991|NCT00661271|urban youth
1327992|NCT00661271|stress reduction
1327993|NCT00661271|adolescent
1327994|NCT00661271|Stress reduction for urban youth
1327995|NCT00661258|HIV antiretroviral treatment adherence intervention China
1327996|NCT00661258|adherence to antiretroviral treatment
1327997|NCT00661258|treatment experienced
1327998|NCT00661232|Myocardial Viability
1327999|NCT00661232|Delayed Enhancement Magnetic Resonance Imaging
1328000|NCT00661232|Functional Recovery
1328001|NCT00661206|Clopidogrel
1328002|NCT00661206|Drug-eluting stent
1328003|NCT00661193|recurrent non-small cell lung cancer
1328004|NCT00661193|stage IIIB non-small cell lung cancer
1328005|NCT00661193|stage IV non-small cell lung cancer
1328006|NCT00661193|adenocarcinoma of the lung
1328007|NCT00661193|large cell lung cancer
1328008|NCT00661193|squamous cell lung cancer
1328009|NCT00661141|acetaldehyde
1328010|NCT00661141|ethanol
1328011|NCT00661141|ALDH2
1328012|NCT00661128|Sudden Cardiac Arrest
1328013|NCT00661115|Erectile dysfunction
1328014|NCT00661115|Sexual Dysfunction
1328015|NCT00661089|stroke
1328016|NCT00661089|shoulder pain
1328017|NCT00661089|spasticity
1328018|NCT00661063|neuropathic pain
1328019|NCT00661063|ketamine
1328020|NCT00661063|clonidine
1328021|NCT00661063|association
1328022|NCT00661024|thyroid surgery
1328023|NCT00661024|recurrent laryngeal nerves visualization
1328024|NCT00661024|intraoperative neuromonitoring
1328025|NCT00661024|predictive values
1328026|NCT00661011|Non-small cell lung carcinoma
1328027|NCT00661011|Concomitant radiochemotherapy
1328028|NCT00661011|Cisplatin
1328029|NCT00661011|Vinorelbine
1328030|NCT00661011|Radiotherapy
1328031|NCT00661011|Chemotherapy
1328032|NCT00661011|Unresectable stage III non-small cell lung carcinoma
1328033|NCT00661011|Surgery
1328034|NCT00661011|Unresectable stage III non-small cell lung carcinoma not suitable for radical radiotherapy after objective response to induction chemotherapy
1328035|NCT00660998|Erectile dysfunction
1328036|NCT00660998|Diabetes mellitus type 1
1328037|NCT00660998|Vardenafil
1328038|NCT00660985|Acne vulgaris
1328039|NCT00660985|Differin
1328040|NCT00660985|Adapalene
1328041|NCT00660972|HIV Integrase Inhibitors
1328042|NCT00660972|HIV Nucleoside Reverse Transcriptase Inhibitors
1328043|NCT00660972|Treatment Naive
1328044|NCT00660972|Viral Load
1328045|NCT00660959|Euvolemic
1328046|NCT00660959|Hyponatremia
1328047|NCT00660959|Serum Sodium
1328048|NCT00660959|Fluid Overload
1328049|NCT00660959|Vasopressin Antagonist
1328050|NCT00660946|anticoagulation in dialysis patients
1328051|NCT00660946|chronic anticoagulation
1328052|NCT00660946|warfarin
1328053|NCT00660946|hemodialysis
1328054|NCT00660946|INR
1328055|NCT00660946|Point of Care
1328056|NCT00660933|postpartum anemia
1328057|NCT00660933|intravenous iron
1328058|NCT00660907|Dapagliflozin
1328059|NCT00660907|efficacy
1328060|NCT00660907|safety
1328061|NCT00660907|metformin
1328062|NCT00660907|Type 2 diabetes
1328063|NCT00660894|adenocarcinoma of the colon
1328064|NCT00660894|stage III colon cancer
1328065|NCT00660881|Lupus
1328066|NCT00660881|Monoclonal antibody
1328067|NCT00660881|B-Cell immunotherapy
1328068|NCT00660868|smell
1328069|NCT00660868|olfaction
1328070|NCT00660868|olfactory sensitivity
1328071|NCT00660868|smell loss
1328072|NCT00660868|chemoreception
1328073|NCT00660855|laparoscopy
1328074|NCT00660842|quality of life
1328075|NCT00660842|weekly therapy
1328076|NCT00660842|neurotoxicity
1328077|NCT00660816|recurrent non-small cell lung cancer
1328078|NCT00660816|stage IIIB non-small cell lung cancer
1328079|NCT00660816|stage IV non-small cell lung cancer
1328080|NCT00660803|Advanced Breast Cancer
1328081|NCT00660803|Hormone Therapy
1328082|NCT00660790|diabetes mellitus type II, therapy non-responders
1328083|NCT00660777|oropharyngeal exercises
1328084|NCT00660777|obstructive sleep apnea
1328085|NCT00660777|speech therapy
1328086|NCT00660764|cholesterol
1328087|NCT00660764|coronary heart disease
1328088|NCT00660764|rosuvastatin
1328089|NCT00660764|LDL-C goal
1328090|NCT00660764|hypercholesterolemia
1328091|NCT00660764|secondary prevention
1328092|NCT00660764|primary prevention
1328093|NCT00660764|CVA
1328094|NCT00660751|Physiology of Serotonergic and Adrenergic systems
1328095|NCT00660738|chronic obstructive pulmonary disease
1328096|NCT00660738|walking
1328097|NCT00660738|exercise test
1328098|NCT00660738|quality of life
1328099|NCT00660738|dyspnea
1328100|NCT00660738|desaturation
1328101|NCT00660725|Gemcitabine
1328102|NCT00660725|Oxaliplatin
1328103|NCT00660725|Vandetanib
1328104|NCT00660725|Phase I
1328105|NCT00660712|Bipolar disorder
1328106|NCT00660712|patient characteristics
1328107|NCT00660712|treatment characteristics
1328108|NCT00660699|Cholangiocarcinoma
1328109|NCT00660699|Gallbladder
1328110|NCT00660699|Pancreatic
1328111|NCT00660699|Ampullary
1328112|NCT00660699|Cancer
1328113|NCT00660686|randomized clinical trial
1328114|NCT00660686|elderly
1328115|NCT00660686|cancer survivor
1328116|NCT00660686|bone health
1328117|NCT00660686|body composition
1328118|NCT00660686|signs and symptoms
1328119|NCT00660686|Androgen Deprivation Therapy
1328120|NCT00660673|levodopa/carbidopa intestinal gel
1328121|NCT00660673|Dyskinesia
1328122|NCT00660673|Carbidopa
1328123|NCT00660673|Parkinson's Disease
1328124|NCT00660673|Severe Motor Fluctuations
1328125|NCT00660673|Levodopa
1328126|NCT00660660|GERD
1328127|NCT00660660|Esophageal Reflux
1328128|NCT00660660|Gastro-Esophageal Reflux
1328129|NCT00660660|Regurgitation
1328130|NCT00660660|Gastric
1328131|NCT00660647|Rheumatoid arthritis, adalimumab, efficacy, adverse events
1328132|NCT00660634|Peripheral arterial obstructive disease
1328133|NCT00660634|Intermittent Claudication
1328134|NCT00660634|Endovascular treatment
1328135|NCT00660634|Flow-mediated dilation
1328136|NCT00660621|High Grade
1328137|NCT00660621|Malignant
1328138|NCT00660621|GBM
1328139|NCT00660608|Transfusion regulation
1328140|NCT00660595|Schizophrenia
1328141|NCT00660595|Schizoaffective psychosis
1328142|NCT00660595|Schizophreniformic psychosis
1328143|NCT00660595|Pilot study
1328144|NCT00660595|Quetiapine Prolong
1328145|NCT00660595|Risperidone
1328146|NCT00660582|Erbitux
1328147|NCT00660582|Colorectal cancer
1328148|NCT00660582|Oxaliplatin
1328149|NCT00660582|Flox
1328150|NCT00660582|Fluorouracil + folinic acid
1328151|NCT00660582|K-RAS
1328152|NCT00660569|asthma treatment
1328153|NCT00660569|utilization
1328154|NCT00660569|real life practice
1328155|NCT00660530|stage 5
1328156|NCT00660530|chronic
1328157|NCT00660530|hemodialysis
1328158|NCT00660504|Extensive Disease-Small Cell Lung Cancer
1328159|NCT00660491|flow mediated dilatation
1328160|NCT00660491|maximal oxygen uptake
1328161|NCT00660491|blood lipid
1328162|NCT00660465|Regional BOLD signal dependency on arterial PaCO2.
1328163|NCT00660465|Effect of breathing exercises on brain regional O2 level.
1328164|NCT00660465|Healthy subjects
1328165|NCT00660452|Allergy
1328166|NCT00660452|SLIT
1328167|NCT00660452|Asthma
1328168|NCT00660452|House Dust Mites
1328169|NCT00660439|PTSD
1328170|NCT00660426|cancer
1328171|NCT00660426|gastrointestinal
1328172|NCT00660426|tumor
1328173|NCT00660413|Acceleromyography
1328174|NCT00660413|Mechanomyography
1328175|NCT00660413|Neuromuscular block
1328176|NCT00660413|Neuromuscular monitoring
1328177|NCT00660413|Dose-response
1328178|NCT00660413|Potency
1328179|NCT00660413|Rocuronium
1328180|NCT00660400|Myeloid
1328181|NCT00660400|Monocytic
1328182|NCT00660387|levodopa-carbidopa
1328183|NCT00660387|Carbidopa
1328184|NCT00660387|levodopa
1328185|NCT00660387|dyskinesia
1328186|NCT00660387|Duodopa
1328187|NCT00660387|levodopa-carbidopa intestinal gel
1328188|NCT00660387|Severe Motor Fluctuations
1328189|NCT00660387|levodopa/carbidopa suspension
1328190|NCT00660387|DUOPA
1328191|NCT00660361|HIV
1328192|NCT00660361|HBV
1328193|NCT00660361|co-infection
1328194|NCT00660361|drug resistance
1328195|NCT00660361|tenofovir
1328196|NCT00660361|HIV-HBV co-infection
1328197|NCT00660348|recurrent pancreatic cancer
1328198|NCT00660348|stage III pancreatic cancer
1328199|NCT00660348|stage IV pancreatic cancer
1328200|NCT00660348|adenocarcinoma of the pancreas
1328201|NCT00660348|pain
1328202|NCT00660348|stage II pancreatic cancer
1328203|NCT00660335|secretin, RG1068, MRCP, pancreas
1328204|NCT00660322|Asthma
1328205|NCT00660322|Telemedicine
1328206|NCT00660322|Randomized controlled trial
1328207|NCT00660309|Type 2 diabetes mellitus
1328208|NCT00660309|renal disease
1328209|NCT00660309|hypertension
1328210|NCT00660309|renal blood flow
1328211|NCT00660309|retinal blood flow
1328212|NCT00660309|aliskiren
1328213|NCT00660309|irbesartan
1328214|NCT00660309|captopril
1328215|NCT00660296|CO2
1328216|NCT00660296|pain
1328217|NCT00660296|colonoscopy
1328218|NCT00660296|cancer
1328219|NCT00660296|screening
1328220|NCT00660283|GBM
1328221|NCT00660283|Newly
1328222|NCT00660283|diagnosed
1328223|NCT00660283|malignant
1328224|NCT00660283|high grade
1328225|NCT00660270|Chemotherapy
1328226|NCT00660270|Radiation
1328227|NCT00660244|Arimidex
1328228|NCT00660244|Post menopausal
1328229|NCT00660244|arthralgia
1328230|NCT00660231|recurrent mycosis fungoides/Sezary syndrome
1328231|NCT00660231|stage IB mycosis fungoides/Sezary syndrome
1328232|NCT00660231|stage II mycosis fungoides/Sezary syndrome
1328233|NCT00660231|stage III mycosis fungoides/Sezary syndrome
1328234|NCT00660231|stage IV mycosis fungoides/Sezary syndrome
1328235|NCT00660231|recurrent cutaneous T-cell non-Hodgkin lymphoma
1328236|NCT00660231|stage IB cutaneous T-cell non-Hodgkin lymphoma
1328237|NCT00660231|stage II cutaneous T-cell non-Hodgkin lymphoma
1328238|NCT00660231|stage III cutaneous T-cell non-Hodgkin lymphoma
1328239|NCT00660231|stage IV cutaneous T-cell non-Hodgkin lymphoma
1328240|NCT00660218|Stage III and IV head and neck cancer
1328241|NCT00660205|DVT
1328242|NCT00660205|PE
1328243|NCT00660205|D-dimer
1328244|NCT00660205|cancer
1328245|NCT00660205|VTE
1328246|NCT00660192|Migraine, refractory migraine, Pain, Botulinum Toxin , Botox
1328247|NCT00660179|pulmonary arterial hypertension SERAPHIN
1328248|NCT00660166|Natural killer cells
1328249|NCT00660166|autologous stem cell transplant
1328250|NCT00660166|immunotherapy
1328251|NCT00660153|Advanced Colorectal Cancer and Other Gastrointestinal Cancers
1328252|NCT00660153|tivozanib
1328253|NCT00660153|AV-951
1328254|NCT00660140|Cholangiocarcinoma
1328255|NCT00660140|Gallbladder
1328256|NCT00660140|Cancer
1328257|NCT00660114|Cough variant asthma
1328258|NCT00660114|Pulmicort® Respules®
1328259|NCT00660114|Chinese patient Eligibility
1328260|NCT00660101|ovarian cancer
1328261|NCT00660101|vaccine
1328262|NCT00660101|immunotherapy
1328263|NCT00660101|autologous
1328264|NCT00660075|Diabetes mellitus
1328265|NCT00660075|Postprandial
1328266|NCT00660075|Hyperlipidemia
1328267|NCT00660075|Atherosclerosis
1328268|NCT00660062|Major depression
1328269|NCT00660062|relapse prevention
1328270|NCT00660062|ECT
1328271|NCT00660062|escitalopram
1328272|NCT00660062|nortriptyline
1328273|NCT00660036|Acute myeloid leukemia
1328274|NCT00660036|Refractory
1328275|NCT00660036|Relapsed
1328276|NCT00660036|Second line
1328277|NCT00660036|Gemtuzumab ozogamicin
1328278|NCT00660036|Mitoxantrone
1328279|NCT00660036|Etoposide
1328280|NCT00660036|Phase I
1328281|NCT00660036|Phase II
1328282|NCT00660010|CPP
1328283|NCT00660010|central precocious puberty
1328284|NCT00660010|pediatrics
1328285|NCT00660010|suppression of LH
1328286|NCT00660010|Lupron
1328287|NCT00660010|leuprolide acetate
1328288|NCT00660010|depot formulation
1328289|NCT00660010|GnRHa
1328290|NCT00660010|GnRH agonist
1328291|NCT00660010|GNRH analog
1328292|NCT00660010|LH
1328293|NCT00660010|Tanner staging
1328294|NCT00659997|Ascariasis
1328295|NCT00659997|Trichuriasis
1328296|NCT00659997|Drug resistance
1328297|NCT00659984|recurrent neuroblastoma
1328298|NCT00659971|oral candidiasis
1328299|NCT00659958|zonisamide
1328300|NCT00659958|partial onset seizures
1328301|NCT00659958|effectiveness
1328302|NCT00659958|tolerability
1328303|NCT00659945|Postoperation, nausea, vomiting, anesthesia, plastic surgery
1328304|NCT00659932|diabetes
1328305|NCT00659932|cognitive behavioural therapy
1328306|NCT00659906|randomized clinical trial
1328307|NCT00659906|cancer survivor
1328308|NCT00659906|bone health
1328309|NCT00659906|body composition
1328310|NCT00659906|signs and symptoms
1328311|NCT00659893|Peplin
1328312|NCT00659893|PEP005
1328313|NCT00659893|Actinic Keratosis
1328314|NCT00659880|Meniscus transplant
1328315|NCT00659880|Meniscal allograft
1328316|NCT00659880|MAT
1328317|NCT00659880|Knee
1328318|NCT00659867|Ulcerative Colitis
1328319|NCT00659867|Endomicroscopy
1328320|NCT00659867|Chromoendoscopy
1328321|NCT00659867|Confocal colonoscope
1328322|NCT00659867|Surveillance colonoscopy
1328323|NCT00659854|obstructive sleep apnea syndrome
1328324|NCT00659854|The study examines the response of infants diagnosed with obstructive sleep apnea syndrome to diet changes
1328325|NCT00659841|Seasonal Allergic Rhinitis
1328326|NCT00659841|Ciclesonide
1328327|NCT00659841|Hay Fever
1328328|NCT00659841|SAR
1328329|NCT00659828|Congenital leptin deficiency
1328330|NCT00659828|Obesity
1328331|NCT00659828|Metabolic Syndrome
1328332|NCT00659828|Diabetes
1328333|NCT00659776|ferumoxytol
1328334|NCT00659763|IBS
1328335|NCT00659763|Diagnosis
1328336|NCT00659750|Perennial Allergic Rhinitis
1328337|NCT00659750|Ciclesonide
1328338|NCT00659750|PAR
1328339|NCT00659737|Post-operative Nausea and Vomiting (PONV)
1328340|NCT00659724|Dialyzer
1328341|NCT00659698|surgical
1328342|NCT00659698|site
1328343|NCT00659698|infection
1328344|NCT00659685|Bioequivalence
1328345|NCT00659685|Ondansetron ODT
1328346|NCT00659685|Fasting
1328347|NCT00659685|To Determine Bioequivalence Under Fasting conditions
1328348|NCT00659672|hypertension
1328349|NCT00659672|prehypertension
1328350|NCT00659672|high blood pressure
1328351|NCT00659672|blood pressure
1328352|NCT00659672|heart disease
1328353|NCT00659646|Diabetes
1328354|NCT00659646|ulcers
1328355|NCT00659646|ulcerations
1328356|NCT00659646|infection
1328357|NCT00659633|lidocaine
1328358|NCT00659633|allodynia
1328359|NCT00659633|chronic regional pain syndrome
1328360|NCT00659633|pain
1328361|NCT00659620|Kidney Transplant
1328362|NCT00659620|Chronic Allograft Nephropathy
1328363|NCT00659620|Mesenchymal Stem Cell infusion
1328364|NCT00659594|Seasonal Allergic rhinitis
1328365|NCT00659594|Ciclesonide
1328366|NCT00659594|Hay Fever
1328367|NCT00659594|SAR
1328368|NCT00659568|unspecified adult solid tumor, protocol specific
1328369|NCT00659568|stage III renal cell cancer
1328370|NCT00659568|stage IV renal cell cancer
1328371|NCT00659568|recurrent renal cell cancer
1328372|NCT00659568|recurrent endometrial carcinoma
1328373|NCT00659568|stage III endometrial carcinoma
1328374|NCT00659568|stage IV endometrial carcinoma
1328375|NCT00659568|recurrent breast cancer
1328376|NCT00659568|stage IIIA breast cancer
1328377|NCT00659568|stage IIIB breast cancer
1328378|NCT00659568|stage IIIC breast cancer
1328379|NCT00659568|stage IV breast cancer
1328380|NCT00659568|recurrent small cell lung cancer
1328381|NCT00659568|extensive stage small cell lung cancer
1328382|NCT00659568|stage III adult Burkitt lymphoma
1328383|NCT00659568|stage III adult diffuse large cell lymphoma
1328384|NCT00659568|stage III adult diffuse mixed cell lymphoma
1328385|NCT00659568|stage III adult diffuse small cleaved cell lymphoma
1328386|NCT00659568|stage III adult Hodgkin lymphoma
1328387|NCT00659568|stage III adult immunoblastic large cell lymphoma
1328388|NCT00659568|stage III adult lymphoblastic lymphoma
1328389|NCT00659568|stage III adult T-cell leukemia/lymphoma
1328390|NCT00659568|stage III cutaneous T-cell non-Hodgkin lymphoma
1328391|NCT00659568|stage III grade 1 follicular lymphoma
1328392|NCT00659568|stage III grade 2 follicular lymphoma
1328393|NCT00659568|stage III grade 3 follicular lymphoma
1328394|NCT00659568|stage III mantle cell lymphoma
1328395|NCT00659568|stage III marginal zone lymphoma
1328396|NCT00659568|stage III small lymphocytic lymphoma
1328397|NCT00659568|stage IV adult Burkitt lymphoma
1328398|NCT00659568|stage IV adult diffuse large cell lymphoma
1328399|NCT00659568|stage IV adult diffuse mixed cell lymphoma
1328400|NCT00659568|stage IV adult diffuse small cleaved cell lymphoma
1328401|NCT00659568|stage IV adult Hodgkin lymphoma
1328402|NCT00659568|stage IV adult immunoblastic large cell lymphoma
1328403|NCT00659568|stage IV adult lymphoblastic lymphoma
1328404|NCT00659568|stage IV adult T-cell leukemia/lymphoma
1328405|NCT00659568|stage IV cutaneous T-cell non-Hodgkin lymphoma
1328406|NCT00659568|stage IV grade 1 follicular lymphoma
1328407|NCT00659568|stage IV grade 2 follicular lymphoma
1328408|NCT00659568|stage IV grade 3 follicular lymphoma
1328409|NCT00659568|stage IV mantle cell lymphoma
1328410|NCT00659568|stage IV marginal zone lymphoma
1328411|NCT00659568|stage IV small lymphocytic lymphoma
1328412|NCT00659568|recurrent adult Burkitt lymphoma
1328413|NCT00659568|recurrent adult diffuse large cell lymphoma
1328414|NCT00659568|recurrent adult diffuse mixed cell lymphoma
1328415|NCT00659568|recurrent adult diffuse small cleaved cell lymphoma
1328416|NCT00659568|recurrent adult grade III lymphomatoid granulomatosis
1328417|NCT00659568|recurrent adult Hodgkin lymphoma
1328418|NCT00659568|recurrent adult immunoblastic large cell lymphoma
1328419|NCT00659568|recurrent adult lymphoblastic lymphoma
1328420|NCT00659568|recurrent adult T-cell leukemia/lymphoma
1328421|NCT00659568|recurrent cutaneous T-cell non-Hodgkin lymphoma
1328422|NCT00659568|recurrent grade 1 follicular lymphoma
1328423|NCT00659568|recurrent grade 2 follicular lymphoma
1328424|NCT00659568|recurrent grade 3 follicular lymphoma
1328425|NCT00659568|recurrent mantle cell lymphoma
1328426|NCT00659568|recurrent marginal zone lymphoma
1328427|NCT00659568|recurrent small lymphocytic lymphoma
1328428|NCT00659568|anaplastic large cell lymphoma
1328429|NCT00659568|angioimmunoblastic T-cell lymphoma
1328430|NCT00659568|recurrent mycosis fungoides/Sezary syndrome
1328431|NCT00659568|stage III mycosis fungoides/Sezary syndrome
1328432|NCT00659568|stage IV mycosis fungoides/Sezary syndrome
1328433|NCT00659568|adult nasal type extranodal NK/T-cell lymphoma
1328434|NCT00659568|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1328435|NCT00659568|nodal marginal zone B-cell lymphoma
1328436|NCT00659568|splenic marginal zone lymphoma
1328437|NCT00659568|Waldenström macroglobulinemia
1328438|NCT00659555|vascular endothelial growth factor,
1328439|NCT00659555|drug interaction,
1328440|NCT00659555|angiogenesis,
1328441|NCT00659555|pharmacokinetics,
1328442|NCT00659555|age-related macular degeneration,
1328443|NCT00659555|pazopanib,
1328444|NCT00659555|ketoconazole
1328445|NCT00659542|inguinal hernia
1328446|NCT00659542|inguinal hernioplasty
1328447|NCT00659542|mesh fixation
1328448|NCT00659542|Lichtenstein hernioplasty
1328449|NCT00659529|cystic fibrosis
1328450|NCT00659529|inflammation
1328451|NCT00659529|pH
1328452|NCT00659529|EBC
1328453|NCT00659529|sputum biomarkers
1328454|NCT00659529|phosphodiesterase inhibitors
1328455|NCT00659503|Seasonal Allergic Rhinitis
1328456|NCT00659503|Ciclesonide
1328457|NCT00659503|Hay Fever
1328458|NCT00659503|SAR
1328459|NCT00659490|Analgesic effect
1328460|NCT00659490|Molar extraction
1328461|NCT00659464|Infrared Spectroscopy
1328462|NCT00659464|Syncope
1328463|NCT00659464|Tilt Table Testing
1328464|NCT00659451|Hypertension
1328465|NCT00659451|Diabetes mellitus
1328466|NCT00659451|Heart
1328467|NCT00659412|Psoriatic arthritis
1328468|NCT00659412|psoriasis
1328469|NCT00659412|Alefacept
1328470|NCT00659399|Pretreated Ovarian Carcinoma
1328471|NCT00659386|Heart failure
1328472|NCT00659386|Parvovirus B19
1328473|NCT00659386|Intravenous immuneglobulin
1328474|NCT00659373|cognitive/functional effects
1328475|NCT00659373|psychosocial effects of cancer and its treatment
1328476|NCT00659373|fatigue
1328477|NCT00659373|sleep disorders
1328478|NCT00659373|stage IA breast cancer
1328479|NCT00659373|stage IB breast cancer
1328480|NCT00659373|stage II breast cancer
1328481|NCT00659373|stage IIIA breast cancer
1328482|NCT00659334|Combidex
1328483|NCT00659334|Diagnostic imaging
1328484|NCT00659308|pain
1328485|NCT00659308|bullous keratopathy
1328486|NCT00659308|amniotic membrane
1328487|NCT00659308|anterior stromal puncture
1328488|NCT00659269|Vitamin B-12
1328489|NCT00659269|Vitamin B-6
1328490|NCT00659269|Chemotherapy-Induced Neuropathy
1328491|NCT00659269|Taxanes
1328492|NCT00659269|Vinca alkaloid
1328493|NCT00659269|Heavy metals
1328494|NCT00659269|Neuropathy
1328495|NCT00659269|Nerve pain
1328496|NCT00659256|Hepatitis C Virus
1328497|NCT00659256|Atherosclerosis
1328498|NCT00659256|Intima-Media Thickness
1328499|NCT00659256|Coronary Artery Calcium Score
1328500|NCT00659256|Hepatitis C
1328501|NCT00659243|Replacement therapy
1328502|NCT00659243|Pasteurized breast milk
1328503|NCT00659243|Preterm infants
1328504|NCT00659243|BSSL
1328505|NCT00659230|PTSD
1328506|NCT00659230|Veterans
1328507|NCT00659230|Nepicastat
1328508|NCT00659230|OIF/OEF
1328509|NCT00659217|Mesenchymal Stem Cells
1328510|NCT00659217|lupus Nephritis
1328511|NCT00659191|Healthy volunteer,
1328512|NCT00659191|HIV infected subjects
1328513|NCT00659178|Doxil,
1328514|NCT00659178|pegylated liposomal doxorubicin,
1328515|NCT00659178|ovarian cancer
1328516|NCT00659178|IL-18,
1328517|NCT00659178|combination study,
1328518|NCT00659178|immunotherapy,
1328519|NCT00659178|cytokine,
1328520|NCT00659165|diabetes
1328521|NCT00659165|insulin dependent diabetes
1328522|NCT00659165|diabetes mellitus
1328523|NCT00659165|detemir
1328524|NCT00659165|levemir
1328525|NCT00659165|glargine
1328526|NCT00659165|lantus
1328527|NCT00659165|insulin
1328528|NCT00659165|appetite
1328529|NCT00659165|satiety
1328530|NCT00659165|centrally acting mediators of satiety
1328531|NCT00659165|three factor eating questionnaire
1328532|NCT00659165|PYY
1328533|NCT00659165|ghrelin
1328534|NCT00659165|leptin
1328535|NCT00659152|ALI/ARDS
1328536|NCT00658086|ALN-RSV01
1328537|NCT00658086|Respiratory Syncytial Virus
1328538|NCT00658073|Kidney transplant
1328539|NCT00658073|Mesenchymal stem cell (MSC)
1328540|NCT00659113|stage IIA esophageal cancer
1328541|NCT00659113|stage IIB esophageal cancer
1328542|NCT00659113|stage IIIA esophageal cancer
1328543|NCT00659113|stage IIIB esophageal cancer
1328544|NCT00659113|stage IIIC esophageal cancer
1328545|NCT00659113|stage IV esophageal cancer
1328546|NCT00659087|Total Knee
1328547|NCT00659087|Range of Motion
1328548|NCT00659087|Pain
1328549|NCT00659074|bioequivalence
1328550|NCT00659074|Ondansetron ODT
1328551|NCT00659074|Fasting
1328552|NCT00659074|To Determine Bioequivalence Under Fasting Conditions
1328553|NCT00659061|micronutrients
1328554|NCT00659048|Perennial Allergic Rhinitis
1328555|NCT00659048|Ciclesonide
1328556|NCT00659048|PAR
1328557|NCT00659035|driving
1328558|NCT00659035|opioids
1328559|NCT00659035|impairment
1328560|NCT00659035|ability
1328561|NCT00659035|patients
1328562|NCT00659035|receiving
1328563|NCT00659035|oral morphine
1328564|NCT00659035|severe
1328565|NCT00659022|colorectal cancer
1328566|NCT00659022|liver metastases
1328567|NCT00659022|angiogenesis
1328568|NCT00659022|metabolism
1328569|NCT00659009|environmental
1328570|NCT00659009|hypobaric hypoxia
1328571|NCT00659009|sleep
1328572|NCT00659009|respiratory-disturbance
1328573|NCT00659009|neurobehavioral performance
1328574|NCT00659009|Effect of altitude on sleep-related respiratory disturbance
1328575|NCT00658970|Open label
1328576|NCT00658970|Dose escalation
1328577|NCT00658957|Diabetes
1328578|NCT00658957|Foot Ulcer
1328579|NCT00658944|Stress urinary incontinence
1328580|NCT00658944|Mixed urinary incontinence
1328581|NCT00658944|surgery
1328582|NCT00658944|trans obturator tape
1328583|NCT00658944|Maximum urethral closure pressure
1328584|NCT00658944|Valsalva leak point pressure
1328585|NCT00658944|outcome
1328586|NCT00658931|Depression
1328587|NCT00658931|Bereavement
1328588|NCT00658931|Pilot Projects
1328589|NCT00658931|Antidepressant Drugs
1328590|NCT00658918|Perennial Allergic Rhinitis
1328591|NCT00658918|Ciclesonide
1328592|NCT00658918|Hay Fever
1328593|NCT00658918|PAR
1328594|NCT00658905|Preterm infants
1328595|NCT00658905|Replacement therapy
1328596|NCT00658905|Infant formula
1328597|NCT00658905|BSSL
1328598|NCT00658905|BSSL is present in fresh mother's milk but not in infant formula.
1328599|NCT00658892|recurrent melanoma
1328600|NCT00658892|stage IV melanoma
1328601|NCT00658866|ertapenem tissue PK
1328602|NCT00658853|COPD
1328603|NCT00658853|training
1328604|NCT00658853|VO2peak
1328605|NCT00658853|performance
1328606|NCT00658853|ventilation
1328607|NCT00658853|high aerobic intensity treadmill walking
1328608|NCT00658853|one leg training by cycling
1328609|NCT00658827|Inflammatory Bowel Disease
1328610|NCT00658827|Rheumatoid Arthritis
1328611|NCT00658827|Psoriatic Arthritis
1328612|NCT00658827|Ankylosing Spondylitis
1328613|NCT00658827|Psoriasis
1328614|NCT00658827|Pregnant women exposed to infliximab
1328615|NCT00658775|GERD
1328616|NCT00658775|erosive GERD
1328617|NCT00658775|erosive esophagitis
1328618|NCT00658749|AIR645
1328619|NCT00658749|Altair Therapeutics
1328620|NCT00658749|IL4
1328621|NCT00658749|IL13
1328622|NCT00658749|IL-4
1328623|NCT00658749|IL-13
1328624|NCT00658710|hemiplegia
1328625|NCT00658710|stroke
1328626|NCT00658710|TRIDENT
1328627|NCT00658697|Rising PSA
1328628|NCT00658697|androgen deprivation
1328629|NCT00658697|bevacizumab (avastin)
1328630|NCT00658697|docetaxel
1328631|NCT00658697|lupron
1328632|NCT00658697|zoladex
1328633|NCT00658697|bicalutamide
1328634|NCT00658658|Epidermal Growth Factor
1328635|NCT00658658|Pediatric
1328636|NCT00658658|Solid Tumors
1328637|NCT00658658|Panitumumab
1328638|NCT00658658|Dose Limiting Toxicity
1328639|NCT00658645|Schizophrenia
1328640|NCT00658645|Antipsychotic
1328641|NCT00658645|Bifeprunox
1328642|NCT00658632|GERD
1328643|NCT00658632|erosive GERD
1328644|NCT00658632|erosive esophagitis
1328645|NCT00658606|plaque psoriasis
1328646|NCT00658606|alefacept
1328647|NCT00658606|Amevive
1328648|NCT00658606|narrow band ultraviolet B
1328649|NCT00658606|phototherapy
1328650|NCT00658593|adenocarcinoma of the extrahepatic bile duct
1328651|NCT00658593|unresectable extrahepatic bile duct cancer
1328652|NCT00658593|recurrent extrahepatic bile duct cancer
1328653|NCT00658593|adenocarcinoma of the gallbladder
1328654|NCT00658593|adenocarcinoma with squamous metaplasia of the gallbladder
1328655|NCT00658593|unresectable gallbladder cancer
1328656|NCT00658593|recurrent gallbladder cancer
1328657|NCT00658593|liver and intrahepatic biliary tract cancer
1328658|NCT00658580|Small cell lung carcinoma
1328659|NCT00658580|Chemotherapy
1328660|NCT00658580|Phase III randomised study
1328661|NCT00658528|GERD
1328662|NCT00658528|erosive GERD
1328663|NCT00658528|erosive esophagitis
1328664|NCT00658476|Adolescent Depression
1328665|NCT00658476|Depression
1328666|NCT00658476|Teenage Depression
1328667|NCT00658476|Los Angeles
1328668|NCT00658463|Diabetes
1328669|NCT00658463|Triglycerides
1328670|NCT00658463|HDL-cholesterol
1328671|NCT00658463|kinetic
1328672|NCT00658463|rosuvastatin
1328673|NCT00658450|Malaria, Cerebral
1328674|NCT00658437|Melanoma, Stage IV, Phase II
1328675|NCT00658411|AML
1328676|NCT00658411|ALL
1328677|NCT00658411|MDS
1328678|NCT00658411|iron overload
1328679|NCT00658411|deferoxamine
1328680|NCT00658398|Alcohol
1328681|NCT00658398|dependency
1328682|NCT00658385|GCSF
1328683|NCT00658372|PD 0332334 phase 3 pivotal trial
1328684|NCT00658359|Immunosuppression
1328685|NCT00658359|JAK3 inhibitor
1328686|NCT00658359|kidney transplantation
1328687|NCT00658346|HIV-1 group O
1328688|NCT00658346|HIV-1 group M
1328689|NCT00658346|Cameroon
1328690|NCT00658346|HIV-1 infection
1328691|NCT00658346|treatment naïve
1328692|NCT00658333|Renal Transplantation
1328693|NCT00658333|Immunosuppression
1328694|NCT00658333|Renal transplant recipients
1328695|NCT00658333|Gastrointestinal symptoms associated with MMF therapy
1328696|NCT00658320|Renal transplantation
1328697|NCT00658320|everolimus
1328698|NCT00658320|mycophenolate mofetil
1328699|NCT00658320|cyclosporine
1328700|NCT00658320|corticosteroid
1328701|NCT00658320|basiliximab
1328702|NCT00658320|Banff diagnosis
1328703|NCT00658320|Acute rejection
1328704|NCT00658320|Therapeutic drug monitoring (TDM)
1328705|NCT00658320|de novo renal transplant recipient
1328706|NCT00658307|repetitive transcranial magnetic stimulation
1328707|NCT00658307|double-blind
1328708|NCT00658307|sham-controlled
1328709|NCT00658307|randomized
1328710|NCT00658281|Breast Cancer
1328711|NCT00658281|On Board Imager Kilovoltage
1328712|NCT00658281|Cone Beam Computed Tomography
1328713|NCT00658281|Electronic Portal Imaging Device
1328714|NCT00658281|Lymph Nodes
1328715|NCT00658281|CBCT
1328716|NCT00658281|OBI KV
1328717|NCT00658268|Surgical procedures operative
1328718|NCT00658268|Prosthesis implantation
1328719|NCT00658268|Arthroplasty replacement
1328720|NCT00658255|stable asthma
1328721|NCT00658255|adults
1328722|NCT00658255|formoterol
1328723|NCT00658255|Symbicort
1328724|NCT00658255|Oxis Turbuhaler
1328725|NCT00658255|bronchodilation
1328726|NCT00658242|craniofacial
1328727|NCT00658242|maxillofacial
1328728|NCT00658242|osteotomy
1328729|NCT00658242|craniectomy
1328730|NCT00658242|craniotomy
1328731|NCT00658229|Exercise
1328732|NCT00658229|Prostatic
1328733|NCT00658229|Neoplasm
1328734|NCT00658229|Androgen
1328735|NCT00658229|Deprivation
1328736|NCT00658216|Diagnosis and prognosis
1328737|NCT00658216|Very elderly population
1328738|NCT00658216|Heart failure
1328739|NCT00658216|Brain natriuretic peptide
1328740|NCT00658216|Observational prospective study
1328741|NCT00658216|Older
1328742|NCT00658216|Dyspneic patients aged 80
1328743|NCT00658203|CRT-P
1328744|NCT00658203|PEA
1328745|NCT00658203|Severe Heart Failure (NYHA Class III or IV)
1328746|NCT00658203|Cardiomyopathy of any etiology
1328747|NCT00658203|Sinus rhythm
1328748|NCT00658203|Reduced Left-Ventricular Ejection Fraction
1328749|NCT00658203|LVEDD>30 mm/m2
1328750|NCT00658203|QRS Duration: > 150 ms or > 120 ms
1328751|NCT00658203|Aortic Pre-Ejection Delay > 140 ms
1328752|NCT00658203|Interventricular Mechanical Delay > 40 ms
1328753|NCT00658203|Delayed activation of postero-lateral Left Ventricular wall
1328754|NCT00658203|Optimal and stable pharmacological treatment
1328755|NCT00658190|Cervical cancer, automation, Internet, telecytology
1328756|NCT00658177|Erectile dysfunction
1328757|NCT00658177|Vardenafil
1328758|NCT00658164|Nonalcoholic fatty liver disease associated with increased iron stores
1328759|NCT00658151|focus
1328760|NCT00658151|study
1328761|NCT00658151|evaluate
1328762|NCT00658151|sonographic
1328763|NCT00658151|findings
1328764|NCT00658151|colon
1328765|NCT00658151|patients
1328766|NCT00658151|developed
1328767|NCT00658060|FMF, Exertional leg pain
1328768|NCT00658047|Arthritis, Rheumatoid
1328769|NCT00658047|Phase II
1328770|NCT00658047|Rheumatoid Arthritis
1328771|NCT00658034|Cancer
1328772|NCT00658034|Fatigue
1328773|NCT00658034|Acupuncture
1328774|NCT00658021|diabetes
1328775|NCT00658021|adolescents
1328776|NCT00658021|exenatide
1328777|NCT00658021|Astra Zeneca
1328778|NCT00658008|PD 0332334 phase 3 pivotal trial
1328779|NCT00657995|pancreatogenic
1328780|NCT00657995|diabetes
1328781|NCT00657995|artificial
1328782|NCT00657995|pancreas
1328783|NCT00657969|Polymorphism, genetic
1328784|NCT00657969|Risk factors
1328785|NCT00657969|Carotid Artery, Internal, Dissection
1328786|NCT00657969|Vertebral Artery Dissection
1328787|NCT00657969|Genetic predisposition
1328788|NCT00657969|Outcome
1328789|NCT00657969|Therapy
1328790|NCT00657956|osteoarthritis
1328791|NCT00657956|arthroplasty
1328792|NCT00657956|knee joint
1328793|NCT00657956|radiography
1328794|NCT00657956|surgery
1328795|NCT00657956|Bone Density
1328796|NCT00657956|Outcome Assessment (Health Care)
1328797|NCT00657943|carotid
1328798|NCT00657943|intima
1328799|NCT00657943|media
1328800|NCT00657943|thickness
1328801|NCT00657943|insulin
1328802|NCT00657943|metformin
1328803|NCT00657917|leishmaniasis
1328804|NCT00657917|cutaneous
1328805|NCT00657917|Old World
1328806|NCT00657917|Leishmania major
1328807|NCT00657917|Treatment
1328808|NCT00657904|androgen antagonists
1328809|NCT00657904|prostate neoplasms
1328810|NCT00657891|Allergic Asthma
1328811|NCT00657891|Anti IgE
1328812|NCT00657891|Xolair
1328813|NCT00657891|Basophil
1328814|NCT00657891|IL-13
1328815|NCT00657891|IL-4
1328816|NCT00657891|Histamine
1328817|NCT00657878|platinum free interval
1328818|NCT00657878|chemotherapy
1328819|NCT00657852|pamidronate,bone loss, liver transplantation
1328820|NCT00657839|Benign Prostate Hyperplasia
1328821|NCT00657839|Vardenafil
1328822|NCT00657839|Genital Disease
1328823|NCT00657839|Male: Signs and symptoms of Benign Prostate Hyperplasia
1328824|NCT00657826|Diseased Heart Valve, Replacement
1328825|NCT00657813|Alzheimer
1328826|NCT00657813|SPECT
1328827|NCT00657800|diabetes, inpatient, education,
1328828|NCT00657787|Posttraumatic Stress Disorder
1328829|NCT00657787|Veterans
1328830|NCT00657787|Health Services
1328831|NCT00657774|Asthma
1328832|NCT00657774|Mild to Moderate
1328833|NCT00657748|Leukodystrophy
1328834|NCT00657748|Canavan disease,
1328835|NCT00657748|Aspartoacylase,
1328836|NCT00657748|Lithium,
1328837|NCT00657748|Glyceryl Triacetate
1328838|NCT00657735|bipolar
1328839|NCT00657735|depression
1328840|NCT00657735|prefrontal
1328841|NCT00657735|cortex
1328842|NCT00657735|antidepressant
1328843|NCT00657735|response
1328844|NCT00657722|Pulmonary hypertension
1328845|NCT00657722|Chronic thromboembolic pulmonary hypertension
1328846|NCT00657722|Operability
1328847|NCT00657722|Thromboendarteriectomy
1328848|NCT00657722|Operative mortality rate
1328849|NCT00657722|Technical failure
1328850|NCT00657722|Pulmonary angiography
1328851|NCT00657722|Computed tomography
1328852|NCT00657709|infant
1328853|NCT00657709|Meningococcal disease
1328854|NCT00657709|prevention
1328855|NCT00657709|vaccination
1328856|NCT00657696|primary health care
1328857|NCT00657696|organizations
1328858|NCT00657696|learning
1328859|NCT00657696|quality of health care
1328860|NCT00657683|GBS
1328861|NCT00657683|GBS prevention
1328862|NCT00657670|refractive error
1328863|NCT00657670|spectacles
1328864|NCT00657670|ready made spectacles
1328865|NCT00657670|vision
1328866|NCT00657670|cost effectiveness
1328867|NCT00657657|Hepatitis
1328868|NCT00657657|vaccine
1328869|NCT00657644|Erectile Dysfunction
1328870|NCT00657631|Acceptance and Commitment Therapy
1328871|NCT00657631|Delusions
1328872|NCT00657618|Leishmaniasis, Sodium stibogluconate, Pentostam, sand fly
1328873|NCT00657605|Congenital leptin deficiency
1328874|NCT00657605|Obesity
1328875|NCT00657605|Metabolic syndrome
1328876|NCT00657605|Diabetes
1328877|NCT00657566|intraabdominal
1328878|NCT00657566|peritonitis
1328879|NCT00657566|sepsis
1328880|NCT00657566|duration
1328881|NCT00657566|antibiotics
1328882|NCT00657540|black widow spider
1328883|NCT00657540|antivenom
1328884|NCT00657540|latrodectism
1328885|NCT00657527|Crestor
1328886|NCT00657527|Rosuvastatin
1328887|NCT00657527|Cholesterol
1328888|NCT00657527|Coronary artery disease
1328889|NCT00657527|Myocardial ischaemia.
1328890|NCT00657514|hemoglobin desaturation kinetics
1328891|NCT00657514|peripheral arterial disease
1328892|NCT00657514|chronic angina
1328893|NCT00657514|exercise tolerance
1328894|NCT00657501|testosterone
1328895|NCT00657501|hypoactive sexual desire disorder
1328896|NCT00657501|menopause
1328897|NCT00657488|Multiple Myeloma, Thalidomide, dose, dexamethasone
1328898|NCT00657475|Heparin low dose
1328899|NCT00657475|Inflammation
1328900|NCT00657475|Blood loss
1328901|NCT00657462|Medical Informatics Applications
1328902|NCT00657462|Software
1328903|NCT00657462|Utilization
1328904|NCT00657449|sprains and strains
1328905|NCT00657436|Acute Coronary Syndrome
1328906|NCT00657436|Myocardial Infarction
1328907|NCT00657436|Coronary Artery Disease
1328908|NCT00657423|Lung Neoplasms
1328909|NCT00657423|Endostatins
1328910|NCT00657423|Vascular Endothelial Growth Factors
1328911|NCT00657423|Fibroblast Growth Factors
1328912|NCT00657423|Survival Rate
1328913|NCT00657410|idiopathic thrombocytopenic purpura
1328914|NCT00657397|Methadone
1328915|NCT00657397|Substance Dependence
1328916|NCT00657384|Specify the primary condition or disease being studied Major Hepatectomy
1328917|NCT00657371|Colorectal Cancer
1328918|NCT00657371|Colonoscopy
1328919|NCT00657371|Third Eye Retroscope
1328920|NCT00657371|Third Eye Retroscope Auxiliary Imaging System
1328921|NCT00657371|Polypectomy
1328922|NCT00657358|lidocaine
1328923|NCT00657358|allodynia
1328924|NCT00657358|chronic regional pain syndrome
1328925|NCT00657358|pain
1328926|NCT00657345|trastuzumab
1328927|NCT00657345|breast cancer
1328928|NCT00657345|her2 positive breast cancer
1328929|NCT00657306|Cirrhosis
1328930|NCT00657306|Ascites
1328931|NCT00657306|Adrenal insufficiency
1328932|NCT00657306|Hepatorenal syndrome
1328933|NCT00657306|Portal hypertension
1328934|NCT00657293|COPD
1328935|NCT00657293|arm training
1328936|NCT00657293|dyspnoea
1328937|NCT00657293|quality of life
1328938|NCT00657267|recurrent glioblastoma
1328939|NCT00657267|temodar
1328940|NCT00657267|temozolomide
1328941|NCT00657254|Extension
1328942|NCT00657254|Sorafenib
1328943|NCT00657254|Survival
1328944|NCT00657241|cardiac work
1328945|NCT00657241|coreg cr
1328946|NCT00657241|valsartan
1328947|NCT00657241|tonometry
1328948|NCT00657228|Anaphylaxis
1328949|NCT00657228|Anaphylactoid reactions
1328950|NCT00657202|NF1
1328951|NCT00657202|neurofibroma
1328952|NCT00657202|ranibizumab
1328953|NCT00657202|Lucentis
1328954|NCT00657189|Sifalimumab
1328955|NCT00657189|MEDI-545
1328956|NCT00657189|Lupus erythematosus, systemic
1328957|NCT00657163|Stroke recovery
1328958|NCT00657163|Pharmacological modulation
1328959|NCT00657163|Selective Serotonin Reuptake Inhibitor (SSRI)
1328960|NCT00657163|Fluoxetine
1328961|NCT00657163|Brain plasticity
1328962|NCT00657163|Ischemic Stroke and Motor impairment
1328963|NCT00657163|Modulation of recovery and cerebral plasticity by Fluoxetine
1328964|NCT00657137|HER2/neu positive
1328965|NCT00657137|locally advanced or metastatic
1328966|NCT00657124|AEN
1328967|NCT00657111|influenza, elderly, United Kingdom
1328968|NCT00657098|Side effects
1328969|NCT00657098|Angiogenesis inhibitors
1328970|NCT00657098|Epidermal growth factor receptor inhibitors
1328971|NCT00657098|Tyrosinekinase inhibitors
1328972|NCT00657085|Laser hair removal
1328973|NCT00657072|scapholunate instability
1328974|NCT00657072|neural networks
1328975|NCT00657072|scaphoid
1328976|NCT00657072|lunate
1328977|NCT00657072|Suspected torn scapholunate interosseous ligament
1328978|NCT00657072|Suspected other torn wrist ligaments
1328979|NCT00657059|IgA nephropathy
1328980|NCT00657059|mycophenolate mofetil
1328981|NCT00657033|Erectile Dysfunction
1328982|NCT00657020|nicotine
1328983|NCT00657020|therapy
1328984|NCT00657020|fMRI/EEG
1328985|NCT00657020|replacement
1328986|NCT00657007|lupus
1328987|NCT00657007|SLE
1328988|NCT00656994|Sleep Disorder
1328989|NCT00656994|Insomnia
1328990|NCT00656981|Moderate Acne Vulgaris
1328991|NCT00656981|Acne
1328992|NCT00656968|peptic ulcer disease
1328993|NCT00656968|gastric cancer
1328994|NCT00656968|therapeutics
1328995|NCT00656955|Survival Study
1328996|NCT00656955|Kidney Cancer
1328997|NCT00656955|Renal Cell Cancer
1328998|NCT00656955|Tumor Markers
1328999|NCT00656955|Heterogeneity
1329000|NCT00656955|Molecular Epidemiology
1329001|NCT00656955|Survival
1329002|NCT00656955|Occupational Exposure
1329003|NCT00656955|Renal Cancer
1329004|NCT00656942|Pain
1329005|NCT00656929|Vitamin D
1329006|NCT00656929|Viral URI
1329007|NCT00656929|Influenza
1329008|NCT00656929|Colds
1329009|NCT00656916|Post-Transplant Constrictive Bronchiolitis
1329010|NCT00656916|Bronchiolitis
1329011|NCT00656916|Fluticasone Propionate
1329012|NCT00656916|Inhaled Corticosteroids
1329013|NCT00656916|Lung Condition
1329014|NCT00656916|PTCB
1329015|NCT00656903|Lucentis
1329016|NCT00656903|Indocyanine Green Angiography
1329017|NCT00656903|Choroidal Neovascularization
1329018|NCT00656903|Macular Degeneration
1329019|NCT00656903|Ranibizumab
1329020|NCT00656903|Age-Related Macular Degeneration
1329021|NCT00656903|AMD
1329022|NCT00656890|ulcerative colitis, rectal bleeding
1329023|NCT00656877|Fat Embolism Total Knee Arthroplasty
1329024|NCT00656864|Diabetes
1329025|NCT00656864|pioglitazone
1329026|NCT00656864|GIP
1329027|NCT00656851|HIV/AIDS
1329028|NCT00656851|Heart disease
1329029|NCT00656851|Diabetes
1329030|NCT00656851|Cardiovascular disease risk
1329031|NCT00656851|Dyslipidemia
1329032|NCT00656851|Visceral adiposity
1329033|NCT00656851|treatment experienced
1329034|NCT00656838|colon
1329035|NCT00656838|rectal
1329036|NCT00656838|cancer
1329037|NCT00656838|screening
1329038|NCT00656825|P144
1329039|NCT00656825|TGF-β1
1329040|NCT00656825|Healthy volunteers
1329041|NCT00656825|Cutaneous tolerability
1329042|NCT00656825|Skin fibrosis
1329043|NCT00656825|systemic scleroderma
1329044|NCT00656825|systemic sclerosis
1329045|NCT00656825|Safety
1329046|NCT00656812|advanced MALT lymphoma
1329047|NCT00656812|Rituximab
1329048|NCT00656812|2CdA
1329049|NCT00656812|chemotherapy
1329050|NCT00656812|immunotherapy
1329051|NCT00656773|morphine, sufentanil, acute pain, opioid, Prehospital Emergency Care
1329052|NCT00656760|unknown primary, head and neck cancer, squamous cell carcinoma
1329053|NCT00656760|Unknown primary head and neck cancer
1329054|NCT00656747|Chronic Obstructive Pulmonary Disease (COPD)
1329055|NCT00656747|Acute exacerbation of COPD (AECOPD)
1329056|NCT00656747|chronic bronchitis
1329057|NCT00656747|bronchitis
1329058|NCT00656747|chest infection
1329059|NCT00656747|smoking
1329060|NCT00656747|lung disease
1329061|NCT00656747|lung
1329062|NCT00656747|lungs
1329063|NCT00656734|Medarex Inc.
1329064|NCT00656721|bronchiectasis
1329065|NCT00656721|physiotherapy
1329066|NCT00656721|flutter valve
1329067|NCT00656721|impulse oscillation technique
1329068|NCT00656708|Burns
1329069|NCT00656708|Wounds
1329070|NCT00656708|Healthcare associated infections
1329071|NCT00656708|MRSA
1329072|NCT00656708|VRE
1329073|NCT00656695|Iminoral
1329074|NCT00656695|Neoral
1329075|NCT00656695|Acute renal transplant rejection
1329076|NCT00656682|Prevention & Control
1329077|NCT00656682|Hyperglycemia
1329078|NCT00656682|Obesity
1329079|NCT00656682|Diabetes Mellitus
1329080|NCT00656682|Cost Benefit Analysis
1329081|NCT00656669|newly diagnosed breast cancer
1329082|NCT00656669|neoadjuvant therapy
1329083|NCT00656656|pemphigus
1329084|NCT00656656|rituximab
1329085|NCT00656656|immunoadsorption
1329086|NCT00656656|dexamethasone
1329087|NCT00656656|treatment
1329088|NCT00656656|management
1329089|NCT00656617|Acute Myeloid Leukemia
1329090|NCT00656617|(AML)
1329091|NCT00656617|Myelodysplastic syndrome
1329092|NCT00656617|(MDS)
1329093|NCT00656617|Leukemia
1329094|NCT00656617|Idarubicin
1329095|NCT00656617|Cytarabine
1329096|NCT00656617|Vorinostat
1329097|NCT00656617|Ara-C
1329098|NCT00656604|recurrent breast cancer
1329099|NCT00656604|stage I breast cancer
1329100|NCT00656604|stage II breast cancer
1329101|NCT00656604|stage IIIA breast cancer
1329102|NCT00656604|stage IIIB breast cancer
1329103|NCT00656604|stage IIIC breast cancer
1329104|NCT00656591|Child mortality, Nepal, Community, care practices
1329105|NCT00656578|Foot
1329106|NCT00656578|Bunion
1329107|NCT00656578|Bunionectomy
1329108|NCT00656578|Hallux Valgus Deformity
1329109|NCT00656578|Surgery for Transpositional first metatarsal osteotomy - Bunionectomy
1329110|NCT00656565|measure inspiratory spirometry with dry powder inhaler device in series with the spirometer
1329111|NCT00656526|analgesia, postlaminectomy , lidocaine, dorsal root
1329112|NCT00656513|hypopharyngeal cancer
1329113|NCT00656513|laryngeal cancer
1329114|NCT00656513|lip and oral cavity cancer
1329115|NCT00656513|nasopharyngeal cancer
1329116|NCT00656513|paranasal sinus and nasal cavity cancer
1329117|NCT00656513|oropharyngeal cancer
1329118|NCT00656513|salivary gland cancer
1329119|NCT00656513|metastatic squamous neck cancer with occult primary
1329120|NCT00656513|xerostomia
1329121|NCT00656513|tongue cancer
1329122|NCT00656500|surgical patients
1329123|NCT00656500|cigarette smoking
1329124|NCT00656500|postoperative complications
1329125|NCT00656500|telephone counseling
1329126|NCT00656500|quitlines
1329127|NCT00656487|Cannabis Dependence
1329128|NCT00656487|Marijuana Dependence
1329129|NCT00656487|Cannabis Withdrawal
1329130|NCT00656487|Rimonabant
1329131|NCT00656487|cannabinoid receptor type 1 (CB1) inverse agonist
1329132|NCT00656487|Neuropsychology
1329133|NCT00656487|functional magnetic resonance imaging (fMRI)
1329134|NCT00656487|Endocannabinoids
1329135|NCT00656487|Cortisol
1329136|NCT00656474|burn wounds
1329137|NCT00656474|wound healing
1329138|NCT00656461|Advanced cancer
1329139|NCT00656448|Acute Myelogenous Leukemia
1329140|NCT00656448|AML
1329141|NCT00656448|Myelodysplastic Syndrome
1329142|NCT00656448|MDS
1329143|NCT00656448|Leukemia
1329144|NCT00656448|Procrit
1329145|NCT00656448|Epoetin Alfa
1329146|NCT00656448|Epogen
1329147|NCT00656435|proliferative diabetic retinopathy
1329148|NCT00656435|bevacizumab (Avastin)
1329149|NCT00656435|vitreous hemorrhage
1329150|NCT00656435|long acting gas
1329151|NCT00656422|insulin therapy
1329152|NCT00656422|hepatic fat
1329153|NCT00656422|type 2 diabetes
1329154|NCT00656422|body composition
1329155|NCT00656422|comparison of insulin detemir and insulin glargine
1329156|NCT00656422|Changes in Hepatic Fat
1329157|NCT00656422|Obesity
1329158|NCT00656409|Ataxia telangiectasia,
1329159|NCT00656409|Conjugated pneumococcal,
1329160|NCT00656409|Prevenar,
1329161|NCT00656409|Immunogenicity ,
1329162|NCT00656409|Vaccine
1329163|NCT00656396|Blood loss
1329164|NCT00656396|Point of care monitoring
1329165|NCT00656396|FFP
1329166|NCT00656396|Major surgery
1329167|NCT00656396|Prothrombin Time
1329168|NCT00656396|Blood coagulation tests
1329169|NCT00656383|venous ulcer, leg ulcer, stasis ulcer
1329170|NCT00656370|Hylenex
1329171|NCT00656370|subcutaneous infusion
1329172|NCT00656370|hyaluronidase
1329173|NCT00656370|rHuPH20
1329174|NCT00656370|recombinant human hyaluronidase
1329175|NCT00656344|PTSD
1329176|NCT00656344|Substance Abuse
1329177|NCT00656344|WTC attacks
1329178|NCT00656344|Iraq War
1329179|NCT00656318|women
1329180|NCT00656318|menses
1329181|NCT00656318|oral contraceptives
1329182|NCT00656318|Healthy menstruating females
1329183|NCT00656305|Bone Cancer
1329184|NCT00656305|Pain Palliation
1329185|NCT00656305|Metastasis
1329186|NCT00656305|Multiple Myeloma
1329187|NCT00656305|Breast Cancer
1329188|NCT00656305|Lung Cancer
1329189|NCT00656305|Prostate Cancer
1329190|NCT00656305|cancer related Pain
1329191|NCT00656305|Tumors
1329192|NCT00656292|Plasma concentrations of inflammatory markers
1329193|NCT00656292|C-Reactive Protein (CRP)
1329194|NCT00656292|Interleukin-6 (IL-6)
1329195|NCT00656292|Tumor Necrosis Factor-Alpha (TNF)
1329196|NCT00656292|Aspartate Aminotransferase (AST)
1329197|NCT00656292|Alanine Aminotransferase (ALT)
1329198|NCT00656292|Creatine Kinase (CK)
1329199|NCT00656279|chronic kidney disease
1329200|NCT00656279|predialysis
1329201|NCT00656279|hyperphosphatemia
1329202|NCT00656279|dietary intervention
1329203|NCT00656279|intensive dietary education
1329204|NCT00656279|low phosphorus diet
1329205|NCT00656266|renal insufficiency and/or renal failure after liver transplantation
1329206|NCT00656214|Lichen Planus
1329207|NCT00656201|Infertility
1329208|NCT00656201|In vitro fertilization
1329209|NCT00656201|Embryo transfer
1329210|NCT00656201|Crinone
1329211|NCT00656201|Intramuscular Progesterone
1329212|NCT00656201|Progesterone support
1329213|NCT00656188|Erectile Dysfunction
1329214|NCT00656188|Vardenafil
1329215|NCT00656175|lipodystrophy
1329216|NCT00656175|fat
1329217|NCT00656175|visceral fat
1329218|NCT00656175|HIV
1329219|NCT00656175|women
1329220|NCT00656175|raltegravir
1329221|NCT00656175|ART
1329222|NCT00656175|anti HIV therapy
1329223|NCT00656175|NNRTI
1329224|NCT00656175|Protease inhibitor
1329225|NCT00656175|integrase inhibitor
1329226|NCT00656175|treatment experienced
1329227|NCT00656149|telerehabilitation
1329228|NCT00656149|functional electrical stimulation
1329229|NCT00656149|spinal cord injury
1329230|NCT00656149|hand function rehabilitation
1329231|NCT00656123|adenocarcinoma of the colon
1329232|NCT00656123|adenocarcinoma of the rectum
1329233|NCT00656123|stage IV colon cancer
1329234|NCT00656123|stage IV rectal cancer
1329235|NCT00656123|liver metastases
1329236|NCT00656110|Restless legs syndrome
1329237|NCT00656110|Morton's neuroma
1329238|NCT00656110|Randomized controlled trial
1329239|NCT00656097|Rabies post-exposure prophylaxis
1329240|NCT00656071|ARDS
1329241|NCT00656071|Acute respiratory distress syndrome
1329242|NCT00656071|Adult respiratory distress syndrome
1329243|NCT00656071|respiratory distress
1329244|NCT00656058|Leukotriene
1329245|NCT00656058|Chronic Graft-Versus-Host Disease
1329246|NCT00656058|Montelukast
1329247|NCT00656058|Stem Cell Transplant
1329248|NCT00656058|Bronchiolitis Obliterans
1329249|NCT00656045|Obesity
1329250|NCT00656045|Physical Activity
1329251|NCT00656045|Weight Loss
1329252|NCT00656045|Exercise
1329253|NCT00656045|Dietary Intake
1329254|NCT00656045|Energy
1329255|NCT00656045|Behavioral
1329256|NCT00656045|Healthy Eating
1329257|NCT00656032|insulin resistance
1329258|NCT00656032|end stage renal disease
1329259|NCT00656006|Hepatitis C
1329260|NCT00656006|Chronic
1329261|NCT00656006|Genotype 2 or 3
1329262|NCT00656006|Treatment naive
1329263|NCT00655993|COPD
1329264|NCT00655993|Inflammation
1329265|NCT00655993|CRP levels
1329266|NCT00655993|simvastatin
1329267|NCT00655954|COPD
1329268|NCT00655954|asthma
1329269|NCT00655954|smokers
1329270|NCT00655954|healthy volunteers
1329271|NCT00655954|bronchiectasis
1329272|NCT00655954|cystic fibrosis
1329273|NCT00655941|Osteoarthritis
1329274|NCT00655941|Obesity
1329275|NCT00655941|Weight loss
1329276|NCT00655941|Dietary instruction
1329277|NCT00655941|Exercise
1329278|NCT00655941|Attention
1329279|NCT00655928|Acute lung injury
1329280|NCT00655928|Lung resection
1329281|NCT00655902|Trans fat
1329282|NCT00655902|Obesity
1329283|NCT00655902|Insulin sensitivity
1329284|NCT00655876|stage IIA esophageal cancer
1329285|NCT00655876|stage IIB esophageal cancer
1329286|NCT00655876|stage IIIA esophageal cancer
1329287|NCT00655876|stage IIIB esophageal cancer
1329288|NCT00655876|stage IIIC esophageal cancer
1329289|NCT00655876|stage IV esophageal cancer
1329290|NCT00655876|squamous cell carcinoma of the esophagus
1329291|NCT00655863|Glucose Metabolism Disorder
1329292|NCT00655863|Dysmetabolic Syndrome
1329293|NCT00655863|Type II Diabetes
1329294|NCT00655863|Diabetes Mellitus
1329295|NCT00655863|Lipoatrophic; Dyslipidemia
1329296|NCT00655863|Drug Therapy
1329297|NCT00655850|Lung Cancer
1329298|NCT00655850|Non-Small Cell Lung Cancer
1329299|NCT00655850|Metronomic Chemotherapy
1329300|NCT00655837|Antigens, CD40
1329301|NCT00655837|Antibodies, Monoclonal
1329302|NCT00655837|Combined Modality Therapy
1329303|NCT00655837|Lymphoma, Large B-Cell, Diffuse
1329304|NCT00655837|Lymphoma, Non-Hodgkin
1329305|NCT00655837|Hematologic Diseases
1329306|NCT00655837|Immunoproliferative Disorders
1329307|NCT00655837|Lymphatic Diseases
1329308|NCT00655837|Lymphoproliferative Disorders
1329309|NCT00655837|Lymphoma
1329310|NCT00655811|Healthy volunteers
1329311|NCT00655785|Epitope peptide
1329312|NCT00655785|CTL
1329313|NCT00655785|Pancreatic cancer
1329314|NCT00655785|Vaccination VEGFR1
1329315|NCT00655785|VEGFR2
1329316|NCT00655772|chlorine
1329317|NCT00655772|dioxide
1329318|NCT00655772|mouthwash
1329319|NCT00655772|organoleptic
1329320|NCT00655772|measurements
1329321|NCT00655772|volatile
1329322|NCT00655772|sulfur
1329323|NCT00655772|compounds
1329324|NCT00655746|Healthy Subjects
1329325|NCT00655720|infant formula
1329326|NCT00655707|Adult stem cell therapy
1329327|NCT00655694|COPD
1329328|NCT00655694|smokers
1329329|NCT00655694|healthy volunteers
1329330|NCT00655681|pediatric osteoporosis
1329331|NCT00655681|pediatric osteopenia
1329332|NCT00655681|pamidronate
1329333|NCT00655681|post operative osteopenia
1329334|NCT00655668|NHL, Non-Hodgkin's Lymphoma, T-cell Lymphoma
1329335|NCT00655629|Erectile Dysfunction
1329336|NCT00655603|GLP-1
1329337|NCT00655603|Glucagon secretion
1329338|NCT00655603|Glucose turn-over
1329339|NCT00655590|Erectile Dysfunction
1329340|NCT00655590|Sildenafil
1329341|NCT00655590|Vardenafil
1329342|NCT00655590|Spermatogenesis
1329343|NCT00655590|Sperm concentration
1329344|NCT00655590|Sperm count
1329345|NCT00655590|Morphology
1329346|NCT00655590|Motility
1329347|NCT00655590|Reproductive hormonal
1329348|NCT00655577|Aging
1329349|NCT00655577|Osteoporosis
1329350|NCT00655577|Exercise
1329351|NCT00655577|Population based
1329352|NCT00655577|Randomized trial
1329353|NCT00655577|Falls
1329354|NCT00655577|Fractures
1329355|NCT00655551|epilepsy
1329356|NCT00655551|seizures
1329357|NCT00655551|Lacosamide
1329358|NCT00655551|Vimpat
1329359|NCT00655551|intravenous
1329360|NCT00655525|inflammation
1329361|NCT00655525|end stage renal disease
1329362|NCT00655512|pimecrolimus
1329363|NCT00655512|hydrocortison
1329364|NCT00655512|betamethasone
1329365|NCT00655512|clobetasol-17-Propionat
1329366|NCT00655512|Optical Coherence Tomography
1329367|NCT00655512|skin healthy probands
1329368|NCT00655499|adenocarcinoma of the colon
1329369|NCT00655499|adenocarcinoma of the rectum
1329370|NCT00655499|stage IV colon cancer
1329371|NCT00655499|recurrent rectal cancer
1329372|NCT00655499|stage IV rectal cancer
1329373|NCT00655499|recurrent colon cancer
1329374|NCT00655486|Epilepsy
1329375|NCT00655486|seizures
1329376|NCT00655486|antiepileptic
1329377|NCT00655486|Lacosamide
1329378|NCT00655486|Vimpat
1329379|NCT00655486|safety
1329380|NCT00655486|adjunctive
1329381|NCT00655460|Glucose
1329382|NCT00655460|Insulin
1329383|NCT00655460|computer
1329384|NCT00655460|critical care
1329385|NCT00655447|oophorectomy
1329386|NCT00655447|ovarian conservation
1329387|NCT00655447|stroke
1329388|NCT00655447|breast cancer
1329389|NCT00655447|ovarian cancer
1329390|NCT00655447|other cancer
1329391|NCT00655447|hip fracture
1329392|NCT00655434|Herpes simplex virus 2
1329393|NCT00655434|HSV 2
1329394|NCT00655434|Antibody status to Herpesvirus 2, Human
1329395|NCT00655421|screening
1329396|NCT00655421|oral precancers
1329397|NCT00655421|tobacco users
1329398|NCT00655421|VELScope
1329399|NCT00655421|Visual Inspection
1329400|NCT00655421|Toluidine Blue
1329401|NCT00655408|Infants
1329402|NCT00655408|Prevalence
1329403|NCT00655408|Iron
1329404|NCT00655408|Deficiency
1329405|NCT00655408|Treatment
1329406|NCT00655395|Leukemia
1329407|NCT00655395|MDS
1329408|NCT00655382|dynamic pelvic mri
1329409|NCT00655382|dynamic mri
1329410|NCT00655382|STARR procedure
1329411|NCT00655382|STARR
1329412|NCT00655382|ODS
1329413|NCT00655382|obstructive defecation syndrome
1329414|NCT00655382|outlet obstruction
1329415|NCT00655382|obstructed defecation
1329416|NCT00655382|stapled trans anal rectal resection
1329417|NCT00655356|Treatment of moderate to severe bilateral nasolabial fold wrinkles
1329418|NCT00655343|GvHD
1329419|NCT00655343|aGvHD prophylaxis
1329420|NCT00655343|Matched unrelated donor
1329421|NCT00655343|ATG
1329422|NCT00655343|SCT
1329423|NCT00655343|BMT
1329424|NCT00655343|polyclonal antibody
1329425|NCT00655343|GvHD prophylaxis for patients with ALL, AML, CML, MDS, OMF
1329426|NCT00655343|Patients with allogeneic BM or PBSC transplantation
1329427|NCT00655343|Patients with a matched unrelated donor
1329428|NCT00655330|Type 2 diabetes mellitus
1329429|NCT00655330|Nephropathy
1329430|NCT00655330|valsartan
1329431|NCT00655330|probucol
1329432|NCT00655330|Proteinuria
1329433|NCT00655317|acupuncture
1329434|NCT00655317|colon surgery
1329435|NCT00655317|post operative ileus
1329436|NCT00655317|post ileus
1329437|NCT00655317|ileus
1329438|NCT00655317|colectomy
1329439|NCT00655317|colorectal pathology
1329440|NCT00655291|pain
1329441|NCT00655278|Movement Disorder
1329442|NCT00655252|Expanded access
1329443|NCT00655252|metastatic renal cell cancer
1329444|NCT00655252|progression despite VEGF receptors
1329445|NCT00655239|Ultra High Risk of Schizophrenia
1329446|NCT00655239|Prodrome
1329447|NCT00655239|Psychosis
1329448|NCT00655239|Schizophrenia
1329449|NCT00655239|Cognitive Remediation
1329450|NCT00655226|Cognitive Behavior Therapy
1329451|NCT00655226|Interferon-alpha
1329452|NCT00655226|Communicable Diseases
1329453|NCT00655226|Liver Diseases
1329454|NCT00655226|Depression
1329455|NCT00655226|Hepatitis, Chronic
1329456|NCT00655226|Interferons
1329457|NCT00655226|Ribavirin
1329458|NCT00655226|Hepatitis, Viral, Human
1329459|NCT00655226|Infection
1329460|NCT00655226|Hepatitis
1329461|NCT00655226|Mood Disorders
1329462|NCT00655226|Peginterferon alfa-2a
1329463|NCT00655226|Hepatitis C
1329464|NCT00655226|Interferon Alfa-2a
1329465|NCT00655226|Interferon Alfa-2b
1329466|NCT00655226|Depressive Disorder, Major
1329467|NCT00655226|Depressive Disorder
1329468|NCT00655213|Pacing, AV conduction disorders, minimized ventricular pacing, AF
1329469|NCT00655174|autism
1329470|NCT00655174|fluvoxamine
1329471|NCT00655174|sertraline
1329472|NCT00655174|selective seratonin reuptake inhibitors
1329473|NCT00655174|paediatrics
1329474|NCT00655161|NSCLC
1329475|NCT00655161|Cancer Immunotherapy
1329476|NCT00655148|DTaP-IPV
1329477|NCT00655148|Clinical Trial
1329478|NCT00655148|Safety
1329479|NCT00655148|Immunogenicity
1329480|NCT00655109|Allergic conjunctivitis
1329481|NCT00655109|Allergic rhinoconjunctivitis
1329482|NCT00655096|Screening Protocol
1329483|NCT00655096|Eye Diseases
1329484|NCT00655083|Infantile colic
1329485|NCT00655083|Abdominal Cramps
1329486|NCT00655083|Colicky Pain
1329487|NCT00655083|Functional gastrointestinal disorders
1329488|NCT00655070|Hibernating Myocardium
1329489|NCT00655070|Blood Flow
1329490|NCT00655070|Ultrasound
1329491|NCT00655070|PET imaging
1329492|NCT00655057|Dopamine Transporter
1329493|NCT00655057|Biomarker
1329494|NCT00655057|SPECT Brain Imaging
1329495|NCT00655057|Antidepressant Therapy
1329496|NCT00655031|Punicaceae
1329497|NCT00655031|Pomegranate
1329498|NCT00655018|Non-Alcoholic Fatty Liver Disease (NAFLD)
1329499|NCT00655018|Non-Alcoholic Steatohepatitis (NASH)
1329500|NCT00655018|Liver histology
1329501|NCT00655018|Insulin Resistance
1329502|NCT00655018|Weight loss
1329503|NCT00655018|Alpha-tocopherol
1329504|NCT00655018|ascorbic acid
1329505|NCT00655005|head and neck cancer
1329506|NCT00654966|Urotensin II
1329507|NCT00654966|Soluble epoxide hydrolase
1329508|NCT00654966|Iontophoresis
1329509|NCT00654966|Healthy volunteers
1329510|NCT00654953|cocaine dependence
1329511|NCT00654953|depressive symptoms
1329512|NCT00654953|relapse
1329513|NCT00654953|sertraline
1329514|NCT00654953|gabapentin
1329515|NCT00654927|multiple sclerosis
1329516|NCT00654927|MS
1329517|NCT00654927|walking
1329518|NCT00654927|leg strength
1329519|NCT00654927|demyelination
1329520|NCT00654914|Sexual Dysfunction
1329521|NCT00654901|Diphtheria
1329522|NCT00654901|Tetanus
1329523|NCT00654901|Pertussis
1329524|NCT00654901|Hepatitis B
1329525|NCT00654901|Poliomyelitis
1329526|NCT00654901|Invasive Haemophilus influenzae type b.
1329527|NCT00654901|Haemophilus Influenzae Type B Infection
1329528|NCT00654888|cataract extraction
1329529|NCT00654888|surgery
1329530|NCT00654888|corneal disease
1329531|NCT00654875|Essential Hypertension
1329532|NCT00654849|Electrosurgery
1329533|NCT00654849|Gyrus Pk
1329534|NCT00654849|abdominal hysterectomy
1329535|NCT00654849|Blood Loss, Surgical
1329536|NCT00654849|Length of stay
1329537|NCT00654849|Overall cost
1329538|NCT00654836|recurrent breast cancer
1329539|NCT00654836|stage III breast cancer
1329540|NCT00654836|stage IV breast cancer
1329541|NCT00654810|functional ability
1329542|NCT00654810|gait
1329543|NCT00654810|musculoskeletal disorder therapy
1329544|NCT00654810|peripheral blood vessel disorder
1329545|NCT00654797|Glucose
1329546|NCT00654797|Insulin
1329547|NCT00654797|computer
1329548|NCT00654797|critical care
1329549|NCT00654784|Duchenne Muscular Dystrophy
1329550|NCT00654784|DMD
1329551|NCT00654784|Duchenne
1329552|NCT00654771|protein/creatinine ratio
1329553|NCT00654771|clean catch urine
1329554|NCT00654771|catheterized urine
1329555|NCT00654758|cancer
1329556|NCT00654758|carcinoma
1329557|NCT00654758|chemotherapy
1329558|NCT00654758|monoclonal antibody therapy
1329559|NCT00654758|anti-angiogenesis
1329560|NCT00654745|blood pressure reduction
1329561|NCT00654732|Hodgkin Lymphoma
1329562|NCT00654732|Lymphoma
1329563|NCT00654732|Adriamycin
1329564|NCT00654732|Doxorubicin Hydrochloride
1329565|NCT00654732|Adriamycin PFS®
1329566|NCT00654732|Adriamycin RDF™
1329567|NCT00654732|Rituxan
1329568|NCT00654732|Rituximab
1329569|NCT00654732|Bleomycin
1329570|NCT00654732|Bleomycin sulfate
1329571|NCT00654732|Blenoxane®
1329572|NCT00654732|BLM
1329573|NCT00654732|Vinblastine
1329574|NCT00654732|Velban
1329575|NCT00654732|Dacarbazine
1329576|NCT00654732|DTIC
1329577|NCT00654732|DTIC-Dome®
1329578|NCT00654732|R-ABVD
1329579|NCT00654732|ABVD
1329580|NCT00654719|Heart failure
1329581|NCT00654719|cachexia
1329582|NCT00654706|Schizophrenia
1329583|NCT00654706|Cognition
1329584|NCT00654706|MATRICS Consensus Cognitive Battery
1329585|NCT00654693|NTX
1329586|NCT00654693|Nihon Kohden
1329587|NCT00654693|mobile monitoring
1329588|NCT00654693|monitoring
1329589|NCT00654693|nihon
1329590|NCT00654693|kohden
1329591|NCT00654693|monitoring device
1329592|NCT00654693|remote monitoring
1329593|NCT00654693|wireless
1329594|NCT00654680|Erectile Dysfunction
1329595|NCT00654680|Traumatic spinal cord injury
1329596|NCT00654680|Vardenafil
1329597|NCT00654667|Resveratrol
1329598|NCT00654667|Insulin Resistance
1329599|NCT00654667|Metabolic Syndrome
1329600|NCT00654667|Sirtuin 1
1329601|NCT00654667|IGF-1
1329602|NCT00654667|Satiety
1329603|NCT00654667|Leptin
1329604|NCT00654667|Adiponectin
1329605|NCT00654641|Surgical Wound Dehiscence
1329606|NCT00654641|Wound Infection
1329607|NCT00654641|Obesity
1329608|NCT00654641|Cesarean Delivery
1329609|NCT00654641|Wound Closure
1329610|NCT00654641|Negative Pressure wound closure
1329611|NCT00654615|unstable metaphyseal distal radius fractures
1329612|NCT00654615|randomized controlled trial
1329613|NCT00654615|surgical fixation
1329614|NCT00654615|volar plate
1329615|NCT00654615|intramedullary distal radius fixation system
1329616|NCT00654602|cholesterol
1329617|NCT00654602|low density lipoproteins
1329618|NCT00654602|dyslipidaemia
1329619|NCT00654602|Rosuvastatin
1329620|NCT00654602|Crestor
1329621|NCT00654589|Hematopoietic stem cell transplantation
1329622|NCT00654589|HCT
1329623|NCT00654589|iron overload
1329624|NCT00654589|chelators
1329625|NCT00654589|ICL670
1329626|NCT00654589|deferasirox
1329627|NCT00654589|serum ferritin
1329628|NCT00654589|LIC
1329629|NCT00654589|transfusional hemosiderosis
1329630|NCT00654589|blood transfusions
1329631|NCT00654589|adults
1329632|NCT00654589|iron chelation
1329633|NCT00654589|3-6 months
1329634|NCT00654589|allogeneic hematopoietic stem cell transplantation
1329635|NCT00654576|schizophrenia
1329636|NCT00654576|antipsychotic
1329637|NCT00654576|outcome
1329638|NCT00654576|psychosocial intervention
1329639|NCT00654563|Memory Disorders
1329640|NCT00654563|Memory loss
1329641|NCT00654563|Age Associated Memory Impairment
1329642|NCT00654550|Photorefractive keratectomy
1329643|NCT00654550|Re-epithelialization
1329644|NCT00654550|Nexagon
1329645|NCT00654550|PRK
1329646|NCT00654550|Coda
1329647|NCT00654537|Cholesterol
1329648|NCT00654537|hypercholesterolemia
1329649|NCT00654537|low density lipoproteins
1329650|NCT00654524|Endometriosis
1329651|NCT00654524|Recurrence
1329652|NCT00654524|Pregnancy Rate
1329653|NCT00654524|Laparoscopy
1329654|NCT00654524|Gonadotropin-Releasing Hormone
1329655|NCT00654511|Dexmedetomidine,
1329656|NCT00654511|fentanyl,
1329657|NCT00654511|tonsillectomy
1329658|NCT00654511|and adenoidectomy,
1329659|NCT00654485|Cholesterol
1329660|NCT00654485|hypercholesterolemia
1329661|NCT00654485|low density lipoproteins
1329662|NCT00654485|metabolic syndrome
1329663|NCT00654485|Rosuvastatin
1329664|NCT00654472|magnetic resonance imaging, mitral valve area
1329665|NCT00654446|Cholesterol
1329666|NCT00654446|low density lipoproteins
1329667|NCT00654446|dyslipidaemia
1329668|NCT00654446|Rosuvastatin
1329669|NCT00654446|Crestor
1329670|NCT00654446|Simvastatin
1329671|NCT00654446|Zocor
1329672|NCT00654446|Renal
1329673|NCT00654446|kidney
1329674|NCT00654433|Hurler Syndrome
1329675|NCT00654433|MPS I
1329676|NCT00654433|Hurler-Scheie Syndrome
1329677|NCT00654433|Hunter Syndrome
1329678|NCT00654433|MPS II
1329679|NCT00654433|Sanfilippo Syndrome
1329680|NCT00654433|MPS III
1329681|NCT00654433|Maroteaux-Lamy Syndrome
1329682|NCT00654433|MPS VI
1329683|NCT00654433|Krabbe Disease
1329684|NCT00654433|Globoid Leukodystrophy
1329685|NCT00654433|Metachromatic Leukodystrophy
1329686|NCT00654433|MLD
1329687|NCT00654433|Adrenoleukodystrophy
1329688|NCT00654433|ALD
1329689|NCT00654433|Adrenomyeloneuropathy
1329690|NCT00654433|AMN
1329691|NCT00654433|Sandhoff Disease
1329692|NCT00654433|Tay Sachs Disease
1329693|NCT00654433|Pelizaeus Merzbacher
1329694|NCT00654433|PMD
1329695|NCT00654433|Niemann-Pick Disease A
1329696|NCT00654433|Niemann-Pick Disease B
1329697|NCT00654433|Alpha-mannosidosis
1329698|NCT00654433|Inherited metabolic diseases
1329699|NCT00654433|Inborn errors of metabolism
1329700|NCT00654433|Lysosomal storage diseases
1329701|NCT00654433|Peroxisomal storage diseases
1329702|NCT00654433|Hematopoietic stem cell transplantation
1329703|NCT00654433|Umbilical cord blood transplantation
1329704|NCT00654433|Mucopolysaccharidosis
1329705|NCT00654433|Mucopolysaccharidosis I
1329706|NCT00654433|Mucopolysaccharidosis II
1329707|NCT00654433|Mucopolysaccharidosis III
1329708|NCT00654433|Mucopolysaccharidosis VI
1329709|NCT00654433|I Cell disease
1329710|NCT00654433|Fucosidosis
1329711|NCT00654433|GM1 Gangliosidosis
1329712|NCT00654433|Canavan Disease
1329713|NCT00654407|Cholesterol
1329714|NCT00654407|hypercholesterolemia
1329715|NCT00654407|Coronary Heart disease
1329716|NCT00654407|low density lipoproteins
1329717|NCT00654407|Rosuvastatin
1329718|NCT00654407|Atorvastatin
1329719|NCT00654407|simvastatin
1329720|NCT00654394|Cholesterol
1329721|NCT00654394|Carotid Artery Stenosis
1329722|NCT00654394|Hypercholesterolemia
1329723|NCT00654394|Rosuvastatin
1329724|NCT00654394|Crestor
1329725|NCT00654368|Amgen
1329726|NCT00654355|atopic dermatitis
1329727|NCT00654355|eczema
1329728|NCT00654342|Sentinel lymph node-colon cancer
1329729|NCT00654329|Dexmedetomidine, transmucosal, myringotomy,
1329730|NCT00654316|TB
1329731|NCT00654316|Tuberculosis
1329732|NCT00654316|MVA85A
1329733|NCT00654316|Vaccine
1329734|NCT00654316|BCG
1329735|NCT00654303|Cholesterol
1329736|NCT00654303|Hypercholesterolaemia
1329737|NCT00654303|Statins
1329738|NCT00654290|Atrial fibrillation
1329739|NCT00654290|coronary bypass
1329740|NCT00654290|Amiodarone
1329741|NCT00654290|Propranolol
1329742|NCT00654290|Coronary Artery Bypass Graft (CABG)
1329743|NCT00654277|bioequivalence
1329744|NCT00654277|Ondansetron ODT
1329745|NCT00654277|Fasting
1329746|NCT00654277|To determine bioequivalence under fasting conditions
1329747|NCT00654251|Spinocerebellar ataxia
1329748|NCT00654251|Machado-Joseph disease
1329749|NCT00654251|Gait monitoring
1329750|NCT00654251|Functional vision assessment
1329751|NCT00654238|Thyroid Cancer
1329752|NCT00654238|Anaplastic
1329753|NCT00654238|Medullary
1329754|NCT00654238|sorafenib
1329755|NCT00654225|Cholesterol
1329756|NCT00654225|low density lipoproteins
1329757|NCT00654225|dyslipidaemia
1329758|NCT00654225|Rosuvastatin
1329759|NCT00654225|Crestor
1329760|NCT00654225|Atorvastatin
1329761|NCT00654225|Lipitor
1329762|NCT00654225|South Asian
1329763|NCT00654212|stenting, laparoscopic surgery, colon cancer
1329764|NCT00654199|CABG
1329765|NCT00654199|Ventricular Asynchrony
1329766|NCT00654199|Normal Sinus Rhythm
1329767|NCT00654186|Androgen Independent Prostate Cancer (AIPC)
1329768|NCT00654186|Chemo naive
1329769|NCT00654173|Cholesterol
1329770|NCT00654173|low density lipoproteins
1329771|NCT00654173|dyslipidaemia
1329772|NCT00654173|Rosuvastatin
1329773|NCT00654173|Crestor
1329774|NCT00654173|Atorvastatin
1329775|NCT00654173|Lipitor
1329776|NCT00654173|Zocor
1329777|NCT00654173|simvastatin
1329778|NCT00654160|stage IIIB anal cancer
1329779|NCT00654160|stage IV anal cancer
1329780|NCT00654160|recurrent anal cancer
1329781|NCT00654160|carcinoma of the appendix
1329782|NCT00654160|stage III colon cancer
1329783|NCT00654160|stage IV colon cancer
1329784|NCT00654160|recurrent colon cancer
1329785|NCT00654160|stage III rectal cancer
1329786|NCT00654160|stage IV rectal cancer
1329787|NCT00654160|recurrent rectal cancer
1329788|NCT00654160|stage III esophageal cancer
1329789|NCT00654160|stage IV esophageal cancer
1329790|NCT00654160|recurrent esophageal cancer
1329791|NCT00654160|recurrent extrahepatic bile duct cancer
1329792|NCT00654160|unresectable extrahepatic bile duct cancer
1329793|NCT00654160|unresectable gallbladder cancer
1329794|NCT00654160|recurrent gallbladder cancer
1329795|NCT00654160|stage III gastric cancer
1329796|NCT00654160|stage IV gastric cancer
1329797|NCT00654160|recurrent gastric cancer
1329798|NCT00654160|metastatic gastrointestinal carcinoid tumor
1329799|NCT00654160|recurrent gastrointestinal carcinoid tumor
1329800|NCT00654160|regional gastrointestinal carcinoid tumor
1329801|NCT00654160|gastrointestinal stromal tumor
1329802|NCT00654160|advanced adult primary liver cancer
1329803|NCT00654160|localized unresectable adult primary liver cancer
1329804|NCT00654160|recurrent adult primary liver cancer
1329805|NCT00654160|stage II pancreatic cancer
1329806|NCT00654160|stage III pancreatic cancer
1329807|NCT00654160|stage IV pancreatic cancer
1329808|NCT00654160|recurrent pancreatic cancer
1329809|NCT00654160|recurrent small intestine cancer
1329810|NCT00654160|small intestine adenocarcinoma
1329811|NCT00654160|small intestine leiomyosarcoma
1329812|NCT00654160|small intestine lymphoma
1329813|NCT00654147|HIV
1329814|NCT00654147|antiretroviral therapy naive
1329815|NCT00654147|Integrase inhibitor
1329816|NCT00654147|HIV/AIDS
1329817|NCT00654147|treatment naïve
1329818|NCT00654121|prevention
1329819|NCT00654108|Escherichia coli, cholera, diarrhea, vaccine
1329820|NCT00654069|Pain
1329821|NCT00654056|Type 2 diabetes
1329822|NCT00654056|Severe insulin resistance
1329823|NCT00654043|Bioequivalence
1329824|NCT00654043|Torsemide Tablets
1329825|NCT00654043|fed
1329826|NCT00654043|To determine bioequivalence under fed conditions.
1329827|NCT00654030|Lung Cancer Vaccine
1329828|NCT00654030|Early Stage Lung Cancer
1329829|NCT00654030|Lung Cancer
1329830|NCT00654004|trifunctional
1329831|NCT00654004|protein
1329832|NCT00654004|deficiency
1329833|NCT00654004|TFP
1329834|NCT00654004|weight
1329835|NCT00654004|regulation
1329836|NCT00653991|HIV/AIDS Prevention
1329837|NCT00653991|Men Who Have Sex With Men (MSM)
1329838|NCT00653991|Risky Sexual Behavior
1329839|NCT00653991|Socially Optimized Learning in a Virtual Environment (SOLVE)
1329840|NCT00653991|HIV Seronegativity
1329841|NCT00653978|ERCP
1329842|NCT00653978|cholangiocarcinoma
1329843|NCT00653978|hilar stricture
1329844|NCT00653965|Cholesterol
1329845|NCT00653965|low density lipoproteins
1329846|NCT00653965|dyslipidaemia
1329847|NCT00653965|Rosuvastatin
1329848|NCT00653965|Crestor
1329849|NCT00653965|Atorvastatin
1329850|NCT00653965|Lipitor
1329851|NCT00653965|Hispanic
1329852|NCT00653952|Paclitaxel HCl
1329853|NCT00653952|CAELYX
1329854|NCT00653952|DOXIL
1329855|NCT00653952|Ovarian Carcinoma
1329856|NCT00653952|Doxorubicin HCl
1329857|NCT00653939|non-small cell lung cancer
1329858|NCT00653939|non-small cell lung carcinoma
1329859|NCT00653939|neoplasms, lung
1329860|NCT00653939|lung cancer
1329861|NCT00653939|tumors
1329862|NCT00653939|NSCLC
1329863|NCT00653926|Postoperative pain
1329864|NCT00653926|Local infiltration analgesia
1329865|NCT00653926|Knee arthroplasty
1329866|NCT00653926|Postoperative pain management following unicompartmental knee arthroplasty
1329867|NCT00653900|Verify now
1329868|NCT00653900|platelet function
1329869|NCT00653900|platelet function testing
1329870|NCT00653900|bleeding risk
1329871|NCT00653900|periprocedural bleeding
1329872|NCT00653900|clopidogrel
1329873|NCT00653900|Our initial goal is to establish if a certain degree of
1329874|NCT00653900|platelet function abnormality can predict a higher bleeding
1329875|NCT00653900|or higher transfusions.
1329876|NCT00653887|Biofeedback
1329877|NCT00653887|anal sphincter
1329878|NCT00653887|cortical excitability
1329879|NCT00653887|magnetic stimulation
1329880|NCT00653887|incontinence
1329881|NCT00653887|constipation
1329882|NCT00653874|jaundice
1329883|NCT00653874|neonates
1329884|NCT00653874|transcutaneous bilirubinometry
1329885|NCT00653874|clinical assessment of bilirubin
1329886|NCT00653861|Aesthetic correction
1329887|NCT00653848|Adjuvant treatment, intermediate and high risk, radical radiotherapy
1329888|NCT00653822|Amevive
1329889|NCT00653822|alefacept
1329890|NCT00653822|pharmacokinetics
1329891|NCT00653822|Japanese
1329892|NCT00653783|Parkinson disease
1329893|NCT00653783|Multiple System Atrophy
1329894|NCT00653783|MSA
1329895|NCT00653783|Progressive Supranuclear Palsy
1329896|NCT00653783|PSP
1329897|NCT00653783|observational
1329898|NCT00653783|biomarker
1329899|NCT00653757|stage I prostate cancer
1329900|NCT00653757|stage II prostate cancer
1329901|NCT00653757|stage III prostate cancer
1329902|NCT00653757|stage IV prostate cancer
1329903|NCT00653744|Cholesterol
1329904|NCT00653744|low density lipoproteins
1329905|NCT00653744|dyslipidaemia
1329906|NCT00653744|Rosuvastatin
1329907|NCT00653744|Crestor
1329908|NCT00653744|Atorvastatin
1329909|NCT00653744|Lipitor
1329910|NCT00653744|African American
1329911|NCT00653731|dementia
1329912|NCT00653731|snoezelen
1329913|NCT00653731|structured reminiscence therapy
1329914|NCT00653731|10-minutes activation
1329915|NCT00653731|apathy
1329916|NCT00653718|Pain
1329917|NCT00653718|Characterize musculoskeletal pain
1329918|NCT00653718|Breast cancer patients treated with aromatase inhibitors
1329919|NCT00653705|Probiotics
1329920|NCT00653705|Children
1329921|NCT00653705|Child Care Center
1329922|NCT00653705|Nutrition
1329923|NCT00653705|Health promotion
1329924|NCT00653692|Substance abuse
1329925|NCT00653692|fetal development
1329926|NCT00653692|vagal tone
1329927|NCT00653679|exercise
1329928|NCT00653679|muscle protein signalling
1329929|NCT00653679|protein synthesis
1329930|NCT00653666|CPT1A
1329931|NCT00653666|steatosis
1329932|NCT00653666|deficiency
1329933|NCT00653666|metabolic
1329934|NCT00653666|response
1329935|NCT00653666|fasting
1329936|NCT00653653|pharmacogenetics
1329937|NCT00653653|pharmacoeconomics
1329938|NCT00653653|adverse events
1329939|NCT00653653|drug metabolism
1329940|NCT00653640|rehabilitation
1329941|NCT00653640|head injury
1329942|NCT00653640|3 months post injury
1329943|NCT00653640|require manual assistance or walking aids to walk
1329944|NCT00653640|very slow walking speed
1329945|NCT00653640|able to follow two step commands
1329946|NCT00653614|Oral contraception
1329947|NCT00653601|GPI
1329948|NCT00653601|glycoprotein IIb/IIIa inhibitor
1329949|NCT00653601|Aggrastat
1329950|NCT00653601|Tirofiban
1329951|NCT00653601|Verify now
1329952|NCT00653601|platelet function testing
1329953|NCT00653601|bridge therapy
1329954|NCT00653588|Cholesterol
1329955|NCT00653588|low density lipoproteins
1329956|NCT00653588|Hypercholesterolemia
1329957|NCT00653588|Coronary Heart Disease
1329958|NCT00653588|Rosuvastatin
1329959|NCT00653588|Crestor
1329960|NCT00653588|Atorvastatin
1329961|NCT00653588|Lipitor
1329962|NCT00653575|Sexual Behavior
1329963|NCT00653575|HIV
1329964|NCT00653575|Sexually Transmitted Diseases
1329965|NCT00653562|polysomnography
1329966|NCT00653562|zolpidem
1329967|NCT00653562|Sleep disorders
1329968|NCT00653562|adolescent
1329969|NCT00653549|Bioequivalence
1329970|NCT00653549|Torsemide Tablets
1329971|NCT00653549|fasting
1329972|NCT00653536|stroke
1329973|NCT00653536|neuroflo
1329974|NCT00653536|device
1329975|NCT00653536|failure to recanalize
1329976|NCT00653510|Type 2 diabetes
1329977|NCT00653510|Dysregulation
1329978|NCT00653510|Metabolism
1329979|NCT00653510|Cardiac output
1329980|NCT00653497|Osteoarthritis
1329981|NCT00653484|colon cancer
1329982|NCT00653484|rectal cancer
1329983|NCT00653484|obesity
1329984|NCT00653471|obesity
1329985|NCT00653471|osa
1329986|NCT00653471|capnography
1329987|NCT00653471|general anesthesia
1329988|NCT00653458|bioequivalence
1329989|NCT00653458|Ondansetron ODT
1329990|NCT00653458|fed
1329991|NCT00653458|To determine bioequivalence under fed conditions
1329992|NCT00653445|Low density lipoproteins
1329993|NCT00653445|Hypercholesterolemia
1329994|NCT00653445|Coronary Heart Disease
1329995|NCT00653445|Rosuvastatin
1329996|NCT00653445|Crestor
1329997|NCT00653445|Ezetimibe
1329998|NCT00653432|Treatment
1329999|NCT00653432|Osteoarthritis
1330000|NCT00653419|bioequivalence
1330001|NCT00653419|buspirone HCl
1330002|NCT00653419|fasting
1330003|NCT00653406|Schizophrenia
1330004|NCT00653406|Risperidone
1330005|NCT00653406|Intramuscular injection
1330006|NCT00653406|Pharmacokinetics
1330007|NCT00653393|bioequivalence, single- dose, fasting
1330008|NCT00653380|bioequivalence
1330009|NCT00653380|doxycycline monohydrate
1330010|NCT00653380|fasting
1330011|NCT00653367|Thoracotomy
1330012|NCT00653367|Nerve section
1330013|NCT00653367|QST
1330014|NCT00653367|Quantitative Sensory Test
1330015|NCT00653367|Muscle sparing Posterolateral thoracotomy
1330016|NCT00653367|Chest
1330017|NCT00653367|Wall
1330018|NCT00653367|Surgical
1330019|NCT00653367|Incision
1330020|NCT00653367|Tumors or cancer of the lung
1330021|NCT00653354|hallux valgus
1330022|NCT00653341|insulin naive
1330023|NCT00653328|recurrent ovarian epithelial cancer
1330024|NCT00653328|fallopian tube cancer
1330025|NCT00653328|peritoneal cavity cancer
1330026|NCT00653315|Bioequivalence, Tramadol APAP, fasting
1330027|NCT00653263|methamphetamine
1330028|NCT00653263|drug abuse
1330029|NCT00653263|withdrawal
1330030|NCT00653250|stage I non-small cell lung cancer
1330031|NCT00653250|stage II non-small cell lung cancer
1330032|NCT00653250|stage IIIA non-small cell lung cancer
1330033|NCT00653224|levocetirizine
1330034|NCT00653224|Xyzal
1330035|NCT00653224|Seasonal Allergic Rhinitis
1330036|NCT00653224|total symptom score
1330037|NCT00653224|quality of life
1330038|NCT00653198|Rotavirus severe gastroenteritis (RV SGE)
1330039|NCT00653185|Glucose Metabolism Disorder
1330040|NCT00653185|Dysmetabolic Syndrome
1330041|NCT00653185|Type II Diabetes
1330042|NCT00653185|Diabetes Mellitus, Lipoatrophic
1330043|NCT00653185|Dyslipidemia
1330044|NCT00653185|Hyperglycemia
1330045|NCT00653172|CAP
1330046|NCT00653172|community acquired pneumonia
1330047|NCT00653159|Intrauterine device, contraception, unplanned pregnancy
1330048|NCT00653146|cervical cancer
1330049|NCT00653146|psychosocial effects of cancer and its treatment
1330050|NCT00653146|human papilloma virus infection
1330051|NCT00653146|atypical squamous cells of undetermined significance
1330052|NCT00653146|low-grade squamous intraepithelial lesion
1330053|NCT00653133|ultrasonography
1330054|NCT00653133|peripheral nerve block
1330055|NCT00653133|peripheral nerve stimulation
1330056|NCT00653120|Bioequivalence, Propranolol ER capsules, fasting
1330057|NCT00653107|Palliation
1330058|NCT00653107|Cancer oesophagus
1330059|NCT00653107|Stent
1330060|NCT00653107|Brachytherapy
1330061|NCT00653107|Randomized
1330062|NCT00653094|crohn
1330063|NCT00653094|fistula
1330064|NCT00653094|surgery
1330065|NCT00653094|fibrin glue
1330066|NCT00653094|seton drainage
1330067|NCT00653081|Shoulder pain
1330068|NCT00653081|Supervised Exercises
1330069|NCT00653081|Radial Shock Wave Therapy
1330070|NCT00653055|Bioequivalence
1330071|NCT00653055|Cabergoline
1330072|NCT00653055|Fasting
1330073|NCT00653042|Myocardial Ischemia
1330074|NCT00653042|kidney failure
1330075|NCT00653042|CABG
1330076|NCT00653042|cardiopulmonary bypass (CPB) pump
1330077|NCT00653042|Coronary Artery Bypass Surgery
1330078|NCT00653042|heart surgery
1330079|NCT00653042|nesiritide
1330080|NCT00653042|Coronary Heart Disease
1330081|NCT00653029|Post concussion syndrome
1330082|NCT00653029|Mild traumatic brain injury
1330083|NCT00653029|Effort
1330084|NCT00653029|fmri
1330085|NCT00653016|Contraception
1330086|NCT00653016|norelgestromin
1330087|NCT00653016|ethinyl estradiol
1330088|NCT00653016|transdermal contraceptive patch
1330089|NCT00653016|EVRA
1330090|NCT00653016|ORTHO EVRA
1330091|NCT00653003|Bioequivalence, Leflunomide, fed
1330092|NCT00652977|sphincter tears
1330093|NCT00652977|Ritgen maneuver
1330094|NCT00652977|perineal tears
1330095|NCT00652977|prevention
1330096|NCT00652977|delivery
1330097|NCT00652964|sleep apnea, PHOX2B, hypoventilation, polysomnography
1330098|NCT00652938|Co-administration
1330099|NCT00652938|HPV vaccine
1330100|NCT00652938|Cervical cancer
1330101|NCT00652925|arthritis
1330102|NCT00652925|juvenile
1330103|NCT00652912|bioequivalence, Clonazepam ODT , fasting
1330104|NCT00652899|recurrent ovarian epithelial cancer
1330105|NCT00652899|recurrent ovarian germ cell tumor
1330106|NCT00652899|stage IV ovarian epithelial cancer
1330107|NCT00652899|stage IV ovarian germ cell tumor
1330108|NCT00652899|fallopian tube cancer
1330109|NCT00652899|peritoneal cavity cancer
1330110|NCT00652886|Bioequivalence, Oxandrolone,fasting
1330111|NCT00652873|Bioequivalence
1330112|NCT00652873|Cabergoline
1330113|NCT00652873|Fed
1330114|NCT00652860|lung metastases
1330115|NCT00652860|stage III adult soft tissue sarcoma
1330116|NCT00652834|Renal transplant recipients
1330117|NCT00652834|Gastrointestinal findings in small bowel capsule endoscopy
1330118|NCT00652834|Mycophenolic acid
1330119|NCT00652834|Mycophenolate Mofetil
1330120|NCT00652834|Mycophenolate Sodium
1330121|NCT00652821|bioequivalence, single-dose, fed
1330122|NCT00652808|knee, OA patients
1330123|NCT00652795|bioequivalence
1330124|NCT00652795|doxycycline monohydrate
1330125|NCT00652795|fasting
1330126|NCT00652769|Lung
1330127|NCT00652769|Cancer
1330128|NCT00652769|Staging
1330129|NCT00652769|Endobronchial
1330130|NCT00652769|Ultrasound
1330131|NCT00652769|Endoscopic
1330132|NCT00652756|Respiration, Artificial
1330133|NCT00652756|Transportation of Patients
1330134|NCT00652756|Intubation, Intratracheal
1330135|NCT00652756|Tracheostomy
1330136|NCT00652743|immunogenicity
1330137|NCT00652743|safety
1330138|NCT00652743|GSK pandemic candidate vaccine
1330139|NCT00652730|bioequivalence
1330140|NCT00652730|buspirone HCl
1330141|NCT00652730|fed
1330142|NCT00652704|Bioequivalence
1330143|NCT00652704|Doxycycline Monohydrate
1330144|NCT00652704|Fed
1330145|NCT00652691|peritoneal cavity cancer
1330146|NCT00652691|ovarian clear cell tumor with proliferating activity
1330147|NCT00652691|ovarian endometrioid adenocarcinoma
1330148|NCT00652691|ovarian mixed epithelial carcinoma
1330149|NCT00652691|recurrent ovarian epithelial cancer
1330150|NCT00652691|ovarian mucinous cystadenocarcinoma
1330151|NCT00652691|ovarian serous cystadenocarcinoma
1330152|NCT00652691|ovarian undifferentiated adenocarcinoma
1330153|NCT00652678|Breast cancer
1330154|NCT00652678|Radiation effects
1330155|NCT00652665|Bioequivalence, single-dose, fasting
1330156|NCT00652652|Congestive Heart Failure (CHF)
1330157|NCT00652652|Heart Failure
1330158|NCT00652652|Chronic Heart Failure
1330159|NCT00652652|Dyspnea
1330160|NCT00652652|nesiritide
1330161|NCT00652652|Natrecor
1330162|NCT00652639|bioequivalence, Clonazepam tablets, fasting
1330163|NCT00652626|MDS
1330164|NCT00652626|AML
1330165|NCT00652626|Solid Tumors
1330166|NCT00652626|Azacitidine
1330167|NCT00652626|PK
1330168|NCT00652626|Pharmacokinetics
1330169|NCT00652626|Renal Impairment
1330170|NCT00652626|Multiple Myeloma
1330171|NCT00652626|Non-Hodgkin's Lymphoma
1330172|NCT00652626|Hodgkin's Disease
1330173|NCT00652613|3DCRT
1330174|NCT00652613|IMRT
1330175|NCT00652613|HNSCC
1330176|NCT00652613|Quality of life
1330177|NCT00652613|Major salivary gland sparing
1330178|NCT00652613|Pattern of local and loco-regional recurrence
1330179|NCT00652613|Disease Free Survival (DFS) & Overall Survival (OAS)
1330180|NCT00652613|Dose reduction to normal structures with IMRT
1330181|NCT00652600|Bioequivalence, Propranolol ER capsules, fed
1330182|NCT00652587|hepatocellular carcinoma
1330183|NCT00652587|hepatectomy
1330184|NCT00652587|chemoembolization
1330185|NCT00652587|randomized controlled trial
1330186|NCT00652587|prognosis
1330187|NCT00652574|Malignant Pleural Mesothelioma
1330188|NCT00652574|Dasatinib
1330189|NCT00652574|BMS-354825
1330190|NCT00652574|Sprycel
1330191|NCT00652574|MPM
1330192|NCT00652548|Clavicle
1330193|NCT00652548|Fracture
1330194|NCT00652548|Ultrasound
1330195|NCT00652548|Radiation
1330196|NCT00652522|AF ablation
1330197|NCT00652522|Pulmonary vein isolation(PVI)
1330198|NCT00652522|reduced LV ejection fraction
1330199|NCT00652522|symptomatic atrial fibrillation
1330200|NCT00652522|persistent AF
1330201|NCT00652470|infants
1330202|NCT00652470|Hydrocephalus
1330203|NCT00652470|Cerebrospinal Fluid Shunt
1330204|NCT00652470|Ventriculostomy
1330205|NCT00652470|neurosurgery
1330206|NCT00652418|Magnevist
1330207|NCT00652418|Magnetic Resonance Angiography
1330208|NCT00652418|Meglumine gadopentetate
1330209|NCT00652418|Determination of effective dose in MRA
1330210|NCT00652405|cephalic phase reflex
1330211|NCT00652405|gene expression
1330212|NCT00652405|inflammation
1330213|NCT00652405|adiponectin
1330214|NCT00652405|pancreatic polypeptide
1330215|NCT00652392|asthma
1330216|NCT00652392|adolescents
1330217|NCT00652392|adults
1330218|NCT00652392|Symbicort
1330219|NCT00652392|budesonide/formoterol
1330220|NCT00652392|budesonide
1330221|NCT00652379|Acromegaly
1330222|NCT00652379|Insulin sensitivity
1330223|NCT00652379|Glucose tolerance
1330224|NCT00652379|Body composition
1330225|NCT00652379|Growth Hormone
1330226|NCT00652353|Clinical decision rule
1330227|NCT00652353|Ottawa Ankle Rule
1330228|NCT00652353|Ottawa Foot Rule
1330229|NCT00652353|Ankle
1330230|NCT00652353|Trauma
1330231|NCT00652353|Education
1330232|NCT00652353|Foot Trauma
1330233|NCT00652314|Hemostatic products
1330234|NCT00652314|Surgical hemostasis
1330235|NCT00652314|Thrombi-gel
1330236|NCT00652314|Gelatin Sponge
1330237|NCT00652314|Time to hemostasis
1330238|NCT00652288|Type I Diabetes Mellitus
1330239|NCT00652275|Malaria
1330240|NCT00652275|vaccine
1330241|NCT00652275|Merozoite surface Antigene
1330242|NCT00652275|Mali
1330243|NCT00652275|Children
1330244|NCT00652262|Vardenafil
1330245|NCT00652262|PDE5 inhibitor
1330246|NCT00652262|Erectile dysfunction
1330247|NCT00652262|Spinal cord injury
1330248|NCT00652249|Hydrocephalus
1330249|NCT00652249|shunt dysfunction
1330250|NCT00652249|shunt flow
1330251|NCT00652236|Low back pain
1330252|NCT00652236|Economics
1330253|NCT00652236|Cost-effectiveness
1330254|NCT00652210|Bladder cancer
1330255|NCT00652210|prostate cancer
1330256|NCT00652210|multiphoton microscopy
1330257|NCT00652197|Hydrocephalus
1330258|NCT00652197|shunt dysfunction
1330259|NCT00652197|shunt flow
1330260|NCT00652184|antiviral
1330261|NCT00652184|herpes zoster
1330262|NCT00652184|postherpetic neuralgia
1330263|NCT00652184|varicella zoster virus
1330264|NCT00652184|shingles
1330265|NCT00652171|Treatment
1330266|NCT00652171|Augmentation
1330267|NCT00652171|Resistant depression
1330268|NCT00652171|Lamotrigine
1330269|NCT00652145|ulcerative colitis
1330270|NCT00652145|inflammatory bowel disease
1330271|NCT00652132|ototoxicity
1330272|NCT00652132|childhood hepatoblastoma
1330273|NCT00652132|stage I childhood liver cancer
1330274|NCT00652132|stage II childhood liver cancer
1330275|NCT00652132|stage III childhood liver cancer
1330276|NCT00652119|Ovarian Cancer
1330277|NCT00652119|Peritoneal Cancer
1330278|NCT00652119|Fallopian Tube Cancer
1330279|NCT00652119|Carcinoma of Mullerian Origin
1330280|NCT00652119|Paclitaxel
1330281|NCT00652119|Taxol
1330282|NCT00652119|Carboplatin
1330283|NCT00652119|Paraplatin®
1330284|NCT00652119|Avastin
1330285|NCT00652119|Bevacizumab
1330286|NCT00652119|Anti-VEGF monoclonal antibody
1330287|NCT00652119|rhuMAb-VEGF
1330288|NCT00652067|Mycobacterium avium-intracellulare
1330289|NCT00652041|Multiple Myeloma
1330290|NCT00652041|Relapsed
1330291|NCT00652041|Refractary
1330292|NCT00652028|Pharmacokinetics
1330293|NCT00652028|Pharmacodynamics
1330294|NCT00652028|Escalating dose
1330295|NCT00652028|Dexmedotimidine
1330296|NCT00652028|Intubated
1330297|NCT00652028|Mechanically ventilated
1330298|NCT00652028|Pediatrics
1330299|NCT00652015|in-stent-thrombosis
1330300|NCT00652015|CD39
1330301|NCT00652015|CD73
1330302|NCT00652015|EPC
1330303|NCT00652002|Asthma
1330304|NCT00652002|Symbicort
1330305|NCT00652002|budesonide/formoterol
1330306|NCT00652002|budesonide
1330307|NCT00652002|formoterol
1330308|NCT00651989|optical coherence tomography
1330309|NCT00651989|spectral domain
1330310|NCT00651989|time domain
1330311|NCT00651976|stage IA breast cancer
1330312|NCT00651976|stage IB breast cancer
1330313|NCT00651976|stage II breast cancer
1330314|NCT00651976|stage III breast cancer
1330315|NCT00651976|HER2-negative breast cancer
1330316|NCT00651976|estrogen receptor-positive breast cancer
1330317|NCT00651950|Hydrocephalus
1330318|NCT00651950|shunt dysfunction
1330319|NCT00651950|shunt flow
1330320|NCT00651937|Multiple Myeloma
1330321|NCT00651937|Primary Amyloidosis
1330322|NCT00651937|Cytokine Modulation
1330323|NCT00651937|Melphalan
1330324|NCT00651937|Alkeran
1330325|NCT00651937|Transplant Induced Symptoms
1330326|NCT00651937|Stem Cell Infusion
1330327|NCT00651937|Autologous stem cell transplant
1330328|NCT00651937|ASCT
1330329|NCT00651937|Granulocyte-colony stimulating factor
1330330|NCT00651937|G-CSF
1330331|NCT00651937|Apheresis
1330332|NCT00651924|chronic pain
1330333|NCT00651924|IVR
1330334|NCT00651924|cognitive-behavior therapy
1330335|NCT00651898|abdominal surgery
1330336|NCT00651898|hypothermia
1330337|NCT00651898|circulating water mattress
1330338|NCT00651885|UT-15C
1330339|NCT00651885|Peripheral Vascular Disease
1330340|NCT00651885|Treprostinil
1330341|NCT00651872|Posttraumatic Stress Disorder
1330342|NCT00651872|Functional Impairment
1330343|NCT00651872|Veterans
1330344|NCT00651872|Military Personnel
1330345|NCT00651846|Contraception
1330346|NCT00651846|Hemostasis
1330347|NCT00651846|Blood Coagulation
1330348|NCT00651820|wound healing
1330349|NCT00651820|scarring
1330350|NCT00651820|collagenase
1330351|NCT00651820|Santyl
1330352|NCT00651794|Neonatal Resuscitation
1330353|NCT00651794|Patient Care Team
1330354|NCT00651794|Medical Errors
1330355|NCT00651781|Acute Myeloid Leukemia
1330356|NCT00651781|Relapsed
1330357|NCT00651781|Refractory
1330358|NCT00651768|asthma
1330359|NCT00651768|adults
1330360|NCT00651768|adolescents
1330361|NCT00651768|safety
1330362|NCT00651768|Symbicort
1330363|NCT00651768|budesonide/formoterol
1330364|NCT00651768|budesonide
1330365|NCT00651755|Non-Hodgkin's Lymphoma
1330366|NCT00651755|Lymphoma
1330367|NCT00651755|Nausea
1330368|NCT00651755|Cyclophosphamide
1330369|NCT00651755|Cytoxan
1330370|NCT00651755|Neosar
1330371|NCT00651755|Doxorubicin
1330372|NCT00651755|AD
1330373|NCT00651755|Hydroxydaunomycin hydrochloride
1330374|NCT00651755|Vincristine
1330375|NCT00651755|Prednisone
1330376|NCT00651755|Rituximab
1330377|NCT00651755|Rituxan
1330378|NCT00651755|Aprepitant
1330379|NCT00651755|Emend
1330380|NCT00651755|L754030
1330381|NCT00651755|MK869
1330382|NCT00651755|Drug Metabolism
1330383|NCT00651755|CHOP
1330384|NCT00651755|R-CHOP
1330385|NCT00651755|NHL
1330487|NCT00651677|hand assisted laparoscopy
1330488|NCT00651677|rectal cancer
1330489|NCT00651677|short term outcomes
1330490|NCT00651677|straight laparoscopy
1330491|NCT00651651|Asthma
1330492|NCT00651651|Symbicort
1330493|NCT00651651|budesonide/formoterol
1330494|NCT00651651|budesonide
1330495|NCT00651651|formoterol
1330496|NCT00651638|PK and safety profile of ARQ 197
1330497|NCT00651625|arthrocentesis
1330498|NCT00651625|injections
1330499|NCT00651625|anesthesia
1330500|NCT00651625|biopsy
1330501|NCT00651625|aspiration
1330502|NCT00651625|syringe
1330503|NCT00651625|safety
1330504|NCT00651625|pain
1330505|NCT00651599|Vasomotor symptoms
1330506|NCT00651599|Vasomotor System
1330507|NCT00651573|Surgery
1330508|NCT00651573|Cardiopulmonary bypass
1330509|NCT00651573|Coronary artery bypass graft
1330510|NCT00651573|Valve procedure
1330511|NCT00651573|Hematocrit level
1330512|NCT00651573|Outcomes
1330513|NCT00651547|Asthma
1330514|NCT00651547|Symbicort
1330515|NCT00651547|budesonide/formoterol
1330516|NCT00651547|budesonide
1330517|NCT00651547|formoterol
1330518|NCT00651547|children
1330519|NCT00651534|Formulation Drug Study, healthy postmenopausal
1330520|NCT00651521|Angiographic CAD
1330521|NCT00651521|Chronic kidney disease
1330522|NCT00651521|Left ventricular dysfunction
1330523|NCT00651521|Body mass index
1330524|NCT00651521|Cardiovascular mortality
1330525|NCT00651521|Coronary angiography
1330526|NCT00651508|Patients with Advanced or Metastatic stage IIIB/IV Non-Small Cell Lung Cancer
1330527|NCT00651495|Decision aids
1330528|NCT00651495|Seniors
1330529|NCT00651495|Chronic disease management
1330530|NCT00651495|Advance directives
1330531|NCT00651469|Moderate Acne Vulgaris
1330532|NCT00651469|Acne
1330533|NCT00651443|galiximab
1330534|NCT00651443|Untreated NHL
1330535|NCT00651443|antibody
1330536|NCT00651443|open-label
1330537|NCT00651430|Balance
1330538|NCT00651430|Voluntary stepping
1330539|NCT00651430|function
1330540|NCT00651430|disability
1330541|NCT00651430|fear of falls
1330542|NCT00651430|Total Hip Arthroplasty
1330543|NCT00651417|Organic germanium
1330544|NCT00651417|fatigue
1330545|NCT00651417|radiation therapy
1330546|NCT00651417|breast cancer
1330547|NCT00651417|prostate cancer
1330548|NCT00651365|Advanced solid tumors
1330549|NCT00651365|Refractory solid tumor
1330550|NCT00651365|Antineoplastic protocol
1330551|NCT00651365|Drug therapy
1330552|NCT00651365|Pharmacokinetics
1330553|NCT00651365|Met inhibitor
1330554|NCT00651352|NRT
1330555|NCT00651352|Bioequivalence
1330556|NCT00651352|Nicotine
1330557|NCT00651339|Cerebral Palsy
1330558|NCT00651339|Balance
1330559|NCT00651339|Gait
1330560|NCT00651326|adenocarcinoma of the prostate
1330561|NCT00651326|stage I prostate cancer
1330562|NCT00651326|stage II prostate cancer
1330563|NCT00651326|stage III prostate cancer
1330564|NCT00651326|stage IV prostate cancer
1330565|NCT00651313|Dysmenorrhea
1330566|NCT00651313|Periods
1330567|NCT00651313|Menstrual
1330568|NCT00651313|Primary dysmenorrhea in women with recurrent dysmenorrhea
1330569|NCT00651261|adult acute basophilic leukemia
1330570|NCT00651261|adult acute eosinophilic leukemia
1330571|NCT00651261|adult acute lymphoblastic leukemia
1330572|NCT00651261|adult acute megakaryoblastic leukemia (M7)
1330573|NCT00651261|adult acute minimally differentiated myeloid leukemia (M0)
1330574|NCT00651261|adult acute monoblastic leukemia (M5a)
1330575|NCT00651261|adult acute monocytic leukemia (M5b)
1330576|NCT00651261|adult acute myeloblastic leukemia with maturation (M2)
1330577|NCT00651261|adult acute myeloblastic leukemia without maturation (M1)
1330578|NCT00651261|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1330579|NCT00651261|adult acute myeloid leukemia with inv(16)(p13;q22)
1330580|NCT00651261|adult acute myeloid leukemia with t(16;16)(p13;q22)
1330581|NCT00651261|adult acute myeloid leukemia with t(8;21)(q22;q22)
1330582|NCT00651261|adult acute myelomonocytic leukemia (M4)
1330583|NCT00651261|adult erythroleukemia (M6a)
1330584|NCT00651261|adult pure erythroid leukemia (M6b)
1330585|NCT00651261|untreated adult acute myeloid leukemia
1330586|NCT00651248|Saliva
1330587|NCT00651248|Oral health
1330588|NCT00651248|Aged
1330589|NCT00651209|Hepatitis B, chronic
1330590|NCT00651209|Telbivudine
1330591|NCT00651209|Tenofovir
1330592|NCT00651209|Roadmap Concept
1330593|NCT00651196|Type 1 diabetes
1330594|NCT00651196|bone
1330595|NCT00651170|Median block nerve
1330596|NCT00651170|Ultrasound
1330597|NCT00651131|post-surgical
1330598|NCT00651131|wound infection
1330599|NCT00651131|superficial
1330600|NCT00651131|deep
1330601|NCT00651131|surgical
1330602|NCT00651105|Diabetes
1330603|NCT00651105|Hyperglycemia
1330604|NCT00651105|Healthy
1330605|NCT00651105|Vildagliptin
1330606|NCT00651105|Adults
1330607|NCT00651092|turbinectomy
1330608|NCT00651079|GSK1247303,
1330609|NCT00651079|Integrase,
1330610|NCT00651079|First Time in Human
1330611|NCT00651066|HIV
1330612|NCT00651066|Tuberculosis
1330613|NCT00651066|Rifabutin
1330614|NCT00651066|Pharmacokinetics
1330615|NCT00651066|Vietnam
1330616|NCT00651040|Polymyositis
1330617|NCT00651040|Dermatomyositis
1330618|NCT00651040|Glucocorticoids
1330619|NCT00651040|Methotrexate
1330620|NCT00651001|fructose
1330621|NCT00651001|leptin
1330622|NCT00651001|metabolic syndrome
1330623|NCT00651001|blood pressure
1330624|NCT00651001|inflammation
1330625|NCT00651001|Relationship of fructose intake to leptin levels
1330626|NCT00651001|Relationship of fructose to metabolic syndrome
1330627|NCT00651001|Relationship of fructose to inflammation parameters
1330628|NCT00651001|Relationship of fructose to blood pressure
1330629|NCT00650988|Barrett's Esophagus
1330630|NCT00650988|Cryospray ablation
1330631|NCT00650988|High Grade Dysplasia
1330632|NCT00650988|Early Esophageal Cancers
1330633|NCT00650988|Esophageal Neoplasms
1330634|NCT00650988|Esophageal Intramucosal Cancer (IMCA)
1330635|NCT00650988|Esophageal Cancer limited to esophageal wall
1330636|NCT00650988|Barretts esophagus High Grade Dysplasia (HGD)
1330637|NCT00650975|STEMI
1330638|NCT00650975|Laser
1330639|NCT00650975|Thrombus
1330640|NCT00650975|Thrombectomy
1330641|NCT00650962|CPR
1330642|NCT00650962|Preshock CPR
1330643|NCT00650962|OHCA
1330644|NCT00650962|EMS
1330645|NCT00650949|Glioblastoma multiforme
1330646|NCT00650949|Glioma
1330647|NCT00650949|Phase Ib/II
1330648|NCT00650949|CYT997
1330649|NCT00650936|Atrial
1330650|NCT00650936|Septal
1330651|NCT00650936|Defect
1330652|NCT00650910|lapatinib
1330653|NCT00650910|Metastatic ErbB2 positive breast cancer
1330654|NCT00650910|digoxin
1330655|NCT00650897|Efficacy
1330656|NCT00650897|Antidepressant
1330657|NCT00650897|Escitalopram
1330658|NCT00650897|Major Depression
1330659|NCT00650897|Diabetes Mellitus
1330660|NCT00650897|Self Care
1330661|NCT00650884|Dynamic Splinting for low-load, prolonged-duration stretch
1330662|NCT00650871|GW679769,
1330663|NCT00650871|sleep,
1330664|NCT00650871|cognitive function,
1330665|NCT00650871|primary insomnia,
1330666|NCT00650871|polysomnography.
1330667|NCT00650858|Intraventricular hemorrhage (IVH)
1330668|NCT00650858|rt-PA
1330669|NCT00650845|contrast-induced nephropathy, creatinemia
1330670|NCT00650832|HIV, anti-infectives
1330671|NCT00650806|Obesity
1330672|NCT00650806|Overweight
1330673|NCT00650806|Weight loss
1330674|NCT00650806|Anti-Obesity Agents
1330675|NCT00650806|Human
1330676|NCT00650793|Schizophrenia
1330677|NCT00650793|paliperidone
1330678|NCT00650780|Viatmin D, 25-hydroxyvitamin D, Vitamin D binding protein
1330679|NCT00650754|DHEA
1330680|NCT00650754|Pregnancy
1330681|NCT00650741|Endothelial Dysfunction
1330682|NCT00650741|FMD
1330683|NCT00650728|radiofrequency ablation
1330684|NCT00650715|Fibromyalgia
1330685|NCT00650715|Whole-Body vibration
1330686|NCT00650715|Exercise
1330687|NCT00650715|IGF-1
1330688|NCT00650702|glaucoma, ocular hypertension, IOP
1330689|NCT00650624|knee osteoarthritis; Japan
1330690|NCT00650598|anterior cruciate ligament, arthroscopy, knee, post-surgical pain
1330691|NCT00650585|smoking
1330692|NCT00650585|alcohol
1330693|NCT00650585|prevention
1330694|NCT00650585|prevention & control
1330695|NCT00650572|human epidermal growth factor receptor 2
1330696|NCT00650572|epidermal growth factor receptor
1330697|NCT00650572|EGFR
1330698|NCT00650572|type I receptor tyrosine kinase
1330699|NCT00650559|COPD
1330700|NCT00650559|Emphysema
1330701|NCT00650559|thorax enlargement
1330702|NCT00650559|LVRS
1330703|NCT00650546|Non-alcoholic steatohepatitis
1330704|NCT00650546|NASH
1330705|NCT00650507|children
1330706|NCT00650507|cardiac surgery
1330707|NCT00650507|remote ischemic preconditioning
1330708|NCT00650507|SHAM
1330709|NCT00650507|ischemia-reperfusion
1330710|NCT00650468|Renal Transplantation
1330711|NCT00650468|Prograf
1330712|NCT00650455|valdecoxib, severe rheumatoid arthritis
1330713|NCT00650260|intraoperative warming
1330714|NCT00650260|anesthesia
1330715|NCT00650260|hypothermia
1330716|NCT00650260|body temperature
1330717|NCT00650182|patch
1330718|NCT00650182|fentanyl
1330719|NCT00650182|chronic pain
1330720|NCT00650143|Stem cell
1330721|NCT00650143|Myocardial infarction
1330722|NCT00650143|G-CSF
1330723|NCT00650143|CD26-inhibition
1330724|NCT00650130|driving under the influence
1330725|NCT00650130|psychoactive substances
1330726|NCT00650130|oral fluid
1330727|NCT00650130|whole blood
1330728|NCT00650130|plasma
1330729|NCT00650130|Ratio of psychoactive substances in whole blood-plasma-oral fluid
1330730|NCT00650130|Prevalence of psychoactive substances in road traffic
1330731|NCT00650104|ropinirole IR
1330732|NCT00650104|efficacy
1330733|NCT00650104|safety
1330734|NCT00650104|open-label
1330735|NCT00650104|long term safety; REQUIP
1330736|NCT00650104|ropinirole XL
1330737|NCT00650104|ropinirole CR
1330738|NCT00650104|Parkinson's disease
1330739|NCT00650091|Idiopathic Pulmonary Fibrosis
1330740|NCT00650091|Prednisone
1330741|NCT00650091|Azathioprine
1330742|NCT00650091|NAC
1330743|NCT00650091|N-acetylcysteine
1330744|NCT00650078|Signs and Symptoms
1330745|NCT00650078|Autoimmune Diseases
1330746|NCT00650078|Joint Diseases
1330747|NCT00650078|Arthritis
1330748|NCT00650078|Connective Tissue Diseases
1330749|NCT00650078|Arthritis, Rheumatoid
1330750|NCT00650078|Rheumatic Diseases
1330751|NCT00650078|Predniso(lo)ne
1330752|NCT00650039|Post surgical pain
1330753|NCT00650039|Anterior Cruciate ligament reconstruction
1330754|NCT00650039|Arthroscopy
1330755|NCT00650039|Perioperative pain
1330756|NCT00649961|Premature Birth
1330757|NCT00649961|Brain injury
1330758|NCT00649961|Neuroprotection
1330759|NCT00649961|Melatonin
1330760|NCT00649961|Pharmacokinetics
1330761|NCT00649922|Vaccines with adalimumab dosing
1330762|NCT00649909|Diabetes Mellitus
1330763|NCT00649909|Type II
1330764|NCT00649909|Aspirin
1330765|NCT00649909|Resistance
1330766|NCT00649883|Influenza
1330767|NCT00649883|vaccine
1330768|NCT00649883|children
1330769|NCT00649792|multiple sclerosis
1330770|NCT00649792|MS
1330771|NCT00649792|walking
1330772|NCT00649792|leg strength
1330773|NCT00649792|demyelination
1330774|NCT00649766|tailored health messages
1330775|NCT00649766|glaucoma
1330776|NCT00649766|diabetic retinopathy
1330777|NCT00649766|dilated fundus exams
1330778|NCT00649766|health behavior
1330779|NCT00649753|sacroiliac joint dysfunction
1330780|NCT00649753|algometer
1330781|NCT00649753|Chiropractic
1330782|NCT00649753|Manual Therapy
1330783|NCT00649753|indicator points associated with sacroiliac joint dysfunction
1330784|NCT00649701|HIV
1330785|NCT00649701|Internet
1330786|NCT00649701|MSM
1330787|NCT00649701|Condom Use
1330788|NCT00649701|Disclosure
1330789|NCT00649610|acute low back pain
1330790|NCT00649584|Antigens, CD30
1330791|NCT00649584|Antibody-Drug Conjugate
1330792|NCT00649584|Antibodies, Monoclonal
1330793|NCT00649584|monomethyl auristatin E
1330794|NCT00649584|Combined Modality Therapy
1330795|NCT00649584|Drug Therapy
1330796|NCT00649584|Immunotherapy
1330797|NCT00649584|Lymphoma, Non-Hodgkin
1330798|NCT00649584|Disease, Hodgkin
1330799|NCT00649584|Lymphoma, Large-Cell, Anaplastic
1330800|NCT00649584|Hematologic Diseases
1330801|NCT00649584|Lymphoma
1330802|NCT00649428|Treatment of moderate to severe bilateral nasolabial fold wrinkles
1330803|NCT00649337|mammography
1330804|NCT00649337|ultrasound
1330805|NCT00649337|breast cancer
1330806|NCT00649337|screening
1330807|NCT00649298|Randomized Controlled Trial
1330808|NCT00649298|Clinical Trial
1330809|NCT00649298|Controlled Clinical Trial
1330810|NCT00649298|Clinical Trial, Phase IV
1330811|NCT00649298|Multicenter Study
1330812|NCT00649298|End Stage Kidney Disease
1330813|NCT00649298|Hemodialysis
1330814|NCT00649298|Renal Dialysis
1330815|NCT00649298|Renal Replacement Therapy
1330816|NCT00649298|Nocturnal Dialysis
1330817|NCT00649298|Extended dialysis
1330818|NCT00649298|Quality of Life
1330819|NCT00649298|Quality Adjusted Life Year
1330820|NCT00649298|Hypertrophy, Left Ventricular
1330821|NCT00649298|Blood Pressure
1330822|NCT00649298|Hypertension
1330823|NCT00649298|Anemia
1330824|NCT00649298|Hematinics
1330825|NCT00649298|Erythropoiesis Stimulating Agents
1330826|NCT00649298|Cost-utility Analysis
1330827|NCT00649298|Economic Evaluation
1330828|NCT00649298|Health Care Utilisation
1330829|NCT00649298|Health Care Costs
1330830|NCT00649298|Health Expenditures
1330831|NCT00649298|Hospitalization
1330832|NCT00649298|Cost Analysis
1330833|NCT00649298|Cardiovascular Diseases
1330834|NCT00649298|Acute Coronary Syndrome
1330835|NCT00649298|Myocardial Infarction
1330836|NCT00649298|Stroke
1330837|NCT00649298|Cerebrovascular Disorders
1330838|NCT00649298|Mortality
1330839|NCT00649298|Arteriovenous Fistula
1330840|NCT00649298|Arteriovenous Shunt, Surgical
1330841|NCT00649298|Thrombosis
1330842|NCT00649298|Infection
1330843|NCT00649246|genetics
1330844|NCT00649246|type 1 diabetes
1330845|NCT00649246|biomarkers
1330846|NCT00649246|autoimmunity
1330847|NCT00649207|WBRT
1330848|NCT00649207|Brain Metastases
1330849|NCT00649207|Radiation
1330850|NCT00649207|ABT-888
1330851|NCT00649207|PARP
1330852|NCT00649142|Groin hernia
1330853|NCT00649142|Chronic postsurgical pain
1330854|NCT00649142|open mesh repair
1330855|NCT00649142|laparoscopic mesh glue fixation
1330856|NCT00649142|Sensory changes after groin hernia repair
1330857|NCT00649025|Asthma
1330858|NCT00649025|Asthma Moderate to Severe
1330859|NCT00648999|Kaletra
1330860|NCT00648986|brittle nails
1330861|NCT00648986|Tazarotene
1330862|NCT00648986|Tazorac
1330863|NCT00648973|Seasonal Allergic Rhinitis, nasal congestion
1330864|NCT00648908|multiple sclerosis
1330865|NCT00648908|MS
1330866|NCT00648908|walking
1330867|NCT00648908|leg strength
1330868|NCT00648908|demyelination
1330869|NCT00648895|Hypertension
1330870|NCT00648895|Blood pressure
1330871|NCT00648895|Nebivolol
1330872|NCT00648895|Bystolic (TM)
1330873|NCT00648895|Metoprolol ER (TM)
1330874|NCT00648869|pharmaceutical preparations
1330875|NCT00648817|HIV-1
1330876|NCT00648817|tenofovir DF
1330877|NCT00648739|B-cell Chronic Lymphocytic Leukemia
1330878|NCT00648739|Leukemia
1330879|NCT00648739|Multiple Myeloma
1330880|NCT00648739|CD200
1330881|NCT00648739|Anti-CD200
1330882|NCT00648687|prematurity
1330883|NCT00648687|retinopathy of prematurity
1330884|NCT00648687|pain
1330885|NCT00648687|very low birth weight infants
1330886|NCT00648635|Rectal Cancer
1330887|NCT00648635|Recurrent Rectal Adenocarcinoma
1330888|NCT00648635|Quality of Life
1330889|NCT00648635|QOL
1330890|NCT00648635|Questionnaire
1330891|NCT00648635|Survey
1330892|NCT00648609|Community based self management of COPD with palliative care
1330893|NCT00648479|Fracture Fixation
1330894|NCT00648453|Fontain II-III stage
1330895|NCT00648375|Propanolol
1330896|NCT00648375|Beta Blockers
1330897|NCT00648375|Reconsolidation
1330898|NCT00648375|Cognitive Therapy
1330899|NCT00648375|PTSD
1330900|NCT00648323|Benign Prostate Hyperplasia
1330901|NCT00648284|Type 2 diabetes
1330902|NCT00648284|CV risk
1330903|NCT00648284|rosiglitazone
1330904|NCT00648284|AVANDIA
1330905|NCT00648258|osteoarthritis, knee
1330906|NCT00648258|osteoarthritis, hip
1330907|NCT00648245|chronic obstructive pulmonary disease
1330908|NCT00648245|COPD
1330909|NCT00648245|Chronic bronchitis
1330910|NCT00648232|HIV
1330911|NCT00648232|AIDS
1330912|NCT00648232|Prevention
1330913|NCT00648232|VCT
1330914|NCT00648232|Voluntary Counseling and Testing
1330915|NCT00648206|driving under the influence
1330916|NCT00648206|psychoactive substances
1330917|NCT00648206|blood samples
1330918|NCT00648206|Prevalence of psychoactive substances in road traffic
1330919|NCT00648167|ESRD
1330920|NCT00648167|end-stage renal disease
1330921|NCT00648167|end stage renal disease
1330922|NCT00648167|hemodialysis
1330923|NCT00648167|dialysis
1330924|NCT00648167|kidney failure
1330925|NCT00648167|renal failure
1330926|NCT00648167|kidney
1330927|NCT00648167|renal
1330928|NCT00648167|phosphate binder
1330929|NCT00648167|phosphorus
1330930|NCT00648115|Veterans
1330931|NCT00648115|Substance-Related Disorders
1330932|NCT00648115|Mental Health
1330933|NCT00648102|Breast cancer
1330934|NCT00648102|Colorectal cancer
1330935|NCT00648102|Pancreatic cancer
1330936|NCT00648102|Bladder cancer
1330937|NCT00648102|Ovarian cancer
1330938|NCT00648102|Metastatic cancer
1330939|NCT00648102|Locally advanced cancer
1330940|NCT00648102|Cancer Vaccine
1330941|NCT00648102|Vaccine
1330942|NCT00648089|Acute ST Elevation Myocardial Infarction
1330943|NCT00648037|RITUXIMAB
1330944|NCT00648037|Lymphoma
1330945|NCT00647998|Surgical complications
1330946|NCT00647998|Spinal ischemia
1330947|NCT00647998|Stroke
1330948|NCT00647998|Neuroprotection
1330949|NCT00647946|lipodystrophy
1330950|NCT00647933|Females
1330951|NCT00647933|Corifollitropin alfa
1330952|NCT00647933|Antibodies
1330953|NCT00647933|Pharmacokinetics
1330954|NCT00647933|Pharmacodynamics
1330955|NCT00647868|pharmacokinetics
1330956|NCT00647868|testosterone
1330957|NCT00647868|hypogonadism
1330958|NCT00647829|pharyngitis, sore throat
1330959|NCT00647790|PET imaging
1330960|NCT00647790|invasive breast cancer
1330961|NCT00647725|Epidural analgesia
1330962|NCT00647725|Latent analgesia
1330963|NCT00647725|Active analgesia
1330964|NCT00647725|Labor delivery
1330965|NCT00647699|keratoconus
1330966|NCT00647699|cross-linking
1330967|NCT00647699|riboflavin
1330968|NCT00647699|UVA light
1330969|NCT00647699|cornea
1330970|NCT00647595|Obesity
1330971|NCT00647595|Physical activity
1330972|NCT00647595|Pregnancy
1330973|NCT00647595|Diabetes mellitus
1330974|NCT00647582|stage I breast cancer
1330975|NCT00647582|stage II breast cancer
1330976|NCT00647569|vertical rectus abdominis musculocutaneus flap
1330977|NCT00647569|mesh repair
1330978|NCT00647569|salvage surgery
1330979|NCT00647530|adenocarcinoma of the colon
1330980|NCT00647530|stage I colon cancer
1330981|NCT00647530|stage II colon cancer
1330982|NCT00647530|stage III colon cancer
1330983|NCT00647504|stent thrombosis
1330984|NCT00647504|stent restenosis
1330985|NCT00647504|intravascular ultrasound
1330986|NCT00647478|Insulin-like Growth Factor
1330987|NCT00647478|Insulin-like Growth Factor binding protein 3
1330988|NCT00647478|Insulin-like Growth Factor-I system component levels
1330989|NCT00647478|Insulin-like Growth Factor-I polymorphism
1330990|NCT00647478|Alzheimer's disease
1330991|NCT00647478|Mild Cognitive Impairment
1330992|NCT00647478|Normal cognitive function
1330993|NCT00647478|Observational cross sectional study
1330994|NCT00647465|Influenza vaccine
1330995|NCT00647465|interferon
1330996|NCT00647465|adjuvant
1330997|NCT00647465|the elderly
1330998|NCT00647452|Lipid metabolism
1330999|NCT00647452|VLDL
1331000|NCT00647452|Exercise
1331001|NCT00647452|Lipid metabolism in exercise
1331002|NCT00647439|OCULAR INFLAMMATORY DISEASE
1331003|NCT00647439|Immune Mediated
1331004|NCT00647439|Gene Expression Patterns
1331005|NCT00647439|Diabetic Retinopathy
1331006|NCT00647439|Age-Related Macular Degeneration
1331007|NCT00647439|AMD
1331008|NCT00647439|Uveitis
1331009|NCT00647426|Stage IIIB/IV
1331010|NCT00647413|smoking
1331011|NCT00647413|passive smoking
1331012|NCT00647413|exposure to environmental smoke
1331013|NCT00647413|home smoking ban
1331014|NCT00647413|urinary cotinine
1331015|NCT00647400|Psoriasis
1331016|NCT00647387|muscular
1331017|NCT00647387|ventricular
1331018|NCT00647387|septal
1331019|NCT00647387|defects
1331020|NCT00647387|VSD
1331021|NCT00647361|respiratory insufficiency
1331022|NCT00647361|respiration
1331023|NCT00647361|ventilators
1331024|NCT00647361|diaphragm
1331025|NCT00647361|electromyography
1331026|NCT00647361|mechanical ventilation
1331027|NCT00647348|Secondary progressive Multiple Sclerosis
1331028|NCT00647348|Simvastatin
1331029|NCT00647348|MRI
1331030|NCT00647322|Intractable epilepsy, Drug Reduction, Antiepileptic medication
1331031|NCT00647296|ALS
1331032|NCT00647296|Amyotrophic Lateral Sclerosis
1331033|NCT00647296|Lou Gehrig
1331034|NCT00647296|Lou Gehrig's
1331035|NCT00647296|Lou Gehrig's disease
1331036|NCT00647296|Motor Neuron Disease
1331037|NCT00647296|Nervous System Diseases
1331038|NCT00647296|KNS-760704
1331039|NCT00647283|Liver Transplantation
1331040|NCT00647283|Tolerance
1331041|NCT00647283|Allograft tolerance
1331042|NCT00647283|Immunosuppression minimization
1331043|NCT00647283|Immunosuppression weaning
1331044|NCT00647283|Immunological tolerance
1331045|NCT00647257|Sick Sinus Syndrome; Atrial Fibrillation; Pacemaker
1331046|NCT00647244|Tenofovir
1331047|NCT00647244|Abacavir
1331048|NCT00647244|Antiretroviral therapy
1331049|NCT00647244|HIV
1331050|NCT00647244|Nucleoside analogue reverse transcriptase inhibitor
1331051|NCT00647231|Osteoarthritis,Knee,Ketoprofen,Pain,Patch,Analgesic
1331052|NCT00647218|stage II breast cancer
1331053|NCT00647218|stage IIIA breast cancer
1331054|NCT00647218|stage IIIB breast cancer
1331055|NCT00647218|stage IIIC breast cancer
1331056|NCT00647205|Interferon, gamma
1331057|NCT00647205|HIV Infections
1331058|NCT00647205|Tuberculosis
1331059|NCT00647192|atrial fibrillation
1331060|NCT00647192|electrical cardioversion
1331061|NCT00647192|prevention of atrial fibrillation recurrence
1331062|NCT00647192|mineralocorticoid receptor blocker
1331063|NCT00647192|eplerenone
1331064|NCT00647192|Recurrence of atrial fibrillation after cardioversion
1331065|NCT00647179|Acromegaly
1331066|NCT00647179|Growth Hormone
1331067|NCT00647179|Insulin resistance
1331068|NCT00647179|Glucose tolerance
1331069|NCT00647179|Body Composition
1331070|NCT00647179|Substrate metabolism
1331071|NCT00647166|Vasculitis
1331072|NCT00647166|Polyarteritis nodosa (PAN)
1331073|NCT00647166|Microscopic polyangiitis (MPA)
1331074|NCT00647166|Eosinophilic granulomatosis with polyangiitis (EGPA)
1331075|NCT00647166|Churg Strauss syndrome (CSS)
1331076|NCT00647166|Azathioprine
1331077|NCT00647153|stage I colon cancer
1331078|NCT00647153|stage II colon cancer
1331079|NCT00647153|stage III colon cancer
1331080|NCT00647153|stage IV colon cancer
1331081|NCT00647153|stage I rectal cancer
1331082|NCT00647153|stage II rectal cancer
1331083|NCT00647153|stage III rectal cancer
1331084|NCT00647153|stage IV rectal cancer
1331085|NCT00647140|Thyroid neoplasm
1331086|NCT00647140|Thyroid carcinoma
1331087|NCT00647140|Medullary carcinoma
1331088|NCT00647140|Positron Emission Tomography (PET)
1331089|NCT00647140|18F-L DOPA
1331090|NCT00647140|Calcitonin
1331091|NCT00647140|Carcinoembryonic Antibodies
1331092|NCT00647140|Cervical ultrasonography
1331093|NCT00647140|Cervical-chest-abdomen tomography
1331094|NCT00647140|Cervical-chest-abdomen magnetic resonance imaging
1331095|NCT00647140|Osseous radionuclide imaging
1331096|NCT00647140|Post-PET surgery
1331097|NCT00647140|Post-PET biopsy
1331098|NCT00647140|Post-PET histology
1331099|NCT00647127|Buprenorphine
1331100|NCT00647127|Fentanyl
1331101|NCT00647127|Analgesic effect
1331102|NCT00647127|Anti-hyperalgesic effect
1331103|NCT00647127|Experimental pain
1331104|NCT00647114|Cancers expressing HER-2 and/or CEA
1331105|NCT00647088|Aortic Valve stenosis
1331106|NCT00647088|Genetic
1331107|NCT00647088|Mineralisation inhibitors
1331108|NCT00647075|Breast cancer
1331109|NCT00647075|undergoing
1331110|NCT00647075|adjuvant/neoadjuvant chemotherapy
1331111|NCT00647075|symptomatic therapy
1331112|NCT00647036|Parenteral nutrition, Infants, Dipeotiven, Microbial invasion
1331113|NCT00646997|atrial fibrillation, left atrium, velocity vector imaging
1331114|NCT00646984|Lipodystrophy
1331115|NCT00646984|Treatment interruption
1331116|NCT00646984|HIV
1331117|NCT00646971|Isoprostane
1331118|NCT00646971|Alkane
1331119|NCT00646971|Exhaled condensate
1331120|NCT00646971|Peripheral arterial tonometry
1331121|NCT00646971|Polysomnography
1331122|NCT00646971|Obstructive Sleep Apnea
1331123|NCT00646971|Hypoxia
1331124|NCT00646945|Patient in a oncology unit who has to undergo a painful or invasive procedure
1331125|NCT00646906|acetaminophen
1331126|NCT00646906|low dose aspirin
1331127|NCT00646906|cyclooxygenase
1331128|NCT00646906|prostaglandin
1331129|NCT00646906|drug interaction
1331130|NCT00646906|platelet inhibition
1331131|NCT00646906|urinary prostaglandin metabolites
1331132|NCT00646906|oxidant stress
1331133|NCT00646906|smoking
1331134|NCT00646893|aneuploidy
1331135|NCT00646893|miscarriage
1331136|NCT00646893|pregnancy loss
1331137|NCT00646893|PGD
1331138|NCT00646893|PGS
1331139|NCT00646893|Preimplantation Genetic Diagnosis
1331140|NCT00646893|chromosome abnormalities
1331141|NCT00646893|IVF
1331142|NCT00646893|ART
1331143|NCT00646867|Tetrix cream, contact dermatitis, effect on burning and itching
1331144|NCT00646854|Lymphoma, T-Cell
1331145|NCT00646854|Lymphoma, T-Cell, Peripheral
1331146|NCT00646854|MabCampath
1331147|NCT00646854|Campath
1331148|NCT00646854|CHOP-14
1331149|NCT00646854|CD52 expression
1331150|NCT00646841|Essential hypertension, doxazosin, ambulatory blood pressure monitoring
1331151|NCT00646828|Pseudohypoaldosteronism type 1
1331152|NCT00646828|Mineralocorticoid receptor
1331153|NCT00646828|Aldosterone
1331154|NCT00646828|Cardiovascular disease
1331155|NCT00646815|insulin sensitivity
1331156|NCT00646815|substrate metabolism
1331157|NCT00646815|fatty liver
1331158|NCT00646815|intramyocellular lipids
1331159|NCT00646815|growth hormone deficiency
1331160|NCT00646815|Growth hormone deficiency (Adult)
1331161|NCT00646750|Z-BEAM
1331162|NCT00646750|Autologous
1331163|NCT00646750|Lymphoma
1331164|NCT00646750|GELTAMO
1331165|NCT00646737|Kidney transplantation
1331166|NCT00646737|conversion
1331167|NCT00646737|mycophenolate mofetil
1331168|NCT00646737|mycophenolate sodium,
1331169|NCT00646737|tacrolimus
1331170|NCT00646724|Islets of Langerhans Transplantation
1331171|NCT00646724|Mesenchymal Stem Cells
1331172|NCT00646724|Type 1 Diabetes Mellitus
1331173|NCT00646698|VLDL-TG kinetics
1331174|NCT00646698|Obesity
1331175|NCT00646698|Body composition
1331176|NCT00646698|Tracers
1331177|NCT00646698|Tissue biopsies
1331178|NCT00646672|ECMO
1331179|NCT00646672|Cerebral Perfusion
1331180|NCT00646672|Carotid Artery
1331181|NCT00646672|Aneurysm
1331182|NCT00646672|Cerebral Circulation
1331183|NCT00646672|Common Carotid Artery Occlusion
1331184|NCT00646659|stage III squamous cell carcinoma of the hypopharynx
1331185|NCT00646659|stage III squamous cell carcinoma of the larynx
1331186|NCT00646659|stage III squamous cell carcinoma of the lip and oral cavity
1331187|NCT00646659|stage III squamous cell carcinoma of the oropharynx
1331188|NCT00646659|stage IV squamous cell carcinoma of the hypopharynx
1331189|NCT00646659|stage IV squamous cell carcinoma of the larynx
1331190|NCT00646659|stage IV squamous cell carcinoma of the lip and oral cavity
1331191|NCT00646659|stage IV squamous cell carcinoma of the oropharynx
1331192|NCT00646659|untreated metastatic squamous neck cancer with occult primary
1331193|NCT00646646|Sedation
1331194|NCT00646646|Eye Movements
1331195|NCT00646633|Cancer
1331196|NCT00646633|Acupuncture
1331197|NCT00646620|asthma
1331198|NCT00646620|bronchodilatation
1331199|NCT00646620|Symbicort
1331200|NCT00646620|budesonide/formoterol
1331201|NCT00646620|Advair Diskus
1331202|NCT00646620|Ventolin
1331203|NCT00646607|colorectal neoplasm
1331204|NCT00646607|high risk
1331205|NCT00646607|stage II/III
1331206|NCT00646594|Asthma
1331207|NCT00646594|inhaled cortocisteroids
1331208|NCT00646594|Symbicort
1331209|NCT00646594|budesonide/formoterol
1331210|NCT00646594|Advair
1331211|NCT00646594|fluticasone/salmeterol
1331212|NCT00646581|Schizophrenia
1331213|NCT00646581|Memory
1331214|NCT00646581|Concentration
1331215|NCT00646581|Insulin
1331216|NCT00646568|IVF
1331217|NCT00646568|ovarian reserve
1331218|NCT00646568|androgens
1331219|NCT00646568|thecal cells
1331220|NCT00646568|Fertility Agents, Female
1331221|NCT00646555|Tissue Samples
1331222|NCT00646555|VEGF Receptors
1331223|NCT00646555|VEGF
1331224|NCT00646555|Microvessel Density
1331225|NCT00646555|Hypoxia Inducible Factor
1331226|NCT00646555|Inflammatory Breast Cancer
1331227|NCT00646555|IBC
1331228|NCT00646542|Type 2 diabetes, vildagliptin
1331229|NCT00646529|asthma
1331230|NCT00646529|children
1331231|NCT00646529|Symbicort
1331232|NCT00646529|budesonide/formoterol
1331233|NCT00646529|Pulmicort
1331234|NCT00646529|budesonide
1331235|NCT00646516|Asthma
1331236|NCT00646516|inhaled corticosteroids
1331237|NCT00646516|Symbicort
1331238|NCT00646516|budesonide/formoterol
1331239|NCT00646516|budesonide
1331243|NCT00646490|serum, pleural effusion, procalcitonin, pneumonia
1331244|NCT00646464|CPT
1331245|NCT00646464|ADHD
1331246|NCT00646451|Essential tremor
1331247|NCT00646451|Activities of Daily Living (ADL's)
1331248|NCT00646438|Diabetes
1331249|NCT00646438|CABG
1331250|NCT00646425|Non-infectious uveitis
1331251|NCT00646412|randomized, controlled, single-blind study
1331252|NCT00646412|Adhesion Prophylaxis
1331253|NCT00646412|Abdominal Surgery
1331254|NCT00646412|Laparotomy, median
1331255|NCT00646399|Staphylococcal
1331256|NCT00646399|Coagulase Negative Staphylococcus
1331257|NCT00646399|Monoclonal antibodies
1331258|NCT00646399|Very Low Birth Weight Infants
1331259|NCT00646399|Prophylaxis
1331260|NCT00646373|Cardiac surgery
1331261|NCT00646373|Pump prime
1331262|NCT00646373|Blood transfusions
1331263|NCT00646360|birth size, gestational age, development, child growth,
1331264|NCT00646360|prenatal nutrition, DHA
1331265|NCT00646347|stroke
1331266|NCT00646347|upper limb rehabilitation
1331267|NCT00646347|treatment
1331268|NCT00646347|movement recovery from sever paralytic upper limb
1331269|NCT00646347|neuro hand orthosis
1331270|NCT00646347|self practice program
1331271|NCT00646347|subacute
1331272|NCT00646334|Large Pore Size Propylene Mesh
1331273|NCT00646334|Incisional Hernia
1331274|NCT00646334|Randomized Controlled Double-blind Study
1331275|NCT00646321|asthma
1331276|NCT00646321|children
1331277|NCT00646321|adolescents
1331278|NCT00646321|Symbicort
1331279|NCT00646321|budesonide/ formoterol
1331280|NCT00646321|budesonide
1331281|NCT00646308|growth hormone deficiency, pituitary tumors
1331282|NCT00646295|TRO
1331283|NCT00646269|Dementia ; Alzheimer's Disease ; Non pharmacological treatments ; cognitive training ; reminiscence therapy ; efficacy assessment
1331284|NCT00646256|schizoaffective
1331285|NCT00646256|schizotypal
1331286|NCT00646243|Heart failure
1331287|NCT00646243|echocardiography
1331288|NCT00646243|cardiac resynchronization therapy
1331289|NCT00646243|left ventricular dyssynchrony
1331290|NCT00646230|recurrent neuroblastoma
1331291|NCT00646217|SELF Care Talk
1331292|NCT00646217|stroke
1331293|NCT00646217|caregivers
1331294|NCT00646217|Caregiving as experienced by older adults caring for a spouse/partner with a first-ever stroke
1331295|NCT00646204|Parkinson's disease
1331296|NCT00646204|non-motor symptoms
1331297|NCT00646165|Leukemia, CLL
1331298|NCT00646152|Antiviral
1331299|NCT00646152|Influenza
1331300|NCT00646152|Interferon
1331301|NCT00646152|Prophylaxis
1331302|NCT00646152|SARS
1331303|NCT00646152|Healthy Volunteer
1331304|NCT00646152|HV
1331305|NCT00646139|unspecified adult solid tumor, protocol specific
1331306|NCT00646139|recurrent adult T-cell leukemia/lymphoma
1331307|NCT00646139|stage III adult T-cell leukemia/lymphoma
1331308|NCT00646139|stage IV adult T-cell leukemia/lymphoma
1331309|NCT00646139|adult grade III lymphomatoid granulomatosis
1331310|NCT00646139|adult nasal type extranodal NK/T-cell lymphoma
1331311|NCT00646139|anaplastic large cell lymphoma
1331312|NCT00646139|angioimmunoblastic T-cell lymphoma
1331313|NCT00646139|splenic marginal zone lymphoma
1331314|NCT00646139|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1331315|NCT00646139|nodal marginal zone B-cell lymphoma
1331316|NCT00646139|stage III adult Burkitt lymphoma
1331317|NCT00646139|stage III adult diffuse large cell lymphoma
1331318|NCT00646139|stage III adult diffuse mixed cell lymphoma
1331319|NCT00646139|stage III adult diffuse small cleaved cell lymphoma
1331320|NCT00646139|stage III adult Hodgkin lymphoma
1331321|NCT00646139|stage III adult immunoblastic large cell lymphoma
1331322|NCT00646139|stage III adult lymphoblastic lymphoma
1331323|NCT00646139|stage III cutaneous T-cell non-Hodgkin lymphoma
1331324|NCT00646139|stage III mycosis fungoides/Sezary syndrome
1331325|NCT00646139|stage III grade 1 follicular lymphoma
1331326|NCT00646139|stage III grade 2 follicular lymphoma
1331327|NCT00646139|stage III grade 3 follicular lymphoma
1331328|NCT00646139|stage III mantle cell lymphoma
1331329|NCT00646139|stage III marginal zone lymphoma
1331330|NCT00646139|stage III small lymphocytic lymphoma
1331331|NCT00646139|stage IV adult Burkitt lymphoma
1331332|NCT00646139|stage IV adult diffuse large cell lymphoma
1331333|NCT00646139|stage IV adult diffuse mixed cell lymphoma
1331334|NCT00646139|stage IV adult diffuse small cleaved cell lymphoma
1331335|NCT00646139|stage IV adult Hodgkin lymphoma
1331336|NCT00646139|stage IV adult immunoblastic large cell lymphoma
1331337|NCT00646139|stage IV adult lymphoblastic lymphoma
1331338|NCT00646139|stage IV cutaneous T-cell non-Hodgkin lymphoma
1331339|NCT00646139|stage IV mycosis fungoides/Sezary syndrome
1331340|NCT00646139|stage IV grade 1 follicular lymphoma
1331341|NCT00646139|stage IV grade 2 follicular lymphoma
1331342|NCT00646139|stage IV grade 3 follicular lymphoma
1331343|NCT00646139|stage IV mantle cell lymphoma
1331344|NCT00646139|stage IV marginal zone lymphoma
1331345|NCT00646139|stage IV small lymphocytic lymphoma
1331346|NCT00646139|recurrent adult Hodgkin lymphoma
1331347|NCT00646139|recurrent adult Burkitt lymphoma
1331348|NCT00646139|recurrent adult diffuse large cell lymphoma
1331349|NCT00646139|recurrent adult diffuse mixed cell lymphoma
1331350|NCT00646139|recurrent adult diffuse small cleaved cell lymphoma
1331351|NCT00646139|recurrent adult grade III lymphomatoid granulomatosis
1331352|NCT00646139|recurrent adult immunoblastic large cell lymphoma
1331353|NCT00646139|recurrent adult lymphoblastic lymphoma
1331354|NCT00646139|recurrent cutaneous T-cell non-Hodgkin lymphoma
1331355|NCT00646139|recurrent mycosis fungoides/Sezary syndrome
1331356|NCT00646139|recurrent grade 1 follicular lymphoma
1331357|NCT00646139|recurrent grade 2 follicular lymphoma
1331358|NCT00646139|recurrent grade 3 follicular lymphoma
1331359|NCT00646139|recurrent mantle cell lymphoma
1331360|NCT00646139|recurrent marginal zone lymphoma
1331361|NCT00646139|recurrent small lymphocytic lymphoma
1331362|NCT00646139|intraocular lymphoma
1331363|NCT00646139|primary central nervous system non-Hodgkin lymphoma
1331364|NCT00646139|post-transplant lymphoproliferative disorder
1331365|NCT00646139|cutaneous B-cell non-Hodgkin lymphoma
1331366|NCT00646139|Waldenstrom macroglobulinemia
1331367|NCT00646139|small intestine lymphoma
1331368|NCT00646100|hepatocellular carcinoma
1331369|NCT00646100|transcatheter arterial chemoembolization
1331370|NCT00646100|prospective control study
1331371|NCT00646100|best support care
1331372|NCT00646100|survival
1331373|NCT00646074|Caregiver
1331374|NCT00646074|Alzheimer's disease
1331375|NCT00646074|Caregiving as experienced by older adults caring for a spouse with Alzheimer's disease or dementia
1331376|NCT00646061|renal colic
1331377|NCT00646048|Abdominal Aortic Aneurysm
1331378|NCT00646048|AAA
1331379|NCT00646048|TriVascular Stent-Graft System
1331380|NCT00646048|Stent-Graft
1331381|NCT00646022|Neuroendocrine
1331382|NCT00646022|PET
1331383|NCT00646022|Gastrointestinal
1331384|NCT00646022|Serotonin
1331385|NCT00646022|Carcinoid Tumor
1331386|NCT00646022|Gastrointestinal Carcinoid Tumor
1331387|NCT00646022|Familial Cancer Tumor
1331388|NCT00646009|asthma
1331389|NCT00646009|adults
1331390|NCT00646009|Symbicort
1331391|NCT00646009|budesonide/formoterol
1331392|NCT00646009|Advair Diskus
1331393|NCT00646009|Ventolin
1331394|NCT00645996|Probiotics
1331395|NCT00645996|vaccines
1331396|NCT00645996|Measles
1331397|NCT00645996|Mumps
1331398|NCT00645996|Rubella
1331399|NCT00645983|Chamomile
1331400|NCT00645983|Anxiety
1331401|NCT00645983|Complementary and Alternative Medicine
1331402|NCT00645970|chronic pain
1331403|NCT00645970|combat injuries
1331404|NCT00645970|pain assessment
1331405|NCT00645970|multiple traumas
1331406|NCT00645970|rehabilitation
1331407|NCT00645957|drainage
1331408|NCT00645957|irrigation
1331409|NCT00645931|Bone Marrow
1331410|NCT00645931|Bone Marrow Transplant
1331411|NCT00645931|Pediatric
1331412|NCT00645931|Psychological Impact
1331413|NCT00645931|Psychology
1331414|NCT00645918|Platelets
1331415|NCT00645918|Platelet Function Tests
1331416|NCT00645918|Clopidogrel
1331417|NCT00645918|Drug Eluting Stents
1331418|NCT00645918|Acute Coronary Syndrome
1331419|NCT00645918|Myocardial Ischemia
1331420|NCT00645918|Stent Thrombosis
1331421|NCT00645918|Heart Diseases
1331422|NCT00645918|Coronary Disease
1331423|NCT00645918|Arterial Occlusive Disease
1331424|NCT00645879|Propionic Acidemia
1331425|NCT00645879|hyperammonemia
1331426|NCT00645879|hypotonia
1331427|NCT00645879|glutamine
1331428|NCT00645879|ornithine alpha ketoglutarate
1331429|NCT00645879|citrate
1331430|NCT00645866|stage IIIA breast cancer
1331431|NCT00645866|stage IIIB breast cancer
1331432|NCT00645866|stage IIIC breast cancer
1331433|NCT00645840|Type 1 diabetes mellitus
1331434|NCT00645840|IL1 beta
1331435|NCT00645840|Anakinra
1331436|NCT00645827|Insulin
1331437|NCT00645827|Blood Glucose
1331438|NCT00645801|Routine screening colonoscopy
1331439|NCT00645801|Colonoscopy Preparation
1331440|NCT00645801|Amitiza
1331441|NCT00645801|GoLYTELY
1331442|NCT00645801|Pegylated Electrolytes
1331443|NCT00645801|Preparation Solution
1331444|NCT00645801|Colonoscopy Solution
1331445|NCT00645788|Ciprofloxacin
1331446|NCT00645788|cystic fibrosis
1331447|NCT00645788|sweat test
1331448|NCT00645788|pulmonary function test
1331449|NCT00645775|Weight loss
1331450|NCT00645775|Antiobesity
1331451|NCT00645775|Metabolic syndrome
1331452|NCT00645775|Leptin
1331453|NCT00645762|Chronic rhinosinusitis
1331454|NCT00645762|Chronic sinusitis
1331455|NCT00645762|Maxillary sinus
1331456|NCT00645762|Anterior ethmoid sinus
1331457|NCT00645762|Ethmoid infundibulum
1331458|NCT00645762|Balloon dilation
1331459|NCT00645762|Endoscopic visualization
1331460|NCT00645762|Local anesthesia
1331461|NCT00645762|Canine fossa
1331462|NCT00645762|Less invasive
1331463|NCT00645736|Chronic Hepatitis B
1331464|NCT00645723|Acinetobacter baumanii
1331465|NCT00645723|Ventilator-associated pneumonia
1331466|NCT00645697|tuberculosis
1331467|NCT00645697|Multifocal serpiginous choroiditis
1331468|NCT00645697|histoplasmosis
1331469|NCT00645697|Harada toxoplasmosis
1331470|NCT00645684|Gastrointestinal Anastomosis
1331471|NCT00645684|Multicentre
1331472|NCT00645684|Randomized controlled single-blind study
1331473|NCT00645684|synthetic, absorbable, braided and coated suture material
1331474|NCT00645684|Laparotomy
1331475|NCT00645645|Holoprosencephaly
1331476|NCT00645645|Agenesis of Corpus
1331477|NCT00645645|Callosum
1331478|NCT00645645|Genetic Tests
1331479|NCT00645632|localized osteosarcoma
1331480|NCT00645619|Pneumonia,viral
1331481|NCT00645619|Pneumonia,bacterial
1331482|NCT00645619|TREM-1 protein,human
1331483|NCT00645606|B-cell chronic lymphocytic leukemia
1331484|NCT00645606|Binet B or C stage chronic lymphocytic leukemia
1331485|NCT00645593|Bladder Cancer
1331486|NCT00645567|Biomechanics
1331487|NCT00645567|Ergonomics
1331488|NCT00645567|Spinal Cord Injury
1331489|NCT00645567|Pain
1331490|NCT00645567|Shoulder
1331491|NCT00645554|Galantamine oral solution
1331492|NCT00645554|Galantamine tablet
1331493|NCT00645554|Bioequivalence
1331494|NCT00645541|Breast Cancer
1331495|NCT00645541|Carcinoma of the Breast
1331496|NCT00645541|Lymph Nodes
1331497|NCT00645541|Lymphazurin
1331498|NCT00645541|Axillary Reverse Mapping
1331499|NCT00645528|insulin
1331500|NCT00645528|teaching
1331501|NCT00645502|Schizophrenia
1331502|NCT00645502|Risperidone
1331503|NCT00645502|Orally-disintegrating tablet
1331504|NCT00645502|Bioequivalence
1331505|NCT00645489|heart failure intervention
1331506|NCT00645476|DSM-IV diagnostic criteria for any bipolar disorder (type I, type II, and NOS)
1331507|NCT00645476|(diagnosed with the use of the Structured Clinical Interview for DSM-IV-TR Mood Module (SCID Mood Module)
1331508|NCT00645450|Stress
1331509|NCT00645450|Posttraumatic
1331510|NCT00645450|PTSD
1331511|NCT00645450|Propranolol
1331512|NCT00645450|Treatment
1331513|NCT00645437|renal diseases
1331514|NCT00645437|levofloxacin
1331515|NCT00645411|Influenza
1331516|NCT00645411|Flu
1331517|NCT00645411|Cell Culture-Derived
1331518|NCT00645411|Egg-Derived
1331519|NCT00645411|Healthy Children
1331520|NCT00645411|Healthy Adolescents
1331521|NCT00645411|Safety
1331522|NCT00645411|Immunogenicity
1331523|NCT00645411|Trivalent
1331524|NCT00645411|Inactivated
1331525|NCT00645411|Vaccination
1331526|NCT00645385|GBM
1331527|NCT00645385|AA
1331528|NCT00645385|AO
1331529|NCT00645385|Brain
1331530|NCT00645385|Tumors
1331531|NCT00645385|Malignant
1331532|NCT00645385|Glioblastoma
1331533|NCT00645385|Multiforme
1331534|NCT00645385|Carmustine
1331535|NCT00645385|implant
1331536|NCT00645385|BCNU
1331537|NCT00645385|Gliadel
1331538|NCT00645385|Wafers
1331539|NCT00645385|MRS
1331540|NCT00645385|Spectroscopy
1331541|NCT00645359|dMRI
1331542|NCT00645359|diffusion MRI
1331543|NCT00645359|Diffuse large B-cell lymphoma
1331544|NCT00645359|DLBCL
1331545|NCT00645346|GBS
1331546|NCT00645333|breast cancer
1331547|NCT00645333|Phase I clinical trial
1331548|NCT00645333|cancer stem cells
1331549|NCT00645333|agents with other mechanisms of action
1331550|NCT00645333|Notch inhibitors
1331551|NCT00645307|paliperidone
1331552|NCT00645307|Schizophrenia
1331553|NCT00645294|Hepatitis B
1331554|NCT00645294|Adefovir dipivoxil
1331555|NCT00645294|Children
1331556|NCT00645294|Adolescents
1331557|NCT00645294|Pharmacokinetics
1331558|NCT00645190|Alzheimer Disease
1331559|NCT00645190|galantamine
1331560|NCT00645177|Breast Cancer
1331561|NCT00645164|wound healing
1331562|NCT00645164|photoallergenicity
1331563|NCT00645164|Healthy subjects
1331564|NCT00645138|breast carcinoma
1331565|NCT00645138|breast cancer
1331566|NCT00645138|paravertebral block
1331567|NCT00645138|comparison of paravertebral block and general anesthesia
1331568|NCT00645138|ultrasound
1331569|NCT00645125|pediatric taste test
1331570|NCT00645125|antibiotic taste test
1331571|NCT00645125|cefdinir
1331572|NCT00645125|amoxicillin
1331573|NCT00645099|Paliperidone ER
1331574|NCT00645099|Olanzapine
1331575|NCT00645099|Schizophrenia
1331576|NCT00645073|Acute Bacterial Sinusitis
1331577|NCT00645060|unspecified adult solid tumor, protocol specific
1331578|NCT00645047|PTSD
1331579|NCT00645047|Telemedicine
1331580|NCT00645047|Patient-Centered Care
1331581|NCT00645047|Professional Patient Relationship
1331582|NCT00645047|Psychotherapy
1331583|NCT00645047|Cognitive Therapy
1331584|NCT00645008|Stressors
1331585|NCT00645008|Patient Satisfaction
1331586|NCT00645008|Cardiothoracic-Intensive Care Unit
1331587|NCT00645008|Coronary bypass patient
1331588|NCT00644995|Depression
1331589|NCT00644995|Smoking
1331590|NCT00644995|Physical Activity
1331591|NCT00644930|ARDS,
1331592|NCT00644930|noninvasive ventilation,
1331593|NCT00644930|intubation,
1331594|NCT00644930|mortality,
1331595|NCT00644930|intensive care
1331596|NCT00644917|wound healing
1331597|NCT00644917|phototoxicity
1331598|NCT00644917|Healthy Subjects
1331599|NCT00644904|Multiple Sclerosis
1331600|NCT00644904|Vitamin D
1331601|NCT00644904|Safety
1331602|NCT00644891|Pediatric taste test
1331603|NCT00644891|Antibiotic taste test
1331604|NCT00644891|cefdinir
1331605|NCT00644891|amoxicillin
1331606|NCT00644878|leukemia
1331607|NCT00644878|chronic myelogenous leukemia
1331608|NCT00644878|chronic phase
1331609|NCT00644878|molecular response
1331610|NCT00644878|nilotinib
1331611|NCT00644878|ENABL
1331612|NCT00644852|Schizophrenia
1331613|NCT00644852|Schizoaffective disorder
1331614|NCT00644852|Risperidone long-acting injectable, Long-term evaluation
1331615|NCT00644826|randomized controlled trial
1331616|NCT00644826|public health
1331617|NCT00644826|Preventive Health Services
1331618|NCT00644787|Pain
1331619|NCT00644787|Cancer
1331620|NCT00644787|Fentanyl
1331621|NCT00644787|JNS020QD
1331622|NCT00644787|JNS005
1331623|NCT00644774|pediatric taste test
1331624|NCT00644774|antibiotic taste test
1331625|NCT00644774|cefdinir
1331626|NCT00644774|azithromycin
1331627|NCT00644761|Hepatitis B
1331628|NCT00644761|Post-Liver Transplantation
1331629|NCT00644761|Adefovir Dipivoxil
1331630|NCT00644761|Tacrolimus
1331631|NCT00644761|Cyclosporine
1331632|NCT00644735|Erosive Esophagitis
1331633|NCT00644735|Nexium
1331634|NCT00644735|Esomeprazole
1331635|NCT00644735|Lansoprazole
1331636|NCT00644735|Heartburn
1331637|NCT00644722|Intubation
1331638|NCT00644722|Out-of-hospital
1331639|NCT00644722|Laryngoscope
1331640|NCT00644722|Blades
1331641|NCT00644722|Emergency
1331642|NCT00644696|Neuroblastoma
1331643|NCT00644696|Irinotecan
1331644|NCT00644696|Bortezomib
1331645|NCT00644683|premenopausal women with breast cancer
1331646|NCT00644657|Platelets, platelet aggregation inhibitors
1331647|NCT00644644|NTX
1331648|NCT00644644|Nihon Kohden
1331649|NCT00644644|mobile monitoring
1331650|NCT00644618|pancreatic cancer
1331651|NCT00644618|locally advanced
1331652|NCT00644592|Healthy Volunteers
1331653|NCT00644579|wart
1331654|NCT00644579|cutaneous
1331655|NCT00644579|transplant
1331656|NCT00644579|Cutaneous warts in immune suppressed, kidney transplant patients
1331657|NCT00644566|ADHD
1331658|NCT00644566|Primary Care
1331659|NCT00644566|Pediatrics
1331660|NCT00644566|Health services
1331661|NCT00644566|shared care
1331662|NCT00644566|care manager
1331663|NCT00644566|screening
1331664|NCT00644540|Influenza
1331665|NCT00644540|vaccines
1331666|NCT00644540|children
1331667|NCT00644527|depression
1331668|NCT00644527|music
1331669|NCT00644527|sound
1331670|NCT00644527|randomized controlled trial
1331671|NCT00644514|LPS endotoxin
1331672|NCT00644514|Asthma
1331673|NCT00644501|type 1 diabetes
1331674|NCT00644501|beta cells
1331675|NCT00644501|immunomodulation
1331676|NCT00644501|immunointervention
1331677|NCT00644475|Hypertension
1331678|NCT00644475|Insulin sensitivity
1331679|NCT00644475|Fibrinolysis
1331680|NCT00644462|wheeze detection
1331681|NCT00644436|tetrix cream
1331682|NCT00644436|substantivity
1331683|NCT00644436|resistance to a gentle wash
1331684|NCT00644436|Tetrix Cream remaining on hands after gentle washing with soap and water.
1331685|NCT00644423|PTSD
1331686|NCT00644423|Cognition
1331687|NCT00644423|Fish Oil
1331688|NCT00644423|Omega-3 Fatty Acid
1331689|NCT00644410|heart failure
1331690|NCT00644410|stem cell
1331691|NCT00644410|mesenchymal stromal cell
1331692|NCT00644410|mesenchymal stem cell
1331693|NCT00644397|distal femur fracture
1331694|NCT00644397|locked plates
1331695|NCT00644397|functional outcomes
1331696|NCT00644397|cost management
1331697|NCT00644397|femur head
1331698|NCT00644397|femur neck
1331699|NCT00644384|basal cell carcinoma of the skin
1331700|NCT00644384|squamous cell carcinoma of the skin
1331701|NCT00644371|Allogeneic
1331702|NCT00644371|Lymphoma
1331703|NCT00644371|GELTAMO
1331704|NCT00644371|Z-RIC
1331705|NCT00644345|Microvolt T wave alternans
1331706|NCT00644345|reproducibility
1331707|NCT00644319|malignant pleural effusion
1331708|NCT00644306|Multiple Myeloma, very elderly patients, thalidomide
1331709|NCT00644280|Glaucoma,Ahmed Valve
1331710|NCT00644267|hypertension
1331711|NCT00644267|cardiovascular risk
1331712|NCT00644267|risk score
1331713|NCT00644254|Prognosis
1331714|NCT00644254|Extracapsular lymph node involvement
1331715|NCT00644241|stem cell therapy
1331716|NCT00644241|T2DM
1331717|NCT00644241|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus
1331718|NCT00644215|injected bleb
1331719|NCT00644215|mitomycin drop
1331720|NCT00644215|5-Fu injection
1331721|NCT00644215|early bleb failure
1331722|NCT00644202|weight control
1331723|NCT00644189|clofarabine
1331724|NCT00644189|Clolar
1331725|NCT00644189|lymphoma
1331726|NCT00644189|NHL
1331727|NCT00644189|oral chemotherapy
1331728|NCT00644163|HIV
1331729|NCT00644163|STI
1331730|NCT00644163|Risk Reduction
1331731|NCT00644163|Couples
1331732|NCT00644163|African American
1331733|NCT00644163|HIV Seronegativity
1331734|NCT00644150|Risk Reduction Counseling
1331735|NCT00644150|Anhui, China
1331736|NCT00644150|HIV
1331737|NCT00644150|STI
1331738|NCT00644137|smoking sensations
1331739|NCT00644137|no cravings
1331740|NCT00644137|desire to smoke
1331741|NCT00644124|Non-Hodgkin's lymphoma
1331742|NCT00644124|angiogenesis inhibitors
1331743|NCT00644124|CHOP protocol
1331744|NCT00644111|Minimally Invasive Decompression and Fusion
1331745|NCT00644111|Postoperative analgesia
1331746|NCT00644111|Epidural
1331747|NCT00644111|Lumbar
1331748|NCT00644085|IVF and ICSI
1331749|NCT00644072|Hsp90 Inhibitor
1331750|NCT00644072|Her2
1331751|NCT00644072|Neoplasms
1331752|NCT00644072|Advanced Cancer
1331753|NCT00644072|Cancer
1331754|NCT00644072|Solid Tumor
1331755|NCT00644072|Lymphoma
1331756|NCT00644059|Influenza
1331757|NCT00644059|vaccine
1331758|NCT00644059|children
1331759|NCT00644046|Chronic Kidney Disease
1331760|NCT00644046|Prevention
1331761|NCT00644046|Cardiovascular disease
1331762|NCT00644020|Hepatocellular carcinoma
1331763|NCT00644020|recurrence
1331764|NCT00644007|Erectile dysfunction
1331765|NCT00644007|Hypertension
1331766|NCT00644007|SK3530
1331767|NCT00643994|Prostate Cancer
1331768|NCT00643994|CyberKnife
1331769|NCT00643994|Stereotactic Radiosurgery
1331770|NCT00643994|Radiotherapy
1331771|NCT00643994|Radiation
1331772|NCT00643994|Prostate Tumor
1331773|NCT00643994|Prostate Surgery
1331774|NCT00643968|HIV virological control
1331775|NCT00643968|Lipid profile and morphological fat distribution
1331776|NCT00643968|Treatment Experienced
1331777|NCT00643955|Evaluation of muscle strength and central activation
1331778|NCT00643214|Tetrix Cream
1331779|NCT00643214|Antigen reaction
1331780|NCT00643214|effect on healing
1331781|NCT00643214|To determine if application of Tetrix Cream to lesions of contact dermatitis interferes with their rate of healing
1331782|NCT00643188|Atrial fibrillation
1331783|NCT00643188|Ablation
1331784|NCT00643188|Heart failure
1331785|NCT00643188|Home Monitoring
1331786|NCT00643175|The main objective is to have an endocrinologist treat osteoporosis in patients with fragility hip fractures.
1331787|NCT00643162|Depression
1331788|NCT00643162|Massage
1331789|NCT00643162|Lexapro
1331790|NCT00643162|Alternative Therapy
1331791|NCT00643162|Anti-depressant
1331792|NCT00643929|thrombopoietin receptor agonist
1331793|NCT00643929|ocular safety
1331794|NCT00643929|HCV
1331795|NCT00643929|SB-497115-GR
1331796|NCT00643929|CIT
1331797|NCT00643929|ITP
1331798|NCT00643929|cataract
1331799|NCT00643929|eltrombopag olamine
1331800|NCT00643929|lens opacity
1331801|NCT00643916|Meningitis; Meningococcal Infection
1331802|NCT00643903|Side Effects
1331803|NCT00643903|Adherence
1331804|NCT00643903|Coping
1331805|NCT00643903|HIV
1331806|NCT00643903|AIDS
1331807|NCT00643903|Complementary Therapies
1331808|NCT00643890|Keywords:
1331809|NCT00643890|Parkinson's disease
1331810|NCT00643890|Gene transfer
1331811|NCT00643890|Gene therapy
1331812|NCT00643890|Subthalamic nucleus
1331813|NCT00643890|Adeno-associated virus
1331814|NCT00643890|Study placed in the following topic categories:
1331815|NCT00643890|Ganglion Cysts
1331816|NCT00643890|Movement Disorders
1331817|NCT00643890|Parkinson Disease
1331818|NCT00643890|Basal Ganglia Diseases
1331819|NCT00643890|Central Nervous System Diseases
1331820|NCT00643890|Parkinsonian Disorders
1331821|NCT00643890|Neurodegenerative Diseases
1331822|NCT00643890|Brain Diseases
1331823|NCT00643890|Additional relevant MeSH terms:
1331824|NCT00643890|Nervous System Diseases
1331825|NCT00643877|Colorectal Neoplasms
1331826|NCT00643877|Regional
1331827|NCT00643877|Liver
1331828|NCT00643877|Neoplasm Metastasis
1331829|NCT00643864|mirror training
1331830|NCT00643864|stroke
1331831|NCT00643864|hemiparesis
1331832|NCT00643864|rehabilitation
1331833|NCT00643825|Temozolomide
1331834|NCT00643825|Phase II
1331835|NCT00643825|Chemotherapy
1331836|NCT00643825|Glioblastoma
1331837|NCT00643825|Progression-free Survival
1331838|NCT00643812|Firearm storage
1331839|NCT00643812|Suicide
1331840|NCT00643812|Unintentional injury
1331841|NCT00643812|Alaska Native
1331842|NCT00643812|Suicide Attempt
1331843|NCT00643773|Elderly
1331844|NCT00643760|Peripheral Diabetic Neuropathy (PDN)
1331845|NCT00643760|Neuropathic Pain
1331846|NCT00643747|retinal dystrophy
1331847|NCT00643747|Leber congenital amaurosis
1331848|NCT00643747|RPE65
1331849|NCT00643747|gene therapy
1331850|NCT00643721|Young healthy athletes
1331851|NCT00643708|anovulation
1331852|NCT00643708|laser
1331853|NCT00643708|ovarian interstitial
1331854|NCT00643708|polycystic ovary syndrome
1331855|NCT00643708|ultrasound-guided
1331856|NCT00643695|hepatitis C
1331857|NCT00643695|depression
1331858|NCT00643695|exercise
1331859|NCT00643682|colonoscopy
1331860|NCT00643682|bowel preparation
1331861|NCT00643682|patient education
1331862|NCT00643682|polyp detection
1331863|NCT00643656|Liver biopsy
1331864|NCT00643643|HIV
1331865|NCT00643643|Treatment Naïve
1331866|NCT00643630|Tetrix crea
1331867|NCT00643630|skin barrier
1331868|NCT00643630|antigen reaction
1331869|NCT00643630|prevention
1331870|NCT00643630|The efficacy of Tetrix Cream to prevent an antigen reaction on the skin.
1331871|NCT00643617|Prostate Cancer
1331872|NCT00643617|CyberKnife
1331873|NCT00643617|Stereotactic Radiosurgery
1331874|NCT00643617|Radiosurgery
1331875|NCT00643617|Prostate Tumor
1331876|NCT00643617|Prostate Surgery
1331877|NCT00643604|Pulmonary arterial hypertension
1331878|NCT00643604|treatment satisfaction
1331879|NCT00643604|rapid switch
1331880|NCT00643604|remodulin
1331881|NCT00643604|Quality of life
1331882|NCT00643591|high grade glioma
1331883|NCT00643591|FDG-PET-CT
1331884|NCT00643591|blood proteins
1331885|NCT00643591|prognosis
1331886|NCT00643578|formoterol
1331887|NCT00643578|methacholine challenge
1331888|NCT00643552|Muscle Strength
1331889|NCT00643526|Rheumatoid arthritis
1331890|NCT00643526|Psoriatic arthritis
1331891|NCT00643526|Ankylosing spondylitis
1331892|NCT00643526|Psoriasis
1331893|NCT00643526|Autoinjector
1331894|NCT00643513|QUALITY OF LIFE
1331895|NCT00643513|POSTMENOPAUSAL WOMEN
1331896|NCT00643513|HORMONE RECEPTOR POSITIVE DISSEMINATED BREAST CANCER
1331897|NCT00643513|FASLODEX
1331898|NCT00643500|Levetiracetam
1331899|NCT00643500|Keppra
1331900|NCT00643487|Observe the mechanical behavior of the IPP
1331901|NCT00643435|self-efficacy
1331902|NCT00643435|chronic illness
1331903|NCT00643435|health behavior
1331904|NCT00643435|education, medical, residency
1331905|NCT00643422|normal eyes
1331906|NCT00643396|small cell lung cancer
1331907|NCT00643396|radiotherapy
1331908|NCT00643370|lung cancer
1331909|NCT00643370|tumor motion
1331910|NCT00643357|children with burns
1331911|NCT00643357|Child between 5 and 15 years of age , burned for many days and who has to undergo at least 3 procedures of care
1331912|NCT00643344|obesity
1331913|NCT00643344|mindfulness based stress reduction
1331914|NCT00643344|diet and exercise
1331915|NCT00643344|mindful eating
1331916|NCT00643344|stress
1331917|NCT00643331|Osteoporosis
1331918|NCT00643331|Exercise
1331919|NCT00643331|Low bone density
1331920|NCT00643331|Falls
1331928|NCT00643305|HIV
1331929|NCT00643305|Motivational Interviewing
1331930|NCT00643305|Skills
1331931|NCT00643305|Prevention
1331932|NCT00643305|Mental illness
1331933|NCT00643305|Risk reduction
1331934|NCT00643305|HIV/AIDS
1331935|NCT00643305|HIV Seronegativity
1331936|NCT00643279|implantable hemodynamic monitor
1331937|NCT00643279|Intracardiac pressures
1331938|NCT00643266|recollection training
1331939|NCT00643266|aging
1331940|NCT00643266|amnestic mild cognitive impairment
1331941|NCT00643266|fMRI
1331942|NCT00643253|exclusive breastfeeding
1331943|NCT00643253|breastfeeding promotion
1331944|NCT00643253|health promotion
1331945|NCT00643240|recurrent adult acute lymphoblastic leukemia
1331946|NCT00643240|recurrent childhood acute lymphoblastic leukemia
1331947|NCT00643240|refractory chronic lymphocytic leukemia
1331948|NCT00643123|Bipolar Disorder
1331949|NCT00643123|Mania
1331950|NCT00643123|Mixed mania
1331951|NCT00643123|Allopurinol
1331952|NCT00643123|Treatment-Resistant mania
1331953|NCT00643110|Hypoglycemia
1331954|NCT00643097|adult giant cell glioblastoma
1331955|NCT00643097|adult gliosarcoma
1331956|NCT00643097|adult glioblastoma
1331957|NCT00643084|Colorectal
1331958|NCT00643084|Bowel preparation
1331959|NCT00643084|Laparoscopic surgery
1331960|NCT00643071|Ulcerative colitis
1331961|NCT00643071|Tacrolimus
1331962|NCT00643071|FK506
1331963|NCT00643071|Treatment outcome
1331964|NCT00643058|LPS endotoxin
1331965|NCT00643045|Parkinson Disease
1331966|NCT00643019|Sexually Transmitted Infections
1331967|NCT00643019|Secondary Prevention
1331968|NCT00643019|Cognitive Behavioral Intervention
1331969|NCT00643006|Fibromyalgia
1331970|NCT00643006|Physical activity
1331971|NCT00643006|Function
1331972|NCT00643006|Pain
1331973|NCT00643006|Exercise
1331974|NCT00643006|Inflammation
1331975|NCT00642980|Pregnancy
1331976|NCT00642980|Preterm delivery
1331977|NCT00642980|Bacterial vaginosis
1331978|NCT00642980|Randomized Clinical Trial
1331979|NCT00642980|Clindamycin
1331980|NCT00642928|Excessive Daytime Sleepiness
1331981|NCT00642928|Parkinson's disease
1331982|NCT00642902|Relapsing Multiple Sclerosis
1331983|NCT00642902|Atacicept
1331984|NCT00642889|Parkinson's disease
1331985|NCT00642863|iron deficiency
1331986|NCT00642863|iron deficiency anemia
1331987|NCT00642863|infant
1331988|NCT00642863|development
1331989|NCT00642863|behavior
1331990|NCT00642837|Health-Related Quality of Life
1331991|NCT00642837|KEQ-5D
1331992|NCT00642837|Sleep disturbance
1331993|NCT00642837|Sleep quality
1331994|NCT00642837|SF-1
1331995|NCT00642837|Pain intensity
1331996|NCT00642837|Pain relief
1331997|NCT00642837|Tramadol
1331998|NCT00642837|Acetaminophen
1331999|NCT00642811|coronary artery disease (CAD)
1332000|NCT00642811|heart attack
1332001|NCT00642811|stable angina
1332002|NCT00642785|herpes
1332003|NCT00642785|HSV
1332004|NCT00642785|zoster
1332005|NCT00642785|HZV
1332006|NCT00642785|shingles
1332007|NCT00642772|Osteoarthritis
1332008|NCT00642772|Veterans
1332009|NCT00642772|Physical Therapy
1332010|NCT00642772|Health Services Research
1332011|NCT00642759|NSCLC
1332012|NCT00642759|Abraxane
1332013|NCT00642759|Carboplatin
1332014|NCT00642759|Bevacizumab
1332015|NCT00642759|Avastin
1332016|NCT00642746|Colon
1332017|NCT00642746|Cancer
1332018|NCT00642746|Metastatic
1332019|NCT00642746|Colorectal
1332020|NCT00642707|HIV
1332021|NCT00642707|Treatment Naïve
1332022|NCT00642694|MDD
1332023|NCT00642694|Major Depressive Disorder
1332024|NCT00642694|Depression
1332025|NCT00642694|Initial Insomnia
1332026|NCT00642694|sleep
1332027|NCT00642694|difficulty sleeping
1332028|NCT00642694|down
1332029|NCT00642694|sad
1332030|NCT00642694|Major Depressive Disorder(MDD) and initial insomnia
1332031|NCT00642655|IVIG
1332032|NCT00642655|Rituximab
1332033|NCT00642655|Highly Sensitized
1332034|NCT00642655|Kidney Transplantation
1332035|NCT00642642|Acne
1332036|NCT00642590|Fertility
1332037|NCT00642590|Pregnancy
1332038|NCT00642590|Conception
1332039|NCT00642590|Infertility
1332040|NCT00642590|Behavioral
1332041|NCT00642590|Lifestyle
1332042|NCT00642590|Nutrition
1332043|NCT00642564|Epilepsy
1332044|NCT00642564|Headache
1332045|NCT00642564|Migraine
1332046|NCT00642551|vitamin K2
1332047|NCT00642551|menaquinone-7
1332048|NCT00642551|bone health
1332049|NCT00642551|vascular health
1332050|NCT00642538|Diabetic adult male, diabetic postmenopausal women
1332051|NCT00642525|detection of anastomotic leakage
1332052|NCT00642525|esophageal resection
1332053|NCT00642525|diagnostic safety
1332054|NCT00642512|CINV
1332055|NCT00642512|chemotherapy
1332056|NCT00642512|nausea
1332057|NCT00642512|vomiting
1332058|NCT00642512|retching
1332059|NCT00642499|HIV
1332060|NCT00642499|AIDS
1332061|NCT00642499|nausea
1332062|NCT00642499|vomiting
1332063|NCT00642499|HAART
1332064|NCT00642499|Treatment Experienced
1332065|NCT00642499|HIV Infections
1332066|NCT00642486|treatment
1332067|NCT00642486|positive airway pressure
1332068|NCT00642486|compliance
1332069|NCT00642486|cost effectiveness
1332070|NCT00642486|clinical trial
1332071|NCT00642447|noninvasive ventilation
1332072|NCT00642447|helium
1332073|NCT00642447|oxygen
1332074|NCT00642447|sulfur mustard
1332075|NCT00642447|chronic bronchitis
1332076|NCT00642447|bronchiolitis
1332077|NCT00642434|diabetes blood pressure oxidative stress
1332078|NCT00642421|Acromegaly
1332079|NCT00642395|Multiple Myeloma
1332080|NCT00642395|Autologous Stem Cells Transplantation
1332081|NCT00642395|High Dose Melphalan
1332082|NCT00642395|Bortezomib
1332083|NCT00642382|Osteoarthritis
1332084|NCT00642382|Hyaluronic Acid
1332085|NCT00642369|Polysomnograph
1332086|NCT00642356|Idiopathic Parkinson's disease
1332087|NCT00642356|carbidopa/levodopa/entacapone
1332088|NCT00642356|non-motor symptoms
1332089|NCT00642356|motor-symptoms
1332090|NCT00642343|Balance
1332091|NCT00642343|Severe, Profound deafness
1332092|NCT00642343|Children
1332093|NCT00642343|unilateral/bilateral cochlear implants
1332094|NCT00642343|unilateral cochlear implant
1332095|NCT00642343|bilateral cochlear implants
1332096|NCT00642330|patent
1332097|NCT00642330|ductus
1332098|NCT00642330|arteriosus
1332099|NCT00642330|ibuprofen
1332100|NCT00642330|premature
1332101|NCT00642330|infant
1332102|NCT00642317|Healthy Control
1332103|NCT00642317|Tobacco Use
1332104|NCT00642317|Tobacco Initiation
1332105|NCT00642317|Smoking
1332106|NCT00642317|Questionnaire
1332107|NCT00642317|Survey
1332108|NCT00642291|Emtricitabine
1332109|NCT00642291|Pediatric
1332110|NCT00642291|HIV-1
1332111|NCT00642291|Treatment of HIV-1
1332112|NCT00642278|Type 2 diabetes mellitus
1332113|NCT00642278|Metformin
1332114|NCT00642278|Hemoglobin A1c
1332115|NCT00642252|remineraliation
1332116|NCT00642252|pre-existing white-spot (non-cavitated) enamel lesions
1332117|NCT00642239|Sodium Glycididazole, Radiochemotherapy, Esophageal Carcinoma
1332118|NCT00642226|Branch Retinal Vein Occlusion
1332119|NCT00642226|BRVO
1332120|NCT00642226|Macular Edema
1332121|NCT00642226|Triamcinolone
1332122|NCT00642226|Vitrectomy
1332123|NCT00642213|stroke
1332124|NCT00642213|ischemic
1332125|NCT00642213|TIA
1332126|NCT00642213|hemorrhage
1332127|NCT00642213|incidence
1332128|NCT00642213|case-fatality
1332129|NCT00642213|risk factors
1332130|NCT00642213|genetic
1332131|NCT00642187|Asthma
1332132|NCT00642187|Pulmicort
1332133|NCT00642187|Turbuhaler
1332134|NCT00642187|Budesonide
1332135|NCT00642187|Flexhaler
1332136|NCT00642161|Asthma
1332137|NCT00642161|Pulmicort
1332138|NCT00642161|Children
1332139|NCT00642161|Paediatrics
1332140|NCT00642161|budesonide
1332141|NCT00642161|Flexhaler
1332142|NCT00642148|GW856553
1332143|NCT00642148|p38 MAPK
1332144|NCT00642148|Chronic Obstructive Pulmonary Disease
1332145|NCT00642135|premature
1332146|NCT00642135|neonates
1332147|NCT00642135|infants
1332148|NCT00642135|children
1332149|NCT00642135|Mydriasert®
1332150|NCT00642135|mydriasis
1332151|NCT00642135|fundus
1332152|NCT00642135|Tropicamide
1332153|NCT00642135|Phenylephrine
1332154|NCT00642135|clinical trial
1332155|NCT00642135|Infant
1332156|NCT00642135|premature newborns
1332157|NCT00642135|bilateral diagnosis fundus
1332158|NCT00642122|Asthma
1332159|NCT00642122|Pulmicort
1332160|NCT00642122|budesonide
1332161|NCT00642122|respules
1332162|NCT00642122|turbuhaler
1332163|NCT00642096|High blood pressure
1332164|NCT00642096|hypertension
1332165|NCT00642096|(TOPROL-XL)
1332166|NCT00642096|metoprolol succinate
1332167|NCT00642096|hydrochlorothiazide
1332168|NCT00642083|outflow stenosis
1332169|NCT00642083|stentgraft
1332170|NCT00642070|Current symptoms of urinary tract infection
1332171|NCT00642057|chorea
1332172|NCT00642057|dyskinesia
1332173|NCT00642057|hyperkinetic
1332174|NCT00642044|Keratoconus
1332175|NCT00642031|Hematologic Malignancies
1332176|NCT00642031|Leukemia
1332177|NCT00642031|Chronic Myelomonocytic Leukemia
1332178|NCT00642031|Acute Lymphocytic Leukemia
1332179|NCT00642031|Chronic Lymphocytic Leukemia
1332180|NCT00642031|Chronic Myelogenous Leukemia
1332181|NCT00642031|Agnogenic Myeloid Metaplasia
1332182|NCT00642031|Triciribine Phosphate Monohydrate
1332183|NCT00642031|Triciribine
1332184|NCT00642031|TCN-PM
1332185|NCT00642031|VD-0002
1332186|NCT00642018|Hormone Refractory Prostate Cancer
1332187|NCT00642005|Humidification
1332188|NCT00642005|Laparoscopy
1332189|NCT00642005|Colon
1332190|NCT00642005|Hemicolectomy
1332191|NCT00642005|Warming
1332192|NCT00641992|amebic liver abscess
1332193|NCT00641992|failure
1332194|NCT00641992|prognosis
1332195|NCT00641979|Allergic rhinitis
1332196|NCT00641979|Nasal symptoms
1332197|NCT00641979|Congestion
1332198|NCT00641979|Rhinorrhea
1332199|NCT00641979|Sneeze
1332200|NCT00641979|budesonide
1332201|NCT00641979|Rhinocort AQUA
1332202|NCT00641953|Foot Pain
1332203|NCT00641953|Diabetic Neuropathy Pain
1332204|NCT00641953|Diabetic Peripheral Neuropathy foot pain
1332205|NCT00641940|Prevention
1332206|NCT00641940|Girls
1332207|NCT00641940|Resilience
1332208|NCT00641927|bipolar disorder
1332209|NCT00641927|bipolar type II disorder
1332210|NCT00641927|antidepressant
1332211|NCT00641927|mood stabilizer
1332212|NCT00641927|venlafaxine
1332213|NCT00641927|lithium carbonate
1332214|NCT00641914|Asthma
1332215|NCT00641914|Pulmicort
1332216|NCT00641914|budesonide
1332217|NCT00641901|gingivitis
1332218|NCT00641901|pregnancy
1332219|NCT00641901|pre-term birth
1332220|NCT00641888|Cardiovascular risk
1332221|NCT00641888|Inflammatory biomarkers
1332222|NCT00641888|Human immunodeficiency virus
1332223|NCT00641875|arterial stiffness
1332224|NCT00641875|artery
1332225|NCT00641875|aortic pulse wave velocity
1332226|NCT00641875|pulse wave analysis
1332227|NCT00641875|augmentation index
1332228|NCT00641875|end stage renal disease
1332229|NCT00641875|nocturnal hemodialysis
1332230|NCT00641875|extended hours of hemodialysis
1332231|NCT00641875|cardiovascular
1332232|NCT00641875|hemodialysis
1332233|NCT00641862|Pregnancy
1332234|NCT00641862|Maternal Nutritional Status
1332235|NCT00641862|Vitamin B12
1332236|NCT00641849|BMI
1332237|NCT00641849|Physical Activity
1332238|NCT00641849|Food
1332239|NCT00641849|Nutrition
1332240|NCT00641849|Dietary behaviors
1332241|NCT00641849|Diet
1332242|NCT00641849|Adult
1332243|NCT00641849|Adults
1332244|NCT00641849|Fat
1332245|NCT00641849|Fats
1332246|NCT00641849|Self monitoring
1332247|NCT00641849|Automated feedback
1332248|NCT00641823|Orthopedic Surgical Procedures
1332249|NCT00641810|Caffeine
1332250|NCT00641810|Snoring
1332251|NCT00641810|Sleep
1332252|NCT00641797|Canalith Repositioning Technique
1332253|NCT00641797|Vertigo
1332254|NCT00641784|Composite Early neonatal Outcome
1332255|NCT00641784|Late Neurological neonatal outcome
1332256|NCT00641758|Coronary Artery Disease
1332257|NCT00641758|endothelial dysfunction
1332258|NCT00641758|Nitric oxide
1332259|NCT00641745|Lurasidone
1332260|NCT00641745|Schizophrenia
1332261|NCT00641745|Latuda
1332262|NCT00641732|venous thromboembolism
1332263|NCT00641732|oral anticoagulant
1332264|NCT00641732|direct factor Xa inhibitor
1332265|NCT00641732|total knee replacement
1332266|NCT00641732|drug therapy
1332267|NCT00641693|Allergic rhinitis
1332268|NCT00641693|Paediatric
1332269|NCT00641693|Nasal symptoms
1332270|NCT00641693|Congestion
1332271|NCT00641693|Rhinorrhea
1332272|NCT00641693|Sneeze
1332273|NCT00641693|budesonide
1332274|NCT00641693|Rhinocort AQUA
1332275|NCT00641680|Seasonal allergic rhinitis
1332276|NCT00641680|Nasal symptoms
1332277|NCT00641680|Congestion
1332278|NCT00641680|Rhinorrhea
1332279|NCT00641680|Sneeze
1332280|NCT00641680|budesonide
1332281|NCT00641680|Rhinocort AQUA
1332282|NCT00641680|Fluticasone propionate
1332283|NCT00641680|Flonase
1332284|NCT00641667|Pain
1332285|NCT00641667|Cancer
1332286|NCT00641667|Fentanyl
1332287|NCT00641667|JNS020QD
1332288|NCT00641654|Chronic hepatitis C
1332289|NCT00641654|genotype 2 or 3
1332290|NCT00641654|relapse
1332291|NCT00641654|pegylated interferon
1332292|NCT00641654|ribavirin
1332293|NCT00641641|Viral compartments
1332294|NCT00641641|integrase inhibitor therapy
1332295|NCT00641641|viral species
1332296|NCT00641628|Nipple sparing mastectomy
1332297|NCT00641628|NAC conservation
1332298|NCT00641602|Erosive Esophagitis
1332299|NCT00641602|Nexium
1332300|NCT00641602|Heartburn
1332301|NCT00641589|Chronic Kidney Disease
1332302|NCT00641589|anemia
1332303|NCT00641589|epoetin alfa
1332304|NCT00641576|Endosseous implants
1332305|NCT00641563|dexmedetomidine
1332306|NCT00641563|midazolam
1332307|NCT00641563|remifentanil
1332308|NCT00641563|Electroencephalography
1332309|NCT00641563|Event related potentials
1332310|NCT00641563|BIS
1332311|NCT00641563|Bispectral Index
1332312|NCT00641563|Response Entropy
1332313|NCT00641563|State Entropy
1332314|NCT00641550|physical exercise
1332315|NCT00641550|maternal complications
1332316|NCT00641550|preterm labor
1332317|NCT00641550|birthweight
1332318|NCT00641550|Apgar scores
1332319|NCT00641524|Non-alcoholic fatty liver disease
1332320|NCT00641524|liver fibrosis
1332321|NCT00641524|metabolic syndrome
1332322|NCT00641524|iron overload
1332323|NCT00641524|phlebotomy
1332324|NCT00641511|PTSD
1332325|NCT00641498|suicide
1332326|NCT00641498|parasuicide
1332327|NCT00641498|prevention
1332328|NCT00641498|individual supportive psychotherapy
1332329|NCT00641472|Asthma
1332330|NCT00641472|Pulmicort
1332331|NCT00641472|Children
1332332|NCT00641472|paediatrics
1332333|NCT00641472|budesonide
1332334|NCT00641459|Behavioral and Psychological Symptoms of Dementia
1332335|NCT00641459|BPSD
1332336|NCT00641459|NPI
1332337|NCT00641459|CGI
1332338|NCT00641459|MMSE
1332339|NCT00641446|Children
1332340|NCT00641446|Asthma
1332341|NCT00641446|Varivax
1332342|NCT00641446|varicella
1332343|NCT00641446|Pulmicort
1332344|NCT00641446|budesonide
1332345|NCT00641433|chemocautery
1332346|NCT00641420|Acne scarring
1332347|NCT00641420|Post inflammatory hyperpigmentation
1332348|NCT00641407|Bedtime insulins
1332349|NCT00641407|Poorly controlled type 2 diabetes
1332350|NCT00641407|Glycemic control
1332351|NCT00641407|HbA1c
1332352|NCT00641394|cortisol
1332353|NCT00641394|hydrocortisone
1332354|NCT00641394|psychotherapy
1332355|NCT00641394|Emotional Freedom Techniques (EFT)
1332356|NCT00641394|Cognitive Behavioral Therapy (CBT)
1332357|NCT00641394|depression
1332358|NCT00641394|anxiety
1332359|NCT00641381|stage III adult Hodgkin lymphoma
1332360|NCT00641381|stage III childhood Hodgkin lymphoma
1332361|NCT00641381|stage IV adult Hodgkin lymphoma
1332362|NCT00641381|stage IV childhood Hodgkin lymphoma
1332363|NCT00641381|recurrent childhood lymphoblastic lymphoma
1332364|NCT00641381|recurrent mantle cell lymphoma
1332365|NCT00641381|recurrent adult Hodgkin lymphoma
1332366|NCT00641381|recurrent/refractory childhood Hodgkin lymphoma
1332367|NCT00641381|recurrent adult T-cell leukemia/lymphoma
1332368|NCT00641381|recurrent cutaneous T-cell non-Hodgkin lymphoma
1332369|NCT00641381|AIDS-related diffuse large cell lymphoma
1332370|NCT00641381|AIDS-related diffuse mixed cell lymphoma
1332371|NCT00641381|AIDS-related immunoblastic large cell lymphoma
1332372|NCT00641381|AIDS-related lymphoblastic lymphoma
1332373|NCT00641381|AIDS-related small noncleaved cell lymphoma
1332374|NCT00641381|Burkitt lymphoma
1332375|NCT00641381|stage III adult diffuse large cell lymphoma
1332376|NCT00641381|stage III adult diffuse mixed cell lymphoma
1332377|NCT00641381|stage IV adult diffuse large cell lymphoma
1332378|NCT00641381|stage IV adult diffuse mixed cell lymphoma
1332379|NCT00641381|stage III grade 3 follicular lymphoma
1332380|NCT00641381|stage IV grade 3 follicular lymphoma
1332381|NCT00641381|stage III adult immunoblastic large cell lymphoma
1332382|NCT00641381|stage IV adult immunoblastic large cell lymphoma
1332383|NCT00641381|stage III adult lymphoblastic lymphoma
1332384|NCT00641381|stage III childhood lymphoblastic lymphoma
1332385|NCT00641381|stage IV adult lymphoblastic lymphoma
1332386|NCT00641381|stage IV childhood lymphoblastic lymphoma
1332387|NCT00641381|stage III adult Burkitt lymphoma
1332388|NCT00641381|stage IV adult Burkitt lymphoma
1332389|NCT00641381|HIV Infections
1332390|NCT00641381|Treatment Experienced
1332391|NCT00641368|Adolescent
1332392|NCT00641368|Child
1332393|NCT00641368|Computer
1332394|NCT00641368|Depression
1332395|NCT00641368|Resilience
1332396|NCT00641342|Parastomal hernia
1332397|NCT00641342|Onlay mesh
1332398|NCT00641342|Sublay mesh
1332399|NCT00641342|Pain
1332400|NCT00641342|Health questionnaire
1332401|NCT00641329|ADHD
1332402|NCT00641329|ADD
1332403|NCT00641329|Attention Deficit Hyperactivity Disorder
1332404|NCT00641329|Attention Deficit
1332405|NCT00641329|Clonidine
1332406|NCT00641329|CLONICEL
1332407|NCT00641329|Addrenex
1332408|NCT00641316|Freeze-dried bone allograft
1332409|NCT00641316|Platelet-rich plasma
1332410|NCT00641316|Platelet-derived growth factors
1332411|NCT00641316|Laser-threaded dental implants
1332412|NCT00641316|Resorbable blast textured dental implants
1332413|NCT00641303|pain
1332414|NCT00641303|fatigue
1332415|NCT00641303|hot flashes
1332416|NCT00641303|sleep disorders
1332417|NCT00641303|depression
1332418|NCT00641303|anxiety disorder
1332419|NCT00641303|stage I breast cancer
1332420|NCT00641303|stage II breast cancer
1332421|NCT00641303|stage IIIA breast cancer
1332422|NCT00641303|stage IIIB breast cancer
1332423|NCT00641303|stage IIIC breast cancer
1332424|NCT00641290|CABG
1332425|NCT00641290|Valve surgery
1332426|NCT00641277|endosseous dental implants
1332427|NCT00641277|dental aesthetics
1332428|NCT00641264|Laryngopharyngeal reflux (LPR)
1332429|NCT00641264|Omeprazole
1332430|NCT00641264|Losec
1332431|NCT00641264|Quality of Life
1332432|NCT00641264|Laryngitis
1332433|NCT00641251|T2 Diabetes
1332434|NCT00641251|Type 2 diabetes CVD event rates and mortality
1332435|NCT00641238|NSCLC
1332436|NCT00641238|lung cancer
1332437|NCT00641225|Ascending Single Dose
1332438|NCT00641225|Safety
1332439|NCT00641225|Pharmacokinetics
1332440|NCT00641225|Open-label
1332441|NCT00641212|Allergic rhinitis
1332442|NCT00641212|Perennial allergic rhinitis
1332443|NCT00641212|Paediatric
1332444|NCT00641212|Growth
1332445|NCT00641212|budesonide
1332446|NCT00641212|Rhinocort AQUA
1332447|NCT00641199|Antibiotic-associated diarrhea
1332448|NCT00641199|Probiotic
1332449|NCT00641199|Quality of life
1332450|NCT00641199|Antibiotics
1332451|NCT00641186|excessive daytime somnolence
1332452|NCT00641186|Parkinson disease
1332453|NCT00641186|sleep disturbance
1332454|NCT00641173|PTSD
1332455|NCT00641173|cortisol
1332456|NCT00641173|hippocampus
1332457|NCT00641173|memory
1332458|NCT00641160|vinorelbine
1332459|NCT00641160|metronomic dosing
1332460|NCT00641160|oral administration
1332461|NCT00641160|nonhematologic malignancies
1332462|NCT00641160|pharmacokinetics
1332463|NCT00641134|Cardiac Rehabilitation
1332464|NCT00641134|Old age
1332465|NCT00641134|Home physical training
1332466|NCT00641108|SPECT Brain Imaging
1332467|NCT00641108|Cognitive Therapy
1332468|NCT00641108|Serotonin Transporter Binding
1332469|NCT00641108|Predictive Biomarker
1332470|NCT00641095|contiguous stage II mantle cell lymphoma
1332471|NCT00641095|noncontiguous stage II mantle cell lymphoma
1332472|NCT00641095|stage I mantle cell lymphoma
1332473|NCT00641095|stage III mantle cell lymphoma
1332474|NCT00641095|stage IV mantle cell lymphoma
1332475|NCT00641069|Cardiac arrest
1332476|NCT00641069|Cardiopulmonary resuscitation
1332477|NCT00641056|diabetes
1332478|NCT00641056|exenatide
1332479|NCT00641056|exenatide once weekly
1332480|NCT00641056|metformin
1332481|NCT00641056|sulfonylurea
1332482|NCT00641056|insulin glargine
1332483|NCT00641056|Amylin
1332484|NCT00641056|Lilly
1332485|NCT00641030|de novo myelodysplastic syndromes
1332486|NCT00641030|previously treated myelodysplastic syndromes
1332487|NCT00641030|secondary myelodysplastic syndromes
1332488|NCT00641030|adult acute lymphoblastic leukemia in remission
1332489|NCT00641030|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1332490|NCT00641030|adult acute myeloid leukemia with inv(16)(p13;q22)
1332491|NCT00641030|adult acute myeloid leukemia with t(15;17)(q22;q12)
1332492|NCT00641030|adult acute myeloid leukemia with t(16;16)(p13;q22)
1332493|NCT00641030|adult acute myeloid leukemia with t(8;21)(q22;q22)
1332494|NCT00641030|adult acute myeloid leukemia in remission
1332495|NCT00641030|recurrent adult acute myeloid leukemia
1332496|NCT00641030|childhood acute myeloid leukemia in remission
1332497|NCT00641030|recurrent childhood acute myeloid leukemia
1332498|NCT00641030|secondary acute myeloid leukemia
1332499|NCT00641030|childhood myelodysplastic syndromes
1332500|NCT00641030|recurrent adult acute lymphoblastic leukemia
1332501|NCT00641030|recurrent childhood acute lymphoblastic leukemia
1332502|NCT00641030|childhood acute lymphoblastic leukemia in remission
1332503|NCT00640991|Clinical Trial
1332504|NCT00640991|Insulin
1332505|NCT00640978|Pancreatic Cancer
1332506|NCT00640978|Advanced Pancreatic Cancer
1332507|NCT00640978|Unresectable
1332508|NCT00640978|Metastatic
1332509|NCT00640978|RAD001
1332510|NCT00640978|Everolimus
1332511|NCT00640978|Erlotinib
1332512|NCT00640978|OSI-774
1332513|NCT00640978|Erlotinib Hydrochloride
1332514|NCT00640978|Tarceva
1332515|NCT00640952|Parkinson's disease
1332516|NCT00640952|impulse control behaviors
1332517|NCT00640952|dopa-dysregulation
1332518|NCT00640939|Tendonitis
1332519|NCT00640939|Bursitis
1332520|NCT00640913|Defunctioning stoma
1332521|NCT00640913|Low anterior resection
1332522|NCT00640913|TME surgery
1332523|NCT00640913|Early stoma reversal
1332524|NCT00640900|overweight
1332525|NCT00640900|obesity
1332526|NCT00640900|weight loss
1332527|NCT00640900|commercial weight loss program
1332528|NCT00640887|HIV
1332529|NCT00640887|Tuberculosis
1332530|NCT00640887|Rifabutin
1332531|NCT00640887|Pharmacokinetics
1332532|NCT00640887|South Africa
1332533|NCT00640874|Prophylaxis
1332534|NCT00640874|pandemic influenza
1332535|NCT00640874|influenza A
1332536|NCT00640874|H5N1 virus
1332537|NCT00640861|stage II breast cancer
1332538|NCT00640861|stage IIIA breast cancer
1332539|NCT00640861|stage IIIB breast cancer
1332540|NCT00640861|stage IIIC breast cancer
1332541|NCT00640861|stage IA breast cancer
1332542|NCT00640861|stage IB breast cancer
1332543|NCT00640861|triple-negative breast cancer
1332544|NCT00640861|HER2-positive breast cancer
1332545|NCT00640835|Opioid dependence
1332546|NCT00640809|Bowel Disease
1332547|NCT00640796|Hematologic malignancies, non-B lineage
1332548|NCT00640796|NK cell expansion
1332549|NCT00640796|CliniMACS device
1332550|NCT00640796|Immunotherapy
1332551|NCT00640783|Metabolic syndrome
1332552|NCT00640783|Mediterranean diet
1332553|NCT00640783|Inflammatory markers
1332554|NCT00640783|Endothelial function
1332555|NCT00640757|Methionine
1332556|NCT00640757|Metabolic syndrome
1332557|NCT00640757|Glucose Metabolism
1332558|NCT00640757|Amino acid
1332559|NCT00640757|Insulin clamp
1332560|NCT00640744|Atherogenesis
1332561|NCT00640744|Atheroma
1332562|NCT00640744|Arteriosclerosis
1332563|NCT00640731|DVT
1332564|NCT00640731|Peripheral Vascular Disease
1332565|NCT00640731|Venous Thrombosis
1332566|NCT00640731|Deep Vein Thrombosis
1332567|NCT00640718|heart and respiratory monitoring
1332568|NCT00640692|Gastrointestinal stromal tumor
1332569|NCT00640692|GIST
1332570|NCT00640692|Sunitinib
1332571|NCT00640692|Imatinib
1332572|NCT00640679|Clopidogrel
1332573|NCT00640679|Drug-eluting Stent
1332574|NCT00640666|Breast cancer
1332575|NCT00640666|Exercise
1332576|NCT00640666|Biomarkers
1332577|NCT00640653|Sexual Behavior
1332578|NCT00640653|Abstinence
1332579|NCT00640653|Intervention Studies
1332580|NCT00640653|HIV
1332581|NCT00640653|Sexually Transmitted Infection
1332582|NCT00640653|Theory of Planned Behavior
1332583|NCT00640653|HIV Seronegativity
1332584|NCT00640640|IOP
1332585|NCT00640640|OPA
1332586|NCT00640640|AMD
1332587|NCT00640640|bevacizumab
1332588|NCT00640640|ranibizumab
1332589|NCT00640640|choroidal blood flow
1332590|NCT00640640|DCT
1332591|NCT00640640|Ocular Pulse Amplitude change following anti VEGF
1332592|NCT00640640|Ocular Pulse Amplitude
1332593|NCT00640614|Dermatitis, Contact
1332594|NCT00640601|Seroquel
1332595|NCT00640601|schizophrenia
1332596|NCT00640601|Extended Release
1332597|NCT00640588|Hepatitis B, chronic
1332598|NCT00640588|Viral kinetics
1332599|NCT00640588|Telbivudine
1332600|NCT00640588|Adefovir
1332601|NCT00640588|Compliance
1332602|NCT00640562|Schizophrenia
1332603|NCT00640562|Depression
1332604|NCT00640562|Quetiapine
1332605|NCT00640549|LDL-subfractions, HDL-subfractions, non insulin dependent diabetes mellitus (NIDDM), hyperlipidemia, atorvastatin
1332606|NCT00640497|acute GVHD
1332607|NCT00640497|immunotoxin
1332608|NCT00640497|anti-CD3
1332609|NCT00640497|anti-CD7
1332610|NCT00640497|Ricin A
1332611|NCT00640471|recurrent colon cancer
1332612|NCT00640471|stage IV colon cancer
1332613|NCT00640471|recurrent rectal cancer
1332614|NCT00640471|stage IV rectal cancer
1332615|NCT00640445|Clinical Trial
1332616|NCT00640445|Combat Disorders
1332617|NCT00640445|PTSD
1332618|NCT00640445|Internet-Based Intervention
1332619|NCT00640445|Mental Health Services
1332620|NCT00640445|Post-deployment Reintegration
1332621|NCT00640393|Etanercept, UVB, Enbrel, Psoriasis.
1332622|NCT00640380|cervical
1332623|NCT00640380|paravertebral
1332624|NCT00640380|block
1332625|NCT00640367|Acute ischemic stroke
1332626|NCT00640367|thrombolysis
1332627|NCT00640367|intra-arterial thrombolysis
1332628|NCT00640354|Automated External Defibrillator
1332629|NCT00640354|Resuscitation
1332630|NCT00640354|Pediatric
1332631|NCT00640328|relapsing forms of multiple sclerosis
1332632|NCT00640328|ofatumumab
1332633|NCT00640328|multiple sclerosis
1332634|NCT00640315|Chronic obstructive pulmonary disease
1332635|NCT00640315|COPD
1332636|NCT00640315|Pulmonary hypertension
1332637|NCT00640302|Index cases
1332638|NCT00640302|pandemic influenza
1332639|NCT00640302|influenza A
1332640|NCT00640302|H5N1 virus
1332641|NCT00640289|Factor XIII Deficiency
1332642|NCT00640289|Rare Bleeding Disorder
1332643|NCT00640289|Hemophilia
1332644|NCT00640289|Fibrogammin P
1332645|NCT00640276|pitavastatin
1332646|NCT00640276|metabolic syndrome
1332647|NCT00640276|metabolic syndrome risk score
1332648|NCT00640276|hypercholesterolemia
1332649|NCT00640263|HIV-1
1332650|NCT00640263|Breastfeeding
1332651|NCT00640263|Prevention
1332652|NCT00640263|lamivudine
1332653|NCT00640263|lopinavir/ritonavir
1332654|NCT00640250|Dermatitis, Contact, Bronopol, Disperse Blue 106
1332655|NCT00640237|Vitamine D State
1332656|NCT00640211|Prophylaxis
1332657|NCT00640211|pandemic influenza
1332658|NCT00640211|influenza A
1332659|NCT00640211|H5N1 virus
1332660|NCT00640198|Aphasia
1332661|NCT00640198|Memantine
1332662|NCT00640198|Constraint-induced language therapy
1332663|NCT00640198|Event-related potentials
1332664|NCT00640159|Parkinson's disease
1332665|NCT00640159|selegiline to Zelapar switch
1332666|NCT00640159|orally disintegrating formulation
1332667|NCT00640133|Deep Brain Stimulation
1332668|NCT00640133|Treatment Refractory
1332669|NCT00640133|Ventral Internal Capsule/Ventral Striatum
1332670|NCT00640133|Neurosurgery
1332671|NCT00640133|Neuroimaging
1332672|NCT00640120|wheeze detection
1332673|NCT00640107|Magnetic Resonance Imaging
1332674|NCT00640094|Melatonin
1332675|NCT00640094|Acute myocardial infarction
1332676|NCT00640094|Primary angioplasty
1332677|NCT00640081|adenocarcinoma of the colon
1332678|NCT00640081|stage IV colon cancer
1332679|NCT00640081|adenocarcinoma of the rectum
1332680|NCT00640081|stage IV rectal cancer
1332681|NCT00640081|stage III colon cancer
1332682|NCT00640081|stage III rectal cancer
1332683|NCT00640081|recurrent colon cancer
1332684|NCT00640081|recurrent rectal cancer
1332685|NCT00640068|coronary artery disease
1332686|NCT00640068|chest pain
1332687|NCT00640068|coronary artery bypass graft
1332688|NCT00640068|stress test
1332689|NCT00640068|Coronary Angiography
1332690|NCT00640055|verbal autopsy
1332691|NCT00640055|stillbirth
1332692|NCT00640055|neonatal death
1332693|NCT00640042|pain
1332694|NCT00640042|opioid
1332695|NCT00640042|abuse
1332696|NCT00640042|moderate-severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time
1332697|NCT00640029|Arthroplasty
1332698|NCT00640029|Arthrodesis
1332699|NCT00640029|Prosthesis
1332700|NCT00640029|Disc replacement
1332701|NCT00640029|Spine
1332702|NCT00640029|Lumbar
1332703|NCT00640029|Cervical
1332704|NCT00640029|Intervertebral disk
1332705|NCT00640029|Cervical or lumbar intervertebral disk
1332706|NCT00640029|Degenerative pathology
1332707|NCT00640016|Asthma
1332708|NCT00640016|CAT-354
1332709|NCT00640016|Tralokinumab
1332710|NCT00640003|AT
1332711|NCT00640003|Ataxia
1332712|NCT00640003|Telangiectasia
1332713|NCT00639990|Intraabdominal pressure
1332714|NCT00639977|Intraocular Pressure
1332715|NCT00639977|Acupuncture
1332716|NCT00639977|Healthy Volunteers
1332717|NCT00639964|diabetes
1332718|NCT00639964|pregnancy
1332719|NCT00639964|macrosomia
1332720|NCT00639964|lipidics markers
1332721|NCT00639964|nutritional factors
1332722|NCT00639964|placenta
1332723|NCT00639964|umbilical blood cord
1332724|NCT00639951|Snake Bite
1332725|NCT00639951|Antivenin Treatment
1332726|NCT00639938|Pregnancy, High-Risk
1332727|NCT00639938|HIV Seronegativity
1332728|NCT00639912|contrast induced nephropathy STEMI PCI
1332729|NCT00639899|Varicocele
1332730|NCT00639873|Uncomplicated P. falciparum malaria
1332731|NCT00639860|extraction
1332732|NCT00639860|implant
1332733|NCT00639860|alveolar ridge preservation
1332734|NCT00639847|Asthma management
1332735|NCT00639847|cost
1332736|NCT00639847|disease management
1332737|NCT00639847|respiratory care
1332738|NCT00639847|nursing
1332739|NCT00639847|health care utilization
1332740|NCT00639847|health related quality of life
1332741|NCT00639834|rheumatoid
1332742|NCT00639834|arthritis
1332743|NCT00639834|RA
1332744|NCT00639834|joint inflammation
1332745|NCT00639834|autoimmune
1332746|NCT00639834|Medarex
1332747|NCT00639834|Rheumatology
1332748|NCT00639821|Gene expression microarray
1332749|NCT00639821|Inflammatory bowel disease
1332750|NCT00639821|Infliximab
1332751|NCT00639808|delayed gastric emptying
1332752|NCT00639808|symptomatic gastroparesis
1332753|NCT00639808|diabetes mellitus
1332754|NCT00639795|Thoracic paravertebral block
1332755|NCT00639795|Cytokines
1332756|NCT00639795|Video assisted thorascopic surgery
1332757|NCT00639795|Pain
1332758|NCT00639782|thromboembolism
1332759|NCT00639782|mechanical heart valves
1332760|NCT00639782|randomized
1332761|NCT00639769|recurrent squamous cell carcinoma of the hypopharynx
1332762|NCT00639769|stage IV squamous cell carcinoma of the hypopharynx
1332763|NCT00639769|stage IV squamous cell carcinoma of the larynx
1332764|NCT00639769|stage IV verrucous carcinoma of the larynx
1332765|NCT00639769|recurrent squamous cell carcinoma of the larynx
1332766|NCT00639769|recurrent verrucous carcinoma of the larynx
1332767|NCT00639769|recurrent squamous cell carcinoma of the lip and oral cavity
1332768|NCT00639769|stage IV squamous cell carcinoma of the lip and oral cavity
1332769|NCT00639769|recurrent verrucous carcinoma of the oral cavity
1332770|NCT00639769|stage IV verrucous carcinoma of the oral cavity
1332771|NCT00639769|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1332772|NCT00639769|recurrent metastatic squamous neck cancer with occult primary
1332773|NCT00639769|untreated metastatic squamous neck cancer with occult primary
1332774|NCT00639769|recurrent squamous cell carcinoma of the nasopharynx
1332775|NCT00639769|stage IV squamous cell carcinoma of the nasopharynx
1332776|NCT00639769|recurrent squamous cell carcinoma of the oropharynx
1332777|NCT00639769|stage IV squamous cell carcinoma of the oropharynx
1332778|NCT00639769|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1332779|NCT00639769|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1332780|NCT00639769|recurrent salivary gland cancer
1332781|NCT00639769|salivary gland squamous cell carcinoma
1332782|NCT00639769|stage IV salivary gland cancer
1332783|NCT00639756|Uric acid
1332784|NCT00639756|Fructose
1332785|NCT00639756|Hypertension
1332786|NCT00639756|Insulin
1332787|NCT00639756|Glucose
1332788|NCT00639756|HOMA
1332789|NCT00639743|Pulmonary embolism
1332790|NCT00639743|Heparin
1332791|NCT00639743|Thrombolytic therapy
1332792|NCT00639743|Bleeding
1332793|NCT00639730|Epilepsy
1332794|NCT00639717|GVHD
1332795|NCT00639704|MRI
1332796|NCT00639704|SPECT
1332797|NCT00639704|Cardiac function
1332798|NCT00639691|Asthma, Anti-immunoglobin E, omalizumab
1332799|NCT00639678|healthy volunteers
1332800|NCT00639665|Cocoa, diabetes, polyphenols
1332801|NCT00639652|Carcinoma, Basal Cell
1332802|NCT00639652|3D-histology
1332803|NCT00639652|Micrographic surgery
1332804|NCT00639652|Mohs surgery
1332805|NCT00639652|Shave excision
1332806|NCT00639652|Recurrence
1332807|NCT00639652|Esthetic outcome
1332808|NCT00639639|adult giant cell glioblastoma
1332809|NCT00639639|adult gliosarcoma
1332810|NCT00639587|Cetirizine
1332811|NCT00639587|Zyrtec
1332812|NCT00639574|Pain, morphine, nefopam, co analgesia, ureteral calculi, emergency
1332813|NCT00639561|digestive system
1332814|NCT00639561|Diet
1332815|NCT00639548|Deep Sedation
1332816|NCT00639548|EEG
1332817|NCT00639548|Event-Related Potentials
1332818|NCT00639548|Evoked potentials, auditory
1332819|NCT00639548|BIS-Index
1332820|NCT00639548|Entropy
1332821|NCT00639548|ICU
1332822|NCT00639535|Radiology
1332823|NCT00639535|MRI
1332824|NCT00639535|Positron emission tomography
1332825|NCT00639535|Breast Abnormalities
1332826|NCT00639535|Dense Breast Tissue
1332827|NCT00639522|Liposomal paclitaxel
1332828|NCT00639522|Maximum tolerated dose
1332829|NCT00639522|Pharmacokinetics
1332830|NCT00639522|Gastric carcinoma
1332831|NCT00639496|Idiopathic Pulmonary Fibrosis
1332832|NCT00639470|Patient Education Handout
1332833|NCT00639470|Parents
1332834|NCT00639470|Patient Education
1332835|NCT00639457|PPAR-gamma agonist
1332836|NCT00639457|glucose metabolism
1332837|NCT00639457|inflammation
1332838|NCT00639457|adipose tissue distribution
1332839|NCT00639457|cardiac function
1332840|NCT00639457|vascular function
1332841|NCT00639457|mass spectrometry
1332842|NCT00639457|Treatment Experienced
1332843|NCT00639431|phantom limb pain
1332844|NCT00639431|limb amputation
1332845|NCT00639431|Amputation
1332846|NCT00639431|Phantom Limb
1332847|NCT00639431|Pain
1332848|NCT00639405|Parathyroid
1332849|NCT00639405|MRI
1332850|NCT00639405|SPECT
1332851|NCT00639392|Sickle cell disease
1332852|NCT00639379|toric contact lenses
1332853|NCT00639379|vision
1332854|NCT00639379|comfort
1332855|NCT00639379|toric fit characteristics
1332856|NCT00639379|slit lamp findings
1332857|NCT00639366|recurrent breast cancer
1332858|NCT00639366|stage IIIA breast cancer
1332859|NCT00639366|stage IIIB breast cancer
1332860|NCT00639366|stage IIIC breast cancer
1332861|NCT00639366|stage IV breast cancer
1332862|NCT00638313|GLP-1
1332863|NCT00639327|Stomach Neoplasms
1332864|NCT00639327|Second line chemotherapy
1332865|NCT00639327|Refractory to S-1
1332866|NCT00639327|irinotecan
1332867|NCT00639327|S-1 and Irinotecan Combination
1332868|NCT00639327|Phase III study
1332869|NCT00639314|pylorus-preserving pancreaticoduodenectomy
1332870|NCT00639314|pylorus-resecting pancreaticoduodenectomy
1332871|NCT00639314|randomized controlled trial
1332872|NCT00639314|delayed gastric empty
1332873|NCT00639314|quality of life
1332874|NCT00639301|Survivor
1332875|NCT00639301|Quality of Life
1332876|NCT00639301|Eye
1332877|NCT00639288|Alcohol Dependence
1332878|NCT00639288|PTSD
1332879|NCT00639288|CPT-C
1332880|NCT00639262|Sorafenib
1332881|NCT00639262|Radiation Therapy
1332882|NCT00639262|Radiotherapy
1332883|NCT00639262|Temozolomide
1332884|NCT00639262|Brain Metastases
1332885|NCT00639262|Brain Tumors
1332886|NCT00639236|COPD
1332887|NCT00639236|Hypertonic saline
1332888|NCT00639236|Quality of life
1332889|NCT00639236|Dyspnoea.
1332890|NCT00639223|Statin related myalgia
1332891|NCT00639223|Hyperlipidemia
1332892|NCT00639223|Red yeast rice
1332893|NCT00639223|Cardiovascular Diseases
1332894|NCT00639223|Nutritional and Metabolic Diseases
1332895|NCT00639210|breast cancer
1332896|NCT00639210|exercise
1332897|NCT00639210|osteoporosis
1332898|NCT00639210|fracture
1332899|NCT00639210|quality of life
1332900|NCT00639197|Tunneling
1332901|NCT00639197|Short term
1332902|NCT00639197|central venous catheters
1332903|NCT00639197|Ultrasound Guided
1332904|NCT00639197|Internal jugular
1332905|NCT00639197|Assess safety and improve technical difficulty
1332906|NCT00639184|asphyxia
1332907|NCT00639184|neurodevelopmental outcome
1332908|NCT00639184|home counseling
1332909|NCT00639171|breast
1332910|NCT00639171|diagnostic radiology
1332911|NCT00639171|suspicious breast tumors
1332912|NCT00639171|MRI
1332913|NCT00639145|HIV
1332914|NCT00639145|Pregnancy
1332915|NCT00639145|Antiretrovirals
1332916|NCT00639145|HIV Seronegativity
1332917|NCT00639145|Treatment Experienced
1332918|NCT00639132|Natural History
1332919|NCT00639132|Metachromatic Leukodystrophy
1332920|NCT00639132|Disease Progression
1332921|NCT00639106|Breast expander
1332922|NCT00639106|Breast reconstruction
1332923|NCT00639106|implants
1332924|NCT00639106|08-024
1332925|NCT00639093|cigarette smoking
1332926|NCT00639093|psychoeducational and motivational program
1332927|NCT00639093|virtual reality
1332928|NCT00639080|Type 2 diabetes
1332929|NCT00639080|Dyslipidemia
1332930|NCT00639067|Cancer of Lung
1332931|NCT00639067|Cancer of the Lung
1332932|NCT00639067|Lung Cancer
1332933|NCT00639067|Neoplasms, Lung
1332934|NCT00639067|Neoplasms, Pulmonary
1332935|NCT00639067|Pulmonary Cancer
1332936|NCT00639067|Pulmonary Neoplasms
1332937|NCT00639054|classification
1332938|NCT00639054|diagnosis
1332939|NCT00639054|genetics
1332940|NCT00639054|mortality
1332941|NCT00639054|pathology
1332942|NCT00639041|n-3 LC-PUFA
1332943|NCT00639041|hypertriglyceridemic
1332944|NCT00639041|human
1332945|NCT00639041|TAG
1332946|NCT00639028|ankle
1332947|NCT00639028|diagnosis
1332948|NCT00639028|sprain
1332949|NCT00639028|care
1332950|NCT00639028|injury
1332951|NCT00639028|stress radiography
1332952|NCT00639028|ultrasonography
1332953|NCT00639015|Sepsis
1332954|NCT00639015|Septic Shock
1332955|NCT00639015|phenylephrine
1332956|NCT00639015|norepinephrine
1332957|NCT00639015|catecholamine
1332958|NCT00638989|Asthma
1332959|NCT00638989|CAT-354
1332960|NCT00638989|Tralokinumab
1332961|NCT00638989|Healthy
1332962|NCT00638976|Eptifibatide
1332963|NCT00638976|IV eptifibatide
1332964|NCT00638976|GP IIB/IIIA inhibitors
1332965|NCT00638976|DES stent
1332966|NCT00638950|n-3 LC-PUFA
1332967|NCT00638950|Rheumatoid arthritis
1332968|NCT00638950|disease activity
1332969|NCT00638950|inflammation
1332970|NCT00638950|oxidative stress
1332971|NCT00638950|immune system
1332972|NCT00638924|healthy sedentary women
1332973|NCT00638885|PTSD
1332974|NCT00638885|hippocampus
1332975|NCT00638885|twins
1332976|NCT00638872|diabetes
1332977|NCT00638872|foot ulcer
1332978|NCT00638872|polydeoxyribonucleotide
1332979|NCT00638859|Community-Acquired pneumonia
1332980|NCT00638859|CAP
1332981|NCT00638859|children
1332982|NCT00638859|Child
1332983|NCT00638846|toric contact lenses
1332984|NCT00638846|vision
1332985|NCT00638846|comfort
1332986|NCT00638846|toric fit characteristics
1332987|NCT00638846|slit lamp findings
1332988|NCT00638833|Multiple Sclerosis
1332989|NCT00638820|osteopetrosis
1332990|NCT00638794|Myocardial Infarction
1332991|NCT00638794|Myocardial Ischemia
1332992|NCT00638781|Acute ischemic stroke
1332993|NCT00638768|physical therapy
1332994|NCT00638768|rehabilitation
1332995|NCT00638768|pain
1332996|NCT00638768|osteoporosis
1332997|NCT00638768|vertebral fracture
1332998|NCT00638755|Allergic Rhinitis
1332999|NCT00638755|Perennial Allergic Rhinitis
1333000|NCT00638755|Allergies to perennial allergens
1333001|NCT00638755|Allergies to perennial allergens (e.g. dog, cat, dust mites, etc.)
1333002|NCT00638742|Latanoprost Pediatrics Pharmacokinetics Safety
1333003|NCT00638729|bispectral index
1333004|NCT00638729|sedation
1333005|NCT00638729|stress hormones
1333006|NCT00638729|cognitive function
1333007|NCT00638716|Type 2 Diabetes Mellitus, incretins, GLP-1, HbA1c, metformin
1333008|NCT00638703|hyperoxaluria
1333009|NCT00638703|PH
1333010|NCT00638703|oxalate
1333011|NCT00638690|Metastatic Castration-Resistant Prostate Cancer
1333012|NCT00638690|CRPC
1333013|NCT00638690|Abiraterone Acetate
1333014|NCT00638690|CB7630
1333015|NCT00638677|Oral microbiology
1333016|NCT00638664|conventional pulse sequences for MR
1333017|NCT00638664|cardiac chambers and walls
1333018|NCT00638664|cardio-thoracic vasculature
1333019|NCT00638664|the great vessels
1333020|NCT00638664|coronary vasculature
1333021|NCT00638664|cardiac
1333022|NCT00638664|great vessels
1333023|NCT00638651|Tattoos
1333024|NCT00638651|Black/blue tattoos
1333025|NCT00638638|Myocardial infarction
1333026|NCT00638638|Angioplasty
1333027|NCT00638638|Coronary stenting
1333028|NCT00638638|Abciximab
1333029|NCT00638638|Myocardial reperfusion
1333030|NCT00638638|Microcirculation
1333031|NCT00638638|EKG
1333032|NCT00638638|ST elevation myocardial infarction within 6 h of symptom onset
1333033|NCT00638625|Needle biopsy
1333034|NCT00638625|CT Scan
1333035|NCT00638625|Lung Tumor
1333036|NCT00638625|Lung Mass
1333037|NCT00638612|Immunotherapy
1333038|NCT00638612|Gene Therapy
1333039|NCT00638612|Cytotoxicity
1333040|NCT00638612|Tumor vaccine
1333041|NCT00638612|Radiation
1333042|NCT00638612|Surgery
1333043|NCT00638612|Chemoradiation
1333044|NCT00638599|Intubation, intratracheal
1333045|NCT00638599|Homeostasis
1333046|NCT00638599|Mastectomy, modified radical
1333047|NCT00638599|Breast Neoplasms
1333048|NCT00638560|PGC-1alpha
1333049|NCT00638560|PPARgamma
1333050|NCT00638560|oxidative stress
1333051|NCT00638560|training intervention
1333052|NCT00638547|Hurler Syndrome
1333053|NCT00638547|mucopolysaccharidosis type I
1333054|NCT00638547|Iduronidase deficiency
1333055|NCT00638534|Acute Otitis Media
1333056|NCT00638534|AOM
1333057|NCT00638534|children
1333058|NCT00638534|Child
1333059|NCT00638521|lipids
1333060|NCT00638521|proteins
1333061|NCT00638521|membrane
1333062|NCT00638521|lipid raft
1333063|NCT00638482|Dent's disease
1333064|NCT00638482|Nephrolithiasis
1333065|NCT00638482|clinical trial
1333066|NCT00638482|thiazides
1333067|NCT00638469|Psoriasis
1333068|NCT00638469|Biologic
1333069|NCT00638469|adalimumab
1333070|NCT00638469|narrowband UVB
1333071|NCT00638469|phototherapy
1333072|NCT00638469|half-side comparison
1333073|NCT00638456|Eosinophils
1333074|NCT00638456|Esophagitis
1333075|NCT00638456|Microscopy
1333076|NCT00638443|Neurogenic claudication, lumbar spinal stenosis, treadmill testing
1333077|NCT00638430|myopia
1333078|NCT00638430|Humphery Matrix 30-2 test
1333079|NCT00638404|Preoperative somatic questions
1333080|NCT00638404|Preoperative audio tone evaluations
1333081|NCT00638404|Preoperative anxiety and previous experience with postop pain
1333082|NCT00638391|Primary early MCa
1333083|NCT00638391|Arimidex
1333084|NCT00638378|Prostate Cancer
1333085|NCT00638365|Cystic Fibrosis, Pseudomonas aeruginosa, Pulmonary CF
1333086|NCT00638352|Core Biopsy
1333087|NCT00638352|Needle Biopsy
1333088|NCT00638352|Percutaneous Biopsy
1333089|NCT00638339|Respiration, artificial
1333090|NCT00638339|respiratory insufficiency
1333091|NCT00638339|noninvasive ventilation
1333092|NCT00638339|sleep deprivation
1333093|NCT00638339|intensive care units
1333094|NCT00638326|Clopidogrel, thrombosis, Percutaneous Transluminal Coronary Angioplasty, stents
1333095|NCT00638300|hemodialysis
1333096|NCT00638300|iron
1333097|NCT00638300|inflammation
1333098|NCT00638300|atomic absorption
1333099|NCT00638300|dialysate
1333100|NCT00638300|advanced oxidation protein products
1333101|NCT00638300|large pore dialysate
1333102|NCT00638300|bicarbonate
1333103|NCT00638300|calcium
1333104|NCT00638300|citrate
1333105|NCT00638300|ligand
1333106|NCT00638287|Subjects with pituitary disease undergoing testing for GH
1333107|NCT00638287|deficiency
1333108|NCT00638287|Subjects with suspicion for (or diagnosis of) acromegaly
1333109|NCT00638287|undergoing OGTT testing
1333110|NCT00638287|Normal controls without evidence of pituitary dysfunction
1333111|NCT00638274|Quality of pain relief with 2 different methods of identifying epidural space
1333112|NCT00638261|Psoriasis
1333113|NCT00638261|Biologic
1333114|NCT00638261|Adalimumab
1333115|NCT00638261|Narrow-band UVB
1333116|NCT00638261|phototherapy
1333117|NCT00638261|half-side comparison
1333118|NCT00638248|Acute ischemic stroke
1333119|NCT00638235|Pelvic floor repair
1333120|NCT00638235|prolapse
1333121|NCT00638235|mesh
1333122|NCT00638222|Carvedilol
1333123|NCT00638222|Heart Disease
1333124|NCT00638222|Vascular Disease
1333125|NCT00638222|Kidney
1333126|NCT00638196|relapsing multiple sclerosis
1333246|NCT00637728|Lung cancer
1333127|NCT00638196|polyunsaturated fatty acids
1333128|NCT00638196|omega-6 fatty acids
1333129|NCT00638170|Urinary Tract Infections
1333130|NCT00638170|Cranberry
1333131|NCT00638170|Prevention
1333132|NCT00638157|Gram-positive bacterial infections
1333133|NCT00638157|Staph Aureus
1333134|NCT00638157|endocarditis
1333135|NCT00638157|bacteremia
1333136|NCT00638157|methicillin-resistant Staphylococcus aureus (MRSA)
1333137|NCT00638144|Hepatitis C
1333138|NCT00638144|liver transplantation
1333139|NCT00638144|antibodies mediated neutralization
1333140|NCT00638144|monoclonal antibodies
1333141|NCT00638092|hypothyroxinemia
1333142|NCT00638092|preterm infants
1333143|NCT00638092|iodine
1333144|NCT00638092|neurodevelopmental outcome
1333145|NCT00638092|Iodine supplementation
1333146|NCT00638092|Randomised controlled trial
1333147|NCT00638079|Pharmacokinetics
1333148|NCT00638079|Food Effect
1333149|NCT00638079|Bioavailability
1333150|NCT00638079|Megace ES
1333151|NCT00638066|vaginismus
1333152|NCT00638066|botulinum toxin A
1333153|NCT00638066|dyspareunia
1333154|NCT00638066|unconsummated marriage
1333155|NCT00638040|hypoxia
1333156|NCT00638040|lactate
1333157|NCT00638040|pH
1333158|NCT00638040|tumor microenvironments
1333159|NCT00638040|survival
1333160|NCT00638027|multiple sclerosis
1333161|NCT00638014|Sternal wound closure
1333162|NCT00638014|cardiac surgery
1333163|NCT00638014|sternal nonunion
1333164|NCT00638001|patients with haemophilia A moderate or severe
1333165|NCT00638001|patients with haemophilia B moderate or severe
1333166|NCT00637988|Barrett's Esophagus
1333167|NCT00637988|Nexium
1333168|NCT00637975|neuropathic pain
1333169|NCT00637975|oxycodone
1333170|NCT00637975|pregabalin
1333171|NCT00637975|Patients with cancer and presenting a neuropathic pain
1333172|NCT00637962|HIV
1333173|NCT00637962|AIDS
1333174|NCT00637962|Vaccine
1333175|NCT00637962|intravaginal
1333176|NCT00637962|mucosal
1333177|NCT00637962|HIV Seronegativity
1333178|NCT00637949|Osteoarthritis
1333179|NCT00637949|lumiracoxib
1333180|NCT00637949|rofecoxib
1333181|NCT00637949|Cox-2
1333182|NCT00637949|Osteoarthritis (primary osteoarthritis hip, hand, knee or spine (cervical or lumbar)
1333183|NCT00637936|perioperative oxygen
1333184|NCT00637936|respiratory complications
1333185|NCT00637923|Hepatitis C, Chronic
1333186|NCT00637910|Advanced NSCLC
1333187|NCT00637910|EGFR
1333188|NCT00637910|EGFR copy number
1333189|NCT00637910|Kras mutations
1333190|NCT00637910|EGRF mutations
1333191|NCT00637910|Docetaxel
1333192|NCT00637910|Erlotinib
1333193|NCT00637910|Polymorphisms
1333194|NCT00637897|recurrent breast cancer
1333195|NCT00637897|stage IV breast cancer
1333196|NCT00637871|Casodex
1333197|NCT00637871|bicalutamide
1333198|NCT00637871|Tamoxifen
1333199|NCT00637871|Gynaecomastia
1333200|NCT00637871|Prostate Cancer
1333201|NCT00637845|Nexium
1333202|NCT00637845|Esomeprazole Magnesium
1333203|NCT00637845|Gastroesophageal Reflux Disease
1333204|NCT00637845|Heartburn
1333205|NCT00637832|recurrent grade 1 follicular lymphoma
1333206|NCT00637832|recurrent grade 2 follicular lymphoma
1333207|NCT00637832|recurrent grade 3 follicular lymphoma
1333208|NCT00637832|contiguous stage II grade 1 follicular lymphoma
1333209|NCT00637832|contiguous stage II grade 2 follicular lymphoma
1333210|NCT00637832|contiguous stage II grade 3 follicular lymphoma
1333211|NCT00637832|noncontiguous stage II grade 1 follicular lymphoma
1333212|NCT00637832|noncontiguous stage II grade 2 follicular lymphoma
1333213|NCT00637832|noncontiguous stage II grade 3 follicular lymphoma
1333214|NCT00637832|stage III grade 1 follicular lymphoma
1333215|NCT00637832|stage III grade 2 follicular lymphoma
1333216|NCT00637832|stage III grade 3 follicular lymphoma
1333217|NCT00637832|stage IV grade 1 follicular lymphoma
1333218|NCT00637832|stage IV grade 2 follicular lymphoma
1333219|NCT00637832|stage IV grade 3 follicular lymphoma
1333220|NCT00637806|Megestrol acetate
1333221|NCT00637806|Anorexia
1333222|NCT00637806|Cachexia
1333223|NCT00637806|Cancer
1333224|NCT00637806|Unintended weight loss
1333225|NCT00637806|Body weight
1333226|NCT00637806|Appetite
1333227|NCT00637806|Megace ES
1333228|NCT00637793|Xerostomia
1333229|NCT00637793|Sjogren's Syndrome
1333230|NCT00637780|Sulfasalazine delayed release tablets
1333231|NCT00637780|azulfidine entabs
1333232|NCT00637780|Pharmacokinetics
1333233|NCT00637780|Juvenile Idiopathic Arthritis (JIA)
1333234|NCT00637767|stage I multiple myeloma
1333235|NCT00637767|stage II multiple myeloma
1333236|NCT00637767|stage III multiple myeloma
1333237|NCT00637754|ICD
1333238|NCT00637754|Sports
1333239|NCT00637741|Peripheral Vascular Disease
1333240|NCT00637741|Intermittent claudication
1333241|NCT00637741|Critical Limb Ischemia
1333242|NCT00637741|TASC
1333243|NCT00637728|Megestrol acetate
1333244|NCT00637728|Anorexia
1333245|NCT00637728|Cachexia
1333247|NCT00637728|Pancreatic cancer
1333248|NCT00637728|Unintended weight loss
1333249|NCT00637728|Body weight
1333250|NCT00637728|Appetite
1333251|NCT00637728|Megace ES
1333252|NCT00637689|Chronic graft versus host disease
1333253|NCT00637689|Allogeneic hematopoietic cell transplantation
1333254|NCT00637689|Biomarkers
1333255|NCT00637689|Response criteria
1333256|NCT00637689|Surrogate endpoints
1333257|NCT00637689|Natural history
1333258|NCT00637676|malignant pleural effusion
1333259|NCT00637676|subcutaneous tunneled drainage
1333260|NCT00637676|talc pleurodesis
1333261|NCT00637663|Chronic hepatitis B
1333262|NCT00637663|Lamivudine
1333263|NCT00637663|Entecavir
1333264|NCT00637637|tumors metastatic to brain
1333265|NCT00637637|stage IV adenoid cystic carcinoma of the oral cavity
1333266|NCT00637637|stage IV adrenocortical carcinoma
1333267|NCT00637637|stage IV adult Burkitt lymphoma
1333268|NCT00637637|stage IV adult diffuse large cell lymphoma
1333269|NCT00637637|stage IV adult diffuse mixed cell lymphoma
1333270|NCT00637637|stage IV adult diffuse small cleaved cell lymphoma
1333271|NCT00637637|stage IV adult Hodgkin lymphoma
1333272|NCT00637637|stage IV adult immunoblastic large cell lymphoma
1333273|NCT00637637|stage IV adult lymphoblastic lymphoma
1333274|NCT00637637|stage IV adult T-cell leukemia/lymphoma
1333275|NCT00637637|stage IV anal cancer
1333276|NCT00637637|stage IV basal cell carcinoma of the lip
1333277|NCT00637637|stage IV bladder cancer
1333278|NCT00637637|stage IV borderline ovarian surface epithelial-stromal tumor
1333279|NCT00637637|stage IV breast cancer
1333280|NCT00637637|stage IV childhood anaplastic large cell lymphoma
1333281|NCT00637637|stage IV childhood Hodgkin lymphoma
1333282|NCT00637637|stage IV childhood large cell lymphoma
1333283|NCT00637637|stage IV childhood liver cancer
1333284|NCT00637637|stage IV childhood lymphoblastic lymphoma
1333285|NCT00637637|stage IV childhood small noncleaved cell lymphoma
1333286|NCT00637637|stage IV chronic lymphocytic leukemia
1333287|NCT00637637|stage IV colon cancer
1333288|NCT00637637|stage IV cutaneous T-cell non-Hodgkin lymphoma
1333289|NCT00637637|stage IV esophageal cancer
1333290|NCT00637637|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1333291|NCT00637637|stage IV follicular thyroid cancer
1333292|NCT00637637|stage IV gastric cancer
1333293|NCT00637637|stage IV grade 1 follicular lymphoma
1333294|NCT00637637|stage IV grade 2 follicular lymphoma
1333295|NCT00637637|stage IV grade 3 follicular lymphoma
1333296|NCT00637637|stage IV hypopharyngeal cancer
1333297|NCT00637637|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1333298|NCT00637637|stage IV laryngeal cancer
1333299|NCT00637637|stage IV lip and oral cavity cancer
1333300|NCT00637637|stage IV lymphoepithelioma of the nasopharynx
1333301|NCT00637637|stage IV lymphoepithelioma of the oropharynx
1333302|NCT00637637|stage IV mantle cell lymphoma
1333303|NCT00637637|stage IV marginal zone lymphoma
1333304|NCT00637637|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1333305|NCT00637637|stage IV mucoepidermoid carcinoma of the oral cavity
1333306|NCT00637637|stage IV mycosis fungoides/Sezary syndrome
1333307|NCT00637637|stage IV nasopharyngeal cancer
1333308|NCT00637637|stage IV non-small cell lung cancer
1333309|NCT00637637|stage IV oropharyngeal cancer
1333310|NCT00637637|stage IV ovarian epithelial cancer
1333311|NCT00637637|stage IV pancreatic cancer
1333312|NCT00637637|stage IV papillary thyroid cancer
1333313|NCT00637637|stage IV paranasal sinus and nasal cavity cancer
1333314|NCT00637637|stage IV penile cancer
1333315|NCT00637637|stage IV prostate cancer
1333316|NCT00637637|stage IV rectal cancer
1333317|NCT00637637|stage IV renal cell cancer
1333318|NCT00637637|stage IV salivary gland cancer
1333319|NCT00637637|stage IV small lymphocytic lymphoma
1333320|NCT00637637|stage IV squamous cell carcinoma of the hypopharynx
1333321|NCT00637637|stage IV squamous cell carcinoma of the larynx
1333322|NCT00637637|stage IV squamous cell carcinoma of the lip and oral cavity
1333323|NCT00637637|stage IV squamous cell carcinoma of the nasopharynx
1333324|NCT00637637|stage IV squamous cell carcinoma of the oropharynx
1333325|NCT00637637|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1333326|NCT00637637|stage IV endometrial carcinoma
1333327|NCT00637637|stage IV verrucous carcinoma of the larynx
1333328|NCT00637637|stage IV verrucous carcinoma of the oral cavity
1333329|NCT00637637|stage IVB vulvar cancer
1333330|NCT00637637|stage IV Wilms tumor
1333331|NCT00637637|stage IVB cervical cancer
1333332|NCT00637637|stage IVB vaginal cancer
1333333|NCT00637637|metastatic adult malignant fibrous histiocytoma of bone
1333334|NCT00637637|metastatic childhood malignant fibrous histiocytoma of bone
1333335|NCT00637637|metastatic gastrointestinal carcinoid tumor
1333336|NCT00637637|metastatic parathyroid cancer
1333337|NCT00637637|metastatic pheochromocytoma
1333338|NCT00637637|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1333339|NCT00637637|metastatic squamous neck cancer with occult primary
1333340|NCT00637637|metastatic transitional cell cancer of the renal pelvis and ureter
1333341|NCT00637637|disseminated neuroblastoma
1333342|NCT00637637|unspecified adult solid tumor, protocol specific
1333845|NCT00635479|Hip bones
1333343|NCT00637637|unspecified childhood solid tumor, protocol specific
1333344|NCT00637637|tongue cancer
1333345|NCT00637624|Acetylcysteine
1333346|NCT00637624|Cisplatin
1333347|NCT00637624|Neuropathy
1333348|NCT00637624|Antioxidants
1333349|NCT00637598|Diagnostic Imaging
1333350|NCT00637598|Mammography
1333351|NCT00637598|Breast Tomosynthesis
1333352|NCT00637572|Weight loss
1333353|NCT00637572|Cachexia
1333354|NCT00637572|Anorexia
1333355|NCT00637572|Megestrol acetate oral suspension
1333356|NCT00637572|Nanocrystal dispersion
1333357|NCT00637572|Nanocrystal technology
1333358|NCT00637572|Body weight changes
1333359|NCT00637572|AIDS wasting
1333360|NCT00637572|HIV wasting
1333361|NCT00637572|Emaciation
1333362|NCT00637572|Megace ES
1333363|NCT00637572|Megace
1333364|NCT00637572|Treatment Experienced
1333365|NCT00637559|Nexium
1333366|NCT00637559|Barrett's esophagus
1333367|NCT00637546|Treatment
1333368|NCT00637546|Efficacy
1333369|NCT00637546|Diabetes
1333370|NCT00637546|Gait
1333371|NCT00637546|Balance
1333372|NCT00637520|Nonalcoholic Fatty Liver Disease
1333373|NCT00637520|Insulin Resistance
1333374|NCT00637520|Lipid Metabolism
1333375|NCT00637507|High-Frequency Ventilation
1333376|NCT00637507|Tracheal Gas Insufflation
1333377|NCT00637507|Respiration, Artificial
1333378|NCT00637507|Respiratory Distress Syndrome
1333379|NCT00637507|Adult
1333380|NCT00637494|psychotic depression
1333381|NCT00637494|major depression with psychotic features
1333382|NCT00637494|psychosis
1333383|NCT00637416|horseness
1333384|NCT00637403|renal impairment
1333385|NCT00637403|end stage renal disease
1333386|NCT00637403|megestrol acetate
1333387|NCT00637403|pharmacokinetics
1333388|NCT00637403|hemodialysis
1333389|NCT00637403|renal dialysis
1333390|NCT00637403|kidney failure, chronic
1333391|NCT00637403|renal insufficiency
1333392|NCT00637403|Megace ES
1333393|NCT00637377|Eye diseases
1333394|NCT00637377|Vision Impairment and Blindness
1333395|NCT00637377|Eyes and Vision
1333396|NCT00637377|Seniors
1333397|NCT00637377|Neovascular Age-Related Macular Degeneration (AMD)
1333398|NCT00637377|Retinal Disease
1333399|NCT00637364|pain
1333400|NCT00637364|pancreas
1333401|NCT00637364|pancreatic cancer
1333402|NCT00637364|pancreatic adenocarcinoma
1333403|NCT00637364|ductal adenocarcinoma
1333404|NCT00637338|Long-acting GLP-1 Diabetes
1333405|NCT00637325|trastuzumab optimization in breast cancer
1333406|NCT00637299|COPD
1333407|NCT00637286|Zolmitriptan
1333408|NCT00637286|ZOMIG
1333409|NCT00637286|migraine
1333410|NCT00637286|headache response
1333411|NCT00637286|headache
1333412|NCT00637286|headache pain
1333413|NCT00637286|MIDAS
1333414|NCT00637286|HCPC
1333415|NCT00637273|diabetes
1333416|NCT00637273|exenatide once weekly
1333417|NCT00637273|Byetta
1333418|NCT00637273|sitagliptin
1333419|NCT00637273|Januvia
1333420|NCT00637273|thiazolidinedione
1333421|NCT00637273|Amylin
1333422|NCT00637273|Lilly
1333423|NCT00637273|Pioglitazone
1333424|NCT00637260|motorcortex stimulation
1333425|NCT00637260|Parkinson's disease
1333426|NCT00637260|neuromodulation
1333427|NCT00637247|pancreatic cancer
1333428|NCT00637247|metastatic
1333429|NCT00637247|chemotherapy naive
1333430|NCT00637221|Safety
1333431|NCT00637221|Tolerability
1333432|NCT00637208|prostate cancer
1333433|NCT00637208|venography
1333434|NCT00637208|male patients
1333435|NCT00637208|Localized microscopic prostate cancer up to Gleason 6 (3+3)
1333436|NCT00637208|PSA level <14
1333437|NCT00637208|presence of varicocele
1333438|NCT00637195|Human papillomavirus (HPV) vaccine
1333439|NCT00637195|Hepatitis B
1333440|NCT00637195|Cervical cancer
1333441|NCT00637195|HPV
1333442|NCT00637195|Papillomavirus
1333443|NCT00637182|Gynecomastia
1333444|NCT00637182|Anastrazole
1333445|NCT00637182|Arimidex
1333446|NCT00637182|Pubertal
1333447|NCT00637182|males
1333448|NCT00637182|boys
1333449|NCT00637169|oxygen therapy
1333450|NCT00637169|neurodevelopmental impairment
1333451|NCT00637156|Symptomatic DDD at Two Adjacent Levels of cervical spine
1333452|NCT00637143|Renal transplant
1333453|NCT00637143|Cyclosporine
1333454|NCT00637143|Tacrolimus
1333455|NCT00637143|Intervention
1333456|NCT00637143|Interstitial Fibrosis Tubular Atrophy
1333457|NCT00637143|Chronic Renal Allograft Failure
1333458|NCT00637117|Lymphoma, Dendritic, Vaccine, Radiotherapy
1333459|NCT00637104|percutaneous transluminal coronary angioplasty
1333460|NCT00637104|stents
1333461|NCT00637104|restenosis
1333462|NCT00637104|biocompatible materials
1333463|NCT00637104|ceramics
1333464|NCT00637078|hypertension
1333465|NCT00637078|hypercholesterolemia
1333466|NCT00637078|family physicians
1333467|NCT00637078|fixed dose combination therapy
1333468|NCT00637078|cluster randomized controlled trial
1333469|NCT00637065|Pulmonary hypertension
1333470|NCT00637065|Interstitial lung disease
1333471|NCT00637065|Idiopathic pulmonary fibrosis
1333472|NCT00637065|Nonspecific interstitial pneumonia
1333473|NCT00637065|Bosentan
1333474|NCT00637065|Endothelin receptor antagonists
1333475|NCT00637065|Pulmonary vascular resistance
1333476|NCT00637052|preleukemia
1333477|NCT00637052|dysplasia of myeloid blood cells
1333478|NCT00637039|Advanced cancer
1333479|NCT00637039|Solid tumour
1333480|NCT00637039|Solid malignancies
1333481|NCT00637039|Neoplasms
1333482|NCT00637026|Iressa, Gefitinib, Breast Cancer, Surgery
1333483|NCT00637013|Subacromial impingement
1333484|NCT00637013|Shoulder
1333485|NCT00637013|RCT
1333486|NCT00637013|Effectiveness
1333487|NCT00637013|Cost-effectiveness
1333488|NCT00637000|Opioid dependence
1333489|NCT00637000|Opioid withdrawal symptoms
1333490|NCT00636987|aortic valve
1333491|NCT00636987|mitral valve
1333492|NCT00636987|heart valve
1333493|NCT00636987|tissue valve
1333494|NCT00636987|bioprosthesis
1333495|NCT00636987|valve disorder
1333496|NCT00636987|valve disease
1333497|NCT00636987|cardiac surgery
1333498|NCT00636987|aortic valve regurgitation
1333499|NCT00636987|aortic valve stenosis
1333500|NCT00636987|mitral valve regurgitation
1333501|NCT00636987|mitral valve stenosis
1333502|NCT00636974|Patients who are going to have regional anaesthesia for lower limbs surgery.
1333503|NCT00636974|Leg Surgery.
1333504|NCT00636961|COPD, Indacaterol Maleate, Exercise testing
1333505|NCT00636948|Rectal cancer surgery
1333506|NCT00636948|Symptomatic anastomotic leakage
1333507|NCT00636948|Defunctioning stoma
1333508|NCT00636948|TME surgery
1333509|NCT00636935|Pneumocystis jirovecii Pneumonia
1333510|NCT00636935|Corticosteroid Therapy
1333511|NCT00636935|HIV
1333512|NCT00636935|Pneumonia
1333513|NCT00636935|Pulmonary Function Testing
1333514|NCT00636935|Antibiotics
1333515|NCT00636935|Prednisone
1333516|NCT00636935|Human Immunodeficiency Virus
1333517|NCT00636935|CD4
1333518|NCT00636935|CD8
1333519|NCT00636935|Viral Load
1333520|NCT00636935|Bactrim
1333521|NCT00636935|Pentamidine
1333522|NCT00636935|Atovaquone
1333523|NCT00636935|Primaquine/Clindamycin
1333524|NCT00636935|Trimethoprim/Dapsone
1333525|NCT00636922|Acute Myeloid Leukemia
1333526|NCT00636922|Elderly
1333527|NCT00636922|Unfit
1333528|NCT00636922|Everolimus
1333529|NCT00636922|RAD001
1333530|NCT00636909|AML
1333531|NCT00636909|ALL
1333532|NCT00636909|CML
1333533|NCT00636909|CLL
1333534|NCT00636909|MDS
1333535|NCT00636909|NHL
1333536|NCT00636909|HODGKIN'S LYMPHOMA
1333537|NCT00636909|APLASTIC ANEMIA
1333538|NCT00636909|MULTIPLE MYELOMA
1333539|NCT00636909|MYELOPROLIFERATIVE DISORDER
1333540|NCT00636909|ALLOGENEIC
1333541|NCT00636909|STEM CELL TRANSPLANT
1333542|NCT00636909|HEMATOLOGIC DISORDERS
1333543|NCT00636909|CYCLOPHOSPHAMIDE
1333544|NCT00636909|FLUDARABINE
1333545|NCT00636909|CYCLOSPORINE
1333546|NCT00636909|METHOTREXATE
1333547|NCT00636909|G-CSF
1333548|NCT00636909|GVHD
1333549|NCT00636909|ENGRAFTMENT
1333550|NCT00636909|CHIMERISM
1333551|NCT00636896|weight gain
1333552|NCT00636896|olanzapine
1333553|NCT00636896|atypical antipsychotic
1333554|NCT00636883|Pancreatic cancer
1333555|NCT00636857|Water-Electrolyte Imbalance
1333556|NCT00636844|chemotherapy, cardiotoxicity
1333557|NCT00636831|Prophylactic
1333558|NCT00636831|Antibiotic
1333559|NCT00636831|Infection
1333560|NCT00636831|Primary case
1333561|NCT00636805|Aloxi
1333562|NCT00636805|Brain Neoplasm, Primary
1333563|NCT00636805|Brain Neoplasms, Malignant
1333564|NCT00636766|cardiovascular events
1333565|NCT00636753|Metabolic and endocrine changes in schizophrenic patients by antipsychotics treatment.
1333566|NCT00636740|Prostate cancer, hormone resistant, bisphosphonate
1333567|NCT00636727|arthrocentesis
1333568|NCT00636727|arthroscopy
1333569|NCT00636727|arthroplasty
1333570|NCT00636714|intensive insulin therapy
1333571|NCT00636714|glucose control
1333572|NCT00636714|nurse directed
1333573|NCT00636714|nomogram directed
1333574|NCT00636701|Cerebrovascular Accident
1333575|NCT00636701|rehabilitation
1333576|NCT00636688|Obesity
1333577|NCT00636688|Lifestyle changes
1333578|NCT00636675|Accidental falls
1333579|NCT00636649|Eating disorder
1333580|NCT00636636|Postherpetic Neuralgia (PHN), shingles
1333581|NCT00636623|Pilates Exercises
1333582|NCT00636623|Connective Tissue Massage
1333583|NCT00636610|Hedgehog
1333584|NCT00636610|CRC
1333585|NCT00636610|Colorectal Cancer
1333586|NCT00636610|Hedgehog Pathway Inhibitor
1333587|NCT00636584|sodium nitroprusside
1333588|NCT00636584|thyroid hormones
1333589|NCT00636584|thoracic surgery
1333590|NCT00636571|Exercise
1333591|NCT00636571|Non-Small Cell Lung Cancer
1333592|NCT00636571|Cardiopulmonary Fitness
1333593|NCT00636558|coxsackie virus
1333594|NCT00636558|melanoma
1333595|NCT00636558|breast cancer
1333596|NCT00636558|prostate cancer
1333597|NCT00636545|Genasense
1333598|NCT00636545|oblimersen
1333599|NCT00636545|antisense
1333600|NCT00636545|Bcl-2 antisense
1333601|NCT00636545|Solid Tumors
1333602|NCT00636519|Botulism Antitoxin,Heptavalent,Bivalent,EDB Muscle,Paralysis
1333603|NCT00636506|Erectile dysfunction
1333604|NCT00636506|Impotence
1333605|NCT00636493|retinal vein occlusion
1333606|NCT00636493|sustained drug delivery implant
1333607|NCT00636493|steroid
1333608|NCT00636493|macular edema
1333609|NCT00636480|Antimicrobial
1333610|NCT00636480|Antisepsis
1333611|NCT00636467|Breast cancer (tumors> 2 cm)
1333612|NCT00636467|Detection
1333613|NCT00636467|Axillary sentinel lymph node
1333614|NCT00636454|OA
1333615|NCT00636454|Pain
1333616|NCT00636454|Cognitive Therapy
1333617|NCT00636454|Behavior Therapy
1333618|NCT00636454|Knee OA
1333619|NCT00636454|Hip OA
1333620|NCT00636441|Early-Stage Breast Cancer
1333621|NCT00636441|Preoperative systemic chemotherapy (PST)
1333622|NCT00636441|Genomic
1333623|NCT00636441|Genomic Predictor
1333624|NCT00636441|Genomic Expression Profiles
1333625|NCT00636441|Randomized
1333626|NCT00636441|Pathologic complete response (pCR)
1333627|NCT00636441|HER2 negative
1333628|NCT00636441|Doxorubicin and docetaxel
1333629|NCT00636441|Doxorubicin and cyclophosphamide
1333630|NCT00636428|endoscopy
1333631|NCT00636428|Midazolam
1333632|NCT00636428|pediatric
1333633|NCT00636428|sedation
1333634|NCT00636428|comfort
1333635|NCT00636415|Analgesia
1333636|NCT00636415|Morphine
1333637|NCT00636415|Bupivacaine
1333638|NCT00636415|Osteoarthritis
1333639|NCT00636415|Knee
1333640|NCT00636402|Vessel Sealing System
1333641|NCT00636402|Cold Knife
1333642|NCT00636402|Tonsillectomy
1333643|NCT00636402|Pain
1333644|NCT00636402|Postoperative
1333645|NCT00636389|Hemodialysis
1333646|NCT00636389|Dialysis, Renal
1333647|NCT00636389|Dialysis, Extracorporeal
1333648|NCT00636389|Extracorporeal Dialysis
1333649|NCT00636376|elevated intracranial pressure
1333650|NCT00636376|inadequate cerebral perfusion
1333651|NCT00636376|secondary brain damage
1333652|NCT00636350|pepper carotenoids
1333653|NCT00636350|xanthophylls
1333654|NCT00636350|healthy volunteers
1333655|NCT00636337|Pediatric
1333656|NCT00636337|Brain Tumor
1333657|NCT00636337|Acute Lymphoblastic Leukemia
1333658|NCT00636337|Inattention
1333659|NCT00636337|Childhood cancer survivors
1333660|NCT00636324|Respiratory distress syndrome
1333661|NCT00636324|Preterm infants
1333662|NCT00636324|Extubation failure
1333663|NCT00636324|Pneumothorax
1333664|NCT00636324|Lung injury
1333665|NCT00636324|Airway pressure
1333666|NCT00636311|Hodgkin disease
1333667|NCT00636311|Salvage therapy
1333668|NCT00636311|Bortezomib
1333669|NCT00636311|Transplantation
1333670|NCT00636298|esophageal carcinoma
1333671|NCT00636298|cancer of the esophagus
1333672|NCT00636298|locally advanced or metastatic esophageal cancer
1333673|NCT00636285|A110
1333674|NCT00636285|Safety
1333675|NCT00636272|ICD
1333676|NCT00636272|CRT-D
1333677|NCT00636259|Prostate cancer
1333678|NCT00636259|Casodex
1333679|NCT00636233|anencephaly
1333680|NCT00636233|acrania
1333681|NCT00636220|HIV-1 Infections
1333682|NCT00636155|Small Lymphocytic Lymphoma
1333683|NCT00636155|Chronic Lymphocytic Leukemia
1333684|NCT00636155|EL625
1333685|NCT00636155|cenersen
1333686|NCT00636129|relaxation
1333687|NCT00636129|relaxation response
1333688|NCT00636129|meditation
1333689|NCT00636129|nitric oxide
1333690|NCT00636129|stress management
1333691|NCT00636129|stress
1333692|NCT00636129|Relaxation Techniques
1333693|NCT00636116|snake bite
1333694|NCT00636116|antivenin treatment
1333695|NCT00636103|Traditional Chinese Medicine
1333696|NCT00636103|Asthma
1333697|NCT00636103|Paediatric
1333698|NCT00636077|Hemodialysis
1333699|NCT00636077|Dialysis, Renal
1333700|NCT00636051|evidence based practice beliefs
1333701|NCT00636051|evidence based practice implementation
1333702|NCT00636051|evidence based practice dissemination
1333703|NCT00636038|beta-carotene
1333704|NCT00636038|yellow maize
1333705|NCT00636038|vitamin A
1333706|NCT00636012|acupuncture
1333707|NCT00636012|Acupuncture points
1333708|NCT00635986|Analgesia
1333709|NCT00635986|Fentanyl
1333710|NCT00635986|Orthopedic
1333711|NCT00635986|Mechanism of action
1333712|NCT00635986|Surgery
1333713|NCT00635973|Iressa
1333714|NCT00635973|Gefitinib
1333715|NCT00635973|Cancer
1333716|NCT00635973|Patients diagnosed with cancer who have previously received Iressa in an Iressa clinical trial
1333717|NCT00635960|Amyotrophic Lateral Sclerosis
1333718|NCT00635960|ALS
1333719|NCT00635960|Growth Hormone
1333720|NCT00635960|IGF-I
1333721|NCT00635947|Amniotic fluid index
1333722|NCT00635947|maternal hydration
1333723|NCT00635947|isotonic solution
1333724|NCT00635947|Amniotic Fluid
1333725|NCT00635934|Lumbar Degenerative Disc Disease at One Level from L4-S1
1333726|NCT00635921|Borderline Personality Disorder
1333727|NCT00635921|ziprasidone
1333728|NCT00635895|Fibromyalgia
1333729|NCT00635895|Manual Lymphatic Drainage
1333730|NCT00635895|Connective Tissue Massage
1333731|NCT00635895|Pain
1333732|NCT00635895|Health Related Quality of Life
1333733|NCT00635895|Randomized Controlled Trial
1333734|NCT00635882|mometasone
1333735|NCT00635882|formoterol
1333736|NCT00635869|evidence based practice beliefs
1333737|NCT00635869|evidence based practice implementation
1333738|NCT00635869|evidence based practice knowledge
1333739|NCT00635869|nurse physician collaboration
1333740|NCT00635856|Iressa
1333741|NCT00635856|Gefitinib
1333742|NCT00635856|Prostate Cancer
1333743|NCT00635856|PSA
1333744|NCT00635843|Lumbar degenerative disc disease at one level from L4-S1
1333745|NCT00635817|CPP
1333746|NCT00635817|central precocious puberty
1333747|NCT00635817|pediatrics
1333748|NCT00635817|suppression of luteinizing hormone
1333749|NCT00635817|Lupron
1333750|NCT00635817|leuprolide acetate
1333751|NCT00635817|depot formulation
1333752|NCT00635817|GnRHa
1333753|NCT00635817|GnRH agonist
1333754|NCT00635817|GnRH analog
1333755|NCT00635817|luteinizing hormone
1333756|NCT00635791|Malignant Solid Tumour
1333757|NCT00635791|Renal cell carcinoma
1333758|NCT00635791|Non small cell lung carcinoma
1333759|NCT00635765|Acromegaly
1333760|NCT00635752|TF-CBT
1333761|NCT00635752|Effectiveness study
1333762|NCT00635752|Trauma
1333763|NCT00635752|Therapy
1333764|NCT00635739|Whey protein
1333765|NCT00635739|Resistance exercise
1333766|NCT00635739|Physical activity
1333767|NCT00635739|Mobility disability
1333768|NCT00635739|Physical function
1333769|NCT00635739|Muscle mass
1333770|NCT00635739|Muscle strength
1333771|NCT00635739|Older Adults
1333772|NCT00635739|Mobility-Limited
1333773|NCT00635726|Bladder Cancer
1333774|NCT00635713|Advanced breast cancer, FASLODEX, ARIMIDEX, Fulvestrant, Anastrozole, postmenopausal
1333775|NCT00635700|psychosis
1333776|NCT00635700|schizophrenia
1333777|NCT00635700|prodrome
1333778|NCT00635700|ziprasidone
1333779|NCT00635700|placebo
1333780|NCT00635687|variceal bleeding
1333781|NCT00635687|transient elastography
1333782|NCT00635674|sleep apnea
1333783|NCT00635674|risk factors
1333784|NCT00635674|continuous positive airway pressure
1333785|NCT00635674|insulin resistance
1333786|NCT00635674|metabolic syndrome
1333787|NCT00635674|compliance
1333788|NCT00635661|function
1333789|NCT00635661|disability
1333790|NCT00635635|Stress Disorders, Post-Traumatic
1333791|NCT00635635|Anxiety,
1333792|NCT00635635|Depression,
1333793|NCT00635635|Guided Imagery
1333794|NCT00635635|Military Sexual Trauma
1333795|NCT00635622|Bacterial Vaginosis
1333796|NCT00635622|BV
1333797|NCT00635622|UCSF
1333798|NCT00635622|SFGH
1333799|NCT00635596|MT110
1333800|NCT00635596|solid tumors
1333801|NCT00635596|phase I
1333802|NCT00635596|BiTE
1333803|NCT00635596|bispecific T-cell engager
1333804|NCT00635583|Bone
1333805|NCT00635583|Dairy Intervention
1333806|NCT00635583|Girls
1333807|NCT00635583|Boys
1333808|NCT00635583|Calcium
1333809|NCT00635583|Bone Mineralization
1333810|NCT00635583|Peak Bone Mass
1333811|NCT00635583|Bone and Bones
1333812|NCT00635583|Female
1333813|NCT00635583|Male
1333814|NCT00635583|Adolescent
1333815|NCT00635583|Healthy
1333816|NCT00635570|Contraception, Compliance, Acceptability
1333817|NCT00635557|Recurrent
1333818|NCT00635557|Relapsed
1333819|NCT00635557|Glioblastoma
1333820|NCT00635557|Multiforme
1333821|NCT00635544|Adolescence
1333822|NCT00635544|Overweight
1333823|NCT00635544|Dietary Fiber
1333824|NCT00635544|Glycemic Index
1333825|NCT00635544|Healthy lifestyle
1333826|NCT00635518|Health Plan Implementation
1333827|NCT00635518|Feeding and Eating Disorders of Childhood
1333828|NCT00635518|Breast Feeding
1333829|NCT00635518|Overweight
1333830|NCT00635518|Child
1333831|NCT00635518|Infant Nutrition Physiology
1333832|NCT00635518|Public Health
1333833|NCT00635505|Asthma
1333834|NCT00635505|albuterol
1333835|NCT00635505|HFA
1333836|NCT00635492|diabetes
1333837|NCT00635492|insulin
1333838|NCT00635492|exenatide
1333839|NCT00635492|Byetta
1333840|NCT00635492|Amylin
1333841|NCT00635492|Lilly
1333842|NCT00635479|Fractures
1333843|NCT00635479|Pelvic bones
1333844|NCT00635479|Acetabulum
1333846|NCT00635466|laparoscopic surgery, rectal carcinoma, phase II trial
1333847|NCT00635453|Breast Feeding
1333848|NCT00635453|Child
1333849|NCT00635453|Infant Nutrition Physiology
1333850|NCT00635453|Public Health
1333851|NCT00635453|Morbidity
1333852|NCT00635453|Health Plan Implementation
1333853|NCT00635440|skeletal muscle
1333854|NCT00635440|ubiquitin
1333855|NCT00635440|proteasome
1333856|NCT00635440|IGF-1
1333857|NCT00635440|MGF
1333858|NCT00635440|protein catabolism
1333859|NCT00635440|neuromuscular electrical stimulation
1333860|NCT00635440|Investigate effect of NMES on muscle metabolism of catabolic patients
1333861|NCT00635427|VPRIV
1333862|NCT00635427|Enzyme Replacement Therapy
1333863|NCT00635427|Gaucher disease
1333864|NCT00635427|glucocerebrosidase
1333865|NCT00635427|beta-glucocerebrosidase
1333866|NCT00635427|Acid beta-glucocerebrosidase
1333867|NCT00635427|glucosylceramidase
1333868|NCT00635427|D-glucosyl-N-acylsphingosine glucohydrolase
1333869|NCT00635427|gene activation
1333870|NCT00635427|human
1333871|NCT00635414|Gastroesophageal Reflux Disease (GERD), esomeprazole, Nexium
1333872|NCT00635362|Contraception
1333873|NCT00635362|Contraceptive Devices
1333874|NCT00635362|Intrauterine Devices
1333875|NCT00635362|Unplanned Pregnancy
1333876|NCT00635362|Postpartum Period
1333877|NCT00635349|WOMAC
1333878|NCT00635349|Knee osteoarthritis pain
1333879|NCT00635349|Pain intensity
1333880|NCT00635349|Tramadol
1333881|NCT00635349|Acetaminophen
1333882|NCT00635349|Meloxicam
1333883|NCT00635349|Aceclofenac
1333884|NCT00635336|Epitope peptide
1333885|NCT00635336|CTL
1333886|NCT00635336|Advanced bladder cancer
1333887|NCT00635336|Vaccination
1333888|NCT00635336|advanced bladder cancer which showed resistance for standard treatments
1333889|NCT00635310|Chronic hepatitis C
1333890|NCT00635310|Chronic hepatitis B
1333891|NCT00635310|Liver biopsy
1333892|NCT00635310|Hemodialysis
1333893|NCT00635310|1-Deamino-8- D-Arginine Vasopressin
1333894|NCT00635297|osteoporosis
1333895|NCT00635297|vertebroplasty
1333896|NCT00635297|prophylactic
1333897|NCT00635297|vertebrae
1333898|NCT00635297|fracture
1333899|NCT00635271|Asthma
1333900|NCT00635271|Biomarker
1333901|NCT00635271|Exhaled Breath Condensate
1333902|NCT00635271|Cytokine
1333903|NCT00635271|Healthy Volunteer
1333904|NCT00635271|HV
1333905|NCT00635258|GnRH antagonist
1333906|NCT00635258|oocyte donation
1333907|NCT00635258|pregnancy
1333908|NCT00635258|implantation
1333909|NCT00635245|stage IA breast cancer
1333910|NCT00635245|stage IB breast cancer
1333911|NCT00635245|stage II breast cancer
1333912|NCT00635232|Hypertension
1333913|NCT00635232|High Blood Pressure
1333914|NCT00635219|Major depressive disorder
1333915|NCT00635219|Placebo-controlled
1333916|NCT00635219|Active reference
1333917|NCT00635219|Multicenter study
1333918|NCT00635219|Randomised study
1333919|NCT00635219|Acute treatment
1333920|NCT00635206|OSA
1333921|NCT00635193|Ovarian neoplasms
1333922|NCT00635193|Angiogenesis inhibitors
1333923|NCT00635193|Angiogenesis
1333924|NCT00635193|Volociximab
1333925|NCT00635193|Ovarian cancer
1333926|NCT00635193|Antibody
1333927|NCT00635193|Monoclonals
1333928|NCT00635180|Isometric exercise
1333929|NCT00635180|intraocular pressure
1333930|NCT00635180|Physiological changes in intraocular pressure during isometric exercise
1333931|NCT00635167|Prostate cancer
1333932|NCT00635167|prostatic vascularity
1333933|NCT00635167|External Beam Radiation treatment
1333934|NCT00635167|Contrast Enhanced transrectal Ultrasound
1333935|NCT00635154|stage I multiple myeloma
1333936|NCT00635154|stage II multiple myeloma
1333937|NCT00635154|stage III multiple myeloma
1333938|NCT00635141|Cystic Fibrosis
1333939|NCT00635141|Lung Clearance Index
1333940|NCT00635141|Hypertonic Saline
1333941|NCT00635141|Pediatrics
1333942|NCT00635128|Diphtheria
1333943|NCT00635128|vaccine
1333944|NCT00635128|DTP
1333945|NCT00635128|Poliomyelitis
1333946|NCT00635128|Pertussis
1333947|NCT00635128|Booster
1333948|NCT00635128|Tetanus
1333949|NCT00635102|Alcohol Dependence, Alcoholism, Glycine, D-Cycloserine
1333950|NCT00635089|Eosinophilic Esophagitis
1333951|NCT00635089|Cinquil
1333952|NCT00635063|Cancer Breakthrough Pain
1333953|NCT00635050|Breast cancer
1333954|NCT00635037|Myofascial pain syndrome
1333955|NCT00635037|Acupuncture
1333956|NCT00635037|Nonsteroidal anti-inflammatory agents
1333957|NCT00635037|Muscle relaxants, central
1333958|NCT00635037|Quality of life.
1333959|NCT00635037|muscle relaxants, analgesia
1333960|NCT00635024|refractory multiple myeloma
1333961|NCT00635024|stage I multiple myeloma
1333962|NCT00635024|stage II multiple myeloma
1333963|NCT00635024|stage III multiple myeloma
1333964|NCT00635011|comorbidity
1333965|NCT00635011|Quality of Life
1333966|NCT00635011|Body Weight Changes
1333967|NCT00634998|Vitamin C
1333968|NCT00634998|Ascorbic Acid
1333969|NCT00634998|Diabetic Neuropathies
1333970|NCT00634972|Retinopathy of Prematurity
1333971|NCT00634972|Premature Infants
1333972|NCT00634972|ACULAR
1333973|NCT00634972|Refresh Tears
1333974|NCT00634959|HIV Infections
1333975|NCT00634959|Treatment Naïve
1333976|NCT00634946|Chemonucleolysis
1333977|NCT00634946|Lumbar Vertebrae
1333978|NCT00634946|Hernia
1333979|NCT00634933|active
1333980|NCT00634933|rheumatoid
1333981|NCT00634933|arthritis
1333982|NCT00634933|anti CD20
1333983|NCT00634920|De novo renal transplantation
1333984|NCT00634907|Genotyping
1333985|NCT00634907|Warfarin dosing
1333986|NCT00634907|arthroplasty
1333987|NCT00634894|Ovarian Cancer
1333988|NCT00634894|Fallopian Tube Cancer
1333989|NCT00634894|Peritoneal Cancer
1333990|NCT00634894|Femara
1333991|NCT00634894|Letrozole
1333992|NCT00634894|Placebo
1333993|NCT00634881|B-cell chronic lymphocytic leukemia
1333994|NCT00634881|stage III chronic lymphocytic leukemia
1333995|NCT00634881|stage IV chronic lymphocytic leukemia
1333996|NCT00634881|stage I chronic lymphocytic leukemia
1333997|NCT00634881|stage II chronic lymphocytic leukemia
1333998|NCT00634868|ulcer wound diabetes
1333999|NCT00634855|Endothelial progenitor cells
1334000|NCT00634855|Endothelial dysfunction
1334001|NCT00634777|HNSCC biopsy-proven
1334002|NCT00634777|T1-T4 oral cavity oropharynx hypopharynx larynx
1334003|NCT00634777|N+ scheduled for an organ preservation treatment protocol based on concomitant
1334004|NCT00634777|chemoradiation
1334005|NCT00634764|Maternal weight gain
1334006|NCT00634764|Neonatal birth weight
1334007|NCT00634764|Weight gain attitude
1334008|NCT00634764|Pregnancy
1334009|NCT00634764|Body fat
1334010|NCT00634764|Maternal Behavior
1334011|NCT00634764|Birth outcomes
1334012|NCT00634751|advanced pancreatic and biliary tract carcinomas
1334013|NCT00634738|ischemic compression;carpal tunnel syndrome
1334014|NCT00634725|adenocarcinoma of the pancreas
1334015|NCT00634725|stage III pancreatic cancer
1334016|NCT00634712|Congestive Heart Failure
1334017|NCT00634712|Atacand
1334018|NCT00634712|Candesartan
1334019|NCT00634686|Omega-3 fatty acids
1334020|NCT00634686|immune response
1334021|NCT00634673|Serum Fatty Acids
1334022|NCT00634673|FABP2 Gene
1334023|NCT00634673|Polymorphism Ala54Thr
1334024|NCT00634647|Chemotherapy
1334025|NCT00634647|Pharmacokinetics
1334026|NCT00634647|Gene Polymorphisms
1334027|NCT00634647|Prostate Cancer
1334028|NCT00634634|breast cancer
1334029|NCT00634634|Postmenopausal Women with Hormone Receptor-Positive Locally Advanced Breast Cancer
1334030|NCT00634621|Bladder
1334031|NCT00634621|Cancer
1334032|NCT00634621|Cystoscopy
1334033|NCT00634621|Hexaminolevulinate
1334034|NCT00634621|Hexvix
1334035|NCT00634595|clinical trial
1334036|NCT00634595|randomized
1334037|NCT00634595|Endostatin
1334038|NCT00634595|gene therapy
1334039|NCT00634595|head and neck cancer
1334040|NCT00634595|head and neck squamous carcinoma
1334041|NCT00634582|adenocarcinoma of the prostate
1334042|NCT00634582|stage IV prostate cancer
1334043|NCT00634582|recurrent prostate cancer
1334044|NCT00634582|bone metastases
1334045|NCT00634569|CVID, XLA, hyper IgM syndrome, Wiskott-Aldrich Syndrome
1334046|NCT00634556|Tourette Syndrome
1334047|NCT00634556|fMRI
1334048|NCT00634556|levodopa
1334049|NCT00634556|working memory
1334050|NCT00634556|dopamine
1334051|NCT00634543|Diabetic neuropathy
1334052|NCT00634543|Ultracet
1334053|NCT00634543|Tramadol hydrochloride
1334054|NCT00634543|Acetaminophen
1334055|NCT00634543|Gabapentin
1334056|NCT00634530|Pregnancy
1334057|NCT00634530|Prenatal Care
1334058|NCT00634530|Weight
1334059|NCT00634530|Nutritional Status
1334060|NCT00634504|high dose methotrexate
1334061|NCT00634504|Voraxaze
1334062|NCT00634504|leucovorin
1334063|NCT00634504|delayed elimination
1334064|NCT00634504|methotrexate toxicity
1334065|NCT00634504|rescue
1334066|NCT00634504|renal insufficiency
1334067|NCT00634478|essential tremor
1334068|NCT00634478|deep brain stimulation
1334069|NCT00634452|Hodgkin's
1334070|NCT00634452|Cancer
1334071|NCT00634452|bi-measurable disease
1334072|NCT00634452|Lymphoma
1334073|NCT00634439|cerebrovascular accident
1334074|NCT00634439|stroke
1334075|NCT00634439|transient ischemic attack
1334076|NCT00634439|TIA
1334077|NCT00634439|CVA
1334078|NCT00634439|attention deficit hyperactivity disorder
1334079|NCT00634439|ADHD
1334080|NCT00634426|Spine
1334081|NCT00634426|Neoplasm metastasis
1334082|NCT00634426|Treatment, surgical
1334083|NCT00634426|Treatment, nonoperative
1334084|NCT00634426|Quality of life
1334085|NCT00634413|COPD
1334086|NCT00634400|Congestive Heart Failure
1334087|NCT00634400|Atacand
1334088|NCT00634400|Candesartan
1334089|NCT00634374|Rx medibottle
1334090|NCT00634374|Oral syringe
1334091|NCT00634374|Liquid medication
1334092|NCT00634374|Bitter-tasting
1334093|NCT00634374|Infants
1334094|NCT00633386|Knee Surgery
1334095|NCT00633386|Arthroscopic Surgery
1334096|NCT00633373|lung
1334097|NCT00633373|transplant
1334098|NCT00633373|transplant rejection
1334099|NCT00633373|Cyclosporine
1334100|NCT00633373|bronchiolitis obliterans
1334101|NCT00633373|aerosol
1334102|NCT00633360|Women
1334103|NCT00633360|PMS
1334104|NCT00633360|Depression
1334105|NCT00633347|oocyte donation
1334106|NCT00633347|endometrial preparation
1334107|NCT00633334|Cancer
1334108|NCT00633334|GI
1334109|NCT00633334|Tumor
1334110|NCT00633334|Gastrointestinal
1334111|NCT00633334|high risk
1334112|NCT00633321|smoking cessation
1334113|NCT00633321|quit smoking
1334114|NCT00633321|smoking vaccine
1334115|NCT00633321|nicotine vaccine
1334116|NCT00633321|TA-NIC
1334117|NCT00633321|Aid for smoking cessation in smokers motivated to quit
1334118|NCT00633308|hemodialysis
1334124|NCT00633282|Nonalcoholic Fatty Liver Disease
1334125|NCT00633282|Pioglitazone
1334126|NCT00633282|Berberine
1334127|NCT00633282|Impaired Glucose Metabolism
1334128|NCT00633269|Poly(ADP ribose) polymerases
1334129|NCT00633269|Metastatic Solid Tumours
1334130|NCT00633230|hepatitis C virus
1334131|NCT00633230|complementary and alternative medicine
1334132|NCT00633230|peginterferon alfa and ribavirin
1334133|NCT00633217|DISKUS
1334134|NCT00633217|Salmeterol
1334135|NCT00633217|Fluticasone Propionate
1334136|NCT00633217|Chronic Obstructive Pulmonary Disease (COPD)
1334137|NCT00633217|Hydroflouroalkane
1334138|NCT00633217|COPD
1334139|NCT00633217|HFA MDI
1334140|NCT00633204|Epitope peptide, CTL, TUR-Bt, Bladder cancer, Vaccination
1334141|NCT00633204|Bladder cancer after surgery
1334142|NCT00633191|Cystic fibrosis
1334143|NCT00633191|Prevention
1334144|NCT00633191|Infection
1334145|NCT00633191|Pseudomonas aeruginosa
1334146|NCT00633191|Gargle
1334147|NCT00633178|Prenatal Depression
1334148|NCT00633178|Postpartum Depression
1334149|NCT00633178|Fetal Development
1334150|NCT00633178|Interpersonal Therapy
1334151|NCT00633165|sarcoma
1334152|NCT00633165|myxoid liposarcoma
1334153|NCT00633152|complicated skin and skin structure infections
1334154|NCT00633152|linezolid
1334155|NCT00633152|ceftaroline
1334156|NCT00633152|clinical response
1334157|NCT00633152|microbiological response
1334158|NCT00633152|Cellulitis
1334159|NCT00633152|Abscess
1334160|NCT00633152|Wound infection
1334161|NCT00633152|Deeper soft tissue
1334162|NCT00633152|Significant surgical intervention
1334163|NCT00633152|Gram-positive bacterial infection
1334164|NCT00633152|Gram-negative bacterial infection
1334165|NCT00633152|bacterial infection
1334166|NCT00633152|cephalosporin
1334167|NCT00633152|broad-spectrum activity
1334168|NCT00634322|osteosarcoma
1334169|NCT00634322|high dose methotrexate
1334170|NCT00634322|leucovorin
1334171|NCT00634309|Congestive Heart Failure
1334172|NCT00634309|Atacand
1334173|NCT00634309|Candesartan
1334174|NCT00634296|Heart failure
1334175|NCT00634296|Systolic dysfunction
1334176|NCT00634296|Inspiratory muscle weakness
1334177|NCT00634270|Plexiform, Neurofibromatosis Type 1, Sirolimus, Phase II
1334178|NCT00634257|Advanced Cancer
1334179|NCT00634257|Solid Tumors
1334180|NCT00634257|Spirituality
1334181|NCT00634257|Religiosity
1334182|NCT00634257|Symptom Distress
1334183|NCT00634257|Quality of Life
1334184|NCT00634257|Caregivers
1334185|NCT00634257|Questionnaire
1334186|NCT00634257|Survey
1334187|NCT00634244|Acute Myelogenous Leukemia (AML), Carboplatin, Topotecan, Flavopiridol, Mitoxantrone, Cytosine Arabinoside, Sirolimus, Etoposide
1334188|NCT00634231|Malignant glioma
1334189|NCT00634231|Glioblastoma multiforme
1334190|NCT00634231|Anaplastic astrocytoma
1334191|NCT00634231|Recurrent ependymoma
1334192|NCT00634231|Gene therapy
1334193|NCT00634231|Immunotherapy
1334194|NCT00634218|nicotine
1334195|NCT00634218|smoking
1334196|NCT00634218|smoking cessation
1334197|NCT00634205|Mesothelioma
1334198|NCT00634205|Valproate
1334199|NCT00634205|Doxorubicin
1334200|NCT00634205|Chemotherapy
1334201|NCT00634205|Phase II
1334202|NCT00634192|Chronic infection with P. aeruginosa in Cystic Fibrosis subjects
1334203|NCT00634179|Lymphoma
1334204|NCT00634166|thermal injuries
1334205|NCT00634166|burns
1334206|NCT00634166|Burn Patients (Subjects with Thermal Injuries Requiring Meshed Autografts)
1334207|NCT00634140|gallbladder
1334208|NCT00634140|ezetimibe for 4 to 6 weeks prior to gallbladder removal
1334209|NCT00634114|Reflux Esophagitis
1334210|NCT00634075|Severe sepsis
1334211|NCT00634075|Proinflammatory cytokines
1334212|NCT00634075|ICU
1334213|NCT00634062|Affective Lability
1334214|NCT00634062|Borderline Personality Disorder
1334215|NCT00634062|Pharmacotherapy
1334216|NCT00634049|invasive fungal infections caused by rare molds, rare yeasts
1334217|NCT00634049|BAL8557
1334218|NCT00634049|Isavuconazole
1334219|NCT00634049|Aspergillosis
1334220|NCT00634049|or by dimorphic fungi
1334221|NCT00634049|ASP9766
1334222|NCT00634036|Asthma
1334223|NCT00634036|obesity
1334224|NCT00634036|exacerbation
1334225|NCT00634036|asthmatics
1334226|NCT00634036|fat
1334227|NCT00634036|overweight
1334228|NCT00634036|adipose tissue
1334229|NCT00634036|leptin
1334230|NCT00634036|adiponectin
1334231|NCT00634036|pioglitazone
1334232|NCT00634036|Actos
1334233|NCT00634036|wheezing
1334234|NCT00634036|Pittsburgh
1334235|NCT00634036|Pennsylvania
1334236|NCT00634036|pulmonary
1334237|NCT00634036|lung
1334238|NCT00634010|Advanced Cancer
1334239|NCT00634010|Solid Tumors
1334240|NCT00634010|Cancer Pain
1334241|NCT00634010|Opioid Pain Killer
1334242|NCT00634010|Morphine
1334243|NCT00634010|Methadone
1334244|NCT00633997|Diabetes mellitus
1334245|NCT00633997|type 2 diabetes
1334246|NCT00633997|vildagliptin
1334247|NCT00633997|pharmacokinetics
1334248|NCT00633984|Social Anxiety Disorder
1334249|NCT00633984|Cognitive Behavioral Group Therapy
1334250|NCT00633984|D-cycloserine
1334251|NCT00633971|Post thrombotic syndrome
1334252|NCT00633971|Thrombosis
1334253|NCT00633971|Deep vein thrombosis
1334254|NCT00633971|Venous thrombosis
1334255|NCT00633971|Edema
1334256|NCT00633971|stasis ulcers
1334257|NCT00633958|18F-FLT
1334258|NCT00633958|FLT
1334259|NCT00633958|PET
1334260|NCT00633958|CNS tumors
1334261|NCT00633958|Newly
1334262|NCT00633958|diagnosed
1334263|NCT00633945|Cutaneous Lupus Erythematosus
1334264|NCT00633945|CLE
1334265|NCT00633945|lenalidomide
1334266|NCT00633945|revlimid
1334267|NCT00633945|thalidomide derivative
1334268|NCT00633945|drug
1334269|NCT00633945|lupus
1334270|NCT00633932|Reflux Esophagitis
1334271|NCT00633919|House dust mites
1334272|NCT00633919|Sublingual immunotherapy
1334273|NCT00633919|Allergy
1334274|NCT00633919|Allergic asthma
1334275|NCT00633906|HIV
1334276|NCT00633906|Sexually Transmitted diseases
1334277|NCT00633906|Adolescents
1334278|NCT00633906|Prevention
1334279|NCT00633906|HIV Seronegativity
1334280|NCT00633880|NOH
1334281|NCT00633880|Neurogenic Orthostatic Hypotension
1334282|NCT00633880|Orthostatic hypotension
1334283|NCT00633880|PAF
1334284|NCT00633880|Pure Autonomic Failure
1334285|NCT00633880|MSA
1334286|NCT00633880|Multiple System Atrophy
1334287|NCT00633880|Neuropathy
1334288|NCT00633880|Autonomic Failure
1334289|NCT00633880|Parkinson
1334290|NCT00633880|Dopamine Deficiency
1334291|NCT00633880|Dopamine
1334292|NCT00633880|Droxidopa
1334293|NCT00633867|Tracheal intubation
1334294|NCT00633867|Laryngoscopy
1334295|NCT00633867|videolaryngoscope
1334296|NCT00633867|McGrath
1334297|NCT00633867|success
1334298|NCT00633867|time
1334299|NCT00633854|annular array ultrasound
1334300|NCT00633854|ophthalmic ultrasound
1334301|NCT00633854|posterior vitreous detachment (PVD)
1334302|NCT00633841|Alzheimer
1334303|NCT00633841|Morbus Alzheimer
1334304|NCT00633841|Alzheimer Vaccine
1334305|NCT00633841|Vaccine
1334306|NCT00633841|AD
1334307|NCT00633841|Aβ immunotherapy
1334308|NCT00633828|Bone Density
1334309|NCT00633828|Bone mass
1334310|NCT00633828|Bone mineral density
1334311|NCT00633828|Bone structure
1334312|NCT00633828|Cardiovascular risk factors
1334313|NCT00633828|Fat Mass
1334314|NCT00633828|Adiposity
1334315|NCT00633815|Supine
1334316|NCT00633815|Upright
1334317|NCT00633802|Risperidone
1334318|NCT00633802|Borderlone Personality Disorder
1334319|NCT00633776|Chronic Obstructive Pulmonary Disease
1334320|NCT00633776|COPD
1334321|NCT00633776|Chronic bronchitis
1334322|NCT00633776|Emphysema
1334323|NCT00633776|Perforomist
1334324|NCT00633776|Foradil
1334325|NCT00633776|CT
1334326|NCT00633776|lung function
1334327|NCT00633763|Diagnostic
1334328|NCT00633763|PET/CT imaging of pancreas
1334329|NCT00633763|Detecting pancreatic beta cell loss during diabetes
1334330|NCT00633750|stage I breast cancer
1334331|NCT00633750|stage II breast cancer
1334332|NCT00633750|stage IIIA breast cancer
1334333|NCT00633750|stage IIIB breast cancer
1334334|NCT00633737|Psychology
1334335|NCT00633737|Laparoscopy
1334336|NCT00633737|Cholecystectomy
1334337|NCT00633737|Psychoneuroimmunology
1334338|NCT00633737|Wound healing
1334339|NCT00633737|Preparation for surgery
1334340|NCT00633737|Stress reduction
1334341|NCT00633737|Stress
1334342|NCT00633737|Relaxation
1334343|NCT00633711|OSAS
1334344|NCT00633711|blood pressure
1334345|NCT00633711|sympathetic nervous system
1334346|NCT00633711|treatment
1334347|NCT00633711|CPAP
1334348|NCT00633698|lipoprotein(a)
1334349|NCT00633698|niacin
1334350|NCT00633698|placebo
1334351|NCT00633698|intervention
1334352|NCT00633685|Posttraumatic Stress Disorder
1334353|NCT00633685|Fluoxetine
1334354|NCT00633685|Factors predicting response
1334355|NCT00633685|Resilience
1334356|NCT00633685|Pharmacologic augmentation strategies
1334357|NCT00633672|NSAID
1334358|NCT00633672|Nexium
1334359|NCT00633672|esomeprazole
1334360|NCT00633672|Gastric Ulcers
1334361|NCT00633659|Hemospan
1334362|NCT00633659|Oxygen carriers
1334363|NCT00633659|Blood substitutes
1334364|NCT00633659|Ischemia
1334365|NCT00633659|Tissue oxygenation
1334366|NCT00633646|nitrogen balance
1334367|NCT00633646|malnutrition
1334368|NCT00633646|chronic kidney disease
1334369|NCT00633646|diet
1334370|NCT00633646|glomerular filtration rate
1334371|NCT00633633|Heart Failure
1334372|NCT00633633|Lifestyle Intervention
1334373|NCT00633633|Exercise
1334374|NCT00633633|Diet
1334375|NCT00633620|colonoscopy
1334376|NCT00633620|narrow band imaging
1334377|NCT00633620|adenoma
1334378|NCT00633620|diagnosis
1334379|NCT00633620|colonoscopic adenoma detection
1334380|NCT00633594|Mantle Cell Lymphoma
1334381|NCT00633594|Rituximab
1334382|NCT00633594|Lenalidomide
1334383|NCT00633594|Bortezomib
1334384|NCT00633594|Phase 1/2
1334385|NCT00633581|fatigue
1334386|NCT00633581|ascorbic acid
1334387|NCT00633581|oxidative stress
1334388|NCT00633568|Non-small cell lung carcinoma
1334389|NCT00633568|Concomitant radiochemotherapy
1334390|NCT00633568|Cisplatin
1334391|NCT00633568|Docetaxel
1334392|NCT00633568|Radiotherapy
1334393|NCT00633568|Chemotherapy
1334394|NCT00633568|Unresectable stage III non-small cell lung carcinoma
1334395|NCT00633542|thalidomide
1334396|NCT00633542|maintenance
1334397|NCT00633542|interferon
1334398|NCT00633542|dexamethasone
1334399|NCT00633542|newly diagnosed multiple myeloma
1334400|NCT00633542|relapsed refractory multiple myeloma
1334401|NCT00633529|Phase 1b
1334402|NCT00633529|Non-Small Cell Lung Cancer
1334403|NCT00633529|Advanced or Metastatic Disease
1334404|NCT00633529|Prior chemotherapy
1334405|NCT00633516|moles
1334406|NCT00633516|melanoma
1334407|NCT00633503|free tissue transfer
1334408|NCT00633503|pedicle tissue transfer
1334409|NCT00633503|complications
1334410|NCT00633503|modulated imaging spectroscopy
1334411|NCT00633503|observation
1334412|NCT00633503|clinical observation/diagnosis
1334413|NCT00633503|tissue defects requiring free tissue transfer
1334414|NCT00633503|tissue defects requiring pedicle tissue transfer
1334415|NCT00633490|Toxicity
1334416|NCT00633490|Efficacy
1334417|NCT00633477|Systemic Inflammatory Response Syndrome
1334418|NCT00633477|Septic Shock
1334419|NCT00633477|Septicemia
1334420|NCT00633477|Drug Therapy
1334421|NCT00633451|shoulder pain
1334422|NCT00633451|shoulder impingement syndrome
1334423|NCT00633451|manual therapy
1334424|NCT00633451|rehabilitation
1334425|NCT00633438|Knee Surgery Arthroscopic Surgery
1334426|NCT00633412|NSAID
1334427|NCT00633412|Nexium
1334428|NCT00633412|esomeprazole
1334429|NCT00633412|Gastric Ulcers
1334430|NCT00633399|Major Depressive Disorder
1334431|NCT00633399|Major Depression
1334432|NCT00633399|Depression
1334433|NCT00633399|Geodon
1334434|NCT00633399|Ziprasidone
1334435|NCT00633399|SSRI Augmentation
1334436|NCT00633399|Treatment Resistant Depression
1334437|NCT00633139|Metazym
1334438|NCT00633139|Late infantile
1334439|NCT00633139|Metachromatic leukodystrophy
1334440|NCT00633139|Long-term safety
1334441|NCT00633126|PK
1334442|NCT00633126|Pharmacokinetics
1334443|NCT00633113|Total Knee Arthroplasty
1334444|NCT00633113|Minimally Invasive Knee Replacement
1334445|NCT00633113|Knee Osteoarthritis
1334446|NCT00633113|Cost effectiveness minimally invasive knee surgery
1334447|NCT00633074|Influenza
1334448|NCT00633061|Childhood Cancer
1334449|NCT00633061|Central Venous Catheter
1334450|NCT00633061|Deep Vein Thrombosis
1334451|NCT00633061|Catheter-related Infection
1334452|NCT00633061|Catheter-related Occlusion
1334453|NCT00633048|ascending single-dose study
1334454|NCT00633048|healthy subjects
1334455|NCT00633035|ulcer
1334456|NCT00633035|esomeprazole
1334457|NCT00633035|famotidine
1334458|NCT00633035|Neurosurgery
1334459|NCT00633022|FDG-PET/CT, atherosclerosis
1334460|NCT00633009|Leishmaniasis
1334461|NCT00633009|Delayed-Type Hypersensitivity (DTH)
1334462|NCT00633009|Skin Test
1334463|NCT00633009|Conversion
1334464|NCT00633009|Prior exposure to Leishmania major
1334465|NCT00632996|shoulder pain
1334466|NCT00632996|shoulder impingement syndrome
1334467|NCT00632996|manual therapy
1334468|NCT00632996|rehabilitation
1334469|NCT00632983|long-term effects secondary to cancer therapy in adults
1334470|NCT00632983|anxiety disorder
1334471|NCT00632983|sexual dysfunction
1334472|NCT00632983|urinary complications
1334473|NCT00632983|stage I prostate cancer
1334474|NCT00632983|stage IIB prostate cancer
1334475|NCT00632983|stage IIA prostate cancer
1334476|NCT00632970|Raltegravir
1334477|NCT00632970|Lopinavir
1334478|NCT00632918|Image quality
1334479|NCT00632918|Dual-source CT
1334480|NCT00632918|Coronary angiography
1334481|NCT00632918|Heart rate
1334482|NCT00632905|Prostate Cancer
1334483|NCT00632905|Prostatic adenoma
1334484|NCT00632905|Prostatic neoplasm
1334485|NCT00632892|oxidative stress markers in urine
1334486|NCT00632892|urine norepinephrine
1334487|NCT00632892|renal tubular enzyme markers
1334488|NCT00632866|auto-immune diseases
1334489|NCT00632866|hydroxychloroquine
1334490|NCT00632866|primary Sjögren's syndrome
1334491|NCT00632866|inflammatory arthritides
1334492|NCT00632866|inflammatory rheumatic diseases
1334493|NCT00632866|dryness
1334494|NCT00632866|joint diseases
1334496|NCT00632814|Kogenate,
1334497|NCT00632814|Children,
1334498|NCT00632814|Factor VIII,
1334499|NCT00632814|Hemophilia A,
1334500|NCT00632814|Prophylactic
1334501|NCT00632801|elective laparoscopic colectomy
1334502|NCT00632801|chewing gum
1334503|NCT00632801|ileus
1334504|NCT00632801|post-operative care
1334505|NCT00632801|colectomy
1334506|NCT00632788|myocardial infarction
1334507|NCT00632788|catheterization
1334508|NCT00632788|angioplasty
1334509|NCT00632788|door-to-balloon time
1334510|NCT00632775|pediatrics
1334511|NCT00632775|Hyponatremia
1334512|NCT00632775|Sodium Chloride
1334513|NCT00632775|maintenance fluids
1334514|NCT00632762|Amantadine benefit
1334515|NCT00632762|Dyskinesia
1334516|NCT00632762|Parkinson's disease
1334517|NCT00632736|ropinirole XL
1334518|NCT00632736|REQUIP
1334519|NCT00632736|Parkinson's disease
1334520|NCT00632736|long term safety
1334521|NCT00632736|efficacy
1334522|NCT00632736|safety
1334523|NCT00632736|ropinirole CR
1334524|NCT00632736|ropinirole IR
1334525|NCT00632736|open-label
1334526|NCT00632723|oestrogen receptor
1334527|NCT00632723|ER negative tumours
1334528|NCT00632723|epidermal growth factor receptor (EGFR)
1334529|NCT00632710|rheumatoid arthritis
1334530|NCT00632710|hands
1334531|NCT00632710|randomized controlled
1334532|NCT00632710|low level laser
1334533|NCT00632697|endometriosis
1334534|NCT00632697|immunomodulation
1334535|NCT00632697|infertility
1334536|NCT00632697|laparoscopic surgery
1334537|NCT00632697|pentoxifylline
1334538|NCT00632684|Family Caregiving
1334539|NCT00632684|Dementia
1334540|NCT00632671|Obesity cohort
1334541|NCT00632658|cGVHD
1334542|NCT00632645|Huntington
1334543|NCT00632645|Neuroleptic
1334544|NCT00632645|Unified Huntington Disease Rating Scale (UHDRS)
1334545|NCT00632645|Independence Scale
1334546|NCT00632645|Neuroleptic Prescription required
1334547|NCT00632632|World Trade Center Victims
1334548|NCT00632632|Iraq War Veterans
1334549|NCT00632632|PTSD
1334550|NCT00632619|Subthreshold Manic States in Children
1334551|NCT00632619|ADHD
1334552|NCT00632606|pregnant women
1334553|NCT00632593|Early Complications of both techniques
1334554|NCT00632593|Fistula rate
1334555|NCT00632593|Dehiscence rate
1334556|NCT00632593|reoperation rate and cause
1334557|NCT00632580|Pain, Postoperative
1334558|NCT00632567|Anal incontinence
1334559|NCT00632567|First delivery was traumatic
1334560|NCT00632567|No anal incontinence
1334561|NCT00632528|MEOPA
1334562|NCT00632528|spasticity
1334563|NCT00632528|multilevel surgery
1334564|NCT00632528|cerebral palsy
1334565|NCT00632528|children
1334566|NCT00632515|Colorectal Cancer
1334567|NCT00632515|CRC
1334568|NCT00632515|Familial CRC
1334569|NCT00632515|Cancer Screening
1334570|NCT00632515|Questionnaire
1334571|NCT00632515|First Degree Relatives
1334572|NCT00632515|FDRs
1334573|NCT00632515|Risk Communication
1334574|NCT00632489|Refractory Malignancy
1334575|NCT00632489|Breast Cancer
1334576|NCT00632489|LBH589
1334577|NCT00632489|Capecitabine
1334578|NCT00632489|Lapatinib
1334579|NCT00632476|Smoking During Pregnancy
1334580|NCT00632476|Vitamin C
1334581|NCT00632476|Newborn Lung Function
1334582|NCT00632476|Ascorbic Acid
1334583|NCT00632463|Transplant
1334584|NCT00632463|Immunosuppression
1334585|NCT00632437|Brain Tumor
1334586|NCT00632437|Craniotomy Surgery
1334587|NCT00632437|Brain Function
1334588|NCT00632437|Intraoperative Optical Imaging
1334589|NCT00632437|Speckle-Contrast Imaging
1334590|NCT00632437|Cortical Mapping
1334591|NCT00632437|Somatosensory Cortex
1334592|NCT00632437|Cerebral blood flow
1334593|NCT00632437|CBF
1334594|NCT00632437|Laser Speckle Contrast Imaging
1334595|NCT00632437|Multi-Spectral Imaging
1334596|NCT00632398|massage
1334597|NCT00632398|oncology massage
1334598|NCT00632398|palliative care
1334599|NCT00632398|supportive care
1334600|NCT00632398|integrative oncology
1334601|NCT00632398|informal caregiving
1334602|NCT00632398|spouse caregiving
1334603|NCT00632398|family caregiving
1334604|NCT00632398|caregiver education
1334605|NCT00632398|psychosocial oncology
1334606|NCT00632398|caregiver stress
1334607|NCT00632398|coping with cancer
1334608|NCT00632398|quality of life
1334609|NCT00632398|end of life care
1334610|NCT00632359|Chronic Lymphocytic Leukemia
1334611|NCT00632359|CLL
1334612|NCT00632359|Lenalidomide
1334613|NCT00632359|Revlimid
1334614|NCT00632346|childhood abuse
1334615|NCT00632346|overweight
1334616|NCT00632346|obesity
1334617|NCT00632346|BMI as a young adult
1334618|NCT00632346|childhood physical abuse
1334619|NCT00632346|childhood emotional abuse
1334620|NCT00632346|childhood sexual abuse
1334621|NCT00632346|childhood physical neglect
1334622|NCT00632346|childhood emotional neglect
1334623|NCT00632346|childhood witnessing of domestic violence
1334624|NCT00632346|parental marital discord
1334625|NCT00632346|household members with substance abuse
1334626|NCT00632346|household members with mental illness
1334627|NCT00632346|household members with criminal behavior
1334628|NCT00632346|cumulative adverse childhood experiences
1334629|NCT00632333|Epitope peptide
1334630|NCT00632333|Vaccination
1334631|NCT00632333|Chemoradiation
1334632|NCT00632333|Esophageal cancer
1334633|NCT00632320|Ventilator, mechanical
1334634|NCT00632320|Ventilator weaning
1334635|NCT00632320|Rapid shallow breathing index
1334636|NCT00632320|Continuous positive airway pressure
1334637|NCT00632320|Receiver operating characteristic curve
1334638|NCT00632320|COPD
1334639|NCT00632307|lung tumor
1334640|NCT00632307|pleural tumor
1334641|NCT00632307|interstitial lung disease
1334642|NCT00632307|airway infection
1334643|NCT00632307|COPD
1334644|NCT00632307|sleep apnea
1334645|NCT00632307|ion mobility spectrometry
1334646|NCT00632307|breath analysis
1334647|NCT00632294|Bone Cancer
1334648|NCT00632294|Allograft Retrieval
1334649|NCT00632294|Allograft Bone
1334650|NCT00632294|Bone Mineral Density
1334651|NCT00632268|mTOR inhibitor
1334652|NCT00632268|RAD001
1334653|NCT00632268|everolimus
1334654|NCT00632268|chemotherapy
1334655|NCT00632268|cisplatin
1334656|NCT00632268|high-dose 5-FU
1334657|NCT00632255|Chronic Myeloid Leukemia
1334658|NCT00632255|Long term Imatinib therapy compliance
1334659|NCT00632255|Newly diagnosed
1334660|NCT00632255|Late side effects
1334661|NCT00632229|Obsessive-Compulsive Disorder; Adults; Medication; Treatment
1334662|NCT00632190|cervical cancer
1334663|NCT00632190|cervical intraepithelial neoplasia grade 1
1334664|NCT00632190|cervical intraepithelial neoplasia grade 2
1334665|NCT00632190|cervical intraepithelial neoplasia grade 3
1334666|NCT00632138|sexual dysfunction
1334667|NCT00632138|psychosocial effects of cancer and its treatment
1334668|NCT00632138|prostate cancer
1334669|NCT00632138|benign prostatic hyperplasia
1334670|NCT00632138|urinary incontinence
1334671|NCT00632125|CKD subjects with or without dialysis treatment
1334672|NCT00632112|large volume nebulizer
1334673|NCT00632099|cocaine
1334674|NCT00632099|treatment
1334675|NCT00632099|progesterone
1334676|NCT00632086|PK
1334677|NCT00632073|HIV Infections
1334678|NCT00632073|Acquired Immunodeficiency Syndrome
1334679|NCT00632073|treatment experienced
1334680|NCT00632060|Low Back Pain
1334681|NCT00632060|Manual / Manipulative Therapy
1334682|NCT00632047|breast cancer
1334683|NCT00632047|cervical cancer
1334684|NCT00632034|fracture
1334685|NCT00632034|tibia
1334686|NCT00632034|stem cell
1334687|NCT00632021|Low Health Literacy
1334688|NCT00632021|Medication Errors
1334689|NCT00632021|Cardiovascular Disease
1334690|NCT00632021|Pharmacist
1334691|NCT00632021|Care Transition
1334692|NCT00631995|Neisseria meningitidis
1334693|NCT00631982|in vitro maturation oocytes
1334694|NCT00631969|Erectile Dysfunction
1334695|NCT00631917|Hypertension, aliskiren, ramipril, colonoscopy
1334696|NCT00631904|Pacemaker
1334697|NCT00631878|Staphylococcal
1334698|NCT00631878|Monoclonal antibodies
1334699|NCT00631878|Very Low Birth Weight Infants
1334700|NCT00631878|Prophylaxis
1334701|NCT00631865|melanocytes
1334703|NCT00631839|Thoracic Neoplasms
1334704|NCT00631839|Platinum-based chemotherapy
1334705|NCT00631839|3-D Conformal Radiotherapy
1334706|NCT00631839|Chemo-radiotherapy induced lung injury
1334707|NCT00631839|Chemo-radiotherapy induced esophagus injury
1334708|NCT00631826|Shoulder
1334709|NCT00631826|Injuries
1334710|NCT00631826|Flexiblity
1334711|NCT00631826|Rotational resistance
1334712|NCT00631800|Staphylococcal
1334713|NCT00631800|Monoclonal antibodies
1334714|NCT00631800|Very Low Birth Weight Infants
1334715|NCT00631800|Prophylaxis
1334716|NCT00631787|Nitric Oxide
1334717|NCT00631787|Hemolysis
1334718|NCT00631787|Plasma Hemoglobin
1334719|NCT00631787|Dimethyl Sulfoxide
1334720|NCT00631787|Organ Dysfuntion
1334721|NCT00631787|Healthy Volunteer
1334722|NCT00631787|HV
1334723|NCT00631774|type 2 diabetes
1334724|NCT00631774|meal replacement
1334725|NCT00631774|postprandial response
1334726|NCT00631774|Glucerna SR
1334727|NCT00631761|urethrocystoscopy
1334728|NCT00631761|cystoscopy
1334729|NCT00631761|objective structured assessment of surgical skills (OSATS)
1334730|NCT00631748|cocaine
1334731|NCT00631748|quetiapine fumarate
1334732|NCT00631748|dependence
1334733|NCT00631748|abuse
1334734|NCT00631748|addiction
1334735|NCT00631748|treatment
1334736|NCT00631735|cancer
1334737|NCT00631735|qualitative
1334738|NCT00631722|PANSS
1334739|NCT00631722|Acute Episode of Schizophrenia
1334740|NCT00631696|Healthy males Human volunteers pregabalin or placebo sperm quality and quantity
1334741|NCT00631657|placebo controlled
1334742|NCT00631657|randomized
1334743|NCT00631657|double blind
1334744|NCT00631644|Adolescents
1334745|NCT00631644|Eating Behavior
1334746|NCT00631644|Eating in the Absence of Hunger
1334747|NCT00631644|Disordered Eating
1334748|NCT00631644|Food Intake
1334749|NCT00631644|Macronutrient Composition
1334750|NCT00631644|Obesity
1334751|NCT00631644|Adolescent
1334752|NCT00631644|Healthy Volunteer
1334753|NCT00631644|HV
1334754|NCT00631631|Drug Therapy
1334755|NCT00631605|eating disorders
1334756|NCT00631605|ghrelin
1334757|NCT00631605|leptin
1334758|NCT00631605|BIA
1334759|NCT00631592|GSK1349572,
1334760|NCT00631592|healthy volunteers,
1334761|NCT00631592|repeat dose,
1334762|NCT00631592|relative bioavailability
1334763|NCT00631592|Healthy subjects
1334764|NCT00631566|HIV
1334765|NCT00631566|Methicillin-resistant Staphylococcus aureus (MRSA)
1334766|NCT00631566|HIV and Staphylococcus aureus infection
1334767|NCT00631540|renal artery stenosis
1334768|NCT00631540|hypertension
1334769|NCT00631540|renovascular
1334770|NCT00631540|renal artery blockage
1334771|NCT00631540|renal artery disease
1334772|NCT00631540|renal arteries
1334773|NCT00631540|angioplasty renal artery
1334774|NCT00631540|renal artery stent
1334775|NCT00631540|renal artery doppler
1334776|NCT00631540|renovascular hypertension
1334777|NCT00631540|kidney stenosis
1334778|NCT00631540|renal artery
1334779|NCT00631540|stent
1334780|NCT00631540|stenting
1334781|NCT00631540|kidney disease
1334782|NCT00631540|renal failure
1334783|NCT00631540|atherosclerosis
1334784|NCT00631540|arterial hypertension
1334785|NCT00631540|stenosis
1334786|NCT00631527|Prostate Cancer
1334787|NCT00631527|Radiation Therapy
1334788|NCT00631527|RT
1334789|NCT00631527|Radiotherapy
1334790|NCT00631527|Hormone Ablation
1334791|NCT00631527|Sunitinib Malate
1334792|NCT00631527|Leuprolide
1334793|NCT00631527|Lupron
1334794|NCT00631527|Zoladex
1334795|NCT00631527|Goserelin
1334796|NCT00631527|Casodex
1334797|NCT00631527|Bicalutamide
1334798|NCT00631527|SU011248
1334799|NCT00631527|Sutent
1334800|NCT00631527|Angiogenesis inhibitor
1334801|NCT00631514|antihypertensive drugs
1334802|NCT00631514|non-steroidal anti-inflammatory drugs
1334803|NCT00631514|interaction
1334804|NCT00631514|family practice
1334805|NCT00631514|arterial blood pressure
1334806|NCT00631501|tendinopathy
1334807|NCT00631501|tennis elbow
1334808|NCT00631501|lateral epicondylitis
1334809|NCT00631501|lateral epicondylalgia
1334810|NCT00631501|MMP-inhibitor
1334811|NCT00631475|Actelion
1334812|NCT00631475|Idiopathic Pulmonary Fibrosis
1334813|NCT00631475|bosentan
1334814|NCT00631475|Tracleer
1334815|NCT00631475|Interstitial Lung Disease
1334816|NCT00631475|BUILD 3 (NCT00391443)
1334817|NCT00631462|primary myelofibrosis
1334818|NCT00631462|post-polycythemia vera myelofibrosis
1334819|NCT00631462|post-essential thrombocythemia myelofibrosis
1334820|NCT00631449|HIV
1334821|NCT00631449|Treatment intensification
1334822|NCT00631449|Low level viremia
1334823|NCT00631449|Suboptimal CD4+ T cell response
1334824|NCT00631449|treatment experienced
1334825|NCT00631436|Diffusion Tensor Imaging
1334826|NCT00631436|Electroencephalography
1334827|NCT00631436|Blast Injury
1334828|NCT00631436|Traumatic Brain Injury
1334829|NCT00631410|Phase 1
1334830|NCT00631410|CRC
1334831|NCT00631410|SU011248
1334832|NCT00631410|Sunitinib
1334833|NCT00631410|FOLFOX
1334834|NCT00631410|Colorectal cancer
1334835|NCT00631410|metastatic carcinoma of the colon or rectum
1334836|NCT00631397|weakening of the bones
1334837|NCT00631384|Voluntary Counseling and Testing
1334838|NCT00631384|HIV
1334839|NCT00631384|HIV seronegativity
1334840|NCT00631371|temsirolimus
1334841|NCT00631371|renal cell carcinoma
1334842|NCT00631371|kidney cancer
1334843|NCT00631371|urogenital cancer
1334844|NCT00631358|Ocular inflammation
1334845|NCT00631345|prediabetes
1334846|NCT00631345|overweight
1334847|NCT00631345|obesity
1334848|NCT00631345|metabolic syndrome
1334849|NCT00631345|community health worker
1334850|NCT00631332|women, dementia, cognition.
1334851|NCT00631332|non-demented women at least age 65
1334852|NCT00631319|OA
1334853|NCT00631319|Chronic Pain
1334854|NCT00631319|Osteoarthritis
1334855|NCT00631319|OA Pain
1334856|NCT00631319|Osteoarthritis Pain
1334857|NCT00631319|Pain
1334858|NCT00631319|Hip Pain
1334859|NCT00631319|Knee Pain
1334860|NCT00631319|Joint Pain
1334861|NCT00631293|Healthy volunteers
1334862|NCT00631280|Decision Aid
1334863|NCT00631280|Informed Choice
1334864|NCT00631280|Adherence
1334865|NCT00631267|reduction
1334866|NCT00631267|satisfaction
1334867|NCT00631267|visual-analog scale
1334868|NCT00631267|complications
1334869|NCT00631267|functional outcome
1334870|NCT00631267|radiological outcome
1334871|NCT00631241|Cervical Cancer
1334872|NCT00631241|Parametrial Lymph Nodes
1334873|NCT00631241|Sentinel Nodes
1334874|NCT00631241|Intraoperative Lymphatic Mapping
1334875|NCT00631241|Single Photon Emission Computed Tomography
1334876|NCT00631241|SPECT/CT
1334877|NCT00631228|drug eluting stents
1334878|NCT00631228|stents
1334879|NCT00631228|Angioplasty
1334880|NCT00631228|coronary artery disease
1334881|NCT00631228|total coronary occlusion
1334882|NCT00631228|coronary artery restenosis
1334883|NCT00631228|stent thrombosis
1334884|NCT00631228|vascular disease
1334885|NCT00631228|myocardial ischemia
1334886|NCT00631228|coronary artery stenosis
1334887|NCT00631215|Hyperbaric
1334888|NCT00631215|Oxygen
1334889|NCT00631215|autism
1334890|NCT00631202|FRDA
1334891|NCT00631202|Erythropoietin
1334892|NCT00631202|Epoetin alfa
1334893|NCT00631189|dyslipidemia
1334894|NCT00631176|oral intubation
1334895|NCT00631176|just in time
1334896|NCT00631176|simulation education
1334897|NCT00631176|high fidelity training
1334898|NCT00631176|intubation training
1334899|NCT00631176|intubation success
1334900|NCT00631163|Iron Overload,
1334901|NCT00631163|Chelation,
1334902|NCT00631163|MDS,
1334903|NCT00631163|Chronic Anemia,
1334904|NCT00631163|Deferasirox,
1334905|NCT00631163|Transfusional hemosiderosis,
1334906|NCT00631150|Levetiracetam
1334907|NCT00631150|Keppra
1334908|NCT00631137|musculoskeletal complications
1334909|NCT00631137|adult anaplastic astrocytoma
1334910|NCT00631137|adult anaplastic oligodendroglioma
1334911|NCT00631137|adult giant cell glioblastoma
1334912|NCT00631137|adult glioblastoma
1334913|NCT00631137|adult gliosarcoma
1334914|NCT00631124|Contraception
1334915|NCT00631111|dental pain
1334916|NCT00631111|analgesic
1334917|NCT00631111|NSAID
1334918|NCT00631111|ibuprofen
1334919|NCT00631111|aspirin
1334920|NCT00631098|Resuscitation
1334921|NCT00631098|venous cannulation
1334922|NCT00631098|external jugular vein
1334923|NCT00631098|cubital vein
1334924|NCT00631085|healthy nonsmoking nonasthmatic volunteers
1334925|NCT00631072|iNKT
1334926|NCT00631072|in vitro autologous iNKT
1334927|NCT00631059|Hitachi
1334928|NCT00631059|Leukemia
1334929|NCT00631059|Relapse
1334930|NCT00631059|Chemotherapy Resistance
1334931|NCT00631046|n-3 LCPUFA
1334932|NCT00631046|Fish oil
1334933|NCT00631046|essential fatty acids
1334934|NCT00631046|infant growth
1334935|NCT00631046|obesity
1334936|NCT00631046|Intestinal microbiota
1334937|NCT00631033|obesity
1334938|NCT00631033|hyperinsulinism
1334939|NCT00631033|diazoxide
1334940|NCT00631033|metformin
1334941|NCT00631020|Youth
1334942|NCT00631020|Smoking
1334943|NCT00631020|Tobacco
1334944|NCT00631020|Adolescent
1334945|NCT00631020|Dependence
1334946|NCT00631020|Teen smoking
1334947|NCT00631020|Smoking and youth
1334948|NCT00631020|Youth and tobacco
1334949|NCT00631007|Type 2 diabetes
1334950|NCT00631007|diabetes
1334951|NCT00631007|diabetes mellitus
1334952|NCT00631007|diabetes mellitus, type 2
1334953|NCT00631007|non-TZD
1334954|NCT00631007|thiazolidinedione
1334955|NCT00631007|selective peroxisome proliferator-activated receptor gamma modulator
1334956|NCT00631007|SPPARM
1334957|NCT00631007|peroxisome proliferator-activated receptor gamma
1334958|NCT00631007|PPAR gamma
1334959|NCT00631007|insulin sensitizer
1334960|NCT00631007|glucose control
1334961|NCT00631007|endocrinopathy
1334962|NCT00631007|hypoglycemic agent
1334963|NCT00631007|sulfonylurea
1334964|NCT00631007|metformin
1334965|NCT00631007|pioglitazone
1334966|NCT00631007|nutritional and metabolic diseases
1334967|NCT00630994|primary myelofibrosis
1334968|NCT00630994|secondary myelofibrosis
1334969|NCT00630994|essential thrombocythemia
1334970|NCT00630994|polycythemia vera
1334971|NCT00630981|dissociative disorders
1334972|NCT00630968|Levetiracetam
1334973|NCT00630968|Keppra
1334974|NCT00630955|Alcohol Drinking
1334975|NCT00630955|Memantine
1334976|NCT00630942|PSC
1334977|NCT00630916|Aortic valve insufficiency
1334978|NCT00630916|Aortic valve
1334979|NCT00630916|Aortic disease
1334980|NCT00630916|Aortic incompetence
1334981|NCT00630890|Hilar Cholangiocarcinoma (Klatskin Tumor)
1334982|NCT00630890|External Beam Radiation
1334983|NCT00630890|Cyberknife
1334984|NCT00630890|Capecitabine
1334985|NCT00630864|Transthyretin, TTR, amyloidosis, TTR amyloidosis, polyneuropathy
1334986|NCT00630838|Hirschsprung disease
1334987|NCT00630838|enterocolitis
1334988|NCT00630838|probiotics
1334989|NCT00630812|cystic fibrosis
1334990|NCT00630812|mannitol
1334991|NCT00630812|mucoactive
1334992|NCT00630799|prostate
1334993|NCT00630799|cancer
1334994|NCT00630773|CPR
1334995|NCT00630773|compression sensor
1334996|NCT00630773|chest compression adjuncts
1334997|NCT00630747|Hunter syndrome
1334998|NCT00630747|hunters syndrome
1334999|NCT00630747|hunter's syndrome
1335000|NCT00630747|hunter disease
1335001|NCT00630747|hunters disease
1335002|NCT00630747|hunter's disease
1335003|NCT00630747|MPS II
1335004|NCT00630747|MPSII
1335005|NCT00630747|MPS2
1335006|NCT00630747|MPS 2
1335007|NCT00630747|mucopolysaccharides
1335008|NCT00630747|lysosomal storage disease
1335009|NCT00630747|lysosomal storage disorder
1335010|NCT00630747|chronic ear infection
1335011|NCT00630747|enlarged adenoids
1335012|NCT00630747|mps symptoms
1335013|NCT00630747|mps diagnosis
1335014|NCT00630747|mps ii therapy
1335015|NCT00630747|MPS II treatment
1335016|NCT00630747|ert treatment
1335017|NCT00630747|elaprase
1335018|NCT00630747|idursulfase
1335019|NCT00630747|iduronate sulfatase
1335020|NCT00630747|iduronate 2 sulfatase
1335021|NCT00630747|enzyme replacement therapy
1335022|NCT00630747|hunter syndrome treatment
1335023|NCT00630747|hunter's syndrome treatment
1335024|NCT00630747|hunter syndrome therapy
1335025|NCT00630747|hunter's disease treatment
1335026|NCT00630747|mps society
1335027|NCT00630734|HIV
1335028|NCT00630734|Pravastatin
1335029|NCT00630734|Darunavir
1335030|NCT00630734|Ritonavir
1335031|NCT00630734|Genetic
1335032|NCT00630708|Renal insufficiency
1335033|NCT00630708|Benazepril
1335034|NCT00630708|Losartan
1335035|NCT00630708|combination treatment
1335036|NCT00630708|Safety
1335037|NCT00630695|Axillary lymphocele breast cancer
1335038|NCT00630682|Methamphetamine
1335039|NCT00630682|Drug Abuse
1335040|NCT00630682|Drug Treatment
1335041|NCT00630682|Addiction
1335042|NCT00630682|Meth
1335043|NCT00630682|Treatment for Methamphetamine Dependence
1335044|NCT00630669|Internal hemorrhoids
1335045|NCT00630669|Rubber band ligation
1335046|NCT00630669|Bipolar coagulation
1335047|NCT00630656|sepsis
1335048|NCT00630656|talactoferrin
1335049|NCT00630656|lactoferrin
1335050|NCT00630656|recombinant human lactoferrin
1335051|NCT00630630|Levetiracetam
1335052|NCT00630630|Keppra
1335053|NCT00630617|Obesity
1335054|NCT00630617|Prevention
1335055|NCT00630617|Childhood
1335056|NCT00630617|Children
1335057|NCT00630617|Primary care-giver
1335058|NCT00629850|spinal cord injury
1335059|NCT00629850|respiratory muscle training
1335060|NCT00629850|sleep quality
1335061|NCT00629837|FVIII
1335062|NCT00629837|Long acting
1335063|NCT00629837|pk
1335064|NCT00629824|chronic hepatitis C
1335065|NCT00629824|sustained virological response
1335066|NCT00629824|rapid virological response
1335067|NCT00629824|peginterferon
1335068|NCT00629824|ribavirin
1335069|NCT00629824|old age
1335070|NCT00629811|Cicatrix
1335071|NCT00629811|Scar
1335072|NCT00629811|TGFβ3
1335073|NCT00629811|Avotermin
1335074|NCT00629811|Juvista
1335075|NCT00629811|RN1001
1335076|NCT00630604|ultrasonography
1335077|NCT00630604|knee
1335078|NCT00630604|early degeneration
1335079|NCT00630604|cartilage
1335080|NCT00630591|Daughters And MothErS Against Breast Cancer
1335081|NCT00630591|DAMES
1335082|NCT00630591|Breast Cancer
1335083|NCT00630591|Weight Loss
1335084|NCT00630591|Home-based weight loss
1335085|NCT00630591|Quality of Life
1335086|NCT00630591|Diet
1335087|NCT00630591|Exercise
1335088|NCT00630591|Daughter
1335089|NCT00630591|Mother
1335090|NCT00630591|Cancer Prevention
1335091|NCT00630591|Prevention
1335092|NCT00630578|PTSD
1335093|NCT00630578|Posttraumatic Stress Disorder
1335094|NCT00630578|Physical Assault
1335095|NCT00630578|Physical Abuse
1335096|NCT00630578|Sexual Assault
1335097|NCT00630578|Sexual Abuse
1335098|NCT00630578|Interpersonal Assault
1335099|NCT00630578|Cognitive Processing Therapy
1335100|NCT00630565|adult acute myeloid leukemia in remission
1335101|NCT00630565|adult acute myeloid leukemia with inv(16)(p13;q22)
1335102|NCT00630565|adult acute myeloid leukemia with t(15;17)(q22;q12)
1335103|NCT00630565|adult acute myeloid leukemia with t(8;21)(q22;q22)
1335104|NCT00630565|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1335105|NCT00630565|adult acute myeloid leukemia with t(16;16)(p13;q22)
1335106|NCT00630565|childhood acute myeloid leukemia in remission
1335107|NCT00630552|AMG 479
1335108|NCT00630552|Gemcitabine
1335109|NCT00630552|TR-2
1335110|NCT00630552|IGF-1R
1335111|NCT00630552|AMG 655
1335112|NCT00630552|Pancreatic cancer
1335113|NCT00630552|Adenocarcinoma of the Pancreas
1335114|NCT00630552|Metastatic Pancreatic Cancer
1335115|NCT00630539|Menopausal symptoms
1335116|NCT00630539|Urogenital atrophy
1335117|NCT00630539|Vulvar and vaginal atrophy in postmenopausal women
1335118|NCT00630539|Vaginal atrophy
1335119|NCT00630513|localized community acquired intra-abdominal infection (IAI)
1335120|NCT00630513|antibiotics
1335121|NCT00630513|localized peritonitis
1335122|NCT00630513|ertapenem
1335123|NCT00630500|Dementia associated with Parkinson's disease
1335124|NCT00630500|Dementia with Lewy bodies
1335125|NCT00630500|Memantine
1335126|NCT00630500|Placebo-controlled
1335127|NCT00630500|Parallel group
1335128|NCT00630474|sleep apnea, rhinitis
1335129|NCT00630461|mild asthma, mild allergies
1335130|NCT00630435|Premarin®
1335131|NCT00630422|Rett Syndrome
1335132|NCT00630422|Selfcare
1335133|NCT00630422|Mobility limitation
1335134|NCT00630422|Interpersonal relations
1335135|NCT00630422|This study avaliated patients with Rett Syndrome
1335136|NCT00630409|Renal cell carcinoma
1335137|NCT00630409|Kidney Cancer
1335138|NCT00630409|Gemcitabine
1335139|NCT00630409|Doxil
1335140|NCT00630409|Chemotherapy
1335141|NCT00630396|stroke
1335142|NCT00630396|ischemic
1335143|NCT00630396|neuroprotection
1335144|NCT00630396|minocycline
1335145|NCT00630396|tissue plasminogen activator (tPA)
1335146|NCT00630396|biomarkers
1335147|NCT00630396|pharmacokinetics
1335148|NCT00630396|antiapoptotic
1335149|NCT00630396|anti-inflammatory
1335150|NCT00630396|treatment
1335151|NCT00630396|matrix metalloproteinase-9 (MMP-9)
1335152|NCT00630396|thrombolysis
1335153|NCT00630396|Minocycline to Improve Neurologic Outcome in Stroke (MINOS)
1335154|NCT00630396|cerebrovascular stroke
1335155|NCT00630396|cerebrovascular accident
1335156|NCT00630396|cerebral stroke
1335157|NCT00630396|cerebrovascular accident (CVA)
1335158|NCT00630383|Parasite
1335159|NCT00630383|Necator
1335160|NCT00630383|immune regulation
1335161|NCT00630383|regulatory T cells
1335162|NCT00630383|foxp3
1335163|NCT00630383|cytokines
1335164|NCT00630383|multiple sclerosis
1335165|NCT00630383|hygiene hypothesis
1335166|NCT00630357|Levetiracetam
1335167|NCT00630357|Keppra
1335168|NCT00630344|RAD001
1335169|NCT00630344|bicalutamide
1335170|NCT00630344|androgen independent prostate cancer
1335171|NCT00630331|Influenza
1335172|NCT00630331|Flu
1335173|NCT00630331|Cell Culture-Derived
1335174|NCT00630331|Egg-Derived
1335175|NCT00630331|Healthy Adults
1335176|NCT00630331|Efficacy
1335177|NCT00630331|Safety
1335178|NCT00630331|Immunogenicity
1335179|NCT00630331|Trivalent
1335180|NCT00630331|Inactivated
1335181|NCT00630331|Influenza-Like Illness
1335182|NCT00630331|Vaccination
1335183|NCT00630318|MR scanning
1335184|NCT00630305|toric
1335185|NCT00630305|endothelial bleb
1335186|NCT00630279|pancreatic exocrine insufficiency
1335187|NCT00630279|chronic pancreatitis
1335188|NCT00630266|Heart failure
1335189|NCT00630266|left ventricular dilation
1335190|NCT00630266|mitral valve repair
1335191|NCT00630266|mitral valve replacement
1335192|NCT00630253|Fanconi anemia
1335193|NCT00630240|epirubicin
1335194|NCT00630240|mitomycin C
1335195|NCT00630240|cisplatin
1335196|NCT00630240|Hepatocellular carcinoma
1335197|NCT00630227|emphysema
1335198|NCT00630227|chronic obstructive pulmonary disease
1335199|NCT00630227|lung volume reduction
1335200|NCT00630214|Total thyroidectomy
1335201|NCT00630214|CND
1335202|NCT00630214|hypocalcemia
1335203|NCT00630214|calcium
1335204|NCT00630214|vitamin D
1335205|NCT00630201|opioid dependence
1335206|NCT00630201|opioid addiction
1335207|NCT00630201|buprenorphine
1335208|NCT00630201|methadone
1335209|NCT00630201|heroin
1335210|NCT00630201|implant
1335211|NCT00630201|opioid withdrawal
1335212|NCT00630201|opioid pain medication
1335213|NCT00630201|suboxone
1335214|NCT00630188|prostate cancer screening
1335215|NCT00630188|shared decision making
1335216|NCT00630188|prostate-specific antigen
1335217|NCT00630188|decision making
1335218|NCT00630188|physician-patient relations
1335219|NCT00630175|Insomnia
1335220|NCT00630162|protozoa
1335221|NCT00630162|Amoeba
1335222|NCT00630149|Nasopharyngeal Neoplasms
1335223|NCT00630149|Pemetrexed
1335224|NCT00630110|Non Small Cell Lung
1335225|NCT00630097|methamphetamine addiction, meth dependence
1335226|NCT00630084|chronic hepatitis C
1335227|NCT00630084|sustained virological response
1335228|NCT00630084|peginterferon
1335229|NCT00630084|ribavirin
1335230|NCT00630084|neoplasms
1335231|NCT00630071|Diagnostic Appendicitis
1335232|NCT00630071|Procalcitonin
1335233|NCT00630058|Chronic Hepatitis C
1335234|NCT00630058|Protease Inhibitor
1335235|NCT00630058|Telaprevir
1335236|NCT00630032|stage II breast cancer
1335237|NCT00630032|stage IIIA breast cancer
1335238|NCT00630032|stage IIIB breast cancer
1335239|NCT00630032|stage IIIC breast cancer
1335240|NCT00630019|Aqueous humor penetration by anti-infectives
1335241|NCT00629993|cervical cancer screening
1335242|NCT00629993|medically underserved women
1335243|NCT00629993|HPV vaccine
1335244|NCT00629967|chronic hepatitis C
1335245|NCT00629967|genotype 1
1335246|NCT00629967|rapid virological response
1335247|NCT00629967|sustained virological response
1335248|NCT00629967|peginterferon
1335249|NCT00629967|ribavirin
1335250|NCT00629967|treatment duration
1335251|NCT00629954|ABUJA HEART STUDY NIGERIA
1335252|NCT00629954|CARDIOVASCULAR DISEASES
1335253|NCT00629928|NSAID, Nexium, esomeprazole, Gastric Ulcers
1335254|NCT00629915|Moyamoya
1335255|NCT00629915|stroke
1335256|NCT00629902|Heart valve prosthesis
1335257|NCT00629889|seizure
1335258|NCT00629889|adult anaplastic astrocytoma
1335259|NCT00629889|adult diffuse astrocytoma
1335260|NCT00629889|adult pineal gland astrocytoma
1335261|NCT00629889|adult glioblastoma
1335262|NCT00629889|adult gliosarcoma
1335263|NCT00629889|adult giant cell glioblastoma
1335264|NCT00629889|adult brain stem glioma
1335265|NCT00629889|adult ependymoblastoma
1335266|NCT00629889|adult medulloblastoma
1335267|NCT00629889|adult supratentorial primitive neuroectodermal tumor (PNET)
1335268|NCT00629889|adult ependymoma
1335269|NCT00629889|adult anaplastic ependymoma
1335270|NCT00629889|adult anaplastic meningioma
1335271|NCT00629889|adult anaplastic oligodendroglioma
1335272|NCT00629889|adult oligodendroglioma
1335273|NCT00629889|adult pineoblastoma
1335274|NCT00629889|adult pineocytoma
1335275|NCT00629889|adult mixed glioma
1335276|NCT00629889|adult papillary meningioma
1335277|NCT00629889|recurrent adult brain tumor
1335278|NCT00629889|adult grade II meningioma
1335279|NCT00629876|Chemotherapy
1335280|NCT00629876|Drug Therapy
1335281|NCT00629863|stage I gastric cancer
1335282|NCT00629863|stage II gastric cancer
1335283|NCT00629863|stage III gastric cancer
1335284|NCT00629863|stage I esophageal cancer
1335285|NCT00629863|stage II esophageal cancer
1335286|NCT00629863|stage III esophageal cancer
1335287|NCT00629798|Busulfan
1335288|NCT00629798|Melphalan
1335289|NCT00629798|Fludarabine
1335290|NCT00629798|08-008
1335291|NCT00629785|asthma
1335292|NCT00629785|pulmonary function tests
1335293|NCT00629785|obesity
1335294|NCT00629772|Palmoplantar psoriasis
1335295|NCT00629772|Infliximab
1335296|NCT00629759|Jennerex
1335297|NCT00629759|unresectable liver tumors
1335298|NCT00629759|primary liver cancer
1335299|NCT00629759|metastatic liver cancer
1335300|NCT00629759|oncolytic virus
1335301|NCT00629759|vaccinia virus
1335302|NCT00629759|Pexa-Vec
1335303|NCT00629746|Thyroid
1335304|NCT00629746|RLN
1335305|NCT00629746|EMG
1335306|NCT00629733|pharmacokinetics
1335307|NCT00629733|ultra low molecular weight heparin
1335308|NCT00629720|elevated detrusor leak point pressure
1335309|NCT00629707|diabetic ketoacidosis
1335310|NCT00629707|DKA
1335311|NCT00629707|cerebral edema
1335312|NCT00629707|brain edema
1335313|NCT00629694|adenoidectomy, myringotomy, tubes insertion, otitis media, adenoid hyperthophy
1335314|NCT00629655|fMRI
1335315|NCT00629655|spinal cord
1335316|NCT00629655|human
1335317|NCT00629655|health
1335318|NCT00629655|cerebral infarction
1335319|NCT00629655|healthy
1335320|NCT00629642|Neurogenic bladder
1335321|NCT00629642|Vesicare
1335322|NCT00629629|Health Plan Implementation
1335323|NCT00629629|Feeding and Eating Disorders of Childhood
1335324|NCT00629629|Breastfeeding
1335325|NCT00629629|Complementary feeding
1335326|NCT00629629|Morbidity
1335327|NCT00629629|Anemia
1335328|NCT00629629|Public policy
1335329|NCT00629616|stage II breast cancer
1335330|NCT00629616|stage IIIA breast cancer
1335331|NCT00629616|stage IIIB breast cancer
1335332|NCT00629616|stage IIIC breast cancer
1335333|NCT00629603|hepatitis C virus infection
1335334|NCT00629603|chronic liver disease
1335335|NCT00629603|fibrosis-related cytokine
1335336|NCT00629577|cervical cancer
1335337|NCT00629577|cervical intraepithelial neoplasia grade 1
1335338|NCT00629577|cervical intraepithelial neoplasia grade 2
1335339|NCT00629577|cervical intraepithelial neoplasia grade 3
1335340|NCT00629564|Gastroesophageal Reflux Disease (GERD), esomeprazole, Nexium
1335341|NCT00629551|Major Depressive Disorder
1335342|NCT00629551|Depression
1335343|NCT00629551|Major Depressive Episode
1335344|NCT00629551|Antidepressant
1335345|NCT00629538|congestive heart failure
1335346|NCT00629538|thoracentesis
1335347|NCT00629538|transudative pleural effusions
1335348|NCT00629512|NSAID, Nexium, esomeprazole, Gastric Ulcers
1335349|NCT00629499|Early Stage Breast Cancer
1335350|NCT00629499|Her2-positive
1335351|NCT00629499|nab paclitaxel
1335352|NCT00629499|cyclophosphamide
1335353|NCT00629499|trastuzumab
1335354|NCT00629486|cytokine gene
1335355|NCT00629486|hepatitis B
1335356|NCT00629486|hepatocellular carcinoma
1335357|NCT00629486|chronic liver disease
1335358|NCT00629473|multiple myeloma
1335359|NCT00629473|leukemias (inc. CLL)
1335360|NCT00629473|lymphomas
1335361|NCT00629473|cutaneous lymphoma
1335362|NCT00629473|marginal zone lymphoma
1335363|NCT00629473|advanced malignancies without standard treatment options
1335364|NCT00629460|Pulmonary Nodules
1335365|NCT00629447|Primary Brain Tumor
1335366|NCT00629447|Venous Thromboembolism
1335367|NCT00629447|Heparin
1335368|NCT00629434|Diabetes Education
1335369|NCT00629434|Telemedicine
1335370|NCT00629395|pediatric
1335371|NCT00629395|brain tumor
1335372|NCT00629395|survivors
1335373|NCT00629382|abdominal sepsis
1335374|NCT00629382|abdominal surgery
1335375|NCT00629382|septic shock
1335376|NCT00629382|polymyxin B
1335377|NCT00629382|hemoperfusion
1335378|NCT00629382|Endotoxins
1335379|NCT00629343|Soft Tissue Sarcoma
1335380|NCT00629343|Mesothelioma
1335381|NCT00629343|Azacitidine
1335382|NCT00629343|Temozolomide
1335383|NCT00629343|Temodar
1335384|NCT00629330|prostate cancer
1335385|NCT00629330|prostate cancer screening
1335386|NCT00629330|prostate specific antigen
1335387|NCT00629330|African American males
1335388|NCT00629317|Skin Aging
1335389|NCT00629317|Rejuvenation
1335390|NCT00629317|Photodynamic Therapy
1335391|NCT00629317|Methyl Aminolevulinate
1335392|NCT00629304|type 1 diabetes
1335393|NCT00629304|PDA phone (Personal Digital Assistant)
1335394|NCT00629304|HbA1c
1335395|NCT00629291|iron overload
1335396|NCT00629291|Thalassemia
1335397|NCT00629291|Anemia, Sickle Cell
1335398|NCT00629291|Magnetic Resonance Imaging
1335399|NCT00629278|stage IA breast cancer
1335400|NCT00629278|stage IB breast cancer
1335401|NCT00629278|stage II breast cancer
1335402|NCT00629278|stage IIIA breast cancer
1335403|NCT00629278|HER2-positive breast cancer
1335404|NCT00629265|Dysphagia
1335405|NCT00629265|Neuromuscular Electrical Stimulation (NMES)
1335406|NCT00629265|Head & Neck Cancer
1335407|NCT00629265|Radiation and ChemoTherapy
1335408|NCT00629252|Schizophrenia
1335409|NCT00629252|PPI
1335410|NCT00629252|P50
1335411|NCT00629252|CANTAB
1335412|NCT00629252|sensory gating
1335413|NCT00629252|Schizophrenic patients according to DSM-IV
1335414|NCT00629239|COPD
1335415|NCT00629239|tolerability
1335416|NCT00629239|inhalation
1335417|NCT00629226|stage IV squamous cell carcinoma of the hypopharynx
1335418|NCT00629226|stage IV squamous cell carcinoma of the larynx
1335419|NCT00629226|stage IV squamous cell carcinoma of the lip and oral cavity
1335420|NCT00629226|stage IV squamous cell carcinoma of the oropharynx
1335421|NCT00629226|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1335422|NCT00629226|recurrent squamous cell carcinoma of the hypopharynx
1335423|NCT00629226|recurrent squamous cell carcinoma of the larynx
1335424|NCT00629226|recurrent squamous cell carcinoma of the lip and oral cavity
1335425|NCT00629226|recurrent squamous cell carcinoma of the nasopharynx
1335426|NCT00629226|recurrent squamous cell carcinoma of the oropharynx
1335427|NCT00629226|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1335428|NCT00629213|prevention,
1335429|NCT00629213|type 2 diabetes,
1335430|NCT00629213|metabolic syndrome,
1335431|NCT00629213|acarbose treatment
1335432|NCT00629200|Advanced Malignancies
1335433|NCT00629200|Solid Tumors
1335434|NCT00629200|Melanoma
1335435|NCT00629200|Renal Cell Carcinoma
1335436|NCT00629200|Phase I Studies
1335437|NCT00629200|Sodium Stibogluconate
1335438|NCT00629200|Interferon Alpha-2b
1335439|NCT00629200|Intron A
1335440|NCT00629200|SSG
1335441|NCT00629187|Lung Neoplasm
1335442|NCT00629187|Breast Neoplasm
1335443|NCT00629187|Melanoma
1335444|NCT00629187|Central Nervous System Neoplasms
1335445|NCT00629187|Neoplasm Metastasis
1335446|NCT00629187|Neoplasm Second Primary
1335447|NCT00629187|Peripheral Blood Stem Cell Transplantation
1335448|NCT00629174|Cognitive function
1335449|NCT00629174|Elderly
1335450|NCT00629174|Exercise
1335451|NCT00629174|Mental activity
1335452|NCT00629148|metastasis
1335453|NCT00629148|chemotherapy
1335454|NCT00629148|breast cancer
1335455|NCT00629148|Vinorelbine
1335456|NCT00629148|Capecitabine
1335457|NCT00629148|sequential chemotherapy
1335458|NCT00629148|TTF
1335459|NCT00629135|abscess
1335460|NCT00629135|intraabdominal abscess
1335461|NCT00629135|Moxifloxacine
1335462|NCT00629135|Moxifloxacin
1335463|NCT00629135|Metronidazole
1335464|NCT00629135|Tazobactam
1335465|NCT00629135|Piperacilline
1335466|NCT00629135|Piperacillin
1335467|NCT00629135|Tazobac
1335468|NCT00629122|Kidney Transplantation
1335469|NCT00629122|Tacrolimus (Prograf)
1335470|NCT00629122|Pharmacokinetics
1335471|NCT00629122|Sublingual administration
1335472|NCT00629122|Drug interactions (Cytochrome P450 and p-glycoprotein)
1335473|NCT00629096|Dilated Cardiomyopathy
1335474|NCT00629096|Marrow stem cells
1335475|NCT00629096|Myocardial regeneration
1335476|NCT00629096|Mesenchymal stem cells
1335477|NCT00629096|Marrow-derived endothelial progenitor cells
1335478|NCT00629083|SUI
1335479|NCT00629083|Bulkamid
1335480|NCT00629083|Urinary Incontinence
1335481|NCT00629070|cerebral palsy
1335482|NCT00629070|muscle strength
1335483|NCT00629070|muscle architecture
1335484|NCT00629070|ultrasound
1335485|NCT00629070|rehabilitation
1335486|NCT00629070|rectus femoris
1335487|NCT00629070|quadriceps muscle
1335488|NCT00629057|androgen-insensitive, non-metastatic, prostate, cancer
1335489|NCT00629031|Visceral leishmaniasis
1335490|NCT00629031|Paromomycin
1335491|NCT00629018|Stem Cells
1335492|NCT00629018|Heart Failure
1335493|NCT00629018|Dilated Cardiomyopathy
1335494|NCT00629005|rehabilitation
1335495|NCT00629005|upper extremity
1335496|NCT00629005|motor skills
1335497|NCT00628992|COPD: chronic obstructive pulmonary disease and acute respiratory failure
1335498|NCT00628953|Asthma
1335499|NCT00628953|Acid Reflux
1335500|NCT00628953|Nexium
1335501|NCT00628953|Esomeprazole
1335502|NCT00628914|Major Depressive Disorder
1335503|NCT00628914|Insomnia
1335504|NCT00628914|Escitalopram
1335505|NCT00628914|Lexapro
1335506|NCT00628914|Eszopiclone
1335507|NCT00628914|Lunesta
1335508|NCT00628914|Cordance
1335509|NCT00628901|Leiomyoma
1335510|NCT00628901|Uterine Fibroids
1335511|NCT00628901|Uterine Fibroid Embolization (UFE)
1335512|NCT00628901|Uterine Artery Embolization (UAE)
1335513|NCT00628901|Uterine Neoplasms
1335514|NCT00628901|Menorrhagia
1335515|NCT00628888|Unipolar Depression
1335516|NCT00628888|Anxiety
1335517|NCT00628888|Adolescent
1335518|NCT00628888|Emotion
1335519|NCT00628888|Cognitive Behavioral
1335520|NCT00628875|mechanical ventilation
1335521|NCT00628875|thoracic impedence
1335522|NCT00628875|defibrillator pads
1335523|NCT00628875|ventilation detection
1335524|NCT00628875|pediatric ventilation
1335525|NCT00628862|Chronic Obstructive Pulmonary Disease
1335526|NCT00628862|COPD
1335527|NCT00628849|Mandible
1335528|NCT00628849|fracture
1335529|NCT00628849|Champy
1335530|NCT00628849|AO technique
1335531|NCT00628836|Neuromuscular stimulator
1335532|NCT00628836|Shoulder subluxation
1335533|NCT00628823|Celiac Disease
1335534|NCT00628823|Endomysial antibodies
1335535|NCT00628823|Mild enteropathy
1335536|NCT00628823|Treatment
1335537|NCT00628823|Gluten-free diet
1335538|NCT00628810|adenocarcinoma of the colon
1335539|NCT00628810|adenocarcinoma of the rectum
1335540|NCT00628810|stage IV colon cancer
1335541|NCT00628810|stage IV rectal cancer
1335542|NCT00628810|recurrent colon cancer
1335543|NCT00628810|recurrent rectal cancer
1335544|NCT00628797|systemic sclerosis
1335545|NCT00628797|skin fibrosis
1335546|NCT00628784|Dysplasia
1335547|NCT00628784|Ablation
1335548|NCT00628784|Squamous dysplasia
1335549|NCT00628784|Early esophageal adenocarcinoma
1335550|NCT00628784|Cryotherapy
1335551|NCT00628771|HIV Prevention
1335552|NCT00628771|Teen Pregnancy
1335553|NCT00628771|Translational Research
1335554|NCT00628771|Group Care
1335555|NCT00628771|Prenatal Care
1335556|NCT00628771|STD Prevention
1335557|NCT00628771|Gonorrhea
1335558|NCT00628771|Chlamydia
1335559|NCT00628771|Adolescent Health
1335560|NCT00628771|Community Health Centers
1335561|NCT00628771|CenteringPregnancy Plus
1335562|NCT00628771|HIV seronegativity
1335563|NCT00628758|Symbicort
1335564|NCT00628758|Turbuhaler
1335565|NCT00628758|Persistent Asthma
1335566|NCT00628745|TRANSTHYRETIN
1335567|NCT00628745|AMYLOIDOSIS
1335568|NCT00628745|TRANSTHYRETIN AMYLOIDOSIS
1335569|NCT00628732|Cyclophosphamide
1335570|NCT00628732|Topotecan
1335571|NCT00628732|Phase II
1335572|NCT00628732|Children
1335573|NCT00628732|Relapsed solid tumors
1335574|NCT00628719|Visceral leishmaniasis
1335575|NCT00628719|India
1335576|NCT00628719|Liposomal Amphotericin B
1335577|NCT00628719|Amphotericin B deoxycholate
1335578|NCT00628706|tetrahydrocannabinol
1335579|NCT00628706|memory
1335580|NCT00628706|reward
1335581|NCT00628706|magnetic resonance imaging
1335582|NCT00628706|endocannabinoids
1335583|NCT00628693|CPR
1335584|NCT00628680|Renal Disease
1335585|NCT00628680|Kidney Failure
1335586|NCT00628680|End Stage Renal Disease
1335587|NCT00628667|Chronic Posterior Laryngitis
1335588|NCT00628667|CPL
1335589|NCT00628667|Pharyngeal acid reflux
1335590|NCT00628667|Esomeprazole
1335591|NCT00628667|Nexium
1335592|NCT00628654|ovarian germ cell tumor
1335593|NCT00628654|ovarian epithelial cancer
1335594|NCT00628628|Tumor Lysis Syndrome
1335595|NCT00628628|TLS
1335596|NCT00628628|hyperuricemia
1335597|NCT00628628|Leukemia
1335598|NCT00628628|Lymphoma
1335599|NCT00628628|Acute myeloid leukemia
1335600|NCT00628628|Chronic myelocytic leukemia
1335601|NCT00628628|CML
1335602|NCT00628628|lactate dehydrogenase
1335603|NCT00628628|LDH
1335604|NCT00628628|Myelodysplastic Syndrome
1335605|NCT00628628|Rasburicase
1335606|NCT00628628|Elitek™
1335607|NCT00628615|Urodynamics
1335608|NCT00628615|Overactive bladder syndrome
1335609|NCT00628615|Lower urinary tract symptoms LUTS
1335610|NCT00628602|Neuromuscular stimulator
1335611|NCT00628602|Pressure ulcer prevention
1335612|NCT00628589|schizophrenia, agitation, acute, treatment
1335613|NCT00628576|Deep Venous Thrombosis
1335614|NCT00628576|lower extremities
1335615|NCT00628576|Chronic Venous Insufficiency
1335616|NCT00628576|Postthrombotic Syndrome
1335617|NCT00628576|Heparins
1335618|NCT00628576|Low-molecular- weight heparin
1335619|NCT00628576|Tinzaparin
1335620|NCT00628550|cardiac arrest
1335621|NCT00628550|cardiopulmonary arrest
1335622|NCT00628550|vasopressin
1335623|NCT00628550|epinephrine
1335624|NCT00628550|pediatrics
1335625|NCT00628550|in hospital cardiopulmonary resuscitation
1335626|NCT00628537|Neuromuscular stimulator
1335627|NCT00628537|Flexor deformities of wrist and fingers
1335628|NCT00628498|VOD
1335629|NCT00628485|swallowing function
1335630|NCT00628485|neuromuscular stimulator
1335631|NCT00628472|botulinum toxin a
1335632|NCT00628472|botox
1335633|NCT00628472|Decreasing botox injection pain
1335634|NCT00628472|injections
1335635|NCT00628459|iron
1335636|NCT00628459|multiple micronutrient
1335637|NCT00628459|malaria
1335638|NCT00628459|anemia
1335639|NCT00628459|preschool children
1335640|NCT00628446|spinal cord injury
1335641|NCT00628446|Coronary artery calcium
1335642|NCT00628446|Dyslipidemia
1335643|NCT00628433|phase I/II
1335644|NCT00628433|ulcerative colitis
1335645|NCT00628433|safety
1335646|NCT00628433|tolerance
1335647|NCT00628433|pharmacokinetics
1335648|NCT00628420|Schizophrenia
1335649|NCT00628420|N-desmethylclozapine
1335650|NCT00628420|clozapine
1335651|NCT00628420|psychosis
1335652|NCT00628420|randomized
1335653|NCT00628420|placebo studies
1335654|NCT00628407|leaning
1335655|NCT00628407|CPR
1335656|NCT00628407|sternal pressure
1335657|NCT00628407|incomplete release
1335658|NCT00628407|chest compressions
1335659|NCT00628407|pediatric
1335660|NCT00628394|Cognition
1335661|NCT00628394|schizophrenia
1335662|NCT00628394|Atomoxetine
1335663|NCT00628394|Strattera
1335664|NCT00628394|cognitive remediation
1335665|NCT00628381|sepsis
1335666|NCT00628381|microcirculation
1335667|NCT00628381|nitric oxide
1335668|NCT00628381|citrulline
1335669|NCT00628368|adenocarcinoma of the esophagus
1335670|NCT00628368|squamous cell carcinoma of the esophagus
1335671|NCT00628368|adenocarcinoma of the rectum
1335672|NCT00628368|recurrent rectal cancer
1335673|NCT00628368|stage I rectal cancer
1335674|NCT00628368|stage II rectal cancer
1335675|NCT00628368|stage III rectal cancer
1335676|NCT00628368|stage IV rectal cancer
1335677|NCT00628368|recurrent esophageal cancer
1335678|NCT00628368|stage I esophageal cancer
1335679|NCT00628368|stage II esophageal cancer
1335680|NCT00628368|stage III esophageal cancer
1335681|NCT00628368|stage IV esophageal cancer
1335682|NCT00628355|lidocaine
1335683|NCT00628355|ischemic compression
1335684|NCT00628355|chronic pelvic pain
1335685|NCT00628355|myofascial pain syndrome
1335686|NCT00628342|Gastroesophageal Reflux Disease
1335687|NCT00628342|GERD
1335688|NCT00628342|Esomeprazole
1335689|NCT00628342|Heartburn
1335690|NCT00628342|Nexium
1335691|NCT00628329|asthma, retinol, cis-retinoic acid
1335692|NCT00628316|tinnitus
1335693|NCT00628316|caffeine
1335694|NCT00628303|Good health
1335695|NCT00628277|Obesity
1335696|NCT00628277|coronary heart disease
1335697|NCT00628277|coronary risk factors
1335698|NCT00628277|weight loss
1335699|NCT00628277|exercise
1335700|NCT00628264|cardiac surgery
1335701|NCT00628264|coronary artery bypass grafting
1335702|NCT00628264|valve surgery
1335703|NCT00628264|acute kidney injury
1335704|NCT00628251|Advanced ovarian cancer
1335705|NCT00628251|BRCA1 protein
1335706|NCT00628251|BRCA2 protein
1335707|NCT00628251|Poly(ADP ribose) polymerases
1335708|NCT00628238|Chronic Lymphocytic Leukemia Research Consortium
1335709|NCT00628238|Chronic lymphocytic leukemia
1335710|NCT00628238|CLL
1335711|NCT00628238|CLL Research Consortium
1335712|NCT00628238|CRC
1335713|NCT00628238|Revlimid
1335714|NCT00628238|lenalidomide
1335715|NCT00628238|Rituximab
1335716|NCT00628238|Rituxan
1335717|NCT00628238|First-line
1335718|NCT00628238|therapy
1335719|NCT00628238|untreated
1335720|NCT00628238|Frontline
1335721|NCT00628225|Smoking cessation
1335722|NCT00628212|insulin resistance
1335723|NCT00628186|pancreaticoduodenectomy
1335724|NCT00628186|stent
1335725|NCT00628186|pancreaticojejunostomy
1335726|NCT00628186|hospital stay
1335727|NCT00628186|complication
1335728|NCT00628186|pancreatic fistula
1335729|NCT00628160|Septic shock
1335730|NCT00628160|Cirrhosis
1335731|NCT00628160|Survival
1335732|NCT00628147|colonic neoplasms
1335733|NCT00628147|colonoscopy
1335734|NCT00628147|narrow band imaging
1335735|NCT00628147|diagnostic techniques
1335736|NCT00628134|cystic fibrosis
1335737|NCT00628134|surfactant
1335738|NCT00628134|aerosol
1335739|NCT00628134|inhaled drug
1335740|NCT00628134|inhaled antibiotic
1335741|NCT00628121|infertility, menstrual cycle, LH surge
1335742|NCT00628108|Xyzal
1335743|NCT00628108|Levocetirizine
1335744|NCT00628108|Allergy
1335745|NCT00628108|Children
1335746|NCT00628108|Seasonal Allergies
1335747|NCT00628095|rheumatoid arthritis DMARD methotrexate
1335748|NCT00628082|Cardiac Energetics
1335749|NCT00628082|Dynamic Diastolic filling Assessment
1335750|NCT00628082|Heart Failure with Preserved Ejection Fraction
1335751|NCT00628082|Arterial and Ventricular Stiffening
1335752|NCT00628069|Orthopedics
1335753|NCT00628069|bone fixation
1335754|NCT00628056|Perhexiline
1335755|NCT00628056|diabetes
1335756|NCT00628056|diabetic cardiomyopathy
1335757|NCT00628056|high energy phosphate kinetics
1335758|NCT00628056|magnetic resonance spectroscopy
1335759|NCT00628043|Cancer
1335760|NCT00628043|patients
1335761|NCT00628043|with
1335762|NCT00628043|chemotherapy
1335763|NCT00628043|induced
1335764|NCT00628043|anemia
1335765|NCT00628030|Behavioral intervention
1335766|NCT00628030|Obesity prevention
1335767|NCT00628017|polyunsaturated fatty acids
1335768|NCT00628017|Alzheimer's disease
1335769|NCT00628017|mild cognitive impairment
1335770|NCT00628017|fish oil
1335771|NCT00628017|cognition
1335772|NCT00627978|breast
1335773|NCT00627965|Sildenafil citrate
1335774|NCT00627965|Prevention
1335775|NCT00627965|High Altitude Pulmonary Edema
1335776|NCT00627965|Acute Mountain Sickness
1335777|NCT00627965|Healthy Lowland Subjects
1335778|NCT00627965|Pulmonary Artery Systolic Pressure
1335779|NCT00627952|hypertension
1335780|NCT00627952|intraglomerular pressure
1335781|NCT00627926|Genotype 1
1335782|NCT00627913|Floppy Iris Syndrome
1335783|NCT00627900|drug-eluting stents
1335784|NCT00627887|Depressive Disorder, Major
1335785|NCT00627887|Electroconvulsive Therapy
1335786|NCT00627887|Lithium Carbonate
1335787|NCT00627887|venlafaxine
1335788|NCT00627848|Alzheimer's disease
1335789|NCT00627848|fmri
1335790|NCT00627848|face recognition
1335791|NCT00627848|rivastigmine
1335792|NCT00627835|squamous cell carcinoma
1335793|NCT00627835|head and neck
1335794|NCT00627835|Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation
1335795|NCT00627822|Medical students
1335796|NCT00627822|Medical education
1335797|NCT00627822|Private hospital
1335798|NCT00627822|Patient satisfaction
1335799|NCT00627822|Questionnaires
1335800|NCT00627809|coronary microcirculation
1335801|NCT00627809|acut myocardial infarction
1335802|NCT00627809|infarct size
1335803|NCT00627809|streptokinase
1335804|NCT00627809|reperfusion
1335805|NCT00627796|GH
1335806|NCT00627796|IGF-I
1335807|NCT00627796|tumor
1335808|NCT00627796|lanreotide
1335809|NCT00627770|Physical Therapy - Therapeutics - Edema
1335810|NCT00627770|Arthroplasty replacement knee
1335811|NCT00627770|Treatment outcome
1335812|NCT00627757|metabolic syndrome
1335813|NCT00627757|weight gain
1335814|NCT00627757|antipsychotic drugs
1335815|NCT00627757|Metabolic syndrome and treatment with antipsychotic drugs
1335816|NCT00627744|Type 2 diabetes, IGT, Myocardial infarction, Incretins
1335817|NCT00627731|Asthma Patients
1335818|NCT00627718|Age-related macular degeneration
1335819|NCT00627718|HRT
1335820|NCT00627718|Macular edema
1335821|NCT00627718|Screening for disease
1335822|NCT00627692|Constipation in elderly patients
1335823|NCT00627679|Pediatric asthma
1335824|NCT00627666|adult acute lymphoblastic leukemia in remission
1335825|NCT00627666|recurrent adult acute lymphoblastic leukemia
1335826|NCT00627666|untreated adult acute lymphoblastic leukemia
1335827|NCT00627666|adult acute myeloid leukemia in remission
1335828|NCT00627666|recurrent adult acute myeloid leukemia
1335829|NCT00627666|untreated adult acute myeloid leukemia
1335830|NCT00627666|acute lymphocytic leukemia
1335831|NCT00627666|secondary acute myeloid leukemia
1335832|NCT00627666|acute undifferentiated leukemia
1335833|NCT00627666|mast cell leukemia
1335834|NCT00627666|accelerated phase chronic myelogenous leukemia
1335835|NCT00627666|blastic phase chronic myelogenous leukemia
1335836|NCT00627666|chronic phase chronic myelogenous leukemia
1335837|NCT00627666|meningeal chronic myelogenous leukemia
1335838|NCT00627666|relapsing chronic myelogenous leukemia
1335839|NCT00627666|chronic myelomonocytic leukemia
1335840|NCT00627666|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1335841|NCT00627666|adult acute myeloid leukemia with inv(16)(p13;q22)
1335842|NCT00627666|adult acute myeloid leukemia with t(15;17)(q22;q12)
1335843|NCT00627666|adult acute myeloid leukemia with t(16;16)(p13;q22)
1335844|NCT00627666|adult acute myeloid leukemia with t(8;21)(q22;q22)
1335845|NCT00627666|de novo myelodysplastic syndromes
1335846|NCT00627666|previously treated myelodysplastic syndromes
1335847|NCT00627666|secondary myelodysplastic syndromes
1335848|NCT00627666|atypical chronic myeloid leukemia, BCR-ABL1 negative
1335849|NCT00627666|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1335850|NCT00627666|refractory anemia with excess blasts in transformation
1335851|NCT00627666|refractory anemia with excess blasts
1335852|NCT00627653|PPAR
1335853|NCT00627653|PET study
1335854|NCT00627653|heart metabolism
1335855|NCT00627614|stage I breast cancer
1335856|NCT00627614|stage II breast cancer
1335857|NCT00627614|stage IIIA breast cancer
1335858|NCT00627614|stage IIIB breast cancer
1335859|NCT00627614|stage IIIC breast cancer
1335860|NCT00627614|stage IV breast cancer
1335861|NCT00627588|ProSavin
1335862|NCT00627588|Parkinson's Disease
1335863|NCT00627588|Gene Therapy
1335864|NCT00627575|drug interaction
1335865|NCT00627575|pharmacokinetics
1335866|NCT00627575|healthy volunteers
1335867|NCT00627562|robotic
1335868|NCT00627562|robot assisted
1335869|NCT00627562|minimally invasive
1335870|NCT00627562|tumors of head and neck
1335871|NCT00627549|cystocele, anterior repair, mesh
1335872|NCT00627536|scarring, Juvista, avotermin, transforming growth factor beta 3, TGFB3
1335873|NCT00627510|Therapeutic Drug Monitoring (TDM)
1335874|NCT00627510|Antidepressant
1335875|NCT00627510|Antipsychotic
1335876|NCT00627510|Treatment adherence
1335877|NCT00627510|Compliance
1335878|NCT00627510|Metabolism
1335879|NCT00627510|Do patients take their psychiatric medication as prescribed?
1335880|NCT00627510|Do psychiatric patients metabolize their medication faster than expected?
1335881|NCT00627510|What are the exact odds that the patient of a physician prescribing antidepressants or antipsychotics has plasma levels that are BELOW those intended?
1335882|NCT00627484|Insulin resistance
1335883|NCT00627484|Insulin sensitivity
1335884|NCT00627484|bariatric surgery
1335885|NCT00627484|diabetes
1335886|NCT00627484|calorie restriction
1335887|NCT00627484|body composition
1335888|NCT00627458|Hexavalent vaccine
1335889|NCT00627458|Booster
1335890|NCT00627432|stage III bladder cancer
1335891|NCT00627432|stage IV bladder cancer
1335892|NCT00627432|transitional cell carcinoma of the bladder
1335893|NCT00627406|GnRH antagonist
1335894|NCT00627406|GnRH agonist
1335895|NCT00627406|hCG
1335896|NCT00627406|OHSS
1335897|NCT00627406|In vitro fertilization
1335898|NCT00627406|ovulation induction
1335899|NCT00627406|Clinical pregnancy rate
1335900|NCT00627393|Granulocyte Transfusions
1335901|NCT00627380|HIV
1335902|NCT00627380|AIDS
1335903|NCT00627380|insulin resistance
1335904|NCT00627380|diabetes
1335905|NCT00627380|dyslipidemia
1335906|NCT00627380|visceral adiposity
1335907|NCT00627380|subcutaneous adipose wasting
1335908|NCT00627380|cardiovascular disease
1335909|NCT00627380|hypertension
1335910|NCT00627380|endothelial function
1335911|NCT00627380|quality of life
1335912|NCT00627380|Complementary Therapies
1335913|NCT00627367|Acute Pain Emergency Department ED Hydromorphone Dilaudid Protocolized Nonprotocolized Usual Care
1335914|NCT00627354|stage IV prostate cancer
1335915|NCT00627354|recurrent prostate cancer
1335916|NCT00627354|adenocarcinoma of the prostate
1335917|NCT00627341|Exposure Therapy
1335918|NCT00627341|Relapse Prevention
1335919|NCT00627341|Anorexia Nervosa
1335920|NCT00627328|Physiologic Pacing
1335921|NCT00627328|Dual Chamber Pacing
1335922|NCT00627328|Atrioventricular Block
1335923|NCT00627328|Bradycardia
1335924|NCT00627328|Sick Sinus Syndrome
1335925|NCT00627315|Obesity
1335926|NCT00627315|Insulin Resistance
1335927|NCT00627315|Bariatric Surgery
1335928|NCT00627315|Gastric Banding
1335929|NCT00627315|Gastric Bypass
1335930|NCT00627302|Quality of Vision
1335931|NCT00627289|Chronic pain
1335932|NCT00627289|groin hernia
1335933|NCT00627289|neuropathic pain
1335934|NCT00627289|chronic postoperative pain
1335935|NCT00627289|Postherniotomy pain
1335936|NCT00627289|Neuroplastic changes
1335937|NCT00627276|ductal breast carcinoma in situ
1335938|NCT00627276|atypical ductal breast hyperplasia
1335939|NCT00627263|ICD
1335940|NCT00627263|Cardiac Arrhythmia
1335941|NCT00627263|Arrhythmia
1335942|NCT00627263|Stress
1335943|NCT00627263|Anger
1335944|NCT00627250|Irritability
1335945|NCT00627250|Aggression
1335946|NCT00627250|Brain Injury
1335947|NCT00627250|Amantadine
1335948|NCT00627250|Irritability and Aggression Due to Traumatic Brain Injury
1335949|NCT00627237|Brain Injuries
1335950|NCT00627237|Cognitive Rehabilitation
1335951|NCT00627237|Executive Functioning
1335952|NCT00627211|quality assessment
1335953|NCT00627211|pain reduction
1335954|NCT00627211|gastroscopy
1335955|NCT00627211|carbondioxide insufflation
1335956|NCT00627211|Patient satisfaction
1335957|NCT00627198|Metastatic; neuroendocrine tumor; clinical trial
1335958|NCT00627185|Tobacco control
1335959|NCT00627185|Tobacco cessation
1335960|NCT00627185|Tobacco use
1335961|NCT00627172|Coronary artery disease
1335962|NCT00627172|MDCT
1335963|NCT00627172|Positron emission tomography
1335964|NCT00627172|Ultrasound
1335965|NCT00627159|community-based
1335966|NCT00627159|culturally-sensitive
1335967|NCT00627159|high risk assessment
1335968|NCT00627159|education classes
1335969|NCT00627159|cardiovascular risk profile
1335970|NCT00627159|Indo-Asian population
1335971|NCT00627146|Diabetes Mellitus, type 1
1335972|NCT00627146|ChAgly CD3
1335973|NCT00627133|Alcohol seizure
1335974|NCT00627120|healthy volunteers
1335975|NCT00627107|ReWalk, Paraplegia, SCI
1335976|NCT00627068|cardiovascular
1335977|NCT00627068|vasodilation
1335978|NCT00627068|endothelium
1335979|NCT00627068|Subjects with high cardiovascular risk
1335980|NCT00627055|Second line antiretroviral therapy
1335981|NCT00627055|HIV genotypic resistance
1335982|NCT00627055|Kaletra monotherapy
1335983|NCT00627055|Thailand
1335984|NCT00627055|48-week efficacy and safety between 2 NRTIs plus lopinavir/ritonavir (LPV/r) and LPV/r monotherapy in patients failing a standard NNRTI-based treatment regimen
1335985|NCT00627055|treatment experienced
1335986|NCT00627042|Liver disease
1335987|NCT00627042|Neoplasms
1335988|NCT00627042|Liver neoplasms
1335989|NCT00627042|Carcinoma, Hepatocellular
1335990|NCT00627029|Care coordination
1335991|NCT00627029|Disease management
1335992|NCT00627029|Medicare
1335993|NCT00627029|Fee-for-service
1335994|NCT00627029|Random assignment
1335995|NCT00627029|Elderly
1335996|NCT00627016|Non-Erosive Gastroesophageal Reflux Disease
1335997|NCT00627016|GERD
1335998|NCT00627016|heartburn
1335999|NCT00627016|sleep disturbance
1336000|NCT00627016|nocturnal Reflux
1336001|NCT00626990|adult anaplastic oligodendroglioma
1336002|NCT00626990|adult anaplastic astrocytoma
1336003|NCT00626977|Analgesia
1336004|NCT00626977|Obstetrical
1336005|NCT00626977|Anesthesia
1336006|NCT00626977|Epidural
1336007|NCT00626977|Newborn
1336008|NCT00626977|Anesthetics, local
1336009|NCT00626977|Clonidine
1336010|NCT00626977|Pregnant women
1336011|NCT00626977|Infant, newborn
1336012|NCT00626964|Arterial stiffness
1336013|NCT00626964|PulseWave velocity
1336014|NCT00626964|Body composition
1336015|NCT00626964|Bioimpedance
1336016|NCT00626964|Morbid Obesity
1336017|NCT00626964|APO A
1336018|NCT00626964|APO B
1336019|NCT00626964|Framingham risk score
1336020|NCT00626964|Prevention of Coronary Heart Disease
1336021|NCT00626964|Lifestyle Intervention
1336022|NCT00626964|Bariatric Surgery
1336023|NCT00626964|Low Energy Diet
1336024|NCT00626951|LMA Supreme
1336025|NCT00626951|LMA ProSeal
1336026|NCT00626951|Laryngeal mask airway
1336027|NCT00626951|Ventilation
1336028|NCT00626938|sarcoidosis
1336029|NCT00626938|protein profile
1336030|NCT00626938|CYP-450
1336031|NCT00626938|TNF-alpha polymorphisms
1336032|NCT00626938|HLA
1336033|NCT00626925|Randomized Trial
1336034|NCT00626925|Medication for Heavy Drinking
1336035|NCT00626925|Topiramate Treatment
1336036|NCT00626912|large aneurysm
1336037|NCT00626912|recurrence
1336038|NCT00626912|hydrocoil
1336039|NCT00626899|Validation of Cardiac Output measurement in hypothermic patients
1336040|NCT00626886|Herniorrhaphy
1336041|NCT00626886|Inguinal Hernia Repair
1336042|NCT00626886|Postoperative pain
1336043|NCT00626873|ovarian germ cell tumor
1336044|NCT00626873|ovarian epithelial cancer
1336045|NCT00626860|melanoma
1336046|NCT00626847|primary open angle glaucoma
1336047|NCT00626847|Nuclear Genetics
1336048|NCT00626847|Mitochondrial DNA
1336049|NCT00626847|POAG
1336050|NCT00626834|cocaine addiction
1336051|NCT00626834|vigabatrin
1336052|NCT00626834|ovation pharmaceuticals
1336053|NCT00626834|cocaine
1336054|NCT00626834|cocaine related disorders
1336055|NCT00626834|behavior addictive
1336056|NCT00626834|mental disorders
1336057|NCT00626834|therapeutic uses
1336058|NCT00626834|physiologic effects of drugs
1336059|NCT00626834|disorder of environmental origin
1336060|NCT00626834|central nervous system stimulants
1336061|NCT00626834|central nervous system agents
1336062|NCT00626834|pharmacological actions
1336063|NCT00626834|substance related disorders
1336064|NCT00626821|Stoma
1336065|NCT00626821|Ostomy
1336066|NCT00626782|glaucoma
1336067|NCT00626782|glucoma filtering surgery
1336068|NCT00626782|ranibizumab
1336069|NCT00626782|mitomycin C
1336070|NCT00626782|patients requiring first time glaucoma filtering surgery
1336071|NCT00626769|Genistein
1336072|NCT00626769|Bone mineral density
1336073|NCT00626769|digital mammography
1336074|NCT00626769|safety
1336075|NCT00626756|fluid
1336076|NCT00626756|Lidco technology
1336077|NCT00626756|guided therapy
1336078|NCT00626756|fluid management guided by Lidco technology
1336079|NCT00626730|adult grade II meningioma
1336080|NCT00626730|adult grade III meningioma
1336081|NCT00626717|Keratoconus
1336082|NCT00626717|Cross linking
1336083|NCT00626717|Riboflavin
1336084|NCT00626704|Sarcoma
1336085|NCT00626704|Soft Tissue Sarcoma
1336086|NCT00626704|Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
1336087|NCT00626704|AMG 655
1336088|NCT00626704|STS
1336089|NCT00626704|Doxorubicin
1336090|NCT00626704|Death receptor
1336091|NCT00626704|TRAIL receptor
1336092|NCT00626704|Apoptosis
1336093|NCT00626691|antioxidant
1336094|NCT00626691|walnut
1336095|NCT00626691|nutritional status
1336096|NCT00626691|Antioxidant capacity
1336097|NCT00626678|Pemphigus Vulgaris
1336098|NCT00626678|Azathioprine
1336099|NCT00626678|Prednisone
1336100|NCT00626665|Raynaud disease
1336101|NCT00626665|Scleroderma
1336102|NCT00626639|palifermin
1336103|NCT00626639|Clinical Trial
1336104|NCT00626639|Oncology
1336105|NCT00626639|Head & Neck
1336106|NCT00626626|leukemia
1336107|NCT00626626|myelodysplastic syndrome
1336108|NCT00626626|chronic myelogenous leukemia
1336109|NCT00626626|lymphoma
1336110|NCT00626626|mantle cell lymphoma
1336111|NCT00626600|Oxycodone Hydrochloride 50mg/mL
1336112|NCT00626600|Observational
1336113|NCT00626600|Infusion
1336114|NCT00626600|Severe cancer pain
1336115|NCT00626587|Endobronchial ultrasonography
1336116|NCT00626587|Peripheral pulmonary lesions
1336117|NCT00626587|Transbronchial needle aspiration
1336118|NCT00626587|Probe location
1336119|NCT00626587|Diagnostic yield
1336120|NCT00626587|EBUS guided TBNA for peripheral pulmonary lesions
1336121|NCT00626574|Epoetin alfa
1336122|NCT00626574|aneurysm
1336123|NCT00626574|subarachnoid hemorrhage
1336124|NCT00626561|Cervical Cancer
1336125|NCT00626561|Uterine Cancer
1336126|NCT00626561|Bevacizumab
1336127|NCT00626561|Avastin
1336128|NCT00626561|Anti-VEGF monoclonal antibody
1336129|NCT00626561|rhuMAb-VEGF
1336130|NCT00626561|Paclitaxel
1336131|NCT00626561|Taxol
1336132|NCT00626548|Hormone Resistant Prostate Cancer
1336133|NCT00626548|Endothelin A Receptor Antagonist
1336134|NCT00626548|Endothelin A
1336135|NCT00626548|Endothelin A antagonist
1336136|NCT00626535|Symptomatic Gastroesophageal Reflux Disease (sGERD)
1336137|NCT00626535|Nexium
1336138|NCT00626535|Esomeprazole
1336139|NCT00626522|Bronchitis
1336140|NCT00626522|Chronic
1336141|NCT00626522|Emphysema
1336142|NCT00626522|Smokers or ex-Smokers
1336143|NCT00626509|stage IV renal cell cancer
1336144|NCT00626483|adult giant cell glioblastoma
1336145|NCT00626483|adult gliosarcoma
1336146|NCT00626470|Trochanter
1336147|NCT00626470|Femur
1336148|NCT00626470|Fracture
1336149|NCT00626431|Lupron Depot
1336150|NCT00626431|prostate cancer
1336151|NCT00626431|leuprolide acetate
1336152|NCT00626405|stage IV melanoma
1336153|NCT00626379|Coronary Heart Disease
1336154|NCT00626379|Subclinical Atherosclerosis
1336155|NCT00626379|CVD-Related Markers of Inflammation
1336156|NCT00626379|Mortality
1336157|NCT00626366|Nasal Spray
1336158|NCT00626366|Nasal Drop
1336159|NCT00626366|Intranasal Medication
1336160|NCT00626353|Stroke
1336161|NCT00626353|rehabilitation
1336162|NCT00626353|motor recovery
1336163|NCT00626353|cognition
1336164|NCT00626353|quality of life
1336165|NCT00626340|menopause
1336166|NCT00626340|women
1336167|NCT00626340|major depressive disorder
1336168|NCT00626340|Magnetic Resonance Spectroscopy
1336169|NCT00626327|vaccine
1336170|NCT00626327|toddlers
1336171|NCT00626327|healthy
1336172|NCT00626327|meningitis
1336173|NCT00626327|meningococcal
1336174|NCT00626327|measles
1336175|NCT00626327|mumps
1336176|NCT00626327|rubella
1336177|NCT00626327|varicella
1336178|NCT00626327|Prevention of Meningococcal disease types ACWY
1336179|NCT00626301|efficacy
1336180|NCT00626301|safety
1336181|NCT00626301|pharmacokinetics
1336182|NCT00626301|LPV/r monotherapy
1336183|NCT00626301|Thai children
1336184|NCT00626301|efficacy safety LPV/r monotherapy maintenance
1336185|NCT00626301|treatment experienced
1336186|NCT00626288|Mesalazine in Irritable Bowel Syndrome
1336187|NCT00626275|Rheumatoid arthritis
1336188|NCT00626275|arthritis
1336189|NCT00626262|Gastroesophageal reflux disease
1336190|NCT00626262|Nexium
1336191|NCT00626262|Esomeprazole
1336192|NCT00626262|Administration methods.
1336193|NCT00626249|Nephropathy
1336194|NCT00626249|Kidney Disease
1336195|NCT00626249|Diabetic
1336196|NCT00626249|Renal
1336197|NCT00626249|Diabetics
1336198|NCT00626236|ADHD and conduct problems
1336199|NCT00626223|ESRD patients
1336200|NCT00626223|C-reactive protein
1336201|NCT00626223|homocysteine
1336202|NCT00626223|5-MTHF
1336203|NCT00626223|survival
1336204|NCT00626223|Hemodialysis patients
1336205|NCT00626210|Mild Cognitive Impairment (MCI)
1336206|NCT00626210|Sleep
1336207|NCT00626210|Fatigue
1336208|NCT00626210|Memory
1336209|NCT00626197|SLE
1336210|NCT00626197|Lupus
1336211|NCT00626197|BELONG
1336212|NCT00626184|Celiac Disease
1336213|NCT00626171|smoking
1336214|NCT00626171|asthma
1336215|NCT00626171|sputum
1336216|NCT00626158|pancreatic cancer
1336217|NCT00626158|biliary cancer
1336218|NCT00626158|gemcitabine
1336219|NCT00626158|capecitabine
1336220|NCT00626145|BMMNC
1336221|NCT00626145|STEMI
1336222|NCT00626145|stem cell
1336223|NCT00626145|intracoronary delivery
1336224|NCT00626132|Blood pressure
1336225|NCT00626132|Herbs
1336226|NCT00626132|Food
1336227|NCT00626119|breast cancer
1336228|NCT00626106|postmenopausal
1336229|NCT00626106|hormone receptor positive
1336230|NCT00626106|locally advanced
1336231|NCT00626106|metastatic
1336232|NCT00626080|Insulin
1336233|NCT00626080|Detemir
1336234|NCT00626080|Brain
1336235|NCT00626080|Glucose metabolism
1336236|NCT00626067|Travatan Dosing Aid
1336237|NCT00626067|compliance monitoring dispenser
1336238|NCT00626054|Colonoscopy
1336239|NCT00626054|PEG Solution
1336240|NCT00626041|Community pharmacies
1336241|NCT00626041|Primary care networks
1336242|NCT00626041|Global risk assessment
1336243|NCT00626041|Blood pressure screening
1336244|NCT00626028|Pulmonary Vasculature
1336245|NCT00626028|Nitric Oxide
1336246|NCT00626028|INOmax®
1336247|NCT00626028|Acute Lung Injury
1336248|NCT00626028|Pulmonary Vasodilator Testing
1336249|NCT00626028|Idiopathic Pulmonary Arterial Hypertension
1336250|NCT00626028|Congenital Heart Disease
1336251|NCT00626028|reversible pulmonary hypertension
1336252|NCT00626028|vasoreactivity
1336253|NCT00626015|adult glioblastoma
1336254|NCT00626015|adult giant cell glioblastoma
1336255|NCT00626015|adult gliosarcoma
1336256|NCT00626015|adult high grade glioma
1336257|NCT00626002|Open label
1336258|NCT00625989|asthma
1336259|NCT00625989|atopy
1336260|NCT00625989|allergen challenge
1336261|NCT00625989|sputum myeloid and plasmacytoid dendritic cells
1336262|NCT00625976|Complex regional pain syndrome type I
1336263|NCT00625976|Graded exposure in vivo
1336264|NCT00625976|Physiotherapy
1336265|NCT00625976|Pain-related fear
1336266|NCT00625963|Pulmonary Hypertension;
1336267|NCT00625963|ILD;
1336268|NCT00625963|CT Imaging;
1336269|NCT00625963|Echocardiogram;
1336270|NCT00625963|Hemodynamic measurements of RHC.
1336271|NCT00625963|Pulmonary Function Tests
1336272|NCT00625950|Hyperprolactinemia
1336273|NCT00625950|Endometriosis
1336274|NCT00625950|laparoscopy
1336275|NCT00625950|angiogenesis, VEGF
1336276|NCT00625937|stage III squamous cell carcinoma of the hypopharynx
1336277|NCT00625937|stage IV squamous cell carcinoma of the hypopharynx
1336278|NCT00625937|stage III verrucous carcinoma of the oral cavity
1336279|NCT00625937|stage IV verrucous carcinoma of the oral cavity
1336280|NCT00625937|stage III squamous cell carcinoma of the lip and oral cavity
1336281|NCT00625937|stage IV squamous cell carcinoma of the lip and oral cavity
1336282|NCT00625937|stage III lymphoepithelioma of the nasopharynx
1336283|NCT00625937|stage III squamous cell carcinoma of the nasopharynx
1336284|NCT00625937|stage IV lymphoepithelioma of the nasopharynx
1336285|NCT00625937|stage IV squamous cell carcinoma of the nasopharynx
1336286|NCT00625937|stage III lymphoepithelioma of the oropharynx
1336287|NCT00625937|stage III squamous cell carcinoma of the oropharynx
1336288|NCT00625937|stage IV lymphoepithelioma of the oropharynx
1336289|NCT00625937|stage IV squamous cell carcinoma of the oropharynx
1336290|NCT00625937|tongue cancer
1336291|NCT00625924|Plastic surgery
1336292|NCT00625924|reconstruction
1336293|NCT00625911|thoracotomy
1336294|NCT00625911|minimally invasive direct coronary artery bypass
1336295|NCT00625911|ketamine
1336296|NCT00625911|pain
1336297|NCT00625898|HER2 positive breast cancer
1336298|NCT00625898|invasive breast cancer
1336299|NCT00625898|bevacizumab
1336300|NCT00625898|NSABP
1336301|NCT00625898|Roche
1336302|NCT00625898|CIRG
1336303|NCT00625898|trastuzumab
1336304|NCT00625898|cyclophosphamide
1336305|NCT00625898|docetaxel
1336306|NCT00625898|carboplatin
1336307|NCT00625898|5-fluorouracil
1336308|NCT00625898|epirubicin
1336309|NCT00625885|Anterior Cruciate Ligament/injuries
1336310|NCT00625885|Anterior Cruciate Ligament/surgery
1336311|NCT00625885|Knee injuries/surgery
1336312|NCT00625885|Outcomes research
1336313|NCT00625885|Prospective Studies
1336314|NCT00625859|pharmacokinetics,
1336315|NCT00625859|pharmacodynamics
1336316|NCT00625859|Healthy adult male volunteers,
1336317|NCT00625820|Kidney Disease
1336318|NCT00625820|Albuminuria
1336319|NCT00625820|Glomerular filtration rate
1336320|NCT00625807|Stress
1336321|NCT00625807|meditation
1336322|NCT00625807|stress reduction
1336323|NCT00625807|fMRI
1336324|NCT00625807|behavioral
1336325|NCT00625781|Gestational diabetes mellitus
1336326|NCT00625781|Impaired glucose Tolerance
1336327|NCT00625781|Pregnancy
1336328|NCT00625781|Fetal macrosomia
1336329|NCT00625781|Treatment
1336330|NCT00625781|Perinatal morbidity
1336331|NCT00625768|Antibody
1336332|NCT00625768|safety
1336333|NCT00625768|tolerability
1336334|NCT00625768|efficacy
1336335|NCT00625768|metastatic renal cell carcinoma
1336336|NCT00625768|metastatic malignant melanoma
1336337|NCT00625755|renal cell carcinoma
1336338|NCT00625755|AJCC Stage IV (primary or relasped) renal cell carcinoma
1336339|NCT00625742|Advanced Cancer
1336340|NCT00625742|Cancer Cachexia
1336341|NCT00625742|Cachexia
1336342|NCT00625742|Melatonin
1336343|NCT00625742|Juven
1336344|NCT00625742|Exercise Training
1336345|NCT00625742|Weight Loss
1336346|NCT00625729|recurrent adult grade III lymphomatoid granulomatosis
1336347|NCT00625729|adult nasal type extranodal NK/T-cell lymphoma
1336348|NCT00625729|Waldenstrom macroglobulinemia
1336349|NCT00625729|recurrent adult Burkitt lymphoma
1336350|NCT00625729|recurrent adult diffuse large cell lymphoma
1336351|NCT00625729|recurrent adult diffuse mixed cell lymphoma
1336352|NCT00625729|recurrent adult diffuse small cleaved cell lymphoma
1336353|NCT00625729|recurrent adult immunoblastic large cell lymphoma
1336354|NCT00625729|recurrent adult lymphoblastic lymphoma
1336355|NCT00625729|recurrent grade 1 follicular lymphoma
1336356|NCT00625729|recurrent grade 2 follicular lymphoma
1336357|NCT00625729|recurrent grade 3 follicular lymphoma
1336358|NCT00625729|recurrent mantle cell lymphoma
1336359|NCT00625729|recurrent marginal zone lymphoma
1336360|NCT00625729|recurrent small lymphocytic lymphoma
1336361|NCT00625729|refractory chronic lymphocytic leukemia
1336362|NCT00625703|Pharmacokinetic
1336363|NCT00625690|lung cancer
1336364|NCT00625677|meningococcal serogroup C vaccine
1336365|NCT00625677|reduced dose
1336366|NCT00625677|meningococcal serogroup C conjugate vaccine
1336367|NCT00625677|pneumococcal conjugate vaccine
1336368|NCT00625664|Cancer
1336369|NCT00625664|Neoplasms
1336370|NCT00625664|Bladder
1336371|NCT00625664|Urothelial Tract
1336372|NCT00625651|Colon Cancer
1336373|NCT00625651|Colorectal Cancer
1336374|NCT00625651|Rectal Cancer
1336375|NCT00625651|AMG 655
1336376|NCT00625651|Bevacizumab
1336377|NCT00625651|Modified FOLFOX6
1336378|NCT00625651|mFOLFOX6
1336379|NCT00625651|FOLFOX
1336380|NCT00625638|Advanced Cancer
1336381|NCT00625638|Caregiver
1336382|NCT00625638|Interactive Voice Response
1336383|NCT00625638|Symptom Control
1336384|NCT00625638|IVR System
1336385|NCT00625638|Questionnaire
1336386|NCT00625625|stage I colon cancer
1336387|NCT00625625|stage II colon cancer
1336388|NCT00625625|stage III colon cancer
1336389|NCT00625625|stage I rectal cancer
1336390|NCT00625625|stage II rectal cancer
1336391|NCT00625625|stage III rectal cancer
1336392|NCT00625586|adenocarcinoma of the pancreas
1336393|NCT00625586|stage IV pancreatic cancer
1336394|NCT00625586|recurrent pancreatic cancer
1336395|NCT00625573|Colon Cancer
1336396|NCT00625573|Abraxis Oncology
1336397|NCT00625573|Abraxane
1336398|NCT00625573|Phase II
1336399|NCT00625573|Colorectal
1336400|NCT00625573|Mt. Sinai Medical Center
1336401|NCT00625573|CCOP
1336402|NCT00625560|Chronic hepatitis B
1336403|NCT00625560|Lamivudine
1336404|NCT00625560|Entecavir
1336405|NCT00625534|Hernia
1336406|NCT00625534|Laparoscopy
1336407|NCT00625534|Pain
1336408|NCT00625534|Sexual
1336409|NCT00625534|Quality
1336410|NCT00625521|Discoid lupus erythematosus
1336411|NCT00625495|Gastroesophageal reflux disease
1336412|NCT00625495|Nexium
1336413|NCT00625495|Esomeprazole
1336414|NCT00625495|Administration methods.
1336415|NCT00625482|BCG vaccine
1336416|NCT00625482|Oral polio vaccine
1336417|NCT00625482|Vitamin A supplementation
1336418|NCT00625482|Low-birth-weigth
1336419|NCT00625482|Sex-differential
1336420|NCT00625482|Prevention
1336421|NCT00625482|Immunological parameters
1336422|NCT00625469|pulmonary arterial hypertension
1336423|NCT00625469|idiopathic pulmonary fibrosis
1336424|NCT00625469|bosentan
1336425|NCT00625456|phase I
1336426|NCT00625456|advanced metastatic solid tumors
1336427|NCT00625456|oncolytic virus
1336428|NCT00625456|vaccinia virus
1336429|NCT00625456|melanoma
1336430|NCT00625456|lung cancer
1336431|NCT00625456|renal cell carcinoma
1336432|NCT00625456|squamous cell carcinoma of the head and neck
1336433|NCT00625456|Pexa-Vec
1336434|NCT00625443|Idiopathic Thrombocytopenic Purpura
1336435|NCT00625443|ITP
1336436|NCT00625443|Chronic Idiopathic Thrombocytopenic Purpura
1336437|NCT00625430|Prostate Cancer
1336438|NCT00625430|Gene Therapy
1336439|NCT00625430|Fludarabine
1336440|NCT00625430|Adenovirus
1336441|NCT00625430|phase I
1336442|NCT00625417|male breast cancer
1336443|NCT00625417|stage IA breast cancer
1336444|NCT00625417|stage IB breast cancer
1336445|NCT00625417|stage II breast cancer
1336446|NCT00625417|stage IIIA breast cancer
1336447|NCT00625417|stage IIIB breast cancer
1336448|NCT00625417|stage IIIC breast cancer
1336449|NCT00625417|stage IV breast cancer
1336450|NCT00625404|Aspartate Aminotransferase (AST)
1336451|NCT00625404|Alanine Aminotransferase (ALT)
1336452|NCT00625404|HIV
1336453|NCT00625404|HIV Prevention
1336454|NCT00625404|Oral PrEP
1336455|NCT00625404|Truvada
1336456|NCT00625404|women
1336457|NCT00625404|Tenofovir
1336458|NCT00625404|TDF
1336459|NCT00625404|FTC
1336460|NCT00625404|emtricitabine
1336461|NCT00625404|hepatitis
1336462|NCT00625404|Pre-exposure Prophylaxis (PrEP)
1336463|NCT00625404|HIV Seronegativity
1336464|NCT00625391|postmenopausal, bone, dietary supplement, mind-body exercise
1336465|NCT00625378|Cancer
1336466|NCT00625378|Sorafenib
1336467|NCT00625378|Extension program
1336468|NCT00625365|DEFINITY
1336469|NCT00625365|Safety
1336470|NCT00625365|Survelliance
1336471|NCT00625352|Carcinoma, Non-Small-Cell Lung
1336472|NCT00625352|Aged
1336473|NCT00625352|Gemcitabine
1336474|NCT00625352|UFT
1336475|NCT00625339|Chronic hepatitis B
1336476|NCT00625339|Lamivudine
1336477|NCT00625339|Entecavir
1336478|NCT00625326|psoriasis
1336479|NCT00625313|Cataract
1336480|NCT00625313|aphakia
1336481|NCT00625313|intraocular lens
1336482|NCT00625313|IOL
1336483|NCT00625313|Optical correction of aphakia
1336484|NCT00625300|repetitive transcranial stimulation
1336485|NCT00625300|Parkinson's Disease
1336486|NCT00625274|Nexium
1336487|NCT00625274|esomeprazole
1336488|NCT00625274|lansoprazole
1336489|NCT00625274|pantoprazole
1336490|NCT00625274|Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
1336491|NCT00625261|Language delay
1336492|NCT00625261|Speech and language disorders
1336493|NCT00625261|Early language intervention
1336494|NCT00625261|Parent-based language intervention
1336495|NCT00625235|Obesity
1336496|NCT00625235|Weight loss
1336497|NCT00625235|Weight maintenance
1336498|NCT00625235|VLED
1336499|NCT00625222|Electroencephalography
1336500|NCT00625222|Seizure frequency
1336501|NCT00625222|Seizure severity
1336502|NCT00625209|septic shock
1336503|NCT00625209|coagulation
1336504|NCT00625209|immunomodulation
1336505|NCT00625209|survival
1336506|NCT00625196|Healthy Japanese volunteers
1336507|NCT00625183|adenocarcinoma of the rectum
1336508|NCT00625183|stage II rectal cancer
1336509|NCT00625183|stage III rectal cancer
1336510|NCT00625170|Antipsychotics
1336511|NCT00625170|Olanzapine
1336512|NCT00625170|Haloperidol
1336513|NCT00625170|Insulin resistance
1336514|NCT00625170|Dyslipidemia
1336515|NCT00625131|Stress Disorders, Posttraumatic
1336516|NCT00625131|Tobacco Use Disorder
1336517|NCT00625118|Hib conjugate vaccine
1336518|NCT00625118|reactogenicity
1336519|NCT00625118|local reactions
1336520|NCT00625118|systemic symptoms
1336521|NCT00625092|peritoneal cavity cancer
1336522|NCT00625079|pulmonary hypertension
1336523|NCT00625079|pulmonary arterial hypertension
1336524|NCT00625079|interstitial lung disease
1336525|NCT00625079|idiopathic pulmonary fibrosis
1336526|NCT00625066|precancerous condition
1336527|NCT00625066|colon cancer
1336528|NCT00625066|rectal cancer
1336529|NCT00625053|Neuroticism
1336530|NCT00625053|Hernia, ventral
1336531|NCT00625053|Laparoscopy
1336532|NCT00625053|Quality of life
1336533|NCT00625040|Incretin effect
1336534|NCT00625040|Gastric banding
1336535|NCT00625040|Glucagon
1336536|NCT00625040|Glucagon-Like Peptide 1
1336537|NCT00625040|Gastric Inhibitory Peptide
1336538|NCT00625040|Glucose Intestinal Peptide
1336539|NCT00625040|Insulin
1336540|NCT00625040|C-peptide
1336541|NCT00625027|Emergency Department Visit
1336542|NCT00625027|Telehealth Ontario
1336543|NCT00625027|Triage Levels
1336544|NCT00625014|Insulin resistance
1336545|NCT00625014|Dyslipidemia
1336546|NCT00625014|Haloperidol
1336547|NCT00625001|Turner Syndrome
1336548|NCT00625001|bone mineral density
1336549|NCT00625001|estrogen replacement therapy
1336550|NCT00625001|dual energy x-ray absorptiometry
1336551|NCT00624988|Spinal cord injury
1336552|NCT00624988|vibration therapy
1336553|NCT00624988|bone density
1336554|NCT00624962|childhood soft tissue sarcoma
1336555|NCT00624962|neuroblastoma
1336556|NCT00624962|childhood hepatoblastoma
1336557|NCT00624962|childhood cerebellar astrocytoma
1336558|NCT00624962|childhood ependymoma
1336559|NCT00624962|childhood brain stem glioma
1336560|NCT00624962|childhood meningioma
1336561|NCT00624962|childhood myelodysplastic syndromes
1336562|NCT00624962|unspecified childhood solid tumor, protocol specific
1336563|NCT00624962|childhood acute myeloid leukemia/other myeloid malignancies
1336564|NCT00624962|central nervous system neoplasm
1336565|NCT00624962|Wilms tumor and other childhood kidney tumors
1336566|NCT00624962|childhood brain tumor
1336567|NCT00624962|childhood medulloblastoma
1336568|NCT00624949|Turner syndrome
1336569|NCT00624949|aortic dimensions
1336570|NCT00624949|blood pressure
1336571|NCT00624949|aortic dilatation
1336572|NCT00624949|aortic rupture
1336573|NCT00624936|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1336574|NCT00624936|adult acute myeloid leukemia with inv(16)(p13;q22)
1336575|NCT00624936|adult acute myeloid leukemia with t(15;17)(q22;q12)
1336576|NCT00624936|adult acute myeloid leukemia with t(16;16)(p13;q22)
1336577|NCT00624936|adult acute myeloid leukemia with t(8;21)(q22;q22)
1336578|NCT00624936|recurrent adult acute myeloid leukemia
1336579|NCT00624936|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1336580|NCT00624936|myelodysplastic syndromes
1336581|NCT00624936|secondary acute myeloid leukemia
1336582|NCT00624923|Coronary Artery Disease
1336583|NCT00624923|Inflammation
1336584|NCT00624923|Overweight
1336585|NCT00624923|Metabolic Syndrome
1336586|NCT00624923|Salsalate
1336587|NCT00624910|Post Operative Pain
1336588|NCT00624910|Hysterectomy
1336589|NCT00624884|Aortic regurgitation,velocity vector imaging
1336590|NCT00624871|Interleukin 1-beta
1336591|NCT00624871|Interleukin 6
1336592|NCT00624871|Vitamin C
1336593|NCT00624871|HIE
1336594|NCT00624871|neonates
1336595|NCT00624858|Depression
1336596|NCT00624858|depressed
1336597|NCT00624858|overweight
1336598|NCT00624858|obese
1336599|NCT00624845|Meniscectomy
1336600|NCT00624832|Asthma
1336601|NCT00624832|allergen challenge
1336602|NCT00624832|bronchoprovocation
1336603|NCT00624832|Methacholine challenge
1336604|NCT00624832|serum Immunoglobulin E
1336605|NCT00624832|Nitric Oxide
1336606|NCT00624832|skin prick test
1336607|NCT00624819|Streptococcus pneumoniae
1336608|NCT00624819|Haemophilus influenzae
1336609|NCT00624819|Pneumococcal conjugate vaccine
1336610|NCT00624819|Antibody persistence
1336611|NCT00624806|Pressure ulcer
1336612|NCT00624806|Telemedicine
1336613|NCT00624793|Nausea
1336614|NCT00624793|Vomiting
1336615|NCT00624793|Retching
1336616|NCT00624793|HIV/AIDS
1336617|NCT00624793|Symptom Management
1336618|NCT00624793|Complementary Therapies
1336619|NCT00624767|insulin
1336620|NCT00624767|insulin aspart
1336621|NCT00624767|Type 2 Diabetes
1336622|NCT00624767|diabetes mellitus
1336623|NCT00624754|Obstructive airway disease
1336624|NCT00624754|bronchiolitis obliterans
1336625|NCT00624754|allogeneic hematopoietic stem cell transplantation
1336626|NCT00624754|bone marrow transplantation
1336627|NCT00624754|inhaled treatment
1336628|NCT00624754|Budesonide Formoterol
1336629|NCT00624741|Parkinson's disease
1336630|NCT00624741|Antiparkinsonian
1336631|NCT00624741|Compassionate use
1336632|NCT00624728|Positron-Emission Tomography
1336633|NCT00624728|Alovudine [Substance Name]
1336634|NCT00624728|18F-FLT
1336635|NCT00624728|Magnetic Resonance Imaging
1336636|NCT00624728|Astrocytoma
1336637|NCT00624728|Glioblastoma
1336638|NCT00624702|Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)
1336639|NCT00624689|Body composition
1336640|NCT00624689|Glucose tolerance
1336641|NCT00624689|Intima-media thickness
1336642|NCT00624689|Visual acuity
1336643|NCT00624689|Neurological development
1336644|NCT00624676|Acne
1336645|NCT00624676|lipophilic hydroxy acid
1336646|NCT00624676|benzoyl peroxide
1336647|NCT00624663|Rivastigmine, Repeated administration, Healthy Volunteers, organophosphate poisoning, protection, pharmacokinetics, behavioral effects
1336648|NCT00624650|Acute Lung Injury
1336649|NCT00624650|Extravascular Lung Water
1336650|NCT00624650|Acute Respiratory Distress Syndrome
1336651|NCT00624637|aromatherapy
1336652|NCT00624637|massage
1336653|NCT00624637|comfort
1336654|NCT00624637|postoperative
1336655|NCT00624637|infants
1336656|NCT00624637|craniofacial surgery
1336657|NCT00624624|hypogonadotropic hypogonadism
1336658|NCT00624624|bariatric surgery
1336659|NCT00624624|serum androgen levels
1336660|NCT00624624|bone density
1336661|NCT00624611|CPB
1336662|NCT00624611|red blood cell washing
1336663|NCT00624585|MDS
1336664|NCT00624585|MDS/MPD
1336665|NCT00624585|MDS/AML
1336666|NCT00624585|CMML
1336667|NCT00624585|Excess Marrow Blasts
1336668|NCT00624572|primary teeth
1336669|NCT00624572|chlorexidine
1336670|NCT00624572|root canal therapy
1336671|NCT00624572|Pulpectomy
1336672|NCT00624559|Salt sensitivity of Blood Pressure
1336673|NCT00624546|GERD
1336674|NCT00624546|gastroesophageal reflux
1336675|NCT00624546|antireflux surgery
1336676|NCT00624546|Barrett's
1336677|NCT00624546|Esophagus
1336678|NCT00624546|Esophagitis
1336679|NCT00624533|Low back Pain
1336680|NCT00624533|Physical Therapy Modalities
1336681|NCT00624533|Exercise Movement Techniques
1336682|NCT00624533|Primary Health Care
1336683|NCT00624520|Stress, Psychological
1336684|NCT00624520|Tachycardia, Ventricular
1336685|NCT00624520|Defibrillators, Implantable
1336686|NCT00624520|Death, Sudden Cardiac
1336687|NCT00624520|Cognitive Therapy
1336688|NCT00624520|Anger
1336689|NCT00624494|venous oxygen saturation
1336690|NCT00624494|transpulmonary thermodilution
1336691|NCT00624481|osteoporosis
1336692|NCT00624481|osteopenia
1336693|NCT00624481|bone mineral density
1336694|NCT00624481|teriparatide
1336695|NCT00624468|atacicept
1336696|NCT00624468|neuritis
1336697|NCT00624455|Gabapentin
1336698|NCT00624455|tonsillectomy
1336699|NCT00624455|post-operative pain
1336700|NCT00624455|morphine requirements
1336701|NCT00624455|randomized double blind
1336702|NCT00624455|adenotonsillectomy
1336703|NCT00624429|Asthma
1336704|NCT00624429|Children
1336705|NCT00624416|Obesity therapy
1336706|NCT00624416|fat
1336707|NCT00624416|drug mechanism
1336708|NCT00624416|adipose tissue
1336709|NCT00624416|cellular pharmacology
1336710|NCT00624403|Anesthesia
1336711|NCT00624403|Laryngeal mask airway
1336712|NCT00624351|Lupus
1336713|NCT00624351|Monoclonal antibody
1336714|NCT00624351|B-Cell immunotherapy
1336715|NCT00624338|Atacicept 75 and 150 mg
1336716|NCT00624338|Placebo
1336717|NCT00624325|genotype 1 nonresponders
1336718|NCT00624312|Procrit
1336719|NCT00624312|Erythropoietin
1336720|NCT00624312|Patients undergoing major surgical oncology operations
1336721|NCT00624299|botox
1336722|NCT00624299|limb reconstructions
1336723|NCT00624299|limb reconstruction surgery
1336724|NCT00624286|chronic obstructive pulmonary disease
1336725|NCT00624286|COPD
1336726|NCT00624286|indacaterol
1336727|NCT00624273|digital ulcers,
1336728|NCT00624273|systemic sclerosis,
1336729|NCT00624273|sildenafil,
1336730|NCT00624273|vasoactive therapies
1336731|NCT00624260|Colorectal cancer
1336732|NCT00624260|Recurrence
1336733|NCT00624260|Positron Emission Tomography
1336734|NCT00624260|Colorectal Cancer with high risk of recurrence stage III
1336735|NCT00624260|Colorectal Cancer with high risk of recurrence stage IV
1336736|NCT00624260|T4N0M0 operated in emergency( because of perforation)
1336737|NCT00624247|routine HIV testing
1336738|NCT00624247|jails
1336739|NCT00624247|criminal justice system
1336740|NCT00624247|substance abuse
1336741|NCT00624247|mental illness
1336742|NCT00624247|HIV
1336743|NCT00624234|neurofibromatosis type 1
1336744|NCT00624234|reading disabilities
1336745|NCT00624234|NF-1
1336746|NCT00624234|learning disabilities
1336747|NCT00624234|tutoring intervention
1336748|NCT00624208|Randomized
1336749|NCT00624208|double-blind
1336750|NCT00624208|4-group clinical interventional study
1336751|NCT00624195|HIV Dementia
1336752|NCT00624195|HAART
1336753|NCT00624195|Cognitive Impairment
1336754|NCT00624195|Antiretroviral Regimen
1336755|NCT00624195|Viral Load
1336756|NCT00624195|CNS Drug Penetration
1336757|NCT00624169|Perforated peptic ulcer
1336758|NCT00624169|Mortality
1336759|NCT00624156|Breast Cancer
1336760|NCT00624143|Antifungal prophylaxis, acute leukemia induction,
1336761|NCT00624130|Contraception,
1336762|NCT00624130|Cycle control,
1336763|NCT00624130|Bleeding pattern
1336764|NCT00624117|shoulder joint
1336765|NCT00624117|recovery of function
1336766|NCT00624117|effectiveness of rehabilitation
1336767|NCT00624117|rehabilitation
1336768|NCT00624104|VLDL
1336769|NCT00624104|Kinetics
1336770|NCT00624104|Hyperinsulinaemia
1336771|NCT00624104|Obesity
1336772|NCT00624091|Early-surgery, infective endocarditis, in-hospital mortality
1336773|NCT00624078|faboterapics
1336774|NCT00624078|treatment
1336775|NCT00624078|scorpion sting
1336776|NCT00624078|envenomation
1336777|NCT00624065|target blood pressure
1336778|NCT00624065|hypertension
1336779|NCT00624065|COREG CR
1336780|NCT00624065|carvedilol CR
1336781|NCT00624065|Stage 1 or 2 essential hypertension
1336782|NCT00624065|lisinopril
1336783|NCT00624039|presbyopia
1336784|NCT00624013|Diabetes
1336785|NCT00624013|Depression
1336786|NCT00624013|diabetes outcomes
1336787|NCT00624013|quality of life
1336788|NCT00624000|Ischemic Stroke
1336789|NCT00623987|Residual vein thrombosis
1336790|NCT00623987|Optimal duration
1336791|NCT00623987|Oral anticoagulants
1336792|NCT00623974|Hypocalcemia
1336793|NCT00623974|Teriparatide
1336794|NCT00623974|Forteo
1336795|NCT00623974|Calcium
1336796|NCT00623974|Calcitriol
1336797|NCT00623974|Rocaltrol
1336798|NCT00623961|Neuropathic Pain
1336799|NCT00623948|Pressure ulcers
1336800|NCT00623948|Electrical Stimulation
1336801|NCT00623948|Spinal Cord Injury
1336802|NCT00623935|AML
1336803|NCT00623922|Patient education
1336804|NCT00623922|Nurse consultation
1336805|NCT00623922|Arthritis
1336806|NCT00623922|Wellbeing
1336807|NCT00623922|Coping
1336808|NCT00623922|Health related quality of life
1336809|NCT00623909|Laser Therapy
1336810|NCT00623909|Post Thoracotomy Pain
1336811|NCT00623909|AvicennaTM laser
1336812|NCT00623896|Nehb
1336813|NCT00623896|ST Elevation Myocardial Infarcton
1336814|NCT00623896|STEMI
1336815|NCT00623896|ECG
1336816|NCT00623883|Human Colonic Aberrant Crypt Foci
1336817|NCT00623857|Micronutrients
1336818|NCT00623857|Zinc
1336819|NCT00623857|Vitamins
1336820|NCT00623857|Trace elements
1336821|NCT00623857|Minerals
1336822|NCT00623857|Vitamin A
1336823|NCT00623857|Vitamin B1
1336824|NCT00623857|Vitamin B2
1336825|NCT00623857|Niacin
1336826|NCT00623857|Vitamin B6
1336827|NCT00623857|Folic acid
1336828|NCT00623857|Vitamin B12
1336829|NCT00623857|Vitamin C
1336830|NCT00623857|Vitamin D
1336831|NCT00623857|Vitamin E
1336832|NCT00623857|Vitamin K
1336833|NCT00623857|Iron
1336834|NCT00623857|Iodine
1336835|NCT00623857|Copper
1336836|NCT00623857|Selenium
1336837|NCT00623857|Magnesium
1336838|NCT00623857|Calcium
1336839|NCT00623857|Malaria
1336840|NCT00623857|Immunity
1336841|NCT00623857|Anthropometry
1336842|NCT00623844|Prevention
1336843|NCT00623844|Physical activity
1336844|NCT00623844|Obesity
1336845|NCT00623844|Motor skills
1336846|NCT00623844|Kindergarten
1336847|NCT00623831|MBV
1336848|NCT00623831|Mixed Bacterial Vaccine
1336849|NCT00623831|NY-ESO-1
1336850|NCT00623818|Mirror Therapy
1336851|NCT00623818|Phantom Limb Pain
1336852|NCT00623818|Amputee
1336853|NCT00623818|Healthy Volunteer
1336854|NCT00623818|HV
1336855|NCT00623792|Morbid obesity
1336856|NCT00623792|Diet therapy
1336857|NCT00623792|Bariatric Surgery
1336858|NCT00623792|Gastric bypass
1336859|NCT00623792|Behavior therapy
1336860|NCT00623792|Randomized controlled trial
1336861|NCT00623792|Weight loss
1336862|NCT00623753|Vaccine
1336863|NCT00623753|Prevention
1336864|NCT00623753|HIV
1336865|NCT00623753|AIDS
1336866|NCT00623753|Human Immunodeficiency Virus
1336867|NCT00623753|HIV Seronegativity, HIV Preventive Vaccine
1336868|NCT00623740|Hydrocortisone
1336869|NCT00623740|Very low birth weight
1336870|NCT00623740|Bronchopulmonary dysplasia
1336871|NCT00623740|Prevention Cerebral palsy
1336872|NCT00623727|Hemophilia A
1336873|NCT00623727|FVIII disease
1336874|NCT00623727|rFVIII
1336875|NCT00623701|sublingual grass pollen preparation
1336876|NCT00623701|IgE-mediated Allergic Disease attributed to grass pollen
1336877|NCT00623688|Metered Dose Inhalers
1336878|NCT00623688|Nebulizers
1336879|NCT00623688|Randomized Controlled Trial
1336880|NCT00623675|zeolites
1336881|NCT00623675|nutraceuticals
1336882|NCT00623675|natural supplements
1336883|NCT00623675|Healthy volunteers
1336884|NCT00623662|Glucose infusion
1336885|NCT00623662|Liver function
1336886|NCT00623662|Liver resection
1336887|NCT00623662|Albumin synthesis
1336888|NCT00623662|Stable isotopes
1336889|NCT00623636|Migraine
1336890|NCT00623610|Diabetes mellitus, type 1
1336891|NCT00623610|pancreatic beta cell
1336892|NCT00623610|transplantation
1336893|NCT00623584|penetrating keratoplasty
1336894|NCT00623584|corneal transplantation
1336895|NCT00623584|corneal grafting
1336896|NCT00623584|corneal grafts
1336897|NCT00623584|culture media
1336898|NCT00623584|corneal culturing
1336899|NCT00623584|in vitro culturing
1336900|NCT00623571|frail elderly
1336901|NCT00623571|hospital at home
1336902|NCT00623571|heart failure
1336903|NCT00623571|Acute exacerbation of chronic heart failure
1336904|NCT00623558|head and neck neoplasm
1336905|NCT00623558|cetuximab
1336906|NCT00623558|docetaxel
1336907|NCT00623558|cisplatin
1336908|NCT00623558|radiotherapy
1336909|NCT00623545|Exenatide
1336910|NCT00623545|Byetta
1336911|NCT00623545|weight loss
1336912|NCT00623545|energy expenditure
1336913|NCT00623545|normal volunteers
1336914|NCT00623532|Tertiary prevention of disability
1336915|NCT00623519|Adjuvant postmenopausal breast cancer women
1336916|NCT00623506|TBI
1336917|NCT00623506|Pregnenolone
1336918|NCT00623506|Cognition
1336919|NCT00623493|Screening
1336920|NCT00623493|Suicide
1336921|NCT00623493|Emergency Department
1336922|NCT00623493|Children and Adolescents
1336923|NCT00623493|Suicide Risk
1336924|NCT00623480|Hemophilia A
1336925|NCT00623467|Central Nervous System Imaging
1336926|NCT00623467|Diagnostic Imaging
1336927|NCT00623454|anxiety
1336928|NCT00623454|panic disorder
1336929|NCT00623454|chest pain
1336930|NCT00623454|palpitations
1336931|NCT00623441|Coronary Artery Disease
1336932|NCT00623441|Drug-eluting stent
1336933|NCT00623402|Metastatic melanoma
1336934|NCT00623402|Pegylated interferon
1336935|NCT00623402|Protein Kinase Inhibitors
1336936|NCT00623402|Sorafenib
1336937|NCT00623402|PegIntron
1336938|NCT00623402|Therapeutic Uses
1336939|NCT00623402|melanoma (skin)
1336940|NCT00623389|Neurologic disorders
1336941|NCT00623389|Rare disease
1336942|NCT00623389|Spinal cord injuries
1336943|NCT00623389|Stroke
1336944|NCT00623389|Paraplegia
1336945|NCT00623389|Tetraplegia
1336946|NCT00623363|Parkinson's Disease
1336947|NCT00623363|motor complications
1336948|NCT00623363|dyskinesia
1336949|NCT00623363|Motor complications associated with Parkinson's
1336950|NCT00623350|Telemedicine
1336951|NCT00623350|Stroke, Acute
1336952|NCT00623350|Rural
1336953|NCT00623350|Thrombolysis
1336954|NCT00623350|Consultation
1336955|NCT00623337|care seeking
1336956|NCT00623337|pregnancy and childbirth
1336957|NCT00623337|newborn care practices
1336958|NCT00623337|low birth weight babies
1336959|NCT00623298|Posttraumatic stress disorder
1336960|NCT00623298|depression
1336961|NCT00623298|Narrative Exposure Therapy
1336962|NCT00623298|Interpersonal Psychotherapy
1336963|NCT00623285|Pain.
1336964|NCT00623285|Postoperative.
1336965|NCT00623285|CABG.
1336966|NCT00623272|The assessment of left ventricular ejection fraction (LVEF)
1336967|NCT00623246|Obstructive Sleep Apnea
1336968|NCT00623246|OSA
1336969|NCT00623246|Adherence
1336970|NCT00623246|CPAP
1336971|NCT00623246|Cognition
1336972|NCT00623233|Breast Neoplasm
1336973|NCT00623220|pain, retinopathy of prematurity, infant, premature, eye exam, nitrous oxide
1336974|NCT00623207|Chest Pain Low work Capacity Rate Incompetence
1336975|NCT00623181|Influenza
1336976|NCT00623181|Influenza virus
1336977|NCT00623168|Ribavirin
1336978|NCT00623168|Hemorrhagic Fever with Renal Syndrome
1336979|NCT00623155|malaria
1336980|NCT00623155|intermittent preventive treatment
1336981|NCT00623155|season
1336982|NCT00623155|children
1336983|NCT00623142|Myocardial protection
1336984|NCT00623142|Ischemic Reperfusion Injury
1336985|NCT00623142|Hyperbaric Oxygen
1336986|NCT00623142|Preconditioning
1336987|NCT00623129|hypopharyngeal cancer
1336988|NCT00623129|lip and oral cavity cancer
1336989|NCT00623129|laryngeal cancer
1336990|NCT00623129|nasopharyngeal cancer
1336991|NCT00623129|oropharyngeal cancer
1336992|NCT00623129|paranasal sinus and nasal cavity cancer
1336993|NCT00623129|salivary gland cancer
1336994|NCT00623129|xerostomia
1336995|NCT00623129|radiation toxicity
1336996|NCT00623116|Kallmann Syndrome
1336997|NCT00623116|hypogonadotropic hypogonadism
1336998|NCT00623103|Parkinson's disease dementia
1336999|NCT00623103|cholinesterase inhibitor
1337000|NCT00623103|rivastigmine
1337001|NCT00623090|prostate cancer screening education
1337002|NCT00623090|behavioral oncology
1337003|NCT00623090|randomized trial
1337004|NCT00623077|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1337005|NCT00623077|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1337006|NCT00623077|childhood hepatoblastoma
1337007|NCT00623077|recurrent childhood liver cancer
1337008|NCT00623077|stage IV childhood liver cancer
1337009|NCT00623077|adult primary liver cancer
1337010|NCT00623077|previously treated childhood rhabdomyosarcoma
1337011|NCT00623077|recurrent childhood rhabdomyosarcoma
1337012|NCT00623077|previously untreated childhood rhabdomyosarcoma
1337013|NCT00623077|metastatic childhood soft tissue sarcoma
1337014|NCT00623077|recurrent childhood soft tissue sarcoma
1337015|NCT00623077|recurrent adult soft tissue sarcoma
1337016|NCT00623077|stage IV adult soft tissue sarcoma
1337017|NCT00623077|recurrent Wilms tumor and other childhood kidney tumors
1337018|NCT00623077|stage IV Wilms tumor
1337019|NCT00623077|stage V Wilms tumor
1337020|NCT00623077|rhabdoid tumor of the kidney
1337021|NCT00623077|stage IV renal cell cancer
1337022|NCT00623077|childhood mixed glioma
1337023|NCT00623077|recurrent childhood cerebellar astrocytoma
1337024|NCT00623077|recurrent childhood cerebral astrocytoma
1337025|NCT00623077|recurrent childhood ependymoma
1337142|NCT00622739|Bipolar Disorder
1337026|NCT00623077|recurrent childhood medulloblastoma
1337027|NCT00623077|recurrent childhood pineoblastoma
1337028|NCT00623077|recurrent childhood supratentorial primitive neuroectodermal tumor
1337029|NCT00623077|recurrent childhood visual pathway glioma
1337030|NCT00623077|untreated childhood brain stem glioma
1337031|NCT00623077|untreated childhood cerebellar astrocytoma
1337032|NCT00623077|childhood infratentorial ependymoma
1337033|NCT00623077|childhood supratentorial ependymoma
1337034|NCT00623077|childhood high-grade cerebellar astrocytoma
1337035|NCT00623077|childhood high-grade cerebral astrocytoma
1337036|NCT00623077|childhood low-grade cerebellar astrocytoma
1337037|NCT00623077|childhood low-grade cerebral astrocytoma
1337038|NCT00623077|newly diagnosed childhood ependymoma
1337039|NCT00623077|childhood atypical teratoid/rhabdoid tumor
1337040|NCT00623077|recurrent retinoblastoma
1337041|NCT00623077|extraocular retinoblastoma
1337042|NCT00623077|intraocular retinoblastoma
1337043|NCT00623077|childhood renal cell carcinoma
1337044|NCT00623077|clear cell renal cell carcinoma
1337045|NCT00623077|recurrent renal cell cancer
1337046|NCT00623077|recurrent childhood visual pathway and hypothalamic glioma
1337047|NCT00623077|unspecified adult solid tumor, protocol specific
1337048|NCT00623077|unspecified childhood solid tumor, protocol specific
1337049|NCT00623064|transitional cell carcinoma of the bladder
1337050|NCT00623064|stage IV bladder cancer
1337051|NCT00623064|stage III bladder cancer
1337052|NCT00623064|metastatic transitional cell cancer of the renal pelvis and ureter
1337053|NCT00623064|regional transitional cell cancer of the renal pelvis and ureter
1337054|NCT00623051|male circumcision
1337055|NCT00623051|HIV
1337056|NCT00623051|sexual behavior
1337057|NCT00623051|HIV prevention
1337058|NCT00623051|HIV Seronegativity
1337059|NCT00623038|Apgar score
1337060|NCT00623038|neonatal assessment
1337061|NCT00623038|preterm infants
1337062|NCT00623038|resuscitation
1337063|NCT00623025|HIV
1337064|NCT00623025|Steatorrhea
1337065|NCT00622999|Malnutrition
1337066|NCT00622999|Colon cancer
1337067|NCT00622999|Colon surgery
1337068|NCT00622999|Outcome
1337069|NCT00622999|Complication rate
1337070|NCT00622973|Prostate cancer
1337071|NCT00622973|Bladder cancer
1337072|NCT00622973|Pelvic lymph node metastases
1337073|NCT00622973|Diffusion-weighted MRI
1337074|NCT00622973|Sinerem (USPIO)-enhanced MRI
1337075|NCT00622973|Imaging influence on surgery
1337076|NCT00622973|Noninvasive detection of pelvic lymph node metastases
1337077|NCT00622973|Influence of imaging protocol on surgical outcome
1337078|NCT00622960|obesity
1337079|NCT00622960|type 2 diabetes
1337080|NCT00622960|weight loss
1337081|NCT00622960|monounsaturated fat
1337082|NCT00622960|diet
1337083|NCT00622947|Depression
1337084|NCT00622947|antidepressant effect
1337085|NCT00622947|rTMS
1337086|NCT00622947|sham
1337087|NCT00622947|cognition
1337088|NCT00622947|saliva cortisol
1337089|NCT00622947|brain derived neurotropic factor
1337090|NCT00622934|multiple trauma
1337091|NCT00622921|PTSD
1337092|NCT00622921|alcohol dependence
1337093|NCT00622895|scleroderma
1337094|NCT00622895|systemic sclerosis
1337095|NCT00622882|Staphylococcus aureus
1337096|NCT00622882|Bacteremia
1337097|NCT00622882|Outcome
1337098|NCT00622882|Mortality
1337099|NCT00622882|Recurrence
1337100|NCT00622882|Infectious Diseases specialists
1337101|NCT00622869|Liver transplantation
1337102|NCT00622869|everolimus
1337103|NCT00622869|calcineurin inhibitors
1337104|NCT00622869|tacrolimus
1337105|NCT00622869|renal function
1337106|NCT00622869|MDRD formula
1337107|NCT00622869|progression of fibrosis
1337108|NCT00622856|diabetes
1337109|NCT00622856|adolescents
1337110|NCT00622856|psychological therapy
1337111|NCT00622843|pneumococcal conjugate vaccine
1337112|NCT00622843|polysaccharide vaccine
1337113|NCT00622843|PPV
1337114|NCT00622843|PCV
1337115|NCT00622843|Streptococcus pneumoniae
1337116|NCT00622843|Prevnar
1337117|NCT00622843|Pneumovax
1337118|NCT00622843|HIV
1337119|NCT00622830|darapladib,
1337120|NCT00622830|SB480848,
1337121|NCT00622830|Japanese healthy volunteers
1337122|NCT00622817|Epinephrine
1337123|NCT00622817|Nasal decongestant
1337124|NCT00622817|RSV
1337125|NCT00622817|xylometazoline
1337126|NCT00622817|Bronchiolitis
1337127|NCT00622804|Stomach cancer
1337128|NCT00622804|Gastrectomy
1337129|NCT00622804|Postgastrectomy syndrome
1337130|NCT00622791|Cardiopulmonary bypass
1337131|NCT00622791|coronary artery bypass graft
1337132|NCT00622791|coronary artery disease
1337133|NCT00622791|propofol
1337134|NCT00622791|pharmacokinetics
1337135|NCT00622791|pharmacodynamics
1337136|NCT00622778|intracranial bleeding
1337137|NCT00622778|computed tomography scan
1337138|NCT00622765|Obesity, Overweight, Body Weight, Body Size, Nutritional and Metabolic Diseases
1337139|NCT00622752|Smoking cessation
1337140|NCT00622752|Craving
1337141|NCT00622752|Smokers
1337143|NCT00622739|Children
1337144|NCT00622739|Adolescents
1337145|NCT00622739|Treatment
1337146|NCT00622726|Vascular Endothelial Growth Factor
1337147|NCT00622726|Angiogenesis Inhibitor
1337148|NCT00622726|Premature infants
1337149|NCT00622726|Bevacizumab
1337150|NCT00622726|Zone I or Posterior Zone II ROP
1337151|NCT00622726|Aggressive Posterior ROP
1337152|NCT00622726|Stage 3 ROP
1337153|NCT00622726|Neonatal Intensive Care Unit
1337154|NCT00622713|Alzheimer's disease
1337155|NCT00622713|cholinesterase inhibitor
1337156|NCT00622713|rivastigmine
1337157|NCT00622700|MS
1337158|NCT00622700|Clinically Isolated Syndrome
1337159|NCT00622700|CIS
1337160|NCT00622700|CDMS
1337161|NCT00622700|relapses
1337162|NCT00622687|iloprost
1337163|NCT00622687|systemic sclerosis
1337164|NCT00622687|digital ulcers
1337165|NCT00622687|observational study
1337166|NCT00622687|randomized
1337167|NCT00622674|recurrent breast cancer
1337168|NCT00622674|recurrent non-small cell lung cancer
1337169|NCT00622674|recurrent small cell lung cancer
1337170|NCT00622674|recurrent colon cancer
1337171|NCT00622674|recurrent pancreatic cancer
1337172|NCT00622674|recurrent head and neck cancer
1337173|NCT00622674|recurrent sarcoma
1337174|NCT00622674|recurrent kidney cancer
1337175|NCT00622674|recurrent renal cell cancer
1337176|NCT00622661|Glycemic response
1337177|NCT00622661|Glycemic index
1337178|NCT00622661|Obesity
1337179|NCT00622661|Carbohydrates
1337180|NCT00622661|Insulin
1337181|NCT00622661|Blood glucose
1337182|NCT00622648|Medical prevention therapy
1337183|NCT00622635|chronic obstructive pulmonary disease
1337184|NCT00622635|COPD
1337185|NCT00622635|indacaterol
1337186|NCT00622609|first time in human,
1337187|NCT00622609|MAG
1337188|NCT00622609|monoclonal antibody,
1337189|NCT00622609|healthy subjects,
1337190|NCT00622609|GSK249320,
1337191|NCT00622596|opiate dependence
1337192|NCT00622596|buprenorphine
1337194|NCT00622570|Traumatic brain injury, barbiturate coma
1337195|NCT00622544|Microalbuminuria
1337196|NCT00622544|Proteinuria
1337197|NCT00622531|heart failure
1337198|NCT00622531|BNP
1337199|NCT00622531|natriuretic peptide
1337200|NCT00622518|otitis media
1337201|NCT00622518|children
1337202|NCT00622505|Multiple myeloma
1337203|NCT00622505|zoledronic acid
1337204|NCT00622505|skeletal complications
1337205|NCT00622505|bone
1337206|NCT00622492|VV-ECMO
1337207|NCT00622492|VA-ECMO
1337208|NCT00622492|PPHN
1337209|NCT00622492|organ circulation
1337210|NCT00622479|Sorafenib
1337211|NCT00622479|Hypophosphatemia
1337212|NCT00622479|Left ventricular ejection fraction (LVEF)
1337213|NCT00622479|Beta-type Natriuretic Peptide (BNP)
1337214|NCT00622466|stage IV breast cancer
1337215|NCT00622466|male breast cancer
1337216|NCT00622466|recurrent breast cancer
1337217|NCT00622466|HER2-negative breast cancer
1337218|NCT00622440|HSIL
1337219|NCT00622440|HGAIN
1337220|NCT00622440|AIN
1337221|NCT00622440|neoplasia
1337222|NCT00622440|dysplasia
1337223|NCT00622440|TCM
1337224|NCT00622440|Traditional Chinese Medicine
1337225|NCT00622401|stage IV breast cancer
1337226|NCT00622401|dendritic cell vaccine
1337227|NCT00622401|tumor fusion vaccine
1337228|NCT00622401|IL-12
1337229|NCT00622375|Pharmacokinetic study
1337230|NCT00622375|Healthy subjects
1337231|NCT00622362|Immunotherapy
1337232|NCT00622362|Allergy
1337233|NCT00622362|Allergoid
1337234|NCT00622362|Depigmented
1337235|NCT00622362|Polymerized
1337236|NCT00622362|Allergen-extract
1337237|NCT00622362|mites
1337238|NCT00622362|Asthma
1337239|NCT00622349|Randomised phase III
1337240|NCT00622349|Chemotherapy
1337241|NCT00622349|Advanced non-small cell lung carcinoma
1337242|NCT00622336|Multiple Myeloma
1337243|NCT00622336|Revlimid
1337244|NCT00622323|diabetes
1337245|NCT00622323|exenatide
1337246|NCT00622323|metformin
1337247|NCT00622323|sulfonylurea
1337248|NCT00622323|Byetta
1337249|NCT00622323|Amylin
1337250|NCT00622323|Lilly
1337251|NCT00622271|Type 1 Diabetes Mellitus
1337252|NCT00622271|Adolescents and Families
1337253|NCT00622271|Group Therapy Intervention
1337254|NCT00622258|everolimus
1337255|NCT00622258|mTOR inhibitor
1337256|NCT00622258|non-Hodgkin's lymphoma
1337257|NCT00622245|Depression
1337258|NCT00622245|Bipolar disorder
1337259|NCT00622245|Placebo-controlled
1337260|NCT00622245|Double-blind
1337261|NCT00622245|Multicenter
1337262|NCT00622245|Clinical study
1337263|NCT00622245|Mania
1337264|NCT00622232|HIV-1
1337265|NCT00622232|treatment experienced, complementary therapies
1337268|NCT00622206|Pharmacokinetics
1337269|NCT00622206|ritonavir
1337270|NCT00622206|saquinavir
1337271|NCT00622206|safety and toxicity
1337272|NCT00622206|treatment experienced
1337273|NCT00622193|NSCLC
1337274|NCT00622180|Vitiligo
1337275|NCT00622180|Light treatment for vitiligo
1337276|NCT00622180|Excilite
1337277|NCT00622167|Plaque characteristics
1337278|NCT00622167|DSCT
1337279|NCT00622167|IVUS
1337280|NCT00622141|bioequivalence
1337281|NCT00622141|ritonavir boosted generic GPO saquinavir
1337282|NCT00622141|saftey
1337283|NCT00622141|pharmacokinetics
1337284|NCT00622128|Behavioral Research
1337285|NCT00622128|Dementia
1337286|NCT00622128|Aggression
1337287|NCT00622102|warfarin
1337288|NCT00622102|adherence
1337289|NCT00622102|Mechanical heart valves
1337290|NCT00622089|diabetes
1337291|NCT00622089|type 2 diabetes
1337292|NCT00622089|cholesterol
1337293|NCT00622076|postoperative
1337294|NCT00622076|Catheterization
1337295|NCT00622076|colporrhaphy
1337296|NCT00622076|cystocele
1337297|NCT00622076|cystitis
1337298|NCT00622063|cancer, solid tumor
1337299|NCT00622024|Arrhythmia
1337300|NCT00622024|Depression
1337301|NCT00622024|Coronary Artery Disease
1337302|NCT00621998|Risperidone
1337303|NCT00621998|Olanzapine
1337304|NCT00621998|Tardive dyskinesia
1337305|NCT00621972|acute renal failure
1337306|NCT00621972|arteriovenous fistula
1337307|NCT00621972|KIM-1
1337308|NCT00621972|chronic kidney disease
1337309|NCT00621959|levocetirizine
1337310|NCT00621959|Xyzal
1337311|NCT00621959|Seasonal Allergic Rhinitis
1337312|NCT00621959|total symptom score
1337313|NCT00621959|quality of life
1337314|NCT00621946|Asthma
1337315|NCT00621946|Depression
1337316|NCT00621946|Escitalopram
1337317|NCT00621907|randomized
1337318|NCT00621907|analgesic
1337319|NCT00621907|caesarean scars
1337320|NCT00621907|locoregional anaesthesia
1337321|NCT00621907|infiltration
1337322|NCT00621907|levobupivacaïne
1337323|NCT00621907|Chirocaïne
1337324|NCT00621907|caesarian
1337325|NCT00621907|unique administration
1337326|NCT00621907|post-caesarian analgesic
1337327|NCT00621894|Immune thrombocytopenic purpura
1337328|NCT00621894|thrombopoietin mimetic
1337329|NCT00621894|ITP
1337330|NCT00621881|hepatic impairment
1337331|NCT00621868|Diabetes Mellitus, Type 2
1337332|NCT00621868|ASP1941
1337333|NCT00621842|Geriatric Psychiatry
1337334|NCT00621842|Aged
1337335|NCT00621842|lamotrigine
1337336|NCT00621816|nitroprusside
1337337|NCT00621816|intensive care unit
1337338|NCT00621816|hypertension
1337339|NCT00621816|blood pressure reduction
1337340|NCT00621803|Probiotic
1337341|NCT00621803|Pseudomonas aeruginosa
1337342|NCT00621803|Gastric colonization
1337343|NCT00621803|Respiratory tract colonization
1337344|NCT00621803|Ventilator aquired pneumoniae
1337345|NCT00621803|determine the effect of oral administration of this probiotic on gastric and respiratory tract colonisation/infection by P. aeruginosa
1337346|NCT00621790|fenoldopam
1337347|NCT00621790|acute renal failure
1337348|NCT00621790|renal replacement therapy
1337349|NCT00621790|mortality
1337350|NCT00621790|cardiac surgery
1337351|NCT00621790|cardiac anesthesia
1337352|NCT00621790|intensive care unit
1337353|NCT00621777|schizophrenia
1337354|NCT00621777|bipolar disorder
1337355|NCT00621777|varenicline
1337356|NCT00621777|smoking cessation
1337357|NCT00621777|relapse prevention
1337358|NCT00621777|cognitive behavioral therapy
1337359|NCT00621764|Japanese encephalitis (JE)
1337360|NCT00621764|Hepatitis A
1337361|NCT00621764|Inactivated Mouse-Brain
1337362|NCT00621751|Brain Injury
1337363|NCT00621751|Irritability
1337364|NCT00621751|Aggression
1337365|NCT00621738|mental stress
1337366|NCT00621738|cardiovascular risk factor
1337367|NCT00621738|platelet adhesion
1337368|NCT00621725|Advanced cancer
1337369|NCT00621725|metastatic
1337370|NCT00621725|hepatic impairment
1337371|NCT00621712|Renal Dialysis
1337372|NCT00621712|Dialysis, Extracorporeal
1337373|NCT00621712|Dialysis, Renal
1337374|NCT00621712|Extracorporeal Dialysis
1337375|NCT00621699|pharmacokinetics
1337376|NCT00621699|drug interactions
1337377|NCT00621699|ezetimibe
1337378|NCT00621699|tacrolimus
1337379|NCT00621699|human experimentation
1337380|NCT00621686|adult glioblastoma
1337381|NCT00621686|adult giant cell glioblastoma
1337382|NCT00621686|adult gliosarcoma
1337383|NCT00621686|recurrent adult brain tumor
1337384|NCT00621673|Hemophilia A,
1337385|NCT00621673|Inhibitor formation,
1337386|NCT00621673|rFVIII
1337387|NCT00621660|Acupuncture therapy
1337388|NCT00621660|Cancer
1337389|NCT00621660|Emesis
1337390|NCT00621660|Expectations
1337391|NCT00621660|Placebo
1337392|NCT00621647|Seroquel
1337393|NCT00621647|dementia
1337394|NCT00621647|agitation symptoms
1337395|NCT00621647|Alzheimer's disease
1337396|NCT00621647|vascular dementia
1337397|NCT00621647|quetiapine fumarate
1337398|NCT00621634|Tardive dyskinesia
1337399|NCT00621634|Schizophrenia
1337400|NCT00621634|Essential fatty acids
1337401|NCT00621621|atrioventricular nodal reentrant tachycardia
1337402|NCT00621621|AVNRT
1337403|NCT00621608|Chronic ulcers
1337404|NCT00621608|Diabetes
1337405|NCT00621608|Hyperbaric Oxygen Therapy
1337406|NCT00621595|School Breakfast
1337407|NCT00621595|Diet
1337408|NCT00621595|Nutrition
1337409|NCT00621595|Brain Function
1337410|NCT00621595|Cognition
1337411|NCT00621595|USDA
1337412|NCT00621595|Healthy Children
1337413|NCT00621569|Blood Pressure
1337414|NCT00621569|Dash Diet
1337415|NCT00621543|Intrauterine Device
1337416|NCT00621543|Induced Abortion
1337417|NCT00621543|Medical Abortion
1337418|NCT00621530|Total hip arthroplasty
1337419|NCT00621530|Total hip replacement
1337420|NCT00621530|Pain, postoperative
1337421|NCT00621530|Ketorolac
1337422|NCT00621530|Patients undergoing unilateral total hip arthroplasty
1337423|NCT00621517|Restless Legs Syndrome
1337424|NCT00621517|Bupropion
1337425|NCT00621504|ceftaroline
1337426|NCT00621504|Community-acquired pneumonia
1337427|NCT00621504|CAP
1337428|NCT00621504|IV (intravenous)
1337429|NCT00621504|Streptococcus pneumoniae
1337430|NCT00621504|Haemophilus influenzae
1337431|NCT00621504|Mycoplasma pneumoniae
1337432|NCT00621504|Chlamydophila spp
1337433|NCT00621504|Legionella spp
1337434|NCT00621504|Multi-drug resistant Streptococcus pneumoniae (MDRSP)
1337435|NCT00621504|antimicrobial resistance
1337436|NCT00621504|pneumococci
1337437|NCT00621504|Ceftriaxone
1337438|NCT00621504|bacteria
1337439|NCT00621504|ß-lactam
1337440|NCT00621504|beta-lactam
1337441|NCT00621504|antibiotic
1337442|NCT00621491|cardiac pacing
1337443|NCT00621491|pacing complication
1337444|NCT00621491|venous thrombosis
1337445|NCT00621491|warfarin
1337446|NCT00621491|anticoagulation
1337447|NCT00621491|randomized trial
1337448|NCT00621465|Psychosis
1337449|NCT00621465|Homelessness
1337450|NCT00621465|Case Management
1337451|NCT00621465|Severe Mental Illness
1337452|NCT00621439|ocular melanoma
1337453|NCT00621426|T wave alternans (TWA)
1337454|NCT00621426|dialysis
1337455|NCT00621426|end stage renal disease
1337456|NCT00621426|sudden cardiac death
1337457|NCT00621426|T-wave alternans
1337458|NCT00621426|Cardiac electrical instability
1337459|NCT00621426|Sympathetic and electrolyte-induced alterations
1337460|NCT00621426|Ventricular repolarization
1337461|NCT00621413|prostate
1337462|NCT00621413|cancer
1337463|NCT00621413|intermediate risk
1337464|NCT00621413|high risk
1337465|NCT00621413|brachytherapy
1337466|NCT00621413|Cesium-131
1337467|NCT00621413|seed brachytherapy
1337468|NCT00621413|intermediate and high risk cancer of the prostate
1337469|NCT00621400|newly-diagnosed light-chain (AL)-amyloidosis
1337470|NCT00621387|reactive arthritis
1337471|NCT00621387|antibiotics
1337472|NCT00621374|Pain Management
1337473|NCT00621374|Cognitive Behavior Therapy
1337474|NCT00621374|Hypnosis
1337475|NCT00621361|Lung Cancer
1337476|NCT00621361|AZD2171
1337477|NCT00621361|cediranib
1337478|NCT00621361|RECENTIN
1337479|NCT00621361|etoposide
1337480|NCT00621361|cisplatin
1337481|NCT00621348|maintenance fluids
1337482|NCT00621348|hyponatremia
1337483|NCT00621348|vasopressin
1337484|NCT00621348|children
1337485|NCT00621335|Open angle glaucoma
1337486|NCT00621335|Ocular hypertension
1337487|NCT00621335|Parallel comparison
1337488|NCT00621335|Combigan
1337489|NCT00621335|Cosopt
1337490|NCT00621322|Tuberculosis vaccine
1337491|NCT00621309|drug interactions
1337492|NCT00621309|cytochrome P4503A4
1337493|NCT00621309|Pregnane X-receptor
1337494|NCT00621309|induction
1337495|NCT00621309|drug metabolism
1337496|NCT00621296|Chronic Hepatitis C
1337497|NCT00621296|Protease Inhibitor
1337498|NCT00621270|Major Depression Neurogenesis
1337499|NCT00621270|Major Depressive Disorder with Concomitant Anxiety
1337500|NCT00621257|IBD
1337501|NCT00621257|Inflammatory Bowel Disease
1337502|NCT00621257|Crohn's Disease
1337503|NCT00621257|Ulcerative Colitis
1337504|NCT00621257|Vitamin D
1337505|NCT00621244|HDAC inhibitor
1337506|NCT00621244|Oral
1337507|NCT00621244|LBH589
1337508|NCT00621244|Lymphoma
1337509|NCT00621244|Leukemia
1337510|NCT00621244|Multiple myeloma
1337511|NCT00620256|Glaucoma
1337512|NCT00620256|Hypertension
1337513|NCT00620243|Ovarian cancer
1337514|NCT00620243|PET
1337515|NCT00620243|CT
1337516|NCT00620243|04-064
1337517|NCT00620230|Allergic rhinitis, anti-interleukin 4
1337518|NCT00620217|heart ischemia
1337519|NCT00620217|coronary artery disease
1337520|NCT00620217|plasmid
1337521|NCT00620217|VEGF
1337522|NCT00620217|FGF
1337523|NCT00620217|percutaneous
1337524|NCT00620217|gene therapy
1337525|NCT00620217|SPECT
1337526|NCT00620217|nuclear magnetic resonance
1337527|NCT00620204|atorvastatin
1337528|NCT00620204|Angina Pectoris, Variant
1337529|NCT00620204|endothelial dysfunction
1337530|NCT00620191|metformin
1337531|NCT00620191|mild cognitive impairment
1337532|NCT00620191|alzheimer's disease
1337533|NCT00620191|overweight
1337534|NCT00620191|insulin
1337535|NCT00620178|candesartan
1337536|NCT00620178|losartan
1337537|NCT00620178|blood pressure
1337538|NCT00620178|cardiovascular disease
1337539|NCT00620178|health care consumption
1337540|NCT00620165|tremor
1337541|NCT00620165|writing
1337542|NCT00620165|feeding
1337543|NCT00620165|pouring
1337544|NCT00620139|head and neck squamous cell carcinoma
1337545|NCT00620139|chemoradiotherapy
1337546|NCT00620139|molecular effects
1337547|NCT00620139|05-016
1337548|NCT00620126|Inflammatory bowel disease
1337549|NCT00620126|Ulcerative colitis
1337550|NCT00620126|Telemedicine
1337551|NCT00620126|Telemanagement
1337552|NCT00620126|Chronic disease
1337553|NCT00621231|Protein Function
1337554|NCT00621231|normal versus high protein intake
1337555|NCT00621218|tretinoin, efficacy, safety, rosacea
1337556|NCT00621205|Insulin resistance, weight reduction, adipose tissue, peripheral
1337557|NCT00621205|mononuclear cells, gene expression profile, transcriptomics
1337558|NCT00621192|meropenem
1337559|NCT00621192|infants
1337560|NCT00621192|intra-abdominal infection
1337561|NCT00621192|pharmacokinetics
1337562|NCT00621192|safety
1337563|NCT00621179|Endometriosis,infertility,in vitro fertilization
1337564|NCT00621166|Generic lopinavir/ritonavir
1337565|NCT00621166|Pharmacokinetics
1337566|NCT00621166|Pregnancy
1337567|NCT00621166|Antiviral activity
1337568|NCT00621166|Safety
1337569|NCT00621153|Candesartan Cilexetil
1337570|NCT00621153|hydrochlorothiazide
1337571|NCT00621153|severe hypertension
1337572|NCT00621114|Dialysis, Extracorporeal
1337573|NCT00621114|Dialysis, Renal
1337574|NCT00621114|Extracorporeal Dialysis
1337575|NCT00621114|Hemodialysis
1337576|NCT00621101|pharmacokinetics
1337577|NCT00621101|drug interactions
1337578|NCT00621101|ezetimibe
1337579|NCT00621101|sirolimus
1337580|NCT00621101|human experimentation
1337581|NCT00621075|PAH; V/Q SCAN;RHC;Echo;CT Scans; Angiography;PFTs
1337582|NCT00621062|varicose
1337583|NCT00621062|vein
1337584|NCT00621062|ligation
1337585|NCT00621062|laser
1337586|NCT00621062|foam
1337587|NCT00621062|sclerotherapy
1337588|NCT00621062|radiofrequency
1337589|NCT00621062|duplex
1337590|NCT00621062|sf36
1337591|NCT00621062|Aberdeen
1337592|NCT00621062|VCSS
1337593|NCT00621062|quality
1337594|NCT00621062|recurrence
1337595|NCT00621049|Non-Small Cell Lung Cancer
1337596|NCT00621049|Resected
1337597|NCT00621049|Carboplatin
1337598|NCT00621049|Docetaxel
1337599|NCT00621049|Bevacizumab
1337600|NCT00621049|Erlotinib
1337601|NCT00621036|primary central nervous system non-Hodgkin lymphoma
1337602|NCT00621036|primary central nervous system Hodgkin lymphoma
1337603|NCT00621036|stage IV adult T-cell leukemia/lymphoma
1337604|NCT00621036|adult nasal type extranodal NK/T-cell lymphoma
1337605|NCT00621036|anaplastic large cell lymphoma
1337606|NCT00621036|angioimmunoblastic T-cell lymphoma
1337607|NCT00621036|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1337608|NCT00621036|stage IV adult Burkitt lymphoma
1337609|NCT00621036|stage IV adult diffuse large cell lymphoma
1337610|NCT00621036|stage IV adult diffuse mixed cell lymphoma
1337611|NCT00621036|stage IV adult diffuse small cleaved cell lymphoma
1337612|NCT00621036|stage IV adult Hodgkin lymphoma
1337613|NCT00621036|stage IV adult immunoblastic large cell lymphoma
1337614|NCT00621036|stage IV adult lymphoblastic lymphoma
1337615|NCT00621036|stage IV childhood Hodgkin lymphoma
1337616|NCT00621036|stage IV childhood large cell lymphoma
1337617|NCT00621036|stage IV childhood lymphoblastic lymphoma
1337618|NCT00621036|stage IV childhood small noncleaved cell lymphoma
1337619|NCT00621036|stage IV cutaneous T-cell non-Hodgkin lymphoma
1337620|NCT00621036|stage IV mycosis fungoides/Sezary syndrome
1337621|NCT00621036|stage IV grade 1 follicular lymphoma
1337622|NCT00621036|stage IV grade 2 follicular lymphoma
1337623|NCT00621036|stage IV grade 3 follicular lymphoma
1337624|NCT00621036|stage IV mantle cell lymphoma
1337625|NCT00621036|stage IV marginal zone lymphoma
1337626|NCT00621036|stage IV small lymphocytic lymphoma
1337627|NCT00621036|intraocular lymphoma
1337628|NCT00621036|post-transplant lymphoproliferative disorder
1337629|NCT00621036|cutaneous B-cell non-Hodgkin lymphoma
1337630|NCT00621036|Waldenstrom macroglobulinemia
1337631|NCT00621036|small intestine lymphoma
1337632|NCT00621036|stage IV childhood anaplastic large cell lymphoma
1337633|NCT00621023|Myelodysplastic syndrome
1337634|NCT00621023|MDS
1337635|NCT00620997|cornea
1337636|NCT00620997|analgesia
1337637|NCT00620997|topical
1337638|NCT00620997|anesthetic
1337639|NCT00620984|Staphylococcus aureus
1337640|NCT00620984|Breastfeeding
1337641|NCT00620984|Lactational Mastitis
1337642|NCT00620984|Polymerase Chain Reaction (PCR) amplification analysis
1337643|NCT00620984|staphylococcal infections
1337644|NCT00620984|staphylococcal Carrier State
1337645|NCT00620971|Non Small Cell Lung Cancer
1337646|NCT00620971|Cisplatin
1337647|NCT00620971|VInorelbine
1337648|NCT00620971|Docetaxel
1337649|NCT00620971|Gemcitabine
1337650|NCT00620971|Bevacizumab
1337651|NCT00620958|Mediation
1337652|NCT00620958|Outcome
1337653|NCT00620958|CBT
1337654|NCT00620958|Child Anxiety Intervention
1337655|NCT00620945|Congenital heart surgery
1337656|NCT00620945|Cardiopulmonary bypass
1337657|NCT00620945|Phenoxybenzamine
1337658|NCT00620906|manipulation
1337659|NCT00620906|manual therapy
1337660|NCT00620906|Sacroiliac joint
1337661|NCT00620906|effects on manipulation on sacroiliac joint
1337662|NCT00620893|Dry eye signs and symptoms
1337663|NCT00620893|refractive regression
1337664|NCT00620841|Tacrolimus
1337665|NCT00620841|Renal Transplantation
1337666|NCT00620841|genetic polymorphisms
1337667|NCT00620841|Drug drug interactions
1337668|NCT00620815|avian flu
1337669|NCT00620815|seasonal influenza vaccine
1337670|NCT00620815|influenza vaccine
1337671|NCT00620815|prepandemic vaccine
1337672|NCT00620815|virus strain with the potential to cause pandemic
1337673|NCT00620815|tetravalent vaccine
1337674|NCT00620815|Prophylaxis of influenza
1337675|NCT00620802|Platelet function testing
1337676|NCT00620802|Healthy volunteers
1337677|NCT00620789|Insomnia
1337678|NCT00620789|Depression
1337679|NCT00620776|Generalized Anxiety Disorder
1337680|NCT00620776|Cognitive Behavioral Therapy
1337681|NCT00620776|Psychotherapy plus medication
1337682|NCT00620776|Combined treatment
1337683|NCT00620763|Meat protein
1337684|NCT00620763|acid load
1337685|NCT00620763|calcium retention
1337686|NCT00620763|postmenopausal women
1337687|NCT00620750|Alcohol dependence
1337688|NCT00620711|Hypoxic ischemic encephalopathy
1337689|NCT00620711|HIE
1337690|NCT00620711|Neonatal encephalopathy
1337691|NCT00620711|Cooling
1337692|NCT00620711|hypothermia
1337693|NCT00620698|amyotrophic lateral sclerosis
1337694|NCT00620698|motor neuron disease
1337695|NCT00620698|outcome measure
1337696|NCT00620698|biomarker
1337697|NCT00620698|impedance
1337698|NCT00620685|Arthritis, rheumatoid
1337699|NCT00620672|n-3 supplementation during pregnancy
1337700|NCT00620672|DHA and pregnancy, infant development
1337701|NCT00620672|n-3 status and gestation
1337702|NCT00620672|DHA and visual acuity and cognition during infancy
1337703|NCT00620646|clopidogrel
1337704|NCT00620646|platelets
1337705|NCT00620646|percutaneous coronary intervention
1337706|NCT00620633|Bone Marrow
1337707|NCT00620620|Healthy adult volunteers
1337708|NCT00620607|gastric
1337709|NCT00620594|Neoplasms
1337710|NCT00620594|breast neoplasms
1337711|NCT00620594|breast diseases
1337712|NCT00620594|solid tumors
1337713|NCT00620594|BEZ235
1337714|NCT00620594|breast cancer
1337715|NCT00620594|PI3K Inhibitor
1337716|NCT00620594|Phosphatidylinositol 3
1337717|NCT00620594|kinase
1337718|NCT00620594|advanced
1337719|NCT00620568|Safety
1337720|NCT00620568|Tolerability
1337721|NCT00620568|Schizophrenia
1337722|NCT00620542|Coronary artery disease
1337723|NCT00620529|polycystic ovary syndrome
1337724|NCT00620529|cardiovascular risk
1337725|NCT00620529|metabolism
1337726|NCT00620529|blood pressure
1337727|NCT00620529|liver fat
1337728|NCT00620529|heart rate variability
1337729|NCT00620503|PK
1337730|NCT00620503|Pharmacokinetics
1337731|NCT00620490|Epidural analgesia
1337732|NCT00620490|Contraindications
1337733|NCT00620490|Paravertebral nerve block analgesia
1337734|NCT00620490|ropivacaine
1337735|NCT00620490|Visual analogical scale
1337736|NCT00620490|Morphine
1337737|NCT00620490|Side effects
1337738|NCT00620490|Pain and thoracotomy
1337739|NCT00620451|Treatment
1337740|NCT00620451|Active
1337741|NCT00620451|Celiac
1337742|NCT00620451|Remission
1337743|NCT00620451|Induction
1337744|NCT00620438|Lumefantrine
1337745|NCT00620438|Efavirenz
1337746|NCT00620438|Nevirapine
1337747|NCT00620438|Rifampicin
1337748|NCT00620438|HIV
1337749|NCT00620425|sumatriptan
1337750|NCT00620425|Intraject
1337751|NCT00620425|Local Site Reactions
1337752|NCT00620412|influenza
1337753|NCT00620412|vaccines
1337754|NCT00620412|probiotics
1337755|NCT00620412|LGG
1337756|NCT00620399|lumbar fusion
1337757|NCT00620386|Intubating conditions
1337758|NCT00620386|Bonfils intubation fiberscope
1337759|NCT00620386|Macintosh laryngoscope
1337760|NCT00620386|neuromuscular blockade
1337761|NCT00620373|Dense breast tissue
1337762|NCT00620373|Breast Cancer Screening
1337763|NCT00620373|Molecular Breast Imaging
1337764|NCT00620373|Breast Cancer
1337765|NCT00620373|Breast
1337766|NCT00620360|dietary fructose
1337767|NCT00620360|plasma lipids
1337768|NCT00620360|healthy humans
1337769|NCT00620360|gender differences
1337770|NCT00620360|hepatic de novo lipogenesis
1337771|NCT00620347|SCLC (small cell lung cancer)
1337772|NCT00620347|ED (extensive disease)
1337773|NCT00620347|RR (response rate)
1337774|NCT00620334|ASTHMA
1337775|NCT00620295|recurrent pancreatic cancer
1337776|NCT00620295|recurrent breast cancer
1337777|NCT00620295|recurrent small cell lung cancer
1337778|NCT00620295|recurrent non-small cell lung cancer
1337779|NCT00620295|recurrent colon cancer
1337780|NCT00620295|recurrent prostate cancer
1337781|NCT00620295|recurrent head and neck cancer
1337782|NCT00620295|ovarian cancer
1337783|NCT00620295|recurrent uterine cancer
1337784|NCT00620295|recurrent kidney cancer
1337785|NCT00620295|recurrent osteosarcoma
1337786|NCT00620269|NSCLC
1337787|NCT00620269|EGFR mutation
1337788|NCT00620269|Erlotinib
1337789|NCT00620269|IP chemotherapy
1337790|NCT00620269|CCRT
1337791|NCT00620087|Atypical lobular hyperplasia
1337792|NCT00620087|Atypical ductal hyperplasia
1337793|NCT00620087|Lobular carcinoma in situ
1337794|NCT00620087|Molecular Breast Imaging
1337795|NCT00620074|invasive aspergillosis, opportunistic mold infection
1337796|NCT00620048|heart
1337797|NCT00620048|stem Cells
1337798|NCT00620048|low EF
1337799|NCT00620048|heart attack
1337800|NCT00620048|cardiomyopathy
1337801|NCT00620048|congestive heart failure
1337802|NCT00620048|cardiovascular disease
1337803|NCT00620048|Heart Failure
1337804|NCT00620048|Low Ejection Fraction
1337805|NCT00620022|indacaterol
1337806|NCT00620022|chronic obstructive pulmonary disease
1337807|NCT00620022|exercise endurance
1337808|NCT00620022|moderate to severe chronic obstructive pulmonary disease
1337809|NCT00620022|COPD
1337810|NCT00620009|Empathy
1337811|NCT00620009|Feedback
1337812|NCT00620009|Psychotherapy
1337813|NCT00619996|Prostate Cancer
1337814|NCT00619996|Sorafenib
1337815|NCT00619996|Nexavar
1337816|NCT00619996|Docetaxel
1337817|NCT00619996|Pisa
1337818|NCT00619996|Ricci
1337819|NCT00619983|Asymmetric Diabetic Proximal Motor Neuropathy
1337820|NCT00619983|Diabetic Autonomic Neuropathy
1337821|NCT00619983|Diabetic Neuralgia
1337822|NCT00619983|Diabetic Neuropathy, Painful
1337823|NCT00619983|Neuralgia, Diabetic
1337824|NCT00619983|Low back pain, chronic
1337825|NCT00619944|HIV
1337826|NCT00619944|lumefantrine
1337827|NCT00619944|lopinavir
1337828|NCT00619944|Africa
1337829|NCT00619944|Antimalarials
1337830|NCT00619944|treatment naïve
1337831|NCT00619931|Healthy adult volunteers
1337832|NCT00619918|bronchiolitis
1337833|NCT00619918|hypertonic saline
1337834|NCT00619905|Rheumatoid Arthritis
1337835|NCT00619905|Anti-interleukin-1 beta
1337836|NCT00619905|ACZ885
1337837|NCT00619892|SSRI Resistant
1337838|NCT00619892|Seroquel SR
1337839|NCT00619892|Seroquel XR
1337840|NCT00619892|Panic Disorder
1337841|NCT00619892|Comorbid Panic Disorder
1337842|NCT00619892|Quetiapine SR
1337843|NCT00619892|Quetiapine XR
1337844|NCT00619879|Leukemia, Myelogenous, Chronic
1337845|NCT00619879|Leukemia, Lymphoblastic, Acute
1337846|NCT00619879|Leukemia, Myelogenous, Acute
1337847|NCT00619879|Myeloproliferative-Myelodysplastic Diseases
1337848|NCT00619879|Juvenile Myelomonocytic Leukemia
1337849|NCT00619879|Dysmyelopoietic Syndromes
1337850|NCT00619879|Lymphoma, Malignant
1337851|NCT00619879|Stem Cell Transplantation, Hematopoietic
1337852|NCT00619879|Allogeneic Transplantation
1337853|NCT00619879|Human Leukocyte Antigens
1337854|NCT00619879|Busulfan
1337855|NCT00619879|Total Body Irradiation
1337856|NCT00619879|VP-16
1337857|NCT00619879|Etoposide
1337858|NCT00619879|Cyclophosphamide
1337859|NCT00619879|Graft-Versus-Host Disease
1337860|NCT00619866|bone mineral density
1337861|NCT00619866|NBI-56418
1337862|NCT00619866|estradiol
1337863|NCT00619866|Endometriosis
1337864|NCT00619866|Pelvic Pain
1337865|NCT00619853|Improving the assisting hand function in children with Hemiplegic Cerebral palsy
1337866|NCT00619840|ADHD
1337867|NCT00619840|Attention Deficit Hyperactivity Disorder
1337868|NCT00619840|adult
1337869|NCT00619840|methylphenidate hydrochloride
1337870|NCT00619840|Medikinet retard
1337871|NCT00619840|long-term observation
1337872|NCT00619840|controlled clinical trial
1337873|NCT00619840|safety
1337874|NCT00619840|randomized, double-blind, placebo-controlled trial
1337875|NCT00619840|treatment
1337876|NCT00619840|central nervous system stimulants
1337877|NCT00619840|therapeutic uses
1337878|NCT00619827|Sublingual immunotherapy
1337879|NCT00619827|Rhinitis
1337880|NCT00619827|Conjunctivitis
1337881|NCT00619827|Allergen challenge
1337882|NCT00619827|Allergen exposition chamber
1337883|NCT00619827|Grass pollen tablet
1337884|NCT00619827|Allergic rhinoconjunctivitis
1337885|NCT00619814|Colon polyps
1337886|NCT00619814|Fecal occult blood test
1337887|NCT00619814|Double contrast barium enema
1337888|NCT00619814|Colonoscopy
1337889|NCT00619801|Xyzal
1337890|NCT00619801|Levocetirizine
1337891|NCT00619801|Allergy
1337892|NCT00619801|Children
1337893|NCT00619801|Seasonal Allergies
1337894|NCT00619775|Carotid Artery Disease
1337895|NCT00619775|Embolic Protection
1337896|NCT00619762|Breast reconstruction
1337897|NCT00619736|Healthy
1337898|NCT00619710|skin infections
1337899|NCT00619710|MERREM
1337900|NCT00619710|PRIMAXIN IV
1337901|NCT00619710|complex abscess
1337902|NCT00619710|perirectal abscess
1337903|NCT00619710|wound infections
1337904|NCT00619710|infected ischemic/diabetic ulcers
1337905|NCT00619710|cellulitis
1337906|NCT00619710|Meropenem
1337907|NCT00619710|Imipenem-cilastatin
1337908|NCT00619671|Rituxan
1337909|NCT00619671|Rituximab
1337910|NCT00619671|Myasthenia Gravis
1337911|NCT00619671|MG
1337912|NCT00619658|telephone follow-up
1337913|NCT00619658|medical abortion
1337914|NCT00619658|induced abortion
1337915|NCT00619645|recurrent adult acute myeloid leukemia
1337916|NCT00619645|adult acute lymphoblastic leukemia in remission
1337917|NCT00619645|refractory anemia with excess blasts
1338149|NCT00619008|energy expenditure
1337918|NCT00619645|refractory anemia with ringed sideroblasts
1337919|NCT00619645|refractory anemia
1337920|NCT00619645|refractory cytopenia with multilineage dysplasia
1337921|NCT00619645|previously treated myelodysplastic syndromes
1337922|NCT00619645|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1337923|NCT00619645|adult acute myeloid leukemia in remission
1337924|NCT00619645|adult acute myeloid leukemia with inv(16)(p13;q22)
1337925|NCT00619645|adult acute myeloid leukemia with t(15;17)(q22;q12)
1337926|NCT00619645|adult acute myeloid leukemia with t(16;16)(p13;q22)
1337927|NCT00619645|adult acute myeloid leukemia with t(8;21)(q22;q22)
1337928|NCT00619645|chronic phase chronic myelogenous leukemia
1337929|NCT00619645|relapsing chronic myelogenous leukemia
1337930|NCT00619645|refractory chronic lymphocytic leukemia
1337931|NCT00619645|recurrent adult Hodgkin lymphoma
1337932|NCT00619645|refractory multiple myeloma
1337933|NCT00619645|recurrent adult acute lymphoblastic leukemia
1337934|NCT00619645|stage III chronic lymphocytic leukemia
1337935|NCT00619645|stage IV chronic lymphocytic leukemia
1337936|NCT00619645|stage III adult Hodgkin lymphoma
1337937|NCT00619645|stage IV adult Hodgkin lymphoma
1337938|NCT00619645|secondary acute myeloid leukemia
1337939|NCT00619645|recurrent small lymphocytic lymphoma
1337940|NCT00619645|stage III small lymphocytic lymphoma
1337941|NCT00619645|stage IV small lymphocytic lymphoma
1337942|NCT00619645|stage III grade 1 follicular lymphoma
1337943|NCT00619645|stage III grade 2 follicular lymphoma
1337944|NCT00619645|stage III grade 3 follicular lymphoma
1337945|NCT00619645|stage IV grade 1 follicular lymphoma
1337946|NCT00619645|stage IV grade 2 follicular lymphoma
1337947|NCT00619645|stage IV grade 3 follicular lymphoma
1337948|NCT00619645|recurrent grade 1 follicular lymphoma
1337949|NCT00619645|recurrent grade 2 follicular lymphoma
1337950|NCT00619645|recurrent grade 3 follicular lymphoma
1337951|NCT00619645|stage III adult diffuse large cell lymphoma
1337952|NCT00619645|stage III adult diffuse mixed cell lymphoma
1337953|NCT00619645|stage III adult diffuse small cleaved cell lymphoma
1337954|NCT00619645|stage IV adult diffuse large cell lymphoma
1337955|NCT00619645|stage IV adult diffuse mixed cell lymphoma
1337956|NCT00619645|stage IV adult diffuse small cleaved cell lymphoma
1337957|NCT00619645|recurrent adult diffuse large cell lymphoma
1337958|NCT00619645|recurrent adult diffuse mixed cell lymphoma
1337959|NCT00619645|recurrent adult diffuse small cleaved cell lymphoma
1337960|NCT00619645|stage III adult immunoblastic large cell lymphoma
1337961|NCT00619645|stage IV adult immunoblastic large cell lymphoma
1337962|NCT00619645|recurrent adult immunoblastic large cell lymphoma
1337963|NCT00619645|stage III adult lymphoblastic lymphoma
1337964|NCT00619645|stage IV adult lymphoblastic lymphoma
1337965|NCT00619645|recurrent adult lymphoblastic lymphoma
1337966|NCT00619645|stage III adult Burkitt lymphoma
1337967|NCT00619645|stage IV adult Burkitt lymphoma
1337968|NCT00619645|recurrent adult Burkitt lymphoma
1337969|NCT00619645|stage I multiple myeloma
1337970|NCT00619645|stage II multiple myeloma
1337971|NCT00619645|stage III multiple myeloma
1337972|NCT00619645|de novo myelodysplastic syndromes
1337973|NCT00619645|secondary myelodysplastic syndromes
1337974|NCT00619619|MDD
1337975|NCT00619619|Child
1337976|NCT00619619|Adolescent
1337977|NCT00619619|Pharmacokinetic
1337978|NCT00619619|Outpatient
1337979|NCT00619619|Pediatrics
1337980|NCT00619619|Depressive Disorder
1337981|NCT00619619|Major
1337982|NCT00619606|prevention of hypoxia
1337983|NCT00619606|prevention of hypercapnia
1337984|NCT00619593|Heart failure
1338110|NCT00619164|Coronary Thrombosis
1337985|NCT00619593|Ventricular Fibrillation
1337986|NCT00619593|Sudden cardiac death
1337987|NCT00619593|Hospitalization due to heart failure
1337988|NCT00619593|Implantable cardioverter-defibrillator
1337989|NCT00619593|Risk of 1st heart failure hospitalization
1337990|NCT00619580|E coli
1337991|NCT00619567|Cognition
1337992|NCT00619567|Rehabilitation
1337993|NCT00619567|Cognitive Stimulation
1337994|NCT00619567|Human Immunodeficiency Virus
1337995|NCT00619567|AIDS
1337996|NCT00619554|Healthy volunteers
1337997|NCT00619541|HCC
1337998|NCT00619541|Sorafenib
1337999|NCT00619541|Pisa
1338000|NCT00619541|Ricci
1338001|NCT00619541|5-FU
1338002|NCT00619541|5FU
1338003|NCT00619541|5 FU
1338004|NCT00619541|Advanced HCC
1338005|NCT00619528|Transplants
1338006|NCT00619528|Kidney Transplantation
1338007|NCT00619528|Immunosuppression
1338008|NCT00619528|HLA Antigens
1338009|NCT00619528|Stem Cells
1338010|NCT00619528|Bone Marrow
1338011|NCT00619515|adenocarcinoma of the prostate
1338012|NCT00619515|stage I prostate cancer
1338013|NCT00619515|stage II prostate cancer
1338014|NCT00619502|Hepatitis B
1338015|NCT00619502|Polio
1338016|NCT00619502|Diphtheria
1338017|NCT00619502|Pertussis
1338018|NCT00619502|H.influenzae type b
1338019|NCT00619476|Neuropathic Pain
1338020|NCT00619476|Post-herpetic neuralgia
1338021|NCT00619476|PHN
1338022|NCT00619463|Traumatic Brain Injury
1338023|NCT00619463|Exercise
1338024|NCT00619463|Cognition
1338025|NCT00619463|Brain Derived Neurotrophic Factor (BDNF)
1338026|NCT00619463|peripheral vascular endothelial growth factor (VEGF)
1338027|NCT00619450|atrial fibrillation
1338028|NCT00619450|cardiac pacing
1338029|NCT00619450|CAT scanner
1338030|NCT00619437|schizophrenia
1338031|NCT00619437|genetics
1338032|NCT00619437|family
1338033|NCT00619437|multiplex
1338034|NCT00619437|haplotypes
1338035|NCT00619424|erlotinib
1338036|NCT00619424|pharmacokinetics
1338037|NCT00619424|Solid tumors
1338038|NCT00619424|pemetrexed
1338039|NCT00619424|anti-angiogenesis
1338040|NCT00619424|pazopanib (GW786034)
1338041|NCT00619424|cytokine and angiogenic factors
1338042|NCT00619411|Major Depression
1338043|NCT00619411|Dysthymic Disorder
1338044|NCT00619411|Adjustment Disorder
1338045|NCT00619411|With Depressed Mood
1338046|NCT00619411|Depressive
1338047|NCT00619411|Disorder Not
1338048|NCT00619411|Otherwise
1338049|NCT00619411|Specified
1338050|NCT00619411|Adolescent
1338051|NCT00619411|Psychotherapy
1338052|NCT00619398|FK506
1338053|NCT00619398|tacrolimus
1338054|NCT00619398|prograf
1338055|NCT00619398|Liver transplantation
1338056|NCT00619385|Pharmacokinetics
1338057|NCT00619372|OKT3
1338058|NCT00619372|beta-glucosylceramide
1338059|NCT00619372|oral tolerance
1338060|NCT00619372|anti-CD3
1338061|NCT00619372|Safety assessment and healthy volunteers
1338062|NCT00619346|Safety
1338063|NCT00619346|Tolerability
1338064|NCT00619346|Assessment of potential adverse events and/or laboratory abnormalities
1338065|NCT00619320|HIV primary prevention
1338066|NCT00619320|Health promotion
1338067|NCT00619320|Health behavior
1338068|NCT00619320|Risk reduction behavior
1338069|NCT00619320|Sexual behavior
1338070|NCT00619320|Safe sex
1338071|NCT00619320|Women's health
1338072|NCT00619320|Minority health
1338073|NCT00619320|Pregnant Women
1338074|NCT00619320|HIV seronegativity
1338075|NCT00619294|Coronary Vasospasm
1338076|NCT00619294|Endothelium, Vascular
1338077|NCT00619294|Vasodilation
1338078|NCT00619294|Hyperemia
1338079|NCT00619281|Cardiac surgery
1338080|NCT00619281|Low cardiac output syndrome
1338081|NCT00619281|Mortality
1338082|NCT00619281|Morbidity
1338083|NCT00619268|Temsirolimus
1338084|NCT00619268|Bevacizumab
1338085|NCT00619268|Metastatic renal cell carcinoma
1338086|NCT00619268|Non-progression
1338087|NCT00619255|Adolescents
1338088|NCT00619255|Quality Assurance and Improvement
1338089|NCT00619255|Substance Abuse
1338090|NCT00619255|Posttraumatic Stress
1338091|NCT00619255|Family Centered Care
1338092|NCT00619255|Trauma Systems
1338093|NCT00619242|Esophageal cancer
1338094|NCT00619229|Alprostadil
1338095|NCT00619229|prostaglandin E1
1338096|NCT00619229|Prostavasin®
1338097|NCT00619229|macular degeneration
1338098|NCT00619216|Orthotopic Liver Transplant Recipients with GI disturbance
1338099|NCT00619203|Bacterial meningitis
1338100|NCT00619203|glycerol
1338101|NCT00619203|high dose paracetamol
1338102|NCT00619203|children
1338103|NCT00619190|open label
1338104|NCT00619190|aripiprazole
1338105|NCT00619190|children
1338106|NCT00619190|adolescents
1338107|NCT00619190|autism spectrum disorders
1338108|NCT00619164|Platelet Aggregation Inhibitors
1338109|NCT00619164|Coronary Stenosis
1338111|NCT00619151|aortic valve
1338112|NCT00619151|heart valve
1338113|NCT00619151|valve replacement
1338114|NCT00619151|Valve disease
1338115|NCT00619138|Cognitive therapy
1338116|NCT00619138|Stepped care
1338117|NCT00619138|Self-help
1338118|NCT00619138|Internet
1338119|NCT00619138|Anxiety
1338120|NCT00619112|adult glioblastoma
1338121|NCT00619112|adult gliosarcoma
1338122|NCT00619112|adult anaplastic astrocytoma
1338123|NCT00619112|adult anaplastic oligodendroglioma
1338124|NCT00619112|adult mixed glioma
1338125|NCT00619112|recurrent adult brain tumor
1338126|NCT00619099|Myelodysplastic Syndrome
1338127|NCT00619099|Decitabine
1338128|NCT00619099|Dacogen
1338129|NCT00619099|MGI PHARMA, Inc.
1338130|NCT00619086|thyroidectomy
1338131|NCT00619086|dexamethasone
1338132|NCT00619086|steroid
1338133|NCT00619086|nausea
1338134|NCT00619073|blood platelets
1338135|NCT00619073|platelet aggregation inhibitors
1338136|NCT00619073|antiplatelet drugs
1338137|NCT00619073|clopidogrel
1338138|NCT00619060|skin cancer
1338139|NCT00619060|healthy, no evidence of disease
1338140|NCT00619021|recurrent non-small cell lung cancer
1338141|NCT00619021|stage I non-small cell lung cancer
1338142|NCT00619021|stage II non-small cell lung cancer
1338143|NCT00619008|obesity
1338144|NCT00619008|low carbohydrate diet
1338145|NCT00619008|high complex carbohydrate diet
1338146|NCT00619008|weight regulation hormones
1338147|NCT00619008|hunger
1338148|NCT00619008|satiety
1338150|NCT00619008|body composition
1338151|NCT00619008|weight loss
1338152|NCT00618982|Kidney cancer,
1338153|NCT00618982|Sorafenib,
1338154|NCT00618982|Dose escalation,
1338155|NCT00618982|No previous treatment
1338156|NCT00618969|Haploidentical
1338157|NCT00618969|peripheral blood stem cell transplantation
1338158|NCT00618969|leukemia
1338159|NCT00618969|myeloma
1338160|NCT00618969|Hodgkin's disease
1338161|NCT00618969|non-Hodgkin's lymphoma
1338162|NCT00618956|NSRI
1338163|NCT00618956|milnacipran
1338164|NCT00618956|fibromyalgia
1338165|NCT00618956|blood pressure
1338166|NCT00618956|hypertension
1338167|NCT00618917|NSCLC
1338168|NCT00618917|lung cancer
1338169|NCT00618917|chemotherapy
1338170|NCT00618917|radiation therapy
1338171|NCT00618917|radiation toxicity
1338172|NCT00618904|Probiotics
1338173|NCT00618904|Functional Gastrointestinal Symptoms
1338174|NCT00618865|Omega-3 Fatty Acids
1338175|NCT00618865|Major Depressive Disorder
1338176|NCT00618865|Pregnancy
1338177|NCT00618865|Women during pregnancy and after childbirth are more vulnerable to psychiatric disorders
1338178|NCT00618865|Pharmacotherapy for depression during pregnancy is a clinical dilemma.
1338179|NCT00618865|Omega-3 polyunsaturated fatty acids (PUFAs) might be a promising alternative of treatment for pregnant women with depression.
1338180|NCT00618852|Pediatrics
1338181|NCT00618852|Erythrocyte Transfusion
1338182|NCT00618852|Furosemide
1338183|NCT00618852|Fluid Overload
1338184|NCT00618839|Complex skin defects
1338185|NCT00618839|Burns
1338186|NCT00618839|Wound infection
1338187|NCT00618839|Skin trauma
1338188|NCT00618826|Breast cancer
1338189|NCT00618800|Falls
1338190|NCT00618800|Elderly
1338191|NCT00618800|Injury
1338192|NCT00618800|Medication
1338193|NCT00618800|Pharmacy
1338194|NCT00618800|Pharmacist
1338195|NCT00618761|glucose clamp
1338196|NCT00618761|beta-cell
1338197|NCT00618748|Bipolar
1338198|NCT00618709|Healthy volunteers
1338199|NCT00618696|recurrent adult acute lymphoblastic leukemia
1338200|NCT00618696|recurrent adult acute myeloid leukemia
1338201|NCT00618696|secondary acute myeloid leukemia
1338202|NCT00618696|previously treated myelodysplastic syndromes
1338203|NCT00618696|blastic phase chronic myelogenous leukemia
1338204|NCT00618696|relapsing chronic myelogenous leukemia
1338205|NCT00618696|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1338206|NCT00618696|adult acute myeloid leukemia with inv(16)(p13;q22)
1338207|NCT00618696|adult acute myeloid leukemia with t(15;17)(q22;q12)
1338208|NCT00618696|adult acute myeloid leukemia with t(16;16)(p13;q22)
1338209|NCT00618696|adult acute myeloid leukemia with t(8;21)(q22;q22)
1338210|NCT00618683|AVNRT
1338211|NCT00618683|Atrioventricular
1338212|NCT00618683|nodal reentrant circuit
1338213|NCT00618683|nodal reentrant tachycardia
1338214|NCT00618683|Paroxysmal supraventricular tachycardia
1338215|NCT00618670|aging
1338216|NCT00618670|gait
1338217|NCT00618670|musculoskeletal disorder therapy
1338218|NCT00618670|peripheral blood vessel disorder
1338219|NCT00618670|muscle function
1338220|NCT00618670|muscle strength
1338221|NCT00618670|quality of life
1338222|NCT00618657|pre-operative
1338223|NCT00618657|neo-adjuvant
1338224|NCT00618657|triple negative
1338225|NCT00618657|HER2 positive
1338226|NCT00618657|hormone receptor positive
1338227|NCT00618657|breast
1338228|NCT00618657|Carboplatin
1338229|NCT00618657|Nab-paclitaxel
1338230|NCT00618657|Trastuzumab
1338231|NCT00618657|Bevacizumab
1338232|NCT00618657|Inflammatory
1338233|NCT00618631|Smoking
1338234|NCT00618631|Nicotine
1338235|NCT00618631|Endogenous Opioids
1338236|NCT00618631|PET Study
1338237|NCT00618631|Carfentanil
1338238|NCT00618605|HIV Seronegativity
1338239|NCT00618605|HIV Preventative Vaccine
1338240|NCT00618592|carbohydrate supplementation
1338241|NCT00618592|cardiac surgery
1338242|NCT00618592|spine surgery
1338243|NCT00618592|insulin resistance
1338244|NCT00618592|insulin sensitivity
1338245|NCT00618592|short insulin tolerance test
1338246|NCT00618592|HOMA
1338247|NCT00618592|outcomes
1338248|NCT00618579|Interaction with LMWH or warfarin
1338249|NCT00618566|Women with physical Disabilities
1338250|NCT00618566|Secondary Conditions
1338251|NCT00618566|Depression
1338252|NCT00618566|Cognitive Behavioral Therapy
1338253|NCT00618566|Consumer Control
1338254|NCT00618553|Lung Cancer
1338255|NCT00618553|Pulmonary Rehabilitation
1338256|NCT00618553|Questionnaire
1338257|NCT00618553|Survey
1338258|NCT00618553|Lung Function
1338259|NCT00618553|Quality of Life
1338260|NCT00618540|childhood Langerhans cell histiocytosis
1338261|NCT00618527|relapsing remitting multiple sclerosis
1338262|NCT00618527|multiple sclerosis
1338263|NCT00618514|Varicose Veins
1338264|NCT00618514|Laser Ablation
1338265|NCT00618514|Laser Wire Fibers
1338266|NCT00618501|untreated adult acute lymphoblastic leukemia
1338267|NCT00618488|Probiotics
1338268|NCT00618488|BB12
1338269|NCT00618488|Gastrointestinal Symptoms
1338270|NCT00618475|Depression
1338271|NCT00618475|End Stage Renal Disease
1338272|NCT00618475|Kidney Disease
1338273|NCT00618475|Mental Health
1338274|NCT00618462|Cognitive Behavioral Therapy
1338275|NCT00618462|Pathological Gambling
1338276|NCT00618449|Trachoma
1338277|NCT00618449|Chlamydia trachomatis
1338278|NCT00618436|Seizures
1338279|NCT00618436|Traumatic Brain Injury
1338280|NCT00618436|Subarachnoid Hemorrhage
1338281|NCT00618423|Neuropathic pain
1338282|NCT00618423|Chronic pain
1338283|NCT00618423|Acute postoperative pain
1338284|NCT00618423|Ketamine
1338285|NCT00618423|Back surgery
1338286|NCT00618423|Anesthesia
1338287|NCT00618423|Perioperative
1338288|NCT00618397|ketamine
1338289|NCT00618397|pharmacokinetics
1338290|NCT00618397|sedation
1338291|NCT00618397|critical care
1338292|NCT00618397|opioid tolerance
1338293|NCT00618397|NMDA Antagonist
1338294|NCT00618384|TACE
1338295|NCT00618384|hepatocellular carcinoma
1338296|NCT00618371|Intensification
1338297|NCT00618371|HIV viremia
1338298|NCT00618371|Human Immunodeficiency Virus
1338299|NCT00618345|refractory multiple myeloma
1338300|NCT00618293|intraoperative bleeding
1338301|NCT00618293|aortic-valve replacement
1338302|NCT00618293|aortic stenosis
1338303|NCT00618293|Von Willebrand
1338304|NCT00618293|HEAMATE
1338305|NCT00618254|Prevention of nausea and vomiting associated with radiation or chemotherapy
1338306|NCT00618241|interactions
1338307|NCT00618241|neuropathic pain
1338308|NCT00618241|pharmacokinetics
1338309|NCT00618215|cluster-randomised trial
1338310|NCT00618215|routine oral examination
1338311|NCT00618215|implementation research
1338312|NCT00618215|practice based research
1338313|NCT00618215|CPG
1338314|NCT00618215|recall interval assignment for routine oral examination
1338315|NCT00618215|prescription bitewing radiographs
1338316|NCT00618215|preventive advice and feed back oral disease
1338317|NCT00618176|Acquired Immunodeficiency Syndrome
1338318|NCT00618176|adverse effects
1338319|NCT00618176|Treatment Outcome
1338320|NCT00618176|Drug Resistance, Viral
1338321|NCT00618176|treatment naïve
1338322|NCT00618163|Anti-inflammatory
1338323|NCT00618150|GERD
1338324|NCT00618150|Dyspepsia
1338325|NCT00618150|Education
1338326|NCT00618150|Information
1338327|NCT00618137|Chronic obstructive pulmonary disease
1338328|NCT00618137|Gene expression profiling
1338329|NCT00618137|Inert dusts
1338330|NCT00618137|Natural course
1338331|NCT00618137|Prospective assessment
1338332|NCT00618124|solid tumor malignancy, SU011248, sunitinib, capecitabine, Phase 1
1338333|NCT00618111|Prevention of nausea and vomiting associated with radiation or chemotherapy
1338334|NCT00618098|anticoagulant reversal
1338335|NCT00618098|urgent surgery
1338336|NCT00618098|invasive procedures
1338337|NCT00618098|vitamin K
1338338|NCT00618098|prothrombin complex concentrate
1338339|NCT00618072|hyperinsulinemia
1338340|NCT00618072|insulin resistance
1338341|NCT00618072|perimenopause
1338342|NCT00618072|obesity
1338343|NCT00618072|overweight
1338344|NCT00618072|women
1338345|NCT00618033|Hemodialysis
1338346|NCT00618033|ESRD
1338347|NCT00618020|CTO
1338348|NCT00618020|Chronic Total Occlusion
1338349|NCT00618020|Revascularization
1338350|NCT00617994|psoriasis
1338351|NCT00617981|hepatocellular carcinoma
1338352|NCT00617981|liver cancer
1338353|NCT00617942|Breast Cancer
1338354|NCT00617929|chronic myelogenous leukemia
1338355|NCT00617929|acute lymphoblastic leukemia
1338356|NCT00617929|chronic myeloid leukemia
1338357|NCT00617929|lymphoblastic leukemia
1338358|NCT00617929|acute myeloid leukemia
1338359|NCT00617929|chronic eosinophilic leukemia
1338360|NCT00617929|primary myelofibrosis
1338361|NCT00617929|chronic myelomonocytic leukemia
1338362|NCT00617929|chronic neutrophilic leukemia
1338363|NCT00617929|de novo myelodysplastic syndromes
1338364|NCT00617929|disseminated neuroblastoma
1338365|NCT00617929|juvenile myelomonocytic leukemia
1338366|NCT00617929|Burkitt lymphoma
1338367|NCT00617929|rhabdomyosarcoma
1338368|NCT00617929|myelodysplastic syndromes
1338369|NCT00617929|Hodgkin lymphoma
1338370|NCT00617929|lymphoblastic lymphoma
1338371|NCT00617929|breast cancer
1338372|NCT00617929|follicular lymphoma
1338373|NCT00617929|mantle cell lymphoma
1338374|NCT00617929|marginal zone lymphoma
1338375|NCT00617929|recurrent neuroblastoma
1338376|NCT00617929|recurrent ovarian epithelial cancer
1338377|NCT00617929|recurrent ovarian germ cell tumor
1338378|NCT00617929|recurrent small lymphocytic lymphoma
1338379|NCT00617929|recurrent malignant testicular germ cell tumor
1338380|NCT00617929|recurrent Wilms tumor and other childhood kidney tumors
1338381|NCT00617929|recurrent/refractory childhood Hodgkin lymphoma
1338382|NCT00617929|refractory hairy cell leukemia
1338383|NCT00617929|refractory multiple myeloma
1338384|NCT00617929|relapsing chronic myelogenous leukemia
1338385|NCT00617929|secondary acute myeloid leukemia
1338386|NCT00617929|secondary myelodysplastic syndromes
1338387|NCT00617929|splenic marginal zone lymphoma
1338388|NCT00617929|stage I multiple myeloma
1338389|NCT00617929|stage II multiple myeloma
1338390|NCT00617929|stage III multiple myeloma
1338391|NCT00617929|stage II ovarian epithelial cancer
1338392|NCT00617929|stage III adult Burkitt lymphoma
1338393|NCT00617929|stage III adult diffuse large cell lymphoma
1338394|NCT00617929|stage III adult diffuse mixed cell lymphoma
1338395|NCT00617929|stage III adult diffuse small cleaved cell lymphoma
1338396|NCT00617929|stage III adult Hodgkin lymphoma
1338397|NCT00617929|stage III adult immunoblastic large cell lymphoma
1338398|NCT00617929|stage III adult lymphoblastic lymphoma
1338399|NCT00617929|stage III chronic lymphocytic leukemia
1338400|NCT00617929|stage III grade 1 follicular lymphoma
1338401|NCT00617929|stage III grade 2 follicular lymphoma
1338402|NCT00617929|stage III grade 3 follicular lymphoma
1338403|NCT00617929|stage III mantle cell lymphoma
1338404|NCT00617929|stage III marginal zone lymphoma
1338405|NCT00617929|stage III ovarian epithelial cancer
1338406|NCT00617929|stage III small lymphocytic lymphoma
1338407|NCT00617929|stage III malignant testicular germ cell tumor
1338408|NCT00617929|stage IIIA breast cancer
1338409|NCT00617929|stage IIIB breast cancer
1338410|NCT00617929|stage IIIC breast cancer
1338411|NCT00617929|stage IV adult Burkitt lymphoma
1338412|NCT00617929|stage IV adult diffuse large cell lymphoma
1338413|NCT00617929|stage IV adult diffuse mixed cell lymphoma
1338414|NCT00617929|stage IV adult diffuse small cleaved cell lymphoma
1338415|NCT00617929|stage IV adult Hodgkin lymphoma
1338416|NCT00617929|stage IV adult immunoblastic large cell lymphoma
1338417|NCT00617929|stage IV adult lymphoblastic lymphoma
1338418|NCT00617929|stage IV breast cancer
1338419|NCT00617929|stage IV chronic lymphocytic leukemia
1338420|NCT00617929|stage IV grade 1 follicular lymphoma
1338421|NCT00617929|stage IV grade 2 follicular lymphoma
1338422|NCT00617929|stage IV grade 3 follicular lymphoma
1338423|NCT00617929|stage IV mantle cell lymphoma
1338424|NCT00617929|stage IV marginal zone lymphoma
1338425|NCT00617929|stage IV ovarian epithelial cancer
1338426|NCT00617929|stage IV small lymphocytic lymphoma
1338427|NCT00617929|refractory chronic lymphocytic leukemia
1338428|NCT00617916|hyperspectral imaging
1338429|NCT00617916|tissue oxygenation
1338430|NCT00617916|diabetic foot ulcers
1338431|NCT00617916|wound healing
1338432|NCT00617916|prevention
1338433|NCT00617903|rosacea
1338434|NCT00617903|papulopustular
1338435|NCT00617903|azelaic acid
1338436|NCT00617903|foam
1338437|NCT00617890|anti-IGF-1R
1338438|NCT00617851|Influenza
1338439|NCT00617851|adults
1338440|NCT00617851|different lots
1338441|NCT00617851|trivalent subunit influenza virus vaccine (IVV)
1338442|NCT00617851|trivalent subunit influenza vaccine
1338443|NCT00617838|Celiac disease
1338444|NCT00617838|genetic risk
1338445|NCT00617838|gluten introduction
1338446|NCT00617838|predicting antibodies
1338447|NCT00617825|chronic venous disorders
1338448|NCT00617825|cryotherapy
1338449|NCT00617825|skin microcirculation
1338450|NCT00617825|skin temperature
1338451|NCT00617812|Vaccine
1338452|NCT00617812|Prevention
1338453|NCT00617812|Diphtheria
1338454|NCT00617812|Tetanus
1338455|NCT00617812|Pertussis
1338456|NCT00617812|Hepatitis B
1338457|NCT00617812|Haemophilus influenzae type b
1338458|NCT00617812|Healthy infants
1338459|NCT00617799|stage IV renal cell cancer
1338460|NCT00617799|stage IV melanoma
1338461|NCT00617786|urinary urgency
1338462|NCT00617786|urinary frequency
1338463|NCT00617786|urge incontinence
1338464|NCT00617786|sacral neuromodulation therapy
1338465|NCT00617786|urgency
1338466|NCT00617786|frequency
1338467|NCT00617773|recurrent ovarian epithelial cancer
1338468|NCT00617773|recurrent fallopian tube cancer
1338469|NCT00617773|recurrent primary peritoneal cancer
1338470|NCT00617747|Zolmitriptan
1338471|NCT00617747|ZOMIG
1338472|NCT00617747|migraine
1338473|NCT00617747|headache response
1338474|NCT00617747|headache
1338475|NCT00617747|headache pain
1338476|NCT00617734|Squamous Cell Carcinoma in Head and Neck
1338477|NCT00617734|Prior Platinum-based chemotherapy
1338478|NCT00617734|Cetuximab
1338479|NCT00617734|Erbitux
1338480|NCT00617734|IMC-A12
1338481|NCT00617721|Defective gene(s) in plasma membrane remodelling.
1338482|NCT00617721|Scott syndrome,
1338483|NCT00617721|Reduced prothrombin consumption,
1338484|NCT00617721|Circulating biomakers of scott syndrome
1338485|NCT00617695|Zolmitriptan
1338486|NCT00617695|ZOMIG
1338487|NCT00617695|migraine
1338488|NCT00617695|headache response
1338489|NCT00617695|headache
1338490|NCT00617695|headache pain
1338491|NCT00617682|Maternal immunization
1338492|NCT00617682|Pneumococcal conjugate vaccine
1338493|NCT00617682|Otitis media
1338494|NCT00617669|Hormone Resistant Prostate Cancer
1338495|NCT00617669|Endothelin A Receptor Antagonist
1338496|NCT00617669|Endothelin A
1338497|NCT00617669|Endothelin A antagonist
1338498|NCT00617656|LUNG CANCER
1338499|NCT00617643|Nevirapine
1338500|NCT00617643|Rifampicin
1338501|NCT00617643|Pharmacokinetics
1338502|NCT00617617|isoflavones
1338503|NCT00617617|soy
1338504|NCT00617604|kidney transplant
1338505|NCT00617604|alefacept
1338506|NCT00617591|Lenalidomide
1338507|NCT00617591|Revlimid
1338508|NCT00617591|Pegylated Liposomal Doxorubicin
1338509|NCT00617591|Doxil
1338510|NCT00617591|Dexamethasone
1338511|NCT00617591|Decadron
1338512|NCT00617578|Antitachy pacing
1338513|NCT00617578|Implantable cardioverter-defibrillator
1338514|NCT00617552|postoperative ileus
1338515|NCT00617552|POI
1338516|NCT00617552|major open abdominal surgery
1338517|NCT00617539|recurrent breast cancer
1338518|NCT00617539|stage IV breast cancer
1338519|NCT00617539|male breast cancer
1338520|NCT00617539|tumors metastatic to brain
1338521|NCT00617526|HIV
1338522|NCT00617526|treatment naïve
1338523|NCT00617500|climacteric
1338524|NCT00617500|complementary therapy
1338525|NCT00617500|hormonal replacement therapy
1338526|NCT00617474|erythropoietin
1338527|NCT00617474|kidney allograft survival
1338528|NCT00617474|Recombinant Erythropoietin
1338529|NCT00617474|erythropoietin (Epo)-induced protein 29, human
1338530|NCT00617461|Post-herpetic neuralgia(PHN)
1338531|NCT00617461|Neuropathic pain
1338532|NCT00617448|diathermy hemorrhoids
1338533|NCT00617448|Ligasure
1338534|NCT00617448|randomized controlled trial
1338535|NCT00617448|Postoperative pain
1338536|NCT00617448|Surgical Procedure, Ambulatory
1338537|NCT00617448|Local Anesthesia
1338538|NCT00617448|Safety procedure long term
1338539|NCT00617448|Day Surgery
1338540|NCT00617435|Trans fatty acid
1338541|NCT00617435|Insulin resistance
1338542|NCT00617435|Skeletal muscle
1338543|NCT00617435|Adipose tissue
1338544|NCT00617409|SCLC
1338545|NCT00617409|vaccine
1338546|NCT00617409|immunize
1338547|NCT00617396|Irritable Bowel Syndrome
1338548|NCT00617396|Seroquel
1338549|NCT00617396|Abdominal Pain
1338550|NCT00617383|demyelinating disease
1338551|NCT00617383|multiple sclerosis
1338552|NCT00617383|female monozygotic identical twins
1338553|NCT00617383|MS
1338554|NCT00617383|non-concordant
1338555|NCT00617383|clinically isolated syndrome - CIS
1338556|NCT00617383|brain MRI
1338557|NCT00617383|proteomics
1338558|NCT00617370|CYCLOPHOSPHAMIDE (CYTOXAN)
1338559|NCT00617370|EPIRUBICIN
1338560|NCT00617370|PEGFILGRASTIM
1338561|NCT00617370|TAXOL (PACLITAXEL)
1338562|NCT00617357|incisional hernia
1338563|NCT00617357|abdominal hernia repair
1338564|NCT00617357|Ventral incisional hernia repair
1338565|NCT00617344|Dengue fever
1338566|NCT00617344|Dengue hemorrhagic fever
1338567|NCT00617344|Dengue virus
1338568|NCT00617331|vaccine, priming, influenza, flu, A/H9N2
1338569|NCT00617318|Pomegranate
1338570|NCT00617318|Influenza
1338571|NCT00617318|Common Cold
1338572|NCT00617318|Cough
1338573|NCT00617318|Severity
1338574|NCT00617318|Efficacy
1338575|NCT00617305|ambrisentan
1338576|NCT00617305|PAH
1338577|NCT00617305|combination therapy
1338578|NCT00617305|phosphodiesterase type-5 inhibitor (PDE-5i)
1338579|NCT00617305|cardiovascular
1338580|NCT00617305|endothelin receptor antagonist
1338581|NCT00617305|ERA
1338582|NCT00617292|21-hydroxylase deficiency
1338583|NCT00617292|21OHD
1338584|NCT00617292|CAH
1338585|NCT00617266|tobacco, cessation, BPO, RCT, KAP
1338586|NCT00617240|antipsychotic
1338587|NCT00617240|metformin
1338588|NCT00617240|children
1338589|NCT00617240|adolescents
1338590|NCT00617227|Enteral vancomycin therapy, serum vancomycin levels, renal failure
1338591|NCT00617214|Schizophrenia
1338592|NCT00617214|Integrated care program
1338593|NCT00617214|Seroquel
1338594|NCT00617201|cocaine
1338595|NCT00617201|dependence
1338596|NCT00617201|stimulants
1338597|NCT00617188|recurrent ovarian epithelial cancer
1338598|NCT00617175|Implantable Cardiac Defibrillator
1338599|NCT00617175|therapies reduction
1338600|NCT00617175|Shocks
1338601|NCT00617175|Quality of Life
1338602|NCT00617149|exercise,
1338603|NCT00617149|excessive weight gain during pregnancy
1338604|NCT00617136|Surgery
1338605|NCT00617136|Anesthesia
1338606|NCT00617136|Hypothermia
1338607|NCT00617136|Temperature
1338608|NCT00617136|Perioperative
1338609|NCT00617136|Temperature Management
1338610|NCT00617110|diesel exhaust particles
1338611|NCT00617110|live attenuated influenza virus vaccine
1338612|NCT00617110|flu vaccine
1338613|NCT00617097|Pain associated with first trimester surgical abortion
1338614|NCT00617084|Drug Eluting Stents
1338615|NCT00617084|Interventional Cardiology
1338616|NCT00617071|colon cancer
1338617|NCT00617071|rectal cancer
1338618|NCT00617058|antipsychotic
1338619|NCT00617058|metformin
1338620|NCT00617058|children
1338621|NCT00617058|adolescents
1338622|NCT00617045|Post Partum Depression
1338623|NCT00617006|Anesthesia Workspace
1338624|NCT00617006|Hospital Acquired Infections
1338625|NCT00617006|Hand Hygiene
1338626|NCT00617006|Alcohol Based Cleanser
1338627|NCT00617006|Bacterial Contamination
1338628|NCT00616980|PAD
1338629|NCT00616980|PVD
1338630|NCT00616980|CLI
1338631|NCT00616980|Stem Cells
1338632|NCT00616967|stage II breast cancer
1338633|NCT00616967|stage IIIA breast cancer
1338634|NCT00616967|stage IIIB breast cancer
1338635|NCT00616967|stage IIIC breast cancer
1338636|NCT00616967|ductal breast carcinoma
1338637|NCT00616967|lobular breast carcinoma
1338638|NCT00616954|mismatched
1338639|NCT00616954|Stem cell transplatation
1338640|NCT00616954|Bone marrow transplantation
1338641|NCT00616954|T cell depletion
1338642|NCT00616954|engraftment
1338643|NCT00616954|Patients undergoing allogeneic haplo-SCT
1338644|NCT00616941|NY-ESO-1 OLP4
1338645|NCT00616941|Ovarian Cancer
1338646|NCT00616941|Cancer Vaccine
1338647|NCT00616928|vaccines
1338648|NCT00616928|immunogenicity
1338649|NCT00616928|human
1338650|NCT00616928|safety
1338651|NCT00616928|influenza
1338652|NCT00616915|Wellbutrin SR
1338653|NCT00616902|Zemplar, paricalcitol, PRIMO II
1338654|NCT00616876|lactulose
1338655|NCT00616876|prebiotic
1338656|NCT00616876|premature infant
1338657|NCT00616876|enteral feeding
1338658|NCT00616876|stools
1338659|NCT00616876|lactobacillus
1338660|NCT00616876|nutrition
1338661|NCT00616876|growth
1338662|NCT00616850|Total Knee Arthroplasty
1338663|NCT00616850|Intravenous Lidocaine Infusion
1338664|NCT00616850|Femoral Block Catheter
1338665|NCT00616837|Remote consultation/*methods
1338666|NCT00616837|Orthopaedics methods
1338667|NCT00616837|Telemedicine
1338668|NCT00616837|Follow-up study
1338669|NCT00616837|Ambulatory care
1338670|NCT00616824|Acellular dermal matrix
1338671|NCT00616824|breast reconstruction
1338672|NCT00616824|tissue expander
1338673|NCT00616824|postoperative pain
1338674|NCT00616824|complication
1338675|NCT00616824|pain
1338676|NCT00616824|patient satisfaction
1338677|NCT00616811|Type 2 diabetes, vildagliptin
1338678|NCT00616785|stage IIIA non-small cell lung cancer
1338679|NCT00616785|stage IIIB non-small cell lung cancer
1338680|NCT00616759|Depression
1338681|NCT00616759|Electroconvulsive therapy
1338682|NCT00616746|Alcohol, nicotine
1338683|NCT00616733|Multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, MRI
1338684|NCT00616720|stage I multiple myeloma
1338685|NCT00616720|stage II multiple myeloma
1338686|NCT00616720|stage III multiple myeloma
1338687|NCT00616720|refractory multiple myeloma
1338688|NCT00616707|Inflammation
1338689|NCT00616707|Oxidative Stress
1338690|NCT00616707|Microalbuminuria
1338691|NCT00616668|Transtibial amputees due to vascular diseases.
1338692|NCT00616655|Anxiety
1338693|NCT00616642|recurrent pituitary tumor
1338694|NCT00616642|ACTH-producing pituitary tumor
1338695|NCT00616642|nonfunctioning pituitary tumor
1338696|NCT00616616|appendectomy
1338697|NCT00616616|cholecystectomy
1338698|NCT00616616|gastric banding
1338699|NCT00616616|adrenalectomy
1338700|NCT00616616|Gastric lap-band placement
1338701|NCT00616603|Total Knee Arthroplasty.
1338702|NCT00616603|Sciatic nerve Blocks.
1338703|NCT00616603|Dexamethasone.
1338704|NCT00616590|sleep disorders
1338705|NCT00616590|psychosocial effects of cancer and its treatment
1338706|NCT00616590|fatigue
1338707|NCT00616590|recurrent squamous cell carcinoma of the hypopharynx
1338708|NCT00616590|stage I squamous cell carcinoma of the hypopharynx
1338709|NCT00616590|stage II squamous cell carcinoma of the hypopharynx
1338710|NCT00616590|stage III squamous cell carcinoma of the hypopharynx
1338711|NCT00616590|stage IV squamous cell carcinoma of the hypopharynx
1338712|NCT00616590|recurrent squamous cell carcinoma of the larynx
1338713|NCT00616590|recurrent verrucous carcinoma of the larynx
1338714|NCT00616590|stage I squamous cell carcinoma of the larynx
1338715|NCT00616590|stage I verrucous carcinoma of the larynx
1338716|NCT00616590|stage II squamous cell carcinoma of the larynx
1338717|NCT00616590|stage II verrucous carcinoma of the larynx
1338718|NCT00616590|stage III squamous cell carcinoma of the larynx
1338719|NCT00616590|stage III verrucous carcinoma of the larynx
1338720|NCT00616590|stage IV squamous cell carcinoma of the larynx
1338721|NCT00616590|stage IV verrucous carcinoma of the larynx
1338722|NCT00616590|recurrent adenoid cystic carcinoma of the oral cavity
1338723|NCT00616590|recurrent mucoepidermoid carcinoma of the oral cavity
1338724|NCT00616590|recurrent verrucous carcinoma of the oral cavity
1338725|NCT00616590|stage I adenoid cystic carcinoma of the oral cavity
1338726|NCT00616590|stage I mucoepidermoid carcinoma of the oral cavity
1338727|NCT00616590|stage I verrucous carcinoma of the oral cavity
1338728|NCT00616590|stage II adenoid cystic carcinoma of the oral cavity
1338729|NCT00616590|stage II mucoepidermoid carcinoma of the oral cavity
1338730|NCT00616590|stage II verrucous carcinoma of the oral cavity
1338731|NCT00616590|stage III adenoid cystic carcinoma of the oral cavity
1338732|NCT00616590|stage III mucoepidermoid carcinoma of the oral cavity
1338733|NCT00616590|stage III verrucous carcinoma of the oral cavity
1338734|NCT00616590|stage IV adenoid cystic carcinoma of the oral cavity
1338735|NCT00616590|stage IV mucoepidermoid carcinoma of the oral cavity
1338736|NCT00616590|stage IV verrucous carcinoma of the oral cavity
1338737|NCT00616590|stage I squamous cell carcinoma of the lip and oral cavity
1338738|NCT00616590|stage II squamous cell carcinoma of the lip and oral cavity
1338739|NCT00616590|stage III squamous cell carcinoma of the lip and oral cavity
1338740|NCT00616590|stage IV squamous cell carcinoma of the lip and oral cavity
1338741|NCT00616590|recurrent basal cell carcinoma of the lip
1338742|NCT00616590|recurrent squamous cell carcinoma of the lip and oral cavity
1338743|NCT00616590|stage I basal cell carcinoma of the lip
1338744|NCT00616590|stage II basal cell carcinoma of the lip
1338745|NCT00616590|stage III basal cell carcinoma of the lip
1338746|NCT00616590|stage IV basal cell carcinoma of the lip
1338747|NCT00616590|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1338748|NCT00616590|recurrent metastatic squamous neck cancer with occult primary
1338749|NCT00616590|recurrent lymphoepithelioma of the nasopharynx
1338750|NCT00616590|recurrent squamous cell carcinoma of the nasopharynx
1338751|NCT00616590|stage I lymphoepithelioma of the nasopharynx
1338752|NCT00616590|stage I squamous cell carcinoma of the nasopharynx
1338753|NCT00616590|stage II lymphoepithelioma of the nasopharynx
1338754|NCT00616590|stage II squamous cell carcinoma of the nasopharynx
1338755|NCT00616590|stage III lymphoepithelioma of the nasopharynx
1338756|NCT00616590|stage III squamous cell carcinoma of the nasopharynx
1338757|NCT00616590|stage IV lymphoepithelioma of the nasopharynx
1338758|NCT00616590|stage IV squamous cell carcinoma of the nasopharynx
1338759|NCT00616590|recurrent lymphoepithelioma of the oropharynx
1338760|NCT00616590|recurrent squamous cell carcinoma of the oropharynx
1338761|NCT00616590|stage I lymphoepithelioma of the oropharynx
1338762|NCT00616590|stage I squamous cell carcinoma of the oropharynx
1338763|NCT00616590|stage II lymphoepithelioma of the oropharynx
1338764|NCT00616590|stage II squamous cell carcinoma of the oropharynx
1338765|NCT00616590|stage III lymphoepithelioma of the oropharynx
1338766|NCT00616590|stage III squamous cell carcinoma of the oropharynx
1338767|NCT00616590|stage IV lymphoepithelioma of the oropharynx
1338768|NCT00616590|stage IV squamous cell carcinoma of the oropharynx
1338769|NCT00616590|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1338770|NCT00616590|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1338771|NCT00616590|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1338772|NCT00616590|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1338773|NCT00616590|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1338774|NCT00616590|stage I inverted papilloma of the paranasal sinus and nasal cavity
1338775|NCT00616590|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1338776|NCT00616590|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1338777|NCT00616590|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1338778|NCT00616590|stage II inverted papilloma of the paranasal sinus and nasal cavity
1338779|NCT00616590|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1338780|NCT00616590|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1338781|NCT00616590|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1338782|NCT00616590|stage III inverted papilloma of the paranasal sinus and nasal cavity
1338783|NCT00616590|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1339037|NCT00615524|Metastatic
1338784|NCT00616590|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1338785|NCT00616590|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1338786|NCT00616590|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1338787|NCT00616590|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1338788|NCT00616590|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1338789|NCT00616590|recurrent salivary gland cancer
1338790|NCT00616590|stage I salivary gland cancer
1338791|NCT00616590|stage II salivary gland cancer
1338792|NCT00616590|stage III salivary gland cancer
1338793|NCT00616590|stage IV salivary gland cancer
1338794|NCT00616577|Caudal Epidural Ropivacaine
1338795|NCT00616564|GM-CSF
1338796|NCT00616564|Interleukin
1338797|NCT00616564|IL-2
1338798|NCT00616564|Sargrostim
1338799|NCT00616551|Acromegaly
1338800|NCT00616538|Atopic
1338801|NCT00616538|Dermatitis
1338802|NCT00616538|eczema
1338803|NCT00616538|skin barrier
1338804|NCT00616538|ceramide
1338805|NCT00616538|topical
1338806|NCT00616538|inflamation
1338807|NCT00616538|steroid
1338808|NCT00616538|SCORAD
1338809|NCT00616538|glucocorticoids
1338810|NCT00616538|EpiCeram
1338811|NCT00616538|Cutivate
1338812|NCT00616538|fluticasone
1338813|NCT00616512|Water
1338814|NCT00616512|oral care
1338815|NCT00616512|oral hygiene
1338816|NCT00616512|dysphagia
1338817|NCT00616512|thin liquid dysphagia
1338818|NCT00616512|thickened liquids
1338819|NCT00616499|stage IIIA non-small cell lung cancer
1338820|NCT00616499|adenocarcinoma of the lung
1338821|NCT00616499|bronchoalveolar cell lung cancer
1338822|NCT00616499|large cell lung cancer
1338823|NCT00616460|safety
1338824|NCT00616460|efficacy
1338825|NCT00616421|vaccine
1338826|NCT00616421|children
1338827|NCT00616421|healthy
1338828|NCT00616421|meningitis
1338829|NCT00616421|meningococcal
1338830|NCT00616421|prevention of meningococcal disease serogroups ACWY
1338831|NCT00616421|Menveo
1338832|NCT00616408|GH
1338833|NCT00616408|IGF-I
1338834|NCT00616408|GH-secreting tumors
1338835|NCT00616408|Octreotide
1338842|NCT00616382|PDA
1338843|NCT00616382|indomethacin
1338844|NCT00616382|pentoxifylline
1338845|NCT00616382|Patent Ductus Arteriosus [PDA] resistant to therapy
1338846|NCT00616369|pulmonary hypertension
1338847|NCT00616369|hypertension
1338848|NCT00616369|cardiomyopathy
1338849|NCT00616369|arrhythmias
1338850|NCT00616356|Yellow Fever
1338851|NCT00616343|ET
1338852|NCT00616317|Antiphospholipid Syndrome
1338853|NCT00616304|severe falciparum malaria
1338854|NCT00616291|recurrent prostate cancer
1338855|NCT00616291|stage IV prostate cancer
1338856|NCT00616278|Growth Failure AND
1338857|NCT00616278|Chronic Renal Insufficiency OR
1338858|NCT00616278|End Stage Renal Disease
1338859|NCT00616265|Sleep apnea
1338860|NCT00616265|Refractory Hypertension
1338861|NCT00616265|Difficult-to-treat hypertension
1338862|NCT00616265|CPAP
1338863|NCT00616252|Antiretroviral
1338864|NCT00616252|Pharmacokinetics
1338865|NCT00616252|Pregnancy
1338866|NCT00616239|Melasma
1338867|NCT00616239|Dark spots on the face
1338868|NCT00616213|unspecified adult solid tumor, protocol specific
1338869|NCT00616200|D-IBS (diarrhea predominant irritable bowel syndrome)
1338870|NCT00616174|Cesarean delivery
1338871|NCT00616174|Active Warming
1338872|NCT00616174|Neonatal Temperature
1338873|NCT00616161|Acute Heart Failure
1338874|NCT00616161|Inotropes
1338875|NCT00616161|Lusitropic agents
1338876|NCT00616161|Istaroxime
1338877|NCT00616161|PST2744
1338878|NCT00616148|Epilepsy
1338879|NCT00616148|Seizures
1338880|NCT00616135|Breast
1338881|NCT00616135|Stem Cell
1338882|NCT00616135|Adipose Derived Stem Cells
1338883|NCT00616135|Adipose Derived Regenerative Cells
1338884|NCT00616135|ADRC
1338885|NCT00616135|Reconstructive Breast Surgery
1338886|NCT00616135|Breast Reconstruction
1338887|NCT00616135|Cancer
1338888|NCT00616135|Carcinoma
1338889|NCT00616135|Autologous fat transplantation
1338890|NCT00616135|Autologous fat
1338891|NCT00616135|Cosmetic breast deformities
1338892|NCT00616135|Functional breast deformity
1338893|NCT00616135|Lumpectomy
1338894|NCT00616135|Segmental mastectomy
1338895|NCT00616135|Quadrantectomy
1338896|NCT00616135|breast conservation therapy
1338897|NCT00616122|recurrent breast cancer
1338898|NCT00616122|stage IV breast cancer
1338899|NCT00616122|male breast cancer
1338900|NCT00616096|Serum Immunoglobulin E above 5000 kU/l
1338901|NCT00616083|Breast Feeding
1338902|NCT00616083|Body Composition
1338903|NCT00616083|Body Fat
1338904|NCT00616083|Infant
1338905|NCT00616083|Diet
1338906|NCT00616083|Healthy Infants
1338907|NCT00616057|fructans supplementation
1338908|NCT00616044|Spinal Anesthesia
1338909|NCT00616044|Epidural Anesthesia
1338910|NCT00616044|Orthopedic procedures
1338911|NCT00616031|stage IIIB non-small cell lung cancer
1338912|NCT00616031|stage IV non-small cell lung cancer
1338913|NCT00616018|acetaminophen
1338914|NCT00616018|protein adducts
1338915|NCT00616018|hepatic function
1338916|NCT00616018|drug safety
1338917|NCT00616018|non drinkers
1338918|NCT00616005|Glioblastoma
1338919|NCT00616005|GBM
1338920|NCT00616005|Brain tumor
1338921|NCT00616005|Temodar
1338922|NCT00616005|Temozolomide
1338923|NCT00616005|Irinotecan
1338924|NCT00616005|CPT-11
1338925|NCT00616005|Camptosar
1338926|NCT00616005|Malignant glioma
1338927|NCT00616005|Anaplastic astrocytoma
1338928|NCT00616005|Glioblastoma multiforme
1338929|NCT00615979|trauma
1338930|NCT00615979|portable ultrasound
1338931|NCT00615979|telemedicine
1338932|NCT00615979|Department of Defense
1338933|NCT00615966|kidney transplantation
1338934|NCT00615966|ischemia-reperfusion injury
1338935|NCT00615966|phosphatidylserine binding
1338936|NCT00615940|HER2negative
1338937|NCT00615927|Glioblastoma
1338938|NCT00615927|Gliosarcoma
1338939|NCT00615927|glioblastoma multiforme (GBM)
1338940|NCT00615927|GBM
1338941|NCT00615927|Imatinib Mesylate
1338942|NCT00615927|Gleevec
1338943|NCT00615927|Hydroxyurea
1338944|NCT00615927|Droxia
1338945|NCT00615927|Hydrea
1338946|NCT00615927|Hydroxycarbamide
1338947|NCT00615927|Imatinib
1338948|NCT00615927|Brain tumor
1338949|NCT00615927|Malignant brain tumor
1338950|NCT00615927|Recurrent glioblastoma multiforme
1338951|NCT00615927|Progressive glioblastoma multiforme
1338952|NCT00615901|cyclophosphamide
1338953|NCT00615901|methotrexate
1338954|NCT00615901|fluorouracil
1338955|NCT00615901|PEG-filgrastim
1338956|NCT00615888|elective open repair
1338957|NCT00615888|complications
1338958|NCT00615888|morbidity and mortality
1338959|NCT00615888|fast track patient management
1338960|NCT00615875|naproxen
1338961|NCT00615875|acute pain
1338962|NCT00615875|postoperative pain
1338963|NCT00615875|thoracic surgery
1338964|NCT00615875|head and neck surgery
1338965|NCT00615875|opiate sparing
1338966|NCT00615862|Sepsis, alcoholism, cortisol, delirium, critical care
1338967|NCT00615849|pneumothorax, thoracoscopy, pleurodesis
1338968|NCT00615823|Pulmonary Arterial Hypertension
1338969|NCT00615810|LDL
1338970|NCT00615810|HDL
1338971|NCT00615810|triglycerides
1338972|NCT00615810|non HDL cholesterol
1338973|NCT00615810|cholesterol
1338974|NCT00615810|HIV 1
1338975|NCT00615810|Metabolic parameters
1338976|NCT00615810|treatment experienced
1338977|NCT00615784|Acute Myeloid Leukemia
1338978|NCT00615784|AML
1338979|NCT00615784|Bexarotene
1338980|NCT00615758|Erlotinib
1338981|NCT00615758|Biological therapy
1338982|NCT00615758|Tyrosin Kinase Inhibitor therapy
1338983|NCT00615745|Human Immunodeficiency Virus
1338984|NCT00615745|treatment experienced
1338985|NCT00615732|qigong
1338986|NCT00615732|traditional chinese medicine
1338987|NCT00615732|exercise therapy
1338988|NCT00615732|neck pain
1338989|NCT00615719|Chest Pain
1338990|NCT00615719|Coronary Angiography
1338991|NCT00615719|Acute Coronary Syndromes
1338992|NCT00615719|Computed Tomography
1338993|NCT00615706|asthma, inhaled corticosteroids
1338994|NCT00615693|Uveitis
1338995|NCT00615693|Macular Edema
1338996|NCT00615667|Refractory Nephrotic syndrome
1338997|NCT00615667|Tacrolimus
1338998|NCT00615654|Hydrotherapy,
1338999|NCT00615654|RCT,
1339000|NCT00615641|Children
1339001|NCT00615641|Nutrition
1339002|NCT00615641|Body Fat
1339003|NCT00615641|Physical Activity
1339004|NCT00615641|Diet
1339005|NCT00615641|Childhood Obesity
1339006|NCT00615641|Healthy Children
1339007|NCT00615628|Inheritance of Osteosarcoma & Paget's Disease through Chromosome 18
1339008|NCT00615615|Levetiracetam
1339009|NCT00615615|Keppra
1339010|NCT00615602|Early breast cancer
1339011|NCT00615602|Axillary node positive
1339012|NCT00615602|HER2 overexpression
1339013|NCT00615602|Adjuvant chemotherapy
1339014|NCT00615602|Dose dense
1339015|NCT00615602|Docetaxel
1339016|NCT00615602|Trastuzumab
1339017|NCT00615602|FEC
1339018|NCT00615589|Stage II/III Multiple Myeloma(within 10 months from diagnosis)
1339019|NCT00615589|high risk
1339020|NCT00615589|relapse
1339021|NCT00615589|persistent
1339022|NCT00615576|Male,
1339023|NCT00615576|Healthy Volunteer,
1339024|NCT00615576|Smoker,
1339025|NCT00615576|Cystic Fibrosis,
1339026|NCT00615576|Chronic Obstructive Lung Disease
1339027|NCT00615550|Preterm
1339028|NCT00615550|Cervix
1339029|NCT00615537|Thyroid Nodule
1339030|NCT00615537|Thyroid Cancer
1339031|NCT00615537|Laser Ablation
1339032|NCT00615537|LITT
1339033|NCT00615537|Nodular Goiter
1339034|NCT00615537|Thyroid Mass
1339035|NCT00615524|Breast cancer
1339036|NCT00615524|Advanced
1339038|NCT00615524|Pazopanib
1339039|NCT00615524|GW786034
1339040|NCT00615524|Exemestane
1339041|NCT00615524|Efficacy
1339042|NCT00615524|Tolerability
1339043|NCT00615524|Health-Related Quality of Life
1339044|NCT00615511|schizophrenia
1339045|NCT00615511|schizoaffective disorder
1339046|NCT00615511|negative symptoms
1339047|NCT00615511|cognition
1339048|NCT00615498|Asthma, obesity, bariatric
1339049|NCT00615485|Examine the risk of osteoporosis in survivors of solid pediatric cancers
1339050|NCT00615472|Parkinson's Disease
1339051|NCT00615472|Deep brain stimulation (DBS)
1339052|NCT00615472|Subthalamic Nucleus
1339053|NCT00615472|Total Intravenous Anesthesia
1339054|NCT00615472|Inhalational Anesthesia
1339055|NCT00615459|Chronic obstructive pulmonary disease, indacaterol, tiotropium, placebo controlled
1339056|NCT00615446|solid tumor malignancy, SU011248, sunitinib, neoplasms
1339057|NCT00615433|Schizophrenia
1339058|NCT00615433|Latuda
1339059|NCT00615433|Lurasidone
1339060|NCT00615420|Mucositis
1339061|NCT00615420|Radiation
1339062|NCT00615420|Honey
1339063|NCT00615407|Asthma, alcohol
1339064|NCT00615394|cardiomyopathy, stem cell, cardiac failure
1339065|NCT00615381|Intracranial Aneurysm, Unruptured
1339066|NCT00615381|Craniotomy
1339067|NCT00615381|Insulin
1339068|NCT00615381|Neuropsychology
1339069|NCT00615368|Type 1 diabetes
1339070|NCT00615368|Hypoglycaemia
1339071|NCT00615368|Cognitive function
1339072|NCT00615368|Erythropoietin
1339073|NCT00615355|vitiligo
1339074|NCT00615355|narrow-band UVB
1339075|NCT00615355|ReCell
1339076|NCT00615355|transplantation
1339077|NCT00615355|laser
1339078|NCT00615329|Create tumor specific gene profiles to improve diagnostic accuracy
1339079|NCT00615329|Perform gene set validation for diagnostic predictive power
1339080|NCT00615329|Define deviant gene list implicated in pathogenesis
1339081|NCT00615303|Bowel preparation, colonoscopy, simethicone, air bubble
1339082|NCT00615277|Young adults
1339083|NCT00615277|Long-chain polyunsaturated fatty acids
1339084|NCT00615277|Cognitive function
1339085|NCT00615277|Mood
1339086|NCT00615277|Supply with omega-3 fatty acids
1339087|NCT00615251|In vitro fertilization
1339088|NCT00615238|overweight, physical activity, body composition, metabolic syndrome
1339089|NCT00615225|brain death
1339090|NCT00615225|inflammation
1339091|NCT00615225|endotoxin
1339092|NCT00615225|transplantation
1339093|NCT00615225|graft
1339094|NCT00615225|apoptosis
1339095|NCT00615225|Systemic inflammatory response
1339096|NCT00615225|Apoptosis activation
1339097|NCT00615225|Graft outcome
1339098|NCT00615212|GSK376501,
1339099|NCT00615212|Cytochrome P450 isoenzymes,
1339100|NCT00615212|Healthy Subjects,
1339101|NCT00615212|Repeat Dose
1339102|NCT00615186|Neuradiab
1339103|NCT00615186|Locoregional glioblastoma multiforme disease
1339104|NCT00615186|Anti-tenascin
1339105|NCT00615186|Radiolabeled antibody therapy
1339106|NCT00615186|Survival
1339107|NCT00615173|Tacrolimus
1339108|NCT00615173|lupus nephritis
1339109|NCT00615160|Metastatic melanoma
1339110|NCT00615160|anti angiogenetic treatment
1339111|NCT00615147|Any cancer
1339112|NCT00615147|suspected pulmonary embolism
1339113|NCT00615134|treatment experienced
1339114|NCT00615121|Smoking
1339115|NCT00615121|Hypertension
1339116|NCT00615121|Diabetes
1339117|NCT00615121|Cardiovascular disease
1339118|NCT00615121|Renal Failure
1339119|NCT00615043|Transurethral resection of bladder tumor
1339120|NCT00615043|TURBT
1339121|NCT00615030|COPD, bronchodilator, long acting beta agonist, LABA
1339122|NCT00615017|Sepsis
1339123|NCT00615017|septic shock
1339124|NCT00615017|Systemic Inflammatory Response Syndrome
1339125|NCT00615004|Acromegaly
1339126|NCT00615004|GH
1339127|NCT00615004|IGF-I
1339128|NCT00615004|Octreotide-LAR
1339129|NCT00615004|Lanreotide
1339130|NCT00615004|Transsphenoidal surgery
1339131|NCT00614991|Healthy Subjects
1339132|NCT00614991|Pharmacokinetics study
1339133|NCT00614991|Pharmacokinetics of medications
1339134|NCT00614978|HER-2 positive; brain metastases
1339135|NCT00614965|Cancer
1339136|NCT00614965|NSCLC
1339137|NCT00614965|second-line chemotherapy
1339138|NCT00614965|irinotecan
1339139|NCT00614965|pemetrexed
1339140|NCT00614939|DPP-4 inhibitors
1339141|NCT00614939|HbA1c
1339142|NCT00614939|incretins
1339143|NCT00614939|Renal Impairment
1339144|NCT00614926|Fatigue
1339145|NCT00614926|low energy
1339146|NCT00614926|ALS
1339147|NCT00614926|treatment
1339148|NCT00614913|Proton
1339149|NCT00614913|Radiotherapy
1339150|NCT00614913|Hepatocellular carcinoma
1339151|NCT00614913|Liver Cancer
1339152|NCT00614900|COPD
1339153|NCT00614900|pulmonary hypertension
1339154|NCT00614900|NT-proBNP
1339155|NCT00614900|6 minutes walk test
1339156|NCT00614887|Subarachnoid hemorrhage
1339157|NCT00614887|Pituitary gland
1339158|NCT00614887|Adrenal gland
1339159|NCT00614874|Asthma
1339160|NCT00614874|Avandia
1339161|NCT00614861|Non-cancer pain
1339162|NCT00614861|Pain
1339163|NCT00614848|restenosis
1339164|NCT00614835|Gemcitabine
1339165|NCT00614835|Docetaxel
1339166|NCT00614835|uterine sarcoma
1339167|NCT00614809|gefitinib
1339168|NCT00614809|brain metastasis
1339169|NCT00614796|COPD
1339170|NCT00614796|Lifestyle
1339171|NCT00614796|Pedometer
1339172|NCT00614783|Screening
1339173|NCT00614770|colonoscopy
1339174|NCT00614744|NICHD Neonatal Research Network
1339175|NCT00614744|Hypoxic-ischemic encephalopathy (HIE)
1339176|NCT00614744|Hypothermia
1339177|NCT00614744|Neonatal depression
1339178|NCT00614744|Perinatal asphyxia
1339179|NCT00614731|Keyhole Limpet Hemocyanin
1339180|NCT00614731|KLH
1339181|NCT00614731|atopic dermatitis
1339182|NCT00614731|IgG antibodies
1339183|NCT00614731|scarification
1339184|NCT00614718|Implantable cardioverter defibrillator
1339185|NCT00614718|lead failure
1339186|NCT00614718|pace/sense lead
1339187|NCT00614718|ICD complication
1339188|NCT00614718|inappropriate therapy
1339189|NCT00614718|Defibrillators
1339190|NCT00614679|biofilm
1339191|NCT00614679|catheter lock solution
1339192|NCT00614679|catheter salvage
1339193|NCT00614666|coccidioidomycosis
1339194|NCT00614666|Valley Fever
1339195|NCT00614666|nikkomycin Z
1339196|NCT00614653|Pancreatic Cancer
1339197|NCT00614653|Bevacizumab
1339198|NCT00614653|Avastin™
1339199|NCT00614653|Anti-VEGF monoclonal antibody
1339200|NCT00614653|rhuMAb-VEGF
1339201|NCT00614653|Erlotinib
1339202|NCT00614653|Erlotinib Hydrochloride
1339203|NCT00614653|Tarceva
1339204|NCT00614653|OSI-774
1339205|NCT00614653|Capecitabine
1339206|NCT00614653|Xeloda
1339207|NCT00614640|HAART
1339208|NCT00614640|Therapeutic vaccine
1339209|NCT00614614|Meningococcal disease
1339210|NCT00614614|Toddlers
1339211|NCT00614614|Neisseria meningitidis
1339212|NCT00614614|Meningococcal vaccines
1339213|NCT00614614|Immunogenicity
1339214|NCT00614614|Human serum bactericidal assay
1339215|NCT00614614|Safety
1339216|NCT00614614|Vaccines, conjugate
1339217|NCT00614614|Booster vaccination
1339218|NCT00614601|pancreatic cancer
1339219|NCT00614601|vaccine therapy
1339220|NCT00614588|temperature
1339221|NCT00614588|monitor
1339222|NCT00614588|surgery
1339223|NCT00614562|critical associated illness polyneuropathy or polymyopathy (CIP/M)
1339224|NCT00614549|Levetiracetam
1339225|NCT00614549|Keppra
1339226|NCT00614549|Epilepsy
1339227|NCT00614549|Efficacy
1339228|NCT00614549|Safety
1339229|NCT00614536|Reflux Symptom Index
1339230|NCT00614536|Reflux Finding Score
1339231|NCT00614536|Rabeprazole
1339232|NCT00614536|LaryngoPharyngeal Reflux Disease
1339233|NCT00614536|GastroEsophageal Reflux Disease
1339234|NCT00614523|MDS
1339235|NCT00614523|Low Risk MDS
1339236|NCT00614523|Intermediate-1 Risk MDS
1339237|NCT00614523|Thrombocytopenia
1339238|NCT00614484|Proton
1339239|NCT00614484|Radiation
1339240|NCT00614458|latent HIV
1339241|NCT00614458|resting CD4+ T cell
1339242|NCT00614458|valproic acid (VPA)
1339243|NCT00614458|Raltegravir (MK-0518) intensification
1339244|NCT00614458|HIV replication
1339245|NCT00614458|treatment experienced
1339246|NCT00614445|Nausea
1339247|NCT00614445|Vomiting
1339248|NCT00614445|Pregnancy
1339249|NCT00614445|Hyperemesis gravidarum
1339250|NCT00614445|Pregnancy complications
1339251|NCT00614432|anticoagulation
1339252|NCT00614432|surgical abortion
1339253|NCT00614419|Hernioplasty
1339254|NCT00614419|polypropylene
1339255|NCT00614419|extracellular matrix
1339256|NCT00614419|xenograft
1339257|NCT00614406|Celebrex
1339258|NCT00614406|prostaglandin inhibitor
1339259|NCT00614406|ovulation
1339260|NCT00614406|menstrual cycles
1339261|NCT00614367|chromosomal abnormalities in single cells
1339262|NCT00614354|99mTc-glucarate imaging to detect acute coronary syndrome
1339263|NCT00614341|diabetes mellitus
1339264|NCT00614341|neuropathy
1339265|NCT00614341|distal symmetric polyneuropathy
1339266|NCT00614341|pulsed electric fild
1339267|NCT00614328|Alcohol
1339268|NCT00614328|Alcohol Abuse
1339269|NCT00614328|Alcohol Drinking
1339270|NCT00614289|Mild to Moderate Hand Dermatitis
1339271|NCT00614289|Hand Eczema
1339272|NCT00614276|Sexual Dysfunction
1339273|NCT00614276|Cancer-related Sexual Dysfunction
1339274|NCT00614276|Female Cancer Survivors
1339275|NCT00614276|Tendrils
1339276|NCT00614276|Website program
1339277|NCT00614276|Self-help tool
1339278|NCT00614276|Sexual counseling
1339279|NCT00614276|Questionnaires
1339280|NCT00614263|Colonoscopy
1339281|NCT00614263|Sedation levels
1339282|NCT00614250|Obstructive sleep apnea
1339283|NCT00614211|Cervix
1339284|NCT00614211|Cervical
1339285|NCT00614211|Cancer
1339286|NCT00614211|Carcinoma
1339287|NCT00614211|Radical hysterectomy
1339288|NCT00614211|Hysterectomy
1339289|NCT00614211|Laparoscopy
1339290|NCT00614211|Laparoscopic
1339291|NCT00614211|Robotic
1339292|NCT00614211|Squamous Cell
1339293|NCT00614211|Adenosquamous
1339294|NCT00614211|Adenocarcinoma
1339295|NCT00614211|Lymphatic Mapping
1339296|NCT00614211|IOLM
1339297|NCT00614211|SPECT
1339298|NCT00614211|Sentinel Node
1339299|NCT00614211|Uterine cervix
1339300|NCT00614198|autism
1339301|NCT00614198|autism spectrum disorder
1339302|NCT00614198|diet
1339303|NCT00614198|gluten
1339304|NCT00614198|casein
1339305|NCT00614198|intervention
1339306|NCT00614198|peptide
1339307|NCT00614198|randomised
1339308|NCT00614198|controlled
1339309|NCT00614198|adaptive design
1339310|NCT00614198|Autism Diagnostic Observation Schedule (ADOS)
1339311|NCT00614198|Gilliam Autism Rating Scale (GARS)
1339312|NCT00614198|Vineland Adaptive Behaviour Scale (VABS)
1339313|NCT00614198|Attention-Deficit Hyperactivity Disorder (ADHD)-IV Scale
1339314|NCT00614172|Proton
1339315|NCT00614172|Radiation
1339316|NCT00614172|Breast cancer
1339317|NCT00614159|Child age 1-10 years having a GI Endoscopy with sedation
1339318|NCT00614146|liver failure, albumin dialysis, liver support
1339319|NCT00614133|protein metabolism
1339320|NCT00614133|surgery
1339321|NCT00614133|parenteral nutrition
1339322|NCT00614107|Atrial Fibrillation post open heart surgery
1339323|NCT00614094|placenta, hypoglycemia
1339324|NCT00614081|Glomerular filtration rate measurement
1339325|NCT00614081|Contrast-enhanced dynamic MR imaging
1339326|NCT00614081|Renal transplant recipients
1339327|NCT00614068|Treatment
1339328|NCT00614068|PTSD
1339334|NCT00614029|sumatriptan
1339335|NCT00614029|Injections
1339336|NCT00614029|Subcutaneous
1339337|NCT00614016|healthy volunteers
1339338|NCT00614003|decisional conflict;
1339339|NCT00614003|decision quality;
1339340|NCT00614003|place of end of life care;
1339341|NCT00614003|provider education
1339342|NCT00613977|fetal lung maturity
1339343|NCT00613977|lamellar body count
1339344|NCT00613964|Natriuretic Peptides
1339345|NCT00613964|Heart Failure
1339346|NCT00613964|Renal Failure
1339347|NCT00613938|Acute pain
1339348|NCT00613938|bunionectomy
1339349|NCT00613938|tapentadol
1339350|NCT00613925|endometrial biopsy
1339351|NCT00613925|pain management
1339352|NCT00613912|Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Perfusion, brain
1339353|NCT00613899|home care
1339354|NCT00613899|home rehabilitation
1339355|NCT00613899|telemedicine
1339356|NCT00613899|ALS
1339357|NCT00613886|NPH
1339358|NCT00613886|Normal Pressure Hydrocephalus
1339359|NCT00613873|colonoscopy
1339360|NCT00613860|Endoscopic lung volume reduction, heterogeneous emphysema, interventional bronchoscopy
1339361|NCT00613847|PET Scan
1339362|NCT00613847|Invasive Solid Tumors
1339363|NCT00613834|Essure sterilization
1339364|NCT00613834|pain management
1339365|NCT00613834|intrauterine lidocaine infusion
1339366|NCT00613821|surgical abortion
1339367|NCT00613821|pain management
1339368|NCT00613808|venous
1339369|NCT00613808|leg
1339370|NCT00613808|ulcer
1339371|NCT00613795|pneumonia
1339372|NCT00613795|ventilator associated pneumonia
1339373|NCT00613795|probiotics
1339374|NCT00613795|Lactobacillus GG
1339375|NCT00613769|Surgical site infections
1339376|NCT00613717|iron deficiency anemia
1339377|NCT00613717|iron deficiency
1339378|NCT00613717|infant
1339379|NCT00613717|development
1339380|NCT00613717|behavior
1339381|NCT00613691|Refractory
1339382|NCT00613691|Progressive
1339383|NCT00613678|pain
1339384|NCT00613678|activities of daily living
1339385|NCT00613678|symptoms
1339386|NCT00613678|self-management
1339387|NCT00613652|solid tumors
1339388|NCT00613652|solid malignancies
1339389|NCT00613626|Extensive Stage
1339390|NCT00613626|Untreated
1339391|NCT00613600|Safety
1339392|NCT00613600|Efficacy
1339393|NCT00613600|Glucomannan
1339394|NCT00613600|Dietary fiber
1339395|NCT00613600|Weight loss
1339396|NCT00613587|Interleukin 13
1339397|NCT00613587|Interleukin 4
1339398|NCT00613587|Leukotrienes
1339399|NCT00613587|Basophil Histamine Release
1339400|NCT00613561|Patients with the Severe Immunodeficiency diseases
1339401|NCT00613561|Severe Immunodeficiency diseases
1339402|NCT00613548|Moderate
1339403|NCT00613548|Mitral
1339404|NCT00613548|Regurgitation
1339405|NCT00613548|CABG
1339406|NCT00613535|Partial Meniscectomy
1339407|NCT00613535|Partial Thickness Knee Tear
1339408|NCT00613535|MR Imaging
1339409|NCT00613535|Mechanical Debridement
1339410|NCT00613535|Crepitus
1339411|NCT00613535|Stability
1339412|NCT00613535|Coblation
1339413|NCT00613535|Bipolar Radiofrequency
1339414|NCT00613535|Debridement
1339415|NCT00613535|Recurrent Knee Pain
1339416|NCT00613535|meniscectomy
1339417|NCT00613535|meniscus
1339418|NCT00613535|cartilage lesion
1339419|NCT00613535|articular cartilage lesion
1339420|NCT00613535|articular cartilage
1339421|NCT00613535|knee
1339422|NCT00613522|Sleep apnea, Berlin, Stroke
1339423|NCT00613509|Melanoma, Cancer
1339424|NCT00613496|Atrial Fibrillation
1339425|NCT00613496|irbesartan
1339426|NCT00613496|AT-II-antagonist
1339427|NCT00613496|Adhesion Molecules
1339428|NCT00613496|oxidative stress markers
1339429|NCT00613496|hsCRP
1339430|NCT00613496|ICAM
1339431|NCT00613496|VCAM
1339432|NCT00613496|MCP-1
1339433|NCT00613496|vWF
1339434|NCT00613496|TGFβ1
1339435|NCT00613496|TNF-α
1339436|NCT00613496|Interleukin-6
1339437|NCT00613496|8isoProstaglandinF2α
1339438|NCT00613470|Depression
1339439|NCT00613470|Antidepressants
1339440|NCT00613444|Acne
1339441|NCT00613444|laser
1339442|NCT00613431|pharmacodynamics
1339443|NCT00613405|substance-related disorders
1339444|NCT00613392|antioxidant
1339445|NCT00613392|oxidant stress
1339446|NCT00613392|trauma
1339447|NCT00613392|free radical
1339448|NCT00613379|HIV
1339449|NCT00613379|treatment naïve
1339450|NCT00613366|intrauterine device
1339451|NCT00613366|cervical dilation
1339452|NCT00613366|nulliparous women
1339453|NCT00613366|pain management
1339454|NCT00613353|Female
1339455|NCT00613340|Cervical pain
1339456|NCT00613340|Zygapophysial joint
1339457|NCT00613340|Specificity
1339458|NCT00613327|Overactive bladder
1339459|NCT00613327|Oxybutynin chloride
1339460|NCT00613327|OROS
1339461|NCT00613288|acute
1339462|NCT00613288|testosterone
1339463|NCT00613288|experimental
1339464|NCT00613288|hypogonadism
1339465|NCT00613288|lipolysis
1339466|NCT00613288|insulin sensitivity
1339467|NCT00613288|protein
1339468|NCT00613288|metabolism
1339469|NCT00613288|Experimental hypogonadism
1339470|NCT00613288|Testosterone substitution
1339471|NCT00613275|PNRP
1339472|NCT00613275|Navigation
1339473|NCT00613275|Navigator
1339474|NCT00613275|Activation
1339475|NCT00613275|Disparities
1339476|NCT00613275|Primary Care
1339477|NCT00613275|Racial and Ethnic Minorities
1339478|NCT00613262|Narrow Band Imaging
1339479|NCT00613249|HIV-1 Infection
1339480|NCT00613249|HIV Seronegativity
1339481|NCT00613223|Malignant Gliomas
1339482|NCT00613223|Etopophos
1339483|NCT00613223|Toposar
1339484|NCT00613223|VePesid
1339485|NCT00613223|Etoposide
1339486|NCT00613223|Vandetanib
1339487|NCT00613223|Zactima
1339488|NCT00613223|ZD6474
1339489|NCT00613223|VP-16
1339490|NCT00613223|Brain Tumor
1339491|NCT00613223|Recurring Malignant Brain Tumor
1339492|NCT00613223|Gliosarcoma
1339493|NCT00613223|Glioblastoma
1339494|NCT00613223|Glioma
1339495|NCT00613223|Malignant Glioma
1339496|NCT00613223|GBM
1339497|NCT00613210|preterm delivery
1339498|NCT00613210|shory cervix
1339499|NCT00613210|amniotic fluid sludge
1339500|NCT00613210|uterine artery doppler
1339501|NCT00613210|singeltone
1339502|NCT00613210|normal amniotic fluid index
1339503|NCT00613210|without rupter of membranes
1339504|NCT00613210|24-34 weeks of gestation
1339505|NCT00613197|Crohn's Disease
1339506|NCT00613184|Respiratory Syncytial virus
1339507|NCT00613184|Bronchiolitis
1339508|NCT00613184|Pediatric
1339509|NCT00613171|Systemic sclerosis, scleroderma, fibrosis, STI571, imatinib
1339510|NCT00613158|Subclincal Atherosclerosis
1339511|NCT00613145|Refractory Malignancy
1339512|NCT00613145|Phase I
1339513|NCT00613145|Sorafenib
1339514|NCT00613145|Capecitabine
1339515|NCT00613132|Glioblastoma
1339516|NCT00613132|Gliosarcoma
1339517|NCT00613132|GBM
1339518|NCT00613132|Brain tumor
1339519|NCT00613132|RAD0001
1339520|NCT00613132|Hydroxyurea
1339521|NCT00613132|Gleevec
1339522|NCT00613132|Imatinib
1339523|NCT00613132|Droxia
1339524|NCT00613132|Everolimus
1339525|NCT00613132|Hydrea
1339526|NCT00613132|Hydroxycarbamide
1339527|NCT00613132|Recurrent GBM
1339528|NCT00613132|Imatinib mesylate
1339529|NCT00613132|Glioblastoma multiforme
1339530|NCT00613119|Inflammation
1339531|NCT00613119|Frontotemporal Dementia
1339532|NCT00613119|Dementia
1339533|NCT00613119|PBR28
1339534|NCT00613119|PET Imaging
1339535|NCT00613093|Temodar
1339536|NCT00613093|Temozolomide
1339537|NCT00613093|O6-BG
1339538|NCT00613093|O6-Benzylguanine
1339539|NCT00613093|NSC 637037
1339540|NCT00613093|Temodar-Resistant Malignant Glioma
1339541|NCT00613093|Brain tumor
1339542|NCT00613093|CNS tumor
1339543|NCT00613093|Cerebral glioblastoma
1339544|NCT00613093|Anaplastic astrocytomas
1339545|NCT00613093|Glioma
1339546|NCT00613080|stage III rectal cancer
1339547|NCT00613080|adenocarcinoma of the rectum
1339548|NCT00613067|Generalized anxiety disorder
1339549|NCT00613067|N100
1339550|NCT00613067|Central serotonergic activity
1339551|NCT00613054|GBM
1339552|NCT00613054|Brain tumor
1339553|NCT00613054|Zactima
1339554|NCT00613054|Gleevec
1339555|NCT00613054|Hydroxyurea
1339556|NCT00613054|Glioblastoma
1339557|NCT00613054|Gliosarcoma
1339558|NCT00613054|Recurrent malignant glioma
1339559|NCT00613054|ZD6474
1339560|NCT00613054|Malignant glioma
1339561|NCT00613054|Imatinib
1339562|NCT00613054|Droxia
1339563|NCT00613054|Hydrea
1339564|NCT00613054|Hydroxycarbamide
1339565|NCT00613054|Vandetanib
1339566|NCT00613028|Glioblastoma
1339567|NCT00613028|Gliosarcoma
1339568|NCT00613028|GBM
1339569|NCT00613028|Bevacizumab
1339570|NCT00613028|Avastin
1339571|NCT00613028|Etoposide
1339572|NCT00613028|Brain tumor
1339573|NCT00613028|Irinotecan
1339574|NCT00613028|Glioblastoma multiforme
1339575|NCT00613028|Temodar
1339576|NCT00613028|Temozolomide
1339577|NCT00613028|Etopophos
1339578|NCT00613028|Toposar
1339579|NCT00613028|VePesid
1339580|NCT00613028|VP-16
1339581|NCT00613028|Camptosar
1339582|NCT00613015|Cocaine Addiction
1339583|NCT00613015|Cocaine Dependence
1339584|NCT00613002|hypoactive sexual desire disorder
1339585|NCT00613002|testosterone
1339586|NCT00613002|menopause
1339587|NCT00612989|Glioblastoma
1339588|NCT00612989|Gliosarcoma
1339589|NCT00612989|GBM
1339590|NCT00612989|Temodar
1339591|NCT00612989|Temozolomide
1339592|NCT00612989|O6-BG
1339593|NCT00612989|O6-Benzylguanine
1339594|NCT00612989|Recurrent GBM
1339595|NCT00612989|Progressive GBM
1339596|NCT00612989|Brain tumor
1339597|NCT00612989|Malignant glioma
1339598|NCT00612989|Neulasta
1339599|NCT00612989|Pegfilgrastim
1339600|NCT00612976|treatment of COPD
1339601|NCT00612976|documentation of relevant data
1339602|NCT00612976|related to the budesonide/formoterole therapy in patients with COPD.
1339603|NCT00612963|Candidiasis, Oral
1339604|NCT00612963|Thrush
1339605|NCT00612963|Candidiasis
1339606|NCT00612937|Group B Streptococci
1339607|NCT00612937|Respiratory Disease
1339608|NCT00612937|Beta Lactam
1339609|NCT00612937|Newborn
1339610|NCT00612937|Respiratory Distress
1339611|NCT00612898|HIV infection
1339612|NCT00612898|Drug resistance
1339613|NCT00612898|Reverse transcriptase inhibitor
1339614|NCT00612898|Nucleoside analogue
1339615|NCT00612898|treatment experienced
1339616|NCT00612859|Levetiracetam
1339617|NCT00612859|Keppra
1339618|NCT00612846|Common Bile Duct Calculi
1339619|NCT00612846|Choledocholithiasis
1339620|NCT00612846|Endoscopic sphincterotomy
1339621|NCT00612846|Cholecystectomy, laparoscopic
1339622|NCT00612846|Laparoscopic bile duct exploration
1339623|NCT00612833|Vasectomy
1339624|NCT00612833|Male contraception
1339625|NCT00612833|Contraceptive effectiveness
1339626|NCT00612833|Semen analysis
1339627|NCT00612833|Surgical techniques
1339628|NCT00612833|Fascial interposition
1339629|NCT00612833|Cautery
1339630|NCT00612833|The relative contraceptive effectiveness of three methods of occluding the vas, in the context of a no-scalpel vasectomy procedure.
1339631|NCT00612820|Vienna Challenge Chamber
1339632|NCT00612820|Seasonal Allergic Rhinitis,
1339633|NCT00612807|Older Adults
1339634|NCT00612794|exenatide
1339635|NCT00612794|Byetta
1339636|NCT00612794|diabetes
1339637|NCT00612794|Amylin
1339638|NCT00612794|Lilly
1339639|NCT00612781|intraocular lens
1339640|NCT00612781|blue-light filtering intraocular lens
1339641|NCT00612781|contrast acuity
1339642|NCT00612781|color vision
1339643|NCT00612768|Bioequivalence
1339644|NCT00612768|Thimerosal
1339645|NCT00612768|Fragrance Mix
1339646|NCT00612768|PVP formulation
1339647|NCT00612768|Contact dermatitis
1339648|NCT00612755|chronic hepatitis C
1339649|NCT00612755|co-infection
1339650|NCT00612755|extend treatment
1339651|NCT00612755|co-infected HIV-HCV
1339652|NCT00612742|Cardiovascular event
1339653|NCT00612742|Breast Cancer
1339654|NCT00612742|Testosterone
1339655|NCT00612742|Menopause
1339656|NCT00612742|Hypoactive Sexual Desire Disorder
1339657|NCT00612729|intraocular lens
1339658|NCT00612729|light filtering intraocular lens
1339659|NCT00612729|contrast acuity
1339660|NCT00612729|color vision
1339661|NCT00612716|stage I multiple myeloma
1339662|NCT00612716|stage II multiple myeloma
1339663|NCT00612716|stage III multiple myeloma
1339664|NCT00612716|refractory multiple myeloma
1339665|NCT00612716|recurrent adult Hodgkin lymphoma
1339666|NCT00612716|recurrent/refractory childhood Hodgkin lymphoma
1339667|NCT00612716|refractory chronic lymphocytic leukemia
1339668|NCT00612716|stage III chronic lymphocytic leukemia
1339669|NCT00612716|stage IV chronic lymphocytic leukemia
1339670|NCT00612716|recurrent adult grade III lymphomatoid granulomatosis
1339671|NCT00612716|adult nasal type extranodal NK/T-cell lymphoma
1339672|NCT00612716|Waldenstrom macroglobulinemia
1339673|NCT00612716|recurrent adult Burkitt lymphoma
1339674|NCT00612716|stage I adult Burkitt lymphoma
1339675|NCT00612716|stage II adult Burkitt lymphoma
1339676|NCT00612716|stage III adult Burkitt lymphoma
1339677|NCT00612716|stage IV adult Burkitt lymphoma
1339678|NCT00612716|recurrent adult diffuse large cell lymphoma
1339679|NCT00612716|recurrent adult diffuse mixed cell lymphoma
1339680|NCT00612716|recurrent adult diffuse small cleaved cell lymphoma
1339681|NCT00612716|recurrent adult immunoblastic large cell lymphoma
1339682|NCT00612716|stage I adult immunoblastic large cell lymphoma
1339683|NCT00612716|stage II adult immunoblastic large cell lymphoma
1339684|NCT00612716|stage III adult immunoblastic large cell lymphoma
1339685|NCT00612716|stage IV adult immunoblastic large cell lymphoma
1339686|NCT00612716|recurrent adult lymphoblastic lymphoma
1339687|NCT00612716|stage I adult lymphoblastic lymphoma
1339688|NCT00612716|stage II adult lymphoblastic lymphoma
1339689|NCT00612716|stage III adult lymphoblastic lymphoma
1339690|NCT00612716|stage IV adult lymphoblastic lymphoma
1339691|NCT00612716|recurrent grade 1 follicular lymphoma
1339809|NCT00612339|Unresectable GBM
1339692|NCT00612716|recurrent grade 2 follicular lymphoma
1339693|NCT00612716|recurrent grade 3 follicular lymphoma
1339694|NCT00612716|recurrent mantle cell lymphoma
1339695|NCT00612716|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1339696|NCT00612716|nodal marginal zone B-cell lymphoma
1339697|NCT00612716|recurrent marginal zone lymphoma
1339698|NCT00612716|splenic marginal zone lymphoma
1339699|NCT00612716|recurrent small lymphocytic lymphoma
1339700|NCT00612716|recurrent childhood anaplastic large cell lymphoma
1339701|NCT00612716|recurrent childhood grade III lymphomatoid granulomatosis
1339702|NCT00612716|childhood diffuse large cell lymphoma
1339703|NCT00612716|childhood immunoblastic large cell lymphoma
1339704|NCT00612716|recurrent childhood large cell lymphoma
1339705|NCT00612716|recurrent childhood lymphoblastic lymphoma
1339706|NCT00612716|childhood nasal type extranodal NK/T-cell lymphoma
1339707|NCT00612716|Burkitt lymphoma
1339708|NCT00612716|recurrent childhood small noncleaved cell lymphoma
1339709|NCT00612716|stage I childhood small noncleaved cell lymphoma
1339710|NCT00612716|stage II childhood small noncleaved cell lymphoma
1339711|NCT00612716|stage III childhood small noncleaved cell lymphoma
1339712|NCT00612716|stage IV childhood small noncleaved cell lymphoma
1339713|NCT00612703|Cancer, oral, erlotinib, tarceva, solid tumor, advanced tumor, phase 1
1339714|NCT00612703|Tumor
1339715|NCT00612690|Children
1339716|NCT00612690|School-Based Mental Health Services
1339717|NCT00612690|Urban Poverty
1339718|NCT00612677|recurrent
1339719|NCT00612677|non-small cell
1339720|NCT00612651|GBM
1339721|NCT00612651|Malignant glioma
1339722|NCT00612651|Brain tumor
1339723|NCT00612651|Temodar
1339724|NCT00612651|Temozolomide
1339725|NCT00612651|SCH 66336
1339726|NCT00612651|Farnesyl transferase inhibitor
1339727|NCT00612651|Glioblastoma multiforme
1339728|NCT00612651|Gliosarcoma
1339729|NCT00612651|Anaplastic astrocytoma
1339730|NCT00612651|Anaplastic oligodendroglioma
1339731|NCT00612651|Anaplastic oligoastrocytoma
1339732|NCT00612638|Temodar
1339733|NCT00612638|Temozolomide
1339734|NCT00612638|O6-Benzylguanine
1339735|NCT00612638|O6-BG
1339736|NCT00612638|NSC 637037
1339737|NCT00612638|Irinotecan
1339738|NCT00612638|CPT-11
1339739|NCT00612638|Recurrent cerebral anaplastic glioma
1339740|NCT00612638|Progressive cerebral anaplastic glioma
1339741|NCT00612638|Malignant glioma
1339742|NCT00612560|breast neoplasms
1339743|NCT00612560|phytoestrogens
1339744|NCT00612560|tumor characteristics
1339745|NCT00612560|proliferation
1339746|NCT00612560|apoptosis
1339747|NCT00612560|estrogen receptor
1339748|NCT00612560|HER2
1339749|NCT00612547|Protozoan Infections
1339750|NCT00612547|Communicable Diseases
1339751|NCT00612547|Malaria Infection
1339752|NCT00612547|Malaria, falciparum
1339753|NCT00612547|Malaria, vivax
1339754|NCT00612547|Artesunate Amodiaquine
1339755|NCT00612521|Coronary artery disease
1339756|NCT00612521|Coronary artery stenting
1339757|NCT00612521|peri-procedural myonecrosis
1339758|NCT00612521|Adenosine
1339759|NCT00612508|contraception
1339760|NCT00612508|NuvaRing
1339761|NCT00612508|Desogen
1339762|NCT00612508|vaginal biopsy
1339763|NCT00612482|Substance abuse
1339764|NCT00612469|dental caries
1339765|NCT00612469|vancomycin
1339766|NCT00612469|chlorhexidine
1339767|NCT00612469|sodium fluoride
1339768|NCT00612469|mutans streptococci
1339769|NCT00612456|angiogenesis
1339770|NCT00612456|pazopanib,
1339771|NCT00612456|age-related macular degeneration (AMD),
1339772|NCT00612456|vascular endothelial growth factor (VEGF),
1339773|NCT00612456|choroidal neovascularization (CNV),
1339774|NCT00612443|breast cancer
1339775|NCT00612430|Glioblastoma
1339776|NCT00612430|Gliosarcoma
1339777|NCT00612430|GBM
1339778|NCT00612430|MG
1339779|NCT00612430|Brain tumor
1339780|NCT00612430|Bevacizumab
1339781|NCT00612430|Avastin
1339782|NCT00612430|Etoposide
1339783|NCT00612430|VP-16
1339784|NCT00612430|Etopophos
1339785|NCT00612430|Toposar
1339786|NCT00612430|VePesid
1339787|NCT00612430|Glioblastoma multiforme
1339788|NCT00612430|Recurrent GBM
1339789|NCT00612430|Anaplastic astrocytoma
1339790|NCT00612430|Malignant glioma
1339791|NCT00612417|Interaction with recombinant FVIII
1339792|NCT00612404|gastrointestinal disorder
1339793|NCT00612404|endoscopy
1339794|NCT00612404|patient with gastrointestinal disorders for whom an endoscopy is performed and who is treated with esomeprazole afterwards.
1339795|NCT00612391|humerus fracture
1339796|NCT00612378|Glabellar Furrowing
1339797|NCT00612365|Body Composition
1339798|NCT00612365|Abdomen
1339799|NCT00612365|Atherosclerosis
1339800|NCT00612339|Glioma
1339801|NCT00612339|Temozolomide
1339802|NCT00612339|Temodar
1339803|NCT00612339|Avastin
1339804|NCT00612339|Bevacizumab
1339805|NCT00612339|GBM
1339806|NCT00612339|Gliosarcoma
1339807|NCT00612339|Multifocal GBM
1339808|NCT00612339|Brain tumor
1339810|NCT00612339|Glioblastoma multiforme
1339811|NCT00612313|Major Depressive Disorder
1339812|NCT00612313|MDD
1339813|NCT00612313|Children
1339814|NCT00612313|Adolescents
1339815|NCT00612313|Antidepressant
1339816|NCT00612313|CBT
1339817|NCT00612300|Ambulatory stroke patients
1339818|NCT00612300|Gait training
1339819|NCT00612300|Lokomat
1339820|NCT00612300|Physical therapy
1339821|NCT00612287|Pain
1339822|NCT00612287|Chronic pain
1339823|NCT00612287|Buprenorphine
1339824|NCT00612287|Drug addiction
1339825|NCT00612274|allogeneic
1339826|NCT00612261|Branch retinal vein occlusion; treatment
1339827|NCT00612248|Osteoarthritis
1339828|NCT00612248|Thumb
1339829|NCT00612248|Splint
1339830|NCT00612248|Pain
1339831|NCT00612248|Function
1339832|NCT00612248|Osteoarthritis of the trapeziometacarpal (TMC) joint
1339833|NCT00612235|epilepsy
1339834|NCT00612235|lamotrigine
1339835|NCT00612235|levetiracetam
1339836|NCT00612235|carbamazepine
1339837|NCT00612235|phenytoin
1339838|NCT00612235|lamictal
1339839|NCT00612235|keppra
1339840|NCT00612235|tegretol
1339841|NCT00612235|carbatrol
1339842|NCT00612235|dilantin
1339843|NCT00612222|Immunotherapy
1339844|NCT00612222|Metastatic Melanoma
1339845|NCT00612222|Vaccination
1339846|NCT00612222|Tumor Regression
1339847|NCT00612222|Skin Cancer
1339848|NCT00612209|ARQ 197, advanced solid tumors, phase 1, dose escalation, pharmacodynamics, safety
1339849|NCT00612196|Safety and tolerability
1339850|NCT00612183|non-Hodgkin's lymphoma
1339851|NCT00612183|mantle cell lymphoma
1339852|NCT00612170|Phase 3, safety and efficacy study, [S,S[-Reboxetine, Fibromyalgia
1339853|NCT00612157|Obstructive Sleep Apnea
1339854|NCT00612157|Continuous Positive Airway Pressure
1339855|NCT00612157|CPAP Compliance
1339856|NCT00612157|Non-benzodiazepine hypnotics
1339857|NCT00612144|Type 2 DM
1339858|NCT00612131|medical residents PGY 2 and 3
1339859|NCT00612118|Allergic rhinitis,
1339860|NCT00612118|Vienna Challenge Chamber
1339861|NCT00612105|Postherpetic Neuralgia, PHN, Shingles,
1339862|NCT00612092|Coronary CT angiography
1339863|NCT00612092|Radiation dose estimates
1339864|NCT00612079|Sertindole
1339865|NCT00612079|sensory gating
1339866|NCT00612079|PPI
1339867|NCT00612079|P50 suppression
1339868|NCT00612079|CANTAB
1339869|NCT00612079|Effect of Sertindole on sensory gating (P50 suppression)
1339870|NCT00612079|on sensorimotor gating (PPI)
1339871|NCT00612079|and cognition (CANTAB)
1339872|NCT00612066|ACTH-producing pituitary tumor
1339873|NCT00612053|cardiovascular disease
1339874|NCT00612053|coronary artery bypass grafting (CABG)
1339875|NCT00612053|coronary artery disease (CAD)
1339876|NCT00612053|percutaneous transluminal coronary angioplasty (PCI)
1339877|NCT00612053|unprotected left main disease
1339878|NCT00612027|gastrointestinal disorder
1339879|NCT00612027|acid associated gastrointestinal symptoms.
1339880|NCT00612027|esomeprazole therapy in patients with gastrointestinal disorders
1339881|NCT00612027|patients with acid associated gastrointestinal symptoms
1339882|NCT00612014|delayed gastric emptying
1339883|NCT00612014|symptomatic gastroparesis
1339884|NCT00612014|diabetes mellitus
1339885|NCT00612001|adult anaplastic astrocytoma
1339886|NCT00612001|adult glioblastoma
1339887|NCT00612001|adult giant cell glioblastoma
1339888|NCT00612001|adult gliosarcoma
1339889|NCT00612001|adult anaplastic oligodendroglioma
1339890|NCT00612001|recurrent adult brain tumor
1339891|NCT00612001|adult mixed glioma
1339892|NCT00611988|Walking therapy
1339893|NCT00611988|Diabetes mellitus
1339894|NCT00611988|Peripheral arterial disease
1339895|NCT00611975|Gonadal Steroid Hormones
1339896|NCT00611975|Healthy Volunteers
1339897|NCT00611975|Antidepressant Side Effects
1339898|NCT00611975|Fluoxetine
1339899|NCT00611975|Bupropion
1339900|NCT00611975|Prolactin
1339901|NCT00611975|Testosterone
1339902|NCT00611975|Estradiol
1339903|NCT00611975|Progesterone
1339904|NCT00611975|Sexual Function
1339905|NCT00611975|Serotonin Reuptake Inhibitors
1339906|NCT00611975|17-OH Pregnenolone
1339907|NCT00611949|Geranium oil
1339908|NCT00611949|Neuropathy
1339909|NCT00611949|Shingles
1339910|NCT00611949|Herpes zoster
1339911|NCT00611936|Atomoxetine
1339912|NCT00611936|Stress
1339913|NCT00611936|d-amphetamine
1339914|NCT00611923|Premenstrual Dysphoric Disorder
1339915|NCT00611923|PMDD
1339916|NCT00611923|PMS
1339917|NCT00611897|NMDA
1339918|NCT00611897|glutamate
1339919|NCT00611897|N-acetylcysteine
1339920|NCT00611897|P3
1339921|NCT00611858|5-FU
1339922|NCT00611858|cetuximab
1339923|NCT00611858|radiation
1339924|NCT00611858|adenocarcinoma of the rectum
1339925|NCT00611858|neoadjuvant therapy
1339926|NCT00611845|CABG surgery requiring CPB and at increased risk of bleeding and blood transfusion
1339927|NCT00611832|behavior problems
1339928|NCT00611832|children
1339929|NCT00611832|prevention
1339930|NCT00611832|television
1339931|NCT00611832|media
1339932|NCT00611832|parenting
1339933|NCT00611819|hepatitis
1339934|NCT00611819|co-infection
1339935|NCT00611806|Cognition
1339936|NCT00611806|Folic Acid
1339937|NCT00611806|B12
1339938|NCT00611793|Refractory Malignancy
1339939|NCT00611793|Advanced Malignancies
1339940|NCT00611793|PTK787/ZK222584
1339941|NCT00611793|Bevacizumab
1339942|NCT00611780|Coronary CT angiography
1339943|NCT00611780|Radiation dose estimates
1339944|NCT00611767|Thiopental
1339945|NCT00611767|Alcohol
1339946|NCT00611767|Family History
1339947|NCT00611767|Vulnerability
1339948|NCT00611767|GABA
1339949|NCT00611741|MRS, glutamate, osmolality
1339950|NCT00611728|Glioblastoma
1339951|NCT00611728|CPT 11
1339952|NCT00611728|Sutent
1339953|NCT00611728|Sunitinib
1339954|NCT00611728|Sunitinib malate
1339955|NCT00611728|Malignant Glioma
1339956|NCT00611728|GBM
1339957|NCT00611728|Irinotecan
1339958|NCT00611728|Camptosar
1339959|NCT00611728|Anaplastic astrocytoma
1339960|NCT00611728|Anaplastic oligodendroglioma
1339961|NCT00611728|Anaplastic oligoastrocytoma
1339962|NCT00611728|SU011248
1339963|NCT00611728|Brain tumor
1339964|NCT00611728|Recurrent malignant glioma
1339965|NCT00611715|recurrent breast cancer
1339966|NCT00611715|stage IV breast cancer
1339967|NCT00611702|ELISPOT
1339968|NCT00611702|RT-PCR
1339969|NCT00611702|Luminex
1339970|NCT00611702|Genomics
1339971|NCT00611689|Refractory Malignancy
1339972|NCT00611689|Solid Tumors
1339973|NCT00611689|PTK787
1339974|NCT00611689|ZK222584
1339975|NCT00611676|osteoarthritis pain
1339976|NCT00611676|activity limitation
1339977|NCT00611676|antidepressant
1339978|NCT00611676|depression
1339979|NCT00611676|single-blind
1339980|NCT00611663|Pneumococcal vaccine
1339981|NCT00611663|SLE
1339982|NCT00611663|Vaccination
1339983|NCT00611663|Immunosuppression
1339984|NCT00611663|SLE as defined by the ACR classification
1339985|NCT00611663|Stable SLE
1339986|NCT00611663|SLE treated by systemic corticosteroids
1339987|NCT00611650|non-small cell lung cancer
1339988|NCT00611650|squamous lung dysplasia
1339989|NCT00611650|tobacco use disorder
1339990|NCT00611637|Immunotherapy
1339991|NCT00611624|MammoSite
1339992|NCT00611624|brachytherapy
1339993|NCT00611572|GABA
1339994|NCT00611572|glutamate
1339995|NCT00611572|NMDA
1339996|NCT00611572|P300
1339997|NCT00611572|MMN
1339998|NCT00611559|Infanrix hexa
1339999|NCT00611559|combined vaccine
1340000|NCT00611546|preterm
1340001|NCT00611546|parenteral nutrition
1340002|NCT00611546|TPN
1340003|NCT00611546|lipid emulsions
1340004|NCT00611546|photo-protection
1340005|NCT00611546|oxidative stress
1340006|NCT00611533|Menopause
1340007|NCT00611533|Cognition
1340008|NCT00611520|treatment of COPD
1340009|NCT00611520|related to the budesonide/formoterole therapy in patients with COPD.
1340010|NCT00611494|Drug tolerance
1340011|NCT00611494|Quality of Life
1340012|NCT00611429|Treatment
1340013|NCT00611429|Adherence
1340014|NCT00611429|Intervention
1340015|NCT00611429|Quality of Life
1340016|NCT00611416|catechins
1340017|NCT00611416|caffeine
1340018|NCT00611416|energy expenditure
1340019|NCT00611416|fat oxidation
1340020|NCT00611416|appetite
1340021|NCT00611403|LASIK
1340022|NCT00611390|Viral laryngitis;
1340023|NCT00611390|Viral tracheitis;
1340024|NCT00611390|Herbal medicine;
1340025|NCT00611390|Traditional medicine;
1340026|NCT00611390|Aromatic essential oils;
1340027|NCT00611377|delirium
1340028|NCT00611377|mechanical ventilation
1340029|NCT00611377|age
1340030|NCT00611377|severity score
1340031|NCT00611364|Physical therapy
1340032|NCT00611364|hypertension
1340033|NCT00611364|aged
1340034|NCT00611364|exercise
1340035|NCT00611364|Physical exercise
1340036|NCT00611364|Physical activity
1340037|NCT00611351|graft versus host disease
1340038|NCT00611351|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1340039|NCT00611351|adult acute myeloid leukemia with inv(16)(p13;q22)
1340040|NCT00611351|adult acute myeloid leukemia with t(15;17)(q22;q12)
1340041|NCT00611351|adult acute myeloid leukemia with t(16;16)(p13;q22)
1340042|NCT00611351|adult acute myeloid leukemia with t(8;21)(q22;q22)
1340043|NCT00611351|recurrent adult acute myeloid leukemia
1340044|NCT00611351|untreated adult acute myeloid leukemia
1340045|NCT00611351|untreated adult acute lymphoblastic leukemia
1340046|NCT00611351|accelerated phase chronic myelogenous leukemia
1340047|NCT00611351|blastic phase chronic myelogenous leukemia
1340048|NCT00611351|chronic phase chronic myelogenous leukemia
1340049|NCT00611351|relapsing chronic myelogenous leukemia
1340050|NCT00611351|stage III multiple myeloma
1340051|NCT00611351|refractory multiple myeloma
1340052|NCT00611351|de novo myelodysplastic syndromes
1340053|NCT00611351|myelodysplastic/myeloproliferative disease, unclassifiable
1340054|NCT00611351|previously treated myelodysplastic syndromes
1340055|NCT00611351|secondary myelodysplastic syndromes
1340056|NCT00611351|secondary myelofibrosis
1340057|NCT00611351|secondary acute myeloid leukemia
1340058|NCT00611351|recurrent adult Burkitt lymphoma
1340059|NCT00611351|recurrent adult diffuse large cell lymphoma
1340060|NCT00611351|recurrent adult diffuse mixed cell lymphoma
1340061|NCT00611351|recurrent adult diffuse small cleaved cell lymphoma
1340062|NCT00611351|recurrent adult Hodgkin lymphoma
1340063|NCT00611351|recurrent adult immunoblastic large cell lymphoma
1340064|NCT00611351|recurrent adult lymphoblastic lymphoma
1340065|NCT00611351|recurrent adult T-cell leukemia/lymphoma
1340066|NCT00611351|recurrent cutaneous T-cell non-Hodgkin lymphoma
1340067|NCT00611351|recurrent grade 1 follicular lymphoma
1340068|NCT00611351|recurrent grade 2 follicular lymphoma
1340069|NCT00611351|recurrent grade 3 follicular lymphoma
1340070|NCT00611351|recurrent mantle cell lymphoma
1340071|NCT00611351|recurrent marginal zone lymphoma
1340072|NCT00611351|recurrent small lymphocytic lymphoma
1340073|NCT00611351|recurrent adult acute lymphoblastic leukemia
1340074|NCT00611351|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1340075|NCT00611351|nodal marginal zone B-cell lymphoma
1340076|NCT00611351|splenic marginal zone lymphoma
1340077|NCT00611351|adult nasal type extranodal NK/T-cell lymphoma
1340078|NCT00611351|stage III adult Hodgkin lymphoma
1340079|NCT00611351|stage IV adult Hodgkin lymphoma
1340080|NCT00611351|stage III adult T-cell leukemia/lymphoma
1340081|NCT00611351|stage IV adult T-cell leukemia/lymphoma
1340082|NCT00611351|stage III adult Burkitt lymphoma
1340083|NCT00611351|stage IV adult Burkitt lymphoma
1340084|NCT00611351|stage III adult diffuse large cell lymphoma
1340085|NCT00611351|stage IV adult diffuse large cell lymphoma
1340086|NCT00611351|stage III adult diffuse mixed cell lymphoma
1340087|NCT00611351|stage IV adult diffuse mixed cell lymphoma
1340088|NCT00611351|stage III adult immunoblastic large cell lymphoma
1340089|NCT00611351|stage IV adult immunoblastic large cell lymphoma
1340090|NCT00611351|stage III adult lymphoblastic lymphoma
1340091|NCT00611351|stage IV adult lymphoblastic lymphoma
1340092|NCT00611351|stage III grade 1 follicular lymphoma
1340093|NCT00611351|stage III grade 2 follicular lymphoma
1340094|NCT00611351|stage III grade 3 follicular lymphoma
1340095|NCT00611351|stage IV grade 1 follicular lymphoma
1340096|NCT00611351|stage IV grade 2 follicular lymphoma
1340097|NCT00611351|stage IV grade 3 follicular lymphoma
1340098|NCT00611351|stage III mantle cell lymphoma
1340099|NCT00611351|stage IV mantle cell lymphoma
1340100|NCT00611351|stage III marginal zone lymphoma
1340101|NCT00611351|stage IV marginal zone lymphoma
1340102|NCT00611351|stage III small lymphocytic lymphoma
1340103|NCT00611351|stage IV small lymphocytic lymphoma
1340104|NCT00611351|stage III adult diffuse small cleaved cell lymphoma
1340105|NCT00611351|stage IV adult diffuse small cleaved cell lymphoma
1340106|NCT00611351|adult acute lymphoblastic leukemia in remission
1340107|NCT00611351|adult acute myeloid leukemia in remission
1340108|NCT00611351|atypical chronic myeloid leukemia
1340109|NCT00611351|noncontiguous stage II adult Burkitt lymphoma
1340110|NCT00611351|noncontiguous stage II adult diffuse large cell lymphoma
1340111|NCT00611351|noncontiguous stage II adult diffuse mixed cell lymphoma
1340112|NCT00611351|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1340113|NCT00611351|noncontiguous stage II adult immunoblastic large cell lymphoma
1340114|NCT00611351|noncontiguous stage II adult lymphoblastic lymphoma
1340115|NCT00611351|noncontiguous stage II grade 1 follicular lymphoma
1340116|NCT00611351|noncontiguous stage II grade 2 follicular lymphoma
1340117|NCT00611351|noncontiguous stage II grade 3 follicular lymphoma
1340118|NCT00611351|noncontiguous stage II mantle cell lymphoma
1340119|NCT00611351|noncontiguous stage II marginal zone lymphoma
1340120|NCT00611351|noncontiguous stage II small lymphocytic lymphoma
1340121|NCT00611351|refractory hairy cell leukemia
1340122|NCT00611351|stage I multiple myeloma
1340123|NCT00611351|stage II multiple myeloma
1340124|NCT00611338|Complementary Therapies
1340125|NCT00611325|Glioblastoma
1340126|NCT00611325|Gliosarcoma
1340127|NCT00611325|Glioblastoma multiforme
1340128|NCT00611325|Recurrent malignant glioma
1340129|NCT00611325|GBM
1340130|NCT00611325|Recurrent GBM
1340131|NCT00611325|Malignant glioma
1340132|NCT00611325|Brain tumor
1340133|NCT00611325|Avastin
1340134|NCT00611325|Bevacizumab
1340135|NCT00611325|Bortezomib
1340136|NCT00611325|Velcade
1340137|NCT00611312|Alzheimer's disease
1340138|NCT00611312|Cognitive training
1340139|NCT00611299|Probiotics
1340140|NCT00611299|Immune response
1340141|NCT00611299|Blood lipids
1340142|NCT00611299|Intestinal microflora
1340143|NCT00611299|Tolerance
1340144|NCT00611286|Drug-eluting stent
1340145|NCT00611286|clopidogrel
1340146|NCT00611286|bare metal stent
1340147|NCT00611286|landmark analysis
1340148|NCT00611286|Patients with coronary artery disease
1340149|NCT00611273|Glabellar Furrowing
1340150|NCT00611260|Meditation
1340151|NCT00611260|Congestive Heart Failure
1340152|NCT00611260|ICD
1340153|NCT00611260|Cardiac Resynchronization Therapy
1340154|NCT00611221|massage
1340155|NCT00611221|labour
1340156|NCT00611195|Anesthesia
1340157|NCT00611195|Children
1340158|NCT00611195|Larynx
1340159|NCT00611182|dyspnea
1340160|NCT00611182|pulmonary fibrosis
1340161|NCT00611182|interstitial lung disease
1340162|NCT00611182|shortness of breath
1340163|NCT00611169|Angioplasty, Transluminal, Percutaneous Coronary
1340164|NCT00611169|tirofiban
1340165|NCT00611169|Magnetic Resonance Imaging
1340166|NCT00611169|Myocardial Infarction
1340167|NCT00611156|Thermogenesis
1340168|NCT00611156|Meal-induced thermogenesis
1340169|NCT00611156|energy expenditure
1340170|NCT00611156|fat oxidation
1340171|NCT00611156|bioactive ingredients
1340172|NCT00611156|spices
1340173|NCT00611156|ginger
1340174|NCT00611156|horseradish
1340175|NCT00611156|black pepper
1340176|NCT00611156|mustard
1340177|NCT00611143|Off-pump coronary artery bypass graft
1340178|NCT00611143|Atorvastatin
1340179|NCT00611143|Postoperative atrial fibrillation
1340180|NCT00611130|Cocaine
1340181|NCT00611130|Addiction
1340182|NCT00611130|Dependence
1340183|NCT00611130|Treatment
1340184|NCT00611117|adaptation to high fat diet
1340185|NCT00611117|activity
1340186|NCT00611117|exercise
1340187|NCT00611104|breast cancer
1340188|NCT00611078|Soft Tissue Sarcoma
1340189|NCT00611078|environment
1340190|NCT00611078|pollutants
1340191|NCT00611078|04-088
1340192|NCT00611052|Depressive Disorder
1340193|NCT00611052|Depressive Disorder, Major
1340194|NCT00611052|Mental Health
1340195|NCT00611052|Prevention
1340196|NCT00611039|Darunavir/ritonavir
1340197|NCT00611039|virtual inhibitory quotient
1340198|NCT00611039|dose reduction
1340199|NCT00611026|Treatment of overactive bladder
1340200|NCT00611013|Development of multi-purpose novel imaging protocols
1340201|NCT00611000|colon cancer
1340202|NCT00611000|rectal cancer
1340203|NCT00610987|Antibiotic Prophylaxis
1340204|NCT00610974|Spinal cord injury
1340205|NCT00610974|walking
1340206|NCT00610974|gait training
1340207|NCT00610974|body-weight supported treadmill training
1340208|NCT00610974|rehabilitation
1340209|NCT00610961|BK Polyomavirus
1340210|NCT00610961|Transplantation, Kidney
1340211|NCT00610961|Transplantation, Pancreas
1340212|NCT00610948|unspecified adult solid tumor, protocol specific
1340213|NCT00610935|Influenza
1340214|NCT00610935|Subjects with uncomplicated acute influenza
1340215|NCT00610922|Performance of motor skills
1340216|NCT00610909|IBS
1340217|NCT00610870|Myocardial infarct size
1340218|NCT00610870|Atorvastatin
1340219|NCT00610870|SPECT
1340220|NCT00610870|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1340221|NCT00610844|lung cancer
1340222|NCT00610844|lung metastasis
1340223|NCT00610844|radiofrequency ablation
1340224|NCT00610805|SLE
1340225|NCT00610805|lupus
1340226|NCT00610805|cardiovascular
1340227|NCT00610805|IMT
1340228|NCT00610805|Systemic Lupus Erythematosus
1340229|NCT00610779|Rhino-sinusitis;
1340230|NCT00610779|Herbal medicine;
1340231|NCT00610779|Traditional medicine;
1340232|NCT00610779|Aromatic essential oils;
1340233|NCT00610766|coronary CT angiography
1340234|NCT00610766|radiation dose estimates
1340235|NCT00610753|Anorexia nervosa
1340236|NCT00610753|Adolescents
1340237|NCT00610753|Family therapy
1340238|NCT00610740|recurrent cervical cancer
1340239|NCT00610740|cervical cancer
1340240|NCT00610740|endometrial carcinoma
1340241|NCT00610740|ovarian epithelial cancer
1340242|NCT00610740|recurrent ovarian epithelial cancer
1340243|NCT00610740|recurrent endometrial carcinoma
1340244|NCT00610727|Migraine, Prochlorperazine aerosol
1340245|NCT00610714|Cancer
1340246|NCT00610714|Tumour
1340247|NCT00610714|Ovarian Neoplasms
1340248|NCT00610714|Ovarian Cancer
1340249|NCT00610675|Fifty two weeks
1340250|NCT00610675|Open label
1340251|NCT00610675|extension
1340252|NCT00610662|cervical cancer
1340253|NCT00610662|cervical intraepithelial neoplasia grade 1
1340254|NCT00610662|cervical intraepithelial neoplasia grade 2
1340255|NCT00610662|cervical intraepithelial neoplasia grade 3
1340256|NCT00610649|randomized
1340257|NCT00610649|placebo controlled
1340258|NCT00610649|maximum tolerated dose
1340259|NCT00610636|FOLFOX-4
1340260|NCT00610636|neoadjuvant chemotherapy
1340261|NCT00610636|colorectal cancer
1340262|NCT00610636|liver metastasis
1340263|NCT00610636|resectability
1340264|NCT00610623|Pseudomonas aeruginosa
1340265|NCT00610623|Pneumonia
1340266|NCT00610623|Ventilator-Associated
1340267|NCT00610623|Quorum Sensing
1340268|NCT00610610|Fibromyalgia
1340269|NCT00610610|Paroxetine
1340270|NCT00610597|liver
1340271|NCT00610597|alcohol
1340272|NCT00610597|lymphocyte
1340273|NCT00610584|seasonal allergic rhinitis
1340274|NCT00610584|acupuncture
1340275|NCT00610584|RCT
1340276|NCT00610584|CAM
1340277|NCT00610571|Temodar
1340278|NCT00610571|Temozolomide
1340279|NCT00610571|Topotecan
1340280|NCT00610571|Hycamtin
1340281|NCT00610571|Malignant Gliomas
1340282|NCT00610571|Brain tumor
1340283|NCT00610571|Anaplastic astrocytoma
1340284|NCT00610571|AA
1340285|NCT00610571|GBM
1340286|NCT00610571|Glioblastoma Multiform
1340287|NCT00610571|Gliosarcoma
1340288|NCT00610545|ATORVASTATIN
1340289|NCT00610545|VASCULAR SURGERY
1340290|NCT00610545|CARDIOVASCULAR OUTCOMES
1340291|NCT00610532|pharmacoresistance
1340292|NCT00610532|healthy volunteers
1340293|NCT00610519|Viral pharyngo-tonsillitis;
1340294|NCT00610519|Herbal medicine;
1340295|NCT00610519|Traditional medicine;
1340296|NCT00610519|Aromatic essential oils;
1340297|NCT00610506|Atypical Depression
1340298|NCT00610493|Advanced Cancer
1340299|NCT00610493|Bevacizumab
1340300|NCT00610493|Temsirolimus
1340301|NCT00610493|Avastin
1340302|NCT00610493|Torisel
1340303|NCT00610493|CCI-779
1340304|NCT00610493|Anti-VEGF monoclonal antibody
1340305|NCT00610493|rhuMAb-VEGF
1340306|NCT00610493|dynamic contrast-enhanced magnetic resonance imaging
1340307|NCT00610493|DCE
1340308|NCT00610493|magnetic resonance imaging
1340309|NCT00610493|MRI
1340310|NCT00610480|Dry Eyes
1340311|NCT00610480|Tear Film Stability
1340312|NCT00610454|Levetiracetam
1340313|NCT00610454|Keppra
1340314|NCT00610441|randomized
1340315|NCT00610441|double blind
1340316|NCT00610441|placebo controlled
1340317|NCT00610428|Migraine, Staccato Prochlorperazine
1340318|NCT00610428|Migraine headache with or without aura.
1340319|NCT00610376|Handwashing
1340320|NCT00610376|Randomized controlled trial
1340321|NCT00610376|Cluster randomization
1340322|NCT00610376|Community intervention trial
1340323|NCT00610376|Disease prevention
1340324|NCT00610376|Pediatric communicable disease
1340325|NCT00610376|Preschool
1340326|NCT00610376|Illness absenteeism
1340327|NCT00610350|Levosimendan
1340328|NCT00610350|pre-conditioning
1340329|NCT00610350|cardiac surgery
1340330|NCT00610350|myocardial function
1340331|NCT00610350|contractility
1340332|NCT00610350|heart
1340333|NCT00610350|ischaemia
1340334|NCT00610324|oropharyngeal cleansing
1340335|NCT00610324|oral decontamination
1340336|NCT00610324|oropharyngeal bacterial flora
1340337|NCT00610324|oropharyngeal colonization
1340338|NCT00610324|critical illness
1340339|NCT00610324|mechanical ventilation
1340340|NCT00610324|tracheal intubation
1340341|NCT00610324|prophylaxis
1340342|NCT00610311|Metastatic Melanoma
1340343|NCT00610311|Immunotherapy
1340344|NCT00610311|Vaccination
1340345|NCT00610311|Tumor Regression
1340346|NCT00610311|Skin Cancer
1340347|NCT00610298|disability affecting strength, balance and coordination
1340348|NCT00610272|single bone metastasis
1340349|NCT00610272|multiple bone metastasis
1340350|NCT00610272|pain relief
1340351|NCT00610272|radiotherapy
1340352|NCT00610259|Depressive disorder
1340353|NCT00610259|Sleep initiation and maintenance disorder
1340354|NCT00610259|Behavior therapy
1340355|NCT00610246|Thorax
1340356|NCT00610246|Abdomen
1340357|NCT00610246|Pelvis
1340358|NCT00610246|Lesion
1340359|NCT00610246|Cancer
1340360|NCT00610246|Radiation
1340361|NCT00610246|Chemotherapy
1340362|NCT00610246|Phase 1
1340363|NCT00610246|Advanced Cancer
1340364|NCT00610246|Sorafenib
1340365|NCT00610246|Nexavar
1340366|NCT00610246|BAY43-9006
1340367|NCT00610233|deep brain stimulation
1340368|NCT00610233|urodynamics
1340369|NCT00610220|pediatrics
1340370|NCT00610220|wrist fractures
1340371|NCT00610220|casting
1340372|NCT00610220|wrist splint
1340373|NCT00610207|Anal fistula
1340374|NCT00610207|fistula in ano
1340375|NCT00610207|anorectal fistula
1340376|NCT00610207|Crohn's Disease
1340377|NCT00610181|Breast Cancer
1340378|NCT00610181|Breast Carcinoma
1340379|NCT00610181|Invasive Lobular Cancer
1340380|NCT00610181|Mixed Invasive Ductal-lobular Carcinoma
1340381|NCT00610181|Magnetic Resonance Imaging
1340382|NCT00610181|MRI
1340383|NCT00610168|dTpa vaccine
1340384|NCT00610168|pertussis
1340385|NCT00610168|Tdap
1340386|NCT00610168|Boostrix
1340387|NCT00610168|booster
1340388|NCT00610168|tetanus
1340389|NCT00610168|diphtheria
1340390|NCT00610142|atopic dermatitis
1340391|NCT00610142|pimecrolimus
1340392|NCT00610142|hydrocortison
1340393|NCT00610142|Optical Coherence Tomography
1340394|NCT00610129|MK-0646
1340395|NCT00610090|UNITE
1340396|NCT00610090|AAA
1340397|NCT00610090|Abdominal Aortic Aneurysms
1340398|NCT00610090|Stent
1340399|NCT00610090|Graft
1340400|NCT00610077|Letrozole
1340401|NCT00610077|Clomiphene citrate
1340402|NCT00610077|Anovulatory infertility
1340403|NCT00610077|Ovulation induction
1340404|NCT00610064|Refractory lower urinary tract dysfunction
1340405|NCT00610064|Sacral neuromodulation
1340406|NCT00610064|Brain effects
1340407|NCT00610064|Neuroimaging
1340408|NCT00610064|Neuromodulation
1340409|NCT00610051|severe heart failure
1340410|NCT00610051|transplants
1340411|NCT00610038|neonatal
1340412|NCT00610038|diabetes mellitus
1340413|NCT00610038|mutation
1340414|NCT00610038|KIR6.2
1340415|NCT00610038|SUR1
1340416|NCT00610038|Neonatal diabetes mellitus with KIR6.2 or SUR1 mutations
1340417|NCT00610025|NOTES
1340418|NCT00610025|transgastric endoscopy
1340419|NCT00610025|obesity surgery
1340420|NCT00610025|Roux-en-Y surgery
1340421|NCT00610012|Advanced Renal Cell Carcinoma
1340422|NCT00610012|MRCC
1340423|NCT00610012|Therapy-reality
1340424|NCT00610012|Observation
1340425|NCT00610012|Registry
1340426|NCT00610012|RCC
1340427|NCT00610012|ARCC
1340428|NCT00610012|Germany
1340429|NCT00610012|Metastatic Renal Cell Carcinoma
1340430|NCT00610012|Renal Cell Carcinoma
1340431|NCT00610012|Renal Cell Cancer
1340432|NCT00610012|Sorafenib
1340433|NCT00610012|Sunitinib
1340434|NCT00610012|Interferon
1340435|NCT00610012|Interleukin
1340436|NCT00610012|Temsirolimus
1340437|NCT00610012|Pazopanib
1340438|NCT00610012|Cytokines
1340439|NCT00610012|VEGF
1340440|NCT00609999|Glioblastoma
1340441|NCT00609999|Gliosarcoma
1340442|NCT00609999|GBM
1340443|NCT00609999|Recurrent MG
1340444|NCT00609999|Erlotinib
1340445|NCT00609999|Dasatinib
1340446|NCT00609999|Brain tumor
1340447|NCT00609999|Malignant glioma
1340448|NCT00609999|Tarceva
1340449|NCT00609999|Sprycel
1340450|NCT00609986|Kidney
1340451|NCT00609986|Transplantation
1340452|NCT00609986|Diabetes
1340453|NCT00609986|Hyperglycemia
1340454|NCT00609973|Postoperative recurrence, inflammatory bowel disease
1340455|NCT00609960|children anesthesia anxiety clowns
1340456|NCT00609934|renal cell carcinoma
1340457|NCT00609934|kidney cancer
1340458|NCT00609934|bone metastases
1340459|NCT00609934|RCC
1340460|NCT00609934|bone pain
1340461|NCT00609934|palliative radiotherapy
1340462|NCT00609934|sorafenib
1340463|NCT00609934|radiation
1340464|NCT00609934|renal cell
1340465|NCT00609882|Nasal CPAP
1340466|NCT00609882|High flow nasal cannula
1340467|NCT00609882|Neonate
1340468|NCT00609843|Bladder cancer
1340469|NCT00609843|Radiotherapy
1340470|NCT00609843|Tumour delineation
1340471|NCT00609843|Markers
1340472|NCT00609830|Glucocorticoids
1340473|NCT00609830|Osteoporosis
1340474|NCT00609830|Rheumatoid Arthritis
1340475|NCT00609830|Prevention
1340476|NCT00609830|GIOP
1340477|NCT00609830|Patient Education
1340478|NCT00609817|Relapsed Multiple Myeloma
1340479|NCT00609817|Refractory Multiple Myeloma
1340480|NCT00609817|GCS 100
1340481|NCT00609804|Non-Small Cell Lung Cancer
1340482|NCT00609804|Advanced
1340483|NCT00609804|Erlotinib
1340484|NCT00609804|Sorafenib
1340485|NCT00609804|Progressing on erlotinib
1340486|NCT00609791|recurrent breast cancer
1340487|NCT00609791|stage IV breast cancer
1340488|NCT00609791|male breast cancer
1340489|NCT00609778|CPR
1340490|NCT00609778|Mechanical
1340491|NCT00609778|Manual
1340492|NCT00609778|Survival
1340493|NCT00609778|ROSC
1340494|NCT00609765|advanced
1340495|NCT00609765|unresectable
1340496|NCT00609765|metastatic
1340497|NCT00609765|endocrine
1340498|NCT00609765|tumors
1340499|NCT00609752|Crohn Disease
1340500|NCT00609752|Children
1340501|NCT00609752|Bone Density
1340502|NCT00609752|Prednisolone
1340503|NCT00609752|Liquid Diet Therapy
1340504|NCT00609752|Quality of Life
1340505|NCT00609752|Metabolic Bone Disease
1340506|NCT00609739|juvenile myelomonocytic leukemia
1340507|NCT00609726|Endoscopic Ultrasonography
1340508|NCT00609726|Pancreatitis
1340509|NCT00609726|EUS
1340510|NCT00609713|Child
1340511|NCT00609713|Obesity
1340512|NCT00609700|burn injury
1340513|NCT00609700|volume replacement
1340514|NCT00609700|Ringer's Lactate solution
1340515|NCT00609700|Ringer's Acetate solution
1340516|NCT00609700|volume replacement with crystalloids
1340517|NCT00609687|sarcoidosis
1340518|NCT00609687|diagnostic vitrectomy
1340519|NCT00609687|vitreous biopsy
1340520|NCT00609687|sarcoidosis-associated ocular inflammation
1340521|NCT00609674|Perennial allergic rhinitis; fluticasone furoate nasal spray
1340522|NCT00609661|Mesenchymal Stem Cells, Burn
1340523|NCT00609648|Dental Anxiety
1340524|NCT00609648|Dental Phobia
1340525|NCT00609648|Odontophobia
1340526|NCT00609635|Respiratory
1340527|NCT00609635|RSV-induced respiratory illness
1340528|NCT00609622|metastatic colorectal cancer sunitinib (Sutent) bevacizumab (Avastin) randomized study
1340529|NCT00609609|Allogeneic stem cell grafts
1340530|NCT00609609|Allogeneic bone marrow graft
1340531|NCT00609609|Blood and Marrow Transplantation
1340532|NCT00609609|Stem cell graft
1340533|NCT00609609|Graft Versus Host Disease
1340534|NCT00609609|GVHD
1340535|NCT00609609|Extracorporeal Photopheresis
1340536|NCT00609609|ECP
1340537|NCT00609609|Photopheresis
1340538|NCT00609609|Methylprednisolone
1340539|NCT00609609|Medrol
1340540|NCT00609609|Depo-Medrol
1340541|NCT00609609|Solu-Medrol
1340542|NCT00609596|dutasteride
1340543|NCT00609596|tamsulosin
1340544|NCT00609596|benign prostatic hyperplasia
1340545|NCT00609570|hypertension
1340546|NCT00609570|supplement
1340547|NCT00609570|HRV
1340548|NCT00609557|osteoarthritis pain
1340549|NCT00609557|activity limitation
1340550|NCT00609557|antidepressant
1340551|NCT00609557|depression
1340552|NCT00609557|single-blind
1340553|NCT00609544|Non Dialysis-dependent chronic kidney disease and anemia
1340554|NCT00609531|Restricted repetitive behaviors
1340555|NCT00609531|restricted interests
1340556|NCT00609531|Aspergers
1340557|NCT00609531|Autism
1340558|NCT00609505|Hereditary Breast and Ovarian Cancer syndrome
1340559|NCT00609505|genetic counseling
1340560|NCT00609505|breast cancer
1340561|NCT00609505|ovarian cancer
1340562|NCT00609505|telemedicine
1340563|NCT00609505|Cancer genetic counseling
1340564|NCT00609479|Distal radius fracture
1340565|NCT00609479|Colle´s fracture
1340566|NCT00609479|Internal fixation
1340567|NCT00609479|External fixation
1340568|NCT00609479|DASH
1340569|NCT00609479|PRWE
1340570|NCT00609466|Opioid
1340571|NCT00609466|Central acting analgesic
1340572|NCT00609466|CG5503 IR
1340573|NCT00609466|Postoperative pain
1340574|NCT00609466|Bunionectomy
1340575|NCT00609466|Morphine
1340576|NCT00609466|Placebo
1340577|NCT00609453|Control participants
1340578|NCT00609440|Morquio's disease; physiotherapy; results
1340579|NCT00609427|cognitive training
1340580|NCT00609427|cognitive rehabilitation
1340581|NCT00609414|Burns
1340582|NCT00609414|Albumin
1340583|NCT00609414|Fluid Resuscitation
1340584|NCT00609401|Sorafenib
1340585|NCT00609401|RCC
1340586|NCT00609401|Metastatic disease
1340587|NCT00609375|Sepsis
1340588|NCT00609375|Bacteremia
1340589|NCT00609375|Intravenous infusions
1340590|NCT00609375|cefepime
1340591|NCT00609362|BMD
1340592|NCT00609362|Rosiglitazone
1340593|NCT00609362|Bone marrow fat
1340594|NCT00609349|risk factors for pulmonary arterial hypertension
1340595|NCT00609323|Pain
1340596|NCT00609323|postherpetic neuralgia
1340597|NCT00609310|clinical trial
1340598|NCT00609310|flavonoid treatment
1340599|NCT00609310|neoplasia recurrence
1340600|NCT00609310|colorectal cancer
1340601|NCT00609310|polypectomy
1340602|NCT00609310|adenoma in Colon
1340603|NCT00609310|Neoplasia Recurrence Rates
1340604|NCT00609310|postpolypectomy patients
1340605|NCT00609297|unspecified adult solid tumor, protocol specific
1340606|NCT00609297|pain
1340607|NCT00609284|Stage III
1340608|NCT00609284|Stage IV
1340609|NCT00609284|locally advanced
1340610|NCT00609245|epilepsy
1340611|NCT00609245|photosensitive
1340612|NCT00609245|valproic acid
1340613|NCT00609219|recurrent nasopharyngeal cancer
1340614|NCT00609219|stage II nasopharyngeal cancer
1340615|NCT00609219|stage III nasopharyngeal cancer
1340616|NCT00609219|stage IV nasopharyngeal cancer
1340617|NCT00609180|Acute Lung Injury
1340618|NCT00609180|Acute Respiratory Distress Syndrome
1340619|NCT00609180|Feeding
1340620|NCT00609180|Critical Care
1340621|NCT00609180|Ventilator
1340622|NCT00609180|Omega-3 Fatty Acid
1340623|NCT00609180|Antioxidant
1340624|NCT00609167|stage II multiple myeloma
1340625|NCT00609167|stage III multiple myeloma
1340626|NCT00609154|Type 2 diabetes
1340627|NCT00609154|Insulin
1340628|NCT00609154|biosynthesis
1340629|NCT00609154|Non diabetic control
1340630|NCT00609128|tears
1340631|NCT00609128|conjunctival epithelial cells
1340632|NCT00609128|olopatadine
1340633|NCT00609128|impression cytology
1340634|NCT00609115|Sub-acute care
1340635|NCT00609115|Robotics
1340636|NCT00609102|Type 2 diabetes
1340637|NCT00609089|Family
1340638|NCT00609089|treatment
1340639|NCT00609089|reinforcement
1340640|NCT00609089|substance
1340641|NCT00609089|trial
1340642|NCT00609089|drug
1340643|NCT00609089|abuse
1340644|NCT00609089|HIV
1340645|NCT00609089|risk
1340646|NCT00609063|Statins
1340647|NCT00609063|Myalgia
1340648|NCT00609063|Muscle Cramp
1340649|NCT00609050|cystic fibrosis
1340650|NCT00609050|exercise
1340651|NCT00609050|perceived exertion
1340652|NCT00609050|aerobic fitness
1340653|NCT00609050|lung function
1340654|NCT00609050|health related quality of life
1340655|NCT00609050|self-regulated exercise
1340656|NCT00609037|Gastric Bypass
1340657|NCT00609037|Body contouring
1340658|NCT00609037|Excessive weight loss
1340659|NCT00609011|Melanoma
1340660|NCT00609011|Metastatic
1340661|NCT00608998|Chronic renal failure
1340662|NCT00608998|Vasculopathy
1340663|NCT00608998|Cardiovascular risk
1340664|NCT00608998|Chronic renal failure patients
1340665|NCT00608985|sleeplessness
1340666|NCT00608985|orexin receptor antagonist
1340667|NCT00608985|almorexant
1340668|NCT00608985|insomnia
1340669|NCT00608972|negative for a protein called HER2/neu
1340670|NCT00608972|negative for estrogen receptors (ER) and progesterone receptors (PR).
1340671|NCT00608972|breast cancer
1340672|NCT00608959|Skin colonization
1340673|NCT00608959|Catheter colonization
1340674|NCT00608959|Catheter site infection
1340675|NCT00608946|efficacy of treatment with copper in patients with mild Alzheimer´s disease
1340676|NCT00608946|cognitive status over time
1340677|NCT00608946|CSF and volumetric data over time (1 year)
1340678|NCT00608933|unspecified adult solid tumor, protocol specific
1340679|NCT00608933|unspecified childhood solid tumor, protocol specific
1340680|NCT00608920|SPECT
1340681|NCT00608894|Autoimmune hepatitis
1340682|NCT00608894|Chronic active hepatitis
1340683|NCT00608881|Huntington's disease
1340684|NCT00608881|Huntington disease
1340685|NCT00608881|HD
1340686|NCT00608881|coenzyme Q10
1340687|NCT00608881|CoQ
1340688|NCT00608868|Carcinoma
1340689|NCT00608868|Non Small Cell Lung
1340690|NCT00608868|EGFR mutation
1340691|NCT00608868|Gefitinib
1340692|NCT00608855|bone metastases
1340693|NCT00608855|pain
1340694|NCT00608855|unspecified adult solid tumor, protocol specific
1340695|NCT00608816|epinephrine
1340696|NCT00608790|Tuberculosis, TB, Mycobacterium tuberculosis, children, South Africa
1340697|NCT00608777|Localized mild breakthrough
1340698|NCT00608764|Chronic Obstructive Pulmonary Disease
1340699|NCT00608764|COPD
1340700|NCT00608764|Emphysema
1340701|NCT00608764|Chronic Bronchitis
1340702|NCT00608764|Genetics
1340703|NCT00608764|Association Studies
1340704|NCT00608764|Computed Tomography
1340705|NCT00608751|Newly Diagnosed head and neck cancer
1340706|NCT00608738|neutropenia
1340707|NCT00608738|infection
1340708|NCT00608738|radiation toxicity
1340709|NCT00608738|chemotherapeutic agent toxicity
1340710|NCT00608738|malnutrition
1340711|NCT00608738|musculoskeletal complications
1340712|NCT00608738|thrombocytopenia
1340713|NCT00608738|unspecified adult solid tumor, protocol specific
1340714|NCT00608725|heart rate
1340715|NCT00608725|blood pressure
1340716|NCT00608725|blood volume
1340717|NCT00608725|sympathetic nervous system
1340718|NCT00608725|orthostatic tachycardia
1340719|NCT00608725|orthostatic intolerance
1340720|NCT00608725|POTS
1340721|NCT00608712|bariatric surgery
1340722|NCT00608712|ulcer prevention
1340723|NCT00608699|Flushing
1340724|NCT00608699|GSK256073A,
1340725|NCT00608699|Dose Escalation,
1340726|NCT00608699|Immediate Release Niacin,
1340727|NCT00608686|NIAAA
1340728|NCT00608686|Alcohol
1340729|NCT00608686|Neurosteroids
1340730|NCT00608686|Intoxication
1340731|NCT00608673|discoid lupus erythematosus
1340732|NCT00608673|pimecrolimus 1% cream
1340733|NCT00608673|betamethasone valerate 0.1% cream
1340734|NCT00608660|Peripheral Facial Paralysis
1340735|NCT00608660|Acupuncture
1340736|NCT00608660|RCT
1340737|NCT00608634|actinic keratosis
1340738|NCT00608621|physostigmine
1340739|NCT00608621|postoperative analgesia
1340740|NCT00608621|pain
1340741|NCT00608621|patient-controlled analgesia
1340742|NCT00608621|Opioid consumption
1340743|NCT00608621|Pain quality (VAS Score)
1340744|NCT00608621|Hemodynamics
1340745|NCT00608621|Mobilisation
1340746|NCT00608621|Side effects
1340747|NCT00608595|adenocarcinoma of the rectum
1340748|NCT00608595|recurrent rectal cancer
1340749|NCT00608595|stage I rectal cancer
1340750|NCT00608595|stage II rectal cancer
1340751|NCT00608595|stage III rectal cancer
1340752|NCT00608582|Transcranial Magnetic Stimulation, Repetitive
1340753|NCT00608582|TMS
1340754|NCT00608582|Treat Naming
1340755|NCT00608582|Aphasia
1340756|NCT00608582|Chronic Stroke
1340757|NCT00608582|Randomized, Controlled Trial
1340758|NCT00608569|Drug Therapy, Combination
1340759|NCT00608569|HIV Non-Nucleoside Reverse Transcriptase Inhibitors
1340760|NCT00608569|HIV Protease Inhibitors
1340761|NCT00608569|Viral Load
1340762|NCT00608569|Virologic Failure
1340763|NCT00608556|Heterotaxy
1340764|NCT00608556|Primary Ciliary Dyskinesia
1340765|NCT00608556|Congenital Heart Disease
1340766|NCT00608556|Genetic Study
1340767|NCT00608556|Situs Inversus
1340768|NCT00608543|cognitive function
1340769|NCT00608543|psychosocial function
1340770|NCT00608543|augmentation
1340771|NCT00608543|treatment refractory depression
1340772|NCT00608530|pain
1340773|NCT00608530|chronic pain
1340774|NCT00608530|chronic back pain
1340775|NCT00608530|randomized clinical trial
1340776|NCT00608517|graft versus host disease
1340777|NCT00608517|accelerated phase chronic myelogenous leukemia
1340778|NCT00608517|adult acute lymphoblastic leukemia in remission
1340779|NCT00608517|adult acute myeloid leukemia in remission
1340780|NCT00608517|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1340781|NCT00608517|adult acute myeloid leukemia with inv(16)(p13;q22)
1340782|NCT00608517|adult acute myeloid leukemia with t(15;17)(q22;q12)
1340783|NCT00608517|adult acute myeloid leukemia with t(16;16)(p13;q22)
1340784|NCT00608517|adult acute myeloid leukemia with t(8;21)(q22;q22)
1340785|NCT00608517|blastic phase chronic myelogenous leukemia
1340786|NCT00608517|childhood acute lymphoblastic leukemia in remission
1340787|NCT00608517|childhood acute myeloid leukemia in remission
1340788|NCT00608517|childhood chronic myelogenous leukemia
1340789|NCT00608517|chronic phase chronic myelogenous leukemia
1340790|NCT00608517|de novo myelodysplastic syndromes
1340791|NCT00608517|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1340792|NCT00608517|myelodysplastic/myeloproliferative disease, unclassifiable
1340793|NCT00608517|nodal marginal zone B-cell lymphoma
1340794|NCT00608517|noncontiguous stage II adult Burkitt lymphoma
1340795|NCT00608517|noncontiguous stage II adult diffuse large cell lymphoma
1340796|NCT00608517|noncontiguous stage II adult diffuse mixed cell lymphoma
1340797|NCT00608517|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1340798|NCT00608517|noncontiguous stage II adult immunoblastic large cell lymphoma
1340799|NCT00608517|noncontiguous stage II adult lymphoblastic lymphoma
1340800|NCT00608517|noncontiguous stage II adult non-Hodgkin lymphoma
1340801|NCT00608517|noncontiguous stage II grade 1 follicular lymphoma
1340802|NCT00608517|noncontiguous stage II grade 2 follicular lymphoma
1340803|NCT00608517|noncontiguous stage II grade 3 follicular lymphoma
1340804|NCT00608517|noncontiguous stage II mantle cell lymphoma
1340805|NCT00608517|noncontiguous stage II marginal zone lymphoma
1340806|NCT00608517|noncontiguous stage II small lymphocytic lymphoma
1340807|NCT00608517|previously treated myelodysplastic syndromes
1340808|NCT00608517|secondary acute myeloid leukemia
1340809|NCT00608517|secondary myelodysplastic syndromes
1340810|NCT00608517|splenic marginal zone lymphoma
1340811|NCT00608517|stage I multiple myeloma
1340812|NCT00608517|stage II multiple myeloma
1340813|NCT00608517|refractory multiple myeloma
1340814|NCT00608517|stage III adult Burkitt lymphoma
1340815|NCT00608517|stage III adult Hodgkin lymphoma
1340816|NCT00608517|stage III adult diffuse large cell lymphoma
1340817|NCT00608517|stage III adult diffuse mixed cell lymphoma
1340818|NCT00608517|stage III adult diffuse small cleaved cell lymphoma
1340819|NCT00608517|stage III adult immunoblastic large cell lymphoma
1340820|NCT00608517|stage III adult lymphoblastic lymphoma
1340821|NCT00608517|stage III chronic lymphocytic leukemia
1340822|NCT00608517|stage III grade 1 follicular lymphoma
1340823|NCT00608517|stage III grade 2 follicular lymphoma
1340824|NCT00608517|stage III grade 3 follicular lymphoma
1340825|NCT00608517|stage III mantle cell lymphoma
1340826|NCT00608517|stage III marginal zone lymphoma
1340827|NCT00608517|stage III multiple myeloma
1340828|NCT00608517|stage III small lymphocytic lymphoma
1340829|NCT00608517|stage IV adult Burkitt lymphoma
1340830|NCT00608517|stage IV adult Hodgkin lymphoma
1340831|NCT00608517|stage IV adult diffuse large cell lymphoma
1340832|NCT00608517|stage IV adult diffuse mixed cell lymphoma
1340833|NCT00608517|stage IV adult diffuse small cleaved cell lymphoma
1340834|NCT00608517|stage IV adult immunoblastic large cell lymphoma
1340835|NCT00608517|stage IV adult lymphoblastic lymphoma
1340836|NCT00608517|stage IV chronic lymphocytic leukemia
1340837|NCT00608517|stage IV grade 1 follicular lymphoma
1340838|NCT00608517|stage IV grade 2 follicular lymphoma
1340839|NCT00608517|stage IV grade 3 follicular lymphoma
1340840|NCT00608517|stage IV mantle cell lymphoma
1340841|NCT00608517|stage IV marginal zone lymphoma
1340842|NCT00608517|stage IV small lymphocytic lymphoma
1340843|NCT00608517|Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia
1340844|NCT00608517|Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia
1340845|NCT00608517|refractory chronic lymphocytic leukemia
1340846|NCT00608517|childhood myelodysplastic syndromes
1340847|NCT00608517|stage III adult T-cell leukemia/lymphoma
1340848|NCT00608517|stage IV adult T-cell leukemia/lymphoma
1340849|NCT00608517|adult nasal type extranodal NK/T-cell lymphoma
1340850|NCT00608517|childhood nasal type extranodal NK/T-cell lymphoma
1340851|NCT00608517|stage III cutaneous T-cell non-Hodgkin lymphoma
1340852|NCT00608517|stage IV cutaneous T-cell non-Hodgkin lymphoma
1340853|NCT00608517|recurrent cutaneous T-cell non-Hodgkin lymphoma
1340854|NCT00608517|recurrent adult T-cell leukemia/lymphoma
1340855|NCT00608504|Behavioral Economics
1340856|NCT00608504|Drug self administration
1340857|NCT00608504|Opioid
1340858|NCT00608491|Acute Decompensated Heart Failure
1340859|NCT00608491|Acute Decompensated Heart Failure With Cardiorenal Syndrome
1340860|NCT00608491|Cardiorenal Syndrome
1340861|NCT00608491|Persistent Congestion
1340862|NCT00608491|Ultra Filtration
1340863|NCT00608465|Fibrolytic Dysfunction
1340864|NCT00608465|Obesity
1340865|NCT00608465|PAI-1
1340866|NCT00608452|Lung
1340867|NCT00608452|Ovarian
1340868|NCT00608452|Breast
1340869|NCT00608452|Hodgkin's
1340870|NCT00608439|CAST
1340871|NCT00608439|Centella asiatica
1340872|NCT00608439|Diabetes
1340873|NCT00608439|Diabetic neuropathy
1340874|NCT00608426|African Americans
1340875|NCT00608426|telephone counseling
1340876|NCT00608426|community health planning
1340877|NCT00608426|ethnic groups
1340878|NCT00608400|CLA
1340879|NCT00608400|PTH
1340880|NCT00608400|nutritional supplement
1340881|NCT00608374|Waldenström macroglobulinemia
1340882|NCT00608374|splenic marginal zone lymphoma
1340883|NCT00608374|stage I marginal zone lymphoma
1340884|NCT00608374|stage III marginal zone lymphoma
1340885|NCT00608374|stage IV marginal zone lymphoma
1340886|NCT00608374|contiguous stage II marginal zone lymphoma
1340887|NCT00608374|noncontiguous stage II marginal zone lymphoma
1340888|NCT00608348|exercise
1340889|NCT00608348|hypoglycemia
1340890|NCT00608348|sympathetic nerve activity
1340891|NCT00608335|Antifungal
1340892|NCT00608335|Echinocandin
1340893|NCT00608335|Candidiasis
1340894|NCT00608335|Micafungin
1340895|NCT00608322|Sepsis
1340896|NCT00608322|Severe sepsis
1340897|NCT00608322|Septic shock
1340898|NCT00608283|Kidney transplant
1340899|NCT00608283|Live donor transplant
1340900|NCT00608244|Tacrolimus
1340901|NCT00608244|Pharmacokinetics
1340902|NCT00608244|Liver Transplantation
1340903|NCT00608218|Asthma
1340904|NCT00608218|ciclesonide
1340905|NCT00608218|inhaled steroids
1340906|NCT00608218|Alvesco
1340907|NCT00608205|stage III squamous cell carcinoma of the hypopharynx
1340908|NCT00608205|stage III squamous cell carcinoma of the lip and oral cavity
1340909|NCT00608205|stage III squamous cell carcinoma of the oropharynx
1340910|NCT00608205|stage III squamous cell carcinoma of the larynx
1340911|NCT00608205|stage IV squamous cell carcinoma of the hypopharynx
1340912|NCT00608205|stage IV squamous cell carcinoma of the lip and oral cavity
1340913|NCT00608205|stage IV squamous cell carcinoma of the oropharynx
1340914|NCT00608205|stage IV squamous cell carcinoma of the larynx
1340915|NCT00608192|HIV
1340916|NCT00608192|viral hepatitis
1340917|NCT00608192|methadone maintenance
1340918|NCT00608192|case management
1340919|NCT00608192|costs
1340920|NCT00608192|vaccination
1340921|NCT00608192|risk reduction education
1340922|NCT00608179|epinephrine
1340923|NCT00608179|glucose clamp
1340924|NCT00608153|essential hypertension
1340925|NCT00608153|ARB
1340926|NCT00608153|compliance
1340927|NCT00608153|candesartan
1340928|NCT00608140|Advanced Heart Failure
1340929|NCT00608140|Non-Ischemic Heart Failure
1340930|NCT00608140|Mitral Regurgitation
1340931|NCT00608140|Mitral Valve Replacement
1340932|NCT00608140|Congestive Heart Failure
1340933|NCT00608140|Surgical Mitral Valvuloplasty
1340934|NCT00608140|Dilated Cardiomyopathy
1340935|NCT00608140|Annular Ring
1340936|NCT00608101|hypoglycemia
1340937|NCT00608101|exercise
1340938|NCT00608101|corticosteroids
1340939|NCT00608088|Breast feeding
1340940|NCT00608088|breastfeeding
1340941|NCT00608088|randomized clinical trial
1340942|NCT00608088|poverty
1340943|NCT00608062|endothelial function
1340944|NCT00608062|women
1340945|NCT00608062|female
1340946|NCT00608062|estrogen deficiency
1340947|NCT00608062|sex hormones
1340948|NCT00608062|adiposity
1340949|NCT00608062|oxidative stress
1340950|NCT00608062|antioxidants
1340951|NCT00608049|Blood Pressure
1340952|NCT00608049|Diabetes
1340953|NCT00608049|Nutrition
1340954|NCT00608049|Dietary Carbohydrate
1340955|NCT00608049|Lipoproteins
1340956|NCT00608049|Insulin Resistance
1340957|NCT00608036|Adolescents
1340958|NCT00608036|Neighborhood
1340959|NCT00608036|Walkability
1340960|NCT00608036|Physical Activity
1340961|NCT00608036|Quality of Life
1340962|NCT00608036|Ecological Analysis
1340963|NCT00608036|Dietary Patterns
1340964|NCT00608036|Weight Status
1340965|NCT00608036|Neighborhood Environment
1340966|NCT00608036|Food Environment
1340967|NCT00608036|Recreation Environment
1340968|NCT00608023|HIV
1340969|NCT00608023|Lipodystrophy
1340970|NCT00608023|Abdominal fat accumulation
1340971|NCT00608023|Growth hormone releasing hormone
1340972|NCT00608023|HIV-associated lipodystrophy
1340973|NCT00608023|Treatment experienced
1340974|NCT00608010|Preservation of supernumerary embryos in an IVF program
1340975|NCT00607997|Leukemia
1340976|NCT00607997|Myeloid
1340977|NCT00607997|Elderly
1340978|NCT00607997|Hematologic
1340979|NCT00607997|Blood
1340980|NCT00607997|Cancer
1340981|NCT00607997|Malignancy
1340982|NCT00607997|SNS-595
1340983|NCT00607997|Sunesis
1340984|NCT00607997|Hematologic Diseases
1340985|NCT00607997|Myelodysplastic Syndromes
1340986|NCT00607997|Older
1340987|NCT00607997|voreloxin
1340988|NCT00607997|reveal-1
1340989|NCT00607984|thiotepa
1340990|NCT00607984|melphalan
1340991|NCT00607984|brain tumor
1340992|NCT00607984|tumors of central nervous system and other solid tumors
1340993|NCT00607971|Constipation predominant irritable bowel syndrome
1340994|NCT00607958|Tipranavir
1340995|NCT00607958|ritonavir
1340996|NCT00607958|dose reduction
1340997|NCT00607958|inhibitory quotient
1340998|NCT00607945|Type 2 diabetes mellitus
1340999|NCT00607945|conjugated linoleic acid
1341000|NCT00607945|weight loss
1341001|NCT00607945|rosiglitazone
1341002|NCT00607945|glucose control
1341003|NCT00607945|insulin sensitivity
1341004|NCT00607932|recurrent prostate cancer
1341005|NCT00607906|safety
1341006|NCT00607906|pharmacodynamics
1341007|NCT00607906|diabetes
1341008|NCT00607906|pharmacokinetics
1341009|NCT00607893|Sleep-Disordered Breathing
1341010|NCT00607880|vascular access device complications
1341011|NCT00607880|unspecified adult solid tumor, protocol specific
1341012|NCT00607867|Diabetes Mellitus (type 2)
1341013|NCT00607867|Diet
1341014|NCT00607867|Glycohemoglobin
1341015|NCT00607867|Lipids
1341016|NCT00607867|Kidney Function
1341017|NCT00607867|Glycemic Index
1341018|NCT00607867|Dietary Protein
1341019|NCT00607867|Dietary Carbohydrate
1341020|NCT00607854|Zevalin
1341021|NCT00607854|Reduced intensity conditioning
1341022|NCT00607854|Allogenic stem cell transplantation
1341023|NCT00607828|adult primary hepatocellular carcinoma
1341024|NCT00607828|advanced adult primary liver cancer
1341025|NCT00607828|localized unresectable adult primary liver cancer
1341026|NCT00607828|recurrent adult primary liver cancer
1341027|NCT00607815|PTSD
1341028|NCT00607815|OEF/OIF
1341029|NCT00607815|Combat
1341030|NCT00607815|Treatment
1341031|NCT00607815|CPT
1341032|NCT00607815|PCT
1341033|NCT00607815|Cognitive
1341034|NCT00607802|unspecified adult solid tumor, protocol specific
1341035|NCT00607802|unspecified childhood solid tumor, protocol specific
1341036|NCT00607776|dry, eyes
1341037|NCT00607776|Amelioration of dry eye symptoms
1341038|NCT00607763|Antifungal
1341039|NCT00607763|Echinocandin
1341040|NCT00607763|Candidiasis
1341041|NCT00607763|Micafungin
1341042|NCT00607750|Wet AMD, Comentis, ATG003, mecamylamine
1341043|NCT00607724|unspecified adult solid tumor, protocol specific
1341044|NCT00607685|Trabeculectomy
1341045|NCT00607685|Wound healing
1341046|NCT00607685|5 Fluorouracil
1341047|NCT00607685|Hyaluronic acid
1341048|NCT00607685|post-operative scarring
1341049|NCT00607672|Angiotensin Converting Enzyme
1341050|NCT00607672|Angiotensin Receptor Blockers
1341051|NCT00607672|Cardiopulmonary Bypass
1341052|NCT00607672|Fibrinolysis
1341053|NCT00607672|Inflammation
1341054|NCT00607659|Chlamydia
1341055|NCT00607659|Chlamydia trachomatis
1341056|NCT00607659|Adolescent Health
1341057|NCT00607659|Female Health
1341058|NCT00607659|Sexually Transmitted Infections
1341059|NCT00607659|Infertility
1341060|NCT00607659|Pelvic Inflammatory Disease
1341061|NCT00607646|hypoglycemia
1341062|NCT00607646|dehydroepiandrosterone
1341063|NCT00607633|essential hypertension
1341064|NCT00607633|ARB
1341065|NCT00607633|left ventricular hypertrophy
1341066|NCT00607633|candesartan
1341067|NCT00607620|Alcohol Abuse
1341068|NCT00607620|Alcohol Dependence
1341069|NCT00607620|Alcohol Use Disorder
1341070|NCT00607620|Screening
1341071|NCT00607620|Brief Intervention
1341072|NCT00607620|Motivational Interviewing
1341073|NCT00607607|ovarian cancer
1341074|NCT00607607|endometrial cancer
1341075|NCT00607581|amyloidosis
1341076|NCT00607581|lenalidomide
1341077|NCT00607581|cyclophosphamide
1341078|NCT00607581|dexamethasone
1341079|NCT00607568|physical stress
1341080|NCT00607568|psychological stress
1341081|NCT00607555|Infant, premature
1341082|NCT00607555|Infant, very low birth weight
1341083|NCT00607555|Apnea
1341084|NCT00607555|Feeding methods
1341085|NCT00607555|Diaphragm
1341086|NCT00607542|spasticity
1341087|NCT00607542|cerebral palsy
1341088|NCT00607542|baclofen
1341089|NCT00607542|pharmacokinetics
1341090|NCT00607542|pharmacodynamics
1341091|NCT00607542|dosing
1341092|NCT00607542|safety
1341093|NCT00607542|efficacy
1341094|NCT00607529|Multiple Diseases
1341095|NCT00607516|fracture
1341096|NCT00607516|arthroplasty
1341097|NCT00607516|wear
1341098|NCT00607516|osteoporosis
1341099|NCT00607516|bone
1341100|NCT00607490|Vulvodynia
1341101|NCT00607490|Vulvar pain
1341102|NCT00607490|Dyspareunia
1341103|NCT00607490|Sexual dysfunction
1341104|NCT00607490|Vestibulitis
1341105|NCT00607464|Hypothermia, premature infants, Polyethylene occlusive wrap
1341106|NCT00607438|Locally Advanced or Metastatic
1341107|NCT00607425|non-small cell lung cancer
1341108|NCT00607425|screening
1341109|NCT00607425|saliva
1341110|NCT00607425|gene expression
1341111|NCT00607425|healthy control subject
1341112|NCT00607412|PTSD
1341113|NCT00607412|substance use disorders
1341114|NCT00607412|psychotherapy
1341115|NCT00607399|Solid tumor
1341116|NCT00607399|Advanced Cancer
1341117|NCT00607399|MET Inhibitor
1341118|NCT00607399|Receptor Tyrosine Kinase Inhibitor (RTKI)
1341119|NCT00607386|Hunter syndrome
1341120|NCT00607386|hunters syndrome
1341121|NCT00607386|hunter's syndrome
1341122|NCT00607386|hunter disease
1341123|NCT00607386|hunters disease
1341124|NCT00607386|hunter's disease
1341125|NCT00607386|MPS II
1341126|NCT00607386|MPSII
1341127|NCT00607386|MPS2
1341128|NCT00607386|MPS 2
1341129|NCT00607386|mucopolysaccharides
1341130|NCT00607386|lysosomal storage disease
1341131|NCT00607386|lysosomal storage disorder
1341132|NCT00607386|chronic ear infection
1341133|NCT00607386|enlarged adenoids
1341134|NCT00607386|mps symptoms
1341135|NCT00607386|mps diagnosis
1341136|NCT00607386|mps ii therapy
1341137|NCT00607386|MPS II treatment
1341138|NCT00607386|ert treatment
1341139|NCT00607386|elaprase
1341140|NCT00607386|idursulfase
1341141|NCT00607386|iduronate sulfatase
1341142|NCT00607386|iduronate 2 sulfatase
1341143|NCT00607386|enzyme replacement therapy
1341144|NCT00607386|hunter syndrome treatment
1341145|NCT00607386|hunter's syndrome treatment
1341146|NCT00607386|hunter syndrome therapy
1341147|NCT00607386|hunter's disease treatment
1341148|NCT00607386|mps society
1341149|NCT00607373|Apolipoprotein B
1341150|NCT00607373|Homozygous Familial Hypercholesterolemia
1341151|NCT00607373|LDL-receptor gene
1341152|NCT00607360|cocaine addiction, treatment, contingency management, employment intervention
1341153|NCT00607347|Keywords by National Institute of General Medical Sciences
1341154|NCT00607347|Hypertension
1341155|NCT00607347|Adverse metabolic effects
1341156|NCT00607347|Beta blockers
1341157|NCT00607347|Dyslipidemia
1341158|NCT00607347|Atenolol
1341159|NCT00607347|New onset diabetes
1341160|NCT00607347|Pharmacokinetic study
1341161|NCT00607347|Oral glucose tolerance test
1341162|NCT00607334|Child Language
1341163|NCT00607334|Language Therapy
1341164|NCT00607334|Vocabulary
1341165|NCT00607321|restenosis
1341166|NCT00607321|Coronary Disease
1341167|NCT00607321|Coronary Arteriosclerosis
1341168|NCT00607321|Arterial Occlusive Diseases
1341169|NCT00607295|chemotherapy
1341170|NCT00607295|hormonal therapy
1341171|NCT00607295|urogenital atrophy
1341172|NCT00607269|Drug Abuse
1341173|NCT00607269|Contingency management
1341174|NCT00607269|Voucher-based Reinforcement Therapy
1341175|NCT00607269|Homosexuality
1341176|NCT00607269|Homeless Persons
1341177|NCT00607243|Smallpox vaccine efficacy
1341178|NCT00607230|type 1 diabetes mellitus
1341179|NCT00607230|immune modulation
1341180|NCT00607230|cure
1341181|NCT00607230|autoimmunity
1341182|NCT00607217|Coronary artery diseases
1341183|NCT00607217|Myocardial infarction
1341184|NCT00607217|Stable angina
1341185|NCT00607217|Influenza
1341186|NCT00607217|Vaccine
1341187|NCT00607204|Basic Research
1341188|NCT00607204|Individual Sleep Duration
1341189|NCT00607204|Melatonin
1341190|NCT00607204|Electroencephalogram
1341191|NCT00607204|Alertness
1341192|NCT00607204|Mood
1341193|NCT00607191|Idiopathic talipes equinovarus (ITEV)
1341194|NCT00607178|Influenza
1341195|NCT00607178|Vaccine
1341196|NCT00607126|impaired ambulation
1341197|NCT00607113|Neuroendocrine Carcinoma
1341198|NCT00607113|Avastin
1341199|NCT00607113|Bevacizumab
1341200|NCT00607113|RAD001
1341201|NCT00607113|Everolimus
1341202|NCT00607100|High-Resolution Optical Coherence Tomography
1341203|NCT00607100|Retinal Nerve Fiber Layer
1341204|NCT00607100|Band Atrophy
1341205|NCT00607061|Glutathione
1341206|NCT00607061|Cysteine
1341207|NCT00607061|Synthesis rate
1341208|NCT00607061|Newborns
1341209|NCT00607061|Low birth weight newborn babies
1341210|NCT00607022|dental implant
1341211|NCT00607022|early loading
1341212|NCT00607022|traditional loading
1341213|NCT00607022|anterior
1341214|NCT00607022|implant stability
1341215|NCT00607022|Subjects presenting with one tooth missing in the anterior
1341216|NCT00607022|incisor/canine) or pre-molar regions of the mandible
1341217|NCT00607022|or maxilla with existing teeth that were healthy
1341218|NCT00607022|or adequately restored shall be screened.
1341219|NCT00606996|Drug Abuse
1341220|NCT00606996|Drug Dependence
1341221|NCT00606996|Alcohol Abuse
1341222|NCT00606996|Alcohol Dependence
1341223|NCT00606996|Major Depressive Disorder
1341224|NCT00606996|Dysthymic Disorder
1341225|NCT00606996|Prisoners
1341226|NCT00606996|Women
1341227|NCT00606970|Chemotherapy
1341228|NCT00606970|Breast Cancer
1341229|NCT00606970|Colon Cancer
1341230|NCT00606970|Lung Cancer
1341231|NCT00606957|Obesity
1341232|NCT00606957|Metabolism
1341233|NCT00606944|enhanced recovery program
1341234|NCT00606931|biopsy
1341235|NCT00606931|PET
1341236|NCT00606931|image-guidance
1341237|NCT00606931|breast cancer
1341238|NCT00606931|FDG
1341239|NCT00606931|PEM
1341240|NCT00606918|Strength testing
1341241|NCT00606918|Disease progression
1341242|NCT00606918|ALS
1341243|NCT00606918|Healthy Adults
1341244|NCT00606905|Recurrent miscarriage
1341245|NCT00606905|Recurrent spontaneous abortion
1341246|NCT00606905|Habitual abortion
1341247|NCT00606905|IVIG
1341248|NCT00606905|Randomized Controlled Trial
1341249|NCT00606892|therapeutic effects
1341250|NCT00606879|Solid tumor
1341251|NCT00606879|Advanced Cancer
1341252|NCT00606879|MET inhibitor
1341253|NCT00606879|Receptor Tyrosine Kinase Inhibitor (RTKI)
1341254|NCT00606866|renal, metastatic, carcinoma
1341255|NCT00606853|Substance abuse
1341256|NCT00606853|Contingency Management
1341257|NCT00606840|overweight
1341258|NCT00606840|prevention of weight gain
1341259|NCT00606840|young adults
1341260|NCT00606840|self-regulation
1341261|NCT00606840|daily weighing
1341262|NCT00606840|weight gain prevention
1341263|NCT00606827|Contrast-induced nephrophaty
1341264|NCT00606827|Contrast media
1341265|NCT00606827|Angiography
1341266|NCT00606827|Coronary percutaneous intervention
1341267|NCT00606814|Solid Tumors, IPI-504, docetaxel,cancer
1341268|NCT00606801|cognitive enhancers
1341269|NCT00606801|Nootropic Agents
1341270|NCT00606788|randomized clinical trials
1341271|NCT00606788|intensive care
1341272|NCT00606788|mechanical ventilation
1341273|NCT00606788|ventilator weaning
1341274|NCT00606788|clinical protocols
1341275|NCT00606788|therapy, computer-assisted
1341276|NCT00606788|humans
1341277|NCT00606788|various surgical diseases requiring mechanical ventilation over 24 hours
1341278|NCT00606775|Adrenergic beta-Antagonists
1341279|NCT00606775|Duchenne Muscular Dystrophy
1341280|NCT00606775|Cardiomyopathies
1341281|NCT00606775|Troponin I
1341282|NCT00606762|laparoscopic cholecystectomy
1341283|NCT00606762|low pressure pneumoperitoneum
1341284|NCT00606736|right ventricular outflow tract arrhythmia
1341285|NCT00606736|sex hormone level
1341286|NCT00606736|menstrual cycle
1341287|NCT00606736|Gonadal Hormones
1341288|NCT00606723|relapsed or refractory AML
1341289|NCT00606723|in children, adolescents and young adults
1341290|NCT00606697|Primary Insomnia Adults
1341291|NCT00606684|Chronic Obstructive Pulmonary Disease (COPD)
1341292|NCT00606684|COPD
1341293|NCT00606684|GW642444
1341294|NCT00606671|polycystic ovary syndrome (PCOS)
1341295|NCT00606658|Insomnia
1341296|NCT00606658|Ayurveda
1341297|NCT00606658|Shirodhara
1341298|NCT00606658|Quality of Life
1341299|NCT00606632|Renal Mass
1341300|NCT00606632|Clear Cell Renal Cell Carcinoma
1341301|NCT00606632|Cancer of Kidney
1341302|NCT00606632|Kidney Cancer
1341303|NCT00606632|Neoplasms
1341304|NCT00606632|cG250
1341305|NCT00606632|antibody, monoclonal
1341306|NCT00606632|Iodine 124
1341307|NCT00606632|Positron-Emission Tomography
1341308|NCT00606632|Kidney
1341309|NCT00606632|Renal Cancer
1341310|NCT00606632|Renal Neoplasms
1341311|NCT00606619|Gastrectomy
1341312|NCT00606619|Oral feeding
1341313|NCT00606619|Nutrition
1341314|NCT00606619|Gastric cancer
1341315|NCT00606593|insomnia
1341316|NCT00606593|elderly
1341317|NCT00606593|sleeplessness
1341318|NCT00606580|cutaneous leishmaniasis, topical treatment, Tunisia
1341319|NCT00606567|Defibrillators, Implantable
1341320|NCT00606554|Respiratory Insufficiency
1341321|NCT00606554|Ventilators, Mechanical
1341322|NCT00606554|Ventilator Weaning
1341323|NCT00606554|Therapy, Computer-Assisted
1341324|NCT00606541|Social Anxiety Disorder
1341325|NCT00606541|Quetiapine XR
1341326|NCT00606541|Prevention
1341327|NCT00606541|tolerability
1341328|NCT00606528|Antiviral therapy
1341329|NCT00606515|Pharmacokinetics
1341330|NCT00606515|Liposomal paclitaxel
1341331|NCT00606502|Stage IIIB/IV non-small cell lung cancer
1341332|NCT00606502|Non-small cell lung cancer
1341333|NCT00606502|NSCLC
1341334|NCT00606502|Lung Cancer
1341335|NCT00606502|Pralatrexate
1341336|NCT00606502|Erlotinib
1341337|NCT00606502|Tarceva
1341338|NCT00606502|PDX
1341339|NCT00606502|Smoking
1341340|NCT00606502|Smoker
1341341|NCT00606450|plaque psoriasis
1341342|NCT00606437|Umbilical Cord Blood Graft
1341343|NCT00606437|Stem Cell Transplantation
1341344|NCT00606424|head and neck cancer
1341345|NCT00606411|Sleep-Related Eating Disorder
1341346|NCT00606411|Topiramate
1341347|NCT00606411|Parasomnia
1341348|NCT00606398|colorectal metastases
1341349|NCT00606385|Recurrence
1341350|NCT00606385|Survival
1341351|NCT00606385|Immunology
1341352|NCT00606385|Laparoscopy
1341353|NCT00606372|Off-pump
1341354|NCT00606372|OPCAB
1341355|NCT00606372|EuroSCORE
1341356|NCT00606372|high-risk patients
1341357|NCT00606372|Quality of life
1341358|NCT00606372|Validity of EuroSCORE
1341359|NCT00606359|Influenza
1341360|NCT00606359|Orthomyxoviridae Infections
1341361|NCT00606359|Renal Transplant
1341362|NCT00606346|Crohn's Disease
1341363|NCT00606346|Ulcerative Colitis
1341364|NCT00606346|Indeterminate Colitis
1341365|NCT00606346|Inflammatory Bowel Diseases
1341366|NCT00606346|Immunomodulators
1341367|NCT00606346|infliximab
1341368|NCT00606346|TNF-alpha
1341369|NCT00606333|Coronary artery disease
1341370|NCT00606333|drug-eluting stents
1341371|NCT00606333|sirolimus-eluting coronary stents
1341372|NCT00606294|Head
1341373|NCT00606294|Neck
1341374|NCT00606294|04-070
1341375|NCT00606268|Antifungal Prophylaxis
1341376|NCT00606268|Hematopoietic Stem Cell Transplant
1341377|NCT00606268|HSCT
1341378|NCT00606268|Micafungin
1341379|NCT00606255|blood pressure
1341380|NCT00606255|compliance
1341381|NCT00606255|treatment
1341382|NCT00606216|MRI
1341383|NCT00606164|Alzheimer's Disease
1341384|NCT00606164|bryostatin 1
1341385|NCT00606164|bryostatin
1341386|NCT00606164|safety
1341387|NCT00606164|efficacy
1341388|NCT00606164|pharmacokinetics
1341389|NCT00606164|pharmacodynamics
1341390|NCT00606164|protein kinase C
1341391|NCT00606151|drug eluding stents
1341392|NCT00606151|perioperative bridging
1341393|NCT00606151|Stents
1341394|NCT00606125|Chemotherapy
1341395|NCT00606125|Solid Tumors
1341396|NCT00606125|Sorafenib
1341397|NCT00606125|Carboplatin
1341398|NCT00606125|Paclitaxel
1341399|NCT00606099|Adults
1341400|NCT00606099|compensated chronic hepatitis B
1341401|NCT00606099|telbivudin
1341402|NCT00606099|aedevofir dipivoxil
1341403|NCT00606086|Hepatitis, HCV, Liver disease, HepC
1341404|NCT00606060|Hemophilia,
1341405|NCT00606060|Continuous Infusion
1341406|NCT00606047|femoroacetabular impingement
1341407|NCT00606034|Type 2 diabetes
1341408|NCT00606034|Insulin Resistance
1341409|NCT00606034|Continuous Subcutaneous Insulin Infusion
1341410|NCT00606034|U-500 Insulin
1341411|NCT00606034|Omnipod
1341412|NCT00606008|Sutent
1341413|NCT00605995|Schizophrenia
1341414|NCT00605995|Randomized trial
1341415|NCT00605995|Statin
1341416|NCT00605995|Placebo
1341417|NCT00605982|MRI
1341418|NCT00605969|femoroacetabular, impingement
1341419|NCT00605956|head lice
1341420|NCT00605956|NatrOVA Creme Rinse - 1% is intended for the treatment of head lice
1341421|NCT00605943|Retinal Disease
1341422|NCT00605943|Bevacizumab
1341423|NCT00605943|Ranibizumab
1341424|NCT00605943|Retinal Eye Disease
1341425|NCT00605943|Macular Degeneration
1341426|NCT00605930|Progressive Supranuclear Palsy
1341427|NCT00605930|PSP
1341428|NCT00605930|Nutriceutical
1341429|NCT00605930|Pyruvate
1341430|NCT00605930|Creatine
1341431|NCT00605930|Niacinamide
1341432|NCT00605904|Chemical Stressor
1341433|NCT00605904|Alcoholism
1341434|NCT00605904|Yohimbine
1341435|NCT00605904|Acamprosate
1341436|NCT00605904|Craving
1341437|NCT00605878|Atopic Dermatitis (Eczema)
1341438|NCT00605878|Bacteria
1341439|NCT00605878|Filaggrin
1341440|NCT00605878|Skin
1341441|NCT00605878|Microbiome
1341442|NCT00605878|Atopic Dermatitis
1341443|NCT00605878|Eczema
1341444|NCT00605878|Health Volunteer
1341445|NCT00605878|HG
1341446|NCT00605852|Allergic rhinitis
1341447|NCT00605852|first time in human
1341448|NCT00605839|mobile technology
1341449|NCT00605839|cell phones
1341450|NCT00605839|type 1 diabetes
1341451|NCT00605800|Liver resection
1341452|NCT00605774|catecholamines
1341453|NCT00605774|diabetes
1341454|NCT00605774|exercise
1341455|NCT00605761|Cystic Fibrosis
1341456|NCT00605761|Lung function
1341457|NCT00605761|Anti-Inflammatory
1341458|NCT00605748|catheter ablation
1341459|NCT00605748|atrial fibrillation
1341460|NCT00605748|pulmonary vein
1341461|NCT00605696|Acute Respiratory Distress Syndrome
1341462|NCT00605696|Acute Lung Injury
1341463|NCT00605657|ALPS
1341464|NCT00605657|Valproic Acid
1341465|NCT00605657|Lymphadenopathy
1341466|NCT00605657|Splenomegaly
1341467|NCT00605657|Histone Deacytelase (HDAC) Inhibitor
1341468|NCT00605657|Autoimmune Lymphoproliferative Syndrome
1341469|NCT00605631|Pacing
1341470|NCT00605605|endothelial function
1341471|NCT00605605|atherosclerosis
1341472|NCT00605605|smoking
1341473|NCT00605605|inflammation
1341474|NCT00605605|antioxidant
1341475|NCT00605592|Type 1 Diabetes
1341476|NCT00605592|Kidney Transplant
1341477|NCT00605592|Hypoglycemic Unawareness
1341478|NCT00605592|Islet Transplant
1341479|NCT00605592|Pancreatic Islet Cell Transplantation
1341480|NCT00605592|University of Virginia
1341481|NCT00605592|Islet Transplantation
1341482|NCT00605592|Kidney Transplantation
1341483|NCT00605566|Neuroendocrine
1341484|NCT00605566|sorafenib
1341485|NCT00605566|cyclophosphamide
1341486|NCT00605566|pharmacodynamic
1341487|NCT00605540|COPD
1341488|NCT00605540|Survival
1341489|NCT00605540|Exacerbation
1341490|NCT00605540|Disease markers
1341491|NCT00605527|Acute Lung Injury
1341492|NCT00605527|Acute Respiratory Distress Syndrome
1341493|NCT00605514|Hemorrhagic Fever
1341494|NCT00605514|Healthy
1341495|NCT00605514|Immunity
1341496|NCT00605514|T-Cells
1341497|NCT00605514|Filovirus
1341498|NCT00605514|Healthy Volunteer
1341499|NCT00605514|HV
1341500|NCT00605488|Pet Scan
1341501|NCT00605475|Type 2 Diabetes Mellitus
1341502|NCT00605475|Canakinumab
1341503|NCT00605475|ACZ885
1341504|NCT00605475|IL-1B antagonist
1341505|NCT00605475|metformin
1341506|NCT00605475|glycemic control
1341507|NCT00605475|insulin sensitivity
1341508|NCT00605449|GSK376501
1341509|NCT00605449|Simvastatin
1341510|NCT00605449|Healthy Subjects
1341511|NCT00605449|Repeat Dose
1341512|NCT00605449|Drug Interaction
1341513|NCT00605449|Randomized
1341514|NCT00605449|Pharmacokinetics
1341515|NCT00605436|overweight
1341516|NCT00605436|sedentary
1341517|NCT00605436|metabolic syndrome
1341518|NCT00605423|AMD
1341519|NCT00605423|Almera
1341520|NCT00605423|Steroid
1341521|NCT00605423|Macular
1341522|NCT00605423|ARMD
1341523|NCT00605410|Methacholine bronchoprovocation
1341524|NCT00605410|Antimuscarinic
1341525|NCT00605397|Cu-64 LABELED TRASTUZUMAB
1341526|NCT00605371|Healthy volunteers
1341527|NCT00605371|Bioequivalence
1341528|NCT00605371|Food Effects
1341529|NCT00605358|geriatric depression
1341530|NCT00605319|BPH
1341531|NCT00605319|BOO
1341532|NCT00605306|Asthma
1341533|NCT00605306|spirometry
1341534|NCT00605306|lung function
1341535|NCT00605306|serum cortisol
1341536|NCT00605306|serum potassium
1341537|NCT00605306|plasma glucose
1341538|NCT00605280|randomized sham-controlled multicenter macular edema
1341539|NCT00605267|Breast Cancer
1341540|NCT00605267|Breast Neoplasms
1341541|NCT00605267|Tumors or cancer of the human BREAST
1341542|NCT00605267|Tumor or cancer of the human MAMMARY GLAND
1341543|NCT00605254|P-Glycoprotein
1341544|NCT00605254|Positron Emission Tomography
1341545|NCT00605254|Blood Brain Barrier
1341546|NCT00605254|Quantitative Imaging
1341547|NCT00605254|Multi-Drug Transporter
1341548|NCT00605254|Healthy Volunteer
1341549|NCT00605254|HV
1341550|NCT00605241|pharmacodynamics,
1341551|NCT00605241|pharmacokinetics,
1341552|NCT00605241|tolerability,
1341553|NCT00605241|Safety,
1341554|NCT00605241|single dose,
1341555|NCT00605241|placebo,
1341556|NCT00605241|Nicotine reward
1341557|NCT00605241|GSK598809
1341558|NCT00605176|Actinic keratosis
1341559|NCT00605176|Skin disease
1341560|NCT00605163|Parkinson disease, observational, longitudinal
1341561|NCT00605150|Unresectable HCC
1341562|NCT00605124|osteoarthritis
1341563|NCT00605124|knee
1341564|NCT00605124|total knee arthroplasty
1341565|NCT00605124|exercise
1341566|NCT00605098|HIV
1341567|NCT00605098|Pregnancy
1341568|NCT00605098|Vertical disease transmission
1341569|NCT00605098|Pharmacokinetics
1341570|NCT00605098|HIV seronegativity
1341571|NCT00605072|cognitive disorders
1341572|NCT00605072|angiotensin receptor blockers
1341573|NCT00605059|Alzheimer
1341574|NCT00605059|SPECT
1341575|NCT00605046|Alzheimer
1341576|NCT00605046|SPECT
1341577|NCT00605007|COPD
1341578|NCT00605007|Diabetes
1341579|NCT00605007|Respiratory Disorders
1341580|NCT00604994|Lymphoedema
1341581|NCT00604994|Gynaecology
1341582|NCT00604994|Oncology
1341583|NCT00604994|Malignant
1341584|NCT00604994|Benign
1341585|NCT00604994|Incidence
1341586|NCT00604955|visceral leishmaniasis
1341587|NCT00604955|kala-azar
1341588|NCT00604955|Bihar, India
1341589|NCT00604942|Oesophagus
1341590|NCT00604942|Dysphagia
1341591|NCT00604942|Impedance
1341592|NCT00604942|High Resolution Manometry
1341593|NCT00604942|Peristalsis
1341594|NCT00604942|Contractile Pressure
1341595|NCT00604942|Coordination of contraction
1341596|NCT00604942|Bolus transport
1341597|NCT00604929|muscle protein synthesis
1341598|NCT00604929|whole-body protein breakdown
1341599|NCT00604929|nutrition
1341600|NCT00604916|oral hygiene
1341601|NCT00604890|Double-Blind
1341602|NCT00604890|Placebo
1341603|NCT00604890|Topical
1341604|NCT00604890|Treatment
1341605|NCT00604890|Dose-Ranging
1341606|NCT00604890|sBCC
1341607|NCT00604877|exercise
1341608|NCT00604877|glucose metabolism
1341609|NCT00604877|insulin sensitivity
1341610|NCT00604877|Vascular Function
1341611|NCT00604864|deep endometriosis
1341612|NCT00604864|pelvic pain
1341613|NCT00604864|infliximab
1341614|NCT00604864|anti TNFa
1341615|NCT00604838|amniotic fluid leakage
1341616|NCT00604838|urinary incontinence
1341617|NCT00604838|pregnancy
1341618|NCT00604838|home test
1341619|NCT00604838|vaginal wetness
1341620|NCT00604825|vasomotor symptoms
1341621|NCT00604825|hormone therapy
1341622|NCT00604825|hot flashes
1341623|NCT00604825|menopause
1341624|NCT00604786|Basophils
1341625|NCT00604786|Mast Cells
1341626|NCT00604786|IgE
1341627|NCT00604786|IgE receptors
1341628|NCT00604786|omalizumab
1341629|NCT00604773|delirium
1341630|NCT00604773|critical care
1341631|NCT00604773|risk factors
1341632|NCT00604773|prediction
1341633|NCT00604747|motor learning
1341634|NCT00604747|hemiplegia
1341635|NCT00604747|stroke
1341636|NCT00604747|practice
1341637|NCT00604747|physiotherapy
1341638|NCT00604695|ST-Elevation Myocardial Infarction
1341639|NCT00604695|Acute Myocardial Infarction
1341640|NCT00604695|No Reflow
1341641|NCT00604682|psoriasis
1341642|NCT00604669|Diabetes
1341643|NCT00604669|Nutrition/Dietics
1341644|NCT00604669|clinical outcomes
1341645|NCT00604669|total parenteral nutrition
1341646|NCT00604643|Abdominal Aneurysm
1341647|NCT00604643|Endovascular Aortic Repair (EVAR)
1341648|NCT00604643|Endovascular Stent Graft
1341649|NCT00604643|Endograft
1341650|NCT00604630|stroke
1341651|NCT00604630|EPO
1341652|NCT00604630|erythropoietin
1341653|NCT00604630|ischemia
1341654|NCT00604630|hypoxia
1341655|NCT00604630|antiapoptosis
1341656|NCT00604630|neuroprotection
1341657|NCT00604630|rtPA
1341658|NCT00604630|thrombolysis
1341659|NCT00604630|stroke, middle cerebral artery
1341660|NCT00604630|Ischemic stroke in the middle cerebral artery territory
1341661|NCT00604617|Mycobacterium tuberculosis
1341662|NCT00604617|Tuberculin Test
1341663|NCT00604617|South Africa
1341664|NCT00604591|Dementia Treatment
1341665|NCT00604591|Frontotemporal Dementia
1341666|NCT00604591|Dopamine
1341667|NCT00604591|Frontotemporal Lobar Degeneration
1341668|NCT00604578|Pioglitazone
1341669|NCT00604578|Asthma
1341670|NCT00604578|Peroxisome Proliferator-Advanced Receptor Gamma
1341671|NCT00604578|Airflow Obstruction
1341672|NCT00604578|Airway Inflammation
1341673|NCT00604565|Hemodialysis
1341674|NCT00604552|Abdominal Aneurysm
1341675|NCT00604552|Endovascular Aortic Repair (EVAR)
1341676|NCT00604552|Endovascular Stent Graft
1341677|NCT00604552|Endograft
1341678|NCT00604539|Chondroitin sulphate
1341679|NCT00604539|Synovitis
1341680|NCT00604539|Knee osteoarthritis
1341681|NCT00604539|Magnetic Resonance Imaging
1341682|NCT00604526|recurrent
1341683|NCT00604487|induction
1341684|NCT00604487|cervix
1341685|NCT00604487|balloon
1341686|NCT00604487|Bishop
1341687|NCT00604474|Deafness
1341688|NCT00604474|Hearing Loss
1341689|NCT00604474|Cochlear Implants
1341690|NCT00604474|Advanced Bionics
1341691|NCT00604474|HiResolution Bionic Ear System
1341692|NCT00604461|Carboplatin
1341693|NCT00604461|Bevacizumab
1341694|NCT00604461|Avastin
1341695|NCT00604461|Pemetrexed
1341696|NCT00604461|Alimta
1341697|NCT00604448|pulses
1341698|NCT00604448|beans
1341699|NCT00604448|obesity
1341700|NCT00604448|overweight
1341701|NCT00604448|metabolic syndrome
1341702|NCT00604435|breast cancer
1341703|NCT00604435|neoadjuvant chemotherapy
1341704|NCT00604435|docetaxel
1341705|NCT00604435|epirubicin
1341706|NCT00604435|recombinant human endostatin (endostar)
1341707|NCT00604435|chemotherapy
1341708|NCT00604435|endostatin
1341709|NCT00604422|Colonic disease
1341710|NCT00604422|Ulcerative colitis
1341711|NCT00604422|suspected or known colonic disease
1341712|NCT00604357|CNI free
1341713|NCT00604357|mTOR inhibition
1341714|NCT00604357|induction
1341715|NCT00604357|IL2 receptor antibodies
1341716|NCT00604357|renal function
1341717|NCT00604357|liver transplantation
1341718|NCT00604331|Pyruvic Acid
1341719|NCT00604331|Shock, Cardiogenic
1341720|NCT00604331|Catecholamines
1341721|NCT00604331|Intra-Aortic Balloon Pumping
1341722|NCT00604331|Cardiac Output
1341723|NCT00604331|Cardiac Index
1341724|NCT00604331|Cardiac Function
1341725|NCT00604318|quality of life
1341726|NCT00604292|Colonic Diseases
1341727|NCT00604279|Schizophrenia
1341728|NCT00604279|Paliperidone
1341729|NCT00604279|Paliperidone palmitate
1341730|NCT00604279|Risperidone
1341731|NCT00604279|Risperidone long acting injection
1341732|NCT00604279|R092670
1341733|NCT00604266|Potentially resectable hilar cholangiocarcinoma as per initial imaging studies.
1341734|NCT00604266|Able to undergo PET/CT and MRI with Gadolinium
1341735|NCT00604240|NICU
1341736|NCT00604240|caregivers
1341737|NCT00604240|discharge instructions
1341738|NCT00604227|high altitude pulmonary edema
1341739|NCT00604227|pulmonary interstitial fluid
1341740|NCT00604227|pulmonary function testing
1341741|NCT00604227|hypoxia
1341742|NCT00604227|pulmonary endothelial function
1341743|NCT00604227|high altitude exposure without prior acclimatization
1341744|NCT00604214|Sepsis
1341745|NCT00604214|Septic shock
1341746|NCT00604201|Myelodyplastic Syndrome (MDS)
1341747|NCT00604201|Severe Aplastic Anemia (SAA)
1341748|NCT00604201|Stem Cell Transplant
1341749|NCT00604201|Haploidentical Stem Cells
1341750|NCT00604201|Umbilical Cord Blood
1341751|NCT00604201|Severe Aplastic Anemia
1341752|NCT00604201|Myelodysplastic Syndrome
1341753|NCT00604201|MDS
1341754|NCT00604175|HIV
1341755|NCT00604175|HPV 6
1341756|NCT00604175|HPV 11
1341757|NCT00604175|HPV 16
1341758|NCT00604175|HPV 18
1341759|NCT00604175|Vaccine
1341760|NCT00604162|Suspected colonic disease
1341761|NCT00604162|Known colonic disease
1341762|NCT00604136|melanoma
1341763|NCT00604136|tumor infiltrating lymphocytes
1341764|NCT00604136|interleukin-2
1341765|NCT00604123|JNJ-17166864
1341766|NCT00604123|allergic rhinitis
1341767|NCT00604123|pharmacokinetics
1341768|NCT00604123|biomarkers
1341769|NCT00604123|rhinitis symptoms
1341770|NCT00604123|mountain cedar pollen
1341771|NCT00604110|Biventricular pacing
1341772|NCT00604110|resynchronisation therapy
1341773|NCT00604110|cardiac surgery
1341774|NCT00604110|ejection fraction of less 45%
1341775|NCT00604097|youth suicide
1341776|NCT00604097|family therapy
1341777|NCT00604097|primary care
1341778|NCT00604097|intervention
1341779|NCT00604084|Scabies
1341780|NCT00604084|Ivermectin
1341781|NCT00604084|Lindane
1341782|NCT00604084|Mass Eradication
1341783|NCT00604071|HMP, CNV, PHP, HPHP, AMD
1341784|NCT00604058|Poliomyelitis
1341785|NCT00604058|intradermal
1341786|NCT00604045|post traumatic stress disorder
1341787|NCT00604045|cognitive bias
1341788|NCT00604045|attention
1341789|NCT00604045|combat
1341790|NCT00604045|neuroimaging
1341791|NCT00604032|Safety when exposed to sunlight
1341792|NCT00604019|sepsis
1341793|NCT00604019|septic shock
1341794|NCT00604006|Prevention of heart failure in individuals at high risk
1341795|NCT00603993|Rheumatoid arthritis
1341796|NCT00603967|Breast Cancer
1341797|NCT00603967|Postmenopausal
1341798|NCT00603967|Aromatase
1341799|NCT00603954|Nonmyeloablative conditioning.
1341800|NCT00603954|Hematological malignancies.
1341801|NCT00603954|GVHD.
1341802|NCT00603941|Anaplastic Thyroid Cancer
1341803|NCT00603941|Neoplasm
1341804|NCT00603941|Tumor
1341805|NCT00603941|Anti-neoplastic Agent
1341806|NCT00603941|First-line treatment of advanced Anaplastic thyroid cancer
1341807|NCT00603928|attitude
1341808|NCT00603928|attitude of health personnel
1341809|NCT00603928|ethics
1341810|NCT00603928|bioethics
1341811|NCT00603928|biomedical ethics
1341812|NCT00603928|patient care
1341813|NCT00603928|physicians
1341814|NCT00603928|placebo effect
1341815|NCT00603928|placebos
1341816|NCT00603928|questionnaires
1341817|NCT00603928|therapy
1341818|NCT00603928|general practice
1341819|NCT00603915|gemcitabine
1341820|NCT00603915|carboplatin
1341821|NCT00603915|cisplatin
1341822|NCT00603915|erlotinib
1341823|NCT00603915|tarceva
1341824|NCT00603915|nasopharyngeal
1341825|NCT00603902|Obesity
1341826|NCT00603902|Weight loss
1341827|NCT00603902|lorcaserin
1341828|NCT00603902|APD356
1341829|NCT00603902|BLOSSOM
1341830|NCT00603902|Hypertension
1341831|NCT00603902|Dyslipidemia
1341832|NCT00603902|Sleep apnea
1341833|NCT00603902|glucose tolerance
1341834|NCT00603902|cardiovascular disease
1341835|NCT00603902|Arena
1341836|NCT00603889|Hookworm
1341837|NCT00603889|Allergy
1341838|NCT00603889|Vaccine
1341839|NCT00603889|Skin test
1341840|NCT00603863|pancreatic cancer
1341841|NCT00603863|hPAM4
1341842|NCT00603863|MUC1 antibody
1341843|NCT00603863|cancer of the pancreas
1341844|NCT00603850|HMP, PHP, AMD, CNV, HPHP
1341845|NCT00603837|Hypothermia
1341846|NCT00603837|Prevention
1341847|NCT00603837|ELGANs(Extremely low gestational age neonates)
1341848|NCT00603837|Polyethylene Wrap
1341849|NCT00603837|Sodium Acetate Transport Mattress
1341850|NCT00603824|heparin-Induced thrombocytopenia
1341851|NCT00603824|fondaparinux
1341852|NCT00603811|Influenza vaccines
1341853|NCT00603811|M2e
1341854|NCT00603798|Actinic keratosis
1341855|NCT00603798|Dermatologic disease
1341856|NCT00603785|Chronic sinusitis
1341857|NCT00603785|Xolair
1341858|NCT00603785|Nasal Discharge
1341859|NCT00603785|Nasal Obstruction
1341860|NCT00603785|Facial Pain
1341861|NCT00603785|Hyposmia
1341862|NCT00603772|Tretinoin
1341863|NCT00603772|exposure to UV light
1341864|NCT00603772|phototoxicity
1341865|NCT00603772|Safety when exposed to sunlight
1341866|NCT00603759|COX2 inhibitor
1341867|NCT00603759|head and neck cancer
1341868|NCT00603759|chemoradiation
1341869|NCT00603746|Adolescents
1341870|NCT00603746|Adults
1341871|NCT00603746|Asthma
1341872|NCT00603746|Pharmacokinetics
1341873|NCT00603746|Pharmacogenetics
1341874|NCT00603746|GW685698X
1341875|NCT00603733|Ulcerative Colitis
1341876|NCT00603733|5-Aminosalicylate
1341877|NCT00603720|PET
1341878|NCT00603720|Heart metabolism
1341879|NCT00603720|Nitric oxide
1341880|NCT00603720|Myocardial remodeling
1341881|NCT00603707|capsule
1341882|NCT00603707|constipation
1341883|NCT00603707|whole gut transit
1341884|NCT00603707|colonic transit
1341885|NCT00603707|gastric emptying
1341886|NCT00603707|small bowel transit
1341887|NCT00603694|Hippocampus
1341888|NCT00603694|Memory
1341889|NCT00603694|Radiation
1341890|NCT00603681|constipation
1341891|NCT00603681|aged
1341892|NCT00603681|polyethylene glycol
1341893|NCT00603668|CLL
1341894|NCT00603655|Diet
1341895|NCT00603655|glycemic load
1341896|NCT00603655|overweight
1341897|NCT00603655|obesity
1341898|NCT00603655|hyperlipidemia
1341899|NCT00603642|AMG 531
1341900|NCT00603642|Idiopathic Thrombocytopenic Purpura
1341901|NCT00603642|ITP
1341902|NCT00603642|Thrombocytopenia
1341903|NCT00603642|Japan
1341904|NCT00603642|Placebo controlled
1341905|NCT00603642|Phase 3
1341906|NCT00603629|Acute Asthma
1341907|NCT00603616|Inflammatory Bowel Disease
1341908|NCT00603616|Crohn disease
1341909|NCT00603616|Crohn's disease
1341910|NCT00603616|Rifaximin
1341911|NCT00603603|C-section
1341912|NCT00603603|Surg Wound Infect
1341913|NCT00603590|Cardiovascular disease
1341914|NCT00603590|primary prevention
1341915|NCT00603590|Polypill
1341916|NCT00603590|efficacy
1341917|NCT00603590|safety
1341918|NCT00603590|ADR
1341919|NCT00603590|Diabetes
1341920|NCT00603590|Adherence
1341921|NCT00603590|Compliance
1341922|NCT00603564|CPAP
1341923|NCT00603564|community-acquired pneumonia
1341924|NCT00603564|acute respiratory failure
1341925|NCT00603564|hypoxemia
1341926|NCT00603564|Continuous Positive Airway Pressure
1341927|NCT00603551|Osteoporosis
1341928|NCT00603551|Cancer
1341929|NCT00603551|Chemotherapy
1341930|NCT00603551|Bone Density
1341931|NCT00603551|DXA Scan
1341932|NCT00603551|Heel Scan
1341933|NCT00603538|CP-751,871, Non-small cell lung cancer, Phase 1
1341934|NCT00603512|Phase II MTX add-on study in Japan
1341935|NCT00603499|Diabetes
1341936|NCT00603499|Hypertension
1341937|NCT00603499|Hypomagnesemia
1341938|NCT00603486|Non-invasive Blood Pressure (NIBP)
1341939|NCT00603486|GE Dinamap
1341940|NCT00603486|SuperSTAT
1341941|NCT00603460|Ovarian Cancer
1341942|NCT00603460|Peritoneal Cancer
1341943|NCT00603434|Methamphetamine
1341944|NCT00603421|borderline personality disorder
1341945|NCT00603421|suicide
1341946|NCT00603421|suicidality
1341947|NCT00603421|suicide attempt
1341948|NCT00603421|suicidal behavior
1341949|NCT00603421|self-injurious behavior
1341950|NCT00603421|self-harm behavior
1341951|NCT00603421|suicide prevention center
1341952|NCT00603421|telephone intervention
1341953|NCT00603408|Breast Cancer
1341954|NCT00603408|Locally Advanced
1341955|NCT00603408|Neoadjuvant
1341956|NCT00603382|Adults
1341957|NCT00603382|Pharmacokinetics
1341958|NCT00603382|Pharmacogenetics
1341959|NCT00603382|Asthma
1341960|NCT00603382|Adolescents
1341961|NCT00603382|GW685698X
1341962|NCT00603369|HIV prevention
1341963|NCT00603369|HIV seronegativity
1341964|NCT00603356|GIST
1341965|NCT00603356|Ovarian Cancer
1341966|NCT00603356|Mesothelioma
1341967|NCT00603356|Renal
1341968|NCT00603356|Colorectal Cancer
1341969|NCT00603356|Sarcoma
1341970|NCT00603356|NSCLC
1341971|NCT00603356|Cancer
1341972|NCT00603343|antimuscarinics
1341973|NCT00603343|children
1341974|NCT00603343|overactive bladder
1341975|NCT00603343|propiverine
1341976|NCT00603343|urinary incontinence
1341977|NCT00603343|urotherapy
1341978|NCT00603330|Mesenchymal stem cells
1341979|NCT00603330|Graft-versus-host disease
1341980|NCT00603330|Poor graft function
1341981|NCT00603330|Chimerism
1341982|NCT00603330|Hematopoietic cell transplantation recipients
1341983|NCT00603330|Low donor T-cell chimerism
1341984|NCT00603317|Warfarin
1341985|NCT00603317|Drug interaction
1341986|NCT00603317|Pharmacogenetics
1341987|NCT00603317|Amoxicillin
1341988|NCT00603317|Clavulanic acid
1341989|NCT00603304|Serenoa repens
1341990|NCT00603304|Urological symptoms
1341991|NCT00603304|hyperplasia
1341992|NCT00603304|BPH
1341993|NCT00603291|obesity
1341994|NCT00603291|weight loss
1341995|NCT00603291|lorcaserin
1341996|NCT00603291|APD356
1341997|NCT00603291|BLOOM-DM
1341998|NCT00603291|hypertension
1341999|NCT00603291|dyslipidemia
1342000|NCT00603291|sleep apnea
1342001|NCT00603291|glucose tolerance
1342002|NCT00603291|cardiovascular disease
1342003|NCT00603291|Arena
1342004|NCT00603278|Adolescents
1342005|NCT00603278|Adults
1342006|NCT00603278|Pharmacokinetics
1342007|NCT00603278|Asthma
1342008|NCT00603278|GW685698X
1342009|NCT00603278|Pharmacogenetics
1342010|NCT00603265|Diabetic Peripheral Neuropathy
1342011|NCT00603265|Neuropathic Pain
1342012|NCT00603252|combined hepatitis A and B vaccine
1342013|NCT00603252|risk factors
1342014|NCT00603239|diabetes
1342015|NCT00603239|exenatide
1342016|NCT00603239|metformin
1342017|NCT00603239|thiazolidinedione
1342018|NCT00603239|Byetta
1342019|NCT00603239|Amylin
1342020|NCT00603239|Lilly
1342021|NCT00603226|Coronary slow flow phenomenon
1342022|NCT00603226|Coronary angiography
1342023|NCT00603226|Acute coronary syndrome
1342024|NCT00603226|Chest pain
1342025|NCT00603226|Unstable angina
1342026|NCT00603213|Congestive Heart Failure
1342027|NCT00603213|Impedance
1342028|NCT00603213|Optivol Thoracid Fluid Status monitoring system
1342029|NCT00603200|Quality of Life
1342030|NCT00603187|Male Contraception
1342031|NCT00603187|Acyline
1342032|NCT00603174|NAVA
1342033|NCT00603174|mechanical ventilation
1342034|NCT00603174|infants
1342035|NCT00603174|pediatric intensive care
1342036|NCT00603174|infant
1342037|NCT00603148|Genetic Polymorphism
1342038|NCT00603148|Integrin alpha2beta1
1342039|NCT00603148|Phenotype
1342040|NCT00603122|altitude illness
1342041|NCT00603122|hypoxia
1342042|NCT00603109|Body weight, fat mass, growth hormone, ghrelin
1342043|NCT00603083|Hip Arthroplasty
1342044|NCT00603083|Treatment Outcome
1342045|NCT00603083|Local Anesthesia
1342046|NCT00603070|Medication Errors
1342047|NCT00603070|Adverse Drug Events
1342048|NCT00603070|Patient Safety
1342049|NCT00603070|Electronic Prescribing Systems
1342050|NCT00603070|Medication Reconciliation
1342051|NCT00603057|Non Small Cell Lung Cancer
1342052|NCT00603018|eating disorders
1342053|NCT00603018|anorexia nervosa
1342054|NCT00603018|anorexia
1342055|NCT00603018|PET
1342056|NCT00603018|brain imaging
1342057|NCT00603018|serotonin
1342058|NCT00603018|fMRI
1342059|NCT00603018|Prozac
1342060|NCT00603018|fluoxetine
1342061|NCT00603005|Glaucoma
1342062|NCT00603005|Adherence
1342063|NCT00602992|3T MRI
1342064|NCT00602992|Gamma Knife Radiosurgery
1342065|NCT00602979|endotracheal intubation
1342066|NCT00602979|intubation
1342067|NCT00602979|laryngoscopy
1342068|NCT00602979|laryngoscope
1342069|NCT00602979|surgery
1342070|NCT00602966|Oocyte cryopreservation
1342071|NCT00602966|slow freeze
1342072|NCT00602966|vitrification
1342073|NCT00602940|PCOS
1342074|NCT00602940|ovulation
1342075|NCT00602940|hormones
1342076|NCT00602940|women
1342077|NCT00602927|Varenicline, Imaging, fMRI
1342078|NCT00602914|MicronJet (microneedles)
1342079|NCT00602914|Intradermal
1342080|NCT00602862|Angiogenesis inhibitors
1342081|NCT00602836|B-cell chronic lymphocytic leukemia
1342082|NCT00602836|stage I chronic lymphocytic leukemia
1342083|NCT00602836|stage II chronic lymphocytic leukemia
1342084|NCT00602836|stage III chronic lymphocytic leukemia
1342085|NCT00602836|stage IV chronic lymphocytic leukemia
1342086|NCT00602836|contiguous stage II small lymphocytic lymphoma
1342087|NCT00602836|noncontiguous stage II small lymphocytic lymphoma
1342088|NCT00602836|stage I small lymphocytic lymphoma
1342089|NCT00602836|stage III small lymphocytic lymphoma
1342206|NCT00602186|Tamsolusin
1342090|NCT00602836|stage IV small lymphocytic lymphoma
1342091|NCT00602758|AIDS
1342092|NCT00602758|Adherence
1342093|NCT00602758|Antiretroviral Therapy
1342094|NCT00602758|HIV
1342095|NCT00602745|pancreatic cancer
1342096|NCT00602732|Partner Abuse
1342097|NCT00602732|Preventive Intervention
1342098|NCT00602732|Postpartum Depression
1342099|NCT00602732|Postpartum PTSD
1342100|NCT00602706|refractory multiple myeloma
1342101|NCT00602706|stage I multiple myeloma
1342102|NCT00602706|stage II multiple myeloma
1342103|NCT00602706|stage III multiple myeloma
1342104|NCT00602693|chronic myelogenous leukemia
1342105|NCT00602693|recurrent mantle cell lymphoma
1342106|NCT00602693|prolymphocytic leukemia
1342107|NCT00602693|advanced chronic lymphocytic leukemia
1342108|NCT00602693|small lymphocytic lymphoma
1342109|NCT00602693|B-cell lymphoma
1342110|NCT00602693|follicular lymphoma
1342111|NCT00602693|diffuse large cell lymphoma
1342112|NCT00602693|anaplastic large cell lymphoma
1342113|NCT00602693|Hodgkin lymphoma
1342114|NCT00602693|multiple myeloma
1342115|NCT00602680|Alzheimer
1342116|NCT00602680|cognitive
1342117|NCT00602667|untreated childhood medulloblastoma
1342118|NCT00602667|untreated childhood supratentorial primitive neuroectodermal tumor
1342119|NCT00602667|untreated childhood pineoblastoma
1342120|NCT00602667|childhood atypical teratoid/rhabdoid tumor
1342121|NCT00602667|childhood choroid plexus tumor
1342122|NCT00602667|childhood high grade glioma
1342123|NCT00602667|newly diagnosed childhood ependymoma
1342124|NCT00602628|ductal breast carcinoma in situ
1342125|NCT00602628|invasive ductal breast carcinoma
1342126|NCT00602628|breast cancer in situ
1342127|NCT00602628|stage I breast cancer
1342128|NCT00602628|stage II breast cancer
1342129|NCT00602628|stage IIIA breast cancer
1342130|NCT00602602|stage IV pancreatic cancer
1342131|NCT00602602|recurrent pancreatic cancer
1342132|NCT00602589|open-label
1342133|NCT00602589|randomized
1342134|NCT00602589|crossover
1342135|NCT00602589|bioequivalence
1342136|NCT00602576|recurrent melanoma
1342137|NCT00602576|stage III melanoma
1342138|NCT00602576|stage IV melanoma
1342139|NCT00602563|Generalized Anxiety Disorder
1342140|NCT00602563|Information Processing
1342141|NCT00602550|HIV
1342142|NCT00602537|Bipolar Type II Disorder
1342143|NCT00602537|Hypomania
1342144|NCT00602537|Antidepressant
1342145|NCT00602537|Mood Stabilizer
1342146|NCT00602537|Venlafaxine
1342147|NCT00602537|Lithium Carbonate
1342148|NCT00602537|Major Depressive Episode
1342149|NCT00602537|Hypomanic Episodes
1342150|NCT00602537|Prevention of Depression Relapse
1342151|NCT00602511|Melfalan refractory multiple myeloma
1342152|NCT00602511|Multiple myeloma
1342153|NCT00602511|Relapsing
1342154|NCT00602511|Refractory
1342155|NCT00602511|Thalidomide
1342156|NCT00602511|Bortezomib
1342157|NCT00602511|Randomized clinical trial
1342158|NCT00602485|adherence, cardiac rehabilitation
1342159|NCT00602446|iron overload
1342160|NCT00602433|advanced nonsmall cell lung cancer
1342161|NCT00602420|pain
1342162|NCT00602420|musculoskeletal complications
1342163|NCT00602420|unspecified adult solid tumor, protocol specific
1342164|NCT00602368|cervical cancer
1342165|NCT00602368|cervical intraepithelial neoplasia grade 1
1342166|NCT00602368|cervical intraepithelial neoplasia grade 2
1342167|NCT00602368|cervical intraepithelial neoplasia grade 3
1342168|NCT00602355|Postpartum
1342169|NCT00602355|Depression
1342170|NCT00602355|Medication Therapy
1342171|NCT00602355|Zoloft
1342172|NCT00602355|Sertraline
1342173|NCT00602355|Interpersonal Psychotherapy
1342174|NCT00602329|recurrent colon cancer
1342175|NCT00602329|recurrent rectal cancer
1342176|NCT00602329|stage III colon cancer
1342177|NCT00602329|stage III rectal cancer
1342178|NCT00602329|stage IV colon cancer
1342179|NCT00602329|stage IV rectal cancer
1342180|NCT00602329|adenocarcinoma of the colon
1342181|NCT00602329|adenocarcinoma of the rectum
1342182|NCT00602316|invasive ductal breast carcinoma
1342183|NCT00602316|stage IA breast cancer
1342184|NCT00602316|stage IB breast cancer
1342185|NCT00602316|stage II breast cancer
1342186|NCT00602316|stage IIIA breast cancer
1342187|NCT00602290|Major Depression
1342188|NCT00602290|Geriatric Major Unipolar Depression
1342189|NCT00602290|Executive Cognitive Dysfunction
1342190|NCT00602290|Elderly
1342191|NCT00602290|Geriatric
1342192|NCT00602290|Executive Cognitive Impairment
1342193|NCT00602290|Quality of Life
1342194|NCT00602290|Disability
1342195|NCT00602290|Comorbidity
1342196|NCT00602290|Medical Burden
1342197|NCT00602290|Safety
1342198|NCT00602290|Candidate Genes
1342199|NCT00602264|Anorexia nervosa
1342200|NCT00602264|Adipokines
1342201|NCT00602264|Ghrelin
1342202|NCT00602264|Fat mass
1342203|NCT00602212|generalized anxiety disorder (GAD)
1342204|NCT00602199|stage IV melanoma
1342205|NCT00602186|female voiding dysfunction
1342207|NCT00602186|prazosin
1342208|NCT00602160|Food allergy
1342209|NCT00602160|Chinese Herbs
1342210|NCT00602160|Investigational new drug
1342211|NCT00602160|Herbs
1342212|NCT00602160|Therapeutic medicine
1342213|NCT00602160|Traditional Chinese medicine
1342214|NCT00602147|mucositis
1342215|NCT00602147|stage I multiple myeloma
1342216|NCT00602147|stage II multiple myeloma
1342217|NCT00602147|stage III multiple myeloma
1342218|NCT00602147|refractory multiple myeloma
1342219|NCT00602108|stage I breast cancer
1342220|NCT00602108|stage II breast cancer
1342221|NCT00602095|Labor induction
1342222|NCT00602095|cervical ripening
1342223|NCT00602095|misoprostol
1342224|NCT00602095|dinoprostone
1342225|NCT00602095|balloon catheter
1342226|NCT00602095|prostaglandin
1342227|NCT00602082|pancreatic alpha cell adenoma
1342228|NCT00602082|pancreatic alpha cell carcinoma
1342229|NCT00602082|pancreatic beta islet cell adenoma
1342230|NCT00602082|pancreatic beta islet cell carcinoma
1342231|NCT00602082|pancreatic delta cell adenoma
1342232|NCT00602082|pancreatic delta cell carcinoma
1342233|NCT00602082|pancreatic G-cell adenoma
1342234|NCT00602082|pancreatic G-cell carcinoma
1342235|NCT00602082|gastrinoma
1342236|NCT00602082|insulinoma
1342237|NCT00602082|glucagonoma
1342238|NCT00602082|pancreatic polypeptide tumor
1342239|NCT00602082|somatostatinoma
1342240|NCT00602082|metastatic gastrointestinal carcinoid tumor
1342241|NCT00602082|recurrent gastrointestinal carcinoid tumor
1342242|NCT00602082|regional gastrointestinal carcinoid tumor
1342243|NCT00602082|islet cell carcinoma
1342244|NCT00602082|recurrent islet cell carcinoma
1342245|NCT00602069|PTSD
1342246|NCT00602069|Intimate Partner Violence
1342247|NCT00602069|Cognitive Behavioral Therapy
1342248|NCT00602069|Empowerment
1342249|NCT00602056|Immunization dropout
1342250|NCT00602056|Immunization card
1342251|NCT00602056|Center based education
1342252|NCT00602030|lung cancer
1342253|NCT00602030|NSCLC
1342254|NCT00602030|lung neoplasms
1342255|NCT00602030|respiratory
1342256|NCT00602004|Arteriovenous fistula
1342257|NCT00602004|hypertrophy
1342258|NCT00602004|losartan
1342259|NCT00601991|untreated adult acute myeloid leukemia
1342260|NCT00601991|recurrent adult acute myeloid leukemia
1342261|NCT00601978|Parkinson's disease
1342262|NCT00601978|carbidopa/levodopa/entacapone
1342263|NCT00601978|carbidopa/levodopa
1342264|NCT00601978|non-motor symptoms
1342265|NCT00601978|event-related potential
1342266|NCT00601978|ERP
1342267|NCT00601978|EEG
1342268|NCT00601978|electroencephalogram
1342269|NCT00601952|post traumatic stress disorder
1342270|NCT00601952|cognitive bias
1342271|NCT00601952|attention
1342272|NCT00601952|combat
1342273|NCT00601939|Abused
1342274|NCT00601939|Female
1342275|NCT00601939|African American
1342276|NCT00601939|Group Empowerment Psychoeducational Intervention
1342277|NCT00601939|Enhanced Treatment as Usual
1342278|NCT00601926|papillary renal cell carcinoma
1342279|NCT00601926|stage III renal cell cancer
1342280|NCT00601926|stage IV renal cell cancer
1342281|NCT00601913|stage I squamous cell carcinoma of the oropharynx
1342282|NCT00601913|stage II squamous cell carcinoma of the oropharynx
1342283|NCT00601913|stage I squamous cell carcinoma of the larynx
1342284|NCT00601913|stage II squamous cell carcinoma of the larynx
1342285|NCT00601913|stage I squamous cell carcinoma of the lip and oral cavity
1342286|NCT00601913|stage II squamous cell carcinoma of the lip and oral cavity
1342287|NCT00601913|stage I squamous cell carcinoma of the hypopharynx
1342288|NCT00601913|stage II squamous cell carcinoma of the hypopharynx
1342289|NCT00601913|stage I verrucous carcinoma of the larynx
1342290|NCT00601913|stage I verrucous carcinoma of the oral cavity
1342291|NCT00601913|stage II verrucous carcinoma of the oral cavity
1342292|NCT00601887|Anti-inflammatory
1342293|NCT00601848|stage IIIA non-small cell lung cancer
1342294|NCT00601848|stage IIIB non-small cell lung cancer
1342295|NCT00601848|malignant pleural effusion
1342296|NCT00601835|Diphtheria
1342297|NCT00601835|Tetanus
1342298|NCT00601809|Gastrointestinal
1342299|NCT00601809|Adhesive Small Intestine Obstruction
1342300|NCT00601809|Oral water soluble contrast
1342301|NCT00601809|Non-operative Conservative Management
1342302|NCT00601809|Operative rate
1342303|NCT00601809|Hospital stay
1342304|NCT00601796|adenocarcinoma of the lung
1342305|NCT00601796|stage IV non-small cell lung cancer
1342306|NCT00601757|Preventive Intervention
1342307|NCT00601757|Postpartum Depression
1342308|NCT00601757|Women on Public Assistance
1342309|NCT00601744|Orbital Exenteration
1342310|NCT00601744|Eye Cancer
1342311|NCT00601744|Social-Psychological Aspects
1342312|NCT00601744|Quality of Life
1342313|NCT00601744|Questionnaire
1342314|NCT00601744|Facial Appearance
1342315|NCT00601744|Survey
1342316|NCT00601744|Interview
1342317|NCT00601731|Prevention of Meningococcal disease
1342318|NCT00601705|adenocarcinoma of the esophagus
1342319|NCT00601705|adenocarcinoma of the stomach
1342320|NCT00601705|stage III esophageal cancer
1342321|NCT00601705|stage IV esophageal cancer
1342322|NCT00601705|stage III gastric cancer
1342323|NCT00601705|stage IV gastric cancer
1342324|NCT00601705|stage II esophageal cancer
1342325|NCT00601705|stage II gastric cancer
1342326|NCT00601692|squamous cell carcinoma of the esophagus
1342327|NCT00601692|adenocarcinoma of the esophagus
1342328|NCT00601692|stage II esophageal cancer
1342329|NCT00601692|stage III esophageal cancer
1342330|NCT00601692|stage IV esophageal cancer
1342331|NCT00601679|CHF treatment&prognosis,NT-proBNP testing.
1342332|NCT00601653|Binge Eating Disorder
1342333|NCT00601653|BED
1342334|NCT00601653|Nutrition
1342335|NCT00601653|Energy Density
1342336|NCT00601653|Cognitive Behavioral Therapy
1342337|NCT00601653|CBT
1342338|NCT00601640|skin cancer
1342339|NCT00601627|adenocarcinoma of the pancreas
1342340|NCT00601627|stage II pancreatic cancer
1342341|NCT00601627|stage III pancreatic cancer
1342342|NCT00601614|unspecified adult solid tumor, protocol specific
1342343|NCT00601601|stage 0 cervical cancer
1342344|NCT00601601|cervical intraepithelial neoplasia grade 1
1342345|NCT00601601|cervical intraepithelial neoplasia grade 2
1342346|NCT00601601|cervical intraepithelial neoplasia grade 3
1342347|NCT00601562|HIV
1342348|NCT00601549|Rectal cancer
1342349|NCT00601549|CCRT
1342350|NCT00601549|Laparoscopic Surgery
1342351|NCT00601549|rectal cancer can be resected by curative and elective surgery
1342352|NCT00601549|rectal adenocarcinoma below peritoneal reflection
1342353|NCT00601549|American Society of Anesthesiology（ASA） classⅠ to Ⅲ lesions
1342354|NCT00601510|stage III gastric cancer
1342355|NCT00601510|stage IV gastric cancer
1342356|NCT00601484|Painful Bladder Syndrome, monoclonal antibody
1342357|NCT00601471|ankle sprain
1342358|NCT00601471|ankle injuries
1342359|NCT00601471|sprains and strains
1342360|NCT00601458|Primary, unilateral, first metatarsal bunionectomy with osteotomy
1342361|NCT00601445|Changes in sleep with aging
1342362|NCT00601432|open-label
1342363|NCT00601432|randomized
1342364|NCT00601432|crossover
1342365|NCT00601432|food effect
1342366|NCT00601406|male breast cancer
1342367|NCT00601406|stage IA breast cancer
1342368|NCT00601406|stage IB breast cancer
1342369|NCT00601406|stage II breast cancer
1342370|NCT00601406|stage I prostate cancer
1342371|NCT00601406|stage IIB prostate cancer
1342372|NCT00601406|stage IIA prostate cancer
1342373|NCT00601406|stage III prostate cancer
1342374|NCT00601406|stage IA cervical cancer
1342375|NCT00601406|stage IB cervical cancer
1342376|NCT00601406|stage IIA cervical cancer
1342377|NCT00601406|stage IIB cervical cancer
1342378|NCT00601406|stage III cervical cancer
1342379|NCT00601406|stage IVA cervical cancer
1342380|NCT00601406|stage IVB cervical cancer
1342381|NCT00601406|stage I vaginal cancer
1342382|NCT00601406|stage II vaginal cancer
1342383|NCT00601406|stage III vaginal cancer
1342384|NCT00601406|stage IVA vaginal cancer
1342385|NCT00601406|stage IVB vaginal cancer
1342386|NCT00601406|stage IA vulvar cancer
1342387|NCT00601406|stage IB vulvar cancer
1342388|NCT00601406|stage II vulvar cancer
1342389|NCT00601406|stage IIIC vulvar cancer
1342390|NCT00601406|stage IIIA vulvar cancer
1342391|NCT00601406|stage IIIB vulvar cancer
1342392|NCT00601406|stage IVB vulvar cancer
1342393|NCT00601406|stage IA ovarian epithelial cancer
1342394|NCT00601406|stage IB ovarian epithelial cancer
1342395|NCT00601406|stage IC ovarian epithelial cancer
1342396|NCT00601406|stage IA ovarian germ cell tumor
1342397|NCT00601406|stage IB ovarian germ cell tumor
1342398|NCT00601406|stage IC ovarian germ cell tumor
1342399|NCT00601406|stage IIA ovarian epithelial cancer
1342400|NCT00601406|stage IIB ovarian epithelial cancer
1342401|NCT00601406|stage IIC ovarian epithelial cancer
1342402|NCT00601406|stage IIA ovarian germ cell tumor
1342403|NCT00601406|stage IIB ovarian germ cell tumor
1342404|NCT00601406|stage IIC ovarian germ cell tumor
1342405|NCT00601406|stage IIIA ovarian epithelial cancer
1342406|NCT00601406|stage IIIB ovarian epithelial cancer
1342407|NCT00601406|stage IIIC ovarian epithelial cancer
1342408|NCT00601406|stage IIIA ovarian germ cell tumor
1342409|NCT00601406|stage IIIB ovarian germ cell tumor
1342410|NCT00601406|stage IIIC ovarian germ cell tumor
1342411|NCT00601406|stage IV ovarian epithelial cancer
1342412|NCT00601406|stage IV ovarian germ cell tumor
1342413|NCT00601406|stage II endometrial carcinoma
1342414|NCT00601406|ovarian stromal cancer
1342415|NCT00601406|ovarian sarcoma
1342416|NCT00601406|stage IA fallopian tube cancer
1342417|NCT00601406|stage IB fallopian tube cancer
1342418|NCT00601406|stage IC fallopian tube cancer
1342419|NCT00601406|stage IIA fallopian tube cancer
1342420|NCT00601406|stage IIB fallopian tube cancer
1342421|NCT00601406|stage IIC fallopian tube cancer
1342422|NCT00601406|stage IIIA fallopian tube cancer
1342423|NCT00601406|stage IIIB fallopian tube cancer
1342424|NCT00601406|stage IIIC fallopian tube cancer
1342425|NCT00601406|stage IV fallopian tube cancer
1342426|NCT00601406|recurrent primary peritoneal cavity cancer
1342427|NCT00601406|stage IA primary peritoneal cavity cancer
1342428|NCT00601406|stage IB primary peritoneal cavity cancer
1342429|NCT00601406|stage IC primary peritoneal cavity cancer
1342430|NCT00601406|stage IIA primary peritoneal cavity cancer
1342431|NCT00601406|stage IIB primary peritoneal cavity cancer
1342432|NCT00601406|stage IIC primary peritoneal cavity cancer
1342433|NCT00601406|stage IIIA primary peritoneal cavity cancer
1342434|NCT00601406|stage IIIB primary peritoneal cavity cancer
1342435|NCT00601406|stage IIIC primary peritoneal cavity cancer
1342436|NCT00601406|stage IV primary peritoneal cavity cancer
1342437|NCT00601406|stage IA endometrial carcinoma
1342438|NCT00601406|stage IB endometrial carcinoma
1342439|NCT00601406|stage IIIA endometrial carcinoma
1342440|NCT00601406|stage IIIB endometrial carcinoma
1342441|NCT00601406|stage IIIC endometrial carcinoma
1342442|NCT00601406|stage IVA endometrial carcinoma
1342443|NCT00601406|stage IVB endometrial carcinoma
1342444|NCT00601406|stage IA uterine sarcoma
1342445|NCT00601406|stage IB uterine sarcoma
1342446|NCT00601406|stage IC uterine sarcoma
1342447|NCT00601406|stage IIA uterine sarcoma
1342448|NCT00601406|stage IIB uterine sarcoma
1342449|NCT00601406|stage IIIA uterine sarcoma
1342450|NCT00601406|stage IIIB uterine sarcoma
1342451|NCT00601406|stage IIIC uterine sarcoma
1342452|NCT00601406|stage IVA uterine sarcoma
1342453|NCT00601406|stage IVB uterine sarcoma
1342454|NCT00601354|Binge Eating
1342455|NCT00601354|Orlistat
1342456|NCT00601354|Alli
1342457|NCT00601354|Guided Self-Help
1342458|NCT00601341|arthralgia
1342459|NCT00601341|joint pain
1342460|NCT00601341|knee injuries
1342461|NCT00601341|knee joint
1342462|NCT00601341|low back pain
1342463|NCT00601289|pituitary chromophobe adenoma
1342464|NCT00601289|recurrent pituitary tumor
1342465|NCT00601289|ACTH-producing pituitary tumor
1342466|NCT00601289|growth hormone-producing pituitary tumor
1342467|NCT00601289|prolactin-producing pituitary tumor
1342468|NCT00601289|pituitary basophilic adenoma
1342469|NCT00601289|pituitary eosinophilic adenoma
1342470|NCT00601289|prolactin secreting adenoma
1342471|NCT00601289|nonfunctioning pituitary tumor
1342472|NCT00601276|pedophilia
1342473|NCT00601276|antiandrogens
1342474|NCT00601276|gonadotropin releasing hormone agonists
1342475|NCT00601263|Chinese Herbal Therapy
1342476|NCT00601263|Asthma
1342477|NCT00601263|Investigational new drug (IND)
1342478|NCT00601263|Complementary and Alternative Medicine
1342479|NCT00601237|HIV Prevention
1342480|NCT00601237|Mobile Phone
1342481|NCT00601237|Technology-Based Intervention
1342482|NCT00601237|HIV
1342483|NCT00601237|HIV Seronegativity
1342484|NCT00601224|Social Cognition
1342485|NCT00601224|Group Therapy
1342486|NCT00601224|Psychosocial Intervention
1342487|NCT00601198|Oxaliplatin-induced Neuropathy
1342488|NCT00601198|Colon and rectum
1342489|NCT00601185|06-009
1342490|NCT00601185|Confocal reflectance microscopy
1342491|NCT00601185|shave-biopsy
1342492|NCT00601172|vomiting
1342493|NCT00601172|colorectal cancer
1342494|NCT00601172|nausea
1342495|NCT00601172|oxaliplatin
1342496|NCT00601159|Metastatic Breast Cancer
1342497|NCT00601159|triple-negative Breast Cancer
1342498|NCT00601159|cisplatin
1342499|NCT00601159|chemotherapy
1342500|NCT00601146|Hodgkin's disease
1342501|NCT00601146|CT scan
1342502|NCT00601133|Solid Tumors
1342503|NCT00601133|Acute Inpatient Rehabilitation
1342504|NCT00601133|Postural Instability
1342505|NCT00601133|Balance
1342506|NCT00601133|Function
1342507|NCT00601133|Walking
1342508|NCT00601133|Questionnaire
1342509|NCT00601133|Survey
1342510|NCT00601120|antiangiogenic therapy
1342511|NCT00601120|RF ablation
1342512|NCT00601107|psoriasis
1342513|NCT00601107|psoriasis vulgaris
1342514|NCT00601107|plaque psoriasis
1342515|NCT00601107|chronic plaque psoriasis
1342516|NCT00601094|stage IIIB non-small cell lung cancer
1342517|NCT00601094|stage IV non-small cell lung cancer
1342518|NCT00601094|recurrent non-small cell lung cancer
1342519|NCT00601081|Very low birth weight infants
1342520|NCT00601081|HMF
1342521|NCT00601081|immune system function
1342522|NCT00601068|osteonecrosis, jaws, bisphosphonate, fosamax, alendronate
1342523|NCT00601055|COPD
1342524|NCT00601055|Geriatric Depression
1342525|NCT00601055|Problem-Solving Therapy
1342526|NCT00601055|Treatment Adherence
1342527|NCT00601042|smoking reduction
1342528|NCT00601042|smoking cessation
1342529|NCT00601042|randomized trial
1342530|NCT00601042|Swedish snus
1342531|NCT00601042|smokeless tobacco
1342532|NCT00601029|Exertional Rhabdomyolysis
1342533|NCT00601016|Infantile hemangioma
1342534|NCT00601016|Hemangioma
1342535|NCT00601016|Hemangioma of Infancy
1342536|NCT00601016|benign tumors of infancy
1342537|NCT00601016|Congenital hemangioma
1342538|NCT00601016|Capillary
1342539|NCT00600990|post-operative nausea and vomiting
1342540|NCT00600990|PONV
1342541|NCT00600977|ALL
1342542|NCT00600977|Chemotherapy
1342543|NCT00600977|Pharmacokinetics of doxorubicin (pegylated or not)
1342544|NCT00600977|elderly ALL
1342545|NCT00600964|CLL
1342546|NCT00600964|obatoclax
1342547|NCT00600938|iron overload
1342548|NCT00600938|cardiac iron
1342549|NCT00600938|haemosiderosis
1342550|NCT00600938|myocardial T2*
1342551|NCT00600938|left ventricular ejection fraction
1342552|NCT00600938|LVEF
1342553|NCT00600938|cardiac dysfunction
1342554|NCT00600938|thalassaemia
1342555|NCT00600938|Diamond Blackfan anemia
1342556|NCT00600938|DBA
1342557|NCT00600938|sideroblastic anemia
1342558|NCT00600938|myelodysplastic syndromes
1342559|NCT00600938|MDS (low and INT-1 risk as per the IPSS for MDS)
1342560|NCT00600938|liver MRI
1342561|NCT00600938|deferasirox
1342562|NCT00600938|deferoxamine
1342563|NCT00600938|ICL670
1342564|NCT00600938|DFO
1342565|NCT00600938|cardiovascular magnetic resonance imaging
1342566|NCT00600925|Colorectal surgery
1342567|NCT00600912|lipid emulsion
1342568|NCT00600912|fish oil
1342569|NCT00600912|parenteral nutrition
1342570|NCT00600912|leucotriene LTB5
1342571|NCT00600912|hepatic function
1342698|NCT00600275|Solid tumors
1342572|NCT00600899|Postoperative pain treatment
1342573|NCT00600886|Acromegaly,
1342574|NCT00600886|adult,
1342575|NCT00600886|growth hormone,
1342576|NCT00600886|insulin-like growth factor I,
1342577|NCT00600886|somatostatin analogue
1342578|NCT00600873|neuroprotection
1342579|NCT00600873|oxidative stress
1342580|NCT00600860|MDS (all IPSS subtypes)
1342581|NCT00600860|Newly diagnosed
1342582|NCT00600847|urticaria
1342583|NCT00600847|cold urticaria
1342584|NCT00600847|acquired cold urticaria
1342585|NCT00600808|SR-hGH, Pharmacokinetics, Pharmacodynamics
1342586|NCT00600795|NPH
1342587|NCT00600795|TGF-beta
1342588|NCT00600782|Tuberculosis vaccine
1342589|NCT00600769|MAC
1342590|NCT00600769|NTM
1342591|NCT00600756|schizophrenia
1342592|NCT00600756|SWNK
1342593|NCT00600743|Eating
1342594|NCT00600743|Food Intake
1342595|NCT00600743|Appetite
1342596|NCT00600730|fMRi
1342597|NCT00600730|hypoglycemia
1342598|NCT00600717|Magnetoencephalography(MEG)
1342599|NCT00600717|Sensorimotor
1342600|NCT00600717|Auditory
1342601|NCT00600717|Visual
1342602|NCT00600717|Language
1342603|NCT00600717|This study focuses on normal MEG data
1342604|NCT00600704|Allogenic Blood Use
1342605|NCT00600704|Total Blood Loss
1342606|NCT00600704|Reinfusion of Washed Shed Blood
1342607|NCT00600691|Finasteride
1342608|NCT00600691|hematuria
1342609|NCT00600691|hematospermia
1342610|NCT00600691|prostate biopsy
1342611|NCT00600678|food for special medical purposes
1342612|NCT00600665|Sickle Cell Anemia
1342613|NCT00600665|Sickle Cell Disease
1342614|NCT00600652|glucocorticoid-receptor
1342615|NCT00600652|flow cytometry
1342616|NCT00600652|glucocorticoid-resistant
1342617|NCT00600652|prediction
1342618|NCT00600639|old patients
1342619|NCT00600639|NIV
1342620|NCT00600639|Intubation
1342621|NCT00600639|COPD
1342622|NCT00600613|Radiation Therapy
1342623|NCT00600587|Carcinoma, Non-Small-Cell Lung
1342624|NCT00600587|Genes, erbB-1
1342625|NCT00600587|tyrosine kinase inhibitor
1342626|NCT00600587|Neoadjuvant Therapy
1342627|NCT00600574|fibromyalgia
1342628|NCT00600574|physical therapies
1342629|NCT00600574|stretching
1342630|NCT00600574|Ai Chi
1342631|NCT00600561|meditation
1342632|NCT00600561|mindfulness
1342633|NCT00600561|HIV
1342634|NCT00600561|CD4
1342635|NCT00600561|Complementary Therapies
1342636|NCT00600548|Cutaneous leishmaniasis
1342637|NCT00600548|Miltefosine
1342638|NCT00600548|Meglumine antimoniate
1342639|NCT00600548|L. braziliensis, L. guyanensis
1342640|NCT00600535|Prostate neoplasms
1342641|NCT00600535|Abiraterone acetate
1342642|NCT00600535|CB7630
1342643|NCT00600535|Prostate cancer
1342644|NCT00600535|Pharmacokinetics
1342645|NCT00600522|intraoperative ultrasonography
1342646|NCT00600522|hepatectomy
1342647|NCT00600522|colorectal liver metastases
1342648|NCT00600522|hepatocellular carcinoma
1342649|NCT00600522|contrast enhanced intraoperative ultrasonography.
1342650|NCT00600509|Levetiracetam
1342651|NCT00600509|Keppra
1342652|NCT00600496|ARRY-142886
1342653|NCT00600496|AZD6244
1342654|NCT00600496|Cancer
1342655|NCT00600496|Colon Cancer
1342656|NCT00600496|Breast Cancer
1342657|NCT00600496|Lung Cancer
1342658|NCT00600496|Melanoma
1342659|NCT00600496|Kidney Cancer
1342660|NCT00600483|obesity
1342661|NCT00600483|diabetes
1342662|NCT00600470|Behavior Problems
1342663|NCT00600470|Behavior Disorders
1342664|NCT00600457|healing time
1342665|NCT00600457|pain
1342666|NCT00600457|infection
1342667|NCT00600444|permanent venous access
1342668|NCT00600444|chemotherapy
1342669|NCT00600444|parenteral nutrition
1342670|NCT00600444|Patients with a benign and/or malignant diseases which demand a safe and permanent venous access, e.g. for chemotherapy and/or parenteral nutrition
1342671|NCT00600444|benign diseases
1342672|NCT00600444|malignant diseases
1342673|NCT00600431|nevus count
1342674|NCT00600431|children
1342675|NCT00600431|chemotherapy
1342676|NCT00600418|PTSD
1342677|NCT00600418|DYADIC TREATMENT
1342678|NCT00600418|WAR AND TERROR
1342679|NCT00600418|Posttraumatic symptoms among toddlers
1342680|NCT00600405|Nephrolithiasis
1342681|NCT00600405|Ureteral Calculi
1342682|NCT00600379|stroke chronic gait deficits virtual reality training
1342683|NCT00600353|nausea
1342684|NCT00600353|cancer
1342685|NCT00600353|CINV
1342686|NCT00600327|Stroke
1342687|NCT00600327|thrombosis
1342688|NCT00600327|thromboembolic
1342689|NCT00600327|Transient Ischemic Attack
1342690|NCT00600327|TIA
1342691|NCT00600314|Graft-Versus-Host Disease
1342692|NCT00600314|Transplantation, Allogeneic
1342693|NCT00600314|Transplantation, Hematopoietic Stem Cell
1342694|NCT00600314|Calorimetry, Respiration
1342695|NCT00600301|Macula
1342696|NCT00600301|Edema
1342697|NCT00600275|BGT226
1342699|NCT00600275|Breast cancer
1342700|NCT00600275|Cowden Syndrome
1342701|NCT00600275|Phosphatidylinositol 3'-kinase (PI3K) inhibitor
1342702|NCT00600275|Advanced solid tumors (including sporadic and Cowden Syndrome) (Phase I part)
1342703|NCT00600275|Advanced breast cancer (including sporadic and Cowden Syndrome) (Phase II part)
1342704|NCT00600262|severe nonproliferative
1342705|NCT00600262|proliferative diabetic retinopathy
1342706|NCT00600262|active photocoagulated diabetic retinopathy
1342707|NCT00600262|intravitreal bevacizumab
1342708|NCT00600249|Breast cancer.
1342709|NCT00600249|Triple negative.
1342710|NCT00600249|Neoadjuvant chemotherapy.
1342711|NCT00600249|Targeted therapy.
1342712|NCT00600236|Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
1342713|NCT00600236|Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy
1342714|NCT00600184|Stroke
1342715|NCT00600184|Rehabilitation
1342716|NCT00600184|Robotics
1342717|NCT00600171|dose ranging
1342718|NCT00600171|placebo
1342719|NCT00600171|asthma
1342720|NCT00600171|safety
1342721|NCT00600171|efficacy
1342722|NCT00600171|pharmacokinetics
1342723|NCT00600158|colectomy
1342724|NCT00600145|Human volunteers
1342725|NCT00600145|amphetamine dependence
1342726|NCT00600119|NKTR, constipation, opioid, induced, bowel, dysfunction, Naloxol, Naloxone, Narcan, PEG naloxol, OIC, OBD, Nektar
1342727|NCT00600093|Amantadine
1342728|NCT00600067|Diabetes
1342729|NCT00600067|Type 2 Diabetes
1342730|NCT00600067|Diabetes Mellitus
1342731|NCT00600067|Metabolic Diseases
1342732|NCT00600067|Glucose Metabolism Disorders
1342733|NCT00600067|Glycemic Control
1342734|NCT00600054|Diffuse intrinsic pontine glioma
1342735|NCT00600054|Common Terminology Criteria
1342736|NCT00600054|Epidermal Growth factor receptor
1342737|NCT00600054|Human antihuman antibody
1342738|NCT00600054|pharmacokinetics
1342739|NCT00600054|monoclonal antibody
1342740|NCT00600054|Informed Consent Form
1342741|NCT00600041|Proton Pump Inhibitors
1342742|NCT00600041|pantoprazole
1342743|NCT00600041|Cardiac Output
1342744|NCT00600041|Echocardiography
1342745|NCT00600041|adverse effects
1342746|NCT00600028|idiopathic pulmonary fibrosis cough
1342747|NCT00600015|Non-Small Cell Lung Cancer
1342748|NCT00600015|Advanced
1342749|NCT00600015|Sorafenib
1342750|NCT00600015|Erlotinib
1342751|NCT00600015|Double-blind
1342752|NCT00600015|Placebo-controlled
1342753|NCT00600002|GM-CSF
1342754|NCT00600002|Leukine
1342755|NCT00599989|long-term effects secondary to cancer therapy in adults
1342756|NCT00599989|skin reactions secondary to radiation therapy
1342757|NCT00599989|stage I breast cancer
1342758|NCT00599989|stage II breast cancer
1342759|NCT00599989|invasive lobular breast carcinoma with predominant in situ component
1342760|NCT00599989|invasive lobular breast carcinoma
1342761|NCT00599989|comedo ductal breast carcinoma
1342762|NCT00599989|ductal breast carcinoma in situ
1342763|NCT00599989|invasive ductal breast carcinoma
1342764|NCT00599989|medullary ductal breast carcinoma with lymphocytic infiltrate
1342765|NCT00599989|mucinous ductal breast carcinoma
1342766|NCT00599989|papillary ductal breast carcinoma
1342767|NCT00599989|tubular ductal breast carcinoma
1342768|NCT00599989|Paget disease of the breast with intraductal carcinoma
1342769|NCT00599989|Paget disease of the breast with invasive ductal carcinoma
1342770|NCT00599989|breast cancer in situ
1342771|NCT00599950|Mitomycin C
1342772|NCT00599950|Corneal epithelium
1342773|NCT00599950|Photorefractive keratectomy (PRK)
1342774|NCT00599950|Confocal microscope
1342775|NCT00599937|APL
1342776|NCT00599924|advanced solid tumors,
1342777|NCT00599924|colorectal cancer,
1342778|NCT00599924|sunitinib (SUTENT),
1342779|NCT00599924|FOLFOX
1342780|NCT00599911|Drug therapy
1342781|NCT00599911|Depressive disorder
1342782|NCT00599911|Antidepressive agents
1342783|NCT00599911|Depressive symptoms
1342784|NCT00599911|Affective disorders
1342785|NCT00599911|Randomized controlled trial
1342786|NCT00599911|Placebo-controlled
1342787|NCT00599911|Double-blind
1342788|NCT00599911|Active reference
1342789|NCT00599911|Multicenter study
1342790|NCT00599898|Preterm labor
1342791|NCT00599898|Atosiban
1342792|NCT00599898|Nifedipine
1342793|NCT00599872|Allergy
1342794|NCT00599872|Sublingual Immunotherapy
1342795|NCT00599872|Allergic Rhinitis
1342796|NCT00599859|lactase
1342797|NCT00599859|lactose
1342798|NCT00599859|microflora
1342799|NCT00599846|age-related macular degeneration
1342800|NCT00599846|geographic atrophy
1342801|NCT00599833|adenocarcinoma of the pancreas
1342802|NCT00599833|stage III pancreatic cancer
1342803|NCT00599820|Angioid Streaks
1342804|NCT00599820|Choroidal Neovascularization
1342805|NCT00599820|Bevacizumab
1342806|NCT00599794|Sepsis
1342807|NCT00599794|Intravascular volume
1342808|NCT00599794|Ultrasound
1342809|NCT00599794|Noninvasive measurement
1342810|NCT00599781|adenosine deaminase
1342811|NCT00599781|SCID
1342812|NCT00599781|gene therapy
1342813|NCT00599781|retroviral vector
1342814|NCT00599742|Balance disorder
1342815|NCT00599742|Vestibular disorder
1342816|NCT00599742|Generalized anxiety disorder
1342817|NCT00599742|Separation anxiety disorder
1342818|NCT00599742|Children
1342819|NCT00599742|Balance training
1342820|NCT00599716|dry eye syndrome
1342821|NCT00599716|dry eye disease
1342822|NCT00599716|Vismed
1342823|NCT00599716|dry eye
1342824|NCT00599716|sodium hyaluronate
1342825|NCT00599716|hyaluronic acid
1342826|NCT00599690|Epi-LASIK-LASIK microkeratome
1342827|NCT00599690|Corneal thickness
1342828|NCT00599690|Confocal microscope
1342829|NCT00599677|acupuncture
1342830|NCT00599677|meridian
1342831|NCT00599677|acupoint
1342832|NCT00599664|Urinary Calculi
1342833|NCT00599664|Urinary Stones
1342834|NCT00599664|Urinary Tract Stones
1342835|NCT00599664|Calculi
1342836|NCT00599651|Respiratory Distress Syndrome
1342837|NCT00599651|Newborn RDS
1342838|NCT00599625|Crohn's Disease
1342839|NCT00599612|GW856553,
1342840|NCT00599612|radiolabel
1342841|NCT00599612|ADME,
1342842|NCT00599599|Prolonged Exposure Therapy
1342843|NCT00599599|Adherence to HIV Medications
1342844|NCT00599599|Complementary Therapies
1342845|NCT00599586|migraine
1342846|NCT00599586|acupuncture
1342847|NCT00599586|efficacy
1342848|NCT00599586|safety
1342849|NCT00599586|meridian
1342850|NCT00599586|acupoint
1342851|NCT00599573|HIV
1342852|NCT00599573|cocaine dependence
1342853|NCT00599573|cocaine abuse
1342854|NCT00599573|cocaine addiction
1342855|NCT00599573|cocaine users
1342856|NCT00599573|cocaine-related disorders
1342857|NCT00599573|HIV Infection
1342858|NCT00599560|Meniere's disease
1342859|NCT00599560|stress
1342860|NCT00599560|vasopressin
1342861|NCT00599560|endolymphatic sac
1342862|NCT00599560|V2 receptor
1342863|NCT00599560|cyclic AMP
1342864|NCT00599560|Plasma vasopressin level and V2R mRNA expression level in the endolymphatic sac both were significantly higher in patients with Meniere's disease.
1342865|NCT00599560|In Meniere's disease, there were significant negative co-relationships between vasopressin and V2R.
1342866|NCT00599560|The cyclic AMP activity was basically up-regulated in the endolymphatic sac in Meniere's disease..
1342867|NCT00599560|The cyclic AMP sensitivity for vasopressin was significantly elevated in the endolymphatic sac in Meniere's disease.
1342868|NCT00599547|Hematopoietic Stem Cell Transplantation
1342869|NCT00599521|Acne Vulgaris
1342870|NCT00599521|Adapalene
1342871|NCT00599508|memory
1342872|NCT00599508|aging
1342873|NCT00599495|Hematopoietic Stem Cell Transplantation
1342874|NCT00599495|Multiple Myeloma
1342875|NCT00599482|HEMOGLOBIN SC DISEASE
1342876|NCT00599482|HEMOGLOBIN C DISEASE
1342877|NCT00599482|SICKLE CELL TRAIT
1342878|NCT00599482|THALASSEMIA
1342879|NCT00599469|Acute Confusional Senile Dementia
1342880|NCT00599469|Alzheimer Type Senile Dementia
1342881|NCT00599469|SENILE PLAQUES
1342882|NCT00599469|NEUROFIBRILLARY TANGLES
1342883|NCT00599469|NEUROPIL THREADS
1342884|NCT00599456|Hot flashes
1342885|NCT00599456|Menopause
1342886|NCT00599456|Omega 3 fatty Acids
1342887|NCT00599443|Cell-derived subunit influenza vaccine
1342888|NCT00599443|Safety
1342889|NCT00599443|Reactogenicity
1342890|NCT00599430|Probiotic
1342891|NCT00599430|Lactobacillus
1342892|NCT00599430|NCFM
1342893|NCT00599430|Bifidobacterium
1342894|NCT00599430|Healthy children
1342895|NCT00599404|Pharmacokinetics study
1342896|NCT00599391|KIDNEY FAILURE, ACUTE
1342897|NCT00599391|KIDNEY FAILURE, CHRONIC
1342898|NCT00599391|RENAL INSUFFICIENCY
1342899|NCT00599365|adherence
1342900|NCT00599365|pharmacist intervention
1342901|NCT00599365|persistence
1342902|NCT00599365|renal clinic
1342903|NCT00599365|pill count
1342904|NCT00599352|Hypovitaminosis
1342905|NCT00599352|Chronic liver disease
1342906|NCT00599339|Rotigotine
1342907|NCT00599339|Neupro
1342908|NCT00599326|Exjade PCT Study
1342909|NCT00599326|PCT Study
1342910|NCT00599326|Porphyria Cutanea Tarda
1342911|NCT00599287|ICU delirium
1342912|NCT00599287|Hypoactive delirium
1342913|NCT00599287|Haloperidol
1342914|NCT00599287|Methylphenidate
1342915|NCT00599287|Rivastigmine
1342916|NCT00599287|Hypoactive ICU delirium
1342917|NCT00599274|Multiple Sclerosis
1342918|NCT00599274|Interferon beta 1a
1342919|NCT00599274|Avonex
1342920|NCT00599261|Cardiac Pacemaker, Artificial
1342921|NCT00599248|osteoarthritis, knee
1342922|NCT00599235|Hypertension
1342923|NCT00599235|Exercise capacity
1342924|NCT00599235|PDE5 inhibitors
1342925|NCT00599222|AMD
1342926|NCT00599222|macular degeneration
1342927|NCT00599222|anti-VEGF
1342928|NCT00599222|laser treatment
1342929|NCT00599196|Rotigotine
1342930|NCT00599196|Neupro®
1342931|NCT00599183|Cervical spine herniation
1342932|NCT00599183|MRI cervical spine
1342933|NCT00599183|Diffusion tensor imaging cervical spine
1342934|NCT00599170|This is a standard phase II trial, in which patients with newly diagnosed diffuse large B cell lymphoma will receive R-CHOP with GM-CSF
1342935|NCT00599144|Cholecystectomy
1342936|NCT00599131|Cancer of Larynx
1342937|NCT00599118|Atrial Fibrillation
1342938|NCT00599118|Genetics
1342939|NCT00599092|pituitary tumor
1342940|NCT00599092|recurrence
1342941|NCT00599079|MAC
1342942|NCT00599066|M-Entropy
1342943|NCT00599053|Ureaplasma
1342944|NCT00599053|Bronchopulmonary dysplasia
1342945|NCT00599053|very low birthweight
1342946|NCT00599014|Cardiomyopathy, heart failure, DNA,
1342947|NCT00599014|echocardiography, messenger RNA, natural history
1342948|NCT00599001|healthy volunteer
1342949|NCT00599001|research subjects
1342950|NCT00599001|Immunostimulatory sequence (ISS)
1342951|NCT00599001|phase 1
1342952|NCT00598988|infectious mononucleosis, mono, acupuncture
1342953|NCT00598975|Phase 2a: Multiple solid tumor types
1342954|NCT00598975|Phase 2b: Second-Line Colorectal Cancer (CRC)
1342955|NCT00598962|MAC
1342956|NCT00598949|Pituitary
1342957|NCT00598949|Adenoma
1342958|NCT00598949|Tumor
1342959|NCT00598949|Acromegaly
1342960|NCT00598949|Prolactinoma
1342961|NCT00598949|Cushing's
1342962|NCT00598936|Hypoxia
1342963|NCT00598936|Cerebral Hypoxia
1342967|NCT00598910|HIV infection
1342968|NCT00598897|MAC
1342969|NCT00598884|Clinical Protocols
1342970|NCT00598884|Behavioral Research
1342971|NCT00598884|Prevention
1342972|NCT00598871|Thymosin beta 4
1342973|NCT00598871|Corneal wound healing
1342974|NCT00598871|Vitrectomy
1342975|NCT00598871|Diabetes
1342976|NCT00598858|prostate cancer
1342977|NCT00598858|Prostatectomy
1342978|NCT00598845|Endometrial cancer
1342979|NCT00598845|Molecular markers
1342980|NCT00598845|Lymph node metastasis
1342981|NCT00598845|Prospective study
1342982|NCT00598845|Prognosis
1342983|NCT00598845|Cancer of Endometrium
1342984|NCT00598845|Tumor Markers, Biological
1342985|NCT00598832|Acne Vulgaris
1342986|NCT00598832|Adapalene
1342987|NCT00598819|Cerebral Oxygenation
1342988|NCT00598819|Oxygen Monitoring
1342989|NCT00598806|Noninvasive Bladder Cancer
1342990|NCT00598780|Levocetirizine
1342991|NCT00598780|Xyzal
1342992|NCT00598780|Rhinitis allergic persistent
1342993|NCT00598780|Rhinitis nonseasonal
1342994|NCT00598767|Aortic valve insufficiency
1342995|NCT00598767|Aortic valve stenosis
1342996|NCT00598767|3D echocardiogram
1342997|NCT00598767|3D computed tomography
1342998|NCT00598754|Aortic valve stenosis
1342999|NCT00598754|Aortic valve insufficiency
1343000|NCT00598754|Two dimensional echocardiography
1343001|NCT00598754|Three dimensional echocardiography
1343002|NCT00598741|Bone
1343003|NCT00598741|Sarcoma
1343004|NCT00598741|04-083
1343005|NCT00598728|Survivors
1343006|NCT00598728|Quality of Life
1343007|NCT00598715|In-stent restenosis
1343008|NCT00598715|In-DES-restenosis
1343009|NCT00598715|paclitaxel
1343010|NCT00598715|sirolimus
1343011|NCT00598689|LASIK
1343012|NCT00598689|Ocular Lubricants
1343013|NCT00598689|Corneal Epithelium
1343014|NCT00598689|Wound Healing
1343015|NCT00598663|Type 1 diabetes
1343016|NCT00598650|Lewy Body Disease
1343017|NCT00598650|Dementia
1343018|NCT00598650|Clinical Trial
1343019|NCT00598650|Phase II
1343020|NCT00598650|E2020
1343021|NCT00598650|donepezil hydrochloride
1343022|NCT00598637|drug eluting stent
1343023|NCT00598637|left main disease
1343024|NCT00598611|urticaria
1343025|NCT00598598|Aortic valve insufficiency
1343026|NCT00598598|Aortic valve stenosis
1343027|NCT00598598|3D echocardiogram
1343028|NCT00598572|Deferoxamine
1343029|NCT00598572|Safety
1343030|NCT00598572|Intracerebral hemorrhage
1343031|NCT00598559|Acute pain
1343032|NCT00598559|Fever
1343033|NCT00598559|IV Acetaminophen
1343034|NCT00598559|Analgesic
1343035|NCT00598546|Stomach
1343036|NCT00598546|Gastric
1343037|NCT00598546|Stomach Tumor
1343038|NCT00598546|Stomach Cancer
1343039|NCT00598507|ZK-EPO
1343040|NCT00598507|ZK219477
1343041|NCT00598507|EpothiloneZK
1343042|NCT00598494|effect of bedrest
1343043|NCT00598494|cardiac atrophy
1343044|NCT00598481|SCID
1343045|NCT00598481|gene therapy
1343046|NCT00598481|Adenosine deaminase
1343047|NCT00598481|retroviral vector
1343048|NCT00598455|angiomyolipomata
1343049|NCT00598455|tuberous sclerosis complex
1343050|NCT00598442|anemia
1343051|NCT00598442|chronic kidney disease
1343052|NCT00598442|CKD
1343053|NCT00598442|chronic renal failure
1343054|NCT00598442|CRF
1343055|NCT00598442|erythropoietin
1343056|NCT00598442|EPO
1343057|NCT00598442|erythropoiesis stimulating agent
1343058|NCT00598442|ESA
1343059|NCT00598442|Hematide™
1343060|NCT00598442|hemoglobin
1343061|NCT00598442|Hb
1343062|NCT00598442|Hgb
1343063|NCT00598442|Omontys
1343064|NCT00598442|peginesatide
1343065|NCT00598442|red blood cell
1343066|NCT00598442|red blood cell production
1343067|NCT00598429|NICHD Neonatal Research Network
1343068|NCT00598429|Hypoxemic respiratory failure (HRF)
1343069|NCT00598429|Persistent pulmonary hypertension of the newborn (PPHN)
1343070|NCT00598429|Prostaglandin E1 (PGE1)
1343071|NCT00598429|Mechanical ventilation
1343072|NCT00598429|Meconium, aspiration
1343073|NCT00598416|Hepatitis C
1343074|NCT00598416|Substance Abuse
1343075|NCT00598416|Psychoeducation
1343076|NCT00598416|Psychiatric functioning
1343077|NCT00598416|Physical Functioning
1343078|NCT00598416|Quality of Life
1343079|NCT00598416|NIAAA
1343080|NCT00598416|Alcohol
1343081|NCT00598403|Cystitis
1343082|NCT00598390|Cannabinoid
1343083|NCT00598390|CB1 Receptor
1343084|NCT00598390|Brain Imaging
1343085|NCT00598390|PET Imaging
1343086|NCT00598390|[11C]MePPEP
1343087|NCT00598390|Healthy Volunteer
1343088|NCT00598390|HV
1343089|NCT00598377|Autosomal dominant polycystic kidney disease
1343090|NCT00598377|Adrenal functions
1343091|NCT00598377|Renal volume
1343092|NCT00598377|Glomerular filtration rate
1343093|NCT00598377|Adrenal Cortex Function Tests
1343094|NCT00598364|thyroid
1343095|NCT00598364|nodule
1343096|NCT00598364|genetic
1343097|NCT00598364|mutation
1343098|NCT00598364|malignancy
1343099|NCT00598351|Meningioma
1343100|NCT00598351|Ependymoma
1343101|NCT00598351|Schwannoma
1343102|NCT00598351|Acoustic Neuroma
1343103|NCT00598351|Vestibular Schwannoma
1343104|NCT00598351|Neurofibromatosis Type 2
1343105|NCT00598351|NF2
1343106|NCT00598325|Nicotine
1343107|NCT00598325|Vaccine
1343108|NCT00598325|Immunogenicity
1343109|NCT00598325|Tobacco
1343110|NCT00598325|Habits
1343111|NCT00598299|corneal epithelium
1343112|NCT00598286|CB1 Receptor
1343113|NCT00598286|PET
1343114|NCT00598286|Cannabinoid
1343115|NCT00598286|[18F]FMPEP-d2
1343116|NCT00598286|Brain Imaging
1343117|NCT00598286|Healthy Volunteer
1343118|NCT00598286|HV
1343119|NCT00598273|anemia
1343120|NCT00598273|chronic kidney disease
1343121|NCT00598273|CKD
1343122|NCT00598273|chronic renal failure
1343123|NCT00598273|CRF
1343124|NCT00598273|erythropoietin
1343125|NCT00598273|EPO
1343126|NCT00598273|erythropoiesis stimulating agent
1343127|NCT00598273|ESA
1343128|NCT00598273|Hematide™
1343129|NCT00598273|hemoglobin
1343130|NCT00598273|Hb
1343131|NCT00598273|Hgb
1343132|NCT00598273|Omontys
1343133|NCT00598273|peginesatide
1343134|NCT00598273|red blood cell
1343135|NCT00598273|red blood cell production
1343136|NCT00598260|active management
1343137|NCT00598260|induction of labor
1343138|NCT00598260|cesarean delivery
1343139|NCT00598260|Cesarean
1343140|NCT00598247|Colon Cancer Rectal Colorectal Women
1343141|NCT00598208|In-vitro fertilization
1343142|NCT00598195|Ketamine
1343143|NCT00598195|Phamacokinetics
1343144|NCT00598195|Cardiopulmonary bypass (CPB)
1343145|NCT00598195|ketamine/norketamine pharmacokinetic parameters
1343146|NCT00598182|Attention Deficit Disorder with Hyperactivity
1343147|NCT00598182|OROS methylphenidate
1343148|NCT00598169|AIDS-related diffuse large cell lymphoma
1343149|NCT00598169|AIDS-related diffuse mixed cell lymphoma
1343150|NCT00598169|AIDS-related diffuse small cleaved cell lymphoma
1343151|NCT00598169|AIDS-related immunoblastic large cell lymphoma
1343152|NCT00598169|AIDS-related lymphoblastic lymphoma
1343153|NCT00598169|AIDS-related peripheral/systemic lymphoma
1343154|NCT00598169|AIDS-related primary CNS lymphoma
1343279|NCT00597584|CKD
1343155|NCT00598169|AIDS-related small noncleaved cell lymphoma
1343156|NCT00598130|Patients undergoing elective open partial nephrectomy surgery
1343157|NCT00598130|Excision of a kidney
1343158|NCT00598117|Esophageal
1343159|NCT00598117|CancerEsophagus
1343160|NCT00598104|Asthma, interleukin-13
1343161|NCT00598091|Solid Tumors
1343162|NCT00598091|Phase I
1343163|NCT00598091|Expanded Cohort
1343164|NCT00598091|Pancreatic Cancer
1343165|NCT00598091|Dasatinib
1343166|NCT00598091|Gemcitabine
1343167|NCT00598065|lung
1343168|NCT00598052|Marijuana dependence withdrawal Escitalopram
1343169|NCT00598026|Tele medicine
1343170|NCT00598026|ICD follow-up
1343171|NCT00598026|Cost / benefit study
1343172|NCT00598013|Kidney Transplantation
1343173|NCT00598013|Thiazolidinediones
1343174|NCT00598013|Insulin Resistance
1343175|NCT00598013|Atherosclerosis
1343176|NCT00598000|Lung cancer
1343177|NCT00598000|Quality of Life
1343178|NCT00598000|VATS
1343179|NCT00598000|thoracotomy
1343180|NCT00598000|05-006
1343181|NCT00597987|BRCA1
1343182|NCT00597974|carotid artery stenosis
1343183|NCT00597974|Neuropsychological tests
1343184|NCT00597974|Stroke
1343185|NCT00597974|Transient ischemia
1343186|NCT00597974|Stenting
1343187|NCT00597961|Lung
1343188|NCT00597961|skin
1343189|NCT00597961|melanoma
1343190|NCT00597948|mental retardation
1343191|NCT00597948|downs syndrome
1343192|NCT00597948|autism
1343193|NCT00597948|autism spectrum disorder
1343194|NCT00597948|cerebral palsy
1343195|NCT00597948|developmental disability
1343196|NCT00597948|developmental disabilities
1343197|NCT00597948|intellectual disability
1343198|NCT00597948|intellectual disabilities
1343199|NCT00597948|health promotion
1343200|NCT00597948|disease prevention
1343201|NCT00597948|physical health
1343202|NCT00597948|emotional health
1343203|NCT00597948|behavioral health
1343204|NCT00597948|mental health
1343205|NCT00597948|spiritual health
1343206|NCT00597948|prevention
1343207|NCT00597935|prolapse
1343208|NCT00597935|urinary incontinence
1343209|NCT00597935|uterosacral vaginal vault ligament suspension
1343210|NCT00597935|sacrospinous ligament fixation
1343211|NCT00597935|behavioral therapy
1343212|NCT00597935|pelvic muscle training
1343213|NCT00597922|Acute Myocardial Infarction
1343214|NCT00597922|Heart Attack
1343215|NCT00597922|Gender Differences
1343216|NCT00597922|Risk Factors
1343217|NCT00597922|Quality of Care
1343218|NCT00597909|Ammonul®
1343219|NCT00597909|sodium phenylacetate and sodium benzoate
1343220|NCT00597909|hepatic encephalopathy
1343221|NCT00597909|Grade 3 or 4 Hepatic Encephalopathy
1343222|NCT00597883|carotid endarterectomy
1343223|NCT00597883|Neuropsychological tests
1343224|NCT00597883|Stroke
1343225|NCT00597883|Transient ischemia
1343226|NCT00597870|TAA
1343227|NCT00597844|type I thyroplasty
1343228|NCT00597844|unilateral vocal fold augmentation
1343229|NCT00597831|depression
1343230|NCT00597831|electroconvulsive therapy
1343231|NCT00597831|Ultrasonography Doppler Transcranial
1343232|NCT00597831|intracranial pressure
1343233|NCT00597792|Gastroesophageal Reflux Disease (GERD)
1343234|NCT00597792|Plicator
1343235|NCT00597792|Full-thickness Plication
1343236|NCT00597779|intertrochanteric fractures
1343237|NCT00597766|CVA
1343238|NCT00597766|Hemiplegia
1343239|NCT00597766|Hemiplegic shoulder pain
1343240|NCT00597766|Subacromial steroid injection
1343241|NCT00597753|anemia
1343242|NCT00597753|chronic kidney disease
1343243|NCT00597753|CKD
1343244|NCT00597753|chronic renal failure
1343245|NCT00597753|CRF
1343246|NCT00597753|dialysis
1343247|NCT00597753|erythropoietin
1343248|NCT00597753|EPO
1343249|NCT00597753|erythropoiesis stimulating agent
1343250|NCT00597753|ESA
1343251|NCT00597753|Hematide™
1343252|NCT00597753|hemodialysis
1343253|NCT00597753|hemoglobin
1343254|NCT00597753|Hb
1343255|NCT00597753|Hgb
1343256|NCT00597753|Omontys
1343257|NCT00597753|peginesatide
1343258|NCT00597753|red blood cell
1343259|NCT00597753|red blood cell production
1343260|NCT00597727|Peanut Allergy
1343261|NCT00597727|Sublingual immunotherapy
1343262|NCT00597714|Stem Cell Transplantation, Non-myeloablative
1343263|NCT00597701|Alcohol withdrawal
1343264|NCT00597701|Delirium tremors
1343265|NCT00597675|Peanut allergy
1343266|NCT00597636|smokers
1343267|NCT00597623|Osteoarthritis
1343268|NCT00597623|Hand
1343269|NCT00597623|Tumor Necrosis Factor-alpha inhibitors
1343270|NCT00597623|Biological Therapy
1343271|NCT00597610|Rectum
1343272|NCT00597610|Rectal
1343273|NCT00597597|Metastatic breast cancer
1343274|NCT00597597|ER and PR hormone receptor negative
1343275|NCT00597597|HER2/neu negative
1343276|NCT00597597|EGFR positive
1343277|NCT00597584|anemia
1343278|NCT00597584|chronic kidney disease
1343280|NCT00597584|chronic renal failure
1343281|NCT00597584|CRF
1343282|NCT00597584|dialysis
1343283|NCT00597584|erythropoietin
1343284|NCT00597584|EPO
1343285|NCT00597584|erythropoiesis stimulating agent
1343286|NCT00597584|ESA
1343287|NCT00597584|Hematide™
1343288|NCT00597584|hemodialysis
1343289|NCT00597584|hemoglobin
1343290|NCT00597584|Hb
1343291|NCT00597584|Hgb
1343292|NCT00597584|Omontys
1343293|NCT00597584|peginesatide
1343294|NCT00597584|red blood cell
1343295|NCT00597584|red blood cell production
1343296|NCT00597558|Egg allergy
1343297|NCT00597545|Carotid Endarterectomy
1343298|NCT00597545|Neuropsychological tests
1343299|NCT00597545|Stroke
1343300|NCT00597545|Transient ischemia
1343301|NCT00597545|Hypoperfusion
1343302|NCT00597545|Ischemia
1343303|NCT00597532|Breast Cancer
1343304|NCT00597532|Soy
1343305|NCT00597532|Milk
1343306|NCT00597532|Supplementation
1343307|NCT00597532|02-062
1343308|NCT00597519|Cancer
1343309|NCT00597519|Leukemia
1343310|NCT00597519|Myelodysplastic Syndrome
1343311|NCT00597519|Non-Hodgkin's Lymphoma
1343312|NCT00597519|Total Body Irradiation
1343313|NCT00597519|Umbilical Cord Blood Grafts
1343314|NCT00597519|06-014
1343315|NCT00597506|colorectal
1343316|NCT00597506|refractory
1343317|NCT00597506|adenocarcinoma
1343318|NCT00597506|bevacizumab
1343319|NCT00597506|everolimus
1343320|NCT00597493|Recurrent Glioblastoma Multiforme
1343321|NCT00597493|GBM
1343322|NCT00597493|Glioblastoma
1343323|NCT00597493|Sorafenib
1343324|NCT00597493|Temozolomide
1343325|NCT00597493|Brain Tumor
1343326|NCT00597493|Recurrent GBM
1343327|NCT00597493|Temodar
1343328|NCT00597493|Gliosarcoma
1343329|NCT00597493|Glioma
1343330|NCT00597493|Nexavar
1343331|NCT00597480|Growth hormone
1343332|NCT00597480|Child
1343333|NCT00597480|insulin resistance
1343334|NCT00597480|metabolic syndrome X
1343335|NCT00597480|children born small for gestational age
1343336|NCT00597467|myopia
1343337|NCT00597467|hyperopia
1343338|NCT00597467|extended wear
1343339|NCT00597467|ametropia
1343340|NCT00597454|Breast
1343341|NCT00597441|unrelated
1343342|NCT00597441|umbilical cord blood transplantation
1343343|NCT00597441|thymus transplantation
1343344|NCT00597415|Osteoarthritis
1343345|NCT00597415|Knee pain
1343346|NCT00597402|Avastin
1343347|NCT00597402|Bevacizumab
1343348|NCT00597402|Temozolomide
1343349|NCT00597402|Temodar
1343350|NCT00597402|Irinotecan
1343351|NCT00597402|Camptosar
1343352|NCT00597402|GBM
1343353|NCT00597402|Glioblastoma Multiforme
1343354|NCT00597402|Gliosarcoma
1343355|NCT00597402|Brain tumor
1343356|NCT00597402|Glioma
1343357|NCT00597402|New GBM
1343358|NCT00597402|Newly diagnosed GBM or gliosarcoma malignant brain tumor
1343359|NCT00597389|posttraumatic stress disorder
1343360|NCT00597389|propranolol
1343361|NCT00597389|inderol
1343362|NCT00597389|child
1343363|NCT00597389|trauma
1343364|NCT00597389|Posttraumatic stress disorders (PTSD)
1343365|NCT00597376|memory loss
1343366|NCT00597363|vascular access site
1343367|NCT00597363|arterial puncture
1343368|NCT00597363|femoral pseudoaneurysm
1343369|NCT00597350|Fenugreek
1343370|NCT00597350|Trigonella foenum-graecum
1343371|NCT00597350|Diabetes mellitus
1343372|NCT00597350|Blood sugar
1343373|NCT00597350|Insulin
1343374|NCT00597350|Glucose
1343375|NCT00597337|bullying
1343376|NCT00597337|victimisation
1343377|NCT00597337|aggressive behavior
1343378|NCT00597324|Allen's test
1343379|NCT00597324|lactate
1343380|NCT00597324|safety
1343381|NCT00597324|radial intervention
1343382|NCT00597324|Patients with coronary artery disease
1343383|NCT00597311|rectal cancer
1343384|NCT00597311|radiotherapy
1343385|NCT00597311|radiochemotherapy
1343386|NCT00597298|diaphragmatic paralysis
1343387|NCT00597298|cardiac surgery
1343388|NCT00597298|respiratory muscle training
1343389|NCT00597285|18-F-Fluoro-2-Deoxy-D-Glucose (FDG)
1343390|NCT00597285|Magnetic Resonance
1343391|NCT00597285|Epilepsy
1343392|NCT00597285|HHV-6B
1343393|NCT00597285|Healthy Volunteer
1343394|NCT00597285|HV
1343395|NCT00597272|melanoma
1343396|NCT00597272|resected local
1343397|NCT00597272|systemic metastasis
1343398|NCT00597259|hepatitis B, entecavir, pegylated interferon alfa-2a
1343399|NCT00597246|Brain
1343400|NCT00597246|CNS
1343401|NCT00597246|Central Nervous System
1343402|NCT00597207|CPR
1343403|NCT00597207|mechanical
1343404|NCT00597207|manual
1343405|NCT00597207|outcome
1343406|NCT00597207|survival
1343407|NCT00597207|quality
1343408|NCT00597194|inguinal hernia
1343409|NCT00597194|laparoscopic repair
1343410|NCT00597194|open repair
1343411|NCT00597194|randomized
1343412|NCT00597181|Inflammatory response
1343413|NCT00597168|Schizophrenia
1343414|NCT00597168|atypical antipsychotic
1343415|NCT00597168|quality of life
1343416|NCT00597168|ambulatory setting
1343417|NCT00597142|renal stent
1343418|NCT00597142|stent
1343419|NCT00597142|atherosclerosis
1343420|NCT00597142|aortorenal ostium
1343421|NCT00597142|renal
1343422|NCT00597142|renal artery
1343423|NCT00597142|PTRA
1343424|NCT00597129|pancreatic cancer
1343425|NCT00597129|cancer of the pancreas
1343426|NCT00597129|pancreas cancer
1343427|NCT00597116|Mesothelioma
1343428|NCT00597116|inoperable
1343429|NCT00597116|relapsed
1343430|NCT00597103|Hemodialysis
1343431|NCT00597103|Frequent Hemodialysis
1343432|NCT00597103|Sleep Apnea
1343433|NCT00597103|Restless Leg Syndrome
1343434|NCT00597103|Cognitive Function
1343435|NCT00597090|Infections
1343436|NCT00597090|lymphoma
1343437|NCT00597064|asthma
1343438|NCT00597064|asthma control questionnaire
1343439|NCT00597064|oral corticosteroid
1343440|NCT00597064|air trapping
1343441|NCT00597064|AQLQ
1343442|NCT00597064|control
1343443|NCT00597064|quality of life
1343444|NCT00597038|Dasatinib
1343445|NCT00597038|Dacarbazine
1343446|NCT00597025|Malnutrition
1343447|NCT00597025|Hypoalbuminemia
1343448|NCT00597025|Dietary Supplements
1343449|NCT00597025|Hemodialysis
1343450|NCT00597025|Peritoneal Dialysis
1343451|NCT00597012|Meniscal Tear
1343452|NCT00597012|Osteoarthritis
1343453|NCT00597012|Arthroscopic Partial Meniscectomy
1343454|NCT00597012|Physical Therapy
1343455|NCT00596999|Myelodysplastic Syndrome (MDS)
1343456|NCT00596999|Acute myelogenous Leukemia (AML)
1343457|NCT00596999|Acute Lymphocytic Leukemia (ALL)
1343458|NCT00596999|Sickle Cell Disease (SCD)
1343459|NCT00596999|Beta Thalassemia
1343460|NCT00596999|Inborn Errors of Metabolism
1343461|NCT00596999|Severe Combined Immunodeficiency Disease (SCID)
1343462|NCT00596986|Depression
1343463|NCT00596986|Duloxetine
1343464|NCT00596986|Psychotherapy
1343465|NCT00596986|Magnetic Resonance Imaging
1343466|NCT00596960|Alcohol Abuse
1343467|NCT00596960|Alcohol Dependence
1343468|NCT00596960|Carbohydrate Deficient Transferrin
1343469|NCT00596960|Drug Dependence
1343470|NCT00596960|Hepatitis C
1343471|NCT00596960|Motivation
1343472|NCT00596947|kidney transplantation
1343473|NCT00596947|tacrolimus
1343474|NCT00596947|Prograf
1343475|NCT00596947|mycophenolate mofetil
1343476|NCT00596947|CellCept
1343477|NCT00596947|corticosteroid withdrawal
1343478|NCT00596947|prednisone withdrawal
1343479|NCT00596947|prednisone maintenance
1343480|NCT00596947|rabbit antithymocyte globulin
1343481|NCT00596947|Thymoglobulin
1343482|NCT00596934|Nonalcoholic fatty liver disease
1343483|NCT00596934|Insulin resistance
1343484|NCT00596934|Obesity
1343485|NCT00596934|Leptin therapy
1343486|NCT00596934|NASH
1343487|NCT00596921|Ultrasonography
1343488|NCT00596921|Central Venous Pressure
1343489|NCT00596921|Noninvasive monitoring
1343490|NCT00596921|Shock
1343491|NCT00596921|Resuscitation
1343492|NCT00596908|Essential Tremor
1343493|NCT00596908|Parkinsonian Tremor
1343494|NCT00596908|Parkinson Disease
1343495|NCT00596908|Upper Extremity Tremor with duration of less than 2 years
1343496|NCT00596895|Isoflavone, PSA, prostate cancer, recurrent, quality of life
1343497|NCT00596882|smoking cessation
1343498|NCT00596882|nicotine dependence
1343499|NCT00596882|message prime
1343500|NCT00596882|recruitment
1343501|NCT00596856|Early childhood caries - ECC
1343502|NCT00596856|Referral behavior
1343503|NCT00596856|Oral health risk assessment
1343504|NCT00596856|Guideline development and dissemination
1343505|NCT00596830|IGF-1R inhibitor
1343506|NCT00596830|Non-small-cell lung carcinoma
1343507|NCT00596830|CP-751
1343508|NCT00596830|871
1343509|NCT00596817|Relapse prevention
1343510|NCT00596817|Antidepressants
1343511|NCT00596817|Placebo-controlled
1343512|NCT00596817|Double-blind
1343513|NCT00596817|Multicentre study
1343514|NCT00596804|NHL
1343515|NCT00596804|Non-Hodgkin's lymphoma
1343516|NCT00596804|follicular lymphoma
1343517|NCT00596804|B-cell lymphoma
1343518|NCT00596804|diffuse large cell lymphoma
1343519|NCT00596804|small lymphoctytic lymphoma
1343520|NCT00596804|Mantle cell lymphoma
1343521|NCT00596804|MALT
1343522|NCT00596804|marginal zone lymphoma
1343523|NCT00596804|High-Grade
1343524|NCT00596804|Intermediate-Grade
1343525|NCT00596804|Low-Grade
1343526|NCT00596804|Mixed
1343527|NCT00596778|Physical therapy specialty
1343528|NCT00596778|Postoperative period. Abdominal surgery
1343529|NCT00596778|Anesthesia recovery period
1343530|NCT00596778|Spirometry
1343531|NCT00596765|Brain Injury
1343532|NCT00596765|Neuropsychology
1343533|NCT00596765|Cognitive Behavioral Therapy
1343534|NCT00596765|Neuropsychological Rehabilitation
1343535|NCT00596752|Alprostadil
1343536|NCT00596752|Prostavasin
1343537|NCT00596752|PAOD
1343538|NCT00596752|Fontaine Stage IV
1343539|NCT00596739|Bariatric surgery, weight loss surgery, male infertility, Roux-En-Y, gastric banding
1343540|NCT00596726|All patients presenting for high-risk cardiac surgery and who might post-operatively meet the study inclusion criteria are potential study candidates.
1343541|NCT00596713|general population
1343542|NCT00596700|Capsule endoscopy
1343543|NCT00596700|Crohn's disease
1343544|NCT00596700|IBD
1343545|NCT00596700|Activity score
1343546|NCT00596700|Small bowel
1343547|NCT00596700|Crohn's disease of the small bowel in any stage
1343548|NCT00596700|Recruiting
1343549|NCT00596687|diabetes
1343550|NCT00596687|post-op complications
1343551|NCT00596687|inpatient hyperglycemia
1343552|NCT00596674|Women
1343553|NCT00596674|Fibromyalgia Syndrome
1343554|NCT00596674|Health Behaviors
1343555|NCT00596674|Quality of Life
1343556|NCT00596661|coronary stent
1343557|NCT00596648|Lung Cancer
1343558|NCT00596648|Non-Small-Cell Lung Cancer
1343559|NCT00596648|NSCLC
1343560|NCT00596635|UTI
1343561|NCT00596635|elderly
1343562|NCT00596635|prevention
1343563|NCT00596635|cranberry
1343564|NCT00596635|E.Coli
1343565|NCT00596622|Major Depressive or Manic Episodes
1343566|NCT00596622|Bipolar
1343567|NCT00596622|Mania
1343568|NCT00596622|Depression
1343569|NCT00596622|Lithium
1343570|NCT00596622|fMRI
1343571|NCT00596622|Pictures
1343572|NCT00596622|Brain Scan
1343573|NCT00596609|Injections, intrathecal
1343574|NCT00596609|Transcranial
1343575|NCT00596609|Spinal Fusion
1343576|NCT00596609|Evoked Potentials, Motor
1343577|NCT00596596|Constipation
1343578|NCT00596596|prucalopride
1343579|NCT00596570|Atrial fibrillation
1343580|NCT00596570|Oral Anticoagulation
1343581|NCT00596570|Percutaneous coronary intervention
1343582|NCT00596557|Renal function, heart transplant, everolimus
1343583|NCT00596544|sexual dysfunction
1343584|NCT00596531|Tinnitus
1343585|NCT00596531|acamprosate
1343586|NCT00596531|clinical trial
1343587|NCT00596505|proliferative diabetic retinopathy
1343588|NCT00596505|bevacizumab (Avastin)
1343589|NCT00596505|vitreous hemorrhage
1343590|NCT00596505|silicone oil
1343591|NCT00596479|CAD
1343592|NCT00596479|G-CSF
1343593|NCT00596479|Collaterals
1343594|NCT00596479|CFI
1343595|NCT00596479|perfusion
1343596|NCT00596466|open-label
1343597|NCT00596466|extension study
1343598|NCT00596466|pregabalin
1343599|NCT00596466|partial epilepsy
1343600|NCT00596453|Prostate Specific Antigen (PSA)
1343601|NCT00596453|Elevated Prostate Specific Antigen (PSA)
1343602|NCT00596440|smoking
1343603|NCT00596440|teachable moment
1343604|NCT00596440|cancer
1343605|NCT00596427|type two diabetes
1343606|NCT00596427|gluconeogenesis
1343607|NCT00596427|glucose
1343608|NCT00596427|lipid synthesis
1343609|NCT00596427|hepatic insulin sensitivity
1343610|NCT00596427|colesevelam HCl
1343611|NCT00596414|liver
1343612|NCT00596414|biopsy
1343613|NCT00596388|HMP, AMD, CNV, PHP, HPHP
1343614|NCT00596375|Lidocaine
1343615|NCT00596375|Infant
1343616|NCT00596375|Urinary Catheterization
1343617|NCT00596375|Emergency Medicine
1343618|NCT00596375|Analgesia
1343619|NCT00596362|Melanoma
1343620|NCT00596362|Eye
1343621|NCT00596362|Avastin
1343622|NCT00596349|epithelial Ovarian Cancer
1343623|NCT00596349|Quality of Life
1343624|NCT00596349|Survivorship
1343625|NCT00596323|antenna
1343626|NCT00596323|continuous glucose monitoring
1343627|NCT00596323|electromagnetic
1343628|NCT00596310|Lung cancer
1343629|NCT00596310|screening
1343630|NCT00596297|Diabetic Retinopathy
1343631|NCT00596297|Vitreous Hemorrhage
1343632|NCT00596297|Bevacizumab
1343633|NCT00596297|pars plana vitrectomy
1343634|NCT00596297|preoperative
1343635|NCT00596284|Cognitive Behavior Therapy
1343636|NCT00596284|Alzheimer's Disease
1343637|NCT00596258|Cervical Intraepithelial Neoplasia (CIN)
1343638|NCT00596258|High-grade Cervical Intraepithelial Neoplasia
1343639|NCT00596258|High-grade Squamous Intraepithelial Lesions (HSIL)
1343640|NCT00596258|Human Papilloma Virus (HPV)
1343641|NCT00596258|High-Grade Cervical Intraepithelial Lesions (CIN 2/3)
1343642|NCT00596245|non-smoking healthy volunteers aged 18 - 35
1343643|NCT00596219|HEAD
1343644|NCT00596219|NECK
1343645|NCT00596219|SQUAMOUS
1343646|NCT00596219|CARCINOMA
1343647|NCT00596193|Hyperalgesia
1343648|NCT00596193|nociceptors
1343649|NCT00596193|Neurons
1343650|NCT00596180|carbon monoxide poisoning
1343651|NCT00596180|brain injury
1343652|NCT00596167|Short-daily hemodialysis
1343653|NCT00596167|pharmacokinetics
1343654|NCT00596167|levofloxacin
1343655|NCT00596167|gentamicin
1343656|NCT00596167|vancomycin
1343657|NCT00596141|oral periodontal gingival intraoral mucosal mucoperiosteal
1343658|NCT00596141|Surgery, Oral
1343659|NCT00596128|Blood glucose
1343660|NCT00596128|Clinical pathways
1343661|NCT00596076|Low back pain
1343662|NCT00596063|pharmacokinetics
1343663|NCT00596063|pharmacodynamics
1343664|NCT00596063|recombinant human insulin
1343665|NCT00596063|healthy volunteers
1343666|NCT00596050|procedural sedation
1343667|NCT00596050|fracture reduction
1343668|NCT00596050|pediatric emergency medicine
1343669|NCT00596050|etomidate
1343670|NCT00596050|ketamine
1343671|NCT00596050|analgesia
1343672|NCT00596037|Growth hormone Deficiency
1343673|NCT00596011|prostate cancer
1343674|NCT00596011|PIN
1343675|NCT00596011|polyphenon E
1343676|NCT00596011|EGCG
1343677|NCT00595998|AMD, HMP, PHP
1343678|NCT00595985|Time to Progression
1343679|NCT00595985|Toxicity
1343680|NCT00595985|Overall survival
1343681|NCT00595985|Response rate
1343682|NCT00595985|Quality of live
1343683|NCT00595985|Toxicities
1343684|NCT00595972|Time to Progression
1343685|NCT00595972|Overall survival
1343686|NCT00595972|Response rate
1343687|NCT00595972|Quality of Live
1343688|NCT00595972|Toxicities
1343689|NCT00595933|Head and Neck cancer
1343690|NCT00595933|Radiation therapy
1343691|NCT00595933|Dry mouth remedies
1343692|NCT00595933|Dry Mouth
1343693|NCT00595933|Xerostomia
1343694|NCT00595920|Tovaxin
1343695|NCT00595920|Autologous
1343696|NCT00595920|T-cell vaccine (TCV)
1343697|NCT00595907|tuberculosis
1343698|NCT00595907|interferon gamma release assays
1343699|NCT00595907|treatment
1343700|NCT00595894|rheumatoid arthritis
1343701|NCT00595894|African Americans
1343702|NCT00595894|osteopenia
1343703|NCT00595894|osteoporosis
1343704|NCT00595894|bone mineral density
1343705|NCT00595881|Bedside emergency ultrasound
1343706|NCT00595881|Abscess
1343707|NCT00595881|Cellulitis
1343708|NCT00595881|Soft tissue infection
1343709|NCT00595881|Methicillin resistant staphylococcus aureus (MRSA)
1343710|NCT00595868|Nicotine
1343711|NCT00595868|Smoking
1343712|NCT00595868|Smoking Cessation
1343713|NCT00595855|glaucoma
1343714|NCT00595855|surgery
1343715|NCT00595855|non penetrating procedures
1343716|NCT00595855|cataract
1343717|NCT00595842|Mineral trioxide aggregate
1343718|NCT00595829|Polycythemia Vera
1343719|NCT00595829|PV
1343720|NCT00595816|low back pain
1343721|NCT00595816|physical fitness
1343722|NCT00595816|injury
1343723|NCT00595816|prevention
1343724|NCT00595816|conscripts
1343725|NCT00595777|Institutional change
1343726|NCT00595777|Improved pain management
1343727|NCT00595764|Buprenorphine
1343728|NCT00595764|Buprenorphine/naloxone
1343729|NCT00595764|Counseling
1343730|NCT00595764|Primary care
1343731|NCT00595751|ADHD, Attention Deficit Hyperactivity Disorder
1343732|NCT00595738|Congestive heart failure
1343733|NCT00595738|Cardiac biomarkers
1343734|NCT00595738|Hemodynamics
1343735|NCT00595738|Tailored therapy
1343736|NCT00595725|Cervix
1343737|NCT00595725|Endometrium
1343738|NCT00595725|Cervical Carcinoma
1343739|NCT00595725|Lymphatic Mapping
1343740|NCT00595712|Genovarum
1343741|NCT00595712|Medial opening-wedge high tibial osteotomy
1343742|NCT00595712|allograft
1343743|NCT00595686|Hematologic Malignancies Hsp90 Hematologic Malignancy
1343744|NCT00595673|Perfusion
1343745|NCT00595673|Echocardiograpy
1343746|NCT00595673|SPECT
1343747|NCT00595673|angiography
1343748|NCT00595673|Chest pain
1343749|NCT00595660|Palpable Breast Mass
1343750|NCT00595660|FNA
1343751|NCT00595660|Cytology
1343752|NCT00595660|Fine needle aspiration
1343753|NCT00595660|Specimen Adequacy
1343754|NCT00595634|Hip
1343755|NCT00595634|Fracture
1343756|NCT00595634|Intertrochanteric
1343757|NCT00595634|intramedullary
1343758|NCT00595608|aftercare
1343759|NCT00595608|nasal septum
1343760|NCT00595608|turbinates
1343761|NCT00595595|Dental Pulp
1343762|NCT00595595|Regenerative Medicine
1343763|NCT00595595|Odontoblasts
1343764|NCT00595595|Stem Cells
1343765|NCT00595595|Growth factor differentiation of stem/progenitor cells
1343766|NCT00595595|Odontoblast-specific cell phenotypes
1343767|NCT00595569|flexible insulin therapy
1343768|NCT00595569|diabetes education
1343769|NCT00595569|diabetes
1343770|NCT00595569|insulin
1343771|NCT00595569|Weekly ambulatory sessions
1343772|NCT00595556|Zonisamide
1343773|NCT00595556|Pharmacotherapy
1343774|NCT00595556|Alcohol dependence
1343775|NCT00595556|anticonvulsant
1343776|NCT00595530|ketamine
1343777|NCT00595530|vasoocclusive pain
1343778|NCT00595517|gastrointestinal
1343779|NCT00595517|GI
1343780|NCT00595517|NSAID
1343781|NCT00595517|Japan
1343782|NCT00595517|Japanese
1343783|NCT00595517|Gastric ulcer
1343784|NCT00595517|duodenal ulcer
1343785|NCT00595504|schizophrenia
1343786|NCT00595504|metabolism
1343787|NCT00595504|antipsychotics
1343788|NCT00595504|diabetes
1343789|NCT00595504|rozerem
1343790|NCT00595491|Asthma
1343791|NCT00595491|Inflammation
1343792|NCT00595491|Allergic
1343793|NCT00595491|Airway
1343794|NCT00595491|Challenge
1343795|NCT00595491|Chemokines
1343796|NCT00595439|Sensory Evoked Potentials (SEPs)
1343797|NCT00595439|Electromyogram
1343798|NCT00595439|Transcranial Magnetic Stimulation (TMS)
1343799|NCT00595439|Complex Regional Pain Syndrome
1343800|NCT00595439|Focal Hand Dystonia
1343801|NCT00595439|Focal Dystonia
1343802|NCT00595439|Chronic Regional Pain Syndrome
1343803|NCT00595439|CRPS
1343804|NCT00595426|Knee Arthroplasty
1343805|NCT00595426|Factor Xa
1343806|NCT00595426|VTE
1343807|NCT00595426|Thrombosis
1343808|NCT00595426|Anticoagulants
1343809|NCT00595413|Rheumatoid arthritis
1343810|NCT00595413|Atacicept
1343811|NCT00595413|Adalimumab
1343812|NCT00595413|Humira®
1343813|NCT00595387|Cognitive Behavioral Therapy
1343814|NCT00595361|asthma
1343815|NCT00595361|exercise induced asthma
1343816|NCT00595361|exercise induced bronchoconstriction
1343817|NCT00595361|long acting beta agonist
1343818|NCT00595361|salmeterol
1343819|NCT00595361|exercise challenge
1343820|NCT00595361|bronchoprotection
1343821|NCT00595361|beta 2 adrenergic receptor polymorphisms
1343822|NCT00595361|pharmacogenetics
1343823|NCT00595335|Thyroid-associated ophthalmopathy
1343824|NCT00595335|Rituximab
1343825|NCT00595335|Proptosis
1343826|NCT00595322|Bevacizumab
1343827|NCT00595322|Radiation Treatment
1343828|NCT00595322|Brain Cancer
1343829|NCT00595296|BreastCancer
1343830|NCT00595296|Sentinel Lymph Nodes
1343831|NCT00595296|Metastasis
1343832|NCT00595283|Preschool Onset Major Depressive Disorder
1343833|NCT00595283|Preschool Depression
1343834|NCT00595283|Emotion Development
1343835|NCT00595283|Parent Child Interaction
1343836|NCT00595257|PAD, CLI, Critical Limb Ischemia, bone marrow, stem cell, injection, infusion
1343837|NCT00595244|Perfusion
1343838|NCT00595244|Echocardiograpy
1343839|NCT00595244|SPECT
1343840|NCT00595244|angiography
1343841|NCT00595244|Chest pain
1343842|NCT00595231|GAD
1343843|NCT00595218|Patient Preferences
1343844|NCT00595218|Patient Satisfaction
1343845|NCT00595218|Patient-Doctor Relationship
1343846|NCT00595205|vaccination
1343847|NCT00595205|intussusception
1343848|NCT00595205|Rotavirus
1343849|NCT00595205|vaccine
1343850|NCT00595179|Infrared
1343851|NCT00595179|Imaging Techniques
1343852|NCT00595179|Kidney Reperfusion
1343853|NCT00595179|Pneumoperitoneum
1343854|NCT00595179|Nephrectomy
1343855|NCT00595166|Women with excessive vaginal tissue that obstruct the examiner's view of the cervix during a vaginal speculum examination
1343856|NCT00595140|Acromegaly,
1343857|NCT00595140|growth hormone receptor antagonist,
1343858|NCT00595140|somatostatin analogue,
1343859|NCT00595140|combined medical treatment,
1343860|NCT00595140|acute effect,
1343861|NCT00595140|endogenous GH
1343862|NCT00595127|Fanconi
1343863|NCT00595127|Anemia
1343864|NCT00595127|Stem Cell
1343865|NCT00595127|Transplant
1343866|NCT00595114|COPD
1343867|NCT00595114|Airway
1343868|NCT00595114|Inflammation
1343869|NCT00595114|Infection
1343870|NCT00595114|Lipid Mediators
1343871|NCT00595114|Oxidative Stress
1343872|NCT00595088|Bladder Cancer
1343873|NCT00595088|Refractory
1343874|NCT00595075|sleep
1343875|NCT00595075|performance
1343876|NCT00595075|night shift
1343877|NCT00595075|Ramelteon
1343878|NCT00595075|Healthy Individuals
1343879|NCT00595062|Breast
1343880|NCT00595062|Cancer
1343881|NCT00595049|pulmonary
1343882|NCT00595049|arterial
1343883|NCT00595049|artery
1343884|NCT00595049|hypertension
1343885|NCT00595049|systemic
1343886|NCT00595049|sclerosis
1343887|NCT00595049|scleroderma
1343888|NCT00595049|remodelling
1343889|NCT00595049|bosentan
1343890|NCT00595049|tracleer
1343891|NCT00595049|intravascular
1343892|NCT00595023|Sentinel lymph node
1343893|NCT00595023|Metastasis
1343894|NCT00595010|Child Maltreatment
1343895|NCT00595010|Child Neglect
1343896|NCT00595010|Child Physical Abuse
1343897|NCT00595010|Evidence-Based Practice
1343898|NCT00594997|Lyme disease
1343899|NCT00594997|educational intervention for children
1343900|NCT00594997|tick borne illness
1343901|NCT00594997|prophylactic therapy in children
1343902|NCT00594997|Self-efficacy
1343903|NCT00594997|tick prevention
1343904|NCT00594997|tick avoidance
1343905|NCT00594997|health behavior modification
1343906|NCT00594971|Health Services Research
1343907|NCT00594971|Family practice
1343908|NCT00594932|lupus, arthritis, mycophenolate, biomarkers
1343909|NCT00594919|acute kidney injury
1343910|NCT00594919|ngal
1343911|NCT00594919|cardiac surgery
1343912|NCT00594906|Fracture Healing
1343913|NCT00594906|Teriparatide
1343914|NCT00594906|Forteo
1343915|NCT00594906|Pelvic Fractures
1343916|NCT00594893|Hip
1343917|NCT00594893|Arthroplasty
1343918|NCT00594893|Minimally Invasive
1343919|NCT00594880|HIV
1343920|NCT00594880|HIV-1
1343921|NCT00594880|Pegasys
1343922|NCT00594880|Peg-IFN-Alpha-2A
1343923|NCT00594880|Viral Suppression
1343924|NCT00594880|ART cessation
1343925|NCT00594880|Immune function
1343926|NCT00594880|Innate Immunity
1343927|NCT00594880|Toxicity
1343928|NCT00594880|Immune-based therapy
1343929|NCT00594880|Treatment interruption
1343930|NCT00594867|Healthy
1343931|NCT00594867|Volunteer
1343932|NCT00594854|NSAID
1343933|NCT00594854|Gastric Ulcer
1343934|NCT00594854|High risk
1343935|NCT00594854|Arthrotec
1343936|NCT00594854|Vimovo
1343937|NCT00594841|Acromioclavicular Joint
1343938|NCT00594841|Shoulder dislocation
1343939|NCT00594841|AC dislocation
1343940|NCT00594828|Patient self-testing
1343941|NCT00594828|Oral anticoagulation therapy
1343942|NCT00594828|Expert Systems
1343943|NCT00594828|Point-of-Care Systems
1343944|NCT00594828|International Normalized Ratio
1343945|NCT00594815|Lymphoma
1343946|NCT00594815|Central Nervous System
1343947|NCT00594802|ALLERGIC REACTION
1343948|NCT00594789|Osteoporosis
1343949|NCT00594789|Fractures
1343950|NCT00594789|Bone densitometry
1343951|NCT00594789|Dual-energy x-ray absorptiometry
1343952|NCT00594776|Cone Beam CT
1343953|NCT00594776|CBCT
1343954|NCT00594776|Bone Tumors
1343955|NCT00594776|Autographs
1343956|NCT00594776|Allographs
1343957|NCT00594763|Turner syndrome
1343958|NCT00594763|Thromboembolic disease
1343959|NCT00594737|PET
1343960|NCT00594737|frontotemporal dementia
1343961|NCT00594737|memantine
1343962|NCT00594737|Pick's disease
1343963|NCT00594724|Tongue
1343964|NCT00594724|Carcinoma
1343965|NCT00594724|Cancer
1343966|NCT00594724|02-093
1343967|NCT00594711|Psychotherapy
1343968|NCT00594711|depression
1343969|NCT00594698|Perfusion
1343970|NCT00594698|Echocardiography
1343971|NCT00594698|Cardiac angiography
1343972|NCT00594698|SPECT
1343973|NCT00594685|Heparin
1343974|NCT00594685|Thromboembolism
1343975|NCT00594685|Thrombosis
1343976|NCT00594672|Age-Related Macular Degeneration (AMD)
1343977|NCT00594672|Cataracts
1343978|NCT00594672|Age Related Macular Degeneration
1343979|NCT00594672|AMD
1343980|NCT00594672|Cataract
1343981|NCT00594659|Marijuana
1343982|NCT00594659|Treatment
1343983|NCT00594659|Behavioral
1343984|NCT00594659|Computer
1343985|NCT00594659|Internet
1343986|NCT00594646|HIV Prevention
1343987|NCT00594646|Non-occupational post-exposure prophylaxis
1343988|NCT00594646|HIV seronegativity
1343989|NCT00594633|Cognitive dysfunction
1343990|NCT00594607|clotting
1343991|NCT00594607|hemodialysis
1343992|NCT00594607|anticoagulation
1343993|NCT00594607|bleeding risk
1343994|NCT00594594|spinal cord injury
1343995|NCT00594594|urinary tract infection
1343996|NCT00594594|probiotics
1343997|NCT00594594|Lactobacilli
1343998|NCT00594581|cicatrix, scarring, TGF-beta3, avotermin, Juvista
1343999|NCT00594555|Blood disease, bone marrow
1344000|NCT00594555|AML
1344001|NCT00594555|CML,Blast Crisis
1344002|NCT00594542|lidocaine
1344003|NCT00594542|local anesthesia
1344004|NCT00594542|Mohs micrographic surgery
1344005|NCT00594529|Neoadjuvant chemotherapy
1344006|NCT00594529|Metastatic liver lesions from colorectal cancers
1344007|NCT00594516|Low Back Pain
1344008|NCT00594516|Dose Equivalence
1344009|NCT00594516|Tapentadol (CG5503)
1344010|NCT00594516|Tapentadol-IR
1344011|NCT00594516|Tapentadol-ER
1344012|NCT00594503|traumatic brain injury
1344013|NCT00594490|Breast, reconstruction, silicone
1344014|NCT00594477|IMRT
1344015|NCT00594477|breast cancer with regional nodal metastasis
1344016|NCT00594464|Rotigotine
1344017|NCT00594464|NEUPRO®
1344018|NCT00594464|Parkinson's Disease (PD)
1344019|NCT00594464|perioperative use
1344020|NCT00594464|anaesthesia,
1344021|NCT00594451|rheumatoid arthritis
1344022|NCT00594451|cigarette smoking
1344023|NCT00594451|gene-environmental interactions
1344024|NCT00594451|autoimmunity
1344025|NCT00594451|disease severity
1344026|NCT00594438|Synthes Reamer-Irrigator-Aspirator (RIA)
1344027|NCT00594438|Zimmer Sentinal Reamer
1344028|NCT00594438|Transesophageal Echocardiogram (TEE)
1344029|NCT00594412|1H-Magnetic Resonance Spectroscopy
1344030|NCT00594412|Hepatic Steatosis
1344031|NCT00594412|Liver Fat
1344032|NCT00594412|Liver Biopsy
1344033|NCT00594412|Liver
1344034|NCT00594412|Hepatitis
1344035|NCT00594412|Fatty Liver
1344036|NCT00594399|Aging
1344037|NCT00594399|Exercise
1344038|NCT00594399|Impaired Glucose Tolerance
1344039|NCT00594399|Obesity
1344040|NCT00594399|Functional Status
1344041|NCT00594399|Disability
1344042|NCT00594399|Health Services Research
1344043|NCT00594399|Randomized Controlled Trial
1344044|NCT00594399|Diabetes
1344045|NCT00594399|Adaptive Randomization Design
1344046|NCT00594386|Rotigotine
1344047|NCT00594386|Neupro
1344048|NCT00594373|Microbicide
1344049|NCT00594373|HIV Seronegativity
1344050|NCT00594360|Exercise Prescription
1344051|NCT00594360|Self-efficacy
1344052|NCT00594360|Decisional Balance
1344053|NCT00594360|Readiness to Change
1344054|NCT00594360|Physical Activity
1344055|NCT00594347|Streptococcus pneumoniae
1344056|NCT00594334|osteopenia
1344057|NCT00594334|periodontitis
1344058|NCT00594321|spinal fractures
1344059|NCT00594269|Antidepressants
1344060|NCT00594269|Antipsychotics
1344061|NCT00594269|Dementia
1344062|NCT00594269|Discontinuation study
1344063|NCT00594269|Behavioural- and Psychological Symptoms in Dementia
1344064|NCT00594256|Schizophrenia
1344065|NCT00594256|Sleep Architecture
1344066|NCT00594256|Sodium Oxybate
1344067|NCT00594256|Insomnia
1344068|NCT00594256|Cognition
1344069|NCT00594230|Myelodysplastic Syndromes (MDS)
1344070|NCT00594230|Refractory
1344071|NCT00594230|LBH589
1344072|NCT00594217|PCOS
1344073|NCT00594191|Statins
1344074|NCT00594191|HMG-CoA reductase inhibitors
1344075|NCT00594191|Cirrhosis
1344076|NCT00594191|Portal hypertension
1344077|NCT00594191|Variceal bleeding
1344078|NCT00594178|spinal cord injury
1344079|NCT00594165|Rotigotine
1344080|NCT00594152|Diabetic autonomic neuropathy
1344081|NCT00594139|non-neurogenic over active bladder
1344082|NCT00594139|urge predominant incontinence
1344083|NCT00594126|Myeloma
1344084|NCT00594126|Multiple Myeloma
1344085|NCT00594126|Relapsed Multiple Myeloma
1344086|NCT00594126|Refractory Multiple Myeloma
1344087|NCT00594126|Relapsed or Refractory Multiple Myeloma
1344088|NCT00594100|carotid artery stenosis
1344089|NCT00594100|embolic protection device
1344090|NCT00594100|GORE Neuro Protection System
1344091|NCT00594100|GORE Flow Reversal System
1344092|NCT00594100|reverse flow
1344093|NCT00594100|proximal occlusion device
1344094|NCT00594100|GNPS
1344095|NCT00594100|Parodi
1344096|NCT00594100|EMPiRE
1344097|NCT00594100|distal embolization
1344098|NCT00594100|minimizing risks of CAS
1344099|NCT00594100|PAES
1344100|NCT00594048|high blood pressure
1344101|NCT00594035|Spinal procedure
1344102|NCT00594035|Dura incision
1344103|NCT00594022|Electric Stimulation
1344104|NCT00594022|Latency to Persistent Sleep (LPS)
1344105|NCT00594022|Transient Insomnia
1344106|NCT00594022|Insomnia
1344107|NCT00593970|influenza
1344108|NCT00593970|vaccine
1344109|NCT00593970|pregnancy
1344110|NCT00593957|Rett Syndrome
1344111|NCT00593957|Dextromethorphan
1344112|NCT00593944|CLL
1344113|NCT00593944|Chronic Lymphocytic Leukemia
1344114|NCT00593944|B cell
1344115|NCT00593944|leukemia
1344116|NCT00593944|lymphocyte
1344117|NCT00593944|antibody
1344118|NCT00593944|monoclonal
1344119|NCT00593944|cancer
1344120|NCT00593944|blood
1344121|NCT00593931|Brain functional MRI
1344122|NCT00593918|RSV, asthma, innate immunity, gene, cytokines
1344123|NCT00593905|Pulmonary Arterial Hypertension
1344124|NCT00593905|Pulmonary Hypertension
1344125|NCT00593905|Pharmacogenomics
1344126|NCT00593905|DNA Testing
1344127|NCT00593905|sitaxsentan
1344128|NCT00593905|bosentan
1344129|NCT00593905|ambrisentan
1344130|NCT00593905|elevated pulmonary artery pressures
1344131|NCT00593905|Letairis
1344132|NCT00593905|Tracleer
1344133|NCT00593905|Thelin
1344134|NCT00593905|Primary Pulmonary Hypertension
1344135|NCT00593905|Pulmonary Artery
1344136|NCT00593892|Cytokine Levels
1344137|NCT00593892|Traumatic Injury
1344138|NCT00593892|Multisystem Organ Failure
1344139|NCT00593879|MDD
1344140|NCT00593879|Depression
1344141|NCT00593879|Mecamylamine
1344142|NCT00593879|Add-on Therapy
1344143|NCT00593879|Major Depressive Disorder
1344144|NCT00593866|Patients who have confirmed cancer arising from the pancreas
1344145|NCT00593853|LHRH-agonist related fatigue
1344146|NCT00593801|extremely low birth weight infants
1344147|NCT00593801|transfusion need
1344148|NCT00593801|erythropoietin
1344149|NCT00593801|trace elements
1344150|NCT00593801|antioxidant enzymes
1344151|NCT00593801|reduction of the transfusion need by EPO treatment
1344152|NCT00593801|trace elements and antioxidant enzymes in blood
1344153|NCT00593788|GIN test
1344154|NCT00593788|gap detection
1344155|NCT00593788|temporal resolution
1344156|NCT00593788|auditory perception
1344157|NCT00593788|psychoacoustics
1344158|NCT00593775|implantation rate
1344159|NCT00593762|Peripheral arterial occlusive disease
1344160|NCT00593762|Aspirin
1344161|NCT00593762|Clopidogrel
1344162|NCT00593762|Resistance
1344163|NCT00593762|Catheter interventional procedure
1344164|NCT00593762|ASA and clopidogrel resistance
1344165|NCT00593749|obesity prevention
1344166|NCT00593749|corner stores
1344167|NCT00593749|schools
1344168|NCT00593736|Delayed sleep phase syndrome; drug therapy
1344169|NCT00593723|IMRT
1344170|NCT00593710|Randomized
1344171|NCT00593710|double-blind superiority trial
1344172|NCT00593697|breast cancer
1344173|NCT00593697|adjuvant therapy
1344174|NCT00593697|trastuzumab
1344175|NCT00593697|chemotherapy
1344176|NCT00593684|neonate
1344177|NCT00593684|central lines
1344178|NCT00593684|very low birth weight
1344179|NCT00593684|silver alginate
1344180|NCT00593671|aneuploidies in 7 chromosomes increased with advanced maternal age
1344181|NCT00593658|hypoxemia
1344182|NCT00593658|liver transplantation evaluation
1344183|NCT00593658|cirrhosis
1344184|NCT00593645|Conditioning regimens
1344185|NCT00593645|Stem Cell Transplantation
1344186|NCT00593645|Hematopoietic Stem Cell Transplantation
1344187|NCT00593645|Allogeneic Stem Cell Transplantation
1344188|NCT00593645|Nonmyeloablative conditioning
1344189|NCT00593645|Clofarabine
1344190|NCT00593645|Cytarabine
1344191|NCT00593645|Anti-thymocyte globulin
1344192|NCT00593632|low HDL
1344193|NCT00593619|Intravenous Iron
1344194|NCT00593619|Safety
1344195|NCT00593619|Perioperative
1344196|NCT00593619|Iron deficiency
1344197|NCT00593619|Non hemodialysis population
1344198|NCT00593619|Perioperative blood conservation
1344199|NCT00593606|Rotigotine
1344200|NCT00593606|NEUPRO
1344201|NCT00593606|Switching trial from ropinirole to rotigotine,
1344202|NCT00593606|safety and tolerability
1344203|NCT00593606|Parkinson disease
1344204|NCT00593593|benign prostate hyperplasia
1344205|NCT00593593|Dutasteride
1344206|NCT00593593|pharmacovigilance
1344207|NCT00593580|Ovarian cancer
1344208|NCT00593580|bone mineral density
1344209|NCT00593580|bisphosphonates
1344210|NCT00593580|chemotherapy
1344211|NCT00593567|Diabetic Foot Ulcer
1344212|NCT00593541|MRI
1344213|NCT00593528|Cirrhosis, STIC TIPS, Portal Hypertension, Transjugular Intrahepatic Portosystemic Shunt , Stents, PTFE
1344214|NCT00593528|cirrhotic HTP
1344215|NCT00593502|influenza
1344216|NCT00593502|children
1344217|NCT00593502|acute otitis media
1344218|NCT00593502|oseltamivir
1344219|NCT00593489|Insulin
1344220|NCT00593489|Diabetes Mellitus
1344221|NCT00593489|Practice Behaviour
1344222|NCT00593489|Preceptor
1344223|NCT00593489|Pharmacy
1344224|NCT00593476|Type 2 Diabetes
1344225|NCT00593476|Glycemic Control
1344226|NCT00593476|Diabetes Support and Education
1344227|NCT00593476|Portion Control
1344228|NCT00593476|Prepackaged meals
1344229|NCT00593463|opioid dependence
1344230|NCT00593463|methadone
1344231|NCT00593463|opioid
1344232|NCT00593450|bevacizumab
1344233|NCT00593450|ranibizumab
1344234|NCT00593450|choroidal neovascularization
1344235|NCT00593437|bone density diagnostic equipment discrepancies
1344236|NCT00593411|MD Analyze
1344237|NCT00593411|Central Nervous System
1344238|NCT00593411|Spine Disease
1344239|NCT00593411|Peripheral Nerve
1344240|NCT00593398|Malaria
1344241|NCT00593398|pregnant women
1344242|NCT00593398|infants
1344243|NCT00593398|Cameroon
1344244|NCT00593385|Symptomatic claudication or rest pain and angiographic confirmation of either de novo or restenotic lesions in the common and/or external iliac artery.
1344245|NCT00593372|Alzheimer's Disease
1344246|NCT00593372|Memory
1344247|NCT00593372|Treatment
1344248|NCT00593359|Spinal surgery
1344249|NCT00593359|Prone spinal surgery
1344250|NCT00593333|Femur Fracture
1344251|NCT00593333|Intramedullary Nailing
1344252|NCT00593333|Trochanteric Nailing
1344253|NCT00593333|Piriformis Starting Portal
1344254|NCT00593333|Trochanteric Insertion Portal
1344255|NCT00593320|SRS
1344256|NCT00593307|glycemic response
1344257|NCT00593307|hunger
1344258|NCT00593294|PCOS
1344259|NCT00593294|oral contraceptives
1344260|NCT00593294|physical exercise
1344261|NCT00593294|CVR
1344262|NCT00593281|Hyaluronidase
1344263|NCT00593281|Hylenex
1344264|NCT00593281|subcutaneous
1344265|NCT00593281|morphine
1344266|NCT00593281|absorption
1344267|NCT00593281|bioavailability
1344268|NCT00593281|PK study of morphine in patients with pain
1344269|NCT00593242|hypoxic-ischemic encephalopathy
1344270|NCT00593242|autologous cord blood cells
1344271|NCT00593242|newborn infants
1344272|NCT00593229|Thrombotic microangiopathy (TMA)
1344273|NCT00593229|Hemolytic uremic syndrome (HUS)
1344274|NCT00593229|Thrombotic thrombocytopenic purpura (TTP)
1344275|NCT00593216|functional magnetic Resonance Imaging
1344276|NCT00593216|vertigo
1344277|NCT00593216|vestibular
1344278|NCT00593177|Plaque psoriasis
1344279|NCT00593177|Psoriasis
1344280|NCT00593164|Hypothermia, Induced
1344281|NCT00593164|Death, Sudden, Cardiac
1344282|NCT00593164|Resuscitation
1344283|NCT00593164|Coma
1344284|NCT00593151|Antimetabolites
1344285|NCT00593151|Virus Diseases
1344286|NCT00593151|Anti-Infective Agents
1344287|NCT00593151|RNA Virus Infections
1344288|NCT00593151|Digestive System Diseases
1344289|NCT00593151|Flaviviridae Infections
1344290|NCT00593151|Antineoplastic Agents
1344291|NCT00593151|Therapeutic Uses
1344292|NCT00593151|Antiviral Agents
1344293|NCT00593151|Molecular Mechanisms of Action
1344294|NCT00593151|Pharmacologic Actions
1344295|NCT00593138|Focalin XR
1344296|NCT00593138|Adult
1344297|NCT00593138|PET scan
1344298|NCT00593125|cocaine
1344299|NCT00593125|opioids
1344300|NCT00593125|heroin
1344301|NCT00593125|levetiracetam
1344302|NCT00593112|HMRS Scanning
1344303|NCT00593112|ADHD
1344304|NCT00593112|Child
1344305|NCT00593112|Adolescent
1344306|NCT00593112|HMRS Scans
1344307|NCT00593099|Bipolar Disorder
1344308|NCT00593099|Nicotine Dependence
1344309|NCT00593099|Smoking Cessation
1344310|NCT00593099|Bupropion, sustained-release
1344311|NCT00593086|wound care
1344312|NCT00593060|Temsirolimus
1344313|NCT00593060|cetuximab
1344314|NCT00593060|metastatic disease
1344315|NCT00593047|hypercholesterolemia
1344316|NCT00593034|Alcohol abuse
1344317|NCT00593034|Drug abuse
1344318|NCT00593021|Obscure Gastrointestinal Bleeding
1344319|NCT00593021|Occult Gastrointestinal Bleeding
1344320|NCT00593021|Overt Gastrointestinal Bleeding
1344321|NCT00593021|Capsule Endoscopy
1344322|NCT00593021|CT Enterography
1344323|NCT00593008|metastatic pancreatic cancer
1344324|NCT00592943|Adults
1344325|NCT00592943|Healthy Volunteers
1344326|NCT00592943|Nuvigil
1344327|NCT00592943|Armodafinil
1344328|NCT00592943|DAT occupancy in healthy volunteers
1344329|NCT00592930|anorexia nervosa, treatment, adolescents, olanzapine
1344330|NCT00592917|osteoporosis
1344331|NCT00592917|fractures
1344332|NCT00592917|risk of fracture
1344333|NCT00592917|vitamin-D
1344334|NCT00592917|calcium
1344335|NCT00592917|falls
1344336|NCT00592917|bone mineral density
1344337|NCT00592917|bone metabolism
1344338|NCT00592904|Neuralgia
1344339|NCT00592904|neuropathy
1344340|NCT00592891|brain injury
1344341|NCT00592891|brain disorders
1344342|NCT00592852|bipolar disorder
1344343|NCT00592852|obsessive compulsive disorder
1344344|NCT00592852|Prozac
1344345|NCT00592839|Nocturnal vasomotor symptoms in postmenopausal women
1344346|NCT00592826|PHP
1344347|NCT00592826|HMP
1344348|NCT00592826|HPHP
1344349|NCT00592826|AMD
1344350|NCT00592826|CNV
1344351|NCT00592813|rehabilitation
1344352|NCT00592813|function
1344353|NCT00592800|statistics
1344354|NCT00592800|probability
1344355|NCT00592774|Post-Herpetic Neuralgia
1344356|NCT00592774|PHN)
1344357|NCT00592761|Deglutition Disorders
1344358|NCT00592761|Mendelsohn Maneuver
1344359|NCT00592761|SEMG
1344360|NCT00592748|charged particle radiation therapy
1344361|NCT00592696|Adolescent depression
1344362|NCT00592696|Adolescent smoking
1344363|NCT00592683|bipolar disorder
1344364|NCT00592683|fish oil
1344365|NCT00592683|aripiprazole
1344366|NCT00592683|children
1344367|NCT00592657|retrospective chart review
1344368|NCT00592657|Jimsonweed ingestion
1344369|NCT00592644|ectasia
1344370|NCT00592644|vascular lesions
1344371|NCT00592644|vocal cords
1344372|NCT00592644|voice
1344373|NCT00592644|pulsed dye laser
1344374|NCT00592631|asthma
1344375|NCT00592631|sleep apnea
1344376|NCT00592618|ESRD
1344377|NCT00592618|Hemodialysis
1344378|NCT00592618|Sleep Apnea
1344379|NCT00592592|pediatric rhabdomyosarcoma
1344380|NCT00592592|proton radiation therapy
1344381|NCT00592566|Severe leptospirosis
1344382|NCT00592566|Pulmonary hemorrhage
1344383|NCT00592553|Duchenne muscular dystrophy
1344384|NCT00592553|Becker muscular dystrophy
1344385|NCT00592553|Nonsense mutation
1344386|NCT00592553|Premature stop codon
1344387|NCT00592553|DMD/BMD
1344388|NCT00592553|PTC124
1344389|NCT00592514|Patients undergoing head and neck surgery that involves the upper aerodigestive tract
1344390|NCT00592501|proton radiation
1344391|NCT00592501|photon radiation
1344392|NCT00592501|5-FU
1344393|NCT00592501|cisplatin
1344394|NCT00592488|Septic shock
1344395|NCT00592488|Acetyl-L-carnitine
1344396|NCT00592475|conivaptan
1344397|NCT00592475|Liver Cirrhosis
1344398|NCT00592475|Hypertension, Portal
1344399|NCT00592462|Breast Cancer
1344400|NCT00592462|Whole Body MRI
1344401|NCT00592462|Magnetic Resonance Imaging
1344402|NCT00592462|Metastases
1344403|NCT00592449|Insomnia
1344404|NCT00592449|Knee pain
1344405|NCT00592449|Osteoarthritis
1344406|NCT00592449|Arthritis
1344407|NCT00592449|Sleep
1344408|NCT00592436|ADHD
1344409|NCT00592436|pediatric
1344410|NCT00592436|children
1344411|NCT00592423|Lateral neck rotation
1344412|NCT00592423|Continuous Positive Airway Pressure
1344413|NCT00592397|Dietary Intervention
1344414|NCT00592397|Nutrigenomics
1344415|NCT00592397|Diet, Carbohydrate-Restricted
1344416|NCT00592397|Gene Expression
1344417|NCT00592397|Gene Expression Profiling
1344418|NCT00592397|Oligonucleotide Array Sequence Analysis
1344419|NCT00592397|Biological Markers
1344420|NCT00592397|Food
1344421|NCT00592397|Obesity
1344422|NCT00592397|Blood
1344423|NCT00592397|Subcutaneous Fat, Abdominal
1344424|NCT00592384|spinal cord injuries
1344425|NCT00592384|major depressive disorder
1344426|NCT00592384|dysthymia
1344427|NCT00592384|antidepressant agents
1344428|NCT00592384|pain
1344429|NCT00592384|quality of life
1344430|NCT00592384|muscle spasticity
1344431|NCT00592384|community participation
1344432|NCT00592384|anxiety
1344433|NCT00592358|bipolar disorder
1344434|NCT00592358|children
1344435|NCT00592358|adolescents
1344436|NCT00592358|Invega
1344437|NCT00592345|sarcoma of the thoracic/lumbar/spine/sacrum
1344438|NCT00592345|paraspinal soft tissues
1344439|NCT00592345|proton radiation therapy
1344440|NCT00592345|photon radiation therapy
1344441|NCT00592345|radiation applicator plaque
1344442|NCT00592319|Papilloma
1344443|NCT00592319|pulsed dye laser
1344444|NCT00592319|Celebrex
1344445|NCT00592319|voice
1344446|NCT00592306|ATG
1344447|NCT00592306|rabbit thymoglobulin
1344448|NCT00592306|reperfusion lung injury
1344449|NCT00592306|primary graft dysfunction
1344450|NCT00592306|lung transplantation
1344452|NCT00592280|Pancreas transplantation
1344453|NCT00592280|graft pancreatitis
1344454|NCT00592280|Two-layer method
1344455|NCT00592280|organ preservation
1344456|NCT00592267|pediatric
1344457|NCT00592267|bipolar disorder
1344458|NCT00592254|ADHD
1344459|NCT00592254|Adults
1344460|NCT00592241|Insulin Pump
1344461|NCT00592228|intermediate lesion
1344462|NCT00592228|drug-eluting stent
1344463|NCT00592228|fractional flow reserve
1344464|NCT00592215|Second trimester labor induction
1344465|NCT00592202|Morbid obesity
1344466|NCT00592202|Adolescents
1344467|NCT00592202|Gastric restrictive procedure
1344468|NCT00592202|Adjustable gastric band
1344469|NCT00592202|Treatment
1344470|NCT00592189|Burns
1344471|NCT00592189|Wound healing
1344472|NCT00592189|Amnion
1344473|NCT00592163|Cancer
1344474|NCT00592163|Arsenic
1344475|NCT00592150|Essential Hypertension
1344476|NCT00592137|calcium carbonate
1344477|NCT00592137|obesity
1344478|NCT00592137|dairy
1344479|NCT00592137|energy expenditure
1344480|NCT00592124|Microbicide
1344481|NCT00592124|HIV Seronegativity
1344482|NCT00592111|Pediatric
1344483|NCT00592111|Hodgkin's Disease
1344484|NCT00592111|96-016
1344485|NCT00592098|Lower limb amputation at least 6 months prior to inclusion
1344486|NCT00592098|Presenting with moderate-to-severe pain intensity
1344487|NCT00592098|Outpatients, aged 18 years and above
1344488|NCT00592085|Tobacco Use
1344489|NCT00592085|Smoking
1344490|NCT00592085|Alcohol Use
1344491|NCT00592085|Smoking Cessation
1344492|NCT00592072|Diabetes Mellitus, Type 1
1344493|NCT00592072|Medium Chain Fatty Acid
1344494|NCT00592072|Hypoglycemia
1344495|NCT00592046|Phase I
1344496|NCT00592046|Hematologic Cancers
1344497|NCT00592046|Blood Cancers
1344498|NCT00592046|Leukemia
1344499|NCT00592046|multiple myeloma
1344500|NCT00592046|myelodysplasia (MDS)
1344501|NCT00592046|Relapsed/refractory leukemia or lymphoma
1344502|NCT00592033|COPD oxygen
1344503|NCT00592033|COPD rehabilitation
1344504|NCT00592033|exercise
1344505|NCT00592020|kidney
1344506|NCT00592020|transplantation
1344507|NCT00592020|minimal invasive
1344508|NCT00592020|short transverse
1344509|NCT00592020|hockey stick
1344510|NCT00592020|incision
1344511|NCT00592020|quality of life
1344512|NCT00592020|planned kidney transplantation
1344513|NCT00592007|Non Small Cell Lung Cancer
1344514|NCT00592007|Stage IIIB
1344515|NCT00592007|Stage IV
1344516|NCT00592007|Stable on Erlotinib
1344517|NCT00592007|Exhibit Positivity for Estrogen or Progesterone Receptor
1344518|NCT00591994|tinnitus
1344519|NCT00591994|piribedil
1344520|NCT00591994|acoustic otoemissions
1344521|NCT00591994|ECoG
1344522|NCT00591981|Geriatric
1344523|NCT00591981|Thoracic
1344524|NCT00591981|neoplasm
1344525|NCT00591981|(Patients over 70 years of age) Geriatric oncology patients with thoracic neoplasms of the lung, esophagus, pleura and thymus.
1344526|NCT00591968|ultrasound
1344527|NCT00591968|telediagnosis
1344528|NCT00591968|teleultrasound
1344529|NCT00591968|telesonography
1344530|NCT00591968|teleultrasonography
1344531|NCT00591968|teleradiology
1344532|NCT00591968|telemedicine
1344533|NCT00591968|dominican republic
1344534|NCT00591968|puntacana
1344535|NCT00591968|veron
1344536|NCT00591968|store-and-forward
1344537|NCT00591968|asynchronous
1344538|NCT00591955|geriatric
1344539|NCT00591955|sepsis
1344540|NCT00591955|outcome assessment(healthcare)
1344541|NCT00591942|dental cement
1344542|NCT00591942|ceramic crowns
1344543|NCT00591942|three-unit bridges
1344544|NCT00591942|sensitivity
1344545|NCT00591916|burn
1344546|NCT00591916|donor site
1344547|NCT00591916|grafting
1344548|NCT00591916|scar
1344549|NCT00591903|Diabetes and Cardiac Proteomics
1344550|NCT00591903|Atrial Appendage and Proteomics
1344551|NCT00591903|Diabetic Cardiomyopathy
1344552|NCT00591903|Tissue Sample
1344553|NCT00591877|GERDCAM: Complementary and alternative medicine
1344554|NCT00591877|NERD: non-erosive reflux disease
1344555|NCT00591877|GERD: gastroesophageal reflux disease
1344556|NCT00591877|AC: acupuncture
1344557|NCT00591877|SAC: sham acupuncture
1344558|NCT00591877|LES: lower esophageal sphincter pressure
1344559|NCT00591877|TLESR: transient lower esophageal sphincter relaxation
1344560|NCT00591877|Acupuncture
1344561|NCT00591877|Yoga
1344562|NCT00591864|Benign breast disease
1344563|NCT00591864|Breast
1344564|NCT00591864|MRI
1344565|NCT00591864|Mammography
1344566|NCT00591864|Ultrasound
1344567|NCT00591864|Molecular Breast Imaging
1344568|NCT00591864|Breast Cancer
1344569|NCT00591851|breast cancer
1344570|NCT00591851|adenocarcinoma of the breast
1344571|NCT00591851|cardiac safety
1344572|NCT00591851|Breast cancer patients seen at the Memorial Sloan-Kettering Cancer Center
1344573|NCT00591838|SBRT
1344574|NCT00591773|Blood pressure
1344575|NCT00591773|Blood pressure monitoring, ambulatory
1344576|NCT00591760|Heart Failure
1344577|NCT00591760|Growth Hormone
1344578|NCT00591760|Anabolism
1344579|NCT00591760|Anabolic Deficiency
1344580|NCT00591760|Hormone replacement
1344581|NCT00591747|randomized clinical trial
1344582|NCT00591747|elderly
1344583|NCT00591747|cancer survivor
1344584|NCT00591747|bone health
1344585|NCT00591747|body composition
1344586|NCT00591747|signs and symptoms
1344587|NCT00591734|Metastatic Melanoma
1344588|NCT00591734|Everolimus
1344589|NCT00591734|RAD001
1344590|NCT00591734|Bevacizumab
1344591|NCT00591721|energy conservation education
1344592|NCT00591721|occupational therapy intervention
1344593|NCT00591721|fatigue management
1344594|NCT00591721|psychoeducation
1344595|NCT00591708|calcium
1344596|NCT00591708|bone
1344597|NCT00591708|bone density
1344598|NCT00591708|adolescence
1344599|NCT00591695|Malignant Colorectal Obstruction
1344600|NCT00591695|Stent Bridge to Surgery
1344601|NCT00591669|Inflammatory bowel disease
1344602|NCT00591669|Crohn's disease
1344603|NCT00591643|Adrenal tumors
1344604|NCT00591643|Adrenal malignancies
1344605|NCT00591643|abnormal hormonal secretions
1344606|NCT00591643|electrolytes abnormalities
1344607|NCT00591643|Imaging
1344608|NCT00591643|Scanning
1344609|NCT00591643|tumor localization
1344610|NCT00591630|Diffuse Large Cell Lymphoma
1344611|NCT00591630|Lymphoma
1344612|NCT00591630|Zevalin
1344613|NCT00591630|Ibritumomab
1344614|NCT00591630|IDEC-Y2B8
1344615|NCT00591630|Carmustine
1344616|NCT00591630|BCNU
1344617|NCT00591630|BiCNU
1344618|NCT00591630|Etoposide
1344619|NCT00591630|VePesid
1344620|NCT00591630|Cytarabine
1344621|NCT00591630|Ara-C
1344622|NCT00591630|Cytosar
1344623|NCT00591630|DepoCyt
1344624|NCT00591630|Cytosine arabinosine hydrochloride
1344625|NCT00591630|Melphalan
1344626|NCT00591630|Rituximab
1344627|NCT00591630|Rituxan
1344628|NCT00591630|BEAM
1344629|NCT00591617|Opioids
1344630|NCT00591617|drug dependence
1344631|NCT00591617|drug abuse
1344632|NCT00591617|treatment
1344633|NCT00591604|burn
1344634|NCT00591604|vitamin D
1344635|NCT00591604|nutrition
1344636|NCT00591604|burn recovery
1344637|NCT00591591|Obstructive Sleep Apnea Syndrome
1344638|NCT00591591|sleep disordered breathing
1344639|NCT00591591|polysomnography (psg)
1344640|NCT00591591|continuous positive airway pressure (cpap)
1344641|NCT00591591|brain vascular autoregulation
1344642|NCT00591591|brain tissue oxygenation
1344643|NCT00591591|near-infrared spectroscopy
1344644|NCT00591591|Obstructive Sleep Apnea
1344645|NCT00591578|Blood pressure
1344646|NCT00591578|blood pressure monitoring, ambulatory
1344647|NCT00591565|Anxiety
1344648|NCT00591565|SSRI
1344649|NCT00591565|SNRI
1344650|NCT00591565|Acamprosate
1344651|NCT00591552|Lung cancer
1344652|NCT00591552|Lymph node dissection
1344653|NCT00591539|Carotid Artery Disease
1344654|NCT00591539|Intima-Media Thickening
1344655|NCT00591539|Carotid Ultrasound
1344656|NCT00591539|Pediatric Cancer Survivors
1344657|NCT00591539|Cancer Survivors
1344658|NCT00591539|Head or Neck Cancer
1344659|NCT00591539|Radiation Therapy
1344660|NCT00591526|APL
1344661|NCT00591513|burns
1344662|NCT00591513|burn scars
1344663|NCT00591513|congenital giant nevi
1344664|NCT00591500|Melanoma
1344665|NCT00591500|Skin cancer
1344666|NCT00591500|Genetic Susceptibility
1344667|NCT00591500|polymorphisms
1344668|NCT00591487|suction
1344669|NCT00591487|assisted
1344670|NCT00591487|lipectomy
1344671|NCT00591487|liposuction
1344672|NCT00591487|contour
1344673|NCT00591487|cosmetic
1344674|NCT00591487|plastic
1344675|NCT00591487|surgery
1344676|NCT00591487|Klein
1344677|NCT00591487|tumescent
1344678|NCT00591487|technique
1344679|NCT00591487|Healthy women wanting Suction Assisted Lipectomy
1344680|NCT00591474|VRE
1344681|NCT00591474|Probiotics
1344682|NCT00591474|colonization
1344683|NCT00591474|gut health
1344684|NCT00591461|Barrett's Esophagus
1344685|NCT00591461|Upper Endoscopy
1344686|NCT00591461|Esophageal biopsies
1344687|NCT00591461|Accuracy
1344688|NCT00591461|Interobserver Agreement
1344689|NCT00591448|Thermal injury
1344690|NCT00591435|Anesthesia
1344691|NCT00591435|Surgery
1344692|NCT00591435|Education
1344693|NCT00591435|Economics
1344694|NCT00591422|Arsenic
1344695|NCT00591422|Cancer
1344696|NCT00591383|Cancer
1344697|NCT00591383|Indibulin
1344698|NCT00591383|Erlotinib
1344699|NCT00591370|Memorial Sloan-Kettering Cancer Center patients with measurable, unresectable stage
1344700|NCT00591370|III or IV melanoma
1344701|NCT00591357|Antibiotic associated diarrhea
1344702|NCT00591357|Clostridium difficile
1344703|NCT00591357|loperamide
1344704|NCT00591344|Parkinson's disease
1344705|NCT00591344|exercise
1344706|NCT00591331|Head Lice
1344707|NCT00591318|Ceftriaxone
1344708|NCT00591318|Psychosis
1344709|NCT00591318|Schizophrenia
1344710|NCT00591318|Schizoaffective Disorder
1344711|NCT00591305|papilloma
1344712|NCT00591305|PDL
1344713|NCT00591305|diindolylmethane
1344714|NCT00591305|recurrence
1344715|NCT00591292|cancer
1344716|NCT00591292|tumor
1344717|NCT00591292|solid tumor
1344718|NCT00591292|advanced tumor
1344719|NCT00591279|large bowel cancer
1344720|NCT00591279|polyps
1344721|NCT00591279|colorectal cancer
1344722|NCT00591266|Blood pressure
1344723|NCT00591266|blood pressure monitoring ambulatory
1344724|NCT00591266|Drug Therapy
1344725|NCT00591253|Blood pressure
1344726|NCT00591253|blood pressure monitoring ambulatory
1344727|NCT00591253|Drug Therapy
1344728|NCT00591240|RNA, ribosomal, 16S
1344729|NCT00591240|Biosensing techniques
1344730|NCT00591240|Microchip analytical procedures
1344731|NCT00591214|Chronic Hepatitis C
1344732|NCT00591214|Protease Inhibitor
1344733|NCT00591201|Spondylarthritis
1344734|NCT00591201|TNF
1344735|NCT00591201|Infliximab
1344736|NCT00591201|Ankylosing spondylitis
1344737|NCT00591201|Juvenile SpA
1344738|NCT00591201|Juvenile arthritis
1344739|NCT00591188|kidney cancer, capecitabine, interferon
1344740|NCT00591162|Bone, Dexa, Parathyroid, Diuretic, Tetracycline
1344741|NCT00591149|cancer
1344742|NCT00591149|head and neck cancer
1344743|NCT00591149|squamous cell cancer
1344744|NCT00591123|Unresectable
1344745|NCT00591123|Metastatic
1344746|NCT00591123|Esophagus
1344747|NCT00591123|Gastric Cardia
1344748|NCT00591097|urine
1344749|NCT00591097|pediatric
1344750|NCT00591097|Normal urine from healthy pediatric population
1344751|NCT00591084|randomized trial
1344752|NCT00591084|ischemic stroke
1344753|NCT00591084|Ginsenoside-Rd
1344754|NCT00591071|hyperglycemia
1344755|NCT00591071|insulin treatment
1344756|NCT00591071|intensive care
1344757|NCT00591071|hypoglycemia
1344758|NCT00591071|mechanical ventilation
1344759|NCT00591071|critically ill patients
1344760|NCT00591058|recurrent glioma
1344761|NCT00591058|Phase I
1344762|NCT00591058|Multi-Center
1344763|NCT00591058|Open label
1344764|NCT00591058|Brain Cancer
1344765|NCT00591058|Brain tumor
1344766|NCT00591058|GBM
1344767|NCT00591058|Glioma
1344768|NCT00591058|Glioblastoma multiforme
1344769|NCT00591045|gastric adenocarcinoma
1344770|NCT00591045|neoadjuvant chemotherapy
1344771|NCT00591045|efficacy
1344772|NCT00591045|safety
1344773|NCT00591045|chemotherapy
1344774|NCT00591032|Critical illness
1344775|NCT00591032|Euthyroid sick syndromes
1344776|NCT00591032|Intensive care
1344777|NCT00591032|Non-thyroidal illness syndrome
1344778|NCT00591032|Low-T3 syndrome
1344779|NCT00591019|P50, Psychomotor Vigilance Test (PVT), Arousal, Reaction Time
1344780|NCT00591006|Phenytoin
1344781|NCT00591006|Dilantin
1344782|NCT00591006|Corticosteroid
1344783|NCT00591006|Neuroprotection
1344784|NCT00591006|Mania
1344785|NCT00591006|Cognition
1344786|NCT00591006|Mood
1344787|NCT00591006|Memory
1344788|NCT00591006|Hydrocortisone
1344789|NCT00591006|Healthy Controls
1344790|NCT00591006|MRI
1344791|NCT00591006|hippocampal activation
1344792|NCT00590993|MRSI
1344793|NCT00590993|MRI
1344794|NCT00590993|Prostate Cancer
1344795|NCT00590980|Stroke
1344796|NCT00590980|TIA (transient ischemic attack)
1344797|NCT00590980|Brain
1344798|NCT00590980|Blood Flow
1344799|NCT00590980|Quantitative magnetic resonance angiography (QMRA)
1344800|NCT00590967|para-aortic lymph nodes
1344801|NCT00590954|Malignant Gliomas
1344802|NCT00590954|CNS
1344803|NCT00590954|Brain Cancer
1344804|NCT00590954|Cancer
1344805|NCT00590954|Perifosine
1344806|NCT00590941|Lymphoma
1344807|NCT00590941|Rituximab
1344808|NCT00590941|CHOP
1344809|NCT00590915|ALL
1344810|NCT00590902|non small cell lung cancer
1344811|NCT00590889|artificial heart valve
1344812|NCT00590889|mitral heart valve
1344813|NCT00590889|aortic heart valve
1344814|NCT00590889|endocarditis
1344815|NCT00590889|Aortic valve disease requiring replacement
1344816|NCT00590889|Mitral valve disease requiring replacement
1344817|NCT00590876|Diabetes Mellitus, Type 1
1344818|NCT00590876|Hypoglycemia
1344819|NCT00590876|Pancreatic Islet Cell Allotransplantation
1344820|NCT00590863|depression, medication, antidepressant, chronic, recurrent
1344821|NCT00590837|AML
1344822|NCT00590837|Chemotherapy
1344823|NCT00590837|older
1344824|NCT00590837|De novo AML
1344825|NCT00590824|Melanoma
1344826|NCT00590824|hu14.18-IL2
1344827|NCT00590811|adolescents
1344828|NCT00590811|young adults
1344829|NCT00590811|dysmenorrhea
1344830|NCT00590811|pelvic pain
1344831|NCT00590798|Cardiac Catheterization
1344832|NCT00590798|Walk
1344833|NCT00590798|Heart Catheterization
1344834|NCT00590798|Coronary Disease
1344835|NCT00590798|Heart Disease
1344836|NCT00590798|Coronary Artery Disease
1344837|NCT00590785|High Risk
1344838|NCT00590785|Breast Cancer
1344839|NCT00590785|Positive Nodes
1344840|NCT00590785|Cyclophosphamide
1344841|NCT00590785|Doxorubicin
1344842|NCT00590785|96-041
1344843|NCT00590772|sleep
1344844|NCT00590772|somnolence
1344845|NCT00590772|allergies
1344846|NCT00590772|rhinitis
1344847|NCT00590772|fatigue
1344848|NCT00590720|Asthma
1344849|NCT00590720|Bronchitis
1344850|NCT00590707|Hip fractures
1344851|NCT00590707|Femoral neck fractures
1344852|NCT00590707|Trochanteric fractures
1344853|NCT00590707|Intertrochanteric fractures
1344854|NCT00590707|Subtrochanteric fractures
1344855|NCT00590707|Delirium
1344856|NCT00590707|Confusion
1344857|NCT00590694|ranibizumab
1344858|NCT00590694|Lucentis
1344859|NCT00590694|Pigment Epithelial Detachment
1344860|NCT00590694|Macular Degeneration
1344861|NCT00590694|PrONTO
1344862|NCT00590668|atrial fibrillation
1344863|NCT00590668|pulmonary vein ablation
1344864|NCT00590668|pulmonary vein stenosis
1344865|NCT00590655|maintenance therapy
1344866|NCT00590642|obsessive compulsive disorder
1344867|NCT00590642|OCD
1344868|NCT00590642|treatment-resistant
1344869|NCT00590642|SSRI
1344870|NCT00590629|Women with and without CAD
1344871|NCT00590616|Aortic atheroma
1344872|NCT00590603|Multiple myeloma
1344873|NCT00590577|Schizophrenia
1344874|NCT00590577|Long-acting injectable antipsychotic medication
1344875|NCT00590564|Hepatitis C
1344876|NCT00590564|Sho-saiko-to
1344877|NCT00590564|SST
1344878|NCT00590564|Interferon Therapy
1344879|NCT00590551|Skin Breakdown
1344880|NCT00590551|Skin Damage
1344881|NCT00590551|Skin Integrity
1344882|NCT00590551|Pressure
1344883|NCT00590551|Slings
1344884|NCT00590525|hsCRP
1344885|NCT00590512|dietary salt
1344886|NCT00590512|sodium
1344887|NCT00590512|blood vessels
1344888|NCT00590512|vascular function
1344889|NCT00590512|endothelial function
1344890|NCT00590512|heart disease risk
1344891|NCT00590512|cardiovascular disease risk
1344892|NCT00590499|agitation
1344893|NCT00590499|craniotomy
1344894|NCT00590499|incidence
1344895|NCT00590499|risk factor
1344896|NCT00590499|outcome
1344897|NCT00590473|Interstitial Cystitis
1344898|NCT00590473|IC
1344899|NCT00590473|Neuromodulation
1344900|NCT00590473|Interstim Therapy
1344901|NCT00590460|Allogeneic Stem Cell Transplant
1344902|NCT00590460|Fanconi Anemia
1344903|NCT00590460|Severe Aplastic Anemia
1344904|NCT00590460|fludarabine
1344905|NCT00590460|campath
1344906|NCT00590460|anti-CD45
1344907|NCT00590447|1st-line therapy
1344908|NCT00590447|single agent rituximab
1344909|NCT00590447|CHOP
1344910|NCT00590447|risk stratification
1344911|NCT00590434|CRC - Colorectal cancer
1344912|NCT00590434|CVA - Cerebral Vascular Accident
1344913|NCT00590434|MI - Myocardial Infarction
1344914|NCT00590434|CAD - Coronary Artery Disease
1344915|NCT00590434|DM - Diabetes Mellitus
1344916|NCT00590434|PVD - Peripheral Vascular Disease
1344917|NCT00590434|NSAIDS - Non-Steroidal Anti inflammatory Drugs
1344918|NCT00590434|screening
1344919|NCT00590434|colonoscopy
1344920|NCT00590408|coenzyme Q10
1344921|NCT00590408|statin
1344922|NCT00590408|myalgia
1344923|NCT00590395|Cholecystitis
1344924|NCT00590395|FDG PET/CT
1344925|NCT00590395|HIDA scan
1344926|NCT00590356|Device closure
1344927|NCT00590304|Asthma, Children, Rural Population, Morbidity, Endotoxin
1344928|NCT00590291|Coronary Artery Disease
1344929|NCT00590291|Arteriovenous Malformations
1344930|NCT00590291|Myocardial Infarction
1344931|NCT00590291|CAD
1344932|NCT00590291|MI
1344933|NCT00590291|Heart Attack
1344934|NCT00590291|AVM
1344935|NCT00590291|genetic
1344936|NCT00590291|familial
1344937|NCT00590278|Tomudex
1344938|NCT00590278|inoperable rectal cancer
1344939|NCT00590278|recurrent rectal cancer
1344940|NCT00590265|bipolar type II disorder
1344941|NCT00590265|depression
1344942|NCT00590265|remission
1344943|NCT00590265|light-therapy
1344944|NCT00590265|efficacy
1344945|NCT00590265|safety
1344946|NCT00590252|Magnetic Resonance
1344947|NCT00590252|Imaging
1344948|NCT00590252|Spectroscopy
1344949|NCT00590239|Barrett's Esophagus
1344950|NCT00590239|Neoplasia
1344951|NCT00590239|Endoscopic mucosal resection
1344952|NCT00590239|High resolution endoscopy
1344953|NCT00590239|Chromoendoscopy
1344954|NCT00590226|type 2 diabetes
1344955|NCT00590226|inpatient hyperglycemia
1344956|NCT00590226|SQ insulin
1344957|NCT00590226|Hospitalized patients with type 2 diabetes
1344958|NCT00590213|Casodex
1344959|NCT00590213|Prostate Cancer
1344960|NCT00590200|CAD
1344961|NCT00590200|Cardiovascular Disease
1344962|NCT00590200|CVD
1344963|NCT00590200|MI
1344964|NCT00590200|Myocardial Infarction
1344965|NCT00590200|Heart Attack
1344966|NCT00590200|CABG
1344967|NCT00590200|Revascularization
1344968|NCT00590200|genetic
1344969|NCT00590174|stent
1344970|NCT00590174|antiplatelet therapy
1344971|NCT00590161|Fatty Liver
1344972|NCT00590161|Nonalcoholic fatty liver disease (NALFD)
1344973|NCT00590161|NAFLD
1344974|NCT00590161|Nonalcoholic steatohepatitis (NASH)
1344975|NCT00590161|NASH
1344976|NCT00590161|pentoxifylline
1344977|NCT00590135|calcific aortic valve stenosis
1344978|NCT00590135|echocardiography, transthoracic
1344979|NCT00590122|Parkinson's disease
1344980|NCT00590122|"time to on"
1344981|NCT00590122|delayed on
1344982|NCT00590109|Breast Cancer
1344983|NCT00590109|Jewish
1344984|NCT00590109|BRCA1
1344985|NCT00590109|BRCA2
1344986|NCT00590109|97-029
1344987|NCT00590096|Neuroblastoma
1344988|NCT00590096|Pheochromocytoma
1344989|NCT00590096|MIBG
1344990|NCT00590083|stem cell transplantation
1344991|NCT00590083|adenovirus
1344992|NCT00590083|Cytotoxic T-Lymphocytes
1344993|NCT00590083|prophylaxis
1344994|NCT00590070|myocardial infarction
1344995|NCT00590070|no reflow
1344996|NCT00590070|primary PCI
1344997|NCT00590070|Coronary no-reflow phenomenon
1344998|NCT00590070|primary percutaneous coronary intervention (primary PCI)
1344999|NCT00590044|Diabetic ketoacidosis
1345000|NCT00590044|insulin therapy
1345001|NCT00590044|DKA
1345002|NCT00590031|Esophageal Carcinoma
1345003|NCT00590031|Cisplatin
1345004|NCT00590031|Irinotecan
1345005|NCT00590031|Radiation Therapy
1345006|NCT00590031|02-045
1345007|NCT00590018|Congenital heart disease.
1345008|NCT00590018|Low cardiac output syndrome.
1345009|NCT00590018|Corticosteroids.
1345010|NCT00590018|Hydrocortisone.
1345011|NCT00590018|Blood pressure.
1345012|NCT00590018|Inotropes.
1345013|NCT00590005|severe asthma
1345014|NCT00590005|poorly controlled asthma
1345015|NCT00589979|Osteoarthritis
1345016|NCT00589979|Knee
1345017|NCT00589979|Lidoderm
1345018|NCT00589979|Lidocaine
1345019|NCT00589979|Topical patch
1345020|NCT00589979|Adjunct therapy
1345021|NCT00589966|prostate cancer treatment
1345022|NCT00589966|treatment side-effects
1345023|NCT00589966|early diagnosis
1345024|NCT00589966|African American Men
1345025|NCT00589966|coping skills training
1345026|NCT00589966|quality of life
1345027|NCT00589966|Prostate cancer treatment side-effects
1345028|NCT00589953|Extreme Prematurity
1345029|NCT00589953|Erythropoietin
1345030|NCT00589953|Perinatal Brain Injury
1345031|NCT00589953|Intraventricular Hemorrhage
1345032|NCT00589953|Periventricular Leukomalacia
1345033|NCT00589953|Neurodevelopmental Outcomes
1345034|NCT00589953|Randomized Clinical Trial
1345035|NCT00589927|stents
1345036|NCT00589927|cilostazol
1345037|NCT00589914|Schizophrenia
1345038|NCT00589914|long-acting injectable antipsychotic medication
1345039|NCT00589901|metastatic breast cancer
1345040|NCT00589901|capecitabine
1345041|NCT00589901|synergistic effect
1345042|NCT00589901|chemotherapy
1345043|NCT00589888|hypertension
1345044|NCT00589888|metabolic syndrome
1345045|NCT00589888|vascular reactivity
1345046|NCT00589888|Elevated blood pressure
1345047|NCT00589888|lipid toxicity
1345048|NCT00589875|Immunotherapy
1345049|NCT00589875|Cytotoxicity
1345050|NCT00589875|Tumor vaccine
1345051|NCT00589862|Drug Eluting Stents
1345052|NCT00589862|Clopidogrel Resistance
1345053|NCT00589862|Aspirin Resistance
1345054|NCT00589849|Myocardial Infarction
1345055|NCT00589849|Arrhythmia
1345056|NCT00589849|T-wave alternans
1345057|NCT00589836|HCM
1345058|NCT00589836|HOCM
1345059|NCT00589836|hypertrophic cardiomyopathy
1345060|NCT00589836|tissue doppler echocardiography
1345061|NCT00589836|myocardial torsion
1345062|NCT00589823|Pain
1345063|NCT00589823|Cancer
1345064|NCT00589823|Breakthrough
1345065|NCT00589810|ISR
1345066|NCT00589810|in-stent restenosis
1345067|NCT00589810|restenosis
1345068|NCT00589810|BMS
1345069|NCT00589810|bare metal stent
1345070|NCT00589810|revascularization
1345071|NCT00589810|genetic
1345072|NCT00589810|cardiac catheterization
1345073|NCT00589797|Degenerative
1345074|NCT00589797|Disc
1345075|NCT00589784|Sunitinib
1345076|NCT00589784|Brain Cancer
1345077|NCT00589784|CNS Cancer
1345078|NCT00589784|meningioma
1345079|NCT00589784|intracranial hemangiopericytoma
1345080|NCT00589784|hemangioblastoma
1345081|NCT00589784|malignant meningioma
1345082|NCT00589784|neurofibromatosis
1345083|NCT00589784|neurofibromatosis type 1
1345084|NCT00589784|neurofibromatosis type 2
1345085|NCT00589784|07-135
1345086|NCT00589771|IBS
1345087|NCT00589771|Saccharomyces boulardii
1345088|NCT00589771|probiotics
1345089|NCT00589771|cytokine
1345090|NCT00589771|histology
1345091|NCT00589771|Efficacy
1345092|NCT00589758|Right Ventricle
1345093|NCT00589758|Echocardiogram
1345094|NCT00589758|Evaluation of Heart Failure
1345095|NCT00589745|Diagnosis
1345096|NCT00589732|stents
1345097|NCT00589732|angiotensin-converting enzyme
1345098|NCT00589719|Asthma; minority; low-income; African American; Arkansas
1345099|NCT00589706|high grade gliomas of the brain
1345100|NCT00589706|anti-body treatment
1345101|NCT00589706|survival
1345102|NCT00589693|Ventilator-Associated Pneumonia
1345103|NCT00589693|Pneumonia, hospital-acquired
1345104|NCT00589693|Doripenem
1345105|NCT00589693|Imipenem-cilastatin
1345106|NCT00589680|Acidosis, Diabetic
1345107|NCT00589680|Diabetic Acidosis
1345108|NCT00589680|Diabetic Ketosis
1345109|NCT00589680|Ketoacidosis, Diabetic
1345110|NCT00589680|Ketosis, Diabetic
1345111|NCT00589667|Head and Neck Cancer
1345112|NCT00589667|GEMCITABINE
1345113|NCT00589667|PEMETREXED
1345114|NCT00589667|ALTIMA
1345115|NCT00589667|epidermoid/squamous cell
1345116|NCT00589667|carcinoma
1345117|NCT00589667|pharynx
1345118|NCT00589667|larynx
1345119|NCT00589667|paranasal sinus
1345120|NCT00589667|head/neck squamous cell carcinoma
1345121|NCT00589654|amenorrhea
1345122|NCT00589654|menstrual cycle
1345123|NCT00589654|Breast cancer
1345124|NCT00589654|questionnaire
1345125|NCT00589654|97-127
1345126|NCT00589641|adolescents
1345127|NCT00589641|suicidal ideation and behavior
1345128|NCT00589641|depression
1345129|NCT00589641|substance abuse
1345130|NCT00589628|Childhood
1345131|NCT00589628|Uveitis
1345132|NCT00589615|vitamin D
1345133|NCT00589615|bone density
1345134|NCT00589602|Adult leukemia
1345135|NCT00589602|lymphoma
1345136|NCT00589602|myelodysplastic syndromes
1345137|NCT00589602|plasma cell disorders
1345138|NCT00589589|burns
1345139|NCT00589589|hypoglycemia
1345140|NCT00589589|hyperglycemia
1345141|NCT00589589|glucose monitoring
1345142|NCT00589563|graft versus host disease
1345143|NCT00589563|infection
1345144|NCT00589563|adult favorable prognosis Hodgkin lymphoma
1345145|NCT00589563|adult unfavorable prognosis Hodgkin lymphoma
1345146|NCT00589563|childhood favorable prognosis Hodgkin lymphoma
1345147|NCT00589563|childhood unfavorable prognosis Hodgkin lymphoma
1345148|NCT00589563|cutaneous B-cell non-Hodgkin lymphoma
1345149|NCT00589563|recurrent adult Hodgkin lymphoma
1345150|NCT00589563|recurrent cutaneous T-cell non-Hodgkin lymphoma
1345151|NCT00589563|recurrent/refractory childhood Hodgkin lymphoma
1345152|NCT00589563|stage I adult Hodgkin lymphoma
1345153|NCT00589563|stage I childhood Hodgkin lymphoma
1345154|NCT00589563|stage I cutaneous T-cell non-Hodgkin lymphoma
1345155|NCT00589563|stage II adult Hodgkin lymphoma
1345156|NCT00589563|stage II childhood Hodgkin lymphoma
1345157|NCT00589563|stage II cutaneous T-cell non-Hodgkin lymphoma
1345158|NCT00589563|stage III adult Hodgkin lymphoma
1345159|NCT00589563|stage III childhood Hodgkin lymphoma
1345160|NCT00589563|stage III cutaneous T-cell non-Hodgkin lymphoma
1345161|NCT00589563|stage IV adult Hodgkin lymphoma
1345162|NCT00589563|stage IV childhood Hodgkin lymphoma
1345163|NCT00589563|stage IV cutaneous T-cell non-Hodgkin lymphoma
1345164|NCT00589563|anaplastic large cell lymphoma
1345165|NCT00589563|angioimmunoblastic T-cell lymphoma
1345166|NCT00589563|Burkitt lymphoma
1345167|NCT00589563|contiguous stage II adult Burkitt lymphoma
1345168|NCT00589563|contiguous stage II adult diffuse large cell lymphoma
1345169|NCT00589563|contiguous stage II adult diffuse mixed cell lymphoma
1345170|NCT00589563|contiguous stage II adult diffuse small cleaved cell lymphoma
1345171|NCT00589563|contiguous stage II adult immunoblastic large cell lymphoma
1345172|NCT00589563|contiguous stage II adult lymphoblastic lymphoma
1345173|NCT00589563|contiguous stage II grade 1 follicular lymphoma
1345174|NCT00589563|contiguous stage II grade 2 follicular lymphoma
1345175|NCT00589563|contiguous stage II grade 3 follicular lymphoma
1345176|NCT00589563|contiguous stage II mantle cell lymphoma
1345177|NCT00589563|contiguous stage II marginal zone lymphoma
1345178|NCT00589563|contiguous stage II small lymphocytic lymphoma
1345179|NCT00589563|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1345180|NCT00589563|nodal marginal zone B-cell lymphoma
1345181|NCT00589563|noncontiguous stage II adult Burkitt lymphoma
1345182|NCT00589563|noncontiguous stage II adult diffuse large cell lymphoma
1345183|NCT00589563|noncontiguous stage II adult diffuse mixed cell lymphoma
1345184|NCT00589563|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1345185|NCT00589563|noncontiguous stage II adult immunoblastic large cell lymphoma
1345186|NCT00589563|noncontiguous stage II adult lymphoblastic lymphoma
1345187|NCT00589563|noncontiguous stage II grade 1 follicular lymphoma
1345188|NCT00589563|noncontiguous stage II grade 2 follicular lymphoma
1345189|NCT00589563|noncontiguous stage II grade 3 follicular lymphoma
1345190|NCT00589563|noncontiguous stage II mantle cell lymphoma
1345191|NCT00589563|noncontiguous stage II marginal zone lymphoma
1345192|NCT00589563|noncontiguous stage II small lymphocytic lymphoma
1345193|NCT00589563|recurrent adult Burkitt lymphoma
1345194|NCT00589563|recurrent adult diffuse large cell lymphoma
1345195|NCT00589563|recurrent adult diffuse mixed cell lymphoma
1345196|NCT00589563|recurrent adult diffuse small cleaved cell lymphoma
1345197|NCT00589563|recurrent adult grade III lymphomatoid granulomatosis
1345198|NCT00589563|recurrent adult immunoblastic large cell lymphoma
1345199|NCT00589563|recurrent adult lymphoblastic lymphoma
1345200|NCT00589563|recurrent adult T-cell leukemia/lymphoma
1345201|NCT00589563|recurrent childhood anaplastic large cell lymphoma
1345202|NCT00589563|recurrent childhood grade III lymphomatoid granulomatosis
1345203|NCT00589563|recurrent childhood lymphoblastic lymphoma
1345204|NCT00589563|recurrent childhood small noncleaved cell lymphoma
1345205|NCT00589563|recurrent grade 1 follicular lymphoma
1345206|NCT00589563|recurrent grade 2 follicular lymphoma
1345207|NCT00589563|recurrent grade 3 follicular lymphoma
1345208|NCT00589563|recurrent grade I lymphomatoid granulomatosis
1345209|NCT00589563|recurrent grade II lymphomatoid granulomatosis
1345210|NCT00589563|recurrent mantle cell lymphoma
1345211|NCT00589563|recurrent marginal zone lymphoma
1345212|NCT00589563|recurrent small lymphocytic lymphoma
1345213|NCT00589563|small intestine lymphoma
1345214|NCT00589563|splenic marginal zone lymphoma
1345215|NCT00589563|stage I adult Burkitt lymphoma
1345216|NCT00589563|stage I adult diffuse large cell lymphoma
1345217|NCT00589563|stage I adult diffuse mixed cell lymphoma
1345218|NCT00589563|stage I adult diffuse small cleaved cell lymphoma
1345219|NCT00589563|stage I adult immunoblastic large cell lymphoma
1345220|NCT00589563|stage I adult lymphoblastic lymphoma
1345221|NCT00589563|stage I adult T-cell leukemia/lymphoma
1345222|NCT00589563|stage III adult Burkitt lymphoma
1345223|NCT00589563|stage III adult diffuse large cell lymphoma
1345224|NCT00589563|stage III adult diffuse mixed cell lymphoma
1345225|NCT00589563|stage III adult diffuse small cleaved cell lymphoma
1345226|NCT00589563|stage III adult immunoblastic large cell lymphoma
1345227|NCT00589563|stage III adult lymphoblastic lymphoma
1345228|NCT00589563|stage III adult T-cell leukemia/lymphoma
1345229|NCT00589563|stage III childhood anaplastic large cell lymphoma
1345230|NCT00589563|stage III childhood lymphoblastic lymphoma
1345231|NCT00589563|stage III childhood small noncleaved cell lymphoma
1345232|NCT00589563|stage III grade 1 follicular lymphoma
1345233|NCT00589563|stage III grade 2 follicular lymphoma
1345234|NCT00589563|stage III grade 3 follicular lymphoma
1345235|NCT00589563|stage III mantle cell lymphoma
1345236|NCT00589563|stage III marginal zone lymphoma
1345237|NCT00589563|stage III small lymphocytic lymphoma
1345238|NCT00589563|stage IV adult Burkitt lymphoma
1345239|NCT00589563|stage IV adult diffuse large cell lymphoma
1345240|NCT00589563|stage IV adult diffuse mixed cell lymphoma
1345241|NCT00589563|stage IV adult diffuse small cleaved cell lymphoma
1345242|NCT00589563|stage IV adult immunoblastic large cell lymphoma
1345243|NCT00589563|stage IV adult lymphoblastic lymphoma
1345244|NCT00589563|stage IV adult T-cell leukemia/lymphoma
1345245|NCT00589563|stage IV childhood anaplastic large cell lymphoma
1345246|NCT00589563|stage IV childhood lymphoblastic lymphoma
1345247|NCT00589563|stage IV childhood small noncleaved cell lymphoma
1345248|NCT00589563|stage IV grade 1 follicular lymphoma
1345348|NCT00589368|Functional Laterality
1345249|NCT00589563|stage IV grade 2 follicular lymphoma
1345250|NCT00589563|stage IV grade 3 follicular lymphoma
1345251|NCT00589563|stage IV mantle cell lymphoma
1345252|NCT00589563|stage IV marginal zone lymphoma
1345253|NCT00589563|stage IV small lymphocytic lymphoma
1345254|NCT00589563|adult acute myeloid leukemia in remission
1345255|NCT00589563|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1345256|NCT00589563|adult acute myeloid leukemia with inv(16)(p13;q22)
1345257|NCT00589563|adult acute myeloid leukemia with t(15;17)(q22;q12)
1345258|NCT00589563|adult acute myeloid leukemia with t(16;16)(p13;q22)
1345259|NCT00589563|adult acute myeloid leukemia with t(8;21)(q22;q22)
1345260|NCT00589563|childhood acute myeloid leukemia in remission
1345261|NCT00589563|recurrent adult acute myeloid leukemia
1345262|NCT00589563|recurrent childhood acute myeloid leukemia
1345263|NCT00589563|secondary acute myeloid leukemia
1345264|NCT00589563|adult acute lymphoblastic leukemia in remission
1345265|NCT00589563|childhood acute lymphoblastic leukemia in remission
1345266|NCT00589563|recurrent adult acute lymphoblastic leukemia
1345267|NCT00589563|recurrent childhood acute lymphoblastic leukemia
1345268|NCT00589563|accelerated phase chronic myelogenous leukemia
1345269|NCT00589563|chronic phase chronic myelogenous leukemia
1345270|NCT00589563|refractory chronic lymphocytic leukemia
1345271|NCT00589563|relapsing chronic myelogenous leukemia
1345272|NCT00589563|stage I chronic lymphocytic leukemia
1345273|NCT00589563|stage II chronic lymphocytic leukemia
1345274|NCT00589563|stage III chronic lymphocytic leukemia
1345275|NCT00589563|stage IV chronic lymphocytic leukemia
1345276|NCT00589563|stage I multiple myeloma
1345277|NCT00589563|stage II multiple myeloma
1345278|NCT00589563|stage III multiple myeloma
1345279|NCT00589563|childhood myelodysplastic syndromes
1345280|NCT00589563|de novo myelodysplastic syndromes
1345281|NCT00589563|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1345282|NCT00589563|previously treated myelodysplastic syndromes
1345283|NCT00589563|secondary myelodysplastic syndromes
1345284|NCT00589563|atypical chronic myeloid leukemia, BCR-ABL negative
1345285|NCT00589563|chronic myelomonocytic leukemia
1345286|NCT00589563|juvenile myelomonocytic leukemia
1345287|NCT00589563|primary myelofibrosis
1345288|NCT00589563|secondary myelofibrosis
1345289|NCT00589550|clear cell renal cell carcinoma
1345290|NCT00589550|stage III renal cell cancer
1345291|NCT00589550|stage IV renal cell cancer
1345292|NCT00589537|testicular seminoma
1345293|NCT00589537|stage I malignant testicular germ cell tumor
1345294|NCT00589524|blocked arteries
1345295|NCT00589524|narrowing arteries
1345296|NCT00589524|IVUS
1345297|NCT00589524|CT
1345298|NCT00589511|Bilateral severe to profound sensorineural hearing loss
1345299|NCT00589459|undiagnosed diabetes
1345300|NCT00589459|undiagnosed pre-diabetes
1345301|NCT00589459|acute coronary syndrome
1345302|NCT00589459|undiagnosed pre-diabetes and undiagnosed diabetes
1345303|NCT00589446|Embryoscopy
1345304|NCT00589446|recurrent miscarriage
1345305|NCT00589446|missed abortion
1345306|NCT00589446|Structural anomalies in recurrent miscarriage
1345307|NCT00589446|Embryoscopically directed biopsy for karyotyping
1345308|NCT00589420|adenocarcinoma of the prostate
1345309|NCT00589420|recurrent prostate cancer
1345310|NCT00589420|stage IV prostate cancer
1345311|NCT00589394|pneumococcal vaccine
1345312|NCT00589394|normal response
1345313|NCT00589394|immunodeficiency
1345314|NCT00589394|Healthy patients
1345315|NCT00589394|Healthy Volunteers
1345316|NCT00589381|unspecified adult solid tumor, protocol specific
1345317|NCT00589381|recurrent adult Hodgkin lymphoma
1345318|NCT00589381|recurrent adult T-cell leukemia/lymphoma
1345319|NCT00589381|anaplastic large cell lymphoma
1345320|NCT00589381|angioimmunoblastic T-cell lymphoma
1345321|NCT00589381|recurrent cutaneous T-cell non-Hodgkin lymphoma
1345322|NCT00589381|recurrent mycosis fungoides/Sezary syndrome
1345323|NCT00589381|recurrent adult grade III lymphomatoid granulomatosis
1345324|NCT00589381|adult nasal type extranodal NK/T-cell lymphoma
1345325|NCT00589381|Waldenström macroglobulinemia
1345326|NCT00589381|recurrent adult Burkitt lymphoma
1345327|NCT00589381|recurrent adult diffuse large cell lymphoma
1345328|NCT00589381|recurrent adult diffuse mixed cell lymphoma
1345329|NCT00589381|recurrent adult diffuse small cleaved cell lymphoma
1345330|NCT00589381|recurrent adult immunoblastic large cell lymphoma
1345331|NCT00589381|recurrent adult lymphoblastic lymphoma
1345332|NCT00589381|recurrent grade 1 follicular lymphoma
1345333|NCT00589381|recurrent grade 2 follicular lymphoma
1345334|NCT00589381|recurrent grade 3 follicular lymphoma
1345335|NCT00589381|recurrent mantle cell lymphoma
1345336|NCT00589381|recurrent marginal zone lymphoma
1345337|NCT00589381|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1345338|NCT00589381|nodal marginal zone B-cell lymphoma
1345339|NCT00589381|splenic marginal zone lymphoma
1345340|NCT00589381|recurrent small lymphocytic lymphoma
1345341|NCT00589368|Brain Infarction
1345342|NCT00589368|pathology
1345343|NCT00589368|physiopathology
1345344|NCT00589368|psychology
1345345|NCT00589368|rehabilitation
1345346|NCT00589368|Fingers
1345347|NCT00589368|Grasp
1345349|NCT00589368|Hand
1345350|NCT00589368|Strength
1345351|NCT00589368|Neuronal Plasticity
1345352|NCT00589368|Psychomotor Performance
1345353|NCT00589368|Biomechanis
1345354|NCT00589368|Touch
1345355|NCT00589368|Weight-Bearing
1345356|NCT00589355|c-reactive protein
1345357|NCT00589355|endothelial dysfunction
1345358|NCT00589355|glucose intolerance
1345359|NCT00589329|Preterm birth
1345360|NCT00589329|antibiotics
1345361|NCT00589329|preterm labor
1345362|NCT00589329|respiratory distress
1345363|NCT00589329|pergnancy
1345364|NCT00589303|Atrial Fibrillation
1345365|NCT00589303|Heart Failure
1345366|NCT00589303|AV Node ablation
1345367|NCT00589303|Cardiac pacemaker
1345368|NCT00589303|Antiarrhythmic drug
1345369|NCT00589290|Histone deacetylase (HDAC) Inhibitors
1345370|NCT00589290|Mediastinal Neoplasm
1345371|NCT00589290|Thymic Carcinoma
1345372|NCT00589290|Thymoma
1345373|NCT00589277|Smoking
1345374|NCT00589277|Tobacco
1345375|NCT00589277|Message Framing
1345376|NCT00589264|zinc
1345377|NCT00589264|iron
1345378|NCT00589264|child development
1345379|NCT00589264|visual attention
1345380|NCT00589264|Peru
1345381|NCT00589251|penicillin allergy, penicillin skin test
1345382|NCT00589238|stage II breast cancer
1345383|NCT00589238|stage IIIA breast cancer
1345384|NCT00589238|stage IIIB breast cancer
1345385|NCT00589238|stage IIIC breast cancer
1345386|NCT00589225|PH
1345387|NCT00589225|PH type I
1345388|NCT00589225|Primary Hyperoxaluria
1345389|NCT00589225|Hyperoxaluria
1345390|NCT00589225|Primary Oxalosis
1345391|NCT00589225|PH type II
1345392|NCT00589225|PH type III
1345393|NCT00589225|Genetic testing for PH
1345394|NCT00589225|Genetic testing for Primary Hyperoxaluria
1345395|NCT00589225|Hereditary study for PH
1345396|NCT00589225|Hereditary study for Primary Hyperoxaluria
1345397|NCT00589212|GliaSite
1345398|NCT00589212|Brain metastases
1345399|NCT00589212|1-3 METS
1345400|NCT00589186|stage IV squamous cell carcinoma of the nasopharynx
1345401|NCT00589186|stage IV lymphoepithelioma of the nasopharynx
1345402|NCT00589186|recurrent squamous cell carcinoma of the nasopharynx
1345403|NCT00589186|recurrent lymphoepithelioma of the nasopharynx
1345404|NCT00589173|Preventive Care
1345405|NCT00589173|Health information technology
1345406|NCT00589173|Personal health record
1345407|NCT00589121|radiation fibrosis
1345408|NCT00589121|radiation toxicity
1345409|NCT00589121|lymphedema
1345410|NCT00589121|musculoskeletal complications
1345411|NCT00589121|stage I adult soft tissue sarcoma
1345412|NCT00589121|stage II adult soft tissue sarcoma
1345413|NCT00589121|adult extraskeletal chondrosarcoma
1345414|NCT00589121|stage III adult soft tissue sarcoma
1345415|NCT00589108|knee arthroplasty
1345416|NCT00589082|AML
1345417|NCT00589082|elderly
1345418|NCT00589082|DaunoXome
1345419|NCT00589056|stage IIIA non-small cell lung cancer
1345420|NCT00589056|stage IIIB non-small cell lung cancer
1345421|NCT00589056|recurrent non-small cell lung cancer
1345422|NCT00588263|Ashkenazi Jewish
1345423|NCT00588263|Cancer
1345424|NCT00588263|00-087
1345425|NCT00588237|ovary
1345426|NCT00588237|BEVACIZUMAB
1345427|NCT00588237|CISPLATIN
1345428|NCT00588237|TAXOL
1345429|NCT00588224|stomach
1345430|NCT00588224|accommodation
1345431|NCT00588224|volume
1345432|NCT00588224|SPECT
1345433|NCT00588224|3 dimensional ultrasonography
1345434|NCT00588224|healthy volunteers
1345435|NCT00588211|Cancer related-Risks
1345436|NCT00588211|Risk Perception
1345437|NCT00588211|Survey
1345438|NCT00588211|Focus Group
1345439|NCT00588211|Smoking cessation
1345440|NCT00588211|tobacco
1345441|NCT00588198|histologically confirmed melanoma of any site
1345442|NCT00588185|Progressive Prostate Cancer
1345443|NCT00588185|[18F]-Fluoro-2-Deoxy-D-Glucose
1345444|NCT00588185|[18F] Dihydro-Testosterone
1345445|NCT00588185|Pet Imaging
1345446|NCT00588185|Pet scan
1345447|NCT00588185|00-095
1345448|NCT00589030|adult primary hepatocellular carcinoma
1345449|NCT00589030|advanced adult primary liver cancer
1345450|NCT00589030|localized unresectable adult primary liver cancer
1345451|NCT00589030|recurrent adult primary liver cancer
1345452|NCT00588978|c-reactive protein
1345453|NCT00588978|obesity
1345454|NCT00588978|women's cardiovascular health
1345455|NCT00588965|QT interval
1345456|NCT00588965|beta-blocker
1345457|NCT00588965|exercise
1345458|NCT00588965|electrocardiogram
1345459|NCT00588965|repolarizaton
1345460|NCT00588939|reflux
1345461|NCT00588939|heartburn
1345462|NCT00588926|Deep Brain Stimulation
1345463|NCT00588926|Movement Disorders
1345464|NCT00588926|Remifentanil
1345465|NCT00588926|Sedation
1345466|NCT00588926|Basal Ganglia electrical activity
1345467|NCT00588913|recurrent renal cell cancer
1345468|NCT00588913|stage IV renal cell cancer
1345469|NCT00588913|clear cell renal cell carcinoma
1345470|NCT00588913|lung metastases
1345471|NCT00588900|stage IV colon cancer
1345472|NCT00588900|stage IV rectal cancer
1345473|NCT00588900|recurrent colon cancer
1345474|NCT00588900|recurrent rectal cancer
1345475|NCT00588874|male osteoporosis
1345476|NCT00588874|male osteopenia
1345477|NCT00588874|calciotropic hormones
1345478|NCT00588848|Obstructive Sleep Apnea Hypopnea Syndrome
1345479|NCT00588848|OSA
1345480|NCT00588848|Postoperative
1345481|NCT00588848|CPAP
1345482|NCT00588835|pharmacokinetics
1345483|NCT00588835|nausea and vomiting post chemotherapy
1345484|NCT00588822|monoclonal gammopathy of undetermined significance
1345485|NCT00588796|fibrinogen
1345486|NCT00588796|burns
1345487|NCT00588796|trauma
1345488|NCT00588796|metabolism
1345489|NCT00588757|IVC filters
1345490|NCT00588757|Trauma
1345491|NCT00588757|Dwell time
1345492|NCT00588718|Necrotizing enterocolitis
1345493|NCT00588718|Progressive necrotizing enterocolitis
1345494|NCT00588718|Proteomics in blood
1345495|NCT00588718|Genomics in blood
1345496|NCT00588718|Multi-center
1345497|NCT00588705|Daughters
1345498|NCT00588705|Communication
1345499|NCT00588705|genetic risk
1345500|NCT00588705|Genetic Counseling
1345501|NCT00588692|Heart Failure
1345502|NCT00588692|Afterload Reduction
1345503|NCT00588692|Sphygmocor
1345504|NCT00588679|Prostate Cancer
1345505|NCT00588679|Cancer
1345506|NCT00588679|MRI
1345507|NCT00588679|Magnetic Resonance Imaging
1345508|NCT00588679|06-035
1345509|NCT00588666|Myeloproliferative Disorder
1345510|NCT00588666|urinary bladder
1345511|NCT00588666|Cancer
1345512|NCT00588666|ureter
1345513|NCT00588666|renal pelvis
1345514|NCT00588666|chemotherapy
1345515|NCT00588653|Crohn's disease
1345516|NCT00588653|capsule endoscopy
1345517|NCT00588653|computed tomography enterography
1345518|NCT00588653|colonoscopy
1345519|NCT00588653|small bowel follow-through
1345520|NCT00588640|Pain
1345521|NCT00588640|HEENT cancer
1345522|NCT00588627|Chronic cough
1345523|NCT00588627|Post nasal drip
1345524|NCT00588588|Ventilator associated pneumonia
1345525|NCT00588588|Intensive Care
1345526|NCT00588588|Antibiotics
1345527|NCT00588588|Mortality
1345528|NCT00588588|Length of stay
1345529|NCT00588575|Barrett's Esophagus
1345530|NCT00588562|PH
1345531|NCT00588562|PH1
1345532|NCT00588562|PH2
1345533|NCT00588562|PH3
1345534|NCT00588562|PHI
1345535|NCT00588562|PHII
1345536|NCT00588562|PHIII
1345537|NCT00588562|PH NonI-NonII
1345538|NCT00588562|Primary Hyperoxaluria
1345539|NCT00588562|Primary Oxalosis
1345540|NCT00588562|Hyperoxaluria
1345541|NCT00588562|Oxalate
1345542|NCT00588562|Cystinuria
1345543|NCT00588562|Cystine
1345544|NCT00588562|APRT
1345545|NCT00588562|Adenine phosphoribosyl transferase deficiency
1345546|NCT00588562|Dent disease
1345547|NCT00588562|Dent
1345548|NCT00588536|Langerhans Cell Histiocytosis
1345549|NCT00588536|LCH
1345550|NCT00588536|6-Thioguanine
1345551|NCT00588536|6-TG
1345552|NCT00588536|Methotrexate
1345553|NCT00588536|MTX
1345554|NCT00588536|94-132
1345555|NCT00588523|Brain
1345556|NCT00588523|CNS
1345557|NCT00588523|TEMOZOLOMIDE
1345558|NCT00588523|Busulfan
1345559|NCT00588523|Thiotepa
1345560|NCT00588510|Sarcoma
1345561|NCT00588510|Bone
1345562|NCT00588497|female sterilization, micro-insert, hysteroscopy
1345563|NCT00588484|Carotid artery
1345564|NCT00588484|Common carotid artery
1345565|NCT00588484|Measurement
1345566|NCT00588484|Ultrasound
1345567|NCT00588458|Primary sclerosing cholangitis
1345568|NCT00588458|Computed tomographic cholangiography
1345569|NCT00588458|MELD score
1345570|NCT00588458|Mayo risk score for PSC
1345571|NCT00588445|Lung Cancer
1345572|NCT00588445|Non-small cell lung cancer
1345573|NCT00588445|Gefitnib
1345574|NCT00588445|Cancer
1345575|NCT00588445|NSCLC
1345576|NCT00588445|bronchioloalveolar cancer
1345577|NCT00588445|smoker
1345578|NCT00588432|Stroke
1345579|NCT00588432|Immobilization
1345580|NCT00588432|Myofacial Pain
1345581|NCT00588432|Hyperthyroid Myopathy
1345582|NCT00588419|Breast Cancer
1345583|NCT00588419|Cancer
1345584|NCT00588419|Breast Sensation
1345585|NCT00588419|Postmastectomy Breast Reconstruction
1345586|NCT00588406|acute, emergency department
1345587|NCT00588380|GLP-1
1345588|NCT00588380|Insulin Secretion
1345589|NCT00588367|Inflammation
1345590|NCT00588367|Pancreas
1345591|NCT00588367|Chronic pancreatitis
1345592|NCT00588367|Alcoholic pancreatitis
1345593|NCT00588367|Carcinoma, pancreatic ductal
1345594|NCT00588367|Pancreatic neoplasms
1345595|NCT00588354|herniated disk
1345596|NCT00588354|radiculopathy
1345597|NCT00588354|clonidine
1345598|NCT00588354|epidural
1345599|NCT00588354|steroid
1345600|NCT00588354|corticosteroid
1345601|NCT00588354|nucleus pulposus
1345602|NCT00588354|transforaminal
1345603|NCT00588341|Melanoma
1345604|NCT00588341|Skin Cancer
1345605|NCT00588341|Cancer
1345606|NCT00588341|Temozolamide
1345607|NCT00588341|TMZ
1345608|NCT00588302|primary biliary cirrhosis
1345609|NCT00588302|ursodeoxycholic acid
1345610|NCT00588289|Pediatric Cancers
1345611|NCT00588289|Oncology
1345612|NCT00588276|measurable disease
1345613|NCT00588276|locally advanced disease
1345614|NCT00588172|Metformin
1345615|NCT00588172|Type 2 diabetes
1345616|NCT00588172|Oct1
1345617|NCT00588159|Preoperative gabapentin
1345618|NCT00588159|Acute pain
1345619|NCT00588159|Post-thoracotomy pain
1345620|NCT00588159|Epidural analgesia
1345621|NCT00588146|anemia
1345622|NCT00588146|HHT
1345623|NCT00588146|Liver disease
1345624|NCT00588146|Hypoxemia
1345625|NCT00588146|Iron deficiency anemia
1345626|NCT00588146|Liver disease with high cardiac output
1345627|NCT00588146|Diffuse pulmonary AVMs with hypoxemia
1345628|NCT00588133|antifibrinolytic, bleeding, heart
1345629|NCT00588120|Hyperoxaluria
1345630|NCT00588120|Unknown Hyperoxaluria
1345631|NCT00588120|Enteric Hyperoxaluria
1345632|NCT00588120|Oxaluric
1345633|NCT00588120|High Oxalate
1345634|NCT00588120|Oxalate
1345635|NCT00588120|C13
1345636|NCT00588120|Oxalate Diet
1345637|NCT00588107|Cancer
1345638|NCT00588107|Smoker
1345639|NCT00588107|Web based intervention
1345640|NCT00588107|Partnership for Health
1345641|NCT00588107|Cancer Survivors
1345642|NCT00588094|Lymphoma
1345643|NCT00588094|ASCT
1345644|NCT00588094|B-cell non-Hodgkin's lymphoma
1345645|NCT00588094|Cancer
1345646|NCT00588094|Second line therapy
1345647|NCT00588094|ICE
1345648|NCT00588094|Stem cell transplant
1345649|NCT00588081|Vaginal Reconstruction
1345650|NCT00588068|Adrenal Gland
1345651|NCT00588068|No stage requirement
1345652|NCT00588042|Angioplasty, Transluminal, Percutaneous Coronary
1345653|NCT00588042|Coronary Artery Disease
1345654|NCT00588042|Coronary Occlusion
1345655|NCT00588029|Family members
1345656|NCT00588016|Itraconazole
1345657|NCT00588003|Breast
1345658|NCT00588003|ANASTROZOLE
1345659|NCT00587990|Chronic Ischemic Left Ventricular Dysfunction
1345660|NCT00587977|Abdominal aortic aneurysm
1345661|NCT00587964|Cancer
1345662|NCT00587964|Brain Metastasis
1345663|NCT00587964|Radiosurgery
1345664|NCT00587964|Bladder cancer
1345665|NCT00587964|Breast cancer
1345666|NCT00587964|Cervical cancer
1345667|NCT00587964|Colon cancer
1345668|NCT00587964|HEENT cancer
1345669|NCT00587964|Lung cancer
1345670|NCT00587964|Melanoma
1345671|NCT00587964|Pancreatic cancer
1345672|NCT00587964|Prostate cancer
1345673|NCT00587964|Rectal cancer
1345674|NCT00587964|Sarcoma
1345675|NCT00587964|Testicular cancer
1345676|NCT00587964|Radiation
1345677|NCT00587951|Clinical decision-making
1345678|NCT00587951|Ictal SPECT
1345679|NCT00587951|Epilepsy surgery
1345680|NCT00587938|congestive heart failure
1345681|NCT00587938|Brain naturietic peptide
1345682|NCT00587938|hospital utilization cost
1345683|NCT00587925|osteoporosis
1345684|NCT00587912|Kaposi's Sarcoma AIDS Related
1345685|NCT00587912|Kaposi's Sarcoma Classical
1345686|NCT00587912|Non-Hodgkin's Lymphoma
1345687|NCT00587912|HEMATOPOIETIC SYSTEM
1345688|NCT00587912|Cancer
1345689|NCT00587912|AIDS
1345690|NCT00587899|Atrial Fibrillation
1345691|NCT00587899|AF
1345692|NCT00587899|A fib
1345693|NCT00587899|cardiac ablation
1345694|NCT00587899|modified maze procedure
1345695|NCT00587886|Cancer
1345696|NCT00587886|Endometrial cancer
1345697|NCT00587886|Ovarian cancer
1345698|NCT00587886|Corpus Uteri
1345699|NCT00587886|Endometrium
1345700|NCT00587873|Relapsed
1345701|NCT00587873|Hodgkin's Disease
1345702|NCT00587873|Methotrexate
1345703|NCT00587873|6-Thioguanine
1345704|NCT00587873|94-030
1345705|NCT00587847|leukemia
1345706|NCT00587821|Breast Cancer
1345707|NCT00587821|Breast biopsy
1345708|NCT00587808|Heart Failure
1345709|NCT00587808|Heart Failure, Diastolic
1345710|NCT00587808|Stroke Volume
1345711|NCT00587769|Smoking
1345712|NCT00587769|Smoking cessation
1345713|NCT00587769|Bupropion
1345714|NCT00587769|Varenicline
1345715|NCT00587769|Tobacco use disorder
1345716|NCT00587756|intraoperative ultrasonography
1345717|NCT00587756|colorectal liver metastases
1345718|NCT00587756|hepatectomy
1345719|NCT00587756|portal vein embolization
1345720|NCT00587756|Liver
1345721|NCT00587730|heart disease
1345722|NCT00587730|cardiac disease
1345723|NCT00587730|chest pain
1345724|NCT00587730|myocardial infarction
1345725|NCT00587730|heart attack
1345726|NCT00587691|Tovaxin
1345727|NCT00587691|TCV
1345728|NCT00587691|Autologous
1345729|NCT00587678|PAD
1345730|NCT00587665|Pain
1345731|NCT00587652|Barrett Esophagus
1345732|NCT00587652|Methylene blue
1345733|NCT00587652|Chromoendoscopy
1345734|NCT00587639|Adolescent
1345735|NCT00587639|Depression
1345736|NCT00587639|rTMS
1345737|NCT00587626|neck pain
1345738|NCT00587626|shoulder pain
1345739|NCT00587626|cervical pain
1345740|NCT00587626|chronic
1345741|NCT00587626|recurrent
1345742|NCT00587600|Barrett's Esophagus
1345743|NCT00587600|High Grade Dysplasia
1345744|NCT00587600|Photodynamic Therapy
1345745|NCT00587574|chronic graft-versus-host disease
1345746|NCT00587561|schizophrenia
1345747|NCT00587561|social cognition
1345748|NCT00587561|cognition
1345749|NCT00587561|treatment
1345750|NCT00587561|outcome
1345751|NCT00587548|locate the ureters during abdominal surgery
1345752|NCT00587535|hemochromatosis
1345753|NCT00587535|liver cirrhosis
1345754|NCT00587535|liver diseases
1345755|NCT00587522|Gastroesophageal Reflux Disease (GERD)
1345756|NCT00587522|NDO Full-thickness Plicator
1345757|NCT00587522|Plicator
1345758|NCT00587522|Endoluminal GERD Therapy
1345759|NCT00587496|HSV DNA
1345760|NCT00587496|volunteers
1345761|NCT00587483|cardiopulmonary bypass
1345762|NCT00587483|reperfusion ventricular fibrillation
1345763|NCT00587483|ventricular fibrillation
1345764|NCT00587483|amiodarone
1345765|NCT00587483|lidocaine
1345766|NCT00587483|cardiac surgery
1345767|NCT00587470|valve, mitral, regurgitation
1345768|NCT00587457|Chronic Lymphocytic Leukemia
1345769|NCT00587457|Prolymphocytic Leukemia
1345770|NCT00587457|Small Lymphocytic Lymphoma
1345771|NCT00587457|Moxetumomab pasudotox
1345772|NCT00587444|heparin management
1345773|NCT00587431|Prostate
1345774|NCT00587431|Cancer
1345775|NCT00587431|Docetaxel
1345776|NCT00587431|03-076
1345777|NCT00587405|Watermelon Stomach
1345778|NCT00587405|Cryotherapy
1345779|NCT00587405|Argon Plasma Coagulation
1345780|NCT00587392|Gastroesophageal Reflux Disease (GERD)
1345781|NCT00587392|Long-term follow-up (LTFU)
1345782|NCT00587392|Endoscopic Full-thickness Plication
1345783|NCT00587392|Plicator
1345784|NCT00587379|testing for Endothelial Dysfunction and coronary angiography
1345785|NCT00587353|tobacco use cessation
1345786|NCT00587353|radiation oncology
1345787|NCT00587353|smoking
1345788|NCT00587314|Photodynamic Therapy
1345789|NCT00587314|Barrett's Esophagus
1345790|NCT00587314|Early Esophageal Adenocarcinoma
1345791|NCT00587301|Child Obesity
1345792|NCT00587288|Cinquil™
1345793|NCT00587288|Reslizumab
1345794|NCT00587275|Gastroesophageal Reflux Disease
1345795|NCT00587275|GERD
1345796|NCT00587262|Cochlear
1345797|NCT00587262|Hearing
1345798|NCT00587262|High frequency hearing loss
1345799|NCT00587249|Malaria, Plasmodium falciparium, Hepatitis B Core Antigen, Circumsporozoite Epitopes
1345800|NCT00587236|Autofluorescence
1345801|NCT00587236|Narrow Band
1345802|NCT00587236|High definition white light
1345803|NCT00587210|Crohn Disease
1345804|NCT00587210|Inflammatory Bowel Disease
1345805|NCT00587197|esophageal varices
1345806|NCT00587197|portal hypertension
1345807|NCT00587197|gastric varices
1345808|NCT00587197|cost effectiveness
1345809|NCT00587184|Barrett's Esophagus
1345810|NCT00587184|Confocal Microscopy
1345811|NCT00587171|Amblyopia
1345812|NCT00587171|Vision Therapy
1345813|NCT00587171|Patching
1345814|NCT00587158|Paricalcitol
1345815|NCT00587158|Parathyroid Hormone
1345816|NCT00587158|Bone Alkaline Phosphatase
1345817|NCT00587158|Chronic Kidney Disease
1345818|NCT00587158|Glomerular Filtration Rate
1345819|NCT00587158|Vitamin D Receptor
1345820|NCT00587158|Interstitial Fibrosis and Tubular Atrophy
1345821|NCT00587158|Zemplar®
1345822|NCT00587145|Stomach Neoplasms
1345823|NCT00587145|Secondary
1345824|NCT00587145|Combination chemotherapy
1345825|NCT00587145|S-1
1345826|NCT00587145|Docetaxel
1345827|NCT00587145|oxaliplatin
1345828|NCT00587132|Diabetes mellitus
1345829|NCT00587132|Peutz-Jeghers syndrome
1345830|NCT00587119|Urso
1345831|NCT00587119|Budesonide
1345832|NCT00587119|PBC
1345833|NCT00587119|overlap AIH
1345834|NCT00587119|PBC with overlap features of autoimmune hepatitis
1345835|NCT00587093|Newly diagnosed
1345836|NCT00587093|CA 125
1345837|NCT00587093|CT scan
1345838|NCT00587093|01-048
1345839|NCT00587067|FUDR
1345840|NCT00587067|FLOXORUIDINE
1345841|NCT00587067|DEXAMETHASONE
1345842|NCT00587067|Hepatic
1345843|NCT00587067|Cancer
1345844|NCT00587067|02-120
1345845|NCT00587054|leukemia
1345846|NCT00587054|non-Hodgkins
1345847|NCT00587054|lymphoblastic lymphoma
1345848|NCT00587054|myelodysplastic syndrome
1345849|NCT00587054|paroxysmal nocturnal hemoglobinuria (PNH)
1345850|NCT00587054|cytoreductive regimen
1345851|NCT00587054|allogeneic stem cell transplant
1345852|NCT00587041|Synbiotic
1345853|NCT00587041|Urine Oxalate
1345854|NCT00587041|Probiotic
1345855|NCT00587041|Kidney Stone
1345856|NCT00587041|Gastric Bypass
1345857|NCT00587041|Crohn's
1345858|NCT00587041|Stone
1345859|NCT00587041|Hyperoxaluria
1345860|NCT00587041|Enteric Hyperoxaluria
1345861|NCT00587028|Colonography
1345862|NCT00587028|Colonoscopy
1345863|NCT00587028|Virtual
1345864|NCT00587028|Computed Tomographic Colonography
1345865|NCT00587028|Large intestine
1345866|NCT00587028|colon
1345867|NCT00587002|Acute Coronary Syndrome
1345868|NCT00587002|Women
1345869|NCT00586989|Barrett's Esophagus
1345870|NCT00586989|Esophageal Cancer
1345871|NCT00586989|High Grade Dysplasia
1345872|NCT00586976|pain, ropivacaine, infusion, sternotomy
1345873|NCT00586963|Erosive Esophagitis
1345874|NCT00586963|Reflux Esophagitis
1345875|NCT00586963|GERD
1345876|NCT00586950|Myocardial Free Fatty Acid metabolism
1345877|NCT00586950|High risk patients
1345878|NCT00586950|End-stage renal failure
1345879|NCT00586950|Cardiovascular events
1345880|NCT00586950|prognosis
1345881|NCT00586937|Lung Cancer Survivors
1345882|NCT00586911|Nonalcoholic Steatohepatitis
1345883|NCT00586911|NASH
1345884|NCT00586911|Betaine
1345885|NCT00586898|Prostate
1345886|NCT00586898|Cancer
1345887|NCT00586898|Hormones
1345888|NCT00586898|01-085
1345889|NCT00586898|ANTIFUNGAL ANTIBIOTICS
1345890|NCT00586898|ESTROGENS
1345891|NCT00586898|LUPRON
1345892|NCT00586898|TESTOSTERONE
1345893|NCT00586898|ZOLADEX
1345894|NCT00586885|Nonalcoholic Steatohepatitis
1345895|NCT00586885|NASH
1345896|NCT00586885|L-Alanine
1345897|NCT00586872|Barrett's Esophagus
1345898|NCT00586872|Early Esophageal Adenocarcinoma
1345899|NCT00586872|Endoscopic Mucosal Resection
1345900|NCT00586859|Gastroesophageal Reflux Disease (GERD)
1345901|NCT00586859|NDO Full-thickness Plicator
1345902|NCT00586859|Plicator
1345903|NCT00586859|Endoluminal GERD Therapy
1345904|NCT00586846|Cisplatin
1345905|NCT00586846|Doxorubicin
1345906|NCT00586846|Methotrexate
1345907|NCT00586846|Osteosarcoma
1345908|NCT00586846|03-074
1345909|NCT00586833|Heart Failure
1345910|NCT00586833|Heart Failure, Diastolic
1345911|NCT00586833|Dyspnea, Paroxysmal
1345912|NCT00586833|Edema, Cardiac
1345913|NCT00586820|Coronary Atherosclerosis
1345914|NCT00586820|Microvascular Dysfunction
1345915|NCT00586820|Non-ST Elevation Myocardial Infarction
1345916|NCT00586807|Ulcerative colitis
1345917|NCT00586807|pediatrics
1345918|NCT00586807|UC
1345919|NCT00586807|protein metabolism
1345920|NCT00586807|energy expenditure
1345921|NCT00586794|Hypertension
1345922|NCT00586794|Eisenmenger
1345923|NCT00586781|ankle replacement
1345924|NCT00586781|end-stage arthritis of the ankle
1345925|NCT00586781|degenerative ankle disease
1345926|NCT00586755|Intensive Induction
1345927|NCT00586755|High Dose Chemotherapy
1345928|NCT00586755|Bone Marrow Transplantation
1345929|NCT00586755|Mantle Cell Lymphoma
1345930|NCT00586742|SLAP lesions
1345931|NCT00586742|labral repair
1345932|NCT00586742|bicepstenodesis
1345933|NCT00586742|conservative treatment
1345934|NCT00586729|Burn
1345935|NCT00586729|Burn wound management
1345936|NCT00586729|Burn graft
1345937|NCT00586703|Stem cell transplant
1345938|NCT00586703|mismatched donor
1345939|NCT00586703|NK infusion
1345940|NCT00586690|Stem cell transplant
1345941|NCT00586690|matched donor
1345942|NCT00586690|NK infusion
1345943|NCT00586677|child abuse
1345944|NCT00586677|child neglect
1345945|NCT00586677|PCIT
1345946|NCT00586677|Lutzker
1345947|NCT00586677|attachment
1345948|NCT00586677|parenting
1345949|NCT00586638|cognition
1345950|NCT00586638|cognition disorders
1345951|NCT00586638|executive function
1345952|NCT00586638|cognitive control
1345953|NCT00586638|attentional control
1345954|NCT00586638|biomedical enhancement
1345955|NCT00586638|cognitive enhancement
1345956|NCT00586638|computerized
1345957|NCT00586638|computer-based
1345958|NCT00586638|video game
1345959|NCT00586612|Conjugate vaccine
1345960|NCT00586612|Persistence
1345961|NCT00586612|Hib vaccine
1345962|NCT00586612|Combination vaccine
1345963|NCT00586612|Meningococcal vaccine
1345964|NCT00586612|Safety
1345965|NCT00586612|Preterm/full-term infants
1345966|NCT00586612|Immunogenicity
1345967|NCT00586599|IBD
1345968|NCT00586599|CD
1345969|NCT00586599|UC
1345970|NCT00586599|Crohn's Disease
1345971|NCT00586599|Ulcerative Colitis
1345972|NCT00586599|Pediatric
1345973|NCT00586599|inflammatory markers
1345974|NCT00586573|ADHD
1345975|NCT00586573|Namenda
1345976|NCT00586560|solid tumors
1345977|NCT00586547|Haploidentical
1345978|NCT00586547|Stem Cell Transplant
1345979|NCT00586547|Graft-Versus-Host disease
1345980|NCT00586534|crack, cocaine, addiction treatment, virtual reality
1345981|NCT00586521|Coagulation Disorders
1345982|NCT00586495|Sorafenib
1345983|NCT00586495|Nexavar
1345984|NCT00586495|Metastatic RCC
1345985|NCT00586495|Renal Cell Carcinoma
1345986|NCT00586495|Unresectable RCC
1345987|NCT00586482|cigarettes, surgery
1345988|NCT00586482|Smokers scheduled for elective surgery
1345989|NCT00586469|Influenza
1345990|NCT00586443|solid tumors
1345991|NCT00586443|avastin
1345992|NCT00586443|Phase I
1345993|NCT00586443|Phase 1
1345994|NCT00586443|combination therapy
1345995|NCT00586443|bevacizumab
1345996|NCT00586443|RAD001
1345997|NCT00586443|everolimus
1345998|NCT00586443|pantitumumab
1345999|NCT00586430|apolipoprotein E e4
1346000|NCT00586430|Alzheimer's disease
1346001|NCT00586430|somnolence
1346002|NCT00586430|Early detection
1346003|NCT00586417|angiogenesis
1346004|NCT00586417|tumor angiogenesis
1346005|NCT00586417|biomarkers
1346006|NCT00586417|healthy volunteers
1346007|NCT00586404|Barrett's Esophagus
1346008|NCT00586404|Esophageal neoplasms
1346009|NCT00586404|gastroesophageal reflux
1346010|NCT00586404|gastrointestinal neoplasms
1346011|NCT00586391|B cell Lymphoma
1346012|NCT00586391|Cancer
1346013|NCT00586391|Chronic Lymphocytic Leukemia
1346014|NCT00586391|CD19 CHIMERIC RECEPTOR EXPRESSING T LYMPHOCYTES
1346015|NCT00586391|Acute Lymphocytic Leukemia
1346016|NCT00586365|complex elbow trauma
1346017|NCT00586365|prevention
1346018|NCT00586365|complication
1346019|NCT00586365|naproxen
1346020|NCT00586365|NSAIDS
1346021|NCT00586352|Pediatric
1346022|NCT00586352|Crohn's disease
1346023|NCT00586352|Ulcerative colitis
1346024|NCT00586339|HPV
1346025|NCT00586339|Human papillomavirus (HPV) vaccine
1346026|NCT00586339|Human Immunodeficiency Virus (HIV)
1346027|NCT00586339|Cervical cancer
1346028|NCT00586339|Papillomavirus
1346029|NCT00586326|MammoSite
1346030|NCT00586326|DCIS
1346031|NCT00586313|EUS Biopsy for Non-alcoholic Fatty Liver Disease
1346032|NCT00586300|Knee pain
1346033|NCT00586287|Phenprocoumon
1346034|NCT00586287|Dosing algorithm
1346035|NCT00586287|loading dose
1346036|NCT00586274|Stem Cell Transplant
1346037|NCT00586274|Anemia
1346038|NCT00586274|Fanconi
1346039|NCT00586261|Kidney Failure, Chronic
1346040|NCT00586261|Renal Insufficiency, Chronic
1346041|NCT00586261|Proteinuria
1346042|NCT00586261|Albuminuria
1346043|NCT00586248|Peripheral nerve stimulator, cardiac pacemaker
1346044|NCT00586235|Fusion
1346045|NCT00586235|Ultrasound
1346046|NCT00586235|Computed tomography
1346047|NCT00586222|Omega-3 Fatty Acids
1346048|NCT00586222|Pediatric Bipolar Disorder
1346049|NCT00586222|Adolescent Bipolar Disorder
1346050|NCT00586222|MRS
1346051|NCT00586209|sickle cell disease
1346052|NCT00586209|sickle cell anemia
1346053|NCT00586209|L-glutamine
1346054|NCT00586209|Sickle Cell Anemia (homozygous and heterozygous)
1346055|NCT00586209|Sickle ß0-Thalassemia
1346056|NCT00586196|Delirium
1346057|NCT00586196|Postoperative confusion
1346058|NCT00586196|Hip fracture
1346059|NCT00586196|Long bone fracture
1346060|NCT00586183|Ventricular Remodeling
1346063|NCT00586157|ADHD
1346064|NCT00586157|Attention Deficit Hyperactivity Disorder
1346065|NCT00586157|Daytrana
1346066|NCT00586157|MTS Patch
1346067|NCT00586157|Methylphenidate Transdermal System
1346068|NCT00586131|end-stage renal disease
1346069|NCT00586131|automated peritoneal dialysis
1346070|NCT00586131|metabolic acidosis
1346071|NCT00586131|nitrogen balances
1346072|NCT00586118|Sedation
1346073|NCT00586118|Volatile anaesthetic
1346074|NCT00586118|Sevoflurane
1346075|NCT00586118|Propofol
1346076|NCT00586118|Recovery
1346077|NCT00586105|Sorafenib
1346078|NCT00586105|Nexavar
1346079|NCT00586105|Metastatic RCC
1346080|NCT00586105|Renal Cell Carcinoma
1346081|NCT00586105|Unresectable RCC
1346082|NCT00586092|Phase I
1346083|NCT00586092|Phase 1
1346084|NCT00586092|avastin
1346085|NCT00586092|bevacizumab
1346086|NCT00586092|ABT-510
1346087|NCT00586092|solid tumors
1346088|NCT00586092|angiogenesis
1346089|NCT00586066|Bipolar disorder
1346090|NCT00586066|Cognitive dysfunction
1346091|NCT00586066|Memantine
1346092|NCT00586066|NMDA antagonist
1346093|NCT00586053|Colonic Polyps
1346094|NCT00586053|Colon
1346095|NCT00586053|Large Intestine
1346096|NCT00586053|Cecum
1346097|NCT00586053|Sigmoid
1346098|NCT00586053|Rectum
1346099|NCT00586053|Colonoscopy
1346100|NCT00586053|Virtual Colonoscopy
1346101|NCT00586053|CT Colonography
1346102|NCT00586053|Computed Tomographic Colonography
1346103|NCT00586053|Colonography
1346104|NCT00586040|skin cancer
1346105|NCT00586040|skin excision
1346106|NCT00586040|laser
1346107|NCT00586040|superficial sutures
1346108|NCT00586040|wound healing
1346109|NCT00586027|cardiac surgery
1346110|NCT00586027|low cardiac output
1346111|NCT00586027|natriuretic peptide B
1346112|NCT00586027|mortality
1346113|NCT00586027|morbidity
1346114|NCT00586014|Multiple myeloma
1346115|NCT00586014|Autologous Stem Cell Transplant
1346116|NCT00586001|Anxiety
1346117|NCT00586001|Emotional Disorders
1346118|NCT00586001|Unified
1346119|NCT00586001|Depression
1346120|NCT00585962|proton beam radiation
1346121|NCT00585910|ADHD
1346122|NCT00585910|Attention Deficit Hyperactivity Disorder
1346123|NCT00585910|Strattera
1346124|NCT00585910|Concerta
1346125|NCT00585910|Atomoxetine
1346126|NCT00585910|OROS Methylphenidate
1346127|NCT00585897|Diabetes
1346128|NCT00585897|Obesity
1346129|NCT00585884|Reconstruction, Silicone prostheses
1346130|NCT00585871|ICD patients with 5 VTs per 3 month period
1346131|NCT00585845|Cancer
1346132|NCT00585845|Ovarian cancer
1346133|NCT00585845|Pancreatic cancer
1346134|NCT00585845|Non-small cell lung cancer
1346135|NCT00585845|Mesothelioma
1346136|NCT00585845|Mesothelin
1346137|NCT00585845|Immunotherapy
1346138|NCT00585832|hypertension
1346139|NCT00585832|pre-hypertension
1346140|NCT00585832|adolescents
1346141|NCT00585832|diet
1346142|NCT00585832|vascular function
1346143|NCT00585806|Heart Failure with preserved ejection fraction
1346144|NCT00585793|HIV/AIDS
1346145|NCT00585767|Hydronephrosis
1346146|NCT00585715|Cellulite
1346147|NCT00585715|Nd:YAG Laser
1346148|NCT00585702|Bipolar Disorder
1346149|NCT00585702|Pregnancy
1346150|NCT00585702|Infant Development
1346151|NCT00585689|Locally advanced urothelial carcinoma of the bladder
1346152|NCT00585650|palmoplantar psoriasis
1346153|NCT00585650|etanercept
1346154|NCT00585650|Enbrel
1346155|NCT00585637|Vitamin D
1346156|NCT00585637|Blacks
1346157|NCT00585637|cancer
1346158|NCT00585637|hypertension
1346159|NCT00585624|Esophagectomy
1346160|NCT00585624|Pancreaticoduodenectomy
1346161|NCT00585624|Whipple
1346162|NCT00585611|Heart Failure, Congestive
1346163|NCT00585572|Normal Tissues/Brains
1346164|NCT00585572|Alzheimer
1346165|NCT00585572|Motor Neuron Disease
1346166|NCT00585572|Dementia
1346167|NCT00585572|Healthy Control Volunteers
1346168|NCT00585572|Populations At Risk
1346169|NCT00585572|MCI
1346170|NCT00585559|Lipid
1346171|NCT00585559|Peroxidation
1346172|NCT00585559|N-Acetylcysteine
1346173|NCT00585559|Acetaminophen
1346174|NCT00585559|Vasospasm
1346175|NCT00585546|heart failure
1346176|NCT00585546|dilated cardiomyopathy
1346177|NCT00585546|heart assist device
1346178|NCT00585546|clenbuterol
1346179|NCT00585546|adrenergic beta agonists
1346180|NCT00585546|heart transplantation
1346181|NCT00585507|hormone receptor positive breast cancer
1346182|NCT00585507|Fulvestrant
1346183|NCT00585481|Epidemiological Study
1346184|NCT00585481|Incidence of severe Respiratory Syncytial Virus
1346185|NCT00585481|Preterm Brazilian children
1346186|NCT00585455|vascular endothelium
1346187|NCT00585455|nitric oxide
1346188|NCT00585455|depression
1346189|NCT00585455|heart failure
1346190|NCT00585455|vascular biology
1346191|NCT00585416|Prostate Cancer
1346192|NCT00585416|Hormone Refractory
1346193|NCT00585416|Metastatic
1346194|NCT00585364|Allergic Bronchopulmonary Aspergillosis
1346195|NCT00585364|Aspergillus fumigatus
1346196|NCT00585364|cytokine expression
1346197|NCT00585338|facial telangiectasia,
1346198|NCT00585338|leg vein telangiectasia
1346199|NCT00585338|Port Wine Stain birthmarks
1346200|NCT00585312|FAP
1346201|NCT00585299|steatosis
1346202|NCT00585299|fatty liver
1346203|NCT00585299|insulin sensitivity
1346204|NCT00585299|fatty liver (steatosis)
1346205|NCT00585286|acne vulgaris
1346206|NCT00585286|scarring
1346207|NCT00585286|laser
1346208|NCT00585260|asthma
1346209|NCT00585260|bronchoprovocation challenge test
1346210|NCT00585260|mannitol
1346211|NCT00585260|methacholine
1346212|NCT00585247|birthmarks
1346213|NCT00585221|Gastrointestinal stromal tumors
1346214|NCT00585221|Imatinib
1346215|NCT00585221|Peginterferon α-2b
1346216|NCT00585221|Immunotherapy
1346217|NCT00585221|Targeted therapy
1346218|NCT00585208|insomnia
1346219|NCT00585208|sleep disturbance
1346220|NCT00585208|bipolar disorder
1346221|NCT00585195|Crizotinib
1346222|NCT00585195|dose-finding
1346223|NCT00585195|drug-drug interaction
1346224|NCT00585195|ALK rearrangements
1346225|NCT00585195|c-Met mutations or amplifications
1346226|NCT00585195|c-Met dependent tumors
1346227|NCT00585195|ROS1 rearrangements
1346228|NCT00585195|c-Met exon 14 deletion
1346229|NCT00585195|c-Met exon 14 skipping
1346230|NCT00585195|c-Met exon 14 alterations
1346231|NCT00585182|Obesity
1346232|NCT00585182|venous thrombosis
1346233|NCT00585182|Anticoagulants
1346234|NCT00585169|Pathological Gambling
1346235|NCT00585169|Compulsive Gambling
1346236|NCT00585169|Gambling Addiction
1346237|NCT00585169|Gambling
1346238|NCT00585169|Treatment
1346239|NCT00585169|Memantine
1346240|NCT00585169|Pharmacology
1346241|NCT00585156|Celebrex, Bone Ingrowth, Pain relief
1346242|NCT00585143|Dyslipidemia
1346243|NCT00585078|capecitabine
1346244|NCT00585078|oxaliplatin
1346245|NCT00585052|Ovarian Cancer
1346246|NCT00585052|Epithelial Ovarian Cancer
1346247|NCT00585052|Lovastatin
1346248|NCT00585052|Paclitaxel
1346249|NCT00585039|child
1346250|NCT00585039|emergency department
1346251|NCT00585026|Refractive error
1346252|NCT00585026|Asthenopia
1346253|NCT00585026|Presbyopia
1346254|NCT00585026|Eyeglasses
1346255|NCT00585026|Productivity
1346256|NCT00585026|Visual comfort
1346257|NCT00585026|Ergonomics
1346258|NCT00585013|Inhaled Nitric Oxide (NO)
1346259|NCT00585013|Anti-inflammatory
1346260|NCT00585013|Anti-reperfusion agent
1346261|NCT00584974|Depression
1346262|NCT00584974|Mental Disorders
1346263|NCT00584974|Mood Disorders
1346264|NCT00584974|Depressive Disorder, Major
1346265|NCT00584974|Dysthymic Disorder
1346266|NCT00584961|Metabolic Syndrome, Bipolar Disorder and Cardiovascular Risk Factors
1346267|NCT00584948|FXTAS, Fragile X Premutation
1346268|NCT00584935|Pemphigoid
1346269|NCT00584935|Blistering Diseases
1346270|NCT00584935|Blindness
1346271|NCT00584935|Autoimmune
1346272|NCT00584935|Rituximab
1346273|NCT00584922|Esophageal injury
1346274|NCT00584922|Catheter Ablation
1346275|NCT00584922|Atrial Fibrillation
1346276|NCT00584896|heart disease
1346277|NCT00584896|coronary artery disease
1346278|NCT00584896|echocardiogram
1346279|NCT00584896|ultrasound
1346280|NCT00584896|angiogram
1346281|NCT00584896|SPECT
1346282|NCT00584896|chest pain
1346283|NCT00584896|perfusion
1346284|NCT00584883|Patients who have newly diagnosed brain tumors
1346285|NCT00584844|Live Vaccine Strain (LVS), Bacterial Infections, Ulceroglandular, Oculoglandular
1346286|NCT00584831|astigmatism
1346287|NCT00584831|visual acuity
1346288|NCT00584831|orientation
1346289|NCT00584831|contact lenses
1346290|NCT00584818|coronary artery disease
1346291|NCT00584818|chest pain
1346292|NCT00584818|healthy volunteers
1346293|NCT00584818|SPECT
1346294|NCT00584818|angiogram
1346295|NCT00584818|ultrasound
1346296|NCT00584818|echocardiogram
1346297|NCT00584818|perfusion
1346298|NCT00584805|EEE
1346299|NCT00584792|Prostate Cancer
1346300|NCT00584779|Gabapentin Pharmacokinetics, renal impairment
1346301|NCT00584753|Breast cancer
1346302|NCT00584740|Crohn's disease, moderate, severe, active, AIN457
1346303|NCT00584727|astigmatism
1346304|NCT00584727|visual acuity
1346305|NCT00584727|fit
1346306|NCT00584727|comfort
1346307|NCT00584727|satisfaction
1346308|NCT00584727|contact lens
1346309|NCT00584714|ultrasound
1346310|NCT00584714|perfusion
1346311|NCT00584714|SPECT
1346312|NCT00584714|coronary artery disease
1346313|NCT00584714|chest pain
1346314|NCT00584714|low probability
1346315|NCT00584714|angiography
1346316|NCT00584714|clinical outcomes
1346317|NCT00584688|anorexia
1346318|NCT00584688|nervosa
1346319|NCT00584688|eating
1346320|NCT00584688|disorder
1346321|NCT00584688|study
1346322|NCT00584688|research
1346323|NCT00584688|clinical
1346324|NCT00584688|trial
1346325|NCT00584688|psychiatry
1346326|NCT00584688|psychiatric
1346327|NCT00584675|GERD
1346328|NCT00584675|laryngopharyngeal reflux disease
1346329|NCT00584662|Rhinitis
1346330|NCT00584649|Inappropriate Sinus Tachycardia
1346331|NCT00584649|Inappropiate Tachycardia
1346332|NCT00584649|Sinus Tachycardia
1346333|NCT00584649|Palpitations
1346334|NCT00584649|Fast Heart rate
1346335|NCT00584636|child
1346336|NCT00584636|emergency department
1346337|NCT00584623|dysphagia
1346338|NCT00584623|videofluoroscopy
1346339|NCT00584623|flexible endoscopic evaluation
1346340|NCT00584610|Women's health
1346341|NCT00584597|Radiation-Induced Mucositis
1346342|NCT00584597|Head and neck cancer
1346343|NCT00584597|TRAUMEEL
1346344|NCT00584597|Mucositis
1346345|NCT00584597|Radiation
1346346|NCT00584597|Oral cancer
1346347|NCT00584597|Inflammation of the mouth
1346348|NCT00584597|Homeopathic Medication
1346349|NCT00584584|Allergic rhinitis, adults, monoclonal antibody, interleukin-13.
1346350|NCT00584558|Arrhythmia
1346351|NCT00584558|Catheter Ablation
1346352|NCT00584545|pharyngeal manometry
1346353|NCT00584545|videofluoroscopy
1346354|NCT00584532|Localized
1346355|NCT00584532|Prostate
1346356|NCT00584532|Cancer
1346357|NCT00584519|Schizophrenia, Overweight, Cardiovascular Risk, Obesity
1346358|NCT00584506|orbital fractures
1346359|NCT00584467|GEM
1346360|NCT00584467|Arteriosclerosis
1346361|NCT00584467|biomarkers
1346362|NCT00584467|Atherosclerosis
1346363|NCT00584454|Coxiella burnetti, Bacterial Infections, Rickettsia, Hepatits, Endocarditis
1346364|NCT00584428|Breast Cancer
1346365|NCT00584428|Cancer Treatment
1346366|NCT00584428|Breast Cancer Treatment
1346367|NCT00584415|Catheter Ablation
1346368|NCT00584415|Atrial Fibrillation
1346369|NCT00584402|liver cancer
1346370|NCT00584389|Obesity
1346371|NCT00584389|Energy expenditure
1346372|NCT00584389|Fatty acid
1346373|NCT00584389|Triglyceride
1346374|NCT00584376|Essential tremor
1346375|NCT00584376|tremor
1346376|NCT00584376|pregabalin
1346377|NCT00584376|lyrica
1346378|NCT00584350|coronary angiogram
1346379|NCT00584350|percutaneous coronary intervention
1346380|NCT00584337|tomography
1346381|NCT00584337|coronary artery disease
1346382|NCT00584337|Stress Test
1346383|NCT00584337|Coronary CT Angiography
1346384|NCT00584337|Diagnostic Accuracy
1346385|NCT00584337|Non invasive testing
1346386|NCT00584324|elective surgery
1346387|NCT00584324|general anesthesia
1346388|NCT00584324|implicit memory
1346389|NCT00584298|Barostat
1346390|NCT00584298|distention
1346391|NCT00584298|IBS
1346392|NCT00584298|irritable
1346393|NCT00584298|bowel
1346394|NCT00584298|syndrome
1346395|NCT00584298|colorectal
1346396|NCT00584298|sensation
1346397|NCT00584298|modulation
1346398|NCT00584298|reproducibility
1346401|NCT00584259|GERD
1346402|NCT00584259|Gastro-Esophageal Disease
1346403|NCT00584246|Restless legs syndrome
1346404|NCT00584246|RLS
1346405|NCT00584246|Pregabalin
1346406|NCT00584246|Lyrica
1346407|NCT00584233|breast cancer
1346408|NCT00584220|Astigmatism
1346409|NCT00584220|vision
1346410|NCT00584220|comfort
1346411|NCT00584220|satisfaction
1346412|NCT00584220|contact lenses
1346413|NCT00584207|uterine fibroids
1346414|NCT00584194|Hemorrhagic Fever, Viral Infections, Neurologic diseases, Arbovirus Infections, RVF
1346415|NCT00584168|UPPP
1346416|NCT00584168|Dexamethasone
1346417|NCT00584168|Uvulopalatopharyngoplasty
1346418|NCT00584168|Pain Management
1346419|NCT00584168|Increasing pain management in patients that have undergone UPPP surgery
1346420|NCT00584155|Cisplatin Ototoxicity
1346421|NCT00584155|Lactated Ringer's
1346422|NCT00584155|Ear Cancer
1346423|NCT00584155|Hearing loss
1346424|NCT00584155|Hearing loss due to Cisplatin Ototoxicity
1346425|NCT00584142|breast cancer
1346426|NCT00584142|survivors
1346427|NCT00584129|Cancer
1346428|NCT00584129|Dysphagia
1346429|NCT00584129|Radiation
1346430|NCT00584129|Patients with H&N cancer who will be receiving chemoradiation
1346431|NCT00584116|Aortic Valve Replacement
1346432|NCT00584116|AVR
1346433|NCT00584103|transradial amputation
1346434|NCT00584103|prosthesis
1346435|NCT00584103|prefabricated prosthesis
1346436|NCT00584103|inexpensive
1346437|NCT00584103|custom prosthesis
1346438|NCT00584103|adult transradial amputation
1346439|NCT00584090|urinary incontinence
1346440|NCT00584090|parkinson's disease
1346441|NCT00584090|vesicare
1346442|NCT00584090|solifenacin succinate
1346443|NCT00584064|patent
1346444|NCT00584064|foramen
1346445|NCT00584064|ovale
1346446|NCT00584064|PFO
1346447|NCT00584051|Control group
1346448|NCT00584038|contraceptive compliance
1346449|NCT00584038|educational intervention
1346450|NCT00584038|oral contraception
1346451|NCT00584025|Parkinson's disease
1346452|NCT00584025|dyskinesia
1346453|NCT00584025|levetiracetam
1346454|NCT00584025|keppra
1346455|NCT00584012|Any cancer
1346456|NCT00584012|Breast cancer
1346457|NCT00584012|Lovastatin
1346458|NCT00584012|Docetaxel
1346459|NCT00583999|leptin, leptin receptors, adiponectin
1346460|NCT00583986|top mounted
1346461|NCT00583986|actuation indicator
1346462|NCT00583986|Asthma
1346463|NCT00583986|COPD
1346464|NCT00583986|Chronic Obstructive Pulmonary Disease
1346465|NCT00583960|swallowing problems
1346466|NCT00583960|tracheal stenosis
1346467|NCT00583947|Asthma
1346468|NCT00583947|Respiratory Tract Diseases
1346469|NCT00583934|esophageal cancer, head and neck cancer, dysplasia
1346470|NCT00583921|Atrial Fibrillation
1346471|NCT00583921|ICD
1346472|NCT00583921|BiV ICD
1346473|NCT00583921|CHF
1346474|NCT00583921|Congestive Heart Failure
1346475|NCT00583921|AF
1346476|NCT00583908|astigmatism
1346477|NCT00583908|orientation
1346478|NCT00583908|visual acuity
1346479|NCT00583908|contact lenses
1346480|NCT00583895|dermatitis
1346481|NCT00583895|atopic
1346482|NCT00583895|ImCOOH
1346483|NCT00583895|safety
1346484|NCT00583895|tolerability
1346485|NCT00583895|efficacy
1346486|NCT00583895|pharmacokinetics
1346487|NCT00583882|Central Venous Catheter
1346488|NCT00583882|Guidewire
1346489|NCT00583882|Burn
1346490|NCT00583869|Post-operative Pain
1346491|NCT00583869|Fracture Patients
1346492|NCT00583869|Pregabalin
1346493|NCT00583869|LYRICA
1346494|NCT00583856|computer aided design
1346495|NCT00583856|maxillofacial fracture
1346496|NCT00583856|orbital design
1346497|NCT00583843|Lumpectomy
1346498|NCT00583843|Ultrasonography
1346499|NCT00583843|Radiotherapy
1346500|NCT00583830|Lung Cancer
1346501|NCT00583804|Spinal Cord Injury
1346502|NCT00583804|Tetraplegia
1346503|NCT00583804|Functional Electrical Stimulation
1346504|NCT00583804|Neuroprosthesis
1346505|NCT00583791|muscular
1346506|NCT00583791|ventricular
1346507|NCT00583791|septal
1346508|NCT00583791|defects
1346509|NCT00583791|VSD
1346510|NCT00583778|Asthma
1346511|NCT00583778|Bronchodilators
1346512|NCT00583778|Levalbuterol
1346513|NCT00583778|Ipratropium
1346514|NCT00583765|Kidney Failure, Acute
1346515|NCT00583765|Hemodialysis
1346516|NCT00583765|Hemofiltration
1346517|NCT00583765|Anticoagulation
1346518|NCT00583765|Citrate
1346519|NCT00583752|prostate cancer
1346520|NCT00583752|vaccine
1346521|NCT00583752|immunotherapy
1346522|NCT00583739|Fatigue
1346523|NCT00583739|Yoga
1346524|NCT00583739|Anxiety
1346525|NCT00583739|Quality of Life
1346526|NCT00583726|chemotherapy
1346527|NCT00583726|exercise
1346528|NCT00583726|diet
1346529|NCT00583726|fruit
1346530|NCT00583726|vegetables
1346531|NCT00583726|low-fat
1346532|NCT00583700|Breast Neoplasms
1346533|NCT00583700|Radiotherapy
1346534|NCT00583687|Arterial pulse contour cardiac output
1346535|NCT00583687|Changing vascular tone
1346536|NCT00583687|Tissue Oxymetry
1346537|NCT00583687|Prediction of Fluid Responsiveness
1346538|NCT00583674|Gastric Cancer
1346539|NCT00583674|Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
1346540|NCT00583674|AMG 386
1346541|NCT00583674|Cisplatin
1346542|NCT00583674|Capecitabine
1346543|NCT00583661|Ventricular Assist Device
1346544|NCT00583661|Pediatric Ventricular Assist Device
1346545|NCT00583648|urinary tract infections
1346546|NCT00583648|urine
1346547|NCT00583648|urinalysis
1346548|NCT00583648|urine protocols
1346549|NCT00583648|urinalysis protocols
1346550|NCT00583648|nursing protocols
1346551|NCT00583648|Emergency Department
1346552|NCT00583635|Preeclampsia
1346553|NCT00583635|Prevention
1346554|NCT00583635|Food Supplement
1346555|NCT00583622|Ovarian Cancer
1346556|NCT00583622|Epithelial Ovarian Cancer
1346557|NCT00583622|Bevacizumab
1346558|NCT00583622|Carboplatin
1346559|NCT00583622|Gemcitabine
1346560|NCT00583622|Docetaxel
1346561|NCT00583622|Melphalan
1346562|NCT00583596|patent ductus arteriosus (PDA)
1346563|NCT00583557|Rheumatoid Arthritis
1346564|NCT00583557|RA
1346565|NCT00583544|Healthy
1346566|NCT00583544|Healthy Volunteers
1346567|NCT00583531|Antibiotic-refractory Pouchitis
1346568|NCT00583531|Pouchitis
1346569|NCT00583531|Ulcerative Colitis
1346570|NCT00583505|membranous
1346571|NCT00583505|ventricular
1346572|NCT00583505|septal
1346573|NCT00583505|defects
1346574|NCT00583505|VSD
1346575|NCT00583492|Prostatic Neoplasms
1346576|NCT00583492|Prostate Cancer
1346577|NCT00583492|Adenocarinomas
1346578|NCT00583492|Tumors of the Prostate
1346579|NCT00583492|Gene Therapy
1346580|NCT00583492|IMRT
1346581|NCT00583466|submucosal cushion
1346582|NCT00583466|polypectomy
1346583|NCT00583466|endoscopic mucosal resection
1346584|NCT00583453|Tonsillectomy
1346585|NCT00583453|Analgesia
1346586|NCT00583453|Pain measurement
1346587|NCT00583453|Celecoxib
1346588|NCT00583440|12-step
1346589|NCT00583440|mutual help
1346590|NCT00583440|dual diagnosis
1346591|NCT00583440|serious mental illness
1346592|NCT00583401|PFO
1346593|NCT00583401|stroke
1346594|NCT00583388|cardiology
1346595|NCT00583388|preventive medicine
1346596|NCT00583388|cardiovascular physiology
1346597|NCT00583388|healthy subjects
1346598|NCT00583375|arthritis
1346599|NCT00583375|ankle pain
1346600|NCT00583375|foot pain
1346601|NCT00583375|hindfoot fracture
1346602|NCT00583375|ankle fracture
1346603|NCT00583362|SLE
1346604|NCT00583362|Lupus
1346605|NCT00583349|Bladder Cancer
1346606|NCT00583349|Chemotherapy
1346607|NCT00583349|Bladder Neoplasms
1346608|NCT00583310|Prehypertension
1346609|NCT00583297|Arrhythmia
1346610|NCT00583297|Heart Failure
1346611|NCT00583297|T wave Alternans (TWA)
1346612|NCT00583297|Implanted Cardioverter Defibrillator(ICD)
1346613|NCT00583297|Biological Markers
1346614|NCT00583297|Molecular Genetics
1346615|NCT00583284|delayed enhancement computed tomography
1346616|NCT00583284|ventricular tachycardia ablation
1346617|NCT00583284|ventricular tachycardia
1346618|NCT00583245|Osteoarthritis
1346619|NCT00583245|Gait training
1346620|NCT00583245|Knee pain
1346621|NCT00583245|Rehabilitation
1346622|NCT00583245|Physical Therapy
1346623|NCT00583232|Pediatric
1346624|NCT00583232|Crohn's disease
1346625|NCT00583232|protein metabolism
1346626|NCT00583232|energy metabolism
1346627|NCT00583206|sepsis
1346628|NCT00583206|atrophy
1346629|NCT00583206|muscle
1346630|NCT00583206|weakness
1346631|NCT00583193|Post Traumatic Stress Disorder
1346632|NCT00583193|Duloxetine
1346633|NCT00583193|Antidepressants
1346634|NCT00583180|Primary and/or secondary hyperalgesia
1346635|NCT00583180|hypoesthesia
1346636|NCT00583167|HIV
1346637|NCT00583167|AIDS
1346638|NCT00583167|CNS
1346639|NCT00583167|brain
1346640|NCT00583167|affects
1346641|NCT00583154|constipation
1346642|NCT00583154|laxative
1346643|NCT00583128|IBS
1346644|NCT00583128|Irritable Bowel Syndrome
1346645|NCT00583102|Acute Myeloid Leukemia
1346646|NCT00583102|AML
1346647|NCT00583102|Lovastatin
1346648|NCT00583102|Cytarabine
1346649|NCT00583076|Pouchitis
1346650|NCT00583076|Active Pouchitis
1346651|NCT00583076|Safety and Efficacy of AST120
1346652|NCT00583037|Neurally Adjusted Ventilatory Assist
1346653|NCT00583037|Sleep quality
1346654|NCT00583037|Adult
1346655|NCT00583037|Critical Care
1346656|NCT00583024|prostate cancer
1346657|NCT00583024|vaccine
1346658|NCT00583024|immunotherapy
1346659|NCT00583011|Amniocentesis
1346660|NCT00583011|Genetic amniocentesis
1346661|NCT00583011|Fetal lung maturity
1346662|NCT00583011|Pain control
1346663|NCT00583011|Pregnancy
1346664|NCT00583011|High risk pregnancy
1346665|NCT00582998|Vacuum Assisted Closure (VAC)
1346666|NCT00582998|Calcaneus Fracture
1346667|NCT00582998|Pilon Fracture
1346668|NCT00582998|Tibial Plateau Fracture
1346669|NCT00582998|Open Reduction and Internal Fixation
1346670|NCT00582985|Tracon
1346671|NCT00582985|CD105
1346672|NCT00582985|Anti CD105
1346673|NCT00582985|TRC105
1346674|NCT00582985|Phase 1
1346675|NCT00582985|Cancer
1346676|NCT00582985|Monoclonal antibody
1346677|NCT00582985|Solid Tumor
1346678|NCT00582972|Calcium Absorption
1346679|NCT00582972|Fractional Calcium Absorption
1346680|NCT00582972|Omeprazole
1346681|NCT00582972|Stable Calcium Isotopes
1346682|NCT00582972|Proton Pump Inhibitor
1346683|NCT00582972|Intestinal Absorption of Calcium
1346684|NCT00582959|radiology imaging
1346685|NCT00582959|malignancy
1346686|NCT00582959|undergoing radiation therapy
1346687|NCT00582946|Hearing Loss, Eardrum, Transducer, Hearing in Noise
1346688|NCT00582933|Cancer
1346689|NCT00582933|Donors
1346690|NCT00582933|Leukemia
1346691|NCT00582933|Myelodysplastic Syndrome
1346692|NCT00582933|Non-Hodgkin's Lymphoma
1346693|NCT00582933|Lymphoma
1346694|NCT00582933|AML
1346695|NCT00582933|ALL
1346696|NCT00582933|CML
1346697|NCT00582933|Allogeneic marrow transplant
1346698|NCT00582933|Bone marrow transplant
1346699|NCT00582920|osseous lesions
1346700|NCT00582920|breast cancer
1346701|NCT00582920|metastatic breast cancer
1346702|NCT00582907|FMF
1346703|NCT00582907|IL1 Trap (Rilonacept)
1346704|NCT00582907|Periodic fever syndromes
1346705|NCT00582907|Autoinflammatory syndromes
1346706|NCT00582907|Familial Mediterranean Fever
1346707|NCT00582907|colchicine
1346708|NCT00582894|Allogenic stem cell transplant
1346709|NCT00582894|Hematologic diseases
1346710|NCT00582881|Anti-RNP/Sm Autoantibody-Positive
1346711|NCT00582881|MCTD
1346712|NCT00582881|SLE
1346713|NCT00582868|Subarachnoid hemorrhage
1346714|NCT00582868|Cerebral Vasospasm
1346715|NCT00582868|Cleaved-tau protein
1346716|NCT00582868|Brain oxygen tension level
1346717|NCT00582855|AQW051
1346718|NCT00582855|Mild Alzheimer's disease
1346719|NCT00582855|Amnestic Mild Cognitive Impairment
1346720|NCT00582842|Early Stage
1346721|NCT00582842|Localized
1346722|NCT00582829|Colorectal
1346723|NCT00582829|Cancer
1346724|NCT00582829|Screening
1346725|NCT00582829|Intervention
1346726|NCT00582829|Family
1346727|NCT00582816|Recurrent or Refractory Leukemia or Solid Tumors in Pediatrics
1346728|NCT00582803|breast cancer
1346729|NCT00582803|germline mutation
1346730|NCT00582803|BRCA1
1346731|NCT00582803|BRCA2
1346732|NCT00582803|family history
1346733|NCT00582803|genetic testing
1346734|NCT00582803|unaffected women over age 25 who are at elevated risk for
1346735|NCT00582803|breast cancer by virtue by a hereditary predisposition
1346736|NCT00582790|Renal Cell Cancer
1346737|NCT00582790|Metastatic
1346738|NCT00582777|nocturnal blood pressure
1346739|NCT00582777|chronic renal disease
1346740|NCT00582777|hypertensive renal disease
1346741|NCT00582777|African Americans
1346742|NCT00582777|ABPM
1346743|NCT00582764|Breast Lesion
1346744|NCT00582764|Lesion
1346745|NCT00582764|Breast
1346746|NCT00582764|Cancer
1346747|NCT00582764|05-091
1346748|NCT00582751|Volumetric Analysis
1346749|NCT00582751|Multiple Diseases
1346750|NCT00582738|Fibrosis progression
1346751|NCT00582738|recurrent hepatitis C
1346752|NCT00582738|viral infection
1346753|NCT00582738|liver transplant recipients
1346754|NCT00582738|everolimus
1346755|NCT00582738|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
1346756|NCT00582725|DLBCL, Elderly
1346757|NCT00582725|previously untreated DLBCL in the elderly
1346758|NCT00582712|medullary thyroid cancer
1346759|NCT00582712|lithium
1346760|NCT00582699|Pancreatic Cancer
1346761|NCT00582699|Pancreatic
1346762|NCT00582686|Calcaneus Fractures
1346763|NCT00582686|Iliac Crest Bone Grafting
1346764|NCT00582686|Open Reduction & Internal Fixation
1346765|NCT00582673|Parkinson's, L-dopa, dyskinesia
1346766|NCT00582634|non small cell lung cancer
1346767|NCT00582634|adjuvant
1346768|NCT00582634|cisplatin
1346769|NCT00582634|docetaxel
1346770|NCT00582621|Genetic Studies
1346771|NCT00582621|00-069
1346772|NCT00582621|blood
1346773|NCT00582621|saliva
1346774|NCT00582621|buccal cell
1346775|NCT00582582|Metastatic
1346776|NCT00582582|Hormone Refractory
1346777|NCT00582582|Prostate Cancer
1346778|NCT00582569|Breast lesion
1346779|NCT00582569|Spectroscopy
1346780|NCT00582569|MRI
1346781|NCT00582556|bone mineral density
1346782|NCT00582543|Prostate Cancer
1346783|NCT00582543|Prostate
1346784|NCT00582530|Prostate Cancer
1346785|NCT00582530|Early Prostate Cancer
1346786|NCT00582530|Radical Prostatectomy
1346787|NCT00582517|Orthopaedic Trauma
1346788|NCT00582517|Knee Dislocation
1346789|NCT00582517|Compass Hinge External Fixator
1346790|NCT00582517|External Brace
1346791|NCT00582504|Encephalitis,VEE
1346792|NCT00582491|Modafinil
1346793|NCT00582491|Sleep
1346794|NCT00582491|Cognition
1346795|NCT00582491|Cocaine Dependence
1346796|NCT00582478|Breast cancer
1346797|NCT00582478|Quality of Life
1346798|NCT00582452|HNPCC
1346799|NCT00582452|prophylactic colectomy
1346800|NCT00582439|Orthopaedic Trauma Fractures
1346801|NCT00582439|Orthopaedic Trauma Non-unions
1346802|NCT00582439|Reamer-Irrigator-Aspirator (RIA)
1346803|NCT00582439|Bone Graft
1346804|NCT00582426|Colorectal cancer
1346805|NCT00582426|diarrhea
1346806|NCT00582426|drug therapy
1346807|NCT00582426|octreotide
1346808|NCT00582426|fluorouracil
1346809|NCT00582426|irinotecan
1346810|NCT00582426|capecitabine
1346811|NCT00582426|prevention
1346812|NCT00582413|Head and Neck Cancer
1346813|NCT00582400|livers, hepatocellular carcinoma (HCC)
1346814|NCT00582374|Periodontal Disease
1346815|NCT00582374|Preterm Birth
1346816|NCT00582374|Low Birth Weight
1346817|NCT00582374|Pregnancy
1346818|NCT00582361|Open Fractures
1346819|NCT00582361|Vacuum Assisted Closure (VAC) device
1346820|NCT00582361|Irrigation and Debridement
1346821|NCT00582348|Lung Cancer
1346822|NCT00582348|Survivor
1346823|NCT00582348|Lung
1346824|NCT00582335|Colorectal cancer
1346825|NCT00582335|Genetic testing
1346826|NCT00582335|Genetic mutations
1346827|NCT00582322|Breast Cancer
1346828|NCT00582322|Ovarian Cancer
1346829|NCT00582322|Family History
1346830|NCT00582322|Genetic Studies
1346831|NCT00582309|Glycemic Control
1346832|NCT00582309|Intravenous Infusion
1346833|NCT00582309|Standard Insulin infusion algorithm
1346834|NCT00582309|Infusion
1346835|NCT00582309|Critically Ill
1346836|NCT00582296|Lynch syndrome
1346837|NCT00582296|04-144
1346838|NCT00582270|non-hodkin's lymphoma
1346839|NCT00582270|follicular
1346840|NCT00582270|non-follicular
1346841|NCT00582270|infectious disease
1346842|NCT00582257|Gastric Cancer
1346843|NCT00582257|Stomach Cancer
1346844|NCT00582257|05-118
1346845|NCT00582244|Menopausal symptoms
1346846|NCT00582244|Quality of Life
1346847|NCT00582244|Breast cancer
1346848|NCT00582244|Multicenter trial
1346849|NCT00582231|Penile injection therapy
1346850|NCT00582231|Erectile dysfunction
1346851|NCT00582231|Radical pelvic surgery
1346852|NCT00582231|Penile Injection Anxiety
1346853|NCT00582218|HIV/AIDS
1346854|NCT00582218|Access to care
1346855|NCT00582205|Ovarian Cancer
1346856|NCT00582205|Fallopian Tube Cancer
1346857|NCT00582205|Primary Peritoneal Carcinoma
1346858|NCT00582205|Uterine Cancer
1346859|NCT00582205|Intraperitoneal Chemotherapy
1346860|NCT00582205|IP Chemotherapy
1346861|NCT00582205|Gynecologic Cancer
1346862|NCT00582205|Women's Cancer
1346863|NCT00582205|Cisplatin
1346864|NCT00582205|Paclitaxel
1346865|NCT00582205|Recurrent Platinum Sensitive Ovarian Cancer
1346866|NCT00582192|Phase I trial
1346867|NCT00582192|Oncologists' Communication Styles
1346868|NCT00582179|Draining Hematoma
1346869|NCT00582179|Vacuum Assisted Closure (VAC)
1346870|NCT00582179|Negative Pressure Wound Therapy (NPWT)
1346871|NCT00582179|Draining Hematoma following orthopaedic surgery
1346872|NCT00582166|Zevalin, High Tumor Burden Indolent Non-Hodgkin's Lymphoma
1346873|NCT00582140|Prostate
1346874|NCT00582140|Cancer
1346875|NCT00582140|Stage D0
1346876|NCT00582140|Non-Metastatic
1346877|NCT00582140|Rising PSA
1346878|NCT00582127|senile
1346879|NCT00582127|dementia
1346880|NCT00582114|Hemodialysis
1346881|NCT00582114|Hypertension
1346882|NCT00582114|Left ventricular hypertrophy
1346883|NCT00582101|HIV
1346884|NCT00582101|prevention
1346885|NCT00582101|families
1346886|NCT00582101|Latinos
1346887|NCT00582101|communication
1346888|NCT00582101|sexuality
1346889|NCT00582101|monitoring
1346890|NCT00582101|health promotion
1346891|NCT00582101|HIV Prevention
1346892|NCT00582101|HIV Seronegativity
1346893|NCT00582088|Encephalitis, Viral Infections, Neurologic diseases, Alphavirus Infections, VEE
1346894|NCT00582075|Cancer
1346895|NCT00582075|Brain metastases
1346896|NCT00582075|Gamma Knife Radiosurgery
1346897|NCT00582075|Temodar
1346898|NCT00582075|Temozolomide
1346899|NCT00582062|Gastric Cancer
1346900|NCT00582062|Pancreatic cancer
1346901|NCT00582049|Retinoblastoma
1346902|NCT00582049|Sporadic heritable retinoblastoma
1346903|NCT00582049|Paternal exposures
1346904|NCT00582036|Hyperglycemia
1346905|NCT00582036|Hematopoietic stem cell transplantation
1346906|NCT00582036|Bone marrow transplant
1346907|NCT00582036|High blood sugar
1346908|NCT00582023|HIV
1346909|NCT00582023|coping
1346910|NCT00582023|emotion
1346911|NCT00582023|affect
1346912|NCT00582023|HIV infection
1346913|NCT00582023|Complimentary therapies
1346914|NCT00582010|ischemia-reperfusion
1346915|NCT00582010|nitric oxide
1346916|NCT00582010|inflammation
1346917|NCT00582010|cell-death
1346918|NCT00582010|Liver-function post transplantation
1346919|NCT00581997|Pulmonary fibrosis, systemic sclerosis
1346920|NCT00581984|breast cancer
1346921|NCT00581984|breast reconstruction
1346922|NCT00581984|silicone implants
1346923|NCT00581971|Radiosensitization
1346924|NCT00581971|COX-2 inhibitor
1346925|NCT00581971|Celecoxib
1346926|NCT00581971|Head and Neck Cancer
1346927|NCT00581971|Chemoradiation
1346928|NCT00581958|total body irradiation
1346929|NCT00581958|Cancer
1346930|NCT00581958|Hematopoietic System
1346931|NCT00581932|clozapine, schizophrenia
1346932|NCT00581919|previously treated multiple myeloma
1346933|NCT00581906|Head and Neck Cancer
1346934|NCT00581906|Head Cancer
1346935|NCT00581906|Neck Cancer
1346936|NCT00581906|Dynamic Contrast Enhanced MRI
1346937|NCT00581906|Magnetic Resonance Spectroscopy (MRS)
1346938|NCT00581906|Diffusion Weighted MRI (DW-MRI)
1346939|NCT00581906|06-007
1346940|NCT00581893|epilepsy
1346941|NCT00581893|cognitive impairment
1346942|NCT00581893|driving simulation
1346943|NCT00581893|cross-over study
1346944|NCT00581880|end stage
1346945|NCT00581880|Terminally Ill
1346946|NCT00581854|untreated mantle cell lymphoma
1346947|NCT00581841|Healthy adult normals
1346948|NCT00581828|Calcium Absorption
1346949|NCT00581828|Intestinal Absorption of Calcium
1346950|NCT00581828|Fractional Calcium Absorption
1346951|NCT00581828|Stable Calcium Isotopes
1346952|NCT00581828|Hypovitaminosis D
1346953|NCT00581828|Vitamin D
1346954|NCT00581828|Bone Mineral Density
1346955|NCT00581828|Physical Function
1346956|NCT00581802|CD4-Positive T-Lymphocytes
1346957|NCT00581802|Treatment Naive
1346958|NCT00581802|Latent HIV Infections
1346959|NCT00581789|non small cell lung cancer
1346960|NCT00581789|sunitinib
1346961|NCT00581789|erlotinib
1346962|NCT00581789|phase 1
1346963|NCT00581776|Untreated Mantle Cell Lymphoma
1346964|NCT00581750|Biopsy
1346965|NCT00581750|Breast
1346966|NCT00581750|01-135
1346967|NCT00581724|breast cancer
1346968|NCT00581724|Colorectal cancer
1346969|NCT00581724|Prostate cancer
1346970|NCT00581724|Head and Neck cancer
1346971|NCT00581724|Lung cancer
1346972|NCT00581724|cancer survivors
1346973|NCT00581724|07-068
1346974|NCT00581724|quality of life
1346975|NCT00581724|Pain in cancer survivors
1346976|NCT00581711|Electronic Health Record
1346977|NCT00581711|Clinical Decision Support
1346978|NCT00581711|Otitis Media
1346979|NCT00581698|Melanoma
1346980|NCT00581698|Negative regional lymph nodes
1346981|NCT00581698|Primary melanomas Clark III and Breslow thickness > 1 mm, or Clark
1346982|NCT00581698|IV-V and any Breslow thickness, and clinically negative regional nodes
1346983|NCT00581685|Chronic pain
1346984|NCT00581685|Preemptive analgesia
1346985|NCT00581685|Pregabalin
1346986|NCT00581685|Celecoxib
1346987|NCT00581685|Hip Arthroplasty
1346988|NCT00581685|Osteoarthritis
1346989|NCT00581672|Anxiety
1346990|NCT00581672|Black men
1346991|NCT00581672|Prostate Cancer
1346992|NCT00581672|07-125
1346993|NCT00581633|saline
1346994|NCT00581633|sodium
1346995|NCT00581633|kidney
1346996|NCT00581633|tachycardia
1346997|NCT00581620|pneumococcus conjugated vaccine
1346998|NCT00581607|Sarcoidosis
1346999|NCT00581594|Pelvic organ prolapse
1347000|NCT00581594|Posterior wall defects
1347001|NCT00581594|Graft-augmented repair
1347002|NCT00581594|Posterior colporrhaphy
1347003|NCT00581581|neonatal encephalopathy
1347004|NCT00581581|therapeutic hypothermia
1347005|NCT00581581|head cooling
1347006|NCT00581581|neonatal asphyxia
1347007|NCT00581568|Skin cooling during laser treatment
1347008|NCT00581555|Psoriasis
1347009|NCT00581529|breast
1347010|NCT00581516|Prostate Cancer
1347011|NCT00581516|PCA3
1347012|NCT00581503|early detection of lung and pleural cancer
1347013|NCT00581503|early detection of prostate cancer
1347014|NCT00581490|Premature pubarche
1347015|NCT00581490|Adrenal hyperandrogenism
1347016|NCT00581490|Metabolic syndrome
1347017|NCT00581477|autonomic nervous system diseases
1347018|NCT00581477|blood pressure
1347019|NCT00581477|congenital
1347020|NCT00581477|orthostasis
1347021|NCT00581477|catecholamines
1347022|NCT00581464|Smoking cessation
1347023|NCT00581464|Tobacco dependence
1347024|NCT00581464|Mindfulness
1347025|NCT00581464|fMRI
1347026|NCT00581464|Craving
1347027|NCT00581438|Approach Haemophilia A and B
1347028|NCT00581425|BCC
1347029|NCT00581425|Basal Cell Carcinoma
1347030|NCT00581425|Intron-A
1347031|NCT00581425|Aldara
1347032|NCT00581425|Basal Cell Carcinoma excluding scalp and face
1347033|NCT00581412|Pelvic organ prolapse
1347034|NCT00581412|Composite biologic/synthetic graft
1347035|NCT00581412|Abdominal sacrocolpopexy
1347036|NCT00581399|Open heart surgery
1347037|NCT00581399|Cardiopulmonary Bypass
1347038|NCT00581399|Coronary Artery Bypass Grafting
1347039|NCT00581399|Chest Tube
1347040|NCT00581399|Valve Replacement
1347041|NCT00581399|Valve Repair
1347042|NCT00581386|Endotracheal Intubation
1347043|NCT00581386|Supraglottic Airway
1347044|NCT00581373|water
1347045|NCT00581373|orthostatic hypotension
1347046|NCT00581373|blood pressure
1347047|NCT00581360|Adenoid cystic carcinoma
1347048|NCT00581360|bortezomib
1347049|NCT00581360|doxorubicin
1347050|NCT00581334|Pelvic organ prolapse
1347051|NCT00581334|Robotic-assisted laparoscopic sacrocolpopexy
1347052|NCT00581334|Post hysterectomy prolapse
1347053|NCT00581334|Symptomatic post hysterectomy prolapse of stage II or greater
1347054|NCT00581321|water
1347055|NCT00581321|blood pressure
1347056|NCT00581321|vascular resistance
1347057|NCT00581321|cardiac transplantation
1347058|NCT00581308|atrial septal defect, septal occluder, HELEX
1347059|NCT00581295|internal bleeding
1347060|NCT00581295|changes in tissue perfusion
1347061|NCT00581282|Cocaine abstinence
1347062|NCT00581282|PET scan
1347063|NCT00581256|left sided
1347064|NCT00581243|Safety,Tolerability, Schizophrenia
1347065|NCT00581230|Endotracheal Intubation
1347066|NCT00581230|Rapid Airway Management Positioner
1347067|NCT00581217|Burn injury
1347068|NCT00581217|Skin graft
1347069|NCT00581217|Donor site dressing
1347070|NCT00581217|Outcomes
1347071|NCT00581217|Infection rate
1347072|NCT00581217|Healing time
1347073|NCT00581217|Cosmetic Result
1347074|NCT00581217|Pain
1347075|NCT00581217|Burn injured patients requiring skin grafting
1347076|NCT00581204|trauma situations
1347077|NCT00581204|Lower Body Negative Pressure (LBNP)
1347078|NCT00581191|SAD
1347079|NCT00581191|Healthy
1347080|NCT00581178|Ureteral Stent
1347081|NCT00581178|Kidney Stones
1347082|NCT00581152|TBX3
1347083|NCT00581126|BENEFIX
1347084|NCT00581126|Hemophilia B
1347085|NCT00581113|whole brain radiotherapy
1347086|NCT00581113|neural stem cell
1347087|NCT00581113|brain metastases
1347088|NCT00581113|radiosurgery
1347089|NCT00581100|Nail Psoriasis
1347090|NCT00581100|Plaque Psoriasis
1347091|NCT00581087|Hypertension, pulmonary
1347092|NCT00581087|DHEA
1347093|NCT00581087|six-minute walk test
1347094|NCT00581087|pulmonary arterial pressure
1347095|NCT00581074|obesity
1347096|NCT00581074|diet
1347097|NCT00581074|weight loss
1347098|NCT00581074|metabolic syndrome
1347099|NCT00581061|Incontinence
1347100|NCT00581061|Robotic Prostatectomy
1347101|NCT00581048|Asthma
1347102|NCT00581048|Allergy
1347103|NCT00581048|Atopy
1347104|NCT00581048|Vitamin E
1347105|NCT00581048|GSTP1
1347106|NCT00581048|Oxidative stress
1347107|NCT00581035|Meningococcal disease
1347108|NCT00581035|pneumococcal disease
1347109|NCT00581035|meningitis
1347110|NCT00581022|postural tachycardia syndrome
1347111|NCT00581022|sleep
1347112|NCT00581022|insomnia
1347113|NCT00581009|Sleep deprivation
1347114|NCT00581009|antidepressant
1347115|NCT00581009|depression
1347116|NCT00581009|chronobiological
1347117|NCT00580996|water
1347118|NCT00580996|orthostatic hypotension
1347119|NCT00580996|blood pressure
1347120|NCT00580983|Head and Neck cancer
1347121|NCT00580970|prostate cancer
1347122|NCT00580970|radiation therapy
1347123|NCT00580970|lovastatin
1347124|NCT00580970|rectal injury
1347125|NCT00580957|Obesity
1347126|NCT00580957|Hypertension
1347127|NCT00580957|Autonomic Nervous System
1347128|NCT00580944|Port wine stain
1347129|NCT00580944|progressive malformation of human skin
1347130|NCT00580931|nutraceutical, dementia, cognition, HDAC inhibitor
1347131|NCT00580918|Mild Traumatic Brain Injury
1347132|NCT00580918|fMRI
1347133|NCT00580905|Adenosine
1347134|NCT00580905|Cytokines
1347135|NCT00580905|Inflammation
1347136|NCT00580905|VEGF
1347137|NCT00580879|Anorectal sphincter laceration
1347138|NCT00580879|Pelvic floor dysfunction
1347139|NCT00580879|Sphincter tear
1347140|NCT00580866|Elbow
1347141|NCT00580866|Upper Extremity Fractures
1347142|NCT00580866|Distal Humerus
1347143|NCT00580866|Elbow Injuries
1347144|NCT00580866|Dislocations
1347145|NCT00580866|Peri-articular Elbow Injuries
1347146|NCT00580853|smoking lapse behavior
1347147|NCT00580853|smoking cessation
1347148|NCT00580853|varenicline
1347149|NCT00580853|bupropion
1347150|NCT00580853|medication effect on smoking lapse behavior
1347151|NCT00580840|Rheumatoid Arthritis
1347152|NCT00580840|Joint Disease
1347153|NCT00580840|Arthritis
1347154|NCT00580840|Certolizumab pegol
1347155|NCT00580840|Cimzia
1347156|NCT00580814|Brookhaven
1347157|NCT00580814|ADHD
1347158|NCT00580814|Dopamine
1347159|NCT00580814|methylphenidate
1347160|NCT00580814|PET
1347161|NCT00580801|Hepatitis C
1347162|NCT00580801|Telaprevir
1347163|NCT00580801|Pegylated-interferon-alfa-2a
1347164|NCT00580801|Pegasys
1347165|NCT00580801|Ribavirin
1347166|NCT00580801|Copegus
1347167|NCT00580788|Endocrine System Diseases
1347168|NCT00580788|MusculoSkeletal System Diseases
1347169|NCT00580788|Hormones
1347170|NCT00580788|Malignancy
1347171|NCT00580788|Postmenopausal Women
1347172|NCT00580788|Bone metabolism
1347173|NCT00580775|Menopause
1347174|NCT00580775|Hormone Replacement Therapy
1347175|NCT00580775|Sudden Cardiac Death
1347176|NCT00580749|Pancreatitis
1347177|NCT00580749|enteral feeding
1347178|NCT00580749|distal jejunal feeding
1347179|NCT00580749|naso gastric feeding
1347180|NCT00580749|pancreatic rest
1347181|NCT00580736|sebaceous hyperplasia
1347182|NCT00580723|acne
1347183|NCT00580723|rosacea
1347184|NCT00580723|acne rosacea
1347185|NCT00580723|papulopustular rosacea
1347186|NCT00580723|erythema
1347187|NCT00580723|telangiectasia
1347188|NCT00580723|flushing
1347189|NCT00580710|type 1 diabetes
1347190|NCT00580710|hypoglycemia
1347191|NCT00580710|magnetic resonance imaging
1347192|NCT00580697|Lower urinary tract symptoms
1347193|NCT00580697|Gynecologic malignancy
1347194|NCT00580697|Urinary incontinence
1347195|NCT00580697|Fecal incontinence
1347196|NCT00580697|Frequency
1347197|NCT00580697|Voiding dysfunction
1347198|NCT00580697|Sexual dysfunction
1347199|NCT00580684|pneumococcus conjugated vaccine 7 valent
1347200|NCT00580671|Adolescent Marijuana Abuse
1347201|NCT00580658|Dystonia
1347202|NCT00580645|alcohol
1347203|NCT00580645|smoking cessation
1347204|NCT00580645|varenicline
1347205|NCT00580645|bupropion
1347206|NCT00580645|smoking cessation medications
1347207|NCT00580619|Chronic fatigue syndrome
1347208|NCT00580619|Postural tachycardia syndrome
1347209|NCT00580619|Autonomic nervous system
1347210|NCT00580606|Food Allergy
1347211|NCT00580606|Peanut Allergy
1347212|NCT00580606|Sublingual Immunotherapy
1347213|NCT00580593|amyotrophic lateral sclerosis
1347214|NCT00580593|ALS
1347215|NCT00580593|nocturnal noninvasive positive pressure ventilation
1347216|NCT00580593|NIPPV
1347217|NCT00580593|forced vital capacity
1347218|NCT00580593|FVC
1347219|NCT00580567|Impulsivity
1347220|NCT00580567|Gambling
1347221|NCT00580567|Pathological Gamblers
1347222|NCT00580567|Problem Gamblers
1347223|NCT00580567|Non-Pathological Gamblers
1347224|NCT00580567|Risk-taking
1347225|NCT00580567|Inhibition
1347226|NCT00580567|Gambling Severity
1347227|NCT00580515|Cancer
1347228|NCT00580515|Randomized Controlled Trial
1347229|NCT00580515|Family Therapy intervention
1347230|NCT00580502|Obesity, 50 lbs overweight
1347231|NCT00580489|helicopter
1347232|NCT00580489|aeromedical
1347233|NCT00580489|pain relief
1347234|NCT00580489|analgesia
1347235|NCT00580489|fentanyl
1347236|NCT00580489|morphine
1347237|NCT00580489|adverse events
1347238|NCT00580476|Breast Cancer
1347239|NCT00580476|Prostate Cancer
1347240|NCT00580463|central nervous system (CNS) tumor
1347241|NCT00580463|tissue collection
1347242|NCT00580385|BONE
1347243|NCT00580359|Stomach Neoplasms
1347244|NCT00580359|Secondary
1347245|NCT00580359|Combination chemotherapy
1347246|NCT00580359|S-1
1347247|NCT00580359|Capecitabine
1347248|NCT00580346|Aspiration pneumonia
1347249|NCT00580346|Implanted laryngeal stimulator
1347250|NCT00580346|Vocal cord closure
1347251|NCT00580346|Modified barium swallow
1347252|NCT00580333|ER negative
1347253|NCT00580333|PR negative
1347254|NCT00580333|HER2 negative
1347255|NCT00580320|melanoma
1347256|NCT00580320|soft tissue sarcoma
1347257|NCT00580320|APUD tumor
1347258|NCT00580320|dacarbazine
1347259|NCT00580320|bortezomib
1347260|NCT00580320|velcade
1347261|NCT00580307|Headache
1347262|NCT00580307|Rhinogenic
1347263|NCT00580307|Nose
1347264|NCT00580307|Nasal septum
1347265|NCT00580307|Deviated septum
1347266|NCT00580307|Surgery
1347267|NCT00580307|Septoplasty
1347268|NCT00580307|Turbinoplasty
1347269|NCT00580307|Contact point
1347270|NCT00580307|HIT-6
1347271|NCT00580294|Sciatica
1347272|NCT00580294|Diabetic Neuropathies
1347273|NCT00580294|Complex Regional Pain Syndromes
1347274|NCT00580294|Low Back Pain
1347275|NCT00580294|Neck Pain
1347276|NCT00580294|Headache
1347277|NCT00580294|Back Pain
1347278|NCT00580294|Arthritis
1347279|NCT00580294|Brachial Plexus Injury (stinger/burner)
1347280|NCT00580294|Chronic Pain
1347281|NCT00580294|Contractures
1347282|NCT00580294|Diabetes
1347283|NCT00580294|Fibromyalgia
1347284|NCT00580294|Foot Pain
1347285|NCT00580294|Fracture
1347286|NCT00580294|Hip
1347287|NCT00580294|Herpes Zoster (shingles)
1347288|NCT00580294|Migraine
1347289|NCT00580294|Neuropathic Pain
1347290|NCT00580294|Osteoarthritis
1347291|NCT00580294|Osteoporosis
1347292|NCT00580294|Rheumatoid Arthritis
1347293|NCT00580294|Scoliosis
1347294|NCT00580294|Nerve pain
1347295|NCT00580294|Opana
1347296|NCT00580294|Opioid
1347297|NCT00580294|Opioid Rotation
1347298|NCT00580294|Oxymorphone
1347299|NCT00580294|Morphine
1347300|NCT00580294|neuropathic
1347301|NCT00580294|oxycodone
1347302|NCT00580281|Gastric cancer
1347303|NCT00580281|Leukemia
1347304|NCT00580281|Chronic Myelogenous Leukemia
1347305|NCT00580281|Imatinib
1347306|NCT00580281|Gleevec
1347313|NCT00580242|Myelodysplasia
1347314|NCT00580229|Rituxan
1347315|NCT00580229|Rituximab
1347316|NCT00580216|stroke
1347317|NCT00580216|systemic thromboembolic events
1347318|NCT00580203|HEENT cancers
1347319|NCT00580203|larynx
1347320|NCT00580203|thyroid
1347321|NCT00580203|sarcoma
1347322|NCT00580203|specimen analysis
1347323|NCT00580177|Inguinal hernia
1347324|NCT00580177|Randomized controlled trial
1347325|NCT00580177|Surgery
1347326|NCT00580177|Complications
1347327|NCT00580177|Surgical mesh
1347328|NCT00580151|Pain not controled by morphine
1347329|NCT00580151|Anxiety not controled by lorazepam
1347330|NCT00580138|Deglutition Disorders
1347331|NCT00580138|Evaluation
1347332|NCT00580138|Real-time internet
1347333|NCT00580112|Breast Neoplasms
1347334|NCT00580112|Trabectedin
1347335|NCT00580112|Yondelis
1347336|NCT00580099|premature infant, body composition, total energy expenditure
1347337|NCT00580099|inflammatory growth mediators
1347338|NCT00580086|Breast cancer
1347339|NCT00580086|MR spectroscopy
1347340|NCT00580086|Neoadjuvant chemotherapy
1347341|NCT00580060|AJCC
1347342|NCT00580060|stage
1347343|NCT00580060|IIB
1347344|NCT00580060|IIC
1347345|NCT00580060|III
1347346|NCT00580060|IV
1347347|NCT00580060|Melanoma
1347348|NCT00580060|HLA-A2+
1347349|NCT00580060|Vaccine
1347350|NCT00580047|bone density
1347351|NCT00580047|osteopenia
1347352|NCT00580047|transplant
1347353|NCT00580047|zoledronic acid
1347354|NCT00580047|alendronate
1347355|NCT00580034|Allogeneic Stem Cell Transplantation, Campath, HLA-Matched
1347356|NCT00580021|Ashkenazi ancestry
1347357|NCT00580021|mutations in BRCA1 or BRCA2
1347358|NCT00580021|Breast Cancer
1347359|NCT00580021|Pancreatic Cancer
1347360|NCT00580008|tomography
1347361|NCT00580008|coronary artery disease
1347362|NCT00580008|coronary artery bypass grafting
1347363|NCT00580008|vein graft
1347364|NCT00579982|Mood disorder
1347365|NCT00579943|very low birth weight infant
1347366|NCT00579943|cerebral autoregulation
1347367|NCT00579943|intraventricular hemorrhage
1347368|NCT00579943|carbon dioxide
1347369|NCT00579943|cerebral blood flow velocity
1347370|NCT00579943|ultrasonography, Doppler, transcranial
1347371|NCT00579943|cerebrovascular circulation
1347372|NCT00579930|Bone
1347373|NCT00579930|Soft Tissue
1347374|NCT00579917|Survivor
1347375|NCT00579917|Behavioral Intervention
1347376|NCT00579917|Bone Marrow
1347377|NCT00579917|Stem Cell Transplantation
1347378|NCT00579904|PCOS
1347379|NCT00579904|polycystic ovary syndrome
1347380|NCT00579904|insulin resistance
1347381|NCT00579904|fish oil
1347382|NCT00579904|walnut-oil
1347383|NCT00579904|walnuts
1347384|NCT00579904|almonds
1347385|NCT00579904|monounsaturated fats
1347386|NCT00579904|polyunsaturated fats
1347387|NCT00579904|MUFA
1347388|NCT00579904|PUFA
1347389|NCT00579891|colorectal cancer
1347390|NCT00579891|tissue collection
1347391|NCT00579865|Quality of Life
1347392|NCT00579852|Lung
1347393|NCT00579839|PreTerm Birth
1347394|NCT00579839|PreTerm Neonate
1347395|NCT00579839|High risk pregnancy
1347396|NCT00579839|Preterm Baby
1347397|NCT00579839|Premature Baby
1347398|NCT00579839|Cord Clamping
1347399|NCT00579839|Milking the cord
1347400|NCT00579813|obesity
1347401|NCT00579813|inflammation
1347402|NCT00579813|diabetes
1347403|NCT00579800|Vibrant-DE
1347404|NCT00579800|IDEAL
1347405|NCT00579800|MRI
1347406|NCT00579800|Breast
1347407|NCT00579800|07-091
1347408|NCT00579787|cervical cancer
1347409|NCT00579787|quality of life assessment
1347410|NCT00579787|behavioral
1347411|NCT00579774|Aging
1347412|NCT00579774|oxidative stress
1347413|NCT00579774|glycoxidative stress
1347414|NCT00579774|glycation
1347415|NCT00579774|inflammation
1347416|NCT00579774|nutrition
1347417|NCT00579774|low AGE intake
1347418|NCT00579774|dietary AGEs
1347419|NCT00579761|Endocarditis
1347420|NCT00579761|neurological deficit
1347421|NCT00579748|OCT imaging
1347422|NCT00579748|Barrett's esophagus
1347423|NCT00579735|Breast cancer
1347424|NCT00579709|Thymus Transplantation
1347425|NCT00579709|DiGeorge Anomaly
1347426|NCT00579709|DiGeorge Syndrome
1347427|NCT00579709|Athymia
1347428|NCT00579709|Low T cell numbers
1347429|NCT00579709|Immunoreconstitution
1347430|NCT00579709|Immunodeficiency
1347431|NCT00579709|Complete DiGeorge
1347432|NCT00579709|Typical DiGeorge
1347433|NCT00579709|Atypical DiGeorge
1347434|NCT00579709|Complete DiGeorge Anomaly
1347435|NCT00579696|Multiple Diseases
1347436|NCT00579696|Queens
1347437|NCT00579683|non-small cell lung cancer
1347438|NCT00579683|NSCLC
1347439|NCT00579683|metastatic disease
1347440|NCT00579683|resistent disease
1347441|NCT00579683|RNA analysis
1347442|NCT00579683|04-103
1347443|NCT00579670|Ziprasidone in patients with schizophrenia
1347444|NCT00579657|parameters of metabolic syndrome
1347445|NCT00579631|survivors
1347446|NCT00579631|adolescent
1347447|NCT00579631|pediatric
1347448|NCT00579618|non-cancer affected volunteers
1347449|NCT00579618|aged 60 years or older
1347450|NCT00579605|Breastfeeding
1347451|NCT00579605|Self-efficacy
1347452|NCT00579605|Motivational Interviewing
1347453|NCT00579579|Bowel function
1347454|NCT00579579|Bladder function
1347455|NCT00579579|Sexual function
1347456|NCT00579579|Quality of life
1347457|NCT00579566|Biochemical Determinants
1347458|NCT00579566|Molecular Determinants
1347459|NCT00579553|Pre Term
1347460|NCT00579553|Pre Term Birth
1347461|NCT00579553|Premature Birth
1347462|NCT00579553|Premature baby
1347463|NCT00579553|High risk pregnancy
1347464|NCT00579553|Progesterone
1347465|NCT00579553|IM Progesterone
1347466|NCT00579553|Vaginal Progesterone
1347467|NCT00579527|DiGeorge Anomaly
1347468|NCT00579527|Thymus Transplantation
1347469|NCT00579527|DiGeorge Syndrome
1347470|NCT00579527|Athymia
1347471|NCT00579527|Parathyroid Transplantation
1347472|NCT00579527|Hypocalcemia
1347473|NCT00579527|Hypoparathyroidism
1347474|NCT00579527|Low T cell numbers
1347475|NCT00579527|Immunoreconstitution
1347476|NCT00579527|Immunodeficiency
1347477|NCT00579527|Complete DiGeorge Anomaly
1347478|NCT00579527|Complete Atypical DiGeorge Anomaly
1347479|NCT00579527|Complete DiGeorge Syndrome
1347480|NCT00579527|Complete Atypical DiGeorge Syndrome
1347481|NCT00579501|Myxoid
1347482|NCT00579501|Liposarcoma
1347483|NCT00579501|Trabectedin
1347484|NCT00579501|Dexamethasone
1347485|NCT00579475|mifepristone
1347486|NCT00579475|leiomyomas
1347487|NCT00579475|breast epithelial cell proliferation
1347488|NCT00579462|Stage III or IV Lung Cancer
1347489|NCT00579449|child abuse
1347490|NCT00579449|child neglect
1347491|NCT00579436|inflammation
1347492|NCT00579436|obesity
1347493|NCT00579436|diabetes
1347494|NCT00579423|prostate
1347495|NCT00579423|cancer
1347496|NCT00579423|vaccine
1347497|NCT00579410|gastric acid
1347498|NCT00579410|esophageal reflux
1347499|NCT00579410|peptic ulcer
1347500|NCT00579410|heartburn
1347501|NCT00579397|Markers of Inflammation
1347502|NCT00579397|acute graft versus host disease
1347503|NCT00579397|predicting aGVHD
1347504|NCT00579384|Photosensitive epilepsy
1347505|NCT00579384|Reflex epilepsy
1347506|NCT00579384|Epilepsy
1347507|NCT00579384|JNJ-26489112
1347508|NCT00579371|islet transplantation
1347509|NCT00579371|type 1 diabetes mellitus
1347510|NCT00579371|steroid-free immunosuppression
1347511|NCT00579371|rabbit anti-thymocyte globulin
1347512|NCT00579358|Congenital heart defects
1347513|NCT00579332|PSA
1347514|NCT00579332|biochemical failure
1347515|NCT00579319|breast cancer
1347516|NCT00579306|hypertension
1347517|NCT00579306|stroke
1347518|NCT00579306|cerebrovascular accident
1347519|NCT00579293|adult survivor of childhood cancer
1347520|NCT00579293|computer assisted screening of survivors (CASS)
1347521|NCT00579280|Randomized
1347522|NCT00579280|Double-Blind
1347523|NCT00579280|Placebo-Controlled
1347524|NCT00579280|Quetiapine
1347525|NCT00579280|DivalproexSodiumER
1347526|NCT00579280|Bipolar
1347527|NCT00579280|Anxiety
1347528|NCT00579280|Panic
1347529|NCT00579280|GAD
1347530|NCT00579267|MINI-KID
1347531|NCT00579267|structured diagnostic interview
1347532|NCT00579267|reliability and validity
1347533|NCT00579267|K-SADS
1347534|NCT00579267|Sheehan Disability Scale
1347535|NCT00579254|Efficacy,safety & tolerability of Caduet In Patients With Cardiovascular Risk Factors
1347536|NCT00579228|Diabetes
1347537|NCT00579228|Vascular risk
1347538|NCT00579228|Inflammation
1347539|NCT00579215|Cancer
1347540|NCT00579215|Enhanced Care
1347541|NCT00579215|Decision-Making
1347542|NCT00579215|Advance Lung Cancer
1347543|NCT00579215|Questionaires
1347544|NCT00579215|Stage III Lung Cancer
1347545|NCT00579215|Stage IV Lung Cancer
1347546|NCT00579202|Dialyzer
1347547|NCT00579189|ear tubes
1347548|NCT00579189|ear drainage
1347549|NCT00579189|ear infection
1347550|NCT00579189|ear drops
1347551|NCT00579163|Blood
1347552|NCT00579163|Salvia
1347553|NCT00579163|Tissue
1347554|NCT00579150|Birth Defects
1347555|NCT00579150|High Risk Pregnancy
1347556|NCT00579150|Type 2 Diabetes
1347557|NCT00579137|Severe Combined Immunodeficiency Disease
1347558|NCT00579137|Severe Primary Immunodeficiency Disorder
1347559|NCT00579137|Undefined T cell Deficiency Disorder
1347560|NCT00579137|Wiskott-Aldrick Syndrome
1347561|NCT00579137|Allogeneic stem cell transplant
1347562|NCT00579137|Fludarabine
1347563|NCT00579137|monoclonal antibodies
1347564|NCT00579124|Blood and Marrow Transplant
1347565|NCT00579124|T cell Depletion
1347566|NCT00579124|Unrelated
1347567|NCT00579124|Related
1347568|NCT00579124|Donor
1347569|NCT00579111|Myelodysplastic and Myeloproliferative Disorders
1347570|NCT00579111|Acute Myelogenous Leukemia
1347571|NCT00579111|Acute Lymphoblastic Leukemia
1347572|NCT00579111|Chronic Myelogenous Leukemia
1347573|NCT00579111|Multiple Myeloma
1347574|NCT00579111|Plasma Cell dyscrasia
1347575|NCT00579111|Lymphoproliferative disorders
1347576|NCT00579111|Hematologic Diseases
1347577|NCT00579111|Fludarabine
1347578|NCT00579111|Busulfan
1347579|NCT00579111|Campath
1347580|NCT00579111|Alemtuzumab
1347581|NCT00579111|allogeneic stem cell transplant
1347582|NCT00579098|Atrial Fibrillation
1347583|NCT00579098|Arrhythmia
1347584|NCT00579098|Pulmonary Vein Isolation
1347585|NCT00579098|Left atrial catheter ablation
1347586|NCT00579098|Inflammation
1347587|NCT00579098|Endothelial dysfunction
1347588|NCT00579072|Prostate
1347589|NCT00579072|cognitive effects
1347590|NCT00579072|06-084
1347591|NCT00579046|Anemia
1347592|NCT00579046|Chronic obstructive Pulmonary Disease
1347593|NCT00579046|Erythropoietin
1347594|NCT00579046|6-minute walk test
1347595|NCT00579033|somatosensory
1347596|NCT00579033|cortex
1347597|NCT00579033|neuroimaging
1347598|NCT00579033|tactile
1347599|NCT00579033|cortical plasticity
1347600|NCT00579033|dystonia
1347601|NCT00579020|cornea
1347602|NCT00579020|inflammation
1347603|NCT00579020|blepharitis
1347604|NCT00579020|lid infection
1347605|NCT00579007|Prophylactic Mastectomy
1347606|NCT00579007|Prophylactic Oophorectomy
1347607|NCT00578994|Unicompartmental Knee
1347608|NCT00578994|Partial Knee
1347609|NCT00578994|Knee arthroplasty
1347610|NCT00578981|Osteoporosis, age-related
1347611|NCT00578981|Osteoporosis, Postmenopausal
1347612|NCT00578981|Bone Loss
1347613|NCT00578981|Low Bone Density
1347614|NCT00578968|COPD
1347615|NCT00578968|Tiotropium
1347616|NCT00578968|Spiriva
1347617|NCT00578955|Blepharoconjunctivitis, Ophthalmology
1347618|NCT00578942|Allogeneic Stem Cell Transplantation, Campath, HLA-Matched
1347619|NCT00578929|allergic rhinitis
1347620|NCT00578929|allergies
1347621|NCT00578929|seasonal allergies
1347622|NCT00578903|Severe Aplastic Anemia
1347623|NCT00578903|Severe
1347624|NCT00578890|diabetic foot
1347625|NCT00578890|osteomyelitis
1347626|NCT00578877|Contraception
1347627|NCT00578877|SILCS Diaphragm
1347628|NCT00578877|Contraceptive Gel
1347629|NCT00578864|Neuroblastoma
1347630|NCT00578864|Etoposide
1347631|NCT00578864|Cisplatin
1347632|NCT00578864|Adriamycin
1347633|NCT00578864|Cyclophosphamide
1347634|NCT00578864|Cytoxan
1347637|NCT00578825|Severe acute respiratory syndrome
1347638|NCT00578799|ulcerative colitis
1347639|NCT00578773|ear tubes
1347640|NCT00578773|ear infection
1347641|NCT00578773|ear drops
1347642|NCT00578773|ear tube surgery
1347643|NCT00578773|acute otitis media
1347644|NCT00578760|hearing loss
1347645|NCT00578760|ototoxicity
1347646|NCT00578760|cisplatin
1347647|NCT00578747|Breast Cancer
1347648|NCT00578747|Breast Neoplasms
1347649|NCT00578747|Targeted Radiotherapy
1347650|NCT00578747|Mastectomy
1347651|NCT00578747|Seroma
1347652|NCT00578721|Colorectal cancer
1347653|NCT00578721|aspirin
1347654|NCT00578708|membranous
1347655|NCT00578708|ventricular
1347656|NCT00578708|septal
1347657|NCT00578708|defect
1347658|NCT00578708|VSD
1347659|NCT00578695|Hyponatremia
1347660|NCT00578695|Serum Sodium
1347661|NCT00578695|Fluid Overload
1347662|NCT00578695|Heart Failure
1347663|NCT00578695|Acute Heart Failure
1347664|NCT00578695|Vasopressin Antagonist
1347665|NCT00578669|Smoking Cessation
1347666|NCT00578669|Tobacco Use Cessation
1347667|NCT00578669|Antidepressants
1347668|NCT00578656|Food Allergy
1347669|NCT00578656|Milk Allergy
1347670|NCT00578643|Stem Cell Transplant
1347671|NCT00578643|Chronic Granulomatous Disease
1347672|NCT00578643|Fludarabine
1347673|NCT00578643|Busulfan
1347674|NCT00578643|Cyclophosphamide
1347675|NCT00578630|pediatric tumors
1347676|NCT00578630|genetic test development
1347677|NCT00578630|All Pediatric patients with a histologically proven tumor.
1347678|NCT00578617|Atrial fibrillation
1347679|NCT00578617|Left Atrial Ablation
1347680|NCT00578617|Pulmonary Vein Isolation
1347681|NCT00578617|Catheter Ablation
1347682|NCT00578617|Antiarrhythmic Drug Therapy
1347683|NCT00578591|Graft Versus Host Disease
1347684|NCT00578591|GVHD
1347685|NCT00578591|allogeneic hematopoietic transplant
1347686|NCT00578591|AHT
1347687|NCT00578591|posttransplant
1347688|NCT00578591|Rituximab
1347689|NCT00578578|Omega3 fatty acids
1347690|NCT00578578|hsCRP
1347691|NCT00578578|CAD
1347692|NCT00578565|Rheumatoid Arthritis
1347693|NCT00578565|Interstitial Pneumonia
1347694|NCT00578565|Rheumatology
1347695|NCT00578565|Rituximab
1347696|NCT00578552|tobacco
1347697|NCT00578552|smoking
1347698|NCT00578552|gabapentin
1347699|NCT00578552|abstinence
1347700|NCT00578539|Stem Cell Transplantation
1347701|NCT00578526|urothelial cancer
1347702|NCT00578526|targeted therapy
1347703|NCT00578526|antiangiogenesis therapy
1347704|NCT00578526|SU011248
1347705|NCT00578526|clinical trial
1347706|NCT00577655|Pediatric, asthma, albuterol-HFA and Placebo
1347707|NCT00577642|aminobisphosphonates
1347708|NCT00577629|high risk non-hodgkins lymphoma
1347709|NCT00577629|NHL
1347710|NCT00577629|Bexxar
1347711|NCT00577629|high dose chemotherapy
1347712|NCT00577616|Endovascular repair
1347713|NCT00577616|Ruptured aorta-iliac aneurysms
1347714|NCT00577616|Mortality at 30 days
1347715|NCT00577603|stoma, hernia, mesh
1347716|NCT00578500|chemotherapy, female, fertility preservation, gonadotoxicity
1347717|NCT00578500|oophorectomy, in vitro maturation, ovarian cryopreservation,
1347718|NCT00578500|oocyte cryopreservation, ovarian transplantation
1347719|NCT00578474|Acute otitis media
1347720|NCT00578474|Tympanostomy tubes
1347721|NCT00578461|Stem Cell Transplant
1347722|NCT00578461|myeloproliferative disease
1347723|NCT00578461|myelodsyplastic disease
1347724|NCT00578461|Leukemia
1347725|NCT00578461|Cancer
1347726|NCT00578461|Lymphoma
1347727|NCT00578461|Lymphoma, Hodgkin
1347728|NCT00578461|Lymphoma, non-Hodgkin
1347729|NCT00578435|ERYTHROPOIESIS
1347730|NCT00578435|Genetic Disorders
1347731|NCT00578435|Sickle Cell Anemia
1347732|NCT00578435|Thalassemia
1347733|NCT00578435|Diamond Blackfan Anemia
1347734|NCT00578422|PAD
1347735|NCT00578422|Peripheral Artery Disease
1347736|NCT00578422|IVUS
1347737|NCT00578422|Plaque
1347738|NCT00578409|castration resistant prostate cancer
1347739|NCT00578409|progressive castrate metastatic prostate cancer
1347740|NCT00578396|Grapes and colon cancer prevention
1347741|NCT00578383|Depression
1347742|NCT00578383|Major depression
1347743|NCT00578383|Bipolar Disorder
1347744|NCT00578383|Bipolar depression
1347745|NCT00578383|LFMS
1347746|NCT00578383|low field magnetic stimulation
1347747|NCT00578383|mood disorders
1347748|NCT00578383|affective disorders
1347749|NCT00578370|Ciclosporin
1347750|NCT00578370|Plaque type psoriasis
1347751|NCT00578370|Psoriasis plaque test
1347752|NCT00578370|Sonography
1347753|NCT00578370|Cyclosporin
1347754|NCT00578370|Psoriasis
1347755|NCT00578357|problem gambling
1347756|NCT00578357|personalized feedback
1347757|NCT00578357|gambling addiction
1347758|NCT00578344|Sickle Cell Disease
1347759|NCT00578344|SCD
1347760|NCT00578344|Hemoglobin SS
1347761|NCT00578344|Hemoglobin SC
1347762|NCT00578344|Hemoglobin Sb0/+
1347763|NCT00578344|HLA genotype
1347764|NCT00578344|Severe anemia
1347765|NCT00578344|Transfusion therapy
1347766|NCT00578331|rhinitis
1347767|NCT00578331|perennial allergic rhinitis
1347768|NCT00578331|allergic rhinitis
1347769|NCT00578292|transfusion-dependent
1347770|NCT00578292|homozygous b0/+-thalassemia
1347771|NCT00578292|severe variants of b0/+-thalassemia
1347772|NCT00578292|chronic transfusion therapy
1347773|NCT00578292|iron chelating agents
1347774|NCT00578292|severe
1347775|NCT00578292|transfusion-dependent homozygous b0/+-thalassemia or severe variants of b0/+-thalassemia
1347776|NCT00578266|Severe Aplastic Anemia (SAA)
1347777|NCT00578266|Transplant for Severe Aplastic Anemia (SAA)
1347778|NCT00578240|benign
1347779|NCT00578240|Rising PSA
1347780|NCT00578240|Clinical Metastases
1347781|NCT00578240|90-040
1347782|NCT00578227|Human papillomavirus infection,
1347783|NCT00578227|cervical cancer
1347784|NCT00578227|HPV vaccine,
1347785|NCT00578214|mohs micrographic surgery
1347786|NCT00578214|skin cancer
1347787|NCT00578214|anxiety
1347788|NCT00578214|basal cell carcinoma
1347789|NCT00578214|squamous cell carcinoma
1347790|NCT00578214|midazolam
1347791|NCT00578214|versed
1347792|NCT00578201|Esophageal neoplasms
1347793|NCT00578201|Cetuximab
1347794|NCT00578201|Oxaliplatin
1347795|NCT00578201|Fluorouracil
1347796|NCT00578201|radiotherapy
1347797|NCT00578188|Adolescent Health
1347798|NCT00578188|Sexually transmitted infection
1347799|NCT00578188|Women's Health
1347800|NCT00578175|Vaccines
1347801|NCT00578175|Rubella
1347802|NCT00578175|Varicella Vaccine
1347803|NCT00578175|Children
1347804|NCT00578175|Humans
1347805|NCT00578175|Mumps
1347806|NCT00578175|Immunogenicity
1347807|NCT00578175|Safety
1347808|NCT00578175|Measles
1347809|NCT00578175|Combined Vaccine
1347810|NCT00578162|Cancer
1347811|NCT00578162|Survivors
1347812|NCT00578149|chemoradiotherapy
1347813|NCT00578149|Lung cancer
1347814|NCT00578136|Rectus Sheath
1347815|NCT00578136|Local infiltration
1347816|NCT00578136|Pain Control
1347817|NCT00578123|Prostate
1347818|NCT00578123|Cancer
1347819|NCT00578123|Quality of Life
1347820|NCT00578123|Questionaires
1347821|NCT00578123|04-094
1347822|NCT00578110|glaucoma VEP detection device diagnosis vision
1347823|NCT00578071|esophageal cancer
1347824|NCT00578032|head
1347825|NCT00578032|neck
1347826|NCT00578032|cancer
1347827|NCT00578032|reconstruction
1347828|NCT00578032|quality of life
1347829|NCT00578032|07-150
1347830|NCT00578019|Comparative
1347831|NCT00578019|Supracondylar Femur Fracture
1347832|NCT00578019|Intramedullary nailing
1347833|NCT00578019|Less Invasive Stabilization System (LISS) Plating
1347834|NCT00578006|toxicity related symptoms
1347835|NCT00578006|04-020
1347836|NCT00577993|Lymphoma
1347837|NCT00577993|Follicular Lymphoma
1347838|NCT00577993|Indolent Lymphoma
1347839|NCT00577993|Fludarabine
1347840|NCT00577993|Novantrone
1347841|NCT00577993|Mitoxantrone
1347842|NCT00577993|Decadron
1347843|NCT00577993|Dexamethasone
1347844|NCT00577993|Rituximab
1347845|NCT00577993|Anti-CD20
1347846|NCT00577993|IDEC-C2B8
1347847|NCT00577993|Chimeric Anti-CD20 Antibody
1347848|NCT00577993|Interferon
1347849|NCT00577993|Interferon Alpha-2b
1347850|NCT00577993|IFN
1347851|NCT00577993|Doxorubicin
1347852|NCT00577993|Vincristine
1347853|NCT00577993|Bleomycin
1347854|NCT00577993|Cyclophosphamide
1347855|NCT00577993|Etoposide
1347856|NCT00577993|Cisplatin
1347857|NCT00577993|Ara-C
1347858|NCT00577993|Methyl-Prednisolone
1347859|NCT00577993|Procarbazine
1347860|NCT00577993|Prednisone
1347861|NCT00577993|FND
1347862|NCT00577980|Prostate Cancer
1347863|NCT00577980|Castration-Resistant Prostate Cancer
1347864|NCT00577980|Testosterone Replacement Therapy
1347865|NCT00577980|Testosterone
1347866|NCT00577980|CRPC
1347867|NCT00577980|TRT
1347868|NCT00577967|Uremic pruritis
1347869|NCT00577954|Coma
1347870|NCT00577954|TBI
1347871|NCT00577954|Stroke
1347872|NCT00577954|SAH
1347873|NCT00577954|Cerebral Anoxia
1347874|NCT00577954|Multimodal MRI
1347875|NCT00577915|Breast cancer
1347876|NCT00577915|MRI spectroscopy
1347877|NCT00577915|Diagnostic radiology
1347878|NCT00577902|head and neck cancer
1347879|NCT00577824|diabetes
1347880|NCT00577824|exenatide
1347881|NCT00577824|LY2148568
1347882|NCT00577824|Byetta
1347883|NCT00577824|Lilly
1347884|NCT00577824|Amylin
1347885|NCT00577811|Special Need Plans
1347886|NCT00577811|Fee for Services
1347887|NCT00577811|Access to Care
1347888|NCT00577811|Medicaid
1347889|NCT00577798|chemotherapeutic agent toxicity
1347890|NCT00577798|cardiac toxicity
1347891|NCT00577798|stage I adult Hodgkin lymphoma
1347892|NCT00577798|stage II adult Hodgkin lymphoma
1347893|NCT00577798|stage III adult Hodgkin lymphoma
1347894|NCT00577798|stage IV adult Hodgkin lymphoma
1347895|NCT00577798|stage I adult T-cell leukemia/lymphoma
1347896|NCT00577798|stage II adult T-cell leukemia/lymphoma
1347897|NCT00577798|stage III adult T-cell leukemia/lymphoma
1347898|NCT00577798|stage IV adult T-cell leukemia/lymphoma
1347899|NCT00577798|anaplastic large cell lymphoma
1347900|NCT00577798|angioimmunoblastic T-cell lymphoma
1347901|NCT00577798|cutaneous B-cell non-Hodgkin lymphoma
1347902|NCT00577798|stage I mycosis fungoides/Sezary syndrome
1347903|NCT00577798|stage II mycosis fungoides/Sezary syndrome
1347904|NCT00577798|stage III mycosis fungoides/Sezary syndrome
1347905|NCT00577798|stage IV mycosis fungoides/Sezary syndrome
1347906|NCT00577798|stage I cutaneous T-cell non-Hodgkin lymphoma
1347907|NCT00577798|stage II cutaneous T-cell non-Hodgkin lymphoma
1347908|NCT00577798|stage III cutaneous T-cell non-Hodgkin lymphoma
1347909|NCT00577798|stage IV cutaneous T-cell non-Hodgkin lymphoma
1347910|NCT00577798|adult grade III lymphomatoid granulomatosis
1347911|NCT00577798|adult nasal type extranodal NK/T-cell lymphoma
1347912|NCT00577798|Waldenstrom macroglobulinemia
1347913|NCT00577798|contiguous stage II adult Burkitt lymphoma
1347914|NCT00577798|noncontiguous stage II adult Burkitt lymphoma
1347915|NCT00577798|stage I adult Burkitt lymphoma
1347916|NCT00577798|stage III adult Burkitt lymphoma
1347917|NCT00577798|stage IV adult Burkitt lymphoma
1347918|NCT00577798|contiguous stage II adult diffuse large cell lymphoma
1347919|NCT00577798|noncontiguous stage II adult diffuse large cell lymphoma
1347920|NCT00577798|stage I adult diffuse large cell lymphoma
1347921|NCT00577798|stage III adult diffuse large cell lymphoma
1347922|NCT00577798|stage IV adult diffuse large cell lymphoma
1347923|NCT00577798|contiguous stage II adult diffuse mixed cell lymphoma
1347924|NCT00577798|noncontiguous stage II adult diffuse mixed cell lymphoma
1347925|NCT00577798|stage I adult diffuse mixed cell lymphoma
1347926|NCT00577798|stage III adult diffuse mixed cell lymphoma
1347927|NCT00577798|stage IV adult diffuse mixed cell lymphoma
1347928|NCT00577798|contiguous stage II adult diffuse small cleaved cell lymphoma
1347929|NCT00577798|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1347930|NCT00577798|stage I adult diffuse small cleaved cell lymphoma
1347931|NCT00577798|stage III adult diffuse small cleaved cell lymphoma
1347932|NCT00577798|stage IV adult diffuse small cleaved cell lymphoma
1347933|NCT00577798|contiguous stage II adult immunoblastic large cell lymphoma
1347934|NCT00577798|noncontiguous stage II adult immunoblastic large cell lymphoma
1347935|NCT00577798|stage I adult immunoblastic large cell lymphoma
1347936|NCT00577798|stage III adult immunoblastic large cell lymphoma
1347937|NCT00577798|stage IV adult immunoblastic large cell lymphoma
1347938|NCT00577798|contiguous stage II adult lymphoblastic lymphoma
1347939|NCT00577798|noncontiguous stage II adult lymphoblastic lymphoma
1347940|NCT00577798|stage I adult lymphoblastic lymphoma
1347941|NCT00577798|stage III adult lymphoblastic lymphoma
1347942|NCT00577798|stage IV adult lymphoblastic lymphoma
1347943|NCT00577798|contiguous stage II grade 1 follicular lymphoma
1347944|NCT00577798|noncontiguous stage II grade 1 follicular lymphoma
1347945|NCT00577798|stage I grade 1 follicular lymphoma
1347946|NCT00577798|stage III grade 1 follicular lymphoma
1347947|NCT00577798|stage IV grade 1 follicular lymphoma
1347948|NCT00577798|contiguous stage II grade 2 follicular lymphoma
1347949|NCT00577798|noncontiguous stage II grade 2 follicular lymphoma
1347950|NCT00577798|stage I grade 2 follicular lymphoma
1347951|NCT00577798|stage III grade 2 follicular lymphoma
1347952|NCT00577798|stage IV grade 2 follicular lymphoma
1347953|NCT00577798|contiguous stage II grade 3 follicular lymphoma
1347954|NCT00577798|noncontiguous stage II grade 3 follicular lymphoma
1347955|NCT00577798|stage I grade 3 follicular lymphoma
1347956|NCT00577798|stage III grade 3 follicular lymphoma
1347957|NCT00577798|stage IV grade 3 follicular lymphoma
1347958|NCT00577798|contiguous stage II mantle cell lymphoma
1347959|NCT00577798|noncontiguous stage II mantle cell lymphoma
1347960|NCT00577798|stage I mantle cell lymphoma
1347961|NCT00577798|stage III mantle cell lymphoma
1347962|NCT00577798|stage IV mantle cell lymphoma
1347963|NCT00577798|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1347964|NCT00577798|nodal marginal zone B-cell lymphoma
1347965|NCT00577798|splenic marginal zone lymphoma
1347966|NCT00577798|contiguous stage II marginal zone lymphoma
1347967|NCT00577798|noncontiguous stage II marginal zone lymphoma
1347968|NCT00577798|stage I marginal zone lymphoma
1347969|NCT00577798|stage III marginal zone lymphoma
1347970|NCT00577798|stage IV marginal zone lymphoma
1347971|NCT00577798|contiguous stage II small lymphocytic lymphoma
1347972|NCT00577798|noncontiguous stage II small lymphocytic lymphoma
1347973|NCT00577798|stage I small lymphocytic lymphoma
1347974|NCT00577798|stage III small lymphocytic lymphoma
1347975|NCT00577798|stage IV small lymphocytic lymphoma
1347976|NCT00577785|cystectomy
1347977|NCT00577772|SmartPill Capsule
1347978|NCT00577772|Digestive System Diseases
1347979|NCT00577772|Small Bowel Bacterial Overgrowth
1347980|NCT00577772|Gastrointestinal Device
1347981|NCT00577772|Oro-cecal
1347982|NCT00577759|Quality assurance, health care
1347983|NCT00577759|primary health care
1347984|NCT00577759|community health services
1347985|NCT00577759|referral and consultation
1347986|NCT00577759|exercise
1347987|NCT00577759|diet
1347988|NCT00577759|tobacco
1347989|NCT00577746|Non Small Cell Lung
1347990|NCT00577733|Pulmonary function test
1347991|NCT00577733|Methacholine challenge
1347992|NCT00577733|Breathing variability
1347993|NCT00577733|Polygraphy
1347994|NCT00577707|Lung Cancer
1347995|NCT00577707|Erlotinib
1347996|NCT00577707|clinical stage IB-IIIA
1347997|NCT00577694|recurrent adult acute myeloid leukemia
1347998|NCT00577681|HIV
1347999|NCT00577681|Lipoproteins
1348000|NCT00577681|Inflammatory Markers
1348001|NCT00577681|Coagulation Markers
1348002|NCT00577681|Treatment Experienced
1348003|NCT00577590|Type II Diabetes Mellitus
1348004|NCT00577590|Diabetes
1348005|NCT00577590|PET
1348006|NCT00577590|Heart Metabolism
1348007|NCT00577590|Lovaza
1348008|NCT00577525|LATENT VIRAL INFECTION
1348009|NCT00577525|GENOME HYBRIDIZATION
1348010|NCT00577525|HERPES VIRUS
1348011|NCT00577525|ADENOVIRUS
1348012|NCT00577499|cystic fibrosis
1348013|NCT00577499|constipation
1348014|NCT00577499|lubiprostone
1348015|NCT00577499|nutrition
1348016|NCT00577499|pulmonary function
1348017|NCT00577447|autism
1348018|NCT00577447|omega-3 fatty acids
1348019|NCT00577447|docosahexaenoic acid
1348020|NCT00577434|Procedural sedation
1348021|NCT00577434|Sedation for diagnostic imaging
1348022|NCT00577408|Opiate Dependence
1348023|NCT00577408|Heroin Dependence
1348024|NCT00577408|Naltrexone
1348025|NCT00577382|Sutent
1348026|NCT00577382|malignant melanoma
1348027|NCT00577369|arterial line
1348028|NCT00577369|end-expiratory desflurane
1348029|NCT00577304|Raynaud's
1348030|NCT00577304|Nitroglycerin
1348031|NCT00577304|Scleroderma
1348032|NCT00577278|graft versus host disease
1348033|NCT00577278|contiguous stage II grade 1 follicular lymphoma
1348034|NCT00577278|contiguous stage II grade 2 follicular lymphoma
1348035|NCT00577278|contiguous stage II grade 3 follicular lymphoma
1348036|NCT00577278|noncontiguous stage II grade 1 follicular lymphoma
1348037|NCT00577278|noncontiguous stage II grade 2 follicular lymphoma
1348038|NCT00577278|noncontiguous stage II grade 3 follicular lymphoma
1348039|NCT00577278|recurrent grade 1 follicular lymphoma
1348040|NCT00577278|recurrent grade 2 follicular lymphoma
1348041|NCT00577278|recurrent grade 3 follicular lymphoma
1348042|NCT00577278|stage I grade 1 follicular lymphoma
1348043|NCT00577278|stage I grade 2 follicular lymphoma
1348044|NCT00577278|stage I grade 3 follicular lymphoma
1348045|NCT00577278|stage III grade 1 follicular lymphoma
1348046|NCT00577278|stage III grade 2 follicular lymphoma
1348047|NCT00577278|stage III grade 3 follicular lymphoma
1348048|NCT00577278|stage IV grade 1 follicular lymphoma
1348049|NCT00577278|stage IV grade 2 follicular lymphoma
1348050|NCT00577278|stage IV grade 3 follicular lymphoma
1348051|NCT00577278|contiguous stage II adult diffuse large cell lymphoma
1348052|NCT00577278|noncontiguous stage II adult diffuse large cell lymphoma
1348053|NCT00577278|recurrent adult diffuse large cell lymphoma
1348054|NCT00577278|stage I adult diffuse large cell lymphoma
1348055|NCT00577278|stage III adult diffuse large cell lymphoma
1348056|NCT00577278|stage IV adult diffuse large cell lymphoma
1348057|NCT00577278|Waldenstrom macroglobulinemia
1348058|NCT00577278|contiguous stage II marginal zone lymphoma
1348059|NCT00577278|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1348060|NCT00577278|nodal marginal zone B-cell lymphoma
1348061|NCT00577278|noncontiguous stage II marginal zone lymphoma
1348062|NCT00577278|recurrent marginal zone lymphoma
1348063|NCT00577278|stage I marginal zone lymphoma
1348064|NCT00577278|stage III marginal zone lymphoma
1348065|NCT00577278|stage IV marginal zone lymphoma
1348066|NCT00577278|B-cell chronic lymphocytic leukemia
1348067|NCT00577278|refractory chronic lymphocytic leukemia
1348068|NCT00577278|stage I chronic lymphocytic leukemia
1348069|NCT00577278|stage II chronic lymphocytic leukemia
1348070|NCT00577278|stage III chronic lymphocytic leukemia
1348071|NCT00577278|stage IV chronic lymphocytic leukemia
1348072|NCT00577278|contiguous stage II mantle cell lymphoma
1348073|NCT00577278|noncontiguous stage II mantle cell lymphoma
1348074|NCT00577278|recurrent mantle cell lymphoma
1348075|NCT00577278|stage I mantle cell lymphoma
1348076|NCT00577278|stage III mantle cell lymphoma
1348077|NCT00577278|stage IV mantle cell lymphoma
1348078|NCT00577278|contiguous stage II adult diffuse mixed cell lymphoma
1348079|NCT00577278|noncontiguous stage II adult diffuse mixed cell lymphoma
1348080|NCT00577278|recurrent adult diffuse mixed cell lymphoma
1348081|NCT00577278|stage I adult diffuse mixed cell lymphoma
1348082|NCT00577278|stage III adult diffuse mixed cell lymphoma
1348083|NCT00577278|stage IV adult diffuse mixed cell lymphoma
1348084|NCT00577278|contiguous stage II small lymphocytic lymphoma
1348085|NCT00577278|noncontiguous stage II small lymphocytic lymphoma
1348086|NCT00577278|recurrent small lymphocytic lymphoma
1348087|NCT00577278|stage I small lymphocytic lymphoma
1348088|NCT00577278|stage III small lymphocytic lymphoma
1348089|NCT00577278|stage IV small lymphocytic lymphoma
1348090|NCT00577265|Asthma Control
1348091|NCT00577252|Cystic fibrosis
1348092|NCT00577252|Adolescents
1348093|NCT00577252|Coping Compliance
1348094|NCT00577252|Adjustment
1348095|NCT00577226|scoliosis, immature spine
1348096|NCT00577213|Diagnosis
1348097|NCT00577213|Hemangiomas
1348098|NCT00577213|Vascular Malformations
1348099|NCT00577213|Venular Malformations
1348100|NCT00577213|Venous Malformations
1348101|NCT00577213|Lymphatic Malformations
1348102|NCT00577213|Arteriovenous Malformations
1348103|NCT00577174|Children
1348104|NCT00577174|Obesity
1348105|NCT00577174|Insulin resistance
1348106|NCT00577174|Diabetes
1348107|NCT00577174|Mitochondrial Function
1348108|NCT00577161|pixantrone
1348109|NCT00577161|NHL
1348110|NCT00577161|rituximab
1348111|NCT00577161|fludarabine
1348112|NCT00577148|NASH
1348113|NCT00577148|chronic liver disease
1348114|NCT00577135|Loop Diuretics
1348115|NCT00577135|Furosemide
1348116|NCT00577135|Fluid Overload
1348117|NCT00577135|Cardio Renal Failure
1348118|NCT00577122|Medroxyprogesterone progesterone acetate (MPA)
1348119|NCT00577122|Cyclophosphamide plus Methotrexate
1348120|NCT00577096|multiple myeloma
1348121|NCT00577096|polysomnography
1348122|NCT00577096|quality of life
1348123|NCT00577096|exercise
1348124|NCT00577083|miss rates
1348125|NCT00577057|Nasopharyngeal Carcinoma
1348126|NCT00577057|Stage III - IVB
1348127|NCT00577044|NAFLD
1348128|NCT00577005|GABAergic
1348129|NCT00577005|levetiracetam
1348130|NCT00576992|Barrett's Esophagus
1348131|NCT00576992|Demographics
1348132|NCT00576992|Questionnaire
1348133|NCT00576992|Heartburn
1348134|NCT00576979|recurrent adult acute lymphoblastic leukemia
1348135|NCT00576979|recurrent childhood acute lymphoblastic leukemia
1348136|NCT00576940|enteral nutrition, immunomodulating nutrition
1348137|NCT00576927|Sleep hygiene
1348138|NCT00576927|Sleep latency
1348139|NCT00576927|Elderly sleep
1348140|NCT00576927|Nursing Home sleep
1348141|NCT00576914|adjuvant therapy
1348142|NCT00576914|non-small cell lung cancer
1348143|NCT00576914|vinorelbine
1348144|NCT00576914|cisplatin
1348145|NCT00576914|recombinant human endostatin(endostar)
1348146|NCT00576888|Multifocal lymphangioendoltheliomatosis with thrombocytopenia
1348147|NCT00576888|Cutaneovisceral angiomatosis with thrombocytopenia
1348148|NCT00576888|Thrombocytopenia
1348149|NCT00576888|Hemangiomas
1348150|NCT00576888|Hemangiomatosis
1348151|NCT00576888|Lymphatic malformation
1348152|NCT00576888|Kasabach-Merritt
1348153|NCT00576888|Blue-rubber bleb nevus
1348154|NCT00576888|Angiomatosis
1348155|NCT00576875|Depression
1348156|NCT00576875|Elderly
1348157|NCT00576875|Neuroimaging
1348158|NCT00576875|Postmortem
1348159|NCT00576875|Knockout mouse
1348160|NCT00576836|Thymus Transplantation
1348161|NCT00576836|DiGeorge Syndrome
1348162|NCT00576836|DiGeorge Anomaly
1348163|NCT00576836|Athymia
1348164|NCT00576836|Parathyroid Transplantation
1348165|NCT00576836|Hypocalcemia
1348166|NCT00576836|Hypoparathyroidism
1348167|NCT00576836|Low T cell numbers
1348168|NCT00576836|Immunoreconstitution
1348169|NCT00576836|Immunodeficiency
1348170|NCT00576836|Complete DiGeorge
1348171|NCT00576836|Complete DiGeorge Anomaly
1348172|NCT00576836|Typical DiGeorge
1348173|NCT00576823|child
1348174|NCT00576823|bladder
1348175|NCT00576823|neuropathic
1348176|NCT00576823|alpha blockers
1348177|NCT00576797|vaginal
1348178|NCT00576797|bacteria
1348179|NCT00576797|microflora
1348180|NCT00576797|bacterial DNA
1348181|NCT00576797|To determine the normal bacteria in the vagina
1348182|NCT00576784|type 2 diabetes
1348183|NCT00576784|insulin treatment
1348184|NCT00576784|ß-cell function
1348185|NCT00576745|Sutures
1348186|NCT00576732|Irritability
1348187|NCT00576732|Risperidone
1348188|NCT00576732|Antipsychotic agent
1348189|NCT00576732|Autism
1348190|NCT00576732|Adolescents
1348191|NCT00576732|Children
1348192|NCT00576706|Patients with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis or any other arthritis-like disease requiring continuous NSAIDs therapy
1348193|NCT00576693|ischemic stroke
1348194|NCT00576693|intracranial stenting
1348195|NCT00576693|vascular risk factor management
1348196|NCT00576680|RAD001
1348197|NCT00576680|temozolomide
1348198|NCT00576667|NASH
1348199|NCT00576667|chronic liver disease
1348200|NCT00576615|healthy volunteers
1348201|NCT00576615|amnesic effects
1348202|NCT00576589|Safety in patients with Asymptomatic cholelithiasis/gallstones.
1348203|NCT00576576|Atherosclerosis, vulnerable plaque, IVUS, shear stress
1348204|NCT00576563|rectal cancer
1348205|NCT00576563|blood proteins
1348206|NCT00576563|irradiation
1348207|NCT00576563|FDG-PET-CT
1348208|NCT00576550|Hand eczema
1348209|NCT00576550|Prevention
1348210|NCT00576537|New/Recurrent Glioblastoma
1348211|NCT00576524|Hypotension during dialysis
1348212|NCT00576524|End Stage Renal Disease
1348213|NCT00576524|Decrease complications during dialysis
1348214|NCT00576524|Low Blood Pressure
1348215|NCT00576511|Constipation
1348216|NCT00576511|Prucalopride
1348217|NCT00576511|Colonic Transit Time
1348218|NCT00576498|GERD
1348219|NCT00576498|NBI
1348220|NCT00576498|AFI
1348221|NCT00576498|IM
1348222|NCT00576498|SSBE
1348223|NCT00576498|LSBE
1348224|NCT00576498|LGD
1348225|NCT00576498|HGD
1348226|NCT00576485|Cataract
1348227|NCT00576485|Intraocular lens
1348228|NCT00576485|Spherical aberration
1348229|NCT00576485|Contrast sensitivity
1348230|NCT00576472|Brain Tumor, Acute Lymphoblastic Leukemia, Methylphenidate, Cognitive Late Effects
1348231|NCT00576407|Thymus Transplantation
1348232|NCT00576407|DiGeorge Syndrome
1348233|NCT00576407|Athymia
1348234|NCT00576407|Low T cell numbers
1348235|NCT00576407|Immunoreconstitution
1348236|NCT00576407|Primary immunodeficiency
1348237|NCT00576407|DiGeorge Anomaly
1348238|NCT00576407|Complete DiGeorge
1348239|NCT00576407|Typical DiGeorge
1348240|NCT00576394|Glucose, Insulin
1348241|NCT00576381|Precedex
1348242|NCT00576381|Open Heart Surgery
1348243|NCT00576381|Dexmedetomidine
1348244|NCT00576381|Sedation
1348245|NCT00576355|Adolescent
1348246|NCT00576355|Psychopathology
1348247|NCT00576355|Interpersonal Therapy
1348248|NCT00576355|Interpersonal and Social Rhythm Therapy
1348249|NCT00576329|vitreoretinal surgery, ketorolac, Acular, mydriasis
1348250|NCT00576316|Asthma
1348251|NCT00576264|open abdominal surgery
1348252|NCT00576264|abdominal laparoscopic surgery
1348253|NCT00576264|peritoneal stem cells
1348254|NCT00576264|patients scheduled for any type of elective intra-abdominal surgery at Cedars-Sinai Medical Center with designated surgeons
1348255|NCT00576251|Ocular inflammation
1348256|NCT00576251|blepharaconjunctivitis
1348257|NCT00576238|Atopic eczema
1348258|NCT00576238|Topical corticosteroid
1348259|NCT00576225|NSCLC
1348260|NCT00576225|women
1348261|NCT00576225|CT-2103
1348262|NCT00576225|paclitaxel
1348263|NCT00576225|carboplatin
1348264|NCT00576212|termination fetal anomaly
1348265|NCT00576212|psychological sequelae pregnancy termination for anomalies
1348266|NCT00576212|supportive follow-up pregnancy termination anomalies
1348267|NCT00576173|Cancer pain
1348268|NCT00576173|Breakthrough pain
1348269|NCT00576173|acetaminophen
1348270|NCT00576173|tramadol hydrochloride
1348271|NCT00576173|Ultracet
1348272|NCT00576160|medication adherence
1348273|NCT00576147|TBI
1348274|NCT00576147|NIRS
1348275|NCT00576147|Hematoma
1348276|NCT00576134|Larynx, tracheotomy, titanium beads
1348277|NCT00576082|Lyme borreliosis
1348278|NCT00576082|Erythema migrans
1348279|NCT00576082|Borrelial lymphocytoma
1348280|NCT00576082|Acrodermatitis chronica atrophicans
1348281|NCT00576082|Borrelia burgdorferi
1348282|NCT00576082|Borrelia afzelii
1348283|NCT00576082|Borrelia garinii
1348284|NCT00576069|asthma
1348285|NCT00576069|lung function
1348286|NCT00576069|inflammation
1348287|NCT00576056|Hepatocellular
1348288|NCT00576056|Carcinoma
1348289|NCT00576056|TACE
1348290|NCT00576056|Sorafenib
1348291|NCT00576056|Transcatheter Arterial Chemoembolization
1348292|NCT00576056|Nexavar
1348293|NCT00576056|Unresectable
1348294|NCT00576043|training
1348295|NCT00576043|Patient satisfaction
1348296|NCT00576043|endoscopy
1348297|NCT00576043|simulator
1348298|NCT00576043|Safety
1348299|NCT00576017|Cancer pain treatment
1348300|NCT00576017|Fentanyl TTS
1348301|NCT00576017|Dihydrocodeine
1348302|NCT00576017|Tramadol
1348303|NCT00576017|Cancer pain
1348304|NCT00576017|Durogesic
1348305|NCT00576017|Ultram
1348306|NCT00576004|Pelvic organ prolapse, Urinary incontinence, Burch colposuspension, surgery
1348307|NCT00575991|conjugated linoleic acid, body fat, children, overweight
1348308|NCT00575978|breast cancer
1348309|NCT00575965|simvastatin
1348310|NCT00575939|HIV
1348311|NCT00575939|IMT
1348312|NCT00575939|coronary
1348313|NCT00575939|Treatment Naive
1348314|NCT00575926|Randomized controlled trial
1348315|NCT00575926|Lingzhi
1348316|NCT00575926|Immune functions
1348317|NCT00575926|Quality of life
1348318|NCT00575926|Survival
1348319|NCT00575900|Adolescent obesity,
1348320|NCT00575900|low carbohydrate diets
1348321|NCT00575900|metabolic risk factors
1348322|NCT00575900|BMI
1348323|NCT00575887|Temozolomide
1348324|NCT00575887|Brain Tumor, Recurrent
1348325|NCT00575887|Chemotherapy
1348326|NCT00575874|rivoglitazone HCl
1348327|NCT00575874|pioglitazone HCl
1348328|NCT00575874|thiazolidinedione
1348329|NCT00575874|peroxisome proliferator-activated receptor gamma (PPAR gamma)
1348330|NCT00575874|type 2 diabetes mellitus
1348331|NCT00575861|asthma
1348332|NCT00575861|nitric oxide gas exchange
1348333|NCT00575861|lung function
1348334|NCT00575848|Schizophrenia
1348335|NCT00575848|Glycine
1348336|NCT00575848|Magnetic Resonance Spectroscopy (MRS)
1348337|NCT00575835|vitamin D
1348338|NCT00575835|seasonal variation
1348339|NCT00575835|PTH
1348340|NCT00575835|bone markers
1348341|NCT00575822|GERD
1348342|NCT00575822|Sham
1348343|NCT00575822|Randomized Controlled Study
1348344|NCT00575822|Endoscopic Full-thickness Plication
1348345|NCT00575822|Plicator
1348346|NCT00575809|Mucositis, hematopoietic stem cell transplantation, chemotherapy
1348347|NCT00575796|pediatrics
1348348|NCT00575796|Low Grade Glioma
1348349|NCT00575796|Vinblastine
1348350|NCT00575783|type 1 diabetes
1348351|NCT00575783|hypoglycemia
1348352|NCT00575783|magnetic resonance imaging
1348353|NCT00575757|Steatosis
1348354|NCT00575757|NASH
1348355|NCT00575744|Sentinel Lymph Node Biopsy
1348356|NCT00575744|Axillary Node Dissection
1348357|NCT00575744|Intraoperative Injection
1348358|NCT00575744|Lumpectomy
1348359|NCT00575744|Mastectomy
1348360|NCT00575718|Quitting tobacco
1348361|NCT00575718|tobacco use
1348362|NCT00575705|cystic kidney disease
1348363|NCT00575705|polycystic kidney disease
1348364|NCT00575705|congenital hepatic fibrosis
1348365|NCT00575705|genetic disease
1348371|NCT00575666|cognition, psychopathology
1348372|NCT00575653|Guillain-Barre Syndrome
1348373|NCT00575653|Meningococcal vaccines
1348374|NCT00575653|Tetravalent Meningococcal Vaccine
1348375|NCT00575653|Vaccination
1348376|NCT00575653|Vaccines
1348377|NCT00575653|Vaccines, Conjugate
1348378|NCT00575627|Hepatitis C
1348379|NCT00575627|persistently normal ALT
1348380|NCT00575627|pNNALT
1348381|NCT00575627|Theraphy for Hepatitis C
1348382|NCT00575627|Pegylated Interferon
1348383|NCT00575627|Combined therapy
1348384|NCT00575614|Constipation
1348385|NCT00575614|Prucalopride
1348386|NCT00575614|Ano-rectal physiology
1348387|NCT00575614|Oro-caecal transit time
1348388|NCT00575614|QOL
1348389|NCT00575601|pco
1348390|NCT00575601|simvastatin
1348391|NCT00575601|ivf
1348392|NCT00575601|embryo transfer
1348393|NCT00575588|DPP-4 Inhibitors
1348394|NCT00575588|HbA1c
1348395|NCT00575588|incretins
1348396|NCT00575575|Suicidal ideation
1348397|NCT00575575|cognitive behavior therapy
1348398|NCT00575536|spasticity
1348399|NCT00575536|rhizotomy
1348400|NCT00575536|surgery
1348401|NCT00575523|atropine
1348402|NCT00575523|percutaneous ethanol instillation
1348403|NCT00575523|hepatoma
1348404|NCT00575523|bradycardia
1348405|NCT00575523|arrhythmia
1348406|NCT00575510|unified theory of behavior
1348407|NCT00575510|Pap test
1348408|NCT00575510|cervical dysplasia
1348409|NCT00575510|women's health
1348410|NCT00575497|Hemodialysis
1348411|NCT00575497|Adequacy
1348412|NCT00575497|Frequency
1348413|NCT00575484|Congestive Heart Failure
1348414|NCT00575484|Renal Insufficiency
1348415|NCT00575484|Hypertonic Saline Solution
1348416|NCT00575484|Diuretic Resistance
1348417|NCT00575484|Cardiorenal Syndrome
1348418|NCT00575471|rivoglitazone HCl
1348419|NCT00575471|thiazolidinedione
1348420|NCT00575471|peroxisome proliferator-activated receptor gamma (PPARgamma)
1348421|NCT00575471|diabetes mellitus, type 2
1348422|NCT00575432|magnetic resonance imaging
1348423|NCT00575432|renal function
1348424|NCT00575432|renal transplant
1348425|NCT00575432|urinary calculi
1348426|NCT00575432|healthy controls
1348427|NCT00575432|kidney
1348428|NCT00575419|Contrast Induced Nephropathy
1348429|NCT00575393|stage IIIB non-small cell lung cancer
1348430|NCT00575393|stage IV non-small cell lung cancer
1348431|NCT00575393|recurrent non-small cell lung cancer
1348432|NCT00575354|Sevoflurane
1348433|NCT00575354|Isoflurane
1348434|NCT00575354|Breast tumor
1348435|NCT00575354|Anesthesia
1348436|NCT00575341|Central Adrenal Insufficiency
1348437|NCT00575341|DHEA
1348438|NCT00575341|Pubes
1348439|NCT00575328|Sexual Dysfunction
1348440|NCT00575328|Bipolar Disorder
1348441|NCT00575315|HIV-HCV Coinfection
1348442|NCT00575315|HIV
1348443|NCT00575315|Histology
1348444|NCT00575302|IVF
1348445|NCT00575302|poor responder
1348446|NCT00575302|recFSH
1348447|NCT00575302|Fertilization in Vitro
1348448|NCT00575302|Poor responders
1348449|NCT00575276|Pain, Cholecystectomy, Cytokines, Sex Differences
1348450|NCT00575263|Pain, Sodium Channel, Dental pulp
1348451|NCT00575250|Osteoporosis/prevention & control
1348452|NCT00575250|Osteoporosis Prevention and Self-Management Course
1348576|NCT00574626|BMT
1348453|NCT00575250|Patient Education/*trends//Questionnaires
1348454|NCT00575250|Adult//Aged//Middle Aged
1348455|NCT00575250|Life Style//
1348456|NCT00575237|Laparoscopic Surgery
1348457|NCT00575237|Shoulder pain
1348458|NCT00575237|PDNV
1348459|NCT00575237|Anesthesia
1348460|NCT00575237|Residual CO2
1348461|NCT00575237|Postoperative Pain
1348462|NCT00575237|Female ASA 1 and 2 outpatients who were scheduled for elective gynecologic laparoscopic surgery
1348463|NCT00575224|Hepatitis C
1348464|NCT00575224|Genotype 6
1348465|NCT00575224|Novel genoytpe
1348466|NCT00575224|HCV
1348467|NCT00575224|Treatment
1348468|NCT00575211|New onset cardiomyopathy
1348469|NCT00575211|Onset of symptoms less than 6 months
1348470|NCT00575211|LVEF < 40%
1348473|NCT00575185|Mono
1348474|NCT00575185|Mononucleosis
1348475|NCT00575185|Epstein-Barr virus
1348476|NCT00575172|type2 diabetes mellitus
1348477|NCT00575172|cardiovascular disease
1348478|NCT00575172|macrovascular event
1348479|NCT00575159|Adult male and females,
1348480|NCT00575159|type 1 Diabetes mellitus, pharmacokinetics,
1348481|NCT00575159|pharmacodynamics
1348482|NCT00575146|glioblastoma
1348483|NCT00575146|ketogenic diet
1348484|NCT00575120|Endothelial Function, MRI, Vascular Biology
1348485|NCT00575081|Physiological Brain Atlas, Brain registry, Brain database
1348486|NCT00575042|PBC
1348487|NCT00575042|Primary Biliary Cirrhosis
1348488|NCT00575042|Fenofibrate
1348489|NCT00575042|Triglide
1348490|NCT00575029|megestrol acetate
1348491|NCT00575029|adrenal insufficiency
1348492|NCT00575029|adrenal suppression
1348493|NCT00574990|Interdisciplinary Communication
1348494|NCT00574990|Safety Management
1348495|NCT00574990|Management, Medication Therapy
1348496|NCT00574990|Cooperative Behavior
1348497|NCT00574990|Drug Therapy Management
1348498|NCT00574990|Physician Nurse Relationships
1348499|NCT00574990|Side Effects
1348500|NCT00574990|Hospital Information Systems
1348501|NCT00574990|Documentation
1348502|NCT00574990|Quality Assurance, Health Care
1348503|NCT00574977|vaccinia
1348504|NCT00574977|virus
1348505|NCT00574977|tumor
1348506|NCT00574977|melanoma
1348507|NCT00574977|breast cancer
1348508|NCT00574977|squamous cell cancer
1348509|NCT00574977|colorectal
1348510|NCT00574977|liver
1348511|NCT00574977|pancreatic
1348512|NCT00574977|adenocarcinoma
1348513|NCT00574951|fallopian tube cancer
1348514|NCT00574951|recurrent ovarian epithelial cancer
1348515|NCT00574951|primary peritoneal cavity cancer
1348516|NCT00574925|H. pylori
1348517|NCT00574912|Type 2 diabetes
1348518|NCT00574912|Insulin Glargine
1348519|NCT00574912|Endogenous Glucose Production
1348520|NCT00574899|Prostate
1348521|NCT00574873|Bosutinib
1348522|NCT00574873|imatinib
1348523|NCT00574873|CML
1348524|NCT00574860|Oral Mucositis
1348525|NCT00574860|Chemoradiation therapy
1348526|NCT00574860|Head and neck cancer
1348527|NCT00574847|ischemic heart disease
1348528|NCT00574847|mental stress-induced myocardial ischemia
1348529|NCT00574847|escitalopram
1348530|NCT00574821|Hypertrophic Cardiomyopathy(HCM)
1348531|NCT00574821|Magnetocardiography (MCG)
1348532|NCT00574808|Primary care
1348533|NCT00574808|Prevention of Cardiovascular Disease
1348534|NCT00574808|Chronic Disease Management
1348535|NCT00574808|Chronic Disease Prevention
1348536|NCT00574808|Chronic Care Model
1348537|NCT00574808|Outreach Facilitation
1348538|NCT00574782|cholesterol, coronary heart disease
1348539|NCT00574782|rosuvastatin
1348540|NCT00574782|LDL-C goal
1348541|NCT00574782|hypercholesterolemia
1348542|NCT00574769|RAD001
1348543|NCT00574769|mTOR inhibition
1348544|NCT00574769|docetaxel
1348545|NCT00574769|bevacizumab
1348546|NCT00574769|adenocarcinoma of the prostate
1348547|NCT00574769|recurrent prostate cancer
1348548|NCT00574769|stage IV prostate cancer
1348549|NCT00574769|prostate cancer
1348550|NCT00574769|Metastatic, androgen independent prostate cancer
1348551|NCT00574743|ERL080A, Heart Transplantation, Mycophenolate, EC-MPS
1348552|NCT00574717|hyperopia
1348553|NCT00574717|ocular refraction
1348554|NCT00574717|infant
1348555|NCT00574717|vision
1348556|NCT00574691|Closure Device
1348557|NCT00574691|Angiography
1348558|NCT00574691|Angioplasty
1348559|NCT00574691|Hemostasis
1348560|NCT00574691|Heart Catheterization
1348561|NCT00574691|Coronary Angiography
1348562|NCT00574678|Screening tool for cancer
1348563|NCT00574665|Type 2 Diabetes
1348564|NCT00574665|Endothelial Function
1348565|NCT00574665|Fibrinolytic Balance
1348566|NCT00574652|HCV+
1348567|NCT00574652|cryoglobulinemia
1348568|NCT00574652|Vasculitis
1348569|NCT00574652|IL-2 treatment
1348570|NCT00574652|safety and efficacy
1348571|NCT00574639|Type 1 Diabetes
1348572|NCT00574639|Alprazolam
1348573|NCT00574639|Exercise
1348574|NCT00574626|NHL
1348575|NCT00574626|Non Hodgkins Lymphoma
1348577|NCT00574626|Bone Marrow Transplant
1348578|NCT00574626|PBSCT
1348579|NCT00574626|Peripheral Blood Stem Cell Transplant
1348580|NCT00574626|PSCT
1348581|NCT00574613|Skin fibrosis
1348582|NCT00574613|systemic scleroderma
1348583|NCT00574613|systemic sclerosis
1348584|NCT00574613|P144
1348585|NCT00574613|orphan drug
1348586|NCT00574613|soluble collagen
1348587|NCT00574613|durometer
1348588|NCT00574613|skin fibrosis in systemic sclerosis
1348589|NCT00574600|HIV Seronegativity
1348590|NCT00574600|HIV Preventive Vaccine
1348591|NCT00574587|Vorinostat
1348592|NCT00574587|Neoadjuvant Chemotherapy
1348593|NCT00574574|cardiovascular disease
1348594|NCT00574574|CVD
1348595|NCT00574574|skin health
1348596|NCT00574574|postmenopausal women
1348597|NCT00574574|anthocyanin
1348598|NCT00574574|inflammation
1348599|NCT00574561|CT angiography (CTA)
1348600|NCT00574561|Magnetocardiography (MCG)
1348601|NCT00574561|heart disease
1348602|NCT00574548|Vaccines, Pneumococcal Conjugate Vaccine
1348603|NCT00574535|Reproductive Hormones
1348604|NCT00574522|HIV
1348605|NCT00574522|AIDS
1348606|NCT00574522|Radiation
1348607|NCT00574522|Far infrared
1348608|NCT00574522|Treatment
1348609|NCT00574522|Acquired Immunodeficiency Syndrome
1348610|NCT00574522|Complimentary therapies
1348611|NCT00574509|NHL
1348612|NCT00574509|Non Hodgkins Lymphoma
1348613|NCT00574509|131Iodine-Anti-B1 Radioimmunotherapy
1348614|NCT00574509|Autologous Hematopoietic Stem Cell Transplant
1348615|NCT00574509|AHSCT
1348616|NCT00574496|recurrent adult Hodgkin lymphoma
1348617|NCT00574496|recurrent/refractory childhood Hodgkin lymphoma
1348618|NCT00574496|adult lymphocyte depletion Hodgkin lymphoma
1348619|NCT00574496|adult nodular sclerosis Hodgkin lymphoma
1348620|NCT00574496|adult mixed cellularity Hodgkin lymphoma
1348621|NCT00574496|childhood lymphocyte depletion Hodgkin lymphoma
1348622|NCT00574496|childhood mixed cellularity Hodgkin lymphoma
1348623|NCT00574496|childhood nodular sclerosis Hodgkin lymphoma
1348624|NCT00574496|stage III adult Hodgkin lymphoma
1348625|NCT00574496|stage IV adult Hodgkin lymphoma
1348626|NCT00574496|stage III childhood Hodgkin lymphoma
1348627|NCT00574496|stage IV childhood Hodgkin lymphoma
1348628|NCT00574483|Renal cell carcinoma
1348629|NCT00574457|Atherosclerosis
1348630|NCT00574457|Cardiovascular Risk Prevention
1348631|NCT00574457|Carotid Ultrasound
1348632|NCT00574457|Handheld ultrasound
1348633|NCT00574457|Office Practice
1348634|NCT00574457|Carotid Intima Media Thickness
1348635|NCT00574457|Carotid Plaque
1348636|NCT00574444|transvaginal peritoneoscopy
1348637|NCT00574431|Critical care
1348638|NCT00574431|Intensive care unit
1348639|NCT00574431|Early enteral nutrition
1348640|NCT00574431|Nutritional management protocol
1348641|NCT00574418|Fibroid Tumor
1348642|NCT00574418|Fibroid Uterus
1348643|NCT00574418|Fibroids, Uterine
1348644|NCT00574418|Fibromyoma
1348645|NCT00574418|Uterine Neoplasms
1348646|NCT00574405|Insulin pump
1348647|NCT00574405|Beta cell
1348648|NCT00574392|skin disorders
1348649|NCT00574379|Allergic Rhinitis
1348650|NCT00574379|Mountain Cedar Pollen
1348651|NCT00574379|Pollen Allergy
1348652|NCT00574379|Rhinoconjunctivitis
1348653|NCT00574366|recurrent breast cancer
1348654|NCT00574366|stage IV breast cancer
1348655|NCT00574366|male breast cancer
1348656|NCT00574353|colorectal cancer
1348657|NCT00574353|07-151
1348658|NCT00574340|Type 2 Diabetes
1348659|NCT00574340|Endothelial Function
1348660|NCT00574340|Fibrinolytic Balance
1348661|NCT00574340|Hypoglycemia
1348662|NCT00574327|Role
1348663|NCT00574327|Registry
1348664|NCT00574327|Barrett's Esophagus
1348665|NCT00574314|women
1348666|NCT00574314|Registry
1348667|NCT00574301|Image Guided Vacuum Assisted Biopsy
1348668|NCT00574301|Radiofrequency Ablation
1348669|NCT00574301|Breast Conservation Therapy
1348670|NCT00574301|Mastectomy
1348671|NCT00574301|MRI
1348672|NCT00574288|Multiple Myeloma
1348673|NCT00574288|Daratumumab
1348674|NCT00574288|Safety
1348675|NCT00574288|HuMax-CD38
1348676|NCT00574288|Dose-escalation
1348677|NCT00574275|metastatic pancreatic cancer
1348678|NCT00574275|angiogenesis inhibitor
1348679|NCT00574275|gemcitabine
1348680|NCT00574262|acute ischemic stroke
1348681|NCT00574262|clinical pathway
1348682|NCT00574262|quality of care
1348683|NCT00574262|secondary prevention
1348684|NCT00574249|Psoriasis
1348685|NCT00574249|Moderate Psoriasis
1348686|NCT00574249|Severe Psoriasis
1348687|NCT00574249|Chronic Plaque Psoriasis
1348688|NCT00574249|Severe Chronic Plaque Psoriasis
1348689|NCT00574210|Seasonal Allergic Rhinitis (SAR)
1348690|NCT00574210|Environmental Exposure Chamber (EEC)
1348691|NCT00574210|Therapeutic Uses
1348692|NCT00574210|Antihistamine Drug
1348693|NCT00574210|Ragweed Pollen
1348694|NCT00574197|Heart Transplant
1348695|NCT00574197|gastrointestinal
1348696|NCT00574197|Cellcept
1348697|NCT00574197|Myfortic
1348698|NCT00574197|GI
1348699|NCT00574197|GI symptoms with Mycophenolate Mofetil after heart transplant
1348700|NCT00574184|ED
1348701|NCT00574184|Erectile Dysfunction
1348702|NCT00574158|ozone
1348703|NCT00574158|inflammatory airway disease
1348704|NCT00574158|polymorphisms
1348705|NCT00574145|fatigue
1348706|NCT00574145|depression
1348707|NCT00574145|psychosocial effects of cancer and its treatment
1348708|NCT00574145|stage I breast cancer
1348709|NCT00574145|stage II breast cancer
1348710|NCT00574145|stage IIIA breast cancer
1348711|NCT00574145|stage IIIB breast cancer
1348712|NCT00574145|stage IIIC breast cancer
1348713|NCT00574145|recurrent breast cancer
1348714|NCT00574119|heart failure
1348715|NCT00574119|positron emission tomography
1348716|NCT00574119|magnetic resonance imaging
1348717|NCT00574119|myocardial energetics
1348718|NCT00574119|myocardial perfusion
1348719|NCT00574106|Cancer
1348720|NCT00574106|Tumors
1348721|NCT00574093|combination therapy
1348722|NCT00574093|Lucentis
1348723|NCT00574093|Visudyne
1348724|NCT00574054|Familial Dementia
1348725|NCT00574054|Semantic Dementia
1348726|NCT00574054|Senile Paranoid Dementia
1348727|NCT00574041|Multiple Sclerosis
1348728|NCT00574041|Avonex
1348729|NCT00574041|side effects
1348730|NCT00574041|flu like symptoms
1348731|NCT00574028|IBD Study
1348732|NCT00574015|toothache
1348733|NCT00574015|regional anesthesia
1348734|NCT00574015|emergency department
1348735|NCT00573989|recurrent squamous cell carcinoma of the hypopharynx
1348736|NCT00573989|recurrent squamous cell carcinoma of the larynx
1348737|NCT00573989|recurrent verrucous carcinoma of the larynx
1348738|NCT00573989|recurrent squamous cell carcinoma of the lip and oral cavity
1348739|NCT00573989|recurrent verrucous carcinoma of the oral cavity
1348740|NCT00573989|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1348741|NCT00573989|recurrent metastatic squamous neck cancer with occult primary
1348742|NCT00573989|recurrent squamous cell carcinoma of the oropharynx
1348743|NCT00573976|SCIM
1348744|NCT00573976|SCIM III
1348745|NCT00573976|Multi-Center
1348746|NCT00573976|United States
1348747|NCT00573963|Cesarean section
1348748|NCT00573950|cilostazol
1348749|NCT00573950|Type 2 Diabetes mellitus
1348750|NCT00573950|Metabolic Syndrome
1348751|NCT00573950|adipocytokines
1348752|NCT00573950|arterial stiffness
1348753|NCT00573950|Pulse wave velocity
1348754|NCT00573937|Neoplasms
1348755|NCT00573937|Pain
1348756|NCT00573937|Methadone
1348757|NCT00573937|Morphine
1348758|NCT00573911|Barrett's esophagus
1348759|NCT00573911|GERD
1348760|NCT00573898|daptomycin
1348761|NCT00573885|non-small cell lung cancer
1348762|NCT00573885|small cell lung cancer
1348763|NCT00573885|tobacco use disorder
1348764|NCT00573872|Radiosurgery
1348765|NCT00573872|Phase II
1348766|NCT00573872|Cancer
1348767|NCT00573872|Spinal
1348768|NCT00573872|AVM
1348769|NCT00573859|Smoking
1348770|NCT00573859|ADHD
1348771|NCT00573859|Stimulant medication
1348772|NCT00573846|IBD
1348773|NCT00573833|adenocarcinoma of the prostate
1348774|NCT00573833|stage IIB prostate cancer
1348775|NCT00573833|stage IIA prostate cancer
1348776|NCT00573820|Tumors or cancer of the prostate
1348777|NCT00573820|Cancer of Prostate
1348778|NCT00573820|Cancer of the Prostate
1348779|NCT00573820|Neoplasms, Prostate
1348780|NCT00573820|Neoplasms, Prostatic
1348781|NCT00573820|Prostate Cancer
1348782|NCT00573820|Prostate Neoplasms
1348783|NCT00573820|Prostatic Cancer
1348784|NCT00573807|Neuralgia, Sciatic
1348785|NCT00573807|Sciatic Neuralgia
1348786|NCT00573807|Sciatica, Bilateral
1348787|NCT00573807|Lower back pain
1348788|NCT00573794|Ulcerative Colitis
1348789|NCT00573781|Systems biology
1348790|NCT00573781|Nutrigenomics
1348791|NCT00573781|Metabolomics
1348792|NCT00573781|Gene expression
1348793|NCT00573781|Fat tissue
1348794|NCT00573781|Peripheral mononuclear cells
1348795|NCT00573781|Gene clusters
1348796|NCT00573781|Gene expression profiles
1348797|NCT00573781|Personal diets
1348798|NCT00573781|Metabolic syndrome
1348799|NCT00573781|Type 2 Diabetes
1348800|NCT00573781|Atherosclerosis
1348801|NCT00573768|Ankle, sprain, diclofenac diethylamine
1348802|NCT00573755|stage IV breast cancer
1348803|NCT00573755|recurrent breast cancer
1348804|NCT00573742|hypertension
1348805|NCT00573729|vascular malformation
1348806|NCT00573716|bone mineral content
1348807|NCT00573716|aripiprazole monotherapy
1348808|NCT00573716|risperidone monotherapy
1348809|NCT00573703|Laparoscopic Burch colposuspension
1348810|NCT00573703|Stress incontinence
1348811|NCT00573703|Surgery
1348812|NCT00573703|TOT
1348813|NCT00573703|Treatment
1348814|NCT00573703|Predominant or genuine stress urinary incontinence
1348815|NCT00573690|unspecified adult solid tumor, protocol specific
1348816|NCT00573664|Cesarean section
1348817|NCT00573664|Gabapentin
1348818|NCT00573651|JIA
1348819|NCT00573651|SEA syndrome
1348820|NCT00573651|AS
1348821|NCT00573651|psoriatic arthritis
1348822|NCT00573651|HPV vaccine
1348823|NCT00573638|glaucoma
1348824|NCT00573638|compliance
1348825|NCT00573638|eye drops
1348826|NCT00573638|deliver aid
1348827|NCT00573638|Patients could range anywhere from 40 to 80 years old
1348828|NCT00573638|Patients must have diagnosis requiring treatment with Xalatan.
1348829|NCT00573638|Patients will be male or female and from any racial/ethnic background.
1348830|NCT00573612|Fibromyalgia
1348831|NCT00573612|Fibromyalgia patients
1348832|NCT00573599|Migraine
1348833|NCT00573599|Emergency
1348834|NCT00573599|imitrex
1348835|NCT00573599|prochlorperazine
1348836|NCT00573599|Acute Migraine Headache in the Emergency Department
1348837|NCT00573573|PRIMARY HYPERPARATHYROIDISM
1348838|NCT00573573|PARATHYROID NEOPLASMS
1348839|NCT00573573|SECONDARY HYPERPARATHYROIDISM
1348840|NCT00573573|HYPOCALCEMIA
1348848|NCT00573547|depression
1348849|NCT00573547|chronic renal failures
1348850|NCT00573547|end stage renal disease
1348851|NCT00573534|Attention Deficit Hyperactivity Disorder
1348852|NCT00573534|ADHD
1348853|NCT00573534|ADD
1348854|NCT00573534|Prevention
1348855|NCT00573534|Substance use
1348856|NCT00573534|Adolescent
1348857|NCT00573521|ESBL positive cultures
1348858|NCT00573508|Overactive Bladder
1348859|NCT00573495|Advanced breast cancer
1348860|NCT00573482|weight gain prevention
1348861|NCT00573482|obesity
1348862|NCT00573482|overweight
1348863|NCT00573482|food environment
1348864|NCT00573482|The intervention group received the education in REDE techniques
1348865|NCT00573482|The control group received no intervention at all.
1348866|NCT00573482|Both groups were exposed to the food labels and the new lower ED foods.
1348867|NCT00573482|Only the intervention group received the education sessions and only they were eligible for the price reductions.
1348868|NCT00573469|gastrointestinal
1348869|NCT00573469|GI
1348870|NCT00573469|Crohn's disease
1348871|NCT00573469|Japan
1348872|NCT00573469|Japanese
1348873|NCT00573456|Thye 1 Diabetes
1348874|NCT00573456|Type 2 Diabetes
1348875|NCT00573443|Amyotrophic Lateral Sclerosis (Lou Gehrig's disease, ALS)
1348876|NCT00573443|Multiple Sclerosis (MS)
1348877|NCT00573430|Candesartan Cilexetil
1348878|NCT00573430|Non-diabetic Nephropathy
1348879|NCT00573430|hypertension
1348880|NCT00573430|urine protein creatinine ratio
1348881|NCT00573417|Schizophrenia
1348882|NCT00573417|Clozapine
1348883|NCT00573417|Cognition
1348884|NCT00573417|Metabolic Syndrome
1348885|NCT00573417|Negative Symptoms
1348886|NCT00573417|Wakefulness
1348887|NCT00573417|Fatigue
1348888|NCT00573404|gastrointestinal stromal tumor
1348889|NCT00573378|CML
1348890|NCT00573365|dermatitis
1348891|NCT00573365|skin
1348892|NCT00573365|radiation
1348893|NCT00573365|light
1348894|NCT00573365|LED photomodulation
1348895|NCT00573365|Gentlewaves
1348896|NCT00573352|Arthritis, Degenerative
1348897|NCT00573352|Osteoarthrosis
1348898|NCT00573352|Osteoarthrosis Deformans
1348899|NCT00573339|Cardiac
1348900|NCT00573339|MRI
1348901|NCT00573339|normal controls
1348902|NCT00573313|Alcoholic Liver Disease (ALD)
1348903|NCT00573313|S-adenosylmethionine
1348904|NCT00573313|SAMe
1348905|NCT00573300|Schizophrenia
1348906|NCT00573300|Immune System
1348907|NCT00573300|Kynurenate
1348908|NCT00573300|tryptophan metabolism
1348909|NCT00573300|NMDA receptor
1348910|NCT00573300|indolamine 2,3-deoxygenase (IDO)
1348911|NCT00573287|Clozapine, risperidone, first episode,
1348912|NCT00573274|Cesarean section
1348913|NCT00573274|Cardiac Output
1348914|NCT00573274|Physioflow
1348915|NCT00573274|Cardiography, Impedance
1348916|NCT00573261|Diabetic neuropathy
1348917|NCT00573261|Pregabalin
1348918|NCT00573261|Lyrica
1348919|NCT00573248|Nicotine
1348920|NCT00573248|ADHD
1348921|NCT00573248|Gender
1348922|NCT00573235|isolates
1348923|NCT00573235|infection
1348924|NCT00573235|E coli isolates
1348925|NCT00573222|Asthma
1348926|NCT00573209|Impotence
1348927|NCT00573209|Male Impotence
1348928|NCT00573209|Male Sexual Impotence
1348929|NCT00573196|Affective Psychosis, Bipolar
1348930|NCT00573196|Depression, Bipolar
1348931|NCT00573196|Mania
1348932|NCT00573196|Manic Disorder
1348933|NCT00573196|Manic State
1348934|NCT00573196|Manic-Depressive Psychosis
1348935|NCT00573196|Psychoses, Manic-Depressive
1348936|NCT00573196|Psychosis, Manic-Depressive
1348937|NCT00573183|Cocaine, methamphetamine, amphetamine, other stimulant drugs
1348938|NCT00573170|Migraine, acute
1348939|NCT00573170|Migraine
1348940|NCT00573170|Butalbital-containing Combination Medication (BCM)
1348941|NCT00573170|Naproxen sodium
1348942|NCT00573170|Sumatriptan succinate
1348943|NCT00573170|TREXIMET®
1348944|NCT00573157|nephritis
1348945|NCT00573157|atacicept
1348946|NCT00573131|Esophageal cancer
1348947|NCT00573131|Localized esophageal cancer
1348948|NCT00573131|Operable esophageal cancer
1348949|NCT00573131|Loco-regional esophageal cancer
1348950|NCT00573131|Esophagectomy
1348951|NCT00573131|Phase 2
1348952|NCT00573131|Paclitaxel
1348953|NCT00573131|Tumor
1348954|NCT00573131|Local
1348955|NCT00573131|Chemotherapy
1348956|NCT00573131|radiation therapy
1348957|NCT00573131|surgery
1348958|NCT00573131|OncoGel
1348959|NCT00573131|Squamous cell carcinoma of the esophagus
1348960|NCT00573118|Pregnancy complications: preeclampsia , severe IUGR , IUFD or placental abruption (n = 5).
1348961|NCT00573092|Cardiovascular Epidemiology
1348962|NCT00573092|Genomics
1348963|NCT00573092|Genome-Wide Association Study
1348964|NCT00573079|Kidney
1348965|NCT00573079|Infants
1348966|NCT00573066|Postoperative from cardiac surgery
1348967|NCT00573066|Dexmedetomidine
1348968|NCT00573053|hypercapneic response
1348969|NCT00573053|hyperoxic response
1348970|NCT00573053|breathing pattern
1348971|NCT00573053|periodic breathing
1348972|NCT00573053|sighs
1348973|NCT00573040|Radiotherapy
1348974|NCT00573040|NSCLC
1348975|NCT00573040|Stage III non-small cell lung cancer
1348976|NCT00573027|microvascular dysfunction
1348977|NCT00573027|Microvascular
1348978|NCT00573014|Obtunded blunt trauma patients
1348979|NCT00573001|naive
1348980|NCT00573001|HIV-1
1348981|NCT00573001|simplified treatment
1348982|NCT00573001|Treatment Experienced
1348983|NCT00572988|symptom management
1348984|NCT00572988|function status
1348985|NCT00572988|physical activity
1348986|NCT00572988|health care utilization
1348987|NCT00572975|New diagnostic test for Cystic Fibrosis.
1348988|NCT00572949|heart disease
1348989|NCT00572949|chest pain
1348990|NCT00572949|coronary artery disease
1348991|NCT00572949|atherosclerosis
1348992|NCT00572936|Glaucoma
1348993|NCT00572936|Ocular Hypertension
1348994|NCT00572936|Timolol®, Latanoprost® and Dorzolamide®
1348995|NCT00572923|radiotherapy
1348996|NCT00572923|LD-SCLC
1348997|NCT00572923|stage I-III small cell lung cancer
1348998|NCT00572897|Myelofibrosis
1348999|NCT00572897|Myeloproliferative disease
1349000|NCT00572897|Stem Cell Transplant
1349001|NCT00572897|Allogeneic Transplant
1349002|NCT00572897|Conditioning Regimen
1349003|NCT00572897|Reduced Intensity Regimen
1349004|NCT00572897|Fludarabine
1349005|NCT00572897|Melphalan
1349006|NCT00572897|ATG
1349007|NCT00572884|permethrin
1349008|NCT00572884|pyrethroid
1349009|NCT00572884|pharmacokinetics
1349010|NCT00572884|metabolism
1349011|NCT00572884|accelerator mass spectrometry
1349012|NCT00572884|human exposure
1349013|NCT00572858|Hypo E
1349014|NCT00572845|Basal Energy Expenditure
1349015|NCT00572845|Spasticity
1349016|NCT00572845|Modified Ashworth Scale
1349017|NCT00572845|Penn Spasm Frequency Score
1349018|NCT00572832|Human Papillomavirus Vaccine
1349019|NCT00572819|Hysteroscopy
1349020|NCT00572819|Misoprostol
1349021|NCT00572819|Postmenopausal women
1349022|NCT00572819|Cervical ripening
1349023|NCT00572819|Dilatation
1349024|NCT00572819|Sequential trial
1349025|NCT00572819|Estradiol
1349026|NCT00572780|Crohn's Disease
1349027|NCT00572780|CT Enteroclysis
1349028|NCT00572767|randomised-controlled trial
1349029|NCT00572767|ischemic stroke
1349030|NCT00572767|motor recovery
1349031|NCT00572767|amphetamine
1349032|NCT00572767|motor recovery of patients after a first-ever ischemic stroke
1349033|NCT00572741|Autism
1349034|NCT00572741|vitamin B 12
1349035|NCT00572741|glutathione
1349036|NCT00572715|kidney
1349037|NCT00572715|neonates
1349038|NCT00572702|Biocompatible Materials
1349039|NCT00572702|Female
1349040|NCT00572702|Humans
1349041|NCT00572702|Pelvic Floor
1349042|NCT00572702|Polypropylenes
1349043|NCT00572702|Prostheses and Implants
1349044|NCT00572702|Surgical Mesh
1349045|NCT00572702|Uterine Prolapse/*therapy
1349046|NCT00572689|Exenatide
1349047|NCT00572689|TCF7L2 polymorphism
1349048|NCT00572689|Pharmacodynamics
1349049|NCT00572689|Pharmacokinetics
1349050|NCT00572663|Proteinuria
1349051|NCT00572663|Antioxidant
1349052|NCT00572663|N-acetylcysteine
1349053|NCT00572650|Type-2 diabetes, DPP-4 inhibitor, vildagliptin
1349054|NCT00572624|Heart Metabolism
1349055|NCT00572624|Obesity
1349056|NCT00572624|Weight loss
1349057|NCT00572624|Gastric bypass surgery
1349058|NCT00572624|Diet and exercise
1349059|NCT00572611|Mass Balance
1349060|NCT00572611|Metabolism
1349061|NCT00572611|Absorption
1349062|NCT00572611|Excretion
1349063|NCT00572611|Pharmacokinetics
1349064|NCT00572598|PET
1349065|NCT00572598|multidrug resistance
1349066|NCT00572598|fluoropaclitaxel
1349067|NCT00572598|paclitaxel
1349068|NCT00572598|breast cancer
1349069|NCT00572598|dosimetry
1349070|NCT00572598|imaging feasibility
1349071|NCT00572585|Ulcerative colitis
1349072|NCT00572585|immunosuppressive therapy
1349073|NCT00572585|AEB071
1349074|NCT00572585|Modified Baron score
1349075|NCT00572585|Partial Mayo score
1349076|NCT00572533|End-Stage Renal Disease
1349077|NCT00572533|Chronic Hemodialysis
1349078|NCT00572520|Depressive Disorder
1349079|NCT00572520|Weight Loss
1349080|NCT00572520|Behavioral Treatment
1349081|NCT00572520|Behavior Therapy
1349082|NCT00572520|Randomized Clinical Trial
1349083|NCT00572507|Absorbable Monofilament Suture Material
1349084|NCT00572507|Safety and Efficacy
1349085|NCT00572507|Abdominal Wall/ Fascia
1349086|NCT00572507|Laparotomy
1349087|NCT00572494|Tibial arteries
1349088|NCT00572494|Absorbable implants
1349089|NCT00572494|Stents
1349090|NCT00572494|Limb salvage
1349091|NCT00572481|Sentinel Lymph Node Biopsy
1349092|NCT00572481|Axillary Node Dissection
1349093|NCT00572481|Prevention of lymphedema
1349094|NCT00572481|Prevention of neuroma
1349095|NCT00572481|Prevention of seroma
1349096|NCT00572468|cancer
1349097|NCT00572468|pre-operative surgery
1349098|NCT00572468|prostate
1349099|NCT00572468|prostatectomy
1349100|NCT00572468|radiation
1349101|NCT00572455|Open-Angle Glaucoma
1349102|NCT00572455|Ocular Hypertension
1349103|NCT00572442|Non-invasive heart scan
1349104|NCT00572442|MCG
1349105|NCT00572442|Cardiac Risk Factors
1349106|NCT00572442|healthy volunteers
1349107|NCT00572429|HIV/AIDS
1349108|NCT00572429|HAART
1349109|NCT00572429|high cholesterol
1349110|NCT00572429|exercise
1349111|NCT00572429|L-carnitine
1349112|NCT00572429|Complimentary therapies
1349113|NCT00572416|fatigue
1349114|NCT00572416|activity-rest
1349115|NCT00572416|sleep-wake
1349116|NCT00572416|psychological distress
1349117|NCT00572416|symptom management
1349118|NCT00572403|microalbuminuria
1349119|NCT00572403|risk factors
1349120|NCT00572377|Sexual
1349121|NCT00572377|Arousal
1349122|NCT00572377|Female
1349123|NCT00572364|Cancer
1349124|NCT00572364|Advanced solid malignancies
1349125|NCT00572351|Wine
1349126|NCT00572325|radiotherapy
1349127|NCT00572325|NSCLC
1349128|NCT00572325|stage III non-small cell lung cancer
1349129|NCT00572312|Proteinuria,
1349130|NCT00572312|atorvastatin
1349131|NCT00572299|glucocorticoids, prednisone, alendronate,osteoclasts
1349132|NCT00572286|heart transplant
1349133|NCT00572286|advanced heart failure
1349134|NCT00572286|orthotropic heart transplantation
1349135|NCT00572286|(MCG) magnetocardiograph
1349136|NCT00572286|echocardiogram
1349137|NCT00572260|MRSA
1349138|NCT00572260|Increased risk for infection
1349139|NCT00572234|Methamphetamine
1349140|NCT00572234|Bupropion SR
1349141|NCT00572221|CQI
1349142|NCT00572221|QA
1349143|NCT00572221|Best Practice
1349144|NCT00572221|Quality Improvement
1349145|NCT00572221|Nursing Facilities
1349146|NCT00572221|Nursing Homes
1349147|NCT00572221|Care
1349148|NCT00572195|Epilepsy
1349149|NCT00572195|Responsive neurostimulation
1349150|NCT00572195|RNS System
1349151|NCT00572195|NeuroPace
1349152|NCT00572195|Brain stimulation
1349153|NCT00572195|Seizures
1349154|NCT00572182|recurrent childhood brain stem glioma
1349155|NCT00572182|childhood central nervous system germ cell tumor
1349156|NCT00572182|recurrent childhood cerebellar astrocytoma
1349157|NCT00572182|recurrent childhood cerebral astrocytoma
1349158|NCT00572182|childhood high-grade cerebral astrocytoma
1349159|NCT00572182|childhood choroid plexus tumor
1349160|NCT00572182|childhood craniopharyngioma
1349161|NCT00572182|recurrent childhood ependymoma
1349162|NCT00572182|recurrent childhood medulloblastoma
1349163|NCT00572182|childhood oligodendroglioma
1349164|NCT00572182|recurrent childhood pineoblastoma
1349165|NCT00572182|recurrent childhood supratentorial primitive neuroectodermal tumor
1349166|NCT00572182|childhood atypical teratoid/rhabdoid tumor
1349167|NCT00572182|childhood spinal cord neoplasm
1349168|NCT00572182|childhood infratentorial ependymoma
1349169|NCT00572182|childhood supratentorial ependymoma
1349170|NCT00572182|recurrent childhood visual pathway and hypothalamic glioma
1349171|NCT00572182|childhood grade III meningioma
1349172|NCT00572156|IGF-1 Deficiency
1349173|NCT00572156|growth
1349174|NCT00572156|ISS
1349175|NCT00572156|Constitutional growth delay
1349176|NCT00572156|Primary IGFD
1349177|NCT00572156|Primary IGF Deficiency
1349178|NCT00572143|Colonic Neoplasms/surgery*
1349179|NCT00572143|Continuity of Patient Care*
1349180|NCT00572143|Follow-Up Studies
1349181|NCT00572143|Quality of Life
1349182|NCT00572143|Patient Satisfaction
1349183|NCT00572130|Tumor-targeted gene medicine
1349184|NCT00572130|Cyclin G1 gene
1349185|NCT00572130|Osteosarcoma
1349186|NCT00572117|Bipolar Disorder
1349187|NCT00572117|Manic Disorder
1349188|NCT00572117|Alcoholism
1349189|NCT00572117|Alcohol Abuse
1349190|NCT00572117|Alcohol Dependence
1349191|NCT00572117|Clinical Trial
1349192|NCT00572117|Evaluation Trial
1349193|NCT00572117|Intervention Trial
1349194|NCT00572117|Validation Studies
1349195|NCT00572091|Heart Failure
1349196|NCT00572091|Mitral Regurgitation
1349197|NCT00572078|solid tumor
1349198|NCT00572039|Age-Related Macular Degeneration
1349199|NCT00572039|AMD
1349200|NCT00572039|Vision Function
1349201|NCT00572039|Problem Solving Treatment
1349202|NCT00572039|PST
1349203|NCT00572026|Attention deficit
1349204|NCT00572026|Hyperactivity
1349205|NCT00572026|Attention deficit hyperactivity disorder
1349206|NCT00571987|Breast cancer
1349207|NCT00571987|Lumpectomy
1349208|NCT00571987|Radiofrequency Ablation
1349209|NCT00571987|Negative margins
1349210|NCT00571987|Breast Conserving Surgery
1349211|NCT00571961|HIV
1349212|NCT00571961|Pharmacokinetics
1349213|NCT00571961|Buprenorphine
1349214|NCT00571961|Kaletra
1349215|NCT00571961|HIV Seronegativity
1349216|NCT00571948|infant, complementary food, iron, meat, LC-PUFA, omega-3,
1349217|NCT00571948|rapeseed oil, diet
1349218|NCT00571922|methamphetamine, crystal, treatment
1349219|NCT00571909|Polycystic Kidney Disease
1349220|NCT00571909|Chronic Kidney Pain
1349221|NCT00571909|Autosomal Dominant Polycystic Kidney
1349222|NCT00571909|Kidney Cyst
1349223|NCT00571909|VSPL
1349224|NCT00571909|video thoracoscopic splanchnicectomy
1349225|NCT00571896|constipation
1349226|NCT00571896|SennaS
1349227|NCT00571883|stage I squamous cell carcinoma of the lip and oral cavity
1349228|NCT00571883|stage II squamous cell carcinoma of the lip and oral cavity
1349229|NCT00571883|tongue cancer
1349230|NCT00571844|High Blood Pressure
1349231|NCT00571844|Exercise
1349232|NCT00571844|Diet
1349233|NCT00571844|Biomarkers
1349234|NCT00571831|macula edema
1349235|NCT00571831|intraocular lens
1349236|NCT00571831|prospective randomized parallel clinical design
1349237|NCT00571818|euglycemic
1349238|NCT00571818|transplant
1349239|NCT00571818|pancreas
1349240|NCT00571818|hyperglycemic
1349241|NCT00571818|kidney
1349242|NCT00571805|cigarette
1349243|NCT00571805|craving
1349244|NCT00571805|reward
1349245|NCT00571792|COPD
1349246|NCT00571792|The cohort will be comprised of normal non-smoking individuals, those individuals
1349247|NCT00571792|who smoke who do not exhibit symptoms of COPD and individuals who smoke who do demonstrate
1349248|NCT00571792|symptoms of COPD
1349249|NCT00571766|chronic hypertension in pregnancy
1349250|NCT00571766|chronic Hypertension
1349251|NCT00571753|pulmonary tuberculosis
1349252|NCT00571753|NAT2 genotyping
1349253|NCT00571753|hepatotoxicity of isoniazid
1349254|NCT00571740|stage IV colon cancer
1349255|NCT00571740|stage IV rectal cancer
1349256|NCT00571740|recurrent colon cancer
1349257|NCT00571740|recurrent rectal cancer
1349258|NCT00571727|growth
1349259|NCT00571727|insulin like growth factor
1349260|NCT00571727|Larons syndrome
1349261|NCT00571714|Chronic hepatitis C
1349262|NCT00571714|Pilot Comparison
1349263|NCT00571714|Peginterferon alph-2a
1349264|NCT00571714|Ribavirin
1349265|NCT00571714|Betaine
1349266|NCT00571714|Genotype 1
1349267|NCT00571714|Treatment naive
1349268|NCT00571701|HPV
1349269|NCT00571701|RRP
1349270|NCT00571688|Bipolar Disorder
1349271|NCT00571688|Depression, Bipolar
1349272|NCT00571688|Mania
1349273|NCT00571675|Prostate Cancer
1349274|NCT00571675|Hormone Refractory Prostate Cancer
1349275|NCT00571675|HRPC
1349276|NCT00571675|Docetaxel
1349277|NCT00571675|Taxotere
1349278|NCT00571675|Prednisone
1349279|NCT00571675|Metastatic (Stage IV) Disease
1349280|NCT00571675|Chemotherapy-naïve metastatic Hormone Refractory Prostate Cancer (HRPC)
1349281|NCT00571649|Acute medical illnesses with increased risk for VTE.
1349282|NCT00571649|Deep vein thrombosis (DVT)
1349283|NCT00571649|Pulmonary embolism (PE),
1349284|NCT00571649|Venous Thromboembolic disease (VTE),
1349285|NCT00571649|Medical illness
1349286|NCT00571636|Opioids infusion
1349287|NCT00571636|mechanical ventilation
1349288|NCT00571623|Brain Injury
1349289|NCT00571623|Intracranial hypertension
1349290|NCT00571623|Human subjects
1349291|NCT00571623|Nursing care
1349292|NCT00571610|Heart Failure
1349293|NCT00571610|Mitral Regurgitation
1349294|NCT00571597|surgery
1349295|NCT00571597|ablation
1349296|NCT00571597|radiofrequency
1349297|NCT00571597|minimaze
1349298|NCT00571597|transtelephonic monitoring
1349299|NCT00571571|Identity difussion
1349300|NCT00571571|Adolescent psychotherapy
1349301|NCT00571571|Transference Focused Psychotherapy for Adolescents
1349302|NCT00571571|Identity
1349303|NCT00571571|Identity crisis
1349304|NCT00571571|Identity pathology
1349305|NCT00571545|Traumatic brain injury
1349306|NCT00571545|Depression
1349307|NCT00571545|Exercise
1349308|NCT00571506|Diabetes Mellitus, Type 2
1349309|NCT00571506|Vascular Diseases
1349310|NCT00571506|Thiazolidinediones
1349311|NCT00571506|Platelet Aggregation
1349312|NCT00571493|non-hodgkin's lymphoma
1349313|NCT00571493|mantle cell lymphoma
1349314|NCT00571493|BEAM
1349315|NCT00571493|Velcade
1349316|NCT00571480|auricular acupuncture
1349317|NCT00571480|pregnancy related low back pain
1349318|NCT00571480|acupuncture
1349319|NCT00571467|Autoimmune Diseases
1349320|NCT00571467|Bleeding Disorders
1349321|NCT00571467|Blood and Blood Disorders
1349322|NCT00571454|depression
1349323|NCT00571454|primary care
1349324|NCT00571454|Latino
1349325|NCT00571454|telephone
1349326|NCT00571454|care management
1349327|NCT00571441|stroke
1349328|NCT00571441|Brain injury
1349329|NCT00571441|nursing
1349330|NCT00571441|Critical care
1349331|NCT00571428|COPD
1349332|NCT00571428|Chronic Bronchitis
1349333|NCT00571428|Emphysema
1349334|NCT00571415|Image guided adaptive radiotherapy
1349335|NCT00571402|Family Treatment
1349336|NCT00571402|Pharmacotherapy
1349337|NCT00571389|Stage IV
1349338|NCT00571389|Advanced Stage III
1349339|NCT00571376|Quality of health care
1349340|NCT00571376|Health care costs
1349341|NCT00571350|Cystocele
1349342|NCT00571350|tension free vaginal tapes
1349343|NCT00571350|urinary incontinence
1349344|NCT00571337|Stop infliximab.
1349345|NCT00571324|hyperinsulinism
1349346|NCT00571324|hypoglycemia
1349347|NCT00571324|KATP channel
1349348|NCT00571324|Kir6.2
1349349|NCT00571311|Assent
1349350|NCT00571311|Adolescent
1349351|NCT00571311|Informed Consent
1349352|NCT00571298|Extrapleural pneumonectomy
1349353|NCT00571298|Pleurectomy Decortication
1349354|NCT00571298|Mesothelioma
1349355|NCT00571298|cisplatin
1349356|NCT00571298|gemcitabine
1349357|NCT00571298|amifostine
1349358|NCT00571298|sodium thiosulfate
1349359|NCT00571285|Parkinson's disease
1349360|NCT00571285|Nutrition
1349361|NCT00571285|Vitamin supplement
1349362|NCT00571285|Motor function
1349363|NCT00571285|Non-motor function
1349364|NCT00571272|Cholestatic Liver Disease
1349365|NCT00571272|Cholestasis
1349366|NCT00571272|Childhood Diseases
1349367|NCT00571272|Genetic Diseases
1349368|NCT00571272|Bile Acid Synthesis and Metabolism Defects
1349369|NCT00571272|Progressive Familial Intrahepatic Cholestasis
1349370|NCT00571259|Sodium citrate
1349371|NCT00571259|Gentamicin
1349372|NCT00571259|Prophylaxis
1349373|NCT00571259|Hemodialysis
1349374|NCT00571259|Central venous catheter
1349375|NCT00571246|treatment
1349376|NCT00571246|Lamotrigine
1349377|NCT00571246|Topiramate
1349378|NCT00571246|alcohol dependence
1349379|NCT00571246|post traumatic stress disorder
1349380|NCT00571233|Single Ventricle
1349381|NCT00571233|Congenital Heart Disease
1349382|NCT00571233|Children
1349383|NCT00571233|Fontan
1349384|NCT00571233|Tricuspid Atresia
1349385|NCT00571233|Hypoplastic Left Heart Syndrome
1349386|NCT00571233|Heart Failure
1349387|NCT00571233|Biomarkers
1349388|NCT00571233|Single ventricle physiology such as:
1349389|NCT00571233|unbalanced AV canal
1349390|NCT00571233|Interested in patients both before and after Fontan Surgery
1349391|NCT00571220|gastric bypass
1349392|NCT00571220|diabetes
1349393|NCT00571220|obesity
1349394|NCT00571220|diet-induced weight loss
1349395|NCT00571220|incretin levels (GLP-1,GIP)
1349396|NCT00571220|incretin effect
1349397|NCT00571207|driving under the influence of drugs
1349398|NCT00571207|on-site oral fluid screening devices
1349399|NCT00571207|checklist
1349400|NCT00571194|pravastatin, peritoneal dialysis, pediatric patients
1349401|NCT00571181|Algorithms
1349402|NCT00571181|Anesthesia, General/*methods
1349403|NCT00571181|Anesthetics, Intravenous/*administration & dosage
1349404|NCT00571181|Drug Delivery Systems/*methods/statistics & numerical data
1349405|NCT00571181|Electroencephalography/drug effects/*methods/
1349406|NCT00571181|Feasibility Studies
1349407|NCT00571181|Propofol/*administration & dosage
1349408|NCT00571181|Remifentanil/*administration & dosage
1349409|NCT00571181|Bronchoscopy/*methods
1349410|NCT00571181|Prospective Studies
1349411|NCT00571181|Software
1349412|NCT00571168|chemotherapy induced nausea and vomiting
1349413|NCT00571168|autologous peripheral blood stemcell transplantation
1349414|NCT00571168|high dose chemotherapy
1349415|NCT00571142|edema
1349416|NCT00571142|retinal thickness
1349417|NCT00571142|diabetic retinopathy
1349418|NCT00571129|Primary,silicone tube,revision,mitomycin C,endoscopic DCR
1349419|NCT00571116|Metastatic Melanoma
1349420|NCT00571116|Disulfiram
1349421|NCT00571116|Arsenic Trioxide
1349422|NCT00571116|Metastatic Melanoma and at Least One Prior Systemic Therapy
1349423|NCT00571103|acamprosate, impulse-control disorders
1349424|NCT00571090|Thyroid nodule
1349425|NCT00571090|Biopsy, Fine-Needle
1349426|NCT00571077|Thyroid neoplasms
1349427|NCT00571077|thyroid nodules
1349428|NCT00571077|electrical impedance scanning
1349429|NCT00571051|MEG, mindfulness, tactile perception
1349430|NCT00571038|Hypertension
1349431|NCT00571038|Self-help groups
1349432|NCT00571038|Community health networks
1349433|NCT00571038|Health knowledge, attitudes, practice
1349434|NCT00571038|Patient participation
1349435|NCT00571038|Randomized clinical trial
1349436|NCT00571025|Mild Cognitive Impairment
1349437|NCT00571025|disease/disorder proneness/risk
1349438|NCT00571025|family genetics
1349439|NCT00571025|genetic counseling
1349440|NCT00571025|genetic marker
1349441|NCT00571025|genetic polymorphism
1349442|NCT00571025|genetic susceptibility
1349443|NCT00571012|glaucoma
1349444|NCT00571012|outflow facility
1349445|NCT00571012|Healthy eye function
1349446|NCT00570999|Peripheral blood stem cell transplantation
1349447|NCT00570999|Palifermin
1349448|NCT00570999|Kepivance
1349449|NCT00570999|Prevenar
1349450|NCT00570999|Placebo
1349451|NCT00570986|Plaque Psoriasis
1349452|NCT00570973|Variceal Bleeding
1349453|NCT00570973|Cirrhosis
1349454|NCT00570973|Encephalopathy
1349455|NCT00570973|Endoscopic band ligation
1349456|NCT00570973|TIPS
1349457|NCT00570960|Peritonitis
1349458|NCT00570947|CPR Anytime
1349459|NCT00570921|Breast cancer
1349460|NCT00570921|Fulvestrant
1349461|NCT00570921|Everolimus
1349462|NCT00570908|brain metastasis
1349463|NCT00570908|breast cancer
1349464|NCT00570908|metastatic breast cancer
1349465|NCT00570895|Iron
1349466|NCT00570895|Absorption
1349467|NCT00570895|Ascorbic Acid
1349468|NCT00570895|Ferrous Fumarate
1349469|NCT00570882|Renal cell carcinoma
1349470|NCT00570882|Sunitinib
1349471|NCT00570882|phase II study
1349472|NCT00570882|Randomized study
1349473|NCT00570869|Infant CPR
1349474|NCT00570856|Folic Acid
1349475|NCT00570856|Homocysteine
1349476|NCT00570856|intima-media thickness
1349477|NCT00570817|Methotrexate
1349478|NCT00570817|Nephrotoxicity
1349479|NCT00570817|Hydration
1349480|NCT00570817|Acute lymphoblastic leukemia
1349481|NCT00570817|Non-Hodgkin's lymphoma
1349482|NCT00570817|Medulloblastoma
1349483|NCT00570817|Ependymoma
1349484|NCT00570817|Prolonged elimination time of methotrexate
1349485|NCT00570804|Smoking Cessation
1349486|NCT00570804|Puerto Rico Quitline
1349487|NCT00570804|Motivational Relapse Prevention
1349488|NCT00570804|Oral Cancer
1349489|NCT00570804|Risk Reduction
1349490|NCT00570804|Tobacco Use
1349491|NCT00570804|Alcohol Use
1349492|NCT00570804|MAPS
1349493|NCT00570804|Motivation and Problem-Solving
1349494|NCT00570804|Telephone Interview
1349495|NCT00570804|Counseling
1349496|NCT00570791|Cornea
1349497|NCT00570791|Tonometers
1349498|NCT00570791|Goldmann applanation
1349499|NCT00570791|Tonopen
1349500|NCT00570791|Shiotz
1349501|NCT00570791|Pneumatonometer
1349502|NCT00570778|QVA, Indacaterol, Glycopyrrolate, Concept1, COPD, cross over study, safety and efficacy, trough FEV1
1349503|NCT00570739|Colesevelam
1349504|NCT00570739|Type 2 Diabetes Mellitus
1349505|NCT00570739|Pre-diabetes
1349506|NCT00570739|Metformin
1349507|NCT00570700|prostate
1349508|NCT00570687|Inhaled Insulin
1349509|NCT00570674|SSCHN
1349510|NCT00570674|Abraxane
1349511|NCT00570674|IMRT
1349512|NCT00570648|Corneal transplantation
1349513|NCT00570635|GIST
1349514|NCT00570635|Gastrointestinal Cancer
1349515|NCT00570622|Cirrhosis
1349516|NCT00570622|oxidative stress
1349517|NCT00570622|pioglitazone
1349518|NCT00570609|CPR
1349519|NCT00570583|Depression
1349520|NCT00570583|Cognitive impairment
1349521|NCT00570583|Dementia
1349522|NCT00570583|Neuroimaging
1349523|NCT00570583|Genetics
1349524|NCT00570570|stroke
1349525|NCT00570570|hemiplegia
1349526|NCT00570570|gait
1349527|NCT00570570|Strengthening
1349528|NCT00570570|Physiotherapy
1349529|NCT00570557|Skill Maintenance
1349530|NCT00570557|Skill Decay
1349531|NCT00570557|Screening
1349532|NCT00570544|copd
1349533|NCT00570544|emphysema
1349534|NCT00570544|tiotropium
1349535|NCT00570544|lung function
1349536|NCT00570544|dynamic hyperinflation
1349537|NCT00570518|driving under the influence
1349538|NCT00570518|psychoactive substances
1349539|NCT00570518|roadside surveys
1349540|NCT00570518|hospital surveys
1349541|NCT00570518|accident involvement risk estimation
1349542|NCT00570492|allergic rhinitis
1349543|NCT00570492|fluticasone furoate nasal spray
1349544|NCT00570492|growth
1349545|NCT00570479|Retisert
1349546|NCT00570479|Uveitis
1349547|NCT00570479|glaucoma
1349548|NCT00570466|Type 2 Diabetes
1349549|NCT00570466|Prevention
1349550|NCT00570466|Children
1349551|NCT00570466|Diet
1349552|NCT00570466|Physical Activity
1349553|NCT00570440|AE adverse event
1349554|NCT00570440|AIDS acquired immunodeficiency syndrome
1349555|NCT00570440|ALT (SGPT) alanine aminotransferase
1349556|NCT00570440|ART antiretroviral therapy
1349557|NCT00570440|AST (SGOT) aspartate aminotransferase
1349558|NCT00570440|DCF data collection forms
1349559|NCT00570440|DMC Data Monitoring Committee
1349560|NCT00570440|FDA (U.S.) Food and Drug Administration
1349561|NCT00570440|GCP Good Clinical Practice guidelines
1349562|NCT00570440|HB sAg Hepatitis B surface antigen
1349563|NCT00570440|ICH International Conference of Harmonisation
1349564|NCT00570440|IND Investigational New Drug Application
1349565|NCT00570440|IRB Institutional Review Board
1349566|NCT00570440|IU international units
1349567|NCT00570440|mg milligram(s)
1349568|NCT00570440|mm3 cubic millimeter(s)
1349569|NCT00570440|PCR polymerase chain reaction
1349570|NCT00570440|SAE serious adverse event
1349571|NCT00570440|µg microgram
1349572|NCT00570440|ULN upper limit of the normal range
1349573|NCT00570440|WB Western Blot
1349574|NCT00570427|psychotherapy
1349575|NCT00570427|behavior therapy
1349576|NCT00570427|counseling
1349577|NCT00570427|aging
1349578|NCT00570427|medically underserved population
1349579|NCT00570401|adenocarcinoma of the lung
1349580|NCT00570401|stage IIIA non-small cell lung cancer
1349581|NCT00570401|stage IIIB non-small cell lung cancer
1349582|NCT00570401|stage IV non-small cell lung cancer
1349583|NCT00570401|recurrent non-small cell lung cancer
1349584|NCT00570388|Neurocognitive
1349585|NCT00570388|Alcohol Dependence
1349586|NCT00570388|Prometa
1349587|NCT00570388|Prometa Protocol
1349588|NCT00570388|Starosta
1349589|NCT00570375|Blood disease, bone marrow
1349590|NCT00570362|Normal tension glaucoma
1349591|NCT00570362|Glutathione
1349592|NCT00570362|Antioxidant
1349593|NCT00570349|Inhaled Nitric oxide
1349594|NCT00570349|Cystic Fibrosis
1349595|NCT00570336|HCV
1349596|NCT00570336|HCV treatment failure
1349597|NCT00570336|Elevated aminotransferases
1349598|NCT00570323|Breast Cancer
1349599|NCT00570323|HORMONE RECEPTOR POSITIVE BREAST CANCER
1349600|NCT00570297|Pediatric
1349601|NCT00570297|Polymorphism, Genetic
1349602|NCT00570297|Adrenergic beta-Agonists
1349603|NCT00570284|Cancer
1349604|NCT00570284|solid tumor
1349605|NCT00570284|food effect
1349606|NCT00570284|HDAC inhibitor
1349607|NCT00570284|oral
1349608|NCT00570284|LBH589
1349609|NCT00570271|placebo effect
1349610|NCT00570271|blood pressure
1349611|NCT00570271|autonomic nervous system
1349612|NCT00570271|prestige
1349613|NCT00570271|basic research on physiological placebo effects
1349614|NCT00570245|Lung transplantation
1349615|NCT00570232|Resectable, recurrent head and neck cancer
1349616|NCT00570206|Probation
1349617|NCT00570206|Motivational
1349618|NCT00570180|newly diagnosed
1349619|NCT00570167|Osteoarthritis
1349620|NCT00570167|Hip
1349621|NCT00570167|Artroplasty
1349622|NCT00570167|Resurfacing
1349623|NCT00570154|Mitochondrial Function in Monocytes
1349624|NCT00570154|Macrophages and Diabetes or Insulin Resistance
1349625|NCT00570154|Peripheral Blood Mononuclear Cells
1349626|NCT00570154|Diabetes
1349627|NCT00570154|Monocyte
1349628|NCT00570154|Macrophages
1349629|NCT00570154|Proteome
1349630|NCT00570154|Type 2 Diabetes
1349631|NCT00570154|Insulin Resistance
1349632|NCT00570154|Insulin Sensitivity
1349633|NCT00570154|Pre-Diabetes
1349634|NCT00570154|Healthy Volunteer
1349635|NCT00570154|HV
1349636|NCT00570128|Down Syndrome
1349637|NCT00570128|trisomy 21
1349638|NCT00570115|Sleep Apnea Syndromes diastolic disfunction left atrium
1349639|NCT00570102|dietary manipulation
1349640|NCT00570102|infants
1349641|NCT00570102|feasibility
1349642|NCT00570102|Type 1 Diabetes Mellitus, Beta-cell Autoimmunity
1349643|NCT00570089|Ranolazine
1349644|NCT00570089|Myocardial ischemia
1349645|NCT00570089|Double blinded
1349646|NCT00570089|Placebo controlled
1349647|NCT00570063|Schizophrenia, acute exacerbation, and PF-02545920
1349648|NCT00570050|Major Depressive Disorder, Memory, Executive function
1349649|NCT00570037|Influenza
1349650|NCT00570037|Vaccine
1349651|NCT00570037|Children
1349652|NCT00570024|Acupuncture
1349653|NCT00570024|Coronary Artery Disease
1349654|NCT00569985|AIDS-related diffuse large cell lymphoma
1349655|NCT00569985|AIDS-related diffuse mixed cell lymphoma
1349656|NCT00569985|AIDS-related diffuse small cleaved cell lymphoma
1349657|NCT00569985|AIDS-related immunoblastic large cell lymphoma
1349658|NCT00569985|AIDS-related small noncleaved cell lymphoma
1349659|NCT00569985|HIV-associated Hodgkin lymphoma
1349660|NCT00569985|Treatment Experienced
1349661|NCT00569959|fasting lipid measures
1349662|NCT00569959|non-fasting lipid measures
1349663|NCT00569959|clinical decision-making
1349664|NCT00569959|LDL-Cholesterol
1349665|NCT00569946|AG-013736
1349666|NCT00569946|RCC
1349667|NCT00569946|Phase 2
1349668|NCT00569933|Hip Surgery
1349669|NCT00569933|Perioperative
1349670|NCT00569933|suggestions/imagery
1349671|NCT00569907|type 2 diabetes
1349672|NCT00569907|continuous glucose monitoring
1349673|NCT00569907|exenatide
1349674|NCT00569907|exenatide use
1349675|NCT00569881|Epithelium
1349676|NCT00569881|Wound Healing
1349677|NCT00569881|PRK
1349678|NCT00569868|PLASMACYTOMA
1349679|NCT00569829|cognitive behavioral therapy
1349680|NCT00569829|anxiety disorders
1349681|NCT00569829|school-based intervention
1349682|NCT00569829|randomized, controlled trial
1349683|NCT00569816|myocardial protection
1349684|NCT00569816|pharmacological preconditioning
1349685|NCT00569816|volatile anesthetics
1349686|NCT00569816|myocardial injury following CABG surgery
1349687|NCT00569790|S-1
1349688|NCT00569790|Irinotecan
1349689|NCT00569790|Bevacizumab
1349690|NCT00569764|schizophrenia
1349691|NCT00569764|metabolic syndrome
1349692|NCT00569764|aripiprazole
1349693|NCT00569751|de novo
1349694|NCT00569751|coronary
1349695|NCT00569751|coronary artery disease
1349696|NCT00569751|coronary disease
1349697|NCT00569738|neuroendocrine tumor
1349698|NCT00569738|somatostatin analog
1349699|NCT00569738|Gallium 68
1349700|NCT00569738|PET
1349701|NCT00569712|non-small cell lung cancer
1349702|NCT00569712|precancerous condition
1349703|NCT00569699|S-1
1349704|NCT00569699|Bevacizumab
1349705|NCT00569686|PAD
1349706|NCT00569686|peripheral artery disease
1349707|NCT00569673|recurrent ovarian epithelial cancer
1349708|NCT00569673|fallopian tube cancer
1349709|NCT00569673|primary peritoneal cavity cancer
1349710|NCT00569660|Myelofibrosis
1349711|NCT00569660|MF
1349712|NCT00569660|Leukemia
1349713|NCT00569660|Azacitidine
1349714|NCT00569660|Vidaza
1349715|NCT00569647|preoperative anxiety
1349716|NCT00569647|burn reconstruction
1349717|NCT00569634|Venous blood gas
1349718|NCT00569634|Arterial blood gas
1349719|NCT00569634|pH
1349720|NCT00569634|pCO2
1349721|NCT00569634|Bicarbonate
1349722|NCT00569608|Parental stress
1349723|NCT00569608|Early discharge
1349724|NCT00569608|Anxiety
1349725|NCT00569608|Depression
1349726|NCT00569608|Neonatal Intensive Care Unit
1349727|NCT00569595|Prevention of Diabetes and other chronic diseases
1349728|NCT00569582|Cushing's Disease
1349729|NCT00569582|Cushing's Syndrome
1349730|NCT00569582|Cushings
1349731|NCT00569582|Pituitary
1349732|NCT00569582|ACTH
1349733|NCT00569582|Adrenocorticotropic hormone
1349734|NCT00569582|Ectopic
1349735|NCT00569582|Adrenal adenoma
1349736|NCT00569582|Adrenal carcinoma
1349737|NCT00569582|Adrenal autonomy
1349738|NCT00569582|Cortisol
1349739|NCT00569582|Hypercortisolemia
1349740|NCT00569582|Cushingoid
1349741|NCT00569582|Moon facies
1349742|NCT00569582|Dorsocervical fat
1349743|NCT00569582|Plethora
1349744|NCT00569582|Hirsutism
1349745|NCT00569582|Violaceous striae
1349746|NCT00569582|Hormone
1349747|NCT00569582|Contraceptive
1349748|NCT00569582|Endocrine
1349749|NCT00569582|Cushing Syndrome
1349750|NCT00569582|Ectopic ACTH Secretion
1349751|NCT00569556|Diabetes Mellitus
1349752|NCT00569556|Chronic Care Model
1349753|NCT00569556|Case Management
1349754|NCT00569543|breast cancer in situ
1349755|NCT00569543|ductal breast carcinoma in situ
1349756|NCT00569543|stage I breast cancer
1349757|NCT00569543|stage II breast cancer
1349758|NCT00569543|stage IIIA breast cancer
1349759|NCT00569543|stage IIIB breast cancer
1349760|NCT00569543|stage IIIC breast cancer
1349761|NCT00569543|stage IV breast cancer
1349762|NCT00569530|nitric oxide
1349763|NCT00569530|surfactant
1349764|NCT00569530|bronchopulmonary dysplasia
1349765|NCT00569530|prematurity
1349766|NCT00569530|neonates
1349767|NCT00569530|iNO
1349768|NCT00569530|Infasurf
1349769|NCT00569530|lung function
1349770|NCT00569530|ventilated infants
1349771|NCT00569517|obesity
1349772|NCT00569517|CBT
1349773|NCT00569517|Atypical antipsychotics
1349774|NCT00569517|metabolic syndrome
1349775|NCT00569504|schizophrenia
1349776|NCT00569504|antipsychotics
1349777|NCT00569504|metabolic syndrome
1349778|NCT00569504|prevalence
1349779|NCT00569478|ICD
1349780|NCT00569478|Rehabilitation
1349781|NCT00569465|nitric oxide
1349782|NCT00569465|oxidative stress
1349783|NCT00569465|diabetes
1349784|NCT00569465|hypertension
1349785|NCT00569465|endothelial dysfunction
1349786|NCT00569439|Labor
1349787|NCT00569439|Carbohydrate
1349788|NCT00569439|Dystocia
1349789|NCT00569413|Sex
1349790|NCT00569413|brain imaging
1349791|NCT00569413|dopamine
1349792|NCT00569413|sexual disorder
1349793|NCT00569387|pancreatic cancer
1349794|NCT00569387|vaccine
1349795|NCT00569361|allergic rhinitis to dust mite
1349796|NCT00569361|allergic rhinitis associated with bronchial hyperreactivity
1350116|NCT00568243|Visuomotor Integration
1349797|NCT00569361|allergic rhinitis associated with asthma
1349798|NCT00569335|S-1, Bevacizumab, Irinotecan
1349799|NCT00569322|ICU
1349800|NCT00569322|Admission
1349801|NCT00569322|BG
1349802|NCT00569309|contiguous stage II mantle cell lymphoma
1349803|NCT00569309|noncontiguous stage II mantle cell lymphoma
1349804|NCT00569309|recurrent mantle cell lymphoma
1349805|NCT00569309|stage I mantle cell lymphoma
1349806|NCT00569309|stage III mantle cell lymphoma
1349807|NCT00569309|stage IV mantle cell lymphoma
1349808|NCT00569309|recurrent adult diffuse large cell lymphoma
1349809|NCT00569309|stage III adult diffuse large cell lymphoma
1349810|NCT00569309|stage IV adult diffuse large cell lymphoma
1349811|NCT00569309|contiguous stage II grade 1 follicular lymphoma
1349812|NCT00569309|contiguous stage II grade 2 follicular lymphoma
1349813|NCT00569309|contiguous stage II grade 3 follicular lymphoma
1349814|NCT00569309|noncontiguous stage II grade 1 follicular lymphoma
1349815|NCT00569309|noncontiguous stage II grade 2 follicular lymphoma
1349816|NCT00569309|noncontiguous stage II grade 3 follicular lymphoma
1349817|NCT00569309|recurrent grade 1 follicular lymphoma
1349818|NCT00569309|recurrent grade 2 follicular lymphoma
1349819|NCT00569309|recurrent grade 3 follicular lymphoma
1349820|NCT00569309|stage I grade 1 follicular lymphoma
1349821|NCT00569309|stage I grade 2 follicular lymphoma
1349822|NCT00569309|stage I grade 3 follicular lymphoma
1349823|NCT00569309|stage III grade 1 follicular lymphoma
1349824|NCT00569309|stage III grade 2 follicular lymphoma
1349825|NCT00569309|stage III grade 3 follicular lymphoma
1349826|NCT00569309|stage IV grade 1 follicular lymphoma
1349827|NCT00569309|stage IV grade 2 follicular lymphoma
1349828|NCT00569309|stage IV grade 3 follicular lymphoma
1349829|NCT00569309|recurrent adult Hodgkin lymphoma
1349830|NCT00569309|stage I multiple myeloma
1349831|NCT00569309|stage II multiple myeloma
1349832|NCT00569309|stage III multiple myeloma
1349833|NCT00569309|refractory multiple myeloma
1349834|NCT00569309|contiguous stage II adult diffuse large cell lymphoma
1349835|NCT00569309|noncontiguous stage II adult diffuse large cell lymphoma
1349836|NCT00569309|stage I adult diffuse large cell lymphoma
1349837|NCT00569309|adult nasal type extranodal NK/T-cell lymphoma
1349838|NCT00569309|angioimmunoblastic T-cell lymphoma
1349839|NCT00569309|anaplastic large cell lymphoma
1349840|NCT00569309|small intestine lymphoma
1349841|NCT00569296|recurrent non-small cell lung cancer
1349842|NCT00569296|stage IV non-small cell lung cancer
1349843|NCT00569283|adult acute lymphoblastic leukemia in remission
1349844|NCT00569283|adult acute myeloid leukemia in remission
1349845|NCT00569283|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1349846|NCT00569283|adult acute myeloid leukemia with inv(16)(p13;q22)
1349847|NCT00569283|adult acute myeloid leukemia with t(15;17)(q22;q12)
1349848|NCT00569283|adult acute myeloid leukemia with t(16;16)(p13;q22)
1349849|NCT00569283|adult acute myeloid leukemia with t(8;21)(q22;q22)
1349850|NCT00569283|accelerated phase chronic myelogenous leukemia
1349851|NCT00569283|atypical chronic myeloid leukemia, BCR-ABL1 negative
1349852|NCT00569283|blastic phase chronic myelogenous leukemia
1349853|NCT00569283|childhood acute lymphoblastic leukemia in remission
1349854|NCT00569283|childhood acute myeloid leukemia in remission
1349855|NCT00569283|chronic eosinophilic leukemia
1349856|NCT00569283|primary myelofibrosis
1349857|NCT00569283|chronic myelomonocytic leukemia
1349858|NCT00569283|chronic neutrophilic leukemia
1349859|NCT00569283|chronic phase chronic myelogenous leukemia
1349860|NCT00569283|de novo myelodysplastic syndromes
1349861|NCT00569283|disseminated neuroblastoma
1349862|NCT00569283|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1349863|NCT00569283|juvenile myelomonocytic leukemia
1349864|NCT00569283|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1349865|NCT00569283|nodal marginal zone B-cell lymphoma
1349866|NCT00569283|noncontiguous stage II adult Burkitt lymphoma
1349867|NCT00569283|noncontiguous stage II adult diffuse large cell lymphoma
1349868|NCT00569283|noncontiguous stage II adult diffuse mixed cell lymphoma
1349869|NCT00569283|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1349870|NCT00569283|noncontiguous stage II adult immunoblastic large cell lymphoma
1349871|NCT00569283|noncontiguous stage II adult lymphoblastic lymphoma
1349872|NCT00569283|noncontiguous stage II grade 1 follicular lymphoma
1349873|NCT00569283|noncontiguous stage II grade 2 follicular lymphoma
1349874|NCT00569283|noncontiguous stage II grade 3 follicular lymphoma
1349875|NCT00569283|noncontiguous stage II mantle cell lymphoma
1349876|NCT00569283|noncontiguous stage II marginal zone lymphoma
1349877|NCT00569283|noncontiguous stage II small lymphocytic lymphoma
1349878|NCT00569283|high risk metastatic gestational trophoblastic tumor
1349879|NCT00569283|previously treated childhood rhabdomyosarcoma
1349880|NCT00569283|previously treated myelodysplastic syndromes
1349881|NCT00569283|recurrent adult acute lymphoblastic leukemia
1349882|NCT00569283|recurrent adult acute myeloid leukemia
1349883|NCT00569283|recurrent adult Burkitt lymphoma
1349884|NCT00569283|recurrent adult diffuse large cell lymphoma
1349885|NCT00569283|recurrent adult diffuse mixed cell lymphoma
1349886|NCT00569283|recurrent adult diffuse small cleaved cell lymphoma
1349887|NCT00569283|recurrent adult Hodgkin lymphoma
1349888|NCT00569283|recurrent adult immunoblastic large cell lymphoma
1349889|NCT00569283|recurrent adult lymphoblastic lymphoma
1349890|NCT00569283|recurrent/refractory childhood Hodgkin lymphoma
1349891|NCT00569283|recurrent childhood acute lymphoblastic leukemia
1349892|NCT00569283|recurrent childhood acute myeloid leukemia
1349893|NCT00569283|recurrent childhood large cell lymphoma
1349894|NCT00569283|recurrent childhood lymphoblastic lymphoma
1349895|NCT00569283|recurrent childhood rhabdomyosarcoma
1349896|NCT00569283|recurrent childhood small noncleaved cell lymphoma
1349897|NCT00569283|recurrent cutaneous T-cell non-Hodgkin lymphoma
1349898|NCT00569283|recurrent mycosis fungoides/Sezary syndrome
1349899|NCT00569283|recurrent grade 1 follicular lymphoma
1349900|NCT00569283|recurrent grade 2 follicular lymphoma
1349901|NCT00569283|recurrent grade 3 follicular lymphoma
1349902|NCT00569283|stage III grade 1 follicular lymphoma
1349903|NCT00569283|stage III grade 2 follicular lymphoma
1349904|NCT00569283|stage III grade 3 follicular lymphoma
1349905|NCT00569283|stage IV grade 1 follicular lymphoma
1349906|NCT00569283|stage IV grade 2 follicular lymphoma
1349907|NCT00569283|stage IV grade 3 follicular lymphoma
1349908|NCT00569283|recurrent mantle cell lymphoma
1349909|NCT00569283|stage III mantle cell lymphoma
1349910|NCT00569283|stage IV mantle cell lymphoma
1349911|NCT00569283|recurrent marginal zone lymphoma
1349912|NCT00569283|splenic marginal zone lymphoma
1349913|NCT00569283|stage III marginal zone lymphoma
1349914|NCT00569283|stage IV marginal zone lymphoma
1349915|NCT00569283|recurrent neuroblastoma
1349916|NCT00569283|recurrent ovarian epithelial cancer
1349917|NCT00569283|recurrent ovarian germ cell tumor
1349918|NCT00569283|recurrent small lymphocytic lymphoma
1349919|NCT00569283|stage III small lymphocytic lymphoma
1349920|NCT00569283|stage IV small lymphocytic lymphoma
1349921|NCT00569283|recurrent malignant testicular germ cell tumor
1349922|NCT00569283|stage III malignant testicular germ cell tumor
1349923|NCT00569283|childhood malignant ovarian germ cell tumor
1349924|NCT00569283|childhood malignant testicular germ cell tumor
1349925|NCT00569283|recurrent Wilms tumor and other childhood kidney tumors
1349926|NCT00569283|refractory chronic lymphocytic leukemia
1349927|NCT00569283|refractory hairy cell leukemia
1349928|NCT00569283|refractory multiple myeloma
1349929|NCT00569283|relapsing chronic myelogenous leukemia
1349930|NCT00569283|secondary acute myeloid leukemia
1349931|NCT00569283|secondary myelodysplastic syndromes
1349932|NCT00569283|stage I multiple myeloma
1349933|NCT00569283|stage II multiple myeloma
1349934|NCT00569283|stage II ovarian epithelial cancer
1349935|NCT00569283|stage III adult Burkitt lymphoma
1349936|NCT00569283|stage III adult diffuse large cell lymphoma
1349937|NCT00569283|stage III adult diffuse mixed cell lymphoma
1349938|NCT00569283|stage III adult diffuse small cleaved cell lymphoma
1349939|NCT00569283|stage III adult immunoblastic large cell lymphoma
1349940|NCT00569283|stage III adult lymphoblastic lymphoma
1349941|NCT00569283|stage III chronic lymphocytic leukemia
1349942|NCT00569283|stage IV chronic lymphocytic leukemia
1349943|NCT00569283|stage III ovarian epithelial cancer
1349944|NCT00569283|stage III multiple myeloma
1349945|NCT00569283|stage IIIA breast cancer
1349946|NCT00569283|stage IIIB breast cancer
1349947|NCT00569283|stage IIIC breast cancer
1349948|NCT00569283|stage IV breast cancer
1349949|NCT00569283|stage III adult Hodgkin lymphoma
1349950|NCT00569283|stage IV adult Burkitt lymphoma
1349951|NCT00569283|stage IV adult diffuse large cell lymphoma
1349952|NCT00569283|stage IV adult diffuse mixed cell lymphoma
1349953|NCT00569283|stage IV adult diffuse small cleaved cell lymphoma
1349954|NCT00569283|stage IV adult Hodgkin lymphoma
1349955|NCT00569283|stage IV adult immunoblastic large cell lymphoma
1349956|NCT00569283|stage IV adult lymphoblastic lymphoma
1349957|NCT00569283|stage IV ovarian epithelial cancer
1349958|NCT00569257|LHRH receptor
1349959|NCT00569257|receptor positive tumors
1349960|NCT00569257|platinum resistant ovarian cancer
1349961|NCT00569244|Primary Dysmenorrhea
1349962|NCT00569244|Menstrual Pain
1349963|NCT00569244|Oral Contraception
1349964|NCT00569231|Warts
1349965|NCT00569231|Candida
1349966|NCT00569231|HPV
1349967|NCT00569231|Injections, Intralesional
1349968|NCT00569231|Immune System
1349969|NCT00569192|asthmatic children
1349970|NCT00569179|Myeloid Malignancies
1349971|NCT00569179|Bone Marrow Transplant
1349972|NCT00569179|AML
1349973|NCT00569179|ALL
1349974|NCT00569179|MDS
1349975|NCT00569179|CML
1349976|NCT00569166|fatigue
1349977|NCT00569166|sleep disorders
1349978|NCT00569166|ductal breast carcinoma in situ
1349979|NCT00569166|lobular breast carcinoma in situ
1349980|NCT00569166|breast cancer
1349981|NCT00569166|hot flashes
1349982|NCT00569153|Androgen-independent prostate cancer, metastatic
1349983|NCT00569088|hemorrhagic stroke
1349984|NCT00569088|Chinese Medicine
1349985|NCT00569088|pathogenesis
1349986|NCT00569088|YURE
1349987|NCT00569075|Apoptic biomarkers
1349988|NCT00569075|Early detection periodontitis
1349989|NCT00569075|Gingival crevicular fluid
1349990|NCT00569075|Healthy subjects
1349991|NCT00569062|Psychomotor retardation,
1349992|NCT00569062|Major Depressive Disorder (MDD),
1349993|NCT00569062|GW856553,
1349994|NCT00569062|cytokines
1349995|NCT00569036|Advanced or Metastatic Solid Tumors or Neoplasms
1349996|NCT00569023|Beta Carotene
1349997|NCT00569023|visual functions
1349998|NCT00569023|Fundus albipunctatus
1349999|NCT00569023|Night Blindness
1350000|NCT00569010|Acute Myelogenous Leukemia
1350001|NCT00569010|AML
1350002|NCT00569010|Myelodysplastic Syndrome
1350003|NCT00569010|MDS
1350004|NCT00569010|Leukemia
1350005|NCT00568997|Atopic dermatitis, eczema, children, pediatric patients, pimecrolimus, malignancy, registry
1350006|NCT00568971|DCF
1350007|NCT00568971|Advanced gastric cancer
1350008|NCT00568971|Phase II study
1350009|NCT00568971|Efficacy
1350010|NCT00568971|Toxicity
1350011|NCT00568958|heavy episodic drinking
1350012|NCT00568958|young adults
1350013|NCT00568958|naltrexone
1350014|NCT00568958|BASICS counseling
1350015|NCT00568958|alcohol-related consequences
1350016|NCT00568958|double-blind trial
1350017|NCT00568958|randomized clinical trial
1350018|NCT00568945|Atrial Fibrillation
1350019|NCT00568945|Capadenoson
1350020|NCT00568880|stage I multiple myeloma
1350021|NCT00568880|stage II multiple myeloma
1350022|NCT00568880|stage III multiple myeloma
1350023|NCT00568880|refractory multiple myeloma
1350024|NCT00568841|advanced Non-Small-Cell Lung Cancer
1350025|NCT00568841|erlotinib
1350026|NCT00568841|FDG-PET
1350027|NCT00568841|FLT-PET
1350028|NCT00568828|Macular Teleangiectasia
1350029|NCT00568828|Macular Pigment
1350030|NCT00568815|DLBCL
1350031|NCT00568815|Rituximab
1350032|NCT00568815|ESHAP
1350033|NCT00568815|Efficacy
1350034|NCT00568815|Toxicity
1350035|NCT00568789|Insomnia
1350036|NCT00568789|Aged
1350037|NCT00568789|Postural Balance
1350038|NCT00568789|Drug Therapy
1350039|NCT00568763|stage IV melanoma
1350040|NCT00568763|recurrent melanoma
1350041|NCT00568750|gastrointestinal stromal tumor
1350042|NCT00568737|Severe Sepsis
1350043|NCT00568724|Hydronephrosis
1350044|NCT00568724|Ureteral obstruction
1350045|NCT00568711|Doxycycline,
1350046|NCT00568711|Rifampin
1350047|NCT00568711|Scrub typhus.
1350048|NCT00568672|Major Depression
1350049|NCT00568672|Olanzapine
1350050|NCT00568672|add-on therapy
1350051|NCT00568672|antidepressant
1350052|NCT00568672|atypical antipsychotic
1350053|NCT00568659|Gas exchange
1350054|NCT00568659|Respiratory mechanics
1350055|NCT00568659|Ventilator Induced Lung Injury
1350056|NCT00568607|NK/T cell lymphoma
1350057|NCT00568607|Response Rate
1350058|NCT00568607|TTP
1350059|NCT00568607|OS
1350060|NCT00568607|Toxicities
1350061|NCT00568594|Apolipoprotein A-I,
1350062|NCT00568594|Atherosclerosis,
1350063|NCT00568594|HDL,
1350064|NCT00568594|Inflammation,
1350065|NCT00568568|Growth Hormone
1350066|NCT00568568|GH signaling
1350067|NCT00568568|Insulin resistance
1350068|NCT00568568|Insulin Signaling
1350069|NCT00568542|cardiomyopathy
1350070|NCT00568542|ischemia
1350071|NCT00568542|percutaneous coronary intervention
1350072|NCT00568542|remodeling
1350073|NCT00568529|Advanced gastric cancer
1350074|NCT00568529|Response rate
1350075|NCT00568529|Side effects
1350076|NCT00568529|time to progression
1350077|NCT00568529|overall survival
1350078|NCT00568516|ASP3550
1350079|NCT00568516|Degarelix
1350080|NCT00568516|Prostate cancer
1350081|NCT00568516|Prostatic neoplasms
1350082|NCT00568503|COPD/TIOTROPIUM/QAX028
1350083|NCT00568477|Rituximab, Heemannn
1350084|NCT00568464|ESFT (Ewing's sarcoma family of tumors)
1350085|NCT00568464|Response rate
1350086|NCT00568464|TTP
1350087|NCT00568464|OS
1350088|NCT00568464|Toxicity
1350089|NCT00568451|stage IV melanoma
1350090|NCT00568451|recurrent melanoma
1350091|NCT00568412|atopic dermatitis
1350092|NCT00568399|Coronary
1350093|NCT00568399|Calcification
1350094|NCT00568399|Dialysis
1350095|NCT00568399|Thiosulfate
1350096|NCT00568399|Cardiovascular
1350097|NCT00568386|Dry eye
1350098|NCT00568373|Gastroparesis
1350099|NCT00568373|Gastric electrical stimulator
1350100|NCT00568347|chronic airflow obstruction
1350101|NCT00568334|chickenpox
1350102|NCT00568334|varicella
1350103|NCT00568334|two-dose schedule
1350104|NCT00568334|second year of life
1350105|NCT00568321|monoclonal antibody
1350106|NCT00568308|Hepatocellular Carcinoma
1350107|NCT00568308|PI-88
1350108|NCT00568308|Phase III
1350109|NCT00568308|Adjuvant Therapy
1350110|NCT00568308|Hepatoma
1350111|NCT00568308|Liver Cancer
1350112|NCT00568269|Recurrence rate after inguinal hernia repair on primary inguinal herina.
1350113|NCT00568256|Ulcerative Colitis
1350114|NCT00568256|IBD Flare-Up
1350115|NCT00568256|Stress
1350117|NCT00568243|Visual Attention
1350118|NCT00568243|Healthy Volunteer
1350119|NCT00568243|HV
1350120|NCT00568230|heart failure
1350121|NCT00568230|mitral regurgitation
1350122|NCT00568204|pruritus, itching, mexyn-a, clearitch, magicool-plus
1350123|NCT00568191|Age-related macular degeneration
1350124|NCT00568191|choroidal neovascularization
1350125|NCT00568191|Stratus OCT
1350126|NCT00568191|Cirrus OCT
1350127|NCT00568165|Heart failure, congestive
1350128|NCT00568165|Echocardiography
1350129|NCT00568165|Patient care team
1350130|NCT00568152|Apples
1350131|NCT00568152|Dietary intervention
1350132|NCT00568152|Procyanidins
1350133|NCT00568139|adrenal cancer
1350134|NCT00568139|mitotane (Lysodren)
1350135|NCT00568139|adverse events
1350136|NCT00568126|Antidepressant Induced Sexual Dysfunction
1350137|NCT00568126|Depression
1350138|NCT00568126|Sexual Dysfunction
1350139|NCT00568113|preterm labour
1350140|NCT00568113|n acetyl cysteine
1350141|NCT00568113|bacterial vaginosis
1350142|NCT00568100|gas exchange
1350143|NCT00568100|pressure support ventilation
1350144|NCT00568100|respiratory mechanics
1350145|NCT00568100|COPD
1350146|NCT00568100|NAVA
1350147|NCT00568087|N-acetylcysteine
1350148|NCT00568087|Alcoholism
1350149|NCT00568087|Treatment
1350150|NCT00568061|INOT44
1350151|NCT00568061|NOMI
1350152|NCT00568048|stage IV melanoma
1350153|NCT00568048|recurrent melanoma
1350154|NCT00568035|diabetic
1350155|NCT00568035|peripheral
1350156|NCT00568035|neuropathy
1350157|NCT00568009|Congestive Heart Failure
1350158|NCT00568009|Impaired Renal Function
1350159|NCT00567996|Chronic obstructive pulmonary disease, indacaterol, salmeterol, placebo controlled
1350160|NCT00567970|liver metastases
1350161|NCT00567957|pre-eclampsia
1350162|NCT00567957|remifentanil
1350163|NCT00567957|anesthesia, general
1350164|NCT00567957|analgesics, opioid
1350165|NCT00567957|anesthetics, intravenous
1350166|NCT00567957|Cesarean section
1350167|NCT00567957|newborn
1350168|NCT00567957|maternal haemodynamic
1350169|NCT00567944|Physical Therapy Modalities
1350170|NCT00567944|Electric Stimulation
1350171|NCT00567944|Postural Balance
1350172|NCT00567918|Keratoconjunctivitis
1350173|NCT00567918|Vernal keratoconjunctivitis
1350174|NCT00567918|FK506
1350175|NCT00567918|Tacrolimus
1350176|NCT00567905|Type 2 Diabetes
1350177|NCT00567905|Green tea extract
1350178|NCT00567905|overweight
1350179|NCT00567892|tinnitus
1350180|NCT00567892|subjective tinnitus
1350181|NCT00567892|therapy
1350182|NCT00567892|repetitive transcranial magnetic stimulation
1350183|NCT00567892|clinical trial
1350184|NCT00567879|Breast Cancer
1350185|NCT00567879|HER2 positive
1350186|NCT00567879|adult-female
1350187|NCT00567879|LBH589
1350188|NCT00567879|HDAC inhibitor
1350189|NCT00567879|panobinostat
1350190|NCT00567853|mitral valve regurgitation
1350191|NCT00567853|mitral valve disease
1350192|NCT00567853|mitral valve repair
1350193|NCT00567853|mitral valve dysfunction
1350194|NCT00567853|heart valve
1350195|NCT00567853|valve disease
1350196|NCT00567853|cardiac surgery
1350197|NCT00567840|Early Bactericidal Activity
1350198|NCT00567840|EBA
1350199|NCT00567840|pulmonary tuberculosis
1350200|NCT00567840|PA-824
1350201|NCT00567840|Pretomanid
1350202|NCT00567840|CL-007
1350203|NCT00567827|Pneumonia
1350204|NCT00567814|Cocaine
1350205|NCT00567814|Dependence
1350206|NCT00567814|Addiction
1350207|NCT00567814|Cortisol
1350208|NCT00567814|GABA
1350209|NCT00567801|Lower Extremity
1350210|NCT00567801|Ischemia
1350211|NCT00567788|Glaucoma, angle-closure
1350212|NCT00567762|Keratoconjunctivitis
1350213|NCT00567762|vernal keratoconjunctivitis
1350214|NCT00567762|FK506
1350215|NCT00567762|Tacrolimus
1350216|NCT00567749|HIV-1 Infections
1350217|NCT00567736|low back pain
1350218|NCT00567736|complementary therapies
1350219|NCT00567697|ranibizumab
1350220|NCT00567697|CRVO
1350221|NCT00567697|macular edema
1350222|NCT00567697|sham
1350223|NCT00567684|Transitional Cell Carcinoma
1350224|NCT00567684|Urothelial Cancer
1350225|NCT00567684|Bladder Cancer
1350226|NCT00567684|Computed Tomography Urography
1350227|NCT00567684|CTU
1350228|NCT00567684|Intravenous Urography
1350229|NCT00567684|IVU
1350230|NCT00567684|TCC
1350231|NCT00567684|transitional cell carcinomas
1350232|NCT00567671|keratoconus
1350233|NCT00567671|ectasia
1350234|NCT00567671|cross-linking
1350235|NCT00567671|riboflavin
1350236|NCT00567671|UVA light
1350237|NCT00567671|cornea
1350238|NCT00567632|Pneumococci
1350239|NCT00567632|Antibody
1350240|NCT00567632|Standard laboratory values
1350241|NCT00566579|Human papillomavirus
1350242|NCT00566579|Clearance
1350243|NCT00566579|Cryotherapy
1350244|NCT00566566|adipocytokines
1350245|NCT00566566|inflammatory markers
1350246|NCT00566566|cardiovascular disease
1350247|NCT00566566|diabetes mellitus
1350248|NCT00566566|Leptin
1350249|NCT00566553|Grape Seed Extract
1350250|NCT00566553|Breast Cancer
1350251|NCT00566553|Estrogen Levels
1350252|NCT00566553|Aromatase Inhibitor
1350253|NCT00566540|stage III squamous cell carcinoma of the hypopharynx
1350254|NCT00566540|stage IV squamous cell carcinoma of the hypopharynx
1350255|NCT00566540|stage III squamous cell carcinoma of the lip and oral cavity
1350256|NCT00566540|stage IV squamous cell carcinoma of the lip and oral cavity
1350257|NCT00566540|stage III squamous cell carcinoma of the oropharynx
1350258|NCT00566540|stage IV squamous cell carcinoma of the oropharynx
1350259|NCT00566540|stage II squamous cell carcinoma of the hypopharynx
1350260|NCT00566514|fibromyalgia
1350261|NCT00566514|ribose
1350262|NCT00566514|d-ribose
1350263|NCT00566514|dextrose
1350264|NCT00566501|Moderate-to-severe
1350265|NCT00566501|Alzheimer's
1350266|NCT00566501|Disease
1350267|NCT00566488|Thymus Transplantation
1350268|NCT00566488|Parathyroid Transplantation
1350269|NCT00566488|DiGeorge Syndrome
1350270|NCT00566488|Hypoparathyroidism
1350271|NCT00566488|Athymia
1350272|NCT00566449|Attention Deficit Hyperactivity Disorder
1350273|NCT00566449|ADHD
1350274|NCT00566449|JNJ-31001074
1350275|NCT00566436|Peripheral Arterial Occlusive Disease
1350276|NCT00566436|Superficial Femoral Artery
1350277|NCT00566436|Remote Endarterectomy
1350278|NCT00566436|Suprageniculate Bypass Surgery
1350279|NCT00566436|Blood Vessel Prosthesis Implantation
1350280|NCT00566436|Vascular Patency
1350281|NCT00566423|PAH
1350282|NCT00566423|Biomarkers
1350283|NCT00566423|MIF
1350284|NCT00566423|BNP
1350285|NCT00566423|6 Minute Walk (6MW)
1350286|NCT00566410|DCA
1350287|NCT00566410|Phase I
1350288|NCT00566410|Dose Escalation
1350289|NCT00566410|Solid Tumours
1350290|NCT00566410|Dichloroacetate
1350291|NCT00566410|Pharmacokinetic
1350292|NCT00566397|RI RI Study Rage Inhibitors
1350293|NCT00566384|Loss of libido
1350294|NCT00566384|Acquired, oral contraceptive -associated female sexual dysfunction
1350295|NCT00567619|GERD
1350296|NCT00567619|NIS
1350297|NCT00567580|stage IIB prostate cancer
1350298|NCT00567580|stage IIA prostate cancer
1350299|NCT00567580|stage III prostate cancer
1350300|NCT00567580|adenocarcinoma of the prostate
1350301|NCT00567554|breast cancer
1350302|NCT00567554|primary systemic therapy
1350303|NCT00567554|pCR Rates
1350304|NCT00567554|Bevacizumab
1350305|NCT00567554|Trastuzumab
1350306|NCT00567554|Lapatinib
1350307|NCT00567554|Everolimus
1350308|NCT00567541|shoulder
1350309|NCT00567541|pain
1350310|NCT00567541|stroke
1350311|NCT00567541|subluxation
1350312|NCT00567528|Soft tissue injuries
1350313|NCT00567528|Topical ibuprofen
1350314|NCT00567528|Adolescent athletes
1350315|NCT00567489|ESRD
1350316|NCT00567489|Diabetes
1350317|NCT00567489|CAPD
1350318|NCT00567489|APD
1350319|NCT00567476|Asthma, anti-immunoglobulin E, omalizumab
1350320|NCT00567463|Asthma
1350321|NCT00567463|Bronchial hyperresponsiveness
1350322|NCT00567463|Methacholine
1350323|NCT00567463|Induced sputum
1350324|NCT00567463|bronchial biopsies
1350325|NCT00567450|sciatic block
1350326|NCT00567450|ropivacaine
1350327|NCT00567450|mepivacaine
1350328|NCT00567450|locoregional anesthesia
1350329|NCT00567437|aortic stenosis
1350330|NCT00567437|prognosis
1350331|NCT00567437|brain natriuretic peptide
1350332|NCT00567424|epilepsy
1350333|NCT00567424|refractory
1350334|NCT00567424|seizure
1350335|NCT00567424|drug interactions
1350336|NCT00567424|pharmacokinetics
1350337|NCT00567411|Glaucoma
1350338|NCT00567411|Laser
1350339|NCT00567411|laser trabeculoplasty
1350340|NCT00567411|selective laser trabeculoplasty
1350341|NCT00567411|intraocular pressure
1350342|NCT00567398|ESRD
1350343|NCT00567398|Diabetes
1350344|NCT00567398|CAPD
1350345|NCT00567398|APD
1350346|NCT00567372|Diffuse diabetic macular edema
1350347|NCT00567372|sub-tenon
1350348|NCT00567372|Bevacizumab
1350349|NCT00567359|NSCLC
1350350|NCT00567359|erlotinib
1350351|NCT00567359|epidermal growth factor receptor
1350352|NCT00567359|EGFR
1350353|NCT00567346|randomised
1350354|NCT00567346|double-blind
1350355|NCT00567346|placebo-controlled
1350356|NCT00567346|efficacy and safety
1350357|NCT00567346|Oralgen® Grass Pollen
1350358|NCT00567346|allergic rhinoconjunctivitis
1350359|NCT00567346|Allergy
1350360|NCT00567346|Rhinoconjunctivitis
1350361|NCT00567346|Immunotherapy
1350362|NCT00567346|Grass pollen extract
1350363|NCT00567320|varenicline
1350364|NCT00567294|Osteoporosis
1350365|NCT00567294|Medication adherence
1350366|NCT00567294|Telephonic education
1350367|NCT00567294|Motivational interviewing
1350368|NCT00567281|Schizoaffective disorder
1350369|NCT00567281|Auditory Hallucinations
1350370|NCT00567281|Voices
1350371|NCT00567281|Repetitive Transcranial Magnetic Stimulation
1350372|NCT00567281|rTMS
1350373|NCT00567281|Wernicke's Area
1350374|NCT00567281|Middle Temporal Cortex
1350375|NCT00567281|Persistent Auditory Hallucinations
1350376|NCT00567281|"Previously Participated in Parent rTMS Protocol"
1350377|NCT00567268|Post-Marketing surveillance
1350378|NCT00567255|Obesity
1350379|NCT00567242|aphasia
1350380|NCT00567242|therapies, investigational
1350381|NCT00567242|rehabilitation of speech and language disorders
1350382|NCT00567242|magnetic resonance imaging, functional
1350383|NCT00567242|language
1350384|NCT00567229|refractory multiple myeloma
1350385|NCT00567190|Herceptin
1350386|NCT00567190|Breast cancer
1350387|NCT00567190|MBC
1350388|NCT00567190|Taxotere
1350389|NCT00567190|HER2
1350390|NCT00567190|HER2 positive breast cancer
1350391|NCT00567190|HER2 + breast cancer
1350392|NCT00567190|HER2-positive
1350393|NCT00567190|HER2-positive metastatic breast cancer
1350394|NCT00567164|Oral Contraception
1350395|NCT00567164|Birth Control pill
1350396|NCT00567164|Healthy women requesting oral contraception
1350397|NCT00567164|Contraceptive efficacy
1350398|NCT00567125|low-pressure pneumoperitoneum
1350399|NCT00567125|laparoscopy
1350400|NCT00567125|cytokines
1350401|NCT00567125|VEGF-A
1350402|NCT00567125|endostatin
1350403|NCT00567099|Psychiatry
1350404|NCT00567099|Antipsychotic
1350405|NCT00567099|Psychopharmacology
1350406|NCT00567099|Clinical Trial
1350407|NCT00567099|Open Label
1350408|NCT00567099|Schizophrenia
1350409|NCT00567099|Sensory Gating
1350410|NCT00567099|Attention
1350411|NCT00567099|Memory
1350412|NCT00567086|Migraine
1350413|NCT00567073|Glycogen Storage Disease Type II (GSD-II)
1350414|NCT00567073|GSD-II
1350415|NCT00567073|Pompe Disease
1350416|NCT00567073|Pompe Disease (Late-Onset)
1350417|NCT00567073|Acid Maltase Deficiency Disease
1350418|NCT00567073|Glycogenosis II
1350419|NCT00567060|Piracetam
1350420|NCT00567060|Nootropil
1350421|NCT00567034|Zyprexa
1350422|NCT00567034|naltrexone
1350423|NCT00567034|schizophrenia
1350424|NCT00567034|Metabolic Syndrome
1350425|NCT00567034|pain
1350426|NCT00567021|reflux
1350427|NCT00567021|NSAR treatment
1350428|NCT00567021|Patients with reflux symptoms or gastrointestinal symptoms after NSAR Treatment
1350429|NCT00567008|cocaine
1350430|NCT00567008|crack cocaine
1350431|NCT00567008|cocaine-related disorders
1350432|NCT00567008|substance-related disorders
1350433|NCT00567008|alpha4beta2 nicotinic acetylcholine receptor
1350434|NCT00566995|Kidney Tumors
1350435|NCT00566995|Clear Cell Renal Cancer
1350436|NCT00566995|VEGFR Inhibitor
1350437|NCT00566995|EGFR Inhibitor
1350438|NCT00566995|VHL
1350439|NCT00566995|Von Hippel Lindau
1350440|NCT00566995|Kidney Tumor
1350441|NCT00566982|Urogenital atrophy
1350442|NCT00566982|Menopausal symptoms
1350443|NCT00566982|Vulvar and vaginal atrophy in postmenopausal women
1350444|NCT00566982|Vaginal atrophy
1350445|NCT00566969|cocaine, opiate, methadone, carvedilol
1350446|NCT00566956|Hydrosalpinx/IVF/Reproductive outcome.
1350447|NCT00566956|Hydrosalpinx
1350448|NCT00566943|Staple Line Reinforcement, Buttress
1350449|NCT00566917|Vagina
1350450|NCT00566917|Prolapse
1350451|NCT00566917|Anterior vaginal wall prolapse
1350452|NCT00566904|Post-herpetic Neuralgia
1350453|NCT00566904|Pain after Shingles
1350454|NCT00566904|Shingles
1350455|NCT00566904|PHN
1350456|NCT00566891|percutaneous coronary angioplasty
1350457|NCT00566891|pci
1350458|NCT00566891|tirofiban
1350459|NCT00566891|side effects
1350460|NCT00566878|Glycogen Storage Disease
1350461|NCT00566878|GSD-II
1350462|NCT00566878|Pompe Disease
1350463|NCT00566878|Pompe Disease (Late-Onset)
1350464|NCT00566878|Acid Maltase Deficiency Disease
1350465|NCT00566878|Glycogenosis II
1350466|NCT00566852|cognitive/functional effects
1350467|NCT00566852|neurotoxicity
1350468|NCT00566852|tumors metastatic to brain
1350469|NCT00566852|unspecified adult solid tumor, protocol specific
1350470|NCT00566839|COPD
1350471|NCT00566839|LVRS
1350472|NCT00566839|Awake surgery
1350473|NCT00566839|Thoracic epidural anesthesia
1350474|NCT00566839|One-lung ventilation
1350475|NCT00566839|Emphysema
1350476|NCT00566839|VATS
1350477|NCT00566839|Lung surgery
1350478|NCT00566826|Physical Function
1350479|NCT00566826|Total Knee Replacement
1350480|NCT00566826|Physical Activity
1350481|NCT00566826|Behavioral Support
1350482|NCT00566826|Arthroplasty
1350483|NCT00566826|Function
1350484|NCT00566826|Self-Care
1350485|NCT00566813|Diabetes Mellitus, Type 1
1350486|NCT00566813|Islets of Langerhans Transplantation
1350487|NCT00566813|Exenatide
1350488|NCT00566813|Soluble tumor necrosis factor receptor
1350489|NCT00566800|esophageal cancer
1350490|NCT00566800|Barrett esophagus
1350491|NCT00566787|AF
1350492|NCT00566787|Atrial Fibrillation
1350493|NCT00566787|afib
1350494|NCT00566787|racing heart
1350495|NCT00566787|cabg
1350496|NCT00566787|valve
1350497|NCT00566787|ablation
1350498|NCT00566787|bipolar
1350499|NCT00566787|radiofrequency
1350500|NCT00566787|rf
1350501|NCT00566774|myocardial infarction
1350502|NCT00566774|secondary prevention
1350503|NCT00566774|health insurance
1350504|NCT00566774|cost-sharing
1350505|NCT00566761|Macular edema
1350506|NCT00566761|central retinal vein occlusion
1350507|NCT00566761|bevacizumab
1350508|NCT00566761|triamcinolone
1350509|NCT00566709|transfusion
1350510|NCT00566709|NIRS
1350511|NCT00566709|cerebral oxygenation
1350512|NCT00566709|red blood cell
1350513|NCT00566709|near infrared spectroscopy
1350514|NCT00566696|Haploidentical stem cell transplant
1350515|NCT00566696|Allogeneic stem cell transplant
1350516|NCT00566696|Mismatched family member stem cell donor transplant
1350517|NCT00566696|Bone marrow transplant
1350518|NCT00566696|High risk hematologic malignancies
1350519|NCT00566696|T cell depletion methodology
1350520|NCT00566696|Miltenyi Biotec CliniMACS stem cell selection device
1350521|NCT00566696|Campath-1H intravenous
1350522|NCT00566683|Propofol
1350523|NCT00566683|colonoscopy
1350524|NCT00566683|sedation
1350525|NCT00566683|pain
1350526|NCT00566683|compare NAPS versus diazemuls in outpatient colonoscopy
1350527|NCT00566670|Hemodialysis
1350528|NCT00566657|Critical Limb Ischemia
1350529|NCT00566657|Peripheral Artery Disease
1350530|NCT00566657|Plasmid based gene therapy
1350531|NCT00566644|endometrial cancer
1350532|NCT00566644|hereditary non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2)
1350533|NCT00566631|Schizophrenia
1350534|NCT00566631|Paliperidone Extended Release (ER)
1350535|NCT00566631|Invega
1350536|NCT00566618|Breast Cancer
1350537|NCT00566618|Bone Metastases
1350538|NCT00566618|Breast Cancer with Bone Metastases
1350539|NCT00566618|Breast Cancer with Metastases to Bone
1350540|NCT00566618|Dasatinib
1350541|NCT00566618|Zometa
1350542|NCT00566618|Zoledronic Acid
1350543|NCT00566618|Zoledronate
1350544|NCT00566618|BMS-345825
1350545|NCT00566618|Sprycel®
1350546|NCT00566371|attention deficit hyperactivity disorder
1350547|NCT00566371|insomnia
1350548|NCT00566371|atomoxetine
1350549|NCT00566358|diabetes mellitus, type 2
1350550|NCT00566358|duodenal exclusion
1350551|NCT00566358|bariatric surgery
1350552|NCT00566358|Glucagon-Like Peptide 1
1350553|NCT00566358|Gastric Inhibitory Polypeptide
1350554|NCT00566358|insulin
1350555|NCT00566358|glucagon
1350556|NCT00566358|ghrelin
1350557|NCT00566332|Waldenström Macroglobulinemia
1350558|NCT00566332|Lymphoplasmacytic lymphoma
1350559|NCT00566332|Splenic Marginal Zone Lymphoma
1350560|NCT00566332|Fludarabine
1350561|NCT00566332|Chlorambucil
1350562|NCT00566319|Exercise
1350563|NCT00566306|Clostridium difficile
1350564|NCT00566306|disinfectant
1350565|NCT00566280|MBI
1350566|NCT00566280|Mammogram
1350567|NCT00566280|Breast Cancer
1350568|NCT00566280|Breast Ultrasound
1350569|NCT00566280|Bloody Nipple Discharge
1350570|NCT00566280|Molecular Breast Imaging
1350571|NCT00566254|Epilepsy
1350572|NCT00566254|paediatric
1350573|NCT00566254|partial onset seizures
1350574|NCT00566241|Body weight
1350575|NCT00566241|Body composition
1350576|NCT00566241|Pulmonary function
1350577|NCT00566241|Carbohydrate tolerance
1350578|NCT00566228|noncontiguous stage II adult diffuse large cell lymphoma
1350579|NCT00566228|stage III adult diffuse large cell lymphoma
1350580|NCT00566228|stage IV adult diffuse large cell lymphoma
1350581|NCT00566228|recurrent adult diffuse large cell lymphoma
1350582|NCT00566215|diabetes mellitus, type 2
1350583|NCT00566215|Insulin resistance
1350584|NCT00566215|Intra-Abdominal Fat
1350585|NCT00566215|Omentum
1350586|NCT00566215|duodenal exclusion
1350587|NCT00566215|bariatric surgery
1350588|NCT00566215|Glucagon-Like Peptide 1
1350589|NCT00566215|Gastric Inhibitory Polypeptide
1350590|NCT00566215|insulin
1350591|NCT00566215|glucagon
1350592|NCT00566215|ghrelin
1350593|NCT00566215|adiponectin
1350594|NCT00566215|Cytokines
1350595|NCT00566202|Major Depressive Disorder
1350596|NCT00566202|Depression
1350597|NCT00566202|JNJ-18038683
1350598|NCT00566202|Escitalopram
1350599|NCT00566189|diabetes mellitus, type 2
1350600|NCT00566189|Insulin resistance
1350601|NCT00566189|Intra-Abdominal Fat
1350602|NCT00566189|Omentum
1350603|NCT00566189|duodenal exclusion
1350604|NCT00566189|bariatric surgery
1350605|NCT00566189|Glucagon-Like Peptide 1
1350606|NCT00566189|Gastric Inhibitory Polypeptide
1350607|NCT00566189|insulin
1350608|NCT00566189|glucagon
1350609|NCT00566189|ghrelin
1350610|NCT00566189|adiponectin
1350611|NCT00566189|Cytokines
1350612|NCT00566176|Atrial Fibrillation
1350613|NCT00566176|AF
1350614|NCT00566176|AFIB
1350615|NCT00566176|racing heart
1350616|NCT00566176|pulmonary vein isolation
1350617|NCT00566176|pvi
1350618|NCT00566176|mini maze
1350619|NCT00566176|maze
1350620|NCT00566150|Keppra
1350621|NCT00566150|Levetiracetam
1350622|NCT00566150|Anticonvulsant
1350623|NCT00566150|Depression
1350624|NCT00566150|Bipolar Disorder
1350625|NCT00566150|Affective Disorders
1350626|NCT00566150|Mood Disorders
1350627|NCT00566150|Double Blind
1350628|NCT00566150|Acute Antidepressant Effects
1350629|NCT00566137|Scleroderma
1350630|NCT00566137|Pulmonary Hypertension
1350631|NCT00566124|Levemir, Lantus, Insulatard, Pharmacodynamics, Healthy humans
1350632|NCT00566111|Ceftriaxone
1350633|NCT00566111|Acute Antidepressant Effects
1350634|NCT00566111|Glutamatergic System
1350635|NCT00566111|Double-Blind
1350636|NCT00566111|Mood Disorders
1350637|NCT00566111|Bipolar Disorder
1350638|NCT00566111|Depression
1350639|NCT00566111|Affective Disorders
1350640|NCT00566098|stage II multiple myeloma
1350641|NCT00566098|stage III multiple myeloma
1350642|NCT00566085|MBI
1350643|NCT00566085|Breast Cancer
1350644|NCT00566085|Neoadjuvant Therapy
1350645|NCT00566085|Molecular Breast Imaging
1350646|NCT00566072|the effect of information on compliance of medication
1350647|NCT00566059|therapeutic advice
1350648|NCT00566033|AUDIT
1350649|NCT00566033|Chronic kidney disease
1350650|NCT00566033|Clinical trial
1350651|NCT00566033|Creatinine
1350652|NCT00566033|Multiple intervents
1350653|NCT00566033|Nephrology guidelines.
1350654|NCT00566020|Open-label extension
1350655|NCT00566020|Tolerability
1350656|NCT00566020|Lamotrigine
1350657|NCT00566020|Safety
1350658|NCT00566020|Bipolar I disorder
1350659|NCT00566007|disc herniation
1350660|NCT00566007|lumbar
1350661|NCT00566007|ozone therapy
1350662|NCT00565994|hemodialysis
1350663|NCT00565994|Vascular access
1350664|NCT00565994|arteriovenous fistula
1350665|NCT00565994|indwelling percutaneous catheters
1350666|NCT00565994|arteriovenous grafts
1350667|NCT00565981|B-CLL
1350668|NCT00565981|refractory
1350669|NCT00565981|molecular profiling
1350670|NCT00565981|alemtuzumab
1350671|NCT00565981|fludarabinephosphate
1350672|NCT00565968|stage IIIB melanoma
1350673|NCT00565968|stage IIIC melanoma
1350674|NCT00565968|recurrent melanoma
1350675|NCT00565955|Montelukast
1350676|NCT00565955|Acute Asthma
1350677|NCT00565942|Integrative medicine
1350678|NCT00565942|Primary care
1350679|NCT00565942|Swedish massage therapy
1350680|NCT00565942|Manual therapy
1350681|NCT00565942|Naprapathy
1350682|NCT00565942|Shiatsu
1350683|NCT00565942|Acupuncture/TCM
1350684|NCT00565942|Qigong
1350685|NCT00565942|Pragmatic RCT
1350686|NCT00565942|Health services research
1350687|NCT00565929|Variola major, smallpox, vaccine, hematopoietic stem cell transplant
1350688|NCT00565916|Post-Menopausal
1350689|NCT00565916|PET
1350690|NCT00565916|Estrogen
1350691|NCT00565916|Progesterone
1350692|NCT00565916|Heart Metabolism
1350693|NCT00565916|Cardiovascular Disease
1350694|NCT00565903|pleuropulmonary blastoma
1350695|NCT00565903|PPB
1350696|NCT00565903|cystic nephroma
1350697|NCT00565903|DICER1
1350698|NCT00565903|miRNA
1350699|NCT00565890|very low birth weight infant
1350700|NCT00565890|hypothyroxinemia
1350701|NCT00565890|outcomes
1350702|NCT00565877|Catheter
1350703|NCT00565877|Peripherally inserted central catheter
1350704|NCT00565877|ultrasound
1350705|NCT00565877|malposition
1350706|NCT00565864|Hypothyroidism
1350707|NCT00565864|Cognition
1350708|NCT00565864|Metabolism
1350709|NCT00565838|Randomized study
1350710|NCT00565838|surgical treatment
1350711|NCT00565838|autologous fascial sling
1350712|NCT00565838|TVT
1350713|NCT00565838|stress urinary incontinence.
1350714|NCT00565812|knee Osteoarthritis Disease Modifying Osteoarthritis Drug
1350715|NCT00565799|DM
1350716|NCT00565760|Acute
1350717|NCT00565760|Pain
1350718|NCT00565747|GM-CSF
1350719|NCT00565747|infertility
1350720|NCT00565721|Static PET imaging
1350721|NCT00565721|Dynamic PET imaging
1350722|NCT00565721|Angiogenesis
1350723|NCT00565721|αvβ3 integrins
1350724|NCT00565721|oncology imaging
1350725|NCT00565708|stage II colon cancer
1350726|NCT00565708|stage III colon cancer
1350727|NCT00565708|stage II rectal cancer
1350728|NCT00565708|stage III rectal cancer
1350729|NCT00565695|Visual Outcomes
1350730|NCT00565695|Patient Satisfaction
1350731|NCT00565695|Cataract Extraction
1350732|NCT00565669|Treatment
1350733|NCT00565669|Dry Eye
1350734|NCT00565656|Myelodysplastic syndromes (int-1, int-2 and high risk according to IPSS) with excess of marrow blasts including CMML with leucocytes<10 000/mm3
1350735|NCT00565643|Adhesion
1350736|NCT00565643|Seprafilm
1350737|NCT00565643|Cesarean section
1350738|NCT00565617|depression
1350739|NCT00565617|epidural
1350740|NCT00565617|cortical stimulation
1350741|NCT00565617|brain stimulation
1350742|NCT00565617|treatment-resistant
1350743|NCT00565617|deep brain stimulation
1350744|NCT00565617|TMS
1350745|NCT00565617|DBS
1350746|NCT00565617|ECS
1350747|NCT00565604|Perforator Veins
1350748|NCT00565604|Incompetent Veins
1350749|NCT00565604|Varicose Veins
1350750|NCT00565591|asthma
1350751|NCT00565591|inhaler device
1350752|NCT00565591|albuterol sulfate
1350753|NCT00565565|Biventriular chronic heart failure, Pulmonary hypertension
1350754|NCT00565552|silicone gel
1350755|NCT00565552|cicatrix
1350756|NCT00565552|wound healing
1350757|NCT00565552|scar
1350758|NCT00565552|keloid
1350759|NCT00565539|PEGylated recombinant interleukin 29
1350760|NCT00565539|interferon lambda
1350761|NCT00565539|interleukin 29
1350762|NCT00565539|hepatitis C
1350763|NCT00565539|virus
1350764|NCT00565539|infection
1350765|NCT00565539|liver
1350766|NCT00565526|Autonomic Nervous System
1350767|NCT00565526|Sjogren's Syndrome
1350768|NCT00565526|Pathogenesis
1350769|NCT00565526|Cholinergic
1350770|NCT00565526|Parasympathetic
1350771|NCT00565526|Sjogren Syndrome
1350772|NCT00565487|Radiotherapy
1350773|NCT00565487|Non-operable pancreatic cancer
1350774|NCT00565487|locally advanced pancreatic cancer
1350775|NCT00565474|Renal transplantation
1350776|NCT00565474|fluvastatin
1350777|NCT00565448|Nasopharyngeal carcinoma
1350778|NCT00565435|Chiari I Malformation
1350779|NCT00565422|Internet addiction
1350780|NCT00565422|Problematic internet use
1350781|NCT00565422|Escitalopram
1350782|NCT00565422|Lexapro
1350783|NCT00565409|Active Rheumatoid Arthritis
1350784|NCT00565383|Pregnancy
1350785|NCT00565383|37 Weeks Gestation
1350786|NCT00565383|Breech Presentation
1350787|NCT00565383|Version Procedure
1350788|NCT00565383|Pain Control
1350789|NCT00565383|Neuraxial analgesia
1350790|NCT00565370|Gastric cancer
1350791|NCT00565370|capecitabine
1350792|NCT00565370|cisplatin
1350793|NCT00565370|sorafenib
1350794|NCT00565370|phase I
1350795|NCT00565370|phase II
1350796|NCT00565357|Postnatal Growth
1350797|NCT00565357|Postnatal Development
1350798|NCT00565357|Noise
1350799|NCT00565357|Neonatal Intensive Care Unit
1350800|NCT00565344|Medicaid
1350801|NCT00565344|Disenrollment
1350802|NCT00565318|Benfotiamine
1350803|NCT00565318|Diabetes
1350804|NCT00565318|Nephropathy
1350805|NCT00565305|Healing Touch
1350806|NCT00565305|NK cytotoxicity
1350807|NCT00565305|cytokines
1350808|NCT00565305|fatigue
1350809|NCT00565279|Seborrhoeic dermatitis
1350810|NCT00565253|pulmonary embolism
1350811|NCT00565253|inhaled nitric oxide
1350812|NCT00565240|ovarian synchronization
1350813|NCT00565240|folliculogenesis
1350814|NCT00565214|vitamin supplements
1350815|NCT00565214|healthy smokers
1350816|NCT00565214|epithelial lung tissue
1350817|NCT00565214|bronchoscopy
1350818|NCT00565214|antioxidant levels
1350819|NCT00565201|Stroke, Cerebrovascular accident, Spasticity, Arm, Hand
1350820|NCT00565175|Treatment resistant
1350821|NCT00565175|Chronic
1350822|NCT00565136|Device study
1350823|NCT00565136|Pelvic floor weakness
1350824|NCT00565136|Fecal incontinence
1350825|NCT00565123|bacterial conjunctivitis levofloxacin fluoroquinolone
1350826|NCT00565097|Polycystic Liver Disease
1350827|NCT00565097|Autosomal Dominant Polycystic Kidney Disease
1350828|NCT00565097|Liver cyst
1350829|NCT00565097|Lanreotide
1350830|NCT00565071|Cost-effectiveness
1350831|NCT00565071|Diagnosis
1350832|NCT00565071|Treatment
1350833|NCT00565071|Malaria
1350834|NCT00565045|hand
1350835|NCT00565045|stroke
1350836|NCT00565045|hemiplegia
1350837|NCT00565045|electrical stimulation
1350838|NCT00565045|recovery
1350839|NCT00565032|postpartum depression
1350840|NCT00565032|thyroxine
1350841|NCT00565032|thyroid antibodies
1350842|NCT00565032|thyroid stimulating hormone
1350843|NCT00565032|Edinburgh Postnatal Depression Scale (EPDS)
1350844|NCT00564980|Randomized
1350845|NCT00564980|Prospective
1350846|NCT00564980|Procedure / Surgery
1350847|NCT00564954|ADHD
1350848|NCT00564954|children
1350849|NCT00564954|laboratory classroom
1350850|NCT00564954|Attention Deficit Hyperactivity Disorder
1350851|NCT00564941|Myelodysplastic Syndromes
1350852|NCT00564941|beta-Thalassemia
1350853|NCT00564941|Iron Overload
1350854|NCT00564941|Iron Chelating Agents
1350855|NCT00564941|deferasirox
1350856|NCT00564928|Hormone resistant prostate cancer
1350857|NCT00564928|castrate resistant prostate cancer
1350858|NCT00564928|HRPC
1350859|NCT00564928|CRPC
1350860|NCT00564915|Epilepsy
1350861|NCT00564902|Macular Pigment Optical Density
1350862|NCT00564902|Skin Carotenoids
1350863|NCT00564902|Lipofuscin
1350864|NCT00564902|Photostress (Glare Recovery)
1350865|NCT00564902|Visual Field Progression
1350866|NCT00564902|Contrast Sensitivity
1350867|NCT00564902|Color Vision
1350868|NCT00564902|Cognitive Function
1350869|NCT00564889|primary systemic amyloidosis
1350870|NCT00564876|Non Small Cell Lung Cancer (NSCLC)
1350871|NCT00564876|carcinoma
1350872|NCT00564876|dasatinib
1350873|NCT00564876|neoadjuvant
1350874|NCT00564876|adjuvant
1350875|NCT00564876|resection
1350876|NCT00564876|genomic signature
1350877|NCT00564876|predictor
1350878|NCT00564876|microarray
1350879|NCT00564863|Diarrhea
1350880|NCT00564863|ETEC
1350881|NCT00564837|Anterior cruciate ligament
1350882|NCT00564837|Reconstruction
1350883|NCT00564837|Rehabilitation
1350884|NCT00564837|Home-based
1350885|NCT00564824|coronary disease
1350886|NCT00564824|atherosclerosis
1350887|NCT00564824|endothelial function
1350888|NCT00564824|caffeine
1350889|NCT00564824|cerebrovascular disease
1350890|NCT00564824|prevention
1350891|NCT00564811|Agaricus blazei (Murrill) ss. Heinemann,
1350892|NCT00564811|Hepatitis C
1350893|NCT00564811|Nutritional status
1350894|NCT00564811|Liver Function Tests
1350895|NCT00564811|Antiviral Agents
1350896|NCT00564798|protocoladolescents
1350897|NCT00564798|children
1350898|NCT00564798|health behaviours/attitudes
1350899|NCT00564798|weight loss/management
1350900|NCT00564798|program evaluation
1350901|NCT00564772|raltegravir
1350902|NCT00564772|lopinavir
1350903|NCT00564772|ritonavir
1350904|NCT00564772|pharmacokinetics
1350905|NCT00564759|CGD
1350906|NCT00564746|radiolabel
1350907|NCT00564746|SB-681323,
1350908|NCT00564746|ADME,
1350909|NCT00564694|adenocarcinoma of the colon
1350910|NCT00564694|recurrent colon cancer
1350911|NCT00564694|stage I colon cancer
1350912|NCT00564694|stage II colon cancer
1350913|NCT00564694|stage III colon cancer
1350914|NCT00564694|stage IV colon cancer
1350915|NCT00564694|adenocarcinoma of the rectum
1350916|NCT00564694|recurrent rectal cancer
1350917|NCT00564694|stage I rectal cancer
1350918|NCT00564694|stage II rectal cancer
1350919|NCT00564694|stage III rectal cancer
1350920|NCT00564694|stage IV rectal cancer
1350921|NCT00564655|pediatrics
1350922|NCT00564655|Gastric Tube Insertion
1350923|NCT00564655|Anesthesia
1350924|NCT00564655|Regional Anesthetic
1350925|NCT00564655|Transversus Abdominal Plane
1350926|NCT00564616|cardiac arrest
1350927|NCT00564616|video cell phone
1350928|NCT00564616|dispatcher-assisted CPR
1350929|NCT00564603|Glucocorticoid
1350930|NCT00564603|Opioids
1350931|NCT00564603|Balanced analgesia
1350932|NCT00564577|Diarrhea ETEC
1350933|NCT00564564|obsessive compulsive disorder
1350934|NCT00564564|pharmacological treatment
1350935|NCT00564564|quetiapine
1350936|NCT00564564|clomipramine
1350937|NCT00564564|SSRI
1350938|NCT00564551|Prediabetes
1350939|NCT00564551|Type 2 diabetes
1350940|NCT00564551|Metabolic syndrome
1350941|NCT00564551|Insulin resistance syndrome
1350942|NCT00564551|Weight loss
1350943|NCT00564551|Milk products
1350944|NCT00564551|Calcium
1350945|NCT00564538|liver transplant
1350946|NCT00564525|children
1350947|NCT00564525|abdominal pain
1350948|NCT00564525|amitriptyline
1350949|NCT00564512|B-cell chronic lymphocytic leukemia
1350950|NCT00564512|stage I chronic lymphocytic leukemia
1350951|NCT00564512|stage II chronic lymphocytic leukemia
1350952|NCT00564512|stage III chronic lymphocytic leukemia
1350953|NCT00564512|stage IV chronic lymphocytic leukemia
1350954|NCT00564499|COPD
1350955|NCT00564499|Symbicort
1350956|NCT00564499|General Practitioners
1350957|NCT00564486|Abdominal Laparoscopic Surgery
1350958|NCT00564473|internal medicine
1350959|NCT00564473|herbal medicine
1350960|NCT00564473|prevalence
1350961|NCT00564473|attitudes
1350962|NCT00564473|herb-drug interaction
1350963|NCT00564434|delirium
1350964|NCT00564434|pathophysiology
1350965|NCT00564434|risk factors
1350966|NCT00564434|pain
1350967|NCT00564434|dementia
1350968|NCT00564382|Acute coronary syndrome
1350969|NCT00564382|Cardiac Magnetic Resonance Imaging
1350970|NCT00564382|Contrast agents
1350971|NCT00564382|Gadolinium
1350972|NCT00564369|HIV testing
1350973|NCT00564369|HIV Seronegativity
1350974|NCT00564356|cataract, phacoemulsification, coumadin, antiaggregants
1350975|NCT00564343|Balance
1350976|NCT00564343|Water based training
1350977|NCT00564343|Physical functioning
1350978|NCT00564343|stepping behavior
1350979|NCT00564330|dental erosion
1350980|NCT00564330|OCT
1350981|NCT00564330|proton pump inhibitor
1350982|NCT00564317|PTSD
1350983|NCT00564317|Depression
1350984|NCT00564317|Suicidality
1350985|NCT00564317|trauma-focussed treatment
1350986|NCT00564317|KIDNET
1350987|NCT00564317|Narrative Exposure Therapy for Children
1350988|NCT00564317|Meditation
1350989|NCT00564317|Relaxation
1350990|NCT00564317|War
1350991|NCT00564304|Nasal Potential Difference
1350992|NCT00564291|OCT
1350993|NCT00564278|Hispanic Americans
1350994|NCT00564278|Major Depressive Disorder
1350995|NCT00564278|Antidepressant Therapy
1350996|NCT00564278|Motivational Interviewing
1350997|NCT00564278|Treatment Retention
1350998|NCT00564278|Treatment Adherence
1350999|NCT00564265|GIST
1351000|NCT00564226|urge urinary incontinence
1351001|NCT00564213|Myopia
1351002|NCT00564213|Mitomycin
1351003|NCT00564200|Multiple Myeloma, transplant
1351004|NCT00564174|recurrent pregnancy loss
1351005|NCT00564174|lupus anticoagulant
1351006|NCT00564174|anti cardiolipin antibodies
1351007|NCT00564174|thrombophilia
1351008|NCT00564174|low molecular weight heparin
1351009|NCT00564174|aspirin
1351010|NCT00564174|randomized clinical trial
1351011|NCT00564148|antiVEGF therapy
1351012|NCT00564135|hysterectomy
1351013|NCT00564135|laparoscopy
1351014|NCT00564135|urinary retention
1351015|NCT00564135|urinary tract infection
1351016|NCT00564135|catheterization
1351017|NCT00564122|Murmur
1351018|NCT00564122|Artificial-Intelligence
1351019|NCT00564122|Stethoscope
1351020|NCT00564122|Congenital Heart Disease
1351021|NCT00564122|Structural Heart Disease
1351022|NCT00564083|Compare the relative differences between the organic and sythentic materials for sacryl colpopexy.
1351023|NCT00564070|Depression
1351024|NCT00564070|Diabetes
1351025|NCT00564070|Adherence
1351026|NCT00564057|HIV
1351027|NCT00564057|blood pressure
1351028|NCT00564057|left ventricle
1351029|NCT00564057|metabolic profile
1351030|NCT00564057|treatment experienced
1351031|NCT00564044|biofilm-infection-related immune hyperreactivity
1351032|NCT00564044|mesh extrusion
1351033|NCT00564044|mid-urethral sling
1351034|NCT00564044|determine the immune reactivity of biofilms in mesh erosion
1351035|NCT00564031|hormone replacement therapy; endothelial function;
1351036|NCT00564018|type 1 diabetes, basal-bolus, honeymoon, C-peptide
1351037|NCT00564005|stroke rehabilitation
1351038|NCT00564005|cortical reorganization
1351039|NCT00564005|kinematic analysis
1351040|NCT00563979|age related macular degeneration
1351041|NCT00563979|supplementation
1351042|NCT00563979|macular pigment
1351043|NCT00563966|smoking pregnancy behaviour polymorphisms
1351044|NCT00563953|Breast
1351045|NCT00563953|Cancer
1351046|NCT00563953|Anthracyclines
1351047|NCT00563953|Cardiopathy
1351048|NCT00563940|diabetic macular edema
1351049|NCT00563940|OCT
1351050|NCT00563927|Nasopharyngeal Carcinoma
1351051|NCT00563927|T1-4N2-3M0
1351052|NCT00563914|Malaria
1351053|NCT00563901|CHD
1351054|NCT00563901|Combined CHD
1351055|NCT00563901|Stroke
1351056|NCT00563901|Combined Cardiovascular Disease (CVD)
1351057|NCT00563901|Pharmacogenetics
1351058|NCT00563901|End-Stage Renal Disease
1351059|NCT00563901|Heart Failure
1351060|NCT00563901|Hospitalized/Fatal Heart Failure
1351061|NCT00563901|Angina
1351062|NCT00563901|Coronary Revascularizations
1351063|NCT00563901|CHD Mortality
1351064|NCT00563901|Lisinopril
1351065|NCT00563901|Chlorthalidone
1351066|NCT00563901|Amlodipine
1351067|NCT00563901|Doxazosin
1351068|NCT00563888|PTSD
1351069|NCT00563888|torture survivors
1351070|NCT00563888|Narrative Exposure Therapy
1351071|NCT00563888|trauma-related memory processes
1351072|NCT00563888|steady state visual evoked fields
1351073|NCT00563875|Platelets
1351074|NCT00563875|Platelet aggregation
1351075|NCT00563875|Drug resistance
1351076|NCT00563875|Aspirin
1351077|NCT00563875|Diabetes mellitus
1351078|NCT00563862|Nasopharyngeal Carcinoma
1351079|NCT00563862|T3-4N0-1M0
1351080|NCT00563836|ovarian cancer
1351081|NCT00563836|catumaxomab
1351082|NCT00563836|phase II
1351083|NCT00563836|intraoperative
1351084|NCT00563836|adjuvant
1351085|NCT00563836|trifunctional antibody
1351086|NCT00563823|stage IV melanoma
1351087|NCT00563823|recurrent melanoma
1351088|NCT00563810|Adult
1351089|NCT00563810|Aged
1351090|NCT00563797|treatment
1351091|NCT00563797|alcohol dependence
1351092|NCT00563797|depression
1351093|NCT00563797|mecamylamine
1351094|NCT00563784|Non-Small Cell Lung Cancer
1351095|NCT00563784|Lung Cancer
1351096|NCT00563784|Squamous Cell Carcinoma
1351097|NCT00563784|Adenocarcinoma
1351098|NCT00563784|Bronchoalveolar Cell Carcinoma
1351099|NCT00563784|Large Cell Anaplastic Carcinoma
1351100|NCT00563784|Giant Cell Carcinoma
1351101|NCT00563784|Clear Cell Carcinoma
1351102|NCT00563784|Erlotinib
1351103|NCT00563784|Erlotinib Hydrocholoride
1351104|NCT00563784|OSI-774
1351105|NCT00563784|Tarceva
1351106|NCT00563784|Carboplatin
1351107|NCT00563784|Paraplatin
1351108|NCT00563784|Paclitaxel
1351109|NCT00563784|Taxol
1351110|NCT00563784|NSCLC
1351111|NCT00563758|Chronic constipation
1351112|NCT00563745|COPD
1351113|NCT00563745|ALS
1351114|NCT00563745|Telemedicine
1351115|NCT00563745|mechanical ventilation
1351116|NCT00563745|Integrated care
1351117|NCT00563745|strict follow up
1351118|NCT00563745|impact and costs on health care resources
1351119|NCT00563745|telemedicine programme
1351120|NCT00563745|home mechanical ventilation (HMV)
1351121|NCT00563745|frail patients
1351122|NCT00563745|chronic respiratory failure (CRF)
1351123|NCT00563693|heart failure
1351124|NCT00563693|cheyne stokes respiration
1351125|NCT00563693|adaptive servo ventilator
1351126|NCT00563680|AMG 479
1351127|NCT00563680|IGF-1R
1351128|NCT00563680|Insulin-like growth factor
1351129|NCT00563680|Insulin-like growth factor receptor
1351130|NCT00563680|Ewing's
1351131|NCT00563680|Sarcoma
1351132|NCT00563667|Pterygium
1351133|NCT00563667|Cataract
1351134|NCT00563667|Astigmatism
1351135|NCT00563654|Benign Prostatic Hyperplasia (BPH)
1351136|NCT00563654|Acute Retention of Urine (AUR)
1351137|NCT00563641|NCPAP
1351138|NCT00563641|Very early surfactant
1351139|NCT00563628|Pattern Scan Laser.
1351140|NCT00563628|Photocoagulation.
1351141|NCT00563628|Diabetic retinopathy treatment.
1351142|NCT00563628|Laser treatment
1351143|NCT00563615|Constipation (idiopathic)
1351144|NCT00563602|Portal hypertension
1351145|NCT00563602|Prevention of rebleeding
1351146|NCT00563602|Complications of cirrhosis
1351147|NCT00563602|Portal hemodynamic
1351148|NCT00563602|Prazosine
1351149|NCT00563602|Nadolol
1351150|NCT00563602|isosorbide mononitrate
1351151|NCT00563589|Acute graft-versus-host disease post high risk allogeneic stem cell transplantation
1351152|NCT00563576|Depo-Provera
1351153|NCT00563576|Medroxyprogesterone Acetate
1351154|NCT00563576|Metrorrhagia
1351155|NCT00563576|Irregular Bleeding
1351156|NCT00563563|Nicotine-dependence in overweight and obese subjects
1351157|NCT00563537|neurology
1351158|NCT00563537|sclerosis
1351159|NCT00563537|imaging
1351160|NCT00563537|tomography
1351161|NCT00563511|smoking cessation
1351162|NCT00563498|Veno-occlusive disease
1351163|NCT00563498|Mucositis
1351164|NCT00563485|Benign Prostatic Hyperplasia (BPH)
1351165|NCT00563485|Acute Retention of Urine (AUR)
1351166|NCT00563472|Healthy female volunteers will participate in this study
1351167|NCT00563459|Epilepsy, seizures
1351168|NCT00563459|partial onset seizures
1351169|NCT00563459|anti-epileptic drugs (AED)
1351170|NCT00563459|carisbamate
1351171|NCT00563459|topiramate
1351172|NCT00563459|levetiracetam
1351173|NCT00563446|Anemia
1351174|NCT00563446|End-stage renal failure
1351175|NCT00563446|Continuous ambulatory peritoneal dialysis
1351176|NCT00563433|diabetic
1351177|NCT00563433|diabetes mellitus
1351178|NCT00563433|foot
1351179|NCT00563433|ulcers
1351180|NCT00563433|Floxin
1351181|NCT00563433|oral antibiotic
1351182|NCT00563433|topical cream
1351183|NCT00563420|Lung cancer
1351184|NCT00563407|skin toxicity prediction
1351185|NCT00563407|cardiac toxicity prediction
1351186|NCT00563394|diabetic
1351187|NCT00563394|diabetes mellitus
1351188|NCT00563394|foot
1351189|NCT00563394|ulcers
1351190|NCT00563394|Floxin
1351191|NCT00563394|oral antibiotic
1351192|NCT00563394|topical cream
1351193|NCT00563355|chronic kidney disease
1351194|NCT00563355|cardiovascular disease
1351195|NCT00563342|Ethanol, lock solution, infection
1351196|NCT00563329|Smokers who are not willing to quit in the near future but intend to reduce smoking
1351197|NCT00563316|colorectal cancer
1351198|NCT00563316|chemotherapy
1351199|NCT00563316|cancer
1351200|NCT00563316|metastatic
1351201|NCT00563316|irinotecan
1351202|NCT00563316|EGFr
1351203|NCT00563316|epidermal growth factor
1351204|NCT00563277|Pterygium
1351205|NCT00563277|Cataract
1351206|NCT00563277|Intraocular lens power calculation accuracy
1351207|NCT00563264|obesity
1351208|NCT00563264|parenting
1351209|NCT00563264|postpartum period
1351210|NCT00563264|family research
1351211|NCT00563251|Bronchiolitis obliterans in bone marrow transplant recipients
1351212|NCT00563238|Extubation
1351213|NCT00563212|Lung Diseases, Interstitial
1351214|NCT00563212|Fibrosis
1351215|NCT00563212|Interferons
1351216|NCT00563212|Pulmonary Fibrosis
1351217|NCT00563212|Pathologic Processes
1351218|NCT00563212|Lung Diseases
1351219|NCT00563212|Fibrosing alveolitis
1351220|NCT00563212|Interferon-gamma, Recombinant
1351221|NCT00563212|Aerosols
1351222|NCT00563199|smoking cessation
1351223|NCT00563199|smoking behaviors
1351224|NCT00563186|infection control
1351225|NCT00563186|nosocomial infection
1351226|NCT00563186|hospital design
1351227|NCT00563186|physical plant design
1351228|NCT00563186|antibiotic resistant organisms
1351229|NCT00563160|lung cancer
1351230|NCT00563147|tivozanib
1351231|NCT00563147|AV-951
1351232|NCT00563134|Suspected or confirmed severe Gram-negative sepsis
1351233|NCT00563121|Retinopathy of Prematurity
1351234|NCT00563121|ROP
1351235|NCT00563121|Vascular Endothelial Growth Factor
1351236|NCT00563121|VEGF
1351237|NCT00563121|Vitreous
1351238|NCT00563121|Subretinal Fluid
1351239|NCT00563121|ELISA
1351240|NCT00563121|VEGF levels in Aqueous, Vitreous and subretinal Fluid
1351241|NCT00563108|Acute graft-versus-host disease post allogeneic stem cell transplantation
1351242|NCT00563095|Hepatocellular carcinoma
1351243|NCT00563082|SLE
1351244|NCT00563082|Genetics
1351245|NCT00563069|diagnostic and therapeutic rigid cystoscopy
1351246|NCT00563056|Formoterol
1351247|NCT00563056|Fluticasone
1351248|NCT00563056|Asthma
1351249|NCT00563043|Pattern Scan Laser.
1351250|NCT00563043|Photocoagulation.
1351251|NCT00563043|Diabetic retinopathy treatment.
1351252|NCT00563043|Laser treatment.
1351253|NCT00563043|Electroretinogram.
1351254|NCT00563043|a wave.
1351255|NCT00563043|b wave.
1351256|NCT00563043|Implicit time.
1351257|NCT00563030|Cardiopulmonary bypass
1351258|NCT00563030|Neutrophils
1351259|NCT00563030|Coronary artery bypass graft surgery
1351260|NCT00563017|Catatonic Schizophrenia
1351261|NCT00563017|Disorganized Schizophrenia
1351262|NCT00563017|Paranoid Schizophrenia
1351263|NCT00563017|Undifferentiated Schizophrenia
1351264|NCT00563017|Schizo-affective disorders
1351265|NCT00563004|Diabetes mellitus
1351266|NCT00563004|Herbal treatment
1351267|NCT00563004|Food supplement
1351268|NCT00562991|exhaled NO
1351269|NCT00562991|asthma
1351270|NCT00562991|child
1351271|NCT00562978|recurrent grade 1 follicular lymphoma
1351272|NCT00562978|recurrent grade 2 follicular lymphoma
1351273|NCT00562978|recurrent grade 3 follicular lymphoma
1351274|NCT00562978|recurrent adult diffuse large cell lymphoma
1351275|NCT00562978|recurrent adult diffuse mixed cell lymphoma
1351276|NCT00562978|recurrent adult diffuse small cleaved cell lymphoma
1351277|NCT00562978|recurrent adult immunoblastic large cell lymphoma
1351278|NCT00562978|recurrent mantle cell lymphoma
1351279|NCT00562978|stage III grade 1 follicular lymphoma
1351280|NCT00562978|stage III grade 2 follicular lymphoma
1351281|NCT00562978|stage III grade 3 follicular lymphoma
1351282|NCT00562978|stage IV grade 1 follicular lymphoma
1351283|NCT00562978|stage IV grade 2 follicular lymphoma
1351284|NCT00562978|stage IV grade 3 follicular lymphoma
1351285|NCT00562978|stage III adult diffuse large cell lymphoma
1351286|NCT00562978|stage III adult diffuse mixed cell lymphoma
1351287|NCT00562978|stage III adult diffuse small cleaved cell lymphoma
1351288|NCT00562978|stage IV adult diffuse large cell lymphoma
1351289|NCT00562978|stage IV adult diffuse mixed cell lymphoma
1351290|NCT00562978|stage IV adult diffuse small cleaved cell lymphoma
1351291|NCT00562978|stage III mantle cell lymphoma
1351292|NCT00562978|stage IV mantle cell lymphoma
1351293|NCT00562978|stage III adult immunoblastic large cell lymphoma
1351294|NCT00562978|stage IV adult immunoblastic large cell lymphoma
1351295|NCT00562952|Natriuretic peptide
1351296|NCT00562952|Prognosis
1351297|NCT00562952|Diabetes
1351298|NCT00562952|Heart failure
1351299|NCT00562952|Heart disease
1351300|NCT00562939|Antibody Formation
1351301|NCT00562939|Antibody Affinity
1351302|NCT00562939|Immunity
1351303|NCT00562939|Pneumococcal Vaccines
1351304|NCT00562939|Oligodeoxyribonucleotides
1351305|NCT00562926|Schizophrenia
1351306|NCT00562926|Schizophrenia spectrum disorder
1351307|NCT00562913|Cancer
1351308|NCT00562913|Sorafenib
1351309|NCT00562913|Cyclophosphamide
1351310|NCT00562913|Doxorubicin
1351311|NCT00562887|Crohn's Disease
1351312|NCT00562874|HIV
1351313|NCT00562874|AIDS
1351314|NCT00562874|WOMEN
1351315|NCT00562874|KENYA
1351316|NCT00562874|NUTRITION
1351317|NCT00562874|HIV/AIDS
1351318|NCT00562874|treatment naive
1351319|NCT00562861|Bipolar Disorder
1351320|NCT00562861|Bipolar Depression
1351321|NCT00562861|Clinical Trials, Phase II
1351322|NCT00562861|Clinical Pharmacology
1351323|NCT00562848|gastric emptying
1351324|NCT00562848|pharmacokinetic
1351325|NCT00562848|tolerability
1351326|NCT00562848|safety
1351327|NCT00562848|GSK962040
1351328|NCT00562848|gut motility
1351329|NCT00562848|First Time in Human
1351330|NCT00562835|ARDS
1351331|NCT00562835|Adult
1351332|NCT00562835|Methylprednisolone
1351333|NCT00562796|Growth Hormone Deficiency
1351334|NCT00562796|Cardiovascular Disease
1351335|NCT00562796|Intra-abdominal Fat
1351336|NCT00562796|Insulin Resistance
1351337|NCT00562783|HBV
1351338|NCT00562783|HCV
1351339|NCT00562783|Liver cirrhosis
1351340|NCT00562770|Chronic Lymphocytic Leukemia
1351341|NCT00562770|CLL
1351342|NCT00562770|Leukemia
1351343|NCT00562757|Wedensky modulation
1351344|NCT00562757|Risk stratification
1351345|NCT00562757|Electrophysiology
1351346|NCT00562757|Noninvasive
1351347|NCT00562757|Ischemic heart disease
1351348|NCT00562757|ICD guidelines
1351349|NCT00562757|Myocardial infarction
1351350|NCT00562718|stage II breast cancer
1351351|NCT00562718|stage IIIA breast cancer
1351352|NCT00562718|stage IIIB breast cancer
1351353|NCT00562718|male breast cancer
1351354|NCT00562718|recurrent breast cancer
1351355|NCT00562705|growth hormone
1351356|NCT00562705|eating regulation
1351357|NCT00562705|nutritional intervention
1351358|NCT00562705|short stature
1351359|NCT00562705|ISS
1351360|NCT00562705|SGA
1351361|NCT00562705|IGHD
1351362|NCT00562705|MPHD
1351363|NCT00562692|Heart failure
1351364|NCT00562692|OAD
1351365|NCT00562692|BNP
1351366|NCT00562692|Heart Failure patients who present to the emergency department
1351367|NCT00562679|Patients with coronary artery disease
1351368|NCT00562666|cell therapy
1351369|NCT00562666|T lymphocytes
1351370|NCT00562666|hepatic intra-arterial injection
1351371|NCT00562653|profile autoantibodies
1351372|NCT00562653|clinical symptoms
1351373|NCT00562640|recurrent ovarian epithelial cancer
1351374|NCT00562640|stage IV ovarian epithelial cancer
1351375|NCT00562640|recurrent primary peritoneal cavity cancer
1351376|NCT00562640|stage IIIA primary peritoneal cavity cancer
1351377|NCT00562640|stage IIIB primary peritoneal cavity cancer
1351378|NCT00562640|stage IIIC primary peritoneal cavity cancer
1351379|NCT00562640|stage IV primary peritoneal cavity cancer
1351380|NCT00562640|recurrent fallopian tube cancer
1351381|NCT00562640|stage IIIA fallopian tube cancer
1351382|NCT00562640|stage IIIB fallopian tube cancer
1351383|NCT00562640|stage IIIC fallopian tube cancer
1351384|NCT00562640|stage IV fallopian tube cancer
1351385|NCT00562640|stage IIIA ovarian epithelial cancer
1351386|NCT00562640|stage IIIB ovarian epithelial cancer
1351387|NCT00562640|stage IIIC ovarian epithelial cancer
1351388|NCT00562640|06-155
1351389|NCT00562627|osteoarthritis
1351390|NCT00562627|knee arthroplasty
1351391|NCT00562627|local infiltration analgesia
1351392|NCT00562627|TKA
1351393|NCT00562627|epidural analgesia
1351394|NCT00562627|operation
1351395|NCT00562627|surgery
1351396|NCT00562601|Leukapheresis
1351397|NCT00562601|Plasmapheresis
1351398|NCT00562601|Lymphocytes
1351399|NCT00562601|Neutrophils
1351400|NCT00562536|Umbilical cord clamping
1351401|NCT00562536|Preterm infants
1351402|NCT00562536|Randomized controlled trial
1351403|NCT00562536|For women giving birth to singleton infants 32 weeks gestational age or less
1351404|NCT00562523|Cancer
1351405|NCT00562523|Docetaxel
1351406|NCT00562523|Sorafenib
1351407|NCT00562510|HIV-1 infection
1351408|NCT00562510|raltegravir
1351409|NCT00562510|immune discordance
1351410|NCT00562510|treatment experienced
1351411|NCT00562497|Acute GVHD
1351412|NCT00562497|Acute Graft Versus Host Disease
1351413|NCT00562471|adhesions
1351414|NCT00562471|gynecologic surgery
1351415|NCT00562471|laparoscopy
1351416|NCT00562471|laparotomy
1351417|NCT00562471|polyethylene glycol
1351418|NCT00562471|hydrogel
1351419|NCT00562471|Adhesions following gynecologic surgery to remove myomas
1351420|NCT00562458|Advanced breast cancer
1351421|NCT00562458|Advanced breast cancer in postmenopausal women
1351422|NCT00562445|Adrenal insufficiency
1351423|NCT00562445|GI bleeding
1351424|NCT00562445|Portal hypertension
1351425|NCT00562445|Acute pancreatitis
1351426|NCT00562445|Critical emergencies in digestive diseases
1351427|NCT00562445|Severe acute pancreatitis
1351428|NCT00562432|atrial fibrillation
1351429|NCT00562432|CABG
1351430|NCT00562432|ganglionated plexi
1351431|NCT00562406|Macular edema secondary to branch retinal vein occlusion
1351432|NCT00562380|cutaneous B-cell non-Hodgkin lymphoma
1351433|NCT00562380|angioimmunoblastic T-cell lymphoma
1351434|NCT00562380|stage IV cutaneous T-cell non-Hodgkin lymphoma
1351435|NCT00562380|adult nasal type extranodal NK/T-cell lymphoma
1351436|NCT00562380|anaplastic large cell lymphoma
1351437|NCT00562380|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1351438|NCT00562380|nodal marginal zone B-cell lymphoma
1351439|NCT00562380|recurrent adult Burkitt lymphoma
1351440|NCT00562380|recurrent adult diffuse large cell lymphoma
1351441|NCT00562380|recurrent adult diffuse mixed cell lymphoma
1351442|NCT00562380|recurrent adult diffuse small cleaved cell lymphoma
1351443|NCT00562380|recurrent adult grade III lymphomatoid granulomatosis
1351444|NCT00562380|recurrent adult immunoblastic large cell lymphoma
1351445|NCT00562380|recurrent adult lymphoblastic lymphoma
1351446|NCT00562380|recurrent cutaneous T-cell non-Hodgkin lymphoma
1351447|NCT00562380|recurrent grade 1 follicular lymphoma
1351448|NCT00562380|recurrent grade 2 follicular lymphoma
1351449|NCT00562380|recurrent grade 3 follicular lymphoma
1351450|NCT00562380|recurrent mantle cell lymphoma
1351451|NCT00562380|recurrent marginal zone lymphoma
1351452|NCT00562380|recurrent small lymphocytic lymphoma
1351453|NCT00562380|small intestine lymphoma
1351454|NCT00562380|splenic marginal zone lymphoma
1351455|NCT00562380|unspecified adult solid tumor, protocol specific
1351456|NCT00562380|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1351457|NCT00562380|adult desmoplastic small round cell tumor
1351458|NCT00562380|recurrent adult soft tissue sarcoma
1351459|NCT00562380|recurrent prostate cancer
1351460|NCT00562354|Vaccines, Pneumococcal Conjugate Vaccine
1351461|NCT00562341|obesity
1351462|NCT00562341|psa
1351463|NCT00562341|prostate cancer
1351464|NCT00562328|stage 0 chronic lymphocytic leukemia
1351465|NCT00562328|stage I chronic lymphocytic leukemia
1351466|NCT00562328|stage II chronic lymphocytic leukemia
1351467|NCT00562302|lung biopsy
1351468|NCT00562289|Stroke
1351469|NCT00562289|Patent Foramen Ovale
1351470|NCT00562289|Atrial septal aneurysm
1351471|NCT00562289|Antiplatelet therapy
1351472|NCT00562289|Oral anticoagulants
1351473|NCT00562289|Transcatheter closure
1351474|NCT00562289|Migraine
1351475|NCT00562276|IUD
1351476|NCT00562276|insertion timing
1351477|NCT00562263|overweight
1351478|NCT00562263|obesity
1351479|NCT00562263|adolescent
1351480|NCT00562263|insulin resistance
1351481|NCT00562263|treatment
1351482|NCT00562237|immunogenicity
1351483|NCT00562237|safety
1351484|NCT00562237|adjuvanted pandemic vaccine
1351485|NCT00562224|PCI-24781
1351486|NCT00562224|Neoplasms by site
1351487|NCT00562224|Lymphoma, non-hodgkin
1351488|NCT00562224|Hodgkin disease
1351489|NCT00562224|Multiple myeloma
1351490|NCT00562224|Leukemia, lymphocytic, chronic
1351491|NCT00562211|children
1351492|NCT00562185|recurrent ovarian epithelial cancer
1351493|NCT00562185|ovarian sarcoma
1351494|NCT00562185|recurrent ovarian germ cell tumor
1351495|NCT00562185|ovarian stromal cancer
1351496|NCT00562159|rhinoconjunctivitis
1351497|NCT00562159|rhinitis
1351498|NCT00562159|conjunctivitis
1351499|NCT00562159|allergy
1351500|NCT00562159|allergen
1351501|NCT00562159|immunotherapy
1351502|NCT00562146|nutrition
1351503|NCT00562146|enteral access
1351504|NCT00562107|Minimized ventricular pacing, clinical outcome, SafeR, AAIsafeR, dual chamber pacemaker therapy, % of ventricular pacing, hospitalizations, symptomatic AF
1351505|NCT00562094|Pantoprazole
1351506|NCT00562094|eGERD (Erosive Gastroesophageal Reflux Disease)
1351507|NCT00562094|NERD (Non-Erosive Reflux Disease)
1351508|NCT00562094|sleep disorders
1351509|NCT00562081|asthma
1351510|NCT00562081|Virtual Asthma Clinic
1351511|NCT00562081|metabolites
1351512|NCT00562081|asthma education
1351513|NCT00562068|recurrent adult T-cell leukemia/lymphoma
1351514|NCT00562068|stage I adult T-cell leukemia/lymphoma
1351515|NCT00562068|stage II adult T-cell leukemia/lymphoma
1351516|NCT00562068|stage III adult T-cell leukemia/lymphoma
1351517|NCT00562068|stage IV adult T-cell leukemia/lymphoma
1351518|NCT00562068|anaplastic large cell lymphoma
1351519|NCT00562068|angioimmunoblastic T-cell lymphoma
1351520|NCT00562068|small intestine lymphoma
1351521|NCT00562068|peripheral T-cell lymphoma
1351522|NCT00562042|pulmonary embolism
1351523|NCT00562042|risk stratification
1351524|NCT00562042|prognosis
1351525|NCT00562042|troponin
1351526|NCT00562042|Brain natriuretic peptide
1351527|NCT00562042|echocardiogram
1351528|NCT00562029|Diabetes Mellitus
1351529|NCT00562029|Surgery
1351530|NCT00562029|Duodenal Bypass
1351531|NCT00562029|Resolution
1351532|NCT00562029|Surgical Procedures
1351533|NCT00562016|Patient undergoing scheduled PCI
1351534|NCT00562003|Ovarian cancer study
1351535|NCT00561990|pancreatic cancer
1351536|NCT00561977|Nutrition
1351537|NCT00561977|Dietary Quality
1351538|NCT00561977|Weight loss
1351539|NCT00561938|Confocal laser endomicroscopy
1351540|NCT00561938|cancerous and non-cancerous conditions
1351541|NCT00561938|tolerance
1351542|NCT00561938|intravenous fluorescein
1351543|NCT00561938|Digestive symptoms or disease requiring an endoscopy procedure (upper GI endoscopy or colonoscopy) performed under general anaesthesia
1351544|NCT00561912|Renal Cell Carcinoma
1351545|NCT00561912|Renal Cell Cancer
1351546|NCT00561912|Clear Cell
1351547|NCT00561912|Kidney
1351548|NCT00561912|Decitabine
1351549|NCT00561912|Dacogen
1351550|NCT00561912|5-Aza-Deoxycytidine
1351551|NCT00561912|Interferon Alfa-2b
1351552|NCT00561912|Intron A®
1351553|NCT00561912|RCC
1351554|NCT00561899|safety
1351555|NCT00561899|tolerability
1351556|NCT00561899|efficacy
1351557|NCT00561899|intermittent prevetive treatment
1351558|NCT00561899|children
1351559|NCT00561886|COPD
1351560|NCT00561886|lung function
1351561|NCT00561886|dysnpea
1351562|NCT00561873|astrocytoma, glioblastoma, intrinsic pontine glioma
1351563|NCT00561860|Obstructive sleep apnea-hypopnea
1351564|NCT00561860|Telemedicine
1351565|NCT00561834|non-arteritic ischemic optic neuropathy
1351566|NCT00561834|ranibizumab
1351567|NCT00561834|naion
1351568|NCT00561821|elderly
1351569|NCT00561821|randomized
1351570|NCT00561821|placebo controlled
1351571|NCT00561808|PCO/PCOD
1351572|NCT00561808|IVM
1351573|NCT00561808|Immature Oocytes
1351574|NCT00561795|AGO
1351575|NCT00561795|Advanced,
1351576|NCT00561795|Gynaecologic cancer(s),
1351577|NCT00561795|Genetics
1351578|NCT00561795|GW786034,
1351579|NCT00561795|Pazopanib,
1351580|NCT00561782|Spinal Cord Injury Pain
1351581|NCT00561782|Chronic Neuropathic Pain
1351582|NCT00561782|SCI Pain
1351583|NCT00561782|Pain, Chronic Neuropathic
1351584|NCT00561782|Spectroscopy, Magnetic Resonance
1351585|NCT00561782|MRS
1351586|NCT00561782|Traumatic Brain Injury Pain
1351587|NCT00561769|poor responder
1351588|NCT00561769|growth hormone
1351589|NCT00561769|luteal
1351590|NCT00561756|cutaneous B-cell non-Hodgkin lymphoma
1351591|NCT00561756|recurrent grade 1 follicular lymphoma
1351592|NCT00561756|recurrent grade 2 follicular lymphoma
1351593|NCT00561756|recurrent grade 3 follicular lymphoma
1351594|NCT00561756|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1351595|NCT00561756|recurrent marginal zone lymphoma
1351596|NCT00561756|recurrent mantle cell lymphoma
1351597|NCT00561756|recurrent adult diffuse large cell lymphoma
1351598|NCT00561756|recurrent adult diffuse mixed cell lymphoma
1351599|NCT00561743|Multiple myeloma
1351600|NCT00561743|response rate
1351601|NCT00561743|peripheral stem cell transplant
1351602|NCT00561743|safety
1351603|NCT00561743|tolerability
1351604|NCT00561730|PPI (Proton Pump Inhibitor) therapy
1351605|NCT00561730|Pantoprazole
1351606|NCT00561730|eGERD (Erosive Gastroesophageal Reflux Disease)
1351607|NCT00561730|NERD (Non-Erosive Reflux Disease)
1351608|NCT00561717|Seasonal Allergic Rhinitis
1351609|NCT00561717|Ragweed
1351610|NCT00561717|Pollen
1351611|NCT00561717|Allergy
1351612|NCT00561704|obese female
1351613|NCT00561704|Type 2 Diabetes
1351614|NCT00561704|Diabetic Nephropathy
1351615|NCT00561704|Glucose Metabolism
1351616|NCT00561704|Angiotensin II Type 1 Receptor Blockers
1351617|NCT00561704|Adiponectin
1351618|NCT00561691|diffuse instrinsic ponitine glioma, brainstem
1351619|NCT00561678|Postoperative Confusion
1351620|NCT00561678|Postoperative Delirium
1351621|NCT00561678|PD
1351622|NCT00561678|Postoperative Cognitive Dysfunction
1351623|NCT00561678|POCD
1351624|NCT00561652|Low back pain
1351625|NCT00561652|Chiropractic
1351626|NCT00561652|Exercise
1351627|NCT00561652|Veterans
1351628|NCT00561639|sepsis
1351629|NCT00561639|immunosuppressed
1351630|NCT00561639|multiplex PCR
1351631|NCT00561639|diagnosis
1351632|NCT00561639|therapeutic
1351633|NCT00561613|Diaphragm
1351634|NCT00561613|postcoital test
1351635|NCT00561613|SILCS
1351636|NCT00561613|nonoxynol-9
1351637|NCT00561600|Hip arthroplasty
1351638|NCT00561600|Acetabular cup replacement
1351639|NCT00561600|Acetabulum arthroplasty
1351640|NCT00561587|novel antipsychotic
1351641|NCT00561587|quetiapine
1351642|NCT00561587|depression
1351643|NCT00561587|psychopathology
1351644|NCT00561574|elderly
1351645|NCT00561574|randomized
1351646|NCT00561574|double blind
1351647|NCT00561561|Schizophrenia
1351648|NCT00561561|Prepulse Inhibition
1351649|NCT00561561|Acoustic Startle
1351650|NCT00561535|IBS
1351651|NCT00561535|Diarrhea
1351652|NCT00561535|Rome III
1351653|NCT00561522|Recurrence
1351654|NCT00561522|Metastasis
1351655|NCT00561522|Hepatocellular Carcinoma
1351656|NCT00561522|Radical Hepatic Resection
1351657|NCT00561522|Drug Prevention
1351658|NCT00561522|Capecitabine
1351659|NCT00561522|Surgery
1351660|NCT00561496|HIV prevention
1351661|NCT00561496|Microbicides
1351662|NCT00561496|Pharmacokinetics
1351663|NCT00561496|vaginal biopsies
1351664|NCT00561483|Acute heart failure
1351665|NCT00561483|cystatin C
1351666|NCT00561483|renal failure
1351667|NCT00561483|biomarker
1351668|NCT00561470|colorectal cancer
1351669|NCT00561470|metastatic
1351670|NCT00561470|anti-angiogenic
1351671|NCT00561470|irinotecan
1351672|NCT00561470|5-FU
1351673|NCT00561470|FOLFIRI
1351674|NCT00561457|Iliac
1351675|NCT00561457|Artery
1351676|NCT00561457|Occlusive
1351677|NCT00561457|Stenosis
1351678|NCT00561444|Prostate Cancer
1351679|NCT00561444|Radical retropubic prostatectomy
1351680|NCT00561444|Robotic prostatectomy
1351681|NCT00561444|Photon external beam radiation
1351682|NCT00561444|Photon external beam radiation with hormone therapy
1351683|NCT00561444|Proton radiation
1351684|NCT00561444|Radioisotopic implant
1351685|NCT00561444|Cryotherapy
1351686|NCT00561444|Quality of Life
1351687|NCT00561444|Questionnaire
1351688|NCT00561444|Survey
1351689|NCT00561444|QOL
1351690|NCT00561431|CVVHDF Dose Study
1351691|NCT00561418|recurrent adult diffuse large cell lymphoma
1351692|NCT00561418|stage III adult diffuse large cell lymphoma
1351693|NCT00561418|stage IV adult diffuse large cell lymphoma
1351694|NCT00561418|recurrent grade 3 follicular lymphoma
1351695|NCT00561418|recurrent adult Hodgkin lymphoma
1351696|NCT00561418|recurrent mantle cell lymphoma
1351697|NCT00561418|adult nasal type extranodal NK/T-cell lymphoma
1351698|NCT00561418|angioimmunoblastic T-cell lymphoma
1351699|NCT00561418|recurrent adult T-cell leukemia/lymphoma
1351700|NCT00561418|stage III adult T-cell leukemia/lymphoma
1351701|NCT00561418|stage IV adult T-cell leukemia/lymphoma
1351702|NCT00561418|small intestine lymphoma
1351703|NCT00561418|anaplastic large cell lymphoma
1351704|NCT00561405|Stroke
1351705|NCT00561405|Walking
1351706|NCT00561405|Motor learning
1351707|NCT00561405|Skill acquisition
1351708|NCT00561392|Alzheimer's Disease
1351709|NCT00561392|Rivastigmine
1351710|NCT00561392|Patch
1351711|NCT00561379|Diffuse Large B Cell Lymphoma
1351712|NCT00561379|not previously treated
1351713|NCT00561366|ALS
1351714|NCT00561366|Lou Gehrig's disease
1351715|NCT00561353|Hepatitis C, Chronic
1351716|NCT00561353|Tibotec
1351717|NCT00561353|TMC435350-TiDP16-C201
1351718|NCT00561353|TMC435350-C201
1351719|NCT00561353|TMC435
1351720|NCT00561353|PEGASYS (peginterferon alpha-2a, PegIFNα-2a)
1351721|NCT00561353|COPEGUS (ribavirin)
1351722|NCT00561340|ADHD
1351723|NCT00561340|Growth
1351724|NCT00561340|Atomoxetine
1351725|NCT00561340|Pediasure
1351726|NCT00561327|hypertension
1351727|NCT00561327|angiotensin receptor blockers
1351728|NCT00561327|peroxisome proliferator activated receptor gamma
1351729|NCT00561314|sexual dysfunction
1351730|NCT00561314|urinary incontinence
1351731|NCT00561314|adenocarcinoma of the prostate
1351732|NCT00561314|stage I prostate cancer
1351733|NCT00561314|stage IIB prostate cancer
1351734|NCT00561314|stage IIA prostate cancer
1351735|NCT00561288|Acetaminophen
1351736|NCT00561288|Social Psychology
1351737|NCT00561288|Affect
1351738|NCT00561288|Interpersonal Rejection
1351739|NCT00561262|adenocarcinoma of the prostate
1351740|NCT00561262|stage I prostate cancer
1351741|NCT00561262|stage IIB prostate cancer
1351742|NCT00561262|stage IIA prostate cancer
1351743|NCT00561262|stage III prostate cancer
1351744|NCT00561223|chronic obstructive pulmonary disease
1351745|NCT00561223|pulmonary hypertension
1351746|NCT00561210|infections
1351747|NCT00561184|H5N1 Pandemic
1351748|NCT00561145|Anorexia of ageing
1351749|NCT00561145|Anorexia of aging
1351750|NCT00561145|Energy balance
1351751|NCT00561145|Elderly
1351752|NCT00561132|vanadium
1351753|NCT00561132|insulin sensitivity
1351754|NCT00561132|impaired glucose tolerance
1351755|NCT00561132|triglycerides
1351756|NCT00561119|maintenance chemotherapy
1351757|NCT00561119|metastatic or recurrent breast cancer
1351758|NCT00561119|gemcitabine
1351759|NCT00561119|paclitaxel(GP)
1351760|NCT00561106|Bell´s palsy
1351761|NCT00561106|prednisone
1351762|NCT00561106|valacyclovir
1351763|NCT00561093|Hypoalbuminemia
1351764|NCT00561093|Protein-energy malnutrition
1351765|NCT00561093|Inflammation
1351766|NCT00561093|Oxidative stress
1351767|NCT00561093|Chronic Kidney disease (CKD) stage 5
1351768|NCT00561093|maintenance hemodialysis
1351769|NCT00561067|Spinal cord injury
1351770|NCT00561067|spinal shock
1351771|NCT00561067|erythropoietin
1351772|NCT00561054|Coimbra
1351773|NCT00561054|NSCLC
1351774|NCT00561054|CETUXIMAB
1351775|NCT00561041|alcohol
1351776|NCT00561041|alcohol use disorder
1351777|NCT00561041|cognitive-behavioral therapy
1351778|NCT00561041|brief phone aftercare intervention
1351779|NCT00561041|individual aftercare therapy
1351780|NCT00561028|Atherosclerosis
1351781|NCT00561028|Coronary artery disease
1351782|NCT00561028|Chlamydia pneumoniae
1351783|NCT00561028|Mycoplasma pneumoniae
1351784|NCT00561015|Hepatitis C, Chronic
1351785|NCT00561015|Genotype 2
1351786|NCT00561015|Genotype 3
1351787|NCT00561015|Telaprevir
1351788|NCT00561002|Influenza Vaccine
1351789|NCT00561002|Influenza Virus
1351790|NCT00561002|Orthomyxoviridae Infections
1351791|NCT00561002|Fluzone®
1351792|NCT00560989|Chronic Beryllium Disease
1351793|NCT00560989|CBD
1351794|NCT00560989|Beryllium
1351795|NCT00560989|Genetic
1351796|NCT00560989|Environmental
1351797|NCT00560976|neutrophil gelatinase associated lipocalin
1351798|NCT00560976|hemodialysis
1351799|NCT00560976|iron
1351800|NCT00560976|inflammation
1351801|NCT00560976|Oxidative Stress
1351802|NCT00560963|Advanced or metastatic pancreas carcinoma
1351803|NCT00560963|gemcitabine
1351804|NCT00560963|everolimus
1351805|NCT00560937|Schizophrenia
1351806|NCT00560937|Pregnenolone
1351807|NCT00560937|Cognition
1351808|NCT00560937|Negative Symptoms
1351809|NCT00560911|oral anticoagulation
1351810|NCT00560911|self-management
1351811|NCT00560911|elderly patients
1351812|NCT00560911|randomised controlled trial
1351813|NCT00560898|staining
1351814|NCT00560898|epithelial barrier function
1351815|NCT00560885|atrial fibrillation
1351816|NCT00560885|af
1351817|NCT00560885|ablation
1351818|NCT00560885|arrhythmia
1351819|NCT00560885|racing heart
1351820|NCT00560885|afib
1351821|NCT00560885|surgical ablation
1351822|NCT00560872|atrial flutter
1351823|NCT00560872|ablation
1351824|NCT00560872|navigation
1351825|NCT00560859|Sleep disordered breathing
1351826|NCT00560859|Sleep apnea
1351827|NCT00560859|Tonsillectomy
1351828|NCT00560859|Adenoidectomy
1351829|NCT00560859|Snoring
1351830|NCT00560859|Neurobehavioral Manifestations
1351831|NCT00560859|Obstructive Sleep Apnea Syndrome
1351832|NCT00560846|Gastric cancer
1351833|NCT00560846|Esophageal cancer
1351834|NCT00560846|Surgical complications
1351835|NCT00560846|Immunonutrition
1351836|NCT00560820|β-thalassemia
1351837|NCT00560820|transfusional iron overload
1351838|NCT00560820|renal function
1351839|NCT00560820|renal biomarkers
1351840|NCT00560820|deferasirox
1351841|NCT00560807|WAD II
1351842|NCT00560807|WAD III
1351843|NCT00560807|mobilization
1351844|NCT00560807|dosage
1351845|NCT00560807|acute whiplash associated disorders (WAD) II and III (113) with a symptom duration of less than 30 days
1351846|NCT00560807|neck pain
1351847|NCT00560794|Minimal Residual Disease
1351848|NCT00560794|adult ALL
1351849|NCT00560794|immunotherapeutic treatment
1351850|NCT00560794|anti-CD19 bispecific antibody derivative
1351851|NCT00560794|Blinatumomab
1351852|NCT00560794|MT103
1351853|NCT00560781|PTSD
1351854|NCT00560781|Pregnenolone
1351855|NCT00560781|Cognition
1351856|NCT00560768|Risk stratification method, negative predictive value, fast ventricular arrhythmias, ICD
1351857|NCT00560768|The negative predictive value of the T amplitude variance as a method for risk stratification for patients with an increased risk for SCD.
1351858|NCT00560755|Prevention of: measles, mumps, rubella and varicella
1351859|NCT00560729|elderly people
1351860|NCT00560690|Hepatitis C
1351861|NCT00560690|metformin
1351862|NCT00560690|Insulin Resistance
1351863|NCT00560677|Schizophrenia
1351864|NCT00560677|PTSD
1351865|NCT00560677|Cognition
1351866|NCT00560664|knee
1351867|NCT00560664|chondral defect
1351868|NCT00560664|osteochondral defect
1351869|NCT00560651|keratoconus
1351870|NCT00560651|cornea
1351871|NCT00560651|cross linking
1351872|NCT00560651|UV-light
1351873|NCT00560651|riboflavin
1351874|NCT00560612|PTSD
1351875|NCT00560612|Paroxetine
1351876|NCT00560612|Subthreshold
1351877|NCT00560599|MRSA
1351878|NCT00560599|Methicillin Resistant Staphylococcus aureus
1351879|NCT00560599|Staphylococcus aureus
1351880|NCT00560599|Skin Infections
1351881|NCT00560599|Body Decolonization
1351882|NCT00560599|Environmental Decolonization
1351883|NCT00560586|sleep fragmentation
1351884|NCT00560586|apnea
1351885|NCT00560586|hypoxia
1351886|NCT00560560|Refractory Colorectal
1351887|NCT00560560|Single arm
1351888|NCT00560560|Phase 2
1351889|NCT00560534|Magnetic resonance
1351890|NCT00560534|whole body
1351891|NCT00560534|angiography
1351892|NCT00560534|venous compression
1351893|NCT00560534|MRI
1351894|NCT00560521|CPAP
1351895|NCT00560521|Tuberculosis
1351896|NCT00560521|Pleural effusion
1351897|NCT00560521|Physiotherapy
1351898|NCT00560495|stage I non-small cell lung cancer
1351899|NCT00560495|stage II non-small cell lung cancer
1351900|NCT00560495|stage IIIA non-small cell lung cancer
1351901|NCT00560495|stage IIIB non-small cell lung cancer
1351902|NCT00560495|adenocarcinoma of the lung
1351903|NCT00560495|adenosquamous cell lung cancer
1351904|NCT00560495|large cell lung cancer
1351905|NCT00560495|squamous cell lung cancer
1351906|NCT00560482|prostate
1351907|NCT00560482|cancer
1351908|NCT00560482|prostatic cancer
1351909|NCT00560482|castrate-resistant prostate cancer (CRPC)
1351910|NCT00560469|Adipokines
1351911|NCT00560469|Inflammation
1351912|NCT00560469|Metabolic syndrome
1351913|NCT00560456|Age, Snoring, Driving simulator, Sleep deprivation, chronic sleep restriction, objective and subjective sleepiness
1351914|NCT00560443|bone fracture
1351915|NCT00560443|ketorolac
1351916|NCT00560443|tramadol
1351917|NCT00560378|Tacrolimus
1351918|NCT00560378|Administration, topical
1351919|NCT00560378|Drug safety
1351920|NCT00560378|Adults
1351921|NCT00560378|Children
1351922|NCT00560365|stage I colon cancer
1351923|NCT00560365|stage II colon cancer
1351924|NCT00560365|stage III colon cancer
1351925|NCT00560365|stage I rectal cancer
1351926|NCT00560365|stage II rectal cancer
1351927|NCT00560365|stage III rectal cancer
1351928|NCT00560339|Congestive Heart Failure
1351929|NCT00560339|Implantable Defibrillators
1351930|NCT00560339|Intrathoracic Impedance
1351931|NCT00560326|Paediatric patients
1351932|NCT00560326|Tacrolimus
1351933|NCT00560326|Dermatitis, Atopic
1351934|NCT00560313|Meningococcal disease
1351935|NCT00560313|prevention
1351936|NCT00560313|vaccination
1351937|NCT00560287|Amyotrophic Lateral Sclerosis
1351938|NCT00560287|Non-invasive ventilation
1351939|NCT00560287|Chronic Respiratory Failure
1351940|NCT00560261|Sickle cell disease;
1351941|NCT00560261|Lung capillary blood volume;
1351942|NCT00560261|Children
1351943|NCT00560248|Chest Pain
1351944|NCT00560248|STEMI
1351945|NCT00560248|UA/NSTEMI
1351946|NCT00560248|ACS
1351947|NCT00560248|Emergency Department
1351948|NCT00560222|randomized controlled trial
1351949|NCT00560222|lactoferrin
1351950|NCT00560222|children
1351951|NCT00560222|diarrhea
1351952|NCT00560222|malnutrition
1351953|NCT00560222|growth
1351954|NCT00560209|ONO-1101
1351955|NCT00560209|Coronary Artery Disease
1351956|NCT00560209|Multi-slice CT
1351957|NCT00560196|Neuropathic pain
1351958|NCT00560196|Chronic pain
1351959|NCT00560196|Depression
1351960|NCT00560196|Anxiety
1351961|NCT00560183|Acute
1351962|NCT00560183|Bunionectomy
1351963|NCT00560170|HMG-CoA Reductase Inhibitors
1351964|NCT00560170|endothelial function
1351965|NCT00560170|HMG-CoA Reductase Inhibitors on vascular protection
1351966|NCT00560157|ICU patients
1351967|NCT00560118|recurrent melanoma
1351968|NCT00560118|stage IV melanoma
1351969|NCT00560105|COPD
1351970|NCT00560092|Magnesium
1351971|NCT00560092|Pain
1351972|NCT00560092|Morphine
1351973|NCT00560092|Intrathecal
1351974|NCT00560092|NMDA
1351975|NCT00560092|Elective total hip replacement under intrathecal anesthesia
1351976|NCT00560066|influenza
1351977|NCT00560066|vaccine
1351978|NCT00560053|Multiple Myeloma
1351979|NCT00560053|Alternating chemotherapy
1351980|NCT00560053|Transplantation
1351981|NCT00560040|Troponin
1351982|NCT00560040|Natriuretic Peptide, Brain
1351983|NCT00560040|Exercise
1351984|NCT00560040|Echocardiography
1351985|NCT00560027|postpartum depression
1351986|NCT00560027|intimate partner violence
1351987|NCT00560001|frail elderly
1351988|NCT00560001|medication errors
1351989|NCT00560001|patient compliance & attitudes
1351990|NCT00560001|guideline adherence
1351991|NCT00559988|Implanted Cardioverter Defibrillator
1351992|NCT00559988|Cardiac Resynchronization Therapy Defibrillator
1351993|NCT00559988|Home Monitoring
1351994|NCT00559988|Oral Anticoagulation
1351995|NCT00559975|Adjuvanted Influenza Vaccine
1351996|NCT00559962|LDL
1351997|NCT00559962|hepatic fat
1351998|NCT00559897|bone metastases
1351999|NCT00559897|stage IIIB non-small cell lung cancer
1352000|NCT00559897|stage IV non-small cell lung cancer
1352001|NCT00559897|recurrent non-small cell lung cancer
1352002|NCT00559884|pharmacokinetics,
1352003|NCT00559884|healthy male and females,
1352004|NCT00559884|pharmacodynamics
1352005|NCT00559871|dyskinesia
1352006|NCT00559871|movement disorders
1352007|NCT00559871|basal ganglia diseases
1352008|NCT00559871|JP-1730
1352009|NCT00559871|Parkinson
1352010|NCT00559871|end-of-dose wearing off
1352011|NCT00559871|fluctuations
1352012|NCT00559858|palmar-plantar erythrodysesthesia
1352013|NCT00559858|breast cancer
1352014|NCT00559858|male breast cancer
1352015|NCT00559858|colon cancer
1352016|NCT00559858|rectal cancer
1352017|NCT00559832|acute mountain sickness
1352018|NCT00559832|intermittent hypoxia
1352019|NCT00559832|acclimatization
1352020|NCT00559819|Alcohol
1352021|NCT00559819|Driving
1352022|NCT00559819|Impairment
1352023|NCT00559806|immobilisation
1352024|NCT00559806|aging
1352025|NCT00559806|resistance training
1352026|NCT00559806|atrophy
1352027|NCT00559806|The effect of immobilisation in elderly compared to young individuals
1352028|NCT00559780|Resistance training
1352029|NCT00559780|Aging
1352030|NCT00559780|hip-surgery
1352031|NCT00559767|Kidney Function
1352032|NCT00559767|Genes
1352033|NCT00559767|Association Analysis
1352034|NCT00559767|Polymorphisms
1352035|NCT00559767|Diabetes
1352036|NCT00559741|stage IV colon cancer
1352037|NCT00559741|recurrent colon cancer
1352038|NCT00559741|stage IV rectal cancer
1352039|NCT00559741|recurrent rectal cancer
1352040|NCT00559715|bevacizumab
1352041|NCT00559715|ranibizumab
1352042|NCT00559715|macular degeneration
1352043|NCT00559715|age-related
1352044|NCT00559715|neovascular
1352045|NCT00559715|intravitreal injection
1352046|NCT00559715|vision loss
1352047|NCT00559715|outpatient setting
1352048|NCT00559702|natalizumab
1352049|NCT00559702|multiple sclerosis
1352050|NCT00559702|Tysabri ®
1352051|NCT00559689|asthma patients
1352052|NCT00559689|well-controlled
1352053|NCT00559676|recurrent colon cancer
1352054|NCT00559676|stage IV colon cancer
1352055|NCT00559676|recurrent rectal cancer
1352056|NCT00559676|stage IV rectal cancer
1352057|NCT00559663|Flavonoid
1352058|NCT00559663|hsCRP
1352059|NCT00559663|HDL
1352060|NCT00559663|LDL
1352061|NCT00559663|platelet reactivity
1352062|NCT00559650|Acute decompensated heart failure
1352063|NCT00559650|Double blind study,
1352064|NCT00559650|BAY58-2667
1352065|NCT00559650|Soluble guanylate cyclase activator
1352066|NCT00559624|safety
1352067|NCT00559624|tolerability
1352068|NCT00559624|dose-escalation
1352069|NCT00559611|Non-Small Lung Cancer
1352070|NCT00559611|Lung Cancer
1352071|NCT00559611|Endobronchial Ultrasound
1352072|NCT00559611|Fine Needle Aspiration
1352073|NCT00559611|Mediastinoscopy
1352074|NCT00559611|EBUS-FNA
1352075|NCT00559611|EBUS
1352076|NCT00559611|Needle Biopsy
1352077|NCT00559611|NSCLC
1352078|NCT00559598|pancreatic cancer
1352079|NCT00559598|extrahepatic bile duct cancer
1352080|NCT00559572|Exercise
1352081|NCT00559572|Group Counseling
1352082|NCT00559572|Obesity
1352083|NCT00559559|Primary and secondary prevention for ventricular tachycardia
1352084|NCT00559520|Patients
1352085|NCT00559520|Suffering
1352086|NCT00559520|Undernutrition
1352087|NCT00559520|Requiring
1352088|NCT00559520|Vascular
1352089|NCT00559520|Surgery
1352090|NCT00559494|complete spinal cord injury
1352091|NCT00559494|incomplete spinal cord injury
1352092|NCT00559494|central cord spinal cord injury
1352093|NCT00559494|traumatic
1352094|NCT00559481|recurrent prostate cancer
1352095|NCT00559442|high altitude pulmonary edema
1352096|NCT00559442|hypoxic pulmonary vasoconstriction
1352097|NCT00559442|right ventricular function
1352098|NCT00559442|hypoxia
1352099|NCT00559429|Prostate Cancer
1352100|NCT00559416|HIV/AIDS
1352101|NCT00559416|HLA-B*57
1352102|NCT00559416|Cell Transfer
1352103|NCT00559416|HIV
1352104|NCT00559416|treatment experienced
1352105|NCT00559403|Human immunodeficiency virus
1352106|NCT00559403|South Africa
1352107|NCT00559403|Intervention Studies
1352108|NCT00559403|Sexual Behavior
1352109|NCT00559403|Adolescents
1352110|NCT00559403|STD
1352111|NCT00559403|HIV Seronegativity
1352112|NCT00559390|Polycystic Ovary Syndrome
1352113|NCT00559390|Metabolic Syndrome
1352114|NCT00559390|PCOS
1352115|NCT00559390|children
1352116|NCT00559390|girls
1352117|NCT00559390|daughters
1352118|NCT00559390|sisters
1352119|NCT00559390|irregular periods
1352120|NCT00559351|esophagectomy
1352121|NCT00559351|chemotherapy
1352122|NCT00559351|chemoradiotherapy
1352123|NCT00559351|combined modality therapy
1352124|NCT00559338|CHF
1352125|NCT00559338|Heart Failure
1352126|NCT00559338|Dyspnea
1352127|NCT00559338|Cardiomyopathy
1352128|NCT00559312|mild COPD
1352129|NCT00559312|dyspnea
1352130|NCT00559312|exercise
1352131|NCT00559312|combination therapy
1352132|NCT00559299|163090
1352133|NCT00559299|placebo-controlled
1352134|NCT00559299|MDD
1352135|NCT00559299|Depression
1352136|NCT00559299|Tolerability
1352137|NCT00559299|MDE
1352138|NCT00559286|perfusion
1352139|NCT00559286|microcirculation
1352140|NCT00559286|RBC function
1352141|NCT00559286|NO metabolism
1352142|NCT00559286|AT receptor blocker
1352143|NCT00559234|Optic Nerve
1352144|NCT00559234|Retina
1352145|NCT00559234|Cornea
1352146|NCT00559234|Lens
1352147|NCT00559234|Ocular Genetic Diseases
1352148|NCT00559234|Inherited Eye Disease
1352149|NCT00559234|Genetic Eye Disease
1352150|NCT00559221|AML
1352151|NCT00559208|Children and Youth
1352152|NCT00559208|Families
1352153|NCT00559208|Differential Response
1352154|NCT00559195|unspecified adult solid tumor, protocol specific
1352155|NCT00559195|anemia
1352156|NCT00559195|fatigue
1352157|NCT00559169|epilepsy
1352158|NCT00559169|seizures
1352159|NCT00559169|menstrual cycle
1352160|NCT00559156|recurrent squamous cell carcinoma of the hypopharynx
1352161|NCT00559156|stage III squamous cell carcinoma of the hypopharynx
1352162|NCT00559156|stage IV squamous cell carcinoma of the hypopharynx
1352163|NCT00559156|stage III squamous cell carcinoma of the larynx
1352164|NCT00559156|stage IV squamous cell carcinoma of the larynx
1352165|NCT00559156|recurrent squamous cell carcinoma of the larynx
1352166|NCT00559156|recurrent squamous cell carcinoma of the lip and oral cavity
1352167|NCT00559156|stage III squamous cell carcinoma of the lip and oral cavity
1352168|NCT00559156|stage IV squamous cell carcinoma of the lip and oral cavity
1352169|NCT00559156|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1352170|NCT00559156|recurrent metastatic squamous neck cancer with occult primary
1352171|NCT00559156|recurrent squamous cell carcinoma of the nasopharynx
1352172|NCT00559156|stage III squamous cell carcinoma of the nasopharynx
1352173|NCT00559156|stage IV squamous cell carcinoma of the nasopharynx
1352174|NCT00559156|recurrent squamous cell carcinoma of the oropharynx
1352175|NCT00559156|stage III squamous cell carcinoma of the oropharynx
1352176|NCT00559156|stage IV squamous cell carcinoma of the oropharynx
1352298|NCT00558675|Hodgkins Lymphoma
1352177|NCT00559156|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1352178|NCT00559156|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1352179|NCT00559156|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1352180|NCT00559156|recurrent salivary gland cancer
1352181|NCT00559156|salivary gland squamous cell carcinoma
1352182|NCT00559156|stage III salivary gland cancer
1352183|NCT00559156|stage IV salivary gland cancer
1352184|NCT00559143|AV conduction disturbances
1352185|NCT00559143|LV function
1352186|NCT00559143|Biventricular Pacing
1352187|NCT00559143|Conductance Catheters
1352188|NCT00559130|Acute Respiratory Distress Syndrome
1352189|NCT00559130|Acute Lung Injury
1352190|NCT00559130|Sepsis
1352191|NCT00559130|Hemoperfusion
1352192|NCT00559104|stage III adult diffuse mixed cell lymphoma
1352193|NCT00559104|stage IV adult diffuse mixed cell lymphoma
1352194|NCT00559104|stage III adult immunoblastic large cell lymphoma
1352195|NCT00559104|stage IV adult immunoblastic large cell lymphoma
1352196|NCT00559104|stage IV mantle cell lymphoma
1352197|NCT00559104|stage III mantle cell lymphoma
1352198|NCT00559104|stage III adult diffuse large cell lymphoma
1352199|NCT00559104|stage IV adult diffuse large cell lymphoma
1352200|NCT00559104|stage III adult Burkitt lymphoma
1352201|NCT00559104|stage IV adult Burkitt lymphoma
1352202|NCT00559091|AML
1352203|NCT00559091|Acute myelocytic leukemia
1352204|NCT00559091|leukemia
1352205|NCT00559091|relapsed
1352206|NCT00559091|refractory
1352207|NCT00559091|M4
1352208|NCT00559091|M5
1352209|NCT00559078|Adrenal Hyperplasia, Congenital
1352210|NCT00559078|Psychosexual Development
1352211|NCT00559078|Sexual Development
1352212|NCT00559078|Intersex
1352213|NCT00559078|Qualitative
1352214|NCT00559078|CAH
1352215|NCT00559078|Interview
1352216|NCT00559078|Disorder of Sex Development
1352217|NCT00559078|Telephone
1352218|NCT00559078|Quality of Life
1352219|NCT00559078|Mental Health
1352220|NCT00559078|Counseling
1352221|NCT00559065|Case-Cohort Study
1352222|NCT00559065|Leukemia
1352223|NCT00559065|Lymphoma
1352224|NCT00559065|Benzene
1352225|NCT00559065|Blood Disorders
1352226|NCT00559065|Solvent Exposure
1352227|NCT00559065|Cancer Risk
1352228|NCT00559052|Enzymes
1352229|NCT00559052|VIOKASE
1352230|NCT00559052|Bioavailability
1352231|NCT00559039|breast cancer
1352232|NCT00559039|unspecified adult solid tumor, protocol specific
1352233|NCT00559013|Staple line reinforcement
1352234|NCT00559013|Staple line buttress
1352235|NCT00559013|Anastomotic reinforcement
1352236|NCT00559000|PTSD
1352237|NCT00559000|Children
1352238|NCT00559000|trauma-focused Treatment
1352239|NCT00559000|KIDNET
1352240|NCT00559000|Narrative Exposure Therapy for Children
1352241|NCT00558987|Discipline
1352242|NCT00558987|Parenting
1352243|NCT00558987|Primary Care
1352244|NCT00558987|Videos
1352245|NCT00558961|CLL
1352246|NCT00558961|chronic lymphocytic leukemia
1352247|NCT00558961|leukemia
1352248|NCT00558961|gleevec
1352249|NCT00558961|chlorambucil
1352250|NCT00558948|Bone Marrow Transplant
1352251|NCT00558948|Bone Mineral Density
1352252|NCT00558948|Survivors
1352253|NCT00558948|Muscle Strength
1352254|NCT00558922|Lung
1352255|NCT00558922|Non small cell
1352256|NCT00558922|antisense
1352257|NCT00558922|oligonucleotide
1352258|NCT00558922|paclitaxel
1352259|NCT00558922|carboplatin
1352260|NCT00558896|stage II multiple myeloma
1352261|NCT00558896|stage III multiple myeloma
1352262|NCT00558896|refractory multiple myeloma
1352263|NCT00558870|Solid Tumors
1352264|NCT00558870|Morphine
1352265|NCT00558870|Methadone
1352266|NCT00558870|Co-Opioid Analgesic
1352267|NCT00558870|Pain
1352268|NCT00558844|Cystic Fibrosis
1352269|NCT00558844|Respiratory Infections
1352270|NCT00558844|Pulmonary Cystic Fibrosis
1352271|NCT00558844|CFTR
1352272|NCT00558831|Acne
1352273|NCT00558779|Coronary artery bypass
1352274|NCT00558779|off pump coronary artery bypass grafting (OPCAB)
1352275|NCT00558766|Disruptive Behavior Disorders
1352276|NCT00558766|Behavior
1352277|NCT00558766|Gambling
1352278|NCT00558766|Dopaminergic Mechanisms
1352279|NCT00558766|Dopamine
1352280|NCT00558766|Parkinson Disease
1352281|NCT00558766|PD
1352282|NCT00558740|Dietary protein
1352283|NCT00558740|Fructose
1352284|NCT00558740|VLDL-triglycerides
1352285|NCT00558740|Hepatic de novo lipogenesis
1352286|NCT00558740|Lipid oxidation
1352287|NCT00558727|Advanced Solid Tumors
1352288|NCT00558727|Solid Tumors
1352289|NCT00558727|Tumor
1352290|NCT00558727|Non-Hodgkin's Lymphoma
1352291|NCT00558727|Chemotherapy
1352292|NCT00558727|Benzoquinone
1352293|NCT00558701|burns
1352294|NCT00558701|donor site
1352295|NCT00558701|healing
1352296|NCT00558701|microcurrent
1352297|NCT00558675|Non-Hodgkins Lymphoma
1352299|NCT00558675|Acute Lymphoblastic Leukemia
1352300|NCT00558675|Chronic Myeloid Leukemia
1352301|NCT00558675|Chronic Lymphocytic Leukemia
1352302|NCT00558675|Multiple Myeloma
1352303|NCT00558675|Immunotherapy
1352304|NCT00558675|Allogeneic Cell Therapy
1352305|NCT00558662|compression therapy
1352306|NCT00558662|venous leg ulcer
1352307|NCT00558662|sub bandage pressure
1352308|NCT00558636|NSCLC
1352309|NCT00558623|lead, blood
1352310|NCT00558623|pregnancy
1352311|NCT00558623|calcium
1352312|NCT00558623|randomized trial
1352313|NCT00558623|dietary supplementation
1352314|NCT00558623|bone resorption
1352315|NCT00558597|Proteomics
1352316|NCT00558597|Lung Transplantation
1352317|NCT00558584|dilated cardiomyopathy
1352318|NCT00558584|immunoadsorption
1352319|NCT00558584|immunoglobulin G
1352320|NCT00558558|Solid Tumors
1352321|NCT00558558|Cancer-Associated Anorexia
1352322|NCT00558558|Weight Loss
1352323|NCT00558558|Haelan
1352324|NCT00558558|Fermented Soy Product
1352325|NCT00558558|Nutrition
1352326|NCT00558558|Cachexia
1352327|NCT00558545|Breast
1352328|NCT00558545|paclitaxel
1352329|NCT00558545|antisense
1352330|NCT00558545|oligonucleotide
1352331|NCT00558532|Morbid obesity
1352332|NCT00558532|Omega-3 fatty acid levels
1352333|NCT00558519|B-cell adult acute lymphoblastic leukemia
1352334|NCT00558519|T-cell adult acute lymphoblastic leukemia
1352335|NCT00558519|untreated adult acute lymphoblastic leukemia
1352336|NCT00558506|Ankylosing spondylitis
1352337|NCT00558506|activity
1352338|NCT00558506|treatment
1352339|NCT00558506|clinical trial
1352340|NCT00558454|Iron supplements
1352341|NCT00558454|Infant
1352342|NCT00558454|Low birth weight
1352343|NCT00558454|Prevention of iron deficiency and its physiological consequences
1352344|NCT00558454|Safety
1352345|NCT00558376|Colonoscopy
1352346|NCT00558363|Prostate Cancer
1352347|NCT00558363|AVODART
1352348|NCT00558363|PSA
1352349|NCT00558363|dutasteride
1352350|NCT00558363|PSADT
1352351|NCT00558363|Prostate specific antigen
1352352|NCT00558363|radical therapy
1352353|NCT00558363|doubling time
1352354|NCT00558350|lobectomy
1352355|NCT00558350|inflammatory reaction
1352356|NCT00558350|intrapulmonary
1352357|NCT00558350|intrapleural
1352358|NCT00558337|Treatment of Parkinson's Disease
1352359|NCT00558324|LASIK
1352360|NCT00558324|Confocal microscopy
1352361|NCT00558324|Flap
1352362|NCT00558311|Aneurysmal
1352363|NCT00558311|Subarachnoid
1352364|NCT00558311|Hemorrhage
1352365|NCT00558311|vasospasm
1352366|NCT00558311|clazosentan
1352367|NCT00558311|PIVLAZ
1352368|NCT00558311|Actelion
1352369|NCT00558311|surgical clipping
1352370|NCT00558298|schizophrenia
1352371|NCT00558298|schizoaffective disorder
1352372|NCT00558298|risperidone
1352373|NCT00558298|intramuscular injection
1352374|NCT00558298|long-acting injectable
1352375|NCT00558285|COPD
1352376|NCT00558285|Chronic Obstructive Pulmonary Disease
1352377|NCT00558285|Indacaterol
1352378|NCT00558285|QVA149
1352379|NCT00558272|breast cancer
1352380|NCT00558272|prostate cancer
1352381|NCT00558272|metastatic bone disease
1352382|NCT00558272|Subjects with breast cancer or prostate cancer with metastatic bone disease
1352383|NCT00558246|Breast Lift
1352384|NCT00558246|Breast Reduction
1352385|NCT00558246|Breast Reconstruction
1352386|NCT00558246|Plastic Surgery
1352387|NCT00558246|Skin Closure
1352388|NCT00558246|Wound Healing
1352389|NCT00558246|Dermabond
1352390|NCT00558233|Colorectal cancer
1352391|NCT00558233|Screening
1352392|NCT00558233|Health literacy
1352393|NCT00558233|Patient education
1352394|NCT00558233|Computer assisted instruction
1352395|NCT00558220|Lymphoma, B-cell
1352396|NCT00558220|Immunotherapy, passive
1352397|NCT00558220|Remission induction
1352398|NCT00558220|Autologous transplantation
1352399|NCT00558207|Pancreatic cancer
1352400|NCT00558207|pancreas cancer
1352401|NCT00558207|Locally advanced or metastatic pancreatic adenocarcioma
1352402|NCT00558194|Weight loss
1352403|NCT00558181|B CLL
1352404|NCT00558181|Chronic B Lymphocytic Leukemia
1352405|NCT00558181|Methylprednisolone
1352406|NCT00558181|Rituximab
1352407|NCT00558168|Anastrazole
1352408|NCT00558168|safety
1352409|NCT00558168|early breast cancer
1352410|NCT00558155|immunonutrition
1352411|NCT00558155|enteral nutrition
1352412|NCT00558155|parenteral nutrition
1352413|NCT00558155|surgery
1352414|NCT00558142|contrast nephropathy
1352415|NCT00558142|radiocontrast-induced nephropathy
1352416|NCT00558142|chronic kidney disease
1352417|NCT00558142|acetylcysteine
1352418|NCT00558142|clinical study
1352419|NCT00558129|Lumbar Spinal Stenosis
1352420|NCT00558129|X-STOP® IPD
1352421|NCT00558129|Interspinous process decompression
1352422|NCT00558129|Neurogenic Intermittent Claudication
1352423|NCT00558116|Carpal Tunnel Syndrome
1352424|NCT00558116|Dynamic Splinting
1352425|NCT00558116|Nerve Conduction Studies
1352426|NCT00558116|Splinting
1352427|NCT00558116|Levine Katz Survey
1352428|NCT00558103|GW572016
1352429|NCT00558103|Breast Cancer
1352430|NCT00558103|RECIST
1352431|NCT00558103|Inflammatory Breast Cancer
1352432|NCT00558103|Pazopanib
1352433|NCT00558103|ErbB2
1352434|NCT00558103|Cutaneous Disease
1352435|NCT00558103|Tykerb
1352436|NCT00558103|Inflammatory
1352437|NCT00558103|Skin
1352438|NCT00558103|Her2
1352439|NCT00558103|Lapatinib
1352440|NCT00558103|GW786034
1352441|NCT00558090|pain
1352442|NCT00558090|Intensive Care Unit
1352443|NCT00558090|morphine
1352444|NCT00558090|pKpD
1352445|NCT00558090|numerical rating scale
1352446|NCT00558090|critically ill patients
1352447|NCT00558077|Anovulation
1352448|NCT00558077|Clomiphene citrate
1352449|NCT00558077|Fertility
1352450|NCT00558077|Metformin
1352451|NCT00558077|Ovulation induction
1352452|NCT00558077|PCOS
1352453|NCT00558077|Sterility
1352454|NCT00558077|Treatment
1352455|NCT00558077|Clomiphene citrate-resistance
1352456|NCT00558051|Colorectal Cancer
1352457|NCT00558051|Colorectal Carcinoma
1352458|NCT00558051|Colorectal Tumors
1352459|NCT00558051|Neoplasms, Colorectal
1352460|NCT00558038|Hepatic
1352461|NCT00558038|Encephalopathy
1352462|NCT00558038|Liver
1352463|NCT00558038|Liver Disease
1352464|NCT00558038|Liver Failure
1352465|NCT00558038|Lactulose
1352466|NCT00558038|AST-120
1352467|NCT00558012|Osteoporosis
1352468|NCT00558012|Bone loss
1352469|NCT00558012|Frail Geriatric Women
1352470|NCT00558012|Nursing Home Patients
1352471|NCT00558012|Fragility Fractures
1352472|NCT00557999|Cardiology
1352473|NCT00557999|Mechanical ventilation
1352474|NCT00557999|Intensive care
1352475|NCT00557986|1-Metastatic breast cancer
1352476|NCT00557986|2-Surgery
1352477|NCT00557986|3-Survival
1352478|NCT00557947|Abdominoplasty
1352479|NCT00557947|Body Lift
1352480|NCT00557947|Plastic Surgery
1352481|NCT00557947|Skin Closure
1352482|NCT00557947|Wound Healing
1352483|NCT00557947|Dermabond
1352484|NCT00557934|tetralogy of Fallot
1352485|NCT00557934|right ventricular dysfunction
1352486|NCT00557934|pulmonary insufficiency
1352487|NCT00557934|pulmonary valve replacement
1352488|NCT00557934|pressure-volume loops
1352489|NCT00557934|long-term follow-up in tetralogy of Fallot
1352490|NCT00557921|ACS
1352491|NCT00557921|CAD
1352492|NCT00557921|MI
1352493|NCT00557921|PCI
1352494|NCT00557921|PTCA
1352495|NCT00557921|NSTEMI
1352496|NCT00557921|STEMI
1352497|NCT00557921|acute coronary syndrome
1352498|NCT00557921|cerebrovascular disorders
1352499|NCT00557921|coronary artery stent placement
1352500|NCT00557921|coronary thrombosis
1352501|NCT00557921|myocardial infarction
1352502|NCT00557921|myocardial ischemia
1352503|NCT00557921|percutaneous coronary intervention
1352504|NCT00557921|percutaneous transluminal coronary angioplasty
1352505|NCT00557921|peripheral vascular diseases
1352506|NCT00557921|duodenal obstruction
1352507|NCT00557921|duodenal ulcer
1352508|NCT00557921|dyspepsia
1352509|NCT00557921|esophagitis, peptic
1352510|NCT00557921|gastric outlet obstruction
1352511|NCT00557921|gastroduodenal ulcer
1352512|NCT00557921|gastroesophageal reflux disease
1352513|NCT00557921|gastrointestinal hemorrhage
1352514|NCT00557921|peptic ulcer
1352515|NCT00557921|peptic ulcer perforation
1352516|NCT00557908|Von Willebrand Disease
1352517|NCT00557908|VWD
1352518|NCT00557908|prophylaxis
1352519|NCT00557895|Asthma
1352520|NCT00557895|Hypersensitivity
1352521|NCT00557895|Peanut Allergy
1352522|NCT00557895|Eosinophilic Esophagitis
1352523|NCT00557895|Eosinophilic Gastroenteritis
1352524|NCT00557882|prolapse
1352525|NCT00557882|uterus
1352526|NCT00557882|mesh
1352527|NCT00557882|bladder
1352528|NCT00557856|Solid Tumors Transforming Growth Factor Beta Activin Receptor-like Kinase 1
1352529|NCT00557843|Bupivacaine
1352530|NCT00557843|Colon
1352531|NCT00557843|Surgery
1352532|NCT00557843|Oxygenation
1352533|NCT00557830|Renal Cell Carcinoma
1352534|NCT00557830|Kidney Cancer
1352535|NCT00557817|HCT
1352536|NCT00557817|autologous
1352537|NCT00557817|erythropoiesis
1352538|NCT00557817|iron saccharate
1352539|NCT00557817|erythropoietin
1352540|NCT00557817|darbepoetin alpha
1352541|NCT00556738|HFPV
1352542|NCT00556738|neonatal respiratory distress
1352543|NCT00556699|NHL
1352544|NCT00556699|Rituxan
1352545|NCT00556699|anti-CD40
1352546|NCT00557804|Congestive Heart Failure
1352547|NCT00557791|AMD
1352548|NCT00557791|ARMD
1352549|NCT00557791|Exudative Macular Degeneration
1352550|NCT00557791|Bevasiranib
1352551|NCT00557791|siRNA
1352552|NCT00557778|prevention
1352553|NCT00557778|dyslipidemia
1352554|NCT00557765|Tuberculosis
1352555|NCT00557765|Latent tuberculosis infection
1352556|NCT00557765|Interferon gamma release assay
1352557|NCT00557765|Contact tracing
1352558|NCT00557739|CRx-191
1352559|NCT00557739|Plaque
1352560|NCT00557739|Psoriasis
1352561|NCT00557739|nortriptyline hydrochloride
1352562|NCT00557739|mometasone furoate
1352563|NCT00557739|psoriatic infiltrate
1352564|NCT00557726|Inflammation
1352565|NCT00557726|Infection
1352566|NCT00557726|Fever
1352567|NCT00557700|Mild to moderate asthma
1352568|NCT00557687|IVF
1352569|NCT00557687|ovarian reserve
1352570|NCT00557687|poor response
1352571|NCT00557661|Heart failure
1352572|NCT00557661|CD-NP
1352573|NCT00557648|Anxiety
1352574|NCT00557648|Children
1352575|NCT00557648|Cognitive-Behavioral Therapy
1352576|NCT00557648|School-Based Interventions
1352577|NCT00557635|pseudo-arthrosis, osseous matrix, cell therapy
1352578|NCT00557622|PTSD (Posttraumatic Stress Disorder)
1352579|NCT00557622|CAPS
1352580|NCT00557622|fMRI
1352581|NCT00557622|Paroxetine
1352582|NCT00557609|Microphthalmia transcription (MiT) factor associated tumors
1352583|NCT00557609|Alveolar soft part sarcoma (ASPS)
1352584|NCT00557609|Clear cell sarcoma (CCS)
1352585|NCT00557609|Renal cell carcinoma (RCC)
1352586|NCT00557596|Pancreatic
1352587|NCT00557596|antisense
1352588|NCT00557596|oligonucleotide
1352589|NCT00557596|gemcitabine
1352590|NCT00557583|VBY-376 Hepatitis C pharmacokinetics safety
1352591|NCT00557570|Antiretroviral
1352592|NCT00557570|Opportunistic Infection
1352593|NCT00557570|treatment experienced
1352594|NCT00557570|treatment naive
1352595|NCT00557557|Colorectal
1352596|NCT00557557|liver
1352597|NCT00557557|cancer
1352598|NCT00557557|metastases
1352599|NCT00557544|migraine
1352600|NCT00557544|metoclopramide
1352601|NCT00557544|ketoprofen
1352602|NCT00557544|child
1352603|NCT00557492|pancreas
1352604|NCT00557492|pancreatic
1352605|NCT00557492|cancer
1352606|NCT00557492|resectable
1352607|NCT00557466|QMF
1352608|NCT00557466|indacaterol
1352609|NCT00557466|TWISTHALER® device
1352610|NCT00557440|Asthma
1352611|NCT00557440|QMF
1352612|NCT00557440|Indacaterol
1352613|NCT00557440|Mometasone
1352614|NCT00557427|mild to moderate depression according to the DSM-IV scale
1352615|NCT00557414|acute respiratory distress syndrome
1352616|NCT00557414|soluble triggering receptor expressed on myeloid cells-1
1352617|NCT00557414|prognosis
1352618|NCT00557388|muscle loss
1352619|NCT00557388|aging
1352620|NCT00557388|protein
1352621|NCT00557388|amino acids
1352622|NCT00557388|exercise
1352623|NCT00557388|protein synthesis
1352624|NCT00557375|Brain Tumors
1352625|NCT00557375|Survey
1352626|NCT00557362|Keratitis
1352627|NCT00557362|Eye Infection, Fungal
1352628|NCT00557362|Fungal Eye Infection
1352629|NCT00557362|Ocular Infection, Fungal
1352630|NCT00557362|Fungal Keratitis
1352631|NCT00557362|Mycotic Infections, Ocular
1352632|NCT00557362|Voriconazole
1352633|NCT00557362|Natamycin
1352634|NCT00557349|gastric bypass surgery
1352635|NCT00557349|anastomosis, Roux-en-Y
1352636|NCT00557349|Complication, Postoperative
1352637|NCT00557310|osteoporosis, teriparatide, postmenopausal, MRI, finite element analysis
1352638|NCT00557297|asthma
1352639|NCT00557297|SMART
1352640|NCT00557297|inhaled
1352641|NCT00557297|glucocorticosteroid
1352642|NCT00557297|reliever
1352643|NCT00557297|maintenance
1352644|NCT00557297|single inhaler
1352645|NCT00557284|Atopic Dermatitis (Eczema) associated with food allergies
1352646|NCT00557245|HIV infection
1352647|NCT00557245|HIV uninfected partners
1352648|NCT00557245|Double Blind
1352649|NCT00557245|Placebo
1352650|NCT00557245|Seroconversion
1352651|NCT00557245|TDF
1352652|NCT00557245|FTC TDF
1352653|NCT00557245|Safety
1352654|NCT00557245|HIV Seronegativity
1352655|NCT00557232|bevacizumab
1352656|NCT00557232|rubeosis iridis
1352657|NCT00557232|glaucoma
1352658|NCT00557219|cardiac surgery
1352659|NCT00557219|fenoldopam
1352660|NCT00557219|ketanserin
1352661|NCT00557219|renal replacement therapy
1352662|NCT00557206|Recurrent Disease
1352663|NCT00557206|Metastatic Disease
1352664|NCT00557206|Squamous Cell Carcinoma
1352665|NCT00557206|Multicenter
1352666|NCT00557206|Phase II
1352667|NCT00557180|Steroid Resistance
1352668|NCT00557180|Inflammation
1352669|NCT00557154|Pediatrics
1352670|NCT00557154|Venous access
1352671|NCT00557154|Emergency
1352672|NCT00557141|Single arm observational retrospective and prospective study
1352673|NCT00557128|COREG CR,
1352674|NCT00557128|lisinopril,
1352675|NCT00557128|hypertension,
1352676|NCT00557128|dose proportionality,
1352677|NCT00557128|fixed dose combination (FDC)
1352678|NCT00557115|Quality of life
1352679|NCT00557115|Quadriceps
1352680|NCT00557115|Muscle
1352681|NCT00557115|Exacerbation
1352682|NCT00557102|liver metastases
1352683|NCT00557102|lung metastases
1352684|NCT00557102|recurrent rectal cancer
1352685|NCT00557102|stage IV rectal cancer
1352686|NCT00557102|adenocarcinoma of the rectum
1352687|NCT00557102|adenocarcinoma of the colon
1352688|NCT00557102|recurrent colon cancer
1352689|NCT00557102|stage IV colon cancer
1352690|NCT00557089|Pediatrics
1352691|NCT00557089|Cystic Fibrosis
1352692|NCT00557089|Lung Clearance Index
1352693|NCT00557089|rhDNAse
1352694|NCT00557076|Randomized Clinical Trial
1352695|NCT00557076|Auditory Stimulation
1352696|NCT00557050|Hamstring
1352697|NCT00557050|Muscle
1352698|NCT00557050|Injury
1352699|NCT00557050|Prevention
1352700|NCT00557050|Muscles
1352701|NCT00557037|Castrate and Non-Castrate Prostate Cancer
1352702|NCT00557024|hepatocellular carcinoma
1352703|NCT00557024|liver cancer
1352704|NCT00557024|radiofrequency ablation
1352705|NCT00557024|radiotherapy
1352706|NCT00557024|adjuvant therapy
1352707|NCT00556998|pharmacokinetics and safety data of voriconazole in immunocompromised adolescents
1352708|NCT00556959|ADHD
1352709|NCT00556959|Clonidine
1352710|NCT00556959|Attention Deficit
1352711|NCT00556959|Hyperactivity
1352712|NCT00556959|CLONICEL
1352713|NCT00556959|Addrenex
1352714|NCT00556946|Vascular Malformation
1352715|NCT00556933|Induction
1352716|NCT00556933|rATG
1352717|NCT00556933|Calcineurin-inhibitor withdrawal
1352718|NCT00556920|Coreg CR
1352719|NCT00556907|DCIS
1352720|NCT00556907|To evaluate Preoperative mammagraphy and MRI to select candiates with DCIS for IORT
1352721|NCT00556868|High school students
1352722|NCT00556868|Boarding school
1352723|NCT00556868|Breakfast
1352724|NCT00556868|Fasting
1352725|NCT00556868|Memory
1352726|NCT00556868|Attention
1352727|NCT00556868|Mood
1352728|NCT00556855|chronic hand dermatitis
1352729|NCT00556855|research study
1352730|NCT00556855|E-do
1352731|NCT00556855|HK-03
1352734|NCT00556816|COPD
1352735|NCT00556816|outpatient on demand clinic
1352736|NCT00556803|hepatocellular carcinoma
1352737|NCT00556803|liver cancer
1352738|NCT00556803|radiofrequency ablation
1352739|NCT00556803|transcatheter arterial chemoembolization
1352740|NCT00556803|adjuvant therapy
1352741|NCT00556777|stage I breast cancer
1352742|NCT00556764|ANAM
1352743|NCT00556764|Parkinson's
1352744|NCT00556751|Electrocardiogram
1352745|NCT00556751|Electrocardiography
1352746|NCT00556751|Cardiovascular Risk Factors
1352747|NCT00556751|Cholesterol
1352748|NCT00556751|Blood Pressure
1352749|NCT00556751|Diabetes
1352750|NCT00556673|Asthma, QMF149, fixed combination of indacaterol and mometasone furoate
1352751|NCT00556660|Alzheimer
1352752|NCT00556660|SPECT
1352753|NCT00556647|fast-track diagnosis
1352754|NCT00556647|PET-CT
1352755|NCT00556647|endoscopic techniques
1352756|NCT00556647|lung cancer
1352757|NCT00556634|HIV
1352758|NCT00556634|efavirenz
1352759|NCT00556634|central nervous system
1352760|NCT00556634|adverse effects
1352761|NCT00556621|stage II bladder cancer
1352762|NCT00556621|stage III bladder cancer
1352763|NCT00556621|transitional cell carcinoma of the bladder
1352764|NCT00556595|atrial fibrillation
1352765|NCT00556595|paroxysmal
1352766|NCT00556595|symptomatic
1352767|NCT00556595|drug-refractory
1352768|NCT00556569|Physical activity
1352769|NCT00556569|Obesity
1352770|NCT00556543|Rib Fracture
1352771|NCT00556543|Rib Fracture Repair
1352772|NCT00556543|Rib Fracture ORIF
1352773|NCT00556543|Flail Chest
1352774|NCT00556543|Implant
1352775|NCT00556543|Prosthesis
1352776|NCT00556543|Rib fracture non-union
1352777|NCT00556543|Chest wall deformity
1352778|NCT00556530|Congenital Heart Defects
1352779|NCT00556530|Single Nucleotide Polymorphisms
1352780|NCT00556530|Copy Number Variations
1352781|NCT00556530|Whole Genome Association Study
1352782|NCT00556517|Hamstring
1352783|NCT00556517|Strain
1352784|NCT00556517|Rehabilitation
1352785|NCT00556517|muscles
1352786|NCT00556504|add-on treatment
1352787|NCT00556504|botanical drug
1352788|NCT00556504|HCV genotype 1
1352789|NCT00556504|TCM-700C
1352790|NCT00556504|genotype I
1352791|NCT00556491|renal
1352792|NCT00556491|kidney
1352793|NCT00556491|injury
1352794|NCT00556491|acute
1352795|NCT00556491|bypass
1352796|NCT00556491|cardiac
1352797|NCT00556491|minocycline
1352798|NCT00556491|prevention
1352799|NCT00556491|Acute Kidney Failure
1352800|NCT00556478|Premature Ejaculation
1352801|NCT00556478|Lidocaine
1352802|NCT00556478|Prilocaine
1352803|NCT00556478|EMLA® cream
1352804|NCT00556478|topical anesthetics
1352805|NCT00556465|diabetic nephropathy
1352806|NCT00556465|proteinuria
1352807|NCT00556465|antioxidant
1352808|NCT00556439|Vasculitis
1352809|NCT00556439|Arteritis
1352810|NCT00556439|Takayasu's
1352811|NCT00556439|Temporal Arteritis
1352812|NCT00556439|Abatacept
1352813|NCT00556426|Venous Thromboembolic Disease
1352814|NCT00556426|IVC Filter
1352815|NCT00556426|Pulmonary Embolism
1352816|NCT00556413|stage IV colon cancer
1352817|NCT00556413|stage IV rectal cancer
1352818|NCT00556413|recurrent colon cancer
1352819|NCT00556413|recurrent rectal cancer
1352820|NCT00556400|Uterine Bleeding
1352821|NCT00556400|Thrombocytopenia
1352822|NCT00556400|Aplastic Anemia
1352823|NCT00556400|Oral Contraceptive Pills
1352824|NCT00556400|Menorrhagia
1352825|NCT00556387|traumatic brain injury
1352826|NCT00556374|confirmed adenocarcinoma
1352827|NCT00556374|non-metastatic breast cancer
1352828|NCT00556374|estrogen receptor positive
1352829|NCT00556374|progesterone receptor positive
1352830|NCT00556374|non-steroidal aromatase
1352831|NCT00556374|aromatase inhibitor therapy
1352832|NCT00556374|postmenopausal woman
1352833|NCT00556374|adjuvant chemotherapy
1352834|NCT00556374|neoadjuvant chemotherapy
1352835|NCT00556348|bevacizumab
1352836|NCT00556348|AMD
1352837|NCT00556348|Complications
1352838|NCT00556348|Visual acuity
1352839|NCT00556348|OCt
1352840|NCT00556348|Age Macular Degeneration
1352841|NCT00556335|manual aspiration
1352842|NCT00556335|conventional
1352843|NCT00556335|length of stay
1352844|NCT00556283|outlet obstruction
1352845|NCT00556283|rectocele
1352846|NCT00556270|pain
1352847|NCT00556270|fentanyl
1352848|NCT00556270|transdermal patch
1352849|NCT00556257|Immunosuppression, JAK3 inhibitor, kidney transplantation
1352850|NCT00556231|NIRS
1352851|NCT00556231|cardiac output
1352852|NCT00556231|anaerobic threshold
1352853|NCT00556231|exercise stress
1352854|NCT00556231|congenital heart defect
1352855|NCT00556218|Breast Cancer
1352856|NCT00556218|Tibetan Meditation
1352857|NCT00556218|Quality of Life
1352858|NCT00556218|Cognitive Function
1352859|NCT00556218|QOL
1352860|NCT00556205|mRCC
1352861|NCT00556205|sunitinib
1352862|NCT00556205|bevacizumab
1352863|NCT00556192|SLE
1352864|NCT00556192|Rituximab
1352865|NCT00556192|Methylprednisolone
1352866|NCT00556192|Cyclophosphamide
1352867|NCT00556166|Enterra therapy
1352868|NCT00556166|Gastric Simulation System
1352869|NCT00556153|brain tumors, children
1352870|NCT00556127|Large B-cell Lymphoma
1352871|NCT00556127|Rituximab
1352872|NCT00556127|ASCT
1352873|NCT00556114|eye exam
1352874|NCT00556114|Retina
1352875|NCT00556101|Magnetic resonance
1352876|NCT00556101|whole body
1352877|NCT00556101|angiography
1352878|NCT00556101|questionnaire
1352879|NCT00556088|LBH589
1352880|NCT00556088|Phase I
1352881|NCT00556088|Solid Tumors
1352882|NCT00556088|Paclitaxel
1352883|NCT00556088|Carboplatin
1352884|NCT00556088|Bevacizumab
1352885|NCT00556088|Dose escalation
1352886|NCT00556075|Endometriosis
1352887|NCT00556075|Pelvic pain
1352888|NCT00556075|Oral progesterone blocker
1352889|NCT00556049|mRCC
1352890|NCT00556049|sunitinib
1352891|NCT00556049|gemcitabine
1352892|NCT00556036|healthy
1352893|NCT00556036|overweight
1352894|NCT00556036|obese
1352895|NCT00556036|anorexia nervosa
1352896|NCT00556036|weight
1352897|NCT00556036|cortisol
1352898|NCT00556036|hormone
1352899|NCT00556036|bone density
1352900|NCT00556036|bone
1352901|NCT00556036|osteopenia
1352902|NCT00556036|osteoporosis
1352903|NCT00556036|amenorrhea
1352904|NCT00556036|menses
1352905|NCT00556036|irregular
1352906|NCT00556036|stress
1352907|NCT00556036|depression
1352908|NCT00556036|exercise
1352909|NCT00556036|diet
1352910|NCT00556023|interventional
1352911|NCT00556023|dose-finding
1352912|NCT00555997|Major Depressive Disorder
1352913|NCT00555997|Major Depression
1352914|NCT00555997|Depression
1352915|NCT00555997|Geodon
1352916|NCT00555997|Ziprasidone
1352917|NCT00555984|Intracranial tumors
1352918|NCT00555984|Inflammatory markers
1352919|NCT00555984|Craniotomy
1352920|NCT00555984|Postoperative complications
1352921|NCT00555958|Obesity
1352922|NCT00555958|Bariatric surgery
1352923|NCT00555958|Excess weight loss
1352924|NCT00555958|Vagus nerve
1352925|NCT00555958|Vagal blocking
1352926|NCT00555958|VBLOC(TM) therapy
1352927|NCT00555945|Intertrochanteric fracture
1352928|NCT00555945|Gamma3 intramedullary nail
1352929|NCT00555945|Sliding hip screw
1352930|NCT00555932|Intracranial Thrombosis
1352931|NCT00555932|Cerebral Sinovenous Thrombosis
1352932|NCT00555932|Pediatrics
1352933|NCT00555932|Cranial Ultrasound
1352934|NCT00555919|Metastatic breast cancer stage IV
1352935|NCT00555919|Metastatic breast cancer
1352936|NCT00555919|mBC
1352937|NCT00555919|Stage IV breast cancer
1352938|NCT00555919|Hormone receptor positive breast cancer
1352939|NCT00555893|randomized
1352940|NCT00555893|blinded
1352941|NCT00555893|controlled
1352942|NCT00555893|efficacy
1352943|NCT00555867|hormone-receptor positive primary breast cancer
1352944|NCT00555867|compliance
1352945|NCT00555867|Postmenopausal women
1352946|NCT00555854|Motivational interviewing,
1352947|NCT00555854|Multidisciplinary
1352948|NCT00555854|Life style changes
1352949|NCT00555854|Prevention
1352950|NCT00555854|Compliance
1352951|NCT00555854|Self Care
1352952|NCT00555854|Behaviour
1352953|NCT00555841|breast cancer
1352954|NCT00555828|Myocardial Infarction
1352955|NCT00555828|Myocardial infarct
1352956|NCT00555828|Infarction
1352957|NCT00555802|Low Back Pain
1352958|NCT00555802|Motor Control Exercise
1352959|NCT00555802|General exercise
1352960|NCT00555802|Ultrasonography, Multifidus
1352961|NCT00555802|Transversus abdominis
1352962|NCT00555802|Randomized Controlled trial.
1352963|NCT00555789|kidney transplantation
1352964|NCT00555789|rejection
1352965|NCT00555789|AEB071
1352966|NCT00555789|tacrolimus
1352967|NCT00555789|mycophenolic acid
1352968|NCT00555789|immunosuppression
1352969|NCT00555776|tinnitus
1352970|NCT00555776|gabapentin
1352971|NCT00555763|Intraocular pressure
1352972|NCT00555763|Goldmann tonometry
1352973|NCT00555763|applanation tonometry
1352974|NCT00555763|Tonometry, Ocular
1352975|NCT00555750|sleep
1352976|NCT00555750|metabolism
1352977|NCT00555750|insulin
1352978|NCT00555750|glucose
1352979|NCT00555750|actigraphy
1352980|NCT00555750|diary
1352981|NCT00555750|volumetry
1352982|NCT00555750|GABA
1352983|NCT00555737|Celiac Disease
1352984|NCT00555737|Capsule Endoscopy
1352985|NCT00555737|small Bowel Disease
1352986|NCT00555724|Relapsed
1352987|NCT00555724|refractory
1352988|NCT00555724|solid tumor
1352989|NCT00555711|Brain tumor
1352990|NCT00555698|DBS
1352991|NCT00555698|Depression
1352992|NCT00555685|Heart Failure
1352993|NCT00555685|Renal failure
1352994|NCT00555685|Hyponatremia
1352995|NCT00555659|Degeneration
1352996|NCT00555659|Spondylosis
1352997|NCT00555659|Spondylolisthesis
1352998|NCT00555659|Stenosis
1352999|NCT00555633|Photoprotection
1353000|NCT00555633|Sunscreen
1353001|NCT00555633|After-sun-lotion
1353002|NCT00555633|DNA repair enzymes
1353003|NCT00555633|liposomes
1353004|NCT00555633|skin cancer
1353005|NCT00555633|Xeroderma pigmentosum
1353006|NCT00555633|Basal cell nevus syndrome
1353007|NCT00555607|asthma
1353008|NCT00555607|COPD
1353009|NCT00555607|severe
1353010|NCT00555607|controlled
1353011|NCT00555607|mild
1353012|NCT00555607|biomarker
1353013|NCT00555607|exacerbation
1353014|NCT00555594|corneal neovascularization
1353015|NCT00555594|Bevacizumab (Avastin)
1353016|NCT00555594|Immunologic rejection
1353017|NCT00555594|vascular endothelial growth factor
1353018|NCT00555581|Systemic Sclerosis
1353019|NCT00555568|mental health
1353020|NCT00555568|group processes
1353021|NCT00555555|Factor VIII deficiency
1353022|NCT00555555|Von Willebrand disease
1353023|NCT00555555|FVIII/VWF concentrate
1353024|NCT00555555|Bleeding disorders
1353025|NCT00555555|Blood disorders
1353026|NCT00555542|B-cell
1353027|NCT00555542|rituximab
1353028|NCT00555542|Rheumatoid Arthritis
1353029|NCT00555529|COPD
1353030|NCT00555529|exhaled breath condensate
1353031|NCT00555529|applanation tonometry
1353032|NCT00555529|induced sputum
1353033|NCT00555529|smokers
1353034|NCT00555529|healthy control
1353035|NCT00555516|Breast Cancer、 Chemotherapy、 Neutropenia、WBC
1353036|NCT00555503|prospective study
1353037|NCT00555503|registry
1353038|NCT00555503|quality of life
1353039|NCT00555503|mastectomy
1353040|NCT00555503|reconstructive surgical procedures
1353041|NCT00555503|BrCa1
1353042|NCT00555503|BrCa2
1353043|NCT00555503|breast cancer prevention
1353044|NCT00555490|Soy
1353045|NCT00555490|Diabetes
1353046|NCT00555490|Nephropathy
1353047|NCT00555477|premenopausal breast cancer with chemotherapy-induced ovarian failure
1353048|NCT00555464|hemangioma, steroid, prednisolone, vincristine
1353049|NCT00555451|phase I
1353050|NCT00555451|safety
1353051|NCT00555451|tolerance
1353052|NCT00555451|insulin resistance
1353053|NCT00555451|obese
1353054|NCT00555451|pharmacokinetics
1353055|NCT00555438|major orthopaedic surgery
1353056|NCT00555438|venous thromboembolic events prevention
1353057|NCT00555438|renal impairment
1353058|NCT00555438|Arixtra
1353059|NCT00555438|anti-Xa activity
1353060|NCT00555425|Buprenorphine
1353061|NCT00555425|Buprenorphine/naloxone
1353062|NCT00555425|Counseling
1353063|NCT00555425|Primary care
1353064|NCT00555412|pharmacokinetic
1353065|NCT00555412|multidose
1353066|NCT00555412|Staccato Loxapine
1353067|NCT00555399|Glioblastoma Multiforme
1353068|NCT00555399|Anaplastic Glioma
1353069|NCT00555399|Vorinostat
1353070|NCT00555399|Suberoylanilide Hydroxamic Acid
1353071|NCT00555399|SAHA
1353072|NCT00555399|MSK-390
1353073|NCT00555399|Zolinza
1353074|NCT00555399|Isotretinoin
1353075|NCT00555399|Accutane
1353076|NCT00555399|13-cis-Retinoic Acid
1353077|NCT00555399|Carboplatin
1353078|NCT00555399|Paraplatin
1353079|NCT00555399|CBT
1353080|NCT00555399|Temozolomide
1353081|NCT00555399|Temodar
1353082|NCT00555386|Selenium
1353083|NCT00555386|Soy
1353084|NCT00555386|Breast Cancer Risk
1353085|NCT00555373|Pediatric
1353086|NCT00555373|Renal
1353087|NCT00555373|Transplant
1353088|NCT00555360|Health Information Technology
1353089|NCT00555360|Patient Care Management
1353090|NCT00555360|Self Care
1353091|NCT00555360|Quality of Life
1353092|NCT00555360|Family or non-Family Informal Caregivers
1353093|NCT00555347|Sarcoidosis
1353094|NCT00555347|Fatigue
1353095|NCT00555334|hepatocellular carcinoma
1353096|NCT00555334|liver cancer
1353097|NCT00555334|radiofrequency ablation
1353098|NCT00555334|lamivudine
1353099|NCT00555308|urolithiasis
1353100|NCT00555308|ultrasound
1353101|NCT00555308|hydronephrosis
1353102|NCT00555282|central venous catheter
1353103|NCT00555282|cvc
1353104|NCT00555282|coated catheter
1353105|NCT00555282|bacteriaemia
1353106|NCT00555282|bloodstream infection
1353107|NCT00555269|Macular pucker
1353108|NCT00555269|Macular hole
1353109|NCT00555269|Membrane Blue
1353110|NCT00555269|Infracyanine Green
1353111|NCT00555269|Peripheral Visual Field
1353112|NCT00555256|NSCLC
1353113|NCT00555243|Laparoscopic Surgical Simulation
1353114|NCT00555230|HMG-CoA reductase inhibitors
1353115|NCT00555230|Crestor
1353116|NCT00555230|Rosuvastatin
1353117|NCT00555217|kidney disease
1353118|NCT00555217|nephropathy
1353119|NCT00555217|type 2 diabetes
1353120|NCT00555217|hyperkalemia
1353121|NCT00555217|acute kidney injury
1353122|NCT00555204|mild to moderate Alzheimer's disease, memory, cognition, dementia
1353123|NCT00555191|fructose
1353124|NCT00555191|Irritable bowel syndrome
1353125|NCT00555191|malabsorption
1353126|NCT00555191|Glut5 transporter gene
1353127|NCT00555178|Polymorphic light eruption
1353128|NCT00555178|Regulatory T cells (Tregs)
1353129|NCT00555178|Seasonal fluctuation
1353130|NCT00555178|UV radiation
1353131|NCT00555178|Phototherapy
1353132|NCT00555165|Macular Degeneration
1353133|NCT00555165|Visual Impairment
1353134|NCT00555165|Quality of Life
1353135|NCT00555165|Implantable Telescope
1353136|NCT00555139|CRF-1 antagonists,
1353137|NCT00555139|depression,
1353138|NCT00555139|anxiety,
1353139|NCT00555139|fMRI
1353140|NCT00555126|Polytrauma
1353141|NCT00555126|Hypothermia
1353142|NCT00555126|Wound Infection
1353143|NCT00555126|Blood Loss
1353144|NCT00555126|Combined perioperative morbidity
1353145|NCT00555113|pseudoxanthoma elasticum
1353146|NCT00555113|Visual acuity
1353147|NCT00555113|Choroidal neovascularization
1353148|NCT00555113|angioid streaks
1353149|NCT00555087|Erectile dysfunction
1353150|NCT00555087|Hypogonadotrophic males
1353151|NCT00555061|SID
1353152|NCT00555061|impetigo
1353153|NCT00555061|pharmacokinetics
1353154|NCT00555061|Retapamulin ointment, 1%
1353155|NCT00555061|Skin abnormalities
1353156|NCT00555061|Dermatoses
1353157|NCT00555061|pediatric
1353158|NCT00555061|infection
1353159|NCT00555061|SITL
1353160|NCT00555048|graft versus host disease
1353161|NCT00555048|adult acute megakaryoblastic leukemia (M7)
1353162|NCT00555048|adult acute monoblastic leukemia (M5a)
1353163|NCT00555048|adult acute monocytic leukemia (M5b)
1353164|NCT00555048|adult acute myeloblastic leukemia with maturation (M2)
1353165|NCT00555048|adult acute myeloblastic leukemia without maturation (M1)
1353166|NCT00555048|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1353167|NCT00555048|adult acute myelomonocytic leukemia (M4)
1353168|NCT00555048|adult acute promyelocytic leukemia (M3)
1353169|NCT00555048|adult erythroleukemia (M6a)
1353170|NCT00555048|adult pure erythroid leukemia (M6b)
1353171|NCT00555048|childhood acute megakaryocytic leukemia (M7)
1353172|NCT00555048|childhood acute monoblastic leukemia (M5a)
1353173|NCT00555048|childhood acute monocytic leukemia (M5b)
1353174|NCT00555048|childhood acute myeloblastic leukemia with maturation (M2)
1353175|NCT00555048|childhood acute myeloblastic leukemia without maturation (M1)
1353176|NCT00555048|childhood acute myelomonocytic leukemia (M4)
1353177|NCT00555048|childhood acute promyelocytic leukemia (M3)
1353294|NCT00554632|Coagulation parameter
1353178|NCT00555048|accelerated phase chronic myelogenous leukemia
1353179|NCT00555048|adult acute lymphoblastic leukemia in remission
1353180|NCT00555048|adult acute myeloid leukemia in remission
1353181|NCT00555048|adult acute myeloid leukemia with inv(16)(p13;q22)
1353182|NCT00555048|adult acute myeloid leukemia with t(15;17)(q22;q12)
1353183|NCT00555048|adult acute myeloid leukemia with t(16;16)(p13;q22)
1353184|NCT00555048|adult acute myeloid leukemia with t(8;21)(q22;q22)
1353185|NCT00555048|blastic phase chronic myelogenous leukemia
1353186|NCT00555048|childhood acute lymphoblastic leukemia in remission
1353187|NCT00555048|childhood acute myeloid leukemia in remission
1353188|NCT00555048|childhood chronic myelogenous leukemia
1353189|NCT00555048|chronic phase chronic myelogenous leukemia
1353190|NCT00555048|recurrent adult acute lymphoblastic leukemia
1353191|NCT00555048|recurrent adult acute myeloid leukemia
1353192|NCT00555048|recurrent childhood acute lymphoblastic leukemia
1353193|NCT00555048|recurrent childhood acute myeloid leukemia
1353194|NCT00555048|relapsing chronic myelogenous leukemia
1353195|NCT00555048|secondary acute myeloid leukemia
1353196|NCT00555048|childhood myelodysplastic syndromes
1353197|NCT00555048|de novo myelodysplastic syndromes
1353198|NCT00555048|myelodysplastic/myeloproliferative diseases
1353199|NCT00555048|secondary myelodysplastic syndromes
1353200|NCT00555035|GSK1349572,
1353201|NCT00555035|healthy volunteers
1353202|NCT00555022|Muscarinic Receptor Antagonist,
1353203|NCT00555022|Anticholinergic,
1353204|NCT00555022|COPD,
1353205|NCT00555022|FTIH,
1353206|NCT00555022|Plethysmography
1353207|NCT00555009|traumatic brain Injury, cognitive function
1353208|NCT00554996|urinary tract infection
1353209|NCT00554996|urinary catheter
1353210|NCT00554996|Escherichia coli
1353211|NCT00554996|biofilm
1353212|NCT00554983|Recombinant birch pollen allergy
1353213|NCT00554983|IgE-mediated allergic disease attributed to birch pollen
1353214|NCT00554970|Adult Asthmatics
1353215|NCT00554944|Fluid Management
1353216|NCT00554944|surgery
1353217|NCT00554944|Obesity
1353218|NCT00554918|adenocarcinoma of the prostate
1353219|NCT00554918|recurrent prostate cancer
1353220|NCT00554918|stage IV prostate cancer
1353221|NCT00554918|bone metastases
1353222|NCT00554905|ablation
1353223|NCT00554905|catheter
1353224|NCT00554905|Carcinoma, Hepatocellular
1353225|NCT00554905|therapy
1353226|NCT00554905|Chemoembolization, Therapeutic
1353227|NCT00554905|Humans
1353228|NCT00554905|Liver Neoplasms
1353229|NCT00554892|Rectal cancer
1353230|NCT00554892|Sphincter preservation
1353231|NCT00554892|Mechanical bowel preparation
1353232|NCT00554892|Post operative morbidity
1353233|NCT00554892|Anastomotic leakage
1353234|NCT00554827|Relapsed or Refractory Cutaneous T-cell Lymphoma
1353235|NCT00554827|Lymphoma
1353236|NCT00554827|Cutaneous T-cell Lymphoma
1353237|NCT00554827|T-cell Lymphoma
1353238|NCT00554827|Mycosis fungoides
1353239|NCT00554827|Sézary syndrome
1353240|NCT00554827|Primary cutaneous anaplastic large cell
1353241|NCT00554814|Iron deficiency
1353242|NCT00554814|Ferritin
1353243|NCT00554814|Encapsulated iron
1353244|NCT00554814|Infant formula
1353245|NCT00554801|Central Auditory Processing
1353246|NCT00554801|Traumatic Brain Injury
1353247|NCT00554801|Hearing Loss
1353248|NCT00554775|tumors metastatic to brain
1353249|NCT00554775|stage IV non-small cell lung cancer
1353250|NCT00554775|recurrent non-small cell lung cancer
1353251|NCT00554762|mechanical pain,
1353252|NCT00554762|heat pain,
1353253|NCT00554762|dose,
1353254|NCT00554762|efficacy
1353255|NCT00554762|dose response,
1353256|NCT00554762|GW842166,
1353257|NCT00554762|Single,
1353258|NCT00554762|pharmacodynamics,
1353259|NCT00554762|repeat dose,
1353260|NCT00554749|Selective mutism
1353261|NCT00554749|Children
1353262|NCT00554749|Treatment
1353263|NCT00554736|Pollen Allergy
1353264|NCT00554736|Allergy
1353265|NCT00554723|Stroke
1353266|NCT00554723|Cerebral infarct
1353267|NCT00554723|Recovery
1353268|NCT00554723|Double blind
1353269|NCT00554723|Randomized
1353270|NCT00554723|Placebo
1353271|NCT00554723|Traditional Chinese Medicine
1353272|NCT00554723|Neuroaid
1353273|NCT00554710|Crohn's disease
1353274|NCT00554710|immunomodulators
1353275|NCT00554710|biologicals
1353276|NCT00554697|tissue oxygenation
1353277|NCT00554697|perioperative
1353278|NCT00554697|outcome
1353279|NCT00554684|Outcome
1353280|NCT00554684|Elderly
1353281|NCT00554684|ICU
1353282|NCT00554684|Quality of Life
1353283|NCT00554671|Diabetes Mellitus
1353284|NCT00554671|Clinical pharmacists
1353285|NCT00554671|guideline adherence
1353286|NCT00554671|group medical visits
1353287|NCT00554671|behavioral modification
1353288|NCT00554671|pharmacotherapy
1353289|NCT00554645|obesity
1353290|NCT00554645|children
1353291|NCT00554645|psychological intervention
1353292|NCT00554632|Contraceptive
1353293|NCT00554632|Venous thrombosis
1353295|NCT00554619|Pulmonary Arterial Hypertension
1353296|NCT00554619|Ambrisentan
1353297|NCT00554606|Rheumatoid Arthritis
1353298|NCT00554606|Anit-interleukin-1 beta
1353299|NCT00554606|ACZ885
1353300|NCT00554580|continuous positive airway pressure
1353301|NCT00554580|outcome measure
1353302|NCT00554580|clinical trial
1353303|NCT00554567|HIV/AIDS
1353304|NCT00554567|Voluntary Counseling and Testing
1353305|NCT00554567|Rural India
1353306|NCT00554567|HIV Care
1353307|NCT00554567|Health Services Research
1353308|NCT00554528|Cervical
1353309|NCT00554528|disc
1353310|NCT00554528|prosthesis
1353311|NCT00554528|adjacent
1353312|NCT00554528|disease
1353313|NCT00554528|randomized
1353314|NCT00554528|prospective
1353315|NCT00554528|study
1353316|NCT00554515|Kidney
1353317|NCT00554515|Renal Cell
1353318|NCT00554515|Metastatic
1353319|NCT00554515|interleukin-2
1353320|NCT00554515|select
1353321|NCT00554489|recurrent adult acute myeloid leukemia
1353322|NCT00554489|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1353323|NCT00554489|adult acute myeloid leukemia with inv(16)(p13;q22)
1353324|NCT00554489|adult acute myeloid leukemia with t(15;17)(q22;q12)
1353325|NCT00554489|adult acute myeloid leukemia with t(16;16)(p13;q22)
1353326|NCT00554489|adult acute myeloid leukemia with t(8;21)(q22;q22)
1353327|NCT00554476|Lateral Epicondylitis
1353328|NCT00554476|Treatment
1353329|NCT00554476|Corticosteroid
1353330|NCT00554476|Elbow Cast
1353331|NCT00554476|Icing
1353332|NCT00554476|NSAIDs
1353333|NCT00554463|limited stage small cell lung cancer
1353334|NCT00554437|Accidental Falls
1353335|NCT00554437|RCT
1353336|NCT00554437|Age 65 and older
1353337|NCT00554437|noninstitualized populations
1353338|NCT00554424|oocyte retrieval
1353339|NCT00554424|pain relief
1353340|NCT00554424|Local anaesthetic
1353341|NCT00554411|Travatan Z
1353342|NCT00554411|glaucoma
1353343|NCT00554411|tear film break up time
1353344|NCT00554398|Raltegravir
1353345|NCT00554398|MK-0518
1353346|NCT00554398|Treatment intensification
1353347|NCT00554398|HIV-1 latency
1353348|NCT00554398|HIV eradication
1353349|NCT00554398|treatment experienced
1353350|NCT00554372|Jennerex
1353351|NCT00554372|HCC
1353352|NCT00554372|unresectable primary hepatocellular carcinoma
1353353|NCT00554372|hepatocellular carcinoma
1353354|NCT00554372|liver cancer
1353355|NCT00554372|Phase 2
1353356|NCT00554372|oncolytic virus
1353357|NCT00554372|Pexa-Vec
1353358|NCT00554359|Acute Kidney Injury
1353359|NCT00554359|Acute Renal Failure
1353360|NCT00554346|COX-2; post-operative ; sports injury; surgical pain
1353361|NCT00554320|vulvodynia
1353362|NCT00554320|painful bladder syndrome
1353363|NCT00554320|myofascial pain syndrome
1353364|NCT00554320|pelvic floor tension myalgia
1353365|NCT00554307|patent ductus arteriosus
1353366|NCT00554307|indomethacin
1353367|NCT00554307|neoprofen
1353368|NCT00554307|blood flow
1353369|NCT00554294|children
1353370|NCT00554294|primary prevention
1353371|NCT00554294|environmental change
1353372|NCT00554294|behavioural change
1353373|NCT00554294|school setting
1353374|NCT00554294|changing of drinking habits
1353375|NCT00554294|promotion of drinking tap water
1353376|NCT00554281|Type 1 diabetes
1353377|NCT00554281|Hypoglycemia
1353378|NCT00554281|Glucose sensor
1353379|NCT00554268|Advanced Cancers
1353380|NCT00554268|Solid Tumors
1353381|NCT00554268|PBI-05204
1353382|NCT00554255|Pharmacodynamics
1353383|NCT00554255|Japanese
1353384|NCT00554255|safety
1353385|NCT00554255|Pharmacokinetics
1353386|NCT00554242|endothelium
1353387|NCT00554242|antioxidants
1353388|NCT00554242|flavonoids
1353389|NCT00554229|Hormone Resistant Prostate Cancer
1353390|NCT00554229|Endothelin A Receptor Antagonist
1353391|NCT00554229|Endothelin A
1353392|NCT00554229|Endothelin A antagonist
1353393|NCT00554216|Obesity, morbid obesity
1353394|NCT00554190|rhinosinusitis, ethmoid
1353395|NCT00554177|sexual
1353396|NCT00554177|combat
1353397|NCT00554177|PTSD
1353398|NCT00554177|Clinical trial
1353399|NCT00554177|Trauma
1353400|NCT00554177|PTSD treatment
1353401|NCT00554177|PTSD medication
1353402|NCT00554177|Post traumatic stress disorder
1353403|NCT00554164|Aggressive non-Hodgkin's lymphoma
1353404|NCT00554164|Positron emission tomography
1353405|NCT00554164|Chemotherapy
1353406|NCT00554138|rosuvastatin
1353407|NCT00554138|dipyridamole
1353408|NCT00554138|caffeine
1353409|NCT00554125|Sirolimus; Orthotopic liver transplantation; HCC
1353410|NCT00554112|Exercise Training
1353411|NCT00554112|Glucose Intolerance
1353412|NCT00554112|Human Aging
1353413|NCT00554112|Insulin Secretion
1353414|NCT00554073|Magnetic resonance
1353415|NCT00554073|whole body
1353416|NCT00554073|angiography
1353417|NCT00554073|vasovist
1353418|NCT00554073|gadofosveset
1353419|NCT00554073|blood pool agent
1353420|NCT00554073|3T
1353421|NCT00554073|1.5T
1353422|NCT00554073|Field strength
1353423|NCT00554047|Dementia
1353424|NCT00554047|Caregivers
1353425|NCT00554047|Costs and cost analysis
1353426|NCT00554047|Multicenter study
1353427|NCT00554047|Randomized controlled trial
1353428|NCT00554047|Quality Adjusted Life Years
1353429|NCT00554047|Quality of life
1353430|NCT00554047|Technology assessment, biomedical; Methods
1353431|NCT00554034|gingivitis, localized treatment
1353432|NCT00554021|Central venous catheter
1353433|NCT00554021|nosocomial infection
1353434|NCT00554008|Appendicitis
1353435|NCT00554008|laparoscopy
1353436|NCT00554008|randomized trial
1353437|NCT00554008|children
1353438|NCT00554008|pediatric
1353439|NCT00553982|Replacement
1353440|NCT00553982|Knee
1353441|NCT00553982|Patella
1353442|NCT00553982|Arthroplasty
1353443|NCT00553969|cardiovascular disease prevention
1353444|NCT00553943|lymphoma
1353445|NCT00553943|cerebral lymphoma
1353446|NCT00553943|central nervous system
1353447|NCT00553943|cytarabine
1353448|NCT00553943|rituximab
1353449|NCT00553943|Diffuse large B-cell lymphomas, with cerebral or neuromeningeal involvement
1353450|NCT00553930|HCV/HIV-coinfected patients
1353451|NCT00553930|Peginterferon alfa-2a
1353452|NCT00553917|Pregnancy
1353453|NCT00553917|Depression
1353454|NCT00553917|Antidepressants
1353455|NCT00553852|Very Severe Obesity
1353456|NCT00553852|Body Composition
1353457|NCT00553852|GH deficiency
1353458|NCT00553852|IGF-I
1353459|NCT00553852|LASGB
1353460|NCT00553852|GH therapy
1353461|NCT00553839|anesthesia
1353462|NCT00553839|children
1353463|NCT00553839|ketamine
1353464|NCT00553839|pharmacokinetics
1353465|NCT00553813|Unresectable
1353466|NCT00553813|Gemcitabine
1353467|NCT00553813|Taxane
1353468|NCT00553813|TPI 287
1353469|NCT00553787|Obesity, Type 2 diabetes
1353470|NCT00553774|CAD Patients on Optimal Treatment
1353471|NCT00553761|Band atrophy
1353472|NCT00553761|Pattern electroretinogram
1353473|NCT00553761|Chiasmal compression
1353474|NCT00553761|Neural loss
1353475|NCT00553761|Electrophysiological tests
1353476|NCT00553735|Dry Eye
1353477|NCT00553735|Graft versus Host Disease
1353478|NCT00553735|GVHD
1353479|NCT00553722|hypertension
1353480|NCT00553722|dialysis
1353481|NCT00553722|hyperaldosteronism
1353482|NCT00553709|nausea
1353483|NCT00553709|vomiting
1353484|NCT00553709|retching
1353485|NCT00553709|emesis
1353486|NCT00553709|surgery
1353487|NCT00553709|anesthesia
1353488|NCT00553696|chemotherapy
1353489|NCT00553696|combination
1353490|NCT00553683|stage IV pancreatic cancer
1353491|NCT00553683|adult primary hepatocellular carcinoma
1353492|NCT00553683|advanced adult primary liver cancer
1353493|NCT00553683|recurrent adult primary liver cancer
1353494|NCT00553683|localized unresectable adult primary liver cancer
1353495|NCT00553683|recurrent pancreatic cancer
1353496|NCT00553683|recurrent colon cancer
1353497|NCT00553683|recurrent breast cancer
1353498|NCT00553683|recurrent gastric cancer
1353499|NCT00553683|recurrent ovarian epithelial cancer
1353500|NCT00553683|recurrent melanoma
1353501|NCT00553683|stage IV breast cancer
1353502|NCT00553683|stage IV gastric cancer
1353503|NCT00553683|stage IV colon cancer
1353504|NCT00553683|stage IV ovarian epithelial cancer
1353505|NCT00553683|stage IV melanoma
1353506|NCT00553683|liver metastases
1353507|NCT00553670|coronary artery
1353508|NCT00553670|bifurcation
1353509|NCT00553670|stent
1353510|NCT00553670|intravascular ultrasound
1353511|NCT00553670|fractional flow reserve
1353512|NCT00553657|Experimental Medicine
1353513|NCT00553631|Enzyme Replacement Therapy
1353514|NCT00553631|Gaucher disease
1353515|NCT00553631|glucocerebrosidase
1353516|NCT00553631|beta-glucocerebrosidase
1353517|NCT00553631|Acid beta-glucocerebrosidase
1353518|NCT00553631|glucosylceramidase
1353519|NCT00553631|D-glucosyl-N-acylsphingosine glucohydrolase
1353520|NCT00553631|gene activation
1353521|NCT00553631|human
1353522|NCT00553618|Interleukin 2
1353523|NCT00553618|Proleukin
1353524|NCT00553618|DTIC
1353525|NCT00553618|Dacarbazine
1353526|NCT00553618|metastatic melanoma
1353527|NCT00553618|adjuvant
1353528|NCT00553605|Renal Colic Pain Urinary Tract Colic
1353529|NCT00553579|contrast sensitivity, retention time
1353530|NCT00553566|stage 0 bladder cancer
1353531|NCT00553566|stage I bladder cancer
1353532|NCT00553566|transitional cell carcinoma of the bladder
1353533|NCT00553553|Intrathecal morphine ITM intravenous morphine remifentanil hepatic resection
1353534|NCT00553553|Adult
1353535|NCT00553553|ASA I-III (stable)
1353536|NCT00553553|Liver dysfunction requiring primary parenchymal resection
1353537|NCT00553540|backache
1353538|NCT00553540|low backpain
1353539|NCT00553540|sciatica
1353540|NCT00553514|Infertility
1353541|NCT00553514|Oligo-anovulation
1353542|NCT00553514|GONAL-f®
1353543|NCT00553514|AS900672-Enriched
1353544|NCT00553514|hyperglycosylated recombinant human follicle stimulating hormone (r-hFSH)
1353545|NCT00553501|stage II grade 1 follicular lymphoma
1353546|NCT00553501|stage II grade 2 follicular lymphoma
1353547|NCT00553501|stage II grade 3 follicular lymphoma
1353548|NCT00553501|stage III grade 1 follicular lymphoma
1353549|NCT00553501|stage III grade 2 follicular lymphoma
1353550|NCT00553501|stage III grade 3 follicular lymphoma
1353551|NCT00553501|stage IV grade 1 follicular lymphoma
1353552|NCT00553501|stage IV grade 2 follicular lymphoma
1353553|NCT00553501|stage IV grade 3 follicular lymphoma
1353554|NCT00553488|diabetes
1353555|NCT00553488|insulin
1353556|NCT00553488|subcutaneous
1353557|NCT00553488|intra-dermal
1353558|NCT00553488|blood glucose
1353559|NCT00553462|stage IIIA non-small cell lung cancer
1353560|NCT00553462|stage IIIB non-small cell lung cancer
1353561|NCT00553462|adenocarcinoma of the lung
1353562|NCT00553462|bronchoalveolar cell lung cancer
1353563|NCT00553462|large cell lung cancer
1353564|NCT00553462|squamous cell lung cancer
1353565|NCT00553449|nocturnal heartburn
1353566|NCT00553449|day-time heartburn
1353567|NCT00553449|rabeprazole
1353568|NCT00553449|GERD
1353569|NCT00553436|colon
1353570|NCT00553436|rectum
1353571|NCT00553436|polyp
1353572|NCT00553436|EMR
1353573|NCT00553436|Established indication for a procedure greater than colonoscopy and colonic polypectomy
1353574|NCT00553410|stage IA breast cancer
1353575|NCT00553410|stage IB breast cancer
1353576|NCT00553410|stage II breast cancer
1353577|NCT00553410|stage IIIA breast cancer
1353578|NCT00553397|Living donor lung transplant
1353579|NCT00553397|End stage lung disease
1353580|NCT00553384|smell
1353581|NCT00553384|olfaction
1353582|NCT00553384|androstadienone
1353583|NCT00553384|women
1353584|NCT00553384|pheromones
1353585|NCT00553384|Healthy Volunteers
1353586|NCT00553384|Physiological Effects of Androstadienone Exposure
1353587|NCT00553371|stage II malignant testicular germ cell tumor
1353588|NCT00553371|stage III malignant testicular germ cell tumor
1353589|NCT00553358|Lapatinib
1353590|NCT00553358|ErbB2+
1353591|NCT00553358|Early Breast Cancer
1353592|NCT00553358|Neoadjuvant
1353593|NCT00553345|transitional cell carcinoma of the bladder
1353594|NCT00553345|stage 0 bladder cancer
1353595|NCT00553345|stage I bladder cancer
1353596|NCT00553319|ADHD
1353597|NCT00553319|Cocaine
1353598|NCT00553319|Treatment
1353599|NCT00553293|infertility
1353600|NCT00553293|in vitro fertilization
1353601|NCT00553293|LH supplementation
1353602|NCT00553293|Benefits
1353603|NCT00553241|TIA
1353604|NCT00553241|prognosis
1353605|NCT00553241|evaluation
1353606|NCT00553241|management
1353607|NCT00553228|maternal immunization
1353608|NCT00553228|whooping cough
1353609|NCT00553228|pertussis
1353610|NCT00553215|transitional cell carcinoma of the bladder
1353611|NCT00553215|stage 0 bladder cancer
1353612|NCT00553215|stage I bladder cancer
1353613|NCT00553215|stage II bladder cancer
1353614|NCT00553202|recurrent childhood acute myeloid leukemia
1353615|NCT00553202|childhood myelodysplastic syndromes
1353616|NCT00553189|PARP Inhibitor
1353617|NCT00553189|Advanced Cancer
1353618|NCT00553189|Combination Therapy
1353619|NCT00553189|Early Trial
1353620|NCT00553189|DNA Damage Repair
1353621|NCT00553189|Topotecan
1353622|NCT00553189|Cancer
1353623|NCT00553189|Solid Tumor
1353624|NCT00553189|Lymphoma
1353625|NCT00553176|Infliximab
1353626|NCT00553176|Immune disorder
1353627|NCT00553176|Remicade
1353628|NCT00553176|Registry
1353629|NCT00553176|Crohn's Disease
1353630|NCT00553163|Hypnotherapy
1353631|NCT00553163|Prevention of relapse
1353632|NCT00553163|ulcerative colitis
1353633|NCT00553150|adult gliosarcoma
1353634|NCT00553150|adult giant cell glioblastoma
1353635|NCT00553150|adult glioblastoma
1353636|NCT00553150|adult anaplastic astrocytoma
1353637|NCT00553150|adult diffuse astrocytoma
1353638|NCT00553150|adult pilocytic astrocytoma
1353639|NCT00553150|adult subependymal giant cell astrocytoma
1353640|NCT00553137|oropharyngeal candidiasis
1353641|NCT00553124|stage 0 bladder cancer
1353642|NCT00553124|stage I bladder cancer
1353643|NCT00553124|stage II bladder cancer
1353644|NCT00553124|transitional cell carcinoma of the bladder
1353645|NCT00553111|syphilis
1353646|NCT00553111|video education
1353647|NCT00553111|knowledge
1353648|NCT00553111|black
1353649|NCT00553111|hispanic
1353650|NCT00553085|anxiety disorders
1353651|NCT00553085|children
1353652|NCT00553085|neurodevelopmental disorder
1353653|NCT00553085|neurodevelopmental delay
1353654|NCT00553085|temperament
1353655|NCT00553072|Asphyxia
1353656|NCT00553072|perinatal
1353657|NCT00553072|magnesium sulphate
1353658|NCT00553059|nausea and vomiting
1353659|NCT00553059|unspecified adult solid tumor
1353660|NCT00553059|Palonosetron
1353661|NCT00553059|Dexamethasone
1353662|NCT00553046|ethics
1353663|NCT00553046|COPD
1353664|NCT00553046|end of life
1353665|NCT00553046|mechanical ventilation
1353666|NCT00553046|CRF home ventilated patients
1353667|NCT00553033|Patients must be candidable to liver resection
1353668|NCT00553007|Periodontal disease
1353669|NCT00553007|Metabolic Syndrome
1353670|NCT00552994|Drug eluting stent
1353671|NCT00552994|Diabetics
1353672|NCT00552994|Intravascular ultrasound
1353673|NCT00552994|Pathophysiologic (neointimal hyperplasia and peri-stent remodeling)
1353674|NCT00552981|common cold
1353675|NCT00552981|Finnish sauna
1353676|NCT00552981|rct
1353677|NCT00552968|trauma
1353678|NCT00552968|pain
1353679|NCT00552955|Lymphangioleiomyomatosis
1353680|NCT00552955|Abdominal Lymphangioleiomyomas
1353681|NCT00552955|Chyle
1353682|NCT00552955|Ascites
1353683|NCT00552955|Tuberous Sclerosis Complex
1353684|NCT00552955|LAM
1353685|NCT00552942|obesity
1353686|NCT00552942|diabetes
1353687|NCT00552942|cytokines
1353688|NCT00552890|obesity
1353689|NCT00552890|atkins
1353690|NCT00552890|weight reduction
1353691|NCT00552890|kidney function
1353692|NCT00552877|PCI
1353693|NCT00552877|Drug-eluting stent
1353694|NCT00552851|acromegaly
1353695|NCT00552851|heart failure
1353696|NCT00552851|hypertrophy
1353697|NCT00552851|cardiomegaly
1353698|NCT00552838|Antimicrobial prescribing
1353699|NCT00552838|Antimicrobial utilization
1353700|NCT00552825|acute lymphoblastic leukemia
1353701|NCT00552825|long-term lung function
1353702|NCT00552812|Aortic Coarctation
1353703|NCT00552812|Heart Defects, Congenital
1353704|NCT00552812|Stents
1353705|NCT00552812|Heart Catheterization
1353706|NCT00552799|cellulitis
1353707|NCT00552799|lymphoedema
1353708|NCT00552799|penicillin
1353709|NCT00552799|clinical trial
1353710|NCT00552786|noise
1353711|NCT00552786|hearing loss
1353712|NCT00552786|temporary threshold shift
1353713|NCT00552773|SINUSITIS
1353714|NCT00552773|CYCLAMEN
1353715|NCT00552747|fenofibrate
1353716|NCT00552747|coronary heart disease
1353717|NCT00552747|mixed hyperlipidemia
1353718|NCT00552734|Type 1 diabetes
1353719|NCT00552734|Improved glycemic control
1353720|NCT00552734|Glucose excursions
1353721|NCT00552734|Target range glucose levels
1353722|NCT00552734|Insulin guidance software
1353723|NCT00552734|Advisor
1353724|NCT00552721|Motor control
1353725|NCT00552721|Spasticity
1353726|NCT00552708|COREG CR
1353727|NCT00552695|intravenous catheter
1353728|NCT00552695|emergency department
1353729|NCT00552695|pain
1353730|NCT00552682|HIV
1353731|NCT00552682|fibromialgy
1353732|NCT00552682|chronic fatigue syndrome
1353733|NCT00552682|duloxetine
1353734|NCT00552682|pain
1353735|NCT00552682|treatment experienced
1353736|NCT00552682|Fibromialgy in patients with HIV-1 infection
1353737|NCT00552669|Drug Eluting Stents
1353738|NCT00552669|Stents Bare Metal
1353739|NCT00552669|Stent Thrombosis
1353740|NCT00552669|Coronary revascularization
1353741|NCT00552669|Survival
1353742|NCT00552656|Angioplasty, Transluminal, Percutaneous Coronary
1353743|NCT00552656|Drug-eluting stents
1353744|NCT00552656|Treatment Outcome
1353745|NCT00552643|Recalcitrant ulcers
1353746|NCT00552643|Chronic wounds
1353747|NCT00552643|Venous insufficiency wounds
1353748|NCT00552643|Ulcers
1353749|NCT00552643|Exposed bones
1353750|NCT00552643|Exposed Tendons
1353751|NCT00552643|Granulation tissue
1353752|NCT00552643|Polyheal 1
1353753|NCT00552643|Wound care
1353754|NCT00552643|Wound healing
1353755|NCT00552643|Diabetic wounds healing
1353756|NCT00552643|Post trauma
1353757|NCT00552643|Post surgery complication
1353758|NCT00552643|Recalcitrant wounds including venous, post-operative and post-traumatic chronic wounds with different etiologies including wounds with exposed bone and tendon.
1353759|NCT00552630|lead poisoning
1353760|NCT00552630|chelation
1353761|NCT00552604|multiple sclerosis
1353762|NCT00552604|muscle stiffness
1353763|NCT00552604|spasticity
1353764|NCT00552604|pain
1353765|NCT00552604|treatment
1353766|NCT00552604|cannabinoids
1353767|NCT00552591|family risk
1353768|NCT00552591|behavior modification
1353769|NCT00552591|lifestyle change
1353770|NCT00552591|prevention of CHD
1353771|NCT00552591|health care costs
1353772|NCT00552578|drug dependence
1353773|NCT00552578|substance abuse
1353774|NCT00552578|substance use disorders
1353775|NCT00552578|myofascial pain syndrome
1353776|NCT00552578|neuralgia
1353777|NCT00552578|back pain
1353778|NCT00552565|IBS, IBS-D, R-verapamil, Arverpamil, Rezular
1353779|NCT00552552|cancer-related fatigue
1353780|NCT00552552|self-management
1353781|NCT00552552|patient education
1353782|NCT00552552|cancer survivors
1353783|NCT00552552|chronic disease
1353784|NCT00552539|syphilis
1353785|NCT00552539|educational video
1353786|NCT00552539|knowledge
1353787|NCT00552539|black
1353788|NCT00552539|Hispanic
1353789|NCT00552526|Epilepsy
1353790|NCT00552526|Children
1353791|NCT00552526|Mental retardation
1353792|NCT00552526|Ketogenic diet
1353793|NCT00552526|Diet
1353794|NCT00552513|timing
1353795|NCT00552513|intervention
1353796|NCT00552513|early
1353797|NCT00552513|delayed
1353798|NCT00552513|acute coronary syndromes
1353799|NCT00552513|PCI
1353800|NCT00552513|angiography
1353801|NCT00552513|Non ST-segment elevation myocardial infarction
1353802|NCT00552513|unstable angina
1353803|NCT00552487|isolated ACTH deficiency
1353804|NCT00552487|Hashimoto disease
1353805|NCT00552487|Hashimoto thyroiditis
1353806|NCT00552487|autoimmune thyroiditis
1353807|NCT00552474|Parkinson disease
1353808|NCT00552474|Movement disorders
1353809|NCT00552474|Deep Brain Stimulation
1353810|NCT00552474|Libra
1353811|NCT00552474|l-dopa
1353812|NCT00552474|levodopa
1353813|NCT00552474|neuromodulation
1353814|NCT00552474|neurostimulation
1353815|NCT00552474|Electrical stimulation of the brain
1353816|NCT00552474|STN
1353817|NCT00552474|Subthalamic nucleus
1353818|NCT00552461|Pulmonary alveolar proteinosis
1353819|NCT00552461|Primary Pulmonary alveolar proteinosis
1353820|NCT00552461|Rituximab
1353821|NCT00552461|Idiopathic
1353822|NCT00552461|Symptomatic
1353823|NCT00552461|GM-CSF Antibody
1353824|NCT00552448|Pediatric, asthma, pediatric ICU
1353825|NCT00552422|gastroparesis
1353826|NCT00552422|gastroesophageal reflux
1353827|NCT00552409|Diabetes mellitus
1353828|NCT00552409|Type 2 diabetes
1353829|NCT00552409|Chronic kidney disease
1353830|NCT00552409|Diabetic kidney disease
1353831|NCT00552409|Microalbuminuria
1353832|NCT00552409|Albuminuria
1353833|NCT00552409|Vitamin D
1353834|NCT00552409|Cholecalciferol
1353835|NCT00552409|Kidney
1353836|NCT00552409|Renal
1353837|NCT00552409|Cardiovascular
1353838|NCT00552409|Clinical trial
1353839|NCT00552409|Placebo
1353840|NCT00552396|multiple myeloma
1353841|NCT00552396|Anti-KIR (1-7F9)
1353842|NCT00552383|Preterm Infant
1353843|NCT00552383|Behaviour
1353844|NCT00552383|Developmental Care
1353845|NCT00552383|NIDCAP
1353846|NCT00552383|Family Centred Care
1353847|NCT00552383|Neurodevelopmental Outcome, preterm infant
1353848|NCT00552344|CDP 870
1353849|NCT00552344|Certolizumab Pegol
1353850|NCT00552344|CIMZIA
1353851|NCT00552344|Crohn's Disease
1353852|NCT00552344|Crohn Disease
1353853|NCT00552344|CD Induction
1353854|NCT00552344|Induction
1353855|NCT00552344|Clinical response
1353856|NCT00552344|Clinical remission
1353857|NCT00552292|metabolic syndrome
1353858|NCT00552292|hypertension
1353859|NCT00552292|obesity
1353860|NCT00552292|dyslipidemia
1353861|NCT00552292|hyperglycemia
1353862|NCT00552292|cardiovascular complications
1353863|NCT00552279|HPV
1353864|NCT00552279|cervical cancer
1353865|NCT00552279|papillomavirus
1353866|NCT00552279|Human papillomavirus (HPV) vaccine
1353867|NCT00552266|Methylphenidate
1353868|NCT00552266|Trichotillomania
1353869|NCT00552266|Attention deficit
1353870|NCT00552214|Nucleic acid test
1353871|NCT00552214|HIV-1
1353872|NCT00552214|hepatitis
1353873|NCT00552214|HBV
1353874|NCT00552214|HCV
1353875|NCT00552214|TMA
1353876|NCT00552214|HIV Seronegativity
1353877|NCT00552201|kidney transplantation
1353878|NCT00552201|Tacrolimus
1353879|NCT00552201|P450 3A5 cytochrome
1353880|NCT00552201|genotype
1353881|NCT00552188|Atherosclerosis
1353882|NCT00552084|Fish Oil
1353883|NCT00552071|Acromegaly
1353884|NCT00552071|Octreotide LAR
1353885|NCT00552071|Ultrasound guidance
1353886|NCT00552058|CDP 870
1353887|NCT00552058|Certolizumab Pegol
1353888|NCT00552058|CIMZIA ®
1353889|NCT00552058|Crohn's disease
1353890|NCT00552058|Induction
1353891|NCT00552058|Clinical remission
1353892|NCT00552058|Clinical response
1353893|NCT00552045|epilepsy
1353894|NCT00552045|localization-related epilepsy
1353895|NCT00552045|idiopathic generalized epilepsy
1353896|NCT00552045|infantile spasms
1353897|NCT00552045|Lennox-Gastaut syndrome
1353898|NCT00552045|polymicrogyria
1353899|NCT00552045|periventricular heterotopias
1353900|NCT00552045|malformations of cortical development
1353901|NCT00552045|phenome
1353902|NCT00552045|genome
1353903|NCT00552045|genotype
1353904|NCT00552045|phenotype
1353905|NCT00552006|PTSD
1353906|NCT00552006|Treatment
1353907|NCT00552006|Randomized Controlled Clinical Trial
1353908|NCT00552006|Combat
1353909|NCT00552006|Child Soldiers
1353910|NCT00552006|Dissemination
1353911|NCT00552006|Narrative Exposure Therapy
1353912|NCT00552006|Africa
1353913|NCT00551993|laparoscopy
1353914|NCT00551993|robot
1353915|NCT00551993|vaginal prolapse
1353916|NCT00551993|sacrocolpopexy
1353917|NCT00551993|sacral colpopexy
1353918|NCT00551980|Headache
1353919|NCT00551980|Cervical Pain
1353920|NCT00551980|Cognitive treatment
1353921|NCT00551980|Relaxation
1353922|NCT00551980|Exercise
1353923|NCT00551967|clinical outcomes
1353924|NCT00551967|radiographic outcomes
1353925|NCT00551967|total hip arthroplasty
1353926|NCT00551967|survivorship
1353927|NCT00551928|Multiple Myeloma
1353928|NCT00551928|Lenalidomide
1353929|NCT00551928|High dose Melphalan
1353930|NCT00551928|Mobilization
1353931|NCT00551928|CD34
1353932|NCT00551902|Glaucoma
1353933|NCT00551902|trabeculectomy
1353934|NCT00551902|anterior chamber maintainer
1353935|NCT00551902|anterior chamber infusion
1353936|NCT00551889|unspecified adult solid tumor, protocol specific
1353937|NCT00551863|alcohol, drugs, aggression, substance use disorder treatment
1353938|NCT00551850|epidermal growth factor inhibitor
1353939|NCT00551850|solid tumors
1353940|NCT00551850|advanced cancer
1353941|NCT00551837|Lung Transplantation
1353942|NCT00551837|Kidney Transplnatation
1353943|NCT00551837|Chroinic Kidney Disease
1353944|NCT00551837|Influenza
1353945|NCT00551824|esophageal stricture
1353946|NCT00551811|SB-656933-AAA,
1353947|NCT00551811|single dose,
1353948|NCT00551811|ozone challenge
1353949|NCT00551798|Hodgkin's Disease
1353950|NCT00551798|Malignant lymphomas high grade
1353951|NCT00551798|Chemoresistance
1353952|NCT00551798|MIBI
1353953|NCT00551798|PGP
1353954|NCT00551798|MRP1
1353955|NCT00551798|Tumor response
1353956|NCT00551785|Hypoactive Sexual Desire Disorder
1353957|NCT00551785|Menopause
1353958|NCT00551785|Androgen
1353959|NCT00551772|Bio-availability, healthy elderly volunteers
1353960|NCT00551759|adenocarcinoma of the esophagus
1353961|NCT00551759|chemoradiotherapy
1353962|NCT00551759|oxaliplatin
1353963|NCT00551759|cetuximab
1353964|NCT00551759|docetaxel
1353965|NCT00551746|purple grape juice
1353966|NCT00551746|antioxidants
1353967|NCT00551746|platelet aggregation
1353968|NCT00551746|anti-thrombotic
1353969|NCT00551733|recurrent non-small cell lung cancer
1353970|NCT00551733|stage IIIB non-small cell lung cancer
1353971|NCT00551733|stage IV non-small cell lung cancer
1353972|NCT00551720|HIV
1353973|NCT00551720|HIV positive
1353974|NCT00551720|AIDS
1353975|NCT00551720|smoking cessation
1353976|NCT00551720|smoking
1353977|NCT00551720|smoking counseling
1353978|NCT00551707|CombinatoRx
1353979|NCT00551707|CRx-102
1353980|NCT00551707|Rheumatoid Arthritis
1353981|NCT00551707|Prednisolone
1353982|NCT00551707|Dipyridamole
1353983|NCT00551707|ACR20
1353984|NCT00551694|GSK256073A
1353985|NCT00551681|cardiac resynchronisation therapy
1353986|NCT00551681|epicardial lead
1353987|NCT00551681|coronary sinus
1353988|NCT00551655|Human Immunodeficiency Viruses
1353989|NCT00551655|Glomerular Filtration Rate
1353990|NCT00551655|Tenofovir
1353991|NCT00551655|Treatment Experienced
1353992|NCT00551642|Preemie, Inhaled Nitric Oxide
1353993|NCT00551603|epoetinum beta once-weekly
1353994|NCT00551603|darbepoetinum once-fortnightly
1353995|NCT00551603|anemia correction
1353996|NCT00551603|hemoglobin stability
1353997|NCT00551590|diabetes mellitus
1353998|NCT00551590|DPP-4 inhibitor
1353999|NCT00551590|sitagliptin
1354000|NCT00551590|exendin(9-39)
1354001|NCT00551590|GLP-1
1354002|NCT00551577|Ovarian neoplasms,
1354003|NCT00551577|Neoadjuvant Therapy,
1354004|NCT00551577|Docetaxel,
1354005|NCT00551577|Neoplasm, Residual
1354006|NCT00551564|total body water
1354007|NCT00551564|T2DM,
1354008|NCT00551564|Healthy Obese,
1354009|NCT00551564|Insulin Resistance,
1354010|NCT00551564|Rosiglitazone maleate,
1354011|NCT00551564|Glucose Disposal,
1354012|NCT00551564|hyperinsulinemic-euglycemic clamp,
1354013|NCT00551551|Pelvic floor
1354014|NCT00551551|Kegel exercises
1354015|NCT00551551|Quality of Life
1354016|NCT00551551|Pelvic Pain
1354017|NCT00551538|Diabetes
1354018|NCT00551538|Diabetic
1354019|NCT00551538|Insulin
1354020|NCT00551538|Glargine
1354021|NCT00551538|Lispro
1354022|NCT00551525|stage IIB prostate cancer
1354023|NCT00551525|stage IIA prostate cancer
1354024|NCT00551525|stage III prostate cancer
1354025|NCT00551525|stage IV prostate cancer
1354026|NCT00551512|cancer
1354027|NCT00551512|solid tumors
1354028|NCT00551499|Sleep Apnea, CRT
1354029|NCT00551486|Pyrosequencing
1354030|NCT00551486|BRAFV600E mutation
1354031|NCT00551486|Thyroid incidentaloma
1354032|NCT00551486|Ultrasound-guided fine-needle aspiration biopsy
1354033|NCT00551473|pharmacodynamics,
1354034|NCT00551473|tolerance
1354035|NCT00551473|H2 antagonist,
1354036|NCT00551473|AH23844,
1354037|NCT00551473|lavoltidine,
1354038|NCT00551473|gastroesophageal reflux disease (GERD), pharmacokinetics,
1354039|NCT00551460|adult acute promyelocytic leukemia (M3)
1354040|NCT00551460|adult acute myeloid leukemia with t(15;17)(q22;q12)
1354041|NCT00551460|adult acute myeloid leukemia with inv(16)(p13;q22)
1354042|NCT00551460|adult acute myeloid leukemia with t(16;16)(p13;q22)
1354043|NCT00551460|untreated adult acute myeloid leukemia
1354044|NCT00551395|glaucoma
1354045|NCT00551395|laser
1354046|NCT00551395|trabeculoplasty
1354047|NCT00551382|Montelukast
1354048|NCT00551382|Upper respiratory tract infection
1354049|NCT00551382|leukotriene
1354050|NCT00551382|Children
1354051|NCT00551369|stage I non-small cell lung cancer
1354052|NCT00551369|stage II non-small cell lung cancer
1354053|NCT00551369|adenocarcinoma of the lung
1354054|NCT00551369|large cell lung cancer
1354055|NCT00551369|squamous cell lung cancer
1354056|NCT00551369|adenosquamous cell lung cancer
1354057|NCT00551356|Diabetes
1354058|NCT00551356|Diabetic
1354059|NCT00551356|Insulin
1354060|NCT00551356|Humalog
1354061|NCT00551356|Lantus
1354062|NCT00551356|Glargine
1354063|NCT00551356|Lispro
1354064|NCT00551330|Treatment Experienced
1354065|NCT00551317|SB480848,
1354066|NCT00551317|Japanese healthy volunteers
1354067|NCT00551317|darapladib,
1354068|NCT00551278|sentinel lymph node
1354069|NCT00551278|metastasis
1354070|NCT00551278|molecular pathology
1354071|NCT00551239|stage I grade 1 follicular lymphoma
1354072|NCT00551239|stage I grade 2 follicular lymphoma
1354073|NCT00551239|stage III grade 1 follicular lymphoma
1354074|NCT00551239|stage III grade 2 follicular lymphoma
1354075|NCT00551239|stage IV grade 1 follicular lymphoma
1354076|NCT00551239|stage IV grade 2 follicular lymphoma
1354077|NCT00551239|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1354078|NCT00551239|nodal marginal zone B-cell lymphoma
1354079|NCT00551239|splenic marginal zone lymphoma
1354080|NCT00551239|contiguous stage II grade 1 follicular lymphoma
1354081|NCT00551239|contiguous stage II grade 2 follicular lymphoma
1354082|NCT00551239|noncontiguous stage II grade 1 follicular lymphoma
1354083|NCT00551239|noncontiguous stage II grade 2 follicular lymphoma
1354084|NCT00551239|recurrent grade 1 follicular lymphoma
1354085|NCT00551239|recurrent grade 2 follicular lymphoma
1354086|NCT00551239|contiguous stage II marginal zone lymphoma
1354087|NCT00551239|noncontiguous stage II marginal zone lymphoma
1354088|NCT00551239|recurrent marginal zone lymphoma
1354089|NCT00551239|stage I marginal zone lymphoma
1354090|NCT00551239|stage III marginal zone lymphoma
1354091|NCT00551239|stage IV marginal zone lymphoma
1354092|NCT00551239|contiguous stage II small lymphocytic lymphoma
1354093|NCT00551239|noncontiguous stage II small lymphocytic lymphoma
1354094|NCT00551239|recurrent small lymphocytic lymphoma
1354095|NCT00551239|stage I small lymphocytic lymphoma
1354096|NCT00551239|stage III small lymphocytic lymphoma
1354097|NCT00551239|stage IV small lymphocytic lymphoma
1354098|NCT00551239|refractory chronic lymphocytic leukemia
1354099|NCT00551239|stage I chronic lymphocytic leukemia
1354100|NCT00551239|stage II chronic lymphocytic leukemia
1354101|NCT00551239|stage III chronic lymphocytic leukemia
1354102|NCT00551239|stage IV chronic lymphocytic leukemia
1354103|NCT00551226|TB
1354104|NCT00551226|Patients with tuberculosis
1354105|NCT00551213|anti-IGF-1R
1354106|NCT00551200|Buphenyl
1354107|NCT00551200|Sodium Phenylbutyrate
1354108|NCT00551200|Urea Cycle Disorder
1354109|NCT00551200|UCD
1354110|NCT00551161|Alzheimer disease
1354111|NCT00551161|memantine
1354112|NCT00551161|cholinesterase inhibitors
1354113|NCT00551161|magnetic resonance spectroscopy
1354114|NCT00551161|N-acetylaspartate
1354115|NCT00551161|inositol
1354116|NCT00551161|cerebrospinal fluid
1354117|NCT00551161|tau proteins
1354118|NCT00551161|amyloid beta-protein
1354119|NCT00551135|postoperative pain chronic pain
1354120|NCT00551122|recurrent malignant testicular germ cell tumor
1354121|NCT00551122|testicular seminoma
1354122|NCT00551122|recurrent ovarian germ cell tumor
1354123|NCT00551122|stage IV ovarian germ cell tumor
1354124|NCT00551122|stage III malignant testicular germ cell tumor
1354125|NCT00551122|testicular choriocarcinoma and seminoma
1354126|NCT00551122|testicular embryonal carcinoma and seminoma
1354127|NCT00551122|testicular embryonal carcinoma and teratoma with seminoma
1354128|NCT00551122|testicular embryonal carcinoma and yolk sac tumor with seminoma
1354129|NCT00551122|testicular yolk sac tumor and teratoma with seminoma
1354130|NCT00551122|recurrent extragonadal non-seminomatous germ cell tumor
1354131|NCT00551122|recurrent extragonadal seminoma
1354132|NCT00551122|stage IV extragonadal non-seminomatous germ cell tumor
1354133|NCT00551122|stage IV extragonadal seminoma
1354134|NCT00551122|recurrent extragonadal germ cell tumor
1354135|NCT00551122|ovarian mixed germ cell tumor
1354136|NCT00551122|adult central nervous system germ cell tumor
1354137|NCT00551096|Advanced Solid Tumors
1354138|NCT00551096|Biliary or Pancreatic Malignancies
1354139|NCT00551044|prostatic neoplasms
1354140|NCT00551044|bicalutamide
1354141|NCT00551044|quality of life
1354142|NCT00551044|osteoporosis
1354143|NCT00551031|Influenza
1354144|NCT00551031|Orthomyxoviruses
1354145|NCT00551031|Myxovirus Infection
1354146|NCT00551031|Inactivated Split-virion influenza vaccine
1354147|NCT00551031|Elderly
1354148|NCT00551018|Treatment Naive
1354149|NCT00551005|unspecified adult solid tumor, protocol specific
1354150|NCT00550992|untreated childhood acute lymphoblastic leukemia
1354151|NCT00550992|T-cell childhood acute lymphoblastic leukemia
1354152|NCT00550992|acute undifferentiated leukemia
1354153|NCT00550979|gestational diabetes mellitus
1354154|NCT00550979|cardiovascular disease risk
1354155|NCT00550979|heart disease risk
1354156|NCT00550966|Fibromyalgia
1354157|NCT00550966|Quality of life
1354158|NCT00550966|Primary Care
1354159|NCT00550966|Non-pharmacological treatment
1354160|NCT00550966|Cost / Cost-efficacy
1354161|NCT00550940|epilepsy
1354162|NCT00550940|attention
1354163|NCT00550940|emotion
1354164|NCT00550940|behavior problems
1354165|NCT00550940|child
1354166|NCT00550940|adolescent
1354167|NCT00550927|unspecified adult solid tumor, protocol specific
1354168|NCT00550914|Papilloma, Papillomatosis, Laser, Laser Surgery
1354169|NCT00550901|unspecified adult solid tumor, protocol specific
1354170|NCT00550888|uterus
1354171|NCT00550888|abdominal delivery
1354172|NCT00550888|suture techniques
1354173|NCT00550875|Allergic rhinoconjunctivitis,
1354174|NCT00550875|Immunotherapy
1354175|NCT00550862|PBC, Primary Biliary Cirrhosis, Liver,
1354176|NCT00550836|adenocarcinoma of the pancreas
1354177|NCT00550836|duct cell adenocarcinoma of the pancreas
1354178|NCT00550836|stage IV pancreatic cancer
1354179|NCT00550810|Sutent
1354180|NCT00550797|Steroid-naive, non-smokers
1354181|NCT00550797|Mild to moderate allergic asthmatic adults
1354182|NCT00550784|recurrent ovarian epithelial cancer
1354183|NCT00550784|stage III ovarian epithelial cancer
1354184|NCT00550784|stage IV ovarian epithelial cancer
1354185|NCT00550784|fallopian tube cancer
1354186|NCT00550784|peritoneal cavity cancer
1354187|NCT00550758|Methacholine challenge; Spirometry, Early childhood
1354188|NCT00550732|Triazoles
1354189|NCT00550706|Prescription point prevalence
1354190|NCT00550706|Drug utilization
1354191|NCT00550706|Define Daily Dose
1354192|NCT00550693|bloodstream infections
1354193|NCT00550693|hemodialysis catheter
1354194|NCT00550667|Attention-deficit hyperactivity disorder
1354195|NCT00550667|adult
1354196|NCT00550667|diagnostic validity
1354197|NCT00550667|neuropsychological functions
1354198|NCT00550667|social functioning
1354199|NCT00550654|unspecified adult solid tumor, protocol specific
1354200|NCT00550654|recurrent adult soft tissue sarcoma
1354201|NCT00550654|recurrent melanoma
1354202|NCT00550654|recurrent osteosarcoma
1354203|NCT00550654|recurrent renal cell cancer
1354204|NCT00550654|recurrent uterine sarcoma
1354205|NCT00550654|stage IV adult soft tissue sarcoma
1354206|NCT00550654|stage IV melanoma
1354207|NCT00550654|stage IV uterine sarcoma
1354208|NCT00550654|ovarian sarcoma
1354209|NCT00550654|chondrosarcoma
1354210|NCT00550654|metastatic osteosarcoma
1354211|NCT00550654|stage IV renal cell cancer
1354212|NCT00550654|lung metastases
1354213|NCT00550654|liver metastases
1354214|NCT00550654|bone metastases
1354215|NCT00550641|fibromyalgia
1354216|NCT00550641|pool-based exercise
1354217|NCT00550628|neoplasm of uncertain malignant potential
1354218|NCT00550628|colon cancer
1354219|NCT00550615|Non-Hodgkins Lymphoma
1354220|NCT00550615|Relapsed Non Hodgkins Lymphoma
1354221|NCT00550615|Refractory Non Hodgkins Lymphoma
1354222|NCT00550615|Dasatinib
1354223|NCT00550602|Tracheomalacia
1354224|NCT00550602|Tracheobronchomalacia
1354225|NCT00550602|Airway Stabilization
1354226|NCT00550602|Bronchoscopy
1354227|NCT00550602|Stent Placement
1354228|NCT00550602|Tracheobronchoplasty
1354229|NCT00550602|COPD
1354230|NCT00550589|high-grade squamous intraepithelial lesion
1354231|NCT00550589|stage 0 anal cancer
1354232|NCT00550576|Digoxin Antibodies
1354233|NCT00550576|Bipolar Disorder
1354234|NCT00550563|recurrent colon cancer
1354235|NCT00550563|stage I colon cancer
1354236|NCT00550563|stage II colon cancer
1354237|NCT00550563|stage III colon cancer
1354238|NCT00550563|stage IV colon cancer
1354239|NCT00550563|recurrent rectal cancer
1354240|NCT00550563|stage I rectal cancer
1354241|NCT00550563|stage II rectal cancer
1354242|NCT00550563|stage III rectal cancer
1354243|NCT00550563|stage IV rectal cancer
1354244|NCT00550550|rhinoconjunctivitis
1354245|NCT00550550|rhinitis
1354246|NCT00550550|conjunctivitis
1354247|NCT00550550|allergy
1354248|NCT00550550|allergen
1354249|NCT00550550|immunotherapy
1354250|NCT00550537|stage IIIB non-small cell lung cancer
1354251|NCT00550537|stage IV non-small cell lung cancer
1354252|NCT00550537|recurrent non-small cell lung cancer
1354253|NCT00550537|squamous cell lung cancer
1354254|NCT00550537|adenosquamous cell lung cancer
1354255|NCT00550537|bronchoalveolar cell lung cancer
1354256|NCT00550537|large cell lung cancer
1354257|NCT00550537|adenocarcinoma of the lung
1354258|NCT00550524|Knee osteoarthritis
1354259|NCT00550511|Abdominal pain
1354260|NCT00550511|ultrasound
1354261|NCT00550511|surgery
1354262|NCT00550511|emergency department
1354263|NCT00550511|diagnostic accuracy
1354264|NCT00550498|Retinal Vasculitis
1354265|NCT00550498|Retinal Edema
1354266|NCT00550498|Behcet's Disease
1354267|NCT00550472|probiotics
1354268|NCT00550472|atopic dermatitis
1354269|NCT00550472|immune system
1354270|NCT00550472|human
1354271|NCT00550472|Lactobacillus
1354272|NCT00550472|Bifidobacterium
1354273|NCT00550472|healthy subjects
1354274|NCT00550459|Hyponatremia
1354275|NCT00550459|Cognitive
1354276|NCT00550459|Neurological Function
1354277|NCT00550459|Elderly
1354278|NCT00550446|Janus Kinase 3 Clinical Trial
1354279|NCT00550420|open-label extension
1354280|NCT00550420|tolerability
1354281|NCT00550420|Alzheimer's disease
1354282|NCT00550420|Rosiglitazone extended-release (XR)
1354283|NCT00550420|safety
1354284|NCT00550420|cognition
1354285|NCT00550420|BRL-049653
1354286|NCT00550407|Lamotrigine
1354287|NCT00550407|Prevention of relapse or recurrence of a mood episode
1354288|NCT00550407|Bipolar I disorder
1354289|NCT00550394|Adolescents
1354290|NCT00550381|healthy subjects
1354291|NCT00550342|Focal segmental glomerulosclerosis
1354292|NCT00550342|FSGS
1354293|NCT00550342|Proteinuria
1354294|NCT00550342|rituximab
1354295|NCT00550342|B cell
1354296|NCT00550342|autoimmune
1354297|NCT00550342|CD20
1354298|NCT00550342|treatment
1354299|NCT00550342|children
1354300|NCT00549614|heart failure
1354301|NCT00549601|Alzheimer's
1354302|NCT00549601|rivastigmine
1354303|NCT00549601|transdermal
1354304|NCT00549601|safety
1354305|NCT00549601|randomized
1354306|NCT00549601|switch
1354307|NCT00549601|patch
1354308|NCT00549588|Polymorphic light eruption
1354309|NCT00549588|UV radiation
1354310|NCT00549588|photoprotection
1354311|NCT00549588|sunscreen
1354312|NCT00549588|DNA repair enzymes
1354313|NCT00549588|after-sun-lotion
1354314|NCT00549575|Severe Intra uterine growth retardation below the third centile with abnormal uterine doppler
1354315|NCT00549575|Severe growth retardation with pathologic uterine Doppler
1354316|NCT00549575|L-Arginine
1354317|NCT00549575|Nitric Oxide Donor
1354318|NCT00549562|Autistic Disorder
1354319|NCT00550290|vulvectomy
1354320|NCT00550290|wound infection
1354321|NCT00550290|wound complication
1354322|NCT00550290|prophylactic antibiotic
1354323|NCT00550290|Post-operative wound complications following vulvectomy
1354324|NCT00550277|Renal Cell Carcinoma
1354325|NCT00550277|Refractory
1354326|NCT00550277|LBH589
1354327|NCT00550264|Hospital Readmission
1354328|NCT00550264|Continuity of Care
1354329|NCT00550264|Quality of Health Care
1354330|NCT00550251|Nausea
1354331|NCT00550251|Vomiting
1354332|NCT00550251|Emesis
1354333|NCT00550251|Palliative
1354334|NCT00550251|Terminal
1354335|NCT00550251|Cancer
1354336|NCT00550238|Parkinson's Disease Psychosis
1354337|NCT00550225|succinate
1354338|NCT00550225|anti-muscarinic
1354339|NCT00550225|b-agonist
1354340|NCT00550212|healthy subjects
1354341|NCT00550199|Solid Tumors
1354342|NCT00550199|Phase I
1354343|NCT00550199|LBH589
1354344|NCT00550199|Gemcitabine
1354345|NCT00550186|spinal anesthesia
1354346|NCT00550186|preload
1354347|NCT00550186|diuresis
1354348|NCT00550186|bladder retention
1354349|NCT00550147|ADHD-Combined TypeDisruptive behavior Disorder
1354350|NCT00550134|Breast Cancer
1354351|NCT00550134|Quality of life
1354352|NCT00550108|pancreatic cyst
1354353|NCT00550108|ethanol injection
1354354|NCT00550095|Microalbuminuria/proteinuria
1354355|NCT00550095|hypertensive patients with type 2 diabetes
1354356|NCT00550095|Valsartan
1354357|NCT00550095|microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes
1354358|NCT00550082|Anticoagulation
1354359|NCT00550082|High-Risk
1354360|NCT00550082|Deep Vein Thrombosis
1354361|NCT00550082|Pulmonary Embolism
1354362|NCT00550082|Surgery
1354363|NCT00550069|late preterm infants
1354364|NCT00550069|near term infants
1354365|NCT00550069|outcome
1354366|NCT00550056|PTSD, Posttraumatic Stress Disorder, refugees, war
1354367|NCT00550043|Rheumatoid arthritis
1354368|NCT00550030|Psoriasis
1354369|NCT00550030|UVB radiation
1354370|NCT00550030|Biologics
1354371|NCT00550030|Etanercept
1354372|NCT00550030|PASI
1354373|NCT00550004|Unresectable
1354374|NCT00550004|locally advanced
1354375|NCT00550004|metastatic pancreatic adenocarcinoma
1354376|NCT00550004|Stage III
1354377|NCT00550004|Stage IV
1354378|NCT00549991|High Blood Pressure
1354379|NCT00549978|Safety and Pharmacokinetics in healthy subjects
1354380|NCT00549939|child
1354381|NCT00549939|bladder
1354382|NCT00549939|neuropathic
1354383|NCT00549939|alpha blockers
1354384|NCT00549913|adjacent vertebral levels between L1 and S1
1354385|NCT00549900|HPV vaccine,
1354386|NCT00549900|Cervical cancer
1354387|NCT00549900|Human papillomavirus infection,
1354388|NCT00549874|insulin resistance
1354389|NCT00549874|type 2 diabetes
1354390|NCT00549874|myocardial perfusion
1354391|NCT00549874|nitrosative stress
1354392|NCT00549874|thiazolidinediones
1354393|NCT00549861|Cardiac Magnetic Resonance Imaging
1354394|NCT00549861|Contrast agents
1354395|NCT00549861|Gadobutrol
1354396|NCT00549861|Fibrosis
1354397|NCT00549861|Prognosis
1354398|NCT00549861|Magnetic Resonance
1354399|NCT00549861|Gadolinium
1354400|NCT00549848|Leukemia
1354401|NCT00549835|mucositis pain
1354402|NCT00549835|cancer
1354403|NCT00549835|pain
1354404|NCT00549835|acupuncture
1354405|NCT00549835|mucositis
1354406|NCT00549835|cancer pain
1354407|NCT00549822|aromatase inhibitor
1354408|NCT00549822|CA 15-3
1354409|NCT00549822|Hormone receptor positive
1354410|NCT00549809|mechanical ventilation; respiratory failure
1354411|NCT00549796|coronary artery disease
1354412|NCT00549796|angioplasty
1354413|NCT00549796|stent
1354414|NCT00549796|percutaneous coronary intervention
1354415|NCT00549796|on-site cardiac surgery
1354416|NCT00549796|randomized trial
1354417|NCT00549770|Hypertension, valsartan, LCZ696
1354418|NCT00549757|Type 2 diabetes mellitus
1354419|NCT00549757|renal morbidity and mortality
1354420|NCT00549757|cardiovascular disease
1354421|NCT00549757|micro-albuminuria
1354422|NCT00549757|macro-albuminuria
1354423|NCT00549757|RAAS
1354424|NCT00549757|renin inhibitor
1354425|NCT00549757|Reduced estimated glomerular filtration rate
1354426|NCT00549744|ASTHMA
1354427|NCT00549744|CLINICAL ENDPOINT,
1354428|NCT00549731|autism
1354429|NCT00549731|autistic
1354430|NCT00549731|language
1354431|NCT00549731|development
1354432|NCT00549731|developmental
1354433|NCT00549731|assessment
1354434|NCT00549718|Schizophrenia
1354435|NCT00549718|SM-13496
1354436|NCT00549718|Latuda
1354437|NCT00549718|Lurasidone
1354438|NCT00549705|Anticoagulation
1354439|NCT00549705|Thrombosis
1354440|NCT00549705|Bleeding
1354441|NCT00549705|Clotting
1354442|NCT00549705|Pulmonary Embolism
1354443|NCT00549705|Deep Vein Thrombosis
1354444|NCT00549679|Chronic Obstructive Pulmonary Disease (COPD)
1354445|NCT00549679|COPD
1354446|NCT00549679|Repeat Dose
1354447|NCT00549679|GSK256066
1354448|NCT00549666|OC DDI
1354449|NCT00549666|lurasidone
1354450|NCT00549666|Latuda
1354451|NCT00549666|schizophenia
1354452|NCT00549653|GW856553,
1354453|NCT00549653|drug-drug interactions,
1354454|NCT00549653|rosuvastatin
1354455|NCT00549640|nicotine dependence
1354456|NCT00549640|tobacco dependence
1354457|NCT00549536|calcium supplementation
1354458|NCT00549536|intracellular ions
1354459|NCT00549536|sodium/hydrogen exchange activity
1354460|NCT00549523|HIV
1354461|NCT00549523|Alternative Medicine
1354462|NCT00549523|Complementary Medicine
1354463|NCT00549510|COREG CR,
1354464|NCT00549510|lisinopril,
1354465|NCT00549510|hypertension,
1354466|NCT00549510|dose proportionality,
1354467|NCT00549510|fixed dose combination (FDC)
1354468|NCT00549497|GW870086X, inhaled, asthma, cortisol, pharmacokinetics, osteocalcin
1354469|NCT00549484|Thrombocytopenia
1354470|NCT00549484|Thrombopoietin
1354471|NCT00549484|Platelet Transfusion
1354472|NCT00549484|Platelet Factor 4
1354473|NCT00549471|children with cerebral palsy ages eight to eleven.
1354474|NCT00549458|Week pelvic floor muscle in females
1354475|NCT00549445|Chronic Obstructive Pulmonary Disease
1354476|NCT00549445|COPD
1354477|NCT00549445|Exacerbation
1354478|NCT00549445|Macrolide
1354479|NCT00549406|Vision
1354480|NCT00549406|Visual attention
1354481|NCT00549406|Postural balance
1354482|NCT00549406|Geriatrics
1354483|NCT00549393|intensive care unit
1354484|NCT00549393|Healthcare associated infections (HAI)
1354485|NCT00549393|pediatric
1354486|NCT00549380|Aneurysmal Disease in Thorax, Abdominal or Extremity
1354487|NCT00549367|Nutritional status
1354488|NCT00549367|Nutrition counselling
1354489|NCT00549367|Nutrition assessment
1354490|NCT00549367|HIV
1354491|NCT00549367|Alternative Medicine
1354492|NCT00549367|Complementary Medicine
1354493|NCT00549354|Abdominal Infrarenal Aortic
1354494|NCT00549354|Aorto-Iliac Aneurysms
1354495|NCT00549341|Torticollis
1354496|NCT00549341|Cervical Dystonia
1354497|NCT00549328|anti-angiogenesis
1354498|NCT00549328|Non-small cell lung cancer,
1354499|NCT00549328|pazopanib (GW786034)
1354500|NCT00549263|Safety
1354501|NCT00549263|Pharmacokinetics
1354502|NCT00549263|Bioequivalence
1354503|NCT00549250|Human papillomavirus 6/11
1354504|NCT00549250|Neonates
1354505|NCT00549250|Human papillomavirus 6 or 11 infection
1354506|NCT00549237|RYGBP
1354507|NCT00549237|Early nutrition
1354508|NCT00549237|Lean body mass
1354509|NCT00549237|Length of stay
1354510|NCT00549237|Body Composition
1354511|NCT00549211|Healthy Subjects,
1354512|NCT00549211|Safety,
1354513|NCT00549211|Tolerability,
1354514|NCT00549211|Pharmacokinetics
1354515|NCT00549198|tenofovir
1354516|NCT00549198|HIV
1354517|NCT00549198|efavirenz
1354518|NCT00549198|naive
1354519|NCT00549198|lamivudine
1354520|NCT00549198|abacavir
1354521|NCT00549198|emtricitabine
1354522|NCT00549198|renal
1354523|NCT00549172|Osteoarthritis, Knee
1354524|NCT00549172|Arthroscopic Surgery
1354525|NCT00549172|Menisci, Medial
1354526|NCT00549172|Placebo Effect
1354527|NCT00549172|Treatment Efficacy
1354528|NCT00549159|menorrhagia
1354529|NCT00549159|dysfunctional uterine bleeding
1354530|NCT00549159|endometrial ablation
1354531|NCT00549146|reversibility
1354532|NCT00549146|COPD
1354533|NCT00549146|lung function
1354534|NCT00549133|Microalbuminaria in hypertensive patients with type II diabetes mellitus
1354535|NCT00549120|Healthy Subjects
1354536|NCT00549120|muscarinic receptor antagonist
1354537|NCT00549120|propranolol
1354538|NCT00549120|beta-blocker
1354539|NCT00549120|beta-agonist
1354540|NCT00549107|low cardiac output syndrome
1354541|NCT00549107|open heart surgery
1354542|NCT00549107|infants
1354543|NCT00549107|Low cardiac output syndrome in infants undergoing corrective open heart surgery
1354544|NCT00549081|DHEA
1354545|NCT00549081|IVF
1354546|NCT00549081|low ovarian response
1354547|NCT00549055|Macugen Age-related macular degeneration (AMD) Observational study
1354548|NCT00549042|Back Pain
1354549|NCT00549042|Chronic Low Back Pain
1354550|NCT00549042|Chronic Back Pain
1354551|NCT00549042|Pain
1354552|NCT00549042|Chronic Pain
1354553|NCT00549029|muscle disorder
1354554|NCT00549029|statins
1354555|NCT00549029|creatine kinase
1354556|NCT00549016|Aneurysm Exclusion
1354557|NCT00548977|spermatogenesis defect
1354558|NCT00548977|male infertility
1354559|NCT00548977|azoospermia
1354560|NCT00548977|oligozoospermia
1354561|NCT00548977|Y chromosome markers
1354562|NCT00548977|estrogen gene
1354563|NCT00548964|Ketamine
1354564|NCT00548964|glutamate
1354565|NCT00548964|N-methyl-D-aspartate
1354566|NCT00548964|treatment resistant
1354567|NCT00548964|major depressive disorder
1354568|NCT00548964|lithium
1354569|NCT00548951|Dementia
1354570|NCT00548938|Brain Tumor
1354571|NCT00548938|GBM
1354572|NCT00548938|Glioblastoma Multiforme
1354573|NCT00548938|Giladel
1354574|NCT00548938|Temozolomide
1354575|NCT00548912|Kidney Failure, Chronic
1354576|NCT00548912|Hemodialysis
1354577|NCT00548912|Spironolactone
1354578|NCT00548899|Neoadjuvant chemotherapy
1354579|NCT00548899|Targeted therapy
1354580|NCT00548886|QT Prolongation
1354581|NCT00548886|QT Interval
1354582|NCT00548886|Epinephrine
1354583|NCT00548886|Stress test
1354584|NCT00548847|Leukemia
1354585|NCT00548834|CDP870
1354586|NCT00548834|Certolizumab Pegol
1354587|NCT00548795|Acute Respiratory Distress Syndrome
1354588|NCT00548795|ARDS
1354589|NCT00548795|Neutrophil
1354590|NCT00548769|SB-683699,
1354591|NCT00548769|firategrast,
1354592|NCT00548769|PK,
1354593|NCT00548769|surface area,
1354594|NCT00548769|multiple sclerosis
1354595|NCT00548756|Brain Cancer
1354596|NCT00548756|Whole Brain Radiation Therapy
1354597|NCT00548756|Quality of Life
1354598|NCT00548756|QOL
1354599|NCT00548756|Questionnaire
1354600|NCT00548756|Survey
1354601|NCT00548756|WBRT
1354602|NCT00548743|Depression
1354603|NCT00548743|Postpartum
1354604|NCT00548743|Dyad satisfaction
1354605|NCT00548743|Parenting comfort
1354606|NCT00548743|Screening
1354607|NCT00548743|Management
1354608|NCT00548743|Follow up
1354609|NCT00548743|Primary care
1354610|NCT00548743|Practice based research
1354611|NCT00548730|Bronchoscopy
1354612|NCT00548730|Endoscopy
1354613|NCT00548730|Image Enhancement
1354614|NCT00548730|Autofluorescence
1354615|NCT00548730|Narrow Band Image
1354616|NCT00548717|GVHD
1354617|NCT00548717|Stem cell transplantation
1354618|NCT00548717|Sirolimus
1354619|NCT00548704|Extravasation
1354620|NCT00548704|Anthracyclines
1354621|NCT00548678|diclofenac, platelet aggregation, ketorolac, aspirin
1354622|NCT00548665|Atherosclerosis
1354623|NCT00548665|Smoking cessation
1354624|NCT00548665|Diagnostic techniques, cardiovascular
1354625|NCT00548665|Ultrasonography
1354626|NCT00548665|Health behavior
1354627|NCT00548652|apathy
1354628|NCT00548652|obesity
1354629|NCT00548652|methylphenidate
1354630|NCT00548652|MOVE
1354631|NCT00548652|medical crisis counselling
1354632|NCT00548626|Pancreatic Cancer
1354633|NCT00548626|Endoscopic Ultrasonography
1354634|NCT00548626|Fine-Needle Aspiration
1354635|NCT00548626|Cytopathology
1354636|NCT00548613|Myocardial Infarction
1354637|NCT00548613|Heart Attack
1354638|NCT00548613|Coronary Artery Bypass Grafting
1354639|NCT00548600|Prostate Cancer
1354640|NCT00548600|Iridium
1354641|NCT00548600|Implant
1354642|NCT00548600|Radiotherapy
1354643|NCT00548587|Acute Coronary Syndrome
1354644|NCT00548561|extravasation
1354645|NCT00548561|anthracyclines
1354646|NCT00548548|Avastin
1354647|NCT00548548|Metastatic Adenocarcinoma
1354648|NCT00548548|AVAGAST
1354649|NCT00547833|language disorders
1354650|NCT00547833|language learning disabilities
1354651|NCT00547833|vocabulary
1354652|NCT00547833|reading
1354653|NCT00548522|Type 1 Diabetes
1354654|NCT00548522|Pregnancy
1354655|NCT00548522|Islet Mass
1354656|NCT00548522|C-peptide
1354657|NCT00548496|fractured wrist
1354658|NCT00548496|Distal radial fracture,
1354659|NCT00548483|Endotracheal intubation
1354660|NCT00548483|Laryngeal edema
1354661|NCT00548483|Cuff-leak test
1354662|NCT00548483|Corticosteroids
1354663|NCT00548483|This study was to ascertain whether administration of dexamethasone to critically intubated patients prevent postextubation airway obstruction.
1354664|NCT00548483|This study was to compare high dose and low dose dexamethasone in preventing noninvasive ventilation or reintubation among critically ill intubated patients
1354665|NCT00548470|schizophrenia
1354666|NCT00548470|varenicline
1354667|NCT00548470|cognition
1354668|NCT00548470|cigarette smoking
1354669|NCT00548457|the function of the endothelium of the arteries in patients suffering from ectatic coronary arteries
1354670|NCT00548444|Tuberculosis
1354671|NCT00548444|Lymphocyte kinetics
1354672|NCT00548444|MVA85A
1354673|NCT00548444|Deuterium
1354674|NCT00548431|Leukemia, Lymphocytic, Acute [C04.557.337.428.511]
1354675|NCT00548431|6-mercaptopurine
1354676|NCT00548431|methotrexate
1354677|NCT00548431|asparaginase
1354678|NCT00548405|Multiple Sclerosis
1354679|NCT00548392|breast
1354680|NCT00548392|cancer
1354681|NCT00548392|ultrasound
1354682|NCT00548392|high risk
1354683|NCT00548392|marker clip
1354684|NCT00548379|vitamin D
1354685|NCT00548379|pneumonia
1354686|NCT00548366|cirrhosis
1354687|NCT00548366|portal hypertension
1354688|NCT00548366|ascites
1354689|NCT00548366|sodium restriction
1354690|NCT00548327|Genes
1354691|NCT00548327|Dorsolateral Prefrontal Cortex
1354692|NCT00548327|Dopamine
1354693|NCT00548327|Functional Magnetic Resonance Imaging
1354694|NCT00548327|Neuropsychological Testing
1354695|NCT00548327|Schizophrenia
1354696|NCT00548327|Atomoxetine
1354697|NCT00548327|Cognitive Study
1354698|NCT00548327|Pharmacogenetics
1354699|NCT00548327|Normal Volunteers
1354700|NCT00548327|Catechol-O-Methyltransferase
1354701|NCT00548327|Healthy Volunteer
1354702|NCT00548314|Matriderm
1354703|NCT00548314|Dermal matrix
1354704|NCT00548314|VAC therapy
1354705|NCT00548314|Split skin graft
1354706|NCT00548314|Burns
1354707|NCT00548314|Scar quality
1354708|NCT00548275|Buprenorphine
1354709|NCT00548275|Drug counseling
1354710|NCT00548275|HIV risk reduction counseling
1354711|NCT00548275|HIV Seronegativity
1354712|NCT00548275|HIV risk behaviors
1354713|NCT00548262|Open-label
1354714|NCT00548262|non-comparative study to evaluate short course of IV anidulafungin
1354715|NCT00548262|followed by oral voriconazole
1354716|NCT00548262|for tx of candidemia/invasive candidiasis.
1354717|NCT00548249|Subjects with ESRD receiving chronic Hemodialysis
1354718|NCT00548236|exercise intervention
1354719|NCT00548236|AACT
1354720|NCT00548223|recurrence of stroke
1354721|NCT00548223|Dengzhan Shengmai Capsule
1354722|NCT00548223|Traditional Chinese Medicine
1354723|NCT00548210|Hypertrophy
1354724|NCT00548210|scarring
1354725|NCT00548210|scar treatment
1354726|NCT00548210|silicone
1354727|NCT00548197|Intravitreal Bevacizumab injection
1354728|NCT00548197|Pars plana vitrectomy
1354729|NCT00548197|tractional retinal detachment
1354730|NCT00548197|Diabetic retinopathy
1354731|NCT00548184|primary breast cancers
1354732|NCT00548184|Locally advanced breast cancers
1354733|NCT00548158|diabetes
1354734|NCT00548145|Pitavastatin
1354735|NCT00548145|Statins
1354736|NCT00548145|Donepezil
1354737|NCT00548145|Alzheimer's Disease
1354738|NCT00548145|Hypercholesterolemia
1354739|NCT00548145|ADAS-Jcog
1354740|NCT00548145|Alzheimer Disease (MMSE 15-23 and CDR1 or 2)
1354741|NCT00548106|infant formula, milk allergy, hydrolized whey
1354742|NCT00548093|non-small cell lung cancer
1354743|NCT00548093|advanced
1354744|NCT00548093|previously treated
1354745|NCT00548067|High blood pressure, hypertension, drug interaction, steady state, valsartan, hydrochlorothiazide, amlodipine
1354746|NCT00548054|cholera
1354747|NCT00548054|vaccine
1354748|NCT00548054|Kolkata
1354749|NCT00548054|West Bengal
1354750|NCT00548054|India
1354751|NCT00548054|immunogenicity
1354752|NCT00548054|safety
1354753|NCT00548054|infants
1354754|NCT00548054|expanded programme on immunization
1354755|NCT00548041|HIV
1354756|NCT00548041|Emergency Department
1354757|NCT00548041|HIV Seronegativity
1354758|NCT00548002|Staphylococcus aureus
1354759|NCT00548002|bacteremia
1354760|NCT00548002|endocarditis
1354761|NCT00548002|sepsis
1354762|NCT00548002|fluoroquinolone
1354763|NCT00548002|rifampin
1354764|NCT00548002|levofloxacin
1354765|NCT00548002|trovafloxacin
1354766|NCT00547989|ASA class I and II
1354767|NCT00547976|Inflammation
1354768|NCT00547976|Unstable Plaque
1354769|NCT00547976|Macrophage
1354770|NCT00547976|Thrombosis
1354771|NCT00547976|Autoradiography
1354772|NCT00547976|Atherosclerosis
1354773|NCT00547976|Vasculitis
1354774|NCT00547963|Alcohol Drinking
1354775|NCT00547963|Marijuana Smoking
1354776|NCT00547963|Substance Use
1354777|NCT00547963|Emergency Department (ED)
1354778|NCT00547937|Sleep Apnea
1354779|NCT00547937|Oxidative Stress
1354780|NCT00547937|Nitric oxide
1354781|NCT00547937|Cardiovascular disease
1354782|NCT00547911|Entacapone
1354783|NCT00547911|Carbidopa
1354784|NCT00547911|Locus Ceruleus/Norepinephrine-Autonomic System
1354785|NCT00547911|Norepinephrine
1354786|NCT00547911|Adrenergic Nervous System
1354787|NCT00547898|HIV
1354788|NCT00547898|AIDS
1354789|NCT00547898|Diarrhea
1354790|NCT00547898|HIV Associated Diarrhea
1354791|NCT00547885|dihydrocodeine
1354792|NCT00547885|opioids, long acting
1354793|NCT00547885|opioids, short acting
1354794|NCT00547885|Chronic pain
1354795|NCT00547885|non-malignant pain
1354796|NCT00547859|microcirculation
1354797|NCT00547859|cardiac surgery
1354798|NCT00547859|metabolism
1354799|NCT00547859|capnometry
1354800|NCT00547846|Cough
1354801|NCT00547846|Antitussive
1354802|NCT00547846|PDC-748
1354803|NCT00547846|PhytoHealth
1354804|NCT00547820|radiation dose
1354805|NCT00547820|VCUG
1354806|NCT00547820|pediatric patients
1354807|NCT00547807|Pain, neonate, nursing care
1354808|NCT00547729|Heart Failure
1354809|NCT00547729|Left Atrial Pressure Monitoring
1354810|NCT00547716|Hepatitis C
1354811|NCT00547716|Omega 3 fatty acids
1354812|NCT00547716|Omacor
1354813|NCT00547716|Interferon
1354814|NCT00547703|Nonulcer dyspepsia
1354815|NCT00547703|Functional dyspepsia
1354816|NCT00547703|Antidepressant use in dyspepsia
1354817|NCT00547703|Nortriptyline
1354818|NCT00547703|Tricyclic antidepressants
1354819|NCT00547677|liver metastases
1354820|NCT00547677|unspecified adult solid tumor, protocol specific
1354821|NCT00547664|Hylenex, time tagged pain pain reduction, hospice population
1354822|NCT00547651|Small Cell Lung Cancer
1354823|NCT00547651|Lung Cancer
1354824|NCT00547651|Limited Disease Sensitive Small Cell Lung Cancer
1354825|NCT00547651|Extensive Disease Sensitive Small Cell Lung Cancer
1354826|NCT00547651|Limited Disease Refractory Small Cell Lung Cancer
1354827|NCT00547651|Extensive Disease Refractory Small Cell Lung Cancer
1354828|NCT00547651|Refractory Small Cell Lung Cancer
1354829|NCT00547651|Sensitive Small Cell Lung Cancer
1354830|NCT00547638|laceration/wound closure
1354831|NCT00547638|topical skin adhesive
1354832|NCT00547612|adenocarcinoma of the pancreas
1354833|NCT00547612|stage I pancreatic cancer
1354834|NCT00547612|stage II pancreatic cancer
1354835|NCT00547612|stage III pancreatic cancer
1354836|NCT00547612|stage IV pancreatic cancer
1354837|NCT00547612|recurrent pancreatic cancer
1354838|NCT00547560|Alzheimer Disease
1354839|NCT00547547|unspecified adult solid tumor, protocol specific
1354840|NCT00547534|Bortezomib
1354841|NCT00547534|Bendamustine
1354842|NCT00547534|Rituximab
1354843|NCT00547534|Relapsed
1354844|NCT00547534|Refractory
1354845|NCT00547534|Mantle Cell
1354846|NCT00547534|Indolent
1354847|NCT00547482|Type 2 Diabetes
1354848|NCT00547482|Overweight
1354849|NCT00547482|Obese
1354850|NCT00547469|Irritable Bowel Syndrome
1354851|NCT00547469|IBS-c
1354852|NCT00547469|IBS constipation
1354853|NCT00547469|women with IBS
1354854|NCT00547469|women with constipation
1354855|NCT00547443|stage IIIA non-small cell lung cancer
1354856|NCT00547443|stage IIIB non-small cell lung cancer
1354857|NCT00547443|recurrent non-small cell lung cancer
1354858|NCT00547443|adenocarcinoma of the lung
1354859|NCT00547443|squamous cell lung cancer
1354860|NCT00547443|large cell lung cancer
1354861|NCT00547443|bronchoalveolar cell lung cancer
1354862|NCT00547443|adenosquamous cell lung cancer
1354863|NCT00547391|adults
1354864|NCT00547391|children
1354865|NCT00547391|tonsillectomy
1354866|NCT00547378|overactive bladder, urinary incontinence, incontinence,Urgency-frequency
1354867|NCT00547365|primary systemic amyloidosis
1354868|NCT00547339|adenocarcinoma of the prostate
1354869|NCT00547339|stage I prostate cancer
1354870|NCT00547339|stage IIB prostate cancer
1354871|NCT00547339|stage IIA prostate cancer
1354872|NCT00547300|Hypertension
1354873|NCT00547300|Nebivolol
1354874|NCT00547300|Beta blocker
1354875|NCT00547300|Tolerability
1354876|NCT00547261|solid tumor
1354877|NCT00547261|antimitotic
1354878|NCT00547261|tubulin binder
1354879|NCT00547248|Booster vaccination.
1354880|NCT00547248|Immunogenicity
1354881|NCT00547248|Pneumococcal vaccine
1354882|NCT00547248|Safety
1354883|NCT00547248|Pneumococcal disease
1354884|NCT00547235|infection
1354885|NCT00547235|precancerous/nonmalignant condition
1354886|NCT00547196|refractory chronic lymphocytic leukemia
1354887|NCT00547196|adult acute myeloid leukemia in remission
1354888|NCT00547196|recurrent adult acute myeloid leukemia
1354889|NCT00547196|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1354890|NCT00547196|adult acute myeloid leukemia with inv(16)(p13;q22)
1354891|NCT00547196|adult acute myeloid leukemia with t(15;17)(q22;q12)
1354892|NCT00547196|adult acute myeloid leukemia with t(16;16)(p13;q22)
1354893|NCT00547196|adult acute myeloid leukemia with t(8;21)(q22;q22)
1354894|NCT00547196|adult acute lymphoblastic leukemia in remission
1354895|NCT00547196|accelerated phase chronic myelogenous leukemia
1354896|NCT00547196|blastic phase chronic myelogenous leukemia
1354897|NCT00547196|chronic phase chronic myelogenous leukemia
1354898|NCT00547196|de novo myelodysplastic syndromes
1354899|NCT00547196|previously treated myelodysplastic syndromes
1354900|NCT00547196|secondary myelodysplastic syndromes
1354901|NCT00547196|recurrent adult Burkitt lymphoma
1354902|NCT00547196|recurrent adult diffuse large cell lymphoma
1354903|NCT00547196|recurrent adult diffuse mixed cell lymphoma
1354904|NCT00547196|recurrent adult diffuse small cleaved cell lymphoma
1354905|NCT00547196|recurrent adult grade III lymphomatoid granulomatosis
1354906|NCT00547196|recurrent adult immunoblastic large cell lymphoma
1354907|NCT00547196|recurrent adult lymphoblastic lymphoma
1354908|NCT00547196|recurrent grade 1 follicular lymphoma
1354909|NCT00547196|recurrent grade 2 follicular lymphoma
1354910|NCT00547196|recurrent grade 3 follicular lymphoma
1354911|NCT00547196|recurrent mantle cell lymphoma
1354912|NCT00547196|recurrent marginal zone lymphoma
1354913|NCT00547196|recurrent small lymphocytic lymphoma
1354914|NCT00547196|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1354915|NCT00547196|nodal marginal zone B-cell lymphoma
1354916|NCT00547196|splenic marginal zone lymphoma
1354917|NCT00547196|relapsing chronic myelogenous leukemia
1354918|NCT00547196|recurrent cutaneous T-cell non-Hodgkin lymphoma
1354919|NCT00547196|secondary acute myeloid leukemia
1354920|NCT00547170|pelvic infection
1354921|NCT00547170|abortion
1354922|NCT00547170|doxycycline
1354923|NCT00547157|head and neck
1354924|NCT00547157|squamous cell carcinoma
1354925|NCT00547157|radiotherapy
1354926|NCT00547157|chemoradiotherapy
1354927|NCT00547157|panitumumab
1354928|NCT00547157|locally advanced head & neck cancer
1354929|NCT00547157|EGFr
1354930|NCT00547157|epidermal growth factor receptor
1354931|NCT00547157|SCCHN
1354932|NCT00547157|locally advanced SCCHN
1354933|NCT00547157|HNC
1354934|NCT00547157|epidermal growth factor
1354935|NCT00547131|tumors metastatic to brain
1354936|NCT00547131|recurrent adult brain tumor
1354937|NCT00547118|Metabolic abnormalities
1354938|NCT00547118|Safety
1354939|NCT00547118|Satiety
1354940|NCT00547105|recurrent non-small cell lung cancer
1354941|NCT00547105|stage IIIB non-small cell lung cancer
1354942|NCT00547105|stage IV non-small cell lung cancer
1354943|NCT00547105|stage IIIA non-small cell lung cancer
1354944|NCT00547066|ITP
1354945|NCT00547066|hA20
1354946|NCT00547066|Treatment
1354947|NCT00547040|calcification
1354948|NCT00547040|bone lesions
1354949|NCT00547027|diabetes
1354950|NCT00547027|physical activity
1354951|NCT00547027|print-based intervention
1354952|NCT00547027|tailored intervention
1354953|NCT00547014|treatment, parallel assignment, double blind, randomized, placebo control, safety study,SLE (Systemic Lupus Erythematosus)
1354954|NCT00547001|Menopause
1354955|NCT00547001|Hot flashes
1354956|NCT00547001|vasomotor symptoms
1354957|NCT00547001|tapering regimen
1354958|NCT00547001|hormonal therapy
1354959|NCT00547001|Other menopausal symptoms including mood changes
1354960|NCT00546988|primary treatment
1354961|NCT00546988|allogeneic stem-cell transplantation
1354962|NCT00546988|high-dose therapy
1354963|NCT00546988|cytogenetics
1354964|NCT00546975|gastrointestinal surgery
1354965|NCT00546975|nutritional intervention
1354966|NCT00546975|functional status
1354967|NCT00546975|quality of life
1354968|NCT00546949|Decompression, Surgical
1354969|NCT00546949|x-stop
1354970|NCT00546949|lumbar decompression
1354971|NCT00546949|spinal stenosis
1354972|NCT00546949|radiculopathy
1354973|NCT00546936|Histoplasmosis
1354974|NCT00546884|End of Life
1354975|NCT00546884|Advance Directives
1355098|NCT00546104|Stage IV Breast Cancer
1354976|NCT00546884|Randomized controlled trial
1354977|NCT00546884|End of life care
1354978|NCT00546884|End of life advance care planning
1354979|NCT00546858|Pelvic pain
1354980|NCT00546858|Vulvar pain
1354981|NCT00546806|Rehabilitation,
1354982|NCT00546806|Treatment outcome,
1354983|NCT00546806|Whiplash injuries,
1354984|NCT00546806|Randomized Clinical Trials
1354985|NCT00546793|humanized anti-CD20 veltuzumab (IMMU-106) administered subcutaneously
1354986|NCT00546780|Multiple Myeloma
1354987|NCT00546780|Heat Shock Protein 90
1354988|NCT00546780|Hsp90
1354989|NCT00546780|KOS-953
1354990|NCT00546780|17-AAG
1354991|NCT00546780|bortezomib
1354992|NCT00546780|first relapse
1354993|NCT00546780|tanespimycin
1354994|NCT00546780|TIME-1
1354995|NCT00546741|Diabetes,NOS
1354996|NCT00546689|HIV
1354997|NCT00546689|aids
1354998|NCT00546689|intestinal parasites
1354999|NCT00546689|eosinophils
1355000|NCT00546689|immunoglobulins
1355001|NCT00546689|HIV/aids
1355002|NCT00546689|Treatment Experienced
1355003|NCT00546663|Cystic Fibrosis, hypertonic saline
1355004|NCT00546650|Focus of study is to compare pharmacokinetics
1355005|NCT00546611|PEP005
1355006|NCT00546611|Common Wart(s)
1355007|NCT00546611|Common warts (verruca[e] vulgaris)
1355008|NCT00546598|Total hip replacement, Total hip arthroplasty
1355009|NCT00546585|influenza, inactivated influenza A/H7N7 vaccine, parent protocol
1355010|NCT00546559|Lipophilic statins
1355011|NCT00546559|Insulin resistance
1355012|NCT00546559|simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
1355013|NCT00546546|Crohn
1355014|NCT00546546|immunosuppressants
1355015|NCT00546546|natural history
1355016|NCT00546546|steroids
1355017|NCT00546520|Asthma
1355018|NCT00546520|Ciclesonide
1355019|NCT00546520|Airway hyperresponsiveness
1355020|NCT00546520|Sputum
1355021|NCT00546520|Nitric oxide
1355022|NCT00546468|stomach cancer
1355023|NCT00546468|laparoscopy
1355024|NCT00546468|gastrectomy
1355025|NCT00546468|QOL
1355026|NCT00546468|survival
1355027|NCT00546468|clinical study
1355028|NCT00546455|Obesity
1355029|NCT00546455|insulin resistance
1355030|NCT00546442|insulin resistance
1355031|NCT00546442|chronic hepatitis C
1355032|NCT00546442|genotype 1
1355033|NCT00546429|Proximal femoral fracture
1355034|NCT00546429|Trochanteric fracture
1355035|NCT00546429|Intramedullary nailing
1355036|NCT00546403|Excessive Daytime Sleepiness
1355037|NCT00546377|B-cell chronic lymphocytic leukemia
1355038|NCT00546377|Waldenstrom macroglobulinemia
1355039|NCT00546377|recurrent mantle cell lymphoma
1355040|NCT00546377|recurrent small lymphocytic lymphoma
1355041|NCT00546377|refractory chronic lymphocytic leukemia
1355042|NCT00546377|recurrent marginal zone lymphoma
1355043|NCT00546377|recurrent grade 1 follicular lymphoma
1355044|NCT00546377|recurrent grade 2 follicular lymphoma
1355045|NCT00546377|recurrent grade 3 follicular lymphoma
1355046|NCT00546351|Lacosamide
1355047|NCT00546299|Ambulatory oxygen therapy
1355048|NCT00546299|COPD
1355049|NCT00546299|exertional hypoxemia
1355050|NCT00546273|LTBI (Latent tuberculosis infection)
1355051|NCT00546273|TB(Tuberculosis)
1355052|NCT00546273|Vaccine
1355053|NCT00546260|STEMI
1355054|NCT00546260|ACS
1355055|NCT00546234|asthma
1355056|NCT00546234|tiotropium
1355057|NCT00546234|smoking
1355058|NCT00546234|eNO
1355059|NCT00546234|metabolites
1355060|NCT00546234|Virtual Asthma Clinic
1355061|NCT00546221|Depression
1355062|NCT00546221|Mental health
1355063|NCT00546221|Exercise
1355064|NCT00546221|Prescribed exercise
1355065|NCT00546221|Physical health
1355066|NCT00546221|Social wellbeing
1355067|NCT00546208|bladder function
1355068|NCT00546208|cutaneous ureterostomy
1355069|NCT00546208|hydronephrosis
1355070|NCT00546195|Cord Blood
1355071|NCT00546195|Neutrophils
1355072|NCT00546195|Polysaccharide
1355073|NCT00546195|Gene Expression
1355074|NCT00546182|Lipophilic statins
1355075|NCT00546182|Insulin resistance
1355076|NCT00546182|hypercholesterolemic patients
1355077|NCT00546169|Patients undergoing elective or acute cholecystectomy
1355078|NCT00546156|ER positive
1355079|NCT00546156|PR positive
1355080|NCT00546143|Asthma, anti-immunoglobulin E, omalizumab
1355081|NCT00546130|ED-SCLC
1355082|NCT00546130|small cell lung cancer
1355083|NCT00546130|CPT-11
1355084|NCT00546130|irinotecan hydrochloride
1355085|NCT00546130|CDDP
1355086|NCT00546130|cisplatin
1355087|NCT00546130|PSK
1355088|NCT00546130|Krestin
1355089|NCT00546117|otitis media with effusion
1355090|NCT00546117|gastroesophageal reflux
1355091|NCT00546117|ear infection
1355092|NCT00546117|proton pump inhibitor
1355093|NCT00546104|Advanced Breast Cancer
1355094|NCT00546104|Breast cancer
1355095|NCT00546104|Dasatinib
1355096|NCT00546104|Inoperable Stage III Breast Cancer
1355097|NCT00546104|Metastatic Breast Cancer
1355099|NCT00546091|Imaging
1355100|NCT00546091|Multi-Spectral Imaging
1355101|NCT00546091|Thermography
1355102|NCT00546091|Laser Doppler Imaging
1355103|NCT00546091|Vasculature
1355104|NCT00546091|Healthy Volunteer
1355105|NCT00546091|HV
1355106|NCT00546078|HPV vaccine
1355107|NCT00546078|Cervical cancer
1355108|NCT00546078|Human papillomavirus infection
1355109|NCT00546065|Barrett's esophagus
1355110|NCT00546065|ablation
1355111|NCT00546065|esomeprazole
1355112|NCT00546065|Barrett's cancer
1355113|NCT00546065|Ablation of Barrett's esophagus
1355114|NCT00546065|Surveillance of Barrett's esophagus after endoscopic resection of Barrett's cancer
1355115|NCT00546065|Recurrence of Barrett's cancer
1355116|NCT00546039|Prostate cancer
1355117|NCT00546039|Localized prostatectomy
1355118|NCT00546039|Laparoscopic prostatectomy
1355119|NCT00546039|Chemoprevention
1355120|NCT00546039|Genistein
1355121|NCT00546039|BONISTEIN™
1355122|NCT00546026|placental function
1355123|NCT00546026|high-risk pregnancies
1355124|NCT00546026|psychological distress
1355125|NCT00546013|abdominal aortic aneurysms
1355126|NCT00546013|pseudoexfoliation syndrome
1355127|NCT00546013|glaucoma
1355128|NCT00545987|HIV vaccine
1355129|NCT00545987|HIV
1355130|NCT00545987|AIDS
1355131|NCT00545987|prevention
1355132|NCT00545987|HIV/AIDS
1355133|NCT00545987|HIV Preventative Vaccine
1355134|NCT00545987|HIV Seronegativity
1355135|NCT00545974|Randomized
1355136|NCT00545974|Double-Blind
1355137|NCT00545974|Placebo-Controlled
1355138|NCT00545974|memantine
1355139|NCT00545974|Namenda
1355140|NCT00545974|Frontotemporal Dementia
1355141|NCT00545974|Semantic Dementia
1355142|NCT00545974|FTD
1355143|NCT00545974|SD
1355144|NCT00545974|dementia
1355145|NCT00545974|behavioral decline
1355146|NCT00545974|cognitive decline
1355147|NCT00545961|respiratory infection
1355148|NCT00545961|sinusitis
1355149|NCT00545961|rhinosinusitis
1355150|NCT00545961|children
1355151|NCT00545961|middle meatal specimens
1355152|NCT00545961|respiratory track bacteria
1355153|NCT00545961|amoxicillin-clavulanate
1355154|NCT00545961|pneumococci
1355155|NCT00545961|haemophilus
1355156|NCT00545961|moraxella
1355157|NCT00545948|Non-Small-Cell Lung Cancer
1355158|NCT00545948|NSCLC
1355159|NCT00545948|Non-Squamous
1355160|NCT00545948|Genomics
1355161|NCT00545948|Guided Therapy
1355162|NCT00545948|Directed Therapy
1355163|NCT00545948|Genomic Expression Profiles
1355164|NCT00545948|Chemotherapy Sensitivity
1355165|NCT00545922|chronic obstructive pulmonary disease
1355166|NCT00545922|anxiety
1355167|NCT00545922|depression
1355168|NCT00545922|cognitive behavioral therapy
1355169|NCT00545883|GERD
1355170|NCT00545883|esophagitis
1355171|NCT00545883|PPI
1355172|NCT00545857|Type 1 diabetes
1355173|NCT00545857|Insulin dependent diabetes
1355174|NCT00545857|Juvenile onset diabetes
1355175|NCT00545857|pioglitazone
1355176|NCT00545831|Home Parenteral Nutrition
1355177|NCT00545831|Sepsis Prevention
1355178|NCT00545831|Central Venous Catheters
1355179|NCT00545831|Taurolidine
1355180|NCT00545805|Insulin resistance
1355181|NCT00545805|Metabolic syndrome X
1355182|NCT00545805|Obesity
1355183|NCT00545805|Intra-Abdominal Fat
1355184|NCT00545805|Omentum
1355185|NCT00545805|Bariatric surgery
1355186|NCT00545805|Glucose Clamp Technique
1355187|NCT00545805|Intravenous Glucose Tolerance Test
1355188|NCT00545805|Adiponectin
1355189|NCT00545805|Cytokines
1355190|NCT00545792|Recurrent Endometrial cancer
1355191|NCT00545792|Recurrent Cervical cancer
1355192|NCT00545792|Recurrent Ovarian cancer
1355193|NCT00545792|Recurrent Vaginal cancer
1355194|NCT00545792|Recurrent Vulvar cancer
1355195|NCT00545792|Vaginal recurrence
1355196|NCT00545792|Brachytherapy
1355197|NCT00545792|Radiation Treatment
1355198|NCT00545792|External Beam Radiation
1355199|NCT00545792|Avastin
1355200|NCT00545792|Bevacizumab
1355201|NCT00545766|Prostate Cancer
1355202|NCT00545766|Hormone Refractory
1355203|NCT00545766|Vinflunine
1355204|NCT00545766|Salvage Chemotherapy
1355205|NCT00545753|Human Head lice
1355206|NCT00545727|Diabetes
1355207|NCT00545727|Children
1355208|NCT00545727|Adolescents
1355209|NCT00545727|Diet
1355210|NCT00545727|Glycemic index
1355211|NCT00545701|Influenza
1355212|NCT00545701|A/H5N1 strain
1355213|NCT00545701|Orthomyxoviridae Infections
1355214|NCT00545701|Influenza Pandemics
1355215|NCT00545662|traumatic brain injury
1355216|NCT00545662|cognition
1355217|NCT00545662|behavioral outcome
1355218|NCT00545662|functional outcome
1355219|NCT00545662|treatment
1355220|NCT00545662|early intervention
1355221|NCT00545662|citicoline
1355222|NCT00545649|Fibromyalgia
1355223|NCT00545649|chronic pain
1355224|NCT00545649|physical
1355225|NCT00545649|exercise
1355226|NCT00545649|activity
1355227|NCT00545649|education
1355228|NCT00545623|HIV/AIDS
1355229|NCT00545623|Alternative Medicine
1355230|NCT00545623|Complementary Medicine
1355231|NCT00545597|adrenoleukodystrophy
1355232|NCT00545597|adrenomyeloneuropathy
1355233|NCT00545558|Antiretroviral Therapy, Highly Active
1355234|NCT00545558|Coinfection
1355235|NCT00545558|Treatment Naive
1355236|NCT00545545|Colorectal
1355237|NCT00545545|Carcinoma
1355238|NCT00545545|Recurrent
1355239|NCT00545545|Progressive
1355240|NCT00545545|Cetuximab
1355241|NCT00545545|Irinotecan
1355242|NCT00545545|5-Fluorouracil
1355243|NCT00545519|Multiple Myeloma
1355244|NCT00545519|Thymoglobulin
1355245|NCT00545506|wound infection
1355246|NCT00545506|tissue oxygen tension
1355247|NCT00545506|local warming
1355248|NCT00545493|Rasmussen encephalitis
1355249|NCT00545493|Chronic encephalitis
1355250|NCT00545493|Cerebral hemiatrophy
1355251|NCT00545493|Hemiparesis
1355252|NCT00545493|Epilepsy
1355253|NCT00545467|Aripiprazole
1355254|NCT00545467|schizophrenia
1355255|NCT00545467|antipsychotics
1355256|NCT00545467|pharmacogenomics
1355257|NCT00545467|cytochrome P450 enzyme
1355258|NCT00545454|Inflammation
1355259|NCT00545454|anti-cytokine
1355260|NCT00545454|anti-chemokine
1355261|NCT00545441|Anal fistula
1355262|NCT00545441|fistula in ano
1355263|NCT00545441|anorectal fistula
1355264|NCT00545428|Nasal acquired diseases
1355265|NCT00545428|Nasal congenital diseases
1355266|NCT00545428|Rhinoplasty
1355267|NCT00545428|Grafts
1355268|NCT00545415|fruit
1355269|NCT00545415|antioxidant
1355270|NCT00545415|Healthy subjects
1355271|NCT00545350|Prevention
1355272|NCT00545350|Falls, accidental falls
1355273|NCT00545350|Fractures
1355274|NCT00545350|Physical injuries
1355275|NCT00545350|Women
1355276|NCT00545350|Elderly
1355277|NCT00545350|Physical exercise
1355278|NCT00545350|Balance exercise
1355279|NCT00545311|multiple inhaled, NVA237, COPD
1355280|NCT00545298|Nitric Oxide
1355281|NCT00545298|Venous Leg Ulcers
1355282|NCT00545285|clinical outcomes
1355283|NCT00545285|radiographic outcomes
1355284|NCT00545285|total hip arthroplasty
1355285|NCT00545285|survivorship
1355286|NCT00545272|QMF
1355287|NCT00545272|indacaterol
1355288|NCT00545272|Twisthaler®
1355289|NCT00545259|Organ transplant, liver, pharmacokinetics, AEB071, immunosuppression
1355290|NCT00545246|VEGF Trap
1355291|NCT00545194|Prostaglandin E2
1355292|NCT00545194|Intravaginal gel
1355293|NCT00545194|Bishop score
1355294|NCT00545194|Induction of labor
1355295|NCT00545194|randomized trial
1355296|NCT00545194|Vaginal insert
1355297|NCT00545181|bacterial vaginosis
1355298|NCT00545181|vaginal acidifying gel
1355299|NCT00545181|recurrence
1355300|NCT00545168|head lice
1355301|NCT00545025|Influenza
1355302|NCT00545025|Influenza vaccine
1355303|NCT00545012|Levetiracetam
1355304|NCT00545012|Keppra
1355305|NCT00544999|recurrent adult acute myeloid leukemia
1355306|NCT00544999|secondary acute myeloid leukemia
1355307|NCT00544999|adult acute minimally differentiated myeloid leukemia (M0)
1355308|NCT00544999|adult acute myeloblastic leukemia without maturation (M1)
1355309|NCT00544999|adult acute myeloblastic leukemia with maturation (M2)
1355310|NCT00544999|adult acute myelomonocytic leukemia (M4)
1355311|NCT00544999|adult acute monoblastic leukemia (M5a)
1355312|NCT00544999|adult acute monocytic leukemia (M5b)
1355313|NCT00544999|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1355314|NCT00544999|adult acute myeloid leukemia with inv(16)(p13;q22)
1355315|NCT00544999|adult acute myeloid leukemia with t(16;16)(p13;q22)
1355316|NCT00544999|adult acute myeloid leukemia with t(8;21)(q22;q22)
1355317|NCT00544986|breast cancer
1355318|NCT00544986|post menopausal women
1355319|NCT00544986|Post menopausal women with hormone sensitive advanced breast cancer
1355320|NCT00544960|AT101
1355321|NCT00544960|AT-101
1355322|NCT00544960|cancer
1355323|NCT00544960|lung
1355324|NCT00544960|non-small cell
1355325|NCT00544960|docetaxel
1355326|NCT00544960|bcl
1355327|NCT00544947|Respiratory Depression
1355328|NCT00544947|Caesarean Section
1355329|NCT00544947|Diamorphine
1355330|NCT00544947|Fentanyl
1355331|NCT00544908|stage IV pancreatic cancer
1355332|NCT00544869|Vasopressin antagonist , Cardiac Edema ,Diuretics
1355333|NCT00544856|mild Alzheimer's disease
1355334|NCT00544856|mild cognitive impairment
1355335|NCT00544830|stage IV prostate cancer
1355336|NCT00544830|adenocarcinoma of the prostate
1355337|NCT00544830|recurrent prostate cancer
1355338|NCT00544817|Concurrent Radiation Therapy
1355339|NCT00544817|Temozolomide
1355340|NCT00544817|Sorafenib
1355341|NCT00544817|First-line
1355342|NCT00544817|Glioblastoma Multiforme
1355343|NCT00544817|Phase II
1355344|NCT00544804|recurrent breast cancer
1355345|NCT00544804|stage IIIA breast cancer
1355346|NCT00544804|stage IIIB breast cancer
1355347|NCT00544804|stage IIIC breast cancer
1355348|NCT00544804|stage IV breast cancer
1355349|NCT00544804|bone metastases
1355350|NCT00544791|Mild Cognitive Impairment
1355351|NCT00544791|Melatonin
1355352|NCT00544791|Antioxidant
1355353|NCT00544791|Memory
1355354|NCT00544791|Alzheimer
1355355|NCT00544778|recurrent adult soft tissue sarcoma
1355356|NCT00544778|stage III adult soft tissue sarcoma
1355357|NCT00544778|stage IV adult soft tissue sarcoma
1355358|NCT00544778|metastatic osteosarcoma
1355359|NCT00544778|recurrent osteosarcoma
1355360|NCT00544778|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1355361|NCT00544778|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1355362|NCT00544778|Ewing sarcoma of bone
1355363|NCT00544765|Breast cancer
1355364|NCT00544765|neoadjuvant therapy
1355365|NCT00544765|pCR rates
1355366|NCT00544752|sleep apnea syndromes, ambient indoor temperature
1355367|NCT00544739|Coronary Artery Disease
1355368|NCT00544739|Premature
1355369|NCT00544739|Female
1355370|NCT00544726|Rehabilitation
1355371|NCT00544700|stage IV colon cancer
1355372|NCT00544700|stage IV rectal cancer
1355373|NCT00544687|Skin
1355374|NCT00544687|Atrophy
1355375|NCT00544687|CRX-191
1355376|NCT00544687|mometasone furoate
1355377|NCT00544687|nortriptyline hydrochloride
1355378|NCT00544687|Skin Thickness in Normal Healthy Volunteers
1355379|NCT00544674|extensive stage small cell lung cancer
1355380|NCT00544674|limited stage small cell lung cancer
1355381|NCT00544674|recurrent small cell lung cancer
1355382|NCT00544648|stage IV non-small cell lung cancer
1355383|NCT00544648|stage IIIB non-small cell lung cancer
1355384|NCT00544622|Stroke treatment
1355385|NCT00544622|Rehabilitation
1355386|NCT00544622|Stroke chain
1355387|NCT00544622|Stroke unit
1355388|NCT00544609|Bladder
1355389|NCT00544609|Sorafenib
1355390|NCT00544609|Radiotherapy
1355391|NCT00544583|Abdominal wall
1355392|NCT00544570|recurrent adult Hodgkin lymphoma
1355393|NCT00544570|recurrent/refractory childhood Hodgkin lymphoma
1355394|NCT00544544|Bipolar
1355395|NCT00544544|depression
1355396|NCT00544531|MI oocytes, FISH,chromosomal aberrations
1355397|NCT00544518|type 2 diabetes
1355398|NCT00544518|Benfluorex
1355399|NCT00544518|Metformin
1355400|NCT00544518|insulin secretion
1355401|NCT00544518|glucose control
1355402|NCT00544492|arteriovenous fistula
1355403|NCT00544492|dialysis access
1355404|NCT00544492|pain
1355405|NCT00544492|anxiety
1355406|NCT00544492|fistula related complications
1355407|NCT00544492|aneurysm
1355408|NCT00544466|acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
1355409|NCT00544466|adult acute lymphoblastic leukemia in remission
1355410|NCT00544466|adult acute myeloid leukemia in remission
1355411|NCT00544466|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1355412|NCT00544466|adult acute myeloid leukemia with del(5q)
1355413|NCT00544466|adult acute myeloid leukemia with inv(16)(p13;q22)
1355414|NCT00544466|adult acute myeloid leukemia with t(15;17)(q22;q12)
1355415|NCT00544466|adult acute myeloid leukemia with t(16;16)(p13;q22)
1355416|NCT00544466|adult acute myeloid leukemia with t(8;21)(q22;q22)
1355417|NCT00544466|untreated adult acute myeloid leukemia
1355418|NCT00544466|recurrent adult acute myeloid leukemia
1355419|NCT00544466|childhood acute myeloid leukemia in remission
1355420|NCT00544466|recurrent childhood acute myeloid leukemia
1355421|NCT00544466|untreated childhood acute myeloid leukemia and other myeloid malignancies
1355422|NCT00544466|de novo myelodysplastic syndromes
1355423|NCT00544466|previously treated myelodysplastic syndromes
1355424|NCT00544466|secondary myelodysplastic syndromes
1355425|NCT00544466|secondary acute myeloid leukemia
1355426|NCT00544466|childhood acute lymphoblastic leukemia in remission
1355427|NCT00544466|recurrent adult acute lymphoblastic leukemia
1355428|NCT00544466|recurrent childhood acute lymphoblastic leukemia
1355429|NCT00544466|untreated adult acute lymphoblastic leukemia
1355430|NCT00544466|untreated childhood acute lymphoblastic leukemia
1355431|NCT00544466|childhood myelodysplastic syndromes
1355432|NCT00544453|SPECT
1355433|NCT00544453|Alzheimer disease
1355434|NCT00544440|Prostate neoplasms
1355435|NCT00544440|Prostate cancer
1355436|NCT00544440|Castration-resistant prostate cancer
1355437|NCT00544440|Abiraterone acetate
1355438|NCT00544440|CB7630
1355439|NCT00544440|Prednisone
1355440|NCT00544440|Testosterone
1355441|NCT00544440|Bone marrow
1355442|NCT00544427|Upper Areo-Digestive tract
1355443|NCT00544414|stage III squamous cell carcinoma of the larynx
1355444|NCT00544414|stage IV squamous cell carcinoma of the larynx
1355445|NCT00544414|stage III squamous cell carcinoma of the hypopharynx
1355446|NCT00544414|stage III squamous cell carcinoma of the oropharynx
1355447|NCT00544414|stage IV squamous cell carcinoma of the hypopharynx
1355448|NCT00544414|stage IV squamous cell carcinoma of the oropharynx
1355449|NCT00544414|stage III squamous cell carcinoma of the lip and oral cavity
1355450|NCT00544414|stage IV squamous cell carcinoma of the lip and oral cavity
1355451|NCT00544414|stage II squamous cell carcinoma of the larynx
1355452|NCT00544414|stage II squamous cell carcinoma of the hypopharynx
1355453|NCT00544414|stage II squamous cell carcinoma of the oropharynx
1355454|NCT00544401|infertility
1355455|NCT00544401|in vitro fertilization
1355456|NCT00544401|intracytoplasmic sperm implantation
1355457|NCT00544401|acupuncture
1355458|NCT00544401|hypnosis
1355459|NCT00544401|hypnopuncture
1355460|NCT00544388|Levocetirizine dihydrochloride
1355461|NCT00544388|Xyzal tablet
1355462|NCT00544362|adenocarcinoma of the esophagus
1355463|NCT00544362|squamous cell carcinoma of the esophagus
1355464|NCT00544362|stage IIIA esophageal cancer
1355465|NCT00544362|stage IIIB esophageal cancer
1355466|NCT00544362|stage IIIC esophageal cancer
1355467|NCT00544362|stage IV esophageal cancer
1355468|NCT00544349|stage IV colon cancer
1355469|NCT00544349|recurrent colon cancer
1355470|NCT00544349|stage IV rectal cancer
1355471|NCT00544349|recurrent rectal cancer
1355472|NCT00544349|liver metastases
1355473|NCT00544336|unspecified adult solid tumor, protocol specific
1355474|NCT00544336|recurrent breast cancer
1355475|NCT00544336|stage I breast cancer
1355476|NCT00544336|stage II breast cancer
1355477|NCT00544336|stage IIIA breast cancer
1355478|NCT00544336|stage IIIB breast cancer
1355479|NCT00544336|stage IIIC breast cancer
1355480|NCT00544336|stage IV breast cancer
1355481|NCT00544336|recurrent prostate cancer
1355482|NCT00544336|stage I prostate cancer
1355483|NCT00544336|stage II prostate cancer
1355484|NCT00544336|stage III prostate cancer
1355485|NCT00544336|stage IV prostate cancer
1355486|NCT00544336|extensive stage small cell lung cancer
1355487|NCT00544336|limited stage small cell lung cancer
1355488|NCT00544336|recurrent non-small cell lung cancer
1355489|NCT00544336|recurrent small cell lung cancer
1355490|NCT00544336|stage I non-small cell lung cancer
1355491|NCT00544336|stage II non-small cell lung cancer
1355492|NCT00544336|stage IIIA non-small cell lung cancer
1355493|NCT00544336|stage IIIB non-small cell lung cancer
1355494|NCT00544336|stage IV non-small cell lung cancer
1355495|NCT00544336|recurrent colon cancer
1355496|NCT00544336|stage I colon cancer
1355497|NCT00544336|stage II colon cancer
1355498|NCT00544336|stage III colon cancer
1355499|NCT00544336|stage IV colon cancer
1355500|NCT00544336|recurrent squamous cell carcinoma of the hypopharynx
1355501|NCT00544336|stage I squamous cell carcinoma of the hypopharynx
1355502|NCT00544336|stage II squamous cell carcinoma of the hypopharynx
1355503|NCT00544336|stage III squamous cell carcinoma of the hypopharynx
1355504|NCT00544336|stage IV squamous cell carcinoma of the hypopharynx
1355505|NCT00544336|recurrent squamous cell carcinoma of the larynx
1355506|NCT00544336|recurrent verrucous carcinoma of the larynx
1355507|NCT00544336|stage I squamous cell carcinoma of the larynx
1355508|NCT00544336|stage I verrucous carcinoma of the larynx
1355509|NCT00544336|stage II squamous cell carcinoma of the larynx
1355510|NCT00544336|stage II verrucous carcinoma of the larynx
1355511|NCT00544336|stage III squamous cell carcinoma of the larynx
1355512|NCT00544336|stage III verrucous carcinoma of the larynx
1355513|NCT00544336|stage IV squamous cell carcinoma of the larynx
1355514|NCT00544336|stage IV verrucous carcinoma of the larynx
1355515|NCT00544336|recurrent adenoid cystic carcinoma of the oral cavity
1355516|NCT00544336|recurrent mucoepidermoid carcinoma of the oral cavity
1355517|NCT00544336|recurrent verrucous carcinoma of the oral cavity
1355518|NCT00544336|stage I adenoid cystic carcinoma of the oral cavity
1355519|NCT00544336|stage I mucoepidermoid carcinoma of the oral cavity
1355520|NCT00544336|stage I verrucous carcinoma of the oral cavity
1355521|NCT00544336|stage II adenoid cystic carcinoma of the oral cavity
1355522|NCT00544336|stage II mucoepidermoid carcinoma of the oral cavity
1355523|NCT00544336|stage II verrucous carcinoma of the oral cavity
1355524|NCT00544336|stage III adenoid cystic carcinoma of the oral cavity
1355525|NCT00544336|stage III mucoepidermoid carcinoma of the oral cavity
1355526|NCT00544336|stage III verrucous carcinoma of the oral cavity
1355527|NCT00544336|stage IV adenoid cystic carcinoma of the oral cavity
1355528|NCT00544336|stage IV mucoepidermoid carcinoma of the oral cavity
1355529|NCT00544336|stage IV verrucous carcinoma of the oral cavity
1355530|NCT00544336|stage I squamous cell carcinoma of the lip and oral cavity
1355531|NCT00544336|stage II squamous cell carcinoma of the lip and oral cavity
1355532|NCT00544336|stage III squamous cell carcinoma of the lip and oral cavity
1355533|NCT00544336|stage IV squamous cell carcinoma of the lip and oral cavity
1355534|NCT00544336|recurrent basal cell carcinoma of the lip
1355535|NCT00544336|recurrent squamous cell carcinoma of the lip and oral cavity
1355536|NCT00544336|stage I basal cell carcinoma of the lip
1355537|NCT00544336|stage II basal cell carcinoma of the lip
1355538|NCT00544336|stage III basal cell carcinoma of the lip
1355539|NCT00544336|stage IV basal cell carcinoma of the lip
1355540|NCT00544336|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1355541|NCT00544336|recurrent metastatic squamous neck cancer with occult primary
1355542|NCT00544336|untreated metastatic squamous neck cancer with occult primary
1355543|NCT00544336|recurrent lymphoepithelioma of the nasopharynx
1355544|NCT00544336|recurrent squamous cell carcinoma of the nasopharynx
1355545|NCT00544336|stage I lymphoepithelioma of the nasopharynx
1355546|NCT00544336|stage I squamous cell carcinoma of the nasopharynx
1355547|NCT00544336|stage II lymphoepithelioma of the nasopharynx
1355548|NCT00544336|stage II squamous cell carcinoma of the nasopharynx
1355549|NCT00544336|stage III lymphoepithelioma of the nasopharynx
1355550|NCT00544336|stage III squamous cell carcinoma of the nasopharynx
1355551|NCT00544336|stage IV lymphoepithelioma of the nasopharynx
1355552|NCT00544336|stage IV squamous cell carcinoma of the nasopharynx
1355553|NCT00544336|recurrent lymphoepithelioma of the oropharynx
1355554|NCT00544336|recurrent squamous cell carcinoma of the oropharynx
1355555|NCT00544336|stage I lymphoepithelioma of the oropharynx
1355556|NCT00544336|stage I squamous cell carcinoma of the oropharynx
1355557|NCT00544336|stage II lymphoepithelioma of the oropharynx
1355558|NCT00544336|stage II squamous cell carcinoma of the oropharynx
1355559|NCT00544336|stage III lymphoepithelioma of the oropharynx
1355560|NCT00544336|stage III squamous cell carcinoma of the oropharynx
1355561|NCT00544336|stage IV lymphoepithelioma of the oropharynx
1355562|NCT00544336|stage IV squamous cell carcinoma of the oropharynx
1355563|NCT00544336|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1355564|NCT00544336|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1355565|NCT00544336|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1355566|NCT00544336|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1355567|NCT00544336|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1355568|NCT00544336|stage I inverted papilloma of the paranasal sinus and nasal cavity
1355569|NCT00544336|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1355570|NCT00544336|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1355571|NCT00544336|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1355572|NCT00544336|stage II inverted papilloma of the paranasal sinus and nasal cavity
1355573|NCT00544336|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1355574|NCT00544336|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1355575|NCT00544336|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1355576|NCT00544336|stage III inverted papilloma of the paranasal sinus and nasal cavity
1355577|NCT00544336|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1355578|NCT00544336|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1355579|NCT00544336|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1355580|NCT00544336|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1355581|NCT00544336|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1355582|NCT00544336|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1355583|NCT00544336|high-grade salivary gland mucoepidermoid carcinoma
1355584|NCT00544336|low-grade salivary gland mucoepidermoid carcinoma
1355585|NCT00544336|recurrent salivary gland cancer
1355586|NCT00544336|salivary gland acinic cell tumor
1355587|NCT00544336|salivary gland adenocarcinoma
1355588|NCT00544336|salivary gland adenoid cystic carcinoma
1355589|NCT00544336|salivary gland anaplastic carcinoma
1355590|NCT00544336|salivary gland malignant mixed cell type tumor
1355591|NCT00544336|salivary gland poorly differentiated carcinoma
1355592|NCT00544336|salivary gland squamous cell carcinoma
1355593|NCT00544336|stage I salivary gland cancer
1355594|NCT00544336|stage II salivary gland cancer
1355595|NCT00544336|stage III salivary gland cancer
1355596|NCT00544336|stage IV salivary gland cancer
1355597|NCT00544323|alveolar bone
1355598|NCT00544323|radiographic alveolar bone changes around oral implants of various designs 12 m post loading
1355599|NCT00544297|Actinic Keratosis
1355600|NCT00544297|Topical
1355601|NCT00544297|Dermatology
1355602|NCT00544297|Hand
1355603|NCT00544284|adult glioblastoma
1355604|NCT00544284|adult anaplastic astrocytoma
1355605|NCT00544284|adult giant cell glioblastoma
1355606|NCT00544284|recurrent adult brain tumor
1355607|NCT00544284|adult gliosarcoma
1355608|NCT00544284|adult mixed glioma
1355609|NCT00544284|adult anaplastic oligodendroglioma
1355610|NCT00544284|primary central nervous system lymphoma
1355611|NCT00544284|adult diffuse astrocytoma
1355612|NCT00544284|adult brain stem glioma
1355613|NCT00544284|adult central nervous system germ cell tumor
1355614|NCT00544284|adult choroid plexus tumor
1355615|NCT00544284|adult craniopharyngioma
1355616|NCT00544284|adult ependymoblastoma
1355617|NCT00544284|adult medulloblastoma
1355618|NCT00544284|adult supratentorial primitive neuroectodermal tumor (PNET)
1355619|NCT00544284|adult anaplastic ependymoma
1355620|NCT00544284|adult ependymoma
1355621|NCT00544284|adult myxopapillary ependymoma
1355622|NCT00544284|adult subependymoma
1355623|NCT00544284|adult anaplastic meningioma
1355624|NCT00544284|adult melanocytic lesion
1355625|NCT00544284|adult meningeal hemangiopericytoma
1355626|NCT00544284|adult grade I meningioma
1355627|NCT00544284|adult grade II meningioma
1355628|NCT00544284|adult grade III meningioma
1355629|NCT00544284|adult papillary meningioma
1355630|NCT00544284|adult oligodendroglioma
1355631|NCT00544284|adult pineoblastoma
1355632|NCT00544284|adult pineocytoma
1355633|NCT00544284|tumors metastatic to brain
1355634|NCT00544284|unspecified adult solid tumor, protocol specific
1355635|NCT00544284|adult pilocytic astrocytoma
1355636|NCT00544284|adult subependymal giant cell astrocytoma
1355637|NCT00544271|BOOSTRIX
1355638|NCT00544271|INFANRIX
1355639|NCT00544258|Pharmacokinetic study
1355640|NCT00544258|Actinic Keratosis
1355641|NCT00544258|Topical
1355642|NCT00544258|Dermatology
1355643|NCT00544245|overweight
1355644|NCT00544245|obesity
1355645|NCT00544245|accelerometer
1355646|NCT00544245|pedometer
1355647|NCT00544245|energy balance
1355648|NCT00544245|weight loss
1355649|NCT00544245|weight maintenance
1355650|NCT00544232|Breast Cancer
1355651|NCT00544232|neoadjuvant therapy
1355652|NCT00544232|pCR rates
1355653|NCT00544219|contiguous stage II adult diffuse large cell lymphoma
1355654|NCT00544219|noncontiguous stage II adult diffuse large cell lymphoma
1355655|NCT00544219|stage I adult diffuse large cell lymphoma
1355656|NCT00544219|stage III adult diffuse large cell lymphoma
1355657|NCT00544219|stage IV adult diffuse large cell lymphoma
1355658|NCT00544193|adenocarcinoma of the extrahepatic bile duct
1355659|NCT00544193|adenocarcinoma of the gallbladder
1355660|NCT00544193|adenocarcinoma of the pancreas
1355661|NCT00544193|adenocarcinoma of the stomach
1355662|NCT00544193|stage I pancreatic cancer
1355663|NCT00544193|stage II pancreatic cancer
1355664|NCT00544193|stage III pancreatic cancer
1355665|NCT00544193|localized extrahepatic bile duct cancer
1355666|NCT00544193|recurrent extrahepatic bile duct cancer
1355667|NCT00544193|unresectable extrahepatic bile duct cancer
1355668|NCT00544193|localized gallbladder cancer
1355669|NCT00544193|recurrent gallbladder cancer
1355670|NCT00544193|unresectable gallbladder cancer
1355671|NCT00544193|recurrent gastric cancer
1355672|NCT00544193|stage II gastric cancer
1355673|NCT00544193|stage III gastric cancer
1355674|NCT00544193|stage IV gastric cancer
1355675|NCT00544193|stage I gastric cancer
1355676|NCT00544193|recurrent pancreatic cancer
1355677|NCT00544193|small intestine adenocarcinoma
1355678|NCT00544193|stage IV pancreatic cancer
1355679|NCT00544167|Breast Cancer
1355680|NCT00544167|Early Stage
1355681|NCT00544167|High Risk
1355682|NCT00544167|Node Positive
1355683|NCT00544167|Doxorubicin
1355684|NCT00544167|Cyclophosphamide
1355685|NCT00544167|Paclitaxel
1355686|NCT00544167|Sorafenib
1355687|NCT00544154|CDP870
1355688|NCT00544154|Certolizumab pegol
1355689|NCT00543426|Fuzheng Huayu Tablets
1355690|NCT00543426|Multicenter clinical study
1355691|NCT00543348|BALLOON ANGIOPLASTY
1355692|NCT00543348|AUTOGENOUS FISTULA
1355693|NCT00543335|Non-Small Cell Lung Cancer
1355694|NCT00543335|Lung Cancer
1355695|NCT00543335|NSCLC
1355696|NCT00543335|Radiation Therapy
1355697|NCT00543335|Sorafenib
1355698|NCT00543335|BAY 43-9006
1355699|NCT00543335|Thoracic Radiation
1355700|NCT00543309|Fontan Operation
1355701|NCT00543309|Cardiopulmonary Bypass
1355702|NCT00543309|Heart Defects, Congenital
1355703|NCT00543309|Milrinone
1355704|NCT00543309|Natriuretic peptide, brain
1355705|NCT00543296|uveitis
1355706|NCT00543296|Cystoid Macular Edema (CME)
1355707|NCT00543296|fluocinolone acetonide
1355708|NCT00543296|non-infectious uveitis affecting the posterior segment
1355709|NCT00543270|EVAR
1355710|NCT00543270|AAA
1355711|NCT00543270|Aneurysm
1355712|NCT00543270|Powerlink
1355713|NCT00543244|Chronic hepatitis C
1355714|NCT00543244|Pegylated interferon
1355715|NCT00543244|Ribavirin
1355716|NCT00543244|Virokinetics
1355717|NCT00543231|ECOG
1355718|NCT00543231|MRT
1355719|NCT00543231|NCI CTC
1355720|NCT00543231|SAE
1355721|NCT00543231|Short Intravenous Infusion to Patients with Solid Tumors
1355722|NCT00544141|Temperature measurement
1355723|NCT00544128|HIV
1355724|NCT00544128|initial therapy
1355725|NCT00544128|once daily
1355726|NCT00544128|randomized trial
1355727|NCT00544128|non inferiority
1355728|NCT00544128|Treatment Naive
1355729|NCT00544115|graft versus host disease
1355730|NCT00544115|recurrent adult acute lymphoblastic leukemia
1355731|NCT00544115|recurrent childhood acute lymphoblastic leukemia
1355732|NCT00544115|untreated adult acute lymphoblastic leukemia
1355733|NCT00544115|untreated childhood acute lymphoblastic leukemia
1355734|NCT00544115|de novo myelodysplastic syndromes
1355735|NCT00544115|previously treated myelodysplastic syndromes
1355736|NCT00544115|secondary myelodysplastic syndromes
1355737|NCT00544115|refractory anemia with excess blasts in transformation
1355738|NCT00544115|refractory anemia with excess blasts
1355739|NCT00544115|atypical chronic myeloid leukemia
1355740|NCT00544115|chronic myelomonocytic leukemia
1355741|NCT00544115|juvenile myelomonocytic leukemia
1355742|NCT00544115|myelodysplastic/myeloproliferative disease, unclassifiable
1355743|NCT00544115|recurrent adult acute myeloid leukemia
1355744|NCT00544115|recurrent childhood acute myeloid leukemia
1355745|NCT00544115|adult acute myeloid leukemia in remission
1355851|NCT00543777|MRE
1355746|NCT00544115|childhood acute myeloid leukemia in remission
1355747|NCT00544115|secondary acute myeloid leukemia
1355748|NCT00544115|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1355749|NCT00544115|adult acute myeloid leukemia with inv(16)(p13;q22)
1355750|NCT00544115|adult acute myeloid leukemia with t(15;17)(q22;q12)
1355751|NCT00544115|adult acute myeloid leukemia with t(16;16)(p13;q22)
1355752|NCT00544115|adult acute myeloid leukemia with t(8;21)(q22;q22)
1355753|NCT00544115|accelerated phase chronic myelogenous leukemia
1355754|NCT00544115|blastic phase chronic myelogenous leukemia
1355755|NCT00544115|childhood chronic myelogenous leukemia
1355756|NCT00544115|chronic phase chronic myelogenous leukemia
1355757|NCT00544115|relapsing chronic myelogenous leukemia
1355758|NCT00544115|chronic eosinophilic leukemia
1355759|NCT00544115|chronic idiopathic myelofibrosis
1355760|NCT00544115|chronic neutrophilic leukemia
1355761|NCT00544115|essential thrombocythemia
1355762|NCT00544115|polycythemia vera
1355763|NCT00544115|Waldenstrom macroglobulinemia
1355764|NCT00544115|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1355765|NCT00544115|nodal marginal zone B-cell lymphoma
1355766|NCT00544115|recurrent adult Burkitt lymphoma
1355767|NCT00544115|recurrent adult diffuse large cell lymphoma
1355768|NCT00544115|recurrent adult diffuse mixed cell lymphoma
1355769|NCT00544115|recurrent adult diffuse small cleaved cell lymphoma
1355770|NCT00544115|recurrent adult immunoblastic large cell lymphoma
1355771|NCT00544115|recurrent adult lymphoblastic lymphoma
1355772|NCT00544115|recurrent grade 1 follicular lymphoma
1355773|NCT00544115|recurrent grade 2 follicular lymphoma
1355774|NCT00544115|recurrent grade 3 follicular lymphoma
1355775|NCT00544115|recurrent mantle cell lymphoma
1355776|NCT00544115|recurrent marginal zone lymphoma
1355777|NCT00544115|recurrent small lymphocytic lymphoma
1355778|NCT00544115|splenic marginal zone lymphoma
1355779|NCT00544115|recurrent childhood grade III lymphomatoid granulomatosis
1355780|NCT00544115|childhood nasal type extranodal NK/T-cell lymphoma
1355781|NCT00544115|recurrent childhood large cell lymphoma
1355782|NCT00544115|childhood diffuse large cell lymphoma
1355783|NCT00544115|childhood immunoblastic large cell lymphoma
1355784|NCT00544115|recurrent childhood lymphoblastic lymphoma
1355785|NCT00544115|Burkitt lymphoma
1355786|NCT00544115|recurrent childhood small noncleaved cell lymphoma
1355787|NCT00544115|anaplastic large cell lymphoma
1355788|NCT00544115|angioimmunoblastic T-cell lymphoma
1355789|NCT00544115|recurrent adult T-cell leukemia/lymphoma
1355790|NCT00544115|recurrent adult grade III lymphomatoid granulomatosis
1355791|NCT00544115|adult nasal type extranodal NK/T-cell lymphoma
1355792|NCT00544115|recurrent adult Hodgkin lymphoma
1355793|NCT00544115|recurrent/refractory childhood Hodgkin lymphoma
1355794|NCT00544115|refractory chronic lymphocytic leukemia
1355795|NCT00544115|refractory multiple myeloma
1355796|NCT00544115|stage III multiple myeloma
1355797|NCT00544115|aplastic anemia
1355798|NCT00544115|paroxysmal nocturnal hemoglobinuria
1355799|NCT00544115|adult acute lymphoblastic leukemia in remission
1355800|NCT00544115|childhood acute lymphoblastic leukemia in remission
1355801|NCT00544115|recurrent cutaneous T-cell non-Hodgkin lymphoma
1355802|NCT00544115|recurrent mycosis fungoides/Sezary syndrome
1355803|NCT00544115|stage II multiple myeloma
1355804|NCT00544102|Insulin Resistance
1355805|NCT00544102|Systemic Lupus Erythematosus
1355806|NCT00544102|Atherosclerosis
1355807|NCT00544102|Lupus
1355808|NCT00544102|SLE
1355809|NCT00544089|azoospermia FISH IL-18 TESTICULAR BIOPSY
1355810|NCT00544063|unspecified adult solid tumor, protocol specific
1355811|NCT00544050|Levetiracetam
1355812|NCT00544050|Keppra
1355813|NCT00544024|Mefloquine
1355814|NCT00544011|stage IV colon cancer
1355815|NCT00544011|stage IV rectal cancer
1355816|NCT00544011|adenocarcinoma of the colon
1355817|NCT00544011|adenocarcinoma of the rectum
1355818|NCT00543998|Sinusitis
1355819|NCT00543985|metabolic syndrome
1355820|NCT00543985|obesity
1355821|NCT00543985|exercise
1355822|NCT00543907|breast reconstruction
1355823|NCT00543907|DIEP flap
1355824|NCT00543894|Antibiotic, ICU, hospital acquired infection.
1355825|NCT00543881|telemedicine
1355826|NCT00543881|remote patient monitoring
1355827|NCT00543881|chronic heart failure
1355828|NCT00543881|mortality
1355829|NCT00543881|health economics
1355830|NCT00543855|Lewy Body Disease
1355831|NCT00543855|Dementia
1355832|NCT00543855|Clinical Trial
1355833|NCT00543855|Phase II
1355834|NCT00543855|E2020
1355835|NCT00543855|donepezil hydrochloride
1355836|NCT00543842|Rectal Cancer
1355837|NCT00543842|Bevacizumab
1355838|NCT00543842|Erlotinib
1355839|NCT00543842|Capecitabine
1355840|NCT00543829|breast cancer
1355841|NCT00543829|doxorubicin
1355842|NCT00543829|docetaxel
1355843|NCT00543829|tamoxifen
1355844|NCT00543777|Liver Cancer
1355845|NCT00543777|Magnetic Resonance Elastography
1355846|NCT00543777|2-Point Dixon Magnetic Resonance Imaging
1355847|NCT00543777|Liver Disease
1355848|NCT00543777|Fatty Liver
1355849|NCT00543777|Liver Fibrosis
1355850|NCT00543777|Liver Cirrhosis
1355852|NCT00543777|2PD MRI
1355853|NCT00543777|phase correction algorithm
1355854|NCT00543764|Intraoperative Pathway
1355855|NCT00543764|Breast Reconstruction
1355856|NCT00543764|DIEP flap
1355857|NCT00543725|Antiretroviral
1355858|NCT00543725|HIV-1
1355859|NCT00543725|AIDS
1355860|NCT00543725|TMC278-C215
1355861|NCT00543725|TMC278-TiDP6-C215
1355862|NCT00543725|Treatment Naive
1355863|NCT00543712|Sarcoma
1355864|NCT00543712|synovial sarcoma
1355865|NCT00543712|APM4171g
1355866|NCT00543686|Pre-School Asthma
1355867|NCT00543686|Responder Profiles
1355868|NCT00543686|Fluticasone
1355869|NCT00543686|Montelukast
1355870|NCT00543686|Leukotriene
1355871|NCT00543686|Children with Pre-School Asthma
1355872|NCT00543673|Healthy term infants
1355873|NCT00543660|Corneal transplantation, Descemet membrane, endothelium
1355874|NCT00543647|Fenofibrate
1355875|NCT00543647|Glomerular filtration rate
1355876|NCT00543647|inulin clearance
1355877|NCT00543647|creatinine
1355878|NCT00543647|healthy volunteers
1355879|NCT00543647|cross-over
1355880|NCT00543608|pneumonia
1355881|NCT00543608|nosocomial pneumonia
1355882|NCT00543569|kidney transplant
1355883|NCT00543569|alefacept
1355884|NCT00543530|HIV
1355885|NCT00543530|Treatment Experienced
1355886|NCT00543504|Advanced Cancer
1355887|NCT00543504|Bevacizumab
1355888|NCT00543504|Avastin
1355889|NCT00543504|Sorafenib
1355890|NCT00543504|BAY 43-9006
1355891|NCT00543504|Erlotinib
1355892|NCT00543504|OSI-774
1355893|NCT00543504|Tarceva
1355894|NCT00543504|Trastuzumab
1355895|NCT00543504|Herceptin
1355896|NCT00543504|Sunitinib
1355897|NCT00543504|SU011248
1355898|NCT00543504|Sutent
1355899|NCT00543504|Cetuximab
1355900|NCT00543504|Lapatinib
1355901|NCT00543504|Tykerb
1355902|NCT00543504|Anti-VEGF monoclonal antibody
1355903|NCT00543504|rhuMAb-VEGF
1355904|NCT00543504|Erlotinib hydrochloride
1355905|NCT00543504|GW572016
1355906|NCT00543504|Sunitinib Malate
1355907|NCT00543478|Irritable bowel syndrome
1355908|NCT00543478|Diarrhea
1355909|NCT00543478|Probiotics
1355910|NCT00543192|Endometrial Cancer
1355911|NCT00543192|Sexual Function
1355912|NCT00543166|Sjögren's syndrome
1355913|NCT00543166|fatigue
1355914|NCT00543166|salivary gland
1355915|NCT00543166|dehydroepiandrosterone
1355916|NCT00543153|Advanced Cancer
1355917|NCT00543153|Exceptional Patient
1355918|NCT00543153|Cancer Care
1355919|NCT00543153|Interview
1355920|NCT00543140|Obesity
1355921|NCT00543140|Morbid Obesity
1355922|NCT00543114|CLL
1355923|NCT00543114|SLL
1355924|NCT00543114|Revlimid
1355925|NCT00543114|lenalidomide
1355926|NCT00543101|HIV/AIDS
1355927|NCT00543101|darunavir
1355928|NCT00543101|Protease inhibitors
1355929|NCT00543101|Dual boosted
1355930|NCT00543101|Treatment experienced
1355931|NCT00543088|Schizophrenia
1355932|NCT00543088|Bipolar Disorder
1355933|NCT00543088|manic episode
1355934|NCT00543088|atypical antipsychotic
1355935|NCT00543088|Schizophrenia or Bipolar Disorder (currently in a manic episode)
1355936|NCT00543075|Renal Function
1355937|NCT00543075|Adult
1355938|NCT00543075|Genasense
1355939|NCT00543075|oblimersen
1355940|NCT00543075|G3139
1355941|NCT00543075|Genta
1355942|NCT00543075|Pharmacokinetics
1355943|NCT00543049|platinum refractory
1355944|NCT00543049|epithelial ovarian cancer
1355945|NCT00543049|primary cancer of the peritoneum
1355946|NCT00543049|cancer of the fallopian tube
1355947|NCT00543036|Cannabis
1355948|NCT00543036|Addiction
1355949|NCT00543036|Craving
1355950|NCT00543036|TMS
1355951|NCT00542997|Subcutaneous immune globulin
1355952|NCT00542997|SCIG
1355953|NCT00542971|Leukemia
1355954|NCT00542971|AML
1355955|NCT00542971|High-Risk MDS
1355956|NCT00542971|Acute Myeloid Leukemia
1355957|NCT00542971|High-Risk Myelodysplastic Disorder
1355958|NCT00542971|Idarubicin
1355959|NCT00542971|Ara-C
1355960|NCT00542971|Cytarabine
1355961|NCT00542971|Sorafenib
1355962|NCT00542971|BAY43-9006
1355963|NCT00542958|Cancer
1355964|NCT00542958|Refractory solid tumor
1355965|NCT00542945|Heart Failure
1355966|NCT00542945|ICD
1355967|NCT00542945|Dilated cardiomyopathy
1355968|NCT00542932|COPD
1355969|NCT00542932|Exercise
1355970|NCT00542932|Home
1355971|NCT00542906|healthy volunteers
1355972|NCT00542906|Somatosensory stimuli
1355973|NCT00542906|fMRI
1355974|NCT00542906|second somatosensory area
1355975|NCT00542906|insular cortex
1355976|NCT00542906|functional anatomy
1355977|NCT00542893|bcl-2
1355978|NCT00542893|CFR
1355979|NCT00542893|DTIC
1355980|NCT00542893|ECOG
1355981|NCT00542893|EMEA
1355982|NCT00542893|MedDRA
1355983|NCT00542893|NCI CTC
1355984|NCT00542893|SAE
1355985|NCT00542880|COPD
1355986|NCT00542880|Symbicort
1355987|NCT00542880|Seretide
1355988|NCT00542867|Hypercholesterolemia
1355989|NCT00542867|Third Joint European Task Force guidelines
1355990|NCT00542867|Survey
1355991|NCT00542854|arrhythmia
1355992|NCT00542854|pacemaker
1355993|NCT00542854|defibrillator
1355994|NCT00542854|electromagnetic interference
1355995|NCT00542841|Adrenal Hyperplasia, Congenital
1355996|NCT00542841|Steroid Biosynthesis Disorders
1355997|NCT00542815|Chronic Kidney Disease
1355998|NCT00542815|Dialysis
1355999|NCT00542815|Hyperphosphatemia
1356000|NCT00542802|post stroke epileptic late onset seizures
1356001|NCT00542789|gastrointestinal
1356002|NCT00542789|GI
1356003|NCT00542789|NSAID
1356004|NCT00542789|Japan
1356005|NCT00542789|Japanese
1356006|NCT00542789|Gastric ulcer
1356007|NCT00542789|duodenal ulcer
1356008|NCT00542776|inflammatory bowel disease (IBD)
1356009|NCT00542776|immunosuppressed or non-immunosuppressed
1356010|NCT00542776|influenza vaccine
1356011|NCT00542776|antibody titers
1356012|NCT00542776|seroprotective titers
1356013|NCT00542776|vaccine-associated adverse events
1356014|NCT00542763|Sjogren's syndrome
1356015|NCT00542763|Mycophenolate sodium
1356016|NCT00542750|Cannabis
1356017|NCT00542750|Marijuana
1356018|NCT00542750|Pharmacotherapy
1356019|NCT00542750|Adolescent
1356020|NCT00542737|Acute Lung Injury
1356021|NCT00542737|Acute Respiratory Distress Syndrome
1356022|NCT00542737|Acute Respiratory Failure
1356023|NCT00542737|Web-Based Intervention
1356024|NCT00542737|Lung Preventive Ventilation
1356025|NCT00542724|Insulin
1356026|NCT00542724|Diabetes Mellitus type I
1356027|NCT00542724|Juvenile diabetes
1356028|NCT00542711|Curcumin
1356029|NCT00542711|Bioavilability
1356030|NCT00542711|Healthy subjects
1356031|NCT00542698|Type 2 Diabetes Mellitus
1356032|NCT00542698|Glucose Monitor graphs
1356033|NCT00542698|Physical Activity
1356034|NCT00542672|Mexican American
1356035|NCT00542672|Dietary Intake
1356036|NCT00542672|Child-Feeding Practices
1356037|NCT00542672|Weight
1356038|NCT00542672|Cultural Values
1356039|NCT00542659|Atrial fibrillation
1356040|NCT00542659|Maze procedure
1356041|NCT00542633|Diabetes mellitus type 2
1356042|NCT00542633|Diabetes
1356043|NCT00542633|Insulin
1356044|NCT00542633|NIDDM
1356045|NCT00542633|Rapid acting
1356046|NCT00542607|Levocetirizine dihydrochloride
1356047|NCT00542607|Xyzal tablets
1356048|NCT00542594|breast cancer
1356049|NCT00542594|anastrozole
1356050|NCT00542581|Visual Outcomes
1356051|NCT00542581|Patient Satisfaction
1356052|NCT00542581|Ophthalmology
1356053|NCT00542581|Cataractous Lens
1356054|NCT00542542|Breast Cancer
1356055|NCT00542542|Reconstructive Surgery
1356056|NCT00542542|Paravertebral Block
1356057|NCT00542542|Anesthesia
1356058|NCT00542542|Propofol
1356059|NCT00542542|Fentanyl
1356060|NCT00542542|Ropivacaine
1356061|NCT00542542|Midazolam
1356062|NCT00542529|Healthy Subjects
1356063|NCT00542516|Hip Replacement Arthroplasty
1356064|NCT00542516|Hydroxyethyl Starch
1356065|NCT00542516|Hemodilution
1356066|NCT00542516|Hetastarch
1356067|NCT00542516|Colloids
1356068|NCT00542503|Cardiac Outcomes
1356069|NCT00542503|MRI
1356070|NCT00542503|Cardiac Stress Testing
1356071|NCT00542490|Endometrial cancer
1356072|NCT00542490|Gynecologic Cancer
1356073|NCT00542490|Vaginal Cuff Brachytherapy
1356074|NCT00542490|Vaginal radiation
1356075|NCT00542464|Safety in Healthy Adult Subjects
1356076|NCT00542451|node-negative breast cancer
1356077|NCT00542451|HER-2 positive
1356078|NCT00542438|Cardiovascular Disease
1356079|NCT00542438|Cancer Prevention
1356080|NCT00542438|Physical Activity
1356081|NCT00542438|Body Composition
1356082|NCT00542438|Environment
1356083|NCT00542438|Exercise
1356084|NCT00542425|osteoporosis
1356085|NCT00542425|postmenopausal
1356086|NCT00542425|bone loss
1356087|NCT00542399|levemir
1356088|NCT00542399|type 1 diabetes
1356089|NCT00542386|Chronic Kidney Disease
1356090|NCT00542386|Dialysis
1356091|NCT00542386|Hyperphosphatemia
1356092|NCT00542386|Dyslipidemia
1356093|NCT00542386|Phosphate binder
1356094|NCT00542373|Oral Cancer
1356095|NCT00542373|Oral Cavity Mucosa
1356096|NCT00542373|Leukoplakia
1356097|NCT00542373|Erythroplakia
1356098|NCT00542373|Fluorescence Imaging
1356099|NCT00542373|Reflectance Imaging
1356100|NCT00542373|Multispectral Digital Microscope
1356101|NCT00542373|Portable Spectroscopy System
1356102|NCT00542373|Fast Excitation-Emission Matrix
1356103|NCT00542373|PS2
1356104|NCT00542373|MDM
1356105|NCT00542373|Fast EEM4
1356106|NCT00542360|Accidental Falls
1356107|NCT00542360|Aged
1356108|NCT00542360|Social Marketing
1356109|NCT00542360|Exercise
1356110|NCT00542360|Accident Prevention
1356111|NCT00542360|Religion
1356112|NCT00542360|Randomized Controlled Trial
1356113|NCT00542347|gastric acid
1356114|NCT00542347|proton pump inhibitors
1356115|NCT00542347|omeprazole
1356116|NCT00542347|esomeprazole
1356117|NCT00542334|Nocturnal Hypoglycemia
1356118|NCT00542334|Type 1 diabetes
1356119|NCT00542334|Children
1356120|NCT00542334|Adolescents
1356121|NCT00542334|CGMS
1356122|NCT00542321|lateral rotation
1356123|NCT00542321|kinetic therapy
1356124|NCT00542321|mechanical ventilation
1356125|NCT00542321|pulmonary complications
1356126|NCT00542282|lung sounds,
1356127|NCT00542282|airway obstruction,
1356128|NCT00542282|asthma,
1356129|NCT00542282|auscultation
1356130|NCT00542269|Hypertension
1356131|NCT00542269|Metabolic Syndrome
1356132|NCT00542269|Dual combination therapy
1356133|NCT00542269|Triple combination therapy
1356134|NCT00542269|Aliskiren
1356135|NCT00542269|Direct Renin inhibitor
1356136|NCT00542256|Apoplexy
1356137|NCT00542256|Cerebral Stroke
1356138|NCT00542256|Cerebrovascular Accident, Acute
1356139|NCT00542256|Cerebrovascular Apoplexy
1356140|NCT00542256|Cerebrovascular Stroke
1356141|NCT00542256|CVA (Cerebrovascular Accident)
1356142|NCT00542256|Stroke
1356143|NCT00542256|Stroke, Acute
1356144|NCT00542256|Vascular Accident, Brain
1356145|NCT00542243|enlarged prostate
1356146|NCT00542243|finasteride
1356147|NCT00542230|Erythrocytes
1356148|NCT00542230|Drug Screen
1356149|NCT00542230|Sickle Cell Trait
1356150|NCT00542230|Sickle Cell Disease
1356151|NCT00542217|Healthy Volunteers
1356152|NCT00542204|Diabetes
1356153|NCT00542204|Blood Glucose Self-Monitoring
1356154|NCT00542204|Home Blood Glucose Monitoring
1356155|NCT00542204|Internet
1356156|NCT00542204|Personal Health Record (PHR)
1356157|NCT00542204|Health Information Technology (HIT)
1356158|NCT00542204|Care management
1356159|NCT00542204|Disease Management
1356160|NCT00542204|Diabetes self-management
1356161|NCT00542204|Consumer Health Information
1356162|NCT00542204|Medical Records Systems, Computerized
1356163|NCT00542204|Computerized Medical Records System
1356164|NCT00542204|Automated Medical Records System
1356165|NCT00542204|Electronic Health Record (EHR)
1356166|NCT00542204|Remote patient monitoring
1356167|NCT00542191|Triple negative (ER/PR negative; HER2 negative)
1356168|NCT00542178|Type 2 Diabetes Mellitus
1356169|NCT00542178|Cardiovascular Diseases
1356170|NCT00542152|IBD
1356171|NCT00542152|Ulcerative colitis
1356172|NCT00542152|refractory to steroids
1356173|NCT00542139|Osteoarthritis
1356174|NCT00542139|Knee arthroplasty
1356175|NCT00542139|Steroid injection
1356176|NCT00542139|Rehabilitation
1356177|NCT00542126|GnRH analog, IVF, infertility, frozen-thawed embryos
1356178|NCT00542113|Parental
1356179|NCT00542113|Parents
1356180|NCT00542113|Prevention
1356181|NCT00542113|Energy balance
1356182|NCT00542113|Glucose regulation
1356183|NCT00542113|Healthy lifestyles
1356184|NCT00542113|Healthy families
1356185|NCT00542113|Active living
1356186|NCT00542074|Bacterial vaginosis
1356187|NCT00542074|recurrence
1356188|NCT00542074|male factor
1356189|NCT00542061|COPD
1356190|NCT00542061|Asthma
1356191|NCT00542061|Lung function
1356192|NCT00542061|Monitoring
1356193|NCT00542061|Primary Care
1356194|NCT00542048|Hepatic metastases
1356195|NCT00542048|Angiogenesis
1356196|NCT00542048|EndoTAG-1
1356197|NCT00542048|Pharmacokinetics
1356198|NCT00542048|Pharmacodynamics
1356199|NCT00542048|Metastases of the liver
1356200|NCT00542035|Analgesia
1356201|NCT00542009|Phase 2A, safety and efficacy trial with CE-326,597 in patients with T2DM.
1356202|NCT00541983|Diabetes
1356203|NCT00541983|Type 2
1356204|NCT00541983|Mellitus
1356205|NCT00541970|viral infections
1356206|NCT00541970|Human Papillomavirus (HPV) vaccine
1356207|NCT00541970|safety
1356208|NCT00541970|vaccine
1356209|NCT00541970|immunogenicity
1356210|NCT00541970|cervical cancer
1356211|NCT00541957|Major depression
1356212|NCT00541957|Primary care
1356213|NCT00541944|hyponatremia
1356214|NCT00541944|diagnosis and treatment of hyponatremia
1356215|NCT00541944|classification of hyponatremia
1356216|NCT00541918|sevoflurane,
1356217|NCT00541918|propofol,
1356218|NCT00541918|heart surgery,
1356219|NCT00541918|cardiopulmonary bypass,
1356220|NCT00541918|memory disorders,
1356221|NCT00541892|Cell Culture Techniques
1356222|NCT00541879|Childhood
1356223|NCT00541879|Prevention
1356224|NCT00541879|Energy balance
1356225|NCT00541879|Glucose regulation
1356226|NCT00541879|Healthy lifestyle
1356227|NCT00541879|Healthy eating
1356228|NCT00541879|Active living
1356229|NCT00541866|Leukemia
1356230|NCT00541866|Acute Myeloid
1356231|NCT00541866|Relapsed
1356232|NCT00541866|Refractory
1356233|NCT00541866|Cancer
1356234|NCT00541866|AML
1356235|NCT00541866|Cytarabine
1356236|NCT00541866|SNS-595
1356237|NCT00541866|Phase 1
1356238|NCT00541866|Voreloxin
1356239|NCT00541853|Autosomal Dominant Polycystic Kidney Disease
1356240|NCT00541853|Hypertension
1356241|NCT00541853|Angiotensin-2 Receptor Blocker
1356242|NCT00541853|Calcium Channel Blocker
1356243|NCT00541853|Kidney Volume
1356244|NCT00541840|Sarcoma
1356245|NCT00541840|Sorafenib
1356246|NCT00541840|GEIS
1356247|NCT00541827|Sepsis. Shock, septic. Mitochondria.
1356248|NCT00541814|Renal Transplantation
1356249|NCT00541814|Calcineurin Inhibitor
1356250|NCT00541814|Cyclosporine
1356251|NCT00541814|Withdrawal
1356252|NCT00541814|Minimisation
1356253|NCT00541762|Neurotensin
1356254|NCT00541762|Human
1356255|NCT00541762|Physiology of neurotensin
1356256|NCT00541762|fat perfusion
1356257|NCT00541762|healthy subjects
1356258|NCT00541749|SLE
1356259|NCT00541736|Familial Hemiplegic Migraine
1356260|NCT00541710|menopause
1356261|NCT00541710|genistein
1356262|NCT00541710|pre-diabetes
1356263|NCT00541671|Narcotics
1356264|NCT00541671|Nausea
1356265|NCT00541619|hypertension
1356266|NCT00541619|sympathetic activity
1356267|NCT00541619|early renal damage
1356268|NCT00541606|Diabetes Mellitus, Type 2
1356269|NCT00541606|Pharmaceutical Care
1356270|NCT00541606|Collaborative Practice
1356271|NCT00541593|Pancreatic pseudocyst
1356272|NCT00541593|NOTES
1356273|NCT00541567|Wheight management in T2D
1356274|NCT00541515|Type 1 diabetes
1356275|NCT00541515|Artificial pancreas
1356276|NCT00541515|Insulin Pump
1356277|NCT00541502|evaluate the effectiveness of improving cognitive function of aripiprazole in treating adolescents and young adults with psychotic disorder in Taiwan
1356278|NCT00541489|Osteoarthritis
1356279|NCT00541489|Osteoarthritis, Hip
1356280|NCT00540800|anthracycline pre-treated
1356281|NCT00540800|chemotherapy
1356282|NCT00540800|first-line
1356283|NCT00540800|metastatic breast cancer
1356284|NCT00540800|locally advanced breast cancer
1356285|NCT00540774|oral cancer
1356286|NCT00540774|oral mucositis
1356287|NCT00540774|oral stomatitis
1356288|NCT00540774|Dry mouth
1356289|NCT00540774|Gingivitis
1356290|NCT00540761|Coronary Artery Disease
1356291|NCT00540761|Atherosclerosis
1356292|NCT00541463|HIV
1356293|NCT00541463|Treatment Experienced
1356294|NCT00541437|Change from baseline of HbA1c after 16 weeks of treatment
1356295|NCT00541437|Change from baseline of FPG after 16 weeks of treatment
1356296|NCT00541437|Change from baseline of diabetes self-care scale by patient on drug administration after 16 weeks of treatment
1356297|NCT00541424|Mantle Cell Lymphoma
1356298|NCT00541424|Lymphoma
1356299|NCT00541424|CT Colonography
1356300|NCT00541424|PET Scan
1356301|NCT00541424|PET/CT Scan
1356302|NCT00541424|Gas Insufflation
1356303|NCT00541398|Antipsychotic polypharmacy
1356304|NCT00541398|Schizophrenia
1356305|NCT00541398|Implementation of clinical guidelines
1356306|NCT00541385|malaria
1356307|NCT00541385|pediatric
1356308|NCT00541385|Africa
1356309|NCT00541385|Phillipines
1356310|NCT00541385|Coartem
1356311|NCT00541385|Artesunate
1356312|NCT00541385|lumefantrine
1356313|NCT00541385|Arthemeter
1356314|NCT00541385|pyronaridine
1356315|NCT00541385|Pyramax
1356316|NCT00541346|Autism
1356317|NCT00541346|Autism Spectrum Disorders
1356318|NCT00541346|ADHD
1356319|NCT00541333|Dry Age Related Macular Degeneration
1356320|NCT00541333|Dry AMD
1356321|NCT00541320|Anti-thrombolytic direct Factor Xa inhibitor
1356322|NCT00541307|Peripheral Arterial Disease
1356323|NCT00541307|Peripheral Vascular Disease
1356324|NCT00541294|Tuberculosis
1356325|NCT00541294|HIV
1356326|NCT00541294|Diagnostics
1356327|NCT00541294|Pediatrics
1356328|NCT00541281|prostate cancer
1356329|NCT00541281|hormone resistant
1356330|NCT00541281|metastatic
1356331|NCT00541281|estramustine combine to docetaxel
1356332|NCT00541281|randomized study
1356333|NCT00541268|Heart Failure
1356334|NCT00541268|ICD
1356335|NCT00541268|Dilated cardiomyopathy
1356336|NCT00541255|Bronchial Asthma
1356337|NCT00541255|Food Allergy
1356338|NCT00541255|Bronchial Hyperresponsiveness
1356339|NCT00541216|congenital myasthenia
1356340|NCT00541216|ephedrine
1356341|NCT00541203|tomography
1356342|NCT00541203|coronary artery disease
1356343|NCT00541203|Stress Test
1356344|NCT00541203|Coronary Angiography
1356345|NCT00541190|cystic fibrosis
1356346|NCT00541190|mucociliary clearance
1356347|NCT00541190|outcome measures
1356348|NCT00541177|prevention myopia
1356349|NCT00541164|CMT
1356350|NCT00541164|Charcot-Marie Tooth
1356351|NCT00541164|CoQ10
1356352|NCT00541164|Coenzyme Q10
1356353|NCT00541151|Stress urinary incontinence in Women
1356354|NCT00541138|tumors metastatic to brain
1356355|NCT00541138|recurrent adult brain tumor
1356356|NCT00541138|adult anaplastic astrocytoma
1356357|NCT00541138|adult diffuse astrocytoma
1356358|NCT00541138|adult giant cell glioblastoma
1356359|NCT00541138|adult gliosarcoma
1356360|NCT00541138|adult pilocytic astrocytoma
1356361|NCT00541138|adult pineal gland astrocytoma
1356362|NCT00541138|adult subependymal giant cell astrocytoma
1356363|NCT00541138|adult brain stem glioma
1356364|NCT00541138|adult anaplastic ependymoma
1356365|NCT00541138|adult ependymoma
1356366|NCT00541138|adult myxopapillary ependymoma
1356367|NCT00541138|adult subependymoma
1356368|NCT00541138|adult anaplastic oligodendroglioma
1356369|NCT00541138|adult oligodendroglioma
1356370|NCT00541138|unspecified adult solid tumor, protocol specific
1356371|NCT00541138|adult mixed glioma
1356372|NCT00541125|recurrent colon cancer
1356373|NCT00541125|stage IV colon cancer
1356374|NCT00541125|recurrent rectal cancer
1356375|NCT00541125|stage IV rectal cancer
1356376|NCT00541125|adenocarcinoma of the colon
1356377|NCT00541125|adenocarcinoma of the rectum
1356378|NCT00541112|stage III rectal cancer
1356379|NCT00541112|stage IV rectal cancer
1356380|NCT00541112|adenocarcinoma of the rectum
1356381|NCT00541099|stage IIIA non-small cell lung cancer
1356382|NCT00541099|stage IIIB non-small cell lung cancer
1356383|NCT00541099|stage IV non-small cell lung cancer
1356384|NCT00541086|stage IA breast cancer
1356385|NCT00541086|stage IB breast cancer
1356386|NCT00541086|stage II breast cancer
1356387|NCT00541086|stage IIIA breast cancer
1356388|NCT00541086|stage IIIB breast cancer
1356389|NCT00541086|stage IIIC breast cancer
1356390|NCT00541086|estrogen receptor-positive breast cancer
1356391|NCT00541086|progesterone receptor-positive breast cancer
1356392|NCT00541073|advanced malignant mesothelioma
1356393|NCT00541073|recurrent malignant mesothelioma
1356394|NCT00541060|caries susceptibility,enamel matrix,candidate genes,mutation
1356395|NCT00541047|sexual dysfunction
1356396|NCT00541047|urinary complications
1356397|NCT00541047|gastrointestinal complications
1356398|NCT00541047|adenocarcinoma of the prostate
1356399|NCT00541047|stage I prostate cancer
1356400|NCT00541047|stage IIB prostate cancer
1356401|NCT00541047|stage IIA prostate cancer
1356402|NCT00541047|stage III prostate cancer
1356403|NCT00541034|B-cell chronic lymphocytic leukemia
1356404|NCT00541034|stage I small lymphocytic lymphoma
1356405|NCT00541034|stage II small lymphocytic lymphoma
1356406|NCT00541034|stage III small lymphocytic lymphoma
1356407|NCT00541034|stage IV small lymphocytic lymphoma
1356408|NCT00541034|stage I chronic lymphocytic leukemia
1356409|NCT00541034|stage II chronic lymphocytic leukemia
1356410|NCT00541034|stage III chronic lymphocytic leukemia
1356411|NCT00541034|stage IV chronic lymphocytic leukemia
1356412|NCT00541021|stage III pancreatic cancer
1356413|NCT00541021|stage IV pancreatic cancer
1356414|NCT00541021|adenocarcinoma of the pancreas
1356415|NCT00541021|recurrent pancreatic cancer
1356416|NCT00541008|type 1 papillary renal cell carcinoma
1356417|NCT00541008|type 2 papillary renal cell carcinoma
1356418|NCT00541008|stage IV renal cell cancer
1356419|NCT00541008|stage III renal cell cancer
1356420|NCT00540982|unspecified adult solid tumor, protocol specific
1356421|NCT00540982|recurrent non-small cell lung cancer
1356422|NCT00540982|stage IIIA non-small cell lung cancer
1356423|NCT00540982|stage IIIB non-small cell lung cancer
1356424|NCT00540982|stage IV non-small cell lung cancer
1356425|NCT00540969|bone metastases
1356426|NCT00540969|pain
1356427|NCT00540969|unspecified adult solid tumor, protocol specific
1356428|NCT00540969|stage IV melanoma
1356429|NCT00540969|stage IV renal cell cancer
1356430|NCT00540956|untreated adult acute myeloid leukemia
1356431|NCT00540956|adult acute megakaryoblastic leukemia (M7)
1356432|NCT00540956|adult acute minimally differentiated myeloid leukemia (M0)
1356433|NCT00540956|adult acute monoblastic leukemia (M5a)
1356434|NCT00540956|adult acute monocytic leukemia (M5b)
1356435|NCT00540956|adult acute myeloblastic leukemia with maturation (M2)
1356436|NCT00540956|adult acute myeloblastic leukemia without maturation (M1)
1356437|NCT00540956|adult acute myelomonocytic leukemia (M4)
1356438|NCT00540956|adult erythroleukemia (M6a)
1356439|NCT00540956|adult pure erythroid leukemia (M6b)
1356440|NCT00540956|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1356441|NCT00540956|adult acute myeloid leukemia with inv(16)(p13;q22)
1356442|NCT00540956|adult acute myeloid leukemia with t(16;16)(p13;q22)
1356443|NCT00540956|adult acute myeloid leukemia with t(8;21)(q22;q22)
1356444|NCT00540943|cetuximab
1356445|NCT00540943|irinotecan,
1356446|NCT00540943|pazopanib,
1356447|NCT00540943|Colorectal cancer,
1356448|NCT00540904|contrast
1356449|NCT00540904|nephropathy
1356450|NCT00540904|bicarbonate
1356451|NCT00540904|prevention
1356452|NCT00540878|Formulation Drug Study
1356453|NCT00540865|Homebound Persons
1356454|NCT00540865|Case Management
1356455|NCT00540865|Problem Solving Therapy
1356456|NCT00540852|Breast cancer receiving chemotherapy
1356457|NCT00540813|bifurcation stenosis
1356458|NCT00540813|Patients with documented ischemia due to a de-novo bifurcation stenosis
1356459|NCT00540748|first trimester abortion
1356460|NCT00540748|oxytocin
1356461|NCT00540696|Anemia
1356462|NCT00540696|Non-Myeloid Malignancies
1356463|NCT00540696|darbepoetin alfa
1356464|NCT00540696|chemotherapy
1356465|NCT00540670|Coronary artery disease
1356466|NCT00540644|Multiple Myeloma
1356467|NCT00540644|Revlimid
1356468|NCT00540631|House Dust Mite Allergen
1356469|NCT00540631|Aluminium hydroxide-adsorbed
1356470|NCT00540605|Microbicide
1356471|NCT00540605|Pregnancy
1356472|NCT00540605|HIV Seronegativity
1356473|NCT00540592|Influenza vaccine GSK576389A
1356474|NCT00540592|Influenza infection
1356475|NCT00540592|Fluarix
1356476|NCT00540579|Pancreas
1356477|NCT00540579|Untreated
1356478|NCT00540579|Advanced
1356479|NCT00540579|Gemcitabine
1356480|NCT00540579|CC-4047
1356481|NCT00540553|SARM,
1356482|NCT00540553|FTIH,
1356483|NCT00540553|pharmacokinetics
1356484|NCT00540527|acute ischemic stroke;thrombolysis;intraarterial thrombolysis
1356485|NCT00540514|Advanced Non-Small Cell Lung Cancer
1356486|NCT00540501|zanamivir,
1356487|NCT00540501|influenza virus,
1356488|NCT00540501|healthy volunteer,
1356489|NCT00540501|PK, drug interaction,
1356490|NCT00540501|IV, and oseltamivir.
1356491|NCT00540475|Idiopathic Pulmonary Fibrosis
1356492|NCT00540475|Interstitial Lung Disease
1356493|NCT00540462|Type II Diabetes Mellitus
1356494|NCT00540462|Gastric bypass
1356495|NCT00540462|Obese-related diabetes mellitus
1356496|NCT00540462|Sugar control
1356497|NCT00540462|treatment of obesity related diabetes mellitus
1356498|NCT00540449|TMC278-C209
1356499|NCT00540449|Antiretroviral
1356500|NCT00540449|Non-nucleoside reverse transcriptase inhibitor
1356501|NCT00540449|HIV-1
1356502|NCT00540449|AIDS
1356503|NCT00540449|TMC278-TiDP6-C209
1356504|NCT00540449|Treatment Naive
1356505|NCT00540436|Ambrisentan
1356506|NCT00540436|Pulmonary Arterial Hypertension
1356507|NCT00540436|6MWD
1356508|NCT00540423|thrombopoietin,
1356509|NCT00540423|immunosuppressive therapy,
1356510|NCT00540423|eltrombopag,
1356511|NCT00540423|idiopathic thrombocytopenic purpura,
1356512|NCT00540423|blood platelet,
1356513|NCT00540423|splenectomy
1356514|NCT00540384|Anemia
1356515|NCT00540384|Solid tumors
1356516|NCT00540384|Multicycle chemotherapy
1356517|NCT00540384|NESP
1356518|NCT00540371|Port Wine Stain
1356519|NCT00540358|Triple negative breast cancer
1356520|NCT00540345|chronic hepatitis C
1356521|NCT00540345|genotype 2
1356522|NCT00540345|rapid virological response
1356523|NCT00540345|sustained virological response
1356524|NCT00540345|peginterferon
1356525|NCT00540345|ribavirin
1356526|NCT00540345|treatment duration
1356527|NCT00540332|Oncology
1356528|NCT00540332|KGF
1356529|NCT00540332|HNC
1356530|NCT00540332|head and neck
1356531|NCT00540332|oral mucositis
1356532|NCT00540332|OM
1356533|NCT00540332|proteinurea
1356534|NCT00540332|palifermin
1356535|NCT00540332|clinical trial
1356536|NCT00540319|Risky behaviors
1356537|NCT00540319|Prenatal care
1356538|NCT00540319|Substance use
1356539|NCT00540319|Domestic violence
1356540|NCT00540306|breast tissue
1356541|NCT00540280|NSCLC
1356542|NCT00540267|Schizophrenia
1356543|NCT00540267|Alcohol Abuse
1356544|NCT00540267|Bone Density
1356545|NCT00540254|Chronic Fatigue
1356546|NCT00540254|Insomnia
1356547|NCT00540254|Cognitive Behavioral Therapy
1356548|NCT00540228|Influenza
1356549|NCT00540228|Influenza Vaccine
1356550|NCT00540202|Effectiveness
1356551|NCT00540202|Oral quinine
1356552|NCT00540202|Coartem
1356553|NCT00540202|Uncomplicated malaria
1356554|NCT00540202|Children
1356555|NCT00540189|appendicitis, perforated, children
1356556|NCT00540176|Dichloroacetate
1356557|NCT00540176|Glioblastoma Multiforme
1356558|NCT00540176|Glioma
1356559|NCT00540150|Immunotherapy
1356560|NCT00540150|Mite
1356561|NCT00540150|Asthma
1356562|NCT00540150|bronchial provocation
1356563|NCT00540150|SIT
1356564|NCT00540150|specific immunotherapy
1356565|NCT00540137|Antiretroviral therapy
1356566|NCT00540137|Neurocognitive function
1356567|NCT00540137|Magnetic resonance spectroscopy
1356568|NCT00540137|HIV disease
1356569|NCT00540137|Treatment Naive
1356570|NCT00540111|Soluble fiber
1356571|NCT00540111|HIV/aids
1356572|NCT00540111|Hypertriglyceridemia
1356573|NCT00540111|Cytokines
1356574|NCT00540111|Alternative Medicine
1356575|NCT00540111|Complementary Medicine
1356576|NCT00540098|panic disorder
1356577|NCT00540098|pharmacotherapy
1356578|NCT00540098|non-pharmacological treatment
1356579|NCT00540098|SSRI
1356580|NCT00540098|paroxetine
1356581|NCT00540098|exercise
1356582|NCT00540072|Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
1356583|NCT00540059|Prostate carcinoma
1356584|NCT00540059|LHRH
1356585|NCT00540059|Zoladex
1356586|NCT00540046|IUD
1356587|NCT00540046|Second trimester termination
1356588|NCT00540046|Contraception
1356589|NCT00540033|probiotics
1356590|NCT00540033|necrotizing enterocolitis
1356591|NCT00540033|preterm very low birth weight infants (VLBW)
1356592|NCT00540020|Brain Injuries
1356593|NCT00540020|Cognition
1356594|NCT00540020|Randomized Trials
1356595|NCT00540020|Rehabilitation
1356596|NCT00540020|Treatment Outcome
1356597|NCT00540007|Hodgkin Lymphoma
1356598|NCT00540007|Lenalidomide
1356599|NCT00540007|Anti-neoplastic agents
1356600|NCT00540007|Thalidomide
1356601|NCT00539994|Altabax
1356602|NCT00539994|SB-275833
1356603|NCT00539994|retapamulin
1356604|NCT00539994|nasal colonization
1356605|NCT00539994|PK
1356606|NCT00539994|tolerability
1356607|NCT00539994|safety
1356608|NCT00539994|efficacy
1356609|NCT00539981|Influenza
1356610|NCT00539955|intimate partner violence
1356611|NCT00539955|alcohol use
1356612|NCT00539955|substance use
1356613|NCT00539942|Randomized Clinical Trials
1356614|NCT00539942|Randomized Controlled Trial
1356615|NCT00539942|Venous thrombosis
1356616|NCT00539942|Anticoagulant Drugs
1356617|NCT00539942|Doppler Ultrasound
1356618|NCT00539942|Postoperative complications
1356619|NCT00539903|Activity Level
1356620|NCT00539877|Gstric cancer
1356621|NCT00539877|Pritoneal seeding
1356622|NCT00539877|Intraperitoneal chemotherapy
1356623|NCT00539877|Irinotecan
1356624|NCT00539864|Influenza
1356625|NCT00539851|Allogenic Stem Cell Transplantation
1356626|NCT00539851|Diabetes Mellitus
1356627|NCT00539838|SLE
1356628|NCT00539825|Anticholinergic,
1356629|NCT00539825|Plethysmography
1356630|NCT00539825|Muscarinic Receptor Antagonist,
1356631|NCT00539825|COPD,
1356632|NCT00539825|FTIH,
1356633|NCT00539812|Intimate partner violence
1356634|NCT00539812|alcohol use
1356635|NCT00539812|substance use
1356636|NCT00539799|systemic lupus erythematosus
1356637|NCT00539799|lupus nephritis
1356638|NCT00539786|Patients with extraesophageal manifestation of gastroesophageal reflux disease
1356639|NCT00538759|Aortic valve stenosis
1356640|NCT00538759|Balloon aortic valvuloplasty
1356641|NCT00538759|Aortic valve restenosis
1356642|NCT00539760|domain antibody
1356643|NCT00539760|Rheumatoid Arthritis,
1356644|NCT00539747|Presymptomatic
1356645|NCT00539747|Huntington Disease
1356646|NCT00539747|Meaning Making
1356647|NCT00539747|Genetic Testing
1356648|NCT00539747|HD
1356649|NCT00539734|age-related macular degeneration (AMD)
1356650|NCT00539734|choroidal neovascularization membrane(CNVM)
1356651|NCT00539734|ranibizumab
1356652|NCT00539734|anti-vascular endothelial growth factor
1356653|NCT00539734|electrophysiology
1356654|NCT00539734|electroretinography
1356655|NCT00539721|Nausea
1356656|NCT00539721|Vomiting
1356657|NCT00539708|Non-invasive ventilation
1356658|NCT00539708|Hypercapnic respiratory failure
1356659|NCT00539708|Mechanical ventilation
1356660|NCT00539708|Respiratory failure after extubation
1356661|NCT00539695|Stem Cell transplant
1356662|NCT00539695|Graft verus host disease
1356663|NCT00539695|IL-2
1356664|NCT00539695|acute lymphoblastic leukemia
1356665|NCT00539695|ALL
1356666|NCT00539695|acute myelogenous leukemia
1356667|NCT00539695|AML
1356668|NCT00539695|chronic myelogenous leukemia
1356669|NCT00539695|myelodysplastic syndrome
1356670|NCT00539695|myeloproliferative disorder
1356671|NCT00539695|Hodgkin lymphoma
1356672|NCT00539695|non-Hodgkin lymphoma
1356673|NCT00539695|non-malignant diseases requiring allogeneic HSCT
1356674|NCT00539656|Cord blood stem cell transplantation
1356675|NCT00539656|Ex vivo expansion
1356676|NCT00539656|Alternative donor
1356677|NCT00539643|Liver Cancer
1356678|NCT00539643|Hepatoma
1356679|NCT00539643|07-099
1356680|NCT00539617|metastatic esophageal cancer
1356681|NCT00539617|erlotinib
1356682|NCT00539617|folfox
1356683|NCT00539617|advanced esophageal cancer
1356684|NCT00539617|unresectable esophageal cancer
1356685|NCT00539604|Comparison study between MDCT and coronary angiography
1356686|NCT00539591|Cutaneous Melanoma
1356687|NCT00539565|biliary atresia
1356688|NCT00539565|Kasai portoenterostomy
1356689|NCT00539565|corticosteroids
1356690|NCT00539513|obsessive-compulsive disorder
1356691|NCT00539513|OCD
1356692|NCT00539513|glutamate
1356693|NCT00539513|N-Acetylcysteine
1356694|NCT00539513|augmentation
1356695|NCT00539500|Neuroblastoma
1356696|NCT00539500|ClinicMACS
1356697|NCT00539500|CliniMACS
1356698|NCT00539500|Stem Cell Transplantation
1356699|NCT00539500|Blood And Marrow Transplantation
1356700|NCT00539500|Pediatric
1356701|NCT00539500|Solid Tumors
1356702|NCT00539500|Carboplatin
1356703|NCT00539500|Paraplatin
1356704|NCT00539500|Etoposide
1356705|NCT00539500|VePesid
1356706|NCT00539500|Melphalan
1356707|NCT00539500|Alkeran
1356708|NCT00539500|CD133+ Cells
1356709|NCT00539474|ROLL trial
1356710|NCT00539474|Minimally invasive surgery
1356711|NCT00539474|Non palpable breast cancer
1356712|NCT00539435|Diabetes Mellitus
1356713|NCT00539435|Pulsatile Intravenous Insulin Therapy
1356714|NCT00539435|Diabetic Cardiac Quality of Life
1356715|NCT00539435|Cardiac Disease
1356716|NCT00539422|breast cancer
1356717|NCT00539422|cytochrome 450
1356718|NCT00539422|CYP2D6*4
1356719|NCT00539422|Ferritin
1356720|NCT00539422|oxidative stress
1356721|NCT00539422|cancer
1356722|NCT00539422|cancer breast
1356723|NCT00539409|Diabetes Mellitus
1356724|NCT00539409|Pulsatile Intravenous Insulin Therapy
1356725|NCT00539409|Diabetic Quality of Life
1356726|NCT00539409|Orthostatic Hypotension
1356727|NCT00539409|Brittle or Labile diabetes
1356728|NCT00539383|Lung cancer
1356729|NCT00539383|Breast cancer
1356730|NCT00539383|Melanoma
1356731|NCT00539383|Hepatocellular carcinoma
1356732|NCT00539383|Brain metastases
1356733|NCT00539370|Scleritis
1356734|NCT00539370|Intermediate Uveitis
1356735|NCT00539370|Posterior Uveitis
1356736|NCT00539370|Intraocular Inflammatory Disease
1356737|NCT00539370|Data Analysis
1356738|NCT00539370|Data Collection
1356739|NCT00539370|Sample Analysis
1356740|NCT00539357|Cranial Electrostimulation Therapy
1356741|NCT00539344|Glioblastoma multiforme
1356742|NCT00539344|Anaplastic astrocytoma
1356743|NCT00539344|Anaplastic oligodendroglioma
1356744|NCT00539331|Non-small Cell Lung Cancer
1356745|NCT00539331|NSCLC
1356746|NCT00539331|AZD2171
1356747|NCT00539331|Paclitaxel/Carboplatin
1356748|NCT00539331|Non-small Cell Lung Cancer (NSCLC)
1356749|NCT00539305|selective androgen receptor modulators (SARMs)
1356750|NCT00539305|hormone replacement therapy
1356751|NCT00539305|age-associated cognitive decline
1356752|NCT00539305|testosterone supplementation
1356753|NCT00539292|pediatrics
1356754|NCT00539292|gastroschisis
1356755|NCT00539292|silastic spring-loaded silo
1356756|NCT00539279|Cognitive- Behavior Therapy
1356757|NCT00539279|Combat Disorders
1356758|NCT00539279|Elderly
1356759|NCT00539279|Geriatrics
1356760|NCT00539279|Implosive therapy
1356761|NCT00539279|Neuropsychological Test
1356762|NCT00539279|Post-traumatic Stress Disorder
1356763|NCT00539279|Psychotherapy
1356764|NCT00539279|Randomized Controlled Trial
1356765|NCT00539279|Relaxation techniques
1356766|NCT00539266|Claudication
1356767|NCT00539266|Critical limb ischemia
1356768|NCT00539266|Cell therapy
1356769|NCT00539266|Bone marrow
1356770|NCT00539253|liver cancer
1356771|NCT00539253|transarterial chemoembolization
1356772|NCT00539240|acid reflux
1356773|NCT00539240|acid regurgitation
1356774|NCT00539240|esophagitis
1356775|NCT00539240|GERD
1356776|NCT00539240|heartburn
1356777|NCT00539240|pain
1356778|NCT00539240|peptic
1356779|NCT00539227|Breast Cancer
1356780|NCT00539227|Nipple-Areolar Complex
1356781|NCT00539227|Mastectomy
1356782|NCT00539227|Prophylactic mastectomy
1356783|NCT00539227|Immediate reconstruction
1356784|NCT00539227|Reconstructive surgery
1356785|NCT00539227|Questionnaire
1356786|NCT00539227|Survey
1356787|NCT00539227|NAC
1356788|NCT00539201|GSK706769,
1356789|NCT00539201|CCR5 inhibitor,
1356790|NCT00539201|HIV
1356791|NCT00539188|Borderline Personality Disorder(BPD)
1356792|NCT00539188|Dialectical Behavioral Therapy (DBT)
1356793|NCT00539188|glutamate
1356794|NCT00539188|N-Acetylcysteine
1356795|NCT00539188|Borderline Personality Disorder with Self-Injurious Behavior
1356796|NCT00539175|diabetes mellitus
1356797|NCT00539175|neuropathy
1356798|NCT00539175|diabetic neuropathy
1356799|NCT00539162|Ovarian Cancer
1356800|NCT00539162|CA 125 Algorithm
1356801|NCT00539162|Cancer Detection
1356802|NCT00539162|Questionnaire
1356803|NCT00539162|Survey
1356804|NCT00539149|Acute otitis media
1356805|NCT00539149|Otitis media with effusion
1356806|NCT00539149|Tympanic membrane perforation
1356807|NCT00539136|GSK561679,
1356808|NCT00539136|Pharmacokinetic,
1356809|NCT00539136|healthy volunteers,
1356810|NCT00539136|Gamma Scintigraphy,
1356811|NCT00539136|PillCam™,
1356812|NCT00539136|acoustic vest
1356813|NCT00539123|buprenorphine
1356814|NCT00539123|drug counseling
1356815|NCT00539123|HIV risk reduction counseling
1356816|NCT00539097|pediatrics
1356817|NCT00539084|microneedles
1356818|NCT00539084|microneedle
1356819|NCT00539084|intradermal
1356820|NCT00539071|schizophrenia
1356821|NCT00539071|schizoaffective disorder
1356822|NCT00539071|long acting injectable
1356823|NCT00539071|treatment resistant
1356824|NCT00539045|myocardial infarction, thrombus
1356825|NCT00539032|N. meningitidis
1356826|NCT00539032|Meningitis
1356827|NCT00539032|Meningococcemia
1356828|NCT00539019|nutrition assessment
1356829|NCT00539019|pediatric
1356830|NCT00539006|fluticasone propionate
1356831|NCT00539006|seasonal allergic rhinitis
1356832|NCT00539006|fluticasone furoate
1356833|NCT00539006|experience
1356834|NCT00539006|GW685698X
1356835|NCT00539006|preference
1356836|NCT00538980|Polycythemia Vera
1356837|NCT00538980|PV
1356838|NCT00538980|P Vera
1356839|NCT00538967|Collagenases
1356840|NCT00538967|MMP
1356841|NCT00538967|Cathepsins
1356842|NCT00538967|Doxycycline
1356843|NCT00538967|Aneurysm
1356844|NCT00538954|Perioperative
1356845|NCT00538954|recovery
1356846|NCT00538954|nutrition
1356847|NCT00538954|enhanced
1356848|NCT00538954|laxative
1356849|NCT00538941|chocolate,
1356850|NCT00538941|heart failure,
1356851|NCT00538941|endothelial function,
1356852|NCT00538941|platelet adhesion,
1356853|NCT00538941|oxidative stress,
1356854|NCT00538941|baroreceptor function,
1356855|NCT00538928|acute respiratory distress syndrome
1356856|NCT00538928|extracorporeal lung support
1356857|NCT00538928|hypoxia
1356858|NCT00538928|hypercapnia
1356859|NCT00538928|acute respiratory distress syndrome (ARDS)
1356860|NCT00538915|immunodeficiency
1356861|NCT00538915|humoral immunity
1356862|NCT00538915|antibody deficiency
1356863|NCT00538915|PID
1356864|NCT00538915|PIDD
1356865|NCT00538902|Humira, methotrexate
1356866|NCT00538889|Adult
1356867|NCT00538850|unspecified adult solid tumor, protocol specific
1356868|NCT00538850|pain
1356869|NCT00538850|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1356870|NCT00538850|adult acute myeloid leukemia with inv(16)(p13;q22)
1356871|NCT00538850|adult acute myeloid leukemia with t(15;17)(q22;q12)
1356872|NCT00538850|adult acute myeloid leukemia with t(16;16)(p13;q22)
1356873|NCT00538850|adult acute myeloid leukemia with t(8;21)(q22;q22)
1356874|NCT00538850|stage IV chronic lymphocytic leukemia
1356875|NCT00538850|accelerated phase chronic myelogenous leukemia
1356876|NCT00538850|blastic phase chronic myelogenous leukemia
1356877|NCT00538850|chronic myelomonocytic leukemia
1356878|NCT00538850|chronic phase chronic myelogenous leukemia
1356879|NCT00538850|noncontiguous stage II adult Burkitt lymphoma
1356880|NCT00538850|noncontiguous stage II adult diffuse large cell lymphoma
1356881|NCT00538850|noncontiguous stage II adult diffuse mixed cell lymphoma
1356882|NCT00538850|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1356883|NCT00538850|noncontiguous stage II adult immunoblastic large cell lymphoma
1356884|NCT00538850|noncontiguous stage II adult lymphoblastic lymphoma
1356885|NCT00538850|noncontiguous stage II small lymphocytic lymphoma
1356886|NCT00538850|noncontiguous stage II marginal zone lymphoma
1356887|NCT00538850|noncontiguous stage II grade 1 follicular lymphoma
1356888|NCT00538850|noncontiguous stage II grade 2 follicular lymphoma
1356889|NCT00538850|noncontiguous stage II grade 3 follicular lymphoma
1356890|NCT00538850|noncontiguous stage II mantle cell lymphoma
1356891|NCT00538850|stage III adult Burkitt lymphoma
1356892|NCT00538850|stage III adult diffuse large cell lymphoma
1356893|NCT00538850|stage III adult diffuse mixed cell lymphoma
1356894|NCT00538850|stage III adult diffuse small cleaved cell lymphoma
1356895|NCT00538850|stage III adult immunoblastic large cell lymphoma
1356896|NCT00538850|stage III adult lymphoblastic lymphoma
1356897|NCT00538850|stage III small lymphocytic lymphoma
1356898|NCT00538850|stage III marginal zone lymphoma
1356899|NCT00538850|stage III grade 1 follicular lymphoma
1356900|NCT00538850|stage III grade 2 follicular lymphoma
1356901|NCT00538850|stage III grade 3 follicular lymphoma
1356902|NCT00538850|stage III mantle cell lymphoma
1356903|NCT00538850|stage IV adult Burkitt lymphoma
1356904|NCT00538850|stage IV adult diffuse large cell lymphoma
1356905|NCT00538850|stage IV adult diffuse mixed cell lymphoma
1356906|NCT00538850|stage IV adult diffuse small cleaved cell lymphoma
1356907|NCT00538850|stage IV adult immunoblastic large cell lymphoma
1356908|NCT00538850|stage IV adult lymphoblastic lymphoma
1356909|NCT00538850|stage IV small lymphocytic lymphoma
1356910|NCT00538850|stage IV marginal zone lymphoma
1356911|NCT00538850|stage IV grade 1 follicular lymphoma
1356912|NCT00538850|stage IV grade 2 follicular lymphoma
1356913|NCT00538850|stage IV grade 3 follicular lymphoma
1356914|NCT00538850|stage IV mantle cell lymphoma
1356915|NCT00538850|recurrent adult Burkitt lymphoma
1356916|NCT00538850|recurrent adult diffuse large cell lymphoma
1356917|NCT00538850|recurrent adult diffuse mixed cell lymphoma
1356918|NCT00538850|recurrent adult diffuse small cleaved cell lymphoma
1356919|NCT00538850|recurrent adult Hodgkin lymphoma
1356920|NCT00538850|recurrent adult immunoblastic large cell lymphoma
1356921|NCT00538850|recurrent adult lymphoblastic lymphoma
1356922|NCT00538850|recurrent cutaneous T-cell non-Hodgkin lymphoma
1356923|NCT00538850|recurrent small lymphocytic lymphoma
1356924|NCT00538850|recurrent marginal zone lymphoma
1356925|NCT00538850|recurrent grade 1 follicular lymphoma
1356926|NCT00538850|recurrent grade 2 follicular lymphoma
1356927|NCT00538850|recurrent grade 3 follicular lymphoma
1356928|NCT00538850|recurrent mantle cell lymphoma
1357546|NCT00536900|representative payee
1356929|NCT00538850|recurrent mycosis fungoides/Sezary syndrome
1356930|NCT00538850|stage I multiple myeloma
1356931|NCT00538850|stage II multiple myeloma
1356932|NCT00538850|stage III multiple myeloma
1356933|NCT00538850|de novo myelodysplastic syndromes
1356934|NCT00538850|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1356935|NCT00538850|previously treated myelodysplastic syndromes
1356936|NCT00538850|secondary myelodysplastic syndromes
1356937|NCT00538850|atypical chronic myeloid leukemia, BCR-ABL1 negative
1356938|NCT00538850|stage II adult Hodgkin lymphoma
1356939|NCT00538850|stage III adult Hodgkin lymphoma
1356940|NCT00538850|stage IV adult Hodgkin lymphoma
1356941|NCT00538850|contiguous stage II adult Burkitt lymphoma
1356942|NCT00538850|stage I adult Burkitt lymphoma
1356943|NCT00538850|contiguous stage II adult diffuse large cell lymphoma
1356944|NCT00538850|contiguous stage II adult diffuse mixed cell lymphoma
1356945|NCT00538850|contiguous stage II adult diffuse small cleaved cell lymphoma
1356946|NCT00538850|contiguous stage II small lymphocytic lymphoma
1356947|NCT00538850|contiguous stage II marginal zone lymphoma
1356948|NCT00538850|stage I adult diffuse large cell lymphoma
1356949|NCT00538850|stage I adult diffuse mixed cell lymphoma
1356950|NCT00538850|stage I adult diffuse small cleaved cell lymphoma
1356951|NCT00538850|stage I small lymphocytic lymphoma
1356952|NCT00538850|stage I marginal zone lymphoma
1356953|NCT00538850|contiguous stage II grade 1 follicular lymphoma
1356954|NCT00538850|contiguous stage II grade 2 follicular lymphoma
1356955|NCT00538850|contiguous stage II grade 3 follicular lymphoma
1356956|NCT00538850|stage I grade 1 follicular lymphoma
1356957|NCT00538850|stage I grade 2 follicular lymphoma
1356958|NCT00538850|stage I grade 3 follicular lymphoma
1356959|NCT00538850|contiguous stage II mantle cell lymphoma
1356960|NCT00538850|stage I mantle cell lymphoma
1356961|NCT00538850|contiguous stage II adult immunoblastic large cell lymphoma
1356962|NCT00538850|stage I adult immunoblastic large cell lymphoma
1356963|NCT00538850|contiguous stage II adult lymphoblastic lymphoma
1356964|NCT00538850|stage I adult lymphoblastic lymphoma
1356965|NCT00538850|refractory multiple myeloma
1356966|NCT00538850|anaplastic large cell lymphoma
1356967|NCT00538850|angioimmunoblastic T-cell lymphoma
1356968|NCT00538850|recurrent adult T-cell leukemia/lymphoma
1356969|NCT00538850|stage I adult T-cell leukemia/lymphoma
1356970|NCT00538850|stage II adult T-cell leukemia/lymphoma
1356971|NCT00538850|stage III adult T-cell leukemia/lymphoma
1356972|NCT00538850|stage IV adult T-cell leukemia/lymphoma
1356973|NCT00538850|stage I cutaneous T-cell non-Hodgkin lymphoma
1356974|NCT00538850|stage II cutaneous T-cell non-Hodgkin lymphoma
1356975|NCT00538850|stage III cutaneous T-cell non-Hodgkin lymphoma
1356976|NCT00538850|stage IV cutaneous T-cell non-Hodgkin lymphoma
1356977|NCT00538850|stage I mycosis fungoides/Sezary syndrome
1356978|NCT00538850|stage II mycosis fungoides/Sezary syndrome
1356979|NCT00538850|stage III mycosis fungoides/Sezary syndrome
1356980|NCT00538850|stage IV mycosis fungoides/Sezary syndrome
1356981|NCT00538850|chronic eosinophilic leukemia
1356982|NCT00538850|primary myelofibrosis
1356983|NCT00538850|chronic neutrophilic leukemia
1356984|NCT00538850|essential thrombocythemia
1356985|NCT00538850|polycythemia vera
1356986|NCT00538850|relapsing chronic myelogenous leukemia
1356987|NCT00538850|T-cell large granular lymphocyte leukemia
1356988|NCT00538850|recurrent adult acute lymphoblastic leukemia
1356989|NCT00538850|recurrent adult acute myeloid leukemia
1356990|NCT00538850|untreated adult acute lymphoblastic leukemia
1356991|NCT00538850|untreated adult acute myeloid leukemia
1356992|NCT00538850|secondary acute myeloid leukemia
1356993|NCT00538850|acute undifferentiated leukemia
1356994|NCT00538850|refractory chronic lymphocytic leukemia
1356995|NCT00538850|stage 0 chronic lymphocytic leukemia
1356996|NCT00538850|stage I chronic lymphocytic leukemia
1356997|NCT00538850|stage II chronic lymphocytic leukemia
1356998|NCT00538850|stage III chronic lymphocytic leukemia
1356999|NCT00538850|refractory hairy cell leukemia
1357000|NCT00538850|progressive hairy cell leukemia, initial treatment
1357001|NCT00538850|prolymphocytic leukemia
1357002|NCT00538850|recurrent adult grade III lymphomatoid granulomatosis
1357003|NCT00538850|Waldenström macroglobulinemia
1357004|NCT00538850|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1357005|NCT00538850|nodal marginal zone B-cell lymphoma
1357006|NCT00538850|splenic marginal zone lymphoma
1357007|NCT00538850|post-transplant lymphoproliferative disorder
1357008|NCT00538850|extramedullary plasmacytoma
1357009|NCT00538850|isolated plasmacytoma of bone
1357010|NCT00538850|monoclonal gammopathy of undetermined significance
1357011|NCT00538850|primary systemic amyloidosis
1357012|NCT00538850|adult acute lymphoblastic leukemia in remission
1357013|NCT00538850|adult acute myeloid leukemia in remission
1357014|NCT00538850|adult grade III lymphomatoid granulomatosis
1357015|NCT00538850|AIDS-related peripheral/systemic lymphoma
1357016|NCT00538850|AIDS-related primary CNS lymphoma
1357017|NCT00538850|intraocular lymphoma
1357018|NCT00538850|meningeal chronic myelogenous leukemia
1357019|NCT00538850|primary central nervous system non-Hodgkin lymphoma
1357020|NCT00538850|primary central nervous system Hodgkin lymphoma
1357021|NCT00538850|stage I adult Hodgkin lymphoma
1357547|NCT00536900|cocaine abuse
1357022|NCT00538850|recurrent squamous cell carcinoma of the hypopharynx
1357023|NCT00538850|stage I squamous cell carcinoma of the hypopharynx
1357024|NCT00538850|stage II squamous cell carcinoma of the hypopharynx
1357025|NCT00538850|stage III squamous cell carcinoma of the hypopharynx
1357026|NCT00538850|stage IV squamous cell carcinoma of the hypopharynx
1357027|NCT00538850|recurrent squamous cell carcinoma of the larynx
1357028|NCT00538850|recurrent verrucous carcinoma of the larynx
1357029|NCT00538850|stage I squamous cell carcinoma of the larynx
1357030|NCT00538850|stage I verrucous carcinoma of the larynx
1357031|NCT00538850|stage II squamous cell carcinoma of the larynx
1357032|NCT00538850|stage II verrucous carcinoma of the larynx
1357033|NCT00538850|stage III squamous cell carcinoma of the larynx
1357034|NCT00538850|stage III verrucous carcinoma of the larynx
1357035|NCT00538850|stage IV squamous cell carcinoma of the larynx
1357036|NCT00538850|stage IV verrucous carcinoma of the larynx
1357037|NCT00538850|recurrent adenoid cystic carcinoma of the oral cavity
1357038|NCT00538850|recurrent mucoepidermoid carcinoma of the oral cavity
1357039|NCT00538850|recurrent verrucous carcinoma of the oral cavity
1357040|NCT00538850|stage I adenoid cystic carcinoma of the oral cavity
1357041|NCT00538850|stage I mucoepidermoid carcinoma of the oral cavity
1357042|NCT00538850|stage I verrucous carcinoma of the oral cavity
1357043|NCT00538850|stage II adenoid cystic carcinoma of the oral cavity
1357044|NCT00538850|stage II mucoepidermoid carcinoma of the oral cavity
1357045|NCT00538850|stage II verrucous carcinoma of the oral cavity
1357046|NCT00538850|stage III adenoid cystic carcinoma of the oral cavity
1357047|NCT00538850|stage III mucoepidermoid carcinoma of the oral cavity
1357048|NCT00538850|stage III verrucous carcinoma of the oral cavity
1357049|NCT00538850|stage IV adenoid cystic carcinoma of the oral cavity
1357050|NCT00538850|stage IV mucoepidermoid carcinoma of the oral cavity
1357051|NCT00538850|stage IV verrucous carcinoma of the oral cavity
1357052|NCT00538850|stage I squamous cell carcinoma of the lip and oral cavity
1357053|NCT00538850|stage II squamous cell carcinoma of the lip and oral cavity
1357054|NCT00538850|stage III squamous cell carcinoma of the lip and oral cavity
1357055|NCT00538850|stage IV squamous cell carcinoma of the lip and oral cavity
1357056|NCT00538850|recurrent basal cell carcinoma of the lip
1357057|NCT00538850|recurrent squamous cell carcinoma of the lip and oral cavity
1357058|NCT00538850|stage I basal cell carcinoma of the lip
1357059|NCT00538850|stage II basal cell carcinoma of the lip
1357060|NCT00538850|stage III basal cell carcinoma of the lip
1357061|NCT00538850|stage IV basal cell carcinoma of the lip
1357062|NCT00538850|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1357063|NCT00538850|recurrent metastatic squamous neck cancer with occult primary
1357064|NCT00538850|untreated metastatic squamous neck cancer with occult primary
1357065|NCT00538850|recurrent lymphoepithelioma of the nasopharynx
1357066|NCT00538850|recurrent squamous cell carcinoma of the nasopharynx
1357067|NCT00538850|stage I lymphoepithelioma of the nasopharynx
1357068|NCT00538850|stage I squamous cell carcinoma of the nasopharynx
1357069|NCT00538850|stage II lymphoepithelioma of the nasopharynx
1357070|NCT00538850|stage II squamous cell carcinoma of the nasopharynx
1357071|NCT00538850|stage III lymphoepithelioma of the nasopharynx
1357072|NCT00538850|stage III squamous cell carcinoma of the nasopharynx
1357073|NCT00538850|stage IV lymphoepithelioma of the nasopharynx
1357074|NCT00538850|stage IV squamous cell carcinoma of the nasopharynx
1357075|NCT00538850|recurrent lymphoepithelioma of the oropharynx
1357076|NCT00538850|recurrent squamous cell carcinoma of the oropharynx
1357077|NCT00538850|stage I lymphoepithelioma of the oropharynx
1357078|NCT00538850|stage I squamous cell carcinoma of the oropharynx
1357079|NCT00538850|stage II lymphoepithelioma of the oropharynx
1357080|NCT00538850|stage II squamous cell carcinoma of the oropharynx
1357081|NCT00538850|stage III lymphoepithelioma of the oropharynx
1357082|NCT00538850|stage III squamous cell carcinoma of the oropharynx
1357083|NCT00538850|stage IV lymphoepithelioma of the oropharynx
1357084|NCT00538850|stage IV squamous cell carcinoma of the oropharynx
1357085|NCT00538850|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1357086|NCT00538850|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1357087|NCT00538850|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1357088|NCT00538850|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1357089|NCT00538850|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1357090|NCT00538850|stage I inverted papilloma of the paranasal sinus and nasal cavity
1357091|NCT00538850|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1357092|NCT00538850|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1357093|NCT00538850|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1357094|NCT00538850|stage II inverted papilloma of the paranasal sinus and nasal cavity
1357095|NCT00538850|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1357096|NCT00538850|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1357097|NCT00538850|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1357098|NCT00538850|stage III inverted papilloma of the paranasal sinus and nasal cavity
1357099|NCT00538850|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1357100|NCT00538850|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1357305|NCT00538850|stage III prostate cancer
1357101|NCT00538850|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1357102|NCT00538850|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1357103|NCT00538850|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1357104|NCT00538850|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1357105|NCT00538850|high-grade salivary gland mucoepidermoid carcinoma
1357106|NCT00538850|low-grade salivary gland mucoepidermoid carcinoma
1357107|NCT00538850|recurrent salivary gland cancer
1357108|NCT00538850|salivary gland acinic cell tumor
1357109|NCT00538850|salivary gland adenocarcinoma
1357110|NCT00538850|salivary gland adenoid cystic carcinoma
1357111|NCT00538850|salivary gland anaplastic carcinoma
1357112|NCT00538850|salivary gland malignant mixed cell type tumor
1357113|NCT00538850|salivary gland poorly differentiated carcinoma
1357114|NCT00538850|salivary gland squamous cell carcinoma
1357115|NCT00538850|stage I salivary gland cancer
1357116|NCT00538850|stage II salivary gland cancer
1357117|NCT00538850|stage III salivary gland cancer
1357118|NCT00538850|stage IV salivary gland cancer
1357119|NCT00538850|adult grade I meningioma
1357120|NCT00538850|adult choroid plexus tumor
1357121|NCT00538850|adult craniopharyngioma
1357122|NCT00538850|adult myxopapillary ependymoma
1357123|NCT00538850|adult diffuse astrocytoma
1357124|NCT00538850|adult pilocytic astrocytoma
1357125|NCT00538850|adult pineocytoma
1357126|NCT00538850|adult ependymoma
1357127|NCT00538850|adult subependymoma
1357128|NCT00538850|adult oligodendroglioma
1357129|NCT00538850|adult subependymal giant cell astrocytoma
1357130|NCT00538850|meningeal melanocytoma
1357131|NCT00538850|adult meningeal hemangiopericytoma
1357132|NCT00538850|adult pineal gland astrocytoma
1357133|NCT00538850|adult central nervous system germ cell tumor
1357134|NCT00538850|adult medulloblastoma
1357135|NCT00538850|adult supratentorial primitive neuroectodermal tumor (PNET)
1357136|NCT00538850|adult ependymoblastoma
1357137|NCT00538850|adult anaplastic astrocytoma
1357138|NCT00538850|adult anaplastic ependymoma
1357139|NCT00538850|adult glioblastoma
1357140|NCT00538850|adult gliosarcoma
1357141|NCT00538850|adult giant cell glioblastoma
1357142|NCT00538850|adult grade III meningioma
1357143|NCT00538850|adult anaplastic oligodendroglioma
1357144|NCT00538850|adult pineoblastoma
1357145|NCT00538850|adult mixed glioma
1357146|NCT00538850|recurrent adult brain tumor
1357147|NCT00538850|adult anaplastic meningioma
1357148|NCT00538850|adult papillary meningioma
1357149|NCT00538850|adult brain stem glioma
1357150|NCT00538850|stage IA cervical cancer
1357151|NCT00538850|stage IB cervical cancer
1357152|NCT00538850|stage IIA cervical cancer
1357153|NCT00538850|stage IIB cervical cancer
1357154|NCT00538850|stage III cervical cancer
1357155|NCT00538850|stage IVA cervical cancer
1357156|NCT00538850|stage IVB cervical cancer
1357157|NCT00538850|recurrent cervical cancer
1357158|NCT00538850|recurrent endometrial carcinoma
1357159|NCT00538850|stage I endometrial carcinoma
1357160|NCT00538850|stage II endometrial carcinoma
1357161|NCT00538850|stage III endometrial carcinoma
1357162|NCT00538850|stage IV endometrial carcinoma
1357163|NCT00538850|fallopian tube cancer
1357164|NCT00538850|recurrent ovarian epithelial cancer
1357165|NCT00538850|recurrent ovarian germ cell tumor
1357166|NCT00538850|stage I ovarian epithelial cancer
1357167|NCT00538850|stage I ovarian germ cell tumor
1357168|NCT00538850|stage II ovarian epithelial cancer
1357169|NCT00538850|stage II ovarian germ cell tumor
1357170|NCT00538850|stage III ovarian epithelial cancer
1357171|NCT00538850|stage III ovarian germ cell tumor
1357172|NCT00538850|stage IV ovarian epithelial cancer
1357173|NCT00538850|stage IV ovarian germ cell tumor
1357174|NCT00538850|ovarian sarcoma
1357175|NCT00538850|ovarian stromal cancer
1357176|NCT00538850|recurrent uterine sarcoma
1357177|NCT00538850|stage I uterine sarcoma
1357178|NCT00538850|stage II uterine sarcoma
1357179|NCT00538850|stage III uterine sarcoma
1357180|NCT00538850|stage IV uterine sarcoma
1357181|NCT00538850|recurrent colon cancer
1357182|NCT00538850|stage I colon cancer
1357183|NCT00538850|stage II colon cancer
1357184|NCT00538850|stage III colon cancer
1357185|NCT00538850|stage IV colon cancer
1357186|NCT00538850|recurrent bladder cancer
1357187|NCT00538850|recurrent gallbladder cancer
1357188|NCT00538850|stage I bladder cancer
1357189|NCT00538850|stage II bladder cancer
1357190|NCT00538850|stage III bladder cancer
1357191|NCT00538850|stage IV bladder cancer
1357192|NCT00538850|recurrent gastric cancer
1357193|NCT00538850|stage I gastric cancer
1357194|NCT00538850|stage II gastric cancer
1357195|NCT00538850|stage III gastric cancer
1357196|NCT00538850|stage IV gastric cancer
1357197|NCT00538850|advanced adult primary liver cancer
1357198|NCT00538850|recurrent small intestine cancer
1357199|NCT00538850|localized transitional cell cancer of the renal pelvis and ureter
1357200|NCT00538850|metastatic transitional cell cancer of the renal pelvis and ureter
1357201|NCT00538850|recurrent renal cell cancer
1357202|NCT00538850|recurrent transitional cell cancer of the renal pelvis and ureter
1357544|NCT00536900|Substance abuse
1357203|NCT00538850|regional transitional cell cancer of the renal pelvis and ureter
1357204|NCT00538850|stage I renal cell cancer
1357205|NCT00538850|stage II renal cell cancer
1357206|NCT00538850|stage III renal cell cancer
1357207|NCT00538850|stage IV renal cell cancer
1357208|NCT00538850|distal urethral cancer
1357209|NCT00538850|proximal urethral cancer
1357210|NCT00538850|recurrent urethral cancer
1357211|NCT00538850|urethral cancer associated with invasive bladder cancer
1357212|NCT00538850|stage I adrenocortical carcinoma
1357213|NCT00538850|stage II adrenocortical carcinoma
1357214|NCT00538850|stage III adrenocortical carcinoma
1357215|NCT00538850|stage IV adrenocortical carcinoma
1357216|NCT00538850|recurrent adrenocortical carcinoma
1357217|NCT00538850|extragonadal germ cell tumor
1357218|NCT00538850|localized gastrointestinal carcinoid tumor
1357219|NCT00538850|metastatic gastrointestinal carcinoid tumor
1357220|NCT00538850|recurrent gastrointestinal carcinoid tumor
1357221|NCT00538850|regional gastrointestinal carcinoid tumor
1357222|NCT00538850|gastrinoma
1357223|NCT00538850|insulinoma
1357224|NCT00538850|WDHA syndrome
1357225|NCT00538850|glucagonoma
1357226|NCT00538850|pancreatic polypeptide tumor
1357227|NCT00538850|somatostatinoma
1357228|NCT00538850|recurrent islet cell carcinoma
1357229|NCT00538850|carcinoma of the appendix
1357230|NCT00538850|localized extrahepatic bile duct cancer
1357231|NCT00538850|recurrent extrahepatic bile duct cancer
1357232|NCT00538850|unresectable extrahepatic bile duct cancer
1357233|NCT00538850|localized gallbladder cancer
1357234|NCT00538850|unresectable gallbladder cancer
1357235|NCT00538850|gastrointestinal stromal tumor
1357236|NCT00538850|localized resectable adult primary liver cancer
1357237|NCT00538850|localized unresectable adult primary liver cancer
1357238|NCT00538850|recurrent adult primary liver cancer
1357239|NCT00538850|stage I pancreatic cancer
1357240|NCT00538850|stage II pancreatic cancer
1357241|NCT00538850|stage III pancreatic cancer
1357242|NCT00538850|stage IV pancreatic cancer
1357243|NCT00538850|recurrent pancreatic cancer
1357244|NCT00538850|small intestine adenocarcinoma
1357245|NCT00538850|small intestine leiomyosarcoma
1357246|NCT00538850|small intestine lymphoma
1357247|NCT00538850|stage I non-small cell lung cancer
1357248|NCT00538850|stage II non-small cell lung cancer
1357249|NCT00538850|stage IIIA non-small cell lung cancer
1357250|NCT00538850|stage IIIB non-small cell lung cancer
1357251|NCT00538850|stage IV non-small cell lung cancer
1357252|NCT00538850|recurrent non-small cell lung cancer
1357253|NCT00538850|pulmonary carcinoid tumor
1357254|NCT00538850|extensive stage small cell lung cancer
1357255|NCT00538850|limited stage small cell lung cancer
1357256|NCT00538850|recurrent small cell lung cancer
1357257|NCT00538850|liver metastases
1357258|NCT00538850|lung metastases
1357259|NCT00538850|primary peritoneal cavity cancer
1357260|NCT00538850|lung papilloma
1357261|NCT00538850|peripheral primitive neuroectodermal tumor of the kidney
1357262|NCT00538850|clear cell sarcoma of the kidney
1357263|NCT00538850|rhabdoid tumor of the kidney
1357264|NCT00538850|congenital mesoblastic nephroma
1357265|NCT00538850|stage II breast cancer
1357266|NCT00538850|stage IIIA breast cancer
1357267|NCT00538850|stage IIIB breast cancer
1357268|NCT00538850|stage IIIC breast cancer
1357269|NCT00538850|stage IV breast cancer
1357270|NCT00538850|recurrent breast cancer
1357271|NCT00538850|male breast cancer
1357272|NCT00538850|breast cancer in situ
1357273|NCT00538850|localized osteosarcoma
1357274|NCT00538850|metastatic osteosarcoma
1357275|NCT00538850|recurrent osteosarcoma
1357276|NCT00538850|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1357277|NCT00538850|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1357278|NCT00538850|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1357279|NCT00538850|chondrosarcoma
1357280|NCT00538850|malignant giant cell tumor of bone
1357281|NCT00538850|desmoid tumor
1357282|NCT00538850|stage I adult soft tissue sarcoma
1357283|NCT00538850|stage II adult soft tissue sarcoma
1357284|NCT00538850|stage III adult soft tissue sarcoma
1357285|NCT00538850|stage IV adult soft tissue sarcoma
1357286|NCT00538850|recurrent adult soft tissue sarcoma
1357287|NCT00538850|recurrent thymoma and thymic carcinoma
1357288|NCT00538850|advanced malignant mesothelioma
1357289|NCT00538850|localized malignant mesothelioma
1357290|NCT00538850|recurrent malignant mesothelioma
1357291|NCT00538850|phosphaturic mesenchymal tumor
1357292|NCT00538850|stage I malignant testicular germ cell tumor
1357293|NCT00538850|stage II malignant testicular germ cell tumor
1357294|NCT00538850|stage III malignant testicular germ cell tumor
1357295|NCT00538850|recurrent malignant testicular germ cell tumor
1357296|NCT00538850|stage 0 penile cancer
1357297|NCT00538850|stage I penile cancer
1357298|NCT00538850|stage II penile cancer
1357299|NCT00538850|stage III penile cancer
1357300|NCT00538850|stage IV penile cancer
1357301|NCT00538850|recurrent penile cancer
1357302|NCT00538850|stage I prostate cancer
1357303|NCT00538850|stage IIB prostate cancer
1357304|NCT00538850|stage IIA prostate cancer
1357545|NCT00536900|Behavior therapy
1357306|NCT00538850|stage IV prostate cancer
1357307|NCT00538850|recurrent prostate cancer
1357308|NCT00538850|stage 0 vaginal cancer
1357309|NCT00538850|stage I vaginal cancer
1357310|NCT00538850|stage II vaginal cancer
1357311|NCT00538850|stage III vaginal cancer
1357312|NCT00538850|stage IVA vaginal cancer
1357313|NCT00538850|stage IVB vaginal cancer
1357314|NCT00538850|recurrent vaginal cancer
1357315|NCT00538850|stage 0 vulvar cancer
1357316|NCT00538850|stage I vulvar cancer
1357317|NCT00538850|stage II vulvar cancer
1357318|NCT00538850|stage III vulvar cancer
1357319|NCT00538850|stage IVB vulvar cancer
1357320|NCT00538850|recurrent vulvar cancer
1357321|NCT00538850|stage 0 anal cancer
1357322|NCT00538850|stage I anal cancer
1357323|NCT00538850|stage II anal cancer
1357324|NCT00538850|stage IIIA anal cancer
1357325|NCT00538850|stage IIIB anal cancer
1357326|NCT00538850|stage IV anal cancer
1357327|NCT00538850|recurrent anal cancer
1357328|NCT00538850|stage 0 rectal cancer
1357329|NCT00538850|stage I rectal cancer
1357330|NCT00538850|stage II rectal cancer
1357331|NCT00538850|stage III rectal cancer
1357332|NCT00538850|stage IV rectal cancer
1357333|NCT00538850|recurrent rectal cancer
1357334|NCT00538850|stage 0 esophageal cancer
1357335|NCT00538850|stage I esophageal cancer
1357336|NCT00538850|stage II esophageal cancer
1357337|NCT00538850|stage III esophageal cancer
1357338|NCT00538850|stage IV esophageal cancer
1357339|NCT00538850|recurrent esophageal cancer
1357340|NCT00538850|stage I thymoma
1357341|NCT00538850|stage II thymoma
1357342|NCT00538850|stage III thymoma
1357343|NCT00538850|stage IVA thymoma
1357344|NCT00538850|stage IVB thymoma
1357345|NCT00538850|recurrent melanoma
1357346|NCT00538850|stage 0 melanoma
1357347|NCT00538850|stage IA melanoma
1357348|NCT00538850|stage IB melanoma
1357349|NCT00538850|stage IIA melanoma
1357350|NCT00538850|stage IIB melanoma
1357351|NCT00538850|stage IIC melanoma
1357352|NCT00538850|stage IIIA melanoma
1357353|NCT00538850|stage IIIB melanoma
1357354|NCT00538850|stage IIIC melanoma
1357355|NCT00538850|stage IV melanoma
1357356|NCT00538824|myeloma
1357357|NCT00538824|relapsed or refractory multiple myeloma
1357358|NCT00538798|Pharmacokinetics
1357359|NCT00538798|Binding Potential
1357360|NCT00538798|Glutamate
1357361|NCT00538798|Positron Emission Tomography
1357362|NCT00538798|Metabolic Glutamate Receptors
1357363|NCT00538798|Healthy Volunteer
1357364|NCT00538798|HV
1357365|NCT00538785|Synagis, motavizumab, palivizumab, children, MEDI-524, RSV, congenital hear disease
1357366|NCT00538772|Metastatic Renal Cell Carcinoma
1357367|NCT00538772|Biomarkers
1357368|NCT00538772|Biomarkers in patients with Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
1357369|NCT00538733|myeloma
1357370|NCT00538733|newly diagnosed multiple myeloma
1357371|NCT00538720|Primary Hyperparathyroidism
1357372|NCT00538720|PHPT
1357373|NCT00538720|Parathyroid glands
1357374|NCT00538720|Vitamin D deficiency
1357375|NCT00538720|Vitamin D
1357376|NCT00538720|Ergocalciferol
1357377|NCT00538707|mental stress
1357378|NCT00538707|platelet adhesion
1357379|NCT00538707|platelet function
1357380|NCT00538707|catecholamines
1357381|NCT00538694|Moderate to severe community-acquired acute bacterial pneumonia due to S. Pneumoniae
1357382|NCT00538668|Prostate
1357383|NCT00538668|Prostate Cancer
1357384|NCT00538668|Prostate Ca
1357385|NCT00538655|amphetamine
1357386|NCT00538655|methamphetamine
1357387|NCT00538655|addition
1357388|NCT00538655|treatment study
1357389|NCT00538655|drug use
1357390|NCT00538655|modafinil
1357391|NCT00538642|schizophrenia
1357392|NCT00538642|antipsychotics
1357393|NCT00538642|diabetes
1357394|NCT00538642|bipolar disorder
1357395|NCT00538616|Brain Injury
1357396|NCT00538590|ologen
1357397|NCT00538590|collagen matrix
1357398|NCT00538590|glaucoma
1357399|NCT00538590|trabeculectomy
1357400|NCT00538590|Mitomycin-C
1357401|NCT00538577|Necrotizing fasciitis
1357402|NCT00538564|prolonged, painful erection
1357403|NCT00538564|priapism
1357404|NCT00538564|sickle cell anemia
1357405|NCT00538551|HD
1357406|NCT00538551|NHL
1357407|NCT00538538|Macular Degeneration
1357408|NCT00538538|AMD
1357409|NCT00538538|Hemorrhage
1357410|NCT00538538|Wet AMD
1357411|NCT00538512|Influenza
1357412|NCT00538512|Live attenuated influenza vaccine
1357413|NCT00538512|Inactivated influenza vaccine
1357414|NCT00538512|Vaccine Efficacy
1357415|NCT00538499|pain
1357416|NCT00538499|perioperative/postoperative complications
1357417|NCT00538486|Hypertension
1357418|NCT00538486|Abdominal obesity
1357419|NCT00538486|Treatment
1357420|NCT00538473|GSK Bio's influenza vaccine GSK576389A
1357421|NCT00538473|Influenza Infection
1357422|NCT00538473|Fluarix
1357423|NCT00538460|tomography
1357424|NCT00538460|coronary artery disease
1357425|NCT00538460|magnetic resonance imaging
1357426|NCT00538447|CML
1357427|NCT00538434|Eosinophilic Esophagitis
1357428|NCT00538434|GERD
1357429|NCT00538434|EE
1357430|NCT00538434|Reslizumab
1357431|NCT00538434|IL-5
1357432|NCT00538434|Interleukin-5
1357433|NCT00538434|Cinquil
1357434|NCT00538421|propofol
1357435|NCT00538421|Anaesthesia
1357436|NCT00538421|Sevoflurane
1357437|NCT00538421|Abdominal
1357438|NCT00538421|Aortic
1357439|NCT00538421|Aneurysm
1357440|NCT00538408|Magnetic resonance
1357441|NCT00538408|whole body
1357442|NCT00538408|angiography
1357443|NCT00538408|vasovist
1357444|NCT00538408|gadofosveset
1357445|NCT00538408|dotarem
1357446|NCT00538408|blood pool agent
1357447|NCT00538382|Malaria
1357448|NCT00538382|Pregnancy
1357449|NCT00538382|Artesunate
1357450|NCT00538382|Pharmacokinetics
1357451|NCT00538382|Pharmacodynamics
1357452|NCT00538382|Democratic Republic of Congo
1357453|NCT00538369|Nursing
1357454|NCT00538369|critical care
1357455|NCT00538369|sedation assessment
1357456|NCT00538369|Bispectral index
1357457|NCT00538356|Heart failure
1357458|NCT00538356|Rehospitalization:
1357459|NCT00538356|Packer composite score
1357460|NCT00538356|Home Monitoring
1357461|NCT00538356|Cardiac resynchronization therapy
1357462|NCT00538356|Implantable cardioverter-defibrillator
1357463|NCT00538343|brain metastases
1357464|NCT00538343|breast cancer
1357465|NCT00538317|Acute myocardial infarction,
1357466|NCT00538317|GPIIbIIIa inhibitors,
1357467|NCT00538317|primary angioplasty,
1357468|NCT00538317|tirofiban
1357469|NCT00538291|recurrent colon cancer
1357470|NCT00538291|stage IV colon cancer
1357471|NCT00538291|recurrent rectal cancer
1357472|NCT00538291|stage IV rectal cancer
1357473|NCT00538278|AML
1357474|NCT00538265|liver transplantation, hepatitis C virus, immunoprophylaxis
1357475|NCT00538252|drug use, antisocial behavior, early intervention, prevention
1357476|NCT00538213|Influenza vaccine GSK576389A
1357477|NCT00538213|Fluarix
1357478|NCT00538213|Influenza infection
1357479|NCT00538200|Nutrition
1357480|NCT00538200|COPD
1357481|NCT00538161|Acute lung injury
1357482|NCT00538161|cardiac surgery
1357483|NCT00538161|The incidence of ARDS after elective cardiac surgery is 1-3%
1357484|NCT00538161|The impairment of lung function and oxygenation may occur in 20-80% of patients undergoing surgery.
1357485|NCT00538161|The purpose of this study is to assess the efficacy of low tidal volume ventilation.
1357486|NCT00538161|Reducing interleukin and cytokine production may prevent or reduce the incidence of acute lung injury.
1357487|NCT00538135|randomised controlled trial
1357488|NCT00538135|borderline personality disorder
1357489|NCT00538135|cognitive behavioural therapy
1357490|NCT00538135|treatment as usual
1357491|NCT00538122|schizophrenia
1357492|NCT00538122|schizoaffective disorder
1357493|NCT00538122|bipolar disorder
1357494|NCT00538122|antipsychotic drug treatment
1357495|NCT00538122|safety
1357496|NCT00538122|arrythmias
1357497|NCT00538109|CML in Blast Crisis
1357498|NCT00538109|Accelerated Phase oe Chronic Phase
1357499|NCT00538096|B-cell Non-Hodgkin's Lymphoma
1357500|NCT00538083|Cocoa
1357501|NCT00538083|Overweight adults
1357502|NCT00538083|Endothelial function
1357503|NCT00538083|Blood pressure
1357504|NCT00538083|Cardiovascular disease risk
1357505|NCT00538083|Dark chocolate
1357506|NCT00538083|Sugar
1357507|NCT00538070|Sarcosine
1357508|NCT00538070|Glycine
1357509|NCT00538070|Magnetic Resonance Spectroscopy
1357510|NCT00538070|Schizophrenia
1357511|NCT00538057|Healthy volunteers
1357512|NCT00538044|pulmonary hypertension
1357513|NCT00538044|simvastatin
1357514|NCT00538044|advanced pulmonary hypertension secondary to congenital heart disease
1357515|NCT00538044|advanced pulmonary hypertension secondary to chronic pulmonary embolism
1357516|NCT00538005|recurrent melanoma
1357517|NCT00538005|stage IV melanoma
1357518|NCT00537992|combined surgery,
1357519|NCT00537992|cataract surgery,
1357520|NCT00537992|vitrectomy,
1357521|NCT00537992|blue light-filter iols
1357522|NCT00537979|Dialysis
1357523|NCT00537979|Hyperparathyroidism
1357524|NCT00537979|Zemplar
1357525|NCT00537966|Primary HIV Infection
1357526|NCT00537953|Leishmaniasis
1357527|NCT00537953|Cutaneous leishmaniasis
1357528|NCT00537953|Miltefosine
1357529|NCT00537953|Glucantime
1357530|NCT00537953|Antimony
1357531|NCT00537953|Pentavalent antimonials
1357532|NCT00537953|Combination therapy
1357533|NCT00537927|laparoscopic correction
1357534|NCT00537927|ventral and incisional hernia
1357535|NCT00537927|mesh fixation
1357536|NCT00537927|postoperative pain
1357537|NCT00537914|Small for Gestational Age, Omnitrope®/Somatropin, rhGH,SGA
1357538|NCT00536926|telemedicine
1357539|NCT00536926|lung transplantation
1357540|NCT00536926|home spirometry
1357541|NCT00536913|Symbicort pMDI
1357542|NCT00536913|spacer
1357543|NCT00536913|children
1357548|NCT00536900|alcohol abuse
1357549|NCT00536900|case management
1357550|NCT00536900|dual diagnosis
1357551|NCT00536874|adenocarcinoma of the pancreas
1357552|NCT00536874|stage IA pancreatic cancer
1357553|NCT00536874|stage IB pancreatic cancer
1357554|NCT00536874|stage IIA pancreatic cancer
1357555|NCT00536874|stage IIB pancreatic cancer
1357556|NCT00536874|stage III pancreatic cancer
1357557|NCT00536861|erlotinib
1357558|NCT00536861|cranial radiotherapy
1357559|NCT00536848|Probiotics
1357560|NCT00536848|HIV
1357561|NCT00536848|AIDS
1357562|NCT00536848|Diarrhea
1357563|NCT00536848|Lactobacillus rhamnosus GR-1
1357564|NCT00536848|Lactobacillus reuteri RC-14
1357565|NCT00536848|Immune system
1357566|NCT00536848|Infectious Diseases
1357567|NCT00536848|Complementary Therapies
1357568|NCT00536848|Treatment Naive
1357569|NCT00536835|Non-Hodgkins Lymphoma
1357570|NCT00536835|Cancer
1357571|NCT00536835|First time in human
1357572|NCT00536835|PLK1 inhibitor
1357573|NCT00536835|Advanced Solid Tumor
1357574|NCT00536835|GSK461364
1357575|NCT00536822|rehabilitation
1357576|NCT00536822|pediatrics
1357577|NCT00536809|fluoropyrimidines cancers
1357578|NCT00536809|Metastatic Colorectal Cancer
1357579|NCT00536809|Advanced Colorectal Cancer
1357580|NCT00536809|oxaliplatin
1357581|NCT00536809|lapatinib
1357582|NCT00536809|capecitabine
1357583|NCT00536796|Hyperlipidemia
1357584|NCT00536796|Need-to-treat
1357585|NCT00536796|NIS
1357586|NCT00536796|Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes
1357587|NCT00536783|Psychiatry
1357588|NCT00536783|Antipsychotic
1357589|NCT00536783|Psychopharmacology
1357590|NCT00536783|Clinical Trial
1357591|NCT00536783|Open Label
1357592|NCT00536783|Schizophrenia
1357593|NCT00536783|Sensory Gating
1357594|NCT00536783|Attention
1357595|NCT00536783|Memory
1357596|NCT00536731|Asthma
1357597|NCT00536731|Symbicort
1357598|NCT00536718|invasive lobular breast carcinoma with predominant in situ component
1357599|NCT00536718|invasive lobular breast carcinoma
1357600|NCT00536718|lobular breast carcinoma in situ
1357601|NCT00536705|asthma
1357602|NCT00536705|child
1357603|NCT00536705|transforming growth factor beta(TGF-β)
1357604|NCT00536705|Leukotriene Antagonists(Montelukast)
1357605|NCT00536692|macular edema
1357606|NCT00536692|DME
1357607|NCT00536692|diabetic
1357608|NCT00536692|mecamylamine
1357609|NCT00536692|Comentis
1357610|NCT00536679|GSK163090
1357611|NCT00536679|Relative Bioavailability
1357612|NCT00536679|Food Effect
1357613|NCT00536679|Randomised
1357614|NCT00536666|Chronic kidney disease
1357615|NCT00536666|Aneamia
1357616|NCT00536666|Iron oligosaccharide
1357617|NCT00536666|Chronic kidney disease patients
1357618|NCT00536653|prostate cancer
1357619|NCT00536653|bone density
1357620|NCT00536653|osteoporosis
1357621|NCT00536653|androgen antagonists
1357622|NCT00537901|Colon and Rectum Cancer
1357623|NCT00537862|Kidney Transplant Patients
1357624|NCT00537862|Immunosuppresion
1357625|NCT00537862|Enteric-coated mycophenolate sodium
1357626|NCT00537836|Hot flushes
1357627|NCT00537836|Therapy of hot flushes
1357628|NCT00537836|17ß-estradiol (E2)
1357629|NCT00537836|Hormone replacement therapy
1357630|NCT00537823|Colorectal Cancer
1357631|NCT00537823|Metastasis
1357632|NCT00537823|Neoadjuvant Therapy
1357633|NCT00537810|Obesity
1357634|NCT00537810|Binge eating
1357635|NCT00537810|Sibutramine
1357636|NCT00537810|Self-help
1357637|NCT00537810|Primary care
1357638|NCT00537797|Thyroid Neoplasms
1357639|NCT00537797|Positron Emission Tomography
1357640|NCT00537797|18FDG
1357641|NCT00537784|platelets tendon ligament
1357642|NCT00537771|Early Breast cancer
1357643|NCT00537771|adjuvant therapy
1357644|NCT00537771|hormone receptor
1357645|NCT00537771|hormonal therapy
1357646|NCT00537771|anastrozole
1357647|NCT00537771|tamoxifen
1357648|NCT00537758|binge eating disorder
1357649|NCT00537758|cognitive behavior therapy
1357650|NCT00537758|combination therapy
1357651|NCT00537758|obesity
1357652|NCT00537758|weight loss
1357653|NCT00537758|body weight
1357654|NCT00537758|clinical trial
1357655|NCT00537758|dietary restriction
1357656|NCT00537758|overeating
1357657|NCT00537758|weight control
1357658|NCT00537732|gastro-oesophageal reflux disease
1357659|NCT00537719|healthy
1357660|NCT00537719|pharmacodynamics
1357661|NCT00537719|glucagon-like peptide 1
1357662|NCT00537719|pharmacokinetics
1357663|NCT00537719|scintigraphy
1357664|NCT00537719|radiation
1357665|NCT00537719|albiglutide
1357666|NCT00537706|Socioeconomic Determinants
1357667|NCT00537706|Health Status
1357668|NCT00537706|Low-income
1357669|NCT00537706|Priority-setting
1357670|NCT00537706|Group Discussion
1357671|NCT00537693|Continuous Renal Replacement Therapy (CRRT)
1357672|NCT00537693|Sepsis
1357673|NCT00537693|Convection
1357674|NCT00537693|Diffusion
1357675|NCT00537680|Friedreich's Ataxia
1357676|NCT00537680|Idebenone
1357677|NCT00537680|ICARS
1357678|NCT00537667|IL-1ra
1357679|NCT00537667|PEG sTNF-RI
1357680|NCT00537667|Synovial biopsy
1357681|NCT00537667|Inflammation
1357682|NCT00537667|Bone and Cartilage Destruction
1357683|NCT00537667|Rheumatoid Arthritis
1357684|NCT00537654|benign prostatic hyperplasia,
1357685|NCT00537654|AVODART,
1357686|NCT00537654|FLOMAX
1357687|NCT00537641|noninvasive ventilation
1357688|NCT00537602|cystic fibrosis
1357689|NCT00537602|miglustat
1357690|NCT00537602|Zavesca
1357691|NCT00537602|Actelion
1357692|NCT00537602|nasal potential difference
1357693|NCT00537602|transmembrane conductance regulator (CFTR)
1357694|NCT00537589|arthrocentesis
1357695|NCT00537589|ultrasound
1357696|NCT00537589|emergency
1357697|NCT00537550|ALL
1357698|NCT00537550|Adult
1357700|NCT00537524|Bird flu
1357701|NCT00537524|seasonal influenza vaccine
1357702|NCT00537524|influenza vaccine
1357703|NCT00537524|prepandemic vaccine
1357704|NCT00537524|virus strain with the potential to cause pandemic
1357705|NCT00537524|toddlers
1357706|NCT00537524|children
1357707|NCT00537524|adolescents
1357708|NCT00537498|urokinase, diabetes, wound healing, major amputation
1357709|NCT00537485|SPM 962
1357710|NCT00537485|rotigotine
1357711|NCT00537485|Parkinson's disease
1357712|NCT00537485|monotherapy
1357713|NCT00537472|Bupivacaine
1357714|NCT00537472|spinal anesthesia
1357715|NCT00537472|total knee arthroplasty
1357716|NCT00537459|Premature ejaculation (PE) ejaculatory latency time (ELT)
1357717|NCT00537446|noninvasive ventilation
1357718|NCT00537433|Medication errors
1357719|NCT00537433|Patient nonadherence
1357720|NCT00537433|Literacy
1357721|NCT00537433|Communication
1357722|NCT00537420|weight loss
1357723|NCT00537420|dieting
1357724|NCT00537407|Hepatitis
1357725|NCT00537407|Hepatitis C
1357726|NCT00537394|Treatment Experienced
1357727|NCT00537381|Prostatic neoplasms
1357728|NCT00537381|CNTO 95
1357729|NCT00537381|Intetumumab
1357730|NCT00537381|Docetaxel
1357731|NCT00537381|Prednisone
1357732|NCT00537368|infusion
1357733|NCT00537368|CNTO 888
1357734|NCT00537368|Phase 1
1357735|NCT00537368|solid tumor
1357736|NCT00537368|cancer
1357737|NCT00537355|ragweed
1357738|NCT00537355|ragweed allergy
1357739|NCT00537355|allergy
1357740|NCT00537355|allergies
1357741|NCT00537355|allergic
1357742|NCT00537355|seasonal allergic rhinitis
1357743|NCT00537355|allergic rhinitis
1357744|NCT00537342|Immunotherapy
1357745|NCT00537342|Allergoid
1357746|NCT00537342|Depigmented
1357747|NCT00537342|Polymerized
1357748|NCT00537342|Allergen-extract
1357749|NCT00537342|Rhinoconjunctivitis
1357750|NCT00537290|antiphospholipid syndrome
1357751|NCT00537264|health-related quality of life
1357752|NCT00537264|primary care
1357753|NCT00537264|computer-assisted instruction
1357754|NCT00537238|Epilepsies partial
1357755|NCT00537238|Partial Seizure Disorder
1357756|NCT00537238|Complex Partial Seizure Disorder
1357757|NCT00537238|Epilepsy
1357758|NCT00537225|peripheral arterial disease
1357759|NCT00537225|walking time
1357760|NCT00537225|lifestyle modification
1357761|NCT00537225|cardiovascular risk reduction
1357762|NCT00537225|exercise
1357763|NCT00537225|diet
1357764|NCT00537225|claudication
1357765|NCT00537212|Psoriasis
1357766|NCT00537212|Weight loss
1357767|NCT00537212|diet
1357768|NCT00537199|Head And Neck
1357769|NCT00537199|Oropharynx
1357770|NCT00537199|Oral Cancer
1357771|NCT00537199|OraTest
1357772|NCT00537199|OraTest Dye
1357773|NCT00537199|Rinse Staining Procedure
1357774|NCT00537199|Visual Examination
1357775|NCT00537186|Congestive heart failure
1357776|NCT00537186|Anaemia
1357777|NCT00537186|Iron oligosaccharide
1357778|NCT00537160|Pediatrics
1357779|NCT00537147|Chimeric West Nile Virus
1357780|NCT00537147|West Nile Virus
1357781|NCT00537147|Dengue Virus
1357782|NCT00537134|Aneurysm
1357783|NCT00537134|Brain
1357784|NCT00537134|Unruptured
1357785|NCT00537134|observation
1357786|NCT00537134|treatment
1357787|NCT00537134|Endovascular
1357788|NCT00537121|recurrent gastric cancer
1357789|NCT00537121|stage IV gastric cancer
1357790|NCT00537121|recurrent esophageal cancer
1357791|NCT00537121|stage IV esophageal cancer
1357792|NCT00537121|adenocarcinoma of the esophagus
1357793|NCT00537121|adenocarcinoma of the stomach
1357794|NCT00537121|squamous cell carcinoma of the esophagus
1357795|NCT00537121|adult primary hepatocellular carcinoma
1357796|NCT00537121|stage III gastric cancer
1357797|NCT00537121|stage III esophageal cancer
1357798|NCT00537121|advanced adult primary liver cancer
1357799|NCT00537121|localized unresectable adult primary liver cancer
1357800|NCT00537121|recurrent adult primary liver cancer
1357801|NCT00537108|Pregnancy in adolescence
1357802|NCT00537095|follicular
1357803|NCT00537095|papillary
1357804|NCT00537082|FTY720,
1357805|NCT00537082|MS
1357806|NCT00537043|hypertension,
1357807|NCT00537043|carvedilol,
1357808|NCT00537043|repeat-dosing
1357809|NCT00537004|primary progressive aphasia
1357810|NCT00537004|frontotemporal dementia
1357811|NCT00537004|semantic dementia
1357812|NCT00537004|progressive nonfluent aphasia
1357813|NCT00537004|progressive aphasia
1357814|NCT00537004|frontotemporal lobar degeneration
1357815|NCT00536978|Lymphoma
1357816|NCT00536978|Leukemia
1357817|NCT00536978|B-Cell Lymphoid Malignancies
1357818|NCT00536978|CLL
1357819|NCT00536978|Cll/Small Lymphocytic Lymphoma
1357820|NCT00536978|Follicular Lymphoma
1357821|NCT00536978|Mantle Cell Lymphoma
1357822|NCT00536978|Diffuse Large Cell Lymphoma
1357823|NCT00536978|Splenic Lymphoma
1357824|NCT00536978|MALT
1357825|NCT00536978|Lymphoplasmacytic Lymphoma
1357826|NCT00536978|Burkitt's Lymphoma
1357827|NCT00536978|ARA-C
1357828|NCT00536978|BCNU
1357829|NCT00536978|Campath-1H
1357830|NCT00536978|Cytoxan
1357831|NCT00536978|Etoposide
1357832|NCT00536978|Fludarabine
1357833|NCT00536978|Melphalan
1357834|NCT00536978|Rituximab
1357835|NCT00536978|Allogeneic Stem Cell Transplant
1357836|NCT00536978|T-Cell Cell Adback
1357837|NCT00536978|Natural Killer (NK) Cell Adback
1357838|NCT00536965|Hyperlipidemia
1357839|NCT00536965|Need-to-treat
1357840|NCT00536965|NIS
1357841|NCT00536965|Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes
1357842|NCT00536952|recurrent squamous cell carcinoma of the hypopharynx
1357843|NCT00536952|stage III squamous cell carcinoma of the hypopharynx
1357844|NCT00536952|stage IV squamous cell carcinoma of the hypopharynx
1357845|NCT00536952|stage III squamous cell carcinoma of the larynx
1357846|NCT00536952|stage IV squamous cell carcinoma of the larynx
1357847|NCT00536952|recurrent squamous cell carcinoma of the larynx
1357848|NCT00536952|recurrent squamous cell carcinoma of the lip and oral cavity
1357849|NCT00536952|stage III squamous cell carcinoma of the lip and oral cavity
1357850|NCT00536952|stage IV squamous cell carcinoma of the lip and oral cavity
1357851|NCT00536952|recurrent squamous cell carcinoma of the nasopharynx
1357852|NCT00536952|stage III squamous cell carcinoma of the nasopharynx
1357853|NCT00536952|stage IV squamous cell carcinoma of the nasopharynx
1357854|NCT00536952|recurrent squamous cell carcinoma of the oropharynx
1357855|NCT00536952|stage III squamous cell carcinoma of the oropharynx
1357856|NCT00536952|stage IV squamous cell carcinoma of the oropharynx
1357857|NCT00536640|Non Small Cell Lung Carcinoma (NSCLC Stage III an IV)
1357858|NCT00536627|DNA vaccine
1357859|NCT00536614|pancreatic cancer
1357860|NCT00536614|metastatic
1357861|NCT00536614|EGFR
1357862|NCT00536614|locally advanced pancreatic cancer
1357863|NCT00536575|Multiple Myeloma
1357864|NCT00536575|Relapsed
1357865|NCT00536575|Refractory
1357866|NCT00536575|Sorafenib
1357867|NCT00536575|Bortezomib
1357868|NCT00536562|Comprehensive Cardiac Rehabilitation
1357869|NCT00536562|Randomized Controlled Trial
1357870|NCT00536562|TIA (Transient Ischemic Attack)
1357871|NCT00536562|Mild Non-Disabling Stroke
1357872|NCT00536562|Vascular Protection
1357873|NCT00536549|Glucose monitoring system
1357874|NCT00536549|life style intervention
1357875|NCT00536536|Childhood
1357876|NCT00536536|Obesity
1357877|NCT00536536|Primary Care
1357878|NCT00536523|constipation, impaction, and bowel obstruction
1357879|NCT00536523|ovarian epithelial cancer
1357880|NCT00536523|peritoneal cavity cancer
1357881|NCT00536523|fallopian tube cancer
1357882|NCT00536510|High Cholesterol
1357883|NCT00536510|Excess lipids
1357884|NCT00536497|GW842166,
1357885|NCT00536497|Healthy volunteers,
1357886|NCT00536497|Inflammatory Pain.
1357887|NCT00536484|Overactive Bladder
1357888|NCT00536458|localized low grade lymphoma
1357889|NCT00536458|Chemotherapy
1357890|NCT00536458|Radiotherapy
1357891|NCT00536458|Molecular analyses
1357892|NCT00536458|primary
1357893|NCT00536445|NAVA
1357894|NCT00536445|Preterm
1357895|NCT00536445|Case study
1357896|NCT00536406|Geriatric
1357897|NCT00536406|Nursing Homes
1357898|NCT00536393|diffuse larg cells lymphoma
1357899|NCT00536393|chemotherapy
1357900|NCT00536393|toxicity
1357901|NCT00536393|diffuse high grade lymphoma
1357902|NCT00536367|Heart Failure, Congestive
1357903|NCT00536367|Mortality Prediction Model
1357904|NCT00536341|Chronic Lymphocytic Leukemia
1357905|NCT00536341|untreated
1357906|NCT00536341|minimally treated
1357907|NCT00536341|fludarabine
1357908|NCT00536341|rituximab
1357909|NCT00536341|lenalidomide
1357910|NCT00536328|Reflux Impact Scale (RIS)
1357911|NCT00536328|predictive value
1357912|NCT00536328|treatment success
1357913|NCT00536328|patient satisfaction
1357914|NCT00536328|proton pump inhibitor
1357915|NCT00536328|gastro-esophageal reflux disease
1357916|NCT00536328|PPU
1357917|NCT00536315|COPD
1357918|NCT00536302|OA
1357919|NCT00536302|Knee arthritis
1357920|NCT00536302|Osteoarthritis
1357921|NCT00536302|Nutritional supplement
1357922|NCT00536302|CAM
1357923|NCT00536302|MRI
1357924|NCT00536289|Blunt needles
1357925|NCT00536289|obstetric lacerations
1357926|NCT00536289|Needlestick injuries
1357927|NCT00536289|Needlestick injuries to physicians
1357928|NCT00536276|vitamin D
1357929|NCT00536250|Pre-Diabetes
1357930|NCT00536250|Childhood Obesity
1357931|NCT00536250|Metabolic Syndrome
1357932|NCT00536250|insulin resistance
1357933|NCT00536250|Impaired Glucose Tolerance
1357934|NCT00536250|Non Alcoholic Fatty Liver Disease
1357935|NCT00536250|High Molecular Weight Adiponectin
1357936|NCT00536250|Hypoadiponectinemia
1357937|NCT00536224|Health promotion
1357938|NCT00536224|Emergency Medical Services
1357939|NCT00536224|Randomized controlled trial
1357940|NCT00536224|Chest pain observation unit
1357941|NCT00536224|Cardiovascular risk factors
1357942|NCT00536211|Exercise
1357943|NCT00536211|Physical Activity
1357944|NCT00536211|Metformin
1357945|NCT00536211|Hyperinsulinemic-Euglycemic Clamp
1357946|NCT00536211|Muscle Biopsy
1357947|NCT00536211|Fatty Acid Oxidation
1357948|NCT00536211|Peroxisome proliferator-activated receptor gamma
1357949|NCT00536211|Detraining
1357950|NCT00536211|Inactivity
1357951|NCT00536211|Skeletal muscle
1357952|NCT00536198|Premenstrual Syndrome
1357953|NCT00536185|ALOX5
1357954|NCT00536185|5-lipoxygenase
1357955|NCT00536185|Heart Disease
1357956|NCT00536185|Blacks
1357957|NCT00536172|Antidepressant
1357958|NCT00536172|Major depression
1357959|NCT00536172|Prevention
1357960|NCT00536172|Head and neck cancer
1357961|NCT00536159|nurse-community health worker team
1357962|NCT00536159|perinatal depression
1357963|NCT00536159|stress
1357964|NCT00536159|Medicaid enhanced prenatal programs
1357965|NCT00536146|Glucocorticoid
1357966|NCT00536146|Steroids
1357967|NCT00536146|Dose-Responsive Curve
1357968|NCT00536146|EC50
1357969|NCT00536146|Stress Response
1357970|NCT00536146|Alcoholism
1357971|NCT00536133|zinc
1357972|NCT00536133|aute lower respiratory infections
1357973|NCT00536120|MS
1357974|NCT00536120|Multiple sclerosis
1357975|NCT00536120|Relapsing forms of Multiple Sclerosis
1357976|NCT00536107|Non-Small Cell Lung Cancer
1357977|NCT00536107|Locally Advanced or Metastatic NSCL Cancer
1357978|NCT00536094|Cognitive behavioral therapy
1357979|NCT00536094|Youth
1357980|NCT00536094|School
1357981|NCT00536094|African American
1357982|NCT00536081|Breast cancer
1357983|NCT00536081|Adjuvant
1357984|NCT00536081|Advanced
1357985|NCT00536081|Chemotherapy
1357986|NCT00536081|G-CSF
1357987|NCT00536081|Pegfilgrastim
1357988|NCT00536081|Prevention
1357989|NCT00536081|Febrile neutropenia
1357990|NCT00536068|platelet
1357991|NCT00536068|aggregation
1357992|NCT00536068|aspirin
1357993|NCT00536055|breast cancer
1357994|NCT00536055|prostate cancer
1357995|NCT00536055|dyadic coping
1357996|NCT00536042|minocycline
1357997|NCT00536042|asthma
1357998|NCT00536042|oral steroids
1357999|NCT00536042|IgE
1358000|NCT00536029|Melanoma
1358001|NCT00536029|SIAscope
1358002|NCT00536029|pigmented skin lesions
1358003|NCT00536016|AMD
1358004|NCT00536016|Neovascular Age-Related Macular Degeneration
1358005|NCT00536003|preterm delivery
1358006|NCT00536003|preterm labor
1358007|NCT00536003|perinatal morbidity
1358008|NCT00536003|perinatal mortality
1358009|NCT00535990|Cholecystectomy
1358010|NCT00535990|Appendectomy
1358011|NCT00535990|Esophageal
1358012|NCT00535990|Surgical
1358013|NCT00535990|Procedures
1358014|NCT00535990|Surgery
1358015|NCT00535990|Gastric
1358016|NCT00535990|bypass
1358017|NCT00535977|Gene expression
1358018|NCT00535977|Prostate
1358019|NCT00535977|Broccoli
1358020|NCT00535977|Cancer
1358021|NCT00535977|Men diagnosed with high-grade Prostatic Intraepithelia Neoplasia
1358022|NCT00535964|Cigarette Smoking
1358023|NCT00535964|Tobacco Use
1358024|NCT00535964|Adolescents
1358025|NCT00535964|Anxiety Sensitivity (AS)
1358026|NCT00535951|Non-small cell lung cancer
1358027|NCT00535951|NSCLC
1358028|NCT00535951|lung cancer
1358029|NCT00535951|pleural mesothelioma
1358030|NCT00535951|malignant
1358031|NCT00535951|advanced stage
1358032|NCT00535951|mesothelioma
1358033|NCT00535951|phase I
1358034|NCT00535951|LBH589
1358035|NCT00535951|dextromethorphan
1358036|NCT00535951|CYP2D6
1358037|NCT00535951|oral
1358038|NCT00535925|type 2 diabetes
1358039|NCT00535925|nephropathy
1358040|NCT00535925|CV events
1358041|NCT00535912|CLL
1358042|NCT00535899|Aortic stenosis
1358043|NCT00535899|Speckle tracking imaging
1358044|NCT00535899|Low ejection fraction
1358045|NCT00535899|Aortic valve replacement
1358046|NCT00535899|Strain
1358047|NCT00535886|Trans Fatty Acids
1358048|NCT00535886|conjugated linoleic acid
1358049|NCT00535886|vaccenic acid
1358050|NCT00535886|High Density Lipoprotein Cholesterol
1358051|NCT00535886|Low Density Lipoprotein Cholesterol
1358052|NCT00535886|Beef
1358053|NCT00535873|Leukemia
1358054|NCT00535873|CLL
1358055|NCT00535873|chronic lymphocytic leukemia
1358056|NCT00535873|SLL
1358057|NCT00535873|small lymphocytic lymphoma
1358058|NCT00535873|Untreated CLL
1358059|NCT00535873|Lenalidomide
1358060|NCT00535873|CC-5013
1358061|NCT00535873|Revlimid
1358062|NCT00535873|Oral
1358063|NCT00535860|Osteoporosis
1358064|NCT00535860|Transdermal
1358065|NCT00535860|hPTH(1-34)
1358066|NCT00535847|Genotype 1
1358067|NCT00535834|stage I prostate cancer
1358068|NCT00535834|stage II prostate cancer
1358069|NCT00535834|stage III prostate cancer
1358070|NCT00535834|adenocarcinoma of the prostate
1358071|NCT00535821|Emergency Department
1358072|NCT00535821|Hemodynamic Optimization
1358073|NCT00535821|Esophageal Doppler monitoring
1358074|NCT00535821|Early Goal-Directed Therapy
1358075|NCT00535769|topical
1358076|NCT00535769|medication adherence
1358077|NCT00535769|adherence
1358078|NCT00535769|compliance
1358079|NCT00535769|medication compliance
1358080|NCT00535769|sunscreen
1358081|NCT00535769|reminder
1358082|NCT00535756|Pancreatic Exocrine Insufficiency After Pancreatic Surgery
1358083|NCT00535717|Urethral stricture
1358084|NCT00535717|Ayurvedic treatment
1358085|NCT00535717|mutra marg sankoch
1358086|NCT00535717|uttarbasti
1358087|NCT00535717|Sesame oil
1358088|NCT00535717|Honey
1358089|NCT00535717|Rock salt
1358090|NCT00535678|Mammography
1358091|NCT00535678|mammogram
1358092|NCT00535678|breast
1358093|NCT00535678|Abnormal and normal breast tissue
1358094|NCT00535639|Tolerability of ALK Tree Tablet in patients with birch pollen induced allergy
1358095|NCT00535600|Bariatric Surgery
1358096|NCT00535600|Insulin Action
1358097|NCT00535600|Insulin Secretion
1358098|NCT00535600|Insulin Resistance
1358099|NCT00535600|Gut Hormones
1358100|NCT00535600|Obesity
1358101|NCT00535587|Fibromyalgia
1358102|NCT00535587|Exercise
1358103|NCT00535587|Mestinon
1358104|NCT00535574|retinoids
1358105|NCT00535574|bexarotene
1358106|NCT00535574|schizophrenia
1358107|NCT00535574|PANSS
1358108|NCT00535574|Positive and negative symptoms of schizophrenia
1358109|NCT00535561|iron deficiency anemia
1358110|NCT00535561|anemia
1358111|NCT00535561|hypothyroidism
1358112|NCT00535561|subclinical hypothyroidism
1358113|NCT00535548|Chronic wounds
1358114|NCT00535548|Pressure sores
1358115|NCT00535548|Hematopoietic stem cells
1358116|NCT00535548|Wound healing
1358117|NCT00535535|Elevated triglycerides
1358118|NCT00535535|Diabetes
1358119|NCT00535535|Cardiovascular disease
1358120|NCT00535522|Pharmacokinetics
1358121|NCT00535522|pharmacodynamics
1358122|NCT00535522|maximal tolerated dose
1358123|NCT00535483|blood microdialysis
1358124|NCT00535483|glucose monitoring
1358125|NCT00535483|glucose control
1358126|NCT00535483|automated blood sampling
1358127|NCT00535483|online-sensor
1358128|NCT00535483|algorithm
1358129|NCT00535483|type 1 diabetes
1358130|NCT00535457|anxiety
1358131|NCT00535457|maladaptive behavior
1358132|NCT00535457|anesthesia
1358133|NCT00535457|Anxiety before anesthesia and maladaptive behavior after anesthesia.
1358134|NCT00535444|Hypertension
1358135|NCT00535444|parish nurse
1358136|NCT00535431|Asthma
1358137|NCT00535431|allergy
1358138|NCT00535431|interleukin-4
1358139|NCT00535431|interleukin-13
1358140|NCT00535431|IL-4
1358141|NCT00535431|IL-13
1358142|NCT00535418|Breast cancer
1358143|NCT00535418|neoadjuvant treatment
1358144|NCT00535418|treatment duration
1358145|NCT00535418|Primary hormone receptor positive
1358146|NCT00535418|breast cancer in postmenopausal women
1358147|NCT00535405|High Cholesterol
1358148|NCT00535392|Epilepsy
1358149|NCT00535392|Child
1358150|NCT00535392|Levetiracetam
1358151|NCT00535392|Keppra®
1358152|NCT00535392|Infusion
1358153|NCT00535392|Intravenous
1358154|NCT00535379|glioblastoma multiforme
1358155|NCT00535379|sunitinib
1358156|NCT00535379|recurrent
1358157|NCT00535379|progressive
1358158|NCT00535353|recurrent colon cancer
1358159|NCT00535353|stage IV colon cancer
1358160|NCT00535353|recurrent rectal cancer
1358161|NCT00535353|stage IV rectal cancer
1358162|NCT00535353|stage III rectal cancer
1358163|NCT00535353|stage III colon cancer
1358164|NCT00535340|Anxiety
1358165|NCT00535340|Anti-Anxiety Agents
1358166|NCT00535327|Mammography
1358167|NCT00535327|mammogram
1358168|NCT00535327|breast
1358169|NCT00535327|Abnormal and normal breast tissue
1358170|NCT00535314|Melanoma
1358171|NCT00535301|cystocele
1358172|NCT00535301|uterine prolapse
1358173|NCT00535301|urinary incontinence
1358174|NCT00535275|NSCLC relapse after adjuvant chemotherapy
1358175|NCT00535262|Bipolar
1358176|NCT00535262|depression
1358177|NCT00535236|Prevention of herpes zoster and HZ-related complications
1358178|NCT00535223|Cognitive Behavior Therapy
1358179|NCT00535223|Group therapy
1358180|NCT00535223|Posttraumatic Stress Disorder
1358181|NCT00535223|Randomized Controlled Trial
1358182|NCT00535223|Treatment outcome
1358183|NCT00535223|Veterans
1358184|NCT00535223|War
1358185|NCT00535210|spinal cord injury
1358186|NCT00535210|exercise rehabilitation
1358187|NCT00535210|inpatient
1358188|NCT00535210|RCT
1358189|NCT00535210|physical function
1358190|NCT00535184|Mammography
1358191|NCT00535184|mammogram
1358192|NCT00535184|breast
1358193|NCT00535184|Abnormal and normal breast tissue
1358194|NCT00535158|Chronic Kidney disease
1358195|NCT00535158|Dialysis
1358196|NCT00535158|Vitamin D
1358197|NCT00535158|Chronic kidney disease is associated with impaired muscle strength, pain and fractures.
1358198|NCT00535145|antipsychotic
1358199|NCT00535145|paliperidone ER
1358200|NCT00535145|liver disease
1358201|NCT00535145|Schizophrenia
1358202|NCT00535145|Schizoaffective Disorder
1358203|NCT00535145|Invega
1358204|NCT00535132|schizophrenia
1358205|NCT00535132|medication satisfaction, Invega
1358206|NCT00535106|Ventricular fibrillation
1358207|NCT00535106|Cardiac arrest
1358208|NCT00535106|Automated external defibrillator
1358209|NCT00535106|AED
1358210|NCT00535106|Waveform based algorithms
1358211|NCT00535106|VF waveform analysis
1358212|NCT00535093|Pharyngitis
1358213|NCT00535093|Community infections
1358214|NCT00535093|Rapid Testing
1358215|NCT00535093|Group A Streptococcus
1358216|NCT00535080|actinic
1358217|NCT00535080|keratoses
1358218|NCT00535080|superficial
1358219|NCT00535080|basal
1358220|NCT00535080|carcinomas
1358221|NCT00535080|Bowen's
1358222|NCT00535080|large or multiple superficial Basal Carcinomas
1358223|NCT00535067|Breast Cancer
1358224|NCT00535067|Questionnaire
1358225|NCT00535067|Survey
1358226|NCT00535067|Neuropathic Pain
1358227|NCT00535067|Cancer Survivors
1358228|NCT00535067|Quality of Life
1358229|NCT00535067|QOL
1358230|NCT00535054|Dry Eye Syndrome
1358231|NCT00535041|Pilot trial of pre-operative chemo/RT using Xeloda and external beam RT followed by definite surgery in patients with localized rectal CA
1358232|NCT00535028|asthma
1358233|NCT00535028|allergy
1358234|NCT00535028|interleukin-4
1358235|NCT00535028|interleukin-13
1358236|NCT00535028|IL-4
1358237|NCT00535028|IL-13
1358238|NCT00535028|atopic
1358239|NCT00535028|late asthmatic response
1358240|NCT00535028|inflammation
1358241|NCT00535002|Cocaine Addiction
1358242|NCT00535002|Cocaine Dependence
1358243|NCT00534989|NHL and HD
1358244|NCT00534963|sonohysterography, catheter placement
1358245|NCT00534287|sepsis
1358246|NCT00534287|antibiotics
1358247|NCT00534287|carbapenems
1358248|NCT00534287|fluoroquinolones
1358249|NCT00534287|Severe sepsis and septic shock
1358250|NCT00534274|stage II breast cancer
1358251|NCT00534274|stage IIIA breast cancer
1358252|NCT00534261|Multiple Sclerosis
1358253|NCT00534261|Avonex
1358254|NCT00534261|Interferon beta-1a
1358255|NCT00534222|Patients with a manic episode
1358256|NCT00534222|Patients diagnosed w/schizophrenia, who start a treatment with an atypical antipsychotic & who are at least scored as moderately ill on the CGI at baseline
1358257|NCT00534209|stage IIIB non-small cell lung cancer
1358258|NCT00534209|stage IV non-small cell lung cancer
1358259|NCT00534196|recurrent prostate cancer
1358260|NCT00534196|stage I prostate cancer
1358261|NCT00534196|stage IIB prostate cancer
1358262|NCT00534196|stage IIA prostate cancer
1358263|NCT00534196|stage III prostate cancer
1358264|NCT00534183|Metabolic syndrome
1358265|NCT00534183|Obesity
1358266|NCT00534183|Diabetes
1358267|NCT00534170|Probiotic
1358268|NCT00534170|Prevention of diarrhoea
1358269|NCT00534170|Nutritional status
1358270|NCT00534157|intracranial pressure
1358271|NCT00534157|intraocular pressure
1358272|NCT00534157|tonometry
1358273|NCT00534118|accelerated phase chronic myelogenous leukemia
1358274|NCT00534118|chronic phase chronic myelogenous leukemia
1358275|NCT00534118|relapsing chronic myelogenous leukemia
1358276|NCT00534118|childhood chronic myelogenous leukemia
1358277|NCT00534118|previously treated myelodysplastic syndromes
1358278|NCT00534118|recurrent adult acute lymphoblastic leukemia
1358386|NCT00534729|RT
1358279|NCT00534118|recurrent childhood acute lymphoblastic leukemia
1358280|NCT00534118|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1358281|NCT00534118|adult acute myeloid leukemia with inv(16)(p13;q22)
1358282|NCT00534118|adult acute myeloid leukemia with t(15;17)(q22;q12)
1358283|NCT00534118|adult acute myeloid leukemia with t(16;16)(p13;q22)
1358284|NCT00534118|adult acute myeloid leukemia with t(8;21)(q22;q22)
1358285|NCT00534118|recurrent adult acute myeloid leukemia
1358286|NCT00534118|recurrent childhood acute myeloid leukemia
1358287|NCT00534118|stage I multiple myeloma
1358288|NCT00534118|stage II multiple myeloma
1358289|NCT00534118|stage III multiple myeloma
1358290|NCT00534118|refractory multiple myeloma
1358291|NCT00534118|recurrent adult Hodgkin lymphoma
1358292|NCT00534118|recurrent/refractory childhood Hodgkin lymphoma
1358293|NCT00534118|recurrent adult Burkitt lymphoma
1358294|NCT00534118|recurrent adult diffuse large cell lymphoma
1358295|NCT00534118|recurrent adult diffuse mixed cell lymphoma
1358296|NCT00534118|recurrent adult diffuse small cleaved cell lymphoma
1358297|NCT00534118|recurrent adult immunoblastic large cell lymphoma
1358298|NCT00534118|recurrent adult lymphoblastic lymphoma
1358299|NCT00534118|recurrent grade 1 follicular lymphoma
1358300|NCT00534118|recurrent grade 2 follicular lymphoma
1358301|NCT00534118|recurrent grade 3 follicular lymphoma
1358302|NCT00534118|recurrent mantle cell lymphoma
1358303|NCT00534118|recurrent marginal zone lymphoma
1358304|NCT00534118|recurrent small lymphocytic lymphoma
1358305|NCT00534118|recurrent adult grade III lymphomatoid granulomatosis
1358306|NCT00534118|Waldenstrom macroglobulinemia
1358307|NCT00534118|recurrent childhood grade III lymphomatoid granulomatosis
1358308|NCT00534118|recurrent childhood large cell lymphoma
1358309|NCT00534118|recurrent childhood lymphoblastic lymphoma
1358310|NCT00534118|childhood diffuse large cell lymphoma
1358311|NCT00534118|childhood immunoblastic large cell lymphoma
1358312|NCT00534118|recurrent childhood small noncleaved cell lymphoma
1358313|NCT00534118|de novo myelodysplastic syndromes
1358314|NCT00534118|secondary acute myeloid leukemia
1358315|NCT00534118|secondary myelodysplastic syndromes
1358316|NCT00534118|splenic marginal zone lymphoma
1358317|NCT00534118|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1358318|NCT00534118|nodal marginal zone B-cell lymphoma
1358319|NCT00534118|recurrent cutaneous T-cell non-Hodgkin lymphoma
1358320|NCT00534118|recurrent mycosis fungoides/Sezary syndrome
1358321|NCT00534118|cutaneous B-cell non-Hodgkin lymphoma
1358322|NCT00534105|Pregnancy
1358323|NCT00534105|Gestational diabetes
1358324|NCT00534105|Hyperlipidemia
1358325|NCT00534092|Lumbar Spinal Stenosis
1358326|NCT00534092|X STOP
1358327|NCT00534079|Cystic Fibrosis and chronic rhinosinusitis
1358328|NCT00534066|Natriuretic Peptide, Brain
1358329|NCT00534053|colon cancer screening
1358330|NCT00534053|mail reminders
1358331|NCT00534053|fecal occult blood test
1358332|NCT00534053|compliance
1358333|NCT00534027|NSCLC
1358334|NCT00534027|Non-Small Cell Lung Cancer
1358335|NCT00534027|Paclitaxel
1358336|NCT00534027|Carboplatin
1358337|NCT00534027|AMG 655
1358338|NCT00534950|Randomized multicenter study of 5 vs 6 weekly fraction of RT in the treatment of SCC of the head and neck
1358339|NCT00534937|Venous stasis ulcer
1358340|NCT00534937|Compression pump
1358341|NCT00534937|Randomized trial
1358342|NCT00534937|Flexitouch compression
1358343|NCT00534924|IR injury
1358344|NCT00534924|MRI
1358345|NCT00534924|Vitamin C
1358346|NCT00534924|Postconditioning
1358347|NCT00534911|Depression
1358348|NCT00534911|Physical Illness
1358349|NCT00534911|Inflammatory Bowel Disease
1358350|NCT00534911|Cognitive Behavioral Therapy
1358351|NCT00534885|inactivated hepatitis A vaccine
1358352|NCT00534885|Healive
1358353|NCT00534885|safety
1358354|NCT00534885|immunogenicity
1358355|NCT00534885|immune persistence
1358356|NCT00534872|4 Parallel cohorts
1358357|NCT00534872|Healthy Female
1358358|NCT00534872|Healthy Elderly
1358359|NCT00534872|Pharmacokinetic
1358360|NCT00534872|Safety and Tolerability
1358361|NCT00534846|premenstrual syndrome
1358362|NCT00534846|mastalgia
1358363|NCT00534846|toremifene
1358364|NCT00534846|selective estrogen receptor modulators
1358365|NCT00534833|Diphtheria
1358366|NCT00534833|Tetanus
1358367|NCT00534833|Pertussis
1358368|NCT00534833|Hepatitis B Hansenula (HB)
1358369|NCT00534833|Haemophilus influenzae type b
1358370|NCT00534820|Cytogenetic Analysis of Bone Marrow Specimen in Non-Hodgkin's Lymphoma or Hodgkin's Disease
1358371|NCT00534781|Achilles
1358372|NCT00534781|Tendinosis
1358373|NCT00534781|Tendinitis
1358374|NCT00534781|Achilles Tendinosis
1358375|NCT00534781|Achilles Tendinitis
1358376|NCT00534781|Coblation
1358377|NCT00534781|Bipolar Radiofrequency
1358378|NCT00534781|Surgical Debridement
1358379|NCT00534781|Debridement
1358380|NCT00534781|Heel Pain
1358381|NCT00534781|Achilles Pain
1358382|NCT00534742|Siblings
1358383|NCT00534729|Organ Preservation
1358384|NCT00534729|Carboplatin
1358385|NCT00534729|Taxol
1358387|NCT00534729|laryngeal & Hypopharyngeal CA
1358388|NCT00534729|Locally advanced laryngeal & Hypopharyngeal CA
1358389|NCT00534716|Cannabis
1358390|NCT00534716|doping
1358391|NCT00534716|THC
1358392|NCT00534716|GC/MS
1358393|NCT00534716|Pharmacokinetics
1358394|NCT00534716|Volunteers
1358395|NCT00534690|Pulmonary disease
1358396|NCT00534690|Intubation, Intratracheal
1358397|NCT00534690|Positive-pressure ventilation
1358398|NCT00534677|Variceal bleed
1358399|NCT00534677|Cirrhosis
1358400|NCT00534677|Vasoactive agents
1358401|NCT00534677|Terlipressin
1358402|NCT00534677|Octreotide
1358403|NCT00534677|Safety & Efficacy
1358404|NCT00534638|HPV vaccine
1358405|NCT00534638|Healthy adolescents
1358406|NCT00534638|Cervical cancer
1358407|NCT00534638|Safety
1358408|NCT00534638|Immunogenicity
1358409|NCT00534638|Cervarix
1358410|NCT00534625|Asthma, exacerbation, pulmonary function
1358411|NCT00534612|Parotid gland neoplasms
1358412|NCT00534599|Generalized anxiety disorders
1358413|NCT00534599|anxiety
1358414|NCT00534599|adjunct treatment in anxiety
1358415|NCT00534599|anxiety disorder
1358416|NCT00534599|partial or non-responder in anxiety
1358417|NCT00534586|Pain
1358418|NCT00534586|SSEP
1358419|NCT00534586|CHEPS
1358420|NCT00534586|Propofol
1358421|NCT00534586|Sevoflurane
1358422|NCT00534586|S-Ketamine
1358423|NCT00534586|Remifentanil
1358424|NCT00534586|Healthy volunteers
1358425|NCT00534534|Pancreatitis
1358426|NCT00534534|acute
1358427|NCT00534534|alcoholic
1358428|NCT00534534|recurrence
1358429|NCT00534534|alcoholism
1358430|NCT00534534|treatment
1358431|NCT00534534|Acute alcoholic pancreatitis
1358432|NCT00534521|overactive bladder
1358433|NCT00534521|posterior tibial nerve stimulation
1358434|NCT00534508|Skin
1358435|NCT00534508|Pharmacokinetics
1358436|NCT00534508|Tacrolimus
1358437|NCT00534508|dermatitis, atopic
1358438|NCT00534495|Systemic Juvenile Idiopathic Arthritis
1358439|NCT00534495|Juvenile Rheumatoid Arthritis
1358440|NCT00534495|Systemic Juvenile Rheumatoid Arthritis
1358441|NCT00534482|fitness
1358442|NCT00534469|adult acute myeloid leukemia in remission
1358443|NCT00534469|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1358444|NCT00534469|adult acute myeloid leukemia with inv(16)(p13;q22)
1358445|NCT00534469|adult acute myeloid leukemia with t(16;16)(p13;q22)
1358446|NCT00534469|adult acute myeloid leukemia with t(8;21)(q22;q22)
1358447|NCT00534469|adult acute basophilic leukemia
1358448|NCT00534469|adult acute eosinophilic leukemia
1358449|NCT00534469|adult erythroleukemia (M6a)
1358450|NCT00534469|adult pure erythroid leukemia (M6b)
1358451|NCT00534469|adult acute megakaryoblastic leukemia (M7)
1358452|NCT00534469|adult acute minimally differentiated myeloid leukemia (M0)
1358453|NCT00534469|adult acute monoblastic leukemia (M5a)
1358454|NCT00534469|adult acute monocytic leukemia (M5b)
1358455|NCT00534469|adult acute myeloblastic leukemia with maturation (M2)
1358456|NCT00534469|adult acute myeloblastic leukemia without maturation (M1)
1358457|NCT00534469|adult acute myelomonocytic leukemia (M4)
1358458|NCT00534456|exploratory study
1358459|NCT00534456|anemia
1358460|NCT00534456|pharmacogenetics testing
1358461|NCT00534456|biomarkers
1358462|NCT00534456|echocardiography
1358463|NCT00534443|peptic ulcer
1358464|NCT00534443|gastritis
1358465|NCT00534443|sTREM-1
1358466|NCT00534443|cytokines
1358467|NCT00534443|Changes of inflammatory status in gastric mucosa
1358468|NCT00534443|sTREM-1 as a disease marker
1358469|NCT00534430|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1358470|NCT00534430|adult acute myeloid leukemia with inv(16)(p13;q22)
1358471|NCT00534430|adult acute myeloid leukemia with t(15;17)(q22;q12)
1358472|NCT00534430|adult acute myeloid leukemia with t(16;16)(p13;q22)
1358473|NCT00534430|adult acute myeloid leukemia with t(8;21)(q22;q22)
1358474|NCT00534430|recurrent adult acute myeloid leukemia
1358475|NCT00534430|adult acute myeloid leukemia in remission
1358476|NCT00534430|recurrent childhood acute myeloid leukemia
1358477|NCT00534430|recurrent adult acute lymphoblastic leukemia
1358478|NCT00534430|recurrent childhood acute lymphoblastic leukemia
1358479|NCT00534430|blastic phase chronic myelogenous leukemia
1358480|NCT00534430|refractory anemia with excess blasts in transformation
1358481|NCT00534430|refractory anemia with excess blasts
1358482|NCT00534430|previously treated myelodysplastic syndromes
1358483|NCT00534430|secondary myelodysplastic syndromes
1358484|NCT00534417|Hormone
1358485|NCT00534417|Receptor
1358486|NCT00534417|Positive
1358487|NCT00534417|Metastatic
1358488|NCT00534417|Breast
1358489|NCT00534417|Cancer
1358490|NCT00534404|Internet-Assisted Tobacco Treatments
1358491|NCT00534404|Online Smoking Cessation Programs
1358492|NCT00534404|Nicotine Patches
1358493|NCT00534404|Telephone Counseling
1358494|NCT00534404|Smoking Abstinence
1358495|NCT00534391|Antibiotics
1358496|NCT00534391|hordeolum
1358497|NCT00534378|Nerve agent
1358498|NCT00534378|Midazolam
1358499|NCT00534378|Seizures
1358500|NCT00534378|Severe recurrent convulsive seizures induced by nerve agent exposure
1358501|NCT00534365|stress urinary incontinence
1358502|NCT00534365|sling procedures
1358503|NCT00534365|tension-free vaginal tape
1358504|NCT00534352|HIV
1358505|NCT00534352|AIDS
1358506|NCT00534352|Immunodeficiency Virus, Human
1358507|NCT00534352|PREZISTA
1358508|NCT00534352|darunavir
1358509|NCT00534352|TMC114
1358510|NCT00534352|TMC125
1358511|NCT00534352|Protease Inhibitor
1358512|NCT00534352|Non-Nucleoside Reverse Transcriptase Inhibitor
1358513|NCT00534352|Truvada
1358514|NCT00534352|Treatment Naive
1358515|NCT00534300|ICD-pacemaker
1358516|NCT00534001|bladder cancer
1358517|NCT00534001|cervical cancer
1358518|NCT00534001|esophageal cancer
1358519|NCT00534001|gastric cancer
1358520|NCT00534001|renal cell carcinoma
1358521|NCT00534001|adult primary liver cancer
1358522|NCT00534001|non-small cell lung cancer
1358523|NCT00534001|small cell lung cancer
1358524|NCT00534001|pancreatic cancer
1358525|NCT00534001|hypopharyngeal cancer
1358526|NCT00534001|laryngeal cancer
1358527|NCT00534001|lip and oral cavity cancer
1358528|NCT00534001|nasopharyngeal cancer
1358529|NCT00534001|oropharyngeal cancer
1358530|NCT00534001|paranasal sinus and nasal cavity cancer
1358531|NCT00534001|adult acute myeloid leukemia
1358532|NCT00534001|tobacco use disorder
1358533|NCT00533988|Central venous catheters
1358534|NCT00533988|Antimicrobial impregnated catheters
1358535|NCT00533988|Duration of catheter use
1358536|NCT00533988|Catheter-related infection
1358537|NCT00533988|Insertion site
1358538|NCT00533988|Parenteral nutrition
1358539|NCT00533988|Critically ill patients (multidisciplinary)
1358540|NCT00533975|Colon Cancer screening
1358541|NCT00533975|immunofecal occult blood test
1358542|NCT00533975|colonoscopy
1358543|NCT00533975|diagnostic validity
1358544|NCT00533962|Glaucoma
1358545|NCT00533962|Anecortave Acetate
1358546|NCT00533962|Intraocular pressure
1358547|NCT00533962|Advanced glaucoma cases with uncontrolled IOP
1358548|NCT00533949|radiation toxicity
1358549|NCT00533949|stage IIIA non-small cell lung cancer
1358550|NCT00533949|stage IIIB non-small cell lung cancer
1358551|NCT00533936|stage II breast cancer
1358552|NCT00533936|stage IIIA breast cancer
1358553|NCT00533936|stage IIIB breast cancer
1358554|NCT00533936|stage IIIC breast cancer
1358555|NCT00533923|Nonmyeloablative Allogeneic Stem Cell Transplantation
1358556|NCT00533923|mini-transplant
1358557|NCT00533923|AML
1358558|NCT00533923|ALL
1358559|NCT00533923|CML
1358560|NCT00533923|CLL
1358561|NCT00533923|Myelodysplastic syndrome
1358562|NCT00533923|Relapsed non-Hodgkin's or Hodgkin's lymphoma
1358563|NCT00533923|Relapsed multiple myeloma
1358564|NCT00533923|Aplastic anemia
1358565|NCT00533923|Myeloproliferative disorder
1358566|NCT00533923|GM-CSF
1358567|NCT00533923|Cyclosporin
1358568|NCT00533923|Fludarabine (FLUDARA)
1358569|NCT00533923|Cyclophosphamide
1358570|NCT00533923|CAMPATH-1H
1358571|NCT00533923|GVHD
1358572|NCT00533923|CMV
1358573|NCT00533923|AML in first remission, first relapse or subsequent remission
1358574|NCT00533923|ALL in first relapse, second or subsequent remission
1358575|NCT00533923|ALL in first remission, in a high-risk category
1358576|NCT00533923|Aplastic anemia characterized by ANC< 1000 and/or platelets < 30 without transfusional support
1358577|NCT00533923|Myeloproliferative disorder (P Vera, CMML, ET)
1358578|NCT00533910|Minimal hepatic encephalopathy
1358579|NCT00533897|Rheumatoid Arthritis (RA)
1358580|NCT00533884|delirium
1358581|NCT00533884|cognitive/functional effects
1358582|NCT00533884|hypopharyngeal cancer
1358583|NCT00533884|laryngeal cancer
1358584|NCT00533884|lip and oral cavity cancer
1358585|NCT00533884|metastatic squamous neck cancer with occult primary
1358586|NCT00533884|nasopharyngeal cancer
1358587|NCT00533884|oropharyngeal cancer
1358588|NCT00533884|paranasal sinus and nasal cavity cancer
1358589|NCT00533884|salivary gland cancer
1358590|NCT00533884|esophageal cancer
1358591|NCT00533884|non-small cell lung cancer
1358592|NCT00533884|small cell lung cancer
1358593|NCT00533871|Natriuretic Peptide Brain
1358594|NCT00533858|Systolic hypertension
1358595|NCT00533832|depression
1358596|NCT00533832|vagus nerve stimulation
1358597|NCT00533819|Exercise intervention
1358598|NCT00533819|Maths Scores
1358599|NCT00533819|Blood pressure
1358600|NCT00533819|Female school children
1358601|NCT00533819|Body mass index
1358602|NCT00533806|Cognitive Behavior Therapy
1358603|NCT00533806|Active Control
1358604|NCT00533806|Relaxation Therapy
1358605|NCT00533806|Young Children
1358606|NCT00533793|bone, tibial shaft fracture
1358607|NCT00533767|Hantavirus cardiopulmonary syndrome, Andes virus, Chile
1358608|NCT00533754|age-related macular degeneration, genetics
1358609|NCT00533741|Severe Acute Respiratory Syndrome, Coronavirus, vaccine
1358610|NCT00533715|Inspiratory Spirometry; Preschool Children; Computer games
1358611|NCT00533715|Health
1358612|NCT00533702|Phase II
1358613|NCT00533702|Melanoma
1358614|NCT00533702|IMC-1121B
1358615|NCT00533702|ImClone
1358616|NCT00533637|Allergic rhinitis
1358617|NCT00533637|Nasal spray
1358618|NCT00533637|Anti-histamine
1358619|NCT00533637|Tolerability
1358620|NCT00533624|Gastrointestinal toxicity
1358621|NCT00533585|Non-Small Cell Lung Cancer
1358622|NCT00533585|Lung Cancer
1358623|NCT00533585|NSCLC
1358624|NCT00533585|malignant pleural effusions
1358625|NCT00533585|Sorafenib
1358626|NCT00533585|Paclitaxel
1358627|NCT00533585|Taxol
1358628|NCT00533585|Carboplatin
1358629|NCT00533585|Paraplatin
1358630|NCT00533585|Bevacizumab
1358631|NCT00533585|Avastin
1358632|NCT00533585|BAY 43-9006
1358633|NCT00533585|Anti-VEGF monoclonal antibody
1358634|NCT00533585|rhuMAb-VEGF
1358635|NCT00533559|type 2 diabetes
1358636|NCT00533559|free fatty acids
1358637|NCT00533559|insulin resistance
1358638|NCT00533559|beta cell lipotoxic effect
1358639|NCT00533546|Acute Ischemic Stroke
1358640|NCT00533533|Docetaxel,Oxaliplatin
1358641|NCT00533533|Phase I/II study
1358642|NCT00533533|Advanced gastric cancer
1358643|NCT00533533|First line treatment
1358644|NCT00533533|Advanced gastric cancer with measurable disease
1358645|NCT00533507|Pneumococcal vaccine.
1358646|NCT00533507|Pneumococcal disease
1358647|NCT00533507|Safety
1358648|NCT00533507|Immunogenicity
1358649|NCT00533507|Primary vaccination
1358650|NCT00533065|Aging
1358651|NCT00533052|Behavioral weight loss
1358652|NCT00532974|HIV
1358653|NCT00532974|Human Immunodeficiency Virus
1358654|NCT00532974|Vaccines
1358655|NCT00532974|HIV Vaccines
1358656|NCT00532974|Peptide
1358657|NCT00532974|Peptide Vaccines
1358658|NCT00532974|HIV 1
1358659|NCT00533468|pain
1358660|NCT00533468|lumbar puncture
1358661|NCT00533468|neonates
1358662|NCT00533468|infants
1358663|NCT00533468|emergency department
1358664|NCT00533468|topical anesthesia
1358665|NCT00533468|LMX4
1358666|NCT00533455|Antipsychotics, tremor
1358667|NCT00533442|Rapamycin
1358668|NCT00533442|Mycophenolate mofetil
1358669|NCT00533442|kidney-pancreas transplant
1358670|NCT00533416|Myelodyplastic Syndrome (MDS)
1358671|NCT00533416|Selective Mitotic Inhibitor
1358672|NCT00533416|Targeted Therapy
1358673|NCT00533416|Myelodysplastic Syndrome
1358674|NCT00533416|MDS
1358675|NCT00533390|efavirenz
1358676|NCT00533390|tuberculosis
1358677|NCT00533390|AIDS
1358678|NCT00533390|rifampicin
1358679|NCT00533390|efficacy
1358680|NCT00533390|safety
1358681|NCT00533390|Treatment Naive
1358682|NCT00533338|Breast Cancer
1358683|NCT00533338|Cancer Survivors
1358684|NCT00533338|Weight Gain Prevention
1358685|NCT00533338|Diet
1358686|NCT00533338|Exercise
1358687|NCT00533338|Questionnaire
1358688|NCT00533338|Survey
1358689|NCT00533299|Epigenetics, hydralazine, valproate, ovarian cancer
1358690|NCT00533286|physiotherapy
1358691|NCT00533286|Tuebingen concept
1358692|NCT00533286|benzodiazepines
1358693|NCT00533286|muscle relaxants
1358694|NCT00533286|disc herniation
1358695|NCT00533260|Patients with a manic episode or patients diagnosed with schizophrenia , patients who are being treated with quetiapine and are on a stable dosing regime
1358696|NCT00533247|Cox-2 Inhibitor
1358697|NCT00533247|Pre-emptive Pain
1358698|NCT00533247|Preoperative Pain
1358699|NCT00533247|Pain Prophylaxis
1358700|NCT00533247|Celebrex
1358701|NCT00533247|Celecoxib
1358706|NCT00533221|growth hormone
1358707|NCT00533221|strength
1358708|NCT00533221|Spinal muscular atrophy type II and III
1358709|NCT00533195|UVA1
1358710|NCT00533195|PUVA
1358711|NCT00533195|atopic dermatitis
1358712|NCT00533182|Influenza Infection
1358713|NCT00533182|Immunocompromised Host
1358714|NCT00533182|Resistance Mutations
1358715|NCT00533182|Prolonged Infection
1358716|NCT00533169|Neuroblastoma
1358717|NCT00533169|ZD6474
1358718|NCT00533169|Zactima
1358719|NCT00533169|Isotretinoin
1358720|NCT00533169|13-Cis Retinoic Acid
1358721|NCT00533169|Accutane
1358722|NCT00533169|Pediatric Neuroblastoma
1358723|NCT00533156|Closure Device
1358724|NCT00533156|Angiography
1358725|NCT00533156|Angioplasty
1358726|NCT00533156|Hemostasis
1358727|NCT00533156|Heart Catheterization
1358728|NCT00533156|Vascular Closure
1358729|NCT00533156|Peripheral Closure
1358730|NCT00533156|Coronary Angiography
1358731|NCT00533143|Solid cancer patient
1358732|NCT00533143|Non-invasive ventilation
1358733|NCT00533143|Acute Respiratory Failure
1358734|NCT00533130|AO
1358735|NCT00533130|Pediatric
1358736|NCT00533130|Classification
1358737|NCT00533130|Long Bones
1358738|NCT00533130|fractures
1358739|NCT00533130|bones
1358740|NCT00533117|suicide
1358741|NCT00533117|self-mutilation
1358742|NCT00533117|fluoxetine
1358743|NCT00533117|placebo
1358744|NCT00533117|dialectical behavior therapy
1358745|NCT00533117|supportive therapy
1358746|NCT00533104|Limb ischemia
1358747|NCT00533104|Cell Therapy
1358748|NCT00533078|omega3 fatty acid
1358749|NCT00533078|parenteral nutrition
1358750|NCT00533078|chemotherapy
1358751|NCT00533078|infection
1358752|NCT00533078|neutropenia
1358753|NCT00532883|Sickle Cell Disease
1358754|NCT00532883|Vaso-occlusive Event
1358755|NCT00532883|Painful Crises
1358756|NCT00532883|Acute Chest Syndrome
1358757|NCT00532870|laparoscopy
1358758|NCT00532870|ventral hernia
1358759|NCT00532870|mesh
1358760|NCT00532870|Ventral hernias are the second most common type of abdominal hernias after inguinal hernias.
1358761|NCT00532870|The majority of ventral hernias are incisional hernias that develop in 11% to 20% of patients who undergo Laparotomy .
1358762|NCT00532870|Surgeons have struggled to reduce the morbidity from incarceration (6% to 15% of cases) and strangulation (2%) of these hernias.
1358763|NCT00532857|Patients with HER2 + stage II/III breast cancer
1358764|NCT00532844|6R-BH4
1358765|NCT00532844|BH4
1358766|NCT00532844|BH4 deficiency
1358767|NCT00532844|sapropterin dihydrochloride
1358768|NCT00532844|endothelial dysfunction
1358769|NCT00532844|NO
1358770|NCT00532844|Hypertension
1358771|NCT00532844|Nitric Oxide
1358772|NCT00532844|Vitamin C
1358773|NCT00532818|Epigenetic therapy
1358774|NCT00532818|Hydralazine
1358775|NCT00532818|Valproate
1358776|NCT00532818|Cervical cancer
1358777|NCT00532818|Randomized
1358778|NCT00532818|Phase III
1358779|NCT00532805|Alpha 1-Antitrypsin Deficiency
1358780|NCT00532792|Avian
1358781|NCT00532792|Pandemic
1358782|NCT00532792|Influenza
1358783|NCT00532792|A/H5N1
1358784|NCT00532779|Obesity
1358785|NCT00532779|Antiobesity agents
1358786|NCT00532779|Antiobesity drugs
1358787|NCT00532779|Overweight drug therapy
1358788|NCT00532779|Obese drug therapy
1358789|NCT00532779|Weight loss drug effects
1358790|NCT00532779|Bupropion administration and dosage
1358791|NCT00532779|Naltrexone administration and dosage
1358792|NCT00532779|Double blind method
1358793|NCT00532779|Combination drug therapy
1358794|NCT00532779|Delayed action preparations
1358795|NCT00532766|Healthy subjects
1358796|NCT00532753|empowerment
1358797|NCT00532753|health
1358798|NCT00532753|education
1358799|NCT00532740|liver metastases
1358800|NCT00532740|advanced adult primary liver cancer
1358801|NCT00532727|Breast Cancer
1358802|NCT00532727|Triple Negative
1358803|NCT00532701|Chronic hepatitis C
1358804|NCT00532701|Genotype
1358805|NCT00532701|Interferon
1358806|NCT00532701|Ribavirin
1358807|NCT00532701|Genotype 2
1358808|NCT00532701|Peginterferon
1358809|NCT00532688|acetylcysteine
1358810|NCT00532688|N-acetylcysteine
1358811|NCT00532688|heart failure
1358812|NCT00532688|renal failure
1358813|NCT00532675|Myeloma
1358814|NCT00532675|Multiple Myeloma
1358815|NCT00532675|Lenalidomide
1358816|NCT00532675|Revlimid
1358817|NCT00532675|Dexamethasone
1358818|NCT00532675|LBH589
1358819|NCT00532675|Combination
1358820|NCT00532662|Epidural
1358821|NCT00532662|Intravenous
1358822|NCT00532662|Ketamine
1358823|NCT00532662|Analgesia
1358824|NCT00532662|Caudal
1358825|NCT00532662|Pediatric
1358826|NCT00532662|Regional
1358827|NCT00532662|Local Anesthetics
1358828|NCT00532636|Airway
1358829|NCT00532636|Airway obstruction
1358830|NCT00532636|Mouth-to-mask resuscitation
1358831|NCT00532636|Respiration artificial
1358832|NCT00532636|Ventilation
1358833|NCT00532636|Ventilation of an unprotected airway
1358834|NCT00532636|Safety and efficiency of mask ventilation
1358835|NCT00532636|Avoidance of stomach inflation
1358836|NCT00532610|Diabetes,
1358837|NCT00532610|ECG,
1358838|NCT00532610|Healthy Volunteers
1358839|NCT00532610|GSK189075,
1358840|NCT00532597|Vascular Endothelium-Dependent Relaxation
1358841|NCT00532597|Hemodialysis
1358842|NCT00532597|Hemodiafiltration
1358843|NCT00532584|COPD
1358844|NCT00532584|inhaled steroids
1358845|NCT00532584|bronchodilator
1358846|NCT00532584|gene expression
1358847|NCT00532584|smoker's lungs
1358848|NCT00532571|CoQ10
1358849|NCT00532571|PSP
1358850|NCT00532571|CBD
1358851|NCT00532558|Hyperlipidemia
1358852|NCT00532558|Drug Therapy
1358853|NCT00532532|Multiple sclerosis
1358854|NCT00532493|Combat Trauma
1358855|NCT00532493|Post traumatic stress disorder
1358856|NCT00532493|PTSD
1358857|NCT00532493|Sleep Disturbance
1358858|NCT00532493|Trauma-Related Nightmares
1358859|NCT00532480|Depression
1358860|NCT00532480|Duloxetine
1358861|NCT00532480|fMRI
1358862|NCT00532480|pictures
1358863|NCT00532467|healthy volunteers
1358864|NCT00532415|Vitrectomy
1358865|NCT00532415|Visualization
1358866|NCT00532402|Monitoring
1358867|NCT00532402|Breathing Gas
1358868|NCT00532402|Propofol
1358869|NCT00532389|Myeloma
1358870|NCT00532389|Multiple Myeloma
1358871|NCT00532389|Bortezomib
1358872|NCT00532389|LBH589
1358873|NCT00532389|Combination
1358874|NCT00532376|epilepsy
1358875|NCT00532376|depression
1358876|NCT00532376|fMRI
1358877|NCT00532376|emotion
1358878|NCT00532350|COPD
1358879|NCT00532350|pharmacokinetics
1358880|NCT00532350|plethysmography
1358881|NCT00532350|cycle ergometry
1358882|NCT00532350|exercise testing
1358883|NCT00532350|spirometry
1358884|NCT00532337|ONO-5334
1358885|NCT00532337|osteoporosis
1358886|NCT00532337|osteopenia
1358887|NCT00532324|Methicillin resistant Staphylococcus aureus
1358888|NCT00532324|Staphylococcus aureus
1358889|NCT00532324|Healthy term and near term neonates
1358890|NCT00532324|Prevention
1358891|NCT00532324|Nasal and Vaginal Colonization rates
1358892|NCT00532324|Pregnant women
1358893|NCT00532311|Hyperlipidemia
1358894|NCT00532311|Drug Therapy
1358895|NCT00532298|Fluarix
1358896|NCT00532298|Influenza Infection
1358897|NCT00532298|GSK Biologicals' influenza vaccine GSK576389A
1358898|NCT00532259|Lymphoma, Large B-Cell, Diffuse
1358899|NCT00532259|Transformed Follicular Lymphoma
1358900|NCT00532259|Stem cell transplantation
1358901|NCT00532259|Relapsed
1358902|NCT00532259|Refractory
1358904|NCT00532220|osteonecrosis
1358905|NCT00532220|bone marrow edema
1358906|NCT00532220|ibandronate
1358907|NCT00532220|bisphosphonate
1358908|NCT00532220|knee
1358909|NCT00532194|ovarian cancer
1358910|NCT00532194|fallopian tube cancer
1358911|NCT00532194|primary serous peritoneal cancer
1358912|NCT00532194|gynaecological carcinoma
1358913|NCT00532194|randomised controlled trial
1358914|NCT00532194|Cediranib
1358915|NCT00532194|AZD2171
1358916|NCT00532194|efficacy
1358917|NCT00532181|Health insurance
1358918|NCT00532181|Health utilization rates
1358919|NCT00532181|Saving Behavior
1358920|NCT00532181|Risk aversion
1358921|NCT00532168|advanced HIV-infected patients
1358922|NCT00532168|late presenters
1358923|NCT00532168|antiretroviral therapy
1358924|NCT00532168|immune reconstitution
1358925|NCT00532168|Treatment Naive
1358926|NCT00532155|lung cancer
1358927|NCT00532155|angiogenesis inhibitor
1358928|NCT00532155|chemotherapy
1358929|NCT00532116|Healthy
1358930|NCT00532116|Elderly
1358931|NCT00532116|Non Elderly
1358932|NCT00532116|Healthy Volunteers
1358933|NCT00532103|Suicidal Ideation
1358934|NCT00532103|Major Depressive Disorder
1358935|NCT00532103|Suicide Risk
1358936|NCT00532103|Antidepressant Medication
1358937|NCT00532077|renal,
1358938|NCT00532077|pharmacology,
1358939|NCT00532077|Osteoporosis
1358940|NCT00532064|Advanced Cancers
1358941|NCT00532064|Cardiotoxicity Detection
1358942|NCT00532064|Heart Damage
1358943|NCT00532064|Troponin 1 Blood Test
1358944|NCT00532064|B-type Natriuretic Peptide Blood Test
1358945|NCT00532064|Questionnaire
1358946|NCT00532064|Survey
1358947|NCT00532064|BNP
1358948|NCT00532051|cataract, lasik, laser refractive surgery
1358949|NCT00532038|Osteoarthritis
1358950|NCT00532038|Pain
1358951|NCT00532025|Sorafenib
1358952|NCT00532025|NSCLC
1358953|NCT00532025|Adjuvant Treatment
1358954|NCT00532025|resected Non-Small Cell Lung Carcinoma
1358955|NCT00532012|Rheumatoid Arthritis
1358956|NCT00532012|RhuDex®
1358957|NCT00532012|Meglumine
1358958|NCT00532012|Oral Bioavailability
1358959|NCT00531999|Raltegravir
1358960|NCT00531999|Euglycaemic clamp
1358961|NCT00531999|healthy volunteer
1358962|NCT00531986|Monotherapy
1358963|NCT00531986|Neuropsychological tests
1358964|NCT00531986|HIV viral load in ZNS
1358965|NCT00531986|HIV viral load in genital
1358966|NCT00531986|Lumbar puncture and HIV viral load in ZNS
1358967|NCT00531986|Monotherapy and compartment failure (ZNS and genital)
1358968|NCT00531986|ZNS viral load under monotherapy
1358969|NCT00531986|Genital viral load under monotherapy
1358970|NCT00531986|Neuropsychological tests (HIV Dementia)
1358971|NCT00531986|Treatment Experienced
1358972|NCT00531973|breast cancer
1358973|NCT00531973|echocardiography
1358974|NCT00531973|neoplasia
1358975|NCT00531947|Mental Health
1358976|NCT00531947|Adolescents
1358977|NCT00531947|Major Depressive Disorder
1358978|NCT00531947|Depression
1358979|NCT00531947|Adolescent Depression
1358980|NCT00531947|Pediatric Depression
1358981|NCT00531921|Heart Diseases
1358982|NCT00531921|Kidney Diseases
1358983|NCT00531921|Liver Diseases
1358984|NCT00531921|Liver Failure
1358985|NCT00531921|Lung Diseases
1358986|NCT00531921|Transplant
1358987|NCT00531921|Transplantation, Homologous
1358988|NCT00531921|Rejection
1358989|NCT00531921|Kidney Failure
1358990|NCT00531908|Growth Hormone
1358991|NCT00531908|Epithelial sodium channel
1358992|NCT00531908|Hypertension
1358993|NCT00531908|A Furosemide
1358994|NCT00531908|Nasal Mucosa
1358995|NCT00531895|major depression
1358996|NCT00531895|chronic headache
1358997|NCT00531895|antidepressant
1358998|NCT00531895|duloxetine
1358999|NCT00531882|healthy volunteers
1359000|NCT00531882|neutrophil migration
1359001|NCT00531882|anti inflammatory non-steroidal agent
1359002|NCT00531882|simvastatin
1359003|NCT00531882|pioglitazone
1359004|NCT00531869|safewater
1359005|NCT00531869|randomized
1359006|NCT00531856|Kidney Transplant, Carbon Monoxide
1359007|NCT00531843|deep vein thrombosis
1359008|NCT00531843|venous thromboembolism
1359009|NCT00531843|pulmonary embolism
1359010|NCT00531830|children with PDD
1359011|NCT00531791|COPD
1359012|NCT00531791|exacerbation
1359013|NCT00531791|fluticasone
1359014|NCT00531791|salmeterol
1359015|NCT00531791|steroid
1359016|NCT00531778|Women with increased risk for developing ovarian cancer
1359017|NCT00531778|early detection
1359018|NCT00531778|biomarker for ovarian cancer
1359019|NCT00531765|contrast-induced-nephropathy,
1359020|NCT00531765|cardiac cath
1359021|NCT00531765|creatinine
1359022|NCT00531765|contrast
1359023|NCT00531765|nephropathy
1359024|NCT00531739|Surgery
1359025|NCT00531739|Colectomy
1359026|NCT00531739|Proctocolectomy
1359027|NCT00531739|Adhesions
1359028|NCT00531713|hypothyroidism, quality og life, depression
1359029|NCT00531700|influenza
1359030|NCT00531700|risk behaviors
1359031|NCT00531700|immunization
1359032|NCT00531700|knowledge attitudes behaviors
1359033|NCT00531700|personally controlled health record
1359034|NCT00531700|Indivo
1359035|NCT00531687|relapse
1359036|NCT00531674|Efficacy of public health intervention (nutrition)
1359037|NCT00531648|Toddlers that having feeding disorders and SPD
1359038|NCT00531635|Mixed hemopoietic chimerism, Fludarabine, TBI, PBSC, immunosuppression, Mycophenolate Mofetil
1359039|NCT00531622|Depression
1359040|NCT00531622|Major Depressive Episode
1359041|NCT00531622|Antidepressant
1359042|NCT00531596|Elderly
1359043|NCT00531596|Non Elderly
1359044|NCT00531596|Healthy Volunteers
1359045|NCT00531583|AML in 1st & 2nd complete remission w/no HLA matched related donor
1359046|NCT00531570|Women with ultrasound defined complex pelvic masses
1359047|NCT00531557|Darunavir
1359048|NCT00531557|Euglycaemic clamp
1359049|NCT00531557|HIV
1359050|NCT00531557|Treatment Experienced
1359051|NCT00531531|pulmonary infection
1359052|NCT00531531|transmission
1359053|NCT00531531|P.Aeruginosa
1359054|NCT00531531|surfaces
1359055|NCT00531518|Schizophrenia
1359056|NCT00531518|Bipolar disorder
1359057|NCT00531518|Psychosis
1359058|NCT00531518|Prodromal psychosis
1359059|NCT00531518|Family psychoeducation
1359060|NCT00531518|Supported education
1359061|NCT00531518|Supported employment
1359062|NCT00531518|Ulra-high-risk for psychosis
1359063|NCT00531518|Major depression
1359064|NCT00531518|Bipolar disorder, with psychotic features
1359065|NCT00531518|Major depression, with psychotic features
1359066|NCT00531518|Attenuated, prodromal psychotic symptoms
1359067|NCT00531505|Obesity
1359068|NCT00531492|Maternal and child health
1359069|NCT00531492|Developing country
1359070|NCT00531492|Skin to skin care
1359071|NCT00531492|Newly born low birth weight infants and their mothers
1359072|NCT00531492|(Delivery at University Hospital Center, Mahajanga, Madagascar)
1359073|NCT00531466|Spinal cord injury
1359074|NCT00531440|Renal transplantation, everolimus, Immunosuppressants
1359075|NCT00531427|Chronic pain,
1359076|NCT00531427|OA of the knee,
1359077|NCT00531427|opioid,
1359078|NCT00531427|transdermal
1359079|NCT00531414|Asthmatic
1359080|NCT00531414|healthy
1359081|NCT00531401|Non-Small-Cell Lung
1359082|NCT00531362|Atherosclerosis
1359083|NCT00531362|Aspirin
1359084|NCT00531362|Resistance,
1359085|NCT00531362|Acute coronary syndromes
1359086|NCT00531349|Endometrial Cancer
1359087|NCT00531349|Anesthesia; regional
1359088|NCT00531349|cancer recurrence
1359089|NCT00531349|Analgesia; opioid
1359090|NCT00531336|age-related Macular degeneration
1359091|NCT00531336|Macugen
1359092|NCT00531336|Avastin
1359093|NCT00531323|Pharmacokinetic
1359094|NCT00531323|TMC125
1359095|NCT00531323|Healthy volunteers
1359096|NCT00531323|Efavarinz
1359097|NCT00531310|CML
1359098|NCT00531310|allogeneic SCT
1359099|NCT00531310|matched family donor
1359100|NCT00531310|unrelated donor
1359101|NCT00531310|cord blood donor
1359102|NCT00531310|persistent disease
1359103|NCT00531284|Non-small cell lung carcinoma
1359104|NCT00531284|Small-cell lung carcinoma
1359105|NCT00531284|Ovarian Cancer
1359106|NCT00531284|Renal Cancer
1359107|NCT00531284|Other solid tumors
1359108|NCT00531284|multiple myeloma
1359109|NCT00531284|lymphoma
1359110|NCT00531258|Depression
1359111|NCT00531258|TBI
1359112|NCT00531258|TMS
1359113|NCT00531258|Major Depression resulting from a mild to moderate closed head injury
1359114|NCT00531245|TS-1 and oxaliplatin
1359115|NCT00531245|Phase I/II study
1359116|NCT00531245|Colorectal cancer
1359117|NCT00531245|First line treatment
1359118|NCT00531232|Previously treated Myelodysplastic Syndromes (MDS)
1359119|NCT00531232|oral clofarabine
1359120|NCT00531232|Intermediate-1, Intermediate-2 and High Risk Myelodysplastic Syndromes (MDS)
1359121|NCT00531232|secondary AML (with history of MDS)
1359122|NCT00531219|appendicitis
1359123|NCT00531219|cholelithiasis
1359124|NCT00531219|gallstones
1359125|NCT00531193|Healthy male volunteers
1359126|NCT00531180|Esophageal Cancer
1359127|NCT00531180|Lung Cancer
1359128|NCT00531180|Thoracic Malignancies
1359129|NCT00531180|4D CT scans
1359130|NCT00531180|Lung Function
1359131|NCT00531167|lamivudine resistant mutations
1359132|NCT00531167|rescue therapy
1359133|NCT00531141|age-related macular degeneration
1359134|NCT00531141|optical coherence tomography
1359135|NCT00531141|retinal thickness
1359136|NCT00531141|exudative age-related macular degeneration
1359137|NCT00531128|Sitosterol
1359138|NCT00531128|Nutrigenomics
1359139|NCT00531128|Gene Expression
1359140|NCT00531128|Insulin Resistance
1359141|NCT00531128|Sitosterolemia
1359142|NCT00531115|metastatic colorectal cancer
1359143|NCT00531115|elderly patients
1359144|NCT00531115|cetuximab, oxaliplatin, capecitabine
1359145|NCT00531102|oxygen
1359146|NCT00531102|continuous positive airway pressure
1359147|NCT00531102|infant, newborn
1359148|NCT00531102|resuscitation
1359149|NCT00531089|TTP
1359150|NCT00531089|thrombotic thrombocytopenic purpura
1359151|NCT00531089|HUS
1359152|NCT00531089|hemolytic uremic syndrome
1359153|NCT00531089|plasma exchange
1359154|NCT00531076|bevacizumab
1359155|NCT00531076|thoracic radiotherapy
1359156|NCT00531076|locally-advanced non-small cell lung cancer
1359157|NCT00531063|Renal transplantation, everolimus, Immunosuppressants
1359158|NCT00531050|COPD
1359159|NCT00531050|cycle ergometry
1359160|NCT00531050|exercise testing
1359161|NCT00531050|spirometry
1359162|NCT00531050|cardiovascular
1359163|NCT00531050|salbutamol
1359164|NCT00531050|indacaterol
1359165|NCT00531050|chronic obstructive pulmonary disease
1359166|NCT00531037|AV block, SND, BTS, AAIsafeR, SafeR, PM implanted
1359167|NCT00531024|Exudative Neovascular
1359168|NCT00531024|AMD
1359169|NCT00531024|Avastin
1359170|NCT00531024|Systemic
1359171|NCT00531024|Exudative Age-Related Macular Degeneration
1359172|NCT00531011|Stents
1359173|NCT00531011|Drug-eluting Stent
1359174|NCT00531011|Angioplasty
1359175|NCT00531011|Coronary Artery stenosis
1359176|NCT00531011|Coronary Artery Stent Restenosis
1359177|NCT00531011|Stent Thrombosis
1359178|NCT00530998|appendicitis
1359179|NCT00530998|cholelithiasis
1359180|NCT00530998|Gallstones
1359181|NCT00530985|disability
1359182|NCT00530985|substance abuse
1359183|NCT00530985|vocational rehabilitation
1359184|NCT00530985|case management
1359185|NCT00530972|co-infected HCV/HIV
1359186|NCT00530972|relapsers
1359187|NCT00530907|Advanced Cancer
1359188|NCT00530907|Valproic Acid
1359189|NCT00530907|Depakene
1359190|NCT00530907|Bevacizumab
1359191|NCT00530907|Avastin
1359192|NCT00530907|Anti-VEGF monoclonal antibody
1359193|NCT00530907|rhuMAb-VEGF
1359194|NCT00530894|Valvular Heart Disease
1359195|NCT00530894|Critical/Severe Aortic Stenosis
1359196|NCT00530894|High risk symptomatic patients
1359197|NCT00530868|Hormonal and antibody therapy for breast cancer
1359198|NCT00530868|Hormonal therapy for breast cancer
1359199|NCT00530868|Antibody therapy for breast cancer
1359200|NCT00530855|Epilepsy
1359201|NCT00530855|Partial-onset Seizures
1359202|NCT00530855|Lacosamide
1359203|NCT00530855|Monotherapy
1359204|NCT00530855|Vimpat
1359205|NCT00530829|diarrhea
1359206|NCT00530829|zinc
1359207|NCT00530829|oral rehydration therapy
1359208|NCT00530803|pain
1359209|NCT00530803|venipuncture
1359210|NCT00530803|children
1359211|NCT00530790|Restless Legs Syndrome
1359212|NCT00530777|Disease Transmission, Vertical
1359213|NCT00530777|valacyclovir
1359214|NCT00530777|Randomized Controlled Trials
1359215|NCT00530777|HIV
1359216|NCT00530777|herpes
1359217|NCT00530777|Herpesvirus 2, Human
1359218|NCT00530777|HIV Seronegativity
1359219|NCT00530764|Pain
1359220|NCT00530764|Cancer
1359221|NCT00530764|Palliative
1359222|NCT00530751|breast cancer
1359223|NCT00530738|HPN
1359224|NCT00530738|lipid emulsion
1359225|NCT00530738|long term
1359226|NCT00530738|insufficient enteral resorption capacity
1359227|NCT00530725|occult pneumothorax
1359228|NCT00530725|mechanical ventilation
1359229|NCT00530725|critical care
1359230|NCT00530725|pneumothorax
1359231|NCT00530725|thoracostomy
1359232|NCT00530712|SFA
1359233|NCT00530712|Popliteal
1359234|NCT00530712|Stent
1359235|NCT00530712|EverFlex
1359236|NCT00530699|Acute Myeloid Leukaemia
1359237|NCT00530699|Phase 1
1359238|NCT00530699|AZD1152
1359239|NCT00530686|Diabetes Mellitus
1359240|NCT00530686|Hypoglycemia
1359241|NCT00530686|Hyperglycemia
1359242|NCT00530686|Type 1 Diabetes
1359243|NCT00530686|Islet cell transplantation
1359244|NCT00530660|Pandemic influenza
1359245|NCT00529971|Mindfulness
1359246|NCT00529971|HIV
1359247|NCT00529971|Male
1359248|NCT00529971|Living with HIV
1359249|NCT00529971|18-70 years of age
1359250|NCT00529971|live within one hour of hospital
1359251|NCT00529971|fluent in English
1359252|NCT00529971|Complementary Therapies
1359253|NCT00529971|HIV Therapeutic Vaccine
1359254|NCT00530647|Brain motor network, Plasticity, functional MRI, Stroke
1359255|NCT00530634|stage II non-small cell lung cancer
1359256|NCT00530634|stage IIIA non-small cell lung cancer
1359257|NCT00530634|stage IIIB non-small cell lung cancer
1359258|NCT00530595|hemodialysis
1359259|NCT00530582|progesterone, postmenopause, sleep-EEG
1359260|NCT00530569|Breast Cancer
1359261|NCT00530569|Herceptin Therapy
1359262|NCT00530543|Robot
1359263|NCT00530543|Gait
1359264|NCT00530543|Stroke
1359265|NCT00530530|ASP8825
1359266|NCT00530530|Restless legs Syndrome
1359267|NCT00530530|XP13512
1359268|NCT00530517|migraine
1359269|NCT00530517|sumatripatan
1359270|NCT00530504|Carotid Artery Disease
1359271|NCT00530504|Embolic Protection
1359272|NCT00530491|lung resection
1359273|NCT00530491|reduced pulmonary function
1359274|NCT00530478|Donepezil
1359275|NCT00530478|Stroke
1359276|NCT00530478|Cognitive function
1359277|NCT00530478|Cognitive neural network
1359278|NCT00530452|COX-2
1359279|NCT00530452|carbonic anhydrase
1359280|NCT00530452|osteoarthritis
1359281|NCT00530452|anti-inflammatory
1359282|NCT00530452|Cyclooxygenase Inhibitors
1359283|NCT00530426|Heart Failure, Congestive
1359284|NCT00530426|Registry
1359285|NCT00530426|Acute Decompensated Heart Failure
1359286|NCT00530426|Dyspnea
1359287|NCT00530400|Antibiotic prophylaxis
1359288|NCT00530400|Bacterial Infections / prevention & control
1359289|NCT00530400|Surgical wound infection / prevention & control
1359290|NCT00530400|Neurosurgery
1359291|NCT00530400|Postoperative Complications / prevention & control
1359292|NCT00530400|Clinical trial [publication type]
1359293|NCT00530387|Photocontact
1359294|NCT00530387|Dermatitis
1359295|NCT00530387|NSAID
1359296|NCT00530387|Sunscreen
1359297|NCT00530387|Photopatch
1359298|NCT00530374|Pediatrics
1359299|NCT00530374|Malnutrition
1359300|NCT00530374|Iron Deficiency
1359301|NCT00530374|Sprinkles
1359302|NCT00530374|Oral Iron Supplementation
1359303|NCT00530361|Myocardial Ischemia
1359304|NCT00530361|Kidney failure
1359305|NCT00530361|CABG
1359306|NCT00530361|Cardiopulmonary bypass (CPB) pump
1359307|NCT00530361|Coronary Artery Bypass Surgery
1359308|NCT00530361|Heart surgery
1359309|NCT00530361|Nesiritide
1359310|NCT00530361|Coronary Heart Disease
1359311|NCT00530348|Multiple Sclerosis
1359312|NCT00530322|Adhesions
1359313|NCT00530322|Laparoscopy
1359314|NCT00530322|Colorectal surgery
1359315|NCT00530322|Colorectal disease
1359316|NCT00530309|GLP-1
1359317|NCT00530309|type 2 diabeted mellitus
1359318|NCT00530309|safety
1359319|NCT00530309|GSK716155
1359320|NCT00530309|GLP-1 receptor agonist
1359321|NCT00530309|tolerability
1359322|NCT00530309|pharmacokinetics
1359323|NCT00530309|pharmacodynamics
1359324|NCT00530296|Depression
1359325|NCT00530296|End stage renal disease
1359326|NCT00530296|Quality of Life
1359327|NCT00530296|Cognitive Behavioral Therapy
1359328|NCT00530283|Squamous
1359329|NCT00530283|Unknown Primary
1359330|NCT00530283|Patients with Squamous cell cancer neck nodes
1359331|NCT00530270|Sickle Cell Disease
1359332|NCT00530270|ACS
1359333|NCT00530270|Acute Chest Syndrome
1359334|NCT00530270|Hgb SS
1359335|NCT00530270|Hgb Sβ0
1359336|NCT00530270|Dexamethasone
1359337|NCT00530257|Attention Deficit Hyperactivity Disorder
1359338|NCT00530257|Methylphenidate
1359339|NCT00530257|Attention
1359340|NCT00530257|Working Memory
1359341|NCT00530244|cystic fibrosis
1359342|NCT00530244|fatty acids
1359343|NCT00530244|docosahexaenoic acid
1359344|NCT00530244|infant formula
1359345|NCT00530244|growth
1359346|NCT00530244|pancreatic function
1359347|NCT00530231|Capsule endoscopy
1359348|NCT00530231|Missing rate
1359349|NCT00530218|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1359350|NCT00530218|adult acute myeloid leukemia with inv(16)(p13;q22)
1359351|NCT00530218|adult acute myeloid leukemia with t(15;17)(q22;q12)
1359352|NCT00530218|adult acute myeloid leukemia with t(16;16)(p13;q22)
1359353|NCT00530218|adult acute myeloid leukemia with t(8;21)(q22;q22)
1359354|NCT00530218|accelerated phase chronic myelogenous leukemia
1359355|NCT00530218|adult acute lymphoblastic leukemia in remission
1359356|NCT00530218|adult acute myeloid leukemia in remission
1359357|NCT00530218|atypical chronic myeloid leukemia
1359358|NCT00530218|blastic phase chronic myelogenous leukemia
1359359|NCT00530218|chronic eosinophilic leukemia
1359360|NCT00530218|chronic idiopathic myelofibrosis
1359361|NCT00530218|chronic myelomonocytic leukemia
1359362|NCT00530218|chronic neutrophilic leukemia
1359363|NCT00530218|chronic phase chronic myelogenous leukemia
1359364|NCT00530218|de novo myelodysplastic syndromes
1359365|NCT00530218|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1359366|NCT00530218|myelodysplastic/myeloproliferative disease, unclassifiable
1359367|NCT00530218|nodal marginal zone B-cell lymphoma
1359368|NCT00530218|noncontiguous stage II adult Burkitt lymphoma
1359369|NCT00530218|noncontiguous stage II adult diffuse large cell lymphoma
1359370|NCT00530218|noncontiguous stage II adult diffuse mixed cell lymphoma
1359371|NCT00530218|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1359372|NCT00530218|noncontiguous stage II adult immunoblastic large cell lymphoma
1359373|NCT00530218|noncontiguous stage II adult lymphoblastic lymphoma
1359374|NCT00530218|noncontiguous stage II grade 1 follicular lymphoma
1359375|NCT00530218|noncontiguous stage II grade 2 follicular lymphoma
1359376|NCT00530218|noncontiguous stage II grade 3 follicular lymphoma
1359377|NCT00530218|noncontiguous stage II mantle cell lymphoma
1359378|NCT00530218|noncontiguous stage II marginal zone lymphoma
1359379|NCT00530218|noncontiguous stage II small lymphocytic lymphoma
1359380|NCT00530218|previously treated myelodysplastic syndromes
1359381|NCT00530218|recurrent adult acute lymphoblastic leukemia
1359382|NCT00530218|recurrent adult acute myeloid leukemia
1359383|NCT00530218|recurrent adult Burkitt lymphoma
1359384|NCT00530218|recurrent adult Hodgkin lymphoma
1359385|NCT00530218|recurrent adult diffuse large cell lymphoma
1359386|NCT00530218|recurrent adult diffuse mixed cell lymphoma
1359387|NCT00530218|recurrent adult diffuse small cleaved cell lymphoma
1359388|NCT00530218|recurrent adult immunoblastic large cell lymphoma
1359389|NCT00530218|recurrent adult lymphoblastic lymphoma
1359390|NCT00530218|recurrent cutaneous T-cell non-Hodgkin lymphoma
1359391|NCT00530218|recurrent grade 1 follicular lymphoma
1359392|NCT00530218|recurrent grade 2 follicular lymphoma
1359393|NCT00530218|recurrent grade 3 follicular lymphoma
1359394|NCT00530218|recurrent mantle cell lymphoma
1359395|NCT00530218|recurrent marginal zone lymphoma
1359396|NCT00530218|recurrent mycosis fungoides/Sezary syndrome
1359397|NCT00530218|recurrent small lymphocytic lymphoma
1359398|NCT00530218|refractory chronic lymphocytic leukemia
1359399|NCT00530218|refractory hairy cell leukemia
1359400|NCT00530218|refractory multiple myeloma
1359401|NCT00530218|relapsing chronic myelogenous leukemia
1359402|NCT00530218|secondary acute myeloid leukemia
1359403|NCT00530218|secondary myelodysplastic syndromes
1359404|NCT00530218|splenic marginal zone lymphoma
1359405|NCT00530218|stage I multiple myeloma
1359406|NCT00530218|stage II multiple myeloma
1359407|NCT00530218|stage III adult Burkitt lymphoma
1359408|NCT00530218|stage III adult Hodgkin lymphoma
1359409|NCT00530218|stage III adult diffuse large cell lymphoma
1359410|NCT00530218|stage III adult diffuse mixed cell lymphoma
1359411|NCT00530218|stage III adult diffuse small cleaved cell lymphoma
1359412|NCT00530218|stage III adult immunoblastic large cell lymphoma
1359413|NCT00530218|stage III adult lymphoblastic lymphoma
1359414|NCT00530218|stage III chronic lymphocytic leukemia
1359415|NCT00530218|stage III grade 1 follicular lymphoma
1359416|NCT00530218|stage III grade 2 follicular lymphoma
1359417|NCT00530218|stage III grade 3 follicular lymphoma
1359418|NCT00530218|stage III mantle cell lymphoma
1359419|NCT00530218|stage III marginal zone lymphoma
1359420|NCT00530218|stage III multiple myeloma
1359421|NCT00530218|stage III small lymphocytic lymphoma
1359422|NCT00530218|stage IV adult Burkitt lymphoma
1359423|NCT00530218|stage IV adult Hodgkin lymphoma
1359424|NCT00530218|stage IV adult diffuse large cell lymphoma
1359425|NCT00530218|stage IV adult diffuse mixed cell lymphoma
1359426|NCT00530218|stage IV adult diffuse small cleaved cell lymphoma
1359427|NCT00530218|stage IV adult immunoblastic large cell lymphoma
1359428|NCT00530218|stage IV adult lymphoblastic lymphoma
1359429|NCT00530218|stage IV chronic lymphocytic leukemia
1359430|NCT00530218|stage IV grade 1 follicular lymphoma
1359431|NCT00530218|stage IV grade 2 follicular lymphoma
1359432|NCT00530218|stage IV grade 3 follicular lymphoma
1359433|NCT00530218|stage IV mantle cell lymphoma
1359434|NCT00530218|stage IV marginal zone lymphoma
1359435|NCT00530218|stage IV small lymphocytic lymphoma
1359436|NCT00530205|weight changes
1359437|NCT00530205|malnutrition
1359438|NCT00530205|stage III non-small cell lung cancer
1359439|NCT00530192|Refractory Cancer
1359440|NCT00530192|Molecular Profile
1359441|NCT00530179|Diffuse Large B-Cell Lymphoma
1359442|NCT00530179|Positron Emission Tomography
1359443|NCT00530179|CHOP Chemotherapy protocol
1359444|NCT00530179|Stem Cell Transplantation
1359445|NCT00530179|Fluorodeoxyglucose F18
1359446|NCT00530166|Asthma
1359447|NCT00530166|persistant asthma
1359448|NCT00530166|controller medications
1359449|NCT00530166|FEV1
1359450|NCT00530153|Eating
1359451|NCT00530153|Food Habits
1359452|NCT00530153|Adolescent
1359453|NCT00530153|Dental Research
1359454|NCT00530140|Follicular Lymphoma
1359455|NCT00530140|Idiotype vaccine
1359456|NCT00530127|Friedreich's ataxia
1359457|NCT00530088|recurrent squamous cell carcinoma of the larynx
1359458|NCT00530088|recurrent squamous cell carcinoma of the lip and oral cavity
1359459|NCT00530088|stage I squamous cell carcinoma of the larynx
1359460|NCT00530088|stage I squamous cell carcinoma of the lip and oral cavity
1359461|NCT00530088|stage 0 laryngeal cancer
1359462|NCT00530088|stage 0 lip and oral cavity cancer
1359463|NCT00530075|Wegener Granulomatosis
1359464|NCT00530075|Vasculitis
1359465|NCT00530075|Gusperimus
1359466|NCT00530075|Immunosuppression
1359467|NCT00530062|Asthma and Poor Coordinators of Asthma Inhalers
1359468|NCT00530049|psychosocial effects of cancer and its treatment
1359469|NCT00530049|hypopharyngeal cancer
1359470|NCT00530049|laryngeal cancer
1359471|NCT00530049|lip and oral cavity cancer
1359472|NCT00530049|metastatic squamous neck cancer with occult primary
1359473|NCT00530049|nasopharyngeal cancer
1359474|NCT00530049|oropharyngeal cancer
1359475|NCT00530049|paranasal sinus and nasal cavity cancer
1359476|NCT00530049|salivary gland cancer
1359477|NCT00530049|tongue cancer
1359478|NCT00530049|07-098
1359479|NCT00530036|Mortality
1359480|NCT00530036|Patient readmission
1359481|NCT00530036|Institutionalization
1359482|NCT00530010|adult primary hepatocellular carcinoma
1359483|NCT00530010|localized unresectable adult primary liver cancer
1359484|NCT00530010|advanced adult primary liver cancer
1359485|NCT00529997|Lumbar Spine
1359486|NCT00529997|Lumbar Spinal Stenosis
1359487|NCT00529997|Spondylolisthesis
1359488|NCT00529997|Dynamic Stabilization
1359489|NCT00529997|Motion Preserving
1359490|NCT00529997|Arthroplasty
1359491|NCT00529997|Randomized
1359492|NCT00529997|Investigational
1359493|NCT00529997|Back Pain
1359494|NCT00529997|Leg Pain
1359495|NCT00529984|CEA
1359496|NCT00529984|CEA-expressing malignancies
1359497|NCT00529984|Metastatic malignancies
1359498|NCT00529984|VRP Vaccine
1359499|NCT00529984|Alphavirus replicons
1359500|NCT00529984|Molecular therapeutics
1359501|NCT00529984|Stage III colon cancer
1359502|NCT00529958|Anterior Cruciate Ligament (ACL) Reconstruction
1359503|NCT00529958|Patellar Tendon
1359504|NCT00529958|Hamstring Tendon
1359505|NCT00529958|Double-Bundle
1359506|NCT00529958|Autograft
1359507|NCT00529945|PFO
1359508|NCT00529945|Stroke
1359509|NCT00529945|Transient Ischemic Attack
1359510|NCT00529945|Migraine
1359511|NCT00529945|Decompression Illness
1359512|NCT00529932|Acute Myocardial Infarction
1359513|NCT00529932|Celltherapy
1359514|NCT00529932|Bone Marrow
1359515|NCT00529919|Overweight
1359516|NCT00529919|Obesity
1359517|NCT00529919|Weight loss
1359518|NCT00529919|Medium chain triglycerides
1359519|NCT00529919|Cardiovascular disease risk
1359520|NCT00529906|attention deficit hyperactivity disorder
1359521|NCT00529906|neuropsychological deficits
1359522|NCT00529906|endophenotype
1359523|NCT00529906|molecular genetics
1359524|NCT00529906|candidate gene
1359525|NCT00529906|family-based association study
1359526|NCT00529893|Attention-deficit/Hyperactivity Disorder
1359527|NCT00529893|neuropsychological functioning
1359528|NCT00529893|Atomoxetine
1359529|NCT00529880|AML
1359530|NCT00529867|Artemether/Lumefantrine suspension
1359531|NCT00529867|P. falciparum malaria
1359532|NCT00529867|children
1359533|NCT00529867|uncomplicated Plasmodium falciparum malaria
1359534|NCT00529854|Intensive care unit
1359535|NCT00529854|medical documentation
1359536|NCT00529854|medical billing
1359537|NCT00529841|Salt Wasting Congenital Adrenal Hyperplasia
1359538|NCT00529841|Subcutaneous Hydrocortisone
1359539|NCT00529828|CLA
1359540|NCT00529828|Industrial trans fatty acids
1359541|NCT00529828|Oleic acid
1359542|NCT00529828|Controlled dietary trial
1359543|NCT00529815|Continuous
1359544|NCT00529815|blood
1359545|NCT00529815|glucose
1359546|NCT00529815|monitoring
1359547|NCT00529815|diabetes
1359548|NCT00529815|type2
1359549|NCT00529802|metastatic
1359550|NCT00529802|renal
1359551|NCT00529802|cell
1359552|NCT00529802|carcinoma
1359553|NCT00529802|cancer
1359554|NCT00529776|Prevention of ventilator associated pneumonia
1359555|NCT00529763|Chronic Phase, Advanced Phase chronic myeloid leukemia
1359556|NCT00529763|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
1359557|NCT00529737|Breast Cancer
1359558|NCT00529737|Marker Clip Migration
1359559|NCT00529737|Vacuum-Assisted Biopsy
1359560|NCT00529737|Postprocedure Mammogram
1359561|NCT00529737|Breast Biopsy
1359562|NCT00529724|Energy metabolism, metabolic syndrome, by chronic bilateral subthalamic stimulation, Parkinson's disease
1359563|NCT00529724|Patients with Parkinson's disease and will be treated by chronic bilateral subthalamic stimulation.
1359564|NCT00529711|coronary
1359565|NCT00529711|artery
1359566|NCT00529711|bypass
1359567|NCT00529711|grafting
1359568|NCT00529711|IV
1359569|NCT00529711|cardiac output
1359570|NCT00529698|HIV
1359571|NCT00529698|Tat protein
1359572|NCT00529698|Preventative vaccine
1359573|NCT00529698|Healthy volunteers
1359574|NCT00529698|HIV-1/2 uninfected
1359575|NCT00529698|HIV Preventive Vaccine
1359576|NCT00529672|endovenous laser therapy
1359577|NCT00529672|sclerotherapy
1359578|NCT00529672|crossectomy and stripping
1359579|NCT00529672|surgery
1359580|NCT00529672|treatment
1359581|NCT00529672|varicose veins
1359582|NCT00529659|Sarcopenia (loss of muscle mass)
1359583|NCT00529646|Healthy adult volunteers
1359584|NCT00529633|Inflammation
1359585|NCT00529633|albumin
1359586|NCT00529620|Malaria
1359587|NCT00529620|IPT
1359588|NCT00529620|preventive treatment
1359589|NCT00529607|myocardial infarction, reperfusion injury, echocardiography, magnetic resonance imaging, inflammation, nitric oxide
1359590|NCT00529594|Laser Photocoagulation
1359591|NCT00529594|Pain relief
1359592|NCT00529581|multiple sclerosis
1359593|NCT00529581|cognitive impairment
1359594|NCT00529581|cognitive dysfunction
1359595|NCT00529581|Cognitive Dysfunction associated with Multiple Sclerosis
1359596|NCT00529568|hepatitis C
1359597|NCT00529568|ribavirin
1359598|NCT00529568|Hepatitis C-related thrombocytopenia
1359599|NCT00529568|thrombopoietin
1359600|NCT00529568|peginterferon alfa-2b
1359601|NCT00529568|platelets
1359602|NCT00529542|Polycystic Ovary Syndrome
1359603|NCT00529529|asthma
1359604|NCT00529529|QAB149
1359605|NCT00529529|indacaterol
1359606|NCT00529516|Fluarix
1359607|NCT00529516|GSK Bio's influenza vaccine GSK576389A
1359608|NCT00529516|Influenza infection
1359609|NCT00529503|Lymphoproliferative Disorders
1359610|NCT00529503|Lymphoma
1359611|NCT00529503|Antigens, CD40
1359612|NCT00529503|Antibody, Monoclonal
1359613|NCT00529503|Combined Modality Therapy
1359614|NCT00529503|Lymphoma, Large B-Cell, Diffuse
1359615|NCT00529503|Lymphoma, Non-Hodgkin
1359616|NCT00529503|Hematologic Diseases
1359617|NCT00529503|Immunoproliferative Disorders
1359618|NCT00529503|Lymphatic Diseases
1359619|NCT00529490|coronary
1359620|NCT00529490|artery
1359621|NCT00529490|bypass
1359622|NCT00529490|grafting
1359623|NCT00529490|I.V.
1359624|NCT00529490|cardiac output
1359625|NCT00529464|Cervical Intraepithelial Neoplasia
1359626|NCT00529464|Cervical Dysplasia
1359627|NCT00529464|Cervical Cancer
1359628|NCT00529464|Fluorescence Spectroscopy
1359629|NCT00529464|Colposcopy
1359630|NCT00529464|Loop Electrical Excision Procedure
1359631|NCT00529464|LEEP
1359632|NCT00529451|Hypertension, Aliskiren, Ramipril
1359633|NCT00529425|Femoral neck fracture
1359634|NCT00529425|Hip fracture
1359635|NCT00529399|immune tolerance
1359636|NCT00529399|immunotherapy
1359637|NCT00529399|antigen-specific tolerance
1359638|NCT00529399|vaccine induced tolerance
1359639|NCT00529399|Beta-cell function
1359640|NCT00529399|T-cells
1359641|NCT00529399|DPT-1
1359642|NCT00529399|treatment of type 1 diabetes
1359643|NCT00529399|new onset type 1 diabetes
1359644|NCT00529399|juvenile diabetes
1359645|NCT00529399|T1D
1359646|NCT00529399|diabetes mellitus
1359647|NCT00529399|Type 1 diabetes TrialNet
1359648|NCT00529399|TrialNet
1359649|NCT00529386|prostatitis
1359650|NCT00529386|Botox
1359651|NCT00529360|Acute Leukemia
1359652|NCT00529360|Allogeneic Stem Cell Transplant
1359653|NCT00529360|Clofarabine
1359654|NCT00529360|Acute Lymphoblastic Leukemia
1359655|NCT00529360|Acute Myelogenous Leukemia
1359656|NCT00529334|Breast Cancer
1359657|NCT00529334|Partial breast irradiation
1359658|NCT00529334|Radiosurgery
1359659|NCT00529334|CyberKnife
1359660|NCT00529334|Radiotherapy
1359661|NCT00529334|PBI
1359662|NCT00529308|Tourette
1359663|NCT00529308|Tourette's
1359664|NCT00529295|misoprostol
1359665|NCT00529295|labor induction
1359666|NCT00529282|Low numbers of neutrophils in the blood
1359667|NCT00529282|increased body temperature
1359668|NCT00529282|cancer chemotherapy
1359669|NCT00529282|ceftobiprole
1359670|NCT00529282|pseudomonas infections
1359671|NCT00529269|Renal Transplant Patients, GI symptom, Enteric-coated mycophenolate sodium
1359672|NCT00529256|Adult smokers
1359673|NCT00529243|Treatment Experience
1359674|NCT00529243|On enfuvirtide
1359675|NCT00529230|Advanced Cancer
1359676|NCT00529230|Chronic Opioid Therapy
1359677|NCT00529230|Secondary Hypogonadism
1359678|NCT00529230|Cancer-Related Pain Syndromes
1359679|NCT00529230|Questionnaire
1359680|NCT00529217|Dissociative
1359681|NCT00529217|Dissociation
1359682|NCT00529217|Depersonalization
1359683|NCT00529217|Depersonalization Disorder
1359684|NCT00529217|Transcranial Magnetic Stimulation
1359685|NCT00529217|TMS
1359686|NCT00529217|Depersonalization Disorder (DPD)
1359687|NCT00529217|rTMS
1359688|NCT00529204|Fatty Liver
1359689|NCT00529204|Nonalcoholic fatty liver disease
1359690|NCT00529204|NAFDL
1359691|NCT00529204|Diabetes
1359692|NCT00529204|ALT
1359693|NCT00529204|exenatide
1359694|NCT00529191|Type I Diabetes (T1DM)
1359695|NCT00529191|Atorvastatin (Lipitor)
1359696|NCT00529191|Insulin
1359697|NCT00529191|Pancreas
1359698|NCT00529191|Beta Cells
1359699|NCT00529165|injection to meal time
1359700|NCT00529165|human insulin
1359701|NCT00529152|Iron Overload
1359702|NCT00529139|Extended dialysis
1359703|NCT00529139|Acute kidney injury
1359704|NCT00529139|Intensive care unit
1359705|NCT00529139|Renal replacement therapy
1359706|NCT00529139|Survival
1359707|NCT00529139|Dialysis
1359708|NCT00529126|hemorrhoidectomy
1359709|NCT00529126|pain
1359710|NCT00529126|Postoperative
1359711|NCT00529126|analgesia
1359712|NCT00529113|pancreatic cancer
1359713|NCT00529113|gemcitabine
1359714|NCT00529087|Opioid-Induced Constipation
1359715|NCT00529074|Epidural Analgesia
1359716|NCT00529061|Sickle Cell Disease
1359717|NCT00529061|Sickle Cell Anemia
1359718|NCT00529048|Type 2 diabetes mellitus
1359719|NCT00529048|Incretin effect
1359720|NCT00529048|Glucagon-Like Peptide 1
1359721|NCT00529048|Gastric Inhibitory Polypeptide
1359722|NCT00529035|Chronic GVHD
1359723|NCT00529035|Steroid refractory GVHD
1359724|NCT00529035|allogeneic stem cell transplantation
1359725|NCT00529022|Advanced Cancer
1359726|NCT00529022|Solid Tumors
1359727|NCT00529022|Ovarian Cancer
1359728|NCT00529022|Fallopian Tube Cancer
1359729|NCT00529022|Peritoneal Cancer
1359730|NCT00529022|Azacitidine
1359731|NCT00529022|5-Azacitidine
1359732|NCT00529022|5-Aza
1359733|NCT00529022|Vidaza™
1359734|NCT00529022|5-AZC
1359735|NCT00529022|AZA-CR
1359736|NCT00529022|Ladakamycin
1359737|NCT00529022|NSC-102816
1359738|NCT00529022|Vidaza
1359739|NCT00529022|Valproic Acid
1359740|NCT00529022|Depakene
1359741|NCT00529022|Carboplatin
1359742|NCT00529022|Paraplatin
1359743|NCT00527241|partner violence, spouse abuse
1359744|NCT00527228|Muscular dystrophy
1359745|NCT00527228|therapy
1359746|NCT00527228|steroids
1359747|NCT00527228|deflazacort
1359748|NCT00527228|dysferlinopathy
1359749|NCT00527228|LGMD
1359750|NCT00527228|MM
1359751|NCT00527189|Arthritis
1359752|NCT00527189|Exercise
1359753|NCT00527189|Balance - Postural Control
1359754|NCT00529009|PK analysis
1359755|NCT00528983|Myelodysplastic Syndromes MDS
1359756|NCT00528983|Acute Myelogenous Leukemia AML
1359757|NCT00528983|Chronic Myelomonocytic Leukemia CMML
1359758|NCT00528970|POI
1359759|NCT00528970|Hernia
1359760|NCT00528970|Ventral Wall Hernia Repair
1359761|NCT00528970|Post Operative Ileus
1359762|NCT00528957|Phase 3
1359763|NCT00528957|Randomized, Open-Label
1359764|NCT00528957|Treatment-Experienced
1359765|NCT00528957|Highly Active Antiretroviral Therapy
1359766|NCT00528957|HIV
1359767|NCT00528957|Tenofovir DF
1359768|NCT00528957|Pediatrics
1359769|NCT00528944|alveolar volume
1359770|NCT00528944|pulmonary function testing
1359771|NCT00528944|emphysema
1359772|NCT00528931|Assessment of AUX I and/or AUX II in human plasma
1359773|NCT00528918|diabetes
1359774|NCT00528918|hyperglycemia
1359775|NCT00528918|insulin
1359776|NCT00528918|Apidra
1359777|NCT00528918|Glargine
1359778|NCT00528905|Schizophrenia
1359779|NCT00528905|Cognitive Deficits
1359780|NCT00528892|Treatment Experienced
1359781|NCT00528879|Diabetes Mellitus, Type 2
1359782|NCT00528879|Diabetes Mellitus
1359783|NCT00528879|Endocrine System Diseases
1359784|NCT00528879|Glucose Metabolism Disorders
1359785|NCT00528879|Metabolic Diseases
1359786|NCT00528879|Metformin
1359787|NCT00528879|Hypoglycemic Agents
1359788|NCT00528879|Pharmacologic Actions
1359789|NCT00528879|Physiological Effects of Drugs
1359790|NCT00528866|adenocarcinoma of the prostate
1359791|NCT00528866|stage IIB prostate cancer
1359792|NCT00528866|stage IIA prostate cancer
1359793|NCT00528866|stage III prostate cancer
1359794|NCT00528866|stage IV prostate cancer
1359795|NCT00528853|Bronchiolitis Obliterans Syndrome
1359796|NCT00528827|Hypertension, High Blood Pressure, Pediatric Hypertension, High blood pressure in children
1359797|NCT00528814|Hand Sanitizer
1359798|NCT00528814|Respiratory Infection
1359799|NCT00528801|Sickle Cell Disease
1359800|NCT00528801|Sickle Cell Anemia
1359801|NCT00528801|Hemoglobin SS
1359802|NCT00528801|Hemoglobin SB0
1359803|NCT00528775|adenocarcinoma of the lung
1359804|NCT00528775|large cell lung cancer
1359805|NCT00528775|squamous cell lung cancer
1359806|NCT00528775|recurrent non-small cell lung cancer
1359807|NCT00528775|stage IIIA non-small cell lung cancer
1359808|NCT00528775|stage IIIB non-small cell lung cancer
1359809|NCT00528775|stage IV non-small cell lung cancer
1359810|NCT00528762|Epidemiology
1359811|NCT00528762|Puberty
1359812|NCT00528762|Body Weight
1359813|NCT00528762|Body Image
1359814|NCT00528762|Focus Group
1359815|NCT00528749|Respiratory effort
1359816|NCT00528749|Upper Airway Resistance Syndrome
1359817|NCT00528736|preterm infants < 28 weeks
1359818|NCT00528736|B-type natriuretic peptide
1359819|NCT00528736|prediction
1359820|NCT00528736|ductus intervention
1359821|NCT00528723|beclomethasone
1359822|NCT00528723|as needed
1359823|NCT00528723|salbutamol
1359824|NCT00528723|wheezing
1359825|NCT00528710|S-Adenosylmethionine
1359826|NCT00528684|Oncolytics Biotech
1359827|NCT00528684|cancer alternative therapies
1359828|NCT00528684|malignant glioma
1359829|NCT00528684|glioblastoma multiforme
1359830|NCT00528684|oncolytic virus
1359831|NCT00528684|reovirus
1359832|NCT00528684|REOLYSIN
1359833|NCT00528671|phenprocoumon
1359834|NCT00528671|INR self-management
1359835|NCT00528671|mechanical heart valve replacement
1359836|NCT00528671|bleeding
1359837|NCT00528671|thromboembolism
1359838|NCT00528658|Soft Tissue Injuries
1359839|NCT00528632|Gallstones
1359840|NCT00528632|Gallbladder
1359841|NCT00528632|Cholesterolosis
1359842|NCT00528632|Serum cholesterol
1359843|NCT00528632|triglycerides
1359844|NCT00528632|Body Mass Index
1359845|NCT00528619|Solid tumor malignancy
1359846|NCT00528619|non-small cell lung cancer
1359847|NCT00528619|sunitinib
1359848|NCT00528619|pemetrexed
1359849|NCT00528619|Phase 1
1359850|NCT00528619|Mesothelioma
1359851|NCT00528593|HIV
1359852|NCT00528593|AIDS
1359853|NCT00528593|neuropathy
1359854|NCT00528593|Procrit
1359855|NCT00528593|epoetin alfa
1359856|NCT00528593|erythropoetin
1359857|NCT00528593|Treatment Experienced
1359858|NCT00528580|Sepsis
1359859|NCT00528580|Statin
1359860|NCT00528580|Infection
1359861|NCT00528580|Immunomodulatory
1359862|NCT00528554|CINV
1359863|NCT00528554|chemotherapy induced nausea and vomiting (CINV)
1359864|NCT00528528|Chronic Hepatitis C
1359865|NCT00528528|Genotype 1
1359866|NCT00528528|Telaprevir
1359867|NCT00528528|Treatment-naïve
1359868|NCT00528528|VX-950-C208
1359869|NCT00528528|VX-950-TiDP24-C208
1359870|NCT00528515|anesthesia intravenous
1359871|NCT00528515|propofol
1359872|NCT00528515|anesthesia inhalation
1359873|NCT00528515|desflurane
1359874|NCT00528515|heart surgery
1359875|NCT00528515|coronary artery by-pass off-pump
1359876|NCT00528515|hemodynamic processes
1359877|NCT00528515|anesthesia
1359878|NCT00528502|Parathyroid Disease
1359879|NCT00528502|Minimal Invasive Parathyroid Surgery
1359880|NCT00528502|MIPS
1359881|NCT00528502|Laryngeal Reflexes
1359882|NCT00528502|Lidocaine
1359883|NCT00528502|Saline
1359884|NCT00528489|HIV Seronegativity
1359885|NCT00528489|DNA Plasmid Vaccine
1359886|NCT00528489|HIV Preventive Vaccine
1359887|NCT00528476|pyelonephritis
1359888|NCT00528476|cystitis
1359889|NCT00528476|risk factor
1359890|NCT00528476|children
1359891|NCT00528476|urodynamics
1359892|NCT00528463|Pre-emptive analgesia
1359893|NCT00528463|Peripheral nerve block (sciatic)
1359894|NCT00528463|phantom lomb pain
1359895|NCT00528450|adult acute promyelocytic leukemia (M3)
1359896|NCT00528450|adult acute myeloid leukemia with t(15;17)(q22;q12)
1359897|NCT00528450|untreated adult acute myeloid leukemia
1359898|NCT00528437|Recurrent or refractory medulloblastoma/PNET
1359899|NCT00528437|CNS germ cell tumors
1359900|NCT00528437|Ependymomas
1359901|NCT00528437|AT/RT
1359902|NCT00528437|High grade glioma
1359903|NCT00528437|Other malignant brain tumors
1359904|NCT00528411|Coronary artery disease
1359905|NCT00528411|CAD
1359906|NCT00528411|heart attack
1359907|NCT00528411|stable angina
1359908|NCT00528411|Stable coronary artery disease
1359909|NCT00528398|adult acute megakaryoblastic leukemia (M7)
1359910|NCT00528398|adult acute minimally differentiated myeloid leukemia (M0)
1359911|NCT00528398|adult acute monoblastic leukemia (M5a)
1359912|NCT00528398|adult acute monocytic leukemia (M5b)
1359913|NCT00528398|adult acute myeloblastic leukemia with maturation (M2)
1359914|NCT00528398|adult acute myeloblastic leukemia without maturation (M1)
1359915|NCT00528398|adult acute myelomonocytic leukemia (M4)
1359916|NCT00528398|adult erythroleukemia (M6a)
1359917|NCT00528398|adult pure erythroid leukemia (M6b)
1359918|NCT00528398|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1359919|NCT00528398|adult acute myeloid leukemia with inv(16)(p13;q22)
1359920|NCT00528398|adult acute myeloid leukemia with t(16;16)(p13;q22)
1359921|NCT00528398|adult acute myeloid leukemia with t(8;21)(q22;q22)
1359922|NCT00528398|secondary acute myeloid leukemia
1360051|NCT00528034|Lymphoscintigraphy
1359923|NCT00528398|untreated adult acute myeloid leukemia
1359924|NCT00528385|Proteinuria
1359925|NCT00528385|Renin-Angiotensin-Aldosterone System
1359926|NCT00528385|Aldosterone Antagonists
1359927|NCT00528359|antipsychotic drugs
1359928|NCT00528359|schizophrenia
1359929|NCT00528359|β-cell function
1359930|NCT00528359|insulin resistance
1359931|NCT00528346|chronic pain
1359932|NCT00528346|functional magnetic resonance imaging
1359933|NCT00528346|fMRI
1359934|NCT00528346|cognitive training
1359935|NCT00528333|Lintuzumab
1359936|NCT00528333|Antigens, CD33
1359937|NCT00528333|Antibodies, Monoclonal
1359938|NCT00528333|Leukemia, Myeloid, Acute
1359939|NCT00528333|Hematologic Diseases
1359940|NCT00528333|Leukemia
1359941|NCT00528320|Congestive Heart Failure
1359942|NCT00528320|Heart Failure
1359943|NCT00528320|Cardiac Resynchronization Therapy
1359944|NCT00528320|ICD
1359945|NCT00528320|Implantable Cardioverter-Defibrillator
1359946|NCT00528320|Defibrillator
1359947|NCT00528307|myocardial perfusion
1359948|NCT00528307|His ablation
1359949|NCT00528307|biventricular pacing
1359950|NCT00528307|His bundle ablation for atrial fibrillation
1359951|NCT00528294|Recurrent head and neck tumors
1359952|NCT00528281|Non Small Cell Lung Cancer (NSCLC)
1359953|NCT00528281|Pemetrexed,
1359954|NCT00528281|Lapatinib (GW572016),
1359955|NCT00528268|Spinal Muscular Atrophy
1359956|NCT00528268|SMA
1359957|NCT00528268|Sodium Phenylbutyrate
1359958|NCT00528255|cervical ripening
1359959|NCT00528255|induction of labor
1359960|NCT00527176|Systemic Lupus Erythematosus
1359961|NCT00527176|Corticosteroid
1359962|NCT00527176|Pulse therapy
1359963|NCT00527176|Diffusion weighted imaging
1359964|NCT00527176|q Space Imaging
1359965|NCT00527163|Echocardiogram
1359966|NCT00527163|Endothelial Dysfunction
1359967|NCT00527163|Malaria
1359968|NCT00527163|Mali
1359969|NCT00527163|Screening
1359970|NCT00527098|Trauma Resuscitation
1359971|NCT00527072|plaque psoriasis
1359972|NCT00527072|psoriasis
1359973|NCT00527072|infliximab
1359974|NCT00527072|remicade
1359975|NCT00527072|etanercept
1359976|NCT00527072|enbrel
1359977|NCT00527072|psunrise
1359978|NCT00527072|C0168Z04
1359979|NCT00527059|Cardiorenal syndrome
1359980|NCT00527033|YM178
1359981|NCT00527033|Urinary Bladder, Overactive
1359982|NCT00527020|qEEG
1359983|NCT00527020|GlyT-1 inhibitor
1359984|NCT00527020|healthy volunteers
1359985|NCT00527020|ERP
1359986|NCT00527020|FTIH
1359987|NCT00527020|MMN
1359988|NCT00527020|GSK1018921
1359989|NCT00527020|schizophrenia
1359990|NCT00527020|single-dose
1359991|NCT00527007|Vasopressor
1359992|NCT00527007|Epinephrine
1359993|NCT00527007|Norepinephrine
1359994|NCT00527007|Cooling
1359995|NCT00527007|Fever
1359996|NCT00527007|ICU
1359997|NCT00526994|intimate partner violence
1359998|NCT00526994|domestic violence
1359999|NCT00526994|spouse abuse
1360000|NCT00526994|screening
1360001|NCT00528216|Analgesics
1360002|NCT00528216|Capsaicin
1360003|NCT00528203|Sickle Cell Disease
1360004|NCT00528203|Sickle Cell Anemia
1360005|NCT00528203|DNA
1360006|NCT00528190|Cystic Fibrosis
1360007|NCT00528190|Aspergillus Fumigatus
1360008|NCT00528190|randomized controlled clinical trials
1360009|NCT00528177|kappa-opioid receptor
1360010|NCT00528177|my-opioid receptor
1360011|NCT00528177|oxycodone
1360012|NCT00528177|morphine
1360013|NCT00528177|postoperative pain
1360014|NCT00528164|children
1360015|NCT00528164|overweight
1360016|NCT00528164|obesity
1360017|NCT00528164|family
1360018|NCT00528164|intervention
1360019|NCT00528164|control
1360020|NCT00528164|randomized
1360021|NCT00528164|physical activity
1360022|NCT00528164|diet
1360023|NCT00528164|nutrition
1360024|NCT00528164|behavior
1360025|NCT00528164|body mass index
1360026|NCT00528151|Curcumin, LHON, antioxidant, visual outcome
1360027|NCT00528138|Appendicitis
1360028|NCT00528138|Hyperbilirubinemia
1360029|NCT00528138|CRP
1360030|NCT00528138|Values of bilirubin
1360031|NCT00528138|Values of liver function test
1360032|NCT00528138|Values of white blood cells
1360033|NCT00528138|Values of CRP
1360034|NCT00528112|Contraception
1360035|NCT00528112|Intrauterine
1360036|NCT00528112|IUD
1360037|NCT00528112|IUS
1360038|NCT00528086|Group visits
1360039|NCT00528073|Rifaximin-EIR
1360040|NCT00528073|Crohn's disease
1360041|NCT00528073|remission
1360042|NCT00528060|HIV infections
1360043|NCT00528060|atazanavir
1360044|NCT00528060|Pharmacokinetics
1360045|NCT00528060|Treatment Naive
1360046|NCT00528047|Cancer
1360047|NCT00528047|Solid Tumor
1360048|NCT00528047|Metastatic
1360049|NCT00528047|Neoplasm, Malignant
1360050|NCT00528034|Vaginal Cancer
1360052|NCT00528034|Lymphatic Mapping
1360053|NCT00528034|Sentinel Lymph Node
1360054|NCT00528034|Isosulfan Blue
1360055|NCT00528034|Lymph
1360056|NCT00528021|Head Lice
1360057|NCT00528021|Lice Infestation
1360058|NCT00528021|Pediculosis
1360059|NCT00528021|Pediculosis Capitis
1360060|NCT00528008|infection
1360061|NCT00528008|sepsis
1360062|NCT00528008|povidone-iodine
1360063|NCT00528008|chlorhexidine gluconate
1360064|NCT00528008|fever
1360065|NCT00528008|erythema
1360066|NCT00528008|leukocytosis
1360067|NCT00528008|drainage
1360068|NCT00528008|vaginal discharge
1360069|NCT00528008|elective cesarean section
1360070|NCT00527982|Head and Neck Cancer
1360071|NCT00527982|Lung Cancer
1360072|NCT00527982|Non-Small Cell Lung Cancer
1360073|NCT00527982|Celecoxib
1360074|NCT00527982|Celebrex
1360075|NCT00527969|American ginseng extract
1360076|NCT00527969|Panax quinquefolius
1360077|NCT00527969|Memory enhancement
1360078|NCT00527969|Cognitive function
1360079|NCT00527969|Working memory
1360080|NCT00527969|Declarative memory
1360081|NCT00527969|Psychomotor speed
1360082|NCT00527969|Executive skills
1360083|NCT00527969|Psychosocial adaptation
1360084|NCT00527956|Breastfeeding premature infants
1360085|NCT00527930|Breast Neoplasms
1360086|NCT00527930|Oxaliplatin
1360087|NCT00527930|S1
1360088|NCT00527917|IC/PBS
1360089|NCT00527917|Interstitial Cystitis/Painful Bladder Syndrome
1360090|NCT00527904|osteoarthritis
1360091|NCT00527904|rheumatoid arthritis
1360092|NCT00527904|ankylosing spondylisit
1360093|NCT00527904|NSAIDS
1360094|NCT00527891|Liver Cancer
1360095|NCT00527891|Magnetic Resonance Imaging
1360096|NCT00527891|Signa Excite 3.0T MRI Scan
1360097|NCT00527878|Hyper-IgE Recurrent Infection Syndrome
1360098|NCT00527878|Ranitidine Therapy
1360099|NCT00527878|Job's Syndrome
1360100|NCT00527878|Cross-Over Study
1360101|NCT00527878|Double-Blind Placebo Controlled
1360102|NCT00527878|Hyper-IgE Syndrome
1360103|NCT00527878|Job Syndrome
1360104|NCT00527878|Immune Deficiency
1360105|NCT00527865|Influenza, Flu, DAS181, Fludase
1360106|NCT00527852|Flocked swab
1360107|NCT00527852|Group A streptococcus
1360108|NCT00527826|Severe and very severe COPD (GOLD stage III / IV) exacerbations
1360109|NCT00527826|health care utilisation
1360110|NCT00527826|Chronic Obstructive Pulmonary Disease (COPD)
1360111|NCT00527826|quality of life
1360112|NCT00527826|compliance
1360113|NCT00527826|salmeterol/fluticasone combination
1360114|NCT00527813|acute respiratory distress syndrome
1360115|NCT00527813|prone position
1360116|NCT00527813|Acute respiratory distress syndrome (ARDS)
1360117|NCT00527800|Malaria
1360118|NCT00527800|HIV
1360119|NCT00527800|Trimethoprim-sulfamethoxazole
1360120|NCT00527800|Artemether-lumefantrine
1360121|NCT00527800|Dihydroartemisinin-piperaquine
1360122|NCT00527800|Acute Infection
1360123|NCT00527787|NSAID
1360124|NCT00527787|gastric ulcers
1360125|NCT00527787|Vimovo
1360126|NCT00527787|Naproxen
1360127|NCT00527787|Esomeprazole
1360128|NCT00527774|Hepatitis C
1360129|NCT00527774|malnutrition-inflammation complex syndrome (MICS)
1360130|NCT00527774|dialysis
1360131|NCT00527774|mortality
1360132|NCT00527774|hospitalization
1360133|NCT00527774|health-related quality of life (HRQOL)
1360134|NCT00527774|peripheral arterial occlusive disease (PAOD)
1360135|NCT00527761|Metastatic Melanoma
1360136|NCT00527761|Temozolomide
1360137|NCT00527761|Temodar
1360138|NCT00527761|Taxotere
1360139|NCT00527761|Cisplatin
1360140|NCT00527761|TTC
1360141|NCT00527748|Range of Motion
1360142|NCT00527748|Ankle Fractures
1360143|NCT00527748|Elderly patients
1360144|NCT00527735|Non Small Cell Lung Cancer (NSCLC)
1360145|NCT00527735|Small Cell Lung Cancer (SCLC)
1360146|NCT00527722|Lung Cancer
1360147|NCT00527722|Bio-Seal Track Plug
1360148|NCT00527722|Lung Biopsy
1360149|NCT00527722|Lung Plug
1360150|NCT00527722|Air Leaks
1360151|NCT00527683|vigabatrin
1360152|NCT00527683|GVG
1360153|NCT00527683|addiction
1360154|NCT00527683|treatment
1360155|NCT00527683|cocaine dependence
1360156|NCT00527670|Genomics
1360157|NCT00527657|Brain Neoplasms
1360158|NCT00527657|Melanoma
1360159|NCT00527657|Metastatic Melanoma
1360160|NCT00527657|Brain Metastasis
1360161|NCT00527657|Temozolomide
1360162|NCT00527657|Temodar
1360163|NCT00527657|Thalidomide
1360164|NCT00527657|Thalomid
1360165|NCT00527657|Lomustine
1360166|NCT00527657|CCNU
1360167|NCT00527657|CeeNU
1360168|NCT00527644|biliary leaks after laparoscopic cholecystectomy
1360169|NCT00527631|advanced ovarian cancer
1360170|NCT00527631|whole abdominal irradiation
1360171|NCT00527631|intensity modulated radiotherapy
1360172|NCT00527631|ovarian cancer stage FIGO III
1360173|NCT00527618|Herpes Simplex Virus Type 2
1360174|NCT00527618|Human Immunodeficiency Virus
1360175|NCT00527618|Treatment Naive
1360176|NCT00527605|placebo control
1360177|NCT00527605|Chinese
1360178|NCT00527605|Dutasteride
1360179|NCT00527605|Randomized
1360180|NCT00527605|Benign Prostatic Hyperplasia
1360181|NCT00527605|Double blind
1360182|NCT00527592|Comfort
1360183|NCT00527579|Epilepsy
1360184|NCT00527579|Taenia Solium
1360185|NCT00527579|Microglia
1360186|NCT00527579|Neuroinflammation
1360187|NCT00527579|Compartment Model
1360188|NCT00527579|Neurocysticercosis
1360189|NCT00527579|Healthy Volunteer
1360190|NCT00527579|HV
1360191|NCT00527566|Churg Strauss Syndrome
1360192|NCT00527553|Macular pigment
1360193|NCT00527553|AMD
1360194|NCT00527553|ARM
1360195|NCT00527514|Hypertension
1360196|NCT00527514|Angiotensin Receptor Blocker
1360197|NCT00527514|Calcium Channel Blocker
1360198|NCT00527514|Stage I and II Hypertension
1360199|NCT00527501|Open-angle glaucoma
1360200|NCT00527501|ocular hypertension
1360201|NCT00527488|Benign Prostate Hyperplasia
1360202|NCT00527488|BPH
1360203|NCT00527488|PK/PD
1360204|NCT00527488|GnRH antagonist
1360205|NCT00527475|Anti-VEGF therapy
1360206|NCT00527475|photodynamic therapy
1360207|NCT00527475|neovascularization
1360208|NCT00527462|Asthma GINA 1
1360209|NCT00527423|VEGF Trap-Eye
1360210|NCT00527423|Macular Degeneration
1360211|NCT00527423|AMD
1360212|NCT00527423|Neovascular Age-Related Macular Degeneration
1360213|NCT00527397|Diabetes Mellitus
1360214|NCT00527384|Stress
1360215|NCT00527371|Benign hyperplasia of the prostate
1360216|NCT00527358|violence
1360217|NCT00527345|Asthma
1360218|NCT00527345|Diesel exhaust
1360219|NCT00527332|Hospitalization
1360220|NCT00527332|Postoperative care
1360221|NCT00527332|Quality of Life
1360222|NCT00527332|Health economy
1360223|NCT00527332|Anesthesia. Spinal
1360224|NCT00527332|Anesthesia, General
1360225|NCT00527319|NSCLC
1360226|NCT00527319|anorexia
1360227|NCT00527319|cachexia
1360228|NCT00527319|grip strength
1360229|NCT00527319|lean body mass
1360230|NCT00527306|aphthous stomatitis
1360231|NCT00527306|canker sores
1360232|NCT00527306|multivitamins
1360233|NCT00527306|vitamin deficiency
1360234|NCT00527293|stage I breast cancer
1360235|NCT00527293|stage II breast cancer
1360236|NCT00527293|invasive ductal breast carcinoma
1360237|NCT00527293|medullary ductal breast carcinoma with lymphocytic infiltrate
1360238|NCT00527293|mucinous ductal breast carcinoma
1360239|NCT00527293|tubular ductal breast carcinoma
1360240|NCT00527293|papillary ductal breast carcinoma
1360241|NCT00527280|Allotransplantation:composite tissue
1360242|NCT00527280|Face transplantation
1360243|NCT00526955|Manual muscle testing
1360244|NCT00526942|ACRD
1360245|NCT00526942|Visual Memory
1360246|NCT00526942|Visual Perception
1360247|NCT00526942|Speed
1360248|NCT00526942|Computerized
1360249|NCT00526942|SAAGE
1360250|NCT00526942|Cognitive Decline
1360251|NCT00526916|Epilepsy
1360252|NCT00526916|Taenia Solium
1360253|NCT00526916|Microglia
1360254|NCT00526916|Neuroinflammation
1360255|NCT00526916|Compartment Model
1360256|NCT00526916|Neurocysticercosis
1360257|NCT00526916|Healthy Volunteer
1360258|NCT00526916|HV
1360259|NCT00526903|IBS
1360260|NCT00526903|abdominal pain
1360261|NCT00526903|recurrent abdominal pain
1360262|NCT00526903|irritable bowel syndrome
1360263|NCT00526903|diarrhea
1360264|NCT00526903|constipation
1360265|NCT00526903|bloating
1360266|NCT00526890|squamous cell lung cancer
1360267|NCT00526890|adenocarcinoma of the lung
1360268|NCT00526890|bronchoalveolar cell lung cancer
1360269|NCT00526890|large cell lung cancer
1360270|NCT00526890|stage IIIA non-small cell lung cancer
1360271|NCT00526890|stage IIIB non-small cell lung cancer
1360272|NCT00526890|adenosquamous cell lung cancer
1360273|NCT00526877|Schizophrenia
1360274|NCT00526877|Schizoaffective disorders
1360275|NCT00526877|Risperidone
1360276|NCT00526877|Risperdal Consta
1360277|NCT00526864|Burden of Illness for Herpes zoster in Thailand.
1360278|NCT00526851|lip and oral cavity cancer
1360279|NCT00526851|oropharyngeal cancer
1360280|NCT00526838|Solid Tumor
1360281|NCT00526838|Multiple Myeloma
1360282|NCT00526786|Low Grade Dysplasia
1360283|NCT00526786|High Grade Dysplasia
1360284|NCT00526786|Barrett's Esophagus
1360285|NCT00526786|Cryospray ablation
1360286|NCT00526786|ICE
1360287|NCT00526786|Cryotherapy
1360288|NCT00526786|Cryo
1360289|NCT00526786|CryoSpray
1360290|NCT00526773|motivational therapy
1360291|NCT00526760|Dexmedetomidine, Sedation, Long-term, Phase 3
1360292|NCT00526734|stage I multiple myeloma
1360293|NCT00526734|stage II multiple myeloma
1360294|NCT00526734|stage III multiple myeloma
1360295|NCT00526721|Hypercholesterolemia
1360296|NCT00526721|Crestor
1360297|NCT00526721|LDL target goal
1360298|NCT00526721|high risk patients
1360299|NCT00526721|Naturalistic
1360300|NCT00526721|Observational
1360301|NCT00526708|dyslipidemia
1360302|NCT00526708|hypertension
1360303|NCT00526708|rosuvastatin
1360304|NCT00526708|efficacy
1360305|NCT00526708|Naturalistic
1360306|NCT00526708|Observational
1360307|NCT00526695|Ischemia/Reperfusion
1360308|NCT00526695|Organ Protection
1360309|NCT00526695|Anesthetics
1360310|NCT00526682|Antiobesity
1360311|NCT00526682|Weight loss
1360312|NCT00526669|tumor biopsy
1360313|NCT00526669|capecitabine
1360314|NCT00526669|first line
1360315|NCT00526669|Gastro Esophageal (GE) Junction Cancer
1360316|NCT00526669|Gastric cancer
1360317|NCT00526669|newly diagnosed
1360318|NCT00526669|GE junction
1360319|NCT00526669|lapatinib
1360320|NCT00526669|metastatic or unresectable
1360321|NCT00526656|transitional cell carcinoma of the bladder
1360322|NCT00526656|stage II bladder cancer
1360323|NCT00526656|stage III bladder cancer
1360324|NCT00526656|stage IV bladder cancer
1360325|NCT00526643|stage IIIB
1360326|NCT00526643|Stage IV
1360327|NCT00526643|chemotherapy
1360328|NCT00526643|monotherapy
1360329|NCT00526643|combination chemotherapy
1360330|NCT00526643|poor performance status
1360331|NCT00526630|freezing
1360332|NCT00526630|gait
1360333|NCT00526630|festination
1360334|NCT00526630|shuffling
1360335|NCT00526630|balance
1360336|NCT00526617|Solid Tumor
1360337|NCT00526617|Melanoma
1360338|NCT00526617|Breast cancer
1360339|NCT00526617|Ovarian cancer
1360340|NCT00526617|Primary peritoneal cancer
1360341|NCT00526617|Fallopian tube cancer
1360342|NCT00526617|Hepatocellular carcinoma
1360343|NCT00526617|HCC
1360344|NCT00526617|BRCA deficient
1360345|NCT00526617|BRCA mutation
1360346|NCT00526617|Temozolomide
1360347|NCT00526617|Temodar
1360348|NCT00526617|TMZ
1360349|NCT00526617|ABT-888
1360350|NCT00526617|PARP inhibitor
1360351|NCT00526604|return to work
1360352|NCT00526604|low back pain
1360353|NCT00526604|work related rehabilitation
1360354|NCT00526591|adenocarcinoma of the prostate
1360355|NCT00526591|stage I prostate cancer
1360356|NCT00526591|stage II prostate cancer
1360357|NCT00526591|stage III prostate cancer
1360358|NCT00526578|Pancreatic Cancer
1360359|NCT00526578|Pancreatic Cancer Genetic Epidemiology
1360360|NCT00526578|PACGENE
1360361|NCT00526578|Healthy Control
1360362|NCT00526578|Familial Pancreatic Cancer
1360363|NCT00526578|FPC
1360364|NCT00526578|Questionnaire
1360365|NCT00526552|dyslipidemia
1360366|NCT00526552|rosuvastatin
1360367|NCT00526552|diabetes
1360368|NCT00526552|cholesterol
1360369|NCT00526552|Naturalistic
1360370|NCT00526552|Observational
1360371|NCT00526539|THR
1360372|NCT00526539|reversed hybrid
1360373|NCT00526539|wear
1360374|NCT00526500|Severe Traumatic Brain Injury
1360375|NCT00526500|Subarachnoid Hemorrhage
1360376|NCT00526500|Anoxic Brain Injury
1360377|NCT00526500|Passive Gait Training
1360378|NCT00526500|Tilt Table With Integrated Stepping System
1360379|NCT00526500|Electroencephalogram
1360380|NCT00526500|Event Related Potentials
1360381|NCT00526487|Thoracic Dissection
1360382|NCT00526487|Dissection
1360383|NCT00526487|Endovascular
1360384|NCT00526461|stage 0 non-small cell lung cancer
1360385|NCT00526461|adenocarcinoma of the lung
1360386|NCT00526461|squamous cell lung cancer
1360387|NCT00526461|large cell lung cancer
1360388|NCT00526448|high dose of ribavirin
1360389|NCT00526448|extend treatment duration
1360390|NCT00526448|tailoring treatment
1360391|NCT00526435|Arthritis
1360392|NCT00526435|osteoarthritis
1360393|NCT00526435|rheumatoid arthritis
1360394|NCT00526435|fibromyalgia
1360395|NCT00526435|lupus
1360396|NCT00526422|Questionnaire, dental caries, diagnosis,treatment
1360397|NCT00526409|Acute Lymphoblastic Leukemia
1360398|NCT00526396|chemotherapy
1360399|NCT00526396|toxicity adjusted dose
1360400|NCT00526383|Major depressive disorder
1360401|NCT00526383|Antidepressants
1360402|NCT00526383|Weight gain
1360403|NCT00526383|Metabolic syndromes
1360404|NCT00526370|self test
1360405|NCT00526370|PAP smear
1360406|NCT00526370|tampon test
1360407|NCT00526370|E6/E7
1360408|NCT00526370|mRNA
1360409|NCT00526370|HPV
1360410|NCT00526357|omega-3 fatty acids
1360411|NCT00526357|asthma
1360412|NCT00526357|airway hyperresponsiveness
1360413|NCT00526357|inflammation
1360414|NCT00526344|remission of asthma
1360415|NCT00526331|Perioperative Therapy
1360416|NCT00526331|Perioperative Hydration
1360417|NCT00526331|Arterial Pressure Based Cardiac Output
1360418|NCT00526331|Vigileo Monitor
1360419|NCT00526331|FloTrac Sensor
1360420|NCT00526331|Fluid Volume
1360421|NCT00526331|APCO
1360422|NCT00526318|localized resectable neuroblastoma
1360423|NCT00526318|localized unresectable neuroblastoma
1360424|NCT00526318|regional neuroblastoma
1360425|NCT00526318|stage 4S neuroblastoma
1360426|NCT00526318|disseminated neuroblastoma
1360427|NCT00526305|Acute Lymphoblastic Leukemia
1360428|NCT00526305|Chromosome Philadelphia positive
1360429|NCT00526292|recurrent adult acute lymphoblastic leukemia
1360430|NCT00526292|recurrent adult acute myeloid leukemia
1360431|NCT00526292|blastic phase chronic myelogenous leukemia
1360432|NCT00526292|previously treated myelodysplastic syndromes
1360433|NCT00526292|childhood myelodysplastic syndromes
1360434|NCT00526292|recurrent childhood acute lymphoblastic leukemia
1360435|NCT00526292|recurrent childhood acute myeloid leukemia
1360436|NCT00526292|childhood chronic myelogenous leukemia
1360437|NCT00526292|relapsing chronic myelogenous leukemia
1360438|NCT00526292|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1360439|NCT00526292|adult acute myeloid leukemia with inv(16)(p13;q22)
1360440|NCT00526292|adult acute myeloid leukemia with t(15;17)(q22;q12)
1360441|NCT00526292|adult acute myeloid leukemia with t(16;16)(p13;q22)
1360442|NCT00526292|adult acute myeloid leukemia with t(8;21)(q22;q22)
1360443|NCT00526279|Hypertension
1360444|NCT00526279|Atacand/Atacand plus
1360445|NCT00526279|COMBAT
1360446|NCT00526279|Compliance
1360447|NCT00526279|Naturalistic
1360448|NCT00526279|Observational
1360449|NCT00526253|Congestive Heart Failure
1360450|NCT00526253|CHF
1360451|NCT00526253|Heart Disease
1360452|NCT00526253|Heart Attack
1360453|NCT00526253|Stem Cell
1360454|NCT00526253|Myoblast
1360455|NCT00526253|Bioheart
1360456|NCT00526214|Spontaneous intracerebral hemorrhage
1360457|NCT00526214|Acute Spontaneous, Supratentorial intracerebral hemorrhage
1360458|NCT00526201|Arthritis
1360459|NCT00526201|Osteoarthritis
1360460|NCT00526201|Rheumatoid Arthritis
1360461|NCT00526201|Fibromyalgia
1360462|NCT00526201|Lupus
1360463|NCT00526188|Primovist
1360464|NCT00526188|Chinese patients
1360465|NCT00526188|Liver MRI
1360466|NCT00526175|Acute Lymphoblastic Leukemia
1360467|NCT00526175|Minimal Residual Disease
1360468|NCT00526149|recurrent squamous cell carcinoma of the hypopharynx
1360469|NCT00526149|recurrent squamous cell carcinoma of the larynx
1360470|NCT00526149|recurrent squamous cell carcinoma of the lip and oral cavity
1360471|NCT00526149|recurrent squamous cell carcinoma of the oropharynx
1360472|NCT00526149|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1360473|NCT00526149|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1360474|NCT00526149|recurrent metastatic squamous neck cancer with occult primary
1360475|NCT00526149|recurrent breast cancer
1360476|NCT00526149|stage IV breast cancer
1360477|NCT00526149|recurrent ovarian epithelial cancer
1360478|NCT00526149|stage IV ovarian epithelial cancer
1360479|NCT00526149|stage III ovarian epithelial cancer
1360480|NCT00526149|recurrent adult soft tissue sarcoma
1360481|NCT00526149|stage III adult soft tissue sarcoma
1360482|NCT00526149|stage IV adult soft tissue sarcoma
1360483|NCT00526149|adult leiomyosarcoma
1360484|NCT00526149|uterine leiomyosarcoma
1360485|NCT00526149|adult alveolar soft-part sarcoma
1360486|NCT00526149|adult angiosarcoma
1360487|NCT00526149|adult desmoplastic small round cell tumor
1360488|NCT00526149|adult epithelioid sarcoma
1360489|NCT00526149|adult fibrosarcoma
1360490|NCT00526149|adult liposarcoma
1360491|NCT00526149|adult malignant fibrous histiocytoma
1360492|NCT00526149|adult malignant mesenchymoma
1360493|NCT00526149|adult neurofibrosarcoma
1360494|NCT00526149|adult rhabdomyosarcoma
1360495|NCT00526149|adult synovial sarcoma
1360496|NCT00526149|endometrial stromal sarcoma
1360497|NCT00526149|ovarian carcinosarcoma
1360498|NCT00526149|ovarian sarcoma
1360499|NCT00526149|recurrent uterine sarcoma
1360500|NCT00526149|stage IV uterine sarcoma
1360501|NCT00526149|recurrent melanoma
1360502|NCT00526149|stage IV melanoma
1360503|NCT00526136|Atrial Fibrillation
1360504|NCT00526123|Dialysis
1360505|NCT00526123|Dialysis Catheter
1360506|NCT00526123|Kidney Disease
1360507|NCT00526123|Dialysis Clinic
1360508|NCT00526123|Chronic Catheter
1360509|NCT00526123|Catheter
1360510|NCT00526123|Kidney
1360511|NCT00526110|Gastrointestinal Diseases
1360512|NCT00526110|Adenocarcinoma of the Stomach
1360513|NCT00526110|Gastroesophageal Junction Cancer
1360514|NCT00526110|Cancer of the Stomach
1360515|NCT00526110|5-Fluorouracil
1360516|NCT00526110|5-FU
1360517|NCT00526110|Adrucil
1360518|NCT00526110|Efudex
1360519|NCT00526110|Docetaxel
1360520|NCT00526110|Oxaliplatin
1360521|NCT00526110|Eloxatin
1360522|NCT00526110|Taxotere
1360523|NCT00526110|Esophagus
1360524|NCT00526084|ALL
1360525|NCT00526084|Healthy subjects
1360526|NCT00526071|Fabry Disease
1360527|NCT00526071|Lysosomal Storage Disorder
1360528|NCT00526058|Heparin
1360529|NCT00526058|Extracorporeal
1360530|NCT00526058|Low Density Lipo-Protein (LDL) Cholesterol
1360531|NCT00526058|Apheresis
1360532|NCT00526058|Device
1360533|NCT00526045|AUY922
1360534|NCT00526045|Solid tumors
1360535|NCT00526045|Breast Cancer
1360536|NCT00526045|Phase I/II
1360537|NCT00526045|Advanced Solid malignancies (Phase I)
1360538|NCT00526045|Breast Cancer ( Phase II )
1360539|NCT00526045|HER2+
1360540|NCT00526045|ER+
1360541|NCT00526045|HSP90
1360542|NCT00526032|Skin Cancer
1360543|NCT00526032|Cancerous skin lesions
1360544|NCT00526032|Melanoma Detection
1360545|NCT00526032|Spectroscopic Oblique-Incidence Reflectometry
1360546|NCT00526032|OIR Imaging Probe
1360547|NCT00526019|remission of asthma
1360548|NCT00526006|Clinical significance of the acid rebound phenomenon after withdrawal of treatment with a PPI
1360549|NCT00525993|sports
1360550|NCT00525993|ankle
1360551|NCT00525993|sprain
1360552|NCT00525993|etoricoxib
1360553|NCT00525993|antiinflammatory
1360554|NCT00525993|treatment outcome
1360555|NCT00525980|Breast Cancer
1360556|NCT00525980|Cancer Risk
1360557|NCT00525980|CD-ROM
1360558|NCT00525980|Focus Group
1360559|NCT00525980|Cancer Genetics
1360560|NCT00525967|Cancer Pain
1360561|NCT00525967|Methadone
1360562|NCT00525967|Morphine
1360563|NCT00525967|Acetaminophen
1360564|NCT00525967|Palliative Care
1360565|NCT00525954|Coronary
1360566|NCT00525954|Artery
1360567|NCT00525954|Artheroschlerosis
1360568|NCT00525954|Phospholipase
1360569|NCT00525954|CAD
1360570|NCT00525954|Coronary Artery Disease (CAD)
1360571|NCT00525928|craving
1360572|NCT00525928|smoking
1360573|NCT00525928|depression
1360574|NCT00525915|Esophageal Cancer
1360575|NCT00525915|Gastroesophageal Cancer
1360576|NCT00525915|Gastroesophageal Junction
1360577|NCT00525915|Radiation Therapy
1360578|NCT00525915|5-Fluorouracil
1360579|NCT00525915|5-FU
1360580|NCT00525915|Adrucil
1360581|NCT00525915|Efudex
1360582|NCT00525915|Oxaliplatin
1360583|NCT00525889|diabetes
1360584|NCT00525889|juvenile diabetes
1360585|NCT00525889|type 1 diabetes
1360586|NCT00525889|diabetes mellitus
1360587|NCT00525889|recent onset
1360588|NCT00525889|new onset
1360589|NCT00525876|Mantle Cell Lymphoma
1360590|NCT00525876|Lymphoma
1360591|NCT00525876|Allogeneic Stem Cell Transplant
1360592|NCT00525876|Rituximab
1360593|NCT00525876|Cyclophosphamide
1360594|NCT00525876|Neosar
1360595|NCT00525876|Cytoxan
1360596|NCT00525876|Fludarabine
1360597|NCT00525876|Fludara
1360598|NCT00525876|Fludarabine phosphate
1360599|NCT00525876|Rituxan
1360600|NCT00525876|Alemtuzumab
1360601|NCT00525876|CAMPATH-1H
1360602|NCT00525876|Campath
1360603|NCT00525876|Total Body Irradiation
1360604|NCT00525876|TBI
1360605|NCT00525863|schizophrenia
1360606|NCT00525863|oxygen therapy
1360607|NCT00525850|cardiovascular disease
1360608|NCT00525850|weight loss
1360609|NCT00525837|varenicline
1360610|NCT00525837|depression
1360611|NCT00525837|anhedonia
1360612|NCT00525837|smoking
1360613|NCT00525824|Hypercholesterolaemia
1360614|NCT00525824|Coronary Heart Disease (CHD)
1360615|NCT00525824|Atherosclerosis
1360616|NCT00525798|Osteoporosis, oral salmon calcitonin, treatment, efficacy, tolerability
1360617|NCT00525785|Stomach Cancer
1360618|NCT00525785|Gastric Cancer
1360619|NCT00525785|Adenocarcinoma of the Stomach
1360620|NCT00525785|Gastroesophageal Junction
1360621|NCT00525785|Esophageal
1360622|NCT00525785|Gastric
1360623|NCT00525785|5-Fluorouracil
1360624|NCT00525785|5-FU
1360625|NCT00525785|Adrucil
1360626|NCT00525785|Efudex
1360627|NCT00525785|Folinic Acid
1360628|NCT00525785|Oxaliplatin
1360629|NCT00525785|Eloxatin
1360630|NCT00525785|Chemoradiotherapy
1360631|NCT00525785|Radiation
1360632|NCT00525785|Radiotherapy
1360633|NCT00525785|XRT
1360634|NCT00525772|asthma
1360635|NCT00525772|exercise induced bronchoconstriction
1360636|NCT00525772|sputum eosinophils
1360637|NCT00525759|Breast cancer
1360638|NCT00525759|Zoledronic acid
1360639|NCT00525759|Neoadjuvant chemotherapy
1360640|NCT00525759|Synergy
1360641|NCT00525759|Apoptosis
1360642|NCT00525746|Acute Myeloid Leukemia
1360643|NCT00525746|Myelodysplastic Syndrome
1360644|NCT00525746|Leukemia
1360645|NCT00525746|MDS
1360646|NCT00525746|AML
1360647|NCT00525746|Malignancy
1360648|NCT00525746|Molecular Epidemiology
1360649|NCT00525746|Epidemiologic markers
1360650|NCT00525746|Clinical markers
1360651|NCT00525746|Constitutional genetic markers
1360652|NCT00525746|Case-comparison study
1360653|NCT00525733|HIV-1
1360654|NCT00525733|Acute Infection
1360655|NCT00525733|Treatment Naive
1360656|NCT00525720|Prostate Cancer
1360657|NCT00525720|Prostatic Carcinoma
1360658|NCT00525720|Intermediate prostate cancer
1360659|NCT00525720|Transperineal Interstitial Permanent Brachytherapy
1360660|NCT00525720|Brachytherapy
1360661|NCT00525720|Prostate brachytherapy
1360662|NCT00525720|Prostate implant
1360663|NCT00525720|Prostate
1360664|NCT00525720|Questionnaire
1360665|NCT00525720|Survey
1360666|NCT00525707|acute heart failure
1360667|NCT00525707|Actelion
1360668|NCT00525707|tezosentan
1360669|NCT00525707|acute decompensation of chronic heart failure
1360670|NCT00525707|New onset of heart failure
1360671|NCT00525681|Obese
1360672|NCT00525681|Calcineurine inhibitor
1360673|NCT00525681|Pharmacokinetics
1360674|NCT00525681|Interaction
1360675|NCT00525668|multiple sclerosis
1360676|NCT00525668|inflammation
1360677|NCT00525668|neurodegeneration
1360678|NCT00525668|neuroprotection
1360679|NCT00525655|Familial Adenomatous Polyposis
1360680|NCT00525655|Colorectal Cancer
1360681|NCT00525655|Multimedia Intervention
1360682|NCT00525655|Questionnaire
1360683|NCT00525655|Survey
1360684|NCT00525655|FAP
1360685|NCT00525642|Breast-adjuvant
1360686|NCT00525642|Breast-chemotherapy
1360687|NCT00525642|Combination chemotherapy regimens
1360688|NCT00525616|bullous pemphigoid
1360689|NCT00525616|mabthera
1360690|NCT00525603|Chronic Lymphocytic Leukemia
1360691|NCT00525603|CML
1360692|NCT00525603|Leukemia
1360693|NCT00525603|Cyclophosphamide
1360694|NCT00525603|Fludarabine
1360695|NCT00525603|Alemtuzumab
1360696|NCT00525603|Rituximab
1360697|NCT00525603|CFAR
1360698|NCT00525590|Gliadel
1360699|NCT00525577|Type 2 diabetes, glycemic control
1360700|NCT00525564|Chronic Obstructive Pulmonary Disease (COPD)
1360701|NCT00525564|Exercise
1360702|NCT00525564|Endurance shuttle walking test
1360703|NCT00525564|Bronchodilation
1360704|NCT00525564|Salmeterol
1360705|NCT00525525|Glioblastoma
1360706|NCT00525525|Gliosarcoma
1360707|NCT00525525|Bevacizumab
1360708|NCT00525525|Avastin
1360709|NCT00525525|Erlotinib
1360710|NCT00525525|Tarceva
1360711|NCT00525525|Temozolomide
1360712|NCT00525525|Temodar
1360713|NCT00525499|acne
1360714|NCT00525486|Nifedipine
1360715|NCT00525486|Tocolysis
1360716|NCT00525486|Maintenance
1360717|NCT00525486|Preterm delivery
1360718|NCT00525486|extended release nifedipine
1360719|NCT00525486|PTL
1360720|NCT00525460|fertility
1360721|NCT00525460|stage I ovarian cancer
1360722|NCT00525460|stage II ovarian cancer
1360723|NCT00525460|fertility sparing
1360724|NCT00525447|Antigens, CD40
1360725|NCT00525447|Antibodies, Monoclonal
1360726|NCT00525447|Combined Modality Therapy
1360727|NCT00525447|Multiple Myeloma
1360728|NCT00525447|Blood Coagulation Disorders
1360729|NCT00525447|Hematologic Diseases
1360730|NCT00525447|Hemorrhagic Disorders
1360731|NCT00525447|Hemostatic Disorders
1360732|NCT00525447|Immunoproliferative Disorders
1360733|NCT00525447|Lymphoproliferative Disorders
1360734|NCT00525447|Paraproteinemias
1360735|NCT00525447|Vascular Diseases
1360736|NCT00525447|Antibody-Dependent Cell Cytotoxicity
1360737|NCT00525434|Laser bonding soft tissue albumin
1360738|NCT00525421|curcuminoids
1360739|NCT00525421|oral lichen planus
1360740|NCT00525421|c reactive protein
1360741|NCT00525421|interleukin 6
1360742|NCT00525408|HRPC
1360743|NCT00525408|Metastatic Hormone Refractory Prostate Cancer
1360744|NCT00525408|Docetaxel
1360745|NCT00525408|Mycobacterium w
1360746|NCT00525395|Phototherapy
1360747|NCT00525395|Vitiligo scoring system
1360748|NCT00525382|Levocetirizine dihydrochloride
1360749|NCT00525382|Xyzal tablets
1360750|NCT00525356|Aorta
1360751|NCT00525356|Dissection
1360752|NCT00525356|Thoracic
1360753|NCT00525343|Avonex pivotal trial
1360754|NCT00525343|Avonex
1360755|NCT00525343|Avonex long term follow-up
1360756|NCT00525343|Avonex outcomes
1360757|NCT00525317|Pregnancy
1360758|NCT00525317|Magnesium
1360759|NCT00525317|Leg Pain
1360760|NCT00525304|medical co-morbidity
1360761|NCT00525304|diabetes
1360762|NCT00525304|heart disease
1360763|NCT00525304|respiratory illness
1360764|NCT00525291|Exercise Therapy
1360765|NCT00525291|Biofeedback (Psychology)
1360766|NCT00525291|Adult
1360767|NCT00525291|Fecal Incontinence/*therapy
1360768|NCT00525291|EMG - Biofeedback
1360769|NCT00525291|EMG - Triggered Stimulation
1360770|NCT00525291|Augmented biofeedback
1360771|NCT00525278|Levocetirizine dihydrochloride
1360772|NCT00525278|Xyzal tablets
1360773|NCT00525265|Vasopressin antagonist
1360774|NCT00525265|Cardiac Edema
1360775|NCT00525265|Diuretics
1360776|NCT00525252|Liver cirrhosis
1360777|NCT00525252|Alcoholism
1360778|NCT00525252|Craving
1360779|NCT00525239|Lipids
1360780|NCT00525239|lipoproteins
1360781|NCT00525239|VLDL
1360782|NCT00525239|triglycerides
1360783|NCT00525239|apo B100
1360784|NCT00525239|HDL
1360785|NCT00525239|apo A1
1360786|NCT00525239|endothelial dysfunction
1360787|NCT00525239|insulin secretion
1360788|NCT00525239|hyperglycemic clamp
1360789|NCT00525239|HIV-seronegative Volunteers
1360790|NCT00525239|HIV-infected subjects starting an efavirenz-based regimen
1360791|NCT00525239|Treatment Experienced
1360792|NCT00525226|Psychiatry
1360793|NCT00525226|Psychology
1360794|NCT00525226|Pregnancy
1360795|NCT00525226|Stress
1360796|NCT00525226|Anxiety
1360797|NCT00525213|Rheumatoid Arthritis
1360798|NCT00525200|predictive marker
1360799|NCT00525200|personalized therapy
1360800|NCT00525200|response assessment
1360801|NCT00525200|p53 genotype
1360802|NCT00525187|onychomycosis
1360803|NCT00525187|diabetic neuropathic patients
1360804|NCT00525187|reliability of the diagnostic of onychomycosis
1360805|NCT00525174|Amblyopia
1360806|NCT00525174|Patching
1360807|NCT00525174|Bangerter filters
1360808|NCT00525161|breast cancer
1360809|NCT00525161|Sorafenib
1360810|NCT00525161|Nexavar
1360811|NCT00525161|Endocrine Therapy
1360812|NCT00525122|hyperthyroidism
1360813|NCT00525122|radioactive iodine
1360814|NCT00525122|antithyroid drugs
1360815|NCT00525122|Hyperthyroidism, treatment with radioactive iodine without antithyroid drugs
1360816|NCT00525109|Cholesterol
1360817|NCT00525109|Hyperlipidemia
1360818|NCT00525109|Gene array
1360819|NCT00525083|hyperlipidemia
1360820|NCT00525083|HDL-C
1360821|NCT00525083|low density lipoprotein
1360822|NCT00525057|Bone Cancer
1360823|NCT00525057|Orthopaedic Oncology
1360824|NCT00525057|Orthopaedics
1360825|NCT00525057|Myeloma
1360826|NCT00525057|Lymphoma
1360827|NCT00525057|Deep Venous Thrombosis
1360828|NCT00525057|DVT Prophylaxis
1360829|NCT00525057|Thromboembolic disease
1360830|NCT00525057|Blood clots
1360831|NCT00525057|Dalteparin
1360832|NCT00525057|Fragmin
1360833|NCT00525057|Surgery
1360834|NCT00525057|Bone Tumor
1360835|NCT00525057|Tumor of soft tissue
1360836|NCT00525057|Lower extremity
1360837|NCT00525057|Leg
1360838|NCT00525057|TED hose
1360839|NCT00525057|Mechanical compression stocking
1360840|NCT00525031|Melanoma
1360841|NCT00525031|Temozolomide
1360842|NCT00525031|Temodar
1360843|NCT00525031|Pegylated Interferon Alpha-2b
1360844|NCT00525031|PEG-Intron
1360845|NCT00525031|PGI
1360846|NCT00525031|Resectable metastatic melanoma
1360847|NCT00525031|Surgery
1360848|NCT00525018|Pain
1360849|NCT00525018|Functional neuroimaging
1360850|NCT00525018|Neuropathy
1360851|NCT00525018|Thermal sensation
1360852|NCT00525005|Stomach Neoplasm
1360853|NCT00525005|Docetaxel
1360854|NCT00525005|Oxaliplatin
1360855|NCT00525005|S-1
1360856|NCT00524992|Focal Segmental Glomerulosclerosis
1360857|NCT00524992|Collapsing Glomerulopathy
1360858|NCT00524992|Anti-Retroviral Toxicity
1360859|NCT00524992|Lipodystrophy
1360860|NCT00524992|Metabolic Syndrome
1360861|NCT00524992|Tubular Injury
1360862|NCT00524992|Renal Biopsy
1360863|NCT00524992|Proteinuria
1360864|NCT00524992|Tenofovir Toxicity
1360865|NCT00524992|HAART Toxicity
1360866|NCT00524992|HIV Positive
1360867|NCT00524992|HIV-Associated Focal Segmental Glomerulosclerosis
1360868|NCT00524953|allogeneic bone marrow transplantation
1360869|NCT00524953|non-T-cell depleted
1360870|NCT00524953|UV-c
1360871|NCT00524953|GVHD
1360872|NCT00524940|Influenza
1360873|NCT00524940|Orthomyxoviruses
1360874|NCT00524940|Inactivated Split-virion influenza vaccine
1360875|NCT00524927|Incident Pain
1360876|NCT00524927|Bone Marrow Biopsy
1360877|NCT00524914|Parkinson's disease
1360878|NCT00524914|Pain
1360879|NCT00524914|Nociceptive threshold
1360880|NCT00524914|Functional imaging
1360881|NCT00524914|Cerebral activity
1360882|NCT00524914|Dopamine agonist.
1360883|NCT00524901|Apoptosis
1360884|NCT00524901|CABG
1360885|NCT00524901|Coronary Artery Disease
1360886|NCT00524901|Three Vessel Disease
1360887|NCT00524901|Erythropoietin
1360888|NCT00524901|EPO-receptor signaling
1360889|NCT00524888|Hand
1360890|NCT00524888|Laceration
1360891|NCT00524888|bioadhesive
1360892|NCT00524888|ER
1360893|NCT00524888|Hand laceration distal to the volar wrist crease
1360894|NCT00524875|Proliferative diabetic retinopathy
1360895|NCT00524875|Bevacizumab
1360896|NCT00524875|Early post-vitrectomy vitreous hemorrhage
1360897|NCT00524862|Implantable Cardioverter Defibrillator
1360898|NCT00524862|Ejection Fraction
1360899|NCT00524862|QRS duration
1360900|NCT00524849|Breast cancer
1360901|NCT00524849|Bone metastasis
1360902|NCT00524849|Circulating VEGF
1360903|NCT00524849|Zoledronic acid
1360904|NCT00524849|Angiogenesis
1360905|NCT00524836|levocetirizine dihydrochloride
1360906|NCT00524836|Xyzal tablets
1360907|NCT00524823|Prostate Cancer
1360908|NCT00524823|Hyperplasia - BPH
1360909|NCT00524823|FACS
1360910|NCT00524823|Prostate Cancer, Hyperplasia - BPH, Malignancy
1360911|NCT00524797|Myelosuppression,
1360912|NCT00524797|chemotherapeutic agents,
1360913|NCT00524797|leucopenia,
1360914|NCT00524797|thrombocytopenia,
1360915|NCT00524797|Profonycia
1360916|NCT00524784|GVHD
1360917|NCT00524784|HSCT
1360918|NCT00524784|BMT
1360919|NCT00524784|APOPTOTIC CELLS
1360920|NCT00524771|Contraception
1360921|NCT00524771|Contraceptive Vaginal Ring
1360930|NCT00524745|Gardasil
1360931|NCT00524745|Human Papillomavirus
1360932|NCT00524745|HPV vaccine
1360933|NCT00524745|Cervical cancer
1360934|NCT00524732|Pertussis
1360935|NCT00524732|Tetanus
1360936|NCT00524732|Diphtheria
1360937|NCT00524706|S-1
1360938|NCT00524706|oral fluoropyrimidine
1360939|NCT00524706|tegafur
1360940|NCT00524706|Gimeracil
1360941|NCT00524706|Oteracil Potassium
1360942|NCT00524706|Leucovorin
1360943|NCT00524706|Calcium Folinate
1360944|NCT00524706|Oxaliplatin
1360945|NCT00524706|L-OHP
1360946|NCT00524706|colorectal cancer
1360947|NCT00524693|Bronchiolitis
1360948|NCT00524693|controlled clinical trial
1360949|NCT00524693|pediatrics
1360950|NCT00524693|Infants
1360951|NCT00524693|montelukast
1360952|NCT00524693|Respiratory syncytial virus
1360953|NCT00524680|adenocarcinoma of the prostate
1360954|NCT00524680|recurrent prostate cancer
1360955|NCT00524680|stage I prostate cancer
1360956|NCT00524680|stage II prostate cancer
1360957|NCT00524680|stage III prostate cancer
1360958|NCT00524680|stage IV prostate cancer
1360959|NCT00524667|Active CLL
1360960|NCT00524654|To determine the effects of cervical spine manipulation on postural control.
1360961|NCT00524641|Asthma
1360962|NCT00524641|Symbicort
1360963|NCT00524641|NIS
1360964|NCT00524615|resistant hypertension treatment
1360965|NCT00524615|spironolactone
1360966|NCT00524615|aldosterone antagonists
1360967|NCT00524615|resistant arterial hypertension
1360968|NCT00524615|refractory arterial hypertension
1360969|NCT00524602|Stereotaxis
1360970|NCT00524602|Arrythmia
1360971|NCT00524602|Catheter ablation
1360972|NCT00524602|Heart
1360973|NCT00524589|recurrent prostate cancer
1360974|NCT00524576|Hepatitis B
1360975|NCT00524576|Persistence
1360976|NCT00524576|Challenge dose
1360977|NCT00524563|Acinetobacter
1360978|NCT00524563|bloodstream infection
1360979|NCT00524563|Isolate
1360980|NCT00524550|Moderate alcohol consumption
1360981|NCT00524550|insulin secretion
1360982|NCT00524550|insulin sensitivity
1360983|NCT00524550|Beta-cell function
1360984|NCT00524550|Adiponectin
1360985|NCT00524550|Appetite
1360986|NCT00524550|Satiety
1360987|NCT00524550|Alcohol-induced gene expression
1360988|NCT00524550|Endocannabinoids
1360989|NCT00524550|Glucose metabolism
1360990|NCT00524550|Lipid metabolism
1360991|NCT00524550|Ratio HMW/total adiponectin
1360992|NCT00524550|Appetite regulation
1360993|NCT00524550|Alcohol-induced adiponectin increase
1360994|NCT00524537|Crohn's Disease
1360995|NCT00524524|solid tumors
1360996|NCT00524524|biopsy
1360997|NCT00524511|cesarean
1360998|NCT00524511|wound
1360999|NCT00524511|Dermabond
1361000|NCT00524511|superglue
1361001|NCT00524511|staples
1361002|NCT00524511|wound complications
1361003|NCT00524498|OPC-18
1361004|NCT00524498|Interferon-alpha
1361005|NCT00524498|Fluorouracil
1361006|NCT00524485|actinic keratosis
1361007|NCT00524472|Hyperinsulinemic glucose control
1361008|NCT00524472|cardiac surgery
1361009|NCT00524472|Outcome
1361010|NCT00524459|stage IIIA breast cancer
1361011|NCT00524459|stage IIIB breast cancer
1361012|NCT00524446|Infant
1361013|NCT00524446|Sub-Saharan Africa
1361014|NCT00524446|Complementary feeding
1361015|NCT00524446|Fortified spread
1361016|NCT00524446|Lipid-based nutrient supplement
1361017|NCT00524446|Malnutrition
1361018|NCT00524446|Stunting
1361019|NCT00524446|Growth
1361020|NCT00524446|Morbidity
1361021|NCT00524446|Development
1361022|NCT00524446|Haemoglobin
1361023|NCT00524433|acute heart failure
1361024|NCT00524433|acute decompensation of chronic heart failure
1361025|NCT00524433|new onset of heart failure
1361026|NCT00524433|tezosentan
1361027|NCT00524433|Actelion
1361028|NCT00524420|Pain
1361029|NCT00524420|Fatigue
1361030|NCT00524420|Chronic Fatigue Syndrome
1361031|NCT00524420|Chronic Fatigue-Fibromyalgia Syndrome
1361032|NCT00524420|Depression
1361033|NCT00524420|Major Depressive Disorder
1361034|NCT00524407|Anemia
1361035|NCT00524407|hemoglobin
1361036|NCT00524407|chemotherapy
1361037|NCT00524407|hematologic response
1361038|NCT00524407|subcutaneous injection
1361039|NCT00524407|Epoetin alfa
1361040|NCT00524407|FACT-An
1361041|NCT00524407|LASA
1361042|NCT00524407|PROCRIT
1361043|NCT00524394|VLBW
1361044|NCT00524394|sepsis
1361045|NCT00524394|diagnosis
1361046|NCT00524394|suspected sepsis
1361047|NCT00524368|Human immunodeficiency virus - type 1
1361048|NCT00524368|HIV-1 Infection
1361049|NCT00524368|TMC-114
1361050|NCT00524368|Darunavir
1361051|NCT00524368|Ritonavir
1361052|NCT00524355|GERD
1361053|NCT00524355|GIS
1361054|NCT00524355|heartburn
1361055|NCT00524355|NIS
1361056|NCT00524355|PPI
1361057|NCT00524342|IL-11
1361058|NCT00524342|von Willebrand disease
1361059|NCT00524342|von Willebrand factor
1361060|NCT00524342|VWFmRNA
1361061|NCT00524342|menorrhagia
1361062|NCT00524329|upper GI-symptoms
1361063|NCT00524329|heartburn
1361064|NCT00524329|NSAID
1361065|NCT00524329|risk
1361066|NCT00524329|PPI
1361067|NCT00524329|Bloating
1361068|NCT00524329|Regurgitation
1361069|NCT00524316|adult primary hepatocellular carcinoma
1361070|NCT00524316|advanced adult primary liver cancer
1361071|NCT00524316|localized unresectable adult primary liver cancer
1361072|NCT00524316|recurrent adult primary liver cancer
1361073|NCT00524303|ErbB2 Overexpressing
1361074|NCT00524303|ErbB2 Positive
1361075|NCT00524303|Lapatinib
1361076|NCT00524303|Invasive Breast Cancer
1361077|NCT00524290|Acinetobacter
1361078|NCT00524290|infection
1361079|NCT00524290|isolate
1361080|NCT00524277|stage I breast cancer
1361081|NCT00524277|stage II breast cancer
1361082|NCT00524277|stage IIIA breast cancer
1361083|NCT00524277|stage IIIB breast cancer
1361084|NCT00524277|stage IIIC breast cancer
1361085|NCT00524277|male breast cancer
1361086|NCT00524251|Patients with reflux complaints
1361087|NCT00524251|GERD
1361088|NCT00524251|quality of life
1361089|NCT00524251|lifestyle adjustments
1361090|NCT00524238|hypothyroidism
1361091|NCT00524238|glucose turnover
1361092|NCT00524238|clamp
1361093|NCT00524238|insulin resistance
1361094|NCT00524238|lipid turnover
1361095|NCT00524238|amino acid turnover
1361096|NCT00524225|IL-11
1361097|NCT00524225|von Willebrand disease
1361098|NCT00524225|von Willebrand factor
1361099|NCT00524225|VWFmRNA
1361100|NCT00524225|surgery
1361101|NCT00524199|homocysteine
1361102|NCT00524199|hemodialysis
1361103|NCT00524199|mesna
1361104|NCT00524186|stage III gastric cancer
1361105|NCT00524186|stage IV gastric cancer
1361106|NCT00524186|adenocarcinoma of the esophagus
1361107|NCT00524186|stage IV esophageal cancer
1361108|NCT00524186|recurrent gastric cancer
1361109|NCT00524186|recurrent esophageal cancer
1361110|NCT00524186|adenocarcinoma of the stomach
1361111|NCT00524173|Emtricitabine
1361112|NCT00524173|Tenofovir
1361113|NCT00524173|Antiviral Therapy
1361114|NCT00524173|Hepatitis B
1361115|NCT00524173|HBV
1361116|NCT00524160|Fentanyl
1361117|NCT00524160|opioid analgesics
1361118|NCT00524160|arthritis
1361119|NCT00524160|osteoarthritis
1361120|NCT00524160|rheumatoid arthritis
1361121|NCT00524160|transdermal administration
1361122|NCT00524147|loculated pleural effusion
1361123|NCT00524147|pigtail drainage
1361124|NCT00524147|pleural effusion
1361125|NCT00524147|pleural thickening
1361126|NCT00524147|tuberculosis
1361127|NCT00524134|Epilepsy
1361128|NCT00524134|Seizure
1361129|NCT00524134|p-glycoprotein
1361130|NCT00524121|adenocarcinoma of the esophagus
1361131|NCT00524121|squamous cell carcinoma of the esophagus
1361132|NCT00524121|stage I esophageal cancer
1361133|NCT00524121|stage II esophageal cancer
1361134|NCT00524121|stage III esophageal cancer
1361135|NCT00524121|stage IV esophageal cancer
1361136|NCT00524108|shunt
1361137|NCT00524108|internal ventriculoperitoneal
1361138|NCT00524095|prophylaxis
1361139|NCT00524095|Antibiotic
1361140|NCT00524095|inhaled steroids
1361141|NCT00524095|bronchiectasis
1361142|NCT00524095|prevalence
1361143|NCT00524095|chronic bronchitis
1361144|NCT00524069|stage I pancreatic cancer
1361145|NCT00524069|stage II pancreatic cancer
1361146|NCT00524069|adenocarcinoma of the pancreas
1361147|NCT00524056|Essential Tremor
1361148|NCT00524056|Tremor
1361149|NCT00524056|Anti-epileptic drug (AED)
1361150|NCT00524043|Schizophrenia
1361151|NCT00524030|Epilepsy
1361152|NCT00524030|partial seizures
1361153|NCT00524030|pregabalin monotherapy
1361154|NCT00524030|double-blind and randomized trial
1361155|NCT00524017|hypopharyngeal cancer
1361156|NCT00524017|laryngeal cancer
1361157|NCT00524017|lip and oral cavity cancer
1361158|NCT00524017|nasopharyngeal cancer
1361159|NCT00524017|oropharyngeal cancer
1361160|NCT00524017|paranasal sinus and nasal cavity cancer
1361161|NCT00524017|salivary gland cancer
1361162|NCT00524017|precancerous condition
1361163|NCT00524004|Passive immunization, Bovine Milk Immunoglobulin
1361164|NCT00523978|Atrial Fibrillation
1361165|NCT00523965|Kala-azar
1361166|NCT00523965|miltefosine
1361167|NCT00523965|liposomal amphotericin B
1361168|NCT00523952|dermatitis, atopic
1361169|NCT00523952|tacrolimus
1361170|NCT00523952|adult
1361171|NCT00523939|Lymphoma
1361172|NCT00523939|Leukemia
1361173|NCT00523939|Leukemic Meningitis
1361174|NCT00523939|Lymphomatous Meningitis
1361175|NCT00523926|Tuberculosis
1361176|NCT00523913|type 2 diabetes mellitus;
1361177|NCT00523913|diabetes;
1361178|NCT00523913|rosiglitazone
1361179|NCT00523913|Avandia;
1361180|NCT00523900|malnutrition
1361181|NCT00523900|underweight
1361182|NCT00523900|low body weight
1361183|NCT00523900|BMI under 19
1361184|NCT00523900|under nourished
1361185|NCT00523900|malnourished
1361186|NCT00523887|Radiation pain
1361187|NCT00523887|Duragesic
1361188|NCT00523887|Fentanyl
1361189|NCT00523887|Pain
1361190|NCT00523861|Glucose
1361191|NCT00523861|Insulin sensitivity
1361192|NCT00523861|Glucose metabolism
1361193|NCT00523861|Appetite
1361194|NCT00523861|Satiety
1361195|NCT00523848|stage I multiple myeloma
1361196|NCT00523848|stage II multiple myeloma
1361197|NCT00523848|stage III multiple myeloma
1361198|NCT00523822|This study seeks to determine if the correction of a sacroiliac lesion can produce a functional change in cervical spine.
1361199|NCT00523809|Breast Cancer
1361200|NCT00523809|Ovarian Cancer
1361201|NCT00523809|Stem Cell Transplantation
1361202|NCT00523809|Bevacizumab
1361203|NCT00523809|Fludarabine
1361204|NCT00523809|Melphalan
1361205|NCT00523809|Avastin
1361206|NCT00523809|Thymoglobulin
1361207|NCT00523809|ATG
1361208|NCT00523809|Antithymocyte Globulin
1361209|NCT00523809|Allogeneic Hematopoietic Stem Cell Transplantation
1361210|NCT00523809|AHSCT
1361211|NCT00523796|dyslipidemia
1361212|NCT00523796|in practice survey
1361213|NCT00523796|Vietnam
1361214|NCT00523783|Schizophrenia
1361215|NCT00523783|Schizoaffective
1361216|NCT00523783|quetiapine
1361217|NCT00523783|long-term efficacy
1361218|NCT00523783|Naturalistic
1361219|NCT00523783|Observational
1361220|NCT00523770|Invasive Pneumococcal Diseases
1361221|NCT00523770|Pneumonia
1361222|NCT00523757|heart failure
1361223|NCT00523757|collagen
1361224|NCT00523757|diastolic function
1361225|NCT00523744|hypertension, valsartan, amlodipine
1361226|NCT00523731|Stem cells
1361227|NCT00523731|Rest pain
1361228|NCT00523731|claudication
1361229|NCT00523731|chronic ischemic or non-healing ulcers
1361230|NCT00523731|Angiogenesis
1361231|NCT00523731|no-option cases
1361232|NCT00523718|obsessive-compulsive disorder
1361233|NCT00523718|OCD
1361234|NCT00523718|glutamate
1361235|NCT00523718|riluzole
1361236|NCT00523718|augmentation
1361237|NCT00523718|treatment
1361238|NCT00523705|premenstrual syndrome
1361239|NCT00523705|PMS
1361240|NCT00523705|PMDD
1361241|NCT00523705|treatment
1361242|NCT00523705|SSRI
1361243|NCT00523692|Early arthritis
1361244|NCT00523692|Rheumatoid arthritis
1361245|NCT00523692|Rheumatoid factor
1361246|NCT00523692|Anti CCP antibody
1361247|NCT00523692|Remission
1361248|NCT00523692|Anti-TNF therapy
1361249|NCT00523692|methotrexate
1361250|NCT00523679|Asthma
1361251|NCT00523679|Symbicort
1361252|NCT00523679|SMART
1361253|NCT00523679|inhaler
1361254|NCT00523679|compliance
1361255|NCT00523679|Naturalistic
1361256|NCT00523679|Observational
1361257|NCT00523666|Alzheimer's disease
1361258|NCT00523666|diffusion tensor imaging
1361259|NCT00523640|metastatic
1361260|NCT00523640|renal cell
1361261|NCT00523640|kidney
1361262|NCT00523640|neoplasm
1361263|NCT00523627|Energy Expenditure
1361264|NCT00523627|Adaptive Thermogenesis
1361265|NCT00523627|Low-protein Overfeeding
1361266|NCT00523627|Fasting
1361267|NCT00523627|Weight Gain
1361268|NCT00523614|venous thromboembolism
1361269|NCT00523601|Bipolar depression
1361270|NCT00523601|quetiapine
1361271|NCT00523601|observational
1361272|NCT00523601|Naturalistic
1361273|NCT00523588|Cutaneous lupus erythematosus
1361274|NCT00523588|Pulsed dye laser
1361275|NCT00523575|Elderly
1361276|NCT00523575|Osteoporosis
1361277|NCT00523575|hip fracture
1361278|NCT00523575|malnutrition
1361279|NCT00523575|nutritional support
1361280|NCT00523562|fructose
1361281|NCT00523562|dietary lipids
1361282|NCT00523562|dietary proteins
1361283|NCT00523562|hepatic steatosis
1361284|NCT00523562|insulin resistance
1361285|NCT00523562|Healthy humans
1361286|NCT00523562|overweight humans
1361287|NCT00523562|obese humans
1361288|NCT00523549|Hypertension
1361289|NCT00523549|systolic blood pressure
1361290|NCT00523549|diastolic dysfunction
1361291|NCT00523549|valsartan
1361292|NCT00523549|amlodipine
1361293|NCT00523536|High Blood Pressure
1361294|NCT00523536|Cardiovascular
1361295|NCT00523523|Rehabilitation
1361296|NCT00523523|hemiplegia
1361297|NCT00523523|stroke
1361298|NCT00523523|upper extremity
1361299|NCT00523523|motor skills
1361300|NCT00523523|therapy
1361301|NCT00523510|breastmilk
1361302|NCT00523510|perinatal HIV
1361303|NCT00523510|infant feeding
1361304|NCT00523510|flash heat
1361305|NCT00523510|pasteurization
1361306|NCT00523510|pmtct
1361307|NCT00523510|HIV
1361308|NCT00523510|HIV Seronegativity
1361309|NCT00523510|Treatment Naive
1361310|NCT00523497|Severe community-acquired pneumonia
1361311|NCT00523497|Noninvasive mechanical ventilation
1361312|NCT00523497|Acute hypoxemic respiratory failure.
1361313|NCT00523484|Beck Anxiety Inventory
1361314|NCT00523484|Prostate Cancer
1361315|NCT00523484|Prostate Specific Antigen
1361316|NCT00523484|Naturalistic
1361317|NCT00523484|Observational
1361318|NCT00523471|prostate cancer
1361319|NCT00523471|gamma H2AX
1361320|NCT00523471|radiosensitivity
1361321|NCT00523458|Co-infection
1361322|NCT00523458|Tuberculosis
1361323|NCT00523458|HIV
1361324|NCT00523458|Drug interactions
1361325|NCT00523458|Non nucleoside reverse transcriptase inhibitors
1361326|NCT00523458|Therapy
1361327|NCT00523458|Treatment Naive
1361328|NCT00523445|Schizophrenia
1361329|NCT00523445|Cognition
1361330|NCT00523445|Varenicline
1361331|NCT00523432|ovarian cancer
1361332|NCT00523432|cervical cancer
1361333|NCT00523432|uterine cancer
1361334|NCT00523432|fallopian tube cancer
1361335|NCT00523432|endometrial cancer
1361336|NCT00523432|vaginal cancer
1361337|NCT00523432|peritoneal cancer
1361338|NCT00523432|reproductive cancer
1361339|NCT00523406|choroidal neovascularisation,
1361340|NCT00523406|vision,
1361341|NCT00523406|macula,
1361342|NCT00523406|macular degeneration
1361343|NCT00523406|optical coherence tomography
1361344|NCT00523406|neovascular age related macular degeneration
1361345|NCT00523367|Gastro Esophageal Reflux Disease (GERD)
1361346|NCT00523367|Chronic Obstructive Pulmonary Disease (COPD)
1361347|NCT00523354|Eosinophilic Esophagitis
1361348|NCT00523354|TNF-alpha
1361349|NCT00523354|TNF-alpha Blockade
1361350|NCT00523354|Infliximab
1361351|NCT00523341|postmenopausal osteoporosis
1361352|NCT00523341|low bone density
1361353|NCT00523341|fractures
1361354|NCT00523341|low bone mass
1361355|NCT00523328|Rheumatoid Arthritis
1361356|NCT00523328|Arthritis
1361357|NCT00523328|BG9924
1361358|NCT00523328|methotrexate
1361359|NCT00523315|Aromatase Inhibitor
1361360|NCT00523315|Breast Cancer
1361361|NCT00523315|compliance
1361362|NCT00523315|Naturalistic
1361363|NCT00523315|Observational
1361364|NCT00523302|Major Depression
1361365|NCT00523302|Fibromyalgia
1361366|NCT00523302|TMS
1361367|NCT00523289|Ropivacaine
1361368|NCT00523289|Bupivacaine
1361369|NCT00523289|Upper Extremity
1361370|NCT00523289|Local anesthetic
1361371|NCT00523276|Severe acute respiratory syndrome, SARS, China
1361372|NCT00523250|Glaucoma
1361373|NCT00523224|Stem cells
1361374|NCT00523224|Coronary Artery Bypass grafting
1361375|NCT00523224|Congestive Heart Failure
1361376|NCT00523224|Coronary Artery Disease
1361377|NCT00523224|Angiogenesis
1361378|NCT00523211|Acquired Immunodeficiency Syndrome
1361379|NCT00523211|Treatment Experienced
1361380|NCT00523198|Cortisol
1361381|NCT00523185|alcohol withdrawal
1361382|NCT00523185|lorazepam
1361383|NCT00523185|diazepam
1361384|NCT00523172|Chiropractic Manipulation
1361385|NCT00523159|clear cell renal cell carcinoma
1361386|NCT00523146|primary dysmenorrhea
1361387|NCT00523146|Herbal remedy
1361388|NCT00523133|alcoholism
1361389|NCT00523133|naltrexone
1361390|NCT00523133|motivational enhancement therapy
1361391|NCT00523107|Fatigue
1361392|NCT00523107|Standard Palliative Care
1361393|NCT00523107|PG2
1361394|NCT00523107|QLQ-C30
1361395|NCT00523107|Compassionate
1361396|NCT00523081|adolescent depression treatment, cognitive behavioral therapy,
1361397|NCT00523081|collaborative care
1361398|NCT00523068|overactive bladder
1361399|NCT00523068|stress urinary incontinence
1361400|NCT00523068|detrusor overactivity
1361401|NCT00523068|urodynamics
1361402|NCT00523055|Pain
1361403|NCT00523055|Brachial Plexus Anesthesia
1361404|NCT00523055|Plasma Lidocaine Levels
1361405|NCT00523055|Ultrasound
1361406|NCT00523029|Self-management programs
1361407|NCT00523029|Chronic medical illness
1361408|NCT00523016|acupuncture
1361409|NCT00523016|electroacupuncture
1361410|NCT00523016|sham acupuncture
1361411|NCT00523016|spinal cord injury
1361412|NCT00523016|neuropathic pain
1361413|NCT00523016|burning pain
1361414|NCT00523003|weight loss
1361415|NCT00523003|obesity
1361416|NCT00523003|high protein
1361417|NCT00523003|meal replacement
1361418|NCT00522977|Myocardial strain
1361419|NCT00522977|Myocardial function
1361420|NCT00522977|Pregnancy
1361421|NCT00522977|Postpartum
1361422|NCT00522977|Echocardiography
1361423|NCT00522977|Myocardial adaptation to pregnancy
1361424|NCT00522977|Systolic function
1361425|NCT00522977|Diastolic function
1361426|NCT00522964|Chinese-American
1361427|NCT00522964|Children
1361428|NCT00522964|Obesity
1361429|NCT00522964|health behaviors
1361430|NCT00522964|Behavioral intervention
1361431|NCT00522964|normal
1361432|NCT00522951|MRI
1361433|NCT00522951|Brain Metastasis
1361434|NCT00522951|Gadolinium
1361435|NCT00522951|Imaging
1361436|NCT00522951|Diagnostic Agent
1361437|NCT00522938|Lung
1361438|NCT00522938|Cancer
1361439|NCT00522938|Non-small
1361440|NCT00522938|Lung Cancer
1361441|NCT00522938|NSCLC
1361442|NCT00522938|erlotinib
1361443|NCT00522938|oral
1361444|NCT00522938|Locally Advanced Non-small Cell Lung Cancer
1361445|NCT00522938|Metastatic Non-small Cell Lung Cancer
1361446|NCT00522925|hypertension
1361447|NCT00522925|high blood pressure
1361448|NCT00522912|Trachoma
1361449|NCT00522912|Trichiasis
1361450|NCT00522912|Surgery
1361451|NCT00522912|Epilation
1361452|NCT00522912|Ethiopia
1361453|NCT00522899|aged
1361454|NCT00522899|exercise
1361455|NCT00522899|cognitive therapy
1361456|NCT00522899|dementia
1361457|NCT00522899|prevention
1361458|NCT00522886|cetuximab
1361459|NCT00522886|concurrent
1361460|NCT00522886|iso-toxic
1361461|NCT00522886|NSCLC
1361462|NCT00522873|Postmenopausal Symptoms e.g.
1361463|NCT00522873|Hot flushes
1361464|NCT00522873|Sweating episodes
1361465|NCT00522873|Vaginal dryness
1361466|NCT00522860|Trichiasis
1361467|NCT00522860|Trachoma
1361468|NCT00522860|Surgery
1361469|NCT00522860|Suture
1361470|NCT00522860|Ethiopia
1361471|NCT00522847|Postmenopausal
1361472|NCT00522847|non dry eye
1361473|NCT00522834|melanoma
1361474|NCT00522834|oncology
1361475|NCT00522834|Stage IV Metastatic Melanoma
1361476|NCT00522821|IgG subclass deficiency
1361477|NCT00522821|Anti-polysaccharide deficiency
1361478|NCT00522821|therapy
1361479|NCT00522821|Immunoglobulins, Intravenous
1361480|NCT00522821|co-trimoxazole
1361481|NCT00522808|HCV
1361482|NCT00522808|antiviral
1361483|NCT00522808|PK
1361484|NCT00522808|Safety
1361485|NCT00522795|Esophageal Cancer
1361486|NCT00522769|binge eating
1361487|NCT00522769|adolescent girls
1361488|NCT00522769|cognitive behavioral therapy
1361489|NCT00522756|Kidney Failure, Acute
1361490|NCT00522756|Cardiac Surgical Procedures
1361491|NCT00522756|Sodium Bicarbonate
1361492|NCT00522756|Sodium Chloride
1361493|NCT00522756|Prevention and control
1361494|NCT00522743|SGA
1361495|NCT00522743|GH
1361496|NCT00522743|GnRHa
1361497|NCT00522743|IGF-1
1361498|NCT00522730|Liver failure
1361499|NCT00522730|Liver cirrhosis
1361500|NCT00522730|Parenteral nutrition
1361501|NCT00522730|Enteral nutrition
1361502|NCT00522730|Lipids
1361503|NCT00522730|Safety
1361504|NCT00522730|Drug tolerance
1361505|NCT00522704|Arteriovenous fistula
1361506|NCT00522704|Access blood flow
1361507|NCT00522704|Extracorporeal blood flow
1361508|NCT00522704|Dynamic arterial line pressure
1361509|NCT00522704|Hemodialysis treatment
1361510|NCT00522691|Fecal incontinence
1361511|NCT00522691|sacral nerve stimulation
1361512|NCT00522678|Healthy Volunteers
1361513|NCT00522652|cancer
1361514|NCT00522652|advanced cancer
1361515|NCT00522652|lymphoma
1361516|NCT00522639|lung cancer
1361517|NCT00522639|FDG-PET-CT
1361518|NCT00522639|blood proteins
1361519|NCT00522639|prognose
1361520|NCT00522626|Fetus
1361521|NCT00522626|Drug abuse
1361522|NCT00522626|Fetal development
1361523|NCT00522626|Substance abuse
1361524|NCT00522626|Opioids
1361525|NCT00522626|Methadone
1361526|NCT00522613|recovery
1361527|NCT00522613|serious mental illness
1361528|NCT00522613|bipolar disorder
1361529|NCT00522613|schizophrenia
1361530|NCT00522613|schizoaffective disorder
1361531|NCT00522600|eyedrops
1361532|NCT00522600|compliance
1361533|NCT00522600|glaucoma medications
1361534|NCT00522600|adherence
1361535|NCT00522574|Myeloproliferative Disorders
1361536|NCT00522561|Healthy volunteers
1361537|NCT00522561|running
1361538|NCT00522561|energetic cost
1361539|NCT00522561|limb mechanical characteristics
1361540|NCT00522561|contractile components
1361541|NCT00522561|elastic components
1361542|NCT00522561|healthy men doing regularly physical activities
1361543|NCT00522548|African American
1361544|NCT00522548|Kidney Transplant
1361545|NCT00522535|AAA
1361546|NCT00522535|Abdominal Aortic Aneurysms
1361547|NCT00522535|Endovascular
1361548|NCT00522535|EVAR
1361549|NCT00522535|Aorta
1361550|NCT00522535|Stent Graft
1361551|NCT00522535|Stent
1361552|NCT00522535|Tortuous
1361553|NCT00522535|High Angle
1361554|NCT00522535|Angled Necks
1361555|NCT00522522|Naturalistic, retrospective, utilization of care services, diagnosis, epilepsy
1361556|NCT00522496|Craniocerebral trauma
1361557|NCT00522496|matrix metalloproteinase
1361558|NCT00522496|microdialysis
1361559|NCT00522457|Breast Cancer
1361560|NCT00522457|investigational drug
1361561|NCT00522457|drug therapy
1361562|NCT00522457|Antineoplastic Protocols
1361563|NCT00522457|Immunotherapy
1361564|NCT00522457|Metastatic breast cancer
1361565|NCT00522457|Advanced breast cancer
1361566|NCT00522457|Stage IV breast cancer
1361567|NCT00522457|Her-2/neu expressing breast cancer
1361568|NCT00522457|Her-2/neu
1361569|NCT00522457|Trastuzumab refractory
1361570|NCT00522431|Hypogonadism
1361571|NCT00522418|Epilepsy
1361572|NCT00522418|VNS Therapy
1361573|NCT00522405|Transarterial chemoembolisation
1361574|NCT00522405|Thalidomide
1361575|NCT00522405|Capecitabine
1361576|NCT00522405|Treatment
1361577|NCT00522392|Consolidation therapy
1361578|NCT00522392|First-line therapy
1361579|NCT00522392|Proteasome inhibitor
1361580|NCT00522392|Thalidomide analogue
1361581|NCT00522392|Quality of life
1361582|NCT00522379|Parkinson's disease
1361583|NCT00522379|rotigotine
1361584|NCT00522379|patch
1361585|NCT00522379|transdermal
1361586|NCT00522379|dopamine agonist
1361587|NCT00522379|off time
1361588|NCT00522379|Neupro
1361589|NCT00522353|obesity
1361590|NCT00522353|weight loss
1361591|NCT00522353|satiety hormones
1361592|NCT00522353|body composition
1361593|NCT00522353|appetite ratings
1361594|NCT00522340|Implantable Cardioverter Defibrillators
1361595|NCT00522340|ICD
1361596|NCT00522340|Exercise
1361597|NCT00522340|Cardiac
1361598|NCT00522340|Inflammation
1361599|NCT00522327|Immigrant
1361600|NCT00522327|Interpreting
1361601|NCT00522314|Non-invasive ventilation
1361602|NCT00522314|Airway clearance
1361603|NCT00522314|Bronchiectasis
1361604|NCT00522301|recurrent ovarian epithelial cancer
1361605|NCT00522301|fallopian tube cancer
1361606|NCT00522301|primary peritoneal cavity cancer
1361607|NCT00522301|stage I ovarian epithelial cancer
1361608|NCT00522301|stage II ovarian epithelial cancer
1361609|NCT00522301|stage III ovarian epithelial cancer
1361610|NCT00522301|stage IV ovarian epithelial cancer
1361611|NCT00522288|Myopia
1361612|NCT00522288|Self-Perception
1361613|NCT00522288|Contact Lenses
1361614|NCT00522288|Glasses
1361615|NCT00522288|Randomized
1361616|NCT00522288|Children
1361617|NCT00522288|Self-esteem
1361618|NCT00522275|Adjunctive treatment in epilepsy
1361619|NCT00522275|add-on treatment for epilepsy
1361620|NCT00522275|partial seizures
1361621|NCT00522275|AEDs
1361622|NCT00522275|antiepileptic drugs
1361623|NCT00522275|seizures
1361624|NCT00522262|Breast Neoplasms
1361625|NCT00522262|Exercise
1361626|NCT00522262|Physical activity
1361627|NCT00522262|Estrone
1361628|NCT00522262|Estradiol
1361629|NCT00522262|Adiposity
1361630|NCT00522262|Breast density
1361631|NCT00522262|Mammographic density
1361632|NCT00522262|Insulin-Like Growth Factor I
1361633|NCT00522262|Insulin Resistance
1361634|NCT00522262|Women
1361635|NCT00522262|Postmenopause
1361636|NCT00522249|Metastatic Renal Cell Carcinoma
1361637|NCT00522249|RCC
1361638|NCT00522249|M3thodist
1361639|NCT00522249|Pegylated Alfa Interferon
1361640|NCT00522249|Sunitinib
1361641|NCT00522249|Tarceva
1361642|NCT00522249|Peg IFN
1361643|NCT00522236|Adjuvanted Influenza Vaccine
1361644|NCT00522223|Cervical Cancer
1361645|NCT00522223|Cancer Survivors
1361646|NCT00522223|Cervix Cancer
1361647|NCT00522223|Sexual Functioning
1361648|NCT00522223|Quality Of Life
1361649|NCT00522223|Questionnaire
1361650|NCT00522223|Radiation Therapy
1361651|NCT00522223|Radical Hysterectomy
1361652|NCT00522210|type 1 diabetes
1361653|NCT00522210|children
1361654|NCT00522210|long acting insulin analogue
1361655|NCT00522210|hemoglobin A1c
1361656|NCT00522197|non-small cell lung cancer
1361657|NCT00522197|small cell lung cancer
1361658|NCT00522197|squamous lung dysplasia
1361659|NCT00522184|intra-articular injection
1361660|NCT00522184|acute synovitis
1361661|NCT00522184|etanercept
1361662|NCT00522171|Harmonic
1361663|NCT00522171|Massive Weight Loss
1361664|NCT00522171|Electro Surgery
1361665|NCT00522171|Skin and Fat Redundancy after massive weight loss
1361666|NCT00522171|Obesity
1361667|NCT00522145|Non-Small-Cell Lung Cancer
1361668|NCT00522132|intravenous artesunate
1361669|NCT00522132|severe malaria
1361670|NCT00522132|Plasmodium falciparum
1361671|NCT00522132|Africa
1361672|NCT00522132|Severe Plasmodium falciparum Malaria
1361673|NCT00522119|Essential Hypertension
1361674|NCT00522119|High Blood Pressure
1361675|NCT00522106|Behavioral graded activity
1361676|NCT00522106|Hip
1361677|NCT00522106|Knee
1361678|NCT00522106|Physical therapy
1361679|NCT00522106|Exercise therapy
1361680|NCT00522093|constipation
1361681|NCT00522067|influenza
1361682|NCT00522067|influenza vaccine
1361683|NCT00522067|adjuvanted influenza vaccine
1361684|NCT00522067|subunit influenza vaccine
1361685|NCT00522067|surface antigen
1361686|NCT00522054|Exercise
1361687|NCT00522054|Physical function
1361688|NCT00522054|Rheumatoid arthritis
1361689|NCT00522054|Tai Chi
1361690|NCT00522041|Pain associated with chronic anal fissure
1361691|NCT00522028|QoL
1361692|NCT00522028|Osteodensitometry
1361693|NCT00522028|Arterial pressure
1361694|NCT00522028|PTH
1361695|NCT00522015|PSP
1361696|NCT00522015|dementia
1361697|NCT00522015|neuropsychology
1361698|NCT00522015|treatment
1361699|NCT00522002|Connective tissue diseases
1361700|NCT00522002|Blood coagulation disorders
1361701|NCT00522002|Leg ulcers
1361702|NCT00522002|Rheumatoid Arthritis
1361703|NCT00522002|Systemic Lupus Erythematosus
1361704|NCT00522002|Systemic Scleroderma
1361705|NCT00522002|Mixed Connective Tissue Disease
1361706|NCT00521989|Osteoarthritis
1361707|NCT00521989|Knee
1361708|NCT00521989|CRx-102
1361709|NCT00521989|prednisolone
1361710|NCT00521989|dipyridamole
1361711|NCT00521989|CombinatoRx
1361712|NCT00521989|WOMAC
1361713|NCT00521976|Risk assessment
1361714|NCT00521976|Chest pain
1361715|NCT00521976|Coronary Artery Disease
1361716|NCT00521976|Acute coronary syndromes
1361717|NCT00521976|Factor XIIa
1361718|NCT00521976|B-type natriuretic peptide (BNP)
1361719|NCT00521976|high-sensitive C-reactive protein (hsCRP)
1361720|NCT00521976|Omega-3
1361721|NCT00521963|Intraarticular injection
1361722|NCT00521963|Infliximab
1361723|NCT00521950|Pharmacogenetics
1361724|NCT00521950|Cost Effectiveness
1361725|NCT00521950|Inflammatory Bowel Diseases
1361726|NCT00521950|Crohn Disease
1361727|NCT00521950|Ulcerative Colitis
1361728|NCT00521950|Randomized Controlled Trials
1361729|NCT00521911|Intervention Studies
1361730|NCT00521911|Randomized Controlled Trials
1361731|NCT00521911|Cognitive Therapy
1361732|NCT00521911|Hospitals, General
1361733|NCT00521911|Prevalence
1361734|NCT00521898|Corneal transplantation, Descemet membrane
1361735|NCT00521885|Bleeding rates
1361736|NCT00521885|Prophylaxis for deep vein thrombosis
1361737|NCT00521872|surgery (STARR operation)
1361738|NCT00521859|Hematologic Malignancies
1361739|NCT00521859|Leukemia
1361740|NCT00521859|Lymphoma
1361741|NCT00521859|Myeloma
1361742|NCT00521859|Hodgkin's Disease
1361743|NCT00521859|Hematopoietic Cell Transplantation
1361744|NCT00521859|Cloretazine
1361745|NCT00521859|VNP40101M
1361746|NCT00521859|Fludarabine
1361747|NCT00521859|Fludarabine Phosphate
1361748|NCT00521859|Fludara
1361749|NCT00521859|ATG
1361750|NCT00521859|Antithymocyte
1361751|NCT00521859|Thymoglobulin
1361752|NCT00521833|Kataract
1361753|NCT00521833|Astigmatism
1361754|NCT00521833|phacoemulsification
1361755|NCT00521820|Glucose Metabolism Disorder
1361756|NCT00521820|Dysmetabolic Syndrome
1361757|NCT00521820|Type II Diabetes
1361758|NCT00521820|Diabetes Mellitus, Lipoatrophic
1361759|NCT00521820|Dyslipidemia
1361760|NCT00521820|Drug Therapy
1361761|NCT00521807|Hypnosis,
1361762|NCT00521807|Chronic widespread pain,
1361763|NCT00521807|CWP,
1361764|NCT00521807|General Practice
1361765|NCT00521794|Arrhythmia
1361766|NCT00521794|Muscle Weakness
1361767|NCT00521794|Periodic Paralysis
1361768|NCT00521794|Channelopathy
1361769|NCT00521781|Unresectable or Metastatic Adenocarcinoma Prostate Cancer
1361770|NCT00521781|Hormonal Therapy
1361771|NCT00521781|Abraxane
1361772|NCT00521781|M3thodist
1361773|NCT00521768|Post traumatic stress disorder
1361774|NCT00521768|Anxiety disorder
1361775|NCT00521768|Comunity base intervention
1361776|NCT00521768|Education
1361777|NCT00521768|Behavioural treatment
1361778|NCT00521755|Laser bonding soft tissue albumin
1361779|NCT00521742|Glucose Metabolism Disorder
1361780|NCT00521742|Dysmetabolic Syndrome
1361781|NCT00521742|Type II Diabetes
1361782|NCT00521742|Diabetes Mellitus, Lipoatrophic
1361783|NCT00521742|Dyslipidemia
1361784|NCT00521742|Drug Therapy
1361785|NCT00521729|Thyroid
1361786|NCT00521729|Thermoregulation
1361787|NCT00521729|Catecholamines
1361788|NCT00521729|Energy Expenditure
1361789|NCT00521729|Obesity
1361790|NCT00521729|Healthy Volunteer
1361791|NCT00521729|HV
1361792|NCT00521716|Hip Prosthesis Implantation
1361793|NCT00521703|endoscopy, gastrointestinal
1361794|NCT00521703|lidocaine
1361795|NCT00521703|propofol
1361796|NCT00521703|child
1361797|NCT00521703|adolescent
1361798|NCT00521677|VAP
1361799|NCT00521677|Oral care
1361800|NCT00521677|Acquired pneumonia
1361801|NCT00521677|Mortality
1361802|NCT00521677|LOS in ICU
1361803|NCT00521677|LOS in hospital
1361804|NCT00521677|All patients on ventilator in the ICU
1361805|NCT00521664|proof of safety and cost effectiveness of the new therapeutic platelet transfusion strategy
1361806|NCT00521651|Physical Activity
1361807|NCT00521651|Cancer Risk
1361808|NCT00521612|sevoflurane
1361809|NCT00521612|isoflurane
1361810|NCT00521612|anaesthesia
1361811|NCT00521586|Pneumococcal Conjugate Vaccine
1361812|NCT00521560|High-Dose Radio-Immuno- and Chemotherapy
1361813|NCT00521560|stem cell transplantation
1361814|NCT00521560|90Y-Ibritumomab-Tiuxetan
1361815|NCT00521547|Acupuncture
1361816|NCT00521547|Analgesia
1361817|NCT00521547|Functional magnetic resonance imaging (fMRI)
1361818|NCT00521547|Neuronal Mechanisms
1361819|NCT00521547|Quantitative Peripheral Sensory Testings
1361820|NCT00521547|Normal Volunteers
1361821|NCT00521534|Sleep related Breathing Disorder
1361822|NCT00521534|Congestive Heart Failure
1361823|NCT00521534|Atrial Overdrive Pacing
1361824|NCT00521534|Cardiac Resynchronization Therapy
1361825|NCT00521508|IgA
1361826|NCT00521508|kidney
1361827|NCT00521508|Berger'disease
1361828|NCT00521508|regulatory T cells
1361829|NCT00521508|pathogenesis of Berger's disease
1361830|NCT00521495|static magnetic field
1361831|NCT00521495|permanent magnet
1361832|NCT00521495|carpal tunnel syndrome
1361833|NCT00521495|median nerve
1361834|NCT00521482|recurrent
1361835|NCT00521482|after standard therapy
1361836|NCT00521469|Disequilibrium
1361837|NCT00521469|Spinal Manipulation
1361838|NCT00521469|Postural control
1361839|NCT00521430|recurrent childhood grade III lymphomatoid granulomatosis
1361840|NCT00521430|childhood diffuse large cell lymphoma
1361841|NCT00521430|recurrent childhood large cell lymphoma
1361842|NCT00521430|childhood immunoblastic large cell lymphoma
1361843|NCT00521430|recurrent childhood lymphoblastic lymphoma
1361844|NCT00521430|childhood nasal type extranodal NK/T-cell lymphoma
1361845|NCT00521430|recurrent childhood small noncleaved cell lymphoma
1361846|NCT00521430|adult acute myeloid leukemia in remission
1361847|NCT00521430|adult acute lymphoblastic leukemia in remission
1361848|NCT00521430|aplastic anemia
1361849|NCT00521430|recurrent childhood acute lymphoblastic leukemia
1361850|NCT00521430|childhood acute lymphoblastic leukemia in remission
1361851|NCT00521430|childhood acute myeloid leukemia in remission
1361852|NCT00521430|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1361853|NCT00521430|adult acute myeloid leukemia with inv(16)(p13;q22)
1361854|NCT00521430|adult acute myeloid leukemia with t(15;17)(q22;q12)
1361855|NCT00521430|adult acute myeloid leukemia with t(16;16)(p13;q22)
1361856|NCT00521430|adult acute myeloid leukemia with t(8;21)(q22;q22)
1361857|NCT00521430|refractory anemia with excess blasts in transformation
1361858|NCT00521430|refractory anemia with excess blasts
1361859|NCT00521430|refractory anemia with ringed sideroblasts
1361860|NCT00521430|refractory anemia
1361861|NCT00521430|refractory multiple myeloma
1361862|NCT00521430|chronic myelomonocytic leukemia
1361863|NCT00521430|accelerated phase chronic myelogenous leukemia
1361864|NCT00521430|blastic phase chronic myelogenous leukemia
1361865|NCT00521430|chronic phase chronic myelogenous leukemia
1361866|NCT00521430|relapsing chronic myelogenous leukemia
1361867|NCT00521430|recurrent adult Hodgkin lymphoma
1361868|NCT00521430|recurrent adult T-cell leukemia/lymphoma
1361869|NCT00521430|anaplastic large cell lymphoma
1361870|NCT00521430|angioimmunoblastic T-cell lymphoma
1361871|NCT00521430|recurrent cutaneous T-cell non-Hodgkin lymphoma
1361872|NCT00521430|recurrent mycosis fungoides/Sezary syndrome
1361873|NCT00521430|adult nasal type extranodal NK/T-cell lymphoma
1361874|NCT00521430|Waldenström macroglobulinemia
1361875|NCT00521430|recurrent adult Burkitt lymphoma
1361876|NCT00521430|recurrent adult diffuse large cell lymphoma
1361877|NCT00521430|recurrent adult diffuse mixed cell lymphoma
1361878|NCT00521430|recurrent adult diffuse small cleaved cell lymphoma
1361879|NCT00521430|recurrent adult grade III lymphomatoid granulomatosis
1361880|NCT00521430|recurrent adult immunoblastic large cell lymphoma
1361881|NCT00521430|recurrent adult lymphoblastic lymphoma
1361882|NCT00521430|recurrent grade 1 follicular lymphoma
1361883|NCT00521430|recurrent grade 2 follicular lymphoma
1361884|NCT00521430|recurrent grade 3 follicular lymphoma
1361885|NCT00521430|recurrent mantle cell lymphoma
1361886|NCT00521430|recurrent marginal zone lymphoma
1361887|NCT00521430|recurrent small lymphocytic lymphoma
1361888|NCT00521430|stage I multiple myeloma
1361889|NCT00521430|stage II multiple myeloma
1361890|NCT00521430|stage III multiple myeloma
1361891|NCT00521430|cutaneous B-cell non-Hodgkin lymphoma
1361892|NCT00521430|unspecified adult solid tumor, protocol specific
1361893|NCT00521430|childhood chronic myelogenous leukemia
1361894|NCT00521430|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1361895|NCT00521430|nodal marginal zone B-cell lymphoma
1361896|NCT00521430|splenic marginal zone lymphoma
1361897|NCT00521430|recurrent adult acute lymphoblastic leukemia
1361898|NCT00521430|recurrent adult acute myeloid leukemia
1361899|NCT00521430|recurrent childhood acute myeloid leukemia
1361900|NCT00521430|recurrent/refractory childhood Hodgkin lymphoma
1361901|NCT00521430|secondary myelodysplastic syndromes
1361902|NCT00521430|de novo myelodysplastic syndromes
1361903|NCT00521430|previously treated myelodysplastic syndromes
1361904|NCT00521417|RCT
1361905|NCT00521404|Pancreatic cancer
1361906|NCT00521404|chemotherapy naive
1362028|NCT00521027|Versajet
1361907|NCT00521404|unresectable or metastatic pancreatic cancer
1361908|NCT00521404|CS1008
1361909|NCT00521404|Gemcitabine
1361910|NCT00521404|Gemzar
1361911|NCT00521391|smoking cessation
1361912|NCT00521391|nicotine
1361913|NCT00521391|physical activity
1361914|NCT00521378|Diabetes
1361915|NCT00521378|Type 1 and Type 2 Diabetes
1361916|NCT00521365|Bipolar Disorder
1361917|NCT00521365|Bipolar Affective Psychosis
1361918|NCT00521365|Mania
1361919|NCT00521365|Manic Disorder
1361920|NCT00521365|Manic State
1361921|NCT00521352|TMS
1361922|NCT00521352|Dorsolateral Prefrontal Cortex
1361923|NCT00521339|Apremilast,
1361924|NCT00521339|Psoriasis,
1361925|NCT00521339|PASI-75,
1361926|NCT00521339|sPGA
1361927|NCT00521326|doppler
1361928|NCT00521326|coronary stenosis
1361929|NCT00521326|non-invasive testing
1361930|NCT00521326|A prospective study of a new diagnostic method.
1361931|NCT00521326|Study consists of a transthoracic doppler of LAD.
1361932|NCT00521326|Doppler to be performed prior to coronary angiography.
1361933|NCT00521326|F/U doppler examination for those who undergo PCI.
1361934|NCT00521326|Doppler results will be compared with coronary angiography.
1361935|NCT00521300|Acromegaly
1361936|NCT00521287|Immunologic Surveillance
1361937|NCT00521287|Vaccination
1361938|NCT00521287|Immunotherapy
1361939|NCT00521287|Dendritic Cells
1361940|NCT00521274|Progressive Hormone Refractory Prostate Cancer
1361941|NCT00521274|HRPC
1361942|NCT00521274|MVA 5T4
1361943|NCT00521274|Trovax®
1361944|NCT00521274|Docetaxel
1361945|NCT00521274|M3thodist
1361946|NCT00521261|recurrent adult Burkitt lymphoma
1361947|NCT00521261|recurrent adult diffuse large cell lymphoma
1361948|NCT00521261|recurrent adult diffuse mixed cell lymphoma
1361949|NCT00521261|recurrent adult diffuse small cleaved cell lymphoma
1361950|NCT00521261|recurrent adult immunoblastic large cell lymphoma
1361951|NCT00521261|recurrent adult lymphoblastic lymphoma
1361952|NCT00521261|recurrent adult T-cell leukemia/lymphoma
1361953|NCT00521261|recurrent cutaneous T-cell non-Hodgkin lymphoma
1361954|NCT00521261|recurrent grade 1 follicular lymphoma
1361955|NCT00521261|recurrent grade 2 follicular lymphoma
1361956|NCT00521261|recurrent grade 3 follicular lymphoma
1361957|NCT00521261|recurrent mantle cell lymphoma
1361958|NCT00521261|recurrent marginal zone lymphoma
1361959|NCT00521261|recurrent small lymphocytic lymphoma
1361960|NCT00521261|Waldenstrom macroglobulinemia
1361961|NCT00521261|adult nasal type extranodal NK/T-cell lymphoma
1361962|NCT00521261|recurrent adult grade III lymphomatoid granulomatosis
1361963|NCT00521261|cutaneous B-cell non-Hodgkin lymphoma
1361964|NCT00521248|Neonatal Abstinence Syndrome
1361965|NCT00521248|buprenorphine
1361966|NCT00521248|neonatal
1361967|NCT00521248|opioid withdrawal
1361968|NCT00521235|risk factors
1361969|NCT00521235|metabolic syndrome
1361970|NCT00521235|dentists
1361971|NCT00521235|trainers
1361972|NCT00521235|Healthy subjects
1361973|NCT00521235|students
1361974|NCT00521235|seniors
1361975|NCT00521222|asthma
1361976|NCT00521222|beta agonist
1361977|NCT00521222|bronchodilator
1361978|NCT00521222|pulmonary
1361979|NCT00521222|genotype
1361980|NCT00521222|pharmacogenomics
1361981|NCT00521222|corticosteroid
1361982|NCT00521222|allergy
1361983|NCT00521222|immunology
1361984|NCT00521209|Impoverished Population
1361985|NCT00521196|migraine
1361986|NCT00521196|headache
1361987|NCT00521196|chronic
1361988|NCT00521196|pain
1361989|NCT00521196|brain
1361990|NCT00521196|neurology
1361991|NCT00521196|stimulation
1361992|NCT00521196|noninvasive
1361993|NCT00521196|transcranial
1361994|NCT00521196|direct
1361995|NCT00521196|current
1361996|NCT00521196|tDCS
1361997|NCT00521196|tms
1361998|NCT00521196|rTMS
1361999|NCT00521196|BIDMC
1362000|NCT00521183|adult tumors metastatic to brain
1362001|NCT00521170|Levocetirizine
1362002|NCT00521170|Wheal and flare
1362003|NCT00521170|Allergic
1362004|NCT00521157|Substance abuse
1362005|NCT00521157|Opiate dependency
1362006|NCT00521157|Treatment
1362007|NCT00521157|Relapse prevention
1362008|NCT00521131|Levocetirizine dihydrochloride
1362009|NCT00521131|Xyzal tablets
1362010|NCT00521105|Type 1 Diabetes
1362011|NCT00521105|Telemedicine
1362012|NCT00521105|Children
1362013|NCT00521092|Treatment Experienced
1362014|NCT00521079|Obesity
1362015|NCT00521079|Bariatric surgery
1362016|NCT00521079|Excess weight loss
1362017|NCT00521079|Vagus nerve
1362018|NCT00521079|Vagal blocking
1362019|NCT00521079|vBloc(TM) therapy
1362020|NCT00521053|immune
1362021|NCT00521053|vaccine
1362022|NCT00521053|systemic
1362023|NCT00521053|Metastatic Melanoma (AJCC Stage III or IV)
1362024|NCT00521040|Levocetirizine dihydrochloride
1362025|NCT00521040|Xyzal tablets
1362026|NCT00521027|Debridement
1362027|NCT00521027|hydrosurgery
1362029|NCT00521027|leg ulcer
1362030|NCT00521014|recurrent grade 1 follicular lymphoma
1362031|NCT00521014|recurrent grade 2 follicular lymphoma
1362032|NCT00521014|recurrent grade 3 follicular lymphoma
1362033|NCT00521001|stage IV melanoma
1362034|NCT00520988|hypertension
1362035|NCT00520988|intervention
1362036|NCT00520988|disease management
1362037|NCT00520988|telephone-based
1362038|NCT00520988|Hypertension: diagnosed but uncontrolled
1362039|NCT00520975|Trastuzumab
1362040|NCT00520975|Bevacizumab
1362041|NCT00520975|Metastatic Breast Cancer
1362042|NCT00520975|HER2/NEU
1362043|NCT00520962|cardiovascular disease
1362044|NCT00520962|glucose intolerance
1362045|NCT00520962|type 2 diabetes
1362046|NCT00520962|endothelial dysfunction
1362047|NCT00520962|inflammation
1362048|NCT00520962|Age> 30 years, male and female
1362049|NCT00520962|Fasting glucose below 126 mg/dl
1362050|NCT00520949|H.pylori
1362051|NCT00520949|Triple therapy failure
1362052|NCT00520949|Quadruple therapy
1362053|NCT00520910|Polypodium leucotomos, Ultraviolet Rays, Heliocare, calaguala, anapsos
1362054|NCT00520910|Skin Aging and Damage
1362055|NCT00520897|chronic HIV infection
1362056|NCT00520897|Human Immunodeficiency Virus
1362057|NCT00520897|Treatment Experienced
1362058|NCT00520884|frailty
1362059|NCT00520884|ghrelin
1362060|NCT00520884|appetite
1362061|NCT00520884|weight loss
1362062|NCT00520871|Cardiovascular disease
1362063|NCT00520871|Blueberruy
1362064|NCT00520871|Antioxidants
1362065|NCT00520871|Oxidative stress
1362066|NCT00520871|Inflammation
1362067|NCT00520845|recurrent non-small cell lung cancer
1362068|NCT00520845|stage IV non-small cell lung cancer
1362069|NCT00520845|stage IIIB non-small cell lung cancer
1362070|NCT00520845|stage IIIA non-small cell lung cancer
1362071|NCT00520832|Primary Insomnia
1362072|NCT00520832|Microcurrent Therapy
1362073|NCT00520832|Sleep Surveys
1362074|NCT00520819|Antioxidants
1362075|NCT00520819|Phytochemicals
1362076|NCT00520819|Oxidative stress
1362077|NCT00520819|Inflammation
1362078|NCT00520819|Endothelial function
1362079|NCT00520806|Heart failure
1362080|NCT00520806|Renal dysfunction
1362081|NCT00520806|Relaxin
1362082|NCT00520806|Vasodilator
1362083|NCT00520780|Chronic Heart Failure
1362084|NCT00520780|Iron deficiency
1362085|NCT00520780|Iron deficiency anaemia
1362086|NCT00520780|Anaemia
1362087|NCT00520780|Heart disease
1362088|NCT00520767|primary systemic amyloidosis
1362089|NCT00520767|light chain deposition disease
1362090|NCT00520754|levocetirizine dihydrochloride Xyzal tablets
1362091|NCT00520741|Epilepsy
1362092|NCT00520741|Partial Onset Seizures
1362093|NCT00520741|Lacosamide
1362094|NCT00520741|Monotherapy
1362095|NCT00520741|Vimpat
1362096|NCT00520728|Schizophrenia
1362097|NCT00520728|Psychosis
1362098|NCT00520728|Occupational Disengagement
1362099|NCT00520728|Occupational Imbalance
1362100|NCT00520715|fluoroquinolone resistance
1362101|NCT00520715|commensal flora
1362102|NCT00520715|carriage
1362103|NCT00520702|Non-Small Cell Lung Cancer
1362104|NCT00520702|Lung Cancer
1362105|NCT00520702|3-Dimensional Conformal Radiation Therapy
1362106|NCT00520702|Intensity Modulated Radiation Therapy
1362107|NCT00520702|3D CRT
1362108|NCT00520702|IMRT
1362109|NCT00520702|NSCLC
1362110|NCT00520702|TRP
1362111|NCT00520702|Treatment related pneumonitis
1362112|NCT00520663|Distribution,
1362113|NCT00520663|SB-649868,
1362114|NCT00520663|Healthy,
1362115|NCT00520663|Excretion,
1362116|NCT00520663|Sleep disturbances
1362117|NCT00520663|Volunteer,
1362118|NCT00520663|Metabolism,
1362119|NCT00520663|Absorption,
1362120|NCT00520624|EIL
1362121|NCT00520611|Obesity
1362122|NCT00520611|Weight Loss
1362123|NCT00520611|Financial Incentives
1362124|NCT00520611|Lottery
1362125|NCT00520611|Deposit
1362126|NCT00520585|atorvastatin
1362127|NCT00520585|repolarisation
1362128|NCT00520585|cardiomyocytes
1362129|NCT00520572|Rheumatoid Arthritis
1362130|NCT00520546|PET
1362131|NCT00520546|MRI
1362132|NCT00520546|Choline
1362133|NCT00520546|FEC
1362134|NCT00520546|prostate cancer
1362135|NCT00520533|Clinical trials
1362136|NCT00520533|cG250 mAb
1362137|NCT00520533|monoclonal antibody G250
1362138|NCT00520533|sunitinib
1362139|NCT00520533|angiogenesis inhibitors
1362140|NCT00520533|Positron-Emission Tomography
1362141|NCT00520533|Pharmacokinetics
1362142|NCT00520533|Pharmacodynamics
1362143|NCT00519831|stage IIIB non-small cell lung cancer
1362144|NCT00519831|stage IV non-small cell lung cancer
1362145|NCT00519831|recurrent non-small cell lung cancer
1362146|NCT00519818|Congenital Adrenal Hyperplasia
1362147|NCT00519818|Hydrocortisone
1362148|NCT00519818|Pharmacokinetic
1362149|NCT00519818|Pharmacodynamic
1362150|NCT00519805|thromboembolism
1362151|NCT00519805|extensive stage small cell lung cancer
1362152|NCT00519805|limited stage small cell lung cancer
1362153|NCT00519805|stage IV non-small cell lung cancer
1362154|NCT00519805|stage II non-small cell lung cancer
1362155|NCT00519805|stage IIIA non-small cell lung cancer
1362156|NCT00519805|stage IIIB non-small cell lung cancer
1362157|NCT00519805|stage I non-small cell lung cancer
1362158|NCT00519792|Relapse
1362159|NCT00519792|HCV
1362160|NCT00519792|Hepatitis C
1362161|NCT00519792|Interferon
1362162|NCT00519792|Ribavirin
1362163|NCT00519779|affect
1362164|NCT00519779|inflammation
1362165|NCT00519766|Ratio of 3-Hydroxycotinine to Cotinine
1362166|NCT00519766|Nicotine Metabolism
1362167|NCT00519766|Pregnancy
1362168|NCT00519753|Glaucoma
1362169|NCT00519740|grass-pollen
1362170|NCT00519740|allergy
1362171|NCT00519740|bronchial hyperreactivity
1362172|NCT00519740|asthma
1362173|NCT00519727|diabetes
1362174|NCT00519701|sickle cell anemia
1362175|NCT00519701|hydroxyurea
1362176|NCT00520520|post resuscitation
1362177|NCT00520520|post ventricular fibrillation
1362178|NCT00520520|patients receiving mild therapeutic hypothermia
1362179|NCT00520507|Depression
1362180|NCT00520507|Bipolar Disorder
1362181|NCT00520507|Major
1362182|NCT00520494|Previously Untreated Patient (PUP)
1362183|NCT00520494|Primary Immunodeficiency (PID)
1362184|NCT00520494|CVID
1362185|NCT00520494|XLA
1362186|NCT00520494|Subcutaneous immunoglobulin (SCIG)
1362187|NCT00520494|IgG trough level
1362188|NCT00520494|Quality of life
1362189|NCT00520494|Common variable immunodeficiency (CVID)
1362190|NCT00520494|X-linked agammaglobulinemia (XLA)
1362191|NCT00520468|Myelodysplastic Syndrome
1362192|NCT00520468|MDS
1362193|NCT00520468|Erythropoietin
1362194|NCT00520468|Darbepoetin alfa
1362195|NCT00520468|Aranesp
1362196|NCT00520468|Erythropoiesis stimulating protein
1362197|NCT00520468|G-CSF
1362198|NCT00520468|Filgrastim
1362199|NCT00520468|Neupogen
1362200|NCT00520468|Prednisone
1362201|NCT00520468|Cyclosporin A
1362202|NCT00520468|Sandimmune
1362203|NCT00520468|CYA
1362204|NCT00520468|Cyclosporine
1362205|NCT00520442|fracture
1362206|NCT00520429|Depression
1362207|NCT00520429|Anxiety
1362208|NCT00520429|Pulmonary Disease, Chronic Obstructive
1362209|NCT00520429|Heart Failure, Congestive
1362210|NCT00520377|Sinus Lift Surgery
1362211|NCT00520377|Sinus Floor Augmentation
1362212|NCT00520377|Insufficient Bone Height
1362213|NCT00520338|celecoxib
1362214|NCT00520338|postoperative pain
1362215|NCT00520338|thyroidectomy
1362216|NCT00520325|MBL deficient oncologic hematologic pediatric fever neutropenia
1362217|NCT00520312|Peripheral Arterial Disease
1362218|NCT00520312|PAD
1362219|NCT00520312|Functional Impairment
1362220|NCT00520312|Magnetic Resonance Imaging
1362221|NCT00520299|metastatic melanoma
1362222|NCT00520299|ADI
1362223|NCT00520299|ADI PEG 20
1362224|NCT00520299|ADI SS PEG 20,000mw
1362225|NCT00520299|arginine
1362226|NCT00520299|enzyme therapy
1362227|NCT00520286|Methamphetamine Dependence
1362228|NCT00520247|enalapril
1362229|NCT00520247|folic acid
1362230|NCT00520247|hyperglycemia
1362231|NCT00520247|hypertension
1362232|NCT00520247|fasting plasma glucose
1362233|NCT00520234|Candida
1362234|NCT00520234|Prophylaxis
1362235|NCT00520234|High risk adults
1362236|NCT00520234|Intensive care unit (ICU)
1362237|NCT00520221|minocycline
1362238|NCT00520221|pleurodesis
1362239|NCT00520221|aspiration
1362240|NCT00520221|pneumothorax
1362241|NCT00520221|Primary spontaneous pneumothorax
1362242|NCT00520221|First attack
1362243|NCT00520221|Successful aspiration
1362244|NCT00520208|ATRA
1362245|NCT00520208|Trisenox
1362246|NCT00520208|Arsenic
1362247|NCT00520208|Arsenic Trioxide
1362248|NCT00520208|APL
1362249|NCT00520169|bioavailability
1362250|NCT00520143|GSD-II, Pompe Disease, Glycogen Storage Disease II
1362251|NCT00520130|Unrelated Donors
1362252|NCT00520130|Reduced Intensity Stem Cell Transplant
1362253|NCT00520130|Leukemia
1362254|NCT00520130|Lymphoma
1362255|NCT00520130|Allogeneic Stem Cell Transplant
1362256|NCT00520130|Myelodysplastic Syndrome
1362257|NCT00520130|Multiple Myeloma
1362258|NCT00520091|adenocarcinoma of the esophagus
1362259|NCT00520091|squamous cell carcinoma of the esophagus
1362260|NCT00520091|stage II esophageal cancer
1362261|NCT00520091|stage III esophageal cancer
1362262|NCT00520091|stage IV esophageal cancer
1362263|NCT00520052|bisphosphonates, prostate cancer, bone density, osteoporosis
1362264|NCT00520039|Otitis Media
1362265|NCT00520039|Effusion
1362266|NCT00520039|OMM
1362267|NCT00520039|OMT
1362268|NCT00520039|Resolution
1362269|NCT00520026|suicide
1362270|NCT00520026|prevention
1362271|NCT00520026|lithium
1362272|NCT00520026|suicidality
1362273|NCT00520000|unspecified adult solid tumor, protocol specific
1362274|NCT00519987|pharmacokinetics
1362275|NCT00519974|psychosocial effects of cancer and its treatment
1362276|NCT00519974|stage I breast cancer
1362277|NCT00519974|stage II breast cancer
1362278|NCT00519974|stage IIIA breast cancer
1362279|NCT00519974|stage IIIB breast cancer
1362280|NCT00519974|stage IIIC breast cancer
1362281|NCT00519974|stage IV breast cancer
1362282|NCT00519974|recurrent breast cancer
1362283|NCT00519935|Insulin Dependent Diabetes Mellitus
1362284|NCT00519935|family therapy
1362285|NCT00519935|adolescents
1362286|NCT00519909|dairy products, calcium, fat excretion, energy excretion
1362287|NCT00519883|Anastrozole
1362288|NCT00519883|Exercise
1362289|NCT00519870|Pulmonary hypertension
1362290|NCT00519870|Angiotensin receptor blocker
1362291|NCT00519870|Calcium channel blocker
1362292|NCT00519688|tegafur
1362293|NCT00519688|thalidomide
1362294|NCT00519688|advanced hepatocellular carcinoma
1362295|NCT00519675|Chronic hand eczema
1362296|NCT00519675|Chronic hand dermatitis
1362297|NCT00519675|Patients with chronic hand eczema, who are refractory to topical corticosteroids
1362298|NCT00519662|Solid
1362299|NCT00519662|Tumors
1362300|NCT00519662|Advanced
1362301|NCT00519649|Hepatitis B vaccine
1362302|NCT00519649|Challenge dose
1362303|NCT00519636|experience
1362304|NCT00519636|GW685698X
1362305|NCT00519636|fluticasone furoate
1362306|NCT00519636|preference
1362307|NCT00519636|seasonal allergic rhinitis
1362308|NCT00519636|fluticasone propionate
1362309|NCT00519623|diabetes
1362310|NCT00519623|insulin
1362311|NCT00519623|blood sugar
1362312|NCT00519623|type 1 diabetes
1362313|NCT00519623|insulin dependent diabetes
1362314|NCT00519623|transdermal
1362315|NCT00519610|portal hypertension, H-graft shunt
1362316|NCT00519597|Coronary Artery Disease
1362317|NCT00519597|Sleep Apnea
1362318|NCT00519597|CPAP
1362319|NCT00519597|Revascularization
1362320|NCT00519597|Mortality
1362321|NCT00519584|Interscalene nerve block
1362322|NCT00519584|Dexamethasone
1362323|NCT00519584|Ropivacaine
1362324|NCT00519571|Dental Implantation, Endosseous
1362325|NCT00519545|breast
1362326|NCT00519545|cancer
1362327|NCT00519545|stage
1362328|NCT00519545|one
1362329|NCT00519545|four
1362330|NCT00519532|Neupro®
1362331|NCT00519532|Rotigotine
1362332|NCT00519532|Parkinson's Disease
1362333|NCT00519519|Rebleeding after endoscopic therapy
1362334|NCT00519506|Pulmonary Embolism
1362335|NCT00519506|PE
1362336|NCT00519493|Clozex
1362337|NCT00519493|Sutures
1362338|NCT00519480|Tolerability
1362339|NCT00519480|GSK189075,
1362340|NCT00519480|Metformin,
1362341|NCT00519480|Safety,
1362342|NCT00519480|Diabetes,
1362343|NCT00519467|dose-ranging study
1362344|NCT00519467|SB-714703
1362345|NCT00519467|artesunate,
1362346|NCT00519467|malaria
1362347|NCT00519467|CDA,
1362348|NCT00519467|chlorproguanil,
1362349|NCT00519467|dapsone,
1362350|NCT00519454|Systemic Lupus Erythematosus
1362351|NCT00519454|Estrogen receptors
1362352|NCT00519454|T cells
1362353|NCT00519454|Hormones
1362354|NCT00519454|Female adult SLE
1362355|NCT00519441|laparoscopic Heller myotomy, achalasia, reflux
1362356|NCT00519428|depression
1362357|NCT00519428|MDD
1362358|NCT00519428|Major Depressive Disorder
1362359|NCT00519415|Tongue plate
1362360|NCT00519415|Facemask
1362361|NCT00519415|class III maxillary deficiency
1362362|NCT00519415|orthodontic angle class three
1362363|NCT00519402|partial tonsillectomy
1362364|NCT00519402|complete tonsillectomy
1362365|NCT00519402|tonsillectomy
1362366|NCT00519402|obstruction sleep disordered breathing OSDB
1362367|NCT00519402|apnea
1362368|NCT00519376|pharmacodynamics,
1362369|NCT00519376|Chronic Obstructive Pulmonary Disease (COPD)
1362370|NCT00519376|safety,
1362371|NCT00519376|COPD patients
1362372|NCT00519376|pharmacokinetics,
1362373|NCT00519376|tolerability,
1362374|NCT00519376|GW642444,
1362375|NCT00519363|Lupus
1362376|NCT00519363|TLR's
1362377|NCT00519363|Hyperlipidemia
1362378|NCT00519363|age eighteen to sixty
1362379|NCT00519363|female with SLE
1362380|NCT00519363|SLEDAI, greater than four
1362381|NCT00519363|LDL cholesterol elevated
1362382|NCT00519350|SIRS, sepsis and related syndromes
1362383|NCT00519337|Atrial Fibrillation
1362384|NCT00519337|cardiac surgery
1362385|NCT00519337|ascorbic acid
1362386|NCT00519337|vitamin-c
1362387|NCT00519337|inflammation
1362388|NCT00519324|Gastric Cancer
1362389|NCT00519324|RAD001
1362390|NCT00519324|mTOR
1362391|NCT00519311|Intellectual disability
1362392|NCT00519311|Health promotion
1362393|NCT00519311|RCT
1362394|NCT00519298|Alzheimer Disease
1362395|NCT00519285|metastatic
1362396|NCT00519285|prostate
1362397|NCT00519285|cancer
1362407|NCT00519246|Breast Neoplasms
1362408|NCT00519246|Non-Steroidal Anti-Inflammatory Agents
1362409|NCT00519246|Analgesia
1362410|NCT00519233|HRPC
1362411|NCT00519233|Advanced hormone refractory prostate cancer
1362412|NCT00519220|achalasia, Heller myotomy
1362413|NCT00519207|pediatrics
1362414|NCT00519207|pain
1362415|NCT00519207|infants
1362416|NCT00519207|newborn screening
1362417|NCT00519207|venipuncture
1362418|NCT00519207|lidocaine
1362419|NCT00519207|sucrose
1362420|NCT00519194|Arrhythmia
1362421|NCT00519194|Atrial Fibrillation
1362422|NCT00519181|HTLV
1362423|NCT00519181|HAM/TSP
1362424|NCT00519181|VALPROIC ACID
1362425|NCT00519181|PROVIRAL LOAD
1362426|NCT00519129|Pain
1362427|NCT00519129|Patient satisfaction
1362428|NCT00519103|microarray
1362429|NCT00519103|Inflammtion
1362430|NCT00519103|fibrosis
1362431|NCT00519090|leukemia
1362432|NCT00519090|bone marrow
1362433|NCT00519090|leukemia symptoms
1362434|NCT00519090|cml
1362435|NCT00519090|complete blood count
1362436|NCT00519090|lymphocyte
1362437|NCT00519090|blood cancer
1362438|NCT00519090|leukocytes
1362439|NCT00519090|chronic leukemia
1362440|NCT00519090|bone marrow biopsy
1362441|NCT00519090|leukemia research
1362442|NCT00519090|leukemia cells
1362443|NCT00519090|bone marrow disease
1362444|NCT00519090|chronic myeloid leukemia
1362445|NCT00519090|blood cancer symptoms
1362446|NCT00519090|white blood cell diseases
1362447|NCT00519090|chronic myelogenous leukemia
1362448|NCT00519090|leukemia treatment
1362449|NCT00519090|leukemia facts
1362450|NCT00519090|leucemia
1362451|NCT00519090|facts about leukemia
1362452|NCT00519090|myelogenous leukemia
1362453|NCT00519090|newly diagnosed CML
1362454|NCT00519090|suboptimal response
1362455|NCT00519090|Philadelphia chromosome positive (Ph+)
1362456|NCT00519090|chronic myelogenous leukemia in chronic phase (CML-CP)
1362457|NCT00519077|cancer
1362458|NCT00519077|squamous cell
1362459|NCT00519077|carcinoma
1362460|NCT00519077|head
1362461|NCT00519077|neck
1362462|NCT00519064|influenza
1362463|NCT00519064|influenza vaccine
1362464|NCT00519064|adjuvanted influenza vaccine
1362465|NCT00519064|H5N1 influenza antigen
1362466|NCT00519051|depression
1362467|NCT00519051|primary care
1362468|NCT00519051|pharmacotherapy
1362469|NCT00519038|Critical Pathways
1362470|NCT00519038|Congestive Heart Failure
1362471|NCT00519038|Randomized Controlled Trial
1362472|NCT00519038|Effectiveness
1362473|NCT00519025|Linezolid
1362474|NCT00519025|Staphylococcus Aureus
1362475|NCT00519025|Infections
1362476|NCT00519012|early nonresponse
1362477|NCT00518999|cognition, attention, memory, executive functions, illness-awareness, insight.
1362478|NCT00518986|Obstructive Sleep Apnea/Hypopnea Syndrome
1362479|NCT00518986|Excessive Sleepiness
1362480|NCT00518960|ProAlgaZyme
1362481|NCT00518960|Algae
1362482|NCT00518960|High density lipoprotein; HDL
1362483|NCT00518960|C-Reactive Protein; CRP
1362484|NCT00518960|Hyperlipidemia
1362485|NCT00518960|Metabolic Syndrome
1362486|NCT00518947|Bipolar Disorder
1362487|NCT00518947|Mania
1362488|NCT00518947|Antimanic
1362489|NCT00518947|Verapamil
1362490|NCT00518947|Lithium
1362491|NCT00518934|Safety and efficiency of angiogenesis for patients with limb
1362492|NCT00518934|ischemia by transplantation of human cord blood mononuclear
1362493|NCT00518934|cells
1362494|NCT00518921|adenosin agonist
1362495|NCT00518921|chronic stable angina
1362496|NCT00518908|Ischemia reperfusion injury
1362497|NCT00518908|Organ protection
1362498|NCT00518895|Melanoma
1362499|NCT00518895|Advanced Melanoma
1362500|NCT00518895|Malignant Melanoma
1362501|NCT00518895|Metastatic Melanoma
1362502|NCT00518895|Skin Cancer
1362503|NCT00518895|Genasense
1362504|NCT00518895|oblimersen
1362505|NCT00518895|antisense
1362506|NCT00518895|Bcl-2 antisense
1362507|NCT00518895|G3139
1362508|NCT00518895|dacarbazine
1362509|NCT00518869|Non-Small Cell Lung Cancer (NSCLC)
1362510|NCT00518869|Complementary and Alternative Medicine (CAM)
1362511|NCT00518869|Chemotherapy
1362512|NCT00518869|Myelosuppression
1362513|NCT00518869|Quality of Life
1362514|NCT00518869|Fatigue
1362515|NCT00518869|EORTC QLQ-C30 and LC13
1362516|NCT00518856|birth asphyxia
1362517|NCT00518856|neonatal sepsis
1362518|NCT00518856|maternal to child transmission of HIV
1362519|NCT00518843|binge eating
1362520|NCT00518843|purging
1362521|NCT00518830|postnatal depression
1362522|NCT00518830|primary care
1362523|NCT00518830|depressed women
1362524|NCT00518817|Dystrophy
1362525|NCT00518817|Cardiomyopathy
1362526|NCT00518791|Integrated health care system
1362527|NCT00518791|Treatment effectiveness
1362528|NCT00518791|Cost effectiveness
1362529|NCT00518791|Program evaluation
1362530|NCT00518778|fusariosis
1362531|NCT00518778|solid organ transplants
1362532|NCT00518765|aliskiren, renal hemodynamics, hormonal response, renin pathway, RAAS biomarkers
1362533|NCT00518752|Ventilator Acquired Pneumonia
1362534|NCT00518752|Oral Hygiene
1362535|NCT00518752|Oral Care
1362536|NCT00518752|Xerostomia
1362537|NCT00518726|Adjuvanted Influenza Vaccine
1362538|NCT00518713|Epilepsy
1362539|NCT00518713|Lennox-Gastaut Syndrome
1362540|NCT00518713|Drop seizures
1362541|NCT00518713|Clobazam
1362542|NCT00517712|Acute promyelocytic leukemia
1362543|NCT00517712|Arsenic trioxide
1362544|NCT00517712|Molecular remission
1362545|NCT00517712|Toxicity profile
1362546|NCT00517712|Maintenance therapy
1362547|NCT00517686|Poor risk factor control
1362548|NCT00517686|Treatment intensification
1362549|NCT00517686|Medication adherence
1362550|NCT00517686|Cardiovascular disease (CVD)
1362551|NCT00517673|Healthy Volunteer
1362552|NCT00517660|Healthy subjects
1362553|NCT00517660|Lower Respiratory Tract Infections
1362554|NCT00517660|Upper Respiratory Tract Infections
1362555|NCT00517647|ADHD
1362556|NCT00517647|atomoxetine
1362557|NCT00517647|preschool children
1362558|NCT00517647|efficacy
1362559|NCT00517647|safety
1362560|NCT00517634|asthma
1362561|NCT00517634|allergen challenge
1362562|NCT00517634|IL-5
1362563|NCT00517634|eosinophils
1362564|NCT00517621|Peritoneal cancer
1362565|NCT00517621|Relapse or progression
1362566|NCT00516581|Pneumocystis Pneumonia
1362567|NCT00516581|Acquired Immune Deficiency Syndrome
1362568|NCT00516581|Highly Active Antiretroviral Therapy
1362569|NCT00516581|Treatment Experienced
1362570|NCT00516581|Treatment Naive
1362571|NCT00516555|Breech Presentation
1362572|NCT00516555|External Cephalic version
1362573|NCT00516555|Thyroid Function Tests
1362574|NCT00516542|stage IV breast cancer
1362575|NCT00516542|recurrent breast cancer
1362576|NCT00516542|male breast cancer
1362577|NCT00516516|muscle cramp
1362578|NCT00516516|pregnancy
1362579|NCT00516516|carnitine
1362580|NCT00516516|randomized controlled clinical trials
1362581|NCT00516490|GnRH agonist
1362582|NCT00516490|IVF/ICSI outcome
1362583|NCT00516490|luteal phase
1362584|NCT00516477|Adeno-Associated Virus (AAV)
1362585|NCT00516477|Leber Congenital Amaurosis
1362586|NCT00516477|Gene transfer
1362587|NCT00516464|Proliferative Diabetic Retinopathy
1362588|NCT00516464|Vitrectomy
1362589|NCT00516464|Ranibizumab
1362590|NCT00516438|malignant solid tumours
1362591|NCT00516438|Poly(ADP ribose)
1362592|NCT00516438|polymerases
1362593|NCT00516425|stage IA breast cancer
1362594|NCT00516425|stage IB breast cancer
1362595|NCT00516425|stage II breast cancer
1362596|NCT00516425|stage IIIA breast cancer
1362597|NCT00516412|contiguous stage II mantle cell lymphoma
1362598|NCT00516412|noncontiguous stage II mantle cell lymphoma
1362599|NCT00516412|recurrent mantle cell lymphoma
1362600|NCT00516412|stage I mantle cell lymphoma
1362601|NCT00516412|stage III mantle cell lymphoma
1362602|NCT00516412|stage IV mantle cell lymphoma
1362603|NCT00518674|pain
1362604|NCT00518674|local infiltration analgesia
1362605|NCT00518661|quinolone resistance
1362606|NCT00518661|ESBL
1362607|NCT00518661|Klebsiella species
1362608|NCT00518661|Infection
1362609|NCT00518648|Accidental falls
1362610|NCT00518648|Prevention
1362611|NCT00518648|Treatment effectiveness
1362612|NCT00518635|Growth hormone
1362613|NCT00518635|Insulin sensitivity
1362614|NCT00518635|Polycystic ovary
1362615|NCT00518609|Neonatal
1362616|NCT00518609|Sepsis
1362617|NCT00518609|Global Network
1362618|NCT00518609|Antibiotics
1362619|NCT00518609|India
1362620|NCT00518609|International
1362621|NCT00518609|Maternal and child health
1362622|NCT00518596|Neonatal
1362623|NCT00518596|Sepsis
1362624|NCT00518596|Global Network
1362625|NCT00518596|Probiotics
1362626|NCT00518596|India
1362627|NCT00518596|International
1362628|NCT00518596|Maternal and child health
1362629|NCT00518583|Breast cancer
1362630|NCT00518583|Over-expressing Her2-neu
1362631|NCT00518570|PMDD
1362632|NCT00518570|PMS
1362633|NCT00518570|Levetiracetam
1362634|NCT00518557|liver cancer
1362635|NCT00518557|interventional radiology
1362636|NCT00518557|Chemoembolization
1362637|NCT00518557|Safety
1362638|NCT00518557|Effectiveness
1362639|NCT00518544|hydroxyethyl starch, blood type, coagulation
1362640|NCT00518531|osteoporosis
1362641|NCT00518531|low bone mineral density
1362642|NCT00518531|alendronate
1362643|NCT00518531|denosumab
1362644|NCT00518531|adherence
1362645|NCT00518531|preference
1362646|NCT00518531|satisfaction
1362647|NCT00518531|postmenopausal
1362648|NCT00518531|women
1362649|NCT00518518|Asthma
1362650|NCT00518518|Sublingual immunotherapy
1362651|NCT00518518|Children
1362652|NCT00518505|GERD, laparoscopic surgery
1362653|NCT00518479|Hypertension
1362654|NCT00518479|Left Ventricular Hypertrophy
1362655|NCT00518466|Obesity
1362656|NCT00518453|Influenza vaccine
1362657|NCT00518440|Liver disease
1362658|NCT00518440|Liver injury
1362659|NCT00518414|infant, formula, LC PUFA
1362660|NCT00518401|A hypoperfusion of the blood through a leg
1362661|NCT00518401|Stem cells
1362662|NCT00518401|Stem cell transplantation
1362663|NCT00518401|Stem cell autologous transplantation
1362664|NCT00518388|Epidemiology
1362665|NCT00518388|Cervical Cancer
1362666|NCT00518388|Human Papillomavirus
1362667|NCT00518388|Focus Group
1362668|NCT00518388|Questionnaire
1362669|NCT00518388|Survey
1362670|NCT00518388|HPV
1362671|NCT00518362|TW
1362672|NCT00518362|Valsartan
1362673|NCT00518362|treatment
1362674|NCT00518362|diabetic nephropathy
1362675|NCT00518362|Proteinuria
1362676|NCT00518323|Schizophrenia
1362677|NCT00518323|Antipsychotic
1362678|NCT00518310|Interstitial lung disease
1362679|NCT00518310|Idiopathic pulmonary fibrosis
1362680|NCT00518310|Usual interstitial pneumonia
1362681|NCT00518310|Cryptogenic fibrosing alveolitis
1362682|NCT00518310|Therapy
1362683|NCT00518310|Azathioprine
1362684|NCT00518310|Steroids
1362685|NCT00518310|Glucocorticoids
1362686|NCT00518310|Corticosteroids
1362687|NCT00518310|Prednisone
1362688|NCT00518297|Antivirals / HIV
1362689|NCT00518284|Restenosis
1362690|NCT00518284|Superficial Femoral Artery
1362691|NCT00518284|Prevention of restenosis
1362692|NCT00518284|Revascularization of the superficial Femoral Artery
1362693|NCT00518258|Parkinson's Disease
1362694|NCT00518258|Magnetic Resonance Imaging (MRI)
1362695|NCT00518258|neuropsychological assessment
1362696|NCT00518245|unstable angina
1362697|NCT00518245|drug therapy
1362698|NCT00518245|myocardial ischemia
1362699|NCT00518245|myocardial infarction
1362700|NCT00518245|hemorrhage
1362701|NCT00518232|Methylphenidate
1362702|NCT00518232|Attention Deficit Hyperactivity Disorder
1362703|NCT00518219|TW
1362704|NCT00518219|Valsartan
1362705|NCT00518219|treatment
1362706|NCT00518219|membranous nephropathy
1362707|NCT00518219|proteinuria
1362708|NCT00518206|Clinical Trial
1362709|NCT00518206|Phase II
1362710|NCT00518206|Cancer Vaccine
1362711|NCT00518206|NY-ESO-1 protein, human
1362712|NCT00518206|ISCOMATRIX, immunological adjuvant
1362713|NCT00518206|Cyclophosphamide
1362714|NCT00518206|T-Cells, Regulatory
1362715|NCT00518180|Meningococcal
1362716|NCT00518180|meningitis
1362717|NCT00518180|vaccine
1362718|NCT00518180|adolescents
1362719|NCT00518167|Type 2 diabetes
1362720|NCT00518167|primary prevention
1362721|NCT00518167|diet
1362722|NCT00518167|physical activity
1362723|NCT00518167|intervention
1362724|NCT00518167|impaired glucose tolerance
1362725|NCT00518167|lifestyle
1362726|NCT00518167|randomized controlled study
1362727|NCT00518154|AIDS
1362728|NCT00518154|Immunological non-responders
1362729|NCT00518154|Neuroimmune modulation
1362730|NCT00518154|Pyridostigmine
1362731|NCT00518154|Treatment Experienced
1362732|NCT00518128|Obstructive Sleep Apnea
1362733|NCT00518128|Leptin
1362734|NCT00518128|Homocysteine
1362735|NCT00518128|C-reactive protein
1362736|NCT00518115|GLP-1,
1362737|NCT00518115|Type 2 Diabetes,
1362738|NCT00518115|pharmacokinetics,
1362739|NCT00518115|pharmacodynamics,
1362740|NCT00518115|GSK716155,
1362741|NCT00518115|metformin,
1362742|NCT00518115|exenatide
1362743|NCT00518115|Type 2 Diabetes Mellitus
1362744|NCT00518102|REGRANEX (becaplermin)
1362745|NCT00518102|Platelet-derived growth factor BB
1362746|NCT00518102|Cancer
1362747|NCT00518102|Cancer incidence
1362748|NCT00518102|Cancer mortality
1362749|NCT00518076|Staphylococcus aureus carriers students nursing
1362750|NCT00518050|Health Behaviors
1362751|NCT00518050|Surveillance
1362752|NCT00518050|06-128
1362753|NCT00518024|tinnitus
1362754|NCT00518024|transcranial magnetic stimulation
1362755|NCT00518024|treatment
1362756|NCT00518024|cortex
1362757|NCT00517998|Lung volume reduction
1362758|NCT00517998|Bronchoscopy
1362759|NCT00517998|Emphysema
1362760|NCT00517998|COPD
1362761|NCT00517998|NETT
1362762|NCT00517998|Lung disease
1362763|NCT00517998|COLD
1362764|NCT00517998|BLVR
1362765|NCT00517985|perimenopausal depression
1362766|NCT00517985|duloxetine
1362767|NCT00517985|cymbalta
1362768|NCT00517985|major depressive disorder
1362769|NCT00517985|women
1362770|NCT00517972|perimenopausal depression
1362771|NCT00517972|omacor
1362772|NCT00517972|major depressive disorder
1362773|NCT00517972|women
1362774|NCT00517959|Stereotactic radiotherapy
1362775|NCT00517959|conformal radiotherapy
1362776|NCT00517959|late sequelae
1362777|NCT00517959|cognition
1362778|NCT00517959|endocrine dysfunction
1362779|NCT00517946|anti-allergy.
1362780|NCT00517946|seasonal allergic rhinitis (SAR),
1362781|NCT00517946|intranasal allergen challenge,
1362782|NCT00517946|MRI,
1362783|NCT00517933|Idiopathic Pulmonary Fibrosis
1362784|NCT00517933|Pulmonary Hypertension
1362785|NCT00517894|lymphoma
1362786|NCT00517894|aggressive
1362787|NCT00517894|chemotherapy
1362788|NCT00517894|dose-dense
1362789|NCT00517868|bladder
1362790|NCT00517868|pain
1362791|NCT00517868|urgency
1362792|NCT00517868|frequency
1362793|NCT00517842|Parkinson's disease
1362794|NCT00517829|metastatic gastric or adenocarcinoma of the GE junction
1362795|NCT00517803|micronutrients
1362796|NCT00517803|immunodeficiency
1362797|NCT00517803|probiotics
1362798|NCT00517803|yogurt
1362799|NCT00517803|Healthy
1362800|NCT00517803|Acquired Immunodeficiency Syndrome
1362801|NCT00517803|Complementary Therapies
1362802|NCT00517790|Refractory
1362803|NCT00517790|Metastatic
1362804|NCT00517777|sleep apnea syndrome
1362805|NCT00517777|metabolic syndrome
1362806|NCT00517777|cardiac remodelling
1362807|NCT00517777|continuous positive airway pressure ventilation
1362808|NCT00517764|major depressive disorder
1362809|NCT00517764|MDD
1362810|NCT00517764|escitalopram
1362811|NCT00517764|open-label
1362812|NCT00517764|major depression
1362813|NCT00517764|serotonin transporter
1362814|NCT00517764|brain-derived neurotrophic factor
1362815|NCT00517751|Lumbar Spinal Stenosis
1362816|NCT00517751|X-STOP Spacer
1362817|NCT00517751|Interspinous process decompression
1362818|NCT00517751|Neurogenic Intermittent Claudication
1362819|NCT00517725|exercise
1362820|NCT00517725|lung diffusion
1362821|NCT00517725|hypoxia
1362822|NCT00517725|chemoreceptor
1362823|NCT00517725|beta-blockers
1362824|NCT00517725|heart failure
1362825|NCT00517595|Non-Small Cell Lung Cancer
1362826|NCT00517582|ACE Inhibitor
1362827|NCT00517582|Angioedema
1362828|NCT00517582|Bradykinin
1362829|NCT00517582|Swelling
1362830|NCT00517569|Gene Therapy
1362831|NCT00517569|GX-12
1362832|NCT00517569|HIV-1
1362833|NCT00517569|Interleukin
1362834|NCT00517569|AIDS
1362835|NCT00517569|HIV-1 type B infection
1362836|NCT00517569|Treatment Naive
1362837|NCT00517556|Dysmenorrhea
1362838|NCT00517556|continuous OCP
1362839|NCT00517543|inflammation
1362840|NCT00517517|Pandemic influenza
1362841|NCT00517504|methylphenidate
1362842|NCT00517504|ritalin
1362843|NCT00517504|attention deficit hyperactivity disorder
1362844|NCT00517504|developmental disorder
1362845|NCT00517504|preschool children
1362846|NCT00517426|heart failure,
1362847|NCT00517426|exercise
1362848|NCT00517426|periodic breathing,
1362849|NCT00517426|acetazolamide
1362850|NCT00517400|PTSD
1362851|NCT00517387|Depression
1362852|NCT00517387|SSRI
1362853|NCT00517387|Atypical Antipsychotic
1362854|NCT00517387|Cognition
1362855|NCT00517387|Mood
1362856|NCT00517387|Quality of Life
1362857|NCT00517348|Adult
1362858|NCT00517335|anorexia nervosa
1362859|NCT00517335|bulimia nervosa
1362860|NCT00517322|left atrial volume
1362861|NCT00517322|hypertension
1362862|NCT00517322|ramipril
1362863|NCT00517322|irbesartan
1362864|NCT00517322|diastolic function
1362865|NCT00517283|diabetes
1362866|NCT00517283|gastric emptying
1362867|NCT00517283|exenatide
1362868|NCT00517283|Byetta
1362869|NCT00517283|Amylin
1362870|NCT00517283|Lilly
1362871|NCT00517270|Non-cardiac chest pain
1362872|NCT00517257|Retinal vein occlusion
1362873|NCT00517257|Retinal vein thrombosis
1362874|NCT00517257|Central retinal vein occlusion
1362875|NCT00517257|Branch retinal vein occlusion
1362876|NCT00517257|Visual loss
1362877|NCT00517257|Atorvastatin
1362878|NCT00517257|Statin
1362879|NCT00517257|Neovascularization
1362880|NCT00517257|Thrombosis
1362881|NCT00517244|Children
1362882|NCT00517244|Healthy Controls
1362883|NCT00517244|Assessment
1362884|NCT00517231|Pulmonary tuberculosis
1362999|NCT00516672|pharmacokinetics,
1362885|NCT00517231|Mycobacterium tuberculosis
1362886|NCT00517231|Cytokines
1362887|NCT00517231|Acute Phase Response
1362888|NCT00517231|Treatment
1362889|NCT00517218|Evaluate the Effect of Genasense on the Efficacy/Safety of Rituximab/Fludarabine Treatment in Untreated Subjects With Chronic Lymphocyctic Leukemia
1362890|NCT00517205|upper ureteric stone
1362891|NCT00517179|Benign Prostatic Hyperplasia (BPH)
1362892|NCT00517179|Erectile Dysfunction (ED)
1362893|NCT00517166|tourniquet
1362894|NCT00517166|extremity injury
1362895|NCT00517166|hemostatic device
1362896|NCT00517153|Zavesca
1362897|NCT00517153|miglustat
1362898|NCT00517153|Niemann-Pick Type C
1362899|NCT00517153|Actelion
1362900|NCT00517140|Pregnancy women with a scarred uterus due to previous caesarean section
1362901|NCT00517127|Intraoperative care
1362902|NCT00517127|Ringer's lactate
1362903|NCT00517127|Voluven
1362904|NCT00517127|Cardiovascular diagnostic technique
1362905|NCT00517127|Doppler effect
1362906|NCT00517114|Reflux laryngitis
1362907|NCT00517101|spondyloarthropathy
1362908|NCT00517101|inflammatory bowel disease
1362909|NCT00517101|antibodies
1362910|NCT00517088|Physical Activity
1362911|NCT00517088|Breast Cancer
1362912|NCT00517075|Transcranial Magnetic Stimulation
1362913|NCT00517075|Repetitive Transcranial Magnetic Stimulation
1362914|NCT00517075|Schizophrenia
1362915|NCT00517075|Schizoaffective Disorder
1362916|NCT00517075|Treatment
1362917|NCT00517075|Negative Symptoms
1362918|NCT00517075|Social Dysfunction
1362919|NCT00517075|TMS
1362920|NCT00517075|rTMS
1362921|NCT00517062|Growth hormone
1362922|NCT00517062|insulin sensitivity
1362923|NCT00517062|cortisol
1362924|NCT00517049|NHL
1362925|NCT00517049|Rituxan
1362926|NCT00517049|Lymphoma
1362927|NCT00517049|CD20-positive
1362928|NCT00517049|B-Cell
1362929|NCT00517049|APM4083g
1362930|NCT00517036|Major Depression
1362931|NCT00517036|Omega-3
1362932|NCT00517036|Major Depressive Disorder
1362933|NCT00517023|Implantable Loop Recorder
1362934|NCT00517023|Home monitoring
1362935|NCT00517023|Syncope/ Falls Clinic
1362936|NCT00517010|Age-related macular degeneration
1362937|NCT00517010|Exudative age-related macular degeneration
1362938|NCT00517010|Wet macular degeneration
1362939|NCT00517010|Intravitreal injection
1362940|NCT00517010|Proton beam irradiation
1362941|NCT00517010|Lucentis
1362942|NCT00517010|Ranibizumab
1362943|NCT00516984|Relationship between Osteopathic Manipulative Therapy (OMT) and the autonomic nervous system
1362944|NCT00516984|LF/HF ratio
1362945|NCT00516971|Non-erosive reflux disease
1362946|NCT00516958|diabetic
1362947|NCT00516958|ulcer
1362948|NCT00516958|infection
1362949|NCT00516958|topical
1362950|NCT00516958|wound
1362951|NCT00516945|hepatitis B during cancer chemotherapy
1362952|NCT00516932|Suicidal Event
1362953|NCT00516932|Behavioral Activation
1362954|NCT00516919|Obesity
1362955|NCT00516919|Binge Eating
1362956|NCT00516919|Monolingual Hispanic Persons
1362957|NCT00516919|Orlistat
1362958|NCT00516919|Behavioral Weight Loss Treatment
1362959|NCT00516893|natalizumab
1362960|NCT00516893|Tysabri
1362961|NCT00516893|Multiple Sclerosis
1362962|NCT00516893|Relapsing Forms of Multiple Sclerosis
1362963|NCT00516880|chronic kidney disease
1362964|NCT00516880|cardiovascular disease
1362965|NCT00516854|Non-cardiac chest pain
1362966|NCT00516841|epithelial ovarian cancer
1362967|NCT00516841|peritoneal cancer
1362968|NCT00516841|platinum-resistant ovarian cancer
1362969|NCT00516841|Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
1362970|NCT00516828|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1362971|NCT00516828|adult acute myeloid leukemia with inv(16)(p13;q22)
1362972|NCT00516828|adult acute myeloid leukemia with t(15;17)(q22;q12)
1362973|NCT00516828|adult acute myeloid leukemia with t(16;16)(p13;q22)
1362974|NCT00516828|adult acute myeloid leukemia with t(8;21)(q22;q22)
1362975|NCT00516828|untreated adult acute myeloid leukemia
1362976|NCT00516828|secondary acute myeloid leukemia
1362977|NCT00516828|de novo myelodysplastic syndromes
1362978|NCT00516828|secondary myelodysplastic syndromes
1362979|NCT00516802|Poly(ADP ribose) polymerases
1362980|NCT00516802|dacarbazine
1362981|NCT00516750|recurrent bladder cancer
1362982|NCT00516750|stage II bladder cancer
1362983|NCT00516750|stage III bladder cancer
1362984|NCT00516750|stage IV bladder cancer
1362985|NCT00516724|malignant solid tumours
1362986|NCT00516724|Poly(ADP ribose) polymerases
1362987|NCT00516711|Surgery with Pringle maneuver needed for liver resection
1362988|NCT00516698|stage I breast cancer
1362989|NCT00516698|stage II breast cancer
1362990|NCT00516698|stage IIIA breast cancer
1362991|NCT00516698|stage IIIC breast cancer
1362992|NCT00516685|LUNG CANCER
1362993|NCT00516685|NSCLC
1362994|NCT00516685|EGF
1362995|NCT00516685|CANCER VACCINE
1362996|NCT00516685|IMMUNOTHERAPY
1362997|NCT00516672|lapatinib,
1362998|NCT00516672|cancer
1363000|NCT00516672|safety,
1363001|NCT00516672|pazopanib,
1363002|NCT00516672|Japanese patients,
1363003|NCT00516659|ETEC
1363004|NCT00516659|Traveler's diarrhea
1363005|NCT00516659|TCI
1363006|NCT00516659|patch vaccine
1363007|NCT00516659|diarrhea prevention
1363008|NCT00516659|epidemiology ETEC
1363009|NCT00516659|Escherichia coli
1363010|NCT00516646|Advanced Glycation End-products (AGEs)
1363011|NCT00516646|Alegebrium
1363012|NCT00516633|Asthma
1363013|NCT00516633|Adherence
1363014|NCT00516633|Burden of asthma
1363015|NCT00516633|Quality of life
1363016|NCT00516633|Questionnaires
1363017|NCT00516620|Body Weight
1363018|NCT00516607|recurrent adult brain tumor
1363019|NCT00516607|adult mixed glioma
1363144|NCT00515983|therapeutic vaccine
1363020|NCT00516607|adult anaplastic astrocytoma
1363021|NCT00516607|adult anaplastic oligodendroglioma
1363022|NCT00516607|adult glioblastoma
1363023|NCT00516607|adult anaplastic ependymoma
1363024|NCT00516607|adult giant cell glioblastoma
1363025|NCT00516607|adult gliosarcoma
1363026|NCT00516607|adult pineal gland astrocytoma
1363027|NCT00516399|Fungal keratitis
1363028|NCT00516399|povidone iodine
1363029|NCT00516399|childhood blindness
1363030|NCT00516399|povidone-iodine
1363031|NCT00516386|Adolescents
1363032|NCT00516386|Anorexia nervosa (AN)
1363033|NCT00516386|Bone formation markers
1363034|NCT00516386|Insulin like growth factor-1 (IGF-I)
1363035|NCT00516373|advanced ovarian cancer
1363036|NCT00516373|BRCA 1 protein
1363037|NCT00516373|BRCA 2 protein
1363038|NCT00516373|Poly(ADP ribose)polymerases
1363039|NCT00516360|Catheter related bloodstream infections
1363040|NCT00516360|Infant, Newborn
1363041|NCT00516360|Intensive Care Units, Neonatal
1363042|NCT00516360|Neonatal Central Line Infections
1363043|NCT00516347|adenocarcinoma of the esophagus
1363044|NCT00516347|esophageal cancer
1363045|NCT00516347|Barrett esophagus
1363046|NCT00516334|brain
1363047|NCT00516334|electroencephalography
1363048|NCT00516334|premature infant
1363049|NCT00516334|neurodevelopment
1363050|NCT00516321|thrombopoietin
1363051|NCT00516321|hepatitis C
1363052|NCT00516321|ribavirin
1363053|NCT00516321|platelets
1363054|NCT00516321|Hepatitis C-related thrombocytopenia
1363055|NCT00516321|peginterferon alfa-2a
1363056|NCT00516308|CLI
1363057|NCT00516308|Critical Limb Ischemia
1363058|NCT00516308|PAD
1363059|NCT00516308|Paripheral Arterial Disease
1363060|NCT00516308|Artherosclerosis
1363061|NCT00516308|Leg pain
1363062|NCT00516308|Cardiovascular
1363063|NCT00516308|Atherectomy
1363064|NCT00516308|NightHawk
1363065|NCT00516282|adult glioblastoma
1363066|NCT00516282|adult giant cell glioblastoma
1363067|NCT00516282|adult gliosarcoma
1363068|NCT00516282|adult anaplastic astrocytoma
1363069|NCT00516282|adult anaplastic oligodendroglioma
1363070|NCT00516282|adult mixed glioma
1363071|NCT00516269|Breast Cancer
1363072|NCT00516269|Gastrointestinal Cancer
1363073|NCT00516269|GI Cancer
1363074|NCT00516269|Fatigue
1363075|NCT00516269|OROS Methylphenidate HCl
1363076|NCT00516269|Methylphenidate
1363077|NCT00516269|Methylphenidate Hydrochloride
1363078|NCT00516269|Concerta
1363079|NCT00516269|Ritalin
1363080|NCT00516269|Placebo
1363081|NCT00516256|Prostate Cancer
1363082|NCT00516256|Quality of Life
1363083|NCT00516256|Cancer Information Mentor
1363084|NCT00516256|CHESS
1363085|NCT00516256|the Comprehensive Health Enhancement Support System
1363086|NCT00516256|Social support
1363087|NCT00516256|Skill-building tools
1363088|NCT00516230|Colonic Neoplasms
1363089|NCT00516230|Lynch syndrome
1363090|NCT00516217|recurrent adult Hodgkin lymphoma
1363091|NCT00516217|adult lymphocyte predominant Hodgkin lymphoma
1363092|NCT00516204|Hyperlipidemia
1363093|NCT00516204|Diabetics
1363094|NCT00516204|NIS
1363095|NCT00516204|Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)
1363096|NCT00516191|Multiple Myeloma
1363097|NCT00516191|Velcade
1363098|NCT00516191|Doxil
1363099|NCT00516191|Melphalan
1363100|NCT00516178|Fish oil supplement
1363101|NCT00516178|n-3 PUFA
1363102|NCT00516178|Cardiac function
1363103|NCT00516178|Membrane incorporation
1363104|NCT00516178|Inflammation
1363105|NCT00516178|Clinical outcome
1363106|NCT00516165|liver cancer
1363107|NCT00516165|RAD001
1363108|NCT00516152|Matched Unrelated Donor
1363109|NCT00516152|Stem Cell Transplantation
1363110|NCT00516152|Busulfan
1363111|NCT00516152|fludarabine
1363112|NCT00516152|Hematopoietic Disorder
1363113|NCT00516139|Epilepsy elderly seizure
1363114|NCT00516126|hemostasis monitoring
1363115|NCT00516126|perioperative blood loss
1363116|NCT00516113|paroxetine
1363117|NCT00516113|onset of action
1363118|NCT00516113|serotonin reuptake inhibitors
1363119|NCT00516100|NSCLC
1363120|NCT00516087|Nasopharyngeal Carcinoma
1363121|NCT00516074|exenatide
1363122|NCT00516074|Byetta
1363123|NCT00516074|type 2 diabetes
1363124|NCT00516074|heart rate
1363125|NCT00516074|Amylin
1363126|NCT00516074|Lilly
1363127|NCT00516048|exenatide
1363128|NCT00516048|Byetta
1363129|NCT00516048|antibodies
1363130|NCT00516048|Amylin
1363131|NCT00516048|Lilly
1363132|NCT00516035|Bird Flu
1363133|NCT00516009|RADICULAR PAIN
1363134|NCT00516009|DISC HERNIATION
1363135|NCT00516009|DEXAMETHASONE
1363136|NCT00516009|VAS
1363137|NCT00515996|panic disorder
1363138|NCT00515996|paroxetine
1363139|NCT00515996|genetic polymorphism
1363140|NCT00515996|serotonin
1363141|NCT00515983|melanoma
1363142|NCT00515983|dendritic cells
1363143|NCT00515983|apoptotic/necrotic cells
1363145|NCT00515970|Carcinoma, Basal Cell
1363146|NCT00515970|Curettage
1363147|NCT00515970|Excision
1363148|NCT00515970|Recurrence
1363149|NCT00515970|Complication
1363150|NCT00515970|Esthetic outcome
1363151|NCT00515944|No condition
1363152|NCT00515944|healthy volunteers
1363153|NCT00515931|Gastrointestinal stromal tumor
1363154|NCT00515931|GIST
1363155|NCT00515931|Sarcoma
1363156|NCT00515931|Radiation therapy
1363157|NCT00515931|Radiotherapy
1363158|NCT00515918|Iron deficiency
1363159|NCT00515918|brain
1363160|NCT00515918|cognition
1363161|NCT00515918|behavior
1363162|NCT00515879|Generalized subtype
1363163|NCT00515866|Advanced pancreatic cancer
1363164|NCT00515866|Poly (ADP ribose) polymerases
1363165|NCT00515866|Advanced Solid Tumours
1363166|NCT00515853|Rectal neoplasms
1363167|NCT00515853|Biofeedback (Psychology)
1363168|NCT00515853|Fecal Incontinence
1363169|NCT00515853|Aged
1363170|NCT00515853|Anterior resection
1363171|NCT00515827|Treatment Experienced
1363172|NCT00515814|Legal blindness
1363173|NCT00515814|Retinopathy pigmentosa
1363174|NCT00515814|Hereditary condition
1363175|NCT00515814|Photo-receptor degeneration
1363176|NCT00515814|Retina implant
1363177|NCT00515814|Subretinal implant
1363178|NCT00515801|diabetes mellitus type 1
1363179|NCT00515801|hypoglycemia
1363180|NCT00515801|sulfonylurea
1363181|NCT00515801|glucagon
1363182|NCT00515788|Neoplastic Meningitis
1363183|NCT00515788|Leptomeningeal Disease
1363184|NCT00515788|Temozolomide
1363185|NCT00515788|Temodar
1363186|NCT00515788|DepoCyt
1363187|NCT00515788|Liposomal Cytarabine
1363188|NCT00515788|Liposomal ara-C
1363189|NCT00515762|persistent alopecia
1363190|NCT00515762|docetaxel
1363191|NCT00515762|breast cancer
1363192|NCT00515736|selenium
1363193|NCT00515736|oxidative stress
1363194|NCT00515736|glutathione peroxidase
1363195|NCT00515736|critically ill
1363196|NCT00515736|outcome
1363197|NCT00515736|supplementation
1363198|NCT00515723|control
1363199|NCT00515723|risperidone
1363200|NCT00515723|olanzapine
1363201|NCT00515723|quetiapine
1363202|NCT00515723|ziprasidone
1363203|NCT00515710|Hemophilia B
1363204|NCT00515710|Gene Transfer
1363205|NCT00515710|Adeno-Associated Virus (AAV)
1363206|NCT00515710|Coagulation Factor IX
1363207|NCT00515710|Long-term Follow-up
1363208|NCT00515710|Delayed Adverse Events
1363209|NCT00515671|self-management
1363210|NCT00515671|recovery
1363211|NCT00515671|severe mental illness
1363212|NCT00515658|Major depression
1363213|NCT00515658|Theta-burst rTMS
1363214|NCT00515658|Cortical excitability
1363215|NCT00515658|Hamilton depression rating scale
1363216|NCT00515645|Autonomic nervous system
1363217|NCT00515645|Immersion
1363218|NCT00515645|Heart rate variability
1363219|NCT00515645|Head-down tilt
1363220|NCT00515645|Healthy volunteers
1363221|NCT00515632|Type 2 diabetes mellitus on Stable insulin therapy
1363222|NCT00515632|Balaglitazone
1363223|NCT00515632|Pioglitazone (Actos®)
1363224|NCT00515632|HbA1c
1363225|NCT00515632|Weight gain
1363226|NCT00515632|Oedema
1363227|NCT00515632|Fasting blood glucose
1363228|NCT00515593|osteoporosis
1363229|NCT00515593|postmenopausal women
1363230|NCT00515593|Severe postmenopausal osteoporosis
1363231|NCT00515580|obstructive sleep apnea
1363232|NCT00515580|upper airway resistance syndrome
1363233|NCT00515580|tongue suture
1363234|NCT00515580|retrolingual tongue collapse
1363235|NCT00515580|minimally invasive
1363236|NCT00515567|explanted lungs
1363237|NCT00515567|pulmonary fibrosis
1363238|NCT00515554|Hodgkin lymphoma
1363239|NCT00515554|PET
1363240|NCT00515554|advances stages
1363241|NCT00515554|Rituximab
1363242|NCT00515541|Platelet
1363243|NCT00515541|Cardiovascular
1363244|NCT00515541|Lipid
1363245|NCT00515541|Fish Oil
1363246|NCT00515541|Omega 3
1363247|NCT00515541|DHA
1363248|NCT00515541|EPA
1363249|NCT00515541|Bleeding
1363250|NCT00515541|Clotting
1363251|NCT00515541|platelet function
1363252|NCT00515541|Lipid profile
1363253|NCT00515541|Weight and Bleeding risk
1363254|NCT00515528|metastatic melanoma
1363255|NCT00515502|chronic obstructive pulmonary disease,
1363256|NCT00515502|GSK573719,
1363257|NCT00515502|muscarinic receptor antagonist
1363258|NCT00515489|Schizophrenia
1363259|NCT00515489|Schizoaffective Disorder
1363260|NCT00515489|Schizophreniform Disorders
1363261|NCT00515476|metabolic syndrome
1363262|NCT00515476|HDL-Cholesterol
1363263|NCT00515476|EPC
1363264|NCT00515476|endothelial function
1363265|NCT00515476|reduced blood HDL-Cholesterol level
1363266|NCT00515463|Osteopenia
1363267|NCT00515463|Osteoporosis
1363268|NCT00515463|AMG 162
1363269|NCT00515463|Postmenopausal
1363270|NCT00515463|Pre-filled syringe
1363271|NCT00515450|Myasthenia Gravis
1363272|NCT00515437|Sialorrhea
1363273|NCT00515424|Glaucoma
1363274|NCT00515424|Ocular Hypertension
1363275|NCT00515424|RKI983
1363276|NCT00515424|Primary Open Angle Glaucoma and Ocular Hypertension
1363277|NCT00515411|gastroesophageal junction
1363278|NCT00515411|gastric cancer
1363279|NCT00515411|adenocarcinoma
1363280|NCT00515411|unresectable gastric cancer
1363281|NCT00515411|metastatic gastric
1363282|NCT00515385|Randomized
1363283|NCT00515385|Double-Blind
1363284|NCT00515385|Dose-Escalation
1363285|NCT00515385|Cohort Study
1363286|NCT00515372|Ovarian Cancer
1363287|NCT00515372|Peritoneal Cancer
1363288|NCT00515372|Fallopian Tube Cancer
1363289|NCT00515372|Depression
1363290|NCT00515372|Telephone Counseling
1363291|NCT00515372|Quality of Life
1363292|NCT00515359|Sedation
1363293|NCT00515359|MRI
1363294|NCT00515359|pediatric
1363295|NCT00515359|propofol
1363296|NCT00515359|brain
1363297|NCT00515359|spine
1363298|NCT00515359|quality of MRI
1363299|NCT00515359|Continuous propofol dosing
1363300|NCT00515359|continuous propofol administration
1363301|NCT00515359|Intermittent propofol dosing
1363302|NCT00515359|intermittent propofol administration
1363303|NCT00515359|Sedative agent
1363304|NCT00515359|propofol continuous infusions
1363305|NCT00515359|Recovery time
1363306|NCT00515359|Complications of sedation
1363307|NCT00515359|bolus dosing
1363308|NCT00515346|CLI
1363309|NCT00515346|Critical Limb Ischemia
1363310|NCT00515333|Alzheimer
1363311|NCT00515333|Dementia
1363312|NCT00515320|Autism
1363313|NCT00515320|children
1363314|NCT00515320|adolescent
1363315|NCT00515320|Fluoxetine
1363316|NCT00515320|Autistic Disorder
1363317|NCT00515320|Repetitive behavior
1363318|NCT00515320|SSRI
1363319|NCT00515320|Selective Serotonin Reuptake Inhibitor
1363320|NCT00515307|Hypercholesterolemia, Familial
1363321|NCT00515307|Bone marrow
1363322|NCT00515307|Mesenchymal stem cell
1363323|NCT00515307|Hepatocyte
1363324|NCT00515294|Caffeine
1363325|NCT00515294|Alcohol
1363326|NCT00515294|Alcohol Consumption
1363327|NCT00515294|Residual Effects
1363328|NCT00515294|Family History
1363329|NCT00515294|Psychomotor Vigilance Test
1363330|NCT00515294|Driving Simulation
1363331|NCT00515294|Reaction Time
1363332|NCT00515281|prematurity
1363333|NCT00515281|nitric oxide
1363334|NCT00515281|bronchopulmonary dysplasia
1363335|NCT00515281|intraventricular hemorrhage
1363336|NCT00515281|periventricular leukomalacia
1363337|NCT00515281|neurodevelopment
1363338|NCT00515268|LPS challenge,
1363339|NCT00515268|Healthy volunteers
1363340|NCT00515255|Obsessive Compulsive Disorder
1363341|NCT00515255|Neuropharm
1363342|NCT00515255|NPL-2003
1363343|NCT00515242|massage therapy
1363344|NCT00515242|relaxation treatments
1363345|NCT00515229|cystic fibrosis
1363346|NCT00515229|ceramide
1363347|NCT00515229|amitriptyline
1363348|NCT00515229|Pseudomonas aeruginosa
1363349|NCT00515229|lung function
1363350|NCT00515216|Phase II
1363351|NCT00515216|Gastric cancer
1363352|NCT00515216|Gastroesophageal cancer
1363353|NCT00515216|Metastatic
1363354|NCT00515216|FOLFOX
1363355|NCT00515216|Thymidylate synthase
1363356|NCT00515216|Pharmacogenomic
1363357|NCT00515203|Immune (Idiopathic) Thrombocytopenic Purpura
1363358|NCT00515203|Pediatric Idiopathic Thrombocytopenic Purpura
1363359|NCT00515190|Stomach Neoplasms
1363360|NCT00515190|Secondary
1363361|NCT00515190|Combination chemotherapy
1363362|NCT00515190|S-1
1363363|NCT00515190|oxaliplatin
1363364|NCT00515177|mindfulness
1363365|NCT00515177|meditation
1363366|NCT00515177|MBSR
1363367|NCT00515177|mindfulness meditation
1363368|NCT00515177|sleep
1363369|NCT00515177|insomnia
1363370|NCT00515177|chronic insomnia
1363371|NCT00515177|primary insomnia
1363372|NCT00515177|Minnesota
1363373|NCT00515164|lung volume reduction
1363374|NCT00515164|emphysema
1363375|NCT00515164|chronic obstructive pulmonary disease
1363376|NCT00515151|Bloodstream Infection
1363377|NCT00515151|Bacteremia
1363378|NCT00515151|Central Venous Catheter
1363379|NCT00515151|Alcohol
1363380|NCT00515151|Disinfection
1363381|NCT00515151|Octenidine Dihydrochloride
1363382|NCT00515138|B-Cell NHL
1363383|NCT00515138|Autologous Stem Cell Transplant
1363384|NCT00515138|RICE
1363385|NCT00515125|Quality of life
1363386|NCT00515125|Supplement
1363387|NCT00515125|Care home
1363388|NCT00515125|Elderly
1363389|NCT00515125|Malnutrition
1363390|NCT00515112|prostate
1363391|NCT00515112|cancer
1363392|NCT00515112|testosterone replacement
1363393|NCT00515112|AndroGel
1363394|NCT00515112|prostatic cancer
1363395|NCT00515112|prostatic neoplasms
1363396|NCT00515099|New-onset Type 1 Diabetes Mellitus
1363397|NCT00515099|New-onset T1DM
1363398|NCT00515099|New-onset Type 1 Diabetes
1363399|NCT00515099|New-onset T1D
1363400|NCT00515099|Newly Diagnosed Type 1 Diabetes Mellitus
1363401|NCT00515099|Autoimmune diabetes
1363402|NCT00515099|Thymoglobulin
1363403|NCT00515099|ATG
1363404|NCT00515099|Rabbit antithymocyte globulin
1363405|NCT00515086|Glioblastoma Multiforme, GBM, RAD001, RAD
1363406|NCT00515073|Endometrial Cancer
1363407|NCT00515073|Papillary Serous Carcinoma
1363408|NCT00515073|Pelvic Radiation Therapy
1363409|NCT00515073|Paclitaxel
1363410|NCT00515073|Taxol
1363411|NCT00515060|Advanced Cancer
1363412|NCT00515060|Therapy-Induced Pain
1363413|NCT00515060|Pain Threshold
1363414|NCT00515060|Sensory Tests
1363415|NCT00515060|Stimuli
1363416|NCT00515060|Pain
1363417|NCT00515047|Atopic Dermatitis
1363418|NCT00515047|Eczema
1363419|NCT00515047|Eczema Herpeticum
1363420|NCT00515047|Molluscum Contagiousum
1363421|NCT00515047|Herpes Simplex
1363422|NCT00515047|Vaccinia
1363423|NCT00515034|Doripenem
1363424|NCT00515034|Imipenem
1363425|NCT00515034|Cilastatin
1363426|NCT00515034|Vancomycin
1363427|NCT00515034|DORIBAX, DORIPREX, FINIBAX, DURAPTA, PRIMAXIN, Anti Bacterial Agents
1363428|NCT00515034|Ileus
1363429|NCT00515034|Hospitalized
1363430|NCT00515034|Fever
1363431|NCT00515021|Metabolic syndrome
1363432|NCT00515021|Aldosterone inhibitor
1363433|NCT00515021|Diurnal drug regimen
1363434|NCT00515021|PAI-1 levels
1363435|NCT00514982|Hermansky-Pudlak Syndrome
1363436|NCT00514982|Colitis
1363437|NCT00514982|Medical Therapy
1363438|NCT00514982|Immunopathogenesis
1363439|NCT00514982|Cytokine
1363440|NCT00514982|Hermansky-Pudlak Syndrome Associated Colitis
1363441|NCT00514982|HPS
1363442|NCT00514969|accelerated and blastic phase
1363443|NCT00514969|STI571
1363444|NCT00514956|Post-Traumatic Stress Syndrome (PTSD)
1363445|NCT00514930|radiofrequency ablation
1363446|NCT00514930|liver cancer
1363447|NCT00514930|complications
1363448|NCT00514930|liver tumors
1363449|NCT00514904|safety
1363450|NCT00514904|meningococcal vaccine
1363451|NCT00514904|immunogenicity
1363452|NCT00514878|nausea
1363453|NCT00514878|postoperative nausea and vomiting
1363454|NCT00514878|postoperative pain
1363455|NCT00514865|ONO-2333Ms
1363456|NCT00514865|Major Depressive Disorder
1363457|NCT00514839|Prescription drug use disorder
1363458|NCT00514839|Brief intervention
1363459|NCT00514839|General hospital
1363460|NCT00514839|Motivational Interviewing
1363461|NCT00514800|Home monitoring
1363462|NCT00514800|Primary care
1363463|NCT00514800|Hypertension
1363464|NCT00514800|TIA
1363465|NCT00514787|Asthma
1363466|NCT00514787|NIS
1363467|NCT00514774|Huntington chorea
1363468|NCT00514774|chorea
1363469|NCT00514774|hereditary
1363470|NCT00514774|tauroursodeoxycholic acid
1363471|NCT00514774|ursodeoxycholic acid
1363472|NCT00514774|TUDCA
1363473|NCT00514774|UDCA
1363474|NCT00514761|colorectal cancer
1363475|NCT00514761|AZD6244
1363476|NCT00514748|breast reconstruction
1363477|NCT00514748|DIEP
1363478|NCT00514748|vessel pedicle
1363479|NCT00514735|atrial fibrillation
1363480|NCT00514722|Hematopoietic malignancies
1363481|NCT00514722|Umbilical cord blood transplantation
1363482|NCT00514722|Lymphoma: diffuse large cell, mantle cell, peripheral T-cell, T-NK cell, or Hodgkin's
1363483|NCT00514709|Diphtheria
1363484|NCT00514709|Tetanus
1363485|NCT00514709|Pertussis
1363486|NCT00514709|Hepatitis B Hansenula (HB)
1363487|NCT00514709|Haemophilus influenzae type b
1363488|NCT00514696|Cancer
1363489|NCT00514696|Leukemia
1363490|NCT00514696|GCS-100
1363491|NCT00514696|CLL
1363492|NCT00514670|Prevention of gastrointestinal and respiratory illness
1363493|NCT00514644|Panorama
1363494|NCT00514644|Carotid stenoses
1363495|NCT00514618|Term Pregnancy
1363496|NCT00514618|Diabetes
1363497|NCT00514618|Cervical Ripening
1363498|NCT00514618|Induction
1363499|NCT00514618|misoprostol
1363500|NCT00514618|Term Gestational Diabetics
1363501|NCT00514605|HIV 1
1363502|NCT00514605|AIDS
1363503|NCT00514605|Assay
1363504|NCT00514605|Rapid Test
1363505|NCT00514605|HIV-1
1363506|NCT00514605|HIV Seronegativity
1363507|NCT00514592|Carotid stenosis
1363508|NCT00514592|Carotid endarterectomy
1363509|NCT00514579|Cord Blood Stem Cell Transplantation
1363510|NCT00514579|Hematologic Malignancies
1363511|NCT00514579|Leukemia
1363512|NCT00514579|Myelodysplastic Syndrome
1363513|NCT00514566|Polyamide
1363514|NCT00514566|Polydioxanone
1363515|NCT00514566|Midline
1363516|NCT00514566|Abdominal
1363517|NCT00514566|Closure
1363518|NCT00514553|Prenatal Testing
1363519|NCT00514553|Test Decision-Making
1363520|NCT00514553|Decision-Making Intervention
1363521|NCT00514553|Theory of Unconscious Thought
1363522|NCT00514553|Informed Choice
1363523|NCT00514553|Decision Making
1363524|NCT00514553|Counseling
1363525|NCT00514540|Prostate Cancer
1363526|NCT00514540|Anaplastic Prostate Cancer
1363527|NCT00514540|Carboplatin
1363528|NCT00514540|Docetaxel
1363529|NCT00514540|Taxotere
1363530|NCT00514540|Paraplatin
1363531|NCT00514514|Everolimus
1363532|NCT00514514|mycophenolate
1363533|NCT00514514|CNI-free
1363534|NCT00514514|kidney transplantation
1363535|NCT00514488|chronic myeloid leukemia
1363536|NCT00514488|STI 571
1363537|NCT00514488|CML022
1363538|NCT00514475|Mantle cell lymphoma
1363539|NCT00514475|Zevalin
1363540|NCT00514475|90Y-ibritumomab tiuxetan
1363541|NCT00514475|Radioimmunotherapy
1363542|NCT00514475|High-dose therapy
1363543|NCT00514475|First line
1363544|NCT00514436|Asthma
1363545|NCT00514436|children
1363546|NCT00514436|low-income, underserved
1363547|NCT00514436|Reduction in hospitalization
1363548|NCT00514410|Depression
1363549|NCT00514410|Folate
1363550|NCT00514410|Folic acid
1363551|NCT00514410|Antidepressants
1363552|NCT00514397|untreated childhood brain stem glioma
1363553|NCT00514371|Multiple Myeloma
1363554|NCT00514371|Heat Shock Protein 90
1363555|NCT00514371|Hsp90
1363556|NCT00514371|KOS-953
1363557|NCT00514371|17-AAG
1363558|NCT00514371|bortezomib
1363559|NCT00514371|relapsed-refractory
1363560|NCT00514371|tanespimycin
1363561|NCT00514358|Fungal
1363562|NCT00514358|Infection
1363563|NCT00514358|sepsis
1363564|NCT00514358|pharmacokinetics
1363565|NCT00514345|chemotherapeutic agent toxicity
1363566|NCT00514345|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1363567|NCT00514345|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1363568|NCT00514345|nonmetastatic childhood soft tissue sarcoma
1363569|NCT00514345|unspecified childhood solid tumor, protocol specific
1363570|NCT00514345|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1363571|NCT00514345|metastatic childhood soft tissue sarcoma
1363572|NCT00514345|recurrent childhood soft tissue sarcoma
1363573|NCT00514345|previously treated childhood rhabdomyosarcoma
1363574|NCT00514345|recurrent childhood rhabdomyosarcoma
1363575|NCT00514332|colorectal stents
1363576|NCT00514332|colonic obstruction
1363577|NCT00514332|colonic adenocarcinoma
1363578|NCT00514332|colorectal surgery
1363579|NCT00514306|Advanced Cancer
1363580|NCT00514306|Breast cancer
1363581|NCT00514306|Renal cancer
1363582|NCT00514306|Ovarian Cancer
1363583|NCT00514306|Metastatic Cancer
1363584|NCT00514306|Non-small cell lung cancer
1363585|NCT00514306|Colorectal cancer
1363586|NCT00514293|recurrent non-small cell lung cancer
1363587|NCT00514293|stage IIIB non-small cell lung cancer
1363588|NCT00514293|stage IV non-small cell lung cancer
1363589|NCT00514280|Lead and Smoke Study in D.C.
1363590|NCT00514280|Birth Weight
1363591|NCT00514280|Gestational Age
1363592|NCT00514280|Lead
1363593|NCT00514280|Tobacco Smoke
1363594|NCT00514267|Prostate Cancer
1363595|NCT00514267|HRPC
1363596|NCT00514267|Hormone Refractory Prostate Cancer
1363597|NCT00514267|YM155
1363598|NCT00514267|Treatment Outcome
1363599|NCT00514267|Solid Tumors
1363600|NCT00514254|endometrial cancer
1363601|NCT00514254|risk factors
1363602|NCT00514254|questionnaire
1363603|NCT00514254|07-093
1363604|NCT00514228|adult primary hepatocellular carcinoma
1363605|NCT00514228|localized unresectable adult primary liver cancer
1363606|NCT00514228|advanced adult primary liver cancer
1363607|NCT00514228|recurrent adult primary liver cancer
1363608|NCT00514215|lung metastases
1363609|NCT00514215|stage I non-small cell lung cancer
1363610|NCT00514215|stage II non-small cell lung cancer
1363611|NCT00514215|stage IIIA non-small cell lung cancer
1363612|NCT00514215|stage IIIB non-small cell lung cancer
1363613|NCT00514215|stage IV non-small cell lung cancer
1363614|NCT00514215|recurrent non-small cell lung cancer
1363615|NCT00514215|recurrent renal cell cancer
1363616|NCT00514215|stage IV renal cell cancer
1363617|NCT00514215|unspecified adult solid tumor, protocol specific
1363618|NCT00514202|cocaine
1363619|NCT00514202|ADHD
1363620|NCT00514202|attention
1363621|NCT00514202|hyperactivity
1363622|NCT00514202|drug
1363623|NCT00514202|dependence
1363624|NCT00514189|Acute Myelogenous Leukemia
1363625|NCT00514189|Leukemia
1363626|NCT00514189|Autologous Dendritic Cells
1363627|NCT00514189|Vaccine
1363628|NCT00514189|AML
1363629|NCT00514189|mRNA
1363630|NCT00514163|pancreatic carcinoma
1363631|NCT00514163|gemcitabine
1363632|NCT00514163|S-1
1363633|NCT00514163|phaseⅡstudy
1363634|NCT00514150|angiography
1363635|NCT00514150|complications
1363636|NCT00514150|contrast media
1363637|NCT00514150|kidney
1363638|NCT00514150|prevention
1363639|NCT00514098|Microbicide
1363640|NCT00514098|Seroconversion
1363641|NCT00514098|Treatment Experienced
1363642|NCT00514098|Treatment Naive
1363643|NCT00514085|recurrent melanoma
1363644|NCT00514085|stage IV melanoma
1363645|NCT00514072|stage IV prostate cancer
1363646|NCT00514072|recurrent prostate cancer
1363647|NCT00514059|Diphteria-tetanus-pertussis-polio vaccine
1363648|NCT00514059|Booster immunization
1363649|NCT00514059|Vaccine effect (Diphtheria-tetanus-acellular pertussis-polio)
1363650|NCT00514059|Immunity
1363651|NCT00514059|Safety
1363660|NCT00514020|adenocarcinoma of the stomach
1363661|NCT00514020|stage IV gastric cancer
1363662|NCT00514020|recurrent gastric cancer
1363663|NCT00514007|Non-small cell lung cancer
1363664|NCT00514007|Ovarian cancer
1363665|NCT00514007|Renal cancer
1363666|NCT00514007|Advanced Cancer
1363667|NCT00514007|Metastatic cancer
1363668|NCT00514007|Breast cancer
1363669|NCT00514007|Colorectal cancer
1363670|NCT00513994|Pharmacokinetics
1363671|NCT00513994|Nitroglycerin
1363672|NCT00513994|pharmacokinetics study of nitroglycerin containing treatments
1363673|NCT00513981|unspecified childhood solid tumor, protocol specific
1363674|NCT00513981|recurrent osteosarcoma
1363675|NCT00513981|recurrent childhood soft tissue sarcoma
1363676|NCT00513981|recurrent childhood ependymoma
1363677|NCT00513981|untreated childhood brain stem glioma
1363678|NCT00513981|recurrent childhood brain stem glioma
1363679|NCT00513955|recurrent mantle cell lymphoma
1363680|NCT00513942|Fetal Movement
1363681|NCT00513942|Maternal-Fetal-Attachment
1363682|NCT00513942|Fetus
1363683|NCT00513929|Severe Pneumonia
1363684|NCT00513929|Zinc
1363685|NCT00513929|Associated pathogens
1363686|NCT00513929|Severe Pneumonia by type of associated pathogens
1363687|NCT00513929|Severe Pneumonia by basal plasma zinc status
1363688|NCT00513916|breast cancer
1363689|NCT00513916|healthy, no evidence of disease
1363690|NCT00513903|Pulmonary Diseases
1363691|NCT00513903|Continuity of Pharmacy Care
1363692|NCT00513890|Bronchiolitis
1363693|NCT00513890|Esophageal pressure mesurement
1363694|NCT00513890|Clinical score
1363695|NCT00513890|Citical care
1363696|NCT00513890|Infant
1363697|NCT00513877|recurrent malignant mesothelioma
1363698|NCT00513877|stage IA malignant mesothelioma
1363699|NCT00513877|stage IB malignant mesothelioma
1363700|NCT00513877|stage II malignant mesothelioma
1363701|NCT00513877|stage III malignant mesothelioma
1363702|NCT00513877|stage IV malignant mesothelioma
1363703|NCT00513864|Opioid Analgesics
1363704|NCT00513864|Morphine
1363705|NCT00513864|Codeine
1363706|NCT00513864|Sickle Cell Disease
1363707|NCT00513851|Advanced Cancer
1363708|NCT00513851|Non-small cell lung cancer
1363709|NCT00513851|Small cell lung cancer
1363710|NCT00513851|Uterine cancer
1363711|NCT00513851|Ovarian cancer
1363712|NCT00513851|Renal cancer
1363713|NCT00513851|Head and neck cancer
1363714|NCT00513851|Cervical cancer
1363715|NCT00513851|Metastatic cancer
1363716|NCT00513851|Colorectal cancer
1363717|NCT00513851|Gastrointestinal stromal tumors
1363718|NCT00513825|Contrast Nephropathy
1363719|NCT00513825|Sodium Bicarbonate
1363720|NCT00513825|Prevention
1363721|NCT00513786|Endometrial Cancer
1363722|NCT00513786|Advanced Stage Endometrial Cancer
1363723|NCT00513786|Stage 3 or 4 endometrial cancer
1363724|NCT00513786|Cancer treatment
1363725|NCT00513786|gyn cancer
1363726|NCT00513773|Abdominal Aortic Aneurysm,
1363727|NCT00513773|Inflammation and Risk Prediction
1363728|NCT00513773|Diagnostic Tool Efficacy
1363729|NCT00513760|Pharmacogenetics
1363730|NCT00513760|Singulair
1363731|NCT00513760|montelukast
1363732|NCT00513760|Leukotriene Antagonists
1363733|NCT00513760|Anti-Asthmatic Agents
1363734|NCT00513760|Intestinal Absorption
1363735|NCT00513760|pharmacokinetics
1363736|NCT00513760|absorption
1363737|NCT00513760|biochemical transport
1363738|NCT00513760|Membrane Transport Proteins
1363739|NCT00513760|Drug Interactions
1363740|NCT00513747|B-cell chronic lymphocytic leukemia
1363741|NCT00513747|stage 0 chronic lymphocytic leukemia
1363742|NCT00513747|stage I chronic lymphocytic leukemia
1363743|NCT00513734|keratopathy
1363744|NCT00513734|exposure
1363745|NCT00513734|intensive care
1363746|NCT00513734|eye
1363747|NCT00513734|ulcer
1363748|NCT00513734|Corneal
1363749|NCT00513721|prostate
1363750|NCT00513721|prostate cancer
1363751|NCT00513721|surgical margins
1363752|NCT00513721|gleason score
1363753|NCT00513721|positive lateral biopsies
1363754|NCT00513708|Detoxification
1363755|NCT00513708|Treatment
1363756|NCT00513682|Cystic Fibrosis
1363757|NCT00513682|Pancreatic insufficiency
1363758|NCT00513682|Steatorrhea
1363759|NCT00513682|Children 7 to 11 years
1363760|NCT00513682|Pancreatic enzyme
1363761|NCT00513669|Malaria
1363762|NCT00513669|Vaccine
1363763|NCT00513669|Falciparum
1363764|NCT00513669|Trial
1363765|NCT00513669|Phase I
1363766|NCT00513669|Safety
1363767|NCT00513669|Immunogenicity
1363768|NCT00513656|Efficacy
1363769|NCT00513656|chronic
1363770|NCT00513656|cancer
1363771|NCT00513656|pain
1363772|NCT00513656|constipation
1363773|NCT00513656|oxycodone
1363774|NCT00513656|naloxone
1363775|NCT00513656|Moderate to severe chronic cancer pain
1363776|NCT00513643|euglycaemic glucose clamp
1363777|NCT00513643|duration of action
1363778|NCT00513643|late metabolic activity
1363779|NCT00513643|hypoglycaemia
1363780|NCT00513617|Sickle Cell Disease
1363781|NCT00513617|Anemia
1363782|NCT00513617|Nitric Oxide
1363783|NCT00513617|Vaso Occlusive Events
1363784|NCT00513617|Arginine Supplementation
1363785|NCT00513604|Clinical Response
1363786|NCT00513604|Immunotherapy
1363787|NCT00513604|Cancer
1363788|NCT00513604|Cytokines
1363789|NCT00513604|Adoptive Cell Therapy
1363790|NCT00513604|Melanoma
1363791|NCT00513604|Skin Cancer
1363792|NCT00513604|Malignant Melanoma
1363793|NCT00513591|Pregnancy
1363794|NCT00513591|Lupus (systemic lupus erythematosus or cutaneous lupus)
1363795|NCT00513591|Rheumatoid Arthritis
1363796|NCT00513591|Sjogren's Syndrome
1363797|NCT00513591|Scleroderma
1363798|NCT00513578|refractory anemia with excess blasts
1363799|NCT00513578|refractory anemia with ringed sideroblasts
1363800|NCT00513578|refractory anemia
1363801|NCT00513578|refractory cytopenia with multilineage dysplasia
1363802|NCT00513578|de novo myelodysplastic syndromes
1363803|NCT00513578|secondary myelodysplastic syndromes
1363804|NCT00513565|GSK561679,
1363805|NCT00513565|single,
1363806|NCT00513565|dose,
1363807|NCT00513565|lorazepam,
1363808|NCT00513565|fMRI,
1363809|NCT00513565|BOLD,
1363810|NCT00513565|healthy volunteers
1363811|NCT00513539|unresectable gallbladder cancer
1363812|NCT00513539|recurrent gallbladder cancer
1363813|NCT00513539|metastatic gallbladder cancer
1363814|NCT00513539|cholangiocarcinoma of the gallbladder
1363815|NCT00513539|unresectable extrahepatic bile duct cancer
1363816|NCT00513539|recurrent extrahepatic bile duct cancer
1363817|NCT00513539|metastatic extrahepatic bile duct cancer
1363818|NCT00513539|cholangiocarcinoma of the extrahepatic bile duct
1363819|NCT00513526|infection
1363820|NCT00513526|low-grade squamous intraepithelial lesion
1363821|NCT00513526|atypical squamous cells of undetermined significance
1363822|NCT00513513|HIV
1363823|NCT00513513|AIDS
1363824|NCT00513513|TMC114
1363825|NCT00513513|Protease inhibitor
1363826|NCT00513513|Darunavir
1363827|NCT00513513|Antiretroviral agents
1363828|NCT00513513|Treatment Naive
1363829|NCT00513500|community health care
1363830|NCT00513500|community health worker
1363831|NCT00513500|malaria
1363832|NCT00513500|pneumonia
1363833|NCT00513500|rapid diagnostic test
1363834|NCT00513487|Allergic Rhinitis
1363835|NCT00513487|dust mites
1363836|NCT00513487|IgE
1363837|NCT00513487|IL-13
1363838|NCT00513487|nasal
1363839|NCT00513487|inflammation
1363840|NCT00513474|graft versus host disease
1363841|NCT00513474|anaplastic large cell lymphoma
1363842|NCT00513474|angioimmunoblastic T-cell lymphoma
1363843|NCT00513474|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1363844|NCT00513474|nodal marginal zone B-cell lymphoma
1363845|NCT00513474|recurrent adult Burkitt lymphoma
1363846|NCT00513474|recurrent adult diffuse large cell lymphoma
1363847|NCT00513474|recurrent adult diffuse mixed cell lymphoma
1363848|NCT00513474|recurrent adult diffuse small cleaved cell lymphoma
1363849|NCT00513474|recurrent adult Hodgkin lymphoma
1363850|NCT00513474|recurrent adult immunoblastic large cell lymphoma
1363851|NCT00513474|recurrent adult lymphoblastic lymphoma
1363852|NCT00513474|recurrent adult T-cell leukemia/lymphoma
1363853|NCT00513474|recurrent cutaneous T-cell non-Hodgkin lymphoma
1363854|NCT00513474|recurrent grade 1 follicular lymphoma
1363855|NCT00513474|recurrent grade 2 follicular lymphoma
1363856|NCT00513474|recurrent grade 3 follicular lymphoma
1363970|NCT00513162|Brain
1363857|NCT00513474|recurrent mantle cell lymphoma
1363858|NCT00513474|recurrent marginal zone lymphoma
1363859|NCT00513474|recurrent mycosis fungoides/Sezary syndrome
1363860|NCT00513474|recurrent small lymphocytic lymphoma
1363861|NCT00513474|splenic marginal zone lymphoma
1363862|NCT00513474|Waldenström macroglobulinemia
1363863|NCT00513474|recurrent adult acute lymphoblastic leukemia
1363864|NCT00513474|refractory chronic lymphocytic leukemia
1363865|NCT00513474|recurrent adult acute myeloid leukemia
1363866|NCT00513474|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1363867|NCT00513474|adult acute myeloid leukemia with inv(16)(p13;q22)
1363868|NCT00513474|adult acute myeloid leukemia with t(15;17)(q22;q12)
1363869|NCT00513474|adult acute myeloid leukemia with t(16;16)(p13;q22)
1363870|NCT00513474|adult acute myeloid leukemia with t(8;21)(q22;q22)
1363871|NCT00513474|accelerated phase chronic myelogenous leukemia
1363872|NCT00513474|blastic phase chronic myelogenous leukemia
1363873|NCT00513474|chronic phase chronic myelogenous leukemia
1363874|NCT00513474|relapsing chronic myelogenous leukemia
1363875|NCT00513474|previously treated myelodysplastic syndromes
1363876|NCT00513474|primary myelofibrosis
1363877|NCT00513474|atypical chronic myeloid leukemia, BCR-ABL1 negative
1363878|NCT00513474|chronic eosinophilic leukemia
1363879|NCT00513474|chronic myelomonocytic leukemia
1363880|NCT00513474|de novo myelodysplastic syndromes
1363881|NCT00513474|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1363882|NCT00513474|refractory hairy cell leukemia
1363883|NCT00513474|refractory multiple myeloma
1363884|NCT00513474|secondary acute myeloid leukemia
1363885|NCT00513474|secondary myelodysplastic syndromes
1363886|NCT00513448|Chronic Disabling Condition
1363887|NCT00513448|Comparative Evaluation
1363888|NCT00513448|Physical Activity
1363889|NCT00513448|Physical Therapy
1363890|NCT00513448|Rehabilitation
1363891|NCT00513422|Osteoarthritis, knee
1363892|NCT00513422|Glucosamine
1363893|NCT00513422|Chondroitin
1363894|NCT00513422|Disease progression
1363895|NCT00513422|NSAIDs
1363896|NCT00513409|Immunogenicity
1363897|NCT00513409|Pneumococcal disease
1363898|NCT00513409|Safety
1363899|NCT00513409|Booster vaccination
1363900|NCT00513409|Pneumococcal vaccine
1363901|NCT00513396|Randomized control trial
1363902|NCT00513396|multidrug resistant tuberculosis
1363903|NCT00513396|isoniazid
1363904|NCT00513396|standardized regimen
1363905|NCT00513396|adjuvant therapy
1363906|NCT00513383|basaloid squamous cell carcinoma
1363907|NCT00513383|undifferentiated carcinoma
1363908|NCT00513383|adenosquamous cell carcinoma
1363909|NCT00513370|Psoriasis
1363910|NCT00513370|adalimumab
1363911|NCT00513357|Gastrointestinal Cancer
1363912|NCT00513357|Lung Cancer
1363913|NCT00513357|Cachexia
1363914|NCT00513357|Melatonin
1363915|NCT00513357|Placebo
1363916|NCT00513357|Anorexia
1363917|NCT00513357|Weight Loss
1363918|NCT00513344|Endothelial function
1363919|NCT00513344|Arterial stiffness
1363920|NCT00513344|Dark chocolate
1363921|NCT00513344|Milk chocolate
1363922|NCT00513344|Polyphenols
1363923|NCT00513331|Barrett's Esophagus
1363924|NCT00513331|GERD
1363925|NCT00513331|Carcinoma
1363926|NCT00513318|Umbilical cord blood transplantation
1363927|NCT00513318|hematopoietic malignancies
1363928|NCT00513305|acute myeloid leukemia, cytarabine, arsenic trioxide.
1363929|NCT00513279|Safety,
1363930|NCT00513279|tolerability,
1363931|NCT00513279|pharmacokinetics,
1363932|NCT00513279|pharmacodynamics,
1363933|NCT00513279|repeat dose,
1363934|NCT00513279|placebo,
1363935|NCT00513279|GSK618334
1363936|NCT00513266|recurrent rectal cancer
1363937|NCT00513266|stage IV rectal cancer
1363938|NCT00513266|recurrent colon cancer
1363939|NCT00513266|stage IV colon cancer
1363940|NCT00513266|adenocarcinoma of the colon
1363941|NCT00513266|adenocarcinoma of the rectum
1363942|NCT00513266|liver metastases
1363943|NCT00513266|lung metastases
1363944|NCT00513253|lapatinib
1363945|NCT00513253|Healthy Adult Volunteer
1363946|NCT00513240|erythropoetin
1363947|NCT00513240|neuroprotection
1363948|NCT00513240|neonate
1363949|NCT00513240|cardiac
1363950|NCT00513240|magnetic resonance imaging
1363951|NCT00513240|brain magnetic resonance imaging
1363952|NCT00513240|electroencephalogram
1363953|NCT00513214|Diabetes
1363954|NCT00513214|Type 2
1363955|NCT00513214|Mellitus
1363956|NCT00513201|lyspro
1363957|NCT00513201|regular insulin
1363958|NCT00513201|cirrhotic patients
1363959|NCT00513188|angioimmunoblastic T-cell lymphoma
1363960|NCT00513188|anaplastic large cell lymphoma
1363961|NCT00513188|adult nasal type extranodal NK/T-cell lymphoma
1363962|NCT00513188|stage IV mycosis fungoides/Sezary syndrome
1363963|NCT00513188|stage IV cutaneous T-cell non-Hodgkin lymphoma
1363964|NCT00513175|Allogeneic SCT
1363965|NCT00513175|Matched unrelated donors
1363966|NCT00513175|hematologic malignancies
1363967|NCT00513175|renal cell carcinoma
1363968|NCT00513175|aplastic anemia
1363969|NCT00513162|Advanced Cancers
1363971|NCT00513162|CNS
1363972|NCT00513162|Neural
1363973|NCT00513162|Pediatrics
1363974|NCT00513162|Spinal
1363975|NCT00513162|Neuroectodermal Tumor
1363976|NCT00513162|Brain Metastases
1363977|NCT00513162|Valproate
1363978|NCT00513162|Valproic Acid
1363979|NCT00513162|Depakene
1363980|NCT00513162|Etoposide
1363981|NCT00513162|VePesid
1363982|NCT00513149|angioplasty
1363983|NCT00513149|clopidogrel
1363984|NCT00513149|coronary artery disease
1363985|NCT00513149|PFA
1363986|NCT00513136|Fatigue
1363987|NCT00513136|Breast Cancer
1363988|NCT00513136|Behavioral Research
1363989|NCT00513136|Quality of Life
1363990|NCT00513123|Digital Colposcopy for Fluorescence
1363991|NCT00513123|DCF
1363992|NCT00513123|Fluorescence Spectroscopy
1363993|NCT00513123|Digital Colposcopy
1363994|NCT00513123|DC
1363995|NCT00513123|Cervical Intraepithelial Neoplasia
1363996|NCT00513123|Cervical Cancer
1363997|NCT00513123|Cervix
1363998|NCT00513123|Vagina
1363999|NCT00513123|Lesions of the cervix
1364000|NCT00513123|Precancerous lesions
1364001|NCT00513110|Endotoxin
1364002|NCT00513110|Adenosine
1364003|NCT00513110|Caffeine
1364004|NCT00513110|AMPD1 polymorphism
1364005|NCT00513097|Epidemiology
1364006|NCT00513097|Cancer Prevention
1364007|NCT00513097|Smoking Cessation
1364008|NCT00513097|Smoking Prevention
1364009|NCT00513097|Focus Groups
1364010|NCT00513084|Behavioral,
1364011|NCT00513084|Self-Determination Theory,
1364012|NCT00513084|Motivational Interviewing,
1364013|NCT00513084|Exercise, Physical Activity,
1364014|NCT00513084|Motivation,
1364015|NCT00513084|Moderators,
1364016|NCT00513084|Mediators,
1364017|NCT00513084|Predictors,
1364018|NCT00513084|Weight
1364019|NCT00513058|metastatic breast cancer
1364020|NCT00513058|advanced breast cancer
1364021|NCT00513045|Nightmares
1364022|NCT00513045|treatment
1364023|NCT00513045|self-help
1364024|NCT00513032|propofol
1364025|NCT00513032|anaesthesia induction
1364026|NCT00513032|parathyroidectomy
1364027|NCT00513032|methylene blue
1364028|NCT00513032|General anesthesia
1364029|NCT00513019|Neurotic Excoriation
1364030|NCT00513019|Pathologic Skin Picking
1364031|NCT00513019|Psychogenic Excoriation
1364032|NCT00512993|Postoperative treatment with zoledronic acid
1364033|NCT00512993|Preoperative anthracycline/taxane containing chemotherapy
1364034|NCT00512980|intermediate stages
1364035|NCT00512967|oxidative stress
1364036|NCT00512967|antioxidants
1364037|NCT00512967|inflammation
1364038|NCT00512967|quercetin
1364039|NCT00512954|airway inflammation
1364040|NCT00512954|susceptibility to infections
1364041|NCT00512954|inflammatory response in blood and urine
1364042|NCT00512954|infective exacerbations
1364043|NCT00512954|asthma
1364044|NCT00512954|COPD
1364045|NCT00512928|vitamin K2
1364046|NCT00512928|oral anticoagulation
1364047|NCT00512928|interference
1364048|NCT00512928|level of anticoagulation
1364049|NCT00512928|carboxylation level of osteocalcin and matrix-gla protein
1364050|NCT00512915|Farfield Sensing
1364051|NCT00512915|Pacing lead
1364052|NCT00512915|Postventricular atrial blanking
1364053|NCT00512915|Bradycardia
1364054|NCT00512902|active alveolitis in systemic sclerosis
1364055|NCT00512889|CTL
1364056|NCT00512889|MART-1
1364057|NCT00512889|Melan-A
1364058|NCT00512889|artificial APC
1364059|NCT00512889|melanoma
1364060|NCT00512889|metastatic melanoma
1364061|NCT00512889|adoptive immunotherapy
1364062|NCT00512889|adoptive cell transfer
1364063|NCT00512889|immunotherapy
1364064|NCT00512850|Folic acid
1364065|NCT00512850|Adenoma of Large Intestine
1364066|NCT00512837|Telemedicine
1364067|NCT00512837|clinical management
1364068|NCT00512837|empowerment
1364069|NCT00512837|engagement
1364070|NCT00512837|education
1364071|NCT00512824|calcium
1364072|NCT00512824|probiotics
1364073|NCT00512824|diarrhea
1364074|NCT00512824|children
1364075|NCT00512824|Indonesia
1364076|NCT00512824|Healthy children
1364077|NCT00512824|acute diarrhea
1364078|NCT00512811|furosemide
1364079|NCT00512811|inhalation
1364080|NCT00512811|dyspnea
1364081|NCT00512811|spirometry
1364082|NCT00512811|mustard gas
1364083|NCT00512811|bronchiolitis
1364084|NCT00512811|sulfur mustard
1364085|NCT00512798|stage III melanoma
1364086|NCT00512798|stage IV melanoma
1364087|NCT00512798|recurrent melanoma
1364088|NCT00512798|unspecified adult solid tumor, protocol specific
1364089|NCT00512798|recurrent adult brain tumor
1364090|NCT00512798|melanoma (skin)
1364091|NCT00512785|Imidafenacin
1364092|NCT00512785|KRP-197/ONO-8025
1364093|NCT00512785|overactive bladder
1364094|NCT00512785|antimuscarinic
1364095|NCT00512772|Time series
1364096|NCT00512772|Implementation
1364097|NCT00512746|small cell lung cancer
1364098|NCT00512746|non-small cell lung cancer
1364099|NCT00512746|precancerous condition
1364100|NCT00512733|Healthy volunteers
1364101|NCT00512720|PAD
1364102|NCT00512720|Peripheral Artery Disease
1364103|NCT00512720|PVD
1364104|NCT00512720|Peripheral Vascular Disease
1364105|NCT00512720|Leg Blockage
1364106|NCT00512720|Angioplasty
1364107|NCT00512720|Stent
1364108|NCT00512720|Claudication
1364109|NCT00512707|testosterone
1364110|NCT00512707|erectile dysfunction
1364111|NCT00512707|sildenafil
1364112|NCT00512694|Lupus
1364113|NCT00512694|Systemic Lupus Erythematosus
1364114|NCT00512694|Cutaneous Lupus
1364115|NCT00512681|Stomach Neoplasms
1364116|NCT00512681|Secondary
1364117|NCT00512681|Combination chemotherapy
1364118|NCT00512681|S-1
1364119|NCT00512681|irinotecan
1364120|NCT00512681|oxaliplatin
1364121|NCT00512655|Fear of falling
1364122|NCT00512655|Intraindividual variability
1364123|NCT00512655|Cognition
1364124|NCT00512655|Fall prevention
1364125|NCT00512655|Fear
1364126|NCT00512655|Frail elderly
1364127|NCT00512655|Intervention
1364128|NCT00512642|Non-Small Cell Lung Cancer
1364129|NCT00512642|p53
1364130|NCT00512642|Smoking
1364131|NCT00512642|Carcinogenesis
1364132|NCT00512642|Loss of Heterozygosity
1364133|NCT00512629|PN
1364134|NCT00512629|cholestasis
1364135|NCT00512629|gastrointestinal disease in infants
1364136|NCT00512629|short bowel syndrome
1364137|NCT00512616|Ceftriaxone
1364138|NCT00512616|Acute Antidepressant Effects
1364139|NCT00512616|Glutamatergic System
1364140|NCT00512616|Double-Blind
1364141|NCT00512616|Mood Disorders
1364142|NCT00512616|Bipolar Disorder
1364143|NCT00512616|Depression
1364144|NCT00512603|cerebro vascular event
1364145|NCT00512590|fibromyalgia
1364146|NCT00512590|relaxation
1364147|NCT00512590|imagery
1364148|NCT00512590|pain
1364149|NCT00512590|functional status
1364150|NCT00512590|self efficacy
1364151|NCT00512590|minority health
1364152|NCT00512577|sickle cell disease
1364153|NCT00512577|pre-operative transfusion
1364154|NCT00512577|blood transfusion
1364155|NCT00512564|Sickle Cell Anemia
1364156|NCT00512564|Sickle Cell Thalassemia
1364157|NCT00512564|Iron overload
1364158|NCT00512564|Non transferrin binding iron
1364159|NCT00512564|Hepcidin
1364160|NCT00512551|Cervical Cancer
1364161|NCT00512551|DNA Array Analysis
1364162|NCT00512551|Gene Expression
1364163|NCT00512551|DNA
1364164|NCT00512538|Diabetic foot
1364165|NCT00512512|transoral
1364166|NCT00512512|transluminal
1364167|NCT00512512|endoscopic
1364168|NCT00512512|laparoscopic
1364169|NCT00512512|liver
1364170|NCT00512512|biopsy
1364171|NCT00512499|Osteoporosis
1364172|NCT00512499|Fragility fractures
1364173|NCT00512499|Fracture clinics
1364174|NCT00512499|Orthopedic surgeons
1364175|NCT00512473|GH, GH receptor blockade, GH signaling, insulin resistance
1364176|NCT00512460|Neoplastic Meningitis
1364177|NCT00512460|Leptomeningeal Disease
1364178|NCT00512460|Solid Tumor
1364179|NCT00512460|Lymphoma
1364180|NCT00512460|Leukemia
1364181|NCT00512460|Brain Tumor
1364182|NCT00512460|RTA 744
1364183|NCT00512447|Aging
1364184|NCT00512434|tibial
1364185|NCT00512434|shaft
1364186|NCT00512434|fracture
1364187|NCT00512434|open
1364188|NCT00512434|bone-marrow
1364189|NCT00512434|graft
1364190|NCT00512434|injection
1364191|NCT00512434|mesenchymal stem cell
1364192|NCT00512408|To assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly CHF patients
1364193|NCT00512395|laparoscopic colorectal surgery
1364194|NCT00512395|epidural analgesia
1364195|NCT00512395|pain score
1364196|NCT00512395|postoperative ileus
1364197|NCT00512382|GER Gastrointestinal reflux
1364198|NCT00512382|Aspiration
1364199|NCT00512382|ASHTMA
1364200|NCT00512382|COUGH
1364201|NCT00512382|WHEEZE
1364202|NCT00512382|PH-IMPEDANCE
1364203|NCT00512382|WEEM Wheezy Monitor
1364204|NCT00512369|Metabolic pathways
1364205|NCT00512369|Atherosclerosis
1364206|NCT00512369|Monocyte Function
1364207|NCT00512343|Synovial Fluid
1364208|NCT00512343|Arthritis
1364209|NCT00512343|Paired serum/synovial fluid samples
1364210|NCT00512330|childhood
1364211|NCT00512330|tuberculosis
1364212|NCT00512330|diagnostic
1364213|NCT00512330|lipoarabinomannan
1364214|NCT00512330|ELISA
1364215|NCT00512330|Tuberculosis in Childhood
1364216|NCT00512317|partial onset epilepsy
1364217|NCT00512317|adult epilepsy
1364218|NCT00512317|partial seizures
1364219|NCT00512317|anticonvulsant
1364220|NCT00512317|catamenial epilepsy
1364221|NCT00512317|adult partial onset epilepsy
1364222|NCT00512291|Advanced Cancer
1364223|NCT00512291|Hyperactive Delirium
1364224|NCT00512291|Mixed Delirium
1364225|NCT00512291|Olanzapine
1364226|NCT00512278|Hepatitis
1364227|NCT00512278|HCV
1364228|NCT00512278|Hepatitis C
1364229|NCT00512265|n-acetylcysteine
1364230|NCT00512265|esophagectomy
1364231|NCT00512265|inflammatory reaction
1364232|NCT00512265|pulmonary morbidity
1364233|NCT00512252|Plerixafor
1364234|NCT00512252|CXCR4
1364235|NCT00512252|Chemosensitization
1364236|NCT00512239|Early Rheumatoid Arthritis
1364237|NCT00512239|Early inflammatory arthritis
1364238|NCT00512239|Biomarkers
1364239|NCT00512239|Autoantibodies
1364240|NCT00512239|Anti-Sa antibodies
1364241|NCT00512239|Anti-CCP antibodies
1364242|NCT00512226|Sickle Cell Anemia
1364243|NCT00512226|Sickle Cell Thalassemia
1364244|NCT00512226|Iron Overload
1364245|NCT00512226|MRI
1364246|NCT00512213|preoperative Immunonutrition
1364247|NCT00512213|major abdominal surgery
1364248|NCT00512213|complication
1364249|NCT00512174|Portable Ultrasound Scanner
1364250|NCT00512174|Non Invasive Bladder Volume Measurement
1364251|NCT00512174|Radical Cystectomy
1364252|NCT00512174|Bladder Reconstruction
1364253|NCT00512161|Any patient undergoing elective cardiac surgery
1364254|NCT00512122|early parenteral nutrition
1364255|NCT00512122|critical illness
1364256|NCT00512122|respiratory failure
1364257|NCT00512122|kidney failure
1364258|NCT00512122|hepatic failure
1364259|NCT00512122|muscle strength
1364260|NCT00512122|rehabilitation
1364261|NCT00512122|overfeeding
1364262|NCT00512122|Reduced Oral Intake
1364263|NCT00512109|vascular risk
1364264|NCT00512109|perioperative
1364265|NCT00512109|vascular events
1364266|NCT00512109|cohort study
1364267|NCT00512109|surgery
1364268|NCT00512096|Genitourinary
1364269|NCT00512096|Penile Cancer
1364270|NCT00512096|Neoadjuvant Chemotherapy
1364271|NCT00512096|Extirpative Surgery
1364272|NCT00512096|TanyN2-3M0 Squamous Cell Carcinoma of the Penis
1364273|NCT00512096|Cisplatin
1364274|NCT00512096|Platinol-AQ
1364275|NCT00512096|Platinol
1364276|NCT00512096|CDDP
1364277|NCT00512096|Ifosfamide
1364278|NCT00512096|Ifex
1364279|NCT00512096|Paclitaxel
1364280|NCT00512096|Taxol
1364281|NCT00512083|Leukemia, Myeloid + Acute Disease
1364282|NCT00512070|schizophrenia
1364283|NCT00512070|schizoaffective disorder
1364284|NCT00512070|bipolar disorder
1364285|NCT00512070|olanzapine
1364286|NCT00512070|melatonin
1364287|NCT00512070|obesity
1364288|NCT00512070|metabolic syndrome
1364289|NCT00512057|cardiac syndrome X
1364290|NCT00512057|endothelial function
1364291|NCT00512044|anesthesia, Longo, mucosectomy, hemorrhoids
1364292|NCT00512031|atherosclerosis
1364293|NCT00512031|metabolic pathways
1364294|NCT00512031|monocyte adhesion,
1364295|NCT00512018|Electric Stimulation
1364296|NCT00512018|Quadriceps Muscle
1364297|NCT00512018|Muscle Strength
1364298|NCT00512018|Neuromuscular Properties
1364299|NCT00512018|Tension-Length Relationship
1364300|NCT00512018|Healthy young adults
1364301|NCT00512005|Functional Mitral Regurgitation (FMR)
1364302|NCT00512005|Ischemic Mitral Regurgitation
1364303|NCT00512005|Less invasive repair
1364304|NCT00512005|Percutaneous MV repair
1364305|NCT00512005|Mitral Valve Repair
1364306|NCT00512005|Heart Failure
1364307|NCT00512005|Left Ventricular Dysfunction
1364308|NCT00511992|Ovarian Cancer
1364309|NCT00511992|Gynecologic Cancer
1364310|NCT00511992|Ovarian Carcinoma
1364311|NCT00511992|Peritoneal Carcinoma
1364312|NCT00511992|IP chemotherapy
1364313|NCT00511992|Intraperitoneal
1364314|NCT00511992|Avastin
1364315|NCT00511992|Bevacizumab
1364316|NCT00511979|Healthy Patients
1364317|NCT00511966|Gastroesophageal Reflux
1364318|NCT00511966|Rabeprazole
1364319|NCT00511953|Hot flashes
1364320|NCT00511953|Hot flushes
1364321|NCT00511953|Postmenopausal symptoms
1364322|NCT00511927|heart
1364323|NCT00511927|failure
1364324|NCT00511927|growth
1364325|NCT00511927|hormone
1364326|NCT00511927|igf
1364327|NCT00511927|dilative
1364328|NCT00511927|cardiomyopathy
1364329|NCT00511914|Influenza vaccine
1364330|NCT00511901|anemia
1364331|NCT00511901|function
1364332|NCT00511901|rehabilitation
1364333|NCT00511888|chronic heart failure
1364334|NCT00511888|hypertension
1364335|NCT00511888|beta blockers
1364336|NCT00511875|diabetic retinopathy
1364337|NCT00511875|diabetes
1364338|NCT00511875|diabetic eye studies
1364339|NCT00511875|neovascularization
1364340|NCT00511862|TheraSphere
1364341|NCT00511862|radioactive microspheres
1364342|NCT00511862|Yttrium-90
1364343|NCT00511862|Yttrium glass microspheres
1364344|NCT00511836|alcoholism
1364345|NCT00511836|addiction
1364346|NCT00511836|alcohol detoxification
1364347|NCT00511823|drug-drug interaction,
1364348|NCT00511823|rosiglitazone,
1364349|NCT00511823|safety
1364350|NCT00511823|CYP2C8,
1364351|NCT00511823|pharmacokinetics,
1364352|NCT00511823|CYP3A4,
1364353|NCT00511823|granisetron,
1364354|NCT00511823|dolasetron,
1364355|NCT00511823|CYP2D6,
1364356|NCT00511823|casopitant,
1364357|NCT00511810|Sadness
1364358|NCT00511810|Insomnia
1364359|NCT00511810|Loss of appetite
1364360|NCT00511810|Fatigue
1364361|NCT00511810|Trouble thinking
1364362|NCT00511797|Dysmenorrhea
1364363|NCT00511797|Dysmenorrheal score
1364364|NCT00511797|Drospirenone
1364365|NCT00511797|DRSP
1364366|NCT00511797|Ethinylestradiol
1364367|NCT00511784|Contraception
1364368|NCT00511784|Hormonal contraception
1364369|NCT00511784|Oral contraception
1364370|NCT00511784|Ethinyl estradiol, Levonorgestrel, Contraception
1364371|NCT00511784|Transdermal
1364372|NCT00511784|Venous thromboembolism
1364373|NCT00511784|Norelgestromin
1364374|NCT00511771|Tegaserod, treatment IND, irritable bowel syndrome with constipation, IBS-C, chronic idiopathic constipation, CIC, chronic constipation, CC
1364375|NCT00511758|Cervical Dysplasia
1364376|NCT00511758|Digital Imaging
1364377|NCT00511758|Colposcopy
1364378|NCT00511758|Cervix
1364379|NCT00511745|Interactions
1364380|NCT00511745|Adjusted doses
1364381|NCT00511745|Duodenal Ulcer
1364382|NCT00511745|Gastric Ulcer
1364383|NCT00511745|Erosive or ulcerate Gastroesophageal Reflux
1364384|NCT00511745|Rabeprazole
1364385|NCT00511745|Gastroesophageal reflux
1364386|NCT00511693|fragility fracture
1364387|NCT00511693|management of osteoporosis
1364388|NCT00511693|osteoporosis coordinator
1364389|NCT00511693|small volume hospitals
1364390|NCT00511654|NK1 receptor antagonists,
1364391|NCT00511654|depression
1364392|NCT00511641|Ovarian Cancer
1364393|NCT00511641|Cancer Screening
1364394|NCT00511641|Quality of Life
1364395|NCT00511641|Questionnaire
1364396|NCT00511641|Screening
1364397|NCT00511641|Survey
1364398|NCT00511628|Schizophrenia
1364399|NCT00511628|Risperidone
1364400|NCT00511628|Schizoaffective disorder
1364401|NCT00511628|Schizophreniform disorder
1364402|NCT00511628|Weight gain
1364403|NCT00511615|Cervical Intraepithelial Neoplasia
1364404|NCT00511615|Loop Electrosurgical Excision Procedure
1364405|NCT00511615|Cervical Cancer
1364406|NCT00511615|Colposcopy
1364407|NCT00511615|Molecular Imaging
1364408|NCT00511615|LEEP
1364409|NCT00511576|Advanced or Metastatic Breast Cancer
1364410|NCT00511576|Breast Cancer
1364411|NCT00511576|Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
1364412|NCT00511576|Hormone Refractory Prostate Cancer
1364413|NCT00511576|Prostate Cancer
1364414|NCT00511576|Gastric Cancer
1364415|NCT00511576|Advanced Gastric Adenocarcinoma
1364416|NCT00511576|HDAC Inhibitor
1364417|NCT00511576|Taxotere
1364418|NCT00511576|Docetaxel
1364419|NCT00511563|Cortisol,
1364420|NCT00511563|stress,
1364421|NCT00511563|response,
1364422|NCT00511563|Irritable Bowel Syndrome,
1364423|NCT00511563|cytokine.
1364424|NCT00511550|peripheral blood stem cells
1364425|NCT00511550|filgrastim-mobilized
1364426|NCT00511550|allogeneic transplantation
1364427|NCT00511550|Unrelated Donors for allogeneic transplantation
1364428|NCT00511537|AML
1364429|NCT00511537|ALL
1364430|NCT00511537|CML
1364431|NCT00511537|Lymphoma
1364432|NCT00511537|Myelodysplasia
1364433|NCT00511537|Unrelated stem cell transplantation
1364434|NCT00511537|Hematopoietic disorders
1364435|NCT00511524|CB2,
1364436|NCT00511524|PET
1364437|NCT00511524|brain,
1364438|NCT00511524|inflammation,
1364439|NCT00511524|analgesia,
1364440|NCT00511511|hypertension
1364441|NCT00511511|angiogenesis inhibitors
1364442|NCT00511511|tyrosine kinase inhibitor
1364443|NCT00511511|Sunitinib
1364444|NCT00511498|Laparoscopic Radical Prostatectomy
1364445|NCT00511498|Nightly sildenafil
1364446|NCT00511485|Cancer
1364447|NCT00511485|Adenocarcinoma
1364448|NCT00511485|Phase II
1364449|NCT00511485|Lung
1364450|NCT00511485|Non-small cell lung cancer
1364451|NCT00511485|NSCLC
1364452|NCT00511485|EC145
1364453|NCT00511485|EC20
1364454|NCT00511459|Randomized
1364455|NCT00511459|4-Arm
1364456|NCT00511459|Placebo controlled
1364457|NCT00511459|Phase 2 Trial
1364458|NCT00511459|AMG 386
1364459|NCT00511459|Paclitaxel
1364460|NCT00511459|Bevacizumab
1364461|NCT00511459|First-line Therapy
1364462|NCT00511459|Her-2 Negative
1364463|NCT00511459|Metastatic or Locally Recurrent Breast Cancer
1364464|NCT00511446|Stomach neoplasms
1364465|NCT00511446|docetaxel
1364466|NCT00511446|oxaliplatin
1364467|NCT00511446|capecitabine
1364468|NCT00511420|cocoa
1364469|NCT00511420|cardiovascular disease
1364470|NCT00511420|blood pressure
1364471|NCT00511407|Acute renal failure
1364472|NCT00511407|Bioartificial kidney
1364473|NCT00511407|Cell therapy
1364474|NCT00511407|Hemofiltration
1364475|NCT00511407|Septic shock
1364476|NCT00511394|Decompensated Cirrhosis with Ascites
1364477|NCT00511381|Hearing Loss
1364478|NCT00511381|Late-Onset Hearing Loss
1364479|NCT00511381|Deafness
1364480|NCT00511368|HIV
1364481|NCT00511368|treatment experienced
1364482|NCT00511368|AIDS
1364483|NCT00511329|growth hormone
1364484|NCT00511329|short stature
1364485|NCT00511329|growth failure
1364486|NCT00511329|chronic illness
1364487|NCT00511303|Philadelphia chromosome
1364488|NCT00511303|protein-tyrosine kinases
1364489|NCT00511290|Primary disease or condition being studied: Asthma -COPD-Interstitial Lung Diseases-Occupational Lung Diseases
1364490|NCT00511277|quetiapine
1364491|NCT00511277|schizophrenia
1364492|NCT00511277|first-episode psychosis
1364493|NCT00511277|depression
1364494|NCT00511277|psychopathology
1364495|NCT00511264|Laparoscopy
1364496|NCT00511264|Ultrasound
1364497|NCT00511264|Cancer
1364498|NCT00511264|Biopsy
1364499|NCT00511251|IS-SEM
1364500|NCT00511238|Onyx
1364501|NCT00511238|PR171
1364502|NCT00511238|carfilzomib
1364503|NCT00511238|multiple myeloma
1364504|NCT00511238|relapsed
1364505|NCT00511238|refractory
1364506|NCT00511225|dialysis
1364507|NCT00511225|Vitamin D
1364508|NCT00511212|severe peritonitis
1364509|NCT00511212|SSI
1364510|NCT00511212|lower digestive tract surgery
1364511|NCT00511212|Severe peritonitis after lower digestive tract surgery
1364512|NCT00511186|Sepsis
1364513|NCT00511186|Alkaline Phosphatase
1364514|NCT00511186|inflammation
1364515|NCT00511186|infection
1364516|NCT00511186|renal failure
1364517|NCT00511173|mechanical valve
1364518|NCT00511160|myocarditis
1364519|NCT00511160|parvovirus B19 (PVB19)
1364520|NCT00511160|human herpes virus 6 (HHV6)
1364521|NCT00511160|cardiac magnetic resonance tomography (CMR)
1364522|NCT00511147|IVIG
1364523|NCT00511147|ITP
1364524|NCT00511134|insomnia
1364525|NCT00511134|nicotine dependence
1364526|NCT00511134|smoking
1364527|NCT00511134|smoking cessation
1364528|NCT00511134|zyban
1364529|NCT00511121|chronic myeloid leukemia
1364530|NCT00511121|tyrosine kinase
1364531|NCT00511108|Type 2 Diabetes Mellitus (T2DM)
1364532|NCT00511095|Hepatitis B vaccine
1364533|NCT00511095|HBV vaccine
1364534|NCT00511095|Hepatitis B
1364535|NCT00511095|Hepatitis
1364536|NCT00511095|HBV
1364537|NCT00511069|Bortezomib
1364538|NCT00511069|CML033
1364539|NCT00511056|HIV
1364540|NCT00511056|Adherence
1364541|NCT00511056|Compliance
1364542|NCT00511056|Highly Active Antiretroviral Therapy (HAART)
1364543|NCT00511056|ARV
1364544|NCT00511056|ART
1364545|NCT00511056|Sexual Risk Behavior
1364546|NCT00511056|Unsafe
1364547|NCT00511056|Transmission
1364548|NCT00511043|PTK787
1364549|NCT00511043|DLCL
1364550|NCT00511043|Diffuse large cell lymphoma
1364551|NCT00511030|Diabetes
1364552|NCT00511017|Solid Tumors
1364553|NCT00511017|Doxercalciferol
1364554|NCT00511017|Pediatric Cancer
1364555|NCT00511017|Recurrent Pediatric Solid Tumors
1364556|NCT00511017|Calcium
1364557|NCT00511017|Vitamin D
1364558|NCT00511004|Brugia Malayi
1364559|NCT00511004|Lymphatic Filariasis
1364560|NCT00511004|Albendazole
1364561|NCT00511004|Diethylcarbamazine
1364562|NCT00510991|ASTHMA
1364563|NCT00510978|Inflammatory Bowel Disease IBD
1364564|NCT00510978|Ulcerative Colitis
1364565|NCT00510978|Crohn's disease
1364566|NCT00510978|Probiotics
1364567|NCT00510978|Gastrointestinal
1364568|NCT00510965|choroidal neovascularization
1364569|NCT00510965|angioid streaks
1364570|NCT00510965|pseudoxanthoma elasticum
1364571|NCT00510965|Groenblad-Strandberg-Syndrome
1364572|NCT00510965|therapy
1364573|NCT00510965|ranibizumab
1364574|NCT00510965|lucentis
1364575|NCT00510965|Choroidal neovascularization in patients with PXE
1364576|NCT00510952|diabetes
1364577|NCT00510952|type 2
1364578|NCT00510939|Acute myeloid leukemia
1364579|NCT00510939|NFkB activity and leukemia
1364580|NCT00510939|expression of NFkB
1364581|NCT00510913|Treatment efficacy
1364582|NCT00510913|Transplantation rejection
1364583|NCT00510913|Kidney transplantation
1364584|NCT00510913|Cyclosporine
1364585|NCT00510913|tacrolimus
1364586|NCT00510887|follicular lymphoma
1364587|NCT00510887|Velcade
1364588|NCT00510887|VR-FND
1364589|NCT00510874|Influenza
1364590|NCT00510874|GSK 1557484A vaccine
1364591|NCT00510861|male age, assisted reproduction, sperm, pregnancy outcome
1364592|NCT00510835|septic shock
1364593|NCT00510835|resuscitation
1364594|NCT00510835|sepsis
1364595|NCT00510835|cost-effectiveness
1364596|NCT00510835|sepsis-induced organ dysfunction
1364597|NCT00510835|early goal directed therapy
1364598|NCT00510835|emergency medicine
1364599|NCT00510835|critical care medicine
1364600|NCT00510822|Cimicoxib
1364601|NCT00510822|Cox-2 inhibitor
1364602|NCT00510822|Sertraline
1364603|NCT00510796|Hereditary Non-Polyposis Colon Cancer
1364604|NCT00510796|Colon Cancer
1364605|NCT00510796|Endometrial Cancer
1364606|NCT00510796|Cancer Screening
1364607|NCT00510796|Interview
1364608|NCT00510796|HNPCC
1364609|NCT00510783|tonic-clonic seizure
1364610|NCT00510783|emergency department
1364611|NCT00510783|IV levetiracetam
1364612|NCT00510783|Keppra
1364613|NCT00510783|seizures
1364614|NCT00510783|phenytoin
1364615|NCT00510783|Dilantin
1364616|NCT00510783|Grand Mal seizure
1364617|NCT00510770|CPAP
1364618|NCT00510770|Post-opreative
1364619|NCT00510770|ARF
1364620|NCT00510770|liver transplant
1364621|NCT00510770|Post-operative hypoxemia in liver transplant
1364622|NCT00510744|obesity, bariatric surgery, pancreatic secretion
1364623|NCT00510731|Ventricular Tachycardia
1364624|NCT00510731|Cardiac Sudden Death
1364625|NCT00510731|Ventricular Fibrillation
1364626|NCT00510731|Heart Rate Variability
1364627|NCT00510718|Prostate
1364628|NCT00510718|Cancer
1364629|NCT00510718|Hormone
1364630|NCT00510718|Refractory
1364631|NCT00510718|Castration
1364632|NCT00510705|adiposity
1364633|NCT00510692|Eicosapentaenoic Acid
1364634|NCT00510692|EPA
1364635|NCT00510692|EPA 99%
1364636|NCT00510692|Fatty acid
1364637|NCT00510692|omega-3
1364638|NCT00510692|apoptosis
1364639|NCT00510692|cell proliferation
1364640|NCT00510692|colonic mucosa
1364641|NCT00510692|polyp
1364642|NCT00510692|Familial Adenomatous Polyposis Coli
1364643|NCT00510692|FAP
1364644|NCT00510692|resolvin
1364645|NCT00510692|Ileo-rectal anastomosis
1364646|NCT00510692|IRA
1364647|NCT00510692|PUFA
1364648|NCT00510692|Endoscopy
1364649|NCT00510679|Benin
1364650|NCT00510679|child health
1364651|NCT00510679|developing country
1364652|NCT00510679|health services research
1364653|NCT00510679|health worker performance
1364654|NCT00510679|Integrated Management of Childhood Illness
1364655|NCT00510666|Pain, Postoperative
1364656|NCT00510666|Analgesics, Opioid
1364657|NCT00510666|Analgesia, Patient-Controlled
1364658|NCT00510666|Pain Measurement
1364659|NCT00510653|Ovarian Cancer
1364660|NCT00510653|Primary Peritoneal Cancer
1364661|NCT00510653|Fallopian Tube Cancer
1364662|NCT00510653|Recurrent Platinum-Resistant
1364663|NCT00510653|Taxane-Resistant
1364664|NCT00510653|Epithelial Ovarian Cancer
1364665|NCT00510653|Imatinib Mesylate
1364666|NCT00510653|Gleevec
1364667|NCT00510653|STI571
1364668|NCT00510653|Protein tyrosine kinase inhibitor
1364669|NCT00510640|thyroid carcinoma
1364670|NCT00510640|Sunitinib
1364671|NCT00510640|RECIST guidelines
1364672|NCT00510627|Metastatic Liver Cancer
1364673|NCT00510627|Colorectal Cancer
1364674|NCT00510627|Radiofrequency Ablation
1364675|NCT00510627|Chemotherapy
1364676|NCT00510614|Bacterial Vaginosis
1364677|NCT00510614|Recurrent Bacterial Vaginosis
1364678|NCT00510588|adiposity
1364679|NCT00510575|Juvenile Scoliosis
1364680|NCT00510575|Adolescent Scoliosis
1364681|NCT00510575|Scoliosis Management
1364682|NCT00510575|Spinal Fusion
1364683|NCT00510575|Scoliosis instrumentation
1364684|NCT00510575|Juvenile or Adolescent Idiopathic Scoliosis
1364685|NCT00510562|Cranial manipulation
1364686|NCT00510562|Visual function
1364687|NCT00510536|Psoriasis, arthritis, arthralgia
1364688|NCT00510523|MS
1364689|NCT00510523|Balance
1364690|NCT00510523|Multiple Sclerosis
1364691|NCT00510510|COPD
1364692|NCT00510510|glycopyrronium bromide
1364693|NCT00510510|antimuscarinic
1364694|NCT00510497|dendritic cell
1364695|NCT00510497|therapeutic vaccine
1364696|NCT00510497|HIV-1
1364697|NCT00510497|apoptotic cells
1364698|NCT00510497|Phase I/II
1364699|NCT00510484|Pancreatic exocrine insufficiency
1364700|NCT00510484|Cystic Fibrosis
1364701|NCT00510445|Non Small Cell Lung Cancer
1364702|NCT00510445|Advanced Non Small Cell Lung Cancer
1364703|NCT00510445|Metastatic Non Small Cell Lung Cancer
1364704|NCT00510432|heparin
1364705|NCT00510432|heparin-induced thrombocytopenia
1364706|NCT00510432|HIT
1364707|NCT00510432|allergy
1364708|NCT00510432|skin
1364709|NCT00510432|dermatology
1364710|NCT00510432|DTH
1364711|NCT00510432|delayed-type hypersensitivity
1364712|NCT00510432|histology
1364713|NCT00510432|Patients receiving sc heparin therapy
1364714|NCT00510432|Age over 18 years
1364715|NCT00510432|Recruitment will stop when 20 patients with skin lesions are included
1364716|NCT00510419|Migraine
1364717|NCT00510406|Lower Urinary Tract Symptoms
1364718|NCT00510406|Treatment
1364719|NCT00510406|Solifenacin succinate
1364720|NCT00510406|Tamsulosin hydrochloride
1364721|NCT00510406|Prostatic Hyperplasia
1364722|NCT00510393|Critical Limb Ischemia
1364723|NCT00510393|CLI
1364724|NCT00510393|Drug Eluting Stent
1364725|NCT00510393|DES
1364726|NCT00510393|Bare Metal Stent
1364727|NCT00510393|BMS
1364728|NCT00510367|Breast Cancer
1364729|NCT00510367|FAC
1364730|NCT00510367|Doxorubicin
1364731|NCT00510367|Adriamycin
1364732|NCT00510367|Rubex
1364733|NCT00510367|5-Fluorouracil
1364734|NCT00510367|5-FU
1364735|NCT00510367|Adrucil
1364736|NCT00510367|Efudex
1364737|NCT00510367|Cyclophosphamide
1364738|NCT00510367|Cytoxan
1364739|NCT00510367|Neosar
1364740|NCT00510367|Pregnancy
1364741|NCT00510354|Progressive GIST
1364742|NCT00510354|Resistance to Imatinib mesylate
1364743|NCT00510341|Behavior Change Counseling
1364744|NCT00510341|Motivational Interviewing
1364745|NCT00510341|Chronic Care Model
1364746|NCT00510341|Communication
1364747|NCT00510341|Residency Training
1364748|NCT00510341|Skill Assessment
1364749|NCT00510328|whole body vibration
1364750|NCT00510328|muscle physiology
1364751|NCT00510315|leukemia
1364752|NCT00510315|survivors
1364753|NCT00510315|women
1364754|NCT00510315|leukemia survivors
1364755|NCT00510315|cancer or a related illness
1364756|NCT00510315|Hodgkin's Lymphoma
1364757|NCT00510315|Non-Hodgkin's Lymphoma
1364758|NCT00510315|myelodysplastic syndrome
1364759|NCT00510315|aplastic anemia
1364760|NCT00510315|treated with total body irradiation
1364761|NCT00510315|followed by an allogeneic or autologous stem cell transplant
1364762|NCT00510302|Ultraviolet Radiation
1364763|NCT00510302|Melanoma
1364764|NCT00510302|Questionnaire
1364765|NCT00510302|Survey
1364766|NCT00510302|First Degree Relative
1364767|NCT00510302|Interview
1364768|NCT00510289|Sorafenib
1364769|NCT00510289|Myelodysplastic Syndromes
1364770|NCT00510289|MDS
1364771|NCT00510263|Prednisolone
1364772|NCT00510263|Valacyclovir
1364773|NCT00510250|Cervix Cancer
1364774|NCT00510250|Cervical Cancer
1364775|NCT00510250|Sorafenib
1364776|NCT00510250|Cisplatin
1364777|NCT00510250|Radiation
1364778|NCT00510250|Radiotherapy
1364779|NCT00510250|Phase I
1364780|NCT00510250|Phase II
1364781|NCT00510250|Carcinoma
1364782|NCT00510250|Cancer
1364783|NCT00510250|Cervix
1364784|NCT00510237|HIV
1364785|NCT00510237|Adolescents newly diagnosed with HIV
1364786|NCT00510198|Heart Disease
1364787|NCT00510198|Congestive Heart Failure
1364788|NCT00510198|Thoracic Fluid Monitoring
1364789|NCT00510185|coronary artery disease
1364790|NCT00510185|coronary angioplasty
1364791|NCT00510185|coronary artery bypass surgery
1364792|NCT00510185|elderly
1364793|NCT00510172|Headache
1364794|NCT00510172|Migraine
1364795|NCT00510172|Vasodilatation
1364796|NCT00510159|Schistosoma haematobium
1364797|NCT00510159|Praziquantel
1364798|NCT00510159|Artesunate + Sulfamethoxypyrazine/pyrimethamine
1364799|NCT00510159|Randomized double blind placebo controlled clinical trial
1364800|NCT00510120|Attention Deficit and Disruptive Behavior Disorders
1364801|NCT00510120|Conduct Disorder
1364802|NCT00510120|Behavior Problems in Youth
1364803|NCT00510120|Argumentativeness
1364804|NCT00510120|Children
1364805|NCT00510120|Therapy
1364806|NCT00510120|Attention Deficit Disorder
1364807|NCT00510094|Social Skills
1364808|NCT00510094|Anger Management
1364809|NCT00510094|Relational Aggression
1364810|NCT00510068|Phase III
1364811|NCT00510068|Advanced Neuroendocrine Tumor in adults
1364812|NCT00510068|RAD001
1364813|NCT00510068|NET
1364814|NCT00510068|everolimus
1364815|NCT00510068|mTOr
1364816|NCT00510068|islet cell
1364817|NCT00510068|neuroendocrine
1364818|NCT00510042|von Willebrand disease
1364819|NCT00510042|von Willebrand factor
1364820|NCT00510042|national study
1364821|NCT00510042|bleeding disorder
1364822|NCT00510042|quality of life
1364823|NCT00510016|infants
1364824|NCT00510016|opioid withdrawal
1364825|NCT00510016|abstinence syndrome
1364826|NCT00510016|methadone
1364827|NCT00510016|heroin
1364828|NCT00510003|Atopic dermatitis, children, pimecrolimus, eczema
1364829|NCT00509990|Atopic dermatitis, pimecrolimus, children
1364830|NCT00509951|Neuroses
1364831|NCT00509951|Evidence-Based Treatment
1364832|NCT00509951|Clinical Investigation
1364833|NCT00509951|Young Patients
1364834|NCT00509951|Phobic Disorders
1364835|NCT00509951|Fear
1364836|NCT00509951|Phobias
1364837|NCT00509938|immunocompromized
1364838|NCT00509938|hLF1-11
1364839|NCT00509938|antimicrobial
1364840|NCT00509938|peptide
1364841|NCT00509938|lactoferrin
1364842|NCT00509860|Advanced Sarcomas
1364843|NCT00509860|Irinotecan
1364844|NCT00509860|Camptosar
1364845|NCT00509860|CPT-11
1364846|NCT00509847|S. epidermidis
1364847|NCT00509847|Staphylococcus
1364848|NCT00509847|Lactoferrin
1364849|NCT00509847|hLF1-11
1364850|NCT00509847|Bacteraemia
1364851|NCT00509834|hLF1-11
1364852|NCT00509834|Candida
1364853|NCT00509834|candidaemia
1364854|NCT00509834|lactoferrin
1364855|NCT00509782|Solid Tumors
1364856|NCT00509782|Anti-Tumor Effects
1364857|NCT00509782|ZIO-101
1364858|NCT00509769|Trastuzumab emtansine
1364859|NCT00509769|MBC
1364860|NCT00509769|Breast cancer
1364861|NCT00509769|HER2-positive breast cancer
1364862|NCT00509769|HER2
1364863|NCT00509756|healthy subjects
1364864|NCT00509743|Adult volunteers
1364865|NCT00509730|stress urinary incontinence
1364866|NCT00509730|urodynamics
1364867|NCT00509730|randomized clinical trial
1364868|NCT00509730|surgery
1364869|NCT00509717|quality of health care
1364870|NCT00509717|prescriptions, drug
1364871|NCT00509717|anticholesteremic agents
1364872|NCT00509717|community pharmacy services
1364873|NCT00509704|Sutent
1364874|NCT00509704|tumor necrosis
1364875|NCT00509704|DCE-MRI (Dynamic enhanced magnetic resonance imaging)
1364876|NCT00509691|infection
1364877|NCT00509691|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1365187|NCT00509080|valvular heart disease
1364878|NCT00509691|adult acute myeloid leukemia with inv(16)(p13;q22)
1364879|NCT00509691|adult acute myeloid leukemia with t(15;17)(q22;q12)
1364880|NCT00509691|adult acute myeloid leukemia with t(16;16)(p13;q22)
1364881|NCT00509691|adult acute myeloid leukemia with t(8;21)(q22;q22)
1364882|NCT00509691|accelerated phase chronic myelogenous leukemia
1364883|NCT00509691|adult acute lymphoblastic leukemia in remission
1364884|NCT00509691|adult acute myeloid leukemia in remission
1364885|NCT00509691|atypical chronic myeloid leukemia, BCR-ABL1 negative
1364886|NCT00509691|blastic phase chronic myelogenous leukemia
1364887|NCT00509691|childhood acute lymphoblastic leukemia in remission
1364888|NCT00509691|childhood acute myeloid leukemia in remission
1364889|NCT00509691|childhood chronic myelogenous leukemia
1364890|NCT00509691|chronic eosinophilic leukemia
1364891|NCT00509691|primary myelofibrosis
1364892|NCT00509691|chronic myelomonocytic leukemia
1364893|NCT00509691|chronic neutrophilic leukemia
1364894|NCT00509691|chronic phase chronic myelogenous leukemia
1364895|NCT00509691|de novo myelodysplastic syndromes
1364896|NCT00509691|disseminated neuroblastoma
1364897|NCT00509691|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1364898|NCT00509691|juvenile myelomonocytic leukemia
1364899|NCT00509691|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1364900|NCT00509691|nodal marginal zone B-cell lymphoma
1364901|NCT00509691|noncontiguous stage II adult Burkitt lymphoma
1364902|NCT00509691|noncontiguous stage II adult diffuse large cell lymphoma
1364903|NCT00509691|noncontiguous stage II adult diffuse mixed cell lymphoma
1364904|NCT00509691|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1364905|NCT00509691|noncontiguous stage II adult immunoblastic large cell lymphoma
1364906|NCT00509691|noncontiguous stage II adult lymphoblastic lymphoma
1364907|NCT00509691|noncontiguous stage II grade 1 follicular lymphoma
1364908|NCT00509691|noncontiguous stage II grade 2 follicular lymphoma
1364909|NCT00509691|noncontiguous stage II grade 3 follicular lymphoma
1364910|NCT00509691|noncontiguous stage II mantle cell lymphoma
1364911|NCT00509691|noncontiguous stage II marginal zone lymphoma
1364912|NCT00509691|noncontiguous stage II small lymphocytic lymphoma
1364913|NCT00509691|high risk metastatic gestational trophoblastic tumor
1364914|NCT00509691|previously treated childhood rhabdomyosarcoma
1364915|NCT00509691|previously treated myelodysplastic syndromes
1364916|NCT00509691|recurrent adult acute lymphoblastic leukemia
1364917|NCT00509691|recurrent adult acute myeloid leukemia
1364918|NCT00509691|recurrent adult Burkitt lymphoma
1364919|NCT00509691|recurrent adult Hodgkin lymphoma
1364920|NCT00509691|recurrent adult diffuse large cell lymphoma
1364921|NCT00509691|recurrent adult diffuse mixed cell lymphoma
1364922|NCT00509691|recurrent adult diffuse small cleaved cell lymphoma
1364923|NCT00509691|recurrent adult immunoblastic large cell lymphoma
1364924|NCT00509691|recurrent adult lymphoblastic lymphoma
1364925|NCT00509691|recurrent breast cancer
1364926|NCT00509691|recurrent/refractory childhood Hodgkin lymphoma
1364927|NCT00509691|recurrent childhood acute lymphoblastic leukemia
1364928|NCT00509691|recurrent childhood acute myeloid leukemia
1364929|NCT00509691|recurrent childhood large cell lymphoma
1364930|NCT00509691|recurrent childhood lymphoblastic lymphoma
1364931|NCT00509691|recurrent childhood rhabdomyosarcoma
1364932|NCT00509691|recurrent childhood small noncleaved cell lymphoma
1364933|NCT00509691|recurrent cutaneous T-cell non-Hodgkin lymphoma
1364934|NCT00509691|recurrent grade 1 follicular lymphoma
1364935|NCT00509691|recurrent grade 2 follicular lymphoma
1364936|NCT00509691|recurrent grade 3 follicular lymphoma
1364937|NCT00509691|recurrent mantle cell lymphoma
1364938|NCT00509691|recurrent marginal zone lymphoma
1364939|NCT00509691|recurrent mycosis fungoides/Sezary syndrome
1364940|NCT00509691|recurrent neuroblastoma
1364941|NCT00509691|recurrent ovarian epithelial cancer
1364942|NCT00509691|recurrent ovarian germ cell tumor
1364943|NCT00509691|recurrent small lymphocytic lymphoma
1364944|NCT00509691|recurrent malignant testicular germ cell tumor
1364945|NCT00509691|recurrent Wilms tumor and other childhood kidney tumors
1364946|NCT00509691|refractory chronic lymphocytic leukemia
1364947|NCT00509691|refractory hairy cell leukemia
1364948|NCT00509691|refractory multiple myeloma
1364949|NCT00509691|relapsing chronic myelogenous leukemia
1364950|NCT00509691|secondary acute myeloid leukemia
1364951|NCT00509691|secondary myelodysplastic syndromes
1364952|NCT00509691|splenic marginal zone lymphoma
1364953|NCT00509691|stage I multiple myeloma
1364954|NCT00509691|stage II multiple myeloma
1364955|NCT00509691|stage III adult Burkitt lymphoma
1364956|NCT00509691|stage III adult Hodgkin lymphoma
1364957|NCT00509691|stage III adult diffuse large cell lymphoma
1364958|NCT00509691|stage III adult diffuse mixed cell lymphoma
1364959|NCT00509691|stage III adult diffuse small cleaved cell lymphoma
1364960|NCT00509691|stage III adult immunoblastic large cell lymphoma
1364961|NCT00509691|stage III adult lymphoblastic lymphoma
1364962|NCT00509691|stage III chronic lymphocytic leukemia
1364963|NCT00509691|stage III grade 1 follicular lymphoma
1364964|NCT00509691|stage III grade 2 follicular lymphoma
1364965|NCT00509691|stage III grade 3 follicular lymphoma
1364966|NCT00509691|stage III mantle cell lymphoma
1364967|NCT00509691|stage III marginal zone lymphoma
1364968|NCT00509691|stage III multiple myeloma
1364969|NCT00509691|stage III small lymphocytic lymphoma
1364970|NCT00509691|stage III malignant testicular germ cell tumor
1364971|NCT00509691|stage IIIA breast cancer
1364972|NCT00509691|stage IIIB breast cancer
1364973|NCT00509691|stage IIIC breast cancer
1364974|NCT00509691|stage IV adult Burkitt lymphoma
1364975|NCT00509691|stage IV adult Hodgkin lymphoma
1364976|NCT00509691|stage IV adult diffuse large cell lymphoma
1364977|NCT00509691|stage IV adult diffuse mixed cell lymphoma
1364978|NCT00509691|stage IV adult diffuse small cleaved cell lymphoma
1364979|NCT00509691|stage IV adult immunoblastic large cell lymphoma
1364980|NCT00509691|stage IV adult lymphoblastic lymphoma
1364981|NCT00509691|stage IV breast cancer
1364982|NCT00509691|stage IV chronic lymphocytic leukemia
1364983|NCT00509691|stage IV grade 1 follicular lymphoma
1364984|NCT00509691|stage IV grade 2 follicular lymphoma
1364985|NCT00509691|stage IV grade 3 follicular lymphoma
1364986|NCT00509691|stage IV mantle cell lymphoma
1364987|NCT00509691|stage IV marginal zone lymphoma
1364988|NCT00509691|stage IV ovarian epithelial cancer
1364989|NCT00509691|stage IV small lymphocytic lymphoma
1364990|NCT00509691|stage IIA ovarian epithelial cancer
1364991|NCT00509691|stage IIA ovarian germ cell tumor
1364992|NCT00509691|stage IIB ovarian epithelial cancer
1364993|NCT00509691|stage IIB ovarian germ cell tumor
1364994|NCT00509691|stage IIC ovarian epithelial cancer
1364995|NCT00509691|stage IIC ovarian germ cell tumor
1364996|NCT00509691|stage IIIA ovarian epithelial cancer
1364997|NCT00509691|stage IIIA ovarian germ cell tumor
1364998|NCT00509691|stage IIIB ovarian epithelial cancer
1364999|NCT00509691|stage IIIB ovarian germ cell tumor
1365000|NCT00509691|stage IIIC ovarian epithelial cancer
1365001|NCT00509691|stage IIIC ovarian germ cell tumor
1365002|NCT00509691|stage IV ovarian germ cell tumor
1365003|NCT00509678|Rituximab
1365004|NCT00509678|Rituxan
1365005|NCT00509678|Psoriatic Arthritis
1365006|NCT00509678|Arthritis
1365007|NCT00509665|recurrent squamous cell carcinoma of the hypopharynx
1365008|NCT00509665|recurrent squamous cell carcinoma of the larynx
1365009|NCT00509665|recurrent verrucous carcinoma of the larynx
1365010|NCT00509665|recurrent adenoid cystic carcinoma of the oral cavity
1365011|NCT00509665|recurrent basal cell carcinoma of the lip
1365012|NCT00509665|recurrent mucoepidermoid carcinoma of the oral cavity
1365013|NCT00509665|recurrent squamous cell carcinoma of the lip and oral cavity
1365014|NCT00509665|recurrent verrucous carcinoma of the oral cavity
1365015|NCT00509665|recurrent metastatic squamous neck cancer with occult primary
1365016|NCT00509665|recurrent lymphoepithelioma of the nasopharynx
1365017|NCT00509665|recurrent squamous cell carcinoma of the nasopharynx
1365018|NCT00509665|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1365019|NCT00509665|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1365020|NCT00509665|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1365021|NCT00509665|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1365022|NCT00509665|recurrent salivary gland cancer
1365023|NCT00509665|recurrent lymphoepithelioma of the oropharynx
1365024|NCT00509665|recurrent squamous cell carcinoma of the oropharynx
1365025|NCT00509652|Hemochromatosis
1365026|NCT00509652|Primary hemochromatosis
1365027|NCT00509652|Hereditary hemochromatosis
1365028|NCT00509652|Therapy
1365029|NCT00509652|Erythrocyte apheresis
1365030|NCT00509652|Phlebotomy
1365031|NCT00509652|Apheresis
1365032|NCT00509652|Efficacy
1365033|NCT00509626|fatigue
1365034|NCT00509626|psychosocial effects of cancer and its treatment
1365035|NCT00509626|weight changes
1365036|NCT00509626|depression
1365037|NCT00509626|stage I breast cancer
1365038|NCT00509626|stage II breast cancer
1365039|NCT00509600|Juvenile Myelomonocytic Leukemia
1365040|NCT00509600|JMML
1365041|NCT00509600|Leukemia
1365042|NCT00509600|Etanercept
1365043|NCT00509600|Enbrel
1365044|NCT00509574|Single Nucleotide Polymorphism
1365045|NCT00509574|statins
1365046|NCT00509574|hyperlipidemia
1365047|NCT00509561|adenocarcinoma of the esophagus
1365288|NCT00508820|blood disorder
1365048|NCT00509561|squamous cell carcinoma of the esophagus
1365049|NCT00509561|stage IA esophageal cancer
1365050|NCT00509561|stage IB esophageal cancer
1365051|NCT00509561|stage IIA esophageal cancer
1365052|NCT00509561|stage IIB esophageal cancer
1365053|NCT00509561|stage IIIA esophageal cancer
1365054|NCT00509561|stage IIIB esophageal cancer
1365055|NCT00509561|stage IIIC esophageal cancer
1365056|NCT00509535|Vitreoscilla filiformis extract
1365057|NCT00509535|SCORAD
1365058|NCT00509535|pruritus
1365059|NCT00509535|microflora
1365060|NCT00509535|TEWL
1365061|NCT00509509|Hereditary Breast Cancer (BRCA1, BRCA2)
1365062|NCT00509496|Refractory
1365063|NCT00509496|Gene Therapy
1365064|NCT00509496|HLA-A2 Positive
1365065|NCT00509496|Stage IV Melanoma
1365066|NCT00509496|Melanoma
1365067|NCT00509496|Skin Cancer
1365068|NCT00509496|Malignant Melanoma
1365069|NCT00509483|multinodular
1365070|NCT00509483|goitre
1365071|NCT00509483|recombinant human TSH
1365072|NCT00509457|NSCLC, vaccination
1365073|NCT00509457|Inoperable NSCLC stage IIIA/B in good performance status
1365074|NCT00509431|adult giant cell glioblastoma
1365075|NCT00509431|adult gliosarcoma
1365076|NCT00509431|adult anaplastic astrocytoma
1365077|NCT00509431|adult anaplastic oligodendroglioma
1365078|NCT00509431|adult mixed glioma
1365079|NCT00509431|recurrent adult brain tumor
1365080|NCT00509431|adult glioblastoma
1365081|NCT00509431|adult pilocytic astrocytoma
1365082|NCT00509431|adult diffuse astrocytoma
1365083|NCT00509431|adult subependymal giant cell astrocytoma
1365084|NCT00509431|adult oligodendroglioma
1365085|NCT00509418|Nonalcoholic steatohepatitis
1365086|NCT00509418|Nonalcoholic Fatty Liver
1365087|NCT00509418|Nutritional supplement
1365088|NCT00509418|Diet
1365089|NCT00509418|Exercise
1365090|NCT00509405|Endogenous acid production
1365091|NCT00509405|metabolic acidosis
1365092|NCT00509405|potassium citrate
1365093|NCT00509405|osteoporosis
1365094|NCT00509405|sarcopenia
1365095|NCT00509405|hypertension
1365096|NCT00509405|Effect of potassium citrate on bone mineral density and bone mass
1365097|NCT00509392|Varicose veins, venous reflux, GSV disease
1365098|NCT00509379|Relapsed/refractory indolent lymphoma
1365099|NCT00509379|Non-follicular Lymphoma
1365100|NCT00509379|Mantle cell non-Hodgkin Lymphoma
1365101|NCT00509379|Patients naïve or sensitive to rituximab
1365102|NCT00509379|Patients not eligible for high dose chemotherapy with ASCT
1365103|NCT00509366|genomics
1365104|NCT00509366|genomics predictor
1365105|NCT00509366|genomics analysis
1365106|NCT00509366|squamous
1365107|NCT00509366|non-squamous
1365108|NCT00509353|recurrent neuroblastoma
1365109|NCT00509340|antiretroviral
1365110|NCT00509340|adherence
1365111|NCT00509340|poor antiretroviral adherence
1365112|NCT00509327|postoperative ileus
1365113|NCT00509327|colorectal surgery
1365114|NCT00509327|bisacodyl
1365115|NCT00509327|laxatives
1365116|NCT00509301|brain cancer
1365117|NCT00509301|Cotara
1365118|NCT00509301|radioactive isotope
1365119|NCT00509301|monoclonal antibody
1365120|NCT00509301|radiation distribution
1365121|NCT00509288|Refractory
1365122|NCT00509288|Gene Therapy
1365123|NCT00509288|HLA-A2 Positive
1365124|NCT00509288|Stage IV Melanoma
1365125|NCT00509288|Melanoma
1365126|NCT00509288|Skin Cancer
1365127|NCT00509288|Malignant Melanoma
1365128|NCT00509223|Type 2 diabetes
1365129|NCT00509223|Obstructive sleep apnea
1365130|NCT00509223|Glycemic control
1365131|NCT00509223|Insulin resistance
1365132|NCT00509223|Sleep disordered breathing
1365133|NCT00509210|Liver Disease
1365134|NCT00509197|Asthma
1365135|NCT00509197|Non-eosinophilic Asthma
1365136|NCT00509197|sputum eosinophils
1365137|NCT00509197|Inhaled Corticosteroids
1365138|NCT00509184|untreated
1365139|NCT00509171|embolism
1365140|NCT00509171|femur fracture
1365141|NCT00509171|lavage
1365142|NCT00509171|TEE
1365143|NCT00509171|reamer
1365144|NCT00509171|IM nail
1365145|NCT00509158|safety
1365146|NCT00509158|immunogenicity
1365147|NCT00509158|efficacy
1365148|NCT00509145|Relapsing
1365149|NCT00509145|Remitting
1365150|NCT00509119|apoplexia
1365151|NCT00509119|Intracranial and intraarterial pressure curves in acute apoplectic patients
1365152|NCT00509106|ceftaroline
1365153|NCT00509106|Community-acquired pneumonia
1365154|NCT00509106|CAP
1365155|NCT00509106|Streptococcus pneumoniae
1365156|NCT00509106|Haemophilus influenzae
1365157|NCT00509106|Mycoplasma pneumoniae
1365158|NCT00509106|Chlamydophila spp
1365159|NCT00509106|Legionella ssp
1365160|NCT00509106|multi-drug resistant Streptococcus pneumoniae (MDRSP)
1365161|NCT00509106|antimicrobial resistance
1365162|NCT00509106|pneumococci
1365163|NCT00509106|beta-lactam
1365164|NCT00509106|ceftaroline fosamil
1365165|NCT00509106|ceftriaxone
1365166|NCT00509106|antibiotic
1365167|NCT00509093|adult acute minimally differentiated myeloid leukemia (M0)
1365168|NCT00509093|adult acute myeloblastic leukemia with maturation (M2)
1365169|NCT00509093|adult acute myeloblastic leukemia without maturation (M1)
1365170|NCT00509093|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1365171|NCT00509093|adult acute myeloid leukemia with inv(16)(p13;q22)
1365172|NCT00509093|adult acute myeloid leukemia with t(16;16)(p13;q22)
1365173|NCT00509093|adult acute myeloid leukemia with t(8;21)(q22;q22)
1365174|NCT00509093|adult acute myelomonocytic leukemia (M4)
1365175|NCT00509093|adult acute megakaryoblastic leukemia (M7)
1365176|NCT00509093|adult acute monoblastic leukemia (M5a)
1365177|NCT00509093|adult acute monocytic leukemia (M5b)
1365178|NCT00509093|adult erythroleukemia (M6a)
1365179|NCT00509093|adult pure erythroid leukemia (M6b)
1365180|NCT00509093|adult acute basophilic leukemia
1365181|NCT00509093|adult acute eosinophilic leukemia
1365182|NCT00509093|adult acute myeloid leukemia in remission
1365183|NCT00509080|mitral regurgitation
1365184|NCT00509080|BNP
1365185|NCT00509080|NT-proBNP
1365186|NCT00509080|natriuretic peptides
1365188|NCT00509067|Schizoaffective Disorder
1365189|NCT00509067|Acetylcholine
1365190|NCT00509067|Nicotinic Receptors
1365191|NCT00509067|Nicotine
1365192|NCT00509067|Galantamine
1365193|NCT00509067|negative symptoms
1365194|NCT00509054|Parastomal hernia, wound infection, stoma care.
1365195|NCT00509041|advanced malignant mesothelioma
1365196|NCT00509041|epithelial mesothelioma
1365197|NCT00509041|recurrent malignant mesothelioma
1365198|NCT00509041|sarcomatous mesothelioma
1365199|NCT00509028|Asthma
1365200|NCT00509028|Bronchial
1365201|NCT00509015|antimalarials
1365202|NCT00509015|malaria transmission
1365203|NCT00509015|mass drug administration
1365204|NCT00509015|artemisinin-based combination therapy
1365205|NCT00509015|primaquine
1365206|NCT00509015|gametocytes
1365207|NCT00509015|QT-NASBA
1365208|NCT00509002|Salivary Gland Cancer
1365209|NCT00509002|Iressa
1365210|NCT00509002|ZD1839
1365211|NCT00508989|Acetylcholine
1365212|NCT00508989|Forearm Blood Flow
1365213|NCT00508989|HDL
1365214|NCT00508989|L-NMMA
1365215|NCT00508989|Sickle Cell Anemia
1365216|NCT00508989|Sickle Cell Disease
1365217|NCT00508976|bupivacaine
1365218|NCT00508976|marcaine
1365219|NCT00508976|lidocaine
1365220|NCT00508976|normal saline
1365221|NCT00508976|narcotics
1365222|NCT00508976|analog pain scale
1365223|NCT00508976|postoperative pain
1365224|NCT00508976|preemptive
1365225|NCT00508976|aerosolization
1365226|NCT00508976|streamed
1365227|NCT00508963|New World Cutaneous or Mucocutaneous Leishmaniasis
1365228|NCT00508950|Vaccines
1365229|NCT00508950|Pneumococcal Conjugate Vaccine
1365230|NCT00508950|Adult
1365231|NCT00508937|Diet
1365232|NCT00508937|Protein
1365233|NCT00508937|Glucose
1365234|NCT00508937|Insulin
1365235|NCT00508937|Cholesterol
1365236|NCT00508937|Triglycerides
1365237|NCT00508937|LDL subclasses
1365238|NCT00508924|Argatroban
1365239|NCT00508924|Direct thrombin inhibitor
1365240|NCT00508924|Percutaneous coronary intervention
1365241|NCT00508924|Activated clotting time
1365242|NCT00508924|PCI
1365243|NCT00508924|ACT
1365244|NCT00508911|open-label,
1365245|NCT00508911|repeat-dose,
1365246|NCT00508911|single-sequence,
1365247|NCT00508911|GW876008,
1365248|NCT00508911|pharmacokinetics,
1365249|NCT00508911|oral contraceptive,
1365250|NCT00508911|Combine Oral Contraceptives,
1365251|NCT00508911|female,
1365252|NCT00508911|volunteers
1365253|NCT00508898|lupus nephritis
1365254|NCT00508898|proteinuria
1365255|NCT00508898|chronic kidney diseases
1365256|NCT00508898|SLE
1365257|NCT00508885|hyperphosphatemia
1365258|NCT00508885|niacinamide
1365259|NCT00508885|ESRD
1365260|NCT00508885|peritoneal dialysis
1365261|NCT00508885|renal osteodystrophy
1365262|NCT00508872|Colorectal Liver Metastases
1365263|NCT00508872|Oxaliplatin
1365264|NCT00508872|Eloxatin
1365265|NCT00508872|Fluorouracil
1365266|NCT00508872|Leucovorin
1365267|NCT00508872|Bevacizumab
1365268|NCT00508872|Anti-VEGF monoclonal antibody
1365269|NCT00508872|rhuMAb-VEGF
1365270|NCT00508872|Folfox-B
1365271|NCT00508872|5-FU
1365272|NCT00508872|Avastin
1365273|NCT00508859|depression
1365274|NCT00508859|adolescents
1365275|NCT00508859|maintenance treatment
1365276|NCT00508859|antidepressant
1365277|NCT00508846|Hereditary Non-Polyposis Colon Cancer
1365278|NCT00508846|Gynecologic Cancers
1365279|NCT00508846|Genetic Counseling
1365280|NCT00508846|Questionnaire
1365281|NCT00508846|Survey
1365282|NCT00508846|HNPCC
1365283|NCT00508833|Adjuvants
1365284|NCT00508833|HBsAg
1365285|NCT00508820|Platelet
1365286|NCT00508820|AMG 531
1365287|NCT00508820|Thrombopoietin
1365289|NCT00508820|bleeding disorder
1365290|NCT00508820|immune thrombocytopenic purpura
1365291|NCT00508820|idiopathic thrombocytopenic purpura
1365292|NCT00508820|immune (idiopathic) thrombocytopenic purpura
1365293|NCT00508820|TPO
1365294|NCT00508820|thrombopoietic protein
1365295|NCT00508807|Lymphoid Malignancies
1365296|NCT00508807|Solid Tumors
1365297|NCT00508807|RTA 402
1365298|NCT00508794|Breast Cancer
1365299|NCT00508794|Tibetan Yoga
1365300|NCT00508794|Stretching Program
1365301|NCT00508794|Yoga
1365302|NCT00508794|Quality of Life
1365303|NCT00508794|Questionnaire
1365304|NCT00508794|Survey
1365305|NCT00508768|Rheumatoid Arthritis
1365306|NCT00508768|Methotrexate
1365307|NCT00508755|cerebrovascular accident
1365308|NCT00508755|electrical stimulation
1365309|NCT00508755|gait training
1365310|NCT00508755|motor learning
1365311|NCT00508742|Nasopharyngeal Colonization
1365312|NCT00508742|Streptococcus pneumoniae
1365313|NCT00508742|Healthy Infants
1365314|NCT00508742|Vaccines
1365315|NCT00508742|Pneumococcal Conjugate Vaccine
1365316|NCT00508716|Congestive Heart Failure
1365317|NCT00508716|Health Literacy
1365318|NCT00508716|Health Education
1365319|NCT00508716|Congestive Heart Failure (inpatients)
1365320|NCT00508703|Uterine Cancer
1365321|NCT00508703|Cervical Cancer
1365322|NCT00508703|Endometrial Cancer
1365323|NCT00508703|Intensity Modulated Radiotherapy
1365324|NCT00508703|IMRT
1365325|NCT00508703|Computed Tomography
1365326|NCT00508703|CT
1365327|NCT00508703|CT Scan
1365328|NCT00508690|Antibiotic Prophylaxis
1365329|NCT00508690|Colorectal Surgery
1365330|NCT00508690|Laparoscopy
1365331|NCT00508677|Attention Deficit Hyperactivity Disorder
1365332|NCT00508677|Mazindol
1365333|NCT00508664|by laryngectomy operable carcinoma of the larynx and the hypopharynx
1365334|NCT00508651|parainfluenza virus, children, vaccine
1365335|NCT00508638|Heart Failure
1365336|NCT00508612|Blood Pressure
1365337|NCT00508612|Systolic Blood Pressure
1365338|NCT00508612|Diastolic Blood Pressure
1365339|NCT00508612|Ambulatory Blood Pressure Monitoring
1365340|NCT00508612|Relaxation
1365341|NCT00508612|Meditation
1365342|NCT00508612|Coping Skills
1365343|NCT00508612|Adolescents
1365344|NCT00508599|type 2 diabetes
1365345|NCT00508599|bed rest
1365346|NCT00508599|insulin resistance
1365347|NCT00508599|insulin
1365348|NCT00508599|glucose
1365349|NCT00508599|orthostatic response
1365350|NCT00508586|Breast cancer
1365351|NCT00508586|PTC299
1365352|NCT00508586|VEGF
1365353|NCT00508586|Angiogenesis
1365354|NCT00508586|Post-transcriptional control
1365355|NCT00508586|Aromatase inhibitors
1365356|NCT00508573|Hereditary Nonpolyposis Colorectal Cancer
1365357|NCT00508573|Lynch Syndrome
1365358|NCT00508573|HNPCC
1365359|NCT00508573|Syndrome Registry
1365360|NCT00508573|Questionnaire
1365361|NCT00508573|Endometrial cancer
1365362|NCT00508573|Ovarian cancer
1365363|NCT00508560|Contingency management
1365364|NCT00508560|Smoking cessation
1365365|NCT00508560|Psychotic disorders
1365366|NCT00508560|Veterans
1365367|NCT00508547|Methotrexate
1365368|NCT00508547|Acitretin
1365369|NCT00508547|Cyclosporine
1365370|NCT00508547|Systemic PUVA
1365371|NCT00508547|Infliximab
1365372|NCT00508547|Adalimumab
1365373|NCT00508547|Alefacept
1365374|NCT00508547|Efalizumab
1365375|NCT00508547|Etanercept
1365376|NCT00508547|Psoriasis
1365377|NCT00508547|Psoriatic arthritis
1365378|NCT00508547|Skin disease
1365379|NCT00508547|Cosentyx
1365380|NCT00508534|pharmacokinetic study,
1365381|NCT00508534|gastric pH
1365382|NCT00508521|cerebrovascular accident
1365383|NCT00508521|electrical stimulation
1365384|NCT00508521|motor learning
1365385|NCT00508521|upper extremity rehabilitation
1365386|NCT00508508|Heart Failure
1365387|NCT00508508|Peer Support
1365388|NCT00508508|Self Management
1365389|NCT00508495|pain, postoperative
1365390|NCT00508495|replacement, total hip
1365391|NCT00508495|total hip replacement
1365392|NCT00508495|arthroplasty, replacement, hip
1365393|NCT00508482|Acupuncture
1365394|NCT00508482|Functional constipation
1365395|NCT00508469|Intraocular pressure
1365396|NCT00508469|Open-angle glaucoma
1365397|NCT00508469|Ocular hypertension
1365398|NCT00508469|Adherence
1365399|NCT00508469|Compliance
1365400|NCT00508456|Glioblastoma Multiforme
1365401|NCT00508456|Methionine Restriction
1365402|NCT00508456|Hominex-2
1365403|NCT00508456|Methionine Restriction Diet
1365404|NCT00508456|Hominex-2 Amino Acid-Modified Medical Food
1365405|NCT00508456|Temozolomide
1365406|NCT00508456|Temodar
1365407|NCT00508443|Stereotactic Spine Radiotherapy System
1365408|NCT00508443|SSRS
1365409|NCT00508443|CT-on-Rails
1365410|NCT00508443|Metastatic Spine Disease
1365411|NCT00508443|Spinal Neoplasms
1365412|NCT00508443|Radiation Therapy
1365413|NCT00508443|Trilogy
1365414|NCT00508443|Cancer
1365415|NCT00508443|Breast Cancer
1365416|NCT00508443|Gastrointestinal Cancer
1365417|NCT00508443|Genitourinary Disease
1365418|NCT00508443|Lung Cancer
1365419|NCT00508443|Lymphoma
1365420|NCT00508443|Melanoma
1365421|NCT00508443|Sarcoma
1365422|NCT00508443|Spinal Cancer
1365423|NCT00508430|ASP8825
1365424|NCT00508430|Diabetic Neuropathies
1365425|NCT00508430|Pain
1365426|NCT00508417|Malaria Incidence
1365427|NCT00508417|Anemia
1365428|NCT00508417|Clinical Malaria
1365429|NCT00508378|Ovarian Cancer
1365430|NCT00508378|Quality of Life
1365431|NCT00508378|Chemotherapy Side-Effects
1365432|NCT00508378|Interview
1365433|NCT00508378|Questionnaire
1365434|NCT00508378|Caregivers
1365435|NCT00508365|lisinopril
1365436|NCT00508365|carvedilol
1365437|NCT00508365|hypertension
1365438|NCT00508352|breast
1365439|NCT00508352|cancer
1365440|NCT00508352|locoregional
1365441|NCT00508352|IMRT
1365442|NCT00508352|tomotherapy
1365443|NCT00508339|Soft Tissue Sarcoma
1365444|NCT00508339|Limb Sparing Surgery
1365445|NCT00508339|Toronto Extremity Salvage Score
1365446|NCT00508339|Radiotherapy
1365447|NCT00508339|Quality of Life
1365448|NCT00508339|Questionnaire
1365449|NCT00508339|Survey
1365450|NCT00508339|TESS
1365451|NCT00508326|Advanced Cancer
1365452|NCT00508326|Solid Tumor
1365453|NCT00508326|Liver Metastasis
1365454|NCT00508326|Hepatic Artery Infusion
1365455|NCT00508326|Liver
1365456|NCT00508326|Paclitaxel
1365457|NCT00508326|Taxol
1365458|NCT00508313|Lung Cancer
1365459|NCT00508313|Healthy Control
1365460|NCT00508313|Thermal Imaging
1365461|NCT00508313|Thermal Signatures
1365462|NCT00508313|Radiation Therapy
1365463|NCT00508313|Chemoradiation Therapy
1365464|NCT00508300|laparoscopic
1365465|NCT00508300|colectomy
1365466|NCT00508300|Fast Track
1365467|NCT00508300|epidural
1365468|NCT00508274|Advanced Metastatic Breast Cancer
1365469|NCT00508274|breast cancer
1365470|NCT00508274|lapatinib
1365471|NCT00508274|HER2+ positive
1365472|NCT00508274|TYVERB
1365473|NCT00508274|TYKERB
1365474|NCT00508261|Meningococcal vaccine
1365475|NCT00508261|Immunogenicity
1365476|NCT00508261|Routine infancy vaccination
1365477|NCT00508261|Safety
1365478|NCT00508248|omega 3fatty acids
1365479|NCT00508235|Neurofibromatosis
1365480|NCT00508235|Quality of Friendships
1365481|NCT00508235|Disease Severity
1365482|NCT00508235|Questionnaire
1365483|NCT00508235|NF-1
1365484|NCT00508222|HIV
1365485|NCT00508222|HCV
1365486|NCT00508222|HIV/HCV Co-infection
1365487|NCT00508222|Kaletra Monotherapy
1365488|NCT00508222|Treatment Experienced
1365489|NCT00508209|high-dose melphalan
1365490|NCT00508209|bortezomib
1365491|NCT00508209|response
1365492|NCT00508209|toxicity
1365493|NCT00508209|relapse
1365494|NCT00508196|right ventricular pacing
1365495|NCT00508196|endothelial function
1365496|NCT00508196|cardiac output
1365497|NCT00508183|full thickness rotator cuff tear
1365498|NCT00508170|Head and Neck Cancer
1365499|NCT00508170|Human Papillomavirus Infection
1365500|NCT00508170|Oropharyngeal Patients
1365501|NCT00508170|Sexual Behavior
1365502|NCT00508170|Questionnaire
1365503|NCT00508144|Non-Small Cell Lung Cancer
1365504|NCT00508144|Lung Cancer
1365505|NCT00508144|NSCLC
1365506|NCT00508144|Malignant pleural effusion
1365507|NCT00508144|Pericardial effusion
1365508|NCT00508144|Pemetrexed
1365509|NCT00508144|Alimta
1365510|NCT00508144|LY231514
1365511|NCT00508144|Poor Performance Status
1365512|NCT00508144|Asymptomatic Brain Metastases
1365513|NCT00508131|Milk fortification
1365514|NCT00508131|Effectivness evaluation
1365515|NCT00508131|Iron deficiency anemia
1365516|NCT00508131|Stunting
1365517|NCT00508131|Zinc deficiency
1365518|NCT00508118|Aortic Arch Reconstruction Surgery
1365519|NCT00508105|Osteoarthritis
1365520|NCT00508105|Shoulder
1365521|NCT00508105|tenotomy
1365522|NCT00508105|ostotomy
1365523|NCT00508092|appendicectomy
1365524|NCT00508092|pain
1365525|NCT00508092|local anaesthetic
1365526|NCT00508092|nerve block
1365527|NCT00508092|Post operative pain following appendicectomy
1365528|NCT00508079|Venous Disease
1365529|NCT00508079|Varicose Veins
1365530|NCT00508079|Chronic Venous Insufficiency
1365531|NCT00508079|PAD
1365532|NCT00508066|Congenital Scoliosis
1365533|NCT00508066|Idiopathic Scoliosis
1365534|NCT00508066|Spinal Fusion
1365535|NCT00508066|Post-Operative Pain Management
1365536|NCT00508066|Infusion Catheter
1365537|NCT00508053|wound infection
1365538|NCT00508053|incisional hernia
1365539|NCT00508053|wound dehiscence
1365540|NCT00508053|wound healing
1365541|NCT00508053|postoperative complications
1365542|NCT00508053|surgical techniques
1365543|NCT00508040|Birdshot Retine choroidopathy
1365544|NCT00508040|Macular edema
1365545|NCT00508040|Prednisone
1365546|NCT00508040|Interferon alpha 2a
1365547|NCT00508040|Associated with Cystoid macular edema
1365548|NCT00508040|With Visual acuity loss
1365549|NCT00508027|sickle cell disease
1365550|NCT00508027|simvastatin
1365551|NCT00508027|statin drugs
1365552|NCT00508027|nitric oxide donors
1365553|NCT00508027|vascular injury
1365554|NCT00508014|Cardiovascular disease
1365555|NCT00508014|Diabetes
1365556|NCT00508014|Quality improvement
1365557|NCT00508014|Peer review
1365558|NCT00508001|Hepatocellular carcinoma
1365559|NCT00508001|Advanced solid, malignant tumour
1365560|NCT00507988|Cognitive Training
1365561|NCT00507988|Complex Problem Solving
1365562|NCT00507988|Goal Management
1365563|NCT00507988|Planning
1365564|NCT00507975|Smoking
1365565|NCT00507975|pregnancy
1365566|NCT00507975|newborn
1365567|NCT00507975|birth weight
1365568|NCT00507975|nicotine patch
1365569|NCT00507975|birth
1365570|NCT00507962|Advanced Cancer
1365571|NCT00507962|Dominant Liver Involvement
1365572|NCT00507962|Hepatic Intraarterial Cisplatin
1365573|NCT00507962|Cisplatin
1365574|NCT00507962|Liposomal Doxorubicin
1365575|NCT00507962|Platinol-AQ
1365576|NCT00507962|Platinol
1365577|NCT00507962|CDDP
1365578|NCT00507962|Doxil
1365579|NCT00507962|Liposomal
1365580|NCT00507962|Doxorubicin Hydrochloride
1365581|NCT00507949|COPD
1365582|NCT00507949|body weight
1365583|NCT00507949|megestrol acetate
1365584|NCT00507949|cytokines
1365585|NCT00507936|Diabetic Neuropathy
1365586|NCT00507936|Painful
1365587|NCT00507936|Diabetic Polyneuropathy
1365588|NCT00507936|Neuralgia
1365589|NCT00507936|Diabetic
1365590|NCT00507936|Diabetic Neuropathies
1365591|NCT00507936|Diabetic Neuralgia
1365592|NCT00507923|Breast Cancer
1365593|NCT00507923|Tibetan Yoga
1365594|NCT00507923|Stretching
1365595|NCT00507923|Yoga
1365596|NCT00507923|Fatigue
1365597|NCT00507923|Sleep
1365598|NCT00507923|Questionnaire
1365599|NCT00507923|Survey
1365600|NCT00507910|ankle fracture
1365601|NCT00507910|pes planus
1365602|NCT00507897|thyroid nodules, blood pressure, thyroid hormones
1365603|NCT00507884|Kidney Neoplasms
1365604|NCT00507884|Renal Tumors
1365605|NCT00507884|Magnetic Resonance Imaging
1365606|NCT00507884|3 Tesla MRI
1365607|NCT00507884|MRI
1365608|NCT00507871|cryptosporidiosis, Cryptosporidium, Uganda, diarrhea
1365609|NCT00507858|Head and Neck Cancer
1365610|NCT00507858|Squamous Cell Cancer
1365611|NCT00507858|Alimta
1365612|NCT00507858|Pemetrexed
1365613|NCT00507858|Dexamethasone
1365614|NCT00507858|HNSCC
1365615|NCT00507858|Decadron
1365616|NCT00507832|Prurigo nodularis
1365617|NCT00507819|Other Single Ventricle Anatomy
1365618|NCT00507819|Hypoplastic Left Heart Syndrome
1365619|NCT00507819|Tricuspid Atresia
1365620|NCT00507806|Acute Ischemic Stroke
1365621|NCT00507806|Microbubbles
1365622|NCT00507806|Transcranial Doppler ultrasound
1365623|NCT00507806|TIBI
1365624|NCT00507806|Symptomatic Intracranial Hemorrhage
1365625|NCT00507806|modified Rankin Scale
1365626|NCT00507806|Recanalization
1365627|NCT00507806|Perflutren
1365628|NCT00507780|GnRH Antagonist
1365629|NCT00507780|Premature Ovarian Failure
1365630|NCT00507780|Fertility
1365631|NCT00507780|Chemotherapy
1365632|NCT00507780|POF
1365633|NCT00507754|Advanced Cancer
1365634|NCT00507754|Solid Tumors
1365635|NCT00507754|Latent Mycobacterium Tuberculosis
1365636|NCT00507754|Tuberculin Skin Test
1365637|NCT00507754|Tuberculosis
1365638|NCT00507754|T-SPOT TB test
1365639|NCT00507754|TB
1365640|NCT00507741|Cancer
1365641|NCT00507741|Ovarian
1365642|NCT00507741|Endometrial
1365643|NCT00507741|Phase II
1365644|NCT00507741|EC145
1365645|NCT00507741|EC20
1365646|NCT00507728|Pharmacogenetics
1365647|NCT00507728|Emotional Reactivity
1365648|NCT00507728|Smoking Cessation Counseling
1365649|NCT00507728|Smoking
1365650|NCT00507728|Bupropion
1365651|NCT00507728|Wellbutrin
1365652|NCT00507728|Wellbutrin SR
1365653|NCT00507728|Zyban
1365654|NCT00507728|Varenicline
1365655|NCT00507728|Chantix
1365656|NCT00507728|Placebo
1365657|NCT00507715|Parkinson's Disease, Idiopathic
1365658|NCT00507715|l-dopa levels
1365659|NCT00507715|plantago ovata husk
1365660|NCT00507689|Truvada
1365661|NCT00507689|HBIg
1365662|NCT00507689|Chronic Hepatitis B Recurrence
1365663|NCT00507689|Post Orthotopic Liver Transplant
1365664|NCT00507676|Asthma
1365665|NCT00507676|Wheezing
1365666|NCT00507676|Infant
1365667|NCT00507663|beta blocker
1365668|NCT00507663|functional recovery
1365669|NCT00507650|Pressure ulcers
1365670|NCT00507650|Geriatrics
1365671|NCT00507650|Nursing home
1365672|NCT00507650|Fluid balance
1365673|NCT00507650|Collagen deposition
1365674|NCT00507611|breast
1365675|NCT00507611|sentinel lymph node
1365676|NCT00507611|node mapping
1365677|NCT00507598|colorectal cancer
1365678|NCT00507598|metabolomics
1365679|NCT00507585|Liver Cancer
1365680|NCT00507585|Liver metastases
1365681|NCT00507585|Metastatic advanced solid tumors
1365682|NCT00507585|Advanced solid tumors metastatic to the liver
1365683|NCT00507585|Hepatic Arterial Infusion
1365684|NCT00507585|Intra-arterial hepatic oxaliplatin
1365685|NCT00507585|Fluorouracil
1365686|NCT00507585|5-FU
1365687|NCT00507585|Adrucil
1365688|NCT00507585|Efudex
1365689|NCT00507585|5-fluorouracil
1365690|NCT00507585|Avastin
1365691|NCT00507585|Leucovorin
1365692|NCT00507585|Oxaliplatin
1365693|NCT00507585|Bevacizumab
1365694|NCT00507572|Solid Tumors
1365695|NCT00507572|Pregnancy
1365696|NCT00507572|Data Collection
1365697|NCT00507546|sleep
1365698|NCT00507546|melatonin
1365699|NCT00507546|spinal cord injury
1365700|NCT00507546|insomnia
1365701|NCT00507546|tetraplegia
1365702|NCT00507533|CPAP
1365703|NCT00507533|Hematologic
1365704|NCT00507533|Neutropenic
1365705|NCT00507533|ARF
1365706|NCT00507520|RCT
1365707|NCT00507520|Almonds
1365708|NCT00507520|Hyperlipidemia
1365709|NCT00507520|Blood Lipids
1365710|NCT00507507|tenofovir
1365711|NCT00507507|monotherapy
1365712|NCT00507507|emtricitabine
1365713|NCT00507507|combination
1365714|NCT00507507|hepatitis B
1365715|NCT00507494|posttransplant diabetes mellitus
1365716|NCT00507494|kidney transplantation
1365717|NCT00507494|filtration fraction
1365718|NCT00507494|proteinuria
1365719|NCT00507481|Sleep
1365720|NCT00507481|ICU
1365721|NCT00507481|Delirium
1365722|NCT00507481|Post surgical ventilated patients
1365723|NCT00507481|ICU patients
1365724|NCT00507468|bone marrow
1365725|NCT00507468|autologous
1365726|NCT00507468|ejection fraction
1365727|NCT00507468|left ventricle
1365728|NCT00507468|heart attack
1365729|NCT00507468|myocardial infarction
1365730|NCT00507468|left ventricular dysfunction post myocardial infarction
1365731|NCT00507455|Lower Urinary Tract Symptoms
1365732|NCT00507455|Bladder Outlet Obstruction
1365733|NCT00507455|Treatment
1365734|NCT00507455|Solifenacin Succinate
1365735|NCT00507455|Tamsulosin hydrochloride
1365736|NCT00507442|Treatment for patients with multiple myeloma
1365737|NCT00507442|who have received no prior treatment
1365738|NCT00507429|thyroid neoplasms
1365739|NCT00507429|thyroid cancer
1365740|NCT00507429|thyroid carcinoma
1365741|NCT00507390|fish oils
1365742|NCT00507377|Esophageal Benign Disease
1365743|NCT00507377|Gastroesophageal Reflux Disease
1365744|NCT00507377|Hiatal Hernia
1365745|NCT00507377|Antireflux Surgery
1365746|NCT00507377|Short Esophagus
1365747|NCT00507351|Breast Cancer
1365748|NCT00507351|Colorectal Cancer
1365749|NCT00507351|Lung Cancer
1365750|NCT00507351|Prostate Cancer
1365751|NCT00507351|Pain Management
1365752|NCT00507351|Questionnaire
1365753|NCT00507351|Survey
1365754|NCT00507338|percutaneous coronary intervention
1365755|NCT00507325|Malignant Melanoma
1365756|NCT00507325|Blood Sample
1365757|NCT00507325|Tumor Sample
1365758|NCT00507325|Long-term storage
1365759|NCT00507325|Sample Collection
1365760|NCT00507312|To assess two new diagnostic devices for detecting early Heart Failure.
1365761|NCT00507299|Child maltreatment
1365762|NCT00507299|Physician education
1365763|NCT00507299|Prevention
1365764|NCT00507273|Gastrointestinal Stromal Tumors
1365765|NCT00507273|Gastrointestinal Cancer
1365766|NCT00507273|GISTs
1365767|NCT00507273|GIST Registry
1365768|NCT00507273|Registry
1365769|NCT00507260|Leukemia
1365770|NCT00507260|Lymphoma
1365771|NCT00507260|Post-Allogeneic Blood and Marrow Transplantation
1365772|NCT00507260|Blood and Marrow Transplantation
1365773|NCT00507260|BMT
1365774|NCT00507260|Cancer-Related Fatigue
1365775|NCT00507260|Fatigue
1365776|NCT00507260|Nutritional Assessment
1365777|NCT00507260|Nutritional Intervention
1365778|NCT00507260|Malnutrition
1365779|NCT00507247|Catheter-Related Infection
1365780|NCT00507247|Bloodstream Infections
1365781|NCT00507247|Staphylococcus Aureus
1365782|NCT00507247|Daptomycin
1365783|NCT00507234|COPD
1365784|NCT00507221|HIV
1365785|NCT00507221|Helminthiasis
1365786|NCT00507221|Co-infection
1365787|NCT00507221|Treatment Naive
1365788|NCT00507208|trismus
1365789|NCT00507208|head and neck cancer
1365790|NCT00507195|Postanethesia cognitive recovery
1365791|NCT00507195|Postoperative delirium
1365792|NCT00507195|hypnotics
1365793|NCT00507195|propofol
1365794|NCT00507195|sevoflurane
1365795|NCT00507195|desflurane
1365914|NCT00506948|Sirolimus
1365796|NCT00507195|postoperative cognitive recovery
1365797|NCT00507182|Oral Mucosa Lesions
1365798|NCT00507182|Oral Cancer
1365799|NCT00507182|Neoplasia and Dysplasia in oral cavity mucosa
1365800|NCT00507182|Fluorescence Spectroscopy
1365801|NCT00507182|Reflectance Spectroscopy
1365802|NCT00507182|Pre-cancerous lesions
1365803|NCT00507182|Cancerous lesions
1365804|NCT00507182|Mouth
1365805|NCT00505154|Heart failure
1365806|NCT00505154|inflammation
1365807|NCT00505154|cytokines
1365808|NCT00505141|Childhood Brain Cancer
1365809|NCT00505141|Childhood Acute Lymphoblastic Leukemia
1365810|NCT00505128|Biliary pancreatitis
1365811|NCT00505128|Bile duct stones
1365812|NCT00505128|EUS Endoscopic UltraSonography
1365813|NCT00505128|Endoscopic sphincterotomy
1365814|NCT00505128|ERCP
1365815|NCT00504023|Paget disease of the vulva
1365816|NCT00504023|recurrent vulvar cancer
1365817|NCT00504023|stage 0 vulvar cancer
1365818|NCT00504023|stage I vulvar cancer
1365819|NCT00504023|stage II vulvar cancer
1365820|NCT00504023|stage III vulvar cancer
1365821|NCT00504023|imiquimod
1365822|NCT00504023|07-029
1365823|NCT00504010|arnica
1365824|NCT00504010|muscle soreness
1365825|NCT00504010|exercise
1365826|NCT00504010|eccentric
1365827|NCT00503997|stage III squamous cell carcinoma of the hypopharynx
1365828|NCT00503997|stage III squamous cell carcinoma of the larynx
1365829|NCT00503997|stage III squamous cell carcinoma of the lip and oral cavity
1365830|NCT00503997|stage III squamous cell carcinoma of the oropharynx
1365831|NCT00503997|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1365832|NCT00503997|stage IV squamous cell carcinoma of the hypopharynx
1365833|NCT00503997|stage IV squamous cell carcinoma of the larynx
1365834|NCT00503997|stage IV squamous cell carcinoma of the lip and oral cavity
1365835|NCT00503997|stage IV squamous cell carcinoma of the oropharynx
1365836|NCT00503997|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1365837|NCT00503997|untreated metastatic squamous neck cancer with occult primary
1365838|NCT00503984|Adenocarcinoma of the prostate
1365839|NCT00503984|Recurrent prostate cancer
1365840|NCT00503984|Stage IV prostate cancer
1365841|NCT00503984|Pain
1365842|NCT00503971|Vorinostat
1365843|NCT00503971|NSCLC
1365844|NCT00503971|EGFR
1365845|NCT00503971|Erlotinib
1365846|NCT00503958|non-small cell lung cancer
1365847|NCT00503958|small cell lung cancer
1365848|NCT00503958|health status unknown
1365849|NCT00503945|sleep apnea
1365850|NCT00503945|continuous positive airway pressure
1365851|NCT00503945|echocardiography
1365852|NCT00503945|Natriuretic peptide
1365853|NCT00503932|Rectal Cancer
1365854|NCT00503932|Capecitabine
1365855|NCT00503932|Proton Therapy
1365856|NCT00503932|Adenocarcinoma of the rectum
1365857|NCT00503932|Gastrointestinal
1365858|NCT00503932|Proton Radiotherapy
1365859|NCT00503919|Cervix
1365860|NCT00503919|Cervical dysplasia
1365861|NCT00503919|Cervical neoplasia
1365862|NCT00503919|Cervical intraepithelial neoplasia
1365863|NCT00503919|Multi-spectral Digital Colposcopy
1365864|NCT00503919|MDC
1365865|NCT00503919|Acetic acid
1365866|NCT00503919|Colposcopy
1365867|NCT00503919|Spectroscopy
1365868|NCT00503919|Fluorescence Spectroscopy
1365869|NCT00503919|Abnormal Pap Smear
1365870|NCT00507143|Colorectal neoplasms
1365871|NCT00507143|Secondary
1365872|NCT00507143|irinotecan
1365873|NCT00507143|Pharmacokinetics
1365874|NCT00507143|Pharmacodynamics
1365875|NCT00507143|SLCO1B1
1365876|NCT00507143|PXR
1365877|NCT00507117|Obstructive Sleep Apnea
1365878|NCT00507117|Polysomnography
1365879|NCT00507117|Non-benzodiazepine hypnotics
1365880|NCT00507104|traumatic brain injury
1365881|NCT00507104|Subarachnoid Hemorrhage
1365882|NCT00507104|Hypopituitarism
1365883|NCT00507091|ZD6474
1365884|NCT00507091|Irinotecan
1365885|NCT00507091|5-Fluorouracil
1365886|NCT00507091|Leucovorin
1365887|NCT00507091|colorectal
1365888|NCT00507078|Obstructive Sleep Apnea
1365889|NCT00507078|Leptin
1365890|NCT00507078|Homocysteine
1365891|NCT00507078|C-reactive Protein
1365892|NCT00507052|Hemodialysis
1365893|NCT00507052|Residual Renal Function
1365894|NCT00507039|PD20 FEV1
1365895|NCT00507039|grass pollen
1365896|NCT00507039|one-step
1365897|NCT00507013|vascular closure device
1365898|NCT00506974|sleep
1365899|NCT00506974|normal sleepers
1365900|NCT00506948|Hematological Malignancies
1365901|NCT00506948|Myelodysplastic Syndrome
1365902|NCT00506948|Graft Versus Host Disease
1365903|NCT00506948|GVHD
1365904|NCT00506948|Allogeneic Hematopoietic Stem Cell Transplantation
1365905|NCT00506948|AHSCT
1365906|NCT00506948|Leukemia
1365907|NCT00506948|Lymphoma
1365908|NCT00506948|T-Cells
1365909|NCT00506948|Thymoglobulin
1365910|NCT00506948|ATG
1365911|NCT00506948|rATG
1365912|NCT00506948|Rabbit Antithymocyte Globulin
1365913|NCT00506948|Rapamune
1365915|NCT00506948|Mycophenolate Mofetil
1365916|NCT00506948|Cellcept
1365917|NCT00506948|MMF
1365918|NCT00506935|methamphetamine
1365919|NCT00506935|GVG
1365920|NCT00506935|vigabatrin
1365921|NCT00506935|stimulant
1365922|NCT00506922|Graft-Versus-Host Disease
1365923|NCT00506922|GVHD Prevention
1365924|NCT00506922|Hodgkin's Disease
1365925|NCT00506922|Leukemia
1365926|NCT00506922|Lymphoma
1365927|NCT00506922|Methotrexate
1365928|NCT00506922|Tacrolimus
1365929|NCT00506922|Pentostatin
1365930|NCT00506909|oxytocin
1365931|NCT00506896|Rheumatoid Arthritis
1365932|NCT00506896|glucocorticoid
1365933|NCT00506896|intraarticular injection
1365934|NCT00506896|arthritis
1365935|NCT00506870|Heart Valve Prosthesis Implantation
1365936|NCT00506870|INR self monitoring
1365937|NCT00506870|cost benefit evaluation
1365938|NCT00506857|Hematologic Malignancies
1365939|NCT00506857|Blood And Marrow Transplantation
1365940|NCT00506857|Leukemia
1365941|NCT00506857|MDS
1365942|NCT00506857|Lymphoma
1365943|NCT00506857|Myeloma
1365944|NCT00506857|Fludarabine
1365945|NCT00506857|Fludara
1365946|NCT00506857|Fludarabine Phosphate
1365947|NCT00506857|Busulfan
1365948|NCT00506857|Busulfex
1365949|NCT00506857|Myleran
1365950|NCT00506857|Progenitor Cell Transplantation
1365951|NCT00506857|Granulocyte colony stimulating factor
1365952|NCT00506857|G-CSF
1365953|NCT00506857|Apheresis
1365954|NCT00506857|Blood cell infusion
1365955|NCT00506844|Rectal neoplasms
1365956|NCT00506844|Neoadjuvant treatment
1365957|NCT00506844|Cetuximab
1365958|NCT00506844|Irinotecan
1365959|NCT00506844|Capecitabine
1365960|NCT00506844|Radiotherapy
1365961|NCT00506844|Combination chemotherapy
1365962|NCT00506818|emotional symptoms
1365963|NCT00506818|vascular risk-factors
1365964|NCT00506805|solid tumor malignancy; Hsp90
1365965|NCT00506792|Cystic fibrosis, QAU145, nasal potential difference
1365966|NCT00506779|Uterine Papillary Serous Carcinoma
1365967|NCT00506779|Uterine Cancer
1365968|NCT00506779|UPSC
1365969|NCT00506779|Taxol
1365970|NCT00506779|Paclitaxel
1365971|NCT00506779|Gleevec
1365972|NCT00506779|Imatinib Mesylate
1365973|NCT00506779|STI571
1365974|NCT00506766|Urinary Incontinence
1365975|NCT00506766|Self efficacy
1365976|NCT00506766|Pelvic floor muscle training
1365977|NCT00506766|Bladder training
1365978|NCT00506753|substance abuse
1365979|NCT00506714|Osteoarthritis
1365980|NCT00506714|Walking Sticks
1365981|NCT00506714|Canes
1365982|NCT00506675|Amblyopia
1365983|NCT00506675|Atropine
1365984|NCT00506675|Patching
1365985|NCT00506649|protocol
1365986|NCT00506649|analgesia
1365987|NCT00506649|sedation
1365988|NCT00506649|delirium
1365989|NCT00506649|coma
1365990|NCT00506623|Rectal neoplasm
1365991|NCT00506623|Neoadjuvant therapy
1365992|NCT00506623|Radiotherapy
1365993|NCT00506623|Combination chemotherapy
1365994|NCT00506623|Irinotecan
1365995|NCT00506623|Capecitabine
1365996|NCT00506610|Pain
1365997|NCT00506610|Postherpetic Neuralgia
1365998|NCT00506610|Neuralgia, Postherpetic
1365999|NCT00506610|Shingles
1366000|NCT00506610|Herpes Zoster
1366001|NCT00506610|Neuropathic Pain
1366002|NCT00506597|Acute Lymphoblastic Leukemia
1366003|NCT00506597|Leukemia
1366004|NCT00506597|Erwinia L-Asparaginase
1366005|NCT00506597|Erwinase
1366006|NCT00506584|Human milk nutritional intervention
1366007|NCT00506584|Pre-term, very low birth weight
1366008|NCT00506584|Fortification of human breast milk
1366009|NCT00506571|colorectal neoplasms
1366010|NCT00506571|secondary
1366011|NCT00506571|Combination chemotherapy
1366012|NCT00506571|S-1
1366013|NCT00506571|irinotecan
1366014|NCT00506571|oxaliplatin
1366015|NCT00506558|cervical spondylotic myelopathy
1366016|NCT00506558|degenerative cervical spondylosis
1366017|NCT00506558|spinal fusion
1366018|NCT00506532|Pulmonary Surfactants
1366019|NCT00506532|Lung transplantation
1366020|NCT00506532|Primary Graft Dysfunction
1366021|NCT00506519|DIC associated with severe sepsis
1366022|NCT00506506|N-acetylcysteine
1366023|NCT00506506|Chronic kidney disease
1366024|NCT00506506|eGFR
1366025|NCT00506506|Cystatin C
1366026|NCT00506506|proteinuria
1366027|NCT00506506|Stage 3 chronic kidney disease
1366028|NCT00506493|Persistent Atrial Fibrillation Surgical RF Ablation
1366029|NCT00506493|Perisistent Atrial Fibrillation
1366030|NCT00506493|Surgical Ablation
1366031|NCT00506480|Embryo Implantation
1366032|NCT00506480|Endometrium
1366033|NCT00506480|endometrial implantation
1366034|NCT00506480|Oocyte Donation
1366035|NCT00506480|in vitro fertilization
1366036|NCT00506480|endometrial sampling
1366037|NCT00506467|Intrathoracic Malignancy
1366038|NCT00506467|Lung Cancer
1366039|NCT00506467|Vibration Response Imaging
1366040|NCT00506467|VRI
1366041|NCT00506454|Fatigue
1366042|NCT00506454|Hemodialysis
1366043|NCT00506454|Endotoxemia
1366044|NCT00506454|Phospholipid
1366045|NCT00506454|Emulsion
1366046|NCT00506441|Chronic Kidney Disease
1366047|NCT00506441|Dialysis
1366048|NCT00506441|Hyperphosphatemia
1366049|NCT00506441|Phosphate binder
1366050|NCT00506428|aging
1366051|NCT00506428|sleep
1366052|NCT00506428|sleep deprivation
1366053|NCT00506428|performance
1366054|NCT00506428|memory
1366055|NCT00506428|metabolism
1366056|NCT00506415|Alzheimer's
1366057|NCT00506415|Patch
1366058|NCT00506415|Cognitive
1366059|NCT00506415|Decline
1366060|NCT00506402|Adult patients with refractory leukemias, MDS or AMM
1366061|NCT00506389|Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic Dyssomnias, Sleep Disorders, Nervous System Diseases, Mental Disorders
1366062|NCT00506376|Cervical Cancer
1366063|NCT00506376|Hysterectomy
1366064|NCT00506376|Interview
1366065|NCT00506363|scar
1366066|NCT00506363|surgery
1366067|NCT00506363|lasers
1366068|NCT00506324|Intensity Modulated Radiotherapy
1366069|NCT00506324|Chemotherapy
1366070|NCT00506324|Head and Neck Neoplasms
1366071|NCT00506324|Dysphagia
1366072|NCT00506311|Superficial Groin Dissection
1366073|NCT00506311|Melanoma
1366074|NCT00506311|Fibrin Tissue Adhesive
1366075|NCT00506311|Fibrin Sealant
1366076|NCT00506311|Tisseel
1366077|NCT00506311|Seroma
1366078|NCT00506298|Diabetes
1366079|NCT00506298|CRx-401
1366080|NCT00506298|Bezafibrate
1366081|NCT00506298|Diflunisal
1366082|NCT00506298|Metformin
1366083|NCT00506298|plasma glucose
1366084|NCT00506285|Attention Deficit Hyperactivity Disorder
1366085|NCT00506285|ADHD
1366086|NCT00506285|Adult
1366087|NCT00506285|Methylphenidate Transdermal System
1366088|NCT00506285|Daytrana
1366089|NCT00506272|diabetes mellitus
1366090|NCT00506272|hyperglycemia
1366091|NCT00506272|hypoglycemia
1366092|NCT00506272|self care
1366093|NCT00506259|Deletion 17p11.2
1366094|NCT00506259|Melatonin
1366095|NCT00506259|Phototherapy
1366096|NCT00506259|Behavioral Phenotype
1366097|NCT00506259|Developmental Delay/MR
1366098|NCT00506259|Smith-Magenis Syndrome
1366099|NCT00506259|Sleep Disturbance
1366100|NCT00506259|SMS
1366101|NCT00506259|Sleep Disorder
1366102|NCT00506246|anaesthesia
1366103|NCT00506233|Graft-Versus-Host Disease
1366104|NCT00506233|GVHD
1366105|NCT00506233|Questionnaire
1366106|NCT00504062|asthma
1366107|NCT00504062|bronchial
1366108|NCT00504049|Cerebral Palsy
1366109|NCT00504049|Electromyography
1366110|NCT00504049|Wavelet Analysis
1366111|NCT00504036|Obesity
1366112|NCT00504036|Morbid obesity
1366113|NCT00504036|Gastric balloon
1366114|NCT00504036|Gastric by-pass
1366115|NCT00504036|Morbid obesity with BMI > 45 kg/m²
1366116|NCT00506207|Gastrointestinal neoplasms
1366117|NCT00506207|Combination chemotherapy
1366118|NCT00506207|S-1
1366119|NCT00506207|Irinotecan
1366120|NCT00506207|Oxaliplatin
1366121|NCT00506194|type 2 diabetes
1366122|NCT00506194|oral glucose tolerance test
1366123|NCT00506194|insulin
1366124|NCT00506194|oral anti-diabetic drug
1366125|NCT00506194|ß-cell function
1366126|NCT00506168|Colorectal neoplasms
1366127|NCT00506168|Secondary
1366128|NCT00506168|Drug therapy, combination
1366129|NCT00506168|Irinotecan
1366130|NCT00506168|Capecitabine
1366131|NCT00506155|Bladder Cancer
1366132|NCT00506155|Urothelial Cancer
1366133|NCT00506155|Avastin
1366134|NCT00506155|Bevacizumab
1366135|NCT00506155|Cisplatin
1366136|NCT00506155|Doxorubicin
1366137|NCT00506155|Methotrexate
1366138|NCT00506155|Vinblastine
1366139|NCT00506155|M-VAC
1366140|NCT00506129|Cutaneous T-Cell Lymphoma
1366141|NCT00506129|CTCL
1366142|NCT00506129|Allogeneic Transplantation
1366143|NCT00506129|Lymphoma
1366144|NCT00506129|Allogeneic peripheral blood progenitor cell
1366145|NCT00506129|PBPC
1366146|NCT00506129|Bone Marrow transplantation
1366147|NCT00506129|Stem Cell Transplant
1366148|NCT00506129|SCT
1366149|NCT00506129|Fludarabine
1366150|NCT00506129|Fludarabine Phosphate
1366151|NCT00506129|Fludara
1366152|NCT00506129|Melphalan
1366153|NCT00506116|Pelvic floor muscle training
1366154|NCT00506116|Self-directed pushing
1366155|NCT00506116|Antenatal perineal massage
1366156|NCT00506103|Thyroidectomy
1366157|NCT00506103|Central neck dissection
1366158|NCT00506103|Harmonic scalpel
1366159|NCT00506103|Perioperative complications
1366160|NCT00506090|scar
1366161|NCT00506090|surgery
1366162|NCT00506090|lasers
1366163|NCT00506077|Undifferentiated schizophrenia
1366164|NCT00506077|residual schizophrenia
1366165|NCT00506064|Breast Cancer
1366166|NCT00506064|Sleep
1366167|NCT00506064|Melatonin
1366168|NCT00506064|Placebo
1366169|NCT00506064|Survey
1366170|NCT00506064|Postoperative Srejic Sleep SAT Survey
1366171|NCT00506051|Non-small cell lung cancer
1366172|NCT00506051|lung cancer
1366173|NCT00506051|alimta
1366174|NCT00506051|vandetanib
1366175|NCT00506051|phase 1
1366176|NCT00506038|Calcific Tendinitis
1366177|NCT00506025|Pregnancy
1366178|NCT00506025|Cranberry
1366179|NCT00506025|Asymptomatic Bacteruria
1366180|NCT00506012|Myoclonus Dystonia
1366181|NCT00506012|Essential Myoclonus
1366182|NCT00506012|Inherited Myoclonus
1366183|NCT00506012|Dyskinesia
1366184|NCT00506012|Movement Disorder
1366185|NCT00505999|Multiple Myeloma
1366186|NCT00505999|Etiology
1366187|NCT00505999|Risk Factors
1366188|NCT00505999|Healthy Controls
1366189|NCT00505999|Questionnaire
1366190|NCT00505999|Survey
1366191|NCT00505947|macular edema
1366192|NCT00505947|diabetes mellitus
1366193|NCT00505947|visual loss
1366194|NCT00505947|diabetic retinopathy
1366195|NCT00505947|macula
1366196|NCT00505947|maculopathy
1366197|NCT00505947|infliximab
1366198|NCT00505934|Epilepsy
1366199|NCT00505934|Child
1366200|NCT00505934|Levetiracetam
1366201|NCT00505934|Keppra®
1366202|NCT00505934|Infusion
1366203|NCT00505934|Intravenous
1366204|NCT00505921|T-Cell Lymphoma
1366205|NCT00505921|Lymphoma
1366206|NCT00505921|Campath-1H
1366207|NCT00505921|Allogenic Transplantation
1366208|NCT00505921|Stem Cell Transplant
1366209|NCT00505921|Alemtuzumab
1366210|NCT00505895|Multiple Myeloma
1366211|NCT00505895|Fludarabine
1366212|NCT00505895|Fludara
1366213|NCT00505895|Fludarabine Phosphate
1366214|NCT00505895|Melphalan
1366215|NCT00505895|Alkeran
1366216|NCT00505895|Stem Cell Infusion
1366217|NCT00505895|Stem Cell Transfusion
1366218|NCT00505895|SCT
1366219|NCT00505895|Allogeneic Peripheral Blood Stem Cell Transfusion
1366220|NCT00505895|APBSCT
1366221|NCT00505895|Bone Marrow Transplantation
1366222|NCT00505895|BMT
1366223|NCT00505895|Rituxan
1366224|NCT00505895|Rituximab
1366225|NCT00505895|FM140
1366226|NCT00505895|FM100
1366227|NCT00505882|Type 1 diabetes
1366228|NCT00505882|Pramlintide
1366229|NCT00505882|Weight gain
1366230|NCT00505882|Intensive insulin therapy
1366231|NCT00505882|Beta cell
1366232|NCT00505869|Pregnant Smokers
1366233|NCT00505869|Mood Management Intervention
1366234|NCT00505869|Health & Wellness Intervention
1366235|NCT00505869|Smoking Cessation
1366236|NCT00505869|Questionnaire
1366237|NCT00505869|Survey
1366238|NCT00505830|Asperger Syndrom
1366239|NCT00505830|Autism Quotient
1366240|NCT00505830|French version
1366241|NCT00505830|screening
1366242|NCT00505830|diagnostic test
1366243|NCT00505830|accuracy
1366244|NCT00505804|dexmedetomidine
1366245|NCT00505804|haloperidol
1366246|NCT00505791|Acute decompensated heart failure
1366247|NCT00505791|Normal left ventricular ejection fraction
1366248|NCT00505791|Vasodilator therapy
1366249|NCT00505765|Cognition
1366250|NCT00505765|Schizophrenia
1366251|NCT00505752|Assisted reproductive technology, follicle stimulating hormone
1366252|NCT00505739|Endometrial Cancer
1366253|NCT00505739|Low Grade Endometrial Stromal Sarcoma
1366254|NCT00505739|RU-486
1366255|NCT00505739|Mifepristone
1366256|NCT00505739|LGESS
1366257|NCT00505726|Cervical Intraepithelial Neoplasia
1366258|NCT00505726|Cervical Cancer
1366259|NCT00505726|Reflectance Confocal Imaging
1366260|NCT00505726|Colposcopy
1366261|NCT00505713|Sarcoma
1366262|NCT00505713|Rexin-G
1366263|NCT00505713|Gene Therapy
1366264|NCT00505700|acute myeloid leukemia
1366265|NCT00505687|Rotigotine
1366266|NCT00505687|Neupro®
1366267|NCT00505661|Ovarian Cancer
1366268|NCT00505661|Fallopian Tube Cancer
1366269|NCT00505661|Peritoneal Cancer
1366270|NCT00505661|Letrozole
1366271|NCT00505661|Femara
1366272|NCT00505648|Hypersensitivity
1366273|NCT00505648|Syndrome
1366274|NCT00505648|Tegeline
1366275|NCT00505635|advanced stage IV melanoma
1366276|NCT00505635|unresectable stage III melanoma
1366277|NCT00505635|Melanoma
1366278|NCT00505635|Temozolomide
1366279|NCT00505635|Velban
1366280|NCT00505635|Vinblastine
1366281|NCT00505635|Cisplatin
1366282|NCT00505635|Interleukin-2
1366283|NCT00505635|Intron-A
1366284|NCT00505635|Interferon Alpha-2b
1366285|NCT00505635|Thalidomide
1366286|NCT00505635|Thalomid
1366287|NCT00505635|Temodar
1366288|NCT00505635|Proleukin
1366289|NCT00505609|fertility awareness-based method
1366290|NCT00505609|family planning
1366291|NCT00505609|Standard Days Method
1366292|NCT00505609|Institute for Reproductive Health
1366293|NCT00505609|Efficacy
1366294|NCT00505609|CycleBeads
1366295|NCT00505596|Prenatal testing
1366296|NCT00505596|Decisionmaking
1366297|NCT00505596|Decision aid
1366298|NCT00505596|Informed choice
1366299|NCT00505570|Migraine
1366300|NCT00505570|Migraine with aura
1366301|NCT00505570|Patent foramen ovale
1366302|NCT00505570|PFO
1366303|NCT00505557|augmentation mammoplasty
1366304|NCT00505557|Dual plane
1366305|NCT00505557|Endoscope
1366306|NCT00505557|Transaxillary incision
1366307|NCT00505544|Advanced Cancer
1366308|NCT00505544|Questionnaire
1366309|NCT00505544|Survey
1366310|NCT00505544|Sleep Disturbance
1366311|NCT00505544|Sleep Quality
1366312|NCT00505531|Pain
1366313|NCT00505518|Major Depressive Disorder
1366314|NCT00505518|Telepsychiatry
1366315|NCT00505518|Chinese American
1366316|NCT00505518|Nursing Home
1366317|NCT00505505|Neurointensive care
1366318|NCT00505505|Intensive insulin infusion
1366319|NCT00505505|Hypoglycemia
1366320|NCT00505505|Postoperative Mortality
1366321|NCT00505505|Postoperative Morbidity
1366322|NCT00505505|Neurologic outcome
1366323|NCT00505492|Malignant Mixed Mesodermal Tumor
1366324|NCT00505492|MMMT
1366325|NCT00505492|Uterine Neoplasms
1366326|NCT00505492|Radiation Therapy
1366327|NCT00505492|Paclitaxel
1366328|NCT00505492|Carboplatin
1366329|NCT00505492|Cisplatin
1366330|NCT00505492|Taxol
1366331|NCT00505479|Congenital Hypothyroidism
1366332|NCT00505479|pregnancy
1366333|NCT00505479|iodine
1366334|NCT00505479|deficiency
1366335|NCT00505466|Human Genetics
1366336|NCT00505466|Genetic Counseling
1366337|NCT00505466|Genetic Testing
1366338|NCT00505466|p53 Mutation
1366339|NCT00505466|Genetics
1366340|NCT00505453|Influenza
1366341|NCT00505427|PCOS
1366342|NCT00505427|polycystic ovary syndrome
1366343|NCT00505427|polycystic ovarian syndrome
1366344|NCT00505427|alpha lipoic acid
1366345|NCT00505427|insulin resistance
1366346|NCT00505427|oxidative stress
1366347|NCT00505414|Chronic Tumor Related Pain
1366348|NCT00505414|Analgesic
1366349|NCT00505414|Tapentadol Extended Release
1366350|NCT00505414|Morphine Sulfate Controlled Release
1366351|NCT00505414|Pain assessment
1366352|NCT00505414|Placebo
1366353|NCT00505401|HIV
1366354|NCT00505401|Tat protein
1366355|NCT00505401|HIV Therapeutic Vaccine
1366356|NCT00505388|asthma
1366357|NCT00505388|bronchial
1366358|NCT00505388|Symbicort
1366359|NCT00505375|CTLA4-Ig
1366360|NCT00505375|Abatacept
1366361|NCT00505375|Beta-cell function
1366362|NCT00505375|T-cells
1366363|NCT00505375|DPT-1
1366364|NCT00505375|treatment
1366365|NCT00505375|treatment of type 1 diabetes
1366366|NCT00505375|new onset type 1 diabetes
1366367|NCT00505375|juvenile diabetes
1366368|NCT00505375|T1D
1366369|NCT00505375|diabetes mellitus
1366370|NCT00505375|Type 1 diabetes TrialNet
1366371|NCT00505375|TrialNet
1366372|NCT00505349|neurotrophic factors
1366373|NCT00505349|cognitive status
1366374|NCT00505349|young adults
1366375|NCT00505349|mature adults
1366376|NCT00505349|cognitive training
1366377|NCT00505336|Diastolic heart failure
1366378|NCT00505336|Markers of collagen turnover
1366379|NCT00505336|Statins
1366380|NCT00505336|Aldosterone receptor blockers
1366381|NCT00505323|Cortex stimulation
1366382|NCT00505323|Focal secondary Dystonia
1366383|NCT00505323|Effectiveness
1366384|NCT00505323|Quality of life improvement
1366385|NCT00505323|Focal dystonias secondary to central grey nuclei lesions
1366386|NCT00505310|Kidney Cancer
1366387|NCT00505310|Renal Cell Carcinoma
1366388|NCT00505310|Emotional Expression
1366389|NCT00505310|Writing
1366390|NCT00505310|Questionnaire
1366391|NCT00505310|Survey
1366392|NCT00505297|Osteoarthritis (OA)
1366393|NCT00505297|Magnetic Resonance Imaging (MRI)
1366394|NCT00505297|delayed Gadolinium Enhanced MRI of cartilage (dGEMRIC)
1366395|NCT00505297|disease modifying osteoarthritis drug (DMOAD)
1366396|NCT00505297|Potentially rapidly progressing osteoarthritis
1366397|NCT00505297|MRI measurement of cartilage
1366398|NCT00505284|Diabetic neuropathy
1366399|NCT00505271|Breast Cancer
1366400|NCT00505271|Rexin-G
1366401|NCT00505271|Gene Therapy
1366402|NCT00505258|Bacteremia
1366403|NCT00505258|Bloodstream infection
1366404|NCT00505258|Staphylococcus aureus
1366405|NCT00505258|Staphylococcal Infections
1366406|NCT00505258|MRSA
1366407|NCT00505258|MSSA
1366408|NCT00505245|Advanced Cancer
1366409|NCT00505245|Symptom Distress
1366410|NCT00505245|MDASI
1366411|NCT00505245|M.D. Anderson Symptom Inventory
1366412|NCT00505245|Quality of Life
1366413|NCT00505245|Questionnaire
1366414|NCT00505245|Interactive voice response telephone system
1366415|NCT00505245|IVR
1366416|NCT00505232|Y-90 Ibritumomab tiuxetan
1366417|NCT00505232|Rituximab
1366418|NCT00505232|Hyper-CVAD
1366419|NCT00505232|Mantle Cell Lymphoma Patients
1366420|NCT00505232|Zevalin(R)
1366421|NCT00505219|Osteonecrosis
1366422|NCT00505180|Hemodialysis
1366423|NCT00505180|Mortality
1366424|NCT00505167|Alzheimer's disease
1366425|NCT00505167|Memantine
1366426|NCT00505167|Donepezil
1366427|NCT00505167|Magnetic resonance Spectroscopy
1366428|NCT00505167|randomized trial
1366429|NCT00505102|Kidney Diseases
1366430|NCT00505102|Heart Transplantation
1366431|NCT00505102|Everolimus
1366432|NCT00505102|Cyclosporine Toxicity
1366433|NCT00505089|pharmacokinetic, pharmacodynamic, subcutaneous, intravenous, ACZ885, patients, rheumatoid, arthritis.
1366434|NCT00505076|Cognition
1366435|NCT00505076|Schizophrenia
1366436|NCT00505063|vaccine
1366437|NCT00505063|childhood
1366438|NCT00505063|cancer
1366439|NCT00505050|heart failure, disease program management, treatment, education
1366440|NCT00505037|ASP1585
1366441|NCT00505037|Renal Dialysis
1366442|NCT00505037|Chronic Kidney Disease
1366443|NCT00505037|Hyperphosphatemia
1366444|NCT00505024|Non-Small Cell Lung Cancer
1366445|NCT00505024|Esophageal Cancer
1366446|NCT00505024|Lung Cancer
1366447|NCT00505024|Interactive Voice Response System
1366448|NCT00505024|IVRS
1366449|NCT00505011|susceptibility
1366450|NCT00505011|genes
1366451|NCT00505011|environment
1366452|NCT00505011|ophthalmopathy
1366453|NCT00505011|outcome
1366454|NCT00504998|Pancreatic cancer
1366455|NCT00504998|Rexin-G
1366456|NCT00504998|Treatment
1366457|NCT00504985|Advanced Cancer
1366458|NCT00504985|Hematologic Malignancy
1366459|NCT00504985|Fatigue
1366460|NCT00504985|Emergency Center
1366461|NCT00504985|Survey
1366462|NCT00504959|Age-related macular degeneration (AMD),
1366463|NCT00504959|choroidal neovascularization (CNV),
1366464|NCT00504959|vascular endothelial growth factor (VEGF)
1366465|NCT00504946|allergen immunotherapy premedication
1366466|NCT00504933|Rhinitis
1366467|NCT00504933|Allergic
1366468|NCT00504933|Seasonal
1366469|NCT00504933|Hay Fever
1366470|NCT00504933|Pollen Allergy
1366471|NCT00504933|Pollinosis
1366472|NCT00504933|Rhinoconjunctivitis
1366473|NCT00504920|Leukemia
1366474|NCT00504920|Myelodysplastic Syndrome
1366475|NCT00504920|Acute Myeloblastic Leukemia
1366476|NCT00504920|Symptom-Related Cytokines
1366477|NCT00504920|Blood or Marrow Transplantation
1366478|NCT00504920|Questionnaire
1366479|NCT00504907|RSV
1366480|NCT00504894|N/A healthy volunteers
1366481|NCT00504881|Epilepsy
1366482|NCT00504881|Brivaracetam
1366483|NCT00504881|Partial Onset Seizures
1366484|NCT00504855|Pressure ulcer
1366485|NCT00504855|Waterproof
1366486|NCT00504855|Gortex
1366487|NCT00504855|Cast padding
1366488|NCT00504855|Pediatric
1366489|NCT00504855|Heel
1366490|NCT00504842|Acute Ischemic Stroke
1366491|NCT00504842|Microbubbles
1366492|NCT00504842|Transcranial Doppler ultrasound
1366493|NCT00504842|TIBI
1366494|NCT00504842|Symptomatic Intracranial Hemorrhage
1366495|NCT00504842|modified Rankin Scale
1366496|NCT00504842|Recanalization
1366497|NCT00504842|Perflutren
1366498|NCT00504829|LCP-AtorFen
1366499|NCT00504829|Non-HDL cholesterol
1366500|NCT00504829|Triglycerides
1366501|NCT00504829|HDL cholesterol
1366502|NCT00504829|LDL cholesterol
1366503|NCT00504829|Atorvastatin
1366504|NCT00504829|Fenofibrate
1366505|NCT00504816|healthy female,
1366506|NCT00504816|pharmacokinetics,
1366507|NCT00504816|pharmacodynamics
1366508|NCT00504816|drug interaction,
1366509|NCT00504803|HCT, nonmyeloablative, mesenchymal stem cells, GVHD
1366518|NCT00504764|Relapsed Acute Promyelocytic Leukemia
1366519|NCT00504764|Arsenic Trioxide
1366520|NCT00504751|diffuse large b cell
1366521|NCT00504738|lung disease
1366522|NCT00504738|chronic obstructive pulmonary disease (COPD)
1366523|NCT00504738|asthma
1366524|NCT00504738|smokers
1366525|NCT00504738|non-smokers
1366526|NCT00504725|Lobectomy
1366527|NCT00504725|VATS
1366528|NCT00504712|Testosterone
1366529|NCT00504712|Hypogonadism
1366530|NCT00504712|Diabetes
1366531|NCT00504712|PVD
1366532|NCT00504712|RCT
1366533|NCT00504699|breast cancer
1366534|NCT00504699|ovarian stimulation
1366535|NCT00504699|aromatase inhibitors
1366536|NCT00504699|letrozole
1366537|NCT00504699|fertility preservation
1366538|NCT00504699|recurrence
1366539|NCT00504660|Anaplastic Glioma
1366540|NCT00504660|Glioblastoma Multiforme
1366541|NCT00504660|Brain Cancer
1366542|NCT00504660|6-Thioguanine
1366543|NCT00504660|Capecitabine
1366544|NCT00504660|Celecoxib
1366545|NCT00504660|Temozolomide
1366546|NCT00504660|Xeloda
1366547|NCT00504660|Temodar
1366548|NCT00504660|TMZ
1366549|NCT00504660|CCNU
1366550|NCT00504660|6-TG
1366551|NCT00504647|Hypertrophic
1366552|NCT00504647|Cardiomyopathy
1366553|NCT00504647|Diastolic
1366554|NCT00504647|Ventricular
1366555|NCT00504647|Interaction
1366556|NCT00504647|Biventricular
1366557|NCT00504647|Pacemaker
1366558|NCT00504634|Multiple Myeloma
1366559|NCT00504634|Post Allogeneic Transplantation
1366560|NCT00504634|Bortezomib
1366561|NCT00504634|Velcade
1366562|NCT00504634|PS-341
1366563|NCT00504621|personality
1366564|NCT00504621|fatigue
1366565|NCT00504621|quality of life
1366566|NCT00504621|health care consumption
1366567|NCT00504595|Rheumatoid Arthritis
1366568|NCT00504582|Axillary Node Dissection
1366569|NCT00504582|Fibrin Sealant
1366570|NCT00504582|Tisseel
1366571|NCT00504582|Melanoma
1366572|NCT00504582|Seroma
1366573|NCT00504556|Anti-coagulant
1366574|NCT00504556|Non-valvular
1366575|NCT00504556|Venous Thromboembolism
1366576|NCT00504556|Prevention of Blood Clots
1366577|NCT00504556|Atrial Fibrillation
1366578|NCT00504556|Non-valvular atrial fibrillation
1366579|NCT00504543|Kidney transplant, AEB071
1366580|NCT00504517|Outpatient continuity training
1366581|NCT00504517|Relevant, Patient-centered curriculum
1366582|NCT00504517|Evaluation
1366583|NCT00504517|New graduation requirements
1366584|NCT00504504|Hodgkin's Disease
1366585|NCT00504504|Lymphoma
1366586|NCT00504504|Rituximab
1366587|NCT00504504|Rituxan
1366588|NCT00504504|Adriamycin
1366589|NCT00504504|Doxorubicin
1366590|NCT00504504|Rubex
1366591|NCT00504504|Bleomycin
1366592|NCT00504504|Bleomycin sulfate
1366593|NCT00504504|Blenoxane
1366594|NCT00504504|BLM
1366595|NCT00504504|Dacarbazine
1366596|NCT00504504|DTIC
1366597|NCT00504504|DTIC-Dome
1366598|NCT00504504|Vincristine
1366599|NCT00504504|Vinblastine
1366600|NCT00504504|Vinblastine Sulfate
1366601|NCT00504504|ABVD
1366602|NCT00504504|ABVD Chemotherapy Treatment
1366603|NCT00504491|Rituximab-CHOP
1366604|NCT00504491|Alemtuzumab
1366605|NCT00504491|Chronic lymphocytic leukaemia
1366606|NCT00504478|Inflammation
1366607|NCT00504478|carbohydrates
1366608|NCT00504478|omega-3
1366609|NCT00504478|overweight
1366610|NCT00504478|diet
1366611|NCT00504465|Labor
1366612|NCT00504465|Labor induction
1366613|NCT00504465|Cervical ripening
1366614|NCT00504465|Dinoprostone
1366615|NCT00504465|Fetal safety
1366616|NCT00504465|Oxytocin
1366617|NCT00504465|Cesarean delivery
1366618|NCT00504452|HIV
1366619|NCT00504452|viral
1366620|NCT00504452|Viral decay acceleration
1366621|NCT00504452|ART
1366622|NCT00504452|HAART
1366623|NCT00504452|Treatment Experienced
1366624|NCT00504439|SB-656933,
1366625|NCT00504439|COPD,
1366626|NCT00504439|CXCR2,
1366627|NCT00504439|CD11b,
1366628|NCT00504439|repeat dose,
1366629|NCT00504439|safety,
1366630|NCT00504439|tolerability.
1366631|NCT00504413|Metabolic Networks and Pathways
1366632|NCT00504413|Methadone
1366633|NCT00504413|Polymorphism, genetic
1366634|NCT00504413|Cytochrome P-450 Enzyme System
1366635|NCT00504400|macular telangiectasia
1366636|NCT00504400|parafoveal telangiectasis
1366637|NCT00504400|nonproliferative
1366638|NCT00504400|therapy
1366639|NCT00504400|intravitreal injection
1366640|NCT00504400|ranibizumab
1366641|NCT00504400|lucentis
1366642|NCT00504387|Burning mouth disorder
1366643|NCT00504387|Taste disorder
1366644|NCT00504387|Quantitative sensory testing
1366645|NCT00504387|Gustatory testing
1366646|NCT00504387|Neuropathic orofacial pain
1366647|NCT00504387|Oral burning
1366648|NCT00504374|Lung Cancer
1366649|NCT00504374|Epidemiology
1366650|NCT00504374|Symptoms
1366651|NCT00504374|Gene Polymorphisms
1366652|NCT00504374|Questionnaire
1366653|NCT00504374|Survey
1366654|NCT00504361|Asthma
1366655|NCT00504361|COPD
1366656|NCT00504361|Interstitial Lung Disease
1366657|NCT00504361|Cystic Fibrosis
1366658|NCT00504361|Lung Cancer
1366659|NCT00504361|smokers
1366660|NCT00504361|non-smokers
1366661|NCT00504348|Interstitial pneumonitis
1366662|NCT00504348|Polymyositis
1366663|NCT00504348|Dermatomyositis
1366664|NCT00504348|Tacrolimus
1366665|NCT00504348|Corticosteroids
1366666|NCT00504348|Interstitial pneumonitis associated with polymyositis or dermatomyositis
1366667|NCT00504335|Acute Radiation Syndrome
1366668|NCT00504335|Hematopoietic Syndrome
1366669|NCT00504335|Radiation Injury
1366670|NCT00504335|BIO 300
1366671|NCT00504322|Esophageal Neoplasms
1366672|NCT00504309|triglycerides
1366673|NCT00504309|hypertriglyceridemia
1366674|NCT00504309|omega-3
1366675|NCT00504309|n-3
1366676|NCT00504309|eicosapentaenoic acid
1366677|NCT00504309|EPA
1366678|NCT00504309|docosahexaenoic acid
1366679|NCT00504309|DHA
1366680|NCT00504309|flow mediated dilation
1366681|NCT00504309|fish
1366682|NCT00504309|Moderate hypertriglyceridemia
1366683|NCT00504296|unspecified adult solid tumor, protocol specific
1366684|NCT00504283|Renal colic, pain, protocol, emergency department
1366685|NCT00504257|recurrent ovarian epithelial cancer
1366686|NCT00504257|recurrent primary peritoneal cavity cancer
1366687|NCT00504257|recurrent fallopian tube cancer
1366688|NCT00504244|SLE
1366689|NCT00504244|SLEDAI
1366690|NCT00504244|Azathioprine
1366691|NCT00504244|Myfortic
1366692|NCT00504231|influenza
1366693|NCT00504231|prevention
1366694|NCT00504231|intradermal
1366695|NCT00504231|vaccine
1366696|NCT00504231|delivery
1366697|NCT00504231|elderly
1366698|NCT00504218|Growth Factor
1366699|NCT00504218|Hypothalamic-Pituitary Dysfunction
1366700|NCT00504218|Primary Disorders of the Thyroid
1366701|NCT00504218|Decreased Bone Mineral Density
1366702|NCT00504218|Endocrine Side Effects Related to Cancer Therapy
1366703|NCT00504218|Primary Gonadal Dysfunction
1366704|NCT00504218|Obesity
1366705|NCT00504218|Impaired Glucose Tolerance
1366706|NCT00504218|Thyroid Disorder
1366707|NCT00504218|Cancer Therapy Endocrine Side Effects
1366708|NCT00504218|Pituitary Dysfunction
1366709|NCT00504218|Childhood Cancer Survivors
1366710|NCT00504205|unspecified adult solid tumor, protocol specific
1366816|NCT00503854|Febrile Neutropenia
1366711|NCT00504205|anaplastic large cell lymphoma
1366712|NCT00504205|angioimmunoblastic T-cell lymphoma
1366713|NCT00504205|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1366714|NCT00504205|intraocular lymphoma
1366715|NCT00504205|nodal marginal zone B-cell lymphoma
1366716|NCT00504205|recurrent adult Burkitt lymphoma
1366717|NCT00504205|recurrent adult diffuse large cell lymphoma
1366718|NCT00504205|recurrent adult diffuse mixed cell lymphoma
1366719|NCT00504205|recurrent adult diffuse small cleaved cell lymphoma
1366720|NCT00504205|recurrent adult Hodgkin lymphoma
1366721|NCT00504205|recurrent adult immunoblastic large cell lymphoma
1366722|NCT00504205|recurrent adult lymphoblastic lymphoma
1366723|NCT00504205|recurrent cutaneous T-cell non-Hodgkin lymphoma
1366724|NCT00504205|recurrent grade 1 follicular lymphoma
1366725|NCT00504205|recurrent grade 2 follicular lymphoma
1366726|NCT00504205|recurrent grade 3 follicular lymphoma
1366727|NCT00504205|recurrent mantle cell lymphoma
1366728|NCT00504205|recurrent marginal zone lymphoma
1366729|NCT00504205|recurrent mycosis fungoides/Sezary syndrome
1366730|NCT00504205|recurrent small lymphocytic lymphoma
1366731|NCT00504205|splenic marginal zone lymphoma
1366732|NCT00504205|stage III adult Burkitt lymphoma
1366733|NCT00504205|stage III adult diffuse large cell lymphoma
1366734|NCT00504205|stage III adult diffuse mixed cell lymphoma
1366735|NCT00504205|stage III adult diffuse small cleaved cell lymphoma
1366736|NCT00504205|stage III adult Hodgkin lymphoma
1366737|NCT00504205|stage III adult immunoblastic large cell lymphoma
1366738|NCT00504205|stage III adult lymphoblastic lymphoma
1366739|NCT00504205|stage III adult T-cell leukemia/lymphoma
1366740|NCT00504205|stage III cutaneous T-cell non-Hodgkin lymphoma
1366741|NCT00504205|stage III grade 1 follicular lymphoma
1366742|NCT00504205|stage III grade 2 follicular lymphoma
1366743|NCT00504205|stage III grade 3 follicular lymphoma
1366744|NCT00504205|stage III mantle cell lymphoma
1366745|NCT00504205|stage III marginal zone lymphoma
1366746|NCT00504205|stage III mycosis fungoides/Sezary syndrome
1366747|NCT00504205|stage III small lymphocytic lymphoma
1366748|NCT00504205|stage IV adult Burkitt lymphoma
1366749|NCT00504205|stage IV adult diffuse large cell lymphoma
1366750|NCT00504205|stage IV adult diffuse mixed cell lymphoma
1366751|NCT00504205|stage IV adult diffuse small cleaved cell lymphoma
1366752|NCT00504205|stage IV adult Hodgkin lymphoma
1366753|NCT00504205|stage IV adult immunoblastic large cell lymphoma
1366754|NCT00504205|stage IV adult lymphoblastic lymphoma
1366755|NCT00504205|stage IV adult T-cell leukemia/lymphoma
1366756|NCT00504205|stage IV cutaneous T-cell non-Hodgkin lymphoma
1366757|NCT00504205|stage IV grade 1 follicular lymphoma
1366758|NCT00504205|stage IV grade 2 follicular lymphoma
1366759|NCT00504205|stage IV grade 3 follicular lymphoma
1366760|NCT00504205|stage IV mantle cell lymphoma
1366761|NCT00504205|stage IV marginal zone lymphoma
1366762|NCT00504205|stage IV mycosis fungoides/Sezary syndrome
1366763|NCT00504205|stage IV small lymphocytic lymphoma
1366764|NCT00504205|Waldenstrom macroglobulinemia
1366765|NCT00504205|primary central nervous system non-Hodgkin lymphoma
1366766|NCT00504179|coronary artery bypass graft
1366767|NCT00504179|osteopathic manipulative treatment
1366768|NCT00504179|cardiovascular disease
1366769|NCT00504140|Osteosarcoma
1366770|NCT00504140|Interferon Alpha
1366771|NCT00504140|IFN-
1366772|NCT00504140|Roferon
1366773|NCT00504140|Recombinant Interferon Alpha
1366774|NCT00504140|Etoposide
1366775|NCT00504140|VP-16
1366776|NCT00504127|Arthritis
1366777|NCT00504127|Degenerative
1366778|NCT00504114|Osteoarthritis, knee
1366779|NCT00504114|anterior cruciate ligament
1366780|NCT00504114|Magnetic Resonance Imaging
1366781|NCT00504101|stage I multiple myeloma
1366782|NCT00504101|stage II multiple myeloma
1366783|NCT00504101|stage III multiple myeloma
1366784|NCT00504088|CLI
1366785|NCT00504088|Critical Limb Ischemia
1366786|NCT00504088|PAD
1366787|NCT00504088|Peripheral Arterial Disease
1366788|NCT00504088|Artherosclerosis
1366789|NCT00504088|Leg Pain
1366790|NCT00504088|Cardiovascular
1366791|NCT00504088|Artherectomy
1366792|NCT00504088|Bypass
1366793|NCT00504088|Peripheral Bypass
1366794|NCT00504088|PROOF
1366795|NCT00504075|Idiopathic Thrombocytopenic Purpura
1366796|NCT00504075|Bleeding disorders
1366797|NCT00504075|Immune System and Disorders
1366798|NCT00503906|stage IV breast cancer
1366799|NCT00503906|recurrent breast cancer
1366800|NCT00503893|Wilms' Tumor
1366801|NCT00503893|Genitourinary Anomalies
1366802|NCT00503893|Beckwith-Wiedemann Hemihypertrophy
1366803|NCT00503893|Aniridia
1366804|NCT00503893|Questionnaire
1366805|NCT00503880|de novo myelodysplastic syndromes
1366806|NCT00503880|previously treated myelodysplastic syndromes
1366807|NCT00503880|secondary myelodysplastic syndromes
1366808|NCT00503867|unresectable hepatocellular carcinoma
1366809|NCT00503867|HCC
1366810|NCT00503867|SIR-Spheres
1366811|NCT00503867|Y-90 Microspheres
1366812|NCT00503867|brachytherapy
1366813|NCT00503867|SIRT
1366814|NCT00503867|liver cancer
1366815|NCT00503854|Solid Tumors
1366817|NCT00503854|Fatigue
1366818|NCT00503854|Symptom Burden
1366819|NCT00503854|Questionnaire
1366820|NCT00503854|Survey
1366821|NCT00503841|stage I breast cancer
1366822|NCT00503841|recurrent breast cancer
1366823|NCT00503841|stage II breast cancer
1366824|NCT00503841|stage IIIA breast cancer
1366825|NCT00503841|stage IIIB breast cancer
1366826|NCT00503841|stage IIIC breast cancer
1366827|NCT00503828|Derris Scandens Benth extract
1366828|NCT00503828|Osteoarthritis
1366829|NCT00503828|WOMAC
1366830|NCT00503828|6-minute walk
1366831|NCT00503815|colonoscopy
1366832|NCT00503815|bowel preparation
1366833|NCT00503815|prep
1366834|NCT00503802|Sleep Apnea
1366835|NCT00503802|Sleep disordered breathing
1366836|NCT00503802|Nasal Obstruction
1366837|NCT00503802|Turbinate
1366838|NCT00503802|Radiofrequency
1366839|NCT00503802|Continuous positive airway pressure
1366840|NCT00503802|CPAP
1366841|NCT00503802|Sleep surgery
1366842|NCT00503789|Healthy infants
1366843|NCT00503776|xerostomia
1366844|NCT00503776|mucositis
1366845|NCT00503776|dysphagia
1366846|NCT00503776|radiation toxicity
1366847|NCT00503776|chemotherapeutic agent toxicity
1366848|NCT00503776|stage III squamous cell carcinoma of the hypopharynx
1366849|NCT00503776|stage IV squamous cell carcinoma of the hypopharynx
1366850|NCT00503776|recurrent squamous cell carcinoma of the hypopharynx
1366851|NCT00503776|stage III squamous cell carcinoma of the larynx
1366852|NCT00503776|stage III verrucous carcinoma of the larynx
1366853|NCT00503776|stage IV squamous cell carcinoma of the larynx
1366854|NCT00503776|stage IV verrucous carcinoma of the larynx
1366855|NCT00503776|recurrent squamous cell carcinoma of the larynx
1366856|NCT00503776|recurrent verrucous carcinoma of the larynx
1366857|NCT00503776|stage III squamous cell carcinoma of the lip and oral cavity
1366858|NCT00503776|stage III verrucous carcinoma of the oral cavity
1366859|NCT00503776|stage IV squamous cell carcinoma of the lip and oral cavity
1366860|NCT00503776|stage IV verrucous carcinoma of the oral cavity
1366861|NCT00503776|recurrent squamous cell carcinoma of the lip and oral cavity
1366862|NCT00503776|recurrent verrucous carcinoma of the oral cavity
1366863|NCT00503776|stage III squamous cell carcinoma of the nasopharynx
1366864|NCT00503776|stage IV squamous cell carcinoma of the nasopharynx
1366865|NCT00503776|recurrent squamous cell carcinoma of the nasopharynx
1366866|NCT00503776|stage III squamous cell carcinoma of the oropharynx
1366867|NCT00503776|stage IV squamous cell carcinoma of the oropharynx
1366868|NCT00503776|recurrent squamous cell carcinoma of the oropharynx
1366869|NCT00503776|salivary gland squamous cell carcinoma
1366870|NCT00503776|stage III salivary gland cancer
1366871|NCT00503776|stage IV salivary gland cancer
1366872|NCT00503776|recurrent salivary gland cancer
1366873|NCT00503763|Smoldering multiple myeloma
1366874|NCT00503763|Simvastatin
1366875|NCT00503763|Paraprotein
1366876|NCT00503750|Breast Cancer
1366877|NCT00503737|colorectal cancer screening
1366878|NCT00503737|National Colorectal Cancer Roundtable Toolbox
1366879|NCT00503724|recurrent childhood brain stem glioma
1366880|NCT00503724|childhood central nervous system germ cell tumor
1366881|NCT00503724|recurrent childhood cerebellar astrocytoma
1366882|NCT00503724|recurrent childhood cerebral astrocytoma
1366883|NCT00503724|childhood choroid plexus tumor
1366884|NCT00503724|childhood craniopharyngioma
1366885|NCT00503724|childhood infratentorial ependymoma
1366886|NCT00503724|childhood supratentorial ependymoma
1366887|NCT00503724|recurrent childhood ependymoma
1366888|NCT00503724|recurrent childhood medulloblastoma
1366889|NCT00503724|childhood oligodendroglioma
1366890|NCT00503724|recurrent childhood supratentorial primitive neuroectodermal tumor
1366891|NCT00503724|recurrent childhood visual pathway and hypothalamic glioma
1366892|NCT00503724|recurrent childhood visual pathway glioma
1366893|NCT00503724|childhood grade I meningioma
1366894|NCT00503724|childhood grade II meningioma
1366895|NCT00503724|childhood grade III meningioma
1366896|NCT00503724|recurrent childhood subependymal giant cell astrocytoma
1366897|NCT00503724|recurrent childhood pineoblastoma
1366898|NCT00503724|recurrent childhood brain tumor
1366899|NCT00503724|disseminated neuroblastoma
1366900|NCT00503724|recurrent neuroblastoma
1366901|NCT00503711|ZD6474 PK
1366902|NCT00503685|Metastatic Colorectal Cancer with Disease Progression
1366903|NCT00503685|Failed prior to Anti-EGFr Therapy
1366904|NCT00503672|Motor Activity
1366905|NCT00503672|Pregnancy
1366906|NCT00503672|Accelerometer
1366907|NCT00503659|PC20 FEV1
1366908|NCT00503659|PD20FEV1
1366909|NCT00503659|bronchial hyperreactivity
1366910|NCT00503659|bronchial asthma
1366911|NCT00503646|psychosocial effects of cancer and its treatment
1366912|NCT00503646|sexual dysfunction and infertility
1366913|NCT00503646|sexuality and reproductive issues
1366914|NCT00503646|stage IIB prostate cancer
1366915|NCT00503646|stage IIA prostate cancer
1366916|NCT00503646|stage I prostate cancer
1366917|NCT00503633|sleep disorders
1366918|NCT00503633|genetics
1366919|NCT00503620|Cerebral Palsy
1366920|NCT00503620|Botulinum Toxin
1366921|NCT00503620|Neuromuscular Function
1366922|NCT00503607|colonoscopy
1366923|NCT00503607|bowel preparation
1366924|NCT00503607|prep
1366925|NCT00503594|Primary central nervous system lymphoma
1366926|NCT00503594|Brain lymphoma
1366927|NCT00503594|Elderly
1366928|NCT00503594|Chemotherapy
1366929|NCT00503594|Methotrexate
1366930|NCT00503594|Temozolomide
1366931|NCT00503594|Procarbazine
1366932|NCT00503594|Vincristine
1366933|NCT00503594|Cytarabine
1366934|NCT00503568|stage IIIB non-small cell lung cancer
1366935|NCT00503568|stage IV non-small cell lung cancer
1366936|NCT00503568|recurrent non-small cell lung cancer
1366937|NCT00503555|Primary Health Care
1366938|NCT00503555|Hispanic Americans
1366939|NCT00503542|Vaginitis
1366940|NCT00503542|Bacterial Vaginosis
1366941|NCT00503542|Vaginal trichomoniasis
1366942|NCT00503542|Vulvovaginal candidiasis
1366943|NCT00503516|weight loss, appetite, dementia, megestrol acetate
1366944|NCT00503477|Japan
1366945|NCT00503477|Phase I
1366946|NCT00503477|solid tumor
1366947|NCT00503477|AZD2171
1366948|NCT00503464|guideline
1366949|NCT00503464|adherence
1366950|NCT00503451|Advanced cancer
1366951|NCT00503451|solid tumors
1366952|NCT00503451|lymphoma
1366953|NCT00503451|HDAC
1366954|NCT00503451|LBH589
1366955|NCT00503451|adults
1366956|NCT00503451|non-Hodgkin's lymphoma
1366957|NCT00503438|Arthritis
1366958|NCT00503438|Osteoarthritis
1366959|NCT00503438|Arthroplasty
1366960|NCT00503412|phase I
1366961|NCT00503412|AZD2171
1366962|NCT00503412|solid tumor
1366963|NCT00503412|metastatic tumor
1366964|NCT00503399|Glucocorticoid Induced
1366965|NCT00503386|chemotherapy-induced nausea and vomiting
1366966|NCT00503386|acute
1366967|NCT00503386|delayed
1366968|NCT00503386|emesis
1366969|NCT00503386|antiemetics
1366970|NCT00503386|5-HT3 receptor antagonist
1366971|NCT00503386|granisetron
1366972|NCT00503386|palonosetron
1366973|NCT00503360|Ocular Hypertension
1366974|NCT00503360|SAD448
1366975|NCT00503347|coinfection with chronic hepatitis C virus and HIV
1366976|NCT00503347|Treatment Naive
1366977|NCT00503321|gastric cancer, TS-1, PSK
1366978|NCT00503308|HIV Seronegativity
1366979|NCT00503295|reovirus
1366980|NCT00503295|oncolytic virus
1366981|NCT00503295|sarcoma
1366982|NCT00503295|REOLYSIN
1366983|NCT00503295|Oncolytics Biotech
1366984|NCT00503269|Haemorrhoidectomy
1366985|NCT00503269|Local anaesthesia
1366986|NCT00503256|Chronic Lymphocytic Leukemia
1366987|NCT00503256|Leukemia
1366988|NCT00503256|Lymphoma
1366989|NCT00503256|Questionnaire
1366990|NCT00503256|Survey
1366991|NCT00503256|CLL
1366992|NCT00503230|tobacco
1366993|NCT00503230|smoking
1366994|NCT00503230|HIV
1366995|NCT00503230|Latino
1366996|NCT00503217|intrauterine insemination
1366997|NCT00503217|GnRH agonist
1366998|NCT00503217|implantation
1366999|NCT00503204|cancer
1367000|NCT00503204|tumor
1367001|NCT00503204|advance solid tumour
1367002|NCT00503204|glioblastoma
1367003|NCT00503204|malignant brain tumour
1367004|NCT00503191|Autism
1367005|NCT00503191|Neurodevelopmental disorder
1367006|NCT00503165|Menitorix
1367007|NCT00503165|vaccine
1367008|NCT00503126|pediatrics
1367009|NCT00503126|bivalirudin
1367010|NCT00503100|Pain
1367011|NCT00503100|Preterm-Born Adolescents
1367012|NCT00503087|Injections
1367013|NCT00503087|Vacuum
1367014|NCT00503087|Pain
1367015|NCT00503087|Pneumatic Skin Flattening
1367016|NCT00503087|PSF
1367017|NCT00503074|Diet, reducing
1367018|NCT00503074|Television
1367019|NCT00503074|Child Behavior
1367020|NCT00503061|pharmaceopidemiological
1367021|NCT00503061|Symbicort SMART
1367022|NCT00503061|GPRD
1367023|NCT00503048|atopy
1367024|NCT00503048|atopic diseases
1367025|NCT00503048|children
1367026|NCT00503048|orphanages
1367027|NCT00503035|Familial Adenomatous Polyposis
1367028|NCT00503035|Colorectal Tumors
1367029|NCT00503035|Molecular Targeting
1367030|NCT00503035|Celecoxib
1367031|NCT00503035|Celebrex
1367032|NCT00503035|SC-58635
1367033|NCT00503035|Apoptosis Induction
1367034|NCT00503035|Colon
1367035|NCT00503035|Rectum
1367036|NCT00503035|colonoscopy
1367037|NCT00503035|Biopsy
1367038|NCT00503022|Wet age-related macular degeneration
1367039|NCT00503022|ACZ885
1367040|NCT00503009|Rhinovirus
1367041|NCT00503009|Asthma
1367042|NCT00502983|Acute Myelogenous Leukemia
1367043|NCT00502983|Epidemiology
1367044|NCT00502983|Leukemia
1367045|NCT00502983|Healthy Control
1367046|NCT00502983|Lifestyle Factors
1367047|NCT00502983|Genetic Susceptibility
1367048|NCT00502983|Interview
1367049|NCT00502983|AML
1367050|NCT00502970|Chronic HCV
1367051|NCT00502970|Treatment
1367052|NCT00502957|biofeedback
1367053|NCT00502957|constipation
1367054|NCT00502944|HIV
1367055|NCT00502944|Testing
1367056|NCT00502944|HIV Seronegativity
1367057|NCT00502905|Acute Myeloid Leukemia
1367058|NCT00502905|Myelodysplastic Syndromes
1367059|NCT00502905|Busulfan
1367060|NCT00502905|Busulfex
1367061|NCT00502905|Myleran
1367062|NCT00502905|Fludarabine
1367063|NCT00502905|Fludarabine Phosphate
1367064|NCT00502905|Fludara
1367065|NCT00502892|Solid Tumors
1367066|NCT00502892|Topotecan
1367067|NCT00502892|Hycamtin
1367068|NCT00502892|Ifosfamide
1367069|NCT00502892|Ifex
1367070|NCT00502892|Carboplatin
1367071|NCT00502892|Paraplatin
1367072|NCT00502892|Pediatric
1367073|NCT00502892|Children
1367074|NCT00502892|Young Adults
1367075|NCT00502866|breastfeeding
1367076|NCT00502866|vitamin D supplementation
1367077|NCT00502866|rickets
1367078|NCT00502827|Human Immunodeficiency Virus
1367079|NCT00502827|HIV positive
1367080|NCT00502827|HIV Positive Smokers
1367081|NCT00502827|AIDS
1367082|NCT00502827|Cell Phone Intervention
1367083|NCT00502827|CPI
1367084|NCT00502827|Smoking Cessation
1367085|NCT00502827|Interview
1367086|NCT00502814|Breast Cancer
1367087|NCT00502814|3-D Optical Surface Scan
1367088|NCT00502814|Soft Tissue Biomechanics
1367089|NCT00502814|Mechanical Testing
1367090|NCT00502814|Skin Ultrasound
1367091|NCT00502814|Magnetic Resonance Imaging
1367092|NCT00502814|CT Scan
1367093|NCT00502801|Pneumonia
1367094|NCT00502801|Lung Infection
1367095|NCT00502801|Bacterial Infection
1367096|NCT00502801|Hospital-Acquired Infection
1367097|NCT00502801|Ventilator Infection
1367098|NCT00502801|Antibiotic Therapy
1367099|NCT00502775|ragweed
1367100|NCT00502775|once daily
1367101|NCT00502775|fexofenadine
1367102|NCT00502775|fluticasone furoate
1367103|NCT00502775|allergic rhinitis
1367104|NCT00502762|small-cell lung cancer
1367105|NCT00502762|refractory
1367106|NCT00502762|topotecan
1367107|NCT00502749|Leukemia
1367108|NCT00502749|Lymphoma
1367109|NCT00502749|Exercise
1367110|NCT00502749|Quality of Life
1367111|NCT00502749|Questionnaire
1367112|NCT00502749|Survey
1367113|NCT00502723|Retropubic Prostatectomy
1367114|NCT00502723|Surgical Procedures
1367115|NCT00502723|Laparoscopic
1367116|NCT00502697|preterm
1367117|NCT00502697|prematurity
1367118|NCT00502697|home visitation
1367119|NCT00502697|system of care
1367120|NCT00502684|breast cancer
1367121|NCT00502684|surgery
1367122|NCT00502684|immune suppression
1367123|NCT00502684|beta blockers
1367124|NCT00502684|COX2 inhibitors
1367125|NCT00502658|Overweight
1367126|NCT00502658|Obese
1367127|NCT00502658|Dietary Supplements
1367128|NCT00502658|Shakes
1367129|NCT00502658|Nutrition
1367130|NCT00502658|Overweight and Obese Adults (BMI 25-35)
1367131|NCT00502645|algorithm
1367132|NCT00502645|cs-1 decision support system
1367133|NCT00502645|insulin
1367134|NCT00502645|hyperglycemia
1367135|NCT00502645|tight glycemic control
1367136|NCT00502645|intensive care
1367137|NCT00502645|adults
1367138|NCT00502632|Pleural empyema
1367139|NCT00502632|Pleural effusion
1367140|NCT00502632|Dornase alfa
1367141|NCT00502632|Urokinase
1367142|NCT00502632|Children
1367143|NCT00502619|Low back pain
1367144|NCT00502619|acupuncture
1367145|NCT00502619|treadmill exercise
1367146|NCT00502606|provisional restoration
1367147|NCT00502606|antibacterial nanoparticles
1367148|NCT00502606|cement
1367149|NCT00502606|biofilm
1367150|NCT00502606|bacteria
1367151|NCT00502606|flora
1367152|NCT00502606|plaque
1367153|NCT00502606|dental
1367154|NCT00502606|prosthesis
1367155|NCT00502593|Influenza
1367156|NCT00502593|Pandemic Influenza Vaccine (GSK1562902A)
1367157|NCT00502580|Oral Cancer
1367158|NCT00502580|Multispectral Digital Microscope
1367159|NCT00502580|Multispectral Digital Imaging
1367160|NCT00502580|Interview
1367161|NCT00502580|MDM
1367162|NCT00502567|advanced solid tumors
1367163|NCT00502567|AZD2171
1367164|NCT00502567|Phase I
1367165|NCT00502554|lung function
1367166|NCT00502554|FEV1
1367167|NCT00502528|Infarction
1367168|NCT00502528|Endothelin
1367169|NCT00502528|Perfusion
1367170|NCT00502515|Diabetes
1367171|NCT00502515|Neuropathy
1367172|NCT00502502|Anal Cancer
1367173|NCT00502502|Colorectal Cancer
1367174|NCT00502502|Esophageal Cancer
1367175|NCT00502502|Gastric Cancer
1367176|NCT00502502|Lung Cancer
1367177|NCT00502502|Questionnaire
1367178|NCT00502502|Survey
1367179|NCT00502502|Chemoradiation Therapy
1367180|NCT00502502|Symptoms
1367181|NCT00502502|Cytokines
1367182|NCT00502489|prolonged mechanical ventilation; weaning;rehabilitation
1367183|NCT00502476|MRSA
1367184|NCT00502476|VRE
1367185|NCT00502476|BSI
1367186|NCT00502463|head and neck cancer, stage III/IV
1367187|NCT00502463|no prior radiotherapy of head and neck region
1367188|NCT00502450|Acute mastoiditis
1367189|NCT00502450|Hearing loss
1367190|NCT00502450|Mastoidectomy
1367191|NCT00502450|Audiogram
1367192|NCT00502424|Rheumatoid Arthritis
1367193|NCT00502424|Hand
1367194|NCT00502424|Splint
1367195|NCT00502424|Occupational Therapy
1367196|NCT00502411|Soft Tissue Sarcoma
1367197|NCT00502411|External Beam Radiotherapy
1367198|NCT00502411|Radiation Therapy
1367199|NCT00502411|Extremity and Trunk
1367200|NCT00502411|EBRT
1367201|NCT00502411|Sarcoma
1367202|NCT00502411|Doxorubicin
1367203|NCT00502411|AD
1367204|NCT00502411|Hydroxydaunomycin hydrochloride
1367205|NCT00502411|XRT
1367206|NCT00502411|RT
1367207|NCT00502411|Radiotherapy
1367208|NCT00502385|Phase I
1367209|NCT00502385|AML
1367210|NCT00502385|de novo or secondary AML
1367211|NCT00502385|AZD2171
1367212|NCT00502359|Gestational diabetes, screening, glucose monitoring
1367213|NCT00502346|Pharmacodynamics
1367214|NCT00502333|back pain
1367215|NCT00502333|neck pain
1367216|NCT00502333|prognosis
1367217|NCT00502333|catastrophizing
1367218|NCT00502333|coping strategies
1367219|NCT00502333|disability
1367220|NCT00502333|Prognosis for back and neck pain
1367221|NCT00502320|Seasonal Affective Disorder
1367222|NCT00502320|Ramelteon
1367223|NCT00502320|Psychiatry
1367224|NCT00502320|Randomized Controlled Trial
1367225|NCT00502320|Hamilton Depression Rating Scale- SAD Version
1367226|NCT00502320|Circadian Rhythm
1367227|NCT00502307|Renal Cell Carcinoma
1367228|NCT00502307|AV-951
1367229|NCT00502307|tivozanib
1367230|NCT00502294|Ulcerative Colitis, UC, Intravenous Steroid-Refractory Ulcerative Colitis, IVSR-UC
1367231|NCT00502281|Gonadotropins
1367232|NCT00502281|Infertility
1367233|NCT00502281|Intrauterine insemination
1367234|NCT00502281|PCOS
1367235|NCT00502281|Timed intercourse
1367236|NCT00502281|Treatment
1367237|NCT00502268|Coronary Calcification
1367238|NCT00502268|Endstage Renal Disease
1367239|NCT00502268|Parathyroid hormone
1367240|NCT00502255|Telemonitoring
1367241|NCT00502255|Cost-effectiveness
1367242|NCT00502255|Heart failure
1367243|NCT00502255|Case management
1367244|NCT00502229|Clomiphene citrate
1367245|NCT00502229|Controlled overian stimulation
1367246|NCT00502229|Infertility
1367247|NCT00502229|Metformin
1367248|NCT00502229|Polycystic ovary syndrome
1367249|NCT00502229|Treatment
1367250|NCT00502216|Tobacco
1367251|NCT00502216|Smoking
1367252|NCT00502216|Weight
1367253|NCT00502216|Naltrexone
1367254|NCT00502216|Varenicline
1367255|NCT00502203|Uterine Neoplasms
1367256|NCT00502203|Endometrial Cancer
1367257|NCT00502203|Paclitaxel
1367258|NCT00502203|Taxol
1367259|NCT00502203|Carboplatin
1367260|NCT00502203|Paraplatin
1367261|NCT00502203|Malignant Mixed Mullerian Tumors
1367262|NCT00502203|MMMT
1367263|NCT00502203|Immunohistochemical markers
1367264|NCT00502190|pessary
1367265|NCT00502190|extending pregnancy
1367266|NCT00502177|Continuous Hyperthermic Peritoneal Perfusion
1367267|NCT00502177|Peritoneal Neoplasms
1367268|NCT00502177|Quality of Life
1367269|NCT00502177|Questionnaire
1367270|NCT00502177|Survey
1367271|NCT00502177|CHPP
1367272|NCT00502164|Advanced Prostate Cancer
1367273|NCT00502138|diabetes
1367274|NCT00502138|insulin
1367275|NCT00502138|pramlintide
1367276|NCT00502138|IDDM
1367277|NCT00502125|Reflectance Confocal Imaging
1367278|NCT00502125|Oral Mucosal Lesions
1367279|NCT00502125|Oral Mucosa Disease
1367280|NCT00502125|Neoplasia Detection
1367281|NCT00502112|Lintuzumab
1367282|NCT00502112|Antigens, CD33
1367283|NCT00502112|Antibodies, Monoclonal
1367284|NCT00502112|Combined Modality Therapy
1367285|NCT00502112|Myelodysplastic Syndromes
1367286|NCT00502112|Hematologic Diseases
1367287|NCT00502112|Preleukemia
1367288|NCT00502099|Chronic hepatitis C
1367289|NCT00502099|pegylated interferon alfa-2a
1367290|NCT00502099|ribavirin, rapid virologic response
1367291|NCT00502099|early virologic response
1367292|NCT00502099|sustained virologic response
1367293|NCT00502086|Chronic hepatitis C
1367294|NCT00502086|Cirrhosis of the liver
1367295|NCT00502086|Mortality
1367296|NCT00502086|Complications
1367297|NCT00502086|Health-related quality of live
1367298|NCT00502086|Hepatocellular carcinoma
1367299|NCT00502086|Nutritional supplement
1367300|NCT00502060|Phase I
1367301|NCT00502060|AZD2171
1367302|NCT00502060|ZD1839
1367303|NCT00502060|solid tumor
1367304|NCT00502047|plantago ovata husk
1367305|NCT00502047|soluble fibre
1367306|NCT00502047|hypercholesterolemia
1367307|NCT00502047|cardiovascular risk factor
1367308|NCT00502034|Carcinoma, Renal Cell
1367309|NCT00502034|Low-dose Interleukin
1367310|NCT00502034|Adjuvant Immunotherapy
1367311|NCT00502021|obesity
1367312|NCT00502021|alpha linolenic acid
1367313|NCT00502021|flaxseed
1367314|NCT00502021|C-reactive protein
1367315|NCT00502021|inflammation
1367316|NCT00502008|Diabetes
1367317|NCT00502008|India
1367318|NCT00502008|Coccinia Cordifolia
1367319|NCT00502008|Coccinia indica
1367320|NCT00502008|Blood glucose levels
1367321|NCT00501995|High Dose Cyclophosphamide
1367322|NCT00501995|Systemic Sclerosis
1367323|NCT00501995|Scleroderma
1367324|NCT00501995|immunoablation
1367325|NCT00501982|surfactant
1367326|NCT00501982|RDS
1367327|NCT00501982|nCPAP
1367328|NCT00501982|Mechanical Ventilation
1367329|NCT00501982|Premature Infants
1367330|NCT00501982|Neonatal Respiratory Distress Syndrome (nRDS)
1367331|NCT00501969|Rotigotine
1367332|NCT00501969|Neupro®
1367333|NCT00501956|chronic renal replacement therapy
1367334|NCT00501956|malnutrition anorexia
1367335|NCT00501956|parenteral nutrition
1367336|NCT00501930|Dose Escalation;
1367337|NCT00501930|Supratherapeutic;
1367338|NCT00501930|GSK189075;
1367339|NCT00501930|Diabetes
1367340|NCT00501917|acute myocardial infarction
1367341|NCT00501904|Anovulation
1367342|NCT00501904|Infertility
1367343|NCT00501904|Metformin
1367344|NCT00501904|PCOS
1367345|NCT00501904|Treatment
1367346|NCT00501891|Glioblastoma Multiforme
1367347|NCT00501891|Brain and Central Nervous System Tumors
1367348|NCT00501891|Recurrent Malignant Glioma
1367349|NCT00501891|Recurrent Glioblastoma Multiforme
1367350|NCT00501891|Avastin
1367351|NCT00501891|Bevacizumab
1367352|NCT00501891|Temodar
1367353|NCT00501891|Temozolomide
1367354|NCT00501878|phenylephrine
1367355|NCT00501878|mydriasis
1367356|NCT00501878|diabetes mellitus
1367357|NCT00501865|healthy volunteers
1367358|NCT00501865|food effect,
1367359|NCT00501865|quantitative pharmacokinetic analysis,
1367360|NCT00501865|GW273225,
1367361|NCT00501852|COPD, Age≥40 yrs, Glycopyrronium Bromide
1367362|NCT00501839|Anovulation
1367363|NCT00501839|Clomiphene citrate
1367364|NCT00501839|Infertility
1367365|NCT00501839|PCOS
1367366|NCT00501839|Treatment
1367367|NCT00501826|Leukemia
1367368|NCT00501826|ALL
1367369|NCT00501826|T-cell ALL
1367370|NCT00501826|Lymphoblastic Lymphoma
1367371|NCT00501826|Hyper-CVAD
1367372|NCT00501826|Doxorubicin
1367373|NCT00501826|Cyclophosphamide
1367374|NCT00501826|Cytarabine
1367375|NCT00501826|Dexamethasone
1367376|NCT00501826|Methotrexate
1367377|NCT00501826|Vincristine
1367378|NCT00501826|Nelarabine
1367379|NCT00501813|Hepatocellular carcinoma
1367380|NCT00501813|Intrahepatic vessels invasion
1367381|NCT00501813|Hepatectomy
1367382|NCT00501813|Transcatheter arterial chemoembolization
1367383|NCT00501813|Local regional treatment
1367384|NCT00501800|Reproductive Health
1367385|NCT00501800|Fertility
1367386|NCT00501800|Infertility
1367387|NCT00501800|Genetics
1367388|NCT00501800|Continental Population Groups
1367389|NCT00501800|Epidemiology
1367390|NCT00501800|Aging
1367391|NCT00501800|Health
1367392|NCT00501787|Anovulation
1367393|NCT00501787|metformin
1367394|NCT00501787|PCOS
1367395|NCT00501787|treatment
1367396|NCT00501774|Localized vulvodynia
1367397|NCT00501774|Helicobacter pylori
1367398|NCT00501774|peptic disease
1367399|NCT00501774|omeprazole
1367400|NCT00501761|Endometrial Cancer
1367401|NCT00501761|Healthy Controls
1367402|NCT00501761|Social Cognitive Theory
1367403|NCT00501761|Behavioral Intervention
1367404|NCT00501761|Physical Activity
1367405|NCT00501761|Exercise Program
1367406|NCT00501761|Questionnaire
1367407|NCT00501748|Neuromyelitis Optica
1367408|NCT00501748|acute transverse myelitis
1367409|NCT00501735|T-Cell
1367410|NCT00501735|Lymphoma
1367411|NCT00501735|Forodesine
1367412|NCT00501735|Mycosis Fungoides
1367413|NCT00501722|cirrhotic ascites
1367414|NCT00501722|hyponatraemia
1367415|NCT00501683|metabolite profiling
1367416|NCT00501683|excretion,
1367417|NCT00501683|radioactivity,
1367418|NCT00501683|pharmacokinetic,
1367419|NCT00501683|mass balance,
1367420|NCT00501670|Herpes zoster
1367421|NCT00501670|PCR
1367422|NCT00501670|Varicella zoster Virus (VZV)
1367423|NCT00501670|Shingles
1367424|NCT00501670|GSK Biologicals
1367425|NCT00501657|gastric emptying
1367426|NCT00501657|glycemia
1367427|NCT00501657|appetite
1367428|NCT00501657|incretin hormones
1367429|NCT00501644|Müllerian Carcinomas
1367430|NCT00501644|Ovarian Cancer
1367431|NCT00501644|Fallopian Tube Cancer
1367432|NCT00501644|Peritoneal Cancer
1367433|NCT00501644|Epithelial Ovarian
1367434|NCT00501644|Peritoneal
1367435|NCT00501644|Fallopian Tube
1367436|NCT00501644|Chemoimmunotherapy
1367437|NCT00501644|Platinum Sensitive Müllerian
1367438|NCT00501644|Carboplatin
1367439|NCT00501644|Paraplatin
1367440|NCT00501644|GM-CSF
1367441|NCT00501644|Sargramostim
1367442|NCT00501644|Interferon Gamma
1367443|NCT00501644|Quality of Life
1367444|NCT00501644|QOL
1367445|NCT00501631|Addiction
1367446|NCT00501631|Alcoholism
1367447|NCT00501631|Inpatient detoxification
1367448|NCT00501618|Schizophrenia
1367449|NCT00501618|Schizoaffective Disorder
1367450|NCT00501618|Orally dissolving clozapine
1367451|NCT00501618|orally disintegrating clozapine
1367452|NCT00501618|bio-equivalence
1367453|NCT00501618|desmethylclozapine
1367454|NCT00501618|clozapine plasma level
1367455|NCT00501618|equivalence
1367456|NCT00501618|fazaclo
1367457|NCT00501618|generic clozapine
1367458|NCT00501605|Phase I
1367459|NCT00501605|AZD2171
1367460|NCT00501605|advanced solid tumors
1367461|NCT00501592|Farnesoid X receptor agonist
1367462|NCT00501592|Metabolic Disorder
1367463|NCT00501592|Diabetes
1367464|NCT00501592|NAFLD
1367465|NCT00501566|cirrhotic ascites
1367466|NCT00501553|Heart Failure,
1367467|NCT00501553|Vitamin D status,
1367468|NCT00501553|NT-proBNP
1367469|NCT00501540|low-grade neuroendocrine tumors
1367470|NCT00501540|lithium
1367471|NCT00501527|Allergoid
1367472|NCT00501527|Depigmented
1367473|NCT00501527|Polymerized
1367474|NCT00501527|Allergen-extract
1367475|NCT00501527|Rhinoconjunctivitis
1367476|NCT00501527|Asthma
1367477|NCT00501514|chronic heart failure
1367478|NCT00501514|cardiopulmonary exercise
1367479|NCT00501514|oxygen consumption
1367480|NCT00501514|growth hormone
1367481|NCT00501501|Rehospitalization
1367482|NCT00501501|Cesarean
1367483|NCT00501501|Vaginal delivery
1367484|NCT00501488|pharmacodynamics
1367485|NCT00501488|insulin resistance
1367486|NCT00501488|therapy
1367487|NCT00501488|volunteer
1367488|NCT00501475|N-acetylcysteine
1367489|NCT00501475|nephropathy
1367490|NCT00501475|bicarbonate
1367491|NCT00501462|Type 2 Diabetes Mellitus
1367492|NCT00501462|renal insufficiency
1367493|NCT00501449|Multiple Endocrine Neoplasia
1367494|NCT00501449|Questionnaire
1367495|NCT00501449|Psychosocial
1367496|NCT00501449|Surveillance Behaviors
1367497|NCT00501449|MEN Syndromes
1367498|NCT00501423|antiplatelet drug
1367499|NCT00501423|resistance
1367500|NCT00501423|atherothrombosis
1367501|NCT00501410|Colorectal Cancer
1367502|NCT00501410|Dual Inhibition of EGFR
1367503|NCT00501410|FOLFOX Chemotherapy
1367504|NCT00501410|5-FU
1367505|NCT00501410|Cetuximab
1367506|NCT00501410|Dasatinib
1367507|NCT00501410|Leucovorin
1367508|NCT00501410|Oxaliplatin
1367509|NCT00501410|5-Fluorouracil
1367510|NCT00501410|BMS-354825
1367511|NCT00501410|Eloxatin
1367512|NCT00501410|Sprycel
1367513|NCT00501410|C225
1367514|NCT00501410|Erbitux
1367515|NCT00501410|IMC-C225
1367516|NCT00501410|Adrucil
1367517|NCT00501410|Efudex
1367518|NCT00501410|Folinic Acid
1367519|NCT00501397|ketoconazole,
1367520|NCT00501397|drug interaction,
1367521|NCT00501397|pharmacokinetics
1367522|NCT00501397|T2DM,
1367523|NCT00501384|cirrhotic ascites
1367524|NCT00501371|Benign Prostatic Hyperplasia
1367525|NCT00501371|MCS
1367526|NCT00501371|Lower Urinary Tract Symptoms
1367527|NCT00501371|International prostate symptom score
1367528|NCT00501371|Voiding
1367529|NCT00501371|Alpha-blockers
1367530|NCT00501358|SLEEP APNEA
1367531|NCT00501358|venous thromboembolism
1367532|NCT00501358|COAGULABILITY
1367533|NCT00501358|COAGULATION FACTORS
1367534|NCT00501358|HYPOXIA
1367535|NCT00501345|Thrombocytopenia
1367536|NCT00501345|Platelet Function
1367537|NCT00501345|Acute Coronary Syndrome
1367538|NCT00501345|Myocardial Infarction
1367539|NCT00501345|Heart Attack
1367540|NCT00501345|Aspirin
1367541|NCT00501332|neutropenia
1367542|NCT00501332|breast
1367543|NCT00501332|cancer
1367544|NCT00501332|chemotherapy
1367545|NCT00501319|Interactive Voice Response Telephone System
1367546|NCT00501319|Non-Small Cell Lung Cancer
1367547|NCT00501319|Lung Cancer
1367548|NCT00501319|Questionnaire
1367549|NCT00501319|Survey
1367550|NCT00501319|NSCLC
1367551|NCT00501319|IVR
1367552|NCT00501306|Condyloma Accuminata
1367553|NCT00501306|Low Grade Squamous Intraepithelial Lesion
1367554|NCT00501306|High Grade Squamous Intraepithelial Lesion
1367555|NCT00501306|Anal Cancer Screening
1367556|NCT00501280|Epidemiology
1367557|NCT00501280|Genetic Susceptibility
1367558|NCT00501280|Migrant Farmworker Children
1367559|NCT00501280|Migrant Education Program
1367560|NCT00501280|Interview
1367561|NCT00501280|Questionnaire
1367562|NCT00501267|solabegron,
1367563|NCT00501267|oxybutynin,
1367564|NCT00501267|healthy adults,
1367565|NCT00501267|drug interaction
1367566|NCT00501254|Slow release ASA
1367567|NCT00501254|Platelet functionalism
1367568|NCT00501254|Secondary cardiovascular prevention
1367569|NCT00501228|Graft-Versus-Host Disease
1367570|NCT00501228|Stem Cell Transplantation
1367571|NCT00501228|Tissue Repair
1367572|NCT00501228|Organ-Specific Tissue Damage
1367573|NCT00501228|Filgrastim
1367574|NCT00501228|RhG-CSF
1367575|NCT00501215|Primary Hyperparathyroidism
1367576|NCT00501215|PHPT
1367577|NCT00501215|Parathyroidectomy
1367578|NCT00501215|Polysomnogram
1367579|NCT00501215|PSG
1367580|NCT00501215|Sleep Quality
1367581|NCT00501215|Interview
1367582|NCT00501202|diabetes mellitus
1367583|NCT00501202|diabetic microvascular injury
1367584|NCT00501202|painful polyneuropathy.
1367585|NCT00501189|Gardasil
1367586|NCT00501189|Human Papilloma Virus
1367587|NCT00501189|Papanicolaou Smear
1367588|NCT00501189|ASCUS
1367589|NCT00501189|LGSIL
1367590|NCT00501189|Human Papilloma Virus Vaccine
1367591|NCT00501189|Human Papillomavirus Infection
1367592|NCT00501176|Pancreas
1367593|NCT00501176|cancer
1367594|NCT00501176|SEMS
1367595|NCT00501176|Plastic
1367596|NCT00501176|stent
1367597|NCT00501176|Whipple
1367598|NCT00501176|Jaundicie
1367599|NCT00501163|Schizophrenia
1367600|NCT00501163|Cardiovascular
1367601|NCT00501163|Risk
1367602|NCT00501150|linezolid
1367603|NCT00501150|vancomycin
1367604|NCT00501150|glycopeptides
1367605|NCT00501150|methicillin resistant staphylococcus aureus
1367606|NCT00501150|resistant gram positive infections
1367607|NCT00501137|HPV
1367608|NCT00501137|HPV vaccine
1367609|NCT00501137|Gardasil
1367610|NCT00501137|Human Papillomavirus
1367611|NCT00501137|vaccine
1367612|NCT00501137|2 dose versus 3
1367613|NCT00501111|Dementia
1367614|NCT00501111|Alzheimer Type
1367615|NCT00501111|Alzheimer Disease
1367616|NCT00501098|Leukemia
1367617|NCT00501098|Prophylaxis
1367618|NCT00501098|Fungal Infections
1367619|NCT00501098|Caspofungin
1367620|NCT00501072|hyperglycemia
1367621|NCT00501072|hypoglycemia
1367622|NCT00501072|glucose variability
1367623|NCT00501072|insulin infusion system; implantable insulin pump
1367624|NCT00501072|continuous glucose monitoring
1367625|NCT00501059|Primary prevention of coronary heart disease
1367626|NCT00501059|Stroke and cardiovascular death
1367627|NCT00501059|Aspirin
1367628|NCT00501046|Kidney Diseases
1367629|NCT00501033|Induction of labor
1367630|NCT00501033|Cesarean
1367631|NCT00501033|Endometritis
1367632|NCT00501033|Foley
1367633|NCT00501033|Infections
1367634|NCT00501020|Type 2 Diabetes
1367635|NCT00501020|metformin
1367636|NCT00501020|rosiglitazone
1367647|NCT00500981|Fluid responsiveness
1367648|NCT00500968|Pancreas
1367649|NCT00500968|Leakage
1367650|NCT00500968|Fistula
1367651|NCT00500968|tail
1367652|NCT00500955|microalbuminuria,
1367653|NCT00500955|Type 2 Diabetes
1367654|NCT00500955|rosiglitazone,
1367655|NCT00500942|Interventional Radiology
1367656|NCT00500942|Pain Quantification
1367657|NCT00500942|Pain Management
1367658|NCT00500942|Patient Satisfaction
1367659|NCT00500942|Questionnaire
1367660|NCT00500942|Survey
1367661|NCT00500929|OHSP
1367662|NCT00500929|High risk
1367663|NCT00500929|Geriatrics
1367664|NCT00500903|Advanced malignancies
1367665|NCT00500890|Choroid Plexus Tumors
1367666|NCT00500890|Carboplatin
1367667|NCT00500890|Cyclophosphamide
1367668|NCT00500890|Etoposide
1367669|NCT00500890|Vincristine
1367670|NCT00500890|Paraplatin
1367671|NCT00500890|Cytoxan
1367672|NCT00500890|Neosar
1367673|NCT00500877|Smoking cessation
1367674|NCT00500877|Phone Counseling
1367675|NCT00500864|COPD
1367676|NCT00500864|Magnesium
1367677|NCT00500864|Pulmonary function
1367678|NCT00500864|Exercise Physiology
1367679|NCT00500851|critical illness
1367680|NCT00500851|enteral nutrition
1367681|NCT00500851|gastrointestinal intubation
1367682|NCT00500838|Cardiac Resynchronization Therapy
1367683|NCT00500838|Transthoracic Impedance
1367684|NCT00500825|Cardiopulmonary resuscitation
1367685|NCT00500825|Therapeutic hypothermia
1367686|NCT00500825|resting energy expenditure
1367687|NCT00500812|biologic drug
1367688|NCT00500812|transport sequence
1367689|NCT00500812|rho
1367690|NCT00500812|spinal cord injury
1367691|NCT00500812|paralysis
1367692|NCT00500812|paraplegia
1367693|NCT00500812|tetraplegia
1367694|NCT00500812|quadraplegia
1367695|NCT00500812|trauma
1367696|NCT00500812|nervous system
1367697|NCT00500812|fibrin sealant
1367698|NCT00500812|neurosurgery
1367699|NCT00500799|Transcranial Magnetic Stimulation (TMS)
1367700|NCT00500799|Blink Reflex
1367701|NCT00500799|Blepharospasm
1367702|NCT00500799|Healthy Volunteer
1367703|NCT00500799|HV
1367704|NCT00500773|cardiovascular risc factors
1367705|NCT00500773|inflammation
1367706|NCT00500773|aerobic and exertional exercise
1367707|NCT00500760|Head and Neck Cancer
1367708|NCT00500760|panitumumab
1367709|NCT00500747|hepatitis C, HCV, vaccine, recombinant vaccine, adjuvant
1367715|NCT00500721|healthy subjects
1367716|NCT00500708|Heart failure
1367717|NCT00500708|Implanted Cardioverter Defibrillator
1367718|NCT00500708|Biological Markers
1367719|NCT00500708|Molecular Genetics
1367720|NCT00500682|Kidney Diseases
1367721|NCT00500669|Varicose veins
1367722|NCT00500669|wound infection
1367723|NCT00500669|recurrence
1367724|NCT00500617|Atherosclerosis
1367725|NCT00500617|Biological Markers
1367726|NCT00500617|Molecular Genetics
1367727|NCT00500591|Endometrial Abnormalities
1367728|NCT00500591|Endometrial Cancer
1367729|NCT00500591|Obesity
1367730|NCT00500591|Survey
1367731|NCT00500591|Questionnaire
1367732|NCT00500578|Hematological Malignancies
1367733|NCT00500578|Respiratory Infection
1367734|NCT00500578|Respiratory Syncytial Virus
1367735|NCT00500578|RSV
1367736|NCT00500578|Ribavirin
1367737|NCT00500578|Virazole
1367738|NCT00500565|Breast Cancer
1367739|NCT00500565|On-Q Pain Relief System
1367740|NCT00500565|Transverse Rectus Abdominous Myocutaneous
1367741|NCT00500565|Breast Reconstruction
1367742|NCT00500565|TRAM flap
1367743|NCT00500565|Bupivicaine
1367744|NCT00500565|Pain Management
1367745|NCT00500552|Perhexiline
1367746|NCT00500552|Hypertrophic Cardiomyopathy
1367747|NCT00500539|Asthma
1367748|NCT00500539|omalizumab
1367749|NCT00500539|safety
1367750|NCT00500539|allergic asthma
1367751|NCT00500539|adolescents
1367752|NCT00500526|COPD
1367753|NCT00500526|Pulmonary function
1367754|NCT00500526|Respiratory muscle
1367755|NCT00500526|Dyspnea
1367756|NCT00500526|Quality of life
1367757|NCT00500513|Lung Cancer
1367758|NCT00500513|Respiratory-Induced Tumor Motion
1367759|NCT00500513|Tumor Motion
1367760|NCT00500513|Pulmonary Function
1367761|NCT00500513|Fiducial Marker
1367762|NCT00500487|HIV prevention
1367763|NCT00500487|HIV seronegativity
1367764|NCT00500474|Meniere's disease
1367765|NCT00500474|inner ear
1367766|NCT00500474|endolymphatic sac drainage
1367767|NCT00500474|steroids
1367768|NCT00500474|declined surgery
1367769|NCT00500474|natural course
1367770|NCT00500474|Efficacy of steroids via endolymphatic sac
1367771|NCT00500474|for intractable Meniere's disease
1367772|NCT00500461|Muscarinic Receptor Antagonist,
1367773|NCT00500461|intravenous infusion,
1367774|NCT00500461|pharmacokinetics
1367775|NCT00500461|healthy subjects,
1367776|NCT00500461|safety,
1367777|NCT00500461|tolerability,
1367778|NCT00500461|Anticholinergic,
1367779|NCT00500461|oral dosing,
1367780|NCT00500448|Arthritis, Knee, Quadriceps, Electrical Stimulation, Women
1367781|NCT00500435|Cervical Cancer
1367782|NCT00500435|Laparoscopy
1367783|NCT00500435|Lymph Node Dissection
1367784|NCT00500435|Extraperitoneal Laparoscopic Lymphadenectomy
1367785|NCT00500422|Solid Tumors
1367786|NCT00500422|Doxil
1367787|NCT00500422|Adriamycin
1367788|NCT00500422|Pegylated Liposomal Doxorubicin
1367789|NCT00500422|Liposomal Doxorubicin
1367790|NCT00500422|Doxorubicin Hydrochloride
1367791|NCT00500422|Gemcitabine
1367792|NCT00500422|Gemzar
1367793|NCT00500422|Bortezomib
1367794|NCT00500422|Velcade
1367795|NCT00500422|PS341
1367796|NCT00500422|PS-341
1367797|NCT00500422|LDP-341
1367798|NCT00500422|MLN341
1367799|NCT00500409|rhPTH(1-34)
1367800|NCT00500409|Osteoporosis
1367801|NCT00500396|Retinopathy of Prematurity.
1367802|NCT00500396|ROP.
1367803|NCT00500396|Vascular Endothelial Growth Factor.
1367804|NCT00500396|VEGF.
1367805|NCT00500396|Vitreous.
1367806|NCT00500396|Subretinal Fluid.
1367807|NCT00500396|ELISA.
1367808|NCT00500383|Breast Cancer Risk
1367809|NCT00500383|BRCA1
1367810|NCT00500383|BRCA2
1367811|NCT00500383|Breast Cancer Susceptibility gene
1367812|NCT00500383|Optical Transillumination Spectroscopy
1367813|NCT00500383|Transillumination Breast Spectroscopy
1367814|NCT00500370|exenatide
1367815|NCT00500370|obesity
1367816|NCT00500370|diabetes
1367817|NCT00500370|Amylin
1367818|NCT00500370|Lilly
1367819|NCT00500344|Age-related Macular Degeneration
1367820|NCT00500344|Choroidal Neovascularization
1367821|NCT00500344|Electroretinography
1367822|NCT00500344|Retinal Function
1367823|NCT00500331|Pioglitazone
1367824|NCT00500331|HbA1c
1367825|NCT00500331|Diabetes mellitus
1367826|NCT00500318|Bronchitis, Chronic; Emphysema
1367827|NCT00500305|indomethacin therapy
1367828|NCT00500305|patent ductus arteriosus
1367829|NCT00500292|colorectal
1367830|NCT00500292|cancer
1367831|NCT00500292|zactima
1367832|NCT00500279|Drug-eluting stent
1367833|NCT00500279|Restenosis
1367834|NCT00500279|Celecoxib
1367835|NCT00500266|pneumococcal conjugate vaccine
1367836|NCT00500266|vaccine
1367837|NCT00500253|exhaled nitric oxide
1367838|NCT00500253|asthma
1367839|NCT00500253|children
1367840|NCT00500253|inhaled glucocorticosteroids
1367841|NCT00500240|Acute Lymphocytic Leukemia
1367842|NCT00500240|Leukemia
1367843|NCT00500240|Lymphoma
1367844|NCT00500240|Burkitts Lymphoma
1367845|NCT00500240|Lymphoblastic Leukemia
1367846|NCT00500240|Blood Sugar
1367847|NCT00500240|Hyperglycemia
1367848|NCT00500240|Insulin Aspart
1367849|NCT00500240|Insulin Glargine
1367850|NCT00500240|Hyper-CVAD
1367851|NCT00500214|inguinal hernia
1367852|NCT00500214|herniorrhaphy
1367853|NCT00500214|mesh repair
1367854|NCT00500214|ilioinguinal neurectomy
1367855|NCT00500214|postoperative pain in cases and controls during one year.
1367856|NCT00500214|postoperative hyposthesia in cases and controls during one year.
1367857|NCT00500201|Healthy Volunteer
1367858|NCT00500188|Gastrointestinal Stromal Tumors
1367859|NCT00500188|GIST
1367860|NCT00500188|Kit expression
1367861|NCT00500188|Resectable
1367862|NCT00500188|Imatinib Mesylate
1367863|NCT00500188|Gleevec
1367864|NCT00500188|STI-571
1367865|NCT00500188|Imatinib
1367866|NCT00500188|NSC-716051
1367867|NCT00500175|diabetes
1367868|NCT00500175|ulceration
1367869|NCT00500175|amputation
1367870|NCT00500175|pressure sores
1367871|NCT00500175|shear friction
1367872|NCT00500136|bias
1367873|NCT00500123|alpha-1
1367874|NCT00500123|antitrypsin
1367875|NCT00500123|AAT
1367876|NCT00500123|genetic testing
1367877|NCT00500123|alpha-1 antitrypsin deficiency
1367878|NCT00500123|AATD
1367879|NCT00500110|Prostate Cancer
1367880|NCT00500110|Hormonal Ablation
1367881|NCT00500110|Docetaxel
1367882|NCT00500110|Imatinib Mesylate
1367883|NCT00500110|STI571
1367884|NCT00500110|Gleevec
1367885|NCT00500110|Taxotere
1367886|NCT00500110|Goserelin Acetate
1367887|NCT00500110|Zoladex
1367888|NCT00500110|Leuprolide
1367889|NCT00500110|Lupron
1367890|NCT00500084|Chronic Pancreatitis
1367891|NCT00500084|Pancreatectomy
1367892|NCT00500058|Rituximab,
1367893|NCT00500058|oncology
1367894|NCT00500058|IL-18,
1367895|NCT00500058|combination study,
1367896|NCT00500058|cytokine,
1367897|NCT00500045|CRVO
1367898|NCT00500045|HRVO
1367899|NCT00500045|BRVO
1367900|NCT00500032|Adult
1367901|NCT00499980|Breast cancer
1367902|NCT00499980|Spectroscopy, Near-Infrared
1367903|NCT00499980|Oximetry
1367904|NCT00499967|genital warts
1367905|NCT00499967|venereal warts
1367906|NCT00499967|human papilloma virus
1367907|NCT00499954|microdialysis
1367908|NCT00499954|subcutaneous adipose tissue
1367909|NCT00499954|glucose sensor
1367910|NCT00499954|glucose monitoring
1367911|NCT00499954|type 1 diabetes
1367912|NCT00499954|Guardian RT
1367913|NCT00499954|Glucoday S
1367914|NCT00499941|Alpha 1-Antitrypsin Deficiency
1367915|NCT00499928|SB-751689
1367916|NCT00499928|osteoporosis
1367917|NCT00499928|metabolism
1367918|NCT00499928|excretion
1367919|NCT00499902|AIS
1367920|NCT00499902|acute ischemic stroke
1367921|NCT00499902|stroke
1367922|NCT00499902|alfimeprase
1367923|NCT00499902|blood clot
1367924|NCT00499902|brain
1367925|NCT00499902|thrombus
1367926|NCT00499902|thrombolytic
1367927|NCT00499902|thrombosis
1367928|NCT00499902|plasminogen activator
1367929|NCT00499902|arterial flow
1367930|NCT00499902|neurology
1367931|NCT00499902|intra-arterial
1367932|NCT00499902|intra-thrombus
1367933|NCT00499902|catheter-directed
1367934|NCT00499902|symptomatic ICH
1367935|NCT00499902|ICH
1367936|NCT00499902|AOL
1367937|NCT00499902|arterial occlusive lesion
1367938|NCT00499902|recanalization
1367939|NCT00499889|Chronic Myelogenous Leukemia
1367940|NCT00499889|Allogeneic Stem Cell Transplantation
1367941|NCT00499889|Leukemia
1367942|NCT00499889|Imatinib Mesylate
1367943|NCT00499889|Gleevec
1367944|NCT00499889|Busulfan
1367945|NCT00499889|Busulfex
1367946|NCT00499889|Myleran
1367947|NCT00499889|Fludarabine
1367948|NCT00499889|ATG
1367949|NCT00499889|STI571
1367950|NCT00499889|Antithymocyte Globulin
1367951|NCT00499889|Thymoglobulin
1367952|NCT00499876|Human immune deficiency virus
1367953|NCT00499876|Acquired immune deficiency syndrome
1367954|NCT00499876|malaria
1367955|NCT00499876|mefloquine
1367956|NCT00499876|prophylaxis
1367957|NCT00499876|HIV/AIDS
1367958|NCT00499876|Treatment Naive
1367959|NCT00499850|ZD6474
1367960|NCT00499850|FOLFOX
1367961|NCT00499850|colorectal
1367962|NCT00499850|adenocarcinoma
1367963|NCT00499824|Diabetes
1367964|NCT00499824|Management guidelines
1367965|NCT00499824|Efficacy
1367966|NCT00499798|infertility
1367967|NCT00499798|chemotherapeutic agent toxicity
1367968|NCT00499798|adult anaplastic astrocytoma
1367969|NCT00499798|adult diffuse astrocytoma
1367970|NCT00499798|adult giant cell glioblastoma
1367971|NCT00499798|adult gliosarcoma
1367972|NCT00499798|adult pilocytic astrocytoma
1367973|NCT00499798|adult brain stem glioma
1367974|NCT00499798|adult central nervous system germ cell tumor
1367975|NCT00499798|adult choroid plexus tumor
1367976|NCT00499798|adult craniopharyngioma
1367977|NCT00499798|adult ependymoblastoma
1367978|NCT00499798|adult medulloblastoma
1367979|NCT00499798|adult supratentorial primitive neuroectodermal tumor (PNET)
1367980|NCT00499798|adult anaplastic ependymoma
1367981|NCT00499798|adult ependymoma
1367982|NCT00499798|adult myxopapillary ependymoma
1367983|NCT00499798|adult subependymoma
1367984|NCT00499798|adult anaplastic meningioma
1367985|NCT00499798|meningeal melanocytoma
1367986|NCT00499798|adult meningeal hemangiopericytoma
1367987|NCT00499798|adult papillary meningioma
1367988|NCT00499798|adult grade I meningioma
1367989|NCT00499798|adult grade II meningioma
1367990|NCT00499798|adult grade III meningioma
1367991|NCT00499798|adult anaplastic oligodendroglioma
1367992|NCT00499798|adult oligodendroglioma
1367993|NCT00499798|adult pineoblastoma
1367994|NCT00499798|adult pineocytoma
1367995|NCT00499798|adult mixed glioma
1367996|NCT00499798|recurrent adult brain tumor
1367997|NCT00499798|adult subependymal giant cell astrocytoma
1367998|NCT00499785|depression
1367999|NCT00499785|cognitive/functional effects
1368000|NCT00499785|untreated adult acute myeloid leukemia
1368001|NCT00499785|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1368002|NCT00499785|adult acute myeloid leukemia with inv(16)(p13;q22)
1368003|NCT00499785|adult acute myeloid leukemia with t(15;17)(q22;q12)
1368004|NCT00499785|adult acute myeloid leukemia with t(16;16)(p13;q22)
1368005|NCT00499785|adult acute myeloid leukemia with t(8;21)(q22;q22)
1368006|NCT00499759|fatigue
1368007|NCT00499759|depression
1368008|NCT00499759|psychosocial effects of cancer and its treatment
1368009|NCT00499759|musculoskeletal complications
1368010|NCT00499759|acute undifferentiated leukemia
1368011|NCT00499759|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1368012|NCT00499759|adult acute myeloid leukemia with inv(16)(p13;q22)
1368013|NCT00499759|adult acute myeloid leukemia with t(15;17)(q22;q12)
1368014|NCT00499759|adult acute myeloid leukemia with t(16;16)(p13;q22)
1368015|NCT00499759|adult acute myeloid leukemia with t(8;21)(q22;q22)
1368016|NCT00499759|untreated adult acute lymphoblastic leukemia
1368017|NCT00499759|untreated adult acute myeloid leukemia
1368018|NCT00499759|recurrent adult acute myeloid leukemia
1368019|NCT00499759|secondary acute myeloid leukemia
1368020|NCT00499759|recurrent adult acute lymphoblastic leukemia
1368021|NCT00499746|drug discrimination
1368022|NCT00499746|opioid pharmacology
1368023|NCT00499746|behavioral pharmacology
1368024|NCT00499746|human research
1368025|NCT00499733|carcinoma of unknown primary
1368026|NCT00499733|recurrent carcinoma of unknown primary
1368027|NCT00499733|stage IIIA non-small cell lung cancer
1368028|NCT00499733|stage IIIB non-small cell lung cancer
1368029|NCT00499733|stage IV non-small cell lung cancer
1368030|NCT00499733|recurrent non-small cell lung cancer
1368031|NCT00499733|extensive stage small cell lung cancer
1368032|NCT00499733|recurrent small cell lung cancer
1368033|NCT00499733|stage III renal cell cancer
1368034|NCT00499733|stage IV renal cell cancer
1368035|NCT00499733|recurrent renal cell cancer
1368036|NCT00499733|stage III prostate cancer
1368037|NCT00499733|stage IV prostate cancer
1368038|NCT00499733|recurrent prostate cancer
1368039|NCT00499733|male breast cancer
1368040|NCT00499733|recurrent breast cancer
1368041|NCT00499733|stage IIIA breast cancer
1368042|NCT00499733|stage IIIB breast cancer
1368043|NCT00499733|stage IIIC breast cancer
1368044|NCT00499733|stage IV breast cancer
1368045|NCT00499733|chondrosarcoma
1368046|NCT00499733|metastatic osteosarcoma
1368047|NCT00499733|recurrent osteosarcoma
1368048|NCT00499733|stage III adult soft tissue sarcoma
1368049|NCT00499733|stage IV adult soft tissue sarcoma
1368050|NCT00499733|recurrent adult soft tissue sarcoma
1368051|NCT00499733|previously treated childhood rhabdomyosarcoma
1368052|NCT00499733|recurrent childhood rhabdomyosarcoma
1368053|NCT00499733|metastatic childhood soft tissue sarcoma
1368054|NCT00499733|recurrent childhood soft tissue sarcoma
1368055|NCT00499733|ovarian sarcoma
1368056|NCT00499733|stage III uterine sarcoma
1368057|NCT00499733|stage IV uterine sarcoma
1368058|NCT00499733|recurrent Kaposi sarcoma
1368059|NCT00499733|classic Kaposi sarcoma
1368060|NCT00499733|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1368061|NCT00499733|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1368062|NCT00499733|stage III colon cancer
1368063|NCT00499733|stage IV colon cancer
1368064|NCT00499733|recurrent colon cancer
1368065|NCT00499733|localized unresectable adult primary liver cancer
1368066|NCT00499733|recurrent adult primary liver cancer
1368067|NCT00499733|recurrent childhood liver cancer
1368068|NCT00499733|stage III childhood liver cancer
1368069|NCT00499733|stage IV childhood liver cancer
1368070|NCT00499733|stage III pancreatic cancer
1368071|NCT00499733|localized osteosarcoma
1368072|NCT00499733|malignant giant cell tumor of bone
1368073|NCT00499733|stage IV melanoma
1368074|NCT00499733|recurrent melanoma
1368075|NCT00499733|stage III squamous cell carcinoma of the hypopharynx
1368076|NCT00499733|stage IV squamous cell carcinoma of the hypopharynx
1368077|NCT00499733|recurrent squamous cell carcinoma of the hypopharynx
1368078|NCT00499733|stage III squamous cell carcinoma of the larynx
1368079|NCT00499733|stage III verrucous carcinoma of the larynx
1368080|NCT00499733|stage IV squamous cell carcinoma of the larynx
1368081|NCT00499733|stage IV verrucous carcinoma of the larynx
1368082|NCT00499733|recurrent squamous cell carcinoma of the larynx
1368083|NCT00499733|recurrent verrucous carcinoma of the larynx
1368084|NCT00499733|stage III basal cell carcinoma of the lip
1368085|NCT00499733|stage III squamous cell carcinoma of the lip and oral cavity
1368086|NCT00499733|stage III verrucous carcinoma of the oral cavity
1368087|NCT00499733|stage IV adenoid cystic carcinoma of the oral cavity
1368088|NCT00499733|stage IV squamous cell carcinoma of the lip and oral cavity
1368089|NCT00499733|recurrent adenoid cystic carcinoma of the oral cavity
1368090|NCT00499733|recurrent mucoepidermoid carcinoma of the oral cavity
1368091|NCT00499733|recurrent squamous cell carcinoma of the lip and oral cavity
1368092|NCT00499733|recurrent verrucous carcinoma of the oral cavity
1368093|NCT00499733|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1368094|NCT00499733|recurrent metastatic squamous neck cancer with occult primary
1368095|NCT00499733|untreated metastatic squamous neck cancer with occult primary
1368096|NCT00499733|stage III squamous cell carcinoma of the nasopharynx
1368097|NCT00499733|stage IV squamous cell carcinoma of the nasopharynx
1368098|NCT00499733|recurrent squamous cell carcinoma of the nasopharynx
1368099|NCT00499733|stage III squamous cell carcinoma of the oropharynx
1368100|NCT00499733|stage IV squamous cell carcinoma of the oropharynx
1368101|NCT00499733|recurrent squamous cell carcinoma of the oropharynx
1368102|NCT00499733|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1368103|NCT00499733|stage III inverted papilloma of the paranasal sinus and nasal cavity
1368104|NCT00499733|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1368105|NCT00499733|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1368106|NCT00499733|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1368107|NCT00499733|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1368108|NCT00499733|high-grade salivary gland mucoepidermoid carcinoma
1368109|NCT00499733|salivary gland adenocarcinoma
1368110|NCT00499733|salivary gland adenoid cystic carcinoma
1368111|NCT00499733|salivary gland anaplastic carcinoma
1368112|NCT00499733|salivary gland malignant mixed cell type tumor
1368113|NCT00499733|salivary gland poorly differentiated carcinoma
1368114|NCT00499733|salivary gland squamous cell carcinoma
1368115|NCT00499733|low-grade salivary gland mucoepidermoid carcinoma
1368116|NCT00499733|salivary gland acinic cell tumor
1368117|NCT00499733|stage III salivary gland cancer
1368118|NCT00499733|stage IV salivary gland cancer
1368119|NCT00499733|recurrent salivary gland cancer
1368120|NCT00499733|intraocular lymphoma
1368121|NCT00499733|recurrent childhood lymphoblastic lymphoma
1368122|NCT00499733|recurrent pancreatic cancer
1368123|NCT00499733|recurrent uterine sarcoma
1368124|NCT00499733|newly diagnosed carcinoma of unknown primary
1368125|NCT00499733|advanced adult primary liver cancer
1368126|NCT00499733|ciliary body and choroid melanoma, medium/large size
1368127|NCT00499733|conjunctival melanoma
1368128|NCT00499733|stage IV pancreatic cancer
1368129|NCT00499733|stage IIIA melanoma
1368130|NCT00499733|stage IIIB melanoma
1368131|NCT00499733|stage IIIC melanoma
1368132|NCT00499733|tongue cancer
1368133|NCT00499720|Cystic Fibrosis
1368134|NCT00499720|Pseudomonas aeruginosa
1368135|NCT00499720|airway infection
1368136|NCT00499720|Aztreonam Lysine for Inhalation
1368137|NCT00499707|HbA1c
1368138|NCT00499707|Drug-naive
1368139|NCT00499707|type 2 diabetes
1368140|NCT00499694|stage IV prostate cancer
1368141|NCT00499694|recurrent prostate cancer
1368142|NCT00499694|adenocarcinoma of the prostate
1368143|NCT00499681|stage I breast cancer
1368144|NCT00499681|stage II breast cancer
1368145|NCT00499681|stage IIIA breast cancer
1368146|NCT00499681|stage IIIB breast cancer
1368147|NCT00499668|unspecified adult solid tumor, protocol specific
1368148|NCT00499668|nausea and vomiting
1368149|NCT00499668|chronic myelogenous leukemia
1368150|NCT00499668|chronic eosinophilic leukemia
1368151|NCT00499668|chronic idiopathic myelofibrosis
1368152|NCT00499668|chronic neutrophilic leukemia
1368153|NCT00499668|essential thrombocythemia
1368154|NCT00499668|polycythemia vera
1368155|NCT00499668|adult acute lymphoblastic leukemia
1368156|NCT00499668|adult acute myeloid leukemia
1368157|NCT00499668|acute undifferentiated leukemia
1368158|NCT00499668|mast cell leukemia
1368159|NCT00499668|adult T-cell leukemia/lymphoma
1368160|NCT00499668|T-cell large granular lymphocyte leukemia
1368161|NCT00499668|chronic lymphocytic leukemia
1368162|NCT00499668|hairy cell leukemia
1368163|NCT00499668|prolymphocytic leukemia
1368164|NCT00499668|AIDS-related lymphoma
1368165|NCT00499668|adult Hodgkin lymphoma
1368166|NCT00499668|anaplastic large cell lymphoma
1368167|NCT00499668|angioimmunoblastic T-cell lymphoma
1368168|NCT00499668|cutaneous B-cell non-Hodgkin lymphoma
1368169|NCT00499668|cutaneous T-cell non-Hodgkin lymphoma
1368170|NCT00499668|mycosis fungoides/Sezary syndrome
1368171|NCT00499668|adult grade III lymphomatoid granulomatosis
1368172|NCT00499668|adult nasal type extranodal NK/T-cell lymphoma
1368173|NCT00499668|Waldenstrom macroglobulinemia
1368174|NCT00499668|adult Burkitt lymphoma
1368175|NCT00499668|adult diffuse large cell lymphoma
1368176|NCT00499668|adult diffuse mixed cell lymphoma
1368177|NCT00499668|adult diffuse small cleaved cell lymphoma
1368178|NCT00499668|adult immunoblastic large cell lymphoma
1368179|NCT00499668|adult lymphoblastic lymphoma
1368180|NCT00499668|grade 1 follicular lymphoma
1368181|NCT00499668|grade 2 follicular lymphoma
1368182|NCT00499668|grade 3 follicular lymphoma
1368183|NCT00499668|mantle cell lymphoma
1368184|NCT00499668|marginal zone lymphoma
1368185|NCT00499668|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1368186|NCT00499668|nodal marginal zone B-cell lymphoma
1368187|NCT00499668|splenic marginal zone lymphoma
1368188|NCT00499668|small lymphocytic lymphoma
1368189|NCT00499668|intraocular lymphoma
1368190|NCT00499668|primary central nervous system lymphoma
1368191|NCT00499668|post-transplant lymphoproliferative disorder
1368192|NCT00499668|multiple myeloma and other plasma cell neoplasms
1368193|NCT00499668|myelodysplastic syndromes
1368194|NCT00499668|atypical chronic myeloid leukemia
1368195|NCT00499668|chronic myelomonocytic leukemia
1368196|NCT00499668|myelodysplastic/myeloproliferative disease, unclassifiable
1368197|NCT00499668|chronic myeloproliferative disorders
1368198|NCT00499668|myelodysplastic/myeloproliferative diseases
1368199|NCT00499642|Healthy Subjects
1368200|NCT00499629|healthy subjects
1368201|NCT00499616|regional neuroblastoma
1368202|NCT00499616|disseminated neuroblastoma
1368203|NCT00499616|stage 4S neuroblastoma
1368204|NCT00499616|localized unresectable neuroblastoma
1368205|NCT00499616|localized resectable neuroblastoma
1368206|NCT00499603|Breast Cancer
1368207|NCT00499603|ER negative
1368208|NCT00499603|PR negative
1368209|NCT00499603|HER2neu negative
1368210|NCT00499603|Tumor Triple Negative Receptors
1368211|NCT00499603|Paclitaxel
1368212|NCT00499603|Taxol
1368213|NCT00499603|RAD001
1368214|NCT00499603|FEC
1368215|NCT00499603|5-Fluorouracil
1368216|NCT00499603|5-FU
1368217|NCT00499603|Adrucil
1368218|NCT00499603|Efudex
1368219|NCT00499603|Epirubicin
1368220|NCT00499603|Cyclophosphamide
1368221|NCT00499590|AMD
1368222|NCT00499590|Macular Degeneration
1368223|NCT00499590|bevasiranib
1368224|NCT00499590|COBALT study
1368225|NCT00499590|age related macular degeneration
1368226|NCT00499590|wet AMD
1368227|NCT00499590|wet age related macular degeneration
1368228|NCT00499577|stage I multiple myeloma
1368229|NCT00499577|stage II multiple myeloma
1368230|NCT00499577|stage III multiple myeloma
1368231|NCT00499577|refractory multiple myeloma
1368232|NCT00499551|Anterior Uveitis
1368233|NCT00499551|Posterior Uveitis
1368234|NCT00499551|Intermediate Uveitis
1368235|NCT00499551|Panuveitis
1368236|NCT00499551|Iontophoresis
1368237|NCT00499551|Dexamethasone
1368238|NCT00499538|healthy subjects
1368239|NCT00499525|male breast cancer
1368240|NCT00499525|recurrent breast cancer
1368241|NCT00499525|stage IIIB breast cancer
1368242|NCT00499525|stage IIIC breast cancer
1368243|NCT00499525|stage IV breast cancer
1368244|NCT00499525|stage IIIA breast cancer
1368245|NCT00499512|Ovarian Cancer
1368246|NCT00499512|Peritoneal Cancer
1368247|NCT00499512|Fallopian Tube Cancer
1368248|NCT00499512|Spirituality
1368249|NCT00499512|Religion
1368250|NCT00499512|Quality of Life
1368251|NCT00499512|Questionnaire
1368252|NCT00499512|Survey
1368253|NCT00499499|Cancer
1368254|NCT00499499|solid tumors
1368255|NCT00499486|recurrent pancreatic cancer
1368256|NCT00499486|stage III pancreatic cancer
1368257|NCT00499486|stage IV pancreatic cancer
1368258|NCT00499486|adenocarcinoma of the pancreas
1368259|NCT00499460|Healthy, No Evidence of Disease
1368260|NCT00499447|stage I non-small cell lung cancer
1368261|NCT00499447|adenocarcinoma of the lung
1368262|NCT00499447|adenosquamous cell lung cancer
1368263|NCT00499447|large cell lung cancer
1368264|NCT00499447|squamous cell lung cancer
1368265|NCT00499434|aids
1368266|NCT00499421|Prostate Cancer
1368267|NCT00499421|External Beam Radiation Therapy
1368268|NCT00499421|Fiducial Markers
1368269|NCT00499421|Acculoc System
1368270|NCT00499421|Center Of Mass
1368271|NCT00499421|EBRT
1368272|NCT00499408|adenocarcinoma of the prostate
1368273|NCT00499408|stage I prostate cancer
1368274|NCT00499408|stage II prostate cancer
1368275|NCT00499408|stage III prostate cancer
1368276|NCT00499395|stage IV colon cancer
1368277|NCT00499395|stage IV rectal cancer
1368278|NCT00499395|recurrent colon cancer
1368279|NCT00499395|recurrent rectal cancer
1368280|NCT00499395|liver metastases
1368281|NCT00499382|Advanced Cancers
1368282|NCT00499382|Cardiac Function
1368283|NCT00499382|Nuclear Medicine Cardiac Scan
1368284|NCT00499382|Positron Emission Tomography
1368285|NCT00499382|Radionuclide Ventriculography
1368286|NCT00499382|Ventricular Ejection Fraction
1368287|NCT00499382|PET/CT
1368288|NCT00499382|RNV
1368289|NCT00499356|friction
1368290|NCT00499356|pressure
1368291|NCT00499356|insole
1368292|NCT00499356|ulcer
1368293|NCT00499356|prevention
1368294|NCT00499343|Non-Hodgkin's Lymphoma
1368295|NCT00499343|Lymphoma
1368296|NCT00499343|Etoposide
1368297|NCT00499343|G-CSF
1368298|NCT00499343|GM-CSF
1368299|NCT00499343|Isophosphamide
1368300|NCT00499343|Rituximab
1368301|NCT00499343|Ifosfamide
1368302|NCT00499343|Sargramostim
1368303|NCT00499343|Leukine
1368304|NCT00499343|Filgrastim
1368305|NCT00499343|Neupogen
1368306|NCT00499343|Apheresis
1368307|NCT00499343|Stem Cell Collection
1368308|NCT00499330|stage IA non-small cell lung cancer
1368309|NCT00499330|adenocarcinoma of the lung
1368310|NCT00499330|squamous cell lung cancer
1368311|NCT00499330|large cell lung cancer
1368312|NCT00499330|adenosquamous cell lung cancer
1368313|NCT00499330|bronchoalveolar cell lung cancer
1368314|NCT00499317|Urgency
1368315|NCT00499317|Frequency
1368316|NCT00499317|Pelvic pain
1368317|NCT00499317|Sexual dysfunction
1368318|NCT00499317|Erectile dysfunction
1368319|NCT00499317|Painful intercourse
1368320|NCT00499304|Forced oscillation Technique (FOT)
1368321|NCT00499304|Expiratory flow limitation (EFL)
1368322|NCT00499304|Breathing artifacts
1368323|NCT00499304|COPD
1368324|NCT00499291|unspecified adult solid tumor, protocol specific
1368325|NCT00499291|recurrent breast cancer
1368326|NCT00499291|stage IIIA breast cancer
1368327|NCT00499291|stage IIIB breast cancer
1368328|NCT00499291|stage IIIC breast cancer
1368329|NCT00499291|recurrent prostate cancer
1368330|NCT00499291|stage III prostate cancer
1368331|NCT00499291|stage IV prostate cancer
1368332|NCT00499291|recurrent non-small cell lung cancer
1368333|NCT00499291|stage IIIA non-small cell lung cancer
1368334|NCT00499291|stage IIIB non-small cell lung cancer
1368335|NCT00499291|stage IV non-small cell lung cancer
1368336|NCT00499291|extensive stage small cell lung cancer
1368337|NCT00499291|recurrent small cell lung cancer
1368338|NCT00499291|recurrent bladder cancer
1368339|NCT00499291|stage III bladder cancer
1368340|NCT00499291|stage IV bladder cancer
1368341|NCT00499291|recurrent renal cell cancer
1368342|NCT00499291|stage III renal cell cancer
1368343|NCT00499291|stage IV renal cell cancer
1368344|NCT00499291|clear cell sarcoma of the kidney
1368345|NCT00499291|rhabdoid tumor of the kidney
1368346|NCT00499291|recurrent malignant testicular germ cell tumor
1368347|NCT00499291|stage III malignant testicular germ cell tumor
1368348|NCT00499291|recurrent cervical cancer
1368349|NCT00499291|stage III cervical cancer
1368350|NCT00499291|stage IVA cervical cancer
1368351|NCT00499291|stage IVB cervical cancer
1368352|NCT00499291|recurrent endometrial carcinoma
1368353|NCT00499291|stage III endometrial carcinoma
1368354|NCT00499291|stage IV endometrial carcinoma
1368355|NCT00499291|fallopian tube cancer
1368356|NCT00499291|recurrent ovarian epithelial cancer
1368357|NCT00499291|stage III ovarian epithelial cancer
1368358|NCT00499291|stage IV ovarian epithelial cancer
1368359|NCT00499291|recurrent ovarian germ cell tumor
1368360|NCT00499291|stage III ovarian germ cell tumor
1368361|NCT00499291|stage IV ovarian germ cell tumor
1368362|NCT00499291|ovarian sarcoma
1368363|NCT00499291|ovarian stromal cancer
1368364|NCT00499291|recurrent uterine sarcoma
1368365|NCT00499291|stage III uterine sarcoma
1368366|NCT00499291|stage IV uterine sarcoma
1368367|NCT00499291|recurrent hypopharyngeal cancer
1368368|NCT00499291|stage III hypopharyngeal cancer
1368369|NCT00499291|stage IV hypopharyngeal cancer
1368370|NCT00499291|recurrent laryngeal cancer
1368371|NCT00499291|stage III laryngeal cancer
1368372|NCT00499291|stage IV laryngeal cancer
1368373|NCT00499291|recurrent lip and oral cavity cancer
1368374|NCT00499291|stage III lip and oral cavity cancer
1368375|NCT00499291|stage IV lip and oral cavity cancer
1368376|NCT00499291|recurrent metastatic squamous neck cancer with occult primary
1368377|NCT00499291|untreated metastatic squamous neck cancer with occult primary
1368378|NCT00499291|recurrent nasopharyngeal cancer
1368379|NCT00499291|stage III nasopharyngeal cancer
1368380|NCT00499291|stage IV nasopharyngeal cancer
1368381|NCT00499291|recurrent oropharyngeal cancer
1368382|NCT00499291|stage III oropharyngeal cancer
1368383|NCT00499291|stage IV oropharyngeal cancer
1368384|NCT00499291|recurrent paranasal sinus and nasal cavity cancer
1368385|NCT00499291|stage III paranasal sinus and nasal cavity cancer
1368386|NCT00499291|stage IV paranasal sinus and nasal cavity cancer
1368387|NCT00499291|recurrent salivary gland cancer
1368388|NCT00499291|stage III salivary gland cancer
1368389|NCT00499291|stage IV salivary gland cancer
1368390|NCT00499291|recurrent esophageal cancer
1368391|NCT00499291|stage III esophageal cancer
1368392|NCT00499291|stage IV esophageal cancer
1368393|NCT00499291|recurrent gastric cancer
1368394|NCT00499291|stage III gastric cancer
1368395|NCT00499291|stage IV gastric cancer
1368396|NCT00499291|adult central nervous system germ cell tumor
1368397|NCT00499291|adult teratoma
1368398|NCT00499291|ovarian teratoma
1368399|NCT00499291|testicular teratoma
1368400|NCT00499291|recurrent adult soft tissue sarcoma
1368401|NCT00499291|stage III adult soft tissue sarcoma
1368402|NCT00499291|stage IV adult soft tissue sarcoma
1368403|NCT00499291|recurrent carcinoma of unknown primary
1368404|NCT00499278|Osteoarthritis
1368405|NCT00499278|joint
1368406|NCT00499278|knee
1368407|NCT00499278|hip
1368408|NCT00499278|surgery
1368409|NCT00499265|recurrent pancreatic cancer
1368410|NCT00499265|stage III pancreatic cancer
1368411|NCT00499265|adenocarcinoma of the pancreas
1368412|NCT00499239|Hematologic Malignancies
1368413|NCT00499239|CLL
1368414|NCT00499239|NHL
1368415|NCT00499239|Chronic Lymphocytic Leukemia
1368416|NCT00499239|Non-Hodgkin's Lymphoma
1368417|NCT00499239|CLL and NHL
1368418|NCT00499239|Multiple Myeloma
1368419|NCT00499239|MM
1368420|NCT00499187|Fanconi
1368421|NCT00499187|Kidney
1368422|NCT00499187|Renal
1368423|NCT00499187|HIV
1368424|NCT00499187|HIV-1
1368425|NCT00499187|Treatment Experienced
1368426|NCT00499174|stage II prostate cancer
1368427|NCT00499174|adenocarcinoma of the prostate
1368428|NCT00499161|Individualized care
1368429|NCT00499161|Relationship based care
1368430|NCT00499161|Negotiated care
1368431|NCT00499161|Patient focused care
1368432|NCT00499122|stage II breast cancer
1368433|NCT00499122|stage IIIC breast cancer
1368434|NCT00499122|inflammatory breast cancer
1368435|NCT00499109|RRM1
1368436|NCT00499109|ERCC1
1368437|NCT00499109|Customized Chemotherapy
1368438|NCT00499096|Chronic Illness
1368439|NCT00499096|Disease management
1368440|NCT00499096|Health Behaviors
1368441|NCT00499096|Mood Disorders-Bipolar
1368442|NCT00499083|stage II breast cancer
1368443|NCT00499083|stage IIIA breast cancer
1368444|NCT00499083|stage IIIB breast cancer
1368445|NCT00499083|stage IIIC breast cancer
1368446|NCT00499070|refractory cytopenia with multilineage dysplasia
1368447|NCT00499070|aplastic anemia
1368448|NCT00499070|Fanconi anemia
1368449|NCT00499070|dyskeratosis congenita
1368450|NCT00499070|Shwachman-Diamond syndrome
1368451|NCT00499070|Pearson marrow-pancreas syndrome
1368452|NCT00499057|early stage breast cancer
1368453|NCT00499044|cognition
1368454|NCT00499044|attention
1368455|NCT00499044|memory
1368456|NCT00499044|concentration
1368457|NCT00499044|schizophrenia
1368458|NCT00499018|Large B-Cell Lymphoma
1368459|NCT00499018|Rituximab
1368460|NCT00499018|Autologous Stem Cell Transplantation
1368461|NCT00498992|dermatologic complications
1368462|NCT00498992|unspecified adult solid tumor, protocol specific
1368463|NCT00498979|stage IV melanoma
1368464|NCT00498979|adult anaplastic astrocytoma
1368465|NCT00498979|adult diffuse astrocytoma
1368466|NCT00498979|adult glioblastoma
1368467|NCT00498979|adult giant cell glioblastoma
1368468|NCT00498979|adult pilocytic astrocytoma
1368469|NCT00498979|adult brain stem glioma
1368470|NCT00498979|adult anaplastic ependymoma
1368471|NCT00498979|adult ependymoma
1368472|NCT00498979|adult myxopapillary ependymoma
1368473|NCT00498979|adult subependymoma
1368474|NCT00498979|adult anaplastic oligodendroglioma
1368475|NCT00498979|adult oligodendroglioma
1368476|NCT00498979|mixed gliomas
1368477|NCT00498979|recurrent adult brain tumor
1368478|NCT00498979|recurrent melanoma
1368479|NCT00498979|adult gliosarcoma
1368480|NCT00498979|adult subependymal giant cell astrocytoma
1368481|NCT00498979|adult pineal gland astrocytoma
1368482|NCT00498966|Kidney
1368483|NCT00498966|perifosine
1368484|NCT00498966|Progression on treatment with sunitinib or sorafenib
1368485|NCT00498953|stage II squamous cell carcinoma of the hypopharynx
1368486|NCT00498953|stage III squamous cell carcinoma of the hypopharynx
1368487|NCT00498953|stage IV squamous cell carcinoma of the hypopharynx
1368488|NCT00498953|stage III squamous cell carcinoma of the larynx
1368489|NCT00498953|stage IV squamous cell carcinoma of the larynx
1368490|NCT00498940|LV function, Compliance, wall motion, echocardiography
1368491|NCT00498927|recurrent adult brain tumor
1368492|NCT00498927|adult giant cell glioblastoma
1368493|NCT00498927|adult glioblastoma
1368494|NCT00498927|adult gliosarcoma
1368495|NCT00498927|adult anaplastic astrocytoma
1368496|NCT00498927|adult diffuse astrocytoma
1368497|NCT00498927|adult pilocytic astrocytoma
1368498|NCT00498927|adult subependymal giant cell astrocytoma
1368499|NCT00498927|adult anaplastic ependymoma
1368500|NCT00498927|adult ependymoma
1368501|NCT00498927|adult myxopapillary ependymoma
1368502|NCT00498927|adult subependymoma
1368503|NCT00498927|adult anaplastic oligodendroglioma
1368504|NCT00498927|adult oligodendroglioma
1368505|NCT00498927|adult brain stem glioma
1368506|NCT00498927|adult mixed glioma
1368507|NCT00498927|adult pineal gland astrocytoma
1368508|NCT00498914|Lymphoma, Large-Cell, Diffuse
1368509|NCT00498914|Lymphoma, B-Cell
1368510|NCT00498914|YM155
1368511|NCT00498914|Treatment outcomes
1368512|NCT00498914|Refractory
1368513|NCT00498901|stage IV breast cancer
1368514|NCT00498901|recurrent breast cancer
1368515|NCT00498888|urge urinary incontinence
1368516|NCT00498888|rehabilitation
1368517|NCT00498888|anticholinergic
1368518|NCT00498875|Oropharyngeal Cancer
1368519|NCT00498875|Head and Neck Cancer
1368520|NCT00498875|Depression
1368521|NCT00498875|Questionnaire
1368522|NCT00498875|Survey
1368523|NCT00498875|Interview
1368524|NCT00498849|Sleep apnea
1368525|NCT00498849|Continuous positive airway pressure
1368526|NCT00498849|Microarray
1368527|NCT00498849|Polysomnography
1368528|NCT00498836|CP-4055
1368529|NCT00498836|Elacyt
1368530|NCT00498836|Cancer
1368531|NCT00498836|Metastatic
1368532|NCT00498836|Malignant melanoma
1368533|NCT00498836|Combination treatment
1368534|NCT00498836|Sorafenib
1368535|NCT00498836|Nexavar
1368536|NCT00498797|prostate cancer
1368537|NCT00498797|zactima
1368538|NCT00498797|vandetanib
1368539|NCT00498797|metastatic
1368540|NCT00498784|Intra-uterine contraception
1368541|NCT00498784|Intrauterine Devices
1368542|NCT00498771|Lymphedema
1368543|NCT00498771|Aquatic Exercise
1368544|NCT00498771|Breast Cancer
1368545|NCT00498758|Parkinson's disease
1368546|NCT00498758|Gait Disturbances
1368547|NCT00498758|Mobility
1368548|NCT00498758|Quality of life
1368549|NCT00497757|Marrow/hematopoietic stem cell transplant
1368550|NCT00497744|CAPD peritonitis
1368551|NCT00497744|Peritoneal Dialysis, Continuous Ambulatory
1368552|NCT00497731|Advanced solid tumors
1368553|NCT00498732|Obstructive sleep apnea syndrome; CPAP, microarray
1368554|NCT00498719|Leukemia
1368555|NCT00498719|Lymphoma
1368556|NCT00498719|Brain Tumor
1368557|NCT00498719|Attention Deficit
1368558|NCT00498719|Cognitive Training Program
1368559|NCT00498719|Central Nervous System
1368560|NCT00498719|CNS
1368561|NCT00498719|CTP
1368562|NCT00498706|Depressive Disorder, Major
1368563|NCT00498706|Cognitive Behavioral Therapy
1368564|NCT00498706|Psychotherapy
1368565|NCT00498706|Telemedicine
1368566|NCT00498706|Primary Care
1368567|NCT00498680|Erectile Dysfunction
1368568|NCT00498680|Treatment
1368569|NCT00498680|PDE5i
1368570|NCT00498667|PET/CT
1368571|NCT00498667|Aggressive non-Hodgkin Lymphoma
1368572|NCT00498654|Prevention of Typhoid Fever in Adult Travelers
1368573|NCT00498641|perceptual learning
1368574|NCT00498641|occlusion therapy
1368575|NCT00498628|Alcoholism
1368576|NCT00498628|Alcohol dependence
1368577|NCT00498628|Quetiapine
1368578|NCT00498615|scleroderma
1368579|NCT00498615|Raynaud's phenomenon
1368580|NCT00498615|Rho-kinase inhibitor
1368581|NCT00498576|hypertension
1368582|NCT00498576|kidney transplant
1368583|NCT00498576|melatonin
1368584|NCT00498576|adiponectin
1368585|NCT00498563|high altitude
1368586|NCT00498563|sleep
1368587|NCT00498563|altitude illness
1368588|NCT00498563|neurobehavioral manifestations
1368589|NCT00498563|psychomotor performance
1368590|NCT00498563|mood states
1368591|NCT00498550|Clozapine
1368592|NCT00498550|Schizophrenia
1368593|NCT00498550|Dual Diagnosis
1368594|NCT00498550|Substance Abuse
1368595|NCT00498550|Cannabis Abuse
1368596|NCT00498537|spironolactone
1368597|NCT00498537|aldosterone
1368598|NCT00498537|diabetic nephropathy
1368599|NCT00498537|proteinuria
1368600|NCT00498537|hyperkalemia
1368601|NCT00498537|albuminuria
1368602|NCT00498537|renal failure
1368603|NCT00498524|implantable cardioverter-defibrillator
1368604|NCT00498524|ischemic cardiomyopathy
1368605|NCT00498524|ventricular arrhythmias
1368606|NCT00498524|sibling concordance
1368607|NCT00498511|Anemia, Iron-Deficiency
1368608|NCT00498511|Endoscopy, Gastrointestinal
1368609|NCT00498511|Male, aged 18 to 40
1368610|NCT00498498|severe head injury
1368611|NCT00498498|Endothelin
1368612|NCT00498498|CSF
1368613|NCT00498498|Plasma
1368614|NCT00498498|Cellular Apoptosis
1368615|NCT00498485|chronic
1368616|NCT00498485|fatigue
1368617|NCT00498485|pain
1368618|NCT00498485|sleep
1368619|NCT00498485|xyrem
1368620|NCT00498485|must have chronic fatigue syndrome
1368621|NCT00498485|no hypertension
1368622|NCT00498485|no sleep apnea
1368623|NCT00498472|BNP
1368624|NCT00498472|heart failure
1368625|NCT00498459|Physical activity
1368626|NCT00498459|Randomised trial
1368627|NCT00498459|Prevention
1368628|NCT00498459|Adolescents
1368629|NCT00498459|Obesity
1368630|NCT00498459|Cardiovascular risk factors
1368631|NCT00498433|Aliskiren
1368632|NCT00498433|Renin-Angiotensin System (RAS)
1368633|NCT00498433|Hypertension
1368634|NCT00498433|Abdominal obesity
1368635|NCT00498420|HUE-MAN
1368636|NCT00498420|Rare disorder
1368637|NCT00498420|Hepatosplenomegaly
1368638|NCT00498420|Dysostosis
1368639|NCT00498407|CP-4055
1368640|NCT00498407|ELACYT(TM)
1368641|NCT00498407|Cancer
1368642|NCT00498407|Colorectal cancer
1368643|NCT00498407|CRC
1368644|NCT00498407|Second line therapy
1368645|NCT00498394|Obesity
1368646|NCT00498394|Weight loss
1368647|NCT00498394|Diet fads
1368648|NCT00498368|Estimated glomerular filtration rate (GFR)
1368649|NCT00498368|Proteinuria
1368650|NCT00498368|Renal Fibrosis
1368651|NCT00498355|uveitis
1368652|NCT00498355|cytoid macular edema
1368653|NCT00498355|steroid
1368654|NCT00498355|Lucentis
1368655|NCT00498329|fMRI
1368656|NCT00498329|Electroencephalogram (EEG)
1368657|NCT00498329|Attention
1368658|NCT00498329|Sensorimotor Integration
1368659|NCT00498329|Human Brain
1368660|NCT00498329|Healthy Volunteer
1368661|NCT00498329|HV
1368662|NCT00498316|Myelodysplastic Syndrome
1368663|NCT00498316|Leukemia
1368664|NCT00498316|Cord Blood Expansion
1368665|NCT00498316|Umbilical Cord Blood
1368666|NCT00498316|Mesenchymal Stem Cells
1368667|NCT00498316|Acute Myelogenous Leukemia
1368668|NCT00498316|Acute Lymphoblastic Leukemia
1368669|NCT00498316|ALL
1368670|NCT00498316|AML
1368671|NCT00498316|MDS
1368672|NCT00498303|influenza vaccine
1368673|NCT00498290|Enhanced Recovery After Surgery Protocol(ERAS)
1368674|NCT00498290|Colorectal Surgery
1368675|NCT00498277|Osteoporosis
1368676|NCT00498277|Magnetic Resonance Imaging
1368677|NCT00498277|Vertebral Fractures
1368678|NCT00498277|Quantitative Diffusion
1368679|NCT00498277|Fat Imaging
1368680|NCT00498277|Spine
1368681|NCT00498264|Exercise
1368682|NCT00498264|Rehabilitation
1368683|NCT00498264|Strength exercise
1368684|NCT00498264|Aerobic exercise
1368685|NCT00498264|Pain
1368686|NCT00498251|lung injury, acute
1368687|NCT00498251|thoracic surgical procedures
1368688|NCT00498251|lung cancer
1368689|NCT00498251|salbutamol
1368690|NCT00498238|Arterial stiffness, Augmentation index, Subclinical Hypothyroidism
1368691|NCT00498225|Pancreatic Cancer
1368692|NCT00498212|Heplisav
1368693|NCT00498212|Hepatitis B
1368694|NCT00498212|Hepatitis
1368695|NCT00498212|HBV
1368696|NCT00498212|Hepatitis B vaccine
1368697|NCT00498212|kidney disease
1368698|NCT00498212|renal disease
1368699|NCT00498212|kidney failure
1368700|NCT00498212|renal failure
1368701|NCT00498199|Multiples sclerosis
1368702|NCT00498199|oscillopsia
1368703|NCT00498199|eye movements
1368704|NCT00498199|motion detection
1368705|NCT00498199|retinal slip
1368706|NCT00498199|nystagmus
1368707|NCT00498186|Rotigotine
1368708|NCT00498186|Neupro®
1368709|NCT00498173|Autistic Disorder
1368710|NCT00498173|Autism Spectrum Disorder
1368711|NCT00498160|Kidney transplant
1368712|NCT00498160|Tolerance
1368713|NCT00498160|Marrow/stem cell transplant
1368714|NCT00498147|amputation
1368715|NCT00498147|angina
1368716|NCT00498147|angiography
1368717|NCT00498147|angioplasty
1368718|NCT00498147|arterial disease
1368719|NCT00498147|artery disease
1368720|NCT00498147|bypass
1368721|NCT00498147|CABG
1368722|NCT00498147|cad
1368723|NCT00498147|carotid
1368724|NCT00498147|cerebral accident
1368725|NCT00498147|CHF
1368726|NCT00498147|CRF
1368727|NCT00498147|CVA
1368728|NCT00498147|endarterectomy
1368729|NCT00498147|heart attack
1368730|NCT00498147|heart failure
1368731|NCT00498147|infarct
1368732|NCT00498147|kidney disease
1368733|NCT00498147|kidney failure
1368734|NCT00498147|laser
1368735|NCT00498147|nephropathy
1368736|NCT00498147|neuropathy
1368737|NCT00498147|pad
1368738|NCT00498147|PCI
1368739|NCT00498147|percutaneous coronary
1368740|NCT00498147|percutaneous transluminal
1368741|NCT00498147|pvd
1368742|NCT00498147|renal failure
1368743|NCT00498147|retinopathy
1368744|NCT00498147|revascularization
1368745|NCT00498147|schemia
1368746|NCT00498147|stenosis
1368747|NCT00498147|stent
1368748|NCT00498147|stroke
1368749|NCT00498147|transient
1368750|NCT00498147|ulcer
1368751|NCT00498147|vascular disease
1368752|NCT00498134|Gastric cancer
1368753|NCT00498121|Ventilator associated pneumonia.
1368754|NCT00498121|Procalcitonin.
1368755|NCT00498108|Rotigotine
1368756|NCT00498108|Restless Legs Syndrome
1368757|NCT00498095|Delayed renal graft function
1368758|NCT00498095|Acute renal allograft dysfunction
1368759|NCT00498069|Critical limb ischemia due to peripheral arterial occlusive disease
1368760|NCT00498069|Autologous bone marrow concentrate
1368761|NCT00498056|HIV Seronegativity
1368762|NCT00498056|HIV Preventive Vaccine
1368763|NCT00498043|Lymphoma
1368764|NCT00498043|PET
1368765|NCT00498043|Chemotherapy
1368766|NCT00498043|Rituximab
1368767|NCT00498030|Insulin Resistance
1368768|NCT00498030|Stress, Psychological
1368769|NCT00498017|Infections
1368770|NCT00498004|Quality of Life
1368771|NCT00498004|Schizophrenia
1368772|NCT00498004|Quetiapine
1368773|NCT00498004|Risperidone
1368774|NCT00497991|AML
1368775|NCT00497991|phase I/II
1368776|NCT00497991|AZD1152
1368777|NCT00497991|Acute Myeloid Leukaemia
1368778|NCT00497965|Balance
1368779|NCT00497965|Chiropractic
1368780|NCT00497965|Older Adults
1368781|NCT00497952|Relapsing-remitting multiple sclerosis
1368782|NCT00497952|Marrow/Stem cell transplant
1368783|NCT00497939|Benign Prostatic Hyperplasia (BPH)
1368784|NCT00497939|Currently on alpha blocker
1368785|NCT00497926|Kidney transplant
1368786|NCT00497926|Tolerance
1368787|NCT00497926|Marrow/Enriched Hematopoetic Stem Cell Transplant
1368788|NCT00497913|Tennis Elbow
1368789|NCT00497913|Botulinum Toxin
1368790|NCT00497874|depression
1368791|NCT00497874|stage of change
1368792|NCT00497874|intervention
1368793|NCT00497874|randomized clinical trial
1368794|NCT00497874|population-based
1368795|NCT00497874|expert system
1368796|NCT00497861|Low back pain
1368797|NCT00497861|Chiropractic
1368798|NCT00497861|Spinal manipulation
1368799|NCT00497861|Activator Methods Chiropractic Technique
1368800|NCT00497835|motor seizures
1368801|NCT00497835|accelerometer
1368802|NCT00497835|algorithm
1368803|NCT00497835|detection
1368804|NCT00497835|alert
1368805|NCT00497822|Dementia
1368806|NCT00497809|Breast Cancer
1368807|NCT00497809|Neutropenia
1368808|NCT00497809|Chemotherapy
1368809|NCT00497809|High risk
1368810|NCT00497796|cytomegalovirus
1368811|NCT00497796|CMV
1368812|NCT00497796|prophylaxis
1368813|NCT00497796|liver
1368814|NCT00497796|liver transplant
1368815|NCT00497705|Ebsteins Anomaly
1368816|NCT00497705|Heart Septal Defects, Ventricle
1368817|NCT00497705|Heart Defects, Congenital
1368818|NCT00497705|Double Outlet Right Ventricle
1368819|NCT00497705|Truncus Arteriosus Persistant
1368820|NCT00497705|Ebstein's Anomaly
1368821|NCT00497705|Congenital Heart Disease
1368822|NCT00497705|Heart Defects
1368823|NCT00497679|advanced solid tumours
1368824|NCT00497666|Diabetes
1368825|NCT00497666|Diabetic nephropathy
1368826|NCT00497666|renal protection
1368827|NCT00497640|sleep apnea, titration, CPAP, neural network
1368828|NCT00497614|Rheumatoid arthritis
1368829|NCT00497614|Positron emission tomodensitometry
1368830|NCT00497614|Tumor necrosis factor alpha inhibitor
1368831|NCT00497601|Visceral Leishmaniasis
1368832|NCT00497601|Amphotericin B
1368833|NCT00497601|Fat emulsion
1368834|NCT00497588|laryngeal cancer
1368835|NCT00497588|RADIOTHERAPY
1368836|NCT00497588|Voice Quality
1368837|NCT00497575|Congenital Hypothyroidism
1368838|NCT00497575|diagnosis
1368839|NCT00497575|L-thyroxine
1368840|NCT00497575|newborn screening
1368841|NCT00497562|Fibromyalgia
1368842|NCT00497562|growth hormone
1368843|NCT00497562|IGF-1
1368844|NCT00497562|FIQ
1368845|NCT00497549|Esophagectomy
1368846|NCT00497549|hand sewn anastomosis
1368847|NCT00497549|side-to-side stapled
1368848|NCT00497536|Type 1 Diabetes Mellitus
1368849|NCT00497536|Continuous Subcutaneous Insulin Infusion (CSII)
1368850|NCT00497523|Asthma
1368851|NCT00497523|Young Children
1368852|NCT00497523|Corticosteroids
1368853|NCT00497523|Beclomethasone
1368854|NCT00497523|Salbutamol
1368855|NCT00497523|Beclomethasone/Salbutamol fixed combination
1368856|NCT00497523|Suspension for nebulisation
1368857|NCT00497510|Balance
1368858|NCT00497510|Chiropractic
1368859|NCT00497510|Older Adults
1368860|NCT00497497|CRC
1368861|NCT00497497|Colon cancer
1368862|NCT00497497|Avastin
1368863|NCT00497497|APM4187g
1368864|NCT00497471|Plasmodium Falciparum
1368865|NCT00497471|Antimlarial chemoprophylaxis
1368866|NCT00497471|Iron supplementation
1368867|NCT00497471|Tanzania
1368868|NCT00497458|breast
1368869|NCT00497458|neoplasms
1368870|NCT00497458|anastrazole
1368871|NCT00497458|testosterone
1368872|NCT00497445|Peripheral arterial disease
1368873|NCT00497445|Exercise therapy
1368874|NCT00497445|Angioplasty
1368875|NCT00497445|Bypass surgery
1368876|NCT00497432|Hyperbaric Oxygen
1368877|NCT00497419|STEMI
1368878|NCT00497419|ST elevation myocardial infarction
1368879|NCT00497406|submandibular salivary gland transfer
1369008|NCT00496951|Vagal tone
1368880|NCT00497406|intensity-modulated radiation therapy
1368881|NCT00497406|helical tomotherapy
1368882|NCT00497406|reduction of xerostomia
1368883|NCT00497393|Emergency department, administration, overcrowding
1368884|NCT00497367|safety
1368885|NCT00497367|feasibility
1368886|NCT00497367|bifurcation
1368887|NCT00497367|lesion
1368888|NCT00497367|de novo
1368889|NCT00497367|intervention
1368890|NCT00497354|Ultrasound, Complications, Regional Anesthesia
1368891|NCT00497341|infection after total knee arthroplasty
1368892|NCT00497328|contrast induced nephropathy
1368893|NCT00497315|Non-Small Cell Lung Cancer
1368894|NCT00497315|NSCLC
1368895|NCT00497315|Chemoradiation
1368896|NCT00497315|locally advanced NSCLC
1368897|NCT00497315|pemetrexed
1368898|NCT00497315|lung cancer
1368899|NCT00497302|cocaine
1368900|NCT00497302|opiate
1368901|NCT00497302|pregnancy
1368902|NCT00497302|post-partum
1368903|NCT00497302|neonatal abstinence syndrome
1368904|NCT00497302|contingency management
1368905|NCT00497302|Reinforcement Based Treatment
1368906|NCT00497302|women
1368907|NCT00497289|n-3 PUFA
1368908|NCT00497289|parenteral nutrition
1368909|NCT00497289|preterm infant
1368910|NCT00497276|Adults
1368911|NCT00497276|Anesthesia recovery period
1368912|NCT00497276|Comparative study
1368913|NCT00497276|Electric stimulation
1368914|NCT00497276|Humans
1368915|NCT00497276|Nerve blocks/methods/indications
1368916|NCT00497276|Patient satisfaction
1368917|NCT00497276|Peripheral nerves
1368918|NCT00497276|Sciatic nerve/ultrasonography
1368919|NCT00497276|Ultrasonography
1368920|NCT00497276|Treatment outcome
1368921|NCT00497276|Nerve blocks/economics
1368922|NCT00497250|Phase 1 Clinical Trials
1368923|NCT00497250|Iressa
1368924|NCT00497250|radiation therapy
1368925|NCT00497250|Chinese
1368926|NCT00497250|NSCLC
1368927|NCT00497250|chemotherapy
1368928|NCT00497237|Asthma
1368929|NCT00497237|Stepdown
1368930|NCT00497237|Beclomethasone
1368931|NCT00497237|Formoterol
1368932|NCT00497237|Corticosteroids
1368933|NCT00497224|Pancreatic Cancer
1368934|NCT00497224|Pancreatic Carcinoma
1368935|NCT00497224|Pancreas
1368936|NCT00497224|Adenocarcinoma
1368937|NCT00497224|Erlotinib
1368938|NCT00497224|Tarceva
1368939|NCT00497224|OSI-774
1368940|NCT00497224|Phase II
1368941|NCT00497211|First large acute myocardial infarction
1368942|NCT00497198|Type 2 Diabetes
1368943|NCT00497198|anion-exchange resin
1368944|NCT00497185|Mindfulness-Based Cognitive Therapy
1368945|NCT00497185|Somatization Disorder
1368946|NCT00497185|Medically Unexplained Symptoms
1368947|NCT00497185|Functional Somatic Symptoms
1368948|NCT00497185|SF-36
1368949|NCT00497159|Trial of Dimebon to treat patients with mild-to-moderate Huntington's disease.
1368950|NCT00497146|paricalcitol
1368951|NCT00497146|Zemplar
1368952|NCT00497146|PRIMO
1368953|NCT00497146|Chronic Kidney Disease Stage 3B/4
1368954|NCT00497133|glucoseintolerance
1368955|NCT00497120|sleep apnea
1368956|NCT00497120|snoring
1368957|NCT00497120|acetazolamide
1368958|NCT00497120|uvulopalatopharyngoplasty
1368959|NCT00497120|daytime sleepiness
1368960|NCT00497120|upper airway
1368961|NCT00497107|UFT/LV
1368962|NCT00497107|PSK
1368963|NCT00497107|Colorectal cancer
1368964|NCT00497107|Adjuvant therapy
1368965|NCT00497094|carotid artery stenting
1368966|NCT00497094|atherosclerosis
1368967|NCT00497094|cerebrovascular
1368968|NCT00497094|stroke
1368969|NCT00497081|Methamphetamine
1368970|NCT00497081|HIV
1368971|NCT00497081|MSM
1368972|NCT00497081|HIV Seronegativity
1368973|NCT00497068|smoking
1368974|NCT00497068|pregnancy
1368975|NCT00497068|neonatal abstinence syndrome
1368976|NCT00497055|Methamphetamine
1368977|NCT00497055|HIV
1368978|NCT00497055|MSM
1368979|NCT00497055|HIV Seronegativity
1368980|NCT00497029|dental caries
1368981|NCT00497029|early childhood caries
1368982|NCT00497029|caries prevention
1368983|NCT00497029|infants
1368984|NCT00497016|hypertension
1368985|NCT00497016|statin
1368986|NCT00497016|sympathetic
1368987|NCT00497003|Endothelial function
1368988|NCT00497003|Beta blocker
1368989|NCT00497003|Type 2 diabetes
1368990|NCT00497003|Chronic heart failure
1368991|NCT00496990|male
1368992|NCT00496990|female
1368993|NCT00496990|couple
1368994|NCT00496990|cocaine
1368995|NCT00496990|opiate
1368996|NCT00496990|methadone
1368997|NCT00496990|detoxification
1368998|NCT00496990|pregnancy
1368999|NCT00496977|lung cancer
1369000|NCT00496977|CT scan
1369001|NCT00496977|screening
1369002|NCT00496964|Botulinum toxin type A
1369003|NCT00496964|Patellofemoral pain syndrome
1369004|NCT00496964|Knee Injuries
1369005|NCT00496964|Exercise Therapy
1369006|NCT00496951|Neonatal abstinence syndrome
1369007|NCT00496951|Methadone
1369009|NCT00496938|Stents
1369010|NCT00496938|Angioplasty
1369011|NCT00496938|Total coronary occlusions
1369012|NCT00496938|Coronary restenosis
1369013|NCT00496938|Stent thrombosis
1369014|NCT00496938|Everolimus
1369015|NCT00496899|Labor
1369016|NCT00496899|Obstetric
1369017|NCT00496899|cervical dilatation
1369018|NCT00496886|Pain
1369019|NCT00496886|Nociception
1369020|NCT00496873|Non-Hodgkin's Lymphoma
1369021|NCT00496873|NHL
1369022|NCT00496873|Lymphoma
1369023|NCT00496873|B-cell chronic lymphocytic leukemia
1369024|NCT00496873|SLL
1369025|NCT00496873|Small Lymphocytic Lymphoma
1369026|NCT00496873|Lymphoplasmacytic lymphoma/immunocytoma
1369027|NCT00496873|Follicular lymphoma
1369028|NCT00496873|Extranodal marginal zone B-cell lymphoma of MALT type
1369029|NCT00496873|Nodal marginal zone B-cell lymphoma
1369030|NCT00496873|Chronic Lymphocytic Leukemia
1369031|NCT00496873|CLL
1369032|NCT00496873|Bulky Lymphoma
1369033|NCT00496873|Nipent
1369034|NCT00496873|Cytoxan
1369035|NCT00496873|Rituxan
1369036|NCT00496873|Cyclophosphamide
1369037|NCT00496873|Rituximab
1369038|NCT00496873|Pentostatin
1369039|NCT00496860|cancer
1369040|NCT00496860|p53
1369041|NCT00496860|immunotherapy
1369042|NCT00496860|targeted
1369043|NCT00496860|metastatic
1369044|NCT00496860|malignancy
1369045|NCT00496860|malignancies
1369046|NCT00496860|interleukin-2
1369047|NCT00496860|IL-2
1369048|NCT00496860|fusion protein
1369049|NCT00496860|antitumor
1369050|NCT00496860|melanoma
1369051|NCT00496860|renal cancer
1369052|NCT00496860|lung cancer
1369053|NCT00496860|kidney cancer
1369054|NCT00496860|breast cancer
1369055|NCT00496860|colorectal cancer
1369056|NCT00496860|colon cancer
1369057|NCT00496860|renal cell carcinoma
1369058|NCT00496860|advanced cancer
1369059|NCT00496860|head and neck cancer
1369060|NCT00496860|breast tumors
1369061|NCT00496860|cancer of head and neck
1369062|NCT00496860|esophagus cancer
1369063|NCT00496860|lymphoma
1369064|NCT00496860|ovarian cancer
1369065|NCT00496860|ovary cancer
1369066|NCT00496860|bladder cancer
1369067|NCT00496860|stomach cancer
1369068|NCT00496860|TCR
1369069|NCT00496860|T-cell receptor
1369070|NCT00496860|P53 gene
1369071|NCT00496860|p53 tumor suppressor protein
1369072|NCT00496847|rhPDGF,
1369073|NCT00496847|periodontal disease
1369074|NCT00496821|Respiratory Syncytial Virus
1369075|NCT00496808|Ductal Carcinoma In Situ
1369076|NCT00496808|Breast Cancer
1369077|NCT00496808|Herceptin
1369078|NCT00496808|Trastuzumab
1369079|NCT00496808|DCIS
1369080|NCT00496795|Breast cancer, chemoresistance, predictive markers.
1369081|NCT00496782|Treatment Experienced
1369082|NCT00496756|clear cell renal cell carcinoma
1369083|NCT00496756|stage III renal cell cancer
1369084|NCT00496756|stage IV renal cell cancer
1369085|NCT00496756|recurrent renal cell cancer
1369086|NCT00496730|Metabolic Disorder
1369087|NCT00496717|Calcium scoring/aorta/ cardiovascular risk factor/scann
1369088|NCT00496717|Patients with at least one cardiovascular risk factor
1369089|NCT00496704|adenocarcinoma of the colon
1369090|NCT00496704|recurrent colon cancer
1369091|NCT00496704|stage III colon cancer
1369092|NCT00496704|stage IV colon cancer
1369093|NCT00496704|adenocarcinoma of the rectum
1369094|NCT00496704|recurrent rectal cancer
1369095|NCT00496704|stage III rectal cancer
1369096|NCT00496704|stage IV rectal cancer
1369097|NCT00496691|HIV prevention
1369098|NCT00496691|HIV Seronegativity
1369099|NCT00496678|PNRP
1369100|NCT00496678|navigation
1369101|NCT00496678|navigator
1369102|NCT00496678|activation
1369103|NCT00496678|disparities
1369104|NCT00496678|randomized control trial
1369105|NCT00496678|primary care
1369106|NCT00496678|racial and ethnic minorities
1369107|NCT00496665|Stage IV breast cancer
1369108|NCT00496665|metronomic chemotherapy
1369109|NCT00496652|Squamous Cell Carcinomas of the Head and Neck
1369110|NCT00496652|Epidermal Growth Factor receptor
1369111|NCT00496652|Antibody
1369112|NCT00496652|Radiotherapy
1369113|NCT00496639|hemodialysis
1369114|NCT00496639|arterio-venous grafts
1369115|NCT00496639|angioplasty
1369116|NCT00496639|stents
1369117|NCT00496639|mechanical thrombectomy
1369118|NCT00496626|HPV infections
1369119|NCT00496613|Breast cancer
1369120|NCT00496613|survivor
1369121|NCT00496587|Genitourinary
1369122|NCT00496587|Kidney Cancer
1369123|NCT00496587|Sarcomatoid Renal Cell Carcinoma
1369124|NCT00496587|Renal Cell Carcinoma
1369125|NCT00496587|RCC
1369126|NCT00496587|Sarcomatoid Carcinoma of the Kidney
1369127|NCT00496587|Unresectable renal cell carcinoma
1369128|NCT00496587|Capecitabine
1369129|NCT00496587|Xeloda
1369130|NCT00496587|Gemcitabine
1369131|NCT00496587|Gemzar
1369132|NCT00496587|Bevacizumab
1369133|NCT00496587|Anti-VEGF monoclonal antibody
1369134|NCT00496587|rhuMAb-VEGF
1369135|NCT00496587|Avastin
1369136|NCT00496587|Vascular Endothelial Growth Factor
1369137|NCT00496587|VEGF
1369138|NCT00496574|asthma
1369139|NCT00496574|immunotherapy
1369140|NCT00496574|efficacy
1369141|NCT00496574|children
1369142|NCT00496574|symptoms score
1369143|NCT00496574|quality of life
1369144|NCT00496574|spirometry
1369145|NCT00496574|PC20M
1369146|NCT00496561|asthma
1369147|NCT00496561|immunotherapy
1369148|NCT00496561|children
1369149|NCT00496561|regulatory T cells
1369150|NCT00496561|ECP
1369151|NCT00496561|PC20M
1369152|NCT00496561|Quality of Life
1369153|NCT00496561|Symptoms score
1369154|NCT00496561|Spirometry
1369155|NCT00496548|Crohn's Disease
1369156|NCT00496535|head
1369157|NCT00496535|neck
1369158|NCT00496535|cancer
1369159|NCT00496535|neoplasm
1369160|NCT00496522|Skull Base Chondrosarcoma
1369161|NCT00496522|Proton Beam Therapy
1369162|NCT00496522|Chondrosarcoma
1369163|NCT00496522|CNS
1369164|NCT00496509|ZD6474
1369165|NCT00496509|Colorectal Cancer
1369166|NCT00496509|Liver Metastases
1369167|NCT00496509|Biomarkers
1369168|NCT00496483|Tacrolimus
1369169|NCT00496483|Pharmacokinetics
1369170|NCT00496483|Kidney Transplantation
1369171|NCT00496470|Chronic Obstructive Pulmonary Disease, COPD
1369172|NCT00496457|Diabetic Neuropathy
1369173|NCT00496457|Painful Peripheral Diabetic Neuropathy
1369174|NCT00496457|TRO19622
1369175|NCT00496457|Trophos
1369176|NCT00496444|Advanced Cancers
1369177|NCT00496444|Azacytidine
1369178|NCT00496444|5-Azacitidine
1369179|NCT00496444|5-aza
1369180|NCT00496444|Vidaza
1369181|NCT00496444|5-AZC
1369182|NCT00496444|AZA-CR
1369183|NCT00496444|Ladakamycin
1369184|NCT00496444|NSC-102816
1369185|NCT00496444|Valproic Acid
1369186|NCT00496444|Depakene
1369187|NCT00496418|colostomy
1369188|NCT00496418|parastomal
1369189|NCT00496418|peristomal
1369190|NCT00496418|hernia
1369191|NCT00496418|mesh
1369192|NCT00496418|surgery
1369193|NCT00496418|Indication for permanent end colostomy
1369194|NCT00496405|Vascular endothelial growth factor.
1369195|NCT00496405|Retinal Thickness
1369196|NCT00496405|Diabetic Macular Edema
1369197|NCT00496405|Optical Coherent Tomography
1369198|NCT00496392|breakthrough pain in patients with cancer
1369199|NCT00496379|metastatic breast cancer
1369200|NCT00496379|invasive breast cancer
1369201|NCT00496379|brain metastases
1369202|NCT00496379|ZK-EPO
1369203|NCT00496353|Neoplasm Malignant
1369204|NCT00496340|Pentostatin
1369205|NCT00496340|Busulfan
1369206|NCT00496340|Rituxan
1369207|NCT00496340|Allogeneic Hematopoietic Stem Cell Transplantation
1369208|NCT00496301|renal
1369209|NCT00496301|sorafenib
1369210|NCT00496301|Unresectable and/or metastatic renal cell cancer
1369211|NCT00496288|BRCA mutation
1369212|NCT00496288|Breast cancer
1369213|NCT00496288|Prophylactic breast irradiation
1369214|NCT00496288|Prevention of contralateral breast cancer
1369215|NCT00496275|NSCLC
1369216|NCT00496275|ZACTIMA
1369217|NCT00496262|Congenital fibrinogen deficiency
1369218|NCT00496262|Fibrinogen concentrate
1369219|NCT00496262|Pharmacokinetics
1369220|NCT00496262|Thrombelastography
1369221|NCT00496249|Prostate
1369222|NCT00496249|cancer
1369223|NCT00496249|brachytherapy
1369224|NCT00496249|radiation
1369225|NCT00496249|semen
1369226|NCT00496249|fertility
1369227|NCT00496236|head
1369228|NCT00496236|neck
1369229|NCT00496236|cancer
1369230|NCT00496236|neoplasm
1369231|NCT00496223|Sunitinib
1369232|NCT00496223|Dacarbazine
1369233|NCT00496223|Melanoma
1369234|NCT00496210|Adaptation
1369235|NCT00496210|Pervasive Developmental Disorder
1369236|NCT00496210|Autism Spectrum Disorders
1369237|NCT00496210|Pervasive Developmental Disorders
1369238|NCT00496210|Caregiver Adaptation
1369239|NCT00496197|candidemia
1369240|NCT00496197|invasive candidiasis
1369241|NCT00496197|fungal bloodstream infection
1369242|NCT00496184|Nifedipine treatment
1369243|NCT00496184|Vestibulitis
1369244|NCT00496184|Placebo
1369245|NCT00496158|Nucleoside Treatment-Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B Virus
1369246|NCT00496158|hepatitis b virus
1369247|NCT00496145|diabetes
1369248|NCT00496145|self management
1369249|NCT00496145|patient education
1369250|NCT00496145|telephone reinforcement
1369251|NCT00496145|Spanish Diabetes
1369252|NCT00496145|Tomando Control de su Diabetes
1369253|NCT00496132|CLL
1369254|NCT00496132|Leukemia
1369255|NCT00496132|Lymph
1369256|NCT00496119|Proton Beam Therapy
1369257|NCT00496119|Skull Base Chordoma
1369258|NCT00496119|Chordoma of the Skull Base
1369259|NCT00496119|Chordoma
1369260|NCT00496080|Menorrhagia associated with Uterine Fibroids
1369261|NCT00496067|Fibroids
1369262|NCT00496067|Menorrhagia
1369263|NCT00496067|Menorrhagia associated with uterine fibroids
1369264|NCT00496041|Stenosis (> 75%) or occlusion of the superficial femoral artery
1369265|NCT00496028|Solid tumors
1369266|NCT00496028|locally advanced or Metastatic Cancer suitable for treatment with carboplatin and/or paclitaxel
1369267|NCT00496015|Streptococcus Pneumoniae Vaccines
1369268|NCT00496015|Meningococcal disease
1369269|NCT00496015|Carriage
1369270|NCT00496015|Prophylactic antipyretic
1369271|NCT00496015|Safety
1369272|NCT00496015|Pneumococcal vaccine
1369273|NCT00496015|Fever
1369274|NCT00496015|Pneumococcal disease
1369275|NCT00496015|Immunogenicity
1369276|NCT00496015|Meningococcal vaccine
1369277|NCT00496015|Booster vaccination
1369278|NCT00496002|Hepatitis B virus
1369279|NCT00496002|Nucleoside Treatment-Naïve Patients with HBeAg Positive
1369280|NCT00495989|Handicapped individuals
1369281|NCT00495976|common cold
1369282|NCT00495976|flu
1369283|NCT00495976|influenza
1369284|NCT00495963|Mechanical ventilation, Ventilator- associated pneumonia, Bronchoalveolar lavage, Pediatric intensive care unit, Flexible bronchoscopy, Critical care
1369285|NCT00495950|Melanoma
1369286|NCT00495950|Lymphedema
1369287|NCT00495950|Limb Swelling
1369288|NCT00495950|Questionnaire
1369289|NCT00495950|Quality of Life
1369290|NCT00495950|Physical Function
1369291|NCT00495950|Survey
1369292|NCT00495885|Sleep problems
1369293|NCT00495885|insomnia
1369294|NCT00495885|sleeplessness
1369295|NCT00495885|primary insomnia
1369296|NCT00495885|insomnia disorder
1369297|NCT00495872|Solid Tumors
1369298|NCT00495872|Advanced Cancer
1369299|NCT00495872|Dasatinib
1369300|NCT00495872|Erlotinib
1369301|NCT00495872|Lapatinib
1369302|NCT00495872|Lenalidomide
1369303|NCT00495872|Sorafenib
1369304|NCT00495872|Erlotinib Hydrochloride
1369305|NCT00495872|Sunitinib Malate
1369306|NCT00495872|Sunitinib
1369307|NCT00495872|Valproic Acid
1369308|NCT00495872|SU011248
1369309|NCT00495859|Immunonutrition
1369310|NCT00495859|immune enhancing diets
1369311|NCT00495859|arginine
1369312|NCT00495859|ω-3 fatty acids
1369313|NCT00495859|nucleotides
1369314|NCT00495859|liver transplantation
1369315|NCT00495859|clinical trial
1369316|NCT00495846|Hepatocellular carcinoma
1369317|NCT00495846|Somatostatin analogues
1369318|NCT00495846|Somatostatin receptors
1369319|NCT00495846|Octreotide
1369320|NCT00495846|Lanreotide
1369321|NCT00495846|IGF-I
1369322|NCT00495846|IGF-II
1369323|NCT00495833|Hypertension
1369324|NCT00495820|Alzheimer's Disease
1369325|NCT00495820|Apathy
1369326|NCT00495820|Dementia
1369327|NCT00495820|Methylphenidate
1369328|NCT00495807|Psychological Tests
1369329|NCT00495807|Pain, Postoperative
1369330|NCT00495807|Nurses
1369331|NCT00495794|diabetes
1369332|NCT00495794|hypertension
1369333|NCT00495794|adherence
1369334|NCT00495794|implementation
1369335|NCT00495794|medications
1369336|NCT00495794|organization of care
1369337|NCT00495781|functional iron deficiency
1369338|NCT00495781|renal anemia
1369339|NCT00495781|dialysis
1369340|NCT00495781|erythropoietin
1369341|NCT00495781|darbepoetin
1369342|NCT00495768|Hepatitis C
1369343|NCT00495768|HCV
1369344|NCT00495768|Depression
1369345|NCT00495768|Interferons
1369346|NCT00495768|Ribavirin
1369347|NCT00495755|Chronic Graft-vs-Host Disease
1369348|NCT00495729|SB-649868,
1369349|NCT00495729|Simvastatin
1369350|NCT00495729|Repeated dose,
1369351|NCT00495703|Cancer survivors
1369352|NCT00495703|Chemotherapy
1369353|NCT00495703|Cognitive function
1369354|NCT00495703|Exercise
1369355|NCT00495703|Physical Activity
1369356|NCT00495690|Zinc recipients
1369357|NCT00495690|Placebo recipients
1369358|NCT00495677|Treatment Experienced
1369359|NCT00495677|Treatment Naive
1369360|NCT00495664|titanium
1369361|NCT00495664|paclitaxel
1369362|NCT00495664|stent
1369363|NCT00495664|myocardial infarction
1369364|NCT00495664|angioplasty
1369365|NCT00495664|PCI
1369366|NCT00495651|HIV
1369367|NCT00495651|HAART
1369368|NCT00495651|Early Intervention
1369369|NCT00495651|Naive patients
1369370|NCT00495638|6-Minute Walk
1369371|NCT00495638|Chuvash Polycythemia
1369372|NCT00495638|Echocardiogram
1369373|NCT00495638|Sickle Cell Anemia
1369374|NCT00495638|Pulmonary Function Tests
1369375|NCT00495638|Sickle Cell Disease
1369376|NCT00495638|SCD
1369377|NCT00495638|Pulmonary Hypertension
1369378|NCT00495625|Hepatocellular cancer (HCC)
1369379|NCT00495625|Sunitinib malate
1369380|NCT00495625|Vascular endothelial growth factor (VEGF)
1369381|NCT00495625|Platelet-derived growth factor (PDGF)
1369382|NCT00495625|Tyrosine kinases
1369383|NCT00495625|Liver
1369384|NCT00495612|Xolair
1369385|NCT00495612|Allergic asthma
1369386|NCT00495612|Cat allergy
1369387|NCT00495599|Obese
1369388|NCT00495599|Adipose Tissue
1369389|NCT00495599|Visfatin
1369390|NCT00495599|Gastric Bypass Surgery
1369391|NCT00495586|COPD
1369392|NCT00495586|Antibiotics
1369393|NCT00495560|induction
1369394|NCT00495560|abortion
1369395|NCT00495560|injection, intra-amniotic
1369396|NCT00495560|misoprostol
1369397|NCT00495547|Myelodysplastic Syndrome
1369398|NCT00495547|Red Cell transfusion dependent
1369399|NCT00495521|Crohn's
1369400|NCT00495521|Crohn's Disease
1369401|NCT00495521|Acute Flare
1369402|NCT00495521|Mild to Moderate Crohn's Disease
1369403|NCT00495521|Children
1369404|NCT00495521|Pediatrics
1369405|NCT00495521|Ileo-cecal
1369406|NCT00495521|Pediatric Crohn's Disease
1369407|NCT00495521|New Onset Crohn's Disease
1369408|NCT00495521|Recently diagnosed Crohn's Disease
1369409|NCT00495508|Quinine
1369410|NCT00495508|Artemether
1369411|NCT00495508|Lumefantrine
1369412|NCT00495508|malaria
1369413|NCT00495508|Uganda
1369414|NCT00495508|Artemisinin- based combination therapy
1369415|NCT00495508|pregnancy
1369416|NCT00495508|Malaria In Pregnancy
1369417|NCT00495482|Euthanasia
1369418|NCT00495482|Assisted Suicide
1369419|NCT00495482|Assisted Dying
1369420|NCT00495482|Palliative Care Medicine
1369421|NCT00495469|Diabetes mellitus HbA1c
1369422|NCT00495456|cardiovascular
1369423|NCT00495456|risk
1369424|NCT00495456|longitudinal
1369425|NCT00495456|prospective
1369426|NCT00495430|Healthy
1369427|NCT00495430|Lung sounds
1369428|NCT00495430|Breath sounds
1369429|NCT00495417|Alzheimer
1369430|NCT00495417|Morbus Alzheimer
1369431|NCT00495417|Alzheimer Vaccine
1369432|NCT00495417|Vaccine
1369433|NCT00495417|AD
1369434|NCT00495417|Aβ immunotherapy
1369435|NCT00495404|chronic non-malignant pain
1369436|NCT00495404|opiates
1369437|NCT00495404|prescriptions
1369438|NCT00495404|addiction
1369439|NCT00495391|Hepatitis C, Chronic
1369440|NCT00495378|PROCRIT
1369441|NCT00495378|Epoetin alfa
1369442|NCT00495378|chemotherapy related anemia
1369443|NCT00495365|Anemia
1369444|NCT00495365|low blood count
1369445|NCT00495365|chronic kidney disease
1369446|NCT00495365|chronic kidney failure
1369447|NCT00495365|darbepoetin alfa
1369448|NCT00495365|epoetin alfa
1369449|NCT00495365|recombinant human erythropoietin
1369450|NCT00495352|Schizophrenia
1369451|NCT00495352|NRT
1369452|NCT00495352|Bupropion
1369453|NCT00495352|Stages of change
1369454|NCT00495326|drug interactions
1369455|NCT00495326|Treatment Naive
1369456|NCT00495313|Rosacea
1369457|NCT00495300|HSC/MUD Transplant
1369458|NCT00495300|NMDP
1369459|NCT00495300|NMDP Data Collection
1369460|NCT00495300|NMDP Samples
1369461|NCT00495300|BMT
1369462|NCT00495300|Samples
1369463|NCT00495287|Acute myelogenous leukemia
1369464|NCT00495287|Adult patients
1369465|NCT00495287|Cytogenetic risk class
1369466|NCT00495287|Clinico-cytogenetic risk model
1369467|NCT00495287|Risk-oriented therapy
1369468|NCT00495274|Bioequivalent
1369469|NCT00495274|pharmacodynamic
1369470|NCT00495274|Reference formulation
1369471|NCT00495274|5 new formulation
1369472|NCT00495274|Food effect
1369473|NCT00495274|Pharmacokinetics
1369474|NCT00495261|Gambling
1369475|NCT00495261|Mindfulness
1369476|NCT00495261|Cognitive Behavioural Therapy
1369477|NCT00495248|group intervention
1369478|NCT00495248|stroke
1369479|NCT00495248|senior centres
1369480|NCT00495248|health promotion
1369481|NCT00495235|Endometrial Cancer
1369482|NCT00495235|Polycystic Ovarian Syndrome
1369483|NCT00495235|Insulin Resistance
1369484|NCT00495235|Pre-diabetes
1369485|NCT00495235|Harris County
1369486|NCT00495235|PCOS
1369487|NCT00495235|Uterus
1369488|NCT00495235|Questionnaire
1369489|NCT00495235|Body mass index
1369490|NCT00495235|BMI
1369491|NCT00495222|gastrojejunostomy
1369492|NCT00495222|stoma
1369493|NCT00495209|Complementary and Alternative Medicine
1369494|NCT00495209|Breast Cancer
1369495|NCT00495209|Qigong
1369496|NCT00495209|Medical Qigong
1369497|NCT00495209|External Qi Therapy
1369498|NCT00495209|EQT
1369499|NCT00495183|cocaine dependence
1369500|NCT00495183|cocaine use
1369501|NCT00495183|CNS stimulants
1369502|NCT00495183|caffeine
1369503|NCT00495183|biperiden
1369504|NCT00495183|placebo
1369514|NCT00495144|Phase I
1369515|NCT00495144|Advanced Solid Tumors
1369516|NCT00495144|Hypoxia
1369517|NCT00495144|Prodrug
1369518|NCT00495144|Multi-Center
1369519|NCT00495144|Open-Label
1369520|NCT00495144|Dose-Escalation
1369521|NCT00495131|Chronic hepatitis C
1369522|NCT00495131|Genotype 1
1369523|NCT00495131|Interferon
1369524|NCT00495131|Ribavirin
1369525|NCT00495118|schizophrenia
1369526|NCT00495118|schizoaffective disorder
1369527|NCT00495118|risperidone
1369528|NCT00495118|intramuscular injection
1369529|NCT00495118|long-acting injectable
1369530|NCT00495092|cocaine dependence
1369531|NCT00495092|cocaine use
1369532|NCT00495092|cocaine craving
1369533|NCT00495079|acute
1369534|NCT00495079|lymphoblastic
1369535|NCT00495079|lymphocytic
1369536|NCT00495079|leukemia
1369537|NCT00495079|leukaemia
1369538|NCT00495079|lukemia
1369539|NCT00495079|leukimia
1369540|NCT00495079|ALL
1369541|NCT00495079|Marqibo
1369542|NCT00495079|Hana Biosciences
1369543|NCT00495079|vincristine
1369544|NCT00495079|liposomal
1369545|NCT00495079|liposome
1369546|NCT00495079|optisome
1369547|NCT00495079|hematology
1369548|NCT00495079|malignancy
1369549|NCT00495079|hematological
1369550|NCT00495079|relapsed
1369551|NCT00495079|anti-leukemia
1369552|NCT00495079|adult
1369553|NCT00495079|chemotherapy
1369554|NCT00495053|overactive bladder, urinary urgency
1369560|NCT00495027|PTSD
1369561|NCT00495027|prevention
1369562|NCT00495027|World Wide Web
1369563|NCT00495027|Behavior Therapy
1369564|NCT00495014|GSK376501,
1369565|NCT00495014|Single Dose,
1369566|NCT00495014|Dose Escalation,
1369567|NCT00495014|Healthy Overweight/Obese Volunteer
1369568|NCT00494949|Anesthesia, spinal
1369569|NCT00494949|Blood substitutes
1369570|NCT00494949|Oxygen therapeutics
1369571|NCT00494949|Orthopedic surgery
1369572|NCT00494949|Plasma expanders
1369573|NCT00494949|Vasoconstriction
1369574|NCT00494949|Hemospan
1369575|NCT00494936|HIV
1369576|NCT00494936|HCV
1369577|NCT00494936|Treatment Naive
1369578|NCT00494936|Treatment Experienced
1369579|NCT00494936|HIV and HCV Coinfection
1369580|NCT00494910|Palliative Care
1369581|NCT00494910|Terminally Ill
1369582|NCT00494910|Group Therapy
1369583|NCT00494910|07-094
1369584|NCT00494884|Type 2 diabetes
1369585|NCT00494884|vildagliptin
1369586|NCT00494884|metformin combination
1369587|NCT00494871|BAY59-7939
1369588|NCT00494871|Rivaroxaban
1369589|NCT00494871|Non-Valvular Atrial Fibrillation
1369590|NCT00494871|Japanese Patients
1369591|NCT00494871|Phase III
1369592|NCT00494871|12620
1369593|NCT00494858|Bulimia nervosa
1369594|NCT00494858|Cognitive Behavioral Therapy
1369595|NCT00494858|Personality Disorders
1369596|NCT00494845|Mindfulness
1369597|NCT00494845|Elderly
1369598|NCT00494845|Chronic Illness
1369599|NCT00494845|Back Pain
1369600|NCT00494845|Chronic Low Back Pain
1369601|NCT00494845|Older adults over the age of sixty-five
1369602|NCT00494845|MMSE score of over 23
1369603|NCT00494845|Speaks English
1369604|NCT00494832|Dexmedetomidine
1369605|NCT00494832|Evoked potentials
1369606|NCT00494832|Spine surgery
1369607|NCT00494819|ADHD, subtype, methylphenidate, neuropsychological measures
1369608|NCT00494806|Postoperative Ileus (POI)
1369609|NCT00494806|Rocking Chair
1369610|NCT00494806|Abdominal Cancer
1369611|NCT00494793|Open abdomen
1369612|NCT00494793|Fascial closure
1369613|NCT00494793|Vacuum assisted wound closure
1369614|NCT00494793|Mesh
1369615|NCT00494793|Abdominal compartment syndrome
1369616|NCT00494793|Intraabdominal pressure
1369617|NCT00494793|Incisional hernia
1369618|NCT00494780|CHOP (cyclophosphamide,doxorubicin,vincristine,prednisolone)
1369619|NCT00494780|ofatumumab
1369620|NCT00494767|body composition
1369621|NCT00494767|hunger
1369622|NCT00494767|weight loss
1369623|NCT00494767|4C model
1369624|NCT00494767|obesity
1369625|NCT00494754|autism spectrum disorder
1369626|NCT00494754|family genetic study
1369627|NCT00494754|gene
1369628|NCT00494754|phenotype
1369629|NCT00494754|endophenotype
1369630|NCT00494728|Smoking
1369631|NCT00494728|Depression
1369632|NCT00494728|Major Depressive Disorder
1369633|NCT00494728|Cognitive Behavioral Analysis System of Psychotherapy
1369634|NCT00494728|Smoking Cessation Treatment
1369635|NCT00494728|Nicotine Replacement Therapy
1369636|NCT00494728|Nicotine Patch
1369637|NCT00494728|CBASP
1369638|NCT00494728|MDD
1369639|NCT00494702|Asphyxia
1369640|NCT00494702|Resuscitation
1369641|NCT00494702|Oxidative stress
1369642|NCT00494702|Prematurity
1369643|NCT00494702|Follow up
1369644|NCT00494689|transcranial sonolysis or monitoring
1369645|NCT00494689|rapid magnetic stimulation
1369646|NCT00494689|cerebral ischemia
1369647|NCT00494689|hydrocephalus
1369648|NCT00494689|Barthel's index
1369649|NCT00494676|Hemianopia
1369650|NCT00494676|Mobility
1369651|NCT00494676|Rehabilitation
1369652|NCT00494676|Low vision
1369653|NCT00494663|diabetes
1369654|NCT00494663|type 2 diabetes
1369655|NCT00494663|cholesterol
1369656|NCT00494650|PTSD
1369657|NCT00494650|Schizophrenia
1369658|NCT00494650|Schizoaffective Disorder
1369659|NCT00494650|Bipolar Disorder
1369660|NCT00494650|Major Depression
1369661|NCT00494624|Wheezing
1369662|NCT00494624|virus
1369663|NCT00494624|child
1369664|NCT00494598|opioids, cerebral perfusion, arterial pharmacokinetics
1369665|NCT00494585|CEP-701
1369666|NCT00494585|Leukemia
1369667|NCT00494585|Myelofibrosis
1369668|NCT00494585|MF
1369669|NCT00494585|JAK2
1369670|NCT00494585|Tyrosine Kinase Inhibitor
1369671|NCT00494585|Lestaurtinib
1369672|NCT00494585|Chronic Idiopathic Myelofibrosis
1369673|NCT00494585|CIMF
1369674|NCT00494572|Montelukast
1369675|NCT00494572|Albuterol
1369676|NCT00494572|Status Asthmaticus
1369677|NCT00494572|Asthma
1369678|NCT00494559|Type 2 Diabetes
1369679|NCT00494559|Pioglitazone
1369680|NCT00494559|restenosis
1369681|NCT00494546|prostate
1369682|NCT00494546|brachytherapy
1369683|NCT00494533|pulmonary arterial hypertension
1369684|NCT00494533|prostacyclin analogue
1369685|NCT00494533|intravenous
1369686|NCT00494520|Anomia
1369687|NCT00494520|Aphasia
1369688|NCT00494520|Traumatic Brain Injury
1369689|NCT00494520|Cerebrovascular Accident
1369690|NCT00494507|periodic paralysis
1369691|NCT00494507|dichlorphenamide
1369692|NCT00494494|cystoid macular edema
1369693|NCT00494494|cataract
1369694|NCT00494494|nonsteroidal antiinflammatory drugs
1369695|NCT00494494|optical coherence tomography
1369696|NCT00494481|Zactima
1369697|NCT00494468|Insomnia
1369698|NCT00494468|Sleep Disorder
1369699|NCT00494468|Sleep Deprivation
1369700|NCT00494455|critical illness
1369701|NCT00494455|hyperglycemia
1369702|NCT00494455|intensive insulin therapy
1369703|NCT00494455|glucose monitoring
1369704|NCT00494455|shock
1369705|NCT00494442|Advanced ovarian cancer
1369706|NCT00494442|Poly(ADP ribose) polymerases
1369707|NCT00494442|KU-0059436
1369708|NCT00494442|AZD2281
1369709|NCT00494442|BRCA1 protein
1369710|NCT00494442|BRCA2 protein
1369711|NCT00494429|Preterm Neonates
1369712|NCT00494429|Morphine
1369713|NCT00494429|Critically ill
1369714|NCT00494403|sprain proprioception
1369715|NCT00494390|Biometry
1369716|NCT00494390|corneal opacity
1369717|NCT00494390|astigmatism
1369718|NCT00494390|refraction
1369719|NCT00494364|ear disease
1369720|NCT00494364|otitis
1369721|NCT00494364|Eustachian tube
1369722|NCT00494364|mastoid air cells
1369723|NCT00494364|Normal healthy volunteers
1369724|NCT00494351|Hidradenitis Suppurativa
1369725|NCT00494351|Nd:YAG laser
1369726|NCT00494338|Metastatic Androgen Independent Prostate Cancer (MAIPC)
1369727|NCT00494325|age related maculopathy, macular pigment
1369728|NCT00494312|Glucose Metabolism Disorder
1369729|NCT00494312|Dysmetabolic Syndrome
1369730|NCT00494312|Type II Diabetes
1369731|NCT00494312|Diabetes Mellitus
1369732|NCT00494312|Lipoatrophic
1369733|NCT00494312|Dyslipidemia
1369734|NCT00494312|Liver
1369735|NCT00494312|Drug Therapy
1369736|NCT00494299|HCC
1369737|NCT00494299|Cancer
1369738|NCT00494299|Liver Cancer
1369739|NCT00494299|TACE
1369740|NCT00494286|Abuse Focused Cognitive Behavioral Therapy
1369741|NCT00494286|Treatment Effectiveness Research
1369742|NCT00494286|Treatment Dissemination
1369743|NCT00494273|Haitian American Adolescents
1369744|NCT00494273|HIV Prevention
1369745|NCT00494273|Cognitive Behavioral Intervention
1369746|NCT00494260|recurrent abdominal pain
1369747|NCT00494260|illness behavior
1369748|NCT00494260|social learning
1369749|NCT00494260|cognitive behavioral therapy
1369750|NCT00494247|acute coronary syndromes
1369751|NCT00494247|endothelial progenitor cells
1369752|NCT00494247|coronary stent
1369753|NCT00494234|Advanced breast cancer
1369754|NCT00494234|Poly(ADP ribose) polymerases
1369755|NCT00494234|AZD2281,KU-0059436 (olaparib)
1369756|NCT00494234|BRCA1 protein
1369757|NCT00494234|BRCA2 protein
1369758|NCT00494221|Colorectal cancer
1369759|NCT00494221|Recentin
1369760|NCT00494221|Metastatic Cancer
1369761|NCT00494221|FOLFOX
1369762|NCT00494208|androgens
1369763|NCT00494208|testosterone
1369764|NCT00494208|testosterone deficiency
1369765|NCT00494208|women
1369766|NCT00494208|menopause
1369767|NCT00494208|surgical Menopause
1369768|NCT00494208|hysterectomy
1369769|NCT00494208|oophorectomy
1369770|NCT00494208|ovariectomy
1369771|NCT00494208|sexual dysfunction
1369772|NCT00494208|sexual function
1369773|NCT00494208|muscle function
1369774|NCT00494208|insulin sensitivity
1369775|NCT00494208|body composition
1369776|NCT00494195|limb girdle muscular dystrophy type 2D
1369777|NCT00494195|alpha-sarcoglycanopathy
1369778|NCT00494195|LGMD
1369779|NCT00494195|LGMD2D
1369780|NCT00494195|gene therapy
1369781|NCT00494195|gene transfer
1369782|NCT00494195|muscular dystrophy
1369783|NCT00494195|SGCA
1369784|NCT00494195|sarcoglycan
1369785|NCT00494195|limb girdle
1369786|NCT00494195|adeno-associated virus
1369787|NCT00494195|AAV
1369788|NCT00494195|AAV1
1369789|NCT00494182|Head and Neck Cancer
1369790|NCT00494182|Squamous Cell Carcinoma
1369791|NCT00494182|Sorafenib
1369792|NCT00494182|BAY 43-9006
1369793|NCT00494182|Carboplatin
1369794|NCT00494182|Paclitaxel
1369795|NCT00494182|SCCHN
1369796|NCT00494169|Idiopathic Hypogonadotropic Hypogonadism
1369797|NCT00494169|Kallmann Syndrome
1369798|NCT00494169|Puberty
1369799|NCT00494169|Pituitary Abnormalities
1369800|NCT00494169|Hypothalamus
1369801|NCT00494169|anosmia
1369802|NCT00494169|GnRH deficiency
1369803|NCT00494143|Amputee
1369804|NCT00494143|Economy
1369805|NCT00494143|Efficiency
1369806|NCT00494143|Foot
1369807|NCT00494143|Gait
1369808|NCT00494143|Kinematics
1369809|NCT00494143|Kinetics
1369810|NCT00494143|Prosthesis
1369811|NCT00494104|vitamin D deficiency
1369812|NCT00494104|breastfed infant
1369813|NCT00494104|northern latitude
1369814|NCT00494104|infant
1369815|NCT00494104|breastfed
1369816|NCT00494104|winter
1369817|NCT00494104|vitamin D status
1369818|NCT00494078|critical illness
1369819|NCT00494078|hyperglycemia
1369820|NCT00494078|intensive insulin therapy
1369821|NCT00494078|glucose monitoring
1369822|NCT00494052|Coronary Heart Disease
1369823|NCT00494052|Choice Behavior
1369824|NCT00494052|Risk Factors
1369825|NCT00494052|Risk Assessment
1369826|NCT00494052|Primary Prevention
1369827|NCT00494052|Decision Making
1369828|NCT00494052|Decision Aids
1369829|NCT00494052|Patient Compliance
1369830|NCT00494039|prostate
1369831|NCT00494039|cancer
1369832|NCT00494039|radiation
1369833|NCT00494039|brachytherapy
1369834|NCT00494013|diabetes
1369835|NCT00494013|type 2
1369836|NCT00493987|Testosterone
1369837|NCT00493987|Androgens
1369838|NCT00493987|Dihydrotestosterone
1369839|NCT00493987|5-alpha reductase
1369840|NCT00493987|Body Composition
1369841|NCT00493987|Muscle
1369842|NCT00493987|Sexual function
1369843|NCT00493987|Men
1369844|NCT00493987|Healthy Men
1369845|NCT00493974|Chronic Obstructive Pulmonary Disease
1369846|NCT00493974|COPD
1369847|NCT00493974|Exacerbation
1369848|NCT00493974|Anti-leukotriene
1369849|NCT00493974|Length of Stay
1369850|NCT00493974|LOS
1369851|NCT00493961|Kallmann Syndrome
1369852|NCT00493961|Idiopathic Hypogonadotropic Hypogonadism
1369853|NCT00493961|GnRH deficiency
1369854|NCT00493935|bedtime snack
1369855|NCT00493935|hypoglycemia
1369856|NCT00493935|Diabetes Mellitus, Type I
1369857|NCT00493935|glucose monitoring
1369858|NCT00493922|Malaria
1369859|NCT00493922|Diagnosis
1369860|NCT00493922|Rapid diagnostic tests
1369861|NCT00493922|Microscopy
1369862|NCT00493922|Clinical diagnosis
1369863|NCT00493922|Africa
1369864|NCT00493909|thoracotomy
1369865|NCT00493909|pain therapy
1369866|NCT00493909|thoracic paravertebral blockade
1369867|NCT00493909|intrathecal opioids
1369868|NCT00493909|thoracic epidural analgesia
1369869|NCT00493909|Analgesia after thoracotomy
1369870|NCT00493896|Venous Thromboembolism Prophylaxis
1369871|NCT00493896|VTE prophylaxis
1369872|NCT00493883|Therasphere
1369873|NCT00493883|Yttrium
1369874|NCT00493883|liver
1369875|NCT00493883|cancer
1369876|NCT00493883|radiation
1369877|NCT00493857|Colorectal cancer
1369878|NCT00493857|Monoclonal antibody
1369879|NCT00493857|Anti-EGFR
1369880|NCT00493844|Chest pain
1369881|NCT00493844|Unstable angina
1369882|NCT00493844|NT-proBNP
1369883|NCT00493844|Exercise test.
1369884|NCT00493831|smoking reduction
1369885|NCT00493831|inflammation
1369886|NCT00493831|harm reduction
1369887|NCT00493831|lipid biomarkers
1369888|NCT00493818|GSK690693,
1369889|NCT00493818|Solid Tumors,
1369890|NCT00493818|Lymphoma,
1369891|NCT00493818|AKT
1369892|NCT00493805|homeostasis model assessment of insulin resistance
1369893|NCT00493766|LBH589
1369894|NCT00493766|Prostate Cancer
1369895|NCT00493766|HRPC
1369896|NCT00493766|Hormone Refractory Prostate Cancer
1369897|NCT00493740|Cephalic phase, oncology patients
1369898|NCT00493727|Oxidative stress
1369899|NCT00493727|N-acetylcysteine
1369900|NCT00493727|NAC
1369901|NCT00493727|Isoprostane
1369902|NCT00493727|Proteinuria
1369903|NCT00493727|Diabetes
1369904|NCT00493727|Mucomyst
1369905|NCT00493727|albuminuria
1369906|NCT00493714|Advanced Cancer
1369907|NCT00493714|Delirium
1369908|NCT00493714|Restlessness
1369909|NCT00493714|Confusion
1369910|NCT00493714|Caregivers
1369911|NCT00493714|Questionnaire
1369912|NCT00493688|Abdominal Cancer
1369913|NCT00493688|Pelvic Cancer
1369914|NCT00493688|Perioperative Energy Dynamics
1369915|NCT00493688|Cardiopulmonary Exercise Testing
1369916|NCT00493688|CPET
1369917|NCT00493675|Cystic duct leakage
1369918|NCT00493636|Breast Cancer
1369919|NCT00493610|Oxidant stress
1369920|NCT00493610|N-acetylcysteine
1369921|NCT00493610|Hepatitis C
1369922|NCT00493610|Liver disease
1369923|NCT00493610|Mucomyst
1369924|NCT00493610|Isoprostane
1369925|NCT00493597|Atherosclerosis
1369926|NCT00493597|Restenosis
1369927|NCT00493597|EPC
1369928|NCT00493597|DC
1369929|NCT00493584|Myocardial Infarction
1369930|NCT00493584|Myocardial Ischemia
1369931|NCT00493584|Myocardial Revascularization
1369932|NCT00493584|Telemedicine
1369933|NCT00493584|Percutaneous Transluminal Coronary Angioplasty
1369934|NCT00493571|Myelodysplastic Syndromes
1369935|NCT00493571|MDS
1369936|NCT00493571|Gimatecan
1369937|NCT00493571|Leukemia
1369938|NCT00493558|Roentgen Stereophotogrammetric Analysis
1369939|NCT00493558|Trabecular Metal Posterior Lumbar Interbody Cage
1369940|NCT00493558|Posterior Lumbar Interbody Fusion Cage
1369941|NCT00493558|Posterior Lumbar spine fusion surgery
1369942|NCT00493545|Multicenter
1369943|NCT00493545|Open-Label
1369944|NCT00493545|Nonrandomized
1369945|NCT00493545|Safety
1369946|NCT00493519|Cephalic phase
1369947|NCT00493519|Anorexia nervosa
1369948|NCT00493519|Bulimia nervosa
1369949|NCT00493519|obese binge eaters
1369950|NCT00493519|VAS
1369951|NCT00493519|EDI
1369952|NCT00493519|shame-feed procedure
1369953|NCT00493506|ProAlgaZyme
1369954|NCT00493506|HIV
1369955|NCT00493506|HAART
1369956|NCT00493506|hsCRP
1369957|NCT00493506|Oxidative stress
1369958|NCT00493506|CD4+ lymphocytes
1369959|NCT00493506|Algae
1369960|NCT00493506|HAART adverse effects
1369961|NCT00493506|HBV
1369962|NCT00493493|Cymetra
1369963|NCT00493467|Non-Hodgkin's Lymphoma
1369964|NCT00493467|Lymphoma
1369965|NCT00493467|Indolent Lymphomas
1369966|NCT00493467|Ibritumomab Tiuxetan
1369967|NCT00493467|Zevalin
1369968|NCT00493454|Indolent Lymphoma
1369969|NCT00493454|Extranodal Marginal
1369970|NCT00493454|Nodal Marginal Zone
1369971|NCT00493454|Splenic Marginal
1369972|NCT00493454|MALT Type
1369973|NCT00493454|Zevalin
1369974|NCT00493454|Ibritumomab Tiuxetan
1369975|NCT00493454|Rituximab
1369976|NCT00493428|Hepatocellular Carcinoma
1369977|NCT00493428|GABAergic Activity
1369978|NCT00493428|Baclofen
1369979|NCT00493415|microcirculation
1369980|NCT00493415|sepsis
1369981|NCT00493415|nitroglycerine
1369982|NCT00493415|SDF imaging
1369983|NCT00493402|Antineoplastic Agents
1369984|NCT00493402|administration & dosage
1369985|NCT00493402|Carcinoma, Hepatocellular
1369986|NCT00493402|Chemoembolization, Therapeutic
1369987|NCT00493402|Humans
1369988|NCT00493402|Liver Neoplasms
1369989|NCT00493402|therapy
1369990|NCT00493389|ACTH stimulation test
1369991|NCT00493389|cortisol
1369992|NCT00493389|stress
1369993|NCT00493376|tirapazamine
1369994|NCT00493376|DNA damage
1369995|NCT00493376|comet assay
1369996|NCT00493363|falciparum malaria
1369997|NCT00493363|artemisinins
1369998|NCT00493363|artesunate
1369999|NCT00493363|resistance
1370000|NCT00493350|Breast Cancer
1370001|NCT00493350|Circulating Tumor Cells
1370002|NCT00493350|Gene Profiling
1370003|NCT00493350|International Stage Stratification Study
1370004|NCT00493350|Blood Sample
1370005|NCT00493350|ISSS
1370006|NCT00493337|Adherence
1370007|NCT00493337|Compliance
1370008|NCT00493337|Statins
1370009|NCT00493337|Intervention
1370010|NCT00493337|Hypercholesterolemia
1370011|NCT00493324|psoriasis
1370012|NCT00493324|alefacept
1370013|NCT00493324|polyvalent pneumococcal vaccine
1370014|NCT00493324|Immunization
1370015|NCT00493298|disease progression
1370016|NCT00493298|Multiple Sclerosis
1370017|NCT00493298|disease activity
1370018|NCT00493298|Tysabri
1370019|NCT00493298|natalizumab
1370020|NCT00493298|long-term safety
1370021|NCT00493285|Lower Respiratory Tract Illness
1370022|NCT00493285|RSV and PIV3 infection
1370023|NCT00493272|Blood coagulation disorder, acquired
1370024|NCT00493272|Hemodilution
1370025|NCT00493272|Fibrinogen
1370026|NCT00493272|Hemostasis
1370027|NCT00493272|HES
1370028|NCT00493259|Health-Related Quality of Life
1370029|NCT00493233|schizophrenia
1370030|NCT00493233|antipsychotics
1370031|NCT00493233|polypharmacy
1370032|NCT00493233|double-blind
1370033|NCT00493233|randomized
1370034|NCT00493220|ceftriaxone
1370035|NCT00493220|cephalosporins
1370036|NCT00493220|pharmacokinetics
1370037|NCT00493220|subcutaneous
1370038|NCT00493220|hyaluronoglucosaminidase
1370039|NCT00493220|hyaluronidase
1370040|NCT00493220|hyaluronan
1370041|NCT00493220|rHuPH20
1370042|NCT00493194|Cyclosporine toxicity
1370043|NCT00493194|Interstitial Fibrosis
1370044|NCT00493194|Chronic allograft nephropathy
1370045|NCT00493194|Sirolimus
1370046|NCT00493181|oprelvekin
1370047|NCT00493181|tyrosine kinase inhibitor
1370048|NCT00493181|Chronic Myelogenous Leukemia
1370049|NCT00493181|Leukemia
1370050|NCT00493181|CML
1370051|NCT00493181|Thrombocytopenia
1370052|NCT00493181|Imatinib
1370053|NCT00493181|IL-11
1370054|NCT00493181|Interleukin 11
1370055|NCT00493181|Neumega
1370056|NCT00493129|Systemic Mastocytosis
1370057|NCT00493129|SM
1370058|NCT00493129|Mast Cell Leukemia
1370059|NCT00493129|Leukemia
1370060|NCT00493129|Denileukin Diftitox
1370061|NCT00493129|Ontak
1370062|NCT00493116|recovery of efficacy
1370063|NCT00493116|MxA protein
1370064|NCT00493116|neutralizing antibodies
1370065|NCT00493116|Multiple sclerosis
1370066|NCT00493103|thyroglobulin gene
1370067|NCT00493103|congenital hypothyroidism
1370068|NCT00493103|gene mutations
1370069|NCT00493103|fetal goiter
1370070|NCT00493103|iodine nutrition
1370071|NCT00493090|Professional
1370072|NCT00493090|patient partnership
1370073|NCT00493090|patient satisfaction
1370074|NCT00493090|professional training
1370075|NCT00493077|Multiple Sclerosis
1370076|NCT00493077|Neutralizing antibodies
1370077|NCT00493077|Safety
1370078|NCT00493077|Low immunogenicity
1370079|NCT00493077|interferon
1370080|NCT00493077|interferon-beta-1a
1370081|NCT00493051|diabetes
1370082|NCT00493051|nonhealing
1370083|NCT00493051|ulcers
1370084|NCT00493051|neuropathic
1370085|NCT00493038|Treatment of acute bacterial rhinosinusitis
1370086|NCT00493025|adenocarcinoma of the esophagus
1370087|NCT00493025|stage II esophageal cancer
1370088|NCT00493025|stage III esophageal cancer
1370089|NCT00493025|stage IV esophageal cancer
1370090|NCT00493012|body weight
1370091|NCT00493012|body compostion
1370092|NCT00493012|vitamin D
1370093|NCT00493012|blood pressure
1370094|NCT00492999|recurrent colon cancer
1370095|NCT00492999|stage IV colon cancer
1370096|NCT00492999|recurrent rectal cancer
1370097|NCT00492999|stage IV rectal cancer
1370098|NCT00492999|adenocarcinoma of the colon
1370099|NCT00492999|adenocarcinoma of the rectum
1370100|NCT00492999|liver metastases
1370101|NCT00492986|Renal Cell Cancer (RCC)
1370102|NCT00492986|Cancer
1370103|NCT00492973|arthroplasty
1370104|NCT00492973|replacement
1370105|NCT00492973|knee
1370106|NCT00492960|Celiac Disease
1370107|NCT00492947|Phase I
1370108|NCT00492947|dendritic cell
1370109|NCT00492947|vaccine
1370110|NCT00492947|intra tumoral
1370111|NCT00492947|squamous cell carcinoma
1370112|NCT00492934|subfertility
1370113|NCT00492934|endometrium thickness
1370114|NCT00492934|implantation rate
1370115|NCT00492934|embryo cryopreservation
1370116|NCT00492934|embryo transfer
1370117|NCT00492921|graft versus host disease
1370118|NCT00492908|Coronary Revascularization
1370119|NCT00492908|Titanium-Nitride-Oxide Coated Stent
1370120|NCT00492908|Zotarolimus-Eluting Stent
1370121|NCT00492882|Polycystic Ovary Syndrome
1370122|NCT00492882|Follicular Arrest
1370123|NCT00492882|Anti-Mullerian Hormone
1370124|NCT00492882|FSH
1370125|NCT00492869|kidney transplantation
1370126|NCT00492869|rejection
1370127|NCT00492869|AEB071
1370128|NCT00492869|tacrolimus
1370129|NCT00492869|mycophenolic
1370130|NCT00492869|basiliximab
1370131|NCT00492869|immunosuppression
1370132|NCT00492856|adult acute myeloid leukemia with t(15;17)(q22;q12)
1370133|NCT00492856|adult acute promyelocytic leukemia (M3)
1370134|NCT00492856|untreated adult acute myeloid leukemia
1370135|NCT00492843|Ibandronate, Lung cancer, bone metastasis
1370136|NCT00492830|Phase 1
1370137|NCT00492830|TRC093
1370138|NCT00492830|denatured collagen
1370139|NCT00492830|solid tumor
1370140|NCT00492830|antibody
1370141|NCT00492830|TRACON
1370142|NCT00492830|Locally advanced solid tumors
1370143|NCT00492830|Metastatic solid tumors
1370144|NCT00492817|Spinal Neoplasms
1370145|NCT00492817|Paraspinal Metastases
1370146|NCT00492817|Stereotactic Body Radiotherapy
1370147|NCT00492817|CT-on-Rails
1370148|NCT00492817|Spinal Cord
1370149|NCT00492817|SBRT
1370150|NCT00492804|inguinal hernia
1370151|NCT00492804|chronic pain
1370152|NCT00492804|neurectomy
1370153|NCT00492804|hypesthesia
1370154|NCT00492791|crohn's disease
1370155|NCT00492791|capsule endoscopes
1370156|NCT00492765|Combination therapy
1370157|NCT00492765|Simvastatin
1370158|NCT00492765|Multiple Sclerosis
1370159|NCT00492765|Interferon-beta-1a
1370160|NCT00492739|Orthotopic liver transplantation
1370161|NCT00492739|Pediatric
1370162|NCT00492739|Immunosuppression
1370163|NCT00492739|Varicella vaccine
1370164|NCT00492739|B cell response
1370165|NCT00492739|T cell response
1370166|NCT00492739|Antibodies
1370167|NCT00492739|Varicella
1370168|NCT00492739|Chickenpox
1370169|NCT00492739|transplantation
1370170|NCT00492726|Complicated Intra-Abdominal Infections
1370171|NCT00492713|Bioavailability
1370172|NCT00492713|Dark Chocolate
1370173|NCT00492713|Milk Chocolate
1370174|NCT00492713|Polyphenols
1370175|NCT00492700|steatosis,
1370176|NCT00492700|fibrosis,
1370177|NCT00492700|diabetes,
1370178|NCT00492700|obesity
1370179|NCT00492687|adult anaplastic astrocytoma
1370180|NCT00492687|adult giant cell glioblastoma
1370181|NCT00492687|adult gliosarcoma
1370182|NCT00492687|adult glioblastoma
1370183|NCT00492674|TKA
1370184|NCT00492674|Arthroplasty
1370185|NCT00492674|Knee
1370186|NCT00492674|Osteoarthritis
1370187|NCT00492674|Rehabilitation
1370188|NCT00492661|Tacrolimus
1370189|NCT00492661|Prograf
1370190|NCT00492661|PRIDE
1370191|NCT00492648|GSK Biologicals
1370192|NCT00492648|Varicella Zoster Virus (VZV)
1370193|NCT00492648|Intracellular cytokine staining (ICS)
1370194|NCT00492648|Vaccine
1370195|NCT00492648|Cell mediated immunity (CMI)
1370196|NCT00492648|Herpes Zoster (HZ)
1370197|NCT00492648|Shingles
1370198|NCT00492622|Gastroparesis
1370199|NCT00492622|Gastroesophageal reflux disease
1370200|NCT00492622|heartburn
1370201|NCT00492609|Surgery
1370202|NCT00492609|Navigation
1370203|NCT00492609|ACL
1370204|NCT00492609|IKDC
1370205|NCT00492609|comparative study
1370206|NCT00492583|probiotic
1370207|NCT00492583|health
1370208|NCT00492583|bifidobacterium lactis
1370209|NCT00492583|BB-12
1370210|NCT00492570|Multiple Sclerosis
1370211|NCT00492570|Cognitive Dysfunction in Multiple sclerosis
1370212|NCT00492570|early treatment
1370213|NCT00492570|Avonex
1370214|NCT00492570|interferon beta 1a
1370215|NCT00492570|Cognitive Dysfunction
1370216|NCT00492557|Pneumococcal Disease
1370217|NCT00492557|Pneumococcal Conjugate Vaccine
1370218|NCT00492544|Human Papillomavirus (HPV) vaccine
1370219|NCT00492544|safety
1370220|NCT00492544|cervical cancer
1370221|NCT00492544|immunogenicity
1370222|NCT00492544|vaccine
1370223|NCT00492544|viral infections
1370224|NCT00492544|pre-adolescent and adolescent females
1370225|NCT00492531|Interventional Study
1370226|NCT00492531|6-Minute Walk
1370227|NCT00492531|Sickle Cell Anemia
1370228|NCT00492531|Sildenafil/Viagra
1370229|NCT00492531|Tricuspid Regurgitant Velocity
1370230|NCT00492531|Sickle Cell Disease
1370231|NCT00492531|Pulmonary Hypertension
1370232|NCT00492518|Contrast Induced Nephropathy
1370233|NCT00492518|Prophylaxis
1370234|NCT00492518|Theophylline
1370235|NCT00492518|Acetylcysteine
1370236|NCT00492518|Coronary angiography
1370237|NCT00492505|stage IIIA melanoma
1370238|NCT00492505|stage IIIB melanoma
1370239|NCT00492505|stage IIIC melanoma
1370240|NCT00492492|radius,
1370241|NCT00492492|pinning,
1370242|NCT00492492|fixed-angle plate,
1370243|NCT00492492|quick-DASH,
1370244|NCT00492492|HERZBERG-score.
1370245|NCT00492466|Multiple Sclerosis
1370246|NCT00492466|antibody
1370247|NCT00492466|Neutralizing antibody
1370248|NCT00492466|Binding antibody
1370249|NCT00492466|MxA protein
1370250|NCT00492440|recurrent renal cell cancer
1370251|NCT00492440|stage IV renal cell cancer
1370252|NCT00492440|stage III renal cell cancer
1370253|NCT00492440|recurrent melanoma
1370254|NCT00492440|stage IV melanoma
1370255|NCT00492414|Panic disorder (PD)
1370256|NCT00492388|breakthrough
1370257|NCT00492388|pain
1370258|NCT00492388|cancer
1370259|NCT00492362|hemodialysis
1370260|NCT00492362|exercise
1370261|NCT00492362|physical fitness
1370262|NCT00492362|dialysis adequacy
1370263|NCT00492349|Varenicline
1370264|NCT00492349|Neurobiology
1370265|NCT00492349|clinical trial
1370266|NCT00492349|cognitive deficits
1370267|NCT00492349|Schizophreniform Disorder
1370268|NCT00492336|Cognitive impairments
1370269|NCT00492336|Negative symptoms
1370270|NCT00492323|pain following the healing of rashes and blisters
1370271|NCT00492323|herpes virus
1370272|NCT00492323|rash
1370273|NCT00492323|varicella-zoster virus
1370274|NCT00492323|shingles.
1370275|NCT00492310|Smoking
1370276|NCT00492310|tobacco
1370277|NCT00492310|women
1370278|NCT00492310|yoga
1370279|NCT00492284|Macular Degeneration
1370280|NCT00492284|AMD
1370281|NCT00492284|CNV
1370282|NCT00492284|Choroidal neovascularization
1370283|NCT00492284|Photodynamic therapy
1370284|NCT00492284|CNV Secondary to Age Related Macular Degeneration
1370285|NCT00492271|Friulimicin B
1370286|NCT00492271|Lipopeptide Antibiotic
1370287|NCT00492271|First in Man
1370288|NCT00492258|stage II renal cell cancer
1370289|NCT00492258|stage III renal cell cancer
1370290|NCT00492258|stage IV renal cell cancer
1370291|NCT00492258|stage I renal cell cancer
1370292|NCT00492258|clear cell renal cell carcinoma
1370293|NCT00492258|papillary renal cell carcinoma
1370294|NCT00492245|PTK
1370295|NCT00492245|corneal opacity
1370296|NCT00492245|mitomycin
1370297|NCT00492232|Chronic Insomnia
1370298|NCT00492232|Sleep Initiation and Maintenance Disorder
1370299|NCT00492232|Drug Therapy
1370300|NCT00492219|arthroplasty
1370301|NCT00492219|replacement
1370302|NCT00492219|knee
1370303|NCT00492219|prosthesis
1370304|NCT00492206|Non Small Cell Lung Cancer
1370305|NCT00492206|NSCLC
1370306|NCT00492206|EGFR Inhibitor
1370307|NCT00492206|Radiation Therapy
1370308|NCT00492193|Hand assist laparoscopic partial large bowel resection
1370309|NCT00492193|Laparoscopic partial large bowel resection
1370310|NCT00492167|recurrent neuroblastoma
1370311|NCT00492167|regional neuroblastoma
1370312|NCT00492167|stage 4S neuroblastoma
1370313|NCT00492167|disseminated neuroblastoma
1370314|NCT00492154|FRACTURE OF DISTAL RADIUS
1370315|NCT00492141|Ewing's Sarcoma
1370316|NCT00492141|Lung Involvement
1370317|NCT00492141|Temozolomide
1370318|NCT00492141|Temodar
1370319|NCT00492141|Aerosol Liposomal 9-Nitro-20(S)-Camptothecin
1370320|NCT00492141|Aerosol L9-NC
1370321|NCT00492141|L9-NC
1370322|NCT00492128|hypertension
1370323|NCT00492128|angiotensin receptor blocker
1370324|NCT00492128|diuretic
1370325|NCT00492128|combination therapy
1370326|NCT00492115|sleep
1370327|NCT00492115|dementia
1370328|NCT00492115|apnea
1370329|NCT00492115|memory
1370330|NCT00492115|Parkinson's disease
1370331|NCT00492102|pharmacokinetics
1370332|NCT00492102|Montelukast
1370333|NCT00492102|bronchopulmonary dysplasia
1370334|NCT00492102|Pharmacokinetics of Montelukast
1370335|NCT00492076|Specific immunotherapy
1370336|NCT00492076|Mite
1370337|NCT00492076|Asthma
1370338|NCT00492063|safety
1370339|NCT00492063|immunogenicity
1370340|NCT00492063|non-inferiority
1370341|NCT00492063|MDCK
1370342|NCT00492063|cell culture-derived
1370343|NCT00492063|subunit influenza vaccine
1370344|NCT00492063|influenza prevention
1370345|NCT00492050|Waldenstrom's Macroglobulinemia
1370346|NCT00492050|Macroglobulinemic Lymphoma
1370347|NCT00492050|Stem Cell Collection
1370348|NCT00492050|Bortezomib
1370349|NCT00492050|LDP-341
1370350|NCT00492050|MLN341
1370351|NCT00492050|PS-341
1370352|NCT00492050|Velcade
1370353|NCT00492050|Rituximab
1370354|NCT00492050|Rituxan
1370355|NCT00492037|hyponatremia
1370356|NCT00492037|hypervolemic
1370357|NCT00492037|euvolemic
1370358|NCT00492037|conivaptan
1370359|NCT00492024|Respiratory Tract Infection
1370360|NCT00492024|Bacterial Sinusitis
1370361|NCT00492011|Circadian Rhythm Disorders
1370362|NCT00492011|Biological Clock Disturbances
1370363|NCT00492011|Jet Lag Syndrome
1370364|NCT00492011|Time Zone Change Syndrome
1370365|NCT00492011|Drug Therapy
1370366|NCT00491985|Influenza A/H5N1 Virus
1370367|NCT00491985|Influenza Pandemic
1370368|NCT00491985|Orthomyxoviridae Infections
1370369|NCT00491959|oral mucosa
1370370|NCT00491959|limbal insufficiency
1370371|NCT00491959|transplantation
1370372|NCT00491959|cornea
1370373|NCT00491959|ocular surface
1370374|NCT00491946|Cancer
1370375|NCT00491946|Actinomycin
1370376|NCT00491946|Vincristine
1370377|NCT00491920|osteoporosis
1370378|NCT00491920|bone mineral density
1370379|NCT00491920|vitamin D
1370380|NCT00491907|folic acid
1370381|NCT00491907|endothelial function
1370382|NCT00491907|baroreceptor function
1370383|NCT00491907|heart failure
1370384|NCT00491894|Mental Retardation
1370385|NCT00491894|Neurological Impairment
1370386|NCT00491894|Cerebral Palsy
1370387|NCT00491894|Drooling
1370388|NCT00491894|Neurological Conditions
1370389|NCT00491881|blood pressure
1370390|NCT00491881|No added salt diet
1370391|NCT00491881|urinary sodium
1370392|NCT00491855|Advanced Peritoneal Carcinomatosis
1370393|NCT00491855|Peritoneal Cancer
1370394|NCT00491855|Bevacizumab
1370395|NCT00491855|Avastin
1370396|NCT00491855|vascular endothelial growth factor
1370397|NCT00491855|Anti-VEGF monoclonal antibody
1370398|NCT00491855|rhuMAb-VEGF
1370399|NCT00491855|Oxaliplatin
1370400|NCT00491855|Eloxatin
1370401|NCT00491855|Paclitaxel
1370402|NCT00491855|Taxol
1370403|NCT00491842|Huntington's Disease
1370404|NCT00491842|Disclosure
1370405|NCT00491842|Adaptation
1370406|NCT00491842|Communication About Huntington's Disease
1370407|NCT00491842|Huntington Disease
1370408|NCT00491842|HD
1370409|NCT00491842|Phone Interview
1370410|NCT00491816|breast
1370411|NCT00491816|cancer
1370412|NCT00491816|breast cancer
1370413|NCT00491803|COPD
1370414|NCT00491790|montelukast
1370415|NCT00491790|Albuterol
1370416|NCT00491790|Status Asthmaticus
1370417|NCT00491790|Asthma
1370418|NCT00491777|Noninvasive
1370419|NCT00491777|Hemodynamic
1370420|NCT00491777|Monitoring
1370421|NCT00491777|Critical Care
1370422|NCT00491777|Swan-Ganz
1370423|NCT00491751|endothelium
1370424|NCT00491751|nitric oxide
1370425|NCT00491751|statins
1370426|NCT00491751|ascorbic acid
1370427|NCT00491738|RCC
1370428|NCT00491738|Renal cell cancer
1370429|NCT00491738|Avastin
1370430|NCT00491738|Sutent
1370431|NCT00491712|Glaucoma
1370432|NCT00491712|Neovascular Glaucoma
1370433|NCT00491712|Drainage implant devices
1370434|NCT00491712|Silicone Ahmed Tube
1370435|NCT00491712|Triamcinolone
1370436|NCT00491699|NSCLC
1370437|NCT00491686|Long-term depression
1370438|NCT00491673|Fracture
1370439|NCT00491673|Femoral neck
1370440|NCT00491673|Arthroplasty
1370441|NCT00491660|Gravity
1370442|NCT00491660|Mechanical ventilation
1370443|NCT00491660|Infants
1370444|NCT00491660|Ventilator-associated pneumonia
1370445|NCT00491660|Types of bacterial colonies in subjects at 2-5 days of mechanical ventilation
1370446|NCT00491660|Colony count of an organism was cultured
1370447|NCT00491647|ADHD, time perception, treatments
1370448|NCT00491634|acute myeloid leukemia
1370449|NCT00491634|myelodysplastic syndrome
1370450|NCT00491634|allogeneic stem cell transplantation
1370451|NCT00491634|reduced-intensity conditioning
1370452|NCT00491634|treosulfan
1370453|NCT00491621|kidney
1370454|NCT00491621|tumor
1370455|NCT00491621|Molecular Markers
1370456|NCT00491621|Cytology
1370457|NCT00491621|Histology
1370458|NCT00491621|Cystic kidney tumor
1370459|NCT00491608|Phase 3b
1370460|NCT00491608|rThrombin
1370461|NCT00491608|spine surgery
1370462|NCT00491608|vascular surgery
1370463|NCT00491608|hemostasis
1370464|NCT00491608|immunogenicity
1370465|NCT00491608|safety
1370466|NCT00491595|Soy isoflavones
1370467|NCT00491595|Genotoxicity
1370468|NCT00491595|Apoptosis
1370469|NCT00491595|Estrogenic effects
1370470|NCT00491569|Schizophrenia
1370471|NCT00491569|sarcosine
1370472|NCT00491569|D-serine
1370473|NCT00491569|NMDA
1370474|NCT00491556|Atazanavir/Ritonavir (ATV/r)
1370475|NCT00491556|highly-active antiretroviral therapy (HAART)
1370476|NCT00491556|Treatment Naive
1370477|NCT00491491|non-Hodgkin's lymphoma
1370478|NCT00491491|autologous stem cell transplantation
1370479|NCT00491491|radioimmunotherapy
1370480|NCT00491491|zevalin
1370481|NCT00491478|Repetitive behavior disorder
1370482|NCT00491478|Stereotypy
1370483|NCT00491478|Sertraline
1370484|NCT00491465|Type 1 Diabetes, physical activity, pediatric, metabolic control
1370485|NCT00491452|Ischemic MR
1370486|NCT00491452|Annuloplasty
1370487|NCT00491439|in vivo confocal microscopy
1370488|NCT00491439|vitrectomy
1370489|NCT00491439|corneal transplantation
1370490|NCT00491439|Epi-LASIK
1370491|NCT00491439|wound healing
1370492|NCT00491426|Infection
1370493|NCT00491426|Anti-Infective Agents
1370494|NCT00491426|Antifungal Agents
1370495|NCT00491426|Proteomics
1370496|NCT00491413|neurodevelopmental outcomes
1370497|NCT00491400|endothelium
1370498|NCT00491400|obesity
1370499|NCT00491400|diabetes mellitus
1370500|NCT00491400|dyslipidemia
1370501|NCT00491387|hypertension
1370502|NCT00491387|sympathetic nervous system
1370503|NCT00491361|ADHD, SNAP-IV, SDQ, ASRS, reliability, validity
1370504|NCT00491348|Generalized anxiety disorder
1370505|NCT00491348|fMRI
1370506|NCT00491348|Worry
1370507|NCT00491335|AIDS
1370508|NCT00491335|Lung Cancer
1370509|NCT00491335|Emphysema
1370510|NCT00491335|Nicotine
1370511|NCT00491335|HIV Infection
1370512|NCT00491335|Smoking
1370513|NCT00491322|Vitamin D
1370514|NCT00491322|Vitamin D deficiency
1370515|NCT00491322|Insulin resistance
1370516|NCT00491322|Diabetes
1370517|NCT00491322|Diabetes mellitus
1370518|NCT00491322|FGF-23
1370519|NCT00491322|FGF23
1370520|NCT00491322|Phosphate
1370521|NCT00491296|S/P Transuretral resection of bladder tumor
1370522|NCT00491296|Recurrent tumor after BCG Treatment
1370523|NCT00491270|Vaginosis, Bacterial
1370524|NCT00491270|Abortion, Spontaneous
1370525|NCT00491270|Premature Birth
1370526|NCT00491257|Influenza
1370527|NCT00491257|Orthomyxoviridae Infections
1370528|NCT00491257|Orthomyxoviruses
1370529|NCT00491257|Split-virion influenza vaccine
1370530|NCT00491244|Chronic hepatitis C
1370531|NCT00491244|Hemodialysis
1370532|NCT00491244|Interferon
1370533|NCT00491244|Ribavirin
1370534|NCT00491231|orthostatic hypotension
1370535|NCT00491231|ambulatory blood pressure monitoring
1370536|NCT00491218|impact of cardiac computed tomography on outpatient angina evaluation
1370537|NCT00491218|downstream resource utilization
1370538|NCT00491192|Fever
1370539|NCT00491192|Acute cerebral damage
1370540|NCT00491192|Normothermia
1370541|NCT00491192|Diclofenac
1370542|NCT00491192|ICU
1370543|NCT00491192|Outcome
1370544|NCT00491192|Intracranial pressure
1370545|NCT00491192|Cerebral perfusion pressure
1370546|NCT00491192|Traumatic brain injury
1370547|NCT00491192|Subarachnoid hemorrhage
1370548|NCT00491179|Chronic hepatitis C
1370549|NCT00491179|hemodialysis
1370550|NCT00491179|interferon
1370551|NCT00491179|ribavirin
1370552|NCT00491166|diabetic macular edema
1370553|NCT00491166|bromfenac ophthalmic solution
1370554|NCT00491153|asthma
1370555|NCT00491153|airway hyperresponsiveness
1370556|NCT00491153|dry powder mannitol inhalation
1370557|NCT00491153|methacholine
1370558|NCT00491140|EGFR
1370559|NCT00491140|KRAS
1370560|NCT00491140|BRAF
1370561|NCT00491140|MET
1370562|NCT00491140|IGFR1
1370563|NCT00491101|Asthma Control
1370564|NCT00491101|Quality of Life
1370565|NCT00491101|Children
1370566|NCT00491101|Polish Version of PAQLQ(S) by Juniper
1370567|NCT00491075|Renal Cell Carcinoma
1370568|NCT00491075|Non-Clear Cell
1370569|NCT00491075|Pemetrexed
1370570|NCT00491075|Gemcitabine
1370571|NCT00491075|LY231514
1370572|NCT00491075|Alimta
1370573|NCT00491075|MTA
1370574|NCT00491075|Multitargeted Antifolate
1370575|NCT00491075|NSC-698037
1370576|NCT00491075|Gemcitabine Hydrochloride
1370577|NCT00491075|Gemzar
1370578|NCT00491075|RCC
1370579|NCT00491062|Parkinson's disease
1370580|NCT00491062|enteric nervous system
1370581|NCT00491049|prophylaxis
1370582|NCT00491049|intraocular surgery
1370583|NCT00491049|endophthalmitis
1370584|NCT00491049|antibiotic
1370585|NCT00491036|Acute myocardial infarction
1370586|NCT00491036|cardiogenic shock
1370587|NCT00491036|percutaneous coronary intervention
1370588|NCT00491036|intraaortic balloon counterpulsation
1370589|NCT00491036|Acute myocardial infarction - cardiogenic shock
1370590|NCT00491010|atrial flutter
1370591|NCT00491010|ablation
1370592|NCT00491010|voltage targeted
1370593|NCT00490997|ketamine
1370594|NCT00490997|propofol
1370595|NCT00490997|sedation
1370596|NCT00490997|pediatric
1370597|NCT00490997|emergency department
1370598|NCT00490997|fracture
1370599|NCT00490984|obstructive sleep apena
1370600|NCT00490984|tongue
1370601|NCT00490984|surgery
1370602|NCT00490971|Bipolar Disorder
1370603|NCT00490971|Mania
1370604|NCT00490971|Depression
1370605|NCT00490971|Manic-Depressive Disorder
1370606|NCT00490958|heart Failure
1370607|NCT00490958|haemodialysis
1370608|NCT00490958|telmisartan
1370609|NCT00490958|angiotensin converting enzyme inhibitor
1370610|NCT00490932|Watery diarrhea
1370611|NCT00490932|Bloody diarrhea
1370612|NCT00490919|Chronic pain
1370613|NCT00490919|opioid
1370614|NCT00490919|transdermal
1370615|NCT00490919|Moderate to severe chronic low back pain
1370616|NCT00490906|MS (Multiple Sclerosis)
1370617|NCT00490893|counterregulation
1370618|NCT00490893|hypoglycemia unawareness
1370619|NCT00490893|insulin therapy
1370620|NCT00490828|Cardiac surgery
1370621|NCT00490828|systemic inflammatory response syndrome
1370622|NCT00490828|health-related quality of life
1370623|NCT00490802|Autism
1370624|NCT00490802|Treatment
1370625|NCT00490802|Oxytocin
1370626|NCT00490802|Adults
1370627|NCT00490802|Autism Spectrum Disorder
1370628|NCT00490789|tuberous sclerosis
1370629|NCT00490789|lymphangioleiomyomatosis
1370630|NCT00490789|sirolimus
1370631|NCT00490789|angiomyolioma
1370632|NCT00490789|rapamycin
1370633|NCT00490789|mTOR
1370634|NCT00490776|Cutaneous T-Cell Lymphoma
1370635|NCT00490776|adults
1370636|NCT00490776|Mycosis Fungoides
1370637|NCT00490776|Sézary Syndrome
1370638|NCT00490776|CTCL
1370639|NCT00490763|Prostate Cancer
1370640|NCT00490763|Active Surveillance
1370641|NCT00490763|Prostate Specific Antigen
1370642|NCT00490763|Questionnaire
1370643|NCT00490763|Survey
1370644|NCT00490750|Heller Dor
1370645|NCT00490750|Heller Toupet
1370646|NCT00490750|Myotomy
1370647|NCT00490737|ESRD
1370648|NCT00490737|dialysis
1370649|NCT00490737|hemodialysis
1370650|NCT00490737|continuous ambulatory peritoneal dialysis
1370651|NCT00490724|Heart failure, congestive
1370652|NCT00490724|Nesiritide and
1370653|NCT00490724|JNS004
1370654|NCT00490698|Kidney Cancer
1370655|NCT00490698|Renal Cell Carcinoma
1370656|NCT00490698|Bone-Targeted Therapy
1370657|NCT00490698|Zoledronate
1370658|NCT00490698|Zometa
1370659|NCT00490698|Atorvastatin
1370660|NCT00490698|Lipitor
1370661|NCT00490698|RCC
1370662|NCT00490672|Hypertension
1370663|NCT00490672|Diabetes Mellitus
1370664|NCT00490672|Hyperlipidaemia
1370665|NCT00490672|Primary Care
1370666|NCT00490672|Community Care
1370667|NCT00490672|Multiple Risk Factors Interventional Strategies
1370668|NCT00490646|Locally advanced and/or metastatic breast cancer
1370669|NCT00490633|Influenza
1370670|NCT00490633|Non Pharmaceutical Intervention
1370671|NCT00490633|Face Mask
1370672|NCT00490633|Hand Hygiene
1370673|NCT00490620|primary biliary cirrhosis C06.552.630.400
1370674|NCT00490620|retroviral infection C02.782.815
1370675|NCT00490607|Hemagiomas of infancy
1370676|NCT00490594|ACL
1370677|NCT00490594|ligament
1370678|NCT00490594|ACL injury
1370679|NCT00490581|Early housing after hospitalization
1370680|NCT00490568|cognition
1370681|NCT00490568|Alzheimer's disease
1370682|NCT00490568|Rosiglitazone extended-release (XR)
1370683|NCT00490568|safety
1370684|NCT00490568|adjunctive therapy
1370685|NCT00490568|BRL-049653
1370686|NCT00490568|tolerability
1370687|NCT00490568|open-label extension
1370688|NCT00490555|Male Contraception
1370689|NCT00490555|Testosterone
1370690|NCT00490555|Testis
1370691|NCT00490555|Contraception
1370692|NCT00490555|Prostate
1370693|NCT00490542|Bipolar Disorder
1370694|NCT00490542|Major Depression
1370695|NCT00490542|Clinical pharmacology
1370696|NCT00490542|Clinical Trial
1370697|NCT00490516|Schizophrenia, psychotic disorders
1370698|NCT00490503|Breast Cancer
1370699|NCT00490503|Magnetic Resonance Imaging
1370700|NCT00490503|Magnetic Resonance Spectroscopy
1370701|NCT00490503|DCE-MRI
1370702|NCT00490503|DW-MRI
1370703|NCT00490503|MRS
1370704|NCT00490503|MRI
1370705|NCT00490477|acute renal failure
1370706|NCT00490477|lipopolysaccharide
1370707|NCT00490477|tubular apoptosis
1370708|NCT00490477|Polymyxin-B fiber
1370709|NCT00490477|Severe sepsis from gram negative infection
1370710|NCT00490464|Patients with SAH or ICH
1370711|NCT00490438|perineometry
1370712|NCT00490438|Modified Oxford Score
1370713|NCT00490438|pelvic muscles evaluation
1370714|NCT00490438|urinary incontinence
1370715|NCT00490438|vaginal palpation
1370716|NCT00490425|probiotics
1370717|NCT00490425|LGG
1370718|NCT00490425|praevention
1370719|NCT00490425|allergic asthma
1370720|NCT00490425|children
1370721|NCT00490412|Vitamin D
1370722|NCT00490412|Treatment Experienced
1370723|NCT00490386|Retrospective
1370724|NCT00490386|Length of Stay
1370725|NCT00490386|Helicobacter pylori
1370726|NCT00490347|VentrAssistTM
1370727|NCT00490347|LVAD
1370728|NCT00490347|End-stage heart failure
1370729|NCT00490347|Cardiomyopathy
1370730|NCT00490334|Carcinomas
1370731|NCT00490334|Squamous Cel
1370732|NCT00490334|Adenocarcinoma
1370733|NCT00490334|Acute Lymphocytic Leukemia
1370734|NCT00490321|VentrAssistTM
1370735|NCT00490321|LVAD
1370736|NCT00490321|End-stage heart failure
1370737|NCT00490321|Cardiomyopathy
1370738|NCT00490308|luteal
1370739|NCT00490308|phase
1370740|NCT00490308|estradiol
1370741|NCT00490308|pregnancy
1370742|NCT00490308|rate
1370743|NCT00490295|biomarkers
1370744|NCT00490295|brain ischemia
1370745|NCT00490295|neonates
1370746|NCT00490295|cardiac surgery
1370747|NCT00490295|congenital heart disease
1370748|NCT00490282|Head and Neck Cancer
1370749|NCT00490282|Oropharyngeal Cancer
1370750|NCT00490282|Adaptive Radiotherapy
1370751|NCT00490282|Intensity Modulated Radiation Therapy
1370752|NCT00490282|IMRT
1370753|NCT00490282|ART
1370754|NCT00490269|Marijuana dependence
1370755|NCT00490256|Selective Cerebral Perfusion
1370756|NCT00490256|Renal Complications
1370757|NCT00490256|Gastrointestinal Complications
1370758|NCT00490256|Aortic Arch Reconstruction
1370759|NCT00490256|Modified Perfusion
1370760|NCT00490256|Cardiopulmonary Bypass
1370761|NCT00490256|Pediatrics
1370762|NCT00490256|Cardiac Defects
1370763|NCT00490256|intestinal ischemia
1370764|NCT00490256|necrotizing entercolitis
1370765|NCT00490256|Near Infra-red spectroscopy
1370766|NCT00490256|Creatinine
1370767|NCT00490256|C-reactive protein levels
1370768|NCT00490243|Asthma
1370769|NCT00490243|Children
1370770|NCT00490243|Exercise
1370771|NCT00490243|Pulmonary Function
1370772|NCT00490243|Budesonide
1370773|NCT00490243|Montelukast
1370774|NCT00490243|Formoterol
1370775|NCT00490230|Paromomycin
1370776|NCT00490230|Gentamicin
1370777|NCT00490217|Spontaneous bacterial peritonitis
1370778|NCT00490217|incidence
1370779|NCT00490217|Finland
1370780|NCT00490217|etiology
1370781|NCT00490217|liver cirrhosis
1370782|NCT00490204|Cetirizine
1370783|NCT00490204|Perennial Allergic Rhinitis
1370784|NCT00490204|Placebo control
1370785|NCT00490204|anti-histamine
1370786|NCT00490178|Type II diabetes
1370787|NCT00490178|dyslipidemia
1370788|NCT00490178|metformin
1370789|NCT00490178|fenofibrate
1370790|NCT00490178|synordia
1370791|NCT00490152|HIV
1370792|NCT00490152|Microbicide Gel
1370793|NCT00490152|HIV Seronegativity
1370794|NCT00490139|Adjuvant
1370795|NCT00490139|ErbB2-overexpressing
1370796|NCT00490139|Early stage breast cancer
1370797|NCT00490139|HER2/neu gene amplified
1370798|NCT00490126|Laparoscopic Surgery
1370799|NCT00490126|Laparoscopy
1370800|NCT00490126|Gynecology
1370801|NCT00490126|Demographics
1370802|NCT00490126|Perioperative Care
1370803|NCT00490100|X-Linked Severe Combined Immune Deficiency (XSCID)
1370804|NCT00490100|Growth Hormone
1370805|NCT00490100|Insulin-Like Growth Factor 1 (IGF)-1
1370806|NCT00490100|Bone Age
1370807|NCT00490100|Growth Failure
1370808|NCT00490100|XSCID
1370809|NCT00490100|X-Linked Severe Combined Immunodeficiency
1370810|NCT00490087|Atypical endometrial polyps
1370811|NCT00490087|Atypical Endometrial Hyperplasia
1370812|NCT00490087|Hysteroscopic resection
1370813|NCT00490087|Conservative treatment
1370814|NCT00490087|Fertile women
1370815|NCT00490074|AIDS Vaccines
1370816|NCT00490074|Vaccines, DNA
1370817|NCT00490074|HIV Preventive Vaccine
1370818|NCT00490074|HIV Seronegativity
1370819|NCT00490048|Ulcerative colits
1370820|NCT00490048|lung
1370821|NCT00490048|Induced sputum
1370822|NCT00490048|Our aim to evaluate lung involvement in Ulcerative colitis patients by induced sputum
1370823|NCT00490035|Epilepsy
1370824|NCT00490035|Brivaracetam
1370825|NCT00490035|Partial Onset Seizures
1370826|NCT00490022|Dihydrotestosterone
1370827|NCT00490022|Androgen
1370828|NCT00490022|Prostate
1370829|NCT00489970|Persistence
1370830|NCT00489970|immunogenicity
1370831|NCT00489957|congenital cardiac disorders
1370832|NCT00489957|echocardiography
1370833|NCT00489944|ciliary body and choroid melanoma, medium/large size
1370834|NCT00489944|extraocular extension melanoma
1370835|NCT00489944|iris melanoma
1370836|NCT00489944|epithelioid cell intraocular melanoma
1370837|NCT00489944|stage IIB intraocular melanoma
1370838|NCT00489944|stage IIIA intraocular melanoma
1370839|NCT00489944|stage IIIB intraocular melanoma
1370840|NCT00489944|stage IIIC intraocular melanoma
1370841|NCT00489944|stage IV intraocular melanoma
1370842|NCT00489931|Avian Influenza
1370843|NCT00489931|Healthy
1370844|NCT00489931|Immunity
1370845|NCT00489931|Preventive
1370846|NCT00489931|Bird Flu
1370847|NCT00489931|Healthy Volunteer
1370848|NCT00489931|HV
1370849|NCT00489905|prostate cancer
1370850|NCT00489905|bone mineral density
1370851|NCT00489892|traumatic brain injury
1370852|NCT00489892|TBI
1370853|NCT00489892|working memory
1370854|NCT00489892|modafinil
1370855|NCT00489892|fMRI
1370856|NCT00489892|MRI
1370857|NCT00489879|Mobile Health Units
1370858|NCT00489879|Chronic Disease
1370859|NCT00489866|PTSD
1370860|NCT00489866|Antidepressant
1370861|NCT00489866|Aripiprazole
1370862|NCT00489866|OEF
1370863|NCT00489866|OIF
1370864|NCT00489853|COPD
1370865|NCT00489840|Chronic Central Serous Chorioretinopathy
1370866|NCT00489827|Coronary Artery Bypass
1370867|NCT00489827|Myocardial Protection
1370868|NCT00489827|Angina, Unstable
1370869|NCT00489827|Myocardial Ischemia
1370870|NCT00489827|Myocardial Infarction
1370871|NCT00489827|Unstable Coronary Artery Disease
1370872|NCT00489827|Glutamate
1370873|NCT00489814|Prostate Cancer
1370874|NCT00489814|Prostate Proton Therapy
1370875|NCT00489814|Proton Radiation Therapy
1370876|NCT00489814|Proton Radiotherapy
1370877|NCT00489814|Quality of Life
1370878|NCT00489814|QOL
1370879|NCT00489814|Questionnaire
1370880|NCT00489801|Cardiac Rehabilitation
1370881|NCT00489801|Exercise
1370882|NCT00489801|Heart failure
1370883|NCT00489801|Coronary heart disease
1370884|NCT00489788|MRI
1370885|NCT00489788|Ventricular Strain
1370886|NCT00489788|Pulmonary Valve Replacement
1370887|NCT00489788|Post Tetralogy of Fallot
1370888|NCT00489762|Childhood
1370889|NCT00489762|Asthma
1370890|NCT00489762|Heating
1370891|NCT00489762|Insulation
1370892|NCT00489762|Respiratory symptoms
1370893|NCT00489749|Achilles tendon rupture
1370894|NCT00489749|Open surgical repair
1370895|NCT00489749|Early functional mobilization
1370896|NCT00489749|Weightbearing
1370897|NCT00489749|Rehabilitation
1370898|NCT00489736|Atrial Fibrillation
1370899|NCT00489736|sinus rhythm
1370900|NCT00489736|amiodarone
1370901|NCT00489723|size of stone 1-2 cm
1370902|NCT00489723|Pt. with no use of alfa bloker prior ESWL
1370903|NCT00489723|Pt. without internal stent
1370904|NCT00489710|stage IV renal cell cancer
1370905|NCT00489710|recurrent renal cell cancer
1370906|NCT00489697|colorectal cancer
1370907|NCT00489697|hepatic metastases
1370908|NCT00489697|bevacizumab
1370909|NCT00489697|anti-angiogenic agent
1370910|NCT00489697|chemotherapy regimens
1370911|NCT00489697|tumor vascularity
1370912|NCT00489697|Contrast-enhanced ultrasound
1370913|NCT00489671|pancreatic cancer
1370914|NCT00489671|precancerous condition
1370915|NCT00489658|Human African trypanosomiasis
1370916|NCT00489658|sleeping sickness
1370917|NCT00489658|Trypanosoma brucei gambiense
1370918|NCT00489658|combination
1370919|NCT00489658|eflornithine
1370920|NCT00489658|nifurtimox
1370921|NCT00489658|Human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense in the late stage (stage 2 or meningo-encephalitic)
1370922|NCT00489645|pramlintide
1370923|NCT00489645|gastric emptying
1370924|NCT00489645|T1DM
1370925|NCT00489645|postprandial
1370926|NCT00489632|Leukemia
1370927|NCT00489632|Pediatrics
1370928|NCT00489632|Cancer
1370929|NCT00489632|Coping
1370930|NCT00489632|Caregiver
1370931|NCT00489632|Questionnaire
1370932|NCT00489632|Children
1370933|NCT00489632|Resiliency
1370934|NCT00489632|Adjustment
1370935|NCT00489632|Illness-related factors
1370936|NCT00489619|Infectious diseases
1370937|NCT00489619|Democratic Republic of Congo
1370938|NCT00489619|Malaria
1370939|NCT00489619|International
1370940|NCT00489619|Maternal and child health
1370941|NCT00489619|Women's Health
1370942|NCT00489619|Global Network
1370943|NCT00489619|Sexually transmitted infections (STIs)
1370944|NCT00489606|SK3530
1370945|NCT00489606|tamsulosin
1370946|NCT00489606|hemodynamic interaction
1370947|NCT00489606|safety
1370948|NCT00489593|Advanced Cancer
1370949|NCT00489593|Weight Loss
1370950|NCT00489593|Cachexia
1370951|NCT00489593|Olanzapine
1370952|NCT00489593|Zyprexa
1370953|NCT00489593|Fluoxetine
1370954|NCT00489593|Symbyax
1370955|NCT00489580|stroke
1370956|NCT00489580|weakness
1370957|NCT00489580|motor recovery
1370958|NCT00489567|Rotavirus gastroenteritis
1370959|NCT00489554|Primary vaccination
1370960|NCT00489554|Safety
1370961|NCT00489554|Pneumococcal vaccine.
1370962|NCT00489554|Pneumococcal disease
1370963|NCT00489554|Immunogenicity
1370964|NCT00489541|paclitaxel-eluting stent
1370965|NCT00489541|PES
1370966|NCT00489528|serostim
1370967|NCT00489528|Dose-Response Relationship, Drug
1370968|NCT00489528|Body Composition
1370969|NCT00489515|adenocarcinoma of the gallbladder
1370970|NCT00489515|stage I pancreatic cancer
1370971|NCT00489515|stage II pancreatic cancer
1370972|NCT00489515|stage III pancreatic cancer
1370973|NCT00489515|stage IV pancreatic cancer
1370974|NCT00489515|stage I colon cancer
1370975|NCT00489515|stage II colon cancer
1370976|NCT00489515|stage III colon cancer
1370977|NCT00489515|stage IV colon cancer
1370978|NCT00489515|stage I gastric cancer
1370979|NCT00489515|stage II gastric cancer
1370980|NCT00489515|stage III gastric cancer
1370981|NCT00489515|stage IV gastric cancer
1370982|NCT00489515|localized gallbladder cancer
1370983|NCT00489515|small intestine adenocarcinoma
1370984|NCT00489515|adenocarcinoma of the colon
1370985|NCT00489515|adenocarcinoma of the pancreas
1370986|NCT00489515|adenocarcinoma of the stomach
1370987|NCT00489489|MS
1370988|NCT00489489|interferon-beta
1370989|NCT00489489|adjunctive therapy
1370990|NCT00489489|relapses
1370991|NCT00489476|Staccato® Loxapine, Migraine
1370992|NCT00489463|LNG-IUS
1370993|NCT00489463|TCu 380A
1370994|NCT00489463|Ultrasonography
1370995|NCT00489463|Doppler color
1370996|NCT00489463|power Doppler
1370997|NCT00489463|female
1370998|NCT00489463|Volunteers
1370999|NCT00489450|SK3530
1371000|NCT00489450|alcohol
1371001|NCT00489450|pharmacokinetics
1371002|NCT00489450|safety
1371003|NCT00489437|diagnosis
1371004|NCT00489424|zoledronic acid
1371005|NCT00489424|post dose symptoms
1371006|NCT00489424|transient
1371007|NCT00489424|acetaminophen
1371008|NCT00489424|fluvastatin
1371009|NCT00489411|unspecified adult solid tumor, protocol specific
1371010|NCT00489411|neurotoxicity
1371011|NCT00489411|pain
1371012|NCT00489411|peripheral neuropathy
1371013|NCT00489385|Fibrosis
1371014|NCT00489385|Viral Kinetics
1371015|NCT00489385|Hepatotoxicity
1371016|NCT00489385|Immunity
1371017|NCT00489385|HIV Infection
1371018|NCT00489385|Hepatitis C
1371019|NCT00489385|HCV
1371020|NCT00489385|Treatment Experienced
1371021|NCT00489385|Treatment Naive
1371022|NCT00489333|ProAlgaZyme
1371023|NCT00489333|Metabolic syndrome
1371024|NCT00489333|Inflammation
1371025|NCT00489333|Cardiovascular
1371026|NCT00489333|hsCRP
1371027|NCT00489333|Lipids
1371028|NCT00489333|Algae
1371029|NCT00489320|Coronary disease
1371030|NCT00489320|Arteries
1371031|NCT00489320|Atherosclerosis
1371032|NCT00489320|Arteriosclerosis
1371033|NCT00489307|Advanced Cancer
1371034|NCT00489307|Solid Tumors
1371035|NCT00489307|Fatigue
1371036|NCT00489307|Pain
1371037|NCT00489307|Nausea
1371038|NCT00489307|Anorexia
1371039|NCT00489307|Dexamethasone
1371040|NCT00489307|Decadron
1371041|NCT00489307|Placebo
1371042|NCT00489294|Human growth hormone
1371043|NCT00489294|idiopathic short stature
1371044|NCT00489294|short stature
1371045|NCT00489281|sickle cell disease
1371046|NCT00489268|Barrett's Esophagus
1371047|NCT00489268|Intestinal Metaplasia
1371048|NCT00489268|Radiofrequency Ablation
1371049|NCT00489255|Parkinson's disease
1371050|NCT00489255|Anti-emetic
1371051|NCT00489255|Nausea
1371052|NCT00489255|Vomiting
1371053|NCT00489229|Rosiglitazone
1371054|NCT00489229|Ramipril
1371055|NCT00489229|Impaired glucose tolerance
1371056|NCT00489229|Arterial stiffness
1371057|NCT00489229|Diabetic vasculopathy
1371058|NCT00489216|Graft Versus Host Disease
1371059|NCT00489216|GVHD
1371060|NCT00489216|Efalizumab
1371061|NCT00489216|Raptiva
1371062|NCT00489216|Steroid
1371063|NCT00489216|Refractory
1371064|NCT00489216|Skin
1371065|NCT00489216|Liver
1371066|NCT00489216|Lineberger
1371067|NCT00489216|University of North Carolina
1371068|NCT00489177|cardiac resynchronization therapy
1371069|NCT00489177|response
1371070|NCT00489177|Defibrillators
1371071|NCT00489164|DIABETIC PATIENTS WITH NATIVE CORONARY ARTERY LESIONS
1371072|NCT00489151|HBV
1371073|NCT00489125|long-term effects secondary to cancer therapy in adults
1371074|NCT00489125|recurrent breast cancer
1371075|NCT00489125|stage I breast cancer
1371076|NCT00489125|stage II breast cancer
1371077|NCT00489125|stage IIIA breast cancer
1371078|NCT00489125|stage IIIB breast cancer
1371079|NCT00489125|stage IIIC breast cancer
1371080|NCT00489125|stage IV breast cancer
1371081|NCT00489086|nevoid basal cell carcinoma syndrome
1371082|NCT00489086|basal cell carcinoma of the skin
1371083|NCT00489060|Cryoablation
1371084|NCT00489060|Radiation
1371085|NCT00489060|Prostate Cancer
1371086|NCT00489034|HIV
1371087|NCT00489034|adolescent females
1371088|NCT00489034|adherence
1371089|NCT00489034|clinical care
1371090|NCT00489034|risk behaviors
1371091|NCT00489021|Subacute care
1371092|NCT00489021|Activities of Daily Living
1371093|NCT00489021|Cognition assessment
1371094|NCT00489021|Mood assessment
1371095|NCT00489021|Incontinence control
1371096|NCT00489008|Lung Cancer
1371097|NCT00489008|Non-Small Cell
1371098|NCT00489008|Stereotactic Body Radiation Therapy
1371099|NCT00489008|SBRT
1371100|NCT00489008|NSCLC
1371101|NCT00488995|HIV Therapeutic Vaccine
1371102|NCT00488982|Metastatic Hormone Refractory Prostate Cancer
1371103|NCT00488969|Morphine
1371104|NCT00488969|Chronic Pain
1371105|NCT00488969|Spinal Cord Injury
1371106|NCT00488969|Neuropathic Pain
1371107|NCT00488956|foot
1371108|NCT00488956|ankle
1371109|NCT00488956|edema
1371110|NCT00488943|Stent-Graft
1371111|NCT00488943|AAA
1371112|NCT00488943|Abdominal Aortic Anuerysm
1371113|NCT00488943|Zenith
1371114|NCT00488943|Endovascular
1371115|NCT00488943|Treatment with Zenith Aortic Stent-Graft for repair Abdominal Aortic Aneurysm
1371116|NCT00488930|Obesity
1371117|NCT00488930|Hyperglycemia
1371118|NCT00488930|Diabetes Mellitus Type I
1371119|NCT00488930|Diabetes Mellitus Type II
1371120|NCT00488917|Liver cirrhosis
1371121|NCT00488917|acute liver failure
1371122|NCT00488917|liver transplantation
1371123|NCT00488917|sepsis, infection
1371124|NCT00488917|endothelium
1371125|NCT00488917|lipids
1371126|NCT00488917|diagnosis
1371127|NCT00488917|prognosis
1371128|NCT00488904|infection
1371129|NCT00488904|colorectalcancer
1371130|NCT00488904|omega-3 fedtsyre
1371131|NCT00488904|complications
1371132|NCT00488891|Schizophrenia
1371133|NCT00488891|Paliperdone ER
1371134|NCT00488891|Invega
1371135|NCT00488891|Observational
1371136|NCT00488891|Antipsychotic agents
1371137|NCT00488878|Ovarian Cancer
1371138|NCT00488878|Ovarian Carcinoma
1371139|NCT00488878|Low-Grade Serous Carcinoma
1371140|NCT00488878|Low Malignant Potential
1371141|NCT00488878|Peritoneum Tumors
1371142|NCT00488878|Psammocarcinoma
1371143|NCT00488878|Data Collection
1371144|NCT00488878|Research Database
1371145|NCT00488865|increased risk for PE require caval interruption
1371146|NCT00488839|Spasticity
1371147|NCT00488839|Multiple Sclerosis
1371148|NCT00488826|Vaccines, Pneumococcal Conjugate Vaccine
1371149|NCT00488813|Tzh-Chi ESBL study
1371150|NCT00488800|Pneumococcal Infections/PC (Prevention & Control)
1371151|NCT00488787|dental
1371152|NCT00488787|surgery
1371153|NCT00488787|analgesia
1371154|NCT00488787|2-4 impacted third molars
1371155|NCT00488774|Colitis, ulcerative
1371156|NCT00488774|Golimumab
1371157|NCT00488774|CNTO 148
1371158|NCT00488761|Tigecycline
1371159|NCT00488761|cSSSI
1371160|NCT00488761|complicated skin and skin structure infections
1371161|NCT00488748|MST
1371162|NCT00488748|Magnetic Seizure Therapy
1371163|NCT00488748|ECT
1371164|NCT00488748|Electroconvulsive Therapy
1371165|NCT00488748|Depression
1371166|NCT00488748|Magnetic
1371167|NCT00488735|Randomized controlled trial
1371168|NCT00488735|Back pain
1371169|NCT00488735|Neck pain
1371170|NCT00488735|Rehabilitation
1371171|NCT00488735|Cognitive-behavioral
1371172|NCT00488735|Primary care
1371173|NCT00488735|Sick-listing
1371174|NCT00488735|Health-care utilization.
1371175|NCT00488722|To observe the biological changes under concurrent Zoladex and CEF as neoadjuvant regimen with respect to the ER,PR,cerbB-2 status before and after therapy
1371176|NCT00488709|Acute Myeloid Leukemia
1371177|NCT00488709|Multi Drug Resistance
1371178|NCT00488696|Aneurysm
1371179|NCT00488696|Aortic Arch
1371180|NCT00488696|Endovascular
1371181|NCT00488696|Stent-Graft
1371182|NCT00488683|Meningococcal disease
1371183|NCT00488683|Prevention
1371184|NCT00488683|Vaccination
1371185|NCT00488670|Alzheimer's disease
1371186|NCT00488670|elderly
1371187|NCT00488670|open-label
1371188|NCT00488670|escitalopram
1371189|NCT00488657|speech
1371190|NCT00488657|Parkinson's disease
1371191|NCT00488657|treatment
1371192|NCT00488657|speech intelligibility
1371193|NCT00488657|speaking rate
1371194|NCT00488644|Hypothyroidism
1371195|NCT00488644|Brain Tumor
1371196|NCT00488644|Levothyroxine
1371197|NCT00488644|Liothyronine
1371198|NCT00488644|Synthroid
1371199|NCT00488644|Cytomel
1371200|NCT00488631|Colitis, Ulcerative
1371201|NCT00488631|Golimumab
1371202|NCT00488631|CNTO 148
1371203|NCT00488618|Mania
1371204|NCT00488618|Bipolar I Disorder
1371205|NCT00488618|Acute Mania Associated with Bipolar I Disorder
1371206|NCT00488592|Myelodysplastic Syndrome (MDS)
1371207|NCT00488592|Acute Myeloid Leukemia (AML)
1371208|NCT00488592|Chronic Myeloid Leukemia (CML)
1371209|NCT00488592|Wilm's Tumor-1
1371210|NCT00488592|Proteinase-3
1371211|NCT00488592|Myelodysplastic Syndrome
1371212|NCT00488592|MDS
1371213|NCT00488592|Acute Myeloid Leukemia
1371214|NCT00488592|AML
1371215|NCT00488592|Chronic Myeloid Leukemia
1371216|NCT00488592|CML
1371217|NCT00488579|iron prophylaxis
1371218|NCT00488579|pregnancy
1371219|NCT00488579|birth weight
1371220|NCT00488579|prematurity
1371221|NCT00488579|perinatal mortality
1371222|NCT00488566|bipolar disorder,
1371223|NCT00488566|single doses,
1371224|NCT00488566|resting motor threshold
1371225|NCT00488566|TMS,
1371226|NCT00488553|Lymphoma
1371227|NCT00488553|Epidemiology
1371228|NCT00488553|Lifestyle Factors
1371229|NCT00488553|Questionnaire
1371230|NCT00488553|Survey
1371231|NCT00488540|newborn
1371232|NCT00488540|infant
1371233|NCT00488540|pain
1371234|NCT00488540|acetaminophen
1371235|NCT00488540|paracetamol
1371236|NCT00488540|mode of delivery
1371237|NCT00488540|vacuum extraction
1371238|NCT00488540|forceps extraction
1371239|NCT00488540|cesarean section
1371240|NCT00488540|EDIN scale
1371241|NCT00488540|Bernese Pain Scale for Neonates
1371242|NCT00488540|pain after different modes of delivery in newborn infants
1371243|NCT00488540|efficacy of acetaminophen as analgesia for newborn infants
1371244|NCT00488514|Long-term Safety
1371245|NCT00488514|Migraine
1371246|NCT00488514|Adolescent Migraine Headache
1371247|NCT00488514|sumatriptan succinate
1371248|NCT00488514|naproxen sodium
1371249|NCT00488501|intrathoracic impedance
1371250|NCT00488501|cardiac resynchronization therapy
1371251|NCT00488501|heart failure
1371252|NCT00488462|obstetric hemorrhage
1371253|NCT00488462|hypovolemic shock
1371254|NCT00488462|non-pneumatic anti-shock garment
1371255|NCT00488462|safe motherhood
1371256|NCT00488462|maternal mortality
1371257|NCT00488462|maternal morbidity
1371258|NCT00488449|Dose Escalation
1371259|NCT00488449|GSK256073A,
1371260|NCT00488436|Myelodysplastic Syndrome
1371261|NCT00488436|Antithymocyte Globulin
1371262|NCT00488436|Cyclosporine
1371263|NCT00488423|diabetes
1371264|NCT00488423|MIDAS
1371265|NCT00488423|gut hormones
1371266|NCT00488423|gastric bypass
1371267|NCT00488423|lap band
1371268|NCT00488410|Chronic heart failure
1371269|NCT00488410|real time three-dimensional echocardiography
1371270|NCT00488410|cardiac resynchronization therapy
1371271|NCT00488410|ventricular asynchrony
1371272|NCT00488410|systolic dysynchrony index
1371273|NCT00488397|Tygacil
1371274|NCT00488397|microdilution method
1371275|NCT00488397|Tigecycline
1371276|NCT00488397|In-Vitro
1371277|NCT00488384|Squamous cell carcinoma of the skin under hemodialysis
1371278|NCT00488371|Streptococcus pneumoniae nasopharyngeal carriage
1371279|NCT00488358|abdominal
1371280|NCT00488358|aortic
1371281|NCT00488358|aneurysm
1371282|NCT00488358|Zenith
1371283|NCT00488358|blood pressure
1371284|NCT00488345|cIAI
1371285|NCT00488345|cSSSI
1371286|NCT00488345|CAP
1371287|NCT00488345|Child
1371288|NCT00488332|Head and Neck Cancer
1371289|NCT00488332|Oral Mucositis
1371290|NCT00488332|Optical Coherence Tomography
1371291|NCT00488332|Fluorescence Spectroscopy
1371292|NCT00488332|Optical Assessment
1371293|NCT00488319|Schizophrenia
1371294|NCT00488319|Adolescent
1371295|NCT00488319|Paliperidone
1371296|NCT00488319|Antipsychotic agents
1371297|NCT00488319|Antipsychotic drugs
1371298|NCT00488319|Psychosis.
1371299|NCT00488306|Tigecycline
1371300|NCT00488306|Complicated intra-abdominal infections
1371301|NCT00488306|cIAI
1371302|NCT00488293|Telemedicine
1371303|NCT00488293|Skin diseases
1371304|NCT00488293|Dermatology
1371305|NCT00488293|Quality of life
1371306|NCT00488293|Economics
1371307|NCT00488280|walking
1371308|NCT00488280|walking recovery
1371309|NCT00488280|physical therapy
1371310|NCT00488280|locomotor training
1371311|NCT00488280|body weight support
1371312|NCT00488280|neuroplasticity
1371313|NCT00488280|step
1371314|NCT00488280|treadmill
1371315|NCT00488280|treadmill training
1371316|NCT00488280|locomotion
1371317|NCT00488267|Osteoarthritis
1371318|NCT00488267|Pain
1371319|NCT00488254|Long QT Syndrome
1371320|NCT00488254|Romano Ward
1371321|NCT00488254|Jervell-Lange Nielson Syndrome
1371322|NCT00488241|Eczema
1371323|NCT00488241|Medical device
1371324|NCT00488215|constipation
1371325|NCT00488215|prucalopride
1371326|NCT00488215|MTD
1371327|NCT00488215|cardiovascular safety
1371328|NCT00488202|Advanced Ovarian Cancer
1371329|NCT00488202|Sexual Function
1371330|NCT00488176|seasonal allergic rhinitis
1371331|NCT00488176|children
1371332|NCT00488176|montelukast
1371333|NCT00488176|cetirizine
1371334|NCT00488163|schizophrenia
1371335|NCT00488163|cognition
1371336|NCT00488163|atomoxetine
1371337|NCT00488163|norepinephrine
1371338|NCT00488163|dopamine
1371339|NCT00488137|constipation
1371340|NCT00488137|prucalopride
1371341|NCT00488137|QOL
1371342|NCT00488137|SCBM
1371343|NCT00488137|PAC-SYM
1371344|NCT00488124|short stature
1371345|NCT00488111|Regional anesthesia
1371346|NCT00488111|Fluid Therapy
1371347|NCT00488111|Hemostasis, Surgical
1371348|NCT00488098|Healthy Bioequivalence
1371349|NCT00488085|Crohn’s disease, obesity, REE, body composition, fat absorption
1371350|NCT00488072|Advanced Cancer
1371351|NCT00488072|Anorexia
1371352|NCT00488072|Weight Loss
1371353|NCT00488072|Insomnia
1371354|NCT00488072|Appetite
1371355|NCT00488072|Mirtazapine
1371356|NCT00488072|Placebo
1371357|NCT00488059|Treatment Experienced
1371358|NCT00488046|Bird Flu
1371359|NCT00488033|Coronary Artery Disease
1371360|NCT00488033|Diabetes
1371361|NCT00488033|CT Angiography
1371362|NCT00488020|rest pain
1371363|NCT00488020|ischemic ulcers
1371364|NCT00488007|Alzheimer disease
1371365|NCT00488007|Cognitive impairment
1371366|NCT00488007|Sensorineural hearing loss
1371367|NCT00488007|Hearing aids
1371368|NCT00487994|Hypercholesterolemia
1371369|NCT00487994|Hyperlipidemia
1371370|NCT00487994|Drug Therapy
1371371|NCT00487981|Pain
1371372|NCT00487981|Implantable stimulation device
1371373|NCT00487981|Neuropathy
1371374|NCT00487968|healthy adult volunteers
1371375|NCT00487968|eltrombopag
1371376|NCT00487955|gastritis
1371377|NCT00487955|helicobacter pylori
1371378|NCT00487955|REE
1371379|NCT00487955|patients with gastritis that refers to helicobacter pylori treatment
1371380|NCT00487929|sleep apnea
1371381|NCT00487929|morbidity
1371382|NCT00487929|cardiovascular
1371383|NCT00487929|cpap
1371384|NCT00487929|oxidative stress
1371385|NCT00487916|Blood Stage
1371386|NCT00487916|Investigational
1371387|NCT00487916|Vaccine
1371388|NCT00487916|Malaria
1371389|NCT00487916|Healthy Volunteer
1371390|NCT00487916|HV
1371391|NCT00487903|Coronary Artery Disease
1371392|NCT00487903|Echocardiogram
1371393|NCT00487903|Contrast
1371394|NCT00487903|Perfusion
1371395|NCT00487903|Ultrasound
1371396|NCT00487903|Normal volunteers
1371397|NCT00487890|Geriatric
1371398|NCT00487890|Abdominal
1371399|NCT00487890|Surgery
1371400|NCT00487890|gastrointestinal surgery
1371401|NCT00487890|intrabdominal surgery
1371402|NCT00487877|metabolism, temperature changing, skin, heart rate
1371403|NCT00487851|Pancreatic
1371404|NCT00487851|cancer
1371405|NCT00487851|Periampullay
1371406|NCT00487851|Neoplasms
1371407|NCT00487851|Biliary
1371408|NCT00487851|Duodenal
1371409|NCT00487851|Jaundice
1371410|NCT00487851|obstruction
1371411|NCT00487851|pancreas cancer
1371412|NCT00487851|Pancreatic cancer
1371413|NCT00487838|Autofluorescence Imaging
1371414|NCT00487838|Early Age-Related Maculopathy
1371415|NCT00487838|Photochemical Changes
1371416|NCT00487838|Colored Sunglasses
1371417|NCT00487838|Pseudophakes
1371418|NCT00487838|Fundus Camera
1371419|NCT00487838|Confocal Scanning Laser Ophthalmoscope
1371420|NCT00487838|Molecular Imaging within Retina
1371421|NCT00487838|Spectral Balance among Photochemical Processes
1371422|NCT00487838|Noninvasive Autofluorescence Imaging
1371423|NCT00487838|Age-Related Maculopathy (AMD)
1371424|NCT00487838|Age-Related Macular Degeneration
1371425|NCT00487838|AMD
1371426|NCT00487838|Age-Related Macular Changes
1371427|NCT00487838|Early Age-Related Macular Changes
1371428|NCT00487825|ACR20, ACR50, ACZ885 (anti-interleukin-1beta monoclonal antibody), rheumatoid arthritis, methotrexate
1371429|NCT00487812|Acute myocardial infarction
1371430|NCT00487812|left ventricular remodelling
1371431|NCT00487812|SPECT imaging
1371432|NCT00487799|Acute Decompensated Heart Failure
1371433|NCT00487799|ADHF
1371434|NCT00487799|Heart Failure
1371435|NCT00487786|Antisense
1371436|NCT00487786|Heat Shock Protein
1371437|NCT00487773|asthma
1371438|NCT00487773|children
1371439|NCT00487773|inhaled glucocorticosteroids
1371440|NCT00487773|bone metabolism
1371441|NCT00487760|Lung Cancer
1371442|NCT00487760|African-American Families
1371443|NCT00487760|Genetic Risk Communication
1371444|NCT00487760|Interest in Genetic Testing and Genetics Research
1371445|NCT00487760|Health Disparities
1371446|NCT00487760|Smoking Cessation
1371447|NCT00487734|Metabolic Syndrome
1371448|NCT00487734|Hypogonadism
1371449|NCT00487734|Insulin Resistance
1371450|NCT00487721|Prostate cancer
1371451|NCT00487708|ACZ885
1371452|NCT00487708|NALP3 mutations
1371453|NCT00487708|Interleukin-1beta
1371454|NCT00487708|Muckle-Wells Syndrome
1371455|NCT00487695|Barrett's esophagus
1371456|NCT00487695|Esophageal adenocarcinoma
1371457|NCT00487695|Endoscopy
1371458|NCT00487695|Confocal laser endomicroscopy
1371459|NCT00487682|herpes zoster
1371460|NCT00487682|ASP2151
1371461|NCT00487682|Valacyclovir hydrochloride
1371462|NCT00487669|paclitaxel poliglumex
1371463|NCT00487669|xyotax
1371464|NCT00487669|alimta
1371465|NCT00487669|advanced non-small cell lung cancer
1371466|NCT00487643|Lacritin
1371467|NCT00487630|Heterozygous females
1371468|NCT00487630|Cardiomyopathy
1371469|NCT00487617|Arteriopathy
1371470|NCT00487617|endothelial function
1371471|NCT00487617|fruit juice
1371472|NCT00487604|Coronary Artery Disease
1371473|NCT00487604|Drug Eluting Stent
1371474|NCT00487604|Bare Metal Stent
1371475|NCT00487604|Subacute thrombosis
1371476|NCT00487604|Bleeding
1371477|NCT00487604|Economic
1371478|NCT00487591|cholesterol
1371479|NCT00487591|dyslipidemia
1371480|NCT00487591|omega 3
1371481|NCT00487578|Post traumatic headache
1371482|NCT00487578|Head trauma
1371483|NCT00487578|Head injury
1371484|NCT00487578|Headache
1371485|NCT00487578|Naratriptan
1371486|NCT00487565|Total knee replacement
1371487|NCT00487565|Total knee arthroplasty
1371488|NCT00487565|Osteoarthritis
1371489|NCT00487565|Rheumatoid or other inflammatory arthritis
1371490|NCT00487565|Post-traumatic or juvenile arthritis
1371491|NCT00487552|endoscopy
1371492|NCT00487552|esophagogastroduodenoscopy
1371493|NCT00487552|gastric outlet obstruction
1371494|NCT00487552|gastro-jejunostomy
1371495|NCT00487552|gastric malignancy
1371496|NCT00487552|duodenal stent
1371497|NCT00487552|Malignant Gastric Outlet Obstruction
1371498|NCT00487539|Colitis, Ulcerative
1371499|NCT00487539|Golimumab
1371500|NCT00487539|CNTO 148
1371501|NCT00487526|Bypass
1371502|NCT00487526|Duodenal jejunal
1371503|NCT00487526|type 2 diabetes
1371504|NCT00487526|non-obese adults
1371505|NCT00487513|Follicular B Cell lymphoma
1371506|NCT00487513|vaccination
1371507|NCT00487500|Major Depressive Disorder
1371508|NCT00487500|Electroconvulsive Therapy
1371509|NCT00487487|Candidates for this study are survivors of paralytic poliomyelitis
1371510|NCT00487461|SAH
1371511|NCT00487461|Vasospasm
1371512|NCT00487448|Myelodysplastic Syndrome
1371513|NCT00487448|Chemotherapy
1371514|NCT00487448|Peripheral blood stem cells transplantation
1371515|NCT00487448|Bone marrow transplantation
1371516|NCT00487448|Secondary Acute Myeloblastic Leukemia
1371517|NCT00487435|CG5503
1371518|NCT00487435|Tapentadol
1371519|NCT00487435|chronic non-malignant pain
1371520|NCT00487435|osteoarthritis
1371521|NCT00487435|lower back pain
1371522|NCT00487435|analgesic
1371523|NCT00487435|opioid
1371524|NCT00487422|constipation
1371525|NCT00487422|prucalopride
1371526|NCT00487422|QOL
1371527|NCT00487422|SCBM
1371528|NCT00487422|PAC-SYM
1371529|NCT00487409|Ulcerative colitis
1371530|NCT00487409|Crohn's disease
1371531|NCT00487409|Colorectal polyps
1371532|NCT00487409|Colorectal malignancy
1371533|NCT00487409|Endometriosis
1371534|NCT00487409|Diverticulitis
1371535|NCT00487409|Colonic inertia
1371536|NCT00487396|capsule endoscopy
1371537|NCT00487396|Crohn's disease
1371538|NCT00487396|small bowel disease
1371539|NCT00487396|inflammatory bowel disease
1371540|NCT00487396|Patients with suspected small bowel Crohn's disease
1371541|NCT00487383|Cerebellum
1371797|NCT00486525|cancer survivor
1371542|NCT00487383|Transcranial Magnetic Stimulation (TMS)
1371543|NCT00487383|Blepharospasm
1371544|NCT00487383|DYT-1 Generalized Dystonia
1371545|NCT00487383|Focal Dystonia
1371546|NCT00487383|Dystonia
1371547|NCT00487383|Healthy Volunteer
1371548|NCT00487383|HV
1371549|NCT00487370|Acupuncture
1371550|NCT00487370|Gold implantation
1371551|NCT00487370|Osteoarthritis
1371552|NCT00487370|Knee osteoarthritis
1371553|NCT00487370|Double-blind, randomized controlled trial
1371554|NCT00487370|Intervention
1371555|NCT00487370|Family practice
1371556|NCT00487357|Epidemiology
1371557|NCT00487357|Cancer Prevention
1371558|NCT00487357|Questionnaire
1371559|NCT00487357|MATCh
1371560|NCT00487357|Survey
1371561|NCT00487344|medicaid
1371562|NCT00487344|insurance
1371563|NCT00487344|education
1371564|NCT00487344|clinical
1371565|NCT00487344|trial
1371566|NCT00487344|healthcare
1371567|NCT00487344|reimburse
1371568|NCT00487344|pay
1371569|NCT00487344|free
1371570|NCT00487344|assist
1371571|NCT00487344|study
1371572|NCT00487344|oklahoma
1371573|NCT00487344|edmond
1371574|NCT00487344|Oklahoma City
1371575|NCT00487344|diet
1371576|NCT00487344|nutrition
1371577|NCT00487344|weight loss
1371578|NCT00487344|body
1371579|NCT00487344|fat
1371580|NCT00487344|obese
1371581|NCT00487344|overweight
1371582|NCT00487344|health
1371583|NCT00487344|medical
1371584|NCT00487344|therapy
1371585|NCT00487344|meal plan
1371586|NCT00487344|jenny craig
1371587|NCT00487344|weight watcher
1371588|NCT00487344|LA Weightloss
1371589|NCT00487344|Bryan Attebery
1371590|NCT00487344|Results
1371591|NCT00487344|YMCA
1371592|NCT00487344|UCO
1371593|NCT00487344|OSU
1371594|NCT00487344|OU
1371595|NCT00487344|clinics
1371596|NCT00487344|physicians
1371597|NCT00487344|surgery
1371598|NCT00487344|pills
1371599|NCT00487344|financial
1371600|NCT00487344|money
1371601|NCT00487331|Solid Tumors
1371602|NCT00487331|Acupuncture
1371603|NCT00487331|Uncontrolled Pain
1371604|NCT00487331|Pain
1371605|NCT00487318|fluvastatin
1371606|NCT00487318|hepatitis C
1371607|NCT00487318|chronic hepatitis C
1371608|NCT00487318|not previously treated with pegylated interferon and ribavirin
1371609|NCT00487305|GM-CSF
1371610|NCT00487305|vaccine
1371611|NCT00487305|K562
1371612|NCT00487292|accidents
1371613|NCT00487292|shift work
1371614|NCT00487292|sleepiness
1371615|NCT00487292|naps
1371616|NCT00487292|bright light pulses
1371617|NCT00487292|sleep
1371618|NCT00487279|Coronary
1371619|NCT00487279|Artery
1371620|NCT00487279|Disease
1371621|NCT00487279|Sudden
1371622|NCT00487279|Cardiac
1371623|NCT00487279|Death
1371624|NCT00487279|ICD
1371625|NCT00487266|Acupuncture
1371626|NCT00487266|Torque
1371627|NCT00487266|Force Decay
1371628|NCT00487253|Cutaneous Leishmaniasis
1371629|NCT00487253|Leishmania Viannia
1371630|NCT00487253|Pediatric
1371631|NCT00487253|Miltefosine
1371632|NCT00487253|Randomized
1371633|NCT00487253|Colombia
1371634|NCT00487240|diabetes
1371635|NCT00487240|type 1
1371636|NCT00487227|caffeine
1371637|NCT00487227|coffee
1371638|NCT00487227|decaffeinated
1371639|NCT00487227|cognition
1371640|NCT00487227|mood
1371641|NCT00487227|autonomic
1371642|NCT00487201|liver transplantation
1371643|NCT00487201|biliary strictures
1371644|NCT00487201|ERCP
1371645|NCT00487175|Pain
1371646|NCT00487175|sensitization
1371647|NCT00487175|analgesia
1371648|NCT00487175|Healthy volunteers and pain
1371649|NCT00487162|glycemic control, diabetes, obesity, comorbidities
1371650|NCT00487149|Repeatability
1371651|NCT00487149|Respiratory Muscle Strength
1371652|NCT00487136|Drug Interaction
1371653|NCT00487136|Pharmacokinetics
1371654|NCT00487136|Pharmacodynamics
1371655|NCT00487123|Hypertension, compliance, Valsartan, hydrochlorothiazide (HCTZ)
1371656|NCT00487110|Pain
1371657|NCT00487110|serotonin
1371658|NCT00487110|interaction
1371659|NCT00487110|Patients with postsurgical pain, after ear surgery
1371660|NCT00487097|intensive care
1371661|NCT00487097|critically ill
1371662|NCT00487097|fish oil
1371663|NCT00487097|pressure sores
1371664|NCT00487084|analgesia
1371665|NCT00487084|tubal ligation
1371666|NCT00487084|chloroprocaine
1371667|NCT00487071|Anal fistula
1371668|NCT00487071|High-type
1371669|NCT00487071|Anal fistula plug
1371670|NCT00487071|Efficacy
1371671|NCT00487071|Recurrence
1371672|NCT00487058|Gimatecan
1371673|NCT00487058|topoisomerase I inhibitor
1371674|NCT00487058|advanced solid tumors
1371675|NCT00487045|Hemorrhoids
1371676|NCT00487045|Thrombosed External Hemorrhoids (TEH)
1371677|NCT00487045|Reduction
1371678|NCT00487045|Prevention
1371679|NCT00487045|Stabilizer Device
1371680|NCT00487045|Pregnant
1371681|NCT00487045|Vaginal Birth
1371682|NCT00487045|Single Birth
1371683|NCT00487045|Asymptomatic Hemorrhoids
1371684|NCT00487032|allergic rhinitis
1371685|NCT00487032|rhinitis medicamentosa
1371686|NCT00487032|imidazolines
1371687|NCT00487032|corticosteroid
1371688|NCT00487019|ampicillin
1371689|NCT00487019|penicillin G
1371690|NCT00487019|gentamicin
1371691|NCT00487019|neonatal sepsis
1371692|NCT00487019|empiric therapy
1371693|NCT00486993|Diet
1371694|NCT00486993|Exercise
1371695|NCT00486993|Smoking
1371696|NCT00486993|Stress
1371697|NCT00486993|Polyphenols
1371698|NCT00486980|influenza
1371699|NCT00486967|Insulin resistance, heart failure, congestive heart failure,
1371700|NCT00486967|Peak VO2, Endothelial Function, Leptin, TNF.
1371701|NCT00486954|lapatinib
1371702|NCT00486954|paclitaxel
1371703|NCT00486954|ErbB2
1371704|NCT00486954|Gastric cancer
1371705|NCT00486954|Advanced gastric cancer
1371706|NCT00486941|Primary Prevention
1371707|NCT00486941|Health Promotion
1371708|NCT00486941|Diet
1371709|NCT00486941|Exercise
1371710|NCT00486941|Risk Factors
1371711|NCT00486941|Randomized Controlled Trial
1371712|NCT00486928|Valves, heart disease, prosthesis.
1371713|NCT00486915|Atrial Fibrillation
1371714|NCT00486915|Left Atrial Appendage
1371715|NCT00486915|Surgical Ligation
1371716|NCT00486915|Thromboembolism
1371717|NCT00486915|Cerebrovascular Accident
1371718|NCT00486902|Ketamine
1371719|NCT00486902|Spinal Anesthesia
1371720|NCT00486902|C-section
1371721|NCT00486889|Glycogenesis 2
1371722|NCT00486876|Irritable bowel syndrome
1371723|NCT00486876|Diarrhea predominant Irritable Bowel Syndrome
1371724|NCT00486876|Alternating Irritable Bowel Syndrome
1371725|NCT00486863|Philippines, Schistosoma japonicum, Schistosomiasis, pregnant women, fetuses, 08-0049
1371726|NCT00486850|RDS
1371727|NCT00486850|Preterm
1371728|NCT00486850|SIMV
1371729|NCT00486850|NIPPV
1371730|NCT00486811|Osteoarthritis
1371731|NCT00486811|Knee
1371732|NCT00486811|Pain Assessment
1371733|NCT00486811|CG5503 PR
1371734|NCT00486811|Centrally acting analgesic
1371735|NCT00486811|Placebo
1371736|NCT00486811|Oxycodone
1371737|NCT00486811|Chronic Pain due to knee Osteoarthritis
1371738|NCT00486811|Tapentadol
1371739|NCT00486798|acute schizophrenia
1371740|NCT00486798|schizoaffective disorder
1371741|NCT00486798|psychosis Not Otherwise Specified (NOS)
1371742|NCT00486798|bipolar mania with psychotic symptoms
1371743|NCT00486772|This study was designed to investigate whether the suggested beneficial effects of sevelamer on VC were related to fetuin-A levels in patients with CKD.
1371744|NCT00486746|sleep apnea
1371745|NCT00486746|lifestyle intervention
1371746|NCT00486746|cardiovascular
1371747|NCT00486733|extracorporeal shock wave therapy
1371748|NCT00486733|soft tissue wounds
1371749|NCT00486707|Ovarian Cancer
1371750|NCT00486707|Questionnaire
1371751|NCT00486707|Genetic Testing
1371752|NCT00486707|Survey
1371753|NCT00486694|Malaria, vivax
1371754|NCT00486694|Afghanistan
1371755|NCT00486694|Sulfadoxine-pyrimethamine
1371756|NCT00486694|drug resistance
1371757|NCT00486681|Glucose monitoring
1371758|NCT00486681|Diabetes management
1371759|NCT00486681|Information system
1371760|NCT00486681|In-patient glycemic control
1371761|NCT00486668|HER2 positive breast cancer
1371762|NCT00486668|invasive breast cancer
1371763|NCT00486668|lapatinib
1371764|NCT00486668|neoadjuvant
1371765|NCT00486668|NSABP
1371766|NCT00486668|paclitaxel
1371767|NCT00486668|trastuzumab
1371768|NCT00486668|doxorubicin
1371769|NCT00486668|cyclophosphamide
1371770|NCT00486655|Cholecystectomy
1371771|NCT00486655|NOTES
1371772|NCT00486655|Transgastric
1371773|NCT00486629|Exercise
1371774|NCT00486629|Diet
1371775|NCT00486629|Pregnancy
1371776|NCT00486629|Obesity
1371777|NCT00486629|Macrosomia
1371778|NCT00486603|adult glioblastoma
1371779|NCT00486603|adult gliosarcoma
1371780|NCT00486603|adult giant cell glioblastoma
1371781|NCT00486590|Human milk fortification
1371782|NCT00486590|Premature neonate
1371783|NCT00486590|Very low birth weight
1371784|NCT00486577|Hearing Disorders, Hearing Loss, Hyperacusis, Tinnitus, chronic cortical stimulation, functional magnetic resonance imaging
1371785|NCT00486564|Treatment
1371786|NCT00486564|Refractory or Relapsed
1371787|NCT00486551|Anger control training
1371788|NCT00486551|Cognitive behavioral therapy
1371789|NCT00486551|Behavior therapy
1371790|NCT00486551|Tourette Syndrome
1371791|NCT00486551|Randomized trial
1371792|NCT00486551|Anger
1371793|NCT00486551|Aggression
1371794|NCT00486525|fatigue
1371795|NCT00486525|depression
1371796|NCT00486525|pain
1371798|NCT00486525|stage IA breast cancer
1371799|NCT00486525|stage IB breast cancer
1371800|NCT00486525|stage II breast cancer
1371801|NCT00486525|stage IIIA breast cancer
1371802|NCT00486525|breast cancer in situ
1371803|NCT00486512|colorectal, adenomas, prevention
1371804|NCT00486499|radiation
1371805|NCT00486499|brachytherapy
1371806|NCT00486499|prostate
1371807|NCT00486499|cancer
1371808|NCT00486486|24-hour IOP control
1371809|NCT00486460|Locally advanced or metastatic adenocarcinoma of the
1371810|NCT00486460|pancreas
1371811|NCT00486460|confirmed by histology or cytology
1371812|NCT00486460|Inoperatable
1371813|NCT00486434|Osteoarthritis, oral salmon calcitonin, treatment, efficacy, tolerability
1371814|NCT00486421|idiopathic thrombocytopenic purpura
1371815|NCT00486408|HIV Seronegativity
1371816|NCT00486408|HIV Preventive Vaccine
1371817|NCT00486408|Adenovirus
1371818|NCT00486395|prematurity
1371819|NCT00486395|randomized trial
1371820|NCT00486395|RDS
1371821|NCT00486395|surfactant
1371822|NCT00486395|CPAP
1371823|NCT00486395|ventilation
1371824|NCT00486382|visceral leishmaniasis
1371825|NCT00486382|vaccine
1371826|NCT00486369|Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers
1371827|NCT00486356|unspecified adult solid tumor, protocol specific
1371828|NCT00486356|recurrent gastric cancer
1371829|NCT00486356|stage IV gastric cancer
1371830|NCT00486356|advanced adult primary liver cancer
1371831|NCT00486356|localized unresectable adult primary liver cancer
1371832|NCT00486356|recurrent adult primary liver cancer
1371833|NCT00486356|recurrent extrahepatic bile duct cancer
1371834|NCT00486356|unresectable extrahepatic bile duct cancer
1371835|NCT00486356|recurrent gallbladder cancer
1371836|NCT00486356|unresectable gallbladder cancer
1371837|NCT00486343|Asthma
1371838|NCT00486343|ICS
1371839|NCT00486343|5-LO Inhibition
1371840|NCT00486343|Leukotrienes
1371841|NCT00486343|Asthma control
1371842|NCT00486343|Asthma exacerbations
1371843|NCT00486330|HIV
1371844|NCT00486330|Pharmacokinetics
1371845|NCT00486330|Buprenorphine
1371846|NCT00486330|Tipranavir
1371847|NCT00486330|HIV Seronegativity
1371848|NCT00486317|Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers
1371849|NCT00486304|cachexia
1371850|NCT00486304|weight changes
1371851|NCT00486304|recurrent oropharyngeal cancer
1371852|NCT00486304|stage I oropharyngeal cancer
1371853|NCT00486304|stage II oropharyngeal cancer
1371854|NCT00486304|stage III oropharyngeal cancer
1371855|NCT00486304|stage IV oropharyngeal cancer
1371856|NCT00486291|Diabetes, Obese diabetics
1371857|NCT00486265|Phase I
1371858|NCT00486265|Phase II
1371859|NCT00486265|acute myelogenous leukemia
1371860|NCT00486265|AML
1371861|NCT00486265|cancer
1371862|NCT00486239|Epilepsy
1371863|NCT00486239|memory
1371864|NCT00486239|emotion
1371865|NCT00486213|dermatologic complications
1371866|NCT00486213|chemotherapeutic agent toxicity
1371867|NCT00486213|palmar-plantar erythrodysesthesia
1371868|NCT00486213|unspecified adult solid tumor, protocol specific
1371869|NCT00486200|Herpes Genitalis
1371870|NCT00486200|Herpes Simplex Virus Genital Infection
1371871|NCT00486200|Genital Herpes
1371872|NCT00486200|ASP2151
1371873|NCT00486200|Treatment Outcome
1371874|NCT00486200|Sexually Transmitted Disease
1371875|NCT00486187|Type 2 Diabetes Mellitus
1371876|NCT00486187|Thiazolidinediones
1371877|NCT00486187|Rosiglitazone
1371878|NCT00486187|Adipokine
1371879|NCT00486187|Inflammation
1371880|NCT00486187|Cardiometabolic risk
1371881|NCT00486187|Angiotensin receptor blocker
1371882|NCT00486174|Sepsis
1371883|NCT00486174|Methylene Blue
1371884|NCT00486174|Norepinephrine
1371885|NCT00486161|Obesity
1371886|NCT00486161|Ghrelin
1371887|NCT00486161|Non-esterified fatty acids
1371888|NCT00486161|Growth hormone
1371889|NCT00486161|Insulin
1371890|NCT00486161|Cycloergometer exercise
1371891|NCT00486148|Formula
1371892|NCT00486148|Feeding
1371893|NCT00486148|Healthy
1371894|NCT00486148|Full
1371895|NCT00486148|Term
1371896|NCT00486148|Infants
1371897|NCT00486135|Cancer
1371898|NCT00486135|Solid tumors
1371899|NCT00486135|Lymphoma
1371900|NCT00486109|Diabetes
1371901|NCT00486096|cannulation
1371902|NCT00486096|infant
1371903|NCT00486096|femoral arterial
1371904|NCT00486070|cardiac anomaly
1371905|NCT00486070|pulmonary veins
1371906|NCT00486070|cyanosis
1371907|NCT00486070|flow reversal
1371908|NCT00486070|TAPAVC
1371909|NCT00486057|Daclizumab
1371910|NCT00486057|Immuno-suppression protocol
1371911|NCT00486057|Heart Transplant
1371912|NCT00486057|Rejection
1371913|NCT00486044|amyloid protein
1371914|NCT00486044|apolipoprotein
1371915|NCT00486044|cerebrospinal fluid
1371916|NCT00486044|cerebrovascular circulation
1371917|NCT00486044|inflammation
1371918|NCT00486044|magnetic resonance imaging
1371919|NCT00486044|prevention & control
1371920|NCT00486031|IBD
1371921|NCT00486031|UC
1371922|NCT00486031|Ulcerative Colitis
1371923|NCT00486031|Inflammatory Bowel Disease
1371924|NCT00486018|Lucentis
1371925|NCT00486018|RVO
1371926|NCT00486018|BRVO
1371927|NCT00486018|Edema
1371928|NCT00485992|blood stream infection
1371929|NCT00485992|CICU
1371930|NCT00485992|pediatric
1371931|NCT00485992|chlorhexidine swabs
1371932|NCT00485979|Breast Cancer
1371933|NCT00485979|Neoadjuvant therapy
1371934|NCT00485966|Adult Leukemia
1371935|NCT00485966|CLL
1371936|NCT00485966|B-CLL
1371937|NCT00485966|Chronic Lymphocytic Leukemia
1371938|NCT00485966|B-cell CLL
1371939|NCT00485953|Osteoporosis
1371940|NCT00485953|breast cancer
1371941|NCT00485953|aromatase inhibitors
1371942|NCT00485953|bone loss
1371943|NCT00485953|bone mineral density
1371944|NCT00485940|constipation
1371945|NCT00485940|prucalopride
1371946|NCT00485940|QOL
1371947|NCT00485940|SCBM
1371948|NCT00485940|PAC-SYM
1371949|NCT00485927|Trauma
1371950|NCT00485927|Stress
1371951|NCT00485927|Simulation
1371952|NCT00485914|employment
1371953|NCT00485914|work
1371954|NCT00485836|CRVO
1371955|NCT00485836|RVO
1371956|NCT00485836|Lucentis
1371957|NCT00485836|Edema
1371958|NCT00485797|attention deficit hyperactivity disorder (ADHD)
1371959|NCT00485797|Dual tasking
1371960|NCT00485797|Postural Control
1371961|NCT00485797|Methylphenidate (Ritalin)
1371962|NCT00485797|The focus of the study is To explore the effects of Ritalin on postural control in ADHD Children, during single and dual task conditions.
1371963|NCT00485784|Identify in a population of patients with a PE, an IUGR and a FD a modification of circulating endothelial biomarkers compared with normal pregnancy.
1371964|NCT00485745|surgery
1371965|NCT00485745|repeat sternotomy
1371966|NCT00485745|pediatrics
1371967|NCT00485732|Cervical neoplasia
1371968|NCT00485732|AS04
1371969|NCT00485732|Randomized
1371970|NCT00485732|Cervical cancer
1371971|NCT00485732|HPV-16/18 L1 VLP AS04
1371972|NCT00485732|Phase IIIb
1371973|NCT00485732|Korea
1371974|NCT00485732|HPV
1371975|NCT00485732|Double-blind
1371976|NCT00485732|Controlled
1371977|NCT00485719|Cancer
1371978|NCT00485719|Solid Tumors
1371979|NCT00485706|dialysis
1371980|NCT00485706|vascular calcification
1371981|NCT00485706|bone mineralism
1371982|NCT00485706|arterial stiffness
1371983|NCT00485706|bone metabolism
1371984|NCT00485706|chronic kidney disease
1371985|NCT00485693|pain
1371986|NCT00485693|postoperative
1371987|NCT00485693|total knee arthroplasty
1371988|NCT00485693|analgesia
1371989|NCT00485667|pain
1371990|NCT00485667|postoperative
1371991|NCT00485654|Heterotaxy Syndrome
1371992|NCT00485654|Intestinal Malrotation
1371993|NCT00485654|Functional Asplenia
1371994|NCT00485654|Complex Cyanotic heart disease
1371995|NCT00485641|Stroke
1371996|NCT00485641|SaeboFlex
1371997|NCT00485641|Hand function
1371998|NCT00485615|eicosapentaenoic acid
1371999|NCT00485615|fish oil
1372000|NCT00485615|Omega 3
1372001|NCT00485615|Social Anxiety Disorder
1372002|NCT00485602|malocclusion
1372003|NCT00485602|aligner
1372004|NCT00485602|crowding
1372005|NCT00485602|expansion
1372006|NCT00485602|orthodontic treatment
1372007|NCT00485589|FILM
1372008|NCT00485589|RA
1372009|NCT00485589|anti-CD20
1372010|NCT00485589|CD20
1372011|NCT00485563|Cancer
1372012|NCT00485563|Vaccine
1372013|NCT00485563|Phase 2
1372014|NCT00485563|folate-hapten conjugate
1372015|NCT00485563|Progressive
1372016|NCT00485563|Metastatic
1372017|NCT00485563|Experimental
1372018|NCT00485537|GnRH antagonist
1372019|NCT00485537|GnRH agonist
1372020|NCT00485537|ICSI
1372021|NCT00485537|miscarriage rate
1372022|NCT00485537|pregnancy outcome
1372023|NCT00485524|Near Infrared Spectroscopy
1372024|NCT00485524|Serum Lactate Levels
1372025|NCT00485524|post operative outcomes
1372026|NCT00485485|Head and Neck Cancer
1372027|NCT00485485|Squamous Cell Cancer
1372028|NCT00485485|Imatinib Mesylate
1372029|NCT00485485|Gleevec
1372030|NCT00485485|Imatinib
1372031|NCT00485485|STI571
1372032|NCT00485485|Docetaxel
1372033|NCT00485485|Taxotere
1372034|NCT00485472|Osteoarthritis
1372035|NCT00485472|lacosamide
1372036|NCT00485472|VIMPAT
1372037|NCT00485433|hernia
1372038|NCT00485433|unilateral
1372039|NCT00485433|postoperative
1372040|NCT00485433|analgesia
1372041|NCT00485420|Internet based disease management program
1372042|NCT00485394|AMD
1372043|NCT00485394|age-related macular degeneration
1372044|NCT00485394|geographic atrophy
1372045|NCT00485394|GA
1372046|NCT00485368|marfan syndrome
1372047|NCT00485368|aortic root diameter
1372048|NCT00485355|hysterectomy
1372049|NCT00485355|Laparoscopy
1372050|NCT00485355|robotics
1372051|NCT00485342|Chronic hepatitis C,Genotype1,Naïf,bitherapy,Ribavirin adaptation,ribavirin AUC
1372052|NCT00485329|Chronic Wounds, Venous Ulcers, Papain, Debridement, Continuous streaming
1372053|NCT00485329|DermaStream-EnzyStream
1372054|NCT00485316|Colorectal carcinoma
1372055|NCT00485316|Rectal carcinoma
1372056|NCT00485316|Laparoscopy
1372057|NCT00485316|Laparoscopic surgery
1372058|NCT00485316|Open surgery
1372059|NCT00485316|Randomized trial
1372060|NCT00485303|Prostatic Neoplasms
1372061|NCT00485303|Prostate cancer
1372062|NCT00485303|Abiraterone acetate
1372063|NCT00485303|CB7630
1372064|NCT00485303|Prednisone
1372065|NCT00485290|cirrhosis, Portal Hypertension, Esophageal Varices, Meal
1372066|NCT00485277|Breast cancer
1372067|NCT00485277|Vaccine
1372068|NCT00485277|Metastatic
1372069|NCT00485277|HER-2-positive
1372070|NCT00485277|Phase I
1372071|NCT00485277|HER-2 Positive Metastatic Breast Cancer
1372072|NCT00485251|operation time in minutes
1372073|NCT00485251|pain score from 1-10
1372074|NCT00485251|recurrence
1372075|NCT00485251|survival
1372076|NCT00485238|glaucoma
1372077|NCT00485212|postoperative pain
1372078|NCT00485199|Pneumatic Retinopexy
1372079|NCT00485199|vitrectomy
1372080|NCT00485199|retinal detachment
1372081|NCT00485199|macular hole
1372082|NCT00485199|treatment
1372083|NCT00485199|multi-center
1372084|NCT00485199|Retinal Detachment due to Myopic Macular hole
1372085|NCT00485160|Patent Ductus Arteriosus
1372086|NCT00485160|Indomethacin
1372087|NCT00485160|Ibuprofen
1372088|NCT00485160|Renal effects
1372089|NCT00485147|Claudication
1372090|NCT00485147|peripheral arterial disease
1372091|NCT00485147|Diagnosis
1372092|NCT00485147|Exercise
1372093|NCT00485147|Walking impairment
1372094|NCT00485147|Disability
1372095|NCT00485121|Ezetimibe
1372096|NCT00485121|Statin
1372097|NCT00485121|Low- density lipoprotein cholesterol
1372098|NCT00485121|Adipokine
1372099|NCT00485121|Adiponectin
1372100|NCT00485121|C-reactive protein
1372101|NCT00485121|Coronary artery disease
1372102|NCT00485121|Metabolic Syndrome
1372103|NCT00485121|Obesity
1372104|NCT00485108|primary open angle glaucoma
1372105|NCT00485108|pseudoexfoliation glaucoma
1372106|NCT00485108|selective laser trabeculoplasty
1372107|NCT00485108|intra ocular pressure
1372108|NCT00485108|anti-inflammatory therapy
1372109|NCT00485108|prednisolone acetate 1%
1372110|NCT00485108|ketorolac tromethamine 0.5%
1372111|NCT00485082|Cystic Fibrosis
1372112|NCT00485082|Disclosure
1372113|NCT00485082|Dating Partner
1372114|NCT00485082|Phone Interview
1372115|NCT00485069|Ropinirole hydrochloride
1372116|NCT00485069|L-dopa
1372117|NCT00485069|Parkinson's Disease
1372118|NCT00485069|Dopamine agonist
1372119|NCT00485056|Diabetes
1372120|NCT00485056|Tissue doppler imaging
1372121|NCT00485056|Wave intensity analysis.
1372122|NCT00485043|T'ai Chi
1372123|NCT00485043|Osteoarthritis
1372124|NCT00485043|Exercise
1372125|NCT00485043|Older adults
1372126|NCT00485030|coronary artery disease
1372127|NCT00485030|stent
1372128|NCT00485030|angioplasty
1372129|NCT00485017|Obesity
1372130|NCT00485017|Weight Loss
1372131|NCT00485004|Coronary artery disease
1372132|NCT00485004|Stent
1372133|NCT00485004|Angioplasty
1372134|NCT00484991|Phenylketonuria
1372135|NCT00484991|PKU
1372136|NCT00484991|Phenylketonurias
1372137|NCT00484991|Hyperphenylalaninaemia
1372138|NCT00484991|Hydroxylase Deficiency
1372139|NCT00484978|Stereotactic Radiosurgery
1372140|NCT00484978|Surgery
1372141|NCT00484978|Metastatic tumor to brain
1372142|NCT00484978|radiation
1372143|NCT00484978|Brain Metastases of all pathologies
1372144|NCT00484965|Coronary stent
1372145|NCT00484965|Inflammation
1372146|NCT00484965|Atherosclerosis
1372147|NCT00484965|Immunosuppressive
1372148|NCT00484952|rotavirus
1372149|NCT00484952|diarrheal diseases
1372150|NCT00484952|hospitalizations
1372151|NCT00484952|multicenter
1372152|NCT00484952|children
1372153|NCT00484952|under five year old
1372154|NCT00484952|Hospitalization due to diarhheal diseases
1372155|NCT00484952|Hospitalization due to rotavirus gastroenteritis
1372156|NCT00484952|Nosocomial rotavirus infections
1372157|NCT00484926|coronary disease
1372158|NCT00484926|stents
1372159|NCT00484926|antiplatelet drugs
1372160|NCT00484926|drug-eluting stents
1372161|NCT00484913|healthy subjects
1372162|NCT00484900|Open randomized multi-centre clinical trial in Africa
1372163|NCT00484900|Uncomplicated P. falciparum malaria
1372164|NCT00484900|Artemisinin-based Combination Therapy
1372165|NCT00484900|Artesunate + sulfalene + pyrimethamine
1372166|NCT00484900|24 hour treatment
1372167|NCT00484900|Artemether + lumefantrine
1372168|NCT00484887|Hernia mesh
1372169|NCT00484887|Implanted mesh material
1372170|NCT00484887|Explanted mesh material
1372171|NCT00484874|Hodgkin's lymphoma
1372172|NCT00484874|Radioimmunotherapy
1372173|NCT00484874|Bexxar
1372174|NCT00484874|I-131 Tositumomab
1372175|NCT00484874|Safety
1372176|NCT00484874|Efficacy
1372177|NCT00484874|Nuclear Medicine
1372178|NCT00484874|Monoclonal antibody
1372179|NCT00484874|Radiolabeled
1372180|NCT00484861|Women
1372181|NCT00484861|Healthy Volunteers
1372182|NCT00484861|Triglyceride
1372183|NCT00484861|Healthy Volunteer
1372184|NCT00484861|HV
1372185|NCT00484848|oncology, medical
1372186|NCT00484848|implantable catheter
1372187|NCT00484848|vascular access ports
1372188|NCT00484848|persistent withdrawal occlusion
1372189|NCT00484848|Vortex®
1372190|NCT00484848|Celsite®
1372191|NCT00484848|Vacutainer®
1372192|NCT00484848|venous cut-down
1372193|NCT00484835|Abdominal
1372194|NCT00484835|Hysterectomy
1372195|NCT00484835|Electrocoagulation forceps
1372196|NCT00484835|Electrosurgery
1372197|NCT00484835|Gyrus plasma open seal forceps
1372198|NCT00484835|Patients undergoing abdominal hysterectomy for various reasons
1372199|NCT00484809|rheumatoid arthritis
1372200|NCT00484809|juvenile rheumatoid arthritis
1372201|NCT00484796|Carotid Surgery
1372202|NCT00484796|Cerebral Ischemia
1372203|NCT00484796|Cognitive Deficits
1372204|NCT00484796|Somatosensory-evoked Potentials
1372205|NCT00484796|Neuromonitoring
1372206|NCT00484783|Laparoscopic Surgical Procedures
1372207|NCT00484783|Endoscopic Surgical Procedures
1372208|NCT00484783|Laparoscopic & endoscopic procedures with a gastrotomy
1372209|NCT00484783|or opening in bladder or urethra
1372210|NCT00484770|heart failure, brain natriuretic peptide
1372211|NCT00484757|Narcolepsy
1372212|NCT00484757|Orexines
1372213|NCT00484757|sleep
1372214|NCT00484757|cognition
1372215|NCT00484757|cytokines
1372216|NCT00484744|pain
1372217|NCT00484744|orthodontic
1372218|NCT00484744|acetaminophen
1372219|NCT00484744|ibuprofen
1372220|NCT00484744|separator
1372221|NCT00484705|Androgens
1372222|NCT00484705|Menstrual pattern
1372223|NCT00484705|Insulin resistance
1372224|NCT00484705|Adipocytes
1372225|NCT00484705|Obesity
1372226|NCT00484705|Stress
1372227|NCT00484705|Muscle sympathetic nerve activity
1372228|NCT00484705|Psychological distress and quality of life
1372229|NCT00484692|randomized controlled trial
1372230|NCT00484692|smoking cessation
1372231|NCT00484692|nicotine dependence
1372232|NCT00484692|sustained-release bupropion
1372233|NCT00484692|psychotherapy
1372234|NCT00484692|psychodynamic model training
1372235|NCT00484666|recurrent
1372236|NCT00484666|platinum
1372237|NCT00484666|resistant
1372238|NCT00484666|ovarian
1372239|NCT00484666|primary
1372240|NCT00484666|peritoneal
1372241|NCT00484666|cancer
1372242|NCT00484653|To achieve a quality and quantitative molecular biology assay for vaginal flora abnormalities
1372243|NCT00484627|Exercise
1372244|NCT00484627|HIV
1372245|NCT00484627|Creatine
1372246|NCT00484627|Muscle
1372247|NCT00484614|Breast Cancer, breast conserving surgery
1372248|NCT00484588|VAP
1372249|NCT00484575|Sevoflurane
1372250|NCT00484575|CABG
1372251|NCT00484575|cardioprotection
1372252|NCT00484575|AnaConDa
1372253|NCT00484562|oxygen
1372254|NCT00484562|COPD
1372255|NCT00484562|exercise
1372256|NCT00484549|Fabry disease, Screening, Ischemic stroke
1372257|NCT00484536|CDP323
1372258|NCT00484536|Relapsing Multiple Sclerosis
1372259|NCT00484536|Magnetic Resonance Imaging
1372260|NCT00484536|Oral Compound
1372261|NCT00484536|MS
1372262|NCT00484523|To constitute a standardized database of multimode neural imaging.
1372263|NCT00484510|Ascorbic Acid
1372264|NCT00484510|Vitamin C
1372265|NCT00484510|Charcot Marie Tooth
1372266|NCT00484510|CMT
1372267|NCT00484510|CMT1a
1372268|NCT00484497|Sleep quality
1372269|NCT00484497|food supplement
1372270|NCT00484497|randomized controlled trial
1372271|NCT00484497|actigraphy
1372272|NCT00484497|Leeds
1372273|NCT00484497|Volunteers presenting moderate primary insomnia
1372274|NCT00484484|Cancer
1372275|NCT00484484|Refractory pain
1372276|NCT00484484|Uncontrolled pain
1372277|NCT00484484|Ketamine
1372278|NCT00484484|Uncontrolled cancer pain
1372279|NCT00484458|Degenerative Disc Disease
1372280|NCT00484458|Total Disc Replacement
1372281|NCT00484445|Chronic critical illness
1372282|NCT00484445|Functional status
1372283|NCT00484445|Outcomes
1372284|NCT00484445|Post-ICU
1372285|NCT00484432|NGR-hTNF
1372286|NCT00484432|Ovarian cancer
1372287|NCT00484432|Doxorubicin
1372288|NCT00484419|Colesevelam HCl,
1372289|NCT00484419|rosiglitazone
1372290|NCT00484419|sitagliptin
1372291|NCT00484419|Type 2 diabetes
1372292|NCT00484419|metformin
1372293|NCT00484406|Matrix Metalloproteinases
1372294|NCT00484406|Atherosclerosis
1372295|NCT00484406|Genetic polymorphism
1372296|NCT00484406|Acute coronary syndromes
1372297|NCT00484380|Valvular surgery
1372298|NCT00484380|Diagnostic accuracy of coronary angiography
1372299|NCT00484380|Coronary stenosis
1372300|NCT00484380|Coronary revascularisation
1372301|NCT00484367|Alcohol abuse
1372302|NCT00484367|Substance abuse
1372303|NCT00484367|Cannabis abuse
1372304|NCT00484367|Adolescents
1372305|NCT00484367|Group therapy
1372306|NCT00484367|Family therapy
1372307|NCT00484354|Acute Renal Failure
1372308|NCT00484354|Cardiac Surgery
1372309|NCT00484354|Sodium Bicarbonate
1372310|NCT00484354|Length of Stay
1372311|NCT00484354|Mortality
1372312|NCT00484341|NGR-hTNF
1372313|NCT00484341|Doxorubicin
1372314|NCT00484341|Soft Tissue Sarcoma
1372315|NCT00484328|hepatitis C
1372316|NCT00484328|Ribavirin
1372317|NCT00484328|Dosage
1372318|NCT00484328|Pharmacokinetics
1372319|NCT00484315|drug-eluting stent
1372320|NCT00484315|paclitaxel-eluting stent
1372321|NCT00484315|DES
1372322|NCT00484302|Marijuana Abuse
1372323|NCT00484302|Psychotic Disorders
1372324|NCT00484302|Schizophrenia
1372325|NCT00484276|NGR-hTNF
1372326|NCT00484276|malignant pleural mesothelioma
1372327|NCT00484250|Oral Lichen Planus
1372328|NCT00484250|Metronidazole
1372329|NCT00484250|Doxycycline
1372330|NCT00484237|Rheumatoid Arthritis
1372331|NCT00484211|NGR-hTNF, Hepatocellular Carcinoma (HCC)
1372332|NCT00484185|Hemophilia B
1372333|NCT00484185|BeneFIX
1372334|NCT00484185|Safety
1372335|NCT00484185|Efficacy
1372336|NCT00484172|Obesity
1372337|NCT00484159|Low back pain of suspected lumbar zygapophysial etiology
1372338|NCT00484146|Sepsis
1372339|NCT00484146|Early Stage
1372340|NCT00484146|Immune System
1372341|NCT00484146|Receptors
1372342|NCT00484146|Cytokines
1372343|NCT00484133|sepsis
1372344|NCT00484133|severe sepsis
1372345|NCT00484133|microcirculation
1372346|NCT00484133|Orthogonal polarisation spectral
1372347|NCT00484120|Osteoarthritis
1372348|NCT00484120|Diclofenac
1372349|NCT00484120|Nano-emulsion
1372350|NCT00484094|Rapamune
1372351|NCT00484094|Safety
1372352|NCT00484094|Efficacy
1372353|NCT00484094|Kidney Transplantation
1372354|NCT00484081|TESE
1372355|NCT00484081|NON-OBSTRUCTIVE
1372356|NCT00484081|MICRODISSECTION
1372357|NCT00484081|AZOOSPERMIA
1372358|NCT00484081|ICSI
1372359|NCT00484068|type 2 diabetes
1372360|NCT00484068|microalbuminuria
1372361|NCT00484068|chicken-based diet
1372362|NCT00484068|ACE inhibitor
1372363|NCT00484055|Antibiotic Prophylaxis
1372364|NCT00484042|pancreatitis
1372365|NCT00484042|polyamine
1372366|NCT00484042|cytokine
1372367|NCT00484029|Temporomandibular Disorders
1372368|NCT00484029|TMD
1372369|NCT00484029|TMJ/TMD
1372370|NCT00484029|Pain Management
1372371|NCT00484029|Pain
1372372|NCT00484029|Headaches
1372373|NCT00484016|adjuvant
1372374|NCT00484016|chemotherapy
1372375|NCT00484016|observation
1372376|NCT00484016|resected
1372377|NCT00484016|cancers
1372378|NCT00484003|Atopic eczema
1372379|NCT00484003|Pimecrolimus
1372380|NCT00484003|Children
1372381|NCT00484003|Quality of life
1372382|NCT00484003|Safety
1372383|NCT00484003|Atopic dermatitis
1372384|NCT00483990|Phase I Study in healthy subjects
1372385|NCT00483964|Schizophrenia
1372386|NCT00483964|Herbal extracts
1372387|NCT00483964|Randomized
1372388|NCT00483964|Controlled
1372389|NCT00483964|Clinical Trial
1372390|NCT00483951|Myocardial Infarction
1372391|NCT00483951|Myocardial Ischemia
1372392|NCT00483951|Atherosclerosis
1372393|NCT00483951|Congenital Heart Disease
1372394|NCT00483951|Valvular Heart Disease
1372395|NCT00483951|Heart Disease
1372396|NCT00483951|Cardiovascular Disease
1372397|NCT00483951|Heart Valve Disease
1372398|NCT00483925|Langerhans cell histiocytosis
1372399|NCT00483925|flow mediated dilatation
1372400|NCT00483925|intima media thickness
1372401|NCT00483925|insulin resistance
1372402|NCT00483925|hypopituitarism
1372403|NCT00483925|glucose and lipid metabolism,
1372404|NCT00483925|structural arterial and functional endothelial properties in patients with multisystem LCH
1372405|NCT00483912|pancreatitis, MARS
1372406|NCT00483912|severe acute pancreatitis with early multiple organ failure
1372407|NCT00483899|GW870086X Asthma Crossover repeat dose inhaled
1372408|NCT00483886|constipation
1372409|NCT00483886|prucalopride
1372410|NCT00483886|QOL
1372411|NCT00483886|SCBM
1372412|NCT00483886|PAC-SYM
1372413|NCT00483873|Cardiac Arrest, Neurological Recovery, EEG, Quantitative EEG
1372414|NCT00483860|Cancer
1372415|NCT00483860|Solid tumor,
1372416|NCT00483860|normal renal function
1372417|NCT00483860|renal impairment,
1372418|NCT00483860|prior platinum-based chemotherapy,
1372419|NCT00483847|TYGRIS - Rest of World (ROW)
1372420|NCT00483847|TYSABRI
1372421|NCT00483847|natalizumab
1372422|NCT00483847|Multiple Sclerosis
1372423|NCT00483834|Bevacizumab
1372424|NCT00483834|Avastin
1372425|NCT00483834|CPT-11
1372426|NCT00483834|Irinotecan
1372427|NCT00483834|Camptothecin-11
1372428|NCT00483834|Capecitabine
1372429|NCT00483834|Xeloda
1372430|NCT00483834|Metastatic
1372431|NCT00483834|Colorectal
1372432|NCT00483834|Colon
1372433|NCT00483834|Rectal
1372434|NCT00483821|stage I squamous cell carcinoma of the hypopharynx
1372435|NCT00483821|stage II squamous cell carcinoma of the hypopharynx
1372436|NCT00483821|stage III squamous cell carcinoma of the hypopharynx
1372437|NCT00483821|stage IV squamous cell carcinoma of the hypopharynx
1372438|NCT00483821|stage I squamous cell carcinoma of the larynx
1372439|NCT00483821|stage II squamous cell carcinoma of the larynx
1372440|NCT00483821|stage III squamous cell carcinoma of the larynx
1372441|NCT00483821|stage IV squamous cell carcinoma of the larynx
1372442|NCT00483821|stage I squamous cell carcinoma of the lip and oral cavity
1372443|NCT00483821|stage II squamous cell carcinoma of the lip and oral cavity
1372444|NCT00483821|stage III squamous cell carcinoma of the lip and oral cavity
1372445|NCT00483821|stage IV squamous cell carcinoma of the lip and oral cavity
1372446|NCT00483821|stage I squamous cell carcinoma of the oropharynx
1372447|NCT00483821|stage II squamous cell carcinoma of the oropharynx
1372448|NCT00483821|stage III squamous cell carcinoma of the oropharynx
1372449|NCT00483821|stage IV squamous cell carcinoma of the oropharynx
1372450|NCT00483821|stage I verrucous carcinoma of the larynx
1372451|NCT00483821|stage II verrucous carcinoma of the larynx
1372452|NCT00483821|stage III verrucous carcinoma of the larynx
1372453|NCT00483821|stage IV verrucous carcinoma of the larynx
1372454|NCT00483821|stage I verrucous carcinoma of the oral cavity
1372455|NCT00483821|stage II verrucous carcinoma of the oral cavity
1372456|NCT00483821|stage III verrucous carcinoma of the oral cavity
1372457|NCT00483821|stage IV verrucous carcinoma of the oral cavity
1372458|NCT00483782|stage IV ovarian epithelial cancer
1372459|NCT00483782|Brenner tumor
1372460|NCT00483782|ovarian carcinosarcoma
1372461|NCT00483782|ovarian clear cell cystadenocarcinoma
1372462|NCT00483782|ovarian endometrioid adenocarcinoma
1372463|NCT00483782|ovarian mixed epithelial carcinoma
1372464|NCT00483782|ovarian mucinous cystadenocarcinoma
1372465|NCT00483782|ovarian serous cystadenocarcinoma
1372466|NCT00483782|ovarian undifferentiated adenocarcinoma
1372467|NCT00483782|stage IA ovarian epithelial cancer
1372468|NCT00483782|stage IB ovarian epithelial cancer
1372469|NCT00483782|stage IC ovarian epithelial cancer
1372470|NCT00483782|stage IIA ovarian epithelial cancer
1372471|NCT00483782|stage IIB ovarian epithelial cancer
1372472|NCT00483782|stage IIC ovarian epithelial cancer
1372473|NCT00483782|stage IIIA ovarian epithelial cancer
1372474|NCT00483782|stage IIIB ovarian epithelial cancer
1372475|NCT00483782|stage IIIC ovarian epithelial cancer
1372476|NCT00483782|stage IA fallopian tube cancer
1372477|NCT00483782|stage IB fallopian tube cancer
1372478|NCT00483782|stage IC fallopian tube cancer
1372479|NCT00483782|stage IIA fallopian tube cancer
1372480|NCT00483782|stage IIB fallopian tube cancer
1372481|NCT00483782|stage IIC fallopian tube cancer
1372482|NCT00483782|stage IIIA fallopian tube cancer
1372483|NCT00483782|stage IIIB fallopian tube cancer
1372484|NCT00483782|stage IIIC fallopian tube cancer
1372485|NCT00483782|stage IV fallopian tube cancer
1372486|NCT00483782|stage IA primary peritoneal cavity cancer
1372487|NCT00483782|stage IB primary peritoneal cavity cancer
1372488|NCT00483782|stage IC primary peritoneal cavity cancer
1372489|NCT00483782|stage IIA primary peritoneal cavity cancer
1372490|NCT00483782|stage IIB primary peritoneal cavity cancer
1372491|NCT00483782|stage IIC primary peritoneal cavity cancer
1372492|NCT00483782|stage IIIA primary peritoneal cavity cancer
1372493|NCT00483782|stage IIIB primary peritoneal cavity cancer
1372494|NCT00483782|stage IIIC primary peritoneal cavity cancer
1372495|NCT00483782|stage IV primary peritoneal cavity cancer
1372496|NCT00483769|Cystis Fibrosis
1372497|NCT00483769|Glucose intolerance
1372498|NCT00483769|Glargine
1372499|NCT00483769|FEV1%
1372500|NCT00483756|Immunosuppression
1372501|NCT00483756|JAK3 inhibitor
1372502|NCT00483756|kidney transplantation.
1372503|NCT00483717|Migraine
1372504|NCT00483717|Ketorolac
1372505|NCT00483704|multiple attacks of moderate to severe migraine headaches
1372506|NCT00483691|Intervention
1372507|NCT00483691|Home Visit
1372508|NCT00483691|Growth
1372509|NCT00483691|Child Development
1372510|NCT00483678|psychosocial effects of cancer and its treatment
1372511|NCT00483678|sexual dysfunction
1372512|NCT00483678|sexuality and reproductive issues
1372513|NCT00483678|recurrent prostate cancer
1372514|NCT00483678|stage III prostate cancer
1372515|NCT00483678|stage IV prostate cancer
1372516|NCT00483665|endoleak
1372517|NCT00483652|multiple sclerosis
1372518|NCT00483652|MS
1372519|NCT00483652|walking
1372520|NCT00483652|leg strength
1372521|NCT00483652|demyelination
1372522|NCT00483639|anxiety disorder
1372654|NCT00483015|never- smokers
1372523|NCT00483639|long-term effects secondary to cancer therapy in adults
1372524|NCT00483639|head and neck cancer
1372525|NCT00483639|non-small cell lung cancer
1372526|NCT00483639|small cell lung cancer
1372527|NCT00483626|hemodynamic
1372528|NCT00483626|pulmonary hypertension
1372529|NCT00483626|sildenafil
1372530|NCT00483613|Daily stress
1372531|NCT00483613|Cognitive-behavioral therapy
1372532|NCT00483613|Quality of life
1372533|NCT00483613|SLEDAI
1372534|NCT00483600|Fondaparinux
1372535|NCT00483600|Pharmacokinetic
1372536|NCT00483587|NSTEMI
1372537|NCT00483587|Acute coronary syndrome
1372538|NCT00483587|Heme arginate
1372539|NCT00483587|HO-1
1372540|NCT00483587|Heme oxygenase-1
1372541|NCT00483574|Menactra® vaccine
1372542|NCT00483574|Meningococcal meningitis
1372543|NCT00483574|Measles
1372544|NCT00483574|Mumps
1372545|NCT00483574|Rubella
1372546|NCT00483574|Varicella virus
1372547|NCT00483574|Haemophilus influenzae type b
1372548|NCT00483574|Pneumococcal conjugate vaccine
1372549|NCT00483561|adenocarcinoma of the prostate
1372550|NCT00483561|recurrent prostate cancer
1372551|NCT00483561|stage III prostate cancer
1372552|NCT00483561|stage IV prostate cancer
1372553|NCT00483535|Gw273225, Oral Contraceptive Interaction
1372554|NCT00483522|Rehabilitation
1372555|NCT00483522|Directive counseling
1372556|NCT00483522|Brain injuries
1372557|NCT00483509|NGR-hTNF
1372558|NCT00483509|SCLC
1372559|NCT00483483|HIV
1372560|NCT00483483|Unsafe sex
1372561|NCT00483483|High-risk sex
1372562|NCT00483483|Needle sharing
1372563|NCT00483483|STDs
1372564|NCT00483470|Hepatitis A
1372565|NCT00483457|unspecified adult solid tumor, protocol specific
1372566|NCT00483444|Rehabilitation
1372567|NCT00483444|Brain injuries
1372568|NCT00483444|Directive counseling
1372569|NCT00483431|vitamin K2
1372570|NCT00483431|dosis-response
1372571|NCT00483431|osteocalcin
1372572|NCT00483431|matrix-gla protein
1372573|NCT00483418|male
1372574|NCT00483418|cancer
1372575|NCT00483405|advanced adult primary liver cancer
1372576|NCT00483405|localized unresectable adult primary liver cancer
1372577|NCT00483405|recurrent adult primary liver cancer
1372578|NCT00483405|adult primary hepatocellular carcinoma
1372579|NCT00483392|insulin
1372580|NCT00483392|rosiglitazone
1372581|NCT00483392|metformin
1372582|NCT00483392|hiv
1372583|NCT00483392|protease inhibitors
1372584|NCT00483366|unspecified adult solid tumor, protocol specific
1372588|NCT00483301|Melanoma
1372589|NCT00483301|Abraxane
1372590|NCT00483301|Sorafenib
1372591|NCT00483301|BAY 43-9006
1372592|NCT00483301|Abraxis
1372593|NCT00483288|cervical cancer
1372594|NCT00483275|Accidental Falls
1372595|NCT00483275|Accident Prevention
1372596|NCT00483275|Patient Education
1372597|NCT00483275|Exercise Training
1372598|NCT00483275|Alfacalcidol
1372599|NCT00483262|Temsirolimus
1372600|NCT00483262|Bortezomib
1372601|NCT00483249|Thoracoabdominal
1372602|NCT00483249|Paravisceral
1372603|NCT00483249|Aneurysm
1372604|NCT00483249|Endovascular
1372605|NCT00483249|Stent-Graft
1372606|NCT00483249|Aorta
1372607|NCT00483236|Non-Ischaemic Cardiomyopathy
1372608|NCT00483223|ER negative
1372609|NCT00483223|PgR negative
1372610|NCT00483223|HER2 negative
1372611|NCT00483223|cisplatin
1372612|NCT00483223|carboplatinum
1372613|NCT00483223|platinum
1372614|NCT00483223|p63
1372615|NCT00483223|p73
1372616|NCT00483197|VentrAssistTM
1372617|NCT00483197|LVAD
1372618|NCT00483197|End-stage heart failure
1372619|NCT00483197|Cardiomyopathy
1372620|NCT00483158|Helicobacter pylori
1372621|NCT00483158|Fluoroquinolones
1372622|NCT00483158|First in Man
1372623|NCT00483119|pemphigus vulgaris
1372624|NCT00483119|IVIg
1372625|NCT00483119|cyclophosphamide
1372626|NCT00483119|treatment
1372627|NCT00483119|pemphigus antibodies
1372628|NCT00483106|Attention Deficit Hyperactivity Disorder
1372629|NCT00483106|Genetics
1372630|NCT00483106|Pharmacogenetics
1372631|NCT00483093|NGR-hTNF
1372632|NCT00483093|cisplatin
1372633|NCT00483093|solid tumors
1372634|NCT00483080|NGR-hTNF
1372635|NCT00483080|CRC
1372636|NCT00483067|Idiopathic Hypereosinophilic Syndrome
1372637|NCT00483067|Leukemia
1372638|NCT00483067|2-Chlorodeoxyadenosine
1372639|NCT00483067|Cladribine
1372640|NCT00483067|Cytarabine
1372641|NCT00483067|Ara-C
1372642|NCT00483067|2-CdA
1372643|NCT00483067|G-CSF
1372644|NCT00483067|HES
1372645|NCT00483054|HIV
1372646|NCT00483054|tuberculosis
1372647|NCT00483054|efavirenz
1372648|NCT00483054|nevirapine
1372649|NCT00483054|rifampicin
1372650|NCT00483054|co-infected HIV and tuberculosis patients
1372651|NCT00483015|presentation
1372652|NCT00483015|outcome
1372653|NCT00483015|response
1372655|NCT00483002|A prospective and observational program to monitor use in real practice including efficacy of Varenicline in Korea.
1372656|NCT00482963|HIV
1372657|NCT00482963|Contraception
1372658|NCT00482963|Antiretroviral agents
1372659|NCT00482963|Pharmacokinetics
1372660|NCT00482937|Safety
1372661|NCT00482937|Heart Failure
1372662|NCT00482924|obesity
1372663|NCT00482924|cardiovascular risk profiles
1372664|NCT00482924|adipokines
1372665|NCT00482924|preatherosclerosis
1372666|NCT00482924|low grade inflammation
1372667|NCT00482924|dyslipidemia
1372668|NCT00482924|insulin resistance
1372669|NCT00482924|brown adipose tissue
1372670|NCT00482924|white adipose tissue
1372671|NCT00482911|recurrent intraocular melanoma
1372672|NCT00482911|metastatic intraocular melanoma
1372673|NCT00482911|ciliary body and choroid melanoma, medium/large size
1372674|NCT00482911|extraocular extension melanoma
1372675|NCT00482911|iris melanoma
1372676|NCT00482911|conjunctival melanoma
1372677|NCT00482885|Esophagus
1372678|NCT00482885|Peristalsis
1372679|NCT00482885|Contractile Pressure
1372680|NCT00482885|Coordination of contraction
1372681|NCT00482885|Bolus transport
1372682|NCT00482885|Esophageal function
1372683|NCT00482872|stage I squamous cell carcinoma of the hypopharynx
1372684|NCT00482872|stage II squamous cell carcinoma of the hypopharynx
1372685|NCT00482872|stage III squamous cell carcinoma of the hypopharynx
1372686|NCT00482872|stage IV squamous cell carcinoma of the hypopharynx
1372687|NCT00482872|recurrent squamous cell carcinoma of the hypopharynx
1372688|NCT00482872|stage I squamous cell carcinoma of the larynx
1372689|NCT00482872|stage II squamous cell carcinoma of the larynx
1372690|NCT00482872|stage III squamous cell carcinoma of the larynx
1372691|NCT00482872|stage IV squamous cell carcinoma of the larynx
1372692|NCT00482872|recurrent squamous cell carcinoma of the larynx
1372693|NCT00482872|stage I squamous cell carcinoma of the lip and oral cavity
1372694|NCT00482872|stage II squamous cell carcinoma of the lip and oral cavity
1372695|NCT00482872|stage III squamous cell carcinoma of the lip and oral cavity
1372696|NCT00482872|stage IV squamous cell carcinoma of the lip and oral cavity
1372697|NCT00482872|recurrent squamous cell carcinoma of the lip and oral cavity
1372698|NCT00482872|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1372699|NCT00482872|recurrent metastatic squamous neck cancer with occult primary
1372700|NCT00482872|untreated metastatic squamous neck cancer with occult primary
1372701|NCT00482872|stage I squamous cell carcinoma of the nasopharynx
1372702|NCT00482872|stage II squamous cell carcinoma of the nasopharynx
1372703|NCT00482872|stage III squamous cell carcinoma of the nasopharynx
1372704|NCT00482872|stage IV squamous cell carcinoma of the nasopharynx
1372705|NCT00482872|recurrent squamous cell carcinoma of the nasopharynx
1372706|NCT00482872|stage I squamous cell carcinoma of the oropharynx
1372707|NCT00482872|stage II squamous cell carcinoma of the oropharynx
1372708|NCT00482872|stage III squamous cell carcinoma of the oropharynx
1372709|NCT00482872|stage IV squamous cell carcinoma of the oropharynx
1372710|NCT00482872|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1372711|NCT00482872|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1372712|NCT00482872|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1372713|NCT00482872|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1372714|NCT00482872|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1372715|NCT00482872|salivary gland squamous cell carcinoma
1372716|NCT00482872|recurrent verrucous carcinoma of the larynx
1372717|NCT00482872|recurrent verrucous carcinoma of the oral cavity
1372718|NCT00482872|stage I verrucous carcinoma of the larynx
1372719|NCT00482872|stage I verrucous carcinoma of the oral cavity
1372720|NCT00482872|stage II verrucous carcinoma of the larynx
1372721|NCT00482872|stage II verrucous carcinoma of the oral cavity
1372722|NCT00482872|stage III verrucous carcinoma of the larynx
1372723|NCT00482872|stage III verrucous carcinoma of the oral cavity
1372724|NCT00482872|stage IV verrucous carcinoma of the larynx
1372725|NCT00482872|stage IV verrucous carcinoma of the oral cavity
1372726|NCT00482872|recurrent squamous cell carcinoma of the oropharynx
1372727|NCT00482859|Fibromyalgia Syndrome
1372728|NCT00482846|mucositis
1372729|NCT00482846|drug/agent toxicity by tissue/organ
1372730|NCT00482846|stage II multiple myeloma
1372731|NCT00482846|stage III multiple myeloma
1372732|NCT00482846|refractory multiple myeloma
1372733|NCT00482833|adult acute promyelocytic leukemia (M3)
1372734|NCT00482833|adult acute myeloid leukemia with t(15;17)(q22;q12)
1372735|NCT00482833|untreated adult acute myeloid leukemia
1372736|NCT00482820|anxiety
1372737|NCT00482820|attention-biases
1372738|NCT00482820|children
1372739|NCT00482807|stage I prostate cancer
1372740|NCT00482807|stage II prostate cancer
1372741|NCT00482807|stage III prostate cancer
1372742|NCT00482807|stage IV prostate cancer
1372743|NCT00482807|adenocarcinoma of the prostate
1372744|NCT00482807|recurrent prostate cancer
1372745|NCT00482794|Antiphospholipid Antibody Syndrome
1372746|NCT00482781|Apnea
1372747|NCT00482781|Bradycardia
1372748|NCT00482781|Preterm Infant
1372749|NCT00482781|Immunization
1372750|NCT00482781|DTaP
1372751|NCT00482768|Diabetes, type II; Primary Health Care; Outpatient Care
1372752|NCT00482755|male breast cancer
1372753|NCT00482755|stage II breast cancer
1372754|NCT00482755|stage IIIA breast cancer
1372755|NCT00482742|Chronic Total Occlusion
1372756|NCT00482716|unspecified adult solid tumor, protocol specific
1372757|NCT00482716|refractory multiple myeloma
1372758|NCT00482716|stage I multiple myeloma
1372759|NCT00482716|stage II multiple myeloma
1372760|NCT00482716|stage III multiple myeloma
1372761|NCT00482716|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1372762|NCT00482716|noncontiguous stage II grade 1 follicular lymphoma
1372763|NCT00482716|noncontiguous stage II grade 2 follicular lymphoma
1372764|NCT00482716|noncontiguous stage II marginal zone lymphoma
1372765|NCT00482716|noncontiguous stage II small lymphocytic lymphoma
1372766|NCT00482716|contiguous stage II adult diffuse small cleaved cell lymphoma
1372767|NCT00482716|contiguous stage II grade 1 follicular lymphoma
1372768|NCT00482716|contiguous stage II grade 2 follicular lymphoma
1372769|NCT00482716|contiguous stage II marginal zone lymphoma
1372770|NCT00482716|contiguous stage II small lymphocytic lymphoma
1372771|NCT00482716|stage I adult diffuse small cleaved cell lymphoma
1372772|NCT00482716|stage III adult diffuse small cleaved cell lymphoma
1372773|NCT00482716|stage IV adult diffuse small cleaved cell lymphoma
1372774|NCT00482716|stage I grade 1 follicular lymphoma
1372775|NCT00482716|stage I grade 2 follicular lymphoma
1372776|NCT00482716|stage III grade 1 follicular lymphoma
1372777|NCT00482716|stage III grade 2 follicular lymphoma
1372778|NCT00482716|stage IV grade 1 follicular lymphoma
1372779|NCT00482716|stage IV grade 2 follicular lymphoma
1372780|NCT00482716|stage I marginal zone lymphoma
1372781|NCT00482716|stage III marginal zone lymphoma
1372782|NCT00482716|stage IV marginal zone lymphoma
1372783|NCT00482716|stage I small lymphocytic lymphoma
1372784|NCT00482716|stage III small lymphocytic lymphoma
1372785|NCT00482716|stage IV small lymphocytic lymphoma
1372786|NCT00482716|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1372787|NCT00482716|nodal marginal zone B-cell lymphoma
1372788|NCT00482716|splenic marginal zone lymphoma
1372789|NCT00482716|recurrent adult diffuse small cleaved cell lymphoma
1372790|NCT00482716|recurrent grade 1 follicular lymphoma
1372791|NCT00482716|recurrent grade 2 follicular lymphoma
1372792|NCT00482716|recurrent marginal zone lymphoma
1372793|NCT00482716|recurrent small lymphocytic lymphoma
1372794|NCT00482716|stage I chronic lymphocytic leukemia
1372795|NCT00482716|stage II chronic lymphocytic leukemia
1372796|NCT00482716|stage III chronic lymphocytic leukemia
1372797|NCT00482716|stage IV chronic lymphocytic leukemia
1372798|NCT00482716|refractory chronic lymphocytic leukemia
1372799|NCT00482716|anemia
1372800|NCT00482703|Imatinib resistant or intolerant chronic phase CML
1372801|NCT00482690|Smoking cessation
1372802|NCT00482690|Biomarkers
1372803|NCT00482690|Aldehydes
1372804|NCT00482690|Exhaled breath
1372805|NCT00482690|Harm Reduction
1372806|NCT00482690|Cigarette smoking
1372807|NCT00482690|cessation
1372808|NCT00482690|reduction
1372809|NCT00482677|adult glioblastoma
1372810|NCT00482677|adult giant cell glioblastoma
1372811|NCT00482677|adult gliosarcoma
1372812|NCT00482586|adult primary liver cancer
1372813|NCT00482586|liver metastases
1372814|NCT00482573|Electrocardiography, ambulatory/methods
1372815|NCT00482573|Blood Pressure monitoring, ambulatory/methods
1372816|NCT00482573|Cardiotocography/methods
1372817|NCT00482573|Dental restoration, permanent
1372818|NCT00482573|Anesthesia, local /methods
1372819|NCT00482573|Lidocaine
1372820|NCT00482573|Vasoconstrictor Agents
1372821|NCT00482573|Epinephrine
1372822|NCT00482573|Pregnancy
1372823|NCT00482573|Rheumatic Heart Disease
1372824|NCT00482560|Sucrose
1372825|NCT00482560|Breastfeeding
1372826|NCT00482560|Heel lance
1372827|NCT00482547|urinary tract infection
1372828|NCT00482547|urinary catheter
1372829|NCT00482521|unspecified adult solid tumor, protocol specific
1372830|NCT00482508|Asthma
1372831|NCT00482508|anti immunoglobulin E
1372832|NCT00482508|omalizumab
1372833|NCT00482495|refractory multiple myeloma
1372834|NCT00482495|stage I multiple myeloma
1372835|NCT00482495|stage II multiple myeloma
1372836|NCT00482495|stage III multiple myeloma
1372837|NCT00482482|Yoga
1372838|NCT00482482|Bipolar disorder
1372839|NCT00482482|Major depression
1372840|NCT00482482|Dysthymia
1372841|NCT00482482|Randomized
1372842|NCT00482469|ischemia-reperfusion
1372843|NCT00482469|ischemia
1372844|NCT00482469|reperfusion
1372845|NCT00482469|DIEP-flap
1372846|NCT00482469|flap
1372847|NCT00482456|Nitrous oxide
1372848|NCT00482456|Homocysteine
1372849|NCT00482456|folate
1372850|NCT00482456|vitamin B12
1372851|NCT00482430|Undifferentiated schizophrenia
1372852|NCT00482430|Residual schizophrenia
1372853|NCT00480649|SERETIDE
1372854|NCT00480649|asthma
1372855|NCT00480649|Korean
1372856|NCT00480649|ACT
1372857|NCT00480623|Prostate Cancer
1372858|NCT00480623|Biochemical Failure
1372859|NCT00480623|Radical Prostatectomy
1372860|NCT00480610|Dermatitis, atopic
1372861|NCT00480610|Tacrolimus
1372862|NCT00480610|Adult
1372863|NCT00480610|treatment outcomes
1372864|NCT00482391|recurrent breast cancer
1372865|NCT00482391|stage I breast cancer
1372866|NCT00482391|stage II breast cancer
1372867|NCT00482391|stage IIIA breast cancer
1372868|NCT00482391|stage IIIB breast cancer
1372869|NCT00482391|stage IIIC breast cancer
1372870|NCT00482391|male breast cancer
1372871|NCT00482378|stage I multiple myeloma
1372872|NCT00482378|stage II multiple myeloma
1372873|NCT00482378|stage III multiple myeloma
1372874|NCT00482378|refractory multiple myeloma
1372875|NCT00482378|pain
1372876|NCT00482365|adult primary hepatocellular carcinoma
1372877|NCT00482365|advanced adult primary liver cancer
1372878|NCT00482365|localized resectable adult primary liver cancer
1372879|NCT00482365|localized unresectable adult primary liver cancer
1372880|NCT00482365|recurrent adult primary liver cancer
1372881|NCT00482339|bacterial contamination
1372882|NCT00482339|platelet concentrates
1372883|NCT00482339|blood donation
1372884|NCT00482339|looxster
1372885|NCT00482339|pureprove
1372886|NCT00482339|bacterial genomic DNA
1372887|NCT00482339|bacterial contamination of platelet concentrates
1372888|NCT00482339|"Preparation of bacterial DNA in blood"
1372889|NCT00482339|comparison of blood culture versus NAT
1372890|NCT00482313|Attention Deficit Hyperactivity Disorder
1372891|NCT00482313|ADHD
1372892|NCT00482313|Prison
1372893|NCT00482313|Treatment
1372894|NCT00482313|Randomized
1372895|NCT00482313|Double-Blind
1372896|NCT00482313|Placebo Control
1372897|NCT00482313|Parallel Assignment
1372898|NCT00482313|Efficacy Study
1372899|NCT00482300|Histologically proved endometrial carcinoma preoperatively supposed stage I-II
1372900|NCT00482274|adenocarcinoma of the prostate
1372901|NCT00482274|recurrent prostate cancer
1372902|NCT00482274|stage I prostate cancer
1372903|NCT00482274|stage II prostate cancer
1372904|NCT00482274|stage III prostate cancer
1372905|NCT00482274|stage IV prostate cancer
1372906|NCT00482261|myeloma
1372907|NCT00482261|relapse
1372908|NCT00482261|refractory
1372909|NCT00482261|elderly
1372910|NCT00482261|lenalidomide
1372911|NCT00482248|Asthma
1372912|NCT00482248|anti-immunoglobulin E
1372913|NCT00482248|omalizumab
1372914|NCT00482248|allergic asthma
1372915|NCT00482222|adenocarcinoma of the colon
1372916|NCT00482222|stage IV colon cancer
1372917|NCT00482222|adenocarcinoma of the rectum
1372918|NCT00482222|stage IV rectal cancer
1372919|NCT00482222|liver metastases
1372920|NCT00482222|recurrent colon cancer
1372921|NCT00482222|recurrent rectal cancer
1372922|NCT00482209|mifepristone, misoprostol, medical abortion
1372923|NCT00482183|Bare metal stent
1372924|NCT00482183|Major adverse cardiac events
1372925|NCT00482183|Pioglitazone
1372926|NCT00482183|Restenosis
1372927|NCT00482183|Sirolimus eluting stent
1372928|NCT00482144|Pulsed-Dye Laser
1372929|NCT00482118|Air Pollution
1372930|NCT00482118|Tumor Markers
1372931|NCT00482118|Genetic Polymorphisms
1372932|NCT00482118|Molecular Epidemiology
1372933|NCT00482118|Environmental Epidemiology
1372934|NCT00482118|Lung Cancer
1372935|NCT00482105|melanoma
1372936|NCT00482092|Crohn's disease
1372937|NCT00482092|adult stem cell therapy
1372938|NCT00482066|Wegener's granulomatosis
1372939|NCT00482066|Microscopic polyangiitis
1372940|NCT00482066|Churg Strauss Syndrome
1372941|NCT00482066|ANCA
1372942|NCT00482040|CPAP
1372943|NCT00482040|Preterm
1372944|NCT00482040|Prematurity
1372945|NCT00482040|Apnea of prematurity
1372946|NCT00482027|HIV vaccine
1372947|NCT00482027|Adeno-associated virus vactored vaccine
1372948|NCT00482027|HIV-1 subtype C
1372949|NCT00482027|Safety
1372950|NCT00482027|Immunogenicity
1372951|NCT00482027|Biodistribution
1372952|NCT00482027|HIV prevention
1372953|NCT00482001|Donepezil
1372954|NCT00482001|Driving
1372955|NCT00482001|Cholinesterase Inhibitors
1372956|NCT00482001|Geriatric Psychiatry
1372957|NCT00482001|Psychopharmacology
1372958|NCT00482001|Aricept
1372959|NCT00481988|depression
1372960|NCT00481988|transcranial direct current stimulation
1372961|NCT00481988|direct current stimulation
1372962|NCT00481988|tdcs
1372963|NCT00481975|binge eating
1372964|NCT00481975|eating disorders
1372965|NCT00481975|obesity
1372966|NCT00481949|Gastro-oesophageal reflux disease
1372967|NCT00481949|pH measurement
1372968|NCT00481949|symptom association
1372969|NCT00481949|wireless pH monitoring system
1372970|NCT00481949|Functional Heartburn
1372971|NCT00481949|Gastro-esophageal reflux disease
1372972|NCT00481936|Neoplasms
1372973|NCT00481936|Neoplasm, Epithelial
1372974|NCT00481936|Neoplasm, Glandular
1372975|NCT00481923|hypocaloric diet
1372976|NCT00481923|energy intake
1372977|NCT00481897|overweight
1372978|NCT00481897|obesity
1372979|NCT00481897|type 2 diabetes
1372980|NCT00481897|diabetes
1372981|NCT00481897|worksite cost
1372982|NCT00481897|nutrition
1372983|NCT00481884|Breast Cancer
1372984|NCT00481884|Radiation Dermatitis
1372985|NCT00481884|RadiaPlexRx Gel
1372986|NCT00481884|Aquaphor
1372987|NCT00481871|Lymphoproliferative malignancies
1372988|NCT00481871|Lymphoma
1372989|NCT00481871|Hodgkin's lymphoma (HL)
1372990|NCT00481871|Non-Hodgkin's lymphoma (NHL)
1372991|NCT00481871|PTCL
1372992|NCT00481871|T/NK-cell leukemia/lymphoma
1372993|NCT00481871|T-cell lymphoma/leukemia (HTLV 1+)
1372994|NCT00481871|Angioimmunoblastic T-cell lymphoma
1372995|NCT00481871|Blastic NK lymphoma
1372996|NCT00481871|Anaplastic large cell lymphoma
1372997|NCT00481871|T/NK-cell lymphoma
1372998|NCT00481871|Enteropathy-type intestinal lymphoma
1372999|NCT00481871|Hepatosplenic T-cell lymphoma
1373000|NCT00481871|Extranodal peripheral T/NK-cell lymphoma
1373001|NCT00481871|Subcutaneous panniculitis T-cell lymphoma
1373002|NCT00481871|Transformed mycosis fungoides
1373003|NCT00481871|PDX
1373004|NCT00481871|Pralatrexate
1373005|NCT00481871|Gemcitabine
1373006|NCT00481871|Gemzar
1373007|NCT00481871|Vitamin B12
1373008|NCT00481871|Folic acid
1373009|NCT00481858|chronic lymphocytic leukemia
1373010|NCT00481858|biomarker
1373011|NCT00481858|prognosis
1373012|NCT00481858|apoptosis
1373013|NCT00481858|neoplasm/cancer diagnosis
1373014|NCT00481858|stable isotope
1373015|NCT00481858|diagnosis evaluation
1373016|NCT00481858|outcomes
1373017|NCT00481858|CD19
1373018|NCT00481858|CD5
1373019|NCT00481819|Kidney Transplantation
1373020|NCT00481819|Tacrolimus
1373021|NCT00481819|Methylprednisolone
1373022|NCT00481819|Prednisolone
1373023|NCT00481819|Mycophenolate Mofetil
1373024|NCT00481806|Virchow's Triad
1373025|NCT00481806|Thrombin
1373026|NCT00481806|Graft Failure
1373027|NCT00481793|Plutonium
1373028|NCT00481793|Ionizing Radiation
1373029|NCT00481793|Polymorphism
1373030|NCT00481793|Biological Marker
1373031|NCT00481793|Russia
1373032|NCT00481767|Cervical cancer;
1373033|NCT00481767|Human papillomavirus (HPV) vaccine
1373034|NCT00481767|HPV;
1373035|NCT00481767|Papillomavirus;
1373036|NCT00481754|Endometrium
1373037|NCT00481754|PTEN
1373038|NCT00481754|Hormones
1373039|NCT00481754|Carcinogenesis
1373040|NCT00481754|Etiology
1373041|NCT00481754|Tissue Evaluation
1373042|NCT00481754|Questionnaire
1373043|NCT00481741|Angioplasty, Percutaneous TransluminalCoronary
1373044|NCT00481715|Web-Based Weight Loss Program
1373045|NCT00481715|Cash Incentive Weight Loss Program
1373046|NCT00481715|North Carolina
1373047|NCT00481689|Cipro
1373048|NCT00481689|Complicated UTI
1373049|NCT00481689|Pseudomonas aeruginosa
1373050|NCT00481676|Chronic urticaria, omalizumab, thyroperoxidase, IgE
1373051|NCT00480597|gemcitabine
1373052|NCT00480597|vinorelbine
1373053|NCT00480597|cisplatin
1373054|NCT00480597|capecitabine
1373055|NCT00480597|pretreated metastatic breast cancer
1373056|NCT00480584|pancreatic
1373057|NCT00480584|gemcitabine
1373058|NCT00480584|erlotinib (HER1/epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor)
1373059|NCT00480584|capecitabine
1373060|NCT00480571|chronic schizophrenia or schizo-affective disorder
1373061|NCT00480558|HIV
1373062|NCT00480558|MVA85A
1373063|NCT00480558|TB
1373064|NCT00480558|Tuberculosis
1373065|NCT00480558|Human Immunodeficiency Virus
1373066|NCT00480558|Safety
1373067|NCT00480558|Immunogenicity
1373068|NCT00480558|Efficacy
1373069|NCT00480558|Treatment Naive
1373070|NCT00480545|Women with bleeding disorders
1373071|NCT00480545|Menstrual cycle
1373072|NCT00480545|Women
1373073|NCT00480545|Healthy volunteers
1373074|NCT00480532|birth control
1373075|NCT00480532|continuous contraception
1373076|NCT00480532|break-through bleeding
1373077|NCT00480519|meatotomy
1373078|NCT00480519|meatal stenosis
1373079|NCT00480519|local anaesthesia
1373080|NCT00480519|feasibility
1373081|NCT00480519|pain control
1373082|NCT00480506|chimerism
1373083|NCT00480506|allogenic hematopoietic transplantation
1373084|NCT00480506|assay
1373085|NCT00480480|Trauma
1373086|NCT00480480|Grief
1373087|NCT00480480|Depression
1373088|NCT00480480|Adolescent
1373089|NCT00480480|War
1373090|NCT00480480|Group
1373091|NCT00480480|Therapy
1373092|NCT00480480|Treatment
1373093|NCT00480480|Intervention
1373094|NCT00480480|School
1373095|NCT00480480|Development
1373096|NCT00480454|TB
1373097|NCT00480454|Tuberculosis
1373098|NCT00480454|Infants
1373099|NCT00480454|EPI
1373100|NCT00480441|Marijuana
1373101|NCT00480441|Addiction
1373102|NCT00480441|Substance Withdrawal Syndrome
1373103|NCT00480441|Clinical Trial
1373104|NCT00480441|Dronabinol
1373105|NCT00480441|Behavioral Therapy
1373106|NCT00480441|Adults
1373107|NCT00480441|Neuroimaging
1373108|NCT00480441|Neuropsychological Testing
1373109|NCT00480441|Neurocognitive Testing
1373110|NCT00480441|Behavioral Probes
1373111|NCT00480428|Radioactive Fallout
1373112|NCT00480428|Childhood Exposures
1373113|NCT00480428|External Radiation Dose
1373114|NCT00480428|Internal Radiation Dose to Thyroid Gland
1373115|NCT00480428|Pasture-Dairy Animal- Milk- Thyroid Pathway
1373116|NCT00480402|preterm birth
1373117|NCT00480402|progesterone
1373118|NCT00480402|twins
1373119|NCT00480402|Preterm birth in twin gestations
1373120|NCT00480389|Clear cell Renal cell carcinoma
1373121|NCT00480389|Metastatic
1373122|NCT00480389|Sorafenib tosylate
1373123|NCT00480389|Preoperative treatment
1373124|NCT00480376|transrectal biopsy
1373125|NCT00480376|prostate
1373126|NCT00480376|prophylaxis antibiotic
1373127|NCT00480363|Smoldering Multiple Myeloma
1373128|NCT00480363|PETHEMA
1373129|NCT00480363|Smoldering
1373130|NCT00480350|HIV
1373131|NCT00480350|virological response
1373132|NCT00480350|CD4
1373133|NCT00480350|food supplement
1373134|NCT00480350|Human Immunodeficiency Virus
1373135|NCT00480350|Complementary Therapies
1373136|NCT00480337|PCOS
1373137|NCT00480337|Fertility Preservation
1373138|NCT00480337|Repeated IVF Failure
1373139|NCT00480337|S/P Hyperstimulation
1373140|NCT00481637|paraneoplastic; autoimmunity;
1373141|NCT00481624|advanced lung cancer
1373142|NCT00481624|Procrit
1373143|NCT00481624|Epoetin Alfa
1373144|NCT00481624|Ferric Gluconate
1373145|NCT00481624|iron supplementation
1373146|NCT00481611|Industry Hygiene
1373147|NCT00481611|Molecular Epidemiology
1373148|NCT00481611|Cancer Susceptibility
1373149|NCT00481611|Genotoxicity
1373150|NCT00481611|Immune Function
1373151|NCT00481611|Cancer Susceptability
1373152|NCT00481585|claudin
1373153|NCT00481585|electrophysiology
1373154|NCT00481585|breast
1373155|NCT00481585|screening
1373156|NCT00481572|Sepsis
1373157|NCT00481572|Septic Shock
1373158|NCT00481572|vasopressin
1373159|NCT00481572|terlipressin
1373160|NCT00481559|Voraxaze
1373161|NCT00481559|glucarpidase
1373162|NCT00481559|carboxypeptidase
1373163|NCT00481559|cancer
1373164|NCT00481559|lymphoma
1373165|NCT00481559|leukemia
1373166|NCT00481559|osteosarcoma
1373167|NCT00481559|methotrexate
1373168|NCT00481559|delayed elimination
1373169|NCT00481559|renal insufficiency
1373170|NCT00481559|toxicity
1373171|NCT00481546|Leber congenital amaurosis
1373172|NCT00481546|LCA
1373173|NCT00481546|RPE65
1373174|NCT00481546|Retinal disease due to RPE65 mutations
1373175|NCT00481546|RPE65-associated Leber congenital amaurosis
1373176|NCT00481533|Cesarean Delivery
1373177|NCT00481533|Uterine Contractility
1373178|NCT00481507|Probiotic
1373179|NCT00481507|Cultured dairy drink
1373180|NCT00481507|Health
1373181|NCT00481507|10 day antibiotic
1373182|NCT00481507|Otherwise healthy
1373183|NCT00481494|Glaucoma
1373184|NCT00481494|Drug compliance
1373185|NCT00481494|Personality
1373186|NCT00481481|Tacrolimus, Kidney Transplantation
1373187|NCT00481468|Coronary artery disease
1373188|NCT00481468|chest pain
1373189|NCT00481455|Glioblastoma Multiforme
1373190|NCT00481455|temozolomide
1373191|NCT00481442|Septic shock
1373192|NCT00481442|Sepsis
1373193|NCT00481442|Norepinephrine
1373194|NCT00481442|Phenylephrine
1373195|NCT00481429|Biomarker
1373196|NCT00481429|Glitazone
1373197|NCT00481429|Diabetes
1373198|NCT00481416|Esophageal Varices
1373199|NCT00481416|PillCam Eso
1373200|NCT00481416|Capsule Endoscopy
1373201|NCT00481416|Given Imaging
1373202|NCT00481416|Inscope
1373203|NCT00481403|Sperm, male fertility, microarrays
1373204|NCT00481390|HIV
1373205|NCT00481390|HLA-B*5701
1373206|NCT00481390|prevalence
1373207|NCT00481390|Treatment Experienced
1373208|NCT00481390|Treatment Naive
1373209|NCT00481377|Ablation
1373210|NCT00481377|Ventricular tachycardia
1373211|NCT00481377|coronary artery disease
1373212|NCT00481377|Implantable cardioverter defibrillator interventions
1373213|NCT00481364|hemodialysis
1373214|NCT00481364|endothelial function
1373215|NCT00481364|coronary artery calcification
1373216|NCT00481364|atherosclerosis
1373217|NCT00481364|statin
1373218|NCT00481351|artificial chilomicrons kinetics
1373219|NCT00481351|ezetimibe plus statin
1373220|NCT00481351|lipid lowering therapy
1373221|NCT00481338|Cohort
1373222|NCT00481338|Quality of life
1373223|NCT00481338|Health resource use
1373224|NCT00481338|Disability
1373225|NCT00481338|Prognosis
1373226|NCT00481312|Initial Sedation
1373227|NCT00481312|Mechanical ventilation
1373228|NCT00481299|Insulin
1373229|NCT00481299|glucose
1373230|NCT00481299|lipids
1373231|NCT00481299|prolactinoma
1373232|NCT00481299|hyperprolactinemia
1373233|NCT00481286|Group clinics
1373234|NCT00481286|Goal setting
1373235|NCT00481286|Diabetes
1373236|NCT00481286|Hypertension
1373237|NCT00481286|Age 50+
1373238|NCT00481273|MDS
1373239|NCT00481260|Hgb C
1373240|NCT00481260|Screening
1373241|NCT00481247|Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
1373242|NCT00481234|Anesthesia, General
1373243|NCT00481234|Abnormalities, Cardiovascular
1373244|NCT00481234|Heart Rate
1373245|NCT00481234|Forecasting
1373246|NCT00481221|Thalassemia
1373247|NCT00481221|Iron Deficiency
1373248|NCT00481221|Carrier screening
1373249|NCT00481208|open-angle glaucoma
1373250|NCT00481208|diurnal fluctuation
1373251|NCT00481208|intraocular pressure
1373252|NCT00481208|peripapillary retinal blood flow
1373253|NCT00481208|latent asymmetric intraocular pressure
1373254|NCT00481182|PK
1373255|NCT00481182|PD
1373256|NCT00481182|FPV
1373257|NCT00481182|RTV
1373258|NCT00481182|APV
1373259|NCT00481182|ritonavir
1373260|NCT00481182|fosamprenavir
1373261|NCT00481182|amprenavir
1373262|NCT00481182|methadone
1373263|NCT00481182|pharmacokinetics
1373264|NCT00481182|pharmacodynamics
1373265|NCT00481169|Postmenopausal Osteoporosis
1373266|NCT00481143|Myelodysplastic Syndrome
1373267|NCT00481143|MDS
1373268|NCT00481143|iron overload
1373269|NCT00481143|chelation
1373270|NCT00481143|chelators
1373271|NCT00481143|ICL670
1373272|NCT00481143|Deferasirox
1373273|NCT00481143|serum ferritin
1373274|NCT00481143|LIC
1373275|NCT00481143|transfusional hemosiderosis
1373276|NCT00481143|Refractory Anemia
1373277|NCT00481143|RA
1373278|NCT00481143|Refractory Anemia with Ringed Sideroblasts
1373279|NCT00481143|RARS
1373280|NCT00481143|blood transfusions
1373281|NCT00481143|Mydelodysplastic Syndrome(s)
1373282|NCT00481130|Alport Syndrome
1373283|NCT00481130|x linked
1373284|NCT00481130|autosomal dominant Alport syndrome
1373285|NCT00481130|glomerular basement membrane
1373286|NCT00481130|hereditary nephritis
1373287|NCT00481130|familial benign haematuria
1373288|NCT00481130|type IV collagen
1373289|NCT00481130|hereditary nephritis with neurosensory deafness
1373290|NCT00481130|vison loss
1373291|NCT00481104|Obesity
1373292|NCT00481065|Bird flu
1373293|NCT00481065|influenza vaccine
1373294|NCT00481065|Seasonal influenza vaccine
1373295|NCT00481065|Prepandemic vaccine
1373296|NCT00481052|Adult
1373297|NCT00481052|CML
1373298|NCT00481052|Philadelphia positive
1373299|NCT00481052|Nilotinib
1373300|NCT00481052|early chronic phase
1373301|NCT00481052|untreated or treated only with Hydroxyurea or Anagrelide
1373302|NCT00481052|Chronic Myeloid Leukemia
1373303|NCT00481039|Sickle cell disease
1373304|NCT00481039|Sickle cell thalassemia
1373305|NCT00481039|Population screening
1373306|NCT00481013|Spinal Muscular Atrophy
1373307|NCT00481013|Adult
1373308|NCT00481000|Dialectical Cognitive Therapy
1373309|NCT00481000|Clinical Psychology
1373310|NCT00480987|High-Risk Myelodysplastic Syndromes
1373311|NCT00480987|Acute Myeloid Leukemia
1373312|NCT00480987|Leukemia
1373313|NCT00480987|Oxaliplatin
1373314|NCT00480987|Fludarabine
1373315|NCT00480987|Cytarabine
1373316|NCT00480987|AML
1373317|NCT00480987|MDS
1373318|NCT00480974|Sickle cell anemia
1373319|NCT00480974|Sickle cell thalassemia
1373320|NCT00480974|Hydroxyurea
1373321|NCT00480948|infant
1373322|NCT00480948|infant formula
1373323|NCT00480948|fatty acids
1373324|NCT00480948|palmitic acid
1373325|NCT00480948|stool
1373326|NCT00480948|calcium
1373327|NCT00480935|Localized
1373328|NCT00480935|Renal Cell Carcinoma
1373329|NCT00480935|Neoadjuvant
1373330|NCT00480935|Sunitinib Malate (Sutent)
1373331|NCT00480922|non-alcoholic fatty liver disease
1373332|NCT00480922|steatohepatitis
1373333|NCT00480922|overweight
1373334|NCT00480922|insulin resistance
1373335|NCT00480896|Dermatitis, atopic
1373336|NCT00480896|Tacrolimus
1373337|NCT00480896|Child
1373338|NCT00480896|treatment outcomes
1373339|NCT00480883|cutaneous leishmaniasis of the old world
1373340|NCT00480870|Alzheimer
1373341|NCT00480870|polysomnography
1373342|NCT00480870|REM sleep
1373343|NCT00480870|donepezil
1373344|NCT00480870|sleep apnea
1373345|NCT00480870|oxygen saturation
1373346|NCT00480857|Prostate
1373347|NCT00480857|Radiation
1373348|NCT00480844|schizophrenia
1373349|NCT00480844|Sertindole
1373350|NCT00480844|Risperidone
1373351|NCT00480844|cognitive impairment
1373352|NCT00480831|NSCLC
1373353|NCT00480831|Cancer
1373354|NCT00480831|Avastin
1373355|NCT00480831|APM4074g
1373356|NCT00480792|Hepatitis B vaccination
1373357|NCT00480792|GenHevac-B Pasteur
1373358|NCT00480792|HIV Infections
1373359|NCT00480779|Prediabetes
1373360|NCT00480779|Metabolic syndrome
1373361|NCT00480779|Prevention
1373362|NCT00480779|Lifestyle intervention
1373363|NCT00480766|Glucocorticoid
1373364|NCT00480753|Raynaud's phenomenon
1373365|NCT00480753|Raynaud's Disease
1373366|NCT00480753|Raynaud's disease secondary to scleroderma
1373367|NCT00480753|Raynaud's phenomenon secondary to autoimmune disease
1373368|NCT00480740|Dexmedetomidine
1373369|NCT00480740|Congenital heart disease
1373370|NCT00480740|pharmacokinetics
1373371|NCT00480740|pharmacodynamics
1373372|NCT00480740|pediatric
1373373|NCT00480740|Bidirectional cavopulmonary anastomosis
1373374|NCT00480740|Fontan physiology
1373375|NCT00480740|Cardiac transplant
1373376|NCT00480727|Halo Thoracic Orthosis
1373377|NCT00480727|Re-tension
1373378|NCT00480727|Pin loosening
1373379|NCT00480714|TB
1373380|NCT00480714|Vaccine
1373381|NCT00480714|BCG
1373382|NCT00480701|Alzheimer
1373383|NCT00480701|Parkinson
1373384|NCT00480701|dementia
1373385|NCT00480701|neurologic
1373386|NCT00480688|TB
1373387|NCT00480688|BCG
1373388|NCT00480675|bursitis
1373389|NCT00480675|injection
1373390|NCT00480675|fluoroscopy
1373391|NCT00480662|Paget's bone disease
1373392|NCT00480311|symptomatic
1373393|NCT00480311|lumbar spinal stenosis
1373394|NCT00480311|disability
1373395|NCT00480311|fear avoidance beliefs
1373396|NCT00480311|quality of life
1373397|NCT00480285|Gastroesophageal reflux disease
1373398|NCT00480285|Laparoscopic Nissen Fundoplication
1373399|NCT00480285|Laparoscopic anterior partial fundoplication
1373400|NCT00480272|rheumatoid arthritis
1373401|NCT00480272|clinical remission
1373402|NCT00480259|blood urea nitrogen
1373403|NCT00480259|nitrogen balance
1373404|NCT00480259|nutrition
1373405|NCT00480259|intensive care
1373406|NCT00480246|receptor oocupancy
1373407|NCT00480233|depression
1373408|NCT00480233|screening
1373409|NCT00480233|primary care
1373410|NCT00480233|validity
1373411|NCT00480233|Hebrew
1373412|NCT00480233|Primary care and general medical patients
1373413|NCT00480220|specific care
1373414|NCT00480220|assistance plan
1373415|NCT00480220|Alzheimer's disease
1373416|NCT00480181|Neuropathic pain
1373417|NCT00480181|Multiple Sclerosis
1373418|NCT00480181|Nabilone
1373419|NCT00480181|Gabapentin
1373420|NCT00480168|child
1373421|NCT00480168|adolescent
1373422|NCT00480168|weight gain
1373423|NCT00480168|endocrine disruptors
1373424|NCT00480129|grass allergies,
1373425|NCT00480129|ragweed allergies,
1373426|NCT00480129|probiotics, lactobacillus,
1373427|NCT00480129|bifidobacterium,
1373428|NCT00480129|functional foods,
1373429|NCT00480129|yogurt,
1373430|NCT00480129|inflammatory cytokines
1373431|NCT00480116|Consistency
1373432|NCT00480116|Immunogenicity
1373433|NCT00480103|Embryo morphological and chromosomal features
1373434|NCT00480103|Implantation and pregnancy rate
1373435|NCT00480090|Prostate
1373436|NCT00480090|Androgen independent
1373437|NCT00480090|Phase II
1373438|NCT00480090|Second line
1373439|NCT00480090|Androgen-independent prostate cancer
1373440|NCT00480077|Heart Failure, randomized, OptiVol® Fluid status monitoring
1373441|NCT00480064|AML
1373442|NCT00480064|older patients
1373443|NCT00480064|lomustine
1373444|NCT00480051|Cardiac Failure
1373445|NCT00480051|Pacemaker
1373446|NCT00480051|Dyssynchrony
1373447|NCT00480051|Cardiac Magnetic Resonance
1373448|NCT00480051|Narrow QRS
1373449|NCT00480038|symptomatic
1373450|NCT00480038|lumbar disc herniation
1373451|NCT00480038|disability
1373452|NCT00480038|fear avoidance beliefs
1373453|NCT00480038|quality of life
1373454|NCT00480025|ASCI
1373455|NCT00480025|Immunotherapeutic
1373456|NCT00480025|MAGRIT
1373457|NCT00480025|Tumor antigen
1373458|NCT00480025|Non-small-cell lung cancer
1373459|NCT00480025|Adjuvant cancer therapy
1373460|NCT00480012|healthy subjects
1373461|NCT00479999|HIV-Negative
1373462|NCT00479999|Healthy
1373463|NCT00479999|Immunity
1373464|NCT00479999|Preventive
1373465|NCT00479999|Virus
1373466|NCT00479999|Healthy Volunteer
1373467|NCT00479999|HV
1373468|NCT00479999|HIV Preventive Vaccine
1373469|NCT00479986|diabetes mellitus
1373470|NCT00479986|monocyte activation
1373471|NCT00479986|cardiovascular risk
1373472|NCT00479973|diabetes
1373473|NCT00479973|non-insulin dependant diabetes
1373474|NCT00479973|type 2 diabetes
1373475|NCT00479973|cinnamon
1373476|NCT00479973|natural health product
1373477|NCT00479973|hypercholesterolemia
1373478|NCT00479973|dyslipidemia
1373479|NCT00479973|elevated cholesterol
1373480|NCT00479960|Asthenozoospermia
1373481|NCT00479960|Azoospermia
1373482|NCT00479960|Oligospermia
1373483|NCT00479960|Omega-3
1373484|NCT00479960|Fatty Acids
1373485|NCT00479947|Yeast vaginitis
1373486|NCT00479947|Probiotics
1373487|NCT00479947|Lactobacilli
1373488|NCT00479947|Fluconazole
1373489|NCT00479934|scleroderma
1373490|NCT00479934|imatinib
1373491|NCT00479934|PDGFR
1373492|NCT00479934|Rodnan
1373493|NCT00479921|Influenza
1373494|NCT00479921|Vaccine
1373495|NCT00479921|CHMP criteria
1373496|NCT00479908|Blood pressure
1373497|NCT00479908|Angina
1373498|NCT00479908|Sildenafil
1373499|NCT00479908|Phosphodiesterase type 5
1373500|NCT00479908|Organic nitrate
1373501|NCT00479908|Glyceryl trinitrate
1373502|NCT00479908|Drug interaction
1373503|NCT00479895|Percutaneous Coronary Intervention
1373504|NCT00479895|Myocardial Ischemia
1373505|NCT00479895|Balloon Occlusion
1373506|NCT00479895|Catheter Lab
1373507|NCT00479856|ErbB1
1373508|NCT00479856|ErbB2
1373509|NCT00479856|GW572016
1373510|NCT00479856|lapatinib
1373511|NCT00479856|Relapsed breast cancer
1373512|NCT00479856|dual tyrosine kinase inhibitor
1373513|NCT00479856|MBC
1373514|NCT00479856|EGFR
1373515|NCT00479856|Her-2/neu
1373516|NCT00479856|FISH amplification
1373517|NCT00479843|Alzheimer Disease
1373518|NCT00479843|Dementia
1373519|NCT00479843|Elderly
1373520|NCT00479843|Nutrition
1373521|NCT00479843|Malnutrition
1373522|NCT00479843|Weight Loss
1373523|NCT00479830|Epidemiology
1373524|NCT00479830|Health Risks
1373525|NCT00479830|Questionnaire
1373526|NCT00479830|Interview
1373527|NCT00479830|South Asian
1373528|NCT00479830|Asian Indian
1373529|NCT00479830|Bangladeshi
1373530|NCT00479830|Pakistani
1373531|NCT00479830|Sri Lankan
1373532|NCT00479817|Advanced Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
1373533|NCT00479804|indication for CMR
1373534|NCT00479791|Type 2 diabetes mellitus
1373535|NCT00479791|Fatty acids
1373536|NCT00479791|Postprandial response
1373537|NCT00479791|Insulin
1373538|NCT00479791|Glucose
1373539|NCT00479791|Triglycerides
1373540|NCT00479778|Postmenopause
1373541|NCT00479765|glioblastoma multiforme
1373542|NCT00479765|recurrent
1373543|NCT00479765|Phase 1
1373544|NCT00479765|Phase 2
1373545|NCT00479765|Phase I
1373546|NCT00479765|Phase II
1373547|NCT00479765|brain
1373548|NCT00479765|cancer
1373549|NCT00479765|paclitaxel
1373550|NCT00479765|intracranial
1373551|NCT00479765|tumor
1373552|NCT00479765|local
1373553|NCT00479765|chemotherapy
1373554|NCT00479765|brain tumor
1373555|NCT00479765|brain cancer
1373556|NCT00479765|glioma
1373557|NCT00479765|OncoGel
1373558|NCT00479739|formoterol/budesonide
1373559|NCT00479739|exacerbations
1373560|NCT00479739|Salmeterol/fluticasone propionate
1373561|NCT00479739|adjustable maintenance dosing
1373562|NCT00479739|asthma control
1373563|NCT00479713|High Cholesterol
1373564|NCT00479687|Osteoarthritis
1373565|NCT00479687|Shoulder
1373566|NCT00479687|HA
1373567|NCT00479674|Metastatic Breast Cancer
1373568|NCT00479674|Advanced Breast Cancer
1373569|NCT00479674|Hormone Receptor AND Her2/neu Negative
1373570|NCT00479674|Triple Negative
1373571|NCT00479674|Triple Negative Breast Cancer
1373572|NCT00479674|Stage IV or Inoperable Stage III Breast Cancer
1373573|NCT00479661|initial sedation
1373574|NCT00479661|mechanical ventilation
1373575|NCT00479635|HRPC
1373576|NCT00479635|TPI 287
1373577|NCT00479635|Taxane
1373578|NCT00479635|MDR
1373579|NCT00479635|Hormone Refractory Prostate Cancer
1373580|NCT00479622|Membranous Nephropathy
1373581|NCT00479622|Systemic Lupus Erythematosus
1373582|NCT00479609|Insulin resistance
1373583|NCT00479609|Glucose tolerance
1373584|NCT00479609|Type 2 diabetes
1373585|NCT00479609|Androgen sensitivity
1373586|NCT00479596|Overactive Bladder
1373587|NCT00479596|OAB
1373588|NCT00479596|Refractory OAB
1373589|NCT00479596|Botox
1373590|NCT00479596|Bladder
1373591|NCT00479583|Cancer (solid tumors)
1373592|NCT00479557|Alzheimer's Disease
1373593|NCT00479557|active immunization
1373594|NCT00479531|Restless Legs Syndrome
1373595|NCT00479531|Sequential Compression Device
1373596|NCT00479531|Sleep Quality
1373597|NCT00479531|Quality of Life
1373598|NCT00479518|stroke
1373599|NCT00479518|transient ischemic attack
1373600|NCT00479518|albuminuria
1373601|NCT00479518|BNP
1373602|NCT00479518|Cystatin C
1373603|NCT00479492|Obesity, weight loss
1373604|NCT00479479|cobalamin
1373605|NCT00479479|methylmalonic acid
1373606|NCT00479479|homocysteine
1373607|NCT00479479|folate
1373608|NCT00479479|newborns
1373609|NCT00479479|infants
1373610|NCT00479479|Deficiency Disease
1373611|NCT00479479|Breastfeeding
1373612|NCT00479479|Infant
1373613|NCT00479427|osteoarthritis pain assessments
1373614|NCT00479375|screening
1373615|NCT00479375|human papillomavirus
1373616|NCT00479362|Pacemaker
1373617|NCT00479362|Cardioverter-defibrillator
1373618|NCT00479362|Hemorrhage
1373619|NCT00479362|Hematoma
1373620|NCT00479362|Thrombosis
1373621|NCT00479362|Embolism
1373622|NCT00479336|OPC-41061
1373623|NCT00479336|Tolvaptan
1373624|NCT00479336|ascites
1373625|NCT00479336|Cirrhosis
1373626|NCT00479323|pneumococcal vaccine, Pneumovax, reference sera, serum 89SF
1373627|NCT00479284|Non-invasive ventilation
1373628|NCT00479284|Polysomnography
1373629|NCT00479284|Average volume assured pressure support
1373630|NCT00479271|RCT
1373631|NCT00479271|Dementia
1373632|NCT00479271|community trial
1373633|NCT00479271|Homebased care
1373634|NCT00479271|caregiver burden
1373635|NCT00479271|Behavioural problems
1373636|NCT00479271|Dementia in subjects
1373637|NCT00479271|behavioral problems in subjects
1373638|NCT00479271|Mental health of carers
1373639|NCT00479245|nonspecific low back pain
1373640|NCT00479245|disability
1373641|NCT00479245|fear avoidance beliefs
1373642|NCT00479245|quality of life
1373643|NCT00479232|Leukemia
1373644|NCT00479232|Myelocytic
1373645|NCT00479232|Acute Myelodysplastic Syndromes
1373646|NCT00479206|artesuante
1373647|NCT00479206|falciparum malaria
1373648|NCT00479206|Cambodia
1373649|NCT00479206|Artemisinin resistance
1373650|NCT00479193|Burns
1373651|NCT00479193|Dressing change
1373652|NCT00479180|Hemodialysis access
1373653|NCT00479180|Arteriovenous graft
1373654|NCT00479180|Arteriovenous fistula
1373655|NCT00479180|End stage renal disease
1373656|NCT00479167|Non-Hodgkin's Lymphoma
1373657|NCT00479167|Follicular Non-Hodgkin's Lymphoma
1373658|NCT00479167|Lymphoma
1373659|NCT00479154|Restless Leg Syndrome
1373660|NCT00479154|Botulinum Toxin
1373661|NCT00479154|RLS
1373662|NCT00479141|Treatment Naive
1373663|NCT00479141|Treatment Experienced
1373664|NCT00479141|Complementary Therapies
1373665|NCT00479128|Solid Tumor
1373666|NCT00479128|Bladder Cancer
1373667|NCT00479128|Ureteral Cancer
1373668|NCT00479128|Urothelial Cancer
1373669|NCT00479128|Urethral Cancer
1373670|NCT00479128|Renal Pelvis Tumor
1373671|NCT00479128|Bortezomib
1373672|NCT00479128|Gemcitabine
1373673|NCT00479128|Doxorubicin
1373674|NCT00479128|Gemzar
1373675|NCT00479128|Adriamycin
1373676|NCT00479128|Velcade
1373677|NCT00479128|LDP-341
1373678|NCT00479128|MLN341
1373679|NCT00479128|PS-341
1373680|NCT00479128|Gemcitabine Hydrochloride
1373681|NCT00479128|AD
1373682|NCT00479128|Hydroxydaunomycin hydrochloride
1373683|NCT00479102|Iron supplementation
1373684|NCT00479102|Babies
1373685|NCT00479102|Prevention
1373686|NCT00479089|Transitional Cell Carcinoma
1373687|NCT00479089|Urothelium
1373688|NCT00479089|Urothelial Cancer
1373689|NCT00479089|Bladder Cancer
1373690|NCT00479089|Docetaxel
1373691|NCT00479089|Taxotere
1373692|NCT00479089|ZD1839
1373693|NCT00479089|Gefitinib
1373694|NCT00479089|Iressa
1373695|NCT00479089|Consolidation Therapy
1373696|NCT00479076|antineoplastic agents
1373697|NCT00479076|VEGF Trap
1373698|NCT00479063|MODIC changes
1373699|NCT00479063|chronic low back pain
1373700|NCT00479063|magnetic resonance imaging (MRI)
1373701|NCT00479063|vertebrae
1373702|NCT00479063|intervertebral disc
1373703|NCT00479050|Hepatocellular carcinoma,treatment
1373704|NCT00479037|postmenopausal women with primary osteoporosis
1373705|NCT00479011|fluid management
1373706|NCT00479011|arterial pulse pressure variation
1373707|NCT00479011|high-risk surgery
1373708|NCT00478998|expulsion therapy
1373709|NCT00478998|tamsulosin
1373710|NCT00478998|ureterolithiasis
1373711|NCT00478998|stents
1373712|NCT00478985|Leukemia
1373713|NCT00478985|Adult Chronic
1373714|NCT00478985|Myeloid
1373715|NCT00478972|obese
1373716|NCT00478972|diabetes
1373717|NCT00478972|cannabinoid-1 receptor
1373718|NCT00478959|Lenalidomide
1373719|NCT00478959|Revlimid
1373720|NCT00478959|Hodgkin's
1373721|NCT00478959|Hodgkin
1373722|NCT00478959|Hodgkin's Lymphoma
1373723|NCT00478959|Hodgkin's Disease
1373724|NCT00478959|Lymphoma
1373725|NCT00478946|colorectal cancer
1373726|NCT00478946|picoplatin
1373727|NCT00478946|FOLFOX
1373728|NCT00478946|FOLPI
1373729|NCT00478946|chemotherapy
1373730|NCT00478933|Arrhythmia
1373731|NCT00478933|Ventricular
1373732|NCT00478933|Atrial
1373733|NCT00478933|Tachycardia
1373734|NCT00478933|Fibrillation
1373735|NCT00478933|Flutter
1373736|NCT00478933|GNB3
1373737|NCT00478933|GNAS
1373738|NCT00478933|GNAQ
1373739|NCT00478907|oculocardiac reflex; strabismus surgery;
1373740|NCT00478894|Anterior cruciate ligament / injuries
1373741|NCT00478894|Anterior cruciate ligament / surgery
1373742|NCT00478894|knee injuries / surgery
1373743|NCT00478894|outcomes research
1373744|NCT00478894|prospective studies
1373745|NCT00478894|osteoarthritis
1373746|NCT00478868|MODIC changes
1373747|NCT00478868|chronic low back pain
1373748|NCT00478868|magnetic resonance imaging (MRI)
1373749|NCT00478868|vertebrae
1373750|NCT00478868|intervertebral disc
1373751|NCT00478842|Gilles de la Tourette syndrome
1373752|NCT00478842|Deep brain stimulation
1373753|NCT00478842|Globus PALLIDUS
1373754|NCT00478816|Bird flu
1373755|NCT00478816|influenza vaccine
1373756|NCT00478816|prepandemic vaccine
1373757|NCT00478803|Standardized surgical procedure
1373758|NCT00478803|Aortic root aneurysm
1373759|NCT00478803|Dystrophic aortic insufficiency
1373760|NCT00478803|Conservative aortic valve surgery
1373761|NCT00478803|Aortic annuloplasty
1373762|NCT00478803|Mechanical aortic valve replacement
1373763|NCT00478803|Sinus of Valsalva
1373764|NCT00478803|Cardiac Surgical Procedures
1373765|NCT00478790|Glaucoma
1373766|NCT00478790|Pterygium
1373767|NCT00478790|collagen matrix
1373768|NCT00478790|OculusGen
1373769|NCT00478790|trabeculectomy
1373770|NCT00478790|Anti scarring
1373771|NCT00478790|pterygium recurrence
1373772|NCT00478790|tissue engineering
1373773|NCT00478790|ologen
1373774|NCT00478790|Aeon Astron
1373775|NCT00478777|CC-5013
1373776|NCT00478777|Revlimid
1373777|NCT00478777|Lenalidomide
1373778|NCT00478777|Celgene
1373779|NCT00478777|Multiple Myeloma
1373780|NCT00478764|intraocular
1373781|NCT00478764|triamcinolone
1373782|NCT00478764|gatifloxicin
1373783|NCT00478764|inflammation
1373784|NCT00478764|visual acuity
1373785|NCT00478751|Visible light, Long UVA,Pigmentation
1373786|NCT00478751|Normal healthy volunteers with dark skin type.
1373787|NCT00478738|b-agonist,
1373788|NCT00478738|COPD.
1373789|NCT00478738|pharmacodynamic,
1373790|NCT00478738|pharmacokinetic,
1373791|NCT00478738|anti muscarinic,
1373792|NCT00478725|Metastatic Cancer
1373793|NCT00478725|Advanced Cancer
1373794|NCT00478712|Hirschsprung
1373795|NCT00478699|SCAT
1373796|NCT00478699|BRCA1
1373797|NCT00478699|BRCA1 mRNA Levels
1373798|NCT00478699|ADJUVANT
1373799|NCT00478699|LUNG
1373800|NCT00478699|GECP-SCAT
1373801|NCT00478686|Breast Cancer
1373802|NCT00478686|Dihydropyrimidine Dehydrogenase
1373803|NCT00478686|DPYD
1373804|NCT00478686|DPYD Variants
1373805|NCT00478686|Toxicity
1373806|NCT00478686|Capecitabine
1373807|NCT00478686|Xeloda
1373808|NCT00478673|NexStent
1373809|NCT00478673|FilterWire EZ
1373810|NCT00478673|Boston Scientific
1373811|NCT00478673|Carotid Artery
1373812|NCT00478673|Carotid Endarterectomy
1373813|NCT00478673|Carotid Revascularization
1373814|NCT00478647|Enzyme Replacement Therapy
1373815|NCT00478647|Gaucher disease
1373816|NCT00478647|glucocerebrosidase
1373817|NCT00478647|beta-glucocerebrosidase
1373818|NCT00478647|Acid beta-glucocerebrosidase
1373819|NCT00478647|glucosylceramidase
1373820|NCT00478647|D-glucosyl-N-acylsphingosine glucohydrolase
1373821|NCT00478647|gene activation
1373822|NCT00478647|human
1373823|NCT00478634|Colorectal Cancer
1373824|NCT00478634|Colorectal Carcinoma
1373825|NCT00478634|Colorectal Tumors
1373826|NCT00478634|Neoplasms, Colorectal
1373827|NCT00478621|HPV
1373828|NCT00478595|obese
1373829|NCT00478595|diabetes
1373830|NCT00478595|cannabinoid-1 receptor
1373831|NCT00478582|Anemia
1373832|NCT00478582|Visual scale
1373833|NCT00478582|nephrological patients
1373834|NCT00478582|Anemia in nephrological patients
1373835|NCT00478556|CT scan
1373836|NCT00478556|oral contrast
1373837|NCT00478543|Loop diuretics
1373838|NCT00478543|Chronic Kidney Disease
1373839|NCT00478543|Hypertension
1373840|NCT00478543|Blood pressure control
1373841|NCT00478543|Left ventricular mass
1373842|NCT00478517|Spinal trauma
1373843|NCT00478517|erythropoietin
1373844|NCT00478517|dose escalation study
1373845|NCT00478504|anovulation
1373846|NCT00478504|ovulation induction,
1373847|NCT00478504|polycystic ovarian syndrome
1373848|NCT00478504|clomifene citrate
1373849|NCT00478504|letrozole
1373850|NCT00478478|Stroke
1373851|NCT00478478|Ischemic
1373852|NCT00478478|Thrombus
1373853|NCT00478478|Embolectomy
1373854|NCT00478478|Thrombectomy
1373855|NCT00478478|Merci
1373856|NCT00478478|Concentric
1373857|NCT00478478|Embolus
1373858|NCT00478478|Embolism
1373859|NCT00478478|Mechanical
1373860|NCT00478465|chronic fatigue syndrome
1373861|NCT00478465|fatigue
1373862|NCT00478465|valganciclovir
1373863|NCT00478465|valcyte
1373864|NCT00478465|Epstein-Barr virus
1373865|NCT00478465|EBV
1373866|NCT00478465|Human herpes virus 6
1373867|NCT00478465|HHV 6
1373868|NCT00478465|herpes viruses
1373869|NCT00478465|herpes
1373870|NCT00478439|aging
1373871|NCT00478439|age-related macular degeneration
1373872|NCT00478439|macular pigment
1373873|NCT00478439|dark adaptation
1373874|NCT00478400|Recovery
1373875|NCT00478400|Magnetic resonance imaging
1373876|NCT00478400|Awareness
1373877|NCT00478400|Neurologic deficits
1373878|NCT00478387|Advanced Ovarian and Primary Peritoneal Cancer in Remission
1373879|NCT00478348|Postoperative Complications
1373880|NCT00478348|Drainage
1373881|NCT00478348|Infection
1373882|NCT00478348|Seroma
1373883|NCT00478348|Hematoma
1373884|NCT00478348|Recurrence
1373885|NCT00478348|Abdominal Wall
1373886|NCT00478348|Hernia
1373887|NCT00478348|Surgical Mesh
1373888|NCT00478335|congenital nephrogenic diabetes insipidus
1373889|NCT00478335|polyuria
1373890|NCT00478335|urine osmolality
1373891|NCT00478335|aquaporin-2
1373892|NCT00478335|vasopressin V2 receptor
1373893|NCT00478322|Diabetes;
1373894|NCT00478322|Type II diabetes;
1373895|NCT00478322|Non-insulin dependent diabetes;
1373896|NCT00478322|Obesity
1373897|NCT00478309|colon cancer
1373898|NCT00478309|rectal cancer
1373899|NCT00478309|healthy, no evidence of disease
1373900|NCT00478296|Pulmonary hypertension
1373901|NCT00478296|Sildenafil
1373902|NCT00478296|Bosentan
1373903|NCT00478296|Trisomy 21
1373904|NCT00478296|Atrial septal defect
1373905|NCT00478283|breast cancer
1373906|NCT00478257|fatigue
1373907|NCT00478257|sleep
1373908|NCT00478257|quality of life
1373909|NCT00478257|light
1373910|NCT00478257|cancer
1373911|NCT00478244|epidermolysis bullosa
1373912|NCT00478244|dystrophic epidermolysis bullosa
1373913|NCT00478231|Multicenter
1373914|NCT00478231|Open Label
1373915|NCT00478231|Non-Comparative Safety Study Of Maraviroc
1373916|NCT00478231|Treatment Experienced
1373917|NCT00478218|stage I multiple myeloma
1373918|NCT00478218|stage II multiple myeloma
1373919|NCT00478218|stage III multiple myeloma
1373920|NCT00478205|Moderate to Severe Alzheimer's Disease
1373921|NCT00478192|hyponatremia
1373922|NCT00478192|hypervolemic
1373923|NCT00478192|euvolemic
1373924|NCT00478192|edematous
1373925|NCT00478192|conivaptan
1373926|NCT00478179|herpes zoster
1373927|NCT00478179|shingles
1373928|NCT00478179|PHN
1373929|NCT00478179|post herpetic neuralgia
1373930|NCT00478179|neuropathic pain
1373931|NCT00478114|Renal Cell Carcinoma
1373932|NCT00478114|Sorafenib
1373933|NCT00478101|Pain
1373934|NCT00478088|Single Level
1373935|NCT00478088|Cervical Disc Disease
1373936|NCT00478075|stage I multiple myeloma
1373937|NCT00478075|stage II multiple myeloma
1373938|NCT00478075|stage III multiple myeloma
1373939|NCT00478075|refractory multiple myeloma
1373940|NCT00478062|stage I adult Hodgkin lymphoma
1373941|NCT00478062|stage II adult Hodgkin lymphoma
1373942|NCT00478062|stage III adult Hodgkin lymphoma
1373943|NCT00478062|stage IV adult Hodgkin lymphoma
1373944|NCT00478049|Non-Small Cell Lung Cancer
1373945|NCT00478036|glaucoma
1373946|NCT00478036|selective laser trabeculoplasty
1373947|NCT00478036|anterior chamber flare
1373948|NCT00478023|Opioid
1373949|NCT00478023|Central acting analgesic
1373950|NCT00478023|Pain postoperative
1373951|NCT00478023|Abdomen acute
1373952|NCT00478023|CG5503 IR
1373953|NCT00478023|Morphine
1373954|NCT00478023|Placebo
1373955|NCT00478010|psychosocial effects of cancer and its treatment
1373956|NCT00478010|stage III colon cancer
1373957|NCT00478010|stage IV colon cancer
1373958|NCT00478010|stage III rectal cancer
1373959|NCT00478010|stage IV rectal cancer
1373960|NCT00478010|stage II pancreatic cancer
1373961|NCT00478010|stage III pancreatic cancer
1373962|NCT00478010|stage IV pancreatic cancer
1373963|NCT00477997|Growth Hormone
1373964|NCT00477997|Insulin Signaling
1373965|NCT00477997|GH signaling
1373966|NCT00477984|Alcohol
1373967|NCT00477984|Driving
1373968|NCT00477984|Multitasking
1373969|NCT00477984|ERP
1373970|NCT00477984|social drinkers
1373971|NCT00477971|primary systemic amyloidosis
1373972|NCT00477958|cognitive/functional effects
1373973|NCT00477958|psychosocial effects of cancer and its treatment
1373974|NCT00477958|unspecified adult solid tumor, protocol specific
1373975|NCT00477945|Non Hodgkin's Lymphoma
1373976|NCT00477945|High Risk or Refractory Non Hodgkin's Lymphoma
1373977|NCT00477945|APBSCT
1373978|NCT00477945|clofarabine
1373979|NCT00477932|Pentalogy of Cantrell
1373980|NCT00477932|mutations
1373981|NCT00477932|DNA
1373982|NCT00477932|RNA
1373983|NCT00477919|stage IV melanoma
1373984|NCT00477919|stage IV renal cell cancer
1373985|NCT00477919|unresectable extrahepatic bile duct cancer
1373986|NCT00477919|advanced malignant mesothelioma
1373987|NCT00477919|stage IV prostate cancer
1373988|NCT00477919|adult giant cell glioblastoma
1373989|NCT00477919|adult gliosarcoma
1373990|NCT00477919|extensive stage small cell lung cancer
1373991|NCT00477919|stage IV non-small cell lung cancer
1373992|NCT00477919|stage IV colon cancer
1373993|NCT00477919|stage IV gastric cancer
1373994|NCT00477919|stage IV esophageal cancer
1373995|NCT00477919|stage IV bladder cancer
1373996|NCT00477919|male breast cancer
1373997|NCT00477919|stage IV breast cancer
1373998|NCT00477919|stage IV ovarian epithelial cancer
1373999|NCT00477919|stage IV ovarian germ cell tumor
1374000|NCT00477919|ovarian sarcoma
1374001|NCT00477919|ovarian stromal cancer
1374002|NCT00477919|fatigue
1374003|NCT00477919|anorexia
1374004|NCT00477919|cachexia
1374005|NCT00477919|pain
1374006|NCT00477919|weight changes
1374007|NCT00477919|depression
1374008|NCT00477919|poor performance status
1374009|NCT00477919|recurrent adult brain tumor
1374010|NCT00477919|clear cell sarcoma of the kidney
1374011|NCT00477919|advanced adult primary liver cancer
1374012|NCT00477919|recurrent adult primary liver cancer
1374013|NCT00477919|recurrent small cell lung cancer
1374014|NCT00477919|recurrent bladder cancer
1374015|NCT00477919|recurrent breast cancer
1374016|NCT00477919|recurrent colon cancer
1374017|NCT00477919|recurrent esophageal cancer
1374018|NCT00477919|recurrent gastric cancer
1374019|NCT00477919|recurrent melanoma
1374020|NCT00477919|recurrent non-small cell lung cancer
1374021|NCT00477919|recurrent ovarian epithelial cancer
1374022|NCT00477919|recurrent ovarian germ cell tumor
1374023|NCT00477919|stage IV pancreatic cancer
1374024|NCT00477919|recurrent prostate cancer
1374025|NCT00477919|recurrent renal cell cancer
1374026|NCT00477919|recurrent pancreatic cancer
1374027|NCT00477919|stage IV rectal cancer
1374028|NCT00477919|recurrent rectal cancer
1374029|NCT00477919|recurrent malignant mesothelioma
1374030|NCT00477919|recurrent carcinoma of unknown primary
1374031|NCT00477919|stage IV adult soft tissue sarcoma
1374032|NCT00477919|recurrent adult soft tissue sarcoma
1374033|NCT00477919|stage IV uterine sarcoma
1374034|NCT00477919|recurrent uterine sarcoma
1374035|NCT00477919|recurrent extrahepatic bile duct cancer
1374036|NCT00477919|unresectable gallbladder cancer
1374037|NCT00477919|recurrent gallbladder cancer
1374038|NCT00477919|adult glioblastoma
1374039|NCT00477906|melanoma
1374040|NCT00477906|vaccine
1374041|NCT00477906|metastatic
1374042|NCT00477906|autologous
1374043|NCT00477880|gastric cancer
1374044|NCT00477880|giant hypertrophic gastritis
1374045|NCT00477867|stage III ovarian epithelial cancer
1374046|NCT00477841|esophageal Cancer
1374047|NCT00477841|Dysphagia
1374048|NCT00477841|Stent
1374049|NCT00477841|interstitial brachytherapy
1374050|NCT00477828|sleep apnea
1374051|NCT00477828|dementia
1374052|NCT00477828|excessive sleepiness
1374053|NCT00477828|cognition
1374054|NCT00477815|stage I multiple myeloma
1374055|NCT00477815|refractory multiple myeloma
1374056|NCT00477815|stage II multiple myeloma
1374057|NCT00477815|stage III multiple myeloma
1374058|NCT00477802|Parkinson's disease
1374059|NCT00477802|levodopa-induced cervical dyskinesias
1374060|NCT00477789|chronic heart failure
1374061|NCT00477789|diastolic dysfunction
1374062|NCT00477789|uric acid
1374063|NCT00477776|Beginning of breastfeeding
1374064|NCT00477750|stage I multiple myeloma
1374065|NCT00477750|stage II multiple myeloma
1374066|NCT00477750|stage III multiple myeloma
1374067|NCT00477737|cardioprotection
1374068|NCT00477737|sevoflurane
1374069|NCT00477737|esophageal Doppler
1374070|NCT00477737|thermodilution
1374071|NCT00477737|coronary artery bypass
1374072|NCT00477724|latent
1374073|NCT00477711|Cetuximab
1374074|NCT00477711|cisplatin
1374075|NCT00477711|capecitabine
1374076|NCT00477711|first line treatment
1374077|NCT00477685|Glaucoma
1374078|NCT00477685|Collagen matrix
1374079|NCT00477685|OculusGen
1374080|NCT00477685|Phacotrabeculectomy
1374081|NCT00477685|anti scarring
1374082|NCT00477685|tissue engineering
1374083|NCT00477685|ologen
1374084|NCT00477685|Aeon Astron
1374085|NCT00477672|Parkinson's disease, psychotic disorders
1374086|NCT00477659|fMRI study; open-label donepezil
1374087|NCT00477646|colon cancer
1374088|NCT00477646|rectal cancer
1374089|NCT00477646|breast cancer
1374090|NCT00477646|cervical cancer
1374091|NCT00477633|Contraception
1374092|NCT00477620|Myopia
1374093|NCT00477620|Prevention
1374094|NCT00477594|Familial Hypercholesterolemia
1374095|NCT00477594|Heterozygous Familial Hypercholesterolemia
1374096|NCT00477594|Homozygous Familial Hypercholesterolemia
1374097|NCT00477594|ISIS 301012
1374098|NCT00477594|mipomersen
1374099|NCT00477594|Open Label Extension
1374100|NCT00477581|diabetes
1374101|NCT00477581|exenatide
1374102|NCT00477581|sitagliptin
1374103|NCT00477581|Amylin
1374104|NCT00477581|Lilly
1374105|NCT00477568|Wheelchair users
1374106|NCT00477568|Back pain
1374107|NCT00477568|Prevalence
1374108|NCT00477568|Risk factors
1374109|NCT00477555|aortic valve
1374110|NCT00477555|concomitant procedures
1374111|NCT00477555|porcine bioprosthesis
1374112|NCT00477555|stented valve
1374113|NCT00477542|Clofarabine
1374114|NCT00477542|allogeneic HSCT
1374115|NCT00477542|refractory malignancies
1374116|NCT00477503|Central Nervous System Tumors
1374117|NCT00477503|Brain Tumors
1374118|NCT00477503|Leptomeningeal Metastasis
1374119|NCT00477503|Cerebral Spinal Fluid
1374120|NCT00477503|Human CSF Flow
1374121|NCT00477503|Nuclear Imaging
1374122|NCT00477503|Gallium-67 Citrate
1374123|NCT00477503|In-111 DTPA
1374124|NCT00477477|overweight
1374125|NCT00477477|metabolic syndrome
1374126|NCT00477477|adolescent
1374127|NCT00477477|cardiovascular
1374128|NCT00477477|risk factors
1374129|NCT00477477|hypertension
1374130|NCT00477477|dyslipidemia
1374131|NCT00477477|inflammation
1374132|NCT00477477|coagulopathy
1374133|NCT00477464|dual kinase inhibitor,
1374134|NCT00477464|EGFR/ErbB1,
1374135|NCT00477464|ErbB2-overexpressing,
1374136|NCT00477464|GW572016,
1374137|NCT00477464|advanced/metastatic breast cancer, Lapatinib,
1374138|NCT00477464|HER-2/new,
1374139|NCT00477464|pharmacokinetics
1374140|NCT00477451|Staccato™ Alprazolam, Panic Attack, Inhaled alprazolam
1374141|NCT00477425|Avastin
1374142|NCT00477412|Mantle Cell Lymphoma
1374143|NCT00477412|Lymphoma
1374144|NCT00477412|Bortezomib
1374145|NCT00477412|LDP-341
1374146|NCT00477412|MLN341
1374147|NCT00477412|Velcade
1374148|NCT00477412|Cyclophosphamide
1374149|NCT00477412|Neosar
1374150|NCT00477412|Cytoxan
1374151|NCT00477412|Doxorubicin
1374152|NCT00477412|Adriamycin
1374153|NCT00477412|Rubex
1374154|NCT00477412|Rituximab
1374155|NCT00477412|Vincristine
1374156|NCT00477412|Methotrexate
1374157|NCT00477412|Cytarabine
1374158|NCT00477412|Cytosar
1374159|NCT00477412|DepoCyt
1374160|NCT00477412|Cytosine arabinosine hydrochloride
1374161|NCT00477412|Mesna
1374162|NCT00477412|Dexamethasone
1374163|NCT00477399|Obesity
1374164|NCT00477399|Weight loss maintenance
1374165|NCT00477399|QOL
1374166|NCT00477399|Life Style
1374167|NCT00477399|Follow Up
1374168|NCT00477386|recurrent ovarian cancer
1374169|NCT00477386|platinum resistant
1374170|NCT00477386|decitabine
1374171|NCT00477347|Liver Transplantation
1374172|NCT00477347|Anesthesia, general
1374173|NCT00477347|Closed-loop
1374174|NCT00477334|Recurrent genital herpes
1374175|NCT00477334|Black population
1374176|NCT00477321|Interleukin 7
1374177|NCT00477321|Immune Reconstitution
1374178|NCT00477321|T Cell Turnover
1374179|NCT00477321|CD4 Lymphenia
1374180|NCT00477321|Immune-Based Therapies
1374181|NCT00477321|HIV Infection
1374182|NCT00477308|HIV children
1374183|NCT00477308|genotypic resistance
1374184|NCT00477308|dual NRTIs
1374185|NCT00477308|Salvage therapy
1374186|NCT00477308|treatment outcome
1374187|NCT00477308|Salvage therapy based on genotyping results
1374188|NCT00477308|Treatment Failure
1374189|NCT00477295|Epilepsy
1374190|NCT00477282|Ovarian
1374191|NCT00477282|Cancer
1374192|NCT00477282|Advanced Ovarian Cancer
1374193|NCT00477269|Pulmonary Arterial Hypertension, tyrosine kinase inhibitor, STI571
1374194|NCT00477256|Pediatric Cancer
1374195|NCT00477256|Child Adjustment
1374196|NCT00477256|School Reintegration
1374197|NCT00477256|Caregiver
1374198|NCT00477256|Questionnaire
1374199|NCT00477256|Quality of Life
1374200|NCT00477256|Survey
1374201|NCT00477243|Advanced Cancer
1374202|NCT00477243|Palliative Care Patients
1374203|NCT00477243|Spirituality
1374204|NCT00477243|Locus of Control
1374205|NCT00477243|Questionnaire
1374206|NCT00477230|AF
1374207|NCT00477230|PAF
1374208|NCT00477230|paroxysmal atrial fibrillation
1374209|NCT00477230|ablation
1374210|NCT00477230|failed drugs
1374211|NCT00477217|Osteonecrosis
1374212|NCT00477217|zoledronic acid
1374213|NCT00477217|knee
1374214|NCT00477204|Type 1 Diabetes Mellitus
1374215|NCT00477204|dyslipidemia
1374216|NCT00477204|adolescents
1374217|NCT00477191|psoriasis
1374218|NCT00477191|metabolic syndrome
1374219|NCT00477191|Syndrome X
1374220|NCT00477191|diabetes
1374221|NCT00477191|insulin resistance
1374222|NCT00477191|obesity
1374223|NCT00477191|hypertension
1374224|NCT00477191|hyperlipidemia
1374225|NCT00477191|hypercholesterolemia
1374226|NCT00477178|possible problems using codeine when driving
1374227|NCT00477165|Irritable bowel syndrome
1374228|NCT00477165|Antidepressant
1374229|NCT00477165|IBS
1374230|NCT00477165|Serotonin-reuptake inhibitor
1374231|NCT00477165|SSRI
1374232|NCT00477165|Visceral sensitivity
1374233|NCT00477165|Barostat
1374234|NCT00477165|Quality of life
1374235|NCT00477165|Depression
1374236|NCT00477152|dehydration
1374237|NCT00477152|fluid therapy
1374238|NCT00477152|pediatrics
1374239|NCT00477152|emergency medicine
1374240|NCT00477152|hyaluronoglucosaminidase
1374241|NCT00477152|hyaluronidase
1374242|NCT00477152|hypodermoclysis
1374243|NCT00477152|clysis
1374244|NCT00477152|subcutaneous hydration
1374245|NCT00477152|subcutaneous rehydration
1374246|NCT00477152|hyaluronan
1374247|NCT00477152|rHuPH20
1374248|NCT00477126|ritonavir generic capsule
1374249|NCT00477126|Norvir®
1374250|NCT00477126|Thailand
1374251|NCT00477126|Determine bioequivalence between Norvir and GPO ritonavir
1374252|NCT00477113|natalizumab
1374253|NCT00477113|MS
1374254|NCT00477113|Tysabri
1374255|NCT00477113|Multiple Sclerosis
1374256|NCT00477113|TYGRIS
1374262|NCT00477074|chronic obstructive pulmonary disease
1374263|NCT00477074|emphysema
1374264|NCT00477074|inflammation
1374265|NCT00477074|repair
1374266|NCT00477061|MORPHINE
1374267|NCT00477061|ANALGESIA
1374268|NCT00477061|ACUTE APPENDICITS
1374269|NCT00477048|IDV nephrotoxicity
1374270|NCT00477022|Diabetic Foot Ulcer
1374271|NCT00477022|Vacuum compression therapy
1374272|NCT00477022|Stereology
1374273|NCT00477022|Ulcer Area
1374274|NCT00477022|Vasotrain
1374275|NCT00477022|Random Controlled Trial.
1374276|NCT00477009|Sleep apnea syndromes
1374277|NCT00477009|Snoring
1374278|NCT00477009|Mandibular advancement
1374279|NCT00477009|Activator appliances
1374280|NCT00477009|Disorders of excessive somnolence
1374281|NCT00477009|Blood pressure
1374282|NCT00477009|Inflammation
1374283|NCT00477009|Oxidative stress
1374284|NCT00477009|Hormones
1374285|NCT00477009|Markers of Metabolic Syndrome X
1374286|NCT00476996|RA
1374287|NCT00476996|SCRIPT
1374288|NCT00476996|anti-CD20
1374289|NCT00476996|CD20
1374290|NCT00476983|saquinavir/ritonavir 1500/100 mg once daily
1374291|NCT00476970|Colorectal Cancer
1374292|NCT00476970|Cancer Screening
1374293|NCT00476970|Patient Navigation
1374294|NCT00476970|Low English Proficiency
1374295|NCT00476957|Drug Eluting Stents
1374296|NCT00476957|Interventional Cardiology
1374297|NCT00476944|CAD
1374298|NCT00476944|Coronary Artery Disease
1374299|NCT00476944|Angiomax
1374300|NCT00476944|Bivalirudin
1374301|NCT00476944|PCI
1374302|NCT00476944|MAVE
1374303|NCT00476944|Heparin
1374304|NCT00476931|Diabetic neuropathy
1374305|NCT00476931|Diabetes Type 1 or 2
1374306|NCT00476931|Moderate to severe sensorimotor diabetic polyneuropathy
1374307|NCT00476931|Unmeasurable nerve conduction velocity
1374308|NCT00476918|diabetic macular edema
1374309|NCT00476918|triamcinolone acetonide
1374310|NCT00476918|intravitreal
1374311|NCT00476918|steroid
1374312|NCT00476905|Basal Cell Carcinoma
1374313|NCT00476905|Squamous Cell Carcinoma
1374314|NCT00476905|Pre-Cancer Lesions
1374315|NCT00476905|Pigmented Lesions
1374316|NCT00476905|Benign Lesions
1374317|NCT00476905|Skin Cancer
1374318|NCT00476905|Spectral Diagnosis
1374319|NCT00476905|Optical Spectroscopy
1374320|NCT00476892|Pelvic organ prolapse
1374321|NCT00476892|Pelvic floor muscle training
1374322|NCT00476892|Prolapse symptoms
1374323|NCT00476892|Urinary symptoms
1374324|NCT00476892|Sexual function
1374325|NCT00476892|randomised controlled trial
1374326|NCT00476879|Growth hormone
1374327|NCT00476879|Fasting
1374328|NCT00476879|Signaltransduction
1374329|NCT00476879|fatty liver
1374330|NCT00476879|insulin sensitivity
1374331|NCT00476879|forearm model
1374332|NCT00476879|protein metabolism
1374333|NCT00476879|respiratory quotient
1374334|NCT00476866|Paraplegia
1374335|NCT00476866|tetraplegia
1374336|NCT00476866|lung compliance
1374337|NCT00476866|work of breathing
1374338|NCT00476866|hyperinflation
1374339|NCT00476866|rehabilitation
1374340|NCT00476853|HIV-TB
1374341|NCT00476853|nevirapine based HAART with rifampin treated TB
1374342|NCT00476853|Compare PK profile, efficacy, safety and tolerability of HAART containing nevirapine 400mg/day versus 600 mg/day in HIV/TB co-infected patients
1374343|NCT00476853|Treatment Naive
1374344|NCT00476827|Breast Cancer
1374345|NCT00476827|Metastatic
1374346|NCT00476827|Brain
1374347|NCT00476827|Anti-angiogenesis
1374348|NCT00476814|cystic fibrosis,
1374349|NCT00476814|nasal potential difference,
1374350|NCT00476814|primary sclerosing cholangitis
1374351|NCT00476801|UVA1
1374352|NCT00476801|scleroderma
1374353|NCT00476801|keloids
1374354|NCT00476801|light therapy
1374355|NCT00476801|morphea
1374356|NCT00476788|pediatrics
1374357|NCT00476788|CSII
1374358|NCT00476788|diabetes
1374359|NCT00476788|C-peptide
1374360|NCT00476788|adverse events
1374361|NCT00476775|obesity
1374362|NCT00476775|prevention
1374363|NCT00476775|girls
1374364|NCT00476775|Latina/Hispanic
1374365|NCT00476775|Dance
1374366|NCT00476775|television
1374367|NCT00476775|screen time
1374368|NCT00476736|COPD
1374369|NCT00476736|Pulmonary function
1374370|NCT00476736|Air trapping
1374371|NCT00476736|Acetyl cystein
1374372|NCT00476723|HIV infection
1374373|NCT00476723|Hepatitis coinfection
1374374|NCT00476710|Type 2 diabetes mellitus
1374375|NCT00476710|Bile acid
1374376|NCT00476710|Stable isotope
1374377|NCT00476710|Colesevelam HCl
1374378|NCT00476710|Impaired Glucose Tolerance
1374379|NCT00476697|UVA1
1374380|NCT00476697|scleroderma
1374381|NCT00476697|keloids
1374382|NCT00476697|morphea
1374383|NCT00476697|light therapy
1374384|NCT00476684|radiofrequency
1374385|NCT00476671|neuropsychiatric
1374386|NCT00476671|neurocognitive
1374387|NCT00476671|psychiatric
1374388|NCT00476671|HIV related dementia
1374389|NCT00476671|MCMD
1374390|NCT00476671|HIV-1
1374391|NCT00476671|Prevalence, risk factors of neurocognitive impairment and psychiatric comorbidities in HIV-1 infected patients with undetectable viral load in the HAART era.
1374392|NCT00476671|Treatment Experienced
1374393|NCT00476658|Obesity
1374394|NCT00476658|macrophage infiltration
1374395|NCT00476658|insulinoresistance
1374396|NCT00476658|inflammation
1374397|NCT00476632|Epidemiology
1374398|NCT00476632|Questionnaire
1374399|NCT00476632|Controls
1374400|NCT00476619|Contrast
1374401|NCT00476619|Nephropathy
1374402|NCT00476619|acute renal failure
1374403|NCT00476619|Erythropoietin
1374404|NCT00476619|CT scan
1374405|NCT00476606|HIV children
1374406|NCT00476606|HAART
1374407|NCT00476606|ARV
1374408|NCT00476606|Second line HAART
1374409|NCT00476606|Viral Load
1374410|NCT00476606|Combination drug
1374411|NCT00476606|Treatment Experienced
1374412|NCT00476606|Treatment Naive
1374413|NCT00476593|Uveitis
1374414|NCT00476593|Iritis
1374415|NCT00476593|Macular Thickness
1374416|NCT00476593|HLA-B27 related
1374417|NCT00476593|Macular edema
1374418|NCT00476593|Macular thickening
1374419|NCT00476593|OCT
1374420|NCT00476593|mfERG
1374421|NCT00476593|Eye drops
1374422|NCT00476593|Dexamethosone
1374423|NCT00476593|Diclofenac
1374424|NCT00476593|Retinal aging
1374425|NCT00476580|Sri Lankan Sinhalese
1374426|NCT00476580|Epidemiology
1374427|NCT00476580|Cancer Risk
1374428|NCT00476580|US Migrant
1374429|NCT00476580|Questionnaire
1374430|NCT00476580|Survey
1374431|NCT00476580|Acculturation
1374432|NCT00476580|Health and Cancer Risks
1374433|NCT00476580|Health Habits
1374434|NCT00476567|exercise
1374435|NCT00476567|pregnancy
1374436|NCT00476567|prevention
1374437|NCT00476567|pregnancy-related diseases
1374438|NCT00476567|labor
1374439|NCT00476567|complications
1374440|NCT00476567|physiotherapy
1374441|NCT00476554|CTCL
1374442|NCT00476541|AML
1374443|NCT00476541|Children
1374444|NCT00476541|Gemtuzumab ozogamicin
1374445|NCT00476541|Stem cell transplantation
1374446|NCT00476528|Posttraumatic amnesia
1374447|NCT00476528|Early intervention
1374448|NCT00476528|A systematic nursing programme in the ICU
1374449|NCT00476528|Early identification of patients with posttraumatic amnesia
1374450|NCT00476515|Kidney transplantation
1374451|NCT00476515|Donor specific antibodies
1374452|NCT00476515|Positive cross match
1374453|NCT00476502|genetic polymorphism
1374454|NCT00476502|CYP 3A
1374455|NCT00476502|MDR-1
1374456|NCT00476502|Thai
1374457|NCT00476502|HIV
1374458|NCT00476502|Treatment Experienced
1374459|NCT00476489|secondary adrenal insuffiency
1374460|NCT00476489|hypothalamus-pituitary-adrenal axis impairement
1374461|NCT00476489|topical steroids
1374462|NCT00476476|Tarceva
1374463|NCT00476476|erlotinib
1374464|NCT00476476|squamous cell carcinoma of the vulvar
1374465|NCT00476463|TDF+FTC
1374466|NCT00476463|FTC
1374467|NCT00476463|HIV/HBV
1374468|NCT00476463|TDF compared to TDF+FTC in HIV/HBV
1374469|NCT00476463|Treatment Naive
1374470|NCT00476450|Oral Microbial Flora
1374471|NCT00476450|Hematopoietic Stem Cell Transplant
1374472|NCT00476450|Allogeneic Stem Cell Transplant
1374473|NCT00476424|once daily Efavirenz 400 mg
1374474|NCT00476424|PK once daily Efavirenz 400 mg versus 600 mg
1374475|NCT00476424|Treatment Experienced
1374476|NCT00476411|isolated HBc
1374477|NCT00476411|HBV vaccine response
1374478|NCT00476411|occult HBV in isolated antiHBC compared HIV to non HIV
1374479|NCT00476398|Capsule endoscopy
1374480|NCT00476398|Wireless imaging
1374481|NCT00476398|esophagus
1374482|NCT00476398|stomach
1374483|NCT00476372|neuropsychology
1374484|NCT00476372|cognitive impairment
1374485|NCT00476372|motor disorder
1374486|NCT00476372|parkinson's disease
1374487|NCT00476359|Lopinavir/r
1374488|NCT00476359|Saquinavir
1374489|NCT00476359|Dual boosted PIs
1374490|NCT00476359|Pharmacokinetics
1374491|NCT00476359|HIV children
1374492|NCT00476359|C min
1374493|NCT00476359|Second line HAART
1374494|NCT00476359|ARV
1374495|NCT00476359|VL failure
1374496|NCT00476359|Dosage
1374497|NCT00476359|To evaluate treatment response
1374498|NCT00476359|Treatment Experienced
1374499|NCT00476346|physical training
1374500|NCT00476346|military training
1374501|NCT00476346|bone
1374502|NCT00476346|fracture prevention
1374503|NCT00476346|young adult
1374504|NCT00476333|EMG
1374505|NCT00476333|Kinetics
1374506|NCT00476333|Kinematics
1374507|NCT00476333|Perturbation
1374508|NCT00476333|Footwear
1374509|NCT00476320|echocardiography
1374510|NCT00476320|myocardial infarction
1374511|NCT00476320|magnetic resonance imaging
1374512|NCT00476320|revascularization
1374513|NCT00476320|viability
1374514|NCT00476307|Flu vaccine
1374515|NCT00476294|Multiple Myeloma
1374516|NCT00476294|Disease-Free Survival
1374517|NCT00476294|AMD3100
1374518|NCT00476294|G-CSF
1374519|NCT00476294|Autologous Transplantation
1374520|NCT00476255|child safety restraint
1374521|NCT00476255|injury prevention
1374522|NCT00476255|automotive
1374523|NCT00476242|heroin abuse
1374524|NCT00476242|opiate abuse
1374525|NCT00476242|opioid dependence
1374526|NCT00476242|naltrexone
1374527|NCT00476242|memantine
1374528|NCT00476229|Non-Hodgkin's Lymphoma
1374529|NCT00476229|Chronic Lymphocytic Leukemia
1374530|NCT00476229|Hodgkin's Lymphoma
1374531|NCT00476229|Lymphoma
1374532|NCT00476229|Leukemia
1374533|NCT00476229|Mycophenolate Mofetil
1374534|NCT00476229|Tacrolimus
1374535|NCT00476229|Thymoglobulin
1374536|NCT00476229|Total Lymphoid Irradiation
1374537|NCT00476216|Non-Small Cell Lung Cancer
1374538|NCT00476216|Venous Thromboembolism
1374539|NCT00476216|VTE
1374540|NCT00476216|Arixtra
1374541|NCT00476203|Breast Cancer
1374542|NCT00476203|Yoga
1374543|NCT00476203|Quality of Life
1374544|NCT00476203|Obesity
1374545|NCT00476203|Fatigue
1374546|NCT00476203|Weight
1374547|NCT00476190|ALL
1374548|NCT00476177|DC
1374549|NCT00476177|DLI
1374550|NCT00476177|graft vs. host disease
1374551|NCT00476177|GVHD
1374552|NCT00476164|chronic allograft nephropathy
1374553|NCT00476164|C4d
1374554|NCT00476164|Anti-CD20
1374555|NCT00476164|B cells
1374556|NCT00476164|Antibody
1374557|NCT00476151|DPN
1374558|NCT00476151|Diabetic
1374559|NCT00476151|Nerve Pain
1374560|NCT00476138|Epigallocatechin-Gallate
1374561|NCT00476138|Glaucoma
1374562|NCT00476138|Optic Nerve
1374563|NCT00476138|Pattern Electroretinogram
1374564|NCT00476138|Retinal Ganglion Cells
1374565|NCT00476112|Atrial flutter
1374566|NCT00476112|RSD1235
1374567|NCT00476086|oxaliplatin
1374568|NCT00476086|gemcitabine
1374569|NCT00476086|MMMT
1374570|NCT00476060|Cirrhosis
1374571|NCT00476060|Bone marrow
1374572|NCT00476060|Mesenchymal stem cell
1374573|NCT00476060|MELD score
1374574|NCT00476060|Quality of life
1374575|NCT00476034|Osteoarthritis
1374576|NCT00476034|lumiracoxib
1374577|NCT00476034|celecoxib
1374578|NCT00476034|Cox-2
1374579|NCT00476034|knee
1374580|NCT00476021|postpartum
1374581|NCT00476021|contraception
1374582|NCT00476021|postplacental IUD
1374583|NCT00476021|intrauterine devices
1374584|NCT00476008|Alzheimer's Disease
1374585|NCT00476008|Mild Alzheimer's Disease
1374586|NCT00476008|Driving
1374587|NCT00476008|Driving Impairment
1374588|NCT00475982|Diet
1374589|NCT00475982|Insulin-like Growth Factor
1374590|NCT00475982|Weight Loss
1374591|NCT00475956|Cancer
1374592|NCT00475956|Tumour
1374593|NCT00475956|Advanced Solid Tumour
1374594|NCT00475956|Lung Cancer
1374595|NCT00475956|Breast Cancer
1374596|NCT00475956|Cholangiocarcinoma
1374597|NCT00475956|Colon Cancer
1374598|NCT00475956|Gastric Cancer
1374599|NCT00475956|Choriocarcinoma
1374600|NCT00475956|Liver Cancer
1374601|NCT00475956|Myeloma
1374602|NCT00475956|Ovarian Cancer
1374603|NCT00475956|Pancreatic Cancer
1374604|NCT00475956|Peritoneal Cancer
1374605|NCT00475943|Swallowing Disorders
1374606|NCT00475943|Swallowing
1374607|NCT00475943|Videofluoroscopy
1374608|NCT00475943|Dysphagia
1374609|NCT00475943|Epiglottis
1374610|NCT00475943|Healthy Volunteer
1374611|NCT00475943|HV
1374612|NCT00475930|MRSA
1374613|NCT00475930|Staphylococcus aureus
1374614|NCT00475917|Advanced malignancies
1374615|NCT00475917|Solid tumor
1374616|NCT00475904|Post Herpetic Neuralgia
1374617|NCT00475904|PHN
1374618|NCT00475904|Neuropathy
1374619|NCT00475904|Nerve Pain
1374620|NCT00475904|Topical
1374621|NCT00475891|isolate
1374622|NCT00475891|infection
1374623|NCT00475891|linezolid
1374624|NCT00475878|opiate use
1374625|NCT00475878|depression
1374626|NCT00475878|buprenorphine
1374627|NCT00475878|escitalopram
1374628|NCT00475865|MS
1374629|NCT00475865|glatiramer acetate
1374630|NCT00475865|adjunctive therapy
1374631|NCT00475865|relapses
1374632|NCT00475852|Heart Decompensation
1374633|NCT00475852|Dyspnea
1374634|NCT00475852|Heart failure
1374635|NCT00475852|Nesiritide
1374636|NCT00475852|Decompensated
1374637|NCT00475852|ADHF
1374638|NCT00475839|stress urinary incontinence
1374639|NCT00475839|sling procedures
1374640|NCT00475839|tension-free vaginal tape
1374641|NCT00475839|transobturator
1374642|NCT00475826|Heterozigous Familial Hypercholesterolemia
1374643|NCT00475826|Sub-clinical atherosclerosis
1374644|NCT00475826|Chylomicrons metabolism
1374645|NCT00475826|Statin plus ezetimibe
1374646|NCT00475826|Coronary artery calcification
1374647|NCT00475813|Paediatric subjects with asthma
1374648|NCT00475800|Osteoarthritis
1374649|NCT00475800|lumiracoxib
1374650|NCT00475800|celecoxib
1374651|NCT00475800|Cox-2
1374652|NCT00475800|knee
1374653|NCT00475787|Older Adults
1374654|NCT00475787|Patient Education
1374655|NCT00475787|Randomized Controlled Trial
1374656|NCT00475787|Sham procedure
1374657|NCT00475787|Spinal Manipulation
1374658|NCT00475787|Veterans
1374659|NCT00475761|Breast biopsy
1374660|NCT00475761|Breast imaging
1374661|NCT00475761|Breast Cancer
1374662|NCT00475761|Mammographic Density
1374663|NCT00475761|Breast
1374664|NCT00475748|cervical spine
1374665|NCT00475748|spinal cord
1374666|NCT00475748|trauma
1374667|NCT00475748|spinal cord injury
1374668|NCT00475748|central cord syndrome
1374669|NCT00475722|cancer
1374670|NCT00475722|colon
1374671|NCT00475722|prevention
1374672|NCT00475722|healthy eating
1374673|NCT00475722|Mediterranean diet
1374674|NCT00475722|PGE2
1374675|NCT00475722|cyclooxygenase
1374676|NCT00475722|lipoxygenase
1374677|NCT00475722|Healthy People 2010 diet
1374678|NCT00475722|dietary prevention of colon cancer
1374679|NCT00475709|aortic valve
1374680|NCT00475709|heart valve
1374681|NCT00475709|tissue valve
1374682|NCT00475709|bioprosthesis
1374683|NCT00475709|valve disorder
1374684|NCT00475709|valve disease
1374685|NCT00475709|cardiac surgery
1374686|NCT00475709|aortic valve stenosis
1374687|NCT00475709|aortic valve regurgitation
1374688|NCT00475683|Doxorubicin
1374689|NCT00475683|Mucositis
1374690|NCT00475683|Prevention
1374691|NCT00475683|Curcumin
1374692|NCT00475631|Clubfoot
1374693|NCT00475631|Chart review
1374694|NCT00475618|Early chilhood caries
1374695|NCT00475618|Prevention
1374696|NCT00475618|Fluoride varnish
1374697|NCT00475618|fluoride toothpaste
1374698|NCT00475618|non fluoride tooth paste
1374699|NCT00475618|Professional cleaning
1374700|NCT00475605|atopic dermatitis
1374701|NCT00475605|child
1374702|NCT00475605|tacrolimus ointment
1374703|NCT00475605|Protopic Ointment
1374704|NCT00475592|Esophageal Varices
1374705|NCT00475592|Gastric Varices
1374706|NCT00475592|Capsule Endoscopy
1374707|NCT00475592|Portal Hypertension
1374708|NCT00475592|Cirrhosis
1374709|NCT00475592|Gastrointestinal Hemorrhage
1374710|NCT00475579|ventilator-associated pneumonia
1374711|NCT00475579|endotracheal tube
1374712|NCT00475579|polyurethane cuff
1374713|NCT00475579|polyvinyl cuff
1374714|NCT00475579|subglottic secretion drainage
1374715|NCT00475553|spotting
1374716|NCT00475553|PMS
1374717|NCT00475553|nuvaring
1374718|NCT00475553|birth control
1374719|NCT00475553|pelvic pain
1374720|NCT00475553|headache
1374721|NCT00475553|mood swings
1374722|NCT00475553|continuous use
1374723|NCT00475540|prolapse
1374724|NCT00475540|uterus
1374725|NCT00475540|pelvic organ
1374726|NCT00475540|vaginal prolpase
1374727|NCT00475514|Menstrually-related Migraine Headache
1374728|NCT00475514|'Difficult to Treat' as specified in protocol
1374729|NCT00475501|anabolic effects
1374730|NCT00475501|finasteride
1374731|NCT00475501|male hypogonadism
1374732|NCT00475501|sarcopenia
1374733|NCT00475501|testosterone
1374734|NCT00475488|radial artery
1374735|NCT00475488|right internal thoracic artery
1374736|NCT00475488|saphenous vein
1374737|NCT00475488|grafts
1374738|NCT00475488|coronary bypass surgery
1374739|NCT00475475|Overweight
1374740|NCT00475475|Obesity
1374741|NCT00475475|Appetite
1374742|NCT00475475|Dietary sugars
1374743|NCT00475475|Fructose
1374744|NCT00475475|Glucose
1374745|NCT00475475|Leptin
1374746|NCT00475475|Insulin
1374747|NCT00475475|Ghrelin
1374748|NCT00475462|Metoprolol and Syncope
1374749|NCT00475449|percutaneous coronary intervention
1374750|NCT00475449|Stent
1374751|NCT00475449|coronary artery bypass grafting
1374752|NCT00475436|muscarinic receptor antagonist
1374753|NCT00475436|GSK573719,
1374754|NCT00475436|chronic obstructive pulmonary disease,
1374755|NCT00475410|Autologous adipose-derived stem cells
1374756|NCT00475410|Complex perianal fistula
1374757|NCT00475410|Inflammatory Bowel Disease
1374758|NCT00475410|Advanced cell therapy
1374759|NCT00475410|Fibrin glue
1374760|NCT00475384|Acute Myelogenous Leukemia
1374761|NCT00475384|Acute Lymphocytic Leukemia
1374762|NCT00475384|Myelodysplastic Syndrome
1374763|NCT00475384|Stem Cell Transplant
1374764|NCT00475384|Haploidentical Donor
1374765|NCT00475384|Leukemia
1374766|NCT00475384|Fludarabine
1374767|NCT00475384|Total Body Irradiation
1374768|NCT00475384|Thiotepa
1374769|NCT00475371|Healthy
1374770|NCT00475371|Diabetes Mellitus: Type II
1374771|NCT00475345|Nocturnal hypoglycemia
1374772|NCT00475345|Bedtime snacks
1374773|NCT00475345|Continuous glucose monitoring
1374774|NCT00475345|Continuous subcutaneous insulin infusion
1374775|NCT00475345|CSII
1374776|NCT00475345|Intensive therapy
1374777|NCT00475319|Dry Eye Syndromes
1374778|NCT00475319|OPC-12759
1374779|NCT00475306|Metoclopramide
1374780|NCT00475306|Nausea
1374781|NCT00475306|Akathisia
1374782|NCT00475306|Emergency department
1374783|NCT00475293|metastatic colorectal cancer
1374784|NCT00475293|2nd-line Therapy
1374785|NCT00475293|panitumumab
1374786|NCT00475293|irinotecan
1374787|NCT00475280|geriatric assessment adapted therapy
1374788|NCT00475280|Leukemia, Lymphoblastic, Acute
1374789|NCT00475280|Older patients
1374790|NCT00475280|> 60 years old
1374791|NCT00475280|Ph negative
1374792|NCT00475267|aortic valve
1374793|NCT00475267|heart valve
1374794|NCT00475267|tissue valve
1374795|NCT00475267|bioprosthesis
1374796|NCT00475267|valve disorder
1374797|NCT00475267|valve disease
1374798|NCT00475267|cardiac surgery
1374799|NCT00475267|aortic valve stenosis
1374800|NCT00475267|aortic valve regurgitation
1374801|NCT00475254|Retinitis Pigmentosa
1374802|NCT00475254|stress
1374803|NCT00475254|sleepiness
1374804|NCT00475254|low vision
1374805|NCT00475254|mind-body
1374806|NCT00475241|Combat Disorders
1374807|NCT00475241|Cortisol
1374808|NCT00475241|Posttraumatic Stress Disorder (PTSD)
1374809|NCT00475241|Psychophysiology
1374810|NCT00475241|Therapy
1374811|NCT00475241|Treatment
1374812|NCT00475241|Veterans
1374813|NCT00475228|levonorgestrel IUD
1374814|NCT00475228|IUD
1374815|NCT00475228|dilation and evacuation
1374816|NCT00475228|contraception
1374817|NCT00475189|birth control
1374818|NCT00475189|PMS
1374819|NCT00475189|headaches
1374820|NCT00475189|mood swings
1374821|NCT00475189|pelvic pain
1374822|NCT00475176|Hepatitis C Virus Genotype 1
1374823|NCT00475176|Non-Responders
1374824|NCT00475176|SAMe
1374825|NCT00475176|Natural Killer Cells
1374826|NCT00475176|Interferon Signaling
1374827|NCT00475176|Ribavirin
1374828|NCT00475176|Peginterferon
1374829|NCT00475176|Hemolysis
1374830|NCT00475176|STAT
1374831|NCT00475176|Hepatitis C
1374832|NCT00475163|Obesity
1374833|NCT00475163|Mentoring
1374834|NCT00475163|Fitness
1374835|NCT00475163|Self-esteem
1374836|NCT00475137|Bipolar II Disorder
1374837|NCT00475137|depression
1374838|NCT00475137|Lamotrigine
1374839|NCT00475137|Add On antidepressant
1374840|NCT00475137|randomized
1374841|NCT00475137|single blind
1374842|NCT00475137|parallel group
1374843|NCT00475124|Pacemaker follow-up
1374844|NCT00475124|Telecardiology
1374845|NCT00475124|Home Monitoring
1374846|NCT00475111|Cognitive Behavioral Intervention
1374847|NCT00475111|Emotion Regulation
1374848|NCT00475111|Pain Management
1374849|NCT00475111|Psychological Adaptation
1374850|NCT00475111|Coping Efficacy
1374851|NCT00475111|Markers of Disease Activity
1374852|NCT00475098|Low molecular weight heparin
1374853|NCT00475098|Lung cancer
1374854|NCT00475098|Non small cell lung cancer
1374855|NCT00475098|Adjuvant therapy
1374856|NCT00475098|Anticoagulants
1374857|NCT00475098|Heparin
1374858|NCT00475085|nausea and vomiting
1374859|NCT00475085|recurrent breast cancer
1374860|NCT00475085|stage I breast cancer
1374861|NCT00475085|stage II breast cancer
1374862|NCT00475085|stage IIIA breast cancer
1374863|NCT00475085|stage IIIB breast cancer
1374864|NCT00475085|stage IIIC breast cancer
1374865|NCT00475085|stage IV breast cancer
1374866|NCT00475085|inflammatory breast cancer
1374867|NCT00475085|male breast cancer
1374868|NCT00475059|kidney transplantation
1374869|NCT00475059|Glomerular filtration rate
1374870|NCT00475059|inulin clearance
1374871|NCT00475059|MDRD equation
1374872|NCT00475059|cystatin C
1374873|NCT00475059|cimetidine
1374874|NCT00475046|smoking
1374875|NCT00475046|post partum
1374876|NCT00475046|relapse prevention
1374877|NCT00475046|motivational interviewing
1374878|NCT00475046|TTM
1374879|NCT00475046|implement motivational enhancement interventions in pediatric practices
1374880|NCT00475046|examine the effectiveness of the intervention
1374881|NCT00475046|develop measurements appropriate to tailor interventions
1374882|NCT00475046|analyze further unfavorable and favorable factors outlined by previous research
1374883|NCT00475020|Idiopathic Myelofibrosis
1374884|NCT00475020|Myelofibrosis
1374885|NCT00475020|Essential Thrombocythemia
1374886|NCT00475020|Polycythemia Vera
1374887|NCT00475020|Busulfan
1374888|NCT00475020|Antithymocyte Globulin
1374889|NCT00475020|ATG
1374890|NCT00475020|Fludarabine
1374891|NCT00475020|Thymoglobulin
1374892|NCT00475007|Emphysema
1374893|NCT00475007|IBV® Valve
1374894|NCT00475007|COPD
1374895|NCT00475007|Shortness of Breath
1374896|NCT00475007|Spiration
1374897|NCT00474994|chondrosarcoma
1374898|NCT00474994|recurrent osteosarcoma
1374899|NCT00474994|localized adult malignant fibrous histiocytoma of bone
1374900|NCT00474994|metastatic adult malignant fibrous histiocytoma of bone
1374901|NCT00474994|recurrent adult malignant fibrous histiocytoma of bone
1374902|NCT00474994|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1374903|NCT00474994|recurrent Kaposi sarcoma
1374904|NCT00474994|recurrent uterine sarcoma
1374905|NCT00474994|adult leiomyosarcoma
1374906|NCT00474994|adult malignant fibrous histiocytoma
1374907|NCT00474994|adult rhabdomyosarcoma
1374908|NCT00474994|dermatofibrosarcoma protuberans
1374909|NCT00474994|stage III adult soft tissue sarcoma
1374910|NCT00474994|stage IV adult soft tissue sarcoma
1374911|NCT00474994|ovarian sarcoma
1374912|NCT00474994|uterine leiomyosarcoma
1374913|NCT00474994|stage III uterine sarcoma
1374914|NCT00474994|stage IV uterine sarcoma
1374915|NCT00474994|desmoid tumor
1374916|NCT00474994|adult angiosarcoma
1374917|NCT00474994|recurrent adult soft tissue sarcoma
1374918|NCT00474994|uterine carcinosarcoma
1375031|NCT00474526|Meningococcal disease
1374919|NCT00474994|endometrial stromal sarcoma
1374920|NCT00474994|fibrosarcomatous osteosarcoma
1374921|NCT00474994|chondrosarcomatous osteosarcoma
1374922|NCT00474994|adult alveolar soft-part sarcoma
1374923|NCT00474994|adult epithelioid sarcoma
1374924|NCT00474994|adult extraskeletal chondrosarcoma
1374925|NCT00474994|adult extraskeletal osteosarcoma
1374926|NCT00474994|adult fibrosarcoma
1374927|NCT00474994|adult malignant hemangiopericytoma
1374928|NCT00474994|adult malignant mesenchymoma
1374929|NCT00474994|adult neurofibrosarcoma
1374930|NCT00474994|adult synovial sarcoma
1374931|NCT00474994|adult desmoplastic small round cell tumor
1374932|NCT00474994|adult liposarcoma
1374933|NCT00474994|anaplastic osteosarcoma
1374934|NCT00474994|mixed osteosarcoma
1374935|NCT00474994|small intestine leiomyosarcoma
1374936|NCT00474994|osteoblastic osteosarcoma
1374937|NCT00474994|telangiectatic osteosarcoma
1374938|NCT00474994|classic Kaposi sarcoma
1374939|NCT00474994|immunosuppressive treatment related Kaposi sarcoma
1374940|NCT00474994|AIDS-related Kaposi sarcoma
1374941|NCT00474981|neonatal mortality
1374942|NCT00474981|infant mortality
1374943|NCT00474981|newborn caring practices
1374944|NCT00474942|Hypertension
1374945|NCT00474942|Metabolic Alkalosis
1374946|NCT00474942|Hypokalemia
1374947|NCT00474929|recurrent adult Hodgkin lymphoma
1374948|NCT00474929|recurrent cutaneous T-cell non-Hodgkin lymphoma
1374949|NCT00474929|stage III multiple myeloma
1374950|NCT00474929|refractory multiple myeloma
1374951|NCT00474929|Waldenström macroglobulinemia
1374952|NCT00474929|recurrent adult Burkitt lymphoma
1374953|NCT00474929|recurrent adult diffuse large cell lymphoma
1374954|NCT00474929|recurrent adult diffuse mixed cell lymphoma
1374955|NCT00474929|recurrent adult diffuse small cleaved cell lymphoma
1374956|NCT00474929|recurrent adult immunoblastic large cell lymphoma
1374957|NCT00474929|recurrent adult lymphoblastic lymphoma
1374958|NCT00474929|recurrent grade 1 follicular lymphoma
1374959|NCT00474929|recurrent grade 2 follicular lymphoma
1374960|NCT00474929|recurrent grade 3 follicular lymphoma
1374961|NCT00474929|recurrent mantle cell lymphoma
1374962|NCT00474929|recurrent marginal zone lymphoma
1374963|NCT00474929|recurrent small lymphocytic lymphoma
1374964|NCT00474929|cutaneous B-cell non-Hodgkin lymphoma
1374965|NCT00474929|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1374966|NCT00474929|nodal marginal zone B-cell lymphoma
1374967|NCT00474929|splenic marginal zone lymphoma
1374968|NCT00474929|recurrent mycosis fungoides/Sezary syndrome
1374969|NCT00474929|recurrent adult grade III lymphomatoid granulomatosis
1374970|NCT00474916|Neuropathic pain
1374971|NCT00474916|Cancer
1374972|NCT00474890|Seasonal allergic rhinitis
1374973|NCT00474877|Clinical
1374974|NCT00474877|Splints
1374975|NCT00474877|Rheumatoid
1374976|NCT00474864|Endothelial Function,
1374977|NCT00474864|vascular compliance,
1374978|NCT00474864|atherosclerosis
1374979|NCT00474851|Endometriosis
1374980|NCT00474851|Adolescents
1374981|NCT00474851|Bone density
1374982|NCT00474851|GnRH Agonist
1374983|NCT00474851|Add-back therapy
1374984|NCT00474838|type 2 diabetes mellitus
1374985|NCT00474838|intensive insulin therapy
1374986|NCT00474786|Metastatic or Advanced Renal Cell Carcinoma
1374987|NCT00474747|Severe Aplastic Anemia
1374988|NCT00474747|Total Body Irradiation
1374989|NCT00474747|Antithymocyte Globulin
1374990|NCT00474747|Cyclophosphamide
1374991|NCT00474747|Cytoxan
1374992|NCT00474747|Neosar
1374993|NCT00474747|Fludarabine
1374994|NCT00474747|Fludara
1374995|NCT00474747|Fludarabine Phosphate
1374996|NCT00474747|Thymoglobulin
1374997|NCT00474747|ATG
1374998|NCT00474747|TBI
1374999|NCT00474747|Cyclosporine
1375000|NCT00474747|Tacrolimus
1375001|NCT00474734|hepatocellular carcinoma
1375002|NCT00474734|liver transplantation
1375003|NCT00474734|staging
1375004|NCT00474734|intravascular ultrasound
1375005|NCT00474721|child
1375006|NCT00474721|pain
1375007|NCT00474721|analgesics
1375008|NCT00474695|Exudative age-related macular degeneration
1375009|NCT00474682|ferric pyrophosphate, iron bioavailability, fortification,
1375010|NCT00474669|Ovarian Carcinoma
1375011|NCT00474656|high frequency oscillation
1375012|NCT00474656|lung-protective ventilation
1375013|NCT00474656|ARDS
1375014|NCT00474656|ventilator-induced lung injury
1375015|NCT00474630|Obesity
1375016|NCT00474630|Overweight
1375017|NCT00474630|Diabetes Mellitus, Type 2
1375018|NCT00474604|breast cancer
1375019|NCT00474591|Coronary artery bypass surgery, fondaparinux, graft patency, graft occlusion, graft failure, anticoagulation
1375020|NCT00474565|Catheter,
1375021|NCT00474565|Aortic root injection,
1375022|NCT00474565|low dose contrast injection,
1375023|NCT00474565|coronary artery angiogarm and
1375024|NCT00474565|coronary artery bypass graft imaging.
1375025|NCT00474539|Vaccine
1375026|NCT00474526|Meningococcal
1375027|NCT00474526|meningitis
1375028|NCT00474526|vaccine
1375029|NCT00474526|infants
1375030|NCT00474526|Meningococcal meningitis
1375032|NCT00474513|AD, H3, Brain, Cognitive Impairment
1375033|NCT00474500|Iron absorption
1375034|NCT00474500|Coca-Cola
1375035|NCT00474487|Meningococcal
1375036|NCT00474487|meningitis
1375037|NCT00474487|vaccine
1375038|NCT00474487|adolescents
1375039|NCT00474487|adults
1375040|NCT00474474|virtual patient
1375041|NCT00474474|therapeutic decision making
1375042|NCT00474461|coronary artery disease
1375043|NCT00474461|Heart Attack
1375044|NCT00474461|Heart failure
1375045|NCT00474461|Cardiac Stem Cells
1375046|NCT00474461|Coronary Artery Bypass
1375047|NCT00474448|Hereditary Multiple Exostoses
1375048|NCT00474448|Survey
1375049|NCT00474448|Quality of Life
1375050|NCT00474448|Hereditary Multiple Exostoses,
1375051|NCT00474448|also known as Multiple Hereditary Exostoses,
1375052|NCT00474448|also known as Hereditary Multiple Osteochondromas
1375053|NCT00474435|Tuberculosis
1375054|NCT00474435|HIV
1375055|NCT00474435|Coinfection
1375056|NCT00474435|Pharmacokinetics
1375057|NCT00474435|Emtricitabine
1375058|NCT00474435|Tenofovir
1375059|NCT00474435|Rifampin
1375060|NCT00474435|Efavirenz
1375061|NCT00474435|Treatment Naive
1375062|NCT00474422|breastfeeding
1375063|NCT00474422|support
1375064|NCT00474409|Vertigo
1375065|NCT00474409|Posterior circulation infarction
1375066|NCT00474396|Uric acid
1375067|NCT00474396|Dairy
1375068|NCT00474396|Diet
1375069|NCT00474383|Prostate neoplasms
1375070|NCT00474383|CB7630
1375071|NCT00474383|Abiraterone acetate
1375072|NCT00474383|Glucocorticoid
1375073|NCT00474383|Prednisone
1375074|NCT00474383|Prednisolone
1375075|NCT00474370|Acquired Immunodeficiency Syndrome
1375076|NCT00474357|Bipolar affective disorder
1375077|NCT00474357|myths
1375078|NCT00474357|preconceived notions
1375079|NCT00474357|stigma
1375080|NCT00474357|hope
1375081|NCT00474344|Genetics
1375082|NCT00474344|Clubfoot
1375083|NCT00474344|DNA
1375084|NCT00474344|Idiopathic Talipes Equinovarus also known as Clubfoot
1375085|NCT00474331|DNA sequencing
1375086|NCT00474331|EXT genes
1375087|NCT00474331|Hereditary Multiple Exostoses,
1375088|NCT00474331|also known as Multiple Hereditary Exostoses,
1375089|NCT00474331|also known as Hereditary Multiple Osteochondromas
1375090|NCT00474318|Adolescents
1375091|NCT00474318|Obesity
1375092|NCT00474318|Bariatrics
1375093|NCT00474318|Surgery for Weight Loss
1375094|NCT00474318|Teen-LABS
1375095|NCT00474305|PTSD
1375096|NCT00474305|Prolonged Exposure
1375097|NCT00474305|Virtual Reality
1375098|NCT00474292|Stroke
1375099|NCT00474292|Rehabilitation
1375100|NCT00474292|Plasticity
1375101|NCT00474292|fMRI
1375102|NCT00474292|Reorganization
1375103|NCT00474279|Growth hormone secretagogue
1375104|NCT00474279|Body composition
1375105|NCT00474279|Functional ability
1375106|NCT00474279|Aging
1375107|NCT00474279|Sarcopenia
1375108|NCT00474266|MMRV vaccine
1375109|NCT00474266|co-administration
1375110|NCT00474266|immunogenicity
1375111|NCT00474266|meningococcal vaccine
1375112|NCT00474266|conjugate vaccine
1375113|NCT00474240|cholesterol
1375114|NCT00474227|obesity
1375115|NCT00474227|weight gain
1375116|NCT00474227|schizophrenia
1375117|NCT00474227|schizoaffective disorder
1375118|NCT00474227|antipsychotic induced weight gain
1375119|NCT00474214|STEMI
1375120|NCT00474214|Primary PCI
1375121|NCT00474214|Length of Stay
1375122|NCT00474214|Early Discharge
1375123|NCT00474201|Pharmacokinetic
1375124|NCT00474201|HIV
1375125|NCT00474201|Drug-Drug Interaction
1375126|NCT00474201|Lopinavir/Ritonavir
1375127|NCT00474201|Gemfibrozil
1375128|NCT00474201|Healthy Volunteer
1375129|NCT00474201|HV
1375130|NCT00474188|Celgene
1375131|NCT00474188|Revlimid
1375132|NCT00474188|Lenalidomide
1375133|NCT00474188|Diffuse Large B-cell lymphoma
1375134|NCT00474188|Non-Hodgkins lymphoma
1375135|NCT00474188|CC-5013
1375136|NCT00474188|Response Rate
1375137|NCT00474188|Tumor Control Rate
1375138|NCT00474188|Duration of Response
1375139|NCT00474188|Time to Progression
1375140|NCT00474188|Progression-free survival and safety
1375141|NCT00474162|Cesarean section
1375142|NCT00474162|coagulation changes
1375143|NCT00474123|angina
1375144|NCT00474123|atherosclerosis
1375145|NCT00474123|simvastatin
1375146|NCT00474123|ezetimibe
1375147|NCT00474123|inflammation
1375148|NCT00474110|Ketamine
1375149|NCT00474110|hydromorphone
1375150|NCT00474110|pediatric mucositis
1375151|NCT00474097|Colorectal Neoplasms
1375152|NCT00474097|Colitis, Ulcerative
1375153|NCT00474097|Diverticulitis
1375154|NCT00474097|Colonic Polyps
1375155|NCT00474097|Crohn Disease
1375156|NCT00474084|Stent
1375157|NCT00474084|Hydroxyapatite
1375158|NCT00474084|Coronary Artery Stenosis
1375159|NCT00474084|Angioplasty
1375160|NCT00474071|Remifentanil
1375161|NCT00474071|endotracheal intubation
1375162|NCT00474071|pediatrics
1375163|NCT00474058|rotigotine
1375164|NCT00474058|Neupro®
1375165|NCT00474058|Parkinson's Disease
1375166|NCT00474032|Idiopathic clubfoot
1375167|NCT00474032|Botox injection
1375168|NCT00474032|Idiopathic Talipes Equinovarus, also known as Idiopathic clubfoot
1375169|NCT00474019|pediatrics
1375170|NCT00474019|neonates
1375171|NCT00473993|Hepatitis C
1375172|NCT00473993|Opioid Maintenance Treatment
1375173|NCT00473993|Methadone
1375174|NCT00473993|Buprenorphine
1375175|NCT00473993|Heroin
1375176|NCT00473993|Interferon, pegylated
1375177|NCT00473980|MHC
1375178|NCT00473980|CTLs
1375179|NCT00473980|Colon carcinoma
1375180|NCT00473980|NSAID
1375181|NCT00473980|Survival
1375182|NCT00473967|Vaccine
1375183|NCT00473967|Hookworm
1375184|NCT00473967|Phase 1
1375185|NCT00473967|Na-ASP-2
1375186|NCT00473941|colorectal cancer
1375187|NCT00473941|colon cancer
1375188|NCT00473941|rectal cancer
1375189|NCT00473928|Macular
1375190|NCT00473928|degeration
1375191|NCT00473928|Complement
1375192|NCT00473876|Chronic Heart Failure
1375193|NCT00473876|Insulin Resistance
1375194|NCT00473876|Metformin
1375195|NCT00473876|Peak VO2
1375196|NCT00473863|Acute coronary syndrome
1375197|NCT00473863|Acute myocardial infarction
1375198|NCT00473863|Unstable angina
1375199|NCT00473863|Coronary computed tomographic angiography
1375200|NCT00473863|Coronary Angiography
1375201|NCT00473863|Tomography, X-Ray Computed
1375202|NCT00473863|Tomography, Spiral Computed
1375203|NCT00473850|DNA sequencing
1375204|NCT00473850|EXT genes
1375205|NCT00473850|Hereditary Multiple Exostoses,
1375206|NCT00473850|also known as Multiple Hereditary Exostoses,
1375207|NCT00473850|also known as Hereditary Multiple Osteochondromas
1375208|NCT00473837|malaria
1375209|NCT00473837|anaemia
1375210|NCT00473837|chloroquine
1375211|NCT00473837|iron delocalisation
1375212|NCT00473837|macrophages
1375213|NCT00473824|hepatitis C
1375214|NCT00473824|liver transplantation
1375215|NCT00473824|immune globulin
1375216|NCT00473811|Glycemic index
1375217|NCT00473811|carbohydrates
1375218|NCT00473811|diabetes mellitus, type 2
1375219|NCT00473811|randomized clinical trial
1375220|NCT00473798|Patient Satisfaction
1375221|NCT00473798|Quality of Life
1375222|NCT00473798|Psychological Distress
1375223|NCT00473798|Cervical Cancer
1375224|NCT00473798|Cervical Cancer Screening
1375225|NCT00473798|Questionnaire
1375226|NCT00473785|Cardiovascular disease
1375227|NCT00473785|Prevention
1375228|NCT00473785|Lifestyle
1375229|NCT00473772|cobalt chromium stent
1375230|NCT00473772|paclitaxel coated balloon catheter
1375231|NCT00473772|DEBlue
1375232|NCT00473772|drug eluting balloon
1375233|NCT00473746|Prostate neoplasms
1375234|NCT00473746|Hormone refractory prostate cancer
1375235|NCT00473746|Abiraterone acetate
1375236|NCT00473746|CB7630
1375237|NCT00473733|PATIENTS WITH DIABETES MELLITUS TYPE 2
1375238|NCT00473733|UNDERGO UPPER ENDOSCOPY
1375239|NCT00473733|BIOPSIES FOR GLP RECEPTORS EXPRESSION
1375240|NCT00473733|PCR ANALYSIS
1375241|NCT00473707|Third stage of labor
1375242|NCT00473668|Hepatitis B
1375243|NCT00473668|Tetanus
1375244|NCT00473668|Diphtheria
1375245|NCT00473668|Pertussis
1375246|NCT00473668|Haemophilus influenzae type b Vaccines
1375247|NCT00473655|Triglycerides
1375248|NCT00473655|hypertriglyceridemia
1375249|NCT00473655|statins
1375250|NCT00473655|rosuvastatin
1375251|NCT00473655|hyperlipoproteinemia
1375252|NCT00473655|Fredrickson Type IIb or IV
1375253|NCT00473642|Ranibizumab
1375254|NCT00473642|Lucentis
1375255|NCT00473642|Verteporfin
1375256|NCT00473642|Visudyne
1375257|NCT00473642|Photodynamic therapy
1375258|NCT00473616|Phase I
1375259|NCT00473616|solid tumors
1375260|NCT00473616|solid malignancies
1375261|NCT00473616|cancer Eligibility
1375262|NCT00473603|androgens
1375263|NCT00473603|fatty acids
1375264|NCT00473590|Avastin
1375265|NCT00473590|AMBER
1375266|NCT00473590|Myeloma
1375267|NCT00473590|Velcade
1375268|NCT00473564|Lesions
1375269|NCT00473564|Biopsy
1375270|NCT00473564|Surgery
1375271|NCT00473551|Chronic Lymphocytic Leukemia
1375272|NCT00473551|Lymphoma
1375273|NCT00473551|Myeloma
1375274|NCT00473551|Leukemia
1375275|NCT00473551|Anti-Third Party Cytolytic Lymphocytes
1375276|NCT00473551|Indolent Lymphoid Malignancies
1375277|NCT00473551|Fludarabine
1375278|NCT00473551|Fludara
1375279|NCT00473551|Rituximab
1375280|NCT00473551|Rituxan
1375281|NCT00473551|Cyclophosphamide
1375282|NCT00473551|Cytoxan®
1375283|NCT00473551|Neosar®
1375284|NCT00473551|Stem Cell Transplantation
1375285|NCT00473551|T-lymphocytes
1375286|NCT00473551|Miltenyi CliniMACS System
1375287|NCT00473551|Graft vs. Host Disease
1375288|NCT00473551|GVHD
1375289|NCT00473551|Allogenic Transplant
1375290|NCT00473551|Sirolimus
1375291|NCT00473551|Rapamycin
1375292|NCT00473538|Structured exercise training program
1375293|NCT00473538|Infertility
1375294|NCT00473538|Menstrual cycle
1375295|NCT00473538|PCOS
1375296|NCT00473538|Treatment
1375297|NCT00473512|Abiraterone acetate
1375298|NCT00473512|CB7630
1375299|NCT00473512|Prostatic neoplasms
1375300|NCT00473512|Hormone refractory prostate cancer
1375301|NCT00473512|Castration resistant prostate cancer
1375302|NCT00473512|Castration refractory prostate cancer
1375303|NCT00473499|drug eluting balloon
1375304|NCT00473499|drug eluting stent
1375305|NCT00473499|stem cells
1375306|NCT00473473|homeopathy
1375307|NCT00473473|Traumeel
1375308|NCT00473473|mechanical ventilation
1375309|NCT00473473|secretions
1375310|NCT00473460|Chronic bronchitis
1375311|NCT00473460|Chronic obstructive pulmonary disease
1375312|NCT00473460|Acute exacerbation of chronic bronchitis
1375313|NCT00473460|Prevention therapy
1375314|NCT00473460|Antibiotics
1375315|NCT00473460|Fluoroquinolone
1375316|NCT00473460|Moxifloxacin
1375317|NCT00473460|AECB
1375318|NCT00473447|Rehabilitation
1375319|NCT00473447|Children
1375320|NCT00473447|Cerebral Palsy
1375321|NCT00473447|Arm
1375322|NCT00473447|Paresis
1375323|NCT00473434|Schizophrenia
1375324|NCT00473434|Drug Therapy
1375325|NCT00473434|Treatment Outcome
1375326|NCT00473408|Glioma
1375327|NCT00473408|DCE-MRI
1375328|NCT00473408|Angiogenesis
1375329|NCT00473408|Cancer stem cells
1375330|NCT00473408|Tumor vasculature
1375331|NCT00473382|Lucentis
1375332|NCT00473382|DME
1375333|NCT00473382|Diabetes
1375334|NCT00473382|Vision loss
1375335|NCT00473369|atypical adenoma
1375336|NCT00473369|Ki-67
1375337|NCT00473369|p53
1375338|NCT00473369|pituitary
1375339|NCT00473369|prognosis
1375340|NCT00473356|Morbid obesity
1375341|NCT00473356|Lean body mass
1375342|NCT00473356|amino acid supplement
1375343|NCT00473356|laparoscopic gastric bypass
1375344|NCT00473343|Photodynamic therapy (PDT)
1375345|NCT00473343|PDT with Metvix cream
1375346|NCT00473343|"High risk BCC"
1375347|NCT00473343|Basal Cell carcinoma
1375348|NCT00473343|Histologically confirmed complete response
1375349|NCT00473330|Lucentis
1375350|NCT00473330|DME
1375351|NCT00473330|Diabetes
1375352|NCT00473330|Vision loss
1375353|NCT00473317|sunlight
1375354|NCT00473317|UVB
1375355|NCT00473317|Vitamin D
1375356|NCT00473304|Safety
1375357|NCT00473304|Efficacy
1375358|NCT00473304|Adaptation
1375359|NCT00473304|myopia and contact lens wear in children
1375360|NCT00473291|pleural effusion
1375361|NCT00473291|lung sounds
1375362|NCT00473291|acoustic monitoring
1375363|NCT00473278|tear protein
1375364|NCT00473252|aspergillus infections
1375365|NCT00473252|immunosuppression
1375366|NCT00473252|kidney transplantation
1375367|NCT00473252|hemodialysis
1375368|NCT00473252|galactomannan test
1375369|NCT00473252|fine dust
1375370|NCT00473252|construction activity
1375371|NCT00473252|airborne aspergillus spores
1375372|NCT00473239|vitamin D
1375373|NCT00473239|cholecalciferol
1375374|NCT00473239|25-hydroxyvitamin D
1375375|NCT00473213|Multiple Sclerosis
1375376|NCT00473213|Interferon
1375377|NCT00473213|Magnetic Resonance
1375378|NCT00473200|hyperhomocysteinemia
1375379|NCT00473200|homocysteine
1375380|NCT00473200|S-adenosylmethionine
1375381|NCT00473200|SAMe
1375382|NCT00473200|Asymmetric dimethylagrinine (ADMA)
1375383|NCT00473187|X-linked dominant hypophosphatemic rickets
1375384|NCT00473187|growth disorders
1375385|NCT00473187|anthropometry
1375386|NCT00473187|human growth hormone
1375387|NCT00473174|Ramipril
1375388|NCT00473174|Ambulatory blood pressure monitoring
1375389|NCT00473174|Chronotherapy
1375390|NCT00473174|Circadian
1375391|NCT00473174|Non-dipper
1375392|NCT00473161|movement disorders
1375393|NCT00473161|childhood
1375394|NCT00473148|Duration of weaning from invasive ventilation
1375395|NCT00473148|Mechanical ventilation
1375396|NCT00473148|Weaning
1375397|NCT00473148|B-type natriuretic peptide
1375398|NCT00473148|Fluid balance
1375399|NCT00473148|Diuretics
1375400|NCT00473148|Intubated patient receiving mechanical ventilation
1375401|NCT00473148|for at least 24 hours
1375402|NCT00473148|Respiratory insufficiency
1375403|NCT00473135|Dengue Fever
1375404|NCT00473135|Dengue Vaccine
1375405|NCT00473135|Dengue Virus
1375406|NCT00473135|Dengue Hemorrhagic Fever
1375407|NCT00473135|Dengue Shock Syndrome
1375408|NCT00473122|Breast Cancer
1375409|NCT00473122|Breast Reconstruction
1375410|NCT00473122|Delayed-Immediate Reconstruction
1375411|NCT00473122|Postmastectomy Radiation Therapy
1375412|NCT00473122|Mastectomy
1375413|NCT00473122|XRT
1375414|NCT00473109|Hemodialysis
1375415|NCT00473109|Heparin
1375416|NCT00473109|Clotting
1375417|NCT00473096|Decision making
1375418|NCT00473096|Patient Education
1375419|NCT00473096|Indigency
1375420|NCT00473096|Minority group
1375421|NCT00473083|Rash
1375422|NCT00473083|Erlotinib
1375423|NCT00473083|Lung Cancer
1375424|NCT00473057|acute stroke
1375425|NCT00473057|middle cerebral artery
1375426|NCT00473057|autologous transplantation
1375427|NCT00473057|bone marrow cells
1375428|NCT00473057|stem cells
1375429|NCT00473057|cell therapy
1375430|NCT00473031|bone mass
1375431|NCT00473031|calcium absorption
1375432|NCT00473031|bone quality
1375433|NCT00473031|fracture risk
1375434|NCT00473018|postexposure prophylaxis
1375435|NCT00473018|HIV Seronegativity
1375436|NCT00472992|Pregnancy
1375437|NCT00472992|TYSABRI
1375438|NCT00472940|Cancer
1375439|NCT00472940|Hypogonadism
1375440|NCT00472940|testosterone
1375441|NCT00472940|cachexia
1375442|NCT00472914|Hypertonia
1375443|NCT00472914|Childhood
1375444|NCT00472901|Polymorphic Light Eruption (PLE)
1375445|NCT00472901|Afamelanotide
1375446|NCT00472901|CUV1647
1375447|NCT00472901|photoprotection
1375448|NCT00472901|sun poisoning
1375449|NCT00472888|Alpha-adrenergic blockers
1375450|NCT00472888|cataract surgery
1375451|NCT00472888|pseudoexfoliation syndrome
1375452|NCT00472888|diabetes mellitus
1375453|NCT00472888|hypertension
1375454|NCT00472888|pupil
1375455|NCT00472875|hypoglycaemia
1375456|NCT00472875|type 1 diabetes mellitus
1375457|NCT00472849|OFAR 2
1375458|NCT00472849|Oxaliplatin
1375459|NCT00472849|Fludarabine
1375460|NCT00472849|Cytarabine
1375461|NCT00472849|Ara-C
1375462|NCT00472849|Rituximab
1375463|NCT00472849|Richter's Transformation
1375464|NCT00472849|Prolymphocytic Leukemia
1375465|NCT00472849|B-Cell Chronic Lymphocytic Leukemia
1375466|NCT00472849|Leukemia
1375467|NCT00472849|CLL
1375468|NCT00472823|cholecalciferol
1375469|NCT00472823|vitamin D deficiency
1375470|NCT00472823|bone density
1375471|NCT00472823|dietary calcium
1375472|NCT00472823|hypercalcemia
1375473|NCT00472823|hypercalciuria
1375474|NCT00472810|Glaucoma
1375475|NCT00472810|Collagen matrix
1375476|NCT00472810|ologen
1375477|NCT00472810|OculusGen
1375478|NCT00472810|Antifibrotic
1375479|NCT00472810|Trabeculectomy
1375480|NCT00472810|anti scarring
1375481|NCT00472810|tissue engineering
1375482|NCT00472810|high risk patient for trabeculectomy
1375483|NCT00472810|Aeon Astron
1375484|NCT00472771|Recurrent extensive small cell lung cancer
1375485|NCT00472745|bone mass
1375486|NCT00472745|calcium absorption
1375487|NCT00472745|bone quality
1375488|NCT00472745|fracture risk
1375489|NCT00472745|arthritis
1375490|NCT00472745|osteoporosis
1375491|NCT00472732|UCD
1375492|NCT00472732|OTCD
1375493|NCT00472732|Ammonia
1375494|NCT00472732|Urea Metabolism
1375495|NCT00472732|Inborn Errors
1375496|NCT00472719|HIV Seronegativity
1375497|NCT00472719|HIV Preventive Vaccine
1375498|NCT00472719|Adenovirus
1375499|NCT00472706|Treatment
1375500|NCT00472706|Excision
1375501|NCT00472706|Photodynamic therapy
1375502|NCT00472706|Recurrence rate
1375503|NCT00472706|Cosmetic outcome
1375504|NCT00472693|Breast cancer
1375505|NCT00472693|Metastatic breast cancer
1375506|NCT00472693|Second-Line Therapy
1375507|NCT00472693|Triple Negative
1375508|NCT00472693|Her-2 negative
1375509|NCT00472693|Hormone receptor negative
1375510|NCT00472693|Abraxane
1375511|NCT00472693|Bevacizumab
1375512|NCT00472680|bone mass
1375513|NCT00472680|calcium absorption
1375514|NCT00472680|bone quality
1375515|NCT00472680|fracture risk
1375516|NCT00472667|Bacterial infections
1375517|NCT00472667|Procalcitonin
1375518|NCT00472667|Intensive care unit
1375519|NCT00472667|Antibiotic therapy
1375520|NCT00472667|Suspicion of bacterial infection or proven
1375521|NCT00472654|bone mass
1375522|NCT00472654|calcium absorption
1375523|NCT00472654|bone quality
1375524|NCT00472654|fracture risk
1375525|NCT00472615|Bipolar Disorder
1375526|NCT00472615|Menstrual Cycle
1375527|NCT00472615|Depression
1375528|NCT00472615|Mania or Hypomania
1375529|NCT00472615|Predictor
1375530|NCT00472602|Opisthorchis viverrini, liver fluke, Thailand, cancer
1375531|NCT00472576|NMDA Receptor
1375532|NCT00472576|Depression Treatment
1375533|NCT00472576|Unipolar Depression
1375534|NCT00472576|Treatment Resistant
1375535|NCT00472576|Glutamatergic
1375536|NCT00472576|Depression
1375537|NCT00472576|Major Depression
1375538|NCT00472563|bicarbonate
1375539|NCT00472563|nephropathy
1375540|NCT00472563|contrast
1375541|NCT00472550|esomeprazole, gastric emptying, reflux
1375542|NCT00472537|Ventral hernia
1375543|NCT00472537|Incisional hernia
1375544|NCT00472069|Stress Urinary Incontinence
1375545|NCT00472069|striated urethral sphincter insufficiency
1375546|NCT00472069|myofibers
1375547|NCT00472069|satellite cells
1375548|NCT00472069|myotubes
1375549|NCT00472069|urethral
1375550|NCT00472069|Muscle fibres
1375551|NCT00472056|Non-Hodgkin's Lymphoma
1375552|NCT00472056|Lymphoid Malignancies
1375553|NCT00472056|Lymphoma
1375554|NCT00472056|BEAM Chemotherapy
1375555|NCT00472056|Carmustine
1375556|NCT00472056|BCNU
1375557|NCT00472056|BiCNU
1375558|NCT00472056|Etoposide
1375559|NCT00472056|VePesid
1375560|NCT00472056|Cytarabine
1375561|NCT00472056|Cytosar
1375562|NCT00472056|DepoCyt
1375563|NCT00472056|Cytosine arabinosine hydrochloride
1375564|NCT00472056|Ara-C
1375565|NCT00472056|Melphalan
1375566|NCT00472056|Rituximab
1375567|NCT00472056|Rituxan
1375568|NCT00472043|Nodular Basal Cell Carcinoma
1375569|NCT00472043|Basal Cell Carcinoma
1375570|NCT00472043|Photodynamic therapy (PDT)
1375571|NCT00472043|Metvix
1375572|NCT00472043|Histological verification
1375573|NCT00472043|PDT with Metvix cream
1375574|NCT00472043|PDT with Placebo cream
1375575|NCT00472030|bullous pemphigoid
1375576|NCT00472030|omalizumab
1375577|NCT00472030|xolair
1375578|NCT00472030|IgE
1375579|NCT00472030|autoimmunity
1375580|NCT00472030|skin disease
1375581|NCT00472017|untreated childhood brain stem glioma
1375582|NCT00471991|Oral contraceptive
1375583|NCT00471991|ovulation inhibitory effect
1375584|NCT00471978|non-small cell lung cancer
1375585|NCT00471978|small cell lung cancer
1375586|NCT00471978|pulmonary carcinoid tumor
1375587|NCT00471952|Migraine
1375588|NCT00471939|Burn, Meshed skin graft, PDGF
1375589|NCT00471939|deep partial thickness or full thickness burns
1375590|NCT00471926|Diabetes Care
1375591|NCT00471913|Femur
1375592|NCT00471913|Fracture
1375593|NCT00471913|Antegrade
1375594|NCT00471913|Nailing
1375595|NCT00471913|Shaft
1375596|NCT00471913|Abductor
1375597|NCT00471887|stage III melanoma
1375598|NCT00471887|stage IV melanoma
1375599|NCT00471887|recurrent melanoma
1375600|NCT00471861|Inflammatory Markers
1375601|NCT00471861|Migraine
1375602|NCT00471848|Thymoglobuline
1375603|NCT00471848|Rabbit ATG
1375604|NCT00471848|Ciclosporin
1375605|NCT00471848|Aplastic Anemia
1375606|NCT00472498|Cardiac Arrest
1375607|NCT00472498|Biphasic Defibrillator
1375608|NCT00472472|restenosis
1375609|NCT00472472|peripheral arterial disease
1375610|NCT00472472|paccocath
1375611|NCT00472472|drug-coated balloon
1375612|NCT00472459|Non-melanoma skin cancer
1375613|NCT00472459|Organ transplant recipients
1375614|NCT00472459|Photodynamic therapy
1375615|NCT00472459|Actinic keratosis
1375616|NCT00472446|Surgery
1375617|NCT00472446|Thyroid gland
1375618|NCT00472446|cervical block
1375619|NCT00472446|Pain, Postoperative
1375620|NCT00472433|Alemtuzumab in autoimmune cytopenias
1375621|NCT00472407|Normal
1375622|NCT00472394|Medical abortion
1375623|NCT00472394|Preferences
1375624|NCT00472394|Willingness to Pay
1375625|NCT00472381|Acute Ischemic Stroke
1375626|NCT00472381|Post-Stroke Hyperglycaemia
1375627|NCT00472381|Insulin treatment
1375628|NCT00472381|Insulin
1375629|NCT00472381|DWI
1375630|NCT00472381|MRI
1375631|NCT00472368|Advanced cancer
1375632|NCT00472368|lymphoma
1375633|NCT00472368|chronic hematological malignancies
1375634|NCT00472368|adult
1375635|NCT00472355|Parkinson's disease
1375636|NCT00472355|PD
1375637|NCT00472355|apomorphine
1375638|NCT00472342|impaired glucose tolerance
1375639|NCT00472342|impaired fasting glucose
1375640|NCT00472342|diabetes
1375641|NCT00472342|adipokine
1375642|NCT00472342|adiponectin
1375643|NCT00472342|RBP-4
1375644|NCT00472342|adrenomedullin
1375645|NCT00472303|Opioid
1375646|NCT00472303|Central acting analgesic
1375647|NCT00472303|CG5503 PR
1375648|NCT00472303|Tumor related pain
1375649|NCT00472303|Cancer related pain
1375650|NCT00472303|Morphine
1375651|NCT00472303|Pain assessment
1375652|NCT00472303|Placebo
1375653|NCT00472290|Hematology
1375654|NCT00472290|MDS
1375655|NCT00472290|Myelodysplastic Syndromes
1375656|NCT00472290|Thrombocytopenia
1375657|NCT00472264|methodology study, PET Imaging, COPD patients
1375658|NCT00472251|dutasteride
1375659|NCT00472251|body mass index
1375660|NCT00472251|testosterone
1375661|NCT00472225|Chronic graft-versus-host disease
1375662|NCT00472225|rituximab
1375663|NCT00472186|Tonsillectomy
1375664|NCT00472186|Pain
1375665|NCT00472173|Apexification
1375666|NCT00472173|Pulp necrosis
1375667|NCT00472173|Calcium hydroxide
1375668|NCT00472173|MTA
1375669|NCT00472173|pulp necrosis of an anterior immature tooth
1375670|NCT00472160|Preoxygenation
1375671|NCT00472160|Non Invasive Ventilation
1375672|NCT00472160|Continuous Positive Airway Pressure,
1375673|NCT00472160|Intubation,
1375674|NCT00472160|Organ failure
1375675|NCT00472134|Hernia
1375676|NCT00472134|Ventral
1375677|NCT00472134|Laparoscopic Hernia Repair
1375678|NCT00472108|Nodular Basal Cell Carcinoma
1375679|NCT00472108|Basal Cell Carcinoma
1375680|NCT00472108|PDT with Metvix 160 mg/g cream
1375681|NCT00472108|PDT with placebo cream
1375682|NCT00472108|Histological verification
1375683|NCT00472095|diabetes
1375684|NCT00472095|fotonovela
1375685|NCT00472095|Latino
1375686|NCT00472082|Immunosuppression
1375687|NCT00472082|Renal Transplantation
1375688|NCT00471835|stage II non-small cell lung cancer
1375689|NCT00471835|stage I non-small cell lung cancer
1375690|NCT00471835|adenocarcinoma of the lung
1375691|NCT00471835|adenosquamous cell lung cancer
1375692|NCT00471835|large cell lung cancer
1375693|NCT00471835|squamous cell lung cancer
1375694|NCT00471822|Streptococcus pneumoniae nasopharyngeal carriage
1375695|NCT00471796|Patients with functional chest pain and functional heartburns
1375696|NCT00471783|gingivitis
1375697|NCT00471783|chlorhexidine
1375698|NCT00471783|dental floss
1375699|NCT00471783|RCT
1375700|NCT00471783|bleeding on probing
1375701|NCT00471783|gingival and plaque indices
1375702|NCT00471757|pnuemonia
1375703|NCT00471757|influenca
1375704|NCT00471744|benign epilepsy
1375705|NCT00471744|pediatrics
1375706|NCT00471744|children
1375707|NCT00471744|rolandic epilepsy
1375708|NCT00471744|levetiracetam
1375709|NCT00471744|sulthiame
1375710|NCT00471731|Ocular Surface Disease
1375711|NCT00471731|Imprinting
1375712|NCT00471731|Eye Abnormalities
1375713|NCT00471731|Ovarian Insufficiency
1375714|NCT00471731|Women's Eye Health and Disease
1375715|NCT00471731|Turner Syndrome
1375716|NCT00471731|TS
1375717|NCT00471731|Premature Ovarian Failure
1375718|NCT00471731|POF
1375719|NCT00471731|Healthy Volunteer
1375720|NCT00471731|HV
1375721|NCT00471718|adenocarcinoma of the prostate
1375722|NCT00471718|stage IV prostate cancer
1375723|NCT00471718|recurrent prostate cancer
1375724|NCT00471705|Miltefosine
1375725|NCT00471705|Leishmaniasis
1375726|NCT00471705|Glucantime
1375727|NCT00471705|Thermotherapy
1375728|NCT00471705|Colombia
1375729|NCT00471679|disseminated neuroblastoma
1375730|NCT00471679|localized unresectable neuroblastoma
1375731|NCT00471679|recurrent neuroblastoma
1375732|NCT00471679|regional neuroblastoma
1375733|NCT00471679|stage 4S neuroblastoma
1375734|NCT00471666|Malaria
1375735|NCT00471666|Filariasis
1375736|NCT00471666|Coinfection
1375737|NCT00471666|Co-Infection
1375738|NCT00471653|thrombocytopenia
1375739|NCT00471653|adult anaplastic oligodendroglioma
1375740|NCT00471653|adult brain stem glioma
1375741|NCT00471653|adult mixed glioma
1375742|NCT00471653|adult giant cell glioblastoma
1375743|NCT00471653|adult gliosarcoma
1375744|NCT00471653|adult glioblastoma
1375745|NCT00471653|adult anaplastic astrocytoma
1375746|NCT00471653|adult anaplastic ependymoma
1375747|NCT00471653|adult pineal gland astrocytoma
1375748|NCT00471640|pneumonia
1375749|NCT00471640|dexamethasone
1375750|NCT00471640|community-acquired pneumonia
1375751|NCT00471614|HIV
1375752|NCT00471614|AIDS
1375753|NCT00471614|uridine
1375754|NCT00471614|mitochondria
1375755|NCT00471614|insulin resistance
1375756|NCT00471614|Treatment Experienced
1375757|NCT00471601|recurrent breast cancer
1375758|NCT00471601|stage IA breast cancer
1375759|NCT00471601|stage IB breast cancer
1375760|NCT00471601|stage II breast cancer
1375761|NCT00471601|stage IIIA breast cancer
1375762|NCT00471601|stage IIIB breast cancer
1375763|NCT00471601|stage IIIC breast cancer
1375764|NCT00471601|stage IV breast cancer
1375765|NCT00471588|Dopamine
1375766|NCT00471588|OCD
1375767|NCT00471588|MRI
1375768|NCT00471588|stimulant users
1375769|NCT00471575|fatty liver
1375770|NCT00471575|pregnancy
1375771|NCT00471575|ultra sound
1375772|NCT00471575|Pregnant women at the end of pregnancy or immediately after birth.
1375773|NCT00471575|controls-women with normal liver
1375774|NCT00471575|correlation between ultrasonography and nutritional, obsthetric and laboratory data.
1375775|NCT00471562|unspecified adult solid tumor, protocol specific
1375776|NCT00471549|Diabetes
1375777|NCT00471549|Dyslipidaemia
1375778|NCT00471549|Atherosclerosis
1375779|NCT00471549|Osteoprotegerin
1375780|NCT00471549|Adhesion molecules
1375781|NCT00471549|Simvastatin
1375782|NCT00471523|Anovulation
1375783|NCT00471523|Clomiphene citrate
1375784|NCT00471523|Infertility
1375785|NCT00471523|Metformin
1375786|NCT00471523|PCOS
1375787|NCT00471523|Treatment
1375788|NCT00471510|androgenetic alopecia
1375789|NCT00471510|male pattern hair loss
1375790|NCT00471510|male pattern baldness
1375791|NCT00471510|androgenetic alopecia or male pattern hair loss
1375792|NCT00471497|leukemia
1375793|NCT00471497|bone marrow
1375794|NCT00471497|leukemia symptoms
1375795|NCT00471497|lukemia
1375796|NCT00471497|cml
1375797|NCT00471497|complete blood count
1375798|NCT00471497|lymphocyte
1375799|NCT00471497|blood cancer
1375800|NCT00471497|leukocytes
1375801|NCT00471497|chronic leukemia
1375802|NCT00471497|bone marrow biopsy
1375803|NCT00471497|leukemia research
1375804|NCT00471497|leukemia cells
1375805|NCT00471497|bone marrow disease
1375806|NCT00471497|chronic myeloid leukemia
1375807|NCT00471497|blood cancer symptoms
1375808|NCT00471497|white blood cell diseases
1375809|NCT00471497|chronic myelogenous leukemia
1375810|NCT00471497|leukemia treatment
1375811|NCT00471497|leukemia facts
1375812|NCT00471497|leucemia
1375813|NCT00471497|facts about leukemia
1375814|NCT00471497|myelogenous leukemia
1375815|NCT00471497|newly diagnosed CML
1375816|NCT00471497|newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
1375817|NCT00471484|adult primary hepatocellular carcinoma
1375818|NCT00471484|localized unresectable adult primary liver cancer
1375819|NCT00471484|advanced adult primary liver cancer
1375820|NCT00471484|childhood hepatocellular carcinoma
1375821|NCT00471484|stage III childhood liver cancer
1375822|NCT00471484|stage IV childhood liver cancer
1375834|NCT00471458|Radioiodine
1375835|NCT00471458|Hyperthyroidism
1375836|NCT00471458|Morbidity
1375837|NCT00471458|Cardiovascular diseases
1375838|NCT00471445|unspecified adult solid tumor, protocol specific
1375839|NCT00471445|pain
1375840|NCT00471445|neurotoxicity
1375841|NCT00471445|peripheral neuropathy
1375842|NCT00471432|recurrent prostate cancer
1375843|NCT00471432|stage IV prostate cancer
1375844|NCT00471432|recurrent renal cell cancer
1375845|NCT00471432|stage IV renal cell cancer
1375846|NCT00471432|recurrent non-small cell lung cancer
1375847|NCT00471432|stage IV non-small cell lung cancer
1375848|NCT00471432|recurrent bladder cancer
1375849|NCT00471432|stage IV bladder cancer
1375850|NCT00471432|recurrent breast cancer
1375851|NCT00471432|stage IV breast cancer
1375852|NCT00471432|recurrent ovarian epithelial cancer
1375853|NCT00471432|stage IV ovarian epithelial cancer
1375854|NCT00471432|unspecified adult solid tumor, protocol specific
1375855|NCT00471432|male breast cancer
1375856|NCT00471393|TMJ
1375857|NCT00471393|Osteoarthritis
1375858|NCT00471393|Degenerative Joint disease
1375859|NCT00471367|Phase I
1375860|NCT00471367|AZD4877
1375861|NCT00471367|Lymphoma
1375862|NCT00471367|B-cell non-Hodgkin lymphoma
1375863|NCT00471341|arteriosclerosis
1375864|NCT00471341|coronary disease
1375865|NCT00471341|inflammation
1375866|NCT00471341|COX-2 inhibition
1375867|NCT00471341|hypertension
1375868|NCT00471328|GIST
1375869|NCT00471328|adults
1375870|NCT00471328|imatinib resistant
1375871|NCT00471328|sunitinib resistant
1375872|NCT00471328|AMN107
1375873|NCT00471328|nilotinib
1375874|NCT00471328|treatment
1375875|NCT00471328|Gastrointestinal stromal tumor (GIST)
1375876|NCT00471315|SOD
1375877|NCT00471315|Common Bile Duct Diseases
1375878|NCT00471315|Sphincterotomy
1375879|NCT00471315|Cholangiopancreatography, Endoscopic Retrograde
1375880|NCT00471302|Healthy Volunteers
1375881|NCT00471302|Immunological Parameters
1375882|NCT00471302|Mali
1375883|NCT00471302|B Lymphocyte
1375884|NCT00471302|Malaria
1375885|NCT00471302|Healthy Volunteer
1375886|NCT00471289|Critical Limb Ischemia
1375887|NCT00471289|Stents
1375888|NCT00471289|Drug Eluting Stents
1375889|NCT00471289|Peripheral arterial disease
1375890|NCT00471289|PAD
1375891|NCT00471289|Paclitaxel
1375892|NCT00471289|TAXUS
1375893|NCT00471289|Infrapopliteal
1375894|NCT00471289|Infragenicular
1375895|NCT00471289|Interventional Radiology
1375896|NCT00471289|CLI
1375897|NCT00471289|DES
1375898|NCT00471276|Metastatic Breast Cancer
1375899|NCT00471250|Bronchoscopy
1375900|NCT00471250|Bronchoalveolar Lavage
1375901|NCT00471250|Nasal Mucosal Biopsy
1375902|NCT00471250|Research Procedures
1375903|NCT00471250|Infection Susceptibility
1375904|NCT00471250|Lung Infection Susceptibility
1375905|NCT00471250|Healthy Volunteer
1375906|NCT00471250|HV
1375907|NCT00471237|bone mineral density,
1375908|NCT00471237|Ronacaleret
1375909|NCT00471237|teriparatide
1375910|NCT00471237|alendronate,
1375911|NCT00471237|Post-menopausal women,
1375912|NCT00471237|osteoporosis,
1375913|NCT00471237|SB-751689
1375914|NCT00471185|Male Contraception
1375915|NCT00471185|Acyline
1375916|NCT00471146|Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For Advanced Pancreatic Cancer.
1375917|NCT00471133|melanoma
1375918|NCT00471133|DNA vaccine
1375919|NCT00471133|tyrosinase
1375920|NCT00471133|electroporation
1375921|NCT00471107|Frontal Lobe
1375922|NCT00471107|Language
1375923|NCT00471107|Dementia
1375924|NCT00471107|Healthy Volunteer
1375925|NCT00471107|HV
1375926|NCT00471094|heartburn
1375927|NCT00471094|erosive esophagitis
1375928|NCT00471094|healing
1375929|NCT00471094|population pharmacokinetics
1375930|NCT00471094|Quality of Life (QoL)
1375931|NCT00471081|Neisseria meningitidis;
1375932|NCT00471081|Humans;
1375933|NCT00471081|Meningococcal vaccines;
1375934|NCT00471081|Safety
1375935|NCT00471081|Vaccines, conjugate;
1375936|NCT00471081|Toddlers;
1375937|NCT00471081|Immunogenicity;
1375938|NCT00471055|osteoarthritis
1375939|NCT00471055|knee
1375940|NCT00471055|capsaicin gel
1375941|NCT00471055|capsicum
1375942|NCT00471042|Heroin Dependence
1375943|NCT00471042|Opioid Dependence
1375944|NCT00471042|Primary Care
1375945|NCT00471042|Buprenorphine
1375946|NCT00471029|pH study, peptic ulcer, proton pump inhibitor
1375947|NCT00471003|Hypertension
1375948|NCT00470990|IHH
1375949|NCT00470990|Kallmann syndrome
1375950|NCT00470990|hypogonadism
1375951|NCT00470964|laser trabeculoplasty, glaucoma, argon, titanium-sapphire
1375952|NCT00470964|IOP lowering effect
1375953|NCT00470964|Adverse effects
1375954|NCT00470964|IOP spikes
1375955|NCT00470951|rectal cancer
1375956|NCT00470951|laparoscopic assisted resection
1375957|NCT00470951|open resection
1375958|NCT00470951|preoperative chemoradiation
1375959|NCT00470951|randomized trial
1375960|NCT00470925|Neurological
1375961|NCT00470925|Dopamine
1375962|NCT00470912|cutaneous lupus erythemaosus
1375963|NCT00470912|photoprotection
1375964|NCT00470912|photoprovocation
1375965|NCT00470912|Sunscreen RV 2547C
1375966|NCT00470899|Feto-maternal transfusion
1375967|NCT00470899|Kleihauer-Betke
1375968|NCT00470847|Herceptin
1375969|NCT00470847|breast cancer
1375970|NCT00470847|radiation therapy
1375971|NCT00470847|stereotactic radiosurgery
1375972|NCT00470847|SRS
1375973|NCT00470847|whole brain radiation
1375974|NCT00470847|WBRT
1375975|NCT00470834|prostate cancer
1375976|NCT00470834|androgen deprivation therapy
1375977|NCT00470821|melatonin
1375978|NCT00470821|actigraphy
1375979|NCT00470821|sedation
1375980|NCT00470821|critical patients
1375981|NCT00470821|ICU
1375982|NCT00470808|Minors
1375983|NCT00470808|Enrollment in another study
1375984|NCT00470808|Males
1375985|NCT00470808|HBA1C greater than 7
1375986|NCT00470808|Drug therapy for DM
1375987|NCT00470795|diabetes
1375988|NCT00470795|gastroparesis
1375989|NCT00470795|acupuncture
1375990|NCT00470795|symptoms
1375991|NCT00470795|gastric emptying
1375992|NCT00470782|colonic neoplasms
1375993|NCT00470782|exercise
1375994|NCT00470782|body composition
1375995|NCT00470782|anthropometry
1375996|NCT00470769|Color-Doppler Ultrasonography
1375997|NCT00470769|Renal scintigraphy
1375998|NCT00470769|Kidney failure
1375999|NCT00470769|GFR
1376000|NCT00470743|Ibuprofen
1376001|NCT00470743|Indomethacin
1376002|NCT00470743|Infant, very low birth weight
1376003|NCT00470743|Prematurity
1376004|NCT00470743|Ductus Arteriosus, patent
1376005|NCT00470717|late preterm infant
1376006|NCT00470717|breastfeeding
1376007|NCT00470717|formula feeding
1376008|NCT00470717|rehospitalization
1376009|NCT00470717|telephone
1376010|NCT00470704|HER2-positive breast cancer
1376011|NCT00470704|Herceptin
1376012|NCT00470704|trastuzumab
1376013|NCT00470678|Age-related
1376014|NCT00470678|macular
1376015|NCT00470678|degeneration
1376016|NCT00470678|AMD
1376017|NCT00470678|Ranibizumab
1376018|NCT00470678|Anti-VEGF
1376019|NCT00470678|choroidal
1376020|NCT00470678|neovascularization
1376021|NCT00470678|CNV
1376022|NCT00470678|Asian patients
1376023|NCT00470678|Korea
1376024|NCT00470678|Taiwan
1376025|NCT00470678|associated
1376026|NCT00470652|pain
1376027|NCT00470652|Pain Measurement
1376028|NCT00470652|Decision Making, Computer-Assisted
1376029|NCT00470652|Informatics
1376030|NCT00470639|TMS
1376031|NCT00470639|Treatment
1376032|NCT00470639|Bipolar
1376033|NCT00470639|Efficacy
1376034|NCT00470626|Pulmonary Embolism
1376035|NCT00470626|Venous Thromboembolism
1376036|NCT00470626|Inferior Vena Cava Filter
1376037|NCT00470626|IVC
1376038|NCT00470626|PE
1376039|NCT00470613|Neoplasm
1376040|NCT00470587|chest pain
1376041|NCT00470587|myocardial infarction
1376042|NCT00470587|unstable angina
1376043|NCT00470574|recurrent breast cancer
1376044|NCT00470574|stage IV breast cancer
1376045|NCT00470574|male breast cancer
1376046|NCT00470561|mammographic breast density aspirin
1376047|NCT00470548|male breast cancer
1376048|NCT00470548|recurrent breast cancer
1376049|NCT00470548|stage IIIA breast cancer
1376050|NCT00470548|stage IIIB breast cancer
1376051|NCT00470548|stage IIIC breast cancer
1376052|NCT00470548|stage IV breast cancer
1376053|NCT00470548|stage IIIA non-small cell lung cancer
1376054|NCT00470548|stage IIIB non-small cell lung cancer
1376055|NCT00470548|stage IV non-small cell lung cancer
1376056|NCT00470548|recurrent non-small cell lung cancer
1376057|NCT00470548|unspecified adult solid tumor, protocol specific
1376058|NCT00470535|adenocarcinoma of the pancreas
1376059|NCT00470535|recurrent pancreatic cancer
1376060|NCT00470535|stage III pancreatic cancer
1376061|NCT00470535|stage IV pancreatic cancer
1376062|NCT00470522|methotrexate
1376063|NCT00470522|folic acid
1376064|NCT00470522|systemic lupus erythematosus
1376065|NCT00470522|steroid
1376066|NCT00470483|PET
1376067|NCT00470483|Social Anxiety Disorder
1376068|NCT00470483|fRMI
1376069|NCT00470444|Cardiac Surgery
1376070|NCT00470444|Transfusion Medicine
1376071|NCT00470444|Cardiac Anesthesia Risk Evaluation (CARE) Score of 3 or 4
1376072|NCT00470444|(Dupuis J-Y et al, Anesthesiology 2001;94: 194-204)
1376073|NCT00470418|Alzheimer Disease
1376074|NCT00470418|Alzheimer Type Senile Dementia
1376075|NCT00470418|Alzheimer's Disease
1376076|NCT00470418|clinical trial
1376077|NCT00470418|dementia
1376078|NCT00470418|diabetes
1376079|NCT00470418|dietary supplements
1376080|NCT00470418|Senile Dementia, Alzheimer Type
1376081|NCT00470418|Therapeutics
1376082|NCT00470405|adult solid tumor
1376083|NCT00470405|unspecified adult solid tumor, protocol specific
1376084|NCT00470405|stage IV adult Hodgkin lymphoma
1376085|NCT00470405|anaplastic large cell lymphoma
1376086|NCT00470405|angioimmunoblastic T-cell lymphoma
1376087|NCT00470405|cutaneous B-cell non-Hodgkin lymphoma
1376088|NCT00470405|stage IV cutaneous T-cell non-Hodgkin lymphoma
1376089|NCT00470405|adult nasal type extranodal NK/T-cell lymphoma
1376090|NCT00470405|adult grade III lymphomatoid granulomatosis
1376091|NCT00470405|Waldenstrom macroglobulinemia
1376092|NCT00470405|stage IV adult Burkitt lymphoma
1376093|NCT00470405|stage IV adult diffuse large cell lymphoma
1376094|NCT00470405|stage IV adult diffuse mixed cell lymphoma
1376095|NCT00470405|stage IV adult diffuse small cleaved cell lymphoma
1376096|NCT00470405|stage IV adult immunoblastic large cell lymphoma
1376097|NCT00470405|stage IV adult lymphoblastic lymphoma
1376098|NCT00470405|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1376099|NCT00470405|stage IV grade 1 follicular lymphoma
1376100|NCT00470405|stage IV grade 2 follicular lymphoma
1376101|NCT00470405|stage IV grade 3 follicular lymphoma
1376102|NCT00470405|stage IV mantle cell lymphoma
1376103|NCT00470405|nodal marginal zone B-cell lymphoma
1376104|NCT00470405|stage IV marginal zone lymphoma
1376105|NCT00470405|stage IV small lymphocytic lymphoma
1376106|NCT00470405|recurrent adult grade III lymphomatoid granulomatosis
1376107|NCT00470405|recurrent adult Burkitt lymphoma
1376108|NCT00470405|recurrent adult diffuse large cell lymphoma
1376109|NCT00470405|recurrent adult diffuse mixed cell lymphoma
1376215|NCT00470262|Inflammation
1376110|NCT00470405|recurrent adult diffuse small cleaved cell lymphoma
1376111|NCT00470405|recurrent adult Hodgkin lymphoma
1376112|NCT00470405|recurrent adult immunoblastic large cell lymphoma
1376113|NCT00470405|recurrent adult lymphoblastic lymphoma
1376114|NCT00470405|recurrent cutaneous T-cell non-Hodgkin lymphoma
1376115|NCT00470405|recurrent grade 1 follicular lymphoma
1376116|NCT00470405|recurrent grade 2 follicular lymphoma
1376117|NCT00470405|recurrent grade 3 follicular lymphoma
1376118|NCT00470405|recurrent mantle cell lymphoma
1376119|NCT00470405|splenic marginal zone lymphoma
1376120|NCT00470405|recurrent marginal zone lymphoma
1376121|NCT00470405|recurrent small lymphocytic lymphoma
1376122|NCT00470405|recurrent mycosis fungoides/Sezary syndrome
1376123|NCT00470405|stage IV mycosis fungoides/Sezary syndrome
1376124|NCT00470392|Erythema
1376125|NCT00470392|optimization
1376126|NCT00470392|Papule
1376127|NCT00470392|Plaque
1376128|NCT00470392|pretreatment
1376129|NCT00470392|T cells
1376130|NCT00470392|UVB laser light
1376131|NCT00470392|psoriasis
1376132|NCT00470392|topical administration
1376133|NCT00470379|stage II melanoma
1376134|NCT00470379|stage III melanoma
1376135|NCT00470379|stage IV melanoma
1376136|NCT00470366|stage II malignant testicular germ cell tumor
1376137|NCT00470366|stage III malignant testicular germ cell tumor
1376138|NCT00470366|testicular choriocarcinoma and embryonal carcinoma
1376139|NCT00470366|testicular choriocarcinoma and seminoma
1376140|NCT00470366|testicular choriocarcinoma and teratoma
1376141|NCT00470366|testicular choriocarcinoma and yolk sac tumor
1376142|NCT00470366|testicular choriocarcinoma
1376143|NCT00470366|testicular embryonal carcinoma and seminoma
1376144|NCT00470366|testicular embryonal carcinoma and teratoma with seminoma
1376145|NCT00470366|testicular embryonal carcinoma and teratoma
1376146|NCT00470366|testicular embryonal carcinoma and yolk sac tumor with seminoma
1376147|NCT00470366|testicular embryonal carcinoma and yolk sac tumor
1376148|NCT00470366|testicular embryonal carcinoma
1376149|NCT00470366|testicular seminoma
1376150|NCT00470366|testicular yolk sac tumor and teratoma with seminoma
1376151|NCT00470366|testicular yolk sac tumor and teratoma
1376152|NCT00470366|testicular yolk sac tumor
1376153|NCT00470366|stage I malignant testicular germ cell tumor
1376154|NCT00470366|adult central nervous system germ cell tumor
1376155|NCT00470366|ovarian choriocarcinoma
1376156|NCT00470366|ovarian dysgerminoma
1376157|NCT00470366|ovarian embryonal carcinoma
1376158|NCT00470366|ovarian yolk sac tumor
1376159|NCT00470366|ovarian immature teratoma
1376160|NCT00470366|ovarian mature teratoma
1376161|NCT00470366|ovarian monodermal and highly specialized teratoma
1376162|NCT00470366|ovarian polyembryoma
1376163|NCT00470366|ovarian mixed germ cell tumor
1376164|NCT00470366|stage IV ovarian germ cell tumor
1376165|NCT00470366|stage IV extragonadal seminoma
1376166|NCT00470366|stage I extragonadal non-seminomatous germ cell tumor
1376167|NCT00470366|stage II extragonadal non-seminomatous germ cell tumor
1376168|NCT00470366|stage III extragonadal non-seminomatous germ cell tumor
1376169|NCT00470366|stage IV extragonadal non-seminomatous germ cell tumor
1376170|NCT00470366|adult teratoma
1376171|NCT00470366|testicular immature teratoma
1376172|NCT00470366|testicular mature teratoma
1376173|NCT00470366|stage IA ovarian germ cell tumor
1376174|NCT00470366|stage IB ovarian germ cell tumor
1376175|NCT00470366|stage IC ovarian germ cell tumor
1376176|NCT00470366|stage IIA ovarian germ cell tumor
1376177|NCT00470366|stage IIB ovarian germ cell tumor
1376178|NCT00470366|stage IIC ovarian germ cell tumor
1376179|NCT00470366|stage IIIA ovarian germ cell tumor
1376180|NCT00470366|stage IIIB ovarian germ cell tumor
1376181|NCT00470366|stage IIIC ovarian germ cell tumor
1376182|NCT00470353|recurrent colon cancer
1376183|NCT00470353|stage I colon cancer
1376184|NCT00470353|stage II colon cancer
1376185|NCT00470353|stage III colon cancer
1376186|NCT00470340|Recurrence
1376187|NCT00470340|Neoplasm Recurrence, Local
1376188|NCT00470340|Liver
1376189|NCT00470340|Liver Neoplasms
1376190|NCT00470340|Liver Cirrhosis
1376191|NCT00470340|Carcinoma, Hepatocellular
1376192|NCT00470340|Iodized Oil
1376193|NCT00470340|gemcitabine [Substance Name]
1376194|NCT00470340|oxaliplatin [Substance Name]
1376195|NCT00470340|gemcitabine-oxaliplatin regimen [Substance Name]
1376196|NCT00470340|Randomized Controlled Trials
1376197|NCT00470340|Multicenter Studies
1376198|NCT00470340|Cisplatin
1376199|NCT00470340|Injections, Intra-Arterial
1376200|NCT00470340|Injections, Intravenous
1376201|NCT00470340|Chemotherapy, Adjuvant
1376202|NCT00470327|Interstitial lung diseases
1376203|NCT00470327|idiopathic pulmonary fibrosis
1376204|NCT00470327|Sarcoidosis
1376205|NCT00470327|mRNA and cytokine expression
1376206|NCT00470314|Acute liver failure
1376207|NCT00470314|Ornithine Aspartate
1376208|NCT00470314|Ammonia
1376209|NCT00470314|Encephalopathy
1376210|NCT00470288|cesarean delivery
1376211|NCT00470288|bladder flaps
1376212|NCT00470275|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1376213|NCT00470262|fatty acid oxidation complex
1376214|NCT00470262|fenofibrate
1376216|NCT00470262|Peroxisome Proliferator-Activated Receptors
1376217|NCT00470262|pioglitazone
1376218|NCT00470262|Prediabetic State
1376219|NCT00470262|insulin resistance
1376220|NCT00470249|stage IIIB breast cancer
1376221|NCT00470249|stage IIIC breast cancer
1376222|NCT00470249|stage IV breast cancer
1376223|NCT00470249|recurrent breast cancer
1376224|NCT00470249|male breast cancer
1376225|NCT00470249|stage IIIA breast cancer
1376226|NCT00470236|Ductal carcinoma in-situ
1376227|NCT00470236|Breast conserving therapy
1376228|NCT00470236|Whole breast radiation therapy
1376229|NCT00470236|Tumour bed boost
1376230|NCT00470236|Fractionation schedules
1376231|NCT00470236|Completely excised non-low risk DCIS
1376232|NCT00470223|localized osteosarcoma
1376233|NCT00470223|metastatic osteosarcoma
1376234|NCT00470210|Ribavirin
1376235|NCT00470210|non-responders
1376236|NCT00470210|HCV co-infected patients
1376237|NCT00470210|sustained virological response
1376238|NCT00470210|Treatment Experienced
1376239|NCT00470184|adenocarcinoma of the esophagus
1376240|NCT00470184|squamous cell carcinoma of the esophagus
1376241|NCT00470184|stage II esophageal cancer
1376242|NCT00470184|stage III esophageal cancer
1376243|NCT00470184|stage IV esophageal cancer
1376244|NCT00470158|zinc
1376245|NCT00470158|iron
1376246|NCT00470158|interaction
1376247|NCT00470158|diarrhea
1376248|NCT00470158|delivery
1376249|NCT00470145|unmilled formulation,
1376250|NCT00470145|micronised formulation
1376251|NCT00470145|relative bioavailability,
1376252|NCT00470132|ventricular shunt
1376253|NCT00470119|breast cancer
1376254|NCT00470119|obesity
1376255|NCT00470119|weight changes
1376256|NCT00470106|Cognition
1376257|NCT00470106|Remediation
1376258|NCT00470106|Schizophrenia
1376259|NCT00470106|Social Cognition
1376260|NCT00470093|refractory multiple myeloma
1376261|NCT00470093|stage I multiple myeloma
1376262|NCT00470093|stage II multiple myeloma
1376263|NCT00470093|stage III multiple myeloma
1376264|NCT00470080|Venepuncture
1376265|NCT00470080|Pain
1376266|NCT00470080|Emla cream
1376267|NCT00470080|Oral sucrose solution
1376268|NCT00470080|Premature infant
1376269|NCT00470080|Premature infant admitted to the care baby unit were
1376270|NCT00470080|included in the study.
1376271|NCT00470080|Programed venepuncture is performed with analgesia.
1376272|NCT00470067|recurrent endometrial carcinoma
1376273|NCT00470067|stage III endometrial carcinoma
1376274|NCT00470067|stage IV endometrial carcinoma
1376275|NCT00470041|Healthy volunteers
1376276|NCT00470028|TMS
1376277|NCT00470028|Treatment
1376278|NCT00470028|Adolescents
1376279|NCT00470028|Safety
1376280|NCT00470028|Efficacy
1376281|NCT00470015|stage II melanoma
1376282|NCT00470015|stage III melanoma
1376283|NCT00470015|stage IV melanoma
1376284|NCT00470015|recurrent melanoma
1376285|NCT00470002|growth hormone
1376286|NCT00470002|nitric oxide
1376287|NCT00470002|nitrate
1376288|NCT00470002|cyclic guanosine monophosphate
1376289|NCT00470002|insulin-like growth factor-1
1376290|NCT00470002|asymmetric dimethylarginine
1376291|NCT00470002|blood pressure
1376292|NCT00470002|endothelial progenitor cells
1376293|NCT00469989|immune system
1376294|NCT00469989|allergy
1376295|NCT00469989|hookworm infection
1376296|NCT00469989|parasite infection
1376297|NCT00469989|asthma
1376298|NCT00469976|stage IIIB non-small cell lung cancer
1376299|NCT00469976|stage IV non-small cell lung cancer
1376300|NCT00469976|recurrent non-small cell lung cancer
1376301|NCT00469963|adult primary hepatocellular carcinoma
1376302|NCT00469963|localized unresectable adult primary liver cancer
1376303|NCT00469963|recurrent adult primary liver cancer
1376304|NCT00469963|advanced adult primary liver cancer
1376305|NCT00469950|PCI
1376306|NCT00469950|stent
1376307|NCT00469950|training
1376308|NCT00469950|endothelial function
1376309|NCT00469950|restenosis
1376310|NCT00469950|late luminal loss
1376311|NCT00469950|heart rate variability
1376312|NCT00469950|oxygen uptake capacity
1376313|NCT00469950|inflammatory markers
1376314|NCT00469937|radiation toxicity
1376315|NCT00469937|neurotoxicity
1376316|NCT00469937|cognitive/functional effects
1376317|NCT00469937|unspecified adult solid tumor, protocol specific
1376318|NCT00469937|adult tumors metastatic to brain
1376319|NCT00469924|Informatics
1376320|NCT00469924|Clinical Laboratory Information Systems
1376321|NCT00469924|Hospital Communication Systems
1376322|NCT00469924|Laboratory Techniques and Procedures
1376323|NCT00469924|Point-of-Care Systems
1376324|NCT00469924|Therapy, Computer-Assisted
1376325|NCT00469911|Heart
1376326|NCT00469911|Transplant
1376327|NCT00469911|MRS
1376328|NCT00469911|MRI
1376329|NCT00469911|Spectroscopy
1376330|NCT00469898|extensive stage small cell lung cancer
1376331|NCT00469885|Smoking cessation
1376332|NCT00469885|cardiovascular disease
1376333|NCT00469885|smoking reduction
1376334|NCT00469885|nicotine replacement
1376335|NCT00469859|recurrent childhood acute myeloid leukemia
1376336|NCT00469859|adult acute myeloid leukemia with t(16;16)(p13;q22)
1376337|NCT00469859|adult acute myeloid leukemia with t(8;21)(q22;q22)
1376338|NCT00469859|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1376339|NCT00469859|adult acute myeloid leukemia with inv(16)(p13;q22)
1376340|NCT00469859|adult acute myeloid leukemia with t(15;17)(q22;q12)
1376341|NCT00469859|recurrent adult acute myeloid leukemia
1376342|NCT00469859|secondary acute myeloid leukemia
1376343|NCT00469846|Pre-Eclampsia
1376344|NCT00469846|Hypertension,pregnancy-induced
1376345|NCT00469846|Preterm labor
1376346|NCT00469833|Diabetes
1376347|NCT00469833|Glucose Tolerance
1376348|NCT00469833|Incretin
1376349|NCT00469833|Insulin
1376350|NCT00469820|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1376351|NCT00469820|adult acute myeloid leukemia with inv(16)(p13;q22)
1376352|NCT00469820|adult acute myeloid leukemia with t(15;17)(q22;q12)
1376353|NCT00469820|adult acute myeloid leukemia with t(16;16)(p13;q22)
1376354|NCT00469820|adult acute myeloid leukemia with t(8;21)(q22;q22)
1376355|NCT00469820|recurrent adult acute lymphoblastic leukemia
1376356|NCT00469820|recurrent adult acute myeloid leukemia
1376357|NCT00469820|secondary acute myeloid leukemia
1376358|NCT00469820|stage III multiple myeloma
1376359|NCT00469820|untreated adult acute lymphoblastic leukemia
1376360|NCT00469820|untreated adult acute myeloid leukemia
1376361|NCT00469820|stage I multiple myeloma
1376362|NCT00469820|stage II multiple myeloma
1376363|NCT00469820|refractory multiple myeloma
1376364|NCT00469807|Ghrelin
1376365|NCT00469807|Pregnancy outcome
1376366|NCT00469794|arrhythmias
1376367|NCT00469794|Athletes
1376368|NCT00469794|exercise
1376369|NCT00469768|HIV-1 infection
1376370|NCT00469768|HIV Seronegativity
1376371|NCT00469742|Cardiology
1376372|NCT00469742|Pediatrics
1376373|NCT00469742|Cardiac Defects
1376374|NCT00469742|Cardiopulmonary Bypass Surgery
1376375|NCT00469742|Aprotinin
1376376|NCT00469742|thrombosis
1376377|NCT00469742|renal dysfunction
1376378|NCT00469729|Tetraethylenepentamine
1376379|NCT00469729|Umbilical Cord Blood Stem Cell Transplantation
1376380|NCT00469729|Hematological Malignancies
1376381|NCT00469729|Acute Lymphoid Leukemia
1376382|NCT00469729|Subjects with high-risk hematologic malignancies who are candidates for allogeneic stem cell transplantation
1376383|NCT00469716|Fluid balance
1376384|NCT00469716|respiratory function
1376385|NCT00469716|cardiac function
1376386|NCT00469716|inflammation
1376387|NCT00469716|Cardiopulmonary bypass
1376388|NCT00469703|Pancreatitis
1376389|NCT00469664|Schizophrenia
1376390|NCT00469664|Schizoaffective
1376391|NCT00469664|Cognitive Impairment
1376392|NCT00469664|Cognition
1376393|NCT00469664|Memory
1376394|NCT00469664|Attention
1376395|NCT00469664|Concentration
1376396|NCT00469651|Malaria
1376397|NCT00469651|vaccine
1376398|NCT00469651|MSP3LSP
1376399|NCT00469651|Safety
1376400|NCT00469651|children
1376401|NCT00469651|Tanzania
1376402|NCT00469638|atrial fibrillation
1376403|NCT00469638|paroxysmal
1376404|NCT00469638|persistent
1376405|NCT00469638|symptomatic
1376406|NCT00469638|ablation
1376407|NCT00469638|catheter
1376408|NCT00469638|introducer
1376409|NCT00469638|Agilis NxT
1376410|NCT00469638|sinus rhythm
1376411|NCT00469638|paroxysmal atrial fibrillation
1376412|NCT00469638|persistent atrial fibrillation
1376413|NCT00469638|symptomatic atrial fibrillation
1376414|NCT00469612|Myopia
1376415|NCT00469612|NeuroVision
1376416|NCT00469612|Visual acuity
1376417|NCT00469612|Contrast sensitivity
1376418|NCT00469599|Hyperparathyroidism, Secondary
1376419|NCT00469599|Kidney Failure, Chronic
1376420|NCT00469599|Renal Insufficiency, Chronic
1376421|NCT00469599|Vitamin D Deficiency
1376422|NCT00469599|Renal Osteodystrophy
1376423|NCT00469599|Hemodialysis
1376424|NCT00469560|MDS
1376425|NCT00469560|Chronic transfusional hemosiderosis
1376426|NCT00469560|Deferasirox
1376427|NCT00469547|ethanol, microbicide, sexually transmitted, Kenya, males
1376428|NCT00469547|HIV Seronegativity
1376429|NCT00469534|minimized time to beam
1376430|NCT00469534|hypofractionated 3D CRT plus IMRT
1376431|NCT00469534|PET-scan
1376432|NCT00469508|Methamphetamine
1376433|NCT00469508|Modafinil
1376434|NCT00469508|Medication
1376435|NCT00469508|Contingency Management
1376436|NCT00469508|Crystal meth
1376437|NCT00469508|Los Angeles
1376438|NCT00469508|Addiction
1376439|NCT00469508|Meth
1376440|NCT00469482|Delirium
1376441|NCT00469482|Cognitive Impairment
1376442|NCT00469482|Sleep
1376443|NCT00469482|Polysomnography
1376444|NCT00469482|Sedation
1376445|NCT00469482|Mechanical Ventilation
1376446|NCT00469482|Critical Illness
1376447|NCT00469469|Adrenal Cortex
1376448|NCT00469469|ACC
1376449|NCT00469456|memantine
1376450|NCT00469456|Alzheimer's Disease
1376451|NCT00469456|communication
1376452|NCT00469443|Metastatic colorectal cancer
1376453|NCT00469443|Irinotecan
1376454|NCT00469443|Capecitabine
1376455|NCT00469443|Bevacizumab
1376456|NCT00469430|appendicitis
1376457|NCT00469430|treatment
1376458|NCT00469430|antibiotics
1376459|NCT00469417|Methyl aminolevulinate
1376460|NCT00469417|Photodynamic therapy
1376461|NCT00469417|Primary Superficial Basal Cell Carcinoma
1376462|NCT00469404|Transdermal patch
1376463|NCT00469404|Centrally acting analgesic
1376464|NCT00469404|Plasma level
1376465|NCT00469404|Healthy volunteers
1376466|NCT00469391|Weight Reduction
1376467|NCT00469378|firategrast
1376468|NCT00469378|lymphocytes
1376469|NCT00469378|leukocytes
1376470|NCT00469378|SB-683699
1376471|NCT00469378|cerebrospinal fluid
1376472|NCT00469378|relapsing forms of multiple sclerosis
1376473|NCT00469365|clinical trial, medication adherence, pharmacy intervention
1376474|NCT00469365|Patients with specific chronic diseases
1376475|NCT00469352|Pharmacogenetics
1376476|NCT00469352|Genetics
1376477|NCT00469352|Treatment response
1376478|NCT00469352|AMD
1376479|NCT00469352|Wet AMD
1376480|NCT00469352|Age-related macular degeneration
1376481|NCT00469339|Diabetes
1376482|NCT00469339|Colon Cancer
1376483|NCT00469339|Cardiovascular Disease
1376484|NCT00469326|coronary artery disease
1376485|NCT00469326|percutaneous coronary intervention
1376486|NCT00469326|atorvastatin
1376487|NCT00469313|copd
1376488|NCT00469313|inspiratory muscle training
1376489|NCT00469313|IF
1376490|NCT00469300|herpes labialis
1376491|NCT00469300|cold sore
1376492|NCT00469300|acyclovir
1376493|NCT00469300|iontophoresis
1376494|NCT00469300|topical
1376495|NCT00469287|diabetes mellitus
1376496|NCT00469287|blood sugar
1376497|NCT00469287|overweight
1376498|NCT00469287|obesity
1376499|NCT00469287|Traditional Chinese medicine
1376500|NCT00469274|Pertussis
1376501|NCT00469274|Healthcare worker
1376502|NCT00469274|Post-exposure prophylaxis
1376503|NCT00469274|Vaccination
1376504|NCT00469274|Pertussis in healthcare workers following occupational
1376505|NCT00469274|exposure to pertussis
1376506|NCT00469261|Myocardial infarction
1376507|NCT00469261|Ventricular remodeling
1376508|NCT00469261|Matrix metalloproteinases
1376509|NCT00469261|Doxycycline
1376510|NCT00469248|Myocardial infarction
1376511|NCT00469248|Cardiogenic shock
1376512|NCT00469248|Systemic inflammatory response syndrome
1376513|NCT00469248|Percutaneous coronary intervention
1376514|NCT00469248|aortic balloon counterpulsation
1376515|NCT00469222|small cell lung cancer
1376516|NCT00469222|radiotherapy dose escalation
1376517|NCT00469209|Multiple Myeloma
1376518|NCT00469209|Melphalan
1376519|NCT00469209|Trisenox
1376520|NCT00469209|Arsenic Trioxide
1376521|NCT00469209|Ascorbic Acid
1376522|NCT00469209|Vitamin C
1376523|NCT00469209|Velcade
1376524|NCT00469209|Bortezomib
1376525|NCT00469196|mesothelioma
1376526|NCT00469196|tomotherapy
1376527|NCT00469170|HIV-1
1376528|NCT00469170|HIV seronegativity
1376529|NCT00469157|compatibility of Optive after PRK or LASIK
1376530|NCT00469144|Stem Cell Transplantation
1376531|NCT00469144|Leukemia
1376532|NCT00469144|Busulfan
1376533|NCT00469144|Fludarabine
1376534|NCT00469144|MDS
1376535|NCT00469144|AML
1376536|NCT00469131|liver transplantation,
1376537|NCT00469131|HCV recurrence,
1376538|NCT00469131|immunosuppression
1376539|NCT00469105|Type 2 Diabetes
1376540|NCT00469105|Diabetes Education
1376541|NCT00469105|Health Literacy
1376542|NCT00469079|Biomarkers
1376543|NCT00469079|Smoking
1376544|NCT00469079|Tobacco
1376545|NCT00469079|Cessation
1376546|NCT00469066|small cell lung cancer
1376547|NCT00469066|bladder cancer
1376548|NCT00469066|conformal radiotherapy
1376549|NCT00469053|Transdermal patch
1376550|NCT00469053|multidose
1376551|NCT00469053|Centrally acting analgesic
1376552|NCT00469053|Plasma level
1376553|NCT00469053|Healthy volunteers
1376554|NCT00469040|GW642444,
1376555|NCT00469040|healthy subjects
1376556|NCT00469040|magnesium stearate,
1376557|NCT00469027|Pulmonary Arterial Hypertension (PAH)
1376558|NCT00469014|Acute Myeloid Leukemia
1376559|NCT00469014|AML
1376560|NCT00469014|Myelodysplastic Syndrome
1376561|NCT00469014|MDS
1376562|NCT00469014|Chronic Myeloid Leukemia
1376563|NCT00469014|CML
1376564|NCT00469014|Busulfan
1376565|NCT00469014|Busulfex
1376566|NCT00469014|Myleran
1376567|NCT00469014|Fludarabine
1376568|NCT00469014|Fludara
1376569|NCT00469014|Fludarabine Phosphate
1376570|NCT00469014|Clofarabine
1376571|NCT00469014|Clofarex
1376572|NCT00469014|Clolar
1376573|NCT00469014|Allogeneic stem cell transplantation
1376574|NCT00469014|ASCT
1376575|NCT00469014|Stem Cell
1376576|NCT00469014|Gleevec
1376577|NCT00469014|Imatinib Mesylate
1376578|NCT00469001|Hospitalization and death from exacerbation CHF.
1376579|NCT00468949|Health-Related Quality of Life
1376580|NCT00468949|Dupuytren's Disease
1376581|NCT00468949|Health Utilities Index
1376582|NCT00468949|Short Form-36;
1376583|NCT00468949|Michigan Hand Outcomes Questionnaire
1376584|NCT00468936|anti-rejection
1376585|NCT00468936|GI side effects
1376586|NCT00468936|heart transplant patients
1376587|NCT00468923|Primary prevention
1376588|NCT00468923|Cholesterol lowering
1376589|NCT00468923|Blood pressure lowering
1376590|NCT00468923|Cardiovascular disease prevention
1376591|NCT00468897|Alzheimers Disease
1376592|NCT00468897|bioequivalence
1376593|NCT00468897|healthy volunteers
1376594|NCT00468884|Kinetics of GLP-1 and PYY3-36; increasing oral doses
1376595|NCT00468858|Dengue
1376596|NCT00468858|Virus
1376597|NCT00468858|Live-attenuated
1376598|NCT00468858|Vaccine
1376599|NCT00468858|Dengue viral infection
1376600|NCT00468858|Dengue Vaccine
1376601|NCT00468845|pain after hysterectomy
1376602|NCT00468845|amount of opioids used
1376603|NCT00468819|Contrast-enhanced MRI
1376604|NCT00468819|MR angiography (MRA) Children 2-17 years
1376605|NCT00468806|PET scan
1376606|NCT00468806|Health Males
1376607|NCT00468793|central venous saturation
1376608|NCT00468793|bowel surgery
1376609|NCT00468793|morbidity
1376610|NCT00468793|intravenous infusions
1376611|NCT00468780|Canadian Triage Acuity Scale
1376612|NCT00468780|paramedics
1376613|NCT00468780|triage nurse
1376614|NCT00468780|triage levels
1376615|NCT00468780|inter-rater reliability
1376616|NCT00468780|health services outcomes
1376617|NCT00468767|Atrial fibrillation
1376618|NCT00468767|RSD1235
1376619|NCT00468767|Atrial fibrillation of 3 hours to 7 days duration.
1376620|NCT00468767|Atrial fibrillation of 3 hours to 45 days duration.
1376621|NCT00468741|Breast Cancer
1376622|NCT00468741|Internet
1376623|NCT00468741|Computer
1376624|NCT00468741|Support
1376625|NCT00468741|Information
1376626|NCT00468741|Education
1376627|NCT00468741|Control Group: Usual care and Internet access
1376628|NCT00468741|CHESS Information Services only
1376629|NCT00468741|CHESS Social Support & Information Services
1376630|NCT00468741|CHESS Information, Social Support & Skills Services
1376631|NCT00468728|CDAD, Clostridium difficile, diarrhea
1376632|NCT00468728|Clostridium difficile-Associated Diarrhea
1376633|NCT00468715|stage IV breast cancer
1376634|NCT00468715|recurrent breast cancer
1376635|NCT00468715|male breast cancer
1376636|NCT00468689|SB-751689,
1376637|NCT00468689|Calcium-sensing receptor antagonist (CaR),
1376638|NCT00468689|Osteoporosis,
1376639|NCT00468689|Parathyroid hormone (PTH),
1376640|NCT00468689|Oral dose
1376641|NCT00468676|major Depressive Disorder
1376642|NCT00468676|Diabetes
1376643|NCT00468676|Heart Disease
1376644|NCT00468663|preeclampsia
1376645|NCT00468663|preterm delivery
1376646|NCT00468663|lipid peroxidation
1376647|NCT00468663|inflammation
1376648|NCT00468637|heart failure
1376649|NCT00468637|cardiovascular high risk
1376650|NCT00468637|erectile dysfunction
1376651|NCT00468637|cardiovascular disease
1376652|NCT00468624|Growth hormone
1376653|NCT00468624|insulin-like growth factor 1
1376654|NCT00468624|pegvisomant
1376655|NCT00468611|Secondary Progressive Multiple Sclerosis
1376656|NCT00468611|Multiple Sclerosis
1376657|NCT00468598|troponin
1376658|NCT00468598|long-term outcome
1376659|NCT00468598|on-pump cardiac surgery
1376660|NCT00468585|Breast cancer
1376661|NCT00468585|Metastatic breast cancer
1376662|NCT00468585|Breast
1376663|NCT00468585|Metastatic
1376664|NCT00468572|Emotion
1376665|NCT00468572|Oxytocin
1376666|NCT00468572|Cortisol
1376667|NCT00468559|pediatrics
1376668|NCT00468559|neonates
1376669|NCT00468533|Arupiprazole, prolacin, PANSS, CGI, AIMS
1376670|NCT00468520|induction of labor
1376671|NCT00468520|cervical ripening
1376672|NCT00468520|Foley catheter
1376673|NCT00468520|oxytocin
1376674|NCT00468507|CCK release
1376675|NCT00468494|non diabetic
1376676|NCT00468494|catabolic energy state
1376677|NCT00468481|Healthy women requesting contraception
1376678|NCT00468481|Folic Acid
1376679|NCT00468468|breast cancer
1376680|NCT00468468|Internet
1376681|NCT00468468|computer
1376682|NCT00468468|support
1376683|NCT00468468|information
1376684|NCT00468468|education
1376685|NCT00468455|Colorectal Surgery
1376686|NCT00468455|Abdominal Surgery
1376687|NCT00468455|Diverticulitis
1376688|NCT00468455|Colon Cancer
1376689|NCT00468455|Rectal Cancer
1376690|NCT00468455|Colon Polyp
1376691|NCT00468455|Rectal Polyp
1376692|NCT00468455|Crohn's Disease
1376693|NCT00468442|Insulin dependence
1376694|NCT00468442|Hypoglycemia
1376695|NCT00468442|Hypoglycemia unawareness
1376696|NCT00468429|Glaucoma
1376697|NCT00468429|Bevacizumab
1376698|NCT00468429|Glaucoma Filtration Surgery
1376699|NCT00468429|Mitomycin C
1376700|NCT00468429|Intraocular Pressure
1376701|NCT00468403|Insulin dependence
1376702|NCT00468403|Hypoglycemia
1376703|NCT00468403|Hypoglycemia unawareness
1376704|NCT00468364|Hypoglycemia, bedtime insulin, long-acting insulin
1376705|NCT00468351|bevacizumab
1376706|NCT00468351|diabetes
1376707|NCT00468351|intravitreal
1376708|NCT00468351|macular edema
1376709|NCT00468351|triamcinolone
1376710|NCT00468351|VEGF
1376711|NCT00468338|general anesthesia
1376712|NCT00468338|dental rehabilitation
1376713|NCT00468338|mental retardation
1376714|NCT00468325|coronary artery disease
1376715|NCT00468325|chest pain
1376716|NCT00468325|emergency room
1376717|NCT00468299|early
1376718|NCT00468299|pregnancy
1376719|NCT00468299|failure
1376720|NCT00468299|mifepristone
1376721|NCT00468299|misoprostol
1376722|NCT00468299|buccal
1376723|NCT00468299|miscarriage
1376724|NCT00468299|fetal
1376725|NCT00468299|demise
1376726|NCT00468299|anembryonic
1376727|NCT00468299|progesterone
1376728|NCT00468286|Prostate Cancer
1376729|NCT00468273|Deficiency Syndromes, Antibody
1376730|NCT00468273|Antibody Deficiency Syndrome
1376860|NCT00467870|Hypogonadism
1376731|NCT00468273|Bruton's agammaglobulinemia
1376732|NCT00468273|Common Variable Immune Deficiency
1376733|NCT00468273|Hyper IgM syndromes
1376734|NCT00468260|Cancer
1376735|NCT00468260|EPO906
1376736|NCT00468260|Patupilone
1376737|NCT00468247|mean systemic pressure
1376738|NCT00468247|fluid therapy
1376739|NCT00468247|closed loop control
1376740|NCT00468247|circulation modelling
1376741|NCT00468234|smoking cessation
1376742|NCT00468234|harm reduction
1376743|NCT00468234|biomarker
1376744|NCT00468234|exhaled breath condensate
1376745|NCT00468221|Ozone
1376746|NCT00468221|Healthy Adults
1376747|NCT00468208|Vasculitis
1376748|NCT00468208|Relapse
1376749|NCT00468208|Wegener's
1376750|NCT00468208|Treatment
1376751|NCT00468195|tomography
1376752|NCT00468195|coronary artery disease
1376753|NCT00468195|obesity
1376754|NCT00468182|Multiple sclerosis
1376755|NCT00468182|Interferon beta
1376756|NCT00468182|plasmacytoid dendritic cells
1376757|NCT00468169|Cetuximab
1376758|NCT00468169|Erbitux
1376759|NCT00468169|locally
1376760|NCT00468169|advanced
1376761|NCT00468169|head
1376762|NCT00468169|neck
1376763|NCT00468169|cancer
1376764|NCT00468169|neoplasms
1376765|NCT00468169|squamous
1376766|NCT00468169|carcinoma
1376767|NCT00468169|lymphoepithelioma
1376768|NCT00468156|fruit
1376769|NCT00468156|vegetables
1376770|NCT00468156|prevention
1376771|NCT00468156|cancer
1376772|NCT00468156|counseling
1376773|NCT00468156|cancer risk
1376774|NCT00468130|Aggression
1376775|NCT00468130|Irritability
1376776|NCT00468130|Global autism severity
1376777|NCT00468117|Hypoglycemia
1376778|NCT00468117|Kidney Transplant
1376779|NCT00468117|Insulin independence
1376780|NCT00468117|Islet Transplantation
1376781|NCT00468117|Intensive Insulin Therapy
1376782|NCT00468104|parapneumonic pleural effusion
1376783|NCT00468104|empyema
1376784|NCT00468104|TPA (Activase, Alteplase)
1376785|NCT00468091|GLP-1
1376786|NCT00468091|exendin(9-39)
1376787|NCT00468091|atropine
1376788|NCT00468091|human
1376789|NCT00468091|motility
1376790|NCT00468078|Parkinson's disease
1376791|NCT00468078|Essential tremor
1376792|NCT00468078|F-18 FPCIT
1376793|NCT00468078|PET
1376794|NCT00468065|intravenous
1376795|NCT00468065|catheter
1376796|NCT00468065|IV
1376797|NCT00468052|obstructive sleep apnea
1376798|NCT00468052|tonsillectomy
1376799|NCT00468052|adenoidectomy
1376800|NCT00468039|metformin
1376801|NCT00468039|vildagliptin
1376802|NCT00468039|initial combination
1376803|NCT00468026|BPH
1376804|NCT00468026|Prostate
1376805|NCT00468026|Stent
1376806|NCT00468026|Benign prostatic hyperplasia (BPH)
1376807|NCT00468013|Fibromyalgia
1376808|NCT00468013|Irritable Bowel
1376809|NCT00468013|Chronic Fatigue
1376810|NCT00468013|Medically Unexplained Symptoms
1376811|NCT00468013|Resilience Building Exercises
1376812|NCT00468013|Depression
1376813|NCT00468013|Well-Being
1376814|NCT00468000|Peripheral Arterial Disease
1376815|NCT00468000|Critical Limb Ischemia
1376816|NCT00468000|Ischemia
1376817|NCT00468000|Peripheral Vascular Disease
1376818|NCT00468000|ixmyelocel-T
1376819|NCT00467961|CML (Chronic Myelogenous Leukemia)
1376820|NCT00467961|CLL (Chronic Lymphocytic Leukemia)
1376821|NCT00467961|AML (Acute Myelogenous Leukemia)
1376822|NCT00467961|Leukemia
1376823|NCT00467961|Chronic Lymphocytic Leukemia
1376824|NCT00467961|CLL
1376825|NCT00467961|Chronic Myelogenous Leukemia
1376826|NCT00467961|CML
1376827|NCT00467961|Acute Myelogenous Leukemia
1376828|NCT00467961|AML
1376829|NCT00467961|Acute B-Lymphoblastic Leukemia
1376830|NCT00467961|ALL
1376831|NCT00467961|Myelodysplastic Syndrome
1376832|NCT00467961|MDS
1376833|NCT00467948|clean contaminated, laryngectomy, wound infection
1376834|NCT00467935|amd
1376835|NCT00467935|disciform
1376836|NCT00467935|fibrosis
1376837|NCT00467935|Lucentis
1376838|NCT00467935|scotoma
1376839|NCT00467922|Hand-assisted colorectal surgery
1376840|NCT00467922|colorectal disease
1376841|NCT00467922|Crohn's
1376842|NCT00467922|diverticulitis
1376843|NCT00467922|Colorectal resections
1376844|NCT00467909|micronutrients
1376845|NCT00467909|cognition
1376846|NCT00467909|DHA
1376847|NCT00467909|healthy children
1376848|NCT00467896|PAH
1376849|NCT00467896|iloprost
1376850|NCT00467896|Ventavis
1376851|NCT00467896|Pulmonary Arterial Hypertension
1376852|NCT00467896|Actelion Pharmaceuticals
1376853|NCT00467896|Cotherix
1376854|NCT00467883|Zygomycosis
1376855|NCT00467883|High dose liposomal amphotericin B
1376856|NCT00467870|investigational
1376857|NCT00467870|testosterone
1376858|NCT00467870|testosterone undecanoate
1376859|NCT00467870|TU
1376861|NCT00467870|primary hypogonadism
1376862|NCT00467870|secondary hypogonadism
1376863|NCT00467857|cyanoacrylates
1376864|NCT00467857|microbial sealants
1376865|NCT00467857|skin flora contamination
1376866|NCT00467857|surgery
1376867|NCT00467844|Cachexia
1376868|NCT00467844|Muscle Wasting
1376869|NCT00467844|Non-Small Cell Lung Cancer
1376870|NCT00467844|Colorectal Cancer
1376871|NCT00467844|Non-Hodgkin's Lymphoma
1376872|NCT00467844|Stage 3 or 4 Breast Cancer
1376873|NCT00467844|Chronis Lymphocytic Leukemia
1376874|NCT00467831|Restrictive Lung Disease
1376875|NCT00467831|Pulmonary Fibrosis
1376876|NCT00467831|Albinism
1376877|NCT00467831|Platelet Storage Pool Deficiency
1376878|NCT00467831|Metabolic Disease
1376879|NCT00467831|Hermansky-Pudlak Syndrome
1376880|NCT00467831|HPS
1376881|NCT00467831|Lung Disease
1376882|NCT00467818|Aggression
1376883|NCT00467818|Irritability
1376884|NCT00467818|Global severity
1376885|NCT00467805|Light exposure
1376886|NCT00467805|light spectrum
1376887|NCT00467805|reproductive hormones
1376888|NCT00467805|women
1376889|NCT00467792|urticaria pigmentosa
1376890|NCT00467792|mastocytosis
1376891|NCT00467792|mastocytomas
1376892|NCT00467766|dementia
1376893|NCT00467766|Counseling
1376894|NCT00467753|Irritability
1376895|NCT00467753|Functional Ability
1376896|NCT00467753|Aggression
1376897|NCT00467753|Mood Instability
1376898|NCT00467727|Diagnostic Mammography
1376899|NCT00467727|Breast Imaging
1376900|NCT00467727|Phase Contrast Mammography
1376901|NCT00467727|X-Ray Mammography
1376902|NCT00467714|RHINOPLASTY ,ESTHETIC SURGERY
1376903|NCT00467701|pneumonia
1376904|NCT00467701|Legionnaires disease
1376905|NCT00467701|risk factors
1376906|NCT00467688|type 1 diabetes
1376907|NCT00467688|glucose excursion
1376908|NCT00467688|hypoglycemia awareness
1376909|NCT00467688|continuous glucose monitoring
1376910|NCT00467675|NonDiabetes
1376911|NCT00467675|CGM
1376912|NCT00467649|Symlin
1376913|NCT00467649|Amylin
1376914|NCT00467649|insulin
1376915|NCT00467649|Humalog
1376916|NCT00467649|Novolog
1376917|NCT00467649|Apidra
1376918|NCT00467636|Chronic Obstructive Pulmonary Disease
1376919|NCT00467636|Corticosteroid induced hyperglycaemia
1376920|NCT00467636|Insulin
1376921|NCT00467623|Pregnancy
1376922|NCT00467623|holotranscobalamin
1376923|NCT00467623|cobalamin
1376924|NCT00467623|vitamin B12 analogues
1376925|NCT00467623|reference interval
1376926|NCT00467610|myelodysplastic
1376927|NCT00467610|MDS
1376928|NCT00467610|Panhematin
1376929|NCT00467610|Hemin
1376930|NCT00467597|Dyskinesia
1376931|NCT00467597|Levodopa
1376932|NCT00467597|Movement Disorders
1376933|NCT00467597|Parkinson Disease
1376934|NCT00467571|chronic idiopathic thrombocytopenic purpura
1376935|NCT00467571|Helicobacter pylori infection
1376936|NCT00467571|platelet
1376937|NCT00467558|Impulse Control Disorder
1376938|NCT00467558|Compulsive Sexual Behavior
1376942|NCT00467519|Tetanus; Diphtheria; Pertussis; ADACEL; DAPTACEL
1376943|NCT00467506|Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery
1376944|NCT00467454|Pyromania
1376945|NCT00467454|Fire Setting
1376946|NCT00467454|Compulsive Fire Setting
1376947|NCT00467428|ADHD
1376948|NCT00467415|Walking
1376949|NCT00467415|Treadmill
1376950|NCT00467415|Partial Weightbearing
1376951|NCT00467402|agomelatine, Major Depressive Disorder, MDD, depression
1376952|NCT00467389|Acetylcholine
1376953|NCT00467389|Acetylcholinesterase
1376954|NCT00467389|Butyrylcholinesterase
1376955|NCT00467389|Cholinesterase Inhibitor
1376956|NCT00467350|constipation
1376957|NCT00467350|treatment
1376958|NCT00467350|fecal impaction
1376959|NCT00467350|pediatric
1376960|NCT00467337|insole
1376961|NCT00467337|osteoarthritis
1376962|NCT00467337|pain
1376963|NCT00467337|valgus knee
1376964|NCT00467324|obstructive sleep apnea
1376965|NCT00467324|surgery
1376966|NCT00467324|tongue
1376967|NCT00467311|Contrast-induced nephropathy
1376968|NCT00467311|Cystatin C
1376969|NCT00467311|Contrast media
1376970|NCT00467311|Creatinine
1376971|NCT00467311|Cardiac Catheterization
1376972|NCT00467298|Exercise
1376973|NCT00467298|heart failure
1376974|NCT00467298|chronic obstructive pulmonary disease
1376975|NCT00467298|patient education
1376976|NCT00467298|costs
1376977|NCT00467298|quality of life
1376978|NCT00467285|Bone Density
1376979|NCT00467285|C-telopeptide
1376980|NCT00467285|Dual-Energy X-Ray Absorptiometry
1376981|NCT00467285|N-telopeptide
1376982|NCT00467285|Osteocalcin
1376983|NCT00467285|Osteoporosis
1376984|NCT00467285|Thiazolidinediones
1376985|NCT00467285|Type 2 Diabetes Mellitus
1376986|NCT00467272|Catheter-Related Bloodstream Infections
1376987|NCT00467272|Bloodstream Infection
1376988|NCT00467272|Daptomycin
1376989|NCT00467272|Cubicin
1376990|NCT00467272|CRBSI
1376991|NCT00467259|Natural Menopause
1376992|NCT00467246|Diabetes emergencies
1376993|NCT00467220|Calorie restriction
1376994|NCT00467220|alternate day fasting
1376995|NCT00467220|calorie intake
1376996|NCT00467194|adult primary hepatocellular carcinoma
1376997|NCT00467194|localized unresectable adult primary liver cancer
1376998|NCT00467194|recurrent adult primary liver cancer
1376999|NCT00467194|advanced adult primary liver cancer
1377000|NCT00467181|cardiac surgery
1377001|NCT00467181|renal dysfunction
1377002|NCT00467168|dietary fatty acid composition
1377003|NCT00467168|postprandial
1377004|NCT00467168|triglyceride-rich lipoprotein
1377005|NCT00467168|type 2 diabetes
1377006|NCT00467155|Helicobacter pylori, children, infants, Gambia
1377007|NCT00467142|stage IV colon cancer
1377008|NCT00467142|stage IV rectal cancer
1377009|NCT00467142|adenocarcinoma of the colon
1377010|NCT00467142|adenocarcinoma of the rectum
1377011|NCT00467142|recurrent colon cancer
1377012|NCT00467142|recurrent rectal cancer
1377013|NCT00467129|stage IV colon cancer
1377014|NCT00467129|stage IV rectal cancer
1377015|NCT00467116|stage III pancreatic cancer
1377016|NCT00467116|adenocarcinoma of the pancreas
1377017|NCT00467116|stage II pancreatic cancer
1377018|NCT00467116|recurrent pancreatic cancer
1377019|NCT00467103|Adult Aphasia
1377020|NCT00467103|Diffusion Tensor Imaging
1377021|NCT00467103|functional Magnetic Resonance Imaging
1377022|NCT00467103|Language Recovery
1377023|NCT00467103|Left Middle Cerebral Artery Stroke
1377024|NCT00467103|Nonfluent Aphasia
1377025|NCT00467090|Parkinson's Disease
1377026|NCT00467090|Gene
1377027|NCT00467090|Genetic
1377028|NCT00467090|Family Studies
1377029|NCT00467090|LRRK-2
1377030|NCT00467090|Parkinson Disease
1377031|NCT00467090|PD
1377032|NCT00467077|recurrent renal cell cancer
1377033|NCT00467077|stage IV renal cell cancer
1377034|NCT00467077|stage III renal cell cancer
1377035|NCT00467064|Disease self-management
1377036|NCT00467064|Community programs
1377037|NCT00467038|affect
1377038|NCT00467038|aggression
1377039|NCT00467038|anger
1377040|NCT00467038|behavior therapy
1377041|NCT00467038|borderline personality disorder
1377042|NCT00467038|MRI, functional
1377043|NCT00467025|Metastatic clear cell carcinoma of the kidney
1377044|NCT00467025|RCC
1377045|NCT00467012|Inoperable metastatic breast cancer
1377046|NCT00466999|misoprostol
1377047|NCT00466999|incomplete abortion
1377048|NCT00466999|PAC
1377049|NCT00466986|recurrent
1377050|NCT00466986|ovarian
1377051|NCT00466986|cancer
1377052|NCT00466986|platinum sensitive
1377053|NCT00466973|Atrial fibrillation
1377054|NCT00466973|ablation device comparison
1377055|NCT00466973|ablation in right atria
1377056|NCT00466947|Otitis media
1377057|NCT00466947|Pneumonia
1377058|NCT00466947|Community acquired pneumonia (CAP)
1377059|NCT00466947|Pneumococcal disease
1377060|NCT00466947|Booster vaccination
1377061|NCT00466947|Immunogenicity
1377062|NCT00466947|Pneumococcal vaccine
1377063|NCT00466947|Safety
1377064|NCT00466947|Efficacy
1377065|NCT00466947|Carriage
1377066|NCT00466934|Cerebral Blood Flow
1377067|NCT00466934|Cerebral Cortex
1377068|NCT00466934|Cognition
1377069|NCT00466934|Optical Imaging
1377070|NCT00466934|Healthy Volunteer
1377071|NCT00466934|HV
1377072|NCT00466921|recurrent mycosis fungoides/Sezary syndrome
1377073|NCT00466921|stage I mycosis fungoides/Sezary syndrome
1377074|NCT00466921|stage II mycosis fungoides/Sezary syndrome
1377075|NCT00466921|stage III mycosis fungoides/Sezary syndrome
1377076|NCT00466921|stage IV mycosis fungoides/Sezary syndrome
1377077|NCT00466895|Leukemia
1377078|NCT00466895|Lenalidomide
1377079|NCT00466882|obese
1377080|NCT00466882|renal failure
1377081|NCT00466882|renal transplant candidate
1377082|NCT00466882|Hemodialysis BMI between 36 and 42
1377083|NCT00466856|neoplastic syndrome
1377084|NCT00466856|metastatic gastrointestinal carcinoid tumor
1377085|NCT00466856|recurrent gastrointestinal carcinoid tumor
1377086|NCT00466856|thyroid gland medullary carcinoma
1377087|NCT00466856|metastatic pheochromocytoma
1377088|NCT00466856|recurrent islet cell carcinoma
1377089|NCT00466856|liver metastases
1377090|NCT00466856|recurrent pheochromocytoma
1377091|NCT00466856|gastrinoma
1377092|NCT00466856|insulinoma
1377093|NCT00466856|WDHA syndrome
1377094|NCT00466856|glucagonoma
1377095|NCT00466856|pancreatic polypeptide tumor
1377096|NCT00466856|somatostatinoma
1377097|NCT00466843|Abnormal hematopoiesis
1377098|NCT00466843|Leukemia
1377099|NCT00466843|Autoimmune Disease
1377100|NCT00466830|pain
1377101|NCT00466830|psychosocial effects of cancer and its treatment
1377102|NCT00466830|stage IIIA breast cancer
1377103|NCT00466830|stage IIIB breast cancer
1377104|NCT00466830|stage I breast cancer
1377105|NCT00466830|stage II breast cancer
1377106|NCT00466830|stage IIIC breast cancer
1377107|NCT00466817|Cytomegalovirus, congenital, infants
1377108|NCT00466804|heart transplant recipients
1377109|NCT00466804|organ transplantation
1377110|NCT00466804|immune biomarkers
1377111|NCT00466804|transplant rejection
1377112|NCT00466765|Fat Grafting
1377113|NCT00466765|Breast Augmentation
1377114|NCT00466765|Liposuctioned Fat Transfer
1377115|NCT00466765|Lumpectomy
1377116|NCT00466765|Mastectomy
1377117|NCT00466765|Micromastia
1377118|NCT00466765|Asymmetry
1377119|NCT00466765|Post Lumpectomy Filling Defects
1377120|NCT00466765|Post implant removal filling defect
1377121|NCT00466765|Post Mastectomy
1377122|NCT00466765|Autologous Fat Transfer
1377123|NCT00466765|Tubular breasts
1377124|NCT00466765|Tuberous breasts
1377125|NCT00466765|Constricted breasts
1377126|NCT00466726|chronic myelogenous leukemia, BCR-ABL1 positive
1377127|NCT00466726|accelerated phase chronic myelogenous leukemia
1377128|NCT00466726|blastic phase chronic myelogenous leukemia
1377129|NCT00466726|chronic phase chronic myelogenous leukemia
1377130|NCT00466726|relapsing chronic myelogenous leukemia
1377131|NCT00466713|Nonischemic dilated cardiomyopathy
1377132|NCT00466700|Helicobacter pylori, Gambia, endoscopy, Africa
1377133|NCT00466687|stage IV melanoma
1377134|NCT00466687|recurrent melanoma
1377135|NCT00466674|Myeloma
1377136|NCT00466674|RICT
1377137|NCT00466674|conditioning
1377138|NCT00466674|allograft
1377139|NCT00466661|Acamprosate
1377140|NCT00466661|Alcoholism
1377141|NCT00466661|Bipolar disorder
1377142|NCT00466661|Comorbidity
1377143|NCT00466661|Craving
1377144|NCT00466661|Depression
1377145|NCT00466661|GABA
1377146|NCT00466661|Glutamate
1377147|NCT00466661|Mania
1377148|NCT00466661|Pharmacotherapy
1377149|NCT00466661|Withdrawal
1377150|NCT00465660|Osteoarthritis
1377151|NCT00465660|Cartilage
1377152|NCT00465660|Exercise
1377153|NCT00465660|Progressive Resistance Training
1377154|NCT00465647|Postoperative pain
1377155|NCT00465647|Hydromorphone oral solution
1377156|NCT00465647|opioid
1377157|NCT00465647|pharmacokinetics
1377158|NCT00465647|pharmacodynamics
1377159|NCT00465634|Screening
1377160|NCT00465634|uterine artery Doppler
1377161|NCT00465634|HELLP syndrome
1377162|NCT00465634|abruption
1377163|NCT00466648|laparoscopy, port site, closure, Dermabond
1377164|NCT00466635|Clostridium difficile Disease
1377165|NCT00466635|Infectious diarrhea
1377166|NCT00466635|C. difficile
1377167|NCT00466635|CDAD
1377168|NCT00466635|Clostridium difficile-associated diarrhea
1377169|NCT00466635|Clostridium difficile diarrhea
1377170|NCT00466635|Antibiotic-Associated Colitis
1377171|NCT00466635|Clostridium Enterocolitis
1377172|NCT00466635|Antibiotic-Associated Diarrhea
1377173|NCT00466635|Pseudomembranous Colitis
1377174|NCT00466635|Clostridium difficile
1377175|NCT00466622|PCOS
1377176|NCT00466622|pregnancy
1377177|NCT00466622|metformin
1377178|NCT00466622|blood flow
1377179|NCT00466622|Pulsatility index
1377180|NCT00466609|clomipramine
1377181|NCT00466609|quetiapine
1377182|NCT00466609|fluoxetine
1377183|NCT00466609|placebo
1377184|NCT00466609|augmentation
1377185|NCT00466609|obsessive compulsive disorder
1377186|NCT00466596|allergic rhinitis
1377187|NCT00466596|mild asthma
1377188|NCT00466596|dust mite allergy
1377189|NCT00466596|gamma tocopherol
1377190|NCT00466583|Carcinoma, Lymphoma
1377191|NCT00466557|Malaria, Plasmodium falciparum, mosquito, Africa, Anopheles
1377192|NCT00466544|Chronic tonsillitis
1377193|NCT00466544|Recurrent tonsillitis
1377194|NCT00466531|refractory chronic lymphocytic leukemia
1377195|NCT00466531|06-138
1377196|NCT00466518|Kidney transplant
1377197|NCT00466518|type 2 diabetes
1377198|NCT00466518|sitagliptin
1377199|NCT00466505|recurrent colon cancer
1377200|NCT00466505|stage IV colon cancer
1377201|NCT00466505|recurrent rectal cancer
1377202|NCT00466505|stage IV rectal cancer
1377203|NCT00466492|Drug Administration Schedule
1377204|NCT00466492|Intensive Care Units
1377205|NCT00466492|Length of Stay
1377206|NCT00466492|Respiration, Artificial
1377207|NCT00466492|Stress Disorders, Post-Traumatic/etiology/*psychology
1377208|NCT00466492|Critical Illness/*psychology
1377209|NCT00466492|Pneumonia/prevention & control
1377210|NCT00466492|Hypnotics and Sedatives/*administration & dosage
1377211|NCT00466479|neuroprotection
1377212|NCT00466479|alpha one agonists
1377213|NCT00466479|glaucoma
1377214|NCT00466479|visual field
1377215|NCT00466466|Small-Cell Lung Cancer
1377216|NCT00466466|SCLC
1377217|NCT00466466|Advanced Lung Cancer
1377218|NCT00466466|RAD
1377219|NCT00466466|RAD001
1377220|NCT00466466|Chemotherapy
1377221|NCT00466466|Cisplatin
1377222|NCT00466466|Etoposide
1377223|NCT00466388|dry mouth
1377224|NCT00466375|hemangioma
1377225|NCT00466375|vascular anomaly
1377226|NCT00466375|infantile hemangioma
1377227|NCT00466362|Obesity
1377228|NCT00466362|Diabetes
1377229|NCT00466362|Weight
1377230|NCT00466362|Lifestyle
1377231|NCT00466362|Follow up
1377232|NCT00466349|SMA Type I
1377233|NCT00466349|SMA Type II
1377234|NCT00466349|SMA Type III
1377235|NCT00466349|SMN
1377236|NCT00466349|Werdnig-Hoffman Disease
1377237|NCT00466349|Spinal Muscular Atrophy
1377238|NCT00466349|Registry
1377239|NCT00466349|SMA Type IV
1377240|NCT00466336|Chronic hepatitis C
1377241|NCT00466336|Non-invasive diagnosis
1377242|NCT00466336|Duplex Doppler ultrasonography
1377243|NCT00466336|Biochemical indices
1377244|NCT00466336|Hepatic fibrosis
1377245|NCT00466336|Cirrhosis
1377246|NCT00466323|Mental Illness
1377247|NCT00466323|Schizophrenia
1377248|NCT00466323|Education
1377249|NCT00466323|Family member treatment
1377250|NCT00466323|Active psychoses
1377251|NCT00466310|Schizophrenia
1377252|NCT00466310|Metabolomics
1377253|NCT00466297|Interprofessional
1377254|NCT00466297|Collaboration
1377255|NCT00466297|Teamwork
1377256|NCT00466297|General internal medicine
1377257|NCT00466297|Cluster randomized
1377258|NCT00466271|Chronic hepatitis C
1377259|NCT00466271|Persistently normal alanine aminotransferase levels
1377260|NCT00466271|Hepatic fibrosis
1377261|NCT00466271|Non-invasive diagnosis
1377262|NCT00466271|Splenic arterial pulsatility index
1377263|NCT00466258|Diffuse large B cell lymphoma
1377264|NCT00466258|HIV
1377265|NCT00466258|R-CHOP
1377266|NCT00466258|Highly active antiretroviral therapy
1377267|NCT00466258|Treatment Experienced
1377268|NCT00466245|MVA Vaccine
1377269|NCT00466232|Small Cell
1377270|NCT00466232|Lung Cancer
1377271|NCT00466232|Treatment
1377272|NCT00466219|Presence of HCV RNA in serum
1377273|NCT00466219|Absence of graft rejection
1377274|NCT00466219|Recurrent hepatitis C after liver transplantation
1377275|NCT00466206|pectus excavatum
1377276|NCT00466206|magnetic alteration
1377277|NCT00466206|chest wall deformity
1377278|NCT00466193|Insomnia
1377279|NCT00466180|Once-a-day
1377280|NCT00466180|Adherence
1377281|NCT00466180|Nevirapine
1377282|NCT00466180|Patient noncompliance
1377283|NCT00466180|Administration and dosage
1377284|NCT00466180|Treatment Experienced
1377285|NCT00466154|Aspirin resistance
1377286|NCT00466154|Platelet activation
1377287|NCT00466154|Hypercholesterolemia
1377288|NCT00466128|fetal membranes, preterm rupture
1377289|NCT00466128|preterm rupture
1377290|NCT00466128|PPROM
1377291|NCT00466115|MDS
1377292|NCT00466115|AML
1377293|NCT00466102|Breast Cancer
1377294|NCT00466102|Bone metastases as only metastatic site
1377295|NCT00466102|Breast cancer, HER2 negative
1377296|NCT00466102|Bone metastasis as only metastatic site
1377297|NCT00466102|Pretreated with endocrine therapy
1377298|NCT00466102|Up to one previous chemotherapy
1377299|NCT00466102|Previous treatment with bisphosphonates allowed
1377300|NCT00466089|NSCLC, lung cancer
1377301|NCT00466089|Patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment.
1377302|NCT00466076|Drusen
1377303|NCT00466076|AMD
1377304|NCT00466076|Dry form of Age related Macular Degeneration
1377305|NCT00466063|Iron overload
1377306|NCT00466063|children
1377307|NCT00466063|deferasirox
1377308|NCT00466063|Transfusion-dependent anemia
1377309|NCT00466050|plaque rupture,
1377310|NCT00466050|acute coronary thrombose,
1377311|NCT00466050|coronary angiography,
1377312|NCT00466050|IVUS
1377313|NCT00466037|Rheumatoid
1377314|NCT00466037|rituximab
1377315|NCT00466037|influenza
1377316|NCT00466024|Asthma
1377317|NCT00466024|persistent
1377318|NCT00466024|children
1377319|NCT00466024|particulates
1377320|NCT00466024|ETS
1377321|NCT00465998|Ultrasound
1377322|NCT00465998|Induced labor
1377323|NCT00465998|Cervical length
1377324|NCT00465998|Engagement of fetal head
1377325|NCT00465998|Occiput posterior
1377326|NCT00465998|Outcome of labor
1377327|NCT00465985|Muckle-Wells Syndrome
1377328|NCT00465985|children
1377329|NCT00465985|systemic autoinflammatory disease
1377330|NCT00465985|CIAS-1 gene
1377331|NCT00465985|NALP-3
1377332|NCT00465985|ACZ885
1377333|NCT00465985|human monoclonal anti-human interleukin-1beta (IL-1beta)
1377334|NCT00465985|antibody
1377335|NCT00465985|autosomal dominant
1377336|NCT00465985|familial autoinflammatory syndrome
1377337|NCT00465972|HIV
1377338|NCT00465972|Insomnia
1377339|NCT00465972|Cytokines
1377340|NCT00465972|Adherence
1377341|NCT00465959|COPD
1377342|NCT00465946|Salt supplementation
1377343|NCT00465946|Vasovagal syncope
1377344|NCT00465946|Orthostatic tolerance
1377345|NCT00465946|Healthy volunteers
1377346|NCT00465933|Acute Promyelocytic Leukemia
1377347|NCT00465933|AIDA
1377348|NCT00465920|schizophrenia
1377349|NCT00465920|cognitive behavioural therapy
1377350|NCT00465920|early onset psychosis
1377351|NCT00465920|Psychotic disorders (schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder according to DSM IV) in adolescents
1377352|NCT00465907|lung cancer with malignant pleural effusion
1377353|NCT00465894|overactive bladder
1377354|NCT00465894|urge leakage
1377355|NCT00465894|nightime urination
1377356|NCT00465894|incontinence
1377357|NCT00465894|urinary frequency
1377358|NCT00465881|Diabetes
1377359|NCT00465881|CGM
1377360|NCT00465868|Acute Myocardial Infarction
1377361|NCT00465868|Coronary Revascularization
1377362|NCT00465868|Microvascular Obstruction
1377363|NCT00465868|Cardiac MR
1377364|NCT00465868|Collagen Turnover
1377365|NCT00465868|Heart failure, post-mi
1377366|NCT00465855|Carbon monoxide poisoning
1377367|NCT00465855|Hyperbaric oxygen therapy
1377368|NCT00465855|Randomized controlled trial
1377369|NCT00465855|Clinical investigation
1377370|NCT00465842|Hepatitis
1377371|NCT00465842|Liver Cirrhosis
1377372|NCT00465842|HCC
1377373|NCT00465829|Obesity
1377374|NCT00465816|non-inferiority
1377375|NCT00465816|adolescents
1377376|NCT00465816|meningococcal vaccine
1377377|NCT00465803|Open-angle glaucoma or ocular hypertension
1377378|NCT00465790|biomarkers
1377379|NCT00465790|neuroimaging
1377380|NCT00465790|genetics
1377381|NCT00465790|PET
1377382|NCT00465790|Genetic and Idiopathic Parkinson
1377383|NCT00465790|Multiple Systemic Atrophy
1377384|NCT00465790|Huntington
1377385|NCT00465790|Dopa Responsive Dystonia
1377386|NCT00465777|malaria
1377387|NCT00465777|mortality
1377388|NCT00465777|hospital
1377389|NCT00465777|incentive
1377390|NCT00465777|personnel
1377391|NCT00465777|paediatric
1377392|NCT00465764|healthy infants
1377393|NCT00465725|Picoplatin
1377394|NCT00465725|tumor
1377395|NCT00465725|cancer
1377396|NCT00465725|sarcoma
1377397|NCT00465725|neoplasm
1377398|NCT00465725|advanced
1377399|NCT00465725|platinum
1377400|NCT00465725|chemotherapy
1377401|NCT00465725|Solid Tumor
1377402|NCT00465712|transabdominal amnioinfusion
1377403|NCT00465712|external cephalic version
1377404|NCT00465712|breech presentation
1377405|NCT00465699|Eczema
1377406|NCT00465699|Pediatric
1377407|NCT00465699|Vitamin B12
1377408|NCT00465686|handwriting
1377409|NCT00465686|child
1377410|NCT00465686|primary school
1377411|NCT00465686|posture
1377412|NCT00465686|assistive device
1377413|NCT00465673|breast cancer
1377414|NCT00465673|brain metastatsis
1377415|NCT00465673|Lipo-Dox
1377416|NCT00465621|Open-angle glaucoma
1377417|NCT00465621|ocular hypertension
1377418|NCT00465608|adults
1377419|NCT00465608|PTSD
1377420|NCT00465608|trauma
1377421|NCT00465608|AZF
1377422|NCT00465608|propranolol
1377423|NCT00465608|reconsolidation
1377424|NCT00465608|Post traumatic stress disorder
1377425|NCT00465608|chronic form
1377426|NCT00465608|PTSD (Post-Traumatic Stress Disorder)
1377427|NCT00465582|carriage
1377428|NCT00465582|Neisseria meningitidis
1377429|NCT00465582|risk factors
1377430|NCT00465569|Food Allergy
1377431|NCT00465569|Oral Immunotherapy
1377432|NCT00465569|Immunoglobulin E
1377433|NCT00465543|Nasal polyposis
1377434|NCT00465543|Mint tea
1377435|NCT00465543|Double-blind
1377436|NCT00465543|Placebo-controlled
1377437|NCT00465543|Crossover
1377438|NCT00465517|Partial onset seizures
1377563|NCT00465010|Parenting
1377439|NCT00465517|Complex-partial seizures
1377440|NCT00465517|Anticonvulsant
1377441|NCT00465517|Partial seizures
1377442|NCT00465517|Catamenial epilepsy
1377443|NCT00465504|local analgesia
1377444|NCT00465504|intra-articular corticosteroid injection
1377445|NCT00465504|iontophoresis
1377446|NCT00465504|Local analgesia for intra-articular corticosteroid injection
1377447|NCT00465491|refractory
1377448|NCT00465491|chemotherapy
1377449|NCT00465491|progressed
1377450|NCT00465491|second-line treatment
1377451|NCT00465491|small cell lung cancer
1377452|NCT00465491|best supportive care
1377453|NCT00465491|picoplatin
1377454|NCT00465478|Diabetes Mellitus
1377455|NCT00465478|Bone Marros Mononuclear Cells
1377456|NCT00465478|Transplantation
1377457|NCT00465465|Tuberculosis
1377458|NCT00465465|TB
1377459|NCT00465465|MVA 85A
1377460|NCT00465465|BCG
1377461|NCT00465439|femoral artery sheath
1377462|NCT00465439|vasovagal reaction
1377463|NCT00465439|pain
1377464|NCT00465439|perception
1377465|NCT00465426|HIV Infection
1377466|NCT00465426|Cardiovascular Disease
1377467|NCT00465426|Antiretroviral Therapy
1377468|NCT00465426|Inflammatory Markers
1377469|NCT00465426|Treatment Experienced
1377470|NCT00465413|metered-dose inhalers (MDI)
1377471|NCT00465413|forced expiratory volume in 1 second (FEV1)
1377472|NCT00465413|forced expiratory flow rate (FEF25-75%)
1377473|NCT00465400|exudative age-related macular degeneration (AMD)
1377474|NCT00465400|non-exudative age-related macular degeneration (AMD)
1377475|NCT00465400|oxidative stress
1377476|NCT00465400|photodynamic therapy
1377477|NCT00465374|ARDS
1377478|NCT00465374|Pressure/time curve
1377479|NCT00465374|Stress Index
1377480|NCT00465361|Growth and Development
1377481|NCT00465361|Child Development
1377482|NCT00465361|Developmental Surveillance
1377483|NCT00465361|Medical Education
1377484|NCT00465361|Internship and Residency
1377485|NCT00465348|normal tension glaucoma
1377486|NCT00465348|vascular dysregulation
1377487|NCT00465335|computed tomography
1377488|NCT00465335|stress test
1377489|NCT00465335|equivocal
1377490|NCT00465335|catheterization
1377491|NCT00465309|Respiratory Insufficiency
1377492|NCT00465309|CO2 removal
1377493|NCT00465309|protective ventilation
1377494|NCT00465309|ARDS
1377495|NCT00465283|Donepezil, ECT, Memory Disfunction
1377496|NCT00465270|Cryptogenic
1377497|NCT00465270|Stroke
1377498|NCT00465270|PFO
1377499|NCT00465244|Prehospital and ED seizures
1377500|NCT00465231|Induction of labour
1377501|NCT00465231|Bupivacaine consumption
1377502|NCT00465231|Prevention
1377503|NCT00465218|Bioprosthesis
1377504|NCT00465218|Thrombosis
1377505|NCT00465218|Cerebral emboli
1377506|NCT00465218|Transcranial Doppler
1377507|NCT00465218|Platelet function tests
1377508|NCT00465205|HIV infection
1377509|NCT00465205|HIV Shedding
1377510|NCT00465205|HSV suppression
1377511|NCT00465205|Co-infected
1377512|NCT00465205|Women
1377513|NCT00465205|Reactivation
1377514|NCT00465205|Valacyclovir
1377515|NCT00465205|Treatment Naive
1377516|NCT00465179|Non-Clear Cell Renal Carcinoma
1377517|NCT00465179|Non-clear cell renal cell cancer
1377518|NCT00465179|Renal Cell Cancer
1377519|NCT00465179|Kidney Cancer
1377520|NCT00465179|Papillary
1377521|NCT00465179|Chromophobe
1377522|NCT00465179|Collecting duct carcinoma
1377523|NCT00465179|CDC
1377524|NCT00465179|Renal medullary carcinoma
1377525|NCT00465179|RMC
1377526|NCT00465179|Sunitinib Malate
1377527|NCT00465179|Sutent
1377528|NCT00465179|SU011248
1377529|NCT00465166|Accidental dural puncture
1377530|NCT00465166|Labour epidural
1377531|NCT00465166|Ultrasound
1377532|NCT00465166|Ligamentum flavum
1377533|NCT00465153|Inflammation
1377534|NCT00465153|cytokines
1377535|NCT00465153|sarcopenia
1377536|NCT00465153|strength
1377537|NCT00465153|muscle
1377538|NCT00465153|aging
1377539|NCT00465153|exercise
1377540|NCT00465114|Preeclampsia
1377541|NCT00465114|Hemodynamic monitoring
1377542|NCT00465101|Benign Prostatic Hyperplasia
1377543|NCT00465101|Transurethral resection of the prostate
1377544|NCT00465101|Lower urinary tract symptoms
1377545|NCT00465101|GreenLight
1377546|NCT00465101|Laserscope
1377547|NCT00465101|Photoselective vaporization of the prostate
1377548|NCT00465101|enlarged prostate
1377549|NCT00465062|Lysosomal Disease
1377550|NCT00465062|Lipids
1377551|NCT00465062|B Lymphocytes
1377552|NCT00465062|Brain Damage
1377553|NCT00465062|Gaucher Disease
1377554|NCT00465062|GD
1377555|NCT00465049|abscess, primary closure, secondary closure
1377556|NCT00465036|fat absorption
1377557|NCT00465036|fibres
1377558|NCT00465023|proton beam irradiation
1377559|NCT00465023|liver cancer
1377560|NCT00465010|Adolescence
1377561|NCT00465010|Sexual health
1377562|NCT00465010|Communication
1377564|NCT00464997|methotrexate aspirin pharmacokinetics
1377565|NCT00464984|Weight loss
1377566|NCT00464984|Physical fitness
1377567|NCT00464984|Quality of life
1377568|NCT00464958|Fatigue
1377569|NCT00464958|Spasticity
1377570|NCT00464958|Sublingual Tizanidine
1377571|NCT00464958|Epworth Sleepiness Scale
1377572|NCT00464958|Fatigue Severity Scale
1377573|NCT00464932|COPD
1377574|NCT00464932|Vasoactive Intestinal Peptide
1377575|NCT00464932|Lung Function
1377576|NCT00464919|Advance, hepatocellular carcinoma
1377577|NCT00464893|gastric cancer
1377578|NCT00464893|catumaxomab
1377579|NCT00464893|neoadjuvant chemotherapy
1377580|NCT00464893|phase II
1377581|NCT00464893|interoperative
1377582|NCT00464893|trifunctional antibody
1377583|NCT00464880|Placebo-controlled study
1377584|NCT00464880|assess the renoprotective effect of renin inhibition
1377585|NCT00464880|Aliskiren as an alternative to irbesartan
1377586|NCT00464880|Type 2 diabetes patients
1377587|NCT00464880|incipient/overt diabetic nephropathy
1377588|NCT00464867|Bifidobacterium breve
1377589|NCT00464867|oral whole cell cholera vaccine
1377590|NCT00464867|immunogenicity
1377710|NCT00464464|depression
1377831|NCT00464178|TRAPPC1 protein, human
1377591|NCT00464867|Supplementation with probiotic improves vibriocidal antibody response in 2-5 year old childern given the killed oral cholera vaccine
1377592|NCT00464867|Supplementation with probiotics results in improving the ASC responses to CT and LPS of V. cholerae O1
1377593|NCT00464854|Glucose control
1377594|NCT00464854|Subcutaneous insulin treatment
1377595|NCT00464854|Multiple daily injections
1377596|NCT00464841|Tsui Test
1377597|NCT00464841|Combined Spinal Epidural
1377598|NCT00464841|Labour
1377599|NCT00464828|Central venous cannulation
1377600|NCT00464828|Internal jugular vein
1377601|NCT00464828|Ultrasound
1377602|NCT00464828|Obstetrics
1377603|NCT00464815|immunogenicity
1377604|NCT00464815|safety
1377605|NCT00464815|meningococcal vaccine
1377606|NCT00464802|healthy
1377607|NCT00464802|safety
1377608|NCT00464789|Postmenopausal
1377609|NCT00464776|Randomized
1377610|NCT00464776|double-blind
1377611|NCT00464776|cross-over
1377612|NCT00464776|4-period
1377613|NCT00464776|4 treatment
1377614|NCT00464776|within-subject placebo-controlled study
1377615|NCT00464776|assess optimal renoprotective dose of Aliskiren
1377616|NCT00464776|hypertensive type 2 diabetes patients
1377617|NCT00464776|incipient or overt nephropathy
1377618|NCT00464763|Mental Health
1377619|NCT00464763|Neurological Disease
1377620|NCT00464763|Heart Valve Repair Surgery
1377621|NCT00464750|Cardiac output
1377622|NCT00464750|Thermodilution
1377623|NCT00464737|Fibromyalgia Syndrome
1377624|NCT00464737|Rotigotine
1377625|NCT00464737|Neupro
1377626|NCT00464724|Prostate Cancer
1377627|NCT00464724|Magnetic Resonance Spectroscopic Imaging
1377628|NCT00464724|Perfluorocarbon Compound
1377629|NCT00464724|AIR-MRSI
1377630|NCT00464724|PFC-MRSI
1377631|NCT00464724|3 Tesla
1377632|NCT00464724|MRSI
1377633|NCT00464724|PFC
1377634|NCT00464711|depression
1377635|NCT00464711|biology
1377636|NCT00464698|OCD
1377637|NCT00464698|Obsessive Compulsive Disorder
1377638|NCT00464698|Obsessions
1377639|NCT00464698|Compulsions
1377640|NCT00464698|Duloxetine
1377641|NCT00464698|Cymbalta
1377642|NCT00464672|Influenza, Egg-Derived, Healthy Children, Healthy Adolescents, Healthy Adults, Safety, Immunogenicity, Trivalent, Inactivated, Vaccination
1377643|NCT00464659|Sleep apnea obstructive syndrome (SAOS)
1377644|NCT00464659|memory deficit
1377645|NCT00464659|Continuous Positive Airway Pression (CPAP)
1377646|NCT00464659|Sham CPAP
1377647|NCT00464646|NSABP
1377648|NCT00464646|Epirubicin
1377649|NCT00464646|Cyclophosphamide
1377650|NCT00464646|Docetaxel
1377651|NCT00464646|Trastuzumab
1377652|NCT00464646|Bevacizumab
1377653|NCT00464646|Neoadjuvant Therapy
1377654|NCT00464646|HER2
1377655|NCT00464646|Locally Advanced Breast Cancer
1377656|NCT00464646|Adjuvant Therapy
1377657|NCT00464646|Pathologic Stage III Breast Cancer
1377658|NCT00464646|Inflammatory Breast Cancer
1377659|NCT00464633|CLL
1377660|NCT00464633|PLL
1377661|NCT00464633|flavopiridol
1377662|NCT00464620|Dasatinib
1377663|NCT00464620|Rhabdomyosarcoma
1377664|NCT00464620|Malignant peripheral nerve sheath tumor
1377665|NCT00464620|Chondrosarcoma
1377666|NCT00464620|Ewing's
1377667|NCT00464620|Alveolar soft part sarcoma (ASPS)
1377668|NCT00464620|Chordoma
1377669|NCT00464620|Epithelioid sarcoma
1377670|NCT00464620|Giant cell tumor of bone
1377671|NCT00464620|Hemangiopericytoma/solitary fibrous tumor
1377672|NCT00464620|Gastrointestinal Stromal Tumor (GIST)
1377673|NCT00464594|Japan Early Diabetes Intervention Study
1377674|NCT00464581|non-ischemic retinopathy
1377675|NCT00464568|Seasonal allergic rhinitis,
1377676|NCT00464568|hayfever
1377677|NCT00464555|Allogeneic Islets
1377678|NCT00464555|Allogeneic Islet Transplantation
1377679|NCT00464555|Type 1 diabetes mellitus
1377680|NCT00464555|Type 1 diabetes
1377681|NCT00464555|T1D
1377682|NCT00464555|T1DM
1377683|NCT00464555|Insulin dependence
1377684|NCT00464555|Hypoglycemia unawareness in T1D
1377685|NCT00464555|Islet transplant
1377686|NCT00464555|Islet transplantation
1377687|NCT00464555|Islet graft
1377688|NCT00464542|herpes simplex virus
1377689|NCT00464529|blood glucose
1377690|NCT00464529|hyperglycemia
1377691|NCT00464529|hypoglycemia
1377692|NCT00464529|Perioperative care
1377693|NCT00464529|inpatient
1377694|NCT00464516|Breast cancer (Estrogen Receptor positive)
1377695|NCT00464503|statins
1377696|NCT00464503|proteinuria
1377697|NCT00464503|proteomic analysis
1377698|NCT00464503|healthy volunteers
1377699|NCT00464490|Weaning
1377700|NCT00464490|Extuvation
1377701|NCT00464490|Dexmedetomidine
1377702|NCT00464477|Autism
1377703|NCT00464477|Autistic disorder
1377704|NCT00464477|Pervasive developmental disorder
1377705|NCT00464477|Asperger syndrome
1377706|NCT00464477|Childhood disintegrative disorder
1377707|NCT00464477|Rett syndrome
1377708|NCT00464464|Parkinson's disease
1377709|NCT00464464|PD
1377711|NCT00464464|cognitive-behavioral therapy
1377712|NCT00464464|social support
1377713|NCT00464425|Electroacupuncture
1377714|NCT00464425|Postoperative ileus
1377715|NCT00464425|Colorectal surgery
1377716|NCT00464425|Laparoscopic surgery
1377717|NCT00464425|Randomised trial
1377718|NCT00464412|Osteoporosis
1377719|NCT00464412|Knowledge
1377720|NCT00464412|Beliefs
1377721|NCT00464412|Education
1377722|NCT00464412|Women
1377723|NCT00464399|De novo renal transplantation
1377724|NCT00464399|CNI-free protocol
1377725|NCT00464399|adults
1377726|NCT00464399|everolimus
1377727|NCT00464399|rejections
1377728|NCT00464386|Severe burns
1377729|NCT00464386|Severe Trauma
1377730|NCT00464386|Closed loop insulin
1377731|NCT00464386|continuous glucose monitoring
1377732|NCT00464373|Prostatitis
1377733|NCT00464373|Chronic Prostatitis with Chronic Pelvic Pain Syndrome
1377734|NCT00464373|Botulinum Toxin Type A
1377735|NCT00464373|Drug therapy
1377736|NCT00464373|Injections, intramuscular
1377737|NCT00464347|AMD
1377738|NCT00464347|wet AMD
1377739|NCT00464347|verteporfin PDT
1377740|NCT00464347|Avastin
1377741|NCT00464347|TAC-PF
1377742|NCT00464308|Gastroesophageal Reflux
1377743|NCT00464308|Heartburn
1377744|NCT00464308|Proton pump inhibitor
1377745|NCT00464308|GORD
1377746|NCT00464295|Hepatocellular Carcinoma
1377747|NCT00464295|Phase 2 Trial
1377748|NCT00464295|Capecitabine
1377749|NCT00464295|Treatment Efficacy
1377750|NCT00464282|Fluorine–18-α–methyltyrosine,
1377751|NCT00464282|Positron emission tomography,
1377752|NCT00464282|Fluorodeoxyglucose
1377753|NCT00464282|Lung cancer,
1377754|NCT00464282|Amino acid transportor 1,
1377755|NCT00464282|Ki-67
1377756|NCT00464282|Proven or suspected non-small cell lung cancer were enrolled in the study
1377757|NCT00464269|Epilepsy
1377758|NCT00464269|Brivaracetam
1377759|NCT00464269|Partial Onset Seizures, Adolescents & Adults
1377760|NCT00464256|abstinence
1377761|NCT00464243|Sleep problems
1377762|NCT00464243|Insomnia
1377763|NCT00464243|Sleeplessness
1377764|NCT00464243|Polysomnographic
1377765|NCT00464230|Displaced Femoral Neck Fractures
1377766|NCT00464230|Treatment
1377767|NCT00464230|Function
1377768|NCT00464230|Pain
1377769|NCT00464230|Quality of life
1377770|NCT00464230|Complications
1377771|NCT00464230|Reoperations
1377772|NCT00464230|Internal Fixation
1377773|NCT00464230|Hemiarthroplasty
1377774|NCT00464230|Activities of Daily Living
1377775|NCT00464217|Acute Myeloblastic Leukaemia
1377776|NCT00464191|bipolar depression
1377777|NCT00464191|SSRI
1377778|NCT00464191|escitalopram
1377779|NCT00464191|bipolar disorder
1377780|NCT00464191|antidepressant
1377781|NCT00464191|treatment trial
1377782|NCT00464191|RCT
1377783|NCT00464178|multiple myeloma
1377784|NCT00464178|myeloma
1377785|NCT00464178|relapsed myeloma
1377786|NCT00464178|refractory myeloma
1377787|NCT00464178|relapsed, refractory myeloma
1377788|NCT00464178|relapsed, refractory multiple myeloma
1377789|NCT00464178|refractory multiple myeloma
1377790|NCT00464178|relapsed multiple myeloma
1377791|NCT00464178|B lymphoid malignancies
1377792|NCT00464178|Myeloma, Plasma-Cell
1377793|NCT00464178|Myeloma Proteins
1377794|NCT00464178|hnRNP A1
1377795|NCT00464178|myeloma helix-destabilizing protein, mouse
1377796|NCT00464178|IgC3kappa Jir protein, human
1377797|NCT00464178|gamma 3 myeloma protein Jir, human
1377798|NCT00464178|M-proteins (Myeloma)
1377799|NCT00464178|M315 myeloma protein, mouse
1377800|NCT00464178|myeloma protein M 315, mouse
1377801|NCT00464178|McPC603 antibody
1377802|NCT00464178|myeloma protein McPC603 antibody
1377803|NCT00464178|multiple myeloma M-proteins
1377804|NCT00464178|M protein, multiple myeloma
1377805|NCT00464178|myeloma cell activator
1377806|NCT00464178|myeloma immunoglobulins
1377807|NCT00464178|myeloma immunoglobulin M603
1377808|NCT00464178|myeloma immunoglobulin S15
1377809|NCT00464178|myeloma protein A48, mouse
1377810|NCT00464178|A48 myeloma protein, mouse
1377811|NCT00464178|ABPC48 myeloma protein, mouse
1377812|NCT00464178|myeloma protein A 48, mouse
1377813|NCT00464178|myeloma protein Dob
1377814|NCT00464178|myeloma protein M 467
1377815|NCT00464178|myeloma protein M467
1377816|NCT00464178|myeloma protein MOPC 141, mouse
1377817|NCT00464178|MOPC141 myeloma protein, mouse
1377818|NCT00464178|myeloma protein MOPC 173
1377819|NCT00464178|myeloma protein Rou
1377820|NCT00464178|IgA2 myeloma protein Rou
1377821|NCT00464178|myeloma protein TEPC15
1377822|NCT00464178|myeloma protein T15
1377823|NCT00464178|myeloma protein TEPC 15
1377824|NCT00464178|myeloma protein W3129
1377825|NCT00464178|myeloma protein WIE
1377826|NCT00464178|myeloma-associated membrane antigen KMA
1377827|NCT00464178|myeloma antigen KMA
1377828|NCT00464178|MYEOV protein, human
1377829|NCT00464178|protein 460
1377830|NCT00464178|myeloma protein MOPC 460
1377832|NCT00464178|multiple myeloma protein 2, human
1377833|NCT00464178|Wis heavy-chain disease protein, human
1377834|NCT00464178|myeloma protein Wis, human
1377835|NCT00464165|abstinence
1377836|NCT00464139|endometriosis
1377837|NCT00464139|prevalence
1377838|NCT00464139|fertility
1377839|NCT00464139|pain
1377840|NCT00464139|ultrasound
1377841|NCT00464126|crystalloid
1377842|NCT00464126|colloid
1377843|NCT00464126|pediatric
1377844|NCT00464126|cardiac
1377845|NCT00464126|resuscitation
1377846|NCT00464126|Postoperative
1377847|NCT00464113|Myeloid Leukemia
1377848|NCT00464113|Lymphocytic Leukemia
1377849|NCT00464113|Ph+ ALL
1377850|NCT00464100|Neurodevelopmental outcomes
1377851|NCT00464100|congenital heart disease
1377852|NCT00464100|NIRS monitoring
1377853|NCT00464100|hypoxia
1377854|NCT00464074|fatigue
1377855|NCT00464074|Tysabri
1377856|NCT00464074|cognition
1377857|NCT00464061|Sleep problems
1377858|NCT00464061|Insomnia
1377859|NCT00464061|Sleeplessness
1377860|NCT00464061|Primary insomnia
1377861|NCT00464061|Insomnia disorder
1377862|NCT00464035|Obesity
1377863|NCT00464035|Calcium
1377864|NCT00464035|Fat absorption
1377865|NCT00464035|Postprandial lipid profile
1377866|NCT00464035|appetite
1377867|NCT00464022|pain, endoscopy
1377868|NCT00464022|Pain, endoscopy, randomised trial
1377869|NCT00464009|Early childhood caries - ECC
1377870|NCT00464009|Prevention
1377871|NCT00464009|Continuing medical education
1377872|NCT00464009|Randomized controlled trial
1377873|NCT00463996|Ovarian cancer
1377874|NCT00463996|MRI
1377875|NCT00463996|Contrast agent
1377876|NCT00463970|Chronic low back pain
1377877|NCT00463970|Brief cognitive intervention
1377878|NCT00463970|Cognitive behavior therapy
1377879|NCT00463970|Seal oil
1377880|NCT00463957|sildenafil
1377881|NCT00463957|tadalafil
1377882|NCT00463957|phosphodiesterase
1377883|NCT00463957|visual persistence
1377884|NCT00463957|reaction time
1377885|NCT00463944|Electronic voting system
1377886|NCT00463931|Schistosomiasis
1377887|NCT00463931|Soiltransmitted helminthiasis
1377888|NCT00463931|Community-based volunteer
1377889|NCT00463931|School based treatment approach
1377890|NCT00463905|osteoporosis
1377891|NCT00463905|vertebral fractures
1377892|NCT00463905|randomised controlled trial
1377893|NCT00463905|screening
1377894|NCT00463892|melanoma
1377895|NCT00463892|lymph nodes
1377896|NCT00463892|magnetic resonance imaging
1377897|NCT00463892|screening
1377898|NCT00463892|detection
1377899|NCT00463879|Schizophrenia
1377900|NCT00463879|Cognition
1377901|NCT00463879|Smoking
1377902|NCT00463879|Galantamine
1377903|NCT00463879|Nicotine
1377904|NCT00463879|Cognitive Deficits
1377905|NCT00463866|Asthma
1377906|NCT00463853|Bone Marrow Cells
1377907|NCT00463853|Cardiovascular Surgery
1377908|NCT00463853|Coronary Artery Bypass Graft
1377909|NCT00463853|Phase I Study
1377910|NCT00463853|Stem Cells
1377911|NCT00463840|Locally advanced pancreatic cancer
1377912|NCT00463840|oxaliplatin
1377913|NCT00463840|chemoradiation
1377914|NCT00463840|5FU
1377915|NCT00463827|asthma
1377916|NCT00463827|smokers
1377917|NCT00463827|statin
1377918|NCT00463827|atorvastatin
1377919|NCT00463827|randomised
1377920|NCT00463827|placebo
1377921|NCT00463827|cigarette
1377922|NCT00463827|blind
1377923|NCT00463827|COPD
1377924|NCT00463814|Advanced Malignancy
1377925|NCT00463814|Cancer Eligibility
1377926|NCT00463814|Malignancy
1377927|NCT00463801|Complicated Skin and Skin-Structure Infections, Daptomycin, MRSA, Diabetic Foot, Abscess, Cellulitis
1377928|NCT00463801|Complicated skin and skin-structure infections
1377929|NCT00463788|cancer
1377930|NCT00463788|breast
1377931|NCT00463788|metastatic
1377932|NCT00463788|triple negative
1377933|NCT00463775|Treatment
1377934|NCT00463775|Topiramate
1377935|NCT00463775|Alcohol Dependence
1377936|NCT00463775|Borderline Personality Disorder
1377937|NCT00463749|primary PCI
1377938|NCT00463749|nephropathy
1377939|NCT00463749|infarct size
1377940|NCT00463749|infarction
1377941|NCT00463749|ST-elevation myocardial infarction
1377942|NCT00463736|short term tocolysis
1377943|NCT00463736|preterm premature rupture of membranes
1377944|NCT00463723|penetrating keratoplasty
1377945|NCT00463723|graft rejection
1377946|NCT00463723|immunosuppression
1377947|NCT00463710|MTI, DWI, Avonex, MRI
1377948|NCT00463697|GW642444,
1377949|NCT00463697|magnesium stearate,
1377950|NCT00463697|asthmatic patients
1377951|NCT00463658|Falls
1377952|NCT00463658|Home Care
1377953|NCT00463658|Aging Population
1377954|NCT00463658|Clinical Effectiveness
1377955|NCT00463658|Health Economics
1377956|NCT00463632|schistosomiasis
1377957|NCT00463632|anaemia
1377958|NCT00463632|pregnancy
1377959|NCT00463593|schistosomiasis
1377960|NCT00463593|helminthes
1377961|NCT00463593|anaemia
1377962|NCT00463580|depression
1377963|NCT00463580|TNF-alpha antagonist
1377964|NCT00463580|infliximab
1377965|NCT00463580|treatment resistant depression
1377966|NCT00463580|major depressive disorder (MDD)
1377967|NCT00463580|bipolar I disorder
1377968|NCT00463580|bipolar II disorder
1377969|NCT00463567|indacaterol
1377970|NCT00463567|long acting beta-2 agonist
1377971|NCT00463554|Incontinence
1377972|NCT00463554|Stress Urinary
1377973|NCT00463541|Urinary Bladder, Overactive
1377974|NCT00463541|Urgency
1377975|NCT00463541|VESIcare®
1377976|NCT00463541|Solifenacin succinate
1377977|NCT00463528|schistosomiasis
1377978|NCT00463528|gender perspectives
1377979|NCT00463515|Non-Small Cell Lung Cancer
1377980|NCT00463515|NSCLC
1377981|NCT00463515|Chemoradiation
1377982|NCT00463515|lung cancer
1377983|NCT00463515|induction chemotherapy
1377984|NCT00463515|chemo-radiotherapy
1377985|NCT00463502|The purpose of study was investigated the effect of
1377986|NCT00463502|metformin on thyroid hormone metabolism in euthyroid patients
1377987|NCT00463502|with type 2 DM. The results revealed significant decreases
1377988|NCT00463502|in TSH and fT4
1377989|NCT00463489|lifestyle intervention
1377990|NCT00463489|breast
1377991|NCT00463489|cancer
1377992|NCT00463489|adjuvant
1377993|NCT00463489|letrozole
1377994|NCT00463489|weight loss
1377995|NCT00463489|BMI
1377996|NCT00463489|post-menopausal
1377997|NCT00463489|estrogen receptor positive
1377998|NCT00463489|progesterone receptor positive
1377999|NCT00463450|Hormone Replacement Therapy
1378000|NCT00463450|Impaired well-being, mood and sexuality
1378001|NCT00463437|Fever.
1378002|NCT00463437|Meningococcal disease.
1378003|NCT00463437|Pneumococcal disease.
1378004|NCT00463437|Meningococcal vaccine.
1378005|NCT00463437|Pneumococcal vaccine.
1378006|NCT00463437|Immunogenicity.
1378007|NCT00463437|Booster vaccination.
1378008|NCT00463437|Safety.
1378009|NCT00463424|Metacarpophalangeal Joint
1378010|NCT00463424|Arthroplasty, Replacement
1378011|NCT00463424|Range of Motion, Articular
1378012|NCT00463424|Randomized Controlled Trials
1378013|NCT00463424|Swanson
1378014|NCT00463424|NeuFlex
1378015|NCT00463411|osteoporosis
1378016|NCT00463411|male
1378017|NCT00463411|fracture risk
1378018|NCT00463411|genetical epidemiology
1378019|NCT00463398|Endometriosis
1378020|NCT00463398|Fertility Surgery
1378021|NCT00463398|Quality of Life
1378022|NCT00463398|Pain
1378023|NCT00463398|Sexual Function
1378024|NCT00463398|Health economics
1378025|NCT00463398|Recurrence
1378026|NCT00463398|Pregnancy
1378027|NCT00463385|Celgene
1378028|NCT00463385|CC-4047
1378029|NCT00463385|Myelofibrosis
1378030|NCT00463385|myelofibrosis with myeloid metaplasia
1378031|NCT00463385|myeloid metaplasia
1378032|NCT00463385|JAK2
1378033|NCT00463385|CC-4047-MMM-001
1378034|NCT00463385|Prednisone
1378035|NCT00463385|Phase II
1378036|NCT00463385|pomalidomide
1378037|NCT00463385|bone marrow histology
1378038|NCT00463385|imids
1378039|NCT00463385|MMM
1378040|NCT00463385|Ashkenazi Jewish Population
1378041|NCT00463385|exposure to Thorotrast
1378042|NCT00463385|exposure to solvents (benzene and toluene)
1378043|NCT00463385|acute megakaryocytic leukemia
1378044|NCT00463385|history of polycythemia vera
1378045|NCT00463359|basal cell carcinoma
1378046|NCT00463359|curettage
1378047|NCT00463359|Imiquimod
1378048|NCT00463359|treatment
1378049|NCT00463346|Treatment
1378050|NCT00463346|Alcohol Dependence
1378051|NCT00463346|Schizophrenia
1378052|NCT00463333|postoperative delirium
1378053|NCT00463333|psychometric testing
1378054|NCT00463333|EEG
1378055|NCT00463333|serum markers
1378056|NCT00463320|Age-related macular degeneration (AMD),
1378057|NCT00463320|vascular endothelial growth factor (VEGF)receptor (VEGFR)
1378058|NCT00463320|choroidal neovascularization,
1378059|NCT00463307|schistosomiasis
1378060|NCT00463307|Schistosoma mansoni
1378061|NCT00463307|Circulating cathodic antigen urine dipstick
1378062|NCT00463294|CABG
1378063|NCT00463294|On-pump
1378064|NCT00463294|Off-pump
1378065|NCT00463281|stroke, ischemic
1378066|NCT00463281|computed tomography
1378067|NCT00463281|thrombolysis
1378068|NCT00463268|osteopenia
1378069|NCT00463268|osteoporosis prevention
1378070|NCT00463268|alendronate
1378071|NCT00463255|Diet
1378072|NCT00463255|elderly
1378073|NCT00463255|age-related diseases
1378074|NCT00463255|prevention
1378075|NCT00463255|cognitive decline
1378076|NCT00463255|Clinical study
1378077|NCT00463242|agomelatine, Major Depressive Disorder, MDD, depression
1378078|NCT00463229|stroke
1378079|NCT00463229|rehabilitation
1378080|NCT00463229|home care services
1378081|NCT00463229|effectiveness
1378082|NCT00463229|quantitative research
1378083|NCT00463229|interdisciplinary
1378084|NCT00463229|cost
1378085|NCT00463229|health services research, integrated
1378086|NCT00463216|back, neck, pain, sick leave
1378087|NCT00463203|primary malignant brain tumor
1378088|NCT00463203|grade II glioma
1378089|NCT00463203|meningeoma
1378090|NCT00463203|ependymoma
1378091|NCT00463203|Recurrence or progression after standard treatment
1378092|NCT00463190|Probiotics
1378093|NCT00463190|Diarrhea
1378094|NCT00463190|Enterocolitis
1378095|NCT00463177|Pain
1378096|NCT00463177|Chronic pain
1378097|NCT00463177|Pain disorder
1378098|NCT00463177|Functional MRI
1378099|NCT00463177|Sensitization
1378100|NCT00463164|functional MRI
1378101|NCT00463151|Rebamipide
1378102|NCT00463151|Enema
1378103|NCT00463151|Ulcerative Colitis
1378104|NCT00463138|perceived increase or decrease in symptoms post treatment
1378105|NCT00463138|Satisfaction with the treatment
1378106|NCT00463125|Scleroderma, systemic
1378107|NCT00463125|therapeutic
1378108|NCT00463125|platelet gel
1378109|NCT00463112|Obesity
1378110|NCT00463112|Polycystic Ovary Syndrome
1378111|NCT00463112|weight loss
1378112|NCT00463112|Hyperadrogonemia
1378113|NCT00463112|Sibutramine
1378114|NCT00463099|Anterior Cruciate Ligament/injuries
1378115|NCT00463099|Anterior Cruciate Ligament/surgery
1378116|NCT00463099|Knee injuries/surgery
1378117|NCT00463099|Outcomes research
1378118|NCT00463099|Prospective Studies
1378119|NCT00463086|Tuberculosis
1378120|NCT00463086|TB
1378121|NCT00463086|Mycobacteria
1378122|NCT00463086|HIV
1378123|NCT00463086|Human immunodeficiency virus
1378124|NCT00463086|Latent tuberculosis infection
1378125|NCT00463086|HAART
1378126|NCT00463086|Highly active anti-retroviral therapy
1378127|NCT00463086|Isoniazid preventive therapy
1378128|NCT00463086|INH
1378129|NCT00463086|Opportunistic infections
1378130|NCT00463086|HIV-1
1378131|NCT00463086|Treatment Experienced
1378132|NCT00463086|AIDS
1378133|NCT00463086|Mycobacterium Tuberculosis
1378134|NCT00463073|Progressive primary Glioblastoma multiforme
1378135|NCT00463047|Breakthrough pain
1378136|NCT00463047|Opioid-tolerant
1378137|NCT00463047|Chronic pain
1378138|NCT00463034|stage IV breast cancer
1378139|NCT00463034|stage I breast cancer
1378140|NCT00463034|stage II breast cancer
1378141|NCT00463034|stage IIIA breast cancer
1378142|NCT00463034|stage IIIB breast cancer
1378143|NCT00463034|stage IIIC breast cancer
1378144|NCT00463021|Hectorol (doxercalciferol capsules)
1378145|NCT00463021|Zemplar (paricalcitol injection)
1378146|NCT00463008|adult anaplastic astrocytoma
1378147|NCT00463008|adult anaplastic oligodendroglioma
1378148|NCT00463008|adult glioblastoma
1378149|NCT00463008|recurrent adult brain tumor
1378150|NCT00463008|adult gliosarcoma
1378151|NCT00463008|adult giant cell glioblastoma
1378152|NCT00462995|Non Small Cell Lung Cancer
1378153|NCT00462995|Lung Cancer
1378154|NCT00462995|Erlotinib
1378155|NCT00462995|Neoadjuvant Treatment
1378156|NCT00462982|stage IV melanoma
1378157|NCT00462982|tumors metastatic to brain
1378158|NCT00462982|stage IV renal cell cancer
1378159|NCT00462982|recurrent melanoma
1378160|NCT00462982|recurrent renal cell cancer
1378161|NCT00462969|Endometrial cancer
1378162|NCT00462969|Sonohysterography
1378163|NCT00462956|lapatinib
1378164|NCT00462956|metastatic breast cancer
1378165|NCT00462956|trastuzumab (Herceptin)
1378166|NCT00462956|Stage IV breast cancer
1378167|NCT00462956|ErbB2
1378168|NCT00462956|ErbB1
1378169|NCT00462943|CML
1378170|NCT00462943|HHT
1378171|NCT00462943|Homoharringtonine
1378172|NCT00462943|Omacetaxine
1378173|NCT00462917|disease /disorder proneness /risk
1378174|NCT00462917|family genetics
1378175|NCT00462917|genetic counseling
1378176|NCT00462917|genetic marker
1378177|NCT00462917|genetic polymorphism
1378178|NCT00462917|genetic screening
1378179|NCT00462917|genetic susceptibility
1378180|NCT00462891|breast cancer
1378181|NCT00462878|Febrile neutropenia
1378182|NCT00462865|breast cancer
1378183|NCT00462865|neoadjuvant chemotherapy
1378184|NCT00462865|adjuvant treatment
1378185|NCT00462865|consolidation therapy
1378186|NCT00462865|anti-angiogenesis therapy
1378187|NCT00462852|thromboembolism
1378188|NCT00462852|stage III pancreatic cancer
1378189|NCT00462852|stage IV pancreatic cancer
1378190|NCT00462852|adenocarcinoma of the pancreas
1378191|NCT00462852|recurrent pancreatic cancer
1378192|NCT00462852|stage II pancreatic cancer
1378193|NCT00462839|Estimated Blood Loss
1378194|NCT00462839|Obstetrics
1378195|NCT00462839|postpartum hemorrhage
1378196|NCT00462813|cervical cancer
1378197|NCT00462813|cervical intraepithelial neoplasia grade 2
1378198|NCT00462813|cervical intraepithelial neoplasia grade 3
1378199|NCT00462813|cervical intraepithelial neoplasia grade 1
1378200|NCT00462787|acute undifferentiated leukemia
1378322|NCT00462449|Botulinum Toxin
1378201|NCT00462787|recurrent childhood acute lymphoblastic leukemia
1378202|NCT00462787|recurrent childhood acute myeloid leukemia
1378203|NCT00462787|recurrent adult acute lymphoblastic leukemia
1378204|NCT00462787|recurrent adult acute myeloid leukemia
1378205|NCT00462774|Myocardial infarction
1378206|NCT00462774|Heart failure
1378207|NCT00462774|Cell therapy
1378208|NCT00462774|Bone marrow
1378209|NCT00462774|CD133
1378210|NCT00462774|Bypass surgery
1378211|NCT00462774|Stem cells
1378212|NCT00462761|RTK
1378213|NCT00462761|kinase
1378214|NCT00462761|inhibitor
1378215|NCT00462761|tyrosine
1378216|NCT00462761|acute
1378217|NCT00462761|FLT3
1378218|NCT00462761|AC220
1378219|NCT00462761|pharmacokinetic
1378220|NCT00462761|pharmacokinetics
1378221|NCT00462761|PK
1378222|NCT00462761|pharmacodynamic
1378223|NCT00462761|pharmacodynamics
1378224|NCT00462761|mutations
1378225|NCT00462761|PD
1378226|NCT00462761|receptor
1378227|NCT00462761|class III
1378228|NCT00462761|relapsed
1378229|NCT00462761|refractory
1378230|NCT00462761|t(8;21)
1378231|NCT00462761|q22;q22
1378232|NCT00462761|AML1/ETO
1378233|NCT00462761|t(16;16
1378234|NCT00462761|p13;q22
1378235|NCT00462761|CBFbeta/MYH11
1378236|NCT00462761|inv(16)
1378237|NCT00462761|p13q22
1378238|NCT00462761|11q23
1378239|NCT00462761|dysplasia
1378240|NCT00462761|myeloid
1378241|NCT00462761|myelomonocytic
1378242|NCT00462761|monoblastic
1378243|NCT00462761|monocytic
1378244|NCT00462761|erythroid
1378245|NCT00462761|erythroleukemia
1378246|NCT00462761|megakaryoblastic
1378247|NCT00462761|basophilic
1378248|NCT00462761|panmyelosis
1378249|NCT00462761|myelofibrosis
1378250|NCT00462735|Cancer of the Nasal Cavity
1378251|NCT00462722|body composition
1378252|NCT00462722|bone density
1378253|NCT00462722|cyclooxygenase inhibitor
1378254|NCT00462722|bone metabolism
1378255|NCT00462722|muscle function
1378256|NCT00462722|muscle strength
1378257|NCT00462709|Hereditary angioedema
1378258|NCT00462709|C1 esterase inhibitor (human)
1378259|NCT00462696|stage II breast cancer
1378260|NCT00462696|stage IIIA breast cancer
1378261|NCT00462696|stage IIIB breast cancer
1378262|NCT00462696|stage IIIC breast cancer
1378263|NCT00462683|Stroke
1378264|NCT00462683|Anoxia
1378265|NCT00462683|Brain Injury
1378266|NCT00462683|Rehabilitation
1378267|NCT00462683|Osteoporosis
1378268|NCT00462683|Osteopenia
1378269|NCT00462670|Cardiac edema
1378270|NCT00462670|OPC-41061
1378271|NCT00462670|Vasopressin antagonist
1378272|NCT00462657|infection
1378273|NCT00462657|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1378274|NCT00462657|adult acute myeloid leukemia with inv(16)(p13;q22)
1378275|NCT00462657|adult acute myeloid leukemia with t(15;17)(q22;q12)
1378276|NCT00462657|adult acute myeloid leukemia with t(16;16)(p13;q22)
1378277|NCT00462657|adult acute myeloid leukemia with t(8;21)(q22;q22)
1378278|NCT00462657|adult acute lymphoblastic leukemia in remission
1378279|NCT00462657|adult acute myeloid leukemia in remission
1378280|NCT00462657|de novo myelodysplastic syndromes
1378281|NCT00462657|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1378282|NCT00462657|previously treated myelodysplastic syndromes
1378283|NCT00462657|recurrent adult acute lymphoblastic leukemia
1378284|NCT00462657|recurrent adult acute myeloid leukemia
1378285|NCT00462657|secondary acute myeloid leukemia
1378286|NCT00462657|secondary myelodysplastic syndromes
1378287|NCT00462657|graft versus host disease
1378288|NCT00462644|adrenal insufficiency
1378289|NCT00462644|etomidate
1378290|NCT00462644|rapid sequence induction
1378291|NCT00462631|coronary artery
1378292|NCT00462631|Diabetes
1378293|NCT00462618|Insomnia
1378294|NCT00462618|Elderly
1378295|NCT00462618|Affective disorders
1378296|NCT00462592|exercise-induced bronchoconstriction (EIB)
1378297|NCT00462592|airway inflammation
1378298|NCT00462579|carbapenem-resistant acinetobacter baumannii
1378299|NCT00462579|positive culture
1378300|NCT00462579|positive culture for carbapenem-resistant acinetobacter
1378301|NCT00462566|Motor cortex stimulation
1378302|NCT00462566|neuropathic
1378303|NCT00462566|pain
1378304|NCT00462566|complex regional pain syndrome
1378305|NCT00462566|deafferentation facial pain
1378306|NCT00462540|COPD
1378307|NCT00462540|Formoterol
1378308|NCT00462540|Ipratropium
1378309|NCT00462540|Crossover
1378310|NCT00462527|Cystatin C
1378311|NCT00462527|Acute renal failure
1378312|NCT00462527|Gastroenteritis
1378313|NCT00462527|Dehydration
1378314|NCT00462501|stage II rectal cancer
1378315|NCT00462501|stage III rectal cancer
1378316|NCT00462501|adenocarcinoma of the rectum
1378317|NCT00462475|GH
1378318|NCT00462475|IGF-I
1378319|NCT00462475|GH deficiency
1378320|NCT00462475|Atherosclerosis
1378321|NCT00462475|Insulin resistance syndrome
1378323|NCT00462449|Ness H200
1378324|NCT00462449|Functional Electrical Stimulation
1378325|NCT00462449|Repetitive Task Practice
1378326|NCT00462436|functional foods
1378327|NCT00462436|soy
1378328|NCT00462436|nuts
1378329|NCT00462436|LDL cholesterol
1378330|NCT00462436|fibre
1378331|NCT00462436|secondary prevention
1378332|NCT00462436|risk reduction
1378333|NCT00462436|endothelial function
1378334|NCT00462436|endothelial progenitor cells
1378335|NCT00462436|inflammation
1378336|NCT00462436|glycemic control
1378337|NCT00462436|HOMA
1378338|NCT00462423|Metastatic malignant melanoma
1378339|NCT00462423|First-line therapy
1378340|NCT00462410|recurrent breast cancer
1378341|NCT00462410|stage I breast cancer
1378342|NCT00462410|stage II breast cancer
1378343|NCT00462410|stage IIIA breast cancer
1378344|NCT00462410|stage IIIB breast cancer
1378345|NCT00462410|stage IIIC breast cancer
1378346|NCT00462410|stage IV breast cancer
1378347|NCT00462397|cervical adenocarcinoma
1378348|NCT00462397|cervical adenosquamous cell carcinoma
1378349|NCT00462397|cervical squamous cell carcinoma
1378350|NCT00462397|stage IB cervical cancer
1378351|NCT00462397|stage IIA cervical cancer
1378352|NCT00462397|stage IIB cervical cancer
1378353|NCT00462397|stage III cervical cancer
1378354|NCT00462397|stage IVA cervical cancer
1378355|NCT00462397|recurrent cervical cancer
1378356|NCT00462371|quality of life
1378357|NCT00462371|child diabetes mellitus type 1
1378358|NCT00462371|Continuous subcutaneous insulin infusion(CSII)
1378359|NCT00462371|metabolic control
1378360|NCT00462332|stage III chronic lymphocytic leukemia
1378361|NCT00462332|stage IV chronic lymphocytic leukemia
1378362|NCT00462306|Obstructive Sleep Apnea
1378363|NCT00462306|Pregnancy
1378364|NCT00462306|Berlin Questionnaire
1378365|NCT00462267|Nutrition
1378366|NCT00462267|Exercise
1378367|NCT00462267|Body mass index
1378368|NCT00462267|Lifestyle change
1378369|NCT00462267|Obesity
1378370|NCT00462267|Overweight
1378371|NCT00462267|Adolescents
1378372|NCT00462267|Teens
1378373|NCT00462254|Ramelteon
1378374|NCT00462254|Parkinson's disease
1378375|NCT00462254|Sleep disturbances
1378376|NCT00462241|Chest pain
1378377|NCT00462241|Chest wall
1378378|NCT00462241|Atypical chest pain
1378379|NCT00462241|Non-cardiac chest pain
1378380|NCT00462241|Undiagnosed chest pain
1378381|NCT00462241|Physical examination
1378382|NCT00462241|Randomized controlled trial
1378383|NCT00462241|Treatment study
1378384|NCT00462241|Chiropractor
1378385|NCT00462228|traumatic brain injury
1378386|NCT00462228|memory
1378387|NCT00462228|attention
1378388|NCT00462202|Diabetes
1378389|NCT00462202|Microalbuminuria
1378390|NCT00462202|Proteinuria
1378391|NCT00462202|Albuminuria
1378392|NCT00462202|KRX-101
1378393|NCT00462202|Sulodexide
1378394|NCT00462202|Nephropathy
1378395|NCT00462202|Keryx
1378396|NCT00462202|Collaborative Study Group
1378397|NCT00462202|Diabetic nephropathy with persistent microalbuminuria
1378398|NCT00462189|CAT-8015
1378399|NCT00462189|HA22
1378400|NCT00462189|HCL
1378401|NCT00462189|Relapse
1378402|NCT00462189|Refractory
1378403|NCT00462189|immunotherapy
1378404|NCT00462189|immunotoxin
1378405|NCT00462176|colorectal endometriosis
1378406|NCT00462176|deep infiltrating endometriosis
1378407|NCT00462176|dysmenorroe
1378408|NCT00462176|dyspareunia
1378409|NCT00462176|quality of life
1378410|NCT00462150|arthritis, rheumatoid
1378411|NCT00462150|expressed emotion
1378412|NCT00462150|randomized controlled trial
1378413|NCT00462150|affect
1378414|NCT00462150|blood sedimentation
1378415|NCT00462150|psychophysiology
1378416|NCT00462150|feasibility studies
1378417|NCT00462150|intervention studies
1378418|NCT00462150|time management
1378419|NCT00462137|GERD
1378420|NCT00462137|Gastroesphageal Reflux Disease (GERD)
1378421|NCT00462124|Prostate
1378422|NCT00462124|cancer
1378423|NCT00462124|radiation
1378424|NCT00462124|biodegradable implantable balloon
1378425|NCT00462124|intrarectal balloon
1378426|NCT00462111|indometacin
1378427|NCT00462111|reaction time
1378428|NCT00462111|postural balance
1378429|NCT00462111|obstacle avoidance
1378430|NCT00462111|accidental falls
1378431|NCT00462098|Osteonecrosis of the jaw
1378432|NCT00462098|hyperbaric oxygen
1378433|NCT00462098|bisphosphonates
1378434|NCT00462085|cerebral palsy
1378435|NCT00462085|ankle foot orthosis
1378436|NCT00462085|emg
1378437|NCT00462085|surface electromyography
1378438|NCT00462085|gait analysis
1378439|NCT00462059|Transition of care
1378440|NCT00462059|Continuity of care
1378441|NCT00462046|Berberine
1378442|NCT00462046|Type 2 diabetes
1378443|NCT00462046|Dyslipidemia
1378444|NCT00462020|appendicitis, perforation, abscess, treatment
1378445|NCT00461994|OBESITY
1378446|NCT00461994|CHILDREN
1378447|NCT00461994|METABOLIC PARAMETERS
1378448|NCT00461994|DIET
1378449|NCT00461994|EXERCISE
1378450|NCT00461981|Live, attenuated influenza virus vaccine (LAIV)
1378451|NCT00461981|Trivalent inactivated influenza virus vaccine (TIV)
1378452|NCT00461981|FluMist
1378453|NCT00461968|Cholesterol
1378454|NCT00461968|LDL
1378455|NCT00461968|Ezetimibe
1378456|NCT00461968|Statin
1378457|NCT00461968|Zetia
1378458|NCT00461968|Zocor
1378459|NCT00461968|Simvastin
1378460|NCT00461955|Symptomatic Multiple Myeloma
1378461|NCT00461955|first line treatment
1378462|NCT00461955|first autologous Stem Cell Transplantation
1378463|NCT00461955|ex vivo amplified autologous peripheral blood stem cells
1378464|NCT00461942|Health Food;
1378465|NCT00461942|Green Tea;
1378466|NCT00461942|Neuroprotection
1378467|NCT00461929|chronic myeloid leukemia
1378468|NCT00461929|gastrointestinal stromal cell tumors
1378469|NCT00461929|chromosome abnormality
1378470|NCT00461929|imatinib
1378471|NCT00461929|bone marrow aspiration
1378472|NCT00461916|half-dose depot triptorelin
1378473|NCT00461916|reduced-dose daily buserelin
1378474|NCT00461916|controlled ovarian stimulation
1378475|NCT00461916|long protocol
1378476|NCT00461916|ICSI
1378477|NCT00461903|essential hypertension
1378478|NCT00461903|symptomatic paroxysmal or persistent atrial fibrillation
1378479|NCT00461890|Alcohol
1378480|NCT00461890|Veterans
1378481|NCT00461890|Primary Care
1378482|NCT00461890|Naltrexone
1378483|NCT00461864|fracture
1378484|NCT00461864|occult
1378485|NCT00461864|hip
1378486|NCT00461851|Advanced/Metastatic Bladder Carcinoma
1378487|NCT00461838|colorectal endometriosis
1378488|NCT00461838|deep infiltrating endometriosis
1378489|NCT00461838|dysmenorroe
1378490|NCT00461838|dyspareunia
1378491|NCT00461838|quality of life
1378492|NCT00461825|Immunosuppression
1378493|NCT00461825|Kidney transplantation
1378494|NCT00461825|multicenter study
1378495|NCT00461799|Crigler-Najjar disease.
1378496|NCT00461799|Bilirubin.
1378497|NCT00461799|Phototherapy.
1378498|NCT00461799|Orlistat.
1378499|NCT00461799|Unconjugated hyperbilirubinemia.
1378500|NCT00461773|Neoadjuvant treatment
1378501|NCT00461760|HPV Screening/Testing for cervical cancer screening
1378502|NCT00461747|Untreated
1378503|NCT00461747|Transplant
1378504|NCT00461747|Younger
1378505|NCT00461734|Right Ventricular High Septal Pacing
1378506|NCT00461734|Right Ventricular Apical Pacing
1378507|NCT00461734|Left Ventricular Dysfunction
1378508|NCT00461734|Heart Block
1378509|NCT00461734|Pacemaker
1378510|NCT00461734|Atrial Fibrillation
1378511|NCT00461734|Ejection Fraction
1378512|NCT00461695|Cytomegalovirus (CMV)
1378513|NCT00461695|Tick-borne encephalitis virus (TBEV)
1378514|NCT00461695|Ageing
1378515|NCT00461695|Vaccine
1378516|NCT00461695|Immunity
1378517|NCT00461682|TRPV1 antagonist
1378518|NCT00461682|Fecal Urgency
1378519|NCT00461682|rectal pain
1378520|NCT00461682|IBS
1378521|NCT00461669|hip
1378522|NCT00461669|fracture
1378523|NCT00461669|ultrasound
1378524|NCT00461656|Antiseptic
1378525|NCT00461656|Povidone-Iodine
1378526|NCT00461643|Anovulation
1378527|NCT00461643|Clomiphene citrate
1378528|NCT00461643|Infertility
1378529|NCT00461643|Metformin
1378530|NCT00461643|PCOS
1378531|NCT00461643|RCT
1378532|NCT00461643|Treatment
1378533|NCT00461630|coronary heart disease
1378534|NCT00461630|cardiovascular disease
1378535|NCT00461630|stroke
1378536|NCT00461630|peripheral arterial disease
1378537|NCT00461630|diabetes mellitus
1378538|NCT00461630|cholesterol
1378539|NCT00461630|HDL cholesterol
1378540|NCT00461630|simvastatin
1378541|NCT00461630|ezetimibe
1378542|NCT00461630|ER niacin
1378543|NCT00461630|laropiprant
1378544|NCT00461617|diabetes
1378545|NCT00461617|rapid and short acting insulin secretagogue
1378546|NCT00461617|α-glucosidase inhibitor
1378547|NCT00461617|HbA1C
1378548|NCT00461617|insulin
1378549|NCT00461604|gastroesophageal reflux disease
1378550|NCT00461604|baclofen
1378551|NCT00461604|impedance
1378552|NCT00461591|Noninvasive Bladder Cancer
1378553|NCT00461578|P.falciparum
1378554|NCT00461578|malaria
1378555|NCT00461578|lapdap+artesunate
1378556|NCT00461578|safety
1378557|NCT00461578|efficay
1378558|NCT00461565|Retina
1378559|NCT00461565|PDE-5
1378560|NCT00461565|Levitra
1378561|NCT00461565|Viagra
1378562|NCT00461565|Normal healthy volunteers for evaluation of retinal function
1378563|NCT00461552|Lipodystrophy
1378564|NCT00461552|HIV
1378565|NCT00461552|HAART
1378566|NCT00461552|HIV Lipodystrophy Syndrome
1378567|NCT00461552|Lipodystrophy syndrome
1378568|NCT00461552|HIV-Associated Lipodystrophy
1378569|NCT00461552|HIV-Associated Lipodystrophy Syndrome
1378570|NCT00461552|Treatment Experienced
1378571|NCT00461539|Tobacco Use
1378572|NCT00461539|Alcohol and Drug Use
1378573|NCT00461539|Obesity
1378574|NCT00461539|Risky Sexual Behavior
1378575|NCT00461526|IBS
1378576|NCT00461526|d-IBS
1378577|NCT00461526|Irritable Bowel Syndrome
1378578|NCT00461513|Heart Failure, Congestive
1378579|NCT00461513|Disease Management
1378580|NCT00461513|Health Status
1378581|NCT00461513|Quality of Life
1378582|NCT00461513|Telemedicine
1378583|NCT00461513|Depression
1378584|NCT00461500|persistent
1378585|NCT00461500|moderate
1378586|NCT00461500|asthma
1378587|NCT00461500|adults
1378588|NCT00461500|Initial
1378589|NCT00461500|Maintenance
1378590|NCT00461500|Therapy
1378591|NCT00461487|Adolescent Behavior
1378592|NCT00461487|Communication
1378593|NCT00461487|Health Behavior
1378594|NCT00461487|Risk-Taking
1378595|NCT00461487|Sexual Behavior
1378596|NCT00461474|Shoulder pain
1378597|NCT00461474|Chronic Spinal Cord Injury
1378598|NCT00461474|Exercise
1378599|NCT00461474|Physical therapy techniques
1378600|NCT00461474|Motor performance
1378601|NCT00461448|Potassium supplement
1378602|NCT00461448|Rheumatoid Arthritis
1378603|NCT00461448|Pain
1378604|NCT00461448|Disease Activity
1378605|NCT00461422|IVF
1378606|NCT00461422|GnRH antagonist
1378607|NCT00461409|Neonatal Seizures
1378608|NCT00461409|Treatment
1378609|NCT00461409|Anticonvulsant
1378610|NCT00461409|Levetiracetam
1378611|NCT00461396|Relapsing-Remitting Multiple Sclerosis
1378612|NCT00461396|First demyelinating event
1378613|NCT00461396|MRI features consistent with MS
1378614|NCT00461370|safety
1378615|NCT00461370|Phase 1
1378616|NCT00461370|pharmacokinetics
1378617|NCT00461370|SRX251
1378618|NCT00461370|Azevan
1378619|NCT00461370|safety in healthy volunteers
1378620|NCT00461357|Old for Old
1378621|NCT00461357|Eurotransplant Senior Program
1378622|NCT00461357|Glomerular Filtration Rate
1378623|NCT00461344|Breast
1378624|NCT00461331|Type 1 diabetes mellitus
1378625|NCT00461331|Glycemic control
1378626|NCT00461331|Continuous subcutaneous insulin infusion
1378627|NCT00461331|Continuous glucose monitoring system
1378628|NCT00461318|vocational rehabilitation
1378629|NCT00461318|psychosis
1378630|NCT00461318|cross country comparison
1378631|NCT00461305|Dysmenorrhea
1378632|NCT00461305|Intracyclic bleeding
1378633|NCT00461305|Drospirenone (DRSP)
1378634|NCT00461305|Ethinylestradiol
1378635|NCT00461279|attachment
1378636|NCT00461279|depression
1378637|NCT00461279|IPT
1378638|NCT00461279|CBT
1378639|NCT00461279|pharmacotherapy
1378640|NCT00461266|Treatment Experienced
1378641|NCT00461253|breast cancer
1378642|NCT00461240|heart
1378643|NCT00461240|MRS
1378644|NCT00461240|acromegaly
1378645|NCT00461240|growth hormone
1378646|NCT00461227|Puerto Rican
1378647|NCT00461227|Allergies
1378648|NCT00461214|laparoscopy
1378649|NCT00461214|surgery
1378650|NCT00461214|technical skills
1378651|NCT00461214|outcomes
1378652|NCT00461214|resident training
1378653|NCT00461201|Health Services Research
1378654|NCT00461201|Nurse Practitioners
1378655|NCT00461201|Outcome and Process Assessment (Health Care)
1378656|NCT00461201|Patient Acceptance of Health Care
1378657|NCT00461201|Patient Satisfaction
1378658|NCT00461201|Primary Health Care
1378659|NCT00461201|Professional Autonomy
1378660|NCT00461188|acromegaly
1378661|NCT00461188|gigantism
1378662|NCT00461188|familial pituitary adenoma
1378663|NCT00461188|Familial acromegaly
1378664|NCT00461188|Familial Isolated Pituitary Adenoma
1378665|NCT00461188|FIPA
1378666|NCT00461188|Pituitary adenoma predisposition
1378667|NCT00461188|PAP
1378668|NCT00461175|Uterine Perforation
1378669|NCT00461149|Acromegaly
1378670|NCT00461149|GH
1378671|NCT00461149|IGF-I
1378672|NCT00461149|Pituitary tumors
1378673|NCT00461149|Octreotide
1378674|NCT00461136|Time course
1378675|NCT00461136|antiproteinuric
1378676|NCT00461136|blood pressure
1378677|NCT00461136|lowering effect
1378678|NCT00461136|initiation of renin inhibition
1378679|NCT00461136|Aliskiren in Type 2 diabetes
1378680|NCT00461136|incipient and/or established nephropathy
1378681|NCT00461097|Egg Allergy
1378682|NCT00461097|Egg Oral Immunotherapy (OIT)
1378683|NCT00461097|Food Allergy
1378684|NCT00461084|Lymphoma
1378685|NCT00461084|Advanced Stage
1378686|NCT00461084|Untreated
1378687|NCT00461084|Advanced Stage Lymphoma
1378688|NCT00461084|Untreated Lymphoma
1378689|NCT00461084|07-038
1378690|NCT00461071|Bulimia nervosa
1378691|NCT00461071|Guided Self-help
1378692|NCT00461071|Psycho-education
1378693|NCT00461045|multiple myeloma
1378694|NCT00461045|proteasome inhibitor
1378695|NCT00461045|relapsed
1378696|NCT00461045|refractory
1378697|NCT00460993|Aging
1378698|NCT00460993|Sleep
1378699|NCT00460993|Nursing Home
1378700|NCT00460993|Sleep in nursing homes
1378701|NCT00460980|resident training
1378702|NCT00460980|laparoscopic skills
1378703|NCT00460980|surgical skills assessment
1378704|NCT00460967|non-Exudative (Dry) Age-Related Macular Degeneration
1378705|NCT00460928|congenital heart block
1378706|NCT00460928|neonatal lupus
1378707|NCT00460928|systemic lupus erythematosus
1378708|NCT00460928|Sjogren syndrome
1378709|NCT00460928|autoantibodies
1378710|NCT00460928|SSA/Ro
1378711|NCT00460928|SSB/La
1378712|NCT00460928|autoimmunity
1378713|NCT00460928|pregnancy
1378714|NCT00460928|intravenous immune globulin
1378715|NCT00460928|IVIG
1378716|NCT00460928|immunoglobulin
1378717|NCT00460915|Lacidipine
1378718|NCT00460915|Amlodipine
1378719|NCT00460902|TMS
1378720|NCT00460902|drug resistant depression
1378721|NCT00460889|hand assist
1378722|NCT00460889|laparoscopy
1378723|NCT00460889|renal donor
1378724|NCT00460889|outcomes
1378725|NCT00460876|topotecan
1378726|NCT00460876|periocular
1378727|NCT00460876|chemotherapy
1378728|NCT00460863|sleep
1378729|NCT00460863|hemodialysis
1378730|NCT00460863|daytime sleepiness
1378731|NCT00460863|temperature
1378732|NCT00460837|colorectal cancer
1378733|NCT00460837|bowel preparation regimen
1378734|NCT00460837|patients with symptoms attributable to colorectal cancer
1378735|NCT00460824|transplant
1378736|NCT00460824|HLA antibodies matching
1378737|NCT00460824|immunologic mismatching
1378738|NCT00460811|Irritable Bowel Syndrome with Constipation
1378739|NCT00460811|IBS
1378740|NCT00460811|Irritable Bowel Syndrome
1378741|NCT00460811|linaclotide acetate
1378742|NCT00460811|linaclotide
1378743|NCT00460811|MD-1100
1378744|NCT00460798|Sunitinib
1378745|NCT00460798|kidney diseases
1378746|NCT00460798|urogenital neoplasms
1378747|NCT00460798|kidney cancer
1378748|NCT00460759|Mycobacterium tuberculosis, rifapentine, moxifloxacin
1378749|NCT00460746|HIV
1378750|NCT00460746|AIDS
1378751|NCT00460746|Immunodeficiency Virus, Human
1378752|NCT00460746|PREZISTA
1378753|NCT00460746|darunavir
1378754|NCT00460746|TMC114
1378755|NCT00460746|TMC125
1378756|NCT00460746|Protease Inhibitor
1378757|NCT00460746|Non-Nucleoside Reverse Transcriptase Inhibitor
1378758|NCT00460746|enfuvirtide
1378759|NCT00460746|Treatment Experienced
1378760|NCT00460720|Attention Deficit Hyperactivity Disorder
1378761|NCT00460720|ADHD
1378762|NCT00460720|Methylphenidate
1378763|NCT00460720|MPH
1378764|NCT00460720|Extended-Release Methylphenidate
1378765|NCT00460707|GW679769
1378766|NCT00460707|healthy adult subjects
1378767|NCT00460707|casopitant
1378768|NCT00460707|ketoconazole
1378769|NCT00460694|allogeneic transplant
1378770|NCT00460694|haematological malignancies
1378771|NCT00460694|allogeneic CIK cells
1378772|NCT00460681|Hepatocellular Carcinoma
1378773|NCT00460681|Thymopentin
1378774|NCT00460681|Recurrence
1378775|NCT00460681|Resection
1378776|NCT00460668|elective thoracotomy
1378777|NCT00460668|pulmonary rehabilitation
1378778|NCT00460668|quality of life
1378779|NCT00460655|Post-Stroke
1378780|NCT00460655|Lower Limb
1378781|NCT00460655|botulinum toxin type A
1378782|NCT00460655|Spasticity
1378783|NCT00460642|Frozen embryo transfers (FET).
1378784|NCT00460642|Egg donation (ED).
1378785|NCT00460642|IVF.
1378786|NCT00460642|ART.
1378787|NCT00460642|Implantation.
1378788|NCT00460642|GnRH antagonist.
1378789|NCT00460642|Cetrotide.
1378790|NCT00460642|Endometrial response.
1378791|NCT00460642|Infertility treatments:
1378792|NCT00460642|Transfer of embryos from egg donation (ED) to recipients.
1378793|NCT00460629|Adoptive immunotherapy
1378794|NCT00460629|BCR-ABL reactive T cells
1378795|NCT00460629|Allogeneic Transplantation
1378796|NCT00460616|Prolactin
1378797|NCT00460616|Prolactinomas
1378798|NCT00460616|Dopamine-Agonists
1378799|NCT00460616|Cabergoline
1378800|NCT00460616|Cardiac valve disease
1378801|NCT00460603|GI neoplasms (phase 1)
1378802|NCT00460590|Tuberculosis
1378803|NCT00460590|TB
1378804|NCT00460590|MVA 85A
1378805|NCT00460577|Asthma, Formoterol, Bronchial Obstruction, Children
1378806|NCT00460564|Spasticity
1378807|NCT00460564|Post-Stroke
1378808|NCT00460564|botulinum toxin type A
1378809|NCT00460564|Upper Limb
1378810|NCT00460538|Seasonal allergic rhinitis
1378811|NCT00460538|lectranal
1378812|NCT00460538|allergy
1378813|NCT00460525|malaria, Mali, children, Plasmodium falciparum, vaccine
1378820|NCT00460499|Diabetes
1378821|NCT00460473|Mental Health
1378822|NCT00460473|Neurological Disease
1378823|NCT00460473|Hip Injuries and Disorders
1378824|NCT00460460|Phase I
1378825|NCT00460460|cancer
1378826|NCT00460460|lymphoma
1378827|NCT00460460|leukemia
1378828|NCT00460460|myeloma
1378829|NCT00460460|AML
1378830|NCT00460460|ALL
1378831|NCT00460460|NHL
1378832|NCT00460460|MM
1378833|NCT00460447|anti-CD33
1378834|NCT00460447|Immunotoxin
1378835|NCT00460447|Acute myeloid leukemia
1378836|NCT00460434|Prolapse
1378837|NCT00460434|Urinary incontinence
1378838|NCT00460434|TVT
1378839|NCT00460421|Oral Mucositis
1378840|NCT00460421|Acute Lymphoblastic Leukemia
1378841|NCT00460421|Acute Myeloid Leukemia
1378842|NCT00460421|Palifermin
1378843|NCT00460421|Kepivance
1378844|NCT00460408|Macular degeneration
1378845|NCT00460408|Safety
1378846|NCT00460408|Non-interventional
1378847|NCT00460408|Non-randomized
1378848|NCT00460395|Brain Metastasis
1378849|NCT00460395|Cerebral Metastases
1378850|NCT00460395|Brain Cancer
1378851|NCT00460395|Stereotactic Radiosurgery
1378852|NCT00460395|Craniotomy
1378853|NCT00460382|HIV infections
1378854|NCT00460382|HIV integrase inhibitor
1378855|NCT00460382|etravirine
1378856|NCT00460382|darunavir
1378857|NCT00460382|MK 0518
1378858|NCT00460382|raltegravir
1378859|NCT00460382|Treatment Experienced
1378860|NCT00460382|Antiviral drug resistance
1378861|NCT00460369|uncomplicated malaria
1378862|NCT00460369|children
1378863|NCT00460369|treatment
1378864|NCT00460369|effectiveness
1378865|NCT00460343|patient non-adherence
1378866|NCT00460343|antihypertensive agents
1378867|NCT00460343|community pharmacy services
1378868|NCT00460343|professional roles
1378869|NCT00460330|diagnosis
1378870|NCT00460330|galactomannan
1378871|NCT00460330|glucan
1378872|NCT00460330|real-time PCR
1378873|NCT00460330|invasive fungal infection
1378874|NCT00460330|aspergillosis
1378875|NCT00460330|Chinese patients
1378876|NCT00460317|lung
1378877|NCT00460317|cancer
1378878|NCT00460317|chemotherapy
1378879|NCT00460317|paclitaxel
1378880|NCT00460317|carboplatin
1378881|NCT00460317|placebo
1378882|NCT00460317|angiogenesis
1378883|NCT00460317|VEGF
1378884|NCT00460317|multi kinase inhibitor
1378885|NCT00460304|Type I diabetes
1378886|NCT00460304|Insulin pump
1378887|NCT00460304|Continuous glucose monitoring
1378888|NCT00460304|Insulin to carbohydrate ratio
1378889|NCT00460304|Correction factor
1378890|NCT00460304|Pramlintide
1378891|NCT00460291|PAD
1378892|NCT00460291|vein bypass
1378893|NCT00460291|supported varicose veins
1378894|NCT00460278|Cancer
1378895|NCT00460278|Solid Tumors
1378896|NCT00460265|Squamous Cell Carcinoma
1378897|NCT00460265|Epidermal Growth Factor
1378898|NCT00460265|Epidermal Growth Factor Receptor
1378899|NCT00460265|SCCHN
1378900|NCT00460265|Metastatic Head and Neck Cancer
1378901|NCT00460265|EGFr
1378902|NCT00460265|Head and Neck Cancer
1378903|NCT00460265|Recurrent Head and Neck Cancer
1378904|NCT00460252|algorithm
1378905|NCT00460252|insulin
1378906|NCT00460252|hyperglycemia
1378907|NCT00460252|tight glycemic control
1378908|NCT00460252|intensive care
1378909|NCT00460252|adults
1378910|NCT00460239|Opioid addiction
1378911|NCT00460239|Opioid dependence
1378912|NCT00460239|Buprenorphine
1378913|NCT00460226|Korean
1378914|NCT00460226|Bipolar I disorder
1378915|NCT00460226|Non-serious rash
1378916|NCT00460226|Lamotrigine
1378917|NCT00460213|home blood pressure
1378918|NCT00460200|depression
1378919|NCT00460200|fatigue
1378920|NCT00460200|sleep disorders
1378921|NCT00460200|psychosocial effects of cancer and its treatment
1378922|NCT00460200|ovarian epithelial cancer
1378923|NCT00460187|carotid artery, distal protection device, carotid stenting
1378924|NCT00460174|stage I pancreatic cancer
1378925|NCT00460174|stage II pancreatic cancer
1378926|NCT00460174|stage III pancreatic cancer
1378927|NCT00460161|acupuncture
1378928|NCT00460161|amputation
1378929|NCT00460161|phantom limb pain
1378930|NCT00460148|ropinirole PR/CR,
1378931|NCT00460148|pharmacokinetic,
1378932|NCT00460148|formulation,
1378933|NCT00460148|food effect,
1378934|NCT00460148|SK&F101468,
1378935|NCT00460148|PD
1378936|NCT00460135|Resistance
1378937|NCT00460135|Training
1378938|NCT00460135|Obesity
1378939|NCT00460135|Children
1378940|NCT00460122|Human Leukocyte Antigens (HLA)
1378941|NCT00460122|Transfusion Reactions
1378942|NCT00460122|Platelet Donors
1378943|NCT00460109|stage III grade 1 follicular lymphoma
1378944|NCT00460109|stage III grade 2 follicular lymphoma
1378945|NCT00460109|stage IV grade 1 follicular lymphoma
1378946|NCT00460109|stage IV grade 2 follicular lymphoma
1378947|NCT00460096|Pulmonary Emphysema
1378948|NCT00460083|Atopic Dermatitis
1378949|NCT00460083|eczema
1378950|NCT00460083|dermatitis
1378951|NCT00460083|skin barrier
1378952|NCT00460083|barrier repair
1378953|NCT00460083|ceramide
1378954|NCT00460083|physiologic lipid
1378955|NCT00460083|pruritus
1378956|NCT00460083|Elidel
1378957|NCT00460083|Epiceram
1378958|NCT00460083|topical steroid
1378959|NCT00460057|osteoporosis
1378960|NCT00460057|alendronate
1378961|NCT00460057|bone marker
1378962|NCT00460044|ADMA
1378963|NCT00460044|Preterms
1378964|NCT00460044|infants
1378965|NCT00460044|mechanical ventilation
1378966|NCT00460044|Preterm infants
1378967|NCT00460031|adenocarcinoma of the prostate
1378968|NCT00460031|stage III prostate cancer
1378969|NCT00460031|stage IV prostate cancer
1378970|NCT00460031|recurrent prostate cancer
1378971|NCT00460018|Gestational Diabetes Mellitus
1378972|NCT00460018|Weight Loss
1378973|NCT00460018|Physical Activity
1378974|NCT00460018|Breastfeeding
1378975|NCT00460018|Pregnancy
1378976|NCT00460018|Postpartum
1378977|NCT00460018|Intervention
1378978|NCT00460018|Prevention
1378979|NCT00460005|Migraine
1378980|NCT00460005|headache
1378981|NCT00460005|observational
1378982|NCT00459992|Obesity
1378983|NCT00459992|Weight Gain
1378984|NCT00459992|Adult
1378985|NCT00459992|Histamine
1378986|NCT00459992|Metabolism
1378987|NCT00459992|Overweight
1378988|NCT00459979|clear cell renal cell carcinoma
1378989|NCT00459979|stage III renal cell cancer
1378990|NCT00459979|stage IV renal cell cancer
1378991|NCT00459979|papillary renal cell carcinoma
1378992|NCT00459940|Growth hormone
1378993|NCT00459940|Lipolysis
1378994|NCT00459940|Insulin resistance
1378995|NCT00459940|Pioglitazone
1378996|NCT00459940|Growth hormone replaced growth hormone deficient adults
1378997|NCT00459927|Adenotonsillectomy
1378998|NCT00459927|Coblation tonsillectomy
1378999|NCT00459927|Floseal
1379000|NCT00459914|sleep apnea
1379001|NCT00459914|refractory hypertension
1379002|NCT00459914|continuous positive airway pressure
1379003|NCT00459901|Metastatic Colorectal Cancer
1379004|NCT00459888|CLI
1379005|NCT00459888|Critical Limb Ischemia
1379006|NCT00459888|Infrapopliteal
1379007|NCT00459888|Cryoplasty
1379008|NCT00459875|recurrent renal cell cancer
1379009|NCT00459875|stage IV renal cell cancer
1379010|NCT00459849|Melanoma
1379011|NCT00459849|Brachytherapy
1379012|NCT00459849|Ultrasonography
1379013|NCT00459836|unspecified adult solid tumor, protocol specific
1379014|NCT00459823|Cancer
1379015|NCT00459823|solid tumors
1379016|NCT00459810|adenocarcinoma of the prostate
1379017|NCT00459810|recurrent prostate cancer
1379018|NCT00459810|stage IV prostate cancer
1379019|NCT00459797|GlideScope
1379020|NCT00459797|cobalt
1379021|NCT00459797|single-use
1379022|NCT00459797|intubation
1379023|NCT00459797|airway
1379024|NCT00459797|Elective surgical patients requiring orotracheal intubation
1379025|NCT00459784|Improvement
1379026|NCT00459784|Dementia early diagnosis
1379027|NCT00459784|Dementia management
1379028|NCT00459784|Primary care
1379029|NCT00459771|angiotensin II-receptor (AT1) blocker
1379030|NCT00459771|prevention
1379031|NCT00459771|trastuzumab
1379032|NCT00459771|cardiotoxicity
1379033|NCT00459758|hypertension
1379034|NCT00459758|Hans
1379035|NCT00459758|Electrical stimulation
1379036|NCT00459745|Cardiovascular Disease
1379037|NCT00459745|Fenofibrate
1379038|NCT00459745|LDL cholesterol
1379039|NCT00459745|HDL cholesterol
1379040|NCT00459745|Hyperlipidemia
1379041|NCT00459745|Pravastatin
1379042|NCT00459745|Triglycerides
1379043|NCT00459732|zinc, thalassemia, bone mineral density
1379044|NCT00459719|Liver Transplantation
1379045|NCT00459719|Tacrolimus
1379046|NCT00459719|Methylprednisolone
1379047|NCT00459719|Prednisolone
1379048|NCT00459706|Rheumatoid Arthritis
1379049|NCT00459693|HIV-Dementia
1379050|NCT00459693|Brain
1379051|NCT00459693|PET
1379052|NCT00459693|PBR28
1379053|NCT00459693|MCMD
1379054|NCT00459693|HIV Positive
1379055|NCT00459693|HIV Dementia
1379056|NCT00459693|AIDS Related Dementia
1379057|NCT00459693|Minor Cognitive Motor Disorder
1379058|NCT00459693|Healthy Volunteer
1379059|NCT00459693|HV
1379060|NCT00459680|hypertension
1379061|NCT00459680|acupuncture
1379062|NCT00459680|laser
1379063|NCT00459667|Relapsing multiple sclerosis
1379064|NCT00459667|interferon beta 1b
1379065|NCT00459667|Betaferon
1379066|NCT00459667|Betaseron
1379067|NCT00459654|HRPC
1379068|NCT00459654|Recurrent Prostate Cancer
1379069|NCT00459654|Metastatic Cancer
1379070|NCT00459641|Osteogenic Gel
1379071|NCT00459641|Solitary Bone Cysts
1379072|NCT00459628|early breast cancer
1379073|NCT00459628|post-operative radiation treatment
1379074|NCT00459602|laparoscopic surgery
1379075|NCT00459589|Cancer
1379076|NCT00459589|elderly
1379077|NCT00459589|malnutrition
1379078|NCT00459589|chemotherapy
1379079|NCT00459589|survival
1379080|NCT00459589|comprehensive geriatric assessment
1379081|NCT00459589|morbidity
1379082|NCT00459576|Asthma
1379083|NCT00459576|Eczema
1379084|NCT00459576|Dermatitis, Atopic
1379085|NCT00459576|Infant
1379086|NCT00459563|vitamin D
1379087|NCT00459563|blood pressure
1379088|NCT00459563|hypertension
1379089|NCT00459563|Vitamin D insufficient
1379090|NCT00459563|Systolic blood pressure between 130 and 150 mmHg
1379091|NCT00459550|Alzheimer's Disease
1379092|NCT00459550|First Time in Human (FTIH) Study
1379093|NCT00459537|Toenail fungus
1379094|NCT00459537|Onychomycosis
1379095|NCT00459537|Nail fungus
1379096|NCT00459537|Toenail fungal infection
1379097|NCT00459537|Tinea unguium
1379098|NCT00459537|Dermatophytes
1379099|NCT00459537|Foot dermatoses
1379100|NCT00459524|Acute Myelogenous Leukemia
1379101|NCT00459524|Myelodysplastic Syndrome
1379102|NCT00459524|Leukemia
1379103|NCT00459524|Quality of Life
1379104|NCT00459524|Questionnaire
1379105|NCT00459524|Survey
1379106|NCT00459524|Neurocognitive Function
1379107|NCT00459524|AML
1379108|NCT00459524|MDS
1379109|NCT00459524|QOL
1379110|NCT00459511|Adrenomedullin
1379111|NCT00459511|Glucose
1379112|NCT00459511|Insulin
1379113|NCT00459511|Systemic Inflammatory response Syndrome
1379114|NCT00459511|Pediatric
1379115|NCT00459511|Cortisol
1379116|NCT00459511|ACTH
1379117|NCT00459498|NIS
1379118|NCT00459498|thyroid adenoma
1379119|NCT00459498|thyroid cancer
1379120|NCT00459498|Iodine uptake
1379121|NCT00459498|expression
1379122|NCT00459485|Plasm zinc concentration
1379123|NCT00459485|Zinc supplementation
1379124|NCT00459485|Assessment of zinc status
1379125|NCT00459485|Plasma zinc concentration
1379126|NCT00459472|resident training
1379127|NCT00459472|laparoscopy
1379128|NCT00459472|virtual reality
1379129|NCT00459472|surgical education
1379130|NCT00459446|Magnetic Resonance Imaging
1379131|NCT00459446|Gadolinium Contrast
1379132|NCT00459446|Gadofosveset
1379133|NCT00459446|Atherosclerosis
1379134|NCT00459446|Chronic Total Arterial Occlusions
1379135|NCT00459446|Cardiovascular Disease
1379136|NCT00459446|Blocked Arteries
1379137|NCT00459446|Peripheral Artery Disease
1379138|NCT00459446|PAD
1379139|NCT00459446|Intermittent Claudication
1379140|NCT00459446|Chronic Total Arterial Occlusion
1379141|NCT00459433|Low back pain
1379142|NCT00459433|Return to work
1379143|NCT00459433|Biopsychosocial
1379144|NCT00459433|Screening
1379145|NCT00459433|SMS
1379146|NCT00459433|Non specific low back pain
1379147|NCT00459420|Parkinson's disease
1379148|NCT00459420|Excessive Daytime Somnolence
1379149|NCT00459420|Caffeine
1379150|NCT00459420|Disease-Modifying
1379151|NCT00459368|asthma
1379152|NCT00459368|patient compliance
1379153|NCT00459368|metered dose inhalers
1379154|NCT00459368|corticosteroids
1379155|NCT00459368|health behaviour
1379156|NCT00459368|prevention & control
1379157|NCT00459355|Alzheimer's disease
1379158|NCT00459355|Dementia
1379159|NCT00459355|Safety
1379160|NCT00459355|Home Care Services
1379161|NCT00459329|Depression
1379162|NCT00459329|Epilepsy
1379163|NCT00459329|Problem-Solving Therapy
1379164|NCT00459329|Mental Health
1379165|NCT00459329|Neurology
1379166|NCT00459329|Home-based health care
1379167|NCT00459329|Community-based program
1379168|NCT00459329|Collaborative care
1379169|NCT00459303|cataract
1379170|NCT00459303|aspherical intraocular lenses
1379171|NCT00459303|functional vision
1379172|NCT00459290|recurrent ovarian epithelial cancer
1379173|NCT00459290|primary peritoneal cavity cancer
1379174|NCT00459290|fallopian tube cancer
1379175|NCT00459277|Pain
1379176|NCT00459277|Cancer
1379177|NCT00459264|Folic Acid
1379178|NCT00459264|Prevention
1379179|NCT00459264|Depression
1379180|NCT00459264|Bipolar Disorder
1379181|NCT00459264|Teenagers
1379182|NCT00459251|N-acetyltransferase
1379183|NCT00459251|Pharmacogenetics
1379184|NCT00459238|unspecified childhood solid tumor, protocol specific
1379185|NCT00459225|Pediatrics
1379186|NCT00459225|Cardiac Defect
1379187|NCT00459225|Cardiac Surgery
1379188|NCT00459225|Single Ventricle
1379189|NCT00459225|Anemia
1379190|NCT00459225|blood transfusions
1379191|NCT00459225|red cell volume
1379192|NCT00459225|red cell distribution
1379193|NCT00459225|oral iron
1379194|NCT00459225|ferrous sulfate
1379195|NCT00459225|Congenital Cardiac Defects
1379196|NCT00459225|Hemoglobin
1379197|NCT00459225|Iron Deficiency
1379198|NCT00459186|prostate cancer
1379199|NCT00459186|RAD001
1379200|NCT00459186|mTOR inhibition
1379201|NCT00459186|docetaxel
1379202|NCT00459173|abstinence
1379203|NCT00459173|maintenance
1379204|NCT00459160|Hypotensive Resuscitation
1379205|NCT00459160|Hypotensive Anesthesia
1379206|NCT00459160|Hemorrhagic Shock
1379207|NCT00459160|Penetrating Trauma
1379208|NCT00459134|sexual dysfunction
1379209|NCT00459134|sexuality and reproductive issues
1379210|NCT00459134|unspecified adult solid tumor, protocol specific
1379211|NCT00459121|stage I non-small cell lung cancer
1379212|NCT00459121|stage II non-small cell lung cancer
1379213|NCT00459121|stage IIIA non-small cell lung cancer
1379214|NCT00459082|Dexmedetomine
1379215|NCT00459082|Post-operative cardiac surgery
1379216|NCT00459069|tumor vaccine
1379217|NCT00459069|GM-CSF
1379218|NCT00459043|SCCHN
1379219|NCT00459030|colon cancer
1379220|NCT00459030|rectal cancer
1379221|NCT00459017|24 hour ambulatory blood pressure measurement
1379222|NCT00459017|Mean blood pressure
1379223|NCT00459017|Wrist manometer
1379224|NCT00459017|Frequent measurement
1379225|NCT00459004|weight loss
1379226|NCT00458991|Recombinant Human Growth Hormone
1379227|NCT00458991|growth hormone deficiency
1379228|NCT00458991|short stature
1379229|NCT00458991|phenotyping
1379230|NCT00458952|MIBG
1379231|NCT00458952|iobenguane
1379232|NCT00458952|iodine
1379233|NCT00458952|I 131
1379234|NCT00458952|radiotherapy
1379235|NCT00458952|radiopharmaceutical
1379236|NCT00458952|dosimetry
1379237|NCT00458952|neuroendocrine tumor
1379238|NCT00458952|Ultratrace
1379239|NCT00458952|no carrier added
1379240|NCT00458952|metaiodobenzyl-guanidine
1379241|NCT00458926|ventilation, mechanical
1379242|NCT00458926|intubation, endotracheal
1379243|NCT00458926|respiratory insufficiency
1379244|NCT00458913|localized malignant mesothelioma
1379245|NCT00458913|recurrent malignant mesothelioma
1379246|NCT00458913|advanced malignant mesothelioma
1379247|NCT00458887|ototoxicity
1379248|NCT00458887|unspecified childhood solid tumor, protocol specific
1379249|NCT00458874|CV risk factors
1379250|NCT00458874|subclinical atherosclerosis
1379251|NCT00458874|lifestyle intervention
1379252|NCT00458874|motivation
1379253|NCT00458861|Active Rheumatoid Arthritis (RA)
1379254|NCT00458848|B-cell adult acute lymphoblastic leukemia
1379255|NCT00458848|T-cell adult acute lymphoblastic leukemia
1379256|NCT00458848|untreated adult acute lymphoblastic leukemia
1379257|NCT00458848|L1 adult acute lymphoblastic leukemia
1379258|NCT00458848|L2 adult acute lymphoblastic leukemia
1379259|NCT00458848|TdT positive adult acute lymphoblastic leukemia
1379260|NCT00458835|Allergic rhinitis
1379261|NCT00458822|primary systemic amyloidosis
1379262|NCT00458809|recurrent colon cancer
1379263|NCT00458809|stage IV colon cancer
1379264|NCT00458809|carcinoma of the appendix
1379265|NCT00458809|recurrent rectal cancer
1379266|NCT00458809|stage IV rectal cancer
1379267|NCT00458809|primary peritoneal cavity cancer
1379268|NCT00458796|hypercalcemia of malignancy
1379269|NCT00458796|musculoskeletal complications
1379270|NCT00458796|pain
1379271|NCT00458796|stage IV breast cancer
1379272|NCT00458796|male breast cancer
1379273|NCT00458796|recurrent breast cancer
1379274|NCT00458796|bone metastases
1379275|NCT00458783|Transfusion
1379276|NCT00458783|Cardiac
1379277|NCT00458783|Blood storage duration
1379278|NCT00458770|Comparison of a spontaneous acute cluster headache attack and rest (no pain) in ten patients with cluster headache defined with IHS criteria
1379279|NCT00458757|Amputees
1379280|NCT00458757|Affordance
1379281|NCT00458757|Peripersonal space
1379282|NCT00458757|Pseudo neglect
1379283|NCT00458757|Reaching
1379284|NCT00458757|Spatial
1379285|NCT00458757|visual
1379286|NCT00458744|juvenile myelomonocytic leukemia
1379287|NCT00458744|relapsing chronic myelogenous leukemia
1379288|NCT00458744|unspecified childhood solid tumor, protocol specific
1379289|NCT00458744|childhood chronic myelogenous leukemia
1379290|NCT00458744|childhood acute promyelocytic leukemia (M3)
1379291|NCT00458744|recurrent childhood acute lymphoblastic leukemia
1379292|NCT00458744|recurrent childhood acute myeloid leukemia
1379293|NCT00458744|childhood central nervous system germ cell tumor
1379294|NCT00458744|childhood choroid plexus tumor
1379295|NCT00458744|childhood craniopharyngioma
1379296|NCT00458744|childhood infratentorial ependymoma
1379297|NCT00458744|childhood grade I meningioma
1379298|NCT00458744|childhood grade II meningioma
1379299|NCT00458744|childhood grade III meningioma
1379300|NCT00458744|childhood supratentorial ependymoma
1379301|NCT00458744|recurrent childhood brain stem glioma
1379302|NCT00458744|recurrent childhood cerebellar astrocytoma
1379303|NCT00458744|recurrent childhood cerebral astrocytoma
1379304|NCT00458744|recurrent childhood ependymoma
1379305|NCT00458744|recurrent childhood medulloblastoma
1379306|NCT00458744|recurrent childhood supratentorial primitive neuroectodermal tumors
1379307|NCT00458744|recurrent childhood visual pathway and hypothalamic glioma
1379308|NCT00458744|recurrent childhood visual pathway glioma
1379309|NCT00458744|high-grade childhood cerebral astrocytoma
1379310|NCT00458744|low-grade childhood cerebral astrocytoma
1379311|NCT00458744|recurrent childhood brain tumor
1379312|NCT00458744|childhood spinal cord tumor
1379313|NCT00458744|recurrent/refractory childhood Hodgkin lymphoma
1379314|NCT00458744|stage IV childhood Hodgkin lymphoma
1379315|NCT00458744|recurrent childhood large cell lymphoma
1379316|NCT00458744|stage IV childhood large cell lymphoma
1379317|NCT00458744|recurrent childhood lymphoblastic lymphoma
1379318|NCT00458744|stage IV childhood lymphoblastic lymphoma
1379319|NCT00458744|recurrent childhood small noncleaved cell lymphoma
1379320|NCT00458744|stage IV childhood small noncleaved cell lymphoma
1379321|NCT00458744|childhood grade III lymphomatoid granulomatosis
1379322|NCT00458744|childhood nasal type extranodal NK/T-cell lymphoma
1379323|NCT00458744|recurrent childhood grade III lymphomatoid granulomatosis
1379324|NCT00458744|recurrent childhood pineoblastoma
1379325|NCT00458718|abstinence
1379326|NCT00458718|nicotine patch
1379327|NCT00458705|stage I multiple myeloma
1379328|NCT00458705|stage II multiple myeloma
1379329|NCT00458705|stage III multiple myeloma
1379330|NCT00458705|refractory multiple myeloma
1379331|NCT00458679|CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
1379332|NCT00458679|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS
1379333|NCT00458666|Amniotic fluid
1379334|NCT00458666|D-dimer
1379335|NCT00458666|coagulation
1379336|NCT00458666|factor X activation
1379337|NCT00458653|DC/tumor cell fusions
1379338|NCT00458653|GM-CSF
1379339|NCT00458653|high dose chemotherapy
1379340|NCT00458627|Plethysmograpy
1379341|NCT00458627|preschool
1379342|NCT00458627|methacholine challenge
1379343|NCT00458627|spirometry
1379344|NCT00458627|asthma
1379345|NCT00458614|Cystic Fibrosis
1379346|NCT00458601|EGFRvIII vaccinetemozolomidecancer vaccineimmunotherapy
1379347|NCT00458588|breast cancer
1379348|NCT00458575|Retinitis Pigmentosa
1379349|NCT00458575|Advanced retinitis pigmentosa (RP)
1379350|NCT00458575|CNTO 2476
1379351|NCT00458575|Subretinal
1379352|NCT00458575|Human umbilical tissue-derived cells (hUTC)
1379353|NCT00458575|Light perception (LP)
1379354|NCT00458575|Hand motion (HM)
1379355|NCT00458562|cervical cancer
1379356|NCT00458562|atypical squamous cells of undetermined significance
1379357|NCT00458562|stage 0 cervical cancer
1379358|NCT00458562|cervical intraepithelial neoplasia grade 1
1379359|NCT00458562|cervical intraepithelial neoplasia grade 2
1379360|NCT00458562|cervical intraepithelial neoplasia grade 3
1379361|NCT00458549|stage I prostate cancer
1379362|NCT00458549|stage II prostate cancer
1379363|NCT00458549|stage III prostate cancer
1379364|NCT00458549|stage IV prostate cancer
1379365|NCT00458536|GM-CSF
1379366|NCT00458536|vaccine
1379367|NCT00458536|debulking nephrectomy
1379368|NCT00458536|dendritic cells
1379369|NCT00458523|B-cell chronic lymphocytic leukemia
1379370|NCT00458523|stage I chronic lymphocytic leukemia
1379371|NCT00458523|stage II chronic lymphocytic leukemia
1379372|NCT00458523|stage III chronic lymphocytic leukemia
1379373|NCT00458523|stage 0 chronic lymphocytic leukemia
1379374|NCT00458523|stage IV chronic lymphocytic leukemia
1379375|NCT00458510|Pain
1379376|NCT00458510|Cancer
1379377|NCT00458510|Breakthrough
1379378|NCT00458497|Holofiber
1379379|NCT00458497|chronic foot pain
1379380|NCT00458497|sleep quality
1379381|NCT00458484|stage I renal cell cancer
1379382|NCT00458484|stage II renal cell cancer
1379383|NCT00458484|stage III renal cell cancer
1379384|NCT00458484|stage IV renal cell cancer
1379385|NCT00458471|Urinary Catheter
1379386|NCT00458471|Spinal Cord Injury
1379387|NCT00458471|Escherichia Coli
1379388|NCT00458471|Urinary Tract Infection
1379389|NCT00458458|Endometriosis
1379390|NCT00458458|Dysmenorrhea
1379391|NCT00458458|Pelvic Pain
1379392|NCT00458458|Period Pain
1379393|NCT00458458|Menstrual Cramps
1379394|NCT00458458|Dyspareunia
1379395|NCT00458458|Norethindrone Acetate
1379396|NCT00458458|Lupron Depot
1379397|NCT00458458|Bone Density
1379398|NCT00458458|Lipid Profile
1379399|NCT00458445|Attention-Deficit Hyperactivity Disorder (ADHD)
1379400|NCT00458432|fMRI
1379401|NCT00458432|Pavlovian Conditioning
1379402|NCT00458432|Functional Activity
1379403|NCT00458432|Brain
1379404|NCT00458432|Fear
1379405|NCT00458432|Healthy Volunteer
1379406|NCT00458432|HV
1379407|NCT00458419|dyspnea; leg discomfort; exercise duration
1379408|NCT00458406|obstructive sleep apnea
1379409|NCT00458406|child
1379410|NCT00458406|CPAP
1379411|NCT00458393|HIV
1379412|NCT00458393|Chemoprophylaxis
1379413|NCT00458393|Hepatitis
1379414|NCT00458393|Viral human hepatitis
1379415|NCT00458393|HIV Seronegativity
1379416|NCT00458380|Doppler ultrasonography
1379417|NCT00458380|Embryos
1379418|NCT00458380|Infertility
1379419|NCT00458380|IVF
1379420|NCT00458380|Oocytes
1379421|NCT00458380|Tubal factor
1379422|NCT00458380|unexplained infertility
1379423|NCT00458367|PASS
1379424|NCT00458367|Safety Assessment
1379425|NCT00458367|Efficacy Assessment
1379426|NCT00458367|long-acting injectable risperidone
1379427|NCT00458354|Spinal Sealant
1379428|NCT00458354|Spinal Sealant System
1379429|NCT00458354|Dural Repair
1379430|NCT00458354|Spinal Surgery
1379431|NCT00458341|Cystic fibrosis
1379432|NCT00458341|Nonsense mutation
1379433|NCT00458341|Premature stop codon
1379434|NCT00458302|HIV
1379435|NCT00458302|Monotherapy
1379436|NCT00458302|Darunavir
1379437|NCT00458302|Protease inhibitor
1379438|NCT00458302|Early pre-treated
1379439|NCT00458302|Undetectable
1379440|NCT00458302|Treatment Experienced
1379441|NCT00458276|Left sided heart disease
1379442|NCT00458276|Elevated pulmonary arterial pressure
1379443|NCT00458276|Right ventricular failure
1379444|NCT00458276|Cardiac surgery
1379445|NCT00458276|heart-lung machine
1379446|NCT00458276|cardiopulmonary bypass
1379447|NCT00458276|tezosentan
1379448|NCT00458276|Actelion
1379449|NCT00458263|Growth Hormone treatment
1379450|NCT00458263|ISS
1379451|NCT00458263|Biochemical markers
1379452|NCT00458263|Growth response
1379453|NCT00458250|Hematopoietic Stem Cell Transplantation
1379454|NCT00458250|Haploidentical
1379455|NCT00458250|Hematologic Neoplasms
1379456|NCT00458250|human, Bone Marrow
1379457|NCT00458250|Granulocyte Colony-stimulating Factor
1379458|NCT00458250|CAMPATH
1379459|NCT00458250|Alemtuzumab
1379460|NCT00458250|AML
1379461|NCT00458250|ALL
1379462|NCT00458250|10. Eligibility
1379463|NCT00458237|HER2 positive
1379464|NCT00458237|metastatic breast cancer
1379465|NCT00458237|RAD001
1379466|NCT00458237|Herceptin
1379467|NCT00458224|overweight
1379468|NCT00458224|obesity
1379469|NCT00458224|child
1379470|NCT00458211|Schizophrenia
1379471|NCT00458211|Ziprasidone
1379472|NCT00458198|Selective Mutism
1379473|NCT00458172|lay theories
1379474|NCT00458172|health concepts
1379475|NCT00458172|survey
1379476|NCT00458172|internet research
1379477|NCT00458172|Ideas about health
1379478|NCT00458159|CC-11006
1379479|NCT00458159|RA
1379480|NCT00458159|MDS
1379481|NCT00458159|Celgene
1379482|NCT00458159|RCMD-RS
1379483|NCT00458159|RARS
1379484|NCT00458159|RAEB-1
1379485|NCT00458159|Low-or Intermediate-1-Risk Myelodysplastic Syndrome (MDS)
1379486|NCT00458133|aerobic exercise
1379487|NCT00458133|resistance exercise
1379488|NCT00458133|type 2 diabetes
1379489|NCT00458133|hemoglobin A1C
1379490|NCT00458133|exercise
1379491|NCT00458120|Dengue Fever
1379492|NCT00458120|Dengue Hemorrhagic Fever
1379493|NCT00458120|Dengue Vaccination
1379494|NCT00458107|Pharmacokinetics
1379495|NCT00458107|Pharmacodynamics
1379496|NCT00458094|Exercise
1379497|NCT00458094|Mental Illness
1379498|NCT00458094|Community Psychiatry
1379499|NCT00458094|Peer Support
1379500|NCT00458094|Mental Disorders
1379501|NCT00458068|preterm infant
1379502|NCT00458068|iron supplementation
1379503|NCT00458068|iron deficiency
1379504|NCT00458068|blood transfusion
1379505|NCT00458055|Lipid lowering agents
1379506|NCT00458055|Drug treatment
1379507|NCT00458055|Statin
1379508|NCT00458055|Fibrate
1379509|NCT00458055|Niacin
1379510|NCT00458055|Cellular cholesterol efflux
1379511|NCT00458042|Ventavis
1379512|NCT00458042|iloporst
1379513|NCT00458042|Remodulin
1379514|NCT00458042|treprostinil
1379515|NCT00458042|PAH
1379516|NCT00458042|prostacyclin
1379517|NCT00458029|type 2 diabetes risk factors
1379518|NCT00458029|obesity
1379519|NCT00458029|prevention
1379520|NCT00458029|adolescence
1379521|NCT00458029|school based
1379522|NCT00458003|Preeclampsia
1379523|NCT00458003|Spinal Anesthesia
1379524|NCT00458003|Hypotension
1379525|NCT00458003|Cesarean Delivery
1379526|NCT00458003|Phenylephrine
1379527|NCT00458003|Ephedrine
1379528|NCT00457990|Neurocognitive outcome
1379529|NCT00457990|preterm infant
1379530|NCT00457990|very low birth weight
1379531|NCT00457990|iron deficiency
1379532|NCT00457990|iron supplementation
1379533|NCT00457977|Chronic Obstructive Pulmonary Disease
1379534|NCT00457977|COPD
1379535|NCT00457977|Pneumococcal
1379536|NCT00457977|Vaccine
1379537|NCT00457977|Opsonization
1379538|NCT00457977|Antibodies
1379539|NCT00457964|Tuberous Sclerosis Complex (TSC)
1379540|NCT00457964|Lymyphangioleiomyomatosis
1379541|NCT00457964|Mammalian Target of Rapamycin (mTOR)
1379542|NCT00457964|RAD001
1379543|NCT00457964|Angiomyolipmas
1379544|NCT00457951|Chronic Obstructive Pulmonary Disease
1379545|NCT00457951|COPD
1379546|NCT00457951|Heparin
1379547|NCT00457951|ODSH
1379548|NCT00457951|Exacerbations of COPD
1379549|NCT00457938|lipodystrophy
1379550|NCT00457925|absorption,
1379551|NCT00457925|metabolism,
1379552|NCT00457925|excretion
1379553|NCT00457925|distribution,
1379554|NCT00457899|schizophrenia
1379555|NCT00457899|schizoaffective disorder
1379556|NCT00457899|quetiapine
1379557|NCT00457899|seroquel
1379558|NCT00457899|titration
1379559|NCT00457873|surgery
1379560|NCT00457860|CLL
1379561|NCT00457860|PLL
1379562|NCT00457860|SLL
1379563|NCT00457860|Relapse
1379564|NCT00457860|Refractory
1379565|NCT00457860|immunotoxin
1379566|NCT00457860|HA22
1379567|NCT00457860|CAT-8015
1379568|NCT00457860|immunotherapy
1379569|NCT00457847|PGD
1379570|NCT00457834|Heart failure
1379571|NCT00457834|Dyssynchrony
1379572|NCT00457834|Cardiac resynchronization therapy
1379573|NCT00457834|Atrial fibrillation
1379574|NCT00457834|RVOT
1379575|NCT00457834|RVapex
1379576|NCT00457821|G551D mutation
1379577|NCT00457821|Fibrosis
1379578|NCT00457821|Pancreatic Diseases
1379579|NCT00457821|Digestive System Diseases
1379580|NCT00457821|Lung Diseases
1379581|NCT00457821|Respiratory Tract Diseases
1379582|NCT00457821|Genetic Diseases, Inborn
1379583|NCT00457821|Infant, Newborn, Diseases
1379584|NCT00457821|Pathologic Processes
1379585|NCT00457808|TSC and LAM
1379586|NCT00457808|Tuberous Sclerosis Complex and sporadic LAM
1379587|NCT00457782|Cancer
1379588|NCT00457782|Blood disorders
1379589|NCT00457782|Leukaemia, Adult Chronic
1379590|NCT00457782|Lymphoma
1379591|NCT00457782|Multiple Myeloma
1379592|NCT00457769|Aricept
1379593|NCT00457769|Donepezil
1379594|NCT00457769|Memory
1379595|NCT00457769|vascular dementia
1379596|NCT00457769|stroke
1379597|NCT00457769|functional tasks
1379598|NCT00457769|self-generation
1379599|NCT00457756|LDL cholesterol
1379600|NCT00457756|HDL cholesterol
1379601|NCT00457756|natural supplement
1379602|NCT00457756|guar gum
1379603|NCT00457756|phytosterols
1379604|NCT00457756|policosanol
1379605|NCT00457756|chrysanthemum
1379606|NCT00457743|Evaluate of RTD for Japanese GIST patients
1379607|NCT00457730|Multiple Sclerosis
1379608|NCT00457730|Duloxetine
1379609|NCT00457730|Pain
1379610|NCT00457717|myopia, auricular acupoint, atropine, RCT
1379611|NCT00457704|MRSA
1379612|NCT00457704|Home Care
1379613|NCT00457704|Risk factors
1379614|NCT00457704|transmissions
1379615|NCT00457704|observational study
1379616|NCT00457691|colorectal neoplasms
1379617|NCT00457678|Vision loss
1379618|NCT00457678|Retina
1379619|NCT00457678|VEG-F
1379620|NCT00457678|Fovea
1379621|NCT00457678|AMD
1379622|NCT00457665|HIV
1379623|NCT00457665|Lipodystrophy
1379624|NCT00457665|Treatment Experienced
1379625|NCT00457652|Rosuvastatin
1379626|NCT00457652|Caffeine
1379627|NCT00457652|Ischemia
1379628|NCT00457652|Reperfusion
1379629|NCT00457639|lipodystrophy
1379630|NCT00457626|Children
1379631|NCT00457626|pediatrics
1379632|NCT00457626|High Blood Pressure
1379633|NCT00457626|Hypertension
1379634|NCT00457626|Valsartan
1379635|NCT00457613|alkaline phosphatase
1379636|NCT00457613|sepsis
1379637|NCT00457613|kidney function
1379638|NCT00457600|information technology
1379639|NCT00457600|emergency department
1379640|NCT00457600|medication error
1379641|NCT00457600|quality of care
1379642|NCT00457600|patient-centered care
1379643|NCT00457561|The relationship between all-cause mortality in patients introduced hemodialysis and recombinant human erythropoietin dose and serum adiponectin level
1379644|NCT00457548|Alcohol use
1379645|NCT00457548|Brief Interventions
1379646|NCT00457548|Injuries
1379647|NCT00457548|Emergency Department Patients
1379648|NCT00457548|Harmful and hazardous alcohol use among ED injured patients
1379649|NCT00457535|recombinant human erythropoietin
1379650|NCT00457535|adiponectin
1379651|NCT00457535|mortality
1379652|NCT00457522|intimate partner violence
1379653|NCT00457522|depression
1379654|NCT00457522|PTSD
1379655|NCT00457522|fatigue
1379656|NCT00457509|Pandemic influenza
1379657|NCT00457509|Avian influenza
1379658|NCT00457509|Orthomyxoviridae Infections
1379659|NCT00457509|A/H5N1
1379660|NCT00457496|Behavior Therapy
1379661|NCT00457496|Relaxation Techniques
1379662|NCT00457496|Cognitive Therapy
1379663|NCT00457496|Exercise Movement Techniques
1379664|NCT00457483|hypertension
1379665|NCT00457483|diuretic
1379666|NCT00457483|angiotensin receptor blockers
1379667|NCT00457483|prediction
1379668|NCT00457457|With or without erectile dysfunction
1379669|NCT00457431|in-hospital cardiac arrest
1379670|NCT00457431|resuscitation
1379671|NCT00457431|mild therapeutic hypothermia
1379672|NCT00457405|ischemia-reperfusion injury
1379673|NCT00457405|atherosclerosis
1379674|NCT00457405|dipyridamole
1379675|NCT00457405|annexin A5 targeting
1379676|NCT00457392|Non-small cell lung cancer
1379677|NCT00457392|sunitinib
1379678|NCT00457392|erlotinib
1379679|NCT00457392|Phase 3
1379680|NCT00457379|Coronary artery disease
1379681|NCT00457379|HDL-Cholesterol
1379682|NCT00457379|Endothelial Function
1379683|NCT00457379|Endothelial Progenitor Cells
1379684|NCT00457379|normal blood HDL-Cholesterol level
1379685|NCT00457340|Tachycardia, Ventricular
1379686|NCT00457340|Ventricular Fibrillation
1379687|NCT00457327|protective ileostomy
1379688|NCT00457327|rectal cancer
1379689|NCT00457327|low anterior resection
1379690|NCT00457314|single-large scale deletions
1379691|NCT00457314|point mutations in mtDNA
1379692|NCT00457301|Lung transplantation, health-related quality of life.
1379693|NCT00457288|Cutaneous Mastocytosis
1379694|NCT00457288|Topical treatment
1379695|NCT00457262|paraoxonase1 activity
1379696|NCT00457262|LDL
1379697|NCT00457262|HDL
1379698|NCT00457262|postmenopausal women
1379699|NCT00457262|postmenopausal women and hyperlipidemia
1379700|NCT00457249|Pertussis
1379701|NCT00457249|Tetanus
1379702|NCT00457249|Diphtheria
1379703|NCT00457249|Tdap
1379704|NCT00457236|Clopidogrel
1379705|NCT00457236|Coronary Artery Disease
1379706|NCT00457236|Dose-Response Relationship, Drug
1379707|NCT00457236|Drug Resistance
1379708|NCT00457236|PCI
1379709|NCT00457223|pterygium
1379710|NCT00457223|pterygia
1379711|NCT00457223|excision
1379712|NCT00457223|amniotic membrane transplantation
1379713|NCT00457223|fibrin glue
1379714|NCT00457223|suture
1379715|NCT00457210|Psychology
1379716|NCT00457197|bipolar disorder
1379717|NCT00457197|alcohol dependence
1379718|NCT00457197|mania
1379719|NCT00457197|manic disorder
1379720|NCT00457197|depression
1379721|NCT00457184|Migraine
1379722|NCT00457184|Thrombosis
1379723|NCT00457184|Thrombophilia
1379724|NCT00457171|GI-270384 colitis patients ECAM oral
1379725|NCT00457158|pulmonary embolism
1379726|NCT00457158|inferior vena cava filters
1379727|NCT00457158|venous thrombosis
1379728|NCT00457158|randomized controlled trial
1379729|NCT00457145|Hyperfluorescence on Fluorescein
1379730|NCT00457145|Idiopathic Juxtafoveal Telangiectasia
1379731|NCT00457145|Retinal Edema/Thinning
1379732|NCT00457145|Vascular Endothelial Growth Factor
1379733|NCT00457145|Macular Telangiectasia
1379734|NCT00457132|Knee
1379735|NCT00457132|Osteoarthritis
1379736|NCT00457132|WOMAC
1379737|NCT00457132|ALF
1379738|NCT00457132|Wedging
1379739|NCT00457119|Non Small Cell Lung Cancer
1379740|NCT00457119|NSCLC
1379741|NCT00457119|Advanced Lung Cancer
1379742|NCT00457119|RAD
1379743|NCT00457119|RAD001
1379744|NCT00457119|chemotherapy
1379745|NCT00457119|carboplatin
1379746|NCT00457119|paclitaxel
1379747|NCT00457119|bevacizumab
1379748|NCT00457106|panic
1379749|NCT00457093|Type 2 Diabetes
1379750|NCT00457093|continuous glucose monitoring
1379751|NCT00457093|basal insulin
1379752|NCT00457080|capnography
1379753|NCT00457080|safety
1379754|NCT00457080|opioids
1379755|NCT00457080|respiratory depression
1379756|NCT00457080|postoperative
1379757|NCT00457080|orthopedic
1379758|NCT00457080|OSA
1379759|NCT00457080|apnea
1379760|NCT00457067|Hyperfluorescence on Fluorescein
1379761|NCT00457067|Idiopathic Juxtafoveal Telangiectasia
1379762|NCT00457067|Retinal Edema/Thinning
1379763|NCT00457067|Vascular Endothelial Growth Factor
1379764|NCT00457067|Macular Telangiectasia
1379765|NCT00457054|Mood Regulating Circuit
1379766|NCT00457054|Lithium
1379767|NCT00457054|fMRI
1379768|NCT00457041|Trust
1379769|NCT00457041|Decision Making
1379770|NCT00457041|Vulnerability
1379771|NCT00457041|Survey
1379772|NCT00457028|Obsessive Compulsive Disorder
1379773|NCT00457028|Anxiety
1379774|NCT00457028|Treatment efficacy
1379775|NCT00457002|Prevention of deep vein thrombosis and pulmonary embolism with acutely ill hospitalized patients
1379776|NCT00456989|Androgen Independent
1379777|NCT00456989|Prostate Cancer
1379778|NCT00456989|Taxotere
1379779|NCT00456989|Doxil
1379780|NCT00456989|AIPC
1379781|NCT00456989|Advanced Androgen-Independent Prostate Cancer
1379782|NCT00456976|Seligiline
1379783|NCT00456976|Negative symptoms
1379784|NCT00456976|Schizopherenia
1379785|NCT00456963|angiotensin converting enzyme inhibitors
1379786|NCT00456963|angiotensin receptor blockers
1379787|NCT00456963|diabetes
1379788|NCT00456963|hypertension
1379789|NCT00456963|therapeutic strategies
1379790|NCT00456950|coronary atherosclerosis
1379791|NCT00456950|magnetic resonance imaging
1379792|NCT00456950|vulnerable plaque
1379793|NCT00456924|progesterone receptor modulator
1379794|NCT00456911|obesity
1379795|NCT00456911|prevention
1379796|NCT00456911|children
1379797|NCT00456911|adults
1379798|NCT00456911|family
1379799|NCT00456911|dietary
1379800|NCT00456911|coaching
1379801|NCT00456911|body mass index
1379802|NCT00456911|fat mass
1379803|NCT00456885|obesity
1379804|NCT00456885|double blind
1379805|NCT00456885|placebo controlled
1379806|NCT00456885|weight loss
1379807|NCT00456885|appetite
1379808|NCT00456885|energy expenditure
1379809|NCT00456872|Pain during injection of the pre-procedure anesthetic
1379810|NCT00456859|chronic kidney disease
1379811|NCT00456859|oral carbonaceous adsorbent
1379812|NCT00456859|randomized clinical trial
1379813|NCT00456859|composite endpoint
1379814|NCT00456846|Metastatic Breast Cancer, ABI-007, Abraxane
1379815|NCT00456833|Non Small Cell Lung Cancer
1379816|NCT00456833|NSCLC
1379817|NCT00456833|Advanced lung cancer
1379818|NCT00456833|RAD
1379819|NCT00456833|RAD001
1379820|NCT00456833|erlotinib
1379821|NCT00456820|Mood Regulating Circuit
1379822|NCT00456820|SSRI
1379823|NCT00456820|fMRI
1379824|NCT00456807|Human Papillomavirus
1379825|NCT00456794|Parkinson's disease
1379826|NCT00456794|Levodopa
1379827|NCT00456794|End of dose wearing off
1379828|NCT00456794|OFF time
1379829|NCT00456781|rotator cuff
1379830|NCT00456781|randomized clinical trial
1379831|NCT00456768|Panic Disorder
1379832|NCT00456768|Anxiety
1379833|NCT00456768|Treatment efficacy
1379834|NCT00456755|Perennial Allergic rhinitis
1379835|NCT00456755|Traditional Chinese Medicine
1379836|NCT00456742|Generalized Anxiety Disorder
1379837|NCT00456742|Anxiety
1379838|NCT00456742|Treatment efficacy
1379839|NCT00456729|Iron deficiency
1379840|NCT00456729|Malabsorption
1379841|NCT00456729|Giardiasis
1379842|NCT00456716|BAC lung cancer
1379843|NCT00456716|adenocarcinoma of the lung
1379844|NCT00456703|fluids,
1379845|NCT00456703|restriction,
1379846|NCT00456703|infection,
1379847|NCT00456703|bowel surgery,
1379848|NCT00456703|open abdominal
1379849|NCT00456690|Thalassemia
1379850|NCT00456690|Nutrition
1379851|NCT00456690|Endocrine
1379852|NCT00456690|BMI
1379853|NCT00456677|minocycline
1379854|NCT00456677|asthma
1379855|NCT00456677|oral corticosteroids
1379856|NCT00456664|CMV
1379857|NCT00456664|IRIS
1379858|NCT00456651|Sleep Apnea
1379859|NCT00456651|Obesity
1379860|NCT00456651|Neuropeptides
1379861|NCT00456651|Hormones
1379862|NCT00456638|OP-CABG
1379863|NCT00456638|Depodur traditional drug
1379864|NCT00456625|Hepatitis B vaccine
1379865|NCT00456625|Challenge dose
1379866|NCT00456586|Parkinson's disease
1379867|NCT00456586|Levodopa therapy
1379868|NCT00456586|End of dose wearing off
1379869|NCT00456586|Off time
1379870|NCT00456573|Pediatric Obstructive sleep apnea syndrome
1379871|NCT00456547|Cesarean hysterectomy
1379872|NCT00456547|Postpartum hemorrhage
1379873|NCT00456547|Coagulation
1379874|NCT00456534|Smoking
1379875|NCT00456521|Obesity
1379876|NCT00456521|Behavior Modification
1379877|NCT00456469|TB
1379878|NCT00456469|latent
1379879|NCT00456469|infection
1379880|NCT00456469|Ethiopia
1379881|NCT00456443|Thalassemia
1379882|NCT00456443|Sickle cell anemia
1379883|NCT00456443|Splenectomy
1379884|NCT00456443|Infections
1379885|NCT00456443|Streptococcal Pneumonia
1379886|NCT00456417|Neurological
1379887|NCT00456417|Alzheimers
1379888|NCT00456404|peppermint water
1379889|NCT00456404|nipple crack
1379890|NCT00456404|lactating women
1379891|NCT00456391|Brain CT scan
1379892|NCT00456391|Pediatric emergency room
1379893|NCT00456365|Autosomal dominant polycystic kidney disease
1379894|NCT00456365|Cystic kidney disease
1379895|NCT00456365|High blood pressure
1379896|NCT00456365|Statin
1379897|NCT00456339|Obstructive sleep apnea syndrome (OSAS) in children
1379898|NCT00456326|Heparin
1379899|NCT00456326|Unfractionated Heparin
1379900|NCT00456326|Low Molecular Weight Heparin
1379901|NCT00456326|Anticoagulation
1379902|NCT00456326|Thrombocytopenia
1379903|NCT00456326|Thrombosis
1379904|NCT00456326|Venous Thrombosis
1379905|NCT00456326|Pulmonary Embolism
1379906|NCT00456313|asthma
1379907|NCT00456313|fluticasone propionate
1379908|NCT00456313|salmeterol/fluticasone propionate
1379909|NCT00456313|combination product
1379910|NCT00456313|innate immune response
1379911|NCT00456313|neutrophil priming
1379912|NCT00456300|Type 1 Diabetes
1379913|NCT00456300|Hyperglycemia
1379914|NCT00456300|Hypoglycemia
1379915|NCT00456287|Sleep Apnea
1379916|NCT00456287|Clotting- fibrinolysis patterns
1379917|NCT00456287|Platelet function markers
1379918|NCT00456287|Endothelial dysfunction
1379919|NCT00456274|Hypothalamic Amenorrhea
1379920|NCT00456274|Idiopathic hypogonadotropic hypogonadism
1379921|NCT00456274|Acquired hypogonadotropic hypogonadism
1379922|NCT00456274|Kallmann's Syndrome
1379923|NCT00456274|Amenorrhea
1379924|NCT00456274|Gonadotropin Releasing Hormone
1379925|NCT00456261|Non Small Cell Lung Cancer
1379926|NCT00456248|Chronic Hepatitis C
1379927|NCT00456248|Liver
1379928|NCT00456248|Pegylated
1379929|NCT00456248|Interferon
1379930|NCT00456248|Ribavirin
1379931|NCT00456248|Combination
1379932|NCT00456248|Nonresponder
1379933|NCT00456248|Relapser
1379934|NCT00456248|HCV
1379935|NCT00456248|Infergen
1379936|NCT00456248|SVR
1379937|NCT00456222|Sleep
1379938|NCT00456222|Circadian rhythms
1379939|NCT00456222|Menstrual cycle
1379940|NCT00456209|Lived Experiences
1379941|NCT00456209|Adolescents
1379942|NCT00456209|Cancer Treatment
1379943|NCT00456209|Occupations
1379944|NCT00456196|COPD
1379945|NCT00456196|Thrombosis
1379946|NCT00456196|Cancer
1379947|NCT00456196|Renal
1379948|NCT00456196|Elderly
1379949|NCT00456196|Surgery
1379950|NCT00456196|Orthopedic Surgery
1379951|NCT00456196|Medically Ill
1379952|NCT00456196|Deep Vein Thrombosis
1379953|NCT00456196|Pulmonary Embolism
1379954|NCT00456196|Anticoagulation
1379955|NCT00456183|Tuberculosis
1379956|NCT00456183|Latent
1379957|NCT00456183|TB
1379958|NCT00456183|Vaccine
1379959|NCT00456183|MVA 85A
1379960|NCT00456170|Vaginal
1379961|NCT00456170|Hysterectomy
1379962|NCT00456170|Harmonic
1379963|NCT00456170|Ligasure
1379964|NCT00456170|Sutures
1379965|NCT00456170|Modern
1379966|NCT00456170|Patients undergoing vaginal hysterectomy for various reasons
1379967|NCT00456157|Osteoarthritis
1379968|NCT00456157|Osteophytes
1379969|NCT00456157|Knee
1379970|NCT00456157|Intra-articular
1379971|NCT00456157|OP-1
1379972|NCT00456144|GnRH
1379973|NCT00456144|Insulin sensitivity
1379974|NCT00456118|recurrent pregnancy losses
1379975|NCT00456118|preeclampsia
1379976|NCT00456118|intervillositis
1379977|NCT00456118|maternofetal alloimmunization
1379978|NCT00456105|Type 2 diabetes
1379979|NCT00456105|Post-op dysglycemia
1379980|NCT00456105|Peripheral vascular disease
1379981|NCT00456105|Infrainguinal bypass surgery
1379982|NCT00456092|psoriatic arthritis
1379983|NCT00456092|ACR
1379984|NCT00456092|PASI
1379985|NCT00456092|DAS
1379986|NCT00456092|pharmacokinetic
1379987|NCT00456092|biopsy
1379988|NCT00456066|Acute myocardial infarction
1379989|NCT00456066|Thromboaspiration
1379990|NCT00456066|Infarct size
1379991|NCT00456066|Left ventricular remodelling
1379992|NCT00456053|Renal Anemia
1379993|NCT00456053|Renal Failure
1379994|NCT00456053|Kidney Disease
1379995|NCT00456053|Human EPO
1379996|NCT00456040|amyloidosis
1379997|NCT00456040|heart failure
1379998|NCT00456040|heart transplant
1379999|NCT00456040|stem cell transplant
1380000|NCT00456027|Type 2 Diabetes
1380001|NCT00456027|LADA
1380002|NCT00456027|Latent Autoimmune Diabetes in Adult
1380003|NCT00456027|Autoimmunity
1380004|NCT00456027|HbA1c
1380005|NCT00456027|C-peptide
1380006|NCT00456014|Major Depression
1380007|NCT00456014|Antidepressants
1380008|NCT00456001|heparin
1380009|NCT00456001|low molecular weight heparin
1380010|NCT00456001|enoxaparin
1380011|NCT00456001|anticoagulation
1380012|NCT00456001|thrombosis
1380013|NCT00456001|venous thrombosis
1380014|NCT00456001|thromboembolism
1380015|NCT00456001|pulmonary embolism
1380016|NCT00456001|medication
1380017|NCT00455988|questionnaire developement
1380018|NCT00455988|regularity
1380019|NCT00455988|lifestyle
1380020|NCT00455988|type 2 diabetes
1380021|NCT00455975|Kidney Cancer
1380022|NCT00455975|Renal Cancer
1380023|NCT00455975|Clear Cell Carcinoma
1380024|NCT00455962|estrogen
1380025|NCT00455962|progesterone
1380026|NCT00455962|African-American
1380027|NCT00455962|Caucasian
1380028|NCT00455962|infusion
1380029|NCT00455962|gonadotropins
1380030|NCT00455962|healthy
1380031|NCT00454948|Obesity prevention
1380032|NCT00454948|Dietary intake
1380033|NCT00454948|Physical activity
1380034|NCT00454948|Mexican American
1380035|NCT00454948|Family Characteristics
1380036|NCT00454935|epilepsy
1380037|NCT00454935|glioma
1380038|NCT00454922|glaucoma
1380039|NCT00454922|patient educator
1380040|NCT00454909|Meningococcal Serogroups A, C, W-135 and/or Y Disease
1380041|NCT00454896|Urinary Bladder, Overactive
1380042|NCT00454896|Urgency
1380043|NCT00454896|VESIcare®
1380044|NCT00454896|Solifenacin succinate
1380045|NCT00454883|Safety of ziprasidone, efficacy of ziprasidone, manic episodes in bipolar disorder, mixed episodes in bipolar disorder, schizoaffective disorder.
1380046|NCT00454870|Alzheimer's Disease
1380047|NCT00454870|Cognition
1380048|NCT00454870|Cognitive impairment
1380049|NCT00454857|Thrombocytopenia
1380050|NCT00454857|Chart Review
1380051|NCT00454857|Platelet
1380052|NCT00454857|Retrospective
1380053|NCT00454857|Prospective
1380054|NCT00454857|Non-interventional
1380055|NCT00454857|Health Resource Utilization (HRU)
1380056|NCT00454857|Quality of Life (QOL)
1380057|NCT00454857|Immune Thrombocytopenic Purpura (ITP)
1380058|NCT00454857|Idiopathic Thrombocytopenic Purpura (ITP)
1380059|NCT00454857|Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
1380060|NCT00454857|Observational
1380061|NCT00454831|Hypercholesterolemia
1380062|NCT00454831|LDL-cholesterol
1380063|NCT00454831|chitosan
1380064|NCT00454831|HEP-40
1380065|NCT00454805|Advanced Breast Cancer
1380066|NCT00454792|Low back pain
1380067|NCT00454792|Modic changes
1380068|NCT00454779|SCCHNC
1380069|NCT00454779|Metastatic
1380070|NCT00454779|Recurrent
1380071|NCT00454766|Patient Education
1380072|NCT00454766|Cervical Dysplasia
1380073|NCT00454766|Questionnaire
1380074|NCT00454753|Myeloid, Chronic
1380075|NCT00454753|Lymphocytic, Acute
1380076|NCT00454740|Urinary Bladder, Overactive
1380077|NCT00454740|Urgency
1380078|NCT00454740|VESIcare®
1380079|NCT00454740|Solifenacin succinate
1380080|NCT00454701|Psoriasis
1380081|NCT00454701|Alefacept
1380082|NCT00454701|Amevive®
1380083|NCT00454701|Drug exposure
1380084|NCT00455936|Adenocarcinoma
1380085|NCT00455936|NSCLC
1380086|NCT00455936|gemcitabine
1380087|NCT00455936|Cisplatin
1380088|NCT00455936|Gefitinib
1380089|NCT00455936|Never smoker
1380090|NCT00455923|asthma
1380091|NCT00455923|exacerbation
1380092|NCT00455923|persistent
1380093|NCT00455923|bronchial hyperresponsiveness
1380094|NCT00455923|mild
1380095|NCT00455923|GINAII
1380096|NCT00455910|Low risk myelodysplastic syndromes
1380097|NCT00455910|MDS
1380098|NCT00455910|Bone marrow diseases
1380099|NCT00455910|Thalidomide
1380100|NCT00455910|Cytopenias
1380101|NCT00455910|Anemia
1380102|NCT00455897|GM-CSF
1380103|NCT00455897|CHOP-R
1380104|NCT00455897|Leukine
1380105|NCT00455897|Sargramostim
1380106|NCT00455897|DLBLCL
1380107|NCT00455897|NHL
1380108|NCT00455897|DLBCL
1380109|NCT00455871|macular degeneration
1380110|NCT00455845|Endometriosis
1380111|NCT00455845|Lng IUD
1380112|NCT00455832|sperm chromatin structure integrity
1380113|NCT00455832|sperm concentration
1380114|NCT00455832|sperm motility
1380115|NCT00455832|sperm morphology
1380116|NCT00455832|peginterferon
1380117|NCT00455832|ribavirin
1380118|NCT00455832|hepatitis C
1380119|NCT00455819|pulmonary embolism
1380120|NCT00455819|pro-BNP
1380121|NCT00455819|home treatment
1380122|NCT00455806|Helicobacter pylori
1380123|NCT00455806|rescue therapy
1380124|NCT00455806|eradication therapy
1380125|NCT00455806|esomeprazole
1380126|NCT00455806|moxifloxacin
1380127|NCT00455806|resistance
1380128|NCT00455793|HIV
1380129|NCT00455793|atherosclerosis
1380130|NCT00455780|Eating
1380131|NCT00455780|Dieting
1380132|NCT00455780|Meal replacements
1380133|NCT00455780|Energy Density
1380134|NCT00455780|Weight Loss Maintenance
1380135|NCT00455767|persistent ARDS
1380136|NCT00455767|alveolar inflammation
1380137|NCT00455767|early pulmonary fibrosis
1380138|NCT00455767|mechanichal ventilation
1380139|NCT00455767|P/V curve
1380140|NCT00455767|Static compliance
1380141|NCT00455767|elastase activity
1380142|NCT00455767|inhibitor of Human Neutrophil Elastase
1380143|NCT00455741|menopause
1380144|NCT00455741|estrogen
1380145|NCT00455741|progesterone
1380146|NCT00455741|hormone replacement
1380147|NCT00455741|aging
1380148|NCT00455741|PET
1380149|NCT00455715|Schizophrenia
1380150|NCT00455715|Cognition
1380151|NCT00455715|Sildenafil
1380152|NCT00455715|PDE5 Inhibitor
1380153|NCT00455702|schizophrenia
1380154|NCT00455702|cognition
1380155|NCT00455702|d-cycloserine
1380156|NCT00455702|memory
1380157|NCT00455689|Lupron
1380158|NCT00455689|Premenopausal
1380159|NCT00455689|Hot flashes
1380160|NCT00455689|PET
1380161|NCT00455689|MRI
1380162|NCT00455676|Scarf Osteotomy
1380163|NCT00455676|Chevron Osteotomy
1380164|NCT00455676|Comparison
1380165|NCT00455663|Schizoaffective Disorder
1380166|NCT00455663|Medication Adherence
1380167|NCT00455650|schizophrenia
1380168|NCT00455650|cognition
1380169|NCT00455650|nicotinic receptors
1380170|NCT00455650|mecamylamine
1380171|NCT00455650|varenicline
1380172|NCT00455624|androgen deprivation therapy
1380173|NCT00455624|insulin resistance
1380174|NCT00455611|Heart Failure, Congestive
1380175|NCT00455611|Continuous Positive Airway Pressure
1380176|NCT00455611|Baroreflex
1380177|NCT00455611|Echocardiography
1380178|NCT00455598|Diabetes
1380179|NCT00455585|Pharmacokinetics
1380180|NCT00455585|Antiretrovirals
1380181|NCT00455585|Uganda
1380182|NCT00455585|HIV
1380183|NCT00455585|Treatment Experienced
1380184|NCT00455572|Immunotherapeutic
1380185|NCT00455572|Adjuvant cancer therapy
1380186|NCT00455572|Non-small-cell lung cancer
1380187|NCT00455572|ASCI
1380188|NCT00455559|Resistant Gastrointestinal Stromal Tumor
1380189|NCT00455559|GIST
1380190|NCT00455559|Perifosine
1380191|NCT00455559|Gleevec
1380192|NCT00455546|Coronary
1380193|NCT00455546|Artery
1380194|NCT00455546|Atherosclerosis
1380195|NCT00455546|Phospholipase
1380196|NCT00455546|CAD
1380197|NCT00455533|Early Breast Cancer
1380198|NCT00455520|Diabetic neuropathy
1380199|NCT00455520|Painful Diabetic Polyneuropathy
1380200|NCT00455520|Polyneuropathy
1380201|NCT00455520|Peripheral neuropathy
1380202|NCT00455507|Parkinson's disease
1380203|NCT00455507|levodopa
1380204|NCT00455507|end of dose wearing off
1380205|NCT00455507|OFF time
1380206|NCT00455494|Drug-resistant malaria
1380207|NCT00455494|Bioavailability
1380208|NCT00455494|Food-effect study
1380209|NCT00455468|Severe pneumonia
1380210|NCT00455468|children
1380211|NCT00455468|day care management
1380212|NCT00455468|hospitalized management
1380213|NCT00455468|Randomized controlled trial
1380214|NCT00455468|Under five children
1380215|NCT00455429|Atopic Dermatitis
1380216|NCT00455429|JNJ-26113100
1380217|NCT00455416|Low grade lymphoma
1380218|NCT00455416|Diet
1380219|NCT00455416|Antioxidants
1380220|NCT00455416|Non Hodgkin Lymphoma - Follicular Lymphoma grade 1&2 stage III/IV
1380221|NCT00455403|Metabolic Syndrome
1380222|NCT00455403|Atherosclerosis
1380223|NCT00455390|Post immediate Psychotherapeutic Intervention
1380224|NCT00455390|Psychotraumatic disorders
1380225|NCT00455390|PTSD post traumatic syndrome disorder
1380226|NCT00455390|CUMP Cellules d’Urgence Médico Psychologique
1380227|NCT00455377|Cement dust exposure
1380228|NCT00455377|Induced sputum
1380229|NCT00455377|Airway inflammation
1380230|NCT00455377|Peripheral blood inflammation markers
1380231|NCT00455364|Fungal infection prophylaxis
1380232|NCT00455364|Lung transplant
1380233|NCT00455364|Fungal infection post lung transplant
1380234|NCT00455351|Palliative treatment
1380235|NCT00455351|Max. tolerable dose
1380236|NCT00455338|meal
1380237|NCT00455338|composition
1380238|NCT00455338|postprandial
1380239|NCT00455338|PCOS
1380240|NCT00455338|androgen
1380241|NCT00455325|Insulin Resistance
1380242|NCT00455325|Atherosclerosis
1380243|NCT00455325|Metabolic Syndrome
1380244|NCT00455312|Dyskeratosis Congenita
1380245|NCT00455312|Hematopoietic Stem Cell Transplantation
1380246|NCT00455312|Severe Aplastic Anemia
1380247|NCT00455299|Laparoscopy, ventral, hernia, repair, surgery
1380248|NCT00455286|CNS Lymphoma
1380249|NCT00455273|Breast Cancer
1380250|NCT00455273|DCE MRI
1380251|NCT00455234|Aggression
1380252|NCT00455234|Violent behaviour in people with psychotic illness
1380253|NCT00455221|CML
1380254|NCT00455221|Imatinib
1380255|NCT00455221|vaccine
1380256|NCT00455221|peptide
1380257|NCT00455221|gene
1380258|NCT00455221|MRD
1380259|NCT00455221|DNA
1380260|NCT00455182|Acupuncture
1380261|NCT00455182|Hip Arthroplasty
1380262|NCT00455182|Knee Arthroplasty
1380263|NCT00455182|Pain Management
1380264|NCT00455169|Influenza
1380265|NCT00455169|Infant, Premature
1380266|NCT00455169|Immunization
1380267|NCT00455169|Vaccination
1380268|NCT00455156|Contraception
1380269|NCT00455156|Vaginal Ring
1380270|NCT00455143|Postoperative delirium
1380271|NCT00455143|PD
1380272|NCT00455143|Postoperative cognitive dysfunction
1380273|NCT00455143|POCD
1380274|NCT00455130|mannitol
1380275|NCT00455130|cystic fibrosis
1380276|NCT00455130|mucolytic
1380277|NCT00455130|mucoactive
1380278|NCT00455117|analgesia
1380279|NCT00455117|pain
1380280|NCT00455117|neurosurgery
1380281|NCT00455117|NSAIDS
1380282|NCT00455117|parecoxib
1380283|NCT00455117|morphine consumption
1380284|NCT00455104|Fabry Disease
1380285|NCT00455104|Enzyme Replacement Therapy (ERT)
1380286|NCT00455091|Post-operative Hepatocellular Carcinoma.
1380287|NCT00455078|Gastric reflux
1380288|NCT00455078|Lung transplant
1380289|NCT00455078|chronic rejection
1380290|NCT00455078|Gastric reflux in lung transplant as it relates to chronic rejection
1380291|NCT00455065|whole grain
1380292|NCT00455065|metabolic syndrome
1380293|NCT00455065|weight loss
1380294|NCT00455052|XMT-1001
1380295|NCT00455052|cancer
1380296|NCT00455052|tumor
1380297|NCT00455052|camptothecin
1380298|NCT00455052|Fleximer
1380299|NCT00455052|polymer
1380300|NCT00455052|Phase 1
1380301|NCT00455052|safety
1380302|NCT00455052|pharmacokinetics
1380303|NCT00455052|maximum tolerated dose
1380304|NCT00455052|NSCLC
1380305|NCT00455052|non-small cell lung cancer
1380306|NCT00455052|SCLC
1380307|NCT00455052|small cell lung cancer
1380308|NCT00455039|neoadjuvant, HER2, Breast,GSK,lapatinib
1380309|NCT00455013|Kidney transplant
1380310|NCT00454987|antibody persistence
1380311|NCT00454987|Meningococcal serogroup C vaccine
1380312|NCT00454987|conjugate vaccine
1380313|NCT00454987|Haemophilus influenzae type b vaccine
1380314|NCT00454974|end stage renal failure
1380315|NCT00454974|dialysis
1380316|NCT00454974|wearable artificial kidney
1380317|NCT00454961|Malaria
1380318|NCT00454961|Plasmodium falciparum
1380319|NCT00454961|artemether-lumefantrine
1380320|NCT00454961|effectiveness
1380321|NCT00454688|Irritable Bowel Syndrome
1380322|NCT00454688|Asimadoline
1380323|NCT00454675|Smokers
1380324|NCT00454675|Chronic Bronchitis
1380325|NCT00454675|Pulmonary Function Test Abnormalities
1380326|NCT00454675|COPD
1380327|NCT00454662|Elderly
1380328|NCT00454662|Hypertension
1380329|NCT00454662|Cardiovascular Diseases
1380330|NCT00454662|Angiotensin II Type 1 Receptor Blockers
1380331|NCT00454662|Calcium Channel Blockers
1380332|NCT00454662|Diuretics
1380333|NCT00454662|Combination Drug Therapy
1380334|NCT00454662|Diabetes
1380335|NCT00454649|axitinib
1380336|NCT00454649|chemotherapy
1380337|NCT00454649|anti-angiogenesis
1380338|NCT00454649|VEGF inhibition
1380339|NCT00454623|Adiponectin
1380340|NCT00454623|diabetes
1380341|NCT00454623|metabolism
1380342|NCT00454623|Adiponectin levels
1380343|NCT00454610|Pediatric
1380344|NCT00454610|Overweight
1380345|NCT00454610|Obesity
1380346|NCT00454610|Intervention
1380347|NCT00454610|Prevention
1380348|NCT00454610|Mexican American
1380349|NCT00454584|Psoriasis
1380350|NCT00454584|CNTO 1275
1380351|NCT00454584|Etanercept
1380352|NCT00454584|Immune diorder
1380353|NCT00454584|Skin disorder
1380354|NCT00454558|Pulmonary Arterial Hypertension (PAH)
1380355|NCT00454558|Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
1380356|NCT00454532|Breast Cancer
1380357|NCT00454532|Bionovo
1380358|NCT00454532|BZL101
1380359|NCT00454532|Chinese Herbs
1380360|NCT00454519|peritoneal carcinomatosis
1380361|NCT00454519|cisplatin
1380362|NCT00454519|mitomycin
1380363|NCT00454519|gastric cancer
1380364|NCT00454519|colorectal cancer
1380365|NCT00454493|omacor
1380366|NCT00454493|fish oil
1380367|NCT00454493|omega 3
1380368|NCT00454493|fatty acids
1380369|NCT00454493|coronary artery disease
1380370|NCT00454493|endothelial function
1380371|NCT00454493|heart rate variability
1380372|NCT00454493|carotid intimal media thickness
1380373|NCT00454493|QT dispersion
1380374|NCT00454480|untreated adult acute myeloid leukemia
1380375|NCT00454480|de novo myelodysplastic syndromes
1380376|NCT00454480|secondary acute myeloid leukemia
1380377|NCT00454480|secondary myelodysplastic syndromes
1380378|NCT00454480|previously treated myelodysplastic syndromes
1380379|NCT00454480|refractory anemia with excess blasts
1380380|NCT00454480|adult acute basophilic leukemia
1380381|NCT00454480|adult acute eosinophilic leukemia
1380382|NCT00454480|adult acute megakaryoblastic leukemia (M7)
1380383|NCT00454480|adult acute minimally differentiated myeloid leukemia (M0)
1380384|NCT00454480|adult acute monoblastic leukemia (M5a)
1380385|NCT00454480|adult acute monocytic leukemia (M5b)
1380386|NCT00454480|adult acute myeloblastic leukemia with maturation (M2)
1380387|NCT00454480|adult acute myeloblastic leukemia without maturation (M1)
1380388|NCT00454480|adult erythroleukemia (M6a)
1380389|NCT00454480|adult pure erythroid leukemia (M6b)
1380390|NCT00454480|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1380391|NCT00454480|adult acute myeloid leukemia with inv(16)(p13;q22)
1380392|NCT00454480|adult acute myeloid leukemia with t(16;16)(p13;q22)
1380393|NCT00454480|adult acute myeloid leukemia with t(8;21)(q22;q22)
1380394|NCT00454480|adult acute myelomonocytic leukemia (M4)
1380395|NCT00454480|childhood myelodysplastic syndromes
1380396|NCT00454454|memory
1380397|NCT00454454|display enhanced testing
1380398|NCT00454441|Sleep Quality
1380399|NCT00454441|Menopausal Symptoms
1380400|NCT00454441|Actigraph
1380401|NCT00454441|Bionovo
1380402|NCT00454441|MF101
1380403|NCT00454428|Bypass Surgery
1380404|NCT00454428|Coronary Artery
1380405|NCT00454415|Diet
1380406|NCT00454415|Body Mass Index
1380407|NCT00454415|BMI
1380408|NCT00454389|Macular
1380409|NCT00454389|Degeneration
1380410|NCT00454389|AMD
1380411|NCT00454389|Wet Age-Related macular degeneration
1380412|NCT00454376|metastatic gastrointestinal carcinoid tumor
1380413|NCT00454376|recurrent gastrointestinal carcinoid tumor
1380414|NCT00454376|pulmonary carcinoid tumor
1380415|NCT00454376|gastrinoma
1380416|NCT00454376|insulinoma
1380417|NCT00454376|WDHA syndrome
1380418|NCT00454376|pancreatic polypeptide tumor
1380419|NCT00454376|somatostatinoma
1380420|NCT00454376|glucagonoma
1380421|NCT00454376|liver metastases
1380422|NCT00454350|Hectorol (doxercalciferol injection)
1380423|NCT00454350|Zemplar (paricalcitol injection)
1380424|NCT00454337|HIV-1 infection
1380425|NCT00454337|enfuvirtide
1380426|NCT00454337|raltegravir
1380427|NCT00454337|treatment experienced
1380428|NCT00454324|Lung cancer
1380429|NCT00454324|Small cell lung cancer
1380430|NCT00454324|Abraxane
1380431|NCT00454324|Paclitaxel
1380432|NCT00454324|Carboplatin
1380433|NCT00454324|Phase II
1380434|NCT00454324|Randomized
1380435|NCT00454324|Lineberger
1380436|NCT00454324|LCCC
1380437|NCT00454311|Pregnancy and implantation rates
1380438|NCT00454311|Efficiency and accuracy of the genetic testing
1380439|NCT00454298|Severe Osteoarthritis
1380440|NCT00454298|Arthritis
1380441|NCT00454285|bacteremia,cultures, infective endocarditis, prophylaxis
1380442|NCT00454272|febrile
1380443|NCT00454272|neutropenia
1380444|NCT00454272|cancer
1380445|NCT00454272|Gram positive infection
1380446|NCT00454259|Postoperative Hyperalgesia
1380447|NCT00454259|Human volunteer
1380448|NCT00454259|Fentanyl
1380449|NCT00454259|Randomized Controlled Trial
1380450|NCT00454259|Pain chronicisation
1380451|NCT00454259|Predictive test
1380452|NCT00454233|Diabetes Mellitus Type 2
1380453|NCT00454233|YM543
1380454|NCT00454233|Treatment
1380455|NCT00454233|Safety
1380456|NCT00454233|efficacy
1380457|NCT00454207|Pulmonary Arterial Hypertension, PAH
1380458|NCT00454194|recurrent non-small cell lung cancer
1380459|NCT00454194|stage IIIB non-small cell lung cancer
1380460|NCT00454194|stage IV non-small cell lung cancer
1380461|NCT00454194|adenosquamous cell lung cancer
1380462|NCT00454194|adenocarcinoma of the lung
1380463|NCT00454181|human immunodeficiency virus
1380464|NCT00454181|human papilloma virus
1380465|NCT00454181|warts, oral
1380466|NCT00454181|papillomatosis
1380467|NCT00454181|treatment experienced
1380468|NCT00454168|adult acute minimally differentiated myeloid leukemia (M0)
1380469|NCT00454168|adult acute myeloblastic leukemia with maturation (M2)
1380470|NCT00454168|adult acute myeloblastic leukemia without maturation (M1)
1380471|NCT00454168|adult acute myeloid leukemia in remission
1380472|NCT00454168|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1380473|NCT00454168|adult acute myeloid leukemia with inv(16)(p13;q22)
1380474|NCT00454168|adult acute myeloid leukemia with t(15;17)(q22;q12)
1380475|NCT00454168|adult acute myeloid leukemia with t(16;16)(p13;q22)
1380476|NCT00454168|adult acute myeloid leukemia with t(8;21)(q22;q22)
1380477|NCT00454168|adult acute myelomonocytic leukemia (M4)
1380478|NCT00454168|adult acute promyelocytic leukemia (M3)
1380479|NCT00454168|secondary acute myeloid leukemia
1380480|NCT00454168|adult acute monoblastic leukemia (M5a)
1380481|NCT00454168|adult acute monocytic leukemia (M5b)
1380482|NCT00454168|adult erythroleukemia (M6a)
1380483|NCT00454168|adult pure erythroid leukemia (M6b)
1380484|NCT00454168|adult acute megakaryoblastic leukemia (M7)
1380485|NCT00454155|HSCT
1380486|NCT00454155|AGVHD
1380487|NCT00454155|Myeloablative
1380488|NCT00454155|Allogeneic
1380489|NCT00454155|Hematopoietic
1380490|NCT00454155|Stem
1380491|NCT00454155|Cell
1380492|NCT00454155|Transplantation
1380493|NCT00454129|Feasibilty of cholangiography via double-balloon enteroscopy
1380494|NCT00454116|Colon Cancer
1380495|NCT00454116|Rectal Cancer
1380496|NCT00454103|adrenocortical carcinoma (ACC)
1380497|NCT00454103|adrenal tumor
1380498|NCT00454103|metastastic adrenocortical carcinoma
1380499|NCT00454090|Advanced Malignancies
1380500|NCT00454077|thyroid cancer; rhTSH; thyroid ablation
1380501|NCT00454064|cognitive-behavioral therapy
1380502|NCT00454064|back pain
1380503|NCT00454064|low back pain
1380504|NCT00454064|biofeedback
1380505|NCT00454064|randomized controlled study
1380506|NCT00454064|EMG biofeedback
1380507|NCT00454051|Asthma, anti-immunoglobulin E, omalizumab, IgE receptors
1380508|NCT00454038|cystectomy
1380509|NCT00454038|augmentation
1380510|NCT00454038|sinus
1380511|NCT00454038|amputation
1380512|NCT00454038|implant
1380513|NCT00454025|glaucoma
1380514|NCT00454025|intraocular pressure
1380515|NCT00454025|postural changes
1380516|NCT00454012|non reassuring fetal heart rate tracing
1380517|NCT00454012|biophysical profile
1380518|NCT00454012|assessing fetal wellbeing
1380519|NCT00453999|influenza
1380520|NCT00453999|flu
1380521|NCT00453986|immunogenicity
1380522|NCT00453986|Meningococcal serogroups A, C, W-135 and/or Y disease
1380523|NCT00453986|co-administration
1380524|NCT00453986|meningococcal vaccine
1380525|NCT00453986|lot-to-lot consistency
1380526|NCT00453986|conjugate vaccine
1380527|NCT00453973|anemia
1380528|NCT00453973|chronic kidney disease
1380529|NCT00453973|CKD
1380530|NCT00453973|chronic renal failure
1380531|NCT00453973|CRF
1380532|NCT00453973|dialysis
1380533|NCT00453973|erythropoietin
1380534|NCT00453973|EPO
1380535|NCT00453973|erythropoiesis stimulating agent
1380536|NCT00453973|ESA
1380537|NCT00453973|Hematide™
1380538|NCT00453973|hemodialysis
1380539|NCT00453973|hemoglobin
1380540|NCT00453973|Hb
1380541|NCT00453973|Hgb
1380542|NCT00453973|Omontys
1380543|NCT00453973|peginesatide
1380544|NCT00453973|red blood cell
1380545|NCT00453973|red blood cell production
1380546|NCT00453960|Endometrial hyperplasia
1380547|NCT00453960|Genistein
1380548|NCT00453960|Isoflavones
1380549|NCT00453960|dysfunctional uterine bleeding
1380550|NCT00453934|Diabetes
1380551|NCT00453934|Type 1 Diabetes
1380552|NCT00453934|Type 2 Diabetes
1380553|NCT00453934|Physiologic Insulin
1380554|NCT00453934|Basal Insulin
1380555|NCT00453934|Bolus Insulin
1380556|NCT00453934|Mealtime insulin
1380557|NCT00453934|Insulin patch
1380558|NCT00453934|Multiple daily injections
1380559|NCT00453921|TBI
1380560|NCT00453921|Memory
1380561|NCT00453921|Methylphenidate
1380562|NCT00453921|Ritalin
1380563|NCT00453921|Memory and Attention Training
1380564|NCT00453895|Adrenal cancer refractory to cytotoxic therapy
1380565|NCT00453895|Sunitinib
1380566|NCT00453895|Multitargeted tyrosine-kinase inhibitor
1380567|NCT00453869|Liver fibrosis
1380568|NCT00453869|Hepatitis B virus and C virus
1380569|NCT00453869|FibroMeter
1380570|NCT00453869|FibroScan®
1380571|NCT00453856|Malaria
1380572|NCT00453856|Sulfadoxine
1380573|NCT00453856|Pyrimethamine
1380574|NCT00453856|Resistance
1380575|NCT00453856|Gabon
1380576|NCT00453843|Stroke
1380577|NCT00453843|movement therapy
1380578|NCT00453843|robotics
1380579|NCT00453843|rehabilitation robotics
1380580|NCT00453843|shoulder, elbow, wrist
1380581|NCT00453830|Diverticulitis; laparoscopy; short term outcome
1380582|NCT00453817|islet transplantation
1380583|NCT00453817|imaging
1380584|NCT00453817|graft monitoring
1380585|NCT00453817|magnetic resonance imaging
1380586|NCT00453804|Alcohol dependence
1380587|NCT00453804|Major Mental Illness
1380588|NCT00453804|Injectable naltrexone
1380589|NCT00453791|GW805858
1380590|NCT00453791|MDI
1380591|NCT00453791|asthma
1380592|NCT00453791|surfactant
1380593|NCT00453778|mild asthma
1380594|NCT00453778|FLIXOTIDE
1380595|NCT00453778|methacholine
1380596|NCT00453778|bronchial challenge
1380597|NCT00453778|leukotriene D4
1380598|NCT00453765|cough
1380599|NCT00453765|hyperreactivity
1380600|NCT00453765|montelukast
1380601|NCT00453752|systemic sclerosis
1380602|NCT00453752|pulmonary hypertension
1380603|NCT00453752|echocardiography
1380604|NCT00453752|N-Terminal proBNP
1380605|NCT00453726|Natriuretic peptide brain
1380606|NCT00453726|Continuous positive airway pressure
1380607|NCT00453726|Intermittent positive pressure breathing
1380608|NCT00453726|Respiratory insufficiency
1380609|NCT00453713|Idiopathic pulmonary fibrosis
1380610|NCT00453713|Interstitial lung disease
1380611|NCT00453713|Diffuse parenchymal lung disease
1380612|NCT00453713|Health disparities
1380613|NCT00453700|chagas
1380614|NCT00453700|trypanosoma cruzi
1380615|NCT00453687|COPD
1380616|NCT00453687|GSK233705,
1380617|NCT00453687|Magnesium Stearate,
1380618|NCT00453674|Adrenal cancer
1380619|NCT00453674|Treatment
1380620|NCT00453674|Surgery
1380621|NCT00453674|Mitotane
1380622|NCT00453661|Breast Cancer
1380623|NCT00453661|Cervical Cancer
1380624|NCT00453661|Prostate Cancer
1380625|NCT00453661|Colorectal Cancer
1380626|NCT00453661|Lung Cancer
1380627|NCT00453661|Cancer Prevention
1380628|NCT00453661|Treatment Demonstration for Ethnic and Racial Minorities
1380629|NCT00453661|Centers for Medicare and Medicaid Services
1380630|NCT00453661|CMS
1380631|NCT00453661|Hispanic American
1380632|NCT00453661|Cancer Screening Assessment
1380633|NCT00453661|Annual Questionnaire
1380634|NCT00453661|Patient Navigator
1380635|NCT00453661|Educational Materials
1380636|NCT00453648|stable isotopes
1380637|NCT00453648|vitamin A
1380638|NCT00453648|beta-carotene
1380639|NCT00453648|orange-fleshed sweet potatoes
1380640|NCT00453648|iron
1380641|NCT00453648|zinc
1380642|NCT00453648|absorption
1380643|NCT00453648|bioavailability
1380644|NCT00453648|vitamin A equivalency
1380645|NCT00453648|Bangladesh
1380646|NCT00453648|women
1380647|NCT00453635|Cancer
1380648|NCT00453635|Breast cancer
1380649|NCT00453635|First line treatment
1380650|NCT00453635|Docetaxel
1380651|NCT00453635|Carboplatin
1380652|NCT00453635|Herceptin
1380653|NCT00453635|Vinorelbine
1380654|NCT00453622|Heart Failure
1380655|NCT00453622|Cardiac Resynchronization Therapy
1380656|NCT00453622|Risk stratification
1380657|NCT00453622|Prediction
1380658|NCT00453622|Proteomics
1380659|NCT00453622|Chemokine
1380660|NCT00453622|cardiac enzymes
1380661|NCT00453622|Brain Natriuretic Peptide
1380662|NCT00453609|Bipolar Disorders
1380663|NCT00453609|Schizophrenia
1380664|NCT00453609|Schizoaffective Disorders
1380665|NCT00453609|Alcohol Dependence
1380666|NCT00453609|Long-lasting injectable naltrexone
1380667|NCT00453596|infertile women
1380668|NCT00453596|thin endometrial thickness
1380669|NCT00453596|implantation failure
1380670|NCT00453583|Pediatric
1380671|NCT00453583|Allergies
1380672|NCT00453583|Antihistamines
1380673|NCT00453583|Non-interventional
1380674|NCT00453570|Diphteria
1380675|NCT00453570|Tetanus
1380676|NCT00453570|Haemophilus influenzae type b
1380677|NCT00453570|Poliomyelitis
1380678|NCT00453570|Pertussis
1380679|NCT00453557|growth hormone, obesity, visceral adiposity
1380680|NCT00453544|computer assisted instruction
1380681|NCT00453544|decision making
1380682|NCT00453544|educational resource design /development
1380683|NCT00453544|executive function
1380684|NCT00453531|Forearm Ischemia
1380685|NCT00453531|Endothelial Function
1380686|NCT00453531|Acetyicholine Vasodilation
1380687|NCT00453531|Venous Plethysmography
1380688|NCT00453531|Healthy Volunteer
1380689|NCT00453531|HV
1380690|NCT00453518|SVG
1380691|NCT00453518|Saphenous Vein Graft
1380692|NCT00453518|Embolic Protection
1380693|NCT00453518|Distal Protection
1380694|NCT00453518|EPD
1380695|NCT00453518|FiberNet
1380696|NCT00453518|Saphenous Vein Graft intervention
1380704|NCT00453479|Chronic obstructive pulmonary disease,
1380705|NCT00453479|muscarinic receptor,
1380706|NCT00453479|bronchodilators
1380707|NCT00453466|women experiencing domestic violence
1380708|NCT00453453|Congestive heart failure
1380709|NCT00453453|observation unit
1380710|NCT00453453|nesiritide
1380711|NCT00453440|HIV
1380712|NCT00453440|HLA-B*5701
1380713|NCT00453440|Abacavir hypersensitivity reaction
1380714|NCT00453427|PTL NOS
1380715|NCT00453427|AILD
1380716|NCT00453427|NHL
1380717|NCT00453427|CHOP
1380718|NCT00453414|PAH
1380719|NCT00453414|Pediatric
1380720|NCT00453414|Pulmonary Arterial Hypertension
1380721|NCT00453401|cold sore
1380722|NCT00453375|Diabetic
1380723|NCT00453375|Diabetes
1380724|NCT00453375|Type 1 Diabetes
1380725|NCT00453375|Type 1 Diabetes Mellitus
1380726|NCT00453375|autoimmune disease
1380727|NCT00453362|NSCLC
1380728|NCT00453362|Tarceva
1380729|NCT00453362|Positron emission technology
1380730|NCT00453362|PET
1380731|NCT00453362|Computerized tomography
1380732|NCT00453362|CT
1380733|NCT00453349|Uncomplicated pelvic inflammatory disease
1380734|NCT00453336|recurrent squamous cell carcinoma of the lip and oral cavity
1380735|NCT00453336|stage II squamous cell carcinoma of the lip and oral cavity
1380736|NCT00453336|stage III squamous cell carcinoma of the lip and oral cavity
1380737|NCT00453336|stage IV squamous cell carcinoma of the lip and oral cavity
1380738|NCT00453336|recurrent squamous cell carcinoma of the oropharynx
1380739|NCT00453336|stage II squamous cell carcinoma of the oropharynx
1380740|NCT00453336|stage III squamous cell carcinoma of the oropharynx
1380741|NCT00453336|stage IV squamous cell carcinoma of the oropharynx
1380742|NCT00453336|recurrent squamous cell carcinoma of the larynx
1380743|NCT00453336|stage II squamous cell carcinoma of the larynx
1380744|NCT00453336|stage III squamous cell carcinoma of the larynx
1380745|NCT00453336|stage IV squamous cell carcinoma of the larynx
1380746|NCT00453336|stage I squamous cell carcinoma of the larynx
1380747|NCT00453336|stage I squamous cell carcinoma of the lip and oral cavity
1380748|NCT00453336|stage I squamous cell carcinoma of the oropharynx
1380749|NCT00453336|oral leukoplakia
1380750|NCT00453323|Esophageal Cancer
1380751|NCT00453323|Phase II
1380752|NCT00453323|Metastatic esophageal cancer
1380753|NCT00453323|Recurrent esophageal cancer
1380754|NCT00453310|recurrent ovarian germ cell tumor
1380755|NCT00453310|stage IV ovarian germ cell tumor
1380756|NCT00453310|ovarian choriocarcinoma
1380757|NCT00453310|ovarian immature teratoma
1380758|NCT00453310|ovarian mature teratoma
1380759|NCT00453310|recurrent malignant testicular germ cell tumor
1380760|NCT00453310|testicular choriocarcinoma
1380761|NCT00453310|testicular seminoma
1380762|NCT00453310|testicular yolk sac tumor
1380763|NCT00453310|ovarian dysgerminoma
1380764|NCT00453310|ovarian embryonal carcinoma
1380765|NCT00453310|ovarian yolk sac tumor
1380766|NCT00453310|ovarian monodermal and highly specialized teratoma
1380767|NCT00453310|ovarian polyembryoma
1380768|NCT00453310|stage III malignant testicular germ cell tumor
1380769|NCT00453310|ovarian mixed germ cell tumor
1380770|NCT00453310|testicular choriocarcinoma and embryonal carcinoma
1380771|NCT00453310|testicular choriocarcinoma and seminoma
1380772|NCT00453310|testicular choriocarcinoma and teratoma
1380773|NCT00453310|testicular choriocarcinoma and yolk sac tumor
1380774|NCT00453310|testicular embryonal carcinoma and seminoma
1380775|NCT00453310|testicular embryonal carcinoma and teratoma with seminoma
1380776|NCT00453310|testicular embryonal carcinoma and teratoma
1380777|NCT00453310|testicular embryonal carcinoma and yolk sac tumor with seminoma
1380778|NCT00453310|testicular embryonal carcinoma and yolk sac tumor
1380779|NCT00453310|testicular yolk sac tumor and teratoma with seminoma
1380780|NCT00453310|testicular yolk sac tumor and teratoma
1380781|NCT00453310|testicular embryonal carcinoma
1380979|NCT00453050|stage III melanoma
1380782|NCT00453310|recurrent extragonadal non-seminomatous germ cell tumor
1380783|NCT00453310|recurrent extragonadal seminoma
1380784|NCT00453310|stage IV extragonadal non-seminomatous germ cell tumor
1380785|NCT00453310|stage IV extragonadal seminoma
1380786|NCT00453310|recurrent extragonadal germ cell tumor
1380787|NCT00453310|testicular immature teratoma
1380788|NCT00453310|testicular mature teratoma
1380789|NCT00453310|adult teratoma
1380790|NCT00453297|Bionovo
1380791|NCT00453297|MF101
1380792|NCT00453297|Herbs
1380793|NCT00453297|The primary goal of this study is to identify the highest safe oral dose of MF101 that is well tolerated in humans.
1380794|NCT00453271|chronic persistent infection of the nail bed or plate
1380795|NCT00453258|ocular proteomics
1380796|NCT00453258|eye disease
1380797|NCT00453258|proteomics
1380798|NCT00453232|stage III malignant testicular germ cell tumor
1380799|NCT00453232|testicular choriocarcinoma and seminoma
1380800|NCT00453232|testicular embryonal carcinoma and seminoma
1380801|NCT00453232|testicular choriocarcinoma and embryonal carcinoma
1380802|NCT00453232|testicular choriocarcinoma and teratoma
1380803|NCT00453232|testicular choriocarcinoma
1380804|NCT00453232|testicular choriocarcinoma and yolk sac tumor
1380805|NCT00453232|testicular embryonal carcinoma and teratoma with seminoma
1380806|NCT00453232|testicular embryonal carcinoma and teratoma
1380807|NCT00453232|testicular embryonal carcinoma and yolk sac tumor with seminoma
1380808|NCT00453232|testicular embryonal carcinoma and yolk sac tumor
1380809|NCT00453232|testicular embryonal carcinoma
1380810|NCT00453232|testicular seminoma
1380811|NCT00453232|testicular yolk sac tumor
1380812|NCT00453232|testicular yolk sac tumor and teratoma with seminoma
1380813|NCT00453232|testicular yolk sac tumor and teratoma
1380814|NCT00453232|recurrent malignant testicular germ cell tumor
1380815|NCT00453232|recurrent extragonadal non-seminomatous germ cell tumor
1380816|NCT00453232|recurrent extragonadal seminoma
1380817|NCT00453232|stage IV extragonadal non-seminomatous germ cell tumor
1380818|NCT00453232|stage IV extragonadal seminoma
1380819|NCT00453232|adult teratoma
1380820|NCT00453232|testicular immature teratoma
1380821|NCT00453232|testicular mature teratoma
1380822|NCT00453232|recurrent extragonadal germ cell tumor
1380823|NCT00453206|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1380824|NCT00453206|adult acute myeloid leukemia with inv(16)(p13;q22)
1380825|NCT00453206|adult acute myeloid leukemia with t(15;17)(q22;q12)
1380826|NCT00453206|adult acute myeloid leukemia with t(16;16)(p13;q22)
1380827|NCT00453206|adult acute myeloid leukemia with t(8;21)(q22;q22)
1380828|NCT00453206|accelerated phase chronic myelogenous leukemia
1380829|NCT00453206|adult acute myeloid leukemia in remission
1380830|NCT00453206|blastic phase chronic myelogenous leukemia
1380831|NCT00453206|primary myelofibrosis
1380832|NCT00453206|chronic phase chronic myelogenous leukemia
1380833|NCT00453206|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1380834|NCT00453206|de novo myelodysplastic syndromes
1380835|NCT00453206|nodal marginal zone B-cell lymphoma
1380836|NCT00453206|noncontiguous stage II adult Burkitt lymphoma
1380837|NCT00453206|noncontiguous stage II adult diffuse large cell lymphoma
1380838|NCT00453206|noncontiguous stage II adult diffuse mixed cell lymphoma
1380839|NCT00453206|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1380840|NCT00453206|noncontiguous stage II adult immunoblastic large cell lymphoma
1380841|NCT00453206|noncontiguous stage II adult lymphoblastic lymphoma
1380842|NCT00453206|noncontiguous stage II grade 1 follicular lymphoma
1380843|NCT00453206|noncontiguous stage II grade 2 follicular lymphoma
1380844|NCT00453206|noncontiguous stage II grade 3 follicular lymphoma
1380845|NCT00453206|noncontiguous stage II mantle cell lymphoma
1380846|NCT00453206|noncontiguous stage II marginal zone lymphoma
1380847|NCT00453206|noncontiguous stage II small lymphocytic lymphoma
1380848|NCT00453206|previously treated myelodysplastic syndromes
1380849|NCT00453206|prolymphocytic leukemia
1380850|NCT00453206|recurrent adult acute myeloid leukemia
1380851|NCT00453206|recurrent adult Burkitt lymphoma
1380852|NCT00453206|recurrent adult Hodgkin lymphoma
1380853|NCT00453206|recurrent adult diffuse large cell lymphoma
1380854|NCT00453206|recurrent adult diffuse mixed cell lymphoma
1380855|NCT00453206|recurrent adult diffuse small cleaved cell lymphoma
1380856|NCT00453206|recurrent adult immunoblastic large cell lymphoma
1380857|NCT00453206|recurrent adult lymphoblastic lymphoma
1380858|NCT00453206|recurrent grade 1 follicular lymphoma
1380859|NCT00453206|recurrent grade 2 follicular lymphoma
1380860|NCT00453206|recurrent grade 3 follicular lymphoma
1381198|NCT00452127|Indolent
1380861|NCT00453206|recurrent mantle cell lymphoma
1380862|NCT00453206|recurrent marginal zone lymphoma
1380863|NCT00453206|recurrent small lymphocytic lymphoma
1380864|NCT00453206|refractory chronic lymphocytic leukemia
1380865|NCT00453206|refractory multiple myeloma
1380866|NCT00453206|relapsing chronic myelogenous leukemia
1380867|NCT00453206|secondary acute myeloid leukemia
1380868|NCT00453206|secondary myelodysplastic syndromes
1380869|NCT00453206|splenic marginal zone lymphoma
1380870|NCT00453206|stage I multiple myeloma
1380871|NCT00453206|stage II multiple myeloma
1380872|NCT00453206|stage III adult Burkitt lymphoma
1380873|NCT00453206|stage III adult Hodgkin lymphoma
1380874|NCT00453206|stage III adult diffuse large cell lymphoma
1380875|NCT00453206|stage III adult diffuse mixed cell lymphoma
1380876|NCT00453206|stage III adult diffuse small cleaved cell lymphoma
1380877|NCT00453206|stage III adult immunoblastic large cell lymphoma
1380878|NCT00453206|stage III adult lymphoblastic lymphoma
1380879|NCT00453206|stage III grade 1 follicular lymphoma
1380880|NCT00453206|stage III grade 2 follicular lymphoma
1380881|NCT00453206|stage III grade 3 follicular lymphoma
1380882|NCT00453206|stage III mantle cell lymphoma
1380883|NCT00453206|stage III marginal zone lymphoma
1380884|NCT00453206|stage III multiple myeloma
1380885|NCT00453206|stage III small lymphocytic lymphoma
1380886|NCT00453206|stage IV adult Burkitt lymphoma
1380887|NCT00453206|stage IV adult Hodgkin lymphoma
1380888|NCT00453206|stage IV adult diffuse large cell lymphoma
1380889|NCT00453206|stage IV adult diffuse mixed cell lymphoma
1380890|NCT00453206|stage IV adult diffuse small cleaved cell lymphoma
1380891|NCT00453206|stage IV adult immunoblastic large cell lymphoma
1380892|NCT00453206|stage IV adult lymphoblastic lymphoma
1380893|NCT00453206|stage IV chronic lymphocytic leukemia
1380894|NCT00453206|stage IV grade 1 follicular lymphoma
1380895|NCT00453206|stage IV grade 2 follicular lymphoma
1380896|NCT00453206|stage IV grade 3 follicular lymphoma
1380897|NCT00453206|stage IV mantle cell lymphoma
1380898|NCT00453206|stage IV marginal zone lymphoma
1380899|NCT00453206|stage IV small lymphocytic lymphoma
1380900|NCT00453206|polycythemia vera
1380901|NCT00453206|stage III chronic lymphocytic leukemia
1380902|NCT00453206|recurrent/refractory childhood Hodgkin lymphoma
1380903|NCT00453206|stage I childhood Hodgkin lymphoma
1380904|NCT00453206|stage II childhood Hodgkin lymphoma
1380905|NCT00453206|stage III childhood Hodgkin lymphoma
1380906|NCT00453206|stage IV childhood Hodgkin lymphoma
1380907|NCT00453206|recurrent childhood anaplastic large cell lymphoma
1380908|NCT00453206|stage I childhood anaplastic large cell lymphoma
1380909|NCT00453206|stage II childhood anaplastic large cell lymphoma
1380910|NCT00453206|stage III childhood anaplastic large cell lymphoma
1380911|NCT00453206|stage IV childhood anaplastic large cell lymphoma
1380912|NCT00453206|recurrent childhood grade III lymphomatoid granulomatosis
1380913|NCT00453206|recurrent childhood large cell lymphoma
1380914|NCT00453206|stage I childhood large cell lymphoma
1380915|NCT00453206|stage II childhood large cell lymphoma
1380916|NCT00453206|stage III childhood large cell lymphoma
1380917|NCT00453206|stage IV childhood large cell lymphoma
1380918|NCT00453206|recurrent childhood lymphoblastic lymphoma
1380919|NCT00453206|stage I childhood lymphoblastic lymphoma
1380920|NCT00453206|stage II childhood lymphoblastic lymphoma
1380921|NCT00453206|stage III childhood lymphoblastic lymphoma
1380922|NCT00453206|stage IV childhood lymphoblastic lymphoma
1380923|NCT00453206|childhood nasal type extranodal NK/T-cell lymphoma
1380924|NCT00453206|recurrent childhood small noncleaved cell lymphoma
1380925|NCT00453206|stage I childhood small noncleaved cell lymphoma
1380926|NCT00453206|stage II childhood small noncleaved cell lymphoma
1380927|NCT00453206|stage III childhood small noncleaved cell lymphoma
1380928|NCT00453206|stage IV childhood small noncleaved cell lymphoma
1380929|NCT00453193|T-Cell Neoplasms
1380930|NCT00453193|Alemtuzumab
1380931|NCT00453193|Pentostatin
1380932|NCT00453193|Campath-1H
1380933|NCT00453193|Deoxycoformycin
1380934|NCT00453193|Lymphoma
1380935|NCT00453193|Leukemia
1380936|NCT00453180|Autistic Disorder
1380937|NCT00453180|Asperger's
1380938|NCT00453180|PDD NOS
1380939|NCT00453180|Pervasive Developmental Disorder
1380940|NCT00453180|Autism
1380941|NCT00453180|N-acetylcysteine
1380942|NCT00453180|acetylcysteine
1380943|NCT00453180|NAC
1380944|NCT00453180|antioxidant
1380945|NCT00453180|treatment
1380946|NCT00453180|core symptoms
1380947|NCT00453180|Autism Spectrum Disorders
1380948|NCT00453180|Asperger's Disorder
1380949|NCT00453180|Pervasive Developmental Disorder Not Otherwise Specified
1380950|NCT00453180|Pervasive Developmental Disorders
1380951|NCT00453167|Small cell lung cancer
1380952|NCT00453167|second-line therapy
1380953|NCT00453141|Betamethasone for preterm labor
1380954|NCT00453141|Preterm delivery
1380955|NCT00453141|Infant Respiratory Distress Syndrome
1380956|NCT00453128|Calcium Pyrophosphate
1380957|NCT00453128|associated conditions
1380958|NCT00453115|Non small cell lung cancer
1380959|NCT00453115|advanced stage IIIB
1380960|NCT00453115|Stage IV
1380961|NCT00453102|Marginal Zone Lymphoma
1380962|NCT00453102|Non-gastric extranodal Marginal Zone Lymphoma
1380963|NCT00453102|Splenic Marginal Zone Lymphoma
1380964|NCT00453102|Nodal Marginal Zone Lymphoma
1380965|NCT00453102|Gastric Marginal Zone Lymphoma
1380966|NCT00453102|MZL
1380967|NCT00453102|Non-gastric extranodal MZL
1380968|NCT00453102|Splenic MZL
1380969|NCT00453102|Nodal MZL
1380970|NCT00453102|Gastric MZL
1380971|NCT00453089|Chinese Herbs
1380972|NCT00453089|Postmenopausal
1380973|NCT00453089|Vaginal Atrophy
1380974|NCT00453089|Vulvar Atrophy
1380975|NCT00453089|Symptoms
1380976|NCT00453089|Bionovo
1380977|NCT00453089|VG101
1380978|NCT00453076|Biliary Obstruction
1380980|NCT00453050|stage IV melanoma
1380981|NCT00453050|skin metastases
1380982|NCT00453037|hypertension
1380983|NCT00453037|self measurement of blood pressure
1380984|NCT00453037|education program
1380985|NCT00453037|life style
1380986|NCT00453024|Advanced glaucoma
1380987|NCT00453024|Ahmed glaucoma implant
1380988|NCT00453024|Anterior segment optical coherence tomography
1380989|NCT00453024|Pericardial patch graft
1380990|NCT00453024|Tissue glue
1380991|NCT00453024|Scleral flap
1380992|NCT00453024|Sutures
1380993|NCT00453011|vitreous loss
1380994|NCT00453011|intraocular lenses
1380995|NCT00453011|Patients undergoing extracapsular cataract surgery
1380996|NCT00453011|Vitreous loss with sufficient capsular support for an unsutured posterior chamber lens
1380997|NCT00453011|5% random sample of patients with no vitreous loss
1380998|NCT00452998|Sequential Laser Iridotomy
1380999|NCT00452998|Q-Switched 532 nm Laser
1381000|NCT00452998|Frequency Doubled Neodymium Yag Laser
1381001|NCT00452972|Cesarean delivery
1381002|NCT00452972|Spinal anesthesia
1381003|NCT00452972|Nausea
1381004|NCT00452972|Vomiting
1381005|NCT00452972|Pain
1381006|NCT00452920|cervical squamous cell carcinoma
1381007|NCT00452920|stage IIB cervical cancer
1381008|NCT00452920|stage III cervical cancer
1381009|NCT00452920|stage IVA cervical cancer
1381010|NCT00452881|Non-small cell lung cancer
1381011|NCT00452881|adjuvant chemotherapy
1381012|NCT00452868|cognitive/functional effects
1381013|NCT00452868|neurotoxicity
1381014|NCT00452868|long-term effects secondary to cancer therapy in children
1381015|NCT00452868|psychosocial effects of cancer and its treatment
1381016|NCT00452868|radiation toxicity
1381017|NCT00452868|childhood central nervous system germ cell tumor
1381018|NCT00452868|childhood choroid plexus tumor
1381019|NCT00452868|childhood craniopharyngioma
1381020|NCT00452868|childhood grade I meningioma
1381021|NCT00452868|childhood grade II meningioma
1381022|NCT00452868|childhood grade III meningioma
1381023|NCT00452868|childhood spinal cord neoplasm
1381024|NCT00452868|childhood brain stem glioma
1381025|NCT00452868|childhood cerebellar astrocytoma
1381026|NCT00452868|childhood medulloblastoma
1381027|NCT00452868|childhood supratentorial primitive neuroectodermal tumor
1381028|NCT00452868|childhood visual pathway and hypothalamic glioma
1381029|NCT00452868|childhood subependymal giant cell astrocytoma
1381030|NCT00452868|childhood ependymoma
1381031|NCT00452868|childhood cerebral astrocytoma/malignant glioma
1381032|NCT00452855|Nausea
1381033|NCT00452855|Vomiting
1381034|NCT00452855|Post operative
1381035|NCT00452855|Propofol remifentanil anaesthesia
1381036|NCT00452855|Sevoflurane remifentanil anaesthesia
1381037|NCT00452816|Chronic Disease
1381038|NCT00452816|Employer Health Costs
1381039|NCT00452816|Health Promotion
1381040|NCT00452816|Insurance Benefits
1381041|NCT00452816|Marketing of Health Services
1381042|NCT00452816|Mass Screening
1381043|NCT00452816|Prevention & Control
1381044|NCT00452816|Tobacco Use Cessation
1381045|NCT00452816|Workplace
1381046|NCT00452803|Non small cell lung cancer
1381047|NCT00452790|Vaccines, Pneumococcal
1381048|NCT00452777|Diabetic neuropathy, painful
1381049|NCT00452777|Adenosine A2A receptor
1381050|NCT00452764|COPD
1381051|NCT00452764|Healthy
1381052|NCT00452764|Regulatory T cell
1381053|NCT00452764|Heme oxygenase-1
1381054|NCT00452764|peripheral blood
1381055|NCT00452751|gastric cancer
1381056|NCT00452751|laparoscopic surgery
1381057|NCT00452751|survival
1381058|NCT00452751|preoperative staging
1381059|NCT00452751|morbidity
1381060|NCT00452751|quality of life
1381061|NCT00452751|acute inflammatory reaction
1381062|NCT00452751|cost
1381063|NCT00452738|animal-assisted intervention
1381064|NCT00452738|pre surgery anxiety
1381065|NCT00452738|post surgery pain medication consumption
1381066|NCT00452712|orthostatism
1381067|NCT00452712|fever
1381068|NCT00452699|fluticasone propionate
1381069|NCT00452699|long-term study
1381070|NCT00452699|Salmeterol
1381071|NCT00452699|FLOVENT 250
1381072|NCT00452699|Asthma
1381073|NCT00452699|ADVAIR 250
1381074|NCT00452686|Chinese DT vaccin
1381075|NCT00452660|IRON
1381076|NCT00452660|oxidative stress
1381077|NCT00452660|MDS
1381199|NCT00452127|Follicular
1381078|NCT00452647|Condition: No specific disease is being studied, few procedures are excluded.
1381079|NCT00452647|Focus: To obtain blood pressure data and detect any trends to a statistically significant degree.
1381080|NCT00452634|Irinotecan
1381081|NCT00452634|cisplatin
1381082|NCT00452634|Simvastatin
1381083|NCT00452634|Extensive disease
1381084|NCT00452634|SCLC
1381085|NCT00452621|blood draw five years after booster-immunization with TBE vaccine to investigate immunogenicity in children
1381086|NCT00452621|TBE
1381087|NCT00452582|ischemic stroke
1381088|NCT00452582|recovery
1381089|NCT00452582|sildenafil
1381090|NCT00452569|Relapsed Refractory Multiple Myeloma
1381091|NCT00452556|Prostatic Neoplasms
1381092|NCT00452556|Radiotherapy
1381093|NCT00452556|Docetaxel
1381094|NCT00452556|Leuprolide Acetate
1381095|NCT00452543|Major depressive disorder
1381096|NCT00452543|Alcoholism
1381097|NCT00452543|Alcohol abuse
1381098|NCT00452543|Alcohol dependence
1381099|NCT00452530|Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery
1381100|NCT00452517|bare metal stents
1381101|NCT00452517|sirolimus-eluting stents
1381102|NCT00452517|coronary polytetrafluoroethylene stent graft
1381103|NCT00452517|acute coronary syndrome
1381104|NCT00452517|quantitative coronary angiography analysis
1381105|NCT00452517|major adverse cardiac events
1381106|NCT00452517|in-stent restenosis
1381107|NCT00452517|target lesion revascularisation
1381108|NCT00452478|Hyperphosphataemia
1381109|NCT00452465|Elderly
1381110|NCT00452465|Nursing care plan
1381111|NCT00452465|Quality of Life
1381112|NCT00452452|Pneumococcal Vaccines
1381113|NCT00452439|Leukemia
1381114|NCT00452439|Lymphoma
1381115|NCT00452439|Acute Lymphocytic Leukemia
1381116|NCT00452439|Lymphoblastic Lymphoma
1381117|NCT00452439|Actonel
1381118|NCT00452439|Risedronate
1381119|NCT00452439|Bone Loss
1381120|NCT00452439|Osteoporosis
1381121|NCT00452426|Propofol
1381122|NCT00452426|Diprivan
1381123|NCT00452426|Colonoscopy
1381124|NCT00452426|Endoscopy, Digestive System
1381125|NCT00452426|Conscious Sedation
1381126|NCT00452387|Prostate Cancer
1381127|NCT00452374|B-cell chronic lymphocytic leukemia
1381128|NCT00452374|Chronic Lymphocytic Leukemia
1381129|NCT00452374|CLL
1381130|NCT00452374|Prolymphocytic Leukemia
1381131|NCT00452374|PLL
1381132|NCT00452374|Richter's Transformation
1381133|NCT00452374|High-grade non-Hodgkin's lymphoma
1381134|NCT00452374|Hodgkin's disease
1381135|NCT00452374|Acute leukemia
1381136|NCT00452374|Small lymphocytic lymphoma
1381137|NCT00452374|Oxaliplatin
1381138|NCT00452374|Eloxatin
1381139|NCT00452374|Fludarabine
1381140|NCT00452374|Cytarabine
1381141|NCT00452374|Ara-C
1381142|NCT00452374|Cytosar
1381143|NCT00452374|DepoCyt
1381144|NCT00452374|Cytosine arabinosine hydrochloride
1381145|NCT00452374|Rituximab
1381146|NCT00452374|Rituxan
1381147|NCT00452348|FLOVENT
1381148|NCT00452348|fluticasone
1381149|NCT00452348|12 month
1381150|NCT00452348|salmeterol
1381151|NCT00452348|asthma
1381152|NCT00452348|ADVAIR
1381153|NCT00452322|Testosterone
1381154|NCT00452322|Hypogonadism
1381155|NCT00452322|Safety
1381156|NCT00452309|peripheral arterial disease
1381157|NCT00452309|pad
1381158|NCT00452309|ankle brachial index
1381159|NCT00452309|abi
1381160|NCT00452296|inpatients with COPD
1381161|NCT00452296|glucose control
1381162|NCT00452270|Common cold, xylometazoline
1381163|NCT00452244|Gefitinib
1381164|NCT00452244|Simvastatin
1381165|NCT00452244|NSCLC
1381166|NCT00452244|Advanced NSCLC
1381167|NCT00452231|Post-traumatic Stress Disorder
1381168|NCT00452231|Cognitive-Behavioral Therapy
1381169|NCT00452218|Pulmonary Arterial Hypertension
1381170|NCT00452218|PAH
1381171|NCT00452205|bone marrow-derived stem cell
1381172|NCT00452205|bone marrow transplantation
1381173|NCT00452205|graft versus host disease
1381174|NCT00452205|gastrointestinal cancer
1381175|NCT00452205|after receiving bone marrow transplantation
1381176|NCT00452192|Metabolic syndrome
1381177|NCT00452179|Sleep maintenance
1381178|NCT00452179|Insomnia
1381179|NCT00452179|Sleep Consolidation
1381180|NCT00452179|Sleep
1381181|NCT00452179|Insomnia, primarily sleep maintenance
1381182|NCT00452153|legionellosis
1381183|NCT00452153|diagnosis of legionellosis
1381184|NCT00452153|PCR
1381185|NCT00452140|Breast Cancer
1381186|NCT00452140|investigational drug
1381187|NCT00452140|drug therapy
1381188|NCT00452140|Antineoplastic Protocols
1381189|NCT00452140|Immunotherapy
1381190|NCT00452140|Metastatic breast cancer
1381191|NCT00452140|Advanced breast cancer
1381192|NCT00452140|Stage III to IV breast cancer
1381193|NCT00452140|Hormonal therapy refractory
1381194|NCT00452140|Failure of hormonal therapy
1381195|NCT00452140|Her-2/neu expressing breast cancer
1381196|NCT00452140|Her-2/neu
1381197|NCT00452127|NHL
1381200|NCT00452114|Bronchiectasis
1381201|NCT00452101|Osteoarthritis
1381202|NCT00452101|Clinical trial
1381203|NCT00452101|Aquamin F
1381204|NCT00452101|Glucosamine
1381205|NCT00452088|Malaria vaccine
1381206|NCT00452088|Safety of MSP 3 LSP
1381207|NCT00452088|Immunogenicity of MSP 3 LSP
1381208|NCT00452088|Burkina Faso children
1381209|NCT00452075|EGFR expression
1381210|NCT00452075|erlotinib
1381211|NCT00452062|cuff-leak test
1381212|NCT00452062|intubation
1381213|NCT00452062|corticosteroids
1381214|NCT00452062|dexamethasone to reduce the occurrence of post-extubation airway obstruction
1381215|NCT00452049|parathyroidectomy
1381216|NCT00452049|arterial stiffness
1381217|NCT00452049|renal function
1381218|NCT00452036|risk factors
1381219|NCT00452036|plain x ray
1381220|NCT00452036|cranial computed tomography
1381221|NCT00452036|minor head injury
1381222|NCT00452023|Myeloproliferative Disorders
1381223|NCT00452023|Essential Thrombocythemia
1381224|NCT00452023|Polycythemia Vera
1381225|NCT00452023|Pegasys
1381226|NCT00452023|IFN-alpha2a
1381227|NCT00452023|Pegylated-Interferon Alpha-2A
1381228|NCT00452023|PEG-IFNa-2a
1381229|NCT00452010|TENS
1381230|NCT00452010|chronic low back pain
1381231|NCT00452010|chronic lumbo-radiculalgia
1381232|NCT00452010|placebo
1381233|NCT00452010|Roland scale
1381234|NCT00451997|AML
1381235|NCT00451997|MDS
1381236|NCT00451997|Gleevec
1381237|NCT00451997|Ara-C
1381238|NCT00451997|C-Kit Positive Acute Myeloid Leukemia
1381239|NCT00451997|High-Risk Myelodysplastic Syndromes
1381240|NCT00451984|interleukin-2
1381241|NCT00451984|vaccination
1381242|NCT00451984|treatment experienced
1381243|NCT00451958|Degarelix
1381244|NCT00451958|prostate cancer
1381245|NCT00450944|B-cell adult acute lymphoblastic leukemia
1381246|NCT00450944|recurrent adult acute lymphoblastic leukemia
1381247|NCT00450931|health status unknown
1381248|NCT00450918|Kartagener Syndrome
1381249|NCT00450905|Chronic musculoskeletal pain secondary to Fibromyalgia
1381250|NCT00450892|inflammatory breast cancer
1381251|NCT00450892|stage II breast cancer
1381252|NCT00450892|stage IIIA breast cancer
1381253|NCT00450892|stage IIIB breast cancer
1381254|NCT00450892|stage IIIC breast cancer
1381255|NCT00450866|recurrent breast cancer
1381256|NCT00450866|stage IV breast cancer
1381257|NCT00450866|tumors metastatic to brain
1381258|NCT00450866|leptomeningeal metastases
1381259|NCT00450866|male breast cancer
1381260|NCT00450853|emesis
1381261|NCT00450853|granisetron
1381262|NCT00450853|pharmacokinetics
1381263|NCT00450853|subcutaneous.
1381264|NCT00450840|septic shock
1381265|NCT00450840|simvastatin
1381266|NCT00450827|recurrent neuroblastoma
1381267|NCT00450801|contiguous stage II mantle cell lymphoma
1381268|NCT00450801|noncontiguous stage II mantle cell lymphoma
1381269|NCT00450801|stage I mantle cell lymphoma
1381270|NCT00450801|stage III mantle cell lymphoma
1381271|NCT00450801|stage IV mantle cell lymphoma
1381272|NCT00450788|Etiology
1381273|NCT00450788|Carcinogens
1381274|NCT00450788|Esophageal Cancer
1381275|NCT00450762|pretreated
1381276|NCT00450762|metastatic
1381277|NCT00450736|chondrosarcoma
1381278|NCT00450736|adult angiosarcoma
1381279|NCT00450736|adult fibrosarcoma
1381280|NCT00450736|adult leiomyosarcoma
1381281|NCT00450736|adult liposarcoma
1381282|NCT00450736|adult neurofibrosarcoma
1381283|NCT00450736|adult synovial sarcoma
1381284|NCT00450736|childhood angiosarcoma
1381285|NCT00450736|childhood fibrosarcoma
1381286|NCT00450736|childhood leiomyosarcoma
1381287|NCT00450736|childhood liposarcoma
1381288|NCT00450736|childhood neurofibrosarcoma
1381289|NCT00450736|childhood synovial sarcoma
1381290|NCT00450736|nonmetastatic childhood soft tissue sarcoma
1381291|NCT00450736|stage II adult soft tissue sarcoma
1381292|NCT00450736|stage III adult soft tissue sarcoma
1381293|NCT00450736|adult malignant fibrous histiocytoma
1381294|NCT00450736|adult malignant hemangiopericytoma
1381295|NCT00450736|childhood malignant hemangiopericytoma
1381296|NCT00450736|localized childhood malignant fibrous histiocytoma of bone
1381297|NCT00450723|stage I breast cancer
1381298|NCT00450723|stage II breast cancer
1381299|NCT00450723|male breast cancer
1381300|NCT00451932|Malononitrilamide
1381301|NCT00451932|Immunosuppression
1381302|NCT00451932|treatment efficacy
1381303|NCT00451932|treatment effectiveness
1381304|NCT00451919|MRI
1381305|NCT00451919|Neuropsychology
1381306|NCT00451893|Inguinal hernia
1381307|NCT00451893|polypropylene mesh
1381308|NCT00451893|heavy-weight mesh
1381309|NCT00451893|light-weight mesh
1381310|NCT00451880|Cancer
1381311|NCT00451880|Solid Tumors
1381312|NCT00451880|NSCLC
1381313|NCT00451867|interstitial cystitis research
1381314|NCT00451867|painful bladder syndrome research
1381315|NCT00451867|pelvic pain research
1381316|NCT00451867|interstitial cystitis and autoimmune
1381317|NCT00451867|interstitial cystitis and cellcept
1381318|NCT00451867|interstitial cystitis and mycophenolate mofetil
1381319|NCT00451867|interstitial cystitis and MMF
1381320|NCT00451867|interstitial cystitis and inflammation
1381321|NCT00451867|inflammatory diseases and immunosupression
1381322|NCT00451854|Drug testing
1381323|NCT00451854|Adolescence
1381324|NCT00451854|Student athlete
1381325|NCT00451854|Substance abuse
1381326|NCT00451854|Alcohol use
1381327|NCT00451854|Drug use
1381328|NCT00451841|Cough
1381329|NCT00451841|Gastroesophageal reflux
1381330|NCT00451841|Exhaled breath condensate
1381331|NCT00451828|Statins
1381332|NCT00451828|Cholesterol
1381333|NCT00451828|Pharmacogenetics
1381334|NCT00451802|Biotechnology
1381335|NCT00451802|Specimen
1381336|NCT00451802|Health Management Center
1381337|NCT00451789|Minor head injury
1381338|NCT00451789|iintracranial bleeding
1381339|NCT00451789|traumatic brain injury
1381340|NCT00451789|Cranial computed tomography
1381341|NCT00451789|anticoagulatory drugs
1381342|NCT00451776|cardiac surgery
1381343|NCT00451776|adrenal insufficiency
1381344|NCT00451776|etomidate
1381345|NCT00451776|propofol
1381346|NCT00451763|Fovea centralis/pathology
1381347|NCT00451763|Fundus oculi
1381348|NCT00451763|Retinal neovascularization
1381349|NCT00451763|Telangiectasis/diagnosis
1381350|NCT00451763|Tomography, optical coherence
1381351|NCT00451763|Vitreous Body/drug effects
1381352|NCT00451750|phobia
1381353|NCT00451750|cortisol
1381354|NCT00451750|memory
1381355|NCT00451750|treatment
1381356|NCT00451737|Six-minute walk test
1381357|NCT00451737|Neuromuscular system
1381358|NCT00451737|Influence factors
1381359|NCT00451724|Prospective
1381360|NCT00451724|Randomized
1381361|NCT00451724|Double blinded
1381362|NCT00451724|Sedation
1381363|NCT00451724|Ketamine
1381364|NCT00451724|Intranasal
1381365|NCT00451711|Prophylaxis
1381366|NCT00451711|Liposomal Amphotericin B
1381367|NCT00451711|Acute myeloid leukaemia
1381368|NCT00451711|Invasive Fungal Infections
1381369|NCT00451698|Erythropoietin
1381370|NCT00451698|Congenital heart surgery
1381371|NCT00451672|aldosteronism, bromocriptin, hypertension
1381372|NCT00451659|PTSD
1381373|NCT00451659|Veterans
1381374|NCT00451659|Deployed
1381375|NCT00451620|Type 2 diabetes
1381376|NCT00451620|Hypoglycemia
1381377|NCT00451620|Oral hypoglycemic agents
1381378|NCT00451620|Insulin levels
1381379|NCT00451607|premature
1381380|NCT00451607|newborn
1381381|NCT00451607|heart rate variability
1381382|NCT00451607|individualized sensorimotor care
1381383|NCT00451607|noise
1381384|NCT00451594|ITP
1381385|NCT00451581|Endoscopic papillary balloon dilatation
1381386|NCT00451581|Endoscopic sphincterotomy
1381387|NCT00451581|Choledocholithiasis
1381388|NCT00451581|Efficacy
1381389|NCT00451581|Complication
1381390|NCT00451568|Polycystic ovary syndrome
1381391|NCT00451542|Bipolar Disorder
1381392|NCT00451542|Relapse
1381393|NCT00451542|Retrospective
1381394|NCT00451516|Plant, medicine
1381395|NCT00451516|Psychiatry
1381396|NCT00451516|Major depressive disorder
1381397|NCT00451516|Anxiety
1381398|NCT00451516|Major Depressive Disorder with comorbid anxiety
1381399|NCT00451503|Hearing
1381400|NCT00451503|Auditory rehabilitation
1381401|NCT00451503|Middle ear implant
1381402|NCT00451503|Surgery
1381403|NCT00451490|agomelatin
1381404|NCT00451490|prozac
1381405|NCT00451490|heart rate variability
1381406|NCT00451490|major depression
1381407|NCT00451490|sleep
1381408|NCT00451490|depressive symptoms
1381409|NCT00451464|Apolipoprotein, Gene polymorphism, Hyperlipidemia
1381410|NCT00451451|relapsing
1381411|NCT00451451|multiple sclerosis
1381412|NCT00451451|oral
1381413|NCT00451451|remitting
1381414|NCT00451438|patellofemoral pain syndrome
1381415|NCT00451438|electromyography
1381416|NCT00451438|gluteus medius
1381417|NCT00451438|tensor fascia lata
1381418|NCT00451425|pregnancy
1381419|NCT00451425|weight gain
1381420|NCT00451425|obesity
1381421|NCT00451425|macrosomia
1381422|NCT00451412|Venous thromboembolism
1381423|NCT00451412|Medical patients
1381424|NCT00451412|Heparin
1381425|NCT00451412|Low molecular weight heparin
1381426|NCT00451412|Deep vein thrombosis
1381427|NCT00451412|Certoparin
1381428|NCT00451412|Embolism and Thrombosis
1381429|NCT00451399|Weight gain
1381430|NCT00451399|antipsychotic
1381431|NCT00451399|lifestyle interventions
1381432|NCT00451399|metformin
1381433|NCT00451399|antipsychotic-induced weight gain.
1381434|NCT00451373|ARF, dialysis, cytokine, free radical, major operations
1381435|NCT00451360|Diacerein
1381436|NCT00451360|Hip osteoarthritis
1381437|NCT00451360|Structure-modifying effect / Chondromodulating effect
1381438|NCT00451360|Double blind study
1381439|NCT00451321|type 1 diabetes mellitus
1381440|NCT00451321|diabetes mellitus type 1
1381441|NCT00451321|type 1 diabetes
1381442|NCT00451321|diabetes mellitus
1381443|NCT00451321|diabetes
1381444|NCT00451308|Induction of labor
1381445|NCT00451308|vaginal delivery
1381446|NCT00451308|cesarean section
1381447|NCT00451308|foley balloon cathether
1381448|NCT00451308|method of labor induction
1381449|NCT00451308|perinatal outcomes
1381450|NCT00451295|Chronic Kidney Disease
1381451|NCT00451295|Dialysis
1381452|NCT00451295|Hyperphosphatemia
1381453|NCT00451269|Malaria
1381454|NCT00451269|Diagnosis
1381455|NCT00451269|RDT
1381456|NCT00451269|pLDH
1381457|NCT00451269|HRP2
1381458|NCT00451269|Patients with fever and history of travel in a malaria
1381459|NCT00451269|country
1381460|NCT00451256|coronary artery bypass
1381461|NCT00451256|cardiovascular disease
1381462|NCT00451243|psoriatic arthritis
1381463|NCT00451230|craving, insulin, leptin
1381464|NCT00451204|Multiple sclerosis
1381465|NCT00451204|estrogen
1381466|NCT00451204|estriol
1381467|NCT00451204|progesterone
1381468|NCT00451191|benign prostatic hyperplasia
1381469|NCT00451191|BPH
1381470|NCT00451191|botulinum toxin
1381471|NCT00451191|BoNT/A
1381472|NCT00451165|Laparoscopic
1381473|NCT00451165|Colon
1381474|NCT00451165|Rectal
1381475|NCT00451165|Surgery
1381476|NCT00451165|Urinary function
1381477|NCT00451165|Sexual function
1381478|NCT00451165|Bowel function
1381479|NCT00451165|Male
1381480|NCT00451152|glaucoma
1381481|NCT00451126|emotion
1381482|NCT00451126|personality
1381483|NCT00451126|social stress
1381484|NCT00451126|appraisal
1381485|NCT00451113|Type 2 diabetes
1381486|NCT00451113|Older adults
1381487|NCT00451113|Incretins
1381488|NCT00451113|Hyperglycemia
1381489|NCT00451113|Insulin resistance
1381490|NCT00451087|mechanical properties
1381491|NCT00451087|electromechanical delay
1381492|NCT00451087|viscoelasticity
1381493|NCT00451087|VMO
1381494|NCT00451087|patellofemoral pain syndrome
1381495|NCT00451074|Stop codon mutations
1381496|NCT00451061|distal ureterolithiasis
1381497|NCT00451061|α adrenoreceptors antagonist
1381498|NCT00451035|Refractory Chronic Myeloid Leukemia in Chronic Phase
1381499|NCT00451035|adults
1381500|NCT00451035|oral LBH589
1381501|NCT00451022|Fowlpox
1381502|NCT00451022|Vaccinia
1381503|NCT00451022|PSA
1381504|NCT00451022|CEA
1381505|NCT00451022|MUC-1
1381506|NCT00451022|Gene Therapy
1381507|NCT00451022|Long Term Survivor
1381508|NCT00451022|Research Specimen
1381509|NCT00451009|IVF
1381510|NCT00451009|Male factor infertility
1381511|NCT00451009|Cryopreservation
1381512|NCT00451009|Cryoprotective agents
1381513|NCT00451009|Egg Freezing
1381514|NCT00450983|graft versus host disease
1381515|NCT00450983|adult acute lymphoblastic leukemia in remission
1381516|NCT00450983|recurrent adult acute lymphoblastic leukemia
1381517|NCT00450983|childhood acute lymphoblastic leukemia in remission
1381518|NCT00450983|recurrent childhood acute lymphoblastic leukemia
1381519|NCT00450983|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1381520|NCT00450983|adult acute myeloid leukemia in remission
1381521|NCT00450983|recurrent adult acute myeloid leukemia
1381522|NCT00450983|childhood acute myeloid leukemia in remission
1381523|NCT00450983|recurrent childhood acute myeloid leukemia
1381524|NCT00450983|secondary acute myeloid leukemia
1381525|NCT00450983|de novo myelodysplastic syndromes
1381526|NCT00450983|previously treated myelodysplastic syndromes
1381527|NCT00450983|secondary myelodysplastic syndromes
1381528|NCT00450983|accelerated phase chronic myelogenous leukemia
1381529|NCT00450983|blastic phase chronic myelogenous leukemia
1381530|NCT00450983|childhood chronic myelogenous leukemia
1381531|NCT00450983|relapsing chronic myelogenous leukemia
1381532|NCT00450983|adult acute myeloid leukemia with inv(16)(p13;q22)
1381533|NCT00450983|adult acute myeloid leukemia with t(15;17)(q22;q12)
1381534|NCT00450983|adult acute myeloid leukemia with t(16;16)(p13;q22)
1381535|NCT00450983|adult acute myeloid leukemia with t(8;21)(q22;q22)
1381536|NCT00450983|childhood myelodysplastic syndromes
1381537|NCT00450970|Hormone Refractory Prostate Cancer (HRPC)
1381538|NCT00450970|Hormone Refractory Prostate Cancer
1381539|NCT00450970|Unlimited Prior Cytotoxic Chemotherapy Regimens
1381540|NCT00450697|Feeding intolerance in premature infants
1381541|NCT00450697|Bolus feeding every 4 hours versus every 3 hours
1381542|NCT00450697|Feeding method in premature infants
1381543|NCT00450671|Fistula-in-ano
1381544|NCT00450671|Anal fistula
1381545|NCT00450671|Perirectal fistula
1381546|NCT00450671|Collagen plug
1381547|NCT00450671|Surgisis
1381548|NCT00450671|Seton
1381549|NCT00450658|ibuprofen
1381550|NCT00450658|famotidine
1381551|NCT00450658|ulcers
1381552|NCT00450658|NSAIDS
1381553|NCT00450658|pain
1381554|NCT00450658|arthritis
1381555|NCT00450658|chronic regional pain syndrome
1381556|NCT00450658|chronic soft tissue pain
1381557|NCT00450658|osteoarthritis
1381558|NCT00450658|rheumatoid arthritis
1381559|NCT00450658|chronic low back pain
1381560|NCT00450645|Cancer
1381561|NCT00450645|Residual vein thrombosis
1381562|NCT00450645|Low Molecular Weight Heparin
1381563|NCT00450645|Optimal duration
1381564|NCT00450632|meningococcal infections
1381565|NCT00450632|biotheque
1381566|NCT00450632|genetic markers
1381567|NCT00450619|Radionuclide
1381568|NCT00450619|Immunotherapy
1381569|NCT00450619|Radiation
1381570|NCT00450619|PSA
1381571|NCT00450619|Hormone Refractory Prostate Cancer
1381572|NCT00450619|Prostate Cancer
1381573|NCT00450593|melanoma
1381690|NCT00450242|vulvar vestibulitis
1381574|NCT00450593|hereditary multiple melanoma
1381575|NCT00450593|recurrent melanoma
1381576|NCT00450593|stage 0 melanoma
1381577|NCT00450593|stage IV melanoma
1381578|NCT00450593|stage IA melanoma
1381579|NCT00450593|stage IB melanoma
1381580|NCT00450593|stage IIA melanoma
1381581|NCT00450593|stage IIB melanoma
1381582|NCT00450593|stage IIC melanoma
1381583|NCT00450593|stage IIIA melanoma
1381584|NCT00450593|stage IIIB melanoma
1381585|NCT00450593|stage IIIC melanoma
1381586|NCT00450580|protease inhibitor,
1381587|NCT00450580|HIV-1,
1381588|NCT00450580|Fosamprenavir,
1381589|NCT00450580|non-HDL cholesterol
1381590|NCT00450580|ritonavir,
1381591|NCT00450580|naive,
1381592|NCT00450567|recurrent non-small cell lung cancer
1381593|NCT00450567|stage I non-small cell lung cancer
1381594|NCT00450567|stage II non-small cell lung cancer
1381595|NCT00450567|stage IIIA non-small cell lung cancer
1381596|NCT00450567|stage IIIB non-small cell lung cancer
1381597|NCT00450567|stage IV non-small cell lung cancer
1381598|NCT00450554|Neisseria meningitidis B:14, P1-7, 16
1381599|NCT00450554|Serum bactericidal activity
1381600|NCT00450554|Menbvac
1381601|NCT00450541|Advanced Cancer
1381602|NCT00450541|Fatigue
1381603|NCT00450541|Interview
1381604|NCT00450541|Questionnaire
1381605|NCT00450541|Survey
1381606|NCT00450528|D-dimers
1381607|NCT00450528|surgery
1381608|NCT00450528|kinetics
1381609|NCT00450515|recurrent breast cancer
1381610|NCT00450515|stage IV breast cancer
1381611|NCT00450515|male breast cancer
1381612|NCT00450502|Cytotoxic
1381613|NCT00450502|Pharmacokinetics
1381614|NCT00450502|Toxicity
1381615|NCT00450502|Neoplasms
1381616|NCT00450502|Pharmacogenomics
1381617|NCT00450502|Solid Tumor
1381618|NCT00450502|Lymphoma
1381619|NCT00450489|Type 1 Diabetes Mellitus
1381620|NCT00450489|Quality of Life
1381621|NCT00450489|Satisfaction of medical care delivery
1381622|NCT00450476|ventilator associated pneumonia
1381623|NCT00450476|prevention
1381624|NCT00450476|endotracheal intubation
1381625|NCT00450476|mechanical ventilation
1381626|NCT00450463|Immunotherapy
1381627|NCT00450463|Hormonal Therapy
1381628|NCT00450463|Combination Therapy
1381629|NCT00450463|Prostate Specific Antigen
1381630|NCT00450463|Immunoassay
1381631|NCT00450463|Prostate Cancer
1381632|NCT00450437|Meningococcal
1381633|NCT00450437|meningitis
1381634|NCT00450437|vaccine
1381635|NCT00450437|adolescents
1381636|NCT00450437|adults
1381637|NCT00450424|colon cancer
1381638|NCT00450424|rectal cancer
1381639|NCT00450424|hereditary non-polyposis colon cancer
1381640|NCT00450424|recurrent colon cancer
1381641|NCT00450424|stage I colon cancer
1381642|NCT00450424|stage IIA colon cancer
1381643|NCT00450424|stage IIB colon cancer
1381644|NCT00450424|stage IIIA colon cancer
1381645|NCT00450424|stage IIIB colon cancer
1381646|NCT00450424|stage IIIC colon cancer
1381647|NCT00450424|stage IVA colon cancer
1381648|NCT00450424|stage IVB colon cancer
1381649|NCT00450424|recurrent rectal cancer
1381650|NCT00450424|stage I rectal cancer
1381651|NCT00450424|stage IIA rectal cancer
1381652|NCT00450424|stage IIB rectal cancer
1381653|NCT00450424|stage IIC rectal cancer
1381654|NCT00450424|stage IIIA rectal cancer
1381655|NCT00450424|stage IIIB rectal cancer
1381656|NCT00450424|stage IIIC rectal cancer
1381657|NCT00450424|stage IVA rectal cancer
1381658|NCT00450424|stage IVB rectal cancer
1381659|NCT00450411|adenocarcinoma of the prostate
1381660|NCT00450411|recurrent prostate cancer
1381661|NCT00450411|stage I prostate cancer
1381662|NCT00450411|stage IIB prostate cancer
1381663|NCT00450411|stage IIA prostate cancer
1381664|NCT00450398|Delayed graft function
1381665|NCT00450385|recurrent adult diffuse large cell lymphoma
1381666|NCT00450385|stage III adult diffuse large cell lymphoma
1381667|NCT00450385|stage IV adult diffuse large cell lymphoma
1381668|NCT00450385|contiguous stage II adult diffuse large cell lymphoma
1381669|NCT00450385|noncontiguous stage II adult diffuse large cell lymphoma
1381670|NCT00450385|stage I adult diffuse large cell lymphoma
1381671|NCT00450372|recurrent melanoma
1381672|NCT00450372|stage IV melanoma
1381673|NCT00450359|breast cancer
1381674|NCT00450333|Chronic
1381675|NCT00450320|AIDS-related Kaposi sarcoma
1381676|NCT00450320|recurrent Kaposi sarcoma
1381677|NCT00450307|recurrent neuroblastoma
1381678|NCT00450307|stage 4S neuroblastoma
1381679|NCT00450307|disseminated neuroblastoma
1381680|NCT00450307|localized unresectable neuroblastoma
1381681|NCT00450307|regional neuroblastoma
1381682|NCT00450281|stage IIIB non-small cell lung cancer
1381683|NCT00450281|stage IIIA non-small cell lung cancer
1381684|NCT00450281|stage IA non-small cell lung cancer
1381685|NCT00450281|stage IB non-small cell lung cancer
1381686|NCT00450281|stage IIA non-small cell lung cancer
1381687|NCT00450281|stage IIB non-small cell lung cancer
1381688|NCT00450268|Graft versus host disease
1381689|NCT00450268|Allogeneic hematpoietic stem cell transplantation
1381691|NCT00450242|vestibulitis
1381692|NCT00450216|ibuprofen
1381693|NCT00450216|famotidine
1381694|NCT00450216|ulcers
1381695|NCT00450216|NSAIDS
1381696|NCT00450216|pain
1381697|NCT00450216|arthritis
1381698|NCT00450216|chronic regional pain syndrome
1381699|NCT00450216|chronic soft tissue pain
1381700|NCT00450216|osteoarthritis
1381701|NCT00450216|rheumatoid arthritis
1381702|NCT00450216|chronic low back pain
1381703|NCT00450203|adenocarcinoma of the stomach
1381704|NCT00450203|adenocarcinoma of the gastro oesophageal junction
1381705|NCT00450203|adenocarcinoma of the lower oesophagus
1381706|NCT00450190|Growth disorders/drug therapy
1381707|NCT00450177|iron
1381708|NCT00450177|critical illness
1381709|NCT00450177|anemia
1381710|NCT00450177|infection
1381711|NCT00450164|Variceal bleeding
1381712|NCT00450164|Secondary profilaxis
1381713|NCT00450164|Hemodynamic
1381714|NCT00450164|Portal hypertension
1381715|NCT00450151|Pediatric
1381716|NCT00450151|Cardiopulmonary bypass Surgery
1381717|NCT00450151|Cardiac Surgery
1381718|NCT00450151|Platelet
1381719|NCT00450151|Platelet Activation Markers
1381720|NCT00450151|Platelet Factor4
1381721|NCT00450151|Transforming Growth Factor Beta
1381722|NCT00450138|Squamous Cell Carcinoma
1381723|NCT00450125|Lung Cancer
1381724|NCT00450125|Lung Resection
1381725|NCT00450125|Exercise Stress Test
1381726|NCT00450125|Six-Minute Walk Test
1381727|NCT00450099|Epidural
1381728|NCT00450099|Labor Analgesia
1381729|NCT00450099|Bupivacaine
1381730|NCT00450099|Dose-response
1381731|NCT00450099|Minimum effective volume
1381732|NCT00450060|postlumbar puncture headache
1381733|NCT00450060|atraumatic needle
1381734|NCT00450060|Sprotte
1381735|NCT00450060|Quincke
1381736|NCT00450060|lumbar puncture
1381737|NCT00450060|headache
1381738|NCT00450060|backache
1381739|NCT00450047|cognitive impairment, ergometer, speed-feedback therapy
1381740|NCT00450034|Frail Elderly
1381741|NCT00450034|Patient Education
1381742|NCT00450034|Drug optimization
1381743|NCT00450034|Underuse
1381744|NCT00450034|Vulnerable
1381745|NCT00450034|Drug related hospitalization
1381746|NCT00450034|Medical intervention
1381747|NCT00450021|PET
1381748|NCT00450021|CB1 Receptor
1381749|NCT00450021|Cannabinoid
1381750|NCT00450021|[11C] MePPEP
1381751|NCT00450021|Brain Imaging
1381752|NCT00450021|Healthy Volunteer
1381753|NCT00450021|HV
1381754|NCT00450008|Prostate Cancer
1381755|NCT00450008|Hormone-Naïve Prostate Cancer
1381756|NCT00450008|adenocarcinoma of the prostate
1381757|NCT00449982|Genital warts
1381758|NCT00449982|Condylomata acuminata
1381759|NCT00449982|Human Papillomavirus
1381760|NCT00449982|Polyphenon E
1381761|NCT00449982|Green tea extract
1381762|NCT00449982|Vulva
1381763|NCT00449982|Penis
1381764|NCT00449982|Anus
1381765|NCT00449969|AED (automated external defibrillation)
1381766|NCT00449969|feedback
1381767|NCT00449969|out of hospital resuscitation
1381768|NCT00449943|Cardiac Invasive Catheterization Angiography
1381769|NCT00449943|Single Photon Emission Computed Tomography
1381770|NCT00449943|Computed Tomography Angiography
1381771|NCT00449917|visual caracteristics
1381772|NCT00449917|macular pigment optical density
1381773|NCT00449917|visual acuity
1381774|NCT00449917|contrast sensibility
1381775|NCT00449917|lutein
1381776|NCT00449917|docosahexaenoic acid (DHA)
1381777|NCT00449904|Cystic fibrosis-related exocrine pancreatic insufficiency
1381778|NCT00449891|Type 1 diabetes mellitus
1381779|NCT00449878|cystic fibrosis-related pancreatic insufficiency
1381780|NCT00449865|Parkinson's disease
1381781|NCT00449865|creatine
1381782|NCT00449865|NET-PD
1381783|NCT00449865|neuroprotection
1381784|NCT00449865|PD
1381785|NCT00449852|Randomized Control Trial
1381786|NCT00449852|Smoking Cessation
1381787|NCT00449852|Secondary Prevention
1381788|NCT00449852|Rehabilitation
1381789|NCT00449852|Counseling
1381790|NCT00449839|Insulin pump treatment CSII
1381791|NCT00449839|Absorption
1381792|NCT00449839|Insulin Aspart
1381793|NCT00449826|ACS
1381794|NCT00449826|Unstable Angina
1381795|NCT00449826|NSTEMI
1381796|NCT00449813|Gastroesophageal reflux disease (GERD)
1381797|NCT00449813|Non erosive reflux disease (NERD)
1381798|NCT00449800|Sepsis
1381799|NCT00449800|Ceftriaxone
1381800|NCT00449800|Pharmacokinetic
1381801|NCT00449800|Intensive care unit
1381802|NCT00449787|Emergency department
1381803|NCT00449787|headache
1381804|NCT00449787|migraine
1381805|NCT00449774|Food effect
1381806|NCT00449774|Safety
1381807|NCT00449774|Tolerability
1381808|NCT00449774|Water effect
1381809|NCT00449774|Bioequivalence
1381810|NCT00449761|Refractory
1381811|NCT00449761|Chronic Myeloid
1381812|NCT00449761|Leukemia
1381813|NCT00449761|accelerated phase
1381814|NCT00449761|blast phase (blast crisis)
1381815|NCT00449761|adults
1381816|NCT00449761|oral LBH589
1381817|NCT00449748|Systemic Mastocytosis
1381818|NCT00449748|RAD001
1381819|NCT00449735|positive isolates
1381820|NCT00449735|ecoli
1381821|NCT00449735|blood cultures
1381822|NCT00449735|positive cultures for ecoli
1381823|NCT00449735|blood stream infections
1381824|NCT00449709|Pre-term labor,
1381825|NCT00449709|modified release formulation
1381826|NCT00449709|pharmacokinetics,
1381827|NCT00449683|Depressive Disorders
1381828|NCT00449683|Excessive Sweating
1381829|NCT00449683|Sweating caused by antidepressants for those a depressive disorder
1381830|NCT00449670|Influenza
1381831|NCT00449670|Influenza Vaccine
1381832|NCT00449644|Tuberculosis
1381833|NCT00449644|MDR TB
1381834|NCT00449631|Glaucoma
1381835|NCT00449631|Drug Resistance, Multiple
1381836|NCT00449631|Trabeculectomy
1381837|NCT00449618|Aspirin
1381838|NCT00449618|Ambulatory blood pressure monitoring
1381839|NCT00449618|Chronotherapy
1381840|NCT00449618|Circadian
1381841|NCT00449605|Diabetes
1381842|NCT00449605|Metformin
1381843|NCT00449592|Stem cell transplantation
1381844|NCT00449592|Mucositis
1381845|NCT00449592|Zinc
1381846|NCT00449579|Ischemia
1381847|NCT00449579|Myocardial
1381848|NCT00449579|HF-ECG
1381849|NCT00449566|Magnetic Resonance Imaging
1381850|NCT00449566|Diffusion Tensor Imaging
1381851|NCT00449553|Glucose Metabolism Disorder
1381852|NCT00449553|Dysmetabolic Syndrome
1381853|NCT00449553|Type II Diabetes
1381854|NCT00449553|Diabetes Mellitus, Lipoatrophic
1381855|NCT00449553|Dyslipidemia
1381856|NCT00449553|Drug Therapy
1381857|NCT00449540|Migraine with aura
1381858|NCT00449540|aura
1381859|NCT00449540|TMS
1381860|NCT00449527|Mild asthma
1381861|NCT00449527|Moderate asthma
1381862|NCT00449514|infertility
1381863|NCT00449514|ovulation dysfunction
1381864|NCT00449514|endometrium
1381865|NCT00449514|tamoxifen
1381866|NCT00449514|clomiphene citrate
1381867|NCT00449501|Mild Asthma
1381868|NCT00449501|Moderate Asthma
1381869|NCT00449488|erythropoietin
1381870|NCT00449488|myocardial infarction
1381871|NCT00449488|PCI
1381872|NCT00449488|left ventricular function
1381873|NCT00449462|CLA
1381874|NCT00449462|liver
1381875|NCT00449462|kidney
1381876|NCT00449449|Pertubation, tubal flushing, intrauterine insemination.
1381877|NCT00449436|HIV
1381878|NCT00449436|treatment experienced
1381879|NCT00449423|Acute heart failure
1381880|NCT00449423|Metabolic modulation
1381881|NCT00449410|Atrial Fibrillation
1381882|NCT00449410|elderly
1381883|NCT00449410|cholesterol lowering
1381884|NCT00449410|neurocognitive function
1381885|NCT00449410|cerebrovascular lesion
1381886|NCT00449397|First Episode Psychosis
1381887|NCT00449384|Severe Impairment Battery
1381888|NCT00449384|Clinical Dementia Rating
1381889|NCT00449358|bcc
1381890|NCT00449345|Latent tuberculosis infection
1381891|NCT00449345|Health care workers
1381892|NCT00449345|Tuberculin skin test
1381893|NCT00449345|Mantoux skin test
1381894|NCT00449345|Interferon gamma
1381895|NCT00449345|Quantiferon
1381896|NCT00449345|Cost effectiveness
1381897|NCT00449332|Chronic rejection, lung transplant, cytokines, bos
1381898|NCT00449319|AML
1381899|NCT00449319|adult
1381900|NCT00449319|Hydroxyurea
1381901|NCT00449319|Transplant
1381902|NCT00449319|Toevaluate biological characteristics at diagnosis.
1381903|NCT00449319|To identify genetic alterations with prognostic relevance.
1381904|NCT00449319|To follow up cases monitoring minimal disease during remission.
1381905|NCT00449319|To evaluate pretreatment therapy in terms of response rate and toxicity.
1381906|NCT00449319|Disease free survival.
1381907|NCT00449319|Overal survival.
1381908|NCT00449306|Atherosclerosis
1381909|NCT00449306|Carotid plaque
1381910|NCT00449306|Abdominal aortic aneurysm
1381911|NCT00449306|Vulnerable plaque
1381912|NCT00449306|Angiogenesis
1381913|NCT00449306|Intraplaque hemorrhage
1381914|NCT00449306|Carotid artery atherosclerosis
1381915|NCT00449293|Smoking cessation
1381916|NCT00449293|Tobacco dependence
1381917|NCT00449293|Mindfulness
1381918|NCT00449293|fMRI
1381919|NCT00449293|Craving
1381920|NCT00449280|metastatic
1381921|NCT00449280|advanced disease
1381922|NCT00449280|phase I
1381923|NCT00449267|Lenses, Intraocular
1381924|NCT00449267|Prospective Studies
1381925|NCT00449267|Visual acuity
1381926|NCT00449267|Clinical Trial
1381927|NCT00449241|Acupuncture, Endoscopy
1381928|NCT00449228|Osteoarthritis,
1381929|NCT00449228|hip replacement,
1381930|NCT00449228|education,
1381931|NCT00449228|randomized controlled trial,
1381932|NCT00449228|mini-invasive surgery
1381933|NCT00449215|Peak Bone Mass; Male; Genetic Polymorphisms
1381934|NCT00449176|Low Back Pain
1381935|NCT00449176|Chronic Pain
1381936|NCT00449176|Pain Assessment
1381937|NCT00449176|Tapentadol
1381938|NCT00449163|stage IV colon cancer
1381939|NCT00449163|stage IV rectal cancer
1381940|NCT00449163|adenocarcinoma of the colon
1381941|NCT00449163|adenocarcinoma of the rectum
1381942|NCT00449150|Cetrorelix
1381943|NCT00449137|recurrent colon cancer
1381944|NCT00449137|stage IV colon cancer
1381945|NCT00449137|recurrent rectal cancer
1381946|NCT00449137|stage IV rectal cancer
1381947|NCT00449124|hepatitis C, vaccine, TG4040
1381948|NCT00449098|Glaucoma
1381949|NCT00449098|Collagen matrix
1381950|NCT00449098|ologen
1381951|NCT00449098|OculusGen
1381952|NCT00449098|Trabeculectomy
1381953|NCT00449098|anti scarring
1381954|NCT00449098|tissue engineering
1381955|NCT00449098|high risk patient for trabeculectomy
1381956|NCT00449098|Aeon Astron
1381957|NCT00449059|heart transplantation
1381958|NCT00449059|cyclosporine
1381959|NCT00449059|hypertension
1381960|NCT00449059|nitroglycerin
1381961|NCT00449046|salmeterol/fluticasone propionate combination
1381962|NCT00449046|pediatric bronchial asthma
1381963|NCT00449033|Non-Small Cell Lung Cancer (NSCLC)
1381964|NCT00449033|Cancer
1381965|NCT00449020|stage IIIA non-small cell lung cancer
1381966|NCT00449020|stage IIIB non-small cell lung cancer
1381967|NCT00449007|Major depressive disorder
1381968|NCT00449007|Alcohol abuse
1381969|NCT00449007|Alcohol dependence
1381970|NCT00449007|Suicide
1381971|NCT00448994|adenovirus, fungal, diagnostics, children
1381972|NCT00448981|Preventing upper respiratory tract infections
1381973|NCT00448981|Preventing influenza
1381974|NCT00448981|Preventing the common cold
1381975|NCT00448981|Hand hygiene and upper respiratory infections
1381976|NCT00448981|Mask use in preventing upper respiratory infections
1381977|NCT00448968|Sepsis
1381978|NCT00448968|Ischemia Modified Albumin
1381979|NCT00448968|Systemic Inflammatory Response Syndrome
1381980|NCT00448942|Staphylococcus aureus [B03.510.400.790.750.100]
1381981|NCT00448942|Enterococcus faecalis [B03.510.400.800.280.280]
1381982|NCT00448942|Enterococcus faecium [B03.510.400.800.280.300]
1381983|NCT00448942|Bacteremia [C01.252.100]
1381984|NCT00448942|Fungemia [C01.703.360]
1381985|NCT00448942|Infection Control [G03.850.780.200.450]
1381986|NCT00448942|Antisepsis [G03.850.780.200.450.150]
1381992|NCT00448916|Partial-onset seizures; epilepsy; pediatric; pregabalin; 1 year extension study; safety; tolerability
1381993|NCT00448903|diabetic
1381994|NCT00448903|foot
1381995|NCT00448903|ulcer
1381996|NCT00448903|bemiparin
1381997|NCT00448903|neuropathy
1381998|NCT00448903|neuroishemic
1381999|NCT00448903|diabetes
1382000|NCT00448890|AMPA positive modulator, healthy volunteers
1382001|NCT00448877|No specific disease is being studied, few procedures are excluded.
1382002|NCT00448877|The focus of the study is to rule out the efficacy of the device, so the aim is to include as wide a variety of procedures as possible.
1382003|NCT00448851|asthma
1382004|NCT00448851|allergy
1382005|NCT00448838|recurrent pancreatic cancer
1382006|NCT00448838|stage III pancreatic cancer
1382007|NCT00448838|stage IV pancreatic cancer
1382008|NCT00448838|stage II pancreatic cancer
1382009|NCT00448825|alcohol dependence
1382010|NCT00448825|alcoholism
1382011|NCT00448825|cocaine addiction
1382012|NCT00448825|cocaine dependence
1382013|NCT00448799|neurological
1382014|NCT00448799|alzheimers
1382015|NCT00448786|gallbladder
1382016|NCT00448786|AMG 706
1382017|NCT00448786|solid tumors
1382018|NCT00448786|Phase 1b
1382019|NCT00448786|Amgen
1382020|NCT00448760|stage II esophageal cancer
1382021|NCT00448760|stage III esophageal cancer
1382022|NCT00448760|adenocarcinoma of the esophagus
1382023|NCT00448747|Ghrelin mimetic, growth hormone secretagogue
1382024|NCT00448734|metastatic
1382025|NCT00448734|hormone-refractory
1382026|NCT00448734|prostate cancer
1382027|NCT00448734|picoplatin
1382028|NCT00448734|platinum drug
1382029|NCT00448734|chemotherapy
1382030|NCT00448734|docetaxel
1382031|NCT00448721|renal cell carcinoma
1382032|NCT00448721|tyrosine kinase inhibitor failure
1382033|NCT00448708|Hemodialysis Access
1382034|NCT00448695|MRI
1382035|NCT00448695|Laser Thermal Therapy
1382036|NCT00448695|Focal Ablation
1382037|NCT00448695|Prostate Cancer
1382038|NCT00448682|recurrent gastric cancer
1382039|NCT00448682|stage IV gastric cancer
1382040|NCT00448682|adenocarcinoma of the stomach
1382041|NCT00448669|HIV incidence
1382042|NCT00448669|HIV prevention
1382043|NCT00448669|Tenofovir
1382044|NCT00448669|Emtricitabine
1382045|NCT00448669|Botswana
1382046|NCT00448669|HIV seronegativity
1382047|NCT00448656|atrial fibrillation
1382048|NCT00448656|epicardial ablation pulmonary veins
1382049|NCT00448656|video assisted thoracic surgery
1382050|NCT00448643|endometrial adenocarcinoma
1382051|NCT00448643|endometrial clear cell carcinoma
1382052|NCT00448643|endometrial papillary carcinoma
1382053|NCT00448643|stage III endometrial carcinoma
1382054|NCT00448643|stage IV endometrial carcinoma
1382055|NCT00448630|Atypical antipsychotics, Metabolic syndrome, Safety
1382056|NCT00448617|live attenuated influenza virus
1382057|NCT00448617|inflammation
1382058|NCT00448617|flu vaccine
1382059|NCT00448617|FluMist
1382060|NCT00448617|smokers
1382061|NCT00448604|procalcitonin
1382062|NCT00448604|acute exacerbation
1382063|NCT00448604|RT-PCR
1382064|NCT00448604|Biological Markers
1382065|NCT00448578|Acute Mania
1382066|NCT00448565|extubation
1382067|NCT00448565|prediction
1382068|NCT00448552|recurrent squamous cell carcinoma of the hypopharynx
1382069|NCT00448552|stage IV squamous cell carcinoma of the hypopharynx
1382070|NCT00448552|recurrent squamous cell carcinoma of the larynx
1382071|NCT00448552|recurrent verrucous carcinoma of the larynx
1382072|NCT00448552|stage IV squamous cell carcinoma of the larynx
1382073|NCT00448552|stage IV verrucous carcinoma of the larynx
1382074|NCT00448552|recurrent squamous cell carcinoma of the lip and oral cavity
1382075|NCT00448552|stage IV squamous cell carcinoma of the lip and oral cavity
1382076|NCT00448552|recurrent basal cell carcinoma of the lip
1382077|NCT00448552|stage IV basal cell carcinoma of the lip
1382078|NCT00448552|recurrent adenoid cystic carcinoma of the oral cavity
1382079|NCT00448552|recurrent mucoepidermoid carcinoma of the oral cavity
1382080|NCT00448552|recurrent verrucous carcinoma of the oral cavity
1382081|NCT00448552|stage IV adenoid cystic carcinoma of the oral cavity
1382082|NCT00448552|stage IV mucoepidermoid carcinoma of the oral cavity
1382083|NCT00448552|stage IV verrucous carcinoma of the oral cavity
1382084|NCT00448552|recurrent metastatic squamous neck cancer with occult primary
1382085|NCT00448552|recurrent lymphoepithelioma of the nasopharynx
1382086|NCT00448552|recurrent squamous cell carcinoma of the nasopharynx
1382087|NCT00448552|stage IV lymphoepithelioma of the nasopharynx
1382088|NCT00448552|stage IV squamous cell carcinoma of the nasopharynx
1382089|NCT00448552|recurrent lymphoepithelioma of the oropharynx
1382090|NCT00448552|recurrent squamous cell carcinoma of the oropharynx
1382091|NCT00448552|stage IV lymphoepithelioma of the oropharynx
1382092|NCT00448552|stage IV squamous cell carcinoma of the oropharynx
1382093|NCT00448552|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1382094|NCT00448552|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1382095|NCT00448552|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1382096|NCT00448552|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1382097|NCT00448552|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1382098|NCT00448552|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1382099|NCT00448552|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1382100|NCT00448552|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1382101|NCT00448552|recurrent salivary gland cancer
1382102|NCT00448552|stage IV salivary gland cancer
1382103|NCT00448552|untreated metastatic squamous neck cancer with occult primary
1382104|NCT00448552|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1382105|NCT00448539|Refractory Partial Onset Seizures, epilepsy
1382106|NCT00448526|Low protein diet, type 2 Diabetic nephropathy
1382107|NCT00448526|Comparing the effect of Low protein Diet on diabetic nephropathy to that of normal protein diet
1382108|NCT00448513|catechin
1382109|NCT00448513|oxidative stress
1382110|NCT00448513|chromosome damage
1382111|NCT00448513|aged
1382112|NCT00448500|COPD
1382113|NCT00448500|exhaled breath condenate
1382114|NCT00448500|Exhaled breath condenate, acute exacerbation of COPD
1382115|NCT00448487|Diabetes
1382116|NCT00448487|Cardiovascular Disease
1382117|NCT00448487|Haptoglobin
1382118|NCT00448474|Disease self-management
1382119|NCT00448474|Community program
1382120|NCT00448461|coronary artery disease
1382121|NCT00448461|percutaneous coronary interventions
1382122|NCT00448448|adolescent idiopathic scoliosis
1382123|NCT00448448|orthotics
1382124|NCT00448448|bracing
1382125|NCT00448448|partially randomized preference design
1382126|NCT00448435|Salmeterol
1382127|NCT00448435|Fluticasone propionate
1382128|NCT00448435|Salmeterol/Fluticasone propionate combination
1382129|NCT00448435|Pediatric bronchial asthma
1382130|NCT00448422|Traveler's
1382131|NCT00448422|Diarrhea
1382132|NCT00448409|Prostate cancer
1382133|NCT00448409|hormone refractory prostate cancer
1382134|NCT00448409|androgen resistant prostate cancer
1382135|NCT00448396|Cancer
1382136|NCT00448396|EPO
1382137|NCT00448396|Patupilone
1382138|NCT00448396|Solid tumors
1382139|NCT00448396|Advanced malignancies
1382140|NCT00448370|Anemia, sickle cell
1382141|NCT00448357|refractory multiple myeloma
1382142|NCT00448357|relapsing chronic myelogenous leukemia
1382143|NCT00448357|secondary acute myeloid leukemia
1382144|NCT00448357|stage II multiple myeloma
1382145|NCT00448357|stage III multiple myeloma
1382146|NCT00448357|stage IV adult Burkitt lymphoma
1382147|NCT00448357|stage IV adult diffuse large cell lymphoma
1382148|NCT00448357|stage IV adult diffuse mixed cell lymphoma
1382149|NCT00448357|stage IV adult diffuse small cleaved cell lymphoma
1382150|NCT00448357|stage IV adult immunoblastic large cell lymphoma
1382151|NCT00448357|stage IV adult lymphoblastic lymphoma
1382152|NCT00448357|stage IV adult Hodgkin lymphoma
1382153|NCT00448357|stage IV grade 1 follicular lymphoma
1382154|NCT00448357|stage IV grade 2 follicular lymphoma
1382155|NCT00448357|stage IV grade 3 follicular lymphoma
1382156|NCT00448357|stage IV mantle cell lymphoma
1382157|NCT00448357|stage IV marginal zone lymphoma
1382158|NCT00448357|stage IV small lymphocytic lymphoma
1382159|NCT00448357|Waldenstrom macroglobulinemia
1382160|NCT00448357|accelerated phase chronic myelogenous leukemia
1382161|NCT00448357|adult acute myeloid leukemia in remission
1382162|NCT00448357|blastic phase chronic myelogenous leukemia
1382163|NCT00448357|chronic eosinophilic leukemia
1382164|NCT00448357|chronic neutrophilic leukemia
1382165|NCT00448357|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1382166|NCT00448357|nodal marginal zone B-cell lymphoma
1382167|NCT00448357|recurrent adult Burkitt lymphoma
1382168|NCT00448357|recurrent adult diffuse large cell lymphoma
1382169|NCT00448357|recurrent adult diffuse mixed cell lymphoma
1382170|NCT00448357|recurrent adult diffuse small cleaved cell lymphoma
1382171|NCT00448357|recurrent adult Hodgkin lymphoma
1382172|NCT00448357|recurrent adult immunoblastic large cell lymphoma
1382173|NCT00448357|recurrent adult lymphoblastic lymphoma
1382174|NCT00448357|recurrent grade 1 follicular lymphoma
1382175|NCT00448357|recurrent grade 2 follicular lymphoma
1382176|NCT00448357|recurrent grade 3 follicular lymphoma
1382177|NCT00448357|recurrent mantle cell lymphoma
1382178|NCT00448357|recurrent marginal zone lymphoma
1382179|NCT00448357|recurrent small lymphocytic lymphoma
1382180|NCT00448357|stage III adult Burkitt lymphoma
1382181|NCT00448357|stage III adult diffuse large cell lymphoma
1382182|NCT00448357|stage III adult diffuse mixed cell lymphoma
1382183|NCT00448357|stage III adult diffuse small cleaved cell lymphoma
1382184|NCT00448357|stage III adult Hodgkin lymphoma
1382185|NCT00448357|stage III adult immunoblastic large cell lymphoma
1382186|NCT00448357|stage III adult lymphoblastic lymphoma
1382187|NCT00448357|stage III grade 1 follicular lymphoma
1382188|NCT00448357|stage III grade 2 follicular lymphoma
1382189|NCT00448357|stage III grade 3 follicular lymphoma
1382190|NCT00448357|stage III mantle cell lymphoma
1382191|NCT00448357|stage III marginal zone lymphoma
1382192|NCT00448357|stage III small lymphocytic lymphoma
1382193|NCT00448357|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1382194|NCT00448357|adult acute myeloid leukemia with inv(16)(p13;q22)
1382195|NCT00448357|adult acute myeloid leukemia with t(15;17)(q22;q12)
1382196|NCT00448357|adult acute myeloid leukemia with t(16;16)(p13;q22)
1382197|NCT00448357|adult acute myeloid leukemia with t(8;21)(q22;q22)
1382198|NCT00448357|primary myelofibrosis
1382199|NCT00448357|chronic phase chronic myelogenous leukemia
1382200|NCT00448357|de novo myelodysplastic syndromes
1382201|NCT00448357|previously treated myelodysplastic syndromes
1382202|NCT00448357|prolymphocytic leukemia
1382203|NCT00448357|recurrent adult acute lymphoblastic leukemia
1382204|NCT00448357|recurrent adult acute myeloid leukemia
1382205|NCT00448357|refractory chronic lymphocytic leukemia
1382206|NCT00448357|secondary myelodysplastic syndromes
1382207|NCT00448357|stage III chronic lymphocytic leukemia
1382208|NCT00448357|stage IV chronic lymphocytic leukemia
1382209|NCT00448357|adult acute lymphoblastic leukemia in remission
1382210|NCT00448357|polycythemia vera
1382211|NCT00448357|essential thrombocythemia
1382212|NCT00448357|splenic marginal zone lymphoma
1382213|NCT00448357|recurrent mycosis fungoides/Sezary syndrome
1382214|NCT00448357|recurrent cutaneous T-cell non-Hodgkin lymphoma
1382215|NCT00448357|stage I multiple myeloma
1382216|NCT00448357|recurrent adult grade III lymphomatoid granulomatosis
1382217|NCT00448357|adult nasal type extranodal NK/T-cell lymphoma
1382218|NCT00448344|veterans
1382219|NCT00448344|smoking cessation
1382220|NCT00448331|Mental Disorders
1382221|NCT00448331|Mentally Ill Persons
1382222|NCT00448331|Emergency Medicine
1382223|NCT00448331|Emergency Department
1382224|NCT00448331|Screening
1382225|NCT00448318|Controlled clinical trial
1382226|NCT00448305|breast cancer
1382227|NCT00448305|metastatic
1382228|NCT00448305|relapsed
1382229|NCT00448305|triple-receptor negative
1382230|NCT00448305|EndoTAG-1
1382231|NCT00448305|metastatic or relapsed breast neoplasm
1382232|NCT00448292|Depression
1382233|NCT00448292|Major Depressive Disorder
1382234|NCT00448292|Major Depression
1382235|NCT00448292|MDD
1382236|NCT00448266|Breast cancer
1382237|NCT00448266|high-dose chemotherapy
1382238|NCT00448266|Homologous Recombination Deficiency
1382239|NCT00448266|Alkylator therapy
1382240|NCT00448266|Peripheral Blood Progenitor Cell Support
1382241|NCT00448253|Inhalational Anthrax
1382242|NCT00448253|Human Immune globulin
1382243|NCT00448227|Infants, Herpes simplex infection
1382244|NCT00448214|Factor Xa inhibitor
1382245|NCT00448214|Atrial fibrillation
1382246|NCT00448214|Stroke
1382247|NCT00448214|Ischemic attack
1382248|NCT00448214|thromboembolism
1382249|NCT00448214|Prevention and control
1382250|NCT00448201|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1382468|NCT00447707|Behavioral intervention
1382251|NCT00448201|adult acute myeloid leukemia with inv(16)(p13;q22)
1382252|NCT00448201|adult acute myeloid leukemia with t(15;17)(q22;q12)
1382253|NCT00448201|adult acute myeloid leukemia with t(16;16)(p13;q22)
1382254|NCT00448201|adult acute myeloid leukemia with t(8;21)(q22;q22)
1382255|NCT00448201|prolymphocytic leukemia
1382256|NCT00448201|accelerated phase chronic myelogenous leukemia
1382257|NCT00448201|adult acute lymphoblastic leukemia in remission
1382258|NCT00448201|adult acute myeloid leukemia in remission
1382259|NCT00448201|blastic phase chronic myelogenous leukemia
1382260|NCT00448201|childhood acute lymphoblastic leukemia in remission
1382261|NCT00448201|childhood acute myeloid leukemia in remission
1382262|NCT00448201|childhood chronic myelogenous leukemia
1382263|NCT00448201|chronic phase chronic myelogenous leukemia
1382264|NCT00448201|de novo myelodysplastic syndromes
1382265|NCT00448201|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1382266|NCT00448201|nodal marginal zone B-cell lymphoma
1382267|NCT00448201|noncontiguous stage II adult Burkitt lymphoma
1382268|NCT00448201|noncontiguous stage II adult diffuse large cell lymphoma
1382269|NCT00448201|noncontiguous stage II adult diffuse mixed cell lymphoma
1382270|NCT00448201|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1382271|NCT00448201|noncontiguous stage II adult immunoblastic large cell lymphoma
1382272|NCT00448201|noncontiguous stage II adult lymphoblastic lymphoma
1382273|NCT00448201|noncontiguous stage II grade 1 follicular lymphoma
1382274|NCT00448201|noncontiguous stage II grade 2 follicular lymphoma
1382275|NCT00448201|noncontiguous stage II grade 3 follicular lymphoma
1382276|NCT00448201|noncontiguous stage II mantle cell lymphoma
1382277|NCT00448201|noncontiguous stage II marginal zone lymphoma
1382278|NCT00448201|noncontiguous stage II small lymphocytic lymphoma
1382279|NCT00448201|previously treated myelodysplastic syndromes
1382280|NCT00448201|recurrent adult acute lymphoblastic leukemia
1382281|NCT00448201|recurrent adult Burkitt lymphoma
1382282|NCT00448201|recurrent adult Hodgkin lymphoma
1382283|NCT00448201|recurrent adult diffuse large cell lymphoma
1382284|NCT00448201|recurrent adult diffuse mixed cell lymphoma
1382285|NCT00448201|recurrent adult diffuse small cleaved cell lymphoma
1382286|NCT00448201|recurrent adult immunoblastic large cell lymphoma
1382287|NCT00448201|recurrent adult lymphoblastic lymphoma
1382288|NCT00448201|recurrent adult acute myeloid leukemia
1382289|NCT00448201|recurrent childhood acute myeloid leukemia
1382290|NCT00448201|recurrent/refractory childhood Hodgkin lymphoma
1382291|NCT00448201|recurrent childhood acute lymphoblastic leukemia
1382292|NCT00448201|recurrent childhood large cell lymphoma
1382293|NCT00448201|recurrent childhood lymphoblastic lymphoma
1382294|NCT00448201|recurrent childhood small noncleaved cell lymphoma
1382295|NCT00448201|recurrent cutaneous T-cell non-Hodgkin lymphoma
1382296|NCT00448201|recurrent grade 1 follicular lymphoma
1382297|NCT00448201|recurrent grade 2 follicular lymphoma
1382298|NCT00448201|recurrent grade 3 follicular lymphoma
1382299|NCT00448201|recurrent mantle cell lymphoma
1382300|NCT00448201|recurrent marginal zone lymphoma
1382301|NCT00448201|recurrent mycosis fungoides/Sezary syndrome
1382302|NCT00448201|recurrent small lymphocytic lymphoma
1382303|NCT00448201|refractory chronic lymphocytic leukemia
1382304|NCT00448201|refractory multiple myeloma
1382305|NCT00448201|relapsing chronic myelogenous leukemia
1382306|NCT00448201|secondary acute myeloid leukemia
1382307|NCT00448201|secondary myelodysplastic syndromes
1382308|NCT00448201|splenic marginal zone lymphoma
1382309|NCT00448201|stage I multiple myeloma
1382310|NCT00448201|stage II multiple myeloma
1382311|NCT00448201|stage III adult Burkitt lymphoma
1382312|NCT00448201|stage III adult Hodgkin lymphoma
1382313|NCT00448201|stage III adult diffuse large cell lymphoma
1382314|NCT00448201|stage III adult diffuse mixed cell lymphoma
1382315|NCT00448201|stage III adult diffuse small cleaved cell lymphoma
1382316|NCT00448201|stage III adult immunoblastic large cell lymphoma
1382317|NCT00448201|stage III adult lymphoblastic lymphoma
1382318|NCT00448201|stage III chronic lymphocytic leukemia
1382319|NCT00448201|stage III grade 1 follicular lymphoma
1382320|NCT00448201|stage III grade 2 follicular lymphoma
1382321|NCT00448201|stage III grade 3 follicular lymphoma
1382322|NCT00448201|stage III mantle cell lymphoma
1382323|NCT00448201|stage III marginal zone lymphoma
1382324|NCT00448201|stage III multiple myeloma
1382325|NCT00448201|stage III small lymphocytic lymphoma
1382326|NCT00448201|stage IV adult Burkitt lymphoma
1382327|NCT00448201|stage IV adult Hodgkin lymphoma
1382328|NCT00448201|stage IV adult diffuse large cell lymphoma
1382329|NCT00448201|stage IV adult diffuse mixed cell lymphoma
1382330|NCT00448201|stage IV adult diffuse small cleaved cell lymphoma
1382580|NCT00447200|Esophagus Doppler
1382331|NCT00448201|stage IV adult immunoblastic large cell lymphoma
1382332|NCT00448201|stage IV adult lymphoblastic lymphoma
1382333|NCT00448201|stage IV chronic lymphocytic leukemia
1382334|NCT00448201|stage IV grade 1 follicular lymphoma
1382335|NCT00448201|stage IV grade 2 follicular lymphoma
1382336|NCT00448201|stage IV grade 3 follicular lymphoma
1382337|NCT00448201|stage IV mantle cell lymphoma
1382338|NCT00448201|stage IV marginal zone lymphoma
1382339|NCT00448201|stage IV small lymphocytic lymphoma
1382340|NCT00448201|primary myelofibrosis
1382341|NCT00448201|Waldenstrom macroglobulinemia
1382342|NCT00448201|adult nasal type extranodal natural killer (NK)/T-cell lymphoma
1382343|NCT00448201|recurrent adult grade III lymphomatoid granulomatosis
1382344|NCT00448201|childhood myelodysplastic syndromes
1382345|NCT00448188|central venous catheter
1382346|NCT00448188|international normalized ratio
1382347|NCT00448188|thrombocytes
1382348|NCT00448188|bleeding risk
1382349|NCT00448188|all patients in need of central venous line
1382350|NCT00448188|comparison of patients with normal hemostasis to such with disorders in hemostasis
1382351|NCT00448175|OAB symptoms of urgency, frequency, and urge incontinence
1382352|NCT00448162|hypertension, ENaC, Liddle's syndrome, variation
1382353|NCT00448149|Kidney cancer
1382354|NCT00448149|Renal cell carcinoma
1382355|NCT00448149|Metastatic RCC
1382356|NCT00448123|Kidney Stones
1382357|NCT00448123|Ureteral Stones
1382358|NCT00448123|Flomax
1382359|NCT00448123|Emergency Medicine
1382360|NCT00448123|Urology
1382361|NCT00448097|Adenocarcinoma of the Prostate
1382362|NCT00448097|Prostate cancer
1382363|NCT00448097|Pre-Prostatectomy
1382364|NCT00448097|Neoadjuvant
1382365|NCT00448084|Psychogenic Movement Disorders
1382366|NCT00448084|Volition
1382367|NCT00448084|fMRI
1382368|NCT00448084|Functional MRI
1382369|NCT00448084|Functional Movement Disorder
1382370|NCT00448084|Healthy Volunteer
1382371|NCT00448084|HV
1382372|NCT00448071|Hypotension
1382373|NCT00448071|End Stage Renal Disease
1382374|NCT00448071|Intra Dialytic Hypotension
1382375|NCT00448071|ESRD
1382376|NCT00448071|Blood Pressure
1382377|NCT00448071|Dialysis
1382378|NCT00448058|Flexible-dose
1382379|NCT00448058|GSK372475
1382380|NCT00448058|MDD
1382381|NCT00448058|Venlafaxine XR
1382382|NCT00448058|Major Depressive Disorder
1382383|NCT00448045|Spinal cord injuries
1382384|NCT00448045|Cough
1382385|NCT00448045|Peak cough flow
1382386|NCT00448045|Respiratory therapy
1382387|NCT00448045|Rehabilitation
1382388|NCT00448019|Chronic Lymphocytic Leukemia
1382389|NCT00448019|Fludarabine
1382390|NCT00448019|Cyclophosphamide
1382391|NCT00448019|Rituximab
1382392|NCT00448019|Bevacizumab
1382393|NCT00448019|CLL
1382394|NCT00448006|common
1382395|NCT00448006|bile
1382396|NCT00448006|duct
1382397|NCT00448006|biliary
1382398|NCT00448006|malignant
1382399|NCT00448006|obstruction
1382400|NCT00448006|stent
1382401|NCT00447993|Retinitis Pigmentosa
1382402|NCT00447993|eye disease
1382403|NCT00447993|retinal disorder
1382404|NCT00447993|CNTF
1382405|NCT00447980|Retinitis Pigmentosa
1382406|NCT00447980|eye disease
1382407|NCT00447980|retinal disorder
1382408|NCT00447980|CNTF
1382409|NCT00447967|Metastatic Gastric Cancer
1382410|NCT00447967|Oxaliplatin
1382411|NCT00447967|Irinotecan
1382412|NCT00447954|eye disease
1382413|NCT00447954|retinal disorder
1382414|NCT00447954|CNTF
1382415|NCT00447928|tendonitis
1382416|NCT00447928|nitroglycerin
1382417|NCT00447928|nitric oxide
1382418|NCT00447928|lateral epicondylitis
1382419|NCT00447902|treatment experienced
1382420|NCT00447837|Chronic Sinusitis
1382421|NCT00447824|Pain
1382422|NCT00447824|Neonates
1382423|NCT00447824|NIDCAP
1382424|NCT00447824|Venous
1382425|NCT00447824|Capillary
1382426|NCT00447811|Methadone
1382427|NCT00447798|HIV positive
1382428|NCT00447798|crack cocaine user
1382429|NCT00447798|inpatient hospital setting
1382430|NCT00447798|HIV knowledge
1382431|NCT00447798|motivation
1382432|NCT00447798|perceived self-efficacy
1382433|NCT00447798|risky sexual behavior
1382434|NCT00447798|HIV seronegativity
1382435|NCT00447785|alcoholism
1382436|NCT00447785|nutrition
1382437|NCT00447785|craving
1382438|NCT00447785|energy supplies
1382439|NCT00447785|water supplies
1382440|NCT00447772|Dysport, Cervical Dystonia
1382441|NCT00447759|Celecoxib
1382442|NCT00447759|Celebrex
1382443|NCT00447759|Ibuprofen
1382444|NCT00447759|Diclofenac
1382445|NCT00447759|NSAID
1382446|NCT00447759|Osteoarthritis
1382447|NCT00447759|Rheumatoid Arthritis
1382448|NCT00447759|Arthritis
1382449|NCT00447759|Safety study
1382450|NCT00447759|Cardiovascular safety
1382451|NCT00447759|Clinical trial
1382452|NCT00447759|PROBE design
1382453|NCT00447759|University of Dundee
1382454|NCT00447759|Medicines Monitoring Unit
1382455|NCT00447759|MEMO
1382456|NCT00447759|Professor Tom MacDonald
1382457|NCT00447746|Comparison between D1 and D2 lymphadenectomy for gastric cancer
1382458|NCT00447733|mental health
1382459|NCT00447733|substance use
1382460|NCT00447733|treatment
1382461|NCT00447720|HIV prevention skills
1382462|NCT00447720|Seriously Mentally Ill (SMI)
1382463|NCT00447720|Substance abuse
1382464|NCT00447720|Philadelphia
1382465|NCT00447720|HIV seronegativity
1382466|NCT00447707|Substance use
1382467|NCT00447707|Unprotected sex
1382469|NCT00447707|HIV care
1382470|NCT00447707|Prevention with Positives
1382471|NCT00447707|HIV seronegativity
1382472|NCT00447694|Iron Chelation
1382473|NCT00447694|Deferasirox
1382474|NCT00447694|Chelator
1382475|NCT00447694|Desferal
1382476|NCT00447694|beta-thalassemia
1382477|NCT00447694|Iron overload
1382478|NCT00447668|Chronic Low Back Pain
1382479|NCT00447668|Yoga
1382480|NCT00447655|Amputation
1382481|NCT00447655|Self-management
1382482|NCT00447655|Rehabilitation
1382483|NCT00447655|Peer support
1382484|NCT00447642|immunology
1382485|NCT00447642|cornea
1382486|NCT00447642|allograft
1382487|NCT00447642|corneal allograft rejection
1382488|NCT00447642|graft failure
1382489|NCT00447616|Prostate Cancer
1382490|NCT00447616|Prostatectomy
1382491|NCT00447564|opioid dependence
1382492|NCT00447564|opioid addiction
1382493|NCT00447564|buprenorphine
1382494|NCT00447564|methadone
1382495|NCT00447564|heroin
1382496|NCT00447564|implant
1382497|NCT00447564|opioid withdrawal
1382498|NCT00447564|opioid pain medication
1382499|NCT00447564|suboxone
1382500|NCT00447551|Aesthetic facial volume enhancement
1382501|NCT00447525|Prevention of : Diphtheria, Tetanus and Poliomyelitis
1382502|NCT00447499|Acromegaly
1382503|NCT00447499|Somatostatin Analogs
1382504|NCT00447499|Somatuline® Autogel®
1382505|NCT00447499|lanreotide
1382506|NCT00447499|growth hormone
1382507|NCT00447499|IGF-1
1382508|NCT00447499|Inappropriate Growth Hormone Secretion Syndrome
1382509|NCT00447499|Somatotropin Hypersecretion Syndrome
1382510|NCT00447499|Inappropriate GH Secretion Syndrome
1382511|NCT00447486|Osteoarthritis,
1382512|NCT00447486|knee,
1382513|NCT00447486|GW842166,
1382514|NCT00447486|pain,
1382515|NCT00447486|efficacy,
1382516|NCT00447486|safety
1382517|NCT00447473|Prostate Cancer
1382518|NCT00447473|progressive hormone refractory prostate cancer
1382519|NCT00447460|Graft-vs-host disease (GVHD)
1382520|NCT00447460|Mesenchymal stem cell (MSC)
1382521|NCT00447460|Allogeneic hematopoietic stem cell transplant
1382522|NCT00447460|Allotransplant
1382523|NCT00447460|Allogenic
1382524|NCT00447460|Refractory
1382525|NCT00447460|CSM/EICH2005
1382526|NCT00447434|Nattokinase
1382527|NCT00447434|fibrinolytic factors
1382528|NCT00447434|blood lipids
1382529|NCT00447434|nutrimental supplement
1382530|NCT00447408|hemodialysis
1382531|NCT00447408|dietary adherence
1382532|NCT00447408|sodium
1382533|NCT00447369|pregabalin
1382534|NCT00447369|Valproic acid
1382535|NCT00447369|migraine
1382536|NCT00447369|prophylaxis
1382537|NCT00447369|prevention
1382538|NCT00447369|treatment
1382539|NCT00447343|Functional MRI
1382540|NCT00447343|Cervical myelopathy
1382541|NCT00447343|Cervical radiculopathy
1382542|NCT00447343|Brain plasticity and regeneration
1382543|NCT00447330|metastatic esophagogastric adenocarcinomas
1382544|NCT00447330|ESOPHAGEAL CANCER
1382545|NCT00447330|GASTRIC CANCER
1382546|NCT00447330|ADENOCARCINOMA
1382547|NCT00447330|TARGTED THERAPY
1382548|NCT00447330|BEVACIZUMAB
1382549|NCT00447330|CAPECITBAINE
1382550|NCT00447330|OXALIPLATIN
1382551|NCT00447330|METASTATIC
1382552|NCT00447317|peritoneal dialysis
1382553|NCT00447317|diet
1382554|NCT00447317|sodium
1382555|NCT00447304|acute cholecystitis
1382556|NCT00447304|cholecystectomy
1382557|NCT00447304|antibiotic treatment
1382558|NCT00447304|moxifloxacin
1382559|NCT00447304|intraabdominal infection
1382560|NCT00447304|morbidity and mortality of patients with acute cholecystitis, early surgery versus conservative therapy
1382561|NCT00447291|Overweight
1382562|NCT00447291|Obesity
1382563|NCT00447291|Fish Oil
1382564|NCT00447252|bereavement
1382565|NCT00447252|grief
1382566|NCT00447239|mechanical ventilated
1382567|NCT00447239|surgical patients
1382568|NCT00447239|pneumonia
1382569|NCT00447239|blood glucose
1382570|NCT00447239|insulin infusion
1382571|NCT00447239|hospital stay
1382572|NCT00447226|Ovarian Cancer
1382573|NCT00447226|Bladder Cancer
1382574|NCT00447226|ErbB2 positive
1382575|NCT00447226|Lapatinib
1382576|NCT00447226|Gastric/Esophageal Cancer
1382577|NCT00447226|Uterine Serous Papillary Cancer
1382578|NCT00447200|Stroke volume
1382579|NCT00447200|SV variation
1382581|NCT00447200|Goal Directed Therapy
1382582|NCT00447187|corneal graft failure
1382583|NCT00447187|corneal graft rejection
1382584|NCT00447187|corneal transplant rejection
1382585|NCT00447174|Grief
1382586|NCT00447174|parental bereavement
1382587|NCT00447135|Elderly
1382588|NCT00447135|Trauma
1382589|NCT00447135|Polymorphonuclear Leukocyte
1382590|NCT00447135|Immunity
1382591|NCT00447122|Pancreatic Cancer
1382592|NCT00447096|Bipolar Type II
1382593|NCT00447096|Depression
1382594|NCT00447096|rTMS
1382595|NCT00447083|Tanning
1382596|NCT00447083|Musculoskeletal
1382597|NCT00447083|Fibromyalgia Syndrome
1382598|NCT00447070|HIV-infection
1382599|NCT00447070|Dyslipidemia
1382600|NCT00447070|Endothelial Dysfunction
1382601|NCT00447070|Atherosclerosis
1382602|NCT00447070|Protease inhibitor
1382603|NCT00447070|treatment experienced
1382604|NCT00447057|nonsquamous
1382605|NCT00447044|Muscle loss and Maintenance of Muscle function
1382606|NCT00447031|age related macular degeneration
1382607|NCT00447031|intravitreal bevacizumab
1382608|NCT00447031|intravitreal triamcinolone acetonide
1382609|NCT00447031|neovascular age related macular degeneration
1382610|NCT00447018|intracranial pressure
1382611|NCT00447018|mannitol
1382612|NCT00447018|hypertonic saline solution
1382613|NCT00447018|brain injury
1382614|NCT00447018|traumatic brain injury
1382615|NCT00447018|Adult patients
1382616|NCT00447018|With elevation of intracranial pressure (ICP > 20 mmHg)
1382617|NCT00447005|Safety
1382618|NCT00447005|PK
1382619|NCT00447005|Biomarker
1382620|NCT00446992|Schizophrenia
1382621|NCT00446992|Schizoaffective
1382622|NCT00446992|psychosis
1382623|NCT00446992|olanzapine
1382624|NCT00446979|Microbicides
1382625|NCT00446979|HIV seronegativity
1382626|NCT00446966|atrial fibrillation
1382627|NCT00446966|coronary artery disease bypass graft surgery
1382628|NCT00446953|Caesarean section
1382629|NCT00446953|Corticosteroids
1382630|NCT00446953|Betamethasone
1382631|NCT00446953|Neonatal distress
1382632|NCT00446927|Pediatrics
1382633|NCT00446927|Cardiology
1382634|NCT00446927|Cardiopulmonary Bypass
1382635|NCT00446927|Heart Surgery
1382636|NCT00446927|Cardiac Catheterization
1382637|NCT00446927|Echocardiography
1382638|NCT00446927|Imaging
1382639|NCT00446927|ICG green dye
1382640|NCT00446914|Hypertension
1382641|NCT00446914|Blood Pressure
1382642|NCT00446901|Prostate Cancer
1382643|NCT00446901|Selenium
1382644|NCT00446901|Chemoprevention
1382645|NCT00446901|Gene expression
1382646|NCT00446888|cancer
1382647|NCT00446888|metastasis
1382648|NCT00446875|Pain
1382649|NCT00446875|Procedural pain
1382650|NCT00446875|Sucrose
1382651|NCT00446875|Infant
1382652|NCT00446862|Definition: Fabry disease
1382653|NCT00446862|Definition: Progression
1382654|NCT00446862|Definition: MDRD GFR
1382655|NCT00446862|Definition: Chronic Kidney Disease
1382656|NCT00446862|Definition: Proteinuria
1382657|NCT00446862|Definition: Enzyme Replacement Therapy
1382658|NCT00446862|Definition: Anti-proteinuric therapy
1382659|NCT00446849|ulcerative colitis
1382660|NCT00446849|compliance
1382661|NCT00446849|mesalamine
1382662|NCT00446849|clinical study
1382663|NCT00446849|clinical trial
1382664|NCT00446849|clinical research
1382665|NCT00446849|maintenance
1382666|NCT00446849|long term
1382667|NCT00446849|uc study
1382668|NCT00446849|uc trial
1382669|NCT00446849|uc research
1382670|NCT00446849|open label
1382671|NCT00446849|once a day
1382672|NCT00446849|once
1382673|NCT00446849|daily
1382674|NCT00446849|daily dosing
1382675|NCT00446849|simple
1382676|NCT00446849|oral
1382677|NCT00446836|Adenocarcinoma of the prostate
1382678|NCT00446836|Recurrent prostate cancer
1382679|NCT00446836|Hormone refractory prostate cancer
1382680|NCT00446823|Wound healing
1382681|NCT00446823|Venous stasis ulcer
1382682|NCT00446823|Cellulose dressing
1382683|NCT00446823|Gauze dressing
1382684|NCT00446823|Chronic wound
1382685|NCT00446810|diabetes
1382686|NCT00446810|endothelial dysfunction
1382687|NCT00446810|benfotiamine
1382688|NCT00446810|postprandial
1382689|NCT00446810|autonomic neuropathy
1382690|NCT00446810|advanced glycation end products
1382691|NCT00446797|Ankle sprain, acute pain, NSAID, celecoxib,
1382692|NCT00446758|Zinc
1382693|NCT00446758|HIV
1382694|NCT00446758|Infants
1382695|NCT00446758|Children
1382696|NCT00446758|Morbidity
1382697|NCT00446758|Child health outcomes
1382698|NCT00446758|treatment naive
1382699|NCT00446758|treatment experienced
1382700|NCT00446745|Nutritional and Metabolic Diseases
1382701|NCT00446745|Insulin resistance
1382702|NCT00446745|Energy Metabolisms
1382703|NCT00446745|Skeletal muscle
1382704|NCT00446745|Visceral Adipose Tissue
1382705|NCT00446719|major depression
1382706|NCT00446719|antidepressant
1382707|NCT00446719|quality of life
1382708|NCT00446719|anxiety
1382709|NCT00446706|Intrinsic PEEP
1382710|NCT00446680|Mannitol
1382711|NCT00446680|Cystic Fibrosis
1382712|NCT00446680|Mucolytic
1382713|NCT00446680|Exacerbation
1382714|NCT00446680|FEV1
1382715|NCT00446680|Quality of Life
1382716|NCT00446641|Infarction, Cerebral
1382717|NCT00446641|Cilostazol
1382718|NCT00446641|Aspirin Resistance
1382719|NCT00446628|Non-pharmaceutical
1382720|NCT00446628|influenza
1382721|NCT00446628|pandemic
1382722|NCT00446615|computer decision support
1382723|NCT00446615|primary care
1382724|NCT00446615|kidney disease, chronic
1382725|NCT00446615|prescribing
1382726|NCT00446602|PROCRIT
1382727|NCT00446602|Epoetin alfa
1382728|NCT00446602|Myelodysplastic Syndromes
1382729|NCT00446602|MDS
1382730|NCT00446576|Anemia
1382731|NCT00446576|early renal insufficiency
1382732|NCT00446563|Left ventricular hypertrophy, hypertension, valsartan, amlodipine
1382733|NCT00446537|Skill Acquisition and the Evolution of Long Term Procedural Memory in participants with ADHD: The Effect of Methylphenidate
1382734|NCT00446524|Hypertension, Valsartan, Amlodipine, high blood pressure
1382735|NCT00446511|children
1382736|NCT00446511|pediatrics
1382737|NCT00446511|high blood pressure
1382738|NCT00446511|hypertension
1382739|NCT00446511|valsartan
1382740|NCT00446511|enalapril
1382741|NCT00446485|ginkgo biloba
1382742|NCT00446485|cerebrovascular insufficiency
1382743|NCT00446485|mild cognitive impairment
1382744|NCT00446485|concentration impairment
1382745|NCT00446472|diabetes mellitus
1382746|NCT00446472|diabetic neuropathies
1382747|NCT00446472|peripheral vascular diseases
1382748|NCT00446459|CellCept
1382749|NCT00446459|Dialysis
1382750|NCT00446459|Kidney
1382751|NCT00446459|Renal
1382752|NCT00446459|Nephropathy
1382753|NCT00446459|Glomerulonephropathy
1382754|NCT00446459|Immunosuppression
1382755|NCT00446459|Allograft
1382756|NCT00446459|Compatibility
1382757|NCT00446459|HLA
1382758|NCT00446459|PRA
1382759|NCT00446459|Transplant
1382760|NCT00446459|Sensitization
1382761|NCT00446459|Antibodies
1382762|NCT00446459|Diabetes
1382763|NCT00446459|Hypertension
1382764|NCT00446459|Transplantation, Kidney
1382765|NCT00446407|Depression
1382766|NCT00446407|Primary Care
1382767|NCT00446407|Developing Countries
1382768|NCT00446407|Common mental disorders (depressive and anxiety disorders)
1382769|NCT00446394|cognition disorder
1382770|NCT00446394|functional ability
1382771|NCT00446394|psychomotor function
1382772|NCT00446394|psychopathology
1382773|NCT00446394|quality of life
1382774|NCT00446381|Proliferative Diabetic Retinopathy
1382775|NCT00446381|Clinically Significant Diabetic Macular Edema
1382776|NCT00446381|VEGF
1382777|NCT00446381|Macugen (pegaptanib)
1382778|NCT00446368|metastatic kidney cancer
1382779|NCT00446368|metastatic renal cell cancer
1382780|NCT00446355|C diff
1382781|NCT00446355|antibiotics
1382782|NCT00446342|leukemia
1382783|NCT00446342|lymphoma
1382784|NCT00446342|myeloma
1382785|NCT00446342|non-Hodgkin's
1382786|NCT00446342|CLL
1382787|NCT00446342|MCL
1382788|NCT00446342|MM
1382789|NCT00446342|Phase 1
1382790|NCT00446342|hematological malignancy
1382791|NCT00446316|Pharmacokinetics
1382792|NCT00446316|Healthy volunteers
1382793|NCT00446316|No condition
1382794|NCT00446316|Pharmacokinetics study
1382795|NCT00446303|MDS
1382796|NCT00446303|Myelodysplastic Syndromes
1382797|NCT00446303|AML
1382798|NCT00446303|Intensive chemotherapy
1382799|NCT00446303|azacitidine
1382800|NCT00446290|To determine maximal tolerated dose of DXO regimen
1382801|NCT00446277|cataract surgery, endothelial cell, cell loss, diabetes
1382802|NCT00446277|mellitus type II
1382803|NCT00446264|diabetes
1382804|NCT00446264|hypoglycemia
1382805|NCT00446251|Dialysis
1382806|NCT00446251|Kidney
1382807|NCT00446251|Renal
1382808|NCT00446251|Nephropathy
1382809|NCT00446251|Glomerulonephropathy
1382810|NCT00446251|Immunosuppression
1382811|NCT00446251|Graft
1382812|NCT00446251|Compatibility
1382813|NCT00446251|Transplant
1382814|NCT00446251|Diabetes
1382815|NCT00446251|Hypertension
1382816|NCT00446251|Transplantation, Kidney
1382817|NCT00446238|Depression
1382818|NCT00446238|Physical Illness
1382819|NCT00446238|Inflammatory Bowel Disease
1382820|NCT00446238|Cognitive Behavioral Therapy
1382821|NCT00446225|Lung
1382822|NCT00446225|cancer
1382823|NCT00446225|EGFR
1382824|NCT00446225|Epidermal Growth Factor Receptor
1382825|NCT00446225|tyrosine kinase
1382826|NCT00446225|Tarceva®
1382827|NCT00446225|Erlotinib
1382828|NCT00446212|anaesthesia
1382829|NCT00446212|propofol
1382830|NCT00446212|desflurane
1382831|NCT00446212|dreaming
1382832|NCT00446212|electroencephalography
1382833|NCT00446199|Vasomotor symptom relief
1382834|NCT00446199|Postmenopausal women
1382835|NCT00446199|Severe to Moderate Vasomotor symptoms
1382836|NCT00446173|Chronic Myelogenous Leukemia
1382837|NCT00446173|Leukemia
1382838|NCT00446173|Philadelphia (Ph) chromosome positive CML
1382839|NCT00446173|Busulfan
1382840|NCT00446173|Busulfex
1382841|NCT00446173|Myleran
1382842|NCT00446173|Cyclophosphamide
1382843|NCT00446173|Cytoxan
1382844|NCT00446173|Neosar
1382845|NCT00446173|G-CSF
1382846|NCT00446173|Filgrastim
1382847|NCT00446173|Neupogen
1382848|NCT00446173|GM-CSF
1382849|NCT00446173|Sargramostim
1382850|NCT00446173|Leukine
1382851|NCT00446160|Congenital Heart Disease
1382852|NCT00446160|Surgery
1382853|NCT00446160|Adult
1382854|NCT00446147|hand-foot syndrome
1382855|NCT00446147|capecitabine
1382856|NCT00446147|pyridoxine
1382857|NCT00446147|prevention
1382858|NCT00446134|Phase 2b Dose-Ranging Study
1382859|NCT00446121|COPD
1382860|NCT00446108|Pulmonary Stenosis
1382861|NCT00446108|Right Ventricular Dilation
1382862|NCT00446108|Right Heart Failure
1382863|NCT00446108|Imaging
1382864|NCT00446108|Tetralogy of Fallot
1382865|NCT00446095|DLCL
1382866|NCT00446095|Nodular lymphoma
1382867|NCT00446095|Mantle cell lymphoma
1382868|NCT00446095|Syk kinase
1382869|NCT00446082|Refractory/ resistant carcinoid disease
1382870|NCT00446082|acromegaly
1382871|NCT00446082|adults
1382872|NCT00446082|pasireotide LAR
1382873|NCT00446082|somatostatin analogue
1382874|NCT00446082|SOM230
1382875|NCT00446082|pharmacokinetics
1382876|NCT00446082|Refractory or resistant carcinoid disease and acromegaly
1382877|NCT00446043|Acne Vulgaris
1382878|NCT00446043|Adapalene
1382879|NCT00446043|Benzoyl Peroxide
1382880|NCT00446017|coronary artery bypass grafting
1382881|NCT00446017|inotropes
1382882|NCT00446017|metabolism
1382883|NCT00446017|renal failure
1382884|NCT00446004|Pharmacokinetics
1382885|NCT00446004|Healthy volunteers
1382886|NCT00446004|No condition
1382887|NCT00446004|Pharmacokinetics study
1382888|NCT00445978|Sickle Cell Disease
1382889|NCT00445978|SCD
1382890|NCT00445978|6R-BH4
1382891|NCT00445978|BH4
1382892|NCT00445978|sapropterin dihydrochloride
1382893|NCT00445978|endothelial dysfunction
1382894|NCT00445978|Nitric Oxide
1382895|NCT00445978|NO
1382896|NCT00445965|recurrent childhood medulloblastoma
1382897|NCT00445965|untreated childhood medulloblastoma
1382898|NCT00445965|adult supratentorial primitive neuroectodermal tumor (PNET)
1382899|NCT00445965|recurrent childhood supratentorial primitive neuroectodermal tumor
1382900|NCT00445965|untreated childhood supratentorial primitive neuroectodermal tumor
1382901|NCT00445965|adult anaplastic astrocytoma
1382902|NCT00445965|adult diffuse astrocytoma
1382903|NCT00445965|adult pilocytic astrocytoma
1382904|NCT00445965|adult subependymal giant cell astrocytoma
1382905|NCT00445965|recurrent childhood subependymal giant cell astrocytoma
1382906|NCT00445965|untreated childhood subependymal giant cell astrocytoma
1382907|NCT00445965|recurrent childhood cerebellar astrocytoma
1382908|NCT00445965|recurrent childhood cerebral astrocytoma
1382909|NCT00445965|untreated childhood cerebellar astrocytoma
1382910|NCT00445965|adult brain stem glioma
1382911|NCT00445965|adult mixed glioma
1382912|NCT00445965|childhood mixed glioma
1382913|NCT00445965|recurrent childhood brain stem glioma
1382914|NCT00445965|recurrent childhood visual pathway and hypothalamic glioma
1382915|NCT00445965|recurrent childhood visual pathway glioma
1382916|NCT00445965|untreated childhood brain stem glioma
1382917|NCT00445965|untreated childhood visual pathway and hypothalamic glioma
1382918|NCT00445965|untreated childhood visual pathway glioma
1382919|NCT00445965|regional neuroblastoma
1382920|NCT00445965|disseminated neuroblastoma
1382921|NCT00445965|recurrent neuroblastoma
1382922|NCT00445965|extraocular retinoblastoma
1382923|NCT00445965|recurrent retinoblastoma
1382924|NCT00445965|adult anaplastic ependymoma
1382925|NCT00445965|adult ependymoblastoma
1382926|NCT00445965|adult ependymoma
1382927|NCT00445965|adult myxopapillary ependymoma
1382928|NCT00445965|adult subependymoma
1382929|NCT00445965|childhood infratentorial ependymoma
1382930|NCT00445965|childhood supratentorial ependymoma
1382931|NCT00445965|recurrent childhood ependymoma
1382932|NCT00445965|childhood atypical teratoid/rhabdoid tumor
1382933|NCT00445965|recurrent melanoma
1382934|NCT00445965|stage IV melanoma
1382935|NCT00445965|adult medulloblastoma
1382936|NCT00445965|chondrosarcoma
1382937|NCT00445965|metastatic osteosarcoma
1382938|NCT00445965|recurrent osteosarcoma
1382939|NCT00445965|metastatic childhood soft tissue sarcoma
1382940|NCT00445965|ovarian sarcoma
1382941|NCT00445965|recurrent childhood soft tissue sarcoma
1382942|NCT00445965|stage III adult soft tissue sarcoma
1382943|NCT00445965|stage IV adult soft tissue sarcoma
1382944|NCT00445965|stage III uterine sarcoma
1382945|NCT00445965|stage IV uterine sarcoma
1382946|NCT00445965|previously treated childhood rhabdomyosarcoma
1382947|NCT00445965|recurrent childhood rhabdomyosarcoma
1382948|NCT00445965|adult anaplastic oligodendroglioma
1382949|NCT00445965|adult desmoplastic small round cell tumor
1382950|NCT00445965|adult oligodendroglioma
1382951|NCT00445965|adult giant cell glioblastoma
1382952|NCT00445965|adult gliosarcoma
1382953|NCT00445965|tumors metastatic to brain
1382954|NCT00445965|adult rhabdomyosarcoma
1382955|NCT00445965|childhood oligodendroglioma
1382956|NCT00445965|childhood desmoplastic small round cell tumor
1382957|NCT00445965|extensive stage small cell lung cancer
1382958|NCT00445965|intraocular retinoblastoma
1382959|NCT00445965|recurrent adult brain tumor
1382960|NCT00445965|recurrent adult soft tissue sarcoma
1382961|NCT00445965|recurrent uterine sarcoma
1382962|NCT00445965|small intestine leiomyosarcoma
1382963|NCT00445965|recurrent small intestine cancer
1382964|NCT00445965|recurrent small cell lung cancer
1382965|NCT00445965|extraocular extension melanoma
1382966|NCT00445965|recurrent intraocular melanoma
1382967|NCT00445965|metastatic intraocular melanoma
1382968|NCT00445965|iris melanoma
1382969|NCT00445965|ciliary body and choroid melanoma, medium/large size
1382970|NCT00445965|newly diagnosed childhood ependymoma
1382971|NCT00445965|adult glioblastoma
1382972|NCT00445965|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1382973|NCT00445965|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1382974|NCT00445965|recurrent childhood pineoblastoma
1382975|NCT00445965|untreated childhood pineoblastoma
1382976|NCT00445965|adult pineal gland astrocytoma
1382977|NCT00445965|stage IIIA melanoma
1382978|NCT00445965|stage IIIB melanoma
1382979|NCT00445965|stage IIIC melanoma
1382980|NCT00445965|recurrent childhood anaplastic astrocytoma
1382981|NCT00445965|untreated childhood anaplastic astrocytoma
1382982|NCT00445965|recurrent childhood anaplastic oligoastrocytoma
1382983|NCT00445965|recurrent childhood anaplastic oligodendroglioma
1382984|NCT00445965|untreated childhood anaplastic oligoastrocytoma
1382985|NCT00445965|untreated childhood anaplastic oligodendroglioma
1382986|NCT00445965|recurrent childhood giant cell glioblastoma
1382987|NCT00445965|recurrent childhood glioblastoma
1382988|NCT00445965|untreated childhood giant cell glioblastoma
1382989|NCT00445965|untreated childhood glioblastoma
1382990|NCT00445965|recurrent childhood gliosarcoma
1382991|NCT00445965|untreated childhood gliosarcoma
1382992|NCT00445965|recurrent childhood gliomatosis cerebri
1382993|NCT00445965|untreated childhood gliomatosis cerebri
1382994|NCT00445965|childhood high-grade cerebellar astrocytoma
1382995|NCT00445965|childhood high-grade cerebral astrocytoma
1382996|NCT00445952|breast cancer in situ
1382997|NCT00445952|stage I breast cancer
1382998|NCT00445952|stage II breast cancer
1382999|NCT00445952|stage IIIA breast cancer
1383000|NCT00445952|stage IIIB breast cancer
1383001|NCT00445952|stage IIIC breast cancer
1383002|NCT00445952|stage IV breast cancer
1383003|NCT00445952|recurrent breast cancer
1383004|NCT00445952|male breast cancer
1383005|NCT00445952|recurrent non-small cell lung cancer
1383006|NCT00445952|stage I non-small cell lung cancer
1383007|NCT00445952|stage II non-small cell lung cancer
1383008|NCT00445952|stage IIIA non-small cell lung cancer
1383009|NCT00445952|stage IIIB non-small cell lung cancer
1383010|NCT00445952|stage IV non-small cell lung cancer
1383011|NCT00445952|extensive stage small cell lung cancer
1383012|NCT00445952|recurrent colon cancer
1383013|NCT00445952|stage I colon cancer
1383014|NCT00445952|stage II colon cancer
1383015|NCT00445952|stage III colon cancer
1383016|NCT00445952|stage IV colon cancer
1383017|NCT00445952|unspecified adult solid tumor, protocol specific
1383018|NCT00445952|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1383019|NCT00445952|adult acute myeloid leukemia with inv(16)(p13;q22)
1383020|NCT00445952|adult acute myeloid leukemia with t(15;17)(q22;q12)
1383021|NCT00445952|adult acute myeloid leukemia with t(16;16)(p13;q22)
1383022|NCT00445952|adult acute myeloid leukemia with t(8;21)(q22;q22)
1383023|NCT00445952|stage IV chronic lymphocytic leukemia
1383024|NCT00445952|accelerated phase chronic myelogenous leukemia
1383025|NCT00445952|blastic phase chronic myelogenous leukemia
1383026|NCT00445952|chronic myelomonocytic leukemia
1383027|NCT00445952|chronic phase chronic myelogenous leukemia
1383028|NCT00445952|noncontiguous stage II adult Burkitt lymphoma
1383029|NCT00445952|noncontiguous stage II adult diffuse large cell lymphoma
1383030|NCT00445952|noncontiguous stage II adult diffuse mixed cell lymphoma
1383031|NCT00445952|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1383032|NCT00445952|noncontiguous stage II adult immunoblastic large cell lymphoma
1383033|NCT00445952|noncontiguous stage II adult lymphoblastic lymphoma
1383034|NCT00445952|noncontiguous stage II small lymphocytic lymphoma
1383035|NCT00445952|noncontiguous stage II marginal zone lymphoma
1383036|NCT00445952|noncontiguous stage II grade 1 follicular lymphoma
1383037|NCT00445952|noncontiguous stage II grade 2 follicular lymphoma
1383038|NCT00445952|noncontiguous stage II grade 3 follicular lymphoma
1383039|NCT00445952|noncontiguous stage II mantle cell lymphoma
1383040|NCT00445952|stage III adult Burkitt lymphoma
1383041|NCT00445952|stage III adult diffuse large cell lymphoma
1383042|NCT00445952|stage III adult diffuse mixed cell lymphoma
1383043|NCT00445952|stage III adult diffuse small cleaved cell lymphoma
1383044|NCT00445952|stage III adult immunoblastic large cell lymphoma
1383045|NCT00445952|stage III adult lymphoblastic lymphoma
1383046|NCT00445952|stage III small lymphocytic lymphoma
1383047|NCT00445952|stage III marginal zone lymphoma
1383048|NCT00445952|stage III grade 1 follicular lymphoma
1383049|NCT00445952|stage III grade 2 follicular lymphoma
1383050|NCT00445952|stage III grade 3 follicular lymphoma
1383051|NCT00445952|stage III mantle cell lymphoma
1383052|NCT00445952|stage IV adult Burkitt lymphoma
1383053|NCT00445952|stage IV adult diffuse large cell lymphoma
1383054|NCT00445952|stage IV adult diffuse mixed cell lymphoma
1383055|NCT00445952|stage IV adult diffuse small cleaved cell lymphoma
1383056|NCT00445952|stage IV adult immunoblastic large cell lymphoma
1383057|NCT00445952|stage IV adult lymphoblastic lymphoma
1383058|NCT00445952|stage IV small lymphocytic lymphoma
1383059|NCT00445952|stage IV marginal zone lymphoma
1383060|NCT00445952|stage IV grade 1 follicular lymphoma
1383061|NCT00445952|stage IV grade 2 follicular lymphoma
1383062|NCT00445952|stage IV grade 3 follicular lymphoma
1383063|NCT00445952|stage IV mantle cell lymphoma
1383064|NCT00445952|recurrent adult Burkitt lymphoma
1383065|NCT00445952|recurrent adult diffuse large cell lymphoma
1383066|NCT00445952|recurrent adult diffuse mixed cell lymphoma
1383067|NCT00445952|recurrent adult diffuse small cleaved cell lymphoma
1383068|NCT00445952|recurrent adult Hodgkin lymphoma
1383069|NCT00445952|recurrent adult immunoblastic large cell lymphoma
1383070|NCT00445952|recurrent adult lymphoblastic lymphoma
1383071|NCT00445952|recurrent cutaneous T-cell non-Hodgkin lymphoma
1383072|NCT00445952|recurrent small lymphocytic lymphoma
1383073|NCT00445952|recurrent marginal zone lymphoma
1383074|NCT00445952|recurrent grade 1 follicular lymphoma
1383075|NCT00445952|recurrent grade 2 follicular lymphoma
1383076|NCT00445952|recurrent grade 3 follicular lymphoma
1383077|NCT00445952|recurrent mantle cell lymphoma
1383078|NCT00445952|recurrent mycosis fungoides/Sezary syndrome
1383079|NCT00445952|stage I multiple myeloma
1383080|NCT00445952|stage II multiple myeloma
1383081|NCT00445952|stage III multiple myeloma
1383082|NCT00445952|de novo myelodysplastic syndromes
1383083|NCT00445952|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1383084|NCT00445952|previously treated myelodysplastic syndromes
1383085|NCT00445952|secondary myelodysplastic syndromes
1383086|NCT00445952|atypical chronic myeloid leukemia, BCR-ABL1 negative
1383087|NCT00445952|stage II adult Hodgkin lymphoma
1383088|NCT00445952|stage III adult Hodgkin lymphoma
1383089|NCT00445952|stage IV adult Hodgkin lymphoma
1383090|NCT00445952|contiguous stage II adult Burkitt lymphoma
1383091|NCT00445952|stage I adult Burkitt lymphoma
1383092|NCT00445952|contiguous stage II adult diffuse large cell lymphoma
1383093|NCT00445952|contiguous stage II adult diffuse mixed cell lymphoma
1383094|NCT00445952|contiguous stage II adult diffuse small cleaved cell lymphoma
1383095|NCT00445952|contiguous stage II small lymphocytic lymphoma
1383096|NCT00445952|contiguous stage II marginal zone lymphoma
1383097|NCT00445952|stage I adult diffuse large cell lymphoma
1383098|NCT00445952|stage I adult diffuse mixed cell lymphoma
1383099|NCT00445952|stage I adult diffuse small cleaved cell lymphoma
1383100|NCT00445952|stage I small lymphocytic lymphoma
1383101|NCT00445952|stage I marginal zone lymphoma
1383102|NCT00445952|contiguous stage II grade 1 follicular lymphoma
1383103|NCT00445952|contiguous stage II grade 2 follicular lymphoma
1383104|NCT00445952|contiguous stage II grade 3 follicular lymphoma
1383105|NCT00445952|stage I grade 1 follicular lymphoma
1383106|NCT00445952|stage I grade 2 follicular lymphoma
1383107|NCT00445952|stage I grade 3 follicular lymphoma
1383108|NCT00445952|contiguous stage II mantle cell lymphoma
1383109|NCT00445952|stage I mantle cell lymphoma
1383110|NCT00445952|contiguous stage II adult immunoblastic large cell lymphoma
1383111|NCT00445952|stage I adult immunoblastic large cell lymphoma
1383112|NCT00445952|contiguous stage II adult lymphoblastic lymphoma
1383113|NCT00445952|stage I adult lymphoblastic lymphoma
1383114|NCT00445952|refractory multiple myeloma
1383115|NCT00445952|anaplastic large cell lymphoma
1383116|NCT00445952|angioimmunoblastic T-cell lymphoma
1383117|NCT00445952|recurrent adult T-cell leukemia/lymphoma
1383118|NCT00445952|stage I adult T-cell leukemia/lymphoma
1383119|NCT00445952|stage II adult T-cell leukemia/lymphoma
1383120|NCT00445952|stage III adult T-cell leukemia/lymphoma
1383121|NCT00445952|stage IV adult T-cell leukemia/lymphoma
1383122|NCT00445952|stage I cutaneous T-cell non-Hodgkin lymphoma
1383123|NCT00445952|stage II cutaneous T-cell non-Hodgkin lymphoma
1383124|NCT00445952|stage III cutaneous T-cell non-Hodgkin lymphoma
1383125|NCT00445952|stage IV cutaneous T-cell non-Hodgkin lymphoma
1383126|NCT00445952|stage I mycosis fungoides/Sezary syndrome
1383127|NCT00445952|stage II mycosis fungoides/Sezary syndrome
1383128|NCT00445952|stage III mycosis fungoides/Sezary syndrome
1383129|NCT00445952|stage IV mycosis fungoides/Sezary syndrome
1383130|NCT00445952|chronic eosinophilic leukemia
1383131|NCT00445952|primary myelofibrosis
1383132|NCT00445952|chronic neutrophilic leukemia
1383133|NCT00445952|essential thrombocythemia
1383134|NCT00445952|polycythemia vera
1383135|NCT00445952|relapsing chronic myelogenous leukemia
1383136|NCT00445952|recurrent adult acute lymphoblastic leukemia
1383137|NCT00445952|recurrent adult acute myeloid leukemia
1383138|NCT00445952|untreated adult acute lymphoblastic leukemia
1383139|NCT00445952|untreated adult acute myeloid leukemia
1383140|NCT00445952|secondary acute myeloid leukemia
1383141|NCT00445952|acute undifferentiated leukemia
1383142|NCT00445952|refractory chronic lymphocytic leukemia
1383143|NCT00445952|stage I chronic lymphocytic leukemia
1383144|NCT00445952|stage II chronic lymphocytic leukemia
1383145|NCT00445952|stage III chronic lymphocytic leukemia
1383146|NCT00445952|refractory hairy cell leukemia
1383147|NCT00445952|progressive hairy cell leukemia, initial treatment
1383148|NCT00445952|prolymphocytic leukemia
1383149|NCT00445952|recurrent adult grade III lymphomatoid granulomatosis
1383150|NCT00445952|Waldenstrom macroglobulinemia
1383151|NCT00445952|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1383152|NCT00445952|nodal marginal zone B-cell lymphoma
1383153|NCT00445952|splenic marginal zone lymphoma
1383154|NCT00445952|post-transplant lymphoproliferative disorder
1383155|NCT00445952|extramedullary plasmacytoma
1383156|NCT00445952|monoclonal gammopathy of undetermined significance
1383157|NCT00445952|primary systemic amyloidosis
1383158|NCT00445952|adult acute lymphoblastic leukemia in remission
1383159|NCT00445952|adult acute myeloid leukemia in remission
1383160|NCT00445952|adult grade III lymphomatoid granulomatosis
1383161|NCT00445952|AIDS-related peripheral/systemic lymphoma
1383162|NCT00445952|AIDS-related primary CNS lymphoma
1383163|NCT00445952|intraocular lymphoma
1383164|NCT00445952|meningeal chronic myelogenous leukemia
1383165|NCT00445952|primary central nervous system non-Hodgkin lymphoma
1383166|NCT00445952|stage I adult Hodgkin lymphoma
1383167|NCT00445952|adult nasal type extranodal NK/T-cell lymphoma
1383168|NCT00445952|infection
1383169|NCT00445952|limited stage small cell lung cancer
1383170|NCT00445952|T-cell large granular lymphocyte leukemia
1383171|NCT00445913|type 1 diabetes
1383172|NCT00445913|dendritic cells
1383173|NCT00445913|cell vaccine
1383174|NCT00445913|safety
1383175|NCT00445913|reversal
1383176|NCT00445900|primary myelofibrosis
1383177|NCT00445900|essential thrombocythemia
1383178|NCT00445900|polycythemia vera
1383179|NCT00445900|secondary myelofibrosis
1383180|NCT00445887|ovarian epithelial cancer
1383181|NCT00445874|allergic conjunctivitis, ophthalmology, multicenter, controlled
1383182|NCT00445861|adenocarcinoma of the esophagus
1383183|NCT00445861|squamous cell carcinoma of the esophagus
1383184|NCT00445861|stage II esophageal cancer
1383185|NCT00445861|stage III esophageal cancer
1383186|NCT00445848|stage IIIB non-small cell lung cancer
1383187|NCT00445848|stage IV non-small cell lung cancer
1383188|NCT00445848|adenocarcinoma of the lung
1383189|NCT00445835|coronary artery disease
1383190|NCT00445835|myocardial infarction
1383191|NCT00445835|atherothrombosis
1383192|NCT00445835|atherosclerosis
1383193|NCT00445822|CML
1383194|NCT00445822|Children
1383195|NCT00445822|Imatinib
1383196|NCT00445822|bcr-abl
1383197|NCT00445822|Response
1383198|NCT00445822|Imatinib mesylate
1383199|NCT00445809|Kidney
1383200|NCT00445809|Renal
1383201|NCT00445809|Cardiac Surgery with bypass
1383202|NCT00445809|Cardiovascular surgery with cardiopulmonary bypass
1383203|NCT00445783|lentigo maligna malignant melanoma
1383204|NCT00445783|stage IV melanoma
1383205|NCT00445783|acral lentiginous malignant melanoma
1383206|NCT00445783|nodular malignant melanoma
1383207|NCT00445783|stage IA melanoma
1383208|NCT00445783|stage IB melanoma
1383209|NCT00445783|stage IIA melanoma
1383210|NCT00445783|stage IIB melanoma
1383211|NCT00445783|stage IIC melanoma
1383212|NCT00445783|stage IIIA melanoma
1383213|NCT00445783|stage IIIB melanoma
1383214|NCT00445783|stage IIIC melanoma
1383215|NCT00445770|Rheumatoid Arthritis
1383216|NCT00445770|Arthritis
1383217|NCT00445757|stage I renal cell cancer
1383218|NCT00445757|stage II renal cell cancer
1383219|NCT00445731|poor performance status
1383220|NCT00445731|unspecified adult solid tumor, protocol specific
1383221|NCT00445731|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1383222|NCT00445731|adult acute myeloid leukemia with inv(16)(p13;q22)
1383223|NCT00445731|adult acute myeloid leukemia with t(15;17)(q22;q12)
1383224|NCT00445731|adult acute myeloid leukemia with t(16;16)(p13;q22)
1383225|NCT00445731|adult acute myeloid leukemia with t(8;21)(q22;q22)
1383226|NCT00445731|accelerated phase chronic myelogenous leukemia
1383227|NCT00445731|adult acute lymphoblastic leukemia in remission
1383228|NCT00445731|adult acute myeloid leukemia in remission
1383229|NCT00445731|atypical chronic myeloid leukemia
1383230|NCT00445731|blastic phase chronic myelogenous leukemia
1383231|NCT00445731|chronic eosinophilic leukemia
1383232|NCT00445731|chronic idiopathic myelofibrosis
1383233|NCT00445731|chronic myelomonocytic leukemia
1383234|NCT00445731|chronic neutrophilic leukemia
1383235|NCT00445731|chronic phase chronic myelogenous leukemia
1383236|NCT00445731|de novo myelodysplastic syndromes
1383237|NCT00445731|disseminated neuroblastoma
1383238|NCT00445731|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1383239|NCT00445731|myelodysplastic/myeloproliferative disease, unclassifiable
1383240|NCT00445731|nodal marginal zone B-cell lymphoma
1383241|NCT00445731|noncontiguous stage II adult Burkitt lymphoma
1383242|NCT00445731|noncontiguous stage II adult diffuse large cell lymphoma
1383243|NCT00445731|noncontiguous stage II adult diffuse mixed cell lymphoma
1383244|NCT00445731|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1383245|NCT00445731|noncontiguous stage II adult immunoblastic large cell lymphoma
1383246|NCT00445731|noncontiguous stage II adult lymphoblastic lymphoma
1383247|NCT00445731|noncontiguous stage II grade 1 follicular lymphoma
1383248|NCT00445731|noncontiguous stage II grade 2 follicular lymphoma
1383249|NCT00445731|noncontiguous stage II grade 3 follicular lymphoma
1383250|NCT00445731|noncontiguous stage II mantle cell lymphoma
1383251|NCT00445731|noncontiguous stage II marginal zone lymphoma
1383252|NCT00445731|noncontiguous stage II small lymphocytic lymphoma
1383253|NCT00445731|poor prognosis metastatic gestational trophoblastic tumor
1383254|NCT00445731|previously treated myelodysplastic syndromes
1383255|NCT00445731|recurrent adult acute lymphoblastic leukemia
1383256|NCT00445731|recurrent adult acute myeloid leukemia
1383257|NCT00445731|recurrent adult Burkitt lymphoma
1383258|NCT00445731|recurrent adult Hodgkin lymphoma
1383259|NCT00445731|recurrent adult diffuse large cell lymphoma
1383260|NCT00445731|recurrent adult diffuse mixed cell lymphoma
1383261|NCT00445731|recurrent adult diffuse small cleaved cell lymphoma
1383262|NCT00445731|recurrent adult immunoblastic large cell lymphoma
1383263|NCT00445731|recurrent adult lymphoblastic lymphoma
1383264|NCT00445731|recurrent breast cancer
1383265|NCT00445731|recurrent cutaneous T-cell non-Hodgkin lymphoma
1383266|NCT00445731|recurrent grade 1 follicular lymphoma
1383267|NCT00445731|recurrent grade 2 follicular lymphoma
1383268|NCT00445731|recurrent grade 3 follicular lymphoma
1383269|NCT00445731|recurrent mantle cell lymphoma
1383270|NCT00445731|recurrent marginal zone lymphoma
1383271|NCT00445731|recurrent mycosis fungoides/Sezary syndrome
1383272|NCT00445731|recurrent neuroblastoma
1383273|NCT00445731|recurrent ovarian epithelial cancer
1383274|NCT00445731|recurrent ovarian germ cell tumor
1383275|NCT00445731|recurrent small lymphocytic lymphoma
1383276|NCT00445731|recurrent malignant testicular germ cell tumor
1383277|NCT00445731|refractory chronic lymphocytic leukemia
1383278|NCT00445731|refractory hairy cell leukemia
1383279|NCT00445731|refractory multiple myeloma
1383280|NCT00445731|relapsing chronic myelogenous leukemia
1383281|NCT00445731|secondary acute myeloid leukemia
1383282|NCT00445731|secondary myelodysplastic syndromes
1383283|NCT00445731|splenic marginal zone lymphoma
1383284|NCT00445731|stage I multiple myeloma
1383285|NCT00445731|stage II multiple myeloma
1383286|NCT00445731|stage II ovarian epithelial cancer
1383287|NCT00445731|stage III adult Burkitt lymphoma
1383288|NCT00445731|stage III adult Hodgkin lymphoma
1383289|NCT00445731|stage III adult diffuse large cell lymphoma
1383290|NCT00445731|stage III adult diffuse mixed cell lymphoma
1383291|NCT00445731|stage III adult diffuse small cleaved cell lymphoma
1383292|NCT00445731|stage III adult immunoblastic large cell lymphoma
1383293|NCT00445731|stage III adult lymphoblastic lymphoma
1383294|NCT00445731|stage III chronic lymphocytic leukemia
1383295|NCT00445731|stage III grade 1 follicular lymphoma
1383296|NCT00445731|stage III grade 2 follicular lymphoma
1383297|NCT00445731|stage III grade 3 follicular lymphoma
1383298|NCT00445731|stage III mantle cell lymphoma
1383299|NCT00445731|stage III marginal zone lymphoma
1383300|NCT00445731|stage III multiple myeloma
1383301|NCT00445731|stage III ovarian epithelial cancer
1383302|NCT00445731|stage III small lymphocytic lymphoma
1383303|NCT00445731|stage III malignant testicular germ cell tumor
1383304|NCT00445731|stage IIIA breast cancer
1383305|NCT00445731|stage IIIB breast cancer
1383306|NCT00445731|stage IIIC breast cancer
1383307|NCT00445731|stage IV adult Burkitt lymphoma
1383308|NCT00445731|stage IV adult Hodgkin lymphoma
1383309|NCT00445731|stage IV adult diffuse large cell lymphoma
1383310|NCT00445731|stage IV adult diffuse mixed cell lymphoma
1383311|NCT00445731|stage IV adult diffuse small cleaved cell lymphoma
1383312|NCT00445731|stage IV adult immunoblastic large cell lymphoma
1383313|NCT00445731|stage IV adult lymphoblastic lymphoma
1383314|NCT00445731|stage IV breast cancer
1383315|NCT00445731|stage IV chronic lymphocytic leukemia
1383316|NCT00445731|stage IV grade 1 follicular lymphoma
1383317|NCT00445731|stage IV grade 2 follicular lymphoma
1383318|NCT00445731|stage IV grade 3 follicular lymphoma
1383319|NCT00445731|stage IV mantle cell lymphoma
1383320|NCT00445731|stage IV marginal zone lymphoma
1383321|NCT00445731|stage IV ovarian epithelial cancer
1383322|NCT00445731|stage IV small lymphocytic lymphoma
1383323|NCT00445679|major depressive disorder
1383324|NCT00445679|MDD
1383325|NCT00445679|depression
1383326|NCT00445653|Barrett esophagus
1383330|NCT00445614|nutrition
1383331|NCT00445614|cardiovascular risk
1383332|NCT00445614|inflammation
1383333|NCT00445614|vascular function
1383334|NCT00445601|transitional cell carcinoma of the bladder
1383335|NCT00445601|stage 0 bladder cancer
1383336|NCT00445601|stage I bladder cancer
1383337|NCT00445601|recurrent bladder cancer
1383338|NCT00445575|fibrous dysplasia of bone
1383339|NCT00445575|Mac Cune Albright syndrome
1383340|NCT00445575|bisphosphonates
1383341|NCT00445575|risedronate
1383342|NCT00445562|male breast cancer
1383343|NCT00445562|recurrent breast cancer
1383344|NCT00445562|stage IA breast cancer
1383345|NCT00445562|stage IB breast cancer
1383346|NCT00445562|stage II breast cancer
1383347|NCT00445562|stage IIIA breast cancer
1383348|NCT00445562|stage IIIB breast cancer
1383349|NCT00445562|stage IIIC breast cancer
1383350|NCT00445562|stage IV breast cancer
1383351|NCT00445549|Ovarian
1383352|NCT00445549|VEGFR2
1383353|NCT00445549|EGFR
1383354|NCT00445549|Angiogenesis
1383355|NCT00445549|Tyrosine Kinase
1383356|NCT00445549|Protein Phosphorylation
1383357|NCT00445549|Vandetanib
1383358|NCT00445549|Ovarian Cancer
1383359|NCT00445549|Fallopian Tube Cancer
1383360|NCT00445549|Peritoneal Cancer
1383361|NCT00445523|Advanced renal cancer
1383362|NCT00445523|metastatic renal cancer
1383363|NCT00445523|RCC
1383364|NCT00445523|kidney cancer
1383365|NCT00445523|M3thodist
1383366|NCT00445510|GSK256066,
1383367|NCT00445510|allergen,
1383368|NCT00445510|challenge,
1383369|NCT00445510|repeat dose,
1383370|NCT00445510|AMP,
1383371|NCT00445510|mild asthmatics
1383372|NCT00445497|psychosocial effects of cancer and its treatment
1383373|NCT00445497|anaplastic large cell lymphoma
1383374|NCT00445497|angioimmunoblastic T-cell lymphoma
1383375|NCT00445497|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1383376|NCT00445497|intraocular lymphoma
1383377|NCT00445497|nodal marginal zone B-cell lymphoma
1383378|NCT00445497|primary central nervous system non-Hodgkin lymphoma
1383379|NCT00445497|primary central nervous system Hodgkin lymphoma
1383380|NCT00445497|recurrent adult Burkitt lymphoma
1383381|NCT00445497|recurrent adult diffuse large cell lymphoma
1383382|NCT00445497|recurrent adult diffuse mixed cell lymphoma
1383383|NCT00445497|recurrent adult diffuse small cleaved cell lymphoma
1383384|NCT00445497|recurrent adult Hodgkin lymphoma
1383385|NCT00445497|recurrent adult immunoblastic large cell lymphoma
1383386|NCT00445497|recurrent adult lymphoblastic lymphoma
1383387|NCT00445497|recurrent cutaneous T-cell non-Hodgkin lymphoma
1383388|NCT00445497|recurrent grade 1 follicular lymphoma
1383389|NCT00445497|recurrent grade 2 follicular lymphoma
1383390|NCT00445497|recurrent grade 3 follicular lymphoma
1383391|NCT00445497|recurrent mantle cell lymphoma
1383392|NCT00445497|recurrent marginal zone lymphoma
1383393|NCT00445497|recurrent mycosis fungoides/Sezary syndrome
1383394|NCT00445497|recurrent small lymphocytic lymphoma
1383395|NCT00445497|small intestine lymphoma
1383396|NCT00445497|splenic marginal zone lymphoma
1383397|NCT00445497|stage III adult Burkitt lymphoma
1383398|NCT00445497|stage III adult diffuse large cell lymphoma
1383399|NCT00445497|stage III adult diffuse mixed cell lymphoma
1383400|NCT00445497|stage III adult diffuse small cleaved cell lymphoma
1383401|NCT00445497|stage III adult Hodgkin lymphoma
1383402|NCT00445497|stage III adult immunoblastic large cell lymphoma
1383403|NCT00445497|stage III adult lymphoblastic lymphoma
1383404|NCT00445497|stage III adult T-cell leukemia/lymphoma
1383405|NCT00445497|stage III cutaneous T-cell non-Hodgkin lymphoma
1383406|NCT00445497|stage III grade 1 follicular lymphoma
1383407|NCT00445497|stage III grade 2 follicular lymphoma
1383408|NCT00445497|stage III grade 3 follicular lymphoma
1383409|NCT00445497|stage III mantle cell lymphoma
1383410|NCT00445497|stage III marginal zone lymphoma
1383411|NCT00445497|stage III mycosis fungoides/Sezary syndrome
1383412|NCT00445497|stage III small lymphocytic lymphoma
1383413|NCT00445497|stage IV adult Burkitt lymphoma
1383414|NCT00445497|stage IV adult diffuse large cell lymphoma
1383415|NCT00445497|stage IV adult diffuse mixed cell lymphoma
1383416|NCT00445497|stage IV adult diffuse small cleaved cell lymphoma
1383417|NCT00445497|stage IV adult Hodgkin lymphoma
1383418|NCT00445497|stage IV adult immunoblastic large cell lymphoma
1383419|NCT00445497|stage IV adult lymphoblastic lymphoma
1383420|NCT00445497|stage IV adult T-cell leukemia/lymphoma
1383421|NCT00445497|stage IV cutaneous T-cell non-Hodgkin lymphoma
1383422|NCT00445497|stage IV grade 1 follicular lymphoma
1383423|NCT00445497|stage IV grade 2 follicular lymphoma
1383424|NCT00445497|stage IV grade 3 follicular lymphoma
1383425|NCT00445497|stage IV mantle cell lymphoma
1383426|NCT00445497|stage IV marginal zone lymphoma
1383427|NCT00445497|stage IV mycosis fungoides/Sezary syndrome
1383428|NCT00445497|stage IV small lymphocytic lymphoma
1383429|NCT00445497|Waldenström macroglobulinemia
1383430|NCT00445497|unspecified adult solid tumor, protocol specific
1383431|NCT00445497|neutropenia
1383432|NCT00445497|stage I adult Burkitt lymphoma
1383433|NCT00445497|stage I adult diffuse large cell lymphoma
1383434|NCT00445497|stage I adult diffuse mixed cell lymphoma
1383435|NCT00445497|stage I adult diffuse small cleaved cell lymphoma
1383436|NCT00445497|stage I adult Hodgkin lymphoma
1383437|NCT00445497|stage I adult immunoblastic large cell lymphoma
1383438|NCT00445497|stage I adult lymphoblastic lymphoma
1383439|NCT00445497|stage II adult Hodgkin lymphoma
1383440|NCT00445497|stage I mycosis fungoides/Sezary syndrome
1383441|NCT00445497|stage II mycosis fungoides/Sezary syndrome
1383442|NCT00445497|stage I cutaneous T-cell non-Hodgkin lymphoma
1383443|NCT00445497|stage II cutaneous T-cell non-Hodgkin lymphoma
1383444|NCT00445497|contiguous stage II adult Burkitt lymphoma
1383445|NCT00445497|contiguous stage II adult diffuse large cell lymphoma
1383446|NCT00445497|contiguous stage II adult diffuse mixed cell lymphoma
1383447|NCT00445497|contiguous stage II adult diffuse small cleaved cell lymphoma
1383448|NCT00445497|contiguous stage II adult immunoblastic large cell lymphoma
1383449|NCT00445497|contiguous stage II adult lymphoblastic lymphoma
1383450|NCT00445497|contiguous stage II grade 1 follicular lymphoma
1383451|NCT00445497|contiguous stage II grade 2 follicular lymphoma
1383452|NCT00445497|contiguous stage II grade 3 follicular lymphoma
1383453|NCT00445497|contiguous stage II mantle cell lymphoma
1383454|NCT00445497|contiguous stage II marginal zone lymphoma
1383455|NCT00445497|contiguous stage II small lymphocytic lymphoma
1383456|NCT00445497|noncontiguous stage II adult Burkitt lymphoma
1383457|NCT00445497|noncontiguous stage II adult diffuse large cell lymphoma
1383458|NCT00445497|noncontiguous stage II adult diffuse mixed cell lymphoma
1383459|NCT00445497|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1383460|NCT00445497|noncontiguous stage II adult immunoblastic large cell lymphoma
1383461|NCT00445497|noncontiguous stage II adult lymphoblastic lymphoma
1383462|NCT00445497|noncontiguous stage II grade 1 follicular lymphoma
1383463|NCT00445497|noncontiguous stage II grade 2 follicular lymphoma
1383464|NCT00445497|noncontiguous stage II grade 3 follicular lymphoma
1383465|NCT00445497|noncontiguous stage II mantle cell lymphoma
1383466|NCT00445497|noncontiguous stage II marginal zone lymphoma
1383467|NCT00445497|noncontiguous stage II small lymphocytic lymphoma
1383468|NCT00445497|recurrent adult T-cell leukemia/lymphoma
1383469|NCT00445497|stage I adult T-cell leukemia/lymphoma
1383470|NCT00445497|stage II adult T-cell leukemia/lymphoma
1383471|NCT00445497|adult grade III lymphomatoid granulomatosis
1383472|NCT00445497|recurrent adult grade III lymphomatoid granulomatosis
1383473|NCT00445497|adult nasal type extranodal NK/T-cell lymphoma
1383474|NCT00445484|stage II multiple myeloma
1383475|NCT00445484|stage III multiple myeloma
1383476|NCT00445484|refractory multiple myeloma
1383477|NCT00445471|Autism Spectrum Disorder
1383478|NCT00445471|Autistic Disorder
1383479|NCT00445471|Pervasive Developmental Disorder
1383480|NCT00445458|cancer
1383481|NCT00445458|HKI-272
1383482|NCT00445458|neratinib
1383483|NCT00445458|paclitaxel
1383484|NCT00445458|Taxol
1383485|NCT00445458|breast cancer
1383486|NCT00445445|stage I breast cancer
1383487|NCT00445445|stage II breast cancer
1383488|NCT00445445|stage IIIA breast cancer
1383489|NCT00445445|stage IIIB breast cancer
1383490|NCT00445445|stage IIIC breast cancer
1383491|NCT00445445|stage IV breast cancer
1383492|NCT00445445|recurrent breast cancer
1383493|NCT00445445|breast cancer in situ
1383494|NCT00445419|Hepatitis C
1383495|NCT00445419|Liver disease
1383496|NCT00445419|Viral infection
1383497|NCT00445419|Virosome
1383498|NCT00445419|Vaccine
1383499|NCT00445419|therapeutic vaccine
1383500|NCT00445419|Chronic hepatitis C virus infection
1383501|NCT00445406|recurrent breast cancer
1383502|NCT00445406|stage IV breast cancer
1383503|NCT00445393|Observation
1383504|NCT00445393|Mental health
1383505|NCT00445393|Scoliosis
1383506|NCT00445393|Screening
1383507|NCT00445393|Adolescent idiopathic scoliosis
1383508|NCT00445367|Multiple Sclerosis
1383509|NCT00445367|Clinically Isolated Syndrome
1383510|NCT00445367|Transverse Myelitis
1383511|NCT00445367|Neuromyelitis Optica
1383512|NCT00445367|Acute Disseminated Encephalomyelitis
1383513|NCT00445367|Optic Neuritis
1383514|NCT00445367|Repository
1383515|NCT00445367|Biobank
1383516|NCT00445354|cinnamon
1383517|NCT00445354|diabetes
1383518|NCT00445354|hemoglobin a1c
1383519|NCT00445341|Microarray
1383520|NCT00445341|Proteomics
1383521|NCT00445341|Hybrid Schedule
1383522|NCT00445341|Tumor Lysis Syndrome
1383523|NCT00445341|Cyclin D1
1383524|NCT00445341|Lymphoma
1383525|NCT00445341|Mantle Cell Lymphoma
1383526|NCT00445341|MCL
1383527|NCT00445341|Diffuse Large B-Cell Lymphoma
1383528|NCT00445341|DLBCL
1383529|NCT00445328|hospitalised acutely medically ill patients; Venous Thromboembolism, Infection, Inflammatory Bowel Diseases, Heart Failure, Congestive, Sciatica
1383530|NCT00445302|AMD3100
1383531|NCT00445289|mechanical ventilation
1383532|NCT00445289|ventilator weaning
1383533|NCT00445289|closed-loop
1383534|NCT00445289|ventilation time
1383535|NCT00445276|Osteoarthritis
1383536|NCT00445276|Knee
1383537|NCT00445276|Diacerein
1383538|NCT00445276|Painful osteoarthritis
1383539|NCT00445276|Clinical trial
1383540|NCT00445263|CORONARY DISEASE
1383541|NCT00445250|Calcipotriol
1383542|NCT00445250|Breast
1383543|NCT00445250|Cancer
1383544|NCT00445250|Radiotherapy
1383545|NCT00445250|Radiodermatitis in Breast Cancer
1383546|NCT00445237|major depression
1383547|NCT00445237|TMS
1383548|NCT00445224|Knee pain
1383549|NCT00445224|Rehabilitation
1383550|NCT00445211|Intraaortic balloon pumping
1383551|NCT00445211|Heparin
1383552|NCT00445211|Limb ischemia
1383553|NCT00445211|Bleeding
1383554|NCT00445198|SCLC
1383555|NCT00445185|Dialysis
1383556|NCT00445185|Pre-dialysis
1383557|NCT00445185|Hepatitis B vaccine
1383558|NCT00445185|vaccine
1383559|NCT00445172|Amyotrophic Lateral Sclerosis
1383560|NCT00445172|Motor Neurons
1383561|NCT00445172|Muscular Atrophy
1383562|NCT00445159|UT-15C SR, Peripheral Vascular Disease, treprostinil
1383563|NCT00445146|Phase 2
1383564|NCT00445146|Open-label
1383565|NCT00445146|Rollover
1383566|NCT00445146|Integrase Inhibitor
1383567|NCT00445146|Antiretroviral Agents
1383568|NCT00445146|Highly Active Antiretroviral Activity
1383569|NCT00445146|HAART
1383570|NCT00445146|HIV, HIV-1, AIDS virus, Human Immunodeficiency Virus
1383571|NCT00445146|Acquired Immune Deficiency Syndrome Virus
1383572|NCT00445146|treatment experienced
1383573|NCT00445133|Neck Pain/Lumbar pain/Magnets/sleep deficiency/ insomnia/
1383574|NCT00445120|Vernal keratoconjunctivitis
1383575|NCT00445120|probiotic
1383576|NCT00445120|Lactobacillus Rhamnosus GG
1383577|NCT00445120|Children
1383578|NCT00445120|Clinical trial
1383579|NCT00445081|atopic dermatitis
1383580|NCT00445081|prednisolone
1383581|NCT00445081|ciclosporine
1383582|NCT00445081|SCORAD
1383583|NCT00445081|DLQI
1383584|NCT00445081|QALY
1383585|NCT00445081|WLQ
1383586|NCT00445068|Multiple myeloma
1383587|NCT00445068|adults
1383588|NCT00445068|LBH589
1383589|NCT00445068|refractory
1383590|NCT00445055|Thyroidectomy
1383591|NCT00445055|Nausea
1383592|NCT00445055|Vomiting
1383593|NCT00445055|Droperidol
1383594|NCT00445042|Metastatic Renal Cell Carcinoma
1383595|NCT00445042|Metastatic RCC
1383596|NCT00445042|Kidney Cancer
1383597|NCT00445042|M3thodist
1383598|NCT00445029|Allergic contact dermatitis
1383599|NCT00445029|para-phenylenediamine
1383600|NCT00445029|effector cells
1383601|NCT00445029|regulatory cells
1383602|NCT00445029|pathophysiology
1383603|NCT00445016|peripheral regional anesthesia
1383604|NCT00445016|nerve damage
1383605|NCT00445016|adverse effects
1383606|NCT00445016|neurologic complication
1383607|NCT00445016|neuropathy
1383608|NCT00445003|Diabetic Retinopathy
1383609|NCT00445003|Diabetic Macular Edema
1383610|NCT00445003|Lucentis
1383611|NCT00445003|Ranibizumab
1383612|NCT00445003|Triamcinolone
1383613|NCT00445003|Panretinal Photocoagulation
1383614|NCT00445003|Combination Therapy
1383615|NCT00445003|pdr
1383616|NCT00444990|Lumbar pain
1383617|NCT00444990|magnets
1383618|NCT00444990|Reduce low back pain
1383619|NCT00444977|HIV positive persons
1383620|NCT00444977|Not received oral health care in the preceding 12 months.
1383621|NCT00444977|treatment naive
1383622|NCT00444977|treatment experienced
1383623|NCT00444951|N meningitidis
1383624|NCT00444912|AMD3100
1383625|NCT00444912|stem cell mobilization
1383626|NCT00444912|autologous transplant
1383627|NCT00444912|Non-Hodgkin Lymphoma
1383628|NCT00444912|Hodgkin Disease
1383629|NCT00444899|Intensive treatment
1383630|NCT00444899|dietician
1383631|NCT00444886|Thoracic Outlet Syndrome (TOS)
1383632|NCT00444886|Botulinum Toxin
1383633|NCT00444886|Botox
1383634|NCT00444886|Pain
1383635|NCT00444873|Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)
1383636|NCT00444847|AIDS
1383637|NCT00444847|HIV
1383638|NCT00444847|Hyperbaric Chamber
1383639|NCT00444847|treatment experienced
1383640|NCT00444821|AAA
1383641|NCT00444821|Aneurysm
1383642|NCT00444821|AneuRx
1383643|NCT00444821|Talent
1383644|NCT00444808|Rib fracture
1383645|NCT00444808|Pain
1383646|NCT00444808|intranasal calcitonin
1383647|NCT00444795|SUTENE
1383648|NCT00444795|post-marketing surveillance
1383649|NCT00444795|GIST
1383650|NCT00444795|RCC
1383651|NCT00444795|Korea
1383652|NCT00444782|Advanced Carcinoma, Hepatocellular
1383653|NCT00444769|analgesia
1383654|NCT00444769|post-operative pain
1383655|NCT00444769|GW842166
1383656|NCT00444769|non-cannabinoid agonist
1383657|NCT00444769|third molar tooth extraction
1383658|NCT00444756|local anesthesia
1383659|NCT00444756|analgesia
1383660|NCT00444756|peripheral IV
1383661|NCT00444756|Local anesthesia prior to peripheral IV insertion
1383662|NCT00444730|Prostate Cancer
1383663|NCT00444730|Prostatectomy
1383664|NCT00444730|Pelvic pain
1383665|NCT00444730|urgency
1383666|NCT00444730|incontinence
1383667|NCT00444730|frequency
1383668|NCT00444717|statin
1383669|NCT00444717|metabolic syndrome
1383670|NCT00444717|oxidative stress
1383671|NCT00444717|inflammation
1383672|NCT00444691|synovitis score
1383673|NCT00444691|sensitivity to change
1383674|NCT00444691|clinical examination
1383675|NCT00444691|ultra-sonography
1383676|NCT00444678|Previously untreated metastatic colorectal cancer
1383677|NCT00444678|Metastatic Colorectal Cancer
1383678|NCT00444678|combined therapy
1383679|NCT00444678|biologics therapy
1383680|NCT00444678|antibody
1383681|NCT00444678|chemotherapy
1383682|NCT00444678|EGFR
1383683|NCT00444665|Glaucoma
1383684|NCT00444652|Thromboprophylaxis
1383685|NCT00444652|Bariatric surgery
1383686|NCT00444652|prevention of venous thromboembolism in bariatric surgery
1383687|NCT00444626|nasolabial folds
1383688|NCT00444626|facial wrinkles
1383689|NCT00444613|Amyotrophic Lateral Sclerosis (ALS)
1383690|NCT00444613|motor neurons
1383691|NCT00444613|muscular atrophy
1383692|NCT00444613|Lou Gehrig's Disease
1383693|NCT00444600|Diabetic Retinopathy
1383694|NCT00444600|Diabetic Macular Edema
1383695|NCT00444600|Lucentis
1383696|NCT00444600|Ranibizumab
1383697|NCT00444600|Triamcinolone
1383698|NCT00444600|Laser photocoagulation
1383699|NCT00444600|Combination Therapy
1383700|NCT00444574|Attention Deficit Hyperactivity Disorder (ADHD)
1383701|NCT00444561|pramlintide
1383702|NCT00444561|Symlin
1383703|NCT00444561|Amylin
1383704|NCT00444548|Equipment
1383705|NCT00444548|Supplies
1383706|NCT00444535|VEGF
1383707|NCT00444535|Tyrosine kinase
1383708|NCT00444535|ErbB2
1383709|NCT00444535|Her2-neu
1383710|NCT00444535|metastatic breast cancer
1383711|NCT00444535|EGFR
1383712|NCT00444535|ErbB1
1383713|NCT00444535|bevacizumab
1383714|NCT00444535|lapatinib
1383715|NCT00444522|Panic attacks, Staccato® Alprazolam
1383716|NCT00444509|Asthmatic Patients
1383717|NCT00444470|tranexamic acid
1383718|NCT00444470|safety
1383719|NCT00444470|efficacy
1383720|NCT00444470|spine surgery
1383721|NCT00444470|spinal fusion and decompression
1383722|NCT00444470|adult
1383723|NCT00444470|perioperative
1383724|NCT00444470|blood loss
1383725|NCT00444470|bleeding
1383726|NCT00444470|blood transfusion
1383727|NCT00444457|Vaccine
1383728|NCT00444457|Infants
1383729|NCT00444457|Pneumococcal Conjugate Vaccines
1383730|NCT00444457|Vaccines, Pneumococcal
1383731|NCT00444444|Autoimmune pancreatitis, HLA, relapse, Sequence-based typing
1383732|NCT00444418|Drinking
1383733|NCT00444418|Alcohol problems
1383734|NCT00444418|Alcoholism
1383735|NCT00444418|Gay men
1383736|NCT00444418|Bisexual men
1383737|NCT00444418|Moderation-oriented treatment
1383738|NCT00444418|Controlled drinking
1383739|NCT00444418|Non-abstinence based treatment
1383740|NCT00444405|lumbar
1383741|NCT00444405|disc
1383742|NCT00444405|herniation
1383743|NCT00444405|discectomy
1383744|NCT00444405|fusion
1383745|NCT00444405|spine
1383746|NCT00444392|Obese
1383747|NCT00444392|type 2 Diabetes Mellitus
1383748|NCT00444392|Gastric Bypass Surgery
1383749|NCT00444392|Risk of CVD
1383750|NCT00444379|Kaposi's sarcoma
1383751|NCT00444379|KSHV
1383752|NCT00444379|AIDS
1383753|NCT00444379|HHV-8
1383754|NCT00444379|treatment naive
1383755|NCT00444327|single nucleotide polymorphism
1383756|NCT00444301|Heart failure
1383757|NCT00444301|Pain
1383758|NCT00444301|Symptoms
1383759|NCT00444301|Advanced heart failure
1383760|NCT00444301|Pain frequency, severity, location, treatments
1383761|NCT00444301|Shortness of breath, anxiety, depression, cognitive function
1383762|NCT00444301|Social support, other conditions and illnesses
1383763|NCT00444288|Cystic Ovaries
1383764|NCT00444288|Hyperandrogenism
1383765|NCT00444288|Anovulation
1383766|NCT00444288|Concordance Rates
1383767|NCT00444288|Baseline Heritability
1383768|NCT00444288|Polycystic Ovary Syndrome
1383769|NCT00444288|POS
1383770|NCT00444275|Gastroesophageal Reflux Disease
1383771|NCT00444275|Acid Reflux
1383772|NCT00444262|Hemodynamic optimisation
1383773|NCT00444262|Esophageal Doppler
1383774|NCT00444262|Hydroxy ethyl starch
1383775|NCT00444262|Hip fracture
1383776|NCT00444262|Outcome
1383777|NCT00444262|Elderly subjects (≥ 70 year old)
1383778|NCT00444262|General anesthesia
1383779|NCT00444249|age-related macular degeneration
1383780|NCT00444249|melatonin
1383781|NCT00444249|blue-light filter
1383782|NCT00444236|asthma
1383783|NCT00444236|GERD
1383784|NCT00444236|reflux
1383785|NCT00444236|exercise
1383786|NCT00444223|stage IIIA non-small cell lung cancer
1383787|NCT00444223|stage IIIB non-small cell lung cancer
1383788|NCT00444223|stage IV non-small cell lung cancer
1383789|NCT00444184|travoprost/timolol fixed combination
1383790|NCT00444171|critically ill
1383791|NCT00444171|insulin resistance
1383792|NCT00444171|intensive insulin therapy
1383793|NCT00444171|computer algorithm
1383794|NCT00444158|opioids
1383795|NCT00444158|chronic pain
1383796|NCT00444132|clopidogrel
1383797|NCT00444132|platelets
1383798|NCT00444132|acute coronary syndrome
1383799|NCT00444132|percutaneous coronary intervention
1383800|NCT00444119|adrenal insufficiency
1383801|NCT00444119|subjective health status
1383802|NCT00444119|quality of life
1383803|NCT00444119|adrenal crisis
1383804|NCT00444119|hormone replacement
1383805|NCT00444119|DHEA
1383806|NCT00444106|Malaria
1383807|NCT00444106|hearing
1383808|NCT00444106|co-artemether
1383809|NCT00444106|auditory
1383810|NCT00444106|Plasmodium falciparum
1383811|NCT00444106|marsh fever
1383812|NCT00444106|Plasmodium infections
1383813|NCT00444106|remittent fever
1383814|NCT00444106|paludism
1383815|NCT00444106|artemether
1383816|NCT00444106|artemisinins
1383817|NCT00444106|benflumetol
1383818|NCT00444106|lumefantrine
1383819|NCT00444093|radiation therapy
1383820|NCT00444093|diarrhea
1383821|NCT00444093|enteritis
1383822|NCT00444093|supportive therapy
1383823|NCT00444093|therapy associated diarrhea
1383824|NCT00444093|therapy associated enteritis
1383825|NCT00444093|radiation therapy of the small pelvis
1383826|NCT00444080|Ex-PRESS
1383827|NCT00444080|TRABECULECTOMY
1383828|NCT00444067|Prevention of CSF leak
1383829|NCT00444054|Diet
1383830|NCT00444054|Cancer
1383831|NCT00444054|Alternative
1383832|NCT00444054|Breast
1383833|NCT00444054|Colon
1383834|NCT00444054|Cervix
1383835|NCT00444054|Uterus
1383836|NCT00444054|Ovary
1383837|NCT00444054|Metastatic
1383838|NCT00444054|Nutrition
1383839|NCT00444054|Carbohydrate
1383840|NCT00444041|metastatic colorectal cancer
1383841|NCT00444041|surgery
1383842|NCT00444041|chemotherapy
1383843|NCT00444028|Schizophrenia, Staccato Loxapine
1383844|NCT00444015|Erlotinib
1383845|NCT00444015|Dasatinib
1383846|NCT00444015|Epidermal growth factor receptor (EGFR)
1383847|NCT00444015|Tyrosine kinase
1383848|NCT00444015|NSCLC
1383849|NCT00444015|Pharmacokinetics (PK)
1383850|NCT00444015|Lung
1383851|NCT00444002|Hepatitis C
1383852|NCT00444002|Steatosis
1383853|NCT00444002|Oxidative Stress
1383854|NCT00444002|Antioxidants
1383855|NCT00444002|Inflammation
1383856|NCT00444002|Fatty acids
1383857|NCT00443989|Perioperative Myocardial Infarction
1383858|NCT00443989|Stroke
1383859|NCT00443989|Cardiac Death
1383860|NCT00443989|Cardiac Arrest
1383861|NCT00443989|Troponin-T
1383862|NCT00443989|Non-Cardiac surgery
1383863|NCT00443989|Death
1383864|NCT00443976|unspecified adult solid tumor, protocol specific
1383865|NCT00443976|recurrent adult Burkitt lymphoma
1383866|NCT00443976|stage III adult Burkitt lymphoma
1383867|NCT00443976|stage IV adult Burkitt lymphoma
1383868|NCT00443976|recurrent grade 2 follicular lymphoma
1383869|NCT00443976|stage III grade 2 follicular lymphoma
1383870|NCT00443976|stage IV grade 2 follicular lymphoma
1383871|NCT00443976|recurrent grade 3 follicular lymphoma
1383872|NCT00443976|stage III grade 3 follicular lymphoma
1383873|NCT00443976|stage IV grade 3 follicular lymphoma
1383874|NCT00443976|recurrent mantle cell lymphoma
1383875|NCT00443976|stage III mantle cell lymphoma
1383876|NCT00443976|stage IV mantle cell lymphoma
1383877|NCT00443976|recurrent adult diffuse large cell lymphoma
1383878|NCT00443976|stage III adult diffuse large cell lymphoma
1383879|NCT00443976|stage IV adult diffuse large cell lymphoma
1383880|NCT00443976|recurrent adult diffuse mixed cell lymphoma
1383881|NCT00443976|stage III adult diffuse mixed cell lymphoma
1383882|NCT00443976|stage IV adult diffuse mixed cell lymphoma
1383883|NCT00443976|recurrent adult diffuse small cleaved cell lymphoma
1383884|NCT00443976|stage III adult diffuse small cleaved cell lymphoma
1383885|NCT00443976|stage IV adult diffuse small cleaved cell lymphoma
1383886|NCT00443976|recurrent adult immunoblastic large cell lymphoma
1383887|NCT00443976|stage III adult immunoblastic large cell lymphoma
1383888|NCT00443976|stage IV adult immunoblastic large cell lymphoma
1383889|NCT00443976|recurrent adult lymphoblastic lymphoma
1383890|NCT00443976|stage III adult lymphoblastic lymphoma
1383891|NCT00443976|stage IV adult lymphoblastic lymphoma
1383892|NCT00443976|recurrent grade 1 follicular lymphoma
1383893|NCT00443976|stage III grade 1 follicular lymphoma
1383894|NCT00443976|stage IV grade 1 follicular lymphoma
1383895|NCT00443976|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1383896|NCT00443976|nodal marginal zone B-cell lymphoma
1383897|NCT00443976|splenic marginal zone lymphoma
1383898|NCT00443976|recurrent marginal zone lymphoma
1383899|NCT00443976|stage III marginal zone lymphoma
1383900|NCT00443976|stage IV marginal zone lymphoma
1383901|NCT00443976|recurrent small lymphocytic lymphoma
1383902|NCT00443976|stage III small lymphocytic lymphoma
1383903|NCT00443976|stage IV small lymphocytic lymphoma
1383904|NCT00443976|recurrent adult grade III lymphomatoid granulomatosis
1383905|NCT00443976|adult grade III lymphomatoid granulomatosis
1383906|NCT00443976|Waldenstrom macroglobulinemia
1383907|NCT00443963|Dyspepsia in patients taking NSAIDs
1383908|NCT00443950|Arthritis
1383909|NCT00443950|Chinese
1383910|NCT00443937|Kidney Transplantation
1383911|NCT00443937|Renal Transplantation
1383912|NCT00443937|Mycophenolate
1383913|NCT00443937|Cyclosporine
1383914|NCT00443937|Everolimus
1383915|NCT00443924|Bilateral ocular hypertension or early primary open angle glaucoma
1383916|NCT00443911|age-related macular degeneration, rheopheresis, lutein
1383917|NCT00443898|Toenail fungus
1383918|NCT00443898|Onychomycosis
1383919|NCT00443898|Nail fungus
1384166|NCT00442858|GH therapy
1383920|NCT00443898|Toenail fungal infection
1383921|NCT00443898|Tinea unguium
1383922|NCT00443898|Dermatophytes
1383923|NCT00443898|Foot dermatoses
1383924|NCT00443885|meropenem
1383925|NCT00443885|imipenem
1383926|NCT00443885|gram negative organism
1383927|NCT00443872|Parkinson's disease
1383928|NCT00443872|Dopamine agonist adverse effects
1383929|NCT00443872|MAO-B inhibitor
1383930|NCT00443872|orally disintegrating selegiline
1383931|NCT00443872|Zelapar
1383932|NCT00443859|Persistent Pulmonary Hypertension
1383933|NCT00443859|N-terminal pro brain natriuretic peptide
1383934|NCT00443846|Prevention of Gastroenteritis due to rotavirus infection. And prevention of Invasive disease caused by Neisseria meningitidis serogroup C.
1383935|NCT00443833|Thyrotoxicosis
1383936|NCT00443833|genetic association study
1383937|NCT00443833|periodic paralysis
1383938|NCT00443833|whole genome scan
1383939|NCT00443820|Toenail fungus
1383940|NCT00443820|Onychomycosis
1383941|NCT00443820|Nail fungus
1383942|NCT00443820|Toenail fungal infection
1383943|NCT00443820|Tinea unguium
1383944|NCT00443820|Dermatophytes
1383945|NCT00443820|Foot dermatoses
1383946|NCT00443794|POLYCAP, Primary Prevention,CVD
1383947|NCT00443781|low back pain, degenerative disc disease
1383948|NCT00443768|Medication
1383949|NCT00443768|Diagnosis
1383950|NCT00443768|Community
1383951|NCT00443755|Inflammatory cytokine
1383952|NCT00443755|Cardiovascular Disease
1383953|NCT00443755|Thrombotic factors
1383954|NCT00443755|Dyslipidemia
1383955|NCT00443742|Depression
1383956|NCT00443742|Validation
1383957|NCT00443742|Adolescent
1383958|NCT00443742|Validation of three key questions and questionnaire
1383959|NCT00443729|treatment experienced
1383960|NCT00443703|treatment experienced
1383961|NCT00443690|heart failure
1383962|NCT00443690|diuretic
1383963|NCT00443690|renal impairment
1383964|NCT00443690|renal function
1383965|NCT00443664|Primary Open Angle Glaucoma
1383966|NCT00443651|Rituxan
1383967|NCT00443651|RA
1383968|NCT00443651|DMARD
1383969|NCT00443651|Active Rheumatoid Arthritis
1383970|NCT00443625|SK3530
1383971|NCT00443625|Food effect
1383972|NCT00443625|Pharmacokinetics
1383973|NCT00443599|Congenital Heart Defects
1383974|NCT00443599|Insulin
1383975|NCT00443599|Euglycemia
1383976|NCT00443599|Normoglycemia
1383977|NCT00443586|Nurse
1383978|NCT00443586|Home Visitation
1383979|NCT00443586|Welfare
1383980|NCT00443586|Social Behavior
1383981|NCT00443573|metastatic colorectal carcinoma (mCRC)
1383982|NCT00443573|colorectal carcinoma (CRC)
1383983|NCT00443573|tissue factor
1383984|NCT00443573|factor VIIa
1383985|NCT00443573|rNAPc2
1383986|NCT00443573|adenocarcinoma
1383987|NCT00443573|targeted therapy
1383988|NCT00443573|coagulation-dependent
1383989|NCT00443573|RECIST
1383990|NCT00443573|5-FU-based chemotherapy
1383991|NCT00443573|FOLFOX
1383992|NCT00443573|FOLFIRI
1383993|NCT00443573|leucovorin
1383994|NCT00443573|XELOX
1383995|NCT00443560|Labor
1383996|NCT00443560|Epidural Analgesia
1383997|NCT00443560|delivery
1383998|NCT00443560|vacuum extraction
1383999|NCT00443560|obstetrical Forceps
1384000|NCT00443547|Prospective
1384001|NCT00443547|Degenerative Disc Disease
1384002|NCT00443547|Cervical
1384003|NCT00443547|Translational Plate
1384004|NCT00443521|Diabetes Mellitus/ complications
1384005|NCT00443521|Diabetic Retinopathy
1384006|NCT00443521|Triamcinolone
1384007|NCT00443521|Laser coagulation
1384008|NCT00443521|Tomography, optical coherence
1384009|NCT00443508|everolimus
1384010|NCT00443508|renal transplant
1384011|NCT00443508|tacrolimus
1384012|NCT00443508|Certican
1384013|NCT00443508|CHRONIC ALLOGRAFT NEPHROPATHY
1384014|NCT00443508|Renal transplant patients
1384015|NCT00443482|Asthma
1384016|NCT00443482|adults
1384017|NCT00443482|B2 agonist
1384018|NCT00443482|formoterol
1384019|NCT00443469|magnetic stimulation
1384020|NCT00443469|neuropathic pain
1384021|NCT00443469|spinal
1384022|NCT00443469|lower limb
1384023|NCT00443469|clinical trial
1384024|NCT00443443|Rituximab
1384025|NCT00443443|RA
1384026|NCT00443443|Sunstone
1384027|NCT00443443|anti-TNF
1384028|NCT00443443|Rituxan
1384029|NCT00443430|Childhood Arthritis
1384030|NCT00443430|Juvenile Arthritis
1384031|NCT00443430|Juvenile Arthritis Treatment
1384411|NCT00441727|low-dose ASA
1384032|NCT00443430|Childhood Arthritis Drug Treatment
1384033|NCT00443430|Juvenile Arthritis Remission
1384034|NCT00443430|Inactive Disease in Juvenile Arthritis
1384035|NCT00443430|Childhood Polyarthritis
1384036|NCT00443430|Extended Oligoarthritis
1384037|NCT00443404|phantom
1384038|NCT00443404|amputation
1384039|NCT00443404|analgesia
1384040|NCT00443404|pain
1384041|NCT00443404|preemptive
1384042|NCT00443404|perioperative
1384043|NCT00443404|lower limb amputation
1384044|NCT00443404|intensity of phantom limb pain
1384045|NCT00443404|preemptive analgesia reduces phantom pain
1384046|NCT00443404|perioperative analgesia reduces phantom pain
1384047|NCT00443404|Severe Phantom Limb Pain (VAS>70 mm)
1384048|NCT00443404|resistant to medical treatment one week before amputation
1384049|NCT00443391|ADHD
1384050|NCT00443378|computer counseling
1384051|NCT00443378|HIV
1384052|NCT00443378|antiretroviral adherence
1384053|NCT00443378|sexual behavior
1384054|NCT00443378|prevention with positives
1384055|NCT00443378|HIV seronegativity
1384056|NCT00443339|Myelodysplastic syndromes with IPSS Low or Int-1
1384057|NCT00443339|Anemia
1384058|NCT00443326|Psoriasis
1384059|NCT00443326|PASI
1384060|NCT00443326|Skin Biopsy
1384061|NCT00443326|Human Monoclonal Antibody
1384062|NCT00443313|Cervical neoplasia
1384063|NCT00443313|Screening
1384064|NCT00443313|HPV
1384065|NCT00443313|Cervical Cancer Screening
1384066|NCT00443300|AML
1384067|NCT00443300|MDS
1384068|NCT00443300|Protected Environment
1384069|NCT00443287|Peripheral
1384070|NCT00443287|Artery
1384071|NCT00443287|Disease
1384072|NCT00443261|Head and Neck Cancer
1384073|NCT00443235|Older patients
1384074|NCT00443235|untreated patients
1384075|NCT00443222|infliximab
1384076|NCT00443222|polymyositis
1384077|NCT00443222|dermatomyositis
1384078|NCT00443222|inclusion body myositis
1384079|NCT00443196|Chemosensitivity
1384080|NCT00443196|Ovarian Cancer
1384081|NCT00443196|Chemotherapy
1384082|NCT00443196|Fallopian Adenocarcinoma
1384083|NCT00443196|Peritoneal Adenocarcinoma
1384084|NCT00443196|Patients with pathological diagnoses of ovarian, fallopian and primary peritoneal adenocarcinomas.
1384085|NCT00443196|Patients with de novo malignancies and no previous chemotherapy
1384086|NCT00443196|Patients with advanced refractory malignancies who received no more than 2 standard chemotherapy treatment protocols.
1384087|NCT00443170|repeat dose,
1384088|NCT00443170|GSK626616AC,
1384089|NCT00443170|pharmacokinetic,
1384090|NCT00443170|single dose,
1384091|NCT00443170|cytochrome P450,
1384092|NCT00443170|First time in human,
1384093|NCT00443170|healthy volunteers
1384094|NCT00443157|meningococcal B vaccine
1384095|NCT00443144|growth hormone receptor polymorphism
1384096|NCT00443144|pharmacogenomics
1384097|NCT00443144|growth promoting therapy
1384098|NCT00443131|Adjuvant
1384099|NCT00443131|Malaria
1384100|NCT00443131|Safety
1384101|NCT00443131|Immunogenicity
1384102|NCT00443118|Bag and mask
1384103|NCT00443118|Neopuff
1384104|NCT00443118|Resuscitation
1384105|NCT00443118|Newborn
1384106|NCT00443118|Intubation
1384107|NCT00443118|devices
1384108|NCT00443118|PEEP
1384109|NCT00443092|osteoarthritis
1384110|NCT00443092|gout
1384111|NCT00443092|pain
1384112|NCT00443092|uric acid
1384113|NCT00443092|tart cherry
1384114|NCT00443092|alternative medicine
1384115|NCT00443092|knees
1384116|NCT00443079|Clinical Trials
1384117|NCT00443079|Pilot Projects
1384118|NCT00443079|Milk Thistle
1384119|NCT00443079|Liver Function Tests
1384120|NCT00443066|pediatric
1384121|NCT00443066|neuromuscular disease
1384122|NCT00443053|superficial vein thrombosis
1384123|NCT00443053|superficial thrombophlebitis
1384124|NCT00443053|fondaparinux
1384125|NCT00443053|deep vein thrombosis
1384126|NCT00443053|venous thromboembolism treatment
1384127|NCT00443053|thrombosis
1384128|NCT00443014|Stimulation therapy
1384129|NCT00443014|Acetylcholinesterase inhibitors
1384130|NCT00443014|Synergetic
1384131|NCT00443001|Non-Invasive Blood Pressure
1384132|NCT00443001|Sinus Rhythm
1384133|NCT00443001|Oscillometric
1384134|NCT00443001|Invasive Blood Pressure
1384135|NCT00443001|AAMI/ANSI SP10 Standard
1384136|NCT00443001|Compliance with ANSI/AAMI SP10 2002 standard
1384137|NCT00442988|NODAT
1384138|NCT00442988|OGTT
1384139|NCT00442988|FPG
1384140|NCT00442988|Renal Transplanation
1384141|NCT00442988|Risk Factors
1384142|NCT00442988|Predictive value
1384143|NCT00442975|Influenza Vaccine
1384144|NCT00442975|CMV
1384145|NCT00442949|Acute coronary syndrome
1384146|NCT00442949|Angioplasty
1384147|NCT00442949|Abciximab
1384148|NCT00442949|Troponin release
1384149|NCT00442923|Methamphetamine
1384150|NCT00442923|Coreg
1384151|NCT00442923|Withdrawal
1384152|NCT00442923|anxiety
1384153|NCT00442923|Substance Addiction
1384154|NCT00442910|Safety and Acceptability
1384155|NCT00442897|Hypercholesterolaemia
1384156|NCT00442884|glucose control in acute stress
1384157|NCT00442871|Renal Impairment,
1384158|NCT00442871|chronic immune thrombocytopenia purpura,
1384159|NCT00442871|thrombocytopenia,
1384160|NCT00442871|chemotherapy induced thrombocytopenia
1384161|NCT00442858|cardiac disease
1384162|NCT00442858|cerebrovascular disease
1384163|NCT00442858|GH deficiency
1384164|NCT00442858|diabetes mellitus
1384165|NCT00442858|hypertension
1384167|NCT00442858|GH deficiency and hypopituitarims
1384168|NCT00442832|cSSSI
1384169|NCT00442832|Staph
1384170|NCT00442832|MRSA
1384171|NCT00442819|Uremic Pruritus
1384172|NCT00442819|Cytokines
1384173|NCT00442819|Polymethylmethacrylate Artificial Kidney
1384174|NCT00442819|Hemodialysis
1384175|NCT00442806|ADRC
1384176|NCT00442806|Stem Cells
1384177|NCT00442806|Myocardial Infarction
1384178|NCT00442806|STEMI
1384179|NCT00442806|Heart Disease
1384180|NCT00442806|Coronary Artery Disease
1384181|NCT00442806|Coronary Disease
1384182|NCT00442806|ST-Elevation
1384183|NCT00442806|AMI
1384184|NCT00442806|Interventional Cardiology
1384185|NCT00442806|Heart Attack
1384186|NCT00442780|early Parkinson's Disease
1384187|NCT00442780|MOBILE
1384188|NCT00442780|BIIB014
1384189|NCT00442767|pediatric
1384190|NCT00442767|juvenile
1384191|NCT00442767|diabetes mellitus
1384192|NCT00442767|Pediatric type 1 diabetes mellitus
1384193|NCT00442754|dendritic cell
1384194|NCT00442754|tumor vaccine
1384195|NCT00442754|NSCLC
1384196|NCT00442741|Cancer
1384197|NCT00442741|EPO906
1384198|NCT00442741|Patupilone
1384199|NCT00442728|Functional electrical stimulation
1384200|NCT00442728|muscular atrophy
1384201|NCT00442728|intensive care
1384202|NCT00442715|Exercise-induced asthma,
1384203|NCT00442715|early childhood;
1384204|NCT00442715|spirometry,
1384205|NCT00442715|exercise challenge
1384206|NCT00442715|Data from preschool children who were referred to the Pediatric
1384207|NCT00442715|Pulmonary Clinic over a 1-year period were recruited
1384208|NCT00442689|Polycystic Ovary Syndrome
1384209|NCT00442689|Metabolic Syndrome
1384210|NCT00442689|PCOS
1384211|NCT00442689|overweight
1384212|NCT00442689|infertility
1384213|NCT00442689|Insulin Resistance
1384214|NCT00442689|menstrual cycle
1384215|NCT00442663|Labor Induction
1384216|NCT00442663|Cervical Ripening
1384217|NCT00442663|Foley Catheter
1384218|NCT00442637|CAIRO3
1384219|NCT00442637|DCCG
1384220|NCT00442637|colorectal cancer
1384221|NCT00442637|induction
1384222|NCT00442637|metronomic chemotherapy
1384223|NCT00442637|observation
1384224|NCT00442637|capecitabine
1384225|NCT00442637|bevacizumab
1384226|NCT00442637|oxaliplatin
1384227|NCT00442624|insomnia
1384228|NCT00442624|glucose metabolism
1384229|NCT00442624|insulin resistance
1384230|NCT00442598|Ovarian
1384231|NCT00442598|Cancer
1384232|NCT00442598|CA-125
1384233|NCT00442598|Third-line
1384234|NCT00442598|Glufosfamide
1384235|NCT00442546|opioid
1384236|NCT00442533|Carcinoid
1384237|NCT00442533|Islet Cell Cancer
1384238|NCT00442533|Paraganglioma
1384239|NCT00442533|Pheochromocytoma
1384240|NCT00442507|Esophagus
1384241|NCT00442507|Esophagogastric Junction
1384242|NCT00442507|Avastin
1384243|NCT00442507|Bevacizumab
1384244|NCT00442507|Erlotinib
1384245|NCT00442494|Atrial fibrillation after cardiac surgery
1384246|NCT00442481|MDD
1384247|NCT00442481|Escitalopram
1384248|NCT00442481|Cipralex
1384249|NCT00442481|Sleep
1384250|NCT00442481|REM
1384251|NCT00442481|SWS
1384252|NCT00442481|Polysomnography
1384253|NCT00442468|Chronic Obstructive Pulmonary Disease (COPD)
1384254|NCT00442468|Chronic Bronchitis
1384255|NCT00442468|Spirometry
1384256|NCT00442455|Head Neck Carcinoma Erlotinib
1384257|NCT00442442|Malaria
1384258|NCT00442442|mosquito control
1384259|NCT00442442|mosquito coils
1384260|NCT00442442|LLIN
1384261|NCT00442429|depression; dialysis; kidney failure, chronic
1384262|NCT00442403|Malaria
1384263|NCT00442403|Plasmodium falciparum
1384264|NCT00442403|Chemotherapy
1384265|NCT00442403|Chloroquine
1384266|NCT00442403|Dehydroepiandrosterone sulphate
1384267|NCT00442390|Cortisol
1384268|NCT00442390|adrenal insufficiency
1384269|NCT00442390|glucose metabolism
1384270|NCT00442390|protein metabolism
1384271|NCT00442390|lipid metabolism
1384272|NCT00442390|insulin sensitivity.
1384273|NCT00442377|Falciparum
1384274|NCT00442377|Plasmodium
1384275|NCT00442377|Malaria
1384276|NCT00442364|PFO
1384277|NCT00442364|Patent Foramen Ovale
1384278|NCT00442364|Right-to-Left Shunt
1384279|NCT00442364|Sclerotherapy
1384280|NCT00442312|Combigan
1384412|NCT00441714|cardiovascular disease
1384281|NCT00442299|hemodialysis, urmeic retention solute, biocompatibility
1384282|NCT00442286|Hypertension
1384283|NCT00442286|High Blood Pressure
1384284|NCT00442286|Blood Pressure
1384285|NCT00442286|Cardiovascular Disease
1384286|NCT00442286|Resistant Hypertension
1384287|NCT00442286|Stage 2 Hypertension
1384288|NCT00442286|Hypertension that is resistant to treatment
1384289|NCT00442260|breast cancer
1384290|NCT00442260|advanced breast cancer
1384291|NCT00442247|anterior vaginal wall prolapse, Pelvicol, biomesh
1384292|NCT00442247|Anterior vaginal wall prolapse
1384293|NCT00442234|Acute
1384294|NCT00442234|pulmonary
1384295|NCT00442234|embolism
1384296|NCT00442234|accompanying
1384297|NCT00442234|hemodynamic
1384298|NCT00442234|instability
1384299|NCT00442221|Migrane headaches
1384300|NCT00442208|Healthy adults
1384301|NCT00442208|Phase I
1384302|NCT00442195|Tissue Procurement
1384303|NCT00442195|Sample Collection
1384304|NCT00442195|Biologic Samples
1384305|NCT00442195|Laboratory Research
1384306|NCT00442195|Healthy Volunteer
1384307|NCT00442195|HV
1384308|NCT00442182|autoinflammatory syndromes
1384309|NCT00442169|West Nile Disease
1384310|NCT00442169|Antibody response
1384311|NCT00442169|Viremia
1384312|NCT00442169|Safety
1384313|NCT00442169|Tolerability
1384314|NCT00442169|Prevention
1384315|NCT00442156|Laser photocoagulation
1384316|NCT00442143|CLI
1384317|NCT00442143|PAOD
1384318|NCT00442143|Severe lower limb ischemia
1384319|NCT00442130|GM-CSF
1384320|NCT00442130|GM-K562
1384321|NCT00442130|vaccine
1384322|NCT00442104|infantile spasms
1384323|NCT00442104|anticonvulsant
1384324|NCT00442104|pediatric epilepsy
1384325|NCT00442104|West Syndrome
1384326|NCT00442104|epileptic spasms
1384327|NCT00442091|Dandelion
1384328|NCT00442091|herbal remedy
1384329|NCT00442091|hand eczema
1384330|NCT00442091|Compositae
1384331|NCT00442078|Incontinence
1384332|NCT00442078|Urinary
1384333|NCT00442078|Male
1384334|NCT00442078|Tape
1384335|NCT00442078|Transobturator
1384336|NCT00442065|Abdominal aortic aneurysm study
1384337|NCT00442052|Gastroprotective effects
1384338|NCT00442052|Aspirin
1384339|NCT00442039|Mania, Lithium, Bipolar, BPCA, pediatrics
1384340|NCT00442026|Cancer
1384341|NCT00442026|NSCLC
1384342|NCT00442026|Elderly
1384343|NCT00442026|Chemotherapy
1384344|NCT00442026|Docetaxel
1384345|NCT00442026|Gemcitabine
1384346|NCT00442000|Prostate Cancer
1384347|NCT00442000|Prostatectomy
1384348|NCT00441987|Japanese
1384349|NCT00441987|Healthy
1384350|NCT00441987|Alzheimers Disease
1384351|NCT00441974|adefovir dipivoxil
1384352|NCT00441974|compensated
1384353|NCT00441974|chronic hepatitis B
1384354|NCT00441974|Chinese
1384355|NCT00441961|Eosinophilic fasciitis, Shulman's syndrome, methotrexate
1384356|NCT00441948|Hirsutism
1384357|NCT00441948|Hypertrichosis
1384358|NCT00441935|Urinary Retention
1384359|NCT00441935|Urinary Incontinence
1384360|NCT00441935|Pelvic Pain
1384361|NCT00441922|Cancer
1384362|NCT00441922|Elderly
1384363|NCT00441922|Chemotherapy
1384364|NCT00441922|Docetaxel
1384365|NCT00441922|Vinorelbine
1384366|NCT00441909|Anti-Infective Agents, Local
1384367|NCT00441909|Healthy Women
1384368|NCT00441909|Microbicides
1384369|NCT00441909|UC-781
1384370|NCT00441909|Vaginal Gel
1384371|NCT00441909|HIV Seronegativity
1384372|NCT00441896|infantile spasms
1384373|NCT00441896|anticonvulsant
1384374|NCT00441896|pediatric epilepsy
1384375|NCT00441896|West Syndrome
1384376|NCT00441896|epileptic spasms
1384377|NCT00441870|Cancer
1384378|NCT00441870|Phase 1
1384379|NCT00441870|EC0225
1384380|NCT00441870|EC20
1384381|NCT00441870|Refractory
1384382|NCT00441870|Metastatic
1384383|NCT00441870|Experimental
1384384|NCT00441857|plant sterols
1384385|NCT00441857|plant stanols
1384386|NCT00441857|cholesterol absorption
1384387|NCT00441844|diabetes, statin, monocyte, crp, inflammation
1384388|NCT00441831|Helicobacter pylori infection
1384389|NCT00441831|peptic ulcer disease
1384390|NCT00441831|distal partial gastrectomy
1384391|NCT00441831|bile reflux
1384392|NCT00441831|gastritis
1384393|NCT00441831|gastrectomy
1384394|NCT00441805|Acne
1384395|NCT00441805|RadioFrequency
1384396|NCT00441792|Sepsis
1384397|NCT00441792|Etomidate
1384398|NCT00441792|midazolam
1384399|NCT00441792|ketamine
1384400|NCT00441779|Microchimerism
1384401|NCT00441779|Injuries
1384402|NCT00441779|Burns
1384403|NCT00441779|Orthopedic Surgery
1384404|NCT00441779|Leukocytes
1384405|NCT00441740|NSCLC
1384406|NCT00441740|1st line treatment
1384407|NCT00441740|Gemcitabine
1384408|NCT00441740|Vinorelbine
1384409|NCT00441740|Docetaxel
1384410|NCT00441727|Peptic ulcer
1384413|NCT00441714|ischemia-reperfusion injury
1384414|NCT00441714|postconditioning
1384415|NCT00441714|annexin targeting
1384416|NCT00441688|HLAgenetics polymorphism
1384417|NCT00441688|Human Immunodeficiency virus
1384418|NCT00441675|Adolescents
1384419|NCT00441675|Asthma
1384420|NCT00441675|long-term follow-up
1384421|NCT00441675|symptoms
1384422|NCT00441675|bronchial hyperresponsiveness
1384423|NCT00441662|Melanoma
1384424|NCT00441662|Uvea
1384425|NCT00441662|Macula
1384426|NCT00441662|Edema
1384427|NCT00441662|Plaque radiotherapy
1384428|NCT00441662|Brachytherapy
1384429|NCT00441662|Triamcinolone
1384430|NCT00441649|ADHD
1384431|NCT00441636|depression
1384432|NCT00441636|CPAP
1384433|NCT00441636|obstructive sleep apnea
1384434|NCT00441623|chronic kidney disease
1384435|NCT00441623|cardiovascular disease
1384436|NCT00441623|risk stratification
1384437|NCT00441610|Gimatecan
1384438|NCT00441610|topoisomerase I inhibitor
1384439|NCT00441610|advanced solid tumors
1384440|NCT00441597|ischemia reperfusion injury
1384441|NCT00441597|atorvastatine
1384442|NCT00441597|preconditioning
1384443|NCT00441597|cardiovascular disease
1384444|NCT00441571|prostate cancer
1384445|NCT00441571|radiolabeled antibody
1384446|NCT00441532|prostate
1384447|NCT00441519|Gastroprotective effects
1384448|NCT00441519|Aspirin
1384449|NCT00441506|interruption
1384450|NCT00441506|critically ill
1384451|NCT00441506|sedation
1384452|NCT00441506|pediatrics
1384453|NCT00441506|critically ill, ventilated children
1384454|NCT00441493|Hepatitis C
1384455|NCT00441493|fluvastatin
1384456|NCT00441480|Hypercholesterolemia
1384457|NCT00441480|Hypertriglyceridemia
1384458|NCT00441480|Plant sterol
1384459|NCT00441480|Cholesterol
1384460|NCT00441480|Fish oil
1384461|NCT00441454|stress urinary incontinence
1384462|NCT00441454|surgery
1384463|NCT00441454|tension-free vaginal tape
1384464|NCT00441454|retropubic
1384465|NCT00441454|transobturator
1384466|NCT00441454|quality-of-life
1384467|NCT00441441|asthma
1384468|NCT00441441|fluticasone propionate
1384469|NCT00441441|children
1384470|NCT00441441|fluticasone propionate/salmeterol
1384471|NCT00441389|Bacteria
1384472|NCT00441389|Viruses
1384473|NCT00441389|COPD
1384474|NCT00441389|infectious etiology for acute exacerbation of COPD
1384475|NCT00441376|Radiofrequency ablation
1384476|NCT00441376|RFA
1384477|NCT00441376|Doxorubicin
1384478|NCT00441376|Liposome
1384479|NCT00441376|HCC
1384480|NCT00441376|MLC
1384481|NCT00441376|hepatocellular carcinoma
1384482|NCT00441376|liver tumor
1384483|NCT00441376|tumor
1384484|NCT00441376|ablation
1384485|NCT00441376|heat therapy
1384486|NCT00441376|anti-tumor
1384487|NCT00441376|liver cancer
1384488|NCT00441376|metastatic liver cancer (MLC)
1384489|NCT00441363|diabetes
1384490|NCT00441363|diabetes mellitus
1384491|NCT00441337|malignancies
1384492|NCT00441337|cancer
1384493|NCT00441337|non small cell lung cancer
1384494|NCT00441337|lung cancer
1384495|NCT00441337|colorectal cancer
1384496|NCT00441337|adenocarcinoma
1384497|NCT00441337|melanoma
1384498|NCT00441337|malignant melanoma
1384499|NCT00441337|renal cancer
1384500|NCT00441337|renal carcinoma
1384501|NCT00441337|carcinoma
1384502|NCT00441337|prostate cancer
1384503|NCT00441337|prostate adenocarcinoma
1384504|NCT00441337|Recurrent or treatment refractory malignancies
1384505|NCT00441324|Ovarian follicle
1384506|NCT00441324|Thecal cells
1384507|NCT00441324|Androgens
1384508|NCT00441324|FSH sensitivity
1384509|NCT00441311|colorectal cancer screening
1384510|NCT00441311|primary care physicians
1384511|NCT00441311|health disparities
1384512|NCT00441311|stratified randomized clinical trial
1384513|NCT00441298|microbicides
1384514|NCT00441298|safety
1384515|NCT00441298|effectiveness
1384516|NCT00441298|Tenofovir gel
1384517|NCT00441298|HIV
1384518|NCT00441298|young women
1384519|NCT00441298|HIV Seronegativity
1384520|NCT00441285|neurocysticercosis
1384521|NCT00441285|NCC
1384522|NCT00441285|praziquantel
1384523|NCT00441285|PZQ
1384524|NCT00441285|albendazole
1384525|NCT00441285|ABZ
1384526|NCT00441285|parasite
1384527|NCT00441285|pig tapeworm
1384528|NCT00441285|Taenia solium
1384529|NCT00441285|epilepsy
1384530|NCT00441285|late-onset epilepsy
1384531|NCT00441285|acquired epilepsy
1384532|NCT00441272|Pioglitazone
1384533|NCT00441272|Hepatic Steatosis
1384534|NCT00441272|Liver Toxicity
1384535|NCT00441272|Liver Biopsy
1384536|NCT00441272|HIV
1384537|NCT00441272|Treatment Experienced
1384538|NCT00441272|Treatment Naive
1384539|NCT00441259|Japanese Encephalitis
1384540|NCT00441246|Acute Respiratory Infection
1384541|NCT00441246|Bronchitis
1384542|NCT00441246|Rhinosinusitis
1384543|NCT00441220|Genetic polymorphisms
1384544|NCT00441220|Cyclophosphamide
1384545|NCT00441220|Cytochrome p450 CYP2C19 (Human)
1384546|NCT00441220|Systemic Lupus Erythematosus
1384547|NCT00441207|IV Ascorbic Acid
1384548|NCT00441207|IV Vitamin C
1384549|NCT00441207|Cancer
1384550|NCT00441207|Advanced Solid Tumors
1384551|NCT00441194|Perimetry
1384552|NCT00441194|Visual Field
1384553|NCT00441194|Octopus
1384554|NCT00441181|Neovascular glaucoma
1384555|NCT00441181|Travoprost
1384556|NCT00441168|Multiple Myeloma
1384557|NCT00441168|bortezomib
1384558|NCT00441168|Cancer
1384559|NCT00441168|Hematology
1384560|NCT00441168|bone marrow
1384561|NCT00441168|immunoglobulin
1384562|NCT00441168|relapse
1384563|NCT00441168|refractory
1384564|NCT00441168|plasma cell
1384565|NCT00441168|Velcade
1384566|NCT00441168|adriamycin
1384567|NCT00441168|dexamethasone
1384568|NCT00441168|vincristine
1384569|NCT00441155|Oncology
1384570|NCT00441155|Cancer
1384571|NCT00441155|Imatinib-Resistant Gastrointestinal Stromal Tumors
1384572|NCT00441155|GIST
1384573|NCT00441155|Nilotinib
1384574|NCT00441155|Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST)
1384575|NCT00441142|Newly diagnosed malignant brain tumors.
1384576|NCT00441129|Improvement of the blood glucose control
1384577|NCT00441116|dutasteride
1384578|NCT00441116|Androgenic alopecia
1384579|NCT00441116|phase 3
1384580|NCT00441103|Subjects with relapsing remitting multiple sclerosis
1384581|NCT00441090|Chronic Idiopathic Thrombocytopenic Purpura
1384582|NCT00441090|Idiopathic Thrombocytopenic Purpura
1384583|NCT00441090|ITP
1384584|NCT00441077|Genetics
1384585|NCT00441077|Family History
1384586|NCT00441077|Latino
1384587|NCT00441077|Information Seeking
1384588|NCT00441077|Lay Health Advisors
1384589|NCT00441077|Cancer
1384590|NCT00441077|Heart Disease
1384591|NCT00441077|Diabetes
1384592|NCT00441077|Information
1384593|NCT00441064|High blood pressure, hypertension, aliskiren, low sodium diet
1384594|NCT00441051|Sunburn, diclofenac, topical NSAID
1384595|NCT00441038|Low back pain
1384596|NCT00441038|disability
1384597|NCT00441038|health education
1384598|NCT00441025|MabCampath + CHOP in PTCL
1384599|NCT00441012|Haemophilus Influenza, type b and Hepatitis B
1384600|NCT00440999|P vivax
1384601|NCT00440999|malaria
1384602|NCT00440999|ACT
1384603|NCT00440986|Clinical Management
1384604|NCT00440986|Phlebotomy
1384605|NCT00440986|Eritrocytoapheresis
1384606|NCT00440973|kidney cancer
1384607|NCT00440973|M3thodist
1384608|NCT00440960|alfentanil
1384609|NCT00440960|anesthesia
1384610|NCT00440960|bronchoscopy
1384611|NCT00440960|lidocaine
1384612|NCT00440960|midazolam
1384613|NCT00440960|propofol.
1384614|NCT00440947|NORVIR
1384615|NCT00440947|ARIES
1384616|NCT00440947|EPZICOM
1384617|NCT00440947|REYATAZ
1384618|NCT00440947|HIV
1384619|NCT00440947|simplification
1384620|NCT00440947|Antiretroviral-naive
1384621|NCT00440934|carcinoma, hepatocellular
1384622|NCT00440934|electromagnetic fields
1384623|NCT00440921|fibrin sealnat
1384624|NCT00440921|knee replacement
1384625|NCT00440921|hip replacement
1384626|NCT00440921|woud healing
1384627|NCT00440921|blood loss
1384628|NCT00440921|clinical trial
1384629|NCT00440921|randomized
1384630|NCT00440908|Dialyzer reuse
1384631|NCT00440908|Inflammatory markers
1384632|NCT00440908|Nutritional status
1384633|NCT00440895|Coronary artery stenting
1384634|NCT00440895|Trans-radial
1384635|NCT00440895|Intracoronary
1384636|NCT00440895|Rescue-PCI
1384637|NCT00440869|N-acetylcysteine
1384638|NCT00440869|oxidative stress
1384639|NCT00440869|muscle fatigue
1384640|NCT00440869|end-stage renal disease
1384641|NCT00440869|hemodialysis
1384642|NCT00440856|Intervertebral disc
1384643|NCT00440856|Lumbar discectomy
1384644|NCT00440856|Outcome
1384645|NCT00440856|Radiculopathy due to prolapsed intervertebral disc.
1384646|NCT00440843|schizophrenia
1384647|NCT00440843|attention
1384648|NCT00440843|task engagement
1384649|NCT00440843|antipsychotics
1384650|NCT00440843|cognition
1384651|NCT00440843|cognitive rehabilitation
1384652|NCT00440830|acute pain
1384653|NCT00440830|nicotine
1384654|NCT00440830|nausea
1384655|NCT00440830|sedation
1384656|NCT00440817|Lymphoma
1384657|NCT00440817|Rheumatoid arthritis
1384658|NCT00440817|Crohn's disease
1384659|NCT00440817|Remicade
1384660|NCT00440817|Infliximab
1384661|NCT00440804|patent ductus arterious
1384662|NCT00440791|Colon
1384663|NCT00440791|colonic disease
1384664|NCT00440791|capsule endoscopy
1384665|NCT00440791|Suspected or known colonic disease
1384666|NCT00440778|Coronary artery stenting
1384667|NCT00440778|Trans-radial
1384668|NCT00440778|Intracoronary
1384669|NCT00440765|Multiple Myeloma
1384670|NCT00440765|hematological Neoplasms
1384671|NCT00440765|chemotherapy
1384672|NCT00440765|efficacy
1384673|NCT00440765|safety
1384674|NCT00440765|bortezomib
1384675|NCT00440765|proteasome inhibitor
1384676|NCT00440752|Artemether-lumefantrine
1384677|NCT00440752|Plasmodium falciparum
1384678|NCT00440752|drug resistance genes
1384679|NCT00440739|postoperative pain, etoticoxib, etoricoxib
1384680|NCT00440739|Pain relief after transurethral resection of prostate.
1384681|NCT00440726|Acute Lymphoblastic Leukemia
1384682|NCT00440726|Pediatrics
1384683|NCT00440726|Relapsed
1384684|NCT00440726|Recurrence
1384685|NCT00440726|Bortezomib
1384686|NCT00440726|Velcade
1384687|NCT00440726|Therapeutic Advances in Childhood Leukemia
1384688|NCT00440726|Investigational
1384689|NCT00440726|Childhood
1384690|NCT00440726|ALL
1384691|NCT00440726|Relapsed ALL
1384692|NCT00440726|Refractory ALL
1384693|NCT00440726|Relapsed pediatric ALL
1384694|NCT00440726|Refractory pediatric ALL
1384695|NCT00440726|TACL
1384696|NCT00440726|Recurrent Pediatric ALL
1384697|NCT00440713|Posttraumatic Stress Disorder
1384698|NCT00440713|Depression
1384699|NCT00440713|Anxiety
1384700|NCT00440713|Efficacy
1384701|NCT00440700|Ventilator
1384702|NCT00440700|chronic obstructive pulmonary disease
1384703|NCT00440700|Anxiety
1384704|NCT00440687|chronic obstructive pulmonary disease
1384705|NCT00440687|primary care
1384706|NCT00440687|randomised trials
1384707|NCT00440687|therapeutic interventions
1384708|NCT00440674|Direct Stenting
1384709|NCT00440674|Angioplasty
1384710|NCT00440674|Pre-dilatation
1384711|NCT00440674|Drug-eluting stent
1384712|NCT00440661|Osteoarthritis, IL-1
1384713|NCT00440635|Multiple myeloma
1384714|NCT00440635|bortezomib, Hematology
1384715|NCT00440622|Cancer
1384716|NCT00440622|Metastatic Breast cancer
1384717|NCT00440622|Her-2 expression
1384718|NCT00440622|Gemcitabine
1384719|NCT00440622|Capecitabine
1384720|NCT00440622|Herceptin
1384721|NCT00440583|CHOP-Z
1384722|NCT00440570|cancer
1384723|NCT00440570|electromagnetic fields
1384724|NCT00440570|treatment
1384725|NCT00440557|Anemia
1384726|NCT00440557|Chronic Kidney disease
1384727|NCT00440557|Kidney disease
1384728|NCT00440557|Epoetin alfa
1384729|NCT00440557|Procrit
1384730|NCT00440544|Tuberculosis
1384731|NCT00440544|vaccine
1384732|NCT00440544|nasal immunization
1384733|NCT00440518|Lacosamide
1384734|NCT00440518|migraine prophylaxis
1384735|NCT00440518|Vimpat
1384736|NCT00440505|chronic pain
1384737|NCT00440505|pelvic pain
1384738|NCT00440505|nicotine patch
1384739|NCT00440479|Multiple Myeloma
1384740|NCT00440479|hematological neoplasms
1384741|NCT00440479|chemotherapy
1384742|NCT00440479|efficacy
1384743|NCT00440479|safety
1384744|NCT00440479|bortezomib
1384745|NCT00440479|proteasome inhibitor
1384746|NCT00440466|Anemia
1384747|NCT00440466|Reduction in the number of erythrocytes
1384748|NCT00440466|Hemoglobin low level
1384749|NCT00440466|Red blood cell deficiency
1384750|NCT00440466|Procrit
1384751|NCT00440466|Epoetin alfa
1384752|NCT00440466|Chronic kidney disease
1384753|NCT00440453|Internal medicine patients
1384754|NCT00440440|hypogonadism
1384755|NCT00440440|diabetes
1384756|NCT00440440|visceral fat
1384757|NCT00440440|hepatic fat
1384758|NCT00440440|lean mass
1384759|NCT00440427|Major Depressive Disorder
1384760|NCT00440427|MDD
1384761|NCT00440414|Cancer
1384762|NCT00440414|Non-small-cell lung cancer
1384763|NCT00440414|Chemotherapy
1384764|NCT00440414|Pemetrexed
1384765|NCT00440414|Erlotinib
1384766|NCT00440401|Surgical treatment of haemorrhage
1384767|NCT00440388|cancer
1384768|NCT00440388|lymphoma
1384769|NCT00440388|Non-Hodgkin's
1384770|NCT00440388|Non-Hodgkins
1384771|NCT00440388|AT-101
1384772|NCT00440388|AT101
1384773|NCT00440388|Rituxan
1384774|NCT00440388|Rituximab
1384775|NCT00440362|Influenza
1384776|NCT00440362|Flu
1384777|NCT00440362|A/Wyoming/03/2003
1384778|NCT00440362|Alphavirus
1384779|NCT00440349|Retroperitoneal fibrosis
1384780|NCT00440349|Tamoxifen
1384781|NCT00440349|Corticosteroids
1384782|NCT00440349|Obstructive uropathy
1384783|NCT00440349|Periaortic fibrosis
1384784|NCT00440349|Chronic periaortitis
1384785|NCT00440336|IOP
1384786|NCT00440336|SLT
1384787|NCT00440336|Laser
1384788|NCT00440336|Cosopt
1384789|NCT00440323|Noise induced Situational insomnia,
1384790|NCT00440323|healthy volunteers
1384791|NCT00440323|SB-649868,
1384792|NCT00440323|Zolpidem,
1384793|NCT00440310|Liver neoplasms
1384794|NCT00440310|Liver metastases
1384795|NCT00440310|MCRC
1384796|NCT00440310|Litx™
1384797|NCT00440310|LS11
1384798|NCT00440310|Colorectal cancer with recurrent liver metastases
1384799|NCT00440297|hepatitis B virus
1384800|NCT00440284|conventional insulin therapy
1384801|NCT00440284|intensive insulin therapy
1384802|NCT00440284|self-management
1384803|NCT00440284|patient education
1384804|NCT00440284|RCT
1384805|NCT00440284|glycosylated hemoglobin
1384806|NCT00440284|hypoglycemia
1384807|NCT00440284|patient preference
1384937|NCT00439803|CMV
1384808|NCT00440258|Ovarian hyperstimulation syndrome, dopamine agonists, cabergoline, hemoconcentration, ascites, ovarian perfusion, dopamine receptor 2
1384809|NCT00440219|Nasal polyps
1384810|NCT00440219|Steroids
1384811|NCT00440219|Prednisone
1384812|NCT00440219|Nasal polypectomy
1384813|NCT00440219|Blood loss, surgical
1384814|NCT00440206|HIV
1384815|NCT00440206|Immune Markers
1384816|NCT00440180|Obesity
1384817|NCT00440180|Low sperm count
1384818|NCT00440180|Male infertility
1384819|NCT00440167|capecitabine
1384820|NCT00440167|gemcitabine
1384821|NCT00440167|Erlotinib
1384822|NCT00440167|pancreatic cancer
1384823|NCT00440167|advanced
1384824|NCT00440128|Casopitant,
1384825|NCT00440128|Neurokinin-1 Receptor Antagonist,
1384826|NCT00440128|Drug-Interaction,
1384827|NCT00440128|CYP3A
1384828|NCT00440128|NK-1 Receptor Antagonist,
1384829|NCT00440128|GW679769,
1384830|NCT00440128|Docetaxel,
1384831|NCT00440102|ETOMIDATE
1384832|NCT00440102|KETAMINE
1384833|NCT00440102|RAPID SEQUENCE INTUBATION
1384834|NCT00440102|PREHOSPITAL
1384835|NCT00440102|During rapid sequence intubation
1384836|NCT00440089|Cancer
1384837|NCT00440089|Fatigue
1384838|NCT00440089|Breast Cancer
1384839|NCT00440089|Healing
1384840|NCT00440089|Energy Healing
1384841|NCT00440089|Complementary
1384842|NCT00440089|Alternative
1384843|NCT00440089|Immune
1384844|NCT00440089|Cytokine
1384845|NCT00440089|Hormone
1384846|NCT00440089|Cortisol
1384847|NCT00440089|Placebo
1384848|NCT00440089|Mock Healing
1384849|NCT00440076|MDS
1384850|NCT00440076|Velcade
1384851|NCT00440050|fish oil
1384852|NCT00440050|omega-3 fatty acids
1384853|NCT00440050|EPA
1384854|NCT00440037|AMG 531
1384855|NCT00440037|ITP
1384856|NCT00440037|Long term treatment
1384857|NCT00440037|Japanese
1384858|NCT00440037|Romiplostim
1384859|NCT00440024|Sun-Damaged Skin
1384860|NCT00440024|Retinoid Intolerance
1384861|NCT00440024|Tazarotene Cream
1384862|NCT00440024|Dove facial cleanser
1384863|NCT00440024|Dove moisturizer
1384864|NCT00439998|Ultrasound
1384865|NCT00439998|Obesity
1384866|NCT00439998|Needle Depth
1384867|NCT00439985|Type 1 Diabetes Mellitus (T1DM)
1384868|NCT00439985|Metabolic Control
1384869|NCT00439985|Adherence
1384870|NCT00439985|Optimism
1384871|NCT00439985|Parent-Child Collaboration
1384872|NCT00439985|Prevention
1384873|NCT00439972|Lipoproteins
1384874|NCT00439972|Apolipoproteins
1384875|NCT00439972|Insulin sensitivity
1384876|NCT00439972|Inflammation
1384877|NCT00439972|Clotting
1384878|NCT00439972|Antioxidant status
1384879|NCT00439972|Vascular reactivity
1384880|NCT00439972|Metabolism
1384881|NCT00439959|GSK625433,
1384882|NCT00439959|Hepatitis C,
1384883|NCT00439959|metabolic probe,
1384884|NCT00439959|food-effect,
1384885|NCT00439959|HCV,
1384886|NCT00439959|FTIH
1384887|NCT00439959|polymerase,
1384888|NCT00439946|pulmonary hypertension
1384889|NCT00439946|PAH
1384890|NCT00439946|Remodulin
1384891|NCT00439946|treprostinil
1384892|NCT00439946|Quality of Life
1384893|NCT00439946|rapid switch
1384894|NCT00439933|Obesity
1384895|NCT00439933|Children
1384896|NCT00439933|Weight loss
1384897|NCT00439933|Endothelial dysfunction
1384898|NCT00439933|Intervention
1384899|NCT00439920|ALL
1384900|NCT00439907|Anal sphincter Delivery
1384901|NCT00439907|Primary repair
1384902|NCT00439907|End-to-end repair
1384903|NCT00439907|Over-lap repair
1384904|NCT00439907|Anal manometry
1384905|NCT00439907|Anal sonography
1384906|NCT00439907|Weksner Score
1384907|NCT00439907|Rupture of the external anal sphincter during delivery
1384908|NCT00439907|Anal sphincter
1384909|NCT00439907|Anal sphincter rupture
1384910|NCT00439894|Rheumatoid Arthritis
1384911|NCT00439894|etanercept
1384912|NCT00439894|Enbrel
1384913|NCT00439894|Amgen
1384914|NCT00439881|inflammation,
1384915|NCT00439881|intravenous,
1384916|NCT00439881|Chronic Obstructive Pulmonary Disease,
1384917|NCT00439881|P38 inhibitor
1384918|NCT00439881|SB-681323,
1384919|NCT00439881|rheumatoid arthritis,
1384920|NCT00439868|WELLBUTRIN XL, intraocular pressure, healthy volunteers
1384921|NCT00439855|Enoxaparin, heparin, hemorrhages
1384922|NCT00439829|follicle
1384923|NCT00439829|ovary
1384924|NCT00439829|poor responder
1384925|NCT00439829|stimulation
1384926|NCT00439829|follicle wave emergence
1384927|NCT00439816|Hypertension Outcomes
1384928|NCT00439816|Health Outcomes
1384929|NCT00439816|Outpatient
1384930|NCT00439816|Racial Preference
1384931|NCT00439816|Blood Pressure Control
1384932|NCT00439816|Clinical Trial
1384933|NCT00439816|Intervention
1384934|NCT00439816|Lifestyle modifications
1384935|NCT00439816|Ethnic Differences
1384936|NCT00439816|Randomized
1384938|NCT00439803|cytomegalovirus
1384939|NCT00439803|Alphavirus
1384940|NCT00439790|implantable cardioverter defibrillator
1384941|NCT00439790|Heart failure
1384942|NCT00439790|Sudden Cardiac Arrest
1384943|NCT00439790|appropriate shock
1384944|NCT00439790|Defibrillators, Implantable
1384945|NCT00439764|Low back pain, health education, physical therapy
1384946|NCT00439751|Prostate Cancer
1384947|NCT00439751|Androgen Deprivation Therapy
1384948|NCT00439751|Recurrence
1384949|NCT00439751|Biochemical Failure
1384950|NCT00439751|Goserelin
1384951|NCT00439738|Obesity, hypertension, valsartan/hydrochlorothiazide
1384952|NCT00439699|Essential Tremor
1384953|NCT00439699|Memantine
1384954|NCT00439699|Clinical Trial
1384955|NCT00439673|MDS
1384956|NCT00439673|5-Azacytidine
1384957|NCT00439673|valproic acid
1384958|NCT00439673|atra
1384959|NCT00439673|intermediate or high risk
1384960|NCT00439673|Age ≥18 yearsAge
1384961|NCT00439660|Rotavirus, diarrhea, vaccine
1384962|NCT00439647|Osteoporosis
1384963|NCT00439647|males
1384964|NCT00439647|vertebral fractures
1384965|NCT00439647|clinical fractures
1384966|NCT00439647|bone mineral density
1384967|NCT00439647|bone biomarkers
1384968|NCT00439647|zoledronic acid
1384969|NCT00439634|psychometrics
1384970|NCT00439634|schizophrenia
1384971|NCT00439621|immunotherapy
1384972|NCT00439621|allergy
1384973|NCT00439608|esophageal cancer
1384974|NCT00439608|gastroesophageal cancer
1384975|NCT00439608|gastric cancer
1384976|NCT00439595|Anaemia
1384977|NCT00439595|Diagnosis
1384978|NCT00439595|Primary
1384979|NCT00439595|Care
1384980|NCT00439595|Treatment
1384981|NCT00439582|Lipoproteins
1384982|NCT00439582|Milk fat
1384983|NCT00439582|Public health nutrition
1384984|NCT00439582|trans fatty acid
1384985|NCT00439569|spinal muscular atrophy type II/III
1384986|NCT00439569|SMA type II/III
1384987|NCT00439569|spinal muscular atrophy
1384988|NCT00439569|SMA
1384989|NCT00439569|sodium phenylbutyrate
1384990|NCT00439569|motor neuron disease
1384991|NCT00439569|neuromuscular
1384992|NCT00439569|survival motor neuron
1384993|NCT00439569|SMN
1384994|NCT00439569|dose escalation
1384995|NCT00439556|Lymphoma
1384996|NCT00439556|Bortezomib
1384997|NCT00439556|Velcade
1384998|NCT00439556|LDP-341
1384999|NCT00439556|MLN341
1385000|NCT00439556|PS-341
1385001|NCT00439556|Carmustine
1385002|NCT00439556|Cytarabine
1385003|NCT00439556|Etoposide
1385004|NCT00439556|Melphalan
1385005|NCT00439556|Rituximab
1385006|NCT00439556|BEAM
1385007|NCT00439556|BCNU
1385008|NCT00439556|BiCNU®
1385009|NCT00439556|ARA-C
1385010|NCT00439556|Cytosar
1385011|NCT00439556|DepoCyt®
1385012|NCT00439556|Cytosine arabinosine hydrochloride
1385013|NCT00439556|VePesid®
1385014|NCT00439556|Rituxan
1385015|NCT00439543|Pulmonary fibrosis
1385016|NCT00439543|pulmonary hypertension
1385017|NCT00439543|Iloprost
1385018|NCT00439543|Efficacy
1385019|NCT00439530|oseltamivir
1385020|NCT00439530|pharmacokinetics
1385021|NCT00439530|probenecid
1385022|NCT00439530|avian influenza
1385023|NCT00439517|Cancer
1385024|NCT00439517|Colorectal
1385025|NCT00439517|Metastatic
1385026|NCT00439517|Untreated
1385027|NCT00439491|Obesity
1385028|NCT00439491|Insulin resistance
1385029|NCT00439491|Hypocaloric diet
1385030|NCT00439491|Adipose tissue
1385031|NCT00439491|adipocytokine
1385032|NCT00439478|Radioiodine, Thyroid Cancer, Sialadenitis, Xerostomia
1385033|NCT00439387|Serotonin
1385034|NCT00439387|Epilepsy
1385035|NCT00439387|Healthy Volunteer
1385036|NCT00439387|HV
1385037|NCT00439374|nulliparous
1385038|NCT00439374|pregnancy
1385039|NCT00439374|short cervix
1385040|NCT00439374|progesterone
1385041|NCT00439361|Hodgkin Lymphoma
1385042|NCT00439361|HL
1385043|NCT00439361|Relapsed Classical Hodgkin Lymphoma
1385044|NCT00439361|Refractory
1385045|NCT00439361|Lymphoma
1385046|NCT00439361|Nodular sclerosis
1385047|NCT00439361|Mixed cellularity
1385048|NCT00439361|Lymphocyte-rich classical HL
1385049|NCT00439361|Bortezomib
1385050|NCT00439361|Velcade
1385051|NCT00439361|LDP-341
1385052|NCT00439361|MLN341
1385053|NCT00439361|PS-341
1385054|NCT00439361|Carboplatin
1385055|NCT00439361|Paraplatin
1385056|NCT00439361|Etoposide
1385057|NCT00439361|VePesid®
1385058|NCT00439361|Ifosfamide
1385059|NCT00439361|Mesna
1385060|NCT00439361|Mesnex
1385061|NCT00439361|ICE
1385062|NCT00439348|Calcium
1385063|NCT00439348|Compliance
1385064|NCT00439348|Medication compliance
1385065|NCT00439348|electronic prescription
1385066|NCT00439348|over-the-counter medications
1385067|NCT00439348|OTC medications
1385068|NCT00439335|Influenza, vaccine, A/H5N1
1385069|NCT00439322|PTSD
1385070|NCT00439296|Acute Lymphoblastic Leukemia
1385071|NCT00439296|Pediatrics
1385072|NCT00439296|Relapsed
1385073|NCT00439296|Recurrence
1385074|NCT00439296|ABT-751
1385075|NCT00439296|Therapeutic Advances in Childhood Leukemia
1385076|NCT00439296|Investigational
1385077|NCT00439296|Childhood
1385078|NCT00439296|ALL
1385079|NCT00439296|Relapsed ALL
1385080|NCT00439296|Refractory ALL
1385081|NCT00439296|Relapsed pediatric ALL
1385082|NCT00439296|Refractory pediatric ALL
1385083|NCT00439296|TACL
1385084|NCT00439283|Ankylosing spondylitis
1385085|NCT00439283|infliximab
1385086|NCT00439283|Systematic regimen
1385087|NCT00439283|On-demand regimen
1385088|NCT00439270|Metastatic hormone refractory prostate cancer
1385089|NCT00439244|Bone Mineral Density (BMD)
1385090|NCT00439244|C-Telopeptides (CTx)
1385091|NCT00439244|dual x-ray absorptiometry (DXA)
1385092|NCT00439244|pro-collagen type 1 N-propeptide (P1NP)
1385093|NCT00439244|teriparatide
1385094|NCT00439244|zoledronic acid
1385095|NCT00439244|Osteoporosis
1385096|NCT00439244|postmenopausal women
1385097|NCT00439231|Monoclonal Antibody Therapy
1385098|NCT00439231|Biologic Response Modifier Therapy
1385099|NCT00439231|CLL
1385100|NCT00439231|SLL
1385101|NCT00439231|chemo-care (CC) 5013- Revlimid
1385102|NCT00439231|Chronic Lymphocytic Leukemia
1385103|NCT00439231|Small Lymphocytic Leukemia
1385104|NCT00439218|spinal muscular atrophy type I
1385105|NCT00439218|SMA type I
1385106|NCT00439218|spinal muscular atrophy
1385107|NCT00439218|SMA
1385108|NCT00439218|sodium phenylbutyrate
1385109|NCT00439218|motor neuron disease
1385110|NCT00439218|neuromuscular
1385111|NCT00439218|survival motor neuron
1385112|NCT00439218|SMN
1385113|NCT00439218|dose escalation
1385114|NCT00439205|Oral Tumors
1385115|NCT00439205|Oral Margin Spectroscopy
1385116|NCT00439205|Oral Spectroscopy
1385117|NCT00439205|Optical Spectroscopy
1385118|NCT00439205|Oral neoplastic lesions
1385119|NCT00439205|FastEEM4 System
1385120|NCT00439205|Multispectral Digital Microscope
1385121|NCT00439205|MDM
1385122|NCT00439205|Nonstandard imaging technology
1385123|NCT00439192|OAB, proof of concept
1385124|NCT00439192|Overactive Bladder (OAB)
1385125|NCT00439192|with incontinence
1385126|NCT00439179|Pancreatic Cancer
1385127|NCT00439166|doxycycline
1385128|NCT00439166|rifampicin
1385129|NCT00439166|cerebrospinal fluid
1385130|NCT00439166|biomarkers
1385131|NCT00439166|beta amyloid
1385132|NCT00439166|tau
1385133|NCT00439127|thyroglobulin
1385134|NCT00439127|thyroid carcinoma
1385135|NCT00439127|tumour marker
1385136|NCT00439127|radioiodine
1385137|NCT00439127|recombinant human TSH
1385138|NCT00439114|Corneal topography, corneal opacity, keratitis, trachoma
1385139|NCT00439101|weight loss
1385140|NCT00439101|malignancy
1385141|NCT00439101|corticosteroids
1385142|NCT00439101|supplemental feeding
1385143|NCT00439101|adrenal insufficiency
1385144|NCT00439101|diabetes
1385145|NCT00439088|Ambulation
1385146|NCT00439088|Ambulatory Monitoring
1385147|NCT00439088|Activities of Daily Living
1385148|NCT00439088|Pedometer
1385149|NCT00439088|Validation Studies [PT]
1385150|NCT00439075|pulmonary disease
1385151|NCT00439075|CPO
1385152|NCT00439075|CPAP
1385153|NCT00439075|oxygenation
1385154|NCT00439075|out-of-hospital intervention
1385155|NCT00439062|Roxithromycin,Rheumatoid arthritis,Macrolides
1385156|NCT00439049|Substance Abuse
1385157|NCT00439049|Treatment
1385158|NCT00439049|Eligibility
1385159|NCT00439036|Opiate
1385160|NCT00439036|Behavior Therapy
1385161|NCT00439036|Methadone
1385162|NCT00439036|Acceptance and Commitment Therapy (ACT)
1385163|NCT00439023|Chronic renal failure, dialysis, hemodialysis,
1385164|NCT00439010|neurological
1385165|NCT00439010|alzheimer
1385166|NCT00438971|Panic Disorder
1385167|NCT00438971|Anxiety Disorder
1385168|NCT00438971|Duloxetine
1385169|NCT00438958|graft versus host disease
1385170|NCT00438958|adult acute myeloid leukemia in remission
1385171|NCT00438958|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1385172|NCT00438958|adult acute myeloid leukemia with inv(16)(p13;q22)
1385173|NCT00438958|adult acute myeloid leukemia with t(15;17)(q22;q12)
1385174|NCT00438958|adult acute myeloid leukemia with t(16;16)(p13;q22)
1385175|NCT00438958|adult acute myeloid leukemia with t(8;21)(q22;q22)
1385176|NCT00438958|accelerated phase chronic myelogenous leukemia
1385177|NCT00438958|chronic phase chronic myelogenous leukemia
1385178|NCT00438958|refractory anemia with excess blasts in transformation
1385179|NCT00438958|refractory anemia with excess blasts
1385180|NCT00438958|refractory anemia with ringed sideroblasts
1385181|NCT00438958|refractory anemia
1385182|NCT00438958|chronic myelomonocytic leukemia
1385183|NCT00438958|de novo myelodysplastic syndromes
1385184|NCT00438958|previously treated myelodysplastic syndromes
1385185|NCT00438958|secondary myelodysplastic syndromes
1385186|NCT00438958|refractory chronic lymphocytic leukemia
1385187|NCT00438958|stage III chronic lymphocytic leukemia
1385188|NCT00438958|stage IV chronic lymphocytic leukemia
1385189|NCT00438958|primary myelofibrosis
1385190|NCT00438958|secondary myelofibrosis
1385191|NCT00438958|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1385192|NCT00438958|nodal marginal zone B-cell lymphoma
1385193|NCT00438958|recurrent adult Burkitt lymphoma
1385194|NCT00438958|recurrent adult diffuse large cell lymphoma
1385195|NCT00438958|recurrent adult diffuse mixed cell lymphoma
1385196|NCT00438958|recurrent adult diffuse small cleaved cell lymphoma
1385197|NCT00438958|recurrent adult Hodgkin lymphoma
1385198|NCT00438958|recurrent adult immunoblastic large cell lymphoma
1385199|NCT00438958|recurrent adult lymphoblastic lymphoma
1385200|NCT00438958|recurrent cutaneous T-cell non-Hodgkin lymphoma
1385201|NCT00438958|recurrent grade 1 follicular lymphoma
1385202|NCT00438958|recurrent grade 2 follicular lymphoma
1385203|NCT00438958|recurrent grade 3 follicular lymphoma
1385204|NCT00438958|recurrent mantle cell lymphoma
1385205|NCT00438958|recurrent marginal zone lymphoma
1385206|NCT00438958|recurrent mycosis fungoides/Sezary syndrome
1385207|NCT00438958|recurrent small lymphocytic lymphoma
1385208|NCT00438958|splenic marginal zone lymphoma
1385209|NCT00438958|stage III adult Burkitt lymphoma
1385210|NCT00438958|stage III adult diffuse large cell lymphoma
1385211|NCT00438958|stage III adult diffuse mixed cell lymphoma
1385212|NCT00438958|stage III adult diffuse small cleaved cell lymphoma
1385213|NCT00438958|stage III adult Hodgkin lymphoma
1385214|NCT00438958|stage III adult immunoblastic large cell lymphoma
1385215|NCT00438958|stage III adult lymphoblastic lymphoma
1385216|NCT00438958|stage III grade 1 follicular lymphoma
1385217|NCT00438958|stage III grade 2 follicular lymphoma
1385218|NCT00438958|stage III grade 3 follicular lymphoma
1385219|NCT00438958|stage III mantle cell lymphoma
1385220|NCT00438958|stage III marginal zone lymphoma
1385221|NCT00438958|stage III small lymphocytic lymphoma
1385222|NCT00438958|stage IV adult Burkitt lymphoma
1385223|NCT00438958|stage IV adult diffuse large cell lymphoma
1385224|NCT00438958|stage IV adult diffuse mixed cell lymphoma
1385225|NCT00438958|stage IV adult diffuse small cleaved cell lymphoma
1385226|NCT00438958|stage IV adult Hodgkin lymphoma
1385227|NCT00438958|stage IV adult immunoblastic large cell lymphoma
1385228|NCT00438958|stage IV adult lymphoblastic lymphoma
1385229|NCT00438958|stage IV grade 1 follicular lymphoma
1385230|NCT00438958|stage IV grade 2 follicular lymphoma
1385231|NCT00438958|stage IV grade 3 follicular lymphoma
1385232|NCT00438958|stage IV mantle cell lymphoma
1385233|NCT00438958|stage IV marginal zone lymphoma
1385234|NCT00438958|stage IV small lymphocytic lymphoma
1385235|NCT00438958|Waldenström macroglobulinemia
1385236|NCT00438958|secondary acute myeloid leukemia
1385237|NCT00438958|childhood myelodysplastic syndromes
1385238|NCT00438932|phosphate, phosphorus, FGF-23, PTH, 1,25D
1385239|NCT00438906|pancreatic lesions
1385240|NCT00438906|pancreatic cancer
1385241|NCT00438906|peutz-jeghers syndrome
1385242|NCT00438906|BRCA 2 gene mutation
1385243|NCT00438906|FAMMM/p16
1385244|NCT00438906|Genes, BRCA2
1385245|NCT00438893|Viscous dietary fiber
1385246|NCT00438893|Soy protein
1385247|NCT00438893|Nuts
1385248|NCT00438893|Plant sterols
1385249|NCT00438893|Dietary Portfolio
1385250|NCT00438893|Compliance
1385251|NCT00438893|Blood lipids
1385252|NCT00438893|Blood pressure
1385253|NCT00438867|angina
1385254|NCT00438867|FGF-4
1385255|NCT00438867|angiogenesis
1385256|NCT00438867|growth factor
1385257|NCT00438867|myocardia ischemia
1385258|NCT00438867|revascularization
1385259|NCT00438854|dasatinib
1385260|NCT00438854|BMS-354825
1385261|NCT00438854|CLL
1385262|NCT00438854|SLL
1385263|NCT00438854|LYN kinase
1385264|NCT00438841|stage I multiple myeloma
1385265|NCT00438841|stage II multiple myeloma
1385266|NCT00438841|stage III multiple myeloma
1385267|NCT00438828|radiation therapy
1385268|NCT00438828|palliative
1385269|NCT00438828|pain
1385270|NCT00438815|Hereditary angioedema
1385271|NCT00438815|C1 esterase inhibitor (human)
1385272|NCT00438802|recurrent cutaneous T-cell non-Hodgkin lymphoma
1385273|NCT00438802|angioimmunoblastic T-cell lymphoma
1385274|NCT00438802|anaplastic large cell lymphoma
1385275|NCT00438802|adult nasal type extranodal NK/T-cell lymphoma
1385276|NCT00438802|recurrent mycosis fungoides/Sezary syndrome
1385277|NCT00438061|Lipoprotein metabolism
1385278|NCT00438061|Cardiovascular disease
1385279|NCT00438061|Obesity
1385280|NCT00438048|Pilocarpine
1385281|NCT00438048|Artificial saliva
1385282|NCT00438048|Xerostomia
1385283|NCT00438048|Xerostomy
1385284|NCT00438048|Primary Sjogren
1385285|NCT00438048|Secondary Sjogren
1385286|NCT00438035|Postoperative pain
1385287|NCT00438035|Heart rate variability, sympathetic, parasympathetic
1385288|NCT00438035|Visual analog pain scale
1385289|NCT00438035|Spectral analysis of ECG
1385290|NCT00438022|Atopic Dermatitis
1385291|NCT00438022|Eczema Herpeticum
1385292|NCT00438009|coxsackievirus type a21
1385293|NCT00438009|oncolytic virus
1385294|NCT00438009|melanoma
1385295|NCT00437996|Labor analgesia - clonidine - epidural
1385296|NCT00437957|histone deacetylase
1385297|NCT00437957|unresectable brain metastases
1385298|NCT00437177|alcoholism
1385299|NCT00437177|apomorphine
1385300|NCT00437177|iodobenzamide
1385301|NCT00437177|imaging
1385302|NCT00437177|spect
1385303|NCT00437177|relapse
1385304|NCT00438763|CMC arthritis
1385305|NCT00438763|splint treatment
1385306|NCT00438763|patient satisfaction
1385307|NCT00438763|DASH questionnaire
1385308|NCT00438750|distal radius fracture
1385309|NCT00438750|rehabilitation
1385310|NCT00438750|volar plate fixation
1385311|NCT00438750|DASH questionnaire
1385312|NCT00438737|liver metastases
1385313|NCT00438737|stage IV colon cancer
1385314|NCT00438737|stage IV rectal cancer
1385315|NCT00438737|recurrent colon cancer
1385316|NCT00438737|recurrent rectal cancer
1385317|NCT00438724|Caregivers
1385318|NCT00438724|Caregiving
1385319|NCT00438724|Spousal relationships
1385320|NCT00438724|cognition disorders
1385321|NCT00438724|therapy
1385322|NCT00438724|mental health
1385323|NCT00438724|psychosocial
1385324|NCT00438698|Nutrition
1385325|NCT00438698|Type 2 Diabetes
1385326|NCT00438685|Substance-Related Disorders
1385327|NCT00438685|Depressive Disorder
1385328|NCT00438685|Anxiety Disorder
1385329|NCT00438685|Adolescent
1385330|NCT00438685|Behavior Therapy
1385331|NCT00438685|Cognitive Therapy
1385332|NCT00438685|Outpatients
1385333|NCT00438685|Family Relations
1385334|NCT00438685|Systems Theory
1385335|NCT00438672|lateral elbow pain
1385336|NCT00438672|tennis elbow
1385337|NCT00438672|pain
1385338|NCT00438672|psychology
1385339|NCT00438659|dermatologic complications
1385340|NCT00438659|skin reactions secondary to radiation therapy
1385341|NCT00438659|radiation toxicity
1385342|NCT00438659|breast cancer in situ
1385343|NCT00438659|recurrent breast cancer
1385344|NCT00438659|stage I breast cancer
1385345|NCT00438659|stage II breast cancer
1385346|NCT00438659|stage IIIA breast cancer
1385347|NCT00438659|stage IIIB breast cancer
1385348|NCT00438659|stage IIIC breast cancer
1385349|NCT00438659|male breast cancer
1385350|NCT00438659|ductal breast carcinoma in situ
1385351|NCT00438659|stage IV breast cancer
1385352|NCT00438646|Allergy
1385353|NCT00438646|Asthma
1385354|NCT00438646|Eczema
1385355|NCT00438646|Hay Fever
1385356|NCT00438646|Epidemiology
1385357|NCT00438633|proximal humerus fracture
1385358|NCT00438633|rehabilitation
1385359|NCT00438633|non-operative treatment
1385360|NCT00438633|DASH and Constant instruments
1385361|NCT00438607|Moderate to late stage Parkinson's Disease
1385362|NCT00438594|nurse
1385363|NCT00438594|paraprofessional
1385364|NCT00438594|home visits
1385365|NCT00438594|pregnancy
1385366|NCT00438594|welfare
1385367|NCT00438594|child development
1385368|NCT00438581|Zevalin
1385369|NCT00438581|Autologous one Marrow Transplant
1385370|NCT00438581|Non-Hodgkin's Lymphoma
1385371|NCT00438568|amyloid protein
1385372|NCT00438568|brain metabolism
1385373|NCT00438568|glucose metabolism
1385374|NCT00438568|insulin sensitivity /resistance
1385375|NCT00438568|cognition disorders
1385376|NCT00438555|obesity,prevention,pediatric
1385377|NCT00438542|Adiponectin, cord blood, pre-eclampsia
1385378|NCT00438516|home visits
1385379|NCT00438516|pregnancy
1385380|NCT00438516|welfare
1385381|NCT00438516|child development
1385382|NCT00438516|mortality
1385383|NCT00438503|Hemodialysis, diabetes mellitus,
1385384|NCT00438503|Chronic renal failure, dialysis ,
1385385|NCT00438490|galactorrhea
1385386|NCT00438490|prolactin
1385387|NCT00438490|bone turnover
1385388|NCT00438490|menstrual cycle
1385389|NCT00438490|Control Groups
1385390|NCT00438490|Women
1385391|NCT00438477|recurrent breast cancer
1385392|NCT00438477|stage IIIA breast cancer
1385393|NCT00438477|stage IIIB breast cancer
1385394|NCT00438477|stage IIIC breast cancer
1385395|NCT00438477|stage II breast cancer
1385396|NCT00438451|elderly
1385397|NCT00438451|focal epilepsy
1385398|NCT00438451|anticonvulsive
1385399|NCT00438451|treatment
1385400|NCT00438451|levetiracetam
1385401|NCT00438451|lamotrigine
1385402|NCT00438451|carbamazepine
1385403|NCT00438438|forced desynchrony
1385404|NCT00438438|circadian rhythms
1385405|NCT00438438|sleep restriction
1385406|NCT00438438|sleep homeostasis
1385407|NCT00438438|neurobehavioral performance
1385408|NCT00438425|Hyperlipidemia
1385409|NCT00438425|Hypercholesterolemia
1385410|NCT00438425|Dietary modification
1385411|NCT00438425|Portfolio
1385412|NCT00438412|Noradrenalin
1385413|NCT00438412|Endothelin-1
1385414|NCT00438412|Angiotensin II
1385415|NCT00438412|Arginine vasopressin
1385416|NCT00438412|Aldosterone
1385417|NCT00438412|Renin
1385418|NCT00438412|Atrial natriuretic peptide
1385419|NCT00438412|Brain natriuretic peptide
1385420|NCT00438412|Blood pressure
1385421|NCT00438412|Apnea
1385422|NCT00438399|1 Galderma,
1385423|NCT00438399|2 Scalp Psoriasis
1385424|NCT00438399|3 Subject preference
1385425|NCT00438399|4 Clobetasol propionate
1385426|NCT00438399|5 Shampoo
1385427|NCT00438386|Generalized Anxiety Disorder
1385428|NCT00438386|Panic Disorder
1385429|NCT00438386|Anxiety Disorder
1385430|NCT00438386|Aripiprazole
1385431|NCT00438373|Subfertility, Luteinizing hormone, receptor
1385432|NCT00438360|Cyclosporine, chronic plaque psoriasis, intermittent therapy
1385433|NCT00438347|Mild Cognitive Impairment
1385434|NCT00438347|cognition disorders
1385435|NCT00438347|brain health
1385436|NCT00438347|psychological aspect of aging
1385437|NCT00438347|exercise
1385438|NCT00438347|physical fitness
1385439|NCT00438334|Benefit
1385440|NCT00438334|Directional microphones
1385441|NCT00438334|Hearing
1385442|NCT00438334|Hearing aids
1385443|NCT00438334|Hearing loss
1385444|NCT00438334|Noise
1385445|NCT00438334|Objective benefit
1385446|NCT00438334|Signal-to-noise ratio
1385447|NCT00438334|Speech understanding
1385448|NCT00438334|Subjective benefit
1385449|NCT00438321|Overweight
1385450|NCT00438321|obesity
1385451|NCT00438321|testosterone
1385452|NCT00438321|diabetes
1385453|NCT00438321|metabolic syndrome
1385454|NCT00438321|aging
1385455|NCT00438308|distal radius fracture
1385456|NCT00438308|rehabilitation
1385457|NCT00438308|volar plate fixation
1385458|NCT00438308|DASH questionnaire
1385459|NCT00438295|glucose in dialysis water, dialysis treatment, temperature
1385460|NCT00438282|nurse
1385461|NCT00438282|home visits
1385462|NCT00438282|pregnancy
1385463|NCT00438282|welfare
1385464|NCT00438282|child development
1385465|NCT00438269|Infection
1385466|NCT00438269|Empiric
1385467|NCT00438269|Antibiotics
1385468|NCT00438269|Nosocomial
1385469|NCT00438269|Pyrexia
1385470|NCT00438269|Leukocytosis
1385471|NCT00438269|Resistance
1385472|NCT00438256|accelerated short course
1385473|NCT00438256|proton beam radiation
1385474|NCT00438243|Pseudophakic macular edema
1385475|NCT00438230|Residual vein thrombosis
1385476|NCT00438230|Optimal duration
1385477|NCT00438230|Oral anticoagulants
1385478|NCT00438217|precocious puberty, genetics, environmental factors
1385479|NCT00438204|stage IIIB non-small cell lung cancer
1385480|NCT00438204|stage IV non-small cell lung cancer
1385481|NCT00438204|adenocarcinoma of the lung
1385482|NCT00438204|bronchoalveolar cell lung cancer
1385483|NCT00438204|large cell lung cancer
1385484|NCT00438204|recurrent non-small cell lung cancer
1385485|NCT00438191|DeQuervain's tenosynovitis
1385486|NCT00438191|splinting
1385487|NCT00438191|grip strength
1385488|NCT00438191|satisfaction
1385489|NCT00438191|DASH questionnaire
1385490|NCT00438165|nurse
1385491|NCT00438165|home visits
1385492|NCT00438165|pregnancy
1385493|NCT00438165|welfare
1385494|NCT00438165|child development
1385495|NCT00438152|Lopinavir
1385496|NCT00438152|Saquinavir
1385497|NCT00438152|Lipids
1385498|NCT00438152|HIV-1
1385499|NCT00438152|Treatment Experienced
1385500|NCT00438139|marijuana dependence
1385501|NCT00438126|diabetes
1385502|NCT00438126|Prevention
1385503|NCT00438126|American Indian
1385507|NCT00438100|Breast Neoplasms
1385508|NCT00438100|Drug Therapy
1385509|NCT00438087|Facial palsy
1385510|NCT00438087|Vestibular schwannoma
1385511|NCT00438087|Anti-inflammatory drugs
1385512|NCT00438087|Post surgery of vestibular schwannoma
1385513|NCT00438087|or of cranial base tumors
1385514|NCT00438074|Breast Cancer
1385515|NCT00438074|Diffuse Optical Spectroscopy
1385516|NCT00437931|hypothyroidism
1385517|NCT00437931|hyperthyroidism
1385518|NCT00437931|thyroid dysfunction
1385519|NCT00437931|ultrasound
1385520|NCT00437931|doppler
1385521|NCT00437905|peripheral vascular disease
1385522|NCT00437905|percutaneous transluminal angioplasty
1385523|NCT00437905|cutting balloon
1385524|NCT00437905|balloon angioplasty
1385525|NCT00437905|randomized controlled trial
1385526|NCT00437905|restenosis
1385527|NCT00437905|inflammation
1385528|NCT00437892|Statins
1385529|NCT00437892|secondary prevention
1385530|NCT00437892|venous thromboembolism
1385531|NCT00437892|d-dimer
1385532|NCT00437879|Breast Cancer
1385533|NCT00437879|Ultrasound
1385534|NCT00437840|smoking,
1385535|NCT00437840|healthy volunteers,
1385536|NCT00437840|safety,
1385537|NCT00437840|tolerability,
1385538|NCT00437840|pharmacokinetics,
1385539|NCT00437840|pharmacodynamics
1385540|NCT00437827|Depression
1385541|NCT00437814|Ketamine
1385542|NCT00437814|Traumatic Brain Injury
1385543|NCT00437814|Intracranial Hypertension
1385544|NCT00437788|imaging
1385545|NCT00437775|Diabetes Mellitus type 2
1385546|NCT00437775|ACE Inhibitors
1385547|NCT00437775|ARBs
1385548|NCT00437775|Adverse drug effect
1385549|NCT00437762|Lateral epicondylitis, tennis elbow, treatment
1385550|NCT00437749|Non small cell lung cancer
1385551|NCT00437749|Advanced
1385552|NCT00437749|Inoperable
1385553|NCT00437749|taxanes
1385554|NCT00437749|carboplatin
1385555|NCT00437749|multi-drug resistance
1385556|NCT00437736|solid tumor
1385557|NCT00437736|phase I study
1385558|NCT00437736|dose-escalation
1385559|NCT00437710|bone marrow, cell transplantation, stem cells, PTCA
1385560|NCT00437697|dalteparin, critically ill, thromboprophylaxis
1385561|NCT00437684|HIV/HCV
1385562|NCT00437684|HIV and HCV coinfected patients
1385563|NCT00437684|Treatment Experienced
1385564|NCT00437671|trismus
1385565|NCT00437671|lockjaw
1385566|NCT00437645|Essential hypertension
1385567|NCT00437645|blood pressure
1385568|NCT00437645|edema
1385569|NCT00437645|valsartan
1385570|NCT00437645|amlodipine
1385571|NCT00437645|combination treatment
1385572|NCT00437632|repeat dose,
1385573|NCT00437632|GSK598809
1385574|NCT00437632|pharmacokinetics,
1385575|NCT00437632|tolerability,
1385576|NCT00437632|placebo,
1385577|NCT00437632|Safety,
1385578|NCT00437632|pharmacodynamics,
1385579|NCT00437593|preretinal membrane
1385580|NCT00437593|vitrectomy
1385581|NCT00437593|uhr-oct
1385582|NCT00437593|hd-oct
1385583|NCT00437580|Vancomycin Resistant Enterococcus, probiotic
1385584|NCT00437567|galacto-oligosaccharides
1385585|NCT00437567|prebiotics
1385586|NCT00437567|NEC
1385587|NCT00437541|Insulation
1385588|NCT00437541|Warmth
1385589|NCT00437541|Humidity
1385590|NCT00437541|Damp
1385591|NCT00437541|Cold
1385592|NCT00437541|Respiratory
1385593|NCT00437541|Mould
1385594|NCT00437528|Heat flow
1385595|NCT00437528|Sensor
1385596|NCT00437528|Overactive bladder
1385597|NCT00437528|Urinary incontinence
1385598|NCT00437502|Immunotherapeutic vaccine
1385599|NCT00437502|Ovarian cancer
1385600|NCT00437502|epithelial ovarian cancer
1385601|NCT00437502|tubal cancer
1385602|NCT00437502|peritoneal cancer
1385603|NCT00437502|immunotherapy
1385604|NCT00437476|HIV/HCV
1385605|NCT00437476|HIV and HCV coinfected patients
1385606|NCT00437476|Treatment Naive
1385607|NCT00437450|Anemia
1385608|NCT00437450|myelodysplastic syndromes
1385609|NCT00437450|Low risk
1385610|NCT00437450|Bone Marrow diseases
1385611|NCT00437437|Advanced or metastatic solid tumors
1385612|NCT00437424|Hepatocellular cancer
1385613|NCT00437424|Other advanced solid malignancies
1385614|NCT00437411|Fibromyalgia
1385615|NCT00437411|Affect
1385616|NCT00437411|Pain
1385617|NCT00437411|Fatigue
1385618|NCT00437411|Sleep
1385619|NCT00437411|Stress
1385620|NCT00437411|Quality of Life
1385621|NCT00437411|Stress, Psychological
1385622|NCT00437411|Psychophysiology
1385623|NCT00437411|Randomized Controlled Trials
1385624|NCT00437398|hypoglycemic unawareness
1385625|NCT00437385|therapy resistant depression, severe depression
1385626|NCT00437372|solid tumor
1385627|NCT00437372|central nervous system
1385628|NCT00437372|head and neck
1385629|NCT00437372|thorax
1385630|NCT00437372|pelvic area
1385631|NCT00437359|Breast Neoplasms
1385632|NCT00437359|Drug Therapy
1385633|NCT00437346|dyspepsia
1385634|NCT00437346|functional dyspepsia
1385635|NCT00437346|treatment
1385636|NCT00437346|drug therapy
1385637|NCT00437346|information
1385638|NCT00437333|Insulin sensitivity
1385639|NCT00437333|Insulin-sensitizing drug
1385640|NCT00437333|Metformin
1385641|NCT00437333|PCOS
1385642|NCT00437333|Treatment
1385643|NCT00437320|PDT
1385644|NCT00437320|Photoaging
1385645|NCT00437320|Galderma
1385646|NCT00437281|Partial-onset seizures; epilepsy; pediatric; pregabalin; safety; tolerability; pharmacokinetics
1385647|NCT00437242|interval,
1385648|NCT00437242|atrial fibrillation
1385649|NCT00437242|QT,
1385650|NCT00437242|odiparcil,
1385651|NCT00437229|GW679769,
1385652|NCT00437229|Casopitant,
1385653|NCT00437229|Dexamethasone,
1385654|NCT00437229|Healthy Human Volunteer
1385655|NCT00437229|Ondansetron,
1385656|NCT00437203|Advanced cancer
1385657|NCT00437190|Cervical Disc Replacement
1385658|NCT00437190|Spondylotic radiculopathy
1385659|NCT00437190|Spondylotic myelopathy
1385660|NCT00437190|Myelopathy
1385661|NCT00437190|Radiculopathy
1385662|NCT00437164|NaBr
1385663|NCT00437164|Sodium Bromide
1385664|NCT00437164|DEXA Deuterium
1385665|NCT00437164|Total Body Water
1385666|NCT00437164|Insulin
1385667|NCT00437164|D2O
1385668|NCT00437164|GW677954
1385669|NCT00437164|Randomized Withdrawal
1385670|NCT00437164|T2DM
1385671|NCT00437138|Air pollution
1385672|NCT00437138|Myocardial ischemia
1385673|NCT00437138|Endothelium
1385674|NCT00437138|Fibrinolysis
1385675|NCT00437138|Pathophysiology
1385676|NCT00437138|Diesel exhaust
1385677|NCT00437086|chronic myelomonocytic leukemia
1385678|NCT00437086|primary myelofibrosis
1385679|NCT00437073|brain metastases
1385680|NCT00437073|ErbB2
1385681|NCT00437073|lapatinib
1385682|NCT00437073|Breast Cancer
1385683|NCT00437073|HYCAMTIN
1385684|NCT00437073|topotecan
1385685|NCT00437073|capecitabine
1385686|NCT00437073|metastatic breast cancer
1385687|NCT00437073|TYKERB
1385688|NCT00437073|XELODA
1385689|NCT00437021|smallpox, vaccine, IMVAMUNE®
1385690|NCT00437008|endothelial dysfunction
1385691|NCT00437008|flow-mediated dilatation
1385692|NCT00437008|advanced glycation end products
1385693|NCT00437008|postprandial
1385694|NCT00436995|Dialysis
1385695|NCT00436995|Anaemia
1385696|NCT00436969|Orthovisc
1385697|NCT00436969|Osteoarthritis
1385698|NCT00436969|Shoulder
1385699|NCT00436969|Randomized
1385700|NCT00436956|VEGF
1385701|NCT00436956|Angiogenesis
1385702|NCT00436956|Hormone-Refractory
1385703|NCT00436956|Bone Metastases
1385704|NCT00436956|Docetaxel-Resistant
1385705|NCT00436956|Prostate Cancer
1385706|NCT00436943|smoking cessation
1385707|NCT00436943|nicotine replacement therapy
1385708|NCT00436943|bupropion
1385709|NCT00436943|smoking
1385710|NCT00436930|recurrent melanoma
1385711|NCT00436930|stage IV melanoma
1385712|NCT00436917|stage I breast cancer
1385713|NCT00436917|stage II breast cancer
1385714|NCT00436917|stage IIIA breast cancer
1385715|NCT00436917|osteoporosis
1385716|NCT00436904|stage 0 chronic lymphocytic leukemia
1385717|NCT00436904|stage I chronic lymphocytic leukemia
1385718|NCT00436904|stage II chronic lymphocytic leukemia
1385719|NCT00436904|B-cell chronic lymphocytic leukemia
1385720|NCT00436891|Group A Streptococcus, scabies, pyoderma, Fiji
1385721|NCT00436878|Eating Behavior
1385722|NCT00436878|Children
1385723|NCT00436878|Portion size
1385724|NCT00436878|Experimental
1385725|NCT00436826|Multiple Sclerosis
1385726|NCT00436826|Relapsing forms
1385727|NCT00436826|Interferon-beta therapy
1385728|NCT00436787|Anticoagulation Prophylaxis
1385729|NCT00436787|Venous Thrombosis
1385730|NCT00436787|Deep Vein Thrombosis
1385731|NCT00436787|Pulmonary Embolism
1385732|NCT00436787|Fondaparinux Sodium
1385733|NCT00436787|Arixtra
1385734|NCT00436787|Pharmakinetics
1385735|NCT00436774|long-term effects secondary to cancer therapy in children
1385736|NCT00436774|neurotoxicity
1385737|NCT00436774|gastrointestinal complications
1385738|NCT00436774|pulmonary complications
1385739|NCT00436774|sexual dysfunction
1385740|NCT00436774|infertility
1385741|NCT00436774|urinary complications
1385742|NCT00436774|childhood extragonadal germ cell tumor
1385743|NCT00436774|childhood malignant ovarian germ cell tumor
1385744|NCT00436774|childhood malignant testicular germ cell tumor
1385745|NCT00436774|childhood teratoma
1385746|NCT00436761|unspecified childhood solid tumor, protocol specific
1385747|NCT00436748|Chronic Kidney Disease
1385748|NCT00436748|Dialysis
1385749|NCT00436748|Anemia
1385750|NCT00436748|Nephrology
1385751|NCT00436748|Pediatric
1385752|NCT00436748|Hemodialysis
1385753|NCT00436748|Peritoneal Dialysis
1385754|NCT00436748|Chronic Renal Insufficiency
1385755|NCT00436722|Liver
1385756|NCT00436722|Transplantation
1385757|NCT00436722|Tolerance
1385758|NCT00436722|Induction
1385759|NCT00436722|Tacrolimus
1385760|NCT00436722|Liver transplantation
1385761|NCT00436722|Adult
1385762|NCT00436709|male breast cancer
1385763|NCT00436709|stage I breast cancer
1385764|NCT00436709|stage II breast cancer
1385765|NCT00436709|stage IIIA breast cancer
1385766|NCT00436696|disseminated neuroblastoma
1385767|NCT00436696|localized resectable neuroblastoma
1385768|NCT00436696|localized unresectable neuroblastoma
1385769|NCT00436696|recurrent neuroblastoma
1385770|NCT00436696|regional neuroblastoma
1385771|NCT00436683|Hyperphosphataemia
1385772|NCT00436683|Phosphate binder
1385773|NCT00436670|Asthma
1385774|NCT00436670|Allergy
1385775|NCT00436670|IL-13
1385776|NCT00436670|IL-4
1385777|NCT00436670|IL-4R
1385778|NCT00436657|Children
1385779|NCT00436657|Pediatric
1385780|NCT00436657|Peritoneal Tumor
1385781|NCT00436657|Retroperitoneal Tumor
1385782|NCT00436657|Gastrointestinal Adenocarcinoma
1385783|NCT00436657|Desmoplastic Round Cell Tumor
1385784|NCT00436657|Neuroblastoma
1385785|NCT00436657|Ovarian Germ Cell
1385786|NCT00436657|Sarcoma
1385787|NCT00436657|Adrenocorticocarcinoma
1385788|NCT00436657|Wilms' Tumor
1385789|NCT00436657|Rhabdomyosarcoma
1385790|NCT00436657|Desmoplastic Small Round Cell Tumor
1385791|NCT00436657|Recurrent Tumors
1385792|NCT00436657|Cisplatin
1385793|NCT00436657|Platinol®-AQ
1385794|NCT00436657|Platinol®
1385795|NCT00436657|CDDP
1385796|NCT00436657|Abdominal Wash
1385797|NCT00436657|Hyperthermic Perfusion
1385798|NCT00436657|Continuous Hyperthermic Peritoneal Perfusion
1385799|NCT00436657|CHPP
1385800|NCT00436644|recurrent ovarian epithelial cancer
1385801|NCT00436644|peritoneal cavity cancer
1385802|NCT00436631|epilepsy
1385803|NCT00436631|seizures
1385804|NCT00436631|intractable
1385805|NCT00436631|ketosis
1385806|NCT00436631|ketogenic
1385807|NCT00436631|diet
1385808|NCT00436618|recurrent adult Burkitt lymphoma
1385809|NCT00436618|recurrent adult Hodgkin lymphoma
1385810|NCT00436618|anaplastic large cell lymphoma
1385811|NCT00436618|angioimmunoblastic T-cell lymphoma
1385812|NCT00436618|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1385813|NCT00436618|nodal marginal zone B-cell lymphoma
1385814|NCT00436618|splenic marginal zone lymphoma
1385815|NCT00436618|small intestine lymphoma
1385816|NCT00436618|recurrent adult diffuse mixed cell lymphoma
1385817|NCT00436618|recurrent adult T-cell leukemia/lymphoma
1385818|NCT00436618|recurrent grade 3 follicular lymphoma
1385819|NCT00436618|recurrent marginal zone lymphoma
1385820|NCT00436618|refractory chronic lymphocytic leukemia
1385821|NCT00436618|recurrent small lymphocytic lymphoma
1385822|NCT00436618|recurrent mycosis fungoides/Sezary syndrome
1385823|NCT00436618|adult nasal type extranodal NK/T-cell lymphoma
1385824|NCT00436618|Waldenstrom macroglobulinemia
1385825|NCT00436618|recurrent adult diffuse large cell lymphoma
1385826|NCT00436618|recurrent adult lymphoblastic lymphoma
1385827|NCT00436618|recurrent mantle cell lymphoma
1385828|NCT00436618|recurrent grade 1 follicular lymphoma
1385829|NCT00436618|recurrent grade 2 follicular lymphoma
1385830|NCT00436618|primary central nervous system non-Hodgkin lymphoma
1385831|NCT00436618|primary central nervous system Hodgkin lymphoma
1385832|NCT00436618|post-transplant lymphoproliferative disorder
1385833|NCT00436618|recurrent adult diffuse small cleaved cell lymphoma
1385834|NCT00436592|acute
1385835|NCT00436592|ischemic
1385836|NCT00436592|stroke
1385837|NCT00436592|device
1385838|NCT00436592|treatment
1385839|NCT00436566|cardiac toxicity
1385840|NCT00436566|male breast cancer
1385841|NCT00436566|stage I breast cancer
1385842|NCT00436566|stage II breast cancer
1385843|NCT00436566|stage IIIA breast cancer
1385844|NCT00436553|Age-related macular degeneration; AMD
1385845|NCT00436553|choroidal neovascularization
1385846|NCT00436553|verteporfin
1385847|NCT00436553|ranibizumab
1385848|NCT00436514|patients
1385849|NCT00436514|medium risk
1385850|NCT00436514|asymptomatic
1385851|NCT00436514|between 50 and 74 years old
1385852|NCT00436514|high risk
1385853|NCT00436514|case
1385854|NCT00436514|history of neoplastic colic
1385855|NCT00436514|cancers
1385856|NCT00436514|polyps
1385857|NCT00436501|primary peritoneal cavity cancer
1385858|NCT00436501|Ovarian Epithelial Cancer
1385859|NCT00436501|Peritoneal Cancer
1385860|NCT00436501|Fallopian Tube Cancer
1385861|NCT00436501|VEGF Trap
1385862|NCT00436501|aflibercept
1385863|NCT00436501|vascular endothelial growth factor trap
1385864|NCT00436501|Zaltrap
1385865|NCT00436501|docetaxel
1385866|NCT00436501|RP 56976
1385867|NCT00436501|Taxotere
1385868|NCT00436501|TXT
1385869|NCT00436488|ICAM-1
1385870|NCT00436488|Obesity
1385871|NCT00436488|Gene variants
1385872|NCT00436475|Glucose intolerance
1385873|NCT00436475|Type 2 diabetes mellitus
1385874|NCT00436475|Metabolic syndrome
1385875|NCT00436462|Steroid receptors
1385876|NCT00436462|Endometrium
1385877|NCT00436462|IVF
1385878|NCT00436462|Follicular phase
1385879|NCT00436436|adult giant cell glioblastoma
1385880|NCT00436436|adult gliosarcoma
1385881|NCT00436436|recurrent adult brain tumor
1385882|NCT00436436|adult glioblastoma
1385883|NCT00436423|pancreatic neoplasm
1385884|NCT00436423|drug therapy
1385885|NCT00436423|gemcitabine
1385886|NCT00436423|TS-1
1385887|NCT00436410|stage IV colon cancer
1385888|NCT00436410|stage IV rectal cancer
1385889|NCT00436410|adult primary hepatocellular carcinoma
1385890|NCT00436410|stage IV pancreatic cancer
1385891|NCT00436410|male breast cancer
1385892|NCT00436410|stage IV breast cancer
1385893|NCT00436410|stage IV melanoma
1385894|NCT00436410|stage I breast cancer
1385895|NCT00436410|stage II breast cancer
1385896|NCT00436410|stage IIIA breast cancer
1385897|NCT00436410|stage IIIB breast cancer
1385898|NCT00436410|stage IIIC breast cancer
1385899|NCT00436410|recurrent breast cancer
1385900|NCT00436410|recurrent adrenocortical carcinoma
1385901|NCT00436410|stage I adrenocortical carcinoma
1385902|NCT00436410|stage II adrenocortical carcinoma
1385903|NCT00436410|stage III adrenocortical carcinoma
1385904|NCT00436410|stage IV adrenocortical carcinoma
1385905|NCT00436410|recurrent colon cancer
1385906|NCT00436410|stage I colon cancer
1385907|NCT00436410|stage II colon cancer
1385908|NCT00436410|stage III colon cancer
1385909|NCT00436410|recurrent rectal cancer
1385910|NCT00436410|stage I rectal cancer
1385911|NCT00436410|stage II rectal cancer
1385912|NCT00436410|stage III rectal cancer
1385913|NCT00436410|advanced adult primary liver cancer
1385914|NCT00436410|localized resectable adult primary liver cancer
1385915|NCT00436410|recurrent adult primary liver cancer
1385916|NCT00436410|recurrent pancreatic cancer
1385917|NCT00436410|stage I pancreatic cancer
1385918|NCT00436410|stage II pancreatic cancer
1385919|NCT00436410|stage III pancreatic cancer
1385920|NCT00436410|recurrent melanoma
1385921|NCT00436410|stage I melanoma
1385922|NCT00436410|stage II melanoma
1385923|NCT00436410|stage III melanoma
1385924|NCT00436410|stage I renal cell cancer
1385925|NCT00436410|stage II renal cell cancer
1385926|NCT00436410|stage III renal cell cancer
1385927|NCT00436410|stage IV renal cell cancer
1385928|NCT00436410|recurrent renal cell cancer
1385929|NCT00436410|recurrent ovarian epithelial cancer
1385930|NCT00436410|stage I ovarian epithelial cancer
1385931|NCT00436410|stage II ovarian epithelial cancer
1385932|NCT00436410|stage III ovarian epithelial cancer
1385933|NCT00436410|stage IV ovarian epithelial cancer
1385934|NCT00436410|gastrointestinal cancer
1385935|NCT00436410|adult fibrosarcoma
1385936|NCT00436410|recurrent adult soft tissue sarcoma
1385937|NCT00436410|stage I adult soft tissue sarcoma
1385938|NCT00436410|stage II adult soft tissue sarcoma
1385939|NCT00436410|stage III adult soft tissue sarcoma
1385940|NCT00436410|stage IV adult soft tissue sarcoma
1385941|NCT00436397|unspecified adult solid tumor, protocol specific
1385942|NCT00436384|liver transplant
1385943|NCT00436384|lung transplant
1385944|NCT00436384|kidney transplant
1385945|NCT00436384|heart transplant
1385946|NCT00436384|CMV CMI
1385947|NCT00436358|Mexico
1385948|NCT00436358|Intussusception
1385949|NCT00436358|Epidemiology
1385950|NCT00436345|analgesia
1385951|NCT00436345|Mechanical ventilation
1385952|NCT00436345|pharmaco-economic
1385953|NCT00436345|ICU
1385954|NCT00436332|recurrent non-small cell lung cancer
1385955|NCT00436332|stage IIIB non-small cell lung cancer
1385956|NCT00436332|stage IV non-small cell lung cancer
1385957|NCT00436332|bronchoalveolar cell lung cancer
1385958|NCT00436332|adenocarcinoma of the lung
1385959|NCT00436319|Infertility, downregulation, stimulation, agonists, long
1385960|NCT00436306|prevention
1385961|NCT00436306|behavior
1385962|NCT00436306|risk reduction behavior
1385963|NCT00436267|recurrent pancreatic cancer
1385964|NCT00436267|stage IV pancreatic cancer
1385965|NCT00436267|liver metastases
1385966|NCT00436228|healthy volunteer,
1385967|NCT00436228|Bioavailability,
1385968|NCT00436228|safety
1385969|NCT00436228|Phase I,
1385970|NCT00436215|Sorafenib
1385971|NCT00436215|Ovarian Cancer
1385972|NCT00436215|Fallopian Cancer
1385973|NCT00436215|Bevacizumab
1385974|NCT00436215|Peritoneal Cancer
1385975|NCT00436215|Fallopian Tube Cancer
1385976|NCT00436202|Anemia
1385977|NCT00436202|Iron
1385978|NCT00436202|Supplement
1385979|NCT00436189|Ovarian
1385980|NCT00436189|Cancer
1385981|NCT00436189|Pelvic
1385982|NCT00436189|Mass
1385983|NCT00436189|Tumor
1385984|NCT00436189|Adnexal
1385985|NCT00436189|Proteomics
1385986|NCT00436176|Diabetes mellitus
1385987|NCT00436176|Quality of Health Care
1385988|NCT00436176|Cultural Competency
1385989|NCT00436176|Performance Feedback
1385990|NCT00436176|Health navigator
1385991|NCT00436176|Health disparities
1385992|NCT00436176|Racial disparities
1385993|NCT00436150|Adolescents
1385994|NCT00436150|Depression, postpartum
1385995|NCT00436137|Colorectal cancer
1385996|NCT00436137|Fecal occult blood test
1385997|NCT00436137|Abnormal test result
1385998|NCT00436137|Missed diagnosis
1385999|NCT00436137|Delayed diagnosis
1386000|NCT00436111|hyperprolactinemia
1386001|NCT00436111|autoantibody
1386002|NCT00436098|congenital heart disease
1386003|NCT00436098|exercise training
1386004|NCT00436098|motorpedagogical exercise
1386005|NCT00436098|children
1386006|NCT00436098|CHD: hemodynamically not significant defects
1386007|NCT00436098|CHD: acyanotic defects after repair
1386008|NCT00436098|CHD: cyanotic defects after repair
1386009|NCT00436072|ZD6474
1386010|NCT00436072|cetuximab
1386011|NCT00436072|irinotecan
1386012|NCT00436046|interferon, vaccine, influenza
1386013|NCT00436020|clinical trial
1386014|NCT00436020|TMS
1386015|NCT00436020|depression
1386016|NCT00436020|bipolar disorder
1386017|NCT00436007|Africa
1386018|NCT00436007|Plasmodium falciparum
1386019|NCT00436007|Malaria
1386020|NCT00435994|Infant
1386021|NCT00435994|Respiratory Syncytial Virus
1386022|NCT00435994|Bronchiolitis
1386023|NCT00435981|Type 1 diabetes
1386024|NCT00435981|GAD65
1386025|NCT00435981|Autoimmunity
1386026|NCT00435981|C-peptide
1386027|NCT00435981|Children
1386028|NCT00435968|NK Cells
1386029|NCT00435968|Cytokines
1386030|NCT00435968|Lymphocytes
1386031|NCT00435968|Immunoglobulins
1386032|NCT00435968|Th1 response
1386033|NCT00435955|Follicular lymphoma
1386034|NCT00435955|age adjusted IPI >1
1386035|NCT00435955|IIL score > 2
1386036|NCT00435955|Molecular remission
1386037|NCT00435955|High dose chemotherapy and autologous transplantation
1386038|NCT00435955|Rituximab
1386039|NCT00435929|Treatment Naive
1386040|NCT00435916|Antigens, CD40
1386041|NCT00435916|Antibody, Monoclonal
1386042|NCT00435916|Lymphoma, Large B-Cell, Diffuse
1386043|NCT00435916|Lymphoma, Non-Hodgkin
1386044|NCT00435916|Hematologic Diseases
1386045|NCT00435916|Immunoproliferative Disorders
1386046|NCT00435916|Lymphatic Diseases
1386047|NCT00435916|Lymphoproliferative Disorders
1386048|NCT00435916|Lymphoma
1386049|NCT00435903|smoking
1386050|NCT00435903|self-monitoring
1386051|NCT00435903|major mental illness
1386052|NCT00435903|palm pilots
1386053|NCT00435903|subjects with DSM-IV Axis I diagnosis
1386054|NCT00435890|ED Overcrowding
1386055|NCT00435890|Length of stay
1386056|NCT00435890|Emergency triage
1386057|NCT00435890|triage
1386058|NCT00435877|Connective Tissue
1386059|NCT00435877|Stromal Cells
1386060|NCT00435877|Surgical Waste
1386061|NCT00435877|In Vivo Studies
1386062|NCT00435877|Tissue Analysis
1386063|NCT00435864|recipient of a HSC graft in Acute Myeloblastic Leukemia therapy
1386064|NCT00435864|recipient of a HSC graft in others pathologies treated in hematology of Nantes university hospital or Angers university hospital
1386065|NCT00435864|donors are healthy subjects
1386066|NCT00435838|HLa-B*5701 Abacavir
1386067|NCT00435812|HBV vaccine
1386068|NCT00435812|Hepatitis B vaccine
1386069|NCT00435812|Hepatitis B
1386070|NCT00435812|Hepatitis
1386071|NCT00435812|HBV
1386072|NCT00435812|Immunostimulatory sequence (ISS)
1386073|NCT00435799|keratoconus
1386074|NCT00435799|corneal cross-linking
1386075|NCT00435799|riboflavine
1386076|NCT00435799|ultraviolet type A rays (UVA)
1386077|NCT00435773|Osteoarthritis
1386078|NCT00435773|Leeching
1386079|NCT00435773|Randomized Controlled Trial
1386080|NCT00435773|Arthralgia
1386081|NCT00435760|COPD
1386082|NCT00435721|schizophrenia
1386083|NCT00435721|family psychoeducation
1386084|NCT00435708|COPD
1386085|NCT00435708|Fruit
1386086|NCT00435708|Vegetables
1386087|NCT00435708|Oxidative stress
1386088|NCT00435708|Inflammation
1386089|NCT00435695|PET scan
1386090|NCT00435695|healthy males
1386091|NCT00435682|The trial is performed on healthy normal males.
1386092|NCT00435669|Advanced or metastatic solid tumors
1386093|NCT00435656|Human immunodeficiency virus
1386094|NCT00435643|Sleep apnea,
1386095|NCT00435643|adiponectin ,
1386096|NCT00435643|HPA axis
1386097|NCT00435630|Education
1386098|NCT00435630|Virtual Reality
1386099|NCT00435630|Laparoscopic Surgery
1386100|NCT00435630|Learning Curve
1386101|NCT00435617|stroke rehabilitation
1386102|NCT00435617|stroke therapy
1386103|NCT00435617|hand therapy
1386104|NCT00435617|stroke
1386105|NCT00435617|cerebrovascular stroke
1386106|NCT00435617|cerebral stroke
1386107|NCT00435604|hyaluronidase
1386108|NCT00435604|subcutaneous drug delivery
1386109|NCT00435604|Volunteer Subjects
1386110|NCT00435591|Hyponatremia
1386111|NCT00435591|Euvolemia
1386112|NCT00435591|Hypervolemia
1386113|NCT00435591|Conivaptan
1386114|NCT00435591|Vaprisol®
1386115|NCT00435591|YM087
1386116|NCT00435578|Recurrent Sensitive Small-Cell Lung Cancer
1386117|NCT00435539|Vitreomacular Traction
1386118|NCT00435539|Maculopathy
1386119|NCT00435539|VMT
1386120|NCT00435539|PVD
1386121|NCT00435526|traveler's diarrhea
1386122|NCT00435526|ETEC diarrhea
1386123|NCT00435526|passive immunization
1386124|NCT00435526|bovine milk prophylaxis
1386125|NCT00435500|Dental caries, topical fluorides
1386126|NCT00435487|Non-ST Elevation Acute Coronary Syndromes coronary interventions
1386127|NCT00435474|Cancer
1386128|NCT00435474|Malignant wounds
1386129|NCT00435474|Quality of life
1386130|NCT00435474|Body-Image
1386131|NCT00435474|Cancer patients
1386132|NCT00435461|once daily
1386133|NCT00435461|mountain cedar
1386134|NCT00435461|fexofenadine
1386135|NCT00435461|allergic rhinitis
1386136|NCT00435461|fluticasone furoate
1386137|NCT00435448|Benign Prostatic Hyperplasia
1386138|NCT00435448|BPH
1386139|NCT00435448|Enlarged Prostate
1386140|NCT00435435|Alcoholism
1386141|NCT00435435|Dependence
1386142|NCT00435435|Randomization
1386143|NCT00435435|Effect
1386144|NCT00435435|Disulfiram
1386145|NCT00435435|Naltrexone
1386146|NCT00435435|Acamprosate
1386147|NCT00435383|Caudal Block
1386148|NCT00435383|Oxygen Saturation
1386149|NCT00435383|Uni or Bilateral Orchidopexy
1386150|NCT00435357|Mobile-bearing
1386151|NCT00435357|arthroplasty
1386152|NCT00435357|fixed-bearing
1386153|NCT00435357|knee
1386154|NCT00435357|patella
1386155|NCT00435357|posterior stabilized TKA
1386156|NCT00435344|Pediatric practice
1386157|NCT00435344|Smoking cessation
1386158|NCT00435344|Smoking prevention
1386159|NCT00435344|Adolescents
1386160|NCT00435331|Pulmonary Arterial Hypertension
1386161|NCT00435331|PPH
1386162|NCT00435305|continuous infusion
1386163|NCT00435305|epithelial lining fluid
1386164|NCT00435305|antibiotics
1386165|NCT00435305|pneumonia
1386166|NCT00435305|critical illness
1386167|NCT00435279|Insomnia
1386168|NCT00435279|Depression
1386169|NCT00435279|Major Depressive Disorder
1386170|NCT00435266|myocardial infarction
1386171|NCT00435266|remote
1386172|NCT00435266|preconditioning
1386173|NCT00435266|perconditioning
1386174|NCT00435266|cardioprotection
1386175|NCT00435253|emphysema
1386176|NCT00435253|COPD
1386177|NCT00435253|lung volume reduction
1386178|NCT00435253|NETT
1386179|NCT00435253|BLVR
1386180|NCT00435253|biologic lung volume reduction
1386181|NCT00435253|bronchoscopic lung volume reduction
1386182|NCT00435227|Respiratory Syncytial Viruses
1386183|NCT00435214|Cytology
1386184|NCT00435214|papilloma virus
1386185|NCT00435214|CIN
1386186|NCT00435214|Screening
1386187|NCT00435214|Cervix
1386188|NCT00435214|Cervical Cancer
1386189|NCT00435188|Aging
1386190|NCT00435188|Cost analysis
1386191|NCT00435188|Counseling
1386192|NCT00435188|Disabled Persons
1386193|NCT00435188|Health Promotion
1386194|NCT00435188|Mobility Limitation
1386195|NCT00435188|Physical Activity
1386196|NCT00435188|Primary Care
1386197|NCT00435188|Randomized Clinical Trial
1386198|NCT00435188|Veterans
1386199|NCT00435175|Estradiol
1386200|NCT00435175|Lipolysis
1386201|NCT00435175|Estrogen receptor
1386202|NCT00435175|Adrenergic receptors
1386203|NCT00435175|UCP2
1386204|NCT00435175|Postmenopausal women
1386205|NCT00435162|Children
1386206|NCT00435162|pediatrics
1386207|NCT00435162|High Blood Pressure
1386208|NCT00435162|Hypertension
1386209|NCT00435162|Valsartan
1386210|NCT00435123|Malnutrition
1386211|NCT00435123|ESRD
1386212|NCT00435123|Hemodialysis
1386213|NCT00435110|ARDS
1386214|NCT00435110|ALI
1386215|NCT00435110|Mechanical Ventilation
1386216|NCT00435110|Outcome
1386217|NCT00435097|colon cancer
1386218|NCT00435097|metastatic colorectal cancer
1386219|NCT00435097|MRI
1386220|NCT00435097|Magnetic resonance imaging
1386221|NCT00435097|Early cancer detection
1386222|NCT00435097|medical image processing
1386223|NCT00435097|machine learning
1386224|NCT00435097|disease modeling
1386225|NCT00435097|Colon Cancer Stage III
1386226|NCT00435084|Refractory B-CLL
1386227|NCT00435084|phase I/II
1386228|NCT00435084|CD38
1386229|NCT00435058|intraocular pressure
1386230|NCT00435058|contrast sensitivity
1386231|NCT00435058|visual function
1386232|NCT00435045|Lovaza
1386233|NCT00435045|Hyperlipidemias
1386234|NCT00435045|Triglycerides
1386235|NCT00435045|Lipids
1386236|NCT00435045|omega-3 fatty acids
1386237|NCT00435045|Hypercholesterolemia
1386238|NCT00435045|Hypertriglyceridemia
1386239|NCT00435045|omega-3-acid ethyl esters
1386240|NCT00435045|Omacor
1386241|NCT00435045|Dyslipidemias
1386242|NCT00435032|ruptured appendicitis
1386243|NCT00435032|children
1386244|NCT00435032|surgery
1386245|NCT00435032|randomized trial
1386246|NCT00434993|Acute Lung Injury
1386247|NCT00434993|Acute Respiratory Distress Syndrome
1386248|NCT00434993|Albuterol
1386249|NCT00434993|Aerosolized
1386250|NCT00434993|Critical Care
1386251|NCT00434993|Ventilator
1386252|NCT00434980|Cognitive adaption
1386253|NCT00434980|Schizophrenia
1386254|NCT00434980|Cognitive rehabilitation
1386255|NCT00434980|Family treatment
1386256|NCT00434980|Cognitive deficits
1386257|NCT00434980|Serious mental illness
1386258|NCT00434967|Blood pressure reduction
1386259|NCT00434967|combination therapy
1386260|NCT00434967|candesartan cilexetil
1386261|NCT00434967|hydrochlorothiazide
1386262|NCT00434954|diabetes
1386263|NCT00434954|exenatide
1386264|NCT00434954|Byetta
1386265|NCT00434954|Amylin
1386266|NCT00434954|Lilly
1386267|NCT00434941|Administration of capecitabine concomitant to radiotherapy
1386268|NCT00434941|Her2: negative
1386269|NCT00434928|observational
1386270|NCT00434928|dietary intake
1386271|NCT00434928|nutrient status
1386272|NCT00434928|serum assessors
1386273|NCT00434928|Attention-Deficit/Hyperactivity Disorder (ADHD)
1386274|NCT00434902|Doppler Echocardiography
1386275|NCT00434902|Pulmonary hypertension
1386276|NCT00434902|Sickle cell disease
1386277|NCT00434889|dementia
1386278|NCT00434889|falls
1386279|NCT00434889|risk factors
1386280|NCT00434876|Alcoholism
1386281|NCT00434876|Insomnia
1386282|NCT00434876|Quetiapine
1386283|NCT00434876|Seroquel
1386284|NCT00434863|botulinum toxin type A
1386285|NCT00434863|Dysport®
1386286|NCT00434863|Botox®
1386287|NCT00434863|hyperfunctional forehead lines
1386288|NCT00434863|randomized controlled trial
1386289|NCT00434863|double-blinded trial
1386290|NCT00434863|electromyogram (EMG)
1386291|NCT00434850|Insulin dependence
1386292|NCT00434850|Hypoglycemia
1386293|NCT00434850|Hyperglycemia unawareness
1386294|NCT00434837|Knee
1386295|NCT00434837|Ligament
1386296|NCT00434837|ACL
1386297|NCT00434837|Reconstruction
1386298|NCT00434837|Cartilage
1386299|NCT00434837|Osteoarthritis
1386300|NCT00434811|Insulin dependence
1386301|NCT00434811|Hypoglycemia
1386302|NCT00434811|Hypoglycemia unawareness
1386303|NCT00434798|Campylobacter infections
1386304|NCT00434772|hypoglycemia
1386305|NCT00434772|glucagon
1386306|NCT00434772|neonatal
1386307|NCT00434772|gestational diabetes
1386308|NCT00434772|insulin
1386309|NCT00434772|glyburide
1386310|NCT00434759|randomized controlled trial
1386311|NCT00434759|stepped-care program
1386312|NCT00434759|cognitive therapy of social phobia according to D.M. Clark
1386313|NCT00434733|Influenza H5N1, pandemic
1386314|NCT00434720|GlideScope
1386315|NCT00434720|Stylet
1386316|NCT00434707|glaucoma
1386317|NCT00434707|catarat
1386318|NCT00434707|small pupils
1386319|NCT00434694|Atrial Fibrillation
1386320|NCT00434694|Catheter ablation
1386321|NCT00434694|Pulmonary Vein
1386322|NCT00434668|Non-Small Cell Lung Cancer
1386323|NCT00434668|NSCLC
1386324|NCT00434668|Adjuvant chemotherapy for completely resected NSCLC
1386325|NCT00434655|Morbid obesity
1386326|NCT00434655|Bariatric surgery
1386327|NCT00434655|Obesity surgery
1386328|NCT00434655|Gastric banding
1386329|NCT00434655|Sleeve gastrectomy
1386330|NCT00434642|Avastin
1386331|NCT00434642|Ovarian carcinoma
1386332|NCT00434642|Peritoneal carcinoma
1386333|NCT00434642|Peritoneal cancer
1386334|NCT00434642|Fallopian tube cancer
1386335|NCT00434642|Fallopian tube carcinoma
1386336|NCT00434642|OCEANS
1386337|NCT00434629|lymphoma
1386338|NCT00434629|Non-Hodgkin's lymphoma
1386339|NCT00434629|B-cell lymphoma
1386340|NCT00434629|Radioimmunotherapy
1386341|NCT00434629|Bexxar
1386342|NCT00434629|tositumomab
1386343|NCT00434629|autologous hematopoietic stem cell transplantation
1386344|NCT00434616|angiogenesis
1386345|NCT00434616|Arterial Occlusive Diseases
1386346|NCT00434616|Leg Ulcer
1386347|NCT00434616|Gangrene
1386348|NCT00434616|Ischemia
1386349|NCT00434616|PAOD
1386350|NCT00434616|Amputation
1386351|NCT00434616|bone marrow
1386352|NCT00434590|Kidney Transplantation
1386353|NCT00434590|Mycophenolic Acid
1386354|NCT00434590|Immunosuppression
1386355|NCT00434590|Cyclosporine
1386356|NCT00434577|GSK Biologicals
1386357|NCT00434577|Herpes Zoster (HZ)
1386358|NCT00434577|Vaccine
1386359|NCT00434577|Varicella Zoster Virus (VZV)
1386360|NCT00434577|Shingles
1386361|NCT00434564|Stress nuclear scan
1386362|NCT00434564|Acute chest pain
1386363|NCT00434551|small bowel Crohn's disease
1386364|NCT00434551|capsule endoscopy
1386365|NCT00434551|PillCam SB
1386366|NCT00434551|Patients with suspected small bowel Crohn's disease
1386367|NCT00434538|Diabetic
1386368|NCT00434538|Foot
1386369|NCT00434538|Ulcer
1386370|NCT00434538|Neuropathic
1386371|NCT00434538|Chitosan
1386372|NCT00434525|Morbid obesity
1386373|NCT00434525|Bariatric Surgery
1386374|NCT00434525|Obesity Surgery
1386375|NCT00434525|Omentectomy
1386376|NCT00434525|Sleeve gastrectomy
1386377|NCT00434512|Gag
1386378|NCT00434512|vaccine
1386379|NCT00434512|adjuvant
1386380|NCT00434512|HIV
1386381|NCT00434512|Pol
1386382|NCT00434512|Nef
1386383|NCT00434499|Green Tea
1386384|NCT00434499|Insulin Resistance
1386385|NCT00434499|Endothelial Dysfunction
1386386|NCT00434499|Nitric Oxide
1386387|NCT00434499|Inflammation
1386388|NCT00434499|Obesity
1386389|NCT00434499|Overweight
1386390|NCT00434499|Diabetes Type 2
1386391|NCT00434499|High Blood Pressure
1386392|NCT00434499|Healthy Volunteer
1386393|NCT00434499|HV
1386394|NCT00434460|Ventilator Associated Pneumonia
1386395|NCT00434460|Knowledge Translation
1386396|NCT00434460|Clinical Practice Guidelines
1386397|NCT00434460|Education
1386398|NCT00434460|Behaviour Change
1386399|NCT00434447|Prostate Cancer
1386400|NCT00434447|Breast Cancer
1386401|NCT00434447|Multiple Myeloma
1386402|NCT00434447|Zoledronic acid
1386403|NCT00434447|Bone metastases
1386404|NCT00434447|Skeletal Related Events (SREs)
1386405|NCT00434447|Renal Impairment
1386406|NCT00434447|Osteonecrosis of the Jaw (ONJ)
1386407|NCT00434447|Bone involvement
1386408|NCT00434447|Multiple Myeloma (MM)
1386409|NCT00434434|AQUA
1386410|NCT00434434|anti-CD11
1386411|NCT00434434|CD11a
1386412|NCT00434434|Asthma
1386413|NCT00434434|Allergy
1386414|NCT00434421|Perennial Allergic Rhinitis
1386415|NCT00434421|Asthma
1386416|NCT00434421|Sublingual Immunotherapy (SLIT)
1386417|NCT00434408|omphalitis
1386418|NCT00434408|neonates
1386419|NCT00434408|umbilical cord
1386420|NCT00434408|infection
1386421|NCT00434408|infant mortality
1386422|NCT00434408|neonate morbidity
1386423|NCT00434408|chlorhexidine
1386424|NCT00434382|auditory evoked potentials
1386425|NCT00434382|sensory processing
1386426|NCT00434382|monitoring
1386427|NCT00434382|general anesthesia
1386428|NCT00434356|Avastin
1386429|NCT00434356|MBC
1386430|NCT00434356|Breast Cancer
1386431|NCT00434356|Sutent
1386432|NCT00434343|Interstitial Cystitis
1386433|NCT00434343|Painful Bladder Syndrome
1386434|NCT00434343|Chronic Prostatitis
1386435|NCT00434343|Chronic Pelvic Pain Syndrome
1386436|NCT00434330|anemia
1386437|NCT00434330|chronic kidney disease
1386438|NCT00434330|CKD
1386439|NCT00434330|chronic renal failure
1386440|NCT00434330|CRF
1386441|NCT00434330|dialysis
1386442|NCT00434330|erythropoietin
1386443|NCT00434330|EPO
1386444|NCT00434330|erythropoiesis stimulating agent
1386445|NCT00434330|ESA
1386446|NCT00434330|Hematide™
1386447|NCT00434330|hemodialysis
1386448|NCT00434330|hemoglobin
1386449|NCT00434330|Hb
1386450|NCT00434330|Hgb
1386451|NCT00434330|Omontys
1386452|NCT00434330|peginesatide
1386453|NCT00434330|red blood cell
1386454|NCT00434330|red blood cell production
1386455|NCT00434317|Metastasis
1386456|NCT00434317|Neoplasm
1386457|NCT00434317|pain
1386458|NCT00434317|breast cancer
1386459|NCT00434317|prostate cancer
1386460|NCT00434317|bone metastasis
1386461|NCT00434304|Parkinson's Disease
1386462|NCT00434304|PD
1386463|NCT00434291|Community-acquired Pneumonia
1386464|NCT00434291|fluoroquinolone
1386465|NCT00434291|TG-873870
1386466|NCT00434291|Nemonoxacin
1386467|NCT00434278|Lung disease
1386468|NCT00434278|CF
1386469|NCT00434278|Pulmozyme
1386470|NCT00434265|Obesity
1386471|NCT00434265|Exercise
1386472|NCT00434265|Fat oxidation
1386473|NCT00434265|Overweigh (IMC>25 and IMC<30)
1386474|NCT00434252|Avastin
1386475|NCT00434252|BEAM
1386476|NCT00434252|Metastatic melanoma
1386477|NCT00434239|Myelodysplasia
1386478|NCT00434239|Lenalidomide
1386479|NCT00434239|Ancestim
1386480|NCT00434239|Pilot trial
1386481|NCT00434239|Biomarkers
1386482|NCT00434226|SABER-L
1386483|NCT00434226|NSCLC
1386484|NCT00434226|Avastin
1386485|NCT00434226|Sutent
1386486|NCT00434200|rheumatoid arthritis
1386487|NCT00434200|exercise
1386488|NCT00434200|damage
1386489|NCT00433498|extensive stage small cell lung cancer
1386490|NCT00433498|limited stage small cell lung cancer
1386491|NCT00433485|basal cell carcinoma of the skin
1386492|NCT00433485|nevoid basal cell carcinoma syndrome
1386493|NCT00433472|adult anaplastic oligodendroglioma
1386494|NCT00433472|adult giant cell glioblastoma
1386495|NCT00433472|adult anaplastic astrocytoma
1386496|NCT00433472|recurrent adult brain tumor
1386497|NCT00433472|adult glioblastoma
1386498|NCT00433472|adult gliosarcoma
1386499|NCT00434187|healthy
1386500|NCT00434174|Lung cancer
1386501|NCT00434174|Non small cell lung cancer
1386502|NCT00434174|NSCLC
1386503|NCT00434174|RAD001
1386504|NCT00434174|Everolimus
1386505|NCT00434174|Afinitor
1386506|NCT00434174|Pemetrexed
1386507|NCT00434161|Palifermin
1386508|NCT00434161|KGF
1386509|NCT00434161|Clinical Trial
1386510|NCT00434161|Oncology
1386511|NCT00434161|Oral Mucositis
1386512|NCT00434161|Multiple Myeloma
1386513|NCT00434161|Cataract
1386514|NCT00434148|Cushing's Disease
1386515|NCT00434148|pasireotide
1386516|NCT00434148|SOM230
1386517|NCT00434135|gemcitabine
1386518|NCT00434135|pemetrexed
1386519|NCT00434135|non-small cell lung cancer
1386520|NCT00434122|Assisted Reproductive Technology (ART)
1386521|NCT00434122|oocyte donors undergoing controlled ovarian hyperstimulation for assisted reproductive technologies
1386522|NCT00434109|Carcinoid
1386523|NCT00434109|Pancreatic
1386524|NCT00434109|Metastatic
1386525|NCT00434109|Neuroendocrine
1386526|NCT00434109|Tumors
1386527|NCT00434109|Hepatic
1386528|NCT00434109|Artery
1386529|NCT00434109|Embolization
1386530|NCT00434109|Angiogenesis
1386531|NCT00434109|Sunitinib
1386532|NCT00434109|Malate
1386533|NCT00434109|Sutent
1386534|NCT00434109|Tyrosine
1386535|NCT00434109|Kinase
1386536|NCT00434109|Inhibitor
1386537|NCT00434096|Obesity disease
1386538|NCT00434096|cannabinoid-1 receptor
1386539|NCT00434083|TREXIMA
1386540|NCT00434083|MIGRAINE HEADACHES
1386541|NCT00434083|Subjects may be enrolled if they are 18-65 years of age, have a demonstrated history of migraine headaches
1386542|NCT00434070|HIV
1386543|NCT00434070|Antiretrovial Therapy
1386544|NCT00434070|Resistance
1386545|NCT00434070|Monitoring
1386546|NCT00434070|TAMS
1386547|NCT00434070|Treatment Experienced
1386548|NCT00434057|Pigmented Skin Lesions
1386549|NCT00434057|Dermatology
1386550|NCT00434057|Skin Cancer
1386551|NCT00434057|Melanoma
1386552|NCT00434057|MelaFind
1386553|NCT00434031|locally advanced
1386554|NCT00434031|stage II
1386555|NCT00434031|stage IIIa
1386556|NCT00434031|stage IIIb
1386557|NCT00434031|HER-2 positive
1386558|NCT00434031|primary
1386559|NCT00434018|Wheelchairs
1386560|NCT00434018|Safety
1386561|NCT00434005|Air pollution
1386562|NCT00434005|diesel
1386563|NCT00434005|antioxidant
1386564|NCT00434005|oxidative stress
1386565|NCT00434005|endothelial
1386566|NCT00434005|HRV
1386567|NCT00434005|BAR
1386568|NCT00433992|Mitochondria
1386569|NCT00433992|Fat apoptosis
1386570|NCT00433992|Lipoatrophy
1386571|NCT00433992|Lipodystrophy
1386572|NCT00433992|Thymidine
1386573|NCT00433992|Treatment experienced
1386574|NCT00433979|Anti-HIV agents
1386575|NCT00433979|Physiological Effects of Drugs
1386576|NCT00433979|ARV-associated Adverse Events
1386577|NCT00433979|HAART
1386578|NCT00433979|Pharmacokinetics
1386579|NCT00433979|Protease Inhibitors
1386580|NCT00433979|Non-nucleoside Reverse Transcriptase Inhibitors
1386581|NCT00433979|Women
1386582|NCT00433966|Myocardial Infarction
1386583|NCT00433966|Angioplasty
1386584|NCT00433966|Myocardial Ischemia
1386585|NCT00433966|Myocardial Reperfusion
1386586|NCT00433966|Stents
1386587|NCT00433966|Heart Disease
1386588|NCT00433953|Pediatric Kidney Transplant
1386589|NCT00433953|Kidney Transplant
1386590|NCT00433953|CellCept
1386591|NCT00433953|Mycophenolate Mofetil
1386592|NCT00433953|Mycophenolic Acid
1386593|NCT00433940|Hemangioma
1386594|NCT00433940|Corticosteroid
1386595|NCT00433940|Prednisone
1386596|NCT00433927|metastatic
1386597|NCT00433914|Meningococcal disease, prevention, vaccination
1386598|NCT00433901|obesity in children
1386599|NCT00433901|childhood disorders
1386600|NCT00433901|overweight children
1386601|NCT00433901|physical activity
1386602|NCT00433901|home environment
1386603|NCT00433862|Polycythemia Vera
1386604|NCT00433862|Essential Thrombocytosis
1386605|NCT00433862|Idiopathic Myelofibrosis
1386606|NCT00433862|Janus Kinase 2
1386607|NCT00433862|CD177
1386608|NCT00433862|Chronic Myeloproliferative Disorders
1386609|NCT00433862|PV
1386610|NCT00433862|Essential Thrombocythemia
1386611|NCT00433862|ET
1386612|NCT00433862|IM
1386613|NCT00433836|Children
1386614|NCT00433836|pediatrics
1386615|NCT00433836|High Blood Pressure
1386616|NCT00433836|Hypertension
1386617|NCT00433836|Valsartan
1386618|NCT00433836|enalapril
1386619|NCT00433823|Very low level of LDL
1386620|NCT00433823|Steroid hormones
1386621|NCT00433823|Atorvastatin
1386622|NCT00433823|Ezetimibe
1386623|NCT00433823|Lipoprotein-a
1386624|NCT00433810|obesity
1386625|NCT00433810|bariatric surgery
1386626|NCT00433810|30-day mortality
1386627|NCT00433797|Prostate cancer
1386628|NCT00433797|PSA
1386629|NCT00433797|antioxidant
1386630|NCT00433797|phytochemical
1386631|NCT00433797|tomatoes
1386632|NCT00433797|PUFA
1386633|NCT00433797|selenium
1386634|NCT00433797|soy
1386635|NCT00433797|pomegranate
1386636|NCT00433797|grapes
1386637|NCT00433784|clopidogrel
1386638|NCT00433784|platelet aggregation
1386639|NCT00433784|CYP3A
1386640|NCT00433784|H2 haplotype
1386641|NCT00433784|polymorphisms
1386642|NCT00433771|Malignant
1386643|NCT00433771|Cholestasis, Extrahepatic
1386644|NCT00433771|Biliary obstruction
1386645|NCT00433758|Diabetes
1386646|NCT00433758|Blood glucose monitoring
1386647|NCT00433758|Non invasive Blood glucose monitoring
1386648|NCT00433745|Myelodysplastic Syndrome (MDS)
1386649|NCT00433745|Acute Myelogenous Leukemia (AML)
1386650|NCT00433745|Chronic Myelogenous Leukemia (CML)
1386651|NCT00433745|Acute Lymphoblastic Leukemia (ALL)
1386652|NCT00433745|Wilm's Tumor-1 Peptide
1386653|NCT00433745|Leukemia
1386654|NCT00433745|Myelodysplastic Syndrome
1386655|NCT00433745|MDS
1386656|NCT00433745|Acute Myelogenous Leukemia
1386657|NCT00433745|AML
1386658|NCT00433745|Chronic Myelogenous Leukemia
1386659|NCT00433745|CML
1386660|NCT00433745|Acute Lymphoblastic Leukemia
1386661|NCT00433745|ALL
1386662|NCT00433732|TREXIMA
1386663|NCT00433732|MIGRAINE HEADACHES
1386664|NCT00433732|Subjects may be enrolled if they are 18-65 years of age, have a demonstrated history of migraine headaches
1386665|NCT00433719|Human immunodeficiency virus
1386666|NCT00433719|Tuberculous meningitis
1386667|NCT00433719|Treatment Naive
1386668|NCT00433706|Prostate adenocarcinoma treated by radiotherapy
1386669|NCT00433680|adolescent
1386670|NCT00433680|female
1386671|NCT00433680|obesity
1386672|NCT00433680|body dissatisfaction
1386673|NCT00433667|RWJ-333369
1386674|NCT00433667|anticonvulsants
1386675|NCT00433667|antiepileptic drugs
1386676|NCT00433654|Bradycardia
1386677|NCT00433654|Slow heart beat
1386678|NCT00433654|Magnetic resonance imaging (MRI)
1386679|NCT00433641|obesity
1386680|NCT00433641|pharmacogenetics
1386681|NCT00433641|sibutramine
1386682|NCT00433641|adrenergic
1386683|NCT00433641|serotonergic
1386684|NCT00433641|body composition
1386685|NCT00433641|gastric emptying
1386686|NCT00433628|Hemoglobin A1C
1386687|NCT00433628|HIV
1386688|NCT00433628|Diabetes
1386689|NCT00433628|Diabetes Type 2
1386690|NCT00433628|Hyperglycemia
1386691|NCT00433602|thromboembolism
1386692|NCT00433602|recurrent breast cancer
1386693|NCT00433602|stage IV breast cancer
1386694|NCT00433602|recurrent colon cancer
1386695|NCT00433602|stage I colon cancer
1386696|NCT00433602|stage II colon cancer
1386697|NCT00433602|stage III colon cancer
1386698|NCT00433602|stage IV colon cancer
1386699|NCT00433602|recurrent rectal cancer
1386700|NCT00433602|stage I rectal cancer
1386701|NCT00433602|stage II rectal cancer
1386702|NCT00433602|stage III rectal cancer
1386703|NCT00433602|stage IV rectal cancer
1386704|NCT00433602|recurrent gastric cancer
1386705|NCT00433602|stage I gastric cancer
1386706|NCT00433602|stage II gastric cancer
1386707|NCT00433602|stage III gastric cancer
1386708|NCT00433602|stage IV gastric cancer
1386709|NCT00433602|recurrent non-small cell lung cancer
1386710|NCT00433602|stage I non-small cell lung cancer
1386711|NCT00433602|stage II non-small cell lung cancer
1386712|NCT00433602|stage IIIA non-small cell lung cancer
1386713|NCT00433602|stage IIIB non-small cell lung cancer
1386714|NCT00433602|stage IV non-small cell lung cancer
1386715|NCT00433602|recurrent small cell lung cancer
1386716|NCT00433602|recurrent ovarian epithelial cancer
1386717|NCT00433602|stage I ovarian epithelial cancer
1386718|NCT00433602|stage II ovarian epithelial cancer
1386719|NCT00433602|stage III ovarian epithelial cancer
1386720|NCT00433602|stage IV ovarian epithelial cancer
1386721|NCT00433602|recurrent ovarian germ cell tumor
1386722|NCT00433602|stage I ovarian germ cell tumor
1386723|NCT00433602|stage II ovarian germ cell tumor
1386724|NCT00433602|stage III ovarian germ cell tumor
1386725|NCT00433602|stage IV ovarian germ cell tumor
1386726|NCT00433602|ovarian sarcoma
1386727|NCT00433602|ovarian stromal cancer
1386728|NCT00433602|recurrent pancreatic cancer
1386729|NCT00433602|stage I pancreatic cancer
1386730|NCT00433602|stage II pancreatic cancer
1386731|NCT00433602|stage III pancreatic cancer
1386732|NCT00433602|stage IV pancreatic cancer
1386733|NCT00433602|recurrent prostate cancer
1386734|NCT00433602|stage III prostate cancer
1386735|NCT00433602|stage IV prostate cancer
1386736|NCT00433602|extensive stage small cell lung cancer
1386737|NCT00433602|limited stage small cell lung cancer
1386738|NCT00433602|stage IIB prostate cancer
1386739|NCT00433602|stage IIA prostate cancer
1386740|NCT00433602|male breast cancer
1386741|NCT00433589|invasive ductal breast carcinoma
1386742|NCT00433589|invasive lobular breast carcinoma
1386743|NCT00433589|stage IA breast cancer
1386744|NCT00433589|stage IB breast cancer
1386745|NCT00433589|stage II breast cancer
1386746|NCT00433589|estrogen receptor-positive breast cancer
1386747|NCT00433589|progesterone receptor-positive breast cancer
1386748|NCT00433563|limited stage small cell lung cancer
1386749|NCT00433524|unspecified adult solid tumor, protocol specific
1386750|NCT00433459|childhood lymphocyte depletion Hodgkin lymphoma
1386751|NCT00433459|childhood mixed cellularity Hodgkin lymphoma
1386752|NCT00433459|childhood nodular sclerosis Hodgkin lymphoma
1386753|NCT00433459|stage I childhood Hodgkin lymphoma
1386754|NCT00433459|stage II childhood Hodgkin lymphoma
1386755|NCT00433459|stage III childhood Hodgkin lymphoma
1386756|NCT00433459|stage IV childhood Hodgkin lymphoma
1386757|NCT00433446|adenocarcinoma of the prostate
1386758|NCT00433446|stage IV prostate cancer
1386759|NCT00433446|recurrent prostate cancer
1386760|NCT00433433|adult mixed cellularity Hodgkin lymphoma
1386761|NCT00433433|adult nodular sclerosis Hodgkin lymphoma
1386762|NCT00433433|stage I adult Hodgkin lymphoma
1386763|NCT00433433|stage II adult Hodgkin lymphoma
1386764|NCT00433433|adult lymphocyte depletion Hodgkin lymphoma
1386765|NCT00433420|stage II breast cancer
1386766|NCT00433420|stage IIIA breast cancer
1386767|NCT00433420|stage IIIB breast cancer
1386768|NCT00433420|stage IIIC breast cancer
1386769|NCT00433407|unspecified adult solid tumor, protocol specific
1386770|NCT00433407|stage I breast cancer
1386771|NCT00433407|stage II breast cancer
1386772|NCT00433407|stage IIIA breast cancer
1386773|NCT00433407|stage IIIB breast cancer
1386774|NCT00433407|stage IIIC breast cancer
1386775|NCT00433407|stage IV breast cancer
1386776|NCT00433407|male breast cancer
1386777|NCT00433407|recurrent breast cancer
1386778|NCT00433407|stage I ovarian epithelial cancer
1386779|NCT00433407|stage II ovarian epithelial cancer
1386780|NCT00433407|stage III ovarian epithelial cancer
1386781|NCT00433407|stage IV ovarian epithelial cancer
1386782|NCT00433407|recurrent ovarian epithelial cancer
1386783|NCT00433407|stage I non-small cell lung cancer
1386784|NCT00433407|stage II non-small cell lung cancer
1386785|NCT00433407|stage IIIA non-small cell lung cancer
1386786|NCT00433407|stage IIIB non-small cell lung cancer
1386787|NCT00433407|stage IV non-small cell lung cancer
1386788|NCT00433407|recurrent non-small cell lung cancer
1386789|NCT00433407|extensive stage small cell lung cancer
1386790|NCT00433407|limited stage small cell lung cancer
1386791|NCT00433407|recurrent small cell lung cancer
1386792|NCT00433407|stage I prostate cancer
1386793|NCT00433407|stage IIB prostate cancer
1386794|NCT00433407|stage IIA prostate cancer
1386795|NCT00433407|stage III prostate cancer
1386796|NCT00433407|stage IV prostate cancer
1386797|NCT00433407|recurrent prostate cancer
1386798|NCT00433407|stage I uterine sarcoma
1386799|NCT00433407|stage II uterine sarcoma
1386800|NCT00433407|stage III uterine sarcoma
1386801|NCT00433407|stage IV uterine sarcoma
1386802|NCT00433407|recurrent uterine sarcoma
1386803|NCT00433394|unspecified childhood solid tumor, protocol specific
1386804|NCT00433368|L-ornithine-L-aspartate,
1386805|NCT00433368|porto-systemic encephalopathy,
1386806|NCT00433368|hepatic encephalopathy,
1386807|NCT00433368|liver cirrhosis,
1386808|NCT00433368|mental state
1386809|NCT00433355|Chronic Fatigue Syndrome
1386810|NCT00433355|Epstein-Barr Virus
1386811|NCT00433342|Antibiotic
1386812|NCT00433342|p-cresol
1386813|NCT00433342|peritoneal dialysis
1386814|NCT00433329|pulmonary arterial hypertension
1386815|NCT00433329|bosentan
1386816|NCT00433329|sildenafil
1386817|NCT00433329|combination therapy
1386818|NCT00433329|Compass 3
1386819|NCT00433316|ropivacaine
1386820|NCT00433316|laparoscopy
1386821|NCT00433316|intraperitoneal
1386822|NCT00433316|nebulization
1386823|NCT00433316|pain
1386824|NCT00433316|local analgesic
1386825|NCT00433316|gynecology
1386826|NCT00433264|peritoneal dialysis
1386827|NCT00433264|endothelium
1386828|NCT00433264|endothelial dysfunction
1386829|NCT00433238|elderly
1386830|NCT00433238|Chinese
1386831|NCT00433238|community living
1386832|NCT00433238|measurement
1386833|NCT00433238|depression
1386834|NCT00433238|dementia
1386835|NCT00433238|Geriatric Depression Scale
1386836|NCT00433238|MiniCog
1386837|NCT00433212|prematurity
1386838|NCT00433212|respiratory insufficiency
1386839|NCT00433212|non-invasive ventilation
1386840|NCT00433212|bronchopulmonary dysplasia
1386841|NCT00433212|hyaline membrane disease
1386842|NCT00433199|Hypogonadism
1386843|NCT00433199|Testosterone Deficiency
1386844|NCT00433186|Scleroderma
1386845|NCT00433173|testosterone
1386846|NCT00433173|insulin sensitivity
1386847|NCT00433173|insulin resistance
1386848|NCT00433173|metabolic disorders
1386849|NCT00433134|renal transplant recipient
1386850|NCT00433134|adherence
1386851|NCT00433134|compliance
1386852|NCT00433134|immunosuppression
1386853|NCT00433121|Antidepressive Agents
1386854|NCT00433121|Neuroleptica
1386855|NCT00433121|Dementia
1386856|NCT00433121|Discontinuation study
1386857|NCT00433121|Behavioural- and Psychological Symptoms in Dementia
1386858|NCT00433108|Hepatitis C
1386859|NCT00433108|antioxidant
1386860|NCT00433108|liver enzymes
1386861|NCT00433108|ALT
1386862|NCT00433095|Navelbine
1386863|NCT00433095|Herceptin
1386864|NCT00433095|oral
1386865|NCT00433095|breast cancer
1386866|NCT00433082|Metabolic syndrome,Ramadan,Fasting,Inflammatory markers,
1386867|NCT00433082|Iran
1386868|NCT00433069|Chronic hepatitis C
1386869|NCT00433069|Insulin resistance
1386870|NCT00433069|Pioglitazone
1386871|NCT00433069|Non-responders
1386872|NCT00433056|STI
1386873|NCT00433056|HIV
1386874|NCT00433056|CD4
1386875|NCT00433056|HIV-RNA
1386876|NCT00433056|HAART
1386877|NCT00433043|Heart Failure
1386878|NCT00433043|Beta blockers
1386879|NCT00433043|Resynchronization
1386880|NCT00433043|Congestive Heart Failure, NYHA III-IV
1386881|NCT00433043|Candidate for BIVPM
1386882|NCT00433043|Not on Target Dose (Coreg 25 Bid or Toprol XL 200 qd)
1386883|NCT00433030|Highly Active Antiretroviral Therapy
1386884|NCT00433030|HIV Viral load
1386885|NCT00433030|HIV drug Resistance
1386886|NCT00433030|Thailand
1386887|NCT00433017|Age-related macular degeneration
1386888|NCT00433017|AMD
1386889|NCT00433017|Choroidal neovascularization
1386890|NCT00433017|Verteporfin
1386891|NCT00433017|Ranibizumab
1386892|NCT00433004|Teen
1386893|NCT00433004|Plan B
1386894|NCT00433004|Post Partum
1386895|NCT00433004|Emergency Contraception
1386896|NCT00432991|Nausea
1386897|NCT00432991|Vomiting
1386898|NCT00432991|Cesarean Section
1386899|NCT00432978|hypoxia
1386900|NCT00432978|endothelin
1386901|NCT00432978|exercise
1386902|NCT00432965|Wound closure
1386903|NCT00432965|Accelerated healing
1386904|NCT00432952|Cardiovascular Heart Disease
1386905|NCT00432939|Primary Hyperparathyroidism
1386906|NCT00432926|HIV
1386907|NCT00432926|STDs
1386908|NCT00432926|Methamphetamine abuse
1386909|NCT00432926|MSM
1386910|NCT00432926|HIV Seronegativity
1386911|NCT00432913|Eicosapentaenoic acid
1386912|NCT00432913|EPA
1386913|NCT00432913|EPA 99%
1386914|NCT00432913|Fatty acid
1386915|NCT00432913|omega-3
1386916|NCT00432913|apoptosis
1386917|NCT00432913|cell proliferation
1386918|NCT00432913|colonic mucosa
1386919|NCT00432913|polyps
1386920|NCT00432913|adenomatous polyps
1386921|NCT00432913|endoscopy
1386922|NCT00432913|PUFA
1386923|NCT00432900|Inflammation
1386924|NCT00432900|Neuroimmunology
1386925|NCT00432900|Multiple Sclerosis
1386926|NCT00432900|MS
1386927|NCT00432900|Healthy Volunteer
1386928|NCT00432900|HV
1386929|NCT00432887|caffeine
1386930|NCT00432887|coffee
1386931|NCT00432887|glucose
1386932|NCT00432887|insulin
1386933|NCT00432861|cystic fibrosis
1386934|NCT00432861|pancreatic insufficiency
1386935|NCT00432861|PANCRECARB® MS-16 (pancrelipase)
1386936|NCT00432861|steatorrhea
1386937|NCT00432835|Nausea
1386938|NCT00432835|Vomiting
1386939|NCT00432835|Delayed gastric emptying
1386940|NCT00432835|Diabetes Mellitus
1386941|NCT00432835|Post-Surgical
1386942|NCT00432835|Idiopathic
1386943|NCT00432822|phenylketonuria
1386944|NCT00432822|phenylalanine hydroxylase deficiency
1386945|NCT00432822|BH4
1386946|NCT00432822|responsive
1386947|NCT00432822|tetrahydrobiopterin
1386948|NCT00432822|newborns
1386949|NCT00432822|infants
1386950|NCT00432822|children
1386951|NCT00432822|adolescents
1386952|NCT00432809|Diabetes Mellitus, Type 2
1386953|NCT00432809|Obesity
1386954|NCT00432796|Anticoagulation
1386955|NCT00432796|Prosthetic heart valves
1386956|NCT00432796|Atrial fibrillation
1386957|NCT00432796|Bridging Therapy
1386958|NCT00432796|Thromboembolism
1386959|NCT00432796|Warfarin
1386960|NCT00432796|Low Molecular Weight Heparin
1386961|NCT00432783|HIV, antiretroviral therapy, adherence, ritonavir
1386962|NCT00432757|allergic conjunctivitis, ophthalmology, multicenter, controlled
1386963|NCT00432744|mitochondrial diseases
1386964|NCT00432744|respiratory chain complex I deficiencies
1386965|NCT00432744|respiratory chain complex II deficiencies
1386966|NCT00432744|respiratory chain complex III deficiencies
1386967|NCT00432744|respiratory chain complex IV deficiencies
1386968|NCT00432744|mutations of a gene coding for a respiratory chain component
1386969|NCT00432731|Prevention of : Varicella
1386970|NCT00432731|Measles
1386971|NCT00432731|Mumps
1386972|NCT00432731|Rubella
1386973|NCT00432718|Pneumonia
1386974|NCT00432718|Ventilator Associated Pneumonia
1386975|NCT00432718|Prevention
1386976|NCT00432705|ankle
1386977|NCT00432705|sensorimotor
1386978|NCT00432705|reflex
1386979|NCT00432705|training
1386980|NCT00432692|osteoporosis
1386981|NCT00432692|falls
1386982|NCT00432692|prevention
1386983|NCT00432692|elderly
1386984|NCT00432692|exercise
1386985|NCT00432692|incidence
1386986|NCT00432692|obstacle avoidance
1386987|NCT00432679|rosiglitazone
1386988|NCT00432679|Avandia
1386989|NCT00432679|type 2 diabetes mellitus
1386990|NCT00432679|diabetes
1386991|NCT00432653|ankylosing spondylitis
1386992|NCT00432653|rituximab
1386993|NCT00432653|therapy
1386994|NCT00432653|magnetic resonance imaging
1386995|NCT00432640|(suspected) Non Small Cell Lung Cancer
1386996|NCT00432627|Hepatic impairment
1386997|NCT00432627|adults
1386998|NCT00432627|deferasirox
1386999|NCT00432614|Mental Disorder
1387000|NCT00432614|Mood Disorder
1387001|NCT00432614|Depressive Disorder
1387002|NCT00432601|decision aid
1387003|NCT00432601|prostate cancer
1387004|NCT00432601|patient-physician communication
1387005|NCT00432601|decision making
1387006|NCT00432601|literacy
1387007|NCT00432588|IUFD
1387008|NCT00432588|POSTTERM
1387009|NCT00432588|ROM
1387010|NCT00432575|tobacco use cessation
1387011|NCT00432575|cigarette smokers
1387012|NCT00432549|Medication overuse
1387013|NCT00432536|Neuro-monitoring
1387014|NCT00432536|Quality Improvement
1387015|NCT00432536|Cerebral emboli
1387016|NCT00432536|Cerebral desaturation
1387017|NCT00432536|Hypotension
1387018|NCT00432523|Prevention of : Measles, Mumps, Rubella and Varicella diseases
1387019|NCT00432510|Hereditary angioedema
1387020|NCT00432510|C1 esterase inhibitor (human)
1387021|NCT00432484|Lingzhi
1387022|NCT00432484|Sen Miao San
1387023|NCT00432484|Rheumatoid Arthritis
1387029|NCT00432458|stage I multiple myeloma
1387030|NCT00432445|Children with retinoblastoma
1387031|NCT00432445|Retinoblastoma
1387032|NCT00432445|Pediatrics
1387033|NCT00432445|Proton Beam Radiation Therapy
1387034|NCT00432445|Radiation Therapy
1387035|NCT00432445|Tumor of the Eye
1387036|NCT00432445|Ophthalmic EUA
1387037|NCT00432445|Examination under anesthesia
1387038|NCT00432445|Bilateral retinoblastoma
1387039|NCT00432445|Unilateral retinoblastoma
1387040|NCT00432445|Extraocular disease
1387041|NCT00432445|Intraocular procedure
1387042|NCT00432432|Ankylosing Spondylitis
1387043|NCT00432432|MTX
1387044|NCT00432432|Infliximab
1387045|NCT00432419|HIV
1387046|NCT00432419|Non-Hodgkin's lymphoma
1387047|NCT00432419|Peripheral blood stem cells transplantation
1387048|NCT00432406|Psoriatic Arthritis
1387049|NCT00432406|TNF-α
1387050|NCT00432406|Cardiovascular risk
1387051|NCT00432406|Immunomodulatory activities
1387052|NCT00432380|Placebo
1387053|NCT00432380|Double blind
1387054|NCT00432380|Gastroenteritis
1387055|NCT00432380|Randomized
1387056|NCT00432380|Oral live attenuated human rotavirus liquid vaccine
1387057|NCT00432367|Malaria in pregnancy
1387058|NCT00432367|Case management
1387059|NCT00432367|Screening
1387060|NCT00432367|RDT
1387061|NCT00432367|IPTp
1387062|NCT00432367|Amodiaquine
1387063|NCT00432367|Artesunate
1387064|NCT00432354|statin
1387065|NCT00432354|systemic lupus erythematosus
1387066|NCT00432354|microcirculation
1387067|NCT00432302|Cancer
1387068|NCT00432302|Tumor
1387069|NCT00432302|Malignancy
1387070|NCT00432302|Mass Balance
1387071|NCT00432302|Chemotherapy
1387072|NCT00432302|Drug
1387073|NCT00432302|Cancer Treatment
1387074|NCT00432302|Intravenous Infusion
1387075|NCT00432302|Epothilone
1387076|NCT00432302|Solid Tumor
1387077|NCT00432289|neurological function
1387078|NCT00432276|Glucose Metabolism Disorder
1387079|NCT00432276|Dysmetabolic Syndrome
1387080|NCT00432276|Type II Diabetes
1387081|NCT00432276|Diabetes Mellitus, Lipoatrophic
1387082|NCT00432276|Dyslipidemia
1387083|NCT00432276|Hyperglycemia
1387084|NCT00432276|Drug Therapy
1387085|NCT00432250|Preterm labor
1387086|NCT00432250|Cervical ultrasonography
1387087|NCT00432250|Hospital stay
1387088|NCT00432198|Insomnia
1387089|NCT00432198|Zolpidem
1387090|NCT00432198|Adolescent
1387091|NCT00432185|sBCC
1387092|NCT00432185|Topical
1387093|NCT00432185|Dermatology
1387094|NCT00432172|Her2neu negative breast cancer.
1387095|NCT00432172|Neoadjuvant treatment.
1387096|NCT00432159|cervical
1387097|NCT00432159|spinal
1387098|NCT00432159|arthroplasty
1387099|NCT00432159|disc
1387100|NCT00432159|surgical
1387101|NCT00432159|ACDF
1387102|NCT00432159|DDD
1387103|NCT00432146|Graves' disease, Lugol's solution
1387104|NCT00432133|Physical Activity
1387105|NCT00432133|Behavior Change
1387106|NCT00432133|Mechanism
1387107|NCT00432133|Environmental
1387108|NCT00432133|Ecological Model of Physical Activity
1387109|NCT00432107|Advanced cutaneous melanoma
1387110|NCT00432107|Phase II study
1387111|NCT00432094|childhood extragonadal germ cell tumor
1387112|NCT00432094|childhood malignant ovarian germ cell tumor
1387113|NCT00432094|childhood malignant testicular germ cell tumor
1387114|NCT00432094|stage III malignant testicular germ cell tumor
1387115|NCT00432094|testicular choriocarcinoma and seminoma
1387116|NCT00432094|testicular embryonal carcinoma and seminoma
1387117|NCT00432094|testicular embryonal carcinoma and teratoma with seminoma
1387118|NCT00432094|testicular embryonal carcinoma and yolk sac tumor with seminoma
1387119|NCT00432094|testicular yolk sac tumor and teratoma with seminoma
1387120|NCT00432094|testicular choriocarcinoma and embryonal carcinoma
1387121|NCT00432094|testicular choriocarcinoma and teratoma
1387122|NCT00432094|testicular choriocarcinoma and yolk sac tumor
1387123|NCT00432094|testicular choriocarcinoma
1387124|NCT00432094|testicular embryonal carcinoma and teratoma
1387125|NCT00432094|testicular embryonal carcinoma and yolk sac tumor
1387126|NCT00432094|testicular embryonal carcinoma
1387127|NCT00432094|testicular yolk sac tumor and teratoma
1387128|NCT00432094|testicular yolk sac tumor
1387129|NCT00432094|testicular seminoma
1387130|NCT00432094|stage IV extragonadal non-seminomatous germ cell tumor
1387131|NCT00432094|stage IV extragonadal seminoma
1387132|NCT00432094|stage I extragonadal non-seminomatous germ cell tumor
1387133|NCT00432094|stage I extragonadal seminoma
1387134|NCT00432094|stage II extragonadal non-seminomatous germ cell tumor
1387135|NCT00432094|stage II extragonadal seminoma
1387136|NCT00432094|stage III extragonadal non-seminomatous germ cell tumor
1387137|NCT00432094|stage III extragonadal seminoma
1387138|NCT00432094|stage II ovarian germ cell tumor
1387139|NCT00432094|stage I malignant testicular germ cell tumor
1387140|NCT00432094|stage II malignant testicular germ cell tumor
1387141|NCT00432094|adult teratoma
1387142|NCT00432094|childhood teratoma
1387143|NCT00432094|testicular immature teratoma
1387144|NCT00432094|testicular mature teratoma
1387145|NCT00432094|adult central nervous system germ cell tumor
1387146|NCT00432094|childhood central nervous system germ cell tumor
1387147|NCT00432081|Dementia
1387148|NCT00432081|Inflammation
1387149|NCT00432081|Anti-Inflammatory Agents
1387150|NCT00432081|Anti-Inflammatory Agents, Non-Steroidal
1387151|NCT00432081|Drug Therapy
1387152|NCT00432068|Healthy volunteers
1387153|NCT00432068|octreotide pamoate
1387154|NCT00432068|pharmacokinetics
1387155|NCT00432055|Adult
1387156|NCT00432055|Cerebral Palsy
1387157|NCT00432055|Spastic contractures
1387158|NCT00432055|Botulinum toxin type A
1387159|NCT00432042|Mumps and Rubella
1387160|NCT00432042|Haemophilus influenzae type b (Infanrix® hexa)
1387161|NCT00432029|Flicker induced vasodilatation
1387162|NCT00432029|Flow mediated vasodilatation
1387163|NCT00432029|Forearm blood flow
1387164|NCT00432029|Retinal vessel diameter
1387165|NCT00432029|Endothelial dysfunction
1387166|NCT00432016|HIV
1387167|NCT00432016|pharmacokinetics
1387168|NCT00432016|zidovudine
1387169|NCT00432016|amdoxovir
1387170|NCT00432016|DAPD
1387171|NCT00432016|AMDX
1387172|NCT00432016|Treatment Naive
1387173|NCT00432003|Treatment Experienced
1387174|NCT00432003|HIV
1387175|NCT00432003|Antiretroviral Therapy, Highly Active
1387176|NCT00431977|Coronary Atherosclerosis
1387177|NCT00431977|Diabetes Mellitus
1387178|NCT00431964|azithromycin, Zithromax
1387179|NCT00431951|Healthy Volunteers
1387180|NCT00431925|head and neck cancer
1387181|NCT00431925|radiation therapy
1387182|NCT00431925|chemotherapy
1387183|NCT00431925|mucositis
1387184|NCT00431925|cytokines
1387185|NCT00431925|gastrostomy
1387186|NCT00431925|radiotherapy
1387187|NCT00431912|cutaneous T-cell lymphoma
1387188|NCT00431912|mycosis fungoides
1387189|NCT00431912|Sézary syndrome
1387190|NCT00431912|APO866
1387191|NCT00431912|phase II study
1387192|NCT00431899|nutrition
1387193|NCT00431899|omega 3 fatty acids
1387194|NCT00431899|insulin resistance
1387195|NCT00431886|Chest pains
1387196|NCT00431886|Computed tomography
1387197|NCT00431886|Emergency
1387198|NCT00431873|Lymphocytic Leukemia, Chronic (Refractory)
1387199|NCT00431873|Phase II
1387200|NCT00431860|Coronary atherosclerosis, Spiral Computed Tomography
1387201|NCT00431847|Anesthesia, Regional
1387202|NCT00431847|Causalgia
1387203|NCT00431847|Trauma
1387204|NCT00431847|Complex Regional Pain Syndrome Type II
1387205|NCT00431847|Neuropathic Pain
1387206|NCT00431847|PTSD
1387207|NCT00431847|Combat Stress Disorders
1387208|NCT00431847|Afghan War, 2001-
1387209|NCT00431847|Iraq War, 2003-
1387210|NCT00431834|Permanent Atrial Fibrillation Surgical RF Ablation
1387211|NCT00431834|Permanent Atrial Fibrillation
1387212|NCT00431821|Exercise
1387213|NCT00431821|Rehabilitation
1387214|NCT00431821|Stroke
1387215|NCT00431808|Malaria
1387216|NCT00431808|vaccine
1387217|NCT00431808|Apical Membrane Antigene
1387218|NCT00431808|Mali
1387219|NCT00431808|Adults
1387220|NCT00431795|Advanced breast cancer
1387221|NCT00431795|Pegylated liposomal doxorubicin
1387222|NCT00431795|Epirubicin
1387223|NCT00431782|Atrial fibrillation
1387224|NCT00431782|Anticoagulation
1387225|NCT00431769|Multiple myeloma
1387226|NCT00431769|Bortezomib
1387227|NCT00431769|Dexamethasone
1387228|NCT00431769|VELCADE
1387229|NCT00431756|Barrett's esophagus
1387230|NCT00431756|gastroesophageal reflux disease (GERD)
1387231|NCT00431756|esophageal cancer
1387232|NCT00431756|DNA methylation
1387233|NCT00431743|Fluid Therapy
1387234|NCT00431743|Crystalloid
1387235|NCT00431743|Colloid
1387236|NCT00431743|Perioperative
1387237|NCT00431743|Optimization
1387238|NCT00431743|Goal-directed Therapy
1387239|NCT00431717|Coronary Atherosclerosis
1387240|NCT00431717|Diabetes Mellitus
1387241|NCT00431704|advanced
1387242|NCT00431704|her-2 positive
1387243|NCT00431678|Community-acquired Pneumonia
1387244|NCT00431665|Renal Plasma Flow
1387245|NCT00431665|Glomerular Filtration Rate
1387246|NCT00431665|Free fatty acids
1387247|NCT00431639|Animal-Assisted Therapy
1387248|NCT00431639|Pain
1387249|NCT00431639|Oncology
1387250|NCT00431639|Cancer Pain
1387251|NCT00431626|Benign
1387252|NCT00431626|Prostatic
1387253|NCT00431626|Hyperplasia
1387254|NCT00431626|Lower
1387255|NCT00431626|Urinary
1387256|NCT00431626|Track
1387257|NCT00431626|Symptoms
1387258|NCT00431626|Laser
1387259|NCT00431626|Transurethral
1387260|NCT00431626|Prostate
1387261|NCT00431613|NSCLC
1387262|NCT00431613|Induction chemotherapy
1387263|NCT00431613|Concurrent chemoradiotherapy
1387264|NCT00431613|Consolidation therapy
1387265|NCT00431613|Docetaxel
1387266|NCT00431613|Gemcitabine
1387267|NCT00431613|Carboplatin
1387268|NCT00431600|Regional Blood Flow
1387269|NCT00431600|Color Doppler Optical Coherence Tomography
1387270|NCT00431600|CDOCT
1387271|NCT00431600|Retinal Blood Flow
1387272|NCT00431600|Hyperoxia
1387273|NCT00431600|Vasoconstriction
1387274|NCT00431600|Laser Doppler Velocimetry
1387275|NCT00431600|Retinal Vessel Analyzer
1387276|NCT00431587|morbid obesity
1387277|NCT00431587|metabolic syndrome
1387278|NCT00431587|visceral fat
1387279|NCT00431587|peripheral fat
1387280|NCT00431574|schizophrenia
1387281|NCT00431574|schizoaffective
1387282|NCT00431574|antipsychotic
1387283|NCT00431574|randomized control trial
1387284|NCT00431561|Glioblastoma
1387285|NCT00431561|Anaplastic astrocytoma
1387286|NCT00431561|Antisense
1387287|NCT00431561|Cancer
1387288|NCT00431561|Transforming growth factor beta2 (TGF-beta2)
1387289|NCT00431561|Targeted therapy
1387290|NCT00431561|Immunotherapy
1387291|NCT00431561|Brain tumor
1387292|NCT00431561|Central nervous system (CNS)
1387293|NCT00431561|Convection-enhanced delivery (CED) / microperfusion
1387294|NCT00431561|Locoregional application
1387295|NCT00431535|Fluid
1387296|NCT00431535|SvO2
1387297|NCT00431535|Mobilisation
1387298|NCT00431535|Orthostatic function
1387299|NCT00431509|Osteoarthritis
1387300|NCT00431509|Arthroplasty
1387301|NCT00431509|Replacement
1387302|NCT00431509|Knee
1387303|NCT00431509|Instrumentation
1387304|NCT00431496|Anemia
1387305|NCT00431496|Intact Parathyroid Hormone (iPTH)
1387306|NCT00431496|Secondary Hyperparathyroidism (SHPT)
1387307|NCT00431483|antibacterial agents
1387308|NCT00431483|surgery
1387309|NCT00431483|pharmacist
1387310|NCT00431483|economics, pharmaceutical
1387311|NCT00431470|Classroom violence, character, bullying, self esteem
1387312|NCT00431444|Osteoporosis
1387313|NCT00431444|Post-menopausal
1387314|NCT00431444|Bone mineral density
1387315|NCT00431405|rheumatoid arthritis
1387316|NCT00431405|cardiovascular disease
1387317|NCT00431405|coronary disease
1387318|NCT00431392|Choroidal blood flow
1387319|NCT00431392|NO-synthase
1387320|NCT00431392|light/dark transition
1387321|NCT00431366|Fatigue
1387322|NCT00431366|Repetitive TMS (rTMS)
1387323|NCT00431366|Parkinson's Disease
1387324|NCT00431366|Peg Board Test
1387325|NCT00431366|Levodopa
1387326|NCT00431366|Parkinson Disease
1387327|NCT00431366|PD
1387328|NCT00431340|Multiple myeloma
1387329|NCT00431340|myeloma
1387330|NCT00431340|plasma cell myeloma
1387331|NCT00431340|bone marrow cancer
1387332|NCT00431340|myelomatosis
1387333|NCT00431340|Kahler's disease
1387334|NCT00431340|PXD101
1387335|NCT00431340|belinostat
1387336|NCT00431340|bortezomib
1387337|NCT00431327|patient navigator
1387338|NCT00431327|peer support
1387339|NCT00431327|colonoscopy
1387340|NCT00431327|adherence
1387341|NCT00431327|None: have to be scheduled for screening or diagnostic colonoscopy
1387342|NCT00431314|End Stage Renal Disease
1387343|NCT00431314|Hemodialysis
1387344|NCT00431314|Critical Limb Ischemia
1387345|NCT00431314|Autofluorescence
1387346|NCT00431301|Progressive Supranuclear Palsy
1387347|NCT00431301|Epidemiology
1387348|NCT00431301|Case-Control
1387349|NCT00431301|Genetic
1387350|NCT00431301|Environmental
1387351|NCT00431301|Neurodegenerative Disease
1387352|NCT00431301|Movement Disorders
1387353|NCT00431301|Atypical Parkinsonism
1387354|NCT00431301|Parkinson Plus
1387355|NCT00431301|Steele-Richardson-Olszewski
1387356|NCT00431301|PSP
1387357|NCT00431288|nutrition
1387358|NCT00431288|adolescent nutrition
1387359|NCT00431288|blood pressure
1387360|NCT00431288|hypertension
1387361|NCT00431288|diet therapy
1387362|NCT00431288|patient education
1387363|NCT00431262|alcoholism
1387364|NCT00431262|antabuse
1387365|NCT00431262|disulfiram
1387366|NCT00431262|abstinence
1387367|NCT00431262|cognitive behavioural therapy
1387368|NCT00431236|highly emetogenic
1387369|NCT00431236|cisplatin
1387370|NCT00431236|CINV
1387371|NCT00431223|fMRI
1387372|NCT00431223|working memory
1387373|NCT00431223|schizophrenia
1387374|NCT00431223|treatment refractory
1387375|NCT00431223|cognitive skills training
1387376|NCT00431223|dorsolateral prefrontal cortex
1387377|NCT00431223|cognitive remediation
1387378|NCT00431223|treatment refractory schizophrenia of > 5 years duration
1387379|NCT00431210|NPC
1387380|NCT00431210|EPV
1387381|NCT00431184|bipolar disorder
1387382|NCT00431184|bipolar mania
1387383|NCT00431184|schizoaffective disorder
1387384|NCT00431184|schizoaffective mania
1387385|NCT00431184|mania
1387386|NCT00431184|kappa opiates
1387387|NCT00431184|opiates
1387388|NCT00431171|spinal cord injuries
1387389|NCT00431171|lithium
1387390|NCT00431158|Acute Respiratory Distress Syndrome
1387391|NCT00431158|ARDS
1387392|NCT00431158|Respiratory failure
1387393|NCT00431158|Mechanical Ventilation
1387394|NCT00431158|Positive end expiratory pressure
1387395|NCT00431158|Lung recruitment maneuver
1387396|NCT00431119|bullous autoimmune disease
1387397|NCT00431119|bullous pemphigoid
1387398|NCT00431119|immunosuppressants
1387399|NCT00431119|corticosteroids
1387400|NCT00431119|mycophenolate mofetil
1387401|NCT00431106|Breast cancer
1387402|NCT00431106|Chemotherapy
1387403|NCT00431106|Vinorelbine
1387404|NCT00431106|Gemcitabine
1387405|NCT00431106|Capecitabine
1387406|NCT00431080|Early breast cancer
1387407|NCT00431080|Axillary node positive
1387408|NCT00431080|Adjuvant chemotherapy
1387409|NCT00431080|Dose dense
1387410|NCT00431080|Docetaxel
1387411|NCT00431080|Paclitaxel
1387412|NCT00431080|FEC
1387413|NCT00431054|Ovarian Cancer
1387414|NCT00431054|Fallopian Tube Cancer
1387415|NCT00431054|Peritoneal Cancer
1387416|NCT00431054|Perifosine
1387417|NCT00431054|Docetaxel
1387418|NCT00431054|Taxotere
1387419|NCT00431041|Solifenacin succinate
1387420|NCT00431041|Oxybutynin immediate release
1387421|NCT00431041|Xerostomia
1387422|NCT00431041|Overactive bladder
1387423|NCT00431028|Cataract
1387424|NCT00431028|Endophthalmitis
1387425|NCT00431028|Antibiotics
1387426|NCT00431028|Anti-Inflammatory Agents
1387427|NCT00431028|Drug Delivery Systems
1387428|NCT00431015|Lung Cancer
1387429|NCT00431015|Cancer of the lung
1387430|NCT00431015|Non-small cell lung cancer
1387431|NCT00431002|Exercise
1387432|NCT00431002|Resistance training
1387433|NCT00430989|Anaesthesia
1387434|NCT00430989|Major Surgery
1387435|NCT00430989|Coronary artery disease
1387436|NCT00430989|Nitrous oxide
1387437|NCT00430989|Effects of Nitrous Oxide following Anaesthesia
1387438|NCT00430989|Anaesthesia and coronary artery disease
1387439|NCT00430976|psychomotor function
1387440|NCT00430976|neuromuscular system
1387441|NCT00430976|memory
1387442|NCT00430976|brain electrical activity
1387443|NCT00430976|Mental Processes
1387444|NCT00430950|Moderate-to-Severe Hypertension
1387445|NCT00430950|Essential Hypertension
1387446|NCT00430950|Combination Therapy
1387447|NCT00430950|Fixed-Combination Dose
1387448|NCT00430937|Complicated Skin and Soft Tissue Infections. Daptomycin, Vancomycin, Teicoplanin
1387449|NCT00430937|Complicated skin and soft tissue infections
1387450|NCT00430924|Kidney Failure, Chronic
1387451|NCT00430924|Proteinuria
1387452|NCT00430924|Aldosterone
1387453|NCT00430924|Renin-Angiotensin System
1387454|NCT00430911|malignant gliomas
1387455|NCT00430898|ulcerative colitis basiliximab
1387456|NCT00430885|Heart failure
1387457|NCT00430885|Myocardial infarction
1387458|NCT00430885|Patients with acute myocardial infarction
1387459|NCT00430872|Spinal Cord Tumor
1387460|NCT00430872|Intramedullary Spinal Cord Tumor
1387461|NCT00430872|Extramedullary Spinal Cord Tumor
1387462|NCT00430872|Symptoms
1387463|NCT00430872|Survey
1387464|NCT00430859|Sepsis
1387465|NCT00430859|Alkaline
1387466|NCT00430859|Phosphatase
1387467|NCT00430859|Lipopolysaccharide
1387468|NCT00430846|Antigens,CD30
1387469|NCT00430846|Antibody-Drug Conjugate
1387470|NCT00430846|Antibodies, Monoclonal
1387471|NCT00430846|Lymphoma, Non-Hodgkin
1387472|NCT00430846|Disease, Hodgkin
1387473|NCT00430846|Lymphoma, Large-Cell, Anaplastic
1387474|NCT00430846|Hematologic Diseases
1387475|NCT00430846|Lymphoma
1387476|NCT00430820|Biomarkers
1387477|NCT00430820|Proteomics
1387478|NCT00430820|Mass spectrometry
1387479|NCT00430820|Atherosclerosis
1387480|NCT00430820|Acute coronary syndromes
1387481|NCT00430820|Myocardial infarction
1387482|NCT00430820|Coronary artery disease
1387483|NCT00430807|giant cell arteritis,
1387484|NCT00430807|hydroxychloroquine,
1387485|NCT00430807|corticosteroid sparing,
1387486|NCT00430807|corticodependence
1387487|NCT00430794|resistant hypertension
1387488|NCT00430794|Spironolactone
1387489|NCT00430794|double-blind
1387490|NCT00430794|randomised controlled trial
1387491|NCT00430794|ambulatory blood pressure monitoring
1387492|NCT00430781|pazopanib
1387493|NCT00430781|ErB1/ErB2
1387494|NCT00430781|lapatinib
1387495|NCT00430781|persistent
1387496|NCT00430781|VEGF
1387497|NCT00430781|recurrent
1387742|NCT00429728|tolerability,
1387498|NCT00430781|metastatic cervical cancer
1387499|NCT00430781|advanced
1387500|NCT00430781|FIGO Stage IVB
1387501|NCT00430768|Gene Transfer Techniques
1387502|NCT00430768|Gene Therapy
1387503|NCT00430768|AAV
1387504|NCT00430768|AAT
1387505|NCT00430768|Phase I
1387506|NCT00430768|Intramuscular transfer
1387507|NCT00430729|Roflumilast
1387508|NCT00430703|severe traumatic brain injury
1387509|NCT00430703|body weight support treadmill training
1387510|NCT00430703|Electroencephalogram
1387511|NCT00430703|Event Related Potentials
1387512|NCT00430664|pleurodesis
1387513|NCT00430664|talc
1387514|NCT00430664|iodopovidone
1387515|NCT00430651|Non Small Cell Lung Cancer
1387516|NCT00430651|2nd line chemotherapy
1387517|NCT00430651|Docetaxel
1387518|NCT00430638|Hypertension
1387519|NCT00430638|Angiotensin Receptor Blocker
1387520|NCT00430638|Calcium Channel Blocker
1387521|NCT00430638|Angiotensin Converting Enzyme Inhibitor
1387522|NCT00430638|Hydrochlorothiazide
1387523|NCT00430638|Stage I and II Hypertension
1387524|NCT00430625|VPRIV®
1387525|NCT00430625|Enzyme Replacement Therapy
1387526|NCT00430625|Gaucher disease
1387527|NCT00430625|glucocerebrosidase
1387528|NCT00430625|beta-glucocerebrosidase
1387529|NCT00430625|Acid beta-glucocerebrosidase
1387530|NCT00430625|glucosylceramidase
1387531|NCT00430625|D-glucosyl-N-acylsphingosine glucohydrolase
1387532|NCT00430625|gene activation
1387533|NCT00430625|human
1387534|NCT00430612|Myocardial Infarction
1387535|NCT00430612|Heart Attack
1387536|NCT00430612|Beta Blockers
1387537|NCT00430612|Survival
1387538|NCT00430573|cognitive-behavior therapy
1387539|NCT00430573|d-cycloserine
1387540|NCT00430573|cognitive enhancer
1387541|NCT00430573|drug dependence
1387542|NCT00430573|opiate dependence
1387543|NCT00430573|exposure
1387544|NCT00430573|isolated doses of d-cycloserine
1387545|NCT00430573|isolated doses of matching pill placebo
1387546|NCT00430573|DCS
1387547|NCT00430560|work therapy
1387548|NCT00430560|cognitive rehabilitation
1387549|NCT00430560|schizophrenia
1387550|NCT00430560|schizoaffective disorder
1387551|NCT00430560|treatment outcome
1387552|NCT00430534|Epstein Barr Virus
1387553|NCT00430534|Belgium
1387554|NCT00430534|Infectious mononucleosis
1387555|NCT00430521|Pandemic Flu
1387556|NCT00430521|Pandemic influenza vaccine (GSK1119711A)
1387557|NCT00430508|Moderate-to-Severe Hypertension
1387558|NCT00430508|Essential Hypertension
1387559|NCT00430508|Combination Therapy
1387560|NCT00430508|Fixed-Combination Dose
1387561|NCT00430495|atacicept
1387562|NCT00430495|arthritis
1387563|NCT00430482|Substance Dependence
1387564|NCT00430482|Cognitive-Behavior Therapy
1387565|NCT00430482|Opiate Dependence
1387566|NCT00430482|Treatment Moderators
1387567|NCT00430469|Lactoferrin
1387568|NCT00430469|hLF
1387569|NCT00430469|Neutropenia
1387570|NCT00430469|Myeloablative
1387571|NCT00430469|Treatment
1387572|NCT00430469|Fungal
1387573|NCT00430469|Bacterial
1387574|NCT00430469|Infections
1387575|NCT00430469|Bone marrow transplant
1387576|NCT00430456|Aerobic exercise
1387577|NCT00430456|Balance, postural
1387578|NCT00430456|Cardiovascular deconditioning
1387579|NCT00430456|Gait
1387580|NCT00430456|MRI, functional
1387581|NCT00430456|Physical therapy techniques
1387582|NCT00430456|Self Efficacy
1387583|NCT00430456|Treadmill test
1387584|NCT00430443|Acute Lymphocytic Leukemia
1387585|NCT00430443|Acute Myelogenous Leukemia
1387586|NCT00430443|Annamycin
1387587|NCT00430443|Liposomal Annamycin
1387588|NCT00430417|Pregnancy
1387589|NCT00430417|Lactation
1387590|NCT00430417|Endocrine System Diseases
1387591|NCT00430417|MusculoSkeletal System Disease
1387592|NCT00430417|Hormone
1387593|NCT00430417|Physiologic Properties
1387594|NCT00430391|DVD
1387595|NCT00430391|Multi-media
1387596|NCT00430391|Schizophrenia
1387597|NCT00430391|Normal Comparison
1387598|NCT00430391|Consent procedures
1387599|NCT00430378|Xerostomia
1387600|NCT00430378|Dry Mouth
1387601|NCT00430378|Mouth Dryness
1387602|NCT00430378|Nasopharyngeal Cancer
1387603|NCT00430378|Acupuncture
1387604|NCT00430365|Myeloma
1387605|NCT00430365|Revlimid
1387606|NCT00430365|Maintenance therapy
1387607|NCT00430365|Autologous Stem Cell Transplantation
1387608|NCT00430313|Nausea
1387609|NCT00430313|Vomiting
1387610|NCT00430313|Electro-Stimulation
1387611|NCT00430313|ES
1387612|NCT00430313|K1 Acupuncture Point
1387613|NCT00430313|Yongquan Acupuncture Point
1387614|NCT00430313|TAI
1387615|NCT00430313|transarterial infusion
1387616|NCT00430313|liver metastasis
1387617|NCT00430313|chemotherapy induced nausea and vomiting
1387618|NCT00430313|CINV
1387619|NCT00430313|Cisplatin
1387620|NCT00430313|Oxaliplatin
1387621|NCT00430300|Dry Powder for Inhalation
1387622|NCT00430300|Chronic Obstructive Pulmonary Disease
1387623|NCT00430300|Lung Function testing
1387624|NCT00430287|primary open angle glaucoma
1387625|NCT00430287|low tension glaucoma
1387626|NCT00430287|pigmentary glaucoma
1387627|NCT00430287|exfoliative glaucoma
1387628|NCT00430274|glaucoma
1387629|NCT00430274|retinal gliosis-like alterations
1387630|NCT00430274|optical coherence tomography
1387631|NCT00430274|automated microperimetry
1387632|NCT00430261|bronchoalveolar carcinoma
1387633|NCT00430261|BAC
1387634|NCT00430261|adenocarcinoma
1387635|NCT00430261|lung cancer
1387636|NCT00430261|oral
1387637|NCT00430261|Stage IIIB and IV lung cancer
1387638|NCT00430261|Any bronchoalveolar carcinoma (BAC)
1387639|NCT00430261|Any adenocarcinoma in a never-smoker
1387640|NCT00430248|tophi
1387641|NCT00430248|hyperuricemia
1387642|NCT00430248|uric acid
1387643|NCT00430248|Drug Therapy
1387644|NCT00430235|prostate
1387645|NCT00430235|cancer
1387646|NCT00430235|BAY 43-9006
1387652|NCT00430170|ischemia-reperfusion injury
1387653|NCT00430170|adenosine
1387654|NCT00430170|dipyridamole
1387655|NCT00430170|caffeine
1387656|NCT00430157|Vienna Challenge Chamber
1387657|NCT00430157|Seasonal Allergic Rhinitis
1387658|NCT00430157|Inflammation
1387659|NCT00430118|T-cell childhood acute lymphoblastic leukemia
1387660|NCT00430118|recurrent childhood acute lymphoblastic leukemia
1387661|NCT00430118|untreated childhood acute lymphoblastic leukemia
1387662|NCT00430118|B-cell childhood acute lymphoblastic leukemia
1387663|NCT00430105|Vasculitis
1387664|NCT00430105|ANCA
1387665|NCT00430105|Wegener's granulomatosis
1387666|NCT00430105|Renal vasculitis
1387667|NCT00430105|Cyclophosphamide
1387668|NCT00430053|stage I cutaneous T-cell non-Hodgkin lymphoma
1387669|NCT00430053|stage II cutaneous T-cell non-Hodgkin lymphoma
1387670|NCT00430053|stage III cutaneous T-cell non-Hodgkin lymphoma
1387671|NCT00430053|stage IV cutaneous T-cell non-Hodgkin lymphoma
1387672|NCT00430053|stage I mycosis fungoides/Sezary syndrome
1387673|NCT00430053|stage II mycosis fungoides/Sezary syndrome
1387674|NCT00430053|stage III mycosis fungoides/Sezary syndrome
1387675|NCT00430053|stage IV mycosis fungoides/Sezary syndrome
1387676|NCT00430040|Type 2 Diabetes Mellitus
1387677|NCT00430040|Hypertension
1387678|NCT00430040|Carvedilol CR
1387679|NCT00430040|Beta-blocker
1387680|NCT00430040|Oxidative stress
1387681|NCT00430040|Inflammation
1387682|NCT00430040|Vascular benefits
1387683|NCT00430027|Esophageal
1387684|NCT00430027|Esophagus
1387685|NCT00430014|Advanced Cancer
1387686|NCT00430014|Relapsed
1387687|NCT00430014|Atiprimod
1387688|NCT00430014|Guanylyl cyclase receptor antagonist
1387689|NCT00430001|Metastatic breast neoplasm
1387690|NCT00429988|breast cancer
1387691|NCT00429975|fluorquinolones,
1387692|NCT00429975|b-lactams,
1387693|NCT00429975|immunomodulation.
1387694|NCT00429962|subfoveal choroidal neovascularization (CNV)
1387695|NCT00429962|age-related macular degeneration
1387696|NCT00429962|ranibizumab monotherapy
1387697|NCT00429962|combined verteporfin-therapy
1387698|NCT00429962|Lucentis® (ranibizumab)
1387699|NCT00429962|Visudyne®
1387700|NCT00429962|photodynamic therapy
1387701|NCT00429949|Dasatinib
1387702|NCT00429949|Plateau phase
1387703|NCT00429936|Dry Age Related Macular Degeneration
1387704|NCT00429936|Geographic Atrophy
1387705|NCT00429910|accelerated phase chronic myelogenous leukemia
1387706|NCT00429910|blastic phase chronic myelogenous leukemia
1387707|NCT00429910|chronic phase chronic myelogenous leukemia
1387708|NCT00429910|meningeal chronic myelogenous leukemia
1387709|NCT00429897|Hypertension
1387710|NCT00429897|Low Renin
1387711|NCT00429884|Atrial fibrillation
1387712|NCT00429871|Metastatic breast cancer;
1387713|NCT00429871|First line chemotherapy;
1387714|NCT00429871|Docetaxel;
1387715|NCT00429871|Epirubicin;
1387716|NCT00429871|Capecitabine
1387717|NCT00429858|recurrent pancreatic cancer
1387718|NCT00429858|stage III pancreatic cancer
1387719|NCT00429858|adenocarcinoma of the pancreas
1387720|NCT00429858|stage IV pancreatic cancer
1387721|NCT00429845|HIV
1387722|NCT00429845|HAART
1387723|NCT00429845|Nutrition
1387724|NCT00429845|Dyslipidemia
1387725|NCT00429832|Nausea, vomiting, antiemetic
1387726|NCT00429806|Vaginal atrophy
1387727|NCT00429806|DHEA
1387728|NCT00429806|Prasterone
1387729|NCT00429806|Menopause
1387730|NCT00429780|Leishmaniasis vaccine
1387731|NCT00429780|Alum-ALM
1387732|NCT00429780|First generation vaccine
1387733|NCT00429780|Leishmanin positive
1387734|NCT00429780|Healthy Volunteers
1387735|NCT00429780|Response to Leishmanin (Leishmanin Skin Test>0)
1387736|NCT00429780|No History of Cutaneous Leishmaniasis
1387737|NCT00429767|Opioid
1387738|NCT00429767|Cocaine
1387739|NCT00429767|Drug Self Administration
1387740|NCT00429754|Nausea and vomiting after using cytostatic drugs
1387741|NCT00429728|Pharmacokinetics,
1387743|NCT00429728|healthy,
1387744|NCT00429728|subjects,
1387745|NCT00429728|smokers,
1387746|NCT00429728|non-smokers
1387747|NCT00429715|Leishmaniasis vaccine
1387748|NCT00429715|Alum-ALM
1387749|NCT00429715|First generation vaccine
1387750|NCT00429715|Healthy volunteers
1387751|NCT00429715|No response to leishmanin
1387752|NCT00429715|No history of cutaneous leishmaniasis
1387753|NCT00429702|nausea
1387754|NCT00429702|vomiting
1387755|NCT00429702|emetic chemotherapy
1387756|NCT00429702|unspecified childhood solid tumor, protocol specific
1387757|NCT00429689|Male, MDD, Testosterone, DHEA-S,Cortisol
1387758|NCT00429689|Male
1387759|NCT00429689|18-65
1387760|NCT00429689|Major Depression
1387761|NCT00429676|Randomized
1387762|NCT00429676|Controlled
1387763|NCT00429676|Trial
1387764|NCT00429676|Delirium
1387765|NCT00429676|Haloperidol
1387766|NCT00429663|distal femur
1387767|NCT00429663|femur fracture
1387768|NCT00429650|Weight maintenance
1387769|NCT00429650|Weight loss
1387770|NCT00429637|EBC pH
1387771|NCT00429637|Airway acidification
1387772|NCT00429637|Condensimetry
1387773|NCT00429637|ARDS
1387774|NCT00429637|RSV
1387775|NCT00429637|ALI
1387776|NCT00429637|Airway reconstruction
1387777|NCT00429624|Neck Pain
1387778|NCT00429624|Chiropractic manipulation
1387779|NCT00429624|Randomized controlled trial
1387780|NCT00429611|biphasic defibrillation
1387781|NCT00429611|inhospital
1387782|NCT00429611|post-resuscitation myocardial function
1387783|NCT00429611|defibrillation efficacy
1387784|NCT00429611|high energy versus low energy
1387785|NCT00429611|cardiac arrest patients
1387786|NCT00429585|tibia fracture
1387787|NCT00429585|proximal tibia
1387788|NCT00429572|Breast Cancer
1387789|NCT00429572|PBPC Transplantation
1387790|NCT00429572|Stem Cell Infusion
1387791|NCT00429572|Fludarabine
1387792|NCT00429572|Melphalan
1387793|NCT00429559|Cancer;
1387794|NCT00429559|Ovarian cancer;
1387795|NCT00429559|Recurrent ovarian cancer platinum-resistant
1387796|NCT00429546|Disclosure
1387797|NCT00429546|Serostatus
1387798|NCT00429507|Breast Cancer
1387799|NCT00429507|Blood Stem Cell
1387800|NCT00429507|Bone Metastases
1387801|NCT00429507|Radiation Therapy
1387802|NCT00429507|Gamma Camera
1387803|NCT00429507|Sm-EDTMP
1387804|NCT00429507|Samarium 153-EDTMP
1387805|NCT00429507|Stem Cell Transplant
1387806|NCT00429507|Autologous Peripheral Blood Stem Cell Transplantation
1387807|NCT00429507|PBSCT
1387808|NCT00429507|Questionnaire
1387809|NCT00429494|Hematopoietic Stem Cell Transplantation
1387810|NCT00429494|GnRH Analogue
1387811|NCT00429494|Gonadotropin-releasing hormone analogue
1387812|NCT00429494|GnRH-a
1387813|NCT00429494|Ovarian Function
1387814|NCT00429494|Fertility
1387815|NCT00429494|Leuprolide Acetate
1387816|NCT00429494|Lupron Depot
1387817|NCT00429494|premature ovarian failure
1387818|NCT00429494|POF
1387819|NCT00429494|Abnormal suppression of menstruation
1387820|NCT00429494|absence of menstruation
1387821|NCT00429481|Oral live attenuated human rotavirus vaccine
1387822|NCT00429481|Gastroenteritis
1387823|NCT00429481|Vomiting
1387824|NCT00429455|Fertility
1387825|NCT00429455|Menopause
1387826|NCT00429455|Hematopoietic Stem Cell Transplantation
1387827|NCT00429455|Questionnaire
1387828|NCT00429455|Survey
1387829|NCT00429442|Simvastatin
1387830|NCT00429442|CNS Inflammation
1387831|NCT00429442|Copaxone
1387832|NCT00429429|Peanut allergy
1387833|NCT00429416|Hematologic Malignancies
1387834|NCT00429416|GVHD
1387835|NCT00429416|Graft-Versus-Host-Disease
1387836|NCT00429416|LLME
1387837|NCT00429416|CD34+ stem cell infusions
1387838|NCT00429416|CD34- fraction
1387839|NCT00429416|Cyclosporine
1387840|NCT00429416|Mycophenolate Mofetil
1387841|NCT00429416|HSCT
1387842|NCT00429416|Hematopoietic stem cell transplantation
1387843|NCT00429403|Breast Cancer
1387844|NCT00429403|Chemotherapy
1387845|NCT00429403|Ovarian Function
1387846|NCT00429403|Goserelin
1387847|NCT00429403|Zoladex
1387848|NCT00429403|Ovary function
1387849|NCT00429403|Fertility
1387850|NCT00429403|Early Menopause
1387851|NCT00429390|Metabolic syndrome
1387852|NCT00429390|Ramadan Fasting
1387853|NCT00429390|Insulin sensitivity
1387854|NCT00429390|Iran
1387855|NCT00429377|tacrolimus
1387856|NCT00429377|FK506
1387857|NCT00429377|lupus nephritis
1387858|NCT00429364|Aortic Root Dissection
1387859|NCT00429364|Aortic Root Dilation
1387860|NCT00429364|Pediatric Heart Network
1387861|NCT00429338|Genitourinary
1387862|NCT00429338|Prostate Cancer
1387863|NCT00429338|Magnetic Resonance Imaging
1387864|NCT00429338|MRI
1387865|NCT00429338|Magnetic Resonance Spectroscopic Imaging
1387866|NCT00429338|MRSI
1387867|NCT00429338|Endorectal MRSI
1387994|NCT00428987|Morbid Obesity
1387868|NCT00429338|Endorectal magnetic resonance spectroscopy imaging
1387869|NCT00429338|3 Tesla
1387870|NCT00429338|3T Scan
1387871|NCT00429338|Endorectal coil
1387872|NCT00429338|Perfluorocarbon compound
1387873|NCT00429338|PFC
1387874|NCT00429338|PFC-filled endorectal coil
1387875|NCT00429338|PFC-MRSI
1387876|NCT00429338|AIR-MRSI
1387877|NCT00429325|acute infectious diarrhea,
1387878|NCT00429325|fecal calprotectin,
1387879|NCT00429325|stool culture,
1387880|NCT00429325|hemoccult test,
1387881|NCT00429325|Guaiac fecal occult blood test (FOBT)
1387882|NCT00429325|fecal lactoferrin
1387883|NCT00429312|Melanoma
1387884|NCT00429312|Oncolytic virus
1387885|NCT00429312|Pexa-Vec
1387886|NCT00429299|neo-adjuvant trastuzumab early breast cancer lapatinib
1387887|NCT00429286|Health Services Research
1387888|NCT00429273|ADHD
1387889|NCT00429273|Guanfacine
1387890|NCT00429273|Methylphenidate
1387891|NCT00429273|Focalin XR
1387892|NCT00429273|Pediatric
1387893|NCT00429273|Cognitive function
1387894|NCT00429273|Combination therapy
1387895|NCT00429260|depression
1387896|NCT00429260|antidepressive agents
1387897|NCT00429247|Occult tumor cells
1387898|NCT00429247|Micrometastatic cells
1387899|NCT00429247|Cytokeratin-19
1387900|NCT00429247|Trastuzumab
1387901|NCT00429247|Completion of Adjuvant Treatment
1387902|NCT00429234|Advanced Cancer
1387903|NCT00429234|Solid Tumors
1387904|NCT00429234|Dasatinib
1387905|NCT00429234|BMS-354825
1387906|NCT00429234|Sprycel
1387907|NCT00429234|Gemcitabine
1387908|NCT00429234|Gemcitabine Hydrochloride
1387909|NCT00429234|Gemzar
1387910|NCT00429221|ADHD
1387911|NCT00429208|Nicotine Dependence
1387912|NCT00429208|Smoking
1387913|NCT00429208|Tobacco Use Disorder
1387914|NCT00429208|Nicotine Use Disorder
1387915|NCT00429195|LIPGENE
1387916|NCT00429195|Fatty acid
1387917|NCT00429195|Dietary intervention
1387918|NCT00429195|Metabolic syndrome
1387919|NCT00429195|Insulin resistance
1387920|NCT00429182|Breast Cancer
1387921|NCT00429182|breast carcinoma
1387922|NCT00429182|Carboplatin
1387923|NCT00429182|Paraplatin
1387924|NCT00429182|Cyclophosphamide
1387925|NCT00429182|Neosar
1387926|NCT00429182|Cytoxan
1387927|NCT00429182|Thiotepa
1387928|NCT00429182|Purged Autologous Stem Cells
1387929|NCT00429182|Circulating Tumor Cells
1387930|NCT00429182|CTCs
1387931|NCT00429169|Major Depressive Disorder
1387932|NCT00429169|MDD
1387933|NCT00429156|Non-invasive ventilation
1387934|NCT00429156|Non-invasive positive pressure ventilation
1387935|NCT00429156|Home ventilation
1387936|NCT00429156|Domiciliary ventilation
1387937|NCT00429156|Chronic obstructive pulmonary disease
1387938|NCT00429156|COPD
1387939|NCT00429156|Respiratory failure
1387940|NCT00429156|Acute hypercapnic respiratory failure
1387941|NCT00429156|NIV
1387942|NCT00429156|NIPPV
1387943|NCT00429156|Type II respiratory failure
1387944|NCT00429143|Hematologic Malignancies
1387945|NCT00429143|Two Step Approach
1387946|NCT00429143|Haploidentical Transplant
1387947|NCT00429117|Spirituality
1387948|NCT00429117|Work Related Stress
1387949|NCT00429117|Religious Beliefs
1387950|NCT00429117|Survey
1387951|NCT00429104|Breast Cancer
1387952|NCT00429104|Carcinoma of the Breast
1387953|NCT00429104|HER-2/neu Overexpression
1387954|NCT00429104|Herceptin
1387955|NCT00429104|Trastuzumab
1387956|NCT00429104|GM-CSF
1387957|NCT00429104|Sargramostim
1387958|NCT00429104|Leukine
1387959|NCT00429078|Gastric Cancer
1387960|NCT00429078|T Cells
1387961|NCT00429078|Gene Transfer
1387962|NCT00429065|Non-Hodgkin lymphoma
1387963|NCT00429065|rituximab
1387964|NCT00429065|immunotherapy
1387965|NCT00429052|Coronary Disease
1387966|NCT00429052|Coronary Stenosis
1387967|NCT00429052|Percutaneous Transluminal Coronary Angioplasty
1387968|NCT00429052|Stents
1387969|NCT00429052|Sirolimus
1387970|NCT00429026|Kidney Cancer
1387971|NCT00429026|Renal Cell Cancer
1387972|NCT00429026|Stem Cell Transplant
1387973|NCT00429026|Cyclophosphamide
1387974|NCT00429026|Fludarabine
1387975|NCT00429026|Melphalan
1387976|NCT00429026|NST
1387977|NCT00429013|Pressure ulcer
1387978|NCT00429013|Lingual electric stimulation
1387979|NCT00429013|Paraplegic patient
1387980|NCT00429013|Pressure Ulcer/Prevention & control
1387981|NCT00429000|Hypothermia
1387982|NCT00429000|Infant mortality
1387983|NCT00429000|Infant morbidity
1387984|NCT00429000|Intervention
1387985|NCT00429000|Randomisation
1387986|NCT00429000|Longitudinal research.
1387987|NCT00429000|Low-income country
1387988|NCT00428987|Energy Expenditure
1387989|NCT00428987|Neurocognitive Function
1387990|NCT00428987|Obesity
1387991|NCT00428987|Metabolism
1387992|NCT00428987|Phenotype
1387993|NCT00428987|Body Composition
1387995|NCT00428987|Overweight
1387996|NCT00428987|Healthy Volunteer
1387997|NCT00428974|Psoriasis
1387998|NCT00428961|diabetes mellitus
1387999|NCT00428961|insulin resistance
1388000|NCT00428961|atherosclerosis
1388001|NCT00428948|ADPKD
1388002|NCT00428948|Polycystic
1388003|NCT00428948|kidney
1388004|NCT00428948|ADPKD (Autosomal Dominant Polycystic Kidney Disease)
1388005|NCT00428935|Duchenne
1388006|NCT00428935|Muscle
1388007|NCT00428935|Muscular Dystrophy
1388008|NCT00428935|Gene Therapy
1388009|NCT00428935|Dystrophin
1388010|NCT00428935|Adeno-Associated Virus
1388011|NCT00428935|AAV
1388012|NCT00428922|Metastatic
1388013|NCT00428922|Breast Cancer
1388014|NCT00428922|MBC
1388015|NCT00428909|Pharmacokinetic
1388016|NCT00428909|STI571
1388017|NCT00428909|imatinib
1388018|NCT00428909|CML
1388019|NCT00428909|Chronic Myeloid Leukemia
1388020|NCT00428909|Philadelphia Chromosome
1388021|NCT00428909|acetaminophen
1388022|NCT00428896|Breast cancer
1388023|NCT00428896|iressa circulating tumor cells
1388024|NCT00428883|Scleroderma, Systemic
1388025|NCT00428883|Scleroderma, Diffuse
1388026|NCT00428870|Shoulder
1388027|NCT00428870|impingement
1388028|NCT00428870|conservative
1388029|NCT00428870|acromioplasty
1388030|NCT00428870|arthroscopy
1388031|NCT00428844|Osteomyelitis
1388032|NCT00428844|Prosthetic Hip
1388033|NCT00428844|Prosthetic Knee
1388034|NCT00428844|MRSA
1388035|NCT00428844|Osteomyelitis Associated with an Infected Prosthetic Hip or Knee Joint
1388036|NCT00428844|Staphylococci
1388037|NCT00428831|influenza, genomic data, nasopharyngeal aspirate
1388038|NCT00428818|MRSA
1388039|NCT00428805|body composition
1388040|NCT00428805|physical activity
1388041|NCT00428805|dietary intake
1388042|NCT00428805|children
1388043|NCT00428792|ADHD
1388044|NCT00428792|methylphenidate
1388045|NCT00428792|children
1388046|NCT00428792|food effect
1388047|NCT00428792|Attention-Deficit Hyperactivity Disorder (ADHD) in children
1388048|NCT00428779|Running during 24 hours
1388049|NCT00428779|Voluntary evoked force on the muscles
1388050|NCT00428779|Electrically evoked force on the muscles
1388051|NCT00428779|EMG activity
1388052|NCT00428779|Muscle biopsy
1388053|NCT00428779|subjects will be recruited among experienced ultra-runners
1388054|NCT00428753|avian influenza, China, H5N1
1388055|NCT00428727|Diabetic foot
1388056|NCT00428727|Ulcer
1388057|NCT00428727|nitric oxide
1388058|NCT00428727|treatment
1388059|NCT00428727|donor
1388060|NCT00428727|controlled trial
1388061|NCT00428701|stress ulcer
1388062|NCT00428701|critically ill
1388063|NCT00428701|gastric acid
1388064|NCT00428701|gastric aspirates
1388065|NCT00428701|esomeprazole
1388066|NCT00428688|Hodgkin's lymphoma
1388067|NCT00428688|cardiovascular disease
1388068|NCT00428688|radiation therapy
1388069|NCT00428688|Brachial artery flow-mediated dilation (FMD)
1388070|NCT00428675|screening
1388071|NCT00428675|fatigue
1388072|NCT00428662|coronary stenting
1388073|NCT00428662|drug eluting stents
1388074|NCT00428662|paclitaxel
1388075|NCT00428662|nanoporous
1388076|NCT00428649|Selenium supplements
1388077|NCT00428649|Selenoprotein P
1388078|NCT00428649|Optimization
1388079|NCT00428636|ileostomy
1388080|NCT00428636|rectal resection
1388081|NCT00428636|proctectomy
1388082|NCT00428636|stoma closure
1388083|NCT00428623|Patient comfort
1388084|NCT00428623|Wound dressings
1388085|NCT00428623|infection
1388086|NCT00428623|vascular surgery
1388087|NCT00428571|Type 2 Diabetes
1388088|NCT00428571|Bariatric surgery
1388089|NCT00428571|Obesity
1388090|NCT00428571|Laparoscopic gastric bypass
1388091|NCT00428571|Laparoscopic adjustable gastric banding
1388092|NCT00428558|acute myeloid leukemia
1388093|NCT00428558|Core Binding Factor
1388094|NCT00428558|t(8;21)
1388095|NCT00428558|inv(16)
1388096|NCT00428558|timed-sequential induction
1388097|NCT00428545|Advanced Malignancy
1388098|NCT00428545|Lymphoma
1388099|NCT00428545|Myeloma
1388100|NCT00428545|Solid Tumors
1388101|NCT00428545|Bevacizumab
1388102|NCT00428545|Avastin
1388103|NCT00428545|Anti-VEGF monoclonal antibody
1388104|NCT00428545|rhuMAb-VEGF
1388105|NCT00428545|Bortezomib
1388106|NCT00428545|Velcade
1388107|NCT00428545|PS-341
1388108|NCT00428545|LDP-341
1388109|NCT00428545|MLN341
1388110|NCT00428519|HIV infection
1388111|NCT00428519|Neurokinin-1 receptor antagonist
1388112|NCT00428519|CCR5 expression
1388113|NCT00428519|Treatment Naive
1388114|NCT00428506|ascites
1388115|NCT00428506|cirrhosis
1388116|NCT00428506|post-paracentesis circulatory dysfunction
1388117|NCT00428506|albumin
1388118|NCT00428506|portal-hypertension
1388119|NCT00428493|human influenza A, H5N1, bird flu, avian influenza, China
1388120|NCT00428467|Heart Failure
1388121|NCT00428467|LV Geometry
1388122|NCT00428467|Heart MRT
1388123|NCT00428454|drug-eluting stent
1388124|NCT00428454|chronic total occlusion
1388125|NCT00428454|sirolimus-eluting stent
1388126|NCT00428454|zotarolimus-eluting stent
1388127|NCT00428454|QCA
1388128|NCT00428441|D-dimer
1388129|NCT00428441|Recurrence
1388130|NCT00428441|Venous thromboembolism
1388131|NCT00428428|kidney stone
1388132|NCT00428428|ureteroscopy
1388133|NCT00428402|Education
1388134|NCT00428402|4th-8th Grade Student
1388135|NCT00428402|MIDAS Project
1388136|NCT00428402|Focus Group Discussion
1388137|NCT00428402|Bastrop
1388138|NCT00428389|Dementia, Alzheimer's, Rivastigmine, donepezil
1388139|NCT00428363|posterior capsule opacification
1388140|NCT00428363|PCO
1388141|NCT00428363|after cataract
1388142|NCT00428363|intraocular lens
1388143|NCT00428363|optic edge design
1388144|NCT00428363|sharp optic edge
1388145|NCT00428337|HIV Seronegativity
1388146|NCT00428337|EP1233
1388147|NCT00428337|MVA-mBN32
1388148|NCT00428337|HIV Preventive Vaccine
1388149|NCT00428311|Polycystic ovary syndrome
1388150|NCT00428311|Hyperandrogenism
1388151|NCT00428311|Hirsutism
1388152|NCT00428311|Cardiovascular risk
1388153|NCT00428311|Chronic inflammation
1388154|NCT00428311|Metformin
1388155|NCT00428311|Cyproterone acetate
1388156|NCT00428311|Oral contraceptives
1388157|NCT00428298|Bipolar
1388158|NCT00428298|Cognitive
1388159|NCT00428298|Attention
1388160|NCT00428298|Memory
1388161|NCT00428298|Manic Depression
1388162|NCT00428298|Bi-polar
1388163|NCT00428285|Human Papilloma Virus
1388164|NCT00428285|HIV infected MSM
1388165|NCT00428285|Treatment Experienced
1388166|NCT00428285|Treatment Naive
1388167|NCT00428285|Anal Intraepithelial Neoplasia
1388168|NCT00428272|Monoclonal Antibody Lexatumumab
1388169|NCT00428272|Interferon Gamma
1388170|NCT00428272|Solid Tumor
1388171|NCT00428272|Phase I
1388172|NCT00428272|Malignant Tumor
1388173|NCT00428272|Metastatic Tumor
1388174|NCT00428272|Pediatric Solid Tumor
1388175|NCT00428272|Ewing Sarcoma
1388176|NCT00428272|Osteosarcoma
1388177|NCT00428272|Neuroblastoma
1388178|NCT00428272|Rhabdomyosarcoma
1388179|NCT00428246|Chronic Kidney Disease
1388180|NCT00428246|Endothelial dysfunction
1388181|NCT00428246|Inflammation
1388182|NCT00428246|Hypertension
1388183|NCT00428246|paricalcitol
1388184|NCT00428246|Blood pressure
1388185|NCT00428246|Vitamin D
1388186|NCT00428246|Glomerular filtration rate
1388187|NCT00428233|CLL
1388188|NCT00428233|vaccine
1388189|NCT00428220|Potentially other tumor types in the future
1388190|NCT00428207|type 1 diabetes, insulin pump therapy, glycemic stability
1388191|NCT00428194|stage IIA cervical cancer
1388192|NCT00428194|stage IB cervical cancer
1388193|NCT00428194|stage IIB cervical cancer
1388194|NCT00428194|stage III cervical cancer
1388195|NCT00428194|stage IVA cervical cancer
1388196|NCT00428194|cervical squamous cell carcinoma
1388197|NCT00428181|Brief alcohol intervention
1388198|NCT00428181|Booster session
1388199|NCT00428181|Personalized feedback
1388200|NCT00428181|Motivational interview
1388201|NCT00428181|Injury recidivism
1388202|NCT00428181|Psychological Interview
1388203|NCT00428181|Risk Reduction Behaviors
1388204|NCT00428168|Betahistine
1388205|NCT00428168|Weight Gain Control
1388206|NCT00428168|Weight Gain due to Olanzapine Treatment
1388207|NCT00428168|Obesity
1388208|NCT00428168|Schizophrenic disorder
1388209|NCT00428155|hemostasis
1388210|NCT00428155|angioplasty
1388211|NCT00428155|stenting
1388212|NCT00428155|closure device
1388213|NCT00428155|angioseal
1388214|NCT00428155|starclose
1388215|NCT00428142|stage III grade 1 follicular lymphoma
1388216|NCT00428142|stage III grade 2 follicular lymphoma
1388217|NCT00428142|stage III grade 3 follicular lymphoma
1388218|NCT00428142|stage IV grade 1 follicular lymphoma
1388219|NCT00428142|stage IV grade 2 follicular lymphoma
1388220|NCT00428142|stage IV grade 3 follicular lymphoma
1388221|NCT00428129|Acute Iliofemoral Deep Vein Thrombosis
1388222|NCT00428116|HIV-1
1388223|NCT00428116|Pediatric
1388224|NCT00428116|HAART
1388225|NCT00428116|Treatment Naive
1388226|NCT00428103|Mitral valve regurgitation
1388227|NCT00428090|apolipoprotein E
1388228|NCT00428090|monotherapy
1388229|NCT00428090|cognition
1388230|NCT00428090|mild
1388231|NCT00428090|rosiglitazone
1388232|NCT00428090|Alzheimer's disease
1388233|NCT00428090|moderate
1388234|NCT00428077|Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia
1388235|NCT00428077|chronic phase chronic myelogenous leukemia
1388236|NCT00428064|Renal allograft
1388237|NCT00428064|Renal
1388238|NCT00428064|Kidney
1388239|NCT00428064|Transplant
1388240|NCT00428051|Epidemiology
1388241|NCT00428051|Surveillance
1388242|NCT00428051|Streptococcal Pneumonia
1388243|NCT00428038|Infant, Premature
1388244|NCT00428038|Bronchopulmonary Dysplasia
1388245|NCT00428038|Asthma
1388246|NCT00428025|pancreatitis
1388247|NCT00428012|quality of life, kidney transplantation
1388248|NCT00427999|Hormone-refractory
1388249|NCT00427999|prostate cancer
1388250|NCT00427999|multitargeted
1388251|NCT00427999|tyrosinkinase
1388252|NCT00427986|Diabetes
1388253|NCT00427986|Macular oedema
1388254|NCT00427986|Osmosis
1388255|NCT00427986|Galactose
1388256|NCT00427986|Intravenous
1388257|NCT00427986|Retinal thickness
1388258|NCT00427986|Starling
1388259|NCT00427960|cholesterol
1388260|NCT00427960|statin
1388261|NCT00427960|Asian
1388262|NCT00427960|LDL-cholesterol
1388263|NCT00427947|phantom limb pain
1388264|NCT00427947|amputation
1388265|NCT00427947|anesthetics, local
1388266|NCT00427947|postoperative analgesia
1388267|NCT00427947|ropivacaine
1388268|NCT00427947|analgesia
1388269|NCT00427908|Meningococcal serogroups A, C, W-135 and/or Y diseases
1388270|NCT00427908|Conjugate vaccine
1388271|NCT00427908|Immunogenicity
1388272|NCT00427908|Meningococcal vaccine
1388273|NCT00427908|Persistence
1388274|NCT00427908|Non-inferiority
1388275|NCT00427895|Vaccine
1388276|NCT00427895|Pneumococcal Infections Prevention and Control
1388277|NCT00427843|osteoarthritis
1388278|NCT00427843|knee
1388279|NCT00427843|gait
1388280|NCT00427843|muscle strength
1388281|NCT00427843|hip
1388282|NCT00427843|exercise
1388283|NCT00427830|Mycobacterium tuberculosis
1388284|NCT00427830|85A antigen
1388285|NCT00427830|Recombinant Modified Vaccinia Ankara
1388286|NCT00427830|Phase I study
1388287|NCT00427830|Immunogenicity
1388288|NCT00427830|BCG
1388289|NCT00427817|Adenoma, Prostatic
1388290|NCT00427817|Prostate
1388291|NCT00427817|Proteomics
1388292|NCT00427817|Urology
1388293|NCT00427804|Calcium absorption
1388294|NCT00427804|Vitamin D
1388295|NCT00427791|Acute Lymphoblastic Leukemia
1388296|NCT00427791|Leukemia
1388297|NCT00427791|Total Body Irradiation
1388298|NCT00427791|Etoposide
1388299|NCT00427791|Rituximab
1388300|NCT00427791|Rituxan
1388301|NCT00427791|TBI
1388302|NCT00427791|ALL
1388303|NCT00427778|incontinence ring
1388304|NCT00427778|pessary
1388305|NCT00427778|urinary incontinence
1388306|NCT00427778|urodynamic study
1388307|NCT00427778|quality of life
1388308|NCT00427778|crossover trial
1388309|NCT00427778|randomised trial
1388310|NCT00427765|Multiple Myeloma
1388311|NCT00427765|Hodgkin's Disease
1388312|NCT00427765|Non-Hodgkin's Lymphoma
1388313|NCT00427765|Leukemia
1388314|NCT00427765|Lymphoma
1388315|NCT00427765|Busulfan
1388316|NCT00427765|Melphalan
1388317|NCT00427765|Autologous bone marrow
1388318|NCT00427765|BMT
1388319|NCT00427765|Peripheral blood stem cell transplant
1388320|NCT00427765|PBSCT
1388321|NCT00427752|Transgastric
1388322|NCT00427752|Endoluminal
1388323|NCT00427752|Peritoneoscopy
1388324|NCT00427752|Diagnostic
1388325|NCT00427752|Feasibility
1388326|NCT00427739|Axial Flow Ventricular Assist Device
1388327|NCT00427739|Cardiac CT
1388328|NCT00427739|Stage IV heart failure
1388329|NCT00427726|Gene Transfer
1388330|NCT00427726|Hematopoietic Stem Cells
1388331|NCT00427726|Follow-Up
1388332|NCT00427713|adenocarcinoma of the rectum
1388333|NCT00427713|stage III rectal cancer
1388334|NCT00427713|stage II rectal cancer
1388335|NCT00427700|Polycystic Ovary Syndrome
1388336|NCT00427700|clomiphene citrate
1388337|NCT00427700|Raloxifene
1388338|NCT00427674|Parkinson
1388339|NCT00427674|Imaging
1388340|NCT00427661|Sickle Cell Disease
1388341|NCT00427661|Thalassemia
1388342|NCT00427661|Hemoglobinopathies
1388343|NCT00427648|Administration, Intravesical
1388344|NCT00427648|Anesthetics, Local
1388345|NCT00427635|neonates
1388346|NCT00427635|infants
1388347|NCT00427635|GERD
1388348|NCT00427635|reflux
1388349|NCT00427622|hot flashes
1388350|NCT00427609|Treatment
1388351|NCT00427609|Psoriasis
1388352|NCT00427609|efficacy
1388353|NCT00427609|Bicillin
1388354|NCT00427596|GW427353 oral tablets,
1388355|NCT00427596|healthy adult subjects,
1388356|NCT00427596|food effect
1388357|NCT00427583|Malignant,
1388358|NCT00427583|peripheral,
1388359|NCT00427583|nerve sheath tumors,
1388360|NCT00427583|MPNST,
1388361|NCT00427583|neurofibromatosis,
1388362|NCT00427583|NF1,
1388363|NCT00427583|Imatinib mesylate
1388364|NCT00427570|stage II colon cancer
1388365|NCT00427570|stage III colon cancer
1388366|NCT00427557|Multiple Myeloma
1388367|NCT00427557|Acute Myeloid Leukemia
1388368|NCT00427557|Myelodysplastic Syndrome
1388369|NCT00427557|Acute Lymphoblastic Leukemia
1388370|NCT00427557|Non-Hodgkin's Lymphoma
1388371|NCT00427557|Hodgkin's Lymphoma
1388372|NCT00427557|Chronic Lymphocytic Leukemia
1388373|NCT00427557|Cellular Therapy
1388374|NCT00427557|Umbilical Cord Blood Cells
1388375|NCT00427557|Cord Blood Transplantation
1388376|NCT00427557|Stem Cells
1388377|NCT00427557|Stem Cell Transplantation
1388378|NCT00427557|Allogeneic
1388379|NCT00427557|Hematopoietic Stem Cell Transplantation
1388380|NCT00427557|Graft vs. Host Disease
1388381|NCT00427557|GVD
1388382|NCT00427557|Fludarabine
1388383|NCT00427557|Fludarabine Phosphate
1388384|NCT00427557|Fludara
1388385|NCT00427557|Melphalan
1388386|NCT00427557|Rituximab
1388387|NCT00427557|Rituxan
1388388|NCT00427557|Leukemia
1388389|NCT00427557|Lymphoma
1388390|NCT00427544|Uterine leiomyomata (Fibroids)
1388391|NCT00427531|hot flashes
1388392|NCT00427505|Interaction
1388393|NCT00427505|healthy volunteers
1388394|NCT00427505|deferasirox
1388395|NCT00427505|midazolam
1388396|NCT00427479|Allergy
1388397|NCT00427479|Food
1388398|NCT00427479|Hay fever
1388399|NCT00427479|Screening
1388400|NCT00427453|Mycobacterium tuberculosis
1388401|NCT00427453|85A antigen
1388402|NCT00427453|Recombinant Modified Vaccinia Virus Ankara
1388403|NCT00427453|Phase I study
1388404|NCT00427453|Immunogenicity
1388405|NCT00427453|BCG
1388406|NCT00427440|Glioma
1388407|NCT00427440|Brain Tumor
1388408|NCT00427427|non-metastatic breast cancer
1388409|NCT00427427|HER-2 positive breast cancer
1388410|NCT00427427|Herceptin (trastuzumab)
1388411|NCT00427427|delayed adjuvant therapy
1388412|NCT00427427|acceptability rate
1388413|NCT00427427|non-metastatic, HER-2 positive breast cancer
1388414|NCT00427414|AIDS-related Kaposi sarcoma
1388415|NCT00427414|recurrent Kaposi sarcoma
1388416|NCT00427388|Cardiac Surgical Procedures
1388417|NCT00427388|Cardiopulmonary Bypass
1388418|NCT00427388|Systemic inflammatory Response Syndrome
1388419|NCT00427388|Steroid
1388420|NCT00427388|Myocardial Infarction
1388421|NCT00427388|Randomized Clinical Trial
1388422|NCT00427375|Rectal cancer surgery
1388423|NCT00427375|Neoadjuvant radiochemotherapy
1388424|NCT00427375|Randomized clinical trial
1388425|NCT00427375|Multicenter study
1388426|NCT00427349|localized gastrointestinal carcinoid tumor
1388427|NCT00427349|recurrent gastrointestinal carcinoid tumor
1388428|NCT00427349|metastatic gastrointestinal carcinoid tumor
1388429|NCT00427349|regional gastrointestinal carcinoid tumor
1388430|NCT00427349|gastrinoma
1388431|NCT00427349|insulinoma
1388432|NCT00427349|WDHA syndrome
1388433|NCT00427349|glucagonoma
1388434|NCT00427349|pancreatic polypeptide tumor
1388435|NCT00427349|somatostatinoma
1388436|NCT00427349|recurrent islet cell carcinoma
1388437|NCT00427349|neuroendocrine tumor
1388438|NCT00427336|Severe Aplastic Anemia
1388439|NCT00427336|Bone Marrow Failure
1388440|NCT00427336|Stem Cell Transplantation
1388441|NCT00427336|Fludarabine
1388442|NCT00427336|Cyclophosphamide
1388443|NCT00427336|Antithymocyte Globulin
1388444|NCT00427336|SAA
1388445|NCT00427336|ATG
1388446|NCT00427336|Cytoxan
1388447|NCT00427336|Neosar
1388448|NCT00427336|Fludarabine Phosphate
1388449|NCT00427336|Thymoglobulin
1388450|NCT00427323|sleep
1388451|NCT00427323|aging
1388452|NCT00427323|biological rhythm
1388453|NCT00427323|melatonin
1388454|NCT00427323|alertness
1388455|NCT00427323|early morning awakening
1388456|NCT00427323|daytime sleepiness
1388457|NCT00427323|difficulty maintaining sleep
1388458|NCT00427323|sleep maintenance insomnia
1388459|NCT00427310|stage I colon cancer
1388460|NCT00427310|stage II colon cancer
1388461|NCT00427310|stage III colon cancer
1388462|NCT00427310|adenocarcinoma of the colon
1388463|NCT00427297|HIV-1
1388464|NCT00427297|Pediatric
1388465|NCT00427297|nevirapine
1388466|NCT00427297|HAART
1388467|NCT00427297|Resistance
1388468|NCT00427297|Treatment Naive
1388469|NCT00427284|Eplerenone auf die Endothelfunktion bei Patienten mit stabiler koronarer Herzkrankheit
1388470|NCT00427271|aspirin
1388471|NCT00427271|enalapril
1388472|NCT00427271|microalbuminuria
1388473|NCT00427271|glomerular filtration rate
1388474|NCT00427258|healthy subjects
1388475|NCT00427245|menopausal symptoms
1388476|NCT00427245|infertility
1388477|NCT00427245|stage IA breast cancer
1388478|NCT00427245|stage IB breast cancer
1388479|NCT00427245|stage II breast cancer
1388480|NCT00427245|stage IIIA breast cancer
1388481|NCT00427245|stage IIIB breast cancer
1388482|NCT00427245|estrogen receptor-negative breast cancer
1388483|NCT00427245|estrogen receptor-positive breast cancer
1388484|NCT00427245|progesterone receptor-negative breast cancer
1388485|NCT00427232|coronary heart disease
1388486|NCT00427232|endothelins
1388487|NCT00427232|coronary angiography
1388488|NCT00427232|blood flow velocity
1388489|NCT00427232|fractional flow reserve, myocardial
1388490|NCT00427219|Benign Prostatic Hyperplasia
1388491|NCT00427219|Prostatic Adenoma, Benign
1388492|NCT00427219|Prostatic Hypertrophy, Benign
1388493|NCT00427219|Enlarged Prostate
1388494|NCT00427219|Prostatism
1388495|NCT00427219|Adenoma, Prostatic
1388496|NCT00427206|acetaminophen
1388497|NCT00427206|alcohol
1388498|NCT00427206|liver injury
1388499|NCT00427193|dietary restriction
1388500|NCT00427193|disease /disorder prevention /control
1388501|NCT00427193|nutrition of aging
1388502|NCT00427193|bioenergetics
1388503|NCT00427193|cardiovascular function
1388504|NCT00427193|disease /disorder proneness /risk
1388505|NCT00427193|insulin sensitivity / resistance
1388506|NCT00427180|Visual Perception
1388507|NCT00427180|Retina
1388508|NCT00427180|Light
1388509|NCT00427180|Retinitis Pigmentosa
1388510|NCT00427180|Visual acuity
1388511|NCT00427180|Retinal Implant
1388512|NCT00427180|Electrical stimulation
1388513|NCT00427167|Blood Stage
1388514|NCT00427167|Investigational
1388515|NCT00427167|Vaccine
1388516|NCT00427167|Malaria
1388517|NCT00427167|Healthy Volunteer
1388518|NCT00427167|HV
1388519|NCT00427141|tolerability,
1388520|NCT00427141|pharmacokinetics,
1388521|NCT00427141|first time in human,
1388522|NCT00427141|food effect
1388523|NCT00427141|safety,
1388524|NCT00427128|Major Depression
1388525|NCT00427128|"true drug response"
1388526|NCT00427128|"placebo response pattern"
1388527|NCT00427128|continuation treatment outcomes
1388528|NCT00427115|Patients undergoing allogeneic stem cell transplantations
1388529|NCT00427102|Oral MRX-1024
1388530|NCT00427102|High-Dose Cisplatin Chemotherapy
1388531|NCT00427102|Standard Radiation Therapy
1388532|NCT00427089|Colon cleansing
1388533|NCT00427089|Polyethylene Glycol
1388534|NCT00427089|Sodium Phosphate
1388535|NCT00427076|vancomycin
1388536|NCT00427076|cotrimoxazole
1388537|NCT00427076|trimethoprim/ sulfamethoxazole
1388538|NCT00427076|methicillin-resistant Staphylococcus aureus
1388539|NCT00427076|Health care association infections
1388540|NCT00427076|MRSA bacteremia or other microbiologically documented MRSA infections (defined clinically by CDC criteria)
1388541|NCT00427076|Suspected neurosurgical meningitis
1388542|NCT00427076|Sepsis during hemodialysis, catheter-associated and catheter-related infections
1388543|NCT00427076|Ventilator-associated pneumonia
1388544|NCT00427076|Surgical site infection in the presence of a foreign body
1388545|NCT00427063|retinal vessels
1388546|NCT00427063|tortuosity
1388547|NCT00427050|Actinic Keratoses (AK)
1388548|NCT00427050|PEP005
1388549|NCT00427050|Topical
1388550|NCT00427050|Dermatology
1388551|NCT00427037|Vitamin D deficiency
1388552|NCT00427037|Chronic Kidney Disease
1388553|NCT00427024|renal transplantation
1388554|NCT00427024|acute rejection
1388555|NCT00427024|transport
1388556|NCT00427024|transporter
1388557|NCT00427024|acute rejection after renal transplantation
1388558|NCT00426998|Choroidal neovascularization due to age-related macular degeneration
1388559|NCT00426985|Tendonitis
1388560|NCT00426985|Bursitis
1388561|NCT00426985|Pain
1388562|NCT00426985|Shoulder Pain
1388563|NCT00426985|Elbow Pain
1388564|NCT00426985|Knee Pain
1388565|NCT00426985|Tendon Injury
1388566|NCT00426985|Muscle, Bone and Cartilage Disorders
1388567|NCT00426959|Adenocarcinoma of the prostate
1388568|NCT00426959|PSA of less than 10 ng/mL
1388569|NCT00426959|Combined Gleason score 6 or less
1388570|NCT00426959|International Prostate Symptom Score (IPSS) must <or= to 18
1388571|NCT00426946|Depression Children Reboxetine
1388572|NCT00426946|A diagnosis of major depressive disorder or a dysthimic disorder according to DSM-IV-TR.
1388573|NCT00426946|Drug naïve or without chronic medication for at least one month.
1388574|NCT00426946|Only children who agree to participate and whose parents will sign and informed consent form will be included.
1388575|NCT00426933|cSSSI
1388576|NCT00426933|MRSA
1388577|NCT00426920|pharmacokinetics
1388578|NCT00426920|pharmacodynamics
1388579|NCT00426920|inhaled
1388580|NCT00426920|recombinant human insulin
1388581|NCT00426907|Osteoarthritis, Knee
1388582|NCT00426907|Osteotomy
1388583|NCT00426907|Healing
1388584|NCT00426907|Rehabilitation
1388585|NCT00426907|Roentgen Stereometric Analysis
1388586|NCT00426894|surveillance cultures
1388587|NCT00426894|children
1388588|NCT00426894|cardiac surgery
1388589|NCT00426894|perioperative prophylaxis
1388590|NCT00426881|Exercise
1388591|NCT00426881|Resistance training
1388592|NCT00426868|ADRC
1388593|NCT00426868|Stem Cells
1388594|NCT00426868|chronic ischemia
1388595|NCT00426868|heart disease
1388596|NCT00426868|coronary artery disease
1388597|NCT00426868|inducible reversible ischemia
1388598|NCT00426855|Lymphoma, Non-Hodgkin, Low-Grade
1388599|NCT00426842|Blood pressure
1388600|NCT00426842|Orthostatic hypotension
1388601|NCT00426842|Spinal Cord Injury
1388602|NCT00426842|Sympathetic vascular control
1388603|NCT00426842|Midodrine
1388604|NCT00426829|Liver Cancer
1388605|NCT00426829|Biliary Tract
1388606|NCT00426829|Hepatocellular Carcinoma
1388607|NCT00426829|Cholangiocarcinoma
1388608|NCT00426829|Bevacizumab
1388609|NCT00426829|Proton Therapy
1388610|NCT00426829|Radiation Therapy
1388611|NCT00426829|PT
1388612|NCT00426829|RT
1388613|NCT00426829|Proton RT
1388614|NCT00426829|Avastin
1388615|NCT00426829|Anti-VEGF monoclonal antibody
1388616|NCT00426829|rhuMAb-VEGF
1388617|NCT00426816|primary insomnia
1388618|NCT00426816|PSG sleep recordings
1388619|NCT00426816|daytime cognitive function
1388620|NCT00426816|Insomnia
1388621|NCT00426816|SB-649868
1388622|NCT00426777|prostate cancer
1388623|NCT00426777|prostatic adenoma
1388624|NCT00426777|prostatic neoplasm
1388625|NCT00426764|peripheral T-cell lymphoma
1388626|NCT00426764|T-cell lymphoma
1388627|NCT00426764|romidepsin
1388628|NCT00426751|Eptifibatide
1388629|NCT00426751|ST-elevation Myocardial Infarction
1388630|NCT00426751|STEMI
1388631|NCT00426751|Abciximab
1388632|NCT00426725|labor
1388633|NCT00426725|pain
1388634|NCT00426725|relief
1388635|NCT00426725|labour
1388636|NCT00426725|device
1388637|NCT00426712|Chronic kidney failure
1388638|NCT00426712|Chronic kidney disease
1388639|NCT00426712|Hemodialysis
1388640|NCT00426712|HBV vaccine
1388641|NCT00426712|Hepatitis B vaccine
1388642|NCT00426712|Hepatitis B
1388643|NCT00426712|Hepatitis
1388644|NCT00426712|HBV
1388645|NCT00426712|Prevention & Control
1388646|NCT00426699|enterovirus
1388647|NCT00426699|meningitis
1388648|NCT00426699|sepsis
1388649|NCT00426699|myocarditis
1388650|NCT00426699|kidney
1388651|NCT00426699|urine
1388652|NCT00426699|glomerulonephritis
1388653|NCT00426686|thrombotic thrombocytopenic purpura
1388654|NCT00426686|prognostic factors
1388655|NCT00426686|ADAMTS13
1388656|NCT00426673|partial onset seizures, phenytoin, dilatin, brivaracetam, interaction
1388657|NCT00426660|HIV Infections
1388658|NCT00426647|Osteoarthritis
1388659|NCT00426647|Pain
1388660|NCT00426647|Norspan
1388661|NCT00426647|Buprenorphine
1388662|NCT00426647|Tramadol
1388663|NCT00426634|Asthma
1388664|NCT00426634|Allergens
1388665|NCT00426634|Mold
1388666|NCT00426634|Asthma Counselor
1388667|NCT00426634|Environmental Remediation
1388668|NCT00426621|Knee osteoarthritis, degenerative joint disease, knee pain, joint pain, topical NSAID,
1388669|NCT00426621|diclofenac sodium
1388670|NCT00426608|cortisol,
1388671|NCT00426608|Healthy volunteers
1388672|NCT00426608|GSK561679,
1388673|NCT00426608|HPA axis,
1388674|NCT00426608|hormones,
1388675|NCT00426582|Cancer
1388676|NCT00426582|maximum tolerated dose
1388677|NCT00426582|dose-limiting toxicity
1388678|NCT00426582|patupilone
1388679|NCT00426582|carboplatin
1388680|NCT00426582|pharmacokinetics
1388681|NCT00426556|Breast cancer
1388682|NCT00426556|Cancer of the breast
1388683|NCT00426556|Human mammary carcinoma
1388684|NCT00426556|HER-2
1388685|NCT00426556|Metastatic
1388686|NCT00426556|everolimus
1388687|NCT00426556|trastuzumab
1388688|NCT00426556|paclitaxel
1388689|NCT00426543|Clinical trial
1388690|NCT00426543|Intervention study
1388691|NCT00426543|Double-blind randomised controlled study
1388692|NCT00426530|HER2-overexpressing metastatic breast cancer
1388693|NCT00426530|Breast cancer
1388694|NCT00426530|Cancer of the breast
1388695|NCT00426530|Human mammary carcinoma
1388696|NCT00426530|HER-2
1388697|NCT00426530|metastatic
1388698|NCT00426530|everolimus
1388699|NCT00426530|trastuzumab
1388700|NCT00426530|vinorelbine
1388701|NCT00426517|MUD Transplant
1388702|NCT00426517|Transplant
1388703|NCT00426517|AlloPBSC
1388704|NCT00426517|HLA Matched Transplant
1388705|NCT00426517|BMT
1388706|NCT00426517|Congenital Immunodeficiency
1388707|NCT00426517|Bone Marrow Transplant
1388708|NCT00426504|Head,
1388709|NCT00426504|Neck,
1388710|NCT00426504|Cancer,
1388711|NCT00426504|Tomotherapy,
1388712|NCT00426504|IMRT,
1388713|NCT00426478|AMPM, SBP, DBP, Valsartan plus Hydrochlorothiazide, Amlodipine, high blood pressure
1388714|NCT00426465|Motor Practice
1388715|NCT00426465|Magnetic Stimulation
1388716|NCT00426465|Stroke
1388717|NCT00426465|Spacing Effect
1388718|NCT00426465|Massed Practice
1388719|NCT00426465|Healthy Volunteer
1388720|NCT00426465|HV
1388721|NCT00426452|Vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitor
1388722|NCT00426452|Vatalinib
1388723|NCT00426452|Proton-pump inhibitors
1388724|NCT00426452|Omeprazole
1388725|NCT00426452|Healthy Postmenopausal Female Volunteers
1388726|NCT00426439|malaria
1388727|NCT00426439|Plasmodium falciparum
1388728|NCT00426439|children
1388729|NCT00426439|Guinea-Bissau
1388730|NCT00426439|artemether
1388731|NCT00426439|lumefantrine
1388732|NCT00426439|chloroquine
1388733|NCT00426439|Coartem
1388734|NCT00426413|ketosis-prone diabetes
1388735|NCT00426413|diabetic ketoacidosis
1388736|NCT00426413|obesity
1388737|NCT00426413|insulin dependence
1388738|NCT00426413|mechanisms
1388739|NCT00426374|HIV
1388740|NCT00426374|AIDS
1388741|NCT00426374|Troponin
1388742|NCT00426374|natriuretic peptide
1388743|NCT00426374|heart failure
1388744|NCT00426374|heart disease children
1388745|NCT00426374|HIV pediatric
1388746|NCT00426374|AIDS pediatric
1388747|NCT00426361|Human Papillomavirus
1388748|NCT00426348|IgA nephropathy
1388749|NCT00426348|probucol
1388750|NCT00426348|valsartan
1388751|NCT00426348|treatment
1388752|NCT00426348|antioxidant
1388753|NCT00426348|IGA nephropathy：a kind of glomerulonephritis,which IgA is the dominant immunodeposit in mesangial areas
1388754|NCT00426335|breast
1388755|NCT00426335|cancer
1388756|NCT00426335|cognitive behaviour therapy
1388757|NCT00426335|psychological
1388758|NCT00426322|maxillary sinus augmentation
1388759|NCT00426322|bone graft
1388760|NCT00426322|bovine bone mineral
1388761|NCT00426322|dental implants
1388762|NCT00426296|HIV
1388763|NCT00426296|Reyataz
1388764|NCT00426296|atazanavir
1388765|NCT00426296|Norvir
1388766|NCT00426296|ritonavir
1388767|NCT00426296|Boosted
1388768|NCT00426296|Lipodystrophy
1388769|NCT00426296|Treatment Experienced
1388770|NCT00426283|Eosinophilic Esophagitis
1388771|NCT00426257|Ovarian Cancer
1388772|NCT00426257|stage III
1388773|NCT00426257|hyperthermic intraperitoneal chemotherapy
1388774|NCT00426257|debulking surgery
1388775|NCT00426257|HIPEC
1388776|NCT00426244|Osteopathic Manipulative Medicine
1388777|NCT00426244|Osteopathic Manipulative Treatment
1388778|NCT00426244|Pregnancy
1388779|NCT00426244|Physiologic
1388780|NCT00426244|Gait
1388781|NCT00426244|Low back pain
1388782|NCT00426244|Heart rate variability
1388783|NCT00426231|Randomized Controlled Trials
1388784|NCT00426231|Health Education
1388785|NCT00426231|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1388786|NCT00426231|Patient Nonadherence
1388787|NCT00426218|Systemic Juvenile Idiopathic Arthritis
1388788|NCT00426218|Immunogenicity
1388789|NCT00426218|Pharmacokinetics
1388790|NCT00426218|Anti-IL-1ß Monoclonal Antibody
1388791|NCT00426218|ACZ885
1388792|NCT00426218|SJIA
1388793|NCT00426218|Pediatrics
1388794|NCT00426205|GM-CSF
1388795|NCT00426205|GVAX
1388796|NCT00426205|Cancer vaccine
1388797|NCT00426205|blood stem cell transplantation
1388798|NCT00426205|MDS
1388799|NCT00426205|AML
1388800|NCT00426205|CML
1388801|NCT00426192|Immunedefense Suppression
1388802|NCT00426192|Cardiopulmonary Bypass
1388803|NCT00426192|Mannitol
1388804|NCT00426192|Hemofiltration
1388805|NCT00426192|Cytokines
1388806|NCT00426192|Receptors, Surface CD14
1388807|NCT00426179|Imatinib, allergic inflammation, out of allergy season, repeated nasal allergen, seasonal allergic rhinitis, sensitive, Timothy grass pollen, c-kit inhibition
1388808|NCT00426140|EPO
1388809|NCT00426140|Patupilone
1388810|NCT00426140|Solid Tumors
1388811|NCT00426127|Pancreatic
1388812|NCT00426127|Docetaxel
1388813|NCT00426127|Doxorubicin
1388814|NCT00426127|Enoxaparin
1388815|NCT00425113|Mycobacterium Tuberculosis
1388816|NCT00425113|Anaerobic
1388817|NCT00425113|FDG-PET-HRCT
1388818|NCT00425113|HRCT
1388819|NCT00425113|Lesion Matrix
1388820|NCT00425113|Tuberculosis
1388821|NCT00425113|TB
1388822|NCT00425074|slow release ASA
1388823|NCT00425074|platelet functionalism
1388824|NCT00425074|secondary cardiovascular prevention
1388825|NCT00425035|Renal Cancer
1388826|NCT00425022|lung cancer
1388827|NCT00425022|video-assisted thoracic surgery
1388828|NCT00425009|Berberine
1388829|NCT00425009|Type 2 diabetes
1388830|NCT00425009|Treatment
1388831|NCT00424983|Multiple myeloma
1388832|NCT00424983|breast cancer
1388833|NCT00424983|zoledronic acid
1388834|NCT00424983|pharmacokinetics
1388835|NCT00424970|high altitude
1388836|NCT00424970|hypoxia
1388837|NCT00424970|pulmonary hypertension
1388838|NCT00424970|polycythemia
1388839|NCT00424970|hypoventilation
1388840|NCT00424957|Ammonia
1388841|NCT00424957|Astrocytes
1388842|NCT00424957|Citric acid cycle
1388843|NCT00424957|Alpha ketoglutarate dehydrogenase
1388844|NCT00424944|Malaria
1388845|NCT00424944|Vaccine
1388846|NCT00424944|GMZ2
1388847|NCT00424944|Safety
1388848|NCT00424944|African
1388849|NCT00424944|immunogenicity
1388850|NCT00424931|narcolepsy
1388851|NCT00424931|sleepiness
1388852|NCT00424918|Dance
1388853|NCT00424918|Peers
1388854|NCT00424918|middle school-based
1388855|NCT00424918|feasibility
1388856|NCT00424866|Peripheral Arterial Disease
1388857|NCT00424866|Ischemia
1388858|NCT00424866|Intermittent Claudication
1388967|NCT00425776|Se-endorphine
1388859|NCT00424840|lung cancer, Carboplatin, bortezomib, Bevacizumab
1388860|NCT00426101|Hemophagocytic lymphohistiocytosis
1388861|NCT00426075|Deep vein thrombosis of the lower extremities
1388862|NCT00426062|Squamous Cell Carcinoma of Tongue and mouth floor
1388863|NCT00426049|Coronary artery disease
1388864|NCT00426049|Stents
1388865|NCT00426049|Immunosuppressive Agents
1388866|NCT00426049|Coronary restenosis
1388867|NCT00426049|Safety
1388868|NCT00426036|Open-label study, healthy subjects, stable impaired renal function, licarbazepine, pharmacokinetics, metabolism, safety.
1388869|NCT00426023|Vernal keratoconjunctivitis
1388870|NCT00426023|Cyclosporine
1388871|NCT00426023|Children
1388872|NCT00426023|Clinical trial
1388873|NCT00426010|Placebo effect
1388874|NCT00426010|Caffeine
1388875|NCT00426010|Systolic BP
1388876|NCT00426010|VAS
1388877|NCT00425997|Hypertension, valsartan/HCTZ, amlodipine and HCTZ
1388878|NCT00425984|HIV
1388879|NCT00425984|Male circumcision
1388880|NCT00425984|Sexually transmitted infections
1388881|NCT00425984|Sexual risk behaviors
1388882|NCT00425984|Adult males
1388883|NCT00425984|Haemophilus ducreyi
1388884|NCT00425984|Human papillomavirus
1388885|NCT00425984|Rakai
1388886|NCT00425984|Uganda
1388887|NCT00425984|HIV seronegativity
1388888|NCT00425984|HPV
1388889|NCT00425984|STI
1388890|NCT00425958|year and more after TBI
1388891|NCT00425958|good vision
1388892|NCT00425958|at least one functinal hand
1388893|NCT00425958|cap[able od doing shopping during everyday life
1388894|NCT00425932|Magnetic Resonance Imaging
1388895|NCT00425932|Rituximab
1388896|NCT00425932|Low Field MRI
1388897|NCT00425932|Biomarkers
1388898|NCT00425919|Type 2 Diabetes
1388899|NCT00425919|Diabetes
1388900|NCT00425906|psychosocial effects of cancer and its treatment
1388901|NCT00425906|unspecified adult solid tumor, protocol specific
1388902|NCT00425906|constipation, impaction, and bowel obstruction
1388903|NCT00425906|anorexia
1388904|NCT00425906|pain
1388905|NCT00425893|influenza
1388906|NCT00425893|masks
1388907|NCT00425893|transmission
1388908|NCT00425893|hand hygiene
1388909|NCT00425893|non-pharmacologic interventions
1388910|NCT00425880|Pregnancy
1388911|NCT00425880|Asthma
1388912|NCT00425880|Tobacco Abuse
1388913|NCT00425880|Exhaled Nitric Oxide
1388914|NCT00425867|PAR1 gene
1388915|NCT00425867|polymorphisms
1388916|NCT00425867|abortions
1388917|NCT00425867|reccurent abortions
1388918|NCT00425867|premature delivery
1388919|NCT00425841|adenocarcinoma of the pancreas
1388920|NCT00425841|stage III pancreatic cancer
1388921|NCT00425841|stage II pancreatic cancer
1388922|NCT00425815|Cognition
1388923|NCT00425815|Ampakines
1388924|NCT00425815|Schizophrenia
1388925|NCT00425802|noncontiguous stage II adult diffuse large cell lymphoma
1388926|NCT00425802|recurrent adult diffuse large cell lymphoma
1388927|NCT00425802|stage III adult diffuse large cell lymphoma
1388928|NCT00425802|stage IV adult diffuse large cell lymphoma
1388929|NCT00425802|B-cell chronic lymphocytic leukemia
1388930|NCT00425802|refractory chronic lymphocytic leukemia
1388931|NCT00425802|stage III chronic lymphocytic leukemia
1388932|NCT00425802|stage IV chronic lymphocytic leukemia
1388933|NCT00425802|noncontiguous stage II mantle cell lymphoma
1388934|NCT00425802|recurrent mantle cell lymphoma
1388935|NCT00425802|stage III mantle cell lymphoma
1388936|NCT00425802|stage IV mantle cell lymphoma
1388937|NCT00425802|noncontiguous stage II grade 1 follicular lymphoma
1388938|NCT00425802|noncontiguous stage II grade 2 follicular lymphoma
1388939|NCT00425802|recurrent grade 1 follicular lymphoma
1388940|NCT00425802|recurrent grade 2 follicular lymphoma
1388941|NCT00425802|stage III grade 1 follicular lymphoma
1388942|NCT00425802|stage III grade 2 follicular lymphoma
1388943|NCT00425802|stage IV grade 1 follicular lymphoma
1388944|NCT00425802|stage IV grade 2 follicular lymphoma
1388945|NCT00425802|noncontiguous stage II small lymphocytic lymphoma
1388946|NCT00425802|recurrent small lymphocytic lymphoma
1388947|NCT00425802|stage III small lymphocytic lymphoma
1388948|NCT00425802|stage IV small lymphocytic lymphoma
1388949|NCT00425802|noncontiguous stage II marginal zone lymphoma
1388950|NCT00425802|recurrent marginal zone lymphoma
1388951|NCT00425802|splenic marginal zone lymphoma
1388952|NCT00425802|stage III marginal zone lymphoma
1388953|NCT00425802|stage IV marginal zone lymphoma
1388954|NCT00425802|noncontiguous stage II adult immunoblastic large cell lymphoma
1388955|NCT00425802|stage III adult immunoblastic large cell lymphoma
1388956|NCT00425802|stage IV adult immunoblastic large cell lymphoma
1388957|NCT00425802|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1388958|NCT00425802|nodal marginal zone B-cell lymphoma
1388959|NCT00425802|recurrent adult immunoblastic large cell lymphoma
1388960|NCT00425789|Deep Chemical Peeling
1388961|NCT00425789|Hyperbaric Therapy
1388962|NCT00425789|post-deep peel
1388963|NCT00425776|Breast cancer
1388964|NCT00425776|Acupuncture
1388965|NCT00425776|Post-menopausal hot flushes
1388966|NCT00425776|Se-estradiol
1388968|NCT00425763|malaria
1388969|NCT00425763|efficacy
1388970|NCT00425763|intermittent preventive therapy in infants
1388971|NCT00425763|drug resistance
1388972|NCT00425750|stage IV squamous cell carcinoma of the lip and oral cavity
1388973|NCT00425750|recurrent squamous cell carcinoma of the lip and oral cavity
1388974|NCT00425750|stage IV squamous cell carcinoma of the oropharynx
1388975|NCT00425750|recurrent squamous cell carcinoma of the oropharynx
1388976|NCT00425750|stage IV squamous cell carcinoma of the hypopharynx
1388977|NCT00425750|recurrent squamous cell carcinoma of the hypopharynx
1388978|NCT00425750|stage IV squamous cell carcinoma of the larynx
1388979|NCT00425750|recurrent squamous cell carcinoma of the larynx
1388980|NCT00425737|Oral live attenuated human rotavirus vaccine
1388981|NCT00425737|Gastroenteritis
1388982|NCT00425724|proteinuria
1388983|NCT00425724|nephritis
1388984|NCT00425724|nephrotic syndrome
1388985|NCT00425724|glomerulonephritis
1388986|NCT00425711|Acamprosate
1388987|NCT00425711|Alcohol Dependence
1388988|NCT00425711|Driving Under the Influence
1388989|NCT00425711|Drug Court
1388990|NCT00425711|DUI Court
1388991|NCT00425685|cardiopulmonary resuscitation, ECMO, shock, survival, heart failure, transplantation, heart assist device.
1388992|NCT00425659|Health utility
1388993|NCT00425659|Home sleep study
1388994|NCT00425646|stage IIIB non-small cell lung cancer
1388995|NCT00425646|stage IV non-small cell lung cancer
1388996|NCT00425646|adenocarcinoma of the lung
1388997|NCT00425646|bronchoalveolar cell lung cancer
1388998|NCT00425646|large cell lung cancer
1388999|NCT00425646|recurrent non-small cell lung cancer
1389000|NCT00425633|Homeopathic
1389001|NCT00425633|Potassium
1389002|NCT00425633|Dichromate
1389003|NCT00425633|Kalium
1389004|NCT00425633|Bichromicum
1389005|NCT00425633|Mechanical
1389006|NCT00425633|Ventilation
1389007|NCT00425633|Secretions
1389008|NCT00425620|Chronic Sinusitis
1389009|NCT00425620|Chronic Rhinosinusitis
1389010|NCT00425607|Hutchinson-Gilford Progeria Syndrome
1389011|NCT00425607|HGPS
1389012|NCT00425607|Progeria
1389013|NCT00425607|FTI
1389014|NCT00425607|Farnesyltransferase Inhibitor
1389015|NCT00425607|Lonafarnib
1389016|NCT00425594|colonoscopy
1389017|NCT00425594|bowel preparation
1389018|NCT00425594|prep
1389019|NCT00425581|N-terminal pro-BNP,
1389020|NCT00425581|Cardiac Troponin-T,
1389021|NCT00425581|Very low birth weight infants
1389022|NCT00425581|hemodynamic instability
1389023|NCT00425581|myocardial dysfunction
1389024|NCT00425568|hypogonadism
1389025|NCT00425568|low testosterone level
1389026|NCT00425568|gonadal deficiency
1389027|NCT00425555|Cutaneous T-Cell Lymphoma, adults
1389028|NCT00425555|Mycosis Fungoides
1389029|NCT00425555|Sézary Syndrome
1389030|NCT00425555|CTCL
1389031|NCT00425542|Pulmonary embolism
1389032|NCT00425542|Outpatient care
1389033|NCT00425542|Prognosis
1389034|NCT00425516|neoadjuvant chemotherapy
1389035|NCT00425516|breast cancer
1389036|NCT00425516|sequential treatment
1389037|NCT00425503|Prostate Cancer
1389038|NCT00425503|Bortezomib
1389039|NCT00425503|Radical Prostatectomy
1389040|NCT00425503|Phase 2 Clinical Trial
1389041|NCT00425477|refractory anemia with excess blasts
1389042|NCT00425477|recurrent adult acute myeloid leukemia
1389043|NCT00425477|untreated adult acute myeloid leukemia
1389044|NCT00425477|secondary acute myeloid leukemia
1389045|NCT00425477|de novo myelodysplastic syndromes
1389046|NCT00425477|previously treated myelodysplastic syndromes
1389047|NCT00425477|secondary myelodysplastic syndromes
1389048|NCT00425477|myelodysplastic/myeloproliferative disease, unclassifiable
1389049|NCT00425477|refractory anemia with ringed sideroblasts
1389050|NCT00425477|refractory cytopenia with multilineage dysplasia
1389051|NCT00425477|chronic myelomonocytic leukemia
1389052|NCT00425477|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1389053|NCT00425477|adult acute minimally differentiated myeloid leukemia (M0)
1389054|NCT00425477|adult acute myeloblastic leukemia without maturation (M1)
1389055|NCT00425477|adult acute myeloblastic leukemia with maturation (M2)
1389056|NCT00425477|adult acute myelomonocytic leukemia (M4)
1389057|NCT00425477|adult acute monoblastic leukemia (M5a)
1389058|NCT00425477|adult acute monocytic leukemia (M5b)
1389059|NCT00425477|adult pure erythroid leukemia (M6b)
1389060|NCT00425477|adult erythroleukemia (M6a)
1389061|NCT00425477|adult acute megakaryoblastic leukemia (M7)
1389062|NCT00425477|adult acute myeloid leukemia with t(16;16)(p13;q22)
1389063|NCT00425477|adult acute myeloid leukemia with t(8;21)(q22;q22)
1389064|NCT00425477|adult acute myeloid leukemia with inv(16)(p13;q22)
1389065|NCT00425451|Periodontitis
1389066|NCT00425451|Dental Care
1389067|NCT00425451|Efficacy
1389068|NCT00425451|Safety
1389069|NCT00425425|squamous cell carcinoma of the esophagus
1389070|NCT00425425|stage IIA esophageal cancer
1389071|NCT00425425|stage IIB esophageal cancer
1389072|NCT00425425|stage IIIA esophageal cancer
1389073|NCT00425425|stage IIIB esophageal cancer
1389074|NCT00425425|stage IIIC esophageal cancer
1389075|NCT00425399|Schizophrenia
1389076|NCT00425399|Shiatsu
1389077|NCT00425386|stage III renal cell cancer
1389078|NCT00425386|stage IV renal cell cancer
1389079|NCT00425386|clear cell renal cell carcinoma
1389080|NCT00425386|recurrent renal cell cancer
1389081|NCT00425373|Hypertension, Valsartan, Amlodipine, high blood pressure
1389082|NCT00425360|stage III pancreatic cancer
1389083|NCT00425360|stage IV pancreatic cancer
1389084|NCT00425360|duct cell adenocarcinoma of the pancreas
1389085|NCT00425360|recurrent pancreatic cancer
1389086|NCT00425347|Multiple myeloma, MM, plasma cell myeloma, cancer
1389087|NCT00425334|Blood loss
1389088|NCT00425334|Ischemia
1389089|NCT00425334|Hemoglobin
1389090|NCT00425334|Blood Substitutes
1389091|NCT00425334|Plasma Expanders
1389092|NCT00425321|Arthritis
1389093|NCT00425321|Joints
1389094|NCT00425321|Auto immune
1389095|NCT00425308|Everolimus, calcineurine inhibitor, renal transplantation in maintenance, chronic allograft nephropathy
1389096|NCT00425282|RWJ-333369
1389097|NCT00425282|anticonvulsants
1389098|NCT00425282|antiepileptic drugs
1389099|NCT00425269|lifestyle intervention
1389100|NCT00425269|Type 2 Diabetes
1389101|NCT00425269|Metabolic syndrome
1389102|NCT00425269|Pakistani women
1389103|NCT00425269|dietary change
1389104|NCT00425269|Physical activity
1389105|NCT00425269|Norway
1389106|NCT00425243|primary insomnia
1389107|NCT00425243|chronic insomnia
1389108|NCT00425178|Chronic wounds
1389109|NCT00425178|Diabetes
1389110|NCT00425178|Ulcers
1389111|NCT00425178|Arterial bypass
1389112|NCT00425178|Angioplasty
1389113|NCT00425178|Diabetic ulcers
1389114|NCT00425152|stage II colon cancer
1389115|NCT00425152|stage III colon cancer
1389116|NCT00425139|Cancer
1389117|NCT00425139|Video game
1389118|NCT00425139|Adolescent
1389119|NCT00425139|Young adult
1389120|NCT00425126|Delayed Graft Function
1389121|NCT00425126|Kidney Transplantation
1389122|NCT00424827|pancreatic cancer, gemcitabine, 5-FU, cetuximab, radiation
1389123|NCT00424814|HIV mother to child prevention
1389124|NCT00424814|HIV Infections
1389125|NCT00424814|Kaletra
1389126|NCT00424814|Combivir
1389127|NCT00424814|HIV Seronegativity
1389128|NCT00424788|multiple sclerosis (MS)
1389129|NCT00424775|Non-Small Cell Lung Cancer (NSCLC)
1389130|NCT00424762|Diabetes Mellitus, Type 2
1389131|NCT00424762|Congestive Heart Failure
1389132|NCT00424762|Cardiopulmonary exercise testing
1389133|NCT00424762|intracellular cardiomyocyte triglycerides
1389134|NCT00424762|thiazolidinedione
1389135|NCT00424762|rosiglitazone
1389136|NCT00424762|nuclear magnetic resonance
1389137|NCT00424749|Antineutrophil cytoplasmic antibody associated vasculitis
1389138|NCT00424749|Glomerulonephritis
1389139|NCT00424749|Rituximab
1389140|NCT00424736|blunt trauma, pediatric patient, imaging, computer tomography
1389141|NCT00424723|pemetrexed
1389142|NCT00424723|neuroendocrine tumors
1389143|NCT00424723|metastatic neuroendocrine tumors
1389144|NCT00424710|choroidal neovascularization
1389145|NCT00424697|Brain imaging,
1389146|NCT00424697|fMRI,
1389147|NCT00424697|stimulation,
1389148|NCT00424697|pharmacodynamics,
1389149|NCT00424697|tolerability,
1389150|NCT00424697|healthy subjects
1389151|NCT00424684|TB
1389152|NCT00424684|Chronic Liver Disease
1389153|NCT00424658|breathing disorders
1389154|NCT00424645|Hematologic Malignancy
1389155|NCT00424645|Solid Tumor
1389156|NCT00424645|Glucarpidase
1389157|NCT00424645|Voraxaze
1389158|NCT00424645|Delayed Methotrexate Clearance
1389159|NCT00424645|Placebo
1389160|NCT00424619|Vitamin D
1389161|NCT00424619|Hip fracture
1389162|NCT00424619|Optimal level
1389163|NCT00424619|Deficiency
1389164|NCT00424619|Functional muscle strength
1389165|NCT00424606|High risk node negative
1389166|NCT00424567|Fracture
1389167|NCT00424567|non union fracture
1389168|NCT00424567|ununited fracture
1389169|NCT00424567|pseudarthrosis
1389170|NCT00424541|Pharmacokinetics, pharmacodynamics, safety, RAS profile, SPP100, aliskiren, Japanese, essential hypertension
1389171|NCT00424541|Mild to moderate essential hypertension
1389172|NCT00424528|COPD including chronic bronchitis and emphysema
1389173|NCT00424515|Imatinib
1389174|NCT00424515|Gleevec
1389175|NCT00424489|Refractory Myasthenia Gravis
1389176|NCT00424489|Autologous Stem Cell Transplantation
1389177|NCT00424489|Cyclophosphamide and ATG
1389178|NCT00424476|Autoimmune Diseases
1389179|NCT00424476|Lupus
1389180|NCT00424476|SLE
1389181|NCT00424476|Systemic Lupus Erythematosus
1389182|NCT00424476|Belimumab
1389183|NCT00424476|Antibodies
1389184|NCT00424463|Amyotrophic lateral sclerosis (ALS)
1389185|NCT00424450|contrast ultrasound
1389186|NCT00424450|muscle perfusion
1389187|NCT00424424|Postoperative Dental Pain
1389188|NCT00424385|AIPC, Prostate cancer
1389189|NCT00424385|prostate
1389190|NCT00424359|Mulitple Sclerosis
1389191|NCT00424359|Ambulation
1389192|NCT00424346|Active Rheumatoid Arthritis
1389193|NCT00424346|anti-interleukin-1beta monoclonal antibody
1389194|NCT00424346|methotrexate
1389195|NCT00424320|Acute kidney failure
1389196|NCT00424320|Contrast-induced nephropathy
1389197|NCT00424320|Non-ionic contrast media
1389198|NCT00424320|Ionic contrast media
1389199|NCT00424320|Iopamidol
1389200|NCT00424320|Percutaneous coronary intervention
1389201|NCT00424320|Coronariography
1389202|NCT00424281|Arixtra, fondaparinux, vasopressor, venous thrombolism
1389203|NCT00424268|COPD
1389204|NCT00424268|Roflumilast
1389205|NCT00424255|Cancer of the Head and Neck
1389206|NCT00424255|Neck cancer
1389207|NCT00424255|Adjuvant
1389208|NCT00424255|Head and neck cancer
1389209|NCT00424255|High-risk head and neck cancer
1389210|NCT00424255|Post-surgery
1389211|NCT00424255|Head cancer
1389212|NCT00424242|unspecified adult solid tumor, protocol specific
1389213|NCT00424242|tumors metastatic to brain
1389214|NCT00424242|leptomeningeal metastases
1389215|NCT00424242|primary central nervous system non-Hodgkin lymphoma
1389216|NCT00424242|primary central nervous system Hodgkin lymphoma
1389217|NCT00424242|meningeal chronic myelogenous leukemia
1389218|NCT00424242|relapsing chronic myelogenous leukemia
1389219|NCT00424242|chronic eosinophilic leukemia
1389220|NCT00424242|primary myelofibrosis
1389221|NCT00424242|chronic neutrophilic leukemia
1389222|NCT00424242|essential thrombocythemia
1389223|NCT00424242|polycythemia vera
1389224|NCT00424242|recurrent adult acute lymphoblastic leukemia
1389225|NCT00424242|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1389226|NCT00424242|adult acute myeloid leukemia with inv(16)(p13;q22)
1389227|NCT00424242|adult acute myeloid leukemia with t(15;17)(q22;q12)
1389228|NCT00424242|adult acute myeloid leukemia with t(16;16)(p13;q22)
1389229|NCT00424242|adult acute myeloid leukemia with t(8;21)(q22;q22)
1389230|NCT00424242|recurrent adult acute myeloid leukemia
1389231|NCT00424242|previously treated myelodysplastic syndromes
1389232|NCT00424242|secondary acute myeloid leukemia
1389233|NCT00424242|acute undifferentiated leukemia
1389234|NCT00424242|mast cell leukemia
1389235|NCT00424242|recurrent adult T-cell leukemia/lymphoma
1389236|NCT00424242|stage IV adult T-cell leukemia/lymphoma
1389237|NCT00424242|T-cell large granular lymphocyte leukemia
1389238|NCT00424242|atypical chronic myeloid leukemia, BCR-ABL negative
1389239|NCT00424242|stage IV chronic lymphocytic leukemia
1389240|NCT00424242|refractory chronic lymphocytic leukemia
1389241|NCT00424242|chronic myelomonocytic leukemia
1389242|NCT00424242|refractory hairy cell leukemia
1389243|NCT00424242|prolymphocytic leukemia
1389244|NCT00424242|stage IV mycosis fungoides/Sezary syndrome
1389245|NCT00424242|recurrent mycosis fungoides/Sezary syndrome
1389246|NCT00424242|stage IV cutaneous T-cell non-Hodgkin lymphoma
1389247|NCT00424242|recurrent cutaneous T-cell non-Hodgkin lymphoma
1389248|NCT00424242|adult grade III lymphomatoid granulomatosis
1389249|NCT00424242|intraocular lymphoma
1389250|NCT00424242|post-transplant lymphoproliferative disorder
1389251|NCT00424242|refractory multiple myeloma
1389252|NCT00424242|stage IV adult Hodgkin lymphoma
1389253|NCT00424242|recurrent adult Hodgkin lymphoma
1389254|NCT00424242|anaplastic large cell lymphoma
1389255|NCT00424242|angioimmunoblastic T-cell lymphoma
1389256|NCT00424242|Waldenstrom macroglobulinemia
1389257|NCT00424242|stage IV adult Burkitt lymphoma
1389258|NCT00424242|recurrent adult Burkitt lymphoma
1389259|NCT00424242|stage IV adult diffuse large cell lymphoma
1389260|NCT00424242|stage IV adult diffuse mixed cell lymphoma
1389261|NCT00424242|stage IV adult diffuse small cleaved cell lymphoma
1389262|NCT00424242|stage IV adult immunoblastic large cell lymphoma
1389263|NCT00424242|stage IV adult lymphoblastic lymphoma
1389264|NCT00424242|stage IV grade 1 follicular lymphoma
1389265|NCT00424242|stage IV grade 2 follicular lymphoma
1389266|NCT00424242|stage IV grade 3 follicular lymphoma
1389267|NCT00424242|stage IV mantle cell lymphoma
1389268|NCT00424242|stage IV marginal zone lymphoma
1389269|NCT00424242|recurrent adult diffuse large cell lymphoma
1389270|NCT00424242|recurrent adult diffuse mixed cell lymphoma
1389271|NCT00424242|recurrent adult diffuse small cleaved cell lymphoma
1389272|NCT00424242|recurrent adult immunoblastic large cell lymphoma
1389273|NCT00424242|recurrent adult lymphoblastic lymphoma
1389274|NCT00424242|recurrent grade 1 follicular lymphoma
1389275|NCT00424242|recurrent grade 2 follicular lymphoma
1389276|NCT00424242|recurrent grade 3 follicular lymphoma
1389277|NCT00424242|recurrent mantle cell lymphoma
1389278|NCT00424242|recurrent marginal zone lymphoma
1389279|NCT00424242|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1389280|NCT00424242|nodal marginal zone B-cell lymphoma
1389281|NCT00424242|splenic marginal zone lymphoma
1389282|NCT00424242|stage IV small lymphocytic lymphoma
1389283|NCT00424242|recurrent small lymphocytic lymphoma
1389284|NCT00424242|adult nasal type extranodal NK/T-cell lymphoma
1389285|NCT00424242|accelerated phase chronic myelogenous leukemia
1389286|NCT00424242|blastic phase chronic myelogenous leukemia
1389287|NCT00424242|chronic phase chronic myelogenous leukemia
1389288|NCT00424242|de novo myelodysplastic syndromes
1389289|NCT00424242|secondary myelodysplastic syndromes
1389290|NCT00424242|secondary myelofibrosis
1389291|NCT00424242|AIDS-related peripheral/systemic lymphoma
1389292|NCT00424242|AIDS-related primary CNS lymphoma
1389293|NCT00424242|recurrent adult grade III lymphomatoid granulomatosis
1389294|NCT00424242|stage III multiple myeloma
1389295|NCT00424242|primary systemic amyloidosis
1389296|NCT00424242|extramedullary plasmacytoma
1389297|NCT00424242|monoclonal gammopathy of undetermined significance
1389298|NCT00424242|isolated plasmacytoma of bone
1389299|NCT00424229|MDS INT-2MDS HIGH RISKDELETION 5q[31]Lenalidomide
1389300|NCT00424216|Mood
1389301|NCT00424216|Emotion
1389302|NCT00424216|Judgment
1389303|NCT00424216|Cortex
1389304|NCT00424216|Brain Stimulation
1389305|NCT00424216|Healthy Volunteer
1389306|NCT00424216|HV
1389307|NCT00424203|cognitive/functional effects
1389308|NCT00424203|depression
1389309|NCT00424203|malnutrition
1389310|NCT00424203|psychosocial effects of cancer and its treatment
1389311|NCT00424203|stage IA breast cancer
1389312|NCT00424203|stage IB breast cancer
1389313|NCT00424203|stage II breast cancer
1389314|NCT00424203|stage IIIA breast cancer
1389315|NCT00424203|stage IIIB breast cancer
1389316|NCT00424203|stage IIIC breast cancer
1389317|NCT00424203|estrogen receptor-negative breast cancer
1389318|NCT00424203|progesterone receptor-negative breast cancer
1389319|NCT00424190|Abscess
1389320|NCT00424190|Antibacterial
1389321|NCT00424190|Antibiotic
1389322|NCT00424190|Antimicrobial
1389323|NCT00424190|Bacterial infection, skin
1389324|NCT00424190|Ceftaroline
1389325|NCT00424190|Ceftaroline acetate
1389326|NCT00424190|Cellulitis
1389327|NCT00424190|Cephalosporin
1389328|NCT00424190|Complicated skin and skin structure infection
1389329|NCT00424190|cSSSI
1389330|NCT00424190|Intravenous
1389331|NCT00424190|Methicillin-resistant Staphylococcus Aureus (MRSA)
1389332|NCT00424190|PPI-0903
1389333|NCT00424190|Prodrug
1389334|NCT00424190|Skin disease, bacterial
1389335|NCT00424190|Skin infection
1389336|NCT00424190|Staphylococcal skin infection
1389337|NCT00424190|Staphylococcus aureus
1389338|NCT00424190|Streptococcal skin infection
1389339|NCT00424190|Surgical site infection
1389340|NCT00424190|TAK-599
1389341|NCT00424177|idiopathic thrombocytopenic purpura
1389342|NCT00424177|ITP
1389343|NCT00424177|thrombocytopenia
1389344|NCT00424177|platelets
1389345|NCT00424164|male breast cancer
1389346|NCT00424164|stage IIIB breast cancer
1389347|NCT00424164|stage IIIC breast cancer
1389348|NCT00424164|stage IV breast cancer
1389349|NCT00424164|recurrent breast cancer
1389350|NCT00424151|Graves' Disease
1389351|NCT00424151|Dysthyroid Ophthalmopathy
1389352|NCT00424151|Thyroid related orbitopathy
1389357|NCT00424125|Asthma
1389358|NCT00424125|Compliance
1389359|NCT00424125|Randomized clinical trial
1389360|NCT00424112|motivation to change
1389361|NCT00424112|treatment motivation
1389362|NCT00424112|alcohol use disorders
1389363|NCT00424099|Advanced Cancer
1389364|NCT00424099|Fatigue
1389365|NCT00424099|Nursing Telephone Intervention
1389366|NCT00424099|NTI
1389367|NCT00424099|Methylphenidate
1389368|NCT00424099|Placebo
1389369|NCT00424099|Ritalin
1389370|NCT00424060|adult glioblastoma
1389371|NCT00424060|recurrent adult brain tumor
1389372|NCT00424060|adult giant cell glioblastoma
1389373|NCT00424060|adult gliosarcoma
1389374|NCT00424047|Multiple Myeloma
1389375|NCT00424047|Celgene
1389376|NCT00424047|Revlimid
1389377|NCT00424047|CC-5013
1389378|NCT00424034|safety
1389379|NCT00424034|Pharmacokinetics
1389380|NCT00424034|effect of food on pharmacokinetics
1389381|NCT00424008|Glucocorticosteroids
1389382|NCT00424008|Dry Powder Inhaler
1389383|NCT00424008|Bronchodilator
1389384|NCT00424008|Metered-Dose Inhaler
1389385|NCT00423969|Depression
1389386|NCT00423969|Cognitive Impairment
1389387|NCT00423956|Teeth root resorption, ultrasound, therapy
1389388|NCT00423943|cognition
1389389|NCT00423943|memory
1389390|NCT00423930|stage II squamous cell carcinoma of the hypopharynx
1389391|NCT00423930|stage III squamous cell carcinoma of the hypopharynx
1389392|NCT00423930|stage IV squamous cell carcinoma of the hypopharynx
1389393|NCT00423930|stage III squamous cell carcinoma of the larynx
1389394|NCT00423930|stage IV squamous cell carcinoma of the larynx
1389395|NCT00423930|stage III squamous cell carcinoma of the lip and oral cavity
1389396|NCT00423930|stage IV squamous cell carcinoma of the lip and oral cavity
1389397|NCT00423930|stage III squamous cell carcinoma of the oropharynx
1389398|NCT00423930|stage IV squamous cell carcinoma of the oropharynx
1389399|NCT00423930|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1389400|NCT00423930|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1389401|NCT00423930|tongue cancer
1389402|NCT00423917|stage IV breast cancer
1389403|NCT00423917|male breast cancer
1389404|NCT00423917|recurrent breast cancer
1389405|NCT00423904|Early intervention
1389406|NCT00423904|Brief intervention
1389407|NCT00423904|alcohol
1389408|NCT00423904|general hospital
1389409|NCT00423865|unspecified adult solid tumor, protocol specific
1389410|NCT00423865|CISPLATIN
1389411|NCT00423865|RAD001 (EVEROLIMUS)
1389412|NCT00423865|06-129
1389413|NCT00423852|recurrent ovarian germ cell tumor
1389414|NCT00423852|stage III ovarian germ cell tumor
1389415|NCT00423852|stage IV ovarian germ cell tumor
1389416|NCT00423852|recurrent malignant testicular germ cell tumor
1389417|NCT00423852|adult central nervous system germ cell tumor
1389418|NCT00423852|stage III malignant testicular germ cell tumor
1389419|NCT00423852|stage II malignant testicular germ cell tumor
1389420|NCT00423852|recurrent extragonadal non-seminomatous germ cell tumor
1389421|NCT00423852|recurrent extragonadal seminoma
1389422|NCT00423852|stage III extragonadal non-seminomatous germ cell tumor
1389423|NCT00423852|stage III extragonadal seminoma
1389424|NCT00423852|stage IV extragonadal non-seminomatous germ cell tumor
1389425|NCT00423852|stage IV extragonadal seminoma
1389426|NCT00423852|recurrent extragonadal germ cell tumor
1389427|NCT00423852|adult teratoma
1389428|NCT00423852|testicular immature teratoma
1389429|NCT00423852|testicular mature teratoma
1389430|NCT00423839|Mycobacterium tuberculosis
1389431|NCT00423839|Antigen 85A
1389432|NCT00423839|Modified Vaccinia Virus Ankara (MVA).
1389433|NCT00423826|accelerated phase chronic myelogenous leukemia
1389434|NCT00423826|blastic phase chronic myelogenous leukemia
1389435|NCT00423826|childhood chronic myelogenous leukemia
1389436|NCT00423826|relapsing chronic myelogenous leukemia
1389437|NCT00423826|adult acute lymphoblastic leukemia in remission
1389438|NCT00423826|recurrent adult acute lymphoblastic leukemia
1389439|NCT00423826|childhood acute lymphoblastic leukemia in remission
1389440|NCT00423826|recurrent childhood acute lymphoblastic leukemia
1389441|NCT00423826|adult acute myeloid leukemia in remission
1389442|NCT00423826|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1389443|NCT00423826|adult acute myeloid leukemia with inv(16)(p13;q22)
1389444|NCT00423826|adult acute myeloid leukemia with t(15;17)(q22;q12)
1389445|NCT00423826|adult acute myeloid leukemia with t(16;16)(p13;q22)
1389446|NCT00423826|adult acute myeloid leukemia with t(8;21)(q22;q22)
1389447|NCT00423826|recurrent adult acute myeloid leukemia
1389448|NCT00423826|adult acute minimally differentiated myeloid leukemia (M0)
1389449|NCT00423826|adult acute myeloblastic leukemia without maturation (M1)
1389450|NCT00423826|adult acute myeloblastic leukemia with maturation (M2)
1389451|NCT00423826|adult acute promyelocytic leukemia (M3)
1389452|NCT00423826|adult acute myelomonocytic leukemia (M4)
1389453|NCT00423826|adult acute monoblastic leukemia (M5a)
1389454|NCT00423826|adult acute monocytic leukemia (M5b)
1389455|NCT00423826|adult erythroleukemia (M6a)
1389456|NCT00423826|adult pure erythroid leukemia (M6b)
1389457|NCT00423826|adult acute megakaryoblastic leukemia (M7)
1389458|NCT00423826|childhood acute myeloblastic leukemia without maturation (M1)
1389459|NCT00423826|childhood acute myeloblastic leukemia with maturation (M2)
1389460|NCT00423826|childhood acute promyelocytic leukemia (M3)
1389461|NCT00423826|childhood acute myelomonocytic leukemia (M4)
1389462|NCT00423826|childhood acute monoblastic leukemia (M5a)
1389463|NCT00423826|childhood acute monocytic leukemia (M5b)
1389464|NCT00423826|childhood acute erythroleukemia (M6)
1389465|NCT00423826|childhood acute megakaryocytic leukemia (M7)
1389466|NCT00423826|childhood acute myeloid leukemia in remission
1389467|NCT00423826|secondary myelodysplastic syndromes
1389468|NCT00423826|recurrent childhood acute myeloid leukemia
1389469|NCT00423826|refractory chronic lymphocytic leukemia
1389470|NCT00423826|recurrent adult Hodgkin lymphoma
1389471|NCT00423826|recurrent/refractory childhood Hodgkin lymphoma
1389472|NCT00423826|adult grade III lymphomatoid granulomatosis
1389473|NCT00423826|adult nasal type extranodal NK/T-cell lymphoma
1389474|NCT00423826|Waldenstrom macroglobulinemia
1389475|NCT00423826|recurrent adult Burkitt lymphoma
1389476|NCT00423826|recurrent adult diffuse large cell lymphoma
1389477|NCT00423826|recurrent adult diffuse mixed cell lymphoma
1389478|NCT00423826|recurrent adult diffuse small cleaved cell lymphoma
1389479|NCT00423826|recurrent adult immunoblastic large cell lymphoma
1389480|NCT00423826|recurrent grade 1 follicular lymphoma
1389481|NCT00423826|recurrent grade 2 follicular lymphoma
1389482|NCT00423826|recurrent grade 3 follicular lymphoma
1389483|NCT00423826|recurrent mantle cell lymphoma
1389484|NCT00423826|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1389485|NCT00423826|nodal marginal zone B-cell lymphoma
1389486|NCT00423826|recurrent marginal zone lymphoma
1389487|NCT00423826|secondary acute myeloid leukemia
1389488|NCT00423826|stage I multiple myeloma
1389489|NCT00423826|stage II multiple myeloma
1389490|NCT00423826|stage III multiple myeloma
1389491|NCT00423826|extramedullary plasmacytoma
1389492|NCT00423826|isolated plasmacytoma of bone
1389493|NCT00423826|monoclonal gammopathy of undetermined significance
1389494|NCT00423826|primary systemic amyloidosis
1389495|NCT00423826|refractory multiple myeloma
1389496|NCT00423826|de novo myelodysplastic syndromes
1389497|NCT00423826|childhood acute minimally differentiated myeloid leukemia (M0)
1389498|NCT00423826|childhood grade III lymphomatoid granulomatosis
1389499|NCT00423826|childhood nasal type extranodal NK/T-cell lymphoma
1389500|NCT00423826|recurrent adult grade III lymphomatoid granulomatosis
1389501|NCT00423826|recurrent childhood large cell lymphoma
1389502|NCT00423826|recurrent childhood lymphoblastic lymphoma
1389503|NCT00423826|childhood diffuse large cell lymphoma
1389504|NCT00423826|childhood immunoblastic large cell lymphoma
1389505|NCT00423826|Burkitt lymphoma
1389506|NCT00423826|recurrent childhood small noncleaved cell lymphoma
1389507|NCT00423826|previously treated myelodysplastic syndromes
1389508|NCT00423826|splenic marginal zone lymphoma
1389509|NCT00423826|recurrent childhood grade III lymphomatoid granulomatosis
1389510|NCT00423826|recurrent adult lymphoblastic lymphoma
1389511|NCT00423826|recurrent small lymphocytic lymphoma
1389512|NCT00423826|secondary myelofibrosis
1389513|NCT00423813|FMS
1389514|NCT00423813|Fibro
1389515|NCT00423813|pain
1389516|NCT00423813|Body pain
1389517|NCT00423813|tenderness
1389518|NCT00423813|stiffness
1389519|NCT00423813|muscular pain
1389520|NCT00423813|joint pain
1389521|NCT00423787|Allergy
1389522|NCT00423787|Allergoid
1389523|NCT00423787|Specific Immunotherapy
1389524|NCT00423774|Allogeneic Hematopoietic Stem Cell Transplant
1389525|NCT00423774|Psychological Distress
1389526|NCT00423774|Coping
1389527|NCT00423774|Cognitive Behavior Therapy
1389528|NCT00423774|Bone Marrow Transplant
1389529|NCT00423774|Coping Skills
1389530|NCT00423761|Pharmacokinetics,
1389531|NCT00423761|tolerability,
1389532|NCT00423761|healthy,
1389533|NCT00423761|subjects
1389534|NCT00423722|Advanced Cancer
1389535|NCT00423722|Hospice Care
1389536|NCT00423722|Caregiver
1389537|NCT00423722|Saline
1389538|NCT00423722|Hydration
1389539|NCT00423722|Dehydration
1389540|NCT00423709|Hodgkin's Disease
1389541|NCT00423709|Allogeneic Blood Stem Cell Transplantation
1389542|NCT00423709|Bone Marrow Transplantation
1389543|NCT00423709|Fludarabine
1389544|NCT00423709|Melphalan
1389545|NCT00423696|stage IV colon cancer
1389546|NCT00423696|stage IV rectal cancer
1389547|NCT00423696|recurrent colon cancer
1389548|NCT00423696|recurrent rectal cancer
1389549|NCT00423683|Cancer
1389550|NCT00423683|thromboembolism
1389551|NCT00423657|Abscess
1389552|NCT00423657|Antibacterial
1389553|NCT00423657|Antibiotic
1389554|NCT00423657|Antimicrobial
1389555|NCT00423657|Bacterial infection, skin
1389556|NCT00423657|Ceftaroline
1389557|NCT00423657|Ceftaroline acetate
1389558|NCT00423657|Cellulitis
1389559|NCT00423657|Cephalosporin
1389560|NCT00423657|Complicated skin and skin structure infection (cSSSI)
1389561|NCT00423657|cSSSI
1389562|NCT00423657|Intravenous
1389563|NCT00423657|Methicillin-resistant Staphylococcus Aureus (MRSA)
1389564|NCT00423657|PPI-0903
1389565|NCT00423657|Prodrug
1389566|NCT00423657|Skin disease, bacterial
1389567|NCT00423657|Skin infection
1389568|NCT00423657|Staphylococcal skin infection
1389569|NCT00423657|Staphylococcus aureus
1389570|NCT00423657|Streptococcal skin infection
1389571|NCT00423657|Surgical site infection
1389572|NCT00423657|TAK-599
1389573|NCT00423644|Multiple Myeloma
1389574|NCT00423644|arsenic
1389575|NCT00423644|cancer study
1389576|NCT00423644|failed treatment
1389577|NCT00423631|Pain
1389578|NCT00423631|Fibromyalgia
1389579|NCT00423631|Internet
1389580|NCT00423618|recurrent adult soft tissue sarcoma
1389581|NCT00423618|stage I adult soft tissue sarcoma
1389582|NCT00423618|stage II adult soft tissue sarcoma
1389583|NCT00423618|stage III adult soft tissue sarcoma
1389584|NCT00423618|adult synovial sarcoma
1389585|NCT00423618|adult angiosarcoma
1389586|NCT00423618|adult epithelioid sarcoma
1389587|NCT00423618|adult extraskeletal chondrosarcoma
1389588|NCT00423618|adult leiomyosarcoma
1389589|NCT00423618|adult liposarcoma
1389590|NCT00423618|adult malignant fibrous histiocytoma
1389591|NCT00423618|adult malignant hemangiopericytoma
1389592|NCT00423618|adult malignant mesenchymoma
1389593|NCT00423618|adult fibrosarcoma
1389594|NCT00423618|adult neurofibrosarcoma
1389595|NCT00423618|adult alveolar soft-part sarcoma
1389596|NCT00423605|FMS
1389597|NCT00423605|Fibro
1389598|NCT00423605|Pain
1389599|NCT00423605|Body Pain
1389600|NCT00423605|Tenderness
1389601|NCT00423605|Joint pain
1389602|NCT00423605|Stiffness
1389603|NCT00423605|Muscular Pain
1389604|NCT00423566|Mycobacterium tuberculosis
1389605|NCT00423566|85A antigen
1389606|NCT00423566|Recombinant Modified Vaccinia virus Ankara
1389607|NCT00423566|Phase I study
1389608|NCT00423566|Immunogenicity
1389609|NCT00423553|Nitrite and Cytoprotection
1389610|NCT00423553|Ischemic Preconditioning
1389611|NCT00423553|Atrial Trabeculae Contractile Function
1389612|NCT00423553|Ischemia
1389613|NCT00423540|magnesium infusion
1389614|NCT00423540|magnesium sulfate
1389615|NCT00423540|rest cramps
1389616|NCT00423540|nocturnal leg cramps
1389617|NCT00423540|muscle cramps
1389618|NCT00423540|fractional urinary excretion
1389619|NCT00423540|urinary excretion
1389620|NCT00423540|24 hour urine
1389621|NCT00423540|serum magnesium
1389622|NCT00423540|magnesium deficiency
1389623|NCT00423540|family practice
1389624|NCT00423540|general practice
1389625|NCT00423540|richmond
1389626|NCT00423540|cramp frequency
1389627|NCT00423540|magnesium status
1389628|NCT00423540|urinary magnesium
1389629|NCT00423540|cramp diary
1389630|NCT00423540|sf 36
1389631|NCT00423527|multiple sclerosis
1389632|NCT00423527|central pain
1389633|NCT00423527|levetiracetam
1389634|NCT00423514|graft versus host disease
1389635|NCT00423514|adult acute lymphoblastic leukemia in remission
1389636|NCT00423514|adult acute myeloid leukemia in remission
1389637|NCT00423514|childhood acute lymphoblastic leukemia in remission
1389638|NCT00423514|childhood chronic myelogenous leukemia
1389639|NCT00423514|recurrent childhood acute myeloid leukemia
1389640|NCT00423514|accelerated phase chronic myelogenous leukemia
1389641|NCT00423514|acute undifferentiated leukemia
1389642|NCT00423514|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1389643|NCT00423514|blastic phase chronic myelogenous leukemia
1389644|NCT00423514|juvenile myelomonocytic leukemia
1389645|NCT00423514|previously treated myelodysplastic syndromes
1389646|NCT00423514|recurrent adult acute lymphoblastic leukemia
1389647|NCT00423514|recurrent adult acute myeloid leukemia
1389648|NCT00423514|relapsing chronic myelogenous leukemia
1389649|NCT00423514|secondary acute myeloid leukemia
1389650|NCT00423514|secondary myelodysplastic syndromes
1389651|NCT00423514|childhood acute myeloid leukemia in remission
1389652|NCT00423514|de novo myelodysplastic syndromes
1389653|NCT00423514|recurrent childhood acute lymphoblastic leukemia
1389654|NCT00423514|chronic phase chronic myelogenous leukemia
1389655|NCT00423514|adult acute myeloid leukemia with inv(16)(p13;q22)
1389656|NCT00423514|adult acute myeloid leukemia with t(15;17)(q22;q12)
1389657|NCT00423514|adult acute myeloid leukemia with t(16;16)(p13;q22)
1389658|NCT00423514|adult acute myeloid leukemia with t(8;21)(q22;q22)
1389659|NCT00423514|childhood myelodysplastic syndromes
1389660|NCT00423475|adenocarcinoma of the prostate
1389661|NCT00423475|stage IIB prostate cancer
1389662|NCT00423475|stage IIA prostate cancer
1389663|NCT00423475|stage III prostate cancer
1389664|NCT00423475|recurrent prostate cancer
1389665|NCT00423475|stage IV prostate cancer
1389666|NCT00423462|Psychotherapy
1389667|NCT00423462|Long-term effects
1389668|NCT00423449|Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
1389669|NCT00423436|Non-Small Cell Lung Cancer
1389670|NCT00423436|Small Cell Lung Cancer
1389671|NCT00423436|Voice Response System
1389672|NCT00423436|Questionnaire
1389673|NCT00423436|Survey
1389674|NCT00423436|NSCLC
1389675|NCT00423410|Cancer
1389676|NCT00423410|Tumor
1389677|NCT00423410|Lymphoma
1389678|NCT00423397|squamous cell carcinoma of the skin
1389679|NCT00423397|recurrent skin cancer
1389680|NCT00423384|Ibandronate
1389681|NCT00423384|Placebo
1389682|NCT00423384|Doubleblind
1389683|NCT00423384|Bone
1389684|NCT00423384|loss
1389685|NCT00423384|Kidney
1389686|NCT00423384|transplant
1389687|NCT00423371|first Carpometacarpal (CMC) Joint
1389688|NCT00423358|rheumatoid arthritis
1389689|NCT00423358|hypovitaminosis D
1389690|NCT00423358|bone turnover
1389691|NCT00423358|ergocalciferol
1389692|NCT00423332|cancer
1389693|NCT00423332|tumour
1389694|NCT00423332|advanced cancer
1389695|NCT00423332|Metastatic renal cell carcinoma
1389696|NCT00423332|kidney cancer
1389697|NCT00423332|RECENTIN
1389698|NCT00423319|Prevention of deep vein thrombosis and
1389699|NCT00423319|pulmonary embolism after total hip replacement surgery
1389700|NCT00423293|stage II anal cancer
1389701|NCT00423293|stage IIIA anal cancer
1389702|NCT00423293|stage IIIB anal cancer
1389703|NCT00423293|basaloid carcinoma of the anus
1389704|NCT00423293|cloacogenic carcinoma of the anus
1389705|NCT00423293|squamous cell carcinoma of the anus
1389706|NCT00423280|Endothelium
1389707|NCT00423280|Nitric Oxide
1389708|NCT00423280|Magnetic Resonance Imaging
1389709|NCT00423280|Tetrahydrobiopterin
1389710|NCT00423254|Cancer Vaccine
1389711|NCT00423228|Alzheimer's disease
1389712|NCT00423228|cognitive impairment
1389713|NCT00423228|cholinesterase inhibitors
1389714|NCT00423228|sustained-release implants
1389715|NCT00423228|long acting treatment
1389716|NCT00423189|LUV
1389717|NCT00423189|Lucentis
1389718|NCT00423189|Visudyne
1389719|NCT00423189|PDT
1389720|NCT00423189|AMD
1389721|NCT00423189|ARMD
1389722|NCT00423189|Age
1389723|NCT00423189|Related
1389724|NCT00423189|Macular
1389725|NCT00423189|Degeneration
1389726|NCT00423163|Aspergillosis/blood
1389727|NCT00423163|micafungin
1389728|NCT00423163|voriconazole
1389729|NCT00423163|Aspergillus
1389730|NCT00423124|Hematological malignancies
1389731|NCT00423124|HSV-TK
1389732|NCT00423124|Haploidentical HCT
1389733|NCT00423124|GvHD
1389734|NCT00423124|GvL
1389735|NCT00423111|Multiple sclerosis
1389736|NCT00423111|Memory
1389737|NCT00423111|Cognitive deficits
1389738|NCT00423111|MRI
1389739|NCT00423111|Hippocampus
1389740|NCT00423111|Prefrontal cortex
1389741|NCT00423098|Lupus Nephritis
1389742|NCT00423098|enteric-coated mycophenolate sodium
1389743|NCT00423098|EC-MPS
1389744|NCT00423098|Myfortic
1389745|NCT00423085|rivastigmine，Alzheimer's Disease, transdermal patch
1389746|NCT00423072|cleft palate
1389747|NCT00423072|palatoplasty
1389748|NCT00423072|otitis
1389749|NCT00423072|middle ear
1389750|NCT00423072|Eustachian tube
1389751|NCT00423059|intravitreal bevacizumab
1389752|NCT00423059|proliferative diabetic retinopathy
1389753|NCT00423059|VEGF
1389754|NCT00423059|PEDF
1389755|NCT00423046|Vaccines
1389756|NCT00423046|Cervical cancer
1389757|NCT00423046|Immunogenicity
1389758|NCT00423046|Humans
1389759|NCT00423046|Safety
1389760|NCT00423046|Viral infections
1389761|NCT00423046|Human papillomavirus (HPV)
1389762|NCT00423046|Comparative study
1389763|NCT00423046|Human papillomavirus vaccine
1389764|NCT00423046|Adults
1389765|NCT00423020|Acute myocardial infarction
1389766|NCT00423020|Restenosis
1389767|NCT00423020|erythropoietin
1389768|NCT00423020|EPOC-AMI
1389769|NCT00422994|end stage renal impairment
1389770|NCT00422994|tolerability
1389771|NCT00422994|ropinirole
1389772|NCT00422994|pharmacokinetics
1389773|NCT00422994|hemodialysis
1389774|NCT00422981|Dementia
1389775|NCT00422981|Memory
1389776|NCT00422981|Alzheimers
1389777|NCT00422981|Cognition
1389778|NCT00422981|Mind
1389779|NCT00422981|Aging
1389780|NCT00422968|Coronary artery disease
1389781|NCT00422968|Stent
1389782|NCT00422968|Bypass surgery, coronary artery
1389783|NCT00422955|fluid retention
1389784|NCT00422955|Autonomic Neuropathy
1389785|NCT00422929|otitis media
1389786|NCT00422929|ear
1389787|NCT00422929|acute otitis
1389788|NCT00422929|middle ear
1389789|NCT00422929|Eustachian tube
1389790|NCT00422929|recurrent acute otitis media
1389791|NCT00422929|chronic otitis media with effusion
1389792|NCT00422929|no significant history of otitis media
1389793|NCT00422903|neo-adjuvant
1389794|NCT00422903|letrozole
1389795|NCT00422903|lapatinib
1389796|NCT00422903|primary breast cancer
1389797|NCT00422890|Acute myeloid leukaemia or Myelodysplastic syndrome
1389798|NCT00422877|Liver Cancer
1389799|NCT00422851|otitis
1389800|NCT00422851|gas diffusion
1389801|NCT00422851|Eustachian tube
1389802|NCT00422851|tympanic membrane
1389803|NCT00422838|Hepatitis C
1389804|NCT00422838|Liver
1389805|NCT00422838|immunology
1389806|NCT00422838|regulation
1389807|NCT00422838|Genotype 1,2,3
1389808|NCT00422838|Treatment
1389809|NCT00422838|Chronic
1389810|NCT00422838|Pegylated interferon
1389811|NCT00422838|Ribavirin
1389812|NCT00422825|Food effect
1389813|NCT00422825|bioavailability
1389814|NCT00422825|pharmacokinetic
1389815|NCT00422825|imatinib
1389816|NCT00422825|STI571
1389817|NCT00422825|modified release formulation of STI571
1389818|NCT00422825|CML
1389819|NCT00422825|Chronic Myeloid Leukemia
1389820|NCT00422825|Philadelphia Chromosome
1389821|NCT00422812|Migraine, Staccato Prochlorperazine
1389822|NCT00422812|Migraine headache with or without aura.
1389823|NCT00422799|relapsed Waldenstrom's macroglobulinemia
1389824|NCT00422799|refractory Waldenstrom's macroglobulinemia
1389825|NCT00422799|Velcade
1389826|NCT00422799|WM
1389827|NCT00422786|Refractory Clear Cell Renal Cell Carcinoma
1389828|NCT00422786|Phase II
1389829|NCT00422786|Thallion
1389830|NCT00422786|TLN-232
1389831|NCT00422786|CAP-232
1389832|NCT00422786|M2PK
1389833|NCT00422773|phase I/II
1389834|NCT00422773|cetuximab
1389835|NCT00422773|oxaliplatin
1389836|NCT00422773|irinotecan
1389837|NCT00422773|5-FU
1389838|NCT00422773|chemotherapy
1389839|NCT00422773|dose escalation
1389840|NCT00422773|safety
1389841|NCT00421798|tuberculosis, paucibacillary, mycobacteria, Mexico, Colombia
1389842|NCT00421785|N-acetylcysteine
1389843|NCT00421785|Peritoneal Dialysis
1389844|NCT00421785|ADMA
1389845|NCT00421772|cerebral ventriculomegaly
1389846|NCT00421772|prenatal diagnostic
1389847|NCT00421772|neuropsychological outcome
1389848|NCT00421759|Sensory loss
1389849|NCT00421759|psychomotor function
1389850|NCT00421759|balance
1389851|NCT00421759|gait
1389852|NCT00421733|Type 2 Diabetic Nephropathy
1389853|NCT00421720|remifentanil
1389854|NCT00421720|sufentanil
1389855|NCT00421720|propofol
1389856|NCT00421720|analgesia
1389857|NCT00421720|sedation
1389858|NCT00421720|mechanically ventilated
1389859|NCT00421720|intensive care
1389860|NCT00421720|pharmacoeconomic
1389861|NCT00421720|weaning
1389862|NCT00421720|delirium
1389863|NCT00421720|randomized
1389864|NCT00421720|Germany
1389865|NCT00421707|Irritable Bowel Syndrome safety
1389866|NCT00421681|Aging
1389867|NCT00421681|exercise
1389868|NCT00421681|health behavior
1389869|NCT00421668|HIV
1389870|NCT00421668|Tanzania
1389871|NCT00421668|Micronutrients
1389872|NCT00421668|Infants/children
1389873|NCT00421668|Infectious Disease
1389874|NCT00421668|Growth faltering
1389875|NCT00421629|health insurance
1389876|NCT00421629|hospitalization insurance
1389877|NCT00421629|community based health insurance
1389878|NCT00421629|health care access
1389879|NCT00421629|developing countries
1389880|NCT00421629|randomized controlled trials
1389881|NCT00422760|esophageal perforation
1389882|NCT00422760|COPD
1389883|NCT00422747|asthma
1389884|NCT00422747|transient wheezing
1389885|NCT00422747|early diagnosis
1389886|NCT00422747|exhaled air
1389887|NCT00422747|nitrogen monoxide
1389888|NCT00422747|airway resistance
1389889|NCT00422721|early severe retinal dystrophy
1389890|NCT00422721|amaurosis of leber
1389891|NCT00422695|HIV
1389892|NCT00422695|Quantitative Sensory Testing
1389893|NCT00422695|Neuropathy
1389894|NCT00422695|Treatment Experienced
1389895|NCT00422695|Treatment Naive
1389896|NCT00422682|Solid tumors
1389897|NCT00422669|Pacemaker
1389898|NCT00422669|Implantable Pulse Generator (IPG)
1389899|NCT00422669|AV Conduction Disturbance
1389900|NCT00422669|Select Site Pacing
1389901|NCT00422656|relapsed Waldenstrom's Macroglobulinemia
1389902|NCT00422656|refractory Waldenstrom's Macroglobulinemia
1389903|NCT00422656|WM
1389904|NCT00422656|perifosine
1389905|NCT00422643|OA,HA,Intra-articular
1389906|NCT00422630|Weight loss
1389907|NCT00422630|Obesity
1389908|NCT00422630|Metabolic Syndrome
1389909|NCT00422630|Diet
1389910|NCT00422630|Hypertension
1389911|NCT00422630|Diabetes
1389912|NCT00422630|Cholesterol
1389913|NCT00422617|psoriasis
1389914|NCT00422617|alefacept
1389915|NCT00422604|COPD
1389916|NCT00422604|plethysmography.
1389917|NCT00422604|muscarinic receptor antagonist
1389918|NCT00422604|anticholinergic
1389919|NCT00422591|Cytarabine, Idarubicin
1389920|NCT00422591|Leukemia
1389921|NCT00422591|Acute Myeloid Leukemia
1389922|NCT00422591|AML
1389923|NCT00422591|Cytarabine
1389924|NCT00422591|Idarubicin
1389925|NCT00422578|erectile dysfunction
1389926|NCT00422578|tadalafil
1389927|NCT00422565|Coronary Artery Disease
1389928|NCT00422565|Stent
1389929|NCT00422565|Myocardial Infarction
1389930|NCT00422552|inspiratory capacity, FEV1, COPD
1389931|NCT00422539|trichloroacetic acid
1389932|NCT00422539|varicella scar
1389933|NCT00422526|Preterm delivery, short cervix, progesterone
1389934|NCT00422500|Lung Cancer
1389935|NCT00422500|Advanced Lung Cancer
1389936|NCT00422500|Chemotherapy Symptoms
1389937|NCT00422500|Disease-Related Symptoms
1389938|NCT00422500|Treatment-Related Symptoms
1389939|NCT00422500|Symptom Management
1389940|NCT00422500|Questionnaire
1389941|NCT00422500|Telephone Interactive System
1389942|NCT00422500|IVR Telephone System
1389943|NCT00422500|DNA Repair Capacity
1389944|NCT00422500|DRC
1389945|NCT00422500|Cognitive Symptoms
1389946|NCT00422487|Type 2 Diabetes Mellitus
1389947|NCT00422474|Ischemic stroke
1389948|NCT00422474|Baroreflex sensitivity
1389949|NCT00422474|Prognosis
1389950|NCT00422474|Cardiovascular autonomic regulation
1389951|NCT00422461|Clinical Trial, Randomized Controlled Trial, Humans, Cyclic Nucleotide Phosphodiesterases Type 5
1389952|NCT00422448|Dermoscopy
1389953|NCT00422448|Histopathology
1389954|NCT00422448|Genetics
1389955|NCT00422448|Nevi
1389956|NCT00422448|Nevogenesis
1389957|NCT00422435|Percutaneous coronary intervention (PCI)
1389958|NCT00422435|Drug eluting stent (DES)
1389959|NCT00422422|Brivaracetam
1389960|NCT00422422|Epilepsy
1389961|NCT00422422|Child
1389962|NCT00422422|Pharmacokinetics
1389963|NCT00422422|Adolescents
1389964|NCT00422409|SEMS
1389965|NCT00422396|Hypertrigliceridemia
1389966|NCT00422396|Metabolic syndrome
1389967|NCT00422396|Obesity
1389968|NCT00422396|Fenofibrate
1389969|NCT00422396|Lipoproteins
1389970|NCT00422396|Cytokines
1389971|NCT00422357|Type 2 Diabetes Mellitus
1389972|NCT00422357|Urtica Dioica (or stinging nettle)
1389973|NCT00422357|Hypoglycemic agents
1389974|NCT00422344|RAD001
1389975|NCT00422344|Sunitinib
1389976|NCT00422344|renal
1389977|NCT00422344|kidney
1389978|NCT00422331|Bipolar I Disorder
1389979|NCT00422331|Bipolar Disorder
1389980|NCT00422331|Lithium
1389981|NCT00422318|Heart Failure
1389982|NCT00422318|Insulin
1389983|NCT00422318|Metabolism
1389984|NCT00422318|Pharmacology
1389985|NCT00422318|Uric Acid
1389986|NCT00422305|Infant, Premature
1389987|NCT00422305|Bronchopulmonary dysplasia
1389988|NCT00422305|asthma
1389989|NCT00422292|Menactra vaccine
1389990|NCT00422292|Meningococcal meningitis
1389991|NCT00422292|Measles
1389992|NCT00422292|Mumps
1389993|NCT00422292|Rubella
1389994|NCT00422292|Varicella vaccines
1389995|NCT00422292|Haemophilus influenzae type b
1389996|NCT00422292|Pneumococcal conjugate vaccine
1389997|NCT00422279|Bone Inductive Implant
1389998|NCT00422266|Dyslipidemia
1389999|NCT00422253|insulin resistance
1390000|NCT00422253|insulin secretion
1390001|NCT00422253|advanced glycation end-products
1390002|NCT00422240|Acne vulgaris
1390003|NCT00422240|Adapalene
1390004|NCT00422240|Benzoyl Peroxide
1390005|NCT00422214|Bipolar Disorder
1390006|NCT00422214|Bipolar Depression,
1390007|NCT00422214|Manic Depression
1390008|NCT00422214|Seroquel
1390009|NCT00422214|Seroquel SR
1390010|NCT00422214|quetiapine fumarate
1390011|NCT00422201|Cortisol
1390012|NCT00422201|Cushing's Syndrome
1390013|NCT00422201|Ectopic ACTH Secretion
1390014|NCT00422201|Cushing Syndrome
1390015|NCT00422175|Safety, tolerability, pharmacokinetics, pharmacodynamics, oral, BAF312, healthy volunteers
1390016|NCT00422149|Sublingual immunotherapy
1390017|NCT00422149|Rhinoconjunctivitis
1390018|NCT00422136|middle ear
1390019|NCT00422136|otitis
1390020|NCT00422136|genetics
1390021|NCT00422123|Bipolar Disorder
1390022|NCT00422123|Bipolar Mania
1390023|NCT00422123|Manic Depression
1390024|NCT00422123|Seroquel
1390025|NCT00422123|Seroquel SR
1390026|NCT00422123|quetiapine fumarate
1390027|NCT00422110|Seletracetam
1390028|NCT00422110|Epilepsies
1390029|NCT00422110|Partial
1390030|NCT00422110|Epilepsy
1390031|NCT00422110|Focal
1390032|NCT00422084|Malaria
1390033|NCT00422084|ACT
1390034|NCT00422084|P falciparum
1390035|NCT00422071|Transcranial Magnetic Stimulation (TMS)
1390036|NCT00422071|Dopamine
1390037|NCT00422071|Gambling
1390038|NCT00422071|Healthy Volunteer
1390039|NCT00422071|HV
1390040|NCT00422032|Myelodysplastic Syndrome
1390041|NCT00422032|Leukemia
1390042|NCT00422032|Clofarabine
1390043|NCT00422032|MDS
1390044|NCT00422019|Renal Cancer
1390045|NCT00422019|Kidney Cancer
1390046|NCT00422006|bariatric surgery planned
1390047|NCT00421993|Acne vulgaris
1390048|NCT00421993|Adapalene
1390049|NCT00421993|Benzoyl Peroxide
1390050|NCT00421967|Postoperative pain
1390051|NCT00421954|psychosis NOS
1390052|NCT00421954|MDD w/ psychotic features
1390053|NCT00421954|bipolar disorder w. psychotic features
1390054|NCT00421941|enteral feeding
1390055|NCT00421941|critical care
1390056|NCT00421941|fish oil
1390057|NCT00421941|surgical
1390058|NCT00421928|Chronic Pain
1390059|NCT00421928|Osteoarthritis, Knee
1390060|NCT00421928|tapentadol
1390061|NCT00421928|Pain Assessment
1390062|NCT00421902|Hot flashes, prostate cancer, acupuncture
1390063|NCT00421902|Prostate cancer patients with hot flashes due to their hormonal treatment
1390064|NCT00421889|Ovarian cancer
1390065|NCT00421889|Ovarian Neoplasms
1390066|NCT00421889|Primary peritoneal
1390067|NCT00421889|Epithelial ovarian
1390068|NCT00421889|Fallopian tube
1390069|NCT00421889|Bladder cancer
1390070|NCT00421889|belinostat
1390071|NCT00421889|PXD101
1390072|NCT00421889|mixed mullerian cancer of ovarian origin
1390073|NCT00421876|cardiac rehabilitation
1390074|NCT00421876|lifestyle management
1390075|NCT00421876|risk factor management
1390076|NCT00421876|myocardial infarction
1390077|NCT00421876|randomized trials
1390078|NCT00421863|hypertension
1390079|NCT00421863|systolic blood pressure
1390080|NCT00421837|influenza, flu, genotypic analysis, sub-study
1390081|NCT00421811|cancer
1390082|NCT00421811|tumors
1390083|NCT00421811|melanoma
1390084|NCT00421811|anticarcinogenic agents
1390085|NCT00421811|antineoplastic agents
1390086|NCT00421811|cadherins
1390087|NCT00421811|solid tumors
1390088|NCT00421616|Calorimetry
1390089|NCT00421616|Overweight
1390090|NCT00421616|Weight loss
1390091|NCT00421616|Appetite
1390092|NCT00421603|Cocaine
1390093|NCT00421603|Adderall
1390094|NCT00421603|Topiramate
1390095|NCT00421603|ADHD
1390096|NCT00421590|Randomized, partially blind, placebo controlled, crossover, drug interaction with concomitant antacid, pharmacokinetics, pharmacodynamics, SMC021
1390097|NCT00421577|Caries Diagnosis
1390098|NCT00421577|Replica technique
1390099|NCT00421564|Menopausal
1390100|NCT00421564|Traditional Chinese Medicine
1390101|NCT00421551|HIV Infections
1390102|NCT00421551|darunavir
1390103|NCT00421551|Ritonavir
1390104|NCT00421551|HIV Protease Inhibitors
1390105|NCT00421551|treatment experienced
1390106|NCT00421538|Deep vein Thrombosis
1390107|NCT00421538|Calf vein thrombosis
1390108|NCT00421538|Low-molecular weight heparin
1390109|NCT00421538|Placebo
1390110|NCT00421538|Elastic contention
1390111|NCT00421538|Compression Ultrasonography
1390112|NCT00421525|multiple myeloma
1390113|NCT00421525|Myeloma, Plasma-Cell
1390114|NCT00421525|PLASMACYTOMA
1390115|NCT00421512|Renal cell carcinoma
1390116|NCT00421512|Metastatic
1390117|NCT00421512|Kidney Cancer
1390118|NCT00421512|Bevacizumab
1390119|NCT00421512|Sunitinib
1390120|NCT00421486|Oral human papillomavirus infection
1390121|NCT00421486|HIV-infection
1390122|NCT00421486|High-risk HPV viral load
1390123|NCT00421486|Oral human papillomavirus infection in HIV-positive men
1390124|NCT00421486|Treatment Experienced
1390125|NCT00421486|Treatment Naive
1390126|NCT00421473|HIV
1390127|NCT00421473|Malaria prophylaxis
1390128|NCT00421473|Treatment Experienced
1390129|NCT00421460|Nebido in hypogonadism with erectile dysfunction
1390130|NCT00421447|Breast Cancer
1390131|NCT00421447|pQCT
1390132|NCT00421447|Anastrozole
1390133|NCT00421447|bone geometry
1390134|NCT00421434|Hepatitis C
1390135|NCT00421421|Acute Urinary Retention
1390136|NCT00421421|Benign Prostatic Hyperplasia
1390137|NCT00421421|Trial Without Catheter
1390138|NCT00421408|Dietary protein
1390139|NCT00421408|Calcium
1390140|NCT00421408|Parathyroid hormone
1390141|NCT00421408|Bone markers
1390142|NCT00421408|Bone mineral density
1390143|NCT00421408|IGF-1
1390144|NCT00421408|Urine Calcium
1390145|NCT00421395|NHL
1390146|NCT00421395|B-cell NHL
1390147|NCT00421395|Non-Hodgkins lymphoma
1390148|NCT00421369|Major depressive disorder
1390149|NCT00421369|Antidepressants
1390150|NCT00421369|Triiodothyronine (T3)
1390151|NCT00421369|Thyroid Function
1390152|NCT00421369|Augmentation
1390153|NCT00421369|Thyroid pathway genes
1390154|NCT00421356|amputation, transfemoral, lower extremity, prosthetic knee
1390155|NCT00421343|disease/disorder proneness/risk
1390156|NCT00421343|osteoporotic fractures
1390157|NCT00421343|accidental falls
1390158|NCT00421343|aging
1390159|NCT00421330|Abdominal aortic aneurysm
1390160|NCT00421330|AAA
1390161|NCT00421330|randomised controlled trial
1390162|NCT00421330|Endovascular repair
1390163|NCT00421330|conventional open repair
1390164|NCT00421317|Ocular, Metastatic melanoma
1390165|NCT00421265|prostate cancer
1390166|NCT00421265|active surveillance
1390167|NCT00421265|indolent features
1390168|NCT00421252|clopidogrel
1390169|NCT00421252|hemorrhagic complication
1390170|NCT00421252|vascular complication
1390171|NCT00421252|antiplatelet agent
1390172|NCT00421252|stenting
1390173|NCT00421252|percutaneous coronary intervention
1390174|NCT00421252|risk
1390175|NCT00421252|ischemia
1390176|NCT00421252|troponin
1390177|NCT00421252|sheath size
1390178|NCT00421239|hypertensive urgency
1390179|NCT00421239|arterial hypertension
1390180|NCT00421226|Safety, tolerability, pharmacokinetics, pharmacodynamics, ACZ885, Japanese,
1390181|NCT00421213|APL
1390182|NCT00421213|Lymphoma
1390183|NCT00421213|T-cell Lymphoma
1390184|NCT00421213|Peripheral T-cell Lymphoma
1390185|NCT00421200|Hip arthroplasty
1390186|NCT00421200|Anesthesia, spinal
1390187|NCT00421200|Hypotension
1390188|NCT00421200|Ischemia
1390189|NCT00421200|Blood substitutes
1390190|NCT00421200|Plasma expanders
1390191|NCT00421187|Antibiotic resistant neutropenic fever
1390192|NCT00421187|ARNF
1390193|NCT00421187|Ambisome
1390194|NCT00421187|Liposomal amphotericin B
1390195|NCT00421174|Etanercept
1390196|NCT00421174|IPS
1390197|NCT00421161|olive oil
1390198|NCT00421161|stasis dermatitis
1390199|NCT00421161|Patients with stasis dermatitis for at least six months.
1390200|NCT00421122|Chinese patients
1390201|NCT00421122|COPD
1390202|NCT00421109|Urticaria
1390203|NCT00421109|Hives
1390204|NCT00421109|Wheals
1390205|NCT00421109|Flare
1390206|NCT00421109|Chronic
1390207|NCT00421109|Idiopathic
1390208|NCT00421109|Erythema
1390209|NCT00421109|Skin diseases, vascular
1390210|NCT00421109|Hypersensitivity, Immediate
1390211|NCT00421109|Allergic
1390212|NCT00421109|Cutaneous
1390213|NCT00421096|uterine cervical cancer
1390214|NCT00421083|Erectile dysfunction as a result of traumatic spinal cord injury
1390215|NCT00421070|Aggression
1390216|NCT00421070|Massage
1390217|NCT00421070|Stress
1390218|NCT00421070|Psychiatric inpatient
1390219|NCT00421057|Breast Cancer
1390220|NCT00421057|Cancer-Related Fatigue
1390221|NCT00421057|Fatigue
1390222|NCT00421057|Exercise
1390223|NCT00421057|Strength Training
1390224|NCT00421057|Endurance Exercise
1390225|NCT00421057|Questionnaire
1390226|NCT00421057|Survey
1390227|NCT00421044|EPO
1390228|NCT00421044|Patupilone
1390229|NCT00421044|Solid Tumors
1390230|NCT00421018|Asthma
1390231|NCT00421018|Allergy
1390232|NCT00421018|Cytokines
1390233|NCT00421018|Glucocorticoids
1390234|NCT00421018|Inflammation
1390235|NCT00421018|Nitric Oxide (NO)
1390236|NCT00421018|Quality of Life
1390237|NCT00421018|Self-Rated Health
1390238|NCT00421018|Stress
1390239|NCT00420992|hip
1390240|NCT00420992|knee
1390241|NCT00420992|pain
1390242|NCT00420992|osteoarthritis
1390243|NCT00420992|OA
1390244|NCT00420992|Kadian
1390245|NCT00420992|Alpharma
1390246|NCT00420992|naltrexone
1390247|NCT00420992|Opioid
1390248|NCT00420992|morphine
1390249|NCT00420992|Embeda
1390250|NCT00420992|ALO-01
1390251|NCT00420966|lower respiratory tract infection
1390252|NCT00420966|respiratory syncytial virus infections
1390253|NCT00420966|palivizumab
1390254|NCT00420966|outcomes
1390255|NCT00420966|utilization
1390256|NCT00420966|compliance
1390257|NCT00420940|vibration
1390258|NCT00420940|mechanical loading
1390259|NCT00420940|bone mineral density
1390260|NCT00420940|women's health
1390261|NCT00420940|osteoporosis
1390262|NCT00420927|Early Rheumatoid Arthritis
1390263|NCT00420927|Tumor Necrosis Factor Optimization
1390264|NCT00420914|Thrombocytopenia
1390265|NCT00420914|Platelets
1390266|NCT00420914|Dose
1390267|NCT00420914|Bleeding
1390268|NCT00420901|function
1390269|NCT00420901|inhibition
1390270|NCT00420875|plantar fasciitis
1390271|NCT00420875|plantar fasciosis
1390272|NCT00420875|Achilles tendinosis
1390273|NCT00420875|Achilles tendinitis
1390274|NCT00420875|heel pain
1390275|NCT00420875|fasciosis
1390276|NCT00420875|fasciitis
1390277|NCT00420875|tendinosis
1390278|NCT00420875|tendinitis
1390279|NCT00420875|conservative treatment
1390280|NCT00420862|Lung neoplasms
1390281|NCT00420862|Early diagnosis
1390282|NCT00420862|Screening
1390283|NCT00420862|Spiral Computed Tomography
1390284|NCT00420862|Randomized Controlled Trial
1390285|NCT00420836|Cystic fibrosis, tobramycin, PARI eFlow, PARI LC Plus, nebulizer, pharmacokinetic
1390286|NCT00420823|First Episode Psychosis
1390287|NCT00420797|Faecal seepage
1390288|NCT00420797|ileal pouch anal anastomosis (IPAA)
1390289|NCT00420797|quality of life
1390290|NCT00420797|faecal incontinence
1390291|NCT00420797|ileo-anal pouch construction
1390292|NCT00420797|phenylephrine hydrochloride gel
1390293|NCT00420797|IPAA-related faecal incontinence
1390294|NCT00420797|placebo
1390295|NCT00420784|Genotype 1
1390296|NCT00420771|Benzodiazepine
1390297|NCT00420771|Gabapentin
1390298|NCT00420771|Methadone
1390299|NCT00420758|Infant
1390300|NCT00420758|Malnutrition
1390301|NCT00420758|Sub-Saharan Africa
1390302|NCT00420758|Treatment
1390303|NCT00420758|Growth
1390304|NCT00420758|Haemoglobin
1390305|NCT00420758|Fortified spread
1390306|NCT00420758|Food supplement
1390307|NCT00420719|ALS
1390308|NCT00420719|Amyotrophic Lateral Sclerosis
1390309|NCT00420719|Lou Gehrig's disease
1390310|NCT00420719|Diaphragm for Ventilatory Assist
1390311|NCT00420719|Diaphragm Pacing
1390312|NCT00420030|upfront abciximab
1390313|NCT00420030|PCI
1390314|NCT00420030|cardiogenic shock
1390315|NCT00420017|Amiodarone
1390316|NCT00420017|Atrial fibrillation
1390317|NCT00420017|Surgical procedures, thoracic
1390318|NCT00419991|Tigecycline
1390319|NCT00419991|Staphylococcal Infections
1390320|NCT00419991|Catheter
1390321|NCT00420667|unfractionated heparin
1390322|NCT00420667|enoxaparin
1390323|NCT00420667|low molecular weight heparin
1390324|NCT00420667|bypass surgery
1390325|NCT00420667|bleeding
1390326|NCT00420654|Turner syndrome
1390327|NCT00420654|growth hormone treatment
1390328|NCT00420654|positron emission tomography
1390329|NCT00420654|heart
1390330|NCT00420641|GSK372475
1390331|NCT00420641|MDD
1390332|NCT00420641|paroxetine
1390333|NCT00420641|flexible-dose
1390334|NCT00420641|Major Depressive Disorder
1390335|NCT00420615|Cancer
1390336|NCT00420615|EPO906
1390337|NCT00420615|Patupilone
1390338|NCT00420589|Weight loss
1390339|NCT00420589|Weight regain
1390340|NCT00420589|Weight maintenance
1390341|NCT00420576|Post-menopausal
1390342|NCT00420576|Traditional Chinese Medicine
1390343|NCT00420576|Randomized
1390344|NCT00420563|Cancer, palliative treatment
1390345|NCT00420550|Interstitial Cystitis
1390346|NCT00420550|Pelvic pain
1390347|NCT00420550|Guided Imagery
1390348|NCT00420537|Kidney
1390349|NCT00420537|Heart Transplantation
1390350|NCT00420537|Creatinine
1390351|NCT00420537|Glomerular Filtration Rate
1390352|NCT00420524|EPO
1390353|NCT00420524|Patupilone
1390354|NCT00420524|Solid Tumors
1390355|NCT00420511|Type 2 diabetes
1390356|NCT00420511|beta-cell function
1390357|NCT00420511|sitagliptin
1390358|NCT00420511|intensive insulin therapy
1390359|NCT00420498|Schizophrenia
1390360|NCT00420498|Prefrontal Cortical Function
1390361|NCT00420498|Smoking
1390362|NCT00420498|Cognition
1390363|NCT00420498|Positive and Negative Symptoms
1390364|NCT00420498|Tobacco
1390365|NCT00420498|Cigarette Smoking
1390366|NCT00420498|Dopamine
1390367|NCT00420485|Maximum Tolerated Dose
1390368|NCT00420485|Solid Tumors
1390369|NCT00420485|Dose Limiting Toxicity
1390370|NCT00420485|Topoisomerase-1 Inhibitor
1390371|NCT00420433|Breast Cancer
1390372|NCT00420433|Bone Metastases
1390373|NCT00420433|Radiography
1390374|NCT00420433|X-Ray
1390375|NCT00420433|Computed Tomography
1390376|NCT00420433|CT Scan
1390377|NCT00420433|Skeletal Scintigraphy
1390378|NCT00420394|Neoadjuvant chemotherapy
1390379|NCT00420394|Adjuvant chemoradiotherapy
1390380|NCT00420394|Adenocarcinoma of stomach and gastroesophageal junction
1390381|NCT00420381|Recurrent Cancer
1390382|NCT00420368|Infant
1390383|NCT00420368|Malnutrition
1390384|NCT00420368|Sub-Saharan Africa
1390385|NCT00420368|Treatment
1390386|NCT00420368|Growth
1390387|NCT00420368|Haemoglobin
1390388|NCT00420368|Fortified spread
1390389|NCT00420368|Food supplement
1390390|NCT00420355|antiretroviral therapy
1390391|NCT00420355|protease inhibitors
1390392|NCT00420355|drug interactions
1390393|NCT00420355|HIV infection
1390394|NCT00420355|acquired immunodeficiency syndrome
1390395|NCT00420355|Treatment Experienced
1390396|NCT00420342|Pre-Hypertension in Postmenopausal Women
1390397|NCT00420316|Intussusception
1390398|NCT00420316|Gastroenteritis
1390399|NCT00420316|Finland
1390400|NCT00420303|Refractory Heel Enthesitis in Spondylarthropathy
1390401|NCT00420303|Spondylarthropathy
1390402|NCT00420303|Refractory Heel Enthesitis
1390403|NCT00420290|inflammation
1390404|NCT00420290|end stage renal disease
1390405|NCT00420277|Hip arthroplasty
1390406|NCT00420277|Anesthesia, spinal
1390407|NCT00420277|Hypotension
1390408|NCT00420277|Ischemia
1390409|NCT00420277|Blood substitutes
1390410|NCT00420277|Plasma expanders
1390411|NCT00420238|Axial Ankylosing Spondylitis
1390412|NCT00420238|Adult
1390413|NCT00420225|Cystocele
1390414|NCT00420225|surgery
1390415|NCT00420225|mesh
1390416|NCT00420225|genital prolapse
1390417|NCT00420212|relapsing
1390418|NCT00420212|oral
1390419|NCT00420212|remitting
1390420|NCT00420212|multiple sclerosis
1390421|NCT00420173|cutaneous lupus erythematosus
1390422|NCT00420173|standardized evaluation
1390423|NCT00420173|core set questionnaire
1390424|NCT00420173|epidemiological data
1390425|NCT00420173|laboratory features
1390426|NCT00420160|Smoking cessation
1390427|NCT00420160|Exercise
1390428|NCT00420160|Nicotine Patch
1390429|NCT00420160|Disease Prevention
1390430|NCT00420147|knee osteoarthritis
1390431|NCT00420147|orthosis
1390432|NCT00420147|wedge
1390433|NCT00420147|gait
1390434|NCT00420134|mesenchymal stem cell
1390435|NCT00420134|end stage liver disease
1390436|NCT00420134|Cirrhosis
1390437|NCT00420134|stem cell therapy
1390438|NCT00420121|standardized evaluation
1390439|NCT00420121|core set questionnaire
1390440|NCT00420121|epidemiological data
1390441|NCT00420121|laboratory analysis
1390442|NCT00420108|Heart Failure, Congestive
1390443|NCT00420108|Cardiac Pacemaker, Artificial
1390444|NCT00420108|Ventricular Pressure
1390445|NCT00420095|diabetes
1390446|NCT00420095|type 1
1390447|NCT00420095|type 2
1390448|NCT00420082|Rhinitis
1390449|NCT00420082|Seasonal
1390450|NCT00420082|Allergic
1390451|NCT00420082|Pollen allergy
1390452|NCT00420082|Environmental Exposure Chamber
1390453|NCT00420082|Challenge Chamber
1390454|NCT00420043|Food effect
1390455|NCT00420043|bioavailability
1390456|NCT00420043|pharmacokinetic
1390457|NCT00420043|STI571
1390458|NCT00420043|modified release formulation of STI571
1390459|NCT00420043|CML
1390460|NCT00420043|Chronic Myeloid Leukemia
1390461|NCT00420043|Philadelphia Chromosome
1390462|NCT00420043|imatinib
1390463|NCT00419952|Moderate Asthma
1390464|NCT00419952|Severe Asthma
1390465|NCT00419939|Severe traumatic brain injury
1390466|NCT00419939|Intensive neurorehabilitation
1390467|NCT00419939|"Patient Participation[Professional-Patient Relations"
1390468|NCT00419939|Re-learning
1390469|NCT00419939|Daily life activities
1390470|NCT00419939|Rehabilitation
1390471|NCT00419926|Renal, Kidney, Intensified, Enteric-coated mycophenolate sodium, Transplant
1390472|NCT00419913|Ovulation Induction
1390473|NCT00419913|In vitro Fertilization
1390474|NCT00419913|Pregnancy
1390475|NCT00419900|breast cancer
1390476|NCT00419900|diagnosis
1390477|NCT00419900|x-ray diffraction
1390478|NCT00419900|synchrotron
1390479|NCT00419900|hair
1390480|NCT00419887|Safety, tolerability, pharmacokinetics, pharmacodynamics, LAF237, vildagliptin, Chinese, healthy volunteers
1390481|NCT00419874|Blood-brain barrier
1390482|NCT00419874|Post traumatic epilepsy
1390483|NCT00419874|Seizures
1390484|NCT00419861|Influenza, surveillance, flu, parent protocol
1390485|NCT00419848|Acne
1390486|NCT00419848|Azithromycin
1390487|NCT00419848|Doxycycline
1390488|NCT00419835|diabetic nephropathy
1390489|NCT00419835|proteinuria
1390490|NCT00419835|CKD progression
1390491|NCT00419835|dialysis
1390492|NCT00419822|Acupuncture
1390493|NCT00419822|Range of Motion
1390494|NCT00419822|Quality of Life
1390495|NCT00419809|methotrexate,
1390496|NCT00419809|SB-681323,
1390497|NCT00419809|p38 MAP Kinase Inhibitor,
1390498|NCT00419809|liver function
1390499|NCT00419809|Rheumatoid Arthritis,
1390500|NCT00419796|Osteoarthritis, controlled hypertension, lumiracoxib, ibuprofen, high blood pressure
1390501|NCT00419783|Allergic rhinitis
1390502|NCT00419783|Urticaria
1390503|NCT00419770|zygomycosis
1390504|NCT00419770|Rhizopus
1390505|NCT00419770|iron
1390506|NCT00419770|iron-chelation
1390507|NCT00419770|adjunctive therapy
1390508|NCT00419757|Moderate asthma
1390509|NCT00419757|Severe asthma
1390510|NCT00419744|COPD
1390511|NCT00419731|nicotine
1390512|NCT00419731|smoking
1390513|NCT00419731|addiction
1390514|NCT00419705|acute stroke
1390515|NCT00419705|infrared laser therapy
1390516|NCT00419705|clinical trial
1390517|NCT00419705|safety
1390518|NCT00419705|effectiveness
1390519|NCT00419692|formulation,
1390520|NCT00419692|controlled release for RLS,
1390521|NCT00419692|pharmacokinetic,
1390522|NCT00419692|RLS
1390523|NCT00419692|food effect,
1390524|NCT00419692|SK&F101468,
1390525|NCT00419679|breast cancer
1390526|NCT00419679|hair
1390527|NCT00419679|fibre
1390528|NCT00419679|synchrotron
1390529|NCT00419679|x-ray diffraction
1390530|NCT00419666|Calcitriol
1390531|NCT00419666|Psoriasis
1390532|NCT00419666|PK
1390533|NCT00419666|Adolescents
1390534|NCT00419653|schizophrenia fMRI drug therapy amisulpride
1390535|NCT00419640|Sinus node disease
1390536|NCT00419640|AV node disease
1390537|NCT00419627|proteomics of solid tumors
1390538|NCT00419601|ventilated newborns (≥ 36 SSW)and infants (≤60 days)
1390539|NCT00419601|of any medical condition
1390540|NCT00419588|infant, premature
1390541|NCT00419588|Bronchopulmonary dysplasia
1390542|NCT00419588|asthma
1390543|NCT00419575|renal
1390544|NCT00419575|transplantation
1390545|NCT00419575|immunosuppression
1390546|NCT00419575|monitoring
1390547|NCT00419562|oral insulin
1390548|NCT00419562|autoantigen
1390549|NCT00419562|self tolerance
1390550|NCT00419562|oral tolerance
1390551|NCT00419562|DPT-1
1390552|NCT00419562|prevention
1390553|NCT00419562|"at risk for developing type 1 diabetes"
1390554|NCT00419562|juvenile diabetes
1390555|NCT00419562|T1D
1390556|NCT00419562|diabetes mellitus
1390557|NCT00419562|Type 1 diabetes TrialNet
1390558|NCT00419562|TrialNet
1390559|NCT00419549|ERCP
1390560|NCT00419549|Pancreatitis
1390561|NCT00419549|Nitroglycerine
1390562|NCT00419549|Valdecoxib
1390563|NCT00419536|LBH
1390564|NCT00419536|LBH589
1390565|NCT00419536|Prostate Cancer
1390566|NCT00419536|HRPC
1390567|NCT00419510|Genetic counseling
1390568|NCT00419510|BRCA1 and BRCA2
1390569|NCT00419510|African American
1390570|NCT00419497|Paleolithic diet
1390571|NCT00419497|Mediterranean-style diet
1390572|NCT00419497|Glucose tolerance
1390573|NCT00419497|Diabetes type 2
1390574|NCT00419497|Weight loss
1390575|NCT00419497|Waist
1390576|NCT00419471|Depression
1390577|NCT00419471|Myocardial infarction
1390578|NCT00419471|Angina, unstable
1390579|NCT00419458|ventilator weaning
1390580|NCT00419458|weaning
1390581|NCT00419458|respiratory failure
1390582|NCT00419458|inspiratory muscle strength training
1390583|NCT00419445|Attention Deficit Hyperactivity Disorder in adults
1390584|NCT00419432|Pediatrics
1390585|NCT00419432|Cerebral Palsy
1390586|NCT00419432|Gait Analysis
1390587|NCT00419432|Orthopedic Surgery
1390588|NCT00419419|Raynaud's
1390589|NCT00419406|UVA1
1390590|NCT00419406|N-B UVB
1390591|NCT00419406|phototherapy
1390592|NCT00419406|atopic dermatitis
1390593|NCT00419406|SCORAD index
1390594|NCT00419393|Keppra XR
1390595|NCT00419393|Levetiracetam XR
1390596|NCT00419393|long term
1390597|NCT00419393|partial seizures
1390598|NCT00419380|clogged ear tubes
1390599|NCT00419354|Pacemaker
1390600|NCT00419354|Tricuspid regurgitation
1390601|NCT00419341|Immune globulin subcutaneous
1390602|NCT00419341|SCIG
1390603|NCT00419341|Primary immunodeficiency
1390604|NCT00419341|PID
1390605|NCT00419328|solid tumors NGR-hTNF
1390606|NCT00419315|alcoholism
1390607|NCT00419315|primary care
1390608|NCT00419315|treatment
1390609|NCT00419289|COPD, rehabilitation, quality of life
1390610|NCT00419276|Total knee arthroplasty, postoperative analgesia
1390611|NCT00419276|Primary, unilateral, total knee arthroplasty
1390612|NCT00419263|influenza
1390613|NCT00419263|flu
1390614|NCT00419250|relapsed
1390615|NCT00419250|refractory
1390616|NCT00419250|fludarabine
1390617|NCT00419250|Revlimid
1390618|NCT00419250|lenalidomide
1390619|NCT00419250|CLL
1390620|NCT00419250|B-cell CLL
1390621|NCT00419250|CC-5013
1390622|NCT00419250|Chronic Lymphocytic Leukemia
1390623|NCT00419237|hepatic impairment pharmacokinetics
1390624|NCT00419224|Peripheral blood stem cell transplantation
1390625|NCT00419224|Non-myeloabalative
1390626|NCT00419224|Influenza vaccination
1390627|NCT00419224|Humoral immune response
1390628|NCT00419224|Immunogenicity
1390629|NCT00419211|Pregnancy, Exercise, Depression
1390630|NCT00419198|Ischemia
1390631|NCT00419198|Reperfusion
1390632|NCT00419198|Myocardial infarction
1390633|NCT00419198|Postconditioning
1390634|NCT00419185|macular hole surgery
1390635|NCT00419185|indocyanine green
1390636|NCT00419185|trypan blue
1390637|NCT00419185|internal limiting membrane
1390638|NCT00419172|Pharmacokinetics
1390639|NCT00419172|Deferasirox
1390640|NCT00419172|Exjade
1390641|NCT00419172|ICL670
1390642|NCT00419172|Rifampicin
1390643|NCT00419172|Healthy, Volunteers
1390644|NCT00419159|Colorectal cancer
1390645|NCT00419159|metastatic colorectal adenocarcinoma
1390646|NCT00419159|anti-EGFR antibody
1390647|NCT00419146|Schizophrenia
1390648|NCT00419146|Schizophreniform disorders
1390649|NCT00419146|Schizoaffective disorder
1390650|NCT00419146|Psychotic disorders
1390651|NCT00419146|Randomized Controlled Trials
1390652|NCT00419146|Longitudinal Studies
1390653|NCT00419146|Fatty Acids, Omega-3
1390654|NCT00419146|Eicosapentaenoic Acid
1390655|NCT00419146|Vitamins
1390656|NCT00419146|Antioxidants
1390657|NCT00419146|Ascorbic Acid
1390658|NCT00419146|Alpha-Tocopherol
1390659|NCT00419146|Placebos
1390660|NCT00419146|Antipsychotic Agents
1390661|NCT00419146|Oxidative Stress
1390662|NCT00419146|Fatty Acids, Unsaturated
1390663|NCT00419146|Phospholipases
1390664|NCT00419146|Niacin
1390665|NCT00419146|Adverse effects
1390666|NCT00419146|Delusions
1390667|NCT00419146|Hallucinations
1390668|NCT00419146|Neuropsychological Tests
1390669|NCT00419146|Attention
1390670|NCT00419146|Memory
1390671|NCT00419146|Hypertriglyceridemia
1390672|NCT00419146|Models, Statistical
1390673|NCT00419133|Cholera
1390674|NCT00419133|Vaccine
1390675|NCT00419133|Kolkata
1390676|NCT00419133|West Bengal
1390677|NCT00419133|India
1390678|NCT00419133|Immunogenicity
1390679|NCT00419133|Safety
1390680|NCT00419094|Keppra XR
1390681|NCT00419094|conversion to monotherapy
1390682|NCT00419094|partial seizures
1390683|NCT00419081|leukemia
1390684|NCT00419081|lymphoma
1390685|NCT00419055|percutaneous coronary intervention
1390686|NCT00419042|cancer
1390687|NCT00419042|Lung cancer
1390688|NCT00419042|None small-cell lung cancer
1390689|NCT00419029|combat
1390690|NCT00419029|depression
1390691|NCT00419029|PTSD
1390692|NCT00419029|substance abuse
1390693|NCT00417976|Advanced Pancreatic Cancer
1390694|NCT00417963|Carotid
1390695|NCT00417963|Artery
1390696|NCT00417963|Stenosis
1390697|NCT00417950|diabetes
1390698|NCT00417950|acarbose
1390699|NCT00417950|alcohol
1390700|NCT00417950|inflammation
1390701|NCT00417950|oxidative stress
1390702|NCT00417950|Mild diabetes mellitus
1390703|NCT00417924|Patient education
1390704|NCT00417924|Patient satisfaction
1390705|NCT00417924|Eye health
1390706|NCT00418990|Multivitamin
1390707|NCT00418990|Academic performance
1390708|NCT00418977|Anorexia Nervosa
1390709|NCT00418964|Anterior cruciate ligament rupture
1390710|NCT00418964|Anterior cruciate ligament(A02.513.514.100)
1390711|NCT00418951|Voriconazole
1390712|NCT00418951|Vfend
1390713|NCT00418951|Liposomal amphotericin B
1390714|NCT00418951|Ambisome
1390715|NCT00418951|Acute Myelogenous Leukemia
1390716|NCT00418951|Myelodysplastic Syndrome
1390717|NCT00418951|AML
1390718|NCT00418951|MDS
1390719|NCT00418938|EGFR
1390720|NCT00418938|FOLFIRI
1390721|NCT00418938|2nd Line Therapy
1390722|NCT00418938|2nd Line mCRC Therapy
1390723|NCT00418938|mCRC
1390724|NCT00418938|Irinotecan
1390725|NCT00418938|panitumumab
1390726|NCT00418938|bevacizumab
1390727|NCT00418899|Brain Tumor
1390728|NCT00418899|Glioma
1390729|NCT00418899|Linkage Study
1390730|NCT00418899|Survey
1390731|NCT00418899|Gliogene
1390732|NCT00418899|High-risk familial brain tumor pedigrees
1390733|NCT00418886|NSCLC
1390734|NCT00418886|Non Small Cell Lung Cancer
1390735|NCT00418873|schizophrenia
1390736|NCT00418873|zotepine
1390737|NCT00418873|risperidone
1390738|NCT00418873|second generation antipsychotic
1390739|NCT00418860|Angioplasty, Transluminal, Percutaneous Coronary
1390740|NCT00418860|Stent thrombosis
1390741|NCT00418860|Zotarolimus-eluting stent
1390742|NCT00418847|pediatrics
1390743|NCT00418847|lysosomal storage diseases
1390744|NCT00418847|Gangliosidoses GM2
1390745|NCT00418847|Tay-Sachs disease
1390746|NCT00418847|Sandhoff disease
1390747|NCT00418847|Infantile GM2-activator deficiency
1390748|NCT00418847|Miglustat
1390749|NCT00418808|motor
1390750|NCT00418808|development
1390751|NCT00418808|multiple pregnancies
1390752|NCT00418808|general movement
1390753|NCT00418808|video recording
1390754|NCT00418795|Acute Intermittent Porphyria
1390755|NCT00418795|treatment
1390756|NCT00418795|Acute attack
1390757|NCT00418769|nilotinib
1390758|NCT00418769|bioavailability
1390759|NCT00418769|tablet
1390760|NCT00418769|capsule
1390761|NCT00418769|PK
1390762|NCT00418769|healthy, subject(s),
1390763|NCT00418756|nilotinib
1390764|NCT00418756|Rifampin
1390765|NCT00418756|PK
1390766|NCT00418756|healthy subjects
1390767|NCT00418743|cancer
1390768|NCT00418743|Lung cancer
1390769|NCT00418743|small-cell lung cancer
1390770|NCT00418730|androgenetic alopecia
1390771|NCT00418730|male pattern hair loss
1390772|NCT00418730|male pattern baldness
1390773|NCT00418730|androgenetic alopecia or male pattern hair loss
1390774|NCT00418704|cancer
1390775|NCT00418704|Lung cancer
1390776|NCT00418704|None small-cell lung cancer
1390777|NCT00418691|Brain Tumor
1390778|NCT00418691|Methylphenidate
1390779|NCT00418691|Ritalin
1390780|NCT00418691|Modafinil
1390781|NCT00418691|Provigil
1390782|NCT00418691|Fatigue
1390783|NCT00418691|Concentration
1390784|NCT00418665|Revlimid
1390785|NCT00418665|Lenalidomide
1390786|NCT00418665|Low Platelet Count
1390787|NCT00418665|Low Risk Myelodysplastic Syndrome
1390788|NCT00418665|Intermediate 1 Myelodysplastic Syndrome
1390789|NCT00418665|MDS
1390790|NCT00418665|Myelodysplastic Syndrome
1390791|NCT00418652|Normal Controls
1390792|NCT00418639|Chronic Hepatitis C
1390793|NCT00418626|nilotinib
1390794|NCT00418626|hepatic impairment
1390795|NCT00418626|Child-Pugh scale
1390796|NCT00418626|PK
1390797|NCT00418626|healthy, subject(s)
1390798|NCT00418626|Subjects with impaired hepatic function and healthy subjects
1390799|NCT00418600|Secondary Hyperparathyroidism
1390800|NCT00418600|Hectorol® (doxercalciferol capsules)
1390801|NCT00418600|Hectorol® (doxercalciferol injection)
1390802|NCT00418587|Vitamin D
1390803|NCT00418587|Lupus
1390804|NCT00418574|Ovarian cancer
1390805|NCT00418574|Abagovomab
1390806|NCT00418561|rhASA
1390807|NCT00418561|MLD
1390808|NCT00418561|Metazym
1390809|NCT00418535|Lymphoma, NK/T-Cell
1390810|NCT00418522|Insulin Glargine Diabetes HbA1c
1390811|NCT00418509|Dose proportionality
1390812|NCT00418509|pharmacokinetics
1390813|NCT00418509|mometasone
1390814|NCT00418509|formoterol
1390815|NCT00418509|Healthy volunteers study
1390816|NCT00418496|Unresectable
1390817|NCT00418496|Metastatic
1390818|NCT00418483|thrombolytic
1390819|NCT00418483|thrombolysis
1390820|NCT00418483|acute peripheral arterial occlusion
1390821|NCT00418483|peripheral vascular disease
1390822|NCT00418483|thrombosis
1390823|NCT00418483|endovascular
1390824|NCT00418470|Cystic fibrosis
1390825|NCT00418470|Catheterization, peripheral
1390826|NCT00418470|Phlebitis
1390827|NCT00418470|Anti-Bacterial Agents
1390828|NCT00418470|Osmolar Concentration
1390829|NCT00418457|Breast Cancer
1390830|NCT00418457|Anesthesia; regional
1390831|NCT00418457|cancer recurrence
1390832|NCT00418457|Anesthesia; inhalational
1390833|NCT00418457|Analgesia; opioid
1390834|NCT00418444|Breast cancer,group psychotherapy,RCT,women's mental health
1390835|NCT00418418|Cell transplantation
1390836|NCT00418418|Heart failure
1390837|NCT00418418|Clinical trials
1390838|NCT00418405|Arthritis, Rheumatoid
1390839|NCT00418405|Cohort Studies
1390840|NCT00418392|pneumothorax, aspiration, minocycline, pleurodesis
1390841|NCT00418379|Sublingual immunotherapy
1390842|NCT00418379|Grass pollen tablet
1390843|NCT00418379|Allergic rhinoconjunctivitis
1390844|NCT00418366|Mild, moderate, severe renal insufficiency
1390845|NCT00418366|End stage renal disease
1390846|NCT00418353|Antenatal corticosteroids
1390847|NCT00418353|Betamethasone
1390848|NCT00418353|Dexamethasone
1390849|NCT00418353|Premature
1390850|NCT00418340|Irritable Bowel Syndrome,
1390851|NCT00418340|Visceral hypersensitivity,
1390852|NCT00418340|probiotic therapy,
1390853|NCT00418340|immune response
1390854|NCT00418327|Tarceva
1390855|NCT00418327|refractory and relapsed malignant brain tumors
1390856|NCT00418327|newly diagnosed brain stem glioma
1390857|NCT00418301|Pain
1390858|NCT00418301|Neurostimulation
1390859|NCT00418288|GLP-1
1390860|NCT00418288|glucose metabolism
1390861|NCT00418288|Type 2 diabetes
1390862|NCT00418288|brain
1390863|NCT00418288|PET
1390864|NCT00418275|Cerebrovascular Stroke
1390865|NCT00418262|fetal alcohol syndrome
1390866|NCT00418262|attention deficit disorder
1390867|NCT00418262|attention deficit disorder with hyperactivity
1390868|NCT00418262|ADD
1390869|NCT00418262|FAS
1390870|NCT00418262|FASD
1390871|NCT00418262|ADHD
1390872|NCT00418249|Androgenetic Alopecia
1390873|NCT00418249|Telogen effluvium
1390874|NCT00418249|Chronic telogen effluvium
1390875|NCT00418249|Menopause
1390876|NCT00418249|Female Androgenetic Alopecia (FAGA)
1390877|NCT00418223|Urinary retention
1390878|NCT00418223|Child birth
1390879|NCT00418223|Catheterization
1390880|NCT00418223|Ultrasound
1390881|NCT00418210|Accelerated Partial Breast Irradiation
1390882|NCT00418210|Conformal Radiation Therapy
1390883|NCT00418210|Feasibility
1390884|NCT00418210|Early breast cancer
1390885|NCT00418197|spinal stenosis
1390886|NCT00418197|low back pain
1390887|NCT00418197|spondylolisthesis
1390888|NCT00418197|lumbar spinal stenosis
1390889|NCT00418197|leg pain
1390890|NCT00418197|spinal diseases
1390891|NCT00418184|ADHD
1390892|NCT00418184|inattentive
1390893|NCT00418184|impulsive
1390894|NCT00418184|hyperactive
1390895|NCT00418184|poor academic performance
1390896|NCT00418184|poor self-discipline
1390897|NCT00418184|low self-esteem
1390898|NCT00418158|Pulmonary complications
1390899|NCT00418145|Relapsing Forms of Multiple Sclerosis
1390900|NCT00418132|SSc
1390901|NCT00418132|Systemic Sclerosis
1390902|NCT00418132|Progressive Systemic Sclerosis
1390903|NCT00418106|Premature birth
1390904|NCT00418106|Pumping breast milk
1390905|NCT00418106|Kangaroo holding
1390906|NCT00418093|mullerian carcinoma
1390907|NCT00418067|Coronary Artery Disease
1390908|NCT00418067|Stent
1390909|NCT00418028|capecitabine
1390910|NCT00418028|schedule
1390911|NCT00418028|breast cancer
1390912|NCT00418015|µ-opioid receptor
1390913|NCT00418015|neuraxial labor analgesia
1390914|NCT00418015|pharmacogenetics
1390915|NCT00418002|Single-rising dose , multiple rising dose, elderly, cognitive, , pharmacokinetic, impairment.
1390916|NCT00418002|Healthy elderly male and female subjects
1390917|NCT00417989|Glycemic control
1390918|NCT00417989|Sensor
1390919|NCT00417911|multiple myeloma
1390920|NCT00417911|autologous stem cell transplantation
1390921|NCT00417911|high-dose melphalan
1390922|NCT00417911|bortezomib
1390923|NCT00417911|consolidation
1390924|NCT00417911|event free survival
1390925|NCT00417911|phase III
1390926|NCT00417898|Stroke
1390927|NCT00417898|Cerebral Ischemia
1390928|NCT00417898|Tissue Plasminogen Activator
1390929|NCT00417898|Aspirin
1390930|NCT00417898|Human
1390931|NCT00417898|Cerebral Reperfusion
1390932|NCT00417872|Clostridium difficile
1390933|NCT00417846|Age-Related Macular Degeneration
1390934|NCT00417846|Optical Coherence Tomography, OCT
1390935|NCT00417846|Preferential Hyperacuity Perimeter, PHP
1390936|NCT00417846|Amsler Grid
1390937|NCT00417820|Safety, tolerability, pharmacodynamics, single administration, BCT194, healthy volunteers, psoriasis
1390938|NCT00417807|refractory desmoplastic small round cell tumors
1390939|NCT00417807|PDGF-R
1390940|NCT00417794|attention deficit hyperactivity disorder
1390941|NCT00417794|ADHD
1390942|NCT00417794|fetal alcohol syndrome
1390943|NCT00417794|FAS
1390944|NCT00417794|FASD
1390945|NCT00417794|atomoxetine hcl
1390946|NCT00417781|ADHD, adolescence, family study, endophenotype, outcome
1390947|NCT00417768|tissue plasminogen activator
1390948|NCT00417768|intraabdominal
1390949|NCT00417768|abscess
1390950|NCT00417768|percutaneous drainage
1390951|NCT00417755|Nutritional intake
1390952|NCT00417755|Mechanical ventilation
1390953|NCT00417755|Enteral feeding
1390954|NCT00417742|headache
1390955|NCT00417742|migraine headache
1390956|NCT00417742|tension headache
1390957|NCT00417729|Diabetes
1390958|NCT00417729|Acarobse
1390959|NCT00417729|Metformin
1390960|NCT00417729|oxidative stress
1390961|NCT00417729|Mean amplitude Glycemic Excursion
1390962|NCT00417729|Meal test
1390963|NCT00417716|Diffuse Diabetic Macular Edema
1390964|NCT00417716|Intravitreal Bevacizumab
1390965|NCT00417716|Anti-VEGF drugs
1390966|NCT00417703|Intraocular Pressure
1390967|NCT00417703|Intravitreous Injection
1390968|NCT00417703|Ranibizumab
1390969|NCT00417690|Crohn's Disease
1390970|NCT00417690|Acute Flare
1390971|NCT00417690|Mild to moderate Crohn's Disease
1390972|NCT00417690|Ileocecal distribution
1390973|NCT00417677|Advanced Renal Carcinoma
1390974|NCT00417664|cardiac surgery
1390975|NCT00417664|valvular surgery
1390976|NCT00417664|delirium
1390977|NCT00417664|postoperative delirium
1390978|NCT00417664|cognitive dysfunction
1390979|NCT00417664|altered mental status
1390980|NCT00417651|Bacterial
1390981|NCT00417651|contamination
1390982|NCT00417651|gastrotomy
1390983|NCT00417651|Complications
1390984|NCT00417638|myocardial infarction
1390985|NCT00417638|acute intervention
1390986|NCT00417638|percutaneous intervention
1390987|NCT00417638|endovascular cooling
1390988|NCT00417638|endovascular rewarming
1390989|NCT00417625|Coronary Artery Perfusion
1390990|NCT00417625|MRI
1390991|NCT00417625|Fractional Flow Reserve
1390992|NCT00417625|Coronary Flow Reserve
1390993|NCT00417625|Collateral Artery Perfusion
1390994|NCT00417625|Cardiovascular Disease
1390995|NCT00417625|Coronary Artery Disease
1390996|NCT00417625|CAD
1390997|NCT00417612|Rickets, Hypophosphatemia
1390998|NCT00417612|Rickets, Vitamin D-Resistant
1390999|NCT00417612|Rickets, X-linked hypophosphatemic
1391000|NCT00417599|Prevention of overweight
1391001|NCT00417599|Prevention of obesity
1391002|NCT00417599|Treatment of overweight
1391003|NCT00417599|Treatment of obesity
1391004|NCT00417586|Stroke
1391005|NCT00417573|Immunodeficiency
1391006|NCT00417573|Gammaglobulin
1391007|NCT00417573|IgG subclass deficiency with recurrent infections
1391008|NCT00417560|Influenza A/H5N1
1391009|NCT00417560|vaccine
1391010|NCT00417560|avian influenza H5N1
1391011|NCT00417560|H5N1
1391012|NCT00417547|Self Concept
1391013|NCT00417547|Eating Disorder
1391014|NCT00417547|Body Mass Index
1391015|NCT00417547|Dressing
1391016|NCT00417547|Islamic Veil
1391017|NCT00417534|Coronary Disease
1391018|NCT00417534|Inflammation
1391019|NCT00417534|Genetics
1391020|NCT00417534|HLA Antigens
1391021|NCT00417534|Aortic Valve
1391022|NCT00417521|Adolescents
1391023|NCT00417521|Anorexia
1391024|NCT00417521|Eating disorder
1391025|NCT00417521|Family therapy
1391026|NCT00417508|function
1391027|NCT00417508|elderly
1391028|NCT00417508|ADL
1391029|NCT00417508|nutritional supplementation
1391030|NCT00417508|Quality of life
1391031|NCT00417508|handgrip strength
1391032|NCT00417508|Body Composition
1391033|NCT00417495|adenocarcinoma, breast, multifocal lesions, surgery
1391034|NCT00417482|Risperidone treatment, psychosis, agitation, aggression,
1391035|NCT00417482|discontinuation, placebo
1391036|NCT00417456|Acne
1391037|NCT00417456|Telemedicine
1391038|NCT00417456|Dermatology
1391039|NCT00417443|epidural
1391040|NCT00417443|clonidine
1391041|NCT00417443|hyperalgesia
1391042|NCT00417443|laparotomy
1391043|NCT00417417|Endothelium
1391044|NCT00417417|Inflammation
1391045|NCT00417417|Nitric Oxide
1391046|NCT00417417|Rilonacept
1391047|NCT00417417|Cytokines
1391048|NCT00417417|Coronary Artery Disease
1391049|NCT00417417|CAD
1391050|NCT00417417|Atherosclerosis
1391051|NCT00417404|preterm
1391052|NCT00417404|nutrition
1391053|NCT00417404|vitamin A
1391054|NCT00417404|electroretinogram
1391055|NCT00417404|conjunctiva
1391056|NCT00417404|vitamin A status
1391057|NCT00417404|conjunctival health
1391058|NCT00417378|ACS
1391059|NCT00417365|odor
1391060|NCT00417365|douching
1391061|NCT00417365|BV
1391062|NCT00417365|vaginitis
1391063|NCT00417365|vaginal
1391064|NCT00417365|yeast
1391065|NCT00417365|ecosystem
1391066|NCT00417365|Lactobacilli
1391067|NCT00417365|Nugent
1391068|NCT00417365|Amsel
1391069|NCT00417352|no intervention
1391070|NCT00417352|bracing restricted forearm and wrist movement
1391071|NCT00417352|bracing with added mass near elbow
1391072|NCT00417352|bracing with added mass near wrist
1391073|NCT00417339|hemodialysis
1391074|NCT00417339|dialysis adequacy
1391075|NCT00417339|uremic retention solute
1391076|NCT00417326|ONO-5046Na
1391077|NCT00417326|acute respiratory failure
1391078|NCT00417326|community-acquired pneumonia
1391079|NCT00417313|knee pain
1391080|NCT00417313|acupuncture /acupressure
1391081|NCT00417313|alternative medicine
1391082|NCT00417313|analgesia
1391083|NCT00417313|arthritis therapy
1391084|NCT00417313|chronic pain
1391085|NCT00417313|functional ability
1391086|NCT00417300|PTSD
1391087|NCT00417300|Cognitive Behavioral Treatment
1391088|NCT00417300|Child Sexual Abuse
1391089|NCT00417287|Pancreas
1391090|NCT00417287|Cancer
1391091|NCT00417287|Carcinoma
1391092|NCT00417274|Cancer of Prostate
1391093|NCT00417274|Prostate Cancer
1391094|NCT00417274|Cancer of the Prostate
1391095|NCT00417274|Neoplasms, Prostate
1391096|NCT00417274|Neoplasms, Prostatic
1391097|NCT00417274|Prostate Neoplasms
1391098|NCT00417274|Prostatic Cancer
1391099|NCT00417274|Androgen-Independent Prostate Cancer
1391100|NCT00417261|ATF936, AXT914, healthy subjects, pharmacokinetics, parathyroid hormone, osteoporosis
1391101|NCT00417261|Healthy male and female subjects
1391102|NCT00417235|catheter related infection
1391103|NCT00417235|catheter dressing
1391104|NCT00417235|prevention
1391105|NCT00417235|Chlorhexidine impregnated dressings
1391106|NCT00417235|Infection
1391107|NCT00417235|catheterization
1391108|NCT00417209|advanced pancreatic cancer
1391109|NCT00417196|pharmacodynamic effects, safety, healthy subjects,
1391110|NCT00417196|Healthy male and female subjects
1391111|NCT00417183|GnRH antagonist
1391112|NCT00417183|GnRH agonist
1391113|NCT00417183|Long protocol
1391114|NCT00417183|Flexible
1391115|NCT00417170|High Blood pressure
1391116|NCT00417170|Hypertension
1391117|NCT00417170|metabolic syndrome
1391118|NCT00417170|insulin resistance
1391119|NCT00417170|endothelial dysfunction
1391120|NCT00417170|pre-diabetic
1391121|NCT00417170|amlodipine,
1391122|NCT00417170|aliskiren,
1391123|NCT00417170|IGT,
1391124|NCT00417170|IFG,
1391125|NCT00417170|MBF
1391126|NCT00417157|GnRH antagonist
1391127|NCT00417157|Poor responders
1391128|NCT00417157|Oocyte donation
1391129|NCT00417157|Modified natural cycle
1391130|NCT00417144|OHSS
1391131|NCT00417144|PCOS
1391132|NCT00417144|GnRH antagonist
1391133|NCT00417144|GnRH agonist
1391134|NCT00417131|Islet transplantation,
1391135|NCT00417131|coagulation,
1391136|NCT00417131|graft destruction,
1391137|NCT00417131|islet imaging
1391138|NCT00417118|Anxiety
1391139|NCT00417118|clinical trials
1391140|NCT00417105|hemodialysis
1391141|NCT00417105|dialysis adequacy
1391142|NCT00417105|chronic kidney disease
1391143|NCT00417092|coronary artery bypass grafting
1391144|NCT00417092|reduced left ventricular function
1391145|NCT00417092|postoperative pacing
1391146|NCT00417092|cardiac resynchronization
1391147|NCT00417079|Cancer
1391148|NCT00417079|Prostate
1391149|NCT00417066|poor responders
1391150|NCT00417066|GnRH antagonist
1391151|NCT00417066|GnRH agonist
1391152|NCT00417066|flare up
1391153|NCT00417066|short protocol
1391154|NCT00417053|disseminated neuroblastoma
1391155|NCT00417053|localized resectable neuroblastoma
1391156|NCT00417053|localized unresectable neuroblastoma
1391157|NCT00417053|regional neuroblastoma
1391158|NCT00417053|stage 4S neuroblastoma
1391162|NCT00417027|Patient controlled epidural analgesia
1391163|NCT00417027|Labor analgesia
1391164|NCT00417027|Epidural analgesia
1391165|NCT00417014|stage I childhood Hodgkin lymphoma
1391166|NCT00417014|stage II childhood Hodgkin lymphoma
1391167|NCT00417014|stage III childhood Hodgkin lymphoma
1391168|NCT00417014|stage IV childhood Hodgkin lymphoma
1391169|NCT00417014|recurrent/refractory childhood Hodgkin lymphoma
1391170|NCT00417001|sedation
1391171|NCT00417001|colonoscopy
1391172|NCT00417001|Aroma therapy
1391173|NCT00416988|melanoma
1391174|NCT00416988|weight changes
1391175|NCT00416975|breast cancer
1391176|NCT00416962|Oseltamivir, amantidine, Symmetrel, Tamiflu
1391177|NCT00416949|anaplastic thyroid cancer
1391178|NCT00416949|insular thyroid cancer
1391179|NCT00416949|thyroid gland medullary carcinoma
1391180|NCT00416949|recurrent thyroid cancer
1391181|NCT00416949|stage I follicular thyroid cancer
1391182|NCT00416949|stage I papillary thyroid cancer
1391183|NCT00416949|stage II follicular thyroid cancer
1391184|NCT00416949|stage II papillary thyroid cancer
1391185|NCT00416949|stage III follicular thyroid cancer
1391186|NCT00416949|stage III papillary thyroid cancer
1391187|NCT00416949|stage IVA follicular thyroid cancer
1391188|NCT00416949|stage IVB follicular thyroid cancer
1391189|NCT00416949|stage IVC follicular thyroid cancer
1391190|NCT00416949|stage IVA papillary thyroid cancer
1391191|NCT00416949|stage IVB papillary thyroid cancer
1391192|NCT00416949|stage IVC papillary thyroid cancer
1391193|NCT00416923|recurrent adult Burkitt lymphoma
1391194|NCT00416923|recurrent adult diffuse large cell lymphoma
1391195|NCT00416923|recurrent adult diffuse mixed cell lymphoma
1391196|NCT00416923|recurrent adult immunoblastic large cell lymphoma
1391197|NCT00416923|recurrent adult lymphoblastic lymphoma
1391198|NCT00416923|recurrent grade 1 follicular lymphoma
1391199|NCT00416923|recurrent grade 2 follicular lymphoma
1391200|NCT00416923|recurrent grade 3 follicular lymphoma
1391201|NCT00416923|recurrent adult diffuse small cleaved cell lymphoma
1391202|NCT00416923|recurrent mantle cell lymphoma
1391203|NCT00416923|recurrent marginal zone lymphoma
1391204|NCT00416923|recurrent small lymphocytic lymphoma
1391205|NCT00416923|stage IV adult Burkitt lymphoma
1391206|NCT00416923|stage IV adult diffuse large cell lymphoma
1391207|NCT00416923|stage IV adult diffuse mixed cell lymphoma
1391208|NCT00416923|stage IV adult diffuse small cleaved cell lymphoma
1391209|NCT00416923|stage IV adult immunoblastic large cell lymphoma
1391210|NCT00416923|stage IV adult lymphoblastic lymphoma
1391211|NCT00416923|stage IV grade 1 follicular lymphoma
1391212|NCT00416923|stage IV grade 2 follicular lymphoma
1391213|NCT00416923|stage IV grade 3 follicular lymphoma
1391214|NCT00416923|stage IV mantle cell lymphoma
1391215|NCT00416923|stage IV marginal zone lymphoma
1391216|NCT00416923|stage IV small lymphocytic lymphoma
1391217|NCT00416923|primary central nervous system non-Hodgkin lymphoma
1391218|NCT00416923|leptomeningeal metastases
1391219|NCT00416923|intraocular lymphoma
1391220|NCT00416923|AIDS-related primary CNS lymphoma
1391221|NCT00416923|Waldenström macroglobulinemia
1391222|NCT00416923|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1391223|NCT00416923|nodal marginal zone B-cell lymphoma
1391224|NCT00416923|splenic marginal zone lymphoma
1391225|NCT00416910|refractory chronic lymphocytic leukemia
1391226|NCT00416910|stage III chronic lymphocytic leukemia
1391227|NCT00416910|stage IV chronic lymphocytic leukemia
1391228|NCT00416910|stage I chronic lymphocytic leukemia
1391229|NCT00416910|stage II chronic lymphocytic leukemia
1391230|NCT00416897|stage I multiple myeloma
1391231|NCT00416897|stage II multiple myeloma
1391232|NCT00416897|stage III multiple myeloma
1391233|NCT00416897|renal failure
1391234|NCT00416884|chronic phase chronic myelogenous leukemia
1391235|NCT00416884|childhood chronic myelogenous leukemia
1391236|NCT00416884|relapsing chronic myelogenous leukemia
1391237|NCT00416871|stage IV renal cell cancer
1391238|NCT00416871|recurrent renal cell cancer
1391239|NCT00416858|stage III esophageal cancer
1391240|NCT00416845|pharmacodynamic effects, cardiac effects, healthy subjects, synthetic sphingosine 1 phosphate (S1P) receptor modulator
1391241|NCT00416845|Healthy male and female subjects
1391242|NCT00416832|stage II childhood Hodgkin lymphoma
1391243|NCT00416832|stage III childhood Hodgkin lymphoma
1391244|NCT00416832|stage IV childhood Hodgkin lymphoma
1391245|NCT00416832|stage I childhood Hodgkin lymphoma
1391246|NCT00416819|primary central nervous system non-Hodgkin lymphoma
1391247|NCT00416819|primary central nervous system Hodgkin lymphoma
1391248|NCT00416780|psychosocial effects of cancer and its treatment
1391249|NCT00416780|recurrent breast cancer
1391250|NCT00416780|stage I breast cancer
1391251|NCT00416780|stage II breast cancer
1391252|NCT00416780|stage IV breast cancer
1391253|NCT00416767|metastatic gastrointestinal carcinoid tumor
1391254|NCT00416767|recurrent gastrointestinal carcinoid tumor
1391255|NCT00416767|regional gastrointestinal carcinoid tumor
1391256|NCT00416767|gastrinoma
1391257|NCT00416767|insulinoma
1391258|NCT00416767|WDHA syndrome
1391259|NCT00416767|glucagonoma
1391260|NCT00416767|pancreatic polypeptide tumor
1391261|NCT00416767|somatostatinoma
1391262|NCT00416767|recurrent islet cell carcinoma
1391263|NCT00416754|breast cancer
1391264|NCT00416754|stage I breast cancer
1391265|NCT00416754|stage II breast cancer
1391266|NCT00416754|stage IIIA breast cancer
1391267|NCT00416754|stage IIIB breast cancer
1391268|NCT00416754|stage IIIC breast cancer
1391269|NCT00416754|stage IV breast cancer
1391270|NCT00416741|Metabolic Syndrome
1391271|NCT00416741|Obesity
1391272|NCT00416741|Hyperlipidemia
1391273|NCT00416741|High blood pressure
1391274|NCT00416741|Diabetes
1391275|NCT00416728|Aliskiren , Valsartan , bioavailability, hypertension
1391276|NCT00416728|Healthy male and female subjects
1391277|NCT00416702|safety study, pharmacokinetic effects, healthy subjects, hepatic impairment, liver
1391278|NCT00416702|Subjects with mild and moderate hepatic impairment and healthy subjects
1391279|NCT00416689|nausea and vomiting
1391280|NCT00416689|pulmonary carcinoid tumor
1391281|NCT00416689|recurrent breast cancer
1391282|NCT00416689|stage I breast cancer
1391283|NCT00416689|stage II breast cancer
1391284|NCT00416689|stage IIIA breast cancer
1391285|NCT00416689|stage IIIB breast cancer
1391286|NCT00416689|stage IIIC breast cancer
1391287|NCT00416689|stage IV breast cancer
1391288|NCT00416689|recurrent non-small cell lung cancer
1391289|NCT00416689|stage I non-small cell lung cancer
1391290|NCT00416689|stage II non-small cell lung cancer
1391291|NCT00416689|stage IIIA non-small cell lung cancer
1391292|NCT00416689|stage IIIB non-small cell lung cancer
1391293|NCT00416689|stage IV non-small cell lung cancer
1391294|NCT00416689|extensive stage small cell lung cancer
1391295|NCT00416689|limited stage small cell lung cancer
1391296|NCT00416689|recurrent small cell lung cancer
1391297|NCT00416676|localized resectable neuroblastoma
1391298|NCT00416676|localized unresectable neuroblastoma
1391299|NCT00416676|regional neuroblastoma
1391300|NCT00416663|Stem cells
1391301|NCT00416663|Progenitor cells
1391302|NCT00416663|Angina Pectoris
1391303|NCT00416663|Heart Failure
1391304|NCT00416663|Angiogenesis
1391305|NCT00416650|stage IIIB non-small cell lung cancer
1391306|NCT00416650|stage IV non-small cell lung cancer
1391307|NCT00416650|bronchoalveolar cell lung cancer
1391308|NCT00416650|recurrent non-small cell lung cancer
1391309|NCT00416637|unspecified adult solid tumor, protocol specific
1391310|NCT00416624|unspecified adult solid tumor, protocol specific
1391311|NCT00416624|extramedullary plasmacytoma
1391312|NCT00416624|isolated plasmacytoma of bone
1391313|NCT00416624|refractory multiple myeloma
1391314|NCT00416624|stage I multiple myeloma
1391315|NCT00416624|stage II multiple myeloma
1391316|NCT00416624|stage III multiple myeloma
1391317|NCT00416624|Waldenstrom macroglobulinemia
1391318|NCT00416624|post-transplant lymphoproliferative disorder
1391319|NCT00416624|stage I adult T-cell leukemia/lymphoma
1391320|NCT00416624|stage II adult T-cell leukemia/lymphoma
1391321|NCT00416624|stage III adult T-cell leukemia/lymphoma
1391322|NCT00416624|stage IV adult T-cell leukemia/lymphoma
1391323|NCT00416624|recurrent adult T-cell leukemia/lymphoma
1391324|NCT00416624|AIDS-related peripheral/systemic lymphoma
1391325|NCT00416624|AIDS-related primary CNS lymphoma
1391326|NCT00416624|angioimmunoblastic T-cell lymphoma
1391327|NCT00416624|anaplastic large cell lymphoma
1391328|NCT00416624|stage I cutaneous T-cell non-Hodgkin lymphoma
1391329|NCT00416624|stage II cutaneous T-cell non-Hodgkin lymphoma
1391330|NCT00416624|stage III cutaneous T-cell non-Hodgkin lymphoma
1391331|NCT00416624|stage IV cutaneous T-cell non-Hodgkin lymphoma
1391332|NCT00416624|recurrent cutaneous T-cell non-Hodgkin lymphoma
1391333|NCT00416624|stage I mycosis fungoides/Sezary syndrome
1391334|NCT00416624|stage II mycosis fungoides/Sezary syndrome
1391335|NCT00416624|stage III mycosis fungoides/Sezary syndrome
1391336|NCT00416624|stage IV mycosis fungoides/Sezary syndrome
1391337|NCT00416624|recurrent mycosis fungoides/Sezary syndrome
1391338|NCT00416624|stage I adult Hodgkin lymphoma
1391339|NCT00416624|stage II adult Hodgkin lymphoma
1391340|NCT00416624|stage III adult Hodgkin lymphoma
1391341|NCT00416624|stage IV adult Hodgkin lymphoma
1391342|NCT00416624|recurrent adult Hodgkin lymphoma
1391343|NCT00416624|adult grade III lymphomatoid granulomatosis
1391344|NCT00416624|stage I adult Burkitt lymphoma
1391345|NCT00416624|stage III adult Burkitt lymphoma
1391346|NCT00416624|stage IV adult Burkitt lymphoma
1391347|NCT00416624|noncontiguous stage II adult Burkitt lymphoma
1391348|NCT00416624|noncontiguous stage II adult diffuse large cell lymphoma
1391349|NCT00416624|noncontiguous stage II adult diffuse mixed cell lymphoma
1391350|NCT00416624|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1391351|NCT00416624|noncontiguous stage II adult immunoblastic large cell lymphoma
1391352|NCT00416624|noncontiguous stage II adult lymphoblastic lymphoma
1391353|NCT00416624|noncontiguous stage II grade 1 follicular lymphoma
1391354|NCT00416624|noncontiguous stage II grade 2 follicular lymphoma
1391355|NCT00416624|noncontiguous stage II grade 3 follicular lymphoma
1391356|NCT00416624|noncontiguous stage II mantle cell lymphoma
1391357|NCT00416624|noncontiguous stage II marginal zone lymphoma
1391358|NCT00416624|noncontiguous stage II small lymphocytic lymphoma
1391359|NCT00416624|contiguous stage II adult Burkitt lymphoma
1391360|NCT00416624|contiguous stage II adult diffuse large cell lymphoma
1391361|NCT00416624|contiguous stage II adult diffuse mixed cell lymphoma
1391362|NCT00416624|contiguous stage II adult diffuse small cleaved cell lymphoma
1391363|NCT00416624|contiguous stage II adult immunoblastic large cell lymphoma
1391364|NCT00416624|contiguous stage II adult lymphoblastic lymphoma
1391365|NCT00416624|contiguous stage II grade 1 follicular lymphoma
1391366|NCT00416624|contiguous stage II grade 2 follicular lymphoma
1391367|NCT00416624|contiguous stage II grade 3 follicular lymphoma
1391368|NCT00416624|contiguous stage II mantle cell lymphoma
1391369|NCT00416624|contiguous stage II marginal zone lymphoma
1391370|NCT00416624|contiguous stage II small lymphocytic lymphoma
1391371|NCT00416624|stage I adult diffuse large cell lymphoma
1391372|NCT00416624|stage I adult diffuse mixed cell lymphoma
1391373|NCT00416624|stage I adult diffuse small cleaved cell lymphoma
1391374|NCT00416624|stage III adult diffuse large cell lymphoma
1391375|NCT00416624|stage III adult diffuse mixed cell lymphoma
1391376|NCT00416624|stage III adult diffuse small cleaved cell lymphoma
1391377|NCT00416624|stage IV adult diffuse large cell lymphoma
1391378|NCT00416624|stage IV adult diffuse mixed cell lymphoma
1391379|NCT00416624|stage IV adult diffuse small cleaved cell lymphoma
1391380|NCT00416624|stage I adult immunoblastic large cell lymphoma
1391381|NCT00416624|stage III adult immunoblastic large cell lymphoma
1391382|NCT00416624|stage IV adult immunoblastic large cell lymphoma
1391383|NCT00416624|stage I adult lymphoblastic lymphoma
1391384|NCT00416624|stage III adult lymphoblastic lymphoma
1391385|NCT00416624|stage IV adult lymphoblastic lymphoma
1391386|NCT00416624|stage I grade 1 follicular lymphoma
1391387|NCT00416624|stage I grade 2 follicular lymphoma
1391388|NCT00416624|stage I grade 3 follicular lymphoma
1391389|NCT00416624|stage III grade 1 follicular lymphoma
1391390|NCT00416624|stage III grade 2 follicular lymphoma
1391391|NCT00416624|stage III grade 3 follicular lymphoma
1391392|NCT00416624|stage IV grade 1 follicular lymphoma
1391393|NCT00416624|stage IV grade 2 follicular lymphoma
1391394|NCT00416624|stage IV grade 3 follicular lymphoma
1391395|NCT00416624|stage I mantle cell lymphoma
1391396|NCT00416624|stage I marginal zone lymphoma
1391397|NCT00416624|stage III mantle cell lymphoma
1391398|NCT00416624|stage III marginal zone lymphoma
1391399|NCT00416624|stage IV mantle cell lymphoma
1391400|NCT00416624|stage IV marginal zone lymphoma
1391401|NCT00416624|stage I small lymphocytic lymphoma
1391402|NCT00416624|stage III small lymphocytic lymphoma
1391403|NCT00416624|stage IV small lymphocytic lymphoma
1391404|NCT00416624|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1391405|NCT00416624|nodal marginal zone B-cell lymphoma
1391406|NCT00416624|splenic marginal zone lymphoma
1391407|NCT00416624|recurrent adult Burkitt lymphoma
1391408|NCT00416624|recurrent adult diffuse large cell lymphoma
1391409|NCT00416624|recurrent adult diffuse mixed cell lymphoma
1391410|NCT00416624|recurrent adult diffuse small cleaved cell lymphoma
1391411|NCT00416624|recurrent adult grade III lymphomatoid granulomatosis
1391412|NCT00416624|recurrent adult immunoblastic large cell lymphoma
1391413|NCT00416624|recurrent adult lymphoblastic lymphoma
1391414|NCT00416624|recurrent grade 1 follicular lymphoma
1391415|NCT00416624|recurrent grade 2 follicular lymphoma
1391416|NCT00416624|recurrent grade 3 follicular lymphoma
1391417|NCT00416624|recurrent mantle cell lymphoma
1391418|NCT00416624|recurrent marginal zone lymphoma
1391419|NCT00416624|recurrent small lymphocytic lymphoma
1391420|NCT00416624|adult acute lymphoblastic leukemia in remission
1391421|NCT00416624|recurrent adult acute lymphoblastic leukemia
1391422|NCT00416624|untreated adult acute lymphoblastic leukemia
1391423|NCT00416624|stage I chronic lymphocytic leukemia
1391424|NCT00416624|stage II chronic lymphocytic leukemia
1391425|NCT00416624|stage III chronic lymphocytic leukemia
1391426|NCT00416624|stage IV chronic lymphocytic leukemia
1391427|NCT00416624|refractory chronic lymphocytic leukemia
1391428|NCT00416624|refractory hairy cell leukemia
1391429|NCT00416624|progressive hairy cell leukemia, initial treatment
1391430|NCT00416624|prolymphocytic leukemia
1391431|NCT00416624|anemia
1391432|NCT00416624|monoclonal gammopathy of undetermined significance
1391433|NCT00416624|primary systemic amyloidosis
1391434|NCT00416624|T-cell large granular lymphocyte leukemia
1391435|NCT00416624|acute undifferentiated leukemia
1391436|NCT00416624|mast cell leukemia
1391437|NCT00416624|adult nasal type extranodal NK/T-cell lymphoma
1391438|NCT00416624|untreated hairy cell leukemia
1391439|NCT00416611|High blood pressure
1391440|NCT00416611|Awareness
1391441|NCT00416611|Treatment
1391442|NCT00416611|Effective Control
1391443|NCT00416611|Coronary heart disease risk reduction
1391444|NCT00416611|Hypertension
1391445|NCT00416585|acne
1391446|NCT00416585|isotretinoin
1391447|NCT00416585|calcium. vitamin D
1391448|NCT00416572|psychosocial effects of cancer and its treatment
1391449|NCT00416572|stage I breast cancer
1391450|NCT00416572|stage II breast cancer
1391451|NCT00416559|long-term effects secondary to cancer therapy in children
1391452|NCT00416559|localized resectable neuroblastoma
1391453|NCT00416559|localized unresectable neuroblastoma
1391454|NCT00416559|regional neuroblastoma
1391455|NCT00416546|Healthy Caucasians
1391456|NCT00416546|Healthy Japanese subjects
1391457|NCT00416546|Immunosuppressant
1391458|NCT00416546|early T-cell activation blockers
1391459|NCT00416546|inhibition of protein kinase C
1391460|NCT00416533|recurrent prostate cancer
1391461|NCT00416533|stage III prostate cancer
1391462|NCT00416533|stage IV prostate cancer
1391463|NCT00416533|adenocarcinoma of the prostate
1391464|NCT00416520|Chronic Kidney Disease
1391465|NCT00416520|Dialysis
1391466|NCT00416520|Hyperphosphatemia
1391467|NCT00416520|Phosphate binder
1391468|NCT00416507|adenocarcinoma of the pancreas
1391469|NCT00416507|stage III pancreatic cancer
1391470|NCT00416507|stage II pancreatic cancer
1391471|NCT00416494|adenocarcinoma of the colon
1391472|NCT00416494|recurrent colon cancer
1391473|NCT00416494|stage IV colon cancer
1391474|NCT00416494|adenocarcinoma of the rectum
1391475|NCT00416494|recurrent rectal cancer
1391476|NCT00416494|stage IV rectal cancer
1391477|NCT00416481|unspecified adult solid tumor, protocol specific
1391478|NCT00416468|Aliskiren , Valsartan, bioavailability, hypertension
1391479|NCT00416468|Healthy male and female subjects
1391480|NCT00416442|healthy subjects, safety, tolerability, dose escalation, pharmacokinetics, benzodiazepine
1391481|NCT00416442|Healthy male and female subjects
1391482|NCT00416429|recurrent renal cell cancer
1391483|NCT00416429|stage IV renal cell cancer
1391484|NCT00416403|breast cancer in situ
1391485|NCT00416403|ductal breast carcinoma in situ
1391486|NCT00416403|stage IA breast cancer
1391487|NCT00416403|stage IB breast cancer
1391488|NCT00416390|benign prostatic hyperplasia
1391489|NCT00416390|stage I prostate cancer
1391490|NCT00416390|stage IIB prostate cancer
1391491|NCT00416390|stage IIA prostate cancer
1391492|NCT00416390|stage III prostate cancer
1391493|NCT00416390|stage IV prostate cancer
1391494|NCT00416377|stage I childhood Hodgkin lymphoma
1391495|NCT00416377|stage II childhood Hodgkin lymphoma
1391496|NCT00416377|stage III childhood Hodgkin lymphoma
1391497|NCT00416377|stage IV childhood Hodgkin lymphoma
1391498|NCT00416377|recurrent/refractory childhood Hodgkin lymphoma
1391499|NCT00416364|hernia
1391500|NCT00416364|inguinal
1391501|NCT00416364|quality of life
1391502|NCT00416351|anaplastic large cell lymphoma
1391503|NCT00416351|angioimmunoblastic T-cell lymphoma
1391504|NCT00416351|recurrent adult lymphoblastic lymphoma
1391505|NCT00416351|recurrent adult T-cell leukemia/lymphoma
1391506|NCT00416351|recurrent mycosis fungoides/Sezary syndrome
1391507|NCT00416351|adult nasal type extranodal NK/T-cell lymphoma
1391508|NCT00416351|prolymphocytic leukemia
1391509|NCT00416351|childhood nasal type extranodal NK/T-cell lymphoma
1391510|NCT00416351|recurrent childhood lymphoblastic lymphoma
1391511|NCT00416351|recurrent cutaneous T-cell non-Hodgkin lymphoma
1391512|NCT00416351|small intestine lymphoma
1391513|NCT00416338|renal failure
1391514|NCT00416338|infection
1391515|NCT00416338|peritonitis
1391516|NCT00416325|prostate cancer
1391609|NCT00416273|Bortezomib
1391517|NCT00416312|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1391518|NCT00416312|nodal marginal zone B-cell lymphoma
1391519|NCT00416312|recurrent adult Burkitt lymphoma
1391520|NCT00416312|recurrent adult diffuse large cell lymphoma
1391521|NCT00416312|recurrent adult diffuse small cleaved cell lymphoma
1391522|NCT00416312|recurrent adult diffuse mixed cell lymphoma
1391523|NCT00416312|recurrent adult immunoblastic large cell lymphoma
1391524|NCT00416312|recurrent adult lymphoblastic lymphoma
1391525|NCT00416312|recurrent grade 1 follicular lymphoma
1391526|NCT00416312|recurrent grade 2 follicular lymphoma
1391527|NCT00416312|recurrent grade 3 follicular lymphoma
1391528|NCT00416312|recurrent mantle cell lymphoma
1391529|NCT00416312|recurrent marginal zone lymphoma
1391530|NCT00416312|recurrent small lymphocytic lymphoma
1391531|NCT00416312|splenic marginal zone lymphoma
1391532|NCT00416312|stage III adult Burkitt lymphoma
1391533|NCT00416312|stage III adult diffuse large cell lymphoma
1391534|NCT00416312|stage III adult diffuse mixed cell lymphoma
1391535|NCT00416312|stage III adult diffuse small cleaved cell lymphoma
1391536|NCT00416312|stage III adult immunoblastic large cell lymphoma
1391537|NCT00416312|stage III adult lymphoblastic lymphoma
1391538|NCT00416312|stage III grade 1 follicular lymphoma
1391539|NCT00416312|stage III grade 2 follicular lymphoma
1391540|NCT00416312|stage III grade 3 follicular lymphoma
1391541|NCT00416312|stage III mantle cell lymphoma
1391542|NCT00416312|stage III marginal zone lymphoma
1391543|NCT00416312|stage III small lymphocytic lymphoma
1391544|NCT00416312|stage IV adult Burkitt lymphoma
1391545|NCT00416312|stage IV adult diffuse large cell lymphoma
1391546|NCT00416312|stage IV adult diffuse small cleaved cell lymphoma
1391547|NCT00416312|stage IV adult diffuse mixed cell lymphoma
1391548|NCT00416312|stage IV adult immunoblastic large cell lymphoma
1391549|NCT00416312|stage IV adult lymphoblastic lymphoma
1391550|NCT00416312|stage IV grade 1 follicular lymphoma
1391551|NCT00416312|stage IV grade 2 follicular lymphoma
1391552|NCT00416312|stage IV grade 3 follicular lymphoma
1391553|NCT00416312|stage IV mantle cell lymphoma
1391554|NCT00416312|stage IV marginal zone lymphoma
1391555|NCT00416312|stage IV small lymphocytic lymphoma
1391556|NCT00416312|Waldenström macroglobulinemia
1391557|NCT00416312|contiguous stage II adult Burkitt lymphoma
1391558|NCT00416312|contiguous stage II adult diffuse large cell lymphoma
1391559|NCT00416312|contiguous stage II adult diffuse mixed cell lymphoma
1391560|NCT00416312|contiguous stage II adult diffuse small cleaved cell lymphoma
1391561|NCT00416312|contiguous stage II adult immunoblastic large cell lymphoma
1391562|NCT00416312|contiguous stage II adult lymphoblastic lymphoma
1391563|NCT00416312|contiguous stage II grade 1 follicular lymphoma
1391564|NCT00416312|contiguous stage II grade 2 follicular lymphoma
1391565|NCT00416312|contiguous stage II grade 3 follicular lymphoma
1391566|NCT00416312|contiguous stage II mantle cell lymphoma
1391567|NCT00416312|contiguous stage II marginal zone lymphoma
1391568|NCT00416312|contiguous stage II small lymphocytic lymphoma
1391569|NCT00416312|noncontiguous stage II adult Burkitt lymphoma
1391570|NCT00416312|noncontiguous stage II adult diffuse large cell lymphoma
1391571|NCT00416312|noncontiguous stage II adult diffuse mixed cell lymphoma
1391572|NCT00416312|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1391573|NCT00416312|noncontiguous stage II adult immunoblastic large cell lymphoma
1391574|NCT00416312|noncontiguous stage II adult lymphoblastic lymphoma
1391575|NCT00416312|noncontiguous stage II grade 1 follicular lymphoma
1391576|NCT00416312|noncontiguous stage II grade 2 follicular lymphoma
1391577|NCT00416312|noncontiguous stage II grade 3 follicular lymphoma
1391578|NCT00416312|noncontiguous stage II mantle cell lymphoma
1391579|NCT00416312|noncontiguous stage II marginal zone lymphoma
1391580|NCT00416312|noncontiguous stage II small lymphocytic lymphoma
1391581|NCT00416312|stage I adult Burkitt lymphoma
1391582|NCT00416312|stage I adult diffuse large cell lymphoma
1391583|NCT00416312|stage I adult diffuse mixed cell lymphoma
1391584|NCT00416312|stage I adult diffuse small cleaved cell lymphoma
1391585|NCT00416312|stage I adult immunoblastic large cell lymphoma
1391586|NCT00416312|stage I adult lymphoblastic lymphoma
1391587|NCT00416312|stage I grade 1 follicular lymphoma
1391588|NCT00416312|stage I grade 2 follicular lymphoma
1391589|NCT00416312|stage I grade 3 follicular lymphoma
1391590|NCT00416312|stage I mantle cell lymphoma
1391591|NCT00416312|stage I marginal zone lymphoma
1391592|NCT00416312|stage I small lymphocytic lymphoma
1391593|NCT00416312|adult grade III lymphomatoid granulomatosis
1391594|NCT00416312|recurrent adult grade III lymphomatoid granulomatosis
1391595|NCT00416312|primary central nervous system non-Hodgkin lymphoma
1391596|NCT00416312|adult nasal type extranodal NK/T-cell lymphoma
1391597|NCT00416299|Cardiac biomarker
1391598|NCT00416299|cardiac surgery
1391599|NCT00416299|elderly
1391600|NCT00416299|postoperative complications
1391601|NCT00416299|Patients aged 75 years or older undergoing cardiac surgery
1391602|NCT00416286|Cetylpyridinium chlorid
1391603|NCT00416286|Sustained release
1391604|NCT00416286|orthodontic patients
1391605|NCT00416286|streptococcus mutans
1391606|NCT00416286|Lactobacillus
1391607|NCT00416286|Rate of bacterial load in saliva of orthodontic patients
1391608|NCT00416273|Multiple Myeloma
1391610|NCT00416273|PS341
1391611|NCT00416273|Proteasome inhibitor
1391612|NCT00416273|Consolidation therapy
1391613|NCT00416260|Respiratory Distress Syndrome, Adult
1391614|NCT00416260|High-Frequency Ventilation
1391615|NCT00416260|Respiration, Artificial
1391616|NCT00416247|Hypnosis
1391617|NCT00416247|TMS
1391618|NCT00416247|Cortical excitability
1391619|NCT00416221|Depression
1391620|NCT00416221|Lexapro
1391621|NCT00416208|Multiple Myeloma
1391622|NCT00416208|Clinical trial
1391623|NCT00416208|Bortezomib
1391624|NCT00416208|PS341
1391625|NCT00416208|Proteasome inhibitor
1391626|NCT00416208|Consolidation therapy
1391627|NCT00416182|Cystic fibrosis
1391628|NCT00416182|chronic sinusitis
1391629|NCT00416182|mucolytic
1391630|NCT00416169|Frontotemporal Dementia
1391631|NCT00416169|Pick Complex
1391632|NCT00416169|galantamine hydrobromide
1391633|NCT00416156|Obesity
1391634|NCT00416156|Inflammation
1391635|NCT00416143|Bed rest for idiopathic sudden sensorineural hearing loss
1391636|NCT00416130|Phase I/II Clinical Trial
1391637|NCT00416130|Vorinostat
1391638|NCT00416130|SAHA
1391639|NCT00416130|Recurrent Breast Cancer
1391640|NCT00416130|Metastatic Breast Cancer
1391641|NCT00416117|Neck pain
1391642|NCT00416117|Cervical pain
1391643|NCT00416117|Radicular pain
1391644|NCT00416117|Manual therapy
1391645|NCT00416117|Mobilization
1391646|NCT00416117|Manipulation
1391647|NCT00416104|analgesia
1391648|NCT00416091|Tourette disorder, ADHD, comorbidity, neuropsychological
1391649|NCT00416078|technology development and assessment
1391650|NCT00416078|internet
1391651|NCT00416078|randomized control trial
1391652|NCT00416052|calcium
1391653|NCT00416052|calciuria
1391654|NCT00416052|PTH
1391655|NCT00416052|1,25-vitamin D
1391656|NCT00416052|Calcitriol
1391657|NCT00416052|bone mineral density
1391658|NCT00416052|osteodensitometry
1391659|NCT00416039|midazolam
1391660|NCT00416039|sublingual
1391661|NCT00416039|oral morphine
1391662|NCT00416039|children
1391663|NCT00416039|bone fracture
1391664|NCT00416039|bone fracture with a deformed member
1391665|NCT00416026|Quality improvement
1391666|NCT00416026|Patient-centered care
1391667|NCT00416026|Acute coronary syndrome
1391668|NCT00416026|Telephone counseling
1391669|NCT00416013|Beta Natriuretic Peptide
1391670|NCT00416013|Troponin
1391671|NCT00416013|Hemodialysis
1391672|NCT00416000|Open/Elective EVAR patients
1391673|NCT00415987|Multiple Myeloma
1391674|NCT00415974|Weight Loss
1391675|NCT00415974|Obesity
1391676|NCT00415974|Overweight
1391677|NCT00415974|Physical Activity
1391678|NCT00415974|Nutrition
1391679|NCT00415974|Primary Care Physicians
1391680|NCT00415974|Primary Care
1391681|NCT00415974|Counseling
1391682|NCT00415974|Adolescent
1391683|NCT00415961|Percutaneous Coronary Intervention (PCI)
1391684|NCT00415961|Drug-eluting stent (DES)
1391685|NCT00415948|Heart
1391686|NCT00415948|Cardiac
1391687|NCT00415948|Acute Coronary Syndrome
1391688|NCT00415948|Sample Procurement
1391689|NCT00415922|Bioequivalence
1391690|NCT00415922|bioavailability
1391691|NCT00415922|carbidopa
1391692|NCT00415922|levodopa
1391693|NCT00415922|entacapone
1391694|NCT00415922|fasting condition
1391695|NCT00415922|Healthy volunteers study
1391696|NCT00415909|Leukemia
1391697|NCT00415909|Chronic Myelogenous Leukemia
1391698|NCT00415909|CML
1391699|NCT00415909|Imatinib
1391700|NCT00415909|Gleevec
1391701|NCT00415909|TALL-104
1391702|NCT00415896|weaning
1391703|NCT00415896|work of breathing
1391704|NCT00415896|spontaneous breathing trial
1391705|NCT00415896|rapid shallow breathing
1391706|NCT00415883|Relative bioavailability, formulation, Japanese, valsartan, healthy subjects
1391707|NCT00415870|Overweight
1391708|NCT00415870|Cell Phone
1391709|NCT00415870|Technology
1391710|NCT00415857|Chronic Myelogenous Leukemia
1391711|NCT00415857|Leukemia
1391712|NCT00415857|Peptide Vaccine
1391713|NCT00415857|PR1 Peptide
1391714|NCT00415857|Imatinib
1391715|NCT00415857|Gleevec
1391716|NCT00415857|GM-CSF
1391717|NCT00415857|Sargramostim
1391718|NCT00415857|Leukine
1391719|NCT00415857|Peginterferon alfa-2b
1391720|NCT00415857|Peg-Intron
1391721|NCT00415844|Bioequivalence
1391722|NCT00415844|bioavailability
1391723|NCT00415844|carbidopa
1391724|NCT00415844|levodopa
1391725|NCT00415844|entacapone
1391726|NCT00415844|fasting condition
1391727|NCT00415844|Healthy volunteers study
1391728|NCT00415831|Bioequivalence
1391729|NCT00415831|bioavailability
1391730|NCT00415831|carbidopa
1391731|NCT00415831|levodopa
1391732|NCT00415831|entacapone
1391733|NCT00415831|fed condition
1391734|NCT00415831|Healthy volunteers study
1391735|NCT00415818|Lung Cancer
1391736|NCT00415818|NSCLC
1391737|NCT00415818|Cancer Vaccine
1391738|NCT00415818|Stage IV Non-Small Cell Lung Cancer
1391739|NCT00415818|Stage IIIb Non-Small Cell Lung Cancer with effusion
1391740|NCT00415792|Ovulation induction
1391741|NCT00415792|hCG
1391742|NCT00415792|GnRH agonist
1391743|NCT00415792|hyper-responders
1391744|NCT00415779|hormone refractory
1391745|NCT00415779|bone metastasis
1391746|NCT00415779|chemotherapy
1391747|NCT00415779|biphosphonates
1391748|NCT00415766|recombinant hCG
1391749|NCT00415766|urinary hCG
1391750|NCT00415740|Bioequivalence
1391751|NCT00415740|bioavailability
1391752|NCT00415740|carbidopa
1391753|NCT00415740|levodopa
1391754|NCT00415740|entacapone
1391755|NCT00415740|fasting
1391756|NCT00415740|Healthy volunteers study
1391757|NCT00415714|Primary Insomnia
1391758|NCT00415714|Chronic Insomnia
1391759|NCT00415714|Biofeedback
1391760|NCT00415714|Sleeplessness
1391761|NCT00415701|Etomidate
1391762|NCT00415701|Propofol
1391763|NCT00415701|Adrenocortical Insufficiency
1391764|NCT00415701|Hemodynamic Process
1391765|NCT00415701|Vasoactive Agonists
1391766|NCT00415701|Coronary Artery Bypass
1391767|NCT00415701|Ischemic Coronary Heart Disease
1391768|NCT00415701|Mitral valve reconstruction/replacement
1391769|NCT00415701|Mitral valve regurgitation
1391770|NCT00415701|Heart Valve Prosthesis
1391771|NCT00415701|Cardiopulmonary Bypass
1391772|NCT00415688|lifestyle modification
1391773|NCT00415688|weight loss
1391774|NCT00415688|hyperglycemia
1391775|NCT00415688|hypoglycemic agents
1391776|NCT00415675|Lung Cancer
1391777|NCT00415675|Abdominal Cancer
1391778|NCT00415675|Tissue Motion
1391779|NCT00415675|Breathing
1391780|NCT00415675|Motion CT Scans
1391781|NCT00415649|HIV Preventive Vaccine
1391782|NCT00415649|HIV Seronegativity
1391783|NCT00415610|cerebral hemorrhage
1391784|NCT00415610|intracerebral hemorrhage
1391785|NCT00415610|stroke
1391786|NCT00415610|hypertension
1391787|NCT00415610|blood pressure
1391788|NCT00415610|nicardipine
1391789|NCT00415610|antihypertensive agent
1391790|NCT00415610|hematoma expansion
1391791|NCT00415597|chronic pain
1391792|NCT00415597|joint pain
1391793|NCT00415597|back pain
1391794|NCT00415597|diabetic peripheral neuropathy
1391795|NCT00415597|post herpetic neuralgia
1391796|NCT00415597|ALO-01
1391797|NCT00415597|Embeda
1391798|NCT00415597|Chronic Non-Malignant Pain
1391799|NCT00415584|hypercalcemia
1391800|NCT00415584|transplant
1391801|NCT00415571|Hypogonadism
1391802|NCT00415571|Erectile Dysfunction
1391803|NCT00415558|Atrial Fibrillation
1391804|NCT00415545|Heart Failure
1391805|NCT00415545|Patient Education
1391806|NCT00415532|splenectomy
1391807|NCT00415532|platelet
1391808|NCT00415532|AMG 531
1391809|NCT00415532|thrombopoietin
1391810|NCT00415532|blood disorder
1391811|NCT00415532|bleeding disorder
1391812|NCT00415532|immune thrombocytopenic purpura
1391813|NCT00415532|idiopathic thrombocytopenic purpura
1391814|NCT00415532|immune (idiopathic) thrombocytopenic purpura
1391815|NCT00415532|TPO
1391816|NCT00415532|thrombopoietic protein
1391817|NCT00415519|Amyotrophic lateral sclerosis
1391818|NCT00415519|free radical scavenger
1391819|NCT00415493|rhinitis
1391820|NCT00415493|non-allergic rhinitis
1391821|NCT00415493|rhinomanometry
1391822|NCT00415493|cold air
1391823|NCT00415493|triggers: cold, dry air inhalation
1391824|NCT00415493|warm, most air inhalation
1391825|NCT00415493|Nonallergic rhinitis; normal controls
1391826|NCT00415467|Brain Tumor
1391827|NCT00415467|Radiation Therapy System
1391828|NCT00415467|GliaSite RTS
1391829|NCT00415454|Pancreatic Cancer
1391830|NCT00415441|physiotherapy
1391831|NCT00415441|exercise
1391832|NCT00415441|manual therapy
1391833|NCT00415441|shoulder pain
1391834|NCT00415441|rotator cuff
1391835|NCT00415415|Racial Disparities
1391836|NCT00415415|Psychosocial Risk Factors
1391837|NCT00415415|Neighborhood Socioeconomic Status
1391838|NCT00415415|CVD
1391839|NCT00415415|CHD
1391840|NCT00415402|Vitamin D3
1391841|NCT00415402|morbidity
1391842|NCT00415402|mortality
1391843|NCT00415402|low birth weight
1391844|NCT00415402|supplementation
1391845|NCT00415402|TH1
1391846|NCT00415402|TH2
1391847|NCT00415402|CRP
1391848|NCT00415402|Neopterin
1391849|NCT00415402|immune response
1391850|NCT00415389|Stroke
1391851|NCT00415389|interactive educational program
1391852|NCT00415389|acute ischemic stroke
1391853|NCT00415376|seizure
1391854|NCT00415376|adult tumors metastatic to brain
1391855|NCT00415376|unspecified adult solid tumor, protocol specific
1391856|NCT00415350|Bronchiectasis
1391857|NCT00415350|Macrolide
1391858|NCT00415350|Azithromycin
1391859|NCT00415350|Antibiotic prophylaxis
1391860|NCT00415350|Immunomodulation
1391861|NCT00415350|Inflammation
1391862|NCT00415350|Lung function
1391863|NCT00415350|Sputum
1391864|NCT00415350|Bacterial colonization
1391865|NCT00415337|lung
1391866|NCT00415337|neoplasm
1391867|NCT00415337|bronchoscopy
1391868|NCT00415337|ultrasonography
1391869|NCT00415337|histology
1391870|NCT00415311|Liver Transplantation
1391871|NCT00415311|rhMBL
1391872|NCT00415298|recurrent squamous cell carcinoma of the hypopharynx
1391873|NCT00415298|recurrent squamous cell carcinoma of the larynx
1391874|NCT00415298|recurrent squamous cell carcinoma of the lip and oral cavity
1391875|NCT00415298|recurrent squamous cell carcinoma of the nasopharynx
1391876|NCT00415298|recurrent squamous cell carcinoma of the oropharynx
1391877|NCT00415298|stage III squamous cell carcinoma of the hypopharynx
1391878|NCT00415298|stage III squamous cell carcinoma of the larynx
1391879|NCT00415298|stage III squamous cell carcinoma of the lip and oral cavity
1391880|NCT00415298|stage III squamous cell carcinoma of the nasopharynx
1391881|NCT00415298|stage III squamous cell carcinoma of the oropharynx
1391882|NCT00415298|stage IV squamous cell carcinoma of the hypopharynx
1391883|NCT00415298|stage IV squamous cell carcinoma of the larynx
1391884|NCT00415298|stage IV squamous cell carcinoma of the lip and oral cavity
1391885|NCT00415298|stage IV squamous cell carcinoma of the nasopharynx
1391886|NCT00415298|stage IV squamous cell carcinoma of the oropharynx
1391887|NCT00415285|Breast
1391888|NCT00415285|Cancer
1391889|NCT00415285|Early-Stage
1391890|NCT00415285|Chemotherapy
1391891|NCT00415233|stage I follicular thyroid cancer
1391892|NCT00415233|stage I papillary thyroid cancer
1391893|NCT00415233|stage II follicular thyroid cancer
1391894|NCT00415233|stage II papillary thyroid cancer
1391895|NCT00415233|stage III follicular thyroid cancer
1391896|NCT00415233|stage III papillary thyroid cancer
1391897|NCT00415233|stage IV follicular thyroid cancer
1391898|NCT00415233|stage IV papillary thyroid cancer
1391899|NCT00415220|Chiropractic
1391900|NCT00415220|Manipulation
1391901|NCT00415220|Back surgery
1391902|NCT00415220|Herniated lumbar disc
1391903|NCT00415220|Sciatica
1391904|NCT00415220|Lumbar microdiscectomy
1391905|NCT00415220|Cost-effectiveness
1391906|NCT00415207|CYP2C8
1391907|NCT00415207|MDR1
1391908|NCT00415207|Pharmacogenetics
1391909|NCT00415207|Paclitaxel
1391910|NCT00415181|CYP2C8
1391911|NCT00415181|MDR1
1391912|NCT00415181|Pharmacogenetics
1391913|NCT00415181|Paclitaxel
1391914|NCT00415142|Depression
1391915|NCT00415142|Major depressive disorders
1391916|NCT00415142|Controlled clinical trial
1391917|NCT00415129|Influenza
1391918|NCT00415129|Orthomyxoviridae Infections
1391919|NCT00415129|Influenza Pandemics
1391920|NCT00415129|A/H5N1 strain
1391921|NCT00415116|unspecified adult solid tumor, protocol specific
1391922|NCT00415103|Emesis
1391923|NCT00415103|Nausea
1391924|NCT00415103|leukemia
1391925|NCT00415103|lymphoma
1391926|NCT00415090|Nevirapine
1391927|NCT00415090|Antiretroviral treatment
1391928|NCT00415090|Triple nucleoside therapy
1391929|NCT00415090|HIV
1391930|NCT00415090|Treatment Experienced
1391931|NCT00415064|Multiple Myeloma
1391932|NCT00415064|Perifosine
1391933|NCT00415064|Lenalidomide
1391934|NCT00415064|Dexamethasone
1391935|NCT00415051|Rift Valley Fever, vaccine
1391936|NCT00415038|hypertension
1391937|NCT00415038|pharmacogenomic
1391938|NCT00415038|adducin
1391939|NCT00415038|ouabain
1391940|NCT00415038|rostafuroxin
1391941|NCT00415025|long-term effects secondary to cancer therapy in adults
1391942|NCT00415025|oral complications of radiation therapy
1391943|NCT00415025|radiation toxicity
1391944|NCT00415025|stage III squamous cell carcinoma of the hypopharynx
1391945|NCT00415025|stage IV squamous cell carcinoma of the hypopharynx
1391946|NCT00415025|stage III squamous cell carcinoma of the larynx
1391947|NCT00415025|stage III verrucous carcinoma of the larynx
1391948|NCT00415025|stage IV squamous cell carcinoma of the larynx
1391949|NCT00415025|stage IV verrucous carcinoma of the larynx
1391950|NCT00415025|stage III lymphoepithelioma of the oropharynx
1391951|NCT00415025|stage III squamous cell carcinoma of the oropharynx
1391952|NCT00415025|stage IV lymphoepithelioma of the oropharynx
1391953|NCT00415025|stage IV squamous cell carcinoma of the oropharynx
1391954|NCT00415025|stage III basal cell carcinoma of the lip
1391955|NCT00415025|stage III squamous cell carcinoma of the lip and oral cavity
1391956|NCT00415025|stage IV basal cell carcinoma of the lip
1391957|NCT00415025|stage IV squamous cell carcinoma of the lip and oral cavity
1391958|NCT00415025|stage III adenoid cystic carcinoma of the oral cavity
1391959|NCT00415025|stage III mucoepidermoid carcinoma of the oral cavity
1391960|NCT00415025|stage III verrucous carcinoma of the oral cavity
1391961|NCT00415025|stage IV adenoid cystic carcinoma of the oral cavity
1391962|NCT00415025|stage IV mucoepidermoid carcinoma of the oral cavity
1391963|NCT00415025|stage IV verrucous carcinoma of the oral cavity
1391964|NCT00415025|metastatic squamous neck cancer with occult primary
1391965|NCT00415025|stage III lymphoepithelioma of the nasopharynx
1392071|NCT00414635|emtricitabine
1391966|NCT00415025|stage III squamous cell carcinoma of the nasopharynx
1391967|NCT00415025|stage IV lymphoepithelioma of the nasopharynx
1391968|NCT00415025|stage IV squamous cell carcinoma of the nasopharynx
1391969|NCT00415025|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1391970|NCT00415025|stage III inverted papilloma of the paranasal sinus and nasal cavity
1391971|NCT00415025|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1391972|NCT00415025|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1391973|NCT00415025|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1391974|NCT00415025|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1391975|NCT00415025|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1391976|NCT00415025|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1391977|NCT00415025|stage III salivary gland cancer
1391978|NCT00415025|stage IV salivary gland cancer
1391979|NCT00415025|recurrent salivary gland cancer
1391980|NCT00415025|recurrent lymphoepithelioma of the nasopharynx
1391981|NCT00415025|recurrent lymphoepithelioma of the oropharynx
1391982|NCT00415025|recurrent squamous cell carcinoma of the hypopharynx
1391983|NCT00415025|recurrent squamous cell carcinoma of the larynx
1391984|NCT00415025|recurrent squamous cell carcinoma of the nasopharynx
1391985|NCT00415025|recurrent squamous cell carcinoma of the oropharynx
1391986|NCT00415025|recurrent verrucous carcinoma of the larynx
1391987|NCT00415025|recurrent adenoid cystic carcinoma of the oral cavity
1391988|NCT00415025|recurrent mucoepidermoid carcinoma of the oral cavity
1391989|NCT00415025|recurrent verrucous carcinoma of the oral cavity
1391990|NCT00415025|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1391991|NCT00415025|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1391992|NCT00415025|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1391993|NCT00415025|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1391994|NCT00415025|recurrent basal cell carcinoma of the lip
1391995|NCT00415025|recurrent squamous cell carcinoma of the lip and oral cavity
1391996|NCT00415025|recurrent metastatic squamous neck cancer with occult primary
1391997|NCT00415025|untreated metastatic squamous neck cancer with occult primary
1391998|NCT00414999|Macular degeneration
1391999|NCT00414999|Vascular diseases
1392000|NCT00414999|Retinal disorders
1392001|NCT00414999|Macular edema
1392002|NCT00414960|Healthy
1392003|NCT00414960|Prevention
1392004|NCT00414947|Bioequivalence
1392005|NCT00414947|safety
1392006|NCT00414947|LAF237
1392007|NCT00414947|vildagliptin
1392008|NCT00414947|Chinese
1392009|NCT00414947|healthy subjects
1392010|NCT00414934|cancer
1392011|NCT00414934|bone scan
1392012|NCT00414934|NaF bone PET
1392013|NCT00414921|Attention deficit hyperactivity disorder
1392014|NCT00414921|ADHD
1392015|NCT00414921|clonidine
1392016|NCT00414921|methylphenidate
1392017|NCT00414921|MPH
1392018|NCT00414908|Chronic Pancreatitis
1392019|NCT00414908|Pancreatectomy
1392020|NCT00414908|Pancreatic Exocrine Insufficiency
1392021|NCT00414882|TB, tuberculosis, Mycobacterium tuberculosis, Brazil
1392022|NCT00414869|Liver
1392023|NCT00414869|Portal pressure
1392024|NCT00414869|Fibrosis
1392025|NCT00414869|Nitric oxide
1392026|NCT00414856|GERD
1392027|NCT00414856|gastroesophageal reflux disease
1392028|NCT00414856|meal-induced gastroesophageal reflux events
1392029|NCT00414843|Storage
1392030|NCT00414843|Bile
1392031|NCT00414843|Biomarkers
1392032|NCT00414843|biliary malignancies
1392033|NCT00414830|prevention
1392034|NCT00414830|health technology assessment
1392035|NCT00414830|population based
1392036|NCT00414830|fracture
1392037|NCT00414817|Inhaled Corticosteroids
1392038|NCT00414817|ICS
1392039|NCT00414817|Adherence
1392040|NCT00414804|Pain
1392041|NCT00414804|Neurostimulation
1392042|NCT00414778|Safety, pharmacokinetics, oral, single dose, multiple dose, LHT344, Chinese, healthy subjects
1392043|NCT00414765|Metastatic Renal Cell Carcinoma
1392044|NCT00414765|Metastatic Melanoma
1392045|NCT00414765|Aldesleukin
1392046|NCT00414765|IL-2
1392047|NCT00414752|Smoking, abstinence, craving, smoker, AFQ056, nicotine, placebo
1392048|NCT00414739|growth of dendritic cells
1392049|NCT00414739|prevention
1392050|NCT00414726|ischemic stroke
1392051|NCT00414726|normobaric oxygen therapy
1392052|NCT00414713|Upper GI bleeding
1392053|NCT00414713|Cirrhosis
1392054|NCT00414713|Portal hypertension
1392055|NCT00414713|Non-variceal bleeding
1392056|NCT00414713|Transfusion
1392057|NCT00414700|Cartilage
1392058|NCT00414700|Articular
1392059|NCT00414700|Femoral
1392060|NCT00414700|Knee
1392061|NCT00414687|Primary or secondary Pulmonary hypertension
1392062|NCT00414687|Iloprost
1392063|NCT00414687|Inhaled
1392064|NCT00414687|Long-term treatment
1392065|NCT00414661|Observational non-interventional long-term safety
1392066|NCT00414648|Lymphangiomyomatosis
1392067|NCT00414648|Lung Disease
1392068|NCT00414635|HIV/AIDS
1392069|NCT00414635|efavirenz
1392070|NCT00414635|tenofovir
1392072|NCT00414635|FOTO
1392073|NCT00414635|treatment interruption
1392074|NCT00414635|Atripla
1392075|NCT00414635|Truvada
1392076|NCT00414635|Treatment Experienced
1392077|NCT00414622|Alzheimer
1392078|NCT00414622|Probable Alzheimer disease
1392079|NCT00414609|myocardial infarction, aliskiren, heart failure
1392080|NCT00414609|Post acute myocardial infarction with systolic dysfunction
1392081|NCT00414583|Cerebrovascular Accident
1392082|NCT00414583|Cerebrovascular Accident, Acute
1392083|NCT00414583|CVA (Cerebrovascular Accident)
1392084|NCT00414583|Cerebral Stroke
1392085|NCT00414583|Stroke, Acute
1392086|NCT00414583|Cerebrovascular Stroke
1392087|NCT00414583|Fabry Disease
1392088|NCT00414583|Anderson-Fabry Disease
1392089|NCT00414583|Fabry's Disease
1392090|NCT00414570|Positron Emission Tomography (PET)
1392091|NCT00414570|3'-deoxy-3'(18F)fluorothymidine ([18F]FLT)
1392092|NCT00414557|Musculoskeletal diseases
1392093|NCT00414557|Joint diseases
1392094|NCT00414544|Nasolabial folds
1392095|NCT00414544|Dermal filler
1392096|NCT00414544|Injectable dermal filler
1392097|NCT00414544|Soft tissue augmentation
1392098|NCT00414518|Acute Infection
1392099|NCT00414518|Early HIV Infection
1392100|NCT00414518|Short-Term Antiretroviral Therapy
1392101|NCT00414518|Treatment Interruption
1392102|NCT00414518|Antiretroviral Drug (ARV)
1392103|NCT00414518|ART
1392104|NCT00414492|metastatic colorectal cancer
1392105|NCT00414492|liver metastasis
1392106|NCT00414492|tumor margins
1392107|NCT00414492|neoadjuvant therapy
1392108|NCT00414479|schistosomiasis
1392109|NCT00414479|anaemia
1392110|NCT00414479|malaria
1392111|NCT00414479|iron deficiency
1392112|NCT00414453|Neuropathic pain
1392113|NCT00414453|Chronic pain
1392114|NCT00414453|Multiple sclerosis
1392115|NCT00414453|Central neuropathic pain
1392116|NCT00414453|Peripheral neuropathic pain
1392117|NCT00414453|Opioid analgesic
1392118|NCT00414453|Lidocaine
1392119|NCT00414440|end-stage renal disease, ESRD, autosomal dominant polycystic kidney disease, ADPKD, everolimus
1392120|NCT00414427|Knee Osteoarthritis
1392121|NCT00414427|Ultrasonography
1392122|NCT00414427|Corticosteroids
1392123|NCT00414414|TB
1392124|NCT00414414|Tuberculosis
1392125|NCT00414414|HIV
1392126|NCT00414414|Co-infection
1392127|NCT00414414|Steroid
1392128|NCT00414414|Prednisone
1392129|NCT00414414|oral corticosteroids
1392130|NCT00414414|TB Treatment
1392131|NCT00414414|South Africa
1392132|NCT00414388|AIPC
1392133|NCT00414375|Perforated Appendicitis
1392134|NCT00414375|Abscess
1392135|NCT00414375|Appendectomy
1392136|NCT00414362|Bacteremia
1392137|NCT00414362|Urinary Tract Infections
1392138|NCT00414362|Fluoroquinolone
1392139|NCT00414349|Topical analgesic
1392140|NCT00414349|Multiple dose
1392141|NCT00414336|Blood Stage
1392142|NCT00414336|Investigational
1392143|NCT00414336|Endemic
1392144|NCT00414336|Malaria
1392145|NCT00414310|Decitabine
1392146|NCT00414310|Dacogen
1392147|NCT00414310|5-AZA
1392148|NCT00414310|Valproic Acid
1392149|NCT00414310|Myelodysplastic Syndrome
1392150|NCT00414310|Acute Myelogenous Leukemia
1392151|NCT00414310|MDS
1392152|NCT00414310|AML
1392153|NCT00414297|CAD
1392154|NCT00414297|ECP
1392155|NCT00414297|CFI
1392156|NCT00414297|CPI
1392157|NCT00414297|MPR
1392158|NCT00414284|HIV/AIDS
1392159|NCT00414284|viremia
1392160|NCT00414284|Kaletra
1392161|NCT00414284|pharmacokinetics
1392162|NCT00414284|viral load
1392163|NCT00414284|LPV/r
1392164|NCT00414284|Treatment Experienced
1392165|NCT00414271|gastric cancer, neo-adjuvant chemotherapy
1392166|NCT00414258|Pain Response
1392167|NCT00414232|Rectal Cancer
1392168|NCT00414232|Chemoradiation
1392169|NCT00414232|Rectal Cancer receiving chemoradiation.
1392170|NCT00414206|AMD
1392171|NCT00414206|Wet AMD
1392172|NCT00414193|AmpC beta-lactamase
1392173|NCT00414193|Bacteremia
1392174|NCT00414193|Piperacillin
1392175|NCT00414193|Tazobactam
1392176|NCT00414167|Binge eating
1392177|NCT00414167|Obesity
1392178|NCT00414167|Medication
1392179|NCT00414167|Craving
1392180|NCT00414167|Emotional eating
1392181|NCT00414154|Group based patient education,
1392182|NCT00414154|multidisciplinary,
1392183|NCT00414154|physical activity,
1392184|NCT00414154|adherence to treatment,
1392185|NCT00414154|quality of life
1392186|NCT00414141|Allergy
1392187|NCT00414141|Allergoid
1392188|NCT00414141|Specific Immunotherapy
1392189|NCT00414128|vasculitis
1392190|NCT00414128|ANCA
1392191|NCT00414128|mycophenolate mofetil
1392192|NCT00414128|cyclophosphamide
1392193|NCT00414128|Anti neutrophil cytoplasm antibody associated vasculitis
1392194|NCT00414115|Observational controlled study
1392195|NCT00414115|Genomic biomarkers
1392196|NCT00414115|Adverse drug reaction
1392197|NCT00414115|In children OR adults
1392198|NCT00414102|Chronic Insomnia
1392199|NCT00414102|Sleep Initiation and Maintenance Disorder
1392200|NCT00414102|Drug Therapy
1392201|NCT00414076|Uterine Leiomyosarcoma
1392202|NCT00414076|Uterine Neoplasm
1392203|NCT00414076|Uterine Sarcomas
1392204|NCT00414076|Uterine Cancer
1392205|NCT00414076|Uterus
1392206|NCT00414076|LMS
1392207|NCT00414076|ER Positivity
1392208|NCT00414076|Femara
1392209|NCT00414076|Letrozole
1392210|NCT00414063|Fecal Energy
1392211|NCT00414063|Urine Energy
1392212|NCT00414063|Bomb Calorimetry
1392213|NCT00414063|Gut Maintenance Flora
1392214|NCT00414063|Obesity
1392215|NCT00414063|Energy Metabolism
1392216|NCT00414037|insomnia
1392217|NCT00414037|lunesta
1392218|NCT00414037|eszopiclone
1392219|NCT00414037|pain
1392220|NCT00414037|fMRI
1392221|NCT00414024|Opioid, constipation, tegaserod
1392222|NCT00414011|Removal of corneal epithelium followed by excimer laser treatment during prk
1392223|NCT00413998|Functional ischaemic mitral regurgitation
1392224|NCT00413985|Low Birth Weight
1392225|NCT00413985|Fortified Human Milk
1392226|NCT00413985|breastfeeding
1392227|NCT00413985|infants
1392228|NCT00413985|growth
1392229|NCT00413959|NHL
1392230|NCT00413946|Premature infant
1392231|NCT00413946|developmental outcome
1392232|NCT00413933|falls
1392233|NCT00413933|prevention
1392234|NCT00413933|elderly
1392235|NCT00413933|multidisciplinary intervention
1392236|NCT00413933|health care utilization
1392237|NCT00413920|Steroids avoidance,
1392238|NCT00413920|enteric-coated mycophenolate sodium (EC-MPS),
1392239|NCT00413920|de novo renal transplantation
1392240|NCT00413881|Residual refractive error left over from initial LASIK correction.
1392241|NCT00413881|Higher Order aberrations measured using a wavefront analyzer.
1392242|NCT00413868|Myopia with our without astigmatism
1392243|NCT00413855|Abdominal pain
1392244|NCT00413855|Appendectomy
1392245|NCT00413855|Laparoscopy
1392246|NCT00413855|Chronic appendicitis
1392247|NCT00413855|Appendicopathy
1392248|NCT00413842|Transcranial Direct Current Stimulation (tDCS)
1392249|NCT00413842|Plasticity
1392250|NCT00413842|Primary Motor Cortex
1392251|NCT00413842|Cerebellum
1392252|NCT00413842|Transcranial Magnetic Stimulation (TMS)
1392253|NCT00413842|Healthy Volunteer
1392254|NCT00413842|HV
1392255|NCT00413829|age related macular degeneration
1392256|NCT00413829|anti-VEGF therapy
1392257|NCT00413816|Anemia
1392258|NCT00413816|Critically ill
1392259|NCT00413803|Hemodialysis
1392260|NCT00413803|Nocturnal dialysis
1392261|NCT00413803|Cardiovascular disease
1392262|NCT00413803|Quality of Life
1392263|NCT00413803|left ventricular hypertrophy
1392264|NCT00413790|Heart rate, overactive bladder
1392265|NCT00413751|Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia
1392266|NCT00413738|Central venous catheter
1392267|NCT00413738|Catheter related bloodstream infection
1392268|NCT00413738|Heparin
1392269|NCT00413738|Chlorhexidine
1392270|NCT00413738|Sulfadiazine
1392271|NCT00413725|HIV Seronegativity
1392272|NCT00413725|HIV Preventive Vaccine
1392273|NCT00413725|Adenovirus
1392274|NCT00413712|Supraventricular Tachycardia
1392275|NCT00413712|Calcium Channel Blockers
1392276|NCT00413712|Verapamil
1392277|NCT00413712|Diltiazem
1392278|NCT00413712|Adenosine
1392279|NCT00413699|long-term
1392280|NCT00413699|open-label
1392281|NCT00413699|safety
1392282|NCT00413686|Mixed solid tumors
1392283|NCT00413673|Naturally occurring low to moderate myopia, with or without low levels of astigmatism in U.S. Army personnel
1392284|NCT00413660|DMARD therapy
1392285|NCT00413647|CardioPET
1392286|NCT00413647|Coronary Artery Disease
1392287|NCT00413647|Electrocardiogram
1392288|NCT00413647|Radiation Dosimetry
1392289|NCT00413621|MRI
1392290|NCT00413621|Alzheimer Disease
1392291|NCT00413621|Amyloid
1392292|NCT00413621|AD
1392293|NCT00413621|Healthy Volunteer
1392294|NCT00413621|HV
1392295|NCT00413608|Human
1392296|NCT00413608|Adults
1392297|NCT00413608|Male
1392298|NCT00413608|Alleles
1392299|NCT00413608|Genotype
1392300|NCT00413608|Platelet Aggregation/drug effects
1392301|NCT00413608|Platelet Aggregation Inhibitors/*pharmacology
1392302|NCT00413608|Platelet Function Tests
1392303|NCT00413608|Pharmacogenetics
1392304|NCT00413608|*Polymorphism, Genetic
1392305|NCT00413608|Ticlopidine/*analogs & derivatives/pharmacology
1392306|NCT00413608|Healthy subjects
1392307|NCT00413595|Cerebrovascular Accident
1392308|NCT00413595|Cerebrovascular Accident, Acute
1392309|NCT00413595|Fabry Disease
1392310|NCT00413595|Fabry's Disease
1392311|NCT00413595|Anderson-Fabry Disease
1392312|NCT00413595|CVA (Cerebrovascular Accident)
1392313|NCT00413595|Stroke, acute
1392314|NCT00413595|Cerebral Stroke
1392315|NCT00413582|Pectus Excavatum
1392316|NCT00413582|Bar Repair
1392317|NCT00413582|Pain Control
1392318|NCT00413582|Pectus Excavatum Repair
1392319|NCT00413556|Rhinitis
1392320|NCT00413556|Oral tablets
1392321|NCT00413556|Ig G4
1392322|NCT00413556|grass pollen
1392323|NCT00413556|inmunotherapy
1392324|NCT00413543|COPD
1392325|NCT00413543|exacerbation
1392326|NCT00413543|pulmonary rehabilitation
1392327|NCT00413543|exercise tolerance
1392328|NCT00413543|exacerbations
1392329|NCT00413543|quality of life
1392330|NCT00413543|readmissions
1392331|NCT00413517|Naturally occurring myopia with or without astigmatism
1392332|NCT00413504|Fondaparinux
1392333|NCT00413504|Monotherapy
1392334|NCT00413504|Deep Vein thrombosis
1392335|NCT00413504|Pulmonary Embolism
1392336|NCT00413504|Anticoagulation
1392337|NCT00413491|Breast Cancer
1392338|NCT00413491|BRCA1 gene
1392339|NCT00413491|BRCA2 gene
1392340|NCT00413491|Magnetic Resonance Imaging
1392341|NCT00413491|Mammography
1392342|NCT00413491|Ultrasonography
1392343|NCT00413478|5-Aza
1392344|NCT00413478|Azacytidine
1392345|NCT00413478|Vidaza
1392346|NCT00413478|CLL
1392347|NCT00413478|Chronic Lymphocytic Leukemia
1392348|NCT00413478|Richter's transformation
1392349|NCT00413478|Leukemia
1392350|NCT00413465|Renal Plasma Flow
1392351|NCT00413465|Endotoxemia
1392352|NCT00413465|Type 2 diabetes
1392353|NCT00413452|Rheumatoid Arthritis
1392354|NCT00413452|Etanercept
1392355|NCT00413452|Enbrel
1392356|NCT00413452|Amgen
1392357|NCT00413439|Isavuconazole
1392358|NCT00413439|BAL8557
1392359|NCT00413439|ASP9766
1392360|NCT00413439|chemotherapy
1392361|NCT00413439|prophylaxis
1392362|NCT00413439|systemic fungal infection
1392363|NCT00413426|Pharmacokinetics
1392364|NCT00413426|oral
1392365|NCT00413426|single dose
1392366|NCT00413426|table
1392367|NCT00413426|suspension
1392368|NCT00413426|release
1392369|NCT00413426|darifenacin
1392370|NCT00413426|healthy subjects
1392371|NCT00413426|Healthy volunteers study
1392372|NCT00413413|Hypertension, valsartan, amlodipine, high blood pressure
1392373|NCT00413400|Inflammation
1392374|NCT00413400|Visceral adiposity
1392375|NCT00413400|TNF
1392376|NCT00413400|Adiponectin
1392377|NCT00413400|glucose tolerance
1392378|NCT00413400|endothelial function
1392379|NCT00413400|metabolic syndrome
1392380|NCT00413387|Asthma
1392381|NCT00413387|Combinations
1392382|NCT00413387|Inhaled therapy
1392383|NCT00413387|Corticosteroids
1392384|NCT00413387|Long acting bronchodilators
1392385|NCT00413387|Beclomethasone
1392386|NCT00413387|Formoterol
1392387|NCT00413387|Budesonide
1392388|NCT00413374|Lovenox
1392389|NCT00413374|Enoxaparin
1392390|NCT00413374|Prophylaxis
1392391|NCT00413374|Pulmonary Embolism
1392392|NCT00413374|Acute Deep Vein Thrombosis
1392393|NCT00413374|Venous Thrombosis
1392394|NCT00413374|Thrombosis
1392395|NCT00413374|Anticoagulation
1392396|NCT00413361|Systemic Lupus Erythematosus
1392397|NCT00413361|Hydroxychloroquine
1392398|NCT00413348|Type 2 diabetes
1392399|NCT00413348|Probiotics
1392400|NCT00413348|Insulin-resistance
1392401|NCT00413348|Inflammation
1392402|NCT00413348|Hyperinsulinemic euglycemic clamp
1392403|NCT00413348|Endotoxin
1392404|NCT00413335|Childhood and Adolescent Obesity
1392405|NCT00413335|Metabolic phenotype
1392406|NCT00413335|Impaired Glucose Tolerance
1392407|NCT00413335|Type 2 Diabetes Mellitus
1392408|NCT00413335|Insulin Sensitivity
1392409|NCT00413335|Insulin Resistance
1392410|NCT00413335|Abdominal fat partitioning
1392411|NCT00413335|Impaired Glucose Tolerance (IGT)
1392412|NCT00413335|Type 2 Diabetes Mellitus (T2DM)
1392413|NCT00413322|Advanced Solid tumor
1392414|NCT00413322|Adenosarcoma
1392415|NCT00413322|Androgen-independent prostate cancer
1392416|NCT00413322|belinostat
1392417|NCT00413322|bladder cancer
1392418|NCT00413322|bladder neoplasms
1392419|NCT00413322|Breast cancer
1392420|NCT00413322|Carcinoma, Bronchogenic
1392421|NCT00413322|Carcinoma, Non-Small-Cell Lung
1392422|NCT00413322|Carcinoma, Small Cell
1392423|NCT00413322|Carcinosarcoma
1392424|NCT00413322|Chondrosarcoma
1392425|NCT00413322|Coin Lesion, Pulmonary
1392426|NCT00413322|colorectal cancer
1392427|NCT00413322|Esophageal Neoplasms
1392428|NCT00413322|Facial Neoplasms
1392429|NCT00413322|Fibrosarcoma
1392430|NCT00413322|head and neck cancer
1392431|NCT00413322|Hemangiosarcoma
1392432|NCT00413322|Histiocytoma, Malignant Fibrous
1392433|NCT00413322|kidney cancer
1392434|NCT00413322|Leiomyosarcoma
1392435|NCT00413322|Liposarcoma
1392436|NCT00413322|lung cancer
1392437|NCT00413322|lung neoplasms
1392438|NCT00413322|Lymphangiosarcoma
1392439|NCT00413322|mesothelioma
1392440|NCT00413322|mesothelioma, cystic
1392441|NCT00413322|Mixed Tumor, Mesodermal
1392442|NCT00413322|Mouth Neoplasms
1392443|NCT00413322|Myosarcoma
1392444|NCT00413322|Myxosarcoma
1392445|NCT00413322|Osteosarcoma
1392446|NCT00413322|Otorhinolaryngologic Neoplasms
1392447|NCT00413322|Ovarian cancer
1392448|NCT00413322|Pancoast's Syndrome
1392449|NCT00413322|Parathyroid Neoplasms
1392450|NCT00413322|Phyllodes Tumor
1392451|NCT00413322|Pulmonary Sclerosing Hemangioma
1392452|NCT00413322|sarcoma
1392453|NCT00413322|thyroid cancer
1392454|NCT00413322|Thyroid Neoplasms
1392455|NCT00413322|Tracheal Neoplasms
1392456|NCT00413322|PXD101
1392457|NCT00413309|Acute Coronary Syndrome
1392458|NCT00413309|Percutaneous Coronary Intervention
1392459|NCT00413309|Antiplatelet Therapy
1392460|NCT00413309|PillCam
1392461|NCT00413309|Endoscopy
1392462|NCT00413296|PTSD
1392463|NCT00413296|Anxiety
1392464|NCT00413296|Pharmacotherapy
1392465|NCT00413296|Levetiracetam
1392466|NCT00413296|Relapse prevention
1392467|NCT00413283|Advanced Non-Small Cell Lung Cancer
1392468|NCT00413283|Chemotherapy Induced Thrombocytopenia
1392469|NCT00413283|CIT
1392470|NCT00413283|NSCLC
1392471|NCT00413283|Stage IIIB NSCLC
1392472|NCT00413283|Stage IV NSCLC
1392473|NCT00413283|Gemcitabine
1392474|NCT00413283|Carboplatin
1392475|NCT00413283|Cisplatin
1392476|NCT00413270|Imatinib resistant,
1392477|NCT00413270|Imatinib intolerant,
1392478|NCT00413270|CML- blast crisis,
1392479|NCT00413270|CML- Accelerated phase,
1392480|NCT00413270|CML- chronic phase,
1392481|NCT00413270|nilotinib,
1392482|NCT00413270|Chronic myelogenous leukemia,
1392483|NCT00413270|blast crisis,
1392484|NCT00413270|accelerated phase,
1392485|NCT00413270|chronic phase
1392486|NCT00413257|Postoperative Hyperalgesia
1392487|NCT00413257|cardiac Surgical Procedures
1392488|NCT00413257|Nefopam
1392489|NCT00413257|Randomized Controlled Trials
1392490|NCT00413257|Pain and chronic disease
1392491|NCT00413244|Hypogonadal
1392492|NCT00413244|coronary artery disease
1392493|NCT00413244|percutaneous coronary intervention (PCI)
1392494|NCT00413231|Thoracic Aneurysm
1392495|NCT00413231|Endovascular Aortic Repair (EVAR)
1392496|NCT00413231|Endovascular Stent Graft
1392497|NCT00413231|Endograft
1392498|NCT00413231|Thoracic Aortic Aneurysm
1392499|NCT00413231|Endovascular procedure
1392500|NCT00413231|Descending Thoracic Aneurysm
1392501|NCT00413231|Valiant Stent Graft System
1392502|NCT00413218|Phase III study
1392503|NCT00413218|Isavuconazole
1392504|NCT00413218|Candidemia
1392505|NCT00413218|Invasive Candida infections
1392506|NCT00413218|Candidemia and other invasive candida infections
1392507|NCT00413218|ASP9766
1392508|NCT00413218|BAL8557
1392509|NCT00413179|Polycystic Ovarian Syndrome
1392510|NCT00413179|Chronic Anovulation
1392511|NCT00413179|Chronic Oligoovulation
1392512|NCT00413179|Infertility
1392513|NCT00413179|Hyperandrogenism
1392514|NCT00413179|Metformin
1392515|NCT00413179|Ovulation induction
1392516|NCT00413166|Acute Promyelocytic Leukemia
1392517|NCT00413166|APL
1392518|NCT00413166|ATRA
1392519|NCT00413166|All-Trans Retinoic Acid
1392520|NCT00413166|Arsenic Trioxide
1392521|NCT00413166|Theophylline
1392522|NCT00413166|Gemtuzumab
1392523|NCT00413153|HIV
1392524|NCT00413153|Kaletra
1392525|NCT00413153|Reyataz
1392526|NCT00413153|Insulin sensitivity
1392527|NCT00413153|Lipids
1392528|NCT00413153|Body Composition
1392529|NCT00413153|Receiving Kaletra
1392530|NCT00413153|Treatment Experienced
1392531|NCT00413140|childhood disease
1392532|NCT00413140|cystic fibrosis
1392533|NCT00413140|exhaled breath condensate
1392534|NCT00413140|exhaled nitric oxide
1392535|NCT00413140|airway inflammation
1392536|NCT00413140|non-invasive inflammatory markers
1392537|NCT00413140|controls
1392538|NCT00413140|children
1392539|NCT00413127|Systemic lidocaine
1392540|NCT00413127|peridural lidocaine
1392541|NCT00413127|perioperative analgesia
1392542|NCT00413127|inflammation
1392543|NCT00413127|Anesthesia
1392544|NCT00413088|renal insufficency
1392545|NCT00413088|low molecular weight heparin
1392546|NCT00413088|pharmacokinetics
1392547|NCT00413088|elderly
1392548|NCT00413075|Solid tumors
1392549|NCT00413075|Adenosarcoma
1392550|NCT00413075|B-cell lymphoma
1392551|NCT00413075|belinostat
1392552|NCT00413075|bladder cancer
1392553|NCT00413075|Breast cancer
1392554|NCT00413075|Carcinoma, Non-Small-Cell Lung
1392555|NCT00413075|Carcinoma, Small Cell
1392556|NCT00413075|Chondrosarcoma
1392557|NCT00413075|colorectal cancer
1392558|NCT00413075|Esophageal Neoplasms
1392559|NCT00413075|Fibrosarcoma
1392560|NCT00413075|head and neck cancer
1392561|NCT00413075|Hemangiosarcoma
1392562|NCT00413075|Hodgkins Disease
1392563|NCT00413075|kidney cancer
1392564|NCT00413075|Leiomyosarcoma
1392565|NCT00413075|Liposarcoma
1392566|NCT00413075|lung cancer
1392567|NCT00413075|lymphoma
1392568|NCT00413075|mesothelioma
1392569|NCT00413075|mesothelioma, cystic
1392570|NCT00413075|Mixed Tumor, Mesodermal
1392571|NCT00413075|Osteosarcoma
1392572|NCT00413075|Otorhinolaryngologic Neoplasms
1392573|NCT00413075|Ovarian cancer
1392574|NCT00413075|Parathyroid Neoplasms
1392575|NCT00413075|Prostate cancer
1392576|NCT00413075|sarcoma
1392577|NCT00413075|T-cell lymphoma
1392578|NCT00413075|thyroid cancer
1392579|NCT00413075|PXD101
1392580|NCT00413049|Hypertension, valsartan, amlodipine, high blood pressure
1392581|NCT00413036|Celgene
1392582|NCT00413036|Revlimid
1392583|NCT00413036|CC-5013
1392584|NCT00413036|Non-hodgkin's lymphoma
1392585|NCT00413036|Lenalidomide
1392586|NCT00413036|CC5013
1392587|NCT00413036|NHL
1392588|NCT00413023|depression
1392589|NCT00413023|major depressive disorder
1392590|NCT00413023|MDD
1392591|NCT00412997|advanced solid tumor
1392592|NCT00412997|Cutaneous T-cell lymphoma
1392593|NCT00412997|Phase I
1392594|NCT00412997|HDAC inhibitor
1392595|NCT00412997|Adult patients
1392596|NCT00412971|Recurrence of bladder cancer
1392597|NCT00412971|Fluorescence cystoscopy
1392598|NCT00412932|Hypertension
1392599|NCT00412932|Angiotensin Receptor Blocker
1392600|NCT00412932|Calcium Channel Blocker
1392601|NCT00412932|Angiotensin Converting Enzyme Inhibitor
1392602|NCT00412932|Hydrochlorothiazide
1392603|NCT00412932|Stage I and II Hypertension
1392604|NCT00412919|Myeloma
1392605|NCT00412919|Relapsed
1392606|NCT00412919|Refractory
1392607|NCT00412906|Low-grade inflammation
1392608|NCT00412906|insulin resistance
1392609|NCT00412906|Metabolism
1392610|NCT00412906|Type 2 diabetes
1392611|NCT00412906|Endotoxemia
1392612|NCT00412906|Fat tissue
1392613|NCT00412906|Muscle tissue
1392614|NCT00412906|RT-PCR
1392615|NCT00412893|Phase III
1392616|NCT00412893|Invasive fungal disease
1392617|NCT00412893|Aspergillus species
1392618|NCT00412893|Filamentous fungi
1392619|NCT00412893|ASP9766
1392620|NCT00412893|BAL8557
1392621|NCT00412893|Isavuconazole
1392622|NCT00412867|Cerebral Infarction
1392623|NCT00412867|acute ischemic stroke
1392624|NCT00412867|Brain ischemia
1392625|NCT00412841|Avascular Necrosis
1392626|NCT00412841|Lipitor
1392627|NCT00412841|SLE
1392628|NCT00412828|Melanoma
1392629|NCT00412828|CR011-vcMMAE
1392630|NCT00412815|insulin sensitivity
1392631|NCT00412815|coronary artery disease
1392632|NCT00412815|exercise training
1392633|NCT00412802|enoxaparine
1392634|NCT00412802|acute coronary syndrome
1392635|NCT00412802|renal failure
1392636|NCT00412802|dose adaptation
1392637|NCT00412789|Advanced solid tumor
1392638|NCT00412789|Patupilone
1392639|NCT00412763|Acute hepatitis
1392640|NCT00412763|Acute viral hepatitis
1392641|NCT00412763|Acute nonviral hepatitis
1392642|NCT00412763|Silymarin
1392643|NCT00412763|Milk Thistle
1392644|NCT00412750|hepatitis B
1392645|NCT00412750|hepatitis B Virus (HBV)
1392646|NCT00412750|chronic hepatitis B
1392647|NCT00412750|telbivudine
1392648|NCT00412750|peginterferon
1392649|NCT00412724|diet
1392650|NCT00412724|acceptability
1392651|NCT00412724|palatability
1392652|NCT00412724|food
1392653|NCT00412724|questionnaire
1392654|NCT00412724|Food habits
1392655|NCT00412672|Myocardial infarction
1392656|NCT00412672|contrast echocardiography
1392657|NCT00412672|collateral circulation
1392658|NCT00412659|Sinus, Pilonidal
1392659|NCT00412659|Pilonidal sinus
1392660|NCT00412659|Pilonidal cysts
1392661|NCT00412659|Pilonidal disease
1392662|NCT00412659|midline excision
1392663|NCT00412659|Karydakis operation
1392664|NCT00412659|expertise based study
1392665|NCT00412659|surgery
1392666|NCT00412659|therapy
1392667|NCT00412646|HIV
1392668|NCT00412646|AIDS
1392669|NCT00412646|Dose finding study
1392670|NCT00412646|TMC125-C203
1392671|NCT00412646|Treatment Experienced
1392672|NCT00412633|Obesity
1392673|NCT00412633|Men
1392674|NCT00412633|Overweight
1392675|NCT00412607|Ventricular Tachycardia
1392676|NCT00412607|Heart Diseases
1392677|NCT00412607|Arrhythmia
1392678|NCT00412594|Hairy Cell Leukemia
1392679|NCT00412594|Leukemia
1392680|NCT00412594|2CDA
1392681|NCT00412594|2-chlorodeoxyadenosine
1392682|NCT00412594|Rituximab
1392683|NCT00412594|Rituxan
1392684|NCT00412594|HCL
1392685|NCT00412581|Melanoma
1392686|NCT00412581|Lenalidomide
1392687|NCT00412581|Dacarbazine
1392688|NCT00412581|CC-5013
1392689|NCT00412581|Revlimid
1392690|NCT00412581|DTIC
1392691|NCT00412568|Naturally occuring myopia with or without astigmatism.
1392692|NCT00412542|Glioblastoma Multiforme
1392693|NCT00412542|Glioma
1392694|NCT00412542|Thalidomide
1392695|NCT00412542|Thalomid
1392696|NCT00412542|CPT-11
1392697|NCT00412542|Irinotecan
1392698|NCT00412542|malignant glioma
1392699|NCT00412529|HBeAg-positive, chronic hepatitis B
1392700|NCT00412529|telbivudine
1392701|NCT00412529|entecavir
1392702|NCT00412529|viral kinetics
1392703|NCT00412516|Japanese Encephalitis
1392704|NCT00412516|Japanese B Encephalitis
1392705|NCT00412516|Japanese B Viral Encephalitis
1392706|NCT00412516|Viral Encephalitis, Japanese B
1392707|NCT00412490|Oral Cavity Cancer
1392708|NCT00412490|Body Image
1392709|NCT00412490|Smoking
1392710|NCT00412490|Appearance
1392711|NCT00412490|Questionnaire
1392712|NCT00412490|Interview
1392719|NCT00412464|fondaparinux
1392720|NCT00412464|thrombosis
1392721|NCT00412464|heparin-induced thrombocytopenia
1392722|NCT00412464|pediatrics
1392723|NCT00412451|Diabetic Macular Edema
1392724|NCT00412451|PVD
1392725|NCT00412451|DME
1392726|NCT00412451|Diabetic Retinopathy
1392727|NCT00412438|Atrial Fibrillation
1392728|NCT00412425|Melanoma
1392729|NCT00412425|Nausea
1392730|NCT00412425|Vomiting
1392731|NCT00412425|Palonosetron
1392732|NCT00412425|Cisplatin
1392733|NCT00412425|Vinblastine
1392734|NCT00412425|Loss of Appetite
1392735|NCT00412425|Weight loss
1392736|NCT00412412|Cancer of Breast
1392737|NCT00412412|Cancer of the Breast
1392738|NCT00412399|Employment
1392739|NCT00412399|Negative workplace events
1392740|NCT00412399|Healthy controls
1392741|NCT00412399|Fatigue
1392742|NCT00412399|Physical activity
1392743|NCT00412386|Pediatric
1392744|NCT00412386|Congenital Heart Disease
1392745|NCT00412386|Imaging
1392746|NCT00412373|Schizoaffective Disorder
1392747|NCT00412373|antipsychotic
1392748|NCT00412373|paliperidone
1392749|NCT00412373|placebo
1392750|NCT00412360|Double cord blood
1392751|NCT00412347|hyperglycemia
1392752|NCT00412347|diabetes
1392753|NCT00412347|insulin drip
1392754|NCT00412347|hypoglycemia
1392755|NCT00412347|general wards
1392756|NCT00412321|Lymphoma, Non-Hodgkin
1392757|NCT00412321|Multiple Myeloma
1392758|NCT00412321|Castleman's disease
1392759|NCT00412321|intravenous
1392760|NCT00412321|IL-6
1392761|NCT00412308|spinal cord injury
1392762|NCT00412308|ventilator dependency
1392763|NCT00412308|ventilator weaning
1392764|NCT00412308|tidal volume
1392765|NCT00412295|Naturally occuring myopia with or without astigmatism.
1392766|NCT00412295|Wavefront errors
1392767|NCT00412269|Insulin Sensitivity
1392768|NCT00412269|Total abdominal fat
1392769|NCT00412269|Visceral abdominal fat
1392770|NCT00412269|Reproductive Hormones
1392771|NCT00412269|Menopause
1392772|NCT00412269|Diabetes
1392773|NCT00412269|Fat Distribution
1392774|NCT00412269|Sex Hormones
1392775|NCT00412256|Treatment
1392776|NCT00412256|Disease activity
1392777|NCT00412256|Clinical trial
1392778|NCT00412243|Burkitt's Lymphoma
1392779|NCT00412243|Lymphoblastic Lymphoma
1392780|NCT00412243|Acute Lymphoblastic Leukemia
1392781|NCT00412243|Clofarabine
1392782|NCT00412243|Clofarex
1392783|NCT00412243|Clolar
1392784|NCT00412243|Cyclophosphamide
1392785|NCT00412243|Neosar
1392786|NCT00412243|Cytoxan
1392787|NCT00412230|Pre-eclampsia
1392788|NCT00412230|Gestational diabetes
1392789|NCT00412230|Insulin resistance
1392790|NCT00412230|hypertension in pregnancy
1392791|NCT00412204|double-blind
1392792|NCT00412204|placebo-controlled
1392793|NCT00412204|crossover
1392794|NCT00412204|effects of tiotropium bromide
1392795|NCT00412204|gas exchange
1392796|NCT00412204|Chronic Obstructive Pulmonary Disease
1392797|NCT00412204|exercise.
1392798|NCT00412191|healthy volunteers
1392799|NCT00412191|bioequivalence
1392800|NCT00412191|food effects
1392801|NCT00412178|Internet
1392802|NCT00412178|mobile communication
1392803|NCT00412178|glucose monitoring
1392804|NCT00412165|Prevention of Type 2 Diabetes
1392805|NCT00412165|Adolescents
1392806|NCT00412165|Obesity
1392807|NCT00412165|Overweight
1392808|NCT00412165|Internet Technology
1392809|NCT00412165|Cell Phone
1392810|NCT00412152|A randomised
1392811|NCT00412152|double blind
1392812|NCT00412152|parallel group
1392813|NCT00412152|multicentre study to demonstrate improvement in symptoms of constipation in subjects with non malignant pain
1392814|NCT00412152|Moderate to severe chronic non-malignant pain
1392815|NCT00412139|vascular calcifications
1392816|NCT00412139|uremic toxins
1392817|NCT00412139|renal osteodystrophy
1392818|NCT00412139|Dialysis
1392819|NCT00412126|Diabetes Mellitus
1392820|NCT00412126|Coronary Restenosis
1392821|NCT00412126|Insulin
1392822|NCT00412126|Angioplasty
1392823|NCT00412100|A randomised
1392824|NCT00412100|double-blind
1392825|NCT00412100|double-dummy
1392826|NCT00412100|parallel-group multicentre study to demonstrate improvement in symptoms of constipation
1392827|NCT00412100|Moderate to severe, chronic non-malignant pain
1392828|NCT00412087|vitamin D
1392829|NCT00412087|cholecalciferol
1392830|NCT00412087|pregnant women
1392831|NCT00412074|Breastfeeding
1392832|NCT00412074|Vitamin D
1392833|NCT00412074|Vitamin D deficiency
1392834|NCT00412061|Cancer
1392835|NCT00412061|Carcinoid
1392836|NCT00412061|Tumor
1392837|NCT00412061|Neuroendocrine
1392838|NCT00412061|Carcinoma
1392839|NCT00412061|Everolimus
1392840|NCT00412061|Octreotide
1392841|NCT00412022|early breast cancer
1392842|NCT00412022|adjuvant therapy
1392843|NCT00412022|premenopause
1392844|NCT00412022|premenopausal
1392845|NCT00412022|menopausal status
1392846|NCT00412022|postmenopause
1392847|NCT00412022|bone mineral density
1392848|NCT00412022|hormone sensitive
1392849|NCT00412022|aromatase inhibitors
1392850|NCT00412022|letrozole
1392851|NCT00412022|disease-free survival
1392852|NCT00412009|tuberculosis
1392853|NCT00412009|control
1392854|NCT00412009|treatment
1392855|NCT00412009|adherence
1392856|NCT00411996|indinavir/ritonavir
1392857|NCT00411996|HIV/TB
1392858|NCT00411996|rifampicin
1392859|NCT00411996|PK and efficacy of IDV/RTV 600/100 mg BID with rifampicin
1392860|NCT00411996|Treatment Naive
1392861|NCT00411983|chronic HIV infection
1392862|NCT00411983|long term cohort of HIV infection
1392863|NCT00411970|23 gauge pars plana vitrectomy
1392864|NCT00411970|conjunctival erythema and injection
1392865|NCT00411970|20 gauge pars plana vitrectomy
1392866|NCT00411970|vitreous and retinal surgery
1392867|NCT00411957|atazanavir/ritonavir
1392868|NCT00411957|pharmacokinetic of ATV/r200/100 OD+2NRTIs
1392869|NCT00411944|tacrolimus pharmacokinetics
1392870|NCT00411944|CYP3A4 - CYP3A5
1392871|NCT00411944|P-glycoprotein
1392872|NCT00411944|single nucleotide polymorphisms
1392873|NCT00411944|renal transplantation
1392874|NCT00411944|calcineurin-inhibitor-associated nephrotoxicity
1392875|NCT00411905|Myelodysplastic syndromes
1392876|NCT00411905|IPSS Int-2 and High risk
1392877|NCT00411905|Bortezomib
1392878|NCT00411905|Low dose Cytarabine
1392879|NCT00411905|Bone Marrow diseases
1392880|NCT00411879|Heart Arrest
1392881|NCT00411879|Cardiopulmonary Resuscitation
1392882|NCT00411879|Epinephrine
1392883|NCT00411879|Vasopressin
1392884|NCT00411879|Adrenal Cortex Hormones
1392885|NCT00411866|safety
1392886|NCT00411866|pharmacokinetics,
1392887|NCT00411853|Prostate, Hormone Refractory, Cancer
1392888|NCT00411840|stem cell therapy
1392889|NCT00411840|peripheral arterial disease
1392890|NCT00411840|limb ischemia
1392891|NCT00411827|Cytology
1392892|NCT00411827|Keratomileusis, Laser In Situ
1392893|NCT00411827|Keratectomy, Photorefractive, Excimer Laser
1392894|NCT00411814|melbourne,
1392895|NCT00411814|healthy
1392896|NCT00411814|antibody,
1392897|NCT00411814|male,
1392898|NCT00411814|Safety and pharmacokinetic study,
1392899|NCT00411814|mild asthmatic patients,
1392900|NCT00411814|australia
1392901|NCT00411814|monoclonal
1392902|NCT00411814|female,
1392903|NCT00411814|volunteers,
1392908|NCT00411788|HER-2 positive
1392909|NCT00411788|breast cancer
1392910|NCT00411788|HER-2 positive breast cancer
1392911|NCT00411762|Pancreatic
1392912|NCT00411736|Cystic Fibrosis
1392913|NCT00411736|Pseudomonas aeruginosa
1392914|NCT00411736|Azithromycin
1392915|NCT00411736|Intermittent pulmonary infection
1392916|NCT00411723|multiple sclerosis, chronic-progressive, relapsing-remitting
1392917|NCT00411671|Lung Cancer
1392918|NCT00411671|Non-Small Cell Lung Cancer
1392919|NCT00411671|NSCLC
1392920|NCT00411671|Sorafenib
1392921|NCT00411671|BAY 43-9006
1392922|NCT00411671|Battle Program
1392923|NCT00411645|prevention
1392924|NCT00411645|prophylaxis
1392925|NCT00411645|Cytomegalovirus
1392926|NCT00411645|CMV
1392927|NCT00411645|allogeneic stem cell transplant
1392928|NCT00411645|SCT
1392929|NCT00411632|Lung Cancer
1392930|NCT00411632|Non-Small Cell Lung Cancer
1392931|NCT00411632|NSCLC
1392932|NCT00411632|Erlotinib
1392933|NCT00411632|Tarceva
1392934|NCT00411632|Bexarotene
1392935|NCT00411632|Targretin
1392936|NCT00411632|OSI-774
1392937|NCT00411632|Battle Program
1392938|NCT00411619|Tuberous Sclerosis Complex (TSC)
1392939|NCT00411619|Subendymal Giant Cell Astrocytomas (SEGA'S)
1392940|NCT00411619|Mammalian Target of Rapamycin (mTOR)
1392941|NCT00411619|Everolimus (RAD001)
1392942|NCT00411619|Tuberous Sclerosis with Subependymal Giant Cell Astrocytomas
1392943|NCT00411606|Healthy
1392944|NCT00411606|Allergy
1392945|NCT00411606|Allergic Rhinoconjunctivitis
1392946|NCT00411593|Non-Small Cell Lung Cancer
1392947|NCT00411593|Lung Cancer
1392948|NCT00411593|NSCLC
1392949|NCT00411593|Bortezomib
1392950|NCT00411593|Bevacizumab
1392951|NCT00411580|Mild, moderate Alzheimer's Disease (AD), Aß-specific antibody, CAD106
1392952|NCT00411567|markers, inflammation, optimal, sub-optimal, corticosteroid, bronchial asthma
1392953|NCT00411541|acute lymphoblastic leukemia, maintenance, BFM protocol
1392954|NCT00411541|intermediate risk childhood acute lymphoblastic leukemia
1392955|NCT00411528|Prostate Cancer
1392956|NCT00411528|Hormone Refractory
1392957|NCT00411528|patupilone
1392958|NCT00411528|docetaxel
1392959|NCT00411463|Interpersonal Therapy
1392960|NCT00411463|Social Rhythm Therapy
1392961|NCT00411463|Bipolar Disorder
1392962|NCT00411463|Depression
1392963|NCT00411463|Seroquel
1392964|NCT00411450|k-ras
1392965|NCT00411450|biomarker
1392966|NCT00411450|colorectal
1392967|NCT00411450|colon
1392968|NCT00411450|rectal
1392969|NCT00411450|FOLFOX
1392970|NCT00411450|FOLFIRI
1392971|NCT00411424|Rheumatoid Arthritis
1392972|NCT00411424|Randomized Control Trial
1392973|NCT00411424|Treatment outcomes
1392974|NCT00411424|Monoclonal antibody
1392975|NCT00411411|GLP-1
1392976|NCT00411411|GIP
1392977|NCT00411411|Incretin hormones
1392978|NCT00411411|DPP-IV inhibitor
1392979|NCT00411411|Hyperglycaemic clamp
1392980|NCT00411411|Meal test
1392981|NCT00411398|Anxiety, SNRI, SSRI,GAD,SAD
1392982|NCT00411385|Chronic Hepatitis C
1392983|NCT00411385|Hepatitis C
1392984|NCT00411385|CHC
1392985|NCT00411385|HepC
1392986|NCT00411385|Genotype 1
1392987|NCT00411385|Hepatitis
1392988|NCT00411385|HCV
1392989|NCT00411372|Questionnaire
1392990|NCT00411372|COPD
1392991|NCT00411372|Shortness of Breath
1392992|NCT00411359|Refractory angina
1392993|NCT00411359|Cardiac rehabilitation
1392994|NCT00411359|Symptomology
1392995|NCT00411359|Physical ability
1392996|NCT00411359|Exercise
1392997|NCT00411359|Psychology
1392998|NCT00411359|Quality of life
1392999|NCT00411359|Risk factors
1393000|NCT00411346|Asthma
1393001|NCT00411346|Self-Monitoring
1393002|NCT00411346|Cost-effectiveness
1393003|NCT00411333|diabetic retinopathy
1393004|NCT00411333|fluorescein angiography
1393005|NCT00411333|steroid
1393006|NCT00411333|anti-angiogenesis
1393007|NCT00411320|Asthma
1393008|NCT00411320|Smoking
1393009|NCT00411320|Steroid Resistance
1393010|NCT00411320|Corticosteroid insensitivity
1393011|NCT00411307|Analgesia
1393012|NCT00411307|Postoperative pain
1393013|NCT00411294|ergocalciferol
1393014|NCT00411294|chronic kidney disease
1393015|NCT00411294|secondary hyperparathyroidism
1393016|NCT00411294|vitamin D deficiency
1393017|NCT00411281|acute myeloid leukemia/transient myeloproliferative disorder
1393018|NCT00411268|Chronic low back pain
1393019|NCT00411268|OROS hydromorphone slow release tablet
1393020|NCT00411268|Quality of Life
1393021|NCT00411255|Blink Reflex
1393022|NCT00411255|Transcranial Magnetic Stimulation (TMS)
1393023|NCT00411255|Dystonia
1393024|NCT00411255|Blepharospasm
1393025|NCT00411255|BSP
1393026|NCT00411255|Focal Dystonia
1393027|NCT00411242|agomelatine, major depressive disorder, MDD, depression
1393028|NCT00411216|vestibular rehabilitation
1393029|NCT00411216|vestibular hypofunction
1393030|NCT00411203|Protein kinase C, tamoxifen, acute mania, clinical trial
1393031|NCT00411190|Osteoporosis
1393032|NCT00411190|Osteoarthritis
1393033|NCT00411190|Postmenopausal
1393034|NCT00411177|end-stage renal disease
1393035|NCT00411177|hemodialysis
1393036|NCT00411177|cardiovascular morbidity and mortality
1393037|NCT00411177|high flux dialyser
1393038|NCT00411177|on-line hemodiafiltration
1393039|NCT00411177|arterial stiffness
1393040|NCT00411177|inflammation
1393041|NCT00411177|life quality
1393042|NCT00411177|left ventricular hypertrophy
1393043|NCT00411164|knee pain
1393044|NCT00411164|hip pain
1393045|NCT00411164|opioid
1393046|NCT00411151|Adenocarcinoma of esophagogastric junction
1393047|NCT00411151|Adenocarcinoma of lower esophagus (Barrett carcinoma)
1393048|NCT00411138|endometrial clear cell carcinoma
1393049|NCT00411138|stage II endometrial carcinoma
1393050|NCT00411138|stage IA grade 3 endometrial carcinoma
1393051|NCT00411138|stage IB endometrial carcinoma
1393052|NCT00411138|stage IIIA endometrial carcinoma
1393053|NCT00411138|stage IIIB endometrial carcinoma
1393054|NCT00411138|stage IIIC endometrial carcinoma
1393055|NCT00411125|Postmenopausal
1393056|NCT00411125|osteoporosis
1393057|NCT00411125|Pharmacokinetics/dynamics
1393058|NCT00411125|Calcitonin
1393059|NCT00411112|Sentinel node
1393060|NCT00411112|Isosulphan blue
1393061|NCT00411112|Isotopic detection
1393062|NCT00411112|Survival
1393063|NCT00411099|agomelatine, major depressive disorder, MDD, depression
1393064|NCT00411086|contiguous stage II grade 1 follicular lymphoma
1393065|NCT00411086|contiguous stage II grade 2 follicular lymphoma
1393066|NCT00411086|contiguous stage II grade 3 follicular lymphoma
1393067|NCT00411086|noncontiguous stage II grade 1 follicular lymphoma
1393068|NCT00411086|noncontiguous stage II grade 2 follicular lymphoma
1393069|NCT00411086|noncontiguous stage II grade 3 follicular lymphoma
1393070|NCT00411086|stage I grade 1 follicular lymphoma
1393071|NCT00411086|stage I grade 2 follicular lymphoma
1393072|NCT00411086|stage I grade 3 follicular lymphoma
1393073|NCT00411086|stage III grade 1 follicular lymphoma
1393074|NCT00411086|stage III grade 2 follicular lymphoma
1393075|NCT00411086|stage III grade 3 follicular lymphoma
1393076|NCT00411086|stage IV grade 1 follicular lymphoma
1393077|NCT00411086|stage IV grade 2 follicular lymphoma
1393078|NCT00411086|stage IV grade 3 follicular lymphoma
1393079|NCT00411086|Granulocyte-Macrophage Colony Stimulating Factor
1393080|NCT00411086|GM-CSF
1393081|NCT00411086|Rituximab
1393082|NCT00411086|Rituxan
1393083|NCT00411073|darapladib
1393084|NCT00411073|moxifloxacin
1393085|NCT00411073|QT study
1393086|NCT00411060|Rotator Cuff Tear
1393087|NCT00411047|stage IIIB non-small cell lung cancer
1393088|NCT00411047|stage IV non-small cell lung cancer
1393089|NCT00411047|adenocarcinoma of the lung
1393090|NCT00411047|bronchoalveolar cell lung cancer
1393091|NCT00411047|large cell lung cancer
1393092|NCT00411034|Opioids
1393093|NCT00411034|Chronic Cancer Pain
1393094|NCT00411034|analgesic
1393095|NCT00410995|Physically fit volunteers
1393096|NCT00410982|Lymphoid Malignancies
1393097|NCT00410982|Hodgkin's Disease
1393098|NCT00410982|Non-Hodgkin's Lymphoma
1393099|NCT00410982|Acute Lymphoblastic Leukemia
1393100|NCT00410982|Chronic Lymphocytic Leukemia
1393101|NCT00410982|Hematopoietic Cell Transplantation
1393102|NCT00410982|Myeloma
1393103|NCT00410982|Leukemia
1393104|NCT00410982|Lymphoma
1393105|NCT00410982|Busulfan
1393106|NCT00410982|Busulfex
1393107|NCT00410982|Myleran
1393108|NCT00410982|Gemcitabine
1393109|NCT00410982|Gemcitabine Hydrochloride
1393110|NCT00410982|Gemzar
1393111|NCT00410982|Melphalan
1393112|NCT00410982|Alkeran
1393113|NCT00410969|resuscitation
1393114|NCT00410969|hypothermia
1393115|NCT00410956|adult primary hepatocellular carcinoma
1393116|NCT00410956|localized unresectable adult primary liver cancer
1393117|NCT00410956|advanced adult primary liver cancer
1393118|NCT00410956|recurrent adult primary liver cancer
1393119|NCT00410956|adult primary cholangiocellular carcinoma
1393120|NCT00410943|Cancer pain
1393121|NCT00410943|Oral analgesic
1393122|NCT00410943|OROS hydromorphone HCI
1393123|NCT00410930|Immunotherapy, major allergen, birch
1393124|NCT00410878|Opioids
1393125|NCT00410878|Chronic cancer pain
1393126|NCT00410878|Analgesic
1393127|NCT00410865|Oral Premalignancies
1393128|NCT00410865|Mouth Cancer
1393129|NCT00410865|Dysplasia/Carcinoma in Situ (CIS) of the Oral Cavity
1393130|NCT00410865|Dysplasia/Carcinoma in situ (CIS) of the Oral Pharynx
1393131|NCT00410865|Advexin
1393132|NCT00410865|Gene Therapy
1393133|NCT00410865|INGN 201
1393134|NCT00410865|Wild Type p53 Gene Induction
1393135|NCT00410852|Insulin
1393136|NCT00410852|Hyperglycemia
1393137|NCT00410852|Hypoglycemia
1393138|NCT00410852|Intensive care
1393139|NCT00410852|Critical care
1393140|NCT00410813|stage IV breast cancer
1393141|NCT00410813|male breast cancer
1393142|NCT00410813|recurrent breast cancer
1393143|NCT00410813|bone metastases
1393144|NCT00410800|Insulin Resistance
1393145|NCT00410800|Body Composition
1393146|NCT00410800|Kinetic Modeling
1393147|NCT00410787|Chronic cancer pain
1393148|NCT00410787|OROS hydromorphone HCI (slow release)
1393149|NCT00410787|long-term repeated dosing
1393150|NCT00410774|stage III pancreatic cancer
1393151|NCT00410774|stage I pancreatic cancer
1393152|NCT00410774|adenocarcinoma of the pancreas
1393153|NCT00410774|stage II pancreatic cancer
1393154|NCT00410761|ZD6474
1393155|NCT00410761|MTC
1393156|NCT00410761|Hereditary Medullary Thyroid Cancer
1393157|NCT00410761|Sporadic Medullary Thyroid Cancer
1393158|NCT00410761|Medullary Thyroid Cancer
1393159|NCT00410748|Chronic cancer pain
1393160|NCT00410748|chronic pain
1393161|NCT00410735|ONO-1078
1393162|NCT00410735|chronic sinusitis
1393163|NCT00410722|Nutrition
1393164|NCT00410722|Type 2 Diabetes
1393165|NCT00410709|Pediculosis Capitis
1393166|NCT00410709|Head Lice
1393167|NCT00410709|Crawlers
1393168|NCT00410709|Ova
1393169|NCT00410709|Nits
1393170|NCT00410696|High-dose chemotherapy
1393171|NCT00410696|Growth factor
1393172|NCT00410696|Pegfilgrastim
1393173|NCT00410683|stage IIIA non-small cell lung cancer
1393174|NCT00410683|stage IIIB non-small cell lung cancer
1393175|NCT00410670|Gene
1393176|NCT00410670|Genetics
1393177|NCT00410670|Family History
1393178|NCT00410670|Radiation Therapy
1393179|NCT00410670|Children
1393180|NCT00410657|graft versus host disease
1393181|NCT00410657|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1393182|NCT00410657|adult acute myeloid leukemia with inv(16)(p13;q22)
1393183|NCT00410657|adult acute myeloid leukemia with t(15;17)(q22;q12)
1393184|NCT00410657|adult acute myeloid leukemia with t(16;16)(p13;q22)
1393185|NCT00410657|adult acute myeloid leukemia with t(8;21)(q22;q22)
1393186|NCT00410657|accelerated phase chronic myelogenous leukemia
1393187|NCT00410657|adult acute lymphoblastic leukemia in remission
1393188|NCT00410657|adult acute myeloid leukemia in remission
1393189|NCT00410657|atypical chronic myeloid leukemia
1393190|NCT00410657|blastic phase chronic myelogenous leukemia
1393191|NCT00410657|childhood chronic myelogenous leukemia
1393192|NCT00410657|chronic phase chronic myelogenous leukemia
1393193|NCT00410657|chronic eosinophilic leukemia
1393194|NCT00410657|chronic idiopathic myelofibrosis
1393195|NCT00410657|chronic myelomonocytic leukemia
1393196|NCT00410657|chronic neutrophilic leukemia
1393197|NCT00410657|de novo myelodysplastic syndromes
1393198|NCT00410657|disseminated neuroblastoma
1393199|NCT00410657|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1393200|NCT00410657|juvenile myelomonocytic leukemia
1393201|NCT00410657|myelodysplastic/myeloproliferative disease, unclassifiable
1393202|NCT00410657|nodal marginal zone B-cell lymphoma
1393203|NCT00410657|noncontiguous stage II adult Burkitt lymphoma
1393204|NCT00410657|stage III adult Burkitt lymphoma
1393205|NCT00410657|stage IV adult Burkitt lymphoma
1393206|NCT00410657|noncontiguous stage II adult diffuse large cell lymphoma
1393207|NCT00410657|stage III adult diffuse large cell lymphoma
1393208|NCT00410657|stage IV adult diffuse large cell lymphoma
1393209|NCT00410657|noncontiguous stage II adult diffuse mixed cell lymphoma
1393210|NCT00410657|stage III adult diffuse mixed cell lymphoma
1393211|NCT00410657|stage IV adult diffuse mixed cell lymphoma
1393212|NCT00410657|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1393213|NCT00410657|stage III adult diffuse small cleaved cell lymphoma
1393214|NCT00410657|stage IV adult diffuse small cleaved cell lymphoma
1393215|NCT00410657|noncontiguous stage II adult immunoblastic large cell lymphoma
1393216|NCT00410657|stage III adult immunoblastic large cell lymphoma
1393217|NCT00410657|stage IV adult immunoblastic large cell lymphoma
1393218|NCT00410657|noncontiguous stage II adult lymphoblastic lymphoma
1393219|NCT00410657|stage III adult lymphoblastic lymphoma
1393220|NCT00410657|stage IV adult lymphoblastic lymphoma
1393221|NCT00410657|noncontiguous stage II grade 1 follicular lymphoma
1393222|NCT00410657|stage III grade 1 follicular lymphoma
1393223|NCT00410657|stage IV grade 1 follicular lymphoma
1393224|NCT00410657|noncontiguous stage II grade 2 follicular lymphoma
1393225|NCT00410657|stage III grade 2 follicular lymphoma
1393226|NCT00410657|stage IV grade 2 follicular lymphoma
1393227|NCT00410657|noncontiguous stage II grade 3 follicular lymphoma
1393228|NCT00410657|stage III grade 3 follicular lymphoma
1393229|NCT00410657|stage IV grade 3 follicular lymphoma
1393230|NCT00410657|noncontiguous stage II mantle cell lymphoma
1393231|NCT00410657|stage III mantle cell lymphoma
1393232|NCT00410657|stage IV mantle cell lymphoma
1393233|NCT00410657|noncontiguous stage II marginal zone lymphoma
1393234|NCT00410657|splenic marginal zone lymphoma
1393235|NCT00410657|stage III marginal zone lymphoma
1393236|NCT00410657|stage IV marginal zone lymphoma
1393237|NCT00410657|noncontiguous stage II small lymphocytic lymphoma
1393238|NCT00410657|stage III small lymphocytic lymphoma
1393239|NCT00410657|stage IV small lymphocytic lymphoma
1393240|NCT00410657|poor prognosis metastatic gestational trophoblastic tumor
1393241|NCT00410657|stage I multiple myeloma
1393242|NCT00410657|stage II multiple myeloma
1393243|NCT00410657|stage III multiple myeloma
1393244|NCT00410657|stage II ovarian epithelial cancer
1393245|NCT00410657|stage III ovarian epithelial cancer
1393246|NCT00410657|stage IV ovarian epithelial cancer
1393247|NCT00410657|aggressive, noncontiguous stage II adult non-Hodgkin lymphoma
1393248|NCT00410657|stage III adult Hodgkin lymphoma
1393249|NCT00410657|stage IV adult Hodgkin lymphoma
1393250|NCT00410657|stage III chronic lymphocytic leukemia
1393251|NCT00410657|stage IV chronic lymphocytic leukemia
1393252|NCT00410657|stage III malignant testicular germ cell tumor
1393253|NCT00410657|stage IIIA breast cancer
1393254|NCT00410657|stage IIIB breast cancer
1393255|NCT00410657|stage IIIC breast cancer
1393256|NCT00410657|stage IV breast cancer
1393257|NCT00410657|childhood acute lymphoblastic leukemia in remission
1393258|NCT00410657|childhood acute myeloid leukemia in remission
1393259|NCT00410657|childhood myelodysplastic syndromes
1393260|NCT00410644|Non-malignant chronic pain
1393261|NCT00410644|pain
1393262|NCT00410644|analgesics
1393263|NCT00410644|opioid
1393264|NCT00410631|localized resectable neuroblastoma
1393265|NCT00410631|localized unresectable neuroblastoma
1393266|NCT00410631|regional neuroblastoma
1393267|NCT00410631|stage 4S neuroblastoma
1393268|NCT00410631|disseminated neuroblastoma
1393269|NCT00410631|recurrent neuroblastoma
1393270|NCT00410618|cognitive/functional effects
1393271|NCT00410618|long-term effects secondary to cancer therapy in adults
1393272|NCT00410618|recurrent colon cancer
1393273|NCT00410618|stage I colon cancer
1393274|NCT00410618|stage II colon cancer
1393275|NCT00410618|stage III colon cancer
1393276|NCT00410618|stage IV colon cancer
1393277|NCT00410592|GERD
1393278|NCT00410592|acid reflux
1393279|NCT00410592|heartburn
1393280|NCT00410592|PPI
1393281|NCT00410592|Hispanic
1393282|NCT00410579|pain
1393283|NCT00410579|fatigue
1393284|NCT00410579|long-term effects secondary to cancer therapy in adults
1393285|NCT00410579|psychosocial effects of cancer and its treatment
1393286|NCT00410579|stage II rectal cancer
1393287|NCT00410579|stage III rectal cancer
1393288|NCT00410579|stage II colon cancer
1393289|NCT00410579|stage III colon cancer
1393290|NCT00410579|adenocarcinoma of the colon
1393291|NCT00410566|Acid sphingomyelinase deficiency
1393292|NCT00410566|Niemann-Pick disease
1393293|NCT00410566|Lysosomal storage disorder
1393294|NCT00410566|Enzyme replacement therapy
1393295|NCT00410566|Treatment
1393296|NCT00410540|Cancer pain
1393297|NCT00410540|Oral analgesic
1393298|NCT00410540|OROS hydromorphone HCL
1393299|NCT00410540|Morphine sulfate
1393300|NCT00410527|Antibacterials
1393301|NCT00410527|Colonization
1393302|NCT00410527|Infection
1393303|NCT00410527|Pneumonia
1393304|NCT00410527|Resistance
1393305|NCT00410514|Beta-3 Receptor Agonist
1393306|NCT00410514|YM178
1393307|NCT00410514|Men
1393308|NCT00410514|Lower Urinary Tract Symptoms
1393309|NCT00410514|Bladder Outlet Obstruction
1393310|NCT00410501|Pharmacokinetics, interaction, QAB149, indacaterol, ketoconazole, healthy subjects
1393311|NCT00410488|Sarcoma
1393312|NCT00410488|Palonosetron
1393313|NCT00410488|Aloxi
1393314|NCT00410488|Nausea
1393315|NCT00410488|Vomiting
1393316|NCT00410475|Ionizing Radiation
1393317|NCT00410475|Cohort Study
1393318|NCT00410475|Radiation-Induced Neoplasms
1393319|NCT00410475|Radiologic Technologists
1393320|NCT00410475|Ultraviolet Radiation
1393321|NCT00410462|recurrent adult soft tissue sarcoma
1393322|NCT00410462|stage IV adult soft tissue sarcoma
1393323|NCT00410462|adult liposarcoma
1393324|NCT00410462|adult fibrosarcoma
1393325|NCT00410462|adult malignant fibrous histiocytoma
1393326|NCT00410462|adult leiomyosarcoma
1393327|NCT00410462|adult rhabdomyosarcoma
1393328|NCT00410462|adult alveolar soft-part sarcoma
1393329|NCT00410462|adult malignant mesenchymoma
1393330|NCT00410462|adult angiosarcoma
1393331|NCT00410462|adult epithelioid sarcoma
1393332|NCT00410462|adult neurofibrosarcoma
1393333|NCT00410462|adult synovial sarcoma
1393334|NCT00410462|recurrent uterine sarcoma
1393335|NCT00410462|stage IV uterine sarcoma
1393336|NCT00410462|ovarian sarcoma
1393337|NCT00410462|small intestine leiomyosarcoma
1393338|NCT00410462|recurrent small intestine cancer
1393339|NCT00410449|End stage renal disease treated by hemodialysis
1393340|NCT00410449|Hemodialysis vascular access patency
1393341|NCT00410449|Vitamin E
1393342|NCT00410449|oxidative markers
1393343|NCT00410449|pentosidine
1393344|NCT00410449|hydroxynonenal
1393345|NCT00410449|levuglandin
1393346|NCT00410436|Type 1 Diabetes
1393347|NCT00410436|Resistance Exercise
1393348|NCT00410436|Aerobic Exercise
1393349|NCT00410423|Leukemia
1393350|NCT00410423|Acute Myeloid Leukemia
1393351|NCT00410423|Acute Lymphoid / Lymphoblastic Leukemia
1393352|NCT00410397|Low back pain
1393353|NCT00410397|Hip pain
1393354|NCT00410384|Antibodies
1393355|NCT00410384|Autoimmune Diseases
1393356|NCT00410384|Systemic Lupus Erythematosus
1393357|NCT00410384|SLE
1393358|NCT00410384|Belimumab
1393359|NCT00410384|Lupus
1393360|NCT00410371|tolerability
1393361|NCT00410371|safety
1393362|NCT00410371|Pharmacokinetic characteristics
1393363|NCT00410358|Gimatecan
1393364|NCT00410358|topoisomerase I inhibitor
1393365|NCT00410358|advanced solid tumors
1393366|NCT00410332|tonsillectomy
1393367|NCT00410332|pain
1393368|NCT00410332|homeopathy
1393369|NCT00410332|Traumeel
1393370|NCT00410306|Hypogonadism
1393371|NCT00410306|Nebido
1393372|NCT00410306|Testosterone
1393373|NCT00410306|Observational Study
1393374|NCT00410293|Heart failure
1393375|NCT00410293|Diagnostic
1393376|NCT00410293|Natriuretic peptide
1393377|NCT00410293|NT-pro B-type natriuretic peptide
1393378|NCT00410293|Length of stay
1393379|NCT00410293|Costs
1393380|NCT00410267|glaucoma
1393381|NCT00410267|Post operative from selective laser trabeculoplasty
1393382|NCT00410241|Genome
1393383|NCT00410241|Cardiovascular Disease
1393384|NCT00410241|Volunteers
1393385|NCT00410241|Genes
1393386|NCT00410241|Atherosclerosis
1393387|NCT00410241|Coronary Artery Calcification
1393388|NCT00410241|Cardiovascular
1393389|NCT00410228|safety, tolerability, pharmacokinetics, pharmacodynamics, AHT956
1393390|NCT00410189|Non-Small Cell Lung Cancer
1393391|NCT00410189|NSCLC
1393392|NCT00410189|Lung Cancer
1393393|NCT00410189|ZD6474
1393394|NCT00410189|Zactima
1393395|NCT00410189|Vandetanib
1393396|NCT00410189|BATTLE Program
1393397|NCT00410163|B-cell
1393398|NCT00410163|cyclophosphamide
1393399|NCT00410163|fludarabine
1393400|NCT00410163|Chronic Lymphocytic Leukemia
1393401|NCT00410163|Ofatumumab
1393402|NCT00410150|Status asthmaticus
1393403|NCT00410150|Asthma
1393404|NCT00410150|Helium
1393405|NCT00410150|Children
1393406|NCT00410124|advanced kidney cancer
1393407|NCT00410124|everolimus
1393408|NCT00410124|kidney cancer
1393409|NCT00410124|oral therapy
1393410|NCT00410111|sepsis
1393411|NCT00410111|encephalopathy
1393412|NCT00410111|cerebral perfusion
1393413|NCT00410111|electroencephalogram
1393414|NCT00410098|asthma
1393415|NCT00410098|yoga
1393416|NCT00410098|heat
1393417|NCT00410098|humidity
1393418|NCT00410098|bikram
1393419|NCT00410059|Non-Small Cell Lung Cancer
1393420|NCT00410059|Lung Cancer
1393421|NCT00410059|NSCLC
1393422|NCT00410059|Erlotinib
1393423|NCT00410059|Tarceva
1393424|NCT00410059|OSI-774
1393425|NCT00410059|Battle Program
1393426|NCT00410020|alpha linolenic acid
1393427|NCT00410020|atrial fibrillation
1393428|NCT00410020|omega 3 fatty acids
1393429|NCT00410020|diet
1393430|NCT00410020|rapeseed oil
1393431|NCT00410020|canola oil
1393432|NCT00410020|cardiovascular diseases
1393433|NCT00410007|ADPKD
1393434|NCT00410007|Urinary Aquaporin-2
1393435|NCT00410007|ENaC
1393436|NCT00410007|Fractional sodium excretion
1393437|NCT00410007|High/low sodium diet
1393438|NCT00409994|Colorectal cancer
1393439|NCT00409994|M-tor inhibitor
1393440|NCT00409994|Rapamycin
1393441|NCT00409981|in stent restenosis
1393442|NCT00409981|paclitaxel coated balloon catheter
1393443|NCT00409981|paccocath
1393444|NCT00409981|drug eluting balloon
1393445|NCT00409968|Lung Cancer
1393446|NCT00409968|Non Small Cell Lung Cancer
1393447|NCT00409968|BATTLE Program
1393448|NCT00409968|Umbrella Trial
1393449|NCT00409968|Tumor Biopsy
1393450|NCT00409968|NSCLC
1393451|NCT00409955|Lamellar transplant
1393452|NCT00409955|Lyophilization
1393453|NCT00409955|Corneas storage
1393454|NCT00409955|Keratoconus patients
1393455|NCT00409955|Best corrected visual acuity < 20/60
1393456|NCT00409955|Signed the consent inform
1393457|NCT00409942|Chronic heart failure
1393458|NCT00409942|Torasemide prolonged release
1393459|NCT00409942|Myocardial fibrosis
1393460|NCT00409942|Loop diuretics
1393461|NCT00409942|Peptide of procollagen type 1
1393462|NCT00409929|Safety, tolerability, pharmacokinetics, pharmacodynamics, AEB071, healthy subjects, transplantation
1393463|NCT00409916|chronic heart failure
1393464|NCT00409916|heart failure
1393465|NCT00409916|congestive heart failure
1393466|NCT00409916|impedance cardiography
1393467|NCT00409916|ICG
1393468|NCT00409916|transthoracic electrical bioimpedance
1393469|NCT00409916|non-invasive
1393470|NCT00409916|TEB
1393471|NCT00409890|Buscopan
1393472|NCT00409890|Hyoscine
1393473|NCT00409890|Shortens
1393474|NCT00409890|Labor
1393475|NCT00409890|Stage
1393476|NCT00409864|Gallbaldder Cancer
1393477|NCT00409864|Endoscopic stenting
1393478|NCT00409864|Percutaneous biliary drainage
1393479|NCT00409851|HYPERTENSION, VALSARTAN, AMLODIPINE,SAFETY
1393480|NCT00409838|Rheumatoid Arthritis, with inadequate response to methotrexate
1393481|NCT00409799|Bone graft substitute
1393482|NCT00409799|Promotion of bone healing
1393483|NCT00409786|Obesity
1393484|NCT00409786|Diabetes
1393485|NCT00409786|Internet
1393486|NCT00409786|Obesity with high cardiovascular risk
1393487|NCT00409760|HYEPRTENSION, VALSARTAN, AMLODIPINE, high blood pressure
1393488|NCT00409747|Immunology
1393489|NCT00409747|Microglia
1393490|NCT00409747|NF-Kappa-B
1393491|NCT00409747|Antibiotic
1393492|NCT00409747|Autism
1393493|NCT00409747|Minocycline
1393494|NCT00409747|Regressive Autism
1393495|NCT00409734|pyloric
1393496|NCT00409734|stenosis
1393497|NCT00409721|Amyotrophic Lateral Sclerosis
1393498|NCT00409721|ALS
1393499|NCT00409721|Motor Neuron Disease
1393500|NCT00409721|MND
1393501|NCT00409721|Memantine
1393502|NCT00409708|Attention Deficit Hyperactivity Disorder,
1393503|NCT00409708|ADHD
1393504|NCT00409708|Cytogenetic abnormalities,
1393505|NCT00409708|extended-release methylphenidate,
1393506|NCT00409695|Acute Graft versus Host Disease
1393507|NCT00409695|aGVHD
1393508|NCT00409695|Blood And Marrow Transplantation
1393509|NCT00409695|Thymoglobulin
1393510|NCT00409695|ATG
1393511|NCT00409682|Crohn's Disease
1393512|NCT00409669|Barraquer tonometer
1393513|NCT00409669|Intraocular pressure
1393514|NCT00409669|Tonometry
1393515|NCT00409643|HYPERTENSION, VALSARTAN, AMLODIPINE, high blood pressure
1393516|NCT00409630|Asthma
1393517|NCT00409591|Thailand
1393518|NCT00409591|Developing Countries
1393519|NCT00409591|Prophylaxis
1393520|NCT00409591|Mother-to-child transmission
1393521|NCT00409591|HIV-1
1393522|NCT00409591|HIV-1 infection
1393523|NCT00409591|HIV Seronegativity
1393524|NCT00409578|Post acute coronary syndrome
1393525|NCT00409578|Acute
1393526|NCT00409578|coronary syndrome
1393527|NCT00409578|B-type natriuretic peptide
1393528|NCT00409578|N-terminal
1393529|NCT00409578|pro-B-type natriuretic peptide
1393530|NCT00409578|myocardial infarctions
1393531|NCT00409565|head and neck cancer
1393532|NCT00409565|cetuximab
1393533|NCT00409565|bevacizumab
1393534|NCT00409565|squamous cell carcinoma
1393535|NCT00409565|SCCHN
1393536|NCT00409565|Squamous Cell Carcinoma of the Head and Neck
1393537|NCT00409526|Iloprost
1393538|NCT00409526|PPHN
1393539|NCT00409526|Newborn
1393540|NCT00409526|Pulmonary Hypertension
1393541|NCT00409526|Term
1393542|NCT00409526|Persistent Pulmonary Hypertension of the Newborn
1393543|NCT00409500|Safety, tolerability, pharmacokinetics, AQW051, food, Japanese, healthy male subjects
1393544|NCT00409500|Healthy volunteers study
1393545|NCT00409487|obstructive sleep apnea
1393546|NCT00409487|hypertension
1393547|NCT00409487|ambulatory bloop pressure monitoring
1393548|NCT00409448|TBI
1393549|NCT00409448|intracranial edema
1393550|NCT00409448|brain edema
1393551|NCT00409448|craniocerebral trauma
1393552|NCT00409448|head injury
1393553|NCT00409448|brain hemorrhage, traumatic
1393554|NCT00409448|subdural hematoma
1393555|NCT00409448|brain concussion
1393556|NCT00409448|head injuries, closed
1393557|NCT00409448|epidural hematoma
1393558|NCT00409448|extra-axial hemorrhage
1393559|NCT00409448|cortical contusion
1393560|NCT00409435|Postural tachycardia syndrome (POTS)
1393561|NCT00409422|pediatric obesity
1393562|NCT00409422|overweight
1393563|NCT00409422|insulin resistance
1393564|NCT00409422|hyperinsulinemia
1393565|NCT00409422|weight management program
1393566|NCT00409422|family-based
1393567|NCT00409409|Sublingual immunotherapy
1393568|NCT00409409|Grass pollen tablet
1393569|NCT00409409|Allergic rhinoconjunctivitis
1393570|NCT00409396|Ulcerative
1393571|NCT00409396|Colitis
1393572|NCT00409396|PGE-M
1393573|NCT00409396|fecal calprotectin
1393574|NCT00409396|disease biomarkers
1393575|NCT00409383|Advanced Melanoma
1393576|NCT00409383|Normal baseline LDH
1393577|NCT00409383|Chemotherapy naive
1393578|NCT00409357|urinary tract
1393579|NCT00409344|Thoracoabdominal Aortic Aneurysm
1393580|NCT00409344|Dexmedetomidine
1393581|NCT00409344|Mechanical ventilation
1393582|NCT00409331|Head and Neck Cancer
1393583|NCT00409331|HNSCC
1393584|NCT00409331|Submandibular and Sublingual Salivary Sparing
1393585|NCT00409331|Amifostine
1393586|NCT00409331|Ethyol
1393587|NCT00409331|Radiation Therapy
1393588|NCT00409318|Inflammation
1393589|NCT00409318|Visceral adiposity
1393590|NCT00409318|TNF
1393591|NCT00409318|CRP
1393592|NCT00409318|Adiponectin
1393593|NCT00409318|Insulin resistance
1393594|NCT00409318|metabolic syndrome
1393595|NCT00409292|RAD001
1393596|NCT00409292|metastatic pancreatic cancer
1393597|NCT00409279|Aging
1393598|NCT00409279|Parent / Adult-child interaction
1393599|NCT00409279|Family caregivers
1393600|NCT00409279|Alzheimer's
1393601|NCT00409279|Caregiving
1393602|NCT00409253|PRE-ECLAMPSIA-URAPIDIL-NICARDIPINE
1393603|NCT00409240|Group Intervention
1393604|NCT00409240|Pharmacotherapy
1393605|NCT00409240|Behavioral Modification
1393606|NCT00409240|Diabetes
1393607|NCT00409227|swl
1393608|NCT00409227|lithotripsy
1393609|NCT00409227|stone disease
1393610|NCT00409227|urolithiasis
1393611|NCT00409227|nephrolithiasis
1393612|NCT00409214|Glioma
1393613|NCT00409214|Litx™
1393614|NCT00409214|LS11
1393615|NCT00409214|Glioblastoma multiforme
1393616|NCT00409214|Anaplastic Astrocytoma
1393617|NCT00409214|GBM
1393618|NCT00409214|AA
1393619|NCT00409201|schizophrenia
1393620|NCT00409201|reboxetine
1393621|NCT00409201|cognitive
1393622|NCT00409201|behavior
1393623|NCT00409188|Non-Small Cell Lung Carcinoma;
1393624|NCT00409188|stage III;
1393625|NCT00409188|unresectable;
1393626|NCT00409188|vaccine; Tecemotide; L-BLP25;
1393627|NCT00409188|Cyclophosphamide;
1393628|NCT00409188|placebo controlled;
1393629|NCT00409188|randomized;
1393630|NCT00409188|double blind;
1393631|NCT00409188|immunotherapy;
1393632|NCT00409175|FAP
1393633|NCT00409175|Fx-1006A
1393634|NCT00409175|transthyretin
1393635|NCT00409175|TTR
1393636|NCT00409175|amyloid
1393637|NCT00409175|polyneuropathy
1393638|NCT00409175|V30M
1393639|NCT00409175|familial
1393640|NCT00409175|hereditary
1393641|NCT00409175|amyloidosis
1393642|NCT00409175|FoldRx
1393643|NCT00409162|Tattoo removal
1393644|NCT00409149|Hypertension
1393645|NCT00409149|Diet
1393646|NCT00409149|physical exercise
1393647|NCT00409149|naturopathic
1393648|NCT00409149|group therapy
1393649|NCT00409149|Qi Gong
1393650|NCT00409136|Alert
1393651|NCT00409136|Deep Vein Thrombosis
1393652|NCT00409136|Pulmonary Embolism
1393653|NCT00409136|Venous Thromboembolism
1393654|NCT00409136|Prophylaxis
1393655|NCT00409136|Anticoagulation
1393656|NCT00409123|vasospastic women
1393657|NCT00409123|controls
1393658|NCT00409123|core cooling
1393659|NCT00409123|core warming
1393660|NCT00409123|external cooling
1393661|NCT00409123|external warming
1393662|NCT00409123|LDF
1393663|NCT00409123|choroidal blood flow
1393664|NCT00409123|temperature
1393665|NCT00409123|vasospastic subjects
1393666|NCT00409123|normal subjects
1393667|NCT00409110|Ocular Pulse Amplitude
1393668|NCT00409110|Dynamic Contour Tonometry
1393669|NCT00409110|Pulsatility Index
1393670|NCT00409110|Choroidal Laser Doppler Flowmetry
1393671|NCT00409110|Finometer
1393672|NCT00409097|ADMA
1393673|NCT00409097|MOF
1393674|NCT00409097|Critical illness
1393675|NCT00409084|varices
1393676|NCT00409084|band ligation
1393677|NCT00409084|portal hypertension
1393678|NCT00409084|primary prophylaxis
1393679|NCT00409084|cirrhosis
1393680|NCT00409084|beta blockers
1393681|NCT00409071|Non metastatic breast cancer
1393682|NCT00409071|Adjuvant chemotherapy
1393683|NCT00409071|Nausea
1393684|NCT00409071|Vomiting
1393685|NCT00409071|Quality of life
1393686|NCT00409071|Homeopathy
1393687|NCT00409058|TBI (Traumatic Brain Injury)
1393688|NCT00409058|Intracranial Edema
1393689|NCT00409058|Brain Edema
1393690|NCT00409058|Craniocerebral Trauma
1393691|NCT00409058|Head Injury
1393692|NCT00409058|Brain Hemorrhage, Traumatic
1393693|NCT00409058|Subdural Hematoma
1393694|NCT00409058|Brain Concussion
1393695|NCT00409058|Head Injuries, Closed
1393696|NCT00409045|Obstructive Sleep Apnea
1393697|NCT00409045|Pulmonary Embolism
1393698|NCT00409045|male and female patients suspected of having a pulmonary embolism.
1393699|NCT00409032|osteoporosis
1393700|NCT00409032|BMD
1393701|NCT00409032|CTX
1393702|NCT00409032|Post menopausal
1393703|NCT00409032|strontium
1393704|NCT00409032|bone turnover
1393705|NCT00409032|clinical development
1393706|NCT00408980|diet
1393707|NCT00408980|breast milk fat
1393708|NCT00408967|Ovarian
1393709|NCT00408967|Cancer
1393710|NCT00408967|Epithelial
1393711|NCT00408967|Recurrent
1393712|NCT00408967|Platinum
1393713|NCT00408967|Second-line therapy
1393714|NCT00408967|Maintenance Therapy
1393715|NCT00408967|Biologic
1393716|NCT00408967|Targeted Therapy
1393717|NCT00408967|Antibody
1393718|NCT00408941|EEG
1393719|NCT00408941|AEP
1393720|NCT00408941|Artefacts
1393721|NCT00408941|Propofol
1393722|NCT00408941|Local Anaesthesia
1393723|NCT00408928|Graft-versus-Host Disease
1393724|NCT00408928|bortezomib
1393725|NCT00408915|Lisuride
1393726|NCT00408915|Continuous Dopaminergic Stimulation
1393727|NCT00408915|Motor Fluctuations
1393728|NCT00408915|Off-Times
1393729|NCT00408915|Troublesome Dyskinesia
1393730|NCT00408915|Parkinson's Disease with motor fluctuations with OFF periods and/or troublesome dyskinesias of more than four hours per day
1393731|NCT00408889|liver transplantation
1393732|NCT00408889|organ failure
1393733|NCT00408889|outcome
1393734|NCT00408863|Breast cancer
1393735|NCT00408863|Tibolone
1393736|NCT00408863|Climacteric symptoms
1393737|NCT00408850|sympathetic nervous system, pioglitazone, metabolic syndrome
1393738|NCT00408824|insulin resistance
1393739|NCT00408824|adipocytokine
1393740|NCT00408824|Metabolic syndrome
1393741|NCT00408824|Diabetes
1393742|NCT00408798|Treatment of Alopecia areata with intracutaneous injections of Botulinum Toxin A
1393743|NCT00408785|Botulinum Toxin Type A
1393744|NCT00408785|safety
1393745|NCT00408785|efficacy
1393746|NCT00408785|glabellar lines
1393747|NCT00408772|liver metastases
1393748|NCT00408772|stage IV colon cancer
1393749|NCT00408772|stage IV rectal cancer
1393750|NCT00408772|adenocarcinoma of the colon
1393751|NCT00408772|adenocarcinoma of the rectum
1393752|NCT00408772|recurrent colon cancer
1393753|NCT00408772|recurrent rectal cancer
1393754|NCT00408759|xerostomia
1393755|NCT00408759|hypnosis
1393756|NCT00408759|dry mouth
1393757|NCT00408759|radiotherapy
1393758|NCT00408759|head and neck cancer
1393759|NCT00408746|stomatognathic system
1393760|NCT00408746|maxilla
1393761|NCT00408746|palate
1393762|NCT00408746|development
1393763|NCT00408720|Spectral OCT
1393764|NCT00408720|SLO
1393765|NCT00408720|Retinal Imagining
1393766|NCT00408707|local infiltration analgesia
1393767|NCT00408707|postoperative pain
1393768|NCT00408707|ropivacaine
1393769|NCT00408668|Malaria Vaccine
1393770|NCT00408642|adherence
1393771|NCT00408642|treatment
1393772|NCT00408642|antiretroviral
1393773|NCT00408642|HAART
1393774|NCT00408642|HIV
1393775|NCT00408642|Treatment Naive
1393776|NCT00408629|Ulcerative Colitis
1393777|NCT00408629|Adalimumab
1393778|NCT00408629|TNF Antagonist
1393779|NCT00408629|Mayo Score
1393780|NCT00408603|second line treatment
1393781|NCT00408603|platinum resistant
1393782|NCT00408603|ovary
1393783|NCT00408603|ovaries
1393784|NCT00408603|cancer
1393785|NCT00408603|epithelial
1393786|NCT00408603|carcinomas
1393787|NCT00408603|tumor
1393788|NCT00408590|ovarian clear cell cystadenocarcinoma
1393789|NCT00408590|ovarian endometrioid adenocarcinoma
1393790|NCT00408590|primary peritoneal cavity cancer
1393791|NCT00408590|ovarian mixed epithelial carcinoma
1393792|NCT00408590|ovarian mucinous cystadenocarcinoma
1393793|NCT00408590|ovarian serous cystadenocarcinoma
1393794|NCT00408590|ovarian undifferentiated adenocarcinoma
1393795|NCT00408590|recurrent ovarian epithelial cancer
1393796|NCT00408590|Brenner tumor
1393797|NCT00408577|glucose intolerance
1393798|NCT00408577|cardiovascular disease
1393799|NCT00408577|insulin resistance
1393800|NCT00408577|endothelial dysfunction
1393801|NCT00408564|adenocarcinoma of the pancreas
1393802|NCT00408564|stage II pancreatic cancer
1393803|NCT00408564|stage III pancreatic cancer
1393804|NCT00408551|stage IV colon cancer
1393805|NCT00408551|stage IV rectal cancer
1393806|NCT00408551|liver metastases
1393807|NCT00408551|recurrent colon cancer
1393808|NCT00408551|recurrent rectal cancer
1393809|NCT00408538|Microbicide
1393810|NCT00408538|HIV
1393811|NCT00408538|Prevention
1393812|NCT00408538|Rectal
1393813|NCT00408538|HIV Prevention
1393814|NCT00408525|memory loss
1393815|NCT00408525|memory problems
1393816|NCT00408525|alzheimer's
1393817|NCT00408525|forgetfulness
1393818|NCT00408525|forgetting
1393819|NCT00408512|treatment
1393820|NCT00408512|adverse events
1393821|NCT00408512|adherence
1393822|NCT00408512|gene
1393823|NCT00408512|polymorphism
1393824|NCT00408499|unspecified adult solid tumor, protocol specific
1393825|NCT00408499|stage IIIA non-small cell lung cancer
1393826|NCT00408499|stage IIIB non-small cell lung cancer
1393827|NCT00408499|stage IV non-small cell lung cancer
1393828|NCT00408499|recurrent non-small cell lung cancer
1393829|NCT00408447|stem cell transplant
1393830|NCT00408447|sickle cell disease
1393831|NCT00408447|thalassemia
1393832|NCT00408447|moderately ablative
1393833|NCT00408447|cord blood transplant
1393834|NCT00408447|matched family donor
1393835|NCT00408434|PPARgamma agonist
1393836|NCT00408434|advanced or metastatic malignancies
1393837|NCT00408434|Tumor
1393838|NCT00408434|Cancer
1393839|NCT00408408|stage I breast cancer
1393840|NCT00408408|stage II breast cancer
1393841|NCT00408408|stage IIIA breast cancer
1393842|NCT00408395|influenza
1393843|NCT00408395|children
1393844|NCT00408395|vaccine
1393845|NCT00408395|influenza disease
1393846|NCT00408382|Lipitor
1393847|NCT00408382|atorvastatin
1393848|NCT00408382|Hypercholesteremia
1393849|NCT00408382|yellow coronary plaque
1393850|NCT00408369|prophylactic
1393851|NCT00408369|malaria
1393852|NCT00408369|challenge
1393853|NCT00408356|Zinc treatment
1393854|NCT00408356|supplementation
1393855|NCT00408356|Enterotoxigenic E. coli
1393856|NCT00408356|diarrhoea
1393857|NCT00408317|Cystic Fibrosis
1393858|NCT00408317|Exocrine Pancreatic Insufficiency
1393859|NCT00408317|Ultrase® MT20
1393860|NCT00408304|interferon alpha
1393861|NCT00408304|depression
1393862|NCT00408304|omega 3
1393863|NCT00408291|fracture
1393864|NCT00408291|shoulder
1393865|NCT00408291|bone density
1393866|NCT00408291|healing
1393867|NCT00408278|Acute Promyelocytic Leukemia
1393868|NCT00408265|Nicotine Dependence
1393869|NCT00408265|Contingency Management
1393870|NCT00408252|recurrent or locally advanced
1393871|NCT00408252|cytokine failure
1393872|NCT00408239|Factor Xa inhibitor
1393873|NCT00408239|Thromboembolism
1393874|NCT00408239|Arthroplasty
1393875|NCT00408239|Knee Replacement
1393876|NCT00408239|Prevention and Control
1393877|NCT00408200|Atrial fibrillation
1393878|NCT00408200|Atrial arrhythmia
1393879|NCT00408187|Randomized Controlled Trials
1393880|NCT00408187|Immunosuppression
1393881|NCT00408187|Adult
1393882|NCT00408187|Chronic Disease
1393883|NCT00408187|Dermatologic Agents
1393884|NCT00408187|Female
1393885|NCT00408187|Humans
1393886|NCT00408187|Male
1393887|NCT00408187|Middle Aged
1393888|NCT00408187|Severity of Illness Index
1393889|NCT00408187|Treatment Outcome
1393890|NCT00408187|Quality of Life
1393891|NCT00408187|Double-Blind Method
1393892|NCT00408174|IBD
1393893|NCT00408174|UC
1393894|NCT00408174|Ulcerative Colitis
1393895|NCT00408174|Inflammatory Bowel Disease
1393896|NCT00408161|Contingency Management
1393897|NCT00408161|Alcohol Dependence
1393898|NCT00408135|Respiratory Tract Infections
1393899|NCT00408135|Skin Diseases
1393900|NCT00408135|Sinusitis
1393901|NCT00408109|Avian Influenza
1393902|NCT00408109|Healthy
1393903|NCT00408109|Immunity
1393904|NCT00408109|Preventive
1393905|NCT00408109|Bird Flu
1393906|NCT00408109|Healthy Volunteer
1393907|NCT00408109|HV
1393908|NCT00408096|osteoarthritis
1393909|NCT00408096|shoulder
1393910|NCT00408096|resurfacing
1393911|NCT00408096|prosthesis
1393912|NCT00408070|ovarian cancer
1393913|NCT00408070|fallopian tube cancer
1393914|NCT00408070|peritoneal cancer
1393915|NCT00408057|lipid lowering
1393916|NCT00408057|target achievement
1393917|NCT00408057|Patients with established cardiovascular disease
1393918|NCT00408031|Major depressive disorder
1393919|NCT00408031|NMDA receptor
1393920|NCT00408031|Treatment-Resistant
1393921|NCT00408031|D-cycloserine
1393922|NCT00407992|Headache
1393923|NCT00407992|Migraine
1393924|NCT00407940|Thrombosis
1393925|NCT00407940|Claudication
1393926|NCT00407914|wrinkles
1393927|NCT00407914|soft tissue filler
1393928|NCT00407914|Aquamid
1393929|NCT00407901|Visually Challenged
1393930|NCT00407901|Legally Blind
1393931|NCT00407901|Functional Assessment Questionnaire
1393932|NCT00407901|Low Functioning
1393933|NCT00407901|High Functioning
1393934|NCT00407875|Prostate
1393935|NCT00407875|Cancer
1393936|NCT00407875|Radiation
1393937|NCT00407862|insulin resistance
1393938|NCT00407862|beta cell function
1393939|NCT00407862|endothelial dysfunction
1393940|NCT00407836|HIV
1393941|NCT00407836|CD4 T cell level
1393942|NCT00407836|CD4 autoimmunity
1393943|NCT00407836|Viral load
1393944|NCT00407836|T cell vaccination
1393945|NCT00407836|HIV Therapeutic Vaccine
1393946|NCT00407823|Child
1393947|NCT00407823|Septic shock
1393948|NCT00407823|Resuscitation
1393949|NCT00407823|Central venous oxygen saturation
1393950|NCT00407823|Cardiac output
1393951|NCT00407823|Goal-directed therapy
1393952|NCT00407797|Lyrica
1393953|NCT00407797|Epilepsies - Partial
1393954|NCT00407784|primary aldosteronism
1393955|NCT00407784|hypertension
1393956|NCT00407784|aldosteron-renin ratio
1393957|NCT00407784|eplerenone
1393958|NCT00407784|aldosteron-receptor antagonist
1393959|NCT00407784|screening
1393960|NCT00407771|platelet function assay
1393961|NCT00407771|Glycoprotein inhibitors
1393962|NCT00407771|percutaneous coronary intervention
1393963|NCT00407771|Diabetes Mellitus
1393964|NCT00407758|recurrent ovarian epithelial cancer
1393965|NCT00407758|primary peritoneal cavity cancer
1393966|NCT00407745|Pain
1393967|NCT00407745|central neuropathic pain
1393968|NCT00407732|hepatitis C
1393969|NCT00407732|mental disorder
1393970|NCT00407732|substance use
1393971|NCT00407732|psychosocial intervention
1393972|NCT00407719|Choroidal Neovascularization
1393973|NCT00407706|Breast Cancer, FACS, SCM, Malignant, Benign, Lymphocytes
1393974|NCT00407693|Dosimetry
1393975|NCT00407693|Effective Dose
1393976|NCT00407693|Radiation-Absorbed Dose
1393977|NCT00407680|Type 2 diabetes mellitus
1393978|NCT00407680|Hypertension
1393979|NCT00407680|Angiotensin II Receptor Blocker
1393980|NCT00407680|Diabetic nephropathy
1393981|NCT00407667|hemiparesis
1393982|NCT00407667|rehabilitation
1393983|NCT00407667|upper limb rehabilitation
1393984|NCT00407667|arm therapy
1393985|NCT00407641|diabetes mellitus
1393986|NCT00407641|chronic hemodialysis
1393987|NCT00407641|anticoagulation
1393988|NCT00407641|outcome
1393989|NCT00407628|Stroke
1393990|NCT00407628|Diffusion spectrum tractography
1393991|NCT00407628|Functional MRI (fMRI)
1393992|NCT00407628|Lower extremity
1393993|NCT00407602|retinitis pigmentosa
1393994|NCT00407602|device
1393995|NCT00407602|retinal implant
1393996|NCT00407602|retinal prosthesis
1393997|NCT00407602|RP
1393998|NCT00407602|outer retinal degeneration
1393999|NCT00407576|Alzheimer's Disease
1394000|NCT00407576|Positron Emission Tomography
1394001|NCT00407576|Brain
1394002|NCT00407576|Neurochemistry
1394003|NCT00407576|Beta-Amyloid Plaques
1394004|NCT00407576|PET
1394005|NCT00407576|MeS-IMPY
1394006|NCT00407576|Alzheimer Disease
1394007|NCT00407576|AD
1394008|NCT00407576|Dementia
1394009|NCT00407576|Healthy Volunteer
1394010|NCT00407576|HV
1394011|NCT00407550|stage IIIB non-small cell lung cancer
1394012|NCT00407550|stage IV non-small cell lung cancer
1394013|NCT00407550|recurrent non-small cell lung cancer
1394014|NCT00407498|P 276-00
1394015|NCT00407498|Advanced Refractory Neoplasm
1394016|NCT00407498|Maximum Tolerated Dose
1394017|NCT00407498|Dose Limiting Toxicity
1394018|NCT00407498|Pharmacokinetics
1394019|NCT00407472|Bio-equivalence study in healthy volunteers, indication
1394020|NCT00407472|of product is growth hormone deficiency
1394021|NCT00407446|PDE5 inhibition
1394022|NCT00407446|chronic heart failure
1394023|NCT00407446|endothelial function
1394024|NCT00407446|exercise ventilation
1394025|NCT00407433|Gemcitabine
1394026|NCT00407433|Oxaliplatine
1394027|NCT00407433|Paediatric solid tumors
1394028|NCT00407433|Other CNS tumors
1394029|NCT00407433|Other miscellaneous solid non-CNS tumours
1394030|NCT00407420|Childhood
1394031|NCT00407420|Obesity
1394032|NCT00407420|Behavior modification
1394033|NCT00407420|Insulin resistance
1394034|NCT00407407|Epithelial ovarian
1394035|NCT00407407|Primary peritoneal or fallopian tube carcinoma
1394036|NCT00407407|Abraxane
1394037|NCT00407407|Carboplatin
1394038|NCT00407394|Pneumonia
1394039|NCT00407394|Wheezing
1394040|NCT00407394|Treatment
1394041|NCT00407394|Children
1394042|NCT00407394|India
1394043|NCT00407381|DME
1394044|NCT00407355|vein occlusion
1394045|NCT00407355|macular edema
1394046|NCT00407342|Psoriasis
1394047|NCT00407342|biologics
1394048|NCT00407342|alefacept
1394049|NCT00407342|Narrowband UVB
1394050|NCT00407342|Phototherapy
1394051|NCT00407342|Half-side comparison
1394052|NCT00407329|BPH
1394053|NCT00407316|Uveitis
1394054|NCT00407316|Quality of life
1394055|NCT00407316|Visual function
1394056|NCT00407290|pregnancy
1394057|NCT00407290|vaginal delivery
1394058|NCT00407277|nicotine dependence
1394059|NCT00407277|smoking
1394060|NCT00407277|nicotine patch
1394061|NCT00407277|double-blind
1394062|NCT00407277|randomized
1394063|NCT00407277|placebo
1394064|NCT00407277|psychosis
1394065|NCT00407277|schizophrenia
1394066|NCT00407277|schizophreniform
1394067|NCT00407277|schizoaffective disorder
1394068|NCT00407264|bronchial squamous metaplasia
1394069|NCT00407264|bronchial squamous dysplasia
1394070|NCT00407251|refractory
1394071|NCT00407251|prostate
1394072|NCT00407251|hormone
1394073|NCT00407238|barrier function, multi-purpose solutions, silicone hydrogel contact lenses
1394074|NCT00407212|early stage idiopathic Parkinson's disease
1394075|NCT00407199|social phobia, anxiety, quetiapine
1394076|NCT00407186|CRITICS
1394077|NCT00407186|gastric cancer
1394078|NCT00407186|surgery
1394079|NCT00407186|adjuvant
1394080|NCT00407186|chemotherapy
1394081|NCT00407186|chemoradiotherapy
1394082|NCT00407186|capecitabine
1394083|NCT00407186|cisplatin
1394084|NCT00407186|epirubicin
1394085|NCT00407160|Kidney transplant
1394086|NCT00407160|Tolerance induction
1394087|NCT00407160|High PRA kidney recipients
1394088|NCT00407147|bacterial infection
1394089|NCT00407147|empiric antibiotic treatment
1394090|NCT00407147|duration antibiotic treatment
1394091|NCT00407147|reduce antibiotic treatment
1394092|NCT00407147|procalcitonin
1394093|NCT00407147|PCT Kryptor
1394094|NCT00407147|sepsis
1394095|NCT00407147|Intensive Care Unit
1394096|NCT00407147|antibiotic treatment
1394097|NCT00407121|Neovascular Membrane
1394098|NCT00407121|Uveitis
1394099|NCT00407121|Bevacizumab
1394100|NCT00407108|vitreoretinal surgery
1394101|NCT00407095|Parkinson Disease
1394102|NCT00407043|Dry Eye Disease
1394103|NCT00407043|Lotemax
1394104|NCT00407043|Restasis
1394105|NCT00407043|Loteprednol
1394106|NCT00407043|Cyclosporine
1394107|NCT00407004|acute-on-chronic liver failure, MARS, Prometheus, bilirubin, bile acids, cytokines
1394108|NCT00406991|retinal blood flow
1394109|NCT00406991|diabetic retinopathy
1394110|NCT00406991|microthrombosis
1394111|NCT00406991|aspirin
1394112|NCT00406991|clopidogrel
1394113|NCT00406978|MYELOMA
1394114|NCT00406978|THALIDOMIDE
1394115|NCT00406978|DEFIBRODITE
1394116|NCT00406939|Gene Therapy
1394117|NCT00406939|Immunology
1394118|NCT00406939|Phase I Clinical Trial
1394119|NCT00406900|uveal melanoma
1394120|NCT00406900|metastatic disease
1394121|NCT00406874|infertility
1394122|NCT00406874|semen quality
1394123|NCT00406874|sexual function
1394124|NCT00406874|blood pressure
1394125|NCT00406874|omega 3 fats
1394126|NCT00406874|folic acid
1394127|NCT00406861|reaction
1394128|NCT00406861|ENL
1394129|NCT00406861|leprosy
1394130|NCT00406835|Whole Brain Radiation Therapy
1394131|NCT00406835|Stereotactic Radiosurgery
1394132|NCT00406835|Brain metastases
1394133|NCT00406822|Glaucoma
1394134|NCT00406822|collagen matrix
1394135|NCT00406822|OculusGen
1394136|NCT00406822|trabeculectomy
1394137|NCT00406822|tissue engineering
1394138|NCT00406809|Sezary syndrome
1394139|NCT00406809|cutaneous T-cell lymphoma
1394140|NCT00406809|follicular lymphoma
1394141|NCT00406809|marginal zone lymphoma
1394142|NCT00406809|indolent T-cell lymphoma
1394143|NCT00406809|Navitoclax
1394144|NCT00406809|Non-Hodgkin's lymphoma
1394145|NCT00406809|peripheral T-cell lymphoma
1394146|NCT00406809|ABT-263
1394147|NCT00406809|lymphoid malignancies
1394148|NCT00406809|chronic lymphoid leukemia
1394149|NCT00406809|mycosis fungoides
1394150|NCT00406809|mantle cell lymphoma
1394151|NCT00406783|Allergic Rhinitis
1394152|NCT00406783|Intermittent Allergic Rhinitis
1394153|NCT00406770|Obesity
1394154|NCT00406770|Light therapy
1394155|NCT00406770|Hypocaloric diet
1394156|NCT00406757|T-cell
1394157|NCT00406757|T-ALL
1394158|NCT00406757|T-LBL
1394159|NCT00406757|506U78
1394160|NCT00406757|ara-G
1394161|NCT00406757|ara-GTP
1394162|NCT00406757|Lymphoma
1394163|NCT00406757|Leukemia
1394164|NCT00406744|neovascularization
1394165|NCT00406731|Endothelin-1
1394166|NCT00406731|L-NG-Monomethyl Arginine
1394167|NCT00406731|Optic Nerve Head blood flow
1394168|NCT00406718|Medication Adherence
1394169|NCT00406718|Psychosocial Treatment
1394170|NCT00406718|Cognitive Adaptation Training
1394171|NCT00406718|Med-e Monitor
1394172|NCT00406718|Adaptive Function
1394173|NCT00406705|Exercise Tolerance
1394174|NCT00406705|Dyspnea
1394175|NCT00406705|Rehabilitation
1394176|NCT00406705|Helium
1394177|NCT00406692|Zonisamide
1394178|NCT00406692|Alcoholism
1394179|NCT00406692|Alcohol
1394180|NCT00406679|pain, postoperative
1394181|NCT00406679|surgery, oral
1394182|NCT00406679|surgery, dental
1394183|NCT00406640|MDD
1394184|NCT00406640|Major Depressive Disorder
1394185|NCT00406640|Depression
1394186|NCT00406627|filariasis, lymphatic filariasis, Egypt
1394187|NCT00406614|High Blood Pressure
1394188|NCT00406588|Parkinson Disease
1394189|NCT00406575|Congestive heart failure
1394190|NCT00406575|Relaxin
1394191|NCT00406575|Hemodynamics
1394192|NCT00406575|Renal function
1394193|NCT00406562|uncontrolled
1394194|NCT00406549|Staphylococcus aureus
1394195|NCT00406549|Nasal colonization
1394196|NCT00406549|pre-surgical patients
1394197|NCT00406549|Sensitivity
1394198|NCT00406549|Specificity
1394199|NCT00406549|Nasal Staphylococcus aureus in pre-surgical patients
1394200|NCT00406536|Cystic Fibrosis
1394201|NCT00406536|Pancreatic Insufficiency
1394202|NCT00406536|LYM-X-SORB™
1394203|NCT00406536|LXS
1394204|NCT00406484|Methadone
1394205|NCT00406484|Counseling
1394206|NCT00406484|HIV risk reduction
1394207|NCT00406484|HIV Seronegativity
1394208|NCT00406471|Ischemic
1394209|NCT00406471|Central
1394210|NCT00406471|Retinal
1394211|NCT00406471|Vein
1394212|NCT00406471|Occlusion
1394213|NCT00406471|Ranibizumab
1394214|NCT00406471|Lucentis
1394215|NCT00406471|CRVO
1394216|NCT00406471|ISCRVO
1394217|NCT00406458|Diabetic neuropathy
1394218|NCT00406458|Diabetes Type I or II
1394219|NCT00406458|Mild to moderate sensorimotor diabetic polyneuropathy
1394220|NCT00406445|Metabolism
1394221|NCT00406445|Li-Fraumeni Syndrome
1394222|NCT00406432|BRL029060/Paroxetine CR
1394223|NCT00406432|pharmacokinetics
1394224|NCT00406432|repeat dose
1394225|NCT00406419|anti-CD20
1394226|NCT00406419|stage
1394227|NCT00406419|CD20
1394228|NCT00406419|RA
1394229|NCT00406393|Acute Myelogenous Leukemia
1394230|NCT00406393|Acute Lymphoblastic Leukemia
1394231|NCT00406393|Chronic Myelogenous Leukemia
1394232|NCT00406380|Telangiectasias
1394233|NCT00406380|Leakage
1394234|NCT00406380|Bevacizumab
1394235|NCT00406380|Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)
1394236|NCT00406380|Idiopathic juxtafoveal retinal telangiectasias
1394237|NCT00406315|ziprasidone, quetiapine (Seroquel) switch, open label, flexible dose, schizophrenia, schizoaffective disorder
1394238|NCT00406302|NSCLC
1394239|NCT00406302|non-small-cell lung cancer
1394240|NCT00406276|Lung Cancer
1394241|NCT00406263|nuclear sclerotic cataract
1394242|NCT00406263|cataract
1394243|NCT00406211|Rubella
1394244|NCT00406211|Varicella
1394245|NCT00406211|Measles
1394246|NCT00406211|Mumps
1394247|NCT00406211|Germany
1394248|NCT00406211|Austria
1394249|NCT00406198|Sepsis syndrom
1394250|NCT00406198|severe sepsis
1394251|NCT00406198|septic shock
1394252|NCT00406198|hemofiltration
1394253|NCT00406198|multiple organ failure
1394254|NCT00406185|Registry
1394255|NCT00406185|cardiac catheterization laboratory
1394256|NCT00406185|coronary heart disease
1394257|NCT00406185|cardiovascular disease
1394258|NCT00405184|PID
1394259|NCT00405184|IVIg
1394260|NCT00405184|IntragamP
1394261|NCT00405171|Efavirenz
1394262|NCT00405171|Nevirapine
1394263|NCT00405171|Dyslipidemia
1394264|NCT00405171|HIV
1394265|NCT00405158|Lactation mastitis
1394266|NCT00405158|Breast inflammation
1394267|NCT00405158|Breastfeeding
1394268|NCT00405158|Care interventions
1394269|NCT00405158|Acupuncture treatment
1394270|NCT00405158|Antibiotic therapy
1394271|NCT00405145|Epilepsy
1394272|NCT00405145|MRI
1394273|NCT00405145|EEG
1394274|NCT00405145|Neuroimaging
1394275|NCT00405119|tolerance
1394276|NCT00405119|pharmacodynamics
1394277|NCT00405119|ranitidine
1394278|NCT00405119|esomeprazole
1394279|NCT00405119|pharmacokinetics
1394280|NCT00405119|gastroesophageal reflux disease (GERD)
1394281|NCT00405119|AH23844
1394282|NCT00405106|stress
1394283|NCT00405106|anxiety
1394284|NCT00405106|myopia progression
1394285|NCT00405106|accommodation
1394286|NCT00405106|vergence
1394287|NCT00405093|cardiopulmonary bypass
1394288|NCT00405093|circulatory arrest
1394289|NCT00405093|aprotinin
1394290|NCT00405093|thoracic aorta surgery
1394291|NCT00405080|Rifampin GW679769
1394292|NCT00405067|Cholesterol
1394293|NCT00406159|Autism
1394294|NCT00406159|Hyperbaric Oxygen Therapy
1394295|NCT00406159|Behavioral assessments
1394296|NCT00406120|eye
1394297|NCT00406120|uvea
1394298|NCT00406120|iris
1394299|NCT00406120|choroid
1394300|NCT00406120|ciliary body
1394301|NCT00406120|melanoma
1394302|NCT00406120|iris melanoma
1394303|NCT00406120|choroidal melanoma
1394304|NCT00406120|ciliary body melanoma
1394305|NCT00406120|uveal melanoma
1394306|NCT00406120|posterior uveal melanoma
1394307|NCT00406120|prognosis
1394308|NCT00406120|metastasis
1394309|NCT00406120|genetic testing
1394310|NCT00406120|molecular testing
1394311|NCT00406120|gene expression profiling
1394312|NCT00406107|branch retinal vein occlusion
1394313|NCT00406107|macular edema
1394314|NCT00406107|pegaptanib sodium
1394315|NCT00406107|vascular endothelial growth factor
1394316|NCT00406094|NARES
1394317|NCT00406094|eosinophils
1394318|NCT00406094|nasal symptoms
1394319|NCT00406068|Bladder neoplasm
1394320|NCT00406068|Intravesical drug administration
1394321|NCT00406068|Neoplasm recurrence, local
1394322|NCT00406068|Transitional cell, carcinoma
1394323|NCT00406068|Carcinoma in situ
1394324|NCT00406068|Mycobacterium
1394325|NCT00406042|glaucoma
1394326|NCT00406042|trabeculoplasty
1394327|NCT00406042|steroids
1394328|NCT00406016|Acute spinal cord injury;
1394329|NCT00406003|BRL029060/Paroxetine CR
1394330|NCT00406003|pharmacokinetics
1394331|NCT00406003|safety
1394332|NCT00405990|HIV
1394333|NCT00405990|MTCT
1394334|NCT00405990|heterosexual behaviour
1394335|NCT00405990|sexual risk behaviour
1394336|NCT00405990|couple counselling
1394337|NCT00405990|Voluntary counselling and testing
1394338|NCT00405990|HIV Seronegativity
1394339|NCT00405977|Neuromuscular block
1394340|NCT00405977|Magnesium
1394341|NCT00405977|Rocuronium
1394342|NCT00405977|Time course of action
1394343|NCT00405938|Breast cancer
1394344|NCT00405938|Metastatic breast cancer
1394345|NCT00405938|Bevacizumab
1394346|NCT00405938|Anastrozole
1394347|NCT00405938|Fulvestrant
1394348|NCT00405925|AIDS
1394349|NCT00405925|Treatment Naive
1394350|NCT00405899|Allergy
1394351|NCT00405899|Seasonal Allergic Rhinitis
1394352|NCT00405899|Perennial Allergic Rhinitis
1394353|NCT00405873|Primary hepatocellular carcinoma
1394354|NCT00405873|Liver cancer
1394355|NCT00405873|Tumour response
1394356|NCT00405873|Quality of life
1394357|NCT00405847|Sleep
1394358|NCT00405847|Critical illness
1394359|NCT00405847|Cytokine
1394360|NCT00405834|Pressure Ulcers
1394361|NCT00405821|AIDS
1394362|NCT00405821|HIV Disease Progression
1394363|NCT00405821|Quality of Life
1394364|NCT00405821|HIV Viral Load
1394365|NCT00405821|Genital Ulcers
1394366|NCT00405821|HIV
1394367|NCT00405821|Treatment Naive
1394368|NCT00405795|Pressure Ulcer
1394369|NCT00405782|metastatic breast cancer
1394370|NCT00405782|exercise intervention
1394371|NCT00405769|statin intolerance
1394372|NCT00405769|hyperlipidemia
1394373|NCT00405769|lifestyle changes
1394374|NCT00405769|red yeast rice
1394375|NCT00405756|Newly Diagnosed Multiple Myeloma
1394376|NCT00405756|Celgene
1394377|NCT00405756|CC-5013
1394378|NCT00405756|Revlimid
1394379|NCT00405756|Lenalidomide
1394380|NCT00405756|Melphalan
1394381|NCT00405756|Prednisone
1394382|NCT00405756|Elderly
1394383|NCT00405743|CP-4055
1394384|NCT00405743|ELACYT™
1394385|NCT00405743|Cancer
1394386|NCT00405743|Refractory
1394387|NCT00405743|Relapsed
1394388|NCT00405743|Hematologic Malignancies
1394389|NCT00405743|Leukemia
1394390|NCT00405743|ALL
1394391|NCT00405743|AML
1394392|NCT00405743|AMM
1394393|NCT00405743|CLL
1394394|NCT00405743|CML
1394395|NCT00405743|CMML
1394396|NCT00405743|MDS
1394397|NCT00405730|Cataracts
1394398|NCT00405717|ischemic heart disease
1394399|NCT00405717|acute coronary syndromes
1394400|NCT00405717|percutaneous transluminal coronary angioplasty
1394401|NCT00405717|statin
1394402|NCT00405717|clopidogrel
1394403|NCT00405704|Vesicoureteral Reflux
1394404|NCT00405704|Urinary Tract Infections
1394405|NCT00405704|Renal Scarring
1394406|NCT00405704|Antibiotic Resistance
1394407|NCT00405704|Controlled Clinical Trial
1394408|NCT00405704|Trimethoprim-Sulfamethoxazole
1394409|NCT00405704|Children
1394410|NCT00405691|Medical Device
1394411|NCT00405691|Spine
1394412|NCT00405691|Lumbar Spinal Stenosis
1394413|NCT00405691|Degenerative Spondylolisthesis
1394414|NCT00405691|Facet Arthrosis
1394415|NCT00405691|Back and Leg Pain
1394416|NCT00405691|Spine Research
1394417|NCT00405691|Medical Device Research
1394418|NCT00405691|Impliant
1394419|NCT00405691|Lumbar Treatment
1394420|NCT00405691|Spinal Treatment
1394421|NCT00405691|Spinal Device
1394422|NCT00405678|Exercise Intervention
1394423|NCT00405678|Breast Cancer
1394424|NCT00405678|Neo-Adjuvant Therapy
1394425|NCT00405678|Operable Breast Cancer Stage I-II receiving neo-adjuvant chemotherapy
1394426|NCT00405665|Cystic Fibrosis
1394427|NCT00405665|L-Arginine
1394428|NCT00405665|Pediatrics
1394429|NCT00405665|pulmonary function
1394430|NCT00405652|Liver transplantation, mycophenolate, GI problems, Quality of Life
1394431|NCT00405626|post partum hemmorhage,Arnica montana,Bellis Perenis
1394432|NCT00405613|Aspirin
1394433|NCT00405613|Bleeding
1394434|NCT00405613|Clinical Trial
1394435|NCT00405613|Dental Extraction
1394436|NCT00405600|Lumbar degenerative disease
1394437|NCT00405600|spinal stenosis
1394438|NCT00405600|spondylolisthesis
1394439|NCT00405600|non instrumented surgery
1394440|NCT00405600|instrumented surgery
1394441|NCT00405600|BMP-2
1394442|NCT00405574|prostate
1394443|NCT00405574|PSA
1394444|NCT00405574|antiangiogenic
1394445|NCT00405574|copper
1394446|NCT00405574|ATN-224
1394447|NCT00405561|Advanced Colorectal Carcinoma
1394448|NCT00405535|OCD
1394449|NCT00405535|Obsessive Compulsive Disorder
1394450|NCT00405535|Glycine
1394451|NCT00405522|Lumbar Puncture
1394452|NCT00405522|Pediatrics
1394453|NCT00405522|Propofol
1394454|NCT00405522|Remifentanil
1394455|NCT00405522|sedation
1394456|NCT00405522|Oncology
1394457|NCT00405509|Upper Respiratory Infection
1394458|NCT00405509|Common Cold
1394459|NCT00405483|arthroplasty
1394460|NCT00405483|RSA
1394461|NCT00405483|micromotion
1394462|NCT00405483|osteoarthritis
1394463|NCT00405483|minimally invasive
1394464|NCT00405483|ProfemurZ
1394465|NCT00405470|arthroplasty
1394466|NCT00405470|RSA
1394467|NCT00405470|micromotion
1394468|NCT00405470|osteoarthritis
1394469|NCT00405444|Pediatrics
1394470|NCT00405444|Pain
1394471|NCT00405444|Voiding Cystourethrogram
1394472|NCT00405444|Catheterization
1394473|NCT00405444|Fentanyl
1394474|NCT00405431|glaucoma filtering surgery
1394475|NCT00405431|restasis
1394476|NCT00405431|conjunctival inflammation
1394477|NCT00405405|Head and neck cancer
1394478|NCT00405405|Parotid gland cancer
1394479|NCT00405405|thyroid gland cancer
1394480|NCT00405405|melanoma
1394481|NCT00405405|Chemoradiotherapy
1394482|NCT00405405|bevacizumab
1394483|NCT00405405|erlotinib
1394484|NCT00405392|Ibandronate
1394485|NCT00405392|risedronate
1394486|NCT00405392|Osteoporosis
1394487|NCT00405392|preference
1394488|NCT00405379|arthroplasty
1394489|NCT00405379|RSA
1394490|NCT00405379|Osteoarthritis
1394491|NCT00405379|trabecular metal mesh
1394492|NCT00405366|stage II renal cell cancer
1394493|NCT00405366|stage III renal cell cancer
1394494|NCT00405366|stage IV renal cell cancer
1394495|NCT00405353|multiple sclerosis
1394496|NCT00405353|testosterone
1394497|NCT00405327|tumor vaccine
1394498|NCT00405327|metastatic solid tumors
1394499|NCT00405327|recurrent tumors
1394500|NCT00405314|respiratory failure
1394501|NCT00405314|non invasive ventilation
1394502|NCT00405314|prehospital
1394503|NCT00405314|endotracheal intubation
1394504|NCT00405314|continuous positive airway pressure
1394505|NCT00405301|Tuberculosis
1394506|NCT00405301|Drug Induced Hepatotoxicity
1394507|NCT00405301|Anti-tuberculosis drugs
1394508|NCT00405301|India
1394509|NCT00405288|Hemorrhoids
1394510|NCT00405288|Pregnancy
1394511|NCT00405288|antihemorrhoidal
1394512|NCT00405288|Proctofoam
1394513|NCT00405288|infants
1394514|NCT00405275|antineoplastic
1394515|NCT00405275|antiparasitics
1394516|NCT00405275|antirheumatics
1394517|NCT00405275|chronic diseases
1394518|NCT00405275|clinical trial
1394519|NCT00405275|connective tissue
1394520|NCT00405275|double-blind
1394521|NCT00405275|drug treatment
1394522|NCT00405275|gastric medications
1394523|NCT00405275|joint
1394524|NCT00405275|multi-site trial
1394525|NCT00405275|musculoskeletal
1394526|NCT00405275|randomized
1394527|NCT00405275|rheumatoid arthritis
1394528|NCT00405262|Pediatrics
1394529|NCT00405262|Postoperative Analgesia
1394530|NCT00405262|orthopedic surgery
1394531|NCT00405262|Iliac Crest Bone Graft
1394532|NCT00405262|Osteotomy
1394533|NCT00405262|cleft palate
1394534|NCT00405249|HIV-1
1394535|NCT00405249|Treatment Experienced
1394536|NCT00405236|inflammation
1394537|NCT00405236|exacerbations
1394538|NCT00405210|hormone-resistant
1394539|NCT00405210|metastatic prostatic cancer
1394540|NCT00405210|pharmacokinetics
1394541|NCT00405210|naïve patient
1394542|NCT00405197|MUFA
1394543|NCT00405197|Mediterranean diet
1394544|NCT00405197|Insulin resistance
1394545|NCT00405197|metabolic syndrome X
1394546|NCT00405015|rosiglitazone
1394547|NCT00405015|ischemia-reperfusion injury
1394548|NCT00405015|human
1394549|NCT00405015|Annexin A5 scintigraphy
1394550|NCT00405015|metabolic syndrome
1394551|NCT00405002|Acute respiratory failure
1394552|NCT00404989|HIV
1394553|NCT00404989|HBV
1394554|NCT00404989|Hepatitis
1394555|NCT00404989|Pregnancy
1394556|NCT00404989|Registry
1394557|NCT00404976|inflammometry
1394558|NCT00404976|exhaled breath condensate
1394559|NCT00404976|fractional exhaled nitric oxide
1394560|NCT00404976|asthma
1394561|NCT00404976|children
1394562|NCT00404963|GSK376501,
1394563|NCT00404963|First Time in Human,
1394564|NCT00404963|Single Dose,
1394565|NCT00404963|Dose Escalation,
1394566|NCT00404963|Healthy Overweight/Obese Volunteer
1394567|NCT00404950|hyperglycemia
1394568|NCT00404950|cardiopulmonary bypass
1394569|NCT00404950|renal injury
1394570|NCT00404950|diabetes
1394571|NCT00404924|Non-Small-Cell Lung Carcinoma
1394572|NCT00404924|Adenocarcinoma
1394573|NCT00404924|Squamous Cell Carcinoma
1394574|NCT00404924|Large Cell Carcinoma
1394575|NCT00404911|Oppositional Defiant Disorder
1394576|NCT00404898|World Trade Center dust
1394577|NCT00404885|uveitis
1394578|NCT00404885|calcineurin
1394579|NCT00404885|inflammation
1394580|NCT00404872|Stroke
1394581|NCT00404859|inflammometry
1394582|NCT00404859|exhaled breath condensate
1394583|NCT00404859|fractional exhaled nitric oxide
1394584|NCT00404859|asthma
1394585|NCT00404859|cystic fibrosis
1394586|NCT00404859|monitoring
1394587|NCT00404859|exacerbations
1394588|NCT00404859|paediatric
1394589|NCT00404846|Hyperbaric oxygenation therapy
1394590|NCT00404846|HBOT
1394591|NCT00404846|Autism
1394592|NCT00404833|idiopathic membranous nephropathy or focal segmental glomerulosclerosis
1394593|NCT00404820|osteoporosis
1394594|NCT00404820|bisphosphonate
1394595|NCT00404820|biomarker
1394596|NCT00404820|zoledronic acid
1394597|NCT00404820|alendronate
1394598|NCT00404820|postmenopausal
1394599|NCT00404807|Continuous positive airway pressure
1394600|NCT00404807|cardiovascular diseases
1394601|NCT00404807|sleep apnea syndromes
1394602|NCT00404807|sleep breathing disorders
1394603|NCT00404807|sham CPAP
1394604|NCT00404794|membranous lupus nephritis
1394605|NCT00404781|ischemic heart disease
1394606|NCT00404781|acute coronary syndromes
1394607|NCT00404781|percutaneous transluminal coronary angioplasty
1394608|NCT00404781|platelet function
1394609|NCT00404781|aspirin
1394610|NCT00404781|clopidogrel
1394611|NCT00404781|cilostazol
1394612|NCT00404768|Premature Labor
1394613|NCT00404768|Pre Term Labor
1394614|NCT00404768|intravenous
1394615|NCT00404768|fetal fibronectin
1394616|NCT00404755|Depression
1394617|NCT00404742|uveitis
1394618|NCT00404742|calcineurin
1394619|NCT00404729|Glaucoma
1394620|NCT00404729|Optic Neuropathy, Ischemic
1394621|NCT00404729|Visual Pathways,
1394622|NCT00404729|Optic nerve
1394623|NCT00404729|Neural conduction
1394624|NCT00404690|Gastroschisis
1394625|NCT00404690|Silo
1394626|NCT00404690|Operative closure
1394627|NCT00404664|influenza vaccine
1394628|NCT00404664|influenza immunization
1394629|NCT00404664|reminder letters
1394630|NCT00404664|raffle prize
1394631|NCT00404651|Diphtheria
1394632|NCT00404651|Tetanus
1394633|NCT00404651|Pertussis
1394634|NCT00404651|Hepatitis B
1394635|NCT00404651|Poliomyelitis
1394636|NCT00404651|Invasive Haemophilus influenzae type b.
1394637|NCT00404638|Enuresis Nocturna
1394638|NCT00404638|Paula Method
1394639|NCT00404638|Circular muscle exercise
1394640|NCT00404638|Sphincter
1394641|NCT00404625|Bacteremia caused by ESBL-producing Enterobacteriaceae
1394642|NCT00404625|Pneumonia caused by ESBL-producing Enterobacteriaceae
1394643|NCT00404625|Abdomen infections due to ESBL-producing Enterobacteriaceae
1394644|NCT00404625|Skin infections caused by ESBL-producing Enterobacteriaceae
1394645|NCT00404625|Urinary infections due to ESBL-producing Enterobacteriaceae
1394646|NCT00404612|uveitis
1394647|NCT00404612|calcineurin
1394648|NCT00404599|simvastatin, atorvastatin, oxidative stress
1394649|NCT00404586|GW784568X
1394650|NCT00404586|Intranasal
1394651|NCT00404586|Environmental Challenge Chamber
1394652|NCT00404573|Schizophrenia
1394653|NCT00404560|CTLA4 Mutation
1394654|NCT00404560|Recurrent Infections
1394655|NCT00404560|Immunodeficiency
1394656|NCT00404560|Phagocytes
1394657|NCT00404560|PI3K
1394658|NCT00404560|DOCK8
1394659|NCT00404560|STAT 1
1394660|NCT00404560|Genetic Mutation
1394661|NCT00404560|Cytokines
1394662|NCT00404560|Auto-antibodies
1394663|NCT00404560|Infection Susceptibility
1394664|NCT00404560|Immune Disorders
1394665|NCT00404560|Immune Defects of Phagocytes
1394666|NCT00404560|Unusual, Chronic Bacterial, Mycobacterial, and Fungal Infections
1394667|NCT00404547|Asthma
1394668|NCT00404547|Alvesco®
1394669|NCT00404547|Ciclesonide
1394670|NCT00404534|functional dyspepsia
1394671|NCT00404534|Helicobacter pylori
1394672|NCT00404534|Anti-Inflammatory Agents, Non-Steroidal
1394673|NCT00404534|Gastritis
1394674|NCT00404521|Tumor
1394675|NCT00404521|PM02734
1394676|NCT00404521|PharmaMar
1394677|NCT00404508|Hydralazine
1394678|NCT00404508|Magnesium Valproate
1394679|NCT00404508|Chemotherapy resistance
1394680|NCT00404508|Epigenetic therapy
1394681|NCT00404482|uveitis
1394682|NCT00404482|jia
1394683|NCT00404482|Cyclosporine A
1394684|NCT00404482|MTX
1394685|NCT00404443|Acupuncture
1394686|NCT00404443|Electroacupuncture
1394687|NCT00404443|Rheumatoid arthritis
1394688|NCT00404430|Endothelial function
1394689|NCT00404430|Peripheral Arterial Tone
1394690|NCT00404430|Systemic Inflammation
1394691|NCT00404430|Oxidative Stress
1394692|NCT00404430|Respiratory and peripheral muscular function
1394693|NCT00404430|Cardiovascular risk
1394694|NCT00404430|COPD severity
1394695|NCT00404417|pain
1394696|NCT00404417|lumbar
1394697|NCT00404404|recurrent breast cancer
1394698|NCT00404404|stage IV breast cancer
1394699|NCT00404391|Moderate to severe pain following bunionectomy surgery
1394700|NCT00404378|Healthy subjects
1394701|NCT00404378|Pharmacokinetics
1394702|NCT00404378|Drug interaction
1394703|NCT00404378|Ketoconazole
1394704|NCT00404378|Casopitant
1394705|NCT00404365|depression
1394706|NCT00404365|extensive stage small cell lung cancer
1394707|NCT00404365|limited stage small cell lung cancer
1394708|NCT00404365|recurrent small cell lung cancer
1394709|NCT00404365|stage I non-small cell lung cancer
1394710|NCT00404365|stage II non-small cell lung cancer
1394711|NCT00404365|stage IIIA non-small cell lung cancer
1394712|NCT00404365|stage IIIB non-small cell lung cancer
1394713|NCT00404365|stage IV non-small cell lung cancer
1394714|NCT00404365|recurrent non-small cell lung cancer
1394715|NCT00404352|Rebif New Formulation
1394716|NCT00404352|Clinical Isolated Syndrome
1394717|NCT00404352|Multiple Sclerosis
1394718|NCT00404339|recurrent squamous cell carcinoma of the lip and oral cavity
1394719|NCT00404339|stage I squamous cell carcinoma of the lip and oral cavity
1394720|NCT00404339|stage II squamous cell carcinoma of the lip and oral cavity
1394721|NCT00404339|stage III squamous cell carcinoma of the lip and oral cavity
1394722|NCT00404339|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1394723|NCT00404339|recurrent metastatic squamous neck cancer with occult primary
1394724|NCT00404339|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1394725|NCT00404339|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1394726|NCT00404339|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1394727|NCT00404339|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1394728|NCT00404339|stage I squamous cell carcinoma of the hypopharynx
1394729|NCT00404339|stage I squamous cell carcinoma of the larynx
1394730|NCT00404339|stage I squamous cell carcinoma of the nasopharynx
1394731|NCT00404339|stage I squamous cell carcinoma of the oropharynx
1394732|NCT00404339|stage II squamous cell carcinoma of the hypopharynx
1394733|NCT00404339|stage II squamous cell carcinoma of the larynx
1394734|NCT00404339|stage II squamous cell carcinoma of the nasopharynx
1394735|NCT00404339|stage II squamous cell carcinoma of the oropharynx
1394736|NCT00404339|stage III squamous cell carcinoma of the hypopharynx
1394737|NCT00404339|stage III squamous cell carcinoma of the larynx
1394738|NCT00404339|stage III squamous cell carcinoma of the nasopharynx
1394739|NCT00404339|stage III squamous cell carcinoma of the oropharynx
1394740|NCT00404339|recurrent squamous cell carcinoma of the hypopharynx
1394741|NCT00404339|recurrent squamous cell carcinoma of the larynx
1394742|NCT00404339|recurrent squamous cell carcinoma of the nasopharynx
1394743|NCT00404339|recurrent squamous cell carcinoma of the oropharynx
1394744|NCT00404339|stage IV squamous cell carcinoma of the hypopharynx
1394745|NCT00404339|stage IV squamous cell carcinoma of the larynx
1394746|NCT00404339|stage IV squamous cell carcinoma of the lip and oral cavity
1394747|NCT00404339|stage IV squamous cell carcinoma of the nasopharynx
1394748|NCT00404339|stage IV squamous cell carcinoma of the oropharynx
1394749|NCT00404339|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1394750|NCT00404339|tongue cancer
1394751|NCT00404326|Cervical carcinoma
1394752|NCT00404326|Epigenetic therapy
1394753|NCT00404326|Hydralazine
1394754|NCT00404326|Valproate
1394755|NCT00404326|Microarray analysis
1394756|NCT00404287|C reactive protein
1394757|NCT00404287|Inflammation
1394758|NCT00404287|Aortic valve stenosis
1394759|NCT00404287|progression
1394760|NCT00404274|healthy human volunteer
1394761|NCT00404274|GW679769
1394762|NCT00404274|warfarin
1394763|NCT00404274|casopitant
1394764|NCT00404261|Fluticasone Propionate
1394765|NCT00404261|healthcare professional satisfaction
1394766|NCT00404261|patient satisfaction
1394767|NCT00404261|metered dose inhaler with counter
1394768|NCT00404261|Salmeterol
1394893|NCT00403546|Schizophrenia
1394769|NCT00404261|Chronic Obstructive Pulmonary Disease (COPD)
1394770|NCT00404248|adult anaplastic astrocytoma
1394771|NCT00404248|adult anaplastic oligodendroglioma
1394772|NCT00404248|adult giant cell glioblastoma
1394773|NCT00404248|recurrent adult brain tumor
1394774|NCT00404248|adult glioblastoma
1394775|NCT00404248|adult gliosarcoma
1394776|NCT00404235|stage IV melanoma
1394777|NCT00404235|recurrent melanoma
1394778|NCT00404222|Acute Pain following Bunionectomy
1394779|NCT00404183|Pain associated with osteoarthritis
1394780|NCT00404170|imaging
1394781|NCT00404170|Parkinson
1394782|NCT00404170|progression
1394783|NCT00404157|Lupus
1394784|NCT00404157|U2970g
1394785|NCT00404144|small vessel
1394786|NCT00404144|paclitaxel coated balloon catheter
1394787|NCT00404144|pepcad
1394788|NCT00404144|drug eluting balloon
1394789|NCT00404118|long-term care
1394790|NCT00404118|satisfaction
1394791|NCT00404118|cost
1394792|NCT00404105|Excimer laser
1394793|NCT00404092|aspergillosis
1394794|NCT00404092|caspofungin
1394795|NCT00404092|maximum tolerated dose
1394796|NCT00404079|Chronic low back pain
1394797|NCT00404014|MCI following CABG surgery
1394798|NCT00404001|Microbia
1394799|NCT00404001|MD-0727
1394800|NCT00404001|Primary Hypercholesterolemia
1394801|NCT00404001|Hypercholesterolemia
1394802|NCT00404001|Hyperlipidemia
1394803|NCT00404001|Dyslipidemia
1394804|NCT00404001|Cholesterol
1394805|NCT00404001|LDL
1394806|NCT00403962|anxiety
1394807|NCT00403962|Social Anxiety Disorder
1394808|NCT00403962|SAD
1394809|NCT00403936|osteopathic manipulation
1394810|NCT00403936|autonomic nervous system
1394811|NCT00403923|Lactose intolerance
1394812|NCT00403923|Ulcerative colitis
1394813|NCT00403923|Lactose
1394814|NCT00403923|Threshold
1394815|NCT00403897|Constipation
1394816|NCT00403884|Drusen
1394817|NCT00403884|Geographic atrophy
1394818|NCT00403884|diabetes
1394819|NCT00403884|macular edema
1394820|NCT00403884|laser
1394821|NCT00403884|retinal pigment epithelium
1394822|NCT00403871|Anaesthesia
1394823|NCT00403871|Pregnency
1394824|NCT00403871|Heart disease
1394825|NCT00403845|chronic obstructive pulmonary disease
1394826|NCT00403845|COPD
1394827|NCT00403845|QAB149
1394828|NCT00403845|indacaterol
1394829|NCT00403845|long acting β2-agonist
1394830|NCT00403806|Adenotonsillectomy
1394831|NCT00403806|Pediatrics
1394832|NCT00403806|Postoperative Nausea and Vomiting
1394833|NCT00403806|Pain
1394834|NCT00403806|Oral intake
1394835|NCT00403806|Dexamethasone
1394836|NCT00403806|Dose finding
1394837|NCT00403780|Critical limb ischemia
1394838|NCT00403780|Pain control
1394839|NCT00403780|Rest pain in lower limb ischemia
1394840|NCT00403780|pregabalin
1394841|NCT00403780|randomized controlled study
1394842|NCT00403780|Ischemia, therapy
1394843|NCT00403780|Lower extremity, blood supply
1394844|NCT00403780|Pain, prevention & control
1394845|NCT00403780|Pain, therapy
1394846|NCT00403767|Atrial Fibrillation
1394847|NCT00403767|Stroke
1394848|NCT00403767|Embolism
1394849|NCT00403767|Non-central nervous system systemic embolism
1394850|NCT00403767|Non-valvular atrial fibrillation
1394851|NCT00403767|Blood Clot
1394852|NCT00403767|Rivaroxaban
1394853|NCT00403767|Warfarin
1394854|NCT00403767|Anticoagulants
1394855|NCT00403767|Arrhythmias, Cardiac
1394856|NCT00403754|asthma
1394857|NCT00403754|QAB149
1394858|NCT00403754|indacaterol
1394859|NCT00403754|long acting β2-agonist
1394860|NCT00403754|bronchodilator
1394861|NCT00403741|behavior
1394862|NCT00403741|physical activity
1394863|NCT00403741|motivation
1394864|NCT00403728|Ischemia
1394865|NCT00403728|Reperfusion
1394866|NCT00403728|Myocardial infarction
1394867|NCT00403728|ciclosporin A
1394868|NCT00403728|acute myocardial infarction
1394869|NCT00403702|Retinal detachment
1394870|NCT00403702|proliferative vitreoretinopathy
1394871|NCT00403702|heavier-than-water internal tamponades
1394872|NCT00403689|Increased non-specific inflammatory markers
1394873|NCT00403676|nurse practitioner
1394874|NCT00403676|rheumatology care
1394875|NCT00403676|outpatient clinic
1394876|NCT00403676|patient satisfaction
1394877|NCT00403663|Body mass index
1394878|NCT00403663|Combined Spinal-Epidural Anesthesia
1394879|NCT00403663|Cesarean section
1394880|NCT00403663|Obesity
1394881|NCT00403650|Sarcoidosis
1394882|NCT00403650|Dyspnea
1394883|NCT00403650|Interstitial lung disease
1394884|NCT00403637|Asthma, indacaterol, long acting β2-agonist
1394885|NCT00403585|Adefovir Dipivoxil(Hepsera)
1394886|NCT00403585|Chronic Hepatitis B (CHB)
1394887|NCT00403572|Preeclampsia
1394888|NCT00403572|Trans cranial Doppler
1394889|NCT00403572|Cardiac output
1394890|NCT00403572|systemic vascular resistance
1394891|NCT00403572|blood pressure
1394892|NCT00403559|seborrheic dermatitis
1394894|NCT00403533|Hepatitis C
1394895|NCT00403533|viral load
1394896|NCT00403533|antiviral therapy
1394897|NCT00403533|cholesterol
1394898|NCT00403533|atorvastatin
1394899|NCT00403520|Alzheimer's disease
1394900|NCT00403520|Mild cognitive impairment
1394901|NCT00403507|Mild Dementia
1394902|NCT00403507|Mild Alzheimer
1394903|NCT00403507|Cognitive Impairment
1394904|NCT00403507|Cholinesterase Inhibitor
1394905|NCT00403507|Exercise
1394906|NCT00403507|Physical activity
1394907|NCT00403507|Behavior
1394908|NCT00403507|Memory loss
1394909|NCT00403494|Intermittent Claudication
1394910|NCT00403494|IC
1394911|NCT00403494|Symptomatic Peripheral Arterial Disease
1394912|NCT00403494|Peripheral Arterial Disease
1394913|NCT00403494|PAD
1394914|NCT00403494|6R-BH4
1394915|NCT00403494|BH4
1394916|NCT00403494|sapropterin dihydrochloride
1394917|NCT00403494|endothelial dysfunction
1394918|NCT00403494|Nitric Oxide
1394919|NCT00403494|NO
1394920|NCT00403481|Hypertension
1394921|NCT00403481|Angiotensin Receptor Blocker
1394922|NCT00403481|Calcium Channel Blocker
1394923|NCT00403481|Angiotensin Converting Enzyme Inhibitor
1394924|NCT00403481|Hydrochlorothiazide
1394925|NCT00403481|Stage I and II Hypertension
1394926|NCT00403481|Type II Diabetes
1394927|NCT00403455|Clinical
1394928|NCT00403455|Genetics
1394929|NCT00403455|Monoamine transporter
1394930|NCT00403455|Pharmacogenetics
1394931|NCT00403455|Post Traumatic Stress Disorder
1394932|NCT00403442|Macular Degeneration
1394933|NCT00403429|oral chemotherapy
1394934|NCT00403429|platinum resistant
1394935|NCT00403429|platinum refractory
1394936|NCT00403429|second line
1394937|NCT00403416|AEB071
1394938|NCT00403416|Tacrolimus
1394939|NCT00403416|Mycophenolic acid
1394940|NCT00403416|Basiliximab
1394941|NCT00403416|Rejection
1394942|NCT00403416|Kidney function
1394943|NCT00403416|Immunosuppression
1394944|NCT00403403|SCLC
1394945|NCT00403403|SALUTE
1394946|NCT00403403|Lung Cancer
1394947|NCT00403403|Avastin
1394948|NCT00403377|melanoma
1394949|NCT00403377|basal cell carcinoma of the skin
1394950|NCT00403377|squamous cell carcinoma of the skin
1394951|NCT00403364|Helicobacter pylori infection
1394952|NCT00403364|Treatment
1394953|NCT00403364|Double blind placebo controlled trial
1394954|NCT00403351|Risk
1394955|NCT00403351|Coronary artery disease
1394956|NCT00403351|Heart Rate variability
1394957|NCT00403351|Pulse wave analysis
1394958|NCT00403351|BNP
1394959|NCT00403351|CRP
1394960|NCT00403338|myocardial ischemia
1394961|NCT00403338|coronary disease
1394962|NCT00403338|heart disease
1394963|NCT00403338|Coronary Stenosis [MeSH heading: C14.280.647.250.285]
1394964|NCT00403325|Central Serous Chorioretinopathy
1394965|NCT00403312|Physical Activity
1394966|NCT00403312|Wellness Programs
1394967|NCT00403312|Pharmacological Smoking Cessation
1394968|NCT00403299|Coronary artery disease
1394969|NCT00403299|Cardiac transplantation
1394970|NCT00403299|Coronary artery disease in heart transplanted patients
1394971|NCT00403286|Chronic
1394972|NCT00403286|Obstructive
1394973|NCT00403286|Pulmonary
1394974|NCT00403286|Disease
1394975|NCT00403286|COPD
1394976|NCT00403286|Safety
1394977|NCT00403286|Efficacy
1394978|NCT00403286|Pharmacokinetic
1394979|NCT00403286|Dose-finding
1394980|NCT00403273|Painful Knee Arthroplasty
1394981|NCT00403273|Botulinum Toxin A
1394982|NCT00403273|Randomized Controlled Trial
1394983|NCT00403273|Pain and Function
1394984|NCT00403260|malaria
1394985|NCT00403260|ACT
1394986|NCT00403260|P falciparum
1394987|NCT00403260|pyronaridine
1394988|NCT00403260|artesunate
1394989|NCT00403247|Schizophrenia
1394990|NCT00403247|Schizoaffective Disorder
1394991|NCT00403247|Homocysteine
1394992|NCT00403247|Vitamins
1394993|NCT00403234|Postoperative pain
1394994|NCT00403234|opioid
1394995|NCT00403234|transdermal
1394996|NCT00403234|TKA (total knee arthroplasty)
1394997|NCT00403221|Gene therapy
1394998|NCT00403221|Prostate cancer
1394999|NCT00403221|Immunology, Angiogenesis inhibition
1395000|NCT00403221|Phase I clinical trial
1395001|NCT00403208|Ventilation, Mechanical
1395002|NCT00403208|Sedation
1395003|NCT00403195|Ocular Ischemic Syndrome
1395004|NCT00403182|recurrent breast cancer
1395005|NCT00403182|stage IIIA breast cancer
1395006|NCT00403182|stage IIIB breast cancer
1395007|NCT00403182|stage IIIC breast cancer
1395008|NCT00403182|stage IV breast cancer
1395009|NCT00403169|stage III renal cell cancer
1395010|NCT00403169|stage IV renal cell cancer
1395011|NCT00403169|recurrent renal cell cancer
1395012|NCT00403156|Macular Degeneration
1395013|NCT00403143|intraocular lens, colour vision, blue-light filtering
1395014|NCT00403117|naltrexone
1395015|NCT00403117|smoked marijuana
1395016|NCT00403117|marijuana use
1395017|NCT00403104|ONO-2506PO
1395018|NCT00403104|Amyotrophic Lateral Sclerosis
1395019|NCT00403104|ALS
1395020|NCT00403091|Diabetes mellitus
1395021|NCT00403091|Internet
1395022|NCT00403091|Education, Professional
1395023|NCT00403091|Quality Indicators, Health Care
1395024|NCT00403091|Quality of Health Care
1395025|NCT00403091|Hypertension
1395026|NCT00403091|Hyperlipidemia
1395027|NCT00403078|Carotid Artery Stenting (Endovascular)
1395028|NCT00403065|recurrent non-small cell lung cancer
1395029|NCT00403065|stage IV non-small cell lung cancer
1395030|NCT00403065|tumors metastatic to brain
1395031|NCT00403052|colorectal
1395032|NCT00403052|cancer
1395033|NCT00403052|carcinoma
1395034|NCT00403052|metastatic
1395035|NCT00403052|colon
1395036|NCT00403052|rectal
1395037|NCT00403052|neoplasm
1395038|NCT00403052|cetuximab
1395039|NCT00403052|irinotecan
1395040|NCT00403052|1018 ISS
1395041|NCT00403052|combination therapy
1395042|NCT00403039|Central Retinal Vein Occlusion
1395043|NCT00403026|Bevacizumab (Avastin)
1395044|NCT00403026|Intravitreal injection
1395045|NCT00403026|VEGF
1395046|NCT00403026|CRVO
1395047|NCT00403026|BRVO
1395048|NCT00403026|PDR
1395049|NCT00403026|CNVM
1395050|NCT00403013|nerve block/*methods
1395051|NCT00403013|Anesthetics, Local/pharmacokinetics
1395052|NCT00403013|*Brachial Plexus
1395053|NCT00403000|recurrent prostate cancer
1395054|NCT00402987|sore throat
1395055|NCT00402987|acute pain
1395056|NCT00402974|osteocalcin
1395057|NCT00402974|vitamin K
1395058|NCT00402974|carboxylation
1395059|NCT00402974|healthy children
1395060|NCT00402961|Acupuncture
1395061|NCT00402961|Post-Colectomy Ileus
1395062|NCT00402961|Abdominal Surgery
1395063|NCT00402961|Colon Surgery
1395064|NCT00402948|High eosinophils level in sputum
1395065|NCT00402935|long-term effects secondary to cancer therapy in adults
1395066|NCT00402935|long-term effects secondary to cancer therapy in children
1395067|NCT00402935|sexual dysfunction and infertility
1395068|NCT00402935|sexuality and reproductive issues
1395069|NCT00402935|adult acute lymphoblastic leukemia in remission
1395070|NCT00402935|childhood acute lymphoblastic leukemia in remission
1395071|NCT00402935|recurrent adult acute lymphoblastic leukemia
1395072|NCT00402935|recurrent childhood acute lymphoblastic leukemia
1395073|NCT00402935|untreated adult acute lymphoblastic leukemia
1395074|NCT00402935|untreated childhood acute lymphoblastic leukemia
1395075|NCT00402935|adult acute myeloid leukemia in remission
1395076|NCT00402935|recurrent adult acute myeloid leukemia
1395077|NCT00402935|recurrent childhood acute myeloid leukemia
1395078|NCT00402935|untreated adult acute myeloid leukemia
1395079|NCT00402935|untreated childhood acute myeloid leukemia and other myeloid malignancies
1395080|NCT00402935|secondary acute myeloid leukemia
1395081|NCT00402935|stage I adult Hodgkin lymphoma
1395082|NCT00402935|stage I childhood Hodgkin lymphoma
1395083|NCT00402935|stage II adult Hodgkin lymphoma
1395084|NCT00402935|stage II childhood Hodgkin lymphoma
1395085|NCT00402935|stage III adult Hodgkin lymphoma
1395086|NCT00402935|stage III childhood Hodgkin lymphoma
1395087|NCT00402935|stage IV adult Hodgkin lymphoma
1395088|NCT00402935|stage IV childhood Hodgkin lymphoma
1395089|NCT00402935|recurrent adult Hodgkin lymphoma
1395090|NCT00402935|recurrent/refractory childhood Hodgkin lymphoma
1395091|NCT00402935|unspecified adult solid tumor, protocol specific
1395092|NCT00402935|unspecified childhood solid tumor, protocol specific
1395093|NCT00402935|childhood acute myeloid leukemia in remission
1395094|NCT00402935|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1395095|NCT00402935|adult acute myeloid leukemia with inv(16)(p13;q22)
1395096|NCT00402935|adult acute myeloid leukemia with t(16;16)(p13;q22)
1395097|NCT00402935|adult acute myeloid leukemia with t(15;17)(q22;q12)
1395098|NCT00402935|adult acute myeloid leukemia with t(8;21)(q22;q22)
1395099|NCT00402922|Coronary Heart Disease
1395100|NCT00402909|Type 2 diabetes,
1395101|NCT00402909|fasting glucose,
1395102|NCT00402909|postprandial glucose,
1395103|NCT00402909|blood sugar,
1395104|NCT00402909|HbA1c,
1395105|NCT00402909|insulin,
1395106|NCT00402909|glargine,
1395107|NCT00402909|metformin,
1395108|NCT00402909|thiazolidinedione
1395109|NCT00402896|Lung Cancer
1395110|NCT00402896|Non-Small Cell Lung Cancer
1395111|NCT00402896|Pleural Effusion
1395112|NCT00402896|Indwelling Intrapleural Denver Catheter
1395113|NCT00402896|ZD6474
1395114|NCT00402896|Vascular Endothelial Growth Factor Receptor
1395115|NCT00402896|VEGFR
1395116|NCT00402896|Epidermal Growth factor Receptor
1395117|NCT00402896|EGFR
1395118|NCT00402896|Tyrosine Kinase Inhibitor
1395119|NCT00402857|Parenting Education
1395120|NCT00402857|Child, Preschool
1395121|NCT00402857|Preventive Intervention
1395122|NCT00402857|Primary Health Care
1395123|NCT00402857|Pediatrics
1395124|NCT00402857|Attention Deficit Disorders
1395125|NCT00402857|Oppositional Defiant Disorder
1395126|NCT00402857|Disruptive Behavior Disorder
1395127|NCT00402844|Multicenter
1395128|NCT00402844|Pelvic organ prolapse
1395129|NCT00402844|Prospective
1395130|NCT00402844|Transvaginal mesh
1395131|NCT00402818|Moderate to severe plaque psoriasis
1395132|NCT00402805|Influenza vaccine
1395133|NCT00402805|Intradermal
1395134|NCT00402805|Lung transplantation
1395135|NCT00402792|Acute pain following bunionectomy surgery
1395136|NCT00402779|Oral Cancer
1395137|NCT00402779|Oral IEN Lesion with LOH
1395138|NCT00402779|Loss of Heterozygosity
1395139|NCT00402779|Intraepithelial Neoplasia
1395140|NCT00402779|Placebo
1395141|NCT00402779|Erlotinib
1395142|NCT00402779|Tarceva
1395143|NCT00402779|OSI-774
1395144|NCT00402766|Mesothelioma
1395145|NCT00402766|Pleural Mesothelioma
1395146|NCT00402766|Peritoneal Mesothelioma
1395147|NCT00402766|PDGF-R
1395148|NCT00402766|Pemetrexed
1395149|NCT00402766|Alimta
1395150|NCT00402766|Cisplatin
1395151|NCT00402766|Imatinib Mesylate
1395152|NCT00402766|Gleevec
1395153|NCT00402766|Platinol
1395154|NCT00402766|Platinol-AQ
1395155|NCT00402766|CDDP
1395156|NCT00402766|Ly231514
1395157|NCT00402766|Multitargeted Antifolate
1395158|NCT00402766|NSC-698037
1395159|NCT00402766|STI571
1395160|NCT00402766|NSSC-716051
1395161|NCT00402753|Cancer, Exercise, Health Related Quality of Life, PBSCT
1395162|NCT00402740|Carotid
1395163|NCT00402740|Artery
1395164|NCT00402740|Disease
1395165|NCT00402740|Stent
1395166|NCT00402740|PROTECT
1395167|NCT00402740|XACT
1395168|NCT00402740|EMBOSHIELD
1395169|NCT00402714|Allogeneic Stem Cell Transplant
1395170|NCT00402701|walking
1395171|NCT00402701|motor activity
1395172|NCT00402701|students
1395173|NCT00402701|schools
1395174|NCT00402701|transportation
1395175|NCT00402701|motor vehicles
1395176|NCT00402688|Chronic Prostatitis
1395177|NCT00402688|Prostatitis
1395178|NCT00402688|levofloxacin
1395179|NCT00402688|Levaquin
1395180|NCT00402675|NSTEMI
1395181|NCT00402675|infarction
1395182|NCT00402675|treatment
1395183|NCT00402675|percutaneous coronary intervention
1395184|NCT00402675|non-ST-elevation myocardial infarction
1395185|NCT00402662|everolimus
1395186|NCT00402662|imatinib
1395187|NCT00402649|influenza, A/H5N1, avian influenza, vaccine
1395188|NCT00402623|sarcoidosis
1395189|NCT00402623|quercetin
1395190|NCT00402623|supplementation
1395191|NCT00402623|oxidative stress
1395192|NCT00402623|inflammation
1395193|NCT00402610|HIV
1395194|NCT00402610|Tuberculosis
1395195|NCT00402610|Chemoprophylaxis
1395196|NCT00402610|Anergy
1395197|NCT00402610|AIDS
1395198|NCT00402597|Acute Coronary Syndrome (ACS)
1395199|NCT00402597|Myocardial Ischemia
1395200|NCT00402597|Rivaroxaban (BAY59-7939)
1395201|NCT00402597|Anti-platelet agents
1395202|NCT00402597|Aspirin
1395203|NCT00402597|Thienopyridine
1395204|NCT00402597|Clopidogrel
1395205|NCT00402571|acetaminophen
1395206|NCT00402571|alcohol
1395207|NCT00402571|liver injury
1395208|NCT00402558|Acute Myeloid Leukemia
1395209|NCT00402558|Chronic Myelogenous Leukemia
1395210|NCT00402558|Myelodysplastic Syndrome
1395211|NCT00402558|Leukemia
1395212|NCT00402558|NK Cells
1395213|NCT00402558|Natural Killer Cells
1395214|NCT00402558|Fludarabine
1395215|NCT00402558|Busulfan
1395216|NCT00402558|Thymoglobulin
1395217|NCT00402558|AML
1395218|NCT00402558|CML
1395219|NCT00402558|MDS
1395220|NCT00402558|ATG
1395221|NCT00402558|Antithymocyte globulin
1395222|NCT00402558|Busulfex
1395223|NCT00402558|Myleran®
1395224|NCT00402558|Fludarabine Phosphate
1395225|NCT00402558|G-CSF
1395226|NCT00402558|Filgrastim
1395227|NCT00402558|Neupogen
1395228|NCT00402558|Interleukin-2
1395229|NCT00402558|IL-2
1395230|NCT00402558|Aldesleukin
1395231|NCT00402558|Proleukin
1395232|NCT00402558|Tacrolimus
1395233|NCT00402558|Prograf
1395234|NCT00402558|Methotrexate
1395235|NCT00402545|SCCHN
1395236|NCT00402545|C-TPF
1395237|NCT00402545|5-FU
1395238|NCT00402545|squamous cell carcinoma of the head and neck
1395239|NCT00402532|Lung Transplantation
1395240|NCT00402532|Immunosuppression
1395241|NCT00402532|Mortality
1395242|NCT00402532|Graft rejection
1395243|NCT00402532|Bronchiolitis obliterans
1395244|NCT00402532|Opportunistic infections
1395245|NCT00402532|Nephrotoxicity
1395246|NCT00402519|accelerated partial breast irradiation
1395247|NCT00402519|multicatheter brachytherapy
1395248|NCT00402519|high dose rate brachytherapy
1395249|NCT00402519|pulsed dose rate brachytherapy
1395250|NCT00402506|coronary
1395251|NCT00402506|surgery
1395252|NCT00402506|ischemia
1395253|NCT00402506|reperfusion injury
1395254|NCT00402506|cardiac
1395255|NCT00402506|heart
1395256|NCT00402506|neurological
1395257|NCT00402506|cardiopulmonary bypass
1395258|NCT00402506|cardioprotection
1395259|NCT00402506|myocardium
1395260|NCT00402506|myocardial
1395261|NCT00402506|myocardial revascularization
1395262|NCT00402493|Glaucoma
1395263|NCT00402493|Ocular Hypertension
1395264|NCT00402493|Xalatan
1395265|NCT00402493|Alpahgan
1395266|NCT00402493|Ibuprofen
1395267|NCT00402493|Non-Steroidal Anti-Inflammatory
1395268|NCT00402493|Brimonidine
1395269|NCT00402493|Latanoprost
1395270|NCT00402493|Eye Pressure
1395271|NCT00402493|Intra-Ocular Pressure
1395272|NCT00402480|Sickle Cell Anemia with Elevated TCD flow velocity
1395273|NCT00402467|Prevention of venous thromboembolism
1395274|NCT00402454|HIV
1395275|NCT00402454|Tuberculosis
1395276|NCT00402454|Prophylaxis
1395277|NCT00402454|AIDS
1395278|NCT00402428|Chronic Hepatitis C
1395279|NCT00402428|Hepatitis C
1395280|NCT00402428|CHC
1395281|NCT00402428|HepC
1395282|NCT00402428|Genotype 1
1395283|NCT00402428|Hepatitis
1395284|NCT00402428|HCV
1395285|NCT00402415|metastatic
1395286|NCT00402415|malignancy
1395287|NCT00402415|advanced solid tumors
1395288|NCT00402415|unresectable
1395289|NCT00402415|Solid Tumors
1395290|NCT00402402|Tuberculin skin test
1395291|NCT00402402|Quantiferon-TB Gold assay
1395292|NCT00402402|Chronic liver disease
1395293|NCT00402402|Liver transplantation
1395294|NCT00402402|Latent tuberculosis infection
1395295|NCT00402389|Perinatal Depression
1395296|NCT00402389|Postpartum Depression
1395297|NCT00402389|Omega-3 Fatty Acids
1395298|NCT00402389|Eicosapentaenoic Acid (EPA)
1395299|NCT00402389|Docosahexaenoic Acid (DHA)
1395300|NCT00402389|Pregnancy
1395301|NCT00402389|Psychotherapy
1395302|NCT00402376|End-stage heart failure
1395303|NCT00402376|heart failure;
1395304|NCT00402376|ventricular assist device;
1395305|NCT00402376|statin;
1395306|NCT00402376|heart transplantation;
1395307|NCT00402376|myocardial function;
1395308|NCT00402376|mitochondrial respiratory function;
1395309|NCT00402363|Lovaza
1395310|NCT00402363|Omega-3 fatty acids
1395311|NCT00402363|Omacor
1395312|NCT00402363|Paroxysmal atrial fibrillation
1395313|NCT00402350|Staccato Fentanyl, Pharmacokinetics, Pharmacodynamics, inhaled fentanyl
1395314|NCT00402337|Constipation
1395315|NCT00402337|Chronic Constipation
1395316|NCT00402337|Microbia
1395317|NCT00402337|linaclotide
1395318|NCT00402337|linaclotide acetate
1395319|NCT00402337|MD-1100
1395320|NCT00402324|Mixed episode associated with Bipolar I
1395321|NCT00402311|Health Services for the Aged
1395322|NCT00402311|Geriatric Psychiatry
1395323|NCT00402298|PTSD
1395324|NCT00402298|MDMA
1395325|NCT00402298|psychotherapy
1395326|NCT00402298|Posttraumatic stress disorder
1395327|NCT00402298|Israel
1395328|NCT00402285|adenocarcinoma of the prostate
1395329|NCT00402285|stage I prostate cancer
1395330|NCT00402285|stage IIB prostate cancer
1395331|NCT00402285|stage IIA prostate cancer
1395332|NCT00402272|drug eluting stents
1395333|NCT00402272|stents
1395334|NCT00402272|Angioplasty
1395335|NCT00402272|coronary artery disease
1395336|NCT00402272|total coronary occlusion
1395337|NCT00402272|coronary artery restenosis
1395338|NCT00402272|stent thrombosis
1395339|NCT00402272|vascular disease
1395340|NCT00402272|myocardial ischemia
1395341|NCT00402272|coronary artery stenosis
1395342|NCT00402259|acute non-variceal upper gastrointestinal bleeding
1395343|NCT00402246|Randomized Controlled Trials
1395344|NCT00402246|Defibrillators
1395345|NCT00402246|Remote Consultation
1395346|NCT00402207|asthma
1395347|NCT00402207|non-invasive inflammometry
1395348|NCT00402207|exhaled nitric oxide
1395349|NCT00402207|exhaled breath condensate
1395350|NCT00402207|paediatric
1395351|NCT00402207|extrafine HFA-beclomethasone
1395352|NCT00402207|HFA-fluticasone
1395353|NCT00402194|Obesity
1395354|NCT00402194|Insulin resistance
1395355|NCT00402194|Impaired glucose tolerance
1395356|NCT00402194|pre-diabetes
1395357|NCT00402181|Myeloma
1395358|NCT00402181|Intravenous
1395359|NCT00402181|Monoclonal antibody
1395360|NCT00402181|Siltuximab
1395361|NCT00402181|Dexamethasone
1395362|NCT00402181|CNTO 328
1395363|NCT00402155|electroretinogram
1395364|NCT00402155|visual evoked potential
1395365|NCT00402155|contrast sensitivity
1395366|NCT00402142|HIV Infection
1395367|NCT00402142|Dendritic cell vaccine
1395368|NCT00402142|Autologous virus
1395369|NCT00402142|Heat inactivated
1395370|NCT00402142|HIV Therapeutic Vaccine
1395371|NCT00402129|Ethnic Skin
1395372|NCT00402129|Laser
1395373|NCT00402129|Photobiology
1395374|NCT00402129|Quality of life
1395375|NCT00402103|Hypertension, aliskiren, amlodipine, HCTZ, blood pressure
1395376|NCT00402090|thiopurines
1395377|NCT00402090|thiopurine methyl transferase
1395378|NCT00402090|toxicity
1395379|NCT00402090|pharmacogenomics
1395380|NCT00402077|overweight
1395381|NCT00402077|obesity
1395382|NCT00402077|pramlintide
1395383|NCT00402077|Symlin
1395384|NCT00402077|sibutramine
1395385|NCT00402077|Meridia
1395386|NCT00402077|phentermine
1395387|NCT00402077|Amylin
1395388|NCT00402064|bisphosphonates
1395389|NCT00402064|children
1395390|NCT00402064|dental
1395391|NCT00402064|Osteomyelitis
1395392|NCT00402064|medication
1395393|NCT00402025|Metastatic
1395394|NCT00402025|Pancreas
1395395|NCT00402025|Adenocarcinoma
1395396|NCT00402012|Diabetes Mellitus, Type 2
1395397|NCT00401999|PET
1395398|NCT00401999|C-11 Raclopride
1395399|NCT00401999|Dopamine
1395400|NCT00401999|OPRM1
1395401|NCT00401999|Alcohol
1395402|NCT00401999|Healthy Volunteer
1395403|NCT00401999|HV
1395404|NCT00401986|Refractory Asthma
1395405|NCT00401986|Bronchial Thermoplasty
1395406|NCT00401986|Alair System
1395407|NCT00401986|RISA (Research in Severe Asthma)
1395408|NCT00401960|Enterococcus
1395409|NCT00401960|Daptomycin
1395410|NCT00401960|Endocarditis
1395411|NCT00401947|HCV
1395412|NCT00401947|Chronic
1395413|NCT00401947|Hepatitis
1395414|NCT00401934|cholera, Vibrio cholerae, diarrhea, Bangladesh, children
1395415|NCT00401908|Acute gastrointestinal bleeding
1395416|NCT00401908|Acute coronary syndrome
1395417|NCT00401895|TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
1395418|NCT00401895|Covered stents
1395419|NCT00401895|portal hypertension
1395420|NCT00401895|hepatic encephalopathy
1395421|NCT00401882|Cardiac arrest
1395422|NCT00401882|Sudden Cardiac Death
1395423|NCT00401882|Ventricular Fibrillation
1395424|NCT00401882|Pulseless Ventricular Tachycardia
1395425|NCT00401882|Cardiopulmonary resuscitation
1395426|NCT00401869|vigor
1395427|NCT00401869|function
1395428|NCT00401869|well-being
1395429|NCT00401869|hand-strength
1395430|NCT00401869|surgery
1395431|NCT00401869|anemia
1395432|NCT00401869|transfusion
1395433|NCT00401869|strength
1395434|NCT00401869|quality-of-life
1395435|NCT00401856|Cardiomyopathy
1395436|NCT00401856|Fibrosis
1395437|NCT00401856|Magnetic-Resonance
1395438|NCT00401856|Eplerenone
1395439|NCT00401843|multiple myeloma
1395440|NCT00401843|Monoclonal Antibody
1395441|NCT00401843|Intravenous
1395442|NCT00401843|refractory or relapsed multiple myeloma
1395443|NCT00401843|velcade
1395444|NCT00401843|bortezomib
1395445|NCT00401830|Fibromyalgia Syndrome
1395446|NCT00401830|Lacosamide
1395447|NCT00401830|Vimpat
1395448|NCT00401830|Harkoseride
1395449|NCT00401804|Multiple Myeloma
1395450|NCT00401804|renal impairment
1395451|NCT00401804|Velcade
1395452|NCT00401778|Lung Cancer
1395453|NCT00401765|Prostatic neoplasm
1395454|NCT00401765|intravenous
1395455|NCT00401765|docetaxel
1395456|NCT00401765|monoclonal antibody
1395457|NCT00401752|NSAID-associated gastric ulcer
1395458|NCT00401726|Major Depressive Disorder
1395459|NCT00401726|Depression
1395460|NCT00401726|Anxiety
1395461|NCT00401713|submacular membrane
1395462|NCT00401713|transplantation of RPE
1395463|NCT00401713|translocation of RPE and Choroid
1395464|NCT00401700|influenza
1395465|NCT00401700|influenza vaccine
1395466|NCT00401700|pregnancy
1395467|NCT00401687|Reduced Heart Function
1395468|NCT00401674|ovarian cancer
1395469|NCT00401674|elderly
1395470|NCT00401674|weekly chemotherapy
1395471|NCT00401674|first-line
1395472|NCT00401648|POC
1395473|NCT00401648|photosensitive
1395474|NCT00401648|epileptic
1395475|NCT00401648|brivaracetam
1395476|NCT00401648|PPR
1395477|NCT00401648|AED
1395478|NCT00401635|advanced
1395479|NCT00401635|recurrent
1395480|NCT00401635|chemotherapy
1395481|NCT00401635|first-line
1395482|NCT00401609|elderly
1395483|NCT00401596|ALTO
1395484|NCT00401583|GW786034 (pazopanib) cytochrome P450 interaction
1395485|NCT00401570|Antibody
1395486|NCT00401570|Pancreas
1395487|NCT00401570|Carcinoma
1395488|NCT00401570|Cancer
1395489|NCT00401570|Pancreatic
1395490|NCT00401557|Leishmaniasis, Leishmania (Viannia), Colombia
1395491|NCT00401544|anemia
1395492|NCT00401544|chemotherapy induced anemia
1395493|NCT00401544|darbepoetin alfa
1395494|NCT00401544|cancer
1395495|NCT00401531|Hepatitis B
1395496|NCT00401531|Polio
1395497|NCT00401531|Diphtheria
1395498|NCT00401531|Pertussis
1395499|NCT00401531|H. influenzae type b
1395500|NCT00401518|Spinal Stenosis
1395501|NCT00401518|Lumbar Spinal Stenosis
1395502|NCT00401518|Facet Arthroplasty
1395503|NCT00401518|Posterior Fusion
1395504|NCT00401518|Facet Arthritis
1395505|NCT00401505|rubella
1395506|NCT00401505|rubella vaccine
1395507|NCT00401505|postpartum
1395508|NCT00401505|immunity
1395509|NCT00401492|elderly
1395510|NCT00401492|chemotherapy
1395511|NCT00401492|quality of life
1395512|NCT00401492|ADL
1395513|NCT00401492|toxicity
1395514|NCT00401479|GW427353
1395515|NCT00401479|b3-Adrenergic Receptor Agonist
1395516|NCT00401479|Irritable Bowel Syndrome (IBS)
1395517|NCT00401479|pharmacokinetics
1395518|NCT00401479|tolerability
1395519|NCT00401479|gastrointestinal transit
1395520|NCT00401466|prophylactic ICD therapy
1395521|NCT00401466|home monitoring
1395522|NCT00401466|follow-up interval
1395523|NCT00401466|remote follow-up
1395524|NCT00401440|Medical termination of pregnancy
1395525|NCT00401440|Induction of abortion
1395526|NCT00401440|Misoprostol
1395527|NCT00401440|MTP in second trimester
1395528|NCT00401440|400 microgram vaginal misoprostol
1395529|NCT00401427|HER2 overexpression
1395530|NCT00401427|combination therapy
1395531|NCT00401414|Warfarin
1395532|NCT00401414|Thrombosis
1395533|NCT00401414|Genetics
1395534|NCT00401414|Nomogram
1395535|NCT00401414|Pulmonary Embolism
1395536|NCT00401414|Deep Vein Thrombosis
1395537|NCT00401414|Dosing
1395538|NCT00401414|INR
1395539|NCT00401414|Anticoagulation
1395540|NCT00401414|Therapy
1395541|NCT00401414|Orthopedic Surgery
1395542|NCT00401388|Chemo Insensitive Sarcomas
1395543|NCT00401388|Chondrosarcomas
1395544|NCT00401388|Alveolar soft part sarcomas
1395545|NCT00401388|Extra skeletal myxoid chondrosarcomas
1395546|NCT00401388|Perifosine
1395547|NCT00401349|Leishmania
1395548|NCT00401349|Mif Alleles
1395549|NCT00401349|Colombia
1395550|NCT00401349|children
1395551|NCT00401336|Magnetic resonance imaging
1395552|NCT00401336|Hepatic iron
1395553|NCT00401336|Steatosis
1395554|NCT00401297|Leishmaniasis
1395555|NCT00401297|L. Viannia
1395556|NCT00401297|Leishmania
1395557|NCT00401297|Colombia
1395558|NCT00401258|IBS
1395559|NCT00401258|irritable bowel syndrome
1395560|NCT00401258|irritable bowel
1395561|NCT00401206|dexmedetomidine
1395562|NCT00401206|sedation
1395563|NCT00401206|bronchoscopy
1395564|NCT00401206|COPD
1395565|NCT00401193|Menorrhagia
1395566|NCT00401193|Heavy Menstrual Bleeding
1395567|NCT00401180|unspecified adult solid tumor, protocol specific
1395568|NCT00401167|Alzheimer's disease
1395569|NCT00401167|behavioral and psychological symptoms of dementia
1395570|NCT00401167|severe Alzheimer's disease
1395571|NCT00401167|memantine
1395572|NCT00401167|agitation
1395573|NCT00401167|aggression
1395574|NCT00401154|Spastic Diplegia
1395575|NCT00401154|Cerebral Palsy
1395576|NCT00401154|Children
1395577|NCT00401154|Adolescents
1395578|NCT00401154|Strengthening
1395579|NCT00401154|Endurance
1395580|NCT00401141|Systemic lupus
1395581|NCT00401141|B lymphocytes
1395582|NCT00401141|transcriptomas
1395583|NCT00401128|clear cell renal cell carcinoma
1395584|NCT00401128|recurrent renal cell cancer
1395585|NCT00401128|papillary renal cell carcinoma
1395586|NCT00401128|stage IV renal cell cancer
1395587|NCT00401102|self-injurious behavior
1395588|NCT00401102|depression
1395589|NCT00401102|adolescents
1395590|NCT00401102|psychotherapy
1395591|NCT00401089|negative symptoms schizophrenia
1395592|NCT00401089|Atypical antipsychotics
1395593|NCT00401089|Neurocognition impairment
1395594|NCT00401089|obesity risk factor
1395595|NCT00401089|Diabetes insulin resistance schizophrenia
1395596|NCT00401076|SA-001
1395597|NCT00401076|Pancreatic Exocrine Insufficiency
1395598|NCT00401076|Chronic Pancreatitis
1395599|NCT00401076|Pancreatectomy
1395600|NCT00401063|Cancer
1395601|NCT00401063|Acupuncture
1395602|NCT00401063|Cancer Pain
1395603|NCT00401063|Quality of life
1395604|NCT00401050|patellofemoral pain syndrome
1395605|NCT00401050|chiropractic
1395606|NCT00401050|knee pain
1395607|NCT00401050|chiropractic manipulation
1395608|NCT00401050|Graston Instrument Soft Tissue Mobilization(GISTM)
1395609|NCT00401024|adult anaplastic oligodendroglioma
1395610|NCT00401024|adult oligodendroglioma
1395611|NCT00401024|adult anaplastic astrocytoma
1395612|NCT00401024|adult giant cell glioblastoma
1395613|NCT00401024|adult gliosarcoma
1395614|NCT00401024|recurrent adult brain tumor
1395615|NCT00401024|adult brain stem glioma
1395616|NCT00401024|adult mixed glioma
1395617|NCT00401024|adult glioblastoma
1395618|NCT00401024|adult pilocytic astrocytoma
1395619|NCT00401024|adult diffuse astrocytoma
1395620|NCT00401024|adult anaplastic ependymoma
1395621|NCT00401024|adult ependymoma
1395622|NCT00401024|adult myxopapillary ependymoma
1395623|NCT00401024|adult subependymoma
1395624|NCT00401024|adult pineal gland astrocytoma
1395625|NCT00401024|adult subependymal giant cell astrocytoma
1395626|NCT00401011|Perifosine
1395627|NCT00401011|Bortezomib
1395628|NCT00401011|Dexamethasone
1395629|NCT00401011|Relapsed or Refractory Multiple Myeloma
1395630|NCT00400998|Seasonal Allergic Rhinitis
1395631|NCT00400998|Quality of Life
1395632|NCT00400998|Efficacy
1395633|NCT00400998|Validation
1395634|NCT00400998|Fluticasone Propionate
1395635|NCT00400985|Heart Failure, Congestive
1395636|NCT00400985|Diagnostic
1395637|NCT00400985|Ambulatory Monitoring
1395638|NCT00400985|Intrathoracic Impedance
1395639|NCT00400972|GlideScope
1395640|NCT00400972|videolaryngoscopy
1395641|NCT00400972|intubation
1395642|NCT00400972|nasal
1395643|NCT00400972|nasotracheal
1395644|NCT00400972|laryngoscopy
1395645|NCT00400972|anesthesia
1395646|NCT00400959|cell therapy
1395647|NCT00400959|acute myocardial infarction
1395648|NCT00400946|drug/agent toxicity by tissue/organ
1395649|NCT00400946|untreated childhood acute lymphoblastic leukemia
1395650|NCT00400946|L1 childhood acute lymphoblastic leukemia
1395651|NCT00400946|L2 childhood acute lymphoblastic leukemia
1395652|NCT00400946|T-cell childhood acute lymphoblastic leukemia
1395653|NCT00400933|Psycho-education
1395654|NCT00400933|Eating disorders
1395655|NCT00400933|Personality disorders
1395656|NCT00400933|Relatives and close friends
1395657|NCT00400933|Caregiver burden
1395658|NCT00400907|long-term effects secondary to cancer therapy in adults
1395659|NCT00400907|stage I adult diffuse large cell lymphoma
1395660|NCT00400907|contiguous stage II adult diffuse large cell lymphoma
1395661|NCT00400907|noncontiguous stage II adult diffuse large cell lymphoma
1395662|NCT00400907|stage III adult diffuse large cell lymphoma
1395663|NCT00400907|stage IV adult diffuse large cell lymphoma
1395664|NCT00400894|prostate cancer
1395665|NCT00400894|annexin A3
1395666|NCT00400894|early detection
1395667|NCT00400894|exprimate urine
1395668|NCT00400881|mechanical ventilation
1395669|NCT00400881|weaning
1395670|NCT00400881|respiratory failure
1395671|NCT00400881|spontaneous breathing trial
1395672|NCT00400868|rheumatoid arthritis, occupational therapy, joint protection
1395673|NCT00400855|Asthma
1395674|NCT00400855|AMP challenge
1395675|NCT00400842|SA-001
1395676|NCT00400842|Pancreatic Exocrine Insufficiency
1395677|NCT00400842|Pancreatectomy
1395678|NCT00400816|adult anaplastic oligodendroglioma
1395679|NCT00400816|adult mixed glioma
1395680|NCT00400803|Carcinoma, Non-Small-Cell Lung
1395681|NCT00400803|Gemcitabine
1395682|NCT00400803|Carboplatin
1395683|NCT00400803|Bevacizumab
1395684|NCT00400803|Biological therapy
1395685|NCT00400803|Drug therapy
1395686|NCT00400790|neurocognitive decline
1395687|NCT00400790|coronary artery bypass surgery
1395688|NCT00400790|composite morbidity
1395689|NCT00400790|postoperative care cost
1395690|NCT00400777|Valsartan
1395691|NCT00400777|hydrochlorothiazide
1395692|NCT00400777|amlodipine
1395693|NCT00400777|hypertension
1395694|NCT00400777|high blood pressure
1395695|NCT00400764|NHL
1395696|NCT00400764|Follicular NHL
1395697|NCT00400764|Rituxan
1395698|NCT00400764|Apo2L/TRAIL
1395699|NCT00400751|Health-compromised smokers, family cessation intervention
1395700|NCT00400738|HIV-1 infection
1395701|NCT00400738|pharmacokinetics
1395702|NCT00400738|protease inhibitor
1395703|NCT00400738|double boosted protease inhibitors
1395704|NCT00400738|PIs
1395705|NCT00400738|Treatment Naive
1395706|NCT00400725|maintenance
1395707|NCT00400725|scalp psoriasis
1395708|NCT00400725|Galderma
1395709|NCT00400712|mobility
1395710|NCT00400712|strength
1395711|NCT00400712|balance
1395712|NCT00400712|function
1395713|NCT00400712|reintegration
1395714|NCT00400712|community
1395715|NCT00400699|psychosocial effects of cancer and its treatment
1395716|NCT00400699|unspecified adult solid tumor, protocol specific
1395717|NCT00400686|anemia
1395718|NCT00400686|stage I multiple myeloma
1395719|NCT00400686|stage II multiple myeloma
1395720|NCT00400686|stage III multiple myeloma
1395721|NCT00400686|refractory multiple myeloma
1395722|NCT00400673|Acute myelogenous leukemia
1395723|NCT00400673|Adult patients
1395724|NCT00400673|Cytogenetic risk class
1395725|NCT00400673|Clinico-cytogenetic risk model
1395726|NCT00400673|Risk-oriented therapy
1395727|NCT00400660|GSK615915 asthma surfactant MDI
1395728|NCT00400647|kidney transplant
1395729|NCT00400647|enteric-coated mycophenolate sodium
1395730|NCT00400647|quality of life
1395731|NCT00400647|gastrointestinal symptoms
1395732|NCT00400621|acetaminophen
1395733|NCT00400621|alcohol
1395734|NCT00400621|liver injury
1395735|NCT00400608|pediatrics
1395736|NCT00400608|ADVAIR Inhaler
1395737|NCT00400608|Asthma
1395738|NCT00400608|ADVAIR DISKUS
1395739|NCT00400595|peritonitis
1395740|NCT00400595|catheter related infection
1395741|NCT00400595|exit site ointments
1395742|NCT00400595|mupirocin
1395743|NCT00400595|Polysporin Triple
1395744|NCT00400582|Heart failure
1395745|NCT00400582|Gene polymorphism
1395746|NCT00400582|Candesartan
1395747|NCT00400582|ACE inhibitors
1395748|NCT00400582|BNP
1395749|NCT00400582|Pharmacogenomics
1395750|NCT00400569|Sunitinib malate
1395751|NCT00400569|SUTENT
1395752|NCT00400569|SU011248
1395753|NCT00400569|Soft tissue sarcoma
1395754|NCT00400569|Gastrointestinal stromal tumors (GIST)
1395755|NCT00400569|MFH
1395756|NCT00400569|Tyrosine kinase inhibitor
1395757|NCT00400569|Imatinib mesylate
1395758|NCT00400569|Phase II
1395759|NCT00400556|mobilization
1395760|NCT00400556|ATRA
1395761|NCT00400556|G-CSF
1395762|NCT00400556|filgrastim
1395763|NCT00400556|retinoids
1395764|NCT00400556|stem cell mobilization
1395765|NCT00400556|hematopoietic stem and progenitor cells
1395766|NCT00400543|obstructive sleep apnea
1395767|NCT00400543|arterial stiffness
1395768|NCT00400543|atherosclerosis
1395769|NCT00400543|CPAP
1395770|NCT00400543|heart disease
1395771|NCT00400517|stage III prostate cancer
1395772|NCT00400517|stage II prostate cancer
1395773|NCT00400517|adenocarcinoma of the prostate
1395774|NCT00400517|stage I prostate cancer
1395775|NCT00400517|stage IV prostate cancer
1395776|NCT00400504|Thrombelastograph
1395777|NCT00400504|Cancer
1395778|NCT00400504|Thromboembolism
1395779|NCT00400504|Hypercoagulable
1395780|NCT00400491|diabetes
1395781|NCT00400491|insulin
1395782|NCT00400491|glycated hemoglobin
1395783|NCT00400491|cholecalciferol
1395784|NCT00400491|vitamin D
1395785|NCT00400478|DLBCL
1395786|NCT00400478|NHL 13
1395787|NCT00400478|Rituximab
1395788|NCT00400478|maintenance
1395789|NCT00400465|thyroid
1395790|NCT00400465|thyroidectomy
1395791|NCT00400465|dressing
1395792|NCT00400452|wheelchair
1395793|NCT00400452|skills
1395794|NCT00400452|long-term-care
1395795|NCT00400452|caregivers
1395796|NCT00400426|Palliative radiotherapy
1395797|NCT00400426|Recurrent
1395798|NCT00400426|Head and neck Neoplasm
1395799|NCT00400426|Quality of life
1395800|NCT00400413|Neuropsychology
1395801|NCT00400413|fMRI
1395802|NCT00400413|Reading
1395803|NCT00400413|Phonology
1395804|NCT00400413|Deafness
1395805|NCT00400400|RenalTransplantation
1395806|NCT00400400|KidneyTransplantation
1395807|NCT00400400|MPA
1395808|NCT00400400|EC-MPS
1395809|NCT00400387|recurrent pregnancy loss
1395810|NCT00400374|Head and Neck Cancer
1395811|NCT00400335|Testosterone
1395812|NCT00400335|Men
1395813|NCT00400335|Hypogonadism
1395814|NCT00400335|Dutasteride
1395815|NCT00400335|DHT
1395816|NCT00400335|Androgen deficiency
1395817|NCT00400322|glioblastoma multiforme
1395818|NCT00400322|cytomegalovirus infection
1395819|NCT00400322|antiviral treatment
1395820|NCT00400322|valganciclovir
1395821|NCT00400270|Asthma
1395822|NCT00400270|Randomised controlled trial
1395823|NCT00400270|Breathing exercises
1395824|NCT00400270|Relaxation exercises
1395825|NCT00400270|Primary care
1395826|NCT00400257|Heart Failure
1395827|NCT00400257|BNP
1395828|NCT00400244|wheelchairs
1395829|NCT00400244|skills
1395830|NCT00400244|french
1395831|NCT00400231|metabolic syndrome
1395832|NCT00400231|Triglycerides
1395833|NCT00400231|Insulin Resistance
1395834|NCT00400231|inflammation
1395835|NCT00400231|Cardiovascular Disease
1395836|NCT00400231|Elevated triglycerides
1395837|NCT00400231|without diabetes
1395838|NCT00400205|Squamous Cell Carcinoma of the Oral Cavity
1395839|NCT00400192|Microchimerism
1395840|NCT00400192|Injuries
1395841|NCT00400192|Leukocytes
1395842|NCT00400192|Immunologic Techniques
1395843|NCT00400179|Gastric Cancer
1395844|NCT00400166|Peer support
1395845|NCT00400166|Psychiatric disability
1395846|NCT00400166|Mutual support
1395847|NCT00400166|Psychiatric Rehabilitation
1395848|NCT00400140|Myopia, defocus
1395849|NCT00400127|transfemoral amputee
1395850|NCT00400127|silicon suspension
1395851|NCT00400127|balance
1395852|NCT00400127|gait
1395853|NCT00400114|esophageal
1395854|NCT00400114|esophagus
1395855|NCT00400114|cancer
1395856|NCT00400114|sutent
1395857|NCT00400114|sunitinib
1395858|NCT00400101|Malaria
1395859|NCT00400101|Vaccine
1395860|NCT00400101|Plasmodium
1395861|NCT00400101|falciparum
1395862|NCT00400101|Phase I
1395863|NCT00400101|Peptide
1395864|NCT00400101|Virosome
1395865|NCT00400101|safety
1395866|NCT00400101|immunogenicity
1395867|NCT00400088|Major Depressive Disorder
1395868|NCT00400088|Depression
1395869|NCT00400088|Bipolar Disorder
1395870|NCT00400088|Manic Depressive Illness
1395871|NCT00400088|Randomized Trial
1395872|NCT00400088|Antidepressant Treatment
1395873|NCT00400088|Lithium Treatment
1395874|NCT00400075|Polyarteritis
1395875|NCT00400075|Vasculitis
1395876|NCT00400075|Therapy
1395877|NCT00400075|Cyclophosphamide
1395878|NCT00400075|Azathioprine
1395879|NCT00400062|Critical care
1395880|NCT00400062|delirium
1395881|NCT00400062|long-term cognitive impairment
1395882|NCT00400062|mechanical ventilation
1395883|NCT00400062|critical illness
1395884|NCT00400062|dementia
1395885|NCT00400062|aging
1395886|NCT00400062|sedatives and analgesics
1395887|NCT00400036|cod protein
1395888|NCT00400036|insulin sensitivity
1395889|NCT00400036|plasma lipids
1395890|NCT00400036|glucose tolerance
1395891|NCT00400036|plasma inflammatory markers
1395892|NCT00400036|skeletal muscle insulin signaling
1395893|NCT00400036|type 2 diabetes
1395894|NCT00400036|humans
1395895|NCT00400023|Advanced Solid Tumors
1395896|NCT00400010|Expert system
1395897|NCT00400010|Transtheoretical Model of Behavior Change
1395898|NCT00400010|Brief intervention
1395899|NCT00400010|General hospital
1395900|NCT00399997|Exercise
1395901|NCT00399997|Exercise referral
1395902|NCT00399997|Lifestyle diseases
1395903|NCT00399997|Sedentary behavior
1395904|NCT00399984|Continuing Medical Education
1395905|NCT00399971|Idiopathic Aplastic Anemia
1395906|NCT00399971|Has Failed Conventional Immunosuppressive Therapy
1395907|NCT00399971|Not Eligible For Bone Marrow Transplantation
1395908|NCT00399971|C15.378.071.085
1395909|NCT00399945|Cystic fibrosis, tobramycin, PARI eFlow, PARI LC Plus, nebulizer, pharmacoscintigraphy
1395910|NCT00399932|metabolic syndrome
1395911|NCT00399932|insulin resistance
1395912|NCT00399932|NASH
1395913|NCT00399932|hepatic fibrosis
1395914|NCT00399932|Fibroscan
1395915|NCT00399932|elastography by MRI
1395916|NCT00399919|Perhipheral Artery Disease
1395917|NCT00399919|Claudication
1395918|NCT00399919|Exercise
1395919|NCT00399919|Intermittent Claudication due to Peripheral Artery Disease
1395920|NCT00399893|Childhood obesity
1395921|NCT00399893|Prader-Willi Syndrome
1395922|NCT00399893|Octreotide
1395923|NCT00399893|Ghrelin
1395924|NCT00399893|Weight loss
1395925|NCT00399893|Body composition
1395926|NCT00399893|Energy expenditure
1395927|NCT00399880|Clinical Trial
1395928|NCT00399880|Behavioral/Social
1395929|NCT00399880|Cardiovascular Disease
1395930|NCT00399880|Risk Factors/Analysis
1395931|NCT00399867|multiple myeloma
1395932|NCT00399867|refractory
1395933|NCT00399867|cell adhesion mediated drug resistance
1395934|NCT00399841|Pain
1395935|NCT00399841|Chronic Pain
1395936|NCT00399841|Neurostimulation
1395937|NCT00399815|Chronic viral hepatitis C
1395938|NCT00399815|HCV RNA
1395939|NCT00399815|Fibroscan
1395940|NCT00399815|Fibrotest
1395941|NCT00399815|hepatic elastography by MRI
1395942|NCT00399789|Non-Small-Cell Lung
1395943|NCT00399789|Perifosine
1395944|NCT00399776|bone mineral
1395945|NCT00399776|antipsychotic therapy
1395946|NCT00399776|bone mineral accrual
1395947|NCT00399776|bone mineral content
1395948|NCT00399763|Adolescent
1395949|NCT00399763|ADHD
1395950|NCT00399763|SUD
1395951|NCT00399737|ACE activity
1395952|NCT00399737|Fermented milk peptides
1395953|NCT00399737|Healthy male volunteers
1395954|NCT00399698|Severe conduct problems
1395955|NCT00399698|Risperidone
1395956|NCT00399698|Risperdal
1395957|NCT00399685|HIV
1395958|NCT00399672|HCV
1395959|NCT00399672|injection drug users
1395960|NCT00399672|ribavirin
1395961|NCT00399672|pegylated interferon
1395962|NCT00399672|illicit drug users
1395963|NCT00399659|Opioid, constipation, tegaserod
1395964|NCT00399633|VIP
1395965|NCT00399633|PACAP
1395966|NCT00399633|CGRP
1395967|NCT00399633|Prostanoids
1395968|NCT00399620|Periodontitis
1395969|NCT00399620|Diabetes
1395970|NCT00399620|Gingival crevicular fluid
1395971|NCT00399620|GCF
1395972|NCT00399620|Saliva
1395973|NCT00399620|Chromogranin
1395974|NCT00399620|Electrophorèse
1395975|NCT00399620|Western Blot
1395976|NCT00399620|RT-HPLC
1395977|NCT00399607|colonic neoplasms
1395978|NCT00399607|colorectal adenoma
1395979|NCT00399607|calcium
1395980|NCT00399607|vitamin D
1395981|NCT00399594|Mechanical dyssynchrony
1395982|NCT00399594|Biventricular pacing
1395983|NCT00399594|Cardiac resynchronization therapy
1395984|NCT00399581|Acute Respiratory Distress Syndrome
1395985|NCT00399581|Acute Lung Injury
1395986|NCT00399581|Mechanical Ventilation
1395987|NCT00399581|Lung
1395988|NCT00399568|Pain
1395989|NCT00399568|Gynecologic
1395990|NCT00399568|IV Acetaminophen
1395991|NCT00399568|Postoperative
1395992|NCT00399568|Analgesic
1395993|NCT00399555|Single Ventricle
1395994|NCT00399555|Hypoplastic Left Heart
1395995|NCT00399555|Developmental
1395996|NCT00399542|Irritable Bowel Syndrome With Constipation
1395997|NCT00399529|Stage IV HER-2/neu overexpressing breast cancer
1395998|NCT00399516|Pain
1395999|NCT00399516|Neurostimulation
1396000|NCT00399516|Back pain
1396001|NCT00399516|Chronic Pain
1396002|NCT00399503|Noninvasive assessment
1396003|NCT00399503|Combined parameter
1396004|NCT00399503|Holter
1396005|NCT00399490|Monoclonal antibody
1396006|NCT00399464|Benign Prostatic Hyperplasia
1396007|NCT00399464|Adrenergic alpha-Antagonists
1396008|NCT00399464|alfuzosin
1396009|NCT00399451|Sleep Apnea,Obstructive
1396010|NCT00399451|apnea-hypopnea index (AHI)
1396011|NCT00399451|polidocanol
1396012|NCT00399451|sclerotherapy
1396013|NCT00399451|pharynges
1396014|NCT00399438|Diarrhea-predominant irritable bowel syndrome
1396015|NCT00399425|Heparin, Low-Molecular-Weight
1396016|NCT00399425|Bemiparin
1396017|NCT00399425|Foot Ulcer, Diabetic
1396018|NCT00399425|Diabetic Angiopathies
1396019|NCT00399425|Primary Health Care
1396020|NCT00399412|S-ICD
1396021|NCT00399412|ICD
1396022|NCT00399412|ECG signals
1396023|NCT00399412|Resting
1396024|NCT00399399|Churg-Strauss
1396025|NCT00399399|Vasculitis
1396026|NCT00399399|Therapy
1396027|NCT00399399|Cyclophosphamide
1396028|NCT00399399|Azathioprine
1396029|NCT00399386|S ICD
1396030|NCT00399386|ICD
1396031|NCT00399386|Ablation
1396032|NCT00399386|EP study
1396033|NCT00399386|Paediatric
1396034|NCT00399386|ECG
1396035|NCT00399373|disease management
1396036|NCT00399373|substance abuse
1396037|NCT00399360|HIV
1396038|NCT00399360|Metabolic Syndrome
1396039|NCT00399360|Lifestyle Modification
1396040|NCT00399360|Metformin
1396041|NCT00399360|Treatment Experienced
1396042|NCT00399347|Diabetes Mellitus, prevalence , Ethiopians Jews, Israel
1396043|NCT00399334|Schizophrenia
1396044|NCT00399334|Schizoaffective
1396045|NCT00399334|relapse
1396046|NCT00399334|risk factors
1396047|NCT00399334|Observational study
1396048|NCT00399334|Antipsychotic medication
1396049|NCT00399321|Post menopause women receiving adjuvant care
1396050|NCT00399308|wound
1396051|NCT00399308|leg
1396052|NCT00399308|venous
1396053|NCT00399308|chronic
1396054|NCT00399308|wound healing
1396055|NCT00399295|Analgesia
1396056|NCT00399282|Rheumatoid arthritis
1396057|NCT00399282|Health related quality of life
1396058|NCT00399282|Omega 3 fatty acids
1396059|NCT00399282|Vitamin E
1396060|NCT00399269|Anemia
1396061|NCT00399256|contrast-induced nephropathy
1396062|NCT00399256|Acetylcysteine
1396063|NCT00399256|Zinc
1396064|NCT00399256|Cystatin C
1396065|NCT00399256|Creatinine
1396066|NCT00399243|cluster headache
1396067|NCT00399243|sumatriptan
1396068|NCT00399217|subcutaneous ICD
1396069|NCT00399217|ICD
1396070|NCT00399217|DFT
1396071|NCT00399217|Pacing threshold
1396072|NCT00399217|Polarity
1396073|NCT00399191|anemia
1396074|NCT00399191|iron deficiency anemia
1396075|NCT00399191|iron deficiency
1396076|NCT00399191|absorption
1396077|NCT00399191|iron absorption
1396078|NCT00399191|iron uptake
1396079|NCT00399178|Osteoarthritis
1396080|NCT00399178|Norspan versus Tramadol
1396081|NCT00399178|Randomised
1396082|NCT00399178|Efficacy and safety
1396083|NCT00399178|OA pain of the hip and/or knee
1396084|NCT00399165|Oral Contraception for Men
1396085|NCT00399165|Contraceptive agent
1396086|NCT00399152|Perifosine
1396087|NCT00399152|Sunitinib Malate
1396088|NCT00399152|Renal cancer
1396089|NCT00399152|GIST
1396090|NCT00399152|advanced cancers
1396091|NCT00399074|Sickle Cell anemia
1396092|NCT00399074|Malaria
1396093|NCT00399074|Presumptive treatment
1396094|NCT00399074|Sulfadoxine- pyrimethamine
1396095|NCT00399074|Children
1396096|NCT00399074|Uganda
1396097|NCT00399048|Pain
1396098|NCT00399048|Osteoarthritis
1396099|NCT00399048|knee Osteoarthritis
1396100|NCT00399048|hip Osteoarthritis .
1396101|NCT00399035|Colorectal Cancer
1396102|NCT00399035|Cediranib
1396103|NCT00399035|RECENTIN
1396104|NCT00399009|Circular stapling devices
1396105|NCT00399009|anastomotic leak
1396106|NCT00399009|anastomotic dehiscence
1396107|NCT00399009|rectal cancer
1396108|NCT00398996|antiretroviral therapy
1396109|NCT00398996|HIV
1396110|NCT00398996|Opportunistic infections
1396111|NCT00398996|CD4
1396112|NCT00398996|Viral load
1396113|NCT00398996|TB/HIV co infection
1396114|NCT00398996|Treatment Naive
1396115|NCT00398983|Acute Myelogenous Leukemia
1396116|NCT00398983|AML
1396117|NCT00398983|Remission
1396118|NCT00398983|Decitabine
1396119|NCT00398983|Maintenance Therapy
1396120|NCT00398970|Endobronchial ultrasonography
1396121|NCT00398970|Fluoroscopy
1396122|NCT00398970|Guide sheath
1396123|NCT00398970|Peripheral pulmonary lesion
1396124|NCT00398970|Transbronchial biopsy
1396125|NCT00398957|Analgesia
1396126|NCT00398944|Guideline based decision support system, Hypertension, Diabetes
1396127|NCT00398905|Prevention of venous thromboembolism
1396128|NCT00398892|Type 2 diabetes mellitus
1396129|NCT00398892|Glycaemic control
1396130|NCT00398892|Lipoic acid
1396131|NCT00398892|Diabetic nephropathy
1396132|NCT00398879|Capecitabine
1396133|NCT00398866|Hyaluronan
1396134|NCT00398866|Carpometacarpal
1396135|NCT00398866|Outcomes
1396136|NCT00398866|Carpometacarpal Joints
1396137|NCT00398853|insulin
1396138|NCT00398853|glucose
1396139|NCT00398853|chromium
1396140|NCT00398840|Cancer
1396141|NCT00398840|Solid Tumors
1396142|NCT00398840|advanced solid tumors
1396143|NCT00398827|American Society of Anesthesiologists (ASA)
1396144|NCT00398827|Observer's Assessment of Alertness Scale (OAA/S)
1396145|NCT00398827|Aldrete Scoring System
1396146|NCT00398827|Surgery or procedure using monitored care anesthesia
1396147|NCT00398827|Surgery or procedure at least 30 minutes in duration
1396148|NCT00398814|Perifosine
1396149|NCT00398814|Sorafenib
1396150|NCT00398814|Renal cancer
1396151|NCT00398814|Hepatocellular cancer
1396152|NCT00398814|other advanced solid tumors
1396153|NCT00398801|gastroparesis
1396154|NCT00398788|Pain
1396155|NCT00398775|procalcitonin guided antibiotic discontinuation
1396156|NCT00398775|fever of unknown origin
1396157|NCT00398749|Anemia
1396158|NCT00398749|Neoplasms
1396159|NCT00398749|Antineoplastic agents
1396160|NCT00398749|Chemotherapy
1396161|NCT00398749|Efficacy
1396162|NCT00398749|Epoetin alfa
1396163|NCT00398736|Presence of severe sepsis and septic shock, mechanical ventilation
1396164|NCT00398723|Narrowband UBV Phototherapy
1396165|NCT00398723|Skin biopsies
1396166|NCT00398710|Waldenström's Macroglobulinemia
1396167|NCT00398710|Perifosine
1396168|NCT00398697|perifosine
1396169|NCT00398697|gemcitabine
1396170|NCT00398684|Thailand
1396171|NCT00398684|Developing countries
1396172|NCT00398684|prophylaxis
1396173|NCT00398684|mother to child transmission
1396174|NCT00398684|HIV-1
1396175|NCT00398684|HIV-1 infection
1396176|NCT00398684|HIV Seronegativity
1396177|NCT00398671|primary successful cardio-pulmonary resuscitation
1396178|NCT00398671|pre-hospital setting
1396179|NCT00398658|Endophthalmitis
1396180|NCT00398658|Post-traumatic Endophthalmitis
1396181|NCT00398658|Bacterial Endophthalmitis
1396182|NCT00398658|Prophylaxis of Endophthalmitis
1396183|NCT00398658|Intra Ocular Injection of antibiotics
1396184|NCT00398645|GW685698X
1396185|NCT00398645|Adults
1396186|NCT00398645|Pharmacokinetics
1396187|NCT00398645|Pharmacogenetics
1396188|NCT00398645|Asthma
1396189|NCT00398645|Adolescents
1396190|NCT00398593|Adherence with therapy
1396191|NCT00398593|Adherence enhancing intervention
1396192|NCT00398593|Nonadherence
1396193|NCT00398593|Ulcerative colitis
1396194|NCT00398580|DHT
1396195|NCT00398580|Testosterone
1396196|NCT00398580|Hypogonadism
1396197|NCT00398580|Dutasteride
1396198|NCT00398580|Androgen deficiency
1396199|NCT00398567|HKI-272
1396200|NCT00398567|neratinib
1396201|NCT00398567|trastuzumab
1396202|NCT00398567|Herceptin
1396203|NCT00398567|breast cancer
1396204|NCT00398554|stage II childhood Hodgkin lymphoma
1396205|NCT00398554|stage III childhood Hodgkin lymphoma
1396206|NCT00398554|stage IV childhood Hodgkin lymphoma
1396207|NCT00398554|stage I childhood Hodgkin lymphoma
1396208|NCT00398554|childhood lymphocyte depletion Hodgkin lymphoma
1396209|NCT00398554|childhood mixed cellularity Hodgkin lymphoma
1396210|NCT00398554|childhood nodular sclerosis Hodgkin lymphoma
1396211|NCT00398528|Multiple Sclerosis
1396212|NCT00398528|Disease Modifying Therapy
1396213|NCT00398489|stage IIIA breast cancer
1396214|NCT00398489|stage IIIB breast cancer
1396215|NCT00398489|stage IIIC breast cancer
1396216|NCT00398489|stage II breast cancer
1396217|NCT00398489|inflammatory breast cancer
1396218|NCT00398476|taste
1396219|NCT00398476|questionnaire
1396220|NCT00398476|preference
1396221|NCT00398476|attributes
1396222|NCT00398476|odor
1396223|NCT00398476|after taste
1396224|NCT00398476|scent
1396225|NCT00398463|tirofiban
1396226|NCT00398463|aspirin resistance
1396227|NCT00398463|clopidogrel resistance
1396228|NCT00398450|recurrent melanoma
1396229|NCT00398450|stage IV melanoma
1396230|NCT00398437|tumors metastatic to brain
1396231|NCT00398437|stage IV breast cancer
1396232|NCT00398424|Impaired Hepatic Function
1396233|NCT00398411|prophylaxis
1396234|NCT00398411|bacteremia
1396235|NCT00398411|moxifloxacin
1396236|NCT00398411|stem cell transplantation
1396237|NCT00398411|Hodgkin disease
1396238|NCT00398411|non-Hodgkin lymphoma
1396239|NCT00398411|multiple myeloma
1396240|NCT00398411|solid tumor
1396241|NCT00398411|autologous stem cell transplantation
1396242|NCT00398398|gastric cancer
1396243|NCT00398398|chemotherapy
1396244|NCT00398398|cetuximab
1396245|NCT00398398|capecitabine
1396246|NCT00398398|oxaliplatin
1396247|NCT00398385|squamous cell lung cancer
1396248|NCT00398385|adenocarcinoma of the lung
1396249|NCT00398385|adenosquamous cell lung cancer
1396250|NCT00398385|bronchoalveolar cell lung cancer
1396251|NCT00398385|large cell lung cancer
1396252|NCT00398385|stage IB non-small cell lung cancer
1396253|NCT00398385|stage IIA non-small cell lung cancer
1396254|NCT00398385|stage IIB non-small cell lung cancer
1396255|NCT00398359|Obesity
1396256|NCT00398359|Overweight
1396257|NCT00398359|Children
1396258|NCT00398359|Behavioral
1396259|NCT00398359|Motivational
1396260|NCT00398359|Family
1396261|NCT00398359|Primary care
1396262|NCT00398333|Colorectal Neoplasms
1396263|NCT00398333|Eicosapentaenoic Acid
1396264|NCT00398333|Quality of Life
1396265|NCT00398333|Nutritional Status
1396266|NCT00398307|Renal Impairment
1396267|NCT00398281|prostate cancer
1396268|NCT00398268|Fracture
1396269|NCT00398268|Forearm
1396270|NCT00398268|Distal
1396271|NCT00398268|Child
1396272|NCT00398268|Treatment
1396273|NCT00398255|arthritis
1396274|NCT00398255|self management
1396275|NCT00398255|patient education
1396276|NCT00398242|fracture
1396277|NCT00398242|forearm
1396278|NCT00398242|midshaft
1396279|NCT00398242|child
1396280|NCT00398242|treatment
1396281|NCT00398229|In-Vitro Fertilization
1396282|NCT00398229|human chorionic gonadotropin
1396283|NCT00398229|frozen-thawed embryo transfer
1396284|NCT00398229|implantation rate
1396285|NCT00398216|Anti-coagulant
1396286|NCT00398216|hip replacement
1396287|NCT00398216|hip replacement surgery
1396288|NCT00398216|unilateral hip replacement surgery
1396289|NCT00398216|DeepVein Thrombosis
1396290|NCT00398216|Venous Thromboembolism
1396291|NCT00398216|pulmonary embolism
1396292|NCT00398216|Prevention of Blood Clots
1396293|NCT00398203|NaviAid™ BGE Device
1396294|NCT00398203|Small Intestine
1396295|NCT00398203|Intestinal Diseases
1396296|NCT00398190|Smoking
1396297|NCT00398190|Tobacco use disorder
1396298|NCT00398138|adult acute myeloid leukemia in remission
1396299|NCT00398138|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1396300|NCT00398138|adult acute myeloid leukemia with inv(16)(p13;q22)
1396301|NCT00398138|adult acute myeloid leukemia with t(15;17)(q22;q12)
1396302|NCT00398138|adult acute myeloid leukemia with t(16;16)(p13;q22)
1396303|NCT00398138|adult acute myeloid leukemia with t(8;21)(q22;q22)
1396304|NCT00398138|de novo myelodysplastic syndromes
1396305|NCT00398138|previously treated myelodysplastic syndromes
1396306|NCT00398138|secondary myelodysplastic syndromes
1396307|NCT00398138|recurrent non-small cell lung cancer
1396308|NCT00398138|stage IIIA non-small cell lung cancer
1396309|NCT00398138|stage IIIB non-small cell lung cancer
1396310|NCT00398138|stage IV non-small cell lung cancer
1396311|NCT00398138|advanced malignant mesothelioma
1396312|NCT00398138|recurrent malignant mesothelioma
1396313|NCT00398138|primary peritoneal cavity cancer
1396314|NCT00398125|GSK364735
1396315|NCT00398125|HIV-1
1396316|NCT00398125|integrase inhibitor
1396317|NCT00398086|Metastatic Pancreatic Cancer, Abraxane, Gemcitabine
1396318|NCT00398073|stage II melanoma
1396319|NCT00398073|stage III melanoma
1396320|NCT00398073|stage IV melanoma
1396321|NCT00398073|recurrent melanoma
1396322|NCT00398073|ciliary body and choroid melanoma, medium/large size
1396323|NCT00398073|ciliary body and choroid melanoma, small size
1396324|NCT00398073|recurrent intraocular melanoma
1396325|NCT00398073|metastatic intraocular melanoma
1396326|NCT00398060|life-style counseling
1396327|NCT00398060|type 2 diabetes
1396328|NCT00398060|prediabetes
1396329|NCT00398060|physical activity
1396330|NCT00398060|diet
1396331|NCT00398060|cognitive-behavioral
1396332|NCT00398047|de novo myelodysplastic syndromes
1396333|NCT00398047|refractory anemia with ringed sideroblasts
1396334|NCT00398047|refractory anemia with excess blasts
1396335|NCT00398047|refractory anemia
1396336|NCT00398047|refractory cytopenia with multilineage dysplasia
1396337|NCT00398047|chronic myelomonocytic leukemia
1396338|NCT00398047|secondary myelodysplastic syndromes
1396339|NCT00398047|childhood myelodysplastic syndromes
1396340|NCT00398034|opioids
1396341|NCT00398034|pain
1396342|NCT00398034|hypogonadism
1396343|NCT00398034|depression
1396344|NCT00398034|fatigue
1396345|NCT00398034|cognition
1396346|NCT00398034|libido
1396347|NCT00398021|constipation
1396348|NCT00398021|bowel habits
1396349|NCT00398008|Buprenorphine
1396350|NCT00398008|Naltrexone
1396351|NCT00398008|HIV risk reduction behavior
1396352|NCT00398008|Counseling
1396353|NCT00398008|HIV Seronegativity
1396354|NCT00397995|Fracture
1396355|NCT00397995|Forearm
1396356|NCT00397995|Distal
1396357|NCT00397995|Child
1396358|NCT00397995|Treatment
1396359|NCT00397969|colon cancer
1396360|NCT00397969|rectal cancer
1396361|NCT00397969|precancerous condition
1396362|NCT00397943|Tuberculosis
1396363|NCT00397930|cancer-related sleep disturbance
1396364|NCT00397930|fatigue
1396365|NCT00397930|sleep disorders
1396366|NCT00397904|adenocarcinoma of the esophagus
1396367|NCT00397904|squamous cell carcinoma of the esophagus
1396368|NCT00397904|recurrent esophageal cancer
1396369|NCT00397904|recurrent gastric cancer
1396370|NCT00397904|adenocarcinoma of the stomach
1396371|NCT00397904|stage IV esophageal cancer
1396372|NCT00397904|stage IV gastric cancer
1396373|NCT00397865|Obesity
1396374|NCT00397865|Overweight
1396375|NCT00397852|Fracture
1396376|NCT00397852|Forearm
1396377|NCT00397852|Distal
1396378|NCT00397852|Child
1396379|NCT00397852|Treatment
1396380|NCT00397839|male osteoporosis
1396381|NCT00397839|osteoporosis
1396382|NCT00397839|bisphonates
1396383|NCT00397839|bone
1396384|NCT00397800|recurrent grade 1 follicular lymphoma
1396385|NCT00397800|recurrent grade 2 follicular lymphoma
1396386|NCT00397800|Waldenstrom macroglobulinemia
1396387|NCT00397800|recurrent mantle cell lymphoma
1396388|NCT00397800|recurrent marginal zone lymphoma
1396389|NCT00397800|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1396390|NCT00397800|nodal marginal zone B-cell lymphoma
1396391|NCT00397800|splenic marginal zone lymphoma
1396392|NCT00397774|Palliative care
1396393|NCT00397774|Physical exercise
1396394|NCT00397774|Physical function
1396395|NCT00397761|inflammatory breast cancer
1396396|NCT00397761|stage II breast cancer
1396397|NCT00397761|stage IIIA breast cancer
1396398|NCT00397761|stage IIIB breast cancer
1396399|NCT00397748|Phospholipase A2
1396400|NCT00397748|D2 Receptors
1396401|NCT00397748|Apomorphine
1396402|NCT00397748|Trimethobenzamide
1396403|NCT00397748|Attention Deficit Hyperactivity Disorder
1396404|NCT00397748|ADHD
1396405|NCT00397748|Healthy Volunteer
1396406|NCT00397748|HV
1396407|NCT00397735|pregnancy
1396408|NCT00397735|chorioamnionitis
1396409|NCT00397735|preterm labor
1396410|NCT00397735|preterm premature rupture of the membranes
1396411|NCT00397735|Intra-amniotic infection
1396412|NCT00397735|Intra-amniotic inflammation
1396413|NCT00397722|effectiveness
1396414|NCT00397722|safety
1396415|NCT00397722|outpatients with a diagnosis of Social Anxiety disorder (SocAD).
1396416|NCT00397709|Latent tuberculosis infection.
1396417|NCT00397709|Isoniazid.
1396418|NCT00397709|Rifampin.
1396419|NCT00397709|Clinical trial.
1396420|NCT00397709|treatment of latent tuberculosis infection
1396421|NCT00397696|Parkinson
1396422|NCT00397696|imaging
1396423|NCT00397696|nicotinic receptors
1396424|NCT00397657|carotid intima media thickness
1396425|NCT00397657|atherosclerosis
1396426|NCT00397657|niacin
1396427|NCT00397657|coronary heart disease
1396428|NCT00397657|HDL-C
1396429|NCT00397657|LDL-C
1396430|NCT00397644|pediatrician
1396431|NCT00397644|well-child care visit
1396432|NCT00397644|low-income children
1396433|NCT00397644|family psychosocial problem
1396434|NCT00397605|bipolar
1396435|NCT00397605|therapeutic potential
1396436|NCT00397605|neurocognitive performance
1396437|NCT00397605|cannabinoids
1396438|NCT00397592|Growth Hormone
1396439|NCT00397592|Cardiovascular System
1396440|NCT00397592|Endothelial Progenitor Cells
1396441|NCT00397579|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1396442|NCT00397579|adult acute myeloid leukemia with inv(16)(p13;q22)
1396443|NCT00397579|adult acute myeloid leukemia with t(15;17)(q22;q12)
1396444|NCT00397579|adult acute myeloid leukemia with t(16;16)(p13;q22)
1396445|NCT00397579|adult acute myeloid leukemia with t(8;21)(q22;q22)
1396446|NCT00397579|recurrent adult acute myeloid leukemia
1396447|NCT00397579|secondary acute myeloid leukemia
1396448|NCT00397579|untreated adult acute myeloid leukemia
1396449|NCT00397579|de novo myelodysplastic syndromes
1396450|NCT00397579|previously treated myelodysplastic syndromes
1396451|NCT00397579|secondary myelodysplastic syndromes
1396452|NCT00397579|blastic plasmacytoid dendritic cell neoplasm
1396453|NCT00397579|plasmacytoid dendritic cell leukemia
1396454|NCT00397579|CD123+
1396455|NCT00397566|HIV
1396456|NCT00397566|Treatment Experienced
1396457|NCT00397540|HBV DNA
1396458|NCT00397540|HCC
1396459|NCT00397540|recurrence
1396460|NCT00397540|PEIT
1396461|NCT00397540|RFTA
1396462|NCT00397514|Biventricular pacing
1396463|NCT00397514|Congenital heart disease
1396464|NCT00397514|Tissue Doppler echocardiography
1396465|NCT00397501|cognitive/functional effects
1396466|NCT00397501|psychosocial effects of cancer and its treatment
1396467|NCT00397501|drug/agent toxicity by tissue/organ
1396468|NCT00397501|recurrent breast cancer
1396469|NCT00397501|stage IV breast cancer
1396470|NCT00397501|adult tumors metastatic to brain
1396471|NCT00397488|recurrent bladder cancer
1396472|NCT00397488|stage IV bladder cancer
1396473|NCT00397488|transitional cell carcinoma of the bladder
1396474|NCT00397488|anterior urethral cancer
1396475|NCT00397488|posterior urethral cancer
1396476|NCT00397488|recurrent urethral cancer
1396477|NCT00397488|metastatic transitional cell cancer of the renal pelvis and ureter
1396478|NCT00397488|recurrent transitional cell cancer of the renal pelvis and ureter
1396479|NCT00397488|urethral cancer associated with invasive bladder cancer
1396480|NCT00397462|Osteoporosis
1396481|NCT00397462|Sarcopenia
1396482|NCT00397462|Calf muscle pump
1396483|NCT00397462|Venous insufficiency
1396484|NCT00397462|DEXA
1396485|NCT00397462|Soleus muscle
1396486|NCT00397462|APG
1396487|NCT00397449|Malaria, malaria vaccine, randomised, safety, immunogenicity
1396488|NCT00397423|Amyotrophic Lateral Sclerosis
1396489|NCT00397423|Granulocyte Colony Stimulating Factor
1396490|NCT00397423|Randomized Control Trial Study
1396491|NCT00397410|hip protectors
1396492|NCT00397410|uptake and adherence
1396493|NCT00397410|Nursing home residents
1396494|NCT00397410|efficacy
1396495|NCT00397410|prevention
1396496|NCT00397397|Urinary Calculi
1396497|NCT00397397|Rowatinex
1396498|NCT00397397|Alfuzosin
1396499|NCT00397397|Drug Therapy
1396500|NCT00397358|Peritoneal Dialysis
1396501|NCT00397358|Hypertriglyceridemia
1396502|NCT00397358|Extraneal(7.5% icodextrin)Peritoneal Dialysis Solution
1396503|NCT00397345|Renal
1396504|NCT00397345|TroVax
1396505|NCT00397345|survival
1396506|NCT00397345|metastatic
1396507|NCT00397345|Kidney
1396508|NCT00397345|cancer
1396509|NCT00397345|immunotherapy
1396510|NCT00397345|Locally advanced or metastatic, measurable, histologically proven clear cell renal carcinoma.
1396511|NCT00397332|GVHD
1396512|NCT00397319|Growth Hormone
1396513|NCT00397319|Cardiovascular System
1396514|NCT00397293|AT101
1396515|NCT00397293|AT-101
1396516|NCT00397293|cancer
1396517|NCT00397293|lung
1396518|NCT00397293|small-cell
1396519|NCT00397293|topotecan
1396520|NCT00397280|Neutrophil
1396521|NCT00397280|Immunity
1396522|NCT00397280|Signal Transduction
1396523|NCT00397280|Lipopolysaccharide
1396524|NCT00397280|Cholesterol
1396525|NCT00397280|Healthy Volunteer
1396526|NCT00397280|HV
1396527|NCT00397267|Dyspnea
1396528|NCT00397267|Cough
1396529|NCT00397254|Migraine
1396530|NCT00397254|rizatriptan
1396531|NCT00397228|Parkinson
1396532|NCT00397228|imaging
1396533|NCT00397228|dopamine transporter
1396534|NCT00397215|H5N1
1396535|NCT00397215|influenza
1396536|NCT00397215|vaccine
1396537|NCT00397202|Menstruation
1396538|NCT00397189|Primary insomnia as defined by DSM IV criteria
1396539|NCT00397163|Coronary artery bypass graft surgery
1396540|NCT00397163|Remote ischemic preconditioning
1396541|NCT00397163|Troponin-T
1396542|NCT00397150|Infant Nutrition [G06.696.259.750]
1396543|NCT00397150|Infant Care [N02.421.088.120] +
1396544|NCT00397150|Diarrhea, Infantile [C23.888.821.214.500]
1396545|NCT00397150|Child Health Services [N02.421.143.130] +
1396546|NCT00397150|Counseling [N02.421.143.303]
1396547|NCT00397150|Growth [G07.574.249] +
1396548|NCT00397150|Micronutrients [D11.430]
1396549|NCT00397150|Breast Feeding [G06.696.259.750.500]
1396550|NCT00397137|Symptomatic haemorrhoids
1396551|NCT00397137|haemorrhoidectomy
1396552|NCT00397137|stapled anopexy
1396553|NCT00397111|Morphometry
1396554|NCT00397111|BOLD
1396555|NCT00397111|fMRI
1396556|NCT00397111|Spectrometry
1396557|NCT00397111|Relaxometry
1396558|NCT00397111|Healthy Volunteer
1396559|NCT00397111|HV
1396560|NCT00397098|Anxiety disorders, Relapse prevention
1396561|NCT00397072|Glioblastoma recurrent,temozolomide, epothilone
1396562|NCT00397059|Escitalopram
1396563|NCT00397059|Pharmacokinetics
1396564|NCT00397059|Pharmacodynamics
1396565|NCT00397059|CYP2C19
1396566|NCT00397059|Pupillometry
1396567|NCT00397059|healthy volunteers
1396568|NCT00397046|Advanced Malignant Solid Tumors
1396569|NCT00397033|Schizoaffective Disorder
1396570|NCT00397033|antipsychotic
1396571|NCT00397033|paliperidone
1396572|NCT00397033|placebo
1396573|NCT00397020|quetiapine
1396574|NCT00397020|divalproex
1396575|NCT00397007|tinnitus
1396576|NCT00397007|biofeedback
1396577|NCT00397007|psychophysiological reactivity
1396578|NCT00397007|intervention
1396579|NCT00396994|biomechanics
1396580|NCT00396994|osteogenesis
1396581|NCT00396994|osteoporosis
1396582|NCT00396994|bone regeneration
1396583|NCT00396981|Intracranial saccular aneurysms
1396584|NCT00396981|Endovascular coiling therapy
1396585|NCT00396981|Retreatment
1396586|NCT00396981|Raymond scale
1396587|NCT00396981|Matrix
1396588|NCT00396981|GDC
1396589|NCT00396981|Guglielmi Detachable Coil
1396590|NCT00396968|AMD3100
1396591|NCT00396968|Acute Myelogenous Leukemai
1396592|NCT00396968|Myelodysplastic Syndromes
1396593|NCT00396968|Allogeneic stem cell transplantation
1396594|NCT00396955|osteoarthritis
1396595|NCT00396955|arthritis
1396596|NCT00396955|pain
1396597|NCT00396942|Electroencephalogram (EEG)
1396598|NCT00396942|Nerve Conduction Study
1396599|NCT00396942|Transcranial Magnetic Stimulation (TMS)
1396600|NCT00396942|Motor Evoked Potential
1396601|NCT00396942|Parkinson Disease
1396602|NCT00396942|PD
1396603|NCT00396942|Healthy Volunteer
1396604|NCT00396942|HV
1396605|NCT00396929|Paclitaxel
1396606|NCT00396929|Restenosis
1396607|NCT00396929|Stent
1396608|NCT00396929|Intracoronary Dosis
1396609|NCT00396929|Paclitaxel-eluting Stent
1396610|NCT00396916|cancer patients
1396611|NCT00396903|Anaesthetic techniques
1396612|NCT00396903|epidural catheters
1396613|NCT00396903|paraesthesia
1396614|NCT00396903|side effects.
1396615|NCT00396890|Theta Burst Stimulation
1396616|NCT00396890|Repetitive TMS (rTMS)
1396617|NCT00396890|Transcranial Magnetic Stimulation (TMS)
1396618|NCT00396890|Primary Motor Cortex
1396619|NCT00396890|Interhemispheric Disinhibition
1396620|NCT00396890|Healthy Volunteer
1396621|NCT00396890|HV
1396622|NCT00396877|cyanotic congenital heart disease
1396623|NCT00396877|shunt palliation
1396624|NCT00396877|thrombosis
1396625|NCT00396877|clopidogrel
1396626|NCT00396864|cutaneous lymphoma
1396627|NCT00396864|marginal zone lymphoma
1396628|NCT00396825|Care giving
1396629|NCT00396825|Alzheimer's Disease
1396630|NCT00396825|Stress management
1396631|NCT00396812|Autoimmune disease
1396632|NCT00396812|Biologic response modifiers
1396633|NCT00396812|Disease-modifying antirheumatic drugs (DMARDS)
1396634|NCT00396812|Immune system
1396635|NCT00396812|Rheumatoid arthritis (RA)
1396636|NCT00396812|Rituximab (anti-CD20 monoclonal antibodies)
1396637|NCT00396786|Prevention of venous thromboembolism
1396638|NCT00396773|electrocoagulation,pregnancy,brian waves
1396639|NCT00396760|cardiac surgery
1396640|NCT00396760|blood transfusion
1396641|NCT00396760|antifibrinolytics
1396642|NCT00396760|aprotinin
1396643|NCT00396760|tranexamic acid
1396644|NCT00396747|Early rheumatoid arthritis,
1396645|NCT00396747|glucocorticoids,
1396646|NCT00396747|pulse therapy,
1396647|NCT00396747|infliximab,
1396648|NCT00396747|TNF blockade
1396649|NCT00396734|Imaging
1396650|NCT00396734|cocaine
1396651|NCT00396734|methadone
1396652|NCT00396734|craving
1396653|NCT00396734|PET
1396654|NCT00396734|FDG
1396655|NCT00396734|D2
1396656|NCT00396734|Modafinil
1396657|NCT00396734|Topiramate
1396658|NCT00396721|Nephropathy, IGA
1396659|NCT00396721|Pilot trial
1396660|NCT00396721|Sirolimus
1396661|NCT00396721|Rapamune
1396662|NCT00396708|Robotics
1396663|NCT00396708|Rehabilitation
1396664|NCT00396708|Arm
1396665|NCT00396708|Stroke
1396666|NCT00396708|Weakness
1396667|NCT00396708|Outpatient
1396668|NCT00396708|Chronic
1396669|NCT00396695|PTSD, traumatic memory
1396670|NCT00396682|HCC
1396671|NCT00396682|T cell
1396672|NCT00396669|Nicotine
1396673|NCT00396669|Dopamine
1396674|NCT00396669|Imaging
1396675|NCT00396669|Raclopride
1396676|NCT00396669|Addiction
1396677|NCT00396669|Genetics
1396678|NCT00396656|hypertension
1396679|NCT00396656|valsartan
1396680|NCT00396656|atenolol
1396681|NCT00396656|hydrochlorothiazide
1396682|NCT00396656|microcirculation
1396683|NCT00396656|arterial compliance
1396684|NCT00396656|pulse wave analysis
1396685|NCT00396643|Ultra-High Risk
1396686|NCT00396643|Psychosis
1396687|NCT00396643|Schizophrenia
1396688|NCT00396643|Omega-3 fatty acids
1396689|NCT00396643|RCT
1396690|NCT00396630|Transmission
1396691|NCT00396630|Gastroenteritis
1396692|NCT00396630|Shedding
1396693|NCT00396630|rotavirus
1396694|NCT00396630|HRV vaccine
1396695|NCT00396617|Laryngeal or pharyngo-laryngeal's carcinoma,
1396696|NCT00396617|voice prosthesis tracheooesophageal shunt,
1396697|NCT00396617|titanium beads,
1396698|NCT00396617|cellular colonization
1396699|NCT00396617|Laryngeal or pharyngo-laryngeal's carcinoma
1396700|NCT00396604|indacaterol
1396701|NCT00396604|long acting beta agonist
1396702|NCT00396591|Ovarian cancer
1396703|NCT00396591|malignant ascites
1396704|NCT00396591|angiogenesis
1396705|NCT00396591|angiogenesis inhibition
1396706|NCT00396591|VEGF-Trap fusion recombinant protein
1396707|NCT00396578|aerosolized antibiotics
1396708|NCT00396578|ventilator associated pneumonia
1396709|NCT00396578|clinical pulmonary infection score
1396710|NCT00396578|bacterial resistance
1396711|NCT00396565|Schizophrenia
1396712|NCT00396565|JNS007ER
1396713|NCT00396565|Positive and Negative Syndrome Scale (PANSS)
1396714|NCT00396565|Paliperidone
1396715|NCT00396565|Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
1396716|NCT00396552|refractory transcranial magnetic stimulation
1396717|NCT00396552|obsessive compulsive disorder
1396718|NCT00396552|randomized
1396719|NCT00396552|placebo-controlled
1396720|NCT00396552|double-blind
1396721|NCT00396526|Nonsevere pneumonia
1396722|NCT00396526|treatment
1396723|NCT00396526|underfives
1396724|NCT00396526|children
1396725|NCT00396526|Community
1396726|NCT00396526|India
1396727|NCT00396513|PCOS
1396728|NCT00396513|Statin
1396729|NCT00396513|Metformin
1396730|NCT00396513|Testosterone
1396731|NCT00396513|Menstrual cycle
1396732|NCT00396513|Lipids
1396733|NCT00396500|Deworming
1396734|NCT00396500|Malnutrition
1396735|NCT00396500|children
1396736|NCT00396500|Community
1396737|NCT00396500|India
1396738|NCT00396487|Metastatic colorectal cancer
1396739|NCT00396487|tailored treatment
1396740|NCT00396487|genetic markers
1396741|NCT00396487|gene polymorphism
1396742|NCT00396487|chemotherapy
1396743|NCT00396474|Small for gestational age, Insulin Sensitivity Index, growth hormone treatment
1396744|NCT00396461|Critical Illness
1396745|NCT00396461|Fat Emulsions, Intravenous
1396746|NCT00396461|Superinfection
1396747|NCT00396461|Parenteral Nutrition
1396748|NCT00396435|anaemia
1396749|NCT00396435|renal transplantation
1396750|NCT00396435|kidney failure
1396751|NCT00396422|psoriasis
1396752|NCT00396422|skin
1396753|NCT00396422|auto immune
1396754|NCT00396396|Creatinine clearance
1396755|NCT00396396|Acetylcysteine
1396756|NCT00396383|Multiple Myeloma
1396757|NCT00396383|Stem cell mobilization
1396758|NCT00396383|apheresis
1396759|NCT00396370|tuberculosis, Bacillus Calmette-Guérin, parent protocol
1396760|NCT00396357|Type 2 diabetes
1396761|NCT00396357|vildagliptin
1396762|NCT00396357|hemoglobin A1c
1396763|NCT00396357|metformin
1396764|NCT00396344|Systemic sepsis
1396765|NCT00396331|Multiple Myeloma
1396766|NCT00396331|Non-Hodgkin's Lymphoma
1396767|NCT00396331|autologous transplantation
1396768|NCT00396331|AMD3100
1396769|NCT00396331|stem cell mobilization
1396770|NCT00396331|plerixafor
1396771|NCT00396318|TNKase
1396772|NCT00396318|CVA
1396773|NCT00396318|CVAD
1396774|NCT00396318|Central venous access catheter
1396775|NCT00396305|Influenza, vaccine, efficacy, elderly
1396776|NCT00396292|Anemia
1396777|NCT00396292|postpartum
1396778|NCT00396292|Postpartum anemia
1396779|NCT00396279|Giant Cell Tumor of Bone
1396780|NCT00396266|Non-Hodgkin's Lymphoma
1396781|NCT00396266|Multiple Myeloma
1396782|NCT00396266|stem cell mobilization
1396783|NCT00396266|AMD3100
1396784|NCT00396266|autologous transplantation
1396785|NCT00396253|HD
1396786|NCT00396253|TNKase
1396787|NCT00396253|Hemodialysis
1396788|NCT00396253|Catheter clearance
1396789|NCT00396240|rosuvastatin
1396790|NCT00396240|hypercholesterolaemia
1396791|NCT00396240|cholesterol
1396792|NCT00396240|LDL-C
1396793|NCT00396240|triglyceride
1396794|NCT00396240|plasma lipids
1396795|NCT00396240|compliance
1396796|NCT00396227|Type 2 diabetes
1396797|NCT00396227|vildagliptin
1396798|NCT00396227|hemoglobin A1c
1396799|NCT00396227|metformin
1396800|NCT00396214|Schizophrenia
1396801|NCT00396214|weight changes
1396802|NCT00396201|Hodgkin's Disease
1396803|NCT00396201|Stem cell mobilization
1396804|NCT00396201|apheresis
1396805|NCT00396188|Keratoconus
1396806|NCT00396188|LASIK
1396807|NCT00396188|Orthokeratology
1396808|NCT00396188|Pellucid Marginal Degeneration
1396809|NCT00396188|Refractive Surgery
1396810|NCT00396188|normal cornea
1396811|NCT00396188|post myopic LASIK
1396812|NCT00396188|post hyperopic LASIK
1396813|NCT00396188|corneal pathologies (e.g. pellucid marginal degeneration)
1396814|NCT00396149|rBet v 1
1396815|NCT00396149|Birch pollen allergy
1396816|NCT00396149|Sublingual Immunotherapy
1396817|NCT00396136|Congestive Heart Failure
1396818|NCT00396136|Cardiac Resynchronization Therapy
1396819|NCT00396136|Left Ventricular Lead
1396820|NCT00396123|Chronic Kidney Disease
1396821|NCT00396123|Anemia
1396822|NCT00396110|cholesterol
1396823|NCT00396110|coronary heart disease
1396824|NCT00396110|rosuvastatin
1396825|NCT00396110|LDL-C goal
1396826|NCT00396110|hypercholesterolemia
1396827|NCT00396097|ISS
1396828|NCT00396097|human growth hormone
1396829|NCT00396084|tuberculosis, linezolid, gatifloxacin, levofloxacin, isoniazid, moxifloxacin, Brazil
1396830|NCT00396071|Type 2 diabetes
1396831|NCT00396071|vildagliptin
1396832|NCT00396071|incretin effect
1396833|NCT00396071|metformin
1396834|NCT00396045|Multiple Myeloma, Lenalidomide, elderly patients
1396835|NCT00396032|HD
1396836|NCT00396032|Hemodialysis
1396837|NCT00396032|Catheter clearance
1396838|NCT00396032|TNKase
1396839|NCT00396032|Renal Insufficiency
1396840|NCT00395993|anemia
1396841|NCT00395993|heavy uterine bleeding
1396842|NCT00395993|menorrhagia
1396843|NCT00395993|Anemia secondary to heavy uterine bleeding
1396844|NCT00395967|Non-Hodgkin's Lymphoma
1396845|NCT00395967|Multiple Myeloma
1396846|NCT00395967|stem cell mobilization
1396847|NCT00395967|autologous transplantation
1396848|NCT00395967|AMD3100
1396849|NCT00395954|Lactose Intolerance
1396850|NCT00395954|Lactose
1396851|NCT00395954|Threshold
1396852|NCT00395928|heart
1396853|NCT00395928|echocardiography
1396854|NCT00395928|diastolic function
1396855|NCT00395928|left ventricle
1396856|NCT00395928|right ventricle
1396857|NCT00395928|cigarette smoking
1396858|NCT00395928|Smoking
1396859|NCT00395928|Heart Ventricles
1396860|NCT00395928|Diastole
1396861|NCT00395928|Doppler Echocardiography
1396862|NCT00395915|schizophrenia
1396863|NCT00395915|antipsychotics
1396864|NCT00395915|treatment non response
1396865|NCT00395915|pragmatic trial
1396866|NCT00395902|Sensipar
1396867|NCT00395902|cinacalcet
1396868|NCT00395902|Mimpara
1396869|NCT00395889|Lung Transplantation
1396870|NCT00395889|Physical Activities in Daily Life
1396871|NCT00395889|Pulmonary Rehabilitation
1396872|NCT00395889|Functional Status
1396873|NCT00395876|TNKase
1396874|NCT00395876|CVA
1396875|NCT00395876|CVAD
1396876|NCT00395876|Central venous access catheter
1396877|NCT00395876|CVA catheter
1396878|NCT00395850|cocaine dependence
1396879|NCT00395850|disulfiram
1396880|NCT00395850|clinical trial
1396881|NCT00395850|methadone maintenance
1396882|NCT00395850|pharmacogenetics
1396883|NCT00395850|dopamine beta-hydroxylase
1396884|NCT00395837|Aging
1396885|NCT00395837|Wellness
1396886|NCT00395837|Aerobic exercise
1396887|NCT00395837|Prevention
1396888|NCT00395824|citrate
1396889|NCT00395824|anticoagulation
1396890|NCT00395824|heparin-coated membrane
1396891|NCT00395811|Myocardial Infarction
1396892|NCT00395811|stem cell therapy
1396893|NCT00395811|Coronary Artery Bypass Grafting
1396894|NCT00395798|cervical intervertebral disc displacement
1396895|NCT00395798|cervical spondylosis
1396896|NCT00395798|radiculopathy
1396897|NCT00395798|neck collar
1396898|NCT00395798|brace
1396899|NCT00395798|physiotherapy
1396900|NCT00395798|treatment
1396901|NCT00395798|rehabilitation
1396902|NCT00395785|Carotid stenosis
1396903|NCT00395785|Intracranial Embolism
1396904|NCT00395785|Carotid artery
1396905|NCT00395785|Carotid stent
1396906|NCT00395785|Embolic protection
1396907|NCT00395785|TriActiv ProGuard System
1396908|NCT00395785|Carotid angioplasty
1396909|NCT00395772|Treatment of venous thromboembolism
1396910|NCT00395759|contrast sensitivity
1396911|NCT00395733|Gadovist
1396912|NCT00395733|Gadavist
1396913|NCT00395733|MRI Imaging
1396914|NCT00395733|vascular diseases
1396915|NCT00395733|Chinese
1396916|NCT00395720|TB
1396917|NCT00395720|Tuberculosis
1396918|NCT00395720|HIV
1396919|NCT00395720|Vaccine
1396920|NCT00395720|MVA85A
1396921|NCT00395720|HIV Therapeutic Vaccine
1396922|NCT00395707|Macular Degeneration
1396923|NCT00395707|Age Related Macular Degeneration
1396924|NCT00395707|Retinal Angiomatous Proliferations
1396925|NCT00395694|epilepsy
1396926|NCT00395694|Incidence of rash
1396927|NCT00395694|safety evaluation for initial dose
1396928|NCT00395694|patients with Valproic acid
1396929|NCT00395681|Obesity
1396930|NCT00395681|Propofol
1396931|NCT00395681|Morbidly obese
1396932|NCT00395681|BMI
1396933|NCT00395668|TETRA
1396934|NCT00395668|EMF
1396935|NCT00395668|Human exposure study
1396936|NCT00395668|Symptoms
1396937|NCT00395668|Well-being
1396938|NCT00395668|Cognitive function
1396939|NCT00395655|locally advanced breast cancer
1396940|NCT00395655|hydralazine
1396941|NCT00395655|magnesium valproate
1396942|NCT00395655|epigenetic therapy
1396943|NCT00395655|gene expression
1396944|NCT00395642|Congestive Heart Failure
1396945|NCT00395642|Cardiac Resynchronization Therapy
1396946|NCT00395642|Home Monitoring
1396947|NCT00395642|Telemonitoring
1396948|NCT00395642|Remote Monitoring
1396949|NCT00395629|Deferasirox
1396950|NCT00395629|ICL670A
1396951|NCT00395629|Iron chelators
1396952|NCT00395629|Deferiprone
1396953|NCT00395629|Transfusional Hemochromatosis
1396954|NCT00395590|OSA inflammatory cytokines, metabolic syndrome
1396955|NCT00395564|Urologic Surgery
1396956|NCT00395551|choroidal neovascularization
1396957|NCT00395551|Choroidal Neovascularization Not related to Age-Related Macular Degeneration
1396958|NCT00395538|Parathyroid
1396959|NCT00395538|Bone Biopsy
1397213|NCT00394550|obstructive sleep apnea
1396960|NCT00395538|Calcium-Sensing Receptor
1396961|NCT00395538|Bone Density
1396962|NCT00395538|Bone Turnover
1396963|NCT00395538|Hypoparathyroidism
1396964|NCT00395512|Glucose Metabolism Disorder
1396965|NCT00395512|Dysmetabolic Syndrome
1396966|NCT00395512|Type II Diabetes
1396967|NCT00395512|Diabetes Mellitus, Lipoatrophic
1396968|NCT00395512|Dyslipidemia
1396969|NCT00395512|Drug Therapy
1396970|NCT00395499|Risperidone
1396971|NCT00395499|9-Hydroxyrisperidone
1396972|NCT00395499|Plasma
1396973|NCT00395499|Saliva
1396974|NCT00395499|children
1396975|NCT00395486|rosuvastatin
1396976|NCT00395486|lipoprotein
1396977|NCT00395486|metabolic syndrome
1396978|NCT00395460|Gadovist
1396979|NCT00395460|Gadavist
1396980|NCT00395460|Contrast agent
1396981|NCT00395460|Brain
1396982|NCT00395460|Spine disease
1396983|NCT00395460|Magnetic Resonance Imaging
1396984|NCT00395447|Cardiac Pacemaker
1396985|NCT00395447|Defibrillator
1396986|NCT00395447|Replacement
1396987|NCT00395447|Upgrade
1396988|NCT00395434|Advanced Solid Tumors
1396989|NCT00395434|Advanced Solid Tumours
1396990|NCT00395434|Advanced Solid Tumor
1396991|NCT00395434|Advanced Solid Tumour
1396992|NCT00395434|Advanced
1396993|NCT00395434|Malignant
1396994|NCT00395434|Solid
1396995|NCT00395434|Tumors
1396996|NCT00395434|Tumours
1396997|NCT00395434|Tumor
1396998|NCT00395434|Tumour
1396999|NCT00395434|Cancer
1397000|NCT00395434|Malignant Solid Tumors
1397001|NCT00395434|Malignant Solid Tumours
1397002|NCT00395434|Malignant Solid Tumor
1397003|NCT00395434|Malignant Solid Tumour
1397004|NCT00395434|Metastatic Cancer
1397005|NCT00395434|Metastatic Disease
1397006|NCT00395434|Advanced Cancer
1397007|NCT00395434|Vascular Disrupting Agent
1397008|NCT00395434|Anti-angiogenesis agent
1397009|NCT00395434|Phase 1
1397010|NCT00395421|treatment-naive
1397011|NCT00395395|Postmenopausal
1397012|NCT00395395|osteoporosis
1397013|NCT00395395|Pharmacokinetics/dynamics
1397014|NCT00395395|Calcitonin
1397015|NCT00395382|Vascular calcification
1397016|NCT00395382|Arterial stiffness
1397017|NCT00395382|Cardiovascular risk
1397018|NCT00395382|Bone mineral metabolism
1397019|NCT00395382|Calcium
1397020|NCT00395369|aprotinin
1397021|NCT00395369|cardiac surgery
1397022|NCT00395369|neurological dysfunction
1397023|NCT00395369|optical coherance tomography
1397024|NCT00395356|Diet
1397025|NCT00395356|Caloric restriction
1397026|NCT00395356|Intermittent diet
1397027|NCT00395356|Obesity
1397028|NCT00395356|Postmenopausal women
1397029|NCT00395330|Respiratory Function Tests
1397030|NCT00395330|Oscillometry
1397031|NCT00395330|World Trade Center Disaster
1397032|NCT00395330|Environmental Exposure
1397033|NCT00395330|Distal Airways
1397034|NCT00395317|magnetic resonance imaging
1397035|NCT00395317|multiple sclerosis
1397036|NCT00395317|SB-683699
1397037|NCT00395291|Chronic kidney disease
1397038|NCT00395291|End stage renal disease
1397039|NCT00395278|KSHV
1397040|NCT00395278|Kaposi's Sarcoma
1397041|NCT00395278|HIV
1397042|NCT00395278|Kaposi Sarcoma
1397043|NCT00395265|Deep Vein Thrombosis
1397044|NCT00395265|Chronic Venous Insufficiency
1397045|NCT00395265|Post Thrombotic Syndrome
1397046|NCT00395265|Blood Coagulation
1397047|NCT00395265|Inflammation
1397048|NCT00395252|pancreatic cancer
1397049|NCT00395252|adjuvant chemotherapy
1397050|NCT00395252|phase 2
1397051|NCT00395252|R0 or R1 resected Adenocarcinoma of the Pancreas
1397052|NCT00395239|Asthma
1397053|NCT00395239|Inhaled corticosteroid
1397054|NCT00395239|ICS
1397055|NCT00395239|Metabolites
1397056|NCT00395239|Induced sputum
1397057|NCT00395239|Virtual Asthma Clinic
1397058|NCT00395226|Rosacea
1397059|NCT00395213|Anxiety
1397060|NCT00395213|Major Depression
1397061|NCT00395213|Anorexia
1397062|NCT00395213|Bulimia
1397063|NCT00395213|OCD
1397064|NCT00395213|Antidepressant
1397065|NCT00395213|SSRI
1397066|NCT00395213|SNRI
1397067|NCT00395200|Multiple Sclerosis
1397068|NCT00395200|Safety
1397069|NCT00395200|Therapeutics
1397070|NCT00395200|Mesenchymal Stem Cells
1397071|NCT00395200|Multipotent Mesenchymal Stromal Cells
1397072|NCT00395200|Optic Neuritis
1397073|NCT00395174|Influenza
1397074|NCT00395161|sepsis
1397075|NCT00395161|prevention
1397076|NCT00395161|mineral supplementation
1397077|NCT00395135|Obesity
1397078|NCT00395135|Weight loss
1397079|NCT00395135|lorcaserin
1397080|NCT00395135|APD356
1397081|NCT00395135|BLOOM
1397082|NCT00395135|Hypertension
1397083|NCT00395135|Dyslipidemia
1397084|NCT00395135|Sleep apnea
1397085|NCT00395135|glucose tolerance
1397086|NCT00395135|cardiovascular disease
1397087|NCT00395135|Arena
1397088|NCT00395122|Band Atrophy
1397089|NCT00395122|Optical Coherence Tomography
1397090|NCT00395122|Scanning Laser Polarimetry
1397091|NCT00395122|Chiasmal Lesions
1397092|NCT00395109|cancer
1397093|NCT00395109|hypoxia
1397094|NCT00395109|PET scan
1397095|NCT00395109|CT scan
1397096|NCT00395096|Exhaled Nitric Oxide
1397097|NCT00395096|Asthma
1397098|NCT00395096|Tobacco Smoke
1397099|NCT00395096|Allergen
1397100|NCT00395070|Melanoma
1397101|NCT00395070|DTIC
1397102|NCT00395070|TMZ
1397103|NCT00395070|Stage 3
1397104|NCT00395070|Stage 4
1397105|NCT00395070|Metastatic
1397106|NCT00395070|Metastatic Melanoma (Stage 3, Stage 4 Melanoma)
1397107|NCT00395044|Cannabis treatment
1397108|NCT00395044|marijuana treatment
1397109|NCT00395031|schizophrenia
1397110|NCT00395031|Schizoaffective Disorder
1397111|NCT00395031|metabolic markers
1397112|NCT00395031|ziprasidone
1397113|NCT00395031|diabetes
1397114|NCT00395018|Chronic Hepatitis B Virus, Liver Transplant
1397115|NCT00395005|Kallikrein
1397116|NCT00395005|Cytokines
1397117|NCT00395005|Proteinuria
1397118|NCT00395005|Renal function
1397119|NCT00395005|Chronic kidney disease
1397120|NCT00394992|Colorectal cancer
1397121|NCT00394992|Liver metastasis
1397122|NCT00394992|Radical resection
1397123|NCT00394992|Adjuvant therapy
1397124|NCT00394992|Bevacizumab
1397125|NCT00394992|Capecitabine
1397126|NCT00394992|Oxaliplatin
1397127|NCT00394992|Hepatica
1397128|NCT00394940|COPD
1397129|NCT00394940|Emphysema
1397130|NCT00394940|Chronic Bronchitis
1397131|NCT00394940|Inflammation
1397132|NCT00394940|CD14
1397133|NCT00394940|TLR4
1397134|NCT00394940|Proteomics
1397135|NCT00394927|Non-Interventional
1397136|NCT00394927|Surveillance
1397137|NCT00394927|Adverse Effects
1397138|NCT00394927|AntiEpileptic Drug treatment
1397139|NCT00394888|Hemangioma
1397140|NCT00394888|PHACE
1397141|NCT00394888|Lumbosacral hemangioma
1397142|NCT00394888|Occult Spinal Dysraphism
1397143|NCT00394875|Randomized controlled trial
1397144|NCT00394875|Delegation, Professional
1397145|NCT00394875|Nurses
1397146|NCT00394849|Tonsillectomy
1397147|NCT00394849|Suturing of tonsillar pillars
1397148|NCT00394849|pain
1397149|NCT00394849|postoperative hemorrhage, bleeding
1397150|NCT00394836|ofatumumab
1397151|NCT00394836|rituximab
1397152|NCT00394836|NHL
1397153|NCT00394836|CD20
1397154|NCT00394836|refractory
1397155|NCT00394823|Hypertension, valsartan, compliance
1397156|NCT00394784|gram negative bacteria
1397157|NCT00394784|culture
1397158|NCT00394784|infection
1397159|NCT00394771|oral contraceptives
1397160|NCT00394771|breakthrough bleeding
1397161|NCT00394771|spotting
1397162|NCT00394758|ultrasonic surgical aspiration
1397163|NCT00394758|CO2 laser surgery
1397164|NCT00394758|vulvar dysplasia
1397165|NCT00394758|vaginal dysplasia
1397166|NCT00394758|recurrence
1397167|NCT00394745|Hypertension, Metabolic Syndrome, lipid subfractions
1397168|NCT00394732|chronic low back pain
1397169|NCT00394732|total disc replacement
1397170|NCT00394732|multidisciplinary rehabilitation
1397171|NCT00394732|clinical effects
1397172|NCT00394732|cost effectiveness
1397173|NCT00394732|randomized controlled trial
1397174|NCT00394732|multicenter study
1397175|NCT00394706|cardiac arrest
1397176|NCT00394706|cardiopulmonary resuscitation
1397177|NCT00394693|Primary CBCL including (WHO/EORTC classification 2005)
1397178|NCT00394693|Primary cutaneous marginal zone B-cell lymphoma
1397179|NCT00394693|Primary cutaneous follicle center B-cell lymphoma
1397180|NCT00394693|Primary cutaneous diffuse large B-cell other than leg type
1397181|NCT00394693|Histologically consistent with primary CBCL
1397182|NCT00394693|Relapse or active disease
1397183|NCT00394680|coronary revascularization
1397184|NCT00394680|stent inmplantation
1397185|NCT00394680|coronary bypass
1397186|NCT00394628|Glioblastoma Multiforme
1397187|NCT00394628|Radiotherapy
1397188|NCT00394628|temozolomide
1397189|NCT00394628|adjuvant temozolomide
1397190|NCT00394602|Gastric Cancer
1397191|NCT00394602|Pancreatic Cancer
1397192|NCT00394602|Cervical Cancer
1397193|NCT00394602|Vulvar Cancer
1397194|NCT00394602|Endometrial Cancer
1397195|NCT00394602|Anal Cancer
1397196|NCT00394602|Quality of Life
1397197|NCT00394602|Questionnaire
1397198|NCT00394602|Interview
1397199|NCT00394602|Emesis
1397200|NCT00394602|Nausea
1397201|NCT00394602|Survey
1397202|NCT00394576|Kidney School
1397203|NCT00394576|Short Test of Functional Health Literacy
1397204|NCT00394576|Chronic Kidney Disease Knowledge Assessment Tool of Nutrition
1397205|NCT00394576|Short Form 12 version 2
1397206|NCT00394576|Kidney Disease Self-Management Survey
1397207|NCT00394576|Three Day Dietary Diary
1397208|NCT00394563|osteoarthritis monoclonal antibody
1397209|NCT00394550|laryngomalacia
1397210|NCT00394550|supraglottoplasty
1397211|NCT00394550|Tonsillectomy
1397212|NCT00394550|Adenoidectomy
1397214|NCT00394550|Laser
1397215|NCT00394550|Polysomnogram
1397216|NCT00394550|airway obstruction
1397217|NCT00394524|ICU
1397218|NCT00394524|hyperglycemia
1397219|NCT00394524|glucommander
1397220|NCT00394498|Myocardial Infarction
1397221|NCT00394498|Stem Cells
1397222|NCT00394485|Chronic Obstructive Pulmonary Disease
1397223|NCT00394485|Procaterol
1397224|NCT00394485|Tiotropium
1397225|NCT00394472|Heartburn
1397226|NCT00394472|Patient reported symptoms
1397227|NCT00394472|Proton pump inhibitor
1397228|NCT00394459|Anaesthetic techniques
1397229|NCT00394459|epidural
1397230|NCT00394459|catheters
1397231|NCT00394459|paraesthesia
1397232|NCT00394459|side effects
1397233|NCT00394459|Anesthesia, Epidural [E03.155.086.131]
1397234|NCT00394446|Solid Tumors
1397235|NCT00394446|Refractory
1397236|NCT00394446|Brain
1397237|NCT00394433|TPCA
1397238|NCT00394433|Taxotere
1397239|NCT00394433|Platinum
1397240|NCT00394433|Avastin
1397241|NCT00394433|Camptosar
1397242|NCT00394433|gastric cancer
1397243|NCT00394407|inpatient
1397244|NCT00394407|diabetes management
1397245|NCT00394407|insulin therapy
1397246|NCT00394381|acute myeloid leukemia
1397247|NCT00394381|myelodysplastic syndrome
1397248|NCT00394381|autologous CIK cells
1397249|NCT00394381|autologous peripheral blood stem cell transplant
1397250|NCT00394368|asthma
1397251|NCT00394368|combinations
1397252|NCT00394368|inhaled therapy
1397253|NCT00394368|corticosteroids
1397254|NCT00394368|long acting bronchodilators
1397255|NCT00394368|salmeterol
1397256|NCT00394368|beclomethasone
1397257|NCT00394368|formoterol
1397258|NCT00394368|fluticasone
1397259|NCT00394316|CD34 Stem Cells
1397260|NCT00394316|Busulfan
1397261|NCT00394316|Gene Therapy
1397262|NCT00394316|Immune Reconstitution
1397263|NCT00394316|Engraftment
1397264|NCT00394316|Chronic Granulomatous Disease (CGD)
1397265|NCT00394316|Gp91 Phox Deficiency
1397266|NCT00394316|Peripheral Blood Stem Cells
1397267|NCT00394316|Bone Marrow Transplantation
1397268|NCT00394316|Chronic Granulomatous Disease
1397269|NCT00394316|CGD
1397270|NCT00394303|Open heart surgery
1397271|NCT00394303|Diabetes mellitus
1397272|NCT00394303|Hyperglycemia
1397273|NCT00394303|Surgical site infection
1397274|NCT00394303|Normoglycemia
1397275|NCT00394290|Down Syndrome
1397276|NCT00394290|Obstructive Sleep Apnea Syndrome
1397277|NCT00394290|Continuous Positive Pressure
1397278|NCT00394290|Hypersomnia
1397279|NCT00394264|low back pain
1397280|NCT00394264|active duty military personnel
1397281|NCT00394264|manual/manipulative therapy
1397282|NCT00394264|osteopathic manipulative treatment
1397283|NCT00394264|physical medicine
1397284|NCT00394251|Adjuvant therapy
1397285|NCT00394251|Bevacizumab
1397286|NCT00394251|Abraxane
1397287|NCT00394251|Early stage breast cancer
1397288|NCT00394225|6-Minute Walk Test
1397289|NCT00394225|COPD
1397290|NCT00394225|Helium-Hyperoxia
1397291|NCT00394225|Exercise
1397292|NCT00394225|Chronic Obstructive Pulmonary Disease (COPD)
1397293|NCT00394212|Weight Loss
1397294|NCT00394212|Transoral Suturing
1397295|NCT00394212|Dilated gastrojejunostomy
1397296|NCT00394212|Inadequate weight loss following primary RYGB
1397297|NCT00394199|Asthma
1397298|NCT00394199|Fluticasone Propionate
1397299|NCT00394199|formoterol fumarate
1397300|NCT00394199|Pressurized metered dose inhaler
1397301|NCT00394199|Hydrofluoroalkane
1397302|NCT00394199|Mild to Moderate Asthma
1397303|NCT00394186|GW427353
1397304|NCT00394186|b3-Adrenergic Receptor Agonist
1397305|NCT00394186|Irritable Bowel Syndrome (IBS)
1397306|NCT00394186|efficacy
1397307|NCT00394186|tolerability
1397308|NCT00394186|pharmacokinetics
1397309|NCT00394173|IBS
1397310|NCT00394173|diarrhea
1397311|NCT00394173|gastrointestinal functional disorder
1397312|NCT00394173|IBS-D
1397313|NCT00394147|advanced
1397314|NCT00394147|head
1397315|NCT00394147|neck
1397316|NCT00394147|cancer
1397317|NCT00394134|Melanoma
1397318|NCT00394134|Sun Exposure
1397319|NCT00394134|Sun Protection
1397320|NCT00394134|Interview
1397321|NCT00394121|Asthma
1397322|NCT00394121|Fluticasone Propionate
1397323|NCT00394121|Formoterol Fumarate
1397324|NCT00394121|Pressurized metered does inhaler
1397325|NCT00394121|Hydrofluoroalkane
1397326|NCT00394121|Mild to moderate-severe asthma
1397327|NCT00394095|Bipolar Disorder
1397328|NCT00394095|Weight Gain
1397329|NCT00394082|Metastatic breast cancer, Abraxane, Bevacizumab
1397330|NCT00394056|placebo
1397331|NCT00394056|balanced
1397332|NCT00394056|paroxetine
1397333|NCT00394056|repeated dose
1397334|NCT00394056|Hearing Loss
1397335|NCT00394056|loudness
1397336|NCT00394056|combination
1397337|NCT00394056|Tinnitus
1397338|NCT00394056|vestipitant (GW597599)
1397339|NCT00394056|randomised
1397340|NCT00394056|annoyance
1397341|NCT00394056|crossover
1397342|NCT00394043|Carpal Tunnel Sydrome
1397343|NCT00394043|Osteopathic Manipulative Treatment
1397344|NCT00394043|Osteopathic Manipulative Medicine
1397345|NCT00394043|Physical Medicine
1397346|NCT00394030|GSK716155 pharmacodynamics pharmacokinetics injection site
1397347|NCT00394017|Heading Health Plan Implementation
1397348|NCT00394017|Computer-Assisted Instruction
1397349|NCT00394017|General Practice
1397350|NCT00394017|Dementia
1397351|NCT00394017|education
1397352|NCT00394004|Decision Making
1397353|NCT00394004|Health Disparities
1397354|NCT00394004|Hispanic
1397355|NCT00394004|African-American
1397356|NCT00394004|Clinical Trials
1397357|NCT00394004|HIV Positive
1397358|NCT00393991|Asthma
1397359|NCT00393991|Fluticasone Propionate
1397360|NCT00393991|Formoterol Fumarate
1397361|NCT00393991|Pressurized metered dose inhaler
1397362|NCT00393991|Hydrofluoroalkane
1397363|NCT00393991|Mild to Moderate Asthma
1397364|NCT00393978|Bipolar mania
1397365|NCT00393978|Cannabis consumption
1397366|NCT00393965|Metastases
1397367|NCT00393965|Refractory
1397368|NCT00393965|Brain
1397369|NCT00393952|Asthma
1397370|NCT00393952|Fluticasone Propionate
1397371|NCT00393952|Formoterol Fumarate
1397372|NCT00393952|Pressurized metered dose inhaler
1397373|NCT00393952|Hydrofluoroalkane
1397374|NCT00393952|Moderate-Severe Asthma
1397375|NCT00393939|advanced breast cancer
1397376|NCT00393939|sunitinib
1397377|NCT00393939|docetaxel
1397378|NCT00393939|Phase 3
1397379|NCT00393926|Robotics
1397380|NCT00393926|Rehabilitation
1397381|NCT00393926|Upper Extremity
1397382|NCT00393926|CVA
1397383|NCT00393913|Sleep Apnea
1397384|NCT00393913|Sleep-Disordered Breathing
1397385|NCT00393913|Snoring
1397386|NCT00393900|otitis media
1397387|NCT00393900|tympanostomy tube
1397388|NCT00393900|eustachian tube function
1397389|NCT00393900|gas exchange
1397390|NCT00393900|tympanostomy tubes
1397391|NCT00393887|Inguinal hernia
1397392|NCT00393887|polypropylene
1397393|NCT00393887|Biodesign IHM
1397394|NCT00393887|lichtenstein
1397395|NCT00393874|Anxiety D/O
1397396|NCT00393874|Mood D/O
1397397|NCT00393861|Germ Cell Tumor
1397398|NCT00393861|Germ Cell Cancer
1397399|NCT00393848|Hip Replacement Arthroplasty
1397400|NCT00393848|Hip Replacement Surgery
1397401|NCT00393848|Hip Surgery
1397402|NCT00393848|Hip Rehabilitation
1397403|NCT00393848|Avascular Necrosis
1397404|NCT00393848|Knee replacement surgery
1397405|NCT00393848|Total knee arthroplasty
1397406|NCT00393822|KGF
1397407|NCT00393822|Palifermin
1397408|NCT00393822|Oral Mucositis
1397409|NCT00393822|Clinical Trial
1397410|NCT00393822|Amgen
1397411|NCT00393822|Oncology
1397412|NCT00393822|Colon Cancer
1397413|NCT00393809|transitional cell carcinoma
1397414|NCT00393809|H19 gene
1397415|NCT00393809|plasmid
1397416|NCT00393809|diphtheria toxin
1397417|NCT00393783|Breast Cancer
1397418|NCT00393783|Metastatic
1397419|NCT00393783|HER2
1397420|NCT00393783|04-101
1397421|NCT00393770|Risk of type 2 diabetes
1397422|NCT00393757|Malaria, Plasmodium falciparum, Kenya
1397423|NCT00393731|labor
1397424|NCT00393731|induction
1397425|NCT00393731|misoprostol
1397426|NCT00393731|oxytocin
1397427|NCT00393705|diabetes
1397428|NCT00393705|type 2
1397429|NCT00393692|Age-related macular degeneration
1397430|NCT00393692|Geographic atrophy
1397431|NCT00393692|drusen
1397432|NCT00393679|Children 6-59 months
1397433|NCT00393679|P.falciparum
1397434|NCT00393679|Haemoglobin
1397435|NCT00393679|Informed consent
1397436|NCT00393679|ACT
1397437|NCT00393666|Absence
1397438|NCT00393666|Epilepsy
1397439|NCT00393666|Seizure
1397440|NCT00393666|Brain
1397441|NCT00393653|osteoarthritis
1397442|NCT00393653|gastroesophageal reflux disease
1397443|NCT00393653|practice-based research
1397444|NCT00393653|N-of-1 trial
1397445|NCT00393653|prescription
1397446|NCT00393653|single-patient trial
1397447|NCT00393640|Early Initiation of lactogenesis II
1397448|NCT00393627|Dementia
1397449|NCT00393627|Sleep disturbance
1397450|NCT00393627|Behavioral strategies
1397451|NCT00393627|Alzheimer's Disease
1397452|NCT00393627|Adult Family Homes
1397453|NCT00393614|CSWS, interiktal epileptiform activity
1397454|NCT00393601|Cystectomy
1397455|NCT00393588|Brain
1397456|NCT00393588|Cognitive Deficits
1397457|NCT00393588|Cognitive Testing
1397458|NCT00393588|MRI
1397459|NCT00393588|Multiple Sclerosis
1397460|NCT00393588|MS
1397461|NCT00393588|Healthy Volunteer
1397462|NCT00393588|HV
1397463|NCT00393575|HIV Prevention
1397464|NCT00393575|HIV positive communities
1397465|NCT00393562|excessive sleepiness
1397466|NCT00393562|hypersomnolence
1397467|NCT00393562|Parkinson's disease
1397468|NCT00393549|Median Neuropathy at the wrist (MNW)
1397469|NCT00393536|Depression
1397470|NCT00393536|Guidelines
1397471|NCT00393536|Educational outreach visiting
1397472|NCT00393536|Prescribing
1397473|NCT00393510|Diabetic Foot Ulcer
1397474|NCT00393510|Traditional Chinese Medicine
1397475|NCT00393497|Breast Cancer
1397476|NCT00393497|lymphedema
1397477|NCT00393471|Arthritis
1397478|NCT00393471|Rheumatoid
1397479|NCT00393471|Safety
1397480|NCT00393458|chronic obstructive pulmonary disease
1397481|NCT00393458|COPD
1397482|NCT00393458|indacaterol
1397483|NCT00393458|long-acting β2 agonist
1397484|NCT00393445|GLP-1
1397485|NCT00393445|Exendin(9-39)
1397486|NCT00393445|Insulin
1397487|NCT00393445|Glucagon
1397488|NCT00393445|Human physiology
1397489|NCT00393432|Action Observation
1397490|NCT00393432|Motor Memory
1397491|NCT00393432|Transcranial Magnetic Stimulation (TMS)
1397492|NCT00393432|Use-Dependent Plasticity
1397493|NCT00393432|Healthy Volunteer
1397494|NCT00393432|HV
1397495|NCT00393419|hypertension
1397496|NCT00393419|hyperlipidemia
1397497|NCT00393419|adherence
1397498|NCT00393419|pharmacist
1397499|NCT00393419|elderly
1397500|NCT00393419|medication
1397501|NCT00393406|Objective Risk
1397502|NCT00393406|Gail Model
1397503|NCT00393406|Subjective Risk
1397504|NCT00393406|Medical Risk-Reducing Strategies
1397505|NCT00393406|Physical Activity, Diet, Alcohol Use
1397506|NCT00393406|Breast Cancer Risk
1397507|NCT00393393|osteoarthritis
1397508|NCT00393393|knee
1397509|NCT00393393|hylan
1397510|NCT00393380|Myelogenous Leukemia, Chronic
1397511|NCT00393380|Myelodysplasia
1397512|NCT00393380|Parathyroid Hormone
1397513|NCT00393380|Umbilical Cord Blood Stem Cell Transplantation
1397514|NCT00393367|Asthma
1397515|NCT00393367|Acute
1397516|NCT00393367|Treatment
1397517|NCT00393367|Children
1397518|NCT00393367|Pediatric
1397519|NCT00393367|Inhaled corticosteroid
1397520|NCT00393367|Budesonide
1397521|NCT00393367|Budesonide inhalation suspension
1397522|NCT00393367|Asthma score
1397523|NCT00393367|Emergency
1397524|NCT00393367|Emergency Department
1397525|NCT00393367|Asthma flare
1397526|NCT00393367|Clinical trial
1397527|NCT00393367|Randomized clinical trial
1397528|NCT00393367|Randomized trial
1397529|NCT00393367|Pulmonary index score
1397530|NCT00393367|Hospitalization
1397531|NCT00393367|Moderate asthma
1397532|NCT00393367|Severe asthma
1397533|NCT00393367|Mixing budesonide
1397534|NCT00393367|Budesonide admixture
1397535|NCT00393367|Albuterol
1397536|NCT00393367|Continuous albuterol
1397537|NCT00393367|Ipratropium bromide
1397538|NCT00393341|Breast Cancer
1397539|NCT00393315|in stent restenosis
1397540|NCT00393315|paclitaxel coated balloon catheter
1397541|NCT00393315|pepcad
1397542|NCT00393315|drug eluting balloon
1397543|NCT00393302|HIV testing in pregnant women
1397544|NCT00393289|Calcium absorption
1397545|NCT00393289|D-vitamin status
1397546|NCT00393289|Whole body calcium retention
1397547|NCT00393289|Calcium intake
1397548|NCT00393289|PTH status
1397549|NCT00393276|Treatment Experienced
1397550|NCT00393276|Treatment Naive
1397551|NCT00393276|Immunizations
1397552|NCT00393250|Hypnosis
1397553|NCT00393250|Symptom Management
1397554|NCT00393250|Pain Management
1397555|NCT00393250|Sickle Cell Disease
1397556|NCT00393250|Pain
1397557|NCT00393224|Epidemiology
1397558|NCT00393224|Nasopharyngeal Carcinoma
1397559|NCT00393224|Genetic
1397560|NCT00393224|Viruses
1397561|NCT00393224|Cancer
1397562|NCT00393224|NPC
1397563|NCT00393198|Intrauterine System
1397564|NCT00393198|Contraception
1397565|NCT00393198|Menorrhagia
1397566|NCT00393185|Immunosuppression
1397567|NCT00393185|Primary Biliary Cirrhosis
1397568|NCT00393185|Allogeneic Hematopoietic Stem Cell
1397569|NCT00393172|exercise
1397570|NCT00393172|breast cancer
1397571|NCT00393172|prevention
1397572|NCT00393172|obesity
1397573|NCT00393172|estrogen metabolism
1397574|NCT00393172|oxidative stress
1397575|NCT00393172|IGF-1
1397576|NCT00393159|Effusion
1397577|NCT00393159|Otitis
1397578|NCT00393159|Media
1397579|NCT00393159|Ear
1397580|NCT00393159|Popper
1397581|NCT00393159|Children
1397582|NCT00393146|Rheumatoid arthritis
1397583|NCT00393146|MRI
1397584|NCT00393120|HIV-infection
1397585|NCT00393120|viral load
1397586|NCT00393120|CCR5
1397587|NCT00393120|viral tropism
1397588|NCT00393120|HIV-1 infection
1397589|NCT00393120|Treatment Naive
1397590|NCT00393107|follicular lymphoma
1397591|NCT00393107|non-Hodgkin lymphoma
1397592|NCT00393107|Fludarabine
1397593|NCT00393107|Cyclophosphamide
1397594|NCT00393107|Rituximab
1397595|NCT00393107|combination
1397596|NCT00393107|immuno-chemotherapy
1397597|NCT00393107|relapsed
1397598|NCT00393094|Brain Tumor
1397599|NCT00393094|Chemotherapy
1397600|NCT00393094|Progression
1397601|NCT00393094|Radiotherapy
1397602|NCT00393094|Antiangiogenesis
1397603|NCT00393094|Glioma
1397604|NCT00393042|Attention Deficit Hyperactivity Disorder
1397605|NCT00393042|sleep
1397606|NCT00393042|side effects
1397607|NCT00393042|stimulants
1397608|NCT00393029|Tumor Regression
1397609|NCT00393029|In Vivo Cell Survival
1397610|NCT00393029|Toxicity Profile
1397611|NCT00393029|Metastatic Renal Cell Cancer
1397612|NCT00393029|Cancer
1397613|NCT00393029|Metastatic Cancer
1397614|NCT00393003|Anesthesia
1397615|NCT00393003|Sedation
1397616|NCT00392990|stage I adult Burkitt lymphoma
1397617|NCT00392990|stage III adult Burkitt lymphoma
1397618|NCT00392990|stage IV adult Burkitt lymphoma
1397619|NCT00392990|contiguous stage II adult Burkitt lymphoma
1397620|NCT00392990|noncontiguous stage II adult Burkitt lymphoma
1397621|NCT00392990|AIDS-related peripheral/systemic lymphoma
1397622|NCT00392977|Manganese
1397623|NCT00392977|Neonatal Intensive Care
1397624|NCT00392977|MRI
1397625|NCT00392977|Parenteral Nutrition
1397626|NCT00392977|Prematurity
1397627|NCT00392964|Antacids
1397628|NCT00392964|Proton pump inhibitors
1397629|NCT00392964|aspirin
1397630|NCT00392964|ischemic heart disease
1397631|NCT00392964|Dyspepsia
1397632|NCT00392951|ALPS
1397633|NCT00392951|Autoimmune
1397634|NCT00392951|Cytopenias
1397635|NCT00392951|Treatment
1397636|NCT00392951|Sirolimus
1397637|NCT00392951|Rapamycin
1397638|NCT00392951|Lymph Nodes
1397639|NCT00392951|Spleen
1397640|NCT00392951|Hemolytic Anemia
1397641|NCT00392951|Immune Thrombocytopenia
1397642|NCT00392951|Neutropenia
1397643|NCT00392951|ITP
1397644|NCT00392951|Lupus
1397645|NCT00392938|recurrent prostate cancer
1397646|NCT00392938|stage IV prostate cancer
1397647|NCT00392938|bone metastases
1397648|NCT00392925|overweight
1397649|NCT00392925|obesity
1397650|NCT00392925|pramlintide
1397651|NCT00392925|leptin
1397652|NCT00392925|Amylin
1397653|NCT00392912|testosterone
1397654|NCT00392912|hypogonadal
1397655|NCT00392912|cerebral glucose metabolism
1397656|NCT00392912|PET scan
1397657|NCT00392912|Alzheimer's disease
1397658|NCT00392899|stage II colon cancer
1397659|NCT00392899|stage II rectal cancer
1397660|NCT00392899|adenocarcinoma of the colon
1397661|NCT00392899|adenocarcinoma of the rectum
1397662|NCT00392886|untreated childhood medulloblastoma
1397663|NCT00392886|untreated childhood supratentorial primitive neuroectodermal tumor
1397664|NCT00392886|childhood infratentorial ependymoma
1397665|NCT00392886|childhood supratentorial ependymoma
1397666|NCT00392886|newly diagnosed childhood ependymoma
1397667|NCT00392886|childhood high-grade cerebral astrocytoma
1397668|NCT00392886|childhood oligodendroglioma
1397669|NCT00392886|childhood atypical teratoid/rhabdoid tumor
1397670|NCT00392886|childhood choroid plexus tumor
1397671|NCT00392886|untreated childhood cerebellar astrocytoma
1397672|NCT00392886|untreated childhood visual pathway and hypothalamic glioma
1397673|NCT00392886|untreated childhood pineoblastoma
1397674|NCT00392873|Amenorrhea
1397675|NCT00392873|Energy deficiency
1397676|NCT00392873|Resting energy expenditure
1397677|NCT00392873|Bone metabolism
1397678|NCT00392873|Bone mineral density
1397679|NCT00392873|Exercise
1397680|NCT00392860|Wheelchair
1397681|NCT00392860|Handrims
1397682|NCT00392860|Rehabilitation
1397683|NCT00392860|Upper extremity
1397684|NCT00392847|Child mental disorder
1397685|NCT00392847|Home visit
1397686|NCT00392847|Postnatal depression
1397687|NCT00392847|Social Support
1397688|NCT00392847|Random selection
1397689|NCT00392834|stage I adult Burkitt lymphoma
1397690|NCT00392834|stage III adult Burkitt lymphoma
1397691|NCT00392834|stage IV adult Burkitt lymphoma
1397692|NCT00392834|contiguous stage II adult Burkitt lymphoma
1397693|NCT00392834|noncontiguous stage II adult Burkitt lymphoma
1397694|NCT00392834|AIDS-related peripheral/systemic lymphoma
1397695|NCT00392808|Meningococcal vaccine
1397696|NCT00392808|Immunization, secondary
1397697|NCT00392808|vaccines conjugated
1397698|NCT00392808|Meningococcal disease
1397699|NCT00392795|Critical Care
1397700|NCT00392795|Delirium
1397701|NCT00392795|Long-term cognitive impairment
1397702|NCT00392795|mechanical ventilation
1397703|NCT00392795|Critical illness
1397704|NCT00392795|dementia
1397705|NCT00392795|sedatives and analgesics
1397706|NCT00392795|aging
1397707|NCT00392782|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1397708|NCT00392782|adult acute myeloid leukemia in remission
1397709|NCT00392782|childhood acute myeloid leukemia in remission
1397710|NCT00392782|de novo myelodysplastic syndromes
1397711|NCT00392782|previously treated myelodysplastic syndromes
1397712|NCT00392782|adult acute myeloid leukemia with inv(16)(p13;q22)
1397713|NCT00392782|adult acute myeloid leukemia with t(15;17)(q22;q12)
1397714|NCT00392782|adult acute myeloid leukemia with t(16;16)(p13;q22)
1397715|NCT00392782|adult acute myeloid leukemia with t(8;21)(q22;q22)
1397716|NCT00392782|recurrent adult acute myeloid leukemia
1397717|NCT00392782|recurrent childhood acute myeloid leukemia
1397718|NCT00392782|secondary acute myeloid leukemia
1397719|NCT00392782|accelerated phase chronic myelogenous leukemia
1397720|NCT00392782|blastic phase chronic myelogenous leukemia
1397721|NCT00392782|childhood chronic myelogenous leukemia
1397722|NCT00392782|relapsing chronic myelogenous leukemia
1397723|NCT00392782|secondary myelodysplastic syndromes
1397724|NCT00392769|Endometrial Cancer
1397725|NCT00392769|Progressive or Recurrent Endometrial Cancer
1397726|NCT00392769|Cetuximab
1397727|NCT00392769|C225
1397728|NCT00392769|Erbitux™
1397729|NCT00392769|IMC-C225
1397730|NCT00392769|Epidermal growth factor receptor
1397731|NCT00392769|EGFR
1397732|NCT00392769|Endometrioid Tumor
1397733|NCT00392769|Serous Tumor
1397734|NCT00392769|Clear cell Tumor
1397735|NCT00392769|Mixed malignant Mullerian Tumors
1397736|NCT00392756|Kallmann Syndrome
1397737|NCT00392756|Hypogonadotropic Hypogonadism
1397738|NCT00392756|GnRH deficiency
1397739|NCT00392756|Pulsatile GnRH
1397740|NCT00392743|Bolus
1397741|NCT00392743|11C-Raclopride
1397742|NCT00392743|Schizophrenia
1397743|NCT00392743|123I-IBZM
1397744|NCT00392743|SPECT
1397745|NCT00392743|Receptor Occupancy
1397746|NCT00392743|PET
1397747|NCT00392743|MRI
1397748|NCT00392743|Antipsychotics
1397749|NCT00392743|Bolus/Infusion
1397750|NCT00392730|Manganese
1397751|NCT00392730|Neonatal Intensive Care
1397752|NCT00392730|MRI
1397753|NCT00392730|Parenteral Nutrition
1397754|NCT00392730|Prematurity
1397755|NCT00392717|lipoprotein metabolism
1397756|NCT00392717|cardiovascular disease
1397757|NCT00392717|obesity
1397758|NCT00392691|recurrent adult Burkitt lymphoma
1397759|NCT00392691|recurrent adult diffuse large cell lymphoma
1397760|NCT00392691|recurrent adult diffuse mixed cell lymphoma
1397761|NCT00392691|recurrent adult diffuse small cleaved cell lymphoma
1397762|NCT00392691|recurrent adult immunoblastic large cell lymphoma
1397763|NCT00392691|recurrent adult lymphoblastic lymphoma
1397764|NCT00392691|recurrent grade 1 follicular lymphoma
1397765|NCT00392691|recurrent grade 2 follicular lymphoma
1397766|NCT00392691|recurrent grade 3 follicular lymphoma
1397767|NCT00392691|recurrent mantle cell lymphoma
1397768|NCT00392691|recurrent marginal zone lymphoma
1397769|NCT00392691|recurrent small lymphocytic lymphoma
1397770|NCT00392691|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1397771|NCT00392691|nodal marginal zone B-cell lymphoma
1397772|NCT00392691|splenic marginal zone lymphoma
1397773|NCT00392691|Waldenström macroglobulinemia
1397774|NCT00392678|Type 2 Diabetes
1397775|NCT00392678|Inflammation
1397776|NCT00392678|Obesity
1397777|NCT00392678|Metabolic Syndrome
1397778|NCT00392665|SCCHN
1397779|NCT00392665|erlotinib
1397780|NCT00392665|tarceva
1397781|NCT00392639|Heart arrest
1397782|NCT00392639|Cardiopulmonary resuscitation
1397783|NCT00392639|Humans
1397784|NCT00392639|Hypothermia
1397785|NCT00392639|Brain diseases
1397786|NCT00392639|Hypoxia-ischemia
1397787|NCT00392639|Cost Benefit Analysis
1397788|NCT00392639|Prospective study
1397789|NCT00392639|Comparative study
1397790|NCT00392639|Treatment outcome
1397791|NCT00392639|Hypothermia for
1397792|NCT00392639|out-of-hospital cardiac arrest
1397793|NCT00392639|from cardiac origin
1397794|NCT00392639|successfully resuscitated
1397795|NCT00392587|Pharmacodynamics
1397796|NCT00392587|Pharmacokinetics
1397797|NCT00392587|Tolerability
1397798|NCT00392587|COPD
1397799|NCT00392587|Safety
1397800|NCT00392574|Gastroenteritis
1397801|NCT00392548|GBM
1397802|NCT00392548|glioblastoma
1397803|NCT00392548|urine
1397804|NCT00392548|VEGF
1397805|NCT00392548|radiation
1397806|NCT00392548|Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
1397807|NCT00392535|adenocarcinoma of the prostate
1397808|NCT00392535|stage IIB prostate cancer
1397809|NCT00392535|stage IIA prostate cancer
1397810|NCT00392535|stage III prostate cancer
1397811|NCT00392522|Anxiety
1397812|NCT00392522|Cough
1397813|NCT00392522|Number of general anaesthesias (due to procedure failure)
1397814|NCT00392522|Patients satisfaction
1397815|NCT00392522|Chest physician satisfaction
1397816|NCT00392509|critical limb ischemia
1397817|NCT00392509|cell therapy for angiogenesis
1397818|NCT00392509|aldehyde dehydrogenase-bright cells
1397819|NCT00392509|peripheral artery disease
1397820|NCT00392509|peripheral vascular disease
1397821|NCT00392509|leg pain
1397822|NCT00392509|PVD
1397823|NCT00392509|PAD
1397824|NCT00392509|CLI
1397825|NCT00392509|amputation
1397826|NCT00392509|limb salvage
1397827|NCT00392483|Heading Health Plan Implementation
1397828|NCT00392483|Computer-Assisted Instruction
1397829|NCT00392483|General Practice
1397830|NCT00392483|Dementia
1397831|NCT00392470|adenocarcinoma of the rectum
1397832|NCT00392470|stage III rectal cancer
1397833|NCT00392470|stage IV rectal cancer
1397834|NCT00392457|Idiopathic Hypogonadotropic Hypogonadism
1397835|NCT00392457|Kallmann Syndrome
1397836|NCT00392457|Agonadal
1397837|NCT00392418|iron deficiency anemia
1397838|NCT00392418|hematologic disease
1397839|NCT00392418|infancy
1397840|NCT00392418|pediatrics
1397841|NCT00392418|Sprinkles®
1397842|NCT00392418|iron
1397843|NCT00392418|micronutrient
1397844|NCT00392405|Contrast Induced Nephropathy
1397845|NCT00392392|Breast Cancer
1397846|NCT00392379|Tobacco use disorder
1397847|NCT00392379|Tobacco cessation
1397848|NCT00392366|MRI guided Laser Therapy
1397849|NCT00392366|Laser Interstitial Thermal Therapy
1397850|NCT00392366|Magnetic Resonance Thermal Imaging
1397851|NCT00392366|Liver Metastasis
1397852|NCT00392340|recurrent neuroblastoma
1397853|NCT00392340|disseminated neuroblastoma
1397854|NCT00392314|hodgkin lymphoma
1397855|NCT00392314|PET/CT
1397856|NCT00392314|Therapy
1397857|NCT00392301|wound healing
1397858|NCT00392301|skin
1397859|NCT00392301|graft donor site
1397860|NCT00392301|donor site
1397861|NCT00392301|transepidermal water loss
1397862|NCT00392288|Bronchial Asthma
1397863|NCT00392275|Cataract
1397864|NCT00392275|Aqueous absorption
1397865|NCT00392275|Funtioning Filtering Blebs
1397866|NCT00392262|Moderate essential hypertension (WHO grade II)
1397867|NCT00392249|Schizophrenia
1397868|NCT00392249|Drug adherence
1397869|NCT00392236|Schizoaffective Disorder
1397870|NCT00392197|OPC-14597
1397871|NCT00392197|Schizophrenia
1397872|NCT00392184|accelerated partial breast irradiation
1397873|NCT00392184|multicatheter brachytherapy
1397874|NCT00392184|high dose rate brachytherapy
1397875|NCT00392184|pulsed dose rate brachytherapy
1397876|NCT00392145|Pediatrics
1397877|NCT00392145|Gastroenteritis
1397878|NCT00392145|Dehydration
1397879|NCT00392145|IV Rehydration
1397880|NCT00392132|HIV
1397881|NCT00392119|MR-guided therapy
1397882|NCT00392119|Laser interstitial thermal therapy
1397883|NCT00392119|brain metastasis
1397884|NCT00392119|Magnetic Resonance Thermal imaging (MRTI)
1397885|NCT00392106|atrial fibrillation
1397886|NCT00392106|arrhythmia
1397887|NCT00392106|AF ablation
1397888|NCT00392106|antiarrhythmic agent
1397889|NCT00392106|catheter ablation
1397890|NCT00392106|pulmonary veins
1397891|NCT00392093|Systemic lupus erythematosus
1397892|NCT00392093|Menopause hormonal therapy
1397893|NCT00392093|Menopausal symptoms
1397894|NCT00392093|Bone mineral density
1397895|NCT00392054|Atrial Fibrillation
1397896|NCT00392054|Paroxysmal
1397897|NCT00392054|Pulmonary Vein Isolation
1397898|NCT00392054|Ablation Catheter
1397899|NCT00392054|Anti-arrhythmic Drug Therapy
1397900|NCT00392054|First Line Therapy
1397901|NCT00392041|Fibromyalgia
1397902|NCT00392041|Insomnia
1397903|NCT00392041|Sleep
1397904|NCT00392041|Eszopiclone
1397905|NCT00392041|Lunesta
1397906|NCT00392028|Ertapenem
1397907|NCT00392028|Bone drug level
1397908|NCT00392028|Blood drug level
1397909|NCT00392028|Tissue drug level
1397910|NCT00392015|Malaria Vaccine
1397911|NCT00392015|Adenovirus
1397912|NCT00392015|Plasmodium falciparum
1397913|NCT00392002|GERD
1397914|NCT00391989|Ph+ Acute Lymphoblastic Leukaemia
1397915|NCT00391989|Dasatinib
1397916|NCT00391989|targeted therapy
1397917|NCT00391989|Patients with Ph positive and or BCR ABL positive ALL
1397918|NCT00391976|Cystic fibrosis
1397919|NCT00391950|Prostate cancer
1397920|NCT00391950|Cancer treatment induced bone loss (CTIBL)
1397921|NCT00391950|Androgen deprivation therapy (ADT)
1397922|NCT00391937|"resurfacing hip [MESH]"
1397923|NCT00391937|"conventional position method"
1397924|NCT00391937|"surgery, computer-assisted [MESH]"
1397925|NCT00391924|Dehydroepiandrosterone
1397926|NCT00391924|Fatigue
1397927|NCT00391924|Quality of life
1397928|NCT00391924|Lupus Erythematosus, Systemic
1397929|NCT00391924|Sjogren's Syndrome
1397930|NCT00391924|Bone mineral density
1397931|NCT00391911|Rhabdomyolysis
1397932|NCT00391911|CRRT
1397933|NCT00391911|N-Acetylcysteine
1397934|NCT00391898|Parkinson's disease, adults, levodopa/carbidopa/entacapone, wearing-off, activities of daily living
1397935|NCT00391872|ACS
1397936|NCT00391872|Acute coronary syndrome
1397937|NCT00391872|Heart attack
1397938|NCT00391872|Unstable angina
1397939|NCT00391872|Coronary artery disease
1397940|NCT00391859|Pharmacist-initiated Intervention Trial in OsteoArthritis
1397941|NCT00391846|Heart Failure
1397942|NCT00391846|Ventricular Dysfunction
1397943|NCT00391846|NTproBNP
1397944|NCT00391833|Alzheimer's disease, Ginseng, CD34
1397945|NCT00391820|constipation
1397946|NCT00391820|chronic
1397947|NCT00391820|bowel function
1397948|NCT00391807|Contraception
1397949|NCT00391794|Memory
1397950|NCT00391794|Alzheimer's disease
1397951|NCT00391794|Dementia
1397952|NCT00391794|Support Group
1397953|NCT00391794|Psychosocial
1397954|NCT00391781|mechanical infertility
1397955|NCT00391781|hysterosalpingogram
1397956|NCT00391781|hysterosalpingography
1397957|NCT00391768|influenza, oseltamivir, Tamiflu®, antiviral, children, infants
1397958|NCT00391755|Migraine Headache
1397959|NCT00391742|Brief intervention
1397960|NCT00391742|Motivational Interviewing
1397961|NCT00391742|Primary care
1397962|NCT00391742|Stepped-care
1397963|NCT00391729|ADHD
1397964|NCT00391716|Alcohol
1397965|NCT00391716|Alcohol treatment
1397966|NCT00391716|Alcoholism
1397967|NCT00391716|Alcohol Dependence
1397968|NCT00391703|Cystic fibrosis
1397969|NCT00391703|mucoviscidosis
1397970|NCT00391703|electrostimulation
1397971|NCT00391703|retraining
1397972|NCT00391690|Serum bone marker
1397973|NCT00391690|Prostate cancer
1397974|NCT00391690|Bisphosphonates
1397975|NCT00391690|Early detection of metastasis
1397976|NCT00391677|Cognitive Rehabilitation
1397977|NCT00391677|Behavior Therapy
1397978|NCT00391664|Endometrial cancer
1397979|NCT00391664|Ovarian Cancer
1397980|NCT00391664|Cervical Cancer
1397981|NCT00391664|Genital Cancer
1397982|NCT00391664|Vulvar Cancer
1397983|NCT00391664|Vaginal Cancer
1397984|NCT00391664|Other Gynecological Cancers
1397985|NCT00391651|UTI
1397986|NCT00391638|HIV and Hepatitis B coinfection
1397987|NCT00391638|Peg interferon
1397988|NCT00391638|tenofovir
1397989|NCT00391638|emtricitabine
1397990|NCT00391638|Hepatitis B e Antigens
1397991|NCT00391638|Treatment Experienced
1397992|NCT00391625|Gaucher disease, Enzyme Replacement Therapy
1397993|NCT00391612|COPD (Chronic Obstructive Pulmonary Disease)
1397994|NCT00391612|Emphysema
1397995|NCT00391612|Hyperinflation
1397996|NCT00391612|Minimally Invasive
1397997|NCT00391599|Cesarean Section,
1397998|NCT00391599|Enema
1397999|NCT00391586|erlotinib
1398000|NCT00391586|NSCLC
1398001|NCT00391586|chemotherapy
1398002|NCT00391586|platinum
1398003|NCT00391586|lung
1398004|NCT00391586|lung cancer
1398005|NCT00391560|refractory leukemia
1398006|NCT00391547|Gingivitis Disease
1398007|NCT00391534|Epilepsy
1398008|NCT00391534|oxcarbazepine
1398009|NCT00391521|Oncology. All solid Tumour disease.
1398010|NCT00391508|Ostomy
1398011|NCT00391508|Peristomal skin
1398012|NCT00391508|Skin complication
1398013|NCT00391495|ADHD
1398014|NCT00391495|Cytokines
1398015|NCT00391495|CR-P
1398016|NCT00391482|IV Drug Users
1398017|NCT00391482|Hepatitis C Virus
1398018|NCT00391482|Human Immunodeficiency Virus
1398019|NCT00391482|Intervention
1398020|NCT00391482|HIV Seronegativity
1398021|NCT00391469|cardiac arrest
1398022|NCT00391469|mild hypothermia
1398023|NCT00391456|animal-assisted therapy
1398024|NCT00391456|dog hospital visit
1398025|NCT00391456|heart failure
1398026|NCT00391443|BUILD 3
1398027|NCT00391443|Idiopathic Pulmonary Fibrosis
1398028|NCT00391443|Tracleer
1398029|NCT00391443|Interstitial Lung Disease
1398030|NCT00391443|bosentan
1398031|NCT00391443|Actelion
1398032|NCT00391430|PTSD
1398033|NCT00391430|Trauma
1398034|NCT00391430|Sexual Abuse
1398035|NCT00391430|Sexual Assault
1398036|NCT00391417|hot flush
1398037|NCT00391417|hot flash
1398038|NCT00391417|estrogen
1398039|NCT00391417|vaginal atrophy
1398040|NCT00391404|Childhood cancer survivors
1398041|NCT00391404|Osteoporosis
1398042|NCT00391404|Bone mineral density
1398043|NCT00391404|Therapy
1398044|NCT00391404|Bisphosphonate
1398045|NCT00391404|Randomized controlled trial
1398046|NCT00391391|Influenza
1398047|NCT00391391|Orthomyxoviruses
1398048|NCT00391391|Inactivated Split-virion influenza vaccine
1398049|NCT00391391|Infants
1398050|NCT00391391|children.
1398051|NCT00391378|Diffusion-Weighted Magnetic Resonance Imaging
1398052|NCT00391378|MRI (Magnetic Resonance Imaging)
1398053|NCT00391378|Stroke
1398054|NCT00391378|Cognition
1398055|NCT00391378|Heart
1398056|NCT00391365|ankle osteoarthritis
1398057|NCT00391365|arthritis
1398058|NCT00391365|arthrodesis
1398059|NCT00391365|arthroplasty
1398060|NCT00391365|Gait
1398061|NCT00391365|step count
1398062|NCT00391365|walking
1398063|NCT00391352|Multiple Sclerosis
1398064|NCT00391352|Disease Modifying Therapy
1398065|NCT00391339|Bryophyllum p.
1398066|NCT00391339|Nifedipine
1398067|NCT00391339|Tocolysis
1398068|NCT00391326|Bivalirudin
1398069|NCT00391326|Heparin
1398070|NCT00391326|Bleeding
1398071|NCT00391326|TIMI flow
1398072|NCT00391326|STEMI
1398073|NCT00391313|Chikungunya
1398074|NCT00391313|Chikungunya disease
1398075|NCT00391300|melanoma
1398076|NCT00391300|basal cell carcinoma of the skin
1398077|NCT00391300|squamous cell carcinoma of the skin
1398078|NCT00391287|Red-Cell Aplasia due to Chronic Kidney Failure
1398079|NCT00391287|Aplastic Anemia
1398080|NCT00391287|Recombinant Erythropoietin
1398081|NCT00391287|Surveillance Registry
1398082|NCT00391287|Registries
1398083|NCT00391261|weight gain
1398084|NCT00391261|obesity
1398085|NCT00391261|metabolism
1398086|NCT00391248|non-small cell lung cancer
1398087|NCT00391248|palliative radiation
1398088|NCT00391248|tarceva
1398338|NCT00390377|synchrotron
1398089|NCT00391248|palliative thoracic radiation therapy
1398090|NCT00391235|bipolar disorder
1398091|NCT00391235|magnetic resonance imaging
1398092|NCT00391235|white matter
1398093|NCT00391235|diffusion tensor imaging
1398094|NCT00391235|children
1398095|NCT00391235|adolescents
1398096|NCT00391222|Bipolar I Disorder
1398097|NCT00391222|Intramuscular injection
1398098|NCT00391222|prevention of mood episodes
1398099|NCT00391222|long acting injectable
1398100|NCT00391222|risperidone
1398101|NCT00391183|Gallbladder cancer
1398102|NCT00391183|Quality of life
1398103|NCT00391183|Stenting
1398104|NCT00391183|Survival
1398105|NCT00391183|Performance status
1398106|NCT00391170|Oral Chronic GVHD
1398107|NCT00391170|Topical Dexamethasone
1398108|NCT00391170|Tissue Markers
1398109|NCT00391170|Salivary Proteomics
1398110|NCT00391170|Quality of Life
1398111|NCT00391170|Oral Chronic Graft Versus Host Disease
1398112|NCT00391170|Oral Pain
1398113|NCT00391170|Mouth Pain
1398114|NCT00391157|Múltiple Myeloma
1398115|NCT00391157|Transplant
1398116|NCT00391157|Patients <65 years.
1398117|NCT00391144|Pattern Dystrophy
1398118|NCT00391144|Choroidal Neovascularization
1398119|NCT00391144|Intravitreal Avastin Injection
1398120|NCT00391131|PID
1398121|NCT00391131|SCIG
1398122|NCT00391131|Ig
1398123|NCT00391131|Quality of Life
1398124|NCT00391131|Serious Bacterial Infections
1398125|NCT00391105|intubation
1398126|NCT00391105|Sedation
1398127|NCT00391105|Analgesia
1398128|NCT00391105|preterm neonate
1398129|NCT00391105|remifentanil
1398130|NCT00391105|morphine
1398131|NCT00391105|respiratory distress syndrome
1398132|NCT00391079|Central Neuropathic Pain
1398133|NCT00391066|CD23+/CD20+ B-cell CLL
1398134|NCT00391066|CLL
1398135|NCT00391053|Influenza
1398136|NCT00391053|Orthomyxoviruses
1398137|NCT00391053|Inactivated Split-virion influenza vaccine
1398138|NCT00391053|Adults
1398139|NCT00391040|diabetes mellitus, structured treatment and teaching, education,
1398140|NCT00391040|elderly patients, geriatrics
1398141|NCT00391027|type 2 diabetes, insulin, glycemic control
1398142|NCT00391014|Acute myeloid Leukemia
1398143|NCT00391014|Allogeneic haematopoietic progenitor cell transplant
1398144|NCT00391014|Acute Invasive Aspergillosis
1398145|NCT00391001|mania
1398146|NCT00391001|bipolar disorder
1398147|NCT00391001|taurine
1398148|NCT00391001|adolescents
1398149|NCT00390988|blood count
1398150|NCT00390988|capillary
1398151|NCT00390988|venous
1398152|NCT00390988|Adult
1398153|NCT00390988|reference values
1398154|NCT00390975|Tegaserod
1398155|NCT00390975|diabetes
1398156|NCT00390975|diabetic gastroparesis
1398157|NCT00390975|gastric emptying
1398158|NCT00390975|gastric retention
1398159|NCT00390975|electrogastrography
1398160|NCT00390962|copeptin
1398161|NCT00390962|vasopressin
1398162|NCT00390962|Adh
1398163|NCT00390962|SIADH
1398164|NCT00390962|diabetes insipidus
1398165|NCT00390962|stroke
1398166|NCT00390962|risk factors
1398167|NCT00390962|Neurological patients with ischemic and hemorrhagic stroke and patients undergoing intracranial surgery.
1398168|NCT00390949|HIV prevention
1398169|NCT00390949|Zimbabwe
1398170|NCT00390949|Core groups
1398171|NCT00390949|Peer education
1398172|NCT00390949|Syndromic management
1398173|NCT00390949|Commercial sex workers
1398174|NCT00390949|Condom distribution
1398175|NCT00390949|HIV Seronegativity
1398176|NCT00390923|smoking
1398177|NCT00390923|nicotine dependence
1398178|NCT00390923|double-blind
1398179|NCT00390923|placebo-controlled
1398180|NCT00390923|randomized
1398181|NCT00390923|full substitution therapy
1398182|NCT00390923|selegiline
1398183|NCT00390910|Pneumococcal vaccine
1398184|NCT00390910|Preterm
1398185|NCT00390910|Safety
1398186|NCT00390910|Pneumococcal disease
1398187|NCT00390910|Immunogenicity
1398188|NCT00390897|chronic myeloid leukaemia
1398189|NCT00390897|Glivec
1398190|NCT00390897|Interferon
1398191|NCT00390884|Fluzone®
1398192|NCT00390884|Influenza
1398193|NCT00390884|Influenza virus infection
1398194|NCT00390884|Influenza vaccine
1398195|NCT00390871|Patient
1398196|NCT00390871|Must be
1398197|NCT00390871|Under
1398198|NCT00390858|β-thalassemia major
1398199|NCT00390858|iron overload
1398200|NCT00390858|deferasirox
1398201|NCT00390858|pediatric rare anemia
1398202|NCT00390845|MAP kinase
1398203|NCT00390845|SB681323
1398204|NCT00390845|neuropathic pain
1398205|NCT00390845|patients
1398206|NCT00390845|P38
1398207|NCT00390845|nerve trauma
1398208|NCT00390832|STEMI
1398209|NCT00390819|Community acquired pneumonia
1398210|NCT00390806|Brain metastases from Non-Small Cell Lung Cancer
1398211|NCT00390806|Brain metastases brain tumor lung cancer oral chemotherapy HYCAMTIN topotecan NSCLC WBRT whole brain radiation
1398212|NCT00390793|Acute Lymphocytic Leukemia
1398213|NCT00390793|Leukemia
1398214|NCT00390793|ALL
1398215|NCT00390793|Philadelphia-Positive ALL
1398216|NCT00390793|BCR-ABL Positive ALL
1398217|NCT00390793|Dasatinib
1398218|NCT00390793|Hyper-CVAD
1398219|NCT00390793|Cyclophosphamide
1398220|NCT00390793|Cytoxan
1398221|NCT00390793|Vincristine
1398222|NCT00390793|Vincasar
1398223|NCT00390793|Doxorubicin
1398224|NCT00390793|Adriamycin
1398225|NCT00390793|Dexamethasone
1398226|NCT00390793|Decadron
1398227|NCT00390793|Sprycel
1398228|NCT00390780|Miconazole Lauriad
1398229|NCT00390780|Oropharyngeal candidiasis
1398230|NCT00390780|HIV patients
1398231|NCT00390780|Mycology
1398232|NCT00390780|Clinical picture of Oropharyngeal candidiasis
1398233|NCT00390780|Candida culture positive
1398234|NCT00390780|Treatment Experienced
1398235|NCT00390767|Peripheral arterial disease
1398236|NCT00390767|Peripheral vascular disease
1398237|NCT00390767|Claudication
1398238|NCT00390767|Cell therapy
1398239|NCT00390767|Gene therapy
1398240|NCT00390767|Endothelial cells
1398241|NCT00390767|Smooth muscle cells
1398242|NCT00390767|Angiogenesis
1398243|NCT00390754|pregnancy
1398244|NCT00390754|unintended
1398245|NCT00390754|menses
1398246|NCT00390741|hip fracture
1398247|NCT00390741|bone mineral density
1398248|NCT00390741|exercise
1398249|NCT00390715|Acute Myeloblastic Leukemia
1398250|NCT00390702|Ventricular septal defect
1398251|NCT00390702|VSD
1398252|NCT00390676|cancer
1398253|NCT00390676|tumors
1398254|NCT00390676|anticarcinogenic agents
1398255|NCT00390676|antineoplastic agents
1398256|NCT00390676|cadherins
1398257|NCT00390676|solid tumors
1398258|NCT00390663|Paediatric
1398259|NCT00390663|Epistaxis
1398260|NCT00390663|Nose bleed
1398261|NCT00390663|Naseptin
1398262|NCT00390650|Anxiety
1398263|NCT00390650|clinical trials
1398264|NCT00390637|Diogenes
1398265|NCT00390637|Diet Intervention
1398266|NCT00390637|Family
1398267|NCT00390637|Glycemic Index
1398268|NCT00390637|Protein
1398269|NCT00390624|Urodilatin
1398270|NCT00390624|Mannitol
1398271|NCT00390624|Acute Kidney Failure
1398272|NCT00390611|Ovarian Cancer
1398273|NCT00390598|colonoscopy
1398274|NCT00390598|large bowel preparation
1398275|NCT00390598|bowel cleansing
1398276|NCT00390598|randomized controlled trial
1398277|NCT00390585|Renal Insufficiency
1398278|NCT00390585|Angioplasty, Transluminal, Percutaneous Coronary
1398279|NCT00390585|Contrast media
1398280|NCT00390572|sleep
1398281|NCT00390572|consultation and referral
1398282|NCT00390572|outcome assessment
1398283|NCT00390572|primary care
1398284|NCT00390559|Nicotine Replacement Therapy
1398285|NCT00390559|Tobacco Smoking
1398286|NCT00390559|Smoking stimuli
1398287|NCT00390559|Gender
1398288|NCT00390533|Anxiety
1398289|NCT00390533|clinical trials
1398290|NCT00390520|Type 2 diabetes
1398291|NCT00390520|vildagliptin
1398292|NCT00390520|glucagon
1398293|NCT00390520|hypoglycemia
1398294|NCT00390507|Acceleromyography
1398295|NCT00390507|TOF-Watch
1398296|NCT00390507|Posttetanic count
1398297|NCT00390507|Train of four
1398298|NCT00390507|Neuromuscular blockade
1398299|NCT00390494|Fibroids
1398300|NCT00390494|Leiomyoma
1398301|NCT00390494|Hysterectomy
1398302|NCT00390494|Myomectomy
1398303|NCT00390494|Uterine Fibroid Embolization
1398304|NCT00390494|Questionnaire
1398305|NCT00390481|Carotid Occlusion
1398306|NCT00390481|Cognition
1398307|NCT00390468|Tandutinib
1398308|NCT00390468|MLN518
1398309|NCT00390468|CT53518
1398310|NCT00390468|pain
1398311|NCT00390468|adenocarcinoma of the prostate
1398312|NCT00390468|recurrent prostate cancer
1398313|NCT00390468|stage IV prostate cancer
1398314|NCT00390468|bone metastases
1398315|NCT00390468|hormone-based castration
1398316|NCT00390442|cardiogenic pulmonary edema
1398317|NCT00390442|non invasive ventilation
1398318|NCT00390442|CPAP
1398319|NCT00390429|stage IIIB non-small cell lung cancer
1398320|NCT00390429|stage IV non-small cell lung cancer
1398321|NCT00390429|recurrent non-small cell lung cancer
1398322|NCT00390429|unspecified adult solid tumor, protocol specific
1398323|NCT00390416|Metastatic
1398324|NCT00390416|Gastroesophageal
1398325|NCT00390416|Docetaxel
1398326|NCT00390416|Cisplatin
1398327|NCT00390416|Fluorouracil
1398328|NCT00390416|Bevacizumab
1398329|NCT00390416|Metastatic Gastroesophageal Adenocarcinoma
1398330|NCT00390416|06-096
1398331|NCT00390403|adult glioblastoma
1398332|NCT00390403|adult gliosarcoma
1398333|NCT00390403|adult giant cell glioblastoma
1398334|NCT00390390|Heartburn, frequent heartburn, proton pump inhibitor, lansoprazole
1398335|NCT00390377|x-ray diffraction
1398336|NCT00390377|hair
1398337|NCT00390377|breast cancer
1398339|NCT00390364|adenocarcinoma of the colon
1398340|NCT00390364|adenocarcinoma of the rectum
1398341|NCT00390364|recurrent colon cancer
1398342|NCT00390364|stage III colon cancer
1398343|NCT00390364|stage IV colon cancer
1398344|NCT00390364|recurrent rectal cancer
1398345|NCT00390364|stage III rectal cancer
1398346|NCT00390364|stage IV rectal cancer
1398347|NCT00390351|Optical coherence tomography
1398348|NCT00390338|recurrent melanoma
1398349|NCT00390338|stage IV melanoma
1398350|NCT00390338|stage IIIA melanoma
1398351|NCT00390338|stage IIIB melanoma
1398352|NCT00390338|stage IIIC melanoma
1398353|NCT00390312|Post operative pain
1398354|NCT00390312|Third molar extraction
1398355|NCT00390312|Dental surgery
1398356|NCT00390312|Morphine
1398357|NCT00390286|Telemedicine
1398358|NCT00390273|diabetes
1398359|NCT00390273|metformin
1398360|NCT00390273|hyperlactatemia
1398361|NCT00390221|MS
1398362|NCT00390221|multiple sclerosis
1398363|NCT00390208|Macular Degeneration
1398364|NCT00390208|Degenerative changes in the macula lutea of the retina.
1398365|NCT00390208|Maculopathy, Age-Related
1398366|NCT00390208|Age-Related Maculopathies
1398367|NCT00390208|Age-Related Maculopathy
1398368|NCT00390208|Maculopathies, Age-Related
1398369|NCT00390208|RETINAL DEGENERATION
1398370|NCT00390208|ARMD
1398371|NCT00390208|AMD
1398372|NCT00390208|Lucentis
1398373|NCT00390208|Visudyne
1398374|NCT00390208|Photodynamic Therapy
1398375|NCT00390208|Verteporfin
1398376|NCT00390208|Ranibizumab
1398377|NCT00390208|Intravitreal Dexamethasone
1398378|NCT00390195|Hepatocellular carcinoma
1398379|NCT00390195|RAD001
1398380|NCT00390195|Rapamycin
1398381|NCT00390195|Randomize
1398382|NCT00390195|Phase I
1398383|NCT00390195|Phase II
1398384|NCT00390195|Pharmacokinetics
1398385|NCT00390182|GI tumors
1398386|NCT00390182|Locally Advanced
1398387|NCT00390182|Metastatic
1398388|NCT00390182|Hepatobiliary
1398389|NCT00390182|Ovary
1398390|NCT00390169|breast neoplasms
1398391|NCT00390169|stress
1398392|NCT00390169|personality
1398393|NCT00390169|psychology
1398394|NCT00390156|refractory
1398395|NCT00390156|prior treatment
1398396|NCT00390156|solid tumors
1398397|NCT00390156|phase I
1398398|NCT00390156|phase 1
1398399|NCT00390143|Immunogenicity
1398400|NCT00390143|Meningococcal vaccine
1398401|NCT00390143|Conjugate vaccine
1398402|NCT00390143|Persistence
1398403|NCT00390130|Vaccination
1398404|NCT00390130|Pediatrics
1398405|NCT00390130|Pain
1398406|NCT00390117|unspecified adult solid tumor, protocol specific
1398407|NCT00390117|recurrent adult Burkitt lymphoma
1398408|NCT00390117|recurrent adult diffuse large cell lymphoma
1398409|NCT00390117|recurrent adult diffuse mixed cell lymphoma
1398410|NCT00390117|recurrent adult immunoblastic large cell lymphoma
1398411|NCT00390117|recurrent adult lymphoblastic lymphoma
1398412|NCT00390117|recurrent adult diffuse small cleaved cell lymphoma
1398413|NCT00390117|recurrent grade 1 follicular lymphoma
1398414|NCT00390117|recurrent grade 2 follicular lymphoma
1398415|NCT00390117|recurrent grade 3 follicular lymphoma
1398416|NCT00390117|recurrent mantle cell lymphoma
1398417|NCT00390117|recurrent marginal zone lymphoma
1398418|NCT00390117|recurrent small lymphocytic lymphoma
1398419|NCT00390117|Waldenstrom macroglobulinemia
1398420|NCT00390117|recurrent adult grade III lymphomatoid granulomatosis
1398421|NCT00390117|adult nasal type extranodal NK/T-cell lymphoma
1398422|NCT00390117|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1398423|NCT00390117|nodal marginal zone B-cell lymphoma
1398424|NCT00390117|splenic marginal zone lymphoma
1398425|NCT00390104|Neuromuscular Disease
1398426|NCT00390104|Muscle weakness
1398427|NCT00390104|Muscle atrophy
1398428|NCT00390091|Lupus
1398429|NCT00390091|Nephritis
1398430|NCT00390091|Kidney
1398431|NCT00390091|SLE
1398432|NCT00390091|Systemic Lupus Erythematosus
1398433|NCT00390091|Nephritis, Lupus
1398434|NCT00390078|Vaccine
1398435|NCT00390078|Safety
1398436|NCT00390078|T-cell epitope
1398437|NCT00390078|Acquired Immune Deficiency Syndrome Virus
1398438|NCT00390078|HIV Therapeutic Vaccine
1398439|NCT00390065|Follow-up
1398440|NCT00390065|Premature infants
1398441|NCT00390065|Nitric Oxide
1398442|NCT00390065|Respiratory function testing
1398443|NCT00390065|Neurodevelopmental outcomes
1398444|NCT00390039|Pain, postoperative
1398445|NCT00390039|Surgery, orthopedic
1398446|NCT00390039|Morphine
1398447|NCT00390026|Neovascular age-related macular degeneration
1398448|NCT00390026|Bevacizumab
1398449|NCT00390026|Photodynamic therapy
1398450|NCT00390013|Vulvar Pain
1398451|NCT00389948|Heartburn, frequent heartburn, proton pump inhibitor, lansoprazole
1398452|NCT00389935|Gastrointestinal Bleeding
1398453|NCT00389935|Arteriovenous Malformation
1398454|NCT00389935|Angiodysplasia
1398455|NCT00389935|Hereditary Hemorrhagic Telangiectasia
1398456|NCT00389935|Obscure Bleeding
1398457|NCT00389922|unspecified adult solid tumor, protocol specific
1398458|NCT00389909|Premature infants
1398459|NCT00389909|Apnea
1398460|NCT00389909|Doxapram
1398461|NCT00389909|pharmacokinetics
1398462|NCT00389883|supratentorial brain tumors
1398463|NCT00389883|propofol
1398464|NCT00389883|sevoflurane
1398465|NCT00389883|remifentanil
1398466|NCT00389883|sufentanil.
1398467|NCT00389870|recurrent colon cancer
1398468|NCT00389870|stage IV colon cancer
1398469|NCT00389870|recurrent rectal cancer
1398470|NCT00389870|stage IV rectal cancer
1398471|NCT00389870|adenocarcinoma of the colon
1398472|NCT00389870|adenocarcinoma of the rectum
1398473|NCT00389857|Influenza
1398474|NCT00389857|Influenza Virus Vaccine
1398475|NCT00389857|Fluzone®
1398476|NCT00389844|hip fracture
1398477|NCT00389844|exercise
1398478|NCT00389844|motivation
1398479|NCT00389831|Rotigotine
1398480|NCT00389831|Rotigotine nasal spray
1398481|NCT00389831|Efficacy, safety and tolerability
1398482|NCT00389831|Restless Legs Syndrome
1398483|NCT00389818|contiguous stage II grade 3 follicular lymphoma
1398484|NCT00389818|noncontiguous stage II grade 3 follicular lymphoma
1398485|NCT00389818|stage I grade 3 follicular lymphoma
1398486|NCT00389818|stage III grade 3 follicular lymphoma
1398487|NCT00389818|stage IV grade 3 follicular lymphoma
1398488|NCT00389818|AIDS-related diffuse large cell lymphoma
1398489|NCT00389818|contiguous stage II adult diffuse large cell lymphoma
1398490|NCT00389818|noncontiguous stage II adult diffuse large cell lymphoma
1398491|NCT00389818|stage I adult diffuse large cell lymphoma
1398492|NCT00389818|stage III adult diffuse large cell lymphoma
1398493|NCT00389818|stage IV adult diffuse large cell lymphoma
1398494|NCT00389818|AIDS-related immunoblastic large cell lymphoma
1398495|NCT00389818|contiguous stage II adult immunoblastic large cell lymphoma
1398496|NCT00389818|noncontiguous stage II adult immunoblastic large cell lymphoma
1398497|NCT00389818|stage I adult immunoblastic large cell lymphoma
1398498|NCT00389818|stage III adult immunoblastic large cell lymphoma
1398499|NCT00389818|stage IV adult immunoblastic large cell lymphoma
1398500|NCT00389818|AIDS-related peripheral/systemic lymphoma
1398501|NCT00389805|recurrent non-small cell lung cancer
1398502|NCT00389805|stage IIIB non-small cell lung cancer
1398503|NCT00389805|stage IV non-small cell lung cancer
1398504|NCT00389805|unspecified adult solid tumor, protocol specific
1398505|NCT00389766|localized unresectable neuroblastoma
1398506|NCT00389766|recurrent neuroblastoma
1398507|NCT00389766|regional neuroblastoma
1398508|NCT00389766|localized resectable neuroblastoma
1398509|NCT00389766|disseminated neuroblastoma
1398510|NCT00389753|Scars
1398511|NCT00389753|Hydratation
1398512|NCT00389753|After Treatment
1398513|NCT00389714|pedodontics
1398514|NCT00389714|carious
1398515|NCT00389714|dental restoration
1398516|NCT00389714|antibacterial
1398517|NCT00389714|nanoparticles
1398518|NCT00389701|stage I multiple myeloma
1398519|NCT00389701|stage II multiple myeloma
1398520|NCT00389701|stage III multiple myeloma
1398521|NCT00389701|refractory multiple myeloma
1398522|NCT00389688|stage I non-small cell lung cancer
1398523|NCT00389688|stage II non-small cell lung cancer
1398524|NCT00389649|congestive heart failure
1398525|NCT00389649|pacemaker
1398526|NCT00389649|heart rate
1398527|NCT00389636|Diabetes
1398528|NCT00389636|Foot
1398529|NCT00389636|Extremity
1398530|NCT00389636|Ulcer
1398531|NCT00389636|Wound
1398532|NCT00389636|Gauze
1398533|NCT00389610|stage I pancreatic cancer
1398534|NCT00389610|stage II pancreatic cancer
1398535|NCT00389610|stage III pancreatic cancer
1398536|NCT00389610|adenocarcinoma of the pancreas
1398537|NCT00389597|degenerative disc disease
1398538|NCT00389597|cervical arthroplasty
1398539|NCT00389597|Mobi C
1398540|NCT00389597|multilevel
1398541|NCT00389597|anterior cervical discectomy and fusion
1398542|NCT00389584|cognitive/functional effects
1398543|NCT00389584|poor performance status
1398544|NCT00389584|long-term effects secondary to cancer therapy in adults
1398545|NCT00389584|long-term effects secondary to cancer therapy in children
1398546|NCT00389584|adult tumors metastatic to brain
1398547|NCT00389584|unspecified adult solid tumor, protocol specific
1398548|NCT00389584|unspecified childhood solid tumor, protocol specific
1398549|NCT00389558|Skin colonization
1398550|NCT00389558|Antiseptic
1398551|NCT00389558|Epicutaneocavous catheter dressing
1398552|NCT00389558|Infant
1398553|NCT00389532|Influenza
1398554|NCT00389532|Influenza Vaccine
1398555|NCT00389519|Hypertension/*etiology
1398556|NCT00389519|Blood Pressure
1398557|NCT00389519|Pediatric
1398558|NCT00389519|Adolescent
1398559|NCT00389519|Child
1398560|NCT00389506|stage II adult Hodgkin lymphoma
1398561|NCT00389506|stage III adult Hodgkin lymphoma
1398562|NCT00389506|stage IV adult Hodgkin lymphoma
1398563|NCT00389506|recurrent adult Hodgkin lymphoma
1398564|NCT00389493|OCD
1398565|NCT00389493|Augmentation
1398566|NCT00389493|Antipsychotics
1398567|NCT00389493|Cognitive-Behavioral Therapy
1398568|NCT00389480|Solid Tumors
1398569|NCT00389480|Solid Malignancies
1398570|NCT00389480|Phase I
1398571|NCT00389467|stroke
1398572|NCT00389467|ischemic stroke
1398573|NCT00389467|blood clot
1398574|NCT00389467|Merci Retriever
1398575|NCT00389467|Penumbra System
1398576|NCT00389467|embolectomy
1398577|NCT00389467|magnetic resonance imaging
1398578|NCT00389467|MRI
1398579|NCT00389467|CT
1398580|NCT00389467|SPOTRIAS
1398581|NCT00389454|Acetaminophen
1398582|NCT00389454|Fever
1398583|NCT00389454|cerebro spinal fluid
1398584|NCT00389454|Infants
1398585|NCT00389441|VEGFR inhibitor
1398586|NCT00389441|tyrosine kinase inhibitor
1398587|NCT00389441|anti-angiogenic
1398588|NCT00389441|carcinoma
1398589|NCT00389441|papillary
1398590|NCT00389441|follicular
1398591|NCT00389441|medullary
1398592|NCT00389441|anaplastic
1398593|NCT00389428|Hematologic malignancies
1398594|NCT00389428|Malignancies, hematologic
1398595|NCT00389428|Hematopoietic malignancies
1398596|NCT00389415|Type 2 Diabetes
1398597|NCT00389415|Vildagliptin
1398598|NCT00389415|HbA1c
1398599|NCT00389402|lipids
1398600|NCT00389402|lipodystrophy
1398601|NCT00389402|fat distribution
1398602|NCT00389402|hiv-1
1398603|NCT00389402|antiretroviral therapy
1398604|NCT00389402|Treatment Naive
1398605|NCT00389389|Advanced Solid Malignancies
1398606|NCT00389389|Advanced solid tumors
1398607|NCT00389389|Cancer
1398608|NCT00389389|Phase I
1398609|NCT00389389|Solid tumors
1398610|NCT00389389|Solid malignancies
1398611|NCT00389337|Sepsis
1398612|NCT00389337|SIRS
1398613|NCT00389337|Biomarkers
1398614|NCT00389337|xMAP
1398615|NCT00389324|Primary immune deficiency
1398616|NCT00389311|Microbicide
1398617|NCT00389311|Safety
1398618|NCT00389311|HIV prevention
1398619|NCT00389311|HIV Seronegativity
1398620|NCT00389298|Chronic hepatitis C
1398621|NCT00389298|Viral kinetics
1398622|NCT00389298|Phase II
1398623|NCT00389298|Pharmacokinetics (PK)
1398624|NCT00389298|Safety and tolerability
1398625|NCT00389285|Carcinoma, renal cell
1398626|NCT00389285|interleukin-21
1398627|NCT00389285|sorafenib
1398628|NCT00389285|Immunotherapy
1398629|NCT00389259|Insecticides
1398630|NCT00389259|Organophosphate
1398631|NCT00389259|Scopolamine
1398632|NCT00389259|randomized control study
1398633|NCT00389259|Organophosphate or carbamate intoxication
1398634|NCT00389246|obesity
1398635|NCT00389246|genetic consultation
1398636|NCT00389246|randomized controlled trial
1398637|NCT00389220|Coronary Disease
1398638|NCT00389220|Coronary Stenosis
1398639|NCT00389220|Angioplasty
1398640|NCT00389220|Coronary Restenosis
1398641|NCT00389220|Drug Eluting Stent
1398642|NCT00389194|HIV-1 infection
1398643|NCT00389194|fat distribution
1398644|NCT00389194|lipodystrophy
1398645|NCT00389194|lipids
1398646|NCT00389194|kidney function
1398647|NCT00389194|Treatment Experienced
1398648|NCT00389181|Unruptured brain arteriovenous malformation
1398649|NCT00389181|AVM
1398650|NCT00389181|BAVM
1398651|NCT00389181|Stroke
1398652|NCT00389181|Intracranial Hemorrhage
1398653|NCT00389168|Hypertension
1398654|NCT00389168|Cardiac hypertrophy
1398655|NCT00389168|Angiotensin
1398656|NCT00389168|Human
1398657|NCT00389155|Advanced or metastatic transitional cell carcinoma of the urothelium
1398658|NCT00389142|pelvic pain
1398659|NCT00389142|urinary frequency
1398660|NCT00389142|painful bladder
1398661|NCT00389142|urinary urgency
1398662|NCT00389129|Platelets
1398663|NCT00389129|Aspirin Resistance
1398664|NCT00389129|Platelet aggregation
1398665|NCT00389090|temozolomide resistant
1398666|NCT00389090|anaplastic glioma
1398667|NCT00389090|anaplastic astrocytoma
1398668|NCT00389090|anaplastic oligodendroglioma
1398669|NCT00389090|anaplastic oligoastrocytoma
1398670|NCT00389077|perifosine
1398671|NCT00389077|solid tumors
1398672|NCT00389077|lymphomas
1398673|NCT00389077|anticancer agent
1398674|NCT00389064|Generalised Anxiety Disorder
1398675|NCT00389064|GAD
1398676|NCT00389051|Non-Hodgkin's Lymphoma
1398677|NCT00389051|Malignant lymphoma
1398678|NCT00389038|headache
1398679|NCT00389038|coping skills training
1398680|NCT00389038|amitriptyline
1398681|NCT00389038|attention control
1398682|NCT00389025|Subject with clinical history of seasonal allergic conjunctivitis
1398683|NCT00389012|rehabilitation
1398684|NCT00389012|hemiplegic gait
1398685|NCT00389012|exercise therapy
1398686|NCT00389012|physical therapy
1398687|NCT00388999|Multiple Myeloma
1398688|NCT00388999|Stem Cell Transplant
1398689|NCT00388999|rhMBL
1398690|NCT00388973|Major Depressive Disorder
1398691|NCT00388973|MDD
1398692|NCT00388960|small cell lung cancer
1398693|NCT00388960|amrubicin
1398694|NCT00388947|vaginal prolapse
1398695|NCT00388947|cystocele
1398696|NCT00388947|rectocele
1398697|NCT00388947|enterocele
1398698|NCT00388947|apical prolapse
1398699|NCT00388947|vaginal vault prolapse
1398700|NCT00388934|Percutaneous coronary intervention
1398701|NCT00388934|Angina pectoris
1398702|NCT00388934|Stent
1398703|NCT00388921|Vitamin A
1398704|NCT00388921|Children
1398705|NCT00388921|Severe malnutrition
1398706|NCT00388921|Retinol
1398707|NCT00388921|Retinol binding protein
1398708|NCT00388921|Diarrhoea
1398709|NCT00388921|ALRI
1398710|NCT00388921|Age 6-59 months
1398711|NCT00388921|Either sex
1398712|NCT00388921|Severe malnutrition as defined by the presence of any of the followings:
1398713|NCT00388921|Bipedal oedema
1398714|NCT00388921|Weight (measured after correction of dehydration) for height Z score <-3 of the National Center for Health Statistics (NCHS) reference
1398715|NCT00388921|Written informed consent of respective parents/ guardians for participation of the children in the study.
1398716|NCT00388921|Children having diarrhoea (watery or invasive) or cough and cold or both for the last 48 hours.
1398717|NCT00388908|vertebral fractures
1398718|NCT00388908|osteoporosis
1398719|NCT00388908|prevention
1398720|NCT00388908|case-finding
1398721|NCT00388908|quality improvement
1398722|NCT00388895|Acute lymphoblastic Leukemia
1398723|NCT00388869|renal artery
1398724|NCT00388869|calcium
1398725|NCT00388869|CT
1398726|NCT00388869|hypertension
1398727|NCT00388856|antioxidant supplementation
1398728|NCT00388856|preeclampsia
1398729|NCT00388856|prevention
1398730|NCT00388843|carotid atherosclerosis
1398731|NCT00388843|magnetic resonance imaging
1398732|NCT00388843|atherosclerosis
1398733|NCT00388843|ultrasound
1398734|NCT00388843|inflammation
1398735|NCT00388843|statins
1398736|NCT00388843|vulnerable plaque
1398737|NCT00388843|stroke
1398738|NCT00388830|Gallbladder
1398739|NCT00388830|Ultrasound
1398740|NCT00388830|Emergency Medicine
1398741|NCT00388817|Hypertension
1398742|NCT00388817|Blood pressure
1398743|NCT00388817|Adherence
1398744|NCT00388817|Compliance
1398745|NCT00388817|Pharmacist
1398746|NCT00388817|Pharmacy
1398747|NCT00388817|Costs
1398748|NCT00388804|Prostate Cancer
1398749|NCT00388804|External Beam Radiotherapy
1398750|NCT00388804|Radiation Therapy
1398751|NCT00388804|Hormone Therapy
1398752|NCT00388804|Bicalutamide
1398753|NCT00388804|Casodex
1398754|NCT00388804|Leuprolide
1398755|NCT00388804|Lupron
1398756|NCT00388804|Goserelin
1398757|NCT00388804|Zoladex
1398758|NCT00388804|Flutamide
1398759|NCT00388804|EBRT
1398760|NCT00388791|symptomatology
1398761|NCT00388791|Schein questionnaire
1398762|NCT00388791|fluoresceien staining
1398763|NCT00388765|bronchoscopy
1398764|NCT00388765|sample bank
1398765|NCT00388765|research study volunteer
1398766|NCT00388752|Acupuncture
1398767|NCT00388752|Phantom limb pain
1398768|NCT00388752|Residual limb pain
1398769|NCT00388752|amputation
1398770|NCT00388752|amputee
1398771|NCT00388752|traumatic
1398772|NCT00388752|surgical
1398773|NCT00388752|Traumatic amputation upper extremity
1398774|NCT00388752|Traumatic amputation lower extremity
1398775|NCT00388752|Surgical amputation upper extremity
1398776|NCT00388752|Surgical amputation lower extremity
1398777|NCT00388739|Pediatric Asthma
1398778|NCT00388739|Pulmicort
1398779|NCT00388739|TEDAS ED
1398780|NCT00388739|Acute exacerbation of asthma
1398781|NCT00388739|Chronic asthma
1398782|NCT00388726|Locally recurrent breast cancer
1398783|NCT00388726|metastatic breast cancer
1398784|NCT00388713|Radiation therapy
1398785|NCT00388713|Radiation-Induced Atherosclerosis
1398786|NCT00388713|Carotid Artery Diseases
1398787|NCT00388713|Breast Cancer
1398788|NCT00388713|Intima Media thickening Ultrasound
1398789|NCT00388700|Colorectal cancer, DAVANAT, colon cancer, 5-FU
1398790|NCT00388687|Hypoxia
1398791|NCT00388687|FAZA
1398792|NCT00388687|PET
1398793|NCT00388687|Radiochemotherapy
1398794|NCT00388674|Chronic Hepatitis B Virus
1398795|NCT00388661|sleep problems
1398796|NCT00388661|quality of life
1398797|NCT00388661|melatonin
1398798|NCT00388661|sleep apnea
1398799|NCT00388661|medication
1398800|NCT00388661|preload
1398801|NCT00388661|nutritional status
1398802|NCT00388661|ProBNP
1398803|NCT00388648|Dialysis
1398804|NCT00388648|Vegan Diet
1398805|NCT00388648|Mortality
1398806|NCT00388648|Morbidity
1398807|NCT00388648|Treatment outcome
1398808|NCT00388635|Multiple Myeloma
1398809|NCT00388635|Patients over 65 years old
1398810|NCT00388622|Heart failure
1398811|NCT00388622|Adherence
1398812|NCT00388622|Compliance
1398813|NCT00388622|Pharmacy
1398814|NCT00388622|Pharmacist
1398815|NCT00388622|Health-related quality of life
1398816|NCT00388622|Clinical exacerbation
1398817|NCT00388622|Costs
1398818|NCT00388596|SB-751689
1398819|NCT00388596|osteoporosis
1398820|NCT00388596|drug interaction
1398821|NCT00388596|ketoconazole
1398822|NCT00388596|atorvastatin
1398823|NCT00388596|rosuvastatin
1398824|NCT00388583|Influenza
1398825|NCT00388583|Orthomyxoviruses
1398826|NCT00388583|Inactivated Split-virion influenza vaccine
1398827|NCT00388583|Elderly.
1398828|NCT00388570|Asthma
1398829|NCT00388570|adult
1398830|NCT00388570|paediatric
1398831|NCT00388570|NIOX MINO®
1398832|NCT00388570|NIOX®
1398833|NCT00388570|nitric oxide
1398834|NCT00388570|airway inflammation
1398835|NCT00388570|open−label
1398836|NCT00388570|single−cohort
1398837|NCT00388531|Acute Lymphoblastic Leucemia
1398838|NCT00388531|Aggressive Non-Hodgkin-Lymphoma
1398839|NCT00388531|CNS relapse
1398840|NCT00388531|Cytarabine liposome
1398841|NCT00388505|tobramycin
1398842|NCT00388492|HIV Infected
1398843|NCT00388466|whole body vibration
1398844|NCT00388466|muscle function
1398845|NCT00388466|cystic fibrosis
1398846|NCT00388466|mechanography
1398847|NCT00388466|chair-rising-test
1398848|NCT00388453|Healthy volunteers
1398849|NCT00388440|Mumps
1398850|NCT00388440|Singapore
1398851|NCT00388440|Rubella
1398852|NCT00388440|Measles
1398853|NCT00388427|advanced cancer
1398854|NCT00388427|solid tumor
1398855|NCT00388427|solid malignancies
1398856|NCT00388427|phase I
1398857|NCT00388401|Postoperative Ileus
1398858|NCT00388388|Remodeling
1398859|NCT00388388|Resistance arteries
1398860|NCT00388388|angiotensin receptor blocker
1398861|NCT00388388|thiazide diuretic
1398862|NCT00388362|GVHD
1398863|NCT00388336|Anemia
1398864|NCT00388336|Neoplasms, Hemoglobin values
1398865|NCT00388336|PROCRIT
1398866|NCT00388336|Epoetin alfa
1398867|NCT00388323|Alcohol
1398868|NCT00388323|Hepatitis
1398869|NCT00388323|Cirrhosis
1398870|NCT00388323|Inflammation
1398871|NCT00388323|Cytokines
1398872|NCT00388323|ADIPOKINES
1398873|NCT00388323|Adipose tissue
1398874|NCT00388310|cellulitis
1398875|NCT00388310|furuncles
1398876|NCT00388310|carbuncles
1398877|NCT00388310|abscess
1398878|NCT00388297|Subclinical Hypothyroidism
1398879|NCT00388297|Hypothyroxinemia
1398880|NCT00388297|Thyroid
1398881|NCT00388297|Pregnancy
1398882|NCT00388297|Intellectual Development
1398883|NCT00388284|hemostasis
1398884|NCT00388284|arterial sealing
1398885|NCT00388271|Alpha-blocker
1398886|NCT00388271|Alfuzosin
1398887|NCT00388271|Xatral
1398888|NCT00388271|ESWL
1398889|NCT00388258|Postoperative ileus
1398890|NCT00388245|PCI
1398891|NCT00388245|CABG
1398892|NCT00388245|Ejection Fraction
1398893|NCT00388245|Myocardial Revascularization
1398894|NCT00388232|COPD
1398895|NCT00388232|prevalence
1398896|NCT00388232|smoke
1398897|NCT00388232|biomass
1398898|NCT00388232|occupational
1398899|NCT00388232|Malatya
1398900|NCT00388232|Turkey
1398901|NCT00388219|Buprenorphine
1398902|NCT00388219|Transdermal patch
1398903|NCT00388219|Centrally acting analgesic
1398904|NCT00388219|Plasma level
1398905|NCT00388219|Healthy volunteers
1398906|NCT00388206|NSCLC
1398907|NCT00388206|Avastin
1398908|NCT00388206|anti-VEGF
1398909|NCT00388206|lung cancer
1398910|NCT00388206|colorectal cancer
1398911|NCT00388206|ARIES
1398912|NCT00388206|Colon Cancer
1398913|NCT00388193|ALL (L3)
1398914|NCT00388193|BURKITT's LYMPHOMA
1398915|NCT00388193|RITUXIMAB
1398916|NCT00388180|cholesterol
1398917|NCT00388180|inflammation
1398918|NCT00388180|fat
1398919|NCT00388167|Invader fungal infection (IFI)
1398920|NCT00388167|Invasive Aspergillosis (AI)
1398921|NCT00388167|Invasive Candidiasis (CI)
1398922|NCT00388167|Caspofungin acetate
1398923|NCT00388154|Endometrial Cancer
1398924|NCT00388154|Gemcitabine
1398925|NCT00388154|Gemzar
1398926|NCT00388154|Gemcitabine Hydrochloride
1398927|NCT00388154|Cisplatin
1398928|NCT00388154|Platinol-AQ
1398929|NCT00388154|Platinol
1398930|NCT00388154|CDDP
1398931|NCT00388141|Preterm Infant;
1398932|NCT00388141|NIDCAP;
1398933|NCT00388141|Neonatal Care,
1398934|NCT00388141|Intervention Study;
1398935|NCT00388141|Growth and Development;
1398936|NCT00388141|Maternal Self-esteem.
1398937|NCT00388141|Maternal Social support
1398938|NCT00388141|NICU
1398939|NCT00388128|Intermittent Claudication
1398940|NCT00388128|PAD
1398941|NCT00388128|Caffeine
1398942|NCT00388128|Walking capacity
1398943|NCT00388128|ABI
1398944|NCT00388128|QoL
1398945|NCT00388128|Growth factor
1398946|NCT00388115|ductal breast carcinoma in situ
1398947|NCT00388115|stage I breast cancer
1398948|NCT00388115|stage II breast cancer
1398949|NCT00388115|breast cancer in situ
1398950|NCT00388089|unspecified adult solid tumor, protocol specific
1398951|NCT00388089|extensive stage small cell lung cancer
1398952|NCT00388089|recurrent small cell lung cancer
1398953|NCT00388076|Pazopanib
1398954|NCT00388076|paclitaxel
1398955|NCT00388076|carboplatin
1398956|NCT00388076|lapatinib
1398957|NCT00388076|TAXOL
1398958|NCT00388076|TYKERB
1398959|NCT00388076|PARAPLATIN
1398960|NCT00388063|Neuroendocrine
1398961|NCT00388063|Carcinoma
1398962|NCT00388063|Atiprimod
1398963|NCT00388063|Carcinoid
1398964|NCT00388050|Decision aid, diabetes, primary care
1398965|NCT00388024|stage III squamous cell carcinoma of the hypopharynx
1398966|NCT00388024|stage III squamous cell carcinoma of the larynx
1398967|NCT00388024|stage III squamous cell carcinoma of the lip and oral cavity
1398968|NCT00388024|stage III squamous cell carcinoma of the nasopharynx
1398969|NCT00388024|stage III squamous cell carcinoma of the oropharynx
1398970|NCT00388024|stage III lymphoepithelioma of the nasopharynx
1398971|NCT00388024|stage III lymphoepithelioma of the oropharynx
1398972|NCT00388024|squamous cell carcinoma of unknown primary
1398973|NCT00388024|newly diagnosed carcinoma of unknown primary
1398974|NCT00388024|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1398975|NCT00388024|untreated metastatic squamous neck cancer with occult primary
1398976|NCT00388024|stage IV squamous cell carcinoma of the hypopharynx
1398977|NCT00388024|stage IV squamous cell carcinoma of the larynx
1398978|NCT00388024|stage IV squamous cell carcinoma of the lip and oral cavity
1398979|NCT00388024|stage IV squamous cell carcinoma of the nasopharynx
1398980|NCT00388024|stage IV squamous cell carcinoma of the oropharynx
1398981|NCT00388024|stage IV lymphoepithelioma of the nasopharynx
1398982|NCT00388024|stage IV lymphoepithelioma of the oropharynx
1398983|NCT00388011|Post surgical pain
1398984|NCT00388011|Bunionectomy
1398985|NCT00388011|Hammer Toe Syndrome
1398986|NCT00388011|Morphine
1398987|NCT00387998|unspecified adult solid tumor, protocol specific
1398988|NCT00387972|Type 2 diabetes mellitus (T2DM)
1398989|NCT00387972|glycosylated hemoglobin (HbA1c)
1398990|NCT00387972|denagliptin
1398991|NCT00387972|diabetes treatment
1398992|NCT00387972|glycemic control
1398993|NCT00387959|recurrent mantle cell lymphoma
1398994|NCT00387959|stage III mantle cell lymphoma
1398995|NCT00387959|stage IV mantle cell lymphoma
1398996|NCT00387959|recurrent adult diffuse large cell lymphoma
1398997|NCT00387959|stage III adult diffuse large cell lymphoma
1398998|NCT00387959|stage IV adult diffuse large cell lymphoma
1398999|NCT00387959|B-cell chronic lymphocytic leukemia
1399000|NCT00387959|refractory chronic lymphocytic leukemia
1399001|NCT00387959|stage III chronic lymphocytic leukemia
1399002|NCT00387959|stage IV chronic lymphocytic leukemia
1399003|NCT00387959|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1399004|NCT00387959|nodal marginal zone B-cell lymphoma
1399005|NCT00387959|recurrent marginal zone lymphoma
1399006|NCT00387959|recurrent adult diffuse small cleaved cell lymphoma
1399007|NCT00387959|splenic marginal zone lymphoma
1399008|NCT00387959|recurrent grade 1 follicular lymphoma
1399009|NCT00387959|recurrent grade 2 follicular lymphoma
1399010|NCT00387959|recurrent grade 3 follicular lymphoma
1399011|NCT00387959|noncontiguous stage II grade 1 follicular lymphoma
1399012|NCT00387959|noncontiguous stage II grade 2 follicular lymphoma
1399013|NCT00387959|noncontiguous stage II grade 3 follicular lymphoma
1399014|NCT00387959|stage III grade 1 follicular lymphoma
1399015|NCT00387959|stage III grade 2 follicular lymphoma
1399016|NCT00387959|stage III grade 3 follicular lymphoma
1399017|NCT00387959|stage IV grade 1 follicular lymphoma
1399018|NCT00387959|stage IV grade 2 follicular lymphoma
1399019|NCT00387959|stage IV grade 3 follicular lymphoma
1399020|NCT00387959|noncontiguous stage II marginal zone lymphoma
1399021|NCT00387959|stage III marginal zone lymphoma
1399022|NCT00387959|stage IV marginal zone lymphoma
1399023|NCT00387959|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1399024|NCT00387959|stage III adult diffuse small cleaved cell lymphoma
1399025|NCT00387959|stage IV adult diffuse small cleaved cell lymphoma
1399026|NCT00387959|noncontiguous stage II adult diffuse large cell lymphoma
1399027|NCT00387959|noncontiguous stage II mantle cell lymphoma
1399028|NCT00387946|smoking
1399029|NCT00387946|cessation
1399030|NCT00387946|tobacco
1399031|NCT00387933|recurrent adult brain tumor
1399032|NCT00387933|adult glioblastoma
1399033|NCT00387933|adult anaplastic astrocytoma
1399034|NCT00387933|adult anaplastic oligodendroglioma
1399035|NCT00387933|adult gliosarcoma
1399036|NCT00387933|adult giant cell glioblastoma
1399037|NCT00387933|adult anaplastic ependymoma
1399038|NCT00387933|adult brain stem glioma
1399039|NCT00387933|adult mixed glioma
1399040|NCT00387933|adult pineal gland astrocytoma
1399041|NCT00387907|Herceptin
1399042|NCT00387907|Taxane
1399043|NCT00387907|Breast Cancer
1399044|NCT00387894|adult glioblastoma
1399045|NCT00387894|adult gliosarcoma
1399046|NCT00387894|recurrent adult brain tumor
1399047|NCT00387881|sumatriptan succinate,
1399048|NCT00387881|naproxen sodium,
1399049|NCT00387881|parallel group,
1399050|NCT00387881|double-blind,
1399051|NCT00387881|placebo-controlled,
1399052|NCT00387881|Combination product,
1399053|NCT00387881|migrainous headache
1399054|NCT00387881|Probable migraine, a sub-type of Migraine
1399055|NCT00387881|probable migraine,
1399056|NCT00387868|Thymoma
1399057|NCT00387868|Thymic carcinoma
1399058|NCT00387868|Preoperative chemotherapy and radiation
1399059|NCT00387868|Response rate
1399060|NCT00387855|suicide
1399061|NCT00387855|depression
1399062|NCT00387777|Buprenorphine
1399063|NCT00387777|Transdermal patch
1399064|NCT00387777|multidose
1399065|NCT00387777|Centrally acting analgesic
1399066|NCT00387777|Plasma level
1399067|NCT00387777|Healthy volunteers
1399068|NCT00387764|renal cell carcinoma
1399069|NCT00387764|pazopanib
1399070|NCT00387764|anti-angiogenic therapy
1399071|NCT00387764|open label
1399072|NCT00387738|Ragweed
1399073|NCT00387738|Allergy
1399074|NCT00387738|Allergic
1399075|NCT00387738|Rhinitis
1399076|NCT00387738|Hay Fever
1399077|NCT00387738|Seasonal
1399078|NCT00387738|Treatment
1399079|NCT00387738|Immunotherapy
1399080|NCT00387738|Vaccine
1399081|NCT00387725|Adolescent
1399082|NCT00387725|Meningococcal
1399083|NCT00387725|Safety
1399084|NCT00387712|exercise
1399085|NCT00387712|inflammation
1399086|NCT00387712|motor performance
1399087|NCT00387712|skeletal muscle
1399088|NCT00387712|chronic stroke survivors
1399089|NCT00387712|treadmill exercise
1399090|NCT00387699|limited stage small cell lung cancer
1399091|NCT00387673|electrical stimulation
1399092|NCT00387673|hand
1399093|NCT00387673|Rehabilitation
1399094|NCT00387673|spinal cord injury
1399095|NCT00387660|extensive stage small cell lung cancer
1399096|NCT00387660|limited stage small cell lung cancer
1399097|NCT00387660|recurrent small cell lung cancer
1399098|NCT00387647|myeloid
1399099|NCT00387647|acute
1399100|NCT00387647|monocytic
1399101|NCT00387634|tick born encephalitis, TBE, adults
1399102|NCT00387621|heart failure
1399103|NCT00387621|diastolic dysfunction
1399104|NCT00387621|systolic dysfunction
1399105|NCT00387621|preclinical
1399106|NCT00387621|natriuretic peptide
1399107|NCT00387621|B-type natriuretic peptide
1399108|NCT00387621|cyclic guanosine monophosphate
1399109|NCT00387608|unspecified adult solid tumor, protocol specific
1399110|NCT00387608|refractory chronic lymphocytic leukemia
1399111|NCT00387608|stage III chronic lymphocytic leukemia
1399112|NCT00387608|stage IV chronic lymphocytic leukemia
1399113|NCT00387608|stage III grade 1 follicular lymphoma
1399114|NCT00387608|stage III grade 2 follicular lymphoma
1399115|NCT00387608|stage IV grade 1 follicular lymphoma
1399116|NCT00387608|stage IV grade 2 follicular lymphoma
1399117|NCT00387608|recurrent grade 1 follicular lymphoma
1399118|NCT00387608|recurrent grade 2 follicular lymphoma
1399119|NCT00387608|recurrent grade 3 follicular lymphoma
1399120|NCT00387608|stage III grade 3 follicular lymphoma
1399121|NCT00387608|stage IV grade 3 follicular lymphoma
1399122|NCT00387595|Family History
1399123|NCT00387595|CAD
1399124|NCT00387595|CAC
1399125|NCT00387595|cIMT
1399126|NCT00387595|CV Risk Factors
1399127|NCT00387582|Diabetes
1399128|NCT00387582|Macular Edema
1399129|NCT00387582|Diabetic Retinopathy
1399130|NCT00387582|Lucentis
1399131|NCT00387582|Ranibizumab
1399132|NCT00387569|Toddlers
1399133|NCT00387569|Vaccine
1399134|NCT00387569|Safety
1399135|NCT00387556|ketamine
1399136|NCT00387556|children
1399137|NCT00387556|emesis
1399138|NCT00387530|recurrent lymphoepithelioma of the nasopharynx
1399139|NCT00387530|post-transplant lymphoproliferative disorder
1399140|NCT00387530|adult nasal type extranodal NK/T-cell lymphoma
1399141|NCT00387530|recurrent adult Hodgkin lymphoma
1399142|NCT00387530|AIDS-related peripheral/systemic lymphoma
1399143|NCT00387530|AIDS-related primary CNS lymphoma
1399144|NCT00387530|recurrent gastric cancer
1399145|NCT00387517|Diastolic
1399146|NCT00387517|systolic
1399147|NCT00387517|hypertension
1399148|NCT00387517|aliskiren
1399149|NCT00387517|blood pressure
1399150|NCT00387517|hydrochlorothiazide
1399151|NCT00387517|HCTZ
1399152|NCT00387504|unspecified adult solid tumor, protocol specific
1399153|NCT00387478|Allergy
1399154|NCT00387478|Specific Immunotherapy
1399155|NCT00387478|Tree
1399156|NCT00387478|Environmental Exposure Chamber
1399157|NCT00387452|Aging
1399158|NCT00387452|Type 2 diabetes
1399159|NCT00387452|exercise
1399160|NCT00387452|aerobic training
1399161|NCT00387452|strength training
1399162|NCT00387452|glucose metabolism arterial baroreceptors
1399163|NCT00387452|heart rate variability
1399164|NCT00387452|cerebral autoregulation
1399165|NCT00387452|tilt table study
1399166|NCT00387452|transcranial Doppler
1399167|NCT00387452|autonomic nervous system
1399168|NCT00387439|Anal incontinence
1399169|NCT00387439|Gastroenterology
1399170|NCT00387439|Anoperineal physiotherapy
1399171|NCT00387439|Randomized clinical trial
1399172|NCT00387413|Duloxetine
1399173|NCT00387413|GSK189254
1399174|NCT00387413|Healthy volunteers
1399175|NCT00387413|Phase I.
1399176|NCT00387413|Electrical hyperalgesia model
1399177|NCT00387400|adult giant cell glioblastoma
1399178|NCT00387400|adult gliosarcoma
1399179|NCT00387400|recurrent adult brain tumor
1399180|NCT00387400|adult glioblastoma
1399181|NCT00387387|pharmacokinetics
1399182|NCT00387387|colorectal cancer
1399183|NCT00387387|pazopanib
1399184|NCT00387387|capecitabine
1399185|NCT00387387|CapeOx
1399186|NCT00387387|5-fluorouracil
1399187|NCT00387387|oxaliplatin
1399188|NCT00387387|combination therapy
1399189|NCT00387387|FOLFOX 6
1399190|NCT00387361|Post-Operative Nausea
1399191|NCT00387361|Nausea
1399192|NCT00387361|Anesthesia
1399193|NCT00387361|Osteopathic Manipulative Treatment
1399194|NCT00387361|Osteopathic Manipulative Medicine
1399195|NCT00387361|Manipulation, Osteopathic
1399196|NCT00387361|Osteopathy
1399197|NCT00387361|Texas College of Osteopathic Medicine
1399198|NCT00387348|fatigue
1399199|NCT00387348|psychosocial effects of cancer and its treatment
1399200|NCT00387348|stage IIIB non-small cell lung cancer
1399201|NCT00387348|stage IV non-small cell lung cancer
1399202|NCT00387348|extensive stage small cell lung cancer
1399203|NCT00387348|advanced adult primary liver cancer
1399204|NCT00387348|depression
1399205|NCT00387348|stage III pancreatic cancer
1399206|NCT00387348|stage IV pancreatic cancer
1399207|NCT00387348|stage IV esophageal cancer
1399208|NCT00387348|stage IV gastric cancer
1399209|NCT00387348|stage IVA colon cancer
1399210|NCT00387348|stage IVB colon cancer
1399211|NCT00387348|stage IVA rectal cancer
1399212|NCT00387348|stage IVB rectal cancer
1399213|NCT00387348|unresectable gallbladder cancer
1399214|NCT00387348|unresectable extrahepatic bile duct cancer
1399215|NCT00387322|unspecified adult solid tumor, protocol specific
1399216|NCT00387322|recurrent non-small cell lung cancer
1399217|NCT00387322|stage IIIB non-small cell lung cancer
1399218|NCT00387322|stage IV non-small cell lung cancer
1399219|NCT00387309|Bowel
1399220|NCT00387283|WNV
1399221|NCT00387283|West Nile virus
1399222|NCT00387283|WNV meningoencephalitis
1399223|NCT00387270|Huntington's disease
1399224|NCT00387270|Dimebon
1399225|NCT00387270|dose-escalation
1399226|NCT00387270|Phase 1-2a
1399227|NCT00387270|randomized
1399228|NCT00387270|controlled
1399229|NCT00387270|double-blind
1399230|NCT00387270|Unified Huntington's Disease Rating Scale
1399231|NCT00387257|platelet aggregation
1399232|NCT00387257|SB-659032
1399233|NCT00387257|rilapladib
1399234|NCT00387244|Pain;
1399235|NCT00387244|Back Pain;
1399236|NCT00387244|Neurostimulation
1399237|NCT00387231|Myocardial Ischemia
1399238|NCT00387231|Randomized Controlled Trials
1399239|NCT00387231|Angioplasty, Transluminal, Percutaneous Coronary
1399240|NCT00387231|Drug Therapy
1399241|NCT00387218|Exercise
1399242|NCT00387218|Physical Functional Ability
1399243|NCT00387218|Spinal Range of Motion
1399244|NCT00387218|Balance
1399245|NCT00387218|Economy of Movement
1399246|NCT00387218|Aerobic Conditioning
1399247|NCT00387218|Quality of Life
1399248|NCT00387218|Adherence
1399249|NCT00387205|chronic administration
1399250|NCT00387205|monotherapy and combination therapies
1399251|NCT00387205|solid
1399252|NCT00387205|lapatinib (TYKERB, TYVERB)
1399253|NCT00387205|malignant tumor
1399254|NCT00387205|Pazopanib
1399255|NCT00387205|GW786034
1399256|NCT00387205|cancer
1399257|NCT00387205|safety
1399258|NCT00387192|Von Willebrand Disease
1399259|NCT00387192|Factor VIII
1399260|NCT00387192|Von Willebrand Factor
1399261|NCT00387192|Pharmacokinetics
1399262|NCT00387179|Circadian Rhythm Sleep Disorders
1399263|NCT00387166|Type 2 Diabetes
1399264|NCT00387166|Cardiovascular
1399265|NCT00387166|Blood Pressure
1399266|NCT00387166|Hispanic
1399267|NCT00387166|Women
1399268|NCT00387166|Social Context
1399269|NCT00387166|Psychosocial
1399270|NCT00387153|Oncology
1399271|NCT00387153|Cancer
1399272|NCT00387153|Blood Cancers
1399273|NCT00387140|Dental Pain, Postoperative
1399274|NCT00387127|Neck Cancer
1399402|NCT00386711|suicide
1399275|NCT00387127|Locally advanced head and neck cancer
1399276|NCT00387127|locally advanced
1399277|NCT00387127|Head and Neck cancer
1399278|NCT00387127|lapatinib
1399279|NCT00387127|EGFR/ErbB2 inhibitor
1399280|NCT00387127|Head Cancer
1399281|NCT00387114|C-reactive protein
1399282|NCT00387114|nitrotyrosine
1399283|NCT00387114|oxidative stress
1399284|NCT00387114|resistin
1399285|NCT00387114|vitamin C
1399286|NCT00387101|Diabetic Foot Ulcer
1399287|NCT00387101|Diabetes Mellitus
1399288|NCT00387101|Debridement
1399289|NCT00387101|Dermal-LSR
1399290|NCT00387101|Standard of Care
1399291|NCT00387075|Parkinson Disease
1399292|NCT00387075|SPECT imaging
1399293|NCT00387062|Breast Cancer
1399294|NCT00387062|Cognitive Impairment
1399295|NCT00387062|Chemofog
1399296|NCT00387062|Chemobrain
1399297|NCT00387062|Post-chemotherapy cognitive impairment
1399298|NCT00387049|Anxiety Sensitivity
1399299|NCT00387023|Non-Hodgkin's Lymphoma
1399300|NCT00387023|Orbital Lymphoma
1399301|NCT00387023|Rituximab
1399302|NCT00387023|Rituxan
1399303|NCT00387023|Zevalin
1399304|NCT00387023|Ibritumomab tiuxetan
1399305|NCT00387023|IDEC-Y2B8
1399306|NCT00387023|Eye
1399307|NCT00386984|hepatocellular carcinoma; Sandostatin-LAR; RCT
1399308|NCT00386971|L-carnitine
1399309|NCT00386971|HIV
1399310|NCT00386971|TGRL metabolism
1399311|NCT00386971|postprandial
1399312|NCT00386971|HIV Treatment Experienced
1399313|NCT00386958|corneal ulcers
1399314|NCT00386958|bacterial keratitis
1399315|NCT00386958|childhood blindness
1399316|NCT00386958|povidone-iodine
1399317|NCT00386945|Tobacco
1399318|NCT00386945|Cessation.
1399319|NCT00386945|Chiropractic patients.
1399320|NCT00386945|Doctors of Chiropractic.
1399321|NCT00386945|Health care providers.
1399322|NCT00386945|Behavioral intervention.
1399323|NCT00386945|Tobacco intervention.
1399324|NCT00386945|Cigarettes.
1399325|NCT00386945|Smokeless tobacco.
1399326|NCT00386945|Smoking intervention.
1399327|NCT00386906|Melanoma
1399328|NCT00386906|Conjunctival Melanoma
1399329|NCT00386906|Malignant Melanoma of the Conjunctiva
1399330|NCT00386906|Malignant Melanoma of the Eyelid
1399331|NCT00386906|Sebaceous Cell Carcinoma
1399332|NCT00386906|Sebaceous Cell Carcinoma of the Conjunctiva
1399333|NCT00386906|Sebaceous Cell Carcinoma of the Eyelid
1399334|NCT00386906|Sentinel Lymph Node
1399335|NCT00386906|Lymphatic Mapping
1399336|NCT00386906|Eyelid
1399337|NCT00386906|Eyelid Lesion
1399338|NCT00386867|medical abortion
1399339|NCT00386867|mifepristone
1399340|NCT00386867|misoprostol
1399341|NCT00386867|buccal administration
1399342|NCT00386854|exercise
1399343|NCT00386854|lipid metabolism
1399344|NCT00386854|lipoproteins
1399345|NCT00386854|insulin resistance
1399346|NCT00386854|inflammation
1399347|NCT00386841|Major depression
1399348|NCT00386841|First degree relatives
1399349|NCT00386841|Escitalopram
1399350|NCT00386841|Cortisol
1399351|NCT00386841|Cognition
1399352|NCT00386841|Personality
1399353|NCT00386841|Endo-phenotype
1399354|NCT00386828|colorectal cancer
1399355|NCT00386828|advanced colorectal cancer
1399356|NCT00386802|Neutropenia
1399357|NCT00386802|Antifungals
1399358|NCT00386789|Typhoid Fever
1399359|NCT00386789|Serological Survey
1399360|NCT00386789|Follow-Up
1399361|NCT00386789|Protection
1399362|NCT00386776|computers
1399363|NCT00386776|diagnosis
1399364|NCT00386776|medical records
1399365|NCT00386776|physician patient relations
1399366|NCT00386776|medical history taking
1399367|NCT00386776|medical informatics applications
1399368|NCT00386763|Marsh fever
1399369|NCT00386763|Plasmodium infections
1399370|NCT00386763|Remittent fever
1399371|NCT00386763|Paludism
1399372|NCT00386763|Artemether
1399373|NCT00386763|Artemisinins
1399374|NCT00386763|Malaria
1399375|NCT00386763|Benflumetol
1399376|NCT00386763|Lumefantrine
1399377|NCT00386750|Malaria
1399378|NCT00386750|hearing
1399379|NCT00386750|co-artemether
1399380|NCT00386750|auditory
1399381|NCT00386750|Plasmodium falciparum
1399382|NCT00386750|marsh fever
1399383|NCT00386750|Plasmodium infections
1399384|NCT00386750|remittent fever
1399385|NCT00386750|paludism
1399386|NCT00386750|artemether
1399387|NCT00386750|artemisinins
1399388|NCT00386750|benflumetol
1399389|NCT00386750|lumefantrine
1399390|NCT00386737|Asthma
1399391|NCT00386737|Breath Testing
1399392|NCT00386737|Laser Spectroscopy
1399393|NCT00386737|eNO
1399394|NCT00386737|Nitric Oxide
1399395|NCT00386737|Lower Airway Inflammation
1399396|NCT00386737|Carbon Dioxide
1399397|NCT00386737|CO2
1399398|NCT00386724|Pain
1399399|NCT00386724|Neurostimulation
1399400|NCT00386724|Leg Pain
1399401|NCT00386724|Back Pain
1399403|NCT00386711|depressed patients
1399404|NCT00386711|primary care
1399405|NCT00386698|Influenza,
1399406|NCT00386698|improved vaccine,
1399407|NCT00386698|influenza disease
1399408|NCT00386698|elderly
1399409|NCT00386685|Cancer
1399410|NCT00386685|Breast
1399411|NCT00386685|metastatic breast cancer
1399412|NCT00386672|Calcium
1399413|NCT00386672|Vitamin D
1399414|NCT00386672|Weight Loss
1399415|NCT00386672|Overweight
1399416|NCT00386672|Obesity
1399417|NCT00386672|Lite Orange Juice
1399418|NCT00386646|Dry eye syndromes therapy
1399419|NCT00386633|Vaccine
1399420|NCT00386633|Safety
1399421|NCT00386633|T-cell epitope
1399422|NCT00386633|Acquired Immune Deficiency Syndrome Virus
1399423|NCT00386633|HIV Preventive Vaccine
1399424|NCT00386620|Breast Cancer
1399425|NCT00386620|Cancer Control
1399426|NCT00386620|Spousal Relationships
1399427|NCT00386620|Questionnaire
1399428|NCT00386620|Interview
1399429|NCT00386620|Pain
1399430|NCT00386607|Hypertension, aliskiren, valsartan, HCTZ, blood pressure
1399431|NCT00386594|Barrett Esophagus
1399432|NCT00386594|High grade dysplasia
1399433|NCT00386594|Carcinoma in situ
1399434|NCT00386594|825A
1399435|NCT00386542|vaccination
1399436|NCT00386542|influenza vaccine
1399437|NCT00386542|jet injection
1399438|NCT00386542|intradermal injection
1399439|NCT00386542|infancy
1399440|NCT00386542|children
1399441|NCT00386542|dose-sparing
1399442|NCT00386542|cutaneous vaccination
1399443|NCT00386542|Dominican Republic
1399444|NCT00386542|pandemic preparedness
1399445|NCT00386542|jet injector
1399446|NCT00386542|reduced dosage
1399447|NCT00386542|immunogenicity
1399448|NCT00386542|reactogenicity
1399449|NCT00386542|safety
1399450|NCT00386542|needle-free
1399451|NCT00386542|immune response
1399452|NCT00386542|hemagglutination inhibition
1399453|NCT00386542|Infant
1399454|NCT00386529|low dose aspirin
1399455|NCT00386529|Hypertension
1399456|NCT00386529|administration time dependent effect
1399457|NCT00386516|cholangiocarcinoma
1399458|NCT00386516|bile duct
1399459|NCT00386516|biliary
1399460|NCT00386516|intra-hepatic
1399461|NCT00386516|extra-hepatic
1399462|NCT00386516|gall bladder
1399463|NCT00386516|cancer
1399464|NCT00386516|carcinoma
1399465|NCT00386516|metastatic
1399466|NCT00386516|metastasis
1399467|NCT00386516|advanced
1399468|NCT00386516|recurrent
1399469|NCT00386477|Povidone iodine
1399470|NCT00386477|postoperative infection
1399471|NCT00386477|presurgical cleansing
1399472|NCT00386464|bipap
1399473|NCT00386464|lou gehrigs disease
1399474|NCT00386464|motor neuron disease
1399475|NCT00386464|respiratory muscles
1399476|NCT00386451|Intravenous chemotherapy
1399477|NCT00386412|Cytomegalovirus infection
1399478|NCT00386399|Advanced Pancreatic Cancer
1399479|NCT00386399|Mutated BRCA2 Gene
1399480|NCT00386399|Recurrent Pancreatic Cancer
1399481|NCT00386386|hydration
1399482|NCT00386386|prehospital
1399483|NCT00386386|mass casualty incident
1399484|NCT00386373|Chronic Myeloid Leukemia
1399485|NCT00386373|CML
1399486|NCT00386373|ALL
1399487|NCT00386373|AML
1399488|NCT00386373|Leukemia
1399489|NCT00386373|Imatinib Mesylate
1399490|NCT00386373|Gleevec
1399491|NCT00386373|Philadelphia-Positive
1399492|NCT00386373|Bone marrow transplant
1399493|NCT00386373|BMT
1399494|NCT00386373|Stem cell transplant
1399495|NCT00386373|SCT
1399496|NCT00386347|HIV
1399497|NCT00386347|repeat dose
1399498|NCT00386347|pharmacokinetics
1399499|NCT00386347|bioavailability
1399500|NCT00386347|single-dose
1399501|NCT00386347|food effect
1399502|NCT00386334|insomnia
1399503|NCT00386334|chronic
1399504|NCT00386334|primary
1399505|NCT00386321|Zevalin
1399506|NCT00386321|Zevalin plus CHOP
1399507|NCT00386321|Diffuse large B-cell lymphoma
1399508|NCT00386321|First line Diffuse large B-cell lymphoma
1399509|NCT00386308|Heavy Menstrual Bleeding
1399510|NCT00386308|Menorrhagia
1399511|NCT00386282|Mifepristone
1399512|NCT00386282|Misoprostol
1399513|NCT00386282|Buccal administration
1399514|NCT00386269|codeine phosphate analgesia
1399515|NCT00386256|telehealth
1399516|NCT00386256|telerehabilitation
1399517|NCT00386256|deconditioning
1399518|NCT00386256|exercise
1399519|NCT00386243|analgesia
1399520|NCT00386243|analgesics
1399521|NCT00386243|cognitive behavioral therapy
1399522|NCT00386243|Pain
1399523|NCT00386243|self-management
1399524|NCT00386243|stepped care
1399525|NCT00386243|musculoskeletal pain
1399526|NCT00386230|transmission
1399527|NCT00386230|infant
1399528|NCT00386230|HIV
1399529|NCT00386230|pregnancy
1399530|NCT00386230|HIV-1 infection
1399531|NCT00386230|HIV Seronegativity
1399532|NCT00386217|Cervical Cancer
1399533|NCT00386217|Breast Cancer
1399534|NCT00386217|Hodgkin's Disease
1399535|NCT00386217|Non-Hodgkin's Lymphoma
1399536|NCT00386217|Female Infertility
1399537|NCT00386217|Telephone Survey
1399538|NCT00386204|Q-switched Ruby laser
1399539|NCT00386191|Platelet Aggregation Inhibitors
1399540|NCT00386191|Ischemic cerebrovascular disease
1399541|NCT00386178|vitamin E
1399542|NCT00386178|gamma tocopherol
1399543|NCT00386178|moderate to severe asthma
1399544|NCT00386178|healthy subjects
1399545|NCT00386152|Anemia
1399546|NCT00386152|Cancer
1399547|NCT00386152|Chemotherapy-Induced Anemia
1399548|NCT00386152|Epoetin alfa
1399549|NCT00386152|Darbepoetin alfa
1399550|NCT00386139|Diastolic
1399551|NCT00386139|systolic
1399552|NCT00386139|hypertension
1399553|NCT00386139|aliskiren
1399554|NCT00386139|blood pressure
1399555|NCT00386139|hydrochlorothiazide, HCTZ
1399556|NCT00386126|Heart Failure
1399557|NCT00386126|Anemia
1399558|NCT00386126|Treatment
1399559|NCT00386113|Influenza
1399560|NCT00386113|improved vaccine
1399561|NCT00386113|elderly
1399562|NCT00386100|Fasting Plasma Glucose
1399563|NCT00386100|Dual energy X ray absorptiometry (DXA)
1399564|NCT00386100|Drug-naive
1399565|NCT00386100|Type 2 diabetes mellitus
1399566|NCT00386100|Bone Mineral Density
1399567|NCT00386100|Hyperglycemia
1399568|NCT00386100|HbA1c
1399569|NCT00386087|Breast Cancer
1399570|NCT00386087|Cancer of the Breast
1399571|NCT00386074|NaFeEDTA
1399572|NCT00386074|electrolytic iron
1399573|NCT00386074|efficacy
1399574|NCT00386074|whole maize flour
1399575|NCT00386074|phytate
1399576|NCT00386074|school-age children
1399577|NCT00386074|controlled trial
1399578|NCT00386074|Africa
1399579|NCT00386061|Obesity
1399580|NCT00386061|risk factors
1399581|NCT00386048|Cognitive Behavioral Therapy
1399582|NCT00386048|Pediatric Sickle Cell Disease
1399583|NCT00386048|Pain Management
1399584|NCT00386035|Treatment Experienced
1399585|NCT00386022|Gonadotropin-releasing hormone
1399586|NCT00386022|Estrogens
1399587|NCT00386022|postmenopausal women
1399588|NCT00386022|Pituitary hormones
1399589|NCT00386009|Benign Prostatic Hyperplasia
1399590|NCT00386009|Benign Prostatic Hypertrophy
1399591|NCT00385996|Carcinoma,non-small cell lung
1399592|NCT00385996|preoperative
1399593|NCT00385996|Tarceva
1399594|NCT00385996|Response rate
1399595|NCT00385983|thyroidectomy
1399596|NCT00385983|thyroid neoplasm
1399597|NCT00385983|postoperative complications
1399598|NCT00385983|cost effectiveness
1399599|NCT00385957|Treatment Naive
1399600|NCT00385931|Hypertension
1399601|NCT00385931|high cholesterol
1399602|NCT00385931|valsartan
1399603|NCT00385931|simvastatin
1399604|NCT00385918|Cardiovascular Fitness
1399605|NCT00385918|Exercise
1399606|NCT00385918|Gait
1399607|NCT00385918|Spinal Cord Injury
1399608|NCT00385918|Treadmill Training
1399609|NCT00385892|Healthy volonteers
1399610|NCT00385892|Abdominal binder
1399611|NCT00385892|IAP
1399612|NCT00385892|MAP
1399613|NCT00385892|APP
1399614|NCT00385866|Patient Navigator
1399615|NCT00385866|Community health
1399616|NCT00385866|Communication
1399617|NCT00385853|PTK
1399618|NCT00385853|temozolomide
1399619|NCT00385853|glioblastoma
1399620|NCT00385840|Influenza vaccine
1399621|NCT00385840|Influenza
1399622|NCT00385827|Cancer
1399623|NCT00385827|Prostate
1399624|NCT00385827|IL-6
1399625|NCT00385827|Mitoxantrone
1399626|NCT00385827|Metastatic prostate cancer
1399627|NCT00385801|cocaine
1399628|NCT00385801|dependence
1399629|NCT00385801|risperidal
1399630|NCT00385801|MRI
1399631|NCT00385788|Hodgkin's Disease
1399632|NCT00385788|Stem Cell Transplantation
1399633|NCT00385788|Antithymocyte Globulin
1399634|NCT00385788|Gemcitabine
1399635|NCT00385788|Gemzar
1399636|NCT00385788|Fludarabine
1399637|NCT00385788|Fludarabine Phosphate
1399638|NCT00385788|Melphalan
1399639|NCT00385788|Allogeneic stem cell transplantation
1399640|NCT00385788|AST
1399641|NCT00385788|SCT
1399642|NCT00385788|ATG
1399643|NCT00385788|Thymoglobulin
1399644|NCT00385775|Cancer
1399645|NCT00385775|solid tumours
1399646|NCT00385775|refractory
1399647|NCT00385775|antisense
1399648|NCT00385775|oligonucleotide
1399649|NCT00385762|Human volunteers
1399650|NCT00385749|Implanted cardioverter defibrillator
1399651|NCT00385749|congestive heart failure
1399652|NCT00385749|right ventricular lead placement
1399653|NCT00385749|select site pacing
1399654|NCT00385736|Moderate to Severe Ulcerative Colitis
1399655|NCT00385736|Double-blind
1399656|NCT00385736|Adalimumab
1399657|NCT00385736|Induction of Clinical Remission
1399658|NCT00385723|affect
1399659|NCT00385723|inflammation
1399660|NCT00385710|Progressive supranuclear palsy (PSP)
1399661|NCT00385697|Randomized
1399662|NCT00385697|Double Blind
1399663|NCT00385697|Parallel Group
1399664|NCT00385697|Controlled Clinical Trial
1399665|NCT00385684|Agitation
1399666|NCT00385684|Alzheimer Disease
1399667|NCT00385684|Analgesics
1399668|NCT00385684|Dementia
1399669|NCT00385684|Narcotics
1399670|NCT00385684|Opioid
1399671|NCT00385684|Pain
1399672|NCT00385684|Palliative Care
1399673|NCT00385684|Psychomotor
1399674|NCT00385684|Suffering, Physical
1399675|NCT00385658|Dyslipidemia
1399676|NCT00385658|metabolic syndrome
1399677|NCT00385658|fluvastatin
1399678|NCT00385658|fenofibrate
1399679|NCT00385658|simvastatin
1399680|NCT00385658|ezetimibe
1399681|NCT00385645|HIV seronegativity
1399682|NCT00385632|Treatment Experienced
1399683|NCT00385606|prolonged continuous infusion
1399684|NCT00385606|Cox-2 inhibitors
1399685|NCT00385567|AIDS
1399686|NCT00385567|Treatment Experienced
1399687|NCT00385554|Microbicide
1399688|NCT00385554|HIV prevention
1399689|NCT00385554|Botswana
1399690|NCT00385554|Preventing acquisition of HIV infection
1399691|NCT00385554|HIV Seronegativity
1399692|NCT00385541|pain
1399693|NCT00385541|morphine
1399694|NCT00385541|hydromorphone
1399695|NCT00385541|nausea
1399696|NCT00385541|vomiting
1399697|NCT00385541|pruritis
1399698|NCT00385528|Case complexity
1399699|NCT00385528|INTERMED
1399700|NCT00385528|Consultation liaison psychiatry
1399701|NCT00385528|depression
1399702|NCT00385502|toenail
1399703|NCT00385502|fungus
1399704|NCT00385502|onychomycosis
1399705|NCT00385502|antifungal
1399706|NCT00385502|anti-fungal
1399707|NCT00385502|nail
1399708|NCT00385476|Advanced Cancer
1399709|NCT00385476|Medication Knowledge
1399710|NCT00385476|Emergency Center
1399711|NCT00385476|Questionnaire
1399712|NCT00385476|Survey
1399713|NCT00385463|Asthma
1399714|NCT00385463|Rhinitis
1399715|NCT00385463|Allergic Asthma
1399716|NCT00385437|Driving safety
1399717|NCT00385437|maintenance of wakefulness test
1399718|NCT00385437|major depressive disorder
1399719|NCT00385437|mirtazapine
1399720|NCT00385398|tumors metastatic to brain
1399721|NCT00385398|stage IV non-small cell lung cancer
1399722|NCT00385372|low pseudoallergen diet
1399723|NCT00385372|elimination diet
1399724|NCT00385372|provocation diet
1399725|NCT00385372|oral provocation
1399726|NCT00385372|natural food ingredients
1399727|NCT00385372|food additives
1399728|NCT00385372|flavours
1399729|NCT00385346|Expressive writing
1399730|NCT00385346|Male infertility
1399731|NCT00385333|Mitochondrion
1399732|NCT00385333|Retina
1399733|NCT00385333|Mitochondria
1399734|NCT00385333|Metabolism
1399735|NCT00385333|In Vivo Imaging
1399736|NCT00385333|Age-Related Macular Degeneration
1399737|NCT00385333|AMD
1399738|NCT00385333|Diabetic Retinopathy
1399739|NCT00385333|DR
1399740|NCT00385333|Hippel-Lindau Disease
1399741|NCT00385333|VHL
1399742|NCT00385307|Depression
1399743|NCT00385307|Clinical Trials
1399744|NCT00385307|Major Depressive Disorder
1399745|NCT00385294|Genetic
1399746|NCT00385294|pain
1399747|NCT00385294|obstetrical
1399748|NCT00385281|proteomic profiling, influenza, vaccine, FluMist
1399749|NCT00385268|cocaine
1399750|NCT00385255|Immunogenicity,
1399751|NCT00385255|Influenza
1399752|NCT00385255|Co-administration,
1399753|NCT00385255|Tdap,
1399754|NCT00385242|coronary artery disease
1399755|NCT00385242|left ventricular dysfunction
1399756|NCT00385242|positron emission tomography
1399757|NCT00385242|viable myocardium
1399758|NCT00385242|revascularization
1399759|NCT00385242|cost effectiveness
1399760|NCT00385229|Asphyxia neonatorum
1399761|NCT00385229|Birth Injury
1399762|NCT00385229|Meconium Aspiration Syndrome
1399763|NCT00385216|Third Molar
1399764|NCT00385216|Pain
1399765|NCT00385203|cancer
1399766|NCT00385203|tumour
1399767|NCT00385203|advanced cancer
1399768|NCT00385203|Metastatic Gastro-Intestinal Stromal Tumours
1399769|NCT00385203|gastro-intestinal cancer
1399770|NCT00385203|RECENTIN
1399771|NCT00384514|Coronary Artery disease with chronic stable angina
1399772|NCT00384501|keratoconus
1399773|NCT00384501|Intacs
1399774|NCT00384488|Diabetes mellitus
1399775|NCT00384488|Weight control
1399776|NCT00384488|Healthy eating
1399777|NCT00384488|Physical Activity
1399778|NCT00384475|Seasonal Allergic Rhinitis
1399779|NCT00384475|Ciclesonide
1399780|NCT00384475|Hay Fever
1399781|NCT00384475|SAR
1399782|NCT00384462|Premature infants (32-35 weeks GA) <6 months of age at the start of the RSV season who are not receiving palivizumab and do not have CLD of prematurity
1399783|NCT00384462|Respiratory Syncytial Viruses
1399784|NCT00384449|Eales
1399785|NCT00384436|Major Depressive Disorder
1399786|NCT00384423|Alzheimer's Disease
1399787|NCT00384423|AD
1399788|NCT00384423|PRX-03140
1399789|NCT00384423|Dementia
1399790|NCT00384423|Epix
1399791|NCT00384423|Predix
1399792|NCT00384423|Cognition enhancing
1399793|NCT00384410|Pain
1399794|NCT00384410|Insomnia
1399795|NCT00384410|Nabilone
1399796|NCT00385190|SAD
1399797|NCT00385164|lung neoplasms
1399798|NCT00385164|positron emissions tomography
1399799|NCT00385164|radiotherapy planning
1399800|NCT00385151|Post conditioning
1399801|NCT00385138|Percutaneous Coronary Intervention (PCI)
1399802|NCT00385138|ACS
1399803|NCT00385125|relapsed
1399804|NCT00385125|refractory
1399805|NCT00385125|CD 20 positive
1399806|NCT00385112|Cardiology
1399807|NCT00385112|Echocardiograms
1399808|NCT00385112|Surgery
1399809|NCT00385112|Valve Disease
1399810|NCT00385112|Heart Valve Disease
1399811|NCT00385099|IBS
1399812|NCT00385099|CRF1
1399813|NCT00385099|stress
1399814|NCT00385086|Sciatica
1399815|NCT00385086|Pain
1399816|NCT00385086|TNF-alpha
1399817|NCT00385086|Discectomy
1399818|NCT00385086|Fibrosis
1399819|NCT00385086|Spine
1399820|NCT00385047|malaria
1399821|NCT00385047|vaccine
1399822|NCT00385047|AMA-1 (apical membrane antigen-1)
1399823|NCT00385047|efficacy
1399824|NCT00385034|randomized controlled trial
1399825|NCT00385034|RCT
1399826|NCT00385034|partner violence
1399827|NCT00385034|IPV
1399828|NCT00385034|screening
1399829|NCT00385034|family practice
1399830|NCT00385034|computer
1399831|NCT00385021|Advanced
1399832|NCT00385021|metastatic
1399833|NCT00385021|colorectal
1399834|NCT00385021|cancer
1399835|NCT00385021|Avastin
1399836|NCT00385008|Combination product, sumatriptan succinate, naproxen sodium, absorption, pharmacokinetics, disintegration, gastric transit, gastric scintigraphy
1399837|NCT00384995|Contrast Induced Nephropathy
1399838|NCT00384995|Chronic Kidney Disease
1399839|NCT00384995|Acute Renal Failure
1399840|NCT00384995|End-stage Renal Disease
1399841|NCT00384995|Cardiovascular diseases
1399842|NCT00384995|Coronary catheterization
1399843|NCT00384995|Percutaneous coronary intervention
1399844|NCT00384995|Intra-arterial angiography
1399845|NCT00384995|Bicarbonate
1399846|NCT00384995|Saline
1399847|NCT00384982|Bone marrow-derived stem cells
1399848|NCT00384982|Acute myocardial infarction
1399849|NCT00384969|RAD001
1399850|NCT00384969|Sorafenib
1399851|NCT00384969|Renal Cell Carcinoma
1399852|NCT00384969|Metastatic
1399853|NCT00384956|MDS either de novo or secondary, fitting any of the WHO classifications.
1399854|NCT00384943|postpartum depression
1399855|NCT00384943|exercise
1399856|NCT00384891|Superficial urothelial cell carcinoma of bladder
1399857|NCT00384891|NMIBC
1399858|NCT00384891|Non Muscle Invasive Bladder Cancer
1399859|NCT00384891|Hyperthermia
1399860|NCT00384891|Bladder instillation
1399861|NCT00384891|Mitomycin C
1399862|NCT00384891|RITE
1399863|NCT00384891|SHTC
1399864|NCT00384891|Intravesical
1399865|NCT00384865|Pulmonary Arterial Hypertension
1399866|NCT00384852|Fracture
1399867|NCT00384852|Humerus
1399868|NCT00384826|Adenocarcinoma, Bronchiolo-Alveolar
1399869|NCT00384787|HIV Seronegativity
1399870|NCT00384787|Adenoviral Vector Vaccine
1399871|NCT00384787|DNA Plasmid Vaccine
1399872|NCT00384787|HIV Preventive Vaccine
1399873|NCT00384774|Migraine
1399874|NCT00384748|Cerebrovascular Accident
1399875|NCT00384748|Rehabilitation
1399876|NCT00384748|Telemedicine
1399877|NCT00384735|bone tumor
1399878|NCT00384735|soft tissue tumor
1399879|NCT00384722|Left ventricular lead
1399880|NCT00384722|Pacing
1399881|NCT00384722|Heart Failure
1399882|NCT00384709|Elderly
1399883|NCT00384709|Hospitalization
1399884|NCT00384709|Geriatrics
1399885|NCT00384709|Mortality
1399886|NCT00384709|Readmission
1399887|NCT00384709|Length of Stay
1399888|NCT00384696|Risk Perception
1399889|NCT00384696|Smoking Cessation
1399890|NCT00384696|Nicotine Replacement Therapy
1399891|NCT00384696|Questionnaire
1399892|NCT00384696|Nicotine
1399893|NCT00384683|Endothelial Dysfunction
1399894|NCT00384683|Endothelial Cells
1399895|NCT00384683|Perioperative Outcome
1399896|NCT00384683|Blood Sample
1399897|NCT00384670|dengue
1399898|NCT00384670|vaccine
1399899|NCT00384657|chronic heart failure
1399900|NCT00384657|chronic kidney disease
1399901|NCT00384657|anemia
1399902|NCT00384657|intravenous iron
1399903|NCT00384644|heart failure
1399904|NCT00384644|sepsis
1399905|NCT00384644|septic shock
1399906|NCT00384644|cardiogenic shock
1399907|NCT00384631|Neovascular
1399908|NCT00384631|Glaucoma
1399909|NCT00384631|Bevacizumab
1399910|NCT00384631|Avastin
1399911|NCT00384631|Intravitreal
1399912|NCT00384631|IOP
1399913|NCT00384618|Kidney, Antioxidants, Statin, Carotid IMT
1399914|NCT00384592|heartburn
1399915|NCT00384592|reflux
1399916|NCT00384592|proton pump inhibitor
1399917|NCT00384592|GERD
1399918|NCT00384592|GORD
1399919|NCT00384579|back
1399920|NCT00384579|pain
1399921|NCT00384540|-Heart Transplant, Allograft Vasculopathy, Dobutamine Stress Echocardiography, Brain Natriuretic Peptide
1399922|NCT00384540|Vasculopathy
1399923|NCT00384527|Clostridium difficile
1399924|NCT00384397|Menactra vaccine
1399925|NCT00384397|Meningococcal meningitis
1399926|NCT00384397|Measles
1399927|NCT00384397|Mumps
1399928|NCT00384397|Rubella
1399929|NCT00384397|Varicella virus
1399930|NCT00384397|Haemophilus influenzae type b
1399931|NCT00384397|Pneumococcal conjugate vaccine
1399932|NCT00384384|Dialysis
1399933|NCT00384384|Serum potassium
1399934|NCT00384384|18b glycyrrhetinic acid
1399935|NCT00384384|insulin sensitivity
1399936|NCT00384371|back
1399937|NCT00384371|pain
1399938|NCT00384358|Fractures
1399939|NCT00384345|bright light treatment
1399940|NCT00384345|exercise
1399941|NCT00384345|body fat index
1399942|NCT00384345|mood
1399943|NCT00384345|sleep
1399944|NCT00384345|fatigue
1399945|NCT00384332|Bipolar Depression
1399946|NCT00384332|Weight gain bipolar medicine
1399947|NCT00384332|side effects olanzapine
1399948|NCT00384332|gastrointestinal hormones bipolar medicine
1399949|NCT00384319|resuscitation
1399950|NCT00384319|hypothermia
1399951|NCT00384306|COPD
1399952|NCT00384306|prednisolone
1399953|NCT00384306|bone biopsy
1399954|NCT00384306|tetracycline labelling
1399955|NCT00384267|malaria, infants, preterm babies, neonates, Mali
1399956|NCT00384254|Tobacco.
1399957|NCT00384254|Cessation.
1399958|NCT00384254|Dental patients.
1399959|NCT00384254|Dentists.
1399960|NCT00384254|Hygienists.
1399961|NCT00384254|Dental assistants.
1399962|NCT00384254|Health care providers.
1399963|NCT00384254|Behavioral intervention.
1399964|NCT00384254|Tobacco intervention.
1399965|NCT00384254|Cigarettes.
1399966|NCT00384254|Smokeless tobacco.
1399967|NCT00384254|Smoking intervention.
1399968|NCT00384241|Blood Pressure, High
1399969|NCT00384241|Stress
1399970|NCT00384241|Inflammation
1399971|NCT00384228|Chronic Myelogenous Leukemia
1399972|NCT00384228|Acute Lymphoblastic Leukemia
1399973|NCT00384202|Tacrolimus
1399974|NCT00384202|Liver Transplantation
1399975|NCT00384189|Asthma
1399976|NCT00384189|Ciclesonide
1399977|NCT00384189|children
1399978|NCT00384176|Metastatic Colorectal Cancer
1399979|NCT00384176|RECENTIN
1399980|NCT00384163|cardiac
1399981|NCT00384163|adult
1399982|NCT00384163|PVR
1399983|NCT00384150|galiximab
1399984|NCT00384150|antibody
1399985|NCT00384150|refractory
1399986|NCT00384150|follicular
1399987|NCT00384150|relapsed
1399988|NCT00384150|NHL
1399989|NCT00384150|rituximab
1399990|NCT00384150|retreatment
1399991|NCT00384137|Tacrolimus
1399992|NCT00384137|Kidney Transplantation
1399993|NCT00384124|Bowens disease
1399994|NCT00384124|Squamous cell carcinoma in situ of the skin
1399995|NCT00384124|imiquimod
1399996|NCT00384098|Psoriasis
1399997|NCT00384072|postmenopausal
1399998|NCT00384072|women
1399999|NCT00384072|SERM
1400000|NCT00384072|osteoporosis
1400001|NCT00384033|MDD
1400002|NCT00384033|Major Depressive Disorder
1400003|NCT00384033|Depression
1400004|NCT00384020|Major Depression Disorder
1400005|NCT00384020|Antidepressant
1400006|NCT00384020|Pharmacogenomics
1400007|NCT00384020|Cytochrome P450
1400008|NCT00384020|Serotonin Transporter
1400009|NCT00384007|back pain
1400010|NCT00384007|herniated disc
1400011|NCT00384007|leg pain
1400012|NCT00384007|pinched nerves
1400013|NCT00384007|sciatica
1400014|NCT00384007|radiculopathy
1400015|NCT00383994|Chronic Lymphocytic Leukemia
1400016|NCT00383994|CLL
1400017|NCT00383994|Non-Hodgkin's Lymphoma
1400018|NCT00383994|B-Cell Lymphoma
1400019|NCT00383994|Lymphoma
1400020|NCT00383994|granulocyte-macrophage colony-stimulating factor
1400021|NCT00383994|Leukemia
1400022|NCT00383994|NK Cells
1400023|NCT00383994|Rituximab
1400024|NCT00383994|GM-CSF
1400025|NCT00383994|Non-myeloablative Allogeneic Stem Cell Transplantation
1400026|NCT00383994|Stem Cell Transplant
1400027|NCT00383981|malondialdehyde optoelectronic vitamin complex
1400028|NCT00383942|Pregnancy
1400029|NCT00383942|Extra amniotic saline infusion
1400030|NCT00383942|Misoprostol
1400031|NCT00383942|Labor induction
1400032|NCT00383929|Blood pressure reduction
1400033|NCT00383929|combination therapy
1400034|NCT00383929|candesartan cilexetil
1400035|NCT00383929|hydrochlorothiazide
1400036|NCT00383916|healthy
1400037|NCT00383890|American Society of Anesthesiologists (ASA)
1400038|NCT00383890|Mallampati Score
1400039|NCT00383890|Ramsay Sedation Scale (RSS)
1400040|NCT00383864|liver fibrosis
1400041|NCT00383864|portal pressure
1400042|NCT00383864|antiviral therapy
1400043|NCT00383851|ATN-224
1400044|NCT00383851|Temozolomide
1400045|NCT00383851|Combination
1400046|NCT00383851|Sequential
1400047|NCT00383851|Anti-angiogenic
1400048|NCT00383851|Copper
1400049|NCT00383838|brief motivational intervention; teens; substance use
1400050|NCT00383825|conjunctival autografts
1400051|NCT00383825|amniotic membrane
1400052|NCT00383825|indocyanine green angiography
1400053|NCT00383825|pterygium surgery
1400054|NCT00383812|Polypoidal choroidal vasculopathy
1400055|NCT00383812|Intravitreal Bevacizumab
1400056|NCT00383799|Ventricular tachycardia
1400057|NCT00383786|PTSD
1400058|NCT00383786|Substance P
1400059|NCT00383786|Treatment Study
1400060|NCT00383786|Placebo
1400061|NCT00383786|Controlled
1400062|NCT00383786|Post Traumatic Stress Disorder
1400063|NCT00383773|retinal vein occlusion
1400064|NCT00383773|rTPA
1400065|NCT00383747|cognition
1400066|NCT00383747|nicotine
1400067|NCT00383747|schizophrenia
1400068|NCT00383734|HIV-Associated Lipodystrophy Syndrome
1400069|NCT00383734|polylactic acid
1400070|NCT00383734|polyacrylamide gels
1400071|NCT00383695|adenocarcinoma of the rectum
1400072|NCT00383695|stage I rectal cancer
1400073|NCT00383695|stage II rectal cancer
1400074|NCT00383695|stage III rectal cancer
1400075|NCT00383682|postamputation pain
1400076|NCT00383682|phantom pain
1400077|NCT00383682|stump pain
1400078|NCT00383682|neuroma pain
1400079|NCT00383682|opioid
1400080|NCT00383682|mexiletine
1400081|NCT00383669|HIV
1400082|NCT00383669|AIDS
1400083|NCT00383669|Disease Progression
1400084|NCT00383669|Multivitamins
1400085|NCT00383669|Anti-Retroviral Therapy
1400086|NCT00383669|HAART
1400087|NCT00383669|Tanzania
1400088|NCT00383669|Africa
1400089|NCT00383656|gonadotropin releasing hormone
1400090|NCT00383656|GnRH deficiency
1400091|NCT00383656|hypothalamic amenorrhea
1400092|NCT00383656|hypogonadotropic hypogonadism
1400093|NCT00383656|Kallman's syndrome
1400094|NCT00383656|infertility
1400095|NCT00383630|End Stage Heart Failure
1400096|NCT00383630|LVAD
1400097|NCT00383630|Bone Marrow Transplantation
1400098|NCT00383630|Stem Cell Transplantation
1400099|NCT00383617|pre-radiographic
1400100|NCT00383617|screening
1400101|NCT00383617|early diagnosis
1400102|NCT00383578|Type 2 diabetes
1400103|NCT00383578|vildagliptin
1400104|NCT00383578|hemoglobin A1c
1400105|NCT00383578|metformin
1400106|NCT00383539|Influenza
1400107|NCT00383539|Orthomyxoviruses
1400108|NCT00383539|Inactivated Split-virion influenza vaccine
1400109|NCT00383539|Adults
1400110|NCT00383526|Influenza
1400111|NCT00383526|Orthomyxoviruses
1400112|NCT00383526|Inactivated Split-virion influenza vaccine
1400113|NCT00383526|elderly
1400114|NCT00383513|Lupus
1400115|NCT00383513|Antibody
1400116|NCT00383513|B-Cell Immunotherapy
1400117|NCT00383461|tobacco use disorder
1400118|NCT00383448|Stem cell transplantation
1400119|NCT00383448|Inborn errors of metabolism
1400120|NCT00383448|Adrenoleukodystrophy (ALD)
1400121|NCT00383448|Metachromatic leukodystrophy (MLD)
1400122|NCT00383448|Globoid cell leukodystrophy (GLD or Krabbe)
1400123|NCT00383448|Tay Sachs
1400124|NCT00383448|Sandhoff
1400125|NCT00383448|Sanfilippo syndrome
1400126|NCT00383448|Mucopolysaccharidosis III (MPS-III)
1400127|NCT00383448|GM1 gangliosidosis
1400128|NCT00383448|I-cell
1400129|NCT00383448|mucolipidosis
1400130|NCT00383409|breast
1400131|NCT00383409|cancer
1400132|NCT00383409|fatigue
1400133|NCT00383409|multivitamins
1400134|NCT00383357|Performance
1400135|NCT00383357|Gait stability
1400136|NCT00383357|sedative
1400137|NCT00383357|hypnotic
1400138|NCT00383357|quality of life
1400139|NCT00383357|sleep disorder
1400140|NCT00383357|wakefulness
1400141|NCT00383357|sleeping pills
1400142|NCT00383357|Cognitive function
1400143|NCT00383344|Crohn Disease
1400144|NCT00383344|Positron Emission Tomography
1400145|NCT00383344|Colonoscopy
1400146|NCT00383318|Neonate
1400147|NCT00383318|Hyperbilirubinemia
1400148|NCT00383318|Jaundice
1400149|NCT00383318|G6PD Deficiency
1400150|NCT00383318|Gilbert's Syndrome
1400151|NCT00383305|neonatal
1400152|NCT00383305|hypoxic
1400153|NCT00383305|ischemic
1400154|NCT00383305|encephalopathy
1400155|NCT00383305|HIE
1400156|NCT00383305|birth asphyxia
1400157|NCT00383305|neonatal encephalopathy
1400158|NCT00383305|Asphyxia Neonatorum
1400159|NCT00383305|hypothermia, therapeutic
1400160|NCT00383305|brain cooling
1400161|NCT00383305|selective head cooling
1400162|NCT00383279|recurrent cervical cancer
1400163|NCT00383279|stage 0 cervical cancer
1400164|NCT00383279|stage IA cervical cancer
1400165|NCT00383279|stage IB cervical cancer
1400166|NCT00383279|stage IIA cervical cancer
1400167|NCT00383279|stage IIB cervical cancer
1400168|NCT00383279|stage III cervical cancer
1400169|NCT00383279|stage IVA cervical cancer
1400170|NCT00383279|stage IVB cervical cancer
1400171|NCT00383279|recurrent uterine sarcoma
1400172|NCT00383279|stage I uterine sarcoma
1400173|NCT00383279|stage II uterine sarcoma
1400174|NCT00383279|stage III uterine sarcoma
1400175|NCT00383279|stage IV uterine sarcoma
1400176|NCT00383279|borderline ovarian surface epithelial-stromal tumor
1400177|NCT00383279|ovarian sarcoma
1400178|NCT00383279|ovarian stromal cancer
1400179|NCT00383279|recurrent ovarian epithelial cancer
1400180|NCT00383279|recurrent ovarian germ cell tumor
1400181|NCT00383279|stage I ovarian epithelial cancer
1400182|NCT00383279|stage I ovarian germ cell tumor
1400183|NCT00383279|stage II ovarian epithelial cancer
1400184|NCT00383279|stage II ovarian germ cell tumor
1400185|NCT00383279|stage III ovarian epithelial cancer
1400186|NCT00383279|stage III ovarian germ cell tumor
1400187|NCT00383279|stage IV ovarian epithelial cancer
1400188|NCT00383279|stage IV ovarian germ cell tumor
1400189|NCT00383214|Lupus,
1400190|NCT00383214|antibody,
1400191|NCT00383214|B-cell immunotherapy
1400192|NCT00383201|Contact Lens Care
1400193|NCT00383188|Arthritis, Rheumatoid
1400194|NCT00383175|Ocular Accommodation
1400195|NCT00383175|Reading
1400196|NCT00383162|Combination Product
1400197|NCT00383162|naproxen sodium
1400198|NCT00383162|sumatriptan succinate
1400199|NCT00383162|short acting triptan
1400200|NCT00383162|migraine, acute
1400201|NCT00383162|Poor response
1400202|NCT00383136|STEMI
1400203|NCT00383136|Primary Angioplasty
1400204|NCT00383136|Abciximab
1400205|NCT00383136|Tirofiban
1400206|NCT00383123|Fluarix
1400207|NCT00383123|Influenza
1400208|NCT00383110|Diabetes
1400209|NCT00383110|Health Outcomes
1400210|NCT00383110|Racial Preference
1400211|NCT00383110|Clinical Trial
1400212|NCT00383110|Ethnic Differences
1400213|NCT00383097|CTLs
1400214|NCT00383097|LMP1
1400215|NCT00383097|LMP2
1400216|NCT00383097|CYTOTOXIC T-LYMPHOCYTES
1400217|NCT00383097|CD45
1400218|NCT00383097|ANTIBODY
1400219|NCT00383097|EBV-POSITIVE HODGKIN'S
1400220|NCT00383097|NON-HODGKIN'S LYMPHOMA
1400221|NCT00383084|Pain
1400222|NCT00383084|Physical Activity
1400223|NCT00383084|Fatigue
1400224|NCT00383084|Lifestyle Activity
1400225|NCT00383071|Apheresis
1400226|NCT00383071|Avian Flu
1400227|NCT00383071|Healthy Volunteers
1400228|NCT00383071|Infectious Diseases
1400229|NCT00383071|IVIG
1400230|NCT00383071|Healthy Volunteer
1400231|NCT00383071|HV
1400232|NCT00383058|obesity
1400233|NCT00383058|green tea
1400234|NCT00383045|Buprenorphine
1400235|NCT00383045|Naltrexone
1400236|NCT00383045|HIV risk reduction behavior
1400237|NCT00383045|Counseling
1400238|NCT00383006|Psychotherapy, Group
1400239|NCT00383006|Stress Disorders, Post-Traumatic
1400240|NCT00383006|Ambulatory Care
1400241|NCT00382993|migraine with or without aura
1400242|NCT00382993|naproxen sodium
1400243|NCT00382993|combination product
1400244|NCT00382993|sumatriptan succinate
1400245|NCT00382993|poor response
1400246|NCT00382993|short acting triptan
1400247|NCT00382993|migraine, acute
1400248|NCT00382980|influenza, vaccine, A/H5N1, aluminum hydroxide, Vero cell
1400249|NCT00382967|Parkinsonian Syndromes, Parkinsonism, DaTSCAN, SPECT, clinical management, quality of life, movement disorder
1400250|NCT00382967|Clinically uncertain Parkinsonian Syndromes
1400251|NCT00382954|Acute Myelogenous Leukemia
1400252|NCT00382954|AML
1400253|NCT00382954|Relapse
1400254|NCT00382954|Elderly
1400255|NCT00382954|Velcade
1400256|NCT00382954|Idarubicin
1400257|NCT00382954|Bortezomib
1400258|NCT00382928|Randomized Controlled Trials
1400259|NCT00382928|Defibrillators
1400260|NCT00382928|Medical Devices
1400261|NCT00382915|Smoking
1400262|NCT00382915|Topography
1400263|NCT00382915|Nicotine
1400264|NCT00382902|Contact Lens Care
1400265|NCT00382889|Anti-Asthmatic Agents
1400266|NCT00382889|corticosteroids
1400267|NCT00382889|symptom-driven
1400268|NCT00382889|beclomethasone
1400269|NCT00382889|salbutamol
1400270|NCT00382876|apnea, hypoxia, car seat, car bed
1400271|NCT00382863|heart failure
1400272|NCT00382863|cardiac support
1400273|NCT00382863|Paracor
1400274|NCT00382863|HeartNet
1400275|NCT00382863|PEERLESS-HF
1400276|NCT00382850|Nissen fundoplication
1400277|NCT00382850|gastroesophageal reflux
1400278|NCT00382837|Lupus,
1400279|NCT00382837|Antibody,
1400280|NCT00382837|B-Cell immunotherapy
1400281|NCT00382824|Progressive Supranuclear Palsy
1400282|NCT00382824|Atypical Parkinsonism
1400283|NCT00382824|CoQ10
1400284|NCT00382811|Recurrent Ovarian Epithelial Cancer
1400285|NCT00382811|Stage IV Ovarian Epithelial Cancer
1400286|NCT00382811|Peritoneal Cavity Cancer
1400287|NCT00382811|Stage III Ovarian Epithelial Cancer
1400288|NCT00382785|online
1400289|NCT00382785|support
1400290|NCT00382785|breast cancer
1400291|NCT00382772|HRV vaccine
1400292|NCT00382772|Diarrhoea
1400293|NCT00382772|Rotavirus
1400294|NCT00382746|Congestive
1400295|NCT00382746|Heart
1400296|NCT00382746|Failure
1400297|NCT00382746|CHF
1400298|NCT00382733|Solid Tumors
1400299|NCT00382707|repetitive transcranial magnetic stimulation
1400300|NCT00382707|low frequency
1400301|NCT00382707|frontal lobe epilepsy
1400302|NCT00382707|brain excitability
1400303|NCT00382707|electromyography
1400304|NCT00382694|Myeloma
1400305|NCT00382694|Induction therapy
1400306|NCT00382694|High-dose melphalan
1400307|NCT00382694|Autologous stem cell support
1400308|NCT00382694|Fludarabine
1400309|NCT00382694|Cyclophosphamide
1400310|NCT00382694|Dexamethasone
1400311|NCT00382694|Safety
1400312|NCT00382694|Toxicity
1400313|NCT00382681|Contact Lens Care
1400314|NCT00382668|hepatically impaired
1400315|NCT00382655|Prevention
1400316|NCT00382655|Emergency Medical Services
1400317|NCT00382655|Emergency Medical Technicians
1400318|NCT00382642|alcoholism, alcohol disorder, drinking,alcohol
1400319|NCT00382629|Multiple sclerosis
1400320|NCT00382629|MS
1400321|NCT00382629|Bayhill
1400322|NCT00382629|BHT-3009
1400323|NCT00382629|immunotherapy
1400324|NCT00382616|behavioral problems
1400325|NCT00382616|learning problems
1400326|NCT00382616|inattentive
1400327|NCT00382616|impulsive
1400328|NCT00382616|hyperactive
1400329|NCT00382616|children
1400330|NCT00382616|phosphatidylserine
1400331|NCT00382616|long-chain polyunsaturated fatty acid
1400332|NCT00382616|eicosapentaenoic acid
1400333|NCT00382616|docosahexaenoic acid
1400334|NCT00382616|omega3:omega6 ratio
1400335|NCT00382616|eicosapentaenoic acid:arachidonic acid ratio
1400336|NCT00382616|Test of Variables of Attention
1400337|NCT00382616|ADHD index scores
1400338|NCT00382603|Contact Lens Care
1400339|NCT00382590|Acute Myelogenous Leukemia
1400340|NCT00382590|AML
1400341|NCT00382590|Myelodysplastic Syndrome
1400342|NCT00382590|Leukemia
1400343|NCT00382590|MDS
1400344|NCT00382590|Azacytidine
1400345|NCT00382590|5-Azacytidine
1400346|NCT00382590|5-aza
1400347|NCT00382590|Vidaza
1400348|NCT00382590|5-AZC
1400349|NCT00382590|AZA-CR
1400350|NCT00382590|Ladakamycin
1400351|NCT00382590|Ara-C
1400352|NCT00382590|Cytarabine
1400353|NCT00382590|Cytosar
1400354|NCT00382590|DepoCyt
1400355|NCT00382590|Cytosine arabinosine hydrochloride
1400356|NCT00382590|Valproic Acid
1400357|NCT00382590|VPA
1400358|NCT00382590|Depakene
1400359|NCT00382564|Imaging
1400360|NCT00382564|Arteriosclerosis
1400361|NCT00382564|Hardening of the arteries
1400362|NCT00382564|MRA
1400363|NCT00382564|Narrowing of Vessels
1400364|NCT00382564|Noninvasive Plaque Imaging
1400365|NCT00382564|Atherosclerotic Disease
1400366|NCT00382564|Plaque
1400367|NCT00382564|Arteries
1400368|NCT00382564|Diabetes
1400369|NCT00382564|Hypertension
1400370|NCT00382551|Alcohol
1400371|NCT00382551|Red wine
1400372|NCT00382551|Endothelial function
1400373|NCT00382551|Flow-mediated vasodilation
1400374|NCT00382551|Cardiovascular disease
1400375|NCT00382538|mifepristone
1400376|NCT00382538|induction
1400377|NCT00382538|abortion
1400378|NCT00382538|injection, intra-amniotic
1400379|NCT00382525|Bradyarrhythmia
1400380|NCT00382525|Atrial Fibrillation
1400381|NCT00382525|Ventricular Tachycardia
1400382|NCT00382525|Ventricular Fibrillation
1400383|NCT00382525|Heart Failure
1400384|NCT00382525|Pacemaker
1400385|NCT00382525|Implantable Cardioverter Defibrillator
1400386|NCT00382525|Cardiac Resynchronization Therapy
1400387|NCT00382525|Loop recorder
1400388|NCT00382525|Registry
1400389|NCT00382512|Moderate Plaque Psoriasis
1400390|NCT00382499|Intravenous Lidocaine
1400391|NCT00382499|Lidocaine Infusion
1400392|NCT00382499|Total Abdominal Hysterectomy
1400393|NCT00382499|Analgesia
1400394|NCT00382499|Anesthesia
1400395|NCT00382499|Adjunct
1400396|NCT00382486|Intestinal transplant
1400397|NCT00382486|Bone marrow
1400398|NCT00382486|Irradiation of allograft
1400399|NCT00382473|Diabetes Mellitus, Type 2
1400400|NCT00382473|Overweight
1400401|NCT00382473|Fatty acid oxidation
1400402|NCT00382473|Mitochondria
1400403|NCT00382473|Exercise
1400404|NCT00382447|breath actuated nebulizer
1400405|NCT00382447|nebulizer
1400406|NCT00382434|emergency pharmacist
1400407|NCT00382434|emergency medicine
1400408|NCT00382434|emergency department
1400409|NCT00382434|medical error
1400410|NCT00382434|adverse event
1400411|NCT00382434|pharmacist
1400412|NCT00382434|patient safety
1400413|NCT00382421|Myocardial Ischemia
1400414|NCT00382421|Randomized Controlled Trials
1400415|NCT00382421|Drug Therapy
1400416|NCT00382408|Acute respiratory disease prevention
1400417|NCT00382408|Adenovirus
1400418|NCT00382395|Glaucoma shunt
1400419|NCT00382395|Ocular implant
1400420|NCT00382395|Gold
1400421|NCT00382395|trabeculectomy
1400422|NCT00382382|Autism
1400423|NCT00382382|Asperger Syndrome
1400424|NCT00382382|Restricted repetitive behavior
1400425|NCT00382382|Stereotyped patterns of behavior
1400426|NCT00382382|Typically Developing children
1400427|NCT00382382|Human Volunteers
1400428|NCT00382369|familial vocal cord paralysis
1400429|NCT00382369|genetic screening
1400430|NCT00382356|Benign Prostatic Enlargement
1400431|NCT00382356|Benign Prostatic Hypertrophy
1400432|NCT00382356|Dutasteride
1400433|NCT00382356|5-alpha reductase inhibitors
1400434|NCT00382356|Hormonal therapy
1400435|NCT00382343|Prevention
1400436|NCT00382343|Pyelonephritis
1400437|NCT00382343|Renal scars
1400438|NCT00382343|Vesico-ureteral reflux
1400439|NCT00382343|Dimercaptosuccinic acid renal scan (DMSA)
1400440|NCT00382330|Vulva
1400441|NCT00382317|MSCT indications
1400442|NCT00382304|Clostridium difficile-associated diarrhea
1400443|NCT00382304|C. difficile
1400444|NCT00382304|CDAD
1400445|NCT00382304|Clostridium difficile
1400446|NCT00382304|Clostridium difficile Disease
1400447|NCT00382304|Clostridium Enterocolitis
1400448|NCT00382304|Antibiotic-Associated Colitis
1400449|NCT00382304|Infectious diarrhea
1400450|NCT00382291|OCD
1400451|NCT00382291|Antidepressive Agents, Second-Generation
1400452|NCT00382291|Placebos
1400453|NCT00382291|Cognitive Behavior Therapy
1400454|NCT00382291|Child Psychiatry
1400455|NCT00382291|Activation Syndrome
1400456|NCT00382291|Psychometrics
1400457|NCT00382278|Stem cell
1400458|NCT00382278|Liver cirrhosis
1400459|NCT00382278|Cellular therapy
1400460|NCT00382278|Autologous
1400461|NCT00382278|Bone marrow
1400462|NCT00382265|urolithiasis
1400463|NCT00382265|renal colic
1400464|NCT00382265|kidney stones
1400465|NCT00382265|urinary stone disease
1400466|NCT00382252|unspecified adult solid tumor, protocol specific
1400467|NCT00382252|lung metastases
1400468|NCT00382239|diabetes
1400469|NCT00382239|exenatide
1400470|NCT00382239|LY2148568
1400471|NCT00382239|Lilly
1400472|NCT00382239|Amylin
1400473|NCT00382239|Japan
1400474|NCT00382226|Glaucoma
1400475|NCT00382200|de novo myelodysplastic syndromes
1400476|NCT00382200|previously treated myelodysplastic syndromes
1400477|NCT00382187|influenza
1400478|NCT00382187|pandemic influenza
1400479|NCT00382187|influenza vaccine
1400480|NCT00382187|adjuvanted influenza vaccine
1400481|NCT00382187|H5N1 influenza antigen
1400482|NCT00382187|MF59
1400483|NCT00382187|Pandemic influenza disease
1400484|NCT00382174|pressure ulcers
1400485|NCT00382174|cutaneous wound- healing
1400486|NCT00382174|chronic wound-healing
1400487|NCT00382174|Thymosin Beta 4
1400488|NCT00382174|laminin-5
1400489|NCT00382161|impotence
1400490|NCT00382161|erectile dysfunction
1400491|NCT00382161|cardiovascular risk factor
1400492|NCT00382161|statin
1400493|NCT00382148|TOPS
1400494|NCT00382148|Peanut allergy
1400495|NCT00382148|Peanut-induced allergy
1400496|NCT00382148|Allergy
1400497|NCT00382135|Impotence
1400498|NCT00382135|erectile dysfunction
1400499|NCT00382135|semen
1400500|NCT00382135|sperm
1400501|NCT00382135|Healthy male volunteers
1400502|NCT00382135|men with mild erectile dysfunction
1400503|NCT00382122|Glaucoma
1400504|NCT00382122|Ocular hypertension
1400505|NCT00382122|Dry eye
1400506|NCT00382122|Ocular surface disease
1400507|NCT00382096|Type 2 diabetes
1400508|NCT00382096|vildagliptin
1400509|NCT00382096|metformin
1400510|NCT00382096|hemoglobin A1c
1400511|NCT00382083|Mammogram
1400512|NCT00382083|Pain
1400513|NCT00382083|Discomfort
1400514|NCT00382083|Breast
1400515|NCT00382083|Pre-medication
1400516|NCT00382070|stage I breast cancer
1400517|NCT00382070|stage II breast cancer
1400518|NCT00382070|stage IIIA breast cancer
1400519|NCT00382057|Testosterone
1400520|NCT00382057|Insulin resistance
1400521|NCT00382057|Insulin sensitivity
1400522|NCT00382057|Metabolic disorders
1400523|NCT00382044|Kidney Failure, Chronic
1400524|NCT00382044|Dialysis
1400525|NCT00382044|Anemia
1400526|NCT00382044|epoetin
1400527|NCT00382018|recurrent breast cancer
1400528|NCT00382018|stage IV breast cancer
1400529|NCT00381992|sexual risk behavior
1400530|NCT00381992|diabetes mellitus
1400531|NCT00381992|hypertension
1400532|NCT00381992|obesity
1400533|NCT00381992|human immunodeficiency virus
1400534|NCT00381992|hyperlipidemia
1400535|NCT00381992|chlamydia
1400536|NCT00381979|Depression
1400537|NCT00381979|Anxiety
1400538|NCT00381979|Adolescents
1400539|NCT00381979|Treatment
1400540|NCT00381979|Supportive Expressive Therapy
1400541|NCT00381966|Prostate Cancer
1400542|NCT00381966|Brachytherapy
1400543|NCT00381927|Breast Cancer Risk
1400544|NCT00381927|Counseling
1400545|NCT00381927|Prevention
1400546|NCT00381927|Anxiety
1400547|NCT00381927|BRCA1 mutation
1400548|NCT00381927|BRCA2 mutation
1400549|NCT00381927|Tamoxifen
1400550|NCT00381914|Infants
1400551|NCT00381914|Vitamin D
1400552|NCT00381914|Dose-response
1400553|NCT00381901|stage II breast cancer
1400554|NCT00381901|stage IIIA breast cancer
1400555|NCT00381901|stage IIIB breast cancer
1400556|NCT00381901|stage IA breast cancer
1400557|NCT00381901|stage IB breast cancer
1400558|NCT00381901|recurrent breast cancer
1400559|NCT00381901|stage IIIC breast cancer
1400560|NCT00381888|thromboembolism
1400561|NCT00381888|cervical cancer
1400562|NCT00381888|endometrial cancer
1400563|NCT00381888|ovarian epithelial cancer
1400564|NCT00381888|ovarian germ cell tumor
1400565|NCT00381888|borderline ovarian surface epithelial-stromal tumor
1400566|NCT00381888|ovarian sarcoma
1400567|NCT00381888|ovarian stromal cancer
1400568|NCT00381888|uterine sarcoma
1400569|NCT00381888|vaginal cancer
1400570|NCT00381888|vulvar cancer
1400571|NCT00381888|fallopian tube cancer
1400572|NCT00381875|HIV infection
1400573|NCT00381862|nausea and vomiting
1400574|NCT00381862|recurrent colon cancer
1400575|NCT00381862|stage IV colon cancer
1400576|NCT00381862|recurrent rectal cancer
1400577|NCT00381862|stage IV rectal cancer
1400578|NCT00381849|Cystone
1400579|NCT00381849|Uricare
1400580|NCT00381849|Computerized tomography
1400581|NCT00381849|Kidney calculi
1400582|NCT00381849|Supersaturation
1400583|NCT00381849|Nephrolithiasis
1400584|NCT00381849|Quantitative CT
1400585|NCT00381836|Prostate Cancer
1400586|NCT00381836|Anemia
1400587|NCT00381836|Blood transfusion
1400588|NCT00381836|Cancer
1400589|NCT00381836|Critical illness
1400590|NCT00381836|Drug efficacy
1400591|NCT00381836|Drug safety
1400592|NCT00381836|Drug tolerability
1400593|NCT00381836|Erythropoietin
1400594|NCT00381836|Fatigue
1400595|NCT00381836|Hemoglobin
1400596|NCT00381836|Human
1400597|NCT00381836|Male
1400598|NCT00381836|Multicenter study
1400599|NCT00381836|Quality of life
1400600|NCT00381836|Questionnaire
1400601|NCT00381836|Randomized controlled trial
1400602|NCT00381836|Recombinant erythropoietin
1400603|NCT00381823|Pregnant women
1400604|NCT00381823|Intervention Studies
1400605|NCT00381823|African Americans
1400606|NCT00381823|Infant Mortality
1400607|NCT00381823|Environmental Tobacco Smoke Pollution
1400608|NCT00381823|Depression
1400609|NCT00381823|Partner Abuse
1400610|NCT00381823|Tobacco Smoke
1400611|NCT00381810|Rituxan
1400612|NCT00381810|SLE
1400613|NCT00381810|Lupus
1400614|NCT00381784|YMSM
1400615|NCT00381784|HIV/AIDS
1400616|NCT00381784|Condom use
1400617|NCT00381784|Drug users
1400618|NCT00381784|Minority women
1400619|NCT00381771|Globus Pharyngeus
1400620|NCT00381771|Xerostomia
1400621|NCT00381771|Salivary Hypofunction
1400622|NCT00381771|Pharyngoxerosis
1400623|NCT00381758|ADHD
1400624|NCT00381758|Methylphenidate
1400625|NCT00381758|Metadate CD
1400626|NCT00381758|Concerta
1400627|NCT00381758|COMACS
1400628|NCT00381758|Attention Deficit Hyperactivity Disorder (ADHD)
1400629|NCT00381732|Impotence
1400630|NCT00381732|erectile dysfunction
1400631|NCT00381706|squamous cell carcinoma of the esophagus
1400632|NCT00381706|adenocarcinoma of the esophagus
1400633|NCT00381706|stage IV esophageal cancer
1400634|NCT00381706|recurrent esophageal cancer
1400635|NCT00381693|primary myelofibrosis
1400636|NCT00381693|polycythemia vera
1400637|NCT00381693|essential thrombocythemia
1400638|NCT00381693|secondary myelofibrosis
1400639|NCT00381667|safety
1400640|NCT00381667|GW642444M
1400641|NCT00381667|Single Dose
1400642|NCT00381667|pharmacodynamics
1400643|NCT00381667|pharmacokinetics
1400644|NCT00381667|GW642444H
1400645|NCT00381667|tolerability
1400646|NCT00381654|Solid Tumors
1400647|NCT00381654|Tyrosine Kinases
1400648|NCT00381628|Anatomy
1400649|NCT00381628|cells
1400650|NCT00381628|epithelial cells
1400651|NCT00381628|blood cells
1400652|NCT00381628|cystic fibrosis
1400653|NCT00381628|equipment and supplies
1400654|NCT00381628|disposable equipment
1400655|NCT00381628|reagent kits
1400656|NCT00381615|Meningococcal disease
1400657|NCT00381615|prevention
1400658|NCT00381615|vaccination
1400659|NCT00381602|End stage renal disease
1400660|NCT00381602|Hemodialysis
1400661|NCT00381602|Malnutrition
1400662|NCT00381602|End stage renal disease (ESRD)
1400663|NCT00381589|clozapine-induced hypersalivation
1400664|NCT00381576|Resistance training
1400665|NCT00381576|Strength training
1400666|NCT00381576|Training adaptations
1400667|NCT00381576|CNS
1400668|NCT00381563|Bracing
1400669|NCT00381563|Patellofemoral
1400670|NCT00381563|Osteoarthritis
1400671|NCT00380107|Minor surgery
1400672|NCT00380107|Volume optimization
1400673|NCT00380107|Volume deficit
1400674|NCT00380107|Epidural anesthesia
1400675|NCT00380094|ACS
1400676|NCT00380094|NSTEMI
1400677|NCT00380094|Myeloperoxidase
1400678|NCT00380094|nonST segment elevation myocardial infarction
1400679|NCT00380081|Insomnia
1400680|NCT00380055|Cancer Screening
1400681|NCT00380055|Navigators
1400682|NCT00380055|Community Outreach
1400683|NCT00380055|Behavioral Change
1400684|NCT00380055|Access
1400685|NCT00380042|Cortical Electrical Stimulation
1400686|NCT00380042|Treatment Resistant Depression
1400687|NCT00380042|Major Depressive Disorder
1400688|NCT00380029|stage II bladder cancer
1400689|NCT00380029|transitional cell carcinoma of the bladder
1400690|NCT00381537|childhood epilepsy
1400691|NCT00381537|Active childhood epilepsy
1400692|NCT00381524|human immunodeficiency virus
1400693|NCT00381524|behavior change
1400694|NCT00381511|pulmonary embolism,
1400695|NCT00381511|deferred diagnosis,
1400696|NCT00381511|protective anticoagulation
1400697|NCT00381511|anticoagulants
1400698|NCT00381472|Parkinson's Disease
1400699|NCT00381472|Dyskinesia
1400700|NCT00381472|Adjunctive Therapy with L-dopa
1400701|NCT00381446|corneal staining
1400702|NCT00381446|contact lens care
1400703|NCT00381446|multipurpose solution
1400704|NCT00381433|HCV
1400705|NCT00381433|Hepatitis C virus
1400706|NCT00381407|ADHD
1400707|NCT00381407|Organizational Skills
1400708|NCT00381407|Contingency Management
1400709|NCT00381394|amphotericin B
1400710|NCT00381394|safety
1400711|NCT00381394|tolerability and pharmacokinetics of oral sitamaquine
1400712|NCT00381394|Visceral leishmaniasis
1400713|NCT00381381|Alzheimer's disease
1400714|NCT00381368|breast cancer
1400715|NCT00381368|skeletal metastases
1400716|NCT00381368|bisphosphonate therapy
1400717|NCT00381368|Breast cancer with painful skeletal metastases
1400718|NCT00381355|asthma
1400719|NCT00381355|children
1400720|NCT00381355|written action plan
1400721|NCT00381355|education
1400722|NCT00381355|guided self-management
1400723|NCT00381355|efficacy
1400724|NCT00381355|compliance
1400725|NCT00381355|b2-agonists
1400726|NCT00381355|inhaled corticosteroids
1400727|NCT00381355|oral steroids
1400728|NCT00381355|relapse
1400729|NCT00381355|randomised controlled trial
1400730|NCT00381355|emergency department
1400731|NCT00381342|diabetes
1400732|NCT00381342|exenatide
1400733|NCT00381342|Amylin
1400734|NCT00381342|Lilly
1400735|NCT00381342|monotherapy
1400736|NCT00381329|Motivational Interviewing
1400737|NCT00381329|Structured Brief Advice
1400738|NCT00381329|Adolescent Smoking
1400739|NCT00381329|Behavioral Intervention
1400740|NCT00381329|Smoking
1400741|NCT00381329|Primary Care
1400742|NCT00381329|Tobacco
1400743|NCT00381303|HIV
1400744|NCT00381303|AIDS
1400745|NCT00381303|Immunodeficiency Virus, Human
1400746|NCT00381303|Females
1400747|NCT00381303|Women
1400748|NCT00381303|PREZISTA
1400749|NCT00381303|darunavir
1400750|NCT00381303|TMC114
1400751|NCT00381303|Protease Inhibitor
1400752|NCT00381290|Arthritis
1400753|NCT00381290|Arthritis, Degenerative
1400754|NCT00381290|Knee Health
1400755|NCT00381290|Obesity
1400756|NCT00381290|Overweight
1400757|NCT00381290|Osteoarthritis
1400758|NCT00381290|Weight Loss
1400759|NCT00381290|Diet
1400760|NCT00381290|Exercise
1400761|NCT00381290|Knee Pain
1400762|NCT00381277|nephrolithiasis
1400763|NCT00381277|citrate
1400764|NCT00381277|oxalate
1400765|NCT00381251|vaginal atrophy
1400766|NCT00381251|postmenopausal osteoporosis
1400767|NCT00381251|menopause
1400768|NCT00381251|hot flashes
1400769|NCT00381238|Alzheimer's Disease
1400770|NCT00381238|Rosiglitazone
1400771|NCT00381225|radio-frequency
1400772|NCT00381225|ablation
1400773|NCT00381225|ultra-sound
1400774|NCT00381225|guidance
1400775|NCT00381225|papillary
1400776|NCT00381225|thyroid
1400777|NCT00381225|cancer
1400778|NCT00381212|Immunotherapeutic injection
1400779|NCT00381199|fibromyalgia
1400780|NCT00381199|cannabinoid
1400781|NCT00381199|chronic pain
1400782|NCT00381199|sleep
1400783|NCT00381199|insomnia
1400784|NCT00381199|diffuse widespread pain
1400785|NCT00381199|antidepressant
1400786|NCT00381186|impaired glucose tolerance
1400787|NCT00381186|type 2 diabetes
1400788|NCT00381173|MGI PHARMA
1400789|NCT00381173|ZYC3-002
1400790|NCT00381173|ZYC300
1400791|NCT00381173|plasmid DNA
1400792|NCT00381173|cyclophosphamide
1400793|NCT00381173|Cytoxan
1400794|NCT00381173|advanced breast cancer
1400795|NCT00381173|advanced ovarian cancer
1400796|NCT00381173|hormone refractory prostate cancer
1400797|NCT00381173|advanced colon cancer
1400798|NCT00381173|advanced renal cancer
1400799|NCT00381173|advanced stage malignancies
1400800|NCT00381173|immune therapy
1400801|NCT00381173|gene therapy
1400802|NCT00381173|biologic therapy
1400803|NCT00381173|T-regulatory cells
1400804|NCT00381173|cancer vaccine
1400805|NCT00381173|vaccine
1400806|NCT00381173|Advanced stage malignancies-ovary, breast, colon, prostate
1400807|NCT00381160|weight loss
1400808|NCT00381160|obesity
1400809|NCT00381160|sugar-sweetened beverages
1400810|NCT00381160|diet
1400811|NCT00381160|adolescence
1400812|NCT00381134|double-blind
1400813|NCT00381134|placebo-controlled
1400814|NCT00381134|nephropathy
1400815|NCT00381134|blood pressure
1400816|NCT00381134|urine albumin to creatinine ratio
1400817|NCT00381134|placebo
1400818|NCT00381121|Tissue Biobank
1400819|NCT00381121|molecular markers
1400820|NCT00381121|molecular pathways
1400821|NCT00381108|BPH
1400822|NCT00381082|Pediculus
1400823|NCT00381082|capitis
1400824|NCT00381082|lice
1400825|NCT00381069|Recreation Centers
1400826|NCT00381069|Families
1400827|NCT00381069|Obesity Prevention
1400828|NCT00381056|labor and delivery care
1400829|NCT00381056|teamwork training
1400830|NCT00381056|crew resource management
1400831|NCT00381056|cluster-randomized trial
1400832|NCT00381043|Alcohol Dependence
1400833|NCT00381043|Family Medicine Setting
1400834|NCT00381043|University of North Carolina at Chapel Hill
1400835|NCT00381030|beta-Adrenergic Blockers
1400836|NCT00381030|Disease Management
1400837|NCT00381004|Chronic Lymphocytic Leukemia
1400838|NCT00381004|Leukemia
1400839|NCT00381004|Cyclophosphamide
1400840|NCT00381004|Fludarabine
1400841|NCT00381004|Sargramostim
1400842|NCT00381004|Rituximab
1400843|NCT00381004|GM-CSF
1400844|NCT00381004|FCR
1400845|NCT00380978|labor pain
1400846|NCT00380978|cesarean section
1400847|NCT00380978|epidural analgesia
1400848|NCT00380978|opioid analgesics
1400849|NCT00380978|local anesthetics
1400850|NCT00380978|labor induced
1400851|NCT00380965|Chemotherapy-induced
1400852|NCT00380965|neuropathy
1400853|NCT00380965|cancer
1400854|NCT00380952|IDC
1400855|NCT00380952|DCIS
1400856|NCT00380952|ILC
1400857|NCT00380926|polyunsatturated fatty acids
1400858|NCT00380926|nutrition
1400859|NCT00380926|low-dose allergen challenge
1400860|NCT00380926|exhaled nitric oxide
1400861|NCT00380887|bioavailability
1400862|NCT00380887|bioequivalence
1400863|NCT00380887|marketed product
1400864|NCT00380887|Premarin
1400865|NCT00380887|Medroxyprogesterone acetate
1400866|NCT00380887|MPA
1400867|NCT00380887|Postmenopausal
1400868|NCT00380887|vasomotor symptoms
1400869|NCT00380874|Pain
1400870|NCT00380874|chemotherapy
1400871|NCT00380861|Total Knee Replacement
1400872|NCT00380861|Flexion
1400873|NCT00380861|Range of Motion
1400874|NCT00380861|Activities of Daily Living
1400875|NCT00380861|Implant design
1400876|NCT00380861|Subject Satisfaction
1400877|NCT00380861|Non-inflammatory arthritis
1400878|NCT00380848|sleep apnea
1400879|NCT00380848|end stage renal disease
1400880|NCT00380848|hemodiafiltration
1400881|NCT00380835|metastatic breast cancer
1400882|NCT00380835|amrubicin
1400883|NCT00380822|alpa-glucosidase inhibitor
1400884|NCT00380796|Chronic Obstructive Pulmonary Disease
1400885|NCT00380796|COPD
1400886|NCT00380016|Angioplasty
1400887|NCT00380016|Stent
1400888|NCT00380016|Coronary Artery Disease
1400889|NCT00380016|Peripheral Artery Disease
1400890|NCT00380016|Percutaneous Coronary Intervention
1400891|NCT00380016|CAD
1400892|NCT00380016|PAD
1400893|NCT00380016|Cardiovascular Disease
1400894|NCT00379990|iNOS
1400895|NCT00379990|Exhaled NO
1400896|NCT00379990|Rheumatoid arthritis
1400897|NCT00379938|Parvovirus B-19, Parvoviridae, vaccine
1400898|NCT00379925|Physical Activity
1400899|NCT00379925|Exercise
1400900|NCT00379925|Dietary Habits
1400901|NCT00379899|calcification
1400902|NCT00379899|vascular calcification
1400903|NCT00379899|coronary vascular calcification
1400904|NCT00379899|chronic kidney disease
1400905|NCT00379899|end stage renal disease
1400906|NCT00379899|dialysis
1400907|NCT00379886|ECT
1400908|NCT00379886|Depression
1400909|NCT00379886|Anesthiticum
1400910|NCT00379886|Propofol
1400911|NCT00379886|Thiopental
1400912|NCT00378859|Children
1400913|NCT00378859|Milk
1400914|NCT00378859|Meat
1400915|NCT00378859|Animal Protein
1400916|NCT00378859|Growth Factors
1400917|NCT00378859|IGF-I
1400918|NCT00378859|IGFBP-3
1400919|NCT00378859|Insulin
1400920|NCT00378846|fever, sweats, and hot flashes
1400921|NCT00378833|Primary Hypercholesterolemia or Mixed Hyperlipidemia
1400922|NCT00378820|Children
1400923|NCT00378820|Whey
1400924|NCT00378820|Casein
1400925|NCT00378820|Milk minerals
1400926|NCT00378820|Growth factors
1400927|NCT00378820|IGF-I
1400928|NCT00378820|Insulin
1400929|NCT00378781|infection
1400930|NCT00378781|poor vascular access
1400931|NCT00378781|thromboembolism
1400932|NCT00378781|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1400933|NCT00378781|adult acute myeloid leukemia with inv(16)(p13;q22)
1400934|NCT00378781|adult acute myeloid leukemia with t(15;17)(q22;q12)
1400935|NCT00378781|adult acute myeloid leukemia with t(16;16)(p13;q22)
1400936|NCT00378781|adult acute myeloid leukemia with t(8;21)(q22;q22)
1400937|NCT00378781|accelerated phase chronic myelogenous leukemia
1400938|NCT00378781|adult acute lymphoblastic leukemia in remission
1400939|NCT00378781|adult acute myeloid leukemia in remission
1400940|NCT00378781|atypical chronic myeloid leukemia, BCR-ABL negative
1400941|NCT00378781|blastic phase chronic myelogenous leukemia
1400942|NCT00378781|childhood acute lymphoblastic leukemia in remission
1400943|NCT00378781|childhood acute myeloid leukemia in remission
1400944|NCT00378781|childhood chronic myelogenous leukemia
1400945|NCT00378781|chronic eosinophilic leukemia
1400946|NCT00378781|primary myelofibrosis
1400947|NCT00378781|chronic myelomonocytic leukemia
1400948|NCT00378781|chronic neutrophilic leukemia
1400949|NCT00378781|chronic phase chronic myelogenous leukemia
1400950|NCT00378781|de novo myelodysplastic syndromes
1400951|NCT00378781|disseminated neuroblastoma
1400952|NCT00378781|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1400953|NCT00378781|juvenile myelomonocytic leukemia
1400954|NCT00378781|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1400955|NCT00378781|nodal marginal zone B-cell lymphoma
1400956|NCT00378781|noncontiguous stage II adult Burkitt lymphoma
1400957|NCT00378781|noncontiguous stage II adult diffuse large cell lymphoma
1400958|NCT00378781|noncontiguous stage II adult diffuse mixed cell lymphoma
1400959|NCT00378781|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1400960|NCT00378781|noncontiguous stage II adult immunoblastic large cell lymphoma
1400961|NCT00378781|noncontiguous stage II adult lymphoblastic lymphoma
1400962|NCT00378781|noncontiguous stage II grade 1 follicular lymphoma
1400963|NCT00378781|noncontiguous stage II grade 2 follicular lymphoma
1400964|NCT00378781|noncontiguous stage II grade 3 follicular lymphoma
1400965|NCT00378781|noncontiguous stage II mantle cell lymphoma
1400966|NCT00378781|noncontiguous stage II marginal zone lymphoma
1400967|NCT00378781|noncontiguous stage II small lymphocytic lymphoma
1400968|NCT00378781|poor prognosis metastatic gestational trophoblastic tumor
1400969|NCT00378781|previously treated myelodysplastic syndromes
1400970|NCT00378781|recurrent adult acute lymphoblastic leukemia
1400971|NCT00378781|recurrent adult acute myeloid leukemia
1400972|NCT00378781|recurrent adult Burkitt lymphoma
1400973|NCT00378781|recurrent adult Hodgkin lymphoma
1400974|NCT00378781|recurrent adult diffuse large cell lymphoma
1400975|NCT00378781|recurrent adult diffuse mixed cell lymphoma
1400976|NCT00378781|recurrent adult diffuse small cleaved cell lymphoma
1400977|NCT00378781|recurrent adult immunoblastic large cell lymphoma
1400978|NCT00378781|recurrent adult lymphoblastic lymphoma
1400979|NCT00378781|recurrent breast cancer
1400980|NCT00378781|recurrent/refractory childhood Hodgkin lymphoma
1400981|NCT00378781|recurrent childhood acute lymphoblastic leukemia
1400982|NCT00378781|recurrent childhood acute myeloid leukemia
1400983|NCT00378781|recurrent childhood large cell lymphoma
1400984|NCT00378781|recurrent childhood lymphoblastic lymphoma
1400985|NCT00378781|recurrent childhood small noncleaved cell lymphoma
1400986|NCT00378781|recurrent cutaneous T-cell non-Hodgkin lymphoma
1400987|NCT00378781|recurrent grade 1 follicular lymphoma
1400988|NCT00378781|recurrent grade 2 follicular lymphoma
1400989|NCT00378781|recurrent grade 3 follicular lymphoma
1400990|NCT00378781|recurrent mantle cell lymphoma
1400991|NCT00378781|recurrent marginal zone lymphoma
1400992|NCT00378781|recurrent mycosis fungoides/Sezary syndrome
1400993|NCT00378781|recurrent neuroblastoma
1400994|NCT00378781|recurrent ovarian epithelial cancer
1400995|NCT00378781|recurrent ovarian germ cell tumor
1400996|NCT00378781|recurrent small lymphocytic lymphoma
1400997|NCT00378781|recurrent malignant testicular germ cell tumor
1400998|NCT00378781|recurrent Wilms tumor and other childhood kidney tumors
1400999|NCT00378781|refractory chronic lymphocytic leukemia
1401000|NCT00378781|refractory hairy cell leukemia
1401001|NCT00378781|refractory multiple myeloma
1401002|NCT00378781|relapsing chronic myelogenous leukemia
1401003|NCT00378781|secondary acute myeloid leukemia
1401004|NCT00378781|secondary myelodysplastic syndromes
1401005|NCT00378781|splenic marginal zone lymphoma
1401006|NCT00378781|stage I multiple myeloma
1401007|NCT00378781|stage II multiple myeloma
1401008|NCT00378781|stage II ovarian epithelial cancer
1401009|NCT00378781|stage III adult Burkitt lymphoma
1401010|NCT00378781|stage III adult Hodgkin lymphoma
1401011|NCT00378781|stage III adult diffuse large cell lymphoma
1401012|NCT00378781|stage III adult diffuse mixed cell lymphoma
1401013|NCT00378781|stage III adult diffuse small cleaved cell lymphoma
1401224|NCT00380315|GERD
1401014|NCT00378781|stage III adult immunoblastic large cell lymphoma
1401015|NCT00378781|stage III adult lymphoblastic lymphoma
1401016|NCT00378781|stage III chronic lymphocytic leukemia
1401017|NCT00378781|stage III grade 1 follicular lymphoma
1401018|NCT00378781|stage III grade 2 follicular lymphoma
1401019|NCT00378781|stage III grade 3 follicular lymphoma
1401020|NCT00378781|stage III mantle cell lymphoma
1401021|NCT00378781|stage III marginal zone lymphoma
1401022|NCT00378781|stage III multiple myeloma
1401023|NCT00378781|stage III ovarian epithelial cancer
1401024|NCT00378781|stage III small lymphocytic lymphoma
1401118|NCT00378781|stage II melanoma
1401025|NCT00378781|stage III malignant testicular germ cell tumor
1401026|NCT00378781|stage IIIA breast cancer
1401027|NCT00378781|stage IIIB breast cancer
1401028|NCT00378781|stage IIIC breast cancer
1401029|NCT00378781|stage IV adult Burkitt lymphoma
1401030|NCT00378781|stage IV adult Hodgkin lymphoma
1401031|NCT00378781|stage IV adult diffuse large cell lymphoma
1401032|NCT00378781|stage IV adult diffuse mixed cell lymphoma
1401033|NCT00378781|stage IV adult diffuse small cleaved cell lymphoma
1401034|NCT00378781|stage IV adult immunoblastic large cell lymphoma
1401035|NCT00378781|stage IV adult lymphoblastic lymphoma
1401036|NCT00378781|stage IV breast cancer
1401037|NCT00378781|stage IV chronic lymphocytic leukemia
1401038|NCT00378781|stage IV grade 1 follicular lymphoma
1401039|NCT00378781|stage IV grade 2 follicular lymphoma
1401040|NCT00378781|stage IV grade 3 follicular lymphoma
1401041|NCT00378781|stage IV mantle cell lymphoma
1401042|NCT00378781|stage IV marginal zone lymphoma
1401043|NCT00378781|stage IV ovarian epithelial cancer
1401044|NCT00378781|stage IV small lymphocytic lymphoma
1401045|NCT00378781|acute undifferentiated leukemia
1401046|NCT00378781|mast cell leukemia
1401047|NCT00378781|stage I adult T-cell leukemia/lymphoma
1401048|NCT00378781|stage II adult T-cell leukemia/lymphoma
1401049|NCT00378781|stage III adult T-cell leukemia/lymphoma
1401050|NCT00378781|stage IV adult T-cell leukemia/lymphoma
1401051|NCT00378781|recurrent adult T-cell leukemia/lymphoma
1401052|NCT00378781|T-cell large granular lymphocyte leukemia
1401053|NCT00378781|stage I chronic lymphocytic leukemia
1401054|NCT00378781|stage II chronic lymphocytic leukemia
1401055|NCT00378781|meningeal chronic myelogenous leukemia
1401056|NCT00378781|prolymphocytic leukemia
1401057|NCT00378781|stage I adult Hodgkin lymphoma
1401058|NCT00378781|stage II adult Hodgkin lymphoma
1401059|NCT00378781|stage I childhood Hodgkin lymphoma
1401060|NCT00378781|stage II childhood Hodgkin lymphoma
1401061|NCT00378781|stage III childhood Hodgkin lymphoma
1401062|NCT00378781|stage IV childhood Hodgkin lymphoma
1401063|NCT00378781|anaplastic large cell lymphoma
1401064|NCT00378781|angioimmunoblastic T-cell lymphoma
1401065|NCT00378781|stage I mycosis fungoides/Sezary syndrome
1401066|NCT00378781|stage II mycosis fungoides/Sezary syndrome
1401067|NCT00378781|stage III mycosis fungoides/Sezary syndrome
1401068|NCT00378781|stage IV mycosis fungoides/Sezary syndrome
1401069|NCT00378781|stage I cutaneous T-cell non-Hodgkin lymphoma
1401070|NCT00378781|stage II cutaneous T-cell non-Hodgkin lymphoma
1401071|NCT00378781|stage III cutaneous T-cell non-Hodgkin lymphoma
1401072|NCT00378781|stage IV cutaneous T-cell non-Hodgkin lymphoma
1401073|NCT00378781|adult grade III lymphomatoid granulomatosis
1401074|NCT00378781|recurrent adult grade III lymphomatoid granulomatosis
1401075|NCT00378781|childhood grade III lymphomatoid granulomatosis
1401076|NCT00378781|recurrent childhood grade III lymphomatoid granulomatosis
1401077|NCT00378781|Waldenstrom macroglobulinemia
1401078|NCT00378781|stage I adult Burkitt lymphoma
1401079|NCT00378781|stage I adult diffuse large cell lymphoma
1401080|NCT00378781|stage I adult diffuse mixed cell lymphoma
1401081|NCT00378781|stage I adult diffuse small cleaved cell lymphoma
1401082|NCT00378781|stage I adult immunoblastic large cell lymphoma
1401083|NCT00378781|stage I adult lymphoblastic lymphoma
1401084|NCT00378781|stage I grade 1 follicular lymphoma
1401085|NCT00378781|stage I grade 2 follicular lymphoma
1401086|NCT00378781|stage I grade 3 follicular lymphoma
1401087|NCT00378781|stage I mantle cell lymphoma
1401088|NCT00378781|stage I marginal zone lymphoma
1401089|NCT00378781|stage I small lymphocytic lymphoma
1401090|NCT00378781|contiguous stage II adult Burkitt lymphoma
1401091|NCT00378781|contiguous stage II adult diffuse large cell lymphoma
1401092|NCT00378781|contiguous stage II adult diffuse mixed cell lymphoma
1401093|NCT00378781|contiguous stage II adult diffuse small cleaved cell lymphoma
1401094|NCT00378781|contiguous stage II adult immunoblastic large cell lymphoma
1401095|NCT00378781|contiguous stage II adult lymphoblastic lymphoma
1401096|NCT00378781|contiguous stage II grade 1 follicular lymphoma
1401097|NCT00378781|contiguous stage II grade 2 follicular lymphoma
1401098|NCT00378781|contiguous stage II grade 3 follicular lymphoma
1401099|NCT00378781|contiguous stage II mantle cell lymphoma
1401100|NCT00378781|contiguous stage II marginal zone lymphoma
1401101|NCT00378781|contiguous stage II small lymphocytic lymphoma
1401102|NCT00378781|stage I childhood large cell lymphoma
1401103|NCT00378781|stage II childhood large cell lymphoma
1401104|NCT00378781|stage III childhood large cell lymphoma
1401105|NCT00378781|stage IV childhood large cell lymphoma
1401106|NCT00378781|stage I childhood lymphoblastic lymphoma
1401107|NCT00378781|stage II childhood lymphoblastic lymphoma
1401108|NCT00378781|stage III childhood lymphoblastic lymphoma
1401109|NCT00378781|stage IV childhood lymphoblastic lymphoma
1401110|NCT00378781|stage I childhood small noncleaved cell lymphoma
1401111|NCT00378781|stage II childhood small noncleaved cell lymphoma
1401112|NCT00378781|stage III childhood small noncleaved cell lymphoma
1401113|NCT00378781|stage IV childhood small noncleaved cell lymphoma
1401114|NCT00378781|primary central nervous system non-Hodgkin lymphoma
1401115|NCT00378781|post-transplant lymphoproliferative disorder
1401116|NCT00378781|intraocular lymphoma
1401117|NCT00378781|stage I melanoma
1401119|NCT00378781|stage III melanoma
1401120|NCT00378781|stage IV melanoma
1401121|NCT00378781|recurrent melanoma
1401122|NCT00378781|unspecified adult solid tumor, protocol specific
1401123|NCT00378781|unspecified childhood solid tumor, protocol specific
1401124|NCT00378781|stage I adult soft tissue sarcoma
1401125|NCT00378781|stage II adult soft tissue sarcoma
1401126|NCT00378781|stage III adult soft tissue sarcoma
1401127|NCT00378781|stage IV adult soft tissue sarcoma
1401128|NCT00378781|recurrent adult soft tissue sarcoma
1401129|NCT00378781|metastatic childhood soft tissue sarcoma
1401130|NCT00378781|nonmetastatic childhood soft tissue sarcoma
1401131|NCT00378781|recurrent childhood soft tissue sarcoma
1401132|NCT00378781|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1401133|NCT00378781|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1401134|NCT00378781|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1401135|NCT00378781|previously treated childhood rhabdomyosarcoma
1401136|NCT00378781|previously untreated childhood rhabdomyosarcoma
1401137|NCT00378781|recurrent childhood rhabdomyosarcoma
1401138|NCT00378781|recurrent uterine sarcoma
1401139|NCT00378781|stage I uterine sarcoma
1401140|NCT00378781|stage II uterine sarcoma
1401141|NCT00378781|stage III uterine sarcoma
1401142|NCT00378781|stage IV uterine sarcoma
1401143|NCT00378781|localized osteosarcoma
1401144|NCT00378781|metastatic osteosarcoma
1401145|NCT00378781|recurrent osteosarcoma
1401146|NCT00378781|chondrosarcoma
1401147|NCT00378781|small intestine leiomyosarcoma
1401148|NCT00378781|recurrent small intestine cancer
1401149|NCT00378781|childhood myelodysplastic syndromes
1401150|NCT00380770|HIV
1401151|NCT00380770|AIDS
1401152|NCT00380770|Kaposi's sarcoma
1401153|NCT00380770|Human herpesvirus 8
1401154|NCT00380757|cardiac arrest
1401155|NCT00380757|CPR
1401156|NCT00380757|resuscitation
1401157|NCT00380757|fatigue
1401158|NCT00380757|quality
1401159|NCT00380731|Social Anxiety Disorder
1401160|NCT00380731|Magnetic Resonance Imaging
1401161|NCT00380731|Cognitive Behavior Therapy
1401162|NCT00380640|Pediatrics
1401163|NCT00380640|Epidermolysis Bullosa
1401164|NCT00380640|Trimethoprim
1401165|NCT00380640|Wound Healing
1401166|NCT00380614|Acute Hepatitis B, Lamivudine
1401167|NCT00380575|hyponatremia
1401168|NCT00380575|hypervolemic
1401169|NCT00380575|euvolemic
1401170|NCT00380575|vasopressins
1401171|NCT00380575|YM087
1401172|NCT00380562|Quality of life
1401173|NCT00380562|Cognitive Functioning
1401174|NCT00380562|Activities of Daily Living
1401175|NCT00380562|Disability prevention
1401176|NCT00380549|osteoarthritis, hip replacement
1401177|NCT00380536|Peer-led Education
1401178|NCT00380510|Family Physicians
1401179|NCT00380510|Adolescents
1401180|NCT00380510|Preventive Care
1401181|NCT00380510|Health Behavior
1401182|NCT00380497|Pediatrics
1401183|NCT00380497|Colonoscopy
1401184|NCT00380497|Bowel cleanout
1401185|NCT00380497|Poly-Ethylene Glycol
1401186|NCT00380497|Pico-Salax
1401187|NCT00380471|bath PUVA
1401188|NCT00380458|Obstructive
1401189|NCT00380458|Sleep
1401190|NCT00380458|Apnea
1401191|NCT00380458|Pain
1401192|NCT00380458|UPPP
1401193|NCT00380458|Tonsillectomy
1401194|NCT00380458|Narcotics
1401195|NCT00380445|Vildagliptin, Type 2 diabetes
1401196|NCT00380419|Pregnancy
1401197|NCT00380419|Postpartum Depression
1401198|NCT00380406|Gonadotropin releasing hormone agonist
1401199|NCT00380406|GnRH
1401200|NCT00380406|Fertility
1401201|NCT00380406|Fertility preservation
1401202|NCT00380406|Oncology
1401203|NCT00380406|Cancer
1401204|NCT00380406|Chemotherapy
1401205|NCT00380393|Malaria
1401206|NCT00380393|Plasmodium
1401207|NCT00380393|RTS
1401208|NCT00380393|S/AS01
1401209|NCT00380393|Falciparum
1401210|NCT00380380|Vildagliptin, type 2 diabetes, gastric emptying
1401211|NCT00380354|allergen
1401212|NCT00380354|methacholine
1401213|NCT00380354|GSK256066
1401214|NCT00380354|mild asthmatics
1401215|NCT00380354|repeat dose
1401216|NCT00380354|challenge
1401217|NCT00380354|late asthmatic response
1401218|NCT00380328|Pharmacokinetic
1401219|NCT00380328|healthy subjects
1401220|NCT00380315|Cough
1401221|NCT00380315|Chronic bronchitis
1401222|NCT00380315|PNDs
1401223|NCT00380315|Post Nasal Drip syndrome
1401225|NCT00380315|gastroesophageal reflux disease
1401226|NCT00380315|bronchiectasis
1401227|NCT00380302|Alzheimer's disease
1401228|NCT00380302|symptomatic
1401229|NCT00380302|cognition
1401230|NCT00380289|Essential hypertension
1401231|NCT00380289|Glucose metabolism
1401232|NCT00380289|Thiazides
1401233|NCT00380289|Beta blockers
1401234|NCT00380276|Alzheimer's
1401235|NCT00380276|Dementia
1401236|NCT00380276|Dementia of Alzheimer Type
1401237|NCT00380237|Bird Flu
1401238|NCT00380237|Avian Flu
1401239|NCT00380224|schizophrenia
1401240|NCT00380211|Thimerosal reduced content
1401241|NCT00380211|Immunogenicity, safety, reactogenicity
1401242|NCT00380211|Young and elderly adults
1401243|NCT00380211|Influenza vaccine
1401244|NCT00380185|Peripheral Arterial Disease
1401245|NCT00380185|Atherosclerosis
1401246|NCT00380172|AMD
1401247|NCT00380172|Macular Degeneration
1401248|NCT00380172|Retinal Degeneration
1401249|NCT00380159|Extension study to ACH443-014A
1401250|NCT00380146|Malaria
1401251|NCT00380146|Intermittent presumptive treatment
1401252|NCT00380146|IPT
1401253|NCT00380146|Pharmacokinetic
1401254|NCT00380146|Efficacy
1401255|NCT00380146|Gametocyte
1401256|NCT00380146|Molecular markers
1401257|NCT00380133|COPD SB-681323 prednisolone biomarkers
1401258|NCT00379847|hyponatremia
1401259|NCT00379847|hypervolemic
1401260|NCT00379847|euvolemic
1401261|NCT00379847|treatment outcomes
1401262|NCT00379847|YM087
1401263|NCT00379834|glaucoma
1401264|NCT00379834|diurnal
1401265|NCT00379834|intraocular pressure
1401266|NCT00379821|chloroquine, malaria, Plasmodium falciparum, Malawi, children
1401267|NCT00379808|coronary heart disease
1401268|NCT00379808|montelukast
1401269|NCT00379808|inflammation
1401270|NCT00379795|CNV
1401271|NCT00379795|Lucentis
1401272|NCT00379795|AMD
1401273|NCT00379795|Age-related macular degeneration
1401274|NCT00379795|RVO
1401275|NCT00379769|diabetes
1401276|NCT00379769|CV outcomes
1401277|NCT00379769|rosiglitazone
1401278|NCT00379769|Type II diabetes
1401279|NCT00379769|sulfonylurea
1401280|NCT00379769|RECORD
1401281|NCT00379769|metformin
1401282|NCT00379756|Erectile dysfunction, impotence
1401283|NCT00379730|CT scan
1401284|NCT00379730|breathing tests
1401285|NCT00379730|lung function tests
1401286|NCT00379730|biomarkers
1401287|NCT00379730|prednisolone
1401288|NCT00379730|IOS
1401289|NCT00379730|COPD
1401290|NCT00379730|clinical outcomes
1401291|NCT00379717|helical tomotherapy
1401292|NCT00379717|dose escalation
1401293|NCT00379717|chemotherapy
1401294|NCT00379704|Tissue factor
1401295|NCT00379704|Obesity
1401296|NCT00379704|Adipose tissue
1401297|NCT00379704|Microparticles
1401298|NCT00379691|spinal
1401299|NCT00379691|Cesarean section
1401300|NCT00379691|hypotension
1401301|NCT00379691|nausea
1401302|NCT00379691|vomiting
1401303|NCT00379691|phenylephrine
1401304|NCT00379678|atopic dermatitis
1401305|NCT00379665|Lung
1401306|NCT00379665|Chemotherapy
1401307|NCT00379665|Cisplatin
1401308|NCT00379665|Intratumoral
1401309|NCT00379665|Bronchoscope
1401310|NCT00379665|Brachytherapy
1401311|NCT00379652|Community Health Centers
1401312|NCT00379652|Diabetes
1401313|NCT00379652|Blood Pressure, High
1401314|NCT00379639|Pancreatic cancer
1401315|NCT00379639|advanced solid tumors
1401316|NCT00379626|Paraphilia
1401317|NCT00379626|Hormonal treatment
1401318|NCT00379626|Cognitive treatment
1401319|NCT00379600|Anti-inflammatory treatment
1401320|NCT00379600|Rheumatoid Arthritis
1401321|NCT00379587|Rituximab
1401322|NCT00379587|Chronic GVHD
1401323|NCT00379574|diffuse large B-cell lymphoma
1401324|NCT00379574|Bortezomib
1401325|NCT00379574|CHOP
1401326|NCT00379574|Lenograstim
1401327|NCT00379561|Prostate Cancer
1401328|NCT00379561|Recurrent Prostate Cancer
1401329|NCT00379561|Non-Metastatic prostate cancer
1401330|NCT00379561|Recurrent Localized Prostate Cancer with Biochemical Failure
1401331|NCT00379535|pregnancy , lack of iodine
1401332|NCT00379535|lack of iodine during pregnancy
1401333|NCT00379522|hemorrhagic
1401334|NCT00379522|shock
1401335|NCT00379522|traumatic
1401336|NCT00379522|shock treatment
1401337|NCT00379522|vasopressin
1401338|NCT00379522|Circulatory Collapse
1401339|NCT00379522|Hypovolemic Shock
1401340|NCT00379509|recurrent breast cancer
1401341|NCT00379509|stage IIIA breast cancer
1401342|NCT00379509|stage IIIB breast cancer
1401343|NCT00379509|stage IIIC breast cancer
1401344|NCT00379509|stage IV breast cancer
1401345|NCT00379509|male breast cancer
1401346|NCT00379496|Fibromyalgia
1401347|NCT00379496|Acupuncture
1401348|NCT00379496|Randomized study
1401349|NCT00379483|Transfusional iron overload
1401350|NCT00379483|Deferasirox
1401351|NCT00379470|Brain tumor
1401352|NCT00379470|Treatment
1401353|NCT00379470|Minimal toxicity
1401354|NCT00379470|GBM
1401355|NCT00379470|Glioblastoma
1401356|NCT00379470|Recurrent
1401357|NCT00379470|TTFields
1401358|NCT00379457|alveolar childhood rhabdomyosarcoma
1401359|NCT00379457|previously untreated childhood rhabdomyosarcoma
1401360|NCT00379457|childhood malignant mesenchymoma
1401361|NCT00379457|nonmetastatic childhood soft tissue sarcoma
1401362|NCT00379457|embryonal childhood rhabdomyosarcoma
1401363|NCT00379457|embryonal-botryoid childhood rhabdomyosarcoma
1401364|NCT00379444|tobacco, intervention, tobacco cessation, ALaska Natives,
1401365|NCT00379444|Native Americans, pregnancy, women
1401366|NCT00379405|Saquinavir/ritonavir
1401367|NCT00379405|Single therapy
1401368|NCT00379405|Virological efficacy
1401369|NCT00379405|Safety
1401370|NCT00379405|HIV-1
1401371|NCT00379392|Stroke
1401372|NCT00379392|Mental Imagery
1401373|NCT00379392|Constraint Induced Therapy
1401374|NCT00379379|electroacupuncture, plasma glucose, plasma insulin
1401375|NCT00379366|Randomized Controlled Trials
1401376|NCT00379366|Renal Dialysis
1401377|NCT00379366|Graft Occlusion, Vascular
1401378|NCT00379366|Angioplasty
1401379|NCT00379366|Vascular Patency
1401380|NCT00379366|Radiation, Ionizing
1401381|NCT00379353|Advanced Cancers
1401382|NCT00379353|Anorexia
1401383|NCT00379353|Fatigue
1401384|NCT00379353|Thalidomide
1401385|NCT00379353|Placebo
1401386|NCT00379327|Pregnancy
1401387|NCT00379327|Acupuncture
1401388|NCT00379327|Pregnancy Outcome
1401389|NCT00379327|Randomized Controlled Trial
1401390|NCT00379327|Double-Blind Method
1401391|NCT00379314|Incontinence
1401392|NCT00379314|Urinary
1401393|NCT00379314|Female
1401394|NCT00379314|Surgery
1401395|NCT00379314|Complications
1401396|NCT00379301|Atrial Fibrillation
1401397|NCT00379301|A-Fib
1401398|NCT00379301|AF
1401399|NCT00379301|Persistent
1401400|NCT00379301|Permanent
1401401|NCT00379301|Pulmonary Vein Isolation
1401402|NCT00379301|Ablation
1401403|NCT00379275|Sarcoidosis
1401404|NCT00379275|Uveitis
1401405|NCT00379275|Pulmonary Sarcoidosis
1401406|NCT00379275|HLA-Typing
1401407|NCT00379275|Cytokines
1401408|NCT00379275|Serum Markers
1401409|NCT00379262|Nasopharyngeal Carcinoma
1401410|NCT00379262|Chemoradiotherapy
1401411|NCT00379262|Accelerated Fractionation
1401412|NCT00379249|hypercholesterolemia
1401413|NCT00379249|statin
1401414|NCT00379249|compliance
1401415|NCT00379236|osteoarthritis
1401416|NCT00379236|knee
1401417|NCT00379223|retinal vein occlusion
1401418|NCT00379223|vitrectomy
1401419|NCT00379223|surgery
1401420|NCT00379223|retinal disorders
1401421|NCT00379223|vascular diseases
1401422|NCT00379210|Attention
1401423|NCT00379210|ERP
1401424|NCT00379210|event-related potentials
1401425|NCT00379210|fMRI
1401426|NCT00379210|functional magnetic resonance imaging
1401427|NCT00379210|MBSR
1401428|NCT00379210|Mindfulness Based Stress Reduction
1401429|NCT00379210|Mindfulness Meditation Training
1401430|NCT00379210|MMT
1401431|NCT00379197|stage IV breast cancer, estrogen receptor positive
1401432|NCT00379197|recurrent breast cancer
1401433|NCT00379197|hormone-refractory, metastatic breast cancer
1401434|NCT00379184|arthritis
1401435|NCT00379171|Children
1401436|NCT00379171|Complementary feeding
1401437|NCT00379171|Breast feeding
1401438|NCT00379171|Cow's milk
1401439|NCT00379171|Formula
1401440|NCT00379171|Protein
1401441|NCT00379171|LCPUFA
1401442|NCT00379171|Fish oil
1401443|NCT00379171|Lipid profile
1401444|NCT00379171|Intestinal inflammation
1401445|NCT00379171|Intestinal microbiota
1401446|NCT00379158|multiple micronutrient supplements
1401447|NCT00379158|home-fortification
1401448|NCT00379158|complementary foods
1401449|NCT00379158|infants
1401450|NCT00379158|Ghana
1401451|NCT00379145|uterine leiomyosarcoma
1401452|NCT00379145|recurrent uterine sarcoma
1401453|NCT00379145|stage III uterine sarcoma
1401454|NCT00379145|stage IV uterine sarcoma
1401455|NCT00379132|Glioma
1401456|NCT00379132|prostatic
1401457|NCT00379132|breast
1401458|NCT00379132|non-small cell lung
1401459|NCT00379132|melanoma
1401460|NCT00379132|colorectal
1401461|NCT00379132|pancreatic
1401462|NCT00379119|adenocarcinoma of the prostate
1401463|NCT00379119|recurrent prostate cancer
1401464|NCT00379119|stage I prostate cancer
1401465|NCT00379119|stage IIB prostate cancer
1401466|NCT00379119|stage IIA prostate cancer
1401467|NCT00379119|stage III prostate cancer
1401468|NCT00379106|Supportive
1401469|NCT00379106|Mastectomy
1401470|NCT00379106|Quality of Life
1401471|NCT00379106|Arm Function
1401472|NCT00379093|Alcohol
1401473|NCT00379093|Comorbidity
1401474|NCT00379093|Aging
1401475|NCT00379093|Brief Advice
1401476|NCT00379093|Randomized Trial
1401477|NCT00379067|Benign Prostatic Hyperplasia
1401478|NCT00379067|Nocturia
1401479|NCT00379067|Actigraphy
1401480|NCT00379067|Tamsulosin
1401481|NCT00379054|social support, smoking, smoking cessation, intervention,
1401482|NCT00379054|telephone counseling
1401483|NCT00379041|stage I adult Hodgkin lymphoma
1401484|NCT00379041|stage II adult Hodgkin lymphoma
1401485|NCT00379028|COPD
1401486|NCT00379015|stage IIIB breast cancer
1401487|NCT00379015|stage IIIC breast cancer
1401488|NCT00379015|stage IV breast cancer
1401489|NCT00379002|Interstitial Cystitis
1401490|NCT00379002|Sexual Dysfunction
1401491|NCT00379002|Vulvodynia
1401492|NCT00379002|Pelvic Pain
1401493|NCT00379002|incontinence
1401494|NCT00378976|HIV infection
1401495|NCT00378976|HIV shedding
1401496|NCT00378976|HSV suppression
1401497|NCT00378976|Co-infected
1401498|NCT00378976|MSM
1401499|NCT00378976|Reactivation
1401500|NCT00378976|Valacyclovir
1401501|NCT00378950|Congestive Heart Failure
1401502|NCT00378937|unspecified adult solid tumor, protocol specific
1401503|NCT00378937|pain
1401504|NCT00378885|HIV-prevention
1401505|NCT00378885|Internet Prevention intervention
1401506|NCT00378885|Online randomized controlled trial
1401507|NCT00378885|Effect evaluation
1401508|NCT00378885|MSM
1401509|NCT00378885|Steady relationships
1401510|NCT00378768|stage I multiple myeloma
1401511|NCT00378768|stage II multiple myeloma
1401512|NCT00378768|stage III multiple myeloma
1401513|NCT00378768|refractory multiple myeloma
1401514|NCT00378755|velcade
1401515|NCT00378755|myeloma
1401516|NCT00378755|VAD regimen
1401517|NCT00378755|Transplantation, Autologous
1401518|NCT00378742|Glaucoma
1401519|NCT00378742|Gene
1401520|NCT00378742|Phenotype-Genotype correlation
1401521|NCT00378742|Molecular Diagnosis
1401522|NCT00378742|Retinal Degeneration
1401523|NCT00378742|Inherited Eye Disease
1401524|NCT00378742|Retinitis Pigmentosa
1401525|NCT00378742|Macular Dystrophy
1401526|NCT00378742|Congenital Glaucoma
1401527|NCT00378729|PCOS
1401528|NCT00378729|FERTILOSCOPY
1401529|NCT00378729|Ovarian hyperstimulation
1401530|NCT00378729|Multiple pregnancies
1401531|NCT00378729|Patient with PCOS (Rotterdam criteria)
1401532|NCT00378729|Failure of treatment with Clomiphene Citrate
1401533|NCT00378729|Age between 18 and 36 years old
1401534|NCT00378729|Spermogram must be normal
1401535|NCT00378729|Permeability of Fallopian tubes
1401536|NCT00378716|stage II colon cancer
1401537|NCT00378716|stage III colon cancer
1401538|NCT00378716|adenocarcinoma of the colon
1401539|NCT00378690|Prostate Cancer
1401540|NCT00378690|Prostate Specific Antigen
1401541|NCT00378677|Powder inhalation
1401542|NCT00378677|Side effects
1401543|NCT00378677|Nephrotoxicity
1401544|NCT00378677|Calcineurin inhibitor
1401545|NCT00378677|Bronchiolitis obliterans syndrome
1401546|NCT00378677|Forced Expiratory Volume
1401547|NCT00378664|urinary incontinence
1401548|NCT00378664|spinal cord injury
1401549|NCT00378664|spina bifida
1401550|NCT00378651|Intubation, Endotracheal
1401551|NCT00378651|Anesthesia, General
1401552|NCT00378638|lymph
1401553|NCT00378638|node
1401554|NCT00378638|positive
1401555|NCT00378638|breast
1401556|NCT00378638|cancer
1401557|NCT00378638|metastases
1401558|NCT00378638|angiogenesis
1401559|NCT00378638|bevacizumab
1401560|NCT00378638|chemotherapy
1401561|NCT00378612|trials
1401562|NCT00378612|stents
1401563|NCT00378612|coronary occlusions
1401564|NCT00378547|Tonsillectomy
1401565|NCT00378547|pregabalin
1401566|NCT00378547|dexamethasone
1401567|NCT00378547|multimodal postoperative analgesia
1401568|NCT00378534|Chronic Myelogenous Leukemia (CML)
1401569|NCT00378534|Acute Myelogenous Leukemia (AML)
1401570|NCT00378534|Chronic Lymphocytic Leukemia (CLL)
1401571|NCT00378534|Acute Lymphoblastic Leukemia (ALL)
1401572|NCT00378534|Myelodysplastic Syndrome (MDS)
1401573|NCT00378534|Leukemia
1401574|NCT00378534|Chronic Myelogenous Leukemia
1401575|NCT00378534|CML
1401576|NCT00378534|Acute Myeloid Leukemia
1401577|NCT00378534|AML
1401578|NCT00378534|Chronic Lymphocytic Leukemia
1401579|NCT00378534|CLL
1401580|NCT00378534|Acute Lymphoblastic Leukemia
1401581|NCT00378534|ALL
1401582|NCT00378534|Myelodysplasia Syndrome
1401583|NCT00378521|Raynaud's
1401584|NCT00378521|Nitroglycerin
1401585|NCT00378521|topical gel
1401586|NCT00378521|cold hands
1401587|NCT00378521|painful hands
1401588|NCT00378521|scleroderma
1401589|NCT00378508|immune therapy
1401590|NCT00378508|autoimmunity
1401591|NCT00378508|insulin secretion
1401592|NCT00378508|diabetes mellitus
1401593|NCT00378495|miltefosine
1401594|NCT00378495|kala azar
1401595|NCT00378495|Brazil
1401596|NCT00378482|Melanoma and other tumors
1401597|NCT00378469|Hepcidin
1401598|NCT00378469|Hemojuvelin
1401599|NCT00378469|Iron
1401600|NCT00378469|Healthy volunteers
1401601|NCT00378417|Otitis Media
1401602|NCT00378417|Pneumococcal Infections
1401603|NCT00378417|Pneumococcal Vaccines
1401604|NCT00378417|Proportional Hazards Models
1401605|NCT00378417|Prospective Studies
1401606|NCT00378417|Streptococcus pneumoniae
1401607|NCT00378417|Vaccines, Conjugate
1401608|NCT00378404|NSCLC
1401609|NCT00378404|Non-Small Cell Lung Cancer
1401610|NCT00378404|Non-Small Cell
1401611|NCT00378404|Lung Cancer
1401612|NCT00378404|Docetaxel
1401613|NCT00378404|Radiation
1401614|NCT00378404|Metastatic
1401615|NCT00378404|Recurrent
1401616|NCT00378391|ST-Elevation Myocardial Infarction
1401617|NCT00378391|upstream abciximab
1401618|NCT00378391|guideline adherence
1401619|NCT00378391|hospital networking
1401620|NCT00378365|Acute promyelocytic leukaemia
1401621|NCT00378365|ATRA
1401622|NCT00378365|Idarubicin
1401623|NCT00378365|Arsenic trioxide
1401624|NCT00378365|Patient with a newly acute promyelocytic leukaemia (APL)
1401625|NCT00378365|Unmapped MeSH term
1401626|NCT00378352|Acute Myocardial Infarction
1401627|NCT00378352|Left Ventricular Remodeling
1401628|NCT00378352|Cardiac Magnetic Resonance Imaging
1401629|NCT00378352|Endothelial Progenitor Cells
1401630|NCT00378352|Infarct Size
1401631|NCT00378339|arthrosis
1401632|NCT00378339|gold
1401633|NCT00378326|paraneoplastic syndrome
1401634|NCT00378313|NSABP
1401635|NCT00378313|gemcitabine
1401636|NCT00378313|epirubicin
1401637|NCT00378313|paclitaxel
1401638|NCT00378313|Taxol
1401639|NCT00378313|breast cancer
1401640|NCT00378313|neoadjuvant chemotherapy
1401641|NCT00378313|primary chemotherapy
1401642|NCT00378300|Atopic Dermatitis
1401643|NCT00378300|Probiotics
1401644|NCT00378300|T Regulatory Cells
1401645|NCT00378287|Acid Reflux
1401646|NCT00378287|Proton Pump Inhibitor
1401647|NCT00378287|GERD
1401648|NCT00378274|Neuropathic pain
1401649|NCT00378274|Chronic pain
1401650|NCT00378274|Depression
1401651|NCT00378274|Anxiety
1401652|NCT00378261|Rheumatoid Arthritis
1401653|NCT00378248|Personality disorders,
1401654|NCT00378248|Day treatment,
1401655|NCT00378248|Group psychotherapy,
1401656|NCT00378248|Combined psychotherapy,
1401657|NCT00378248|Outcome,
1401658|NCT00378248|Attachment pattern
1401659|NCT00378235|neurosurgery, craniotomy
1401660|NCT00378235|convection-enhanced delivery
1401661|NCT00378235|CNS interstitial infusion
1401662|NCT00378235|recombinant toxins
1401663|NCT00378235|malignant glioma, recurrent
1401664|NCT00378235|catheter,
1401665|NCT00378235|intratumoral therapy
1401666|NCT00378235|positive pressure microinfusion
1401667|NCT00378222|Myeloma previously untreated
1401668|NCT00378222|Single autologous transplantation
1401669|NCT00378222|Double autologous transplantation
1401670|NCT00378222|Complete response
1401671|NCT00378209|relapsed multiple myeloma
1401672|NCT00378209|refractory multiple myeloma
1401673|NCT00378196|Idiopathic Parafoveal Telangiectasia (IPT)
1401674|NCT00378196|Also Known As Idiopathic Juxtafoveal Telangiectasia (IJFT)
1401675|NCT00378183|weight loss
1401676|NCT00378183|behavioral therapy
1401677|NCT00378183|risperidone
1401678|NCT00378183|switching antipsychotics
1401679|NCT00378183|schizoaffective disorder
1401680|NCT00378183|Risperdal
1401681|NCT00378183|schizophrenia
1401682|NCT00378183|olanzapine
1401683|NCT00378183|Zyprexa
1401684|NCT00378170|intubation
1401685|NCT00378170|difficulty
1401686|NCT00378170|Macintosh
1401687|NCT00378170|dental damage
1401688|NCT00378170|complications
1401689|NCT00378157|autism
1401690|NCT00378157|joint attention
1401691|NCT00378157|intervention
1401692|NCT00378157|joint engagement
1401693|NCT00378157|language
1401694|NCT00378118|HIV-1
1401695|NCT00378118|HIV-2
1401696|NCT00378105|newly diagnosed multiple myeloma
1401697|NCT00378092|Schizophrenia
1401698|NCT00378092|Risperidone
1401699|NCT00378092|Risperdal consta
1401700|NCT00378053|Radiation
1401701|NCT00378053|Exposure
1401702|NCT00378053|Hand
1401703|NCT00378053|Orthopaedic
1401704|NCT00378053|Surgeons
1401705|NCT00378027|Pulmonary Embolism
1401706|NCT00378027|PE
1401707|NCT00378027|Outpatient
1401708|NCT00378027|Anticoagulation
1401709|NCT00378014|Liver transplantation, everolimus, CNI
1401710|NCT00378001|Infertility, FSH, IVF, Ovarian stimulation
1401711|NCT00377988|Contraception
1401712|NCT00377988|Hormonal contraception
1401713|NCT00377988|Oral contraception
1401714|NCT00377988|Ethinyl estradiol
1401715|NCT00377988|Progestin
1401716|NCT00377988|Transdermal
1401717|NCT00377988|Thrombosis
1401718|NCT00377988|Venous thromboembolism
1401719|NCT00377975|UCP-1
1401720|NCT00377975|ephedrine
1401721|NCT00377975|caffeine
1401722|NCT00377975|pioglitazone
1401723|NCT00377962|thoracic transplant recipients
1401724|NCT00377962|everolimus
1401725|NCT00377962|immunosuppressants
1401726|NCT00377949|Systemic Sclerosis
1401727|NCT00377949|Scleroderma
1401728|NCT00377949|Pulmonary Hypertension
1401729|NCT00377949|PHAROS
1401730|NCT00377949|PHROS
1401731|NCT00377949|Exercise Echocardiogram
1401732|NCT00377949|Pulmonary Functional Tests
1401733|NCT00377949|Six minute walk tests
1401734|NCT00377949|6 minute walk tests
1401735|NCT00377949|Right heart catheterization
1401736|NCT00377936|Adenocarcinoma of the pancreas
1401737|NCT00377936|Locally advanced
1401738|NCT00377936|Metastatic
1401739|NCT00377923|pharmacodynamic and pharmacokinetic study
1401740|NCT00377923|Progesterone
1401741|NCT00377923|healthy volunteers
1401742|NCT00377923|Endometrial decidualisation
1401743|NCT00377910|Chronic Achilles tendinopathy
1401744|NCT00377910|Polidocanol
1401745|NCT00377910|Ultrasound
1401746|NCT00377910|Efficacy
1401747|NCT00377910|RCT
1401748|NCT00377897|critical leg ischemia
1401749|NCT00377897|PAD
1401750|NCT00377897|cell therapy
1401751|NCT00377884|THA
1401752|NCT00377871|Stentless
1401753|NCT00377871|Biological
1401754|NCT00377871|aortic
1401755|NCT00377871|heart
1401756|NCT00377871|valve
1401757|NCT00377871|prosthesis
1401758|NCT00377871|artificial
1401759|NCT00377858|diabetes
1401760|NCT00377858|type 2
1401761|NCT00377845|self test
1401762|NCT00377845|PAP smear
1401763|NCT00377845|tampon test
1401764|NCT00377845|cervical dysplasia
1401765|NCT00377832|Fetal tachycardia
1401766|NCT00377832|Fever in labor
1401767|NCT00377832|Acetaminophen
1401768|NCT00377832|Non reassuring fetal status
1401769|NCT00377819|RANKL
1401770|NCT00377819|RANK
1401771|NCT00377819|denosumab
1401772|NCT00377819|AMG 162
1401773|NCT00377819|osteoporosis
1401774|NCT00377819|bone turnover
1401775|NCT00377819|bone mineral density
1401776|NCT00377819|clinical trial
1401777|NCT00377819|postmenopausal osteoporosis
1401778|NCT00377819|alendronate
1401779|NCT00377819|total hip bone mineral density
1401780|NCT00377806|Superficial thrombophlebitis, diclofenac gel, non steroidal antiinflammatory drugs
1401781|NCT00377780|Breast cancer
1401782|NCT00377780|metastatic
1401783|NCT00377780|cardiotoxicity
1401784|NCT00377780|liposomal
1401785|NCT00377780|doxorubicin
1401786|NCT00377780|trastuzumab
1401787|NCT00377780|docetaxel
1401788|NCT00377780|HER2/neu positive metastatic breast cancer
1401789|NCT00377767|Chronic Care Model
1401790|NCT00377767|Obesity
1401791|NCT00377767|Overweight
1401792|NCT00377767|Children
1401793|NCT00377767|Body Mass Index
1401794|NCT00377767|Primary Care
1401795|NCT00377754|dengue virus, immunity, hemorrhagic fever, Philippines
1401796|NCT00377728|Seasonal Allergic Rhinitis Inflammation Vienna CHallenge Chamber
1401797|NCT00377715|Dimebon, Alzheimer's Disease, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)
1401798|NCT00377702|Coronary Heart Disease
1401799|NCT00377702|Risk Factors
1401800|NCT00377702|Heart Failure
1401801|NCT00377689|Accidental falls
1401802|NCT00377689|Cerebrovascular accident
1401803|NCT00377689|Balance
1401804|NCT00377689|ADL
1401805|NCT00377689|Self efficacy
1401806|NCT00377689|Quality of Life
1401807|NCT00377689|Gait parameters
1401808|NCT00377676|diabetes
1401809|NCT00377676|diabetes mellitus
1401810|NCT00377611|Influenza vaccine
1401811|NCT00377598|Herpes Zoster
1401812|NCT00377598|Neuralgia
1401813|NCT00377598|Drug Therapy
1401814|NCT00377585|Elderly
1401815|NCT00377585|Improved vaccine
1401816|NCT00377585|Influenza
1401817|NCT00377585|Influenza disease
1401818|NCT00377572|Immunoglobulins
1401819|NCT00377572|Immunoglobulin E
1401820|NCT00377572|omalizumab
1401821|NCT00377572|anti-IgE
1401822|NCT00377559|Breast cancer
1401823|NCT00377559|metastatic
1401824|NCT00377559|cardiotoxicity
1401825|NCT00377559|liposomal
1401826|NCT00377559|doxorubicin
1401827|NCT00377559|docetaxel
1401828|NCT00377559|HER2/neu negative metastatic breast cancer
1401829|NCT00375583|Lymphatic Filariasis
1401830|NCT00375583|Diethylcarbamazine
1401831|NCT00375583|Microfilariae
1401832|NCT00375583|Helminths
1401833|NCT00375583|Nematode
1401834|NCT00377546|Retinal Surgery
1401835|NCT00377533|wheelchairs
1401836|NCT00377533|caregivers
1401837|NCT00377533|skills
1401838|NCT00377507|catechin
1401839|NCT00377507|elderly
1401840|NCT00377507|mouth washing
1401841|NCT00377507|disabled
1401842|NCT00377507|colonized
1401843|NCT00377494|malaria, Plasmodium falciparum, vaccine, Ghana
1401844|NCT00377468|THC
1401845|NCT00377468|CRPS
1401846|NCT00377468|Pain
1401847|NCT00377468|Complex Regional Pain Syndrome
1401848|NCT00377468|Neuropathic Pain
1401849|NCT00377468|Chronic
1401850|NCT00377468|Prevention
1401851|NCT00377455|scleroderma
1401852|NCT00377455|systemic sclerosis
1401853|NCT00377455|bosentan
1401854|NCT00377455|pulmonary hypertension
1401855|NCT00377455|PHAROS
1401856|NCT00377455|PHROS
1401857|NCT00377455|exercise echocardiogram
1401858|NCT00377429|Epithelial Cancer
1401859|NCT00377429|Epithelial Carcinoma
1401860|NCT00377429|Epithelial Ovarian Cancer
1401861|NCT00377429|Epithelial Ovarian Carcinoma
1401862|NCT00377429|Fallopian Tube Cancer
1401863|NCT00377429|Fallopian Tube Carcinoma
1401864|NCT00377429|Ovarian Cancer
1401865|NCT00377429|Ovarian Carcinoma
1401866|NCT00377429|Ovarian Epithelial Cancer
1401867|NCT00377429|Ovarian Epithelial Carcinoma
1401868|NCT00377429|Peritoneal Cancer
1401869|NCT00377429|Peritoneal Carcinoma
1401870|NCT00377429|Advanced Epithelial Ovarian Cancer
1401871|NCT00377416|Gene Transfer Techniques
1401872|NCT00377416|Gene Therapy
1401873|NCT00377403|rhinosinusitis, sinusitis, amoxicillin
1401874|NCT00377390|Immunoglobulin
1401875|NCT00377390|IgE
1401876|NCT00377390|Omalizumab
1401877|NCT00377377|GH release
1401878|NCT00377377|Pharmacokinetics
1401879|NCT00377377|Safety
1401880|NCT00377364|Acetaminophen
1401881|NCT00377364|corticosteroids
1401882|NCT00377364|prednisone
1401883|NCT00377351|Public Health
1401884|NCT00377351|Elderly Population
1401885|NCT00377351|Neurodegenerative Diseases
1401886|NCT00377351|Exposure
1401887|NCT00377351|Lifestyle
1401888|NCT00377338|Bronchoscopy
1401889|NCT00377338|Diagnostic imaging
1401890|NCT00377338|Laser scanning confocal microscopy
1401891|NCT00377338|Pulmonary Alveoli
1401892|NCT00377338|Healthy volunteers
1401893|NCT00377338|Diffuse peripheral lung disease
1401894|NCT00377338|Focal peripheral lung disease
1401895|NCT00377312|Endocrine System Diseases
1401896|NCT00377312|MusculoSkeletal System Disease
1401897|NCT00377312|Hormone
1401898|NCT00377312|Physiologic Properties
1401899|NCT00377299|Amphetamine Abuse
1401900|NCT00377299|Amphetamine Dependence
1401901|NCT00377299|Bipolar Disorder
1401902|NCT00377299|Major Depressive Disorder
1401903|NCT00377299|Citicoline
1401904|NCT00377286|Osteoarthritis
1401905|NCT00377286|Knee Pain
1401906|NCT00377286|Glucosamine
1401907|NCT00377286|MRI
1401908|NCT00377286|CTX-II
1401909|NCT00377286|Biomarkers
1401910|NCT00377286|Skin quality
1401911|NCT00377260|acute otitis media, infants, children
1401912|NCT00377247|Carcinoma
1401913|NCT00377247|Head
1401914|NCT00377247|Neck
1401915|NCT00377247|Oral Cavity
1401916|NCT00377247|Oropharynx
1401917|NCT00377247|Mouth
1401918|NCT00377208|Blood Pressure, High
1401919|NCT00377195|Marginal Zone Lymphoma
1401920|NCT00377195|Involved field radiotherapy
1401921|NCT00377195|H. pylori
1401922|NCT00377169|Treatment Experienced
1401923|NCT00377156|cognitive/functional effects
1401924|NCT00377156|tumors metastatic to brain
1401925|NCT00377156|stage IV breast cancer
1401926|NCT00377156|stage IV prostate cancer
1401927|NCT00377156|stage IV non-small cell lung cancer
1401928|NCT00377156|male breast cancer
1401929|NCT00377156|recurrent breast cancer
1401930|NCT00377156|recurrent prostate cancer
1401931|NCT00377156|recurrent non-small cell lung cancer
1401932|NCT00377143|warfarin
1401933|NCT00377143|pharmacogenomic
1401934|NCT00377143|CYP2C9
1401935|NCT00377143|VKORC1
1401936|NCT00377143|polymorphism, single nucleotide
1401937|NCT00377130|psychosocial effects of cancer and its treatment
1401938|NCT00377130|unspecified adult solid tumor, protocol specific
1401939|NCT00377091|pulmonary embolism
1401940|NCT00377091|venous thromboembolism
1401941|NCT00377091|pharmacoeconomic
1401942|NCT00377091|heparin
1401943|NCT00377091|unfractionated heparin
1401944|NCT00377091|fondaparinux
1401945|NCT00377091|length of stay
1401946|NCT00377091|costs
1401947|NCT00377091|bleeding
1401948|NCT00377091|thrombosis
1401949|NCT00377078|recombinant human lactoferrin
1401950|NCT00377052|recurrent mantle cell lymphoma
1401951|NCT00377039|ACR 1990 Fibromyalgia
1401952|NCT00377039|Fibromyalgia Impact Questionnaire
1401953|NCT00377026|weight loss
1401954|NCT00377026|postpartum
1401955|NCT00377026|weight retention
1401956|NCT00376987|renal cell carcinoma
1401957|NCT00376987|bladder cancer
1401958|NCT00376987|cervical cancer
1401959|NCT00376987|esophageal cancer
1401960|NCT00376987|gastric cancer
1401961|NCT00376987|adult acute myeloid leukemia
1401962|NCT00376987|pancreatic cancer
1401963|NCT00376987|hypopharyngeal cancer
1401964|NCT00376987|lip and oral cavity cancer
1401965|NCT00376987|laryngeal cancer
1401966|NCT00376987|nasopharyngeal cancer
1401967|NCT00376987|oropharyngeal cancer
1401968|NCT00376987|paranasal sinus and nasal cavity cancer
1401969|NCT00376987|non-small cell lung cancer
1401970|NCT00376987|small cell lung cancer
1401971|NCT00376987|adult primary liver cancer
1401972|NCT00376987|tongue cancer
1401973|NCT00376987|tobacco use disorder
1401974|NCT00376974|glaucoma
1401975|NCT00376974|compliance
1401976|NCT00376974|intraocular pressure
1401977|NCT00376974|video
1401978|NCT00376961|contiguous stage II mantle cell lymphoma
1401979|NCT00376961|noncontiguous stage II mantle cell lymphoma
1401980|NCT00376961|stage III mantle cell lymphoma
1401981|NCT00376961|stage IV mantle cell lymphoma
1402175|NCT00376805|stage IV breast cancer
1401982|NCT00376948|adenocarcinoma of the pancreas
1401983|NCT00376948|stage III pancreatic cancer
1401984|NCT00376948|stage IV pancreatic cancer
1401985|NCT00376948|recurrent pancreatic cancer
1401986|NCT00376935|Treatment Experienced
1401987|NCT00376922|pain
1401988|NCT00376922|psychosocial effects of cancer and its treatment
1401989|NCT00376922|accelerated phase chronic myelogenous leukemia
1401990|NCT00376922|acute undifferentiated leukemia
1401991|NCT00376922|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1401992|NCT00376922|adult acute myeloid leukemia with inv(16)(p13;q22)
1401993|NCT00376922|adult acute myeloid leukemia with t(15;17)(q22;q12)
1401994|NCT00376922|adult acute myeloid leukemia with t(16;16)(p13;q22)
1401995|NCT00376922|adult acute myeloid leukemia with t(8;21)(q22;q22)
1401996|NCT00376922|atypical chronic myeloid leukemia, BCR-ABL1 negative
1401997|NCT00376922|blastic phase chronic myelogenous leukemia
1401998|NCT00376922|chronic eosinophilic leukemia
1401999|NCT00376922|primary myelofibrosis
1402000|NCT00376922|chronic myelomonocytic leukemia
1402001|NCT00376922|chronic neutrophilic leukemia
1402002|NCT00376922|chronic phase chronic myelogenous leukemia
1402003|NCT00376922|de novo myelodysplastic syndromes
1402004|NCT00376922|essential thrombocythemia
1402005|NCT00376922|extramedullary plasmacytoma
1402006|NCT00376922|meningeal chronic myelogenous leukemia
1402007|NCT00376922|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1402008|NCT00376922|polycythemia vera
1402009|NCT00376922|previously treated myelodysplastic syndromes
1402010|NCT00376922|primary systemic amyloidosis
1402011|NCT00376922|progressive hairy cell leukemia, initial treatment
1402012|NCT00376922|prolymphocytic leukemia
1402013|NCT00376922|secondary acute myeloid leukemia
1402014|NCT00376922|secondary myelodysplastic syndromes
1402015|NCT00376922|stage III adult T-cell leukemia/lymphoma
1402016|NCT00376922|stage III chronic lymphocytic leukemia
1402017|NCT00376922|stage III multiple myeloma
1402018|NCT00376922|stage IV adult T-cell leukemia/lymphoma
1402019|NCT00376922|stage IV chronic lymphocytic leukemia
1402020|NCT00376922|relapsing chronic myelogenous leukemia
1402021|NCT00376922|adult acute lymphoblastic leukemia in remission
1402022|NCT00376922|recurrent adult acute lymphoblastic leukemia
1402023|NCT00376922|untreated adult acute lymphoblastic leukemia
1402024|NCT00376922|adult acute myeloid leukemia in remission
1402025|NCT00376922|recurrent adult acute myeloid leukemia
1402026|NCT00376922|untreated adult acute myeloid leukemia
1402027|NCT00376922|mast cell leukemia
1402028|NCT00376922|stage I adult T-cell leukemia/lymphoma
1402029|NCT00376922|stage II adult T-cell leukemia/lymphoma
1402030|NCT00376922|T-cell large granular lymphocyte leukemia
1402031|NCT00376922|stage I chronic lymphocytic leukemia
1402032|NCT00376922|stage II chronic lymphocytic leukemia
1402033|NCT00376922|refractory hairy cell leukemia
1402034|NCT00376922|recurrent adult T-cell leukemia/lymphoma
1402035|NCT00376922|refractory chronic lymphocytic leukemia
1402036|NCT00376922|untreated hairy cell leukemia
1402037|NCT00376922|recurrent adult Hodgkin lymphoma
1402038|NCT00376922|stage I adult Hodgkin lymphoma
1402039|NCT00376922|stage II adult Hodgkin lymphoma
1402040|NCT00376922|stage III adult Hodgkin lymphoma
1402041|NCT00376922|stage IV adult Hodgkin lymphoma
1402042|NCT00376922|anaplastic large cell lymphoma
1402043|NCT00376922|angioimmunoblastic T-cell lymphoma
1402044|NCT00376922|recurrent mycosis fungoides/Sezary syndrome
1402045|NCT00376922|stage I mycosis fungoides/Sezary syndrome
1402046|NCT00376922|stage II mycosis fungoides/Sezary syndrome
1402047|NCT00376922|stage III mycosis fungoides/Sezary syndrome
1402048|NCT00376922|stage IV mycosis fungoides/Sezary syndrome
1402049|NCT00376922|recurrent cutaneous T-cell non-Hodgkin lymphoma
1402050|NCT00376922|stage I cutaneous T-cell non-Hodgkin lymphoma
1402051|NCT00376922|stage II cutaneous T-cell non-Hodgkin lymphoma
1402052|NCT00376922|stage III cutaneous T-cell non-Hodgkin lymphoma
1402053|NCT00376922|stage IV cutaneous T-cell non-Hodgkin lymphoma
1402054|NCT00376922|adult grade III lymphomatoid granulomatosis
1402055|NCT00376922|recurrent adult grade III lymphomatoid granulomatosis
1402056|NCT00376922|Waldenström macroglobulinemia
1402057|NCT00376922|contiguous stage II adult Burkitt lymphoma
1402058|NCT00376922|noncontiguous stage II adult Burkitt lymphoma
1402059|NCT00376922|recurrent adult Burkitt lymphoma
1402060|NCT00376922|stage I adult Burkitt lymphoma
1402061|NCT00376922|stage III adult Burkitt lymphoma
1402062|NCT00376922|stage IV adult Burkitt lymphoma
1402063|NCT00376922|contiguous stage II adult diffuse large cell lymphoma
1402064|NCT00376922|contiguous stage II adult diffuse mixed cell lymphoma
1402065|NCT00376922|contiguous stage II adult diffuse small cleaved cell lymphoma
1402066|NCT00376922|noncontiguous stage II adult diffuse large cell lymphoma
1402067|NCT00376922|noncontiguous stage II adult diffuse mixed cell lymphoma
1402068|NCT00376922|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1402069|NCT00376922|recurrent adult diffuse large cell lymphoma
1402070|NCT00376922|recurrent adult diffuse mixed cell lymphoma
1402071|NCT00376922|recurrent adult diffuse small cleaved cell lymphoma
1402072|NCT00376922|stage I adult diffuse large cell lymphoma
1402073|NCT00376922|stage I adult diffuse mixed cell lymphoma
1402074|NCT00376922|stage I adult diffuse small cleaved cell lymphoma
1402176|NCT00376805|male breast cancer
1402075|NCT00376922|stage III adult diffuse large cell lymphoma
1402076|NCT00376922|stage III adult diffuse mixed cell lymphoma
1402077|NCT00376922|stage III adult diffuse small cleaved cell lymphoma
1402078|NCT00376922|stage IV adult diffuse large cell lymphoma
1402079|NCT00376922|stage IV adult diffuse mixed cell lymphoma
1402080|NCT00376922|stage IV adult diffuse small cleaved cell lymphoma
1402081|NCT00376922|contiguous stage II adult immunoblastic large cell lymphoma
1402082|NCT00376922|noncontiguous stage II adult immunoblastic large cell lymphoma
1402083|NCT00376922|recurrent adult immunoblastic large cell lymphoma
1402084|NCT00376922|stage I adult immunoblastic large cell lymphoma
1402085|NCT00376922|stage III adult immunoblastic large cell lymphoma
1402086|NCT00376922|stage IV adult immunoblastic large cell lymphoma
1402087|NCT00376922|contiguous stage II adult lymphoblastic lymphoma
1402088|NCT00376922|noncontiguous stage II adult lymphoblastic lymphoma
1402089|NCT00376922|recurrent adult lymphoblastic lymphoma
1402090|NCT00376922|stage I adult lymphoblastic lymphoma
1402091|NCT00376922|stage III adult lymphoblastic lymphoma
1402092|NCT00376922|stage IV adult lymphoblastic lymphoma
1402093|NCT00376922|contiguous stage II grade 1 follicular lymphoma
1402094|NCT00376922|contiguous stage II grade 2 follicular lymphoma
1402095|NCT00376922|contiguous stage II grade 3 follicular lymphoma
1402096|NCT00376922|noncontiguous stage II grade 1 follicular lymphoma
1402097|NCT00376922|noncontiguous stage II grade 2 follicular lymphoma
1402098|NCT00376922|noncontiguous stage II grade 3 follicular lymphoma
1402099|NCT00376922|recurrent grade 1 follicular lymphoma
1402100|NCT00376922|recurrent grade 2 follicular lymphoma
1402101|NCT00376922|recurrent grade 3 follicular lymphoma
1402102|NCT00376922|stage I grade 1 follicular lymphoma
1402103|NCT00376922|stage I grade 2 follicular lymphoma
1402104|NCT00376922|stage I grade 3 follicular lymphoma
1402105|NCT00376922|stage III grade 1 follicular lymphoma
1402106|NCT00376922|stage III grade 2 follicular lymphoma
1402107|NCT00376922|stage III grade 3 follicular lymphoma
1402108|NCT00376922|stage IV grade 1 follicular lymphoma
1402109|NCT00376922|stage IV grade 2 follicular lymphoma
1402110|NCT00376922|stage IV grade 3 follicular lymphoma
1402111|NCT00376922|contiguous stage II mantle cell lymphoma
1402112|NCT00376922|noncontiguous stage II mantle cell lymphoma
1402113|NCT00376922|recurrent mantle cell lymphoma
1402114|NCT00376922|stage I mantle cell lymphoma
1402115|NCT00376922|stage III mantle cell lymphoma
1402116|NCT00376922|stage IV mantle cell lymphoma
1402117|NCT00376922|contiguous stage II marginal zone lymphoma
1402118|NCT00376922|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1402119|NCT00376922|nodal marginal zone B-cell lymphoma
1402120|NCT00376922|noncontiguous stage II marginal zone lymphoma
1402121|NCT00376922|recurrent marginal zone lymphoma
1402122|NCT00376922|splenic marginal zone lymphoma
1402123|NCT00376922|stage I marginal zone lymphoma
1402124|NCT00376922|stage III marginal zone lymphoma
1402125|NCT00376922|stage IV marginal zone lymphoma
1402126|NCT00376922|contiguous stage II small lymphocytic lymphoma
1402127|NCT00376922|noncontiguous stage II small lymphocytic lymphoma
1402128|NCT00376922|recurrent small lymphocytic lymphoma
1402129|NCT00376922|stage I small lymphocytic lymphoma
1402130|NCT00376922|stage III small lymphocytic lymphoma
1402131|NCT00376922|stage IV small lymphocytic lymphoma
1402132|NCT00376922|isolated plasmacytoma of bone
1402133|NCT00376922|monoclonal gammopathy of undetermined significance
1402134|NCT00376922|refractory multiple myeloma
1402135|NCT00376922|stage I multiple myeloma
1402136|NCT00376922|stage II multiple myeloma
1402137|NCT00376922|post-transplant lymphoproliferative disorder
1402138|NCT00376922|primary central nervous system non-Hodgkin lymphoma
1402139|NCT00376909|breast cancer
1402140|NCT00376909|cervical cancer
1402141|NCT00376909|colon cancer
1402142|NCT00376909|rectal cancer
1402143|NCT00376896|IBS fMRI
1402144|NCT00376883|multiple myeloma
1402145|NCT00376883|pamidronate prophylaxis
1402146|NCT00376883|dose comparison
1402147|NCT00376883|quality of life
1402148|NCT00376883|skeletal event
1402149|NCT00376883|response
1402150|NCT00376883|survival
1402151|NCT00376870|PCI
1402152|NCT00376870|STENT
1402153|NCT00376870|Coronary
1402154|NCT00376870|Type 2 Diabetes Mellitus
1402155|NCT00376857|Indocyanine green, toxicity, epiretinal membrane, visual field defect
1402156|NCT00376844|stage I endometrial carcinoma
1402157|NCT00376831|colonoscopy
1402158|NCT00376831|conscious sedation
1402159|NCT00376831|midazolam
1402160|NCT00376831|ketamine
1402161|NCT00376831|fentanyl
1402162|NCT00376818|psychosocial effects of cancer and its treatment
1402163|NCT00376818|adult anaplastic astrocytoma
1402164|NCT00376818|adult anaplastic ependymoma
1402165|NCT00376818|adult anaplastic oligodendroglioma
1402166|NCT00376818|adult giant cell glioblastoma
1402167|NCT00376818|adult gliosarcoma
1402168|NCT00376818|adult medulloblastoma
1402169|NCT00376818|adult anaplastic meningioma
1402170|NCT00376818|adult papillary meningioma
1402171|NCT00376818|adult mixed glioma
1402172|NCT00376818|recurrent adult brain tumor
1402173|NCT00376818|adult glioblastoma
1402174|NCT00376818|adult grade III meningioma
1402177|NCT00376805|recurrent breast cancer
1402178|NCT00376792|stage IIB prostate cancer
1402179|NCT00376792|stage IIA prostate cancer
1402180|NCT00376792|stage III prostate cancer
1402181|NCT00376792|adenocarcinoma of the prostate
1402182|NCT00376779|Haemophilus influenzae type b
1402183|NCT00376779|Double-blind
1402184|NCT00376779|Finland
1402185|NCT00376779|randomized
1402186|NCT00376779|phase 2
1402187|NCT00376779|GSK Biologicals
1402188|NCT00376779|DTPa-HBV-IPV/Hib
1402189|NCT00376766|Cluster seizure
1402190|NCT00376766|seizure clustering
1402191|NCT00376766|repetitive seizure
1402192|NCT00376766|Drug resistant epilepsy
1402193|NCT00376766|Levetiracetam
1402194|NCT00376766|keppra
1402195|NCT00376753|Transcranial Magnetic Stimulation (TMS)
1402196|NCT00376753|Writer's Cramp
1402197|NCT00376753|Electromyogram
1402198|NCT00376753|Focal Hand Dystonia
1402199|NCT00376753|FHD
1402200|NCT00376753|Healthy Volunteer
1402201|NCT00376753|HV
1402202|NCT00376740|breast cancer, postmenopausal, letrozole, zoledronic acid, adjuvant,bone mineral density
1402203|NCT00376727|unspecified adult solid tumor, protocol specific
1402204|NCT00376714|plethysmography
1402205|NCT00376714|muscarinic receptor antagonist
1402206|NCT00376714|COPD
1402207|NCT00376714|repeat dosing
1402208|NCT00376701|Choroidal Neovascularization
1402209|NCT00376701|Photodynamic Therapy
1402210|NCT00376701|Age Related Macular Degeneration
1402211|NCT00376701|Triamcinolone Acetonide
1402212|NCT00376701|Avastin
1402213|NCT00376701|Visudyne
1402214|NCT00376675|fatigue
1402215|NCT00376675|unspecified adult solid tumor, protocol specific
1402216|NCT00376662|HRT
1402217|NCT00376662|Etidronate
1402218|NCT00376662|Fractures
1402219|NCT00376662|Osteoporosis
1402220|NCT00376662|Asthma
1402221|NCT00376662|Glucocorticoids
1402222|NCT00376649|crohns
1402223|NCT00376649|quality of life
1402224|NCT00376649|lifestyle changing
1402225|NCT00376649|remmision
1402226|NCT00375544|Laser Therapy, Low-Level
1402227|NCT00375544|Osteoarthritis
1402228|NCT00375544|Phototherapy
1402229|NCT00375544|Osteoarthritis, knee
1402230|NCT00375544|Light-emitting diode
1402231|NCT00375531|Post Traumatic Stress Disorder
1402232|NCT00375531|Mindfulness Meditation
1402233|NCT00375518|Thoracic Surgery
1402234|NCT00375518|Cardiopulmonary complications
1402235|NCT00375518|Atorvastatin
1402236|NCT00376597|lymphedema
1402237|NCT00376597|stage IA breast cancer
1402238|NCT00376597|stage IB breast cancer
1402239|NCT00376597|stage II breast cancer
1402240|NCT00376597|stage IIIA breast cancer
1402241|NCT00376597|stage IIIB breast cancer
1402242|NCT00376597|stage IIIC breast cancer
1402243|NCT00376584|Primary Hypercholesteremia
1402244|NCT00376584|Mixed Hyperlipidemia
1402245|NCT00376571|PCI
1402246|NCT00376571|Bifurcation lesion
1402247|NCT00376558|cocaine dependence
1402248|NCT00376545|Functional Magnetic Resonance Imaging (fMRI)
1402249|NCT00376545|Visuomotor
1402250|NCT00376545|Occipital Cortex
1402251|NCT00376545|Prefrontal Cortex
1402252|NCT00376545|Healthy Volunteer
1402253|NCT00376545|HV
1402254|NCT00376532|Cardiac Ischemia
1402255|NCT00376532|Cardiac Arrhythmia
1402256|NCT00376532|Defibrillator
1402257|NCT00376532|Matrix Metalloproteinase
1402258|NCT00376532|Genetic Polymorphism
1402259|NCT00376519|graft versus host disease
1402260|NCT00376519|adult acute lymphoblastic leukemia in remission
1402261|NCT00376519|adult acute myeloid leukemia in remission
1402262|NCT00376519|secondary acute myeloid leukemia
1402263|NCT00376519|refractory anemia with excess blasts
1402264|NCT00376519|myelodysplastic syndromes
1402265|NCT00376519|chronic myelogenous leukemia
1402266|NCT00376519|refractory anemia
1402267|NCT00376519|prolymphocytic leukemia
1402268|NCT00376519|stage IV adult lymphoblastic lymphoma
1402269|NCT00376519|recurrent adult Burkitt lymphoma
1402270|NCT00376519|stage I adult Burkitt lymphoma
1402271|NCT00376519|stage III adult Burkitt lymphoma
1402272|NCT00376519|stage IV adult Burkitt lymphoma
1402273|NCT00376519|follicular lymphoma
1402274|NCT00376519|mantle cell lymphoma
1402275|NCT00376519|chronic idiopathic myelofibrosis
1402276|NCT00376519|secondary myelofibrosis
1402277|NCT00376519|refractory chronic lymphocytic leukemia
1402278|NCT00376519|recurrent small lymphocytic lymphoma
1402279|NCT00376519|recurrent marginal zone lymphoma
1402280|NCT00376519|marginal zone lymphoma
1402281|NCT00376519|diffuse large cell lymphoma
1402282|NCT00376519|anaplastic large cell lymphoma
1402283|NCT00376519|lymphoblastic lymphoma
1402284|NCT00376519|immunoblastic large cell lymphoma
1402285|NCT00376519|multiple myeloma
1402286|NCT00376506|Aspiration
1402287|NCT00376506|Rehabilitation
1402288|NCT00376506|Swallowing Disorders
1402289|NCT00376506|Stroke
1402290|NCT00376506|Parkinson's Disease
1402291|NCT00376506|Dysphagia
1402292|NCT00376506|Parkinson Disease
1402293|NCT00376506|PD
1402294|NCT00376493|Abortion
1402295|NCT00376493|Infection
1402296|NCT00376493|Antibiotics
1402297|NCT00376493|Treatment
1402298|NCT00376493|Pregnancy complications
1402299|NCT00376480|refractory anemia with excess blasts in transformation
1402300|NCT00376480|adult acute lymphoblastic leukemia in remission
1402301|NCT00376480|refractory anemia with excess blasts
1402302|NCT00376480|refractory anemia
1402303|NCT00376480|adult acute myeloid leukemia in remission
1402304|NCT00376480|childhood acute lymphoblastic leukemia in remission
1402305|NCT00376480|childhood acute myeloid leukemia in remission
1402306|NCT00376480|de novo myelodysplastic syndromes
1402307|NCT00376480|previously treated myelodysplastic syndromes
1402308|NCT00376480|secondary acute myeloid leukemia
1402309|NCT00376480|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1402310|NCT00376480|adult acute myeloid leukemia with inv(16)(p13;q22)
1402311|NCT00376480|adult acute myeloid leukemia with t(15;17)(q22;q12)
1402312|NCT00376480|adult acute myeloid leukemia with t(16;16)(p13;q22)
1402313|NCT00376480|adult acute myeloid leukemia with t(8;21)(q22;q22)
1402314|NCT00376480|secondary myelodysplastic syndromes
1402315|NCT00376480|childhood myelodysplastic syndromes
1402316|NCT00376467|Acute Lymphoblastic Leukemia
1402317|NCT00376467|Philadelphia positive
1402318|NCT00376467|Adult
1402319|NCT00376467|Elderly
1402320|NCT00376467|Imatinib
1402321|NCT00376454|neuropathic pain
1402322|NCT00376441|vaginal
1402323|NCT00376441|incontinence
1402324|NCT00376441|sexual function
1402325|NCT00376428|Cystic Fibrosis Transmembrane Conductance Regulator
1402326|NCT00376428|Premature termination codon
1402327|NCT00376428|Gentamicin-induced readthrough
1402328|NCT00376415|Lessertia frutescens
1402329|NCT00376415|Sutherlandia frutescens
1402330|NCT00376415|Phase 1 clinical trial
1402331|NCT00376415|Human safety study
1402332|NCT00376402|Pandemic
1402333|NCT00376402|Influenza
1402334|NCT00376402|Prevention
1402335|NCT00376402|Vaccine
1402336|NCT00376402|Prevention of Pandemic Influenza
1402337|NCT00376376|levofloxacin
1402338|NCT00376376|pharmacodynamic
1402339|NCT00376376|bactericidal
1402340|NCT00376363|glaucoma
1402341|NCT00376363|Ahmed implant
1402342|NCT00376363|Baerveldt implant
1402343|NCT00376350|Low Back Pain
1402344|NCT00376350|Chronic
1402345|NCT00376350|Manipulation
1402346|NCT00376350|Chiropractic
1402347|NCT00376350|Massage
1402348|NCT00376337|Invasive Aspergillosis
1402349|NCT00376337|Salvage Therapy
1402350|NCT00376337|Micafungin
1402351|NCT00376324|pharmacokinetics
1402352|NCT00376324|human bone
1402353|NCT00376311|Lequesne's algo-functional score
1402354|NCT00376311|Biomarkers of joint metabolism
1402355|NCT00376298|incontinence
1402356|NCT00376298|prostate cancer
1402357|NCT00376298|interstitial cystitis
1402358|NCT00376272|atrial fibrillation,atrial remodeling,dysrhythmias,valsartan
1402359|NCT00376259|lamivudine resistance
1402360|NCT00376259|Hepatitis B virus
1402361|NCT00376233|Schizophrenia,
1402362|NCT00376233|Cannabinoids,
1402363|NCT00376233|Arachidonic Acid,
1402364|NCT00376233|Niacin,
1402365|NCT00376233|Prostaglandins
1402366|NCT00376220|Bipolar
1402367|NCT00376220|Depression
1402368|NCT00376207|Cerebral infarct
1402369|NCT00376207|physical exercise
1402370|NCT00376207|insulin sensitivity
1402371|NCT00376207|low grade chronic inflammation
1402372|NCT00376207|intervention
1402373|NCT00376207|HOMA
1402374|NCT00376207|PASE
1402375|NCT00376194|Pervasive Developmental Disorder
1402376|NCT00376194|Alternative Therapy
1402377|NCT00376194|Autism
1402378|NCT00376194|Asperger's Disorder
1402379|NCT00376194|Clinical Trial
1402380|NCT00376194|Autism Spectrum Disorder
1402381|NCT00376194|ASD
1402382|NCT00376194|Asperger Disorder
1402383|NCT00376181|type 2 diabetes
1402384|NCT00376181|hypertension
1402385|NCT00376181|blood pressure
1402386|NCT00376181|diastolic blood pressure
1402387|NCT00376155|malaria
1402388|NCT00376155|prevention
1402389|NCT00376155|intermittent
1402390|NCT00376155|drugs
1402391|NCT00376142|Intention
1402392|NCT00376142|Behaviour
1402393|NCT00376142|Evidence-based practice
1402394|NCT00376142|Intervention
1402395|NCT00376116|Implantable cardioverter-defibrillator
1402396|NCT00376116|Pacemaker
1402397|NCT00376116|Cardiac resynchronisation therapy
1402398|NCT00376116|Heart failure
1402399|NCT00376116|Predictor
1402400|NCT00376116|Mortality
1402401|NCT00376116|Rehospitalization
1402402|NCT00376116|Telemedicine
1402403|NCT00376116|Home Monitoring
1402404|NCT00376103|Brain Tumor
1402405|NCT00376103|GBM
1402406|NCT00376103|Glioblastoma Multiforme
1402407|NCT00376103|Glioblastoma
1402408|NCT00376103|Brachytherapy
1402409|NCT00376103|Temozolomide
1402410|NCT00376103|Temodar
1402411|NCT00376090|MVA vector
1402412|NCT00376090|Immunogenicity
1402413|NCT00376090|HIV vaccine
1402414|NCT00376090|HIV preventative vaccine
1402415|NCT00376077|Thrombocytopenia
1402416|NCT00376077|pediatric
1402417|NCT00376077|methylprednisolone
1402418|NCT00376077|intracranial hemorrhage
1402419|NCT00376077|intravenous immune globulin
1402420|NCT00376064|Growth hormone (GH)
1402421|NCT00376064|IGF-1
1402422|NCT00376064|Acromegaly
1402423|NCT00376064|Pituitary adenoma
1402424|NCT00376064|Brain tumor
1402425|NCT00376064|Brain cancer
1402426|NCT00376064|Octreotide acetate
1402427|NCT00376051|frontotemporal lobar degeneration
1402428|NCT00376051|frontotemporal dementia
1402429|NCT00376051|serotonin
1402430|NCT00376051|dementia
1402431|NCT00376051|behavioural disturbances
1402432|NCT00376038|GSK189074
1402433|NCT00376038|T2DM
1402434|NCT00376038|GSK189075
1402435|NCT00376038|Glucophage
1402436|NCT00376038|Obesity
1402437|NCT00376038|Diabetes
1402438|NCT00376038|Metformin
1402439|NCT00376038|Type 2 Diabetes Mellitus
1402440|NCT00376038|Drug Interaction
1402441|NCT00376025|Kashin-Beck Disease
1402442|NCT00376025|Kashin-Beck Osteoarthropathy
1402443|NCT00376012|Chemotherapy for TB in HIV infection
1402444|NCT00375986|Cesarean delivery
1402445|NCT00375986|Placental removal
1402446|NCT00375986|Blood loss
1402447|NCT00375973|Fatigue
1402448|NCT00375973|Fatigue syndrome, chronic
1402449|NCT00375973|Chronic fatigue syndrome
1402450|NCT00375973|CFS
1402451|NCT00375973|Fibromyalgia
1402452|NCT00375960|Pain associated with diabetes Type I or Type II
1402453|NCT00375960|Neuropathic Pain due to diabetes
1402454|NCT00375960|Diabetic peripheral neuropathic pain
1402455|NCT00375960|Pain
1402456|NCT00375960|Diabetes with burning sensation in the arms and/or legs
1402457|NCT00375960|Diabetes with tingling sensation in the arms and/or legs
1402458|NCT00375960|Neuropathic Pain Due to Diabetes Type I or Type II
1402459|NCT00375947|exercise
1402460|NCT00375947|hand disability
1402461|NCT00375947|arthritis
1402462|NCT00375947|AUSCAN
1402463|NCT00375934|Bunionectomy
1402464|NCT00375934|Bunion surgery
1402465|NCT00375934|Post-operative pain
1402466|NCT00375921|diet
1402467|NCT00375921|food
1402468|NCT00375921|taste
1402469|NCT00375921|smell
1402470|NCT00375921|head and neck
1402471|NCT00375921|radiation
1402472|NCT00375921|chemotherapy
1402473|NCT00375908|Neonatal Encephalopathy
1402474|NCT00375908|Hypoxic-Ischemic Brain Injury
1402475|NCT00375908|Umbilical Cord Blood
1402476|NCT00375908|Proteomics
1402477|NCT00375895|Cyclosporin
1402478|NCT00375895|Peginterferon
1402479|NCT00375895|Ribavirin
1402480|NCT00375895|Chronic hepatitis C
1402481|NCT00375895|Liver transplantation
1402482|NCT00375869|Neuroprotection
1402483|NCT00375869|neuron specific enolase
1402484|NCT00375869|CSF glutamate levels
1402485|NCT00375869|Darbepoetin Alfa
1402486|NCT00375856|arthroplasty
1402487|NCT00375856|knee
1402488|NCT00375856|computer-assist
1402489|NCT00375856|gait
1402490|NCT00375856|Total knee arthroplasty
1402491|NCT00375856|knee prostheses
1402492|NCT00375804|Endometrial Cancer
1402493|NCT00375791|Relapsed Multiple Myeloma
1402494|NCT00375791|Refractory Multiple Myeloma
1402495|NCT00375778|Parkinson's Disease
1402496|NCT00375778|Positron Emission Tomography
1402497|NCT00375778|Memantine
1402498|NCT00375778|NMDA antagonists
1402499|NCT00375778|Cerebral Blood Flow
1402500|NCT00375778|Cerebral Metabolic Rate of Oxygen
1402501|NCT00375765|Dutasteride
1402502|NCT00375765|BPH
1402503|NCT00375765|Prostate cancer
1402504|NCT00375765|Gene expression
1402505|NCT00375765|PSA
1402506|NCT00375752|Breast cancer
1402507|NCT00375752|Anti tumor potential
1402508|NCT00375752|Letrozole
1402509|NCT00375752|Zoledronic acid
1402510|NCT00375752|Neoadjuvant treatment
1402511|NCT00375752|Hormone responsive breast cancer
1402512|NCT00375739|Actinic Keratosis
1402513|NCT00375739|Topical
1402514|NCT00375739|Solar Keratosis
1402515|NCT00375739|Sun Spots
1402516|NCT00375739|Dermatology
1402517|NCT00375726|Dengue Fever
1402518|NCT00375726|Dengue Vaccine
1402519|NCT00375726|Dengue Virus
1402520|NCT00375726|Dengue Hemorrhagic Fever
1402521|NCT00375726|Dengue Shock Syndrome
1402522|NCT00375713|Dermatitis
1402523|NCT00375713|Eczema
1402524|NCT00375713|Pruritus
1402525|NCT00375713|Xyzal
1402526|NCT00375713|Zyrtec
1402527|NCT00375713|Levocetirizine
1402528|NCT00375713|Cetirizine
1402529|NCT00375700|food
1402530|NCT00375700|diet
1402531|NCT00375700|oral supplement
1402532|NCT00375700|head and neck cancer
1402533|NCT00375700|radiation
1402534|NCT00375687|Prostate cancer
1402535|NCT00375661|hepatocellular carcinoma
1402536|NCT00375648|Prostate
1402537|NCT00375648|Cancer
1402538|NCT00375648|Bone metastases
1402539|NCT00375648|Zoledronic acid
1402540|NCT00375648|Bone metastases-related pain
1402541|NCT00375648|Prostate cancer
1402542|NCT00375635|mFPSA
1402543|NCT00375635|Uremic toxins
1402544|NCT00375635|Protein bound toxins
1402545|NCT00375635|Uremia
1402546|NCT00375635|Chronic hemodialysis
1402547|NCT00375622|HHT
1402548|NCT00375622|Epistaxis
1402549|NCT00375622|Tamoxifen
1402550|NCT00375622|Hemoglobin
1402551|NCT00375609|Prevention of Venous Thromboembolism
1402552|NCT00375505|Breast Cancer
1402553|NCT00375505|Premenopausal
1402554|NCT00375505|Bone mineral density
1402555|NCT00375505|Cancer therapy induced bone loss
1402556|NCT00375505|zoledronic acid
1402557|NCT00375492|diabetes
1402558|NCT00375492|overweight
1402559|NCT00375492|obesity
1402560|NCT00375492|weight loss
1402561|NCT00375492|exenatide
1402562|NCT00375492|Amylin
1402563|NCT00375492|Lilly
1402564|NCT00375466|Hemorrhage
1402565|NCT00375466|Transfusion
1402566|NCT00375466|Blood components
1402567|NCT00375466|Fibrinolysis
1402568|NCT00375466|Platelet activation
1402569|NCT00375453|Paclitaxel
1402570|NCT00375453|Advanced Solid Tumors
1402571|NCT00375440|Tranexamic Acid
1402572|NCT00375440|Revision Total Hip Replacement
1402573|NCT00375440|Reduction in Blood Loss
1402574|NCT00375427|Breast cancer
1402575|NCT00375427|Zoledronic acid
1402576|NCT00375427|Skeletal related events (SRE)
1402577|NCT00375414|Enteral tube feeding,
1402578|NCT00375414|endoscopic gastropexy,
1402579|NCT00375414|percutaneous endoscopic gastrostomy,
1402580|NCT00375414|PEG
1402581|NCT00375388|Type 2 diabetes mellitus
1402582|NCT00375388|Metformin on top of insulin therapy
1402583|NCT00375388|Randomized placebo-controlled trial
1402584|NCT00375388|Diabetes regulation
1402585|NCT00375388|Daily dose of insulin
1402586|NCT00375388|Body Weight
1402587|NCT00375388|Patients with type 2 diabetes
1402588|NCT00375388|Intensive insulin therapy
1402589|NCT00375388|Age: 30-80 years
1402590|NCT00375388|Body mass index
1402591|NCT00375388|Lipids
1402592|NCT00375388|Blood Pressure
1402593|NCT00375388|Endothelial function
1402594|NCT00375388|Low grade inflammation
1402595|NCT00375388|Fibrinolysis
1402596|NCT00375388|Microvascular complications
1402597|NCT00375388|Macrovascular complications
1402598|NCT00375375|Minimal hepatic encephalopathy
1402599|NCT00375375|Hepatic encephalopathy
1402600|NCT00375375|Subclinical hepatic encephalopathy
1402601|NCT00375375|Health related quality of life
1402602|NCT00375362|nitroglycerin
1402603|NCT00375362|morphine
1402604|NCT00375362|patient controlled analgesia
1402605|NCT00375362|total knee arthroplasty
1402606|NCT00375349|fatty liver
1402607|NCT00375349|statin
1402608|NCT00375349|non-alcoholic
1402609|NCT00375336|Aortic valve
1402610|NCT00375336|Calcification
1402611|NCT00375336|Endothelial dysfunction
1402612|NCT00375336|Calcium metabolism
1402613|NCT00375336|Coronary artery disease
1402614|NCT00375323|factor VIII inhibitor
1402615|NCT00375310|Phase I
1402616|NCT00375310|Pancreas Cancer
1402617|NCT00375310|Chemo-radiotherapy
1402618|NCT00375297|antidepressants
1402619|NCT00375297|sexual dysfunction
1402620|NCT00375297|women
1402621|NCT00375297|sildenafil
1402622|NCT00375297|PDE5 inhibitors
1402623|NCT00375297|serotonin reuptake inhibitor antidepressants
1402624|NCT00375271|Monitoring, Intraoperative
1402625|NCT00375271|Hemodynamic Processes
1402626|NCT00375271|Treatment Protocols
1402627|NCT00375258|Adult trauma patients with ongoing significant haemorrhage or at risk of significant haemorrhage
1402628|NCT00375245|phase I
1402629|NCT00375245|metastatic
1402630|NCT00375245|advanced cancer
1402631|NCT00375245|lung cancer
1402632|NCT00375245|renal cancer
1402633|NCT00375245|kidney cancer
1402634|NCT00375245|head and neck cancer
1402635|NCT00375245|bladder cancer
1402636|NCT00375245|breast cancer
1402637|NCT00375245|colorectal cancer
1402638|NCT00375245|esophagus
1402639|NCT00375245|GIST
1402640|NCT00375245|liver cancer
1402641|NCT00375245|melanoma
1402642|NCT00375245|mesothelioma
1402643|NCT00375245|lymphoma
1402644|NCT00375245|ovary cancer
1402645|NCT00375245|ovarian cancer
1402646|NCT00375245|pancreas cancer
1402647|NCT00375245|pancreatic cancer
1402648|NCT00375245|prostate cancer
1402649|NCT00375245|stomach cancer
1402650|NCT00375245|thyroid cancer
1402651|NCT00375245|Metastatic solid tumor
1402652|NCT00375232|Exercise-Induced Bronchospasm
1402653|NCT00375232|Asthma
1402654|NCT00375232|Cardiopulmonary Stress Test
1402655|NCT00375232|Eucapnic Voluntary Hyperventilation
1402656|NCT00375232|Induced sputum
1402657|NCT00375219|Chronic Myeloid Leukemia
1402658|NCT00375219|CML
1402659|NCT00375219|HHT
1402660|NCT00375219|Homoharringtonine
1402661|NCT00375219|Omacetaxine
1402662|NCT00375219|T315i
1402663|NCT00375219|ChemGenex
1402664|NCT00375219|ChemGenex Pharmaceuticals
1402665|NCT00375206|PowderMed, DNA vaccine, influenza
1402666|NCT00375193|small cell lung cancer
1402667|NCT00375193|amrubicin
1402668|NCT00375180|food
1402669|NCT00375180|diet
1402670|NCT00375180|mucositis
1402671|NCT00375180|xerostomia
1402672|NCT00375180|dysphagia
1402673|NCT00375180|taste
1402674|NCT00375180|smell
1402675|NCT00375180|head and neck
1402676|NCT00375180|radiation
1402677|NCT00375180|chemotherapy
1402678|NCT00375167|Recovery, Hope, Empowerment, Randomized Control Trial
1402679|NCT00375154|Acute respiratory failure
1402680|NCT00375154|Prehospital care
1402681|NCT00375154|Noninvasive ventilation
1402682|NCT00375154|Emergency
1402683|NCT00375128|Malaria
1402684|NCT00375128|Vaccine
1402685|NCT00375128|Prime-boost
1402686|NCT00375128|Challenge
1402687|NCT00375102|acupuncture
1402688|NCT00375102|relaxation response
1402689|NCT00375102|homeless
1402690|NCT00375102|veterans
1402691|NCT00375102|randomized trials
1402692|NCT00375089|Early-onset Morbid Obesity
1402693|NCT00375063|left main stenosis
1402694|NCT00375063|Percutaneous Coronary Intervention
1402695|NCT00375063|Coronary Artery Bypass Grafting
1402696|NCT00375037|hand washing
1402697|NCT00375037|cluster randomized trial
1402698|NCT00375037|performance feedback
1402699|NCT00375037|healthcare workers
1402700|NCT00375037|Hand hygiene
1402701|NCT00375037|hand washing adherence
1402702|NCT00375024|Patient navigation
1402703|NCT00375024|Breast cancer
1402704|NCT00375024|Colon cancer
1402705|NCT00375024|Questionnaire
1402706|NCT00375011|MELD-Model of End Stage Liver Disease score
1402707|NCT00375011|CTP-Child-Turcotte-Pugh score
1402708|NCT00375011|MEGX-monoethylglycinexylidide-resultant of metabolism of lidocaine
1402709|NCT00375011|HCC-Hepatocellular carcinoma
1402710|NCT00375011|HCV-Hepatitis C virus
1402711|NCT00375011|NASH-Non-alcoholic Steatohepatitis
1402712|NCT00374998|Malaria
1402713|NCT00374998|Vaccine
1402714|NCT00374998|Prime-boost
1402715|NCT00374985|chemoradiation
1402716|NCT00374985|docetaxel
1402717|NCT00374985|oxaliplatin
1402718|NCT00374985|gastric
1402719|NCT00374985|neoadjuvant
1402720|NCT00374985|radiochemotherapy
1402721|NCT00374959|Prevention of pneumonia
1402722|NCT00374959|ceftriaxone
1402723|NCT00374959|continuous aspiration
1402724|NCT00374959|subglottic secretions
1402725|NCT00374959|Mechanical ventilation with Endotracheal intubation.
1402726|NCT00374959|Absence of infection
1402727|NCT00374933|AML
1402728|NCT00374933|ALL
1402729|NCT00374933|MDS
1402730|NCT00374933|Allogeneic transplant
1402731|NCT00374933|Acute Myelogenous Leukemia
1402732|NCT00374933|Acute Lymphoblastic Leukemia
1402733|NCT00374933|Myelodysplastic Syndrome
1402734|NCT00374933|Adoptive cell therapy
1402735|NCT00374933|Non-myeloablative
1402736|NCT00374920|bipolar
1402737|NCT00374920|mania
1402738|NCT00374920|mixed
1402739|NCT00374894|2,3-dimercaptosuccinic acid
1402740|NCT00374894|Blood Lead Levels
1402741|NCT00374894|children
1402742|NCT00374894|multi-nutrients
1402743|NCT00374842|Influenza vaccine
1402744|NCT00374842|Prophylaxis Influenza vaccine
1402745|NCT00374829|randomised prospective trial
1402746|NCT00374829|medication refill compliance
1402747|NCT00374829|hypertension
1402748|NCT00374829|ambulatory blood pressure monitoring
1402749|NCT00374829|information technology based patient support system
1402750|NCT00374829|process of care, quality of life, pharmacoeconomics
1402751|NCT00374829|multidisciplinary patient management
1402752|NCT00374803|Kidney
1402753|NCT00374803|Transplant
1402754|NCT00374803|Corticosteroid
1402755|NCT00374803|Myfortic
1402756|NCT00374790|Lead toxicity
1402757|NCT00374777|Insomnia
1402758|NCT00374777|schizophrenia
1402759|NCT00374777|manic-depressive psychosis
1402760|NCT00374777|zolpidem
1402761|NCT00374764|Autism, Applied Behavioral Analysis, Risperidone
1402762|NCT00374751|Samarium
1402763|NCT00374751|Kyphoplasty
1402764|NCT00374751|Pain management
1402765|NCT00374751|Bone metastases
1402766|NCT00374751|Histologically proven malignancy in the primary site
1402767|NCT00374751|Radiographic evidence of bone metastasis
1402768|NCT00374751|Significant pain equal or more than score 5
1402769|NCT00374751|Karnofsky Performance status >40
1402770|NCT00374751|The patient must sign a study specific informed consent
1402771|NCT00374738|Guided Imagery for Trauma (GIFT)
1402772|NCT00374738|Posttraumatic Stress Disorder (PTSD)
1402773|NCT00374738|Military Sexual Trauma (MST)
1402774|NCT00374738|Military Sexual Trauma - related PTSD
1402775|NCT00374725|Ulcerative Colitis
1402776|NCT00374725|Probiotic
1402777|NCT00374725|Placebo controlled trial
1402778|NCT00374725|Lactobacillus rhamnosus
1402779|NCT00374725|Lactobacillus acidophilus
1402780|NCT00374712|Phosphate
1402781|NCT00374712|Dialysis
1402782|NCT00374712|Klotho
1402783|NCT00374712|Hemodialysis
1402784|NCT00374699|Velcade
1402785|NCT00374699|Bortezomib
1402786|NCT00374699|CHOP
1402787|NCT00374699|Peripheral T-cell lymphomas(PTCLs)
1402788|NCT00374699|natural killer (NK)-cell lymphomas
1402789|NCT00374686|cytomegalovirus
1402790|NCT00374686|kidney
1402791|NCT00374686|transplantation
1402792|NCT00374686|valganciclovir
1402793|NCT00374686|preemptive
1402794|NCT00374673|TMS
1402795|NCT00374673|chronic pain
1402796|NCT00374673|fibromyalgia
1402797|NCT00374673|IBS
1402798|NCT00374673|burning mouth syndrome
1402799|NCT00374673|predictive factors
1402800|NCT00374660|Irofulven
1402801|NCT00374660|Oxaliplatin
1402802|NCT00374647|Renal
1402803|NCT00374647|Kidney
1402804|NCT00374647|Transplant
1402805|NCT00374608|pediatric
1402806|NCT00374608|congenital complete heart block
1402807|NCT00374608|dual chamber pacemaker
1402808|NCT00374595|Kidney Transplant
1402809|NCT00374595|Vascular Risk
1402810|NCT00374595|inflammation
1402811|NCT00374595|Diabetes
1402812|NCT00374595|Insulin resistance
1402813|NCT00374595|Chronic kidney disease
1402814|NCT00374582|Bioelectric impedance analysis
1402815|NCT00374582|BIA
1402816|NCT00374582|ESLD
1402817|NCT00374582|LVP
1402818|NCT00374582|Large volume paracentesis
1402819|NCT00374582|Ascites
1402820|NCT00374582|Liver
1402821|NCT00374582|Hepatic
1402822|NCT00374569|Gymnastics, Computerized Dynamic Posturography, Balance
1402823|NCT00374556|eszopiclone
1402824|NCT00374556|insomnia
1402825|NCT00374543|Bipolar Disorder
1402826|NCT00374543|Generalized Anxiety Disorder
1402827|NCT00374543|Double-blind
1402828|NCT00374543|Placebo-controlled
1402829|NCT00374543|Ziprasidone
1402830|NCT00374517|Mycobacterium Tuberculosis
1402831|NCT00374517|Pimonidazole Hydrochloride
1402832|NCT00374517|Recurrent Tuberculosis
1402833|NCT00374517|Hypoxyprobe
1402834|NCT00374517|mRNA Expression
1402835|NCT00374517|Pulmonary Tuberculosis
1402836|NCT00374491|ACL
1402837|NCT00374491|Bone Screw
1402838|NCT00374491|Knee
1402839|NCT00374478|Scopolamine
1402840|NCT00374478|Antiemetic
1402841|NCT00374478|Task performance and analysis
1402842|NCT00374478|Psychomotor vigilance test
1402843|NCT00374465|Dilated Cardiomyopathy
1402844|NCT00374465|Heart Failure
1402845|NCT00374452|hypertension
1402846|NCT00374452|practice guidelines
1402847|NCT00374452|quality of health care
1402848|NCT00374452|decision support systems
1402849|NCT00374452|evidence-based medicine
1402850|NCT00374452|medical informatics
1402851|NCT00374439|depression
1402852|NCT00374439|adolescents
1402853|NCT00374439|prevention
1402854|NCT00374439|schools
1402855|NCT00374426|depression
1402856|NCT00374426|diabetes mellitus
1402857|NCT00374426|depression recurrence
1402858|NCT00374413|DDD
1402859|NCT00374413|artificial disc
1402860|NCT00374400|Kidney
1402861|NCT00374400|Transplant
1402862|NCT00374400|Paired donation
1402863|NCT00374400|Living donor
1402864|NCT00374387|Healthy women
1402865|NCT00374374|probiotic
1402866|NCT00374361|insulin sensitivity
1402867|NCT00374361|endothelial function
1402868|NCT00374361|adolescence
1402869|NCT00374361|lipids
1402870|NCT00374361|puberty
1402871|NCT00374348|Schizophrenia with OCD
1402872|NCT00374348|Schizophrenia with-comorbid symptoms of Obsessive Compulsive Disorder(OCD)
1402873|NCT00374335|prospective cohort study
1402874|NCT00374322|Breast Cancer
1402875|NCT00374322|ErbB2-overexpressing
1402876|NCT00374322|early-stage breast cancer
1402877|NCT00374322|adjuvant
1402878|NCT00374309|Hemorrhagic Fever
1402879|NCT00374309|Healthy
1402880|NCT00374309|Immunity
1402881|NCT00374309|T -Cells
1402882|NCT00374309|Filovirus
1402883|NCT00374309|Healthy Volunteer
1402884|NCT00374309|HV
1402885|NCT00374296|Leukemia
1402886|NCT00374296|MDS
1402887|NCT00374296|Phase II
1402888|NCT00374296|Acute Myelogenous Leukemia (AML)
1402889|NCT00374296|High Risk Myelodysplastic Syndromes (MDS)
1402890|NCT00374283|Monitoring
1402891|NCT00374283|Polyomavirus
1402892|NCT00374283|Kidney
1402893|NCT00374283|Pancreas
1402894|NCT00374283|Transplant
1402895|NCT00374270|Diabetes (type I and type II)
1402896|NCT00374257|NB-UVB
1402897|NCT00374257|cGVHD
1402898|NCT00374244|schizophrenia
1402899|NCT00374244|pimozide
1402900|NCT00374244|clozapine
1402901|NCT00374231|Liver
1402902|NCT00374231|Transplant
1402903|NCT00374231|Corticosteroid withdrawal
1402904|NCT00374231|Tacrolimus
1402905|NCT00374231|CellCept
1402906|NCT00374231|MMF
1402907|NCT00374231|Mycophenolate mofetil
1402908|NCT00374218|Carbohydrate
1402909|NCT00374218|Glycemic index
1402910|NCT00374218|Randomized
1402911|NCT00374218|Double-blind
1402912|NCT00374218|Glucose
1402913|NCT00374218|Insulin
1402914|NCT00374218|C-reactive protein
1402915|NCT00374205|Ghana
1402916|NCT00374205|Effectiveness
1402917|NCT00374205|Safety
1402918|NCT00374205|Drug-Resistance
1402919|NCT00374205|ACT
1402920|NCT00374205|Coartem
1402921|NCT00374205|Arsucam
1402922|NCT00374192|Menopause
1402923|NCT00374192|Insomnia
1402924|NCT00374192|Depression
1402925|NCT00374192|Anxiety
1402926|NCT00374192|Sleep
1402927|NCT00374192|Lunesta
1402928|NCT00374192|Quality of Life
1402929|NCT00374166|Anti-anxiety agents
1402930|NCT00374166|antidepressive agents
1402931|NCT00374166|controlled clinical trial
1402932|NCT00374153|Alcohol
1402933|NCT00374153|Drinking
1402934|NCT00374153|College
1402935|NCT00374153|Motivational
1402936|NCT00374153|Feedback
1402937|NCT00374153|Assessment
1402938|NCT00374140|small cell
1402939|NCT00374140|lung
1402940|NCT00374127|Marijuana
1402941|NCT00374127|Comparison between joints and blunts
1402942|NCT00374127|Pharmacokinetic effects
1402943|NCT00374114|cervical
1402944|NCT00374114|dysplasia
1402945|NCT00374101|PPIs,
1402946|NCT00374101|endoscopic therapy,
1402947|NCT00374101|peptic ulcers,
1402948|NCT00374101|upper gastrointestinal bleeding,
1402949|NCT00374101|non-variceal upper gastrointestinal bleeding
1402950|NCT00374088|N-acetylcysteine
1402951|NCT00374088|Myocardial dysfunction
1402952|NCT00374088|Transposition of the Great Arteries
1402953|NCT00374075|Spinal Muscular Atrophy (SMA)
1402954|NCT00374075|Valproic Acid
1402955|NCT00374062|Mohs Surgery
1402956|NCT00374049|Prostate
1402957|NCT00374049|vaccine
1402958|NCT00374049|immunosuppression
1402959|NCT00374049|dendritic cells
1402960|NCT00374036|chemotherapy
1402961|NCT00374036|stomach cancer metastatic
1402962|NCT00374036|Capecitabine
1402963|NCT00374036|Irinotecan
1402964|NCT00374023|Zinc
1402965|NCT00374023|vitamin A
1402966|NCT00374023|immunity
1402967|NCT00374023|morbidity
1402968|NCT00374023|height gain
1402969|NCT00374023|weight gain
1402970|NCT00374023|Children aged between 1 and 3 years
1402971|NCT00374023|Weight for age between 70% and 61% of NCHS standard
1402972|NCT00374023|Acute diarrhoeal Patients
1402973|NCT00374023|No signs of vitamin A deficiency
1402974|NCT00374023|Who has not received measles vaccine
1402975|NCT00374010|end-of-life decision making
1402976|NCT00374010|advance care planning
1402977|NCT00373984|shoulder
1402978|NCT00373984|thoracotomy
1402979|NCT00373971|Activities of daily living
1402980|NCT00373971|Elderly
1402981|NCT00373971|Nutrition
1402982|NCT00373971|Postoperative
1402983|NCT00373971|Hip fractures
1402984|NCT00373971|Hip replacement
1402985|NCT00373971|Knee replacement
1402986|NCT00373945|HLA-B*5701
1402987|NCT00373945|pharmacogenetic marker
1402988|NCT00373945|hypersensitivity to abacavir,
1402989|NCT00373945|retrospective analysis
1402990|NCT00373932|Exercise
1402991|NCT00373932|Physical Activity
1402992|NCT00373932|Adherence
1402993|NCT00373906|MALT Lymphoma, Bortezomib
1402994|NCT00373893|Pain
1402995|NCT00373893|Hyperalgesia
1402996|NCT00373893|capsaicin
1402997|NCT00373880|Aripiprazole
1402998|NCT00373880|Cocaine abuse
1402999|NCT00373867|Secondary prevention
1403000|NCT00373867|Physical therapy
1403001|NCT00373867|Fear-avoidance beliefs
1403002|NCT00373867|Disability
1403003|NCT00373854|Hypoglycemia
1403004|NCT00373854|Endothelial function
1403005|NCT00373841|Lung
1403006|NCT00373841|Fibrosis
1403007|NCT00373841|Idiopathic
1403008|NCT00373841|Biomarkers
1403009|NCT00373841|Genomics
1403010|NCT00373841|Longitudinal
1403011|NCT00373828|Chest Pain
1403012|NCT00373828|Chest Wall
1403013|NCT00373828|Angina Pectoris
1403014|NCT00373828|Atypical Chest Pain
1403015|NCT00373828|Physical Examination
1403016|NCT00373828|Myocardial Perfusion Imaging
1403017|NCT00373828|Observational Study
1403018|NCT00373828|Non-Cardiac Chest Pain
1403019|NCT00373828|Ischemic Heart Disease
1403020|NCT00373815|acute GVHD
1403021|NCT00373815|Immunosuppression
1403022|NCT00373789|Botulinum Toxin A
1403023|NCT00373789|Urinary Incontinence
1403024|NCT00373789|Detrusor Overactivity
1403025|NCT00373776|mucosal
1403026|NCT00373776|leishmaniasis
1403027|NCT00373776|miltefosine
1403028|NCT00373763|Congenital diaphragmatic hernia
1403029|NCT00373763|tracheal occlusion
1403030|NCT00373763|fetus
1403031|NCT00373763|fetal surgery
1403032|NCT00373763|fetoscopy
1403033|NCT00373750|Native American health
1403034|NCT00373750|Teen pregnancy
1403035|NCT00373750|Family strengthening
1403036|NCT00373750|Substance abuse prevention
1403037|NCT00373750|Injury prevention
1403038|NCT00373724|sacroiliac joint
1403039|NCT00373724|low back pain
1403040|NCT00373724|radiofrequency
1403041|NCT00373698|Stress Disorders, Posttraumatic
1403042|NCT00373698|Delivery of Health Care, Integrated
1403043|NCT00373698|Primary Health Care
1403044|NCT00373698|Veterans
1403045|NCT00373698|Depression
1403046|NCT00373685|GI events in patients with moderate GI risk treated with NSAIDS
1403047|NCT00373672|schizophrenia
1403048|NCT00373672|cognition
1403049|NCT00373659|Neovascularization
1403050|NCT00373659|Age-related macular degeneration
1403051|NCT00373659|Ranibizumab (Lucentis)
1403052|NCT00373659|Optical coherence tomography
1403053|NCT00373659|Intravitreal injection
1403054|NCT00373646|MALT Lymphoma
1403055|NCT00373646|thalidomide
1403056|NCT00373646|disseminated MALT Lymphoma or at relapse following HP-eradication
1403057|NCT00373646|or chemotherapy or radiation
1403058|NCT00373633|THoracic Surgery
1403059|NCT00373633|thoracic epidural
1403060|NCT00373633|epidural
1403061|NCT00373633|thoracotomy
1403062|NCT00373633|intercostal nerve block
1403063|NCT00373633|intercostal
1403064|NCT00373633|nerve block
1403065|NCT00373620|endometrial cancer
1403066|NCT00373620|high risk
1403067|NCT00373620|weekly paclitaxel
1403068|NCT00373620|Cuncurrent chemoradiation
1403069|NCT00373607|Non complicated malaria
1403070|NCT00373607|Microscopy
1403071|NCT00373607|Adult
1403072|NCT00373607|Children
1403073|NCT00373594|Cold agglutinin disease
1403074|NCT00373594|Hemolytic
1403075|NCT00373594|Anemia
1403076|NCT00373594|Lymphoproliferative disease
1403077|NCT00373594|Monoclonal antibodies
1403078|NCT00373594|Rituximab
1403079|NCT00373594|Fludarabine
1403080|NCT00373581|Vigabatrin
1403081|NCT00373581|GABA levels
1403082|NCT00373581|Smoked cocaine
1403083|NCT00373568|mucosal
1403084|NCT00373568|miltefosine
1403085|NCT00373555|Sarcoidosis
1403086|NCT00373555|mediastinal adenopathy
1403087|NCT00373555|bronchoscopy
1403088|NCT00373555|Transbronchial needle aspiration
1403089|NCT00373555|endobronchial ultrasonography
1403090|NCT00373542|Restless Legs Syndrome
1403091|NCT00373542|ropinirole
1403092|NCT00373542|polysomnography
1403093|NCT00373542|RLS
1403094|NCT00373542|PSG
1403095|NCT00373529|Acute myelogenous leukemia
1403096|NCT00373529|Acute myeloid leukemia
1403097|NCT00373529|newly Diagnosed AML
1403098|NCT00373529|Clofarabine
1403099|NCT00373529|CLASSIC II
1403100|NCT00373529|CLO243
1403101|NCT00373516|psoriasis
1403102|NCT00373516|topical therapy
1403103|NCT00373503|Lofexidine
1403104|NCT00373503|Oral THC
1403105|NCT00373503|Cannabinoids
1403106|NCT00373477|Depression
1403107|NCT00373477|Primary Care
1403108|NCT00373477|Care Manager
1403109|NCT00373464|Postoperative pain
1403110|NCT00373464|Opioid
1403111|NCT00373464|Etoricoxib
1403112|NCT00373464|Ketorolac
1403113|NCT00373464|Laparoscopic Surgery
1403114|NCT00373464|Surgical Procedures, Gynecologic
1403115|NCT00373451|NSTEMI
1403116|NCT00373438|Congenital diaphragmatic hernia
1403117|NCT00373438|tracheal occlusion
1403118|NCT00373438|fetus
1403119|NCT00373438|fetal surgery
1403120|NCT00373438|fetoscopy
1403121|NCT00373438|ECMO
1403122|NCT00373425|Adjuvant Non-small Cell Lung Cancer
1403123|NCT00373425|Tarceva
1403124|NCT00373425|Early-stage Lung Cancer
1403125|NCT00373425|Adjuvant
1403126|NCT00373425|RADIANT
1403127|NCT00373425|NSCLC
1403128|NCT00373425|EGFR-positive tumor
1403129|NCT00373425|Stage IB Non-small Cell Lung Cancer
1403130|NCT00373425|Stage II Non-small Cell Lung Cancer
1403131|NCT00373425|Stage IIIA Non-small Cell Lung Cancer
1403132|NCT00373412|cytomegalovirus
1403133|NCT00373412|vaccine
1403134|NCT00373412|T cell
1403135|NCT00373412|antibodies
1403136|NCT00373399|Cannabinoids
1403137|NCT00373399|Risk taking
1403138|NCT00373399|Decision making
1403139|NCT00373386|growth hormone
1403140|NCT00373386|endothelial function
1403141|NCT00373373|Sorafenib
1403142|NCT00373373|Acute Myeloid Leukemia
1403143|NCT00373373|Flt3
1403144|NCT00373373|AML
1403145|NCT00373373|Kinase Inhibitor
1403146|NCT00373360|pulmonary hypertension
1403147|NCT00373360|PAH
1403148|NCT00373360|Remodulin
1403149|NCT00373360|treprostinil
1403150|NCT00373360|Quality of Life
1403151|NCT00373360|Rapid Switch
1403152|NCT00373334|gastroesophageal reflux disease
1403153|NCT00373334|GERD
1403154|NCT00373334|heartburn
1403155|NCT00373308|Quality of Life
1403156|NCT00373295|Baclofen
1403157|NCT00373295|Marijuana Dependence
1403158|NCT00373295|Marijuana Withdrawal
1403159|NCT00373282|PVR
1403160|NCT00373282|Retinal detachment
1403161|NCT00373282|Silicone oil
1403162|NCT00373282|Triamcinolone
1403163|NCT00373269|Acute ischemic stroke
1403164|NCT00373269|Stroke
1403165|NCT00373269|Hyperglycemia
1403166|NCT00373269|Procoagulation
1403167|NCT00373269|Diabetes
1403168|NCT00373269|Blood coagulation
1403169|NCT00373256|Breast cancer
1403170|NCT00373256|advanced
1403171|NCT00373256|sunitinib
1403172|NCT00373256|bevacizumab
1403173|NCT00373256|paclitaxel
1403174|NCT00373256|Phase 3
1403175|NCT00373243|hepatic impairment pharmacokinetics
1403176|NCT00373230|weight loss
1403177|NCT00373230|telemedicine
1403178|NCT00373230|african-american
1403179|NCT00373230|rural
1403180|NCT00373217|fallopian tube cancer
1403181|NCT00373217|stage III ovarian epithelial cancer
1403182|NCT00373217|stage IV ovarian epithelial cancer
1403183|NCT00373217|primary peritoneal cavity cancer
1403184|NCT00373204|Advanced non-small cell lung cancer
1403185|NCT00373204|Non-small cell lung cancer
1403186|NCT00373204|Lung cancer
1403187|NCT00373204|Metastatic lung cancer
1403188|NCT00373204|Second line treatment for advanced lung cancer
1403189|NCT00373204|Cancer
1403190|NCT00373204|Advanced lung cancer
1403191|NCT00373191|stage I breast cancer
1403192|NCT00373191|stage II breast cancer
1403193|NCT00373191|stage IIIA breast cancer
1403194|NCT00373191|stage IIIB breast cancer
1403195|NCT00373191|stage IIIC breast cancer
1403196|NCT00373191|ductal breast carcinoma in situ
1403197|NCT00373178|rosiglitazone
1403198|NCT00373178|metformin
1403199|NCT00373165|Renal Transplantation
1403200|NCT00373165|CMV
1403201|NCT00373165|Ganciclovir
1403202|NCT00373165|Prophylaxis
1403203|NCT00373165|Preemptive Therapy
1403204|NCT00373165|Graft Survival
1403205|NCT00373165|Proteomics
1403206|NCT00373152|stage I breast cancer
1403207|NCT00373152|stage II breast cancer
1403208|NCT00373152|stage IIIA breast cancer
1403209|NCT00373152|stage IIIC breast cancer
1403210|NCT00373152|stage IV breast cancer
1403211|NCT00373139|Pregnancy,
1403212|NCT00373139|Screening,
1403213|NCT00373139|Whole Blood
1403214|NCT00373126|nicotine
1403215|NCT00373126|schizophrenia
1403216|NCT00373126|reward
1403217|NCT00373126|withdrawal
1403218|NCT00373113|advanced breast cancer
1403219|NCT00373113|metastatic breast cancer
1403220|NCT00373113|treatment resistant
1403221|NCT00373113|treatment failure
1403222|NCT00373100|Zinc
1403223|NCT00373100|placebo
1403224|NCT00373100|severe pneumonia
1403225|NCT00373100|children
1403226|NCT00373087|Parkinson's disease
1403227|NCT00373087|Catechol O-methyltransferase
1403228|NCT00373087|Entacapone
1403229|NCT00373087|pharmacogenetic
1403230|NCT00373074|Spinal Puncture Headache
1403231|NCT00373061|Expect
1403232|NCT00373048|HIV-1 malaria Clinical Trial
1403233|NCT00373035|prostate cancer
1403234|NCT00373022|depression
1403235|NCT00373022|anxiety disorder
1403236|NCT00373022|psychosocial effects of cancer and its treatment
1403237|NCT00373022|stage II colon cancer
1403238|NCT00373022|stage III colon cancer
1403239|NCT00373022|stage II rectal cancer
1403240|NCT00373022|stage III rectal cancer
1403241|NCT00373009|Low back pain
1403242|NCT00373009|Primary prevention
1403243|NCT00373009|Secondary prevention
1403244|NCT00373009|Lumbar stabilization
1403245|NCT00373009|Psychosocial education
1403246|NCT00372983|chronic HCV
1403247|NCT00372983|Failed treatment
1403248|NCT00372983|genotype 1
1403249|NCT00372983|failed treatment with pegylated interferon plus ribavirin
1403250|NCT00372970|gastroparesis
1403251|NCT00372970|vomiting
1403252|NCT00372970|nausea
1403253|NCT00372970|bloating
1403254|NCT00372970|dyspepsia
1403255|NCT00372957|Diabetes
1403256|NCT00372957|pharmacodynamics
1403257|NCT00372957|pharmacokinetics
1403258|NCT00372944|advanced pancreatic cancer
1403259|NCT00372944|metastatic pancreatic cancer
1403260|NCT00372944|AZD6244
1403261|NCT00372905|follicular lymphoma
1403262|NCT00372892|Idiopathic Thrombocytopenic Purpura
1403263|NCT00372892|Rituximab
1403264|NCT00372892|Feasibility study
1403265|NCT00372879|amyotrophic lateral sclerosis
1403266|NCT00372879|vitamin E
1403267|NCT00372879|muscle cramp
1403268|NCT00372840|psychosocial effects of cancer and its treatment
1403269|NCT00372840|stage I breast cancer
1403270|NCT00372840|stage II breast cancer
1403271|NCT00372840|stage IIIA breast cancer
1403272|NCT00372840|stage IIIA colon cancer
1403273|NCT00372840|stage I prostate cancer
1403274|NCT00372840|stage IIB prostate cancer
1403275|NCT00372840|stage IIA prostate cancer
1403276|NCT00372840|stage III prostate cancer
1403277|NCT00372840|stage I non-small cell lung cancer
1403278|NCT00372840|stage II non-small cell lung cancer
1403279|NCT00372840|stage IIIA non-small cell lung cancer
1403280|NCT00372840|limited stage small cell lung cancer
1403281|NCT00372840|stage I rectal cancer
1403282|NCT00372840|stage IIA rectal cancer
1403283|NCT00372840|stage IIB rectal cancer
1403284|NCT00372840|stage IIC rectal cancer
1403285|NCT00372840|stage IIIA rectal cancer
1403286|NCT00372840|pulmonary carcinoid tumor
1403287|NCT00372840|stage I thymoma
1403288|NCT00372840|stage II thymoma
1403289|NCT00372840|stage III thymoma
1403290|NCT00372840|stage I colon cancer
1403291|NCT00372840|stage IIA colon cancer
1403292|NCT00372840|stage IIB colon cancer
1403293|NCT00372840|stage IIC colon cancer
1403294|NCT00372840|stage IA malignant mesothelioma
1403295|NCT00372840|stage IB malignant mesothelioma
1403296|NCT00372840|stage II malignant mesothelioma
1403297|NCT00372840|stage III malignant mesothelioma
1403298|NCT00372814|diabetes
1403299|NCT00372814|regimen adherence
1403300|NCT00372814|metabolic control
1403301|NCT00372814|adolescents
1403302|NCT00372814|family therapy
1403303|NCT00372801|Osteoarthritis
1403304|NCT00372801|Ibuprofen
1403305|NCT00372801|COX2
1403306|NCT00372801|VAS
1403307|NCT00372801|knee
1403308|NCT00372801|single dose
1403309|NCT00372788|NSCLC
1403310|NCT00372788|Advanced Non-Small Cell Lung Cancer
1403311|NCT00372788|AZD6244
1403312|NCT00372775|brain metastases
1403313|NCT00372775|Sunitinib
1403314|NCT00372775|Phase 2
1403315|NCT00372762|Insulin resistance
1403316|NCT00372762|heart failure
1403317|NCT00372762|diuretic therapy
1403318|NCT00372749|Alcohol dependence
1403319|NCT00372749|Craving
1403320|NCT00372749|Disulfiram
1403321|NCT00372749|Cue exposure
1403322|NCT00372736|unspecified adult solid tumor, protocol specific
1403323|NCT00372723|toxic epidermal necrlysis
1403324|NCT00372723|ten
1403325|NCT00372710|Breast cancer
1403326|NCT00372710|Palliation
1403327|NCT00372710|Bone metastasis
1403328|NCT00372710|Zoledronic acid
1403329|NCT00372697|acromegaly
1403330|NCT00372697|octreotide acetate
1403331|NCT00372697|partial responder patients
1403332|NCT00372684|Plasmodium falciparum
1403333|NCT00372684|Malaria
1403334|NCT00372684|Imported malaria
1403335|NCT00372684|Severe malaria
1403336|NCT00372684|Uncomplicated malaria
1403337|NCT00372684|Intensive Care Units
1403338|NCT00372684|Polymorphism, Genetic
1403339|NCT00372684|Parasitic Sensitivity Tests
1403340|NCT00372684|Inflammation Mediators
1403341|NCT00372671|Cardiac Rehabilitation
1403342|NCT00372671|Improving Cardiac Rehabilitation Participation
1403343|NCT00372658|hysterosalpingogram
1403344|NCT00372658|intracervical local anesthesia
1403345|NCT00372658|pain perception
1403346|NCT00372658|visual analogue scale
1403347|NCT00372645|Healthy
1403348|NCT00372632|Pregnancy malaria prevention
1403349|NCT00372619|recurrent childhood acute lymphoblastic leukemia
1403350|NCT00372619|recurrent childhood acute myeloid leukemia
1403351|NCT00372619|acute undifferentiated leukemia
1403352|NCT00372619|adult acute minimally differentiated myeloid leukemia (M0)
1403353|NCT00372619|childhood acute minimally differentiated myeloid leukemia (M0)
1403354|NCT00372619|adult acute myeloblastic leukemia without maturation (M1)
1403355|NCT00372619|childhood acute myeloblastic leukemia without maturation (M1)
1403356|NCT00372619|adult acute myeloblastic leukemia with maturation (M2)
1403357|NCT00372619|childhood acute myeloblastic leukemia with maturation (M2)
1403358|NCT00372619|adult acute myelomonocytic leukemia (M4)
1403359|NCT00372619|childhood acute myelomonocytic leukemia (M4)
1403360|NCT00372619|adult acute monoblastic leukemia (M5a)
1403361|NCT00372619|childhood acute monoblastic leukemia (M5a)
1403362|NCT00372619|adult acute monocytic leukemia (M5b)
1403363|NCT00372619|childhood acute monocytic leukemia (M5b)
1403364|NCT00372619|adult erythroleukemia (M6a)
1403365|NCT00372619|adult pure erythroid leukemia (M6b)
1403366|NCT00372619|childhood acute erythroleukemia (M6)
1403367|NCT00372619|adult acute megakaryoblastic leukemia (M7)
1403368|NCT00372619|childhood acute megakaryocytic leukemia (M7)
1403369|NCT00372619|recurrent adult acute lymphoblastic leukemia
1403370|NCT00372619|recurrent adult acute myeloid leukemia
1403371|NCT00372606|Obesity
1403372|NCT00372606|Overweight
1403373|NCT00372606|Hispanics
1403374|NCT00372606|Online
1403375|NCT00372606|Weight Loss
1403376|NCT00372593|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1403377|NCT00372593|adult acute myeloid leukemia with inv(16)(p13;q22)
1403378|NCT00372593|adult acute myeloid leukemia with t(16;16)(p13;q22)
1403379|NCT00372593|adult acute myeloid leukemia with t(8;21)(q22;q22)
1403380|NCT00372593|untreated adult acute myeloid leukemia
1403381|NCT00372593|untreated childhood acute myeloid leukemia and other myeloid malignancies
1403382|NCT00372593|adult acute basophilic leukemia
1403383|NCT00372593|adult acute eosinophilic leukemia
1403384|NCT00372593|adult acute minimally differentiated myeloid leukemia (M0)
1403385|NCT00372593|adult acute myeloblastic leukemia without maturation (M1)
1403386|NCT00372593|adult acute myeloblastic leukemia with maturation (M2)
1403387|NCT00372593|adult acute myelomonocytic leukemia (M4)
1403388|NCT00372593|adult acute monoblastic leukemia (M5a)
1403389|NCT00372593|adult acute monocytic leukemia (M5b)
1403390|NCT00372593|adult erythroleukemia (M6a)
1403391|NCT00372593|adult pure erythroid leukemia (M6b)
1403392|NCT00372593|adult acute megakaryoblastic leukemia (M7)
1403393|NCT00372593|childhood acute basophilic leukemia
1403394|NCT00372593|childhood acute eosinophilic leukemia
1403395|NCT00372593|childhood acute minimally differentiated myeloid leukemia (M0)
1403396|NCT00372593|childhood acute myeloblastic leukemia without maturation (M1)
1403397|NCT00372593|childhood acute myeloblastic leukemia with maturation (M2)
1403398|NCT00372593|childhood acute myelomonocytic leukemia (M4)
1403399|NCT00372593|childhood acute monocytic leukemia (M5b)
1403400|NCT00372593|childhood acute monoblastic leukemia (M5a)
1403401|NCT00372593|childhood acute erythroleukemia (M6)
1403402|NCT00372593|childhood acute megakaryocytic leukemia (M7)
1403403|NCT00372541|ceftriaxone
1403404|NCT00372541|chloramphenicol
1403405|NCT00372541|severe pneumonia
1403406|NCT00372541|children
1403407|NCT00372515|epidermal growth factor
1403408|NCT00372515|EGFR
1403409|NCT00372515|lung cancer
1403410|NCT00372515|Iressa
1403411|NCT00372515|Gefitinib
1403412|NCT00372502|sepsis
1403413|NCT00372502|shock
1403414|NCT00372502|emergency department
1403415|NCT00372502|resuscitation
1403416|NCT00372489|anemia
1403417|NCT00372489|chronic kidney disease
1403418|NCT00372489|CKD
1403419|NCT00372489|chronic renal failure
1403420|NCT00372489|CRF
1403421|NCT00372489|dialysis
1403422|NCT00372489|erythropoietin
1403423|NCT00372489|EPO
1403424|NCT00372489|erythropoiesis stimulating agent
1403425|NCT00372489|ESA
1403426|NCT00372489|Hematide™
1403427|NCT00372489|hemodialysis
1403428|NCT00372489|hemoglobin
1403429|NCT00372489|Hb
1403430|NCT00372489|Hgb
1403431|NCT00372489|Omontys
1403432|NCT00372489|peginesatide
1403433|NCT00372489|red blood cell
1403434|NCT00372489|red blood cell production
1403435|NCT00372476|Breast cancer
1403436|NCT00372476|Tyrosine inhibitor
1403437|NCT00372476|Chemotherapy
1403438|NCT00372476|Imatinib
1403439|NCT00372463|diabetes
1403440|NCT00372463|type 2 diabetes
1403441|NCT00372463|type II diabetes
1403442|NCT00372463|diabetes mellitus
1403443|NCT00372463|diabetes type 2
1403444|NCT00372463|diabetes type II
1403445|NCT00372463|diabetes education
1403446|NCT00372463|patient education
1403447|NCT00372463|workshop
1403448|NCT00372463|class
1403449|NCT00372463|education
1403450|NCT00372463|online
1403451|NCT00372463|on-line
1403452|NCT00372463|internet
1403453|NCT00372463|web
1403454|NCT00372450|recurrent esophageal cancer
1403455|NCT00372450|stage III esophageal cancer
1403456|NCT00372450|stage IV esophageal cancer
1403457|NCT00372450|squamous cell carcinoma of the esophagus
1403458|NCT00372450|adenocarcinoma of the esophagus
1403459|NCT00372450|gastrointestinal complications
1403460|NCT00372437|Refractory solid tumors
1403461|NCT00372437|Phase I/II
1403462|NCT00372437|Refractory and solid tumors
1403463|NCT00372424|Breast cancer over-expressing HER2. First-line treatment with sunitinib/docetaxel/trastuzumab.
1403464|NCT00372411|Stroke
1403465|NCT00372411|Rehabilitation
1403466|NCT00372411|Single-blind
1403467|NCT00372411|Clinical Trial
1403468|NCT00372411|Randomized controlled trial
1403469|NCT00372411|Upper extremity
1403470|NCT00372411|Robotics
1403471|NCT00372398|scleroderma
1403472|NCT00372398|sclerosis
1403473|NCT00372398|atherosclerosis
1403474|NCT00372372|corticosteroids, bone mineral, risedronate, bisphosphonate
1403475|NCT00372359|Attention Deficit Disorder
1403476|NCT00372359|Hyperactivity
1403477|NCT00372359|Methylphenidate
1403478|NCT00372333|musculoskeletal pain; soft tissue inflammation; IDEA-033
1403479|NCT00372320|Adenovirus
1403480|NCT00372320|Aquaporin-1
1403481|NCT00372320|Gene Transfer
1403482|NCT00372320|Radiation-Induced Salivary Hypofunction
1403483|NCT00372320|Salivary Gland
1403484|NCT00372320|Xerostomia
1403485|NCT00372320|Salivary Dysfunction
1403486|NCT00372320|Hyposalivation
1403487|NCT00372320|Dry mouth
1403488|NCT00372320|head and neck cancer
1403489|NCT00372320|side effects radiation damage
1403490|NCT00372294|Toxoplasmosis
1403491|NCT00372294|Chorioretinitis
1403492|NCT00372294|Intravitreal Clindamycin
1403493|NCT00372294|Dexamethasone in chorioretinitis
1403494|NCT00372294|Toxoplasmic
1403495|NCT00372281|MRI, CLIAVIST, MACROPHAGE, INFECTION, SPINE
1403496|NCT00372268|Comparison of four conditionings of the insufflated gas during laparoscopy and their consequences on the core temperature and the post-operative pain.
1403497|NCT00372268|Women with womb pathology needing laparoscopic surgery
1403498|NCT00372268|No emergency
1403499|NCT00372268|Aged over 18 years
1403500|NCT00372242|Mal-nutrition
1403501|NCT00372242|Morbidity
1403502|NCT00372242|Nutrition Education
1403503|NCT00372242|Complementary Feeding
1403504|NCT00372242|Weight gain
1403505|NCT00372242|Height
1403506|NCT00372216|myocardial infarction
1403507|NCT00372216|Clopidogrel
1403508|NCT00372216|primary PCI
1403509|NCT00372216|TIMI-flow
1403510|NCT00372216|STEMI within 6 hrs.
1403511|NCT00372203|Non-small cell lung cancer
1403512|NCT00372203|NSCLC
1403513|NCT00372203|EBUS
1403514|NCT00372203|Endobronchial ultrasound
1403515|NCT00372203|mediastinoscopy
1403516|NCT00372190|Pelvic organ prolapse
1403517|NCT00372190|recurrence
1403518|NCT00372190|mesh
1403519|NCT00372190|complications
1403520|NCT00372190|treatment
1403521|NCT00372177|monoclonal antibody
1403522|NCT00372177|diagnostics
1403523|NCT00372177|RA
1403524|NCT00372177|Immunoglobulins
1403525|NCT00372177|molecular target
1403526|NCT00372177|Tc99m-pertechnetate
1403527|NCT00372177|Fab-fragment of Anti-human CD4
1403528|NCT00372177|Radiopharmaceutical
1403529|NCT00372177|chronic inflammatory diseases
1403530|NCT00372177|active Rheumatoid Arthritis
1403531|NCT00372164|ASIPP
1403532|NCT00372164|Guidelines
1403533|NCT00372151|Schizophrenia
1403534|NCT00372151|Schizoaffective disorders
1403535|NCT00372151|Theonine
1403536|NCT00372151|Augmentation
1403537|NCT00372138|Abdominal aortic aneurysms
1403538|NCT00372138|Endoleaks
1403539|NCT00372138|Prevention
1403540|NCT00372125|Prader-Willi syndrome
1403541|NCT00372125|Growth hormone
1403542|NCT00372125|Body composition
1403543|NCT00372112|Chronic Obstructive Pulmonary Disease (COPD)
1403544|NCT00372112|COPD
1403545|NCT00372099|Postmenopausal women
1403546|NCT00372099|bone microarchitecture
1403547|NCT00372099|peripheral quantitative micro-CT
1403548|NCT00372099|salmon calcitonin
1403549|NCT00372034|contact lenses
1403550|NCT00372034|intolerance
1403551|NCT00372034|punctal plugs
1403552|NCT00372034|tear volume
1403553|NCT00372034|Intolerance to contact lens wear due to dryness symptoms
1403554|NCT00372021|non arthritic ischemic optic neuropathy
1403555|NCT00372021|anterior ischemic optic neuropathy
1403556|NCT00372021|Optic nerve Neurotomy
1403557|NCT00371995|Visceral leishmaniasis
1403558|NCT00371995|kala-azar
1403559|NCT00371995|miltefosine
1403560|NCT00371995|AmBisome
1403561|NCT00371982|Fish oil
1403562|NCT00371982|Type 2 diabetic women
1403563|NCT00371982|adiposity
1403564|NCT00371982|adipose tissue inflammation
1403565|NCT00371982|PAI-1
1403566|NCT00371982|Insulin sensitivity
1403567|NCT00371969|Unsafe drinking
1403568|NCT00371969|Human Immunodeficiency Virus
1403569|NCT00371969|Motivational Interviewing
1403570|NCT00371956|raloxifene
1403571|NCT00371956|estrogen
1403572|NCT00371956|receptor
1403573|NCT00371956|modulation
1403574|NCT00371956|osteoporosis
1403575|NCT00371956|steroid
1403576|NCT00371956|Steroids
1403577|NCT00371943|variceal bleeding,band ligation, beta-blocker
1403578|NCT00371943|had history of esophageal variceal bleeding
1403579|NCT00371904|Rituximab
1403580|NCT00371904|donor
1403581|NCT00371904|sensitised
1403582|NCT00371904|antibody
1403583|NCT00371904|rejection
1403584|NCT00371878|Vaccine
1403585|NCT00371878|Lung
1403586|NCT00371878|Bronchoalveolar lavage
1403587|NCT00371878|Lymphocyte
1403588|NCT00371878|Immunoglobulin
1403589|NCT00371878|HIV
1403590|NCT00371878|Streptococcus pneumoniae
1403591|NCT00371878|Conjugate vaccine
1403592|NCT00371865|Behavior therapy
1403593|NCT00371865|Chronic pain
1403594|NCT00371865|Cognitive therapy
1403595|NCT00371865|Meditation
1403596|NCT00371865|Mindfulness
1403597|NCT00371865|Psychotherapy
1403598|NCT00371839|Hearing Loss
1403599|NCT00371839|Hearing Aids
1403600|NCT00371839|Rehabilitation of hearing impaired
1403601|NCT00371826|Renal transplantation
1403602|NCT00371826|everolimus
1403603|NCT00371826|Immunosuppressants
1403604|NCT00371800|Cinnamon
1403605|NCT00371800|Type 1 Diabetes
1403606|NCT00371800|Adolescent
1403607|NCT00371800|HbA1c
1403608|NCT00371774|Psoriasis
1403609|NCT00371774|Plaque Psoriasis
1403610|NCT00371774|Amevive®
1403611|NCT00371774|alefacept
1403612|NCT00371761|Hepatitis B virus
1403613|NCT00371761|Pegylated interferon alfa-2b (PegIntron)
1403614|NCT00371735|Malaria CDA LAPDAP Africa
1403615|NCT00371722|Cesarean section
1403616|NCT00371722|Appendectomy
1403617|NCT00371683|Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery
1403618|NCT00371670|Knee, osteoarthritis, pain, disease modifying
1403619|NCT00371657|obesity
1403620|NCT00371657|small for gestation age
1403621|NCT00371657|intrauterine growth restriction
1403622|NCT00371644|Stress Disorders, Post-Traumatic
1403994|NCT00370240|Anesthetics,local
1403623|NCT00371644|Cognitive Processing Therapy
1403624|NCT00371644|Military sexual trauma
1403625|NCT00371644|Psychology, Military
1403626|NCT00371644|Veterans
1403627|NCT00371644|Rape
1403628|NCT00371644|Veterans, psychology
1403629|NCT00371644|Healthcare utilization
1403630|NCT00371631|biofilm
1403631|NCT00371631|clinical trial
1403632|NCT00371631|Escherichia coli
1403633|NCT00371631|urinary catheter
1403634|NCT00371618|Fluoroscopy
1403635|NCT00371618|Interventional Pain Management Procedures
1403636|NCT00371605|Voriconazole
1403637|NCT00371605|Liver Transplant
1403638|NCT00371605|Fungal Infection
1403639|NCT00371592|Treatment Naive
1403640|NCT00371579|rosuvastatin
1403641|NCT00371579|hepatitis C
1403642|NCT00371579|geranylgeranylation
1403643|NCT00371579|HCV-RNA load
1403644|NCT00371566|squamous cell carcinoma of head and neck
1403645|NCT00371566|lapatinib
1403646|NCT00371566|ErbB1/ErbB2 inhibitor
1403647|NCT00371566|apoptosis
1403648|NCT00371553|relapsed or cisplatin-refractory germ cell cancer
1403649|NCT00371553|germ cell cancer
1403650|NCT00371553|SU011248 (Sunitinib)
1403651|NCT00371540|Africa
1403652|NCT00371540|Antiretrovirals
1403653|NCT00371527|Bronchitis
1403654|NCT00371527|Acute bronchitis
1403655|NCT00371527|Ipratropium
1403656|NCT00371527|Cough
1403657|NCT00371527|Metered dose inhaler
1403658|NCT00371527|Antibiotic prescriptions
1403659|NCT00371527|Sputum production
1403660|NCT00371501|lupus
1403661|NCT00371501|atherosclerosis
1403662|NCT00371501|thrombosis
1403663|NCT00371501|statin
1403664|NCT00371501|lipid
1403665|NCT00371488|ErbB2
1403666|NCT00371488|Stage IV breast cancer
1403667|NCT00371488|ErbB1
1403668|NCT00371488|breast cancer
1403669|NCT00371488|lapatinib
1403670|NCT00371488|Herceptin
1403671|NCT00371488|trastuzumab
1403672|NCT00371462|intervention study
1403673|NCT00371462|technology
1403674|NCT00371462|weight loss
1403675|NCT00371449|hearing loss
1403676|NCT00371449|hearing aids
1403677|NCT00371436|Counseling
1403678|NCT00371436|Education
1403679|NCT00371436|Evaluation studies
1403680|NCT00371436|Quality of health care
1403681|NCT00371436|Rehabilitation of hearing impaired
1403682|NCT00371436|Triage
1403683|NCT00371410|Vitrectomy
1403684|NCT00371410|Intravitreal triamcinolone acetonide
1403685|NCT00371410|Macular focal laser photocoagulation
1403686|NCT00371410|Best-corrected visual acuity
1403687|NCT00371410|Central macular thickness
1403688|NCT00371397|yoga
1403689|NCT00371397|immune function
1403690|NCT00371397|stress
1403691|NCT00371397|health
1403692|NCT00371397|mood
1403693|NCT00371397|skin barrier repair
1403694|NCT00371384|massage
1403695|NCT00371384|back pain
1403696|NCT00371384|effectiveness
1403697|NCT00371371|clinical trial
1403698|NCT00371371|chronic critical limb ischemia
1403699|NCT00371371|leg pain
1403700|NCT00371371|cell therapy
1403701|NCT00371371|bone marrow
1403702|NCT00371371|mononuclear
1403703|NCT00371371|progenitor cell
1403704|NCT00371371|stem cell
1403705|NCT00371371|critical limb ischemia
1403706|NCT00371371|nonhealing leg ulcer
1403707|NCT00371345|Recurrent, locally-advanced, or metastatic breast cancer
1403708|NCT00371332|chronic periodontitis, mouth
1403709|NCT00371332|Moderate to advanced chronic periodontitis
1403710|NCT00371319|lupus
1403711|NCT00371319|nephritis
1403712|NCT00371319|tacrolimus
1403713|NCT00371319|mycophenolate mofetil
1403714|NCT00371306|Diabetes
1403715|NCT00371306|Pregnancy
1403716|NCT00371293|Sleep Apnea
1403717|NCT00371293|C-Reactive Protein
1403718|NCT00371293|Obesity
1403719|NCT00371293|Insulin Resistance
1403720|NCT00371293|Arterial stiffness
1403721|NCT00371280|hydroxyapatite
1403722|NCT00371280|peg
1403723|NCT00371280|prosthetic motility
1403724|NCT00371280|orbital implant
1403725|NCT00371267|cognitive behavioral therapy
1403726|NCT00371267|pain
1403727|NCT00371254|Recurrent, locally-advanced, or 'triple negative' metastatic breast cancer
1403728|NCT00371241|ECMO
1403729|NCT00371241|extracorporeal membrane oxygenation
1403730|NCT00371241|cytokines
1403731|NCT00371241|chemokines
1403732|NCT00371228|cord clamping
1403733|NCT00371228|hematocrit
1403734|NCT00371228|hemoglobin
1403735|NCT00371228|timing
1403736|NCT00371215|hemostasis
1403737|NCT00371215|grafting, skin
1403738|NCT00371215|hemostatics
1403739|NCT00371215|phase 2
1403740|NCT00371202|keratoconus, penetrating keratoplasty,
1403741|NCT00371202|deep lamellar keratoplasty
1403742|NCT00371202|big bubble technique
1403743|NCT00371189|circumsporozoite, malaria, vaccine
1403744|NCT00371176|Cognitive Behavior Therapy
1403745|NCT00371176|Cognitive enhancers
1403746|NCT00371176|Combat Disorders
1403747|NCT00371176|D-Cycloserine
1404118|NCT00369772|QoL
1403748|NCT00371176|Stress Disorders, Post-Traumatic
1403749|NCT00371163|Identification of genes by microarray analyses.
1403750|NCT00371137|FMS
1403751|NCT00371137|Fibro
1403752|NCT00371137|pain
1403753|NCT00371137|Body pain
1403754|NCT00371137|tenderness
1403755|NCT00371137|joint pain
1403756|NCT00371137|stiffness
1403757|NCT00371137|muscular pain
1403758|NCT00371124|Myopia treatment
1403759|NCT00371124|Atropine
1403760|NCT00371111|Resistant uveitic cystoid macular edema
1403761|NCT00371111|intravitreal triamcinolone
1403762|NCT00371111|intravitreal bevacizumab
1403763|NCT00371098|influenza vaccination
1403764|NCT00371098|coronary artery disease
1403765|NCT00371098|prevention
1403766|NCT00371098|acute coronary syndromes
1403767|NCT00371085|heart failure
1403768|NCT00371085|quality improvement
1403769|NCT00371085|patient education
1403770|NCT00371085|health care economics
1403771|NCT00371072|Aphakic Glaucoma
1403772|NCT00371072|trabeculectomy with mitomycin- C
1403773|NCT00371072|Ahmed glaucoma implant
1403774|NCT00371059|Agitation
1403775|NCT00371059|Dementia
1403776|NCT00371059|Alzheimer's
1403777|NCT00371046|preterm labor
1403778|NCT00371046|transvaginal ultrasound cervical length
1403779|NCT00371046|fetal fibronectin
1403780|NCT00371046|preterm birth
1403781|NCT00371020|silicone oil
1403782|NCT00371020|PVR
1403783|NCT00371020|retinal redetachment
1403784|NCT00371020|low molecular weight heparin
1403785|NCT00371020|5-FU
1403786|NCT00370994|post-lumbar surgery syndrome
1403787|NCT00370994|percutaneous lumbar epidural adhesiolysis
1403788|NCT00370994|hypertonic saline neurolysis
1403789|NCT00370981|investigational drug
1403790|NCT00370981|ejaculation
1403791|NCT00370968|Children
1403792|NCT00370968|India
1403793|NCT00370968|Hospital
1403794|NCT00370968|Zinc
1403795|NCT00370968|Malnutrition
1403796|NCT00370968|Treatment
1403797|NCT00370955|Phacoemulsification
1403798|NCT00370955|Corneal endothelial cell loss
1403799|NCT00370955|Hydrodynamic parameters
1403800|NCT00370955|Total ultrasound energy
1403801|NCT00370955|Total infused fluids
1403802|NCT00370942|GW823093C
1403803|NCT00370942|diabetes
1403804|NCT00370942|type 2 diabetes mellitus
1403805|NCT00370942|DPP-IV inhibitor
1403806|NCT00370916|Clinical Decision Support Systems
1403807|NCT00370916|Continuity of Patient Care
1403808|NCT00370916|Medication Errors
1403809|NCT00370916|Drug Adverse Effects
1403810|NCT00370903|cesarean
1403811|NCT00370903|planned
1403812|NCT00370903|emergent
1403813|NCT00370903|postpartum depression
1403814|NCT00370890|nasopharyngeal cancer
1403815|NCT00370890|adjuvant chemotherapy
1403816|NCT00370890|EBV DNA
1403817|NCT00370890|PET CT scan
1403818|NCT00370877|Post-partum hemorrhage
1403819|NCT00370877|Arterial embolization
1403820|NCT00370877|Surgery
1403821|NCT00370877|Hysterectomy
1403822|NCT00370877|Activated recombinant human factor VII
1403823|NCT00370864|Pandemic
1403824|NCT00370864|Influenza
1403825|NCT00370864|Prevention
1403826|NCT00370864|Vaccine
1403827|NCT00370864|Prevention of Pandemic Influenza
1403828|NCT00370851|intravitreal Avastin
1403829|NCT00370851|BRVO
1403830|NCT00370851|Macular edema
1403831|NCT00370838|Tics
1403832|NCT00370838|Tourette syndrome
1403833|NCT00370838|levetiracetam
1403834|NCT00370838|clonidine
1403835|NCT00370825|Visceral leishmaniasis
1403836|NCT00370825|miltefosine
1403837|NCT00370825|AmBisome
1403838|NCT00370825|Combination
1403839|NCT00370812|amniotic membrane transplantation
1403840|NCT00370812|ocular chemical burns
1403841|NCT00370799|Caudal Epidural injections
1403842|NCT00370799|lumbar disc herniation
1403843|NCT00370799|spinal stenosis
1403844|NCT00370799|discogenic pain
1403845|NCT00370799|post-lumbar laminectomy syndrome
1403846|NCT00370786|Choroidal neovascularization (CNV)
1403847|NCT00370786|Bevacizumab
1403848|NCT00370786|Non AMD
1403849|NCT00370786|High myopia
1403850|NCT00370786|angioid streaks
1403851|NCT00370786|Ocular histoplasmosis
1403852|NCT00370786|Idiopathic
1403853|NCT00370773|Failed Back Surgery Syndrome
1403854|NCT00370773|Back Pain
1403855|NCT00370773|Chronic Pain
1403856|NCT00370773|Spinal Cord Stimulation
1403857|NCT00370760|PVR
1403858|NCT00370760|Oral colchicine
1403859|NCT00370760|Dexamethasone
1403860|NCT00370760|low molecular weight heparin
1403861|NCT00370760|5-FU
1403862|NCT00370734|botulinum toxin
1403863|NCT00370734|thyroid eye disease
1403864|NCT00370734|lid retraction
1403865|NCT00370721|Proliferative diabetic retinopathy(PDR)
1403866|NCT00370721|Pan retinal photocoagulation (PRP)
1403867|NCT00370721|Vitreous hemorrhage
1403868|NCT00370721|Traction retinal detachment
1403869|NCT00370721|Neovascularization on disc (NVD)
1403870|NCT00370721|Neovascularization elsewhere (NVE)
1403871|NCT00370721|Fibrous proliferation on disc (FPD)
1403872|NCT00370721|Fibrous proliferaiton elsewhere (FPE)
1403873|NCT00370708|Cesarean
1403874|NCT00370708|Oral
1403875|NCT00370708|Intake
1403876|NCT00370695|Chronic back pain
1403877|NCT00370695|Intractable neuropathic back pain
1403878|NCT00370695|Lumbar radiculopathy
1403879|NCT00370695|Spinal cord stimulation
1403880|NCT00370669|Bevacizumab
1403881|NCT00370669|CSME
1403882|NCT00370669|MPC
1403883|NCT00370669|Triamcinolone acetonide
1403884|NCT00370656|Diabetic Peripheral Neuropathy
1403885|NCT00370643|hyperglycaemia
1403886|NCT00370643|open heart surgery
1403887|NCT00370643|intensive care unit
1403888|NCT00370630|CRVO
1403889|NCT00370630|Intravitreal Avastin
1403890|NCT00370630|Intravitreal triamcinolone
1403891|NCT00370617|chronic hepatitis C
1403892|NCT00370617|insulin resistance
1403893|NCT00370617|therapy
1403894|NCT00370604|Parturient
1403895|NCT00370604|Obstetrics
1403896|NCT00370604|Pregnancy
1403897|NCT00370604|Labour
1403898|NCT00370604|Labor
1403899|NCT00370604|Headache
1403900|NCT00370604|Epidural
1403901|NCT00370604|Analgesia
1403902|NCT00370604|Anesthesia
1403903|NCT00370604|Anaesthesia
1403904|NCT00370591|Inhaled corticosteroids
1403905|NCT00370591|Asthma
1403906|NCT00370578|STEMI, THROMBUS, ASPIRATION DEVICE, NO REFLOW
1403907|NCT00370539|Photodynamic therapy,
1403908|NCT00370539|Bevacizumab,
1403909|NCT00370539|Triamcinolone,
1403910|NCT00370539|Age-related macular degeneration,
1403911|NCT00370539|Choroidal neovascular membrane
1403912|NCT00370526|heart failure
1403913|NCT00370526|resynchronization
1403914|NCT00370526|CRT
1403915|NCT00370526|Bi-V pacemaker
1403916|NCT00370526|LV lead placement
1403917|NCT00370526|hemodynamic assessment
1403918|NCT00370526|CRT Outcomes
1403919|NCT00370513|liver cancer
1403920|NCT00370513|pazopanib
1403921|NCT00370513|hepatocellular cancer
1403922|NCT00370500|Schizophrenia
1403923|NCT00370500|Dopamine transporter gene
1403924|NCT00370500|DNA methylation
1403925|NCT00370500|Epigenetics
1403926|NCT00370487|Abortion
1403927|NCT00370487|Midlevel providers
1403928|NCT00370487|South Africa
1403929|NCT00370487|Viet Nam
1403930|NCT00370474|Bi-V lead
1403931|NCT00370474|Magnetic Navigation
1403932|NCT00370474|Cardiac Resynchronization Therapy
1403933|NCT00370461|Basic Cardiac Life Support
1403934|NCT00370461|Termination of Resuscitation
1403935|NCT00370461|Emergency Medical Services
1403936|NCT00370461|Primary Care Paramedics
1403937|NCT00370461|Out of Hospital Cardiac Arrest
1403938|NCT00370435|rheumatoid arthritis
1403939|NCT00370435|safety
1403940|NCT00370435|GW274150
1403941|NCT00370435|pharmacokinetics
1403942|NCT00370435|tolerability
1403943|NCT00370422|Cystoid macular edema
1403944|NCT00370422|Diabetic macular edema
1403945|NCT00370422|Hard exudates
1403946|NCT00370422|Intravitreal bevacizumab
1403947|NCT00370422|Intravitreal triamcinolone
1403948|NCT00370422|Macular thickness
1403949|NCT00370409|Rebleeding
1403950|NCT00370409|Diabetic vitreous hemorrhage
1403951|NCT00370409|Cryotherapy
1403952|NCT00370396|Streptococcus pneumonia, pneumococcal conjugate vaccine
1403953|NCT00370383|Non Small Cell Lung Cancer
1403954|NCT00370383|PATIENTS ≥ 70 YEARS WITH UNRESECTABLE STAGE 3 OR 4 NSCLC
1403955|NCT00370370|Bevacizumab,
1403956|NCT00370370|Triamcinolone
1403957|NCT00370370|Age-related macular degeneration
1403958|NCT00370370|Choroidal neovascular membrane
1403959|NCT00370357|Microbicide
1403960|NCT00370357|SPL7013
1403961|NCT00370357|VivaGel
1403962|NCT00370344|Gallbladder diseases
1403963|NCT00370344|gallstones
1403964|NCT00370344|cholecystectomy
1403965|NCT00370344|minilaparotomy
1403966|NCT00370344|laparoscopy
1403967|NCT00370331|ITP
1403968|NCT00370331|idiopathic
1403969|NCT00370331|platelets
1403970|NCT00370331|purpura
1403971|NCT00370331|thrombocytopenia
1403972|NCT00370331|Idiopathic Thrombocytopenic Purpura
1403973|NCT00370331|thrombocytopenic
1403974|NCT00370318|Pneumococcal Disease
1403975|NCT00370305|11ß-hydroxysteroid dehydrogenase
1403976|NCT00370305|rosiglitazone
1403977|NCT00370305|insulin sensitivity
1403978|NCT00370305|Impaired glucose tolerance
1403979|NCT00370279|Pseudophakic retinal detachment,
1403980|NCT00370279|Aphakic retinal detachment,
1403981|NCT00370279|Scleral buckling,
1403982|NCT00370279|Primary vitrectomy,
1403983|NCT00370279|Proliferative vitreoretinopathy
1403984|NCT00370266|Macular edema
1403985|NCT00370266|Branch retinal vein occlusion
1403986|NCT00370266|Intravitreal triamcinolone
1403987|NCT00370266|Macular thickness
1403988|NCT00370266|Retinal neovascularization
1403989|NCT00370253|hepatorenal syndrome
1403990|NCT00370253|ascites
1403991|NCT00370253|portal hypertension
1403992|NCT00370253|cirrhosis
1403993|NCT00370240|Female
1403995|NCT00370227|Streptococcus pneumonia, pneumococcal conjugate vaccine
1403996|NCT00370214|Pulmonary arterial hypertension
1403997|NCT00370214|Lung diseases
1403998|NCT00370214|Heart diseases
1403999|NCT00370214|Pulmonary circulation
1404000|NCT00370214|Vascular resistance
1404001|NCT00370214|PAH
1404002|NCT00370214|Hypertension
1404003|NCT00370201|retinal detachment
1404004|NCT00370201|proliferative vitreoretinopathy
1404005|NCT00370188|problem gambling
1404006|NCT00370188|topiramate
1404007|NCT00370123|endometriosis
1404008|NCT00370123|apoptosis
1404009|NCT00370123|regulatory T cells
1404010|NCT00370097|Asthma infants FLOVENT spacer
1404011|NCT00370071|MS
1404012|NCT00370058|ect
1404013|NCT00370058|depression
1404014|NCT00370058|homocysteine
1404015|NCT00370058|mthfr genotype
1404016|NCT00370032|mucosal blood flow d-IBS
1404017|NCT00370019|Premature Ovarian Failure
1404018|NCT00370019|Ovulation
1404019|NCT00370019|Fertility
1404020|NCT00370019|Estrogen Replacement
1404021|NCT00370019|Follicle Function
1404022|NCT00370019|Premature Menopause
1404023|NCT00370019|POF
1404024|NCT00370006|cytomegalovirus
1404025|NCT00370006|vaccine
1404026|NCT00370006|T cell
1404027|NCT00370006|antibodies
1404028|NCT00369993|asthma
1404029|NCT00369993|spacer
1404030|NCT00369967|Contraception
1404031|NCT00369967|Adolescents
1404032|NCT00369967|Contraceptive vaginal ring
1404033|NCT00369967|Quick start
1404034|NCT00369954|recurrent ovarian epithelial cancer
1404035|NCT00369954|fallopian tube cancer
1404036|NCT00369954|peritoneal cavity cancer
1404037|NCT00369915|Cholinergic
1404038|NCT00369915|Unipolar
1404039|NCT00369915|Bipolar
1404040|NCT00369915|Depression
1404041|NCT00369915|Muscarinic
1404042|NCT00369915|Scopolamine
1404043|NCT00369915|Major Depressive Disorder
1404044|NCT00369915|MDD
1404045|NCT00369915|Bipolar Disorder
1404046|NCT00369915|BP
1404047|NCT00369902|pain
1404048|NCT00369902|acupuncture
1404049|NCT00369889|Thymoma
1404050|NCT00369889|Thymic Cancer
1404051|NCT00369876|Burns
1404052|NCT00369876|Anorexia
1404053|NCT00369876|Neuropeptide
1404054|NCT00369876|Leptin
1404055|NCT00369876|Adiponectin
1404056|NCT00369876|Gherlin
1404057|NCT00369863|Cystoid macular edema
1404058|NCT00369863|Diabetic macular edema
1404059|NCT00369863|Hard exudates
1404060|NCT00369863|Intravitreal triamcinolone
1404061|NCT00369863|Macular thickness
1404062|NCT00369850|osteoporosis
1404063|NCT00369850|stage I breast cancer
1404064|NCT00369850|stage II breast cancer
1404065|NCT00369850|stage IIIA breast cancer
1404066|NCT00369824|HPV
1404067|NCT00369824|HPV, diptheria, pertussis, tetanus, meningitis
1404068|NCT00369811|Cholecystectomy, postoperative
1404069|NCT00369798|Unipolar Depression
1404070|NCT00369798|Phosphorylation
1404071|NCT00369798|Affinity States
1404072|NCT00369798|Compartment Analysis
1404073|NCT00369798|(R)-(11)C Rolipram
1404074|NCT00369798|Depression
1404075|NCT00369798|Major Depressive Disorder
1404076|NCT00369798|MDD
1404077|NCT00369798|Healthy Volunteer
1404078|NCT00369798|HV
1404079|NCT00369785|cognitive/functional effects
1404080|NCT00369785|fatigue
1404081|NCT00369785|psychosocial effects of cancer and its treatment
1404082|NCT00369785|radiation toxicity
1404083|NCT00369785|tumors metastatic to brain
1404084|NCT00369785|adult brain stem glioma
1404085|NCT00369785|adult central nervous system germ cell tumor
1404086|NCT00369785|adult choroid plexus tumor
1404087|NCT00369785|adult craniopharyngioma
1404088|NCT00369785|adult mixed glioma
1404089|NCT00369785|adult anaplastic meningioma
1404090|NCT00369785|meningeal melanocytoma
1404091|NCT00369785|adult meningeal hemangiopericytoma
1404092|NCT00369785|adult grade I meningioma
1404093|NCT00369785|adult grade II meningioma
1404094|NCT00369785|adult grade III meningioma
1404095|NCT00369785|adult papillary meningioma
1404096|NCT00369785|adult anaplastic oligodendroglioma
1404097|NCT00369785|adult oligodendroglioma
1404098|NCT00369785|adult pineoblastoma
1404099|NCT00369785|adult pineocytoma
1404100|NCT00369785|adult anaplastic astrocytoma
1404101|NCT00369785|adult diffuse astrocytoma
1404102|NCT00369785|adult glioblastoma
1404103|NCT00369785|adult giant cell glioblastoma
1404104|NCT00369785|adult gliosarcoma
1404105|NCT00369785|adult pilocytic astrocytoma
1404106|NCT00369785|adult ependymoblastoma
1404107|NCT00369785|adult medulloblastoma
1404108|NCT00369785|adult supratentorial primitive neuroectodermal tumor (PNET)
1404109|NCT00369785|adult anaplastic ependymoma
1404110|NCT00369785|adult ependymoma
1404111|NCT00369785|adult myxopapillary ependymoma
1404112|NCT00369785|adult subependymoma
1404113|NCT00369772|Aranesp
1404114|NCT00369772|Anemia
1404115|NCT00369772|Kidney Disease
1404116|NCT00369772|Hemoglobin
1404117|NCT00369772|darbepoetin alfa
1404119|NCT00369759|Acute Lower Respiratory Infection
1404120|NCT00369759|Retractions
1404121|NCT00369759|Bronchiolitis or pneumonia
1404122|NCT00369759|Wheezing
1404123|NCT00369759|Rales
1404124|NCT00369759|Crackles
1404125|NCT00369746|Depression
1404126|NCT00369746|Alcohol Abuse
1404127|NCT00369746|Alcohol Dependence
1404128|NCT00369733|Aranesp
1404129|NCT00369733|Anemia
1404130|NCT00369733|Kidney Disease
1404131|NCT00369733|Hemoglobin
1404132|NCT00369733|darbepoetin alfa
1404133|NCT00369733|QoL
1404134|NCT00369720|Prematurity
1404135|NCT00369720|Resuscitation
1404136|NCT00369720|Room Air
1404137|NCT00369707|Non-Hodgkin's Lymphoma
1404138|NCT00369694|Esophageal varices
1404139|NCT00369694|Portal Hypertension
1404140|NCT00369694|Melena
1404141|NCT00369694|Hematemesis
1404142|NCT00369694|Gastrointestinal Hemorrhage
1404143|NCT00369694|Terlipressin
1404144|NCT00369694|Efficacy
1404145|NCT00369694|Safety
1404146|NCT00369681|stage II adult Hodgkin lymphoma
1404147|NCT00369681|stage III adult Hodgkin lymphoma
1404148|NCT00369681|stage IV adult Hodgkin lymphoma
1404149|NCT00369681|adult lymphocyte depletion Hodgkin lymphoma
1404150|NCT00369681|adult mixed cellularity Hodgkin lymphoma
1404151|NCT00369681|adult nodular sclerosis Hodgkin lymphoma
1404152|NCT00369668|Rehabilitation
1404153|NCT00369668|Physical Therapy Techniques
1404154|NCT00369668|Occupational Therapy
1404155|NCT00369668|Upper Extremity; Motor skills
1404156|NCT00369642|Cognitive-behavioral therapy
1404157|NCT00369642|Children
1404158|NCT00369642|Obsessive-compulsive disorder
1404159|NCT00369642|Intensive Cognitive-behavioral therapy
1404160|NCT00369642|Weekly Cognitive-behavioral therapy
1404161|NCT00369629|recurrent mycosis fungoides/Sezary syndrome
1404162|NCT00369629|stage I mycosis fungoides/Sezary syndrome
1404163|NCT00369629|stage II mycosis fungoides/Sezary syndrome
1404164|NCT00369629|stage III mycosis fungoides/Sezary syndrome
1404165|NCT00369629|stage IV mycosis fungoides/Sezary syndrome
1404166|NCT00369629|stage I cutaneous T-cell non-Hodgkin lymphoma
1404167|NCT00369629|stage II cutaneous T-cell non-Hodgkin lymphoma
1404168|NCT00369629|stage III cutaneous T-cell non-Hodgkin lymphoma
1404169|NCT00369629|stage IV cutaneous T-cell non-Hodgkin lymphoma
1404170|NCT00369629|recurrent cutaneous T-cell non-Hodgkin lymphoma
1404171|NCT00369603|Alzheimer's Disease
1404172|NCT00369603|fMRI
1404173|NCT00369603|Functional Neuroimaging
1404174|NCT00369603|Allosteric Nicotinic Receptor Modulation
1404175|NCT00369603|Acetylcholinesterase Inhibition
1404176|NCT00369603|Head to head
1404177|NCT00369603|Dose escalation
1404178|NCT00369603|Biomarker
1404179|NCT00369577|Agitation
1404180|NCT00369577|Schizophrenia
1404181|NCT00369564|neurotoxicity
1404182|NCT00369564|peripheral neuropathy
1404183|NCT00369564|stage I Wilms tumor
1404184|NCT00369564|stage II Wilms tumor
1404185|NCT00369564|stage III Wilms tumor
1404186|NCT00369564|stage IV Wilms tumor
1404187|NCT00369564|stage V Wilms tumor
1404188|NCT00369564|previously untreated childhood rhabdomyosarcoma
1404189|NCT00369564|childhood grade III lymphomatoid granulomatosis
1404190|NCT00369564|childhood diffuse large cell lymphoma
1404191|NCT00369564|childhood immunoblastic large cell lymphoma
1404192|NCT00369564|stage I childhood large cell lymphoma
1404193|NCT00369564|stage II childhood large cell lymphoma
1404194|NCT00369564|stage III childhood large cell lymphoma
1404195|NCT00369564|stage IV childhood large cell lymphoma
1404196|NCT00369564|stage I childhood lymphoblastic lymphoma
1404197|NCT00369564|stage II childhood lymphoblastic lymphoma
1404198|NCT00369564|stage III childhood lymphoblastic lymphoma
1404199|NCT00369564|stage IV childhood lymphoblastic lymphoma
1404200|NCT00369564|childhood Burkitt lymphoma
1404201|NCT00369564|stage I childhood small noncleaved cell lymphoma
1404202|NCT00369564|stage II childhood small noncleaved cell lymphoma
1404203|NCT00369564|stage III childhood small noncleaved cell lymphoma
1404204|NCT00369564|stage IV childhood small noncleaved cell lymphoma
1404205|NCT00369564|untreated childhood acute lymphoblastic leukemia
1404206|NCT00369538|Podocyte - podocyturia - microparticles - angiotensin receptor antagonist - glomerulosclerosis
1404207|NCT00369538|Patients presenting with stable glomerular nephropathy with proteinuria, normal or slightly altered renal function, with hypertension
1404208|NCT00369512|Phase II
1404209|NCT00369512|Erlotinib
1404210|NCT00369512|Radiotherapy
1404211|NCT00369512|Squamous Cell Carcinomas
1404212|NCT00369512|Cutaneous
1404213|NCT00369512|Stage III
1404214|NCT00369486|diabetic
1404215|NCT00369486|macular
1404216|NCT00369486|edema
1404217|NCT00369486|peribulbar
1404218|NCT00369486|triamcinolone
1404219|NCT00369486|acetonide
1404220|NCT00369486|laser
1404221|NCT00369486|photocoagulation
1404222|NCT00369486|intraocular
1404223|NCT00369486|DME
1404224|NCT00369473|rheumatoid arthritis
1404225|NCT00369460|recurrent pancreatic cancer
1404226|NCT00369460|stage III pancreatic cancer
1404227|NCT00369460|adenocarcinoma of the pancreas
1404480|NCT00368381|fludrocortisone
1404228|NCT00369460|stage IV pancreatic cancer
1404229|NCT00369447|Non small cell lung cancer
1404230|NCT00369447|NSCLC
1404231|NCT00369447|Nimotuzumab
1404232|NCT00369447|TheraCIM
1404233|NCT00369447|h-R3
1404234|NCT00369447|YM BioSciences
1404235|NCT00369447|Radiation
1404236|NCT00369447|Non small cell lung cancer, Stage IIb, III and IV
1404245|NCT00369408|Randomized Trial
1404246|NCT00369408|Medication for Heavy Drinking
1404247|NCT00369408|Naltrexone Treatment
1404248|NCT00369408|Daily vs. Targeted Administration
1404249|NCT00369395|melanoma
1404250|NCT00369395|antibody
1404251|NCT00369395|angiogenesis
1404252|NCT00369395|volociximab
1404253|NCT00369382|Heart Transplant
1404254|NCT00369382|Kidney Failure
1404255|NCT00369343|Major Depressive Disorder
1404256|NCT00369343|vasomotor symptoms
1404257|NCT00369343|menopause
1404258|NCT00369343|diabetic neuropathy
1404259|NCT00369343|fibromyalgia
1404260|NCT00369330|atrial fibrillation
1404261|NCT00369330|early cardioversion
1404262|NCT00369330|electrical cardioversion
1404263|NCT00369304|Health
1404264|NCT00369278|Renal transplantation, mycophenolate
1404265|NCT00369265|Gastroesophageal reflux
1404266|NCT00369265|Laryngitis
1404267|NCT00369265|Hoarseness
1404268|NCT00369265|Dysphonia
1404269|NCT00369265|Proton pump inhibitor
1404270|NCT00369252|Nimotuzumab
1404271|NCT00369252|TheraCIM
1404272|NCT00369252|H-R3
1404273|NCT00369252|Solid tumours
1404274|NCT00369252|EGFR
1404275|NCT00369252|Monoclonal antibody
1404276|NCT00369239|Early psychosis
1404277|NCT00369239|premorbid functioning
1404278|NCT00369239|Scale for Assessment of Insight
1404279|NCT00369239|Risperdal Consta
1404280|NCT00369239|risperidone long acting injectable
1404281|NCT00369226|Velcade
1404282|NCT00369226|Bortezomib
1404283|NCT00369226|Allogeneic Stem Cell Transplant
1404284|NCT00369226|GVHD
1404285|NCT00369213|Crossover trial
1404286|NCT00369213|condom failure
1404287|NCT00369213|additional spermicidal lubricant
1404288|NCT00369148|glinides
1404289|NCT00369148|premixed insulin
1404290|NCT00369148|combination therapy
1404291|NCT00369148|glycemic control
1404292|NCT00369135|work
1404293|NCT00369135|Musculoskeletal Disorders
1404294|NCT00369109|recurrent colon cancer
1404295|NCT00369109|stage III colon cancer
1404296|NCT00369109|stage IV colon cancer
1404297|NCT00369109|recurrent rectal cancer
1404298|NCT00369109|stage III rectal cancer
1404299|NCT00369109|stage IV rectal cancer
1404300|NCT00369109|recurrent pancreatic cancer
1404301|NCT00369109|stage II pancreatic cancer
1404302|NCT00369109|stage III pancreatic cancer
1404303|NCT00369109|stage IV pancreatic cancer
1404304|NCT00369109|recurrent breast cancer
1404305|NCT00369109|stage IIIA breast cancer
1404306|NCT00369109|stage IIIB breast cancer
1404307|NCT00369109|stage IIIC breast cancer
1404308|NCT00369109|stage IV breast cancer
1404309|NCT00369096|Peritoneal Dialysis
1404310|NCT00369096|Bemiparin
1404311|NCT00369096|Icodextrin
1404312|NCT00369096|Peritoneal Transport Disorders
1404313|NCT00369083|Frail elderly
1404314|NCT00369083|Hospital at home
1404315|NCT00369070|AMG 706
1404316|NCT00369070|Bevacizumab
1404317|NCT00369070|Paclitaxel and Carboplatin
1404318|NCT00369070|Randomized
1404319|NCT00369070|Non-Small Cell Lung Cancer
1404320|NCT00369057|Intraocular pressure
1404321|NCT00369057|Prostatectomy
1404322|NCT00369057|Robotic
1404323|NCT00369057|Glaucoma
1404324|NCT00369057|Carbon dioxide
1404325|NCT00369044|decompensated heart failure
1404326|NCT00369044|prednisone
1404327|NCT00369044|diuretics
1404328|NCT00369044|diuresis
1404329|NCT00369031|HIV
1404330|NCT00369031|vaccine
1404331|NCT00369031|nasal immunization
1404332|NCT00369018|photodynamic therapy
1404333|NCT00369018|methyl aminolevulinate
1404334|NCT00369018|hexaminolevulinate
1404335|NCT00369018|dose-finding
1404336|NCT00369018|cervical dysplasia
1404337|NCT00369005|Transfusions
1404338|NCT00369005|Erythrocyte
1404339|NCT00369005|Anemia
1404340|NCT00369005|Brain
1404341|NCT00369005|Infant, Premature
1404342|NCT00368979|Benign Prostatic Hyperplasia BPH dutasteride
1404343|NCT00368966|Pneumococcal
1404344|NCT00368966|Pediatric
1404345|NCT00368966|Vaccine
1404346|NCT00368940|Memory Deficits
1404347|NCT00368940|Geriatric Depression
1404348|NCT00368940|Cognitive Impairment
1404349|NCT00368940|Executive Dysfunction
1404350|NCT00368940|Disability
1404351|NCT00368940|Problem Solving Therapy
1404604|NCT00367952|reverse transcriptase
1404352|NCT00368914|unspecified adult solid tumor, protocol specific
1404353|NCT00368901|Aranesp
1404354|NCT00368901|Anemia
1404355|NCT00368901|Kidney Disease
1404356|NCT00368901|Hemoglobin
1404357|NCT00368901|darbepoetin alfa
1404358|NCT00368901|QoL
1404359|NCT00368862|Alcoholism
1404360|NCT00368862|Depression
1404361|NCT00368862|Efficacy study
1404362|NCT00368862|Memantine
1404363|NCT00368862|Escitalopram
1404364|NCT00368849|Huntington Disease
1404365|NCT00368849|Chorea
1404366|NCT00368849|Attention
1404367|NCT00368849|ADHD
1404368|NCT00368849|ADD
1404369|NCT00368849|Strattera
1404370|NCT00368849|Atomoxetine
1404371|NCT00368836|Capnography
1404372|NCT00368836|Thromboembolism
1404373|NCT00368836|Arthroplasty
1404374|NCT00368836|D-dimer
1404375|NCT00368823|point of care
1404376|NCT00368823|evidence based medicine
1404377|NCT00368810|Children
1404378|NCT00368810|Cross-Sectional
1404379|NCT00368810|Glycosylphosphatidylinositol
1404380|NCT00368810|Cytokines
1404381|NCT00368810|Peripheral Blood Mononuclear Cells
1404382|NCT00368810|Malaria
1404383|NCT00368797|Gene Therapy
1404384|NCT00368797|PAOD
1404385|NCT00368797|CLI
1404386|NCT00368771|Irritable Bowel Syndrome
1404387|NCT00368771|Abdominal Pain
1404388|NCT00368771|Abdominal Discomfort
1404389|NCT00368771|Diarrhea
1404390|NCT00368771|Constipation
1404391|NCT00368771|IBS
1404392|NCT00368758|Meteorism
1404393|NCT00368758|Bloating
1404394|NCT00368758|Irritable bowel syndrome (IBS)
1404395|NCT00368758|Probiotics
1404396|NCT00368758|Bowel gas
1404397|NCT00368732|Congenital Heart Defects
1404398|NCT00368706|solifenacin
1404399|NCT00368706|Overactive bladder
1404400|NCT00368706|Urinary incontinence
1404401|NCT00368706|Treatment outcomes
1404402|NCT00368706|VESIcare
1404403|NCT00368680|Respiratory Distress Syndrome
1404404|NCT00368680|Early Bubble CPAP
1404405|NCT00368680|Mechanical Ventilation
1404406|NCT00368680|Surfactant
1404407|NCT00368667|Anorexia Nervosa
1404408|NCT00368667|Body Composition
1404409|NCT00368667|Metabolic Rate
1404410|NCT00368628|acute ischemic stroke
1404411|NCT00368628|sleep apnea
1404412|NCT00368628|continuous positive airway pressure
1404413|NCT00368615|melanoma
1404414|NCT00368615|malignant melanoma
1404415|NCT00368589|atherosclerotic plaque
1404416|NCT00368589|USPIO
1404417|NCT00368589|Atheroma
1404418|NCT00368589|thrombo-embolic stroke
1404419|NCT00368589|magnetic resonance imaging
1404420|NCT00368589|Ultra small Super-Paramagnetic Iron Oxide
1404421|NCT00368576|SB-480848
1404422|NCT00368576|methacholine challenge
1404423|NCT00368576|asthma
1404424|NCT00368576|inhaled steroid
1404425|NCT00368550|Alcohol Drinking
1404426|NCT00368550|Alcohol Dependence
1404427|NCT00368550|Sertraline Pharmacotherapy
1404428|NCT00368550|Alcoholism Subtypes
1404429|NCT00368550|Early- versus Late-Onset Alcoholism
1404430|NCT00368537|skin infection
1404431|NCT00368537|antibiotics
1404432|NCT00368524|cocaine dependence
1404433|NCT00368524|mental disorder
1404434|NCT00368524|dual diagnoses
1404435|NCT00368524|homelessness
1404436|NCT00368511|Fall Prevention
1404437|NCT00368511|Dynamic Posturography
1404438|NCT00368511|Nolwenn Effect
1404439|NCT00368511|Music Listening
1404440|NCT00368498|teicoplanin
1404441|NCT00368485|diaphragm electrical activity
1404442|NCT00368485|non invasive ventilation
1404443|NCT00368485|patient ventilator interaction
1404444|NCT00368472|Refractory
1404445|NCT00368472|Partial
1404446|NCT00368472|Seizures
1404447|NCT00368459|raloxifene, women
1404448|NCT00368446|Nontuberculous Mycobacterial Infection
1404449|NCT00368446|Primary Ciliary Dyskinesia
1404450|NCT00368446|Cystic Fibrosis
1404451|NCT00368446|Pseudohypoaldosteronism
1404452|NCT00368446|Chronic Granulomatous Disease
1404453|NCT00368446|Mycobacterial Infection
1404454|NCT00368446|PCD
1404455|NCT00368446|CF
1404456|NCT00368446|PHA
1404457|NCT00368446|Healthy Volunteer
1404458|NCT00368446|HV
1404459|NCT00368433|Sensory Processing
1404460|NCT00368433|Electromyogram
1404461|NCT00368433|Tic Disorder
1404462|NCT00368433|Tourette Syndrome
1404463|NCT00368433|Tourette's Syndrome
1404464|NCT00368433|Healthy Volunteer
1404465|NCT00368433|HV
1404466|NCT00368420|ovarian cancer
1404467|NCT00368420|recurrence
1404468|NCT00368420|surgery
1404469|NCT00368407|308-nm excimer laser
1404470|NCT00368407|vitiligo
1404471|NCT00368394|Insulin glulisine
1404472|NCT00368394|Euglycaemic clamp
1404473|NCT00368394|Diabetes mellitus Type 1
1404474|NCT00368381|sepsis
1404475|NCT00368381|septicemia
1404476|NCT00368381|sepsis syndrome
1404477|NCT00368381|adrenal insufficiency
1404478|NCT00368381|adrenal cortex hormones
1404479|NCT00368381|hydrocortisone
1404481|NCT00368355|haploidenticalstem cell transplant
1404482|NCT00368355|acute lymphoblastic leukemia
1404483|NCT00368355|Non Hodgkins Lymphoma
1404484|NCT00368355|Myelodysplastic Syndrome
1404485|NCT00368355|Acute myeloid leukemia
1404486|NCT00368355|Chronic myelogenous leukemia
1404487|NCT00368355|Hemophagocytic lymphohistiocytosis (HLH)
1404488|NCT00368355|Familial hemophagocytic lymphohistiocytosis (FLH)
1404489|NCT00368355|Viral-associated hemophagocytic syndrome (VAHS)
1404490|NCT00368355|X-linked lymphoproliferative disease (XLP)
1404491|NCT00367679|pazopanib
1404492|NCT00367679|I-ELCAP
1404493|NCT00367679|non-small cell lung cancer
1404494|NCT00367679|antiangiogenesis
1404495|NCT00367679|NSCLC
1404496|NCT00367679|GW786034
1404497|NCT00368316|Dysentery
1404498|NCT00368316|S. sonnei
1404499|NCT00368316|Antibody Response
1404500|NCT00368316|Protection
1404501|NCT00368303|Major Depression
1404502|NCT00368303|paroxetine controlled release (CR)
1404503|NCT00368303|paroxetine immediate release (IR)
1404504|NCT00368290|cocaine dependence
1404505|NCT00368290|hiv prevention
1404506|NCT00368277|Systolic hypertension
1404507|NCT00368277|hypertension
1404508|NCT00368277|aliskiren
1404509|NCT00368277|blood pressure
1404510|NCT00368277|ramipril
1404511|NCT00368277|HTN
1404512|NCT00368264|lupus
1404513|NCT00368264|nephritis
1404514|NCT00368264|membraneous
1404515|NCT00368264|proteinuria
1404516|NCT00368264|TNF
1404517|NCT00368264|infliximab
1404518|NCT00368264|azathioprine
1404519|NCT00368264|autoantibodies
1404520|NCT00368251|Unverricht-Lundborg Disease
1404521|NCT00368251|Baltic Myoclonus
1404522|NCT00368251|Progressive Myoclonic Epilepsies
1404523|NCT00368251|Myoclonus
1404524|NCT00368251|Brivaracetam
1404525|NCT00368238|Platelet function tests
1404526|NCT00368238|Erythropoietin
1404527|NCT00368238|Aspirin
1404528|NCT00368238|Clopidogrel
1404529|NCT00368225|Viral Hepatitis
1404530|NCT00368225|Hepatitis C
1404531|NCT00368225|HCV
1404532|NCT00368225|Liver Transplant
1404533|NCT00368225|Renal Transplant
1404534|NCT00368225|Kidney Transplant
1404535|NCT00368212|Somatization
1404536|NCT00368212|Refractory Symptoms
1404537|NCT00368199|single photon emission computer tomography (SPECT)
1404538|NCT00368199|transcranial sonography
1404539|NCT00368199|transcranial duplex scanning
1404540|NCT00368199|parkinson's disease
1404541|NCT00368199|atypical parkinson syndromes
1404542|NCT00368199|parkinsonism
1404543|NCT00368199|parkinsonian
1404544|NCT00368199|diagnostic
1404545|NCT00368199|progressive supranuclear paralysis
1404546|NCT00368160|Next day driving
1404547|NCT00368147|Hemodialysis
1404548|NCT00368147|Arteriovenous Fistula
1404549|NCT00368147|Arteriovenous Graft
1404550|NCT00368147|Left Ventricular Hypertrophy
1404551|NCT00368147|Brain Natriuretic Peptide
1404552|NCT00368134|Type 2 Diabetes
1404553|NCT00368134|Vildagliptin
1404554|NCT00368134|HbA1c
1404555|NCT00368121|Multiple Myeloma
1404556|NCT00368121|Cetuximab
1404557|NCT00368095|DM
1404558|NCT00368095|HT
1404559|NCT00368095|Dyslipidemia
1404560|NCT00368095|Obesity
1404561|NCT00368095|Cardiovascular disease
1404562|NCT00368095|Cerebrovascular disease
1404563|NCT00368095|Myocardial infarction
1404564|NCT00368095|stroke
1404565|NCT00368095|Metabolic syndrome
1404566|NCT00368095|CVD-CAD
1404567|NCT00368082|EBV-Positive Lymphoma
1404568|NCT00368082|Hodgkin´s Disease (HD)
1404569|NCT00368082|Non-Hodgkin's lymphoma (NHL)
1404570|NCT00368082|relapsed Hodgkin's disease
1404571|NCT00368082|relapsed non-Hodgkin's disease
1404572|NCT00368082|lymphoma
1404573|NCT00368082|TGFbeta resistant LMP-specific CTLs
1404574|NCT00368082|cytotoxic T cells
1404575|NCT00368069|Epilepsy
1404576|NCT00368069|Keppra® XR
1404577|NCT00368069|Levetiracetam XR
1404578|NCT00368069|Extended release
1404579|NCT00368043|Pituitary
1404580|NCT00368043|Adrenal
1404581|NCT00368043|Growth
1404582|NCT00368043|Cortisol
1404583|NCT00368043|Stress Response
1404584|NCT00368043|Adoption
1404585|NCT00368043|Thyroid Hormone
1404586|NCT00368043|Psychosocial Adjustment
1404587|NCT00368043|Healthy Volunteer
1404588|NCT00368043|HV
1404589|NCT00368030|Insomnia related to major depressive disorder.
1404590|NCT00368004|Coloboma
1404591|NCT00368004|Genetics
1404592|NCT00368004|Optic Nerve Coloboma
1404593|NCT00368004|Chorioretinal Coloboma
1404594|NCT00368004|Iris Coloboma
1404595|NCT00368004|Uveal Coloboma
1404596|NCT00367991|Platelet function tests
1404597|NCT00367991|Erythropoietin
1404598|NCT00367991|Myocardial infarction
1404599|NCT00367978|Hypertension, diabetes, African-American, amlodipine/benazepril
1404600|NCT00367965|Insomnia related to rheumatoid arthritis (RA)
1404601|NCT00367952|HIV
1404602|NCT00367952|apricitabine
1404603|NCT00367952|drug resistance
1404605|NCT00367952|lamivudine
1404606|NCT00367939|Hypertension
1404607|NCT00367926|ginseng
1404608|NCT00367926|polysaccharides
1404609|NCT00367926|postprandial glycemia
1404610|NCT00367926|area under the glucose curve
1404611|NCT00367926|peak incremental glucose
1404612|NCT00367913|pulmonary disease
1404613|NCT00367913|Treatment of Opportunist Mycobacteria
1404614|NCT00367913|Clarithromycin
1404615|NCT00367913|Ciprofloxacin
1404616|NCT00367913|M.vaccae
1404617|NCT00367913|Pulmonary diseases caused by Opportunist Mycobacteria
1404618|NCT00367900|Diet
1404619|NCT00367900|Lifestyle
1404620|NCT00367900|Neurodegenerative Diseases
1404621|NCT00367900|Elderly Population
1404622|NCT00367900|Public Health
1404623|NCT00367900|Parkinson Disease
1404624|NCT00367900|Environment
1404625|NCT00367887|Hepatitis C
1404626|NCT00367874|Opiate dependence
1404627|NCT00367874|Benzodiazepine dependence
1404628|NCT00367874|Polydrug Abuse
1404629|NCT00367874|Detoxification
1404630|NCT00367874|Withdrawal Treatment
1404631|NCT00367861|GIST
1404632|NCT00367861|Glivec®
1404633|NCT00367861|randomized
1404634|NCT00367861|phase III
1404635|NCT00367848|suspected fractures in the ankle and wrist
1404636|NCT00367822|Restless Legs Syndrome
1404637|NCT00367822|dopamine agonist
1404638|NCT00367822|lisuride
1404639|NCT00367822|ropinirole
1404640|NCT00367809|Meditation
1404641|NCT00367809|Mindfulness
1404642|NCT00367809|Organ Transplant
1404643|NCT00367809|Transplantation
1404644|NCT00367809|Minnesota
1404645|NCT00367809|Immune suppressive therapy
1404646|NCT00367796|Craniosynostosis
1404647|NCT00367796|Philadelphia Type
1404648|NCT00367770|bosentan
1404649|NCT00367770|PAH related to Eisenmenger physiology
1404650|NCT00367770|Tracleer
1404651|NCT00367757|paroxysmal atrial fibrillation
1404652|NCT00367757|persistent atrial fibrillation
1404653|NCT00367757|high burden of atrial fibrillation
1404654|NCT00367757|atrial fibrillation ablation
1404655|NCT00367757|Pulmonary vein isolation
1404656|NCT00367757|AF trigger
1404657|NCT00367757|complex fractionated electrograms
1404658|NCT00367757|CFE
1404659|NCT00367757|CFAE
1404660|NCT00367757|complex fractionated atrial electrograms
1404661|NCT00367757|refractory antiarrhythmic medication
1404662|NCT00367757|PVAI
1404663|NCT00367757|Ensite NavX
1404664|NCT00367757|NavX
1404665|NCT00367757|CoolPath catheter
1404666|NCT00367757|irrigated ablation catheter
1404667|NCT00367757|high burden of paroxysmal or persistent atrial fibrillation
1404668|NCT00367757|candidates for AF ablation
1404669|NCT00367757|symptomatic AF
1404670|NCT00367757|AF is refractory to at least one antiarrhythmic medication
1404671|NCT00367744|mitochondria
1404672|NCT00367744|HIV
1404673|NCT00367744|lipoatrophy
1404674|NCT00367731|HIV
1404675|NCT00367731|AIDS
1404676|NCT00367731|Neurological complications
1404677|NCT00367731|HAART
1404678|NCT00367692|Scleritis
1404679|NCT00367640|Sublingual immunotherapy
1404680|NCT00367640|Grass pollen tablet
1404681|NCT00367640|Allergic rhinoconjunctivitis
1404682|NCT00367627|Children
1404683|NCT00367627|Malnutrition
1404684|NCT00367627|Ascaris Lumbricoides
1404685|NCT00367627|Trichuris trichiura Morbidity
1404686|NCT00367627|Helminthiasis
1404687|NCT00367627|Children 2-5 years
1404688|NCT00367627|Stool RME +ve for helminthiasis
1404689|NCT00367614|Adolescents
1404690|NCT00367614|GERD
1404691|NCT00367588|chemotherapy
1404692|NCT00367588|diet
1404693|NCT00367588|hematological malignancy
1404694|NCT00367588|infection prevention
1404695|NCT00367588|protective isolation
1404696|NCT00367588|Patients with cytopenia due to intensive chemotherapy for hematological malignancy
1404697|NCT00367575|alcoholism
1404698|NCT00367575|drinking
1404699|NCT00367575|randomized
1404700|NCT00367575|internet personalized alcohol feedback
1404701|NCT00367562|IGA NEPHROPATHY
1404702|NCT00367562|STEROIDS
1404703|NCT00367562|ENALAPRIL
1404704|NCT00367562|VALSARTAN
1404705|NCT00367562|PROTEINURIA
1404706|NCT00367562|IMMUNOGLOBULIN A NEPHROPATHY (IGA NEPHROPATHY)
1404707|NCT00367549|Labor
1404708|NCT00367549|instrumental delivery
1404709|NCT00367549|nutrition
1404710|NCT00367549|epidural anesthesia
1404711|NCT00367549|oxytocin
1404712|NCT00367536|Health
1404713|NCT00367523|Echocardiogram
1404714|NCT00367523|Nigeria
1404715|NCT00367523|Screening
1404716|NCT00367523|Sickle Cell Disease
1404717|NCT00367523|Genetics
1404718|NCT00367497|aggressive non-Hodgkin's lymphoma
1404719|NCT00367497|salvage chemotherapy
1404720|NCT00367497|rituximab
1404721|NCT00367471|metastatic
1404722|NCT00367471|paclitaxel
1404723|NCT00367471|lapatinib
1404724|NCT00367471|trastuzumab
1404725|NCT00367471|carboplatin
1404726|NCT00367471|breast cancer
1404727|NCT00367458|Viremia
1404728|NCT00367458|Statin
1404729|NCT00367458|HIV Replication
1404730|NCT00367458|Cholesterol
1404731|NCT00367458|Lipid Raft
1404732|NCT00367458|HIV Infection
1404733|NCT00367458|HIV Positive
1404734|NCT00367432|Epilepsies
1404735|NCT00367432|Partial
1404736|NCT00367432|Keppra
1404737|NCT00367432|levetiracetam
1404738|NCT00367393|Pimecrolimus, skin atrophy, dermoscopy, atopic dermatitis, eczema
1404739|NCT00367380|Malaria
1404740|NCT00367380|Sporozoite
1404741|NCT00367380|Challenge Model
1404742|NCT00367380|Plasmodium vivax
1404743|NCT00367380|Human Volunteers
1404744|NCT00367367|embryo transfer
1404745|NCT00367367|hysteroscopy
1404746|NCT00367367|curettage
1404747|NCT00367367|iv-vitro fertilization
1404748|NCT00367367|molecular markers
1404749|NCT00367367|endometrial receptivity
1404750|NCT00367367|endometrial dating
1404751|NCT00367354|Imaging Technology
1404752|NCT00367354|Cardiology
1404753|NCT00367341|Depression, Treatment, Imaging
1404754|NCT00367328|Hidradenitis Supperativa
1404755|NCT00367315|Osteoarthritis, lumiracoxib, celecoxib, cyclooxygenase-2 inhibitors
1404756|NCT00367302|addiction
1404757|NCT00367302|jail
1404758|NCT00367302|opiates
1404759|NCT00367302|buprenorphine
1404760|NCT00367302|clinical trial
1404761|NCT00367276|Females requiring contraceptives
1404762|NCT00367263|Asthma
1404763|NCT00367224|vitiligo
1404764|NCT00367224|tolerance
1404765|NCT00367224|ultraviolet B.
1404766|NCT00367211|Gastric Ulcers
1404767|NCT00367211|NSAID
1404768|NCT00367211|Arthritis
1404769|NCT00367185|Multiple myeloma
1404770|NCT00367185|Elderly patients
1404771|NCT00367185|Thalidomide
1404772|NCT00367185|Autologous transplantation
1404773|NCT00367172|human immunodeficiency virus
1404774|NCT00367172|acquired immunodeficiency syndrome
1404775|NCT00367172|substance abuse
1404776|NCT00367172|directly administered antiretroviral therapy
1404777|NCT00367172|adherence, directly observed therapy
1404778|NCT00367159|Vesico-ureteral reflux, autologous adipocytes, adipocytes graft
1404779|NCT00367146|liver transplantation
1404780|NCT00367146|children
1404781|NCT00367146|immunosuppression
1404782|NCT00367146|mycophenolatmofetil
1404783|NCT00367146|calcineurin inhibitor
1404784|NCT00367146|kidney disease
1404785|NCT00367133|diabetic
1404786|NCT00367133|macular
1404787|NCT00367133|edema
1404788|NCT00367133|intravitreal
1404789|NCT00367133|triamcinolone
1404790|NCT00367133|laser
1404791|NCT00367133|photocoagulation
1404792|NCT00367133|DME
1404793|NCT00367107|Autism spectrum disorders
1404794|NCT00367107|long-term outcomes
1404795|NCT00367107|caregiver burden
1404796|NCT00367107|birth cohort
1404797|NCT00367107|nested case-control study
1404798|NCT00367094|Hypertension, benazepril, hydrochlorothiazide, fixed combination
1404799|NCT00367081|Toxoplasmic Encephalitis
1404800|NCT00367081|AIDS
1404801|NCT00367068|Cerebral palsy
1404802|NCT00367068|Spasticity
1404803|NCT00367068|Child
1404804|NCT00367068|Baclofen
1404805|NCT00367068|Intrathecal injection
1404806|NCT00367055|Beta cell function
1404807|NCT00367055|Type 2 diabetes
1404808|NCT00367055|Combination treatment
1404809|NCT00367029|Physical Activity
1404810|NCT00367003|Depression, Unipolar, Bipolar-II, DBS, Imaging
1404811|NCT00366990|Arterial Stiffening
1404812|NCT00366977|Cessation
1404813|NCT00366977|Smoking
1404814|NCT00366977|Quitline
1404815|NCT00366977|Policies
1404816|NCT00366977|Counseling
1404817|NCT00366951|Cervical Ripening
1404818|NCT00366951|Labor, Induced
1404819|NCT00366951|Balloon Dilation
1404820|NCT00366951|Oxytocin
1404821|NCT00366938|Osteoarthritis, lumiracoxib, celecoxib, Cox-2
1404822|NCT00366912|work of breathing
1404823|NCT00366912|pressure time product
1404824|NCT00366912|muscle pressures
1404825|NCT00366899|Vaccine
1404826|NCT00366899|Infants
1404827|NCT00366886|cardiac
1404828|NCT00366886|pediatric
1404829|NCT00366886|surgery
1404830|NCT00366886|blood markers
1404831|NCT00366873|Infant
1404832|NCT00366873|Term
1404833|NCT00366860|soy
1404834|NCT00366860|isoflavones
1404835|NCT00366860|bone resorption
1404836|NCT00366860|osteogenesis
1404837|NCT00366860|diet
1404838|NCT00366860|hyperlipidemia
1404839|NCT00366847|cardiac
1404840|NCT00366847|MRI
1404841|NCT00366847|pediatrics
1404842|NCT00366834|Anthracycline
1404843|NCT00366834|Cyclophosphamide
1404844|NCT00366834|Moderately
1404845|NCT00366834|Nausea
1404846|NCT00366834|Emetogenic
1404847|NCT00366834|Vomiting
1404848|NCT00366821|cardiac
1404849|NCT00366821|pediatric
1404850|NCT00366821|genetic
1404851|NCT00366782|Respiratory Tract Disease
1404852|NCT00366782|Bovine
1404853|NCT00366782|Chimeric Vaccine
1404854|NCT00366756|Vision
1404855|NCT00366756|Visual Acuity
1404856|NCT00366730|Amebiasis
1404857|NCT00366730|Entamoeba histolytica
1404858|NCT00366717|Cancer under chemotherapy
1404859|NCT00366704|Schizophrenia
1404860|NCT00366691|cataract
1404861|NCT00366678|Safety
1404862|NCT00366678|Vaccine
1404863|NCT00366652|Healthy
1404864|NCT00366639|Heart failure, congestive
1404865|NCT00366639|Heart decompensation
1404866|NCT00366626|Alcohol dependence
1404867|NCT00366626|Alcoholism
1404868|NCT00366626|Craving
1404869|NCT00366626|Genetic
1404870|NCT00366613|Cataract
1404871|NCT00366613|Cataract Extraction
1404872|NCT00365898|Chronic non-malignant pain, opioid
1404873|NCT00365885|Medical Informatics
1404874|NCT00365885|Decision Support Systems, Clinical
1404875|NCT00365885|Community Health Services
1404876|NCT00365885|Costs and Cost analysis
1404877|NCT00365872|Sarcoma
1404878|NCT00365872|Intratumoral injection
1404879|NCT00365872|Dendritic cells
1404880|NCT00365872|Neo-adjuvant treatment
1404881|NCT00365872|Immunotherapy
1404882|NCT00365872|Pheresis
1404883|NCT00365872|Radiation
1404884|NCT00365859|Serious behavioral problems in children and adolescents with AD
1404885|NCT00365859|behavioral problems
1404886|NCT00365846|prevent kidney rejection
1404887|NCT00365833|Transplantation
1404888|NCT00365833|Cardiovascular
1404889|NCT00365833|Renal
1404890|NCT00365820|Opioid, constipation, tegaserod
1404891|NCT00365820|Opioid-induced constipation
1404892|NCT00365807|Obesity
1404893|NCT00365807|Overweight
1404894|NCT00365807|Behavioral treatment
1404895|NCT00365807|Family involvement
1404896|NCT00365794|Aging
1404897|NCT00365794|Older men
1404898|NCT00365794|Abdominal obesity
1404899|NCT00365794|Central obesity
1404900|NCT00365794|Insulin resistance
1404901|NCT00365794|Low testosterone
1404902|NCT00365781|Injection Site Reaction
1404903|NCT00365781|Subcutaneous administration
1404904|NCT00365781|Dermatological effects
1404905|NCT00365781|Antisense
1404906|NCT00365768|stage II childhood lymphoblastic lymphoma
1404907|NCT00365768|stage III childhood lymphoblastic lymphoma
1404908|NCT00365768|stage II childhood small noncleaved cell lymphoma
1404909|NCT00365768|stage I Wilms tumor
1404910|NCT00365768|stage II Wilms tumor
1404911|NCT00365768|stage III Wilms tumor
1404912|NCT00365768|stage IV Wilms tumor
1404913|NCT00365768|stage V Wilms tumor
1404914|NCT00365768|childhood grade III lymphomatoid granulomatosis
1404915|NCT00365768|childhood diffuse large cell lymphoma
1404916|NCT00365768|childhood immunoblastic large cell lymphoma
1404917|NCT00365768|stage I childhood large cell lymphoma
1404918|NCT00365768|stage I childhood lymphoblastic lymphoma
1404919|NCT00365768|stage I childhood small noncleaved cell lymphoma
1404920|NCT00365768|stage II childhood large cell lymphoma
1404921|NCT00365768|stage III childhood large cell lymphoma
1404922|NCT00365768|stage IV childhood large cell lymphoma
1404923|NCT00365768|stage IV childhood lymphoblastic lymphoma
1404924|NCT00365768|stage IV childhood small noncleaved cell lymphoma
1404925|NCT00365768|childhood Burkitt lymphoma
1404926|NCT00365768|stage III childhood small noncleaved cell lymphoma
1404927|NCT00365768|untreated childhood acute lymphoblastic leukemia
1404928|NCT00365768|childhood nasal type extranodal NK/T-cell lymphoma
1404929|NCT00365768|previously untreated childhood rhabdomyosarcoma
1404930|NCT00365768|localized Ewing sarcoma/PNET
1404931|NCT00365768|metastatic Ewing sarcoma/PNET
1404932|NCT00365768|neurotoxicity
1404933|NCT00365768|peripheral neuropathy
1404934|NCT00365755|disseminated neuroblastoma
1404935|NCT00365742|red yeast rice
1404936|NCT00365742|pharmaceutical grade fish oil
1404937|NCT00365742|simvastatin
1404938|NCT00365742|primary prevention
1404939|NCT00365729|genitoanal HPV infection
1404940|NCT00365729|HIV infection
1404941|NCT00365716|HPV 6/11/16/18 infection and related genital disease
1404942|NCT00365703|Infant, Premature
1404943|NCT00365703|Tube feeding
1404944|NCT00365690|AIDS
1404945|NCT00365690|Older Adults
1404946|NCT00365690|Telephone
1404947|NCT00365690|Telemedicine
1404948|NCT00366600|Breast Cancer
1404949|NCT00366600|Health
1404950|NCT00366600|Pharmacokinetics
1404951|NCT00366600|healthy subjects
1404952|NCT00366561|neonates
1404953|NCT00366561|neurological complications
1404954|NCT00366561|surgery
1404955|NCT00366548|Vaccine
1404956|NCT00366548|Infant
1404957|NCT00366535|Muscle Pain
1404958|NCT00366535|Fibrositis Allodynia
1404959|NCT00366535|Stiffness
1404960|NCT00366535|Tender Points
1404961|NCT00366535|Fibromyalgia
1404962|NCT00366522|Safety
1404963|NCT00366522|Healthy
1404964|NCT00366522|healthy subjects
1404965|NCT00366509|Vac A Toxin
1404966|NCT00366509|Lung
1404967|NCT00366509|Bronchoscopy
1404968|NCT00366509|Endoscopy
1404969|NCT00366509|Cytotoxin
1404970|NCT00366509|Pulmonary Disease
1404971|NCT00366509|Lung Disease
1404972|NCT00366509|Genetic Disease
1404973|NCT00366509|Oropharyngeal Disease
1404974|NCT00366509|Pulmonary Fibrosis
1404975|NCT00366509|Asthma
1404976|NCT00366483|healthy young volunteers
1404977|NCT00366483|healthy elderly volunteers
1404978|NCT00366483|Alzheimer's disease
1404979|NCT00366483|5HT1A antagonist
1404980|NCT00366483|Health
1404981|NCT00366483|Pharmacokinetics
1404982|NCT00366444|Bunionectomy
1404983|NCT00366444|Bunion surgery
1404984|NCT00366444|Post-operative pain
1404985|NCT00366431|OIBD
1404986|NCT00366431|OIC
1404987|NCT00366431|Opioid
1404988|NCT00366431|Constipation
1404989|NCT00366431|Laxative
1404990|NCT00366418|CLL
1404991|NCT00366418|Monoclonal Antibody Therapy
1404992|NCT00366418|Anti CD20
1404993|NCT00366418|Biologic Response Modifier Therapy
1404994|NCT00366418|Fractionated-Dose
1404995|NCT00366418|Low-Dose
1404996|NCT00366418|Chronic Lymphocytic Leukemia
1404997|NCT00366405|cataract
1404998|NCT00366392|Low Vision
1404999|NCT00366392|Optical Aids
1405000|NCT00366353|Mechanical Ventilation
1405001|NCT00366353|Spontaneous Breathing Trial
1405002|NCT00366353|Sedation
1405003|NCT00366340|safety
1405004|NCT00366340|Vaccine
1405005|NCT00366327|Schizophrenia
1405006|NCT00366314|Blood samples
1405007|NCT00366314|Medication administration
1405008|NCT00366314|CICU
1405009|NCT00366314|PICU
1405010|NCT00366314|NICU
1405011|NCT00366301|type 2 diabetes
1405012|NCT00366301|insulin
1405013|NCT00366301|insulin injection
1405014|NCT00366301|metformin
1405015|NCT00366301|C-reactive protein
1405016|NCT00366301|insulin sensitivity
1405017|NCT00366301|glycemic control
1405018|NCT00366301|inflammation
1405019|NCT00366288|Healthy
1405020|NCT00366288|Safety
1405021|NCT00366275|follicular lymphoma
1405022|NCT00366275|rituximab
1405023|NCT00366275|immunochemotherapy
1405024|NCT00366275|peripheral blood stem cells (PBSC) mobilization
1405025|NCT00366275|in vivo purging
1405026|NCT00366275|autotransplant
1405027|NCT00366275|bcl-2 rearrangement
1405028|NCT00366275|molecular response
1405029|NCT00366262|Health
1405030|NCT00366249|Diabetic foot infection
1405031|NCT00366249|Osteomyelitis
1405032|NCT00366249|Diabetes Complications
1405033|NCT00366249|Foot ulcer
1405034|NCT00366249|Skin infection
1405035|NCT00366236|Amebiasis
1405036|NCT00366236|Entamoeba histolytica
1405037|NCT00366223|infection
1405038|NCT00366223|candida
1405039|NCT00366210|stroke
1405040|NCT00366210|rehabilitation
1405041|NCT00366210|physical therapy
1405042|NCT00366210|occupational therapy
1405043|NCT00366210|arm
1405044|NCT00366197|Rapid Shallow Breathing Index
1405045|NCT00366197|Mechanical Ventilation
1405046|NCT00366184|Neuromodulation
1405047|NCT00366184|Stroke
1405048|NCT00366184|Motor Cortex
1405049|NCT00366184|Motor Learning
1405050|NCT00366184|L-Dopa
1405051|NCT00366184|Transcranial Magnetic Stimulation
1405052|NCT00366184|Levodopa
1405053|NCT00366184|Healthy Volunteer
1405054|NCT00366184|HV
1405055|NCT00366171|Schizophrenia
1405056|NCT00366158|Patients with intact AV conduction
1405057|NCT00366145|acute GVHD
1405058|NCT00366145|steroid refractory GVHD
1405059|NCT00366145|severe steroid refractory acute GVHD
1405060|NCT00366145|steroid refractory
1405061|NCT00366145|Steroid Refractory Acute Graft Versus Host Disease
1405062|NCT00366132|Diabetic
1405063|NCT00366132|Foot Ulcers
1405064|NCT00366132|TRT
1405065|NCT00366132|DermaGold
1405066|NCT00366132|Shockwave
1405067|NCT00366132|ESWT
1405068|NCT00366132|Diabetes Mellitus
1405069|NCT00366119|hypertension
1405070|NCT00366119|ramipril
1405071|NCT00366119|blood pressure
1405072|NCT00366119|artery stiffness
1405073|NCT00366119|BNP
1405074|NCT00366119|CRP
1405075|NCT00366106|Relapsed Multiple Myeloma
1405076|NCT00366106|Refractory Multiple Myeloma
1405077|NCT00366093|Menopause
1405078|NCT00366093|Perimenopause
1405079|NCT00366080|GSK189254 H3 Histamine Narcolepsy
1405080|NCT00366067|Bronchial asthma
1405081|NCT00366067|Phenytoin
1405082|NCT00366067|Antiepileptic drugs
1405083|NCT00366067|Efficacy
1405084|NCT00366028|Organization Innovation
1405085|NCT00366028|Diffusion of Innovation
1405086|NCT00366028|Evidence-based Medicine
1405087|NCT00366028|Infection Control
1405088|NCT00366015|Coronary Artery Disease
1405089|NCT00366015|PCI
1405090|NCT00366015|Drug eluting stents
1405091|NCT00366015|Coronary Hybrid Revascularization
1405092|NCT00366015|Robotic CABG
1405093|NCT00366002|Darifenacin,Overactive Bladder,antimuscarinic,M3 muscarinic receptor antagonist
1405094|NCT00365989|Fibroids
1405095|NCT00365989|leiomyoma
1405096|NCT00365989|neoplasm
1405097|NCT00365989|benign tumors
1405098|NCT00365976|Insomnia
1405099|NCT00365976|Low Back Pain
1405100|NCT00365976|Hypnotics
1405101|NCT00365976|Eszopiclone
1405102|NCT00365976|Pain
1405103|NCT00365976|Disability
1405104|NCT00365963|lung cancer, caregivers, support, resources, education
1405105|NCT00365950|Duration of anticoagulation
1405106|NCT00365950|Deep vein thrombosis and/or pulmonary embolism
1405107|NCT00365937|immunotherapy
1405108|NCT00365937|adjuvants
1405109|NCT00365937|IMP321
1405110|NCT00365937|Montanide ISA51 VG
1405111|NCT00365937|tumor-specific peptides
1405112|NCT00365924|12 month therapy with postmenopausal women with osteoporosis to examine changes in bone quality parameters
1405113|NCT00365911|No specific condition
1405114|NCT00365651|obesity
1405115|NCT00365651|overweight
1405116|NCT00365638|PCOS
1405117|NCT00365638|statin
1405118|NCT00365638|testosterone
1405119|NCT00365638|lipids
1405120|NCT00365625|Psoriasis
1405121|NCT00365625|JAM3 protein, human
1405122|NCT00365625|Cell Adhesion Molecules
1405123|NCT00365625|Skin
1405124|NCT00365625|Inflammation
1405125|NCT00365625|Lymphocytes
1405126|NCT00365612|HIV
1405127|NCT00365612|HIV-1
1405128|NCT00365612|AIDS
1405129|NCT00365612|Human Immunodeficiency Virus
1405130|NCT00365612|HIV-1 Infection
1405131|NCT00365599|Breast cancer
1405132|NCT00365599|Suberoylanilide hydroxamic acid (SAHA)
1405133|NCT00365599|Vorinostat
1405134|NCT00365599|Tamoxifen
1405135|NCT00365599|Anti-hormonal therapy
1405136|NCT00365599|Estrogen receptor positive
1405137|NCT00365599|Progesterone receptor positive
1405138|NCT00365599|Metastatic disease
1405139|NCT00365599|Aromatase inhibitors (Ais)
1405140|NCT00365599|Histone deacetylase (HDAC) inhibitors
1405141|NCT00365599|Selective estrogen receptor modulators(SERMS)
1405142|NCT00365586|Pain
1405143|NCT00365586|Osteoarthritis
1405144|NCT00365586|Knee
1405145|NCT00365586|NSAID
1405146|NCT00365547|recurrent non-small cell lung cancer
1405147|NCT00365547|stage IIIB non-small cell lung cancer
1405148|NCT00365547|stage IV non-small cell lung cancer
1405149|NCT00365547|adenocarcinoma of the lung
1405150|NCT00365547|bronchoalveolar cell lung cancer
1405151|NCT00365547|large cell lung cancer
1405152|NCT00365534|First colonoscopy examination
1405153|NCT00365521|Organ transplant patients receiving immunosuppressive therapy
1405154|NCT00365508|bladder cancer
1405155|NCT00365508|cervical cancer
1405156|NCT00365508|esophageal cancer
1405157|NCT00365508|gastric cancer
1405158|NCT00365508|renal cell carcinoma
1405159|NCT00365508|adult primary liver cancer
1405160|NCT00365508|non-small cell lung cancer
1405161|NCT00365508|small cell lung cancer
1405162|NCT00365508|pancreatic cancer
1405163|NCT00365508|hypopharyngeal cancer
1405164|NCT00365508|laryngeal cancer
1405165|NCT00365508|lip and oral cavity cancer
1405166|NCT00365508|nasopharyngeal cancer
1405167|NCT00365508|oropharyngeal cancer
1405168|NCT00365508|paranasal sinus and nasal cavity cancer
1405169|NCT00365508|adult acute myeloid leukemia
1405170|NCT00365508|tongue cancer
1405171|NCT00365508|tobacco use disorder
1405172|NCT00365495|Type 2 diabetes
1405173|NCT00365495|physical training
1405174|NCT00365495|mitochondrial function
1405175|NCT00365482|Epilepsy
1405176|NCT00365482|Bipolar Disorder
1405177|NCT00365469|Probiotics
1405178|NCT00365469|Eczema
1405179|NCT00365469|Asthma
1405180|NCT00365469|Allergic Rhinitis
1405181|NCT00365469|Prevention
1405182|NCT00365469|Immunological responses
1405183|NCT00365456|Lumbar Spine Bone Mineral Density (BMD)
1405184|NCT00365443|anogenital warts
1405185|NCT00365443|premalignancy
1405186|NCT00365443|HPV
1405187|NCT00365443|Human papillomavirus
1405188|NCT00365430|Patient safety
1405189|NCT00365430|Adverse event
1405190|NCT00365430|Prevention
1405191|NCT00365430|Knowledge
1405192|NCT00365430|Inpatient
1405193|NCT00365430|Hospital
1405194|NCT00365430|Nursing home
1405195|NCT00365430|Long term care
1405196|NCT00365430|Nurse
1405197|NCT00365417|NSABP
1405198|NCT00365417|Doxorubicin
1405199|NCT00365417|Cyclophosphamide
1405200|NCT00365417|Bevacizumab
1405201|NCT00365417|Capecitabine
1405202|NCT00365417|Docetaxel
1405203|NCT00365417|Breast cancer
1405204|NCT00365417|Locally advanced
1405205|NCT00365417|Neoadjuvant
1405206|NCT00365417|Locally advanced breast cancer
1405207|NCT00365404|Behavioral change
1405208|NCT00365404|Weight management
1405209|NCT00365404|Physical activity
1405210|NCT00365339|HIV
1405211|NCT00365339|Protease Inhibitor
1405212|NCT00365326|AC133
1405213|NCT00365326|coronary
1405214|NCT00365326|bone marrow
1405215|NCT00365326|autologous
1405216|NCT00365326|coronary artery disease
1405217|NCT00365313|celecoxib
1405218|NCT00365313|oesomeprazole
1405219|NCT00365313|arthritis
1405220|NCT00365313|ulcer bleeding
1405221|NCT00365300|GERD
1405222|NCT00365300|Infants
1405223|NCT00365300|Gastroesophageal Reflux
1405224|NCT00365287|stage IV breast cancer
1405225|NCT00365287|recurrent renal cell cancer
1405226|NCT00365287|stage III renal cell cancer
1405227|NCT00365287|stage IV renal cell cancer
1405228|NCT00365287|adult acute myeloid leukemia in remission
1405229|NCT00365287|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1405230|NCT00365287|adult acute myeloid leukemia with inv(16)(p13;q22)
1405231|NCT00365287|adult acute myeloid leukemia with t(15;17)(q22;q12)
1405232|NCT00365287|adult acute myeloid leukemia with t(16;16)(p13;q22)
1405233|NCT00365287|adult acute myeloid leukemia with t(8;21)(q22;q22)
1405234|NCT00365287|recurrent adult acute myeloid leukemia
1405235|NCT00365287|recurrent childhood acute myeloid leukemia
1405236|NCT00365287|accelerated phase chronic myelogenous leukemia
1405237|NCT00365287|chronic phase chronic myelogenous leukemia
1405238|NCT00365287|relapsing chronic myelogenous leukemia
1405239|NCT00365287|recurrent adult Hodgkin lymphoma
1405457|NCT00364884|chronic kidney disease
1405240|NCT00365287|recurrent/refractory childhood Hodgkin lymphoma
1405241|NCT00365287|stage III adult Hodgkin lymphoma
1405242|NCT00365287|stage IV adult Hodgkin lymphoma
1405243|NCT00365287|stage III chronic lymphocytic leukemia
1405244|NCT00365287|stage IV chronic lymphocytic leukemia
1405245|NCT00365287|stage I multiple myeloma
1405246|NCT00365287|stage II multiple myeloma
1405247|NCT00365287|stage III multiple myeloma
1405248|NCT00365287|de novo myelodysplastic syndromes
1405249|NCT00365287|previously treated myelodysplastic syndromes
1405250|NCT00365287|secondary myelodysplastic syndromes
1405251|NCT00365287|refractory anemia
1405252|NCT00365287|adult acute lymphoblastic leukemia in remission
1405253|NCT00365287|blastic phase chronic myelogenous leukemia
1405254|NCT00365287|childhood acute lymphoblastic leukemia in remission
1405255|NCT00365287|childhood acute myeloid leukemia in remission
1405256|NCT00365287|childhood chronic myelogenous leukemia
1405257|NCT00365287|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1405258|NCT00365287|nodal marginal zone B-cell lymphoma
1405259|NCT00365287|noncontiguous stage II adult Burkitt lymphoma
1405260|NCT00365287|noncontiguous stage II adult diffuse large cell lymphoma
1405261|NCT00365287|noncontiguous stage II adult diffuse mixed cell lymphoma
1405262|NCT00365287|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1405263|NCT00365287|noncontiguous stage II adult immunoblastic large cell lymphoma
1405264|NCT00365287|noncontiguous stage II adult lymphoblastic lymphoma
1405265|NCT00365287|noncontiguous stage II grade 1 follicular lymphoma
1405266|NCT00365287|noncontiguous stage II grade 2 follicular lymphoma
1405267|NCT00365287|noncontiguous stage II grade 3 follicular lymphoma
1405268|NCT00365287|noncontiguous stage II mantle cell lymphoma
1405269|NCT00365287|noncontiguous stage II marginal zone lymphoma
1405270|NCT00365287|noncontiguous stage II small lymphocytic lymphoma
1405271|NCT00365287|recurrent adult acute lymphoblastic leukemia
1405272|NCT00365287|recurrent adult Burkitt lymphoma
1405273|NCT00365287|recurrent adult diffuse large cell lymphoma
1405274|NCT00365287|recurrent adult diffuse mixed cell lymphoma
1405275|NCT00365287|recurrent adult diffuse small cleaved cell lymphoma
1405276|NCT00365287|recurrent adult immunoblastic large cell lymphoma
1405277|NCT00365287|recurrent adult lymphoblastic lymphoma
1405278|NCT00365287|recurrent childhood acute lymphoblastic leukemia
1405279|NCT00365287|recurrent childhood lymphoblastic lymphoma
1405280|NCT00365287|recurrent childhood large cell lymphoma
1405281|NCT00365287|recurrent childhood small noncleaved cell lymphoma
1405282|NCT00365287|recurrent grade 1 follicular lymphoma
1405283|NCT00365287|recurrent grade 2 follicular lymphoma
1405284|NCT00365287|recurrent grade 3 follicular lymphoma
1405285|NCT00365287|recurrent mantle cell lymphoma
1405286|NCT00365287|recurrent marginal zone lymphoma
1405287|NCT00365287|recurrent small lymphocytic lymphoma
1405288|NCT00365287|refractory chronic lymphocytic leukemia
1405289|NCT00365287|refractory multiple myeloma
1405290|NCT00365287|secondary acute myeloid leukemia
1405291|NCT00365287|splenic marginal zone lymphoma
1405292|NCT00365287|stage III adult Burkitt lymphoma
1405293|NCT00365287|stage III adult diffuse large cell lymphoma
1405294|NCT00365287|stage III adult diffuse mixed cell lymphoma
1405295|NCT00365287|stage III adult diffuse small cleaved cell lymphoma
1405296|NCT00365287|stage III adult immunoblastic large cell lymphoma
1405297|NCT00365287|stage III adult lymphoblastic lymphoma
1405298|NCT00365287|stage III grade 1 follicular lymphoma
1405299|NCT00365287|stage III grade 2 follicular lymphoma
1405300|NCT00365287|stage III grade 3 follicular lymphoma
1405301|NCT00365287|stage III mantle cell lymphoma
1405302|NCT00365287|stage III marginal zone lymphoma
1405303|NCT00365287|stage III small lymphocytic lymphoma
1405304|NCT00365287|stage IV adult Burkitt lymphoma
1405305|NCT00365287|stage IV adult diffuse large cell lymphoma
1405306|NCT00365287|stage IV adult diffuse mixed cell lymphoma
1405307|NCT00365287|stage IV adult diffuse small cleaved cell lymphoma
1405308|NCT00365287|stage IV adult immunoblastic large cell lymphoma
1405309|NCT00365287|stage IV adult lymphoblastic lymphoma
1405310|NCT00365287|stage IV grade 1 follicular lymphoma
1405311|NCT00365287|stage IV grade 2 follicular lymphoma
1405312|NCT00365287|stage IV grade 3 follicular lymphoma
1405313|NCT00365287|stage IV mantle cell lymphoma
1405314|NCT00365287|stage IV marginal zone lymphoma
1405315|NCT00365287|stage IV small lymphocytic lymphoma
1405316|NCT00365287|refractory anemia with excess blasts in transformation
1405317|NCT00365287|refractory anemia with ringed sideroblasts
1405318|NCT00365287|refractory cytopenia with multilineage dysplasia
1405319|NCT00365287|refractory anemia with excess blasts
1405320|NCT00365287|childhood myelodysplastic syndromes
1405321|NCT00365274|non-Hodgkin's lymphoma
1405322|NCT00365274|NHL
1405323|NCT00365274|murine monoclonal antibody
1405324|NCT00365274|mAb
1405325|NCT00365274|SGN-30
1405326|NCT00365274|CHOP
1405327|NCT00365274|Cyclophosphamide
1405328|NCT00365274|Doxorubicin Hydrochloride
1405329|NCT00365274|Vincristine
1405330|NCT00365274|Prednisone
1405331|NCT00365274|anaplastic large cell lymphoma
1405332|NCT00365274|Lymphoma
1405333|NCT00365274|Lymphoma, Large B-Cell, Diffuse
1405334|NCT00365274|Lymphoma, Non-Hodgkin
1405335|NCT00365274|Lymphoma, Large-Cell, Anaplastic
1405336|NCT00365274|Neoplasms by Histologic Type
1405337|NCT00365274|Neoplasms
1405338|NCT00365274|Lymphoproliferative Disorders
1405339|NCT00365274|Lymphatic Diseases
1405340|NCT00365274|Immunoproliferative Disorders
1405341|NCT00365274|Immune System Diseases
1405342|NCT00365274|Lymphoma, B-Cell
1405343|NCT00365274|Lymphoma, T-Cell
1405344|NCT00365274|Antibodies
1405345|NCT00365274|Antibodies, Monoclonal
1405346|NCT00365274|Immunologic Factors
1405347|NCT00365274|Physiological Effects of Drugs
1405348|NCT00365274|Pharmacologic Actions
1405349|NCT00365274|Immunosuppressive Agents
1405350|NCT00365274|Antirheumatic Agents
1405351|NCT00365274|Therapeutic Uses
1405352|NCT00365274|Antineoplastic Agents, Alkylating
1405353|NCT00365274|Alkylating Agents
1405354|NCT00365274|Molecular Mechanisms of Pharmacological Action
1405355|NCT00365274|Antineoplastic Agents
1405356|NCT00365274|Myeloablative Agonists
1405357|NCT00365274|Antibiotics
1405358|NCT00365274|Antineoplastic
1405359|NCT00365261|pain
1405360|NCT00365261|fatigue
1405361|NCT00365261|sleep
1405362|NCT00365261|bone marrow transplant
1405363|NCT00365261|cancer
1405364|NCT00365248|Surgical resection of the liver with or without segmental transplantation
1405365|NCT00365222|Temozolomide
1405366|NCT00365222|Temodar
1405367|NCT00365222|Glioblastoma
1405368|NCT00365222|Gliosarcoma
1405369|NCT00365222|Brain Tumor
1405370|NCT00365222|Quality of Life
1405371|NCT00365222|Neurological
1405372|NCT00365196|Autonomic Nervous System
1405373|NCT00365183|Non Small Cell Lung Cancer
1405374|NCT00365183|Lung Cancer
1405375|NCT00365183|Metastatic Lung Cancer
1405376|NCT00365183|Inoperable Lung Cancer
1405377|NCT00365183|Advanced Lung Cancer
1405378|NCT00365183|Large Cell Lung Cancer
1405379|NCT00365183|Adenocarcinoma, lung
1405380|NCT00365183|Squamous Cell Carcinoma, lung
1405381|NCT00365183|Squamous Cell Lung Cancer
1405382|NCT00365183|Large Cell Carcinoma, lung
1405383|NCT00365183|Cancer of the Lung
1405384|NCT00365183|Carcinoma
1405385|NCT00365183|Bronchogenic
1405386|NCT00365144|stage IV pancreatic cancer
1405387|NCT00365144|adenocarcinoma of the pancreas
1405388|NCT00365144|recurrent pancreatic cancer
1405389|NCT00365131|Type I Gaucher disease
1405390|NCT00365131|Glucocerebrosidase Deficiency Disease
1405391|NCT00365118|Port wine stains
1405392|NCT00365118|naevus flammeus
1405393|NCT00365105|pain
1405394|NCT00365105|bone metastases
1405395|NCT00365105|extensive stage small cell lung cancer
1405396|NCT00365105|recurrent breast cancer
1405397|NCT00365105|stage IV breast cancer
1405398|NCT00365105|recurrent non-small cell lung cancer
1405399|NCT00365105|stage IV non-small cell lung cancer
1405400|NCT00365105|recurrent prostate cancer
1405401|NCT00365105|stage IV prostate cancer
1405402|NCT00365092|Insertion of tympanostomy tubes
1405403|NCT00365092|Otitis media with effusion
1405404|NCT00365092|Child development
1405405|NCT00365092|Literacy
1405406|NCT00365092|Attention
1405407|NCT00365092|Middle-ear effusion
1405408|NCT00365092|Educational status
1405409|NCT00365092|Behavior
1405410|NCT00365092|Social behavior
1405411|NCT00365092|Achievement
1405412|NCT00365040|myopia
1405413|NCT00365040|excimer laser
1405414|NCT00365027|GNRH agonist
1405415|NCT00365027|ovarian hyperstimulation syndrome
1405416|NCT00365027|Embryo cryopreservation
1405417|NCT00365014|aplastic anemia
1405418|NCT00365014|myelodysplastic syndromes
1405419|NCT00365014|cytopenias
1405420|NCT00365014|acute myeloid leukemia
1405421|NCT00365014|myelodysplastic/myeloproliferative diseases
1405422|NCT00365014|benzene poisoning
1405423|NCT00364988|pioglitazone
1405424|NCT00364988|losartan
1405425|NCT00364988|proteinuria
1405426|NCT00364988|end stage renal disease (ESRD)
1405427|NCT00364975|gourmet healthy cooking
1405428|NCT00364975|quality of life
1405429|NCT00364975|adjuvant chemotherapy
1405430|NCT00364975|weight
1405431|NCT00364975|breast cancer
1405432|NCT00364962|NPC
1405433|NCT00364962|Nasopharyngectomy
1405434|NCT00364962|KTP laser
1405435|NCT00364962|recurrence
1405436|NCT00364949|Polycystic Ovary Syndrome
1405437|NCT00364949|PCOS
1405438|NCT00364949|Pregnant
1405439|NCT00364949|Cord Blood
1405440|NCT00364936|palliative care
1405441|NCT00364936|hospice
1405442|NCT00364936|end-of-life
1405443|NCT00364936|symptom control
1405444|NCT00364936|evaluation
1405445|NCT00364936|effectiveness
1405446|NCT00364923|Peripheral T-cell Lymphoma
1405447|NCT00364923|T-cell Lymphoma
1405448|NCT00364923|Lymphoma
1405449|NCT00364923|PDX
1405450|NCT00364923|Pralatrexate
1405451|NCT00364923|Vitamin B12
1405452|NCT00364923|Folic acid
1405453|NCT00364910|Myocardial Infarction (MI)
1405454|NCT00364910|Cognitive Behavioral Therapy (CBT)
1405455|NCT00364910|Adherence
1405456|NCT00364910|Depression
1405458|NCT00364871|Obesity
1405459|NCT00364858|Type 1 Gaucher Disease
1405460|NCT00364858|Glucocerebrosidase Deficiency Disease
1405461|NCT00364845|Quality of Life
1405462|NCT00364845|Chronic Kidney Disease
1405463|NCT00364845|Anemia
1405464|NCT00364819|Primary Biliary Cirrhosis
1405465|NCT00364806|Migraine
1405466|NCT00364806|Headache
1405467|NCT00364793|HIV, Pediatric
1405468|NCT00364767|Moderate alcohol consumption
1405469|NCT00364767|Fat and carbohydrate oxidative capacity
1405470|NCT00364767|Postprandial glycemic response
1405471|NCT00364754|Tesmilifene
1405472|NCT00364754|DPPE
1405473|NCT00364754|Breast cancer
1405474|NCT00364754|Cyclophosphamide
1405475|NCT00364754|Epirubicin
1405476|NCT00364754|Pharmacokinetic
1405477|NCT00364715|Nuclear localization, annexin A1, oral SCC
1405478|NCT00364702|Virtual Reality
1405479|NCT00364702|ADHD
1405480|NCT00364702|Methylphenidate
1405481|NCT00364689|Encephalopathy, Hepatic
1405482|NCT00364689|Portosystemic Encephalopathy
1405483|NCT00364689|Encephalopathy, Hepatocerebral
1405484|NCT00364689|Encephalopathy, Portal-Systemic
1405485|NCT00364689|Encephalopathy, Portosystemic
1405486|NCT00364689|Hepatic Coma
1405487|NCT00364689|Hepatic Stupor
1405488|NCT00364689|Hepatocerebral Encephalopathy
1405489|NCT00364689|Portal-Systemic Encephalopathy
1405490|NCT00364676|Vinorelbine
1405491|NCT00364676|solid tumors
1405492|NCT00364676|Hodgkins
1405493|NCT00364676|Non hodgkins
1405494|NCT00364676|Lymphoma
1405495|NCT00364676|Advanced solid tumors
1405496|NCT00364663|NSCLC
1405497|NCT00364663|staging
1405498|NCT00364663|18F-FDG PET
1405499|NCT00364663|decision tree model
1405500|NCT00364663|cost-effectiveness
1405501|NCT00364650|Renal transplantation
1405502|NCT00364650|Diarrhea
1405503|NCT00364650|Immunosuppression
1405504|NCT00364650|Probiotics
1405505|NCT00364637|Sevoflurane
1405506|NCT00364637|Anesthesia
1405507|NCT00364637|Troponin
1405508|NCT00364637|Myocardial Preconditioning
1405509|NCT00364637|Surgery, Cardiac
1405510|NCT00364637|Stents
1405511|NCT00364637|Non-cardiac Surgery
1405512|NCT00364637|Surgery
1405513|NCT00364624|lung cancer
1405514|NCT00364624|adrenal insufficiency
1405515|NCT00364598|Anginera
1405516|NCT00364598|LVAD
1405517|NCT00364598|Transplant
1405518|NCT00364598|Histology
1405519|NCT00364598|LVAD implantation as a bridge to transplant
1405520|NCT00364572|sciatica
1405521|NCT00364572|low back pain
1405522|NCT00364572|epidural
1405523|NCT00364572|tumor necrosis factor
1405524|NCT00364559|intracerebral hemorrhage
1405525|NCT00364559|statins
1405526|NCT00364559|rosuvastatin
1405527|NCT00364559|stroke
1405528|NCT00364546|Osteoarthritis
1405529|NCT00364546|Pain
1405530|NCT00364546|Low Back Pain
1405531|NCT00364546|Hip Pain
1405532|NCT00364546|Knee Pain
1405533|NCT00364546|Backache
1405534|NCT00364546|tapentadol
1405535|NCT00364533|Arthralgia
1405536|NCT00364533|Pain
1405537|NCT00364533|Pain Assessment
1405538|NCT00364533|Hip Replacement
1405539|NCT00364533|Tapentadol
1405540|NCT00364520|Hematologic Diseases
1405541|NCT00364520|Benzene
1405542|NCT00364520|Genetic Polymorphisms
1405543|NCT00364494|Hematocrit
1405544|NCT00364494|Hemodilution
1405545|NCT00364494|Blood Transfusion
1405546|NCT00364494|Cardiopulmonary Bypass
1405547|NCT00364494|Multiple Organ Failure
1405548|NCT00364494|Surgery, Cardiac
1405549|NCT00364494|Kidney Failure
1405550|NCT00364494|Cardiac Surgical Procedures
1405551|NCT00364481|apnea
1405552|NCT00364481|tongue
1405553|NCT00364481|exercises
1405554|NCT00364481|reflux
1405555|NCT00364481|airway
1405556|NCT00364481|upper
1405557|NCT00364481|fatigue
1405558|NCT00364468|pegfilgrastim
1405559|NCT00364468|neutropenia
1405560|NCT00364468|cancer patients
1405561|NCT00364468|lymphoma
1405562|NCT00364455|Hormone refractory prostate cancer
1405563|NCT00364455|Anemia
1405564|NCT00364455|Quality-of-life
1405565|NCT00364442|asthma
1405566|NCT00364429|schizophrenic patients
1405567|NCT00364429|SPET
1405568|NCT00364429|NMDA receptor
1405569|NCT00364429|ligand [123]I-CNS 1261
1405570|NCT00364416|Heart Failure, congestive
1405571|NCT00364416|Heart decompensation
1405572|NCT00364403|Glycemic index
1405573|NCT00364403|Glycemic load
1405574|NCT00364403|Low fat
1405575|NCT00364403|Impaired glucose tolerance
1405576|NCT00364403|Large for gestational age infant
1405577|NCT00364403|Excessive body weight
1405578|NCT00364390|CABG
1405579|NCT00364390|Anginera
1405580|NCT00364390|CAD
1405581|NCT00364351|Non Small Cell Lung Cancer
1405582|NCT00364351|NSCLC
1405583|NCT00364338|gourmet healthy cooking
1405584|NCT00364338|quality of life
1405585|NCT00364338|preimenopause
1405586|NCT00364338|weight
1405587|NCT00364338|lipids
1405588|NCT00364325|Heart failure, congestive
1405589|NCT00364325|Heart decompensation
1405590|NCT00364312|behavior therapy
1405591|NCT00364312|dietary control
1405592|NCT00364312|exercise
1405593|NCT00364312|diabetes mellitus
1405594|NCT00364312|behavior modification
1405595|NCT00364312|blood glucose
1405596|NCT00364312|clinical trial
1405597|NCT00364312|diabetes education
1405598|NCT00364312|health behavior
1405599|NCT00364312|health care service utilization
1405600|NCT00364312|obesity
1405601|NCT00364312|quality of life
1405602|NCT00364299|Ventilator-associated pneumonia
1405603|NCT00364299|Mechanical ventilation
1405604|NCT00364299|Tracheal tube cuff pressure
1405605|NCT00364286|Chronic Lymphocytic Leukemia
1405606|NCT00364286|Small Lymphocytic Lymphoma
1405607|NCT00364286|Prolymphocytic Leukemia
1405608|NCT00364286|Leukemia
1405609|NCT00364286|Lymphoma
1405610|NCT00364286|Dasatinib
1405611|NCT00364286|BMS-354825
1405612|NCT00364273|Asthma
1405613|NCT00364260|Anemia
1405614|NCT00364260|epoetin alfa
1405615|NCT00364247|Acute pain
1405616|NCT00364247|bunionectomy
1405617|NCT00364234|Renal Osteodystrophy
1405618|NCT00364195|Metastatic breast cancer
1405619|NCT00364195|Tesmilifene
1405620|NCT00364195|DPPE
1405621|NCT00364182|Hemophilia B
1405622|NCT00364182|BeneFIX
1405623|NCT00364169|constipation
1405624|NCT00364169|cancer
1405625|NCT00364169|surgery
1405626|NCT00364169|intervention
1405627|NCT00364169|nursing
1405628|NCT00364169|postoperative
1405629|NCT00364143|Cancer
1405630|NCT00364143|Advanced Solid Tumor
1405631|NCT00364143|Oncology
1405632|NCT00364117|150 discharges
1405633|NCT00364117|adults
1405634|NCT00364117|Internal Medicine
1405635|NCT00364104|Iron deficiency
1405636|NCT00364104|Helicobacter infection
1405637|NCT00364104|Epidemiology
1405638|NCT00364091|allergic conjunctivitis, ophthalmology, multicenter, controlled
1405639|NCT00364078|Cross-sectional correlational study
1405640|NCT00364078|Uncertainty
1405641|NCT00364078|Locus of Control
1405642|NCT00364078|Quality of life
1405643|NCT00364078|Transitoriness
1405644|NCT00364078|Cancer care
1405645|NCT00364052|Valganciclovir, Oral Ganciclovir, Liver transplant
1405646|NCT00364013|Oncology
1405647|NCT00364013|Cancer
1405648|NCT00364013|metastatic colorectal cancer
1405649|NCT00364013|EGFr
1405650|NCT00364013|Panitumumab
1405651|NCT00364013|Clinical Trail
1405652|NCT00364013|Amgen
1405653|NCT00364000|haemodialysis
1405654|NCT00364000|hyperphosphatemia
1405655|NCT00364000|sevelamer
1405656|NCT00364000|calcium acetate
1405657|NCT00363987|nephropathy with type 2 diabetes
1405658|NCT00363974|AML
1405659|NCT00363974|leukemia
1405660|NCT00363974|relapse
1405661|NCT00363974|refractory
1405662|NCT00363974|antisense
1405663|NCT00363974|oligonucleotide
1405664|NCT00363961|End stage renal disease
1405665|NCT00363961|Maintenance dialysis
1405666|NCT00363961|Resistance exercise
1405667|NCT00363961|Muscle wasting
1405668|NCT00363961|Disability
1405669|NCT00363948|MK-0431
1405670|NCT00363948|ONO-5435
1405671|NCT00363948|Type 2 diabetes mellitus
1405672|NCT00363922|Coronary Artery Bypass [E04.100.376.719.332]
1405673|NCT00363909|psychosocial effects of cancer and its treatment
1405674|NCT00363909|hot flashes
1405675|NCT00363909|breast cancer
1405676|NCT00363896|COPD
1405677|NCT00363896|Lung function
1405678|NCT00363896|Exacerbations
1405679|NCT00363896|Quality of Life
1405680|NCT00363870|Influenza vaccine
1405681|NCT00363870|Prophylaxis Influenza vaccine
1405682|NCT00363857|fatigue
1405683|NCT00363857|sleep
1405684|NCT00363857|sleep disorder
1405685|NCT00363857|Legs
1405686|NCT00363857|RLS
1405687|NCT00363857|Restless Legs Syndrome
1405688|NCT00363857|Ropinirole
1405689|NCT00363844|MK-0431
1405690|NCT00363844|ONO-5435
1405691|NCT00363844|Type 2 diabetes mellitus
1405692|NCT00363818|Endothelial function
1405693|NCT00363818|Platelet function
1405694|NCT00363818|Coronary artery disease
1405695|NCT00363818|Thrombosis
1405696|NCT00363818|Aggregation
1405697|NCT00363805|lung cancer
1405698|NCT00363805|prevention
1405699|NCT00363805|green tea
1405700|NCT00363805|former smokers
1405701|NCT00363792|Healthy subjects
1405702|NCT00363779|Large Granular Lymphocyte (LGL)
1405703|NCT00363779|LGL
1405704|NCT00363779|Leukemia
1405705|NCT00363779|Cyclosporine
1405706|NCT00363779|Microarray
1405707|NCT00363779|Gene Expression
1405708|NCT00363779|Cyclosporin
1405709|NCT00363779|Large Granular Lymphocyte Leukemia
1405710|NCT00363779|LGL Leukemia
1405711|NCT00363753|Transient ischemic attack
1405712|NCT00363753|Stroke
1405713|NCT00363753|Aspirin
1405714|NCT00363753|Clopidogrel
1405715|NCT00363740|GW685698X
1405716|NCT00363740|allergic rhinitis
1405717|NCT00363740|Seasonal Allergic Rhinitis
1405718|NCT00363727|dyskinesia
1405719|NCT00363727|SINEMET
1405720|NCT00363727|Parkinson's disease
1405721|NCT00363727|controlled release ropinirole
1405722|NCT00363701|Protonpumpinhibitors
1405723|NCT00363701|withdrawal
1405724|NCT00363701|longterm treatment
1405725|NCT00363701|dyspepsia
1405726|NCT00363701|functional dyspepsia
1405727|NCT00363701|gastrooesophageal reflux
1405728|NCT00363701|upper endoscopy
1405729|NCT00363688|Non life threatening allergic reaction
1405730|NCT00363688|oral challenge
1405731|NCT00363688|penicillin
1405732|NCT00363688|skin testing
1405733|NCT00363675|Hand Burns
1405734|NCT00363675|Pediatrics
1405735|NCT00363649|Philadelphia chromosome positive chronic myelogenous leukemia
1405736|NCT00363649|chronic phase chronic myelogenous leukemia
1405737|NCT00363636|relapsed
1405738|NCT00363636|NHL
1405739|NCT00363636|pharmacokinetics
1405740|NCT00363636|antibody
1405741|NCT00363636|safety
1405742|NCT00363636|galiximab
1405743|NCT00363636|efficacy
1405744|NCT00363636|rituximab
1405745|NCT00363636|refractory
1405746|NCT00363610|Advanced and/or Metastatic Solid Tumors and Lymphoma
1405747|NCT00363597|dyspepsia
1405748|NCT00363597|gastrointestinal disease
1405749|NCT00363597|indigestion
1405750|NCT00363584|localized resectable adult primary liver cancer
1405751|NCT00363584|cholangiocarcinoma of the extrahepatic bile duct
1405752|NCT00363584|cholangiocarcinoma of the gallbladder
1405753|NCT00363584|adenocarcinoma of the gallbladder
1405754|NCT00363584|adenocarcinoma with squamous metaplasia of the gallbladder
1405755|NCT00363584|anaplastic carcinoma of the gallbladder
1405756|NCT00363584|localized gallbladder cancer
1405757|NCT00363584|localized extrahepatic bile duct cancer
1405758|NCT00363584|squamous cell carcinoma of the gallbladder
1405759|NCT00363584|adult primary cholangiocellular carcinoma
1405760|NCT00363558|skin graft
1405761|NCT00363558|fixation
1405762|NCT00363558|cyanoacrylate glue
1405763|NCT00363558|skin staples
1405764|NCT00363545|Prophylaxis against gastroenteritis caused by Rotavirus
1405765|NCT00363532|migraine with out aura
1405766|NCT00363519|MK-0431
1405767|NCT00363519|ONO-5435
1405768|NCT00363519|Type 2 diabetes mellitus
1405769|NCT00363506|nutritional
1405770|NCT00363506|C10.228.140.546.399.750
1405771|NCT00363480|Asthma
1405772|NCT00363480|Asthma Control Test
1405773|NCT00363480|SERETIDE
1405774|NCT00363467|Busulfan
1405775|NCT00363467|Acute myeloid leukemia (AML)
1405776|NCT00363467|Hematopoietic Stem Cell Transplantation (HSCT)
1405777|NCT00363467|Dendritic cells
1405778|NCT00363467|Bone marrow transplantation
1405779|NCT00363467|PBSC mobilization
1405780|NCT00363467|Autologous stem cells
1405781|NCT00363454|Phase I
1405782|NCT00363454|Pharmacokinetics
1405783|NCT00363454|TCN-PM
1405784|NCT00363454|VD-0002
1405785|NCT00363454|Immunohistochemistry
1405786|NCT00363454|Serum tumor marker
1405787|NCT00363454|Akt phosphorylation
1405788|NCT00363454|Ex vivo testing
1405789|NCT00363454|metastatic
1405790|NCT00363441|head and neck neoplasms
1405791|NCT00363441|squamous cell cancer
1405792|NCT00363441|intensity modulated radiotherapy
1405793|NCT00363428|pulmonary complications
1405794|NCT00363428|perioperative/postoperative complications
1405795|NCT00363428|tobacco use disorder
1405796|NCT00363428|non-small cell lung cancer
1405797|NCT00363428|small cell lung cancer
1405798|NCT00363402|Cystic Fibrosis
1405799|NCT00363389|Hysteroscopy
1405800|NCT00363389|Misoprostol
1405801|NCT00363389|Uterine hemorrhage
1405802|NCT00363389|Uterine cervix
1405803|NCT00363389|Dilatation
1405804|NCT00363376|olanzapine
1405805|NCT00363376|zonisamide
1405806|NCT00363376|weight gain
1405807|NCT00363376|bipolar disorder
1405808|NCT00363376|psychotic disorders
1405809|NCT00363363|Pediatrics
1405810|NCT00363363|Fontan Procedure
1405811|NCT00363363|Physical Activity
1405812|NCT00363363|Physical Fitness
1405813|NCT00363363|Congenital Heart Defects
1405814|NCT00363363|exercise rehabilitation
1405815|NCT00363337|Adults
1405816|NCT00363337|Bipolar Depression
1405817|NCT00363337|Bipolar Disorder
1405818|NCT00363337|Bipolar I
1405819|NCT00363337|Bipolar II
1405820|NCT00363337|Depression
1405821|NCT00363324|stem cell
1405822|NCT00363324|acute myocardial infarction
1405823|NCT00363311|Dutasteride Prostate Cancer Expectant management REDEEM
1405824|NCT00363298|D-amphetamine, dextro-amphetamine, stimulant drug
1405825|NCT00363285|adenocarcinoma of the prostate
1405826|NCT00363285|stage III prostate cancer
1405827|NCT00363285|stage IV prostate cancer
1405828|NCT00363246|Elderly
1405829|NCT00363246|Fall risk
1405830|NCT00363246|Veterans
1405831|NCT00363246|WheelChairs
1405832|NCT00363246|Injury
1405833|NCT00363233|type 2 diabetes
1405834|NCT00363233|lignans
1405835|NCT00363233|flaxseed
1405836|NCT00363233|cholesterol
1405837|NCT00363220|Infection
1405838|NCT00363220|E coli
1405839|NCT00363220|Klebsiella
1405840|NCT00363220|ESBL
1405841|NCT00363207|behavior
1405842|NCT00363207|local anesthesia
1405843|NCT00363207|behavior after dental local anesthesia
1405844|NCT00363194|Pazopanib GW786034 Advanced cancer Metastatic cancer
1405845|NCT00363181|Insulin resistance
1405846|NCT00363181|Metabolic problems
1405847|NCT00363181|Weight gain
1405848|NCT00363181|Mental health problems
1405849|NCT00363181|Mental disorders
1405850|NCT00363181|Antipsychotic medication
1405851|NCT00363181|Olanzapine
1405852|NCT00363168|Hemorrhagic Choroidal Neovascularization
1405853|NCT00363155|chronic
1405854|NCT00363155|hepatitis b
1405855|NCT00363142|HIV-1 LEXIVA Ritonavir Once-daily
1405856|NCT00363129|neurotoxicity
1405857|NCT00363129|unspecified adult solid tumor, protocol specific
1405858|NCT00363116|Kidney transplant
1405859|NCT00363116|Pancreas transplant
1405860|NCT00363116|Daclizumab
1405861|NCT00363116|Tacrolimus
1405862|NCT00363116|Mycophenolate mofetil
1405863|NCT00363116|Steroids
1405864|NCT00363116|Immunosuppression
1405865|NCT00363116|Acute allograft rejection
1405866|NCT00363090|contiguous stage II adult diffuse large cell lymphoma
1405867|NCT00363090|contiguous stage II adult diffuse mixed cell lymphoma
1405868|NCT00363090|noncontiguous stage II adult diffuse large cell lymphoma
1405869|NCT00363090|noncontiguous stage II adult diffuse mixed cell lymphoma
1405870|NCT00363090|stage III adult diffuse large cell lymphoma
1405871|NCT00363090|stage III adult diffuse mixed cell lymphoma
1405872|NCT00363090|stage IV adult diffuse large cell lymphoma
1405873|NCT00363090|stage IV adult diffuse mixed cell lymphoma
1405874|NCT00363090|angioimmunoblastic T-cell lymphoma
1405875|NCT00363090|anaplastic large cell lymphoma
1405876|NCT00363090|stage II adult T-cell leukemia/lymphoma
1405877|NCT00363090|stage III adult T-cell leukemia/lymphoma
1405878|NCT00363090|stage IV adult T-cell leukemia/lymphoma
1405879|NCT00363077|Influenza vaccine
1405880|NCT00363077|Prophylaxis Influenza vaccine
1405881|NCT00363051|Pancreatic
1405882|NCT00363051|Tumor
1405883|NCT00363051|Islet Cell
1405884|NCT00363051|Carcinoma
1405885|NCT00363051|Neuroendocrine
1405886|NCT00363051|Endocrine
1405887|NCT00363051|Atypical Carcinoid
1405888|NCT00363051|RADIANT1
1405889|NCT00363051|RADIANT-1
1405890|NCT00363038|Bruising
1405891|NCT00363038|Topical 20% arnica
1405892|NCT00363025|Acute myeloid leukemia
1405893|NCT00363025|Older patients
1405894|NCT00363025|Patient aged 65 years or more
1405895|NCT00363012|stage IIIA breast cancer
1405896|NCT00363012|stage IIIB breast cancer
1405897|NCT00363012|stage IIIC breast cancer
1405898|NCT00363012|stage IV breast cancer
1405899|NCT00363012|male breast cancer
1405900|NCT00362999|Allergic
1405901|NCT00362999|Rhinitis
1405902|NCT00362999|Pharmacogenetics
1405903|NCT00362999|Histamine
1405904|NCT00362986|dermatologic complications
1405905|NCT00362986|unspecified adult solid tumor, protocol specific
1405906|NCT00362973|male breast cancer
1405907|NCT00362973|recurrent breast cancer
1405908|NCT00362973|stage I breast cancer
1405909|NCT00362973|stage II breast cancer
1405910|NCT00362973|stage IIIA breast cancer
1405911|NCT00362973|stage IIIB breast cancer
1405912|NCT00362973|stage IIIC breast cancer
1405913|NCT00362973|stage IV breast cancer
1405914|NCT00362960|Type 2 Diabetes Mellitus
1405915|NCT00362960|Diabetic Nephropathy
1405916|NCT00362960|Inflammatory Markers
1405917|NCT00362960|Proteinuria
1405918|NCT00362960|Renal Disease
1405919|NCT00362947|Superficial vein thrombosis
1405920|NCT00362947|thrombophlebitis
1405921|NCT00362947|LMWH
1405922|NCT00362947|parnaparin
1405923|NCT00362934|Hyperlipidemia Combined
1405924|NCT00362934|efficacy combination fenofibrate simvastatin versus atorvastatin
1405925|NCT00362921|adult glioblastoma multiforme
1405926|NCT00362921|adult gliosarcoma
1405927|NCT00362921|recurrent adult brain tumor
1405928|NCT00362908|Obesity
1405929|NCT00362908|Hypertension
1405930|NCT00362908|Insulin Resistance
1405931|NCT00362869|Enteroaggregative Escherichia coli, diarrhea, challenge
1405932|NCT00362843|11C-Leucine
1405933|NCT00362843|Positron Emission Tomography (PET)
1405934|NCT00362843|Cerebral Protein Synthesis
1405935|NCT00362843|Propofol
1405936|NCT00362843|Fragile X
1405937|NCT00362843|Fragile X Syndrome
1405938|NCT00362817|Recurrent
1405939|NCT00362817|Symptomatic
1405940|NCT00362804|tetrabenazine
1405941|NCT00362804|partial response
1405942|NCT00362804|psychosis
1405943|NCT00362804|schizophrenia
1405944|NCT00362804|schizoaffective disorder
1405945|NCT00362804|partial response to antipsychotics
1405946|NCT00362791|voluntary counseling and testing
1405947|NCT00362791|HIV/STD prevention counseling
1405948|NCT00362791|HIV/STD prevention intervention
1405949|NCT00362791|counseling efficacy
1405950|NCT00362765|Type 2 Diabetes
1405951|NCT00362765|Dyslipidemia
1405952|NCT00362765|Hyperinsulinemic
1405953|NCT00362765|Clamp
1405954|NCT00362765|Metformin
1405955|NCT00362765|Fenofibrate
1405956|NCT00362752|norfloxacin
1405957|NCT00362752|hepatopulmonary syndrome
1405958|NCT00362726|HIV
1405959|NCT00362687|HIV, HAART
1405960|NCT00362661|PTSD
1405961|NCT00362661|cortisol
1405962|NCT00362661|memory
1405963|NCT00362661|treatment
1405964|NCT00362622|Travalert
1405965|NCT00362622|open angle glaucoma
1405966|NCT00362609|Safety
1405967|NCT00362596|Acyclovir
1405968|NCT00362596|HIV
1405969|NCT00362596|HSV
1405970|NCT00362583|Cancer pain with breakthrough pain episodes
1405971|NCT00362570|Newly diagnosed
1405972|NCT00362544|antifungal prophylaxis
1405973|NCT00362544|allogeneic stem-cell transplantation
1405974|NCT00362544|acute leukaemia
1405975|NCT00362544|antifungal prophylaxis treatment of allogeneic stem-cell transplantation and acute leukaemia
1405976|NCT00362518|atherosclerosis
1405977|NCT00362518|vitamin C
1405978|NCT00362518|vitamin E
1405979|NCT00362492|TKR
1405980|NCT00362492|Ultrasonography
1405981|NCT00362492|asymptomatic deep venous thrombosis
1405982|NCT00362492|extended duration prophylaxis
1405983|NCT00362492|short duration prophylaxis
1405984|NCT00362479|pregnancy prevention
1405985|NCT00362479|oral contraceptives
1405986|NCT00362466|Leukemia (chronic myeloid leukemia - chronic phase)
1405987|NCT00362440|HIV lipodystrophy
1405988|NCT00362440|Leptin
1405989|NCT00362440|Fat wasting
1405990|NCT00362440|Pioglitazone
1405991|NCT00362440|Insulin resistance
1405992|NCT00362427|Hepatitis B
1405993|NCT00362427|Pertussis
1405994|NCT00362427|Diphtheria
1405995|NCT00362427|Tetanus
1405996|NCT00362427|H. influenzae type b
1405997|NCT00362427|Polio
1405998|NCT00362414|Stroke
1405999|NCT00362401|Psychoacoustics
1406000|NCT00362401|Quality of Life
1406001|NCT00362401|Heart Valve Prosthesis
1406002|NCT00362388|Coronary artery disease
1406003|NCT00362388|Ischemic heart disease
1406004|NCT00362388|Angiogenesis
1406005|NCT00362388|Cells
1406006|NCT00362388|Cardiac surgery
1406007|NCT00362375|Adult
1406008|NCT00362375|*HIV Infections/pc [Prevention & Control]
1406009|NCT00362375|Female
1406010|NCT00362375|Humans
1406011|NCT00362375|Risk-Taking
1406012|NCT00362375|Safe Sex
1406013|NCT00362375|Sexual Behavior
1406014|NCT00362375|HIV Testing
1406015|NCT00362362|Amyotrophic Lateral Sclerosis
1406016|NCT00362362|Primary Lateral Sclerosis
1406017|NCT00362362|Genetics
1406018|NCT00362362|Blood Sample
1406019|NCT00362362|PLS
1406020|NCT00362362|ALS
1406021|NCT00362349|ITP
1406022|NCT00362349|IVIg
1406023|NCT00362349|Platelet count
1406024|NCT00362349|Bleeding
1406025|NCT00362336|Hepatitis B
1406026|NCT00362336|Polio
1406027|NCT00362336|Diphtheria
1406028|NCT00362336|Pertussis
1406029|NCT00362336|H. influenzae type b
1406030|NCT00362323|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
1406031|NCT00362310|classical kaposi's sarcoma
1406032|NCT00362310|treatment
1406033|NCT00362310|HIV protease inhibitor indinavir
1406034|NCT00362284|Alzheimer's disease
1406035|NCT00362284|coping
1406036|NCT00362284|quality of life
1406037|NCT00362284|caregiving
1406038|NCT00362271|Healthy Subjects
1406039|NCT00362245|Amikacin
1406040|NCT00362245|Pharmacokinetics
1406041|NCT00362245|Pharmacodynamics
1406042|NCT00362245|Intra-Thecal injection
1406043|NCT00362232|Prevention of venous thromboembolism
1406044|NCT00362219|topical
1406045|NCT00362219|morphine
1406046|NCT00362219|pain
1406047|NCT00362219|skin-wound
1406048|NCT00362219|skin-graft
1406049|NCT00362219|peripheral analgesia
1406050|NCT00362219|burn
1406051|NCT00362206|Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin versus pravastatin
1406052|NCT00362206|Hyperlipidemia Combined
1406053|NCT00362193|Diabetes
1406054|NCT00362193|Chronic disease management
1406055|NCT00362193|Relapse
1406056|NCT00362180|LDL-cholesterol
1406057|NCT00362180|apoB-100
1406058|NCT00362180|apoB-48
1406059|NCT00362180|triglyceride
1406060|NCT00362180|HeFH
1406061|NCT00362180|FHBL
1406062|NCT00362167|Clinical Experience
1406063|NCT00362167|Educational Training
1406064|NCT00362167|Pain Syndromes
1406065|NCT00362167|Analgesia
1406066|NCT00362167|Pain Medicine
1406067|NCT00362167|Therapy
1406068|NCT00362167|Neuropathic
1406069|NCT00362167|Chronic Pain
1406070|NCT00362167|Acute Pain
1406071|NCT00362167|Analgesics
1406072|NCT00362167|Medication
1406073|NCT00362167|Evaluation
1406074|NCT00362141|levetiracetam
1406075|NCT00362141|status
1406076|NCT00362141|epilepticus
1406077|NCT00362128|Blood Pressure, High
1406078|NCT00362128|Obesity
1406079|NCT00362128|Tobacco Use Disorder
1406080|NCT00362115|hypertension
1406081|NCT00362115|blood pressure
1406082|NCT00362115|diastolic blood pressure
1406083|NCT00362115|drug therapy
1406084|NCT00362102|EGFR-detectable metastatic colorectal carcinoma with documented progressive disease to irinotecan-based chemotherapy and failure
1406085|NCT00362089|n-3 fatty acids
1406086|NCT00362089|n-6 fatty acids
1406087|NCT00362089|long chain polyunsaturated fatty acids
1406088|NCT00362089|pregnancy
1406089|NCT00362089|lactation
1406090|NCT00362089|breast feeding
1406091|NCT00362089|breast milk
1406092|NCT00362089|adipose tissue
1406093|NCT00362089|newborn
1406094|NCT00362089|fetal development
1406095|NCT00362076|Perception
1406096|NCT00362076|Development
1406097|NCT00362076|Cognition
1406098|NCT00362076|Vision
1406099|NCT00362076|Infants
1406100|NCT00362076|Autonomic Function
1406101|NCT00362076|Cardiac Vagal Tone
1406102|NCT00362076|Categorization
1406103|NCT00362076|Habituation
1406104|NCT00362076|Motion-Carried Information
1406105|NCT00362063|growth hormone
1406106|NCT00362050|malaria, falciparum
1406107|NCT00362050|uncomplicated Plasmodium falciparum malaria
1406108|NCT00361998|Uncomplicated Cystitis
1406109|NCT00361998|Nitrofurantoin Macrocrystals
1406110|NCT00361985|Gastric bypass
1406111|NCT00361985|Anastomotic stricture
1406112|NCT00361985|Morbid obesity
1406113|NCT00361985|Bariatric surgery
1406114|NCT00361985|Omeprazole
1406115|NCT00361959|fluticasone propionate/salmeterol combination
1406116|NCT00361959|tiotropium
1406117|NCT00361959|SERETIDE
1406118|NCT00361959|COPD exacerbation
1406119|NCT00361946|Type 2 diabetes
1406120|NCT00361946|Lean
1406121|NCT00361946|Obese
1406122|NCT00361920|steroid resistant asthma
1406123|NCT00361907|Pulsatile intravenous insulin
1406124|NCT00361907|Oral carbohydrate loading
1406125|NCT00361907|Respiratory Quotients
1406126|NCT00361907|Hypoglycemia
1406127|NCT00361907|Diabetic Complications
1406128|NCT00361907|Circulating vascular and inflammatory markers
1406129|NCT00361868|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
1406130|NCT00361855|MI
1406131|NCT00361842|Colorectal cancer
1406132|NCT00361842|Colorectal carcinoma
1406133|NCT00361842|Colonic cancer
1406134|NCT00361842|Rectal cancer
1406135|NCT00361829|Development
1406136|NCT00361829|Childhood Growth
1406137|NCT00361816|Maternal Effect Gene
1406138|NCT00361816|Embryonic Development
1406139|NCT00361816|Infertility
1406140|NCT00361803|chemotherapy
1406141|NCT00361803|recurrent
1406142|NCT00361803|refractory
1406143|NCT00361803|research
1406144|NCT00361803|cancer
1406145|NCT00361803|pharmacokinetics
1406146|NCT00361790|Healthy Subjects
1406147|NCT00361777|Obesity
1406148|NCT00361777|Pseudo-Cushing State
1406149|NCT00361777|Hypercortisolism
1406150|NCT00361777|Cushing's Syndrome
1406151|NCT00361777|Cushing Syndrome
1406152|NCT00361751|Glucose metabolism
1406153|NCT00361751|Fat Metabolism
1406154|NCT00361751|Insulin Resistance
1406155|NCT00361751|Protein Metabolism
1406156|NCT00361751|Tracer Methodology
1406157|NCT00361738|Type 2 Diabetes Mellitus
1406158|NCT00361725|severe sepsis
1406159|NCT00361725|organ failure
1406160|NCT00361725|activated protein C
1406161|NCT00361725|thrombomodulin
1406162|NCT00361725|EPCR
1406163|NCT00361712|Epidural
1406164|NCT00361712|analgesia
1406165|NCT00361712|labor
1406166|NCT00361712|cytokines
1406167|NCT00361699|stroke
1406168|NCT00361699|brain ischemia
1406169|NCT00361699|cerebrovascular accident
1406170|NCT00361699|statin
1406171|NCT00361699|hydroxymethylglutaryl-CoA reductase inhibitors
1406172|NCT00361699|cholesterol
1406173|NCT00361699|hypercholesterolemia
1406174|NCT00361699|hyperlipidemia
1406175|NCT00361699|multicenter studies
1406176|NCT00361699|prospective studies
1406177|NCT00361699|endpoint determination
1406178|NCT00361699|randomized controlled trials
1406179|NCT00361699|recurrence
1406180|NCT00361699|pravastatin
1406181|NCT00361699|c-reactive Protein
1406182|NCT00361686|tramadol
1406183|NCT00361686|remifentanyl
1406184|NCT00361686|patient controlled analgesia
1406185|NCT00361686|abortion
1406186|NCT00361673|Health Disparities
1406187|NCT00361673|Built Environments
1406188|NCT00361660|Motor skills
1406189|NCT00361660|Occupational Therapy
1406190|NCT00361660|Physical Therapy Techniques
1406191|NCT00361660|Rehabilitation
1406192|NCT00361660|Upper Extremity
1406193|NCT00361660|Stroke
1406194|NCT00361634|Etanercept
1406195|NCT00361634|Enbrel
1406196|NCT00361634|DCE-MRI
1406197|NCT00361634|RA
1406198|NCT00361621|VELCADE
1406199|NCT00361608|diabetes
1406200|NCT00361608|hypoglycemia
1406201|NCT00361608|monitor
1406202|NCT00361608|children with Type I Diabetes
1406203|NCT00361595|osteoporosis
1406204|NCT00361595|zoledronic acid
1406205|NCT00361595|forteo
1406206|NCT00361582|Osteoarthritis
1406207|NCT00361582|tapentadol
1406208|NCT00361582|knee-replacement
1406209|NCT00361582|hip replacement
1406210|NCT00361582|pain
1406211|NCT00361569|vaginal atrophy
1406212|NCT00361569|vaginal dryness
1406213|NCT00361569|vaginal itching
1406214|NCT00361569|vaginal pain
1406215|NCT00361556|low back pain
1406216|NCT00361556|disability
1406217|NCT00361556|health education
1406218|NCT00361556|primary care
1406219|NCT00361543|Schizophrenia
1406220|NCT00361543|Mental Illness
1406221|NCT00361543|SERM
1406222|NCT00361543|Raloxifene
1406223|NCT00361543|Cognition
1406224|NCT00361530|stroke
1406225|NCT00361530|brain ischemia
1406226|NCT00361530|cerebrovascular accident
1406227|NCT00361530|statin
1406228|NCT00361530|hydroxymethylglutaryl-CoA Reductase Inhibitors
1406229|NCT00361530|cholesterol
1406230|NCT00361530|hypercholesterolemia
1406231|NCT00361530|hyperlipidemia
1406232|NCT00361530|multicenter studies
1406233|NCT00361530|prospective studies
1406234|NCT00361530|endpoint determination
1406235|NCT00361530|randomized controlled trials
1406236|NCT00361530|recurrence
1406237|NCT00361530|pravastatin
1406238|NCT00361530|plaque
1406239|NCT00361530|tunica intima
1406240|NCT00361530|tunica media
1406241|NCT00361530|ultrasonography
1406242|NCT00361530|carotid arteries
1406243|NCT00361517|GM monitoring
1406244|NCT00361517|Immunocompromised
1406245|NCT00361517|hematological disorder
1406246|NCT00361517|Allogenic HSCT recipients
1406247|NCT00361517|Aspergillus PCR assay
1406248|NCT00361504|Osteoarthritis
1406249|NCT00361504|Pain
1406250|NCT00361504|Low Back Pain
1406251|NCT00361504|Hip Pain
1406252|NCT00361504|Knee Pain
1406253|NCT00361504|Backache
1406254|NCT00361504|Tapentadol
1406255|NCT00361491|Depression
1406256|NCT00361491|antidepressive disorders
1406257|NCT00361491|controlled clinical trial
1406258|NCT00361478|exercise
1406259|NCT00361478|postnatal depression
1406260|NCT00361478|psychological health
1406261|NCT00361478|well-being
1406262|NCT00361426|COPD
1406263|NCT00361426|Respiration Rate
1406264|NCT00361426|Monitoring
1406265|NCT00361413|Stem cell transplantation
1406266|NCT00361413|GVHD
1406267|NCT00361413|Graft Versus Host Disease
1406268|NCT00361400|pregnancy
1406269|NCT00361400|hormonal contraception
1406270|NCT00361387|Sarcoidosis
1406271|NCT00361387|Sarcoid
1406272|NCT00361374|Depression
1406273|NCT00361374|Omega-3
1406274|NCT00361374|Boston
1406275|NCT00361348|Palifermin
1406276|NCT00361348|drug interaction
1406277|NCT00361335|Rheumatoid arthritis
1406278|NCT00361335|Golimumab
1406279|NCT00361335|Methotrexate
1406280|NCT00361335|Tumor Necrosis Factor-alpha
1406281|NCT00361335|Immunology
1406282|NCT00361309|liver cancer
1406283|NCT00361309|HCC
1406284|NCT00361296|refractory anemia with excess blasts
1406285|NCT00361296|refractory anemia with ringed sideroblasts
1406286|NCT00361296|refractory anemia
1406287|NCT00361296|refractory cytopenia with multilineage dysplasia
1406288|NCT00361296|de novo myelodysplastic syndromes
1406289|NCT00361296|previously treated myelodysplastic syndromes
1406290|NCT00361296|secondary myelodysplastic syndromes
1406291|NCT00361270|Biofeedback
1406292|NCT00361270|Hypnosis
1406293|NCT00361270|Low Back Pain, Recurrent
1406294|NCT00361270|Pain beliefs
1406295|NCT00361270|Pain coping strategies
1406296|NCT00361270|Pain intensity
1406297|NCT00361270|Pain interference
1406298|NCT00361270|Pain quality
1406299|NCT00361270|Self-help treatment
1406300|NCT00361270|Sleep dysfunction
1406301|NCT00361257|Treatment Experienced
1406302|NCT00361244|Sutent
1406303|NCT00361231|Avastin
1406304|NCT00361231|GEMOX
1406305|NCT00361218|depression
1406306|NCT00361218|biology
1406307|NCT00361205|Parkinson's Disease, pharmacology, compliance, dopaminergic
1406308|NCT00361192|temporal arteritis
1406309|NCT00361192|duplex of temporal artery
1406310|NCT00361192|biopsy of temporal artery
1406311|NCT00361179|Observation
1406312|NCT00361179|Post-treatment
1406313|NCT00361166|Schizophrenia
1406314|NCT00361166|psychosis
1406315|NCT00361166|delusions
1406316|NCT00361166|hallucination
1406317|NCT00361140|Busulfan
1406318|NCT00361140|Fludarabine
1406319|NCT00361140|Chimerism
1406320|NCT00361140|Allogeneic stem cell transplantation (HCT)
1406321|NCT00361140|Myelodysplastic Syndromes
1406322|NCT00361140|Leukemia Myeloproliferative disorders (MPD)
1406323|NCT00361140|Leukemia, Lymphocytic
1406324|NCT00361140|Myeloma
1406325|NCT00361140|Lymphoma
1406326|NCT00361140|AUC
1406327|NCT00361140|Hematologic malignancies
1406328|NCT00361127|Heart failure
1406329|NCT00361127|pulmonary edema
1406330|NCT00361127|ACE-inhibitors
1406331|NCT00361127|lung diffusion
1406332|NCT00361127|exercise capacity
1406333|NCT00361127|Chronic heart failure
1406334|NCT00361101|HIV
1406335|NCT00361101|X4 tropic virus
1406336|NCT00361088|Velcade (PS-341)
1406337|NCT00361088|Bortezomib
1406338|NCT00361088|Zarnestra (R115777)
1406339|NCT00361088|Tipifarnib
1406340|NCT00361075|Perimenopause
1406341|NCT00361075|Abdominal adipose tissue
1406342|NCT00361075|Women's health
1406343|NCT00361075|Cholesterol
1406344|NCT00361075|Lipid Metabolism
1406345|NCT00361062|aggressive
1406346|NCT00361062|SSRI's
1406347|NCT00361062|simulation
1406348|NCT00361062|behavioral
1406349|NCT00361062|Side Effects, Psychological
1406350|NCT00361062|adverse effects
1406351|NCT00361062|Serotonin Reuptake Inhibitors
1406352|NCT00361062|aggressive behavior
1406353|NCT00361062|computer simulation
1406354|NCT00361049|graft versus host disease
1406355|NCT00361049|unspecified adult solid tumor, protocol specific
1406356|NCT00361049|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1406357|NCT00361049|adult acute myeloid leukemia with inv(16)(p13;q22)
1406358|NCT00361049|adult acute myeloid leukemia with t(15;17)(q22;q12)
1406359|NCT00361049|adult acute myeloid leukemia with t(16;16)(p13;q22)
1406360|NCT00361049|adult acute myeloid leukemia with t(8;21)(q22;q22)
1406361|NCT00361049|accelerated phase chronic myelogenous leukemia
1406362|NCT00361049|adult acute lymphoblastic leukemia in remission
1406363|NCT00361049|adult acute myeloid leukemia in remission
1406364|NCT00361049|atypical chronic myeloid leukemia
1406365|NCT00361049|blastic phase chronic myelogenous leukemia
1406366|NCT00361049|chronic eosinophilic leukemia
1406367|NCT00361049|primary myelofibrosis
1406368|NCT00361049|chronic myelomonocytic leukemia
1406369|NCT00361049|chronic neutrophilic leukemia
1406370|NCT00361049|chronic phase chronic myelogenous leukemia
1406371|NCT00361049|de novo myelodysplastic syndromes
1406372|NCT00361049|disseminated neuroblastoma
1406373|NCT00361049|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1406374|NCT00361049|myelodysplastic/myeloproliferative disease, unclassifiable
1406375|NCT00361049|nodal marginal zone B-cell lymphoma
1406376|NCT00361049|noncontiguous stage II adult Burkitt lymphoma
1406377|NCT00361049|noncontiguous stage II adult diffuse large cell lymphoma
1406378|NCT00361049|noncontiguous stage II adult diffuse mixed cell lymphoma
1406379|NCT00361049|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1406380|NCT00361049|noncontiguous stage II adult immunoblastic large cell lymphoma
1406381|NCT00361049|noncontiguous stage II adult lymphoblastic lymphoma
1406382|NCT00361049|noncontiguous stage II grade 1 follicular lymphoma
1406383|NCT00361049|noncontiguous stage II grade 2 follicular lymphoma
1406384|NCT00361049|noncontiguous stage II grade 3 follicular lymphoma
1406385|NCT00361049|noncontiguous stage II mantle cell lymphoma
1406386|NCT00361049|noncontiguous stage II marginal zone lymphoma
1406387|NCT00361049|noncontiguous stage II small lymphocytic lymphoma
1406388|NCT00361049|poor prognosis metastatic gestational trophoblastic tumor
1406389|NCT00361049|previously treated myelodysplastic syndromes
1406390|NCT00361049|secondary acute myeloid leukemia
1406391|NCT00361049|secondary myelodysplastic syndromes
1406392|NCT00361049|splenic marginal zone lymphoma
1406393|NCT00361049|stage I multiple myeloma
1406394|NCT00361049|stage II multiple myeloma
1406395|NCT00361049|stage II ovarian epithelial cancer
1406396|NCT00361049|stage III adult Burkitt lymphoma
1406397|NCT00361049|stage III adult Hodgkin lymphoma
1406398|NCT00361049|stage III adult diffuse large cell lymphoma
1406399|NCT00361049|stage III adult diffuse mixed cell lymphoma
1406400|NCT00361049|stage III adult diffuse small cleaved cell lymphoma
1406401|NCT00361049|stage III adult immunoblastic large cell lymphoma
1406402|NCT00361049|stage III adult lymphoblastic lymphoma
1406403|NCT00361049|stage III chronic lymphocytic leukemia
1406404|NCT00361049|stage III grade 1 follicular lymphoma
1406405|NCT00361049|stage III grade 2 follicular lymphoma
1406406|NCT00361049|stage III grade 3 follicular lymphoma
1406407|NCT00361049|stage III mantle cell lymphoma
1406408|NCT00361049|stage III marginal zone lymphoma
1406409|NCT00361049|stage III multiple myeloma
1406410|NCT00361049|stage III ovarian epithelial cancer
1406411|NCT00361049|stage III small lymphocytic lymphoma
1406412|NCT00361049|stage III malignant testicular germ cell tumor
1406413|NCT00361049|stage IIIA breast cancer
1406414|NCT00361049|stage IIIB breast cancer
1406415|NCT00361049|stage IIIC breast cancer
1406416|NCT00361049|stage IV adult Burkitt lymphoma
1406417|NCT00361049|stage IV adult Hodgkin lymphoma
1406418|NCT00361049|stage IV adult diffuse large cell lymphoma
1406419|NCT00361049|stage IV adult diffuse mixed cell lymphoma
1406420|NCT00361049|stage IV adult diffuse small cleaved cell lymphoma
1406421|NCT00361049|stage IV adult immunoblastic large cell lymphoma
1406422|NCT00361049|stage IV adult lymphoblastic lymphoma
1406423|NCT00361049|stage IV breast cancer
1406424|NCT00361049|stage IV chronic lymphocytic leukemia
1406425|NCT00361049|stage IV grade 1 follicular lymphoma
1406426|NCT00361049|stage IV grade 2 follicular lymphoma
1406427|NCT00361049|stage IV grade 3 follicular lymphoma
1406428|NCT00361049|stage IV mantle cell lymphoma
1406429|NCT00361049|stage IV marginal zone lymphoma
1406430|NCT00361049|stage IV ovarian epithelial cancer
1406431|NCT00361049|stage IV small lymphocytic lymphoma
1406432|NCT00361036|Leiomyoma
1406433|NCT00361036|Leiomyomatosis
1406434|NCT00361036|Uterine Neoplasms
1406435|NCT00361036|BeadBlock
1406436|NCT00361036|Embsophere
1406437|NCT00361036|Embolization
1406438|NCT00361036|Uterine fibroid embolization
1406439|NCT00361023|Angiotensin type 1 receptor blocker (ARB)
1406440|NCT00361023|losartan
1406441|NCT00361023|type 2 diabetes
1406442|NCT00361023|insulin sensitivity and secretion
1406443|NCT00361023|glucose metabolism
1406444|NCT00361010|Keppra
1406445|NCT00361010|Epilepsy
1406446|NCT00361010|Childhood Absence Epilepsy
1406447|NCT00361010|Seizures
1406448|NCT00360997|Stroke rehabilitation
1406449|NCT00360997|Physical therapy
1406450|NCT00360984|CSII
1406451|NCT00360984|insulin analog
1406452|NCT00360984|severe hypoglycaemia
1406453|NCT00360984|altered hypoglycaemia awareness
1406454|NCT00360984|diabetes quality of life
1406455|NCT00360984|CGMS
1406456|NCT00360971|mucositis
1406457|NCT00360971|pain
1406458|NCT00360971|radiation toxicity
1406459|NCT00360971|stage III squamous cell carcinoma of the hypopharynx
1406460|NCT00360971|stage IV squamous cell carcinoma of the hypopharynx
1406461|NCT00360971|stage III squamous cell carcinoma of the larynx
1406462|NCT00360971|stage IV squamous cell carcinoma of the larynx
1406463|NCT00360971|stage III squamous cell carcinoma of the lip and oral cavity
1406464|NCT00360971|stage IV squamous cell carcinoma of the lip and oral cavity
1406465|NCT00360971|stage III squamous cell carcinoma of the oropharynx
1406466|NCT00360971|stage IV squamous cell carcinoma of the oropharynx
1406467|NCT00360958|ultrafiltration
1406468|NCT00360958|heart failure
1406469|NCT00360958|fluid overload
1406470|NCT00360945|childhood oligodendroglioma
1406471|NCT00360945|untreated childhood cerebellar astrocytoma
1406472|NCT00360945|childhood high-grade cerebral astrocytoma
1406473|NCT00360945|childhood low-grade cerebral astrocytoma
1406474|NCT00360945|recurrent childhood cerebellar astrocytoma
1406475|NCT00360945|recurrent childhood cerebral astrocytoma
1406476|NCT00360945|recurrent childhood brain tumor
1406477|NCT00360932|facial lipoatrophy
1406478|NCT00360932|HIV/AIDs
1406479|NCT00360919|casomorphin
1406480|NCT00360919|cheese
1406481|NCT00360919|craving
1406482|NCT00360919|casein
1406483|NCT00360919|milk
1406484|NCT00360906|RRMS
1406485|NCT00360906|Omega-3
1406486|NCT00360906|Treatment
1406487|NCT00360867|Extension study
1406488|NCT00360867|solid tumors
1406489|NCT00360854|untreated childhood brain stem glioma
1406490|NCT00360854|recurrent childhood cerebellar astrocytoma
1406491|NCT00360854|recurrent childhood cerebral astrocytoma
1406492|NCT00360854|recurrent childhood ependymoma
1406493|NCT00360854|recurrent childhood medulloblastoma
1406494|NCT00360854|recurrent childhood supratentorial primitive neuroectodermal tumor
1406495|NCT00360854|recurrent childhood visual pathway and hypothalamic glioma
1406496|NCT00360854|childhood central nervous system germ cell tumor
1406497|NCT00360854|childhood choroid plexus tumor
1406498|NCT00360854|childhood craniopharyngioma
1406499|NCT00360854|childhood grade I meningioma
1406500|NCT00360854|childhood grade II meningioma
1406501|NCT00360854|childhood grade III meningioma
1406502|NCT00360854|childhood low-grade cerebral astrocytoma
1406503|NCT00360854|childhood infratentorial ependymoma
1406504|NCT00360854|childhood supratentorial ependymoma
1406505|NCT00360854|recurrent childhood brain tumor
1406506|NCT00360854|recurrent childhood subependymal giant cell astrocytoma
1406507|NCT00360854|recurrent childhood pineoblastoma
1406508|NCT00360841|auricular
1406509|NCT00360841|acupuncture
1406510|NCT00360828|Recurrent Anaplastic Astrocytoma
1406511|NCT00360828|Mixed Malignant Glioma
1406512|NCT00360828|Oligodendroglioma
1406513|NCT00360828|Irinotecan
1406514|NCT00360828|Brain tumor
1406515|NCT00360828|Nitrosoureas
1406516|NCT00360828|Brain and nervous system
1406517|NCT00360802|chronic low back pain
1406518|NCT00360802|cognitive-behavioral therapy
1406519|NCT00360802|Mindful Based Stress Reduction
1406520|NCT00360802|pain clinics
1406521|NCT00360802|anxiety
1406522|NCT00360802|quality of life
1406523|NCT00360802|chronic pain
1406524|NCT00360789|STROKE REHABILITATION
1406525|NCT00360789|pHYSICAL THERAPY
1406526|NCT00360750|intraocular retinoblastoma
1406527|NCT00360750|extraocular retinoblastoma
1406528|NCT00360737|Clinical Trials
1406529|NCT00360737|Investigational Drug
1406530|NCT00360737|Healthy Volunteers
1406531|NCT00360737|Botulinum Antitoxin
1406532|NCT00360737|Phoenix, Arizona
1406533|NCT00360724|dysthymia
1406534|NCT00360724|dysthymic disorder
1406535|NCT00360724|chronic depression
1406536|NCT00360724|chronic low-grade depression
1406537|NCT00360724|atypical depression
1406538|NCT00360724|minor depression
1406539|NCT00360724|depression NOS
1406540|NCT00360724|depression
1406541|NCT00360724|depressive disorder
1406542|NCT00360724|mood disorder
1406543|NCT00360724|unipolar depression
1406544|NCT00360724|low-grade depression
1406545|NCT00360711|Moral Distress
1406546|NCT00360711|Nondirectiveness
1406547|NCT00360711|Ethical Dilemma
1406548|NCT00360685|Tacrolimus
1406549|NCT00360685|Methotrexate
1406550|NCT00360685|Mycophenolate mofetil
1406551|NCT00360685|Mucositis
1406552|NCT00360685|Acute graft-versus-host disease (aGVHD)
1406553|NCT00360685|Engraftment
1406554|NCT00360685|hemolytic/uremic syndrome (HUS)
1406555|NCT00360685|Thrombotic thrombocytopenic purpura (TTP)
1406556|NCT00360672|Acute Myelogenous Leukemia
1406557|NCT00360672|Myelodysplastic Syndrome
1406558|NCT00360659|Obstructive sleep Apnea
1406559|NCT00360659|Hypertension
1406560|NCT00360659|Vasoactive hormones
1406561|NCT00360646|LIVER DIS
1406562|NCT00360646|CHEM IND
1406563|NCT00360646|Drugs
1406564|NCT00360646|Drug induced liver injury
1406565|NCT00360646|phenotype
1406566|NCT00360646|cholestatic liver injury
1406567|NCT00360646|hepatocellular liver injury
1406568|NCT00360646|mixed liver injury
1406569|NCT00360646|genotype
1406570|NCT00360633|Parkinson's Disease
1406571|NCT00360633|Impulse control disorder
1406572|NCT00360633|Dopamine agonist withdrawal syndrome
1406573|NCT00360633|Anxiety
1406574|NCT00360633|Depression
1406575|NCT00360633|Healthcare Utilization
1406576|NCT00360633|Disability
1406577|NCT00360633|Quality of life
1406578|NCT00360633|Cognitive function
1406579|NCT00360633|Psychosis
1406580|NCT00360633|Apathy
1406581|NCT00360633|Dyskinesias
1406582|NCT00360633|Wearing off
1406583|NCT00360594|alcoholism
1406584|NCT00360581|Smoking abstinence
1406585|NCT00360568|carbidopa
1406586|NCT00360568|severe motor fluctuations
1406587|NCT00360568|intestinal gel
1406588|NCT00360568|levodopa
1406589|NCT00360568|efficacy
1406590|NCT00360568|levodopa carbidopa intestinal gel
1406591|NCT00360568|dyskinesia
1406592|NCT00360568|Parkinson's Disease
1406593|NCT00360568|Duodopa
1406594|NCT00360568|levodopa-carbidopa
1406595|NCT00360568|DUOPA
1406596|NCT00360516|healthy volunteers
1406597|NCT00360503|Cystic fibrosis
1406598|NCT00360503|Antibiotic resistance
1406599|NCT00360503|Microbiology
1406600|NCT00360490|Idiopathic Menorrhagia
1406601|NCT00360477|Kidney stone removal surgery
1406602|NCT00360451|Prevention
1406603|NCT00360451|Child
1406604|NCT00360451|Adolescent
1406605|NCT00360451|Parent
1406606|NCT00360438|Leukemia
1406607|NCT00360438|Lymphoma
1406608|NCT00360438|Tumor Lysis Syndrome
1406609|NCT00360438|TLS
1406610|NCT00360438|Rasburicase
1406611|NCT00360438|Elitek
1406612|NCT00360425|anemia
1406613|NCT00360425|intravenous iron
1406614|NCT00360425|pharmacokinetics
1406615|NCT00360425|QTc
1406616|NCT00360399|Escitalopram
1406617|NCT00360399|Duloxetine
1406618|NCT00360399|Cognitive Behavioral Therapy
1406619|NCT00360399|PET
1406620|NCT00360399|fMRI
1406621|NCT00360373|bariatric
1406622|NCT00360373|obesity
1406623|NCT00360373|insulin resistance
1406624|NCT00360373|gastric bypass
1406625|NCT00360373|adolescent
1406626|NCT00360360|Neoplasm, Unknown Primary
1406627|NCT00360334|diabetes
1406628|NCT00360334|exenatide
1406629|NCT00360334|insulin glargine
1406630|NCT00360334|Lilly
1406631|NCT00360334|Amylin
1406632|NCT00360282|Migraine
1406633|NCT00360282|Triptans
1406634|NCT00360282|Motion Sickness
1406635|NCT00360256|Depression
1406636|NCT00360256|Amplichip P450 tests
1406637|NCT00360256|Antidepressants
1406638|NCT00360230|Malaria
1406639|NCT00360230|Plasmodium falciparum
1406640|NCT00360230|Vaccine
1406641|NCT00360230|Prophylaxis Plasmodium falciparum malaria
1406642|NCT00360217|Omega-3
1406643|NCT00360217|Triglyceride
1406644|NCT00360217|Hyperlipidemia
1406645|NCT00360217|Coronary Artery Disease
1406646|NCT00360217|Fatty Acids
1406647|NCT00360217|Safety
1406648|NCT00360217|Fish Oil
1406649|NCT00360217|Docosohexanoic Acid
1406650|NCT00360204|Infant health
1406651|NCT00360204|parenting competence
1406652|NCT00360204|Home nurse visit
1406653|NCT00360204|maternal post-partum care
1406654|NCT00360204|postpartum health utilization
1406655|NCT00360204|Breastfeeding
1406656|NCT00360178|hypertension
1406657|NCT00360178|valsartan
1406658|NCT00360178|amlodipine
1406659|NCT00360178|hydrochlorothiazide
1406660|NCT00360152|Breast Cancer
1406661|NCT00360152|Axilla
1406662|NCT00360152|Ultrasound
1406663|NCT00360152|FNA
1406664|NCT00360152|Molecular Analysis
1406665|NCT00360139|Sculptra
1406666|NCT00360139|lipoatrophy
1406667|NCT00360139|emaciation
1406668|NCT00360139|facial
1406669|NCT00360139|dermal filler
1406670|NCT00360139|poly-L-lactic acid
1406671|NCT00360139|Dermik
1406672|NCT00360139|SpaMD
1406673|NCT00360139|Sanofi
1406674|NCT00360139|Facial lipoatrophy
1406675|NCT00360139|Facial emaciation
1406676|NCT00360126|Lamictal
1406677|NCT00360126|lamotrigine
1406678|NCT00360126|Open-Label Extension Study
1406679|NCT00360126|Bipolar Disorder
1406680|NCT00360087|Treatment Study
1406681|NCT00360087|Sickle Cell Anemia
1406682|NCT00360087|6-Minute Walk
1406683|NCT00360087|Right Heart Catheterization
1406684|NCT00360087|Tracleer
1406685|NCT00360087|Sickle Cell
1406686|NCT00360087|SCD
1406687|NCT00360074|secondary hypothyroidism
1406688|NCT00360074|body weight adjusted thyroxin dose
1406689|NCT00360074|triiodothyronine supplementation
1406690|NCT00360061|Type 1 Diabetes Mellitus
1406691|NCT00360061|Adolescents
1406692|NCT00360061|Cognitive Behaviour Therapy
1406693|NCT00360048|oxytocin
1406694|NCT00360048|tnf
1406695|NCT00360048|sepsis
1406696|NCT00360048|lps
1406697|NCT00360009|Parkinson's disease
1406698|NCT00360009|Parkinson disease
1406699|NCT00360009|PD
1406700|NCT00360009|deep brain stimulation
1406701|NCT00360009|DBS
1406702|NCT00360009|subthalamic nucleus
1406703|NCT00360009|STN
1406704|NCT00360009|globus pallidus interna
1406705|NCT00360009|GPi
1406706|NCT00360009|mood
1406707|NCT00360009|motor symptoms
1406708|NCT00360009|cognition
1406709|NCT00360009|emotion
1406710|NCT00360009|memory
1406711|NCT00360009|attention
1406712|NCT00360009|tremor
1406713|NCT00360009|rigidity
1406714|NCT00360009|bradykinesia
1406715|NCT00359996|diabetes
1406716|NCT00359996|quality improvement
1406717|NCT00359996|community health center
1406718|NCT00359996|health disparities
1406719|NCT00359983|Humans
1406720|NCT00359983|Meningococcal vaccines
1406721|NCT00359983|Immunogenicity
1406722|NCT00359983|Vaccines
1406723|NCT00359983|H. influenzae type b vaccine
1406724|NCT00359983|Conjugate
1406725|NCT00359983|Toddlers
1406726|NCT00359983|Comparative study
1406727|NCT00359983|Neisseria meningitidis
1406728|NCT00359970|Diarrhea
1406729|NCT00359970|Travel
1406730|NCT00359970|Travelers' diarrhea
1406731|NCT00359970|Azithromycin
1406732|NCT00359970|Loperamide
1406733|NCT00359970|Treatment
1406734|NCT00359970|Antibiotic
1406735|NCT00359957|Pediatric obesity
1406736|NCT00359957|Physical activity
1406737|NCT00359957|Visceral fat
1406738|NCT00359957|Weight
1406739|NCT00359944|Alzheimer
1406740|NCT00359944|Dementia
1406741|NCT00359931|Neural Networks
1406742|NCT00359931|Mathematical Modeling
1406743|NCT00359931|Auditory Processing
1406744|NCT00359931|Tinnitis
1406745|NCT00359931|Hearing Loss
1406746|NCT00359918|infarction
1406747|NCT00359918|facilitated PCI
1406748|NCT00359918|primary PCI
1406749|NCT00359918|infarct size
1406750|NCT00359918|fibrinolysis
1406751|NCT00359918|ST-elevation myocardial infarction (STEMI)
1406752|NCT00359905|Benign prostatic hyperplasia
1406753|NCT00359905|alpha-blockers
1406754|NCT00359879|diabetes
1406755|NCT00359879|exenatide
1406756|NCT00359879|Lilly
1406757|NCT00359879|Amylin
1406758|NCT00359853|Norfloxacin, primary prophylaxis, SBP
1406759|NCT00359840|darbepoetin alfa
1406760|NCT00359840|anemia
1406761|NCT00359840|cancer patients
1406762|NCT00359840|chemotherapy
1406763|NCT00359814|Cyclosporine
1406764|NCT00359814|renal insufficiency, chronic
1406765|NCT00359814|long-term care
1406766|NCT00359801|Large Simple Trial
1406767|NCT00359775|Coping
1406768|NCT00359775|psychosocial
1406769|NCT00359775|Quality of Life
1406770|NCT00359775|problem solving
1406771|NCT00359762|exenatide
1406772|NCT00359762|diabetes
1406773|NCT00359762|Amylin
1406774|NCT00359762|Lilly
1406775|NCT00359762|glimepiride
1406776|NCT00359736|alveolitis, fibrosing
1406777|NCT00359736|exercise, aerobic
1406778|NCT00359736|fibrosis, pulmonary
1406779|NCT00359736|hypertension, pulmonary
1406780|NCT00359723|Parkinson's disease
1406781|NCT00359723|PD
1406782|NCT00359723|methylphenidate
1406783|NCT00359723|Ritalin
1406784|NCT00359723|MPD
1406785|NCT00359710|Multiracial Populations
1406786|NCT00359710|Human Genetic Variation
1406787|NCT00359710|Family History
1406788|NCT00359710|Admixture
1406789|NCT00359710|Physician-Patient Communication
1406790|NCT00359710|Ancestry
1406791|NCT00359710|Self-Identified Multiracial Adults
1406792|NCT00359710|Interview
1406793|NCT00359684|Cystinosis
1406794|NCT00359684|Cystine
1406795|NCT00359684|Lysomal Storage Disease
1406796|NCT00359684|Mutation Analysis
1406797|NCT00359684|Metabolic Disease
1406798|NCT00359658|Cyclosporine
1406799|NCT00359658|Glucocorticoids
1406800|NCT00359658|renal insufficiency, chronic
1406801|NCT00359658|long-term care
1406802|NCT00359645|Screening
1406803|NCT00359645|Upper aerodigestive tract cancer
1406804|NCT00359645|Alcohol
1406805|NCT00359645|Tobacco
1406806|NCT00359645|Randomized trial
1406807|NCT00359632|Optic neuropathy following long-term linezolid use
1406808|NCT00359619|HPV vaccine
1406809|NCT00359606|DNA Methylation
1406810|NCT00359606|Advanced Cancer
1406811|NCT00359606|Methyltransferase Inhibitor
1406812|NCT00359606|Epigenetics
1406813|NCT00359606|Gene Re-Expression
1406814|NCT00359593|Stroke
1406815|NCT00359593|Rehabilitation
1406816|NCT00359593|Knowledge translation
1406817|NCT00359593|Evidence based practice
1406818|NCT00359593|Outcomes
1406819|NCT00359580|Ancestry
1406820|NCT00359567|nausea and vomiting
1406821|NCT00359554|Influenza
1406822|NCT00359541|CYP2C9
1406823|NCT00359541|CYP2C19
1406824|NCT00359541|Pharmacology
1406825|NCT00359541|Genotype
1406826|NCT00359541|Metabolism
1406827|NCT00359515|Archived Samples
1406828|NCT00359515|Mutation Screening
1406829|NCT00359515|Genotype-Phenotype Correlation
1406830|NCT00359515|Pediatric Developmental Disorder
1406831|NCT00359515|Cataracts
1406832|NCT00359515|Mutation Detection
1406833|NCT00359515|Lowe Syndrome
1406834|NCT00359515|Genotype
1406835|NCT00359476|Locally advanced/metastatic gastric adenocarcinoma
1406836|NCT00359476|adenocarcinoma-gastroesophageal junction
1406837|NCT00359476|Gastric Adenocarcinoma
1406838|NCT00359463|hepatitis C-associated thrombocytopenia
1406839|NCT00359463|chemotherapy induced thrombocytopenia
1406840|NCT00359463|thrombocytopenia
1406841|NCT00359463|hepatic impairment
1406842|NCT00359463|chronic immune thrombocytopenia purpura
1406843|NCT00359450|Locally advanced or metastatic non-small cell lung cancer
1406844|NCT00359424|acute ischemic stroke
1406845|NCT00359424|rt-PA
1406846|NCT00359424|thrombolytic
1406847|NCT00359424|recombinant tissue plasminogen activator
1406848|NCT00359424|recanalization
1406849|NCT00359424|blood clot
1406850|NCT00359424|stroke
1406851|NCT00359424|clot-dissolving
1406852|NCT00359424|Activase®
1406853|NCT00359424|Actilyse®
1406854|NCT00359424|Concentric Merci® Retriever
1406855|NCT00359424|EKOS® Micro-Infusion catheter (MicroLysus)
1406856|NCT00359424|The Penumbra System™
1406857|NCT00359424|Standard microcatheter
1406858|NCT00359411|Epstein-Barr Virus
1406859|NCT00359411|B-Cell Lymphoma
1406860|NCT00359411|Herpes Virus
1406861|NCT00359411|Infectious Mononucleosis
1406862|NCT00359398|Cardiopulmonary bypass
1406863|NCT00359398|Blood component removal
1406864|NCT00359385|primary hyperparathyroidism
1406865|NCT00359385|hyperparathyroidism
1406866|NCT00359385|PHPT
1406867|NCT00359385|PTH
1406868|NCT00359385|hypercalcemia
1406869|NCT00359385|bone density
1406870|NCT00359385|osteoporosis
1406871|NCT00359385|bone turnover
1406872|NCT00359385|DXA
1406873|NCT00359385|pQCT
1406874|NCT00359385|cQCT
1406875|NCT00359385|alendronate
1406876|NCT00359385|Fosamax
1406877|NCT00359385|parathyroid hormone
1406878|NCT00359385|parathyroid surgery
1406879|NCT00359385|parathyroidectomy
1406880|NCT00359385|Silverberg
1406881|NCT00359385|Rubin
1406882|NCT00359385|Bilezikian
1406883|NCT00359385|treatment
1406884|NCT00359372|Chronic Heart Failure
1406885|NCT00359372|Cardiac Resynchronization
1406886|NCT00359372|Magnetic Resonance Imaging
1406887|NCT00359372|Biventricular Pacing
1406888|NCT00359372|Heart Function
1406889|NCT00359372|CRT
1406890|NCT00359359|Small Cell Lung Cancer
1406891|NCT00359346|Plasmapheresis
1406892|NCT00359346|Auto-antibodies
1406893|NCT00359346|Autonomic Nervous System
1406894|NCT00359346|Dysautonomia
1406895|NCT00359346|Sympathetic Nervous System
1406896|NCT00359346|Autonomic Failure
1406897|NCT00359320|Pancreaticoduodenectomy
1406898|NCT00359320|Pancreaticojejunostomy
1406899|NCT00359320|Pancreatic Cancer
1406900|NCT00359307|Genetic
1406901|NCT00359307|Longitudinal
1406902|NCT00359307|Prospective
1406903|NCT00359307|Epidemiology
1406904|NCT00359307|Heart Attack
1406905|NCT00359294|Tumor
1406906|NCT00359294|Lymphoma
1406907|NCT00359294|Zalypsis
1406908|NCT00359294|PharmaMar
1406909|NCT00359294|PM00104
1406910|NCT00359281|healthy volunteers
1406911|NCT00359268|Polymerase Chain Reaction
1406912|NCT00359268|Random Priming
1406913|NCT00359268|Nucleic Acid
1406914|NCT00359268|Viral Genome
1406915|NCT00359268|Virus
1406916|NCT00359268|Identification
1406917|NCT00359255|Exercise
1406918|NCT00359255|rehabilitation
1406919|NCT00359255|upper limb
1406920|NCT00359255|inpatient
1406921|NCT00359255|RCT
1406922|NCT00359255|activities of daily living
1406923|NCT00359242|Infant Sleep
1406924|NCT00359242|Infant Diet
1406925|NCT00359242|Infant Temperament
1406926|NCT00359242|Rapid Infant weight gain
1406927|NCT00359242|Infant Development
1406928|NCT00359242|Parenting Competence
1406929|NCT00359242|infant weight gain
1406930|NCT00359216|Hypopnea Syndrome
1406931|NCT00359203|syncope
1406932|NCT00359203|implantable loop recorder
1406933|NCT00359190|lapatinib
1406934|NCT00359190|breast cancer
1406935|NCT00359190|treatment-naive
1406936|NCT00359177|emesis liver problems hepatic impairment GW679769
1406937|NCT00359164|AMD
1406938|NCT00359164|Avastin
1406939|NCT00359164|Visudyne
1406940|NCT00359164|Medical condition being studied AMD
1406941|NCT00359151|Perioperative care of total arthroplasty assessing opioid consumption
1406942|NCT00359138|Histamine H1 Antagonists
1406943|NCT00359138|Anti-Allergic Agents
1406944|NCT00359125|bipolar
1406945|NCT00359125|RU-486
1406946|NCT00359125|mifepristone
1406947|NCT00359125|neurocognition
1406948|NCT00359125|mood
1406949|NCT00359125|cortisol
1406950|NCT00359125|HPA axis
1406951|NCT00359112|Type 2 diabetes
1406952|NCT00359112|overweight
1406953|NCT00359112|AVANDAMET
1406954|NCT00359112|metformin
1406955|NCT00359112|sulphonylurea
1406956|NCT00359099|Hepatic Medicine
1406957|NCT00359099|Surgery
1406958|NCT00359086|Relapsed and Refractory Lymphoma
1406959|NCT00359086|Phase II
1406960|NCT00359073|asthma
1406961|NCT00359073|leukotrienes
1406962|NCT00359073|rhinovirus
1406963|NCT00359060|Physical activity
1406964|NCT00359060|Sex steroid hormones
1406965|NCT00359060|Breast cancer risk
1406966|NCT00359060|Intervention study
1406967|NCT00359060|Postmenopausal women
1406968|NCT00359047|Osteoporosis
1406969|NCT00359047|Fragility fracture
1406970|NCT00359047|Women
1406971|NCT00359047|Randomised control trial
1406972|NCT00359047|Patient education
1406973|NCT00359047|Diagnosis
1406974|NCT00359047|Treatment
1406975|NCT00359034|Doppler ultrasound
1406976|NCT00359034|pulsewave velocity
1406977|NCT00359034|intrauterine growth restriction
1406978|NCT00359034|Fetal Pulsewave Velocity
1406979|NCT00359021|HIV-1
1406980|NCT00359021|treatment experienced
1406981|NCT00359021|virologic failure
1406982|NCT00359008|AMD
1406983|NCT00359008|CNV
1406984|NCT00359008|PHP
1406985|NCT00358995|Cognitive Behavioral Therapy
1406986|NCT00358995|Primary Obsessions
1406987|NCT00358995|Obsessive Compulsive Disorder
1406988|NCT00358995|Compulsive Disorder
1406989|NCT00358982|Relapsed or Refractory Hodgkin's Lymphoma
1406990|NCT00358982|Phase II
1406991|NCT00358969|borderline personality disorder
1406992|NCT00358969|guanfacine
1406993|NCT00358969|impulsivity
1406994|NCT00358969|aggression
1406995|NCT00358969|affective instability
1406996|NCT00358956|medullary thyroid cancer
1406997|NCT00358956|MTC
1406998|NCT00358956|hereditary medullary thyroid cancer
1406999|NCT00358956|thyroid cancer
1407000|NCT00358943|Gaucher Disease
1407001|NCT00358943|Glucocerebrosidase Deficiency Disease
1407002|NCT00358930|squamous cell carcinoma of the head and neck
1407003|NCT00358202|intramuscular antibiotics
1407004|NCT00358202|nursing home acquired pneumonia
1407005|NCT00358202|nhap
1407006|NCT00358202|pharmacoeconomics
1407007|NCT00358202|cefepime
1407008|NCT00358202|ceftriaxone
1407009|NCT00358189|deep brain stimulation
1407010|NCT00358189|gait
1407011|NCT00358189|manual dexterity
1407012|NCT00358189|parkinson's disease
1407013|NCT00358176|Treatment osteoporosis postmenopausal
1407014|NCT00358163|angiogenesis
1407015|NCT00358163|taxane
1407016|NCT00358163|tyrosine kinase
1407017|NCT00358163|pharmacokinetics
1407018|NCT00358163|Vatalanib
1407019|NCT00358163|Taxol
1407020|NCT00358150|Type 1 Gaucher Disease
1407021|NCT00358150|Glucocerebrosidase Deficiency Disease
1407022|NCT00358137|Blood Pressure, High
1407023|NCT00358111|high-grade disease
1407024|NCT00358111|Cervical examination
1407025|NCT00358111|targeting biopsies
1407026|NCT00358111|dysplasia
1407027|NCT00358111|cancer
1407028|NCT00358098|PET
1407029|NCT00358098|hormone positive breast cancer
1407030|NCT00358085|Endovascular
1407031|NCT00358085|Vascular Surgical Procedures
1407032|NCT00358085|Aneurysm
1407033|NCT00358085|Expertise Based Methodology
1407034|NCT00358072|Acute lymphoblastic leukemia
1407035|NCT00358072|Adult patients
1407036|NCT00358072|Minimal residual disease
1407037|NCT00358072|Risk-oriented therapy
1407038|NCT00358059|diabetes mellitus
1407039|NCT00358059|adolescence
1407040|NCT00358059|adherence
1407041|NCT00358059|glycemic control
1407042|NCT00358059|adaptation
1407043|NCT00358059|communication
1407044|NCT00358046|Hyperphosphatemia
1407045|NCT00358046|Chronic kidney disease
1407046|NCT00358046|Dialysis
1407047|NCT00358046|Hyperphosphatemia in CKD patients on dialysis
1407048|NCT00358904|Hill Sachs
1407049|NCT00358904|Weber osteotomy
1407050|NCT00358904|shoulder dislocation
1407051|NCT00358891|Prematurity
1407052|NCT00358891|Chronic Lung Disease
1407053|NCT00358891|Respiratory Health
1407054|NCT00358891|Neurodevelopment
1407055|NCT00358891|Preschool
1407056|NCT00358891|Influencing Factors
1407057|NCT00358878|Ascites
1407058|NCT00358878|Liver Cirrhosis
1407059|NCT00358865|Virtual Reality
1407060|NCT00358865|ABI
1407061|NCT00358865|Projected system
1407062|NCT00358852|Schizophrenia
1407063|NCT00358852|Mental disorder
1407064|NCT00358852|Schizoaffective disorder
1407065|NCT00358852|Schizophreniform disorder
1407066|NCT00358852|Epidemiological study
1407067|NCT00358852|Scale validation
1407068|NCT00358852|Relapse
1407069|NCT00358852|Short Term Hospitalization
1407070|NCT00358852|PRE-COG
1407071|NCT00358852|RISSCH4075
1407072|NCT00358839|Familial hemiplegic migraine type 1 and 2
1407073|NCT00358839|CGRP
1407074|NCT00358839|middle cerebral artery
1407075|NCT00358839|superficial temporal artery
1407076|NCT00358839|headache
1407077|NCT00358839|genotype
1407078|NCT00358839|Healthy Volunteers
1407079|NCT00358813|emesis
1407080|NCT00358813|renal impairment
1407081|NCT00358813|GW679769
1407082|NCT00358813|kidney problems
1407083|NCT00358800|OSAHS and REMStar Auto with C-Flex
1407084|NCT00358787|Supracondylar fracture
1407085|NCT00358787|humerus
1407086|NCT00358787|ulnar nerve injury
1407087|NCT00358787|Baumann's angle
1407088|NCT00358787|Supracondylar fracture of the humerus
1407089|NCT00358774|homeopathic
1407090|NCT00358774|common cold
1407091|NCT00358774|Research Subjects
1407092|NCT00358761|Lone Star Tick
1407093|NCT00358761|Borrelia
1407094|NCT00358761|Skin Biopsy
1407095|NCT00358761|Spirochete
1407096|NCT00358761|Erythema Migrans
1407097|NCT00358761|Southern Tick-Assoicated Rash Illness
1407098|NCT00358761|STARI
1407099|NCT00358748|Preterm
1407100|NCT00358748|hypotension
1407101|NCT00358748|steroids
1407102|NCT00358748|hydrocortisone
1407103|NCT00358735|SAFE
1407104|NCT00358735|CECT
1407105|NCT00358735|SFT
1407106|NCT00358735|ActiveCare
1407107|NCT00358735|ActiveCare+SFT
1407108|NCT00358735|Deep Vein Thrombosis prevention
1407109|NCT00358735|Total Hip Replacement
1407110|NCT00358735|Total Hip Arthroplasty
1407111|NCT00358735|Low Molecular Weight Heparin
1407112|NCT00358735|MCS
1407113|NCT00358709|Cognitive-behavioral therapy
1407114|NCT00358709|symptom management
1407115|NCT00358709|first psychotic episode
1407116|NCT00358696|tenofovir
1407117|NCT00358696|didanosine
1407118|NCT00358696|hiv
1407119|NCT00358696|hepatitis c virus infection
1407120|NCT00358696|treatment
1407121|NCT00358683|certolizunab pegol
1407122|NCT00358683|long term safety follow-up
1407123|NCT00358683|Chrohn's disease
1407124|NCT00358683|infliximab failures patients
1407125|NCT00358683|Greek population
1407126|NCT00358644|Acute Myeloid Leukemia
1407127|NCT00358644|AML
1407128|NCT00358644|Decitabine
1407129|NCT00358644|Dacogen
1407130|NCT00358644|MGI PHARMA, INC.
1407131|NCT00358631|depression
1407132|NCT00358631|antidepressive agents
1407133|NCT00358631|controlled clinical trial
1407134|NCT00358618|Randomized
1407135|NCT00358618|double-blind
1407136|NCT00358618|3-group clinical interventional study
1407137|NCT00358605|OSAHS
1407138|NCT00358605|Oral Appliance
1407139|NCT00358605|Hypopnoea Syndrome
1407140|NCT00358592|surgical instruments
1407141|NCT00358592|cesarean section
1407142|NCT00358592|obesity
1407143|NCT00358579|Vasopressin
1407144|NCT00358579|Adrenaline
1407145|NCT00358579|Survival
1407146|NCT00358579|Return of spontaneous of circulation
1407147|NCT00358566|Advanced
1407148|NCT00358566|Unresesctable
1407149|NCT00358566|Adenocarcinoma
1407150|NCT00358566|Pancreatic cancer
1407151|NCT00358553|Human Volunteers
1407152|NCT00358540|sarcoma
1407153|NCT00358540|thrombocytopenia
1407154|NCT00358540|eltrombopag
1407155|NCT00358540|thrombopoiesis
1407156|NCT00358514|Tibia
1407157|NCT00358514|fracture
1407158|NCT00358514|compartment syndrome
1407159|NCT00358514|fasciotomy
1407160|NCT00358501|Defibrotide
1407161|NCT00358501|Severe veno occlusive disease
1407162|NCT00358501|Multi organ failure
1407163|NCT00358501|Stem cell transplant
1407164|NCT00358501|Liver
1407165|NCT00358501|Regimen related toxicity
1407166|NCT00358501|Day 100 survival
1407167|NCT00358488|Safety
1407168|NCT00358488|Asthmatic patients
1407169|NCT00358488|GSK159797
1407170|NCT00358488|Efficacy
1407171|NCT00358475|perennial allergic rhinitis
1407172|NCT00358462|NGU, M genitalium, Ureaplasma, azithromycin, doxycycline
1407173|NCT00358449|eosinophilic
1407174|NCT00358449|mepolizumab
1407175|NCT00358449|esophagitis
1407176|NCT00358436|COPD
1407177|NCT00358436|Lung function
1407178|NCT00358436|Exacerbations
1407179|NCT00358436|Quality of Life
1407180|NCT00358423|CME
1407181|NCT00358423|Pegaptanib
1407182|NCT00358423|Post-Surgical Ocular Inflammation
1407183|NCT00358410|Functional Dyspepsia
1407184|NCT00358410|Barostat
1407185|NCT00358410|Stomach
1407186|NCT00358397|Solid Tumor
1407187|NCT00358397|Clostridial
1407188|NCT00358397|Spore-forming bacteria
1407189|NCT00358397|hypoxia
1407190|NCT00358397|anaerobes
1407191|NCT00358397|Clostridium novyi
1407192|NCT00358397|Bacteria
1407193|NCT00358397|Bacteriolytic
1407194|NCT00358397|Tumor lysis
1407195|NCT00358397|Necrosis
1407196|NCT00358397|Colon Cancer
1407197|NCT00358397|Lung Cancer
1407198|NCT00358397|Sarcoma
1407199|NCT00358397|Bladder Cancer
1407200|NCT00358397|Rectal Cancer
1407201|NCT00358397|Gastric Cancer
1407202|NCT00358397|Pancreatic Cancer
1407203|NCT00358397|Experimental Therapy
1407204|NCT00358397|Solid Tumors
1407205|NCT00358384|tolerability
1407206|NCT00358384|safety
1407207|NCT00358384|angiogenesis
1407208|NCT00358384|vascular endothelial growth factor
1407209|NCT00358384|pharmacodynamics
1407210|NCT00358384|pharmacokinetics
1407211|NCT00358384|microplaque
1407212|NCT00358384|VEGF
1407213|NCT00358384|GW786034
1407214|NCT00358371|bioavailability flucloxacillin
1407215|NCT00358358|COPD
1407216|NCT00358358|Impulse Oscillometry System
1407217|NCT00358358|Computerized Tomography
1407218|NCT00358345|AMD
1407219|NCT00358332|malaria, vaccine, Mali, children
1407220|NCT00358319|Valproic Acid (VPA)
1407221|NCT00358319|Karenitecin
1407222|NCT00358319|Malignant Melanoma
1407223|NCT00358319|Histone deacetylases (HDAC)inhibitors
1407224|NCT00358319|Topoisomerase I inhibitor
1407225|NCT00358319|metastatic
1407226|NCT00358306|Endothelium
1407227|NCT00358306|Chronic Kidney Disease
1407228|NCT00358306|Acute Kidney Injury
1407229|NCT00358306|Hemolytic-uremic syndrome (HUS)
1407230|NCT00358293|Multiple Sclerosis
1407231|NCT00358293|Spasticity
1407232|NCT00358293|Sublingual Tizanidine
1407233|NCT00358293|Ashworth Scores
1407234|NCT00358293|Spasticity in Multiple Sclerosis Patients
1407235|NCT00358280|Patients ASA category I ～ II
1407236|NCT00358280|Unilateral Lower limb surgery
1407237|NCT00358280|Spinal Anesthesia
1407238|NCT00358267|Inferior Turbinate Reduction
1407239|NCT00358267|Partial Resection of Inferior Turbinates (PRIT)
1407240|NCT00358267|Radiofrequency Ablation (RFA)
1407241|NCT00358267|NOSE scale
1407242|NCT00358267|Nasal Obstruction
1407243|NCT00358241|Nerve block, postoperative pain, analgesia
1407244|NCT00358228|Smoking cessation
1407245|NCT00358228|Abstinence
1407246|NCT00358215|Survival study
1407247|NCT00358215|morbidity and mortality
1407248|NCT00358215|heart failure hospitalization
1407249|NCT00358215|all-cause death
1407250|NCT00358215|patient-reported outcomes
1407251|NCT00358215|Kansas City Cardiomyopathy questionnaire
1407252|NCT00358215|anemia treatment
1407253|NCT00358020|MYELOMA, THALIDOMIDE, BORTEZOMIB
1407254|NCT00358007|Kilovoltage Imaging
1407255|NCT00358007|Cone-beam CT
1407256|NCT00358007|CBCT
1407257|NCT00358007|radiation therapy
1407258|NCT00358007|head and neck neoplasms
1407259|NCT00357994|carbidopa
1407260|NCT00357994|levodopa-carbidopa
1407261|NCT00357994|levodopa
1407262|NCT00357994|levodopa/carbidopa suspension
1407263|NCT00357994|dyskinesia
1407264|NCT00357994|Duodopa
1407265|NCT00357994|levodopa-carbidopa intestinal gel
1407266|NCT00357994|Severe Motor Fluctuations
1407267|NCT00357994|DUOPA
1407268|NCT00357981|Contraceptive patch
1407269|NCT00357981|menstruation
1407270|NCT00357981|economics
1407271|NCT00357942|Morphine
1407272|NCT00357942|Mouthwash
1407273|NCT00357942|Mucositis
1407274|NCT00357942|Pain
1407275|NCT00357942|Cancer
1407276|NCT00357942|Child
1407277|NCT00357942|Adolescent
1407278|NCT00357929|permissive hypercarbia
1407279|NCT00357929|weaning from mechanical ventilation
1407280|NCT00357916|PEP005
1407281|NCT00357916|Safety
1407282|NCT00357903|Rheumatoid Arthritis, Etanercept, Long-term Safety, Enbrel
1407283|NCT00357890|type 1 diabetes
1407284|NCT00357890|diabetes
1407285|NCT00357890|new onset
1407286|NCT00357890|CSII
1407287|NCT00357890|insulin glargine
1407288|NCT00357890|insulin sensitivity
1407289|NCT00357890|beta cell function
1407290|NCT00357890|beta cell preservation
1407291|NCT00357851|pancreatitis, blood loss
1407292|NCT00357838|normal healthy women
1407293|NCT00357812|Herpes Simplex Virus Type 1
1407294|NCT00357812|Herpes Simplex Keratitis
1407295|NCT00357812|Cornea
1407296|NCT00357812|Dendretic Ulcer
1407297|NCT00357812|In vivo Confocal Microscopy
1407298|NCT00357812|Nested Multi-plex PCR
1407299|NCT00357812|Monoclonal Antibody
1407300|NCT00357812|Glycoprotein D
1407301|NCT00357812|Glycoprotein C
1407302|NCT00357799|Venipuncture
1407303|NCT00357799|Randomized Controlled Trial
1407304|NCT00357799|Intravenous Access
1407305|NCT00357799|Children
1407306|NCT00357799|Emergency Department Nursing
1407307|NCT00357799|VeinViewer
1407308|NCT00357799|Pediatrics
1407309|NCT00357799|Emergency Nursing
1407310|NCT00357786|Lysosomal Disease
1407311|NCT00357786|Glycolipid
1407312|NCT00357786|Stroke
1407313|NCT00357786|Peripheral Neuropathy
1407314|NCT00357786|Storage Disorder
1407315|NCT00357760|Metastatic Renal Cell Carcinoma
1407316|NCT00357760|VEGF Trap
1407317|NCT00357747|unspecified adult solid tumor, protocol specific
1407318|NCT00357734|lung cancer
1407319|NCT00357734|breast cancer
1407320|NCT00357695|Praxis
1407321|NCT00357695|Grasping
1407322|NCT00357695|Premotor Cortex
1407323|NCT00357695|Visuo-Motor Integration
1407324|NCT00357695|Motor Imagination
1407325|NCT00357682|esophageal cancer
1407326|NCT00357682|Barrett's esophagus
1407327|NCT00357669|Unverricht-Lundborg disease
1407328|NCT00357669|Baltic myoclonus
1407329|NCT00357669|progressive myoclonic epilepsies
1407330|NCT00357669|myoclonus
1407331|NCT00357669|brivaracetam
1407332|NCT00357656|Hemophilia A (severe or moderately severe)
1407333|NCT00357643|calcium
1407334|NCT00357643|vitamin D
1407335|NCT00357643|bone loss
1407336|NCT00357630|adenocarcinoma of unknown primary
1407337|NCT00357630|newly diagnosed carcinoma of unknown primary
1407338|NCT00357630|undifferentiated carcinoma of unknown primary
1407339|NCT00357630|pain
1407340|NCT00357617|stage I squamous cell carcinoma of the hypopharynx
1407341|NCT00357617|stage II squamous cell carcinoma of the hypopharynx
1407342|NCT00357617|stage III squamous cell carcinoma of the hypopharynx
1407343|NCT00357617|stage IV squamous cell carcinoma of the hypopharynx
1407344|NCT00357617|stage I squamous cell carcinoma of the larynx
1407345|NCT00357617|stage II squamous cell carcinoma of the larynx
1407346|NCT00357617|stage III squamous cell carcinoma of the larynx
1407347|NCT00357617|stage IV squamous cell carcinoma of the larynx
1407348|NCT00357617|stage I squamous cell carcinoma of the lip and oral cavity
1407349|NCT00357617|stage II squamous cell carcinoma of the lip and oral cavity
1407350|NCT00357617|stage III squamous cell carcinoma of the lip and oral cavity
1407351|NCT00357617|stage IV squamous cell carcinoma of the lip and oral cavity
1407352|NCT00357617|stage I squamous cell carcinoma of the oropharynx
1407353|NCT00357617|stage II squamous cell carcinoma of the oropharynx
1407354|NCT00357617|stage III squamous cell carcinoma of the oropharynx
1407355|NCT00357617|stage IV squamous cell carcinoma of the oropharynx
1407356|NCT00357617|recurrent squamous cell carcinoma of the hypopharynx
1407357|NCT00357617|recurrent squamous cell carcinoma of the larynx
1407358|NCT00357617|recurrent squamous cell carcinoma of the lip and oral cavity
1407359|NCT00357617|recurrent squamous cell carcinoma of the oropharynx
1407360|NCT00357604|HIV
1407361|NCT00357604|Protease Inhibitor
1407362|NCT00357591|Heart Failure
1407363|NCT00357591|Acute Decompensation
1407364|NCT00357591|Chronic Heart Failure
1407365|NCT00357578|Macrophages
1407366|NCT00357578|Biopsy
1407367|NCT00357578|Genetic Analysis
1407368|NCT00357578|Geographic Atrophy
1407369|NCT00357578|Choroidal Neovascularization
1407370|NCT00357578|Fibroblast
1407371|NCT00357578|Disciform
1407372|NCT00357578|Age-Related Macular Degeneration
1407373|NCT00357565|MDS
1407374|NCT00357565|AML
1407375|NCT00357552|Treatment Experienced
1407376|NCT00357526|vaginal ring
1407377|NCT00357526|Oral contraceptive pills
1407378|NCT00357526|Teenagers
1407379|NCT00357526|Young women
1407380|NCT00357526|Patient satisfaction
1407381|NCT00357513|Cerebrovascular Disease
1407382|NCT00357513|Gene Chip
1407383|NCT00357513|Inflammation
1407384|NCT00357513|Pathophysiology Stroke
1407385|NCT00357513|Stroke Genomics
1407386|NCT00357513|Stroke Subtypes
1407387|NCT00357513|Neuroimaging
1407388|NCT00357513|Clinical Outcome Measures
1407389|NCT00357513|Stroke
1407390|NCT00357513|CVA
1407391|NCT00357513|Healthy Volunteer
1407392|NCT00357513|HV
1407393|NCT00357513|Normal Control
1407394|NCT00357500|Metronomic
1407395|NCT00357500|antiangiogenic
1407396|NCT00357487|Sentinel lymph node
1407397|NCT00357487|Breast cancer
1407398|NCT00357487|Lymphoscintigraphy
1407399|NCT00357487|Probe
1407400|NCT00357487|Operative gamma camera
1407401|NCT00357487|Breast cancer and sentinel lymph node biopsy
1407402|NCT00357487|Use of lymphoscintigraphy
1407403|NCT00357487|Use of intraoperative gamma camera
1407404|NCT00357487|Use of intraoperative probe
1407405|NCT00357474|HCC, TACE, PEIT
1407406|NCT00357461|stage IV melanoma
1407407|NCT00357461|recurrent melanoma
1407408|NCT00357435|Cornea
1407409|NCT00357435|Genetics
1407410|NCT00357435|Dystrophy
1407411|NCT00357435|Gene
1407412|NCT00357435|Mapping
1407413|NCT00357435|Molecular
1407414|NCT00357435|Bietti
1407415|NCT00357435|Fleck
1407416|NCT00357435|Positional Cloning
1407417|NCT00357435|Linkage
1407418|NCT00357422|HCC, operation, percutaneous ethanol injection
1407419|NCT00357409|GABA
1407420|NCT00357409|Occipital
1407421|NCT00357409|Vision
1407422|NCT00357409|Plasticity
1407423|NCT00357409|MRS
1407424|NCT00357409|Blind
1407425|NCT00357396|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1407426|NCT00357396|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1407427|NCT00357357|Alzheimer's disease
1407428|NCT00357344|Obesity
1407429|NCT00357344|Gray Matter
1407430|NCT00357344|Eating Behavior
1407431|NCT00357344|Brain MRI
1407432|NCT00357344|Body Weight Regulation
1407433|NCT00357331|postmenopausal osteopenia
1407434|NCT00357331|treatment
1407435|NCT00357331|bone loss
1407436|NCT00357266|Uveitis
1407437|NCT00357266|Interleukin 2
1407438|NCT00357266|Interleukin 2 Receptor
1407439|NCT00357266|Microarrays
1407440|NCT00357266|Genetic Expression
1407441|NCT00357266|Daclizumab
1407442|NCT00357266|HAT
1407443|NCT00357266|Zenapax
1407444|NCT00357266|Proteins
1407445|NCT00357266|RNA
1407446|NCT00357266|Ocular Inflammatory Disease
1407447|NCT00357253|untreated childhood brain stem glioma
1407448|NCT00357253|childhood high-grade cerebral astrocytoma
1407449|NCT00357253|untreated childhood cerebellar astrocytoma
1407450|NCT00357240|Protease inhibitor
1407451|NCT00357227|Atrial fibrillation
1407452|NCT00357227|Stroke
1407453|NCT00357227|Vascular Dementia
1407454|NCT00357227|Mild Cognitive Impairment
1407455|NCT00357214|bone turnover
1407456|NCT00357214|calcium excretion
1407457|NCT00357214|nitrogen excretion
1407458|NCT00357214|potassium bicarbonate
1407459|NCT00357214|muscle loss
1407460|NCT00357214|muscle atrophy
1407461|NCT00357214|bone loss
1407462|NCT00357123|abdominal sepsis
1407463|NCT00357123|sepsis
1407464|NCT00357123|rosuvastatin
1407465|NCT00357110|Breast neoplasms
1407466|NCT00357110|breast cancer
1407467|NCT00357110|early breast cancer
1407468|NCT00357110|oncology
1407469|NCT00357110|cancer
1407470|NCT00357110|breast cancer micrometastasis
1407471|NCT00357110|fulvestrant
1407472|NCT00357097|randomised
1407473|NCT00357097|ropinirole
1407474|NCT00357097|depression
1407475|NCT00357097|RLS
1407476|NCT00357097|placebo
1407477|NCT00357097|mood
1407478|NCT00357097|double-blind
1407479|NCT00357097|restless legs syndrome
1407480|NCT00357097|germany
1407481|NCT00357084|graft versus host disease
1407482|NCT00357084|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1407483|NCT00357084|adult acute myeloid leukemia with inv(16)(p13;q22)
1407484|NCT00357084|adult acute myeloid leukemia with t(15;17)(q22;q12)
1407485|NCT00357084|adult acute myeloid leukemia with t(16;16)(p13;q22)
1407486|NCT00357084|adult acute myeloid leukemia with t(8;21)(q22;q22)
1407487|NCT00357084|accelerated phase chronic myelogenous leukemia
1407488|NCT00357084|adult acute lymphoblastic leukemia in remission
1407489|NCT00357084|adult acute myeloid leukemia in remission
1407490|NCT00357084|atypical chronic myeloid leukemia
1407491|NCT00357084|blastic phase chronic myelogenous leukemia
1407492|NCT00357084|childhood acute lymphoblastic leukemia in remission
1407493|NCT00357084|childhood acute myeloid leukemia in remission
1407494|NCT00357084|childhood chronic myelogenous leukemia
1407495|NCT00357084|chronic eosinophilic leukemia
1407496|NCT00357084|chronic idiopathic myelofibrosis
1407497|NCT00357084|chronic myelomonocytic leukemia
1407498|NCT00357084|chronic neutrophilic leukemia
1407499|NCT00357084|chronic phase chronic myelogenous leukemia
1407500|NCT00357084|de novo myelodysplastic syndromes
1407501|NCT00357084|disseminated neuroblastoma
1407502|NCT00357084|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1407503|NCT00357084|juvenile myelomonocytic leukemia
1407598|NCT00357058|Cortical Reorganization
1407504|NCT00357084|myelodysplastic/myeloproliferative disease, unclassifiable
1407505|NCT00357084|nodal marginal zone B-cell lymphoma
1407506|NCT00357084|noncontiguous stage II adult Burkitt lymphoma
1407507|NCT00357084|noncontiguous stage II adult diffuse large cell lymphoma
1407508|NCT00357084|noncontiguous stage II adult diffuse mixed cell lymphoma
1407509|NCT00357084|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1407510|NCT00357084|noncontiguous stage II adult immunoblastic large cell lymphoma
1407511|NCT00357084|noncontiguous stage II adult lymphoblastic lymphoma
1407512|NCT00357084|noncontiguous stage II grade 1 follicular lymphoma
1407513|NCT00357084|noncontiguous stage II grade 2 follicular lymphoma
1407514|NCT00357084|noncontiguous stage II grade 3 follicular lymphoma
1407515|NCT00357084|noncontiguous stage II mantle cell lymphoma
1407516|NCT00357084|noncontiguous stage II marginal zone lymphoma
1407517|NCT00357084|noncontiguous stage II small lymphocytic lymphoma
1407518|NCT00357084|poor prognosis metastatic gestational trophoblastic tumor
1407519|NCT00357084|previously treated childhood rhabdomyosarcoma
1407520|NCT00357084|previously treated myelodysplastic syndromes
1407521|NCT00357084|recurrent adult acute lymphoblastic leukemia
1407522|NCT00357084|recurrent adult acute myeloid leukemia
1407523|NCT00357084|recurrent adult Burkitt lymphoma
1407524|NCT00357084|recurrent adult Hodgkin lymphoma
1407525|NCT00357084|recurrent adult diffuse large cell lymphoma
1407526|NCT00357084|recurrent adult diffuse mixed cell lymphoma
1407527|NCT00357084|recurrent adult diffuse small cleaved cell lymphoma
1407528|NCT00357084|recurrent adult immunoblastic large cell lymphoma
1407529|NCT00357084|recurrent adult lymphoblastic lymphoma
1407530|NCT00357084|recurrent/refractory childhood Hodgkin lymphoma
1407531|NCT00357084|recurrent childhood acute lymphoblastic leukemia
1407532|NCT00357084|recurrent childhood acute myeloid leukemia
1407533|NCT00357084|recurrent childhood large cell lymphoma
1407534|NCT00357084|recurrent childhood lymphoblastic lymphoma
1407535|NCT00357084|recurrent childhood rhabdomyosarcoma
1407536|NCT00357084|recurrent childhood small noncleaved cell lymphoma
1407537|NCT00357084|recurrent cutaneous T-cell non-Hodgkin lymphoma
1407538|NCT00357084|recurrent grade 1 follicular lymphoma
1407539|NCT00357084|recurrent grade 2 follicular lymphoma
1407540|NCT00357084|recurrent grade 3 follicular lymphoma
1407541|NCT00357084|recurrent mantle cell lymphoma
1407542|NCT00357084|recurrent marginal zone lymphoma
1407543|NCT00357084|recurrent mycosis fungoides/Sezary syndrome
1407544|NCT00357084|recurrent small lymphocytic lymphoma
1407545|NCT00357084|recurrent Wilms tumor and other childhood kidney tumors
1407546|NCT00357084|refractory chronic lymphocytic leukemia
1407547|NCT00357084|refractory hairy cell leukemia
1407548|NCT00357084|refractory multiple myeloma
1407549|NCT00357084|relapsing chronic myelogenous leukemia
1407550|NCT00357084|secondary acute myeloid leukemia
1407551|NCT00357084|secondary myelodysplastic syndromes
1407552|NCT00357084|splenic marginal zone lymphoma
1407553|NCT00357084|stage I multiple myeloma
1407554|NCT00357084|stage II multiple myeloma
1407555|NCT00357084|stage II ovarian epithelial cancer
1407556|NCT00357084|stage III adult Burkitt lymphoma
1407557|NCT00357084|stage III adult Hodgkin lymphoma
1407558|NCT00357084|stage III adult diffuse large cell lymphoma
1407559|NCT00357084|stage III adult diffuse mixed cell lymphoma
1407560|NCT00357084|stage III adult diffuse small cleaved cell lymphoma
1407561|NCT00357084|stage III adult immunoblastic large cell lymphoma
1407562|NCT00357084|stage III adult lymphoblastic lymphoma
1407563|NCT00357084|stage III chronic lymphocytic leukemia
1407564|NCT00357084|stage III grade 1 follicular lymphoma
1407565|NCT00357084|stage III grade 2 follicular lymphoma
1407566|NCT00357084|stage III grade 3 follicular lymphoma
1407567|NCT00357084|stage III mantle cell lymphoma
1407568|NCT00357084|stage III marginal zone lymphoma
1407569|NCT00357084|stage III multiple myeloma
1407570|NCT00357084|stage III small lymphocytic lymphoma
1407571|NCT00357084|stage III malignant testicular germ cell tumor
1407572|NCT00357084|stage IV adult Burkitt lymphoma
1407573|NCT00357084|stage IV adult Hodgkin lymphoma
1407574|NCT00357084|stage IV adult diffuse large cell lymphoma
1407575|NCT00357084|stage IV adult diffuse mixed cell lymphoma
1407576|NCT00357084|stage IV adult diffuse small cleaved cell lymphoma
1407577|NCT00357084|stage IV adult immunoblastic large cell lymphoma
1407578|NCT00357084|stage IV adult lymphoblastic lymphoma
1407579|NCT00357084|stage IV chronic lymphocytic leukemia
1407580|NCT00357084|stage IV grade 1 follicular lymphoma
1407581|NCT00357084|stage IV grade 2 follicular lymphoma
1407582|NCT00357084|stage IV grade 3 follicular lymphoma
1407583|NCT00357084|stage IV mantle cell lymphoma
1407584|NCT00357084|stage IV marginal zone lymphoma
1407585|NCT00357084|stage IV small lymphocytic lymphoma
1407586|NCT00357084|Waldenstrom macroglobulinemia
1407587|NCT00357084|childhood myelodysplastic syndromes
1407588|NCT00357071|Autoimmunity
1407589|NCT00357071|Cell Mediated Immunity
1407590|NCT00357071|S Antigen
1407591|NCT00357071|Cell Proliferation
1407592|NCT00357071|Uveitis
1407593|NCT00357071|Cell Proliferation Assays
1407594|NCT00357071|Auto-Antibody
1407595|NCT00357071|Auto-Antigens
1407596|NCT00357058|Deafferentiation-Induced Plasticity
1407597|NCT00357058|fMRI
1407599|NCT00357058|Tactile Performance
1407600|NCT00357058|Transcranial Magnetic Stimulation
1407601|NCT00357058|Tactile Discrimination
1407602|NCT00357058|Plasticity
1407603|NCT00357058|Healthy Volunteer
1407604|NCT00357058|HV
1407605|NCT00357058|Normal Control
1407606|NCT00357006|Schizophrenia
1407607|NCT00357006|Estrogen
1407608|NCT00357006|Psychosis
1407609|NCT00356993|nicotine replacement therapy
1407610|NCT00356993|smoking cessation
1407611|NCT00356980|unspecified adult solid tumor, protocol specific
1407612|NCT00356967|smoking
1407613|NCT00356967|cessation
1407614|NCT00356967|tobacco
1407615|NCT00356967|smoking cessation
1407616|NCT00356967|tobacco use cessation
1407617|NCT00356954|Kidney failure
1407618|NCT00356954|Contrast media
1407619|NCT00356954|Antioxidant
1407620|NCT00356954|Prevention
1407621|NCT00356941|recurrent non-small cell lung cancer
1407622|NCT00356941|stage II non-small cell lung cancer
1407747|NCT00356343|Cerebral Palsy
1407623|NCT00356941|stage IIIA non-small cell lung cancer
1407624|NCT00356941|stage IIIB non-small cell lung cancer
1407625|NCT00356928|previously treated myelodysplastic syndromes
1407626|NCT00356928|secondary myelodysplastic syndromes
1407627|NCT00356928|secondary acute myeloid leukemia
1407628|NCT00356928|chronic myelomonocytic leukemia
1407629|NCT00356928|de novo myelodysplastic syndromes
1407630|NCT00356915|Nail fungus
1407631|NCT00356915|Onychomycosis
1407632|NCT00356915|Itraconazole
1407633|NCT00356915|Toenail
1407634|NCT00356863|Intervention
1407635|NCT00356863|Awareness
1407636|NCT00356863|Cardiac Rehabilitation (CR)
1407637|NCT00356863|Coronary Artery Patients
1407638|NCT00356863|Coronary Artery Bypass Grafting Surgery (CABG)
1407639|NCT00356824|Child
1407640|NCT00356811|Lapatinib
1407641|NCT00356811|Metastatic breast cancer
1407642|NCT00356811|Paclitaxel
1407643|NCT00356811|ErbB2-amplification
1407644|NCT00356811|GW572016
1407645|NCT00356798|pandemic
1407646|NCT00356798|influenza
1407647|NCT00356798|H5N1
1407648|NCT00356798|vaccine
1407649|NCT00356785|lifestyle
1407650|NCT00356785|diet
1407651|NCT00356785|exercise
1407652|NCT00356785|physical activity
1407653|NCT00356785|obesity
1407654|NCT00356759|warfarin
1407655|NCT00356759|prothrombin time
1407656|NCT00356759|monitoring
1407657|NCT00356746|Perioperative inflammatory response
1407658|NCT00356746|General anesthesia
1407659|NCT00356746|Toll-Like Receptors
1407660|NCT00356733|cardiorenal syndrome
1407661|NCT00356733|erythropoietin
1407662|NCT00356733|Heart Failure, Congestive
1407663|NCT00356733|Renal Insufficiency, Chronic
1407664|NCT00356707|Body Mass Index
1407665|NCT00356681|AMG 706
1407666|NCT00356681|Paclitaxel
1407667|NCT00356681|Metastatic Breast Cancer
1407668|NCT00356681|Antiangiogenic
1407669|NCT00356681|Bevacizumab
1407670|NCT00356668|HFNC
1407671|NCT00356668|NCPAP
1407672|NCT00356668|nasal continuous positive airway pressure
1407673|NCT00356668|humidified high flow nasal cannula
1407674|NCT00356668|esophageal pressure
1407675|NCT00356668|gas flow
1407676|NCT00356655|Depressive disorder
1407677|NCT00356655|Patient compliance
1407678|NCT00356655|Antidepressive Agents
1407679|NCT00356655|Patient education
1407680|NCT00356655|Community pharmacy services
1407681|NCT00356655|Counseling
1407682|NCT00356642|PK
1407683|NCT00356642|GW842470X
1407684|NCT00356642|safety
1407685|NCT00356642|tolerability
1407686|NCT00356642|PD
1407687|NCT00356642|Atopic Dermatitis
1407688|NCT00356629|bronchopulmonary ignition
1407689|NCT00356629|condensate of exhaled air
1407690|NCT00356629|Mucoviscidosis
1407691|NCT00356629|Asthma
1407692|NCT00356616|Antiretroviral treatment
1407693|NCT00356616|virological failure
1407694|NCT00356616|HIV
1407695|NCT00356603|Migraine
1407696|NCT00356603|Sumatriptan Succinate Injection Kit
1407697|NCT00356603|Cluster Headache
1407698|NCT00356603|self-injection
1407699|NCT00356590|Rheumatoid Arthritis
1407700|NCT00356590|Etanercept
1407701|NCT00356590|Long-term Safety
1407702|NCT00356590|Enbrel
1407703|NCT00356564|Prophylaxis for hepatitis B disease
1407704|NCT00356551|Teen pregnancy
1407705|NCT00356551|Family strengthening
1407706|NCT00356551|Substance abuse prevention
1407707|NCT00356551|Depression prevention
1407708|NCT00356551|Parent involvement
1407709|NCT00356512|Phosphate
1407710|NCT00356512|Vitamin D
1407711|NCT00356512|Hypoparathyroidism
1407712|NCT00356512|Phosphatonin
1407713|NCT00356512|Clamp
1407714|NCT00356486|Chronic Hepatitis C
1407715|NCT00356486|Co-infection
1407716|NCT00356486|Induction dose
1407717|NCT00356486|HIV
1407718|NCT00356486|HIV Infections
1407719|NCT00356473|Rheumatoid arthritis
1407720|NCT00356473|Atherosclerosis
1407721|NCT00356473|High density lipoprotein (HDL) cholesterol
1407722|NCT00356473|Statins
1407723|NCT00356473|HDL anti-inflammatory properties
1407724|NCT00356473|Atorvastatin
1407725|NCT00356434|deep vein thrombosis
1407726|NCT00356434|thrombophilia
1407727|NCT00356434|pregnancy
1407728|NCT00356434|thromboprophylaxis
1407729|NCT00356434|decreased mobility
1407730|NCT00356434|hospitalization
1407731|NCT00356408|CDP870
1407732|NCT00356408|certolizumab pegol
1407733|NCT00356408|Crohn's Disease
1407734|NCT00356395|endothelial function, insulin resistance, adipocytokines
1407735|NCT00356382|probiotic
1407736|NCT00356382|Lactobacillus (L.) casei
1407737|NCT00356382|cultured dairy drink
1407738|NCT00356382|Health
1407739|NCT00356369|Immunogenicity
1407740|NCT00356369|Healthy
1407741|NCT00356369|Persistence
1407742|NCT00356369|Meningococcal vaccine
1407743|NCT00356369|Non-inferiority
1407744|NCT00356369|Meningococcal A C W Y Diseases
1407745|NCT00356369|meningococcal serogroups A, C, W & Y diseases
1407746|NCT00356343|NMES
1407748|NCT00356343|Spastic Diplegia
1407749|NCT00356343|Electrical Stimulation
1407750|NCT00356343|Children
1407751|NCT00356330|pacemaker
1407752|NCT00356330|magnetic resonance imaging
1407753|NCT00356330|safety
1407754|NCT00356317|Culture
1407755|NCT00356317|Family
1407756|NCT00356317|Therapy
1407757|NCT00356304|Dysthymia
1407758|NCT00356304|Major Depression
1407759|NCT00356304|Hispanics
1407760|NCT00356304|Latinos
1407761|NCT00356304|Motivational Interviewing
1407762|NCT00356304|Adherence
1407763|NCT00356291|HIV
1407764|NCT00356291|AIDS
1407765|NCT00356291|Prevention
1407766|NCT00356291|Serious Mental Illness
1407767|NCT00356278|D-Cycloserine
1407768|NCT00356278|Virtual Reality
1407769|NCT00356278|Exposure Therapy
1407770|NCT00356278|Veterans
1407771|NCT00356278|Cognitive Behavior Therapy
1407772|NCT00356278|Translational Research
1407773|NCT00356265|Blood Pressure Nitric Oxide
1407774|NCT00356265|L-NMMA
1407775|NCT00356265|Phenylephrine
1407776|NCT00356265|Vasoreactivity
1407777|NCT00356265|Blood Pressure
1407778|NCT00356239|Defibrillators, Implantable
1407779|NCT00356239|Heart Failure, Congestive
1407780|NCT00356239|Magnetic Resonance Imaging
1407781|NCT00356226|norepinephrine
1407782|NCT00356226|renin
1407783|NCT00356226|aldosterone
1407784|NCT00356226|hemodynamics
1407785|NCT00356226|spironolactone
1407786|NCT00356213|morbid obesity
1407787|NCT00356213|bariatric surgery
1407788|NCT00356213|sleeve-gastrectomy
1407789|NCT00356213|Roux-Y-gastric bypass
1407790|NCT00356213|outcome
1407791|NCT00356213|weight loss
1407792|NCT00356174|Food Allergy
1407793|NCT00356161|colorectal neoplasms
1407794|NCT00356161|hepatocellular carcinoma
1407795|NCT00356161|gallbladder cancer
1407796|NCT00356161|bile duct cancer
1407797|NCT00356161|hepatic arterial infusion
1407798|NCT00356148|breast cancer
1407799|NCT00356148|breast surgery
1407800|NCT00356148|clean wound
1407801|NCT00356148|overweight
1407802|NCT00356148|prophylaxis
1407803|NCT00356148|antibiotics
1407804|NCT00356122|Lung
1407805|NCT00356122|non-small cell
1407806|NCT00356122|chemotherapy
1407807|NCT00356122|tumor
1407808|NCT00356122|advanced
1407809|NCT00356122|recurrent
1407810|NCT00356122|metastatic
1407811|NCT00356122|Non-Small Cell Lung Cancer (NSCLC)
1407812|NCT00356070|Attention Deficit Hyperactivity Disorder, treatment,
1407813|NCT00356070|Strattera,
1407814|NCT00356070|rehabilitation
1407815|NCT00356057|atrial fibrillation
1407816|NCT00356057|AV node ablation
1407817|NCT00356057|pacemaker
1407818|NCT00356057|congestive heart failure
1407819|NCT00356044|Transradial access
1407820|NCT00356044|Femoral access
1407821|NCT00356044|Femoral vs radial access
1407822|NCT00356031|Avastin
1407823|NCT00356018|Epilepsy
1407824|NCT00356018|Compliance
1407825|NCT00356005|falciparum malaria
1407826|NCT00356005|therapy
1407827|NCT00356005|azithromycin
1407828|NCT00356005|artesunate
1407829|NCT00356005|Coartem
1407830|NCT00356005|Bangladesh
1407831|NCT00355992|Myocardial Ischemia
1407832|NCT00355992|Chest pain
1407833|NCT00355992|Ischemia Modified Albumin
1407834|NCT00355992|Acute Coronary Syndrome
1407835|NCT00355979|Obesity, intragastric balloon, Pharmacotherapy
1407836|NCT00355966|Premature rupture of membranes
1407837|NCT00355966|Induction of labour with Misoprostol
1407838|NCT00355966|Induction of labour with PGE2 gel
1407839|NCT00355953|Post-Menopausal Women
1407840|NCT00355953|Osteoporosis
1407841|NCT00355953|Phytoestrogen
1407842|NCT00355953|Genistein
1407843|NCT00355940|endovascular
1407844|NCT00355940|aortic
1407845|NCT00355940|repair
1407846|NCT00355940|navigation
1407847|NCT00355940|DynaCT
1407848|NCT00355940|position
1407849|NCT00355940|sensor
1407850|NCT00355927|Deep brain stimulation
1407851|NCT00355927|Microelectrode recordings
1407852|NCT00355927|Basal Ganglia
1407853|NCT00355927|Sedation
1407854|NCT00355927|Propofol
1407855|NCT00355914|Lumbar Facet Joint Nerve Block
1407856|NCT00355901|Ulcerative Colitis
1407857|NCT00355901|Colitis
1407858|NCT00355901|Steroid-Refractory
1407859|NCT00355901|Visilizumab
1407860|NCT00355901|Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
1407861|NCT00355888|Cancer
1407862|NCT00355888|Advanced or Metastatic Solid Tumor
1407863|NCT00355875|newborn
1407864|NCT00355875|preterm
1407865|NCT00355875|resuscitation
1407866|NCT00355875|oxidative injury
1407867|NCT00355875|protein carbonyl
1407868|NCT00355862|Sirolimus
1407869|NCT00355862|mTOR
1407870|NCT00355862|HCC-recurrence free survival
1407871|NCT00355862|Liver transplant recipients
1407872|NCT00355862|HCC recurrence free survival
1407873|NCT00355836|Motor Imagery
1407874|NCT00355836|Stroke
1407875|NCT00355836|Neuro-rehabilitation
1407876|NCT00355836|health psychology
1407877|NCT00355836|neuroscience
1407878|NCT00355836|randomised controlled trial
1407879|NCT00355823|electric field
1407880|NCT00355823|wound current
1407881|NCT00355823|wound healing
1407882|NCT00355823|bioelectric field
1407883|NCT00355823|chronic ulcer
1407884|NCT00355823|diabetic
1407885|NCT00355823|Diabetes
1407886|NCT00355823|aging
1407887|NCT00355810|Probiotics
1407888|NCT00355797|Bradycardia
1407889|NCT00355797|Sinus Node Dysfunction
1407890|NCT00355797|Chronotropic incompetence
1407891|NCT00355797|Pacemaker
1407892|NCT00355797|Rate adaptive
1407893|NCT00355784|growth hormone
1407894|NCT00355784|overfeeding
1407895|NCT00355784|energy expenditure
1407896|NCT00355784|protein metabolism
1407897|NCT00355784|lipid metabolism
1407898|NCT00355771|allergic rhinitis
1407899|NCT00355771|histamine antagonist
1407900|NCT00355771|sleep disorder
1407901|NCT00355758|Prostate Cancer Detection by Serum Proteomic Profiling
1407902|NCT00355745|Breast
1407903|NCT00355745|tumor
1407904|NCT00355745|ultrasound
1407905|NCT00355745|biopsy
1407906|NCT00355745|Breast mammographic or ultrasound findings
1407907|NCT00355732|Respiration
1407908|NCT00355732|COPD
1407909|NCT00355732|Mechanical Ventilation
1407910|NCT00355732|Ventilator Weaning
1407911|NCT00355732|Respiratory Failure
1407912|NCT00355732|ICU
1407913|NCT00355732|Pressure Support Ventilation
1407914|NCT00355719|Nevirapine
1407915|NCT00355719|Atazanavir
1407916|NCT00355719|Pharmacokinetics
1407917|NCT00355719|Interactions
1407918|NCT00355706|chronic low back pain
1407919|NCT00355706|thoracic facet joint
1407920|NCT00355706|nerve block
1407921|NCT00355693|Anxiety
1407922|NCT00355693|Dental
1407923|NCT00355693|Oral
1407924|NCT00355693|Surgery
1407925|NCT00355693|Colonoscopy
1407926|NCT00355693|Propofol
1407927|NCT00355693|Sedation
1407928|NCT00355693|Effect
1407929|NCT00355693|Reaction
1407930|NCT00355680|Retina
1407931|NCT00355680|Retinal Diseases
1407932|NCT00355680|Retinal Vessels
1407933|NCT00355680|Laser Coagulation
1407934|NCT00355667|diuretics
1407935|NCT00355667|furosemide
1407936|NCT00355667|azosemide
1407937|NCT00355667|congestive heart failure
1407938|NCT00355654|Diphtheria
1407939|NCT00355654|Tetanus
1407940|NCT00355654|Pertussis
1407941|NCT00355654|Poliomyelitis
1407942|NCT00355654|Haemophilus influenzae type b
1407943|NCT00355654|Hepatitis B
1407944|NCT00355641|Ropinirole
1407945|NCT00355641|Restless Legs Syndrome
1407946|NCT00355641|RLS
1407947|NCT00355628|Pain
1407948|NCT00355628|Cancer
1407949|NCT00355628|Neoplasm
1407950|NCT00355628|Continual Reassessment Method
1407951|NCT00355628|Pain Associated with Cancer/Neoplasms
1407952|NCT00355615|Heterozygous Familial Hypercholesterolemia
1407953|NCT00355602|Antibiotics
1407954|NCT00355602|Controlled Clinical Trial
1407955|NCT00355589|Hypertension
1407956|NCT00355589|High Blood Pressure
1407957|NCT00355589|Diuretic
1407958|NCT00355589|Angiotensin converting enzyme inhibitor
1407959|NCT00355589|Ambulatory blood pressure monitoring
1407960|NCT00355576|Amyotrophic Lateral Sclerosis
1407961|NCT00355576|Celecoxib
1407962|NCT00355576|Creatine
1407963|NCT00355576|Minocycline
1407964|NCT00355576|Combination
1407965|NCT00355576|Selection
1407966|NCT00355576|ALS
1407967|NCT00355576|Motor Neuron Disease
1407968|NCT00355550|Mild Cognitive Impairment
1407969|NCT00355550|Cognition disorders
1407970|NCT00355550|nutritional supplement
1407971|NCT00355550|dietary supplement
1407972|NCT00355524|HIV-1
1407973|NCT00355524|Darunavir
1407974|NCT00355524|Ritonavir
1407975|NCT00355524|TMC114
1407976|NCT00355511|heart failure, congestive
1407977|NCT00355511|patient care team
1407978|NCT00355511|randomized controlled trial
1407979|NCT00355511|disease management
1407980|NCT00355511|drug therapy
1407981|NCT00355511|diet therapy
1407982|NCT00355511|hospitalization
1407983|NCT00355511|mortality
1407984|NCT00355498|functional magnetic resonance imaging
1407985|NCT00355498|positron emission tomography
1407986|NCT00355498|beta-amyloid
1407987|NCT00355498|tau
1407988|NCT00355485|Acne
1407989|NCT00355485|Microdermabrasion
1407990|NCT00355472|Adult T-Cell Leukemia
1407991|NCT00355472|ATL
1407992|NCT00355472|Adult Peripheral T-Cell Lymphoma
1407993|NCT00355472|PTCL
1407994|NCT00355459|Meibomian Gland Dystrophy
1407995|NCT00355446|Cataract
1407996|NCT00355446|Human Aqueous
1407997|NCT00355433|urinary incontinence
1407998|NCT00355433|urodynamics
1407999|NCT00355433|temperature
1408000|NCT00355407|Aranesp
1408001|NCT00355407|allogeneic stem cell transplant
1408002|NCT00355381|Information Services
1408003|NCT00355381|Randomized Controlled Trials
1408004|NCT00355381|Medical Records Systems, Computerized
1408005|NCT00355381|Internet
1408006|NCT00355381|Librarians
1408007|NCT00355381|Breast Neoplasms
1408008|NCT00355381|Patient Satisfaction
1408009|NCT00355381|Health Personnel
1408010|NCT00355381|Costs and Cost Analysis
1408011|NCT00355381|Premature Birth
1408012|NCT00355368|intubation
1408013|NCT00355368|intensive care
1408014|NCT00355368|neuromuscular depolarizing agents
1408015|NCT00355368|neuromuscular nondepolarizing agents
1408016|NCT00355368|neuromuscular blocking agents
1408017|NCT00355355|Hepatocellular carcinoma
1408018|NCT00355355|HCC
1408019|NCT00355355|Liver Neoplasms
1408020|NCT00355355|Talaporfin Sodium (LS11)
1408021|NCT00355355|Light emitting diodes (LEDs)
1408022|NCT00355355|Light activation
1408023|NCT00355342|Osteoporosis
1408024|NCT00355342|Bone Mineral Density
1408025|NCT00355342|Osteopenia
1408026|NCT00355342|Chronic Obstructive Pulmonary Disease
1408027|NCT00355342|COPD
1408028|NCT00355329|Traditional Chinese Medicine (TCM)
1408029|NCT00355329|Autism
1408030|NCT00355329|Autistic Spectrum Disorder
1408031|NCT00355329|Tongue Acupuncture (TAC)
1408032|NCT00355329|18F-fluorodeoxyglucose Positron Emission Tomography (PET)
1408033|NCT00355329|children
1408034|NCT00355316|Breast Cancer
1408035|NCT00355316|Peripheral
1408036|NCT00355316|Blood
1408037|NCT00355303|Premature rupture of membranes at term
1408038|NCT00355303|Induction of labour
1408039|NCT00355303|Misoprostol
1408040|NCT00355303|PGE2 gel
1408041|NCT00355303|Immediate induction with PGE2 gel
1408042|NCT00355303|Immediate induction with Misoprostol
1408043|NCT00355290|Chronic Oral Anticoagulation
1408044|NCT00355277|Tricyclic antidepressants
1408045|NCT00355277|Neuropathic pain
1408046|NCT00355277|Local anaesthesia
1408047|NCT00355277|Transcutaneous
1408048|NCT00355251|Atorvastatin
1408049|NCT00355251|Viral replication
1408050|NCT00355251|HIV-1
1408051|NCT00355251|plasma cholesterol
1408052|NCT00355251|Cell membrane cholesterol
1408053|NCT00355225|insecticide-treated bednets
1408054|NCT00355225|malaria
1408055|NCT00355225|africa
1408056|NCT00355225|social marketing
1408057|NCT00355225|ante-natal care
1408058|NCT00355225|ITN coverage
1408059|NCT00355225|ITn use
1408060|NCT00355212|percutaneous ethanol injection
1408061|NCT00355212|radiofrequency
1408062|NCT00355212|liver cirrhosis
1408063|NCT00355212|carcinoma, hepatocellular
1408064|NCT00355199|DLBCL
1408065|NCT00355199|R-HDS
1408066|NCT00355199|R-CHOP14
1408067|NCT00355186|acute myocardial infarction
1408068|NCT00355186|MRI
1408069|NCT00355186|bone marrow cells
1408070|NCT00355186|stem cells
1408071|NCT00355186|remodeling
1408072|NCT00355160|Headache
1408073|NCT00355160|Sinusitis
1408074|NCT00355160|Rhinitis
1408075|NCT00355160|Facial Pain
1408076|NCT00355147|Ischemic stroke
1408077|NCT00355147|Preventive medicine
1408078|NCT00355147|Transient Ischemic Attack
1408079|NCT00355147|Neurology
1408080|NCT00355147|Risk management
1408081|NCT00355134|fingolimod
1408082|NCT00355134|FTY720
1408083|NCT00355134|relapsing-remitting multiple sclerosis
1408084|NCT00355134|MS
1408085|NCT00355134|RRMS
1408086|NCT00355121|Meningococcal meningitis
1408087|NCT00355121|Tetanus
1408088|NCT00355121|Diphtheria
1408089|NCT00355121|Pertussis
1408090|NCT00355121|Poliomyelitis
1408091|NCT00355121|Neisseria meningitidis
1408092|NCT00355108|Rendu Osler syndrome
1408093|NCT00355108|Epistaxis
1408094|NCT00355108|Tranexamic acid
1408095|NCT00355108|clinical trial
1408096|NCT00355095|multiple sclerosis
1408097|NCT00355095|add-on Therapy
1408098|NCT00355095|erythropoietin
1408099|NCT00355095|methylprednisolone
1408100|NCT00355095|autoimmune optic neuritis
1408101|NCT00355082|epilepsy
1408102|NCT00355082|lamotrigine
1408103|NCT00355082|Lamictal
1408104|NCT00355082|monotherapy
1408105|NCT00355069|pediatric
1408106|NCT00355069|asthma
1408107|NCT00355069|translational research
1408108|NCT00355069|health information technology
1408109|NCT00355056|Migraine
1408110|NCT00355056|PFO
1408111|NCT00355056|Migraine Headache
1408112|NCT00355056|patent foramen ovale
1408113|NCT00355043|Zinc treatment
1408114|NCT00355043|Bronchiolitis
1408115|NCT00355043|Wheezing
1408116|NCT00355043|Children aged 2 months to 23 months
1408117|NCT00355043|Diagnosed case of acute bronchiolitis
1408118|NCT00355004|colon cancer
1408119|NCT00355004|rectal cancer
1408120|NCT00354978|Colorectal Cancer
1408121|NCT00354978|FOLFIRI
1408122|NCT00354978|Irinotecan
1408123|NCT00354978|CPT-11
1408124|NCT00354978|Leucovorin
1408125|NCT00354978|LV
1408126|NCT00354978|Folinic Acid
1408127|NCT00354978|Fluorouracil
1408128|NCT00354978|5-FU
1408129|NCT00354978|Adrucil
1408130|NCT00354978|Efudex
1408131|NCT00354978|Bevacizumab
1408132|NCT00354978|Avastin
1408133|NCT00354978|Anti-VEGF monoclonal antibody
1408134|NCT00354978|rhuMAb-VEGF
1408135|NCT00354965|ABS
1408136|NCT00354965|Acute Bacterial
1408137|NCT00354965|Sinusitis
1408138|NCT00354965|Bacterial Sinusitis
1408139|NCT00354952|Healthy volunteers
1408140|NCT00354952|Antibiotic exposure
1408141|NCT00354952|Resistance selection
1408142|NCT00354926|Non-Hodgkin's Lymphoma
1408143|NCT00354926|rituximab
1408144|NCT00354926|humanized monoclonal antibody
1408145|NCT00354926|anti-CD20 monoclonal antibody
1408146|NCT00354913|adult grade I meningioma
1408147|NCT00354913|adult grade II meningioma
1408148|NCT00354913|adult grade III meningioma
1408149|NCT00354913|adult papillary meningioma
1408150|NCT00354913|adult anaplastic meningioma
1408151|NCT00354913|recurrent adult brain tumor
1408152|NCT00354913|glioblastoma multiforme (GBM)
1408153|NCT00354913|Imatinib
1408154|NCT00354913|Imatinib mesylate
1408155|NCT00354913|Hydroxyurea
1408156|NCT00354913|Droxia
1408157|NCT00354913|Hydrea
1408158|NCT00354913|Hydroxycarbamide
1408159|NCT00354913|Gleevec
1408160|NCT00354913|Meningioma
1408161|NCT00354900|breast cancer
1408162|NCT00354900|fibrinolysis
1408163|NCT00354900|urokinase-type plasminogen activator
1408164|NCT00354900|plasminogen activator inhibitor
1408165|NCT00354900|aprotinin
1408166|NCT00354900|plasmin/alpha-2-antiplasmin complex
1408167|NCT00354887|Gastrointestinal Cancer
1408168|NCT00354887|Small Bowel Cancer
1408169|NCT00354887|Ampulla of Vater
1408170|NCT00354887|Capecitabine
1408171|NCT00354887|Xeloda
1408172|NCT00354887|Oxaliplatin
1408173|NCT00354887|Eloxatin
1408174|NCT00354874|GW642444 asthmatic subjects safety tolerability PD and PK
1408175|NCT00354861|Healthy volunteers
1408176|NCT00354861|IMP321
1408177|NCT00354861|Adjuvant
1408178|NCT00354861|Pharmacodynamics
1408179|NCT00354822|Zevalin
1408180|NCT00354822|Lymphoma, Non-Hodgkin
1408181|NCT00354809|cognition
1408182|NCT00354809|Primary Insomnia
1408183|NCT00354809|sleep
1408184|NCT00354809|polysomnography
1408185|NCT00354796|bleeding
1408186|NCT00354796|anticoagulation
1408187|NCT00354796|LMWH
1408188|NCT00354796|Enoxaparin
1408189|NCT00354783|Very low birth weight premature infants
1408190|NCT00354783|Kicking
1408191|NCT00354783|Stepping
1408192|NCT00354783|Walking
1408193|NCT00354783|Motor development
1408194|NCT00354783|Kinematics
1408195|NCT00354770|Trichotillomania
1408196|NCT00354770|Hair-pulling
1408197|NCT00354757|gastroesophageal reflux disease, proton-pump inhibitor test
1408198|NCT00354744|adult rhabdomyosarcoma
1408199|NCT00354744|previously untreated childhood rhabdomyosarcoma
1408200|NCT00354744|adult malignant mesenchymoma
1408201|NCT00354744|childhood malignant mesenchymoma
1408202|NCT00354744|metastatic childhood soft tissue sarcoma
1408203|NCT00354744|stage IV adult soft tissue sarcoma
1408204|NCT00354731|nephrotic syndrome, pentoxifylline, corticosteroid
1408205|NCT00354705|Colon Cancer
1408206|NCT00354705|Adenocarcinoma of the Colon
1408207|NCT00354705|Cancer Recurrence
1408208|NCT00354705|Survey
1408209|NCT00354705|Chemotherapy
1408210|NCT00354705|Surgery
1408211|NCT00354679|adenocarcinoma of the esophagus
1408212|NCT00354679|recurrent esophageal cancer
1408213|NCT00354679|stage III esophageal cancer
1408214|NCT00354679|stage II esophageal cancer
1408215|NCT00354666|inhaled
1408216|NCT00354666|asthmatic subjects
1408217|NCT00354666|GSK159797
1408218|NCT00354666|safety and tolerability
1408219|NCT00354666|efficacy
1408220|NCT00354666|dry powder
1408221|NCT00354653|HBeAg
1408222|NCT00354653|HBV
1408223|NCT00354653|CHRONIC HEPATITIS
1408224|NCT00354653|lamivudine
1408225|NCT00354640|breast cancer
1408226|NCT00354640|breast cancer in situ
1408227|NCT00354640|ductal breast carcinoma in situ
1408228|NCT00354640|stage I breast cancer
1408229|NCT00354640|stage II breast cancer
1408230|NCT00354640|stage IIIA breast cancer
1408231|NCT00354640|stage IIIB breast cancer
1408232|NCT00354640|stage IIIC breast cancer
1408233|NCT00354627|HIV-1
1408234|NCT00354627|Early Access Program (EAP)
1408235|NCT00354627|TMC125
1408236|NCT00354627|treatment-experienced
1408237|NCT00354627|failing multiple antiretroviral (ARV) regimens
1408238|NCT00354627|limited to no treatment options
1408239|NCT00354601|fallopian tube cancer
1408240|NCT00354601|peritoneal cavity cancer
1408241|NCT00354601|recurrent ovarian epithelial cancer
1408242|NCT00354601|ovarian clear cell cystadenocarcinoma
1408243|NCT00354601|ovarian endometrioid adenocarcinoma
1408244|NCT00354601|ovarian mucinous cystadenocarcinoma
1408245|NCT00354601|ovarian serous cystadenocarcinoma
1408246|NCT00354601|ovarian undifferentiated adenocarcinoma
1408247|NCT00354588|chronic renal failure
1408248|NCT00354588|arterial stiffness
1408249|NCT00354588|arterial wave reflections
1408250|NCT00354575|Constipation;
1408251|NCT00354575|Chinese herb;
1408252|NCT00354575|Long-term care;
1408253|NCT00354575|Integrative Chinese Medicine and Western Medicine;
1408254|NCT00354562|Lung Cancer
1408255|NCT00354562|Non-Small Cell Lung Cancer
1408256|NCT00354562|NSCLC
1408257|NCT00354562|ABT-751
1408258|NCT00354562|docetaxel
1408259|NCT00354562|Taxotere
1408260|NCT00354549|recurrent non-small cell lung cancer
1408261|NCT00354549|stage IIIB non-small cell lung cancer
1408262|NCT00354549|stage IV non-small cell lung cancer
1408263|NCT00354549|adenocarcinoma of the lung
1408264|NCT00354549|bronchoalveolar cell lung cancer
1408265|NCT00354549|large cell lung cancer
1408266|NCT00354536|GSK716155
1408267|NCT00354536|albiglutide
1408268|NCT00354536|pharmacodynamics
1408269|NCT00354536|pharmacokinetics
1408270|NCT00354523|Solid Tumor
1408271|NCT00354523|Thyroid Cancer
1408272|NCT00354523|Medullary Thyroid Cancer
1408273|NCT00354523|MTC
1408274|NCT00354523|Advanced Metastatic Medullary Thyroid Carcinoma
1408275|NCT00354523|Capecitabine
1408276|NCT00354523|Dacarbazine
1408277|NCT00354523|Imatinib
1408278|NCT00354523|Gleevec
1408279|NCT00354523|Imatinib Mesylate
1408280|NCT00354523|DTIC-Dome
1408281|NCT00354523|Xeloda
1408282|NCT00354510|atopic dermatitis
1408283|NCT00354510|GW842470X
1408284|NCT00354510|PDE4 inhibitor
1408285|NCT00354497|prostate cancer
1408286|NCT00354484|anemia
1408287|NCT00354484|postpartum
1408288|NCT00354458|heart failure
1408289|NCT00354458|diuretic
1408290|NCT00354458|renal impairment
1408291|NCT00354458|renal function
1408292|NCT00354445|Age-Related Macular Degeneration (AMD)
1408293|NCT00354445|pegaptanib sodium
1408294|NCT00354445|subfoveal CNV
1408295|NCT00354445|macugen
1408296|NCT00354432|recurrent prostate cancer
1408297|NCT00354432|stage I prostate cancer
1408298|NCT00354432|stage IIB prostate cancer
1408299|NCT00354432|stage IIA prostate cancer
1408300|NCT00354432|stage III prostate cancer
1408301|NCT00354432|stage IV prostate cancer
1408302|NCT00354432|hot flashes
1408303|NCT00354406|Abciximab
1408304|NCT00354406|Magnetic Resonance Imaging
1408305|NCT00354406|Percutaneous Transluminal Coronary Angioplasty
1408306|NCT00354393|localized malignant mesothelioma
1408307|NCT00354393|sarcomatous mesothelioma
1408308|NCT00354393|advanced malignant mesothelioma
1408309|NCT00354393|epithelial mesothelioma
1408310|NCT00354380|Malaria
1408311|NCT00354380|Africa
1408312|NCT00354380|Methalyne-blue
1408313|NCT00354380|Artesunate
1408314|NCT00354380|Amodiaquine
1408315|NCT00354367|Crohn Disease
1408316|NCT00354367|Certolizumab pegol
1408317|NCT00354367|Fistula
1408318|NCT00354354|COPD
1408319|NCT00354354|Combivent
1408320|NCT00354354|Exercise
1408321|NCT00354354|Bronchodilator
1408322|NCT00354354|Kinetics
1408323|NCT00354328|HCM
1408324|NCT00354328|Echocardiography
1408325|NCT00354328|Diastolic Dysfunction
1408326|NCT00354328|Enalapril
1408327|NCT00354315|Shared decision making
1408328|NCT00354315|Optimal drug prescription
1408329|NCT00354302|osteoporosis
1408330|NCT00354302|stage I breast cancer
1408331|NCT00354302|stage II breast cancer
1408332|NCT00354302|stage IIIA breast cancer
1408333|NCT00354276|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1408334|NCT00354276|adult acute myeloid leukemia with t(16;16)(p13;q22)
1408335|NCT00354276|untreated adult acute myeloid leukemia
1408336|NCT00354276|adult acute myelomonocytic leukemia (M4)
1408337|NCT00354276|adult acute monocytic leukemia (M5b)
1408338|NCT00354276|adult erythroleukemia (M6a)
1408339|NCT00354276|adult pure erythroid leukemia (M6b)
1408340|NCT00354276|adult acute monoblastic leukemia (M5a)
1408341|NCT00354276|adult acute megakaryoblastic leukemia (M7)
1408342|NCT00354276|adult acute basophilic leukemia
1408343|NCT00354276|adult acute myeloblastic leukemia without maturation (M1)
1408344|NCT00354276|adult acute myeloblastic leukemia with maturation (M2)
1408345|NCT00354276|adult acute eosinophilic leukemia
1408346|NCT00354276|adult acute minimally differentiated myeloid leukemia (M0)
1408347|NCT00354263|Healthy male volunteers
1408348|NCT00354263|IMP321
1408349|NCT00354263|Adjuvant
1408350|NCT00354263|Monotherapy
1408351|NCT00354263|Pharmacokinetics/Pharmacodynamics
1408352|NCT00354237|diabetes mellitus
1408353|NCT00354237|cardiac rehabilitation
1408354|NCT00354237|insulin
1408355|NCT00354224|recurrent gastric cancer
1408356|NCT00354224|stage III gastric cancer
1408357|NCT00354224|stage IV gastric cancer
1408358|NCT00354211|Cardiac Output
1408359|NCT00354211|Hemodynamic Phenomena
1408360|NCT00354198|rapidly progressive glomerulonephritis
1408361|NCT00354198|pentoxifylline
1408362|NCT00354172|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1408363|NCT00354172|adult acute myeloid leukemia with inv(16)(p13;q22)
1408364|NCT00354172|adult acute myeloid leukemia with t(15;17)(q22;q12)
1408365|NCT00354172|adult acute myeloid leukemia with t(16;16)(p13;q22)
1408366|NCT00354172|adult acute myeloid leukemia with t(8;21)(q22;q22)
1408367|NCT00354172|atypical chronic myeloid leukemia
1408368|NCT00354172|blastic phase chronic myelogenous leukemia
1408369|NCT00354172|childhood chronic myelogenous leukemia
1408370|NCT00354172|previously treated myelodysplastic syndromes
1408371|NCT00354172|recurrent adult acute myeloid leukemia
1408372|NCT00354172|recurrent childhood acute myeloid leukemia
1408373|NCT00354172|relapsing chronic myelogenous leukemia
1408374|NCT00354172|secondary acute myeloid leukemia
1408375|NCT00354172|secondary myelodysplastic syndromes
1408376|NCT00354172|childhood myelodysplastic syndromes
1408377|NCT00354159|Implantable cardioverter defibrillator
1408378|NCT00354159|Intracardiac pressures
1408379|NCT00354146|Farnesyl transferase inhibitor
1408380|NCT00354146|relapsed or refractory acute myeloid leukemia
1408381|NCT00354133|Parkinson Disease
1408382|NCT00354133|Deep Brain Stimulation
1408383|NCT00354133|PDQ-39
1408384|NCT00354081|Coronary Artery Disease
1408385|NCT00354081|Myocardial Infarction
1408386|NCT00354081|Cerebrovascular Stroke
1408387|NCT00354081|Homocysteine
1408388|NCT00354081|Folic Acid
1408389|NCT00354081|Vitamin B 12
1408390|NCT00354081|Vitamin B 6
1408391|NCT00354068|adult anaplastic oligodendroglioma
1408392|NCT00354068|adult giant cell glioblastoma
1408393|NCT00354068|adult gliosarcoma
1408394|NCT00354068|adult mixed glioma
1408395|NCT00354068|adult anaplastic astrocytoma
1408396|NCT00354068|recurrent adult brain tumor
1408397|NCT00354068|adult glioblastoma
1408398|NCT00354042|GW597901X
1408399|NCT00354042|Asthma
1408400|NCT00354042|Crossover
1408401|NCT00354042|dose ascending
1408402|NCT00354042|repeat dose
1408403|NCT00354042|inhaled
1408404|NCT00354029|hemorrhoids
1408405|NCT00354029|hemorrhoidectomy
1408406|NCT00354029|S (+) ketamine
1408407|NCT00354029|pain
1408408|NCT00354016|influenza
1408409|NCT00354016|vaccine
1408410|NCT00354003|Parkinson
1408411|NCT00354003|Imaging
1408412|NCT00353990|insulin
1408413|NCT00353990|bioavailability
1408414|NCT00353990|duodenum
1408415|NCT00353990|infusion
1408416|NCT00353990|healthy
1408417|NCT00353990|diabetes
1408418|NCT00353990|absorption
1408419|NCT00353977|Cytomegalovirus
1408420|NCT00353977|Vaccine
1408421|NCT00353977|CMV
1408422|NCT00353977|Immunization
1408423|NCT00353977|Peripheral Blood Stem Cell Transplantation
1408424|NCT00353977|Stem Cell Allotransplant
1408425|NCT00353951|primary care
1408426|NCT00353951|lower respiratory tract infection
1408427|NCT00353951|antibiotics
1408428|NCT00353951|cough
1408429|NCT00353938|PTSD, MDMA, psychotherapy, Switzerland
1408430|NCT00353925|Hypertrophy
1408431|NCT00353925|LVH
1408432|NCT00353925|Cardiac
1408433|NCT00353925|Blood Pressure
1408434|NCT00353925|Papillary Muscle
1408435|NCT00353912|Blood
1408436|NCT00353912|Venous
1408437|NCT00353912|Systolic
1408438|NCT00353912|Diastolic
1408439|NCT00353912|Pulse
1408440|NCT00353912|Pressure
1408441|NCT00353899|Magnetic Resonance Imaging
1408442|NCT00353899|Pediatric
1408443|NCT00353899|Normal Volunteer
1408444|NCT00353899|Electrocardiogram
1408445|NCT00353899|Cardiac
1408446|NCT00353899|Healthy Volunteer
1408447|NCT00353899|HV
1408448|NCT00353886|Retrospective
1408449|NCT00353886|Epilepsy
1408450|NCT00353886|Antiepileptic Drugs
1408451|NCT00353886|Behavioral Development
1408452|NCT00353886|Intellectual Development
1408453|NCT00353873|FLIXOTIDE
1408454|NCT00353873|asthmatics children 4-11 years
1408455|NCT00353873|SERETIDE
1408456|NCT00353873|asthma-control
1408457|NCT00353860|Leukemia
1408458|NCT00353860|Transplant - Mortality
1408459|NCT00353860|Immunosuppression
1408460|NCT00353860|Radiation
1408461|NCT00353860|Cure
1408462|NCT00353860|Peripheral Blood Stem Cells
1408463|NCT00353860|Graft-Versus Leukemia/Myeloma
1408464|NCT00353860|Graft-Versus-Host Disease
1408465|NCT00353860|Cyclosporine
1408466|NCT00353860|Fludarabine
1408467|NCT00353847|acupuncture, RCTs, chronic LBP
1408468|NCT00353834|endothelial dysfunction
1408469|NCT00353834|subclinical inflammation
1408470|NCT00353834|flow mediated brachial artery dilation
1408471|NCT00353834|pulse wave analysis
1408472|NCT00353834|glucagon like polypeptide mimetics
1408473|NCT00353834|type 2 diabetes mellitus
1408474|NCT00353821|Tumor Necrosis Factor Alpha (TNF-Alpha)
1408475|NCT00353821|Interferon-Gamma (IFN-Gamma)
1408476|NCT00353821|Interleukin-10 (IL-10)
1408477|NCT00353821|Interleukin-6 (IL-6)
1408478|NCT00353821|Interleukin-1 (IL-1 Ra)
1408479|NCT00353821|Interleukin-1 Receptor Antagonist (IL-1 Ra)
1408480|NCT00353821|Vitamin D Receptor (VitD R)
1408481|NCT00353795|MESA
1408482|NCT00353795|MRI
1408483|NCT00353795|Cardiovascular
1408484|NCT00353795|Cardiac
1408485|NCT00353795|Coronary
1408486|NCT00353795|Atherosclerosis
1408487|NCT00353782|Dyslipidemia
1408488|NCT00353782|Hypertriglyceridemia
1408489|NCT00353782|Hyperalphalipoproteinemia
1408490|NCT00353782|Atheroembolism
1408491|NCT00353782|Atherosclerosis
1408492|NCT00353782|Dyslipoproteinemia
1408493|NCT00353782|Hypercholesterolemia
1408494|NCT00353782|hypoalphalipoproteinemia
1408495|NCT00353769|scalp laceration
1408496|NCT00353769|tissue adhesive
1408497|NCT00353769|wound care
1408498|NCT00353769|cost effectiveness
1408499|NCT00353743|infected abortion
1408500|NCT00353743|treatment period
1408501|NCT00353743|doxycycline
1408502|NCT00353743|metronidazole
1408503|NCT00353743|placebo
1408504|NCT00353730|Serial Analysis of Gene Expression
1408505|NCT00353730|Carotid Artery Plaque
1408506|NCT00353730|Atherosclerosis
1408507|NCT00353717|breast
1408508|NCT00353717|basal like
1408509|NCT00353717|carcinoma
1408510|NCT00353717|metastatic
1408511|NCT00353717|EGFR
1408512|NCT00353704|Intervertebral disk displacement
1408513|NCT00353704|disk prolapse
1408514|NCT00353704|pregabalin
1408515|NCT00353678|Hip replacement
1408516|NCT00353678|Arthroplasty
1408517|NCT00353678|Prevention
1408518|NCT00353678|Thromboembolism
1408519|NCT00353678|Treatment outcomes
1408520|NCT00353678|Arthroplasty, replacement, hip
1408521|NCT00353665|amyotrophic lateral sclerosis
1408522|NCT00353665|motor neuron disease
1408523|NCT00353665|memantine
1408524|NCT00353665|clinical trial
1408525|NCT00353652|Blood Pressure, High
1408526|NCT00353639|Ulcera
1408527|NCT00353639|Telomerase
1408528|NCT00353639|TERT
1408529|NCT00353639|TERC
1408530|NCT00353639|SBDS
1408531|NCT00353639|DNA Helicase
1408532|NCT00353639|Inflammatory Bowel Disease
1408533|NCT00353639|IBD
1408534|NCT00353626|Amputation
1408535|NCT00353626|trans tibial
1408536|NCT00353626|prosthesis
1408537|NCT00353626|motion analysis
1408538|NCT00353613|Antibiotic prophylaxis
1408539|NCT00353600|Proteinuria
1408540|NCT00353600|Renal Failure
1408541|NCT00353600|Angiotension Converting Enzyme Inhibitor
1408542|NCT00353600|Glomerular Filtration Rate
1408543|NCT00353587|insulin sensitizer
1408544|NCT00353587|type 2 diabetes
1408545|NCT00353587|diabetes
1408546|NCT00353587|glucose control
1408547|NCT00353574|Resistant Hypertension
1408548|NCT00353548|Bulimia Nervosa
1408549|NCT00353548|Binge Eating Disorder
1408550|NCT00353548|Obesity
1408551|NCT00353548|Anorexia Nervosa
1408552|NCT00353535|glomerulosclerosis, focal
1408553|NCT00353535|pretransplant immunosuppression
1408554|NCT00353535|total lymphoid irradiation
1408555|NCT00353535|renal transplant
1408556|NCT00353535|recurrence
1408557|NCT00353496|Non functioning entero-pancreatic tumours
1408558|NCT00353483|Breast Cancer
1408559|NCT00353483|Neoadjuvant
1408560|NCT00353470|PD
1408561|NCT00353470|CBT
1408562|NCT00353470|PFPP
1408563|NCT00353457|Adjuvant therapy
1408564|NCT00353457|Rectal cancer
1408565|NCT00353457|Capecitabine
1408566|NCT00353457|Oxaliplatin
1408567|NCT00353457|Cetuximab
1408568|NCT00353457|Erbitux
1408569|NCT00353444|head injury
1408570|NCT00353444|transcranial Doppler
1408571|NCT00353444|pulsatility index
1408572|NCT00353444|vasospasm in head injury
1408573|NCT00353431|Hyperglycaemia
1408574|NCT00353431|algorithm
1408575|NCT00353431|emergency
1408576|NCT00353431|s.c. insulin therapy
1408577|NCT00353431|Emergency patient
1408578|NCT00353405|Adolescents
1408579|NCT00353405|Sexually Transmitted Infections
1408580|NCT00353405|Gonorrhea
1408581|NCT00353405|Chlamydia Infections
1408582|NCT00353366|safety
1408583|NCT00353366|Post-marketing surveillance (PMS)
1408584|NCT00353366|Rotarix
1408585|NCT00353366|oral
1408586|NCT00353366|Filipino
1408587|NCT00353366|Rotavirus
1408588|NCT00353366|Gastroenteritis
1408589|NCT00353366|Human Rotavirus (HRV) vaccine
1408590|NCT00353353|no specific conditions
1408591|NCT00353340|sodium bicarbonate,
1408592|NCT00353340|n-acetylcisteine,
1408593|NCT00353340|contrast nephropathy,
1408594|NCT00353340|cardiac catheterisation
1408595|NCT00353327|HIV
1408596|NCT00353327|Passive immunotherapy
1408597|NCT00353301|Carcinoma, Renal Cell
1408598|NCT00353301|Receptor, Epidermal Growth Factor
1408599|NCT00353301|mTOR protein
1408600|NCT00353301|Sirolimus
1408601|NCT00353301|Erlotinib
1408602|NCT00353275|Strict glycemic control
1408603|NCT00353249|Cognitive Behavioral Therapy
1408604|NCT00353249|CBT
1408605|NCT00353249|Homeless Women
1408606|NCT00353236|delivery of preterm infant and/or twins
1408607|NCT00353223|Heart Failure
1408608|NCT00353223|Functional Impairment
1408609|NCT00353223|Health-Related Quality of Life
1408610|NCT00353223|Telemedicine
1408611|NCT00353210|IVF
1408612|NCT00353210|embryos
1408613|NCT00353210|research
1408614|NCT00353210|donation
1408615|NCT00353210|surplus
1408616|NCT00353210|stem cells
1408617|NCT00353210|abnormal embryo
1408618|NCT00353210|screening
1408619|NCT00353197|IVF
1408620|NCT00353197|embryos
1408621|NCT00353197|research
1408622|NCT00353197|donation
1408623|NCT00353197|surplus
1408624|NCT00353197|stem cells
1408625|NCT00353184|Acute
1408626|NCT00353184|Asthma
1408627|NCT00353184|Child
1408628|NCT00353184|Pediatric
1408629|NCT00353184|Emergency
1408630|NCT00353184|Oral
1408631|NCT00353184|Montelukast
1408632|NCT00353184|Forced Expiratory Volume in One Second
1408633|NCT00353184|FEV1
1408634|NCT00353171|Smoking
1408635|NCT00353171|PCB
1408636|NCT00353171|DDE
1408637|NCT00353171|Menstrual Cycle
1408638|NCT00353171|NC Infant Feeding Study
1408639|NCT00353158|Phototesting
1408640|NCT00353158|UVR/UVA
1408641|NCT00353158|Sunburn
1408642|NCT00353158|Doxycycline
1408643|NCT00353158|Voriconazole
1408644|NCT00353158|Phototoxicity
1408645|NCT00353158|Healthy Volunteer
1408646|NCT00353158|HV
1408647|NCT00353145|Unknown Primary Neoplasms
1408648|NCT00353145|UPC
1408649|NCT00353145|Unknown Primary Cancer
1408650|NCT00353145|Questionnaire
1408651|NCT00353145|Gemcitabine
1408652|NCT00353145|Gemcitabine Hydrochloride
1408653|NCT00353145|Gemzar
1408654|NCT00353145|Oxaliplatin
1408655|NCT00353145|Eloxatin
1408656|NCT00353145|Gemox
1408657|NCT00353119|Palmoplantar pustulosis
1408658|NCT00353119|Psoriasis
1408659|NCT00353119|Etanercept
1408660|NCT00353106|Graft-Versus-Host Disease
1408661|NCT00353106|GVHD
1408662|NCT00353106|Chronic Graft-Versus-Host Disease
1408663|NCT00353106|cGVHD
1408664|NCT00353106|Interview
1408665|NCT00353106|Questionnaire
1408666|NCT00353106|Survey
1408667|NCT00353106|Caregiver
1408668|NCT00353093|deep vein thrombosis,D-dimer,ultrasonography
1408669|NCT00353080|Prevention of postmenopausal osteoporosis
1408670|NCT00353067|unstable angina
1408671|NCT00353067|myocardial infarction
1408672|NCT00353067|coronary thrombosis
1408673|NCT00353067|coronary atherosclerosis
1408674|NCT00353054|Caltrate
1408675|NCT00353054|Lipoproteins
1408676|NCT00353054|Glucose
1408677|NCT00353054|Insulin
1408678|NCT00353054|Blood pressure
1408679|NCT00353054|Body fat
1408680|NCT00353054|Body weight
1408681|NCT00353054|Women
1408682|NCT00353054|Diet
1408683|NCT00353054|Macronutrients
1408684|NCT00353041|topical
1408685|NCT00353041|anesthetic
1408686|NCT00353041|pain
1408687|NCT00353028|Fluvoxamine Maleate
1408688|NCT00353028|Depression
1408689|NCT00353028|Children and Adolescents
1408690|NCT00353015|Gastrointestinal cancer
1408691|NCT00353015|high grade gastrointestinal neuroendocrine carcinoma
1408692|NCT00353015|High grade neuroendocrine carcinoma of unknown primary site
1408693|NCT00353015|Cisplatin
1408694|NCT00353015|Platinol-AQ
1408695|NCT00353015|Platinol
1408696|NCT00353015|CDDP
1408697|NCT00353015|CPT-11
1408698|NCT00353015|Irinotecan
1408699|NCT00353002|Pain
1408700|NCT00353002|Ametop
1408701|NCT00353002|Liposomal Lidocaine
1408702|NCT00353002|Venous cannulation
1408703|NCT00352976|Bone Marrow transplant
1408704|NCT00352976|stem cell transplant
1408705|NCT00352976|cord blood transplant
1408706|NCT00352976|total body irradiation
1408707|NCT00352976|thymic shielding
1408708|NCT00352963|Open, phase 3, Infanrix hexa™, Hib-MenC, co-administered
1408709|NCT00352950|NSCLC, Lung cancer
1408710|NCT00352950|Panitumumab
1408711|NCT00352950|Sirolimus
1408712|NCT00352950|mTOR
1408713|NCT00352950|Monoclonal antibody
1408714|NCT00352937|Coronary Arteriosclerosis
1408715|NCT00352937|Tomography, X-Ray Computed
1408716|NCT00352937|Tomography, Emission-Computed, Single-Photon
1408720|NCT00352911|HIV-1
1408721|NCT00352885|Cancer
1408722|NCT00352885|IL-2 therapy
1408723|NCT00352885|Antidepressant
1408724|NCT00352885|Immune system
1408725|NCT00352885|Neuroendocrine response
1408726|NCT00352872|Pharmacogenetics
1408727|NCT00352872|Toxicity
1408728|NCT00352872|Pre-Menopausal
1408729|NCT00352872|Women
1408730|NCT00352872|Doxorubicin
1408731|NCT00352872|Cyclophosphamide
1408732|NCT00352872|Breast Cancer
1408733|NCT00352872|Chemotherapy
1408734|NCT00352859|Cancer
1408735|NCT00352859|Renal Cell Cancer
1408736|NCT00352859|RCC
1408737|NCT00352846|Non-Hodgkin's Lymphoma
1408738|NCT00352846|Lymphoma
1408739|NCT00352846|Zoledronic Acid
1408740|NCT00352846|Zoledronate
1408741|NCT00352846|Zometa
1408742|NCT00352846|Vitamin D
1408743|NCT00352846|Calcium Carbonate
1408744|NCT00352846|Bone Loss
1408745|NCT00352833|gastric cancer
1408746|NCT00352833|investigational drug
1408747|NCT00352833|adjuvant therapy
1408748|NCT00352833|intraoperative
1408749|NCT00352833|intraperitoneal
1408750|NCT00352833|EpCAM-positive tumor
1408751|NCT00352820|Caregiver
1408752|NCT00352820|Brain cancer
1408753|NCT00352820|Glioma
1408754|NCT00352820|Questionnaire
1408755|NCT00352820|Survey
1408756|NCT00352820|Interview
1408757|NCT00352807|Cataract
1408758|NCT00352794|Combination chemotherapy
1408759|NCT00352794|Myelofibrosis (MF)
1408760|NCT00352781|nicotine replacement therapy
1408761|NCT00352781|smoking cessation
1408762|NCT00352768|Fluvoxamine Maleate
1408763|NCT00352768|OCD
1408764|NCT00352768|Children and Adolescents
1408765|NCT00352742|Multiple myeloma
1408766|NCT00352742|bortezomib
1408767|NCT00352742|ATN-224
1408768|NCT00352742|refractory
1408769|NCT00352742|relapsed
1408770|NCT00352742|antiangiogenic
1408771|NCT00352729|Burns
1408772|NCT00352729|ACell
1408773|NCT00352729|Donor Site
1408774|NCT00352703|Oral mucositis
1408775|NCT00352703|Non-Hodgkin's lymphoma (NHL)
1408776|NCT00352703|conditioning chemotherapy
1408777|NCT00352703|autologous PBSCT
1408778|NCT00352703|multiple myeloma (MM)
1408779|NCT00352703|Melphalan
1408780|NCT00352664|Advanced Cancer
1408781|NCT00352664|Cancer Pain
1408782|NCT00352664|Donepezil
1408783|NCT00352664|Sedation
1408784|NCT00352664|Placebo
1408785|NCT00352651|Acute Herpes Zoster (AHZ)
1408786|NCT00352651|Postherpetic Neuralgia (PHN)
1408787|NCT00352651|Pregabalin
1408788|NCT00352651|Lyrica
1408789|NCT00352651|Pain
1408790|NCT00352638|colon cancer
1408791|NCT00352638|rectal cancer
1408792|NCT00352625|Tendonitis
1408793|NCT00352625|Bursitis
1408794|NCT00352625|Pain
1408795|NCT00352625|Shoulder Pain
1408796|NCT00352625|Elbow Pain
1408797|NCT00352625|Knee Pain
1408798|NCT00352625|Tendon Injury
1408799|NCT00352625|Muscle, Bone and Cartilage Disorders
1408800|NCT00352612|clinical trial
1408801|NCT00352612|randomized
1408802|NCT00352612|blinded
1408803|NCT00352612|controlled
1408804|NCT00352599|Neurofibromatosis Type 1
1408805|NCT00352599|NF1
1408806|NCT00352599|Lovastatin
1408807|NCT00352599|statin
1408808|NCT00352586|Classical Conditioning
1408809|NCT00352586|Learning
1408810|NCT00352586|NMDA
1408811|NCT00352586|Startle
1408812|NCT00352586|Eyeblink
1408813|NCT00352586|Anxiety
1408814|NCT00352586|Fear Conditioning
1408815|NCT00352586|Fear Potentiated Startle
1408816|NCT00352586|Extinction
1408817|NCT00352586|D-cycloserine
1408818|NCT00352586|Healthy Volunteer
1408819|NCT00352586|HV
1408820|NCT00352586|Normal Control
1408821|NCT00352573|Ethics, Clinical
1408822|NCT00352573|Physician's Role
1408823|NCT00352573|Health Care Rationing
1408824|NCT00352573|Knowledge, Attitudes, Practices
1408825|NCT00352573|Questionnaires
1408826|NCT00352573|Survey
1408827|NCT00352573|Ethics
1408828|NCT00352560|Patients with Paroxysmal Atrial Fibrillation (PAF)
1408829|NCT00352547|Immunosuppresant
1408830|NCT00352547|Genetic Polymorphism
1408831|NCT00352547|Drug Metabolism
1408832|NCT00352547|Pharmacogenetics
1408833|NCT00352547|Rapamycin
1408834|NCT00352521|adult anaplastic astrocytoma
1408835|NCT00352521|adult mixed glioma
1408836|NCT00352521|adult giant cell glioblastoma
1408837|NCT00352521|adult gliosarcoma
1408838|NCT00352521|recurrent adult brain tumor
1408839|NCT00352521|adult glioblastoma
1408840|NCT00352521|adult anaplastic ependymoma
1408841|NCT00352521|adult anaplastic oligodendroglioma
1408842|NCT00352521|adult pineal gland astrocytoma
1408843|NCT00352508|Internet, dietary advice, saturated fat
1408844|NCT00352495|childhood low-grade cerebral astrocytoma
1408845|NCT00352495|recurrent childhood cerebellar astrocytoma
1408846|NCT00352495|recurrent childhood cerebral astrocytoma
1408847|NCT00352495|childhood oligodendroglioma
1408848|NCT00352495|neurofibromatosis type 1
1408849|NCT00352495|recurrent childhood visual pathway and hypothalamic glioma
1408850|NCT00352495|untreated childhood visual pathway and hypothalamic glioma
1408851|NCT00352482|Pulmonary Hypertension
1408852|NCT00352482|Idiopathic Pulmonary Fibrosis
1408853|NCT00352469|Alcoholism
1408854|NCT00352469|Anxiety
1408855|NCT00352469|GAD
1408856|NCT00352469|PTSD
1408857|NCT00352469|Panic Disorder
1408858|NCT00352469|OCD
1408859|NCT00352456|Amygdala
1408860|NCT00352456|Facial Affect
1408861|NCT00352456|Instrumental Learning
1408862|NCT00352456|Psychopathy
1408863|NCT00352456|Emotion
1408864|NCT00352456|Orbitofrontal Cortex
1408865|NCT00352456|Healthy Volunteer
1408866|NCT00352456|HV
1408867|NCT00352443|adult grade III lymphomatoid granulomatosis
1408868|NCT00352443|recurrent adult grade III lymphomatoid granulomatosis
1408869|NCT00352443|Waldenstrom macroglobulinemia
1408870|NCT00352443|recurrent adult Burkitt lymphoma
1408871|NCT00352443|stage IV adult Burkitt lymphoma
1408872|NCT00352443|recurrent adult diffuse large cell lymphoma
1408873|NCT00352443|recurrent adult diffuse mixed cell lymphoma
1408874|NCT00352443|recurrent adult diffuse small cleaved cell lymphoma
1408875|NCT00352443|recurrent adult immunoblastic large cell lymphoma
1408876|NCT00352443|recurrent adult lymphoblastic lymphoma
1408877|NCT00352443|recurrent grade 1 follicular lymphoma
1408878|NCT00352443|recurrent grade 2 follicular lymphoma
1408879|NCT00352443|recurrent grade 3 follicular lymphoma
1408880|NCT00352443|recurrent mantle cell lymphoma
1408881|NCT00352443|recurrent marginal zone lymphoma
1408882|NCT00352443|recurrent small lymphocytic lymphoma
1408883|NCT00352443|stage IV adult diffuse large cell lymphoma
1408884|NCT00352443|stage IV adult diffuse mixed cell lymphoma
1408885|NCT00352443|stage IV adult diffuse small cleaved cell lymphoma
1408886|NCT00352443|stage IV adult immunoblastic large cell lymphoma
1408887|NCT00352443|stage IV adult lymphoblastic lymphoma
1408888|NCT00352443|stage IV grade 1 follicular lymphoma
1408889|NCT00352443|stage IV grade 2 follicular lymphoma
1408890|NCT00352443|stage IV grade 3 follicular lymphoma
1408891|NCT00352443|stage IV mantle cell lymphoma
1408892|NCT00352443|stage IV marginal zone lymphoma
1408893|NCT00352443|stage IV small lymphocytic lymphoma
1408894|NCT00352443|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1408895|NCT00352443|nodal marginal zone B-cell lymphoma
1408896|NCT00352443|splenic marginal zone lymphoma
1408897|NCT00352443|unspecified adult solid tumor, protocol specific
1408898|NCT00352443|anaplastic large cell lymphoma
1408899|NCT00352443|angioimmunoblastic T-cell lymphoma
1408900|NCT00352443|adult nasal type extranodal NK/T-cell lymphoma
1408901|NCT00352430|Nitric Oxide
1408902|NCT00352430|PDE Inhibitors
1408903|NCT00352430|Pulmonary Hypertension
1408904|NCT00352430|Sickle Cell
1408905|NCT00352430|Thalassemia
1408906|NCT00352430|Sickle Cell Anemia
1408907|NCT00352404|Endomicroscopy
1408908|NCT00352404|Chromoendoscopy
1408909|NCT00352404|Chromoscopy
1408910|NCT00352404|Ulcerative Colitis
1408911|NCT00352404|Intraepithelial Neoplasia
1408912|NCT00352391|Non-Small Cell Lung Cancer
1408913|NCT00352391|Head And Neck Cancer
1408914|NCT00352391|Lung Cancer
1408915|NCT00352391|Bronchoscopy
1408916|NCT00352391|Laryngoscopy
1408917|NCT00352391|NSCLC
1408918|NCT00352391|Disease Free Survival
1408919|NCT00352391|Current Smoker
1408920|NCT00352391|Former Smoker
1408921|NCT00352378|Primary
1408922|NCT00352352|Traditional Chinese Medicine (TCM)
1408923|NCT00352352|Alternative Medicine (AM)
1408924|NCT00352352|Tongue Acupuncture (TAC)
1408925|NCT00352352|Autism Spectrum Disorder (ASD)
1408926|NCT00352352|Autism
1408927|NCT00352352|Children
1408928|NCT00352339|Schizophrenia
1408929|NCT00352339|Switching
1408930|NCT00352339|Early stage
1408931|NCT00352339|Risperidone
1408932|NCT00352339|Aripirazole
1408933|NCT00352313|adult anaplastic oligodendroglioma
1408934|NCT00352313|adult gliosarcoma
1408935|NCT00352313|adult mixed glioma
1408936|NCT00352313|adult anaplastic astrocytoma
1408937|NCT00352313|recurrent adult brain tumor
1408938|NCT00352313|adult glioblastoma
1408939|NCT00352313|adult giant cell glioblastoma
1408940|NCT00352287|Visceral fat
1408941|NCT00352287|Impaired glucose tolerance
1408942|NCT00352287|Insulin resistance
1408943|NCT00352287|Growth hormone
1408944|NCT00352287|Thiazolidinedione
1408945|NCT00352261|Barrett's Esophagus
1408946|NCT00352248|Alternative Medicine (AM)
1408947|NCT00352248|Traditional Chinese Medicine
1408948|NCT00352248|Tongue Acupuncture
1408949|NCT00352248|Autistic Spectrum Disorder
1408950|NCT00352248|Autism
1408951|NCT00352248|Children
1408952|NCT00352235|Chronic hepatitis C
1408953|NCT00352235|KRN7000
1408954|NCT00352235|a-GalCer
1408955|NCT00352235|immunotherapy
1408956|NCT00352235|Natural Killer T cells
1408957|NCT00352235|interferon
1408958|NCT00352222|iliac arteries
1408959|NCT00352222|implantation
1408960|NCT00352222|treatment of atherosclerotic disease
1408961|NCT00352222|stenosed
1408962|NCT00352222|occlusive
1408963|NCT00352209|Cyclophosphamide
1408964|NCT00352209|Preparative Regimens
1408965|NCT00352209|Risk Factors
1408966|NCT00352209|Chart Review
1408967|NCT00352209|Incidence
1408968|NCT00352196|Asperger's Disorder
1408969|NCT00352196|Risperidone
1408970|NCT00352196|Magnetic Resonance Spectroscopy
1408971|NCT00352196|Social Skills
1408972|NCT00352183|Hyperlipidemia Combined
1408973|NCT00352183|Combination of fenofibrate and simvastatin
1408974|NCT00352170|calcium
1408975|NCT00352170|vitamin D
1408976|NCT00352170|secondary hyperparathyroidism
1408977|NCT00352170|osteoporotic fractures
1408978|NCT00352157|Soy
1408979|NCT00352157|Dermatology
1408980|NCT00352157|Skin
1408981|NCT00352157|Hair
1408982|NCT00352157|Finger Nails
1408983|NCT00352157|Weight Loss
1408984|NCT00352157|Body Mass Index
1408985|NCT00352157|Photoaging of Skin
1408986|NCT00352157|Skin Wrinkling
1408987|NCT00352131|unspecified adult solid tumor, protocol specific
1408988|NCT00352131|stage II pancreatic cancer
1408989|NCT00352131|stage III pancreatic cancer
1408990|NCT00352131|stage IV pancreatic cancer
1408991|NCT00352131|recurrent pancreatic cancer
1408992|NCT00352118|oral complications of radiation therapy
1408993|NCT00352118|oral complications of chemotherapy
1408994|NCT00352118|mucositis
1408995|NCT00352118|xerostomia
1408996|NCT00352118|stage III squamous cell carcinoma of the hypopharynx
1408997|NCT00352118|stage IV squamous cell carcinoma of the hypopharynx
1408998|NCT00352118|stage III squamous cell carcinoma of the larynx
1408999|NCT00352118|stage IV squamous cell carcinoma of the larynx
1409000|NCT00352118|stage III squamous cell carcinoma of the lip and oral cavity
1409001|NCT00352118|stage IV squamous cell carcinoma of the lip and oral cavity
1409002|NCT00352118|stage III squamous cell carcinoma of the oropharynx
1409003|NCT00352118|stage IV squamous cell carcinoma of the oropharynx
1409004|NCT00352105|stage III squamous cell carcinoma of the hypopharynx
1409005|NCT00352105|stage IV squamous cell carcinoma of the hypopharynx
1409006|NCT00352105|stage III squamous cell carcinoma of the larynx
1409007|NCT00352105|stage IV squamous cell carcinoma of the larynx
1409008|NCT00352105|stage III squamous cell carcinoma of the lip and oral cavity
1409009|NCT00352105|stage IV squamous cell carcinoma of the lip and oral cavity
1409010|NCT00352105|stage III squamous cell carcinoma of the oropharynx
1409011|NCT00352105|stage IV squamous cell carcinoma of the oropharynx
1409012|NCT00352092|Kidney disease
1409013|NCT00352092|Renal transplant
1409014|NCT00352092|HLA Identical
1409015|NCT00352092|Living Donor
1409016|NCT00352092|Corticosteroid free
1409017|NCT00352092|Calcineurin sparing
1409018|NCT00352092|Adults
1409019|NCT00352079|transitional cell carcinoma of the bladder
1409020|NCT00352079|stage 0 bladder cancer
1409021|NCT00352079|stage I bladder cancer
1409022|NCT00352079|recurrent bladder cancer
1409023|NCT00352066|Human Immunodeficiency Virus
1409024|NCT00352066|anti-retroviral therapy
1409025|NCT00352066|nucleoside analogue
1409026|NCT00352066|reverse transcriptase
1409027|NCT00352066|apricitabine
1409028|NCT00352066|tipranavir
1409029|NCT00352066|bioequivalence
1409030|NCT00352066|drug-drug interaction
1409031|NCT00352066|pharmacokinetics
1409032|NCT00352053|Phase 3
1409033|NCT00352053|Randomized, Double-Blind
1409034|NCT00352053|Control
1409035|NCT00352053|Treatment-Experienced
1409036|NCT00352053|OBR
1409037|NCT00352053|Optimized background regimen
1409038|NCT00352053|Highly Active Antiretroviral Therapy
1409039|NCT00352053|HAART
1409040|NCT00352053|HIV
1409041|NCT00352053|HIV-1
1409042|NCT00352053|AIDS Virus
1409043|NCT00352053|Human Immunodeficiency Virus
1409044|NCT00352053|Acquired Immune Deficiency Syndrome Virus
1409045|NCT00352053|Virus
1409046|NCT00352053|Human Immunodeficiency
1409047|NCT00352053|Pediatrics
1409048|NCT00352027|Hodgkin's Disease
1409049|NCT00352014|Monitoring of antiplatelet therapy
1409050|NCT00352014|antiplatelet therapy
1409051|NCT00352014|platelet function assays
1409052|NCT00352014|Aspirin
1409053|NCT00352014|Clopidogrel
1409054|NCT00352014|elective PCI
1409055|NCT00352001|refractory anemia with excess blasts
1409056|NCT00352001|previously treated myelodysplastic syndromes
1409057|NCT00352001|chronic myelomonocytic leukemia
1409058|NCT00352001|de novo myelodysplastic syndromes
1409059|NCT00352001|secondary myelodysplastic syndromes
1409060|NCT00351988|Lung Cancer
1409061|NCT00351988|Non-Small Cell Lung Cancer
1409062|NCT00351988|Breast Cancer
1409063|NCT00351988|Psychosocial
1409064|NCT00351988|Behavioral
1409065|NCT00351988|Caregiver
1409066|NCT00351988|Interview
1409067|NCT00351988|Questionnaire
1409068|NCT00351988|Minority Caregiver
1409069|NCT00351988|Non-Minority Caregiver
1409070|NCT00351988|Survey
1409071|NCT00351962|lung neoplasms
1409072|NCT00351962|metastatic lung cancer
1409073|NCT00351962|stereotactic radiation
1409074|NCT00351949|Advanced or metastatic renal cell carcinoma
1409075|NCT00351949|IMP321
1409076|NCT00351949|Monotherapy
1409077|NCT00351949|LAG-3
1409078|NCT00351949|CD223
1409079|NCT00351936|Schizophrenia
1409080|NCT00351936|Diabetes
1409081|NCT00351936|Obesity
1409082|NCT00351936|Olanzapine
1409083|NCT00351936|Insulin Resistance
1409084|NCT00351910|Major Depressive Disorder
1409085|NCT00351910|MDD
1409086|NCT00351884|Type 2 diabetes
1409087|NCT00351884|vildagliptin
1409088|NCT00351884|Hemoglobin A1c
1409089|NCT00351871|HCV
1409090|NCT00351858|Breast Cancer
1409091|NCT00351858|investigational drug
1409092|NCT00351858|drug therapy
1409093|NCT00351858|Antineoplastic Protocols
1409094|NCT00351858|Immunotherapy
1409095|NCT00351858|Metastatic breast cancer
1409096|NCT00351858|Advanced breast cancer
1409097|NCT00351858|Stage III to IV breast cancer
1409098|NCT00351858|Hormonal therapy refractory
1409099|NCT00351858|Failure of hormonal therapy
1409100|NCT00351858|Her-2/neu expressing breast cancer
1409101|NCT00351858|low to moderate Her-2/neu expression
1409102|NCT00351832|Type 2 diabetes
1409103|NCT00351832|Vildagliptin
1409104|NCT00351832|Hemoglobin A1c
1409105|NCT00351819|Testosterone
1409106|NCT00351819|Pain
1409107|NCT00351819|Opioid
1409108|NCT00351819|Hypogonadism
1409109|NCT00351806|acute intracerebral infarction
1409110|NCT00351780|fractional flow reserve
1409111|NCT00351780|bifurcation
1409112|NCT00351780|stent
1409113|NCT00351767|Diabetes
1409114|NCT00351767|Dabetic Feet
1409115|NCT00351741|Burns
1409116|NCT00351715|Sublingual Methadone
1409117|NCT00351715|Cancer related breakthrough pain
1409118|NCT00351715|feasibility study
1409119|NCT00351715|Phase II/open label
1409120|NCT00351715|Outpatients
1409121|NCT00351715|Safety/ efficacy
1409122|NCT00351715|previously receiving opioids
1409123|NCT00351715|speak English
1409124|NCT00351702|Preventive therapy
1409125|NCT00351689|Probiotic bacteria
1409126|NCT00351689|cutaneous immune homeostasis
1409127|NCT00351689|UV radiation
1409128|NCT00351689|dietary supplement
1409129|NCT00351676|Drug Therapy
1409130|NCT00351676|Hospitals, Teaching
1409131|NCT00351676|Hospitals, Community
1409132|NCT00351676|Interprofessional relations
1409133|NCT00351676|Patient Care Team
1409134|NCT00351676|Pharmacists
1409135|NCT00351676|Pharmacy Service, Hospital
1409136|NCT00351676|Comparative Study
1409137|NCT00351676|Hospitalization
1409138|NCT00351663|Venous Thrombosis
1409139|NCT00351663|Critical Illness
1409140|NCT00351663|Blood Coagulation
1409141|NCT00351663|Factor Xa
1409142|NCT00351650|Imaging
1409143|NCT00351650|Type 1 Diabetes Mellitus (T1DM)
1409144|NCT00351650|Islet
1409145|NCT00351650|B Cell Mass
1409146|NCT00351650|Pet Scan
1409147|NCT00351650|Type 1 Diabetes
1409148|NCT00351650|T1DM
1409149|NCT00351650|Pancreas
1409150|NCT00351650|Healthy Volunteer
1409151|NCT00351650|HV
1409152|NCT00351637|Sublingual methadone
1409153|NCT00351637|iatrogenic
1409154|NCT00351637|treatment related incident breakthrough pain
1409155|NCT00351637|feasibility study
1409156|NCT00351637|Phase II/open-label
1409157|NCT00351637|inpatients
1409158|NCT00351637|Safety/efficacy
1409159|NCT00351637|Cancer related breakthrough pain
1409160|NCT00351637|previously receiving opioids
1409161|NCT00351637|speak English
1409162|NCT00351624|DHA supplementation
1409163|NCT00351624|Cognitive function
1409164|NCT00351624|Preschool children
1409165|NCT00351624|Attention and behavior
1409166|NCT00351624|Healthy Children
1409167|NCT00351611|epilepsy partial seizure treatment with pregabalin or placebo
1409168|NCT00351611|vision testing
1409169|NCT00351598|Tumour Volume
1409170|NCT00351598|Prognostic value
1409171|NCT00351585|Vildagliptin
1409172|NCT00351585|Type 2 diabetes
1409173|NCT00351585|Insulin secretion
1409174|NCT00351585|Beta cell
1409175|NCT00351572|colon cancer
1409176|NCT00351559|allograft
1409177|NCT00351559|rejection
1409178|NCT00351559|biopsy
1409179|NCT00351559|gene
1409180|NCT00351559|expression
1409181|NCT00351559|cardiac
1409182|NCT00351559|heart
1409183|NCT00351559|transplant
1409184|NCT00351546|Vildagliptin
1409185|NCT00351546|Type 2 diabetes
1409186|NCT00351546|Insulin sensitivity
1409187|NCT00351546|Insulin action
1409188|NCT00351533|Respiratory distress syndrome, adult
1409189|NCT00351533|Acute lung injury
1409190|NCT00351533|Acute respiratory distress syndrome
1409191|NCT00351533|ARDS, human
1409192|NCT00351533|Fish oils
1409193|NCT00351533|Fatty Acids, Omega-3
1409194|NCT00351533|Docosahexaenoic Acids
1409195|NCT00351533|Eicosapentaenoic Acid
1409196|NCT00351520|Anthoponotic Cutaneous leishmaniasis
1409197|NCT00351520|Glucantime
1409198|NCT00351520|Miltefosine
1409199|NCT00351507|Vildagliptin
1409200|NCT00351507|Type 2 diabetes
1409201|NCT00351494|embolization
1409202|NCT00351494|contrast enhanced ultrasound
1409203|NCT00351494|myoma
1409204|NCT00351494|uterine artery
1409205|NCT00351494|microvascularisation
1409206|NCT00351481|IVF
1409207|NCT00351481|endometrial receptivity
1409208|NCT00351481|embryo implantation
1409209|NCT00351481|recurrent implantation failure
1409210|NCT00351468|eltrombopag olamine
1409211|NCT00351468|SB-497115-GR
1409212|NCT00351468|idiopathic thrombocytopenic purpura
1409213|NCT00351468|thrombocytopenia
1409214|NCT00351468|ITP
1409215|NCT00351468|platelets
1409216|NCT00351455|hernia
1409217|NCT00351455|incisional hernia
1409218|NCT00351455|ventral hernia
1409219|NCT00351455|umbilical hernia
1409220|NCT00351442|Host Resistance
1409221|NCT00351429|Glaucoma
1409222|NCT00351429|Trabeculectomy
1409223|NCT00351429|Sutures
1409224|NCT00351416|GnRH deficiency
1409225|NCT00351416|GnRH antagonist
1409226|NCT00351416|Letrozole
1409227|NCT00351416|GnRH
1409228|NCT00351416|FSH
1409229|NCT00351416|LH
1409230|NCT00351416|Inhibins
1409231|NCT00351403|Chronic HCV infection
1409232|NCT00351403|Genotype 1
1409233|NCT00351403|Individually adapted therapy
1409234|NCT00351403|Peginterferon alfa-2b
1409235|NCT00351403|Ribavirin
1409236|NCT00351403|Sustained viral response (SVR)
1409237|NCT00351390|congestive heart failure treatment
1409238|NCT00351390|congestive heart failure, prognosis
1409239|NCT00351390|NT-proBNP testing
1409240|NCT00351377|Autoimmune disease, mycophenolate, GI problems
1409241|NCT00351364|atherosclerosis
1409242|NCT00351364|inflammation
1409243|NCT00351364|leukotriene blockade
1409244|NCT00351364|endothelial function
1409245|NCT00351351|Kidney Stones
1409246|NCT00351351|Renal Calculi
1409247|NCT00351312|Pressure ulcers
1409248|NCT00351312|socks
1409249|NCT00351312|foot pressure
1409250|NCT00351299|Delirium
1409251|NCT00351299|Agitation
1409252|NCT00351299|Sedation
1409253|NCT00351299|Dexmedetomidine
1409254|NCT00351299|Surgical
1409255|NCT00351286|peripheral arterial disease
1409256|NCT00351286|peripheral vascular disease
1409257|NCT00351286|claudication
1409258|NCT00351273|Chlamydia
1409259|NCT00351260|Bifurcation
1409260|NCT00351260|Coronary
1409261|NCT00351260|Stenosis
1409262|NCT00351260|Stent
1409263|NCT00351260|drug elution
1409264|NCT00351247|Myocardial Infarction
1409265|NCT00351247|Primary PCI
1409266|NCT00351247|Postconditioning
1409267|NCT00351247|MRI
1409268|NCT00351234|Diabetes Mellitus Type I,
1409269|NCT00351234|Hypoglycemia,
1409270|NCT00351234|Carnitine
1409271|NCT00351208|Spinal cord stimulation
1409272|NCT00351208|Spinal cord stimulation efficacy
1409273|NCT00351208|Spinal cord stimulators
1409274|NCT00351208|Stimulation frequencies
1409275|NCT00351208|Stimulation pulse-widths
1409276|NCT00351208|Varying settings
1409277|NCT00351195|Hepatocellular carcinoma
1409278|NCT00351195|Etoposide
1409279|NCT00351195|Oxaliplatin
1409280|NCT00351195|Capecitabine
1409281|NCT00351182|Scrub typhus
1409282|NCT00351182|Telithromycin
1409283|NCT00351182|Doxycycline
1409284|NCT00351182|5 day Course of Telithromycin versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus
1409285|NCT00351169|Major Depressive Disorder
1409286|NCT00351169|MDD
1409287|NCT00351156|Gaucher Disease
1409288|NCT00351156|Gaucher Disease, Type 1
1409289|NCT00351156|Gaucher Disease, Type 2
1409290|NCT00351156|Gaucher Disease, Type 3
1409291|NCT00351156|Neuronopathic Gaucher Disease
1409292|NCT00351156|Non-Neuronopathic Gaucher Disease
1409293|NCT00351156|Lysosomal Storage Disease
1409294|NCT00351156|Metabolism, Inborn Errors
1409295|NCT00351156|Metabolic Diseases
1409296|NCT00351156|Sphingolipidoses
1409297|NCT00351156|Genetic Diseases, Inborn
1409298|NCT00351143|QoL
1409299|NCT00351143|Asthma
1409300|NCT00351143|asthma compliance enhancement
1409301|NCT00351143|Salmeterol/fluticasone
1409302|NCT00351143|Total control
1409303|NCT00351143|SERETIDE
1409304|NCT00351143|FEV1
1409305|NCT00351130|Hypertension,
1409306|NCT00351130|stage 1 hypertension,
1409307|NCT00351130|stage 2 hypertension,
1409308|NCT00351130|valsartan,
1409309|NCT00351130|amlodipine,
1409310|NCT00351117|St. John's Wort
1409311|NCT00351117|Selective Serotonin Receptor Inhibitor
1409312|NCT00351117|Microvasculature
1409313|NCT00351117|Natural Health Products
1409314|NCT00351104|Sprain
1409315|NCT00351104|Strain
1409316|NCT00351104|Pain
1409317|NCT00351104|Ankle Pain
1409318|NCT00351104|Muscle, Bone and Cartilage Disorders
1409319|NCT00351078|Cystic fibrosis
1409320|NCT00351078|Nonsense mutation
1409321|NCT00351078|Premature stop codon
1409322|NCT00351078|CF
1409323|NCT00351078|PTC124
1409324|NCT00351065|erectile dysfunction, PDE-5 inhibitor
1409325|NCT00351052|Pimecrolimus, Atopic Dermatitis, Eczema, Pediatric
1409326|NCT00351026|opioid dependence
1409327|NCT00351026|methadone
1409328|NCT00351026|HIV
1409329|NCT00351013|malaria
1409330|NCT00351013|Plasmodium falciparum
1409331|NCT00351013|Tropica Nosode
1409332|NCT00351013|Homeopathy
1409333|NCT00351000|Schizophrenia
1409334|NCT00351000|Ziprasidone
1409335|NCT00351000|Diabetes
1409336|NCT00351000|Insulin Resistance
1409337|NCT00350987|Procalcitonin, guidelines, LRTI, non-inferiority
1409338|NCT00350987|COLD
1409339|NCT00350961|Cholangiocarcinoma
1409340|NCT00350961|Fixed dose rate
1409341|NCT00350961|Gemcitabine
1409342|NCT00350961|Oxaliplatin
1409343|NCT00350961|Capecitabine
1409344|NCT00350948|Ovary
1409345|NCT00350935|fMRI
1409346|NCT00350935|Visual perception
1409347|NCT00350935|Attention
1409348|NCT00350909|drug abuse
1409349|NCT00350896|trapezotrapezoidial
1409350|NCT00350896|scaphotrapezial
1409351|NCT00350896|thumb
1409352|NCT00350896|pain
1409353|NCT00350896|orthoses
1409354|NCT00350896|Osteoarthritis in the BTOA concerns the trapezometacarpal joint
1409355|NCT00350883|Cognitive Therapy
1409356|NCT00350883|Negative Symptoms
1409357|NCT00350883|Functional Outcomes
1409358|NCT00350883|Schizophrenia
1409359|NCT00350883|Schizoaffective Disorder
1409360|NCT00350870|disulfiram
1409361|NCT00350870|cognitive behavioral therapy
1409362|NCT00350870|contingency management
1409363|NCT00350870|drug abuse therapy
1409364|NCT00350870|educational/resource design/development
1409365|NCT00350844|Sickle Cell Disease
1409366|NCT00350844|Pulmonary Hypertension
1409367|NCT00350831|Solid tumor
1409368|NCT00350818|Acute Myelogenous Leukemia
1409369|NCT00350818|Myelodysplastic Syndrome
1409370|NCT00350818|Allogeneic Transplantation
1409371|NCT00350818|Leukemia
1409372|NCT00350818|Azacitidine
1409373|NCT00350818|Vidaza
1409374|NCT00350805|Schizophrenia
1409375|NCT00350805|Time perception
1409376|NCT00350805|Cortical synchronization
1409377|NCT00350805|Electroencephalography
1409378|NCT00350779|Type 2 Diabetes Mellitus
1409379|NCT00350766|Myocardial Infarction
1409380|NCT00350766|Myocardial Ischemia
1409381|NCT00350766|Ventricular Remodeling
1409382|NCT00350766|Bone Marrow Cell Transplantation
1409383|NCT00350766|Stem cells
1409384|NCT00350753|Cholangiocarcinoma
1409385|NCT00350727|relapsed
1409386|NCT00350727|lapatinib
1409387|NCT00350727|Pazopanib
1409388|NCT00350727|glioblastoma
1409389|NCT00350714|HCV (Hepatitis C Virus)
1409390|NCT00350714|MBT (Methacetin Breath Test)
1409391|NCT00350714|Hepatitis C Virus Patients
1409392|NCT00350701|DM type 2
1409393|NCT00350701|Hypogonadism
1409394|NCT00350701|Testosterone
1409395|NCT00350701|AndroGel
1409396|NCT00350688|Bladder,
1409397|NCT00350688|Cancer,
1409398|NCT00350688|Chemoradiation,
1409399|NCT00350688|IMRT,
1409400|NCT00350688|tomotherapy
1409401|NCT00350662|Deferiprone
1409402|NCT00350662|L1
1409403|NCT00350662|Desferrioxamine
1409404|NCT00350662|Hemochromatosis
1409405|NCT00350662|Iron overload
1409406|NCT00350662|Thalassemia
1409407|NCT00350649|behavior modification
1409408|NCT00350649|cognitive behavioral therapy
1409409|NCT00350649|combination therapy
1409410|NCT00350649|drug abuse therapy
1409411|NCT00350649|drug addition
1409412|NCT00350649|human therapy evaluation
1409413|NCT00350649|psychotherapy
1409414|NCT00350649|clinical trial phase II
1409415|NCT00350649|coping
1409416|NCT00350649|drug and alcohol abstinence
1409417|NCT00350649|longitudinal human study
1409418|NCT00350649|outcomes research
1409419|NCT00350649|outpatient care
1409420|NCT00350649|psychological reinforcement
1409421|NCT00350649|therapy compliance
1409422|NCT00350649|behavior and social research tag
1409423|NCT00350649|human subjects
1409424|NCT00350649|neuropsychological test
1409425|NCT00350649|patient oriented research
1409426|NCT00350636|OAB, anticholineric, oxybutynin, urge urinary incontinence
1409427|NCT00350623|AIDS
1409428|NCT00350610|cognitive behavior therapy
1409429|NCT00350610|computer assisted instruction
1409430|NCT00350610|drug abuse therapy
1409431|NCT00350610|educational resource design and development
1409432|NCT00350597|Malignant Melanoma
1409433|NCT00350597|Adjuvant Therapy
1409434|NCT00350597|Cytokine Therapy
1409435|NCT00350597|Immunologic Testing
1409436|NCT00350584|Mindfulness
1409437|NCT00350584|Psychoeducation
1409438|NCT00350584|Telehealth Intervention
1409439|NCT00350571|behavior therapy
1409440|NCT00350571|counseling
1409441|NCT00350571|drug abuse therapy
1409442|NCT00350571|outpatient care
1409443|NCT00350571|therapy compliance
1409444|NCT00350571|clinical trial phase I
1409445|NCT00350571|coping
1409446|NCT00350571|outcomes research
1409447|NCT00350571|satisfaction
1409448|NCT00350571|social psychology
1409449|NCT00350571|patient oriented research
1409450|NCT00350532|pain, chronic pain
1409451|NCT00350532|acetylcholine
1409452|NCT00350532|clonidine
1409453|NCT00350532|a2-adrenergic agonists
1409454|NCT00350532|alpha2-adrenergic agonists
1409455|NCT00350519|Hemostasis, Surgical
1409456|NCT00350519|Epoetin alfa
1409457|NCT00350519|Surgery
1409458|NCT00350519|Abdomen
1409459|NCT00350519|Pelvis
1409460|NCT00350519|PROCRIT
1409461|NCT00350519|pRBC
1409462|NCT00350519|Blood transfusion
1409463|NCT00350519|Packed red blood cell transfusion
1409464|NCT00350480|acute uterine bleeding
1409465|NCT00350467|Schizophrenia
1409466|NCT00350467|DSM-IV
1409467|NCT00350467|PANSS
1409468|NCT00350467|informed consent
1409469|NCT00350441|Sildenafil Citrate
1409470|NCT00350441|Cardiopulmonary bypass
1409471|NCT00350441|Open heart surgery
1409472|NCT00350428|Acute primary angle closure
1409473|NCT00350428|Laser preipheral iridotomy
1409474|NCT00350428|Phacoemulsification
1409475|NCT00350415|ulcerative colitis, inflammatory bowel disease
1409476|NCT00350402|Parkinson's disease
1409477|NCT00350402|PD
1409478|NCT00350402|masked faces
1409479|NCT00350402|diminished facial expressivity
1409480|NCT00350402|diminished facial expression
1409481|NCT00350402|high intensity respiratory muscle strength training
1409482|NCT00350402|MST
1409483|NCT00350389|Falls, Older persons
1409484|NCT00350376|asthma
1409485|NCT00350376|allergies
1409486|NCT00350376|Xolair
1409487|NCT00350376|Advair
1409488|NCT00350350|XEROSTOMIA
1409489|NCT00350350|MOUTH DRYNESS
1409490|NCT00350350|ELDERLY
1409491|NCT00350350|ORAL LUBRICANT
1409492|NCT00350298|Monoclonal antibody,
1409493|NCT00350298|Clostridium difficile Associated Diarrhea
1409494|NCT00350285|cannabis
1409495|NCT00350285|marijuana
1409496|NCT00350272|HIV-1 treatment naive
1409497|NCT00349219|first-line
1409498|NCT00349219|second-line
1409499|NCT00349219|targeted therapy
1409500|NCT00350233|Bone Tumors
1409501|NCT00350233|Bone Cancer
1409502|NCT00350233|Prostate Cancer
1409503|NCT00350233|lung cancer
1409504|NCT00350220|Single ventricle
1409505|NCT00350220|Bidirectional Glenn
1409506|NCT00350220|Fontan
1409507|NCT00350220|Congenital cardiac disease
1409508|NCT00350220|Red blood cell transfusion
1409509|NCT00350220|oxygen utilization
1409510|NCT00350220|lactate level
1409511|NCT00350220|hemoglobin level
1409512|NCT00350194|Fatty Acids, Omega-3
1409513|NCT00350168|Blood pressure
1409514|NCT00350168|Venous pressure
1409515|NCT00350168|Systolic pressure
1409516|NCT00350168|Diastolic pressure
1409517|NCT00350168|Pulse pressure
1409518|NCT00350155|Video capsule endoscopy, healthy volunteers, naproxen, omeprazole, lumiracoxib, small bowel
1409519|NCT00350142|Stereotactic Body Radiotherapy (SBRT)
1409520|NCT00350142|pancreas cancer
1409521|NCT00350142|locally advanced
1409522|NCT00350142|local control
1409523|NCT00350142|Gemcitabine
1409524|NCT00350129|glucose
1409525|NCT00350129|vasospasm
1409526|NCT00350129|RVA
1409527|NCT00350129|LDF
1409528|NCT00350129|vasospastic subjects
1409529|NCT00350129|non-vasospastic subjects
1409530|NCT00350116|plaque psoriasis
1409531|NCT00350116|Vitamin B12
1409532|NCT00350090|Anemia
1409533|NCT00350090|Neoplasms
1409534|NCT00350090|Hemoglobin values
1409535|NCT00350077|Burns
1409536|NCT00350064|Metabolic Syndrome
1409537|NCT00350064|Obesity
1409538|NCT00350064|Exercise
1409539|NCT00350064|Diabetes
1409540|NCT00350064|Physical Activity
1409541|NCT00350051|Prostate cancer
1409542|NCT00350051|Metastatic androgen-independent prostate cancer
1409543|NCT00350025|urothelial
1409544|NCT00350025|urologic
1409545|NCT00350025|neoplasm
1409546|NCT00350025|advanced
1409547|NCT00350025|metastatic
1409548|NCT00350012|stroke
1409549|NCT00350012|visual
1409550|NCT00350012|spatial neglect
1409551|NCT00349999|Vibrio cholerae, Cholera, Bangladesh, esophagogastroduodenoscopy, sub-study
1409552|NCT00349973|Schizophrenia
1409553|NCT00349973|Positive symptoms
1409554|NCT00349973|Negative symptoms
1409555|NCT00349973|Cognitive deficits
1409556|NCT00349960|Erythropoiesis stimulating agent
1409557|NCT00349960|Dosing frequency
1409558|NCT00349960|Hemodialysis
1409559|NCT00349960|Therapeutic equivalence
1409560|NCT00349934|Metastatic breast cancer
1409561|NCT00349934|IMP321
1409562|NCT00349934|hLAG-3Ig
1409563|NCT00349934|LAG-3
1409564|NCT00349934|CD223
1409565|NCT00349934|Chemotherapy
1409566|NCT00349934|Paclitaxel
1409567|NCT00349934|Combination therapy
1409568|NCT00349921|pain
1409569|NCT00349921|chronic pain
1409570|NCT00349921|clonidine
1409571|NCT00349921|adenosine
1409572|NCT00349921|complex regional pain syndrome
1409573|NCT00349921|CRPS
1409574|NCT00349921|a2-adrenergic agonists
1409575|NCT00349921|alpha2-adrenergic agonists
1409576|NCT00349908|Atherosclerosis,Wide Neck Aneurysm
1409577|NCT00349895|Percutaneous Transluminal Coronary Angioplasty
1409578|NCT00349895|Stent implantation
1409579|NCT00349869|inflammatory arthritis
1409580|NCT00349869|rheumatoid arthritis
1409581|NCT00349869|knee osteoarthritis
1409582|NCT00349869|arthritis
1409583|NCT00349869|yoga
1409584|NCT00349804|temperature
1409585|NCT00349804|Temperature Homeostasis
1409586|NCT00349791|Natural Menopause
1409587|NCT00349765|cardiovascular disease
1409588|NCT00349765|saturated fat
1409589|NCT00349765|trans fat
1409590|NCT00349765|polyunsaturated fat
1409591|NCT00349765|diet
1409592|NCT00349765|intramyocellular lipid
1409593|NCT00349752|certolizumab pegol
1409594|NCT00349752|Cimzia
1409595|NCT00349752|Crohn's Disease
1409596|NCT00349752|Inflammatory Bowel Disease
1409597|NCT00349739|age related macular degeneration
1409838|NCT00348764|lauromacrogol
1409604|NCT00349713|Plasmodium falciparum Malaria, Mali, adjuvant
1409605|NCT00349700|healing
1409606|NCT00349700|skin
1409607|NCT00349700|infection
1409608|NCT00349700|wound therapy
1409609|NCT00349674|Wegener's granulomatosis,
1409610|NCT00349674|microscopic polyangiitis,
1409611|NCT00349674|ANCA-associated vasculitis,
1409612|NCT00349674|methotrexate,
1409613|NCT00349674|azathioprine
1409614|NCT00349661|clopidogrel
1409615|NCT00349661|omeprazole
1409616|NCT00349648|subacromial
1409617|NCT00349648|impingement
1409618|NCT00349648|acromioplasty
1409619|NCT00349648|physiotherapy
1409620|NCT00349635|Weight loss and diet.
1409621|NCT00349622|amyotrophic lateral sclerosis
1409622|NCT00349622|ALS
1409623|NCT00349622|ceftriaxone
1409624|NCT00349622|cephalosporin antibiotic
1409625|NCT00349622|motor neurons
1409626|NCT00349596|Hypomethylating agent
1409627|NCT00349596|Chemotherapy
1409628|NCT00349596|Relapsed or refractory ALL
1409629|NCT00349596|Acute Lymphocytic Leukemia (ALL)
1409630|NCT00349570|thrombus
1409631|NCT00349570|aspiration catheter
1409632|NCT00349557|Prostate Cancer
1409633|NCT00349557|High-Risk Prostate Cancer
1409634|NCT00349557|1st line therapy
1409635|NCT00349544|Neck pain
1409636|NCT00349544|Cervicalgia
1409637|NCT00349544|Quality of life
1409638|NCT00349544|Disability
1409639|NCT00349518|Chronic and Advanced Phase CML and
1409640|NCT00349518|Philadelphia Chromosome Positive ALL with imatinib intolerance or resistance
1409641|NCT00349505|previous treatment surgery + 6 cycles of platinum based chemotherapy
1409642|NCT00349492|Small Cell Lung Cancer
1409643|NCT00349492|Extensive Disease
1409644|NCT00349492|Chemotherapy
1409645|NCT00349492|Randomisation
1409646|NCT00349479|stroke
1409647|NCT00349479|tissue plasminogen activator
1409648|NCT00349479|t-PA
1409649|NCT00349479|barrier assessment and interactive educational intervention
1409650|NCT00349479|BA-IEI
1409651|NCT00349466|Keratoconjunctivitis Sicca
1409652|NCT00349466|KCS
1409653|NCT00349466|Dry Eye
1409654|NCT00349453|Deferiprone
1409655|NCT00349453|L1
1409656|NCT00349453|Desferrioxamine
1409657|NCT00349453|Hemochromatosis
1409658|NCT00349453|Iron overload
1409659|NCT00349453|Thalassemia
1409660|NCT00349440|Dry eye
1409661|NCT00349427|Insulin
1409662|NCT00349427|BRL49653 /rosiglitazone
1409663|NCT00349427|Type 2 Diabetes Mellitus
1409664|NCT00349414|Advanced glaucoma
1409665|NCT00349414|Refractory glaucoma
1409666|NCT00349414|Cyclophotocoagulation
1409667|NCT00349414|Transscleral cyclophotocoagulation
1409668|NCT00349414|Micropulse transscleral cyclophotocoagulation
1409669|NCT00349401|pain
1409670|NCT00349401|chronic pain
1409671|NCT00349401|morphine
1409672|NCT00349401|ketorolac
1409673|NCT00349388|Mesalamine
1409674|NCT00349388|Ulcerative Colitis
1409675|NCT00349375|Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin
1409676|NCT00349323|Community directed treatment,
1409677|NCT00349323|soil-transmitted helminth infections,
1409678|NCT00349323|treatment coverage,
1409679|NCT00349323|Zambia
1409680|NCT00349284|Hyperlipidemia Combined and features of the metabolic syndrome, efficacy combination fenofibrate ezetimibe
1409681|NCT00349271|Chagas Cardiomyopathy
1409682|NCT00349271|Dilated Cardiomyopathy
1409683|NCT00349271|stem cells
1409684|NCT00349271|Therapeutics
1409685|NCT00349271|Randomized Controlled Trials
1409686|NCT00349258|OHSS
1409687|NCT00349258|PCOS
1409688|NCT00349258|Previous high response
1409689|NCT00349258|GnRH antagonist
1409690|NCT00349258|GnRH agonist
1409691|NCT00349258|IVF
1409692|NCT00349245|Endotracheal
1409693|NCT00349245|Awake fiberoptic intubation
1409694|NCT00349245|Dexmedetomidine
1409695|NCT00349245|Remifentanil
1409696|NCT00349232|childhood obesity
1409697|NCT00349232|lifestyle intervention
1409698|NCT00349232|school health program
1409699|NCT00349232|special primary education
1409700|NCT00349193|Relapsing Remitting Multiple Sclerosis
1409701|NCT00349180|Total Hip Replacement
1409702|NCT00349180|Enoxaparin
1409703|NCT00349167|unspecified adult solid tumor, protocol specific
1409704|NCT00349141|Pandemic influenza
1409705|NCT00349128|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
1409706|NCT00349102|Non-small-cell lung cancer
1409707|NCT00349102|Breath-hold
1409708|NCT00349102|Radiation pneumonitis
1409709|NCT00349102|Serum cytokines
1409710|NCT00349102|LENT-SOMA scale
1409711|NCT00349102|Non-metastatic non-small-cell lung cancer
1409712|NCT00349089|Non-small cell lung cancer
1409713|NCT00349089|adjuvant therapy
1409714|NCT00349089|clinical feasibility rate
1409715|NCT00349050|trigeminal neuralgia
1409716|NCT00349050|neuropathic pain
1409717|NCT00349050|complex regional pain syndrome
1409718|NCT00349050|reflex sympathetic dystrophy
1409719|NCT00349050|pain
1409720|NCT00349050|chronic pain
1409721|NCT00349050|transcranial magnetic stimulation
1409722|NCT00349050|TMS
1409723|NCT00349050|laboratory pain assessment
1409724|NCT00349037|DNA vaccine
1409725|NCT00349037|influenza
1409726|NCT00349037|immunogenicity
1409727|NCT00349037|tolerability
1409728|NCT00349037|PMED
1409729|NCT00349037|efficacy
1409730|NCT00349037|challenge virus
1409731|NCT00349024|unspecified childhood solid tumor, protocol specific
1409732|NCT00349024|pain
1409733|NCT00349024|childhood acute lymphoblastic leukemia
1409734|NCT00349024|childhood Hodgkin lymphoma
1409735|NCT00349024|chondrosarcoma
1409736|NCT00349024|osteosarcoma
1409737|NCT00349024|childhood soft tissue sarcoma
1409738|NCT00349024|Wilms tumor and other childhood kidney tumors
1409739|NCT00349024|neuroblastoma
1409740|NCT00349024|childhood acute myeloid leukemia/other myeloid malignancies
1409741|NCT00349024|childhood large cell lymphoma
1409742|NCT00349024|childhood lymphoblastic lymphoma
1409743|NCT00349024|childhood small noncleaved cell lymphoma
1409744|NCT00349024|childhood rhabdomyosarcoma
1409745|NCT00349024|childhood brain stem glioma
1409746|NCT00349024|childhood central nervous system germ cell tumor
1409747|NCT00349024|childhood cerebellar astrocytoma
1409748|NCT00349024|childhood cerebral astrocytoma/malignant glioma
1409749|NCT00349024|childhood choroid plexus tumor
1409750|NCT00349024|childhood craniopharyngioma
1409751|NCT00349024|childhood ependymoma
1409752|NCT00349024|childhood medulloblastoma
1409753|NCT00349024|childhood meningioma
1409754|NCT00349024|childhood oligodendroglioma
1409755|NCT00349024|childhood atypical teratoid/rhabdoid tumor
1409756|NCT00349024|childhood spinal cord neoplasm
1409757|NCT00349024|childhood supratentorial primitive neuroectodermal tumor
1409758|NCT00349024|childhood visual pathway and hypothalamic glioma
1409759|NCT00349024|chordoma
1409760|NCT00349024|mucositis
1409761|NCT00349024|Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)
1409762|NCT00349011|menopause
1409763|NCT00349011|genetic counseling
1409764|NCT00349011|breast cancer
1409765|NCT00349011|tamoxifen
1409766|NCT00349011|chemoprevention
1409767|NCT00348998|adenocarcinoma of the prostate
1409768|NCT00348998|stage IIB prostate cancer
1409769|NCT00348998|stage IIA prostate cancer
1409770|NCT00348998|stage III prostate cancer
1409771|NCT00348998|stage IV prostate cancer
1409772|NCT00348972|Glargine
1409773|NCT00348972|prediabetes
1409774|NCT00348972|impaired glucose tolerance
1409775|NCT00348972|impaired fasting glucose
1409776|NCT00348959|Haematological Malignancies
1409777|NCT00348959|Autologous Stem Cell Transplantation
1409778|NCT00348959|Allogeneic Stem Cell Transplantation
1409779|NCT00348959|Quality of Life
1409780|NCT00348959|Life Threatening Illness
1409781|NCT00348959|Art in Health Care
1409782|NCT00348959|Randomised Controlled Trial
1409783|NCT00348959|Mixed Methods Research
1409784|NCT00348946|Klinefelter syndrome
1409785|NCT00348946|androgen
1409786|NCT00348946|androgen oxandrolone
1409787|NCT00348933|Developmental Delay
1409788|NCT00348933|Mental Retardation
1409789|NCT00348933|Ataxia
1409790|NCT00348933|Microcephaly
1409791|NCT00348933|Seizures
1409792|NCT00348920|Aortic Valve
1409793|NCT00348920|Aortic Stenosis
1409794|NCT00348920|High Spinal Anesthesia
1409795|NCT00348920|Total Spinal Anesthesia
1409796|NCT00348920|Stress Response
1409797|NCT00348920|Inflammatory Mediators
1409798|NCT00348920|Renal Function
1409799|NCT00348920|Hemodynamic Stability
1409800|NCT00348907|doppler
1409801|NCT00348907|CIVIQ quality of life
1409802|NCT00348907|Hydrotherapy
1409803|NCT00348907|anticoagulants
1409804|NCT00348881|Diphtheria
1409805|NCT00348881|Tetanus
1409806|NCT00348881|Pertussis
1409807|NCT00348881|Hepatitis B Hansenula (HB)
1409808|NCT00348881|Haemophilus influenzae type b
1409809|NCT00348868|HIV Infection
1409810|NCT00348868|Opioid dependence
1409811|NCT00348868|DSM-IV criteria for opioid dependence
1409812|NCT00348855|High Blood Pressure
1409813|NCT00348855|High cardiovascular risk
1409814|NCT00348855|Type 2 diabetes
1409815|NCT00348855|Reaching goals
1409816|NCT00348842|Immunotherapy
1409817|NCT00348829|CHF
1409818|NCT00348829|mitral insufficiency
1409819|NCT00348829|conductance catheter
1409820|NCT00348829|mitral valve repair
1409821|NCT00348816|stage I prostate cancer
1409822|NCT00348816|stage IIB prostate cancer
1409823|NCT00348816|stage IIA prostate cancer
1409824|NCT00348816|stage III prostate cancer
1409825|NCT00348816|stage IV prostate cancer
1409826|NCT00348790|adult grade I meningioma
1409827|NCT00348790|adult grade II meningioma
1409828|NCT00348790|adult grade III meningioma
1409829|NCT00348790|adult malignant hemangiopericytoma
1409830|NCT00348790|adult anaplastic meningioma
1409831|NCT00348790|adult papillary meningioma
1409832|NCT00348790|adult melanocytic lesion
1409833|NCT00348790|recurrent adult brain tumor
1409834|NCT00348777|Visual analogic Scale of pain
1409835|NCT00348777|Womac indice
1409836|NCT00348777|SF-36 quality of life
1409837|NCT00348777|Hydrotherapy
1409839|NCT00348764|Sclerotherapy
1409840|NCT00348738|radiotherapy
1409841|NCT00348738|clinical trial
1409842|NCT00348738|erythropoietin
1409843|NCT00348738|cervix cancer
1409844|NCT00348738|Phase III
1409845|NCT00348738|2 Arms
1409846|NCT00348725|Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus
1409847|NCT00348686|LVH
1409848|NCT00348660|Screening for Hepatitis C in Pregnancy
1409849|NCT00348647|Prevention
1409850|NCT00348647|Exercise
1409851|NCT00348647|Overuse
1409852|NCT00348647|Anterior knee pain syndrome
1409853|NCT00348647|Exertional lower leg pain
1409854|NCT00348647|Prospective
1409855|NCT00348647|Risk factors
1409856|NCT00348647|Hip
1409857|NCT00348634|Constipation, Tegaserod, orocecal transit, colonic transit, gastric emptying
1409858|NCT00348621|cataract surgery
1409859|NCT00348621|refractive correction
1409860|NCT00348621|low vision services
1409861|NCT00348621|nursing home
1409862|NCT00348621|visual impairment
1409863|NCT00348608|Coronary
1409864|NCT00348608|Angiography
1409865|NCT00348608|X-ray
1409866|NCT00348608|CAD
1409867|NCT00348595|Prostate Cancer
1409868|NCT00348569|CT
1409869|NCT00348569|Coronary
1409870|NCT00348569|Cardiac
1409871|NCT00348569|Angiography
1409872|NCT00348569|X-ray
1409873|NCT00348569|CAD
1409874|NCT00348569|Chest pain
1409875|NCT00348543|age-related macula degeneration
1409876|NCT00348543|prophylactic laser treatment
1409877|NCT00348543|exudative complication
1409878|NCT00348530|Systolic heart failure; Therapy; Cardiomyopathy
1409879|NCT00348491|Dental surgery
1409880|NCT00348491|acute pain
1409881|NCT00348491|lumiracoxib
1409882|NCT00348491|celecoxib
1409883|NCT00348491|Moderate to severe pain following dental surgery
1409884|NCT00348478|trachoma
1409885|NCT00348478|chlamydia trachomatis
1409886|NCT00348478|water
1409887|NCT00348478|health education
1409888|NCT00348478|face washing
1409889|NCT00348465|Brachytherapy
1409890|NCT00348465|Prostate volume
1409891|NCT00348452|osteoarthritis pain; knee; hip; extended release analgesia; opioid
1409892|NCT00348426|Food Borne Botulism
1409893|NCT00348413|Graves ophthalmopathy/therapy
1409894|NCT00348413|Randomized controlled trial
1409895|NCT00348413|Methylprednisolone
1409896|NCT00348413|Methotrexate
1409897|NCT00348387|Imovax polio
1409898|NCT00348387|poliomyelitis
1409899|NCT00348374|type two diabetes, insulin, HbA1c
1409900|NCT00348361|Hay fever
1409901|NCT00348361|biomarkers
1409902|NCT00348309|apolipoprotein E
1409903|NCT00348309|Alzheimer's disease
1409904|NCT00348309|cognition
1409905|NCT00348309|rosiglitazone
1409906|NCT00348309|adjunctive therapy
1409907|NCT00348296|Scleroderma, Systemic
1409908|NCT00348270|Cataract
1409909|NCT00348270|Intraocular lens
1409910|NCT00348270|Aberration
1409911|NCT00348270|Wavefront
1409912|NCT00348231|diabetes mellitus, biphasic insulin analogue
1409913|NCT00348218|Neurovision
1409914|NCT00348218|Myopia Therapy
1409915|NCT00348192|Alzheimer's Disease
1409916|NCT00348192|cognition global functioning
1409917|NCT00348192|symptomatic
1409918|NCT00348192|SB-742457
1409919|NCT00348179|Vascular abnormalities
1409920|NCT00348179|Type 1 diabetes
1409921|NCT00348179|Healthy control subjects
1409922|NCT00348153|Uveitis
1409923|NCT00348153|Adalimumab
1409924|NCT00348153|TNF alpha
1409925|NCT00348140|adjunctive therapy
1409926|NCT00348140|moderate
1409927|NCT00348140|Alzheimer's disease
1409928|NCT00348140|apolipoprotein E
1409929|NCT00348140|mild
1409930|NCT00348140|rosiglitazone
1409931|NCT00348140|cognition
1409932|NCT00348127|Neurovision
1409933|NCT00348127|Myopia Therapy
1409934|NCT00348114|autologous
1409935|NCT00348114|transplantation ex-vivo expanded limbal epithelium
1409936|NCT00348114|limbal deficiency
1409937|NCT00348101|Patients undergoing major vascular surgery having documented CAD or risk factors for CAD
1409938|NCT00348088|Metastatic
1409939|NCT00348088|Melanoma
1409940|NCT00348088|Untreated
1409941|NCT00348088|Biomarker
1409942|NCT00348075|Neurovision
1409943|NCT00348075|Adult myopia
1409944|NCT00348075|Therapy
1409945|NCT00348049|LASIK
1409946|NCT00348049|PRK
1409947|NCT00348049|Myopia
1409948|NCT00348036|Major Depression
1409949|NCT00348036|Trauma
1409950|NCT00348036|Primary Care
1409951|NCT00348036|Low-Income Patients
1409952|NCT00348010|osteoarthritis
1409953|NCT00348010|knee pain
1409954|NCT00348010|extended release analgesia
1409955|NCT00348010|opioid
1409956|NCT00347971|Lymphoma, Non-Hodgkin
1409957|NCT00347971|interleukin-21
1409958|NCT00347971|rituximab
1409959|NCT00347971|Immunotherapy
1409960|NCT00347958|Tetanus,
1409961|NCT00347958|Diphtheria,
1409962|NCT00347958|Pertussis
1409963|NCT00347945|convergence insufficiency, vision therapy, orthoptics
1409964|NCT00347919|GW786034
1409965|NCT00347919|Quality of Life
1409966|NCT00347919|GW572016
1409967|NCT00347919|Lapatinib
1409968|NCT00347919|Pazopanib
1409969|NCT00347919|Metastatic
1409970|NCT00347919|Breast cancer
1409971|NCT00347919|Genetics
1409972|NCT00347919|FISH
1409973|NCT00347919|Advanced
1409974|NCT00347204|PRK
1409975|NCT00347204|laser vision correction
1409976|NCT00347204|surface ablation
1409977|NCT00347204|pain
1409978|NCT00347204|wound healing
1409979|NCT00347204|corneal haze
1409980|NCT00347191|Corneal thickness
1409981|NCT00347191|Intraocular pressure
1409982|NCT00347191|Instrumentation
1409983|NCT00347191|Glaucoma
1409984|NCT00347191|Keratoconus
1409985|NCT00347178|Asymptomatic Narrow Angles
1409986|NCT00347178|Primary Angle Closure Suspects
1409987|NCT00347178|Laser Peripheral Iridotomy
1409988|NCT00347178|Randomised Controlled Trial
1409989|NCT00347165|macular degeneration
1409990|NCT00347165|angiogenesis
1409991|NCT00347165|antibodies
1409992|NCT00347152|Intellectual disabilities
1409993|NCT00347152|development disabilities
1409994|NCT00347152|behavior disorders
1409995|NCT00347152|stable epilepsy
1409996|NCT00347893|Primary open angle glaucoma
1409997|NCT00347893|Ocular hypertension
1409998|NCT00347893|Pseudo-exfoliative glaucoma
1409999|NCT00347893|Pigment Dispersion glaucoma
1410000|NCT00347893|selective laser trabeculoplasty
1410001|NCT00347893|intraocular pressure
1410002|NCT00347880|Bronchiolitis
1410003|NCT00347880|ANP
1410004|NCT00347880|BNP
1410005|NCT00347880|Atrial Natriuretic Peptide
1410006|NCT00347880|Brain Natriuretic Peptide
1410007|NCT00347880|Vasopressin
1410008|NCT00347880|ADH
1410009|NCT00347880|Pediatric
1410010|NCT00347880|Respiratory Distress
1410011|NCT00347880|Fluid Balance
1410012|NCT00347867|IUGR
1410013|NCT00347867|PET
1410014|NCT00347867|Pregnancy
1410015|NCT00347867|Viagra
1410016|NCT00347867|Sildenafil citrate
1410017|NCT00347854|Normal, healthy eyes (other than correction for visual acuity)
1410018|NCT00347828|Antibiotic prophylaxis
1410019|NCT00347828|Vigamox
1410020|NCT00347828|Moxifloxacin
1410021|NCT00347828|Zymar
1410022|NCT00347828|Gatifloxacin
1410023|NCT00347828|Preoperative antibiotic
1410024|NCT00347828|Eye infection
1410025|NCT00347789|glaucoma
1410026|NCT00347789|trabeculectomy
1410027|NCT00347789|filtering bleb revision
1410028|NCT00347789|intraocular pressure
1410029|NCT00347789|needling procedure
1410030|NCT00347789|mitomycin C
1410031|NCT00347776|trichiasis
1410032|NCT00347776|azithromycin
1410033|NCT00347776|trichiasis surgery
1410034|NCT00347776|topical tetracycline
1410035|NCT00347763|trachoma
1410036|NCT00347763|chlamydia
1410037|NCT00347763|flies
1410038|NCT00347763|permethrin
1410039|NCT00347750|Lopinavir
1410040|NCT00347750|Pharmacokinetic
1410041|NCT00347750|Pharmacodynamic
1410042|NCT00347750|Ethiopian population
1410043|NCT00347750|Caucasian population
1410044|NCT00347724|chronic low back pain; chronic pain; low back pain; extended-release analgesia; opioid
1410045|NCT00347698|diabetic retinopathy
1410046|NCT00347698|bevacizumab
1410047|NCT00347698|photocoagulation
1410048|NCT00347685|chronic non-malignant pain; chronic pain; non-malignant
1410049|NCT00347685|pain; moderate pain; severe pain
1410050|NCT00347672|Bird Flu
1410051|NCT00347659|Lung volume reduction
1410052|NCT00347659|Bronchoscopy
1410053|NCT00347659|Emphysema
1410054|NCT00347659|COPD
1410055|NCT00347659|NETT
1410056|NCT00347659|Lung disease
1410057|NCT00347659|COLD
1410058|NCT00347659|BLVR
1410059|NCT00347607|trachoma
1410060|NCT00347607|chlamydia trachomatis
1410061|NCT00347607|surveillance
1410062|NCT00347607|azithromycin
1410063|NCT00347594|Corneal surface topography
1410064|NCT00347594|Ocular aberrations
1410065|NCT00347581|convergence insufficiency
1410066|NCT00347581|base-in prism
1410067|NCT00347581|orthoptics
1410068|NCT00347581|vision therapy
1410069|NCT00347568|decision aids
1410070|NCT00347568|high risk
1410071|NCT00347568|breast cancer
1410072|NCT00347568|breast cancer prevention
1410073|NCT00347555|malaria, falciparum, Plasmodium falciparum malaria, vaccine
1410074|NCT00347542|Vitamin D
1410075|NCT00347542|Diabetes
1410076|NCT00347542|Insulin sensitivity
1410077|NCT00347542|Obesity
1410078|NCT00347529|DNA vaccine, influenza, immunogenicity, tolerability, PMED, pandemic
1410079|NCT00347516|IOL formula
1410080|NCT00347516|High myopia
1410081|NCT00347516|axial length
1410082|NCT00347477|cardiac arrest
1410083|NCT00347477|hypothermia
1410084|NCT00347477|neurologic outcome
1410085|NCT00347477|edema
1410086|NCT00347464|Kleinfelter
1410087|NCT00347451|myopia
1410088|NCT00347451|optical coherence tomography
1410089|NCT00347438|breast cancer
1410090|NCT00347438|neoadjuvant
1410091|NCT00347438|locally advanced
1410092|NCT00347425|Switch Study
1410093|NCT00347425|Schizophrenia
1410094|NCT00347425|Atypical Antipsychotics
1410095|NCT00347412|NSCLC
1410096|NCT00347412|Stage IIIb
1410097|NCT00347412|Stage IV
1410098|NCT00347412|Non Small Cell Lung Cancer (NSCLC)
1410099|NCT00347412|NSCLC Stage IIIb with malignant pleural/pericardial effusion
1410100|NCT00347412|NSCLC Stage IV
1410101|NCT00347399|macular degeneration
1410102|NCT00347399|antibodies
1410103|NCT00347399|angiogenesis inhibitor
1410104|NCT00347386|Infants
1410105|NCT00347386|India
1410106|NCT00347386|Zinc
1410107|NCT00347386|Bacterial illness
1410108|NCT00347386|Treatment
1410109|NCT00347373|conjugated linoleic acid
1410110|NCT00347373|obesity
1410111|NCT00347373|body composition
1410112|NCT00347373|body fat mass
1410113|NCT00347373|lean body mass
1410114|NCT00347360|carvedilol
1410115|NCT00347360|hypertension
1410116|NCT00347360|lisinopril
1410117|NCT00347360|factorial
1410118|NCT00347334|Torticollis
1410119|NCT00347334|infant home positioning
1410120|NCT00347334|head control
1410121|NCT00347321|Percutaneous tracheostomy
1410122|NCT00347321|Endotracheal intubation
1410123|NCT00347321|Mechanical ventilation
1410124|NCT00347321|Cardiac surgery
1410125|NCT00347321|Ventilator-free days
1410126|NCT00347308|brow ptosis, facial aesthetics, browlift, facelift
1410127|NCT00347282|Post enucleation socket syndrome
1410128|NCT00347282|Multi-slice computed tomography scan
1410129|NCT00347282|Prospective studies
1410130|NCT00347282|Tomography, X Ray Computed
1410131|NCT00347269|Anxiety Disorders
1410132|NCT00347269|Post-traumatic Stress Disorder
1410133|NCT00347269|Generalized Anxiety Disorder
1410134|NCT00347269|Panic Disorder
1410135|NCT00347269|Social Anxiety Disorder
1410136|NCT00347269|Stress
1410137|NCT00347269|Stress Disorders, Traumatic
1410138|NCT00347269|Stress Disorders, Post-Traumatic
1410139|NCT00347269|Mental Health Disorders
1410140|NCT00347230|Intacs ring segments
1410141|NCT00347230|Keratoconus
1410142|NCT00347217|Cholesterol
1410143|NCT00347217|rosuvastatin
1410144|NCT00347217|LDL-C goal
1410145|NCT00347217|observational study
1410146|NCT00347217|primary prevention
1410147|NCT00347217|secondary prevention
1410148|NCT00347139|Tolerability
1410149|NCT00347139|Pharmacodynamics
1410150|NCT00347139|Safety
1410151|NCT00347139|Pharmacokinetics
1410152|NCT00347139|GW642444
1410153|NCT00347139|Asthmatic patients
1410154|NCT00347139|Efficacy
1410155|NCT00347126|Glaucoma
1410156|NCT00347126|Latanoprost
1410157|NCT00347126|Travoprost
1410158|NCT00347126|Intraocular pressure
1410159|NCT00347126|Hyperemia
1410160|NCT00347113|P. falciparum
1410161|NCT00347113|malaria
1410162|NCT00347113|schistosome infections
1410163|NCT00347113|soil-transmitted helminths infection
1410164|NCT00347113|anaemia
1410165|NCT00347113|immune response
1410166|NCT00347113|Tanzania
1410167|NCT00347087|Insulin sensitivity
1410168|NCT00347087|chronic heart failure
1410169|NCT00347087|metabolism
1410170|NCT00347074|Keratoconus, corneal topography, ocular aberrometry, visual outcome, contact lens wear, quality of life
1410171|NCT00347061|Benign Prostatic Hyperplasiam
1410172|NCT00347061|Adrenergic alpha-antagonist
1410173|NCT00347048|Ulcerative colitis
1410174|NCT00347048|tacrolimus
1410175|NCT00347048|FK506
1410176|NCT00347048|treatment outcome
1410177|NCT00347022|Multislice computed tomography (MSCT)indications
1410178|NCT00347009|Cirrhosis
1410179|NCT00347009|Advanced Fibrosis
1410180|NCT00347009|Chronic Hepatitis B
1410181|NCT00347009|Adefovir Dipivoxil
1410182|NCT00346996|diabetes
1410183|NCT00346996|insulin
1410184|NCT00346996|insulin analogues
1410185|NCT00346996|hypoglycaemia
1410186|NCT00346996|severe hypoglycaemia
1410187|NCT00346970|Metabolic Syndrome
1410188|NCT00346970|High Density Lipoprotein
1410189|NCT00346970|Extended-Release Niacin
1410190|NCT00346970|Endothelial Function
1410191|NCT00346970|Endothelial Progenitor Cells
1410192|NCT00346931|glaucoma
1410193|NCT00346931|cataract
1410194|NCT00346931|surgery
1410195|NCT00346931|intraocular pressure
1410196|NCT00346931|phacoemulsification
1410197|NCT00346931|trabeculotomy
1410198|NCT00346918|ADPKD
1410199|NCT00346918|autosomal dominant polycystic kidney disease
1410200|NCT00346918|Sirolimus
1410201|NCT00346918|volumetry
1410202|NCT00346905|GERD
1410203|NCT00346905|Gastroesophageal Reflux Disease
1410204|NCT00346905|Reflux
1410205|NCT00346905|Enteryx
1410206|NCT00346892|Prophylaxis rotavirus
1410207|NCT00346879|fondaparinux for prevention of blood clots
1410208|NCT00346853|Dark adaptation inhibition
1410209|NCT00346853|Stargardt macular dystrophy
1410210|NCT00346853|4-Methylpyrazole (4-MP)
1410211|NCT00346853|Antizol
1410212|NCT00346853|Fomepizole
1410213|NCT00346840|Labor induction
1410214|NCT00346840|cervical ripening
1410215|NCT00346840|misoprostol
1410216|NCT00346840|vaginal insert
1410217|NCT00346814|Retinopathy of prematurity
1410218|NCT00346814|antiangiogenic therapy
1410219|NCT00346801|Non-Small Cell Lung Cancer
1410220|NCT00346801|Lung Cancer
1410221|NCT00346801|Celecoxib
1410222|NCT00346801|Cisplatin
1410223|NCT00346801|Platinol
1410224|NCT00346801|CPT-11
1410225|NCT00346801|Irinotecan
1410226|NCT00346801|SC-58635
1410227|NCT00346801|Celebrex
1410228|NCT00346801|Radiation Therapy
1410229|NCT00346775|questionnaire
1410230|NCT00346775|nasal spray
1410231|NCT00346775|Seasonal allergic rhinitis
1410232|NCT00346775|nasal spray questionnaire
1410233|NCT00346775|allergic rhinitis
1410234|NCT00346762|Former Plasma Donors
1410235|NCT00346762|Commercial Plasma Donors
1410236|NCT00346762|Long-Term Nonprogressors
1410237|NCT00346762|Host Factors
1410238|NCT00346762|Viral Factors
1410239|NCT00346762|HIV
1410240|NCT00346749|Inflammation
1410241|NCT00346749|FEV1
1410242|NCT00346749|Sputum
1410243|NCT00346736|Alternative medicine
1410244|NCT00346736|Traditional Chinese medicine
1410245|NCT00346736|Acupuncture
1410246|NCT00346736|Autistic Spectrum Disorder
1410247|NCT00346736|Autism
1410248|NCT00346736|Children
1410249|NCT00346723|Influenza, Vaccine, CHMP criteria
1410250|NCT00346710|communication
1410251|NCT00346710|patient experience
1410252|NCT00346710|fellowship training
1410253|NCT00346697|AIDS
1410254|NCT00346697|HIV
1410255|NCT00346697|HAART
1410256|NCT00346697|Lipids
1410257|NCT00346697|Triglycerides
1410258|NCT00346697|Cholesterol
1410259|NCT00346697|omega-3 fatty acids
1410260|NCT00346697|bone turnover
1410261|NCT00346697|inflammation
1410262|NCT00346697|insulin resistance
1410263|NCT00346684|Lymphoma
1410264|NCT00346684|LPHD
1410265|NCT00346684|Rituximab
1410266|NCT00346671|Reiki
1410267|NCT00346671|Stress
1410268|NCT00346671|CAM
1410269|NCT00346658|Osteoporosis
1410270|NCT00346658|bone density
1410271|NCT00346658|magnesium
1410272|NCT00346658|vitamin D
1410273|NCT00346645|NON-SMALL CELL LUNG CANCER METASTATIC
1410274|NCT00346632|AML
1410275|NCT00346632|ALL
1410276|NCT00346632|MDS
1410277|NCT00346632|CML
1410278|NCT00346632|Kinase Inhibitor
1410279|NCT00346606|Chronic Idiopathic Urticaria
1410280|NCT00346606|Desloratadine
1410281|NCT00346606|Denosin
1410282|NCT00346606|Levocetirizine
1410283|NCT00346567|mother-to-child-transmission
1410284|NCT00346567|PMTCT
1410285|NCT00346567|HIV
1410286|NCT00346567|resistance
1410287|NCT00346567|NNRTI
1410288|NCT00346554|COPD
1410289|NCT00346554|Sleep disorders
1410290|NCT00346554|pulmonary rehabilitation
1410291|NCT00346541|glaucoma
1410292|NCT00346541|polymorphism, genetic
1410293|NCT00346515|carotid artery
1410294|NCT00346515|carotid stenosis
1410295|NCT00346515|carotid stenting
1410296|NCT00346515|embolic protection
1410297|NCT00346489|Trabeculectomy
1410298|NCT00346489|5-fluorouracil
1410299|NCT00346489|Mitomycin C
1410300|NCT00346476|TB
1410301|NCT00346476|Transmission
1410302|NCT00346476|Genetic Diversity
1410303|NCT00346476|Genetic Testing
1410304|NCT00346476|RFLP
1410305|NCT00346463|Allopurinol
1410306|NCT00346463|Fetal Growth Retardation
1410307|NCT00346463|Oxidative Stress
1410308|NCT00346463|Placental Insufficiency
1410309|NCT00346450|Culture
1410310|NCT00346450|Conjunctiva
1410311|NCT00346450|transplantation
1410312|NCT00346450|pterygium
1410313|NCT00346450|ocular surface
1410314|NCT00346437|angina
1410315|NCT00346437|FGF-4
1410316|NCT00346437|angiogenesis
1410317|NCT00346437|adenovector
1410318|NCT00346437|growth factor
1410319|NCT00346437|myocardial ischemia
1410320|NCT00346437|revascularization
1410321|NCT00346424|occluded central catheter
1410322|NCT00346424|central venous access devices dysfunction
1410323|NCT00346424|withdrawal occlusion
1410324|NCT00346424|Thrombosis
1410325|NCT00346424|Venous thrombosis
1410326|NCT00346411|rheumatoid arthritis
1410327|NCT00346411|mood
1410328|NCT00346411|adherence
1410329|NCT00346411|medication
1410330|NCT00346398|asthma
1410331|NCT00346398|allergen
1410332|NCT00346398|allergic disease
1410333|NCT00346398|allergen immunotherapy
1410334|NCT00346398|allergic sensitization
1410335|NCT00346398|atopic dermatitis
1410336|NCT00346398|eczema
1410337|NCT00346398|food allergy
1410338|NCT00346398|oral mucosal immunoprophylaxis (OMIP)
1410339|NCT00346385|recurrent small cell lung cancer
1410340|NCT00346385|merkel cell carcinoma
1410341|NCT00346385|ovarian cancer
1410342|NCT00346372|Ocular Melanoma
1410343|NCT00346372|Optical Coherence Tomography
1410344|NCT00346372|Eye Tumor
1410345|NCT00346372|Choroidal Melanoma
1410346|NCT00346372|Uveal Melanoma
1410347|NCT00346359|graft versus host disease
1410348|NCT00346359|chronic phase chronic myelogenous leukemia
1410349|NCT00346359|childhood chronic myelogenous leukemia
1410350|NCT00346359|blastic phase chronic myelogenous leukemia
1410351|NCT00346359|accelerated phase chronic myelogenous leukemia
1410352|NCT00346359|relapsing chronic myelogenous leukemia
1410353|NCT00346359|adult acute myeloid leukemia in remission
1410354|NCT00346359|recurrent adult acute myeloid leukemia
1410355|NCT00346359|childhood acute myeloid leukemia in remission
1410356|NCT00346359|recurrent childhood acute myeloid leukemia
1410357|NCT00346359|de novo myelodysplastic syndromes
1410358|NCT00346359|previously treated myelodysplastic syndromes
1410359|NCT00346359|secondary myelodysplastic syndromes
1410360|NCT00346359|atypical chronic myeloid leukemia
1410361|NCT00346359|chronic myelomonocytic leukemia
1410362|NCT00346359|juvenile myelomonocytic leukemia
1410363|NCT00346359|myelodysplastic/myeloproliferative disease, unclassifiable
1410364|NCT00346359|secondary acute myeloid leukemia
1410365|NCT00346359|chronic eosinophilic leukemia
1410366|NCT00346359|chronic idiopathic myelofibrosis
1410367|NCT00346359|chronic neutrophilic leukemia
1410368|NCT00346359|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1410369|NCT00346359|adult acute myeloid leukemia with inv(16)(p13;q22)
1410370|NCT00346359|adult acute myeloid leukemia with t(15;17)(q22;q12)
1410371|NCT00346359|adult acute myeloid leukemia with t(16;16)(p13;q22)
1410372|NCT00346359|adult acute myeloid leukemia with t(8;21)(q22;q22)
1410373|NCT00346359|childhood myelodysplastic syndromes
1410374|NCT00346346|Immunity
1410375|NCT00346346|Memory
1410376|NCT00346346|ELISPOT
1410377|NCT00346346|Malaria
1410378|NCT00346346|Prospective
1410379|NCT00346333|Retinitis Pigmentosa, Inherited Retinal Degeneration
1410380|NCT00346320|stage I non-small cell lung cancer
1410381|NCT00346320|stage II non-small cell lung cancer
1410382|NCT00346320|adenocarcinoma of the lung
1410383|NCT00346320|adenosquamous cell lung cancer
1410384|NCT00346320|bronchoalveolar cell lung cancer
1410385|NCT00346320|large cell lung cancer
1410386|NCT00346320|squamous cell lung cancer
1410387|NCT00346294|Rheumatoid Arthritis
1410388|NCT00346294|Device
1410389|NCT00346294|Auto-injector
1410390|NCT00346294|SureClick
1410391|NCT00346294|Enbrel
1410392|NCT00346294|Etanercept
1410393|NCT00346281|unresectable pancreatic cancer
1410394|NCT00346281|brachytherapy
1410395|NCT00346281|32P
1410396|NCT00346281|BioSilicon
1410397|NCT00346281|locally advanced
1410398|NCT00346281|gemcitabine
1410399|NCT00346281|intratumourally
1410400|NCT00346281|unresectable
1410401|NCT00346255|stage I multiple myeloma
1410402|NCT00346255|stage II multiple myeloma
1410403|NCT00346255|stage III multiple myeloma
1410404|NCT00346242|thalassemia
1410405|NCT00346242|zoledronic acid
1410406|NCT00346242|skeletal events
1410407|NCT00346229|stage III B breast cancer
1410408|NCT00346229|stage III C breast cancer
1410409|NCT00346229|stage IV breast cancer
1410410|NCT00346229|inflammatory breast cancer
1410411|NCT00346229|recurrent breast cancer
1410412|NCT00346177|heart
1410413|NCT00346177|stem Cells
1410414|NCT00346177|low EF
1410415|NCT00346177|heart attack
1410416|NCT00346177|cardiomyopathy
1410417|NCT00346177|congestive heart failure
1410418|NCT00346177|cardiovascular disease
1410419|NCT00346177|Heart Failure
1410420|NCT00346177|Low Ejection Fraction
1410421|NCT00346151|renal transplantation
1410422|NCT00346151|kidney transplantation
1410423|NCT00346151|renal allograft recipient
1410424|NCT00346151|anti-rejection drugs
1410425|NCT00346151|immunosuppression protocol
1410426|NCT00346151|immunosuppression withdrawal
1410427|NCT00346125|soft tissue sarcoma
1410428|NCT00346125|Malignant fibrous histiocytoma
1410429|NCT00346125|Liposarcoma
1410430|NCT00346125|Fibrosarcoma
1410431|NCT00346125|Leiomyosarcoma
1410432|NCT00346125|Synovial sarcoma
1410433|NCT00346125|Malignant peripheral nerve sheath tumor (MPNST)
1410434|NCT00346125|Epithelioid sarcoma
1410435|NCT00346112|ICD
1410436|NCT00346112|distress
1410437|NCT00346112|anxiety
1410438|NCT00346112|quality-of-life
1410439|NCT00346099|NSABP
1410440|NCT00346099|panitumumab
1410441|NCT00346099|rectal cancer
1410442|NCT00346099|colorectal cancer
1410443|NCT00346099|oxaliplatin
1410444|NCT00346099|capecitabine
1410445|NCT00346099|combined modality therapy
1410446|NCT00346099|combined pelvic radiation therapy
1410447|NCT00346099|Rectal cancer with or without metastasis
1410448|NCT00346086|CpG oligonucleotide vaccine
1410449|NCT00346086|ragweed immunotherapy
1410450|NCT00346073|Prophylaxis for diphtheria, tetanus, pertussis
1410451|NCT00346073|Immunogenicity, booster, dTpa
1410452|NCT00346060|Dry age related macular degeneration.
1410453|NCT00346060|Retinal Transplant
1410454|NCT00346060|Fetal Tissue
1410455|NCT00346060|Early treatment diabetic retinopathy study
1410456|NCT00346060|20/200 or worse.
1410457|NCT00346021|Children's behavior towards hat use
1410458|NCT00346008|melanoma
1410459|NCT00346008|recurrent melanoma
1410460|NCT00346008|stage I melanoma
1410461|NCT00346008|stage II melanoma
1410462|NCT00346008|stage III melanoma
1410463|NCT00346008|stage IV melanoma
1410464|NCT00345982|Schizophrenia
1410465|NCT00345982|Treatment-resistant
1410466|NCT00345982|sertindole
1410467|NCT00345982|clozapine
1410468|NCT00345969|Testosterone Replacement Therapy
1410469|NCT00345969|Physical Frailty
1410470|NCT00345969|Hip Fracture
1410471|NCT00345956|Prophylaxis against gastroenteritis caused by Rotavirus
1410472|NCT00345943|Eating Disorders
1410473|NCT00345943|Bulimia Nervosa
1410474|NCT00345943|Bulimia
1410475|NCT00345943|fMRI
1410476|NCT00345943|Magnetic Resonance Imaging
1410477|NCT00345930|Complementary and alternative medicine
1410478|NCT00345930|Complementary therapies
1410479|NCT00345930|Alternative therapies
1410480|NCT00345930|Prescription Drugs
1410481|NCT00345930|Non prescription Drugs
1410482|NCT00345930|Liver Disease
1410483|NCT00345930|Chemical Ind
1410484|NCT00345930|Phenotype
1410485|NCT00345930|Proteomics
1410486|NCT00345930|Metabolomics
1410487|NCT00345930|Cholestatic Liver Injury
1410488|NCT00345930|Hepatocellular Liver Injury
1410489|NCT00345930|Mixed Liver Injury
1410490|NCT00345930|Matched Case Control Studies
1410491|NCT00345930|Genotype
1410492|NCT00345930|Liver Dis
1410493|NCT00345930|Chem Ind
1410494|NCT00345917|Retinitis Pigmentosa
1410495|NCT00345917|Retinal Transplant
1410496|NCT00345917|Fetal Tissue
1410497|NCT00345917|Early treatment diabetic retinopathy study
1410498|NCT00345917|20/200 or worse.
1410499|NCT00345904|influenza, vaccine
1410500|NCT00345904|prophylaxis of influenza
1410501|NCT00345891|Lung neoplasms
1410502|NCT00345891|Family
1410503|NCT00345891|Stress
1410504|NCT00345878|HPV-16/18 L1 VLP AS04
1410505|NCT00345878|Cervical neoplasia
1410506|NCT00345878|Cervical cancer
1410507|NCT00345878|Human Papillomavirus (HPV)
1410508|NCT00345878|Double-blind
1410509|NCT00345878|AS04
1410510|NCT00345865|Hodgkin lymphoma
1410511|NCT00345865|non-Hodgkin lymphoma
1410512|NCT00345865|HIV-associated lymphoma
1410513|NCT00345852|twin to twin transfusion syndrome
1410514|NCT00345852|fetoscopic selective laser photocoagulation
1410515|NCT00345852|amnioreduction
1410516|NCT00345839|Cinacalcet HCl
1410517|NCT00345839|Cinacalcet
1410518|NCT00345839|AMG 073
1410519|NCT00345839|Sensipar
1410520|NCT00345839|Mimpara
1410521|NCT00345839|Calcimimetic
1410522|NCT00345839|Hemodialysis
1410523|NCT00345839|CKD
1410524|NCT00345839|Secondary hyperparathyroidism (HPT)
1410525|NCT00345826|accelerated phase chronic myelogenous leukemia
1410526|NCT00345826|blastic phase chronic myelogenous leukemia
1410527|NCT00345826|chronic phase chronic myelogenous leukemia
1410528|NCT00345826|relapsing chronic myelogenous leukemia
1410529|NCT00345826|recurrent adult acute lymphoblastic leukemia
1410530|NCT00345826|chronic myelogenous leukemia, BCR-ABL1 positive
1410531|NCT00345813|adenocarcinoma of the prostate
1410532|NCT00345813|stage I prostate cancer
1410533|NCT00345813|stage IIB prostate cancer
1410534|NCT00345813|stage IIA prostate cancer
1410535|NCT00345813|stage III prostate cancer
1410536|NCT00345813|stage IV prostate cancer
1410537|NCT00345800|Endocrine Evaluation cataplexy
1410538|NCT00345800|sodium oxybate (xyrem)
1410539|NCT00345787|Osteoarthritic Pain
1410540|NCT00345774|Pulmonary Hypertension
1410541|NCT00345774|PH
1410542|NCT00345774|Pulmonary Arterial Hypertension
1410543|NCT00345774|PAH
1410544|NCT00345774|Chronic Obstructive Pulmonary Disease
1410545|NCT00345774|COPD
1410546|NCT00345774|PRX-08066
1410547|NCT00345774|Predix
1410548|NCT00345761|Advanced and/or metastatic colorectal cancer
1410549|NCT00345735|Cancer pain with breakthrough pain episodes
1410550|NCT00345722|Strawberry
1410551|NCT00345722|Almond
1410552|NCT00345722|Soy protein
1410553|NCT00345722|viscous dietary fibre
1410554|NCT00345722|plant sterols
1410555|NCT00345722|portfolio diet
1410556|NCT00345722|blood lipids
1410557|NCT00345722|compliance
1410558|NCT00345722|blood pressure
1410559|NCT00345709|Ovarian Cancer
1410560|NCT00345709|Peritoneal Cancer
1410561|NCT00345709|Fallopian Tube Cancer
1410562|NCT00345709|Elizabeth Registry
1410563|NCT00345709|Questionnaire
1410564|NCT00345709|Registry
1410565|NCT00345709|Survey
1410566|NCT00345696|Capecitabine
1410567|NCT00345696|Oxaliplatin
1410568|NCT00345696|Bevacizumab
1410569|NCT00345696|First line
1410570|NCT00345683|H. influenzae type B vaccine
1410571|NCT00345683|Infants
1410572|NCT00345683|Neisseria meningitidis
1410573|NCT00345683|Vaccines, conjugate
1410574|NCT00345683|Meningococcal vaccines
1410575|NCT00345683|Prophylaxis
1410576|NCT00345683|Comparative study
1410577|NCT00345683|Safety
1410578|NCT00345683|Humans
1410579|NCT00345670|Lower respiratory tract illness
1410580|NCT00345670|RSV and PIV3 infection
1410581|NCT00345657|Hyperlipidemia
1410582|NCT00345657|Dyslipidemia
1410583|NCT00345657|Niacin
1410584|NCT00345657|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1410585|NCT00345657|Combination lipid therapy
1410586|NCT00345657|Lovastatin
1410587|NCT00345644|Postmenopausal
1410588|NCT00345631|Closure Device
1410589|NCT00345631|Angiography
1410590|NCT00345631|Angioplasty
1410591|NCT00345631|Hemostasis
1410592|NCT00345631|Heart Catheterization
1410593|NCT00345631|Peripheral Angiography
1410594|NCT00345631|Femoral Closure
1410595|NCT00345631|Vascular Closure
1410596|NCT00345631|Coronary Angiography
1410597|NCT00345618|Deep venous thrombosis
1410598|NCT00345618|pulmonary embolism
1410599|NCT00345618|anticoagulant drugs
1410600|NCT00345605|Argininosuccinic Acid Lyase Deficiency
1410601|NCT00345605|ASA
1410602|NCT00345579|Prophylaxis
1410603|NCT00345579|Neisseria meningitidis Vaccines, conjugate
1410604|NCT00345579|Infants
1410605|NCT00345579|Meningococcal vaccines
1410606|NCT00345579|H. influenzae type B vaccine
1410607|NCT00345579|Humans
1410608|NCT00345579|Safety
1410609|NCT00345566|cerebral palsy
1410610|NCT00345566|protein composition
1410611|NCT00345566|gastric emptying rate
1410612|NCT00345566|tube feeding
1410613|NCT00345553|Biliary Atresia
1410614|NCT00345553|Cholestasis
1410615|NCT00345540|Platinum Resistant Tumors of Ovarian Origin
1410616|NCT00345527|Problem gambling
1410617|NCT00345527|Clinically significant anger
1410618|NCT00345514|Children
1410619|NCT00345514|Self-efficacy
1410620|NCT00345514|Organization
1410621|NCT00345514|Process of care
1410622|NCT00345501|contrast media
1410623|NCT00345501|contrast nephropathy
1410624|NCT00345475|Birth Defects
1410625|NCT00345475|Epilepsy
1410626|NCT00345475|High Risk Pregnancy
1410627|NCT00345462|Influenza, Vaccine, CHMP criteria
1410628|NCT00345449|cystic fibrosis,
1410629|NCT00345449|lung disease,
1410630|NCT00345449|lung transplantation,
1410631|NCT00345449|decision aid
1410632|NCT00345436|Insulin Sensitivity
1410633|NCT00345436|Moderate intensity
1410634|NCT00345436|Insulin Resistance
1410635|NCT00345436|Exercise Intervention
1410636|NCT00345410|obesity and dyslipidemia
1410637|NCT00345397|cecostomy
1410638|NCT00345397|colonoscopy
1410639|NCT00345397|colostomy
1410640|NCT00345397|constipation
1410641|NCT00345397|endoscopy, gastrointestinal
1410642|NCT00345397|fecal incontinence
1410643|NCT00345397|percutaneous
1410644|NCT00345397|quality of life
1410645|NCT00345397|spinal cord injury
1410646|NCT00345384|Dexmedetomidine
1410647|NCT00345384|Sedation
1410648|NCT00345384|Opioid
1410649|NCT00345384|Respiratory depression
1410650|NCT00345371|methamphetamine addiction
1410651|NCT00345358|Booster vaccination
1410652|NCT00345358|Catch-up vaccination
1410653|NCT00345358|Pneumococcal vaccine
1410654|NCT00345358|Immunogenicity
1410655|NCT00345358|Safety
1410656|NCT00345358|Pneumococcal disease
1410657|NCT00345345|Neutropenia
1410658|NCT00345345|Monoclonal Antibody Therapy
1410659|NCT00345345|Anti-CD52
1410660|NCT00345345|T-LGL Leukemia
1410661|NCT00345345|LGL Leukemia
1410662|NCT00345345|Anemia
1410663|NCT00345345|Immunosuppression
1410664|NCT00345345|Chronic T Cell Lymphocytosis with Neutropenia
1410665|NCT00345345|Leukemia
1410666|NCT00345319|rabies
1410667|NCT00345319|vaccine
1410668|NCT00345319|post-exposure prophylaxis
1410669|NCT00345306|endometrial preparation
1410670|NCT00345306|Utrogestan
1410671|NCT00345306|Endometrin
1410672|NCT00345293|Prostate Cancer
1410673|NCT00345280|Cystic fibrosis
1410674|NCT00345280|eye
1410675|NCT00345280|inflammation
1410676|NCT00345280|apoptosis
1410677|NCT00345280|C11+
1410678|NCT00345267|Asthma
1410679|NCT00345267|Children
1410680|NCT00345267|Integrated Care Pathway
1410681|NCT00345267|Evidence based medicine
1410682|NCT00345267|Prescribing errors
1410683|NCT00345241|Blepharitis
1410684|NCT00345228|High myopia
1410685|NCT00345228|Choroidal neovascularisation
1410686|NCT00345228|Lacquer crack
1410687|NCT00345228|Fundus fluorescein angiography
1410688|NCT00345228|Indocyanine green angiography
1410689|NCT00345228|Axial length
1410690|NCT00345215|Urinary Aquaporin 2
1410691|NCT00345215|High/low Sodium Diet
1410692|NCT00345215|Fractional Sodium Excretion
1410693|NCT00345202|HMG-COA reductase inhibition
1410694|NCT00345202|GFR
1410695|NCT00345202|RPF
1410696|NCT00345202|FE
1410697|NCT00345202|CL
1410698|NCT00345189|Hsp90 inhibitor
1410699|NCT00345189|CNF2024
1410700|NCT00345189|Advanced Solid Tumors
1410701|NCT00345176|age-related macular degeneration
1410702|NCT00345176|AMD
1410703|NCT00345176|lutein
1410704|NCT00345176|zeaxanthin
1410705|NCT00345176|docosahexaenoic acid
1410706|NCT00345176|eicosapentaenoic acid
1410707|NCT00345163|Glioblastoma Multiforme
1410708|NCT00345163|Avastin
1410709|NCT00345163|Brain Cancer
1410710|NCT00345163|GBM
1410711|NCT00345150|hypertension
1410712|NCT00345150|nitric oxide
1410713|NCT00345150|renal hemodynamics
1410714|NCT00345137|Renal hemodynamics
1410715|NCT00345137|Nitric oxide
1410716|NCT00345124|urinary aquaporin-2
1410717|NCT00345124|ENaC
1410718|NCT00345124|fractional sodium excretion
1410719|NCT00345124|High/low sodium diet
1410720|NCT00345111|Restor IOL versus Conventional IOL
1410721|NCT00345098|Depression, Antidepressive agents
1410722|NCT00345098|Clinical Trial
1410723|NCT00345098|Phase III
1410724|NCT00345098|Multicenter study
1410725|NCT00345072|Menopause
1410726|NCT00345072|Decision aids
1410727|NCT00345072|Internet
1410728|NCT00345072|Hormone Replacement Therapy
1410729|NCT00345072|Breast Cancer
1410730|NCT00345072|Cardiovascular Disease
1410731|NCT00345072|Osteoporosis
1410732|NCT00345059|second line
1410733|NCT00345059|monochemotherapy
1410734|NCT00345059|combination chemotherapy
1410735|NCT00345059|platinum refractory
1410736|NCT00345059|previously treated
1410737|NCT00345046|Glaucoma
1410738|NCT00345046|Cataract
1410739|NCT00345033|Glucose Metabolism
1410740|NCT00345020|Deep Lamellar Endotheliam Keratoplasty
1410741|NCT00345007|Retinal detachment
1410742|NCT00345007|Macular function
1410743|NCT00345007|Multifocal electrophysiology
1410744|NCT00344994|Restless Legs Syndrome
1410745|NCT00344994|Mirapex (pramipexole)
1410746|NCT00344994|Requip(Ropinirole)
1410747|NCT00344994|Dopamine Agonist
1410748|NCT00344981|Cell Cycle Agents
1410749|NCT00344955|HMG-COA reductase inhibition
1410750|NCT00344955|GFR
1410751|NCT00344955|RPF
1410752|NCT00344955|FE
1410753|NCT00344955|CL
1410754|NCT00344916|Renal hemodynamics
1410755|NCT00344916|Nitric oxide
1410756|NCT00344903|Atherosclerosis
1410757|NCT00344903|Heart Failure
1410758|NCT00344903|Ventricular Hypertrophy
1410759|NCT00344903|Myocardial Infarction
1410760|NCT00344903|Screening
1410761|NCT00344903|Hypertension
1410762|NCT00344903|Diabetes
1410763|NCT00344903|Obesity
1410764|NCT00344903|Metabolic Syndrome
1410765|NCT00344890|Cervical fusion
1410766|NCT00344890|Anterior Cervical Discectomy and Fusion
1410767|NCT00344890|ACDF
1410768|NCT00344877|Epilepsy
1410769|NCT00344877|Temporal Lobe Epilepsy
1410770|NCT00344877|Cortical Excitability
1410771|NCT00344877|Transcranial Direct Current Stimulation (tDCS)
1410772|NCT00344877|Memory Testing
1410773|NCT00344877|Seizures
1410774|NCT00344877|Transcranial Magnetic Stimulation (TMS)
1410775|NCT00344877|Memory
1410776|NCT00344877|Plasticity
1410777|NCT00344864|Contact Lenses Higher Order Aberrations
1410778|NCT00344851|menstrual cyclicity
1410779|NCT00344851|insulin resistance
1410780|NCT00344851|body fat distribution
1410781|NCT00344851|pancreatic ß-cell function
1410782|NCT00344851|inflammatory markers
1410783|NCT00344851|liver function tests
1410784|NCT00344838|LADARWave™
1410785|NCT00344838|WaveScan Wavefront™ Systems
1410786|NCT00344825|B- Chronic Lymphocytic Leukemia
1410787|NCT00344799|Choroidal Melanoma
1410788|NCT00344799|Choroidal Malignant Melanoma
1410789|NCT00344799|Ocular Melanoma
1410790|NCT00344799|Uveal Melanoma
1410791|NCT00344786|CLL
1410792|NCT00344786|CNF2024
1410793|NCT00344786|Hsp90 inhibitor
1410794|NCT00344773|Locally advanced (IIIB) pulmonary adenocarcinoma with EGFR mutation
1410795|NCT00344773|Metastatic (IV) pulmonary adenocarcinoma with EGFR mutation
1410796|NCT00344773|Recurrent pulmonary adenocarcinoma with EGFR mutation
1410797|NCT00344747|intervention program
1410798|NCT00344747|diet
1410799|NCT00344747|physical activity
1410800|NCT00344747|adolescents
1410801|NCT00344747|obesity
1410802|NCT00344734|Nitric oxide
1410803|NCT00344734|Renal hemodynamics
1410804|NCT00344721|Meibomian Gland Syndrome
1410805|NCT00344721|Blepharitis
1410806|NCT00344708|Tissue-Cultured Human Amniotic Epithelial Cells onto damaged corneal surface
1410807|NCT00344682|memantine
1410808|NCT00344682|Namenda
1410809|NCT00344682|augmentation
1410810|NCT00344682|add-on
1410811|NCT00344682|depression
1410812|NCT00344682|MDD (major depressive disorder)
1410813|NCT00344682|unipolar depression
1410814|NCT00344682|NMDA
1410815|NCT00344682|ketamine
1410816|NCT00344682|uncompetitive NMDA receptor antagonist
1410817|NCT00344669|underweight
1410818|NCT00344669|preschool
1410819|NCT00344669|mass deworming
1410820|NCT00344656|Eating Disorders
1410821|NCT00344656|Anorexia Nervosa
1410822|NCT00344643|Comparison of Daily wear versus Extended wear in bacterial binding and corneal epithelial thickness
1410823|NCT00344617|Choroidal neovascularisation
1410824|NCT00344617|Polypoidal choroidal vasculopathy
1410825|NCT00344617|Intravitreal injection
1410826|NCT00344617|Avastin
1410827|NCT00344604|Patients who have undergone routine LASIK as a primary refractive procedure for myopia, hyperopia, or astigmatism.
1410828|NCT00344591|HIV
1410829|NCT00344591|AIDS
1410830|NCT00344578|Higher Order Abberations
1410831|NCT00344539|asexual blood stage vaccine, Plasmodium falciparum malaria
1410832|NCT00344526|AL amyloidosis
1410833|NCT00344526|Autologous stem cell transplantation
1410834|NCT00344526|Melphalan
1410835|NCT00344526|Dexamethasone
1410836|NCT00344513|registry
1410837|NCT00344513|OPTIMIZE
1410838|NCT00344513|Heart failure
1410839|NCT00344513|OPTIMIZE-HF
1410840|NCT00344500|Antipsychotic
1410841|NCT00344500|Bipolar
1410842|NCT00344500|Diabetes
1410843|NCT00344500|Mental Illness
1410844|NCT00344500|Nutrition
1410845|NCT00344500|Obesity
1410846|NCT00344500|Schizoaffective
1410847|NCT00344500|Schizophrenia
1410848|NCT00344500|Weight Gain
1410849|NCT00344500|Weight Loss
1410850|NCT00344474|Prevention
1410851|NCT00344474|Addiction
1410852|NCT00344474|Personality
1410853|NCT00344474|Adolescents
1410854|NCT00344474|Binge Drinking
1410855|NCT00344474|Alcohol Abuse
1410856|NCT00344474|Comorbidity
1410857|NCT00344474|Depression
1410858|NCT00344474|Anxiety
1410859|NCT00344474|Antisocial Behaviour
1410860|NCT00344448|Adhesion Molecule
1410861|NCT00344448|Interventional Study
1410862|NCT00344448|Immunomodulation
1410863|NCT00344448|Autoimmunity
1410864|NCT00344448|Sjogren Syndrome
1410865|NCT00344448|SS
1410866|NCT00344435|Hemophilia
1410867|NCT00344435|Antibody
1410868|NCT00344435|Mutations
1410869|NCT00344435|SNP
1410870|NCT00344435|clotting
1410871|NCT00344422|Anthracyclines
1410872|NCT00344422|Liposomes
1410873|NCT00344422|Liposomal
1410874|NCT00344422|Vincristine
1410875|NCT00344422|Doxorubicin
1410876|NCT00344422|Dexamethasone
1410877|NCT00344422|Pegylated Liposomal Doxorubicin
1410878|NCT00344422|DOXIL
1410879|NCT00344422|drug resistant myeloma
1410880|NCT00344409|darbepoetin alfa
1410881|NCT00344409|anemia
1410882|NCT00344409|cancer patients
1410883|NCT00344409|platinum containing chemotherapy
1410884|NCT00344383|oral contraceptive
1410885|NCT00344383|breakthrough bleeding
1410886|NCT00344383|spotting
1410887|NCT00344370|Pitavastatin
1410888|NCT00344370|Type II Diabetes Mellitus
1410889|NCT00344370|Combined Dyslipidemia
1410890|NCT00344344|Asthma
1410891|NCT00344344|Cockroach
1410892|NCT00344344|Dust Mite
1410893|NCT00344344|Extermination
1410894|NCT00344344|Targeted Cleaning
1410895|NCT00344344|Allergy
1410896|NCT00344344|Prevention
1410897|NCT00344331|Lysosomal Storage
1410898|NCT00344331|Biomarkers
1410899|NCT00344331|Longitudinal
1410900|NCT00344331|Niemann Pick Type C
1410901|NCT00344331|NPC
1410902|NCT00344331|Lysosomal Storage Disorder
1410903|NCT00344318|Immunogenicity
1410904|NCT00344318|Safety
1410905|NCT00344318|Pneumococcal vaccine
1410906|NCT00344318|Pneumococcal disease
1410907|NCT00344305|children, FluMist, shedding,
1410908|NCT00344292|Polymorphism, Genetic
1410909|NCT00344292|Coronary Artery Disease
1410910|NCT00344292|Coronary Arteriosclerosis
1410911|NCT00344292|Polymorphism, Single Nucleotide
1410912|NCT00344292|SNPs
1410913|NCT00344279|Coinfection
1410914|NCT00344279|AIDS
1410915|NCT00344279|Lymphatic Filariasis
1410916|NCT00344279|Diethylcarbamazine (DEC)
1410917|NCT00344279|Albendazole
1410918|NCT00344266|Obesity
1410919|NCT00344266|Adipose Tissue
1410920|NCT00344266|Microarrays
1410921|NCT00344266|Cytokines
1410922|NCT00344266|Eicosanoids
1410923|NCT00344266|Gene Expression
1410924|NCT00344266|Adipokines
1410925|NCT00344266|Inflammation
1410926|NCT00344266|Weight Loss
1410927|NCT00344266|Lipid Products
1410928|NCT00344253|Uveitis
1410929|NCT00344253|Macular Edema
1410930|NCT00344253|Interferon
1410931|NCT00344253|Multiple Sclerosis
1410932|NCT00344253|Encephalomyelitis disseminata (ED)
1410933|NCT00344240|type 2 diabetes
1410934|NCT00344240|exercise
1410935|NCT00344240|activity guidance
1410936|NCT00344240|health education
1410937|NCT00344227|neovascularization
1410938|NCT00344227|age-related macular degeneration
1410939|NCT00344227|vascular endothelial growth factor (VEGF)
1410940|NCT00344227|antigen-binding fragment (Fab)
1410941|NCT00344227|antiangiogenesis
1410942|NCT00344227|optical coherence tomography (OCT)
1410943|NCT00344214|HIV
1410944|NCT00344214|STDs
1410945|NCT00344214|Methamphetamine
1410946|NCT00344201|Pterygium
1410947|NCT00344201|Fibrin adhesive
1410948|NCT00344201|Conjunctival graft
1410949|NCT00344201|Ocular surface reconstruction
1410950|NCT00344188|Cutaneous
1410951|NCT00344188|Visceral
1410952|NCT00344188|PCR
1410953|NCT00344188|Mucocutaneous
1410954|NCT00344188|Biopsy
1410955|NCT00344188|Leishmanial Infection
1410956|NCT00344188|Leishmaniasis
1410957|NCT00344175|hypercholesterolemia
1410958|NCT00344175|dyslipidemia
1410959|NCT00344175|CHD
1410960|NCT00344175|pitavastatin
1410961|NCT00344175|simvastatin
1410962|NCT00344175|2 or more risk factors for coronary heart disease
1410963|NCT00344175|combined dyslipidemia
1410964|NCT00344162|Epidemiology
1410965|NCT00344162|Population
1410966|NCT00344162|Pregnancy
1410967|NCT00344162|Preeclampsia
1410968|NCT00344149|Idiopathic Thrombocytopenic Purpura
1410969|NCT00344149|Rituximab
1410970|NCT00344149|Splenectomy
1410971|NCT00344149|Response
1410972|NCT00344149|Treatment
1410973|NCT00344149|treatment of Idiopathic Thrombocytopenic Purpura
1410974|NCT00344136|Blood Pressure, High
1410975|NCT00344136|Stroke
1410976|NCT00344136|Hypertension
1410977|NCT00344136|Diabetes Mellitus
1410978|NCT00344136|Obesity
1410979|NCT00344136|Cerebrovascular Accident
1410980|NCT00344136|Atherosclerosis
1410981|NCT00344123|HIV
1410982|NCT00344110|Hypertension, aliskiren, blood pressure, renin
1410983|NCT00344097|soy protein
1410984|NCT00344097|pain
1410985|NCT00344097|thoracotomy
1410986|NCT00344084|Leishmania Major
1410987|NCT00344084|Phlebotomus Duboscqi
1410988|NCT00344084|Dermatology
1410989|NCT00344084|Vector-Transmitted Disease
1410990|NCT00344084|Africa
1410991|NCT00344084|Cutaneous Leishmaniasis
1410992|NCT00344084|CL
1410993|NCT00344071|Clinical
1410994|NCT00344071|Tissue
1410995|NCT00344071|Photographs
1410996|NCT00344071|Women
1410997|NCT00344071|Case-Control
1410998|NCT00344058|pregnancy
1410999|NCT00344058|preeclampsia
1411000|NCT00344058|treatment
1411001|NCT00344045|Subjects with postoperative pain after Total Hip Arthroplasty
1411002|NCT00344032|Double-blind
1411003|NCT00344032|Human Papillomavirus
1411004|NCT00344032|Phase IIIb
1411005|NCT00344032|Controlled
1411006|NCT00344032|Randomized
1411007|NCT00344032|India
1411008|NCT00344019|Acute coronary syndrome
1411009|NCT00344019|Percutaneous coronary intervention
1411010|NCT00344019|Peri-procedure myocardial infarction
1411011|NCT00344006|Malaria CDA COARTEM Africa pediatrics children
1411012|NCT00343993|noninvasive positive pressure ventilation
1411013|NCT00343993|acute lung injury
1411014|NCT00343993|acute respiratory distress syndrome
1411015|NCT00343954|sickle cell disease
1411016|NCT00343941|HIV-1 infection
1411017|NCT00343941|Tucaresol
1411018|NCT00343941|Viral suppression
1411019|NCT00343915|Persistence
1411020|NCT00343915|Hepatitis B vaccine
1411021|NCT00343902|Hawthorn
1411022|NCT00343902|Crataegus
1411023|NCT00343902|Herbs
1411024|NCT00343889|Diphtheria
1411025|NCT00343889|Tetanus
1411026|NCT00343889|Pertussis
1411027|NCT00343889|Hepatitis B Hansenula (HB)
1411028|NCT00343889|Haemophilus influenzae type b
1411029|NCT00343889|Haemophilus Influenzae
1411030|NCT00343876|hs-CRP
1411031|NCT00343876|aspirin
1411032|NCT00343876|clopidogrel
1411033|NCT00343850|idiopathic chronic inflammatory disease of large intestine
1411034|NCT00343850|ulcerative colitis
1411035|NCT00343850|inactive ulcerative colitis
1411036|NCT00343850|chronic disease of large intestine
1411037|NCT00343850|medication adherence
1411038|NCT00343850|Asacol
1411039|NCT00343850|mesalamine
1411040|NCT00343824|Burn wounds - Silver Dressings - Bacterial Control
1411041|NCT00343811|Attention-Deficit/Hyper Activity Disorder
1411042|NCT00343811|ADHD
1411043|NCT00343759|Breast cancer
1411044|NCT00343759|Tyrosine kinase inhibitors
1411045|NCT00343759|Lapatinib
1411046|NCT00343759|Biologic response modifiers
1411047|NCT00343759|Magnetic resonance imaging
1411048|NCT00343759|Treatment-naive, operable
1411049|NCT00343746|macular degeneration
1411050|NCT00343746|glaucoma
1411051|NCT00343746|diabetic retinopathy
1411052|NCT00343746|retinopathy, eye diseases
1411053|NCT00343733|diabetic peripheral neuropathy
1411054|NCT00343733|postherpetic neuralgia
1411055|NCT00343733|traumatic injury
1411056|NCT00343733|complex regional pain syndrome
1411057|NCT00343733|back pain
1411058|NCT00343733|neck pain
1411059|NCT00343733|fibromyalgia
1411060|NCT00343733|chronic pancreatitis
1411061|NCT00343733|osteoarthritis
1411062|NCT00343720|VELCADE
1411063|NCT00343720|Alimta
1411064|NCT00343720|locally advanced
1411065|NCT00343720|metastatic
1411066|NCT00343720|non-small cell lung cancer
1411067|NCT00343720|complete response
1411068|NCT00343720|partial response
1411069|NCT00343720|Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1411070|NCT00343707|Social Anxiety Disorder
1411071|NCT00343707|brain imaging
1411072|NCT00343707|Positron Emission Tomography
1411073|NCT00343707|antidepressant
1411074|NCT00343681|Influenza
1411075|NCT00343681|Orthomyxoviridae Infections
1411076|NCT00343681|Orthomyxoviruses
1411077|NCT00343681|Split-virion influenza vaccine
1411078|NCT00343668|advanced gastric cancer
1411079|NCT00343668|First-line therapy
1411080|NCT00343668|S-1
1411081|NCT00343668|irinotecan
1411082|NCT00343655|Hypercholesterolemia
1411083|NCT00343642|Crohn's disease
1411084|NCT00343642|Fructooligosaccharide
1411085|NCT00343642|Inulin
1411086|NCT00343642|Diet
1411087|NCT00343642|Treatment
1411088|NCT00343642|Bacterial flora
1411089|NCT00343642|Oxidative stress
1411090|NCT00343629|unspecified adult solid tumor, protocol specific
1411091|NCT00343616|cognitive/functional effects
1411092|NCT00343616|fatigue
1411093|NCT00343616|psychosocial effects of cancer and its treatment
1411094|NCT00343616|stage I breast cancer
1411095|NCT00343616|stage II breast cancer
1411096|NCT00343616|stage IIIA breast cancer
1411097|NCT00343603|maculopathy
1411098|NCT00343577|proteinuria
1411099|NCT00343577|ARBs
1411100|NCT00343577|agalsidase-beta
1411101|NCT00343577|MDRD estimated GFR
1411102|NCT00343577|Chronic kidney disease
1411103|NCT00343551|Hypertension, ambulatory blood pressure, missed dose, aliskiren
1411104|NCT00343525|HCV
1411105|NCT00343525|monoclonal antibody
1411106|NCT00343525|phase 1
1411107|NCT00343512|inflammatory breast cancer
1411108|NCT00343512|stage II breast cancer
1411109|NCT00343512|stage IIIA breast cancer
1411110|NCT00343512|stage IIIB breast cancer
1411111|NCT00343512|stage IIIC breast cancer
1411112|NCT00343499|atrial fibrillation
1411113|NCT00343499|valsartan
1411114|NCT00343499|sinus rhythm
1411115|NCT00343499|persistent atrial fibrillation undergoing electrical cardioversion to restore normal sinus rhythm
1411116|NCT00343486|Overactive Bladder
1411117|NCT00343473|Fuch's dystrophy
1411118|NCT00343473|corneal disorders
1411119|NCT00343473|cornea
1411120|NCT00343473|lasik
1411121|NCT00343473|refractive surgery
1411122|NCT00343460|nausea and vomiting
1411123|NCT00343460|unspecified adult solid tumor, protocol specific
1411124|NCT00343447|stage I chronic lymphocytic leukemia
1411125|NCT00343447|stage II chronic lymphocytic leukemia
1411126|NCT00343447|stage III chronic lymphocytic leukemia
1411127|NCT00343447|stage IV chronic lymphocytic leukemia
1411128|NCT00343434|stage I breast cancer
1411129|NCT00343434|stage II breast cancer
1411130|NCT00343434|stage IIIA breast cancer
1411131|NCT00343434|stage IIIB breast cancer
1411132|NCT00343434|stage IIIC breast cancer
1411133|NCT00343434|obesity
1411134|NCT00343421|Diphtheria
1411135|NCT00343421|Tetanus
1411136|NCT00343421|Pertussis
1411137|NCT00343421|Poliomyelitis
1411138|NCT00343421|Haemophilus influenzae type b
1411139|NCT00343421|Pneumococcal infections
1411140|NCT00343408|recurrent non-small cell lung cancer
1411141|NCT00343408|stage IIIB non-small cell lung cancer
1411142|NCT00343408|stage IV non-small cell lung cancer
1411143|NCT00343408|recurrent colon cancer
1411144|NCT00343408|stage III colon cancer
1411145|NCT00343408|stage IV colon cancer
1411146|NCT00343408|recurrent rectal cancer
1411147|NCT00343408|stage III rectal cancer
1411148|NCT00343408|stage IV rectal cancer
1411149|NCT00343395|rosiglitazone
1411150|NCT00343395|metformin
1411151|NCT00343395|hs-CRP
1411152|NCT00343395|inflammation
1411153|NCT00343382|sexuality and reproductive issues
1411154|NCT00343382|sexual dysfunction
1411155|NCT00343382|recurrent breast cancer
1411156|NCT00343382|stage I breast cancer
1411157|NCT00343382|stage II breast cancer
1411158|NCT00343382|stage IIIA breast cancer
1411159|NCT00343382|stage IIIB breast cancer
1411160|NCT00343382|stage IIIC breast cancer
1411161|NCT00343382|stage IV breast cancer
1411162|NCT00343369|B-cell childhood acute lymphoblastic leukemia
1411163|NCT00343369|recurrent childhood acute lymphoblastic leukemia
1411164|NCT00343369|T-cell childhood acute lymphoblastic leukemia
1411165|NCT00343369|untreated childhood acute lymphoblastic leukemia
1411166|NCT00343356|Bladder neoplasm;
1411167|NCT00343356|Carcinoma;
1411168|NCT00343356|Epirubicin;
1411169|NCT00343356|BCG;
1411170|NCT00343356|Perfusion
1411171|NCT00343317|puerperal sepsis
1411172|NCT00343317|HIV infection
1411173|NCT00343317|prophylactic antibiotics
1411174|NCT00343304|Stroke.Robot.Ergometer.Group OT
1411175|NCT00343291|Non-Small Cell Lung Cancer
1411176|NCT00343291|Malignant pleural effusions
1411177|NCT00343278|Valaciclovir Hydrochloride
1411178|NCT00343278|hemodialysis patient
1411179|NCT00343278|ALDH
1411180|NCT00343278|pharmacokinetics
1411181|NCT00343278|Japanese
1411182|NCT00343265|Preterm birth
1411183|NCT00343265|Multiple pregnancy
1411184|NCT00343265|Vaginal progesterone
1411185|NCT00343265|Preterm birth in multiple pregnancy
1411186|NCT00343226|Basiliximab, transplantation, liver, renal function
1411187|NCT00343213|Prognostic value of p16INK4a
1411188|NCT00343213|CIN 1
1411189|NCT00343213|LSIL
1411190|NCT00343213|HPV
1411191|NCT00343187|Tarceva
1411192|NCT00343187|Rash
1411193|NCT00343187|EGFR-1 Rash
1411194|NCT00343187|erlotinib
1411195|NCT00343187|Aczone
1411196|NCT00343187|Dapsone
1411197|NCT00343187|Non-small Cell Lung Cancer
1411198|NCT00343187|subjects treated with Tarceva for non-small cell lung cancer (NSCLC) who subsequently develop a rash suspected to be related to Tarceva
1411199|NCT00343174|stroke
1411200|NCT00343174|vascular diseases
1411201|NCT00343161|Nexium
1411202|NCT00343135|Skin
1411203|NCT00343135|AUGMENTIN
1411204|NCT00343135|1gm
1411205|NCT00343135|Soft
1411206|NCT00343135|tissue
1411207|NCT00343135|Infections
1411208|NCT00343122|liver
1411209|NCT00343122|cirrhosis
1411210|NCT00343122|hepatopulmonary syndrome
1411211|NCT00343096|intranasal
1411212|NCT00343096|buccal
1411213|NCT00343096|lorazepam
1411214|NCT00343096|paediatric
1411215|NCT00343096|convulsions
1411216|NCT00343083|Head and Neck Neoplasms
1411217|NCT00343044|platinum resistant ovarian cancer
1411218|NCT00343044|recurrent ovarian cancer
1411219|NCT00343044|platinum resistant cancer
1411220|NCT00343031|Insecticides
1411221|NCT00343031|Children
1411222|NCT00343031|Women
1411223|NCT00343031|Infection
1411224|NCT00343031|DDT
1411225|NCT00343031|Contaminant
1411226|NCT00343018|Preschoolers
1411227|NCT00343018|Young Children
1411228|NCT00343018|Eyewitness
1411229|NCT00343018|Memory
1411230|NCT00343005|Blood-Stage
1411231|NCT00343005|Investigational
1411232|NCT00343005|Endemic
1411233|NCT00343005|Malaria
1411234|NCT00343005|Vaccine
1411235|NCT00342992|Vitamin E
1411236|NCT00342992|Micronutrients
1411237|NCT00342992|Genetics
1411238|NCT00342992|Smoking
1411239|NCT00342992|Biomarkers
1411240|NCT00342966|Metabolism
1411241|NCT00342966|Tracer Studies
1411242|NCT00342966|Chemoprevention
1411243|NCT00342966|Selenomethionine
1411244|NCT00342966|Plasma Selenoproteins
1411245|NCT00342953|saline
1411246|NCT00342953|silicone
1411247|NCT00342953|Breast Implants
1411248|NCT00342953|augmentation mammoplasty
1411249|NCT00342953|visk
1411250|NCT00342940|influenza
1411251|NCT00342940|influenza vaccine
1411252|NCT00342940|flu
1411253|NCT00342940|vaccination
1411254|NCT00342940|immunogenicity
1411255|NCT00342927|American Indians
1411256|NCT00342927|Complications
1411257|NCT00342927|Genetics
1411258|NCT00342927|Linkage
1411259|NCT00342927|Type 2 Diabetes
1411260|NCT00342927|Diabetic Kidney Disease
1411261|NCT00342888|Childhood Cancer
1411262|NCT00342888|Pesticides
1411263|NCT00342888|Polychlorinated Biphenyls
1411264|NCT00342888|Organochlorines
1411265|NCT00342888|Polybrominated Diphenyl Ethers
1411266|NCT00342875|Bladder Cancer
1411267|NCT00342875|Exposure
1411268|NCT00342875|Drinking Water
1411269|NCT00342862|Pregnancy
1411270|NCT00342862|Amevive
1411271|NCT00342862|alefacept
1411272|NCT00342862|Registry
1411273|NCT00342862|Psoriasis
1411274|NCT00342849|Clinical Trial
1411275|NCT00342849|Low-level Lead Poisoning
1411276|NCT00342849|Chelation
1411277|NCT00342849|Developmental Assessment
1411278|NCT00342849|Succimer
1411279|NCT00342836|Akt
1411280|NCT00342836|Immunohistochemistry
1411281|NCT00342836|Myoinositol
1411282|NCT00342836|Bronchial Specimens
1411283|NCT00342836|Phosphorylation
1411284|NCT00342823|Linkage Analysis
1411285|NCT00342823|Canidate Gene Analysis
1411286|NCT00342823|Genome Scan
1411287|NCT00342823|L. Chagasi
1411288|NCT00342823|Visceral Leishmania
1411289|NCT00342810|Eye Diseases
1411290|NCT00342797|second primary cancer
1411291|NCT00342797|retinoblastoma
1411292|NCT00342797|RB1 germline mutation
1411293|NCT00342784|Mutation
1411294|NCT00342784|Cancer Genetics
1411300|NCT00342758|Asthma
1411301|NCT00342758|Wheeze
1411302|NCT00342758|Environment
1411303|NCT00342758|Diet
1411304|NCT00342758|Infection
1411305|NCT00342732|Genetics
1411306|NCT00342732|Fat Intake
1411307|NCT00342732|Pima Indians
1411308|NCT00342732|Weight Control
1411309|NCT00342732|Appetite Control
1411310|NCT00342706|Teen Pregnancy
1411311|NCT00342706|Short Inter-Pregnancy Intervals
1411312|NCT00342693|Radiation
1411313|NCT00342693|Screening
1411314|NCT00342693|Cancer
1411315|NCT00342693|Nodules
1411316|NCT00342693|Nuclear
1411317|NCT00342693|Thyroid Screening
1411318|NCT00342693|Thyroid Gland
1411319|NCT00342667|Preterm Birth
1411320|NCT00342667|Predictors of Outcome
1411321|NCT00342667|Neonatal/Infant Complications
1411322|NCT00342667|Neurologic Development
1411323|NCT00342667|(SqrRoot) mniotic Fluid
1411324|NCT00342667|Cerebral Palsy
1411325|NCT00342667|Risk Factors
1411326|NCT00342654|Epidemiology
1411327|NCT00342654|Cancer
1411328|NCT00342654|Environment
1411329|NCT00342654|Genetics
1411330|NCT00342654|Nutrition
1411331|NCT00342641|Lymphoma
1411332|NCT00342641|Multiple Myeloma
1411333|NCT00342641|Thyroiditis
1411334|NCT00342641|Cohort Study
1411335|NCT00342641|Record linkage study
1411336|NCT00342641|Hepatitis C
1411337|NCT00342628|Antibody
1411338|NCT00342628|Reactions
1411339|NCT00342628|Vaccine
1411340|NCT00342628|Conjugate Vaccine
1411341|NCT00342628|Typhoid Fever
1411342|NCT00342628|Trial
1411343|NCT00342628|Safety
1411344|NCT00342628|Immunogenicity
1411345|NCT00342628|Comparability
1411346|NCT00342628|DTP
1411347|NCT00342602|JC Virus
1411348|NCT00342602|Opportunistic Infection
1411349|NCT00342602|Single Nucleotide Polymorphism
1411350|NCT00342602|Genotype
1411351|NCT00342602|Sequencing
1411352|NCT00342589|Pneumocystis
1411353|NCT00342589|HIV
1411354|NCT00342589|Oral Wash
1411355|NCT00342589|PCR
1411356|NCT00342589|Drug Resistance
1411357|NCT00342576|Filarial Parasites
1411358|NCT00342576|Wuchereria Bancrofti
1411359|NCT00342576|Brugia Malayi
1411360|NCT00342576|Diethylcarbamazine (DEC)
1411361|NCT00342576|Ivermectin
1411362|NCT00342563|mecamylamine
1411363|NCT00342563|treatment
1411364|NCT00342563|alcohol dependence
1411365|NCT00342563|smoking
1411366|NCT00342550|Pregnancy
1411367|NCT00342550|Preterm Birth
1411368|NCT00342550|Pregnancy Complications
1411369|NCT00342537|Pathology
1411370|NCT00342537|Genetics
1411371|NCT00342537|Testicular Cancer
1411372|NCT00342537|Familial
1411373|NCT00342537|Cancer Epidemiology
1411374|NCT00342524|IVIG
1411375|NCT00342524|Plasmapheresis
1411376|NCT00342524|Blood Collection
1411377|NCT00342524|Immune Globulin
1411378|NCT00342524|Severe Acute Respiratory Syndrome
1411379|NCT00342524|SARS
1411380|NCT00342511|Pap
1411381|NCT00342511|Hybrid Capture 2
1411382|NCT00342511|HSIL
1411383|NCT00342511|Colposcopy
1411384|NCT00342511|CIN
1411385|NCT00342511|Specimen Collection
1411386|NCT00341445|Environmental Intervention
1411387|NCT00341445|Indoor Allergens
1411388|NCT00341445|Environment
1411389|NCT00341432|NRT Study
1411390|NCT00341432|Smoking Cessation
1411391|NCT00341419|ABC Transporter
1411392|NCT00341419|ABCC6
1411393|NCT00341419|Slkin Laxity
1411394|NCT00341419|Genetic Association
1411395|NCT00341419|Angiod Streaks
1411396|NCT00341419|Pseudoxanthoma Elasticum
1411397|NCT00341419|PXE
1411401|NCT00341393|HIV Infection
1411402|NCT00341393|AIDS
1411403|NCT00341393|Viral Load
1411404|NCT00341393|Retroviral Treatment
1411405|NCT00341393|Uganda
1411406|NCT00341380|Cancer
1411407|NCT00341380|Lung Cancer
1411408|NCT00341380|Surgical Resection
1411409|NCT00341380|Non-Small Cell Lung Cancer
1411410|NCT00341380|NSCLC
1411411|NCT00341367|Analgesic
1411412|NCT00341367|Back Pain
1411413|NCT00341367|Lumbar Disc
1411414|NCT00341367|Nerve
1411415|NCT00341367|Radiculopathy
1411416|NCT00341354|Pneumonia
1411417|NCT00341354|Bacterial Infection
1411418|NCT00341354|Nosocomial Infection
1411419|NCT00341354|Trachea
1411420|NCT00341354|Biofilm
1411421|NCT00341354|Mucus Shaver
1411422|NCT00342498|DNA
1411423|NCT00342498|Hormone
1411424|NCT00342498|Resistance
1411425|NCT00342498|Skeleton
1411426|NCT00342485|Cellular Immunity
1411427|NCT00342485|HIV-infected
1411428|NCT00342485|Immune Deficiency
1411429|NCT00342485|Cancer
1411430|NCT00342485|Transplantation
1411431|NCT00342472|Esophageal Cancer
1411432|NCT00342472|Polycyclic Aromatic Hydrocarbons
1411433|NCT00342446|GONADOTROPIN
1411434|NCT00342446|CLOMIPHENE
1411435|NCT00342446|Ovulation-Stimulating Drugs
1411436|NCT00342433|Androgens
1411437|NCT00342433|Serum
1411438|NCT00342433|Tissue
1411439|NCT00342407|Cancer Risk
1411440|NCT00342407|Cosmic Radiation
1411441|NCT00342407|Airlines
1411442|NCT00342407|Flight Attendants
1411443|NCT00342407|Circadian Rhythm
1411444|NCT00342394|Biological Monitoring
1411445|NCT00342394|Exposure Determinants
1411446|NCT00342394|Exposure Validation
1411447|NCT00342394|Occupational Exposure
1411448|NCT00342394|Pesticides
1411449|NCT00342394|Agriculture
1411450|NCT00342381|Motor fatigue
1411451|NCT00342381|Cognitive fatigue
1411452|NCT00342368|CPAP
1411453|NCT00342368|ARDS
1411454|NCT00342368|ALI
1411455|NCT00342368|Hypoxemia
1411456|NCT00342368|Intubation
1411457|NCT00342355|Protease Inhibitors
1411458|NCT00342355|Reverse Transcriptase Inhibitors
1411459|NCT00342355|AIDS
1411460|NCT00342355|Opportunistic Infections
1411461|NCT00342355|Resource-Poor
1411462|NCT00342342|Genetics
1411463|NCT00342329|Case-Control
1411464|NCT00342329|Hydrocarbons
1411465|NCT00342329|Metals
1411466|NCT00342329|Silica
1411467|NCT00342329|Tobacco Smoke
1411468|NCT00342329|Lupus Nephritis
1411469|NCT00342329|Environmental Exposures
1411470|NCT00342329|Occupational Exposures
1411471|NCT00342316|Acute Myeloid Leukemia
1411472|NCT00342316|Stem Cell Transplantation
1411473|NCT00342316|Reduced Intensity Conditioning
1411474|NCT00342316|Survival
1411475|NCT00342316|Relapse
1411476|NCT00342303|Premature Infants
1411477|NCT00342303|Fatty Acid Metabolism
1411478|NCT00342303|Polyunsaturated Fatty Acids
1411479|NCT00342303|Infant Formula
1411480|NCT00342303|Gas-chromatography
1411481|NCT00342303|Mass Spectrometry
1411482|NCT00342290|Pathophysiological Volume Measurement
1411483|NCT00342290|Power Doppler Ultrasound
1411484|NCT00342290|Prediction of Adverse Pregnancy Outcome
1411485|NCT00342290|Subchorionic Hemorrhage
1411486|NCT00342277|Premature Rupture of Membranes
1411487|NCT00342277|Genetic Risk Factors
1411488|NCT00342277|Tissue Specific Expression
1411489|NCT00342277|Quantitative Real Time PCR
1411490|NCT00342277|Preterm Birth
1411491|NCT00342277|Expression Profiling
1411492|NCT00342277|Microarrays
1411493|NCT00342264|Lung Cancer
1411494|NCT00342264|Smoking
1411495|NCT00342264|Diesel Exhaust
1411496|NCT00342251|Macular Degeneration
1411497|NCT00342251|Retinal Images
1411498|NCT00342251|Risk Factors
1411499|NCT00342251|Linkage Analysis
1411500|NCT00342251|Gene
1411501|NCT00342251|Mutation
1411502|NCT00342225|Observation
1411503|NCT00342225|Mothers
1411504|NCT00342225|Description
1411505|NCT00342212|Walking
1411506|NCT00342212|Jogging
1411507|NCT00342212|Bridging Study
1411508|NCT00342212|Data Comparability
1411509|NCT00342212|Healthy Adults
1411510|NCT00342212|Healthy Volunteer
1411511|NCT00342212|HV
1411512|NCT00342199|Incidence
1411513|NCT00342199|Prevalence
1411514|NCT00342199|Immunity
1411515|NCT00342199|Bacteriology
1411516|NCT00342199|Pathogenesis
1411517|NCT00342186|China
1411518|NCT00342186|Cancer
1411519|NCT00342186|Hepatitis B
1411520|NCT00342186|Genetics
1411521|NCT00342186|Liver Disease
1411522|NCT00342186|HBV
1411523|NCT00342173|Cervix
1411524|NCT00342173|Natural History
1411525|NCT00342173|Neoplasia
1411526|NCT00342173|HPV
1411527|NCT00342173|Costa Rica
1411528|NCT00342160|AIDS
1411529|NCT00342160|HIV Infectiousness
1411530|NCT00342160|Immunity
1411531|NCT00342160|CTL
1411532|NCT00342160|Epidemiology
1411533|NCT00342147|EBV
1411534|NCT00342147|NPC
1411535|NCT00342134|Demyelination
1411536|NCT00342134|Inflammation
1411537|NCT00342134|Immunosuppression
1411538|NCT00342134|Autoimmunity
1411539|NCT00342134|Bone Marrow
1411540|NCT00342134|Multiple Sclerosis
1411541|NCT00342121|Cancer
1411542|NCT00342121|NHL
1411543|NCT00342121|Pesticides
1411544|NCT00342121|Atrazine
1411545|NCT00342121|Organophosphates
1411546|NCT00342121|Cancer Risk
1411547|NCT00342121|Normal Control
1411548|NCT00342095|Autoimmune Diseases
1411549|NCT00342095|Estrogen
1411550|NCT00342095|Silica
1411551|NCT00342095|Pesticides
1411552|NCT00342095|Major Histocompatibility Complex
1411553|NCT00342095|Genetic Susceptibility
1411554|NCT00342082|Zidovudine
1411555|NCT00342082|HIV
1411556|NCT00342082|Cord Blood
1411557|NCT00342069|Decision Making
1411558|NCT00342069|Genetic Counseling
1411559|NCT00342069|Pregnancy Options
1411560|NCT00342069|Attitudes Toward Reproductive Options
1411561|NCT00342069|Beliefs About Down Syndrome Risk
1411562|NCT00342069|Down Syndrome Risk
1411563|NCT00342069|Pregnancy
1411564|NCT00342056|Pharmacogenetics
1411565|NCT00342056|Transporter Proteins
1411566|NCT00342056|Drug Exposure
1411567|NCT00342056|Imatinib
1411568|NCT00342056|Retrospective
1411569|NCT00342056|Cancer
1411570|NCT00342043|Sickle Trait
1411571|NCT00342043|Fetal Hemoglobin
1411572|NCT00342043|Hemoglobin C
1411573|NCT00342043|Beta-Thalassemia
1411574|NCT00342043|Artesunate-Amodiaquine
1411575|NCT00342030|Respiratory
1411576|NCT00342030|Polymorphism
1411577|NCT00342030|Fruit
1411578|NCT00342030|COPD
1411579|NCT00342030|Prospective
1411580|NCT00342030|Diet
1411581|NCT00342017|Filarial Infections
1411582|NCT00342017|Helminths
1411583|NCT00342017|Tuberculosis
1411584|NCT00342017|Filarial Infection
1411585|NCT00342004|Shanghai
1411586|NCT00342004|Residential History
1411587|NCT00342004|Exposure Assessment
1411588|NCT00342004|Cohort Study
1411589|NCT00342004|Molecular Epidemiology
1411590|NCT00341991|DNA Repair
1411591|NCT00341991|Genes
1411592|NCT00341991|Pigmentation
1411593|NCT00341991|Skin Cancer
1411594|NCT00341991|Sun Exposure
1411595|NCT00341965|DDT
1411596|NCT00341965|DDE
1411597|NCT00341965|Androgen Levels
1411598|NCT00341965|Farming
1411599|NCT00341965|Antiandrogen
1411600|NCT00341952|Case-Control Study
1411601|NCT00341952|Non-Hodgkin Lymphoma
1411602|NCT00341939|Drug Therapy
1411603|NCT00341939|Pharmacogenetics
1411604|NCT00341939|Cancer
1411605|NCT00341939|Pharmacodynamics
1411606|NCT00341939|Parmacokinetics
1411607|NCT00341913|Research
1411608|NCT00341913|Repository
1411609|NCT00341913|Registry
1411610|NCT00341913|Surveillance
1411611|NCT00341913|Databases
1411612|NCT00341900|Chromosome Translocations
1411613|NCT00341900|Cosmic Radiation
1411614|NCT00341900|Airline Flight Crew
1411615|NCT00341900|Airlines
1411616|NCT00341900|Flight Crew
1411617|NCT00341900|Occupational Exposure
1411618|NCT00341887|Screening
1411619|NCT00341887|AIDS
1411620|NCT00341887|Antiretrovirals
1411621|NCT00341887|Military
1411622|NCT00341887|Force readiness
1411623|NCT00341874|DNA Mutations
1411624|NCT00341874|Genetic Variation
1411625|NCT00341874|GENETIC LINKAGE
1411626|NCT00341874|Gene Expression Patterns
1411627|NCT00341874|Hereditary Hearing Disorder
1411628|NCT00341861|Bladder Cancer
1411629|NCT00341861|Occupational and Environmental Risks
1411630|NCT00341861|Lifestyle Factors
1411631|NCT00341861|Epidemiology
1411632|NCT00341861|Genetic Susceptibility
1411633|NCT00341848|Apoptosis
1411634|NCT00341848|Environment
1411635|NCT00341848|Infection
1411636|NCT00341848|Inflammation
1411637|NCT00341848|Leiomyoma
1411638|NCT00341848|Uterine Leiomyoma
1411639|NCT00341848|Uterus
1411640|NCT00341835|Linkage Analysis
1411641|NCT00341835|Cancer Susceptibility Alleles
1411642|NCT00341835|Cancer Genetics
1411643|NCT00341835|Linkage Mapping
1411644|NCT00341835|Linkage Disequilibrium
1411645|NCT00341822|Amniocentesis
1411646|NCT00341822|Chorionic Villus Sampling
1411647|NCT00341822|Fertility
1411648|NCT00341822|Genetic Counseling
1411649|NCT00341822|Decisional Conflict
1411650|NCT00341822|Prenatal Testing
1411651|NCT00341822|Questionnaire
1411652|NCT00341809|Natural Killer Cells
1411653|NCT00341809|Autoimmune Disease
1411654|NCT00341809|Chronic Inflammation
1411655|NCT00341809|Two-Locus Interaction
1411656|NCT00341809|Allele/Haplotype Analysis
1411657|NCT00341796|AIDS
1411658|NCT00341796|HIV
1411659|NCT00341796|Perinatal
1411660|NCT00341796|Transmission
1411661|NCT00341796|Antiretroviral
1411662|NCT00341796|Outcomes
1411663|NCT00341783|Plasmodium
1411664|NCT00341783|Falciparum
1411665|NCT00341783|Screening
1411666|NCT00341783|Malaria
1411667|NCT00341757|Family Reports
1411668|NCT00341757|Cancer
1411669|NCT00341757|Questionnaire
1411670|NCT00341757|Validity
1411671|NCT00341757|Surveillance
1411672|NCT00341744|Vision
1411673|NCT00341744|Aids
1411674|NCT00341731|Cystic Ovaries
1411675|NCT00341731|Environmental Factors
1411676|NCT00341731|Heritability
1411677|NCT00341731|Hyperandrogenism
1411678|NCT00341731|Twin Study
1411679|NCT00341718|Interview
1411680|NCT00341718|Genetics
1411681|NCT00341705|AIDS
1411682|NCT00341705|Cancer
1411683|NCT00341705|Hepatitis C Virus
1411684|NCT00341705|HIV
1411685|NCT00341705|Natural History
1411686|NCT00341705|Hemophilia
1411687|NCT00341705|Hepatitis C
1411688|NCT00341692|Mammary
1411689|NCT00341692|Development
1411690|NCT00341692|Cancer
1411691|NCT00341692|Risk
1411692|NCT00341692|Genes
1411693|NCT00341679|Autoimmune Diseases
1411694|NCT00341679|Genetic Risk Factors
1411695|NCT00341679|Polymyositis
1411696|NCT00341679|Dermatomyositis
1411697|NCT00341679|Connective Tissue Disorders
1411698|NCT00341679|Idiopathic Inflammatory Myopathies
1411699|NCT00341679|Inclusion Body Myositis
1411700|NCT00341679|Pathogenesis
1411701|NCT00341679|Environmental Risk Factor
1411702|NCT00341679|IIM
1411703|NCT00341666|Immune Regulation
1411704|NCT00341666|Co-Infection
1411705|NCT00341666|Filariasis
1411706|NCT00341666|Immunology
1411707|NCT00341666|Filarial Infection
1411708|NCT00341653|Asthma
1411709|NCT00341653|Pulmonary Function
1411710|NCT00341653|Air Pollution
1411711|NCT00341653|Genetic Polymorphism
1411712|NCT00341653|Environmental Tobacco Agents
1411713|NCT00341640|Teen Pregnancy
1411714|NCT00341627|Bone Tumor
1411715|NCT00341627|Familial Chordoma
1411716|NCT00341627|Gene Mapping
1411717|NCT00341627|Genetics
1411718|NCT00341627|Sporadic Chordoma
1411719|NCT00341614|Exercise
1411720|NCT00341614|Diabetes Mellitus, Type 2
1411721|NCT00341614|Postmenopause
1411722|NCT00341614|Diet
1411723|NCT00341601|Mycobacterium Tuberculosis
1411724|NCT00341601|TLR-2
1411725|NCT00341601|Recurrent Tuberculosis
1411726|NCT00341601|Phenolic Glycolipid
1411727|NCT00341601|mRNA Expression Profiles
1411728|NCT00341588|Testicular Cancer
1411729|NCT00341588|Epidemiology
1411730|NCT00341588|Testicular Germ Cell Cancer
1411731|NCT00341588|TGCT
1411732|NCT00341588|Healthy Volunteer
1411733|NCT00341575|Family Systems
1411734|NCT00341575|Communication
1411735|NCT00341575|Information Diffusion
1411736|NCT00341575|Social Networks
1411737|NCT00341575|Family Dynamics
1411738|NCT00341562|Gene Expression Profiling
1411739|NCT00341562|Vascular Disease
1411740|NCT00341549|Linkage
1411741|NCT00341549|Genetics
1411742|NCT00341549|Mapping
1411743|NCT00341549|Gene
1411744|NCT00341549|Susceptibility
1411745|NCT00341549|Myopia
1411746|NCT00341549|Nearsightedness
1411747|NCT00341549|Refraction
1411748|NCT00341549|Eye
1411749|NCT00341536|Diet
1411750|NCT00341536|Pilot
1411751|NCT00341536|Cohort
1411752|NCT00341536|Environmental
1411753|NCT00341536|Chronic Disease
1411754|NCT00341523|Cytology
1411755|NCT00341523|Endoscopy
1411756|NCT00341523|Esophageal Cancer
1411757|NCT00341523|Early Detection
1411758|NCT00341523|Treatment
1411759|NCT00341510|Risk Behavior
1411760|NCT00341510|Health Status
1411761|NCT00341510|Adolescence
1411762|NCT00341510|Positive Health Behaviors
1411763|NCT00341510|Social Support
1411764|NCT00341510|Health Behavior
1411765|NCT00341510|Survey
1411766|NCT00341497|Leukoplakia
1411767|NCT00341497|Oral Mucosa
1411768|NCT00341497|Biomarkers
1411769|NCT00341484|Genetics
1411770|NCT00341484|Liver Cancer
1411771|NCT00341484|HIV
1411772|NCT00341471|School
1411773|NCT00341471|Sixth Grade
1411774|NCT00341471|Curricular
1411775|NCT00341471|Howard University
1411776|NCT00341471|D.C.
1411777|NCT00341471|Adolescent Pregnancy
1411778|NCT00341471|Intervention
1411779|NCT00341458|Breast Cancer
1411780|NCT00341458|Environment
1411781|NCT00341458|Genetics
1411782|NCT00341458|Epidemiology
1411783|NCT00341341|Smoking
1411784|NCT00341341|Smoking Cessation
1411785|NCT00341341|GSTM1
1411786|NCT00341341|Glutathione S. Transferase
1411787|NCT00341341|Lung Cancer
1411788|NCT00341341|Smokers
1411789|NCT00341341|Genetic Risk Communication
1411790|NCT00341328|India
1411791|NCT00341328|Pulmonary Tuberculosis
1411792|NCT00341328|Category-I Pulmonary Tuberculosis
1411793|NCT00341328|Immunomodulator
1411794|NCT00341328|Mycobacterium w
1411795|NCT00341315|Epidemiology
1411796|NCT00341315|DDT
1411797|NCT00341315|BMI
1411798|NCT00341315|Serum
1411799|NCT00341315|Case-Control Study
1411800|NCT00341302|HIV
1411801|NCT00341302|AIDS
1411802|NCT00341302|Perinatal
1411803|NCT00341302|Transmission
1411804|NCT00341302|Antiretroviral
1411805|NCT00341302|Outcomes
1411806|NCT00341289|Submersion
1411807|NCT00341289|Epidemiology
1411808|NCT00341289|Fatal
1411809|NCT00341289|Child
1411810|NCT00341289|Swim
1411811|NCT00341289|Drowning
1411812|NCT00341289|Survey
1411813|NCT00341276|Esophageal Cancer
1411814|NCT00341276|Genetics
1411815|NCT00341276|Polymorphism
1411816|NCT00341276|Susceptibility Genes
1411817|NCT00341276|Tumor
1411818|NCT00341263|Twins
1411819|NCT00341263|Clinical Research
1411820|NCT00341263|Endocrinology
1411821|NCT00341263|Breast Cancer
1411822|NCT00341263|Biochemical Epidemiology
1411823|NCT00341250|Blood Stage
1411824|NCT00341250|Investigational
1411825|NCT00341250|Endemic
1411826|NCT00341250|Malaria
1411832|NCT00341224|Aggression
1411833|NCT00341224|Violence
1411834|NCT00341224|Adolescents
1411835|NCT00341224|Randomized Trial
1411836|NCT00341224|Behavioral Intervention
1411837|NCT00341211|AIDS
1411838|NCT00341211|Cancer
1411839|NCT00341211|Epidemiology
1411840|NCT00341211|Immunology
1411841|NCT00341211|Virology
1411842|NCT00341198|Rheumatoid Arthritis
1411843|NCT00341198|Lupus
1411844|NCT00341198|Scleroderma
1411845|NCT00341198|Sjogren's Syndrome
1411846|NCT00341198|Farming
1411847|NCT00341198|Autoimmune Disease
1411848|NCT00341198|Exposure
1411849|NCT00341185|Biodosimetry
1411850|NCT00341185|Dose Reconstruction
1411851|NCT00341185|Radioactive Fallout
1411852|NCT00341185|Thyroid Screening
1411853|NCT00341185|Ultrasound
1411854|NCT00341172|Retinitis
1411855|NCT00341172|Cytomegalovirus
1411856|NCT00341172|HIV-1
1411857|NCT00341172|Polymorphisms
1411858|NCT00341172|HAART
1411859|NCT00341159|Breast
1411860|NCT00341159|BRCA1
1411861|NCT00341159|BRCA2
1411862|NCT00341159|Inherited
1411863|NCT00341159|Association
1411864|NCT00341159|Breast Cancer
1411865|NCT00341159|Population-Based
1411866|NCT00341159|Cancer Susceptibility Alleles
1411867|NCT00341146|Cancer
1411868|NCT00341146|Catonese Chinese
1411869|NCT00341146|Genetic Predisposition
1411870|NCT00341146|Genotyping
1411871|NCT00341146|Triad analysis
1411872|NCT00341146|Nasopharyngeal Cancer
1411873|NCT00341146|NPC
1411874|NCT00341133|Laterality
1411875|NCT00341133|Heterotaxy
1411876|NCT00341133|Holoprosencephaly
1411877|NCT00341133|Genetic Testing
1411878|NCT00341133|Congential Cardiac Malformations
1411879|NCT00341133|Disturbed Internal Organ Positioning
1411880|NCT00341120|Genotypes
1411881|NCT00341120|Mutation
1411882|NCT00341120|Folate
1411883|NCT00341120|Male Infertility
1411884|NCT00341120|Nutrition
1411885|NCT00341107|Cancer
1411886|NCT00341107|Genes
1411887|NCT00341107|Screening
1411888|NCT00341107|Primary Care
1411889|NCT00341107|Inherited Susceptibility
1411890|NCT00341094|Cohort
1411891|NCT00341094|Radiation
1411892|NCT00341094|In Utero
1411893|NCT00341094|Genomic
1411894|NCT00341081|Short Tandem Repeat
1411895|NCT00341081|Molecular Epidemiology
1411896|NCT00341081|Viral Infection
1411897|NCT00341081|Mixture Detection
1411898|NCT00341081|Intervention & Education
1411899|NCT00341081|Intervention
1411900|NCT00341081|Education
1411901|NCT00341068|Birth Defects
1411902|NCT00341068|Genetics
1411903|NCT00341068|Folic Acid
1411904|NCT00341068|Gene-Environment Interactions
1411905|NCT00341068|Neural Tube Defects
1411906|NCT00341068|Cleft Lip
1411907|NCT00341068|Cleft Palate
1411908|NCT00341068|Mutations
1411909|NCT00341055|Anemia
1411910|NCT00341055|Hemoglobin
1411911|NCT00341055|Chemotherapy
1411912|NCT00341055|Epoetin alfa
1411913|NCT00341042|Normal Values
1411914|NCT00341042|Complete Blood Count
1411915|NCT00341042|HIV
1411916|NCT00341042|Tuberculosis
1411917|NCT00341042|Flow Cytometry
1411918|NCT00341029|Longitudinal Study
1411919|NCT00341029|Chromosomal Effects
1411920|NCT00341029|Sister Chromatid Exchanges
1411921|NCT00341029|Micronuclei
1411922|NCT00341029|Stimulants
1411923|NCT00341029|Attention Deficit Hyperactivity Disorder
1411924|NCT00341029|ADHD
1411925|NCT00341016|Radiation
1411926|NCT00341003|Plasmodium Falciparum
1411927|NCT00341003|Hemoglobin E
1411928|NCT00341003|Mefloquine
1411929|NCT00341003|Artemisinin
1411930|NCT00341003|Piperaquine
1411931|NCT00341003|Malaria
1411932|NCT00340990|Tuberculosis
1411933|NCT00340990|HIV
1411934|NCT00340990|CD4+ T Cell
1411935|NCT00340990|Interferon-Gamma
1411936|NCT00340990|Lymphocyte Proliferation
1411937|NCT00340977|Birth Defects
1411938|NCT00340977|Case-Control Studies
1411939|NCT00340977|Genetic Susceptibility
1411940|NCT00340964|Photography
1411941|NCT00340964|Self-Esteem
1411942|NCT00340964|Perceived Social Stigma
1411943|NCT00340964|Hopefulness
1411944|NCT00340964|Cleft Lip and Palate
1411945|NCT00340964|Hemifacial Microsomia
1411946|NCT00340964|Treacher Collins Syndrome
1411947|NCT00340964|Mobius Syndrome
1411948|NCT00340964|Apert Syndrome
1411949|NCT00340964|Videography
1411950|NCT00340964|Craniofacial Differences
1411951|NCT00340964|Self -Esteem
1411952|NCT00340951|Regulatory T Cells
1411953|NCT00340951|Bronchiolitis Obliterans Syndrome
1411954|NCT00340951|Genetic Polymorphism
1411955|NCT00340951|Innate Immunity
1411956|NCT00340951|Transplantation
1411957|NCT00340951|Lung Transplantation
1411958|NCT00340938|Adherence
1411959|NCT00340938|Education
1411960|NCT00340938|Problem Solving
1411961|NCT00340938|Motivation
1411962|NCT00340938|Locus of Responsibility
1411963|NCT00340912|Skin Biopsy
1411964|NCT00340899|Perinatal Mortality
1411965|NCT00340899|Perinatal Morbidity
1411966|NCT00340899|Preterm Birth
1411967|NCT00340899|Pregnancy Complications
1411968|NCT00340899|Pregnancy
1411969|NCT00340886|Genetic Susceptibility
1411970|NCT00340886|Single Nucleotide Polymorphism
1411971|NCT00340886|Environmental Risk Factor
1411972|NCT00340886|Allelic Variants
1411973|NCT00340886|Ascertainment by Genotype
1411974|NCT00340873|Molecular Epidemiology
1411975|NCT00340873|Cross-Sectional
1411976|NCT00340873|Gene-Enviroment Interaction
1411977|NCT00340860|Ultrasound
1411978|NCT00340860|Biobank
1411979|NCT00340860|Urine
1411980|NCT00340860|Blood
1411981|NCT00340860|Exposure
1411982|NCT00340860|Norway Mother and Child Study
1411983|NCT00340847|Molecular Profiling
1411984|NCT00340847|In Situ Hybridization
1411985|NCT00340847|SAGE
1411986|NCT00340847|Tumor Markers
1411987|NCT00340847|IHC
1411988|NCT00340847|Lung Cancer
1411989|NCT00340847|Genetics
1411990|NCT00340834|FTY720
1411991|NCT00340834|Interferon
1411992|NCT00340834|RRMS
1411993|NCT00340834|Multiple Sclerosis
1411994|NCT00340834|Efficacy
1411995|NCT00340821|HTLV-I
1411996|NCT00340808|Endometrial Cancer
1411997|NCT00340808|Epidemiology
1411998|NCT00340808|Questionnaire
1411999|NCT00340808|Etiology
1412000|NCT00340808|Biomarkers
1412001|NCT00340795|Media Analysis
1412002|NCT00340795|Nutrition
1412003|NCT00340795|Physical Activity
1412004|NCT00340795|After-School
1412005|NCT00340795|Exercise
1412006|NCT00340782|Menstrual Cycles
1412007|NCT00340782|Early Pregnancy
1412008|NCT00340782|Reproductive Hormones
1412009|NCT00340782|Stress
1412010|NCT00340782|Adrenal Function
1412011|NCT00340769|Cytokines
1412012|NCT00340769|Inflammation
1412013|NCT00340769|mRNA Stability
1412014|NCT00340769|Pygmy
1412015|NCT00340769|Zinc Finger Proteins
1412016|NCT00340769|Ethnic Group
1412017|NCT00340756|GCMS
1412018|NCT00340756|LCMS-MS
1412019|NCT00340743|Heterocyclic Aminos
1412020|NCT00340743|Cruciferous Vegetables
1412021|NCT00340743|Yogurt
1412022|NCT00340743|Chlorophyllin
1412023|NCT00340743|Comet Assay
1412024|NCT00340743|Diet
1412025|NCT00340743|Healthy Volunteer
1412026|NCT00340730|Health Education
1412027|NCT00340730|Mentoring
1412028|NCT00340730|Parenting
1412029|NCT00340730|Social Skills Training
1412030|NCT00340730|Violence
1412031|NCT00340730|Intervention
1412032|NCT00340730|Youth Injury
1412033|NCT00340717|Methylation
1412034|NCT00340717|Genes
1412035|NCT00340717|Screening
1412036|NCT00340717|Prospective
1412037|NCT00340717|Diagnosis
1412038|NCT00340704|tamsulosin
1412039|NCT00340704|pediatric
1412040|NCT00340704|neurogenic bladder
1412041|NCT00340691|Parasite
1412042|NCT00340691|Chemotherapy
1412043|NCT00340691|Wuchereria Bancrofti
1412044|NCT00340678|Angiotensin II Receptor Antagonist
1412045|NCT00340678|Therapeutic Trial
1412046|NCT00340678|Glomerular Filtration Rate
1412047|NCT00340678|Kidney Biopsy
1412048|NCT00340678|Non-Insulin Dependent Diabetes Mellitus
1412049|NCT00340665|Soy
1412050|NCT00340665|Infant Formula
1412051|NCT00340665|Sexual Development
1412052|NCT00340665|Hormone
1412053|NCT00340665|Isoflavones
1412054|NCT00340652|Soy
1412055|NCT00340652|Isoflavones
1412056|NCT00340652|Infant Formula
1412057|NCT00340652|Sexual Development
1412058|NCT00340652|Hormone
1412059|NCT00340639|Adherence
1412060|NCT00340639|Chronic Illness
1412061|NCT00340639|Adolescent
1412062|NCT00340639|Family
1412063|NCT00340639|Self-Regulation
1412064|NCT00340626|Whole Genome Sequencing
1412065|NCT00340626|Cleft Palate
1412066|NCT00340613|Type 1 Diabetes
1412067|NCT00340613|Poorly controlled glucose
1412068|NCT00340613|adolescents
1412069|NCT00340600|Cancer
1412070|NCT00340600|DES
1412071|NCT00340600|Endocrine Disrupting Chemicals
1412072|NCT00340600|In Utero
1412073|NCT00340587|Zona Pellucida
1412074|NCT00340587|Human Eggs
1412075|NCT00340587|ZP1, ZP2, ZP3
1412076|NCT00340587|Fertilization
1412077|NCT00340574|Human
1412078|NCT00340574|Clinical Trial
1412079|NCT00340574|Mosquito
1412080|NCT00340574|Healthy Volunteer
1412081|NCT00340574|HV
1412082|NCT00340561|Test Track
1412083|NCT00340561|Distraction
1412084|NCT00340561|Motor Vehicle
1412085|NCT00340561|Learning
1412086|NCT00340561|Inexperience
1412087|NCT00340548|Genotyping
1412088|NCT00340548|Polymorphisms
1412089|NCT00340548|Co-Infection
1412090|NCT00340548|Chemokines
1412091|NCT00340548|Associations
1412092|NCT00340548|HIV
1412093|NCT00340548|HCV
1412094|NCT00340548|Hepatitis C
1412095|NCT00340548|Hemophilia
1412096|NCT00340535|Disinfection byproducts
1412097|NCT00340535|Genetic Variation
1412098|NCT00340535|Trihalomethanes
1412099|NCT00340522|Sarcoma
1412100|NCT00340522|Brain Tumor
1412101|NCT00340522|Embryonal Tumor
1412102|NCT00340522|Tumor Array
1412103|NCT00340522|Childhood Cancer
1412104|NCT00340522|Plexiform Neurofibromas
1412105|NCT00340522|Drug Screening
1412106|NCT00340522|Immunohistochemistry
1412107|NCT00340509|Genetics
1412108|NCT00340509|Population
1412109|NCT00340509|CHD Risk
1412110|NCT00340509|Epidemiology
1412111|NCT00340509|Gene Mapping
1412112|NCT00340496|Schwannoma
1412113|NCT00340496|Meningioma
1412114|NCT00340496|Follow-Up
1412115|NCT00340496|Radiation Therapy
1412116|NCT00340496|Cohort
1412117|NCT00340483|Smoking Cessation
1412118|NCT00340483|Young Adults
1412119|NCT00340483|Quit Smoking
1412120|NCT00340483|Email
1412121|NCT00340483|Social Marketing
1412122|NCT00340470|Injury
1412123|NCT00340470|Motor Vehicle
1412124|NCT00340470|Parenting
1412125|NCT00340470|Randomized Trial
1412126|NCT00340470|Behavioral Intervention
1412127|NCT00340457|Case-Control Study
1412128|NCT00340457|Renal Cell Carcinoma
1412129|NCT00340457|Kidney Cancer
1412130|NCT00340457|Diet
1412131|NCT00340457|Occupation
1412132|NCT00340444|Linkage
1412133|NCT00340444|Covariates
1412134|NCT00340444|Association
1412135|NCT00340444|Fine Mapping
1412136|NCT00340444|Inflammatory Bowel Disease
1412137|NCT00340444|Ulcerative Colitis
1412138|NCT00340444|Crohn's Disease
1412139|NCT00340431|Human
1412140|NCT00340431|Clinical Trial
1412141|NCT00340431|Mosquito
1412142|NCT00340418|Bronchoalveolar Lavage
1412143|NCT00340418|Acute Rejection
1412144|NCT00340418|Chronic Rejection
1412145|NCT00340418|Genetic Polymorphisms
1412146|NCT00340418|Innate Immunity
1412147|NCT00340418|Lung Transplantation
1412148|NCT00340418|Lung Allograft Rejection
1412149|NCT00340405|Blood
1412150|NCT00340405|Lung Cancer
1412151|NCT00340405|Occupational Exposure
1412152|NCT00340405|Radon
1412153|NCT00340405|Arsenic
1412154|NCT00340392|Mammary Stem Cells
1412155|NCT00340392|Breast Cancer
1412156|NCT00340392|Cancer Stem Cells
1412157|NCT00340392|Gene Expression Profiling
1412158|NCT00340379|Psychotic
1412159|NCT00340366|Homocysteine
1412160|NCT00340366|Vitamin B12
1412161|NCT00340366|Birth Defects
1412162|NCT00340366|Pregnancy
1412163|NCT00340366|Folate
1412164|NCT00340366|Irish Individuals
1412165|NCT00340353|Gene Expression
1412166|NCT00340353|Drug Sensitivity
1412167|NCT00340353|TFE3
1412168|NCT00340353|ASPL-TFE3
1412169|NCT00340353|NOD-SCID Mice
1412170|NCT00340353|Sarcoma
1412171|NCT00340353|Alveolar Soft Part Sarcoma
1412172|NCT00340353|ASPS
1412173|NCT00340340|Population-Based Case Control Study
1412174|NCT00340340|Lung Cancer
1412175|NCT00340340|Epidemiology
1412176|NCT00340340|Smoking
1412177|NCT00340340|Smokers
1412178|NCT00340340|Genetics
1412179|NCT00339274|Repositories
1412180|NCT00339274|Pathology
1412181|NCT00339274|Belarus
1412182|NCT00339274|Russia
1412183|NCT00339274|Ukraine
1412184|NCT00339261|Cardiovascular
1412185|NCT00339261|Renal
1412186|NCT00339261|Autoimmune Disease
1412187|NCT00339261|Genetics
1412188|NCT00339261|Mortality
1412189|NCT00339248|Hyperplasia
1412190|NCT00339248|Atypia
1412191|NCT00339248|Polymorphism
1412192|NCT00339248|Progression
1412193|NCT00339248|Epidemiology
1412194|NCT00339235|Preterm Birth Prevention
1412195|NCT00339235|Preterm Birth
1412196|NCT00339235|Pregnancy
1412197|NCT00339235|Pregnancy Complications
1412198|NCT00339222|Genetics
1412199|NCT00339222|Kindreds
1412200|NCT00339222|Mediterranean Population
1412201|NCT00339222|Nevi
1412202|NCT00339222|Pigmentation
1412203|NCT00339222|Melanoma-Prone Families
1412204|NCT00339222|Sun Exposure
1412205|NCT00339222|Melanoma
1412206|NCT00339209|Genetic Polymorphisms
1412207|NCT00339209|Acute Rejection
1412208|NCT00339209|Bronchiolitis Obliterans Syndrome
1412209|NCT00339209|Transplant Rejection
1412210|NCT00339209|Innate Immunity
1412211|NCT00339209|Lung Transplantation Rejection
1412212|NCT00339196|AML
1412213|NCT00339196|MDS High risk
1412214|NCT00339196|Demethylating agents
1412215|NCT00339196|HDAC Inhibitors
1412216|NCT00339183|Oncology
1412217|NCT00339183|Cancer
1412218|NCT00339183|Metastatic Colorectal Cancer
1412219|NCT00339183|EGFr
1412220|NCT00339183|Panitumumab
1412221|NCT00339183|Clinical Trial
1412222|NCT00339183|Amgen
1412223|NCT00339170|Schizoaffective Disorder
1412224|NCT00339170|Schizophrenic Disorders
1412225|NCT00339170|Psychotic Disorders
1412226|NCT00339170|Cognition
1412227|NCT00339157|IDIOPATHIC JUVENILE ARTHRITIS
1412228|NCT00339157|PEDIATRICS
1412229|NCT00339157|ORPHAN DISEASE
1412230|NCT00339157|INTERLEUKIN - 1
1412231|NCT00339157|RECEPTORS , INTERLEUKINS
1412232|NCT00339157|ANTAGONISTS
1412233|NCT00339144|Solid tumors (including relapsed disease) that are refractory to standard therapies or for which no effective standard therapy exists
1412234|NCT00339131|radiopharmaceutical
1412235|NCT00339131|radiation dosimetry
1412236|NCT00339131|iodine
1412237|NCT00339131|MIBG
1412238|NCT00339131|iobenguane
1412239|NCT00339131|Ultratrace
1412240|NCT00339131|neuroendocrine tumors
1412241|NCT00338442|Immune compromised
1412242|NCT00338442|Varicella Zoster Virus ( VZV) Infection
1412243|NCT00338442|Pediatric
1412244|NCT00338429|sleep onset latency
1412245|NCT00338429|bedtime resistance
1412246|NCT00338416|Chemotherapy Induced Anemia
1412247|NCT00338416|PROCRIT (Epoetin alfa)
1412248|NCT00338416|Chemotherapy
1412249|NCT00338416|Epoetin alfa
1412250|NCT00338403|CPAP pressure of -5cm/water during cold, dry air exposure
1412251|NCT00338403|CPAP pressure of 0cm/water during cold, dry air exposure
1412252|NCT00338403|CPAP pressure of 5cm/water during cold, dry air exposure
1412253|NCT00338403|CPAP pressure of 10cm/water during cold, dry air exposure
1412254|NCT00338390|Antiretrovirals
1412255|NCT00338390|CD4 cell count
1412256|NCT00338390|toxicity
1412257|NCT00338377|Melanoma
1412258|NCT00338377|Regional nodal disease
1412259|NCT00338377|Dendritic Cell Immunization
1412260|NCT00338377|Lymphodepletion
1412261|NCT00338377|Adoptive Cell Transfer
1412262|NCT00338377|T Cells
1412263|NCT00338377|Vaccine
1412264|NCT00338377|Cyclosphosphamide
1412265|NCT00338377|Cytoxan
1412266|NCT00338377|Neosar
1412267|NCT00338377|Dendritic Cells
1412268|NCT00338377|Tumor Infiltrating Lymphocytes
1412269|NCT00338377|TIL Cells
1412270|NCT00338377|MART Peptide
1412271|NCT00338377|Fludarabine
1412272|NCT00338377|Fludarabine Phosphate
1412273|NCT00338377|Fludara
1412274|NCT00338377|Proleukin
1412275|NCT00338377|IL-2
1412276|NCT00338377|Interleukin-2
1412277|NCT00338377|Leptomeningeal disease
1412278|NCT00338364|Pediatric pain
1412279|NCT00338364|Pediatric anxiety
1412280|NCT00338364|Painful procedures
1412281|NCT00340327|healthy subjects
1412282|NCT00340314|symptomatic
1412283|NCT00340314|paroxysmal
1412284|NCT00340314|atrial fibrillation
1412285|NCT00340301|Polymorphism
1412286|NCT00340301|Neurodegenerative Diseases
1412287|NCT00340301|ALS
1412288|NCT00340288|Fibroids
1412289|NCT00340288|Life Style/Endrocrinology
1412290|NCT00340288|Magnetic Resonance Imaging
1412291|NCT00340288|Molecular Characterization
1412292|NCT00340288|Symptoms/Clinical Outcome
1412293|NCT00340288|Uterine Fibroids
1412294|NCT00340275|Bacterial Vaginosis
1412295|NCT00340275|Vaginal Infection
1412296|NCT00340275|Vaginitis
1412297|NCT00340275|Cohort Study
1412298|NCT00340275|Sexually Transmitted Disease
1412299|NCT00340262|Supplemental Hormone Use
1412300|NCT00340262|Osteoporosis
1412301|NCT00340262|Endogenous Sex Hormones
1412302|NCT00340249|Premature Rupture of the Membranes (PROM)
1412303|NCT00340249|Preterm Delivery
1412304|NCT00340249|In-Utero Fetal Demise
1412305|NCT00340249|Chorioamnionitis
1412306|NCT00340249|Spontaneous Abortion
1412307|NCT00340223|Immunity
1412308|NCT00340223|Mutations
1412309|NCT00340223|Viral Selection
1412310|NCT00340223|Disease Progression
1412311|NCT00340223|RNA
1412312|NCT00340210|Biomarkers
1412313|NCT00340210|Breast Cancer
1412314|NCT00340210|Etiology
1412315|NCT00340210|Hormones
1412316|NCT00340210|Prospective Study
1412317|NCT00340184|concurrent
1412318|NCT00340184|chemoradiation
1412319|NCT00340184|paclitaxel
1412320|NCT00340184|carboplatin
1412321|NCT00340171|Intrauterine Growth Retardation
1412322|NCT00340171|Macrosomia
1412323|NCT00340171|Fetal Volume
1412324|NCT00340171|Fetal Anatomy
1412325|NCT00340171|Prediction of Birthweight
1412326|NCT00340171|3D Ultrasonography
1412327|NCT00340171|Fetus
1412328|NCT00340171|Prenatal Diagnosis
1412329|NCT00340158|Mammary
1412330|NCT00340158|Diagnosis
1412331|NCT00340158|Aggressive
1412332|NCT00340158|Pathology
1412333|NCT00340158|Epidemiology
1412334|NCT00340132|Non-Insulin Dependent Diabetes
1412335|NCT00340132|Insulin Resistance
1412336|NCT00340132|Insulin Secretion
1412337|NCT00340132|Glucose Tolerance
1412338|NCT00340132|Adipose Tissue
1412339|NCT00340132|Preadipocytes
1412340|NCT00340119|CHOICE Cohort
1412341|NCT00340119|End Stage Renal Disease
1412342|NCT00340119|Epidemiology
1412343|NCT00340119|Prevention
1412344|NCT00340119|Single Nucleotide Polymorphisms
1412345|NCT00340119|ESRD
1412346|NCT00340106|Infant Health Study
1412347|NCT00340106|Environmental Tobacco Smoke
1412348|NCT00340106|Infant Health
1412349|NCT00340093|Adherence
1412350|NCT00340093|Behavioral Intervention
1412351|NCT00340093|Adolescence
1412352|NCT00340093|Self-Regulation
1412353|NCT00340093|Behavioral Medicine
1412354|NCT00340093|Diabetes
1412355|NCT00340080|Abacavir
1412356|NCT00340080|Pharmacogenetics
1412357|NCT00340080|hypersensitivity
1412358|NCT00340080|HLA-B*5701
1412359|NCT00340054|brain tumor
1412360|NCT00340028|Ovulation
1412361|NCT00340028|Diary Record
1412362|NCT00340028|Urine Collection
1412363|NCT00340028|Leutinizing Hormone
1412364|NCT00340028|Blood Collection
1412365|NCT00340028|Pregnancy
1412366|NCT00340015|Cancer
1412367|NCT00340015|Mortality
1412368|NCT00340015|Lifestyle Factors
1412369|NCT00340015|Cohort
1412370|NCT00340002|Fetal Anatomy
1412371|NCT00340002|Pregnancy
1412372|NCT00340002|Prenatal Diagnosis
1412373|NCT00339989|Molecular Markers
1412374|NCT00339989|Human Papillomavirus
1412375|NCT00339989|Cervix
1412376|NCT00339989|Cancer
1412377|NCT00339989|Microarray
1412378|NCT00339976|Case-Control Study
1412379|NCT00339976|Death Certificates
1412380|NCT00339976|National Death Index
1412381|NCT00339976|Cause of Death Information
1412382|NCT00339976|Lead Exposure
1412383|NCT00339976|Amyotrophic Lateral Sclerosis
1412384|NCT00339976|ALS
1412385|NCT00339963|Microarray
1412386|NCT00339963|Lymphoma
1412387|NCT00339963|Gene Expression
1412388|NCT00339963|Molecular Diagnosis
1412389|NCT00339963|Prognosis
1412390|NCT00339963|Leukemia
1412391|NCT00339963|Myeloma
1412392|NCT00339963|Lymphoid Malignancy
1412393|NCT00339950|Colorectal adenoma
1412394|NCT00339950|Screening
1412395|NCT00339950|Polyp
1412396|NCT00339950|Diet
1412397|NCT00339950|Nutrition
1412398|NCT00339950|Polymorphism
1412399|NCT00339950|Cooking
1412400|NCT00339950|Risk Factors
1412401|NCT00339937|Human Herpes virus 8 (HHV8)
1412402|NCT00339937|Kaposi sarcoma (KS)
1412403|NCT00339924|Clinical Decision-Making
1412404|NCT00339924|Physician Bias
1412405|NCT00339924|Genetics
1412406|NCT00339924|Race
1412407|NCT00339924|Ethnicity
1412408|NCT00339924|Human Genetic Variation
1412409|NCT00339911|Repository
1412410|NCT00339911|Phlebotomy
1412411|NCT00339911|Venipuncture
1412412|NCT00339911|Anemia
1412413|NCT00339911|Occupational Health Services
1412414|NCT00339898|Minimal Residual Disease
1412415|NCT00339898|Ewings Sarcoma
1412416|NCT00339885|Type 2 Diabetes
1412417|NCT00339872|healthy subjects
1412418|NCT00339859|Molecular Epidemiology of Lung Cancer
1412419|NCT00339859|Health Disparities
1412420|NCT00339846|Craniosynostosis
1412421|NCT00339846|Craniofrontonasal Syndrome
1412422|NCT00339846|CFNS
1412423|NCT00339833|Salsalate
1412424|NCT00339833|Insulin Resistance
1412425|NCT00339833|Diabetes Mellitus
1412426|NCT00339833|Inflammation
1412427|NCT00339833|Diabetes
1412428|NCT00339833|HCV
1412429|NCT00339807|Retrovirus
1412430|NCT00339807|Caribbean
1412431|NCT00339807|Transmission
1412432|NCT00339807|Genetic
1412433|NCT00339807|Viral Markers
1412434|NCT00339807|HTLV-1
1412435|NCT00339794|Racial Profiling
1412436|NCT00339794|Genomics
1412437|NCT00339794|Genetic Testing
1412438|NCT00339794|Family History
1412439|NCT00339794|Family Physician
1412440|NCT00339781|Fetomaternal Microchimerism
1412441|NCT00339781|Cell Trafficking
1412442|NCT00339781|Discordant Twins
1412443|NCT00339781|Maternofetal Microchimerism
1412444|NCT00339781|Diabetes Type I
1412445|NCT00339781|Twins
1412446|NCT00339768|Helicobacter Pylori
1412447|NCT00339768|Gastric Cancer Prevention
1412448|NCT00339768|Precancerous Gastric Lesions
1412449|NCT00339742|Esophageal Cancer
1412450|NCT00339742|Case-Control Study
1412451|NCT00339742|Environmental Risk Factors
1412452|NCT00339742|Genetic Risk Factors
1412453|NCT00339729|Children
1412454|NCT00339729|Behavior
1412455|NCT00339729|Epidemiology
1412456|NCT00339729|Lead
1412457|NCT00339729|Learning Disorder
1412458|NCT00339716|Cohort
1412459|NCT00339716|Radiation
1412460|NCT00339716|In Utero
1412461|NCT00339703|Resistin
1412462|NCT00339703|Asthma
1412463|NCT00339703|CRP
1412464|NCT00339703|Diabetes
1412465|NCT00339703|FIZZ
1412466|NCT00339690|Asthma
1412467|NCT00339690|Allergy
1412468|NCT00339690|Intervention
1412469|NCT00339690|Behaviors
1412470|NCT00339690|Test-Kit
1412471|NCT00339690|Dust Mites Allergen
1412472|NCT00339677|Measurement Error
1412473|NCT00339677|Dietary Assessment
1412474|NCT00339677|Dietary Intake
1412475|NCT00339677|Energy
1412476|NCT00339677|Protein
1412477|NCT00339664|Pharmacokinetics
1412478|NCT00339664|Quantify
1412479|NCT00339664|HPLC
1412480|NCT00339664|LC/MS
1412481|NCT00339664|Pharmacodynamics
1412482|NCT00339651|Precursors
1412483|NCT00339651|Endometrial Cancer
1412484|NCT00339651|Hyperplasia
1412485|NCT00339651|Progression
1412486|NCT00339638|Epidemiology
1412487|NCT00339638|Risk Prediction
1412488|NCT00339638|Biomarkers
1412489|NCT00339638|Nested Case Control
1412490|NCT00339625|Intervention
1412491|NCT00339625|Diet
1412492|NCT00339625|Colon
1412493|NCT00339612|Perinatal
1412494|NCT00339612|HIV
1412495|NCT00339612|AIDS
1412496|NCT00339599|Atherosclerosis
1412497|NCT00339599|Single Nucleotide Polymorphisms
1412498|NCT00339599|Monocyte Chemotactic Protein-1
1412499|NCT00339599|Inflammation
1412500|NCT00339599|Eotaxin
1412501|NCT00339586|Non-small cell lung cancer
1412502|NCT00339586|tyrosine kinase inhibition
1412503|NCT00339586|first-line treatment
1412504|NCT00339586|mutant EGFR-gene
1412505|NCT00339573|Asthma
1412506|NCT00339573|Dust Mite
1412507|NCT00339573|Cockroach
1412508|NCT00339573|Lead Toxicity
1412509|NCT00339573|Allergy
1412510|NCT00339560|Ampulla of Vater
1412511|NCT00339560|Gallbaldder
1412512|NCT00339560|Cancer
1412513|NCT00339560|Extrahepatic Bile Duct
1412514|NCT00339547|Leiomyomas
1412515|NCT00339547|Ultrasound
1412516|NCT00339547|Hysterectomy
1412517|NCT00339547|Epidemiology
1412518|NCT00339547|Hyperinsulinemia
1412519|NCT00339534|African Men
1412520|NCT00339534|Case-Control Study
1412521|NCT00339534|Prostate Cancer
1412522|NCT00339534|Cancer
1412523|NCT00339521|Asthma
1412524|NCT00339521|Mexico
1412525|NCT00339521|Candidate Genes
1412526|NCT00339521|Triads
1412527|NCT00339521|Polymorphism
1412528|NCT00339508|Linkage Analysis
1412529|NCT00339508|Cancer Genetics
1412530|NCT00339508|Software
1412531|NCT00339508|Bug Reports
1412532|NCT00339508|Computer Programs
1412533|NCT00339508|Data Analysis
1412534|NCT00339495|Prostate
1412535|NCT00339495|Screening Trail
1412536|NCT00339495|Ovarian
1412537|NCT00339495|Lung
1412538|NCT00339495|Colorectal
1412539|NCT00339482|Epidemiology
1412540|NCT00339482|Type 2 Diabetes
1412541|NCT00339482|Vascular Complications
1412542|NCT00339482|Retinopathy
1412543|NCT00339482|Nephropathy
1412544|NCT00339482|Genetics
1412545|NCT00339469|Prevention
1412546|NCT00339469|Colorectal Neoplasms
1412547|NCT00339469|Insulin Resistance
1412548|NCT00339469|Inflammation Obesity
1412549|NCT00339469|Adenoma
1412550|NCT00339456|Therapy
1412551|NCT00339456|Africa
1412552|NCT00339456|Structured
1412553|NCT00339456|Interruption
1412554|NCT00339456|Antiretroviral
1412555|NCT00339456|HIV
1412556|NCT00339443|Buccal Cells
1412557|NCT00339443|Concordance
1412558|NCT00339443|DNA Yields
1412559|NCT00339443|pH Meter
1412560|NCT00339443|Urine pH
1412561|NCT00339443|Calibration
1412562|NCT00339430|Genotyping
1412563|NCT00339430|HIV
1412564|NCT00339430|HPV
1412565|NCT00339430|HCV
1412566|NCT00339430|HBV
1412567|NCT00339417|Lymphatic Filariasis
1412568|NCT00339417|Chemotherapy
1412569|NCT00339404|Genotyping
1412570|NCT00339404|Linkage Analysis
1412571|NCT00339404|Cancer
1412572|NCT00339404|Hereditary Melanoma
1412573|NCT00339391|Adjustment
1412574|NCT00339391|Environmental Complexity
1412575|NCT00339391|Mental Illness
1412576|NCT00339391|Non-literate
1412577|NCT00339391|West Africa
1412578|NCT00339391|Stress
1412579|NCT00339391|Knowledge
1412580|NCT00339391|Mental Health
1412581|NCT00339391|AIDS
1412582|NCT00339378|Record Linkage
1412583|NCT00339378|Retrospective
1412584|NCT00339378|Cohort
1412585|NCT00339378|Registries
1412586|NCT00339378|Agricultural
1412587|NCT00339365|Infants
1412588|NCT00339365|Toddlers
1412589|NCT00339365|Attachment
1412590|NCT00339365|Maltreatment
1412591|NCT00339365|Foster Care
1412592|NCT00339352|Brain
1412593|NCT00339352|Exposures
1412594|NCT00339352|Genetics
1412595|NCT00339352|Glioma
1412596|NCT00339352|Occupations
1412597|NCT00339339|Dental Materials
1412598|NCT00339339|Resins
1412599|NCT00339339|BisDMA
1412600|NCT00339339|Absorption
1412601|NCT00339339|Systemic
1412602|NCT00339326|Human Herpes virus 8 (HHV8)
1412603|NCT00339326|Kaposis sarcoma (KS)
1412604|NCT00339326|Kaposi Sarcoma
1412605|NCT00339326|Karposi Sarcoma-Associated Herpesvirus
1412606|NCT00339326|KSHV
1412607|NCT00339326|KS
1412608|NCT00339313|Obesity
1412609|NCT00339313|Etiology
1412610|NCT00339313|Macronutrient Selection
1412611|NCT00339313|Taste Preference
1412612|NCT00339313|Mixed Meal Test
1412613|NCT00339300|Etiology
1412614|NCT00339300|Brain Cancer
1412615|NCT00339300|Epidemiology
1412616|NCT00339300|Brain Tumors
1412617|NCT00339300|Glioma
1412618|NCT00339287|Inflammation
1412619|NCT00339287|Innate Immunity
1412620|NCT00339287|Macrophages
1412621|NCT00339287|Neutrophils
1412622|NCT00339287|Pathogenesis
1412623|NCT00339105|Acute
1412624|NCT00339105|Coronary
1412625|NCT00339105|Syndrome
1412626|NCT00339105|HyperQ
1412627|NCT00339105|High
1412628|NCT00339105|Frequency
1412629|NCT00339105|ECG
1412630|NCT00339105|chest
1412631|NCT00339105|pain
1412632|NCT00339092|HIV
1412633|NCT00339092|ART
1412634|NCT00339066|Late-Life Depression
1412635|NCT00339053|thoracic aortic aneurysm
1412636|NCT00339053|immunonutrition
1412637|NCT00339053|respiratory failure
1412638|NCT00339053|lenght of stay ICU
1412639|NCT00339040|HPV
1412640|NCT00339027|child care centers
1412641|NCT00339027|community based research
1412642|NCT00339027|behavioral health
1412643|NCT00339027|health literacy
1412644|NCT00339027|unmet healthcare needs
1412645|NCT00339001|Erythropoietin
1412646|NCT00339001|Iron
1412647|NCT00339001|Retinopathy of prematurity
1412648|NCT00338988|Gastrointestinal
1412649|NCT00338988|Capecitabine
1412650|NCT00338988|Oxaliplatin
1412651|NCT00338988|Carcinoma of the Gallbladder
1412652|NCT00338988|Carcinoma of the Intrahepatic or Extrahepatic Biliary Tract
1412653|NCT00338988|Xeloda
1412654|NCT00338988|Eloxatin
1412655|NCT00338975|Psychotic Disorders
1412656|NCT00338975|Schizoaffective Disorder
1412657|NCT00338975|Cognitive Behavioral Therapy
1412658|NCT00338975|Social Skills Training
1412659|NCT00338962|SSRI
1412660|NCT00338962|treatment
1412661|NCT00338962|naltrexone
1412662|NCT00338962|alcohol dependence
1412663|NCT00338962|Desipramine
1412664|NCT00338962|depression
1412665|NCT00338962|PTSD
1412666|NCT00338949|Ziprasidone
1412667|NCT00338949|Olanzapine
1412668|NCT00338949|Risperidone
1412669|NCT00338949|Schizoaffective Disorder
1412670|NCT00338949|Insulin Sensitivity
1412671|NCT00338949|Visceral Adiposity
1412672|NCT00338949|Metabolic Syndrome
1412673|NCT00338936|Hypertension
1412674|NCT00338936|Valsartan
1412675|NCT00338936|Hydrochlorothiazide
1412676|NCT00338910|healthy volunteers
1412677|NCT00338897|Venous Thromboembolism
1412678|NCT00338897|Prevention
1412679|NCT00338897|Arthroplasty
1412680|NCT00338897|Replacement
1412681|NCT00338897|Hip
1412682|NCT00338897|orthopedic surgery
1412683|NCT00338845|STDs
1412684|NCT00338832|Lifestyle Intervention
1412685|NCT00338832|Schizoaffective Disorder
1412686|NCT00338819|DVT prevention
1412687|NCT00338819|Hemodynamic study
1412688|NCT00338819|IPC
1412689|NCT00338819|CECT
1412690|NCT00338806|Prevention
1412691|NCT00338806|Mood Disorders
1412692|NCT00338806|Unipolar Depression
1412693|NCT00338793|Tuberculosis;
1412694|NCT00338793|Pleural effusion;
1412695|NCT00338793|Corticosteroids.
1412696|NCT00338780|Chronic Hepatitis B
1412697|NCT00338780|Lamivudine
1412698|NCT00338780|HBeAg negative
1412699|NCT00338767|AIDS
1412700|NCT00338767|DOT
1412701|NCT00338767|Directly Observed Therapy
1412702|NCT00338728|Breast Cancer
1412703|NCT00338728|Letrozole
1412704|NCT00338728|Imatinib Mesylate
1412705|NCT00338728|Gleevec
1412706|NCT00338728|Femara
1412707|NCT00338715|Effectiveness
1412708|NCT00338715|Pulmonary Vein Isolation Procedure
1412709|NCT00338715|Coronary Artery Bypass Surgery
1412710|NCT00338715|Atrial Fibrillation
1412711|NCT00338702|Diabetic
1412712|NCT00338702|Foot
1412713|NCT00338702|Ulcer
1412714|NCT00338702|Autologous
1412715|NCT00338702|Platelet
1412716|NCT00338702|Gel
1412717|NCT00338689|infant formula
1412718|NCT00338689|protein content
1412719|NCT00338689|growth
1412720|NCT00338689|obesity
1412721|NCT00338689|breast feeding
1412722|NCT00338676|Aortic stenosis
1412723|NCT00338676|Elderly
1412724|NCT00338663|anterior cruciate ligament reconstruction
1412725|NCT00338663|knee immobilization
1412726|NCT00338663|postoperative pain
1412727|NCT00338624|lower urinary tract symptoms
1412728|NCT00338624|DITROPAN XL
1412729|NCT00338624|oxybutynin extended release tablets
1412730|NCT00338611|vision therapy
1412731|NCT00338611|orthoptics
1412732|NCT00338611|pencil push-up therapy
1412733|NCT00338598|glycine
1412734|NCT00338598|treatment
1412735|NCT00338598|alcohol dependence
1412736|NCT00338598|schizophrenia
1412737|NCT00338585|PAO
1412738|NCT00338585|acute peripheral arterial occlusion
1412739|NCT00338585|thrombolysis
1412740|NCT00338585|blood clot
1412741|NCT00338585|leg attack
1412742|NCT00338585|alfimeprase
1412743|NCT00338585|thrombus
1412744|NCT00338585|embolism
1412745|NCT00338585|thromboembolism
1412746|NCT00338585|claudication
1412747|NCT00338585|thrombolytic
1412748|NCT00338585|thrombosis
1412749|NCT00338585|plasminogen activator
1412750|NCT00338585|arterial flow
1412751|NCT00338572|Inflammation
1412752|NCT00338572|Blood Pressure, High
1412753|NCT00338559|Strabismus
1412754|NCT00338559|LMA
1412755|NCT00338559|ET Tube
1412756|NCT00338559|POV
1412757|NCT00338546|Cocaine
1412758|NCT00338546|Sympathetic nerve activity
1412759|NCT00338546|Blood pressure
1412760|NCT00338546|Cutaneous vasoconstriction
1412761|NCT00338546|Coronary vasoconstriction
1412762|NCT00338533|childhood glaucoma
1412763|NCT00338520|Cerebral malaria, phenylalanine, Tanzania
1412764|NCT00338507|Chronic Bronchitis
1412765|NCT00338507|Chronic Obstructive Pulmonary Disease
1412766|NCT00338468|Anemia
1412767|NCT00338468|Elderly
1412768|NCT00338468|Hemoglobin level
1412769|NCT00338468|Chronic Kidney Disease
1412770|NCT00338455|Congestive heart failure
1412771|NCT00338455|cardiac transplantation
1412772|NCT00338455|renal insufficiency
1412773|NCT00338455|renal failure
1412774|NCT00338455|dialysis
1412775|NCT00338455|ultrafiltration
1412776|NCT00338455|vasodilator
1412777|NCT00338455|Natrecor (nesiritide)
1412778|NCT00338338|essential hypertension
1412779|NCT00338338|Amlodipine
1412780|NCT00338338|blood pressure
1412781|NCT00338338|lacidipine
1412782|NCT00338325|Pediatric Anxiety
1412783|NCT00338325|Pediatric Pain
1412784|NCT00338312|Natural Menopause
1412785|NCT00338312|HSDD
1412786|NCT00338299|Anemia
1412787|NCT00338299|hemoglobin
1412788|NCT00338299|chemotherapy
1412789|NCT00338299|subcutaneous injection
1412790|NCT00338299|Epoetin alfa
1412791|NCT00338286|anemia
1412792|NCT00338286|metastatic breast cancer
1412793|NCT00338286|Hemoglobin
1412794|NCT00338286|progression-free survival (PFS)
1412795|NCT00338286|erythropoiesis-stimulating agents (ESA)
1412796|NCT00338273|Bipolar I disorder with major depressive episode
1412797|NCT00338247|advanced
1412798|NCT00338247|TYKERB
1412799|NCT00338247|HER2 positive
1412800|NCT00338247|Stage IIIc
1412801|NCT00338247|ErbB2 positive
1412802|NCT00338247|GW572016
1412803|NCT00338247|metastatic
1412804|NCT00338247|Stage IIIb
1412805|NCT00338247|breast cancer
1412806|NCT00338234|anemia
1412807|NCT00338234|intensive care
1412808|NCT00338234|cardiac surgery
1412809|NCT00338234|iron metabolism
1412810|NCT00338234|hepcidin
1412811|NCT00338221|Diarrhea, Malnutrition, Brazil
1412812|NCT00338208|low vision
1412813|NCT00338208|glaucoma
1412814|NCT00338195|Caffeine dependence
1412815|NCT00338195|Caffeine withdrawal
1412816|NCT00338182|Solid tumor
1412817|NCT00338156|Left Ventricle Remodelling
1412818|NCT00338156|Collagen markers
1412819|NCT00338156|Neurohormones
1412820|NCT00338156|Cardiac MRI
1412821|NCT00338143|Plaque psoriasis
1412822|NCT00338143|Antipsoriatic
1412823|NCT00338130|Melanoma
1412824|NCT00338130|Phase II
1412825|NCT00338130|AZD6244
1412826|NCT00338130|temozolomide
1412827|NCT00338117|Dementia
1412828|NCT00338117|neurodegenerative disorder
1412829|NCT00338117|impairment of memory
1412830|NCT00338117|galantamine
1412831|NCT00338117|galanthamine
1412832|NCT00338117|acetylcholinesterase inhibitor
1412833|NCT00338117|Mini Mental State Examination score
1412834|NCT00338104|insulin
1412835|NCT00338104|glargine
1412836|NCT00338104|intravenous
1412837|NCT00338104|subcutaneous
1412838|NCT00338104|hospital
1412839|NCT00338104|diabetes
1412840|NCT00338104|glucose
1412841|NCT00338104|inpatient
1412842|NCT00338091|Renal Insufficiency,Chronic
1412843|NCT00338091|Disease Progression
1412844|NCT00338091|Proteinuria
1412845|NCT00338091|Dose-Response Relationship,Drug
1412846|NCT00338091|Benazepril
1412847|NCT00338091|Losartan
1412848|NCT00338065|Intraocular Pressure
1412849|NCT00338052|Contraception
1412850|NCT00338039|Pancreatic Cancer
1412851|NCT00338039|Cetuximab
1412852|NCT00338039|C225
1412853|NCT00338039|Erbitux
1412854|NCT00338039|Gemcitabine
1412855|NCT00338039|Oxaliplatin
1412856|NCT00338039|Eloxatin
1412857|NCT00338039|Capecitabine
1412858|NCT00338039|Xeloda
1412859|NCT00338026|Solid Tumors
1412860|NCT00338026|Thallion
1412861|NCT00338026|TLN-4601
1412862|NCT00338026|Ecopia
1412863|NCT00338026|ECO-4601
1412864|NCT00338026|Patients with histologically confirmed solid tumors:
1412865|NCT00338026|High Grade Glioma
1412866|NCT00338026|Colorectal
1412867|NCT00338026|Lung
1412868|NCT00338026|Breast
1412869|NCT00338026|Ovarian
1412870|NCT00338026|Pancreatic
1412871|NCT00338026|Prostate
1412872|NCT00338013|sleep
1412873|NCT00338000|Chronic renal failure
1412874|NCT00338000|left ventricular hypertrophy
1412875|NCT00338000|epoetin alfa
1412876|NCT00337974|cognitive enhancement
1412877|NCT00337974|memory
1412878|NCT00337974|auditory memory
1412879|NCT00337974|speech
1412880|NCT00337974|computerized
1412881|NCT00337961|Optic Nerve Sheath Fenestration
1412882|NCT00337948|Anemia
1412883|NCT00337948|Epoetin Alfa
1412884|NCT00337948|Chemotherapy
1412885|NCT00337948|Anemia due to Cancer
1412886|NCT00337935|Long Term Care Facilities
1412887|NCT00337935|subcutaneous injections
1412888|NCT00337935|PROCRIT
1412889|NCT00337935|Epoetin alfa
1412890|NCT00337935|Anemia
1412891|NCT00337922|EPZICOM
1412892|NCT00337922|Lamivudine
1412893|NCT00337922|Abacavir
1412894|NCT00337922|pharmacokinetics
1412895|NCT00337922|Japanese
1412896|NCT00337909|cognitive enhancement
1412897|NCT00337909|memory
1412898|NCT00337909|auditory memory
1412899|NCT00337909|speech
1412900|NCT00337909|computerized
1412901|NCT00337896|vaccine, influenza, A/H5N1, CMI, sub-study
1412902|NCT00337883|Glioblastoma Multiforme
1412903|NCT00337883|glioma
1412904|NCT00337883|Grade IV glioma
1412905|NCT00337870|Pediatric Anxiety
1412906|NCT00337870|Pediatric Pain
1412907|NCT00337870|Emergency room procedures
1412908|NCT00337818|Non-inferiority
1412909|NCT00337818|Immunogenicity
1412910|NCT00337818|HPV Vaccine Consistency
1412911|NCT00337805|colloid
1412912|NCT00337805|crystalloid
1412913|NCT00337805|hemodynamics
1412914|NCT00337805|flow-directed
1412915|NCT00337805|resuscitation
1412916|NCT00337766|Blood Loss
1412917|NCT00337766|Postoperative Blood loss
1412918|NCT00337753|Gambling
1412919|NCT00337714|Central venous catheter,
1412920|NCT00337714|bloodstream infections,
1412921|NCT00337714|intensive care unit
1412922|NCT00337688|Cerebral Palsy
1412923|NCT00337688|Spasticity
1412924|NCT00337688|Joystick
1412925|NCT00337688|Wheelchair
1412926|NCT00337688|rehabilitation
1412927|NCT00337636|NCL
1412928|NCT00337636|INCL
1412929|NCT00337636|LINCL
1412930|NCT00337636|Batten disease
1412931|NCT00337636|Infantile Neuronal Ceroid Lipofuscinosis (INCL)
1412932|NCT00337636|Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
1412933|NCT00337623|Cataracts
1412934|NCT00337623|Corticosteroids
1412935|NCT00337623|Scheimpflug
1412936|NCT00337623|Lens autofluorescence
1412937|NCT00337597|Normal saline
1412938|NCT00337597|Dextrose 5% in water
1412939|NCT00337597|neurostimulation
1412940|NCT00337597|Continuous regional analgesia after total knee arthroplasty
1412941|NCT00337584|out patient surgery
1412942|NCT00337584|quality improvement
1412943|NCT00337571|Serious behavioral problems in children and adolescents with AD
1412944|NCT00337558|treatment outcomes
1412945|NCT00337558|Overactive bladder
1412946|NCT00337558|Solifenacin succinate
1412947|NCT00337558|urinary incontinence
1412948|NCT00337558|urge incontinence
1412949|NCT00337558|frequency
1412950|NCT00337545|Metastatic
1412951|NCT00337545|Refractory
1412952|NCT00337519|chronic lymphocytic leukemia
1412953|NCT00337519|reduced intensity conditioning
1412954|NCT00337519|alemtuzumab
1412955|NCT00337519|allogeneic stem cell transplantation
1412956|NCT00337506|the efficacy and safety of Velcade plus dexamethasone
1412957|NCT00337506|Multiple Myeloma
1412958|NCT00337480|acute coronary syndrome
1412959|NCT00337480|cardiovascular risk factors
1412960|NCT00337480|smoking habits
1412961|NCT00337480|obesity
1412962|NCT00337480|sedentary lifestyle
1412963|NCT00337480|overweight
1412964|NCT00337480|education
1412965|NCT00337480|follow up after hospitalization
1412966|NCT00337467|HIV-Infected Patients Evidencing Virologic Suppression
1412967|NCT00337454|Imatinib resistant or intolerant CML
1412968|NCT00337454|Treatment resistant or intolerant Ph+ALL
1412969|NCT00337441|Chronic Anemia
1412970|NCT00337441|Anemia
1412971|NCT00337441|Chronic Diseases
1412972|NCT00337441|Elderly
1412973|NCT00337441|Epoetin alfa
1412974|NCT00337441|Fatigue
1412975|NCT00337441|Quality of life
1412976|NCT00337441|Mobility
1412977|NCT00337402|Gastrostomy
1412978|NCT00337402|Quality of life
1412979|NCT00337389|Metastatic
1412980|NCT00337389|Colorectal
1412981|NCT00337389|Cancer
1412982|NCT00337389|CoFactor
1412983|NCT00337389|Stage IV
1412984|NCT00337350|Schizophrenia
1412985|NCT00337350|Glucose Metabolism
1412986|NCT00337350|Insulin Resistance
1412987|NCT00337337|Diabetes
1412988|NCT00337337|rice
1412989|NCT00337337|fiber
1412990|NCT00337324|Diabetic neuropathy
1412991|NCT00337324|Complications of diabetes
1412992|NCT00337324|Neuropathies
1412993|NCT00337324|Electromagnetic stimulation
1412994|NCT00337324|Neuropathic pain
1412995|NCT00337298|Diabetes
1412996|NCT00337298|Retinopathy
1412997|NCT00337298|Blood Pressure
1412998|NCT00337298|Amlodipine
1412999|NCT00337298|Lisinopril
1413000|NCT00337285|Attention Deficit Hyperactivity Disorder
1413001|NCT00337285|Attention Deficit Disorders with Hyperactivity
1413002|NCT00337285|Attention Deficit Hyperactivity Disorders
1413003|NCT00337272|chronic insomnia
1413004|NCT00337259|marginal zone lymphoma
1413005|NCT00337259|gemcitabine
1413006|NCT00337246|refractory chronic lymphocytic leukemia
1413007|NCT00337246|stage I chronic lymphocytic leukemia
1413008|NCT00337246|stage II chronic lymphocytic leukemia
1413009|NCT00337246|stage III chronic lymphocytic leukemia
1413010|NCT00337246|stage IV chronic lymphocytic leukemia
1413011|NCT00337233|fatigue
1413012|NCT00337233|psychosocial effects of cancer and its treatment
1413013|NCT00337233|recurrent breast cancer
1413014|NCT00337233|stage I breast cancer
1413015|NCT00337233|stage II breast cancer
1413016|NCT00337233|stage IIIA breast cancer
1413017|NCT00337233|stage IIIB breast cancer
1413018|NCT00337233|stage IIIC breast cancer
1413019|NCT00337233|stage IV breast cancer
1413020|NCT00337233|recurrent ovarian epithelial cancer
1413021|NCT00337233|recurrent ovarian germ cell tumor
1413022|NCT00337233|stage I ovarian epithelial cancer
1413023|NCT00337233|stage I ovarian germ cell tumor
1413024|NCT00337233|stage II ovarian epithelial cancer
1413025|NCT00337233|stage II ovarian germ cell tumor
1413026|NCT00337233|stage III ovarian epithelial cancer
1413027|NCT00337233|stage III ovarian germ cell tumor
1413028|NCT00337233|stage IV ovarian epithelial cancer
1413029|NCT00337233|stage IV ovarian germ cell tumor
1413030|NCT00337220|allograft
1413031|NCT00337220|graft
1413032|NCT00337207|adult glioblastoma
1413033|NCT00337207|adult gliosarcoma
1413034|NCT00337207|recurrent adult brain tumor
1413035|NCT00337207|adult anaplastic astrocytoma
1413036|NCT00337207|adult giant cell glioblastoma
1413037|NCT00337181|HIV-1
1413038|NCT00337181|Natural History
1413039|NCT00337181|HIV vaccine
1413040|NCT00337181|Thailand
1413041|NCT00337168|recurrent adult acute lymphoblastic leukemia
1413042|NCT00337168|L1 adult acute lymphoblastic leukemia
1413043|NCT00337168|L2 adult acute lymphoblastic leukemia
1413044|NCT00337168|B-cell adult acute lymphoblastic leukemia
1413045|NCT00337168|T-cell adult acute lymphoblastic leukemia
1413046|NCT00337155|Recurrent Prostate Cancer
1413047|NCT00337155|metastatic Cancer
1413048|NCT00337142|gestational diabetes
1413049|NCT00337142|newborn
1413050|NCT00337142|hypoglycemia
1413051|NCT00337129|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1413052|NCT00337129|recurrent metastatic squamous neck cancer with occult primary
1413053|NCT00337129|recurrent squamous cell carcinoma of the hypopharynx
1413054|NCT00337129|recurrent squamous cell carcinoma of the larynx
1413055|NCT00337129|recurrent squamous cell carcinoma of the lip and oral cavity
1413056|NCT00337129|recurrent squamous cell carcinoma of the oropharynx
1413057|NCT00337129|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1413058|NCT00337129|stage IV squamous cell carcinoma of the hypopharynx
1413059|NCT00337129|stage IV squamous cell carcinoma of the larynx
1413060|NCT00337129|stage IV squamous cell carcinoma of the lip and oral cavity
1413061|NCT00337129|stage IV squamous cell carcinoma of the oropharynx
1413062|NCT00337129|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1413063|NCT00337129|untreated metastatic squamous neck cancer with occult primary
1413064|NCT00337129|salivary gland squamous cell carcinoma
1413065|NCT00337090|Over Active Bladder
1413066|NCT00337090|Urinary incontinence
1413067|NCT00337090|YM178
1413068|NCT00337090|Symptomatic Over Active Bladder
1413069|NCT00337077|Eribulin Mesylate
1413070|NCT00337077|metastatic hormone refractory prostate cancer
1413071|NCT00337077|Halichondrin B Analog
1413072|NCT00337064|Breast cancer treatment
1413073|NCT00337064|Partial breast radiation
1413074|NCT00337064|Radiation Therapy
1413075|NCT00337064|Adjuvant Treatment
1413076|NCT00337051|Renal transplantation
1413077|NCT00337051|renal allograft
1413078|NCT00337051|end-stage renal disease
1413079|NCT00337051|renal failure
1413080|NCT00337051|general anaesthesia
1413081|NCT00337051|inhaled anaesthetic
1413082|NCT00337051|Sevoflurane
1413083|NCT00337051|ischemia
1413084|NCT00337051|reperfusion
1413085|NCT00337051|ischemic lesions
1413086|NCT00336973|Plaque Psoriasis
1413087|NCT00336973|Raptiva
1413088|NCT00336973|Anti-TNF
1413089|NCT00336960|stage II rectal cancer
1413090|NCT00336960|stage III rectal cancer
1413091|NCT00336960|adenocarcinoma of the rectum
1413092|NCT00336947|stage III squamous cell carcinoma of the hypopharynx
1413093|NCT00336947|stage IV squamous cell carcinoma of the hypopharynx
1413094|NCT00336947|stage III squamous cell carcinoma of the larynx
1413095|NCT00336947|stage IV squamous cell carcinoma of the larynx
1413096|NCT00336947|stage III squamous cell carcinoma of the lip and oral cavity
1413097|NCT00336947|stage IV squamous cell carcinoma of the lip and oral cavity
1413098|NCT00336947|stage III squamous cell carcinoma of the oropharynx
1413099|NCT00336947|stage IV squamous cell carcinoma of the oropharynx
1413100|NCT00336947|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1413101|NCT00336947|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1413102|NCT00336934|adenocarcinoma of the prostate
1413103|NCT00336934|recurrent prostate cancer
1413104|NCT00336934|stage I prostate cancer
1413105|NCT00336934|stage II prostate cancer
1413106|NCT00336934|stage III prostate cancer
1413107|NCT00336934|stage IV prostate cancer
1413108|NCT00336908|Intensive Care,Neonatal
1413109|NCT00336908|Parenteral nutrition
1413110|NCT00336908|Fat emulsions,Intravenous
1413111|NCT00336895|Liver transplantation
1413112|NCT00336895|mycophenolate mofetil
1413113|NCT00336895|gastrointestinal
1413114|NCT00336895|adverse effects
1413115|NCT00336882|traumatic brain injury
1413116|NCT00336882|propofol
1413117|NCT00336882|oxidative stress
1413118|NCT00336882|microdialysis
1413119|NCT00336856|Colon Cancer
1413120|NCT00336843|Zevalin
1413121|NCT00336843|B-cell non-Hodgkin's lymphoma
1413122|NCT00336843|autologous stem cell transplantation
1413123|NCT00336843|BuCyE regimen
1413124|NCT00336830|Cardiac Rehabilitation
1413125|NCT00336830|Improving Cardiac Rehabilitation Participation
1413126|NCT00336830|coronary angioplasty
1413127|NCT00336830|coronary artery bypass surgery
1413128|NCT00336817|Liver transplantation
1413129|NCT00336817|mycophenolate mofetil
1413130|NCT00336817|gastrointestinal
1413131|NCT00336817|adverse effects
1413132|NCT00336791|Breast Cancer
1413133|NCT00336791|Gene Expression
1413134|NCT00336791|Fluorouracil
1413135|NCT00336791|Cyclophosphamide
1413136|NCT00336791|Doxorubicin
1413137|NCT00336791|Paclitaxel
1413138|NCT00336765|solid tumors
1413139|NCT00336752|undisplaced ,unstable wEBER B ankle fractures
1413140|NCT00336752|operative intervention
1413141|NCT00336752|non operative intervention
1413142|NCT00336739|Gastric acidity determination
1413143|NCT00336739|Calcium sensing receptor
1413144|NCT00336713|depression
1413145|NCT00336713|antidepressive agents
1413146|NCT00336713|controlled clinical trial
1413147|NCT00336700|Pancreas
1413148|NCT00336700|Cancer
1413149|NCT00336700|Pancreatic
1413150|NCT00336687|Thrombopenia
1413151|NCT00336687|Reanimation
1413152|NCT00336687|Thrombopenia in reanimation
1413153|NCT00336674|Type 1 diabetes
1413154|NCT00336661|Periodontitis
1413155|NCT00336661|Chronic Periodontitis
1413156|NCT00336661|Gingivitis
1413157|NCT00336661|PERIOWAVE
1413158|NCT00336661|Photodynamic Disinfection
1413159|NCT00336648|Pancreatic Neoplasms
1413160|NCT00336648|Bevacizumab
1413161|NCT00336648|Gemcitabine
1413162|NCT00336648|Radiation Therapy
1413163|NCT00336648|adenocarcinoma of the pancreatic head
1413164|NCT00336648|adenocarcinoma of the uncinate process
1413165|NCT00336635|smallpox, vaccine, immunity
1413166|NCT00336622|Carpal Tunnel Syndrome
1413167|NCT00336622|Splints
1413168|NCT00336596|middle cerebral artery occlusion
1413169|NCT00336596|intracranial embolism and thrombosis
1413170|NCT00336596|ultrasound enhanced thrombolysis
1413171|NCT00336596|Patients receiving iv thrombolytic therapy (t-PA)
1413172|NCT00336583|oxaliplatin
1413173|NCT00336583|ESHAOX
1413174|NCT00336583|refractory
1413175|NCT00336583|relapsed
1413176|NCT00336583|non-hodgkin's lymphoma
1413177|NCT00336570|Oxidative Stress
1413178|NCT00336570|Endothelial Function
1413179|NCT00336570|Flow Mediated Dilation
1413180|NCT00336557|High-Dose Interferon
1413181|NCT00336557|Neutralizing Antibodies
1413182|NCT00336544|Pneumonia
1413183|NCT00336544|Respiratory
1413184|NCT00336544|Infection
1413185|NCT00336544|Infectious
1413186|NCT00336544|Advanced
1413187|NCT00336544|Life
1413188|NCT00336544|Sciences
1413189|NCT00336544|Lung
1413190|NCT00336544|Pulmonary
1413191|NCT00336544|Cethromycin
1413192|NCT00336544|Clarithromycin
1413193|NCT00336544|Biaxin
1413194|NCT00336531|prophylactic itraconazole
1413195|NCT00336531|Relapsed pediatric solid tumors
1413196|NCT00336531|Embryonal brain tumor
1413197|NCT00336505|Pneumonia
1413198|NCT00336505|Respiratory
1413199|NCT00336505|Infection
1413200|NCT00336505|Infectious
1413201|NCT00336505|Advanced
1413202|NCT00336505|Life
1413203|NCT00336505|Sciences
1413204|NCT00336505|Lung
1413205|NCT00336505|Pulmonary
1413206|NCT00336505|Cethromycin
1413207|NCT00336505|Restanza
1413208|NCT00336505|Clarithromycin
1413209|NCT00336505|Biaxin
1413210|NCT00336492|Ulcerative colitis
1413211|NCT00336492|inflammatory bowel disease
1413212|NCT00336492|children
1413213|NCT00336466|Cardiac bypass surgery
1413214|NCT00336453|Influenza
1413215|NCT00336427|MRSA
1413216|NCT00336427|Colonization
1413217|NCT00336427|Pregnancy
1413218|NCT00336427|Neonates
1413219|NCT00336414|Juvenile Systemic Lupus Erythematosus nephritis
1413220|NCT00336414|randomised actively controlled clinical trial
1413221|NCT00336414|cyclophosphamide
1413222|NCT00336414|prednisone
1413223|NCT00336414|azathioprine
1413224|NCT00336414|methylprednisolone
1413225|NCT00336401|anesthesia
1413226|NCT00336401|non cardiac surgery
1413227|NCT00336401|cardiac outcomes
1413228|NCT00336388|Malaria
1413229|NCT00336362|Beta Thalassemia Major
1413230|NCT00336362|Hematopoietic Stem Cell Mobilization
1413231|NCT00336362|Gene Transfer Techniques
1413232|NCT00336349|diabetes mellitus
1413233|NCT00336349|neuropathic pain
1413234|NCT00336323|diabetic
1413235|NCT00336323|macular
1413236|NCT00336323|edema
1413237|NCT00336323|avastin
1413238|NCT00336323|bevacizumab
1413239|NCT00336323|anti-VEGF
1413240|NCT00336323|retinal thickness
1413241|NCT00336323|visual acuity
1413242|NCT00336323|DME
1413243|NCT00336310|Diabetes Mellitus
1413244|NCT00336310|Treatment
1413245|NCT00336310|Repaglinide
1413246|NCT00336297|screening
1413247|NCT00336297|screening methods
1413248|NCT00336297|intimate partner violence
1413249|NCT00336284|Telemonitoring
1413250|NCT00336284|ICD
1413251|NCT00336284|Reduction of office follow-ups
1413252|NCT00336271|coffee
1413253|NCT00336271|caffeine
1413254|NCT00336271|healthy subjects
1413255|NCT00336258|Deep Vein Thrombosis
1413256|NCT00336258|Cancer
1413257|NCT00336258|US- Doppler
1413258|NCT00336258|Procoagulant Microparticles
1413259|NCT00336258|Asymptomatic
1413260|NCT00336245|Contraception
1413261|NCT00336245|Women
1413262|NCT00336245|HIV/AIDS
1413263|NCT00336245|IUD
1413264|NCT00336245|IUCD
1413265|NCT00336232|Vitamin K metabolism
1413266|NCT00336232|Bone health
1413267|NCT00336232|Metabolism
1413268|NCT00336219|GERD
1413269|NCT00336219|Pantoprazole
1413270|NCT00336206|Low dose Alemtuzumab
1413271|NCT00336206|Chronic lymphocytic leukemia
1413272|NCT00336206|B-Cell
1413273|NCT00336193|home visitation
1413274|NCT00336193|family outcomes
1413275|NCT00336193|competency training
1413276|NCT00336180|Adolescent
1413277|NCT00336180|Adolescent behavior
1413278|NCT00336180|Adolescent development
1413279|NCT00336180|Drinking behavior
1413280|NCT00336180|Health behavior
1413281|NCT00336180|Reproductive Behavior
1413282|NCT00336180|Sexual Behavior
1413283|NCT00336180|South Africa
1413284|NCT00336167|carnitine palmitoyl transferase 2 deficiency
1413285|NCT00336167|Fatty acid oxidation
1413286|NCT00336167|Mitochondria
1413287|NCT00336128|infant
1413288|NCT00336128|kindergarten
1413289|NCT00336128|obesity
1413290|NCT00336128|adiposity
1413291|NCT00336115|pertussis
1413292|NCT00336115|bone marrow transplant
1413293|NCT00336102|fatigue
1413294|NCT00336102|hypothyroidism
1413295|NCT00336102|stage I breast cancer
1413296|NCT00336102|stage II breast cancer
1413297|NCT00336102|stage IIIA breast cancer
1413298|NCT00336102|stage IIIB breast cancer
1413299|NCT00336089|fatigue
1413300|NCT00336089|pain
1413301|NCT00336089|cancer survivor
1413302|NCT00336089|breast cancer in situ
1413303|NCT00336089|inflammatory breast cancer
1413304|NCT00336089|stage IA breast cancer
1413305|NCT00336089|stage IB breast cancer
1413306|NCT00336089|stage II breast cancer
1413307|NCT00336089|stage IIIA breast cancer
1413308|NCT00336089|stage IIIB breast cancer
1413309|NCT00336089|stage IIIC breast cancer
1413310|NCT00336089|stage IV breast cancer
1413311|NCT00336089|recurrent breast cancer
1413312|NCT00336076|Mast cell disease
1413313|NCT00336076|Anaphylaxis
1413314|NCT00336076|c-kit
1413315|NCT00336076|Mutation
1413316|NCT00336076|Mastocytosis (suspected or proven)
1413317|NCT00336050|Air Pollution
1413318|NCT00336050|Pulmonary Function
1413319|NCT00336011|pacemaker
1413320|NCT00336011|magnetic resonance imaging
1413321|NCT00336011|safety
1413322|NCT00335985|polymyositis, dermatomyositis
1413323|NCT00335985|High-dose intravenous immunoglobulin
1413324|NCT00335985|Venoglobulin-IH
1413325|NCT00335985|Steroid-resistant polymyositis(PM) and dermatomyositis(DM)
1413326|NCT00335972|Carotid Endarterectomy patients
1413327|NCT00335959|adenocarcinoma of the stomach
1413328|NCT00335959|stage I gastric cancer
1413329|NCT00335959|stage II gastric cancer
1413330|NCT00335959|stage III gastric cancer
1413331|NCT00335933|Postherpetic Neuralgia (PHN)
1413332|NCT00335920|Sudden Hearing Loss
1413333|NCT00335920|intratympanic
1413334|NCT00335920|steroids
1413335|NCT00335907|Clinical trial
1413336|NCT00335907|Controlled clinical trial
1413337|NCT00335907|Shock, Septic
1413338|NCT00335894|Infertility
1413339|NCT00335894|IVF
1413340|NCT00335894|ART
1413341|NCT00335894|hMG
1413342|NCT00335881|Prophylaxis for hepatitis B disease
1413343|NCT00335868|accelerated phase chronic myelogenous leukemia
1413344|NCT00335868|blastic phase chronic myelogenous leukemia
1413345|NCT00335868|chronic phase chronic myelogenous leukemia
1413346|NCT00335868|relapsing chronic myelogenous leukemia
1413347|NCT00335855|Device, influenza
1413348|NCT00335829|localized unresectable adult primary liver cancer
1413349|NCT00335829|adult primary hepatocellular carcinoma
1413350|NCT00335829|advanced adult primary liver cancer
1413351|NCT00335829|recurrent adult primary liver cancer
1413352|NCT00335816|stage II rectal cancer
1413353|NCT00335816|stage III rectal cancer
1413354|NCT00335816|adenocarcinoma of the rectum
1413355|NCT00335751|recurrent adult soft tissue sarcoma
1413356|NCT00335751|stage I adult soft tissue sarcoma
1413357|NCT00335751|localized osteosarcoma
1413358|NCT00335751|metastatic osteosarcoma
1413359|NCT00335751|recurrent osteosarcoma
1413360|NCT00335751|stage II adult soft tissue sarcoma
1413361|NCT00335751|stage III adult soft tissue sarcoma
1413362|NCT00335751|stage IV adult soft tissue sarcoma
1413363|NCT00335725|Ovarian stimulation
1413364|NCT00335725|Infertility
1413365|NCT00335725|ICSI
1413366|NCT00335725|FSH
1413367|NCT00335712|ONO-5129
1413368|NCT00335712|type 2 diabetes mellitus
1413369|NCT00335699|Hypercholesterolemia with nondiabetic metabolic syndrome
1413370|NCT00335686|Mitochondrial toxicity
1413371|NCT00335686|Lopinavir-rtv
1413372|NCT00335686|Nevirapine
1413373|NCT00335686|DNA mitochondrial/DNA nuclear
1413374|NCT00335660|Idiopathic Detrusor Overactivity
1413375|NCT00335660|NK-1 Receptor Antagonist
1413376|NCT00335660|Neurokinin
1413377|NCT00335660|Urge Incontinence
1413378|NCT00335647|stage III multiple myeloma
1413379|NCT00335647|refractory multiple myeloma
1413380|NCT00335647|stage II multiple myeloma
1413381|NCT00335634|Prostate Cancer
1413382|NCT00335634|Radical Prostatectomy
1413383|NCT00335634|Sexual Dysfunction
1413384|NCT00335634|Intimacy
1413385|NCT00335634|Adaptation
1413386|NCT00335634|Psychosocial Oncology
1413387|NCT00335621|COPD
1413388|NCT00335621|ipratropium
1413389|NCT00335621|tiotropium
1413390|NCT00335595|colorectal cancer
1413391|NCT00335595|Bevacizumab
1413392|NCT00335595|capecitabine
1413393|NCT00335595|oxaliplatin
1413394|NCT00335582|alpha 2 agonists
1413395|NCT00335582|cardiac events
1413396|NCT00335582|non cardiac surgery
1413397|NCT00335569|Infertility, sterility, hCG, IVF
1413398|NCT00335543|adenocarcinoma of the pancreas
1413399|NCT00335543|stage I pancreatic cancer
1413400|NCT00335543|stage II pancreatic cancer
1413401|NCT00335543|stage III pancreatic cancer
1413402|NCT00335517|Lumbar surgery
1413403|NCT00335517|Surgery L3-S1
1413404|NCT00335517|DepoDur
1413405|NCT00335517|Post-operative pain
1413406|NCT00335517|Pain control
1413407|NCT00335517|Pain relief
1413408|NCT00335491|small cell lung cancer
1413409|NCT00335491|non-small cell lung cancer
1413410|NCT00335491|colon cancer
1413411|NCT00335491|prostate cancer
1413412|NCT00335491|breast cancer
1413413|NCT00335491|male breast cancer
1413414|NCT00335491|fatigue
1413415|NCT00335491|lymphoma
1413416|NCT00335491|ovarian epithelial cancer
1413417|NCT00335491|bladder cancer
1413418|NCT00335491|esophageal cancer
1413419|NCT00335478|neutropenia
1413420|NCT00335478|infection
1413421|NCT00335478|unspecified adult solid tumor, protocol specific
1413422|NCT00335478|fever, sweats, and hot flashes
1413423|NCT00335452|platelet aggregation inhibitors
1413424|NCT00335452|acute coronary disease
1413425|NCT00335452|percutaneous coronary
1413426|NCT00335413|Renal autoregulation
1413427|NCT00335413|Glomerular filtration rate
1413428|NCT00335413|Type 1 diabetes
1413429|NCT00335374|Parkinson's disease
1413430|NCT00335361|Male Contraceptive Devices
1413431|NCT00335361|Intra Vas Device (IVD)
1413432|NCT00335361|Male Sterilization
1413433|NCT00335361|Vasectomy
1413434|NCT00335361|Intra Vas Deferens Occlusion
1413435|NCT00335361|Vas Occlusion
1413436|NCT00335348|Multiple Myeloma
1413437|NCT00335348|Relapse
1413438|NCT00335348|Bortezomib
1413439|NCT00335348|Dexamethasone
1413440|NCT00335348|Maintenance
1413441|NCT00335335|Coronary
1413442|NCT00335335|Angiography
1413443|NCT00335335|X-ray
1413444|NCT00335335|CAD
1413445|NCT00335322|Human Immunodeficiency Virus (HIV)
1413446|NCT00335309|chronic rhinosinusitis
1413447|NCT00335309|sinus irrigation
1413448|NCT00335296|PFO
1413449|NCT00335296|Migraine
1413450|NCT00335296|Stroke
1413451|NCT00335296|TIA (transient ischemic attack)
1413452|NCT00335296|Decompression Illness
1413453|NCT00335270|HIV Type 1
1413454|NCT00335257|Drospirenone
1413455|NCT00335257|Safety
1413456|NCT00335257|INAS
1413457|NCT00335231|Post-cataract surgery endophthalmitis
1413458|NCT00335218|Early postmenopausal state
1413459|NCT00335218|Climacteric symptoms
1413460|NCT00335218|Hormone replacement therapy
1413461|NCT00335205|ropinirole
1413462|NCT00335205|dopamine
1413463|NCT00335205|D2
1413464|NCT00335205|depression
1413465|NCT00335205|bipolar
1413466|NCT00335192|Intracellular concentrations
1413467|NCT00335192|Plasma concentration
1413468|NCT00335192|Abacavir
1413469|NCT00335192|Tenofovir
1413470|NCT00335192|Lamivudine (3TC)
1413471|NCT00335192|Pharmacokinetic interactions
1413472|NCT00335179|Actinic keratosis
1413473|NCT00335179|AK
1413474|NCT00335179|imiquimod
1413475|NCT00335179|confocal microscopy
1413476|NCT00335179|gene microarray
1413477|NCT00335166|Parkinson Disease
1413478|NCT00335153|severe motor fluctuations
1413479|NCT00335153|levodopa
1413480|NCT00335153|levodopa/carbidopa intestinal gel
1413481|NCT00335153|efficacy
1413482|NCT00335153|dyskinesia
1413483|NCT00335153|Parkinson's Disease
1413484|NCT00335153|carbidopa
1413485|NCT00335153|DUOPA
1413486|NCT00335140|primary central nervous system non-Hodgkin lymphoma
1413487|NCT00335114|cyclosporine, dry eye syndrome, contact lens
1413488|NCT00335101|Coronary Artery Disease (CAD), Renal Impairment, Serum creatinine (SCr), Iodixanol, Ioversol, Iopromide, Contrast Induced Nephropathy (CIN)
1413489|NCT00335088|Prophylaxis,
1413490|NCT00335088|Intraocular surgery
1413491|NCT00335088|Lacrimal sac
1413492|NCT00335088|Eye lid
1413493|NCT00335088|No conditions
1413494|NCT00335062|Autoimmune thyroid disease
1413495|NCT00335062|Children and Adolescents
1413496|NCT00335062|TSH Receptor Antibodies
1413497|NCT00335049|myopia progression
1413498|NCT00335049|bifocal
1413499|NCT00335036|Implantable Cardioverter Defibrillator
1413500|NCT00335036|Ventricular Arrhythmia
1413501|NCT00335036|Sudden Cardiac Death
1413502|NCT00335036|Congenital Heart Disease
1413503|NCT00335036|Pediatric Electrophysiology
1413504|NCT00335023|postpartum hemorrhage
1413505|NCT00335023|red blood cell transfusion
1413506|NCT00335023|health related quality of life
1413507|NCT00335010|Nitroglycerine
1413508|NCT00335010|gastroesophageal anastomosis
1413509|NCT00335010|microvascular bloodflow
1413510|NCT00335010|microvascular hemoglobinsaturation
1413511|NCT00334997|stage I squamous cell carcinoma of the larynx
1413512|NCT00334997|stage II squamous cell carcinoma of the larynx
1413513|NCT00334997|stage 0 laryngeal cancer
1413514|NCT00334984|childhood fibrosarcoma
1413515|NCT00334984|childhood neurofibrosarcoma
1413516|NCT00334984|childhood synovial sarcoma
1413517|NCT00334984|chondrosarcoma
1413518|NCT00334984|localized osteosarcoma
1413519|NCT00334984|metastatic osteosarcoma
1413520|NCT00334984|metastatic childhood soft tissue sarcoma
1413521|NCT00334984|nonmetastatic childhood soft tissue sarcoma
1413522|NCT00334984|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1413523|NCT00334984|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1413524|NCT00334984|previously treated childhood rhabdomyosarcoma
1413525|NCT00334984|previously untreated childhood rhabdomyosarcoma
1413526|NCT00334984|childhood alveolar soft-part sarcoma
1413527|NCT00334984|childhood angiosarcoma
1413528|NCT00334984|childhood epithelioid sarcoma
1413529|NCT00334984|childhood leiomyosarcoma
1413530|NCT00334984|childhood liposarcoma
1413531|NCT00334984|localized childhood malignant fibrous histiocytoma of bone
1413532|NCT00334984|metastatic childhood malignant fibrous histiocytoma of bone
1413533|NCT00334984|childhood malignant mesenchymoma
1413534|NCT00334984|dermatofibrosarcoma protuberans
1413535|NCT00334984|childhood desmoplastic small round cell tumor
1413536|NCT00334971|African-American
1413537|NCT00334971|estradiol
1413538|NCT00334971|luteinizing hormone
1413539|NCT00334971|follicle stimulating hormone
1413540|NCT00334971|androstenedione
1413541|NCT00334971|aromatase
1413542|NCT00334971|inhibins
1413543|NCT00334971|ovarian
1413544|NCT00334971|Healthy volunteers
1413545|NCT00334971|Fragile X
1413546|NCT00334945|Fibroblast Growth Factors
1413547|NCT00334945|Bone development
1413548|NCT00334932|refractory multiple myeloma
1413549|NCT00334932|stage I multiple myeloma
1413550|NCT00334932|stage II multiple myeloma
1413551|NCT00334932|stage III multiple myeloma
1413552|NCT00334919|Diabetes
1413553|NCT00334919|Pre-Diabetes
1413554|NCT00334919|Anti-Inflammatory Diet
1413555|NCT00334919|Diet Study
1413556|NCT00334919|Inflammation
1413557|NCT00334919|Diabetic Diet
1413558|NCT00334906|memantine
1413559|NCT00334906|Alzheimer's disease
1413560|NCT00334906|MRI
1413561|NCT00334906|moderate Alzheimer's disease
1413562|NCT00334880|Attention Deficit Hyperactivity Disorder
1413563|NCT00334880|Attention Deficit Disorders with Hyperactivity
1413564|NCT00334880|Attention Deficit Hyperactivity Disorders
1413565|NCT00334867|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1413566|NCT00334854|childhood synovial sarcoma
1413567|NCT00334854|nonmetastatic childhood soft tissue sarcoma
1413568|NCT00334854|childhood alveolar soft-part sarcoma
1413569|NCT00334854|childhood angiosarcoma
1413570|NCT00334854|childhood epithelioid sarcoma
1413571|NCT00334854|childhood fibrosarcoma
1413572|NCT00334854|childhood leiomyosarcoma
1413573|NCT00334854|childhood liposarcoma
1413574|NCT00334854|childhood neurofibrosarcoma
1413575|NCT00334854|localized childhood malignant fibrous histiocytoma of bone
1413576|NCT00334854|childhood malignant hemangiopericytoma
1413577|NCT00334854|dermatofibrosarcoma protuberans
1413578|NCT00334854|chondrosarcoma
1413579|NCT00334828|Severe sepsis
1413580|NCT00334828|septic shock
1413581|NCT00334828|sepsis
1413582|NCT00334776|recurrent melanoma
1413583|NCT00334776|stage IV melanoma
1413584|NCT00334776|ciliary body and choroid melanoma, medium/large size
1413585|NCT00334776|iris melanoma
1413586|NCT00334776|recurrent intraocular melanoma
1413587|NCT00334776|extraocular extension melanoma
1413588|NCT00334763|recurrent non-small cell lung cancer
1413589|NCT00334763|stage IIIB non-small cell lung cancer
1413590|NCT00334763|stage IV non-small cell lung cancer
1413591|NCT00334763|squamous cell lung cancer
1413592|NCT00334750|Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian
1413593|NCT00334737|erythropoietin
1413594|NCT00334737|darbepoetin
1413595|NCT00334737|transfusions
1413596|NCT00334737|neonates
1413597|NCT00334737|outcomes
1413598|NCT00334737|neurodevelopment
1413599|NCT00334724|Cardiovascular disease
1413600|NCT00334724|Vascular disease
1413601|NCT00334724|Hypertension
1413602|NCT00334724|Home blood pressure measurement
1413603|NCT00334711|Permanent Neonatal Diabetes
1413604|NCT00334711|Kir6.2
1413605|NCT00334711|KCNJ11
1413606|NCT00334711|Infancy onset diabetes
1413607|NCT00334711|Sulfonylurea
1413608|NCT00334672|hemophagocytic lymphohistiocytosis
1413609|NCT00334659|HIV-1 Infection
1413610|NCT00334646|cyclophosphamide
1413611|NCT00334646|CINV
1413612|NCT00334646|Chemotherapy induced nausea and vomiting
1413613|NCT00334633|bacterial vaginosis
1413614|NCT00334633|tinidazole
1413615|NCT00334620|randomised double-blinded trial
1413616|NCT00334620|rehabilitation
1413617|NCT00334620|radon spa therapy
1413618|NCT00334620|long-term effectiveness
1413619|NCT00334607|HRV vaccine
1413620|NCT00334607|diarrhoea
1413621|NCT00334607|rotavirus
1413622|NCT00334594|epithelial mesothelioma
1413623|NCT00334594|sarcomatous mesothelioma
1413624|NCT00334594|stage IA malignant mesothelioma
1413625|NCT00334594|stage IB malignant mesothelioma
1413626|NCT00334594|stage II malignant mesothelioma
1413627|NCT00334594|stage III malignant mesothelioma
1413628|NCT00334568|AVANDIA
1413629|NCT00334568|Alzheimers Disease
1413630|NCT00334555|trichomoniasis
1413631|NCT00334555|partner notification
1413632|NCT00334542|breast cancer
1413633|NCT00334542|ductal breast carcinoma in situ
1413634|NCT00334542|breast cancer in situ
1413635|NCT00334542|stage I breast cancer
1413636|NCT00334542|stage II breast cancer
1413637|NCT00334542|stage IIIA breast cancer
1413638|NCT00334542|stage IIIB breast cancer
1413639|NCT00334542|stage IIIC breast cancer
1413640|NCT00334529|Tamiflu
1413641|NCT00334529|Flu
1413642|NCT00334529|Antiviral
1413643|NCT00334529|Neuraminidase Inhibitor
1413644|NCT00334529|Pharmacokinetic Trial
1413645|NCT00334529|Healthy Volunteer
1413646|NCT00334529|HV
1413647|NCT00334516|Motor Neuron Disease
1413648|NCT00334516|Cognitive Testing
1413649|NCT00334516|Movement-Related Potential
1413650|NCT00334516|MRI
1413651|NCT00334516|Neuropsychologic Testing
1413652|NCT00334516|Primary Lateral Sclerosis
1413653|NCT00334516|PLS
1413654|NCT00334516|Amyotrophic Lateral Sclerosis
1413655|NCT00334516|ALS
1413656|NCT00334516|Healthy Volunteer
1413657|NCT00334516|HV
1413658|NCT00334503|alpa-glucosidase inhibitor,Biguanide
1413659|NCT00334490|Pulmonary Hypertension
1413660|NCT00334490|Sildenafil
1413661|NCT00334490|Viagra
1413662|NCT00334490|Cardiac Surgery
1413663|NCT00334490|Cardiopulmonary Bypass
1413664|NCT00334477|erectile dysfunction
1413665|NCT00334477|chronic renal dysfunction
1413666|NCT00334477|tadalafil
1413667|NCT00334464|warfarin metabolism
1413668|NCT00334464|CYP2C0
1413669|NCT00334464|anticoagulation
1413670|NCT00334464|genotyping
1413671|NCT00334464|DVT
1413672|NCT00334464|PE
1413673|NCT00334451|Heart Failure
1413674|NCT00334451|Remote Monitoring
1413675|NCT00334451|Implantable Device
1413676|NCT00334438|recurrent grade 1 follicular lymphoma
1413677|NCT00334438|recurrent grade 2 follicular lymphoma
1413678|NCT00334438|recurrent grade 3 follicular lymphoma
1413679|NCT00334438|recurrent mantle cell lymphoma
1413680|NCT00334438|recurrent small lymphocytic lymphoma
1413681|NCT00334399|alpa-glucosidase inhibitor,Biguanide
1413682|NCT00334386|Hypertension
1413683|NCT00334386|Anti-hypertensive effect
1413684|NCT00334386|Diuretic
1413685|NCT00334373|Myocardial infarction
1413686|NCT00334373|Magnetic Resonance Imaging
1413687|NCT00334373|Coronary Angioplasty
1413688|NCT00334334|Streptococcus pneumonia, vaccine
1413689|NCT00334321|IMRT
1413690|NCT00334321|Tomotherapy
1413691|NCT00334321|Post-Hysterectomy
1413692|NCT00334321|Endometrial Cancer
1413693|NCT00334295|Recurrent or metastatic endometrial carcinoma
1413694|NCT00334282|Metastatic
1413695|NCT00334282|Anti-angiogenesis
1413696|NCT00334282|GW786034
1413697|NCT00334282|Pazopanib
1413698|NCT00334269|obesity
1413699|NCT00334269|physical activity
1413700|NCT00334269|daily energy intake
1413701|NCT00334269|nutrition
1413702|NCT00334269|healthy lifestyle
1413703|NCT00334269|Aboriginal
1413704|NCT00334269|body fat
1413705|NCT00334269|exercise
1413706|NCT00334269|education
1413707|NCT00334269|family
1413708|NCT00334269|body mass index
1413709|NCT00334269|knowledge
1413710|NCT00334269|randomized controlled trial
1413711|NCT00334269|community
1413712|NCT00334269|intervention
1413713|NCT00334269|Six Nations Indian Reserve
1413714|NCT00334269|household
1413715|NCT00334269|health counselling
1413716|NCT00334256|PMTCT
1413717|NCT00334256|Resistance
1413718|NCT00334256|HIV infection
1413719|NCT00334256|Pregnancy
1413720|NCT00334243|in vitro fertilization
1413721|NCT00334243|infertile
1413722|NCT00334243|infertility
1413723|NCT00334243|pregnancy
1413724|NCT00334243|pregnancy rates
1413725|NCT00334243|microflare protocol
1413726|NCT00334243|antagonist protocol
1413727|NCT00334243|demi-halt protocol
1413728|NCT00334243|poor responders
1413729|NCT00334243|low antral follicle count
1413730|NCT00334243|Infertile Patients undergoing in vitro fertilization (IVF)
1413731|NCT00334243|Patients with a previous poor response to ovarian stimulation
1413732|NCT00334243|Patients with an antral follicle count of less than 10
1413733|NCT00334230|Functional Magnetic Resonance Imaging (fMRI)
1413734|NCT00334230|Transcranial Magnetic Stimulation (TMS)
1413735|NCT00334230|Locomotion
1413736|NCT00334230|Cortical Reorganization
1413737|NCT00334230|Rehabilitation
1413738|NCT00334230|fMRI
1413739|NCT00334230|Stroke
1413740|NCT00334230|Healthy Volunteer
1413741|NCT00334230|HV
1413742|NCT00334217|Psychology: cognitive aspects
1413743|NCT00334217|Substance-Related Disorders
1413744|NCT00334217|treatment efficacy
1413745|NCT00334204|Platelet Function Analyser-100 (PFA-100)
1413746|NCT00334204|renal failure
1413747|NCT00334204|kidney biopsy
1413748|NCT00334204|bleeding
1413749|NCT00334204|hematoma
1413750|NCT00334191|Cardiac surgery,
1413751|NCT00334191|Cardiopulmonary bypass,
1413752|NCT00334191|Oxidative stress,
1413753|NCT00334191|Acute renal dysfunction,
1413754|NCT00334191|Sodium Bicarbonate
1413755|NCT00334178|Migraine
1413756|NCT00334178|Migraine prophylaxis
1413757|NCT00334152|NK-1
1413758|NCT00334152|antiemetics
1413759|NCT00334152|casopitant mesylate
1413760|NCT00334152|postoperative nausea and vomiting
1413761|NCT00334152|ondansetron hydrochloride
1413762|NCT00334152|5HT3
1413763|NCT00334152|ZOFRAN
1413764|NCT00334152|PONV
1413765|NCT00334139|serum bone markers
1413766|NCT00334139|bone metastasis
1413767|NCT00334139|prostate cancer
1413768|NCT00334139|breast cancer
1413769|NCT00334139|quality of life
1413770|NCT00334139|bisphosphonates
1413771|NCT00334126|Schizophrenia
1413772|NCT00334126|Antipsychotic
1413773|NCT00334126|paliperidone
1413774|NCT00334126|quetiapine
1413775|NCT00334126|Seroquel
1413776|NCT00334126|placebo
1413777|NCT00334113|Diabetes Mellitus
1413778|NCT00334113|Exercise
1413779|NCT00334113|Obesity
1413780|NCT00334113|Telemedicine
1413781|NCT00334100|Exercise
1413782|NCT00334100|multiple sclerosis
1413783|NCT00334100|treadmill
1413784|NCT00334087|primary dental prevention
1413785|NCT00334087|early childhood caries
1413786|NCT00334087|prenatal oral care
1413787|NCT00334074|AML
1413788|NCT00334074|MDS
1413789|NCT00334074|CML
1413790|NCT00334074|Relapsed
1413791|NCT00334074|Refractory
1413792|NCT00334074|Chemo treatment
1413793|NCT00334074|Clofarabine
1413794|NCT00334074|Cytarabine
1413795|NCT00334074|standard or poor cytogenetic risk AML
1413796|NCT00334074|untreated high-risk (>10% blasts) MDS
1413797|NCT00334074|CML in accelerated phase or blast crisis
1413798|NCT00334074|Elderly AML patients with risk of anthracycline toxicity
1413799|NCT00334061|Penumbra
1413800|NCT00334061|Ischemic
1413801|NCT00334061|Stroke
1413802|NCT00334061|Intervention
1413803|NCT00334061|Neurovascular
1413804|NCT00334061|Thrombus
1413805|NCT00334061|Embolectomy
1413806|NCT00334061|Ischemic stroke
1413807|NCT00334048|Medication-induced sexual dysfunction
1413808|NCT00334048|SSRI-induced sexual dysfunction
1413809|NCT00334048|Anorgasmia
1413810|NCT00334048|Delayed ejaculation
1413811|NCT00334048|Sexual dysfunction
1413812|NCT00334048|Antidepressant-induced sexual dysfunction
1413813|NCT00334048|Requip
1413814|NCT00334048|Ropinirole
1413815|NCT00334048|Dopamine agonist
1413816|NCT00334048|Serotonin reuptake inhibitor
1413817|NCT00334048|Sexual dysfunction, physiological, medication-induced
1413818|NCT00334022|Fuzeon
1413819|NCT00334022|Viral Decay
1413820|NCT00334009|Cardiac Surgery
1413821|NCT00334009|Cardiopulmonary Bypass
1413822|NCT00334009|COMT-Polymorphism
1413823|NCT00334009|Vasoplegia
1413824|NCT00334009|Catecholamines
1413825|NCT00334009|Acute Renal Failure
1413826|NCT00333034|Psoriasis
1413827|NCT00333021|Fondaparinux Abdominal surgery Japanese VTE
1413828|NCT00333970|cognition
1413829|NCT00333970|neuropsychology
1413830|NCT00333970|Rehabilitation
1413831|NCT00333970|treatment efficacy
1413832|NCT00333970|cognitive remediation
1413833|NCT00333957|capsule endoscopy
1413834|NCT00333944|Organophosphorus poisoning
1413835|NCT00333944|Atropine
1413836|NCT00333944|Pralidoxime
1413837|NCT00333944|Intermediate syndrome.
1413838|NCT00333931|Impulsive Aggression
1413839|NCT00333931|Posttraumatic Stress Disorder
1413840|NCT00333918|Cataract Extraction
1413841|NCT00333918|Anti-Inflammatory Agents, Non-Steroidal
1413842|NCT00333905|Exercise
1413843|NCT00333905|Exercise Therapy
1413844|NCT00333892|primary HIV infection
1413845|NCT00333892|chronic HIV infection
1413846|NCT00333879|Rehabilitation
1413847|NCT00333879|Sensory Aid
1413848|NCT00333840|CML
1413849|NCT00333840|STI571
1413850|NCT00333840|imatinib
1413851|NCT00333840|interferon
1413852|NCT00333840|interferon alpha
1413853|NCT00333840|cytosine arabinoside
1413854|NCT00333840|chronic myeloid leukemia
1413855|NCT00333840|Philadelphia chromosome positive
1413856|NCT00333827|Dilated Cardiomyopathy
1413857|NCT00333827|stem cells
1413858|NCT00333827|Therapeutics
1413859|NCT00333827|Randomized Controlled Trials
1413860|NCT00333801|Posttraumatic Stress Disorder
1413861|NCT00333801|Veterans
1413862|NCT00333801|Vocational Rehabilitation
1413863|NCT00333801|Supported Employment
1413864|NCT00333801|Individual Placement and Support
1413865|NCT00333788|Crohn's Disease
1413866|NCT00333788|Certolizumab pegol
1413867|NCT00333788|CDP870
1413868|NCT00333788|Cimzia
1413869|NCT00333762|aging
1413870|NCT00333762|blindness
1413871|NCT00333762|wheelchairs
1413872|NCT00333762|spinal cord injury
1413873|NCT00333749|children
1413874|NCT00333736|Injection site reactions
1413875|NCT00333736|enfuvirtide administration
1413876|NCT00333723|Rosiglitazone
1413877|NCT00333723|Glyburide
1413878|NCT00333723|Type 2 Diabetes Mellitus
1413879|NCT00333723|African American
1413880|NCT00333723|Hispanic
1413881|NCT00333710|Rehabilitation
1413882|NCT00333710|Telecommunication
1413883|NCT00333697|Deep vein thrombosis
1413884|NCT00333697|Duplex ultrasound
1413885|NCT00333697|Pulmonary embolism
1413886|NCT00333671|Macular oedema
1413887|NCT00333671|Diabetes
1413888|NCT00333671|Pathogenesis
1413889|NCT00333671|Osmolality
1413890|NCT00333671|Retinal thickness
1413891|NCT00333658|psychotherapy, group
1413892|NCT00333658|rehabilitation, vocational
1413893|NCT00333658|treatment outcome
1413894|NCT00333645|Liver transplantation
1413895|NCT00333645|Invasive fungal infection
1413896|NCT00333645|Invasive aspergillosis
1413897|NCT00333645|Prophylaxis
1413898|NCT00333645|Caspofungin
1413899|NCT00333632|Sleep
1413900|NCT00333632|Dexmedetomidine
1413901|NCT00333632|Postoperative care
1413902|NCT00333632|Sedation
1413903|NCT00333619|sleep disorders
1413904|NCT00333619|rehabilitation
1413905|NCT00333619|rehabilitation outcomes
1413906|NCT00333593|Dialysis
1413907|NCT00333593|Large pore dialyser
1413908|NCT00333593|Cytokines
1413909|NCT00333593|Noradrenaline
1413910|NCT00333580|Ethnography
1413911|NCT00333580|Psychometrics
1413912|NCT00333580|Qualitative Research
1413913|NCT00333567|arthroscopic knee surgery
1413914|NCT00333567|cyclooxygenase-2 inhibitors
1413915|NCT00333567|lumiracoxib
1413916|NCT00333567|COX189
1413917|NCT00333567|Ambulatory arthroscopic knee surgery
1413918|NCT00333554|DHA
1413919|NCT00333554|docosahexaenoic acid
1413920|NCT00333554|omega-3 fatty acid
1413921|NCT00333554|fish oil
1413922|NCT00333554|pregnancy
1413923|NCT00333554|infancy
1413924|NCT00333554|prevention
1413925|NCT00333554|"at risk for developing type 1 diabetes"
1413926|NCT00333554|juvenile diabetes
1413927|NCT00333554|T1D
1413928|NCT00333554|diabetes mellitus
1413929|NCT00333554|Type 1 diabetes TrialNet
1413930|NCT00333554|TrialNet
1413931|NCT00333554|dietary supplementation
1413932|NCT00333554|nutrition
1413933|NCT00333541|Contraceptive behavior
1413934|NCT00333541|Internet Use
1413935|NCT00333541|Adolescent pregnancy
1413936|NCT00333541|Unintended pregnancy
1413937|NCT00333528|Chemical Nerve Agent Intoxication
1413938|NCT00333528|Chemical Warfare Agents
1413939|NCT00333528|Chemical Terrorism
1413940|NCT00333515|Chemical nerve agent intoxication
1413941|NCT00333502|Cancer, Neoplasms, Solid Tumor, Ovarian Cancer, Lung Cancer,
1413942|NCT00333502|Non Small Cell Lung Cancer, Pancreatic Cancer,
1413943|NCT00333502|Breast Cancer, Colon Cancer, Endometrial Cancer,
1413944|NCT00333502|Kidney (Renal Cell) Cancer, Melanoma, Prostate Cancer,
1413945|NCT00333502|Skin Cancer, Thyroid Cancer,
1413946|NCT00333502|Solid Malignancies
1413947|NCT00333489|valsartan
1413948|NCT00333489|amlodipine
1413949|NCT00333489|hypertension
1413950|NCT00333437|Scleroderma, Systemic
1413951|NCT00333424|HIV
1413952|NCT00333424|Human Immunodeficiency Virus
1413953|NCT00333424|Prophylactic vaccine
1413954|NCT00333398|CSL Influenza Vaccine, influenza, vaccine, immunogenicity
1413955|NCT00333385|Ceftazidime
1413956|NCT00333385|Continuous infusion
1413957|NCT00333385|Antibiotic course
1413958|NCT00333333|Thrombocytopenia
1413959|NCT00333333|Small for Gestational Age (SGA)
1413960|NCT00333333|Preeclampsia
1413961|NCT00333320|acute myocardial infarction
1413962|NCT00333320|postconditioning
1413963|NCT00333320|coronary reserve
1413964|NCT00333320|ejection fraction
1413965|NCT00333307|relaxin
1413966|NCT00333307|preeclampsia
1413967|NCT00333281|Healthy Volunteers
1413968|NCT00333242|Pain
1413969|NCT00333242|opioid
1413970|NCT00333242|hyperalgesia
1413971|NCT00333242|methadone
1413972|NCT00333229|Breast Cancer
1413973|NCT00333229|premenopausal
1413974|NCT00333229|Bone Mineral density
1413975|NCT00333229|Cancer therapy induced bone loss
1413976|NCT00333229|zoledronic acid
1413977|NCT00333203|epimacular membrane
1413978|NCT00333190|stem cell transplant
1413979|NCT00333190|graft versus host disease
1413980|NCT00333190|GVHD
1413981|NCT00333190|CD+8 T cell depletion
1413982|NCT00333177|Schizoaffective Disorder, Depressed Type
1413983|NCT00333177|Schizophreniform Disorder
1413984|NCT00333177|First-Episode Schizophrenia
1413985|NCT00333177|Supported Employment
1413986|NCT00333177|Cognitive Remediation
1413987|NCT00333177|Health Behavior Training
1413988|NCT00333177|Antipsychotic Medication
1413989|NCT00333164|intracranial arteriosclerosis
1413990|NCT00333164|cilostazol
1413991|NCT00333164|Platelete aggrigation inhibitors dual antiplatelet therapy
1413992|NCT00333164|Drug therapy, combination
1413993|NCT00333164|Clinical trials
1413994|NCT00333138|FTY720
1413995|NCT00333138|MS
1413996|NCT00333138|Multiple Sclerosis
1413997|NCT00333138|RRMS
1413998|NCT00333112|Treatment Outcome
1413999|NCT00333112|Urology
1414000|NCT00333112|Solifenacin succinate
1414001|NCT00333112|Urinary Incontinence
1414002|NCT00333099|Enteral nutrition
1414003|NCT00333099|immunonutrients
1414004|NCT00333099|head and neck cancer
1414005|NCT00333099|esophageal cancer
1414006|NCT00333099|chemoradiotherapy
1414007|NCT00333099|H&N or esophageal cancer patients with a chemoradiotherapy treatment.
1414008|NCT00333086|Endometrial Cancer
1414009|NCT00333086|Aromatase inhibitor
1414010|NCT00333086|Letrozole
1414011|NCT00333073|urinary incontinence
1414012|NCT00333073|Bulkamid
1414013|NCT00333047|Metastatic breast cancer
1414014|NCT00333047|Aromatase inhibitor
1414015|NCT00333047|Letrozole
1414016|NCT00333008|Diffuse Large B Cell Lymphoma
1414017|NCT00333008|CDOP
1414018|NCT00333008|Dose Dense
1414019|NCT00333008|Anne Arbor Stage I-IV
1414020|NCT00333008|Any IPI score
1414021|NCT00332995|HIV Seronegativity
1414022|NCT00332982|best practices, performance improvement, intensive care, measurement
1414023|NCT00332969|Open label
1414024|NCT00332969|phase II
1414025|NCT00332969|disease
1414026|NCT00332969|clinical trial
1414027|NCT00332969|Octreotide
1414028|NCT00332969|thymoma
1414029|NCT00332969|cancer
1414030|NCT00332969|tumor
1414031|NCT00332943|colorectal polyps
1414032|NCT00332943|colorectal cancer
1414033|NCT00332943|Virtual colonoscopy
1414034|NCT00332943|Fecal tagging
1414035|NCT00332943|MR colonography
1414036|NCT00332930|HIV
1414037|NCT00332930|Therapeutic vaccine
1414038|NCT00332917|Parkinson's disease
1414039|NCT00332904|betablocker
1414040|NCT00332904|aldosterone antagonist
1414041|NCT00332904|peripheral haemodynamics
1414042|NCT00332904|cardiac haemodynamics
1414043|NCT00332904|oxygenation
1414044|NCT00332891|Anxiety
1414045|NCT00332891|Anti-Anxiety Agents
1414046|NCT00332891|controlled Clinical Trials
1414047|NCT00332878|Behavioral Intervention
1414048|NCT00332878|HIV
1414049|NCT00332878|HSV2
1414050|NCT00332865|Head and neck cancer
1414051|NCT00332865|Radiotherapy
1414052|NCT00332865|Dysphagia
1414053|NCT00332865|Exercise
1414054|NCT00332865|Deglutition
1414055|NCT00332865|Randomized controlled trial
1414056|NCT00332865|Quality of life
1414057|NCT00332865|Tube feeding
1414058|NCT00332852|Postive breast cancer
1414059|NCT00332852|postmenopausal
1414060|NCT00332852|disease free survival
1414061|NCT00332852|letrozole
1414062|NCT00332852|early adjuvant treatment
1414063|NCT00332852|primary hormone receptor
1414064|NCT00332839|enteric-coated mycophenolate sodium, everolimus, CNI-free regimen
1414065|NCT00332826|Inhaled insulin
1414066|NCT00332826|Diabetes Type I and II with Asthma
1414067|NCT00332813|HIV Risk Behavior
1414068|NCT00332813|Pregnancy
1414069|NCT00332813|Drug Abuse
1414070|NCT00332800|Stroke-Nutritional Supplementation-Functional Recovery
1414071|NCT00332787|Major Depressive Disorder
1414072|NCT00332735|spinal
1414073|NCT00332735|anesthesia
1414074|NCT00332735|articaine
1414075|NCT00332735|bupivacaine
1414076|NCT00332735|outpatient
1414077|NCT00332735|surgery
1414078|NCT00332735|limbs
1414079|NCT00332709|Breast cancer
1414080|NCT00332709|postmenopausal
1414081|NCT00332709|bone mineral density
1414082|NCT00332709|Zoledronic acid
1414083|NCT00332709|Letrozole
1414084|NCT00332709|extended adjuvant treatment.
1414085|NCT00332709|Postmenopausal women with primary hormone receptor positive breast cancer
1414086|NCT00332696|bowel obstruction,
1414087|NCT00332696|peritoneal carcinomatosis
1414088|NCT00332696|Octreotide
1414089|NCT00332696|inoperable
1414090|NCT00332683|Dysphagia
1414091|NCT00332683|spine surgery
1414092|NCT00332683|cuff pressure
1414093|NCT00332670|(Non-seasonal) Depression
1414094|NCT00332670|bright light therapy
1414220|NCT00332163|colorectal cancer
1414095|NCT00332670|randomized controlled trial
1414096|NCT00332670|suprachiasmatic nucleus
1414097|NCT00332670|HPA-axis
1414098|NCT00332670|DHEA
1414099|NCT00332670|melatonin
1414100|NCT00332670|actigraphy
1414101|NCT00332670|elderly
1414102|NCT00332670|self-efficacy
1414103|NCT00332670|social support
1414104|NCT00332631|Cardiac surgery,
1414105|NCT00332631|Cardiopulmonary bypass,
1414106|NCT00332631|Oxidative stress,
1414107|NCT00332631|Acute renal dysfunction,
1414108|NCT00332631|N-acetylcysteine
1414109|NCT00332618|MULTICENTER
1414110|NCT00332618|CONTROLLED
1414111|NCT00332618|PARALLEL GROUPS
1414112|NCT00332605|Methamphetamine Dependence
1414113|NCT00332592|Necrotizing Enterocolitis
1414114|NCT00332592|Intragastric microdialysis
1414115|NCT00332592|Peritoneal microdialysis
1414116|NCT00332592|Infants
1414117|NCT00332579|Compulsive Shoplifting
1414118|NCT00332579|Kleptomania
1414119|NCT00332579|Compulsive Stealing
1414120|NCT00332514|pharmacist intervention
1414121|NCT00332514|post-discharge telephone call
1414122|NCT00332514|black hole
1414123|NCT00332462|Liver transplantation, Cyclosporine
1414124|NCT00332449|early breast feeding
1414125|NCT00332449|hypoglycemia
1414126|NCT00332449|newborn
1414127|NCT00332410|Voriconazole
1414128|NCT00332410|renal transplant
1414129|NCT00332410|kidney function
1414130|NCT00332410|kidneys
1414131|NCT00331279|polycystic ovary syndrome
1414132|NCT00331279|insulin resistance
1414133|NCT00331279|cinnamon
1414134|NCT00331253|Indocyanine Green-Mediated Photothrombosis
1414135|NCT00331253|Neovascular
1414136|NCT00331253|Age-Related Macular Degeneration
1414137|NCT00331227|flavonoids
1414138|NCT00331227|food supplements
1414139|NCT00331227|endothelial function
1414140|NCT00331227|no conditions allowed, healthy volunteers only
1414141|NCT00331214|Surgical menopause
1414142|NCT00331214|HSDD
1414143|NCT00331201|NEC
1414144|NCT00331188|Esophageal Variceal Bleeding
1414145|NCT00331188|Portal Hypertension
1414146|NCT00331188|Hepatic Cirrhosis
1414147|NCT00331188|Cirrhosis
1414148|NCT00331188|Liver Cirrhosis
1414149|NCT00331188|Somatostatin Analog
1414150|NCT00331188|Vapreotide
1414151|NCT00331188|Acute Esophageal Variceal Bleeding
1414152|NCT00332371|Intensive Care
1414153|NCT00332371|Shock, Septic
1414154|NCT00332371|Adsorption
1414155|NCT00332371|Sorption Detoxification
1414156|NCT00332332|Phase IV
1414157|NCT00332332|Psoriasis
1414158|NCT00332332|Inflammation
1414159|NCT00332319|spinal cord injury
1414160|NCT00332319|urgency
1414161|NCT00332319|Overactive bladder
1414162|NCT00332319|neurogenic
1414163|NCT00332319|neurometry
1414164|NCT00332319|frequency
1414165|NCT00332319|urge incontinence
1414166|NCT00332306|Once daily antiretroviral treatment
1414167|NCT00332306|Concomitant antituberculosis treatment
1414168|NCT00332306|HIV Infections
1414169|NCT00332280|solid tumors
1414170|NCT00332280|clinical benefit
1414171|NCT00332280|quality of life
1414172|NCT00332280|esophageal cancer
1414173|NCT00332280|colon cancer
1414174|NCT00332280|pancreatic cancer
1414175|NCT00332280|gastric cancer
1414176|NCT00332280|liver cancer
1414177|NCT00332280|gall bladder cancer
1414178|NCT00332280|prostate cancer
1414179|NCT00332280|gynecological cancer
1414180|NCT00332280|lung cancer
1414181|NCT00332280|Tumors of GI tract, prostate and gynaecological
1414182|NCT00332267|Sepsis
1414183|NCT00332267|Hypoxia
1414184|NCT00332267|Altitude Sickness
1414185|NCT00332267|Endotoxin
1414186|NCT00332267|Cytokines
1414187|NCT00332267|Cerebral blood flow
1414188|NCT00332267|Cerebral metabolism
1414189|NCT00332267|Reactive oxygen species
1414190|NCT00332254|Anterior cruciate ligament tear
1414191|NCT00332254|Meniscus tear
1414192|NCT00332254|Chondral injury
1414193|NCT00332241|Serious behavioral problems in children and adolescents with AD
1414194|NCT00332241|Behavioral Problems
1414195|NCT00332228|opiate dependence
1414196|NCT00332228|heroin dependence
1414197|NCT00332228|naltrexone
1414198|NCT00332228|cognitive behavioral therapy
1414199|NCT00332215|Cystic Fibrosis
1414200|NCT00332215|Antioxidants
1414201|NCT00332215|Inhalational therapy
1414202|NCT00332215|Induced sputum
1414203|NCT00332215|Airway inflammation
1414204|NCT00332189|PKU
1414205|NCT00332176|Hepatitis C
1414206|NCT00332176|Celgosivir
1414207|NCT00332176|HCV
1414208|NCT00332176|Genotype 1
1414209|NCT00332176|Treatment-naive
1414210|NCT00332176|Early viral kinetics
1414211|NCT00332163|STEPP
1414212|NCT00332163|STEP
1414213|NCT00332163|STEEP
1414214|NCT00332163|mCRC
1414215|NCT00332163|Skin Toxicities
1414216|NCT00332163|Skin Rash
1414217|NCT00332163|Metastatic Colorectal Cancer
1414218|NCT00332163|Anti-EGFr Skin Rash
1414219|NCT00332163|colon cancer
1414221|NCT00332163|rectal cancer
1414222|NCT00332150|parents
1414223|NCT00332150|newborn
1414224|NCT00332150|clinical trials
1414225|NCT00332111|transplant
1414226|NCT00332111|pancreas
1414227|NCT00332098|Childhood Mood Disorders
1414228|NCT00332098|Family Treatment
1414229|NCT00332098|Psychoeducation
1414230|NCT00332098|Pharmacotherapy
1414231|NCT00332098|Family Functioning
1414232|NCT00332098|Psychosocial Intervention
1414233|NCT00331162|Renal Transplantation
1414234|NCT00331162|Pancreas Transplantation
1414235|NCT00331162|Graft Rejection
1414236|NCT00331162|Immunosuppression
1414237|NCT00331162|Kidney failure, chronic
1414238|NCT00331162|Diabetes Mellitus, Type 1
1414239|NCT00331162|Diabetes Mellitus, Type 2
1414240|NCT00331149|safety
1414241|NCT00331149|efficacy
1414242|NCT00331149|L-dopa
1414243|NCT00331149|ropinirole PR
1414244|NCT00331149|Parkinson's disease
1414245|NCT00331149|ropinirole IR
1414246|NCT00331149|adjunctive therapy
1414247|NCT00331149|superiority
1414248|NCT00331149|REQUIP
1414249|NCT00331149|health outcomes
1414250|NCT00331136|malaria
1414251|NCT00331136|pyronaridine
1414252|NCT00331136|artesunate
1414253|NCT00331136|falciparum
1414254|NCT00331136|ACT
1414255|NCT00331123|Surgical menopause
1414256|NCT00331123|HSDD
1414257|NCT00332046|fMRI placebo GW679769 Social Anxiety Disorder SAD
1414258|NCT00332033|Fibroids
1414259|NCT00332033|Leiomyoma
1414260|NCT00332033|Pirfenidone
1414261|NCT00332033|Misoprostol
1414262|NCT00332033|Non-Surgical
1414263|NCT00332033|Collagen
1414264|NCT00332033|Uterus
1414265|NCT00332033|Uterine Fibroids
1414266|NCT00332033|Uterine Leiomyoma
1414267|NCT00331942|Breast
1414268|NCT00331942|Cancer
1414269|NCT00331942|Associated
1414270|NCT00331942|Antibodies
1414271|NCT00331929|Asthma
1414272|NCT00331929|Allergy
1414273|NCT00331929|Respiratory
1414274|NCT00331929|Pollution
1414275|NCT00331929|Children
1414276|NCT00331929|Air pollution
1414277|NCT00331890|Neuroprotection
1414278|NCT00331890|Acute ischemic stroke
1414279|NCT00331890|Cerebral infarction
1414280|NCT00331877|family
1414281|NCT00331877|end-of-life
1414282|NCT00331877|intensive care unit
1414283|NCT00331864|AMD, ranibizumab
1414284|NCT00331838|Prevention
1414285|NCT00331838|Venous Thrombosis
1414286|NCT00331838|Orthopedic Surgery
1414287|NCT00331825|Schizophrenia, EPS, risperidone, olanzapine
1414288|NCT00331812|Hypermetabolism
1414289|NCT00331812|Mitochondrial abnormalities
1414290|NCT00331812|Oxidant/antioxidant status
1414291|NCT00331799|Depression
1414292|NCT00331799|Pharmacotherapy
1414293|NCT00331799|Duloxetine
1414294|NCT00331786|colon cancer
1414295|NCT00331786|rectal cancer
1414296|NCT00331773|adenocarcinoma of the prostate
1414297|NCT00331773|stage IIB prostate cancer
1414298|NCT00331773|stage IIA prostate cancer
1414299|NCT00331760|stage I endometrial carcinoma
1414300|NCT00331760|stage II endometrial carcinoma
1414301|NCT00331760|stage III endometrial carcinoma
1414302|NCT00331760|endometrial adenoacanthoma
1414303|NCT00331760|endometrial adenocarcinoma
1414304|NCT00331760|endometrial adenosquamous cell carcinoma
1414305|NCT00331760|stage IB cervical cancer
1414306|NCT00331760|stage IIA cervical cancer
1414307|NCT00331760|stage IIB cervical cancer
1414308|NCT00331760|cervical adenocarcinoma
1414309|NCT00331760|cervical adenosquamous cell carcinoma
1414310|NCT00331760|cervical squamous cell carcinoma
1414311|NCT00331721|Acute Ischemic Stroke
1414312|NCT00331708|Malaria
1414313|NCT00331708|Efficacy
1414314|NCT00331708|Pharmacokinetic
1414315|NCT00331708|Gametocyte
1414316|NCT00331708|Molecular markers
1414317|NCT00331708|Sulfadoxine-pyrimethamine
1414318|NCT00331708|Artesunate
1414319|NCT00331708|Artemisinin
1414320|NCT00331695|Progesterone
1414321|NCT00331695|Preterm delivery
1414322|NCT00331695|Preterm labor
1414323|NCT00331695|Cervical length
1414324|NCT00331695|ultrasonography
1414325|NCT00331669|deep brain stimulation
1414326|NCT00331669|pallidum
1414327|NCT00331669|tardive dystonia
1414328|NCT00331669|randomized
1414329|NCT00331669|double blind
1414330|NCT00331669|multicenter
1414331|NCT00331656|noninvasive
1414332|NCT00331656|positive
1414333|NCT00331656|cuirass
1414334|NCT00331656|ventilation
1414335|NCT00331656|respiratory
1414336|NCT00331656|failure
1414337|NCT00331630|stage I breast cancer
1414338|NCT00331630|stage II breast cancer
1414339|NCT00331630|stage IIIA breast cancer
1414340|NCT00331630|stage IIIB breast cancer
1414341|NCT00331630|stage IIIC breast cancer
1414342|NCT00331565|Bariatric surgery
1414343|NCT00331565|Bioavailability
1414344|NCT00331565|Bioequivalence
1414345|NCT00331565|Atorvastatin
1414346|NCT00331565|CYP's
1414347|NCT00331565|P-gp
1414348|NCT00331565|OATP
1414349|NCT00331539|Cochlear implant
1414350|NCT00331539|threshold (T) measurement
1414351|NCT00331539|comfort (C) level
1414352|NCT00331539|profound hearing loss
1414353|NCT00331539|auditory stimuli
1414354|NCT00331539|profound hearing loss patients eligible for the study should be capable of providing reliable
1414355|NCT00331539|subjective counted thresholds and has good NRT recordings, implanted with
1414356|NCT00331539|the Nucleus Freedom system
1414357|NCT00331526|adult glioblastoma
1414358|NCT00331526|adult gliosarcoma
1414359|NCT00331526|adult giant cell glioblastoma
1414360|NCT00331487|Glucose Metabolism Disorder
1414361|NCT00331487|Dysmetabolic Syndrome
1414362|NCT00331487|Type II Diabetes
1414363|NCT00331487|Diabetes Mellitus
1414364|NCT00331487|Lipoatrophic
1414365|NCT00331487|Dyslipidemia
1414366|NCT00331487|Drug Therapy
1414367|NCT00331474|BCG
1414368|NCT00331474|HIV
1414369|NCT00331474|Immune responses
1414370|NCT00331474|Delayed vaccination
1414371|NCT00331474|Infant morbidity
1414372|NCT00331474|Nutritional status
1414373|NCT00331474|Morbidity
1414374|NCT00331474|Mortality
1414375|NCT00331448|Treatment Experienced
1414376|NCT00331448|Lipoatrophy
1414377|NCT00331448|Lipohypertrophy
1414378|NCT00331448|Glucose
1414379|NCT00331448|Cholesterol
1414380|NCT00331448|Triglycerides
1414381|NCT00331448|MRI
1414382|NCT00331448|DXA
1414383|NCT00331448|Carotid IMT
1414384|NCT00331448|LDL
1414385|NCT00331448|HDL
1414386|NCT00331435|AMD
1414387|NCT00331435|PCV
1414388|NCT00331435|PDT
1414389|NCT00331422|ovarian clear cell cystadenocarcinoma
1414390|NCT00331422|ovarian endometrioid adenocarcinoma
1414391|NCT00331422|ovarian mixed epithelial carcinoma
1414392|NCT00331422|ovarian mucinous cystadenocarcinoma
1414393|NCT00331422|ovarian serous cystadenocarcinoma
1414394|NCT00331422|ovarian undifferentiated adenocarcinoma
1414395|NCT00331422|stage III ovarian epithelial cancer
1414396|NCT00331422|stage IV ovarian epithelial cancer
1414397|NCT00331422|peritoneal cavity cancer
1414398|NCT00331422|fallopian tube cancer
1414399|NCT00331422|Brenner tumor
1414400|NCT00331409|stage III renal cell cancer
1414401|NCT00331409|stage IV renal cell cancer
1414402|NCT00331409|clear cell renal cell carcinoma
1414403|NCT00331409|recurrent renal cell cancer
1414404|NCT00331357|acute idiopathic thrombocytopenic purpura
1414405|NCT00331357|paediatric
1414406|NCT00331357|quality of life
1414407|NCT00331331|Uveitis
1414408|NCT00331331|Intermediate Uveitis
1414409|NCT00331331|Pars Planitis
1414410|NCT00331331|Macular Edema
1414411|NCT00331331|Vasculitis
1414412|NCT00331331|Ocular Inflammatory Disease
1414413|NCT00331318|Transcranial Direct Current Stimulation (tDCS)
1414414|NCT00331318|Transcranial Magnetic Stimulation (TMS)
1414415|NCT00331318|Motor Learning
1414416|NCT00331318|Brain Plasticity
1414417|NCT00331318|Healthy Volunteer
1414418|NCT00331318|HV
1414419|NCT00331305|Exercise
1414420|NCT00331292|Asthma bronchoscopy
1414421|NCT00331097|elderly
1414422|NCT00331097|adjuvant therapy
1414423|NCT00331097|intermediate risk
1414424|NCT00331097|high risk
1414425|NCT00331084|prevention of post inflammation in cataract surgery
1414426|NCT00331071|Contraception
1414427|NCT00331071|Hormonal contraception
1414428|NCT00331071|Oral contraception
1414429|NCT00331071|Ethinyl estradiol, Progestin, Contraception
1414430|NCT00331071|Transdermal
1414432|NCT00331045|Opioids
1414433|NCT00331045|cancer
1414434|NCT00331045|constipation
1414435|NCT00331032|VivaGel™, sexually transmitted, microbicide, herpes simplex
1414436|NCT00331019|Streptococcus Group B
1414437|NCT00331019|Pregnancy
1414438|NCT00331006|Blood Coagulation Factor Inhibitors
1414439|NCT00330993|mifepristone
1414440|NCT00330993|misoprostol
1414441|NCT00330993|medical abortion
1414442|NCT00330993|buccal administration
1414443|NCT00330980|Cognition
1414444|NCT00330980|Statins
1414445|NCT00330980|Serotonin
1414446|NCT00330980|Cholesterol
1414447|NCT00330967|Fat Emulsions, Intravenous
1414448|NCT00330967|Free Fatty Acids
1414449|NCT00330967|Glucose Clamp Technique
1414450|NCT00330967|Inflammation
1414451|NCT00330967|Insulin Resistance
1414452|NCT00330967|Muscle, Skeletal
1414453|NCT00330967|NF-Kappa B
1414454|NCT00330954|viral response genes
1414455|NCT00330902|malaria
1414456|NCT00330902|subpatent parasitaemia
1414457|NCT00330902|dry season
1414458|NCT00330902|primaquine
1414459|NCT00330902|Plasmodium falciparum infection detected by PCR
1414460|NCT00330889|Rheumatoid Arthritis
1414461|NCT00330876|pitavastatin
1414462|NCT00330876|hypercholesterolemia
1414463|NCT00330876|combined dyslipidemia
1414464|NCT00330863|Relapse
1414465|NCT00330863|Prevention
1414466|NCT00330863|Schizophrenia
1414467|NCT00330863|Injectable Medication
1414468|NCT00330850|Migraine
1414469|NCT00330850|Photophobia
1414470|NCT00330850|Phonophobia
1414471|NCT00330850|Aura
1414472|NCT00330824|prevention of post inflammation in LASIK surgery
1414473|NCT00330811|Pediatrics
1414474|NCT00330811|Non-cardiac Illness
1414475|NCT00330811|B-type Natriuretic Peptide (BNP)
1414476|NCT00330798|Photorefractive Keratectomy
1414477|NCT00330772|Cardiac Surger
1414478|NCT00330772|Coronary Artery Bypass Grafting
1414479|NCT00330772|Graft patency
1414480|NCT00330772|Aspirin
1414481|NCT00330772|Clopidogrel
1414482|NCT00330772|Hemorrhage
1414483|NCT00330772|Transfusion
1414484|NCT00330759|Bone metastases
1414485|NCT00330759|lytic bone lesions
1414486|NCT00330759|advanced cancer
1414487|NCT00330759|multiple myeloma
1414488|NCT00330759|lymphoma
1414489|NCT00330759|solid tumors
1414490|NCT00330759|skeletal related events
1414491|NCT00330759|skeletal fractures
1414492|NCT00330759|spinal cord compressions, radiation to bone
1414493|NCT00330759|surgery to bone, bisphosphonates
1414494|NCT00330759|denosumab
1414495|NCT00330746|elderly
1414496|NCT00330746|chemotherapy
1414497|NCT00330746|targeted therapy
1414498|NCT00330746|combination therapy
1414499|NCT00330746|sequential therapy
1414500|NCT00330746|randomized phase II
1414501|NCT00330746|one year survival
1414502|NCT00330733|Cardiovascular Disease
1414503|NCT00330733|Inflammation
1414504|NCT00330733|Insulin Resistance
1414505|NCT00330733|Type 2 DM
1414506|NCT00330720|Personal Emergency Response System
1414507|NCT00330720|Anxiety
1414508|NCT00330720|Fear of Falling
1414509|NCT00330720|RCT
1414510|NCT00330707|bladder cancer
1414511|NCT00330707|BCG
1414512|NCT00330707|interferon alpha
1414513|NCT00330694|Physical Therapy
1414514|NCT00330694|Organisation of care
1414515|NCT00330681|Amyotrophic lateral sclerosis
1414516|NCT00330681|free radical scavenger
1414517|NCT00330668|Insulin-like Growth Factor Deficiency
1414518|NCT00330668|IGF-1
1414519|NCT00330668|Short Stature
1414520|NCT00330655|Binge eating
1414521|NCT00330655|Obesity
1414522|NCT00330655|Eating disorder
1414523|NCT00330642|Streptococcus Group B
1414524|NCT00330642|Pregnancy
1414525|NCT00330616|WELLBUTRIN
1414526|NCT00330616|elderly
1414527|NCT00330616|depression
1414528|NCT00330616|Pharmacokinetics
1414529|NCT00330603|Cough
1414530|NCT00330603|Gastroesophageal Reflux
1414531|NCT00330590|Central Venous
1414532|NCT00330590|Ultrasonography
1414533|NCT00330590|Catheterization
1414534|NCT00330564|VHL Syndrome
1414535|NCT00330564|Von Hippel-Lindau Syndrome
1414536|NCT00330564|VHL Disease
1414537|NCT00330564|Kidney
1414538|NCT00330564|Retina
1414539|NCT00330564|Brain
1414540|NCT00330564|Spinal cord
1414541|NCT00330564|Pancreas
1414542|NCT00330564|Inner ear
1414543|NCT00330564|Cysts
1414544|NCT00330564|Tumors
1414545|NCT00330564|Sunitinib Malate
1414546|NCT00330564|SU011248
1414547|NCT00330564|Sutent
1414548|NCT00330564|VHL
1414549|NCT00330564|Sunitinib
1414550|NCT00330564|Renal cell carcinoma
1414551|NCT00330564|Hemangioblastoma
1414552|NCT00330564|Endothelium
1414553|NCT00330551|Schizoaffective Disorder, Depressed Type
1414554|NCT00330551|Schizophreniform Disorder
1414555|NCT00330551|First-episode Schizophrenia
1414556|NCT00330551|Injectable Risperidone
1414557|NCT00330538|Osteoporosis
1414558|NCT00330538|Childhood acute lymphoblastic leukemia
1414559|NCT00330512|regional anestesia
1414560|NCT00330512|cesarean section
1414561|NCT00330512|hypotention
1414562|NCT00330512|newborn
1414563|NCT00330499|Locally invasive
1414564|NCT00330499|Bladder cancer
1414565|NCT00330499|Chemoradiotherapy
1414566|NCT00330499|Efficacy
1414567|NCT00330499|Organ conservation
1414568|NCT00330486|Acamprosate
1414569|NCT00330486|Addiction
1414570|NCT00330486|Alcoholism
1414571|NCT00330486|Alcohol dependence
1414572|NCT00330486|Bipolar disorder
1414573|NCT00330486|Depression
1414574|NCT00330486|Impulsivity
1414575|NCT00330486|Mania
1414576|NCT00330486|Substance abuse
1414577|NCT00330460|Osteoporosis
1414578|NCT00330460|Osteopenia
1414579|NCT00330460|AMG 162
1414580|NCT00330460|Fracture - hip
1414581|NCT00330460|Postmenopausal
1414582|NCT00330447|pregnancy
1414583|NCT00330447|in utero
1414584|NCT00330447|chemotherapy
1414585|NCT00330447|radiotherapy
1414586|NCT00330447|cancer
1414587|NCT00330447|offspring
1414588|NCT00330447|neonatal
1414589|NCT00330447|long term
1414590|NCT00330447|follow up
1414591|NCT00330447|cancer during pregnancy
1414592|NCT00330447|chemotherapy and radiotherapy during pregnancy
1414593|NCT00330447|long term follow up of children
1414594|NCT00330434|Alcohol
1414595|NCT00330434|Bupropion
1414596|NCT00330434|Chlorzoxazone
1414597|NCT00330434|Interaction
1414598|NCT00330434|Induction
1414599|NCT00330434|Depression
1414600|NCT00330434|Smoking
1414601|NCT00330434|Drinking
1414602|NCT00330434|Cytochrome P450 Enzyme
1414603|NCT00330434|CYP2B6
1414604|NCT00330434|CYP2E1
1414605|NCT00330434|Pharmacogenetics
1414606|NCT00330434|Pharmacokinetics
1414607|NCT00330434|Pharmacodynamics
1414608|NCT00330434|Boston
1414609|NCT00330434|Tufts University
1414610|NCT00330408|Adherence
1414611|NCT00330408|GP training
1414612|NCT00330408|Medication Event Monitoring System(MEMS)
1414613|NCT00330408|Antihypertensive Medication
1414614|NCT00330408|Hypertension
1414615|NCT00330356|Dietary Salt
1414616|NCT00330356|Blood Pressure
1414617|NCT00330356|Normotensives
1414618|NCT00330343|morphine
1414619|NCT00330343|naloxone
1414620|NCT00330343|pediatrics
1414621|NCT00330343|adverse effects
1414622|NCT00330343|pain
1414623|NCT00330330|Fasting plasma glucose
1414624|NCT00330330|HbA1c
1414625|NCT00330317|Letrozole
1414626|NCT00330317|Breast Conserving Surgery
1414627|NCT00330317|NeoAdjuvant
1414628|NCT00330317|Early Breast Cancer
1414629|NCT00330304|Tuberculosis
1414630|NCT00330304|Child
1414631|NCT00330304|HIV
1414632|NCT00330304|prophylaxis
1414633|NCT00330304|mortality
1414634|NCT00330291|PTSD
1414635|NCT00330291|Xyrem
1414636|NCT00330291|Sleep problems
1414637|NCT00330278|Cesarean section
1414638|NCT00330278|Antibiotic prophylaxis
1414639|NCT00330278|Cefazolin
1414640|NCT00330252|Chronic Lymphocytic Leukemia
1414641|NCT00330252|Relapsed Chronic Lymphocytic Leukemia
1414642|NCT00330252|Alemtuzumab
1414643|NCT00330252|Campath
1414644|NCT00330252|Rituximab
1414645|NCT00330252|Rituxan
1414646|NCT00330239|Substance Abuse
1414647|NCT00330239|Trauma
1414648|NCT00330239|Dependence
1414649|NCT00330226|schizophrenia
1414650|NCT00330226|bipolar disorder
1414651|NCT00330226|atypical antipsychotics
1414652|NCT00330226|mood stabilizers
1414653|NCT00330226|biological markers
1414654|NCT00330213|transthoracic
1414655|NCT00330213|echocardiography
1414656|NCT00330213|red wine
1414657|NCT00330213|cognac
1414658|NCT00330213|coronary reactivity
1414659|NCT00330200|Fasting plasma glucose
1414660|NCT00330200|HbA1c
1414661|NCT00330200|Metabolism
1414662|NCT00330187|nicotine dependence
1414663|NCT00330187|bupropion SR
1414664|NCT00330187|smoking cessation
1414665|NCT00330187|adolescents
1414666|NCT00330187|contingency management
1414667|NCT00330174|Alcoholism
1414668|NCT00330174|Mood
1414669|NCT00330174|Anxiety
1414670|NCT00330174|Acamprosate
1414671|NCT00330148|trypanosomiasis
1414672|NCT00330148|gambiense
1414673|NCT00330148|combination drug therapy
1414674|NCT00330148|sleeping sickness
1414675|NCT00330148|Uganda
1414676|NCT00330135|hip osteoarthritis
1414677|NCT00330135|Hyaluronic acid
1414678|NCT00330135|Viscosupplementation
1414679|NCT00330135|intra-articular injections
1414680|NCT00330122|radius articular displaced fractures
1414681|NCT00330122|fore locked plate
1414682|NCT00330122|external radiocarpal fixer
1414683|NCT00330109|glioma
1414684|NCT00330109|machine learning
1414685|NCT00330109|advanced diagnostic imaging
1414686|NCT00330096|bone loss, osteoporosis, prevention, hesperidin
1414687|NCT00330070|8-week treatment
1414688|NCT00330070|oral tablets
1414689|NCT00330070|persistent moderate to severe asthma
1414690|NCT00330070|AQLQ
1414691|NCT00330070|asthma control
1414692|NCT00330070|quality of life
1414693|NCT00330018|BMT
1414694|NCT00330018|CMV
1414695|NCT00330018|GVHD
1414696|NCT00330005|psychotherapy
1414697|NCT00330005|bipolar disorder
1414698|NCT00330005|psychodynamic
1414699|NCT00330005|psychoeducation
1414700|NCT00330005|illness management
1414701|NCT00330005|controlled trial
1414702|NCT00330005|pilot study
1414703|NCT00329979|aortic stenosis
1414704|NCT00329979|radial
1414705|NCT00329979|femoral
1414706|NCT00329979|vascular access site
1414707|NCT00329979|embolism
1414708|NCT00329979|cerebral
1414709|NCT00329979|MRI
1414710|NCT00329979|stroke
1414711|NCT00329966|Influenza
1414712|NCT00329966|adult
1414713|NCT00329966|elderly
1414714|NCT00329966|vaccine
1414715|NCT00329940|Letrozole
1414716|NCT00329940|breast cancer
1414717|NCT00329940|critical musculoskeletal
1414718|NCT00329940|postmenopausal
1414719|NCT00329940|rheumatologic tolerance
1414720|NCT00329927|Adjuvanted Influenza Vaccine
1414721|NCT00329914|Preterm delivery
1414722|NCT00329914|Prevention
1414723|NCT00329914|Twins
1414724|NCT00329914|Progesterone
1414725|NCT00329901|Meningitis
1414726|NCT00329901|healthy subject
1414727|NCT00329901|vaccine
1414728|NCT00329888|Endoscopic papillary balloon dilatation
1414729|NCT00329888|Endoscopic sphincterotomy
1414730|NCT00329862|Laparoscopic Adjustable Gastric Banding
1414731|NCT00329862|Truncal Vagotomy
1414732|NCT00329862|Lap Band
1414733|NCT00329862|Lap Banding
1414734|NCT00329862|Obesity Surgery
1414735|NCT00329862|Bariatric surgery
1414736|NCT00329862|Weight Loss Surgery
1414737|NCT00329849|Meningitis
1414738|NCT00329849|children
1414739|NCT00329849|vaccine
1414740|NCT00329849|safety
1414741|NCT00329849|efficacy
1414742|NCT00329823|Hidradenitis suppurativa, etanercept
1414743|NCT00329797|osteoporosis
1414744|NCT00329797|adenocarcinoma of the prostate
1414745|NCT00329797|stage IIB prostate cancer
1414746|NCT00329797|stage IIA prostate cancer
1414747|NCT00329797|stage III prostate cancer
1414748|NCT00329797|stage IV prostate cancer
1414749|NCT00329784|peanut allergy
1414750|NCT00329784|egg allergy
1414751|NCT00329784|eczema
1414752|NCT00329784|peanut
1414753|NCT00329784|allergy
1414754|NCT00329784|allergies
1414755|NCT00329784|allergic reaction
1414756|NCT00329784|anaphylaxis
1414757|NCT00329784|infants
1414758|NCT00329784|children
1414759|NCT00329758|moderate head injury
1414760|NCT00329758|rosuvastatin
1414761|NCT00329758|statin
1414762|NCT00329758|amnesia
1414763|NCT00329758|orientation
1414764|NCT00329745|Rotavirus Gastroenteritis
1414765|NCT00329745|Human rotavirus vaccine, efficacy, infants
1414766|NCT00329706|mild cognitive impairment
1414767|NCT00329706|Alzheimer's disease
1414768|NCT00329706|dementia
1414769|NCT00329706|FDG
1414770|NCT00329706|PET
1414771|NCT00329680|Sepsis
1414772|NCT00329680|Severe Sepsis
1414773|NCT00329680|Septic Shock
1414774|NCT00329680|Enteral Nutrition
1414775|NCT00329680|Antioxidants
1414776|NCT00329680|EPA
1414777|NCT00329680|GLA
1414778|NCT00329680|Nutrition
1414779|NCT00329680|Intensive Care
1414780|NCT00329680|ICU
1414781|NCT00329667|heart valve
1414782|NCT00329667|mitral
1414783|NCT00329667|aortic
1414784|NCT00329667|valvular disease
1414785|NCT00329654|Burn wounds, light therapy
1414786|NCT00329628|Prevention
1414787|NCT00329628|Thromboembolism
1414788|NCT00329615|Cancer cachexia
1414789|NCT00329615|Tumor host metabolism
1414790|NCT00329602|Moderate
1414791|NCT00329602|Restless Legs Syndrome
1414792|NCT00329602|Severe
1414793|NCT00329602|ropinirole
1414794|NCT00329589|Malignancies of the central nervous system, head and neck area
1414795|NCT00329589|and cervix
1414796|NCT00329563|Cardiac Arrest
1414797|NCT00329563|Hypothermia
1414798|NCT00329550|Certolizumab pegol
1414799|NCT00329550|Cimzia
1414800|NCT00329550|CZP
1414801|NCT00329537|Crohn's Disease
1414802|NCT00329537|Sargramostim
1414803|NCT00329537|CDAI
1415057|NCT00328549|Hepatitis C Infection
1414804|NCT00329537|Moderately to severely active Crohn's Disease
1414805|NCT00329524|Tinnitus
1414806|NCT00329524|TMS
1414807|NCT00329524|Transcranial Magnetic Stimulation
1414808|NCT00329511|pregnancy
1414809|NCT00329511|hypertension
1414810|NCT00329511|compliance
1414811|NCT00329511|clonidine patch
1414812|NCT00329511|methyldopa
1414813|NCT00329498|ascorbic acid
1414814|NCT00329485|Elevated BNP Levels in CHF patients
1414815|NCT00329459|menstrual migraine
1414816|NCT00329459|headache
1414817|NCT00329459|early intervention
1414818|NCT00329459|dysmenorrhea
1414819|NCT00329446|GAD
1414820|NCT00329446|anxiety
1414821|NCT00329433|Deep venous thrombosis
1414822|NCT00329433|DVT
1414823|NCT00329433|Heparin induced thrombocytopenia
1414824|NCT00329433|HIT
1414825|NCT00329433|Direct thrombin inhibitor
1414826|NCT00329420|Crohn's Disease
1414827|NCT00329420|CDP870
1414828|NCT00329420|Certolizumab pegol
1414829|NCT00329420|CZP
1414830|NCT00329407|Alcoholism
1414831|NCT00329407|Heavy Drinking
1414832|NCT00329407|Alcohol Dependence
1414833|NCT00329394|Ketamine
1414834|NCT00329394|Analgesia
1414835|NCT00329394|Alcool-dependent
1414836|NCT00329394|carcinological surgery
1414837|NCT00329381|Allergic
1414838|NCT00329381|Asthma
1414839|NCT00329381|Immunotherapy
1414840|NCT00329368|Cancer
1414841|NCT00329368|Vaccine
1414842|NCT00329368|Phase I
1414843|NCT00329368|FolateImmune
1414844|NCT00329368|Recurrent
1414845|NCT00329368|Refractory
1414846|NCT00329368|Experimental
1414847|NCT00329355|menstrual migraine
1414848|NCT00329355|headache
1414849|NCT00329355|early intervention
1414850|NCT00329355|dysmenorrhea
1414851|NCT00329342|Low back pain;
1414852|NCT00329342|Return to work;
1414853|NCT00329342|Posture
1414854|NCT00329329|Advanced solid malignancies
1414855|NCT00329316|Pre-term labor
1414856|NCT00329316|progesterone
1414857|NCT00329303|Moderate to severe chronic plaque psoriasis
1414858|NCT00329303|anti TNF α
1414859|NCT00329303|CDP 870
1414860|NCT00329303|Cimzia®
1414861|NCT00329303|certolizumab pegol
1414862|NCT00329303|retreatment
1414863|NCT00329290|pregnancy
1414864|NCT00329290|anticoagulation
1414865|NCT00329290|enoxaparin
1414866|NCT00329290|prosthetic heart valves
1414867|NCT00329277|age-related macular degeneration
1414868|NCT00329277|preferred retinal locus
1414869|NCT00329277|macular perimetry
1414870|NCT00329264|GAD
1414871|NCT00329264|anxiety
1414872|NCT00329251|HIV
1414873|NCT00329251|Viral load
1414874|NCT00329251|Vaccines
1414875|NCT00329251|Immunotherapy
1414876|NCT00329225|Type 2 Diabetes Mellitus Thiazolidinediones Insulin
1414877|NCT00329212|Pharmacokinetics
1414878|NCT00329212|Bioavailability
1414879|NCT00329212|Therapeutic Equivalency
1414880|NCT00329199|Depression
1414881|NCT00329199|Adolescents
1414882|NCT00329199|Family Therapy
1414883|NCT00329199|Primary Care
1414884|NCT00329199|Family Conflict
1414885|NCT00329186|Healthy Subjects
1414886|NCT00329186|Major Depressive Disorder
1414887|NCT00329186|Depression
1414888|NCT00329186|Cytochrome P-450 CYP2D6
1414889|NCT00329186|Pharmacokinetics
1414890|NCT00329186|Health
1414891|NCT00329147|Healthy Subjects
1414892|NCT00329147|Major Depressive Disorder
1414893|NCT00329147|Depression
1414894|NCT00329121|SCCIS
1414895|NCT00329121|Bowens disease
1414896|NCT00329121|PEP005
1414897|NCT00329121|Topical
1414898|NCT00329121|Dermatology
1414899|NCT00329121|Cutaneous Squamous Cell Carcinoma in situ
1414900|NCT00329095|Glaucoma
1414901|NCT00329095|Compliance
1414902|NCT00329069|statin
1414903|NCT00329069|atorvastatin
1414904|NCT00329069|hypercholesterolemia
1414905|NCT00329069|coronary artery disease
1414906|NCT00329069|monocyte
1414907|NCT00329069|collateral formation
1414908|NCT00329069|arteriogenesis
1414909|NCT00329069|chemotaxis
1414910|NCT00329069|migration
1414911|NCT00329069|growth factors
1414912|NCT00329069|vascular endothelial growth factor A
1414913|NCT00329069|placenta growth factor 1
1414914|NCT00329069|hepatocyte growth factor
1414915|NCT00329069|monocyte chemotactic protein 1
1414916|NCT00329056|Parkinson's disease
1414917|NCT00329056|MitoQ
1414918|NCT00329056|UPDRS
1414919|NCT00329043|Prostate Cancer
1414920|NCT00329043|Adenocarcinoma of the Prostate
1414921|NCT00329043|Ductal Adenocarcinoma of the Prostate
1414922|NCT00329043|Hormonal Ablation
1414923|NCT00329043|Radical Prostatectomy
1414924|NCT00329043|LHRH Agonist
1414925|NCT00329043|Lupron
1414926|NCT00329043|Leuprolide
1414927|NCT00329043|Sunitinib Malate
1414928|NCT00329043|SU011248
1414929|NCT00329030|Large B-Cell Lymphoma
1414930|NCT00329030|Non-Hodgkin's Lymphoma
1414931|NCT00329017|SNPs
1414932|NCT00329017|single nucleotide polymorphism
1414933|NCT00329017|breast atypia
1414934|NCT00329017|breast epithelial hyperplasia
1414935|NCT00329017|high risk for breast cancer
1414936|NCT00329004|Solid Tumors
1414937|NCT00328991|wart
1414938|NCT00328991|common wart
1414939|NCT00328991|verruca vulgaris
1414940|NCT00328991|verruca plantaris
1414941|NCT00328991|plantar wart
1414942|NCT00328991|duct tape
1414943|NCT00328991|occlusion therapy
1414944|NCT00328978|schizophrenia
1414945|NCT00328978|schizoaffective disorders
1414946|NCT00328965|Korean patients
1414947|NCT00328965|Type 2 diabetes
1414948|NCT00328965|Endothelial function
1414949|NCT00328965|lacidipine
1414950|NCT00328965|Essential hypertension
1414951|NCT00328952|schizophrenia
1414952|NCT00328952|auditory verbal hallucination
1414953|NCT00328952|antipsychotic treatment
1414954|NCT00328939|ARIXTRA
1414955|NCT00328939|prevention of DVT
1414956|NCT00328926|Hypogonadotropic Hypogonadism (LH <1.2 IU/L)
1414957|NCT00328926|Placebo
1414958|NCT00328926|Luveris® 75 IU
1414959|NCT00328926|Luveris® 25 IU
1414960|NCT00328926|Recombinant human chorionic gonadotropin (r-hCG)
1414961|NCT00328913|satiety
1414962|NCT00328913|food intake
1414963|NCT00328913|mood
1414964|NCT00328913|wellness
1414965|NCT00328913|weight management
1414966|NCT00328900|Galvanic skin response
1414967|NCT00328900|Anesthesia
1414968|NCT00328900|Atropine
1414969|NCT00328887|Esophageal Neoplasms
1414970|NCT00328874|Progressive Supranuclear Palsy
1414971|NCT00328874|Coenzyme Q10
1414972|NCT00328861|Adoptive Cell Therapy
1414973|NCT00328861|Cutaneous Melanoma
1414974|NCT00328861|Clinical Response
1414975|NCT00328861|Rate of Repopulation
1414976|NCT00328861|Toxicity Profile
1414977|NCT00328861|Metastatic Melanoma
1414978|NCT00328861|Metastatic Kidney Cancer
1414979|NCT00328848|patient care management
1414980|NCT00328848|chronic disease
1414981|NCT00328835|Optic Nerve
1414982|NCT00328835|Glaucoma
1414983|NCT00328822|Primary insomnia
1414984|NCT00328822|Quetiapine
1414985|NCT00328822|Randomized controlled trial
1414986|NCT00328822|Double blind
1414987|NCT00328796|Perineal
1414988|NCT00328796|repair
1414989|NCT00328796|episiotomies
1414990|NCT00328796|midwives
1414991|NCT00328796|pain relief
1414992|NCT00328796|Episiotomy
1414993|NCT00328783|Breast cancer
1414994|NCT00328783|Active Breathing Control
1414995|NCT00328783|Active Breathing Coordinator
1414996|NCT00328783|ABC
1414997|NCT00328770|liver transplant
1414998|NCT00328770|hepatocellular carcinoma
1414999|NCT00328770|sirolimus
1415000|NCT00328757|gynecologic cancer
1415001|NCT00328757|cervical cancer
1415002|NCT00328757|ovarian cancer
1415003|NCT00328757|endometrial cancer
1415004|NCT00328757|radical abdominal hysterectomy
1415005|NCT00328757|pelvic lymphadenectomy
1415006|NCT00328757|surgical staging
1415007|NCT00328757|postoperative feeding
1415008|NCT00328757|Early-stage gynecologic cancer patients
1415009|NCT00328744|Weight
1415010|NCT00328744|Dietary intake
1415011|NCT00328744|Energy
1415012|NCT00328744|Hedonics
1415013|NCT00328744|Behavioral
1415014|NCT00328744|Sensory-specific satiety
1415015|NCT00328744|Monotony
1415016|NCT00328731|Allergy
1415017|NCT00328731|NAET
1415018|NCT00328718|Persistent Asthma
1415019|NCT00328718|pediatric asthmatic
1415020|NCT00328718|asthma control
1415021|NCT00328705|Sensing
1415022|NCT00328705|Capture Management
1415023|NCT00328705|Heart Failure
1415024|NCT00328705|ICD Indication
1415025|NCT00328692|heart failure
1415026|NCT00328692|diuretic
1415027|NCT00328692|renal impairment
1415028|NCT00328692|renal function
1415029|NCT00328679|abdominal
1415030|NCT00328679|stomach
1415031|NCT00328679|dyspepsia
1415032|NCT00328679|food allergy
1415033|NCT00328653|vernal keratoconjunctivitis (VKC), eye, allergy, cyclosporin
1415034|NCT00328640|CVA
1415035|NCT00328640|Ischemic stroke
1415036|NCT00328627|Diabetes Mellitus, Type 2
1415037|NCT00328627|Drug Therapy
1415038|NCT00328627|Diabetes Mellitus, Non Insulin Dependent
1415039|NCT00328627|Glucose Intolerance
1415040|NCT00328627|Hyperglycemia
1415041|NCT00328614|Locally advanced prostate cancer
1415042|NCT00328614|positive lymph nodes
1415043|NCT00328588|Treatment Efficacy
1415044|NCT00328588|Treatment Effectiveness
1415045|NCT00328588|Disease Management
1415046|NCT00328588|Treatment
1415047|NCT00328588|Safety
1415048|NCT00328575|Brain metastases
1415049|NCT00328575|Parenchymal
1415050|NCT00328575|Neoplasm
1415051|NCT00328575|IMRT
1415052|NCT00328575|Intensity Modulated Radiation Therapy
1415053|NCT00328562|Advanced NSCLC
1415054|NCT00328562|Non-Small Cell Lung Carcinoma
1415055|NCT00328562|Stage IV NSCLC
1415056|NCT00328549|Natural History,
1415058|NCT00328549|Ribavirin
1415059|NCT00328549|Pegylated Interferon
1415060|NCT00328549|Interferon
1415061|NCT00328536|flow-mediated vasodilatation
1415062|NCT00328536|endothelial dysfunction
1415063|NCT00328536|omega-3 fatty acids
1415064|NCT00328536|type 2 diabetes mellitus
1415065|NCT00328536|postprandial state
1415066|NCT00328510|Stereotactic radiotherapy
1415067|NCT00328484|COPD
1415068|NCT00328484|Chronic Obstructive Pulmonary Disease
1415069|NCT00328484|Exercise
1415070|NCT00328484|Emphysema
1415071|NCT00328484|Chronic Bronchitis
1415072|NCT00328471|patient care management
1415073|NCT00328471|cerebrovascular accident
1415074|NCT00328458|CNS and head and neck cancers
1415075|NCT00328458|Histologically confirmed CNS malignancy head and neck
1415076|NCT00328458|there is on standard therapy or
1415077|NCT00328458|have failed standard therapy
1415078|NCT00328445|Curriculum
1415079|NCT00328445|Classroom management
1415080|NCT00328445|School-wide climate
1415081|NCT00328445|Parent involvement
1415082|NCT00328432|early breast cancer
1415083|NCT00328432|double-blind randomized placebo-controlled
1415084|NCT00328432|RCT
1415085|NCT00328432|pre-surgical model
1415086|NCT00328432|DCIS model
1415087|NCT00328432|COX-2 inhibitor
1415088|NCT00328432|celecoxib
1415089|NCT00328432|Ki-67 placebo
1415090|NCT00328419|Photoprotection,
1415091|NCT00328419|Parenteral nutrition
1415092|NCT00328419|Oxidant stress
1415093|NCT00328419|Infant, Premature
1415094|NCT00328393|Hypertension
1415095|NCT00328380|Travelers' Diarrhea
1415096|NCT00328380|Xifaxan
1415097|NCT00328380|Rifaximin
1415098|NCT00328380|Escherichia coli
1415099|NCT00328380|E coli
1415100|NCT00328380|EAEC
1415101|NCT00328380|Enteroaggregative E coli
1415102|NCT00328380|ETEC
1415103|NCT00328380|Enterotoxigenic E coli
1415104|NCT00328367|schizophrenia
1415105|NCT00328367|aripiprazole
1415106|NCT00328367|clozapine
1415107|NCT00328341|traumatic brain injury
1415108|NCT00328341|hemorrhagic shock
1415109|NCT00328341|multisystem trauma
1415110|NCT00328341|under resuscitation
1415111|NCT00328341|tissue oxygen monitoring
1415112|NCT00328315|Myocardial Perfusion SPECT
1415113|NCT00328302|Diabetes
1415114|NCT00328302|Kidney function
1415115|NCT00328302|24 ambulatory blood pressure
1415116|NCT00328302|Kidney biopsy
1415117|NCT00328289|Dialysis associated hypotension
1415118|NCT00328289|Urea removal
1415119|NCT00328263|Bio-K+CL1285
1415120|NCT00328263|Probiotics
1415121|NCT00328263|Antibiotics-associated diarrhea
1415122|NCT00328263|Clostridium difficile-associated diarrhea
1415123|NCT00328263|Lactobacillus acidophilus
1415124|NCT00328263|Clostridium Difficile
1415125|NCT00328250|Internet
1415126|NCT00328250|CBT
1415127|NCT00328250|Insomnia
1415128|NCT00328250|Sleep
1415129|NCT00328237|Cord Blood Transplant
1415130|NCT00328237|Umbilical cord blood transplant
1415131|NCT00328237|Transplant
1415132|NCT00328237|Fludarabine
1415133|NCT00328237|Total Body Irradiation
1415134|NCT00328237|Cyclophosphamide
1415135|NCT00328224|ritalin
1415136|NCT00328224|ADHA
1415137|NCT00328224|dental status
1415138|NCT00328224|periodontal status
1415139|NCT00328224|Attention-Deficit Hyperactivity Disorder
1415140|NCT00328224|Dental trauma
1415141|NCT00328198|CAMPATH
1415142|NCT00328198|Alemtuzumab
1415143|NCT00328198|Leukemia
1415144|NCT00328198|MabCampath
1415145|NCT00328198|Chronic
1415146|NCT00328198|Subcutaneous
1415147|NCT00328198|CLL
1415148|NCT00328198|C-CLL
1415149|NCT00328198|Relapsed
1415150|NCT00328198|Refractory
1415151|NCT00328198|Chronic Lymphocytic Leukemia
1415152|NCT00328185|pediatric
1415153|NCT00328185|heart disease
1415154|NCT00328185|orthotopic heart transplantation
1415155|NCT00328185|allograft fibrosis
1415156|NCT00328159|FAO disorders
1415157|NCT00328159|long-chain FAO enzyme defects
1415158|NCT00328159|inborn errors of metabolism
1415159|NCT00328159|carnitine palmitoyltransferase 1 (CPT1),
1415160|NCT00328159|carnitine-acylcarnitine translocase (CAT),
1415161|NCT00328159|carnitine palmitoyltransferase 2 (CPT2),
1415162|NCT00328159|very-long chain acyl-CoA dehydrogenase (VLCAD),
1415163|NCT00328159|L-3-hydroxy-acyl-CoA dehydrogenase (LCHAD)
1415164|NCT00328159|or trifunctional protein (MTP).
1415165|NCT00328146|pediatric
1415166|NCT00328146|cardiac
1415167|NCT00328146|re-operative surgery
1415168|NCT00328133|recombinant Factor VIIa
1415169|NCT00328133|traumatic hemorrhage
1415170|NCT00328133|hemorrhagic shock
1415171|NCT00328133|coagulopathy
1415172|NCT00328120|Advanced breast cancer
1415173|NCT00328120|Faslodex
1415174|NCT00328107|Influenza
1415175|NCT00328094|Tight
1415176|NCT00328094|Glycemic
1415177|NCT00328094|control
1415178|NCT00328094|outcomes
1415179|NCT00328094|peripheral vascular disease
1415180|NCT00328094|infection
1415181|NCT00328094|cardiovascular
1415182|NCT00328094|morbidity
1415183|NCT00328094|mortality
1415184|NCT00328081|Obesity
1415185|NCT00328081|Weight gain
1415186|NCT00328081|Anti-obesity medication
1415187|NCT00328081|Anti-obesity management strategies
1415188|NCT00328081|Body Weight
1415189|NCT00328068|ASAS classification
1415190|NCT00328068|ASAS diagnostic criteria
1415191|NCT00328068|spondyloarthritis
1415192|NCT00328068|spondyloarthropathy
1415193|NCT00328068|spondylitis, ankylosing
1415194|NCT00328068|modified New York criteria for AS
1415195|NCT00328068|ESSG criteria for SpA
1415196|NCT00328068|Amor criteria for SpA
1415197|NCT00328068|arthritis
1415198|NCT00328068|enthesitis
1415199|NCT00328068|magnetic resonance imaging
1415200|NCT00328055|functional ability
1415201|NCT00328055|patient care management
1415202|NCT00328055|communication
1415203|NCT00328055|literacy
1415204|NCT00328042|Self-care
1415205|NCT00328042|Quality of Life
1415206|NCT00328042|Chronic disease
1415207|NCT00328029|Busulfan
1415208|NCT00328029|pharmacokinetic
1415209|NCT00328029|respiratory function assessment
1415210|NCT00328029|Busulfan pharmacokinetic and respiratory function tests
1415211|NCT00328016|hypertension
1415212|NCT00328016|high blood pressure
1415213|NCT00328016|meditation
1415214|NCT00327990|ibandronate
1415215|NCT00327990|osteoporosis
1415216|NCT00327990|preference
1415217|NCT00327990|case-finding
1415218|NCT00327990|post-menopausal
1415219|NCT00327990|alendronate
1415220|NCT00327977|hypoxemia
1415221|NCT00327977|palliative neonatal surgery
1415222|NCT00327964|malaria
1415223|NCT00327964|fever
1415224|NCT00327964|Uganda
1415225|NCT00327964|children
1415226|NCT00327964|rapid diagnostic tests
1415227|NCT00327964|RDTs
1415228|NCT00327964|Africa
1415229|NCT00327951|pediatric
1415230|NCT00327951|cardiac
1415231|NCT00327951|weight gain pre-operative
1415232|NCT00327951|trisomy 21
1415487|NCT00326885|Fallopian Tube Cancer
1415233|NCT00327951|complete atrioventricular canal
1415234|NCT00327938|Remifentanil
1415235|NCT00327938|Skin Conductance
1415236|NCT00327938|Anesthesia
1415237|NCT00327938|Analgesics, Opioid
1415238|NCT00327925|Ovarian
1415239|NCT00327925|Cancer
1415240|NCT00327925|Antibodies
1415241|NCT00327925|Ovarian Cancer Associated Antibodies
1415242|NCT00327912|Obesity
1415243|NCT00327912|Surgery
1415244|NCT00327912|Gastric bypass
1415245|NCT00327912|Biliopancreatic diversion with Duodenal switch
1415246|NCT00327912|Laparoscopy
1415247|NCT00327899|pediatric
1415248|NCT00327899|congestive heart failure
1415249|NCT00327899|inotropes
1415250|NCT00327886|pediatric
1415251|NCT00327886|Glenn operation
1415252|NCT00327886|Cyanosis
1415253|NCT00327873|breathlessness
1415254|NCT00327873|shortness of breath
1415255|NCT00327873|end-of-life care
1415256|NCT00327873|hospice
1415257|NCT00327808|Smokers
1415258|NCT00327808|Adults
1415259|NCT00327808|Inflammatory markers
1415260|NCT00327795|congenital heart disease
1415261|NCT00327795|pediatric
1415262|NCT00327795|surgical outcomes
1415263|NCT00327782|pediatric
1415264|NCT00327782|palliative care
1415265|NCT00327782|end stage heart failure
1415266|NCT00327769|Advanced breast cancer
1415267|NCT00327769|fulvestrant
1415268|NCT00327769|anastrozole
1415269|NCT00327756|Depression
1415270|NCT00327756|Magnetic Resonance Spectroscopy
1415271|NCT00327756|Mitochondrial Enhancer
1415272|NCT00327756|Manic Depressive
1415273|NCT00327756|Bioenergetics
1415274|NCT00327756|Bipolar Disorder
1415275|NCT00327756|Manic Depression
1415276|NCT00327743|Cancer Alternative Therapies
1415277|NCT00327743|Metastatic Breast Cancer
1415278|NCT00327730|Muscle
1415279|NCT00327730|Spasm
1415280|NCT00327730|Back
1415281|NCT00327730|Pain
1415282|NCT00327717|Epilepsy
1415283|NCT00327717|Partial seizures
1415284|NCT00327704|Septic Shock
1415285|NCT00327691|Major cardiovascular event
1415286|NCT00327691|Major Coronary event
1415287|NCT00327691|Revascularization
1415288|NCT00327678|ALL,
1415289|NCT00327678|young patients,
1415290|NCT00327678|chemotherapy,
1415291|NCT00327678|Mabtera,
1415292|NCT00327678|Imatinib,
1415293|NCT00327678|allogeneic transplant
1415294|NCT00327665|pneumonia
1415295|NCT00327665|pneumococcal vaccine
1415296|NCT00327665|elderly subjects
1415297|NCT00327665|invasive pneumococcal diseases
1415298|NCT00327665|Prophylaxis
1415299|NCT00327652|carcinoma
1415300|NCT00327652|liver
1415301|NCT00327652|hepatic
1415302|NCT00327652|metastasis
1415303|NCT00327652|Listeria
1415304|NCT00327626|Fasting plasma glucose
1415305|NCT00327626|HbA1c
1415306|NCT00327626|Oral antidiabetic agent(s)
1415307|NCT00327613|PEX
1415308|NCT00327613|glaucoma
1415309|NCT00327613|MMP
1415310|NCT00327613|DNA degradation
1415311|NCT00327613|POAG
1415312|NCT00327613|Healthy subjects
1415313|NCT00327587|hypertension
1415314|NCT00327587|valsartan
1415315|NCT00327587|amlodipine
1415316|NCT00327587|HCTZ
1415317|NCT00327561|Inflammation
1415318|NCT00327561|Periodontitis
1415319|NCT00327561|Endothelial function
1415320|NCT00327561|Atherosclerosis
1415321|NCT00327561|Controlled trial
1415322|NCT00327509|mRNA
1415323|NCT00327509|glaucoma
1415324|NCT00327483|Transplant
1415325|NCT00327483|Medication error
1415326|NCT00327483|Patient Safety
1415327|NCT00327483|Information technology
1415328|NCT00327470|neovascular age related macular degeneration
1415329|NCT00327470|choroidal neovascularization
1415330|NCT00327457|colorectal cancer screening
1415331|NCT00327457|sigmoidoscopy
1415332|NCT00327457|colonoscopy
1415333|NCT00327444|Ovarian neoplasm
1415334|NCT00327444|Ascites
1415335|NCT00327444|Angiogenesis inhibitor
1415336|NCT00327444|Vascular Endothelial Growth Factor A
1415337|NCT00327444|Recombinant fusion protein
1415338|NCT00327431|Hypertension
1415339|NCT00327431|Blood Pressure
1415340|NCT00327431|Psychosocial Factors
1415341|NCT00327405|POAG
1415342|NCT00327405|Primary Open Angle Glaucoma
1415343|NCT00327405|Trabeculectomy
1415344|NCT00327405|Combined Phacotrabeculectomy
1415345|NCT00327405|Combined Glaucoma Cataract Surgery
1415346|NCT00327405|Releasable Suture
1415347|NCT00327405|Ocular Compresssion
1415348|NCT00327392|Arthroscopy
1415349|NCT00327392|AV Shunt
1415350|NCT00327392|Bunion
1415351|NCT00327392|Dilatation and Curettage
1415352|NCT00327392|Esophagogastroduodenoscopy
1415353|NCT00327392|Hysteroscopy
1415354|NCT00327392|Lithotripsy
1415355|NCT00327392|Rotator Cuff/ Shoulder
1415356|NCT00327392|Transesophageal Echocardiography
1415357|NCT00327392|Ureteroscopy
1415358|NCT00327392|AQUAVAN
1415359|NCT00327392|Sedation
1415360|NCT00327379|Bloodloss
1415361|NCT00327379|Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
1415362|NCT00327366|Menstrual Cycle
1415363|NCT00327366|Light Therapy
1415364|NCT00327366|Sex Hormones
1415365|NCT00327366|Ovulation
1415366|NCT00327353|Asthma
1415367|NCT00327353|Salmeterol
1415368|NCT00327353|Formoterol
1415369|NCT00327353|Airway resistance
1415370|NCT00327340|Metastatic hormone refractory prostate cancer (HRPC)
1415371|NCT00327301|POAG
1415372|NCT00327301|Parkinson's disease
1415373|NCT00327301|cellular proteome
1415374|NCT00327301|human leucocytes
1415375|NCT00327301|vasospasm
1415376|NCT00327301|POAG patients
1415377|NCT00327301|Patients with Parkinson's disease
1415378|NCT00327301|Healthy subjects
1415379|NCT00327288|Hormone refractory prostate cancer
1415380|NCT00327262|chronic myeloid leukemia
1415381|NCT00327262|Ph+
1415382|NCT00327262|bcr/abl+
1415383|NCT00327262|imatinib
1415384|NCT00327236|Paraneoplastic Neurologic Syndromes
1415385|NCT00327223|Metastatic cancer
1415386|NCT00327223|Disseminated malignant disease
1415387|NCT00327210|BGAT
1415388|NCT00327210|Blood Glucose Awareness Training
1415389|NCT00327210|Diabetes
1415390|NCT00327210|T1DM
1415391|NCT00327210|Internet
1415392|NCT00327210|Web
1415393|NCT00327210|Intervention
1415394|NCT00327210|Treatment
1415395|NCT00327210|Behavior
1415396|NCT00327210|Education
1415397|NCT00327210|Awareness
1415398|NCT00327197|bronchoscopy
1415399|NCT00327197|Sputum induction
1415400|NCT00327197|Prednisolone
1415401|NCT00327197|Asthma
1415402|NCT00327197|biomarkers
1415403|NCT00327171|ovarian cancer
1415404|NCT00327171|angiogenesis
1415405|NCT00327171|angiogenesis inhibition
1415406|NCT00327171|VEGF-Trap fusion recombinant protein
1415407|NCT00327171|Cancer and other neoplasms
1415408|NCT00327158|Reaming
1415409|NCT00327158|fracture
1415410|NCT00327158|emboli
1415411|NCT00327145|HCTZ
1415412|NCT00327145|hypertension
1415413|NCT00327145|valsartan
1415414|NCT00327145|amlodipine
1415415|NCT00327132|Early-stage Lg/Hg Gastric MALT Lymphoma
1415416|NCT00327132|Eradication of Helicobacter pylori (Hp)
1415417|NCT00327119|EGFR
1415418|NCT00327119|Fully human
1415419|NCT00327119|Monoclonal antibody
1415420|NCT00327119|Panitumumab
1415421|NCT00327119|ABX-EGF
1415422|NCT00327119|AMG954
1415423|NCT00327119|Colorectal Cancer
1415424|NCT00327119|Japan
1415425|NCT00327106|hip fracture
1415426|NCT00327106|transfusion
1415427|NCT00327106|tranexamic acid
1415428|NCT00327106|fondaparinux
1415429|NCT00327093|Colorectal cancer,
1415430|NCT00327093|immunohistochemistry,
1415431|NCT00327093|monoclonal antibodies,
1415432|NCT00327093|predictive model,
1415433|NCT00327093|antiangiogenic agents,
1415434|NCT00327093|medical imaging
1415435|NCT00327093|Colorectal cancer with liver metastases
1415436|NCT00327080|HIV
1415437|NCT00327080|AIDS
1415438|NCT00327080|Pulmonary Hypertension
1415439|NCT00327080|Blood Flow Studies
1415440|NCT00327080|Right Heart Catheterization
1415441|NCT00327080|HIV Infection
1415442|NCT00327080|HIV Associated Pulmonary Hypertension
1415443|NCT00327080|Healthy Volunteer
1415444|NCT00327080|HV
1415445|NCT00327067|Hemoglobin
1415446|NCT00327067|Iron Supplementation
1415447|NCT00327067|Donor Retention
1415448|NCT00327067|Iron Stores
1415449|NCT00327067|Ferritin
1415450|NCT00327067|Transferrin Saturation
1415451|NCT00327067|Healthy Volunteer
1415452|NCT00327067|HV
1415453|NCT00327067|Blood Donors
1415454|NCT00327054|Dyslipidaemia
1415455|NCT00327054|Herbal medicine
1415456|NCT00327054|Home remedy
1415457|NCT00327054|Alternative medicine
1415458|NCT00327054|Metabolic syndrome
1415459|NCT00327041|Aspirin
1415460|NCT00327041|Clopidogrel
1415461|NCT00327041|Balloon Angioplasty
1415462|NCT00327041|Coronary Thrombosis
1415463|NCT00327028|Bronchial asthma
1415464|NCT00327028|Phenytoin, Diphenine
1415465|NCT00327028|Antiepileptic drugs
1415466|NCT00327028|Efficacy
1415467|NCT00327002|Low HDL
1415468|NCT00327002|Metabolic syndrome
1415469|NCT00327002|low HDL Cholesterol in setting of metabolic syndrome
1415470|NCT00326989|Extracorporal shock wave therapy
1415471|NCT00326989|Cell therapy
1415472|NCT00326976|Angioplasty, Transluminal, Percutaneous Coronary
1415473|NCT00326976|Myocardial Revascularization
1415474|NCT00326950|Cancer
1415475|NCT00326950|Tumors
1415476|NCT00326950|Phase I
1415477|NCT00326950|E7389
1415478|NCT00326924|Transfusion
1415479|NCT00326898|Sorafenib
1415480|NCT00326898|Sunitinib
1415481|NCT00326898|Renal Carcinoma
1415482|NCT00326885|Ascites
1415483|NCT00326885|Epithelial Cancer
1415484|NCT00326885|Epithelial Carcinoma
1415485|NCT00326885|Epithelial Ovarian Cancer
1415486|NCT00326885|Epithelial Ovarian Carcinoma
1415488|NCT00326885|Fallopian Tube Carcinoma
1415489|NCT00326885|Malignant Ascites
1415490|NCT00326885|Ovarian Cancer
1415491|NCT00326885|Ovarian Carcinoma
1415492|NCT00326885|Ovarian Epithelial Cancer
1415493|NCT00326885|Ovarian Epithelial Carcinoma
1415494|NCT00326885|Peritoneal Cancer
1415495|NCT00326885|Peritoneal Carcinoma
1415496|NCT00326885|Recurrent Ascites
1415497|NCT00326885|Recurrent Malignant Ascites
1415498|NCT00326885|Recurrent Symptomatic Malignant Ascites
1415499|NCT00326885|Symptomatic Malignant Ascites
1415500|NCT00326885|Symptomatic Ascites
1415501|NCT00326885|Neoplasms, Glandular and Epithelial
1415502|NCT00326885|Ovarian Neoplasms
1415503|NCT00326885|Fallopian Tube Neoplasms
1415504|NCT00326885|Peritoneal Neoplasms
1415505|NCT00326859|analgesia strategies
1415506|NCT00326859|pain
1415507|NCT00326859|extensive dressing change
1415508|NCT00326833|Vitamin B12 deficiency
1415509|NCT00326833|Vitamin B12 absorption
1415510|NCT00326833|Holotranscobalamin
1415511|NCT00326820|hypercalcemia of malignancy
1415512|NCT00326820|stage IV breast cancer
1415513|NCT00326820|bone metastases
1415514|NCT00326820|recurrent breast cancer
1415515|NCT00326820|male breast cancer
1415516|NCT00326807|naltrexone
1415517|NCT00326807|alcohol
1415518|NCT00326807|gambling
1415519|NCT00326807|concurrent
1415520|NCT00326794|Nonsurgical proximal humerus fracture
1415521|NCT00326794|Rehabilitation
1415522|NCT00326794|Physiotherapy
1415523|NCT00326794|randomised controlled trial
1415524|NCT00326781|Nicotine nasal spray + counseling
1415525|NCT00326781|Transdermal nicotine + counseling
1415526|NCT00326742|Alcoholism
1415527|NCT00326742|Risk factors
1415528|NCT00326742|Adolescence
1415529|NCT00326742|Stress test
1415530|NCT00326742|HPA system
1415531|NCT00326742|Family adversity
1415532|NCT00326742|Candidate genes
1415533|NCT00326742|Cortisol
1415534|NCT00326742|Adrenocorticotrophin
1415535|NCT00326729|burns
1415536|NCT00326729|thermal injury
1415537|NCT00326729|hemodynamics
1415538|NCT00326729|microcirculation
1415539|NCT00326716|HIV-1 infected pregnant women, either treatment naive or on ATV/RTV combined with ZDV/3TC
1415540|NCT00326703|hypoxia
1415541|NCT00326703|hypobaric
1415542|NCT00326703|altitude
1415543|NCT00326690|Congestive Heart Failure
1415544|NCT00326690|Coronary Artery Disease
1415545|NCT00326690|Ischemic Cardiomyopathy
1415546|NCT00326690|Idiopathic Cardiomyopathy
1415547|NCT00326677|Depression Prevention
1415548|NCT00326677|Prevention of Depression
1415549|NCT00326677|Depression in the Elderly
1415550|NCT00326677|Late Life Depression
1415551|NCT00326677|Depression in Old Age
1415552|NCT00326677|Treatment of Depression in Primary Care Patients
1415553|NCT00326677|Sub syndromal depression
1415554|NCT00326677|Minor Depression
1415555|NCT00326651|infertility
1415556|NCT00326651|pregnancy
1415557|NCT00326651|conception
1415558|NCT00326651|conceive
1415559|NCT00326651|conceiving
1415560|NCT00326651|trying to conceive
1415561|NCT00326651|get pregnant
1415562|NCT00326651|conception kit
1415563|NCT00326651|conception cap
1415564|NCT00326651|fertility
1415565|NCT00326651|Women who are actively trying to become pregnant
1415566|NCT00326638|prostate, IMRT, tomotherapy, radiation, cancer
1415567|NCT00326612|Seizures
1415568|NCT00326599|recurrent non-small cell lung cancer
1415569|NCT00326599|stage IIIB non-small cell lung cancer
1415570|NCT00326599|stage IV non-small cell lung cancer
1415571|NCT00326599|squamous cell lung cancer
1415572|NCT00326573|Diabetes
1415573|NCT00326573|Teenagers
1415574|NCT00326573|Motivational Interviewing
1415575|NCT00326560|Pterygium excision
1415576|NCT00326560|Cut and paste
1415577|NCT00326560|Tisseel fibrin glue
1415578|NCT00326560|Conjunctival autograft
1415579|NCT00326534|Sarcoidosis
1415580|NCT00326534|Rickettsia
1415581|NCT00326534|Serological reactions
1415582|NCT00326534|Polymerase chain reaction
1415583|NCT00326521|Pregnant Women
1415584|NCT00326521|Epidural Anesthesia
1415585|NCT00326521|Fever
1415586|NCT00326521|Chorioamnionitis
1415587|NCT00326521|Intrauterine pressure catheter
1415588|NCT00326521|Pregnancy
1415589|NCT00326508|T Lymphocytes
1415590|NCT00326508|IL-2 Conjugate
1415591|NCT00326508|CD25
1415592|NCT00326508|T Regulatory Cells
1415593|NCT00326508|Autoimmunity
1415594|NCT00326508|Uveitis
1415595|NCT00326508|Daclizumab
1415596|NCT00326508|Denileukin Diftitox
1415597|NCT00326508|Immune Tolerance
1415598|NCT00326508|T Cell
1415599|NCT00326495|Sorafenib
1415600|NCT00326495|Cetuximab
1415601|NCT00326495|Advanced Cancer
1415602|NCT00326495|Phase II
1415603|NCT00326495|Colorectal Cancer
1415604|NCT00326495|Colon Cancer
1415605|NCT00326495|Rectal Cancer
1415606|NCT00326495|CRC
1415607|NCT00326495|Metastatic Colorectal Cancer
1415608|NCT00326482|Drug Toxicity
1415609|NCT00326482|Steatohepatitis
1415610|NCT00326482|Hepatotoxicity
1415611|NCT00326482|Liver Biopsy
1415612|NCT00326482|Elevated transaminases
1415613|NCT00326482|HIV
1415614|NCT00326482|Liver Fibrosis
1415615|NCT00326456|ovarian cancer
1415616|NCT00326456|chemotherapy
1415617|NCT00326456|first-line
1415618|NCT00326443|Salmonella, vaccine, typhoid fever, S. Typhi
1415619|NCT00326430|Social Phobia
1415620|NCT00326430|Cognitive Therapy
1415621|NCT00326430|Interpersonal Therapy
1415622|NCT00326430|Efficacy
1415623|NCT00326430|Process-Outcome
1415624|NCT00326417|Severe Aplastic Anemia
1415625|NCT00326404|Oral Contraceptives
1415626|NCT00326404|Adolescents
1415627|NCT00326404|Compliance
1415628|NCT00326391|Attention Deficit Disorder with Hyperactivity, ADHD, Attention Deficit Disorder Adult
1415629|NCT00326365|mechanical ventilation
1415630|NCT00326365|secretions
1415631|NCT00326365|viscosity
1415632|NCT00326365|homeopathy
1415633|NCT00326365|kalium bichromate
1415634|NCT00326365|extubation
1415635|NCT00326352|Sedation
1415636|NCT00326352|Propofol
1415637|NCT00326352|Remifentanil
1415638|NCT00326352|recovery
1415639|NCT00326339|R935788
1415640|NCT00326339|Rheumatoid Arthritis
1415641|NCT00326339|Syk Kinase
1415642|NCT00326313|Group B streptococci
1415643|NCT00326313|virulent
1415644|NCT00326313|morbidity
1415645|NCT00326313|mortality
1415646|NCT00326300|Attention Deficit Hyperactivity Disorder, ADHD, Attention Deficit Disorder Adult
1415647|NCT00326287|Community-Acquired Pneumonia
1415648|NCT00326287|Cephalosporins
1415649|NCT00326287|Methicillin-Resistant Staphylococcus Aureus
1415650|NCT00326248|postoperative nausea and vomiting PONV antiemetics NK-1 5HT3 casopitant mesylate ZOFRAN ondansetron hydrochloride
1415651|NCT00326235|Opioid withdrawal
1415652|NCT00326235|Buspirone
1415653|NCT00326235|Methadone taper
1415654|NCT00326222|Patient Education as a Topic
1415655|NCT00326222|Self-Management Program
1415656|NCT00326222|Health promotion
1415657|NCT00326222|Self Efficacy
1415658|NCT00326222|Quality of life
1415659|NCT00326209|UC
1415660|NCT00326209|Ulcerative colitis
1415661|NCT00326209|Inflammatory bowel disease
1415662|NCT00326209|IBD
1415663|NCT00326196|CABG
1415664|NCT00326196|Coronary Disease
1415665|NCT00326196|Diabetes
1415666|NCT00326196|PCI
1415667|NCT00326170|Combination Chemotherapy
1415668|NCT00326170|MDS
1415669|NCT00326170|High-Risk Myelodysplastic Syndrome
1415670|NCT00326170|AML
1415671|NCT00326170|Acute myelogenous leukemia
1415672|NCT00326170|valproic acid
1415673|NCT00326170|VPA
1415674|NCT00326170|Depakene
1415675|NCT00326170|5-azacytidine
1415676|NCT00326170|5-aza
1415677|NCT00326170|Azacitidine
1415678|NCT00326170|5-AZC
1415679|NCT00326170|Vidaza
1415680|NCT00326170|AZA-CR
1415681|NCT00326170|Ladakamycin
1415682|NCT00326170|NSC-102816
1415683|NCT00326170|All-trans retinoic acid
1415684|NCT00326170|ATRA
1415685|NCT00326170|Tretinoin
1415686|NCT00326170|Vesanoid
1415687|NCT00326157|antifungal primary prophylaxis treatment
1415688|NCT00326157|allogeneic stem-cell transplantation
1415689|NCT00326157|antifungal primary prophylaxis treatment of high risk patients undergoing allogeneic stem-cell transplantation
1415690|NCT00326144|MDD
1415691|NCT00326144|Depression
1415692|NCT00326118|Meningococcal serogroup C diseases
1415693|NCT00326118|H.influenzae type b diseases
1415694|NCT00326105|MDD
1415695|NCT00326105|Depression
1415696|NCT00326079|Open angle
1415697|NCT00326079|Glaucoma
1415698|NCT00326079|Surgery
1415699|NCT00326066|Open angle
1415700|NCT00326066|Glaucoma
1415701|NCT00326066|Surgery
1415702|NCT00326066|Cataract
1415703|NCT00326053|Asthma Reoccurrence
1415704|NCT00326053|Acute Asthma
1415705|NCT00326053|Patient Discharge
1415706|NCT00326053|Emergency Service, Hospital
1415707|NCT00326053|Asthma Exacerbation
1415708|NCT00326053|Asthma Relapse
1415709|NCT00326040|Open angle
1415710|NCT00326040|Glaucoma
1415711|NCT00326040|Refractory
1415712|NCT00326040|Surgery
1415713|NCT00326027|GERD
1415714|NCT00326027|Pantoprazole
1415715|NCT00326027|NERD
1415716|NCT00326014|Open angle
1415717|NCT00326014|Glaucoma
1415718|NCT00326014|Cataract
1415719|NCT00326014|Surgery
1415720|NCT00326001|Transvenous Catheter Ablation
1415721|NCT00326001|Radiofrequency Catheter Ablation
1415722|NCT00326001|Atrial flutter
1415723|NCT00326001|Catheter Ablation
1415724|NCT00325988|Neuroimmunology
1415725|NCT00325988|Demyelinating Disease
1415726|NCT00325988|Genetics
1415727|NCT00325988|Proteins
1415728|NCT00325975|Smallpox
1415729|NCT00325975|Variola
1415730|NCT00325975|Orthopoxvirus
1415731|NCT00325975|Virus
1415732|NCT00325975|Immunogenicity
1415733|NCT00325975|Smallpox Vaccine
1415734|NCT00325962|Hypertension
1415735|NCT00325962|Type 2 Diabetes
1415736|NCT00325962|6R-BH4
1415737|NCT00325962|BH4
1415738|NCT00325962|BH4 deficiency
1415739|NCT00325962|sapropterin dihydrochloride
1415740|NCT00325962|endothelial dysfunction
1415741|NCT00325962|NO
1415742|NCT00325962|Nitric Oxide
1415743|NCT00325936|metabolic syndrome
1415744|NCT00325936|Hypertension
1415745|NCT00325936|CCB
1415746|NCT00325936|cilnidipine
1415747|NCT00325923|Decision making
1415748|NCT00325923|Decision support
1415749|NCT00325923|Decisional conflict
1415750|NCT00325923|Menopause
1415751|NCT00325923|Natural health products
1415752|NCT00325923|Herbs
1415753|NCT00325923|Complementary medicine
1415754|NCT00325923|Complementary therapies
1415755|NCT00325910|Diabetes
1415756|NCT00325910|Heart Failure
1415757|NCT00325910|Mortality
1415758|NCT00325910|Hospitalization
1415759|NCT00325910|Feasability
1415760|NCT00325884|coronary artery disease
1415761|NCT00325884|bifurcation lesions
1415762|NCT00325884|percutaneous interventions
1415763|NCT00325884|stenting
1415764|NCT00325884|outcomes
1415765|NCT00325884|death
1415766|NCT00325884|myocardial infarction
1415767|NCT00325858|osteoarthritis pain
1415768|NCT00325858|knee
1415769|NCT00325858|hip
1415770|NCT00325858|extended-release analgesia
1415771|NCT00325858|opioid
1415772|NCT00325845|Investigational
1415773|NCT00325845|Therapeutic
1415774|NCT00325845|Efficacy
1415775|NCT00325845|Safety
1415776|NCT00325845|Outcomes
1415777|NCT00325845|Lumbar facet joint arthrosis
1415778|NCT00325845|Lumbar facet joint arthropathy
1415779|NCT00325832|Hypertension
1415780|NCT00325832|Blood Pressure
1415781|NCT00325832|Systolic Pressure
1415782|NCT00325832|Diastolic Pressure
1415783|NCT00325832|Blood Pressure Monitoring, Ambulatory
1415784|NCT00325819|Acetaminophen
1415785|NCT00325819|Vaccination
1415786|NCT00325819|Immunization
1415787|NCT00325793|nicardipine
1415788|NCT00325793|hypertension
1415789|NCT00325793|intracerebral hemorrhage
1415790|NCT00325793|ischemic stroke
1415791|NCT00325780|Kowa
1415792|NCT00325780|Hypercholesterolemia
1415793|NCT00325780|dyslipidemia
1415794|NCT00325780|pitavastatin
1415795|NCT00325780|NK-104
1415796|NCT00325780|Hypercholesterolemia or combined dyslipidemia
1415797|NCT00325767|mucociliary clearance
1415798|NCT00325767|beta-adrenergic drugs
1415799|NCT00325767|inhalation
1415800|NCT00325767|aerosol
1415801|NCT00325754|Chronic Obstructive Pulmonary Disease
1415802|NCT00325754|COPD
1415803|NCT00325741|Lupus
1415804|NCT00325741|Systemic Lupus Erythematosus
1415805|NCT00325741|Blood Stem Cell Transplantation
1415806|NCT00325728|Chronic Insomnia
1415807|NCT00325728|Sleep Initiation and Maintenance Disorder
1415808|NCT00325728|Drug Therapy
1415809|NCT00325728|Alzheimer disease
1415810|NCT00325702|HIV
1415811|NCT00325702|prevention
1415812|NCT00325676|GERD
1415813|NCT00325676|Pantoprazole
1415814|NCT00325676|Complete Remission
1415815|NCT00325663|acupuncture
1415816|NCT00325663|double-blind
1415817|NCT00325663|sham control
1415818|NCT00325663|osteoarthritis
1415819|NCT00325663|pain
1415820|NCT00325650|Prediabetic state
1415821|NCT00325650|Impaired fasting glucose
1415822|NCT00325650|Impaired glucose Tolerance
1415823|NCT00325637|CHERISH
1415824|NCT00325637|Ischemic Stroke
1415825|NCT00325624|Blood Pressure
1415826|NCT00325624|Diabetes mellitus
1415827|NCT00325624|Hypertension
1415828|NCT00325624|Home Care
1415829|NCT00325624|Glucometer
1415830|NCT00325611|Palliative care
1415831|NCT00325611|End of life care
1415832|NCT00325585|Human Immunodeficiency Viruses
1415833|NCT00325585|Acquired Immunodeficiency Syndrome
1415834|NCT00325585|Substance Abuse
1415835|NCT00325585|Sexually Transmitted Disease, Viral
1415836|NCT00325585|Intervention Studies
1415837|NCT00325585|Women's Health
1415838|NCT00325546|Obesity
1415839|NCT00325533|Blood Pressure, High
1415840|NCT00325533|Blacks
1415841|NCT00325533|African Americans
1415842|NCT00325507|Renal cell cancer
1415843|NCT00325507|requiring IL-2 treatment
1415844|NCT00325507|Locally advanced or metastatic renal cell carcinoma
1415845|NCT00325494|Pancreatic Cancer
1415846|NCT00325494|Mesothelioma
1415847|NCT00325494|Ovarian Cancer
1415848|NCT00325494|Non-Small Cell Lung Cancer
1415849|NCT00325494|Mesothelin
1415850|NCT00325468|bone loss
1415851|NCT00325468|osteoporosis
1415852|NCT00325442|Pulmonary Arterial Hypertension
1415853|NCT00325429|Type 2 diabetes
1415854|NCT00325429|Vildagliptin
1415855|NCT00325429|HbA1c
1415856|NCT00325416|melphalan
1415857|NCT00325416|topotecan
1415858|NCT00325416|topoisomerase
1415859|NCT00325416|bone marrow transplant
1415860|NCT00325416|drug sequence
1415861|NCT00325403|Pulmonary Arterial Hypertension
1415862|NCT00325390|SR25990C
1415863|NCT00325390|Platelet Aggregation Inhibitors
1415864|NCT00325390|NSTEACS
1415865|NCT00325377|low back pain
1415866|NCT00325377|pain
1415867|NCT00325377|magnetism
1415868|NCT00325377|electromagnetic fields
1415869|NCT00325377|visual analogue pain scale
1415870|NCT00325351|Ovarian cancer
1415871|NCT00325351|Ovarian neoplasms, epithelium
1415872|NCT00325338|Allergy
1415873|NCT00325338|Specific Immunotherapy
1415874|NCT00325338|Ragweed
1415875|NCT00325338|Environmental Exposure Chamber
1415876|NCT00325325|Kidney Transplantation
1415877|NCT00325312|Neck Pain
1415878|NCT00325312|Complementary Therapies
1415879|NCT00325312|Subcutaneous Carbon Dioxide Insufflations
1415880|NCT00325312|Acute Treatment
1415881|NCT00325273|Lactobacillus rhamnosus
1415882|NCT00325273|Atopic dermatitis
1415883|NCT00325273|Allergic rhinitis
1415884|NCT00325273|Asthma
1415885|NCT00325273|Infant
1415886|NCT00325273|Pregnancy
1415887|NCT00325260|influenza
1415888|NCT00325260|non-inferiority
1415889|NCT00325260|Influvac
1415890|NCT00325260|Agrippal
1415891|NCT00325260|healthy subjects
1415892|NCT00325247|ZINC SUPPLEMENTATION
1415893|NCT00325247|ACUTE DIARRHOEA
1415894|NCT00325247|UNDER FIVE CHILDREN
1415895|NCT00325247|RURAL BANGLADESH
1415896|NCT00325221|implantable cardioverter-defibrillator
1415897|NCT00325221|telemedicine
1415898|NCT00325221|Home Monitoring
1415899|NCT00325221|psychosomatic
1415900|NCT00325221|ventricular tachyarrhythmia
1415901|NCT00325221|quality of life
1415902|NCT00325221|Electric Countershock
1415903|NCT00325182|Alcoholism
1415904|NCT00325169|Cross-over
1415905|NCT00325169|Tiotropium
1415906|NCT00325169|Triple
1415907|NCT00325169|COPD
1415908|NCT00325169|SERETIDE 50/500
1415909|NCT00325169|Dyspnoea
1415910|NCT00325169|Impulse oscillometry
1415911|NCT00325169|Plethysmography
1415912|NCT00325117|Type 2 diabetes
1415913|NCT00325117|Vildagliptin
1415914|NCT00325117|HbA1c
1415915|NCT00325104|Multiple Endocrine Neoplasia
1415916|NCT00325104|Gastrinoma
1415917|NCT00325104|Prolacinoma
1415918|NCT00325104|Medullary Thyroid Cancer
1415919|NCT00325104|Insulinoma
1415920|NCT00325104|MEN1
1415921|NCT00325104|MEN2A
1415922|NCT00325104|Familial Primary Hyperparathytoidism
1415923|NCT00325091|Writer's Cramp
1415924|NCT00325091|Electroencephalogram (EEG)
1415925|NCT00325091|Transcranial Magnetic Stimulation (TMS)
1415926|NCT00325091|Fine Motor Skills
1415927|NCT00325091|Focal Hand Dystonia
1415928|NCT00325091|Writer Cramp
1415929|NCT00325091|Healthy Volunteer
1415930|NCT00325091|HV
1415931|NCT00325078|Remicade
1415932|NCT00325078|Crohn's Disease
1415933|NCT00325078|IBD
1415934|NCT00325078|CGD Infection
1415935|NCT00325078|Infliximab
1415936|NCT00325078|Chorionic Granulomatous Disease
1415937|NCT00325078|CGD
1415938|NCT00325078|Inflammatory Bowel Disease
1415939|NCT00325065|Amygdala
1415940|NCT00325065|Emotion
1415941|NCT00325065|Memory
1415942|NCT00325065|Threat
1415943|NCT00325065|Peptides
1415944|NCT00325065|Neuropeptides
1415945|NCT00325065|Oxytocin
1415946|NCT00325065|Vasopressin
1415947|NCT00325065|Mood Disorder
1415948|NCT00325039|Urinary Incontinence, Stress
1415949|NCT00325039|Surgery
1415950|NCT00325026|Preterm gestation
1415951|NCT00325026|Cervical ripening
1415952|NCT00325026|Labor induction
1415953|NCT00325026|Misoprostol
1415954|NCT00325026|Foley bulb
1415955|NCT00325013|Primary Sclerosing Cholangitis
1415956|NCT00325013|PSC
1415957|NCT00325013|DHA
1415958|NCT00325013|Docosahexaenoic Acid
1415959|NCT00324974|Gastroesophageal Reflux Disease
1415960|NCT00324974|infant
1415961|NCT00324974|lansoprazole oral suspension
1415962|NCT00324974|PPI
1415963|NCT00324961|adefovir dipivoxil
1415964|NCT00324961|e Antigen negative
1415965|NCT00324961|chronic hepatitis B
1415966|NCT00324961|Chinese
1415967|NCT00324948|Female sexual arousal disorder
1415968|NCT00324948|Female sexual dysfunction
1415969|NCT00324922|Vancomycin
1415970|NCT00324922|Trimethoprim-Sulfamethoxazole Combination
1415971|NCT00324896|Parkinson's
1415972|NCT00324896|insomnia
1415973|NCT00324896|drug
1415974|NCT00324896|eszopiclone
1415975|NCT00324896|placebo
1415976|NCT00324883|sodium intake
1415977|NCT00324883|sodium excretion
1415978|NCT00324883|chloride excretion
1415979|NCT00324883|creatinine
1415980|NCT00324883|hypertension
1415981|NCT00324857|Osteoarthritis, Knee
1415982|NCT00324857|race
1415983|NCT00324857|ethnicity
1415984|NCT00324857|knee replacement
1415985|NCT00324831|contiguous stage II adult diffuse large cell lymphoma
1415986|NCT00324831|noncontiguous stage II adult diffuse large cell lymphoma
1415987|NCT00324831|stage III adult diffuse large cell lymphoma
1415988|NCT00324831|stage IV adult diffuse large cell lymphoma
1415989|NCT00324818|bacterial vaginosis
1415990|NCT00324818|treatment
1415991|NCT00324779|B-cell childhood acute lymphoblastic leukemia
1415992|NCT00324779|untreated childhood acute lymphoblastic leukemia
1415993|NCT00324779|stage I childhood large cell lymphoma
1415994|NCT00324779|stage II childhood large cell lymphoma
1415995|NCT00324779|stage III childhood large cell lymphoma
1415996|NCT00324779|stage IV childhood large cell lymphoma
1415997|NCT00324779|stage I childhood lymphoblastic lymphoma
1415998|NCT00324779|stage II childhood lymphoblastic lymphoma
1415999|NCT00324779|stage III childhood lymphoblastic lymphoma
1416000|NCT00324779|stage IV childhood lymphoblastic lymphoma
1416001|NCT00324779|stage I childhood small noncleaved cell lymphoma
1416002|NCT00324779|stage II childhood small noncleaved cell lymphoma
1416003|NCT00324779|stage III childhood small noncleaved cell lymphoma
1416004|NCT00324779|stage IV childhood small noncleaved cell lymphoma
1416005|NCT00324753|cancer
1416006|NCT00324753|screening
1416007|NCT00324753|communication
1416008|NCT00324753|prevention
1416009|NCT00324727|liver metastases
1416010|NCT00324727|extraocular extension melanoma
1416011|NCT00324727|stage IV melanoma
1416012|NCT00324727|recurrent melanoma
1416013|NCT00324727|recurrent intraocular melanoma
1416014|NCT00324727|metastatic intraocular melanoma
1416015|NCT00324727|iris melanoma
1416016|NCT00324727|ciliary body and choroid melanoma, medium/large size
1416017|NCT00324714|osteoporosis
1416018|NCT00324714|ductal breast carcinoma in situ
1416019|NCT00324714|breast cancer in situ
1416020|NCT00324701|Mental Health
1416021|NCT00324701|Geriatric Medicine
1416022|NCT00324701|Depression
1416023|NCT00324701|Health Service Delivery
1416024|NCT00324701|Aged
1416025|NCT00324688|HIV-1
1416026|NCT00324688|Methadone
1416027|NCT00324688|HIV-1 infection
1416028|NCT00324675|type 2 diabetes,
1416029|NCT00324675|glomerular filtration rate,
1416030|NCT00324675|renal plasma flow,
1416031|NCT00324675|endothelial dysfunction,
1416032|NCT00324675|proteinuria,
1416033|NCT00324675|diabetic nephropathy
1416034|NCT00324662|Implantable cardioverter-defibrillator
1416035|NCT00324662|Ventricular tachyarrhythmia
1416036|NCT00324662|Supraventricular tachyarrhythmia
1416037|NCT00324662|Electric Countershock
1416038|NCT00324649|HIV-1
1416039|NCT00324623|stage IV melanoma
1416040|NCT00324623|recurrent melanoma
1416041|NCT00324610|fluoropyrimidines
1416042|NCT00324610|metastases
1416043|NCT00324610|pharmacokinetics
1416044|NCT00324610|phase 1-2 study
1416045|NCT00324597|unspecified adult solid tumor, protocol specific
1416046|NCT00324597|recurrent adult grade III lymphomatoid granulomatosis
1416047|NCT00324597|stage III grade 1 follicular lymphoma
1416048|NCT00324597|stage III grade 2 follicular lymphoma
1416049|NCT00324597|stage III grade 3 follicular lymphoma
1416050|NCT00324597|stage IV grade 1 follicular lymphoma
1416051|NCT00324597|stage IV grade 2 follicular lymphoma
1416052|NCT00324597|stage IV grade 3 follicular lymphoma
1416053|NCT00324597|stage III mantle cell lymphoma
1416054|NCT00324597|stage IV mantle cell lymphoma
1416055|NCT00324597|stage III marginal zone lymphoma
1416056|NCT00324597|stage IV marginal zone lymphoma
1416057|NCT00324597|stage III small lymphocytic lymphoma
1416058|NCT00324597|stage III cutaneous T-cell non-Hodgkin lymphoma
1416059|NCT00324597|stage IV cutaneous T-cell non-Hodgkin lymphoma
1416060|NCT00324597|stage III adult T-cell leukemia/lymphoma
1416061|NCT00324597|recurrent adult Hodgkin lymphoma
1416062|NCT00324597|recurrent adult immunoblastic large cell lymphoma
1416063|NCT00324597|recurrent adult lymphoblastic lymphoma
1416064|NCT00324597|recurrent adult T-cell leukemia/lymphoma
1416065|NCT00324597|recurrent cutaneous T-cell non-Hodgkin lymphoma
1416066|NCT00324597|recurrent grade 1 follicular lymphoma
1416067|NCT00324597|recurrent grade 2 follicular lymphoma
1416068|NCT00324597|recurrent grade 3 follicular lymphoma
1416069|NCT00324597|recurrent mantle cell lymphoma
1416070|NCT00324597|recurrent marginal zone lymphoma
1416071|NCT00324597|recurrent small lymphocytic lymphoma
1416072|NCT00324597|splenic marginal zone lymphoma
1416073|NCT00324597|stage III adult Burkitt lymphoma
1416074|NCT00324597|stage III adult diffuse large cell lymphoma
1416075|NCT00324597|stage III adult diffuse mixed cell lymphoma
1416076|NCT00324597|stage III adult diffuse small cleaved cell lymphoma
1416077|NCT00324597|stage III adult Hodgkin lymphoma
1416078|NCT00324597|stage III adult immunoblastic large cell lymphoma
1416079|NCT00324597|stage III adult lymphoblastic lymphoma
1416080|NCT00324597|Waldenström macroglobulinemia
1416081|NCT00324597|recurrent mycosis fungoides/Sezary syndrome
1416082|NCT00324597|stage III mycosis fungoides/Sezary syndrome
1416083|NCT00324597|stage IV mycosis fungoides/Sezary syndrome
1416084|NCT00324597|stage IV adult Burkitt lymphoma
1416085|NCT00324597|stage IV adult diffuse large cell lymphoma
1416086|NCT00324597|stage IV adult diffuse mixed cell lymphoma
1416087|NCT00324597|stage IV adult diffuse small cleaved cell lymphoma
1416088|NCT00324597|stage IV adult Hodgkin lymphoma
1416089|NCT00324597|stage IV adult immunoblastic large cell lymphoma
1416090|NCT00324597|stage IV adult lymphoblastic lymphoma
1416091|NCT00324597|stage IV adult T-cell leukemia/lymphoma
1416092|NCT00324597|adenocarcinoma of the lung
1416093|NCT00324597|bronchoalveolar cell lung cancer
1416094|NCT00324597|large cell lung cancer
1416095|NCT00324597|stage IIIA non-small cell lung cancer
1416096|NCT00324597|stage IIIB non-small cell lung cancer
1416097|NCT00324597|stage IV non-small cell lung cancer
1416098|NCT00324597|recurrent adult Burkitt lymphoma
1416099|NCT00324597|recurrent adult diffuse large cell lymphoma
1416100|NCT00324597|recurrent adult diffuse mixed cell lymphoma
1416101|NCT00324597|recurrent adult diffuse small cleaved cell lymphoma
1416102|NCT00324597|stage IV small lymphocytic lymphoma
1416103|NCT00324597|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1416104|NCT00324597|nodal marginal zone B-cell lymphoma
1416105|NCT00324597|anaplastic large cell lymphoma
1416106|NCT00324597|angioimmunoblastic T-cell lymphoma
1416107|NCT00324597|post-transplant lymphoproliferative disorder
1416108|NCT00324597|recurrent non-small cell lung cancer
1416109|NCT00324584|type 1 diabetes mellitus
1416110|NCT00324584|telecare
1416111|NCT00324584|telemedicine
1416112|NCT00324584|insulin pump therapy
1416113|NCT00324558|Bemiparin
1416114|NCT00324558|small cell lung carcinoma
1416115|NCT00324545|Obesity
1416116|NCT00324545|Diets
1416117|NCT00324545|Heart Disease
1416118|NCT00324545|Randomized controlled trial
1416119|NCT00324545|Ischemia.
1416120|NCT00324519|second trimester
1416121|NCT00324519|pregnancy termination
1416122|NCT00324519|misoprostol
1416123|NCT00324519|foley bulb
1416124|NCT00324493|Severe Hemophilia
1416125|NCT00324493|Musculoskeletal Function
1416126|NCT00324493|Factor Replacement
1416127|NCT00324467|NON-HODGKIN'S LYMPHOMA
1416128|NCT00324467|POSITRON EMISSION TOMOGRAPHY
1416129|NCT00324467|PET
1416130|NCT00324467|DLBCL
1416131|NCT00324467|R-CHOP
1416132|NCT00324467|R-ICE
1416133|NCT00324454|motor neuron disease
1416134|NCT00324454|amyotrophic lateral sclerosis primary lateral
1416135|NCT00324454|sclerosis; progressive muscular atrophy
1416136|NCT00324454|cramps
1416137|NCT00324454|spasticity
1416138|NCT00324441|Fibromyalgia
1416139|NCT00324441|Rehabilitation
1416140|NCT00324441|Physical Medicine
1416141|NCT00324441|Whole-Body Hyperthermia
1416142|NCT00324441|Water-Filtered Near Infrared
1416143|NCT00324428|TMS
1416144|NCT00324428|Visceral Pain
1416145|NCT00324428|Analgesia
1416146|NCT00324428|Pancreatic Cancer
1416147|NCT00324428|Cancer
1416148|NCT00324428|Electric stimulation therapy
1416149|NCT00324428|Electric stimulation
1416150|NCT00324428|Pain
1416151|NCT00324428|Safety
1416152|NCT00324415|stage I anal cancer
1416153|NCT00324415|stage II anal cancer
1416154|NCT00324415|stage IIIA anal cancer
1416155|NCT00324415|stage IIIB anal cancer
1416156|NCT00324415|squamous cell carcinoma of the anus
1416157|NCT00324415|basaloid carcinoma of the anus
1416158|NCT00324415|cloacogenic carcinoma of the anus
1416159|NCT00324402|brain natriuretic peptide
1416160|NCT00324402|pregnancy
1416161|NCT00324402|biomarker
1416162|NCT00324389|Interferon, Gene Expression in Liver, Lymphocytes, High Density Oligonucleotide Microarray Expression Analysis, African American, Hepatitis C
1416163|NCT00324363|exenatide
1416164|NCT00324363|diabetes
1416165|NCT00324363|Amylin
1416166|NCT00324363|Lilly
1416167|NCT00324363|China
1416168|NCT00324350|Diabetes Mellitus
1416169|NCT00324350|Fracture
1416170|NCT00324350|Falls
1416171|NCT00324350|Height Loss
1416172|NCT00324324|infection
1416173|NCT00324324|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1416174|NCT00324324|adult acute myeloid leukemia with inv(16)(p13;q22)
1416175|NCT00324324|adult acute myeloid leukemia with t(15;17)(q22;q12)
1416176|NCT00324324|adult acute myeloid leukemia with t(16;16)(p13;q22)
1416177|NCT00324324|adult acute myeloid leukemia with t(8;21)(q22;q22)
1416178|NCT00324324|accelerated phase chronic myelogenous leukemia
1416179|NCT00324324|adult acute lymphoblastic leukemia in remission
1416180|NCT00324324|adult acute myeloid leukemia in remission
1416181|NCT00324324|atypical chronic myeloid leukemia, BCR-ABL negative
1416182|NCT00324324|blastic phase chronic myelogenous leukemia
1416183|NCT00324324|chronic eosinophilic leukemia
1416184|NCT00324324|primary myelofibrosis
1416185|NCT00324324|chronic myelomonocytic leukemia
1416186|NCT00324324|chronic neutrophilic leukemia
1416187|NCT00324324|chronic phase chronic myelogenous leukemia
1416188|NCT00324324|de novo myelodysplastic syndromes
1416189|NCT00324324|disseminated neuroblastoma
1416190|NCT00324324|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1416191|NCT00324324|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1416192|NCT00324324|nodal marginal zone B-cell lymphoma
1416193|NCT00324324|noncontiguous stage II adult Burkitt lymphoma
1416194|NCT00324324|noncontiguous stage II adult diffuse large cell lymphoma
1416195|NCT00324324|noncontiguous stage II adult diffuse mixed cell lymphoma
1416196|NCT00324324|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1416197|NCT00324324|noncontiguous stage II adult immunoblastic large cell lymphoma
1416198|NCT00324324|noncontiguous stage II adult lymphoblastic lymphoma
1416199|NCT00324324|noncontiguous stage II grade 1 follicular lymphoma
1416200|NCT00324324|noncontiguous stage II grade 2 follicular lymphoma
1416201|NCT00324324|noncontiguous stage II grade 3 follicular lymphoma
1416202|NCT00324324|noncontiguous stage II mantle cell lymphoma
1416203|NCT00324324|noncontiguous stage II marginal zone lymphoma
1416204|NCT00324324|noncontiguous stage II small lymphocytic lymphoma
1416205|NCT00324324|poor prognosis metastatic gestational trophoblastic tumor
1416206|NCT00324324|previously treated myelodysplastic syndromes
1416207|NCT00324324|recurrent adult acute lymphoblastic leukemia
1416208|NCT00324324|recurrent adult acute myeloid leukemia
1416209|NCT00324324|recurrent adult Burkitt lymphoma
1416210|NCT00324324|recurrent adult Hodgkin lymphoma
1416211|NCT00324324|recurrent adult diffuse large cell lymphoma
1416212|NCT00324324|recurrent adult diffuse mixed cell lymphoma
1416213|NCT00324324|recurrent adult diffuse small cleaved cell lymphoma
1416214|NCT00324324|recurrent adult immunoblastic large cell lymphoma
1416215|NCT00324324|recurrent adult lymphoblastic lymphoma
1416216|NCT00324324|recurrent cutaneous T-cell non-Hodgkin lymphoma
1416217|NCT00324324|recurrent grade 1 follicular lymphoma
1416218|NCT00324324|recurrent grade 2 follicular lymphoma
1416219|NCT00324324|recurrent grade 3 follicular lymphoma
1416220|NCT00324324|recurrent mantle cell lymphoma
1416221|NCT00324324|recurrent marginal zone lymphoma
1416222|NCT00324324|recurrent mycosis fungoides/Sezary syndrome
1416223|NCT00324324|recurrent neuroblastoma
1416224|NCT00324324|recurrent ovarian epithelial cancer
1416225|NCT00324324|recurrent ovarian germ cell tumor
1416226|NCT00324324|recurrent small lymphocytic lymphoma
1416227|NCT00324324|recurrent malignant testicular germ cell tumor
1416228|NCT00324324|refractory chronic lymphocytic leukemia
1416229|NCT00324324|refractory hairy cell leukemia
1416230|NCT00324324|refractory multiple myeloma
1416231|NCT00324324|relapsing chronic myelogenous leukemia
1416232|NCT00324324|secondary acute myeloid leukemia
1416233|NCT00324324|secondary myelodysplastic syndromes
1416234|NCT00324324|splenic marginal zone lymphoma
1416235|NCT00324324|stage I multiple myeloma
1416236|NCT00324324|stage II multiple myeloma
1416237|NCT00324324|stage II ovarian epithelial cancer
1416238|NCT00324324|stage III adult Burkitt lymphoma
1416239|NCT00324324|stage III adult Hodgkin lymphoma
1416240|NCT00324324|stage III adult diffuse large cell lymphoma
1416241|NCT00324324|stage III adult diffuse mixed cell lymphoma
1416242|NCT00324324|stage III adult diffuse small cleaved cell lymphoma
1416243|NCT00324324|stage III adult immunoblastic large cell lymphoma
1416244|NCT00324324|stage III adult lymphoblastic lymphoma
1416245|NCT00324324|stage III chronic lymphocytic leukemia
1416246|NCT00324324|stage III grade 1 follicular lymphoma
1416247|NCT00324324|stage III grade 2 follicular lymphoma
1416248|NCT00324324|stage III grade 3 follicular lymphoma
1416249|NCT00324324|stage III mantle cell lymphoma
1416250|NCT00324324|stage III marginal zone lymphoma
1416251|NCT00324324|stage III multiple myeloma
1416252|NCT00324324|stage III ovarian epithelial cancer
1416253|NCT00324324|stage III small lymphocytic lymphoma
1416254|NCT00324324|stage III malignant testicular germ cell tumor
1416255|NCT00324324|stage IIIA breast cancer
1416256|NCT00324324|stage IIIB breast cancer
1416257|NCT00324324|stage IIIC breast cancer
1416258|NCT00324324|stage IV adult Burkitt lymphoma
1416259|NCT00324324|stage IV adult Hodgkin lymphoma
1416260|NCT00324324|stage IV adult diffuse large cell lymphoma
1416261|NCT00324324|stage IV adult diffuse mixed cell lymphoma
1416262|NCT00324324|stage IV adult diffuse small cleaved cell lymphoma
1416263|NCT00324324|stage IV adult immunoblastic large cell lymphoma
1416264|NCT00324324|stage IV adult lymphoblastic lymphoma
1416265|NCT00324324|stage IV breast cancer
1416266|NCT00324324|stage IV chronic lymphocytic leukemia
1416267|NCT00324324|stage IV grade 1 follicular lymphoma
1416268|NCT00324324|stage IV grade 2 follicular lymphoma
1416269|NCT00324324|stage IV grade 3 follicular lymphoma
1416270|NCT00324324|stage IV mantle cell lymphoma
1416271|NCT00324324|stage IV marginal zone lymphoma
1416272|NCT00324324|stage IV ovarian epithelial cancer
1416273|NCT00324324|stage IV small lymphocytic lymphoma
1416274|NCT00324298|drug/agent toxicity by tissue/organ
1416275|NCT00324298|stage III malignant testicular germ cell tumor
1416276|NCT00324285|Diarrhoea
1416277|NCT00324285|severe malnutrition
1416278|NCT00324285|amylase resistant starch
1416279|NCT00324285|ORS
1416280|NCT00324272|Groin dissection
1416281|NCT00324272|Axilla (or axillary) dissection
1416282|NCT00324272|Lymph node dissection
1416283|NCT00324272|Lymphadenectomy
1416284|NCT00324272|Seroma
1416285|NCT00324272|Wound drainage
1416286|NCT00324272|Fibrin sealant
1416287|NCT00324272|Malignant melanoma
1416288|NCT00324272|Squamous cell carcinoma
1416289|NCT00324246|vaginal infection
1416290|NCT00324246|color appearance
1416291|NCT00324246|new developed indicator strips (NEW NORMA-SENSE)
1416292|NCT00324246|in-vitro
1416293|NCT00324246|vaginal secretion
1416294|NCT00324246|elevated pH
1416295|NCT00324233|Residual urine
1416296|NCT00324233|Hematuria
1416297|NCT00324233|Ultra sound
1416298|NCT00324220|Phase I/II
1416299|NCT00324207|Type 1 diabetes mellitus
1416300|NCT00324207|Insulin mRNA
1416301|NCT00324194|Leukemia
1416302|NCT00324194|Myelodysplastic Syndromes
1416303|NCT00324194|Phase I
1416304|NCT00324181|normal-tension glaucoma
1416305|NCT00324181|psychopathology
1416306|NCT00324181|Hong Kong
1416307|NCT00324168|Bacterial Infections
1416308|NCT00324168|Eye Diseases
1416309|NCT00324168|Bacterial Keratitis
1416310|NCT00324168|Visual Acuity
1416311|NCT00324155|Stage IIIc N3 (unresectable)
1416312|NCT00324155|Stage IV melanoma
1416313|NCT00324142|Bacterial vaginosis
1416314|NCT00324142|Tinidazole
1416315|NCT00324142|Vaginitis
1416316|NCT00324129|Leukemia
1416317|NCT00324129|Myelodysplastic Syndromes
1416318|NCT00324129|Phase I
1416319|NCT00324103|HIV
1416320|NCT00324103|Chronic Infection
1416321|NCT00324103|Clinical Trial
1416322|NCT00324103|Structured Treatment Interruption
1416323|NCT00324077|Chronic phase chronic myelogenous leukemia (CML)
1416324|NCT00324064|Growth hormone deficiency
1416325|NCT00324038|OA
1416326|NCT00324038|Elderly
1416327|NCT00324038|Pain
1416328|NCT00324038|OA of the hips and/or knees
1416329|NCT00324025|Cryptococcal meningitis
1416330|NCT00324012|Adrenocortical Carcinoma
1416331|NCT00324012|cisplatin
1416332|NCT00324012|taxotere
1416333|NCT00323999|Hysteroscopic resection
1416334|NCT00323999|Menorrhagia
1416335|NCT00323999|fibroids
1416336|NCT00323999|polyps
1416337|NCT00323986|COPD
1416338|NCT00323986|tracheotomy
1416339|NCT00323986|azithromycin
1416340|NCT00323986|exacerbation
1416341|NCT00323986|hospitalisation
1416342|NCT00323986|exhaled breath condensate
1416343|NCT00323973|Chagas, Heart failure, Cardiomiopathy
1416344|NCT00323960|Juvenile dermatomyositis
1416345|NCT00323960|randomised actively controlled clinical trial
1416346|NCT00323960|prednisone
1416347|NCT00323960|cyclosporine
1416348|NCT00323960|methotrexate
1416349|NCT00323960|effectiveness
1416350|NCT00323947|ADHD
1416351|NCT00323947|Seizures
1416352|NCT00323947|Methylphenidate
1416353|NCT00323947|Stimulant
1416354|NCT00323934|metastatic solid tumor
1416355|NCT00323934|aggressive non Hodgkin's Lymphoma
1416356|NCT00323934|Phase I
1416357|NCT00323934|Advanced Solid Tumors
1416358|NCT00323908|Breast Cancer
1416359|NCT00323908|prevention
1416360|NCT00323908|tissue sampling
1416361|NCT00323908|polymorphisms
1416362|NCT00323908|steroid and carcinogen metabolism
1416363|NCT00323882|Prostate Cancer
1416364|NCT00323882|Oncology
1416365|NCT00323882|Prostate
1416366|NCT00323882|Cancer
1416367|NCT00323882|Metastatic
1416368|NCT00323882|Hormone
1416369|NCT00323882|PSA
1416370|NCT00323882|Metastatic Hormone-Refractory Prostate Cancer (HRPC)
1416371|NCT00323856|Hemophilia A
1416372|NCT00323856|Plasma-derived treatment
1416373|NCT00323856|Factor VIII
1416374|NCT00323856|Inhibitor
1416375|NCT00323843|Kidney stone
1416376|NCT00323843|ureteropyeloscopy
1416377|NCT00323843|renal pelvic pressure
1416378|NCT00323830|gastric cancer
1416379|NCT00323830|radiotherapy
1416380|NCT00323830|postoperative therapy
1416381|NCT00323830|chemotherapy
1416382|NCT00323804|Maintenance therapy
1416383|NCT00323804|Non-responder patients
1416384|NCT00323804|Ribavirin/peginterferon combination therapy
1416385|NCT00323804|Hepatitis C, Chronic
1416386|NCT00323791|recurrent renal cell cancer
1416387|NCT00323791|clear cell renal cell carcinoma
1416388|NCT00323791|papillary renal cell carcinoma
1416389|NCT00323791|stage IV renal cell cancer
1416390|NCT00323778|hyalgan
1416391|NCT00323778|knee
1416392|NCT00323778|osteoarthritis
1416393|NCT00323778|MRI
1416394|NCT00323765|Transcranial Magnetic Stimulation (TMS)
1416395|NCT00323765|Cervical Dystonia
1416396|NCT00323765|Plasticity
1416397|NCT00323765|Healthy Volunteer
1416398|NCT00323765|HV
1416399|NCT00323752|Blood loss, Erythropoetin
1416400|NCT00323739|kidney cancer
1416401|NCT00323739|bevacizumab
1416402|NCT00323713|Chronic renal insufficiency
1416403|NCT00323713|CKD stage 4
1416404|NCT00323713|CKD stage 5
1416405|NCT00323713|Protein intake
1416406|NCT00323713|Low protein diet
1416407|NCT00323713|Very low protein diet
1416408|NCT00323713|Ketoanalogs
1416409|NCT00323713|Renal death
1416410|NCT00323700|ADHD
1416411|NCT00323700|Effectiveness
1416412|NCT00323700|ODD
1416413|NCT00323687|HIV-1 Infection
1416414|NCT00323674|Hernia Inguinalis
1416415|NCT00323661|Pacing
1416416|NCT00323661|Rate-adaptive
1416417|NCT00323661|Quality of life
1416418|NCT00323661|Cognitive performance
1416419|NCT00323661|Atrial fibrillation
1416420|NCT00323661|Pacemaker sensor
1416421|NCT00323635|nocturia
1416422|NCT00323635|urinary incontinence
1416423|NCT00323635|overactive bladder
1416424|NCT00323635|tolterodine
1416425|NCT00323635|sleep
1416426|NCT00323635|sleep disorder
1416427|NCT00323635|menopause
1416428|NCT00323635|midlife women
1416429|NCT00323635|psychological tests
1416430|NCT00323609|Kyphoplasty
1416431|NCT00323609|Vertebroplasty
1416432|NCT00323609|Balloon Kyphoplasty
1416433|NCT00323609|Inflatable Bone Tamp
1416434|NCT00323609|Spine
1416435|NCT00323609|Back Pain
1416436|NCT00323609|Vertebral Compression Fracture
1416437|NCT00323609|Vertebral Body Compression Fracture
1416438|NCT00323583|Cancer
1416439|NCT00323583|Pancreatic Cancer
1416440|NCT00323583|Cancer Alternative Therapies
1416441|NCT00323583|Living with Cancer
1416442|NCT00323557|Chronic Lymphocytic Leukemia
1416443|NCT00323557|Leukemia
1416444|NCT00323557|Sargramostim
1416445|NCT00323557|Pneumococcal Pneumonia
1416446|NCT00323557|Pneumococcal Vaccine
1416447|NCT00323557|Prevnar
1416448|NCT00323557|GM-CSF
1416449|NCT00323557|CLL
1416450|NCT00323544|HIV 1
1416451|NCT00323544|HIV 1 infection
1416452|NCT00323531|thoracoscopy
1416453|NCT00323531|fibrinolysis
1416454|NCT00323531|empyema
1416455|NCT00323531|children
1416456|NCT00323518|oral mucositis
1416457|NCT00323518|hematologic
1416458|NCT00323518|autologous stem cell transplant
1416459|NCT00323518|velafermin
1416460|NCT00323518|stomatitis
1416461|NCT00323518|oncology - supportive care
1416462|NCT00323518|mouth diseases
1416463|NCT00323492|HIV 1 Infection
1416464|NCT00323479|breast cancer treatment
1416465|NCT00323479|joint disorders
1416466|NCT00323453|Appendectomy
1416467|NCT00323453|Surgery
1416468|NCT00323453|Infection
1416469|NCT00323440|Familial Mediterranean fever
1416470|NCT00323440|Inflammation
1416471|NCT00323440|Attacks
1416472|NCT00323440|Remission
1416473|NCT00323440|RNA
1416474|NCT00323440|Cytokines
1416475|NCT00323440|Inflammatory proteins
1416476|NCT00323440|MEFV
1416477|NCT00323440|mutations
1416478|NCT00323440|Colchicine
1416479|NCT00323440|Treatment
1416480|NCT00323440|microarray RNA analysis
1416481|NCT00323427|Audiology
1416482|NCT00323427|Coping behaviors
1416483|NCT00323427|Counseling
1416484|NCT00323427|Hearing aids
1416485|NCT00323427|Hearing impairment
1416486|NCT00323427|Patient-centered care
1416487|NCT00323427|Psychological adaptation
1416488|NCT00323427|Psychological adjustment
1416489|NCT00323427|Rehabilitation
1416490|NCT00323427|Social adjustment
1416491|NCT00323427|Aural Rehabilitation
1416492|NCT00323414|PUFA
1416493|NCT00323414|NASH
1416494|NCT00323414|Fatty Liver
1416495|NCT00323414|Insulin resistance
1416496|NCT00323414|Metabolic syndrome
1416497|NCT00323414|Nonalcoholic fatty liver disease
1416498|NCT00323414|Nonalcoholic steatohepatitis
1416499|NCT00323414|Type 2 Diabetes Mellitus
1416500|NCT00323401|Pregnancy
1416501|NCT00323401|Parturition
1416502|NCT00323401|Depression
1416503|NCT00323401|Randomized
1416504|NCT00323401|Antenatal classes
1416505|NCT00323375|Malaria
1416506|NCT00323375|Aminoquinolines
1416507|NCT00323375|Drug Resistance
1416508|NCT00323375|Chloroquine Resistance
1416509|NCT00323362|recurrent non-small cell lung cancer
1416510|NCT00323362|stage IV non-small cell lung cancer
1416511|NCT00323349|Glucose Tolerance Test
1416512|NCT00323349|Health Knowledge, Attitudes, Practice
1416513|NCT00323349|Motivation
1416514|NCT00323349|Communication
1416515|NCT00323349|Health Behavior
1416516|NCT00323323|Untreated
1416517|NCT00323323|CD-20 Negative
1416518|NCT00323323|Large B-Cell Lymphomas
1416519|NCT00323310|disease of the central nervous system (brain or spine)
1416520|NCT00323284|Open angle
1416521|NCT00323284|Glaucoma
1416522|NCT00323284|Cataract
1416523|NCT00323284|Surgery
1416524|NCT00323271|Chronic pain
1416525|NCT00323271|Cognitive behavioral therapy
1416526|NCT00323271|Multiple sclerosis
1416527|NCT00323271|Randomized controlled trial
1416528|NCT00323258|Heart disease
1416529|NCT00323258|Coronary disease
1416530|NCT00323258|Patient compliance
1416531|NCT00323258|Treatment refusal
1416532|NCT00323258|Pharmacists
1416533|NCT00323258|Continuity of patient care
1416534|NCT00323258|Evidence-based medicine
1416535|NCT00323258|Patient education
1416536|NCT00323258|Adherence
1416537|NCT00323245|Randomized clinical trial
1416538|NCT00323245|osteoporosis
1416539|NCT00323245|urinary incontinence
1416540|NCT00323245|physiotherapy
1416541|NCT00323245|education
1416542|NCT00323232|DHS, Intertrochanteric
1416543|NCT00323219|Cellulitis, RCT, emergency Department, Double-blind, Equivalence trial, Moxifloxacin, Cefazolin, Probenecid.
1416544|NCT00323206|melanoma
1416545|NCT00323206|electroporation
1416546|NCT00323206|IL-12
1416547|NCT00323206|gene therapy
1416548|NCT00323206|gene transfer
1416549|NCT00323193|Behavioral interventions
1416550|NCT00323193|Mental Illness
1416551|NCT00323193|Obesity
1416552|NCT00323193|Psycho-educational interventions
1416553|NCT00323193|Weight management
1416554|NCT00323167|Variant Cystic Fibrosis
1416555|NCT00323167|Primary Ciliary Dyskinesia
1416556|NCT00323154|Morphine, analgesia
1416557|NCT00323141|Hernia umbilicalis
1416558|NCT00323115|immunotherapy
1416559|NCT00323115|cancer vaccine
1416560|NCT00323115|glioblastoma multiforme
1416561|NCT00323089|microcoil
1416562|NCT00323089|subcentimetre nodules
1416563|NCT00323063|recurrent breast cancer
1416564|NCT00323063|stage IV breast cancer
1416565|NCT00323063|male breast cancer
1416566|NCT00323063|stage IIIA breast cancer
1416567|NCT00323063|stage IIIB breast cancer
1416568|NCT00323063|stage IIIC breast cancer
1416569|NCT00323037|heart failure
1416570|NCT00323024|Pulmonary Arterial Hypertension
1416571|NCT00323024|Pulmonary Hypertension
1416572|NCT00323024|Idiopathic PAH
1416573|NCT00323024|PH associated with connective tissue disease (CTD)
1416574|NCT00323024|PH associated with interstitial lung disease (ILD)
1416575|NCT00323024|PH associated with congestive heart failure (CHF)
1416576|NCT00323024|PH associated with chronic obstructive pulmonary disease (COPD)
1416577|NCT00322985|T-cell lymphoma
1416578|NCT00322985|lenalidomide
1416579|NCT00322972|Bacterial Infections
1416580|NCT00322972|Chlamydia Infections
1416581|NCT00322972|Eye Diseases
1416582|NCT00322959|dendritic cells
1416583|NCT00322959|Tai-Chi-Chuan
1416584|NCT00322946|Dengue Fever
1416585|NCT00322946|Dengue Vaccine
1416586|NCT00322946|Dengue Virus
1416587|NCT00322946|Dengue Hemorrhagic Fever
1416588|NCT00322946|Dengue Shock Syndrome
1416589|NCT00322933|intermittent renal replacement therapy
1416590|NCT00322933|continuous renal replacement therapy
1416591|NCT00322933|acute renal failure
1416592|NCT00322933|renal recovery
1416593|NCT00322933|mortality
1416594|NCT00322920|cervical cancer
1416595|NCT00322920|topotecan
1416596|NCT00322920|Stage IVB cervical cancer
1416597|NCT00322920|Persistent or recurrent cervical cancer
1416598|NCT00322907|malaria
1416599|NCT00322907|treatment
1416600|NCT00322907|cotrifazid
1416601|NCT00322907|clinical trial
1416602|NCT00322907|efficacy
1416603|NCT00322894|Breast cancer
1416604|NCT00322894|Risk factors
1416605|NCT00322894|Treatment
1416606|NCT00322894|Clinico-pathologic
1416607|NCT00322894|Outcomes
1416608|NCT00322894|Tissue repository
1416609|NCT00322894|Registry
1416610|NCT00322881|carboplatin
1416611|NCT00322881|paclitaxel
1416612|NCT00322881|elderly women
1416613|NCT00322868|Prescription drugs
1416614|NCT00322868|Administration, oral
1416615|NCT00322868|Durable medical equipment
1416616|NCT00322868|Kinetics
1416617|NCT00322842|Non-Hodgkin's lymphoma
1416618|NCT00322842|Multiple Myeloma
1416619|NCT00322842|Stem cell mobilization
1416620|NCT00322829|Group B Streptococcus, Strepotococcus agalactiae, detection
1416621|NCT00322816|Malaria, Plasmodium falciparum, Gambia, larvicides
1416622|NCT00322803|panic disorder
1416623|NCT00322803|proof of concept
1416624|NCT00322777|Major depression
1416625|NCT00322777|Spirituality
1416626|NCT00322777|Randomized clinical trial
1416627|NCT00322764|manic depression
1416628|NCT00322764|bipolar disorder
1416629|NCT00322764|depression
1416630|NCT00322764|uridine
1416631|NCT00322764|RG2417
1416632|NCT00322738|malaria, Plasmodium falciparum, Gambia, larvicides, vector
1416633|NCT00322699|Bladder Cancer
1416634|NCT00322699|Photodynamic Therapy
1416635|NCT00322699|Photofrin
1416636|NCT00322699|Photosensitization
1416637|NCT00322699|Photoradiation
1416638|NCT00322686|oglemilast
1416639|NCT00322686|asthma
1416640|NCT00322686|allergen
1416641|NCT00322686|prevention
1416642|NCT00322686|prophylaxis
1416643|NCT00322686|Allergen-Induced Asthma
1416644|NCT00322673|acute myeloid leukemia
1416645|NCT00322673|AML
1416646|NCT00322608|Solid Tumors
1416647|NCT00322608|Lymphomas
1416648|NCT00322595|Anxiety
1416649|NCT00322595|GAD
1416650|NCT00322582|familial cardiomyopathy
1416651|NCT00322582|genetics analysis
1416652|NCT00322569|Percutaneous coronary intervention (PCI)
1416653|NCT00322569|Drug eluting stent (DES)
1416654|NCT00322556|Immunoglobulin Intravenous
1416655|NCT00322556|Agammaglobulinemia
1416656|NCT00322556|Hypogammaglobulinemia
1416657|NCT00322556|Common variable immunodeficiency
1416658|NCT00322556|Immunoglobulin G
1416659|NCT00322556|Children
1416660|NCT00322543|Percutaneous coronary intervention (PCI)
1416661|NCT00322543|Drug eluting stent (DES)
1416662|NCT00322491|Non-Hodgkin's Lymphoma
1416663|NCT00322491|Multiple Myeloma
1416664|NCT00322491|Stem cell mobilization
1416665|NCT00322465|non-gonococcal urethritis, doxycycline, azithromycin, sexually transmitted, tinidazole
1416666|NCT00322452|NSCLC
1416667|NCT00322452|Gefitinib
1416668|NCT00322439|plaque Psoriasis patients
1416669|NCT00322439|TNF-inhibitor naïve
1416670|NCT00322426|Freezing of Gait
1416671|NCT00322426|Parkinson's Disease
1416672|NCT00322426|Sensory Cues
1416673|NCT00322413|Epoetin alfa
1416674|NCT00322413|Epoetin omega
1416675|NCT00322413|Comparative efficacy trial
1416676|NCT00322413|Renal anemia
1416677|NCT00322400|Clinical trial
1416678|NCT00322400|AMG 706
1416679|NCT00322400|Anti-angiogenesis
1416680|NCT00322400|Locally Recurrent
1416681|NCT00322400|Metastatic
1416682|NCT00322400|Breast Cancer
1416683|NCT00322400|VEGF
1416684|NCT00322400|Angiogenesis Inhibitor
1416685|NCT00322400|Oral
1416686|NCT00322400|Multi-kinase Inhibitor
1416687|NCT00322400|Anti-tumor
1416688|NCT00322400|PDGF receptor
1416689|NCT00322400|Paclitaxel
1416690|NCT00322400|Docetaxel
1416691|NCT00322400|Targeted Therapy
1416692|NCT00322400|Oncology
1416693|NCT00322400|Amgen
1416694|NCT00322400|c-Kit
1416695|NCT00322387|Non-Hodgkin's Lymphoma
1416696|NCT00322387|Multiple Myeloma
1416697|NCT00322387|Stem cell mobilization
1416698|NCT00322348|oncology
1416699|NCT00322348|cancer
1416700|NCT00322348|breast cancer
1416701|NCT00322335|H.influenzae type b Disease
1416702|NCT00322322|L-carnitine supplementation
1416703|NCT00322322|Hemodialysis
1416704|NCT00322322|Anaemia
1416705|NCT00322322|Erythropoietin responsiveness
1416706|NCT00322309|Cocaine
1416707|NCT00322309|Substance Abuse
1416708|NCT00322296|Parapsoriasis
1416709|NCT00322296|Cutaneous T-cell lymphoma
1416710|NCT00322296|Mycosis fungoides
1416711|NCT00322296|Bexarotene
1416712|NCT00322296|Retinoids
1416713|NCT00322283|oglemilast
1416714|NCT00322283|asthma
1416715|NCT00322283|exercise
1416716|NCT00322283|prevention
1416717|NCT00322283|prophylaxis
1416718|NCT00322270|Occluded Central Venous Access Devices
1416719|NCT00322270|Occluded Catheters
1416720|NCT00322270|Thrombosis
1416721|NCT00322270|thrombosis, catheter
1416722|NCT00322270|alfimeprase
1416723|NCT00322270|thrombotic occlusion
1416724|NCT00322270|thrombosis, CVAD
1416725|NCT00322270|thrombosis, catheters
1416726|NCT00322244|Osteoarthritis
1416727|NCT00322244|Massage therapy
1416728|NCT00322192|Stroke rehabilitation
1416729|NCT00322192|Physical Therapy
1416730|NCT00322179|Microarray Analysis
1416731|NCT00322179|Obesity
1416732|NCT00322179|Chronic Hepatitis C
1416733|NCT00322166|accidental falls
1416734|NCT00322166|vitamin D
1416735|NCT00322166|parathyroid hormone
1416736|NCT00322166|osteoporosis
1416737|NCT00322153|memantine
1416738|NCT00322153|Alzheimer's disease
1416739|NCT00322153|moderate to severe Alzheimer's disease
1416740|NCT00322140|Metastatic
1416741|NCT00322140|Triterpenoids
1416742|NCT00322140|2-Cyano-3,12-Dioxooleana-1,9(11)Dien-28oic Acid
1416743|NCT00322140|Dose-Limiting
1416744|NCT00322140|Pharmacokinetic
1416745|NCT00322140|Solid Tumor
1416746|NCT00322140|Lymphoma
1416747|NCT00322127|Hematopoietic Stem Cells
1416748|NCT00322127|Stem Cell Mobilization
1416749|NCT00322127|CXCR4
1416750|NCT00322127|SDF-1
1416751|NCT00322127|Healthy Volunteer
1416752|NCT00322127|HV
1416753|NCT00322114|prostate cancer
1416754|NCT00322062|Colon cleansing
1416755|NCT00322049|Dengue, Vaccine, Thailand
1416756|NCT00322036|Alzheimer Disease
1416757|NCT00322036|Dementia
1416758|NCT00322023|Negative symptoms
1416759|NCT00322023|NMDA
1416760|NCT00322023|Glutamate
1416761|NCT00322023|Glycine
1416762|NCT00322010|mechanical ventilation
1416763|NCT00322010|physical therapy
1416764|NCT00322010|occupational therapy
1416765|NCT00322010|mobilization
1416766|NCT00322010|clinical protocols
1416767|NCT00322010|ICU acquired weakness
1416768|NCT00322010|critical illness myopathy
1416769|NCT00322010|muscle atrophy
1416770|NCT00322010|intensive care unit
1416771|NCT00322010|randomized controlled trial
1416772|NCT00321997|AMD
1416773|NCT00321997|Age-Related Macular Degeneration
1416774|NCT00321997|Macular Degeneration
1416775|NCT00321997|Macugen
1416776|NCT00321997|pegaptanib sodium
1416777|NCT00321984|Gastroesophageal Reflux Disease(GERD)
1416778|NCT00321984|Heartburn
1416779|NCT00321971|Anxiety
1416780|NCT00321971|Mild Cognitive Impairment
1416781|NCT00321971|MCI
1416782|NCT00321971|Cognitive Impairment
1416783|NCT00321971|Alzheimer's Disease
1416784|NCT00321971|Caregiver Burden
1416785|NCT00321971|Caregiver Stress
1416786|NCT00321971|Family Dementia Caregiving
1416787|NCT00321971|Spousal Dementia Caregiving
1416788|NCT00321958|Barrett Esophagus
1416789|NCT00321958|Esophageal Neoplasm
1416790|NCT00321958|Deglutition disorders
1416791|NCT00321958|Cryotherapy
1416792|NCT00321958|Cryosurgery
1416793|NCT00321958|GERD
1416794|NCT00321958|Neoplasm
1416795|NCT00321958|Esophagus
1416796|NCT00321958|Endoscopy, Digestive System
1416797|NCT00321945|Atrial Fibrillation
1416798|NCT00321945|Atrial Flutter
1416799|NCT00321945|Angiotensin Converting Enzyme Inhibitor
1416800|NCT00321945|Angiotensin Receptor Blocker
1416801|NCT00321906|Rejection in lung transplant
1416802|NCT00321893|Small cell lung cancer
1416803|NCT00321893|Non-small cell lung cancer
1416804|NCT00321893|Budesonide
1416805|NCT00321893|Entocort EC
1416806|NCT00321893|Pulmicort Respules
1416807|NCT00321893|Rhinocort aqua
1416808|NCT00321893|Aerosol budesonide treatment
1416809|NCT00321893|Smoking
1416810|NCT00321880|fatigue
1416811|NCT00321880|psychosocial effects of cancer and its treatment
1416812|NCT00321880|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1416813|NCT00321880|adult acute myeloid leukemia with inv(16)(p13;q22)
1416814|NCT00321880|adult acute myeloid leukemia with t(15;17)(q22;q12)
1416815|NCT00321880|adult acute myeloid leukemia with t(16;16)(p13;q22)
1416816|NCT00321880|adult acute myeloid leukemia with t(8;21)(q22;q22)
1416817|NCT00321880|recurrent adult acute lymphoblastic leukemia
1416818|NCT00321880|recurrent adult acute myeloid leukemia
1416819|NCT00321880|untreated adult acute lymphoblastic leukemia
1416820|NCT00321880|untreated adult acute myeloid leukemia
1416821|NCT00321867|rectocele
1416822|NCT00321867|pelvic prolapse
1416823|NCT00321867|graft
1416824|NCT00321867|surgical repair
1416825|NCT00321828|adenocarcinoma of the colon
1416826|NCT00321828|stage IV colon cancer
1416827|NCT00321815|advanced carcinoma non-small cell lung EGFR positive Erlotinib Tarceva PF-3512676 Phase II immunotherapy immune modulator
1416828|NCT00321802|atrial fibrillation
1416829|NCT00321802|statin therapy
1416830|NCT00321802|CRP levels
1416831|NCT00321802|Paroxysmal Atrial Fibrillation
1416832|NCT00321789|self care
1416833|NCT00321789|social support
1416834|NCT00321763|Influenza
1416835|NCT00321763|Influenza vaccine
1416836|NCT00321750|Oral erosive lichen planus
1416837|NCT00321750|pimecrolimus cream
1416838|NCT00321737|Erosive Esophagitis
1416839|NCT00321711|MDS
1416840|NCT00321711|Myelodysplastic Syndromes
1416841|NCT00321711|Refractory Cytopenias
1416842|NCT00321711|Thrombocytopenia
1416843|NCT00321698|adenocarcinoma of the prostate
1416844|NCT00321698|stage II prostate cancer
1416845|NCT00321698|stage III prostate cancer
1416846|NCT00321672|Analgesics
1416847|NCT00321672|Capsaicin
1416848|NCT00321672|Neuropathic pain
1416849|NCT00321672|Neuropathy
1416850|NCT00321672|Distal sensory polyneuropathy
1416851|NCT00321672|Peripheral neuropathy
1416852|NCT00321672|Dermal assessment
1416853|NCT00321672|Pain measurement
1416854|NCT00321659|fibromyalgia
1416855|NCT00321659|self-management
1416856|NCT00321659|exercise
1416857|NCT00321659|patient education
1416858|NCT00321646|prostate cancer
1416859|NCT00321646|bevacizumab
1416860|NCT00321646|docetaxel
1416861|NCT00321646|radical prostatectomy
1416862|NCT00321633|stage IV breast cancer
1416863|NCT00321633|recurrent breast cancer
1416864|NCT00321633|hereditary breast/ovarian cancer (BRCA1, BRCA2)
1416865|NCT00321633|BRCA1 mutation carrier
1416866|NCT00321633|BRCA2 mutation carrier
1416867|NCT00321620|Bone metastases
1416868|NCT00321620|Hormone-refractory prostate cancer
1416869|NCT00321620|Skeletal
1416870|NCT00321620|Fractures
1416871|NCT00321620|Compressions
1416872|NCT00321620|Bisphosphonates
1416873|NCT00321581|VEGFR2
1416874|NCT00321581|Tyrosine Kinase Inhibitor
1416875|NCT00321581|Antiangiogenesis
1416876|NCT00321581|Solid Tumors
1416877|NCT00321581|Childhood Cancer
1416878|NCT00321581|Solid Tumor
1416879|NCT00321581|Recurrent Solid Tumor
1416880|NCT00321581|Treatment Resistant Solid Tumor
1416881|NCT00321581|Acute Myelogenous Leukemia
1416882|NCT00321581|AML
1416883|NCT00321568|Multiple Sclerosis
1416884|NCT00321568|Magnetic Resonance
1416885|NCT00321568|MRI
1416886|NCT00321568|Magnetic Field
1416887|NCT00321568|MS
1416888|NCT00321555|Biologic Therapy
1416889|NCT00321555|Monoclonal Antibody
1416890|NCT00321555|Immunotherapy
1416891|NCT00321555|Pseudomonas Exotoxin
1416892|NCT00321555|Targeted Therapy
1416893|NCT00321555|Hairy Cell Leukemia
1416894|NCT00321555|HCL
1416895|NCT00321542|Computed tomography
1416896|NCT00321542|Diabetes mellitus
1416897|NCT00321542|Coronary atherosclerosis
1416898|NCT00321542|Non-invasive imaging
1416899|NCT00321529|Cervical spine instability
1416900|NCT00321529|Penning Study
1416901|NCT00321516|Bipolar type I Disorder
1416902|NCT00321503|acid reflux
1416903|NCT00321503|LPR
1416904|NCT00321503|gastroesophageal reflux
1416905|NCT00321503|GERD
1416906|NCT00321503|pH probe
1416907|NCT00321503|proton pump inhibitor
1416908|NCT00321503|PPI
1416909|NCT00321490|MDD
1416910|NCT00321490|Quetiapine fumarate, sustained release
1416911|NCT00321490|Depression
1416912|NCT00321477|Overactive Bladder
1416913|NCT00321464|Fractures
1416914|NCT00321464|Compressions
1416915|NCT00321464|Bisphosphonates
1416916|NCT00321464|Bone metastases
1416917|NCT00321464|Breast cancer
1416918|NCT00321464|Skeletal
1416919|NCT00321464|Radiation
1416920|NCT00321464|Surgery to Bone
1416921|NCT00321451|insomnia
1416922|NCT00321451|cognitive behavior therapy
1416923|NCT00321438|HIV-1
1416924|NCT00321438|GW873140
1416925|NCT00321438|CCR5 antagonist
1416926|NCT00321438|experienced
1416927|NCT00321438|treatment experienced
1416928|NCT00321412|Crohn's disease
1416929|NCT00321412|IBD
1416930|NCT00321412|Inflammatory Bowel Disease
1416931|NCT00321412|Fistula
1416932|NCT00321399|CORONARY ANATOMY
1416933|NCT00321399|Coronary Artery Disease
1416934|NCT00321399|SPECT
1416935|NCT00321399|PET
1416936|NCT00321399|PET/CT
1416937|NCT00321399|CTA
1416938|NCT00321386|Glaucoma
1416939|NCT00321386|Open Angle
1416940|NCT00321386|Normal Tension
1416941|NCT00321373|Influenza
1416942|NCT00321373|Influenza vaccine
1416943|NCT00321360|propofol
1416944|NCT00321360|sedation
1416945|NCT00321347|Cancer
1416946|NCT00321347|Pain
1416947|NCT00321347|Lidocaine
1416948|NCT00321334|non-small cell lung cancer
1416949|NCT00321334|Chemotherapy
1416950|NCT00321334|surgery
1416951|NCT00321334|neo-adjuvant
1416952|NCT00321334|adjuvant
1416953|NCT00321334|RCT
1416954|NCT00321321|Type 2 diabetes mellitus
1416955|NCT00321321|Glucose dependent insulinotropic polypeptide
1416956|NCT00321321|Sulfonylurea compounds
1416957|NCT00321321|insulin secretion
1416958|NCT00321321|Sulfonylurea receptor subunit-SUR1
1416959|NCT00321321|Impaired incretin effect
1416960|NCT00321308|advanced carcinoma, non-small cell lung cancer, phase II, pemetrexed, Alimta, PF-3512676, immunotherapy, immunomodulator
1416961|NCT00321295|Bi-ventricular pacing
1416962|NCT00321295|Cardiac Surgery
1416963|NCT00321295|Cardiomyopahty
1416964|NCT00321295|Heart Failure
1416965|NCT00321282|Atrial Fibrillation
1416966|NCT00321282|Coronary Artery Bypass Graft
1416967|NCT00321282|Risk Stratification
1416968|NCT00321269|Home Monitoring
1416969|NCT00321269|Heart Failure
1416970|NCT00321269|Depression
1416971|NCT00321256|islet transplantation
1416972|NCT00321256|brittle diabetes
1416973|NCT00321256|severe hypoglycemia
1416974|NCT00321256|type 1 diabetes mellitus
1416975|NCT00321243|triage
1416976|NCT00321230|Colon cleansing
1416977|NCT00321217|rheumatoid arthritis
1416978|NCT00321217|pharmacogenetics
1416979|NCT00321217|anti-TNF
1416980|NCT00321217|high throughput genotyping
1416981|NCT00321204|Atrial Fibrillation
1416982|NCT00321204|Atrial Flutter
1416983|NCT00321204|Cardiac Surgery
1416984|NCT00321204|Thiazolidinediones
1416985|NCT00321178|Mycobacterium ulcerans
1416986|NCT00321178|Buruli ulcer
1416987|NCT00321178|Ghana
1416988|NCT00321178|randomized comparison
1416989|NCT00321178|streptomycin
1416990|NCT00321178|rifampicin
1416991|NCT00321178|clarithromycin
1416992|NCT00321165|nutrition
1416993|NCT00321165|parenteral
1416994|NCT00321165|infection
1416995|NCT00321165|katheter
1416996|NCT00321165|taurolidine
1416997|NCT00321165|acridine orange
1416998|NCT00321165|prevention
1416999|NCT00321139|biomarkers
1417000|NCT00321139|oxidative stress
1417001|NCT00321139|intravascular ultrasound
1417002|NCT00321126|Zinc
1417003|NCT00321126|Shigella
1417004|NCT00321126|Children
1417005|NCT00321126|Bangladesh
1417006|NCT00321113|MARGINAL KIDNEY
1417007|NCT00321113|TACROLIMUS
1417008|NCT00321113|IMMUNOSUPPRESSION
1417009|NCT00321113|ELDERLY RECEPIENTS
1417010|NCT00321100|metastatic
1417011|NCT00321100|colorectal
1417012|NCT00321100|cancer
1417013|NCT00321100|initial therapy
1417014|NCT00321087|Movement Disorder
1417015|NCT00321074|IMMUNOSUPPRESSION
1417016|NCT00321074|TACROLIMUS
1417017|NCT00321074|MARGINAL LIVERS
1417018|NCT00321074|PHARMACOKINETICS
1417019|NCT00321061|HIV Negative
1417020|NCT00321061|Healthy
1417021|NCT00321061|Immunity
1417022|NCT00321061|Preventive
1417023|NCT00321061|Virus
1417024|NCT00321061|Healthy Volunteer
1417025|NCT00321061|HV
1417026|NCT00321048|breast cancer
1417027|NCT00321048|SPECT
1417028|NCT00321048|ABC device
1417029|NCT00321048|Invasive adenocarcinoma of the left breast
1417030|NCT00321048|Ductal Carcinoma In Situ of the left breast
1417031|NCT00321035|Glaucoma
1417032|NCT00321035|Pterygium
1417033|NCT00321035|collagen matrix
1417034|NCT00321035|oculusgen
1417035|NCT00321035|ologen
1417036|NCT00321035|trabeculectomy
1417037|NCT00321035|anti scarring
1417038|NCT00321035|prevent recurrence
1417039|NCT00321035|tissue engineering
1417040|NCT00321035|Aeon Astron
1417041|NCT00321022|Transient Ischemic Attack (TIA)
1417042|NCT00321022|Diagnostic Protocol
1417043|NCT00321022|Observational Medicine
1417044|NCT00321022|Emergency Department Observational Unit
1417045|NCT00321009|Myocardial Infarction
1417046|NCT00321009|Left Ventricular Mural Thrombus
1417047|NCT00321009|Low Molecular Weight Heparin
1417048|NCT00321009|Enoxaparin
1417049|NCT00321009|Warfarin
1417050|NCT00321009|Echocardiograms
1417051|NCT00319982|Hypertrophic Cardiomyopathy
1417052|NCT00319982|Left ventricular hypertrophy
1417053|NCT00319982|Diltiazem
1417054|NCT00319969|small cell lung cancer
1417055|NCT00319969|amrubicin
1417056|NCT00319956|premature infant
1417057|NCT00319956|respiratory distress syndrome
1417058|NCT00319956|mechanical ventilation
1417059|NCT00319943|Cognitive remediation
1417060|NCT00319943|Cognitive impairment
1417061|NCT00319943|computer
1417062|NCT00319943|training
1417063|NCT00319930|Chronic lymphocytic leukemia
1417064|NCT00319930|CLL
1417065|NCT00319930|ZAP-70
1417066|NCT00319930|Hsp90 inhibitor
1417067|NCT00319917|Tacrolimus
1417068|NCT00319917|Rheumatoid Arthritis
1417069|NCT00319917|Tacrolimus anhydrous
1417070|NCT00319904|Schizophrenia
1417071|NCT00319904|DNA
1417072|NCT00319891|Alzheimer's
1417073|NCT00319891|AD
1417074|NCT00319891|Mild Cognitive Impairment
1417075|NCT00319891|Dementia
1417076|NCT00319891|Cognitive remediation
1417077|NCT00319891|computer-based training
1417078|NCT00319865|Multiple Myeloma Relapsed
1417079|NCT00320996|Pelvic mass
1417080|NCT00320983|Cancer
1417081|NCT00320983|Cervix
1417082|NCT00320970|TGF-Beta 1
1417083|NCT00320970|Angiotensin II
1417084|NCT00320970|Advanced glycation end products
1417085|NCT00320957|Glaucoma
1417086|NCT00320957|Pterygium
1417087|NCT00320957|collagen matrix
1417088|NCT00320957|OculusGen
1417089|NCT00320957|trabeculectomy
1417090|NCT00320957|Anti scarring
1417091|NCT00320957|pterygium recurrence
1417092|NCT00320957|tissue engineering
1417093|NCT00320957|Aeon Astron
1417094|NCT00320957|ologen
1417095|NCT00320931|Coronary artery disease
1417096|NCT00320931|PET CT scan
1417097|NCT00320931|Stress test
1417098|NCT00320931|Rubudium
1417099|NCT00320918|Unresectable/metastatic cholangiocarcinoma
1417100|NCT00320918|Cancer
1417101|NCT00320918|Chart Review
1417102|NCT00320905|Cardiac Rehabilitation
1417103|NCT00320905|Cognitive functioning
1417104|NCT00320905|Cardiovascular disease
1417105|NCT00320892|Death Rattle
1417106|NCT00320892|Noise level
1417107|NCT00320892|Primary Care
1417108|NCT00320879|diabetes
1417109|NCT00320879|microalbuminuria
1417110|NCT00320879|angiotensin II receptor blockade
1417111|NCT00320879|irbesartan
1417112|NCT00320879|dose-response
1417113|NCT00320879|randomized
1417114|NCT00320879|double-blind
1417115|NCT00320879|renin-angiotensin-aldosterone system
1417116|NCT00320879|clinical
1417117|NCT00320879|hypertension
1417118|NCT00320866|Hypodermoclysis
1417119|NCT00320866|Evaluation of Symptoms
1417120|NCT00320853|Diabetes
1417121|NCT00320853|Vitamin D
1417122|NCT00320853|Insulin sensitivity
1417123|NCT00320853|Insulin secretion
1417124|NCT00320840|preterm infants
1417125|NCT00320840|twins
1417126|NCT00320840|motherhood
1417127|NCT00320840|internal resources
1417128|NCT00320840|familial resources
1417129|NCT00320827|Apoptosis
1417130|NCT00320827|Death receptor 5
1417131|NCT00320827|Cancer
1417132|NCT00320827|Advanced solid malignancies and lymphomas (without leukemic component)
1417133|NCT00320801|Chronic pain
1417134|NCT00320801|osteoarthritis
1417135|NCT00320801|transdermal
1417136|NCT00320788|Neovascular Age-Related Macular Degeneration
1417137|NCT00320775|Neovascular Age-Related Macular Degeneration
1417138|NCT00320762|Glaucoma
1417139|NCT00320762|Pterygium
1417140|NCT00320762|collagen matrix
1417141|NCT00320762|OculusGen
1417142|NCT00320762|trabeculectomy
1417143|NCT00320762|Anti scarring
1417144|NCT00320762|pterygium recurrence
1417145|NCT00320762|tissue engineering
1417146|NCT00320762|Aeon Astron
1417147|NCT00320749|Advanced Pancreatic Cancer
1417148|NCT00320736|schizophrenia
1417149|NCT00320736|cognitive function
1417150|NCT00320736|cholinergic medication
1417151|NCT00320736|nicotinic receptor agonist
1417152|NCT00320723|schizophrenia
1417153|NCT00320723|smoking cessation
1417154|NCT00320723|nicotine
1417155|NCT00320723|patch
1417156|NCT00320723|bupropion
1417157|NCT00320723|nicotine replacement therapy
1417158|NCT00320723|cognitive behavioral therapy
1417159|NCT00320710|Breast cancer
1417160|NCT00320710|zoledronic acid
1417161|NCT00320710|bone metastases
1417162|NCT00320697|schizophrenia
1417163|NCT00320697|smoking cessation
1417164|NCT00320697|relapse prevention
1417165|NCT00320697|nicotine
1417166|NCT00320697|bupropion
1417541|NCT00318981|Efficacy trial
1417167|NCT00320697|cognitive behavioral therapy
1417168|NCT00320697|nicotine replacement therapy
1417169|NCT00320684|Serotonin Transporter
1417170|NCT00320684|Positron-Emission Tomography
1417171|NCT00320671|First-episode
1417172|NCT00320671|Schizoaffective Disorder
1417173|NCT00320671|Schizophreniform Disorder
1417174|NCT00320671|Psychotic Disorder Not Otherwise Specified NOS
1417175|NCT00320671|Aripiprazole
1417176|NCT00320671|Clozapine
1417177|NCT00320671|Risperidone
1417178|NCT00320658|Plasmodium falciparum
1417179|NCT00320632|Major Depressive Disorder
1417180|NCT00320632|MDD
1417181|NCT00320619|Aminocaproic Acids
1417182|NCT00320619|Blood Transfusion
1417183|NCT00320606|allograft function
1417184|NCT00320606|anti-rejection
1417185|NCT00320606|immunosuppression withdrawal
1417186|NCT00320606|liver transplant
1417187|NCT00320606|liver transplantation
1417188|NCT00320606|living donor transplant
1417189|NCT00320593|Myopia
1417190|NCT00320593|Progressive Addition Lenses (PALs)
1417191|NCT00320593|Single Vision Lenses (SVLs)
1417192|NCT00320593|Accommodative lags
1417193|NCT00320593|Near esophoria
1417194|NCT00320593|Refractive error
1417195|NCT00320580|Metrorrhagia
1417196|NCT00320580|oral contraception
1417197|NCT00320580|breakthrough bleeding
1417198|NCT00320580|spotting
1417199|NCT00320567|osteoporosis
1417200|NCT00320567|anorexia nervosa
1417201|NCT00320567|pediatric
1417202|NCT00320541|Breast Cancer
1417203|NCT00320541|Cancer of Breast
1417204|NCT00320541|Cancer of the breast
1417205|NCT00320541|Breast Neoplasms
1417206|NCT00320476|Multiple myeloma
1417207|NCT00320450|SB-681323
1417208|NCT00320450|CRP
1417209|NCT00320450|Rheumatoid Arthritis SB-681323 CRP RA
1417210|NCT00320450|Rheumatoid Arthritis
1417211|NCT00320450|RA
1417212|NCT00320437|trauma
1417213|NCT00320437|anxiety
1417214|NCT00320437|antenatal
1417215|NCT00320437|mothers
1417216|NCT00320437|children
1417217|NCT00320437|Gene x Environment Interaction
1417218|NCT00320424|Xa factor
1417219|NCT00320424|VTE
1417220|NCT00320424|MOSLL
1417221|NCT00320424|pentasaccharide
1417222|NCT00320411|Stage IV breast cancer
1417223|NCT00320411|Herceptin
1417224|NCT00320411|metastatic breast cancer
1417225|NCT00320411|ErbB1
1417226|NCT00320411|ErbB2
1417227|NCT00320411|trastuzumab
1417228|NCT00320411|lapatinib
1417229|NCT00320398|Fondaparinux
1417230|NCT00320398|Hip Replacement Arthroplasty
1417231|NCT00320398|VTE
1417232|NCT00320398|THR
1417233|NCT00320398|MOSLL
1417234|NCT00320398|pentasaccharide
1417235|NCT00320398|Xa factor
1417236|NCT00320385|lapatinib
1417237|NCT00320385|GW572016
1417238|NCT00320385|ErbB2
1417239|NCT00320385|EGFR
1417240|NCT00320385|ErbB1
1417241|NCT00320385|MBC
1417242|NCT00320385|FISH amplification
1417243|NCT00320385|Metastatic Breast Cancer
1417244|NCT00320385|dual tyrosine kinase inhibitor
1417245|NCT00320385|Her-2/neu
1417246|NCT00320372|Major Depressive Disorder
1417247|NCT00320372|Treatment-resistant Depression
1417248|NCT00320359|First-line Cisplatin
1417249|NCT00320359|Small Cell Lung Cancer
1417250|NCT00320359|topotecan
1417251|NCT00320359|etoposide
1417252|NCT00320359|Extensive Disease
1417253|NCT00320346|Pandemic
1417254|NCT00320346|Influenza
1417255|NCT00320346|Prevention
1417256|NCT00320346|Vaccine
1417257|NCT00320346|Prevention of Pandemic Influenza
1417258|NCT00320333|COPD
1417259|NCT00320333|rehabilitation
1417260|NCT00320333|health services research
1417261|NCT00320320|No prior chemotherapy
1417262|NCT00320307|Human Immunodeficiency Virus
1417263|NCT00320307|HIV
1417264|NCT00320307|Abacavir regime
1417265|NCT00320307|ABC
1417266|NCT00320281|Botox
1417267|NCT00320268|MDD
1417268|NCT00320268|Quetiapine fumarate, sustained release
1417269|NCT00320268|Depression
1417270|NCT00320255|anticoagulant
1417271|NCT00320242|Parkinson's disease
1417272|NCT00320242|laser cane
1417273|NCT00320242|freezing of gait
1417274|NCT00320242|visual cues
1417275|NCT00320229|angioplasty
1417276|NCT00320229|stent
1417277|NCT00320229|abciximab
1417278|NCT00320229|Platelet Glycoprotein GPIIb-IIIa Complex
1417279|NCT00320229|myocardial infarction
1417280|NCT00320216|Psoriasis
1417281|NCT00320216|CNTO 1275
1417282|NCT00320216|Ustekinumab
1417283|NCT00320216|Stelara
1417284|NCT00320216|Interleukin-12
1417285|NCT00320216|IL-12
1417286|NCT00320216|Interleukin-23
1417287|NCT00320216|IL-23
1417288|NCT00320203|open-angle
1417289|NCT00320203|glaucoma
1417290|NCT00320190|Chronic phase CML, with a suboptimal response after treatment with imatinib
1417291|NCT00320177|Binge Eating
1417292|NCT00320177|Food Intake
1417293|NCT00320177|Obesity
1417542|NCT00318968|Acid Reflux
1417294|NCT00320177|Melanocortin-4 Receptor Gene
1417295|NCT00320177|Child
1417296|NCT00320177|Macronutrient Composition
1417297|NCT00320164|Healthy Volunteers
1417298|NCT00320151|chronic lung disease
1417299|NCT00320138|PTSD
1417300|NCT00320138|Posttraumatic Stress
1417301|NCT00320138|Acupuncture
1417302|NCT00320138|Randomized Controlled Trial
1417303|NCT00320138|Complementary medicine
1417304|NCT00320138|Alternative medicine
1417305|NCT00320138|Chinese medicine
1417306|NCT00320138|military healthcare
1417307|NCT00320125|Dairy
1417308|NCT00320125|Calcium
1417309|NCT00320125|Pregnancy
1417310|NCT00320125|Fetus
1417311|NCT00320125|Bone mineralization
1417312|NCT00320112|telemedicine
1417313|NCT00320112|case management
1417314|NCT00320112|insulin
1417315|NCT00320112|self-care
1417316|NCT00320099|septic shock
1417317|NCT00320099|adrenal insufficiency
1417318|NCT00320099|glucose control
1417319|NCT00320099|mineralocorticoids
1417320|NCT00320073|unspecified adult solid tumor, protocol specific
1417321|NCT00320060|Diabetic nephropathy
1417322|NCT00320060|Advanced Glycation Endproduct Inhibitor
1417323|NCT00320060|Pyridorin
1417324|NCT00320060|Pyridoxamine
1417325|NCT00320047|Binge Eating Disorder
1417326|NCT00320034|levalbuterol
1417327|NCT00320034|asthma
1417328|NCT00320034|allergen provocation
1417329|NCT00320034|airway inflammation
1417330|NCT00320034|clinical trial
1417331|NCT00320021|Diabetic nephropathy
1417332|NCT00320021|Advanced Glycation Endproduct Inhibitor
1417333|NCT00320021|Pyridorin
1417334|NCT00320021|Pyridoxamine
1417335|NCT00319852|Diphteria;
1417336|NCT00319852|Tetanus;
1417337|NCT00319852|Pertussis;
1417338|NCT00319852|Poliomyelitis;
1417339|NCT00319852|acellular
1417340|NCT00319839|Head cancer
1417341|NCT00319839|Neck cancer
1417342|NCT00319826|Staphylococcus aureus, S. aureus, bacteremia, sepsis
1417343|NCT00319774|End-stage renal disease
1417344|NCT00319774|Hemodialysis
1417345|NCT00319774|Hypertension
1417346|NCT00319774|Hypotension
1417347|NCT00319774|Blood volume
1417348|NCT00319774|Hypervolemia
1417349|NCT00319774|Quality of life
1417350|NCT00319774|Biofeedback system
1417351|NCT00319761|glomerulonephritis
1417352|NCT00319761|proteinuria
1417353|NCT00319761|chronic kidney diseases
1417354|NCT00319748|Breast
1417355|NCT00319748|Ovarian
1417356|NCT00319748|Endometrial
1417357|NCT00319748|Cervical
1417358|NCT00319748|Metastatic
1417359|NCT00319748|852A
1417360|NCT00319748|IRM
1417361|NCT00319748|Oncology
1417362|NCT00319748|Metastatic Cervical Cancer
1417363|NCT00319748|Metastatic Ovarian Cancer
1417364|NCT00319748|Metastatic Breast Cancer
1417365|NCT00319748|Metastatic Endometrial Cancer
1417366|NCT00319722|autism
1417367|NCT00319722|pervasive developmental disorder
1417368|NCT00319722|evoked potentials
1417369|NCT00319722|EEG
1417370|NCT00319722|Coherence
1417371|NCT00319709|depression
1417372|NCT00319709|antidepressive agents
1417373|NCT00319709|controlled clinical trial
1417374|NCT00319696|systemic sclerosis
1417375|NCT00319696|digital ulcers
1417376|NCT00319696|bosentan
1417377|NCT00319696|open label
1417378|NCT00319696|finger ulcers
1417379|NCT00319683|Cancer
1417380|NCT00319683|Tumors
1417381|NCT00319683|Neoplasms
1417382|NCT00319683|Anticarcinogenic Agents
1417383|NCT00319683|Antineoplastic Agents
1417384|NCT00319683|Dihydrouracil Dehydrogenase (NADP)
1417385|NCT00319670|constipation
1417386|NCT00319670|pediatric
1417387|NCT00319657|Kidney Transplantation
1417388|NCT00319657|Blood Stem Cell Transplantation
1417389|NCT00319631|Respiratory Distress Syndrome, Adult
1417390|NCT00319605|Cross sectional study
1417391|NCT00319605|acceptability
1417392|NCT00319605|levetiracetam
1417393|NCT00319605|oral solution
1417394|NCT00319605|Keppra
1417395|NCT00319592|Japanese encephalitis
1417396|NCT00319592|ChimeriVax™-JE
1417397|NCT00319592|JE-VAX®
1417398|NCT00319579|living kidney donors
1417399|NCT00319579|prospective
1417400|NCT00319579|medical
1417401|NCT00319579|psychosocial
1417402|NCT00319566|Coronary Heart Disease
1417403|NCT00319566|Hormone replacement therapy
1417404|NCT00319566|Estrogen
1417405|NCT00319566|Postmenopausal women
1417406|NCT00319553|Tetanus
1417407|NCT00319553|diphtheria
1417408|NCT00319553|acellular pertussis
1417409|NCT00319540|Depression
1417410|NCT00319540|psychoeducation
1417411|NCT00319540|RCT
1417412|NCT00319540|primary health services
1417413|NCT00319527|long term outcome
1417414|NCT00319527|living kidney donor
1417415|NCT00319501|Acute Repetitive Seizures
1417416|NCT00319501|ARS
1417417|NCT00319501|Diazepam
1417418|NCT00319501|Cluster Seizures
1417419|NCT00319488|Wheezing
1417420|NCT00319488|Respiratory Tract Illness
1417421|NCT00319462|point A, cervical cancer, radiotherapy
1417422|NCT00319436|parenting intervention
1417423|NCT00319436|family intervention
1417424|NCT00319436|maternal substance abuse
1417425|NCT00319436|mother-child relations
1417426|NCT00319436|parent-child relations
1417427|NCT00319423|Hip Osteoarthritis, Exercise therapy, Patient Education
1417428|NCT00319410|Menorrhagia
1417429|NCT00319410|intrauterine diagnosis
1417430|NCT00319410|visual analogue scale
1417431|NCT00319397|vascular resistance
1417432|NCT00319397|vasomotion
1417433|NCT00319397|coronary disorder
1417434|NCT00319397|hemodynamics
1417435|NCT00319397|physical fitness
1417436|NCT00319384|congestive heart failure
1417437|NCT00319384|heart failure
1417438|NCT00319384|ultrafiltration therapy
1417439|NCT00319384|fluid overload
1417440|NCT00319371|vasospasm
1417441|NCT00319371|circadian
1417442|NCT00319371|sleep-disorders
1417443|NCT00319358|chronic pancreatitis
1417444|NCT00319358|antioxidant supplementation
1417445|NCT00319358|oxidative stress
1417446|NCT00319345|Traumatic brain injury
1417447|NCT00319345|Intracranial pressure
1417448|NCT00319345|Osmotherapy
1417449|NCT00319345|Glasgow outcome score
1417450|NCT00319345|Mannitol
1417451|NCT00319345|Sodium-Lactate
1417452|NCT00319332|non-Hodgkin's Lymphoma
1417453|NCT00319332|follicular lymphoma
1417454|NCT00319332|BEXXAR
1417455|NCT00319332|ZEVALIN
1417456|NCT00319332|Iodine I 131 Tositumomab
1417457|NCT00319332|Ibritumomab Tiuxetan
1417458|NCT00319332|Follicular, mixed small-cleaved and large-cell
1417459|NCT00319332|Diffuse large cell non-Hodgkin's lymphoma following or concurrent with a diagnosis of follicular lymphoma
1417460|NCT00319319|major depressive disorder,
1417461|NCT00319319|serotonin selective reuptake inhibitor,
1417462|NCT00319319|mecamylamine,
1417463|NCT00319319|controlled trial,
1417464|NCT00319319|cigarette smoking
1417465|NCT00319306|Respiratory Tract Diseases
1417466|NCT00319306|Bronchial Diseases
1417467|NCT00319306|Anti-asthmatic agents
1417468|NCT00319306|Anti-asthmatic drugs
1417469|NCT00319306|Bronchodilators
1417470|NCT00319280|Osteoarthritis, Knee
1417471|NCT00319280|Osteotomy
1417472|NCT00319280|Healing
1417473|NCT00319280|Roentgen Stereometric Analysis
1417474|NCT00319267|bosentan
1417475|NCT00319267|children
1417476|NCT00319267|pharmacokinetics
1417477|NCT00319267|pulmonary arterial hypertension
1417478|NCT00319254|Advanced Breast Cancer
1417479|NCT00319241|parenting intervention
1417480|NCT00319241|substance abuse treatment
1417481|NCT00319241|mother-child relations
1417482|NCT00319241|parent-child relations
1417483|NCT00319241|child abuse and neglect
1417484|NCT00319228|AT-III deficiency
1417485|NCT00319228|AT-III concentrate
1417486|NCT00319228|Bleeding disorders
1417487|NCT00319228|Blood disorders
1417488|NCT00319215|ramelteon
1417489|NCT00319215|zopiclone
1417490|NCT00319215|driving
1417491|NCT00319215|memory
1417492|NCT00319215|balance
1417493|NCT00319215|psychomotor
1417494|NCT00319202|Impaired fasting glucose
1417495|NCT00319202|Abdominal obesity
1417496|NCT00319202|HOMA
1417497|NCT00319202|Angiotensin-receptor blocker
1417498|NCT00319189|Nateglinide
1417499|NCT00319189|Renal
1417500|NCT00319189|Kidney
1417501|NCT00319189|Transplantation
1417502|NCT00319189|Diabets
1417503|NCT00319189|Glucose
1417504|NCT00319176|Pregnancy
1417505|NCT00319176|Enoxaparin
1417506|NCT00319176|Anticoagulation
1417507|NCT00319163|oral contraceptive
1417508|NCT00319163|therapeutic equivalency
1417509|NCT00319163|contraceptives, oral, combined
1417510|NCT00319150|Erythropoetin resistance
1417511|NCT00319150|End Stage Renal Disease on hemodialysis
1417512|NCT00319137|GW274150
1417513|NCT00319137|Nitric Oxide
1417514|NCT00319137|acute migraine
1417515|NCT00319124|Hip Osteoarthritis, muscle strength, range of motion, aerobic capacity, functional capacity, health-related quality of life
1417516|NCT00319111|pulmonary hypertension
1417517|NCT00319111|bosentan
1417518|NCT00319111|BENEFIT
1417519|NCT00319111|CTEPH
1417520|NCT00319111|inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
1417521|NCT00319098|Adjuvanted pandemic influenza candidate vaccine
1417522|NCT00319098|Influenza
1417523|NCT00319085|Arthroplasty,
1417524|NCT00319085|Hip,
1417525|NCT00319085|Pre-heating,
1417526|NCT00319085|Radiostereometric analysis,
1417527|NCT00319085|Dual-Energy Radiographic Absorptiometry,
1417528|NCT00319046|Type 1 Gaucher Disease
1417529|NCT00319046|miglustat
1417530|NCT00319046|enzyme replacement therapy
1417531|NCT00319033|interstitial lung disease
1417532|NCT00319033|scleroderma
1417533|NCT00319033|bosentan
1417534|NCT00319020|bosentan
1417535|NCT00319020|pulmonary arterial hypertension
1417536|NCT00319020|children
1417537|NCT00319020|FUTURE 1
1417538|NCT00318981|Medication trial
1417539|NCT00318981|ADHD
1417540|NCT00318981|Concerta
1417543|NCT00318968|Nexium
1417544|NCT00318968|Esomeprazole
1417545|NCT00318955|Dexmedetomidine, Sedation, Extubation, Phase 4
1417546|NCT00318942|Sepsis
1417547|NCT00318942|Multiple Trauma
1417548|NCT00318942|Hypovolemic Shock
1417549|NCT00318929|Treatment Efficacy
1417550|NCT00318929|pharmacokinetics
1417551|NCT00318903|Chemotherapy for cancer of the esophagus
1417552|NCT00318903|Radiotherapy for cancer of the esophagus
1417553|NCT00318903|Surgery for cancer of the esophagus
1417554|NCT00318903|Chemotherapy, radiotherapy, surgery for esophageal cancer
1417555|NCT00318890|Chemotherapy and Radiotherapy for Head and Neck Cancer
1417556|NCT00318890|Chemotherapy, Radiotherapy Squamous Cell Carcinoma Head Neck
1417557|NCT00318877|Obesity
1417558|NCT00318877|Physical activity
1417559|NCT00318864|depression
1417560|NCT00318864|cardiovascular risk
1417561|NCT00318864|mechanisms
1417562|NCT00318851|Carotid Artery stenting
1417563|NCT00318851|Stroke
1417564|NCT00318825|Pain
1417565|NCT00318825|Colonoscopy
1417566|NCT00318825|Sedation
1417567|NCT00318812|Randomized controlled trial (RCT)
1417568|NCT00318812|Prospective Studies
1417569|NCT00318812|ferric oxide, saccharated
1417570|NCT00318812|Peptides
1417571|NCT00318812|Heme
1417572|NCT00318812|Iron
1417573|NCT00318812|Erythropoietin,
1417574|NCT00318812|Recombinant
1417575|NCT00318812|Ferritin
1417576|NCT00318812|Transferrin
1417577|NCT00318812|Treatment Outcome
1417578|NCT00318799|prevention of unintended pregnancies
1417579|NCT00318773|PMS
1417580|NCT00318773|PMDD
1417581|NCT00318773|sertraline
1417582|NCT00318773|antidepressant
1417583|NCT00318773|extended treatment
1417584|NCT00318773|relapse
1417585|NCT00318760|Drug Cue
1417586|NCT00318760|Relapse
1417587|NCT00318760|Stress
1417588|NCT00318760|Craving
1417589|NCT00318747|Amb a 1-Immunostimulatory Oligodeoxyribonucleotide Conjugate
1417590|NCT00318747|AIC
1417591|NCT00318747|Amb a I Protein
1417592|NCT00318747|Ragweed Allergy
1417593|NCT00318747|Hay Fever
1417594|NCT00318747|Wheeze
1417595|NCT00318747|Immunotherapy
1417596|NCT00318747|Tolerance
1417597|NCT00318747|Immunostimulatory
1417598|NCT00318747|Ragweed Season
1417599|NCT00318747|Asthma
1417600|NCT00318747|Asthmatics
1417601|NCT00318747|Asthmatic
1417602|NCT00318721|Leishmania donovani
1417603|NCT00318721|cluster-randomised control trial
1417604|NCT00318721|Long Lasting Impregnated Nets
1417605|NCT00318721|Bednets
1417606|NCT00318721|Sandflies
1417607|NCT00318695|Probiotics
1417608|NCT00318695|Eczema
1417609|NCT00318695|Asthma
1417610|NCT00318695|Allergic Rhinitis
1417611|NCT00318695|Prevention
1417612|NCT00318695|Immunological responses
1417613|NCT00318682|biopsy
1417614|NCT00318682|FIBROSCAN
1417615|NCT00318669|Anxiety
1417616|NCT00318669|SAD
1417617|NCT00318669|Social
1417618|NCT00318669|Disorder
1417619|NCT00318656|type 2 diabetes
1417620|NCT00318656|rosiglitazone
1417621|NCT00318656|metformin
1417622|NCT00318656|glimepiride
1417623|NCT00318656|glycemia
1417624|NCT00318643|Non-invasive bladder cancer
1417625|NCT00318643|Chemophase
1417626|NCT00318643|Intravesical administration
1417627|NCT00318643|Superficial Bladder Cancer
1417628|NCT00318630|Asthma AVANDIA Inflammation
1417629|NCT00318617|peroxisome proliferator activated receptors,
1417630|NCT00318617|PPARs,
1417631|NCT00318617|Heart Failure,
1417632|NCT00318617|cardiac energetics,
1417633|NCT00318617|MRI,
1417634|NCT00318617|GW501516X
1417635|NCT00318617|fatty acid metabolism,
1417636|NCT00318604|plasma circulating DNA
1417637|NCT00318604|hean and neck cancers
1417638|NCT00318604|esophageal cancer
1417639|NCT00318604|localized head and neck cancers
1417640|NCT00318604|localized esophageal cancer
1417641|NCT00318578|convulsive status epilepticus
1417642|NCT00318578|outcome
1417643|NCT00318578|prognosis factors
1417644|NCT00318578|seizure duration
1417645|NCT00318578|adult
1417646|NCT00318578|electroencephalogram
1417647|NCT00318578|intensive care unit
1417648|NCT00318565|Heart Disease
1417649|NCT00318565|Atrial Flutter
1417650|NCT00318565|Typical Atrial Flutter
1417651|NCT00318552|Antibiotic Therapy
1417652|NCT00318552|sepsis treatment
1417653|NCT00318552|Meropenem
1417654|NCT00318539|Obsessive Compulsive Disorder
1417655|NCT00318513|breast cancer
1417656|NCT00318513|lymphedema
1417657|NCT00318513|extremity
1417658|NCT00318513|women
1417659|NCT00318500|Endometriosis
1417660|NCT00318500|Dysmenorrhea
1417661|NCT00318500|Pelvic pain
1417662|NCT00318500|Dyspareunia
1417663|NCT00318487|Dental implants
1417664|NCT00318474|Proteinuria
1417665|NCT00318474|Immunoglobulin A
1417666|NCT00318448|Child Psychology
1417667|NCT00318448|Pediatric Psychology
1417668|NCT00318448|Insomnia
1417669|NCT00318448|Sleeplessness
1417670|NCT00318409|Methamphetamine
1417671|NCT00318409|HIV
1417672|NCT00318396|THA
1417673|NCT00318383|Vaccine
1417674|NCT00318383|Immunogenicity
1417675|NCT00318383|Randomized Controlled Trial
1417676|NCT00318370|Ovarian Cancer
1417677|NCT00318370|Primary Fallopian Tube Cancer
1417678|NCT00318370|Peritoneal Cancer
1417679|NCT00318357|Cardiac Resynchronization therapy (CRT)
1417680|NCT00318357|All-cause mortality
1417681|NCT00318357|Long-term follow-up
1417682|NCT00317369|OPC-6535
1417683|NCT00317369|Crohn's disease
1417684|NCT00317356|OPC-6535
1417685|NCT00317356|ulcerative colitis
1417686|NCT00317343|Patients candidate to a PCI with a planned anticoagulation regime other than unfractionated heparin in monotherapy
1417687|NCT00317317|IVF
1417688|NCT00317317|Acupuncture
1417689|NCT00317317|Pregnant
1417690|NCT00317304|Hot flashes
1417691|NCT00317304|vasomotor symptoms
1417692|NCT00317304|menopause
1417693|NCT00317304|mindfulness based stress reduction
1417694|NCT00317304|meditation
1417695|NCT00317291|Acupuncture
1417696|NCT00317291|HIV
1417697|NCT00317291|AIDS
1417698|NCT00317291|Symptom management
1417699|NCT00317291|Non-invasive
1417700|NCT00317291|Complementary Therapies
1417701|NCT00317291|Treatment Experienced
1417702|NCT00317278|Massage
1417703|NCT00317278|immune system
1417704|NCT00317278|preterm infants
1417705|NCT00317265|coronary artery disease
1417706|NCT00317265|coronary bypass surgery
1417707|NCT00317265|complete arterial coronary surgery
1417708|NCT00317265|internal mammary artery
1417709|NCT00317252|contrast induced nephropathy
1417710|NCT00317252|contrast nephropathy
1417711|NCT00317252|contrast media
1417712|NCT00317252|kidney diseases
1417713|NCT00317252|angiotensin converting enzyme inhibitors
1417714|NCT00317239|Anemia
1417715|NCT00317239|Chronic Kidney Disease
1417716|NCT00317239|Iron
1417717|NCT00317226|Anemia
1417718|NCT00317226|CKD
1417719|NCT00317226|Chronic Kidney Disease
1417720|NCT00317226|Iron
1417721|NCT00317226|Maintenance Dose
1417722|NCT00317213|Smoking
1417723|NCT00317213|Nicotine
1417724|NCT00317213|Withdrawal
1417725|NCT00317213|Phospholipids
1417726|NCT00317213|Cell membrane fluidity
1417727|NCT00317213|Smoking cessation
1417728|NCT00318331|Glutamine
1417729|NCT00318331|Critical Illness
1417730|NCT00318331|Enteral Feeding
1417731|NCT00318331|Blood Volume Analysis
1417732|NCT00318318|Premarin,
1417733|NCT00318318|HRT,
1417734|NCT00318318|RNA,
1417735|NCT00318318|Gene Expression.
1417736|NCT00318318|Postmenopausal Women
1417737|NCT00318292|preemptive analgesia
1417738|NCT00318292|paracervical block
1417739|NCT00318292|vaginal hysterectomy
1417740|NCT00318279|Surgical education
1417741|NCT00318279|Vascular anastomosis
1417742|NCT00318279|Simulator
1417743|NCT00318279|Randomized controlled trial
1417744|NCT00318266|Detection of Bladder Cancer using NMP22 Urine Test Kit
1417745|NCT00318253|Cranberry juice
1417746|NCT00318253|Antiadhesion
1417747|NCT00318253|Urinary tract infection
1417748|NCT00318253|vaginosis
1417749|NCT00318240|High Intensity Focused Ultrasound
1417750|NCT00318240|Men
1417751|NCT00318240|Locally recurrent prostate cancer.
1417752|NCT00318227|Postoperative care
1417753|NCT00318227|Cardiac Surgery
1417754|NCT00318227|Blood Transfusion
1417755|NCT00318214|toe ulcer
1417756|NCT00318214|heel ulcer
1417757|NCT00318214|foot ulcer
1417758|NCT00318214|diabetic feet
1417759|NCT00318214|diabetic foot
1417760|NCT00318214|complications of diabetes
1417761|NCT00318201|Healthy Subjects
1417762|NCT00318188|scleroderma
1417763|NCT00318188|HAQ
1417764|NCT00318188|Intensive care reeducation, readaptation
1417765|NCT00318175|Systemic Scleroderma
1417766|NCT00318175|Dermal Sclerosis
1417767|NCT00318175|Bosentan
1417768|NCT00318175|Endothelin Receptor Antagonist
1417769|NCT00318175|Rodnan Skin Score
1417770|NCT00318162|autism
1417771|NCT00318162|PDD
1417772|NCT00318162|LDN
1417773|NCT00318162|naltrexone
1417774|NCT00318136|BRIDGE
1417775|NCT00318136|NSCLC
1417776|NCT00318136|Lung Cancer
1417777|NCT00318136|Avastin
1417778|NCT00318123|Simplification therapy
1417779|NCT00318123|Efficacy
1417780|NCT00318123|Safety
1417781|NCT00318123|Virological effectiveness
1417782|NCT00318123|Immunological effectiveness
1417783|NCT00318123|HIV
1417784|NCT00318110|Metastatic
1417785|NCT00318110|Renal
1417786|NCT00318110|Cell
1417787|NCT00318110|Carcinoma
1417788|NCT00318110|Unrelated
1417789|NCT00318110|Donor
1417790|NCT00318110|Transplant
1417791|NCT00318110|stage IV
1417792|NCT00318110|clear cell
1417793|NCT00318097|McCune Albright Syndrome
1417794|NCT00318097|Histamine regulation
1417795|NCT00318084|Gastroesophageal reflux disease
1417796|NCT00318084|Heartburn
1417797|NCT00318084|Acid-related diseases
1417798|NCT00318084|Acid reflux disease
1417799|NCT00318084|Nexium
1417800|NCT00318071|Stroke
1417801|NCT00318071|Ischemic
1417802|NCT00318071|Thrombus
1417803|NCT00318071|Embolectomy
1417804|NCT00318071|Thrombectomy
1417805|NCT00318071|Merci
1417806|NCT00318071|Concentric
1417807|NCT00318071|Embolus
1417808|NCT00318071|Embolism
1417809|NCT00318071|Mechanical
1417810|NCT00318045|Refractive error
1417811|NCT00318045|Asthenopia
1417812|NCT00318032|Randomised control trial
1417813|NCT00318032|Screening
1417814|NCT00318032|Intensive management
1417815|NCT00318032|Diabetes mellitus
1417816|NCT00318032|Type 2 diabetes
1417817|NCT00318019|Energy
1417818|NCT00318019|Energy Level
1417819|NCT00318006|chronic
1417820|NCT00318006|nasal
1417821|NCT00318006|sinus
1417822|NCT00318006|symptoms
1417823|NCT00317980|Cutaneous leishmaniasis
1417824|NCT00317980|Leishmania braziliensis
1417825|NCT00317980|Pentavalent antimony
1417826|NCT00317980|Meglumine antimoniate
1417827|NCT00317967|Hypertrophic cardiomyopathy
1417828|NCT00317967|Statin therapy
1417829|NCT00317967|Regression
1417830|NCT00317967|Heart failure
1417831|NCT00317967|Arrhythmias
1417832|NCT00317967|Sudden cardiac death
1417833|NCT00317954|Diabetic nephropathy
1417834|NCT00317954|Spironolactone
1417835|NCT00317954|Aldosterone antagonism
1417836|NCT00317954|Renoprotection
1417837|NCT00317941|Multiple Sclerosis
1417838|NCT00317941|RRMS
1417839|NCT00317928|Polycystic Ovary Syndrome
1417840|NCT00317928|Metformin
1417841|NCT00317928|Metabolic Syndrome
1417842|NCT00317928|Hyperandrogenism
1417843|NCT00317928|Ovulation
1417844|NCT00317902|Anemia
1417845|NCT00317902|erythropoetin
1417846|NCT00317902|Epoetin alfa
1417847|NCT00317902|erythropoetin recombinant
1417848|NCT00317902|HIV, AIDS
1417849|NCT00317889|THA
1417850|NCT00317876|Fanconi anemia
1417851|NCT00317837|Fracture of Femoral Neck
1417852|NCT00317811|stage I multiple myeloma
1417853|NCT00317811|stage II multiple myeloma
1417854|NCT00317811|stage III multiple myeloma
1417855|NCT00317798|drug/agent toxicity by tissue/organ
1417856|NCT00317798|stage I multiple myeloma
1417857|NCT00317798|stage II multiple myeloma
1417858|NCT00317798|stage III multiple myeloma
1417859|NCT00317798|refractory multiple myeloma
1417860|NCT00317785|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1417861|NCT00317785|adult acute myeloid leukemia with inv(16)(p13;q22)
1417862|NCT00317785|adult acute myeloid leukemia with t(15;17)(q22;q12)
1417863|NCT00317785|adult acute myeloid leukemia with t(16;16)(p13;q22)
1417963|NCT00317707|obesity
1417864|NCT00317785|adult acute myeloid leukemia with t(8;21)(q22;q22)
1417865|NCT00317785|accelerated phase chronic myelogenous leukemia
1417866|NCT00317785|adult acute lymphoblastic leukemia in remission
1417867|NCT00317785|adult acute myeloid leukemia in remission
1417868|NCT00317785|blastic phase chronic myelogenous leukemia
1417869|NCT00317785|chronic phase chronic myelogenous leukemia
1417870|NCT00317785|de novo myelodysplastic syndromes
1417871|NCT00317785|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1417872|NCT00317785|nodal marginal zone B-cell lymphoma
1417873|NCT00317785|noncontiguous stage II adult Burkitt lymphoma
1417874|NCT00317785|noncontiguous stage II adult diffuse large cell lymphoma
1417875|NCT00317785|noncontiguous stage II adult diffuse mixed cell lymphoma
1417876|NCT00317785|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1417877|NCT00317785|noncontiguous stage II adult immunoblastic large cell lymphoma
1417878|NCT00317785|noncontiguous stage II adult lymphoblastic lymphoma
1417879|NCT00317785|noncontiguous stage II grade 1 follicular lymphoma
1417880|NCT00317785|noncontiguous stage II grade 2 follicular lymphoma
1417881|NCT00317785|noncontiguous stage II grade 3 follicular lymphoma
1417882|NCT00317785|noncontiguous stage II mantle cell lymphoma
1417883|NCT00317785|noncontiguous stage II marginal zone lymphoma
1417884|NCT00317785|noncontiguous stage II small lymphocytic lymphoma
1417885|NCT00317785|previously treated myelodysplastic syndromes
1417886|NCT00317785|recurrent adult acute lymphoblastic leukemia
1417887|NCT00317785|recurrent adult acute myeloid leukemia
1417888|NCT00317785|recurrent adult Burkitt lymphoma
1417889|NCT00317785|recurrent adult Hodgkin lymphoma
1417890|NCT00317785|recurrent adult diffuse large cell lymphoma
1417891|NCT00317785|recurrent adult diffuse mixed cell lymphoma
1417892|NCT00317785|recurrent adult diffuse small cleaved cell lymphoma
1417893|NCT00317785|recurrent adult immunoblastic large cell lymphoma
1417894|NCT00317785|recurrent adult lymphoblastic lymphoma
1417895|NCT00317785|recurrent cutaneous T-cell non-Hodgkin lymphoma
1417896|NCT00317785|recurrent grade 1 follicular lymphoma
1417897|NCT00317785|recurrent grade 2 follicular lymphoma
1417898|NCT00317785|recurrent grade 3 follicular lymphoma
1417899|NCT00317785|recurrent mantle cell lymphoma
1417900|NCT00317785|recurrent marginal zone lymphoma
1417901|NCT00317785|recurrent mycosis fungoides/Sezary syndrome
1417902|NCT00317785|recurrent small lymphocytic lymphoma
1417903|NCT00317785|relapsing chronic myelogenous leukemia
1417904|NCT00317785|secondary acute myeloid leukemia
1417905|NCT00317785|secondary myelodysplastic syndromes
1417906|NCT00317785|splenic marginal zone lymphoma
1417907|NCT00317785|stage III adult Burkitt lymphoma
1417908|NCT00317785|stage III adult Hodgkin lymphoma
1417909|NCT00317785|stage III adult diffuse large cell lymphoma
1417910|NCT00317785|stage III adult diffuse mixed cell lymphoma
1417911|NCT00317785|stage III adult diffuse small cleaved cell lymphoma
1417912|NCT00317785|stage III adult immunoblastic large cell lymphoma
1417913|NCT00317785|stage III adult lymphoblastic lymphoma
1417914|NCT00317785|stage III grade 1 follicular lymphoma
1417915|NCT00317785|stage III grade 2 follicular lymphoma
1417916|NCT00317785|stage III grade 3 follicular lymphoma
1417917|NCT00317785|stage III mantle cell lymphoma
1417918|NCT00317785|stage III marginal zone lymphoma
1417919|NCT00317785|stage III small lymphocytic lymphoma
1417920|NCT00317785|stage IV adult Burkitt lymphoma
1417921|NCT00317785|stage IV adult Hodgkin lymphoma
1417922|NCT00317785|stage IV adult diffuse large cell lymphoma
1417923|NCT00317785|stage IV adult diffuse mixed cell lymphoma
1417924|NCT00317785|stage IV adult diffuse small cleaved cell lymphoma
1417925|NCT00317785|stage IV adult immunoblastic large cell lymphoma
1417926|NCT00317785|stage IV adult lymphoblastic lymphoma
1417927|NCT00317785|stage IV grade 1 follicular lymphoma
1417928|NCT00317785|stage IV grade 2 follicular lymphoma
1417929|NCT00317785|stage IV grade 3 follicular lymphoma
1417930|NCT00317785|stage IV mantle cell lymphoma
1417931|NCT00317785|stage IV marginal zone lymphoma
1417932|NCT00317785|stage IV small lymphocytic lymphoma
1417933|NCT00317772|Epithelial Ovarian Cancer
1417934|NCT00317772|Peritoneal Cancer
1417935|NCT00317772|Fallopian Tube Cancer
1417936|NCT00317772|Epidermal Growth Factor
1417937|NCT00317772|Platinum Hypersensitivity
1417938|NCT00317772|Hycamtin
1417939|NCT00317772|Gefitinib
1417940|NCT00317772|Iressa
1417941|NCT00317772|Topotecan
1417942|NCT00317772|EGFR
1417943|NCT00317759|stage IV melanoma
1417944|NCT00317759|recurrent melanoma
1417945|NCT00317746|HIV/HCV Co-infection
1417946|NCT00317746|Depression
1417947|NCT00317746|Citalopram
1417948|NCT00317733|Ketoprofen
1417949|NCT00317733|Transfersome
1417950|NCT00317733|Osteoarthritis, Knee
1417951|NCT00317720|Breast Cancer
1417952|NCT00317720|Metastatic Breast Cancer
1417953|NCT00317720|Trastuzumab
1417954|NCT00317720|RAD001
1417955|NCT00317720|Herceptin
1417956|NCT00317707|cardiovascular risk
1417957|NCT00317707|cardiovascular diseases
1417958|NCT00317707|cardiovascular prevention
1417959|NCT00317707|polyunsaturated fatty acids
1417960|NCT00317707|diabetes
1417961|NCT00317707|hypertension
1417962|NCT00317707|hypercholesterolemia
1417964|NCT00317694|Hyperphosphatemia
1417965|NCT00317694|Phosphate binder
1417966|NCT00317681|Cutaneous lupus erythematosus
1417967|NCT00317681|Tacrolimus ointment
1417968|NCT00317681|Topical treatment
1417969|NCT00317681|Skin lesions
1417970|NCT00317655|back pain
1417971|NCT00317642|acute myelogenous leukemia
1417972|NCT00317642|acute myeloid leukemia
1417973|NCT00317642|relapsed AML
1417974|NCT00317642|refractory AML
1417975|NCT00317642|clofarabine
1417976|NCT00317642|cytarabine
1417977|NCT00317642|CLO341
1417978|NCT00317642|clolar
1417979|NCT00317629|leishmaniasis
1417980|NCT00317629|nitric oxide
1417981|NCT00317629|treatment
1417982|NCT00317629|donor
1417983|NCT00317629|controlled trial
1417984|NCT00317616|FALS
1417985|NCT00317616|SOD1
1417986|NCT00317616|familial
1417987|NCT00317616|genetic testing
1417988|NCT00317616|genetic counseling
1417989|NCT00317616|ALS
1417990|NCT00317616|C9ORF72
1417991|NCT00317616|TARDBP
1417992|NCT00317616|VCP
1417993|NCT00317616|FUS
1417994|NCT00317616|PFN1
1417995|NCT00317603|autologous vaccination
1417996|NCT00317603|GM-CSF
1417997|NCT00317603|adenoviral mediated gene transfer
1417998|NCT00317603|Stage IV breast cancer
1417999|NCT00317590|Diagnosis
1418000|NCT00317590|Rapid Diagnostic Test
1418001|NCT00317590|Management
1418002|NCT00317590|Attributable Fraction
1418003|NCT00317590|Threshold
1418004|NCT00317577|Low-pressure glaucoma
1418005|NCT00317577|Normal tension glaucoma
1418006|NCT00317577|Neuroprotection
1418007|NCT00317577|Brimonidine
1418008|NCT00317577|Visual field progression
1418009|NCT00317564|Birth Defects
1418010|NCT00317564|High Risk Pregnancy
1418011|NCT00317564|Multiple Sclerosis
1418012|NCT00317551|Aberration control
1418013|NCT00317551|Accommodative facility
1418014|NCT00317551|Accommodative response
1418015|NCT00317551|Peripheral refraction
1418016|NCT00317551|Accommodative convergence to accommodation ratio
1418017|NCT00317538|Rheumatoid Arthritis
1418018|NCT00317538|Switching
1418019|NCT00317538|Structural Damage
1418020|NCT00317538|MRI
1418021|NCT00317525|Refractive error
1418022|NCT00317525|Asthenopia
1418023|NCT00317512|Hemoglobin Based Oxygen carrier
1418024|NCT00317512|HBOC 201
1418025|NCT00317512|Percutaneous Revascularization
1418026|NCT00317512|Percutaneous Coronary Intervention
1418027|NCT00317512|Non ST-segment Elevation Myocardial Infarction
1418028|NCT00317512|Tissue Oxygenation
1418029|NCT00317512|Transluminal Percutaneous Coronary Angioplasty
1418030|NCT00317486|pulmonary arterial hypertension
1418031|NCT00317486|Eisenmenger physiology
1418032|NCT00317486|bosentan
1418033|NCT00317473|Vaccine
1418034|NCT00317473|Phase 1
1418035|NCT00317473|Plasmodium falciparum
1418036|NCT00317473|Malaria
1418037|NCT00317473|Merozoite surface protein-1
1418038|NCT00317473|MSP-1
1418039|NCT00317473|Falciparum malaria protein 1
1418040|NCT00317473|FMP-1
1418041|NCT00317473|AS02A
1418042|NCT00317460|Drug Abuse
1418043|NCT00317460|Drug Addiction
1418044|NCT00317460|Drug Dependence
1418045|NCT00317460|Drug Use Disorders
1418046|NCT00317460|Drug Use Disorder
1418047|NCT00317460|Substance Abuse
1418048|NCT00317460|Substance Use Disorder
1418049|NCT00317460|Buprenorphine
1418050|NCT00317460|Opiate Addiction
1418051|NCT00317447|Sciatica
1418052|NCT00317447|Lower back pain
1418053|NCT00317447|Prednisone
1418054|NCT00317447|Randomized, controlled clinical trial
1418055|NCT00317434|ovarian cancer
1418056|NCT00317421|Phosphodiesterase 5
1418057|NCT00317421|Sildenafil
1418058|NCT00317421|Hypertension
1418059|NCT00317421|Blood pressure
1418060|NCT00317421|Arterial stiffness
1418061|NCT00317421|Endothelial function
1418062|NCT00317408|anaplastic large cell lymphoma
1418063|NCT00317408|recurrent childhood anaplastic large cell lymphoma
1418064|NCT00317408|stage III childhood anaplastic large cell lymphoma
1418065|NCT00317408|stage IV childhood anaplastic large cell lymphoma
1418066|NCT00317395|Non ST elevation Acute Coronary Syndrome
1418067|NCT00317395|Early invasive strategy
1418068|NCT00317395|Percutaneous Coronary Intervention
1418069|NCT00317382|lumbar puncture
1418070|NCT00317382|headache
1418071|NCT00317382|traumatic tap
1418072|NCT00317148|Hot Flashes
1418073|NCT00317148|Menopause
1418074|NCT00317148|Quality of Life
1418075|NCT00317148|Hot flushes
1418076|NCT00317109|meningococcal serogroups A and C diseases
1418077|NCT00317109|tetanus
1418078|NCT00317109|hepatitis B
1418079|NCT00317109|pertussis
1418080|NCT00317109|Haemophilus influenzae type b
1418081|NCT00317109|meningococcal vaccine
1418082|NCT00317109|Prophylaxis diphtheria
1418083|NCT00317096|Drug Therapy
1418084|NCT00317096|Maintenance
1418085|NCT00317096|rituximab
1418086|NCT00317083|Cough Reflex
1418087|NCT00317083|Citric acid
1418088|NCT00317083|Obesity
1418089|NCT00317083|Sleep apnea syndrome
1418090|NCT00317070|PBS/IC
1418091|NCT00317070|Painful bladder syndrome including Interstitial cystitis
1418092|NCT00317057|chronic obstructive pulmonary disease
1418093|NCT00317057|Outpatient management
1418094|NCT00317057|nurse-lead patient education
1418095|NCT00317044|Moderate to severe Asthma
1418096|NCT00317044|Gastroesophageal Reflux Disease
1418097|NCT00317044|esomeprazole
1418098|NCT00317044|GERD
1418099|NCT00317031|Alcoholism
1418100|NCT00317031|Drug Therapy
1418101|NCT00317018|depression
1418102|NCT00317018|quality improvement
1418103|NCT00317018|implementation
1418104|NCT00317018|translation
1418105|NCT00317018|evidence-based practice
1418106|NCT00317018|collaborative care
1418107|NCT00317018|adoption
1418108|NCT00317018|sustainability
1418109|NCT00317018|cost-effectiveness
1418110|NCT00317018|rural
1418111|NCT00317005|hemodialysis
1418112|NCT00317005|chronic uremia
1418113|NCT00317005|hyperhomocysteinemia
1418114|NCT00317005|folate
1418115|NCT00316992|Insomnia
1418116|NCT00316992|Chronic Obstructive Pulmonary Disease
1418117|NCT00316992|Drug Therapy
1418118|NCT00316979|migraine
1418119|NCT00316979|transcranial magnetic stimulation
1418120|NCT00316979|repetitive transcranial magnetic stimulation
1418121|NCT00316979|rTMS
1418122|NCT00316966|Nutritional status, dietary intervention, health care use, costs
1418123|NCT00316940|stage I multiple myeloma
1418124|NCT00316940|stage II multiple myeloma
1418125|NCT00316940|stage III multiple myeloma
1418126|NCT00316940|refractory multiple myeloma
1418127|NCT00316927|adenocarcinoma of the prostate
1418128|NCT00316927|stage III prostate cancer
1418129|NCT00316927|stage IV prostate cancer
1418130|NCT00316914|neurotoxicity
1418131|NCT00316914|stage II colon cancer
1418132|NCT00316914|stage III colon cancer
1418133|NCT00316914|adenocarcinoma of the colon
1418134|NCT00316914|stage II rectal cancer
1418135|NCT00316914|stage III rectal cancer
1418136|NCT00316914|stage IV rectal cancer
1418137|NCT00316914|stage IV colon cancer
1418138|NCT00316914|adenocarcinoma of the rectum
1418139|NCT00316901|stage IV renal cell cancer
1418140|NCT00316901|stage IV melanoma
1418141|NCT00316901|recurrent melanoma
1418142|NCT00316901|recurrent renal cell cancer
1418143|NCT00316888|squamous cell carcinoma of the anus
1418144|NCT00316888|stage I anal cancer
1418145|NCT00316888|stage II anal cancer
1418146|NCT00316888|stage IIIA anal cancer
1418147|NCT00316888|stage IIIB anal cancer
1418148|NCT00316888|basaloid carcinoma of the anus
1418149|NCT00316888|cloacogenic carcinoma of the anus
1418150|NCT00316875|stage IV breast cancer
1418151|NCT00316875|recurrent breast cancer
1418152|NCT00316875|male breast cancer
1418153|NCT00316862|adenocarcinoma of the esophagus
1418154|NCT00316862|stage II esophageal cancer
1418155|NCT00316862|stage III esophageal cancer
1418156|NCT00316836|stage I breast cancer
1418157|NCT00316836|stage II breast cancer
1418158|NCT00316836|stage IIIA breast cancer
1418159|NCT00316823|thyroid cancer
1418160|NCT00316810|Campath 1H
1418161|NCT00316810|Alemtuzumab
1418162|NCT00316810|Tacrolimus
1418163|NCT00316810|Pancreas-kidney transplantation
1418164|NCT00316810|immunosuppression
1418165|NCT00316810|prevention of acute rejection
1418166|NCT00316797|SPECT
1418167|NCT00316797|Nuclear Medicine
1418168|NCT00316784|osteoarthritis; knee; IDEA-033
1418169|NCT00316745|irinotecan
1418170|NCT00316745|S-1
1418171|NCT00316745|Oxaliplatin
1418172|NCT00316745|l-leucovorin
1418173|NCT00316745|Fluorouracil
1418174|NCT00316745|Metastatic colorectal cancer
1418175|NCT00316745|phase III
1418176|NCT00316732|Avodart
1418177|NCT00316732|IPSS
1418178|NCT00316732|BPH
1418179|NCT00316732|dutasteride
1418180|NCT00316732|EQ-5D
1418181|NCT00316732|Observational
1418182|NCT00316719|treatment naive
1418183|NCT00316719|CHB
1418184|NCT00316719|adefovir
1418185|NCT00316719|monotherapy
1418186|NCT00316706|Prophylaxis HPV-16/18 infections and cervical neoplasia
1418187|NCT00316693|HPV Vaccine Efficacy
1418188|NCT00316667|epidemiology
1418189|NCT00316667|risk factors
1418190|NCT00316654|Prevention of Meningococcal Meningitis
1418191|NCT00316654|vaccines, conjugate
1418192|NCT00316654|immunology
1418193|NCT00316654|child
1418194|NCT00316654|antibody persistence
1418195|NCT00316628|influenza
1418196|NCT00316628|elderly
1418197|NCT00316628|vaccine
1418198|NCT00316615|influenza
1418199|NCT00316615|non elderly adult and elderly
1418200|NCT00316615|vaccine
1418201|NCT00316602|Atopic dermatitis
1418202|NCT00316602|Smallpox
1418203|NCT00316602|Vaccination
1418204|NCT00316589|HIV
1418205|NCT00316589|treatment experienced
1418206|NCT00316589|treatment vaccinia naive
1418207|NCT00316576|Kidney failure, Acute
1418208|NCT00316576|Genetic Polymorphism
1418209|NCT00316576|Angiotensin-converting enzyme
1418210|NCT00316563|cannabinoids
1418211|NCT00316563|taste disorders
1418212|NCT00316563|olfaction disorders
1418213|NCT00316563|cancer
1418214|NCT00316563|palliative medicine
1418215|NCT00316563|caloric intake
1418216|NCT00316563|appetite
1418217|NCT00316563|reward
1418218|NCT00316563|tetrahydrocannabinol/therapeutic use
1418219|NCT00316563|anorexia/drug therapy
1418220|NCT00316563|quality of life
1418221|NCT00316563|chemosensory changes/drug therapy
1418222|NCT00316550|Irritable Bowel Syndrome (IBS)
1418223|NCT00316537|diabetes
1418224|NCT00316537|foot ulcers
1418225|NCT00316537|nicotine gel
1418226|NCT00316537|wound healing
1418227|NCT00316524|Smallpox
1418228|NCT00316524|Vaccination
1418229|NCT00316524|Prevention
1418230|NCT00316511|advanced solid malignancies
1418231|NCT00316511|B-cell lymphoma
1418232|NCT00316511|Aroplatin
1418233|NCT00316511|L-NDDP
1418234|NCT00316511|MTD
1418235|NCT00316511|advanced solid malignancies or B-cell lymphoma
1418236|NCT00316498|Eye Movement
1418237|NCT00316498|Niemann Pick C
1418238|NCT00316485|Bone
1418239|NCT00316485|Microbiology
1418240|NCT00316485|Dental Pulp Stem Cell
1418241|NCT00316485|Wisdom Teeth
1418242|NCT00316485|Biopsy
1418243|NCT00316485|Third Molar Extraction
1418244|NCT00316472|Hyperphosphatemia
1418245|NCT00316472|End Stage Renal Disease
1418246|NCT00316472|Renal Osteodystrophy
1418247|NCT00316459|Healthy
1418248|NCT00316459|Cardiac
1418249|NCT00316459|Pharmacokinetics
1418250|NCT00316394|Preventive Health Care
1418251|NCT00316394|Annual Health Check-up
1418252|NCT00316394|Primary Care
1418253|NCT00316394|Reminders
1418254|NCT00316381|stem cells
1418255|NCT00316381|acute myocardial infarction
1418256|NCT00316381|regeneration
1418257|NCT00316381|left ventricular ejection fraction
1418258|NCT00316368|Bi-Ventricular pacing post coronary artery bypass graft
1418259|NCT00316368|coronary artery bypass graft
1418260|NCT00316355|Anxiety
1418261|NCT00316355|Behavior therapy
1418262|NCT00316355|Cognitive-behavioral therapy
1418263|NCT00316355|Stepped care
1418264|NCT00316355|Cost-effectiveness
1418265|NCT00316342|Low back pain
1418266|NCT00316342|Industrial workers
1418267|NCT00316342|Recurrent back pain
1418268|NCT00316342|Back supports
1418269|NCT00316342|Back health education
1418270|NCT00316342|Rehabilitation
1418271|NCT00316316|OCD
1418272|NCT00316303|Serious Mental Illness
1418273|NCT00316303|Dual Diagnosis
1418274|NCT00316303|Mental Disorders
1418275|NCT00316303|Substance-Related Disorders
1418276|NCT00316290|ADHD
1418277|NCT00316290|Cognitive Behavioral Therapy
1418278|NCT00316290|Parent Training
1418279|NCT00316277|Opiate Analgesic Dependence
1418280|NCT00316264|Respiratory Syncytial Virus
1418281|NCT00316264|Premature and under 6 mos. of age
1418282|NCT00316264|Chronic Lung Disease over 6 mos. of age
1418283|NCT00316264|palivizumab
1418284|NCT00316264|motavizumab
1418285|NCT00316264|RSV
1418286|NCT00316251|Somatosensory dysfunction
1418287|NCT00316212|Coronary Artery Bypass Graft Surgery involving Cardiopulmonary Bypass
1418288|NCT00316186|chemonaive
1418289|NCT00316186|small cell lung cancer
1418290|NCT00316186|untreated
1418291|NCT00316186|Lung cancer
1418292|NCT00316186|HYCAMTIN
1418293|NCT00316186|first-line
1418294|NCT00316186|extensive disease
1418295|NCT00316173|HYCAMTIN
1418296|NCT00316173|ovarian cancer
1418297|NCT00316173|recurrent
1418298|NCT00316173|relapsed
1418299|NCT00316173|carboplatin
1418300|NCT00316173|topotecan
1418301|NCT00316173|potentially platinum-sensitive
1418302|NCT00316160|sexual dysfunction
1418303|NCT00316160|Depression
1418304|NCT00316160|MDD
1418305|NCT00316147|diphtheria
1418306|NCT00316147|tetanus
1418307|NCT00316147|poliomyelitis
1418308|NCT00316147|pertussis
1418309|NCT00316147|hepatitis B
1418310|NCT00316147|Prophylaxis
1418311|NCT00316147|Haemophilus influenza type b diseases
1418312|NCT00316134|Pleural Diseases
1418313|NCT00316134|Pleural Effusion
1418314|NCT00316134|Pleural Effusion, Malignant
1418315|NCT00316134|Pleural Neoplasms
1418316|NCT00316134|Neoplasms, Pleural
1418317|NCT00316121|One or Two Level Degenerative Disc Disease
1418318|NCT00316108|Carotid
1418319|NCT00316108|Carotid Artery Stenting
1418320|NCT00316108|Stent
1418321|NCT00316108|Carotid Endarterectomy
1418322|NCT00316108|Stroke
1418323|NCT00316108|Transient Ischemic Attack
1418324|NCT00316108|Stenosis
1418325|NCT00316108|Atherosclerotic Disease
1418326|NCT00316069|Erythropoiesis
1418327|NCT00316069|Leukapheresis
1418328|NCT00316069|G-CSF
1418329|NCT00316069|Mobilization
1418330|NCT00316069|Stem Cells
1418331|NCT00316069|Apheresis
1418332|NCT00316069|Blood Donation
1418333|NCT00316069|Healthy Volunteer
1418334|NCT00316069|HV
1418335|NCT00316056|Genetic Literacy
1418336|NCT00316056|Learning
1418337|NCT00316056|Genetic Knowledge
1418338|NCT00316056|Public Understanding of Science
1418339|NCT00316056|Science Education
1418340|NCT00316056|Healthy Volunteer
1418341|NCT00316056|HV
1418342|NCT00316043|Urinary tract infections
1418343|NCT00316043|Renal failure
1418344|NCT00316043|Renal scarring
1418345|NCT00316043|Prevention
1418346|NCT00316043|Primary Care
1418347|NCT00316043|General Practice
1418348|NCT00316043|Intervention Studies
1418349|NCT00316043|Children
1418350|NCT00316030|AML
1418351|NCT00316030|Acute Myeloid Leukemia
1418352|NCT00316030|Bexarotene
1418353|NCT00316030|Leukemia
1418354|NCT00316017|Trauma
1418355|NCT00316017|Shock
1418356|NCT00316004|Traumatic
1418357|NCT00316004|Brain injury
1418358|NCT00315991|BG perception
1418359|NCT00315991|hypoglycemic awareness
1418360|NCT00315991|pediatric T1DM
1418361|NCT00315978|Risk Assessment
1418362|NCT00315978|Decision Support Technique
1418363|NCT00315978|Physician-Patient Relations
1418364|NCT00315978|Prevention and Control
1418365|NCT00315965|Diffusion
1418366|NCT00315965|Membrane diffusing capacity
1418367|NCT00315965|Alveolar capillary gas diffusion
1418368|NCT00315965|Transfer factor
1418369|NCT00315965|Nitric oxide diffusion
1418370|NCT00315952|type 1 diabetes mellitus
1418371|NCT00315952|inhaled insulin
1418372|NCT00315952|Positron Emission Tomography
1418373|NCT00315939|Diabetes
1418374|NCT00315939|hypoglycemic episodes
1418375|NCT00315926|Cardiac morbidity
1418376|NCT00315926|Melatonin
1418377|NCT00315926|Surgery
1418378|NCT00315926|Postoperative
1418379|NCT00315913|Labor
1418380|NCT00315913|Dysfunctional Labor
1418381|NCT00315913|Labor Arrest
1418382|NCT00315913|Primary Cesarean Section Prevention
1418383|NCT00315900|Seroquel
1418384|NCT00315900|Depakote ER
1418385|NCT00315900|Nursing Home
1418386|NCT00315900|Quetiapine
1418387|NCT00315900|Divalproex ER
1418388|NCT00315900|Agitation
1418389|NCT00315887|low back pain
1418390|NCT00315887|opioid
1418391|NCT00315887|transdermal
1418392|NCT00315874|chronic back pain
1418393|NCT00315874|opioid
1418394|NCT00315874|transdermal
1418395|NCT00315861|ovarian carcinoma
1418396|NCT00315861|endometrial carcinoma
1418397|NCT00315861|cervical carcinoma
1418398|NCT00315861|lung carcinoma
1418399|NCT00315848|chronic pain
1418400|NCT00315848|osteoarthritis
1418401|NCT00315848|opioid
1418402|NCT00315848|transdermal
1418403|NCT00315835|postoperative pain
1418404|NCT00315835|opioid
1418405|NCT00315835|transdermal
1418406|NCT00315822|Surgery
1418407|NCT00315822|colon
1418408|NCT00315809|leprosy, Philippines
1418409|NCT00315796|Mind-Body Intervention
1418410|NCT00315796|Distraction
1418411|NCT00315796|Biophilic
1418412|NCT00315796|Cancer
1418413|NCT00315796|pain
1418414|NCT00315796|Bedscapes
1418415|NCT00315796|procedures
1418416|NCT00315796|bone marrow aspirate
1418417|NCT00315796|bone marrow biopsy
1418418|NCT00315783|hypertrophic cardiomyopathy
1418419|NCT00315783|echocardiography
1418420|NCT00315783|magnetic resonance imaging
1418421|NCT00315770|overweight
1418422|NCT00315770|Metabolic syndrome
1418423|NCT00315744|moderate asthma
1418424|NCT00315744|fluticasone
1418425|NCT00315744|children
1418426|NCT00315744|salmeterol
1418427|NCT00315744|steroid-sparing
1418428|NCT00315744|Asthma
1418429|NCT00315731|Bexxar
1418430|NCT00315731|tositumomab and iodine I 131 tositumomab therapeutic regiment
1418431|NCT00315731|fission
1418432|NCT00315731|Non-Hodgkin's lymphoma
1418433|NCT00315731|Iodine I 131 Tositumomab
1418434|NCT00315731|pharmacokinetics
1418435|NCT00315731|tellurium
1418436|NCT00315718|Hintonia latiflora extract
1418437|NCT00315718|Diabetes mellitus type 2
1418438|NCT00315718|HbA1c
1418439|NCT00315718|Safety
1418440|NCT00315718|Liver function tests
1418441|NCT00315705|clofarabine
1418442|NCT00315705|acute leukemia
1418443|NCT00315705|ALL
1418444|NCT00315705|AML
1418445|NCT00315705|clolar
1418446|NCT00315705|CLO218
1418447|NCT00315692|Ovarian Neoplasms
1418448|NCT00315679|recurrent aphthous stomatitis
1418449|NCT00315679|recurrent mouth ulcers
1418450|NCT00315679|pentoxifylline
1418451|NCT00315679|clinical trial
1418452|NCT00315679|double blind
1418453|NCT00315679|placebo controlled
1418454|NCT00315679|randomized
1418455|NCT00315666|Chronic tension-type headache
1418456|NCT00315653|Bladder Cancer
1418457|NCT00315653|Cancer of Bladder
1418458|NCT00315653|Bladder Tumors
1418459|NCT00315653|Cancer of the Bladder
1418460|NCT00315653|Neoplasms, Bladder
1418461|NCT00315640|Elevated IOP due to intravitreal triamcinolone therapy
1418462|NCT00315627|Islet Transplantation
1418463|NCT00315614|Islet Transplantation
1418464|NCT00315601|Telithromycin (drug)
1418465|NCT00315601|Azithromycin (drug)
1418466|NCT00315601|Bronchoalveolar lavage (procedure)
1418467|NCT00315601|Pharmacokinetics
1418468|NCT00315588|Islet Transplantation
1418469|NCT00315575|Dementia
1418470|NCT00315575|brain circulation
1418471|NCT00315575|disease /disorder proneness /risk
1418472|NCT00315575|neuropathology
1418473|NCT00315575|neurophysiology
1418474|NCT00315575|aging
1418475|NCT00315575|apolipoprotein E
1418476|NCT00315575|genotype
1418477|NCT00315575|hemodynamics
1418478|NCT00315575|memory
1418479|NCT00315575|temporal lobe /cortex
1418480|NCT00315562|stroke
1418481|NCT00315562|carotid stenosis
1418482|NCT00315562|carotid endarterectomy
1418483|NCT00315562|timing
1418484|NCT00315549|Tonsillitis
1418485|NCT00315549|pharyngitis
1418486|NCT00315549|penicillin
1418487|NCT00315549|telithromycin
1418488|NCT00315549|ketolides
1418489|NCT00315549|clinical trials
1418490|NCT00315523|Levocetirizine
1418491|NCT00315523|Xyzal
1418492|NCT00315523|Rhinitis
1418493|NCT00315523|Allergic
1418494|NCT00315523|Seasonal
1418495|NCT00315523|Ragweed
1418496|NCT00315510|Ischemia-reperfusion
1418497|NCT00315510|Annexin A5
1418498|NCT00315497|Giant Cell Arteritis
1418499|NCT00315484|Anemia
1418500|NCT00315484|chemotherapy
1418501|NCT00315484|hemoglobin level
1418502|NCT00315484|recombinant human erythropoietin
1418503|NCT00315484|epoetin alfa
1418504|NCT00315484|darbepoetin alfa
1418505|NCT00315471|Vasculitis
1418506|NCT00315458|osteoarthritis
1418507|NCT00315458|opioid
1418508|NCT00315458|transdermal
1418509|NCT00315445|chronic back pain
1418510|NCT00315445|opioid
1418511|NCT00315445|transdermal
1418512|NCT00315432|Natural History, Hepatitis C Infection, HIV Infection, HCV/HIV co-infection Ribavirin, Pegylated Interferon, Interferon
1418513|NCT00315419|Large Granular Lymphocyte Leukemia
1418514|NCT00315419|Amegakaryocytic Thrombocytopenic Purpura
1418515|NCT00315419|Idiopathic Pure Red Cell Aplasia
1418516|NCT00315419|Paroxysmal Nocturnal Hemoglobinuria
1418517|NCT00315406|PAN
1418518|NCT00315406|Periarteritis Nodosa
1418519|NCT00315393|GPA
1418520|NCT00315393|MPA
1418521|NCT00315393|WG
1418522|NCT00315380|EGPA
1418523|NCT00315380|CSS
1418524|NCT00315367|Multiple Sclerosis
1418525|NCT00315367|Memory impairment
1418526|NCT00315354|obesity
1418527|NCT00315354|nutrition
1418528|NCT00315328|Amblyopia
1418529|NCT00315328|Atropine
1418530|NCT00315328|Patching
1418531|NCT00315315|Nasolacrimal duct obstruction
1418532|NCT00315315|Balloon catheter nasolacrimal duct dilation
1418533|NCT00315315|Nasolacrimal intubation
1418534|NCT00315315|Simple Nasolacrimal duct probing
1418535|NCT00315302|Amblyopia
1418536|NCT00315302|Atropine
1418537|NCT00315302|Plano lens
1418538|NCT00315289|Nasolacrimal duct obstruction
1418539|NCT00315289|Simple probing
1418540|NCT00315289|Balloon catheter dilation
1418541|NCT00315289|Nasolacrimal intubation
1418542|NCT00315276|ADHD
1418543|NCT00315263|DNA
1418544|NCT00315263|Genomics
1418545|NCT00315263|SNPs
1418546|NCT00315263|Neonatology
1418547|NCT00315263|Chronic Lung Disease
1418548|NCT00315263|Periventricular Brain Injury
1418549|NCT00315263|Hypoxic Respiratory Failure
1418550|NCT00315250|Parkinson
1418551|NCT00315224|Isolated systolic Hypertension
1418552|NCT00315224|exercise
1418553|NCT00315224|pulse pressure
1418554|NCT00315224|endothelium
1418555|NCT00315211|Small Cell Lung Cancer Recurrent
1418556|NCT00315198|amblyopia
1418557|NCT00315198|patching
1418558|NCT00315198|visual activities
1418559|NCT00315185|Advanced Non-small Cell Lung Cancer
1418560|NCT00315185|First Line Treatment
1418561|NCT00315172|Adipose Tissue
1418562|NCT00315172|Weight Gain
1418563|NCT00315172|Pediatric
1418564|NCT00315172|Body Composition
1418565|NCT00315172|Thermogenesis
1418566|NCT00315172|Exercise
1418567|NCT00315172|Healthy Volunteer
1418568|NCT00315172|HV
1418569|NCT00315159|Squamous
1418570|NCT00315159|Cell
1418571|NCT00315159|Carcinoma
1418572|NCT00315159|Vulva
1418573|NCT00315159|Sentinel Node
1418574|NCT00315146|Body Composition
1418575|NCT00315146|Sarcopenia
1418576|NCT00315146|Weight loss trials
1418577|NCT00315146|Intervention studies
1418578|NCT00315146|Elderly
1418579|NCT00315133|Diabetes mellitus
1418580|NCT00315133|Stem cells
1418581|NCT00315133|Autologous stem cell transplantation
1418582|NCT00315133|Autoimmune diseases
1418583|NCT00315120|Randomized controlled trial
1418584|NCT00315120|Low back pain
1418585|NCT00315120|Spinal manipulative therapy
1418586|NCT00315120|Spinal manipulation
1418587|NCT00315120|Osteopathic manipulation
1418588|NCT00315120|Osteopathic medicine
1418589|NCT00315120|Physical therapy modalities
1418590|NCT00315094|home parenteral nutrition
1418591|NCT00315081|Schizophrenia
1418592|NCT00315081|Hyperprolactinemia
1418593|NCT00315081|Risperidone
1418594|NCT00315081|Bromocriptin
1418595|NCT00315068|arrythmia
1418596|NCT00315068|atrial fibrillation
1418597|NCT00315068|proteins
1418598|NCT00315055|Hepatitis B
1418599|NCT00315055|Polio
1418600|NCT00315055|Diphtheria
1418601|NCT00315055|Pertussis
1418602|NCT00315055|H influenzae type b
1418603|NCT00315042|Tonsillitis
1418604|NCT00315042|pharyngitis
1418605|NCT00315042|penicillin
1418606|NCT00315042|telithromycin
1418607|NCT00315042|ketolides
1418608|NCT00315042|clinical trials
1418609|NCT00315029|Implementation
1418610|NCT00315029|Single embryo transfer
1418611|NCT00315029|ICSI
1418612|NCT00315029|IVF
1418613|NCT00315029|prevention
1418614|NCT00315016|albuminuria
1418615|NCT00315016|eplerenone
1418616|NCT00315016|ACE inhibition
1418617|NCT00315016|renal function
1418618|NCT00315016|endothelial function
1418619|NCT00315003|Otitis Media
1418620|NCT00315003|Suppurative
1418621|NCT00315003|Purulent
1418622|NCT00315003|Ketolide
1418623|NCT00315003|Azithromycin
1418624|NCT00315003|Telithromycin
1418625|NCT00315003|Controlled Clinical Trials
1418626|NCT00314990|Venous thrombosis
1418627|NCT00314990|Deep-vein thrombosis
1418628|NCT00314990|Pulmonary embolism
1418629|NCT00314990|Homocysteine
1418630|NCT00314990|B-vitamins
1418631|NCT00314990|Folate
1418632|NCT00314990|Vitamin B12
1418633|NCT00314990|Vitamin B6
1418634|NCT00314977|Large resectable breast cancer
1418635|NCT00314977|Locally advanced breast cancer
1418636|NCT00314977|Neoadjuvant therapy
1418637|NCT00314951|CDAD, Clostridium difficile, diarrhea
1418638|NCT00314951|Clostridium difficile-Associated Diarrhea
1418639|NCT00314925|advanced carcinoma
1418640|NCT00314925|carcinoid
1418641|NCT00314925|neuroendocrine features
1418642|NCT00314925|oncolytic virus
1418643|NCT00314925|phase I study
1418644|NCT00314925|dose escalation study
1418645|NCT00314925|rhabdomyosarcoma
1418646|NCT00314925|alveolar rhabdomyosarcoma
1418647|NCT00314925|medulloblastoma
1418648|NCT00314925|rhabdoid
1418649|NCT00314925|glioblastoma
1418650|NCT00314925|ewing's sarcoma
1418651|NCT00314925|pediatric oncologies
1418652|NCT00314925|neuroblastoma
1418653|NCT00314925|wilms' tumor
1418654|NCT00314925|retinoblastoma
1418655|NCT00314925|Large cell lung cancer
1418656|NCT00314899|Malaria, Plasmodium falciparum, Kenya, immunity
1418657|NCT00314886|Diet
1418658|NCT00314886|Fiber
1418659|NCT00314886|Irritable Bowel Syndrome
1418660|NCT00314886|Colonic Flora
1418661|NCT00314873|Thymic malignancy
1418662|NCT00314873|Thymic Carcinoma
1418663|NCT00314860|Restless Legs Syndrome
1418664|NCT00314847|Myocardial infarction
1418665|NCT00314847|Cardiogenic shock
1418666|NCT00314847|Extracorporeal Life Support-Impella
1418667|NCT00314834|hemodialysis
1418668|NCT00314834|intradialytic parenteral nutrition
1418669|NCT00314834|oral supplementation
1418670|NCT00314834|survival
1418671|NCT00314834|hospitalization
1418672|NCT00314834|serum albumin
1418673|NCT00314834|prealbumin
1418674|NCT00314834|transthyretin
1418675|NCT00314821|bipolar disorder, ropinirole, depression
1418676|NCT00314808|primary gliomas
1418677|NCT00314808|brain tumors
1418678|NCT00314808|vomiting
1418679|NCT00314808|appetite suppression
1418680|NCT00314808|appetite
1418681|NCT00314795|pure red cell aplasia
1418682|NCT00314795|PRCA
1418683|NCT00314795|chronic kidney disease
1418684|NCT00314795|CKD
1418685|NCT00314795|chronic renal failure
1418686|NCT00314795|CRF
1418687|NCT00314795|anemia
1418688|NCT00314795|erythropoietin
1418689|NCT00314795|EPO
1418690|NCT00314795|erythropoiesis stimulating agent
1418691|NCT00314795|ESA
1418692|NCT00314795|hemoglobin
1418693|NCT00314795|Hb
1418694|NCT00314795|Hgb
1418695|NCT00314795|red blood cell
1418696|NCT00314795|red blood cell production
1418697|NCT00314782|metastatic hormone-refractory prostate cancer (HRPC)
1418698|NCT00314769|Transcranial Direct Current Stimulation (TDCS)
1418699|NCT00314769|Motor Learning
1418700|NCT00314769|Transcranial Magnetic Stimulation (TMS)
1418701|NCT00314769|Cortical Re-Organization
1418702|NCT00314769|Neuroplasticity
1418703|NCT00314769|Neurorehabilitation
1418704|NCT00314769|TBI
1418705|NCT00314769|Stroke
1418706|NCT00314769|Healthy Volunteer
1418707|NCT00314769|HV
1418708|NCT00314756|imiquimod cream
1418709|NCT00314756|nodular basal cell carcinoma
1418710|NCT00314756|curettage
1418711|NCT00314743|Patients with Non-Hodgkins Lymphoma or Multiple Myeloma
1418712|NCT00314704|shock
1418713|NCT00314704|hypotension
1418714|NCT00314704|circulatory failure
1418715|NCT00314704|septic shock
1418716|NCT00314704|cardiogenic shock
1418717|NCT00314691|fetal DNA
1418718|NCT00314691|prenatal diagnosis
1418719|NCT00314691|maternal plasma
1418720|NCT00314691|Diagnostic potential of cell-free fetal DNA circulating in maternal blood
1418721|NCT00314678|Ovarian
1418722|NCT00314678|Peritoneal
1418723|NCT00314665|Sarcoidosis
1418724|NCT00314665|Chronic Uveitis
1418725|NCT00314665|Uveitis
1418726|NCT00314665|Thalidomide
1418727|NCT00314652|Osteoarthritis
1418728|NCT00314652|chronic pain
1418729|NCT00314652|opioid
1418730|NCT00314652|transdermal
1418731|NCT00314626|Antiviral efficacy
1418732|NCT00314626|Tolerability
1418733|NCT00314626|Immunologic response
1418734|NCT00314626|Virologic response
1418735|NCT00314626|HIV
1418736|NCT00314613|Schizophreniform; Schizophrenia; Schizoaffective Disorders
1418737|NCT00314600|Fracture
1418738|NCT00314600|Forearm
1418739|NCT00314600|Midshaft
1418740|NCT00314600|Child
1418741|NCT00314600|Cast
1418742|NCT00314587|fracture
1418743|NCT00314587|forearm
1418744|NCT00314587|midshaft
1418745|NCT00314587|child
1418746|NCT00314587|treatment
1418747|NCT00314574|Persistent Asthma
1418748|NCT00314574|EXTRA
1418749|NCT00314574|Xolair
1418750|NCT00314574|Difficult Breathing
1418751|NCT00314561|Rosiglitazone
1418752|NCT00314561|Pioglitazone
1418753|NCT00314561|FMD
1418754|NCT00314561|PWV
1418755|NCT00314561|atherosclerosis
1418756|NCT00314548|ARDS
1418757|NCT00314548|pulmonary hypertension
1418758|NCT00314548|prostacyclins
1418759|NCT00314509|Asthma
1418760|NCT00314509|Ciclesonide
1418761|NCT00314509|Formoterol Fumarate
1418762|NCT00314509|Long-acting beta2-agonists
1418763|NCT00314509|LABA
1418764|NCT00314509|Steroids
1418765|NCT00314483|Mesenchymal stem cells
1418766|NCT00314483|GVHD
1418767|NCT00314483|Treatment
1418768|NCT00314483|Steroid refractory GVHD
1418769|NCT00314457|pain control
1418770|NCT00314457|intra-articular pain control device
1418771|NCT00314457|ACL repair
1418772|NCT00314457|Bankart Repair
1418773|NCT00314444|Psychogenic
1418774|NCT00314444|Psychogenic Movement Disorders
1418775|NCT00314431|neonatal chronic lung disease
1418776|NCT00314431|bronchopulmonary dysplasia
1418777|NCT00314431|prematurity
1418778|NCT00314431|telephone follow up
1418779|NCT00314431|care coordination
1418780|NCT00314431|children with special health care needs
1418781|NCT00314418|Colonoscopy
1418782|NCT00314418|technique
1418783|NCT00314418|time
1418784|NCT00314418|duration
1418785|NCT00314418|position
1418786|NCT00314418|abdominal pressure
1418787|NCT00314405|sentinel lymph node
1418788|NCT00314405|SLN
1418789|NCT00314405|probe
1418790|NCT00314405|breast cancer
1418791|NCT00314405|lymphoscintigraphy
1418792|NCT00314405|methylene blue dye
1418793|NCT00314392|Experimental pain
1418794|NCT00314392|Placebo analgesia
1418795|NCT00314392|Heart rate variability
1418796|NCT00314392|Skin conductance
1418797|NCT00314379|Diabetes
1418798|NCT00314379|Endothelial Function
1418799|NCT00314379|Haptoglobin
1418800|NCT00314366|stem cell
1418801|NCT00314366|autologous
1418802|NCT00314366|ischemia
1418803|NCT00314353|NSABP
1418804|NCT00314353|bevacizumab
1418805|NCT00314353|capecitabine
1418806|NCT00314353|oxaliplatin
1418807|NCT00314353|irinotecan
1418808|NCT00314353|rectal cancer
1418809|NCT00314353|colon cancer
1418810|NCT00314353|colorectal cancer
1418811|NCT00314340|Chronic Pain
1418812|NCT00314340|Opioids
1418813|NCT00314327|first episode
1418814|NCT00314327|schizophrenia
1418815|NCT00314327|risperidone
1418816|NCT00314314|Bipolar Disorder, memory, executive functioning
1418817|NCT00314301|cerebral palsy
1418818|NCT00314301|resistance
1418819|NCT00314301|movement
1418820|NCT00314301|biomechanics
1418821|NCT00314288|Parkinson's Disease
1418822|NCT00314288|Dyskinesia
1418823|NCT00314288|L-dopa-induced dyskinesia
1418824|NCT00314275|Pharmacokinetics
1418825|NCT00314275|Coronary Artery Disease
1418826|NCT00314275|PCI
1418827|NCT00314275|Drug Eluting Stent
1418828|NCT00314262|Skin Lesions
1418829|NCT00314262|Premalignant Lesion
1418830|NCT00314249|Fibromyalgia
1418831|NCT00314236|Cartilage repair
1418832|NCT00314236|Cartilage
1418833|NCT00314236|Knee
1418834|NCT00314236|Knee Pain
1418835|NCT00314236|Microfracture
1418836|NCT00314236|arthroscopy
1418837|NCT00314236|bone marrow stimulation
1418838|NCT00314236|Chondrogenesis
1418839|NCT00314236|Scaffold
1418840|NCT00314236|Chitosan
1418841|NCT00314236|A02.165.165
1418842|NCT00314236|A10.165.382.332
1418843|NCT00314236|G07.574.500.325.377.625.180
1418844|NCT00314236|A10.165.382.400
1418845|NCT00314236|Articular Cartilage Repair
1418846|NCT00314210|Generalised Anxiety Disorder
1418847|NCT00314197|automated counseling system
1418848|NCT00314197|telephone-based intervention
1418849|NCT00314197|behavior change
1418850|NCT00314184|Bipolar I disorder.
1418851|NCT00314171|open-angle glaucoma
1418852|NCT00314171|ocular hypertension
1418853|NCT00314132|Japanese Encephalitis
1418854|NCT00314132|Encephalitis virus
1418855|NCT00314132|ChimeriVax™-JE Vaccine
1418859|NCT00314106|Clinical Response
1418860|NCT00314106|Stage IV Melanoma
1418861|NCT00314106|Adoptive Cell Therapy
1418862|NCT00314106|Tumor Infiltrating Lymphocytes
1418863|NCT00314106|Immunologic Response
1418864|NCT00314106|Metastatic Melanoma
1418865|NCT00314093|Clinical Response
1418866|NCT00314093|Stage IV Melanoma
1418867|NCT00314093|Immunotoxin
1418868|NCT00314093|T Regulatory Cells
1418869|NCT00314093|CD25+ Cells
1418870|NCT00314093|Metastatic Melanoma
1418871|NCT00314080|Botulism
1418872|NCT00314080|Botulinum anti-toxin
1418873|NCT00314080|Repetitive nerve stimulation
1418874|NCT00314080|Respiratory failure
1418875|NCT00314067|Quality of Health Care
1418876|NCT00314067|Primary Health Care
1418877|NCT00314067|Education
1418878|NCT00314067|E-Learning
1418879|NCT00314067|Alcohol-related Disorders
1418880|NCT00314054|Hepatitis C
1418881|NCT00314054|Hepatic Impairment
1418882|NCT00314054|Healthy Volunteer
1418883|NCT00314054|Phase 1
1418884|NCT00314054|Hepacivirus
1418885|NCT00314041|Infant
1418886|NCT00314041|Conjugate vaccine
1418887|NCT00314041|Meningococcal
1418888|NCT00314041|Antibody
1418889|NCT00314041|Immune memory
1418890|NCT00314041|Health
1418891|NCT00314041|Meningococcal Vaccines
1418892|NCT00314028|African American
1418893|NCT00314028|Men
1418894|NCT00314028|Sexually Transmitted Diseases
1418895|NCT00314028|Condoms
1418896|NCT00314002|Massive pulmonary embolism
1418897|NCT00314002|Catheter thrombectomy
1418898|NCT00313976|Multiple Sclerosis
1418899|NCT00313976|Early secondary progressive Multiple Sclerosis
1418900|NCT00313963|Anemia, Sickle Cell
1418901|NCT00313963|Magnesium Sulfate
1418902|NCT00313963|pediatric
1418903|NCT00313950|measles
1418904|NCT00313950|rubella
1418905|NCT00313950|mumps
1418906|NCT00313950|hepatitis A
1418907|NCT00313924|URGENCY FREQUENCY SYNDROME
1418908|NCT00313924|URGE INCONTINENCE
1418909|NCT00313911|Diphtheria
1418910|NCT00313911|Tetanus
1418911|NCT00313911|Pertussis
1418912|NCT00313911|Recombinant Hepatitis B
1418913|NCT00313911|Poliomyelitis
1418914|NCT00313911|Haemophilus influenzae type b
1418915|NCT00313911|Tetanus protein
1418916|NCT00313898|quality of sexual life, Mild erectile dysfunction
1418917|NCT00313872|gastric cancer
1418918|NCT00313872|chemotherapy
1418919|NCT00313872|irinotecan
1418920|NCT00313872|docetaxel
1418921|NCT00313859|colorectal cancer
1418922|NCT00313859|metastatic
1418923|NCT00313846|Chronic pain
1418924|NCT00313846|opioid
1418925|NCT00313846|transdermal
1418926|NCT00313846|osteoarthritis
1418927|NCT00313833|Chronic pain
1418928|NCT00313833|elderly
1418929|NCT00313833|supervised living
1418930|NCT00313833|opioid
1418931|NCT00313833|transdermal
1418932|NCT00313820|Post-stroke pain, pregabalin
1418933|NCT00313807|contrast nephropathy
1418934|NCT00313807|renal failure
1418935|NCT00313807|Travasol
1418936|NCT00313781|randomized
1418937|NCT00313781|non-comparative
1418938|NCT00313781|efficacy
1418939|NCT00313768|advanced carcinoma, non-small cell lung, Phase II, paclitaxel, Taxol, carboplatin, Paraplatin, bevacizumab, Avastin, PF-3512676, immunotherapy, immunomodulator
1418940|NCT00313755|colonoscopy, narrow band imaging,
1418941|NCT00313755|high definition endoscopy
1418942|NCT00313755|colorectal cancer
1418943|NCT00313755|dysplasia
1418944|NCT00313755|hereditary non-polyposis colorectal cancer
1418945|NCT00313755|Lynch Syndrome
1418946|NCT00313755|HNPCC
1418947|NCT00313729|adult oligodendroglioma
1418948|NCT00313729|adult mixed glioma
1418949|NCT00313729|adult diffuse astrocytoma
1418950|NCT00313729|adult pilocytic astrocytoma
1418951|NCT00313729|adult pineal gland astrocytoma
1418952|NCT00313716|anemia
1418953|NCT00313716|traumatic brain injury
1418954|NCT00313716|recombinant human erythropoietin
1418955|NCT00313716|rhEpo
1418956|NCT00313716|erythropoietin
1418957|NCT00313716|TBI
1418958|NCT00313716|Epo
1418959|NCT00313703|headache
1418960|NCT00313703|emergency department
1418961|NCT00313703|migraine
1418962|NCT00313703|recurrent headache
1418963|NCT00313690|Lung Cancer
1418964|NCT00313677|muscular dystrophy
1418965|NCT00313677|MD
1418966|NCT00313677|fukutin-related protein gene
1418967|NCT00313677|limb girdle
1418968|NCT00313677|FKRP gene
1418969|NCT00313677|congenital muscular dystrophy
1418970|NCT00313677|childhood onset LGMD
1418971|NCT00313677|adult onset LGMD
1418972|NCT00313677|POMT1
1418973|NCT00313677|POMT2
1418974|NCT00313677|POMGnT
1418975|NCT00313677|LARGE
1418976|NCT00313677|alpha dystroglycan
1418977|NCT00313677|dystroglycanopathy
1418978|NCT00313677|ISPD
1418979|NCT00313677|DPM
1418980|NCT00313677|GMPPB
1418981|NCT00313677|B3GNT1
1418982|NCT00313677|B3GALNT2
1418983|NCT00313677|GTDC2
1418984|NCT00313677|TMEM5
1418985|NCT00313677|Fukutin
1418986|NCT00313677|DAG1
1418987|NCT00313677|POMK
1418988|NCT00313625|stage I multiple myeloma
1418989|NCT00313625|stage II multiple myeloma
1418990|NCT00313625|stage III multiple myeloma
1418991|NCT00313625|refractory multiple myeloma
1418992|NCT00313599|recurrent breast cancer
1418993|NCT00313599|stage IV breast cancer
1418994|NCT00313599|recurrent non-small cell lung cancer
1418995|NCT00313599|stage IV non-small cell lung cancer
1418996|NCT00313599|recurrent prostate cancer
1418997|NCT00313599|stage IV prostate cancer
1418998|NCT00313599|recurrent bladder cancer
1418999|NCT00313599|stage IV bladder cancer
1419000|NCT00313599|recurrent gastric cancer
1419001|NCT00313599|stage IV gastric cancer
1419002|NCT00313599|recurrent esophageal cancer
1419003|NCT00313599|stage IV esophageal cancer
1419004|NCT00313599|recurrent ovarian germ cell tumor
1419005|NCT00313599|stage IV ovarian germ cell tumor
1419006|NCT00313599|adult central nervous system germ cell tumor
1419007|NCT00313599|ovarian choriocarcinoma
1419008|NCT00313599|ovarian dysgerminoma
1419009|NCT00313599|ovarian embryonal carcinoma
1419010|NCT00313599|ovarian yolk sac tumor
1419011|NCT00313599|ovarian mixed germ cell tumor
1419012|NCT00313599|recurrent ovarian epithelial cancer
1419013|NCT00313599|stage IV ovarian epithelial cancer
1419014|NCT00313599|recurrent extragonadal non-seminomatous germ cell tumor
1419015|NCT00313599|recurrent extragonadal seminoma
1419016|NCT00313599|stage IV extragonadal non-seminomatous germ cell tumor
1419017|NCT00313599|stage IV extragonadal seminoma
1419018|NCT00313599|recurrent extragonadal germ cell tumor
1419019|NCT00313573|unspecified adult solid tumor, protocol specific
1419020|NCT00313573|pain
1419021|NCT00313573|depression
1419022|NCT00313560|adenocarcinoma of the pancreas
1419023|NCT00313560|stage I pancreatic cancer
1419024|NCT00313560|stage II pancreatic cancer
1419025|NCT00313547|Blood pressure
1419026|NCT00313547|Hypertension
1419027|NCT00313547|Renin
1419028|NCT00313547|Aldosterone
1419029|NCT00313547|Heart rate variability
1419030|NCT00313534|recurrent prostate cancer
1419031|NCT00313534|stage IIB prostate cancer
1419032|NCT00313534|stage IIA prostate cancer
1419033|NCT00313534|stage III prostate cancer
1419034|NCT00313534|stage I prostate cancer
1419035|NCT00313521|untreated childhood cerebellar astrocytoma
1419036|NCT00313521|childhood high-grade cerebral astrocytoma
1419037|NCT00313508|stage IV melanoma
1419038|NCT00313508|recurrent melanoma
1419039|NCT00313508|ciliary body and choroid melanoma, medium/large size
1419040|NCT00313508|recurrent intraocular melanoma
1419041|NCT00313508|metastatic intraocular melanoma
1419042|NCT00313508|extraocular extension melanoma
1419043|NCT00313508|iris melanoma
1419044|NCT00313495|Huntington disease, observational, family members, biomarker
1419045|NCT00313469|Pharmacokinetics/Pharmacodynamics
1419046|NCT00313469|Elderly
1419047|NCT00313469|Anticoagulants
1419048|NCT00313443|Anti-Arrhythmia Agents
1419049|NCT00313443|Amiodarone, chronic treatment
1419050|NCT00313443|Amiodarone, adverse effects
1419051|NCT00313443|Biopsy, Fine-Needle, Adipose tissue
1419052|NCT00313443|Drug concentrations in tissues
1419053|NCT00313443|Drug accumulation in tissues
1419054|NCT00313430|Urine concentration ability
1419055|NCT00313430|chronic renal insufficiency
1419056|NCT00313430|hypertension
1419057|NCT00313430|aquaporin2
1419058|NCT00313430|Patients with chronic renal insufficiency
1419059|NCT00313430|Patients with hypertension
1419060|NCT00313430|Healthy volunteers
1419061|NCT00313417|Creatine
1419062|NCT00313417|major depressive disorders
1419063|NCT00313404|Norovirus
1419064|NCT00313404|Gastroenteritis
1419065|NCT00313404|Clinical Trial
1419066|NCT00313404|Stomach flu
1419067|NCT00313378|Thoracotomy
1419068|NCT00313378|Neuropathic pain
1419069|NCT00313378|Nerve trauma
1419070|NCT00313378|Ketamine
1419071|NCT00313378|NMDA receptors
1419072|NCT00313352|adult
1419073|NCT00313352|cardiac
1419074|NCT00313352|transposition of great arteries
1419075|NCT00313352|beta-adrenergic blockers
1419076|NCT00313339|myocardial infarction
1419077|NCT00313339|bone marrow
1419078|NCT00313339|cd34+
1419079|NCT00313339|stem cells
1419080|NCT00313326|Adaptive Support ventilation
1419081|NCT00313326|Weaning
1419082|NCT00313248|Breast Cancer
1419083|NCT00313248|Metastatic Breast Cancer
1419084|NCT00313235|Dendritic Vaccine
1419085|NCT00313235|Melanoma
1419086|NCT00313235|Cyclophosphamide (CPA)
1419087|NCT00313222|CTEPH
1419088|NCT00313222|bosentan
1419089|NCT00313209|Roflumilast
1419090|NCT00313209|Salmeterol
1419091|NCT00313209|COPD
1419092|NCT00313209|Chronic obstructive pulmonary disease
1419093|NCT00313196|Pulmonary Hypertension
1419094|NCT00313196|Sickle Cell Disease
1419095|NCT00313196|Sickle cell anemia
1419096|NCT00313196|bosentan
1419097|NCT00313196|ASSET
1419098|NCT00313196|ASSET-2
1419099|NCT00313183|Type 1 Diabetes
1419100|NCT00313183|pediatric
1419101|NCT00313183|pramlintide
1419102|NCT00313183|Symlin
1419103|NCT00313183|Amylin
1419104|NCT00313170|oncology
1419105|NCT00313170|cancer
1419106|NCT00313170|breast cancer
1419107|NCT00313157|Atrial fibrillation
1419108|NCT00313131|bacterial vaginosis
1419109|NCT00313131|vaginal candidiasis
1419110|NCT00313131|trichomoniasis
1419111|NCT00313131|vaginitis
1419112|NCT00313131|Ghana
1419113|NCT00313131|Togo
1419114|NCT00313131|Mali
1419115|NCT00313131|Guinea
1419116|NCT00313118|oxidative stress parameters
1419117|NCT00313105|smoking cessation
1419118|NCT00313105|smokeless tobacco
1419119|NCT00313105|nicotine patch
1419120|NCT00313105|nicotine buccal tablets
1419121|NCT00313105|retreatment
1419122|NCT00313105|adherence
1419123|NCT00313092|OSAS
1419124|NCT00313092|glaucoma
1419125|NCT00313092|MMP
1419126|NCT00313066|CTGF
1419127|NCT00313066|fibrogenic cytokine
1419128|NCT00313066|FGF
1419129|NCT00313066|pleural fibrosis
1419130|NCT00313040|physical activity
1419131|NCT00313040|sedentary
1419132|NCT00313040|behavioral medicine
1419133|NCT00313040|motivational interviewing
1419134|NCT00313014|Low back pain
1419135|NCT00313014|opioid
1419136|NCT00313014|transdermal
1419137|NCT00313014|Butrans
1419138|NCT00312988|Ovarian cancer
1419139|NCT00312962|Schizoaffective Disorder
1419140|NCT00312962|Cognitive Remediation
1419141|NCT00312962|fMRI
1419142|NCT00312949|Patient participation
1419143|NCT00312949|Patient education
1419144|NCT00312949|Consumer involvement
1419145|NCT00312936|Medication adherence
1419146|NCT00312936|Medication compliance
1419147|NCT00312936|Quality of Life
1419148|NCT00312936|Stress reduction
1419149|NCT00312936|mindfulness based stress reduction
1419150|NCT00312936|HIV/AIDS
1419151|NCT00312936|treatment experienced
1419152|NCT00312923|HIV
1419153|NCT00312923|lipids
1419154|NCT00312923|dyslipidemia
1419155|NCT00312923|policosanol
1419156|NCT00312923|treatment experienced
1419157|NCT00312910|Cirrhosis
1419158|NCT00312910|Probiotics
1419159|NCT00312910|Hepatic encephalopathy
1419160|NCT00312910|Ammonia
1419161|NCT00312897|Adolescents
1419162|NCT00312897|Depression
1419163|NCT00312897|Fish Oil
1419164|NCT00312897|Omega-3 Fatty Acids
1419165|NCT00312897|Psychiatry
1419166|NCT00312884|telemonitoring
1419167|NCT00312884|heart failure
1419168|NCT00312884|randomised
1419169|NCT00312884|hospitalisation
1419170|NCT00312884|HomMed
1419171|NCT00312871|Chronic renal failure
1419172|NCT00312871|Anemia
1419173|NCT00312871|Renal replacement therapy
1419174|NCT00312871|Epoetin
1419175|NCT00312871|Epoetin alfa
1419176|NCT00312871|erythropoietin
1419177|NCT00312871|Chronic kidney failure
1419178|NCT00312871|end-stage renal disease
1419179|NCT00312858|Hepatitis A Virus
1419180|NCT00312845|B-cell Non-Hodgkin's Lymphoma
1419181|NCT00312832|HIV
1419182|NCT00312832|d4T
1419183|NCT00312832|TDF
1419184|NCT00312832|lipoatrophy
1419185|NCT00312832|treatment experienced
1419186|NCT00312832|HIV-infection
1419187|NCT00312819|Non-small cel lung cancer
1419188|NCT00312819|chemotherapy
1419189|NCT00312819|randomized phaseII
1419190|NCT00312819|disulfiram
1419191|NCT00312819|antiangiogenesis
1419192|NCT00312819|placebo
1419193|NCT00312806|Gastroesophageal Reflux Disease
1419194|NCT00312806|GERD
1419195|NCT00312806|Pantoprazole
1419196|NCT00312806|ReQuestTM
1419197|NCT00312793|Anterior Cruciate Ligament reconstruction surgery
1419198|NCT00312780|albuminuria
1419199|NCT00312780|diabetic nephropathy
1419200|NCT00312780|diabetes
1419201|NCT00312767|Agalsidase beta
1419202|NCT00312767|alpha Galactosidase A
1419203|NCT00312767|aGAL
1419204|NCT00312767|rh aGAL
1419205|NCT00312767|Fabry
1419206|NCT00312767|GL3
1419207|NCT00312767|Fabrazyme
1419208|NCT00312767|dialysis
1419209|NCT00312767|hemodialysis
1419210|NCT00312741|community-acquired pneumonia
1419211|NCT00312741|microbiological tests
1419212|NCT00312741|urinary antigen
1419213|NCT00312741|selection of antibiotic treatment
1419214|NCT00312728|Brain Cancer
1419215|NCT00312728|Brain Metastases
1419216|NCT00312728|Avastin
1419217|NCT00312728|NSCLC
1419218|NCT00312728|Lung Cancer
1419219|NCT00312728|PASSPORT
1419220|NCT00312715|Deiodinase
1419221|NCT00312715|Levothyroxine
1419222|NCT00312715|Liothyronine
1419223|NCT00312715|Lipid Metabolism
1419224|NCT00312715|Healthy Volunteer
1419225|NCT00312715|HV
1419226|NCT00312702|Vaccine
1419227|NCT00312702|Malaria
1419228|NCT00312702|Liver Stage Antigen-1
1419229|NCT00312702|Falciparum Malaria Protein-11
1419230|NCT00312702|AS02A
1419231|NCT00312702|adjuvant
1419232|NCT00312689|congenital
1419233|NCT00312689|lacrimal
1419234|NCT00312689|stenosis
1419235|NCT00312689|bacteria
1419236|NCT00312689|microbiological
1419237|NCT00312676|Tolerability
1419238|NCT00312676|Depakote DR
1419239|NCT00312676|Depakote ER
1419240|NCT00312676|Elderly
1419241|NCT00312676|Conversion
1419242|NCT00312663|Vaccine
1419243|NCT00312663|Phase I/II
1419244|NCT00312663|Malaria
1419245|NCT00312663|Liver Stage Antigen -1
1419246|NCT00312663|Falciparum Malaria Protein -11
1419247|NCT00312663|AS01B
1419248|NCT00312663|adjuvant
1419249|NCT00312650|ovarian cancer
1419250|NCT00312650|recurrent
1419251|NCT00312650|progressive
1419252|NCT00312637|Breast Cancer Staging
1419253|NCT00312624|ICD implantation
1419254|NCT00312624|cardiac MRI
1419255|NCT00312624|cardiomyopathy
1419256|NCT00312624|ventricular arrhythmias
1419257|NCT00312624|LVEF 35% or less
1419258|NCT00312624|indication for ICD implantation as part of standard of care
1419259|NCT00312611|Gastric pacing device
1419260|NCT00312611|Obesity
1419261|NCT00312598|schizophrenia
1419262|NCT00312598|BMI
1419263|NCT00312598|weight
1419264|NCT00312598|aripiprazole
1419265|NCT00312598|antipsychotic
1419266|NCT00312598|Mood Disorders with psychotic features
1419267|NCT00312585|pregnancy
1419268|NCT00312585|acupuncture
1419269|NCT00312572|Osteoarthritis, opioid, transdermal
1419270|NCT00312559|Parkinson's Disease
1419271|NCT00312546|Virus Latency
1419272|NCT00312546|Valproic Acid
1419273|NCT00312546|Histone Deacetylase
1419274|NCT00312533|knee
1419275|NCT00312533|injection
1419276|NCT00312533|function
1419277|NCT00312533|osteoarthritis
1419278|NCT00312507|Meconium Aspiration Syndrome
1419279|NCT00312507|Surfactant
1419280|NCT00312507|Bronchoalveolar Lavage
1419281|NCT00312507|newborns
1419282|NCT00312468|AIDS
1419283|NCT00312455|Substance abuse
1419284|NCT00312455|Depression
1419285|NCT00312455|Aggression
1419286|NCT00312442|Prostate cancer after radiation therapy
1419287|NCT00312429|Hematological Malignancies
1419288|NCT00312429|Leukemia
1419289|NCT00312429|Lymphoma
1419290|NCT00312429|Myelodysplasia
1419291|NCT00312429|Multiple Myeloma
1419292|NCT00312416|Choroidal blood flow
1419293|NCT00312416|Clonidin
1419294|NCT00312416|Brimonidin
1419295|NCT00312403|Glaucoma
1419296|NCT00312403|Gene Polymorphism
1419297|NCT00312403|Metalloproteinase
1419298|NCT00312390|Amblyopia
1419299|NCT00312390|Retinal vessel diameters
1419300|NCT00312390|Retinal blood flow
1419301|NCT00312390|Flicker
1419302|NCT00312377|Non-small cell lung cancer
1419303|NCT00312377|NSCLC
1419304|NCT00312364|toe ulcer
1419305|NCT00312364|heel ulcer
1419306|NCT00312364|foot ulcer
1419307|NCT00312364|diabetic feet
1419308|NCT00312364|diabetic foot
1419309|NCT00312364|complications of diabetes
1419310|NCT00312351|AMD
1419311|NCT00312351|Age-Related Macular Degeneration
1419312|NCT00312351|Macular Degeneration
1419313|NCT00312351|Macugen
1419314|NCT00312351|pegaptanib sodium
1419315|NCT00312351|ERG
1419316|NCT00312351|specular microscopy
1419317|NCT00312351|Age-Related Mcular Degeneration (AMD)
1419318|NCT00312325|Optic nerve head blood flow
1419319|NCT00312325|Choroidal blood flow
1419320|NCT00312325|Prednisolone
1419321|NCT00312325|Graves´ Ophthalmopathy
1419322|NCT00312325|optic neuritis
1419323|NCT00312312|Asthma
1419324|NCT00312312|Allergic rhinitis
1419325|NCT00312312|Atopy
1419326|NCT00312312|Exhaled nitric oxide
1419327|NCT00312312|Specific immunotherapy
1419328|NCT00312312|Atopic diseases
1419329|NCT00312299|Double-Blind Method
1419330|NCT00312299|Clinical Trials, Randomized
1419331|NCT00312299|Lenses, Intraocular
1419332|NCT00312299|Prospective Studies
1419333|NCT00312299|PMMA
1419334|NCT00312299|Visual acuity
1419335|NCT00312286|Cervical Neoplasms
1419336|NCT00312286|Drug Therapy
1419337|NCT00312286|Human Papillomavirus
1419338|NCT00312286|Cervical Human Papillomavirus
1419339|NCT00312286|Cervical Dysplasia
1419340|NCT00312286|Chemoprevention
1419341|NCT00312286|High Risk Cervical Human Papillomavirus
1419342|NCT00312286|Atypical Squamous Cells of Undetermined Significance
1419343|NCT00312286|Low Grade Intraepithelial Lesions
1419344|NCT00312273|Heart Arrest
1419345|NCT00312273|Cardiopulmonary Resuscitation
1419346|NCT00312273|Aminophylline
1419347|NCT00312273|Bradycardia
1419348|NCT00312273|Humans
1419349|NCT00312273|Emergency Medical Services
1419350|NCT00312260|Pain
1419351|NCT00312260|Analgesia
1419352|NCT00312260|Gabapentin
1419353|NCT00312260|Amitriptyline
1419354|NCT00312260|Pediatrics
1419355|NCT00312247|Walking
1419356|NCT00312247|Muscle Strength
1419357|NCT00312247|Energy Cost
1419358|NCT00312247|Quality of Life
1419359|NCT00312234|Muscular Disease
1419360|NCT00312234|Fibromyalgia
1419361|NCT00312234|Exercise Therapy
1419362|NCT00312234|Qigong
1419363|NCT00312234|Aerobic Exercise
1419364|NCT00312234|pediatrics
1419365|NCT00312221|Osteoarthritis, opioid, transdermal
1419366|NCT00312195|Chronic pain
1419367|NCT00312195|opioid
1419368|NCT00312195|transdermal
1419369|NCT00312195|Butrans™ [BTDS]
1419370|NCT00312169|HIV
1419371|NCT00312169|NNRTI
1419372|NCT00312169|Incomplete virologic suppression
1419373|NCT00312169|treatment experienced
1419374|NCT00312143|De novo Kidney Transplant recipients, enteric-coated mycophenolate sodium
1419375|NCT00312130|Vildaglptin
1419376|NCT00312130|Pre-diabetes
1419377|NCT00312117|contrast induced nephropathy
1419378|NCT00312117|sodium bicarbonate
1419379|NCT00312117|cardiac catheterization
1419380|NCT00312091|Pharmacokinetics
1419381|NCT00312091|Treatment Experienced
1419382|NCT00312078|Minimal Hepatic Encephalopathy
1419383|NCT00312078|Cirrhosis
1419384|NCT00312065|servocontrolled
1419385|NCT00312065|radiant warmer
1419386|NCT00312065|thermistor
1419387|NCT00312065|heat shield
1419388|NCT00312052|Coronary Artery Disease
1419389|NCT00312039|HIV-1
1419390|NCT00312039|treatment experienced
1419391|NCT00312026|Plaque Psoriasis
1419392|NCT00312026|Hands
1419393|NCT00312026|Feet
1419394|NCT00312026|Hand
1419395|NCT00312013|low molecular weight heparin
1419396|NCT00312013|nadroparin
1419397|NCT00312013|non-small cell lung cancer
1419398|NCT00312013|cancer survival
1419399|NCT00312013|prostate cancer
1419400|NCT00312013|pancreatic cancer
1419401|NCT00312000|colorectal
1419402|NCT00312000|cancer
1419403|NCT00312000|capecitabine
1419404|NCT00312000|irinotecan
1419405|NCT00312000|oxaliplatin
1419406|NCT00311987|Hypercholesterolemia
1419407|NCT00311987|Thyroid hormone
1419408|NCT00311987|Diiodothyropropionic acid
1419409|NCT00311987|Therapy
1419410|NCT00311974|Dihydralazine
1419411|NCT00311974|Sympathetic activation
1419412|NCT00311974|Fractional sodium excretion
1419413|NCT00311961|COPD
1419414|NCT00311961|Exacerbations
1419415|NCT00311961|Corticosteroids
1419416|NCT00311961|Oral
1419417|NCT00311961|Intravenous
1419418|NCT00311961|Chronic Obstructive Pulmonary Disease (COPD)
1419419|NCT00311948|Teen smokers
1419420|NCT00311948|Quithelper
1419421|NCT00311948|Tobacco
1419422|NCT00311948|Tobacco Website
1419423|NCT00311948|Website Intervention
1419424|NCT00311948|Tobacco counseling
1419425|NCT00311948|Tobacco abstinence
1419426|NCT00311935|Hernia
1419427|NCT00311935|Inguinal
1419428|NCT00311935|Groin
1419429|NCT00311935|Laparoscopic
1419430|NCT00311935|Open
1419431|NCT00311935|Abdominal wall
1419432|NCT00311922|Diabetes
1419433|NCT00311922|Education
1419434|NCT00311922|Health Literacy
1419435|NCT00311909|Tourette Syndrome
1419436|NCT00311909|Deep Brain Stimulation
1419437|NCT00311909|Video assessment
1419438|NCT00311909|YGTSS
1419439|NCT00311909|TSSL
1419440|NCT00311896|Cancer
1419441|NCT00311896|Thrombosis
1419442|NCT00311896|Catheter
1419443|NCT00311896|Bemiparin
1419444|NCT00311896|Prophylaxis
1419445|NCT00311883|Cystic Fibrosis
1419446|NCT00311883|Induced sputum
1419447|NCT00311883|Lung inflammation
1419448|NCT00311857|Cetuximab
1419449|NCT00311831|Pediatrics
1419450|NCT00311831|Gastroenteritis
1419451|NCT00311831|Education
1419452|NCT00311792|training
1419453|NCT00311792|teaching
1419454|NCT00311792|curriculum
1419455|NCT00311779|Pediculosis capitis
1419456|NCT00311779|Head Lice
1419457|NCT00311779|Crawlers
1419458|NCT00311779|Ova
1419459|NCT00311766|Epidermolysis Bullosa
1419460|NCT00311766|cutaneous wound-healing
1419461|NCT00311766|chronic wound-healing
1419462|NCT00311766|Thymosin Beta 4
1419463|NCT00311766|laminin-5
1419464|NCT00311753|heparin, thromboprophylaxis, medical patients, acutely ill
1419465|NCT00311753|Acutely ill non surgical patients
1419466|NCT00311753|Immobilization
1419467|NCT00311740|Hypertension,
1419468|NCT00311740|Valsartan,
1419469|NCT00311740|Hydrochlorothiazide
1419470|NCT00311727|Cell-Mediated Immune Responses, Influenza, A/H5N1, Vaccine, sub-study
1419471|NCT00311714|Influenza, United Kingdom
1419472|NCT00311701|Influenza, pediatric
1419473|NCT00311688|IL-2
1419474|NCT00311688|Immunomodulatory Therapies
1419475|NCT00311675|influenza, A/H5N1, vaccine
1419476|NCT00311649|H5N1, Influenza
1419477|NCT00311636|stage I breast cancer
1419478|NCT00311636|stage II breast cancer
1419479|NCT00311636|stage IIIA breast cancer
1419480|NCT00311636|stage IIIB breast cancer
1419481|NCT00311636|stage IIIC breast cancer
1419482|NCT00311623|stage III prostate cancer
1419483|NCT00311623|stage I prostate cancer
1419484|NCT00311623|stage IIB prostate cancer
1419485|NCT00311623|stage IIA prostate cancer
1419486|NCT00311623|adenocarcinoma of the prostate
1419487|NCT00311610|recurrent colon cancer
1419488|NCT00311610|stage IV colon cancer
1419489|NCT00311610|recurrent rectal cancer
1419490|NCT00311610|stage IV rectal cancer
1419491|NCT00311597|unspecified adult solid tumor, protocol specific
1419492|NCT00311584|recurrent neuroblastoma
1419493|NCT00311571|bedrest
1419494|NCT00311571|spaceflight
1419495|NCT00311571|Weightlessness
1419496|NCT00311571|Countermeasure
1419497|NCT00311558|stage IV melanoma
1419498|NCT00311558|stage IV adult soft tissue sarcoma
1419499|NCT00311558|recurrent melanoma
1419500|NCT00311545|recurrent renal cell cancer
1419501|NCT00311545|stage IV renal cell cancer
1419502|NCT00311545|stage III renal cell cancer
1419503|NCT00311519|Subcutaneous hydration
1419504|NCT00311519|Hylenex
1419505|NCT00311519|Hyaluronidase
1419506|NCT00311506|Pulmozyme
1419507|NCT00311493|TBE
1419508|NCT00311493|vaccine
1419509|NCT00311493|adults
1419510|NCT00311480|influenza
1419511|NCT00311480|pandemic influenza
1419512|NCT00311480|influenza vaccine
1419513|NCT00311480|adjuvanted influenza vaccine
1419514|NCT00311467|renal cell cancer
1419515|NCT00311441|TBE, children, vaccine
1419516|NCT00311428|Influenza
1419517|NCT00311428|Children
1419518|NCT00311428|Vaccine
1419519|NCT00311415|Prevention of Meningococcal Meningitis
1419520|NCT00311415|meningococcal vaccines
1419521|NCT00311415|conjugate
1419522|NCT00311415|immunology
1419523|NCT00311415|infant
1419524|NCT00311415|antibody persistence
1419525|NCT00311389|Glaucoma
1419526|NCT00311389|POAG
1419527|NCT00311389|OAG
1419528|NCT00311389|OHT
1419529|NCT00311350|Safety
1419530|NCT00311350|Health
1419531|NCT00311350|Pharmacokinetics
1419532|NCT00311350|ileus
1419533|NCT00311337|VELCADE
1419534|NCT00311337|bortezomib
1419535|NCT00311337|maintenance treatment
1419536|NCT00311337|multiple myeloma
1419537|NCT00311337|primary disease
1419538|NCT00311324|behavioral intervention
1419539|NCT00311311|Kidney transplant
1419540|NCT00311311|Renal transplant
1419541|NCT00311311|Immunosuppression
1419542|NCT00311311|Atherosclerosis
1419543|NCT00311311|Graft Rejection
1419544|NCT00311298|tuberculosis
1419545|NCT00311298|hiv
1419546|NCT00311298|diabetes
1419547|NCT00311298|protein-energy
1419548|NCT00311298|micronutrients
1419549|NCT00311285|Electromyography
1419550|NCT00311285|Glucocorticoids
1419551|NCT00311285|Heart Rate
1419552|NCT00311285|Physical workload
1419553|NCT00311285|Mental workload
1419554|NCT00311285|Ergonomics
1419555|NCT00311285|Laparoscopy
1419556|NCT00311285|Workload
1419557|NCT00311285|Biomechanics
1419558|NCT00311272|dendritic cells
1419559|NCT00311272|antigens, neoplasm
1419560|NCT00311246|Sarcoidosis
1419561|NCT00311246|Humira
1419562|NCT00311246|Adalimumab
1419563|NCT00311246|Tumor Necrosis Factor Inhibitors
1419564|NCT00311233|child
1419565|NCT00311233|psychosocial
1419566|NCT00311233|predictors
1419567|NCT00311233|cohort
1419568|NCT00311233|recurrent
1419569|NCT00311220|tuberculosis
1419570|NCT00311220|latent tuberculosis
1419571|NCT00311220|tuberculin skin test
1419572|NCT00311220|quantiferon TB-RD1
1419573|NCT00311220|contact screening
1419574|NCT00311220|elderly
1419575|NCT00311207|diagnostic kit
1419576|NCT00311207|immunochromatography test
1419577|NCT00311207|PCR detection kit
1419578|NCT00311207|luminex
1419579|NCT00311194|Heart failure
1419580|NCT00311194|Education
1419581|NCT00311194|CD-ROM
1419582|NCT00311194|Randomization
1419583|NCT00311194|Hospitalization
1419584|NCT00311194|Readmission
1419585|NCT00311194|Death
1419586|NCT00311194|Knowledge
1419587|NCT00311181|ICD
1419588|NCT00311181|Defibrillation
1419589|NCT00311181|ULV
1419590|NCT00311181|Tuned
1419591|NCT00311155|Olmesartan medoxomil
1419592|NCT00311155|Hypertension
1419593|NCT00311142|Sleep pattern
1419594|NCT00311142|newborn
1419595|NCT00311142|actigraphy
1419596|NCT00311142|delivery mode
1419597|NCT00311142|Parents' approval
1419598|NCT00311116|Vitamin E
1419599|NCT00311116|Cancer
1419600|NCT00311116|pediatrics
1419601|NCT00311116|supportive care
1419602|NCT00311116|oral mucositis
1419603|NCT00311116|Bayesian analysis
1419604|NCT00311116|N-of-1 trial
1419605|NCT00311116|prophylaxis
1419606|NCT00311103|Elderly
1419607|NCT00311103|Disability
1419608|NCT00311103|Musculoskeletal diseases
1419609|NCT00311090|Deep Venous Thrombosis
1419610|NCT00311051|Asthma
1419611|NCT00311051|Allergens
1419612|NCT00311051|house dust mites
1419613|NCT00311051|Ramatroban
1419614|NCT00311051|Montelukast
1419615|NCT00311051|Bronchial Provocation Tests
1419616|NCT00311038|ONO-1101
1419617|NCT00311038|Landiolol Hydrochloride
1419618|NCT00311038|Multi-slice CT
1419619|NCT00311038|Coronary Artery Disease
1419620|NCT00311025|stroke
1419621|NCT00311025|physical therapy
1419622|NCT00311025|rehabilitation
1419623|NCT00311025|exercise
1419624|NCT00311025|longterm follow-up
1419625|NCT00311012|Hypertension, Aliskiren
1419626|NCT00310999|Cervical Vertebrae
1419627|NCT00310999|Intubation, Intratracheal
1419628|NCT00310999|Laryngoscopes
1419629|NCT00310999|Fluoroscopy
1419630|NCT00310986|Attention Deficit Disorder with Hyperactivity
1419631|NCT00310986|meditation
1419632|NCT00310986|breathing meditation
1419633|NCT00310986|Anapanasathi
1419634|NCT00310986|randomized controlled trial
1419635|NCT00310986|nonpharmacologic treatment
1419636|NCT00310986|complementary and alternative medicine
1419637|NCT00310973|HIV
1419638|NCT00310973|Prevention
1419639|NCT00310973|Risk Behavior Reduction
1419640|NCT00310973|Roma
1419641|NCT00310973|Bulgaria
1419642|NCT00310973|HIV seronegativity
1419643|NCT00310960|infantile esotropia
1419644|NCT00310960|acquired non-accommodative esotropia
1419645|NCT00310960|acquired partially accommodative esotropia
1419646|NCT00310947|Coronary artery disease
1419647|NCT00310947|Coronary flow reserve
1419648|NCT00310947|Heart failure
1419649|NCT00310947|prospective randomised
1419650|NCT00310934|heroin dependence
1419651|NCT00310934|methadone
1419652|NCT00310934|buprenorphine
1419653|NCT00310934|contingency management
1419654|NCT00310934|relapse prevention
1419655|NCT00310908|Renal
1419656|NCT00310908|Colic
1419657|NCT00310908|Calculi
1419658|NCT00310908|Treatment
1419659|NCT00310895|Refractory
1419660|NCT00310895|Relapsed
1419661|NCT00310882|breast cancer
1419662|NCT00310882|digitalis like compounds
1419663|NCT00310882|prognostic factor
1419671|NCT00310856|meningitis
1419672|NCT00310856|children
1419673|NCT00310856|vaccine
1419674|NCT00310830|Pulmonary Arterial Hypertension
1419675|NCT00310830|Pulmonary hypertension
1419676|NCT00310830|Sickle Cell Disease
1419677|NCT00310830|Sickle cell anemia
1419678|NCT00310830|ASSET
1419679|NCT00310830|ASSET-1
1419680|NCT00310817|meningitis
1419681|NCT00310817|children
1419682|NCT00310817|vaccine
1419683|NCT00310804|Influenza
1419684|NCT00310804|Flu
1419685|NCT00310804|Cell-Derived
1419686|NCT00310804|Egg-Derived
1419687|NCT00310804|Healthy Adults
1419688|NCT00310804|Safety
1419689|NCT00310804|Immunogenicity
1419690|NCT00310804|Vaccination
1419691|NCT00310791|anorexia nervosa
1419692|NCT00310791|adolescents
1419693|NCT00310791|dual-energy x-ray absorptiometry
1419694|NCT00310791|dehydroepiandrosterone (DHEA)
1419695|NCT00310791|osteoporosis
1419696|NCT00310778|High sodium diet
1419697|NCT00310778|Low sodium diet
1419698|NCT00310778|Renin-angiotensin system blockers
1419699|NCT00310778|AT1 receptor (AT1R) antagonist
1419700|NCT00310778|ACE inhibition
1419701|NCT00310765|abdominal pain
1419702|NCT00310765|surgical adhesions
1419703|NCT00310050|stage II pancreatic cancer
1419704|NCT00310050|stage III pancreatic cancer
1419705|NCT00310050|stage IV pancreatic cancer
1419706|NCT00310726|Mother to Child Transmission of HIV
1419707|NCT00310726|Postnatal HIV transmission
1419708|NCT00310726|HIV
1419709|NCT00310726|Breastfeeding
1419710|NCT00310726|Perinatal HIV Transmission
1419711|NCT00310726|HIV Seronegativity
1419712|NCT00310713|Prevention of Meningococcal Meningitis
1419713|NCT00310713|vaccines
1419714|NCT00310713|conjugate
1419715|NCT00310713|immunology
1419716|NCT00310713|children
1419717|NCT00310713|antibody persistence
1419718|NCT00310700|Prevention of Meningococcal Meningitis
1419719|NCT00310700|vaccines, conjugate
1419720|NCT00310700|immunology
1419721|NCT00310700|infant
1419722|NCT00310700|antibody persistence
1419723|NCT00310687|Prevention of Meningococcal Meningitis
1419724|NCT00310687|vaccines
1419725|NCT00310687|conjugate
1419726|NCT00310687|immunology
1419727|NCT00310687|antibody persistence
1419728|NCT00310674|Prevention of Meningococcal Meningitis
1419729|NCT00310674|meningococcal vaccines
1419730|NCT00310674|conjugate
1419731|NCT00310674|Immunology
1419732|NCT00310674|infant
1419733|NCT00310661|sarizotan
1419734|NCT00310661|neuroleptic-induced tardive dyskinesia
1419735|NCT00310648|Influenza, elderly, vaccine
1419736|NCT00310635|Prevention of meningococcal infection
1419737|NCT00310622|HyperQ
1419738|NCT00310622|Ischemia
1419739|NCT00310622|dobutamine
1419740|NCT00310609|Structural abnormalities of the aortic arch and cerebral branches
1419741|NCT00310596|ECG safety
1419742|NCT00310583|tactile hyperalgesia
1419743|NCT00310583|neuropathic pain
1419744|NCT00310583|enriched design
1419745|NCT00310583|peripheral nerve lesion
1419746|NCT00310583|plexus lesion
1419747|NCT00310583|radicular lesion
1419748|NCT00310583|spinal lesion
1419749|NCT00310583|polyneuropathy
1419750|NCT00310583|postzosteric neuralgia
1419751|NCT00310570|distal
1419752|NCT00310570|interphalangeal
1419753|NCT00310570|extensor tendon
1419754|NCT00310570|avulsion
1419755|NCT00310505|visceral leishmaniasis
1419756|NCT00310505|amphotericin B
1419757|NCT00310505|Kala-azar
1419758|NCT00310479|Magnetic Resonance Imaging
1419759|NCT00310479|prostate cancer imaging
1419760|NCT00310479|3T MRS
1419761|NCT00310479|functional imaging
1419762|NCT00310440|Degenerative disc disease
1419763|NCT00310440|P-15 Bone Putty
1419764|NCT00310440|Bone graft
1419765|NCT00310440|Cervical discectomy
1419766|NCT00310440|Cervical spine
1419767|NCT00310427|Anxiety
1419768|NCT00310427|Alcohol Dependence
1419769|NCT00310427|Alcoholism
1419770|NCT00310414|Imaging Studies
1419771|NCT00310414|Botulinum Toxin
1419772|NCT00310414|Writer's Cramp
1419773|NCT00310414|Focal Hand Dystonia
1419774|NCT00310414|FHD
1419775|NCT00310414|Writer Cramp
1419776|NCT00310414|Healthy Volunteer
1419777|NCT00310414|HV
1419778|NCT00310401|brain death
1419779|NCT00310401|organ donor
1419780|NCT00310401|pulmonary edema
1419781|NCT00310401|albuterol
1419782|NCT00310401|hypoxia
1419783|NCT00310401|lung transplantation
1419784|NCT00310401|infiltrates
1419785|NCT00310388|Partial Seizures
1419786|NCT00310388|Epilepsy
1419787|NCT00310388|RTG115097
1419788|NCT00310388|Complex Partial Seizures
1419789|NCT00310388|Anticonvulsant
1419790|NCT00310388|Potassium Channels
1419791|NCT00310388|Epilepsies, Partial
1419792|NCT00310375|Epilepsy
1419793|NCT00310375|Partial Seizures
1419794|NCT00310375|Potassium Channels
1419795|NCT00310375|Anticonvulsant
1419796|NCT00310375|Complex Partial Seizures
1419797|NCT00310375|Epilepsies, Partial
1419798|NCT00310375|RTG115098
1419799|NCT00310362|telephone
1419800|NCT00310362|telemedicine
1419801|NCT00310362|mass screening
1419802|NCT00310362|patient education
1419803|NCT00310362|Patient compliance
1419804|NCT00310349|pneumococcal vaccine
1419805|NCT00310349|clinical trial
1419806|NCT00310349|Indigenous
1419807|NCT00310349|Maternal
1419808|NCT00310349|Streptococcus pneumoniae
1419809|NCT00310323|sleep apnea
1419810|NCT00310323|phenotyping
1419811|NCT00310323|cytochrome P450
1419812|NCT00310323|drug metabolism
1419813|NCT00310323|child
1419814|NCT00310310|Continuous positive airway pressure
1419815|NCT00310310|Patient compliance
1419816|NCT00310310|Self-care
1419817|NCT00310284|Insomnia
1419818|NCT00310284|Sleep
1419819|NCT00310271|DNA vaccine, immunotherapy, HSV-2, PMED
1419820|NCT00310245|CD4-guided STI
1419821|NCT00310245|Keywords:
1419822|NCT00310245|HAART
1419823|NCT00310245|Clinical outcome
1419824|NCT00310245|Resistance
1419825|NCT00310245|Costs
1419826|NCT00310245|Prognostic factors
1419827|NCT00310245|pulse therapy
1419828|NCT00310245|treatment experienced
1419829|NCT00310245|treatment interruption
1419830|NCT00310232|Quality of Life
1419831|NCT00310232|Blood transfusion
1419832|NCT00310219|stage II non-small cell lung cancer
1419833|NCT00310219|stage IIIA non-small cell lung cancer
1419834|NCT00310219|stage IIIB non-small cell lung cancer
1419835|NCT00310219|recurrent non-small cell lung cancer
1419836|NCT00310206|Influenza, pandemic, H5N1, vaccine
1419837|NCT00310167|stage I grade 1 follicular lymphoma
1419838|NCT00310167|stage I grade 2 follicular lymphoma
1419839|NCT00310167|stage I grade 3 follicular lymphoma
1419840|NCT00310167|contiguous stage II grade 1 follicular lymphoma
1419841|NCT00310167|noncontiguous stage II grade 1 follicular lymphoma
1419842|NCT00310167|contiguous stage II grade 2 follicular lymphoma
1419843|NCT00310167|noncontiguous stage II grade 2 follicular lymphoma
1419844|NCT00310167|contiguous stage II grade 3 follicular lymphoma
1419845|NCT00310167|noncontiguous stage II grade 3 follicular lymphoma
1419846|NCT00310167|stage III grade 1 follicular lymphoma
1419847|NCT00310167|stage III grade 2 follicular lymphoma
1419848|NCT00310167|stage III grade 3 follicular lymphoma
1419849|NCT00310167|stage IV grade 1 follicular lymphoma
1419850|NCT00310167|stage IV grade 2 follicular lymphoma
1419851|NCT00310167|stage IV grade 3 follicular lymphoma
1419852|NCT00310167|recurrent grade 1 follicular lymphoma
1419853|NCT00310167|recurrent grade 2 follicular lymphoma
1419854|NCT00310167|recurrent grade 3 follicular lymphoma
1419855|NCT00310167|Marginal zone lymphoma
1419856|NCT00310154|stage IIIA non-small cell lung cancer
1419857|NCT00310154|stage IIIB non-small cell lung cancer
1419858|NCT00310154|adenosquamous cell lung cancer
1419859|NCT00310154|bronchoalveolar cell lung cancer
1419860|NCT00310154|large cell lung cancer
1419861|NCT00310154|squamous cell lung cancer
1419862|NCT00310154|adenocarcinoma of the lung
1419863|NCT00310141|non-small cell lung cancer
1419864|NCT00310141|small cell lung cancer
1419865|NCT00310128|AIDS-related diffuse large cell lymphoma
1419866|NCT00310128|AIDS-related peripheral/systemic lymphoma
1419867|NCT00310128|AIDS-related small noncleaved cell lymphoma
1419868|NCT00310128|AIDS-related diffuse mixed cell lymphoma
1419869|NCT00310128|AIDS-related immunoblastic large cell lymphoma
1419870|NCT00310128|contiguous stage II grade 2 follicular lymphoma
1419871|NCT00310128|contiguous stage II grade 3 follicular lymphoma
1419872|NCT00310128|noncontiguous stage II grade 2 follicular lymphoma
1419873|NCT00310128|noncontiguous stage II grade 3 follicular lymphoma
1419874|NCT00310128|recurrent grade 2 follicular lymphoma
1419875|NCT00310128|recurrent grade 3 follicular lymphoma
1419876|NCT00310128|stage I grade 2 follicular lymphoma
1419877|NCT00310128|stage I grade 3 follicular lymphoma
1419878|NCT00310128|stage III grade 2 follicular lymphoma
1419879|NCT00310128|stage III grade 3 follicular lymphoma
1419880|NCT00310128|stage IV grade 2 follicular lymphoma
1419881|NCT00310128|stage IV grade 3 follicular lymphoma
1419882|NCT00310128|contiguous stage II adult Burkitt's lymphoma
1419883|NCT00310128|noncontiguous stage II adult Burkitt's lymphoma
1419884|NCT00310128|recurrent adult Burkitt's lymphoma
1419885|NCT00310128|stage I adult Burkitt's lymphoma
1419886|NCT00310128|stage III adult Burkitt's lymphoma
1419887|NCT00310128|stage IV adult Burkitt's lymphoma
1419888|NCT00310128|anaplastic large cell lymphoma
1419889|NCT00310128|contiguous stage II adult diffuse large cell lymphoma
1419890|NCT00310128|noncontiguous stage II adult diffuse large cell lymphoma
1419891|NCT00310128|recurrent adult diffuse large cell lymphoma
1419892|NCT00310128|stage I adult diffuse large cell lymphoma
1419893|NCT00310128|stage III adult diffuse large cell lymphoma
1419894|NCT00310128|stage IV adult diffuse large cell lymphoma
1419895|NCT00310128|contiguous stage II adult diffuse mixed cell lymphoma
1419998|NCT00309842|refractory anemia
1419896|NCT00310128|noncontiguous stage II adult diffuse mixed cell lymphoma
1419897|NCT00310128|recurrent adult diffuse mixed cell lymphoma
1419898|NCT00310128|stage I adult diffuse mixed cell lymphoma
1419899|NCT00310128|stage III adult diffuse mixed cell lymphoma
1419900|NCT00310128|stage IV adult diffuse mixed cell lymphoma
1419901|NCT00310128|contiguous stage II adult immunoblastic large cell lymphoma
1419902|NCT00310128|noncontiguous stage II adult immunoblastic large cell lymphoma
1419903|NCT00310128|recurrent adult immunoblastic large cell lymphoma
1419904|NCT00310128|stage I adult immunoblastic large cell lymphoma
1419905|NCT00310128|stage III adult immunoblastic large cell lymphoma
1419906|NCT00310128|stage IV adult immunoblastic large cell lymphoma
1419907|NCT00310115|non-small cell lung cancer
1419908|NCT00310115|small cell lung cancer
1419909|NCT00310115|bladder cancer
1419910|NCT00310115|cervical cancer
1419911|NCT00310115|esophageal cancer
1419912|NCT00310115|gastric cancer
1419913|NCT00310115|renal cell carcinoma
1419914|NCT00310115|adult primary liver cancer
1419915|NCT00310115|pancreatic cancer
1419916|NCT00310115|hypopharyngeal cancer
1419917|NCT00310115|lip and oral cavity cancer
1419918|NCT00310115|laryngeal cancer
1419919|NCT00310115|nasopharyngeal cancer
1419920|NCT00310115|oropharyngeal cancer
1419921|NCT00310115|paranasal sinus and nasal cavity cancer
1419922|NCT00310115|adult acute myeloid leukemia
1419923|NCT00310115|tobacco use disorder
1419924|NCT00310089|stage IIIA breast cancer
1419925|NCT00310089|stage IIIB breast cancer
1419926|NCT00310089|stage IIIC breast cancer
1419927|NCT00310089|inflammatory breast cancer
1419928|NCT00310076|carcinoma of the appendix
1419929|NCT00310076|stage II colon cancer
1419930|NCT00310076|stage III colon cancer
1419931|NCT00310076|stage IV colon cancer
1419932|NCT00310076|recurrent colon cancer
1419933|NCT00310076|stage II rectal cancer
1419934|NCT00310076|stage III rectal cancer
1419935|NCT00310076|stage IV rectal cancer
1419936|NCT00310076|recurrent rectal cancer
1419937|NCT00310063|nausea and vomiting
1419938|NCT00310063|unspecified childhood solid tumor, protocol specific
1419939|NCT00310011|metastatic transitional cell cancer of the renal pelvis and ureter
1419940|NCT00310011|recurrent transitional cell cancer of the renal pelvis and ureter
1419941|NCT00310011|transitional cell carcinoma of the bladder
1419942|NCT00310011|regional transitional cell cancer of the renal pelvis and ureter
1419943|NCT00310011|stage IV bladder cancer
1419944|NCT00310011|recurrent bladder cancer
1419945|NCT00309998|stage IIIB non-small cell lung cancer
1419946|NCT00309998|stage IV non-small cell lung cancer
1419947|NCT00309998|adenocarcinoma of the lung
1419948|NCT00309998|bronchoalveolar cell lung cancer
1419949|NCT00309998|large cell lung cancer
1419950|NCT00309998|recurrent non-small cell lung cancer
1419951|NCT00309985|metastatic hormone-sensitive prostate cancer
1419952|NCT00309985|docetaxel
1419953|NCT00309972|stage IIIA non-small cell lung cancer
1419954|NCT00309972|stage IIIB non-small cell lung cancer
1419955|NCT00309933|cognitive/functional effects
1419956|NCT00309933|spiritual concerns
1419957|NCT00309933|sexuality and reproductive issues
1419958|NCT00309933|psychosocial effects of cancer and its treatment
1419959|NCT00309933|cancer survivor
1419960|NCT00309933|stage I breast cancer
1419961|NCT00309933|stage II breast cancer
1419962|NCT00309933|stage IIIA breast cancer
1419963|NCT00309933|stage IIIB breast cancer
1419964|NCT00309933|stage IIIC breast cancer
1419965|NCT00309920|stage IIIA breast cancer
1419966|NCT00309920|stage IIIC breast cancer
1419967|NCT00309894|adenocarcinoma of the prostate
1419968|NCT00309894|recurrent prostate cancer
1419969|NCT00309881|refractory chronic lymphocytic leukemia
1419970|NCT00309881|stage I chronic lymphocytic leukemia
1419971|NCT00309881|stage II chronic lymphocytic leukemia
1419972|NCT00309881|stage III chronic lymphocytic leukemia
1419973|NCT00309881|stage IV chronic lymphocytic leukemia
1419974|NCT00309868|heart catheterization
1419975|NCT00309868|echocardiogram
1419976|NCT00309868|nesiritide
1419977|NCT00309842|blastic phase chronic myelogenous leukemia
1419978|NCT00309842|primary myelofibrosis
1419979|NCT00309842|chronic myelomonocytic leukemia
1419980|NCT00309842|myelodysplastic syndromes
1419981|NCT00309842|juvenile myelomonocytic leukemia
1419982|NCT00309842|recurrent adult Burkitt lymphoma
1419983|NCT00309842|recurrent adult immunoblastic large cell lymphoma
1419984|NCT00309842|recurrent lymphoblastic lymphoma
1419985|NCT00309842|recurrent childhood acute myeloid leukemia
1419986|NCT00309842|recurrent childhood large cell lymphoma
1419987|NCT00309842|recurrent follicular lymphoma
1419988|NCT00309842|recurrent marginal zone lymphoma
1419989|NCT00309842|recurrent small lymphocytic lymphoma
1419990|NCT00309842|refractory chronic lymphocytic leukemia
1419991|NCT00309842|refractory multiple myeloma
1419992|NCT00309842|chronic myelogenous leukemia
1419993|NCT00309842|secondary acute myeloid leukemia
1419994|NCT00309842|secondary myelodysplastic syndromes
1419995|NCT00309842|multiple myeloma
1419996|NCT00309842|adult lymphoblastic lymphoma
1419997|NCT00309842|refractory anemia with excess blasts
1419999|NCT00309842|Burkitt lymphoma
1420000|NCT00309842|childhood large cell lymphoma
1420001|NCT00309842|adult Burkitt lymphoma
1420002|NCT00309842|mantle cell lymphoma
1420003|NCT00309842|childhood lymphoblastic lymphoma
1420004|NCT00309842|childhood myelodysplastic syndromes
1420005|NCT00309816|Exercise stress test
1420006|NCT00309803|Carotid artery
1420007|NCT00309803|distal protection device
1420008|NCT00309790|exercise stress test
1420009|NCT00309777|hypercholesterolemia
1420010|NCT00309777|kowa
1420011|NCT00309777|dyslipidemia
1420012|NCT00309777|pitavastatin
1420013|NCT00309777|NK-104
1420014|NCT00309777|Primary Hypercholesterolemia or Combined Dyslipidemia
1420015|NCT00309751|Kowa
1420016|NCT00309751|Type II Diabetes Mellitus
1420017|NCT00309751|Combined Dyslipidemia
1420018|NCT00309751|pitavastatin
1420019|NCT00309751|NK-104
1420020|NCT00309751|Atorvastatin
1420021|NCT00309738|Kowa
1420022|NCT00309738|KRE
1420023|NCT00309738|Hypercholesterolemia
1420024|NCT00309738|combined dyslipidemia
1420025|NCT00309738|dyslipidemia
1420026|NCT00309738|pitavastatin
1420027|NCT00309738|NK-104
1420028|NCT00309738|simvastatin
1420029|NCT00309725|Alzheimer's Disease
1420030|NCT00309725|cardiac arrhythmias
1420031|NCT00309712|diabetes
1420032|NCT00309712|combination lipid treatment
1420033|NCT00309712|statin
1420034|NCT00309712|fibrate
1420035|NCT00309712|hypercholesteremia
1420036|NCT00309712|mixed dyslipidemia
1420037|NCT00309699|Affective psychosis
1420038|NCT00309699|mixed-state
1420039|NCT00309699|bipolar disorder
1420040|NCT00309699|manic disorder
1420041|NCT00309699|manic-depressive psychosis
1420042|NCT00309699|mania
1420043|NCT00309699|manic state
1420044|NCT00309699|paliperidone
1420045|NCT00309699|paliperidone ER.
1420046|NCT00309686|Affective psychosis
1420047|NCT00309686|bipolar disorder
1420048|NCT00309686|manic disorder
1420049|NCT00309686|manic-depressive psychosis
1420050|NCT00309686|mania
1420051|NCT00309686|manic state
1420052|NCT00309686|paliperidone
1420053|NCT00309686|paliperidone ER
1420054|NCT00309686|adjunctive therapy
1420055|NCT00309673|tuberculosis, tuberculin, childhood, pain
1420056|NCT00309660|PPARgamma ligand
1420057|NCT00309660|Rosiglitazone
1420058|NCT00309660|Enema
1420059|NCT00309647|prophylaxis of pandemic influenza
1420060|NCT00309634|prophylaxis of pandemic influenza
1420061|NCT00309621|Hand Dermatoses,
1420062|NCT00309621|hand dermatitis
1420063|NCT00309621|hand eczema
1420064|NCT00309621|chronic hand dermatitis
1420065|NCT00309621|retinoid
1420066|NCT00309569|Cyclophosphamide
1420067|NCT00309569|Methotrexate
1420068|NCT00309569|Fluorouracil
1420069|NCT00309569|Epirubicine
1420070|NCT00309569|Breast Cancer
1420071|NCT00309556|Epirubicin
1420072|NCT00309556|Docetaxel
1420073|NCT00309556|Capecitabine
1420074|NCT00309556|Herceptin
1420075|NCT00309556|Breast cancer
1420076|NCT00309543|Fluorouracil
1420077|NCT00309543|Leucovorin
1420078|NCT00309543|Colon cancer
1420079|NCT00309530|Fluorouracil
1420080|NCT00309530|Levamisol
1420081|NCT00309530|Interferon
1420082|NCT00309530|Colon cancer
1420083|NCT00309517|Fluorouracil
1420084|NCT00309517|Leucovorin
1420085|NCT00309517|MAb 17-1A
1420086|NCT00309517|Rectal cancer
1420087|NCT00309504|magnetic resonance imaging
1420088|NCT00309504|magnetic resonance spectroscopy
1420089|NCT00309491|Tamoxifen
1420090|NCT00309491|Aminoglutethimide
1420091|NCT00309491|Breast cancer
1420092|NCT00309478|Cyclophosphamide
1420093|NCT00309478|Methotrexate
1420094|NCT00309478|Fluorouracil
1420095|NCT00309478|Goserelin
1420096|NCT00309478|Tamoxifen
1420097|NCT00309478|Breast cancer
1420098|NCT00309465|Diabetes
1420099|NCT00309465|Insulin Glargine
1420100|NCT00309465|Surgery
1420101|NCT00309452|First episode psychosis
1420102|NCT00309452|Specialized care
1420103|NCT00309452|Phase-specific treatment
1420104|NCT00309452|Schizophrenia
1420105|NCT00309452|Disorders with psychotic features
1420106|NCT00309426|atherosclerosis
1420107|NCT00309413|Schizophrenia and Disorders with Psychotic Features
1420108|NCT00309400|History
1420109|NCT00309400|Phenylketonuria
1420110|NCT00309400|Galactosemia
1420111|NCT00309400|Screening
1420112|NCT00309400|Treatment
1420113|NCT00309387|Cataract
1420114|NCT00309387|Nutritional supplements
1420115|NCT00309374|LPS
1420116|NCT00309374|Statins
1420117|NCT00309374|leukocyte mRNA expression profiles
1420118|NCT00309361|Soft Tissue Anesthesia (Numbness)
1420119|NCT00309335|Soft Tissue Anesthesia (Numbness)
1420120|NCT00309322|Soft Tissue Anesthesia (Numbness)
1420121|NCT00309296|smoking cessation
1420122|NCT00309296|smoking reduction
1420123|NCT00309296|nicotine replacement therapy
1420124|NCT00309270|Campath-1H, low-dose immunosuppression, T regulatives cells
1420125|NCT00309231|diabetes mellitus
1420126|NCT00309231|islet transplantation
1420127|NCT00309218|Pediatric renal transplantation
1420128|NCT00309218|Steroid withdrawal
1420129|NCT00309218|Mycophenolate Mofetil
1420130|NCT00309218|Cyclosporine A
1420131|NCT00309218|Stable graft function
1420132|NCT00309218|children
1420133|NCT00309218|renal transplantation
1420134|NCT00309205|HIV seronegativity
1420135|NCT00309192|Diabetes, Macular Edema, Triamcinolone
1420136|NCT00309179|Advanced colorectal cancer
1420137|NCT00309127|Type 2 Diabetes Mellitus
1420138|NCT00309127|DM Nephropathy
1420139|NCT00309127|Structured care
1420140|NCT00309114|UTI
1420141|NCT00309114|SCI
1420142|NCT00309114|E coli
1420143|NCT00309114|Prevention
1420144|NCT00309101|Tacrolimus
1420145|NCT00309101|Myasthenia Gravis
1420146|NCT00309088|Tacrolimus
1420147|NCT00309088|Myasthenia Gravis
1420148|NCT00309075|Stenosis of the calf and/or pedal arteries
1420149|NCT00309062|Allergy
1420150|NCT00309062|Birch pollen
1420151|NCT00309062|Recombinant
1420152|NCT00309036|Allergy
1420153|NCT00309036|Grass pollen
1420154|NCT00309036|Recombinant
1420155|NCT00309023|Advanced Solid Tumors
1420156|NCT00309010|Focal Hand Dystonia
1420157|NCT00309010|Motor Planning
1420158|NCT00309010|Transcranial Magnetic Stimulation (TMS)
1420159|NCT00309010|MRI (Magnetic Resonance Imaging)
1420160|NCT00309010|FHD
1420161|NCT00309010|Writer's Cramp
1420162|NCT00309010|Healthy Volunteer
1420163|NCT00309010|HV
1420164|NCT00308997|Auditory Hallucinations
1420165|NCT00308997|Schizophrenia
1420166|NCT00308997|Schizoaffective Disorder
1420167|NCT00308997|Repetitive Transcranial Magnetic Stimulation
1420168|NCT00308997|Wernicke's Area
1420169|NCT00308997|Superior Temporal Gyrus
1420170|NCT00308984|Pediatrics
1420171|NCT00308984|Intraoperative Awareness
1420172|NCT00308984|Pediatric Anesthesia
1420173|NCT00308958|cystic fibrosis
1420174|NCT00308958|chest physiotherapy
1420175|NCT00308958|airway clearance
1420176|NCT00308958|bronchiectasis
1420177|NCT00308945|Glaucoma
1420178|NCT00308945|Blood flow
1420179|NCT00308945|Choroid
1420180|NCT00308945|Retina
1420181|NCT00308945|Prostaglandin analogues
1420182|NCT00308932|fluticasone
1420183|NCT00308932|asthma therapy
1420184|NCT00308932|spacer inhaler
1420185|NCT00308932|HFA-134a
1420186|NCT00308906|infection
1420187|NCT00308906|renal dysfunction
1420188|NCT00308906|aminoglycoside
1420189|NCT00308906|protein
1420190|NCT00308906|child
1420191|NCT00308893|Antidepressants
1420192|NCT00308893|escitalopram
1420193|NCT00308893|Genetic polymorphism
1420194|NCT00308880|Tranexamic acid
1420195|NCT00308880|head neck surgery
1420196|NCT00308867|PDT
1420197|NCT00308867|AK
1420198|NCT00308867|Cryosurgery
1420199|NCT00308854|AK
1420200|NCT00308854|PDT
1420201|NCT00308841|"Objective: To evaluate the efficacy of intrauterine lidocaine instillation in reducing patient discomfort during the removal of a lost IUD"
1420202|NCT00308815|Resuscitation
1420203|NCT00308815|Out-of-hospital cardiac arrest
1420204|NCT00308815|cardiac arrest
1420205|NCT00308815|CPR
1420206|NCT00308802|Kidney
1420207|NCT00308802|Transplant
1420208|NCT00308802|Rejection
1420209|NCT00308802|Kidney Disease
1420210|NCT00308802|Kidney Failure
1420211|NCT00308802|End Stage Renal Disease
1420212|NCT00308789|Continuous Positive Airway Pressure
1420213|NCT00308789|Infant,newborn
1420214|NCT00308789|Artificial respiration
1420215|NCT00308763|Smoking Cessation
1420216|NCT00308763|Nicotine Dependence
1420217|NCT00308724|Generalized Anxiety Disorder
1420218|NCT00308724|Geriatric
1420219|NCT00308711|Cervical ripening
1420220|NCT00308711|Induction of labor
1420221|NCT00308711|Dinoprostone vaginal insert
1420222|NCT00308711|Cervidil
1420223|NCT00308711|Misoprostol vaginal insert
1420224|NCT00308711|Modified Bishop's Score
1420225|NCT00308711|PGE2
1420226|NCT00308711|PGE1
1420227|NCT00308711|Uterine Hyperstimulation
1420228|NCT00308711|Cesarean section
1420229|NCT00308698|recombinant human erythropoietin
1420230|NCT00308698|adiponectin
1420231|NCT00308698|mortality
1420232|NCT00308685|Asthma
1420233|NCT00308685|Pediatric asthma
1420234|NCT00308633|Cardiac Rehabilitation
1420235|NCT00308633|Apoptosis
1420236|NCT00308633|Gene Expression
1420237|NCT00308633|Nitric Oxide
1420238|NCT00308633|Reactive Oxygen Species
1420239|NCT00308633|Coronary Artery Disease
1420240|NCT00308633|CAD
1420241|NCT00308620|HIV
1420242|NCT00308620|chloroquine
1420243|NCT00308620|disease progression
1420244|NCT00308620|inflammation
1420245|NCT00308620|treatment naive
1420246|NCT00308607|melanoma
1420247|NCT00308607|metastatic
1420248|NCT00308607|bevacizumab
1420249|NCT00308594|cervical radiculopathy
1420250|NCT00308594|dexamethasone
1420251|NCT00308594|corticosteroid
1420252|NCT00308594|oral
1420253|NCT00308581|Crohn's Disease
1420254|NCT00308581|Certolizumab pegol
1420255|NCT00308568|screening colonoscopy
1420256|NCT00308568|adherence
1420257|NCT00308555|Cannabis
1420258|NCT00308555|Morphine
1420259|NCT00308555|Oxycodone
1420260|NCT00308555|Marijuana
1420261|NCT00308555|chronic pain
1420262|NCT00308542|eye diseases
1420263|NCT00308542|diabetic eye problems
1420264|NCT00308529|Carcinoma Small Cell Lung
1420265|NCT00308529|Lung Cancer
1420266|NCT00308516|Rectal Cancer
1420267|NCT00308516|Cancer of the Rectum
1420268|NCT00308516|Colorectal Cancer
1420269|NCT00308516|Bevacizumab
1420270|NCT00308503|Primary Insomnia
1420271|NCT00308503|Sleep Maintenance Insomnia
1420272|NCT00308503|Awakening
1420273|NCT00308477|eye diseases
1420274|NCT00308451|chromium
1420275|NCT00308451|chromium picolinate
1420276|NCT00308451|type 2 diabetes mellitus
1420277|NCT00308451|fructosamine
1420278|NCT00308451|glycemic control
1420279|NCT00308451|OGTT
1420280|NCT00308438|Crohn Disease
1420281|NCT00308438|Crohn's Disease
1420282|NCT00308425|Renal transplantation, EC-MPS
1420283|NCT00308412|Respiratory Tract Infection
1420284|NCT00308386|Nurse Case Management
1420285|NCT00308386|Diabetes
1420286|NCT00308386|Hypertension
1420287|NCT00308386|Hyperlipidemia
1420288|NCT00308386|Behavior therapy
1420289|NCT00308386|Motivational interviewing
1420290|NCT00308360|Hostility
1420291|NCT00308360|Impulsivity
1420292|NCT00308360|Aggression
1420293|NCT00308334|Domperidone
1420294|NCT00308334|breast milk
1420295|NCT00308334|breast milk composition
1420296|NCT00308334|preterm infant
1420297|NCT00308334|neonate
1420298|NCT00308334|nutrition
1420299|NCT00308269|Cancer
1420300|NCT00308269|Phase I
1420301|NCT00308269|EC145
1420302|NCT00308269|Recurrent
1420303|NCT00308269|Refractory
1420304|NCT00308269|Solid Tumors
1420305|NCT00308269|Experimental
1420306|NCT00308256|Type1 diabetes;
1420307|NCT00308256|nurse-counselling;
1420308|NCT00308256|adolescent
1420309|NCT00308243|Cystic Fibrosis
1420310|NCT00308243|Sodium Pyruvate
1420311|NCT00308243|Reactive Oxygen Species
1420312|NCT00308243|Inflammation of Lung
1420313|NCT00308230|Congenital, BNP
1420314|NCT00308217|Heart Disease, Congenital
1420315|NCT00308217|Single Ventricle
1420316|NCT00308217|Hypoplastic Left Heart Syndrome
1420317|NCT00308204|discoid lupus
1420318|NCT00308204|lupus
1420319|NCT00308204|discoid lupus erythematosus
1420320|NCT00308204|lupus of the scalp
1420321|NCT00308191|COPD
1420322|NCT00308191|Formoterol
1420323|NCT00308191|Tiotropium
1420324|NCT00308178|Abraxane
1420325|NCT00308178|dose-dense chemotherapy
1420326|NCT00308178|taxol
1420327|NCT00308165|Recurrent Primary Malignant Brain Tumors
1420328|NCT00308165|Brain Tumors
1420329|NCT00308165|Neoplasms, Brain
1420330|NCT00308165|Brain Cancer
1420331|NCT00308165|Brain cancer treatment
1420332|NCT00308165|Topotecan
1420333|NCT00308152|Colonoscopy
1420334|NCT00308152|Rehydration
1420335|NCT00308152|Sedation
1420336|NCT00308139|diabetes
1420337|NCT00308139|exenatide
1420338|NCT00308139|long acting release
1420339|NCT00308139|LAR
1420340|NCT00308139|Amylin
1420341|NCT00308139|Lilly
1420342|NCT00308126|Abdominal operation
1420343|NCT00308113|Muscular dystrophy
1420344|NCT00308113|Duchenne
1420345|NCT00308113|CoQ10
1420346|NCT00308113|prednisone
1420347|NCT00308100|Liver Transplantation
1420348|NCT00308087|Sargramostim
1420349|NCT00308087|Leukine
1420350|NCT00308087|NHL
1420351|NCT00308074|behavioral problems
1420352|NCT00308074|aggression
1420353|NCT00308074|autism
1420354|NCT00308074|aripiprazole
1420355|NCT00308061|Plasmodium falciparum
1420356|NCT00308061|malaria
1420357|NCT00308061|merozoite surface protein-1
1420358|NCT00308048|Interferon
1420359|NCT00308048|Pegylated interferon
1420360|NCT00308048|Pegylated interferon alfa 2b
1420361|NCT00308048|Hepatitis C
1420362|NCT00308048|Genotype 2
1420363|NCT00308048|Genotype 3
1420364|NCT00308048|Rapid virological response
1420365|NCT00308048|Short treatment
1420366|NCT00308048|14 weeks treatment
1420367|NCT00308048|health related quality of life
1420368|NCT00308048|sick leave
1420369|NCT00308048|Injecting drug use
1420370|NCT00308022|Acute Lung Injury
1420371|NCT00308022|Acute Respiratory Distress Syndrome
1420372|NCT00308022|High Frequency Percussive Ventilation
1420373|NCT00308022|Ventilator Associated Pneumonia
1420374|NCT00308009|Pelvic Organ Prolapse
1420375|NCT00308009|Urinary stress incontinence
1420376|NCT00308009|Surgery
1420377|NCT00307996|CoQ10
1420378|NCT00307996|hemodialysis
1420379|NCT00307996|oxidative marker
1420380|NCT00307996|antioxidant
1420381|NCT00307970|fluticasone
1420382|NCT00307970|asthma therapy
1420383|NCT00307970|spacer inhaler
1420384|NCT00307970|HFA-134a
1420385|NCT00307957|Obstructive Sleep Apnea
1420386|NCT00307957|Daytime Sleepiness
1420387|NCT00307957|Pillar Palatal Implants
1420388|NCT00307944|Acid Reflux
1420389|NCT00307944|Obstructive Sleep Apnea
1420390|NCT00307944|Daytime Sleepiness
1420391|NCT00307931|Certolizumab pegol
1420392|NCT00307931|Cimzia
1420393|NCT00307931|Crohn's disease
1420394|NCT00307931|Greek patients
1420395|NCT00307918|acupuncture, intraocular pressure, glaucoma
1420396|NCT00307905|homeopathy
1420397|NCT00307905|pain
1420398|NCT00307905|traumeel s
1420399|NCT00307905|Fracture of neck of femur
1420400|NCT00307905|Surgical correction of fracture of neck of hip
1420401|NCT00307892|Homeopathy
1420402|NCT00307892|Traumeel S
1420403|NCT00307892|Arthroscopy
1420404|NCT00307892|Pain management
1420405|NCT00307892|Post-operative pain following arthroscopy
1420406|NCT00307879|Myocardial infarction
1420407|NCT00307879|revascularization
1420408|NCT00307879|granulocyte colony stimulating factor (G-CSF)
1420409|NCT00307866|Known or suspected focal liver lesions detected by spiral CT
1420410|NCT00307853|homeopathy
1420411|NCT00307853|pain
1420412|NCT00307853|traumeel s
1420413|NCT00307853|total knee arthroplasty
1420414|NCT00307853|total hip arthroplasty
1420415|NCT00307840|hemodialysis; secondary hyperparathyroidism; hypercalcemia; hyperphosphatemia; vitamin D
1420416|NCT00307827|Steroid-Refractory
1420417|NCT00307827|IVSR-UC
1420418|NCT00307827|Ulcerative Colitis
1420419|NCT00307814|Anemia
1420420|NCT00307814|Low Blood Count
1420421|NCT00307814|Chronic Kidney Failure
1420422|NCT00307814|Chronic Kidney Disease
1420423|NCT00307814|epoetin alfa
1420424|NCT00307814|recombinant human erythropoietin
1420425|NCT00307801|Dysfunctional uterine bleeding
1420426|NCT00307788|Psychiatric Comorbidity
1420427|NCT00307788|Acupuncture
1420428|NCT00307788|expectancy
1420429|NCT00307775|oestradiol, faecal incontinence, post menopausal
1420430|NCT00307775|post menopausal women with faecal incontinence
1420431|NCT00307762|Stroke
1420432|NCT00307762|Physiotherapy
1420433|NCT00307762|Effectiveness
1420434|NCT00307762|Gait trainer
1420435|NCT00307749|Neuropathy
1420436|NCT00307749|Nerve Conduction
1420437|NCT00307736|Fluorouracil
1420438|NCT00307736|bevacizumab
1420439|NCT00307736|erlotinib
1420440|NCT00307736|external beam radiation therapy
1420441|NCT00307736|EBRT
1420442|NCT00307723|EBRT
1420443|NCT00307723|advanced pancreatic cancer
1420444|NCT00307710|Non-Hodgkin's Lymphoma
1420445|NCT00307710|Influenza Vaccination
1420446|NCT00307710|Trivalent Baculovirus-Expressed Influenza HA vaccine
1420447|NCT00307710|Antineoplastic Therapy
1420448|NCT00307697|Letter intervention
1420449|NCT00307697|Depression
1420450|NCT00307697|Anxiety
1420451|NCT00307697|Primary health care
1420452|NCT00307684|Attention Deficit Hyperactivity Disorder
1420453|NCT00307684|Adult
1420454|NCT00307684|Long term safety
1420455|NCT00307684|Efficacy
1420456|NCT00307684|Quality of life
1420457|NCT00307671|Systemic necrotizing vasculitides
1420458|NCT00307671|corticosteroids; azathioprine; mycophenolate mofetil;
1420459|NCT00307671|cyclophosphamide
1420460|NCT00307671|Elderly patients
1420461|NCT00307671|Randomized controlled trial
1420462|NCT00307658|ANCA associated Vasculitides
1420463|NCT00307658|Relapse
1420464|NCT00307658|intravenous Immunoglobulins
1420465|NCT00307658|Corticosteroid
1420466|NCT00307658|Immunosuppressant
1420467|NCT00307645|ANCA associated systemic vasculitis
1420468|NCT00307645|Maintenance therapy
1420469|NCT00307645|Azathioprine
1420470|NCT00307645|Mycophenolate mofetil
1420471|NCT00307632|Contraception
1420472|NCT00307632|Hormonal patch
1420473|NCT00307632|Norelgestromine
1420474|NCT00307632|Ethinyl estradiol
1420475|NCT00307619|Binge-Eating Disorder
1420476|NCT00307606|Mastectomy
1420477|NCT00307606|Seroma
1420478|NCT00307606|Breast cancer
1420479|NCT00307606|Glucocorticoid
1420480|NCT00307593|Systemic ANCA+ vascularizes
1420481|NCT00307593|Relapse
1420482|NCT00307593|Corticosteroids
1420483|NCT00307593|Immunosuppressant
1420484|NCT00307593|Infliximab/rituximab
1420485|NCT00307593|Patients with relapsing or refractory forms of ANCA
1420486|NCT00307593|associated vasculitides Microscopic polyangiitis
1420487|NCT00307580|CVADS
1420488|NCT00307502|protease inhibitors
1420489|NCT00307502|non-nucleoside analog reverse transcriptase inhibitors
1420490|NCT00307502|pharmacokinetic models
1420491|NCT00307502|treatment experienced
1420492|NCT00307502|HIV
1420493|NCT00307476|Fecal Incontinence
1420494|NCT00307476|Fecal Containment Devices
1420495|NCT00307476|Skin Integrity
1420496|NCT00307463|end-stage renal disease
1420497|NCT00307463|hemodialysis
1420498|NCT00307463|volume control
1420499|NCT00307463|ultrafiltration
1420500|NCT00307463|inflammation
1420501|NCT00307463|cardiovascular disease
1420502|NCT00307463|left ventricular hypertrophy
1420503|NCT00307463|dietary salt restriction
1420504|NCT00307450|Dyskinesias
1420505|NCT00307450|Parkinson's disease
1420506|NCT00307450|Levetiracetam
1420507|NCT00307450|Treatment
1420508|NCT00307437|Moderate to Severe Plaque-Type Psoriasis
1420509|NCT00307437|interleukin 23
1420510|NCT00307437|IL-12
1420511|NCT00307437|interleukin-12
1420512|NCT00307437|interleukin-23
1420513|NCT00307437|CNTO1275
1420514|NCT00307437|biologic
1420515|NCT00307437|Psoriasis
1420516|NCT00307437|CNTO 1275
1420517|NCT00307437|IL23
1420518|NCT00307437|interleukin 12
1420519|NCT00307437|IL-23
1420520|NCT00307437|IL12
1420521|NCT00307437|ustekinumab
1420522|NCT00307411|Metabolic syndrome
1420523|NCT00307398|AMD
1420524|NCT00307398|Dry AMD
1420525|NCT00307398|Drusen
1420526|NCT00307398|CNV
1420527|NCT00307385|Motor Recovery
1420528|NCT00307385|Transcranial Direct Current Stimulation (tDCS)
1420529|NCT00307385|Homeostatic Plasticity
1420530|NCT00307385|Ipsilesional Primary Motor Cortex
1420531|NCT00307385|Paretic Fingers Motor Sequence
1420532|NCT00307385|Motor Cortex
1420533|NCT00307385|Motor Function
1420534|NCT00307385|Motor Learning
1420535|NCT00307385|Premotor Cortex
1420536|NCT00307385|Primary Motor Cortex
1420537|NCT00307385|Stroke
1420538|NCT00307385|Healthy Volunteer
1420539|NCT00307385|HV
1420540|NCT00307346|Movement-Related Potential
1420541|NCT00307346|Electroencephalogram
1420542|NCT00307346|Psychogenic Movement Disorders
1420543|NCT00307346|Psychogenic Movement Disorder
1420544|NCT00307346|Healthy Volunteer
1420545|NCT00307346|HV
1420546|NCT00307333|very low birth weight infants
1420547|NCT00307333|heart rate characteristics
1420548|NCT00307320|pregnancy
1420549|NCT00307320|stress
1420550|NCT00307320|anxiety
1420551|NCT00307307|atherosclerosis
1420552|NCT00307307|HDL cholesterol
1420553|NCT00307307|niacin
1420554|NCT00307307|MR imaging
1420555|NCT00307294|Prostate
1420556|NCT00307294|Androgen
1420557|NCT00307294|AIPC
1420558|NCT00307294|Doxil
1420559|NCT00307268|ADHD Effectiveness
1420560|NCT00307255|unspecified adult solid tumor
1420561|NCT00307255|protocol specific
1420562|NCT00307255|Paclitaxel
1420563|NCT00307255|Abraxane
1420564|NCT00307255|Gemcitabine
1420565|NCT00307255|Gemzar
1420566|NCT00307255|Phase I
1420567|NCT00307255|Lineberger
1420568|NCT00307242|Adefovir Dipivoxil
1420569|NCT00307242|Lamivudine
1420570|NCT00307242|Hepatitis B
1420571|NCT00307229|metastatic breast cancer
1420572|NCT00307229|recurrent breast cancer
1420573|NCT00307216|First Episode Psychosis
1420574|NCT00307216|Early Psychosis
1420575|NCT00307216|Psychosocial Intervention
1420576|NCT00307203|Bupropion
1420577|NCT00307203|Zyban
1420578|NCT00307203|Wellbutrin
1420579|NCT00307203|Smoking cessation
1420580|NCT00307203|Schizophrenia
1420581|NCT00307203|Schizoaffective disorder
1420582|NCT00307203|Cognitive Behavioral Therapy
1420583|NCT00307190|BED
1420584|NCT00307177|influenza vaccine, baculovirus, immunogenicity, lymphoma
1420585|NCT00307164|Treatment Experienced
1420586|NCT00307164|Uridine
1420587|NCT00307151|Treatment Naive
1420588|NCT00307151|Mother-To-Child Transmission
1420589|NCT00307151|MTCT
1420590|NCT00307151|Pediatrics
1420591|NCT00307151|Viral resistance
1420592|NCT00307138|Coronary artery bypass, Off-pump
1420593|NCT00307138|Hetastarch
1420594|NCT00307138|Plasma substitutes
1420595|NCT00307138|Equivalence
1420596|NCT00307125|Organ Transplantation
1420597|NCT00307125|Graft function/survival
1420598|NCT00307125|Immunosuppression
1420599|NCT00307125|anti-CD20 (rituximab)
1420600|NCT00307112|Group A streptococcus, Nicaragua, Rheumatic Heart Disease
1420601|NCT00307099|bacterial diseases
1420602|NCT00307073|Pacemaker
1420603|NCT00307073|Managed Ventricular Pacing
1420604|NCT00307073|Ventricular Pacing
1420605|NCT00307047|Stents
1420606|NCT00307047|Angioplasty
1420607|NCT00307047|Total coronary occlusion
1420608|NCT00307047|coronary restenosis
1420609|NCT00307047|stent thrombosis
1420610|NCT00307034|Primary vaccination
1420611|NCT00307034|Pneumococcal disease
1420612|NCT00307034|Safety
1420613|NCT00307034|Booster vaccination
1420614|NCT00307034|Immunogenicity
1420615|NCT00307034|Pneumococcal vaccine
1420616|NCT00307034|Dose comparison
1420617|NCT00307021|Parasitic Diseases
1420618|NCT00307021|Malaria, Falciparum
1420619|NCT00307021|Malaria
1420620|NCT00307021|Coccidiosis
1420621|NCT00307008|Prophylaxis Invasive pneumococcal diseases and pneumonia
1420622|NCT00306995|prophylaxis of pandemic influenza
1420623|NCT00306982|Prophylaxis Influenza vaccine
1420624|NCT00306969|mycosis fungoides, Sézary Syndrome
1420625|NCT00306956|Infant
1420626|NCT00306956|Newborn
1420627|NCT00306956|pacifier
1420628|NCT00306956|dummies
1420629|NCT00306956|breastfeeding
1420630|NCT00306956|Sudden Infant Death
1420631|NCT00306956|SIDS
1420632|NCT00306956|Pacifiers
1420633|NCT00306930|Total Hip Replacement
1420634|NCT00306930|post-traumatic arthritis
1420635|NCT00306917|Total Hip Replacement
1420636|NCT00306904|Macular
1420637|NCT00306904|Edema
1420638|NCT00306904|Diabetic
1420639|NCT00306904|Retinopathy
1420640|NCT00306891|Advanced solid tumours
1420641|NCT00306891|Advanced cancer
1420642|NCT00306891|tumor
1420643|NCT00306891|tumour
1420644|NCT00306891|RECENTIN
1420645|NCT00306865|Neurotransmitter
1420646|NCT00306865|Neuroimaging
1420647|NCT00306865|Movement Disorder
1420648|NCT00306865|Focal Hand Dystonia
1420649|NCT00306865|FHD
1420650|NCT00306865|HV
1420651|NCT00306852|Glaucoma
1420652|NCT00306852|Trabeculectomy
1420653|NCT00306852|Tube shunt surgery
1420654|NCT00306839|Tissucol
1420655|NCT00306839|Tisseel
1420656|NCT00306839|Lichtenstein
1420657|NCT00306839|hernia
1420658|NCT00306839|inguinal
1420659|NCT00306826|Impaired glucose tolerance
1420660|NCT00306813|refractory or relapsed multiple myeloma
1420661|NCT00306813|CC-5013
1420662|NCT00306813|Revlimid
1420663|NCT00306813|lenalidomide
1420664|NCT00306813|RAD
1420665|NCT00306800|Methyl aminolevulinate
1420666|NCT00306800|Photodynamic therapy
1420667|NCT00306800|Aktilite CL128 LED light source
1420668|NCT00306800|Multiple Actinic Keratosis
1420669|NCT00306787|Herpes simplex
1420670|NCT00306787|genital herpes
1420671|NCT00306787|famciclovir
1420672|NCT00306787|valacyclovir
1420673|NCT00306787|Recurrent genital herpes
1420674|NCT00306774|osteoarthritis
1420675|NCT00306774|vitamin D
1420676|NCT00306774|knee pain
1420677|NCT00306774|cartilage loss
1420678|NCT00306774|WOMAC
1420679|NCT00306774|MRI
1420680|NCT00306774|cartilage volume
1420681|NCT00306774|OA
1420682|NCT00306774|physical function
1420683|NCT00306774|web-based
1420684|NCT00306774|internet-based
1420685|NCT00306748|Chronic Constipation
1420686|NCT00306748|Chronic Idiopathic Constipation
1420687|NCT00306748|Constipation
1420688|NCT00306748|CIC
1420689|NCT00306748|CC
1420690|NCT00306748|MD-1100
1420691|NCT00306748|MD-1100 Acetate
1420692|NCT00306748|Microbia
1420693|NCT00306748|Microbia, Inc.
1420694|NCT00306748|linaclotide
1420695|NCT00306748|linaclotide acetate
1420696|NCT00306735|Multiple Myeloma
1420697|NCT00306735|Stem Cell Transplantation
1420698|NCT00306735|CINV
1420699|NCT00306722|Bronchoscopy
1420700|NCT00306722|Sedation
1420701|NCT00306722|AQUAVAN
1420702|NCT00306722|fospropofol disodium
1420703|NCT00306722|Flexible bronchoscopy
1420704|NCT00306709|obesity
1420705|NCT00306709|behavior change
1420706|NCT00306709|cultural adaptations
1420707|NCT00306709|weight loss
1420708|NCT00306696|rosiglitazone
1420709|NCT00306696|fluid retention
1420710|NCT00306696|Type 2 diabetes
1420711|NCT00306696|diuretics
1420712|NCT00306683|Hypothalamic-pituitary lesions
1420713|NCT00306683|Craniopharyngioma
1420714|NCT00306683|Obesity
1420715|NCT00306683|Diazoxide
1420716|NCT00306683|Hyperinsulinemia
1420717|NCT00306683|Pediatric neurosurgery
1420718|NCT00306683|Oncology
1420719|NCT00306683|Pituitary
1420720|NCT00306683|Hypothalamus
1420721|NCT00306670|Acquired Hemophilia A
1420722|NCT00306670|Anti-Factor VIII antibodies
1420723|NCT00306670|Anti-Factor VIII inhibitors
1420724|NCT00306670|Hemophilia A
1420725|NCT00306670|Factor VIII inhibitors
1420726|NCT00306657|Glaucoma Open-Angle
1420727|NCT00306657|Normal tension glaucoma progressive
1420728|NCT00306657|chronic open angle glaucoma progressive
1420729|NCT00306657|optic nerve sheath fenestration
1420730|NCT00306657|cerebrospinal fluid
1420731|NCT00306657|Beta-Trace Protein
1420732|NCT00306644|rosiglitazone
1420733|NCT00306644|Type 2 diabetes
1420734|NCT00306644|intima media thickness
1420735|NCT00306644|Insulin resistance
1420736|NCT00306631|Advanced and Metastatic Breast Cancer
1420743|NCT00306592|Multiple Sclerosis
1420744|NCT00306592|MS
1420745|NCT00306579|Ischemic Stroke
1420746|NCT00306579|Myocardial ischemia
1420747|NCT00306579|Myocardial necrosis
1420748|NCT00306527|Influenza
1420749|NCT00306527|adult/elderly
1420750|NCT00306527|flu cell culture
1420751|NCT00306527|vaccine
1420752|NCT00306514|metastatic malignant melanoma of the skin
1420753|NCT00306501|Training
1420754|NCT00306501|Cortical Stimulation
1420755|NCT00306501|Sensory Stimulation
1420756|NCT00306501|Brain Imaging
1420757|NCT00306501|Transcranial Magnetic Stimulation (TMS)
1420758|NCT00306501|Swallowing
1420759|NCT00306501|Dysphagia
1420760|NCT00306501|Stroke
1420761|NCT00306501|CVA
1420762|NCT00306501|Cerebral Vascular Accident
1420763|NCT00306501|Healthy Volunteer
1420764|NCT00306501|HV
1420765|NCT00306488|Retinal Pigment Epithelium
1420766|NCT00306488|Dynamic Light Scattering (DLS)
1420767|NCT00306488|Visual Acuity Decrease
1420768|NCT00306488|Intra-ocular Pressure
1420769|NCT00306488|Autofluorescence of Retina
1420770|NCT00306488|Age-Related Macular Degeneration
1420771|NCT00306488|AMD
1420772|NCT00306475|schizophrenia, cognition, mood stabilizer
1420773|NCT00306462|Premature Labor
1420774|NCT00306462|Premature Birth
1420775|NCT00306462|Magnesium sulfate
1420776|NCT00306462|Nifedipine
1420777|NCT00306449|Weight gain
1420778|NCT00306449|obesity
1420779|NCT00306449|overweight
1420780|NCT00306449|young adults
1420781|NCT00306449|lipid disorders
1420782|NCT00306449|insulin resistance
1420783|NCT00306449|randomized controled study
1420784|NCT00306436|Diabetes
1420785|NCT00306436|renal deficiency
1420786|NCT00306436|hypertension
1420787|NCT00306423|exercise
1420788|NCT00306410|Vitamin D deficiency
1420789|NCT00306410|HIV/AIDS
1420790|NCT00306410|HAART
1420791|NCT00306410|T-Lymphocytes, Regulatory
1420792|NCT00306410|insulin resistance
1420793|NCT00306410|bone density
1420794|NCT00306397|Kidney transplantation
1420795|NCT00306397|Steroid free
1420796|NCT00306397|Calcineurin inhibitor free
1420797|NCT00306397|Tacrolimus
1420798|NCT00306397|Sirolimus
1420799|NCT00306384|Glucose Metabolism Disorder
1420800|NCT00306384|Dysmetabolic Syndrome
1420801|NCT00306384|Type II Diabetes
1420802|NCT00306384|Diabetes Mellitus,
1420803|NCT00306384|Lipoatrophic
1420804|NCT00306384|Dyslipidemia
1420805|NCT00306384|Drug Therapy
1420806|NCT00306371|diode
1420807|NCT00306371|laser
1420808|NCT00306371|acne
1420809|NCT00306371|acne scar
1420810|NCT00306358|absorption test
1420811|NCT00306358|cobalamin
1420812|NCT00306358|holotranscobalamin
1420813|NCT00306358|vitamin B12
1420814|NCT00306345|Outreach
1420815|NCT00306345|Major general surgery
1420816|NCT00306345|Intensive care
1420817|NCT00306345|Serious adverse events
1420818|NCT00306332|Allogeneic Stem cell transplantation
1420819|NCT00306332|T-cell depletion
1420820|NCT00306332|B-cell depletion
1420821|NCT00306332|Immunomagnetic selection
1420822|NCT00306319|Tuberculosis
1420823|NCT00306293|Recurrent Genital Herpes
1420824|NCT00306280|Helicobacter pylori
1420825|NCT00306280|phototherapy
1420826|NCT00306280|peptic ulcer
1420827|NCT00306280|gastric cancer
1420828|NCT00306267|Anemia
1420829|NCT00306267|non-chemotherapy-induced
1420830|NCT00306267|non-radiation therapy-induced
1420831|NCT00306267|cancer
1420832|NCT00306267|non-myeloid
1420833|NCT00306241|Cervical neoplasia
1420834|NCT00306241|Cervical cancer
1420835|NCT00306241|Double-blind
1420836|NCT00306241|HPV-16/18 L1 VLP AS04
1420837|NCT00306241|HPV
1420838|NCT00306241|AS04
1420839|NCT00306228|ST elevation acute myocardial infarction
1420840|NCT00306228|Thrombolysis
1420841|NCT00306228|Early routine percutaneous coronary intervention
1420842|NCT00306228|tirofiban
1420843|NCT00306228|paclitaxel
1420844|NCT00306215|double-blind
1420845|NCT00306215|placebo-controlled
1420846|NCT00306215|multicenter
1420847|NCT00306215|efficacy
1420848|NCT00306215|safety
1420849|NCT00306202|Relapsed and Refractory Leukemia
1420850|NCT00306189|RANKL
1420851|NCT00306189|RANK
1420852|NCT00306189|denosumab
1420853|NCT00306189|AMG 162
1420854|NCT00306189|osteoporosis
1420855|NCT00306189|bone turnover
1420856|NCT00306189|bone mineral density
1420857|NCT00306189|Japanese
1420858|NCT00306176|rosiglitazone,exercise,cardiovascular risk factors
1420859|NCT00306163|Asthma
1420860|NCT00306163|AMP
1420861|NCT00306163|Ciclesonide
1420862|NCT00306163|Fluticasone propionate
1420863|NCT00306150|Prevention of blood loss
1420864|NCT00306150|Blood Loss, Surgical
1420865|NCT00306150|Blood Loss, Postoperative
1420866|NCT00306124|Dementia
1420867|NCT00306124|Mild Cognitive Impairment
1420868|NCT00306124|MCI
1420869|NCT00306124|levodopa
1420870|NCT00306124|learning
1420871|NCT00306124|enhancement
1420872|NCT00306111|stem cell transplantation
1420873|NCT00306111|stem cell mobilization
1420874|NCT00306111|high-dose therapy
1420875|NCT00306098|Transplantation, Islets of Langerhans
1420876|NCT00306085|Peripheral arterial disease,
1420877|NCT00306085|blood marrow cells,
1420878|NCT00306085|therapeutic angiogenesis.
1420879|NCT00306046|PETScan
1420880|NCT00306046|Positron-Emission Tomography
1420881|NCT00306046|Bisphosphonate
1420882|NCT00306046|Biochemical Markers
1420883|NCT00306046|Paget's Disease of Bone (monostotic and polyostotic)
1420884|NCT00306033|myasthenia gravis
1420885|NCT00306033|immunoglobulin
1420886|NCT00306033|intravenous immunoglobulin
1420887|NCT00306033|treatment
1420888|NCT00306020|Skin ulcers
1420889|NCT00306020|Topical morphine
1420890|NCT00306020|Chronic pain
1420891|NCT00306020|Cancer
1420892|NCT00306007|Pregnancy
1420893|NCT00306007|Unplanned pregnancy
1420894|NCT00306007|Psychosocial
1420895|NCT00306007|Measure
1420896|NCT00305968|Quality of life
1420897|NCT00305968|Gastrointestinal symptoms
1420898|NCT00305968|Health related costs
1420899|NCT00305955|amblyopia
1420900|NCT00305955|bilateral amblyopia
1420901|NCT00305955|refractive error
1420902|NCT00305942|Lung Cancer
1420903|NCT00305942|Carcinoma, Small Cell
1420904|NCT00305929|Treatment of localized prostate cancer
1420905|NCT00305929|Localized prostate cancer
1420906|NCT00305916|MSCT
1420907|NCT00305916|Idiopathic Cardiomyopathy
1420908|NCT00305916|Sinus rhythm
1420909|NCT00305903|Dementia,
1420910|NCT00305903|Alzheimer's,
1420911|NCT00305903|Rivastigmine,
1420912|NCT00305903|Memantine
1420913|NCT00305851|fatigue
1420914|NCT00305851|pain
1420915|NCT00305851|psychosocial effects of cancer and its treatment
1420916|NCT00305851|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1420917|NCT00305851|adult acute myeloid leukemia with inv(16)(p13;q22)
1420918|NCT00305851|adult acute myeloid leukemia with t(15;17)(q22;q12)
1420919|NCT00305851|adult acute myeloid leukemia with t(16;16)(p13;q22)
1420920|NCT00305851|adult acute myeloid leukemia with t(8;21)(q22;q22)
1420921|NCT00305851|accelerated phase chronic myelogenous leukemia
1420922|NCT00305851|adult acute lymphoblastic leukemia in remission
1420923|NCT00305851|adult acute myeloid leukemia in remission
1420924|NCT00305851|atypical chronic myeloid leukemia, BCR-ABL1 negative
1420925|NCT00305851|blastic phase chronic myelogenous leukemia
1420926|NCT00305851|childhood acute lymphoblastic leukemia in remission
1420927|NCT00305851|childhood acute myeloid leukemia in remission
1420928|NCT00305851|childhood chronic myelogenous leukemia
1420929|NCT00305851|chronic eosinophilic leukemia
1420930|NCT00305851|primary myelofibrosis
1420931|NCT00305851|chronic myelomonocytic leukemia
1420932|NCT00305851|chronic neutrophilic leukemia
1420933|NCT00305851|chronic phase chronic myelogenous leukemia
1420934|NCT00305851|de novo myelodysplastic syndromes
1420935|NCT00305851|disseminated neuroblastoma
1420936|NCT00305851|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1420937|NCT00305851|juvenile myelomonocytic leukemia
1420938|NCT00305851|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1420939|NCT00305851|nodal marginal zone B-cell lymphoma
1420940|NCT00305851|noncontiguous stage II adult Burkitt lymphoma
1420941|NCT00305851|noncontiguous stage II adult diffuse large cell lymphoma
1420942|NCT00305851|noncontiguous stage II adult diffuse mixed cell lymphoma
1420943|NCT00305851|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1420944|NCT00305851|noncontiguous stage II adult immunoblastic large cell lymphoma
1420945|NCT00305851|noncontiguous stage II adult lymphoblastic lymphoma
1420946|NCT00305851|noncontiguous stage II grade 1 follicular lymphoma
1420947|NCT00305851|noncontiguous stage II grade 2 follicular lymphoma
1420948|NCT00305851|noncontiguous stage II grade 3 follicular lymphoma
1420949|NCT00305851|noncontiguous stage II mantle cell lymphoma
1420950|NCT00305851|noncontiguous stage II marginal zone lymphoma
1420951|NCT00305851|noncontiguous stage II small lymphocytic lymphoma
1420952|NCT00305851|high risk metastatic gestational trophoblastic tumor
1420953|NCT00305851|previously treated childhood rhabdomyosarcoma
1420954|NCT00305851|previously treated myelodysplastic syndromes
1420955|NCT00305851|recurrent adult acute lymphoblastic leukemia
1420956|NCT00305851|recurrent adult acute myeloid leukemia
1420957|NCT00305851|recurrent adult Burkitt lymphoma
1420958|NCT00305851|recurrent adult Hodgkin lymphoma
1420959|NCT00305851|recurrent adult diffuse large cell lymphoma
1420960|NCT00305851|recurrent adult diffuse mixed cell lymphoma
1420961|NCT00305851|recurrent adult diffuse small cleaved cell lymphoma
1420962|NCT00305851|recurrent adult immunoblastic large cell lymphoma
1420963|NCT00305851|recurrent adult lymphoblastic lymphoma
1420964|NCT00305851|recurrent/refractory childhood Hodgkin lymphoma
1420965|NCT00305851|recurrent childhood acute lymphoblastic leukemia
1420966|NCT00305851|recurrent childhood acute myeloid leukemia
1420967|NCT00305851|recurrent childhood large cell lymphoma
1420968|NCT00305851|recurrent childhood lymphoblastic lymphoma
1420969|NCT00305851|recurrent childhood rhabdomyosarcoma
1420970|NCT00305851|recurrent childhood small noncleaved cell lymphoma
1420971|NCT00305851|recurrent cutaneous T-cell non-Hodgkin lymphoma
1420972|NCT00305851|recurrent grade 1 follicular lymphoma
1420973|NCT00305851|recurrent grade 2 follicular lymphoma
1420974|NCT00305851|recurrent grade 3 follicular lymphoma
1420975|NCT00305851|recurrent mantle cell lymphoma
1420976|NCT00305851|recurrent marginal zone lymphoma
1420977|NCT00305851|recurrent mycosis fungoides/Sezary syndrome
1420978|NCT00305851|recurrent neuroblastoma
1420979|NCT00305851|recurrent ovarian epithelial cancer
1420980|NCT00305851|recurrent ovarian germ cell tumor
1420981|NCT00305851|recurrent small lymphocytic lymphoma
1420982|NCT00305851|recurrent malignant testicular germ cell tumor
1420983|NCT00305851|recurrent Wilms tumor and other childhood kidney tumors
1420984|NCT00305851|refractory chronic lymphocytic leukemia
1420985|NCT00305851|refractory hairy cell leukemia
1420986|NCT00305851|relapsing chronic myelogenous leukemia
1420987|NCT00305851|secondary acute myeloid leukemia
1420988|NCT00305851|secondary myelodysplastic syndromes
1420989|NCT00305851|splenic marginal zone lymphoma
1420990|NCT00305851|stage III adult Burkitt lymphoma
1420991|NCT00305851|stage III adult Hodgkin lymphoma
1420992|NCT00305851|stage III adult diffuse large cell lymphoma
1420993|NCT00305851|stage III adult diffuse mixed cell lymphoma
1420994|NCT00305851|stage III adult diffuse small cleaved cell lymphoma
1420995|NCT00305851|stage III adult immunoblastic large cell lymphoma
1420996|NCT00305851|stage III adult lymphoblastic lymphoma
1420997|NCT00305851|stage III chronic lymphocytic leukemia
1420998|NCT00305851|stage III grade 1 follicular lymphoma
1420999|NCT00305851|stage III grade 2 follicular lymphoma
1421000|NCT00305851|stage III grade 3 follicular lymphoma
1421001|NCT00305851|stage III mantle cell lymphoma
1421002|NCT00305851|stage III marginal zone lymphoma
1421003|NCT00305851|stage III small lymphocytic lymphoma
1421004|NCT00305851|stage III malignant testicular germ cell tumor
1421005|NCT00305851|stage IV adult Burkitt lymphoma
1421006|NCT00305851|stage IV adult Hodgkin lymphoma
1421007|NCT00305851|stage IV adult diffuse large cell lymphoma
1421008|NCT00305851|stage IV adult diffuse mixed cell lymphoma
1421009|NCT00305851|stage IV adult diffuse small cleaved cell lymphoma
1421010|NCT00305851|stage IV adult immunoblastic large cell lymphoma
1421011|NCT00305851|stage IV adult lymphoblastic lymphoma
1421012|NCT00305851|stage IV chronic lymphocytic leukemia
1421013|NCT00305851|stage IV grade 1 follicular lymphoma
1421014|NCT00305851|stage IV grade 2 follicular lymphoma
1421015|NCT00305851|stage IV grade 3 follicular lymphoma
1421016|NCT00305851|stage IV mantle cell lymphoma
1421017|NCT00305851|stage IV marginal zone lymphoma
1421018|NCT00305851|stage IV ovarian epithelial cancer
1421019|NCT00305851|stage IV small lymphocytic lymphoma
1421020|NCT00305851|stage II ovarian epithelial cancer
1421021|NCT00305851|stage III ovarian epithelial cancer
1421022|NCT00305851|childhood myelodysplastic syndromes
1421023|NCT00305851|Ewing sarcoma
1421024|NCT00305851|childhood brain tumor
1421025|NCT00305851|adult brain tumor
1421026|NCT00305851|osteosarcoma
1421027|NCT00305838|stage IV ovarian epithelial cancer
1421028|NCT00305838|recurrent ovarian epithelial cancer
1421029|NCT00305838|stage IIIA ovarian epithelial cancer
1421030|NCT00305838|stage IIIB ovarian epithelial cancer
1421031|NCT00305838|stage IIIC ovarian epithelial cancer
1421032|NCT00305838|recurrent fallopian tube cancer
1421033|NCT00305838|stage IIIA fallopian tube cancer
1421034|NCT00305838|stage IIIB fallopian tube cancer
1421035|NCT00305838|stage IIIC fallopian tube cancer
1421036|NCT00305838|stage IV fallopian tube cancer
1421037|NCT00305838|recurrent primary peritoneal cavity cancer
1421038|NCT00305838|stage IIIA primary peritoneal cavity cancer
1421039|NCT00305838|stage IIIB primary peritoneal cavity cancer
1421040|NCT00305838|stage IIIC primary peritoneal cavity cancer
1421041|NCT00305838|stage IV primary peritoneal cavity cancer
1421042|NCT00305825|recurrent breast cancer
1421043|NCT00305825|stage IIIA breast cancer
1421044|NCT00305825|stage IIIB breast cancer
1421045|NCT00305825|stage IIIC breast cancer
1421046|NCT00305825|stage IV breast cancer
1421047|NCT00305812|stage I multiple myeloma
1421048|NCT00305812|stage II multiple myeloma
1421049|NCT00305812|stage III multiple myeloma
1421050|NCT00305799|neurotoxicity
1421051|NCT00305799|unspecified adult solid tumor, protocol specific
1421052|NCT00305786|recurrent non-small cell lung cancer
1421053|NCT00305786|stage IIIB non-small cell lung cancer
1421054|NCT00305786|stage IV non-small cell lung cancer
1421055|NCT00305760|stage III pancreatic cancer
1421056|NCT00305760|recurrent pancreatic cancer
1421057|NCT00305760|duct cell adenocarcinoma of the pancreas
1421058|NCT00305760|adenocarcinoma of the pancreas
1421059|NCT00305760|stage IV pancreatic cancer
1421060|NCT00305747|recurrent prostate cancer
1421061|NCT00305747|stage I prostate cancer
1421062|NCT00305747|stage II prostate cancer
1421063|NCT00305747|stage III prostate cancer
1421064|NCT00305747|adenocarcinoma of the prostate
1421065|NCT00305747|stage IV prostate cancer
1421066|NCT00305708|thrombocytopenia
1421067|NCT00305708|childhood acute myeloid leukemia in remission
1421068|NCT00305708|childhood chronic myelogenous leukemia
1421069|NCT00305708|Diamond-Blackfan anemia
1421070|NCT00305708|congenital amegakaryocytic thrombocytopenia
1421071|NCT00305708|Fanconi anemia
1421072|NCT00305708|severe congenital neutropenia
1421073|NCT00305708|chronic phase chronic myelogenous leukemia
1421074|NCT00305695|osteoporosis
1421075|NCT00305695|hereditary breast/ovarian cancer (BRCA1, BRCA2)
1421076|NCT00305695|ovarian epithelial cancer
1421077|NCT00305669|adenocarcinoma of the prostate
1421078|NCT00305669|stage I prostate cancer
1421079|NCT00305669|stage IIB prostate cancer
1421080|NCT00305669|stage IIA prostate cancer
1421081|NCT00305669|stage III prostate cancer
1421082|NCT00305643|Hand-Foot Syndrome
1421083|NCT00305643|cancer-related problem/condition
1421084|NCT00305643|drug/agent toxicity by tissue/organ
1421085|NCT00305643|pain
1421086|NCT00305643|palmar-plantar erythrodysesthesia
1421087|NCT00305643|stage IV breast cancer
1421088|NCT00305643|male breast cancer
1421089|NCT00305643|recurrent breast cancer
1421090|NCT00305643|stage IV colon cancer
1421091|NCT00305643|stage IV rectal cancer
1421092|NCT00305643|recurrent colon cancer
1421093|NCT00305643|recurrent rectal cancer
1421094|NCT00305643|Celecoxib
1421095|NCT00305643|Celebrex
1421096|NCT00305643|Capecitabine
1421097|NCT00305643|Xeloda
1421098|NCT00305630|Corticosteroids
1421099|NCT00305630|Triamcinolone
1421100|NCT00305630|Photodynamic therapy
1421101|NCT00305630|Choroidal neovascularization
1421102|NCT00305630|Age-related macular degeneration
1421103|NCT00305617|stage IIIA non-small cell lung cancer
1421104|NCT00305617|stage IIIB non-small cell lung cancer
1421105|NCT00305591|magnetic resonance imaging
1421106|NCT00305591|magnetic resonance spectroscopy
1421107|NCT00305591|functional magnetic resonance imaging
1421108|NCT00305591|cirrhosis
1421109|NCT00305591|hepatic encephalopathy
1421110|NCT00305591|l-ornithine l-aspartate
1421111|NCT00305578|Bipolar
1421112|NCT00305578|Depression
1421113|NCT00305578|Incomplete Response
1421114|NCT00305565|Depression
1421115|NCT00305565|Chronic Depression
1421116|NCT00305565|Bipolar Disorder
1421117|NCT00305552|Randomized controlled trial
1421118|NCT00305552|Thalidomide vs placebo
1421119|NCT00305552|skin sarcoidosis
1421120|NCT00305552|Thalidomide
1421121|NCT00305539|Giant Cell Arteritis
1421122|NCT00305539|Placebo
1421123|NCT00305539|Anti-TNF
1421124|NCT00305539|Multicenter-randomized-trial
1421125|NCT00305539|Proved GCA according to ACR criteria (HUNDER et al 1990)
1421126|NCT00305513|right hemispheric CVA
1421127|NCT00305513|neglect
1421128|NCT00305513|phasic alert treatment
1421129|NCT00305513|PET scan
1421130|NCT00305513|patients post right hemispheric CVA (stroke)
1421131|NCT00305500|OCD
1421132|NCT00305500|Escitalopram
1421133|NCT00305487|Hay Fever
1421134|NCT00305487|Seasonal Allergic Rhinitis
1421135|NCT00305487|Nasal spray
1421136|NCT00305487|Ciclesonide
1421137|NCT00305487|Allergic Rhinitis
1421138|NCT00305474|Negative symptoms
1421139|NCT00305474|neuropsychological deficits
1421140|NCT00305474|Cognitive function
1421141|NCT00305474|diagnostic
1421142|NCT00305474|prevention
1421143|NCT00305461|Asthma
1421144|NCT00305461|Quality of Life
1421145|NCT00305461|Ciclesonide
1421146|NCT00305448|oncology
1421147|NCT00305448|cancer
1421148|NCT00305448|breast cancer
1421149|NCT00305435|AMG 531, ITP, Phase 2, Japanese
1421150|NCT00305409|Crohn's
1421151|NCT00305409|TNF-alpha
1421152|NCT00305409|Synbiotic
1421153|NCT00305409|Probiotic
1421154|NCT00305396|Kidney transplantation
1421155|NCT00305396|immunosuppression
1421156|NCT00305396|sirolimus
1421157|NCT00305396|Thymoglobulin
1421158|NCT00305383|Viramidine
1421159|NCT00305383|Peginterferon alfa-2b
1421160|NCT00305383|Valeant
1421161|NCT00305383|Hepatitis C
1421162|NCT00305383|Rapid virologic response
1421163|NCT00305383|HCV RNA
1421164|NCT00305370|clinical trial
1421165|NCT00305370|aripiprazole
1421166|NCT00305370|methylphenidate
1421167|NCT00305370|Bipolar Disorder
1421168|NCT00305370|Attention-Deficit Hyperactivity Disorder
1421169|NCT00305370|ADHD
1421170|NCT00305357|Post-Herpetic Neuralgia
1421171|NCT00305357|Acute Herpes Zoster
1421172|NCT00305344|Type 1 Diabetes Mellitus
1421173|NCT00305344|Umbilical Cord
1421174|NCT00305344|Regeneration
1421175|NCT00305344|Insulin
1421176|NCT00305344|Islets of Langerhans
1421177|NCT00305331|Parkinson's disease
1421178|NCT00305331|Domperidone
1421179|NCT00305331|Peripheral edema
1421180|NCT00305331|Pramipexole
1421181|NCT00305331|Ropinirole
1421182|NCT00305305|Agenesis Corpus Callosum
1421183|NCT00305305|Polymicrogyria
1421184|NCT00305305|Dandy-Walker
1421185|NCT00305305|Brain Malformation
1421186|NCT00305305|Autism
1421187|NCT00305305|Epilepsy
1421188|NCT00305305|Mental Retardation
1421189|NCT00305305|MRI
1421190|NCT00305305|Agenesis of the Corpus Callosum (complete or partial)
1421191|NCT00305305|Confirmed by a brain MRI.
1421192|NCT00305305|Aicardi Syndrome.
1421193|NCT00305266|CIDP
1421194|NCT00305266|IVIG
1421195|NCT00305266|gammaglobulin
1421196|NCT00305266|Chronic Inflammatory Demyelinating Polyradiculoneuropathy
1421197|NCT00305253|maternal mortality
1421198|NCT00305253|obstetric hemorrhage
1421199|NCT00305240|Myocardial Infarction
1421200|NCT00305240|Microvolt T Wave Alternans Test
1421201|NCT00305240|Implantable Cardioverter Defibrillator (ICD)
1421202|NCT00305240|Ventricular Arrythmias
1421203|NCT00305227|urinary tract infection
1421204|NCT00305227|cystitis
1421205|NCT00305227|Lactobacillus
1421206|NCT00305227|probiotic
1421207|NCT00305227|prevention
1421208|NCT00305214|Myocardial Infarction
1421209|NCT00305214|Microvolt T Wave Alternans Test
1421210|NCT00305214|Implantable Cardioverter Defibrillator (ICD)
1421211|NCT00305214|Ventricular Arrhythmia
1421212|NCT00305201|Mucocutaneous Lymph Node Syndrome
1421213|NCT00305201|Kawasaki disease
1421214|NCT00305201|Endothelial dysfunction
1421215|NCT00305201|Pravastatin
1421216|NCT00305201|Statin therapy
1421217|NCT00305188|Neurotoxicity syndromes
1421218|NCT00305188|Paresthesia
1421219|NCT00305188|Oxaliplatin
1421220|NCT00305188|Xaliproden
1421221|NCT00305175|Hydroxyurea
1421222|NCT00305175|Sickle Cell Anemia
1421223|NCT00305162|Acute Coronary Syndrome (ACS)
1421224|NCT00305162|Percutaneous Coronary Intervention (PCI)
1421225|NCT00305162|non-ST-segment elevation myocardial infarction (NSTEMI)
1421226|NCT00305162|ST-segment elevation myocardial infarction (STEMI)
1421227|NCT00305149|Hodgkin Lymphoma
1421228|NCT00305149|BEACOPP
1421229|NCT00305149|PET
1421230|NCT00305149|Gallium
1421231|NCT00305149|Tailored therapy
1421232|NCT00305136|thoracotomy
1421233|NCT00305136|post-operative pain
1421234|NCT00305136|chronic pain
1421235|NCT00305136|endogenous analgesia
1421236|NCT00305136|temporal summation
1421237|NCT00305136|central sensitization
1421238|NCT00305136|prediction
1421239|NCT00305136|Patients Who Should Undergo Thoracotomy
1421240|NCT00305123|Pharyngitis, Mali, Group A Streptococcus, Children
1421241|NCT00305110|Pain
1421242|NCT00305110|Acute
1421243|NCT00305110|Emergency Department
1421244|NCT00305110|Severe
1421245|NCT00305110|Hydromorphone
1421246|NCT00305110|Dilaudid
1421247|NCT00305110|Adult
1421248|NCT00305097|coffee
1421249|NCT00305097|caffeine
1421250|NCT00305097|glucose tolerance
1421251|NCT00305097|body weight
1421252|NCT00305097|insulin sensitivity
1421253|NCT00305097|randomized controlled trial
1421254|NCT00305084|NGR-hTNF
1421255|NCT00305084|doxorubicin
1421256|NCT00305084|solid tumors
1421257|NCT00305071|pyuria
1421258|NCT00305071|urinary tract infections
1421259|NCT00305071|Vaccinium macrocarpon
1421260|NCT00305058|Elderly
1421261|NCT00305058|Hydromorphone
1421262|NCT00305058|Morphine
1421263|NCT00305058|Pain
1421264|NCT00305058|Acute
1421265|NCT00305058|Emergency Department
1421266|NCT00305045|Major Depressive Disorder
1421267|NCT00305045|Repetitive Transcranial Magnetic Stimulation
1421268|NCT00305045|Treatment resistance
1421269|NCT00305006|cerebral palsy
1421270|NCT00305006|constraint-induced therapy
1421271|NCT00305006|constraint-induced movement therapy
1421272|NCT00305006|CP
1421273|NCT00305006|hemiplegia
1421274|NCT00305006|hand
1421275|NCT00305006|forced use
1421276|NCT00305006|motor control
1421277|NCT00305006|children
1421278|NCT00305006|HABIT
1421279|NCT00305006|Hand-arm bimanual intensive therapy
1421280|NCT00305006|Bilateral training
1421281|NCT00305006|Bimanual training
1421282|NCT00305006|functional therapy
1421283|NCT00305006|physical therapy
1421284|NCT00305006|occupational therapy
1421285|NCT00305006|intensive
1421286|NCT00305006|pediatric
1421287|NCT00305006|development
1421288|NCT00305006|upper extremity
1421289|NCT00305006|hemiplegic
1421290|NCT00304993|fenofibrate
1421291|NCT00304993|niacin
1421292|NCT00304993|rosiglitazone
1421293|NCT00304993|LDL phenotype pattern B
1421294|NCT00304993|small, dense LDL
1421295|NCT00304993|insulin resistance
1421296|NCT00304993|Metabolic Syndrome
1421297|NCT00304967|Cataract
1421298|NCT00304967|Normal Lenses
1421299|NCT00304967|Lens Crystallines
1421300|NCT00304967|Dynamic or Quasielastic Light Scattering (DLS)
1421301|NCT00304967|Eye Examinations
1421302|NCT00304967|Healthy Volunteer
1421303|NCT00304967|HV
1421304|NCT00304967|Eye Examination
1421305|NCT00304954|Age-Related Macular Degeneration
1421306|NCT00304954|Rapamycin
1421307|NCT00304954|Remicade
1421308|NCT00304954|Daclizumab
1421309|NCT00304954|Immunosuppression
1421310|NCT00304954|Infliximab
1421311|NCT00304954|Choroidal Neovascularization
1421312|NCT00304954|Sirolimus
1421313|NCT00304954|AMD
1421314|NCT00304954|Ocular Inflammation
1421315|NCT00304941|Breast Cancer
1421316|NCT00304941|Family History
1421317|NCT00304941|Pre/Post Menopausal
1421318|NCT00304941|Prevention
1421319|NCT00304941|Risk-Factor
1421320|NCT00304941|Body-Mass-Index
1421321|NCT00304941|BRCA1
1421322|NCT00304941|Insulin
1421323|NCT00304941|Genetic Counseling
1421324|NCT00304941|Penetrance
1421325|NCT00304941|Risk Assessment
1421326|NCT00304941|Healthy Volunteer
1421327|NCT00304941|HV
1421328|NCT00304915|HIV, depression
1421329|NCT00304915|patient care management
1421330|NCT00304915|patient care team
1421331|NCT00304902|MRSA
1421332|NCT00304902|Methicillin Resistant Staphylococcus aureus
1421333|NCT00304902|Staphylococcus aureus Bacteremia
1421334|NCT00304889|Clostridium difficile
1421335|NCT00304876|Clostridium difficile associated diarrhea
1421336|NCT00304863|CDAD
1421337|NCT00304863|Clostridium difficile Associated Diarrhea
1421338|NCT00304850|polyamines
1421339|NCT00304850|pain
1421340|NCT00304850|breast cancer
1421341|NCT00304850|mastectomy
1421342|NCT00304850|post operative pain
1421343|NCT00304837|Nonhealing leg ulcers
1421344|NCT00304837|Ischemic rest pain
1421345|NCT00304824|Glaucoma
1421346|NCT00304824|Olfactory functions
1421347|NCT00304824|Sniffing Sticks Test
1421348|NCT00304811|MRSA
1421349|NCT00304811|Methicillin Resistant Staphylococcus aureus
1421350|NCT00304798|Transient Ischemic Attack (TIA).
1421351|NCT00304798|Stroke.
1421352|NCT00304798|Hospital admission.
1421353|NCT00304772|Candida
1421354|NCT00304772|bloodstream infection
1421355|NCT00304772|fluconazole
1421356|NCT00304772|micafungin
1421357|NCT00304772|randomized controlled trial
1421358|NCT00304759|prostate cancer
1421359|NCT00304759|localized prostate cancer
1421360|NCT00304759|intermediate risk
1421361|NCT00304759|prostate specific antigen
1421362|NCT00304759|PSA
1421363|NCT00304759|radiation fractionation
1421364|NCT00304759|shorter schedule
1421365|NCT00304759|quality of life
1421366|NCT00304733|neuropathic foot ulcerations - total contact cast - custom -made footwear - off-loading
1421367|NCT00304720|Lymphoma
1421368|NCT00304720|Leukemia
1421369|NCT00304694|NPC
1421370|NCT00304694|Induction chemotherapy
1421371|NCT00304694|Therapeutic response
1421372|NCT00304694|18F-FDG PET
1421373|NCT00304681|Attention Deficit Hyperactivity Disorder
1421374|NCT00304681|OROS* Methylphenidate
1421375|NCT00304668|HIV-1
1421376|NCT00304668|HIV Seronegativity
1421377|NCT00304655|Schizophrenia
1421378|NCT00304655|Schizoaffective disorder
1421379|NCT00304655|Aripiprazole
1421380|NCT00304642|HIV-1
1421381|NCT00304642|HIV Seronegativity
1421382|NCT00304629|Alzheimer's disease
1421383|NCT00304629|cholinesterase inhibitors
1421384|NCT00304629|galantamine
1421385|NCT00304616|Schizophrenia
1421386|NCT00304616|Aripiprazole
1421387|NCT00304603|Obesity
1421388|NCT00304603|Type 2 Diabetes Mellitus
1421389|NCT00304603|Topiramate
1421390|NCT00304603|Pharmacogenomics
1421391|NCT00304603|DNA Polymorphism
1421392|NCT00304577|Strabismus
1421393|NCT00304577|Esotropia
1421394|NCT00304577|Surgical techniques
1421395|NCT00304564|Posturography, Fall Prevention, Geriatrics, Nolwenn Effect
1421396|NCT00304551|CHC with compensated LC
1421397|NCT00304538|diabetes
1421398|NCT00304525|Anti-angiogenesis therapy
1421399|NCT00304525|Kinase inhibitor therapy
1421400|NCT00304525|Raf inhibitor
1421401|NCT00304525|Locally Advanced Melanoma
1421402|NCT00304499|OROS®
1421403|NCT00304499|middle age
1421404|NCT00304499|elderly
1421405|NCT00304499|oxybutynin
1421406|NCT00304499|urinary incontinenence
1421407|NCT00304499|women
1421408|NCT00304473|Schizophrenia
1421409|NCT00304460|Serum Protein Levels
1421410|NCT00304460|Lymphocyte Phenotypes
1421411|NCT00304460|Predictive Analysis
1421412|NCT00304460|Serum Cytokines
1421413|NCT00304460|Kidney Cancer
1421414|NCT00304460|Renal Cell Cancer
1421415|NCT00304460|Melanoma
1421416|NCT00304460|Metastatic Melanoma
1421417|NCT00304447|Leukemia
1421418|NCT00304447|Mylotarg
1421419|NCT00304447|Safety
1421420|NCT00304447|Adverse Events
1421421|NCT00304434|Adverse effects
1421422|NCT00304434|Antiviral
1421423|NCT00304434|Clinical trial
1421424|NCT00304434|Oseltamivir
1421425|NCT00304434|Pharmacokinetics
1421426|NCT00304434|Probenecid
1421427|NCT00304421|Gastroesophageal Reflux Disease
1421428|NCT00304421|Proton Pump Inhibitors
1421429|NCT00304421|Gastric pH
1421430|NCT00304421|Gastric Acid Secretion
1421431|NCT00304408|Clostridium difficile
1421432|NCT00304395|Community Acquired Pneumonia
1421433|NCT00304395|CAP
1421434|NCT00304382|Pneumococcus
1421435|NCT00304382|Pneumococcal pneumonia
1421436|NCT00304369|Clostridium difficile
1421437|NCT00304356|Clostridium difficile Associated Diarrhea
1421438|NCT00304330|gram negative infection
1421439|NCT00304317|calculi
1421440|NCT00304317|ureteral calculi
1421441|NCT00304317|ureter
1421442|NCT00304304|child care centers
1421443|NCT00304304|asthma triggers
1421444|NCT00304304|community-based research
1421445|NCT00304291|Novantrone
1421446|NCT00304278|Head and Neck Cancer
1421447|NCT00304278|Erlotinib
1421448|NCT00304278|RADPLAT
1421449|NCT00304265|Pertussis,
1421450|NCT00304265|Diphtheria,
1421451|NCT00304265|Tetanus,
1421452|NCT00304265|Poliomyelitis
1421453|NCT00304239|Methyl aminolevulinate
1421454|NCT00304239|Photodynamic therapy
1421455|NCT00304239|Aktilite CL128 LED light source
1421456|NCT00304239|Multiple Actinic Keratosis
1421457|NCT00304226|Valsartan,
1421458|NCT00304226|amlodipine,
1421459|NCT00304226|hydrochlorothiazide
1421460|NCT00304213|hypogonadism
1421461|NCT00304213|testosterone
1421462|NCT00304213|aging
1421463|NCT00304213|Total testosterone < 300 ng/dL
1421464|NCT00304213|Bioavailable testosterone < 70 ng/dL
1421465|NCT00304200|Metastatic Malignant Melanoma
1421466|NCT00304187|Binge-Eating Disorder
1421467|NCT00304161|Depression
1421468|NCT00304161|Parkinson's Disease
1421469|NCT00304161|Atomoxetine
1421470|NCT00304148|Renal Insufficiency Chronic
1421471|NCT00304135|localized unresectable adult primary liver cancer
1421472|NCT00304135|unresectable extrahepatic bile duct cancer
1421473|NCT00304135|unresectable gallbladder cancer
1421474|NCT00304096|recurrent breast cancer
1421475|NCT00304096|stage IIIA breast cancer
1421476|NCT00304096|stage IIIB breast cancer
1421477|NCT00304096|stage IIIC breast cancer
1421478|NCT00304096|stage IV breast cancer
1421479|NCT00304096|male breast cancer
1421480|NCT00304096|invasive lobular breast carcinoma
1421481|NCT00304083|adult neurofibrosarcoma
1421482|NCT00304083|childhood neurofibrosarcoma
1421483|NCT00304083|metastatic childhood soft tissue sarcoma
1421484|NCT00304083|nonmetastatic childhood soft tissue sarcoma
1421485|NCT00304083|stage IV adult soft tissue sarcoma
1421486|NCT00304083|neurofibromatosis type 1
1421487|NCT00304031|adult glioblastoma
1421488|NCT00304031|adult giant cell glioblastoma
1421489|NCT00304031|adult gliosarcoma
1421490|NCT00304018|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1421491|NCT00304018|recurrent adult acute myeloid leukemia
1421492|NCT00304018|secondary acute myeloid leukemia
1421493|NCT00304018|adult acute myeloid leukemia in remission
1421494|NCT00304018|adult acute erythroid leukemia (M6)
1421495|NCT00304018|adult acute megakaryoblastic leukemia (M7)
1421496|NCT00304018|adult acute monoblastic leukemia (M5a)
1421497|NCT00304018|adult acute monocytic leukemia (M5b)
1421498|NCT00304018|refractory multiple myeloma
1421499|NCT00304018|adult acute lymphoblastic leukemia in remission
1421500|NCT00304018|accelerated phase chronic myelogenous leukemia
1421501|NCT00304018|blastic phase chronic myelogenous leukemia
1421502|NCT00304018|relapsing chronic myelogenous leukemia
1421503|NCT00304018|chronic phase chronic myelogenous leukemia
1421504|NCT00304018|stage II multiple myeloma
1421505|NCT00304018|stage III multiple myeloma
1421506|NCT00304018|recurrent adult acute lymphoblastic leukemia
1421507|NCT00304018|recurrent adult diffuse large cell lymphoma
1421508|NCT00304018|stage III adult diffuse large cell lymphoma
1421509|NCT00304018|recurrent mantle cell lymphoma
1421510|NCT00304018|stage III mantle cell lymphoma
1421511|NCT00304018|recurrent adult Hodgkin lymphoma
1421512|NCT00304018|stage III adult Hodgkin lymphoma
1421513|NCT00304018|adult acute myeloid leukemia with inv(16)(p13;q22)
1421514|NCT00304018|adult acute myeloid leukemia with t(15;17)(q22;q12)
1421515|NCT00304018|adult acute myeloid leukemia with t(16;16)(p13;q22)
1421516|NCT00304018|adult acute myeloid leukemia with t(8;21)(q22;q22)
1421517|NCT00304018|de novo myelodysplastic syndromes
1421518|NCT00304018|previously treated myelodysplastic syndromes
1421519|NCT00304018|secondary myelodysplastic syndromes
1421520|NCT00304018|recurrent adult T-cell leukemia/lymphoma
1421521|NCT00304018|stage IV adult diffuse large cell lymphoma
1421522|NCT00304018|stage IV adult Hodgkin lymphoma
1421523|NCT00304018|stage IV adult T-cell leukemia/lymphoma
1421524|NCT00304018|stage IV mantle cell lymphoma
1421525|NCT00304018|stage III adult T-cell leukemia/lymphoma
1421526|NCT00304018|stage I multiple myeloma
1421527|NCT00304005|refractory chronic lymphocytic leukemia
1421528|NCT00304005|recurrent adult diffuse large cell lymphoma
1421529|NCT00304005|recurrent adult Hodgkin lymphoma
1421530|NCT00303992|stage IV breast cancer
1421531|NCT00303992|recurrent breast cancer
1421532|NCT00303979|Systolic Heart Failure
1421533|NCT00303979|Quality of Care
1421534|NCT00303979|Outcomes
1421535|NCT00303979|Evidence-based Guidelines
1421536|NCT00303979|Recommended Therapies
1421537|NCT00303940|unspecified childhood solid tumor, protocol specific
1421538|NCT00303940|recurrent childhood rhabdomyosarcoma
1421539|NCT00303940|recurrent childhood soft tissue sarcoma
1421540|NCT00303940|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1421541|NCT00303940|recurrent osteosarcoma
1421542|NCT00303940|recurrent neuroblastoma
1421543|NCT00303940|recurrent Wilms tumor and other childhood kidney tumors
1421544|NCT00303940|recurrent childhood malignant germ cell tumor
1421545|NCT00303940|recurrent childhood liver cancer
1421546|NCT00303940|recurrent childhood brain stem glioma
1421547|NCT00303940|recurrent childhood cerebellar astrocytoma
1421548|NCT00303940|recurrent childhood cerebral astrocytoma
1421549|NCT00303940|recurrent childhood ependymoma
1421550|NCT00303940|recurrent childhood medulloblastoma
1421551|NCT00303940|recurrent childhood supratentorial primitive neuroectodermal tumor
1421552|NCT00303940|childhood atypical teratoid/rhabdoid tumor
1421553|NCT00303940|childhood low-grade cerebral astrocytoma
1421554|NCT00303940|childhood high-grade cerebral astrocytoma
1421555|NCT00303940|childhood choroid plexus tumor
1421556|NCT00303940|childhood craniopharyngioma
1421557|NCT00303940|childhood infratentorial ependymoma
1421558|NCT00303940|childhood supratentorial ependymoma
1421559|NCT00303940|childhood oligodendroglioma
1421560|NCT00303940|recurrent childhood visual pathway and hypothalamic glioma
1421561|NCT00303940|recurrent childhood brain tumor
1421562|NCT00303940|childhood central nervous system germ cell tumor
1421563|NCT00303940|childhood grade I meningioma
1421564|NCT00303940|childhood grade II meningioma
1421565|NCT00303940|childhood grade III meningioma
1421566|NCT00303940|childhood malignant ovarian germ cell tumor
1421567|NCT00303940|childhood malignant testicular germ cell tumor
1421568|NCT00303940|childhood teratoma
1421569|NCT00303927|recurrent pancreatic cancer
1421570|NCT00303927|stage IV pancreatic cancer
1421571|NCT00303914|pain
1421572|NCT00303914|psychosocial effects of cancer and its treatment
1421573|NCT00303914|cognitive/functional effects
1421574|NCT00303914|recurrent breast cancer
1421575|NCT00303914|stage I breast cancer
1421576|NCT00303914|stage II breast cancer
1421577|NCT00303914|stage IIIA breast cancer
1421578|NCT00303914|stage IIIB breast cancer
1421579|NCT00303914|stage IIIC breast cancer
1421580|NCT00303914|stage IV breast cancer
1421581|NCT00303914|recurrent colon cancer
1421582|NCT00303914|stage I colon cancer
1421583|NCT00303914|stage II colon cancer
1421584|NCT00303914|stage III colon cancer
1421585|NCT00303914|stage IV colon cancer
1421586|NCT00303914|recurrent rectal cancer
1421587|NCT00303914|stage I rectal cancer
1421588|NCT00303914|stage II rectal cancer
1421589|NCT00303914|stage III rectal cancer
1421590|NCT00303914|stage IV rectal cancer
1421591|NCT00303914|extensive stage small cell lung cancer
1421592|NCT00303914|limited stage small cell lung cancer
1421593|NCT00303914|recurrent small cell lung cancer
1421594|NCT00303914|recurrent non-small cell lung cancer
1421595|NCT00303914|stage I non-small cell lung cancer
1421596|NCT00303914|stage II non-small cell lung cancer
1421597|NCT00303914|stage IIIA non-small cell lung cancer
1421598|NCT00303914|stage IIIB non-small cell lung cancer
1421599|NCT00303914|stage IV non-small cell lung cancer
1421600|NCT00303914|recurrent prostate cancer
1421601|NCT00303914|stage I prostate cancer
1421602|NCT00303914|stage IIB prostate cancer
1421603|NCT00303914|stage IIA prostate cancer
1421604|NCT00303914|stage III prostate cancer
1421605|NCT00303914|stage IV prostate cancer
1421606|NCT00303914|male breast cancer
1421607|NCT00303914|pulmonary carcinoid tumor
1421608|NCT00303901|lung metastases
1421609|NCT00303901|recurrent non-small cell lung cancer
1421610|NCT00303901|recurrent small cell lung cancer
1421611|NCT00303901|stage I non-small cell lung cancer
1421612|NCT00303901|stage II non-small cell lung cancer
1421613|NCT00303901|stage IIIA non-small cell lung cancer
1421614|NCT00303901|stage IIIB non-small cell lung cancer
1421615|NCT00303901|stage IV non-small cell lung cancer
1421616|NCT00303901|extensive stage small cell lung cancer
1421617|NCT00303901|limited stage small cell lung cancer
1421618|NCT00303901|pulmonary carcinoid tumor
1421619|NCT00303888|recurrent ovarian epithelial cancer
1421620|NCT00303888|stage IV ovarian epithelial cancer
1421621|NCT00303888|stage IIIA ovarian epithelial cancer
1421622|NCT00303888|stage IIIB ovarian epithelial cancer
1421623|NCT00303888|stage IIIC ovarian epithelial cancer
1421624|NCT00303888|recurrent primary peritoneal cavity cancer
1421625|NCT00303888|stage IIIA primary peritoneal cavity cancer
1421626|NCT00303888|stage IIIB primary peritoneal cavity cancer
1421627|NCT00303888|stage IIIC primary peritoneal cavity cancer
1421628|NCT00303888|stage IV primary peritoneal cavity cancer
1421629|NCT00303888|recurrent fallopian tube cancer
1421630|NCT00303888|stage IIIA fallopian tube cancer
1421631|NCT00303888|stage IIIB fallopian tube cancer
1421632|NCT00303888|stage IIIC fallopian tube cancer
1421633|NCT00303888|stage IV fallopian tube cancer
1421634|NCT00303875|recurrent prostate cancer
1421635|NCT00303875|stage I prostate cancer
1421636|NCT00303875|stage IIB prostate cancer
1421637|NCT00303875|stage IIA prostate cancer
1421638|NCT00303875|stage III prostate cancer
1421639|NCT00303875|stage IV prostate cancer
1421640|NCT00303875|recurrent breast cancer
1421641|NCT00303875|stage I breast cancer
1421642|NCT00303875|stage II breast cancer
1421643|NCT00303875|stage IIIA breast cancer
1421644|NCT00303875|stage IIIB breast cancer
1421645|NCT00303875|stage IIIC breast cancer
1421646|NCT00303875|stage IV breast cancer
1421647|NCT00303875|recurrent colon cancer
1421648|NCT00303875|stage I colon cancer
1421649|NCT00303875|stage II colon cancer
1421650|NCT00303875|stage III colon cancer
1421651|NCT00303875|stage IV colon cancer
1421652|NCT00303875|recurrent rectal cancer
1421653|NCT00303875|stage I rectal cancer
1421654|NCT00303875|stage II rectal cancer
1421655|NCT00303875|stage III rectal cancer
1421656|NCT00303875|stage IV rectal cancer
1421657|NCT00303810|childhood infratentorial ependymoma
1421658|NCT00303810|childhood supratentorial ependymoma
1421659|NCT00303810|untreated childhood medulloblastoma
1421660|NCT00303810|newly diagnosed childhood ependymoma
1421661|NCT00303810|untreated childhood supratentorial primitive neuroectodermal tumor
1421662|NCT00303784|hot flashes
1421663|NCT00303784|anemia
1421664|NCT00303784|osteoporosis
1421665|NCT00303784|cardiovascular complications
1421666|NCT00303784|recurrent prostate cancer
1421667|NCT00303784|stage III prostate cancer
1421668|NCT00303784|stage IV prostate cancer
1421669|NCT00303784|adenocarcinoma of the prostate
1421670|NCT00303771|adenocarcinoma of the rectum
1421671|NCT00303771|stage IV rectal cancer
1421672|NCT00303771|stage IV colon cancer
1421673|NCT00303771|adenocarcinoma of the colon
1421674|NCT00303771|recurrent colon cancer
1421675|NCT00303771|recurrent rectal cancer
1421676|NCT00303758|adenocarcinoma of the pancreas
1421677|NCT00303758|recurrent pancreatic cancer
1421678|NCT00303758|stage IV pancreatic cancer
1421679|NCT00303745|adenocarcinoma of the colon
1421680|NCT00303745|recurrent colon cancer
1421681|NCT00303745|stage IV colon cancer
1421682|NCT00303745|adenocarcinoma of the rectum
1421683|NCT00303745|recurrent rectal cancer
1421684|NCT00303745|stage IV rectal cancer
1421685|NCT00303732|unspecified adult solid tumor, protocol specific
1421686|NCT00303732|recurrent renal cell cancer
1421687|NCT00303732|stage IV renal cell cancer
1421688|NCT00303719|leukemia
1421689|NCT00303719|lymphoma
1421690|NCT00303719|myeloma
1421691|NCT00303706|CABG, Endoscopic, Radial Artery
1421692|NCT00303706|Radial Artery Conduit
1421693|NCT00303706|Coronary Artery Bypass Surgery
1421694|NCT00303706|Endoscopic technique
1421695|NCT00303667|NK cells
1421696|NCT00303667|natural killer cells
1421697|NCT00303667|immunotherapy
1421698|NCT00303667|hematopoietic cell transplant
1421699|NCT00303667|acute myelogenous leukemia
1421700|NCT00303654|recurrent bladder cancer
1421701|NCT00303654|stage I bladder cancer
1421702|NCT00303654|stage II bladder cancer
1421703|NCT00303654|stage III bladder cancer
1421704|NCT00303654|stage IV bladder cancer
1421705|NCT00303641|Cardiopulmonary bypass
1421706|NCT00303641|Inflammatory reaction
1421707|NCT00303628|Rectal cancer
1421708|NCT00303628|Bevacizumab
1421709|NCT00303615|ER (-) and PR (-)
1421710|NCT00303576|HIV-1
1421711|NCT00303576|HIV Seronegativity
1421712|NCT00303550|skin infection
1421713|NCT00303550|complicated skin infection
1421714|NCT00303550|skin structure infection
1421715|NCT00303550|Complicated Skin and Skin Structure Infection
1421716|NCT00303537|hepatitis
1421717|NCT00303537|metformin
1421718|NCT00303537|non-alcoholic fatty liver (NAFLD)
1421719|NCT00303537|non-alcoholic steatohepatitis (NASH)
1421720|NCT00303537|Nonalcoholic fatty liver disease
1421721|NCT00303511|adult
1421722|NCT00303511|pacemaker
1421723|NCT00303511|bradycardia
1421724|NCT00303511|tachycardia
1421725|NCT00303511|heart failure
1421726|NCT00303472|MDS
1421727|NCT00303472|Myelodysplastic Syndromes
1421728|NCT00303472|Refractory Cytopenias
1421729|NCT00303472|Thrombocytopenia
1421730|NCT00303459|sildenafil
1421731|NCT00303459|Combination Drug Therapy
1421732|NCT00303459|bosentan
1421733|NCT00303459|Pulmonary Hypertension
1421734|NCT00303459|Pulmonary Arterial Hypertension
1421735|NCT00303459|Multicenter Study
1421736|NCT00303459|Antihypertensive Agents
1421737|NCT00303459|Tracleer
1421738|NCT00303459|endothelin receptor antagonist
1421739|NCT00303459|Randomized Controlled Trial
1421740|NCT00303459|Phosphodiesterase type 5 inhibitor (PDE5i)
1421741|NCT00303459|Outcome Assessment
1421742|NCT00303446|Motor Neuron
1421743|NCT00303446|Androgen Receptor
1421744|NCT00303446|Polyglutamine
1421745|NCT00303446|X-Linked
1421746|NCT00303446|Ligand Dependency
1421747|NCT00303446|Spinal and Bulbar Muscular Atrophy
1421748|NCT00303446|SBMA
1421749|NCT00303446|Kennedy Disease
1421750|NCT00303433|Prevention
1421751|NCT00303433|Post-Operative tates
1421752|NCT00303433|Delirium
1421753|NCT00303433|Namenda
1421754|NCT00303420|catheter
1421755|NCT00303420|hemodialysis
1421756|NCT00303420|dysfunction
1421757|NCT00303420|thrombolytic
1421758|NCT00303420|alteplase
1421759|NCT00303394|Type 2 Diabetes, IL-1, inflammation, glucotoxicity, insulin
1421760|NCT00303368|Neurofibromatosis (NF1)
1421761|NCT00303368|Tibial Dysplasia (TD)
1421762|NCT00303355|jugular venous pulse
1421763|NCT00303342|sleep
1421764|NCT00303342|arousal
1421765|NCT00303342|stress
1421766|NCT00303342|cortisol
1421767|NCT00303342|catecholamines
1421768|NCT00303329|β-thalassemia
1421769|NCT00303329|rare chronic anemia
1421770|NCT00303329|iron overload
1421771|NCT00303329|deferasirox
1421772|NCT00303329|chronic anemias
1421773|NCT00303329|transfusional hemosiderosis
1421774|NCT00303316|Diphtheria
1421775|NCT00303316|Tetanus
1421776|NCT00303316|Pertussis
1421777|NCT00303316|whooping cough
1421778|NCT00303316|Haemophilus influenzae type b
1421779|NCT00303316|Hepatitis B
1421780|NCT00303316|Poliomyelitis
1421781|NCT00303303|Snake envenomation
1421782|NCT00303303|Antivenins
1421783|NCT00303303|Disability evaluation
1421784|NCT00303303|Activities of daily living
1421785|NCT00303290|Early Chronic Phase CML
1421786|NCT00303290|Peg Interferon Alpha 2b
1421787|NCT00303290|Peg Intron
1421788|NCT00303290|Ara-C
1421789|NCT00303290|Cytosine Arabinoside
1421790|NCT00303277|Alzheimer's disease
1421791|NCT00303277|beta-amyloid
1421792|NCT00303277|statins
1421793|NCT00303264|functional dyspepsia
1421794|NCT00303264|cholecystokinin
1421795|NCT00303264|CCK
1421796|NCT00303264|gastrointestinal
1421797|NCT00303264|intestinal transit
1421798|NCT00303264|GI motility
1421799|NCT00303264|bloating
1421800|NCT00303264|upper GI discomfort
1421801|NCT00303264|upper GI
1421802|NCT00303264|early satiety
1421803|NCT00303264|nausea
1421804|NCT00303264|belching
1421805|NCT00303264|retching
1421806|NCT00303264|vomiting
1421807|NCT00303264|GERD
1421808|NCT00303251|Locally Advanced or Metastatic Melanoma
1421809|NCT00303238|Inflammation
1421810|NCT00303238|Interleukin-1
1421811|NCT00303238|C-reactive protein
1421812|NCT00303238|Genotype
1421813|NCT00303238|Rose Hips
1421814|NCT00303238|Blueberry
1421815|NCT00303238|Blackberry
1421816|NCT00303238|Aframomum melegueta
1421817|NCT00303238|Resveravine
1421818|NCT00303225|Biodefense
1421819|NCT00303225|Smallpox
1421820|NCT00303225|Monkeypox
1421821|NCT00303225|Vaccinia
1421822|NCT00303225|Prophylaxis
1421823|NCT00303225|Healthy Volunteer
1421824|NCT00303225|HV
1421825|NCT00303212|heart failure
1421826|NCT00303212|CHF
1421827|NCT00303212|telemedicine
1421828|NCT00303212|disease management
1421829|NCT00303199|Multiple Myeloma
1421830|NCT00303199|Arsenic
1421831|NCT00303199|Cancer study
1421832|NCT00303199|Failed treatment
1421833|NCT00303186|Rheumatoid Arthritis
1421834|NCT00303173|Pre-eclampsia
1421835|NCT00303173|hypertension
1421836|NCT00303173|blood pressure
1421837|NCT00303173|pregnancy
1421838|NCT00303173|randomized clinical trial
1421839|NCT00303173|guided imagery
1421840|NCT00303173|relaxation
1421841|NCT00303173|psychophysiology
1421842|NCT00303173|mind-body
1421843|NCT00303160|heliobacter pylori infection
1421844|NCT00303160|reactive oxygen species
1421845|NCT00303160|antioxidants
1421846|NCT00303147|Expressive Writing
1421847|NCT00303147|Written Emotional Expression
1421848|NCT00303147|Caregiver Stress
1421849|NCT00303147|Cognition
1421850|NCT00303134|islet cell
1421851|NCT00303134|diabetes
1421852|NCT00303134|transplant
1421853|NCT00303134|immunosuppression
1421854|NCT00303134|autoimmunity
1421855|NCT00303134|alloimmunity
1421856|NCT00303121|Glaucoma
1421857|NCT00303121|Compliance
1421858|NCT00303121|Therapy
1421859|NCT00303121|Administration technique
1421860|NCT00303082|Probiotics
1421861|NCT00303082|Bacterial Vaginosis
1421862|NCT00303082|Premature birth
1421863|NCT00303082|Intra-uterine Infection
1421864|NCT00303082|Periventricular leukomalacia
1421865|NCT00303069|S. aureus;
1421866|NCT00303069|Vaccine
1421867|NCT00303069|FIM
1421868|NCT00303056|Osteoarthritis
1421869|NCT00303056|knee
1421870|NCT00303043|Hemodynamic monitoring
1421871|NCT00303043|Mixed venous saturation
1421872|NCT00303043|Critically ill patients
1421873|NCT00303030|Fecal incontinence
1421874|NCT00303030|Biofeedback
1421875|NCT00303030|Patient Satisfaction
1421876|NCT00303030|Quality of LifeTreatment Outcome
1421877|NCT00303030|Injections
1421878|NCT00302991|Observational
1421879|NCT00302991|cross-sectional
1421880|NCT00302991|health-related quality of life
1421881|NCT00302991|adverse effects
1421882|NCT00302991|Baker´s AEP scale validation
1421883|NCT00302991|epilepsy
1421884|NCT00302978|Height phobia
1421885|NCT00302978|fear of heights
1421886|NCT00302978|specific phobia
1421887|NCT00302965|Plasma
1421888|NCT00302965|Trauma
1421889|NCT00302965|Critical Care
1421890|NCT00302952|Arthritis, Rheumatoid
1421891|NCT00302939|Aging
1421892|NCT00302926|Weight loss
1421893|NCT00302926|obesity
1421894|NCT00302926|energy restriction
1421895|NCT00302913|Clopidogrel
1421896|NCT00302913|Coronary Artery Disease
1421897|NCT00302913|Dose-Response Relationship, Drug
1421898|NCT00302913|Drug Resistance
1421899|NCT00302913|PCI
1421900|NCT00302900|Blood Donation
1421901|NCT00302900|Syncope
1421902|NCT00302900|Vasovagal Reactions
1421903|NCT00302887|fibromyalgia
1421904|NCT00302887|connective tissue manipulation
1421905|NCT00302887|ultrasound therapy
1421906|NCT00302887|high voltage pulsed galvanic stimulation
1421907|NCT00302874|diabetes
1421908|NCT00302874|hyperglycemia
1421909|NCT00302874|hospital
1421910|NCT00302874|medicine ward
1421911|NCT00302861|B-Cll
1421912|NCT00302848|Venous thromboembolism
1421913|NCT00302848|Drospirenone
1421914|NCT00302835|Analgesics
1421915|NCT00302835|Chronic Kidney Failure
1421916|NCT00302822|HIV infections
1421917|NCT00302822|Fuzeon
1421918|NCT00302822|Truvada
1421919|NCT00302822|AIDS
1421920|NCT00302822|Treatment Naive
1421921|NCT00302809|Flavonoids
1421922|NCT00302809|Arterial stiffness
1421923|NCT00302809|Blood pressure
1421924|NCT00302809|Endothelium
1421925|NCT00302809|Inflammation
1421926|NCT00302796|Low Back Pain,
1421927|NCT00302783|Education, Medical
1421928|NCT00302783|Education, Competency-Based
1421929|NCT00302783|Multi-Source Feedback
1421930|NCT00302783|Communication
1421931|NCT00302783|Professionalism
1421932|NCT00302770|Patients with SAD
1421933|NCT00302757|NHL
1421934|NCT00302757|low and high grade non-Hodgkin lymphoma
1421935|NCT00302744|Anxiety
1421936|NCT00302744|Depression
1421937|NCT00302744|Mood
1421938|NCT00302744|Cancer
1421939|NCT00302744|Quality of Life
1421940|NCT00302744|Psychiatric
1421941|NCT00302744|Psilocybin
1421942|NCT00302744|Alternative
1421943|NCT00302744|Los Angeles
1421944|NCT00302718|Physician Incentive Plan
1421945|NCT00302718|Quality of Health Care
1421946|NCT00302718|Reimbursement, Incentive
1421947|NCT00302718|Randomized Controlled Trial
1421948|NCT00302718|Physicians
1421949|NCT00302718|Reward
1421950|NCT00302705|Ambulatory blood pressure monitoring
1421951|NCT00302705|Valsartan
1421952|NCT00302705|Enalapril
1421953|NCT00302705|Missing dose
1421954|NCT00302679|Colonoscopy
1421955|NCT00302679|Sigmoidoscopy
1421956|NCT00302679|Colon cancer screening
1421957|NCT00302679|Pain
1421958|NCT00302679|Screening
1421959|NCT00302666|Contraception, Bleeding pattern
1421960|NCT00302627|bisphosphonates
1421961|NCT00302627|vitamin D
1421962|NCT00302627|calcium supplement
1421963|NCT00302627|corticosteroid therapy
1421964|NCT00302627|fractures
1421965|NCT00302614|obstructive sleep apnea
1421966|NCT00302614|snoring
1421967|NCT00302614|collapsibility
1421968|NCT00302614|upper airway
1421969|NCT00302601|Pulmonary embolism
1421970|NCT00302601|Right heart strain
1421971|NCT00302601|Lung scintigraphy
1421972|NCT00302601|Pulmonary angiography
1421973|NCT00302588|metastatic carcinoma
1421974|NCT00302588|cervical lymph nodes
1421975|NCT00302588|unknown primary
1421976|NCT00302588|diagnosis
1421977|NCT00302588|result
1421978|NCT00302575|Substance-Related Disorders
1421979|NCT00302575|Prisoners
1421980|NCT00302562|laryngeal cancer
1421981|NCT00302562|hypopharyngeal cancer
1421982|NCT00302562|CXCR4
1421983|NCT00302562|CXCL12
1421984|NCT00302562|matrix metalloproteinases(MMPs)
1421985|NCT00302562|metastasis
1421986|NCT00302549|Tacrolimus
1421987|NCT00302549|Cyclophosphamide
1421988|NCT00302549|Treatment
1421989|NCT00302549|Lupus Nephritis
1421990|NCT00302536|Idiopathic Focal Segmental Glomerulosclerosis
1421991|NCT00302536|Treatment
1421992|NCT00302536|Steroids
1421993|NCT00302523|Idiopathic Membranous Nephropathy
1421994|NCT00302523|Treatment
1421995|NCT00302523|Tacrolimus
1421996|NCT00302523|Cyclophosphamide
1421997|NCT00302510|lipoprotein glomerulopathy
1421998|NCT00302510|treatment
1421999|NCT00302510|immunoadsorption
1422000|NCT00302510|apolipoprotein E
1422001|NCT00302458|healthy volunteers
1422002|NCT00302432|smoking reduction
1422003|NCT00302432|group therapy
1422004|NCT00302432|cigarette holders
1422005|NCT00302432|"Flowers Menthol"
1422006|NCT00302419|Acute myocardial infarction
1422007|NCT00302419|primary angioplasty
1422008|NCT00302419|streptokinase
1422009|NCT00302419|microvasculature
1422010|NCT00302393|healthy volunteers
1422011|NCT00302341|Pulmonary disease
1422012|NCT00302341|Dyspnea
1422013|NCT00302341|Hypoxemia
1422014|NCT00302341|AIDS
1422015|NCT00302341|Pneumocystis jiroveci
1422016|NCT00302315|postcesarean physiotherapy
1422017|NCT00302315|incisional pain
1422018|NCT00302315|functional activity
1422019|NCT00302315|connective tissue manipulation
1422020|NCT00302315|transcutaneous electrical nerve stimulation
1422021|NCT00302302|Blood glucose
1422022|NCT00302302|Insulin
1422023|NCT00302302|Triglyceride
1422024|NCT00302302|GIP
1422025|NCT00302302|GLP-1
1422026|NCT00302302|L-arabinose
1422027|NCT00302302|Appetite
1422028|NCT00302302|Energy intake
1422029|NCT00302289|green tea
1422030|NCT00302289|caffeine
1422031|NCT00302289|tyrosine
1422032|NCT00302289|energy expenditure
1422033|NCT00302289|energy intake
1422034|NCT00302276|Body fat loss
1422035|NCT00302276|energy expenditure
1422036|NCT00302276|capsaicin
1422037|NCT00302276|caffeine
1422038|NCT00302276|green tea
1422039|NCT00302276|calcium
1422040|NCT00302276|fecal fat
1422041|NCT00302276|fecal energy
1422042|NCT00302263|Green tea
1422043|NCT00302263|capsaicin
1422044|NCT00302263|tyrosine
1422045|NCT00302263|caffeine
1422046|NCT00302263|energy expenditure
1422047|NCT00302263|catecholamines
1422048|NCT00302250|Cardiovascular
1422049|NCT00302250|Flow-mediated vasodilation (FMD)
1422050|NCT00302250|Pulse perfusion-mediated vasodilation (PPMV)
1422051|NCT00302250|Endothelial function
1422052|NCT00302250|Heart failure
1422053|NCT00302237|carotid, stenting, angioplasty
1422054|NCT00302224|safety
1422055|NCT00302224|type 2 diabetes
1422056|NCT00302211|PAH
1422057|NCT00302211|Pulmonary Arterial Hypertension
1422058|NCT00302198|Amyotrophic Lateral Sclerosis
1422059|NCT00302185|Palliative Care
1422060|NCT00302185|Acupuncture
1422061|NCT00302185|Symptom Management
1422062|NCT00302185|Quality of Life
1422063|NCT00302172|Cancer
1422064|NCT00302172|solid tumor
1422065|NCT00302172|metastatic
1422066|NCT00302172|primary tumor
1422067|NCT00302159|Chemotherapy
1422068|NCT00302159|Radiation
1422069|NCT00302159|Brain Tumor
1422070|NCT00302159|GBM
1422071|NCT00302159|Radiosensitizer
1422072|NCT00302159|Glioblastoma
1422073|NCT00302159|Glioblastoma Multiforme
1422074|NCT00302146|Lysosomal Storage Disorder
1422075|NCT00302146|Carrier
1422076|NCT00302146|L-Dopa Uptake
1422077|NCT00302146|Glucocerebrosidase
1422078|NCT00302146|Pathogenesis
1422079|NCT00302146|Carbidopa
1422080|NCT00302146|Gaucher Disease
1422081|NCT00302146|Parkinson Disease
1422082|NCT00302146|[O-15]-Water
1422083|NCT00302146|6-[F-18]Fluoro-L-dopa
1422084|NCT00302146|Healthy Volunteer
1422085|NCT00302146|HV
1422086|NCT00302133|Alcoholism Bipolar Disorder Pharmacotherapy Naltrexone
1422087|NCT00302120|Magnetic Resonance Imaging
1422088|NCT00302120|Breast Neoplasms
1422089|NCT00302120|Diagnostic Trial
1422090|NCT00302107|Mirtazapine
1422091|NCT00302107|PTSD
1422092|NCT00302107|Veterans
1422093|NCT00302107|antidepressant
1422094|NCT00302081|Hepatitis C, Chronic
1422095|NCT00302081|Genotype 2 and Genotype 3
1422096|NCT00302068|Exercise
1422097|NCT00302029|Cytomegalovirus, risk factors, seroprevalence
1422098|NCT00302016|Chronic myeloid leukemia
1422099|NCT00302016|AMN 107
1422100|NCT00302016|Imatinib resistant or intolerant
1422101|NCT00302016|nilotinib
1422102|NCT00302016|enact
1422103|NCT00301990|stage IV renal cell cancer
1422104|NCT00301990|recurrent renal cell cancer
1422105|NCT00301990|clear cell renal cell carcinoma
1422106|NCT00301951|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1422107|NCT00301951|adult acute myeloid leukemia with inv(16)(p13;q22)
1422108|NCT00301951|adult acute myeloid leukemia with t(15;17)(q22;q12)
1422109|NCT00301951|adult acute myeloid leukemia with t(16;16)(p13;q22)
1422110|NCT00301951|adult acute myeloid leukemia with t(8;21)(q22;q22)
1422111|NCT00301951|accelerated phase chronic myelogenous leukemia
1422112|NCT00301951|adult acute lymphoblastic leukemia in remission
1422113|NCT00301951|adult acute myeloid leukemia in remission
1422114|NCT00301951|angioimmunoblastic T-cell lymphoma
1422115|NCT00301951|blastic phase chronic myelogenous leukemia
1422116|NCT00301951|chronic myelomonocytic leukemia
1422117|NCT00301951|chronic phase chronic myelogenous leukemia
1422118|NCT00301951|de novo myelodysplastic syndromes
1422119|NCT00301951|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1422120|NCT00301951|anaplastic large cell lymphoma
1422121|NCT00301951|nodal marginal zone B-cell lymphoma
1422122|NCT00301951|previously treated myelodysplastic syndromes
1422123|NCT00301951|recurrent adult acute lymphoblastic leukemia
1422124|NCT00301951|recurrent adult acute myeloid leukemia
1422125|NCT00301951|recurrent adult T-cell leukemia/lymphoma
1422126|NCT00301951|recurrent adult Hodgkin lymphoma
1422127|NCT00301951|recurrent adult diffuse large cell lymphoma
1422128|NCT00301951|recurrent cutaneous T-cell non-Hodgkin lymphoma
1422129|NCT00301951|recurrent grade 1 follicular lymphoma
1422130|NCT00301951|recurrent grade 2 follicular lymphoma
1422131|NCT00301951|recurrent grade 3 follicular lymphoma
1422132|NCT00301951|recurrent mantle cell lymphoma
1422133|NCT00301951|recurrent marginal zone lymphoma
1422134|NCT00301951|recurrent mycosis fungoides/Sezary syndrome
1422135|NCT00301951|recurrent small lymphocytic lymphoma
1422136|NCT00301951|refractory chronic lymphocytic leukemia
1422137|NCT00301951|stage III adult T-cell leukemia/lymphoma
1422138|NCT00301951|refractory multiple myeloma
1422139|NCT00301951|relapsing chronic myelogenous leukemia
1422140|NCT00301951|secondary acute myeloid leukemia
1422141|NCT00301951|secondary myelodysplastic syndromes
1422142|NCT00301951|splenic marginal zone lymphoma
1422143|NCT00301951|stage I multiple myeloma
1422144|NCT00301951|stage II multiple myeloma
1422145|NCT00301951|stage IV adult T-cell leukemia/lymphoma
1422146|NCT00301951|stage III adult Hodgkin lymphoma
1422147|NCT00301951|stage III adult diffuse large cell lymphoma
1422148|NCT00301951|stage III chronic lymphocytic leukemia
1422149|NCT00301951|stage III grade 1 follicular lymphoma
1422150|NCT00301951|stage III grade 2 follicular lymphoma
1422151|NCT00301951|stage III grade 3 follicular lymphoma
1422152|NCT00301951|stage III mantle cell lymphoma
1422153|NCT00301951|stage III marginal zone lymphoma
1422154|NCT00301951|stage III multiple myeloma
1422155|NCT00301951|stage III small lymphocytic lymphoma
1422156|NCT00301951|stage IV adult Hodgkin lymphoma
1422157|NCT00301951|stage IV adult diffuse large cell lymphoma
1422158|NCT00301951|stage IV chronic lymphocytic leukemia
1422159|NCT00301951|stage IV grade 1 follicular lymphoma
1422160|NCT00301951|stage IV grade 2 follicular lymphoma
1422161|NCT00301951|stage IV grade 3 follicular lymphoma
1422162|NCT00301951|stage IV mantle cell lymphoma
1422163|NCT00301951|stage IV marginal zone lymphoma
1422164|NCT00301951|stage IV small lymphocytic lymphoma
1422165|NCT00301925|stage I breast cancer
1422166|NCT00301925|stage II breast cancer
1422167|NCT00301925|stage IIIA breast cancer
1422168|NCT00301925|male breast cancer
1422169|NCT00301912|chronic phase chronic myelogenous leukemia
1422170|NCT00301912|accelerated phase chronic myelogenous leukemia
1422171|NCT00301912|blastic phase chronic myelogenous leukemia
1422172|NCT00301912|adult acute myeloid leukemia in remission
1422173|NCT00301912|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1422174|NCT00301912|adult acute myeloid leukemia with inv(16)(p13;q22)
1422175|NCT00301912|adult acute myeloid leukemia with t(15;17)(q22;q12)
1422176|NCT00301912|adult acute myeloid leukemia with t(16;16)(p13;q22)
1422177|NCT00301912|adult acute myeloid leukemia with t(8;21)(q22;q22)
1422178|NCT00301912|recurrent adult acute myeloid leukemia
1422179|NCT00301912|secondary acute myeloid leukemia
1422180|NCT00301912|de novo myelodysplastic syndromes
1422181|NCT00301912|previously treated myelodysplastic syndromes
1422182|NCT00301912|secondary myelodysplastic syndromes
1422183|NCT00301912|atypical chronic myeloid leukemia
1422184|NCT00301912|myelodysplastic/myeloproliferative disease, unclassifiable
1422185|NCT00301912|adult acute lymphoblastic leukemia in remission
1422186|NCT00301912|recurrent adult lymphoblastic lymphoma
1422187|NCT00301912|anemia
1422188|NCT00301912|refractory chronic lymphocytic leukemia
1422394|NCT00301431|Double-Blind Method
1422189|NCT00301912|stage III chronic lymphocytic leukemia
1422190|NCT00301912|stage IV chronic lymphocytic leukemia
1422191|NCT00301912|Waldenstrom macroglobulinemia
1422192|NCT00301912|stage II multiple myeloma
1422193|NCT00301912|stage III multiple myeloma
1422194|NCT00301912|refractory multiple myeloma
1422195|NCT00301912|polycythemia vera
1422196|NCT00301912|essential thrombocythemia
1422197|NCT00301912|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1422198|NCT00301912|nodal marginal zone B-cell lymphoma
1422199|NCT00301912|splenic marginal zone lymphoma
1422200|NCT00301912|recurrent adult Burkitt lymphoma
1422201|NCT00301912|recurrent adult diffuse large cell lymphoma
1422202|NCT00301912|recurrent adult diffuse mixed cell lymphoma
1422203|NCT00301912|recurrent adult immunoblastic large cell lymphoma
1422204|NCT00301912|recurrent grade 3 follicular lymphoma
1422205|NCT00301912|recurrent mantle cell lymphoma
1422206|NCT00301912|recurrent adult diffuse small cleaved cell lymphoma
1422207|NCT00301912|recurrent grade 1 follicular lymphoma
1422208|NCT00301912|recurrent grade 2 follicular lymphoma
1422209|NCT00301912|recurrent marginal zone lymphoma
1422210|NCT00301912|recurrent small lymphocytic lymphoma
1422211|NCT00301912|relapsing chronic myelogenous leukemia
1422212|NCT00301912|chronic eosinophilic leukemia
1422213|NCT00301912|chronic idiopathic myelofibrosis
1422214|NCT00301912|chronic myelomonocytic leukemia
1422215|NCT00301912|chronic neutrophilic leukemia
1422216|NCT00301912|noncontiguous stage II adult Burkitt lymphoma
1422217|NCT00301912|noncontiguous stage II adult diffuse large cell lymphoma
1422218|NCT00301912|noncontiguous stage II adult diffuse mixed cell lymphoma
1422219|NCT00301912|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1422220|NCT00301912|noncontiguous stage II adult immunoblastic large cell lymphoma
1422221|NCT00301912|noncontiguous stage II adult lymphoblastic lymphoma
1422222|NCT00301912|noncontiguous stage II grade 1 follicular lymphoma
1422223|NCT00301912|noncontiguous stage II grade 2 follicular lymphoma
1422224|NCT00301912|noncontiguous stage II grade 3 follicular lymphoma
1422225|NCT00301912|noncontiguous stage II mantle cell lymphoma
1422226|NCT00301912|noncontiguous stage II marginal zone lymphoma
1422227|NCT00301912|noncontiguous stage II small lymphocytic lymphoma
1422228|NCT00301912|stage III adult Burkitt lymphoma
1422229|NCT00301912|stage III adult diffuse large cell lymphoma
1422230|NCT00301912|stage III adult diffuse mixed cell lymphoma
1422231|NCT00301912|stage III adult diffuse small cleaved cell lymphoma
1422232|NCT00301912|stage III adult immunoblastic large cell lymphoma
1422233|NCT00301912|stage III adult lymphoblastic lymphoma
1422234|NCT00301912|stage III grade 1 follicular lymphoma
1422235|NCT00301912|stage III grade 2 follicular lymphoma
1422236|NCT00301912|stage III grade 3 follicular lymphoma
1422237|NCT00301912|stage III mantle cell lymphoma
1422238|NCT00301912|stage III marginal zone lymphoma
1422239|NCT00301912|stage III small lymphocytic lymphoma
1422240|NCT00301912|stage IV adult Burkitt lymphoma
1422241|NCT00301912|stage IV adult diffuse large cell lymphoma
1422242|NCT00301912|stage IV adult diffuse mixed cell lymphoma
1422243|NCT00301912|stage IV adult diffuse small cleaved cell lymphoma
1422244|NCT00301912|stage IV adult immunoblastic large cell lymphoma
1422245|NCT00301912|stage IV adult lymphoblastic lymphoma
1422246|NCT00301912|stage IV grade 1 follicular lymphoma
1422247|NCT00301912|stage IV grade 2 follicular lymphoma
1422248|NCT00301912|stage IV grade 3 follicular lymphoma
1422249|NCT00301912|stage IV mantle cell lymphoma
1422250|NCT00301912|stage IV marginal zone lymphoma
1422251|NCT00301912|stage IV small lymphocytic lymphoma
1422252|NCT00301912|recurrent adult acute lymphoblastic leukemia
1422253|NCT00301912|stage I multiple myeloma
1422254|NCT00301912|childhood myelodysplastic syndromes
1422255|NCT00301899|recurrent breast cancer
1422256|NCT00301899|male breast cancer
1422257|NCT00301899|stage IIIA breast cancer
1422258|NCT00301899|stage IIIB breast cancer
1422259|NCT00301899|stage IIIC breast cancer
1422260|NCT00301899|stage IV breast cancer
1422261|NCT00301886|pain
1422262|NCT00301886|hypercalcemia of malignancy
1422263|NCT00301886|stage IV breast cancer
1422264|NCT00301886|bone metastases
1422265|NCT00301886|recurrent breast cancer
1422266|NCT00301873|osteoporosis
1422267|NCT00301873|adult anaplastic astrocytoma
1422268|NCT00301873|adult giant cell glioblastoma
1422269|NCT00301873|adult anaplastic oligodendroglioma
1422270|NCT00301873|adult gliosarcoma
1422271|NCT00301873|adult mixed glioma
1422272|NCT00301873|recurrent adult brain tumor
1422273|NCT00301873|adult glioblastoma
1422274|NCT00301860|childhood acute lymphoblastic leukemia in remission
1422275|NCT00301860|childhood acute myeloid leukemia in remission
1422276|NCT00301860|recurrent childhood acute lymphoblastic leukemia
1422277|NCT00301860|recurrent childhood acute myeloid leukemia
1422278|NCT00301860|recurrent childhood small noncleaved cell lymphoma
1422279|NCT00301860|juvenile myelomonocytic leukemia
1422280|NCT00301860|chronic phase chronic myelogenous leukemia
1422281|NCT00301860|accelerated phase chronic myelogenous leukemia
1422282|NCT00301860|relapsing chronic myelogenous leukemia
1422283|NCT00301860|recurrent childhood large cell lymphoma
1422284|NCT00301860|recurrent childhood lymphoblastic lymphoma
1422285|NCT00301860|recurrent/refractory childhood Hodgkin lymphoma
1422286|NCT00301860|childhood chronic myelogenous leukemia
1422287|NCT00301847|tumors metastatic to brain
1422288|NCT00301847|recurrent renal cell cancer
1422289|NCT00301847|stage IV renal cell cancer
1422290|NCT00301834|de novo myelodysplastic syndromes
1422291|NCT00301834|previously treated myelodysplastic syndromes
1422292|NCT00301834|secondary myelodysplastic syndromes
1422293|NCT00301834|childhood acute myeloid leukemia in remission
1422294|NCT00301834|childhood chronic myelogenous leukemia
1422295|NCT00301834|congenital amegakaryocytic thrombocytopenia
1422296|NCT00301834|Diamond-Blackfan anemia
1422297|NCT00301834|severe congenital neutropenia
1422298|NCT00301834|secondary acute myeloid leukemia
1422299|NCT00301834|chronic phase chronic myelogenous leukemia
1422300|NCT00301834|childhood myelodysplastic syndromes
1422301|NCT00301821|contiguous stage II adult diffuse large cell lymphoma
1422302|NCT00301821|noncontiguous stage II adult diffuse large cell lymphoma
1422303|NCT00301821|stage III adult diffuse large cell lymphoma
1422304|NCT00301821|stage IV adult diffuse large cell lymphoma
1422305|NCT00301808|stage IIIA non-small cell lung cancer
1422306|NCT00301808|stage IIIB non-small cell lung cancer
1422307|NCT00301782|testicular choriocarcinoma and embryonal carcinoma
1422308|NCT00301782|testicular choriocarcinoma and teratoma
1422309|NCT00301782|testicular choriocarcinoma and yolk sac tumor
1422310|NCT00301782|testicular choriocarcinoma
1422311|NCT00301782|testicular embryonal carcinoma and teratoma
1422312|NCT00301782|testicular embryonal carcinoma and yolk sac tumor
1422313|NCT00301782|testicular embryonal carcinoma
1422314|NCT00301782|testicular yolk sac tumor
1422315|NCT00301782|testicular yolk sac tumor and teratoma
1422316|NCT00301782|stage I malignant testicular germ cell tumor
1422317|NCT00301782|stage II malignant testicular germ cell tumor
1422318|NCT00301782|stage III malignant testicular germ cell tumor
1422319|NCT00301782|recurrent malignant testicular germ cell tumor
1422320|NCT00301782|recurrent extragonadal non-seminomatous germ cell tumor
1422321|NCT00301782|stage I extragonadal non-seminomatous germ cell tumor
1422322|NCT00301782|stage II extragonadal non-seminomatous germ cell tumor
1422323|NCT00301782|stage III extragonadal non-seminomatous germ cell tumor
1422324|NCT00301782|stage IV extragonadal non-seminomatous germ cell tumor
1422325|NCT00301782|recurrent extragonadal germ cell tumor
1422326|NCT00301782|testicular immature teratoma
1422327|NCT00301782|testicular mature teratoma
1422328|NCT00301782|adult teratoma
1422329|NCT00301730|lung metastases
1422330|NCT00301730|stage IV breast cancer
1422331|NCT00301730|recurrent breast cancer
1422332|NCT00301691|unspecified adult solid tumor, protocol specific
1422333|NCT00301678|unspecified adult solid tumor, protocol specific
1422334|NCT00301652|ANCA
1422335|NCT00301652|vasculitis
1422336|NCT00301652|mycophenolate mofetil
1422337|NCT00301652|cyclophosphamide
1422338|NCT00301652|treatment
1422339|NCT00301626|tobacco
1422340|NCT00301626|nicotine
1422341|NCT00301626|smoking reduction
1422342|NCT00301613|Henoch-Schonlein purpura nephritis Mycophenolate mofetil
1422343|NCT00301613|Cyclophosphamide
1422344|NCT00301613|treatment
1422345|NCT00301600|Crescentic IgA nephropathy
1422346|NCT00301600|Mycophenolate mofetil
1422347|NCT00301600|Cyclophosphamide
1422348|NCT00301600|treatment
1422349|NCT00301587|spina bifida
1422350|NCT00301587|birth defects
1422351|NCT00301587|folic acid
1422352|NCT00301587|nervous system diseases
1422353|NCT00301587|folate
1422354|NCT00301587|Vitamin B
1422355|NCT00301574|Alzheimer's disease
1422356|NCT00301574|Cognitive dysfunction
1422357|NCT00301561|Antiretroviral treatment
1422358|NCT00301561|Expanded access
1422359|NCT00301561|Africa
1422360|NCT00301561|Treatment Naive
1422361|NCT00301548|antineoplastic protocols
1422362|NCT00301548|neoadjuvant therapy
1422363|NCT00301548|perioperative chemotherapy
1422364|NCT00301548|fluorouracil
1422365|NCT00301535|Coronary Artery Bypass Graft
1422366|NCT00301535|memory loss after cardiac surgery
1422367|NCT00301535|side effects of bypass
1422368|NCT00301522|Coronary
1422369|NCT00301522|Artery
1422370|NCT00301522|Stenosis
1422371|NCT00301522|Drug-eluting
1422372|NCT00301522|stent
1422373|NCT00301522|restenosis
1422374|NCT00301522|revascularization
1422375|NCT00301483|multiple trauma
1422376|NCT00301483|bleeding injuries
1422377|NCT00301483|gunshot wounds
1422378|NCT00301483|stab wounds
1422379|NCT00301483|penetrating injuries
1422380|NCT00301483|blunt trauma
1422381|NCT00301483|multiple wounds
1422382|NCT00301470|Ureter, obstruction
1422383|NCT00301470|Diagnostic techniques, urological
1422384|NCT00301470|MRI, functional
1422388|NCT00301444|phantom limb pain
1422389|NCT00301444|limb amputation
1422390|NCT00301431|Fibromyalgia
1422391|NCT00301431|Adults
1422392|NCT00301431|Outpatients
1422393|NCT00301431|Adult
1422395|NCT00301418|Glioblastoma Multiforme
1422396|NCT00301418|Anaplastic Astrocytoma
1422397|NCT00301418|High Grade Glial Neoplasms
1422398|NCT00301418|Brain Tumor
1422399|NCT00301405|prostatitis
1422400|NCT00301405|pelvic pain
1422401|NCT00301392|Glucose intolerance
1422402|NCT00301392|Diabetes mellitus
1422403|NCT00301392|Statins,HMG-CoA
1422404|NCT00301379|Cholangiocarcinoma
1422405|NCT00301379|Observational
1422406|NCT00301366|alpha 1-Antitrypsin Deficiency
1422407|NCT00301366|alpha 1-Antitrypsin
1422408|NCT00301366|pulmonary emphysema
1422409|NCT00301353|early menopause
1422410|NCT00301353|isoflavones/phyto-estrogens
1422411|NCT00301353|bone metabolism
1422412|NCT00301353|bone mineral density
1422413|NCT00301353|hormones
1422414|NCT00301249|Diabetes
1422415|NCT00301249|Nephropathy
1422416|NCT00301249|Diabetic Nephropathy
1422417|NCT00301249|Genome Scan
1422418|NCT00301249|Genetic Research
1422419|NCT00301236|ADHD, children, CADS-T, Dexmethylphenidate-HCl, extended release
1422420|NCT00301197|Childhood obesity
1422421|NCT00301197|intervention
1422422|NCT00301197|obesity
1422423|NCT00301197|weight loss
1422424|NCT00301197|behavior therapy
1422425|NCT00301197|peer group
1422426|NCT00301197|social support network
1422427|NCT00301197|child
1422428|NCT00301197|clinical research
1422429|NCT00301197|human subject
1422430|NCT00301184|HIV Seronegativity
1422431|NCT00301184|HIV Preventive Vaccine
1422432|NCT00301184|HIV DNA Vaccine
1422433|NCT00301184|Modified Vaccinia Ankara Vaccine
1422434|NCT00301171|Wheezing
1422435|NCT00301158|unspecified adult solid tumor, protocol specific
1422436|NCT00301145|unspecified adult solid tumor, protocol specific
1422437|NCT00301119|small cell lung cancer
1422438|NCT00301119|non-small cell lung cancer
1422439|NCT00301119|smoker lung cancer screening
1422440|NCT00301119|low dose spiral CT screening
1422441|NCT00301106|stage IV breast cancer
1422442|NCT00301106|liver metastases
1422443|NCT00301093|chronic phase chronic myelogenous leukemia
1422444|NCT00301093|Philadelphia chromosome positive chronic myelogenous leukemia
1422445|NCT00301080|pain
1422446|NCT00301080|neurotoxicity
1422447|NCT00301080|breast cancer
1422448|NCT00301067|stage IV melanoma
1422449|NCT00301067|recurrent melanoma
1422450|NCT00301054|Anaemia
1422451|NCT00301054|Malaria
1422452|NCT00301054|Rural Area in Ghana
1422453|NCT00301041|invasive ductal breast carcinoma
1422454|NCT00301041|invasive lobular breast carcinoma
1422455|NCT00301041|stage I breast cancer
1422456|NCT00301041|stage II breast cancer
1422457|NCT00301041|stage IIIA breast cancer
1422458|NCT00301028|stage IV squamous cell carcinoma of the oropharynx
1422459|NCT00301028|stage IV squamous cell carcinoma of the hypopharynx
1422460|NCT00301028|stage IV squamous cell carcinoma of the larynx
1422461|NCT00301028|stage IV squamous cell carcinoma of the nasopharynx
1422462|NCT00301028|stage IV squamous cell carcinoma of the lip and oral cavity
1422463|NCT00301002|safety
1422464|NCT00301002|effectiveness
1422465|NCT00301002|Alefacept
1422466|NCT00301002|Palmar
1422467|NCT00301002|Plantar
1422468|NCT00301002|Pustulosis
1422469|NCT00300976|Blood glucose
1422470|NCT00300976|Blood pressure
1422471|NCT00300976|Lipids
1422472|NCT00300963|psychosis
1422473|NCT00300963|cognition
1422474|NCT00300950|Pancreas Cancer
1422475|NCT00300950|resected pancreas cancer
1422476|NCT00300950|non-metastatic pancreas cancer
1422477|NCT00300911|Natriuretic Peptide, Brain
1422478|NCT00300911|Heart Failure, Congestive
1422479|NCT00300898|contained lumbar herniated disc
1422480|NCT00300898|nucleoplasty
1422481|NCT00300898|percutaneous decompression
1422482|NCT00300898|Dekompressor
1422483|NCT00300898|intervertebral electrothermal disc decompression
1422484|NCT00300898|IDET
1422485|NCT00300885|Non-Small Cell Lung Cancer
1422486|NCT00300885|NSCLC
1422487|NCT00300820|Bipolar Disorder
1422488|NCT00300820|Affected Adults and Adult Siblings
1422489|NCT00300820|Interest in Genetic Counseling
1422490|NCT00300820|Bipolar
1422491|NCT00300820|Genes
1422492|NCT00300820|Familial
1422493|NCT00300820|Education
1422494|NCT00300820|Testing
1422495|NCT00300820|BP
1422496|NCT00300820|Adult Siblings
1422497|NCT00300807|Hepatitis C
1422498|NCT00300807|Monoclonal Antibody
1422499|NCT00300807|failed IFN/RBV treatment
1422500|NCT00300781|phase 2
1422501|NCT00300781|HER2+ breast cancer
1422502|NCT00300781|monotherapy neratinib
1422503|NCT00300768|onchocerciasis
1422504|NCT00300768|onchocerca volvulus
1422505|NCT00300768|river blindness
1422506|NCT00300768|ivermectin
1422507|NCT00300768|moxidectin
1422508|NCT00300755|GERD
1422509|NCT00300755|Children
1422510|NCT00300755|Child
1422511|NCT00300755|Child, Preschool
1422512|NCT00300742|drinking
1422513|NCT00300742|eating
1422514|NCT00300742|obesity
1422515|NCT00300742|alcohol
1422516|NCT00300742|binge eating
1422517|NCT00300729|Cyclooxygenase-2 inhibitors
1422518|NCT00300729|Celecoxib
1422519|NCT00300729|Carcinoma, non-small-cell lung
1422520|NCT00300729|Antineoplastic agents
1422521|NCT00300729|Therapy, palliative
1422522|NCT00300729|Survival
1422523|NCT00300716|Multiple Sclerosis
1422524|NCT00300716|Cognitive impairment
1422525|NCT00300716|Memantine
1422526|NCT00300716|Placebo
1422527|NCT00300716|Neuropsychological tests
1422528|NCT00300716|Quality of life
1422529|NCT00300716|Fatigue
1422530|NCT00300703|Cardiac Arrest
1422531|NCT00300690|Lower extremity bypass surgery
1422532|NCT00300690|femoro-popliteal bypass
1422533|NCT00300690|Dacron material
1422534|NCT00300690|PTFE material
1422535|NCT00300677|Pharmacokinetics
1422536|NCT00300677|Voriconazole
1422537|NCT00300677|Magnetic Resonance Spectroscopy
1422538|NCT00300651|Cognitive Behavioral Therapy
1422539|NCT00300651|Schizophrenia
1422540|NCT00300651|Cognitive Biases
1422541|NCT00300651|Efficacy
1422542|NCT00300638|Alcoholism
1422543|NCT00300638|Emotion
1422544|NCT00300638|Cognition
1422545|NCT00300638|Brain scans
1422546|NCT00300625|Syncope
1422547|NCT00300625|Near syncope
1422548|NCT00300625|San Francisco Syncope rule
1422549|NCT00300586|Non-small cell lung cancer ;
1422550|NCT00300586|metastatic ;
1422551|NCT00300586|chemotherapy ;
1422552|NCT00300586|erlotinib
1422553|NCT00300573|dexelvucitabine
1422554|NCT00300573|DFC
1422555|NCT00300573|Treatment Experienced
1422556|NCT00300573|HIV-1
1422557|NCT00300560|ESBL-producing E.coli Infections
1422558|NCT00300560|ESBL-producing Klebsiella pneumoniae Infections
1422559|NCT00300560|Colistin
1422560|NCT00300547|colorectal cancer
1422561|NCT00300547|polyps
1422562|NCT00300547|Virtual colonoscopy
1422563|NCT00300547|synchronous carcinoma
1422564|NCT00300547|MR colonography
1422565|NCT00300534|Diagnosis
1422566|NCT00300521|hepatocellular carcinoma
1422567|NCT00300521|liver transplantation
1422568|NCT00300521|adenovirus-thymidine kinase enzyme
1422569|NCT00300521|gene therapy
1422570|NCT00300521|immunosuppression
1422571|NCT00300508|Hormone receptor positive breast cancer
1422572|NCT00300495|Atrial fibrillation
1422573|NCT00300495|Lung cancer
1422574|NCT00300495|Pulmonary resection
1422575|NCT00300495|Post-operative complications
1422576|NCT00300482|Dyslipidemia
1422577|NCT00300482|Coronary Heart Disease
1422578|NCT00300482|Mixed Dyslipidemia
1422579|NCT00300469|Mixed Dyslipidemia
1422580|NCT00300469|Coronary Heart Disease
1422581|NCT00300469|Dyslipidemia
1422582|NCT00300456|Dyslipidemia
1422583|NCT00300456|Coronary Heart Disease
1422584|NCT00300456|Mixed Dyslipidemia
1422585|NCT00300417|Flavivirus
1422586|NCT00300417|Mosquito
1422587|NCT00300417|Immunity
1422588|NCT00300417|Preventive
1422589|NCT00300417|West Nile Fever
1422590|NCT00300417|West Nile Virus
1422591|NCT00300417|Vaccine
1422592|NCT00300417|Healthy Volunteer
1422593|NCT00300417|HV
1422594|NCT00300404|Schizophrenia
1422595|NCT00300404|Psychosis
1422596|NCT00300404|Depression
1422597|NCT00300404|Affective Disorder
1422598|NCT00300391|Delirium
1422599|NCT00300391|Mechanical ventilation
1422600|NCT00300391|Intensive care
1422601|NCT00300391|Haloperidol
1422602|NCT00300378|Depression
1422603|NCT00300378|Adult
1422604|NCT00300378|Outpatients
1422605|NCT00300365|HDL cholesterol
1422606|NCT00300365|Metabolic syndrome
1422607|NCT00300352|Coronary artery disease
1422608|NCT00300352|Folic acid
1422609|NCT00300352|Endothelial function
1422610|NCT00300300|ACL computer-assisted surgery graft
1422611|NCT00300287|Type 2 diabetes
1422612|NCT00300287|Vildagliptin
1422613|NCT00300274|Everolimus
1422614|NCT00300274|heart transplant
1422615|NCT00300274|heart disease
1422616|NCT00300274|transplantation
1422617|NCT00300274|heart IVUS assessment at 12 months
1422618|NCT00300274|rate of graft loss
1422619|NCT00300274|acute rejection episodes
1422620|NCT00300274|survival
1422621|NCT00300261|Heart Failure
1422622|NCT00300248|Acute Respiratory Distress Syndrome
1422623|NCT00300248|Acute Lung Injury
1422624|NCT00300248|Respiratory Failure
1422625|NCT00300248|ARDS, Human
1422626|NCT00300235|Sickle Cell Anemia
1422627|NCT00300222|dermal assessment
1422628|NCT00300222|pain measurement
1422629|NCT00300222|diary
1422630|NCT00300222|PHN
1422631|NCT00300222|shingles
1422632|NCT00300222|neuropathy
1422633|NCT00300222|analgesics
1422634|NCT00300222|capsaicin
1422635|NCT00300222|postherpetic neuralgia
1422636|NCT00300196|Stroke
1422637|NCT00300196|Fibrinogen
1422638|NCT00300196|Reperfusion
1422639|NCT00300196|Thrombolysis
1422640|NCT00300183|HIV
1422641|NCT00300183|health services accessibility
1422765|NCT00299780|Parathyroid Hormone
1422642|NCT00300183|health services research
1422643|NCT00300183|homeless
1422644|NCT00300183|social support
1422645|NCT00300183|AIDS
1422646|NCT00300183|substance abuse
1422647|NCT00300183|mental health
1422648|NCT00300183|quality of life
1422649|NCT00300183|outreach
1422650|NCT00300183|harm reduction
1422651|NCT00300170|HIV
1422652|NCT00300170|race
1422653|NCT00300170|unstable housing
1422654|NCT00300170|health services accessibility
1422655|NCT00300170|health services utilization
1422656|NCT00300170|substance abuse
1422657|NCT00300170|AIDS
1422658|NCT00300170|health services research
1422659|NCT00300170|social support
1422660|NCT00300170|depression
1422661|NCT00300170|trust
1422662|NCT00300170|discrimination
1422663|NCT00300157|Left main coronary artery stenosis, stent, Taxus
1422664|NCT00300157|Unprotected left main coronary artery disease
1422665|NCT00300157|Percutaneous coronary intervention with Taxus stent
1422666|NCT00300131|Bioabsorbable
1422667|NCT00300131|Coronary Stent
1422668|NCT00300131|Everolimus
1422669|NCT00300131|drug eluting stents
1422670|NCT00300131|stents
1422671|NCT00300131|angioplasty
1422672|NCT00300131|coronary artery disease
1422673|NCT00300131|total coronary occlusion
1422674|NCT00300131|coronary artery restenosis
1422675|NCT00300131|stent thrombosis
1422676|NCT00300131|vascular disease
1422677|NCT00300131|myocardial ischemia
1422678|NCT00300131|coronary artery stenosis
1422679|NCT00300105|Patients diagnosed with type 2 diabetes who have participated in and completed the randomized, double-blind, parallel-group, multi-center study GALLANT 4
1422680|NCT00300079|Ocular Hypertension Patients
1422681|NCT00300066|Glomerular Filtration Rate
1422682|NCT00300066|Serum Cystatin C
1422683|NCT00300066|Body Composition
1422684|NCT00300066|bioelectrical impedance spectroscopy
1422685|NCT00300053|angina
1422686|NCT00300040|Amputation
1422687|NCT00300040|Lower limb
1422688|NCT00300040|Critical Limb Ischemia
1422689|NCT00300040|residual limb
1422690|NCT00300040|Peripheral Vascular Disease
1422691|NCT00300040|re-amputation
1422692|NCT00300040|Lower Limb Ischemia
1422693|NCT00300040|PVD
1422694|NCT00300027|Advanced Gastrointestinal Malignancies
1422695|NCT00300014|Post vitrectomy
1422696|NCT00300014|Recurrent diabetic vitreous hemorrhage
1422697|NCT00300014|Intravitreal triamcinolone injection
1422698|NCT00300001|Cancer
1422699|NCT00300001|Symptom Management
1422700|NCT00300001|Supportive Symptom Interventions
1422701|NCT00300001|Symptom Severity
1422702|NCT00300001|quality of life
1422703|NCT00300001|Home-based symptom monitoring
1422704|NCT00299988|Immunotherapy
1422705|NCT00299988|Amyloid beta protein
1422706|NCT00299988|Antibodies
1422707|NCT00299988|Alzheimer's
1422708|NCT00299988|Dementia
1422709|NCT00299975|Randomized Controlled Trials
1422710|NCT00299975|Medicine, Chinese Traditional
1422711|NCT00299975|Medicine, Herbal
1422712|NCT00299975|Constipation
1422713|NCT00299962|gene therapy
1422714|NCT00299962|immunotherapy
1422715|NCT00299936|hepatitis C
1422716|NCT00299936|chronic hepatitis C
1422717|NCT00299936|ribavirin
1422718|NCT00299936|WIN-R
1422719|NCT00299923|drug therapy
1422720|NCT00299923|Interferon
1422721|NCT00299897|HIV
1422722|NCT00299897|AIDS
1422723|NCT00299897|Treatment Resistance
1422724|NCT00299897|Treatment Failure
1422725|NCT00299897|Mutations
1422726|NCT00299897|GP120
1422727|NCT00299897|Entry Inhibitors
1422728|NCT00299897|HAART
1422729|NCT00299897|antiretroviral
1422730|NCT00299897|antiviral
1422731|NCT00299897|ARV
1422732|NCT00299897|CCR5
1422733|NCT00299897|CXCR4
1422734|NCT00299897|receptors
1422735|NCT00299897|intracellular fluid
1422736|NCT00299897|lipid rafts
1422737|NCT00299897|cholesterol
1422738|NCT00299897|chemokine
1422739|NCT00299897|Treatment Experienced
1422740|NCT00299884|Randomized
1422741|NCT00299884|non-blinded
1422742|NCT00299884|prospective
1422743|NCT00299884|open-label
1422744|NCT00299884|LDL-C
1422745|NCT00299884|HDL-C
1422746|NCT00299871|Type 2 diabetes
1422747|NCT00299858|Chronic Obstructive Pulmonary Disease
1422748|NCT00299858|Theophylline
1422749|NCT00299858|Exercise testing
1422750|NCT00299845|gastroesophageal reflux
1422751|NCT00299845|children
1422752|NCT00299845|lansoprazole
1422753|NCT00299845|cytochrome P450 2C19 (CYP2C19)
1422754|NCT00299845|pharmacogenomics
1422755|NCT00299845|genetic polymorphisms
1422756|NCT00299845|individualized medicine
1422757|NCT00299845|pharmacokinetics/dynamics
1422758|NCT00299832|Hypertension, aliskiren, blood pressure, rennin
1422759|NCT00299819|Lupus
1422760|NCT00299806|Hypertension, aliskiren, blood pressure, rennin
1422761|NCT00299793|Epilepsy
1422762|NCT00299793|Quality of life
1422763|NCT00299780|Mobilization
1422764|NCT00299780|Stem Cell
1422766|NCT00299754|Low dose misoprostol
1422767|NCT00299754|dinoprostone
1422768|NCT00299754|cervical priming
1422769|NCT00299741|Sutent
1422770|NCT00299741|Sunitinib
1422771|NCT00299741|Bone
1422772|NCT00299741|Metastatic
1422773|NCT00299741|Hormone-refractory
1422774|NCT00299741|Biomarkers
1422775|NCT00299728|NY-ESO-1
1422776|NCT00299728|Vaccine
1422777|NCT00299728|Adjuvant or metastatic setting
1422778|NCT00299728|Several tumor types eligible
1422779|NCT00299715|Affective psychosis
1422780|NCT00299715|mixed-state
1422781|NCT00299715|bipolar disorder
1422782|NCT00299715|manic disorder
1422783|NCT00299715|manic-depressive
1422784|NCT00299715|psychosis
1422785|NCT00299715|mania
1422786|NCT00299715|manic state
1422787|NCT00299715|paliperidone
1422788|NCT00299715|paliperidone ER.
1422789|NCT00299702|Schizophrenia
1422790|NCT00299702|Relapse
1422791|NCT00299702|Remission
1422792|NCT00299702|Treatment Outcome
1422793|NCT00299702|long-acting injectable
1422794|NCT00299689|Melanoma
1422795|NCT00299689|Metastatic
1422796|NCT00299689|Stage IV
1422797|NCT00299689|Ontak
1422798|NCT00299676|Alzheimer's Disease
1422799|NCT00299676|Dementia
1422800|NCT00299676|Post Marketing
1422801|NCT00299676|Prospective Studies
1422802|NCT00299676|Longitudinal Studies
1422803|NCT00299676|New Zealand
1422804|NCT00299676|Cholinesterase Inhibitors
1422805|NCT00299676|Observational
1422806|NCT00299676|Outcomes
1422807|NCT00299663|group A streptococcal infection
1422808|NCT00299663|genital tract
1422809|NCT00299663|CARRIER
1422810|NCT00299663|patients with GAS isolation
1422811|NCT00299663|Streptococcus Group A
1422812|NCT00299650|ARDS
1422813|NCT00299650|mortality
1422814|NCT00299650|mechanical ventilation
1422815|NCT00299650|pneumonia
1422816|NCT00299650|muscle relaxants
1422817|NCT00299624|venous thromboembolism risk,
1422818|NCT00299624|elderly,
1422819|NCT00299624|hypercoagulability
1422820|NCT00299624|fibrinolysis
1422821|NCT00299624|microparticles
1422822|NCT00299611|OCD
1422823|NCT00299611|Anxiety
1422824|NCT00299611|Pharmacotherapy
1422825|NCT00299611|Sertraline
1422826|NCT00299611|Levetiracetam
1422827|NCT00299598|antibacterial
1422828|NCT00299598|composite
1422829|NCT00299598|polyethylenimine
1422830|NCT00299598|nanoparticle
1422831|NCT00299585|dental implant
1422832|NCT00299585|dental implantation
1422833|NCT00299585|osseointegration
1422834|NCT00299585|bone cement
1422835|NCT00299585|osteoconductivity
1422836|NCT00299585|brushite
1422837|NCT00299585|calcium phosphate
1422838|NCT00299585|bone augmentation
1422839|NCT00299585|primary stability
1422840|NCT00299585|immediate implantation
1422841|NCT00299585|Mandibular Ridge Augmentation
1422842|NCT00299585|Maxillary Ridge Augmentation
1422843|NCT00299585|synthetic implants for rebuilding the alveolar ridge
1422844|NCT00299572|alendronate
1422845|NCT00299572|peritoneal dialysis
1422846|NCT00299572|vascular calcification
1422847|NCT00299572|bone mineral density
1422848|NCT00299559|common cold
1422849|NCT00299559|organic chemicals
1422850|NCT00299559|menthol
1422851|NCT00299559|cineole
1422852|NCT00299559|camphor
1422853|NCT00299559|etheric oils
1422854|NCT00299559|alternative medicine
1422855|NCT00299559|smart textiles
1422856|NCT00299546|Rheumatoid Arthritis
1422857|NCT00299546|Anti-TNFa agents
1422858|NCT00299546|subcutaneous injection
1422859|NCT00299520|skin infection
1422860|NCT00299520|complicated skin infection
1422861|NCT00299520|skin structure infection
1422862|NCT00299507|exudative AMD
1422863|NCT00299507|age-related macular degeneration (AMD)
1422864|NCT00299494|Lymphoma
1422865|NCT00299494|NHL
1422866|NCT00299481|Tissue Bank
1422867|NCT00299481|Endometrial neoplasm
1422868|NCT00299481|uterine cervical neoplasm
1422869|NCT00299481|ovarian neoplasm
1422870|NCT00299481|leiomyoma
1422871|NCT00299481|DNA
1422872|NCT00299481|RNA
1422873|NCT00299481|Protein
1422874|NCT00299481|Serum
1422875|NCT00299468|hypertension
1422876|NCT00299468|home care
1422877|NCT00299468|patient activation
1422878|NCT00299468|stages-of-change
1422879|NCT00299442|behavior
1422880|NCT00299442|conduct
1422881|NCT00299442|child
1422882|NCT00299442|parenting
1422883|NCT00299442|self-help
1422884|NCT00299442|media-based
1422885|NCT00299429|Stent
1422886|NCT00299429|drug-eluting stent
1422887|NCT00299429|Minimally invasive bypass surgery
1422888|NCT00299429|left anterior descending
1422889|NCT00299416|Stroke
1422890|NCT00299416|Nonhemorrhagic
1422891|NCT00299416|hypothermia
1422892|NCT00299403|Depressive disorder,
1422893|NCT00299403|Antidepressant effect,
1422894|NCT00299403|rTMS,
1422895|NCT00299403|ECT,
1422896|NCT00299403|cognition,
1422897|NCT00299403|Saliva cortisol
1422898|NCT00299403|noninferiority trial
1422899|NCT00299390|Sagopilone
1422900|NCT00299390|Epothilone
1422901|NCT00299390|SCLC
1422902|NCT00299390|Small Cell Lung Cancer
1422903|NCT00299390|Lung Cancer
1422904|NCT00299377|STEMI
1422905|NCT00299377|infarct size
1422906|NCT00299377|primary PCI
1422907|NCT00299377|no-reflow
1422908|NCT00299377|ST-elevation myocardial infarction
1422909|NCT00299364|Climacteric symptoms
1422910|NCT00299364|Black Cohosh
1422911|NCT00299364|Efficacy
1422912|NCT00299364|Safety
1422913|NCT00299338|HIV
1422914|NCT00299338|AIDS
1422915|NCT00299338|CD4
1422916|NCT00299338|HAART
1422917|NCT00299338|antiretroviral
1422918|NCT00299338|treatment failure
1422919|NCT00299338|resistance
1422920|NCT00299338|CCR4
1422921|NCT00299338|CXCR5
1422922|NCT00299338|gp120
1422923|NCT00299338|gp41
1422924|NCT00299338|cholesterol
1422925|NCT00299338|lipid rafts
1422926|NCT00299338|intracellular fluid
1422927|NCT00299338|receptors
1422928|NCT00299338|chemokine
1422929|NCT00299338|antigens
1422930|NCT00299338|Treatment Experienced
1422931|NCT00299312|Loss of Purposeful Hand Use Syndrome
1422932|NCT00299312|Loss of Communication
1422933|NCT00299312|Stereotypic Hand Movements
1422934|NCT00299312|MECP2 mutation
1422935|NCT00299312|MECP2 duplication
1422936|NCT00299312|CDKL5 mutation
1422937|NCT00299312|FOXG1 mutation
1422938|NCT00299286|Ki67
1422939|NCT00299286|Molecular
1422940|NCT00299286|antiproliferative
1422941|NCT00299273|Obesity;
1422942|NCT00299273|Low calorie high fat/protein diet;
1422943|NCT00299273|Low-carbohydrate diet
1422944|NCT00299273|Weight Loss
1422945|NCT00299260|cytomegalovirus, glycoprotein B vaccine, allograft
1422946|NCT00299247|Malaria, Plasmodium falciparum, drug resistance, Colombia
1422947|NCT00299234|Attention Deficit Hyperactivity Disorder
1422948|NCT00299221|immunosuppression
1422949|NCT00299221|steroid withdrawal
1422950|NCT00299221|rejection
1422951|NCT00299221|coronary disease
1422952|NCT00299221|cytomegalovirus infection
1422953|NCT00299208|Malaria
1422954|NCT00299195|Oral Leukoplakia
1422955|NCT00299195|Benign Neoplasms
1422956|NCT00299195|Chemoprevention
1422957|NCT00299195|Pan-cyclooxygenase (COX) inhibitor
1422958|NCT00299195|sulindac
1422959|NCT00299195|04-099
1422960|NCT00299182|Non-Hodgkin's Lymphoma
1422961|NCT00299182|Lymphoma
1422962|NCT00299182|Mantle Cell Lymphoma
1422963|NCT00299182|AMG 531
1422964|NCT00299182|Romiplostim
1422965|NCT00299182|Placebo
1422966|NCT00299182|R-HyperCVAD
1422967|NCT00299182|R-Ara-C/MTX
1422968|NCT00299182|Cyclophosphamide
1422969|NCT00299182|Cytarabine
1422970|NCT00299182|Dexamethasone
1422971|NCT00299182|Doxorubicin
1422972|NCT00299182|Methotrexate
1422973|NCT00299182|Rituximab
1422974|NCT00299182|Vincristine
1422975|NCT00299182|Decadron
1422976|NCT00299182|Neosar
1422977|NCT00299182|AD
1422978|NCT00299182|Hydroxydaunomycin hydrocholoride
1422979|NCT00299182|Ara-C
1422980|NCT00299182|Cytosar
1422981|NCT00299182|DepoCyt
1422982|NCT00299182|Cytosine arabinosine hydrochloride
1422983|NCT00299169|N of 1 trial
1422984|NCT00299169|diabetes mellitus
1422985|NCT00299169|HMG CoA Reductase Inhibitors
1422986|NCT00299169|cardiovascular disease
1422987|NCT00299156|Myelodysplastic Syndrome
1422988|NCT00299156|MDS
1422989|NCT00299156|Chronic Myelomonocytic Leukemia
1422990|NCT00299156|CMML
1422991|NCT00299156|Clofarabine
1422992|NCT00299156|Clofarex
1422993|NCT00299156|Clolar
1422994|NCT00299156|Chemotherapy
1422995|NCT00299143|SIPA
1422996|NCT00299143|acute coronary syndrome
1422997|NCT00299130|RA
1422998|NCT00299130|Rituxan
1422999|NCT00299130|SERENE
1423000|NCT00299117|Smoking cessation
1423001|NCT00299117|Stress
1423002|NCT00299117|Nicotine dependence
1423003|NCT00299117|Complication, postoperative
1423004|NCT00299104|Rituxan
1423005|NCT00299104|MTX
1423006|NCT00299104|RA
1423007|NCT00299104|IMAGE
1423008|NCT00299104|WA17047
1423009|NCT00299091|Therapeutic drug monitoring
1423010|NCT00299091|Treatment Naive
1423011|NCT00299091|Treatment Experienced
1423012|NCT00299091|HIV
1423013|NCT00299065|Asthma, bronchial
1423014|NCT00299065|Asthma, exercise-induced
1423015|NCT00299065|Anti-asthmatic agents
1423016|NCT00299052|Tibia
1423017|NCT00299052|Fracture
1423018|NCT00299052|DBM
1423019|NCT00299039|Randomized controlled trial
1423020|NCT00299039|Clinical trial
1423021|NCT00299039|Breast tumor surgery
1423022|NCT00299039|Outpatient surgery
1423023|NCT00299039|Analgesia
1423024|NCT00299039|Outpatient analgesia
1423025|NCT00299039|Post surgical analgesia
1423026|NCT00299039|≥ 18 and ≤ 70 years of age
1423027|NCT00299039|Elective outpatient breast surgery for:
1423028|NCT00299039|lumpectomy/quadrantectomy +/- Sentinel Lymph Node Biopsy
1423029|NCT00299039|lumpectomy/quadrantectomy with Axillary Node Dissection
1423030|NCT00299039|simple mastectomy +/- Sentinel Lymph Node Biopsy
1423031|NCT00299039|Modified Radical mastectomy
1423032|NCT00299026|Coronary Artery Disease
1423033|NCT00299026|Percutaneous Coronary Intervention
1423034|NCT00299026|Stent Implant
1423035|NCT00299026|Drug-coated Stent
1423036|NCT00299013|Ulcerative colitis
1423037|NCT00298987|Chronic Myeloid Leukemia Accelerated and Blast Phase
1423038|NCT00298987|Leukemia, Acute, Philadelphia-Positive
1423039|NCT00298974|Osteoarthritis of the hip or knee
1423040|NCT00298935|Randomized Controlled Trial
1423041|NCT00298935|Pregnant Women
1423042|NCT00298922|Cystic Fibrosis
1423043|NCT00298922|Burkholderia cepacia complex
1423044|NCT00298896|Lung
1423045|NCT00298896|Squamous Cell
1423046|NCT00298896|Small Cell
1423047|NCT00298896|Carcinoma
1423048|NCT00298896|Cancer
1423049|NCT00298896|Small Cell Lung Cancer
1423050|NCT00298883|Renal
1423051|NCT00298883|Transplant
1423052|NCT00298883|PRA
1423053|NCT00298870|pulmonary tuberculosis
1423054|NCT00298870|isoniazid
1423055|NCT00298870|arylamine N-acetyltransferase 2
1423056|NCT00298870|pharmacogenomics
1423057|NCT00298870|genetic polymorphisms
1423058|NCT00298870|individualized medicine
1423059|NCT00298870|drug-induced hepatotoxity
1423060|NCT00298857|Healthy
1423061|NCT00298857|Obesity
1423062|NCT00298857|Pharmacokinetics
1423063|NCT00298844|Type 2 diabetes mellitus
1423064|NCT00298844|Macrovascular disease
1423065|NCT00298844|Diastolic dysfunction
1423066|NCT00298844|Intima media thickness
1423067|NCT00298844|Single- photon emission computed tomography (SPECT)
1423068|NCT00298818|Epilepsy
1423069|NCT00298818|Mental Retardation
1423070|NCT00298818|Developmental Disabilities
1423071|NCT00298805|Migraine
1423072|NCT00298805|Headache
1423073|NCT00298805|Depression
1423074|NCT00298805|Quality of Life
1423075|NCT00298792|Cognitive Behavioral Treatment
1423076|NCT00298792|Alcohol Dependence
1423077|NCT00298792|Functional Analysis
1423078|NCT00298792|Experience Sampling
1423079|NCT00298792|Interactive Voice Response
1423080|NCT00298779|patients with advanced solid tumors or Non-Hodgkins's Lymphoma
1423081|NCT00298727|Knowledge transfer
1423082|NCT00298727|Clinical decision-making
1423083|NCT00298727|Outcome measures
1423084|NCT00298714|Hepatitis C, Chronic
1423085|NCT00298701|Allergy
1423086|NCT00298662|Multiple Sclerosis
1423087|NCT00298662|Betaseron-Prograf
1423088|NCT00298662|patients of Multiple Sclerosis
1423089|NCT00298662|Secondary Progressive type
1423090|NCT00298662|Relapsing-Remitting type
1423091|NCT00298649|pesticide safety
1423092|NCT00298649|migrant and seasonal farmworkers
1423093|NCT00298649|Latino/Hispanic
1423094|NCT00298649|agricultural health
1423095|NCT00298649|occupational health
1423096|NCT00298610|Uncomplicated Malaria
1423097|NCT00298610|GMP artesunate
1423098|NCT00298584|Diagnostic techniques, urological
1423099|NCT00298584|urinary catheterization
1423100|NCT00298584|Aspiration
1423101|NCT00298584|Neonates
1423102|NCT00298584|Neonatal Intensive Care Unit
1423103|NCT00298584|Infant, Newborn
1423104|NCT00298584|Infant, Premature
1423105|NCT00298584|Infant, Low-birth weight
1423106|NCT00298571|Cesarean Delivery
1423107|NCT00298571|Post-operative
1423108|NCT00298571|Pain
1423109|NCT00298571|Local Anesthetic
1423110|NCT00298558|cognition disorder
1423111|NCT00298558|cognitive behavior therapy
1423112|NCT00298558|functional ability
1423113|NCT00298532|Pediatrics
1423114|NCT00298532|Seizure
1423115|NCT00298532|Trauma
1423116|NCT00298532|Respiratory
1423117|NCT00298532|Cardiac
1423118|NCT00298532|Arrest
1423119|NCT00298506|Tacrolimus
1423120|NCT00298506|Mycophenolate mofetil
1423121|NCT00298506|Cyclophosphamide
1423122|NCT00298506|Lupus nephritis
1423123|NCT00298506|Treatment
1423124|NCT00298493|ICU
1423125|NCT00298493|Sedation strategies
1423126|NCT00298493|Daily sedative interruption
1423127|NCT00298493|Sedation protocols
1423128|NCT00298480|preterm labor
1423129|NCT00298480|transvaginal ultrasound
1423130|NCT00298480|dynamic cervical change
1423131|NCT00298467|ALCL
1423132|NCT00298467|csALCL
1423133|NCT00298467|pcALCL
1423134|NCT00298467|Lymphoma
1423135|NCT00298467|Non-Hodgkin's Lymphoma
1423136|NCT00298467|Anaplastic Large Cell Lymphoma
1423137|NCT00298467|classic systemci Anaplastic Large Cell Lymphoma (csALCL)
1423138|NCT00298467|primary cutaneous Anaplastic Large Cell Lymphoma (pcALCL)
1423139|NCT00298454|renal failure
1423140|NCT00298454|oliguric
1423141|NCT00298454|critically ill
1423142|NCT00298454|furosemide
1423143|NCT00298441|intravenous iron administration
1423144|NCT00298428|stent
1423145|NCT00298428|percutaneous coronary intervention
1423146|NCT00298428|platelet aggregation
1423147|NCT00298428|clopidogrel
1423148|NCT00298428|shear
1423149|NCT00298428|metabolic syndrome
1423150|NCT00298415|2-years survival
1423151|NCT00298402|macrophage
1423152|NCT00298402|MMP
1423153|NCT00298402|CT scan
1423154|NCT00298389|macrophage
1423155|NCT00298389|phagocytosis
1423156|NCT00298389|exacerbation
1423157|NCT00298376|Cow’s milk allergy,
1423158|NCT00298376|food allergy
1423159|NCT00298376|oral tolerance,
1423160|NCT00298376|infant,
1423161|NCT00298376|regulatory T cells,
1423162|NCT00298376|intestinal microflora
1423163|NCT00298363|Hepatitis; Hepatitis B virus; Tenofovir
1423164|NCT00298350|Phase 2
1423165|NCT00298350|Phase II
1423166|NCT00298350|Randomized
1423167|NCT00298350|Controlled
1423168|NCT00298350|Comparator
1423169|NCT00298350|Partially Blind
1423170|NCT00298350|Protease Inhibitors
1423171|NCT00298350|Integrase Inhibitors
1423172|NCT00298350|Antiviral Agents
1423173|NCT00298350|Antiretroviral Agents
1423174|NCT00298350|ART
1423175|NCT00298350|ARV
1423176|NCT00298350|Highly Activity Antiretroviral Therapy
1423177|NCT00298350|HAART
1423178|NCT00298350|Treatment Experienced
1423179|NCT00298324|GvHD
1423180|NCT00298324|graft versus host disease
1423181|NCT00298324|extensive
1423182|NCT00298324|myfortic
1423183|NCT00298298|lung cancer
1423184|NCT00298298|non-small cell lung cancere
1423185|NCT00298298|vaccine
1423186|NCT00298298|immunotherapy
1423187|NCT00298285|mechanical valve replacement
1423188|NCT00298285|warfarin
1423189|NCT00298246|Neurodevelopmental Disorders
1423190|NCT00298246|Neurological Disorder
1423191|NCT00298246|Children- Onset
1423192|NCT00298246|Children
1423193|NCT00298246|Pervasive Developmental Disorder
1423194|NCT00298246|PDD
1423195|NCT00298246|Autism
1423196|NCT00298246|Healthy Volunteer
1423197|NCT00298246|HV
1423198|NCT00298233|Antibody Response
1423199|NCT00298233|Antiviral Efficacy
1423200|NCT00298233|Bird Flu
1423201|NCT00298233|Severe Respiratory Distress
1423202|NCT00298233|Viral Replication and Shedding
1423203|NCT00298220|Family Practice
1423204|NCT00298220|Intervention Studies
1423205|NCT00298220|Prevention and Control
1423206|NCT00298207|high blood pressure
1423207|NCT00298207|hypertension
1423208|NCT00298207|adult
1423209|NCT00298207|African Americans
1423210|NCT00298207|Walking
1423211|NCT00298168|Delayed Graft Function
1423212|NCT00298142|Cervicogenic Headache
1423213|NCT00298142|Migraine
1423214|NCT00298142|Tension Type Headache
1423215|NCT00298103|Antibiotic resistant
1423216|NCT00298103|Infection
1423217|NCT00298090|Oxygenation
1423218|NCT00298077|Infection
1423219|NCT00298077|transplant recipients
1423220|NCT00298064|Cervical cancer
1423221|NCT00298064|EGFR
1423222|NCT00298064|cervical
1423223|NCT00298064|genomic
1423224|NCT00298064|DNA
1423225|NCT00298064|markers
1423226|NCT00298064|prognostic
1423227|NCT00298064|gene
1423228|NCT00298064|epidermal growth factor
1423229|NCT00298051|Iron-deficiency anemia
1423230|NCT00298051|Umbilical cord clamping
1423231|NCT00298051|Infant
1423232|NCT00298025|Infertility
1423233|NCT00298025|Cetrotide
1423234|NCT00298025|Antagon
1423235|NCT00298025|Recombinant human follicle stimulating hormone (r-hFSH)
1423236|NCT00298025|Human Menopausal Gonadotropin (hMG)
1423237|NCT00298025|Recombinant Human Choriogonadotropin (r-hCG)
1423238|NCT00298012|Methotrexate
1423239|NCT00298012|Magnetic Resonance Imaging
1423240|NCT00298012|Anterior uveitis
1423241|NCT00297947|schizophrenia
1423242|NCT00297947|quetiapine
1423243|NCT00297947|schizoaffective disorder
1423244|NCT00297934|dual-task
1423245|NCT00297934|postural control
1423246|NCT00297934|cognitive
1423247|NCT00297908|Ethanol levels
1423248|NCT00297908|Dermal absorbtion
1423249|NCT00297895|sentinel lymph node dissection
1423250|NCT00297895|complete lymph node dissection
1423251|NCT00297895|surgical
1423252|NCT00297882|Efficacy
1423253|NCT00297882|Safety
1423254|NCT00297882|Children
1423255|NCT00297882|Cameroon
1423256|NCT00297856|Boostrix
1423257|NCT00297830|Heart Transplantation
1423258|NCT00297830|Liver Transplantation
1423259|NCT00297830|Immunosuppression
1423260|NCT00297830|Bone Density/drug effects
1423261|NCT00297830|Alendronate
1423262|NCT00297830|Zoledronic acid
1423263|NCT00297830|Comparative study
1423264|NCT00297830|Humans
1423265|NCT00297817|Meningococcal Disease; Meningococcal Meningitis; Vaccine
1423266|NCT00297804|Coronary Artery Disease
1423267|NCT00297804|Percutaneous Coronary Intervention
1423268|NCT00297804|Stent Implant
1423269|NCT00297804|Drug-coated Stent
1423270|NCT00297791|rectal cancer
1423271|NCT00297791|laparoscopic technique
1423272|NCT00297791|open technique
1423273|NCT00297791|clinical trial
1423274|NCT00297791|multicenter study
1423275|NCT00297791|randomized controlled trial
1423276|NCT00297791|Tumor Below 15cm
1423277|NCT00297791|curative surgical resection
1423278|NCT00297791|no evidence for distant metastases
1423279|NCT00297765|Renal Transplantation
1423280|NCT00297765|Therapeutics
1423281|NCT00297765|Treatment Outcome
1423282|NCT00297765|Safety
1423283|NCT00297752|facial burns
1423284|NCT00297752|cerium flammazine
1423285|NCT00297752|quality of life
1423286|NCT00297752|randomised clinical trial
1423287|NCT00297739|Aggression
1423288|NCT00297739|ADHD
1423289|NCT00297739|Antipsychotic
1423290|NCT00297726|Osteoarthritis, Knee
1423291|NCT00297726|Osteoarthritis, Hip
1423292|NCT00297726|Osteoarthritis, Ankle
1423293|NCT00297726|Arthritis
1423294|NCT00297726|Self-Management
1423295|NCT00297700|Smoking
1423296|NCT00297700|Dental
1423297|NCT00297700|Cessation
1423298|NCT00297700|Prevention
1423299|NCT00297700|Control
1423300|NCT00297700|Quitline
1423301|NCT00297700|5A-Model
1423302|NCT00297700|Cost-effective
1423303|NCT00297687|Vaccines
1423304|NCT00297687|Healthy Adults
1423305|NCT00297687|Health
1423306|NCT00297687|Adult
1423307|NCT00297687|Meningococcal Vaccines
1423308|NCT00297674|clarithromycin
1423309|NCT00297674|sepsis
1423310|NCT00297674|immunomodulation
1423311|NCT00297661|Coronary Revascularization
1423312|NCT00297661|Sirolimus-eluting stents
1423313|NCT00297661|Paclitaxel-eluting stents
1423314|NCT00297648|Certolizumab pegol
1423315|NCT00297648|Crohn's disease
1423316|NCT00297648|Mucosal healing
1423317|NCT00297635|Hyperglycemia
1423318|NCT00297635|Insulin Infusion Systems
1423319|NCT00297635|Blood Glucose Self-Monitoring
1423320|NCT00297609|Resuscitation medication errors
1423321|NCT00297609|critical care
1423322|NCT00297609|pediatrics
1423323|NCT00297609|clinical decision support systems
1423324|NCT00297609|computerized physician order entry
1423325|NCT00297596|Metastatic
1423326|NCT00297596|HER2/neu+
1423327|NCT00297570|CML
1423328|NCT00297570|Imatinib
1423329|NCT00297570|Pegylated Interferon
1423330|NCT00297570|Philadelphia Positive CML
1423331|NCT00297544|impotence
1423332|NCT00297544|endothelial function
1423333|NCT00297544|autonomic nervous system
1423334|NCT00297531|Chronic Periodontitis
1423335|NCT00297531|Periodontitis
1423336|NCT00297531|Photodynamic disinfection
1423337|NCT00297531|PDD
1423338|NCT00297531|PDT
1423339|NCT00297531|Periowave
1423340|NCT00297531|Scaling and Root Planing
1423341|NCT00297531|SRP
1423342|NCT00297518|Adult Periodontitis
1423343|NCT00297518|Chronic Periodontitis
1423344|NCT00297518|PDD
1423345|NCT00297518|PDT
1423346|NCT00297518|Photodynamic Disinfection
1423347|NCT00297518|SRP
1423348|NCT00297518|Scaling and Root Planing
1423349|NCT00297505|Cocaine; citalopram; impulsivity; serotonin
1423350|NCT00297492|Smoking Cessation
1423351|NCT00297492|Tobacco
1423352|NCT00297479|Tobacco Cessation
1423353|NCT00297479|Smoking Cessation
1423354|NCT00297466|tobacco use
1423355|NCT00297466|smoking cessation
1423356|NCT00297466|emergency department
1423357|NCT00297440|Smoking
1423358|NCT00297440|Exercise
1423359|NCT00297440|Adolescent
1423360|NCT00297440|Girls
1423361|NCT00297427|urinary incontinence
1423362|NCT00297414|Mild Cognitive Impairment
1423363|NCT00297414|Dementia
1423364|NCT00297414|Galantamine
1423365|NCT00297414|Memory disorders
1423366|NCT00297414|Isolated memory impairment
1423367|NCT00297414|Alzheimer's disease
1423368|NCT00297388|schizophrenia
1423369|NCT00297388|schizoaffective disorder
1423370|NCT00297388|long-acting risperidone
1423371|NCT00297388|intramuscular injection risperidone
1423372|NCT00297388|risperidone
1423373|NCT00297375|treatment
1423374|NCT00297375|Pain
1423375|NCT00297375|acute
1423376|NCT00297375|migraine
1423377|NCT00297375|headache
1423378|NCT00297362|Alzheimer Disease
1423379|NCT00297362|Dementia
1423380|NCT00297362|Brain Disease
1423381|NCT00297362|Memory Loss
1423382|NCT00297362|Caregiver
1423383|NCT00297362|Galantamine hydrobromide
1423384|NCT00297362|Nervous System Diseases
1423385|NCT00297362|Mental Disorders
1423386|NCT00297349|Seizures
1423387|NCT00297349|Epilepsy
1423388|NCT00297349|Tonic-clonic
1423389|NCT00297349|Lennox-Gastaut Syndrome
1423390|NCT00297349|Focal Epilepsy
1423391|NCT00297349|Topiramate
1423392|NCT00297349|Epilepsy in Children
1423393|NCT00297336|Topiramate
1423394|NCT00297336|Migraine
1423395|NCT00297336|Headache
1423396|NCT00297336|Chronic headache
1423397|NCT00297336|Chronic migraine
1423398|NCT00297323|Seizures
1423399|NCT00297323|Epilepsy
1423400|NCT00297323|Topiramate
1423401|NCT00297323|Epilepsy in Children
1423402|NCT00297310|Tacrolimus
1423403|NCT00297310|Kidney transplantation
1423404|NCT00297310|Transplantation
1423405|NCT00297310|Kidney failure
1423406|NCT00297310|chronic
1423407|NCT00297310|P-Glycoprotein
1423408|NCT00297297|Solitary solid and scintigraphically cold thyroid nodules
1423409|NCT00297284|systemic lupus erythematosus
1423410|NCT00297284|cognitive efficiency
1423411|NCT00297284|cognitive dysfunction
1423412|NCT00297284|cognition
1423413|NCT00297284|memory
1423414|NCT00297284|attention
1423415|NCT00297284|modafinil
1423416|NCT00297284|provigil
1423417|NCT00297271|Dementia
1423418|NCT00297271|Mild Cognitive Impairment
1423419|NCT00297271|Patient Registries
1423420|NCT00297271|Prospective Studies
1423421|NCT00297271|Longitudinal Studies
1423422|NCT00297271|Australia
1423423|NCT00297271|Cholinesterase Inhibitors
1423424|NCT00297271|Observational
1423425|NCT00297271|Non-randomized
1423426|NCT00297258|Sarcoma
1423427|NCT00297258|Synovial sarcoma
1423428|NCT00297258|Pazopanib(GW786034)
1423429|NCT00297258|Adipocytic tumors
1423430|NCT00297258|Leiomyosarcoma
1423431|NCT00297258|Phase II
1423432|NCT00297245|gastrodin
1423433|NCT00297232|Multiple Sclerosis
1423434|NCT00297232|MS
1423435|NCT00297219|Hemodialysis
1423436|NCT00297219|Coronary artery calcification
1423437|NCT00297219|Adynamic bone disease
1423438|NCT00297219|Dialysate calcium
1423439|NCT00297219|Bone mineral density
1423440|NCT00297219|Bone histomorphometry
1423441|NCT00297206|pharmacokinetics herpes varicella herpes labialis Epstein-Barr virus
1423442|NCT00297193|Crohn's Disease
1423443|NCT00297193|HSCT
1423444|NCT00297193|Autologous
1423445|NCT00297193|EBMT
1423446|NCT00297193|ECCO
1423447|NCT00297180|hunger
1423448|NCT00297180|obesity
1423449|NCT00297180|sodium-dependent glucose transporter
1423450|NCT00297180|GW869682
1423451|NCT00297180|body composition
1423452|NCT00297180|SGLT2 inhibitor
1423453|NCT00297180|weight loss
1423454|NCT00297167|CF
1423455|NCT00297167|Cystic Fibrosis
1423456|NCT00297167|EPI
1423457|NCT00297167|Exocrine Pancreatic Insufficiency
1423458|NCT00297167|Pancreatic
1423459|NCT00297167|Enzyme
1423460|NCT00297167|PEP
1423461|NCT00297154|Heart failure, congestive
1423462|NCT00297154|Metabolic Syndrome X
1423463|NCT00297154|Obesity
1423464|NCT00297141|Preoperative
1423465|NCT00297141|Radiochemotherapy
1423466|NCT00297141|Newly Diagnosed
1423467|NCT00297141|Primary Operable
1423468|NCT00297141|Locally Advanced
1423469|NCT00297141|Rectal Carcinoma
1423470|NCT00297141|T3
1423471|NCT00297141|Lower Rectum
1423472|NCT00297141|Middle Rectum
1423473|NCT00297141|ABCSG
1423474|NCT00297141|TAKO
1423475|NCT00297141|95
1423476|NCT00297141|05
1423477|NCT00297128|pilot study
1423478|NCT00297128|rectal
1423479|NCT00297128|cancer
1423480|NCT00297128|phase II
1423481|NCT00297128|preoperative
1423482|NCT00297128|chemoradiation
1423483|NCT00297128|capecitabine
1423484|NCT00297128|cetuximab
1423485|NCT00297128|operable
1423486|NCT00297128|T4
1423487|NCT00297128|ABCSG
1423488|NCT00297128|TAKO
1423489|NCT00297128|R03
1423490|NCT00297128|96
1423491|NCT00297128|06
1423492|NCT00297115|Roflumilast
1423493|NCT00297115|COPD
1423494|NCT00297115|Chronic obstructive pulmonary disease
1423495|NCT00297102|Roflumilast
1423496|NCT00297102|COPD
1423497|NCT00297102|Chronic obstructive pulmonary disease
1423498|NCT00297089|Lung Cancer
1423499|NCT00297089|ABT-751
1423500|NCT00297089|NSCLC
1423501|NCT00297089|Alimta
1423502|NCT00297089|Non-Small-Cell Lung Cancer
1423503|NCT00297089|pemetrexed
1423504|NCT00297076|HIV-1
1423505|NCT00297076|GW873140
1423506|NCT00297076|CCR5 antagonist
1423507|NCT00297076|experienced
1423508|NCT00297076|Treatment Experienced
1423509|NCT00297063|rosiglitazone
1423510|NCT00297063|vandia
1423511|NCT00297063|Type 2 diabetes mellitus
1423512|NCT00297063|diabetes;
1423513|NCT00297050|Influenza Virus
1423514|NCT00297050|Avian Influenza
1423515|NCT00297050|Normal Volunteers
1423516|NCT00297050|Neuraminidase Inhibitor
1423517|NCT00297050|Viral Disease
1423518|NCT00297050|Healthy Volunteer
1423519|NCT00297050|HV
1423520|NCT00297037|oral lichen planus, pimecrolimus 1% cream
1423521|NCT00296985|Cardiac surgery
1423522|NCT00296985|Cellsaver
1423523|NCT00296985|Neurocognitive Function
1423524|NCT00296985|Neuronal Protection
1423525|NCT00296985|Quality of Life
1423526|NCT00296972|peg interferon
1423527|NCT00296972|ribavirin
1423528|NCT00296972|HAART
1423529|NCT00296972|HIV
1423530|NCT00296972|Chronic Hepatitis C
1423531|NCT00296972|Treatment Experienced
1423532|NCT00296959|Dyskinesia
1423533|NCT00296959|AMPA receptor antagonists
1423534|NCT00296946|Sialorrhoea
1423535|NCT00296933|Major Depression
1423536|NCT00296933|Antidepressant
1423537|NCT00296933|Pharmacotherapy
1423538|NCT00296933|Memory functioning
1423539|NCT00296933|Memory Impairment
1423540|NCT00296920|Deep Brain Stimulation
1423541|NCT00296920|Treatment failure
1423542|NCT00296907|cancer
1423543|NCT00296907|siblings
1423544|NCT00296907|behavior
1423545|NCT00296907|psychological adaptation
1423546|NCT00296907|intervention
1423547|NCT00296881|Periodontitis
1423548|NCT00296881|Photodynamic Disinfection
1423549|NCT00296881|PERIOWAVE
1423550|NCT00296881|Scaling and Root Planing
1423551|NCT00296881|SRP
1423552|NCT00296868|reflex sympathetic dystrophy
1423553|NCT00296868|ascorbic acid
1423554|NCT00296868|primary prevention
1423555|NCT00296868|radius fractures
1423556|NCT00296855|Peripheral artery disease
1423557|NCT00296842|posttraumatic stress disorder
1423558|NCT00296842|children
1423559|NCT00296842|injury
1423560|NCT00296842|road traffic accident
1423561|NCT00296829|Influenza;
1423562|NCT00296829|Orthomyxoviruses;
1423563|NCT00296829|Inactivated Split-virion influenza vaccine;
1423564|NCT00296829|Elderly.
1423565|NCT00296803|metabolic syndrome
1423566|NCT00296777|Major Depression
1423567|NCT00296777|Dysthymia
1423568|NCT00296777|f-MRI
1423569|NCT00296777|Escitalopram
1423570|NCT00296777|Bupropion
1423571|NCT00296777|Imipramine
1423572|NCT00296777|Neuropsychologic test
1423573|NCT00296777|Dichotic listening
1423574|NCT00296777|EEG
1423575|NCT00296777|ERP
1423576|NCT00296764|Happy Puppet Syndrome
1423577|NCT00296764|Developmental Disorders
1423578|NCT00296725|Major Depression
1423579|NCT00296725|Dysthymia
1423580|NCT00296725|Depression NOS
1423581|NCT00296725|Dichotic Listening
1423582|NCT00296725|Fluoxetine
1423583|NCT00296725|Imipramine
1423584|NCT00296725|Placebo
1423585|NCT00296725|Predictors
1423586|NCT00296712|Major Depression
1423587|NCT00296712|Dysthymia
1423588|NCT00296712|Depression NOS
1423589|NCT00296712|Escitalopram
1423590|NCT00296712|Bupropion
1423591|NCT00296712|Dual Therapy
1423592|NCT00296712|Combination Therapy
1423593|NCT00296699|Atypical Depression
1423594|NCT00296699|Major Depressive Disorder
1423595|NCT00296699|Dysthymic Disorder
1423596|NCT00296699|Atypical Features
1423597|NCT00296699|Duloxetine
1423598|NCT00296686|Major Depression
1423599|NCT00296686|Refractory Depression
1423600|NCT00296686|Tranylcypromine
1423601|NCT00296686|Dextroamphetamine
1423602|NCT00296686|Triiodothyronine
1423603|NCT00296673|Rehabilitation, Side Bridge test, Muscular endurance
1423604|NCT00296660|Acute Infection
1423605|NCT00296634|H5N1, Influenza, vaccine
1423606|NCT00296621|glutamine
1423607|NCT00296621|nutrition
1423608|NCT00296621|children
1423609|NCT00296621|pediatrics
1423610|NCT00296621|randomized controlled clinical trial
1423611|NCT00296621|therapy
1423612|NCT00296621|supplement
1423613|NCT00296621|oral administration
1423614|NCT00296621|handicap
1423615|NCT00296608|stage II rectal cancer
1423616|NCT00296608|stage III rectal cancer
1423617|NCT00296608|adenocarcinoma of the rectum
1423618|NCT00296556|Ulcerative colitis
1423619|NCT00296556|EP4 agonist
1423620|NCT00296556|PGE2
1423621|NCT00296543|hemodialysis
1423622|NCT00296543|sudden cardiac death
1423623|NCT00296530|Asthma
1423624|NCT00296530|Allergic Rhinitis
1423625|NCT00296517|depression
1423626|NCT00296517|double-blind
1423627|NCT00296517|placebo-controlled
1423628|NCT00296517|bupropion hydrochloride
1423629|NCT00296517|SSRI
1423630|NCT00296517|comparative study
1423631|NCT00296517|non-responder
1423632|NCT00296504|antiretroviral therapy naive subjects
1423633|NCT00296504|fosamprenavir
1423634|NCT00296504|HIV-1
1423635|NCT00296504|protease inhibitor
1423636|NCT00296504|pro-drug
1423637|NCT00296504|antiretroviral therapy
1423638|NCT00296504|LEXIVA
1423639|NCT00296504|AGENERASE
1423640|NCT00296504|GW433908
1423641|NCT00296504|amprenavir
1423642|NCT00296491|Allergic Rhinitis
1423643|NCT00296491|Asthma
1423644|NCT00296452|cancer
1423645|NCT00296452|nutrition
1423646|NCT00296426|Adverse Drug Event
1423647|NCT00296426|Inpatients
1423648|NCT00296426|Outcome assessment
1423649|NCT00296413|epilepsy
1423650|NCT00296413|menstrual cycle
1423651|NCT00296413|valproate
1423652|NCT00296413|lamotrigine
1423653|NCT00296413|oral contraceptive
1423654|NCT00296400|Hyperlipidemia
1423655|NCT00296400|Proteinuria
1423656|NCT00296400|Diabetes Mellitus
1423657|NCT00296374|Hyperlipidemia
1423658|NCT00296374|Proteinuria
1423659|NCT00296374|Diabetes Mellitus
1423660|NCT00296361|Tacrolimus
1423661|NCT00296361|Kidney Transplantation
1423662|NCT00296361|Immunosuppression
1423663|NCT00296361|Adult
1423664|NCT00296361|Treatment Outcomes
1423665|NCT00296348|Tacrolimus
1423666|NCT00296348|Kidney Transplantation
1423667|NCT00296348|Child
1423668|NCT00296348|Treatment Outcome
1423669|NCT00296348|Immunosuppression
1423670|NCT00296335|Stomach cancer
1423671|NCT00296335|Adjuvant chemotherapy
1423672|NCT00296335|Mitomycin
1423673|NCT00296335|Cisplatin
1423674|NCT00296335|Doxifluridine
1423675|NCT00296322|stomach cancer
1423676|NCT00296322|adjuvant chemotherapy
1423677|NCT00296322|mitomycin
1423678|NCT00296322|cisplatin
1423679|NCT00296322|doxifluridine
1423680|NCT00296309|Tacrolimus
1423681|NCT00296309|Kidney Transplantation
1423682|NCT00296309|Immunosuppression
1423683|NCT00296309|Adult
1423684|NCT00296309|Treatment Outcomes
1423685|NCT00296296|kidney Transplant
1423686|NCT00296296|Type II Diabetes
1423687|NCT00296296|Diabetic Nephropathy
1423688|NCT00296296|Immunosuppression
1423689|NCT00296296|Cyclosporin
1423690|NCT00296296|Tacrolimus
1423691|NCT00296283|Relatives
1423692|NCT00296283|Bipolar Disorder
1423693|NCT00296283|Psychoeducation
1423694|NCT00296244|steroid-free immunosuppression
1423695|NCT00296244|liver transplantation
1423696|NCT00296231|premature infants
1423697|NCT00296231|very low birthweight infants
1423698|NCT00296231|high frequency ventilation
1423699|NCT00296231|nasal ventilation
1423700|NCT00296205|Multiple Sclerosis
1423701|NCT00296205|Cyclophosphamide
1423702|NCT00296205|autoimmune
1423703|NCT00296192|Rotigotine
1423704|NCT00296192|Rotigotine nasal spray
1423705|NCT00296192|Efficacy, safety and tolerability
1423706|NCT00296192|Parkinson's disease
1423707|NCT00296166|Atrial fibrillation
1423708|NCT00296166|Permanent Atrial fibrillation
1423709|NCT00296166|catheter ablation
1423710|NCT00296166|thoracoscopy
1423711|NCT00296166|Arrhythmia
1423712|NCT00296166|Heart
1423713|NCT00296153|Human immunodeficiency Virus (HIV)
1423714|NCT00296153|Highly Active Antiviral Therapy (HAART)
1423715|NCT00296153|Ischemic Heart Disease
1423716|NCT00296153|OMACOR
1423717|NCT00296153|Triglycerides
1423718|NCT00296153|Endothelial function
1423719|NCT00296153|Treatment Experienced
1423720|NCT00296114|Cancer
1423721|NCT00296114|Pancreas
1423722|NCT00296101|Physical Inactivity
1423723|NCT00296088|Mechanical Ventilation
1423724|NCT00296088|Critical Care
1423725|NCT00296088|Respiratory Failure
1423726|NCT00296062|unspecified adult solid tumor, protocol specific
1423727|NCT00296062|stage III colon cancer
1423728|NCT00296062|stage IV colon cancer
1423729|NCT00296062|stage III rectal cancer
1423730|NCT00296062|stage IV rectal cancer
1423731|NCT00296062|recurrent colon cancer
1423732|NCT00296062|recurrent rectal cancer
1423733|NCT00296049|unspecified adult solid tumor, protocol specific
1423734|NCT00296049|infection
1423735|NCT00296049|neutropenia
1423736|NCT00296049|unspecified childhood solid tumor, protocol specific
1423737|NCT00296036|drug/agent toxicity by tissue/organ
1423738|NCT00296036|stage I breast cancer
1423739|NCT00296036|stage II breast cancer
1423740|NCT00296036|stage IIIA breast cancer
1423741|NCT00296036|stage IIIB breast cancer
1423742|NCT00296036|stage IIIC breast cancer
1423743|NCT00296036|stage IV breast cancer
1423744|NCT00296036|unspecified adult solid tumor, protocol specific
1423745|NCT00296023|stage III chronic lymphocytic leukemia
1423746|NCT00296023|stage IV chronic lymphocytic leukemia
1423747|NCT00296023|stage III adult diffuse small cleaved cell lymphoma
1423748|NCT00296023|stage IV adult diffuse small cleaved cell lymphoma
1423749|NCT00296023|noncontiguous stage II grade 1 follicular lymphoma
1423750|NCT00296023|noncontiguous stage II grade 2 follicular lymphoma
1423751|NCT00296023|noncontiguous stage II grade 3 follicular lymphoma
1423752|NCT00296023|stage III grade 1 follicular lymphoma
1423753|NCT00296023|stage III grade 2 follicular lymphoma
1423754|NCT00296023|stage III grade 3 follicular lymphoma
1423755|NCT00296023|stage IV grade 1 follicular lymphoma
1423756|NCT00296023|stage IV grade 2 follicular lymphoma
1423757|NCT00296023|stage IV grade 3 follicular lymphoma
1423758|NCT00296023|noncontiguous stage II marginal zone lymphoma
1423759|NCT00296023|stage III marginal zone lymphoma
1423760|NCT00296023|stage IV marginal zone lymphoma
1423761|NCT00296023|noncontiguous stage II small lymphocytic lymphoma
1423762|NCT00296023|stage III small lymphocytic lymphoma
1423763|NCT00296023|stage IV small lymphocytic lymphoma
1423764|NCT00296023|noncontiguous stage II adult Burkitt lymphoma
1423765|NCT00296023|stage III adult Burkitt lymphoma
1423766|NCT00296023|stage IV adult Burkitt lymphoma
1423767|NCT00296023|stage III adult diffuse large cell lymphoma
1423768|NCT00296023|stage IV adult diffuse large cell lymphoma
1423769|NCT00296023|noncontiguous stage II adult diffuse mixed cell lymphoma
1423770|NCT00296023|stage III adult diffuse mixed cell lymphoma
1423771|NCT00296023|stage IV adult diffuse mixed cell lymphoma
1423772|NCT00296023|noncontiguous stage II adult immunoblastic large cell lymphoma
1423773|NCT00296023|stage III adult immunoblastic large cell lymphoma
1423774|NCT00296023|stage IV adult immunoblastic large cell lymphoma
1423775|NCT00296023|noncontiguous stage II adult lymphoblastic lymphoma
1423776|NCT00296023|stage III adult lymphoblastic lymphoma
1423777|NCT00296023|stage IV adult lymphoblastic lymphoma
1423778|NCT00296023|noncontiguous stage II mantle cell lymphoma
1423779|NCT00296023|stage III mantle cell lymphoma
1423780|NCT00296023|stage IV mantle cell lymphoma
1423781|NCT00296023|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1423782|NCT00296023|nodal marginal zone B-cell lymphoma
1423783|NCT00296023|splenic marginal zone lymphoma
1423784|NCT00296023|stage II multiple myeloma
1423785|NCT00296023|stage III multiple myeloma
1423786|NCT00296023|chronic phase chronic myelogenous leukemia
1423787|NCT00296023|primary myelofibrosis
1423788|NCT00296023|polycythemia vera
1423789|NCT00296023|prolymphocytic leukemia
1423790|NCT00296023|stage II adult Hodgkin lymphoma
1423791|NCT00296023|stage III adult Hodgkin lymphoma
1423792|NCT00296023|stage IV adult Hodgkin lymphoma
1423793|NCT00296023|de novo myelodysplastic syndromes
1423794|NCT00296023|previously treated myelodysplastic syndromes
1423795|NCT00296023|secondary myelodysplastic syndromes
1423796|NCT00296023|refractory anemia with excess blasts in transformation
1423797|NCT00296023|refractory anemia with excess blasts
1423798|NCT00296023|chronic myelomonocytic leukemia
1423799|NCT00296023|adult acute myeloid leukemia in remission
1423800|NCT00296023|secondary acute myeloid leukemia
1423801|NCT00296023|Waldenström macroglobulinemia
1423802|NCT00296023|essential thrombocythemia
1423803|NCT00296023|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1423804|NCT00296023|adult acute myeloid leukemia with inv(16)(p13;q22)
1423805|NCT00296023|adult acute myeloid leukemia with t(15;17)(q22;q12)
1423806|NCT00296023|adult acute myeloid leukemia with t(16;16)(p13;q22)
1423807|NCT00296023|adult acute myeloid leukemia with t(8;21)(q22;q22)
1423808|NCT00296023|noncontiguous stage II adult diffuse large cell lymphoma
1423809|NCT00296023|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1423810|NCT00296023|stage I multiple myeloma
1423811|NCT00296010|stage I breast cancer
1423812|NCT00296010|stage II breast cancer
1423813|NCT00296010|stage IIIA breast cancer
1423814|NCT00295997|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1423815|NCT00295997|adult acute myeloid leukemia with inv(16)(p13;q22)
1423816|NCT00295997|adult acute myeloid leukemia with t(15;17)(q22;q12)
1423817|NCT00295997|adult acute myeloid leukemia with t(16;16)(p13;q22)
1423818|NCT00295997|accelerated phase chronic myelogenous leukemia
1423819|NCT00295997|adult acute lymphoblastic leukemia in remission
1423820|NCT00295997|adult acute myeloid leukemia in remission
1423821|NCT00295997|atypical chronic myeloid leukemia, BCR-ABL1 negative
1423822|NCT00295997|blastic phase chronic myelogenous leukemia
1423823|NCT00295997|childhood acute lymphoblastic leukemia in remission
1423824|NCT00295997|childhood acute myeloid leukemia in remission
1423825|NCT00295997|childhood chronic myelogenous leukemia
1423826|NCT00295997|chronic eosinophilic leukemia
1423827|NCT00295997|primary myelofibrosis
1423828|NCT00295997|chronic myelomonocytic leukemia
1423829|NCT00295997|chronic neutrophilic leukemia
1423830|NCT00295997|chronic phase chronic myelogenous leukemia
1423831|NCT00295997|de novo myelodysplastic syndromes
1423832|NCT00295997|essential thrombocythemia
1423833|NCT00295997|juvenile myelomonocytic leukemia
1423834|NCT00295997|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1423835|NCT00295997|polycythemia vera
1423836|NCT00295997|previously treated myelodysplastic syndromes
1423837|NCT00295997|recurrent adult acute myeloid leukemia
1423838|NCT00295997|prolymphocytic leukemia
1423839|NCT00295997|recurrent adult Hodgkin lymphoma
1423840|NCT00295997|recurrent adult diffuse large cell lymphoma
1423841|NCT00295997|recurrent adult immunoblastic large cell lymphoma
1423842|NCT00295997|recurrent adult lymphoblastic lymphoma
1423843|NCT00295997|recurrent/refractory childhood Hodgkin lymphoma
1423844|NCT00295997|recurrent childhood acute lymphoblastic leukemia
1423845|NCT00295997|recurrent childhood acute myeloid leukemia
1423846|NCT00295997|recurrent childhood large cell lymphoma
1423847|NCT00295997|recurrent grade 1 follicular lymphoma
1423848|NCT00295997|recurrent grade 2 follicular lymphoma
1423849|NCT00295997|recurrent grade 3 follicular lymphoma
1423850|NCT00295997|recurrent mantle cell lymphoma
1423851|NCT00295997|refractory chronic lymphocytic leukemia
1423852|NCT00295997|refractory multiple myeloma
1423853|NCT00295997|relapsing chronic myelogenous leukemia
1423854|NCT00295997|secondary acute myeloid leukemia
1423855|NCT00295997|secondary myelodysplastic syndromes
1423856|NCT00295997|stage II multiple myeloma
1423857|NCT00295997|stage III chronic lymphocytic leukemia
1423858|NCT00295997|stage III grade 1 follicular lymphoma
1423859|NCT00295997|stage III grade 2 follicular lymphoma
1423860|NCT00295997|stage III grade 3 follicular lymphoma
1423861|NCT00295997|stage III multiple myeloma
1423862|NCT00295997|stage IV chronic lymphocytic leukemia
1423863|NCT00295997|stage IV grade 1 follicular lymphoma
1423864|NCT00295997|stage IV grade 2 follicular lymphoma
1423865|NCT00295997|stage IV grade 3 follicular lymphoma
1423866|NCT00295997|recurrent renal cell cancer
1423867|NCT00295997|stage IV renal cell cancer
1423868|NCT00295997|noncontiguous stage II grade 1 follicular lymphoma
1423869|NCT00295997|noncontiguous stage II grade 2 follicular lymphoma
1423870|NCT00295997|noncontiguous stage II grade 3 follicular lymphoma
1423871|NCT00295997|recurrent adult acute lymphoblastic leukemia
1423872|NCT00295997|childhood myelodysplastic syndromes
1423873|NCT00295984|classic Kaposi sarcoma
1423874|NCT00295984|recurrent Kaposi sarcoma
1423875|NCT00295971|childhood acute lymphoblastic leukemia in remission
1423876|NCT00295971|childhood acute myeloid leukemia in remission
1423877|NCT00295971|de novo myelodysplastic syndromes
1423878|NCT00295971|previously treated myelodysplastic syndromes
1423879|NCT00295971|secondary myelodysplastic syndromes
1423880|NCT00295971|secondary acute myeloid leukemia
1423881|NCT00295971|juvenile myelomonocytic leukemia
1423882|NCT00295971|chronic phase chronic myelogenous leukemia
1423883|NCT00295971|refractory anemia with excess blasts in transformation
1423884|NCT00295971|refractory anemia with excess blasts
1423885|NCT00295971|severe congenital neutropenia
1423886|NCT00295971|congenital amegakaryocytic thrombocytopenia
1423887|NCT00295971|childhood chronic myelogenous leukemia
1423888|NCT00295971|childhood myelodysplastic syndromes
1423889|NCT00295958|recurrent melanoma
1423890|NCT00295958|stage IV melanoma
1423891|NCT00295958|skin cancer
1423892|NCT00295945|pain
1423893|NCT00295945|perioperative/postoperative complications
1423894|NCT00295945|stage III cervical cancer
1423895|NCT00295945|recurrent cervical cancer
1423896|NCT00295945|stage IB cervical cancer
1423897|NCT00295945|stage IIB cervical cancer
1423898|NCT00295945|stage IVB cervical cancer
1423899|NCT00295945|stage IA cervical cancer
1423900|NCT00295945|stage IIA cervical cancer
1423901|NCT00295945|stage IVA cervical cancer
1423902|NCT00295945|stage I endometrial carcinoma
1423903|NCT00295945|stage II endometrial carcinoma
1423904|NCT00295945|stage III endometrial carcinoma
1423905|NCT00295945|stage IV endometrial carcinoma
1423906|NCT00295945|recurrent endometrial carcinoma
1423907|NCT00295945|stage I uterine sarcoma
1423908|NCT00295945|stage II uterine sarcoma
1423909|NCT00295945|stage III uterine sarcoma
1423910|NCT00295945|stage IV uterine sarcoma
1423911|NCT00295945|recurrent uterine sarcoma
1423912|NCT00295945|ovarian sarcoma
1423913|NCT00295945|recurrent ovarian epithelial cancer
1423914|NCT00295945|recurrent ovarian germ cell tumor
1423915|NCT00295945|stage IV ovarian epithelial cancer
1423916|NCT00295945|stage IV ovarian germ cell tumor
1423917|NCT00295945|ovarian stromal cancer
1423918|NCT00295945|recurrent fallopian tube cancer
1423919|NCT00295945|stage IA fallopian tube cancer
1423920|NCT00295945|stage IB fallopian tube cancer
1423921|NCT00295945|stage IC fallopian tube cancer
1423922|NCT00295945|stage IIA fallopian tube cancer
1423923|NCT00295945|stage IIB fallopian tube cancer
1423924|NCT00295945|stage IIC fallopian tube cancer
1423925|NCT00295945|stage IIIA fallopian tube cancer
1423926|NCT00295945|stage IIIB fallopian tube cancer
1423927|NCT00295945|stage IIIC fallopian tube cancer
1423928|NCT00295945|stage IV fallopian tube cancer
1423929|NCT00295945|stage IA ovarian epithelial cancer
1423930|NCT00295945|stage IB ovarian epithelial cancer
1423931|NCT00295945|stage IC ovarian epithelial cancer
1423932|NCT00295945|stage IIA ovarian epithelial cancer
1423933|NCT00295945|stage IIB ovarian epithelial cancer
1423934|NCT00295945|stage IIC ovarian epithelial cancer
1423935|NCT00295945|stage IIIA ovarian epithelial cancer
1423936|NCT00295945|stage IIIB ovarian epithelial cancer
1423937|NCT00295945|stage IIIC ovarian epithelial cancer
1423938|NCT00295945|stage IA ovarian germ cell tumor
1423939|NCT00295945|stage IB ovarian germ cell tumor
1423940|NCT00295945|stage IC ovarian germ cell tumor
1423941|NCT00295945|stage IIA ovarian germ cell tumor
1423942|NCT00295945|stage IIB ovarian germ cell tumor
1423943|NCT00295945|stage IIC ovarian germ cell tumor
1423944|NCT00295945|stage IIIA ovarian germ cell tumor
1423945|NCT00295945|stage IIIB ovarian germ cell tumor
1423946|NCT00295945|stage IIIC ovarian germ cell tumor
1423947|NCT00295932|recurrent grade 1 follicular lymphoma
1423948|NCT00295932|recurrent grade 2 follicular lymphoma
1423949|NCT00295932|recurrent grade 3 follicular lymphoma
1423950|NCT00295932|recurrent small lymphocytic lymphoma
1423951|NCT00295932|recurrent marginal zone lymphoma
1423952|NCT00295932|Waldenstrom macroglobulinemia
1423953|NCT00295932|recurrent mantle cell lymphoma
1423954|NCT00295932|refractory chronic lymphocytic leukemia
1423955|NCT00295932|B-cell chronic lymphocytic leukemia
1423956|NCT00295932|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1423957|NCT00295932|nodal marginal zone B-cell lymphoma
1423958|NCT00295932|splenic marginal zone lymphoma
1423959|NCT00295919|recurrent neuroblastoma
1423960|NCT00295906|melanoma
1423961|NCT00295906|skin cancer
1423962|NCT00295893|inflammatory breast cancer
1423963|NCT00295893|stage II breast cancer
1423964|NCT00295893|stage IIIA breast cancer
1423965|NCT00295893|stage IIIB breast cancer
1423966|NCT00295893|stage IIIC breast cancer
1423967|NCT00295893|male breast cancer
1423968|NCT00295893|Paget disease of the breast with invasive ductal carcinoma
1423969|NCT00295893|invasive ductal breast carcinoma with predominant intraductal component
1423970|NCT00295893|invasive ductal breast carcinoma
1423971|NCT00295893|medullary ductal breast carcinoma with lymphocytic infiltrate
1423972|NCT00295893|comedo ductal breast carcinoma
1423973|NCT00295893|invasive lobular breast carcinoma with predominant in situ component
1423974|NCT00295893|invasive lobular breast carcinoma
1423975|NCT00295893|mucinous ductal breast carcinoma
1423976|NCT00295893|papillary ductal breast carcinoma
1423977|NCT00295893|tubular ductal breast carcinoma
1423978|NCT00295880|adult acute myeloid leukemia in remission
1423979|NCT00295880|adult acute myeloid leukemia
1423980|NCT00295880|childhood acute myeloid leukemia in remission
1423981|NCT00295880|secondary acute myeloid leukemia
1423982|NCT00295880|accelerated phase chronic myelogenous leukemia
1423983|NCT00295880|childhood chronic myelogenous leukemia
1423984|NCT00295880|chronic phase chronic myelogenous leukemia
1423985|NCT00295880|relapsing chronic myelogenous leukemia
1423986|NCT00295880|refractory anemia with excess blasts
1423987|NCT00295880|de novo myelodysplastic syndromes
1423988|NCT00295880|myelodysplastic syndromes
1423989|NCT00295880|adult diffuse large cell lymphoma
1423990|NCT00295880|adult diffuse mixed cell lymphoma
1423991|NCT00295880|adult diffuse small cleaved cell lymphoma
1423992|NCT00295880|adult lymphoblastic lymphoma
1423993|NCT00295880|grade 3 follicular lymphoma
1423994|NCT00295880|mantle cell lymphoma
1423995|NCT00295880|childhood large cell lymphoma
1423996|NCT00295880|childhood lymphoblastic lymphoma
1423997|NCT00295880|adult acute lymphoblastic leukemia
1423998|NCT00295880|acute lymphoblastic leukemia
1423999|NCT00295880|refractory anemia
1424000|NCT00295880|refractory cytopenia
1424001|NCT00295880|childhood acute myeloid leukemia
1424002|NCT00295880|adult immunoblastic large cell lymphoma
1424003|NCT00295880|blastic phase chronic myelogenous leukemia
1424004|NCT00295880|chronic eosinophilic leukemia
1424005|NCT00295880|chronic neutrophilic leukemia
1424006|NCT00295880|childhood small noncleaved cell lymphoma
1424007|NCT00295880|childhood myelodysplastic syndromes
1424008|NCT00295867|stage I breast cancer
1424009|NCT00295867|stage II breast cancer
1424010|NCT00295867|stage IIIA breast cancer
1424011|NCT00295867|stage IIIB breast cancer
1424012|NCT00295867|stage IIIC breast cancer
1424013|NCT00295854|Interstitial Cystitis
1424014|NCT00295854|urgency
1424015|NCT00295854|frequency
1424016|NCT00295854|MN-001
1424017|NCT00295854|Global Response Assessment
1424018|NCT00295854|bladder pain/urgency
1424019|NCT00295854|O'Leary Sant IC Symptom and Problem Index
1424020|NCT00295841|recurrent adult acute lymphoblastic leukemia
1424021|NCT00295841|recurrent adult acute myeloid leukemia
1424022|NCT00295841|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1424023|NCT00295841|adult acute myeloid leukemia with inv(16)(p13;q22)
1424024|NCT00295841|adult acute myeloid leukemia with t(16;16)(p13;q22)
1424025|NCT00295841|adult acute myeloid leukemia with t(8;21)(q22;q22)
1424026|NCT00295841|adult acute basophilic leukemia
1424027|NCT00295841|adult acute eosinophilic leukemia
1424028|NCT00295841|adult erythroleukemia (M6a)
1424029|NCT00295841|adult pure erythroid leukemia (M6b)
1424030|NCT00295841|adult acute megakaryoblastic leukemia (M7)
1424031|NCT00295841|adult acute minimally differentiated myeloid leukemia (M0)
1424032|NCT00295841|adult acute monoblastic leukemia (M5a)
1424033|NCT00295841|adult acute monocytic leukemia (M5b)
1424034|NCT00295841|adult acute myeloblastic leukemia with maturation (M2)
1424035|NCT00295841|adult acute myeloblastic leukemia without maturation (M1)
1424036|NCT00295841|adult acute myelomonocytic leukemia (M4)
1424037|NCT00295828|VEGF
1424038|NCT00295828|iris neovascularization
1424039|NCT00295828|diabetic retinopathy
1424040|NCT00295828|Macugen
1424041|NCT00295802|Prostate Cancer
1424042|NCT00295802|HIFU
1424043|NCT00295802|EDAP
1424044|NCT00295802|Low Risk, Localized Prostate Cancer
1424045|NCT00295789|cervical cancer
1424046|NCT00295789|palliative chemotherapy
1424047|NCT00295789|recurrent
1424048|NCT00295789|persistent
1424049|NCT00295789|stageⅣb
1424050|NCT00295789|cisplatin
1424051|NCT00295789|carboplatin
1424052|NCT00295789|paclitaxel
1424053|NCT00295776|Inclusion Criteria:Minimum of 4 on the Likert Pain Scale.If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks.
1424054|NCT00295776|Exclusion Criteria:
1424055|NCT00295776|Currently on any antiepilepic drugs (AED), except for Gabapentin.
1424056|NCT00295776|Currently taking opioid or unwilling to washout prior to the study,
1424057|NCT00295776|Pregnant and lactating,
1424058|NCT00295776|Have active severe systemic disease,
1424059|NCT00295776|History of Stevens-Johnson syndrome or TEN,
1424060|NCT00295763|papillary thyroid cancer
1424061|NCT00295763|follicular thyroid cancer
1424062|NCT00295763|recombinant human TSH
1424063|NCT00295763|Thyrogen
1424064|NCT00295763|thyroid stimulating hormone
1424065|NCT00295763|thyroid remnant ablation
1424066|NCT00295763|radioiodine
1424067|NCT00295750|Prostate Cancer
1424068|NCT00295737|allergic rhinitis
1424069|NCT00295724|bicifadine
1424070|NCT00295724|chronic low back pain
1424071|NCT00295711|bicifadine
1424072|NCT00295711|chronic low back pain
1424073|NCT00295698|HIV
1424074|NCT00295698|Lymphatic filariasis
1424075|NCT00295698|Diethylcarbamazine
1424076|NCT00295698|Interaction
1424077|NCT00295698|Tanzania
1424078|NCT00295685|Reflux
1424079|NCT00295685|GERD
1424080|NCT00295672|Non-Small-Cell Lung,radiotherapy, Chemotherapy, vinorelbine
1424081|NCT00295659|Gestational Diabetes
1424082|NCT00295659|Screening
1424083|NCT00295659|Cost-effectiveness
1424084|NCT00295659|obstetrical outcomes
1424085|NCT00295646|ABCSG
1424086|NCT00295646|12
1424087|NCT00295646|Phase 3
1424088|NCT00295646|breast cancer
1424089|NCT00295646|anastrozole
1424090|NCT00295646|tamoxifen
1424091|NCT00295646|zoledronic acid
1424092|NCT00295646|premenopausal
1424093|NCT00295646|hormone receptor-positive
1424094|NCT00295646|Stage I
1424095|NCT00295646|Stage II
1424096|NCT00295646|bone mineral density
1424097|NCT00295646|BMD
1424098|NCT00295646|bisphosphonate
1424099|NCT00295646|zoledronate
1424100|NCT00295620|Hormone receptor positive breast cancer
1424101|NCT00295607|Tacrolimus
1424102|NCT00295607|Liver Transplantation
1424103|NCT00295607|Immunosuppression
1424104|NCT00295607|Adult
1424105|NCT00295607|Treatment Outcome
1424106|NCT00295594|Tacrolimus
1424107|NCT00295594|Liver Transplantation
1424108|NCT00295594|Treatment Outcome
1424109|NCT00295594|Immunosuppression
1424110|NCT00295581|Human
1424111|NCT00295581|Clinical Trial
1424112|NCT00295581|Mosquito
1424113|NCT00295581|Healthy Volunteer
1424114|NCT00295581|HV
1424115|NCT00295568|Transcranial Magnetic Stimulation (TMS)
1424116|NCT00295568|Motor Learning
1424117|NCT00295568|Accuracy
1424118|NCT00295568|Tracking Motor Task
1424119|NCT00295568|Healthy Volunteer
1424120|NCT00295568|HV
1424121|NCT00295555|ambulatory blood pressure monitoring
1424122|NCT00295555|doxazosin
1424123|NCT00295555|alpha1-adrenergic antagonists
1424124|NCT00295555|sympathetic nervous activity
1424125|NCT00295555|diabetic nephropathy
1424126|NCT00295555|essential hypertension
1424127|NCT00295555|power spectral analysis
1424128|NCT00295555|morning surge
1424129|NCT00295542|ambulatory blood pressure monitoring
1424130|NCT00295542|cardiovascular risk
1424131|NCT00295542|chronotherapy
1424132|NCT00295542|circadian pattern
1424133|NCT00295529|Primary health care
1424134|NCT00295529|Breast neoplasm
1424135|NCT00295529|Education
1424136|NCT00295516|Rhesus
1424137|NCT00295516|Isoimmunization
1424138|NCT00295516|Red Cell Alloimmunization
1424139|NCT00295516|Fetal Hemolytic Anemia
1424140|NCT00295516|Erythroblastosis fetalis
1424141|NCT00295503|mesothelioma
1424142|NCT00295503|bevacizumab
1424143|NCT00295503|chemotherapy
1424144|NCT00295490|double blind randomised controlled trial
1424145|NCT00295490|phase II
1424146|NCT00295490|Devil's Claw
1424147|NCT00295490|osteoarthritis of the knee
1424148|NCT00295490|osteoarthritis of the hip
1424149|NCT00295477|HIV
1424150|NCT00295477|Treatment Experienced
1424151|NCT00295464|Antenatal glucocorticoid
1424152|NCT00295464|Premature birth
1424153|NCT00295438|robot-based tele-echography
1424154|NCT00295438|tele-medicine
1424155|NCT00295425|psoriasis
1424156|NCT00295425|randomized clinical trial
1424157|NCT00295425|cyclosporine A
1424158|NCT00295425|mycophenolate mofetil
1424159|NCT00295425|immunosuppression
1424160|NCT00295399|cerebrovascular accident
1424161|NCT00295399|traumatic brain injury
1424162|NCT00295399|stroke
1424163|NCT00295399|telerehabilitation
1424164|NCT00295373|Hypercholesterolemia
1424165|NCT00295373|Exercise
1424166|NCT00295373|Statin
1424167|NCT00295373|Rosuvastatin
1424168|NCT00295373|TLR4
1424169|NCT00295373|Inflammation
1424170|NCT00295360|cholestasis
1424171|NCT00295360|BCRP
1424172|NCT00295360|multidrug resistance
1424173|NCT00295360|duodenum
1424174|NCT00295360|bile acids
1424175|NCT00295360|ABCG2
1424176|NCT00295334|adherence
1424177|NCT00295334|glycemic control
1424178|NCT00295308|Opioid Dependence
1424179|NCT00295308|Clonidine
1424180|NCT00295308|Buprenorphine
1424181|NCT00295308|Opioid Abstinence
1424182|NCT00295308|Relapse
1424183|NCT00295295|vibration
1424184|NCT00295295|bone density
1424185|NCT00295282|Ulcerative Colitis
1424186|NCT00295282|UC
1424187|NCT00295282|Colitis
1424188|NCT00295256|randomized trial
1424189|NCT00295256|diabetes
1424190|NCT00295256|pregnancy
1424191|NCT00295230|respiratory distress syndrome
1424192|NCT00295230|very low birth weight infant
1424193|NCT00295230|mechanical ventilation
1424194|NCT00295217|Fibroids
1424195|NCT00295217|Uterine Leiomyomas
1424196|NCT00295217|ExAblate
1424197|NCT00295217|MrgFUS
1424198|NCT00295204|Syncope
1424199|NCT00295204|pre-syncope
1424200|NCT00295204|palpitations
1424201|NCT00295191|end-stage renal disease
1424202|NCT00295191|hemodialysis
1424203|NCT00295191|cardiovascular morbidity and mortality
1424204|NCT00295191|high flux dialyser
1424205|NCT00295191|ultrapure dialysate
1424206|NCT00295191|coronary vascular calcifications
1424207|NCT00295191|carotid intima-media thickness
1424208|NCT00295191|atherosclerosis
1424209|NCT00295152|elderly/aged
1424210|NCT00295152|occupational therapy
1424211|NCT00295152|daily activities
1424212|NCT00295152|caregivers
1424213|NCT00295152|sense of competence
1424214|NCT00295139|treatment
1424215|NCT00295139|dual diagnosis
1424216|NCT00295126|Edentulous
1424217|NCT00295126|Tooth Loss
1424218|NCT00295126|APC
1424219|NCT00295126|Autologous platelet concentrate
1424220|NCT00295113|Pulmonary arterial pressure
1424221|NCT00295113|COPD
1424222|NCT00295113|Cardiac output
1424223|NCT00295113|pulmonary and cardiac functions
1424224|NCT00295113|pulmonary arterial pressure measurements
1424225|NCT00295100|Tamoxifen
1424226|NCT00295100|Prevention
1424227|NCT00295100|Breast Cancer
1424228|NCT00295100|MRI
1424229|NCT00295087|Premature Ovarian Failure
1424230|NCT00295087|X-Chromosome Inactivation
1424231|NCT00295074|traumatic brain injury
1424232|NCT00295074|head injury
1424233|NCT00295074|concussion
1424234|NCT00295074|neuropsychologic test
1424235|NCT00295061|alpha 1-Antitrypsin Deficiency
1424236|NCT00295061|alpha 1-Antitrypsin
1424237|NCT00295061|pulmonary emphysema
1424238|NCT00295048|treatment
1424239|NCT00295048|cognition
1424240|NCT00295048|schizophrenia
1424241|NCT00295022|Levocetirizine
1424242|NCT00295022|Xyzal
1424243|NCT00295022|Rhinitis
1424244|NCT00295022|Allergic
1424245|NCT00295022|Seasonal
1424246|NCT00295022|Ragweed
1424247|NCT00294996|Metastatic Her2+ Breast cancer
1424248|NCT00294996|Myocet
1424249|NCT00294996|liposomal doxorubicin
1424250|NCT00294996|trastuzumab
1424251|NCT00292422|Arthritis, Rheumatoid
1424252|NCT00292422|Methotrexate
1424253|NCT00292422|Antirheumatic Agents
1424254|NCT00292383|Cardiac Pacing, artificial
1424255|NCT00292383|Atrial Fibrillation
1424256|NCT00292383|Heart failure
1424257|NCT00292383|Pacemaker leads
1424258|NCT00292383|Lead position
1424259|NCT00292383|Higher degree AV-Block
1424260|NCT00292370|Atypical Antipsychotics
1424261|NCT00292370|Controlled Trial
1424262|NCT00292370|Paroxetine
1424263|NCT00292370|Quetiapine
1424264|NCT00292370|Stress Disorders, Post-Traumatic
1424265|NCT00292370|Treatment refractory
1424266|NCT00292370|Treatment resistant
1424267|NCT00292344|Travelers' diarrhea
1424268|NCT00292344|rifaximin
1424269|NCT00292344|loperamide
1424270|NCT00292344|enterotoxigenic E. coli
1424271|NCT00292331|gastric varices
1424272|NCT00292331|liver cirrhosis
1424273|NCT00292331|hepatocelluar carcinoma
1424274|NCT00292331|rebleeding
1424275|NCT00292331|long-term
1424276|NCT00294931|Lung Cancer, Small Cell
1424277|NCT00294931|Extensive
1424278|NCT00294918|Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
1424279|NCT00294918|Human Immunodeficiency Virus Infections
1424280|NCT00294918|Serostim®
1424281|NCT00294918|recombinant human growth hormone (r-hGH)
1424282|NCT00294905|COPD
1424283|NCT00294905|smoking cessation
1424284|NCT00294905|implementation
1424285|NCT00294905|patient counseling
1424286|NCT00294905|general practice
1424287|NCT00294892|HIV
1424288|NCT00294892|mother to child transmission; MTCT
1424289|NCT00294892|nevirapine resistance
1424290|NCT00294892|pharmacokinetics
1424291|NCT00294892|Treatment Naive
1424292|NCT00294866|End Stage Renal Disease
1424293|NCT00294866|Inflammation
1424294|NCT00294853|Coronary calcium score
1424295|NCT00294853|Coronary artery disease
1424296|NCT00294853|Cardiac transplantation
1424297|NCT00294853|Coronary calcium score in heart transplanted patients
1424298|NCT00294853|Coronary artery disease in heart transplanted patients
1424299|NCT00294827|Liver transplantation
1424300|NCT00294814|Cardiac Surgery
1424301|NCT00294814|CABG
1424302|NCT00294814|Microemboli
1424303|NCT00294814|Transcranial Doppler
1424304|NCT00294814|Cognitive Decline
1424305|NCT00294814|Anastomotic Device
1424306|NCT00294814|Proximal Anastomosis
1424307|NCT00294814|Coronary Artery Bypass Graft (CABG)
1424308|NCT00294801|knee osteoarthritis
1424309|NCT00294788|Influenza
1424310|NCT00294788|bioadjuvant
1424311|NCT00294788|probiotic
1424312|NCT00294788|HAI
1424313|NCT00294788|immunity
1424314|NCT00294788|vaccine
1424315|NCT00294788|Immune response to influenza vaccine
1424316|NCT00294775|diastolic dysfunction
1424317|NCT00294775|Reverse Remodelling
1424318|NCT00294762|NSCLC
1424319|NCT00294762|Erlotinib
1424320|NCT00294762|Tarceva
1424321|NCT00294762|Lung Cancer
1424322|NCT00294749|Prostate,
1424323|NCT00294749|Infection,
1424324|NCT00294749|Biopsy,
1424325|NCT00294749|Antibiotic,
1424326|NCT00294749|Prophylaxis
1424327|NCT00294736|lung cancer
1424328|NCT00294736|erlotinib
1424329|NCT00294736|NSCLC
1424330|NCT00294736|smokers
1424331|NCT00294710|Hypertension, aliskiren, hydrochlorothiazide, amlodipine
1424332|NCT00294697|polymorphisms
1424333|NCT00294697|innate immune response
1424334|NCT00294697|immunomonitoring
1424335|NCT00294697|immuno paralysis
1424336|NCT00294684|biliary atresia
1424337|NCT00294684|hepatoportoenterostomy
1424338|NCT00294684|corticosteroids
1424339|NCT00294671|familial amyloid polyneuropathy
1424340|NCT00294671|familial amyloidosis
1424341|NCT00294671|diflunisal
1424342|NCT00294671|amyloidosis
1424343|NCT00294671|transthyretin
1424344|NCT00294671|peripheral neuropathy
1424345|NCT00294671|autonomic neuropathy
1424346|NCT00294671|amyloid cardiomyopathy
1424347|NCT00294658|myasthenia gravis
1424348|NCT00294658|thymectomy
1424349|NCT00294658|prednisone
1424350|NCT00294658|corticosteroid
1424351|NCT00294658|extended transsternal thymectomy
1424352|NCT00294658|ETTX
1424353|NCT00294658|MG
1424354|NCT00294658|thymus
1424355|NCT00294658|thymoma
1424356|NCT00294645|Remote Follow Up
1424357|NCT00294645|Diagnostic
1424358|NCT00294645|Bradycardia
1424359|NCT00294632|Mantle Cell Lymphoma
1424360|NCT00294632|B-Cell Non-Hodgkin's Lymphoma
1424361|NCT00294632|Transformed Large Cell Lymphoma
1424362|NCT00294632|Follicular Lymphoma
1424363|NCT00294632|Lymphoma
1424364|NCT00294632|MCL
1424365|NCT00294632|Lenalidomide
1424366|NCT00294632|CC-5013
1424367|NCT00294632|Revlimid™
1424368|NCT00294632|Rituximab
1424369|NCT00294632|Rituxan
1424370|NCT00294619|Growth hormone deficiency
1424371|NCT00294606|vasopressor agents
1424372|NCT00294606|carotid endarterectomy
1424373|NCT00294606|cardiac function
1424374|NCT00294606|transesophageal echocardiography
1424375|NCT00294606|wall motion abnormalities
1424376|NCT00294593|Down syndrome
1424377|NCT00294593|folinic acid therapy
1424378|NCT00294593|cognitive functions
1424379|NCT00294580|Malaria
1424380|NCT00294580|Cognition
1424381|NCT00294580|Prevention & control
1424382|NCT00294580|Anemia
1424383|NCT00294580|Chemoprophylaxis
1424384|NCT00294580|Mortality
1424385|NCT00294580|Children
1424386|NCT00294580|Randomized controlled trial
1424387|NCT00294580|Education
1424388|NCT00294580|Long-term effects
1424389|NCT00294580|The Gambia
1424390|NCT00294580|Africa, West
1424391|NCT00294567|Hypertension
1424392|NCT00294567|PCI
1424393|NCT00294567|Calcium Channel Blockers
1424394|NCT00294567|IVUS
1424395|NCT00294567|Plaque
1424396|NCT00294554|Parkinson's Disease
1424397|NCT00294554|Cognitive Impairment
1424398|NCT00294554|Dementia
1424399|NCT00294554|Memory
1424400|NCT00294541|sickle cell disease
1424401|NCT00294541|sickle cell anemia
1424402|NCT00294528|osteoarthritis, knee
1424403|NCT00294528|total knee arthroplasty
1424404|NCT00294528|range of motion
1424405|NCT00294528|satisfaction
1424406|NCT00294489|HCV
1424407|NCT00294489|Fibrosis
1424408|NCT00294489|Breath test
1424409|NCT00294476|IVIg
1424410|NCT00294476|Cancer
1424411|NCT00294476|Melanoma
1424412|NCT00294463|postmenopause
1424413|NCT00294463|endometrium
1424414|NCT00294463|Gene Expression Profiling
1424415|NCT00294463|Histology, Comparative
1424416|NCT00294463|Hormone Replacement Therapy
1424417|NCT00294463|Hormones
1424418|NCT00294437|Prostate Cancer
1424419|NCT00294437|Zometa
1424420|NCT00294424|Waiting time
1424421|NCT00294424|Total hip replacement
1424422|NCT00294424|Total knee replacement
1424423|NCT00294424|Quality of life
1424424|NCT00294424|The15D
1424425|NCT00294424|Harris Hip Score
1424426|NCT00294424|Knee Score
1424427|NCT00294424|Pain measurement
1424428|NCT00294424|Cost-effectiveness
1424429|NCT00294424|Medication
1424430|NCT00294424|Health services
1424431|NCT00294424|Social services
1424432|NCT00294424|Randomized Controlled Trial
1424433|NCT00294398|Asthma, Controller Medications
1424434|NCT00294385|Breast Cancer
1424435|NCT00294385|Docetaxel
1424436|NCT00294359|colorectal neoplasm
1424437|NCT00294346|Social Anxiety Disorder
1424438|NCT00294346|Social Phobia
1424439|NCT00294320|Aldara
1424440|NCT00294320|Actinic Keratosis
1424441|NCT00294307|Nursing Models of Care
1424442|NCT00294307|Collaborative Care
1424443|NCT00294307|Care Management
1424444|NCT00294307|Transitional Care
1424445|NCT00294307|Advanced Practice Nurse Care Interventions
1424446|NCT00294307|Cognitive Impairment
1424447|NCT00294307|Dementia
1424448|NCT00294307|Delirium
1424449|NCT00294294|vaccine
1424450|NCT00294294|infant
1424451|NCT00294281|Pain
1424452|NCT00294281|Tenderness
1424453|NCT00294281|Depression
1424454|NCT00294281|Work Disability
1424455|NCT00294281|Physical Function
1424456|NCT00294281|Quality of Life
1424457|NCT00294281|Chronic Pain
1424458|NCT00294268|obesity
1424459|NCT00294268|CBT
1424460|NCT00294268|motivational enhancement therapy
1424461|NCT00294268|weight loss maintenance
1424462|NCT00294255|mixed mania
1424463|NCT00294255|depression
1424464|NCT00294255|irritability
1424465|NCT00294242|pregnancy
1424466|NCT00294242|membranes sweeping
1424467|NCT00294242|prelabor rupture of membranes
1424468|NCT00294229|Low back pain
1424469|NCT00294229|Spinal manipulative therapy
1424470|NCT00294229|Randomised controlled trial
1424471|NCT00294216|Omacor
1424472|NCT00294216|Omega-3 PUFA
1424473|NCT00294216|Endarterectomy
1424474|NCT00294216|Carotid Plaque stability
1424475|NCT00294216|Structural changes
1424476|NCT00294216|inflammation
1424477|NCT00294203|Digestive System Surgical Procedures
1424478|NCT00294203|Post-Operative Care
1424479|NCT00294203|Fatigue
1424480|NCT00294203|Quality of Life
1424481|NCT00294203|Erythrocyte Transfusion
1424482|NCT00294203|Esophagectomy
1424483|NCT00294203|Gastric Cancer
1424484|NCT00294203|Hepatectomy
1424485|NCT00294203|Pancreatic Cancer
1424486|NCT00294203|Rectum
1424487|NCT00294190|Lung Cancer
1424488|NCT00294190|Extensive stage
1424489|NCT00294190|Small Cell Lung Cancer
1424490|NCT00294177|Trophoblastic Neoplasms
1424491|NCT00294177|Chorionic Gonadotropin
1424492|NCT00294177|Molecular Conformation
1424493|NCT00294164|Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
1424494|NCT00294164|Human Immunodeficiency Virus Infections
1424495|NCT00294164|recombinant human growth hormone (r-hGH)
1424496|NCT00294164|Serostim®
1424497|NCT00294164|Placebo
1424498|NCT00294151|breast cancer
1424499|NCT00294151|prostate cancer
1424500|NCT00294151|vertebral metastasis
1424501|NCT00294151|vertebroplasty
1424502|NCT00294151|vertebral metastasis from breast cancer
1424503|NCT00294151|vertebral metastasis from prostate cancer
1424504|NCT00294125|Medical Food
1424505|NCT00294125|Botanicals
1424506|NCT00294125|Phytochemicals
1424507|NCT00294112|mesenchymal stem cells
1424508|NCT00294099|A/H5N1, Influenza, Vaccine
1424509|NCT00294086|valsartan,
1424510|NCT00294086|chronic heart failure,
1424511|NCT00294073|femoral block
1424512|NCT00294073|fascia iliaca block
1424513|NCT00294073|ACL repair
1424514|NCT00294073|post-operative analgesia
1424515|NCT00294073|knee surgery
1424516|NCT00294073|ACL damage
1424517|NCT00294073|knee damage
1424518|NCT00294060|Pacemaker
1424519|NCT00294060|Bradycardia
1424520|NCT00294047|Vaccine
1424521|NCT00294047|Human papillomavirus
1424522|NCT00294047|Cervical Cancer
1424523|NCT00294047|Cervical Infection
1424524|NCT00294034|Registry
1424525|NCT00294034|Pacemaker
1424526|NCT00294034|Diagnostics
1424527|NCT00294008|Schizophrenia
1424528|NCT00294008|Treatment adherence
1424529|NCT00294008|Antipsychotic agents
1424530|NCT00294008|Risperidone
1424531|NCT00294008|Long-acting injectable
1424532|NCT00294008|Risperdal tablet
1424533|NCT00294008|Risperidal Consta
1424534|NCT00292318|adequate relief
1424535|NCT00292318|anorectal manometry
1424536|NCT00292318|biofeedback therapy
1424537|NCT00292318|fecal incontinence
1424538|NCT00292305|PCI
1424539|NCT00292305|Bifurcation lesion
1424540|NCT00292279|Impact of Omega 3 fatty acid on outcome
1424541|NCT00292279|Omega-3 fatty acid
1424542|NCT00292279|Carcinoma surgery
1424543|NCT00292279|Digestive System
1424544|NCT00292279|Parenteral Nutrition
1424545|NCT00292279|Fat Emulsions, Intravenous
1424546|NCT00292279|Clinical outcome
1424547|NCT00292279|SIRS
1424548|NCT00292279|Infectious complication
1424549|NCT00292279|Postoperative hospital stay
1424550|NCT00292279|Cost of postoperative period
1424551|NCT00292279|Post-operative nutritional cost & total treatment cost
1424552|NCT00293982|Patient satisfaction
1424553|NCT00293982|Patient expectations
1424554|NCT00293982|Pediatric emergency department
1424555|NCT00293969|Pain
1424556|NCT00293969|Morphine
1424557|NCT00293956|hypothyroxinemia
1424558|NCT00293956|full term infants
1424559|NCT00293956|near term infants
1424560|NCT00293956|respiratory distress
1424561|NCT00293956|thyroid disease
1424562|NCT00293943|Atrial fibrillation
1424563|NCT00293943|Pulmonary vein ablation
1424564|NCT00293943|Linear lesions
1424565|NCT00293930|Treatment Outcome
1424566|NCT00293930|Tacrolimus
1424567|NCT00293930|Safety
1424568|NCT00293930|Psoriasis
1424569|NCT00293917|Treatment Outcome
1424570|NCT00293917|Tacrolimus
1424571|NCT00293917|Safety
1424572|NCT00293917|Psoriasis
1424573|NCT00293904|Allergy
1424574|NCT00293904|Grass Pollen
1424575|NCT00293904|Systemic Immunotherapy
1424576|NCT00293891|Treatment Outcome
1424577|NCT00293891|Tacrolimus
1424578|NCT00293891|Safety
1424579|NCT00293891|Psoriasis
1424580|NCT00293865|Breast infiltrative cancer
1424581|NCT00293852|Heart failure, Congestive
1424582|NCT00293852|Metabolic Syndrome X
1424583|NCT00293852|Ambulatory Care
1424584|NCT00293852|Health behavior
1424585|NCT00293839|bladder
1424586|NCT00293839|overactive
1424587|NCT00293826|ACR criteria
1424588|NCT00293826|methotrexate
1424589|NCT00293826|DMARDs
1424590|NCT00293826|patient reported outcomes
1424591|NCT00293826|joint assessment
1424592|NCT00293813|Post Menopausal
1424593|NCT00293813|Osteoporosis
1424594|NCT00293813|MicroCT
1424595|NCT00293813|Amgen
1424596|NCT00293813|denosumab
1424597|NCT00293813|Extreme CT
1424598|NCT00293813|XCT
1424599|NCT00293813|Fosamax
1424600|NCT00293813|Alendronate
1424601|NCT00293800|Open-angle
1424602|NCT00293800|glaucoma
1424603|NCT00293800|ocular
1424604|NCT00293800|hypertension
1424605|NCT00293787|Open-angle
1424606|NCT00293787|glaucoma
1424607|NCT00293787|ocular
1424608|NCT00293787|hypertension
1424609|NCT00293774|Prospective
1424610|NCT00293774|Conventional therapy
1424611|NCT00293774|Registry
1424612|NCT00293774|Metal-on-metal
1424613|NCT00293774|Ceramic-on-ceramic
1424614|NCT00293774|Hip Arthroplasty
1424615|NCT00293761|open-angle
1424616|NCT00293761|glaucoma
1424617|NCT00293761|ocular
1424618|NCT00293761|hypertension
1424619|NCT00293748|Genomics
1424620|NCT00293748|Statins
1424621|NCT00293748|Coronary Heart Disease
1424622|NCT00293748|Stroke
1424623|NCT00293748|Inflammation
1424624|NCT00293748|Gene Expression
1424625|NCT00293748|Vascular Risk
1424626|NCT00293748|Peripheral Blood Mononuclear Cells
1424627|NCT00293748|Atorvastatin
1424628|NCT00293748|Vascular Disease
1424629|NCT00293748|Vascular Disease Risk
1424630|NCT00293735|Preeclampsia
1424631|NCT00293735|Pregnancy
1424632|NCT00293735|Hypertension
1424633|NCT00293735|Eclampsia
1424634|NCT00293735|HELLP Syndrome
1424635|NCT00293735|Seizures
1424636|NCT00293735|Prevention
1424637|NCT00293722|Arthritis
1424638|NCT00293709|Arthritis
1424639|NCT00293696|biomarker study
1424640|NCT00293696|Patients with clinically localised prostate cancer
1424641|NCT00293683|cesarean
1424642|NCT00293683|closure
1424643|NCT00293683|skin
1424644|NCT00293683|staple
1424645|NCT00293683|absorbable
1424646|NCT00293683|metal
1424647|NCT00293644|Pregnancy Complications
1424648|NCT00293644|Hyperemesis Gravidarum
1424649|NCT00293644|Diclectin
1424650|NCT00293644|doxylamine succinate
1424651|NCT00293644|pyridoxine hydrochloride
1424652|NCT00293618|Implementation of prediction rules
1424653|NCT00293618|Decision Support Systems, Clinical
1424654|NCT00293618|PONV
1424655|NCT00293618|Emesis
1424656|NCT00293618|Nausea
1424657|NCT00293618|Vomiting
1424658|NCT00293618|Postoperative
1424659|NCT00293618|Implementation
1424660|NCT00293618|prediction rule
1424661|NCT00293618|impact study
1424662|NCT00293618|decision support
1424663|NCT00293618|clinical decision support
1424664|NCT00293605|aseptic loosening
1424665|NCT00293605|femoral stem design
1424666|NCT00293592|Heart surgery
1424667|NCT00293592|Cardiopulmonary bypass
1424668|NCT00293592|Systemic Inflammatory Response Syndrome (SIRS)
1424669|NCT00293579|head and neck cancer
1424670|NCT00293540|metastatic
1424671|NCT00293540|secondary
1424672|NCT00293540|Hormone Receptor-Positive Breast Cancer
1424673|NCT00293527|Metastatic
1424674|NCT00293514|standard surgical treatment for air leakage in pulmonary lobectomy
1424675|NCT00293501|clear cell renal cell carcinoma
1424676|NCT00293501|stage IV renal cell cancer
1424677|NCT00293501|recurrent renal cell cancer
1424678|NCT00293488|anaplastic large cell lymphoma
1424679|NCT00293488|angioimmunoblastic T-cell lymphoma
1424680|NCT00293488|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1424681|NCT00293488|nodal marginal zone B-cell lymphoma
1424682|NCT00293488|recurrent adult Burkitt lymphoma
1424683|NCT00293488|recurrent adult diffuse large cell lymphoma
1424684|NCT00293488|recurrent adult Hodgkin lymphoma
1424685|NCT00293488|recurrent adult T-cell leukemia/lymphoma
1424686|NCT00293488|recurrent cutaneous T-cell non-Hodgkin lymphoma
1424687|NCT00293488|recurrent grade 1 follicular lymphoma
1424688|NCT00293488|recurrent grade 2 follicular lymphoma
1424689|NCT00293488|recurrent grade 3 follicular lymphoma
1424690|NCT00293488|recurrent mantle cell lymphoma
1424691|NCT00293488|recurrent marginal zone lymphoma
1424692|NCT00293488|recurrent mycosis fungoides/Sezary syndrome
1424693|NCT00293488|splenic marginal zone lymphoma
1424694|NCT00293462|mucositis
1424695|NCT00293462|radiation toxicity
1424696|NCT00293462|recurrent squamous and basal cell carcinoma of the hypopharynx,larynx,lip,nasopharynx
1424697|NCT00293462|oropharynx, paranasal sinus and nasal cavity
1424698|NCT00293462|stage I-IV lymphoepithelioma of the nasopharynx
1424699|NCT00293462|stage I-IV lymphoepithelioma of the oropharynx
1424700|NCT00293462|Recurrent and stage I-IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1424701|NCT00293462|Recurrent and stage I-IV inverted papilloma of the paranasal sinus and nasal cavity
1424702|NCT00293462|Recurrent and stage I-IV midline lethal granuloma of the paranasal sinus and nasal cavity
1424703|NCT00293462|untreated, current,metastatic squamous neck cancer with occult primary
1424704|NCT00293462|recurrent verrucous carcinoma of the larynx
1424705|NCT00293462|recurrent lymphoepithelioma of the oropharynx
1424706|NCT00293462|stage I verrucous carcinoma of the larynx
1424707|NCT00293462|recurrent verrucous carcinoma of the oral cavity
1424708|NCT00293462|stage I verrucous carcinoma of the oral cavity
1424709|NCT00293462|stage II verrucous carcinoma of the larynx
1424710|NCT00293462|stage II verrucous carcinoma of the oral cavity
1424711|NCT00293462|stage III verrucous carcinoma of the larynx
1424712|NCT00293462|stage III verrucous carcinoma of the oral cavity
1424713|NCT00293462|stage IV verrucous carcinoma of the larynx
1424714|NCT00293462|stage IV verrucous carcinoma of the oral cavity
1424715|NCT00293462|recurrent adenoid cystic carcinoma of the oral cavity
1424716|NCT00293462|stage I adenoid cystic carcinoma of the oral cavity
1424717|NCT00293462|stage II adenoid cystic carcinoma of the oral cavity
1424718|NCT00293462|stage III adenoid cystic carcinoma of the oral cavity
1424719|NCT00293462|stage IV adenoid cystic carcinoma of the oral cavity
1424720|NCT00293462|recurrent mucoepidermoid carcinoma of the oral cavity
1424721|NCT00293462|stage I mucoepidermoid carcinoma of the oral cavity
1424722|NCT00293462|stage II mucoepidermoid carcinoma of the oral cavity
1424723|NCT00293462|stage III mucoepidermoid carcinoma of the oral cavity
1424724|NCT00293462|stage IV mucoepidermoid carcinoma of the oral cavity
1424725|NCT00293462|recurrent squamous cell carcinoma of the lip and oral cavity
1424726|NCT00293462|stage I squamous cell carcinoma of the lip and oral cavity
1424727|NCT00293462|stage II squamous cell carcinoma of the lip and oral cavity
1424728|NCT00293462|stage III squamous cell carcinoma of the lip and oral cavity
1424729|NCT00293462|stage IV squamous cell carcinoma of the lip and oral cavity
1424730|NCT00293462|tongue cancer
1424731|NCT00293436|adult primary hepatocellular carcinoma
1424732|NCT00293436|advanced adult primary liver cancer
1424733|NCT00293436|localized resectable adult primary liver cancer
1424734|NCT00293423|adult glioblastoma
1424735|NCT00293423|recurrent adult brain tumor
1424736|NCT00293410|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1424737|NCT00293410|adult acute myeloid leukemia with inv(16)(p13;q22)
1424738|NCT00293410|adult acute myeloid leukemia with t(15;17)(q22;q12)
1424739|NCT00293410|adult acute myeloid leukemia with t(16;16)(p13;q22)
1424740|NCT00293410|adult acute myeloid leukemia with t(8;21)(q22;q22)
1424741|NCT00293410|recurrent adult acute myeloid leukemia
1424742|NCT00293410|recurrent childhood acute myeloid leukemia
1424743|NCT00293410|secondary acute myeloid leukemia
1424744|NCT00293410|myelodysplastic/myeloproliferative disease, unclassifiable
1424745|NCT00293410|accelerated phase chronic myelogenous leukemia
1424746|NCT00293410|chronic idiopathic myelofibrosis
1424747|NCT00293410|chronic myelomonocytic leukemia
1424748|NCT00293410|juvenile myelomonocytic leukemia
1424749|NCT00293410|recurrent adult acute lymphoblastic leukemia
1424750|NCT00293410|recurrent childhood acute lymphoblastic leukemia
1424751|NCT00293410|acute undifferentiated leukemia
1424752|NCT00293410|blastic phase chronic myelogenous leukemia
1424753|NCT00293410|childhood chronic myelogenous leukemia
1424754|NCT00293410|adult acute basophilic leukemia
1424755|NCT00293410|adult acute eosinophilic leukemia
1424756|NCT00293410|adult acute megakaryoblastic leukemia (M7)
1424757|NCT00293410|adult acute minimally differentiated myeloid leukemia (M0)
1424758|NCT00293410|adult acute monoblastic leukemia (M5a)
1424759|NCT00293410|adult acute monocytic leukemia (M5b)
1424760|NCT00293410|adult acute myeloblastic leukemia with maturation (M2)
1424761|NCT00293410|adult acute myeloblastic leukemia without maturation (M1)
1424762|NCT00293410|adult acute myelomonocytic leukemia (M4)
1424763|NCT00293410|adult acute promyelocytic leukemia (M3)
1424764|NCT00293410|adult erythroleukemia (M6a)
1424765|NCT00293410|adult pure erythroid leukemia (M6b)
1424766|NCT00293410|childhood acute basophilic leukemia
1424767|NCT00293410|childhood acute monocytic leukemia (M5b)
1424768|NCT00293410|childhood acute eosinophilic leukemia
1424769|NCT00293410|childhood acute erythroleukemia (M6)
1424770|NCT00293410|childhood acute megakaryocytic leukemia (M7)
1424771|NCT00293410|childhood acute minimally differentiated myeloid leukemia (M0)
1424772|NCT00293410|childhood acute myeloblastic leukemia with maturation (M2)
1424773|NCT00293410|childhood acute myeloblastic leukemia without maturation (M1)
1424774|NCT00293410|childhood acute myelomonocytic leukemia (M4)
1424775|NCT00293410|childhood acute monoblastic leukemia (M5a)
1424981|NCT00293098|Iron overload
1424776|NCT00293410|childhood acute promyelocytic leukemia (M3)
1424777|NCT00293397|adult primary hepatocellular carcinoma
1424778|NCT00293397|localized unresectable adult primary liver cancer
1424779|NCT00293384|nausea and vomiting
1424780|NCT00293384|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1424781|NCT00293384|adult acute myeloid leukemia with inv(16)(p13;q22)
1424782|NCT00293384|adult acute myeloid leukemia with t(15;17)(q22;q12)
1424783|NCT00293384|adult acute myeloid leukemia with t(16;16)(p13;q22)
1424784|NCT00293384|adult acute myeloid leukemia with t(8;21)(q22;q22)
1424785|NCT00293384|accelerated phase chronic myelogenous leukemia
1424786|NCT00293384|adult acute lymphoblastic leukemia in remission
1424787|NCT00293384|adult acute myeloid leukemia in remission
1424788|NCT00293384|atypical chronic myeloid leukemia, BCR-ABL negative
1424789|NCT00293384|blastic phase chronic myelogenous leukemia
1424790|NCT00293384|chronic eosinophilic leukemia
1424791|NCT00293384|primary myelofibrosis
1424792|NCT00293384|chronic myelomonocytic leukemia
1424793|NCT00293384|chronic neutrophilic leukemia
1424794|NCT00293384|chronic phase chronic myelogenous leukemia
1424795|NCT00293384|de novo myelodysplastic syndromes
1424796|NCT00293384|disseminated neuroblastoma
1424797|NCT00293384|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1424798|NCT00293384|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1424799|NCT00293384|nodal marginal zone B-cell lymphoma
1424800|NCT00293384|noncontiguous stage II adult Burkitt lymphoma
1424801|NCT00293384|noncontiguous stage II adult diffuse large cell lymphoma
1424802|NCT00293384|noncontiguous stage II adult diffuse mixed cell lymphoma
1424803|NCT00293384|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1424804|NCT00293384|noncontiguous stage II adult immunoblastic large cell lymphoma
1424805|NCT00293384|noncontiguous stage II adult lymphoblastic lymphoma
1424806|NCT00293384|noncontiguous stage II grade 1 follicular lymphoma
1424807|NCT00293384|noncontiguous stage II grade 2 follicular lymphoma
1424808|NCT00293384|noncontiguous stage II grade 3 follicular lymphoma
1424809|NCT00293384|noncontiguous stage II mantle cell lymphoma
1424810|NCT00293384|noncontiguous stage II marginal zone lymphoma
1424811|NCT00293384|noncontiguous stage II small lymphocytic lymphoma
1424812|NCT00293384|poor prognosis metastatic gestational trophoblastic tumor
1424813|NCT00293384|previously treated myelodysplastic syndromes
1424814|NCT00293384|recurrent adult acute lymphoblastic leukemia
1424815|NCT00293384|recurrent adult acute myeloid leukemia
1424816|NCT00293384|recurrent adult Burkitt lymphoma
1424817|NCT00293384|recurrent adult Hodgkin lymphoma
1424818|NCT00293384|recurrent adult diffuse large cell lymphoma
1424819|NCT00293384|recurrent adult diffuse mixed cell lymphoma
1424820|NCT00293384|recurrent adult diffuse small cleaved cell lymphoma
1424821|NCT00293384|recurrent adult immunoblastic large cell lymphoma
1424822|NCT00293384|recurrent adult lymphoblastic lymphoma
1424823|NCT00293384|recurrent cutaneous T-cell non-Hodgkin lymphoma
1424824|NCT00293384|recurrent grade 1 follicular lymphoma
1424825|NCT00293384|recurrent grade 2 follicular lymphoma
1424928|NCT00292214|intravenous
1424826|NCT00293384|recurrent grade 3 follicular lymphoma
1424827|NCT00293384|recurrent mantle cell lymphoma
1424828|NCT00293384|recurrent marginal zone lymphoma
1424829|NCT00293384|recurrent mycosis fungoides/Sezary syndrome
1424830|NCT00293384|recurrent neuroblastoma
1424831|NCT00293384|recurrent ovarian epithelial cancer
1424832|NCT00293384|recurrent ovarian germ cell tumor
1424833|NCT00293384|recurrent small lymphocytic lymphoma
1424834|NCT00293384|recurrent malignant testicular germ cell tumor
1424835|NCT00293384|refractory chronic lymphocytic leukemia
1424836|NCT00293384|refractory hairy cell leukemia
1424837|NCT00293384|refractory multiple myeloma
1424838|NCT00293384|relapsing chronic myelogenous leukemia
1424839|NCT00293384|secondary acute myeloid leukemia
1424840|NCT00293384|secondary myelodysplastic syndromes
1424841|NCT00293384|splenic marginal zone lymphoma
1424842|NCT00293384|stage I multiple myeloma
1424843|NCT00293384|stage II multiple myeloma
1424844|NCT00293384|stage II ovarian epithelial cancer
1424845|NCT00293384|stage III adult Burkitt lymphoma
1424846|NCT00293384|stage III adult Hodgkin lymphoma
1424847|NCT00293384|stage III adult diffuse large cell lymphoma
1424848|NCT00293384|stage III adult diffuse mixed cell lymphoma
1424849|NCT00293384|stage III adult diffuse small cleaved cell lymphoma
1424850|NCT00293384|stage III adult immunoblastic large cell lymphoma
1424851|NCT00293384|stage III adult lymphoblastic lymphoma
1424852|NCT00293384|stage III chronic lymphocytic leukemia
1424853|NCT00293384|stage III grade 1 follicular lymphoma
1424854|NCT00293384|stage III grade 2 follicular lymphoma
1424855|NCT00293384|stage III grade 3 follicular lymphoma
1424856|NCT00293384|stage III mantle cell lymphoma
1424857|NCT00293384|stage III marginal zone lymphoma
1424858|NCT00293384|stage III multiple myeloma
1424859|NCT00293384|stage III ovarian epithelial cancer
1424860|NCT00293384|stage III small lymphocytic lymphoma
1424861|NCT00293384|stage III malignant testicular germ cell tumor
1424862|NCT00293384|stage IIIA breast cancer
1424863|NCT00293384|stage IIIB breast cancer
1424864|NCT00293384|stage IIIC breast cancer
1424865|NCT00293384|stage IV adult Burkitt lymphoma
1424866|NCT00293384|stage IV adult Hodgkin lymphoma
1424867|NCT00293384|stage IV adult diffuse large cell lymphoma
1424868|NCT00293384|stage IV adult diffuse mixed cell lymphoma
1424869|NCT00293384|stage IV adult diffuse small cleaved cell lymphoma
1424870|NCT00293384|stage IV adult immunoblastic large cell lymphoma
1424871|NCT00293384|stage IV adult lymphoblastic lymphoma
1424872|NCT00293384|stage IV breast cancer
1424873|NCT00293384|stage IV chronic lymphocytic leukemia
1424874|NCT00293384|stage IV grade 1 follicular lymphoma
1424875|NCT00293384|stage IV grade 2 follicular lymphoma
1424876|NCT00293384|stage IV grade 3 follicular lymphoma
1424877|NCT00293384|stage IV mantle cell lymphoma
1424878|NCT00293384|stage IV marginal zone lymphoma
1424879|NCT00293384|stage IV ovarian epithelial cancer
1424880|NCT00293384|stage IV small lymphocytic lymphoma
1424881|NCT00293371|adenocarcinoma of the prostate
1424882|NCT00293371|recurrent prostate cancer
1424883|NCT00293371|stage IV prostate cancer
1424884|NCT00293358|childhood central nervous system germ cell tumor
1424885|NCT00293358|adult central nervous system germ cell tumor
1424886|NCT00293358|childhood central nervous system choriocarcinoma
1424887|NCT00293358|childhood central nervous system embryonal tumor
1424888|NCT00293358|childhood central nervous system yolk sac tumor
1424889|NCT00293332|stage I non-small cell lung cancer
1424890|NCT00293332|stage II non-small cell lung cancer
1424891|NCT00293332|stage IIIA non-small cell lung cancer
1424892|NCT00293319|recurrent neuroblastoma
1424893|NCT00293293|stage I ovarian epithelial cancer
1424894|NCT00293293|stage II ovarian epithelial cancer
1424895|NCT00293293|stage III ovarian epithelial cancer
1424896|NCT00293293|stage IV ovarian epithelial cancer
1424897|NCT00293293|peritoneal cavity cancer
1424898|NCT00293280|stage IIIB non-small cell lung cancer
1424899|NCT00293280|stage IV non-small cell lung cancer
1424900|NCT00293280|adenocarcinoma of the lung
1424901|NCT00293280|adenosquamous cell lung cancer
1424902|NCT00293280|bronchoalveolar cell lung cancer
1424903|NCT00293280|large cell lung cancer
1424904|NCT00293280|recurrent non-small cell lung cancer
1424905|NCT00293280|squamous cell lung cancer
1424906|NCT00293267|Treatment Experienced
1424907|NCT00293254|Treatment Experienced
1424908|NCT00293241|Pacemaker or ICD replacement
1424909|NCT00293228|Latent tuberculosis
1424910|NCT00293228|biomarkers
1424911|NCT00293228|isoniazid
1424912|NCT00293228|ELISPOT
1424913|NCT00293228|PPD positive individuals
1424914|NCT00293202|etanercept
1424915|NCT00293202|malnutrition
1424916|NCT00293202|inflammation
1424917|NCT00293202|hemodialysis
1424918|NCT00292266|Relapsing-remitting Multiple Sclerosis
1424919|NCT00292266|Rebif®
1424920|NCT00292266|Avonex®
1424921|NCT00292266|interferon-beta-1a
1424922|NCT00292253|MS
1424923|NCT00292240|brief motivational intervention; teens; substance use
1424924|NCT00292227|advanced-stage idiopathic Parkinson's disease
1424925|NCT00292214|paracetamol
1424926|NCT00292214|acetaminophen
1424927|NCT00292214|pharmacokinetic
1424929|NCT00292214|oral
1424930|NCT00292214|analgesia
1424931|NCT00292214|pain
1424932|NCT00292214|opioid
1424933|NCT00292201|Asthma
1424934|NCT00292201|Statin
1424935|NCT00292188|Phase 4, post-traumatic neuropathic pain, neuropathic pain, Nep, post surgical pain, nerve injury, phantom limb pain, international
1424936|NCT00292175|colonoscopy, narrow band imaging (NBI), ulcerative colitis
1424937|NCT00292162|Chronic Heart Failure
1424938|NCT00292162|Atrial Fibrillation
1424939|NCT00292162|Radiofrequency Ablation
1424940|NCT00292136|Cocaine Dependence
1424941|NCT00292136|Drug Relapse
1424942|NCT00292136|Pharmacokinetics
1424943|NCT00292136|EMA
1424944|NCT00292136|Polydrug Abuse
1424945|NCT00292110|HIV
1424946|NCT00292110|Opiate Substitution
1424947|NCT00292110|Pharmacokinetics
1424948|NCT00292110|ECG
1424949|NCT00292110|Polydrug Abuse
1424950|NCT00292097|Respiratory failure
1424951|NCT00292097|Tracheostomy
1424952|NCT00292097|Percutaneous dilatation tracheostomy
1424953|NCT00292097|Endotracheal Conversion
1424954|NCT00292097|Traumatic brain injury
1424955|NCT00292084|Hepatitis C
1424956|NCT00292084|Celgosivir
1424957|NCT00292084|HCV
1424958|NCT00292084|Genotype 1
1424959|NCT00292084|Non-responders
1424960|NCT00292084|End of Treatment Response
1424961|NCT00292084|Sustained Viral Response
1424962|NCT00292058|Telepsychiatry
1424963|NCT00292058|Videoconference
1424964|NCT00292058|Psychiatric consultation
1424965|NCT00292058|Equivalence trial
1424966|NCT00293189|hip fracture
1424967|NCT00293189|epidemiology
1424968|NCT00293189|genetics
1424969|NCT00293189|p2x7
1424970|NCT00293176|Cognitive impairment
1424971|NCT00293176|Memory Loss
1424972|NCT00293150|diastolic heart failure
1424973|NCT00293150|heart failure
1424974|NCT00293137|Chronic systolic heart failure
1424975|NCT00293137|Heart Failure
1424976|NCT00293124|Gastrointestinal Stromal Tumors
1424977|NCT00293124|Glivec
1424978|NCT00293111|Multiple Myeloma
1424979|NCT00293111|Relapsed Multiple Myeloma
1424980|NCT00293111|Refractory Multiple Myeloma
1424982|NCT00293098|Thalassemia
1424983|NCT00293098|Iron induced heart disease
1424984|NCT00293098|deferoxamine (Desferal)
1424985|NCT00293098|Deferiprone
1424986|NCT00293085|NSCLC
1424987|NCT00293085|Docetaxel
1424988|NCT00293072|Rituximab, ANCA, vasculitis, lupus,
1424989|NCT00293059|Dysfunctional Uterine Bleeding
1424990|NCT00293046|Allergy
1424991|NCT00293033|Breakthrough Pain in Cancer Patients
1424992|NCT00293020|Breakthrough Pain in Cancer Patients
1424993|NCT00292994|Metabolic Syndrome
1424994|NCT00292994|Hyperlipidemia
1424995|NCT00292994|Type 2 diabetes mellitus
1424996|NCT00292994|Insulin resistance
1424997|NCT00292994|Weight loss
1424998|NCT00292994|Obesity
1424999|NCT00292994|Exercise
1425000|NCT00292994|Hypertension
1425001|NCT00292981|C1 Inhibitor
1425002|NCT00292981|Hereditary angioedema
1425003|NCT00292981|Acute HAE attack
1425004|NCT00292968|Health Behavior
1425005|NCT00292968|Prevention
1425006|NCT00292968|Informatics
1425007|NCT00292968|Electronic Health Record
1425008|NCT00292955|Cervical Cancer, Cetuximab, Phase II Clinical Trials
1425009|NCT00292955|Stage IB2-IVB Carcinoma of the Cervix
1425010|NCT00292942|artesunate
1425011|NCT00292942|artemisinin
1425012|NCT00292942|falciparum
1425013|NCT00292929|artesunate
1425014|NCT00292929|artemisinin
1425015|NCT00292929|falciparum
1425016|NCT00292916|whole body vibration
1425017|NCT00292916|exercise
1425018|NCT00292916|elderly woman
1425019|NCT00292916|Bone Mineral Density
1425020|NCT00292916|falls
1425021|NCT00292916|higher age
1425022|NCT00292903|Perinatal Depression
1425023|NCT00292903|Interpersonal Psychotherapy
1425024|NCT00292890|injection devices
1425025|NCT00292890|injection technique
1425026|NCT00292890|insulin needles
1425027|NCT00292890|insulin administration
1425028|NCT00292877|1. Eosinophilic bronchitis, 2. Asthma, 3. Steroid dependent asthma, 4. Sputum eosinophils, 5. SB-240563 (Mepolizumab)
1425029|NCT00292864|Cancer
1425030|NCT00292864|Carcinoma
1425031|NCT00292864|Adenocarcinoma
1425032|NCT00292864|Tumor
1425033|NCT00292864|Advanced solid tumors
1425034|NCT00292838|Eosinophilic bronchitis with asthma
1425035|NCT00292838|Eosinophilic bronchitis without asthma
1425036|NCT00292825|vasovagal syncope
1425037|NCT00292825|syncope
1425038|NCT00292825|cardioinhibitory syncope
1425039|NCT00292825|neurocardiogenic syncope
1425040|NCT00292825|pacing
1425041|NCT00292825|closed loop pacing
1425042|NCT00292825|tilt table
1425043|NCT00292812|Infant nutrition
1425044|NCT00292812|Nucleotides
1425045|NCT00292812|Infant formula
1425046|NCT00292799|Polycystic ovary syndrome
1425047|NCT00292799|Obesity
1425048|NCT00292799|metformin
1425049|NCT00292799|orlistat
1425050|NCT00292786|Functional Electrical Stimulation
1425051|NCT00292786|FES
1425052|NCT00292786|Walking
1425053|NCT00292786|Practice
1425054|NCT00292786|Coordination
1425055|NCT00292786|Posture
1425056|NCT00292773|Anovulation
1425057|NCT00292773|Obesity
1425058|NCT00292773|bariatric surgery
1425059|NCT00292708|Antibiotics
1425060|NCT00292708|Prophylaxis
1425061|NCT00292708|Surgical wound infection
1425062|NCT00292656|Allergy
1425063|NCT00292591|vitamin D
1425064|NCT00292591|cholecalciferol
1425065|NCT00292591|pregnancy
1425066|NCT00292591|bone mineral density
1425067|NCT00292578|Allergy
1425068|NCT00292578|Sugar Intolerance
1425069|NCT00292578|Fatigue
1425070|NCT00292552|Chronic Obstructive Pulmonary Disease (COPD)
1425071|NCT00292552|longitudinal
1425072|NCT00292552|eclipse
1425073|NCT00292539|Pacemaker
1425074|NCT00292539|NYHA class
1425075|NCT00292539|Ejection fraction
1425076|NCT00292539|Heart Failure
1425077|NCT00292526|Chemotherapy induced cardiotoxicity
1425078|NCT00292526|Troponin
1425079|NCT00292526|Heart failure
1425080|NCT00292500|CABG, anastomotic device; myocardial revascularization
1425081|NCT00292474|coronary artery disease
1425082|NCT00292474|percutaneous coronary interventions
1425083|NCT00292474|stent implant
1425084|NCT00292474|drug-coated stent
1425085|NCT00292461|Epilepsy
1425086|NCT00292461|seizures
1425087|NCT00292045|NY-ESO-1 protein, immunization, advanced prostate cancer
1425088|NCT00292032|cardiac arrest
1425089|NCT00292032|diagnosis
1425090|NCT00292032|genetics
1425091|NCT00292032|testing
1425092|NCT00292006|clinical scaphoid fracture
1425093|NCT00292006|pediatric
1425094|NCT00291993|Obstructive sleep apnea
1425095|NCT00291993|Vasoactive hormones
1425096|NCT00291993|Blood pressure
1425097|NCT00291980|Dialysis
1425098|NCT00291980|Pre-dialysis
1425099|NCT00291980|Hepatitis B vaccine
1425100|NCT00291980|Prophylaxis hepatitis B infection
1425101|NCT00291954|Dialysis
1425102|NCT00291954|Pre-dialysis
1425103|NCT00291954|Hepatitis B vaccine
1425104|NCT00291954|Prophylaxis hepatitis B infection
1425105|NCT00291941|Dialysis
1425106|NCT00291941|Pre-dialysis
1425107|NCT00291941|Hepatitis B vaccine
1425108|NCT00291941|Prophylaxis
1425109|NCT00291915|early arthritis, methotrexate, adalimumab
1425110|NCT00291902|CHD
1425111|NCT00291902|coronary heart disease
1425112|NCT00291902|atherosclerosis
1425113|NCT00291902|inflammation
1425114|NCT00291876|HAVRIX™
1425115|NCT00291876|Hepatitis A
1425116|NCT00291863|end stage renal failure
1425117|NCT00291863|peritoneal dialysis
1425118|NCT00291863|simvastatin
1425119|NCT00291863|endothelium
1425120|NCT00291863|vasodilation
1425121|NCT00291850|NSCLC
1425122|NCT00291837|ovarian
1425123|NCT00291837|CT-2106
1425124|NCT00291824|Cardiovascular risks
1425125|NCT00291824|Motivational interviewing
1425126|NCT00291824|Behavior change
1425127|NCT00291824|Primary care setting
1425128|NCT00291811|AMD3100
1425129|NCT00291811|G-CSF
1425130|NCT00291798|pilot study
1425131|NCT00291798|exemestane
1425132|NCT00291798|endocrinotherapy
1425133|NCT00291798|mamma carcinoma
1425134|NCT00291798|neoadjuvant
1425135|NCT00291798|ABCSG
1425136|NCT00291798|17
1425137|NCT00291785|colorectal cancer
1425138|NCT00291785|camptothecin
1425139|NCT00291772|Type 1 Diabetes
1425140|NCT00291772|hypoglycemia
1425141|NCT00291772|hyperglycemia
1425142|NCT00291746|GERD
1425143|NCT00291733|Levetiracetam
1425144|NCT00291733|Levodopa-induced dyskinesias
1425145|NCT00291733|Parkinson's
1425146|NCT00291720|Aldosterone
1425147|NCT00291720|Spironolactone
1425148|NCT00291720|Chronic Kidney Disease
1425149|NCT00291720|Arterial Stiffness
1425150|NCT00291707|head
1425151|NCT00291707|neck
1425152|NCT00291707|Cetuximab
1425153|NCT00291707|Pemetrexed
1425154|NCT00291694|breast atypia
1425155|NCT00291694|double-blind randomized clinical trial
1425156|NCT00291694|RCT
1425157|NCT00291694|celecoxib
1425158|NCT00291694|COX-2 inhibitor
1425159|NCT00291694|placebo
1425160|NCT00291694|high risk for breast cancer
1425161|NCT00291694|breast epithelial hyperplasia
1425162|NCT00291694|ki-67
1425163|NCT00291694|chemoprevention
1425164|NCT00291681|Inflammatory Bowel Disease
1425165|NCT00291681|B cell selection
1425166|NCT00291668|Crohn's Disease
1425167|NCT00291668|CDP870, Certolizumab pegol
1425168|NCT00291655|NEWLY DIAGNOSED EPILEPSY
1425169|NCT00291655|LEVETIRACETAM
1425170|NCT00291655|KEPPRA
1425171|NCT00291655|N01175 (NCT00175903)
1425172|NCT00291642|Levocetirizine, Xyzal, Rhinitis, Allergic, Seasonal, Ragweed
1425173|NCT00291629|Myocardial infarction
1425174|NCT00291629|revascularization
1425175|NCT00291629|drug eluting stents
1425176|NCT00291616|chronic hepatitis B, pegylated interferon, thymosin alpha
1425177|NCT00291603|dialysis
1425178|NCT00291603|Renal Dialysis
1425179|NCT00291603|inflammation
1425180|NCT00291603|quality of life
1425181|NCT00291603|End Stage Kidney Failure
1425182|NCT00291590|diabetes
1425183|NCT00291590|behavioral change
1425184|NCT00291590|chronic care model
1425185|NCT00291590|stage of change
1425186|NCT00291590|Medicaid
1425187|NCT00291590|Dual eligible
1425188|NCT00291590|ethnic
1425189|NCT00291590|self-care
1425190|NCT00291577|advanced
1425191|NCT00291577|sunitinib (Sutent)
1425192|NCT00291577|docetaxel
1425193|NCT00291577|Phase 1B
1425194|NCT00291564|Observational
1425195|NCT00291564|Heart Failure
1425196|NCT00291564|Continuous Cardiac Resynchronization Therapy
1425197|NCT00291525|valve
1425198|NCT00291525|prosthesis
1425199|NCT00291525|antithrombotics
1425200|NCT00291525|randomized
1425201|NCT00291512|HIV
1425202|NCT00291512|STDs
1425203|NCT00291512|Methamphetamine abuse
1425204|NCT00291512|MSM
1425205|NCT00291499|symptomatic OA of the hand
1425206|NCT00291460|COPD
1425207|NCT00291460|respiratory failure
1425208|NCT00291460|inspiratory muscle training
1425209|NCT00291434|Head and neck cancer
1425210|NCT00291434|Fractionation
1425211|NCT00291434|Radiotherapy
1425212|NCT00291434|Conventional fractionation
1425213|NCT00291434|Hyperfractionation
1425214|NCT00291434|Accelerated fractionation
1425215|NCT00291421|Alzheimer's Disease
1425216|NCT00291421|Dementia
1425217|NCT00291421|Brain Disease
1425218|NCT00291421|Memory Loss
1425219|NCT00291421|Caregiver
1425220|NCT00291421|Primary Caregiver
1425221|NCT00291421|Observation
1425222|NCT00291421|galantamine
1425223|NCT00291421|donepezil
1425224|NCT00291421|rivastigmine
1425225|NCT00291421|Quality of life
1425226|NCT00291382|Total asthma control
1425227|NCT00291382|airway hyper-responsiveness
1425228|NCT00291382|adult
1425229|NCT00291382|Asthma
1425230|NCT00291369|Metastatic renal cell carcinoma
1425231|NCT00291369|Interleukin-2
1425232|NCT00291369|Interferon alfa
1425233|NCT00291369|Cytokines
1425234|NCT00291369|Survival
1425235|NCT00291356|Diabetes
1425236|NCT00291356|sodium dependent glucose transporter
1425237|NCT00291356|SGLT2
1425238|NCT00291356|GSK189075
1425239|NCT00291356|GSK189074
1425240|NCT00291356|SGLT1
1425241|NCT00291356|GW869683
1425242|NCT00291343|hepatitis B
1425243|NCT00291343|meningococcal vaccine
1425244|NCT00291343|pertussis
1425245|NCT00291343|Prophylaxis diphtheria
1425246|NCT00291343|meningococcal serogroups A and C diseases
1425247|NCT00291343|tetanus
1425248|NCT00291343|Haemophilus influenzae type b
1425249|NCT00291317|pediatric spinal cord injury
1425250|NCT00291317|FES cycling
1425251|NCT00291317|bone mineral density
1425252|NCT00291317|quality of life
1425253|NCT00291304|Magnetic Resonance Imaging
1425254|NCT00291304|Pathology
1425255|NCT00291278|Endometriosis
1425256|NCT00291278|Bone Mineral Density
1425257|NCT00291278|Osteopenia
1425258|NCT00291278|Osteoporosis
1425259|NCT00291278|DEXA Scan
1425260|NCT00291278|Menopause
1425261|NCT00291278|Screening
1425262|NCT00291278|Healthy Volunteer
1425263|NCT00291278|HV
1425264|NCT00291265|Bradykinesia
1425265|NCT00291265|Tremor
1425266|NCT00291265|Speech
1425267|NCT00291265|Rigidity
1425268|NCT00291265|Neurodegeneration
1425269|NCT00291265|Parkinson Disease
1425270|NCT00291265|PD
1425271|NCT00291226|schizophrenia prodrome
1425272|NCT00291200|Psychosis
1425273|NCT00291200|Basic Symptoms
1425274|NCT00291174|Ventricular Arrhythmia
1425275|NCT00291174|Myocardial Infarction
1425276|NCT00291174|Ventricular Dysfunction
1425277|NCT00291174|Coronary Artery Disease
1425278|NCT00291174|Structural Heart Disease
1425279|NCT00291174|Arrhythmia
1425280|NCT00291174|Cardiomyopathies
1425281|NCT00291161|Delivery of Health Care, Integrated
1425282|NCT00291161|United States Department of Veterans Affairs
1425283|NCT00291161|Dementia
1425284|NCT00291161|Patient Care Management
1425285|NCT00291148|Neuropathic pain
1425286|NCT00291148|Multiple Sclerosis
1425287|NCT00291148|pregabalin
1425288|NCT00291148|paroxetine
1425289|NCT00291135|breast atypia
1425290|NCT00291135|open label pilot study
1425291|NCT00291135|letrozole
1425292|NCT00291135|fine needle aspiration
1425293|NCT00291135|high risk for breast cancer
1425294|NCT00291135|breast epithelial hyperplasia
1425295|NCT00291135|Ki-67
1425296|NCT00291135|hormones plus chemoprevention
1425297|NCT00291135|chemoprevention
1425298|NCT00291122|breast atypia
1425299|NCT00291122|breast epithelial hyperplasia
1425300|NCT00291122|ki-67
1425301|NCT00291122|RTPCR
1425302|NCT00291122|microdissection
1425303|NCT00291109|breast atypia
1425304|NCT00291109|breast epithelial hyperplasia
1425305|NCT00291109|Ki-67
1425306|NCT00291109|RTPCR
1425307|NCT00291109|microdissection
1425308|NCT00291096|breast atypia
1425309|NCT00291096|fine needle aspiration
1425310|NCT00291096|high risk for breast cancer
1425311|NCT00291096|breast epithelial hyperplasia
1425312|NCT00291083|NAF
1425313|NCT00291083|nipple aspirate fluid
1425314|NCT00291083|breast atypia
1425315|NCT00291083|high risk for breast cancer
1425316|NCT00291083|breast epithelial hyperplasia
1425317|NCT00291083|Ki-67
1425318|NCT00291083|hormones plus chemoprevention
1425319|NCT00291083|chemoprevention
1425320|NCT00291070|ADHD
1425321|NCT00291070|attention
1425322|NCT00291070|insomnia
1425323|NCT00291070|hyperactivity
1425324|NCT00291070|anxiety
1425325|NCT00291057|Pediculosis
1425326|NCT00291057|Head Lice
1425327|NCT00291044|pregnancy, genital herpes
1425328|NCT00291031|nightmare
1425329|NCT00291031|sleep disorder
1425330|NCT00291031|sleep
1425331|NCT00291031|imagery rehearsal
1425332|NCT00291031|anxiety disorders
1425333|NCT00291031|mood disorders
1425334|NCT00291031|personality disorders
1425335|NCT00291018|ProDisc
1425336|NCT00291018|ProDisc-C
1425337|NCT00291018|Spinal Fusion
1425338|NCT00291018|Anterior cervical diskectomy
1425339|NCT00291018|Cervical spine
1425340|NCT00291018|Disc disease
1425341|NCT00291018|Implant
1425342|NCT00291018|Degenerative disc disease
1425343|NCT00291018|Intervertebral disc
1425344|NCT00291005|Prostate cancer
1425345|NCT00291005|HRPC
1425346|NCT00291005|AIPC
1425347|NCT00291005|Hormone refractory
1425348|NCT00291005|Androgen independent
1425349|NCT00291005|Docetaxel
1425350|NCT00291005|Taxotere
1425351|NCT00291005|prednisolone
1425352|NCT00290992|urate oxidase, hyperuricemia, lymphoma, leukemia
1425353|NCT00290979|HMR1964, insulin glulisine, Diabetes Mellitus, Type 1
1425354|NCT00290966|docetaxel
1425355|NCT00290966|stomach neoplasm
1425356|NCT00290953|Metastases
1425357|NCT00290940|Diabetes mellitus, Type 2
1425358|NCT00290940|High blood sugar
1425359|NCT00290940|Hyperglycemia
1425765|NCT00290251|Progesterone
1425360|NCT00290940|Antihyperglycemic agents
1425361|NCT00290940|CS-917
1425362|NCT00290927|HMR1964, insulin glulisine, Diabetes Mellitus, Type 2
1425363|NCT00290888|Rotator Cuff Tear
1425364|NCT00290888|Tendon Repair
1425365|NCT00290888|Acromioplasty
1425366|NCT00290888|Arthroscopy
1425367|NCT00290888|Orthopedic Surgery
1425368|NCT00290875|cspine injury
1425369|NCT00290875|radiography
1425370|NCT00290875|clinical impact
1425371|NCT00290875|dissemination
1425372|NCT00290862|Osteoporosis
1425373|NCT00290862|Spine fracture
1425374|NCT00290862|Back Pain
1425375|NCT00290862|Vertebroplasty
1425376|NCT00290862|Vertebral compression fractures related to osteoporosis
1425377|NCT00290823|Taenia
1425378|NCT00290823|Seizures
1425379|NCT00290823|Tapeworm
1425380|NCT00290823|Parasite
1425381|NCT00290771|imatinib mesylate
1425382|NCT00290771|hydroxyurea
1425383|NCT00290771|protein tyrosine kinases
1425384|NCT00290771|glioma
1425385|NCT00290771|glioblastoma multiforme
1425386|NCT00290771|recurrent glioblastoma multiforme
1425387|NCT00290771|GBM
1425388|NCT00290771|MacDonald criteria
1425389|NCT00290745|breast cancer in situ
1425390|NCT00290745|ductal breast carcinoma in situ
1425391|NCT00290732|stage I breast cancer
1425392|NCT00290732|stage II breast cancer
1425393|NCT00290732|stage IIIA breast cancer
1425394|NCT00290732|stage IIIC breast cancer
1425395|NCT00290732|stage IV breast cancer
1425396|NCT00290732|breast cancer in situ
1425397|NCT00290732|ductal breast carcinoma in situ
1425398|NCT00290719|adenocarcinoma of the esophagus
1425399|NCT00290719|squamous cell carcinoma of the esophagus
1425400|NCT00290719|stage II esophageal cancer
1425401|NCT00290719|stage III esophageal cancer
1425402|NCT00290706|recurrent adult diffuse large cell lymphoma
1425403|NCT00290706|recurrent adult diffuse mixed cell lymphoma
1425404|NCT00290706|recurrent adult immunoblastic large cell lymphoma
1425405|NCT00290706|recurrent adult lymphoblastic lymphoma
1425406|NCT00290706|recurrent grade 3 follicular lymphoma
1425407|NCT00290706|recurrent cutaneous T-cell non-Hodgkin lymphoma
1425408|NCT00290706|recurrent mycosis fungoides/Sezary syndrome
1425409|NCT00290693|recurrent pancreatic cancer
1425410|NCT00290693|adenocarcinoma of the pancreas
1425411|NCT00290693|stage IV pancreatic cancer
1425412|NCT00290680|unspecified adult solid tumor, protocol specific
1425413|NCT00290667|contiguous stage II adult diffuse large cell lymphoma
1425414|NCT00290667|noncontiguous stage II adult diffuse large cell lymphoma
1425415|NCT00290667|stage I adult diffuse large cell lymphoma
1425416|NCT00290667|stage III adult diffuse large cell lymphoma
1425417|NCT00290667|stage IV adult diffuse large cell lymphoma
1425418|NCT00290667|contiguous stage II adult immunoblastic large cell lymphoma
1425419|NCT00290667|noncontiguous stage II adult immunoblastic large cell lymphoma
1425420|NCT00290667|stage I adult immunoblastic large cell lymphoma
1426208|NCT00288210|Sirolimus
1425421|NCT00290667|stage III adult immunoblastic large cell lymphoma
1425422|NCT00290667|stage IV adult immunoblastic large cell lymphoma
1425423|NCT00290667|contiguous stage II adult Burkitt lymphoma
1425424|NCT00290667|noncontiguous stage II adult Burkitt lymphoma
1425425|NCT00290667|stage I adult Burkitt lymphoma
1425426|NCT00290667|stage III adult Burkitt lymphoma
1425427|NCT00290667|stage IV adult Burkitt lymphoma
1425428|NCT00290667|contiguous stage II adult diffuse mixed cell lymphoma
1425429|NCT00290667|noncontiguous stage II adult diffuse mixed cell lymphoma
1425430|NCT00290667|stage I adult diffuse mixed cell lymphoma
1425431|NCT00290667|stage III adult diffuse mixed cell lymphoma
1425432|NCT00290667|stage IV adult diffuse mixed cell lymphoma
1425433|NCT00290667|contiguous stage II adult diffuse small cleaved cell lymphoma
1425434|NCT00290667|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1425435|NCT00290667|stage I adult diffuse small cleaved cell lymphoma
1425436|NCT00290667|stage III adult diffuse small cleaved cell lymphoma
1425437|NCT00290667|stage IV adult diffuse small cleaved cell lymphoma
1425438|NCT00290667|contiguous stage II grade 1 follicular lymphoma
1425439|NCT00290667|contiguous stage II grade 2 follicular lymphoma
1425440|NCT00290667|contiguous stage II grade 3 follicular lymphoma
1425441|NCT00290667|noncontiguous stage II grade 1 follicular lymphoma
1425442|NCT00290667|noncontiguous stage II grade 2 follicular lymphoma
1425443|NCT00290667|noncontiguous stage II grade 3 follicular lymphoma
1425444|NCT00290667|stage I grade 1 follicular lymphoma
1425445|NCT00290667|stage I grade 2 follicular lymphoma
1425446|NCT00290667|stage I grade 3 follicular lymphoma
1425447|NCT00290667|stage III grade 1 follicular lymphoma
1425448|NCT00290667|stage III grade 2 follicular lymphoma
1425449|NCT00290667|stage III grade 3 follicular lymphoma
1425450|NCT00290667|stage IV grade 1 follicular lymphoma
1425451|NCT00290667|stage IV grade 2 follicular lymphoma
1425452|NCT00290667|stage IV grade 3 follicular lymphoma
1425453|NCT00290654|ductal breast carcinoma in situ
1425454|NCT00290654|breast cancer in situ
1425455|NCT00290641|adult acute myeloid leukemia in remission
1425456|NCT00290641|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1425457|NCT00290641|adult acute myeloid leukemia with inv(16)(p13;q22)
1425458|NCT00290641|adult acute myeloid leukemia with t(15;17)(q22;q12)
1425459|NCT00290641|adult acute myeloid leukemia with t(16;16)(p13;q22)
1425460|NCT00290641|adult acute myeloid leukemia with t(8;21)(q22;q22)
1425461|NCT00290641|childhood acute myeloid leukemia in remission
1425462|NCT00290641|secondary acute myeloid leukemia
1425463|NCT00290641|accelerated phase chronic myelogenous leukemia
1425464|NCT00290641|childhood chronic myelogenous leukemia
1425465|NCT00290641|chronic phase chronic myelogenous leukemia
1425466|NCT00290641|relapsing chronic myelogenous leukemia
1425467|NCT00290641|refractory anemia with excess blasts
1425468|NCT00290641|de novo myelodysplastic syndromes
1425469|NCT00290641|previously treated myelodysplastic syndromes
1425470|NCT00290641|secondary myelodysplastic syndromes
1425471|NCT00290641|noncontiguous stage II adult Burkitt lymphoma
1425472|NCT00290641|recurrent adult Burkitt lymphoma
1425473|NCT00290641|stage III adult Burkitt lymphoma
1425474|NCT00290641|stage IV adult Burkitt lymphoma
1425475|NCT00290641|noncontiguous stage II adult diffuse large cell lymphoma
1425476|NCT00290641|recurrent adult diffuse large cell lymphoma
1425477|NCT00290641|stage III adult diffuse large cell lymphoma
1425478|NCT00290641|stage IV adult diffuse large cell lymphoma
1425479|NCT00290641|noncontiguous stage II adult diffuse mixed cell lymphoma
1425480|NCT00290641|recurrent adult diffuse mixed cell lymphoma
1425481|NCT00290641|stage III adult diffuse mixed cell lymphoma
1425482|NCT00290641|stage IV adult diffuse mixed cell lymphoma
1425483|NCT00290641|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1425484|NCT00290641|recurrent adult diffuse small cleaved cell lymphoma
1425485|NCT00290641|stage III adult diffuse small cleaved cell lymphoma
1425486|NCT00290641|stage IV adult diffuse small cleaved cell lymphoma
1425487|NCT00290641|contiguous stage II adult lymphoblastic lymphoma
1425488|NCT00290641|noncontiguous stage II adult lymphoblastic lymphoma
1425489|NCT00290641|stage III adult lymphoblastic lymphoma
1425490|NCT00290641|stage IV adult lymphoblastic lymphoma
1425491|NCT00290641|noncontiguous stage II grade 3 follicular lymphoma
1425492|NCT00290641|recurrent grade 3 follicular lymphoma
1425493|NCT00290641|stage III grade 3 follicular lymphoma
1425494|NCT00290641|stage IV grade 3 follicular lymphoma
1425495|NCT00290641|noncontiguous stage II mantle cell lymphoma
1425496|NCT00290641|recurrent mantle cell lymphoma
1425497|NCT00290641|stage III mantle cell lymphoma
1425498|NCT00290641|stage IV mantle cell lymphoma
1425499|NCT00290641|recurrent childhood large cell lymphoma
1425500|NCT00290641|recurrent childhood lymphoblastic lymphoma
1425501|NCT00290641|recurrent childhood small noncleaved cell lymphoma
1425502|NCT00290641|adult acute lymphoblastic leukemia in remission
1425503|NCT00290641|childhood acute lymphoblastic leukemia in remission
1425504|NCT00290641|refractory anemia with excess blasts in transformation
1425505|NCT00290641|refractory cytopenia with multilineage dysplasia
1425506|NCT00290641|recurrent adult acute myeloid leukemia
1425507|NCT00290641|recurrent childhood acute myeloid leukemia
1425508|NCT00290641|noncontiguous stage II adult immunoblastic large cell lymphoma
1426209|NCT00288210|abciximab
1425509|NCT00290641|recurrent adult immunoblastic large cell lymphoma
1425510|NCT00290641|stage III adult immunoblastic large cell lymphoma
1425511|NCT00290641|stage IV adult immunoblastic large cell lymphoma
1425512|NCT00290641|blastic phase chronic myelogenous leukemia
1425513|NCT00290641|chronic idiopathic myelofibrosis
1425514|NCT00290641|chronic eosinophilic leukemia
1425515|NCT00290641|chronic neutrophilic leukemia
1425516|NCT00290641|contiguous stage II adult Burkitt lymphoma
1425517|NCT00290641|stage I adult Burkitt lymphoma
1425518|NCT00290641|contiguous stage II adult diffuse large cell lymphoma
1425519|NCT00290641|stage I adult diffuse large cell lymphoma
1425520|NCT00290641|contiguous stage II adult diffuse mixed cell lymphoma
1425521|NCT00290641|stage I adult diffuse mixed cell lymphoma
1425522|NCT00290641|contiguous stage II adult diffuse small cleaved cell lymphoma
1425523|NCT00290641|stage I adult diffuse small cleaved cell lymphoma
1425524|NCT00290641|contiguous stage II adult immunoblastic large cell lymphoma
1425525|NCT00290641|stage I adult immunoblastic large cell lymphoma
1425526|NCT00290641|stage I adult lymphoblastic lymphoma
1425527|NCT00290641|stage I childhood lymphoblastic lymphoma
1425528|NCT00290641|stage II childhood lymphoblastic lymphoma
1425529|NCT00290641|stage I childhood small noncleaved cell lymphoma
1425530|NCT00290641|stage II childhood small noncleaved cell lymphoma
1425531|NCT00290641|stage III childhood small noncleaved cell lymphoma
1425532|NCT00290641|stage IV childhood small noncleaved cell lymphoma
1425533|NCT00290641|contiguous stage II grade 3 follicular lymphoma
1425534|NCT00290641|stage I grade 3 follicular lymphoma
1425535|NCT00290641|contiguous stage II mantle cell lymphoma
1425536|NCT00290641|stage I mantle cell lymphoma
1425537|NCT00290641|stage I childhood large cell lymphoma
1425538|NCT00290641|stage II childhood large cell lymphoma
1425539|NCT00290641|stage III childhood large cell lymphoma
1425540|NCT00290641|stage IV childhood large cell lymphoma
1425541|NCT00290641|stage III childhood lymphoblastic lymphoma
1425542|NCT00290641|stage IV childhood lymphoblastic lymphoma
1425543|NCT00290641|recurrent adult lymphoblastic lymphoma
1425544|NCT00290641|childhood myelodysplastic syndromes
1425545|NCT00290628|graft versus host disease
1425546|NCT00290628|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1425547|NCT00290628|adult acute myeloid leukemia with inv(16)(p13;q22)
1425548|NCT00290628|adult acute myeloid leukemia with t(15;17)(q22;q12)
1425549|NCT00290628|adult acute myeloid leukemia with t(16;16)(p13;q22)
1425550|NCT00290628|adult acute myeloid leukemia with t(8;21)(q22;q22)
1425551|NCT00290628|accelerated phase chronic myelogenous leukemia
1425552|NCT00290628|adult acute lymphoblastic leukemia in remission
1425553|NCT00290628|adult acute myeloid leukemia in remission
1425554|NCT00290628|atypical chronic myeloid leukemia
1425555|NCT00290628|blastic phase chronic myelogenous leukemia
1425556|NCT00290628|childhood acute lymphoblastic leukemia in remission
1425557|NCT00290628|childhood acute myeloid leukemia in remission
1425558|NCT00290628|childhood chronic myelogenous leukemia
1425559|NCT00290628|chronic eosinophilic leukemia
1425560|NCT00290628|chronic idiopathic myelofibrosis
1425561|NCT00290628|chronic myelomonocytic leukemia
1425562|NCT00290628|chronic neutrophilic leukemia
1425563|NCT00290628|chronic phase chronic myelogenous leukemia
1425564|NCT00290628|de novo myelodysplastic syndromes
1425565|NCT00290628|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1425566|NCT00290628|juvenile myelomonocytic leukemia
1425567|NCT00290628|myelodysplastic/myeloproliferative disease, unclassifiable
1425568|NCT00290628|nodal marginal zone B-cell lymphoma
1425569|NCT00290628|noncontiguous stage II adult Burkitt lymphoma
1425570|NCT00290628|noncontiguous stage II adult diffuse large cell lymphoma
1425571|NCT00290628|noncontiguous stage II adult diffuse mixed cell lymphoma
1425572|NCT00290628|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1425573|NCT00290628|noncontiguous stage II adult immunoblastic large cell lymphoma
1425574|NCT00290628|noncontiguous stage II adult lymphoblastic lymphoma
1425575|NCT00290628|noncontiguous stage II grade 1 follicular lymphoma
1425576|NCT00290628|noncontiguous stage II grade 2 follicular lymphoma
1425577|NCT00290628|noncontiguous stage II grade 3 follicular lymphoma
1425578|NCT00290628|noncontiguous stage II mantle cell lymphoma
1425579|NCT00290628|noncontiguous stage II marginal zone lymphoma
1425580|NCT00290628|noncontiguous stage II small lymphocytic lymphoma
1425581|NCT00290628|previously treated myelodysplastic syndromes
1425582|NCT00290628|recurrent adult acute lymphoblastic leukemia
1425583|NCT00290628|recurrent adult acute myeloid leukemia
1425584|NCT00290628|recurrent adult Burkitt lymphoma
1425585|NCT00290628|recurrent adult Hodgkin lymphoma
1425586|NCT00290628|recurrent adult diffuse large cell lymphoma
1425587|NCT00290628|recurrent adult diffuse mixed cell lymphoma
1425588|NCT00290628|recurrent adult diffuse small cleaved cell lymphoma
1425589|NCT00290628|recurrent adult immunoblastic large cell lymphoma
1425590|NCT00290628|recurrent adult lymphoblastic lymphoma
1425591|NCT00290628|recurrent/refractory childhood Hodgkin lymphoma
1425592|NCT00290628|recurrent childhood acute lymphoblastic leukemia
1425593|NCT00290628|recurrent childhood acute myeloid leukemia
1425594|NCT00290628|recurrent childhood large cell lymphoma
1425595|NCT00290628|recurrent childhood lymphoblastic lymphoma
1425596|NCT00290628|recurrent childhood small noncleaved cell lymphoma
1425597|NCT00290628|recurrent cutaneous T-cell non-Hodgkin lymphoma
1425598|NCT00290628|recurrent grade 1 follicular lymphoma
1425599|NCT00290628|recurrent grade 2 follicular lymphoma
1425600|NCT00290628|recurrent grade 3 follicular lymphoma
1425601|NCT00290628|recurrent mantle cell lymphoma
1425602|NCT00290628|recurrent marginal zone lymphoma
1425603|NCT00290628|recurrent mycosis fungoides/Sezary syndrome
1425604|NCT00290628|recurrent small lymphocytic lymphoma
1425605|NCT00290628|refractory chronic lymphocytic leukemia
1425606|NCT00290628|refractory hairy cell leukemia
1425607|NCT00290628|refractory multiple myeloma
1425608|NCT00290628|relapsing chronic myelogenous leukemia
1425609|NCT00290628|secondary acute myeloid leukemia
1425610|NCT00290628|secondary myelodysplastic syndromes
1425611|NCT00290628|splenic marginal zone lymphoma
1425612|NCT00290628|stage III adult Burkitt lymphoma
1425613|NCT00290628|stage III adult Hodgkin lymphoma
1425614|NCT00290628|stage III adult diffuse large cell lymphoma
1425615|NCT00290628|stage III adult diffuse mixed cell lymphoma
1425616|NCT00290628|stage III adult diffuse small cleaved cell lymphoma
1425617|NCT00290628|stage III adult immunoblastic large cell lymphoma
1425618|NCT00290628|stage III adult lymphoblastic lymphoma
1425619|NCT00290628|stage III chronic lymphocytic leukemia
1425620|NCT00290628|stage III grade 1 follicular lymphoma
1425621|NCT00290628|stage III grade 2 follicular lymphoma
1425622|NCT00290628|stage III grade 3 follicular lymphoma
1425623|NCT00290628|stage III mantle cell lymphoma
1425624|NCT00290628|stage III marginal zone lymphoma
1425625|NCT00290628|stage III small lymphocytic lymphoma
1425626|NCT00290628|stage IV adult Burkitt lymphoma
1425627|NCT00290628|stage IV adult Hodgkin lymphoma
1425628|NCT00290628|stage IV adult diffuse large cell lymphoma
1425629|NCT00290628|stage IV adult diffuse mixed cell lymphoma
1425630|NCT00290628|stage IV adult diffuse small cleaved cell lymphoma
1425631|NCT00290628|stage IV adult immunoblastic large cell lymphoma
1425632|NCT00290628|stage IV adult lymphoblastic lymphoma
1425633|NCT00290628|stage IV chronic lymphocytic leukemia
1425634|NCT00290628|stage IV grade 1 follicular lymphoma
1425635|NCT00290628|stage IV grade 2 follicular lymphoma
1425636|NCT00290628|stage IV grade 3 follicular lymphoma
1425637|NCT00290628|stage IV mantle cell lymphoma
1425638|NCT00290628|stage IV marginal zone lymphoma
1425639|NCT00290628|stage IV small lymphocytic lymphoma
1425640|NCT00290628|Diamond-Blackfan anemia
1425641|NCT00290628|Fanconi anemia
1425642|NCT00290628|childhood myelodysplastic syndromes
1425643|NCT00290615|adenocarcinoma of the colon
1425644|NCT00290615|recurrent colon cancer
1425645|NCT00290615|stage IV colon cancer
1425646|NCT00290615|adenocarcinoma of the rectum
1425647|NCT00290615|recurrent rectal cancer
1425648|NCT00290615|stage IV rectal cancer
1425649|NCT00290602|Acute respiratory distress syndrome
1425650|NCT00290602|corticosteroids
1425651|NCT00290602|postoperative complications
1425652|NCT00290602|cytokines
1425653|NCT00290589|low back pain
1425654|NCT00290589|emergency department
1425655|NCT00290589|corticosteroids
1425656|NCT00290576|Digestive and Nutritional Effects
1425657|NCT00290576|Safety and Growth
1425658|NCT00290576|Feeding Tolerance
1425659|NCT00290550|Advanced Non-Small Cell Lung Cancer
1425660|NCT00290550|NSCLC
1425661|NCT00290537|Non-Small Cell Lung Cancer
1425662|NCT00290537|Lung Cancer
1425663|NCT00290537|Carboplatin
1425664|NCT00290537|Paclitaxel
1425665|NCT00290537|ZD6474
1425666|NCT00290537|NSCLC
1425667|NCT00290524|Oral alimentation following colorectal surgery
1425668|NCT00290524|anastomosis
1425669|NCT00290524|laparoscopy
1425670|NCT00290524|hospitalization stay
1425671|NCT00290511|Follicular Lymphoma
1425672|NCT00290511|Zevalin
1425673|NCT00290511|Ibritumomab Tiuxetan
1425674|NCT00290511|IDEC-Y2B8
1425675|NCT00290511|Fludarabine
1425676|NCT00290511|Fludara
1425677|NCT00290511|Dexamethasone
1425678|NCT00290511|Mitoxantrone
1425679|NCT00290511|Rituximab
1425680|NCT00290511|Rituxan
1425681|NCT00290511|R-FND
1425682|NCT00290511|Fludarabine Phosphate
1425683|NCT00290511|Decadron
1425684|NCT00290498|Non-Hodgkin's Lymphoma
1425685|NCT00290498|B-Cell Non-Hodgkin's Lymphoma
1425686|NCT00290498|Lymphoma
1425687|NCT00290498|Cyclophosphamide
1425688|NCT00290498|Cytarabine
1425689|NCT00290498|Doxorubicin
1425690|NCT00290498|Hyper-CVAD
1425691|NCT00290498|Methotrexate
1425692|NCT00290498|Prednisone
1425693|NCT00290498|Rituximab
1425694|NCT00290498|Vincristine
1425695|NCT00290498|R-CHOP
1425696|NCT00290498|R-HCVAD
1425697|NCT00290498|Dexamethasone
1425698|NCT00290498|Decadron
1425699|NCT00290498|Leucovorin
1425700|NCT00290498|Ara-C
1425701|NCT00290498|Cytosar
1425702|NCT00290498|Cytoxan
1425703|NCT00290498|DepoCyt
1425704|NCT00290498|Cytosine arabinosine hydrochloride
1425705|NCT00290498|AD
1425706|NCT00290498|Hydroxydaunomycin hydrochloride
1425707|NCT00290498|Neosar
1425708|NCT00290485|non-resectable tumor
1425709|NCT00290485|high-risk tumor
1425710|NCT00290485|metastasis
1425711|NCT00290485|Response Evaluation Criteria in Solid Tumors (RECIST)
1425712|NCT00290485|Gleevec
1425713|NCT00290485|Imatinib mesylate
1425714|NCT00290459|Gynecologic Disease
1425715|NCT00290459|Gynecologic Cancer
1425716|NCT00290459|Prognostic Markers
1425717|NCT00290433|Lymphoma
1425718|NCT00290433|Peripheral T Cell
1425719|NCT00290433|HCVIDDOXIL Regimen
1425720|NCT00290433|ARA-C
1425721|NCT00290433|Cytosar
1425722|NCT00290433|DepoCyt
1425723|NCT00290433|Cytosine arabinosine hydrochloride
1425724|NCT00290433|Pegylated Liposomal Doxorubicin
1425725|NCT00290433|Doxorubicin hydrochloride
1425726|NCT00290433|Doxil
1425727|NCT00290433|Cyclophosphamide
1425728|NCT00290433|Cytoxan
1425729|NCT00290433|Neosar
1425730|NCT00290433|Dexamethasone
1425731|NCT00290433|Decadron
1425732|NCT00290433|Mesna
1425733|NCT00290433|Methotrexate
1425734|NCT00290433|Vincristine
1425735|NCT00290433|G-CSF
1425736|NCT00290433|Filgrastim
1425737|NCT00290433|Neupogen
1425738|NCT00290420|malaria
1425739|NCT00290420|Plasmodium vivax
1425740|NCT00290420|pregnancy
1425741|NCT00290420|chemoprophylaxis
1425742|NCT00290407|chronic lymphocytic leukemia
1425743|NCT00290407|small lymphocytic lymphoma
1425744|NCT00290407|rituximab
1425745|NCT00290407|beta-glucan
1425746|NCT00290394|Blood Pressure,
1425747|NCT00290394|rosiglitazone,Diabetes Mellitus, Type 2,
1425748|NCT00290381|Allergic rhinitis
1425749|NCT00290368|Nasal allergen challenge
1425750|NCT00290368|Allergic rhinitis
1425751|NCT00290368|Timothy grass pollen
1425752|NCT00290368|inflammatory mediators
1425753|NCT00290329|Safety
1425754|NCT00290329|Meningococcal disease
1425755|NCT00290329|Meningitidis serogroups A, C,W & Y diseases
1425756|NCT00290329|Meningococcal vaccine
1425757|NCT00290316|Hepatocellular carcinoma
1425758|NCT00290316|Cholangiocarcinoma
1425759|NCT00290316|Metastasis
1425760|NCT00290316|Liver neoplasm
1425761|NCT00290290|Prevention
1425762|NCT00290290|Antiseptic Preoperative Scrub
1425763|NCT00290290|Postoperative Wound Infection
1425764|NCT00290251|Endometrium
1425766|NCT00290251|Estrogen
1425767|NCT00290251|Fibroid
1425768|NCT00290251|Hysterectomy
1425769|NCT00290251|Leiomyoma
1425770|NCT00290251|Uterine Fibroids
1425771|NCT00290251|Fibroids
1425772|NCT00290238|Chronic Low Back Pain
1425773|NCT00290238|Lower Extremity Pain
1425774|NCT00290238|Central Sensitization
1425775|NCT00290238|Percutaneous Neuromodulation Therapy
1425776|NCT00290225|Posttraumatic stress disorder
1425777|NCT00290225|depression
1425778|NCT00290225|disaster mental health
1425779|NCT00290225|yoga
1425780|NCT00290225|Breathwork
1425781|NCT00290225|exposure treatments
1425782|NCT00290212|Women
1425783|NCT00290212|Bone density
1425784|NCT00290212|Menopause
1425785|NCT00290212|Dietary Supplements
1425786|NCT00290212|Vitamin K2
1425787|NCT00290199|Fetal Membranes, Premature Rupture
1425788|NCT00290199|Labor, Induced
1425789|NCT00290199|Foley Catheter
1425790|NCT00290186|Cerebral Palsy
1425791|NCT00290186|Spastic Cerebral Palsy
1425792|NCT00290186|CP
1425793|NCT00290186|Hyperbaric
1425794|NCT00290186|HBOT
1425795|NCT00290173|pre term labor
1425796|NCT00290173|therapy
1425797|NCT00290173|maintenance
1425798|NCT00290160|Hyperkalemia
1425799|NCT00290160|Protein
1425800|NCT00290160|Hyperglycemia
1425801|NCT00290160|ELBW
1425802|NCT00290147|Dengue
1425803|NCT00290147|DNA vaccine
1425804|NCT00290134|Hypogonadism
1425805|NCT00290134|Testosterone
1425806|NCT00290121|Schizophrenia
1425807|NCT00290121|Atypical antipsychotics
1425808|NCT00290121|Weight gain
1425809|NCT00290121|Appetite
1425810|NCT00290121|fMRI
1425811|NCT00290108|BIS
1425812|NCT00290108|Propofol
1425813|NCT00290108|hemodynamic
1425814|NCT00290108|pharmacokinetic
1425815|NCT00290095|Multiple Myeloma
1425816|NCT00290095|Quality of Life
1425817|NCT00290095|Response Shift
1425818|NCT00290095|Clinically Important Difference
1425819|NCT00290082|sedation
1425820|NCT00290082|midazolam
1425821|NCT00290082|loxapine
1425822|NCT00290082|agitation
1425823|NCT00290082|emergency department
1425824|NCT00290082|toxicological analysis
1425825|NCT00290069|Renal function
1425826|NCT00290069|Serum creatinine
1425827|NCT00290069|Immunosuppression
1425828|NCT00290069|Rejection
1425829|NCT00290056|CHD
1425830|NCT00290056|Arrhythmia
1425831|NCT00290056|ICD
1425832|NCT00290056|Omega-3 PUFA
1425833|NCT00290056|Nutrition
1425834|NCT00290043|Insulin glulisine
1425835|NCT00290043|Diabetes mellitus Type 1
1425836|NCT00290043|Postprandial Period
1425837|NCT00290043|Pharmacokinetics
1425838|NCT00290043|Glucodynamics
1425839|NCT00290030|acute urinary retention
1425840|NCT00290030|International Prostate Symptom Score (IPSS)
1425841|NCT00290004|Chronic Lymphocytic Leukemia
1425842|NCT00290004|Small Lymphocytic Lymphoma
1425843|NCT00290004|Leukemia
1425844|NCT00290004|Lymphoma
1425845|NCT00290004|Motexafin Gadolinium
1425846|NCT00290004|Relapsed Chronic Lymphocytic Leukemia
1425847|NCT00290004|Relapsed Small Lymphocytic Lymphoma
1425848|NCT00290004|Refractory Chronic Lymphocytic Leukemia
1425849|NCT00290004|Refractory Small Lymphocytic Lymphoma
1425850|NCT00289978|Multiple Sclerosis
1425851|NCT00289978|FTY720
1425852|NCT00289978|Fingolimod
1425853|NCT00289965|Alcohol Abuse
1425854|NCT00289965|Alcohol Drinking
1425855|NCT00289965|Intervention Studies
1425856|NCT00289965|Computer-Assisted Instruction
1425857|NCT00289965|College Students
1425858|NCT00289952|HIV infections
1425859|NCT00289952|Histone deacetylase Inhibitor
1425860|NCT00289952|HIV Reservoirs
1425861|NCT00289952|Peripheral Blood Mononuclear Cells
1425862|NCT00289952|Valproic Acid
1425863|NCT00289952|Treatment Experienced
1425864|NCT00289939|women
1425865|NCT00289939|women's health
1425866|NCT00289939|HIV
1425867|NCT00289939|risk factors
1425868|NCT00289939|risk behaviors
1425869|NCT00289939|prevention
1425870|NCT00289939|motivational interviewing
1425871|NCT00289939|domestic violence
1425872|NCT00289939|partner violence
1425873|NCT00289939|behavioral trial
1425874|NCT00289939|community justice
1425875|NCT00289939|criminal justice
1425876|NCT00289926|low libido
1425877|NCT00289926|lack of wellbeing
1425878|NCT00289913|Hepatitis A virus
1425879|NCT00289861|Schizophrenia
1425880|NCT00289861|risperidone
1425881|NCT00289861|prolactin
1425882|NCT00289861|clozapine
1425883|NCT00289835|Coronary Artery Bypass Grafting
1425884|NCT00289835|Drug Eluting Stent
1425885|NCT00289835|Saphenous Vein Graft
1425886|NCT00289822|chronic heart failure
1425887|NCT00289822|myocardial infarction
1425888|NCT00289783|Primary and booster vaccination
1425889|NCT00289783|Neisseria meningitidis
1425890|NCT00289783|Hib disease
1425891|NCT00289783|Meningococcal vaccine
1425892|NCT00289783|Meningococcal disease
1425893|NCT00289783|Children
1425894|NCT00289783|Immunogenicity
1425895|NCT00289783|Safety
1425896|NCT00289783|Infants
1425897|NCT00289770|TWINRIX™ ADULT
1425898|NCT00289770|Hepatitis A
1425899|NCT00289770|Hepatitis B
1425900|NCT00289757|Havrix™
1425901|NCT00289757|Hepatitis A
1425902|NCT00289744|Hepatitis B
1425903|NCT00289744|TWINRIX™ ADULT
1425904|NCT00289744|Hepatitis A
1425905|NCT00289731|Combined hepatitis A and hepatitis B vaccine
1425906|NCT00289731|Hepatitis B
1425907|NCT00289731|Hepatitis A
1425908|NCT00289731|Monovalent hepatitis A and hepatitis B vaccines
1425909|NCT00289718|Combined Hepatitis A and B vaccine
1425910|NCT00289718|Hepatitis A
1425911|NCT00289718|Hepatitis B
1425912|NCT00289705|Obesity
1425913|NCT00289705|Surgery
1425914|NCT00289705|Adolescent
1425915|NCT00289705|Roux-en-Y gastric bypass
1425916|NCT00289705|Laparoscopic
1425917|NCT00289666|Sleep Disorder
1425918|NCT00289666|CPAP
1425919|NCT00289653|nicotine dependence,
1425920|NCT00289653|transdermal nicotine patch,
1425921|NCT00289653|smoking while receiving nicotine replacement,
1425922|NCT00289653|comorbidities
1425923|NCT00289640|Stage III (unresectable)
1425924|NCT00289640|Stage IV melanoma
1425925|NCT00289627|Previously treated melanoma
1425926|NCT00289627|Unresectable Stage III
1425927|NCT00289627|Stage IV
1425928|NCT00289614|contrast induced nephropathy
1425929|NCT00289601|aspirin
1425930|NCT00289601|clopidogrel
1425931|NCT00289601|resistance
1425932|NCT00289601|angioplasty
1425933|NCT00289601|percutaneous coronary intervention
1425934|NCT00289601|myocardial infarction
1425935|NCT00289588|Methicillin-resistant Staphylococcus aureus
1425936|NCT00289588|Staphylococcus aureus
1425937|NCT00289588|MRSA
1425938|NCT00289588|CA-MRSA
1425939|NCT00289575|Femur head aseptic osteonecrosis
1425940|NCT00289575|Bone reconstruction
1425941|NCT00289575|Macroporous biphasic calcium phosphate granules
1425942|NCT00289562|B-cell
1425943|NCT00289562|leukemia
1425944|NCT00289562|B-lymphoblastic leukemia
1425945|NCT00289562|lymphoma
1425946|NCT00289562|B-All
1425947|NCT00289549|CLL
1425948|NCT00289549|Chronic lymphocytic leukemia
1425949|NCT00289549|leukemia
1425950|NCT00289549|Advanced, fludarabine-refractory CLL
1425951|NCT00289523|Major Depressive Disorder, Depressive Disorder, Unipolar Depression, Antidepressants, Electroencephalography
1425952|NCT00289497|Charcot
1425953|NCT00289497|foot
1425954|NCT00289497|ulceration
1425955|NCT00289497|neuropathy
1425956|NCT00289484|Mood disorder
1425957|NCT00289471|Sensitivity and specificity
1425958|NCT00289471|Physician's practice patterns
1425959|NCT00289471|Health Care costs
1425960|NCT00289471|Quality of Health Care
1425961|NCT00289458|older adults, falls, arthritis, aquatic, exercise
1425962|NCT00289419|Arthroplasty, Replacement, Hip
1425963|NCT00289419|Anesthetics, Local
1425964|NCT00289419|Pain, Postoperative
1425965|NCT00289406|hypertension
1425966|NCT00289380|Nutritional Risk Screening(NRS)
1425967|NCT00289380|Malnutrition
1425968|NCT00289380|Overweight
1425969|NCT00289380|Obesity
1425970|NCT00289380|Clinical nutritional support
1425971|NCT00289380|Clinical outcome
1425972|NCT00289380|Cost effectiveness
1425973|NCT00289380|Complication
1425974|NCT00289380|Infective complications
1425975|NCT00289354|chromium
1425976|NCT00289354|chromium picolinate
1425977|NCT00289354|type 2 diabetes mellitus
1425978|NCT00289354|HbA1c
1425979|NCT00289354|hyperglycemia
1425980|NCT00289354|cholesterol
1425981|NCT00289302|Heart Failure
1425982|NCT00289302|Cardiac pacing
1425983|NCT00289302|Cardiac resynchronization therapy
1425984|NCT00289302|Implantable Cardioverter Defibrillator
1425985|NCT00289289|Atrial Fibrillation
1425986|NCT00289289|Atrial Tachyarrhythmia
1425987|NCT00289289|Arrhythmia
1425988|NCT00289289|Bradycardia
1425989|NCT00289289|Cardiac Pacemaker
1425990|NCT00289289|IPG Indication
1425991|NCT00289289|Pacing
1425992|NCT00289276|Cardiomyopathy
1425993|NCT00289276|Ventricular Ejection Fraction
1425994|NCT00289276|Congestive Heart Failure
1425995|NCT00289276|Impedance
1425996|NCT00289263|metastatic breast cancer
1425997|NCT00289263|maintenance chemotherapy
1425998|NCT00289250|Malaria
1425999|NCT00289250|Gametocytes
1426000|NCT00289250|Asymptomatic carriers
1426001|NCT00289237|Lifestyle intervention
1426002|NCT00289237|Behavioural changes
1426003|NCT00289237|CHD
1426004|NCT00289237|Type 2 diabetes
1426005|NCT00289224|bivalent killed whole cell oral cholera vaccine
1426006|NCT00289224|double blind randomized clinical trial
1426007|NCT00289211|Hereditary angioedema
1426008|NCT00289211|HAE
1426009|NCT00289211|C1 esterase inhibitor (human)
1426010|NCT00289211|C1INH-nf
1426011|NCT00289198|GW685698X
1426012|NCT00289198|perennial allergic rhinitis
1426013|NCT00289198|allergic rhinitis
1426014|NCT00289185|Coccidiosis
1426015|NCT00289185|Parasitic Diseases
1426016|NCT00289185|Malaria, Falciparum
1426017|NCT00289185|Malaria
1426018|NCT00289159|aged 18-50
1426019|NCT00289159|remitting evolution
1426020|NCT00289159|less than two years of evolution
1426021|NCT00289159|MS patients
1426022|NCT00289146|kidney cancer, immunology
1426023|NCT00289133|Arthroplasty, Replacement, Knee
1426024|NCT00289120|urolithiasis, cola
1426025|NCT00289107|Total Knee Replacement
1426026|NCT00289107|Knee Prosthesis
1426027|NCT00289081|Total Knee Replacement
1426028|NCT00289068|cataract surgery
1426029|NCT00289068|phacoemulsification sleeve
1426030|NCT00289055|Peripheral Artery Occlusive Disease
1426031|NCT00289042|atrial fibrillation
1426032|NCT00289042|atrial thrombus
1426033|NCT00289042|cardioversion
1426034|NCT00289042|enoxaparin
1426035|NCT00289042|low molecular weight heparin
1426036|NCT00289042|transesophageal echocardiography
1426037|NCT00289016|gene transfer
1426038|NCT00289016|gene therapy
1426039|NCT00289016|oncolytic virus
1426040|NCT00289016|GM-CSF
1426041|NCT00289016|melanoma
1426042|NCT00288990|MS
1426043|NCT00288977|Diabetes
1426044|NCT00288977|Islet Transplantation
1426045|NCT00288964|balloon
1426046|NCT00288964|fiber
1426047|NCT00288964|respiratory
1426048|NCT00288964|oxygenator
1426049|NCT00288964|Heart Failure
1426050|NCT00288964|ARDS
1426051|NCT00288964|COPD
1426052|NCT00288938|Suspicious mole
1426053|NCT00288938|Congenital Nevus
1426054|NCT00288938|Skin Cancer
1426055|NCT00288938|Moles
1426056|NCT00288938|Pigmented lesion
1426057|NCT00288938|LCMN
1426058|NCT00288912|Self-Care
1426059|NCT00288912|Telemedicine
1426060|NCT00288912|Pain
1426061|NCT00288912|Veterans
1426062|NCT00288899|Informed Consent
1426063|NCT00288899|Medical Record Systems, computerized
1426064|NCT00288899|Comprehension
1426065|NCT00288899|Anxiety
1426066|NCT00288899|Personal Satisfactin
1426067|NCT00288886|Compliance
1426068|NCT00288886|Aftercare
1426069|NCT00288886|Reinforcement, social
1426070|NCT00288886|Alcoholics Anonymous
1426071|NCT00288886|Support Groups
1426072|NCT00288886|Treatment Outcome
1426073|NCT00288873|Vitamin D deficiency
1426074|NCT00288873|Secondary hyperparathyroidism
1426075|NCT00288873|Obesity
1426076|NCT00288860|telemedicine
1426077|NCT00288860|treatment compliance
1426078|NCT00288860|mental health
1426079|NCT00288847|Patella Dislocation
1426080|NCT00288847|Surface EMG
1426081|NCT00288847|Gender difference
1426082|NCT00288834|stroke
1426083|NCT00288834|dysphagia
1426084|NCT00288834|rehabilitation
1426085|NCT00288834|biofeedback
1426210|NCT00288145|worksite
1426086|NCT00288821|Gynaecological malignancy
1426087|NCT00288821|Diagnostic Accuracy
1426088|NCT00288821|DWIBS
1426089|NCT00288821|Lymph Nodes
1426090|NCT00288821|Metastasis
1426091|NCT00288808|Blood
1426092|NCT00288808|Coagulation
1426093|NCT00288808|PT/InR
1426094|NCT00288808|Warfarin
1426095|NCT00288808|Mechanical Valve
1426096|NCT00288795|Fatigue
1426097|NCT00288795|Polarity
1426098|NCT00288795|Massage
1426099|NCT00288782|Mirtazapine
1426100|NCT00288782|Antidepressant
1426101|NCT00288782|Positron Emission Tomography
1426102|NCT00288769|Recurrent aphthous stomatitis
1426103|NCT00288769|vitamin B12
1426104|NCT00288756|arrythmias
1426105|NCT00288730|Heart Failure
1426106|NCT00288730|Renal Dysfunction
1426107|NCT00288730|Cardiomyopathy
1426108|NCT00288730|Heart Decompensation
1426109|NCT00288730|Dyspnea Paroxysmal
1426110|NCT00288704|Familial Cold Autoinflammatory Syndrome (FCAS)
1426111|NCT00288704|Muckle-Wells Syndrome (MWS)
1426112|NCT00288704|CIAS1
1426113|NCT00288704|NLRP-3
1426114|NCT00288704|PYPAF1
1426115|NCT00288704|Cryopyrin
1426116|NCT00288704|CAPS
1426117|NCT00288704|Interleukin-1
1426118|NCT00288691|Treatment-resistant menorrhagia
1426119|NCT00288678|Diabetic shared care
1426120|NCT00288678|Health manager
1426121|NCT00288678|Prospective Study
1426122|NCT00288678|Health Care Quality, Access, and Evaluation
1426123|NCT00288665|Myocardial infarction
1426124|NCT00288665|aspiration
1426125|NCT00288665|thrombectomy
1426126|NCT00288665|ventricular remodeling
1426127|NCT00288639|Pregabalin for partial seizures
1426128|NCT00288626|hematopoietic stem cell transplantation
1426129|NCT00288626|HCT- autologous hematopoietic cell transplant
1426130|NCT00288626|HDIT-high-dose immunosuppressive therapy
1426131|NCT00288626|BEAM -Carmustine (BCNU), Etoposide (VP-16), Cytarabine (ara-C), and Melphalan
1426132|NCT00288613|ESRD
1426133|NCT00288613|Daily Hemodialysis
1426134|NCT00288613|Hemodialysis
1426135|NCT00288613|Kidney Failure
1426136|NCT00288613|Kidney Disease
1426137|NCT00288600|Immunoglobulins, Intravenous
1426138|NCT00288600|Hyperbilirubinemia
1426139|NCT00288600|Erythroblastosis, Fetal
1426140|NCT00288600|Exchange Transfusion, Whole Blood
1426141|NCT00288587|Heart Failure
1426142|NCT00288587|Congestive Heart Failure
1426143|NCT00288587|CHF
1426144|NCT00288574|Depression
1426145|NCT00288561|ARMD, ranibizumab, verteporfin
1426146|NCT00288535|coronary bifurcation ; PCI; modified T-Stenting; sirolimus stent
1426147|NCT00288496|mechanical bowel preparation, colorectal surgery, anastomotic dehiscence
1426148|NCT00288444|Advanced malignancies.
1426149|NCT00288431|cancer
1426150|NCT00288431|sarcoma
1426151|NCT00288418|Colonization of the catheter
1426152|NCT00288418|Catheter related bloodstream infection
1426153|NCT00288405|Intracranial
1426154|NCT00288405|Wide-neck
1426155|NCT00288405|Saccular
1426156|NCT00288405|Aneurysms
1426157|NCT00288379|Asthma
1426158|NCT00288379|allergen challenge
1426159|NCT00288379|airway responsiveness
1426160|NCT00288379|airway inflammation
1426161|NCT00288379|Symbicort®
1426162|NCT00288366|schizophrenia
1426163|NCT00288366|schizoaffective disorder
1426164|NCT00288366|bipolar disorder
1426165|NCT00288366|metabolic syndrome
1426166|NCT00288353|schizophrenia
1426167|NCT00288353|schizoaffective disorder
1426168|NCT00288353|bipolar disorder
1426169|NCT00288353|metabolic syndrome
1426170|NCT00288340|psychotic disorders
1426171|NCT00288340|auditory hallucinations
1426172|NCT00288340|brain structure
1426173|NCT00288340|psychiatric disorder with auditory hallucinations (at least one every 20 minutes)
1426174|NCT00288340|schizophrenia/schizoaffective disorder without auditory hallucinations
1426175|NCT00288327|diet
1426176|NCT00288327|physical activity
1426177|NCT00288327|smoking cessation
1426178|NCT00288314|PTSD
1426179|NCT00288314|MRI, Functional
1426180|NCT00288314|Anxiety
1426181|NCT00288314|Working Memory
1426182|NCT00288314|Processing speed
1426183|NCT00288301|diet
1426184|NCT00288301|physical activity
1426185|NCT00288301|weight management
1426186|NCT00288275|Ovarian Cancer
1426187|NCT00288275|Fallopian Tube Cancer
1426188|NCT00288275|Peritoneal Cancer
1426189|NCT00288275|Assay
1426190|NCT00288275|Chemotherapy
1426191|NCT00288275|Recurrent
1426192|NCT00288275|Refractory
1426193|NCT00288275|Persistent
1426194|NCT00288275|Chemoresponse
1426195|NCT00288275|Sensitivity
1426196|NCT00288275|Precision Therapeutics
1426197|NCT00288262|hot flashes
1426198|NCT00288262|melatonin
1426199|NCT00288262|depression
1426200|NCT00288262|sleep
1426201|NCT00288262|luteinizing hormone
1426202|NCT00288262|postmenopause
1426203|NCT00288249|Breast Cancer
1426204|NCT00288249|Breast Neoplasms
1426205|NCT00288236|Type 2 diabetes mellitus
1426206|NCT00288210|Myocardial Infarction
1426207|NCT00288210|Stents
1426211|NCT00288145|weight gain prevention (among adults)
1426212|NCT00288145|obesity (among adults)
1426213|NCT00288145|physical activity
1426214|NCT00288145|nutrition
1426215|NCT00288132|Diabetes
1426216|NCT00288132|self-management
1426217|NCT00288132|telemedicine
1426218|NCT00288132|retinal
1426219|NCT00288132|screening
1426220|NCT00288119|Barrett's Esophagus
1426221|NCT00288106|recurrent prostate cancer
1426222|NCT00288106|stage I prostate cancer
1426223|NCT00288106|stage II prostate cancer
1426224|NCT00288106|stage III prostate cancer
1426225|NCT00288106|stage IV prostate cancer
1426226|NCT00288080|stage III prostate cancer
1426227|NCT00288080|stage IIB prostate cancer
1426228|NCT00288080|stage IIA prostate cancer
1426229|NCT00288080|stage IV prostate cancer
1426230|NCT00288054|stage IIIA non-small cell lung cancer
1426231|NCT00288054|stage IIIB non-small cell lung cancer
1426232|NCT00288054|adenocarcinoma of the lung
1426233|NCT00288054|large cell lung cancer
1426234|NCT00288054|squamous cell lung cancer
1426235|NCT00288028|stage I multiple myeloma
1426236|NCT00288028|stage II multiple myeloma
1426237|NCT00288028|stage III multiple myeloma
1426238|NCT00288028|refractory multiple myeloma
1426239|NCT00288015|adult angiosarcoma
1426240|NCT00288015|recurrent adult soft tissue sarcoma
1426241|NCT00288015|stage I adult soft tissue sarcoma
1426242|NCT00288015|stage II adult soft tissue sarcoma
1426243|NCT00288015|stage III adult soft tissue sarcoma
1426244|NCT00288015|stage IV adult soft tissue sarcoma
1426245|NCT00288002|inflammatory breast cancer
1426246|NCT00288002|stage II breast cancer
1426247|NCT00288002|stage IIIA breast cancer
1426248|NCT00288002|stage IIIB breast cancer
1426249|NCT00288002|stage IIIC breast cancer
1426250|NCT00288002|stage IA breast cancer
1426251|NCT00288002|stage IB breast cancer
1426252|NCT00288002|estrogen receptor-negative breast cancer
1426253|NCT00288002|estrogen receptor-positive breast cancer
1426254|NCT00288002|HER2-negative breast cancer
1426255|NCT00288002|HER2-positive breast cancer
1426256|NCT00287989|recurrent non-small cell lung cancer
1426257|NCT00287989|stage IIIB non-small cell lung cancer
1426258|NCT00287989|stage IV non-small cell lung cancer
1426259|NCT00287976|childhood hepatoblastoma
1426260|NCT00287976|recurrent childhood liver cancer
1426261|NCT00287963|adenocarcinoma of the lung
1426262|NCT00287963|adenosquamous cell lung cancer
1426263|NCT00287963|bronchoalveolar cell lung cancer
1426264|NCT00287963|combined type small cell lung cancer
1426265|NCT00287963|intermediate type small cell lung cancer
1426266|NCT00287963|large cell lung cancer
1426267|NCT00287963|lymphocyte-like type small cell lung cancer
1426268|NCT00287963|recurrent non-small cell lung cancer
1426269|NCT00287963|recurrent small cell lung cancer
1426270|NCT00287963|squamous cell lung cancer
1426271|NCT00287950|disseminated neuroblastoma
1426272|NCT00287950|localized resectable neuroblastoma
1426273|NCT00287950|localized unresectable neuroblastoma
1426274|NCT00287950|regional neuroblastoma
1426275|NCT00287950|stage 4S neuroblastoma
1426276|NCT00287924|childhood infratentorial ependymoma
1426277|NCT00287924|childhood supratentorial ependymoma
1426278|NCT00287924|newly diagnosed childhood ependymoma
1426279|NCT00287911|cervical adenocarcinoma
1426280|NCT00287911|cervical adenosquamous cell carcinoma
1426281|NCT00287911|cervical squamous cell carcinoma
1426282|NCT00287911|stage IB cervical cancer
1426283|NCT00287911|stage IIA cervical cancer
1426284|NCT00287911|stage IIB cervical cancer
1426285|NCT00287911|stage III cervical cancer
1426286|NCT00287911|stage IVA cervical cancer
1426287|NCT00287898|breast cancer
1426288|NCT00287885|recurrent cervical cancer
1426289|NCT00287885|stage III cervical cancer
1426290|NCT00287885|stage IVA cervical cancer
1426291|NCT00287885|stage IVB cervical cancer
1426292|NCT00287885|stage III endometrial carcinoma
1426293|NCT00287885|recurrent endometrial carcinoma
1426294|NCT00287885|stage IV endometrial carcinoma
1426295|NCT00287885|fallopian tube cancer
1426296|NCT00287885|stage III ovarian epithelial cancer
1426297|NCT00287885|stage IV ovarian epithelial cancer
1426298|NCT00287885|stage III ovarian germ cell tumor
1426299|NCT00287885|recurrent ovarian germ cell tumor
1426300|NCT00287885|stage IV ovarian germ cell tumor
1426301|NCT00287885|recurrent ovarian epithelial cancer
1426302|NCT00287885|recurrent uterine sarcoma
1426303|NCT00287885|stage III uterine sarcoma
1426304|NCT00287885|stage IV uterine sarcoma
1426305|NCT00287885|stage III vaginal cancer
1426306|NCT00287885|recurrent vaginal cancer
1426307|NCT00287885|stage IVA vaginal cancer
1426308|NCT00287885|stage IVB vaginal cancer
1426309|NCT00287885|stage III vulvar cancer
1426310|NCT00287885|recurrent vulvar cancer
1426311|NCT00287885|stage IV vulvar cancer
1426312|NCT00287885|ovarian sarcoma
1426313|NCT00287885|ovarian stromal cancer
1426314|NCT00287885|peritoneal cavity cancer
1426315|NCT00287872|stage II multiple myeloma
1426316|NCT00287872|stage III multiple myeloma
1426317|NCT00287859|fallopian tube cancer
1426318|NCT00287859|peritoneal cavity cancer
1426319|NCT00287859|recurrent ovarian epithelial cancer
1426320|NCT00287846|desmoid tumor
1426321|NCT00287820|schizophrenia
1426322|NCT00287820|diabetes
1426323|NCT00287820|metabolic syndrome
1426324|NCT00287820|hyperglycemia
1426325|NCT00287820|glucose
1426326|NCT00287820|insulin
1426327|NCT00287820|lipids
1426328|NCT00287820|IL-6
1426329|NCT00287820|prolactin
1426330|NCT00287807|Diabetes mellitus, type 2
1426331|NCT00287807|Blood Glucose Self-Monitoring
1426332|NCT00287807|life style
1426333|NCT00287794|rheumatoid arthritis
1426334|NCT00287794|sleep disturbance
1426335|NCT00287781|Migraine
1426336|NCT00287781|Lidocaine
1426337|NCT00287781|Headache
1426338|NCT00287768|gastric cancer
1426339|NCT00287768|advanced gastric cancer
1426340|NCT00287768|S-1
1426341|NCT00287768|docetaxel
1426342|NCT00287768|phase III study
1426343|NCT00287755|gastric cancer
1426344|NCT00287755|S-1
1426345|NCT00287755|chemosensitivity
1426346|NCT00287755|adjuvant
1426347|NCT00287742|risperidone
1426348|NCT00287742|antipsychotic agents
1426349|NCT00287742|Alzheimer's disease
1426350|NCT00287742|dementia
1426351|NCT00287742|psychosis
1426352|NCT00287729|Idiopathic
1426353|NCT00287729|Pulmonary
1426354|NCT00287729|Fibrosis
1426355|NCT00287729|Lung
1426356|NCT00287729|Pirfenidone
1426357|NCT00287729|InterMune
1426358|NCT00287716|Idiopathic
1426359|NCT00287716|Pulmonary
1426360|NCT00287716|Fibrosis
1426361|NCT00287716|Lung
1426362|NCT00287716|Pirfenidone
1426363|NCT00287716|InterMune
1426364|NCT00287703|Major depression
1426365|NCT00287703|Treatment resistant
1426366|NCT00287703|PEMF
1426367|NCT00287703|AQT
1426368|NCT00287703|Hamilton
1426369|NCT00287690|arteries
1426370|NCT00287690|blood flow
1426371|NCT00287690|coronary artery disease
1426372|NCT00287690|diet
1426373|NCT00287677|Growth Hormone
1426374|NCT00287677|HIV-1
1426375|NCT00287677|Vaccination
1426376|NCT00287677|Thymopoiesis
1426377|NCT00287677|HIV-specific responses
1426378|NCT00287677|Treatment Experienced
1426379|NCT00287664|hepatorenal syndrome
1426380|NCT00287664|terlipressin
1426381|NCT00287664|albumin
1426382|NCT00287664|cirrhosis
1426383|NCT00287651|Pulsatile intravenous insulin
1426384|NCT00287651|Oral carbohydrate loading
1426385|NCT00287651|Respiratory Quotients
1426386|NCT00287651|Hypoglycemia
1426387|NCT00287638|Obstructive sleep apnea
1426388|NCT00287625|Chronic obstructive pulmonary disease
1426389|NCT00287625|Pulmonary rehabilitation
1426390|NCT00287612|GERD
1426391|NCT00287612|Hiatal Hernia
1426392|NCT00287612|Recurrence
1426393|NCT00287599|Surgical wound infections
1426394|NCT00287599|Real-time PCR
1426395|NCT00287599|Rapid identification of bacteria
1426396|NCT00287599|Cloning
1426397|NCT00287599|16S rRNA sequencing
1426398|NCT00287586|Testosterone Replacement
1426399|NCT00287586|Heart Disease
1426400|NCT00287586|Vascular Disease
1426401|NCT00287586|Risk Factors for Cardiovascular Disease
1426402|NCT00287586|Cholesterol
1426403|NCT00287586|Obesity
1426404|NCT00287586|Blood pressure
1426405|NCT00287586|Quality of Life
1426406|NCT00287534|Early Breast Cancer
1426407|NCT00287521|open
1426408|NCT00287521|angle
1426409|NCT00287521|glaucoma
1426410|NCT00287521|ocular
1426411|NCT00287521|hypertension
1426412|NCT00287508|Carotid stenting
1426413|NCT00287508|Carotid endarterectomy
1426414|NCT00287508|Carotid artery disease with severe narrowing of the artery
1426415|NCT00287508|Stroke prevention
1426416|NCT00287508|cerebral infarction
1426417|NCT00287495|AIDS
1426418|NCT00287495|HIV
1426419|NCT00287495|Antiangiogenesis
1426420|NCT00287495|VEGF
1426421|NCT00287495|AIDS Malignancy
1426422|NCT00287495|Kaposi Sarcoma
1426423|NCT00287495|KS
1426424|NCT00287482|Treatment side effects
1426425|NCT00287482|Quality of Life
1426426|NCT00287482|Transition
1426427|NCT00287482|Survivorship
1426428|NCT00287469|Hepatitis E
1426429|NCT00287469|clinical hepatitis
1426430|NCT00287469|vaccine
1426431|NCT00287469|efficacy
1426432|NCT00287469|Nepal
1426433|NCT00287417|Nucal translucency
1426434|NCT00287417|Down syndrome
1426435|NCT00287417|MSS
1426436|NCT00287417|Risk assessment
1426437|NCT00287404|type 2 diabetes
1426438|NCT00287404|hyperlipidemia
1426439|NCT00287404|dyslipidemia
1426440|NCT00287404|fasting lipids
1426441|NCT00287404|postprandial lipids
1426442|NCT00287404|Non-HDL cholesterol
1426443|NCT00287404|NMR lipoanalysis
1426444|NCT00287404|ATP III guidelines
1426445|NCT00287391|Insomnia
1426446|NCT00287391|Gastroesophageal Reflux Disease (GERD)
1426447|NCT00287391|Sleep Disturbance
1426448|NCT00287352|First episode psychosis
1426449|NCT00287339|Cough
1426450|NCT00287339|GERD
1426451|NCT00287326|Epidural
1426452|NCT00287326|Bupivacaine
1426453|NCT00287326|Clonidine
1426454|NCT00287313|Unstable INRs
1426455|NCT00287313|Warfarin
1426456|NCT00287313|Vitamin K
1426457|NCT00287300|Malaria
1426458|NCT00287300|Pregnancy
1426459|NCT00287300|Efficacy
1426460|NCT00287300|Azithromycin
1426461|NCT00287300|Artesunate
1426462|NCT00287287|Lenalidomide
1426463|NCT00287287|Clinical Trials phase II
1426464|NCT00287287|Carcinomas, thyroid
1426465|NCT00287287|Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas
1426466|NCT00287261|myelofibrosis
1426467|NCT00287261|D009191
1426468|NCT00287248|Alzheimer
1426469|NCT00287248|Alzheimer disease
1426470|NCT00287248|Alzheimer disease (AD)
1426471|NCT00287235|Hepatic Encephalopathy
1426472|NCT00287235|End Stage Liver Disease
1426473|NCT00287235|Cirrhosis
1426474|NCT00287235|MARS
1426475|NCT00287235|Albumin Dialysis
1426476|NCT00287222|Inoperable and Metastatic Hepatocellular Carcinoma
1426477|NCT00287209|RASCABG 1 - study
1426478|NCT00287209|Postoperative atrial fibrillation
1426479|NCT00287209|Randomized, controlled trial
1426480|NCT00287209|Amiodarone
1426481|NCT00287196|Melanoma
1426482|NCT00287196|Lymph node disease
1426483|NCT00287196|Adjuvant radiotherapy
1426484|NCT00287196|Lymphoedema
1426485|NCT00287170|Crohn's Disease
1426486|NCT00287170|Local Ileal Delivery
1426487|NCT00287170|Delayed-Release Formulations
1426488|NCT00287170|6-Mercaptopurine
1426489|NCT00287170|Calcitriol
1426490|NCT00287157|Traumatic Brain Injury
1426491|NCT00287157|Actigraphy
1426492|NCT00287157|Spasticity, Cognition and Functioning
1426493|NCT00287144|Hypothyroidism
1426494|NCT00287131|melanoma
1426495|NCT00287131|metastatic melanoma
1426496|NCT00287131|adoptive immunotherapy
1426497|NCT00287131|IL-2
1426498|NCT00287105|Chemotherapy
1426499|NCT00287105|Leukemia
1426500|NCT00287105|Children
1426501|NCT00287105|Philadelphia chromosome
1426502|NCT00287105|Protein-tyrosine kinase inhibitor
1426503|NCT00287092|Haemophilus influenzae type b;
1426504|NCT00287092|Corynebacterium diphtheriae;
1426505|NCT00287092|Clostridium tetani;
1426506|NCT00287092|Bordetella pertussis;
1426507|NCT00287092|poliovirus types 1, 2 and 3;
1426508|NCT00287092|Vero cell;
1426509|NCT00287092|Influenza;
1426510|NCT00287092|Diphtheria
1426511|NCT00287053|divalproex sodium
1426512|NCT00287053|valproic acid
1426513|NCT00287053|food intake
1426514|NCT00287053|energy expenditure
1426515|NCT00287053|posture allocation
1426516|NCT00287053|None, the population of study is healthy
1426517|NCT00287040|Breast Cancer
1426518|NCT00287040|Mammography
1426519|NCT00287027|psychotic disorders
1426520|NCT00287027|family burden
1426521|NCT00287027|long acting injectible antipsychotic medication
1426522|NCT00287014|Rift valley fever, Kenya
1426523|NCT00287001|Acquired bilateral nevus of Ota-like macules
1426524|NCT00287001|Postinflammatory hyperpigmentation
1426525|NCT00287001|Cold air cooling
1426526|NCT00286988|Preventative
1426527|NCT00286988|Open-Label
1426528|NCT00286988|Safety/Efficacy
1426529|NCT00286975|Leadership skills
1426530|NCT00286975|Management skills
1426531|NCT00286975|Postgraduate medical education
1426532|NCT00286962|Diabetes mellitus, type 1
1426533|NCT00286962|insulin infusion systems
1426534|NCT00286962|continuous intraperitoneal insulin infusion
1426535|NCT00286962|cross-over studies
1426536|NCT00286949|Parkinson's disease
1426537|NCT00286949|executive dysfunction
1426538|NCT00286949|impairment
1426539|NCT00286949|motor skills
1426540|NCT00286949|cognitive
1426541|NCT00286936|Hip fracture
1426542|NCT00286936|delirium
1426543|NCT00286936|sleep disturbance
1426544|NCT00286936|hypnotic
1426545|NCT00286923|migraine
1426546|NCT00286923|chronic headache
1426547|NCT00286923|hyperexcitability
1426548|NCT00286923|Magnetic stimulation
1426549|NCT00286910|AQP-2
1426550|NCT00286910|NPHS2-gene
1426551|NCT00286845|Chemosensitivity
1426552|NCT00286845|Acute Myeloid Leukemia
1426553|NCT00286845|Apoptosis
1426554|NCT00286845|MiCK Assay
1426555|NCT00286832|Non-Hodgkin's lymphoma
1426556|NCT00286832|Diffuse large B-cell lymphoma
1426557|NCT00286832|PET
1426558|NCT00286832|Prognosis
1426559|NCT00286819|early breast cancer,
1426560|NCT00286819|Fluorouracil
1426561|NCT00286793|at-101
1426562|NCT00286793|at101
1426563|NCT00286793|cancer
1426564|NCT00286793|hormone refractory
1426565|NCT00286793|prostate
1426566|NCT00286793|docetaxel
1426567|NCT00286793|prednisone
1426568|NCT00286780|AT101
1426569|NCT00286780|AT-101
1426570|NCT00286780|cancer
1426571|NCT00286780|lymphoctic
1426572|NCT00286780|lukemia
1426573|NCT00286780|Rituximab
1426574|NCT00286767|Opportunistic Infections
1426575|NCT00286767|Immune Restoration Disease
1426576|NCT00286767|Mycobacterial Infections
1426577|NCT00286767|HIV-1 Infection
1426578|NCT00286767|HIV
1426579|NCT00286767|ART Naive
1426580|NCT00286754|Hypertension
1426581|NCT00286754|Behavior modification
1426582|NCT00286754|Randomized controlled trial
1426583|NCT00286754|Treatment effectiveness
1426584|NCT00286754|Telemedicine
1426585|NCT00286754|Prevention
1426586|NCT00286741|Diabetes
1426587|NCT00286741|Hypertension
1426588|NCT00286741|Randomized controlled trials
1426589|NCT00286741|cost-effectiveness
1426590|NCT00286741|health services
1426591|NCT00286728|self-help groups
1426592|NCT00286728|referral and consultation
1426593|NCT00286702|splints
1426594|NCT00286702|Occupational Therapy
1426595|NCT00286663|AIH, Autoimmune Hepatitis
1426596|NCT00286650|Paracetamol
1426597|NCT00286637|OCT
1426598|NCT00286637|CSLO
1426599|NCT00286637|SLP
1426600|NCT00286637|Perimetry
1426601|NCT00286637|electrophysiology
1426602|NCT00286637|glaucoma
1426603|NCT00286637|macular degeneration
1426604|NCT00286637|retinopathy
1426605|NCT00286637|diabetes
1426606|NCT00286637|macular hole
1426607|NCT00286611|Amifostine
1426608|NCT00286598|foot ulcer
1426609|NCT00286598|diabetes mellitus
1426610|NCT00286598|motor activity
1426611|NCT00286598|randomized controlled trial
1426612|NCT00286598|prevention
1426613|NCT00286585|preconditioning
1426614|NCT00286585|cardiac protection
1426615|NCT00286585|morbidity
1426616|NCT00286585|mortality
1426617|NCT00286585|major non-cardiac surgery
1426618|NCT00286585|cardiac mortality and morbidity
1426619|NCT00286585|high cardiac perioperative risk
1426620|NCT00286572|insulin-dependent diabetes mellitus
1426621|NCT00286572|non-insulin-dependent diabetes mellitus
1426622|NCT00286572|coronary artery disease
1426623|NCT00286572|long-term mortality
1426624|NCT00286559|Coronary artery disease
1426625|NCT00286559|Coronary artery bypass graft surgery
1426626|NCT00286559|SPECT
1426627|NCT00286559|Adenosin
1426628|NCT00286546|Testosterone
1426629|NCT00286546|Major Depression
1426630|NCT00286546|Men
1426631|NCT00286533|Implant
1426632|NCT00286520|Constipation
1426633|NCT00286520|Fecal incontinence
1426634|NCT00286520|Spinal cord injury
1426635|NCT00286520|transanal irrigation
1426636|NCT00286520|quality of life
1426637|NCT00286507|Full thickness macular hole
1426638|NCT00286507|Internal limiting membrane (ILM)
1426639|NCT00286507|Vitreo retinal surgery
1426640|NCT00286507|Vitrectomy
1426641|NCT00286494|Glucose Metabolism Disorder
1426642|NCT00286494|Dysmetabolic Syndrome
1426643|NCT00286494|Type II Diabetes
1426644|NCT00286494|Diabetes Mellitus
1426645|NCT00286494|Lipoatrophic
1426646|NCT00286494|Dyslipidemia
1426647|NCT00286494|Drug Therapy
1426648|NCT00286481|Hyperlipidemia
1426649|NCT00286481|Drug Therapy
1426650|NCT00286468|Glucose Metabolism Disorder
1426651|NCT00286468|Dysmetabolic Syndrome
1426652|NCT00286468|Type II Diabetes
1426653|NCT00286468|Diabetes Mellitus
1426654|NCT00286468|Lipoatrophic
1426655|NCT00286468|Dyslipidemia
1426656|NCT00286468|Drug Therapy
1426657|NCT00286455|Glucose Metabolism Disorder
1426658|NCT00286455|Dysmetabolic Syndrome
1426659|NCT00286455|Type II Diabetes; Diabetes Mellitus
1426660|NCT00286455|Lipoatrophic
1426661|NCT00286455|Dyslipidemia
1426662|NCT00286455|Drug Therapy
1426663|NCT00286442|Glucose Metabolism Disorder
1426664|NCT00286442|Dysmetabolic Syndrome
1426665|NCT00286442|Type II Diabetes
1426666|NCT00286442|Diabetes Mellitus
1426667|NCT00286442|Lipoatrophic
1426668|NCT00286442|Dyslipidemia
1426669|NCT00286442|Drug Therapy
1426670|NCT00286429|Glucose Metabolism Disorder
1426671|NCT00286429|Dysmetabolic Syndrome
1426672|NCT00286429|Type II Diabetes
1426673|NCT00286429|Diabetes Mellitus
1426674|NCT00286429|Lipoatrophic
1426675|NCT00286429|Dyslipidemia
1426676|NCT00286429|Drug Therapy
1426677|NCT00286416|AERD
1426678|NCT00286416|aspirin
1426679|NCT00286416|allergy
1426680|NCT00286416|omalizumab
1426681|NCT00286403|Acute Tubular Necrosis
1426682|NCT00286403|antioxidants
1426683|NCT00286403|Fenoldopam
1426684|NCT00286338|Fluid therapy
1426685|NCT00286338|Monitoring
1426686|NCT00286312|Acute myocardial infarction
1426687|NCT00286312|Primary angioplasty
1426688|NCT00286312|Reperfusion damage
1426689|NCT00286312|Atorvastatin
1426690|NCT00286312|Placebo
1426691|NCT00286312|Early left ventricular remodelling
1426692|NCT00286312|Late left ventricular remodelling
1426693|NCT00286312|Cardiac MRI
1426694|NCT00286312|Statin
1426695|NCT00286312|Transluminal, Percutaneous Coronary
1426696|NCT00286312|Angioplasty
1426697|NCT00286299|Schizophrenia
1426698|NCT00286299|Cardiovascular disease
1426699|NCT00286299|Aerobic capacity
1426700|NCT00286299|Mortality
1426701|NCT00286299|Exercise
1426702|NCT00286286|Laparoscopy
1426703|NCT00286286|Laparoscopic Surgical Procedures
1426704|NCT00286286|Laparoscopic Surgery
1426705|NCT00286286|Gastric Bypass
1426706|NCT00286286|Drug Delivery Systems
1426707|NCT00286286|Pain Measurement
1426708|NCT00286273|kidney failure, acute
1426709|NCT00286273|venovenous hemofiltration
1426710|NCT00286273|hemorrhage
1426711|NCT00286273|heparin, low-molecular-weight
1426712|NCT00286273|nadroparin
1426713|NCT00286273|citrates
1426714|NCT00286260|polyneuropathy
1426715|NCT00286260|neuropathic pain
1426716|NCT00286260|levetiracetam
1426717|NCT00286234|triglycerides
1426718|NCT00286234|HDL-cholesterol
1426719|NCT00286234|insulin resistance
1426720|NCT00286234|omega-3 fatty acids
1426721|NCT00286234|niacin
1426722|NCT00286208|Medical abortion
1426723|NCT00286208|mifepristone
1426724|NCT00286208|misoprostol
1426725|NCT00286182|Heart Failure
1426726|NCT00286182|Elderly
1426727|NCT00286182|Diastolic Dysfunction
1426728|NCT00286182|Anemia
1426729|NCT00286182|Ventricular End Diastolic Volume
1426730|NCT00286182|Aged
1426731|NCT00286169|Extensive-disease small-cell lung cancer (ED-SCLC)
1426732|NCT00286156|ADPKD
1426733|NCT00286130|metastatic colorectal cancer
1426734|NCT00286130|FOLFOX 6
1426735|NCT00286130|FOLFIRI
1426736|NCT00286117|Breast Cancer
1426737|NCT00286104|Ventriculitis
1426738|NCT00286104|External ventricular catheter
1426739|NCT00286104|Antibiotic-impregnated
1426740|NCT00286091|Hormone refractory prostate cancer
1426741|NCT00286091|androgen independent
1426742|NCT00286091|ADT
1426743|NCT00286091|bone metastasis
1426744|NCT00286078|Headache
1426745|NCT00286078|Migraine
1426746|NCT00286078|Refractory
1426747|NCT00286078|Chronic
1426748|NCT00286078|Pain
1426749|NCT00286065|Pain
1426750|NCT00286065|Fentanyl
1426751|NCT00286065|Analgesics
1426752|NCT00286065|Opioid
1426753|NCT00286065|Inhalation
1426754|NCT00286026|Chlamydia trachomatis
1426755|NCT00285246|combat disorders
1426756|NCT00285246|stress, psychological
1426757|NCT00285246|somatoform disorders
1426758|NCT00285246|life change events
1426759|NCT00285246|utilization
1426760|NCT00285207|Cervical Intraepithelial Neoplasia (CIN)
1426761|NCT00285207|High-grade Cervical Intraepithelial Neoplasia
1426762|NCT00285207|High-grade Squamous Intraepithelial Lesions (HSIL)
1426763|NCT00285207|Human Papilloma Virus (HPV)
1426764|NCT00285207|High-Grade Cervical Intraepithelial Lesions (CIN 2/3)
1426765|NCT00285181|persons
1426766|NCT00285168|Osteoporosis
1426767|NCT00285168|Fractures, Bone
1426768|NCT00285168|Bone Mineral Density
1426769|NCT00285155|bupropion
1426770|NCT00285155|repeated dose
1426771|NCT00285155|healthy volunteers
1426772|NCT00285155|cognitive function
1426773|NCT00285155|behaviour
1426774|NCT00285155|tolerance
1426775|NCT00285155|Persons
1426776|NCT00285142|rosiglitazone
1426777|NCT00285142|insulin secretion
1426778|NCT00285142|clinical trial
1426779|NCT00285142|healthy
1426780|NCT00285142|persons
1426781|NCT00282893|aneurysm
1426782|NCT00282893|vasospasm
1426783|NCT00282893|subarachnoid hemorrhage
1426784|NCT00282893|transluminal ballooning
1426785|NCT00282867|stroke
1426786|NCT00282867|acute ischemic stroke
1426787|NCT00282867|hyperglycemia
1426788|NCT00282867|glucose
1426789|NCT00282867|insulin
1426790|NCT00282867|insulin and potassium therapy
1426791|NCT00282867|GIK
1426792|NCT00282854|epilepsy
1426793|NCT00282854|Rolandic epilepsy
1426794|NCT00282841|stroke
1426795|NCT00282841|ultrasound
1426796|NCT00282841|occlusion
1426797|NCT00282841|blockage
1426798|NCT00282841|contrast solution
1426799|NCT00282828|Social Anxiety Disorder
1426800|NCT00282828|Pharmacotherapy
1426801|NCT00282828|Genetics
1426802|NCT00282828|Treatment Refractory
1426803|NCT00282815|obstructive sleep apnea
1426804|NCT00282815|stroke
1426805|NCT00282815|OSA
1426806|NCT00282815|CPAP
1426807|NCT00282815|continuous positive airway pressure
1426808|NCT00282802|Parkinson's Disease
1426809|NCT00282802|twins
1426810|NCT00282802|SPECT
1426811|NCT00282802|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort Registry
1426812|NCT00282802|NAS/NRC
1426813|NCT00282802|World War II Veteran Twins
1426814|NCT00281814|psychosocial effects of cancer and its treatment
1426815|NCT00281814|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1426816|NCT00281814|adult acute myeloid leukemia with inv(16)(p13;q22)
1426817|NCT00281814|adult acute myeloid leukemia with t(15;17)(q22;q12)
1426818|NCT00281814|adult acute myeloid leukemia with t(16;16)(p13;q22)
1426819|NCT00281814|adult acute myeloid leukemia with t(8;21)(q22;q22)
1426820|NCT00281814|accelerated phase chronic myelogenous leukemia
1426821|NCT00281814|adult acute lymphoblastic leukemia in remission
1426822|NCT00281814|adult acute myeloid leukemia in remission
1426823|NCT00281814|atypical chronic myeloid leukemia
1426824|NCT00281814|blastic phase chronic myelogenous leukemia
1426825|NCT00281814|chronic idiopathic myelofibrosis
1426826|NCT00281814|chronic myelomonocytic leukemia
1426827|NCT00281814|chronic phase chronic myelogenous leukemia
1426828|NCT00281814|de novo myelodysplastic syndromes
1426829|NCT00281814|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1426830|NCT00281814|myelodysplastic/myeloproliferative disease, unclassifiable
1426831|NCT00281814|nodal marginal zone B-cell lymphoma
1426832|NCT00281814|noncontiguous stage II adult Burkitt lymphoma
1426833|NCT00281814|noncontiguous stage II adult diffuse large cell lymphoma
1426834|NCT00281814|noncontiguous stage II adult diffuse mixed cell lymphoma
1426835|NCT00281814|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1426836|NCT00281814|noncontiguous stage II adult immunoblastic large cell lymphoma
1426837|NCT00281814|noncontiguous stage II adult lymphoblastic lymphoma
1426838|NCT00281814|noncontiguous stage II grade 1 follicular lymphoma
1426839|NCT00281814|noncontiguous stage II grade 2 follicular lymphoma
1426840|NCT00281814|noncontiguous stage II grade 3 follicular lymphoma
1426841|NCT00281814|noncontiguous stage II mantle cell lymphoma
1426842|NCT00281814|noncontiguous stage II marginal zone lymphoma
1426843|NCT00281814|noncontiguous stage II small lymphocytic lymphoma
1426844|NCT00281814|previously treated myelodysplastic syndromes
1426845|NCT00281814|recurrent adult acute lymphoblastic leukemia
1426846|NCT00281814|recurrent adult acute myeloid leukemia
1426847|NCT00281814|recurrent adult Burkitt lymphoma
1426848|NCT00281814|recurrent adult Hodgkin lymphoma
1426849|NCT00281814|recurrent adult diffuse large cell lymphoma
1426850|NCT00281814|recurrent adult diffuse mixed cell lymphoma
1426851|NCT00281814|recurrent adult diffuse small cleaved cell lymphoma
1426852|NCT00281814|recurrent adult immunoblastic large cell lymphoma
1426853|NCT00281814|recurrent adult lymphoblastic lymphoma
1426854|NCT00281814|recurrent cutaneous T-cell non-Hodgkin lymphoma
1426855|NCT00281814|recurrent grade 1 follicular lymphoma
1426856|NCT00281814|recurrent grade 2 follicular lymphoma
1427058|NCT00285558|body mass index
1426857|NCT00281814|recurrent grade 3 follicular lymphoma
1426858|NCT00281814|recurrent mantle cell lymphoma
1426859|NCT00281814|recurrent marginal zone lymphoma
1426860|NCT00281814|recurrent small lymphocytic lymphoma
1426861|NCT00281814|refractory chronic lymphocytic leukemia
1426862|NCT00281814|refractory hairy cell leukemia
1426863|NCT00281814|relapsing chronic myelogenous leukemia
1426864|NCT00281814|secondary acute myeloid leukemia
1426865|NCT00281814|secondary myelodysplastic syndromes
1426866|NCT00281814|splenic marginal zone lymphoma
1426867|NCT00281814|stage I multiple myeloma
1426868|NCT00281814|stage II multiple myeloma
1426869|NCT00281814|stage III adult Burkitt lymphoma
1426870|NCT00281814|stage III adult Hodgkin lymphoma
1426871|NCT00281814|stage III adult diffuse large cell lymphoma
1426872|NCT00281814|stage III adult diffuse mixed cell lymphoma
1426873|NCT00281814|stage III adult diffuse small cleaved cell lymphoma
1426874|NCT00281814|stage III adult immunoblastic large cell lymphoma
1426875|NCT00281814|stage III adult lymphoblastic lymphoma
1426876|NCT00281814|stage III chronic lymphocytic leukemia
1426877|NCT00281814|stage III grade 1 follicular lymphoma
1426878|NCT00281814|stage III grade 2 follicular lymphoma
1426879|NCT00281814|stage III grade 3 follicular lymphoma
1426880|NCT00281814|stage III mantle cell lymphoma
1426881|NCT00281814|stage III marginal zone lymphoma
1426882|NCT00281814|stage III multiple myeloma
1426883|NCT00281814|stage III small lymphocytic lymphoma
1426884|NCT00281814|stage IV adult Burkitt lymphoma
1426885|NCT00281814|stage IV adult Hodgkin lymphoma
1426886|NCT00281814|stage IV adult diffuse large cell lymphoma
1426887|NCT00281814|stage IV adult diffuse mixed cell lymphoma
1426888|NCT00281814|stage IV adult diffuse small cleaved cell lymphoma
1426889|NCT00281814|stage IV adult immunoblastic large cell lymphoma
1426890|NCT00281814|stage IV adult lymphoblastic lymphoma
1426891|NCT00281814|stage IV chronic lymphocytic leukemia
1426892|NCT00281814|stage IV grade 1 follicular lymphoma
1426893|NCT00281814|stage IV grade 2 follicular lymphoma
1426894|NCT00281814|stage IV grade 3 follicular lymphoma
1426895|NCT00281814|stage IV mantle cell lymphoma
1426896|NCT00281814|stage IV marginal zone lymphoma
1426897|NCT00281814|stage IV small lymphocytic lymphoma
1426898|NCT00281801|psychosocial effects of cancer and its treatment
1426899|NCT00281801|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1426900|NCT00281801|adult acute myeloid leukemia with inv(16)(p13;q22)
1426901|NCT00281801|adult acute myeloid leukemia with t(15;17)(q22;q12)
1426902|NCT00281801|adult acute myeloid leukemia with t(16;16)(p13;q22)
1426903|NCT00281801|adult acute myeloid leukemia with t(8;21)(q22;q22)
1426904|NCT00281801|accelerated phase chronic myelogenous leukemia
1426905|NCT00281801|adult acute lymphoblastic leukemia in remission
1426906|NCT00281801|adult acute myeloid leukemia in remission
1426907|NCT00281801|atypical chronic myeloid leukemia
1426908|NCT00281801|blastic phase chronic myelogenous leukemia
1426909|NCT00281801|chronic idiopathic myelofibrosis
1426910|NCT00281801|chronic myelomonocytic leukemia
1426911|NCT00281801|chronic phase chronic myelogenous leukemia
1426912|NCT00281801|de novo myelodysplastic syndromes
1426913|NCT00281801|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1426914|NCT00281801|myelodysplastic/myeloproliferative disease, unclassifiable
1426915|NCT00281801|nodal marginal zone B-cell lymphoma
1426916|NCT00281801|noncontiguous stage II adult Burkitt lymphoma
1426917|NCT00281801|noncontiguous stage II adult diffuse large cell lymphoma
1426918|NCT00281801|noncontiguous stage II adult diffuse mixed cell lymphoma
1426919|NCT00281801|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1426920|NCT00281801|noncontiguous stage II adult immunoblastic large cell lymphoma
1426921|NCT00281801|noncontiguous stage II adult lymphoblastic lymphoma
1426922|NCT00281801|noncontiguous stage II grade 1 follicular lymphoma
1426923|NCT00281801|noncontiguous stage II grade 2 follicular lymphoma
1426924|NCT00281801|noncontiguous stage II grade 3 follicular lymphoma
1426925|NCT00281801|noncontiguous stage II mantle cell lymphoma
1426926|NCT00281801|noncontiguous stage II marginal zone lymphoma
1426927|NCT00281801|noncontiguous stage II small lymphocytic lymphoma
1426928|NCT00281801|previously treated myelodysplastic syndromes
1426929|NCT00281801|recurrent adult acute lymphoblastic leukemia
1426930|NCT00281801|recurrent adult acute myeloid leukemia
1426931|NCT00281801|recurrent adult Burkitt lymphoma
1426932|NCT00281801|recurrent adult Hodgkin lymphoma
1426933|NCT00281801|recurrent adult diffuse large cell lymphoma
1426934|NCT00281801|recurrent adult diffuse mixed cell lymphoma
1426935|NCT00281801|recurrent adult diffuse small cleaved cell lymphoma
1426936|NCT00281801|recurrent adult immunoblastic large cell lymphoma
1426937|NCT00281801|recurrent adult lymphoblastic lymphoma
1426938|NCT00281801|recurrent cutaneous T-cell non-Hodgkin lymphoma
1426939|NCT00281801|recurrent grade 1 follicular lymphoma
1426940|NCT00281801|recurrent grade 2 follicular lymphoma
1426941|NCT00281801|recurrent grade 3 follicular lymphoma
1426942|NCT00281801|recurrent mantle cell lymphoma
1426943|NCT00281801|recurrent marginal zone lymphoma
1426944|NCT00281801|recurrent small lymphocytic lymphoma
1426945|NCT00281801|refractory chronic lymphocytic leukemia
1426946|NCT00281801|refractory hairy cell leukemia
1426947|NCT00281801|relapsing chronic myelogenous leukemia
1426948|NCT00281801|secondary acute myeloid leukemia
1426949|NCT00281801|secondary myelodysplastic syndromes
1426950|NCT00281801|splenic marginal zone lymphoma
1426951|NCT00281801|stage I multiple myeloma
1426952|NCT00281801|stage II multiple myeloma
1426953|NCT00281801|stage III adult Burkitt lymphoma
1426954|NCT00281801|stage III adult Hodgkin lymphoma
1426955|NCT00281801|stage III adult diffuse large cell lymphoma
1426956|NCT00281801|stage III adult diffuse mixed cell lymphoma
1426957|NCT00281801|stage III adult diffuse small cleaved cell lymphoma
1426958|NCT00281801|stage III adult immunoblastic large cell lymphoma
1426959|NCT00281801|stage III adult lymphoblastic lymphoma
1426960|NCT00281801|stage III chronic lymphocytic leukemia
1426961|NCT00281801|stage III grade 1 follicular lymphoma
1426962|NCT00281801|stage III grade 2 follicular lymphoma
1426963|NCT00281801|stage III grade 3 follicular lymphoma
1426964|NCT00281801|stage III mantle cell lymphoma
1426965|NCT00281801|stage III marginal zone lymphoma
1426966|NCT00281801|stage III multiple myeloma
1426967|NCT00281801|stage III small lymphocytic lymphoma
1426968|NCT00281801|stage IV adult Burkitt lymphoma
1426969|NCT00281801|stage IV adult Hodgkin lymphoma
1426970|NCT00281801|stage IV adult diffuse large cell lymphoma
1426971|NCT00281801|stage IV adult diffuse mixed cell lymphoma
1426972|NCT00281801|stage IV adult diffuse small cleaved cell lymphoma
1426973|NCT00281801|stage IV adult immunoblastic large cell lymphoma
1426974|NCT00281801|stage IV adult lymphoblastic lymphoma
1426975|NCT00281801|stage IV chronic lymphocytic leukemia
1426976|NCT00281801|stage IV grade 1 follicular lymphoma
1426977|NCT00281801|stage IV grade 2 follicular lymphoma
1426978|NCT00281801|stage IV grade 3 follicular lymphoma
1426979|NCT00281801|stage IV mantle cell lymphoma
1426980|NCT00281801|stage IV marginal zone lymphoma
1426981|NCT00281801|stage IV small lymphocytic lymphoma
1426982|NCT00281788|stage I esophageal cancer
1426983|NCT00281788|stage II esophageal cancer
1426984|NCT00281788|stage III esophageal cancer
1426985|NCT00285961|Fractures of the wrist, forearm, elbow, ankle, foot
1426986|NCT00285961|Distortions of the wrist, elbow, ankle
1426987|NCT00285961|Wounds without tendon injuries
1426988|NCT00285935|Major Depressive Disorder
1426989|NCT00285935|MDD
1426990|NCT00285935|Neurobiology
1426991|NCT00285935|Selective Serotonin Reuptake Inhibitor
1426992|NCT00285935|SSRI
1426993|NCT00285935|Depression
1426994|NCT00285922|myocardial infarction
1426995|NCT00285922|electrocardiography
1426996|NCT00285922|myocardial ischemia
1426997|NCT00285922|emergency medicine
1426998|NCT00285922|monitoring, physiologic
1426999|NCT00285909|Moderate alcohol consumption
1427000|NCT00285909|Alcohol dehydrogenase 1c polymorphism
1427001|NCT00285909|PPAR-gamma activated gene expression
1427002|NCT00285896|GLP-1
1427003|NCT00285896|fasting
1427004|NCT00285896|hypoglycaemia
1427005|NCT00285883|Invirase
1427006|NCT00285883|HIV
1427007|NCT00285883|DOT
1427008|NCT00285883|Treatment Experienced
1427009|NCT00285857|duct cytology
1427010|NCT00285844|obesity
1427011|NCT00285844|insulin resistance
1427012|NCT00285844|thiazolidinedione
1427013|NCT00285844|weight loss
1427014|NCT00285844|adipose tissue
1427015|NCT00285844|metabolic syndrome
1427016|NCT00285844|diabetes prevention
1427017|NCT00285844|cardiovascular disease prevention
1427018|NCT00285805|Rosiglitazone
1427019|NCT00285805|Furosemide
1427020|NCT00285805|Amiloride
1427021|NCT00285805|Epithelial sodium channel
1427022|NCT00285805|Sodium excretion
1427023|NCT00285792|Preschool, Physical Activity
1427024|NCT00285766|Depression
1427025|NCT00285753|psychosocial intervention
1427026|NCT00285753|mild cognitive impairment
1427027|NCT00285753|support group
1427028|NCT00285753|caregivers
1427029|NCT00285753|Mild Cognitive Impairment (MCI)
1427030|NCT00285753|Cognitive Impairment No Dementia (CIND)
1427031|NCT00285714|3D computer assisted imaging
1427032|NCT00285714|maxillofacial surgery
1427033|NCT00285714|cephalometry
1427034|NCT00285714|normative value
1427035|NCT00285688|H. Pylori, Clarithromycin resistant, gene
1427036|NCT00285675|Calcitriol, DN-101, Androgen Independent Prostate Cancer (AIPC), Prostate Cancer, Non Small Cell Lung Cancer (NSCLC)
1427037|NCT00285662|IPTi
1427038|NCT00285662|Malaria
1427039|NCT00285662|Anemia
1427040|NCT00285662|Prevention
1427041|NCT00285662|Infant
1427042|NCT00285662|Artesunate
1427043|NCT00285662|SP
1427044|NCT00285662|Amodiaquine
1427045|NCT00285662|Papua New Guinea
1427046|NCT00285649|Spinal Manipulation
1427047|NCT00285636|Long Term Follow-Up
1427048|NCT00285623|Collection of all thromboembolic events,
1427049|NCT00285623|immunological events and drug interactions leading to thromboembolic events or major
1427050|NCT00285623|bleeding after exposure to TachoSil®.
1427051|NCT00285584|HIV infection
1427052|NCT00285584|Depression
1427053|NCT00285584|Men who have sex with men
1427054|NCT00285584|Drug abuse
1427055|NCT00285558|obesity
1427056|NCT00285558|adolescent
1427057|NCT00285558|weight loss
1427059|NCT00285558|evaluation studies
1427060|NCT00285558|peer group
1427061|NCT00285558|behavior therapy
1427062|NCT00285558|diet
1427063|NCT00285558|exercise
1427064|NCT00285558|self efficacy
1427065|NCT00285558|parents
1427066|NCT00285545|Blood Supply
1427067|NCT00285545|Mesentery
1427068|NCT00285532|Blood Lead
1427069|NCT00285532|Pesticides
1427070|NCT00285532|Community-based
1427071|NCT00285532|Sampling Kits
1427072|NCT00285519|Morning hypertension
1427073|NCT00285506|Healthy Volunteers
1427074|NCT00285493|low back pain
1427075|NCT00285467|kidney, parathyroid hormone, vitamin d
1427076|NCT00285441|HIV
1427077|NCT00285428|treatment
1427078|NCT00285428|NHL
1427079|NCT00285428|CD20+ B-cell NHL
1427080|NCT00285428|Lymphoma
1427081|NCT00285415|Advanced endometrial adenocarcinoma, stage III A, B, C
1427082|NCT00285402|Migraine
1427083|NCT00285402|Migraine prophylaxis
1427084|NCT00285402|Migraine prevention
1427085|NCT00285402|Chronic migraine treatment
1427086|NCT00285389|Mantle cell lymphoma
1427087|NCT00285389|Chemotherapy
1427088|NCT00285389|Autologous PBSCT
1427089|NCT00285389|Molecular evaluation
1427090|NCT00285376|Depression. Genetics, Pharmacogenetics
1427091|NCT00285363|cancer
1427092|NCT00285363|quality of life
1427093|NCT00285363|adolescents
1427094|NCT00285350|myasthenia gravis
1427095|NCT00285337|Myelopathy
1427096|NCT00285337|Laminectomy
1427097|NCT00285337|Laminoplasty
1427098|NCT00285337|Decompression of Spinal Cord
1427099|NCT00285337|Cervical Spondylosis
1427100|NCT00285324|Glioma
1427101|NCT00285324|Glioblastoma Multiforme
1427102|NCT00285324|Brain Cancer
1427103|NCT00285324|Diffusion-Weighted Magnetic Resonance Imaging
1427104|NCT00285324|Brain Tumor
1427105|NCT00285298|proteinuria
1427106|NCT00285298|Kidney failure, chronic
1427107|NCT00285285|Point-of-care Testing
1427108|NCT00285285|Pediatric Emergency Department
1427109|NCT00285285|Length of Stay
1427110|NCT00285285|Efficiency
1427111|NCT00285259|cytomegalovirus infection
1427112|NCT00285259|infectious disease
1427113|NCT00285259|viremia
1427114|NCT00285259|cytomegalovirus disease
1427115|NCT00285259|stem cell transplant
1427116|NCT00285259|allogeneic
1427117|NCT00285259|bone marrow transplant
1427118|NCT00285259|hematopoietic cell transplant
1427119|NCT00285259|Acute Lymphoblastic Leukemia
1427120|NCT00285259|Chronic Myelogenous Leukemia
1427121|NCT00285259|Acute Myelogenous Leukemia
1427122|NCT00285259|Hodgkin's Lymphoma
1427123|NCT00285259|Non-Hodgkin's Lymphoma
1427124|NCT00285259|Myelodysplastic Syndrome
1427125|NCT00285103|Antisense, mRNA antagonist, Bcl-2, CLL
1427126|NCT00285090|Burn Injury
1427127|NCT00285090|Calcium
1427128|NCT00285090|Vitamin D
1427129|NCT00285090|Bone Mineral Density
1427130|NCT00285077|Alzheimer disease
1427131|NCT00285077|nerve growth factors
1427132|NCT00285077|Clinical Trial
1427133|NCT00285064|MDCT
1427134|NCT00285064|viability
1427135|NCT00285051|emesis, nausea,
1427136|NCT00285038|Deep vein thrombosis
1427137|NCT00285038|Gynecological cancer
1427138|NCT00285025|Alzheimer disease
1427139|NCT00285025|nerve growth factors
1427140|NCT00285025|Clinical Trial
1427141|NCT00285012|smoking cessation
1427142|NCT00285012|smoking cessation in COPD
1427143|NCT00284986|GVHD
1427144|NCT00284986|Graft vs Host Disease
1427145|NCT00284986|Graft versus Host Disease
1427146|NCT00284973|malaria
1427147|NCT00284960|erectile dysfunction
1427148|NCT00284960|metabolic syndrome
1427149|NCT00284960|insulin resistance
1427150|NCT00284960|etiology
1427151|NCT00284947|Side effects
1427152|NCT00284947|calcineurin inhibitors
1427153|NCT00284947|maintenance
1427154|NCT00284947|basiliximab
1427155|NCT00284947|Kidney maintenance transplant
1427156|NCT00284934|Dose optimization
1427157|NCT00284934|immune suppressive regimen
1427158|NCT00284934|enteric-coated mycophenolate sodium
1427159|NCT00284934|EC-MPS
1427160|NCT00284934|renal transplantation
1427161|NCT00284934|kidney
1427162|NCT00284934|transplant
1427163|NCT00284934|maintenance patients
1427164|NCT00284934|Renal transplantation in maintenance
1427165|NCT00284921|kidney transplant, hepatitis C, enteric-coated mycophenolate sodium
1427166|NCT00284908|S-Tenatoprazole-Na
1427167|NCT00284908|Pharmacokinetic
1427168|NCT00284908|intragastric pH recording
1427169|NCT00284908|dose-response
1427170|NCT00284895|Obesity
1427171|NCT00284895|Bariatric Surgery
1427172|NCT00284895|Weight Loss Surgery
1427173|NCT00284895|Asthma
1427174|NCT00284882|Streptococcus, Fiji, pyoderma, pharyngitis, scabies
1427175|NCT00284869|LPS
1427176|NCT00284869|ethnicity
1427177|NCT00284869|neutrophils
1427178|NCT00284869|TNF
1427179|NCT00284843|Streptococcus, Fiji, pyoderma, scabies, rheumatic disease
1427180|NCT00284830|Right Ventricular Pacing
1427181|NCT00284830|Persistent Atrial Fibrillation
1427182|NCT00284830|Atrioventricular Conduction
1427183|NCT00284830|Heart Failure Hospitalization
1427184|NCT00284830|Cardiovascular Health Care Utilization
1427185|NCT00284830|Sinus-node Disease
1427186|NCT00284830|Minimized Ventricular Pacing
1427187|NCT00284804|relapsed or refractory Hodgkin's Disease
1427188|NCT00284778|lung cancer
1427189|NCT00284778|second line treatment
1427190|NCT00284778|cost-minimization trial
1427191|NCT00284778|Pharmaco-economic study
1427192|NCT00284778|docetaxel
1427193|NCT00284778|pemetrexed
1427194|NCT00284752|Prostate
1427195|NCT00284752|Cancer
1427196|NCT00284752|Metastatic
1427197|NCT00283309|Corticosteroids
1427198|NCT00283309|Riluzole
1427199|NCT00283309|Memantine
1427200|NCT00283309|Memory
1427201|NCT00283296|manual wheelchair
1427202|NCT00283296|assistive technology
1427203|NCT00283296|travel wheelchair
1427204|NCT00283283|Influenza
1427205|NCT00283270|Mental health
1427206|NCT00283270|Screening
1427207|NCT00283270|Elderly
1427208|NCT00283270|Chinese
1427209|NCT00283270|Problem-solving counselling
1427212|NCT00283244|stage IIIB non-small cell lung cancer
1427213|NCT00283244|stage IV non-small cell lung cancer
1427214|NCT00283231|Hot Flashes
1427215|NCT00283231|Menopausal Symptoms
1427216|NCT00283231|Paced respiration
1427217|NCT00283231|RESPeRATE
1427218|NCT00283205|Menopausal Symptoms
1427219|NCT00283205|Hot Flashes
1427220|NCT00283205|Yoga
1427221|NCT00283192|Menopausal Symptoms
1427222|NCT00283192|Hot flashes
1427223|NCT00283179|Aripiprazole
1427224|NCT00283179|Risperidone
1427225|NCT00283179|Schizophrenia
1427226|NCT00283179|Schizoaffective disorder
1427227|NCT00283166|Palliative Care
1427228|NCT00283153|Traumatic Brain Injury
1427229|NCT00283153|Stroke
1427230|NCT00283153|Emotion Recognition
1427231|NCT00283153|Affect
1427232|NCT00283153|Interventions
1427233|NCT00283127|Chlamydia trachomatis
1427234|NCT00283127|Mass screening
1427235|NCT00283127|Home sampling
1427236|NCT00283127|Urine test
1427237|NCT00283114|Lintuzumab
1427238|NCT00283114|Antigens, CD33
1427239|NCT00283114|Antibodies, Monoclonal
1427240|NCT00283114|Leukemia, Myeloid, Acute
1427241|NCT00283114|Myelodysplastic Syndromes
1427242|NCT00283114|Hematologic Diseases
1427243|NCT00283114|Myeloproliferative Disorders
1427244|NCT00283114|Leukemia
1427245|NCT00283101|Antigens, CD40
1427246|NCT00283101|Antibody, Monoclonal
1427247|NCT00283101|Leukemia, Lymphocytic, Chronic, B-Cell
1427248|NCT00283101|Hematologic Diseases
1427249|NCT00283101|Immunoproliferatic Disorders
1427250|NCT00283101|Lymphatic Diseases
1427251|NCT00283101|Lymphoproliferative Disorders
1427252|NCT00283101|Leukemia
1427253|NCT00283088|stroke
1427254|NCT00283088|hypothermia
1427255|NCT00283088|cooling
1427256|NCT00283088|tissue plasminogen activator
1427257|NCT00283088|tPA
1427258|NCT00283088|thrombolysis
1427259|NCT00283075|intraabdominal cancer (carcinomas)
1427260|NCT00283075|agarose macrobeads
1427261|NCT00283075|mouse kidney cancer cells
1427262|NCT00283075|cancer cell growth inhibition
1427263|NCT00283023|All selective craniotomy
1427264|NCT00284726|Cytokines in lung transplantation
1427265|NCT00284726|Cold storage solutions
1427266|NCT00284726|Ischemic reperfusion injury
1427267|NCT00284700|Helicobacter pylori
1427268|NCT00284700|Iron deficiency anemia
1427269|NCT00284700|children
1427270|NCT00284687|bone marrow transplantation
1427271|NCT00284687|CMV disease
1427272|NCT00284661|Meniscal repair
1427273|NCT00284661|Meniscal suturing
1427274|NCT00284661|Meniscal tear
1427275|NCT00284648|Achilles tendon
1427276|NCT00284648|Rupture
1427277|NCT00284648|Non-operative
1427278|NCT00284648|Operative
1427279|NCT00284622|HTO
1427280|NCT00284622|Arthroscopy
1427281|NCT00284622|Osteoarthritis
1427282|NCT00284622|Alignement
1427283|NCT00284622|Varus gonarthrosis
1427284|NCT00284609|Type 2 diabetes,
1427285|NCT00284609|rehabilitation,
1427286|NCT00284609|quality of life,
1427287|NCT00284609|glycaemic control,
1427288|NCT00284609|lifestyle intervention,
1427289|NCT00284609|patient education,
1427290|NCT00284609|physical training,
1427291|NCT00284609|group visits,
1427292|NCT00284609|reminders
1427293|NCT00284596|Opening wedge high tibial osteotomy
1427294|NCT00284596|Radio Sterometric Analysis
1427295|NCT00284596|Locking screw fixation
1427296|NCT00284583|Morton's Neuroma
1427297|NCT00284583|Alcohol
1427298|NCT00284583|Steroid
1427299|NCT00284570|pediatrics
1427300|NCT00284570|congenital heart disease
1427301|NCT00284570|cardiac
1427302|NCT00284570|cardiopulmonary bypass
1427303|NCT00284570|infection
1427304|NCT00284570|sepsis
1427305|NCT00284570|postoperative
1427306|NCT00284570|marker for infection
1427307|NCT00284570|inflammation
1427308|NCT00284570|cardiac surgery
1427309|NCT00284557|Behavioral/Social
1427310|NCT00284557|Obesity
1427311|NCT00284557|Pediatrics
1427312|NCT00284557|Preventive Medicine
1427313|NCT00284531|cardiac transplantation
1427314|NCT00284531|allograft rejection
1427315|NCT00284531|anti-CD25
1427316|NCT00284505|cytokine
1427317|NCT00284505|arachnoiditis
1427318|NCT00284505|neuropathic pain
1427319|NCT00284505|tumor necrosis factor
1427320|NCT00284492|Women
1427321|NCT00284492|Acupuncture
1427322|NCT00284492|Menopause
1427323|NCT00284492|Hot flashes
1427324|NCT00284492|Health related quality of life
1427325|NCT00284479|walking intervention
1427326|NCT00284479|cardiovascular risk
1427327|NCT00284479|inflammatory markers
1427328|NCT00284479|aerobic fitness
1427329|NCT00284479|fatness
1427330|NCT00284466|coronary artery disease
1427331|NCT00284466|cardiac catheterization
1427332|NCT00284466|CT coronary angiography
1427333|NCT00284466|coronary angiography
1427334|NCT00284453|ventricular
1427335|NCT00284453|arrhythmias
1427336|NCT00284453|ICD
1427337|NCT00284453|VT storm
1427338|NCT00284453|ICD patients with VT storm
1427339|NCT00284440|Visual field progression
1427340|NCT00284440|Choroidal blood flow
1427341|NCT00283010|cognitive enhancement
1427342|NCT00283010|memory
1427343|NCT00283010|auditory memory
1427344|NCT00283010|speech
1427345|NCT00283010|computerized
1427346|NCT00283010|cognitive decline
1427347|NCT00282971|Type 2 diabetes melllitus
1427348|NCT00284401|Reversed prosthesis
1427349|NCT00284336|breast cancer
1427350|NCT00284336|elderly
1427351|NCT00284336|adjuvant chemotherapy
1427352|NCT00284336|Caelyx
1427353|NCT00284323|Acute Myocardial Infarction
1427354|NCT00284323|PCI
1427355|NCT00284323|Adenosine
1427356|NCT00284323|Postconditioning
1427357|NCT00284310|Wrist surgery: 4-corner arthrodesis or proximal row carpectomy
1427358|NCT00284271|Hodgkin´s Lymphoma
1427359|NCT00284271|eldery patients
1427360|NCT00284271|primary diagnosis
1427361|NCT00284258|Colorectal Cancer
1427362|NCT00284245|Chronic Pain
1427363|NCT00284245|Pain
1427364|NCT00284245|Computer Analysis
1427365|NCT00284245|Pain Diagrams
1427366|NCT00284232|HbA1c
1427367|NCT00284232|Self-monitoring blood glucose (SMBG)
1427368|NCT00284232|Diabetes treatment
1427369|NCT00284232|quality of care
1427370|NCT00284219|rTMS, smoking, dopamine, acotinine
1427371|NCT00284206|methamphetamine, cognition, outpatient, risperidone
1427372|NCT00284180|Breast Neoplasms
1427373|NCT00284180|Breast Cancer
1427374|NCT00284180|Vinflunine
1427375|NCT00284180|Vinca Alkaloid
1427376|NCT00284180|Javlor
1427377|NCT00284167|tailored
1427378|NCT00284167|web-based
1427379|NCT00284167|weight management
1427380|NCT00284167|obesity
1427381|NCT00284167|efficacy
1427382|NCT00284154|Extensive stage
1427383|NCT00284154|Relapsed
1427384|NCT00284141|lung
1427385|NCT00284141|cancer
1427386|NCT00284141|non-small-cell lung cancer
1427387|NCT00284141|metastatic
1427388|NCT00284141|carcinoma
1427389|NCT00284141|lung neoplasm
1427390|NCT00284141|lung diseases
1427391|NCT00284141|angiogenesis
1427392|NCT00284141|anti-angiogenesis
1427393|NCT00284141|anti-angiogenesis inhibitors
1427394|NCT00284141|cancer and other neoplasms
1427395|NCT00284141|respiratory tract
1427396|NCT00284141|(lung and bronchial) diseases
1427397|NCT00284128|Cardiovascular Disease C14
1427398|NCT00284128|vascular disease C14.907
1427399|NCT00284128|hypertension C14.907.489
1427400|NCT00284115|Gait trainer
1427401|NCT00284115|Hemiplegia
1427402|NCT00284115|Rehabilitation
1427403|NCT00284115|Stroke
1427404|NCT00284102|gas exchange
1427405|NCT00284102|dead space
1427406|NCT00284102|respiratory failure
1427407|NCT00284102|ALI/ARDS patients
1427408|NCT00284089|Subfoveal CNV, AMD, ranibizumab
1427409|NCT00284063|spinal manipulation, zygapophysial joints
1427410|NCT00284050|DME
1427411|NCT00284050|Diabetic macular edema
1427412|NCT00284050|ranibizumab
1427413|NCT00284050|Diabetic macular edema with center involvement
1427414|NCT00284037|obstructive sleep apnea,
1427415|NCT00284037|baroreceptors
1427416|NCT00284024|breastfeeding
1427417|NCT00284024|domperidone
1427418|NCT00284024|efficacy
1427419|NCT00284024|randomized controlled trial
1427420|NCT00284024|compliance
1427421|NCT00284011|SAMe
1427422|NCT00284011|AdoMet
1427423|NCT00284011|Methylation
1427424|NCT00284011|Homocysteine
1427425|NCT00284011|Dietary Supplement
1427426|NCT00284011|S-Adenosyl-L-Methionine
1427427|NCT00283998|Odontoid
1427428|NCT00283998|Type II fractures
1427429|NCT00283998|Elderly patients
1427430|NCT00283998|Surgical vs. conservative treatment
1427431|NCT00283985|NK/T-cell lymphoma
1427432|NCT00283985|Lymphoma
1427433|NCT00283985|L-asparaginase
1427434|NCT00283985|Nasal NK-cell lymphoma
1427435|NCT00283985|Nasal-type NK-cell Lymphoma
1427436|NCT00283972|Health Outcome Study
1427437|NCT00283946|zolpidem
1427438|NCT00283946|sleep initiation and maintenance disorders Hypnotics and sedatives
1427439|NCT00283946|double-blind study
1427440|NCT00283946|comparative study
1427441|NCT00283920|Pharmacokinetics
1427442|NCT00283920|Compartmental Analysis
1427443|NCT00283920|Distribution Volume
1427444|NCT00283920|Identitiability
1427445|NCT00283920|Healthy Volunteer
1427446|NCT00283920|HV
1427447|NCT00283907|Electroencephalogram (EEG)
1427448|NCT00283907|Sense of Agency
1427449|NCT00283907|Coherence
1427450|NCT00283907|Voluntary Movement
1427451|NCT00283907|Self-Agency
1427452|NCT00283907|Healthy Volunteer
1427453|NCT00283907|HV
1427454|NCT00283894|Obesity
1427455|NCT00283894|Leptin
1427456|NCT00283894|Sleep Attacks
1427457|NCT00283894|Energy Metabolism
1427458|NCT00283894|Healthy Control
1427459|NCT00283894|Narcolepsy
1427460|NCT00283894|Healthy Volunteer
1427461|NCT00283894|HV
1427462|NCT00283881|Haptic Skills
1427463|NCT00283881|Implicit Tactile Learning
1427464|NCT00283881|Functional Magnetic Resonance Imaging (fMRI)
1427465|NCT00283881|Transcranial Magnetic Stimulation (TMS)
1427466|NCT00283881|Transcranial Direct Current Stimulation (tDCS)
1427467|NCT00283881|Stroke
1427468|NCT00283881|Healthy Volunteer
1427469|NCT00283881|HV
1427470|NCT00283868|stroke
1427471|NCT00283868|digital video
1427472|NCT00283868|SPOTRIAS
1427473|NCT00283855|Rheumatoid Arthritis
1427474|NCT00283855|Self-Management
1427475|NCT00283855|Internet
1427476|NCT00283842|neuropathic pain
1427477|NCT00283842|diabetic peripheral neuropathy
1427478|NCT00283829|Immunotherapy
1427479|NCT00283816|Polycystic Ovary Syndrome
1427480|NCT00283816|Overweight Adolescent Girls
1427481|NCT00283816|Irregular Menstrual Cycles
1427482|NCT00283777|insulin
1427483|NCT00283777|glucose
1427484|NCT00283777|body weight
1427485|NCT00283777|chromium
1427486|NCT00283738|migraine
1427487|NCT00283738|aura
1427488|NCT00283738|Patent Foramen Ovale (PFO)
1427489|NCT00283738|cardiac defects
1427490|NCT00283738|Heart Septal Defects, Atrial
1427491|NCT00283738|Cephalalgia
1427492|NCT00283725|Dementia
1427493|NCT00283725|Alzheimer's Disease
1427494|NCT00283725|Acetylcholinesterase inhibitor
1427495|NCT00283725|Galantamine
1427496|NCT00283725|Nursing Home Admission
1427497|NCT00283712|Skin Diseases
1427498|NCT00283712|Autoimmune Diseases
1427499|NCT00283699|neurocysticercosis
1427500|NCT00283699|albendazole
1427501|NCT00283699|tape worm
1427502|NCT00283686|polycystic kidney disease
1427503|NCT00283686|polycystic
1427504|NCT00283686|kidney
1427505|NCT00283686|disease
1427506|NCT00283686|adpkd
1427507|NCT00283686|halt
1427508|NCT00283686|pkd
1427509|NCT00283686|blood pressure
1427510|NCT00283686|bp
1427511|NCT00283686|hypertension
1427512|NCT00283686|renal
1427513|NCT00283686|renin-angiotensin-aldosterone-system
1427514|NCT00283686|RAAS
1427515|NCT00283660|Zinc
1427516|NCT00283660|Dietary Supplements
1427517|NCT00283660|Nutritional Supplements
1427518|NCT00283660|Child
1427519|NCT00283660|Mental Health
1427520|NCT00283660|School
1427521|NCT00283660|Guatemala
1427522|NCT00283647|lead exposure
1427523|NCT00283647|magnetic resonance imaging
1427524|NCT00283647|magnetic resonance spectroscopy
1427525|NCT00283647|functional magnetic resonance
1427526|NCT00283647|brain development
1427527|NCT00283621|Aranesp
1427528|NCT00283621|Darbepoetin Alfa
1427529|NCT00283621|Pegfilgrastim
1427530|NCT00283621|Neulasta
1427531|NCT00283621|Sarcoma
1427532|NCT00283621|Adriamycin
1427533|NCT00283621|Doxorubicin Hydrocholoride
1427534|NCT00283621|Adriamycin PFS
1427535|NCT00283621|Adriamycin RDF
1427536|NCT00283621|Ifosfamide
1427537|NCT00283608|stage I breast cancer
1427538|NCT00283608|stage II breast cancer
1427539|NCT00283608|stage IIIA breast cancer
1427540|NCT00283608|stage IIIB breast cancer
1427541|NCT00283608|stage IIIC breast cancer
1427542|NCT00283595|Anorexia Nervosa
1427543|NCT00283595|Eating disorder
1427544|NCT00283595|Bone
1427545|NCT00283595|Growth hormone
1427546|NCT00283595|Osteopenia
1427547|NCT00283595|Osteoporosis
1427548|NCT00283569|Glioma
1427549|NCT00283556|High Dose Irinotecan
1427550|NCT00283556|CPT-11
1427551|NCT00283556|Camptosar
1427552|NCT00283556|Malignant Glioma
1427553|NCT00283556|Unresectable
1427554|NCT00283543|Glioma
1427555|NCT00283543|Gliadel Wafer
1427556|NCT00283530|Cancer
1427557|NCT00283530|Cancer receiving chemotherapy
1427558|NCT00283530|Tumor biopsy
1427559|NCT00283517|Risperidone long-acting injection
1427560|NCT00283517|Antipsychotic medication
1427561|NCT00283517|Schizophrenia
1427562|NCT00283517|Treatment retention
1427563|NCT00283517|Observational study
1427564|NCT00283491|Iron absorption
1427565|NCT00283491|Organic acids
1427566|NCT00283491|Lactobacillus
1427567|NCT00283491|Probiotic
1427568|NCT00283478|Advanced stage
1427569|NCT00283478|Lung cancer
1427570|NCT00283465|Anemia
1427571|NCT00283465|cancer
1427572|NCT00283465|neoplasm
1427573|NCT00283465|transfusion
1427574|NCT00283465|quality of life
1427575|NCT00283465|tumor response
1427576|NCT00283465|survival
1427577|NCT00283465|chemotherapy
1427578|NCT00283465|hemoglobin
1427579|NCT00283465|standard care
1427580|NCT00283465|epoetin alfa
1427581|NCT00283465|epoetin
1427582|NCT00283465|erythropoietin
1427583|NCT00283452|Physical activity maintenance
1427584|NCT00283452|Interactive phone and mail-based intervention
1427585|NCT00283452|Older adults
1427586|NCT00283439|NHL
1427587|NCT00283439|chemotherapy induced thrombocytopenia
1427588|NCT00283439|CIT
1427589|NCT00283439|ICE
1427590|NCT00283439|RICE
1427591|NCT00283439|Hodgkin's Lymphoma
1427592|NCT00283439|Non-Hodgkin's Lymphoma
1427593|NCT00283439|CHOP
1427594|NCT00283439|ESHAP
1427595|NCT00283439|DHAP
1427596|NCT00283439|R-CHOP
1427597|NCT00283439|R-ESHAP
1427598|NCT00283439|R-DHAP
1427599|NCT00283413|Covered Stent System
1427600|NCT00283413|Saphenous Vein Graft
1427601|NCT00283413|Coronary Artery Bypass[MeSH]
1427602|NCT00283413|Stents[MeSH]
1427603|NCT00283400|subarachnoid hemorrhage
1427604|NCT00283400|SAH
1427605|NCT00283400|human albumin
1427606|NCT00283400|HA
1427607|NCT00283400|cerebral vasospasm
1427608|NCT00283400|aneurysm
1427609|NCT00283400|neuroprotective
1427610|NCT00283387|Primary Hyperoxaluria
1427611|NCT00283374|Metabolic Syndrome
1427612|NCT00283374|Obesity
1427613|NCT00283374|Nonalcoholic fatty liver disease
1427614|NCT00283374|Nonalcoholic steatohepatitis
1427615|NCT00283374|Bariatric Surgery
1427616|NCT00283348|Renal Transplantation
1427617|NCT00283348|Immunosuppression
1427618|NCT00283348|Chronic Rejection
1427619|NCT00283322|Heparin Induced Thrombocytopenia
1427620|NCT00283322|HIT
1427621|NCT00283322|HITT
1427622|NCT00283322|Thrombosis
1427623|NCT00283322|Thromboembolism
1427624|NCT00282776|Postpartum Depression
1427625|NCT00282776|Telephone Care Management
1427626|NCT00282776|Screening for Postpartum Depression
1427627|NCT00282750|"Surgery[MeSH]"
1427628|NCT00282750|"Surgical Sponges[MeSH]"
1427629|NCT00282750|"Automatic Data Processing[MeSH]"
1427630|NCT00282724|Lamellar ichthyosis
1427631|NCT00282724|Liarozole
1427632|NCT00282724|Investigator's Global Assessment
1427633|NCT00282724|Scaling
1427634|NCT00282711|Diagnostic Techniques, Radioisotope
1427635|NCT00282711|Radionuclide Imaging
1427636|NCT00282711|Diagnostic Techniques, Cardiovascular
1427637|NCT00282711|Heart Function tests
1427638|NCT00282685|Patients with symmetric peripheral diabetic neuropathy
1427639|NCT00282672|Barrett's Esophagus
1427640|NCT00282672|Dysplasia
1427641|NCT00282672|Radiofrequency Ablation
1427642|NCT00282659|Hemodynamics
1427643|NCT00282659|Hypertension
1427644|NCT00282659|Dyslipidemia
1427645|NCT00282659|Diabetes
1427646|NCT00282659|Implantable Cardioverter Defibrillator
1427647|NCT00282659|Blood Pressure
1427648|NCT00282646|critical limb ischemia
1427649|NCT00282646|peripheral arterial occlusive disease
1427650|NCT00282646|[C14.907.137]
1427651|NCT00282633|Cesarean Delivery
1427652|NCT00282633|Wound closure
1427653|NCT00282633|Suture
1427654|NCT00282633|Alternative therapy
1427655|NCT00282633|Surgery
1427656|NCT00282620|Implantable Cardioverter Defibrillator
1427657|NCT00282620|Magnesium
1427658|NCT00282620|Electrocardiogram
1427659|NCT00282620|Ventricular Arrhythmia
1427660|NCT00282607|Erectile Dysfunction
1427661|NCT00282594|Intensive Insulin Therapy
1427662|NCT00282594|General Surgical
1427663|NCT00282594|Vascular Surgical
1427664|NCT00282594|Tight Glycemic Control
1427665|NCT00282581|HIV
1427666|NCT00282581|Smallpox
1427667|NCT00282581|MVA
1427668|NCT00282568|Pharmacokinetics
1427669|NCT00282568|Therapy
1427670|NCT00282568|Immunosuppression
1427671|NCT00282568|Drugs, Investigational
1427672|NCT00282568|Adult
1427673|NCT00282555|Esophagitis, Reflux
1427674|NCT00282555|S-Tenatoprazole-Na
1427675|NCT00282555|Heartburn
1427676|NCT00282555|Esophageal endoscopy
1427677|NCT00282542|Hepatocytes
1427678|NCT00282529|lymphedema, screening, treatment
1427679|NCT00282516|asthma
1427680|NCT00282516|telemedicine
1427681|NCT00282516|case management
1427682|NCT00282516|clinic
1427683|NCT00282516|children
1427684|NCT00282516|pediatric
1427685|NCT00282503|aGvHD
1427686|NCT00282490|Overactive bladder
1427687|NCT00282490|Children
1427688|NCT00282490|Nerve stimulation
1427689|NCT00282490|TENS
1427690|NCT00282477|cyclist
1427691|NCT00282464|Bipolar I Depression
1427692|NCT00282399|Myelodysplastic Syndrome
1427693|NCT00282399|MGI Pharma
1427694|NCT00282399|Decitabine
1427695|NCT00282399|Dacogen
1427696|NCT00282360|coronary artery disease
1427697|NCT00282360|diabetes mellitus
1427698|NCT00282347|Class IV LN
1427699|NCT00282347|Lupus
1427700|NCT00282347|LUNAR
1427701|NCT00282347|LN
1427702|NCT00282334|Telemedicine
1427703|NCT00282334|Blood pressure
1427704|NCT00282334|Quality of life
1427705|NCT00282334|Cost-effectiveness
1427706|NCT00282308|RA
1427707|NCT00282308|Rituxan
1427708|NCT00282308|SIERRA
1427709|NCT00282295|tetanus
1427710|NCT00282295|pertussis
1427711|NCT00282295|Prophylaxis
1427712|NCT00282295|meningococcus
1427713|NCT00282295|diptheria
1427714|NCT00282282|non-myeloablative peripheral blood stem cell
1427715|NCT00282282|PBSCT
1427716|NCT00282282|tacrolimus
1427717|NCT00282282|sirolimus
1427718|NCT00282269|Traumatic Brain Injury
1427719|NCT00282269|Children
1427720|NCT00282269|Hypothermia
1427721|NCT00282269|Outcome
1427722|NCT00282269|Intensive Care
1427723|NCT00282269|Magnetic resonance Imaging
1427724|NCT00282256|Child
1427725|NCT00282256|Pharmacokinetics
1427726|NCT00282256|Immunosuppression Drugs
1427727|NCT00282256|Hepatic transplant
1427728|NCT00282256|Liver Transplantation
1427729|NCT00282243|Pharmacokinetics
1427730|NCT00282243|Therapy
1427731|NCT00282243|Immunosuppression
1427732|NCT00282243|Drugs, Investigational
1427733|NCT00282243|Adult
1427734|NCT00282230|Malononitrilamide
1427735|NCT00282230|immunosuppression
1427736|NCT00282230|treatment efficacy
1427737|NCT00282230|treatment outcome
1427738|NCT00282217|Kidney Failure
1427739|NCT00282217|Kidney Transplant
1427740|NCT00282217|Graft Rejection
1427741|NCT00282217|Kidney Transplantation
1427742|NCT00282204|Hypnosis
1427743|NCT00282204|Hypnotherapy
1427744|NCT00282204|Childbirth
1427745|NCT00282204|Analgesia
1427746|NCT00282191|spasticity
1427747|NCT00282191|mental retardation
1427748|NCT00282178|Metabolic
1427749|NCT00282178|Hypertension
1427750|NCT00282178|Abdominal obesity
1427751|NCT00282178|Insulin sensitivity
1427752|NCT00282178|Hyperinsulinemic euglycemic clamp
1427753|NCT00282152|Early Stage Parkinson's Disease
1427754|NCT00282152|Parkinson's Disease
1427755|NCT00282152|Deep Brain Stimulation
1427756|NCT00282152|PD
1427757|NCT00282152|DBS
1427758|NCT00282126|Calcium balance
1427759|NCT00282113|Probiotic
1427760|NCT00282113|Prebiotic
1427761|NCT00282113|NEC
1427762|NCT00282113|Premature infants
1427763|NCT00282113|commensal flora
1427764|NCT00282087|early stage
1427765|NCT00282087|high grade
1427766|NCT00282087|uterine leiomyosarcoma
1427767|NCT00282087|adjuvant treatment
1427768|NCT00282061|3 conditions in a within-subject design:
1427769|NCT00282061|1-ad-lib sleep wake
1427770|NCT00282061|2-forced morning wake-up
1427771|NCT00282061|3- ad-lib sleep wake after treatment with melatonin
1427772|NCT00282035|breast cancer
1427773|NCT00282035|breast tumour
1427774|NCT00282035|DCIS
1427775|NCT00282035|female
1427776|NCT00282035|breast conserving surgery
1427777|NCT00282035|irradiation
1427778|NCT00282035|whole breast irradiation
1427779|NCT00282035|3D CRT accelerated partial breast irradiation
1427780|NCT00282035|cosmetic outcome
1427781|NCT00282035|quality of life
1427782|NCT00282022|recurrent small cell lung cancer
1427783|NCT00282022|extensive stage small cell lung cancer
1427784|NCT00282022|limited stage small cell lung cancer
1427785|NCT00282009|unspecified adult solid tumor, protocol specific
1427786|NCT00281996|recurrent pancreatic cancer
1427787|NCT00281996|stage III pancreatic cancer
1427788|NCT00281996|stage IV pancreatic cancer
1427789|NCT00281983|B-cell chronic lymphocytic leukemia
1427790|NCT00281983|refractory chronic lymphocytic leukemia
1427791|NCT00281983|stage III chronic lymphocytic leukemia
1427792|NCT00281983|stage IV chronic lymphocytic leukemia
1427793|NCT00281983|Waldenström macroglobulinemia
1427794|NCT00281970|stage I non-small cell lung cancer
1427795|NCT00281970|stage II non-small cell lung cancer
1427796|NCT00281970|stage IIIA non-small cell lung cancer
1427797|NCT00281970|stage IIIB non-small cell lung cancer
1427798|NCT00281931|prolymphocytic leukemia
1427799|NCT00281918|B-cell chronic lymphocytic leukemia
1427800|NCT00281918|stage I chronic lymphocytic leukemia
1427801|NCT00281918|stage II chronic lymphocytic leukemia
1427802|NCT00281918|stage III chronic lymphocytic leukemia
1427803|NCT00281918|stage IV chronic lymphocytic leukemia
1427804|NCT00281905|untreated childhood brain stem glioma
1427805|NCT00281905|childhood high-grade cerebral astrocytoma
1427806|NCT00281905|childhood low-grade cerebral astrocytoma
1427807|NCT00281905|untreated childhood cerebellar astrocytoma
1427808|NCT00281905|childhood choroid plexus tumor
1427809|NCT00281905|childhood infratentorial ependymoma
1427810|NCT00281905|childhood supratentorial ependymoma
1427811|NCT00281905|newly diagnosed childhood ependymoma
1427812|NCT00281905|untreated childhood medulloblastoma
1427813|NCT00281905|childhood oligodendroglioma
1427814|NCT00281905|untreated childhood supratentorial primitive neuroectodermal tumor
1427815|NCT00281905|disseminated neuroblastoma
1427816|NCT00281905|localized resectable neuroblastoma
1427817|NCT00281905|localized unresectable neuroblastoma
1427818|NCT00281905|regional neuroblastoma
1427819|NCT00281905|stage 4S neuroblastoma
1427820|NCT00281892|anemia
1427821|NCT00281892|refractory chronic lymphocytic leukemia
1427822|NCT00281892|stage 0 chronic lymphocytic leukemia
1427823|NCT00281892|stage I chronic lymphocytic leukemia
1427824|NCT00281892|stage II chronic lymphocytic leukemia
1427825|NCT00281892|stage III chronic lymphocytic leukemia
1427826|NCT00281892|stage IV chronic lymphocytic leukemia
1427827|NCT00281879|adult acute lymphoblastic leukemia in remission
1427828|NCT00281879|L1 adult acute lymphoblastic leukemia
1427829|NCT00281879|L2 adult acute lymphoblastic leukemia
1427830|NCT00281879|L3 adult acute lymphoblastic leukemia
1427831|NCT00281879|recurrent adult acute lymphoblastic leukemia
1427832|NCT00281879|accelerated phase chronic myelogenous leukemia
1427833|NCT00281879|blastic phase chronic myelogenous leukemia
1427834|NCT00281879|chronic phase chronic myelogenous leukemia
1427835|NCT00281879|relapsing chronic myelogenous leukemia
1427836|NCT00281879|childhood acute lymphoblastic leukemia in remission
1427837|NCT00281879|L1 childhood acute lymphoblastic leukemia
1427838|NCT00281879|L2 childhood acute lymphoblastic leukemia
1427839|NCT00281879|L3 childhood acute lymphoblastic leukemia
1427840|NCT00281879|recurrent childhood acute lymphoblastic leukemia
1427841|NCT00281879|recurrent adult Hodgkin lymphoma
1427842|NCT00281879|recurrent/refractory childhood Hodgkin lymphoma
1427843|NCT00281879|stage IV adult Hodgkin lymphoma
1427844|NCT00281879|stage IV childhood Hodgkin lymphoma
1427845|NCT00281879|adult acute myeloid leukemia in remission
1427846|NCT00281879|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1427847|NCT00281879|adult acute myeloid leukemia with t(15;17)(q22;q12)
1427848|NCT00281879|adult acute myeloid leukemia with t(16;16)(p13;q22)
1427849|NCT00281879|childhood acute myeloid leukemia in remission
1427850|NCT00281879|recurrent adult acute myeloid leukemia
1427851|NCT00281879|recurrent childhood acute myeloid leukemia
1427852|NCT00281879|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1427853|NCT00281879|previously treated myelodysplastic syndromes
1427854|NCT00281879|secondary myelodysplastic syndromes
1427855|NCT00281879|secondary acute myeloid leukemia
1427856|NCT00281879|refractory anemia with excess blasts in transformation
1427857|NCT00281879|refractory anemia with excess blasts
1427858|NCT00281879|refractory anemia
1427859|NCT00281879|chronic myelomonocytic leukemia
1427860|NCT00281879|childhood chronic myelogenous leukemia
1427861|NCT00281879|chronic eosinophilic leukemia
1427862|NCT00281879|primary myelofibrosis
1427863|NCT00281879|chronic neutrophilic leukemia
1427864|NCT00281879|de novo myelodysplastic syndromes
1427865|NCT00281879|atypical chronic myeloid leukemia, BCR-ABL negative
1427866|NCT00281879|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1427867|NCT00281879|juvenile myelomonocytic leukemia
1427868|NCT00281879|nodal marginal zone B-cell lymphoma
1427869|NCT00281879|noncontiguous stage II adult Burkitt lymphoma
1427870|NCT00281879|noncontiguous stage II adult diffuse large cell lymphoma
1427871|NCT00281879|noncontiguous stage II adult diffuse mixed cell lymphoma
1427872|NCT00281879|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1427873|NCT00281879|noncontiguous stage II adult immunoblastic large cell lymphoma
1427874|NCT00281879|noncontiguous stage II adult lymphoblastic lymphoma
1427875|NCT00281879|noncontiguous stage II grade 1 follicular lymphoma
1427876|NCT00281879|noncontiguous stage II grade 2 follicular lymphoma
1427877|NCT00281879|noncontiguous stage II grade 3 follicular lymphoma
1427878|NCT00281879|noncontiguous stage II mantle cell lymphoma
1427879|NCT00281879|noncontiguous stage II marginal zone lymphoma
1427880|NCT00281879|noncontiguous stage II small lymphocytic lymphoma
1427881|NCT00281879|recurrent adult Burkitt lymphoma
1427882|NCT00281879|recurrent adult diffuse large cell lymphoma
1427883|NCT00281879|recurrent adult diffuse mixed cell lymphoma
1427884|NCT00281879|recurrent adult diffuse small cleaved cell lymphoma
1427885|NCT00281879|recurrent adult immunoblastic large cell lymphoma
1427886|NCT00281879|recurrent adult lymphoblastic lymphoma
1427887|NCT00281879|recurrent childhood large cell lymphoma
1427888|NCT00281879|recurrent childhood lymphoblastic lymphoma
1427889|NCT00281879|recurrent childhood small noncleaved cell lymphoma
1427890|NCT00281879|recurrent grade 1 follicular lymphoma
1427891|NCT00281879|recurrent grade 2 follicular lymphoma
1427892|NCT00281879|recurrent grade 3 follicular lymphoma
1427893|NCT00281879|recurrent mantle cell lymphoma
1427894|NCT00281879|recurrent marginal zone lymphoma
1427895|NCT00281879|recurrent small lymphocytic lymphoma
1427896|NCT00281879|refractory chronic lymphocytic leukemia
1427897|NCT00281879|refractory hairy cell leukemia
1427898|NCT00281879|refractory multiple myeloma
1427899|NCT00281879|splenic marginal zone lymphoma
1427900|NCT00281879|stage I multiple myeloma
1427901|NCT00281879|stage II multiple myeloma
1427902|NCT00281879|stage III adult Burkitt lymphoma
1427903|NCT00281879|stage III adult Hodgkin lymphoma
1427904|NCT00281879|stage III adult diffuse large cell lymphoma
1427905|NCT00281879|stage III adult diffuse mixed cell lymphoma
1427906|NCT00281879|stage III adult diffuse small cleaved cell lymphoma
1427907|NCT00281879|stage III adult immunoblastic large cell lymphoma
1427908|NCT00281879|stage III adult lymphoblastic lymphoma
1427909|NCT00281879|stage III chronic lymphocytic leukemia
1427910|NCT00281879|stage III grade 1 follicular lymphoma
1427911|NCT00281879|stage III grade 2 follicular lymphoma
1427912|NCT00281879|stage III grade 3 follicular lymphoma
1427913|NCT00281879|stage III mantle cell lymphoma
1427914|NCT00281879|stage III marginal zone lymphoma
1427915|NCT00281879|stage III multiple myeloma
1427916|NCT00281879|stage III small lymphocytic lymphoma
1427917|NCT00281879|stage IV adult Burkitt lymphoma
1427918|NCT00281879|stage IV adult diffuse large cell lymphoma
1427919|NCT00281879|stage IV adult diffuse mixed cell lymphoma
1427920|NCT00281879|stage IV adult diffuse small cleaved cell lymphoma
1427921|NCT00281879|stage IV adult immunoblastic large cell lymphoma
1427922|NCT00281879|stage IV adult lymphoblastic lymphoma
1427923|NCT00281879|stage IV chronic lymphocytic leukemia
1427924|NCT00281879|stage IV grade 1 follicular lymphoma
1427925|NCT00281879|stage IV grade 2 follicular lymphoma
1427926|NCT00281879|stage IV grade 3 follicular lymphoma
1427927|NCT00281879|stage IV mantle cell lymphoma
1427928|NCT00281879|stage IV marginal zone lymphoma
1427929|NCT00281879|stage IV small lymphocytic lymphoma
1427930|NCT00281879|stage III childhood Hodgkin lymphoma
1427931|NCT00281879|stage III childhood large cell lymphoma
1427932|NCT00281879|stage III childhood lymphoblastic lymphoma
1427933|NCT00281879|stage III childhood small noncleaved cell lymphoma
1427934|NCT00281879|stage IV childhood large cell lymphoma
1427935|NCT00281879|stage IV childhood lymphoblastic lymphoma
1427936|NCT00281879|stage IV childhood small noncleaved cell lymphoma
1427937|NCT00281879|unusual cancers of childhood
1427938|NCT00281879|childhood myelodysplastic syndromes
1427939|NCT00281866|stage IV squamous cell carcinoma of the hypopharynx
1427940|NCT00281866|stage IV squamous cell carcinoma of the larynx
1427941|NCT00281866|stage IV squamous cell carcinoma of the lip and oral cavity
1427942|NCT00281866|stage IV squamous cell carcinoma of the nasopharynx
1427943|NCT00281866|stage IV squamous cell carcinoma of the oropharynx
1427944|NCT00281866|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1427945|NCT00281866|recurrent squamous cell carcinoma of the hypopharynx
1427946|NCT00281866|recurrent squamous cell carcinoma of the larynx
1427947|NCT00281866|recurrent squamous cell carcinoma of the lip and oral cavity
1427948|NCT00281866|recurrent squamous cell carcinoma of the nasopharynx
1427949|NCT00281866|recurrent squamous cell carcinoma of the oropharynx
1427950|NCT00281866|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1427951|NCT00281866|recurrent metastatic squamous neck cancer with occult primary
1427952|NCT00281866|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1427953|NCT00281853|neurotoxicity
1427954|NCT00281853|unspecified adult solid tumor, protocol specific
1427955|NCT00281840|stage III squamous cell carcinoma of the hypopharynx
1427956|NCT00281840|stage IV squamous cell carcinoma of the hypopharynx
1427957|NCT00281840|stage III squamous cell carcinoma of the larynx
1427958|NCT00281840|stage IV squamous cell carcinoma of the larynx
1427959|NCT00281840|stage III squamous cell carcinoma of the lip and oral cavity
1427960|NCT00281840|stage IV squamous cell carcinoma of the lip and oral cavity
1427961|NCT00281840|stage III squamous cell carcinoma of the nasopharynx
1427962|NCT00281840|stage IV squamous cell carcinoma of the nasopharynx
1427963|NCT00281840|stage III squamous cell carcinoma of the oropharynx
1427964|NCT00281840|stage IV squamous cell carcinoma of the oropharynx
1427965|NCT00281827|adenocarcinoma of the lung
1427966|NCT00281827|squamous cell lung cancer
1427967|NCT00281827|large cell lung cancer
1427968|NCT00281827|stage II non-small cell lung cancer
1427969|NCT00281827|stage IIIA non-small cell lung cancer
1427970|NCT00281762|AQP-2
1427971|NCT00281762|NSAID
1427972|NCT00281762|Urinary concentrating ability
1427973|NCT00281749|ALZHEIMER'S D-SE
1427974|NCT00281749|PARKINSON'S D-SE
1427975|NCT00281749|FRAILTY
1427976|NCT00281736|adenocarcinoma of the esophagus
1427977|NCT00281736|recurrent esophageal cancer
1427978|NCT00281736|stage 0 esophageal cancer
1427979|NCT00281736|stage I esophageal cancer
1427980|NCT00281736|precancerous condition
1427981|NCT00281723|Aphthous
1427982|NCT00281723|oral
1427983|NCT00281710|AQP-2
1427984|NCT00281710|Methylprednisolone
1427985|NCT00281710|Urinary concentrating ability
1427986|NCT00281697|Ribbon 2
1427987|NCT00281697|Avastin
1427988|NCT00281697|MBC
1427989|NCT00281697|Breast cancer
1427990|NCT00281684|Acute Pain
1427991|NCT00281684|Dental Pain
1427992|NCT00281684|Vanilloid
1427993|NCT00281684|VR1
1427994|NCT00281684|TRPV1
1427995|NCT00281684|Inflammation
1427996|NCT00281671|Nesiritide
1427997|NCT00281671|Natriuretic Peptide, Brain
1427998|NCT00281671|Heart Defects, Congenital
1427999|NCT00281671|Cardiopulmonary Bypass
1428000|NCT00281671|Diuretics
1428001|NCT00281658|ErbB2 positive
1428002|NCT00281658|Her2+
1428003|NCT00281658|metastatic breast cancer
1428004|NCT00281658|FISH positive
1428005|NCT00281658|Stage IV
1428006|NCT00281632|Pazopanib
1428007|NCT00281632|Fallopian tube cancer
1428008|NCT00281632|Ovarian epithelial cancer
1428009|NCT00281632|Peritoneal cancer
1428010|NCT00281619|Pediatric Kidney Transplant
1428011|NCT00281619|Kidney Transplant
1428012|NCT00281619|CellCept
1428013|NCT00281619|Mycophenolate mofetil
1428014|NCT00281619|Mycophenolic Acid
1428015|NCT00281619|MPA
1428016|NCT00281606|Lopinavir
1428017|NCT00281606|antiretroviral therapy
1428018|NCT00281606|cross-over
1428019|NCT00281606|tolerability
1428020|NCT00281554|Investigational Therapies
1428021|NCT00281554|Atrial Fibrillation
1428022|NCT00281554|Treatment Efficacy
1428023|NCT00281554|Treatment Effectiveness
1428024|NCT00281554|Safety
1428025|NCT00281554|RSD1235
1428026|NCT00281541|Treatment Efficacy
1428027|NCT00281541|Treatment Effectiveness
1428028|NCT00281541|Disease Management
1428029|NCT00281541|Treatment
1428030|NCT00281541|Safety
1428031|NCT00281541|Malignant Melanoma
1428032|NCT00281528|First Line Metastatic Breast Cancer
1428033|NCT00281502|Hepatic Encephalopathy
1428034|NCT00281502|Hepatitis C
1428035|NCT00281502|Liver Cirrhosis
1428036|NCT00281502|Bacterial Overgrowth
1428037|NCT00281489|Recall
1428038|NCT00281489|Awareness
1428039|NCT00281489|BIS
1428040|NCT00281489|Anesthesia
1428041|NCT00281489|Explicit Recall
1428042|NCT00281476|multiple myeloma
1428043|NCT00281476|statins
1428044|NCT00281476|bone
1428045|NCT00281463|wheelchair
1428046|NCT00281463|spinal cord injury
1428047|NCT00281463|rehabilitation
1428048|NCT00281437|exercise
1428049|NCT00281437|adherence
1428050|NCT00281437|lifestyle
1428051|NCT00281437|choice
1428052|NCT00281437|autonomy
1428053|NCT00281424|exercise adherence
1428054|NCT00281424|cardiac patients
1428055|NCT00281424|walking
1428056|NCT00281411|Blood Vessel Prosthesis Implantation
1428057|NCT00281411|Endovascular aneurysm repair
1428058|NCT00281411|Magnetic Resonance Angiography
1428059|NCT00281411|Computed Tomography Angiography
1428060|NCT00281411|Endoleak
1428061|NCT00281398|homelessness
1428062|NCT00281398|Attitudes of medical trainees towards the homeless
1428063|NCT00281385|adherence
1428064|NCT00281385|lifestyle
1428065|NCT00281385|exercise
1428066|NCT00281385|pedometer
1428067|NCT00281385|training
1428068|NCT00281372|sexual dysfunction
1428069|NCT00281372|male
1428070|NCT00281372|female
1428071|NCT00281372|dental care
1428072|NCT00281372|need of control
1428073|NCT00281359|cerebral palsy
1428074|NCT00281359|dynamic splinting
1428075|NCT00281359|contractures
1428076|NCT00281359|heat therapy
1428077|NCT00281346|Doppler echocardiography
1428078|NCT00281346|coronary stenosis
1428079|NCT00281346|Coronary angiography
1428080|NCT00281307|Rhinitis
1428081|NCT00281307|Vitamin E
1428082|NCT00281307|Intranasal
1428083|NCT00281294|Arthritis, Rheumatoid
1428084|NCT00281281|Extracorporeal Membrane Oxygenation
1428085|NCT00281281|vancomycin
1428086|NCT00281242|Chronic Obstructive Pulmonary Disease
1428087|NCT00281242|COPD
1428088|NCT00281229|Chronic Obstructive Pulmonary Disease
1428089|NCT00281229|COPD
1428090|NCT00281216|Chronic Obstructive Pulmonary Disease
1428091|NCT00281216|COPD
1428092|NCT00281203|Chronic Obstructive Pulmonary Disease
1428093|NCT00281203|COPD
1428094|NCT00281190|Chronic Obstructive Pulmonary Disease
1428095|NCT00281190|COPD
1428096|NCT00281125|Non-Small Cell Lung Cancer
1428097|NCT00281125|Pleural Mesothelioma
1428098|NCT00281099|ICD
1428099|NCT00281099|Pacing
1428100|NCT00281099|Heart Failure
1428101|NCT00281073|Intra-Cardiac Echocardiography
1428102|NCT00281073|Cardioversion
1428103|NCT00281060|endovascular
1428104|NCT00281060|balloon angioplasty
1428105|NCT00281060|stents
1428106|NCT00281047|Helicobacter pylori (H. pylori)
1428107|NCT00281047|FP-10
1428108|NCT00281047|amoxicillin
1428109|NCT00281047|clarithromycin
1428110|NCT00281047|lansoprazole
1428111|NCT00281034|brain infarction
1428112|NCT00281034|SF-36
1428113|NCT00281034|HRQOL
1428114|NCT00281034|Japan
1428115|NCT00281034|Post-stroke syndrome
1428116|NCT00281021|non-small cell lung cancer
1428117|NCT00281021|Erlotinib
1428118|NCT00281021|Digoxin
1428119|NCT00281008|LDL-cholesterol
1428120|NCT00281008|apoB-100
1428121|NCT00281008|Heterozygous Familial Hypercholesterolemia
1428122|NCT00280995|LDL-cholesterol
1428123|NCT00280995|apoB-100
1428124|NCT00280995|Homozygous Familial Hypercholesterolemia
1428125|NCT00280982|dendritic cells, immunotherapy, vaccination, mesothelioma
1428126|NCT00280969|HIV infection
1428127|NCT00280969|treatment
1428128|NCT00280969|efavirenz
1428129|NCT00280969|atazanavir
1428130|NCT00280969|ritonavir
1428131|NCT00280943|All NC LTC facilities having ten residents with a hip fracture or osteoporosis on the MDS will be invited to participate in the trial
1428132|NCT00280930|letrozole
1428133|NCT00280930|breast cancer
1428134|NCT00280930|menopause
1428135|NCT00280917|Rheumatoid Arthritis
1428136|NCT00280917|RA
1428137|NCT00280904|Hydrocephalus
1428138|NCT00280904|Shunt
1428139|NCT00280891|head and neck
1428140|NCT00280891|cancer
1428141|NCT00280891|palliation
1428142|NCT00280891|radiotherapy
1428143|NCT00280878|Lymphoma
1428144|NCT00280878|CD20+
1428145|NCT00280865|Tesaglitazar
1428146|NCT00280865|type 2 diabetes
1428147|NCT00280176|recurrent rectal cancer
1428148|NCT00280176|stage II rectal cancer
1428149|NCT00280176|stage III rectal cancer
1428150|NCT00280176|stage IV rectal cancer
1428151|NCT00280176|adenocarcinoma of the rectum
1428152|NCT00280163|Genomics, cardiac surgery
1428153|NCT00280150|stage IIIA non-small cell lung cancer
1428154|NCT00280150|stage IIIB non-small cell lung cancer
1428155|NCT00280150|recurrent non-small cell lung cancer
1428156|NCT00280150|squamous cell lung cancer
1428157|NCT00280137|Quality of Life
1428158|NCT00280137|Pediatric Systemic Lupus Erythematosus
1428159|NCT00280111|rotavirus
1428160|NCT00280111|vaccine
1428161|NCT00280111|safety
1428162|NCT00280111|immunogenicity
1428163|NCT00280111|infants
1428164|NCT00280852|anaplastic thyroid cancer
1428165|NCT00280852|chemotherapy
1428166|NCT00280852|radiotherapy
1428167|NCT00280826|OCT
1428168|NCT00280826|Retinal Disease
1428169|NCT00280826|Adhesion Molecule
1428170|NCT00280826|Ocular Inflammation
1428171|NCT00280826|Raptiva
1428172|NCT00280826|Macular Edema
1428173|NCT00280826|Uveitis
1428174|NCT00280826|Immunosuppression
1428175|NCT00280813|treatment
1428176|NCT00280813|dual diagnosis
1428177|NCT00280800|randomized
1428178|NCT00280800|controlled
1428179|NCT00280800|double blind
1428180|NCT00280800|effectiveness
1428181|NCT00280800|auto CPAP
1428182|NCT00280800|treatment
1428183|NCT00280800|sleep apnea
1428184|NCT00280787|unresectable
1428185|NCT00280787|induction
1428186|NCT00280787|radiotherapy
1428187|NCT00280787|ZD1839
1428188|NCT00280774|corticosteroid
1428189|NCT00280774|prednisone
1428190|NCT00280774|memantine
1428191|NCT00280774|Patients who are taking a corticosteroid for a
1428192|NCT00280774|pulmonary illness
1428193|NCT00280774|rheumatic illness
1428194|NCT00280774|kidney transplant
1428195|NCT00280761|adenocarcinoma of the rectum
1428196|NCT00280761|recurrent rectal cancer
1428197|NCT00280761|stage II rectal cancer
1428198|NCT00280761|stage III rectal cancer
1428199|NCT00280761|stage IV rectal cancer
1428203|NCT00280735|stage I non-small cell lung cancer
1428204|NCT00280735|stage II non-small cell lung cancer
1428205|NCT00280735|stage IIIA non-small cell lung cancer
1428206|NCT00280722|Randomised
1428207|NCT00280722|Intervention
1428208|NCT00280722|Leaflet
1428209|NCT00280722|Information
1428210|NCT00280722|Awareness
1428211|NCT00280722|Behaviour
1428212|NCT00280722|Research
1428213|NCT00280709|Bile duct
1428214|NCT00280709|Bile duct obstruction
1428215|NCT00280709|Biliary stent
1428216|NCT00280709|Metal stent
1428217|NCT00280709|ERCP
1428218|NCT00280709|Patency
1428219|NCT00280709|Complication
1428220|NCT00280709|Stent occlusion
1428221|NCT00280696|Epilepsies, Partial,
1428222|NCT00280696|Keppra, levetiracetam
1428223|NCT00280683|Airway Inflammation
1428224|NCT00280683|Moderate persistent asthma
1428225|NCT00280683|Severe Persistent Asthma
1428226|NCT00280657|Acne papulopustulosa
1428227|NCT00280592|Prophylaxis
1428228|NCT00280592|Cranberry
1428229|NCT00280592|Neurogenic bladder
1428230|NCT00280553|analgesia
1428231|NCT00280553|laparoscopic surgical procedures
1428232|NCT00280553|length of stay
1428233|NCT00280540|Hypertension
1428234|NCT00280540|High blood pressure
1428235|NCT00280540|Blood pressure control
1428236|NCT00280540|Blood pressure reduction
1428237|NCT00280540|Valsartan
1428238|NCT00280527|NAFLD
1428239|NCT00280527|NASH
1428240|NCT00280527|Obesity
1428241|NCT00280527|Bariatric Surgery
1428242|NCT00280527|Weight Reduction
1428243|NCT00280514|abscess
1428244|NCT00280514|penetration
1428245|NCT00280514|antibiotics
1428246|NCT00280514|cefpirome
1428247|NCT00280514|moxifloxacin
1428248|NCT00280514|abdominal cyst
1428249|NCT00280501|Sulpiride
1428250|NCT00280501|Quetiapine
1428251|NCT00280501|Light/dark transition
1428252|NCT00280501|Choroidal blood flow
1428253|NCT00280488|Motivational Interviewing
1428254|NCT00280488|Alcohol Abuse
1428255|NCT00280488|Alcohol Dependence
1428256|NCT00280488|Emergency Care Setting
1428257|NCT00280475|Randomized Controlled Trials
1428258|NCT00280475|Brain Neoplasms/Secondary
1428259|NCT00280475|Brain Neoplasms/Radiotherapy
1428260|NCT00280475|Radiosurgery
1428261|NCT00280462|Nifedipine
1428262|NCT00280462|Choroidal blood flow
1428263|NCT00280462|Choroidal autoregulation
1428264|NCT00280462|Isometric exercise
1428265|NCT00280449|people living with HIV
1428266|NCT00280449|quality of life
1428267|NCT00280436|Polysomnography
1428268|NCT00280436|Electroencephalography
1428269|NCT00280436|Primary Insomnia
1428270|NCT00280436|Cognition
1428271|NCT00280436|Sleep
1428272|NCT00280423|Cognition
1428273|NCT00280423|Polysomnography
1428274|NCT00280423|Primary Insomnia
1428275|NCT00280423|Electroencephalography
1428276|NCT00280423|Sleep
1428277|NCT00280397|Cancer, solid tumors
1428278|NCT00280371|COPD
1428279|NCT00280371|Chronic Obstructive Pulmonary Disease
1428280|NCT00280371|formoterol
1428281|NCT00280358|Fluticasone
1428282|NCT00280358|Formoterol
1428283|NCT00280358|PK Study
1428284|NCT00280358|Pharmacokinetics
1428285|NCT00280345|pigmentary glaucoma
1428286|NCT00280345|primary open angle glaucoma
1428287|NCT00280345|cataract
1428288|NCT00280345|trabeculectomy
1428289|NCT00280345|cataract surgery
1428290|NCT00280332|colonic adenoma, colonic advanced neoplasm
1428291|NCT00280319|randomized controlled trial
1428292|NCT00280319|depression
1428293|NCT00280319|Uganda
1428294|NCT00280319|adolescents
1428295|NCT00280293|Bipolar Disorder
1428296|NCT00280293|Cocaine Dependence
1428297|NCT00280293|Dual Diagnosis
1428298|NCT00280280|spasticity
1428299|NCT00280280|Botox
1428300|NCT00280280|baclofen
1428301|NCT00280267|hip fracture
1428302|NCT00280267|testosterone
1428303|NCT00280267|muscle weakness
1428304|NCT00280267|frail elderly
1428305|NCT00280267|aging
1428306|NCT00280254|Heart Failure
1428307|NCT00280254|Hemodynamics
1428308|NCT00280254|Echocardiography
1428309|NCT00280241|Chronic
1428310|NCT00280241|Lymphocytic
1428311|NCT00280241|Leukemia
1428312|NCT00280241|Fludarabine
1428313|NCT00280241|Cyclophosphamide
1428314|NCT00280241|Rituximab
1428315|NCT00280228|ADHD
1428316|NCT00280228|Oppositional Defiant Disorder
1428317|NCT00280228|Conduct Disorder
1428318|NCT00280228|Substance Use
1428319|NCT00280228|Drug and Alcohol Use
1428320|NCT00280215|Primary Hyperoxaluria
1428321|NCT00280202|Non-small cell lung cancer
1428322|NCT00280202|Carcinogenesis
1428323|NCT00280202|Genomic changes leading to malignant phenotypes in NSCLC.
1428324|NCT00280202|Simultaneous mutagenesis of epithelial cells.
1428447|NCT00279539|Gene Therapy
1428325|NCT00280202|Chromosomal abnormalities/mutations in bronchial tissues.
1428326|NCT00280202|Detect micrometastases in histologically neg. lymph nodes
1428327|NCT00280189|Radiofrequency ablation
1428328|NCT00280189|Pulmonary malignancies
1428329|NCT00280189|Primary lung cancer
1428330|NCT00280189|Pulmonary metastasis
1428331|NCT00280189|Primary lung tumors
1428332|NCT00280189|Secondary lung tumors
1428333|NCT00280189|Coagulation necrosis of soft tissue tumors
1428334|NCT00280072|Renal Failure, Acute
1428335|NCT00280072|Acute Kidney Failure
1428336|NCT00280072|Acute Renal Failure
1428337|NCT00280072|Acute Tubular Necrosis
1428338|NCT00280072|Anuria
1428339|NCT00280072|Renal Dialysis
1428340|NCT00280072|Acute Kidney Injury
1428341|NCT00280059|Epilepsy
1428342|NCT00280059|partial seizures
1428343|NCT00280059|pregabalin monotherapy
1428344|NCT00280059|lamotrigine comparator
1428345|NCT00280059|double-blind and randomized trial
1428346|NCT00280033|H5N1, Influenza, vaccine, parent protocol
1428347|NCT00280020|sleep disorders
1428348|NCT00280020|meditation
1428349|NCT00280020|cognitive behavior therapy
1428350|NCT00280007|hepatocellular carcinoma
1428351|NCT00280007|TACE
1428352|NCT00280007|transarterial chemoembolisation
1428353|NCT00280007|portal hypertension
1428354|NCT00280007|angiogenesis
1428355|NCT00280007|VEGF
1428356|NCT00280007|bevacizumab
1428357|NCT00279994|Intermittent claudication
1428358|NCT00279994|Exercise therapy
1428359|NCT00279994|Therapy feedback
1428360|NCT00279994|Accelerometer
1428361|NCT00279994|Physiotherapy
1428362|NCT00279994|PAD;
1428363|NCT00279994|peripheral arterial disease according to Fontaine stage II)
1428364|NCT00279981|Atrial fibrillation
1428365|NCT00279981|Stroke
1428366|NCT00279981|Pacemaker
1428367|NCT00279981|Implantable Cardiac Defibrillator
1428368|NCT00279981|Resynchronization systems
1428369|NCT00279968|ICD
1428370|NCT00279968|Registry
1428371|NCT00279968|Ventricular tachycardia
1428372|NCT00279968|Ventricular Fibrillation
1428373|NCT00279955|Heart Failure, Congestive
1428374|NCT00279955|Implantable Cardioverter-Defibrillators
1428375|NCT00279942|Fibromyalgia
1428376|NCT00279942|Dietary Supplements
1428377|NCT00279942|Rheumatologic Diseases
1428378|NCT00279942|Complementary and Alternative Medicine
1428379|NCT00279851|idiopathic seizure
1428380|NCT00279851|hypoglycemia
1428381|NCT00279851|hyperammonemia/hyperinsulinism syndrome
1428382|NCT00279812|Immune response
1428383|NCT00279812|Selenomethionine
1428384|NCT00279812|Selenium enriched foods
1428385|NCT00279812|Selenium status
1428386|NCT00279812|Selenium biomarkers
1428387|NCT00279799|Sexually Transmitted Diseases, HIV, condom use, adolescents
1428388|NCT00279786|pediatric
1428389|NCT00279773|Acute
1428390|NCT00279773|Myeloid
1428391|NCT00279773|Leukemia
1428392|NCT00279734|Rheumatoid Arthritis
1428393|NCT00279721|thyroid neoplasms
1428394|NCT00279721|intensity modulated radiation
1428395|NCT00279721|radiotherapy
1428396|NCT00279708|Granulomatous Inflammation
1428397|NCT00279708|Steroid-Sparing
1428398|NCT00279708|Pulmonary Function
1428399|NCT00279708|Sarcoidosis, Pulmonary
1428400|NCT00279708|Statins (Atorvastatin)
1428401|NCT00279708|Biomarkers
1428402|NCT00279708|Nitric Oxide
1428403|NCT00279708|Disease Activity
1428404|NCT00279708|Quality of Life
1428405|NCT00279708|Corticosteroids
1428406|NCT00279708|Pulmonary Sarcoidosis
1428407|NCT00279708|Sarcoidosis
1428408|NCT00279695|Glaucoma
1428409|NCT00279695|Accommodation
1428410|NCT00279695|Ocular Tumors
1428411|NCT00279695|Age-Related Macular Degeneration
1428412|NCT00279695|Ultrasound
1428413|NCT00279695|Eye
1428414|NCT00279682|depression
1428415|NCT00279682|suicide
1428416|NCT00279682|geriatric
1428417|NCT00279682|elderly
1428418|NCT00279682|primary care
1428419|NCT00279669|Retinopathy of Prematurity
1428420|NCT00279669|Ultrasound
1428421|NCT00279669|Eye
1428422|NCT00279656|Frail elderly
1428423|NCT00279656|Pharmaceutical services
1428424|NCT00279656|Drug therapy
1428425|NCT00279656|Geriatrics
1428426|NCT00279656|Randomized controlled trial
1428427|NCT00279656|Hospitals, teaching
1428428|NCT00279643|Laser
1428429|NCT00279643|immunohistochemical staining
1428430|NCT00279643|Laser Hair Removal
1428431|NCT00279643|follicular stem cells
1428432|NCT00279643|keratin 15
1428433|NCT00279630|Tibialis Posterior Tendinopathy
1428434|NCT00279578|haemophilia A
1428435|NCT00279578|thrombelastography
1428436|NCT00279578|recombinant factor VIII
1428437|NCT00279578|thrombin generation
1428438|NCT00279565|buprenorphine
1428439|NCT00279565|methadone
1428440|NCT00279565|Peg-Intron
1428441|NCT00279565|Rebetol
1428442|NCT00279552|Vitamin B12 deficiency
1428443|NCT00279552|Vitamin B12 malabsorption
1428444|NCT00279552|Intrinsic factor
1428445|NCT00279552|Holotranscobalamin
1428446|NCT00279539|Cardiovascular
1428448|NCT00279539|DNA
1428449|NCT00279539|Stem Cells
1428450|NCT00279539|Congestive Heart Failure
1428451|NCT00279539|Coronary Artery Disease
1428452|NCT00279539|CHF
1428453|NCT00279539|Cardiomyopathy
1428454|NCT00279526|Depression
1428455|NCT00279526|Health services utilization
1428456|NCT00279526|Elderly
1428457|NCT00279526|Primary Care
1428458|NCT00279513|homeopathy
1428459|NCT00279513|hallux valgus
1428460|NCT00279513|pain
1428461|NCT00279513|traumeel s
1428462|NCT00279487|Patients undergoing total knee replacement who received pain management by the following modality:
1428463|NCT00279487|IV PCA opioid
1428464|NCT00279487|Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine
1428465|NCT00279474|cancer patients
1428466|NCT00279474|family
1428467|NCT00279474|cognitive behavior
1428468|NCT00279474|distress
1428469|NCT00279461|Rheumatoid Arthritis
1428470|NCT00279461|Vitamin D
1428471|NCT00279435|Intravenous, Steroid-Refractory, Ulcerative Colitis
1428472|NCT00279422|Intravenous, Steroid-Refractory, Ulcerative Colitis
1428473|NCT00279409|Attention Deficit Hyperactivity Disorder
1428474|NCT00279409|ADHD
1428475|NCT00279409|Treatment resistant
1428476|NCT00279409|Partial responder
1428477|NCT00279409|Non-responder
1428478|NCT00279409|Atypical Antipsychotic
1428479|NCT00279383|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
1428480|NCT00279370|SSRI Exposure
1428481|NCT00279370|Pregnancy
1428482|NCT00279370|Infant Development
1428483|NCT00279357|NBI
1428484|NCT00279357|high risk group for adenomas
1428485|NCT00279331|HIV Seronegativity
1428486|NCT00279331|Men who have Sex with Men
1428487|NCT00279331|MSM
1428488|NCT00279331|Peru
1428489|NCT00279331|Ecuador
1428490|NCT00279331|Incidence
1428491|NCT00279331|Prevalence
1428492|NCT00279331|Drug resistance, viral
1428493|NCT00279318|Environment
1428494|NCT00279318|Exposures
1428495|NCT00279318|Diet
1428496|NCT00279318|Toxins
1428497|NCT00279318|Psychosocial
1428498|NCT00279318|Infectious Agents
1428499|NCT00279318|Bacterial
1428500|NCT00279318|Viral
1428501|NCT00279318|Immunizations
1428502|NCT00279318|Autoantibody
1428503|NCT00279305|Newly diagnosed type 1 diabetes
1428504|NCT00279305|New Onset type 1 diabetes
1428505|NCT00279305|Preservation of insulin secretion
1428506|NCT00279305|Type 1 diabetes
1428507|NCT00279305|Juvenile Onset Diabetes
1428508|NCT00279305|Insulin Dependent Diabetes
1428509|NCT00279305|T1D
1428510|NCT00279292|Pancreatic neoplasm
1428511|NCT00279279|Implantable cardioverter defibrillator (ICD)
1428512|NCT00279279|Sudden Cardiac Death
1428513|NCT00279279|Primary Prevention
1428514|NCT00279266|Diabetic Peripheral Neuropathy
1428515|NCT00279266|Peripheral Neuropathy
1428516|NCT00279266|Diabetes Mellitus
1428517|NCT00279253|clonidine
1428518|NCT00279253|glaucoma
1428519|NCT00279240|Impaired glucose tolerance
1428520|NCT00279240|Intervention
1428521|NCT00279240|Prevention
1428522|NCT00279227|coronary artery disease
1428523|NCT00279227|epicardial adipose tissue
1428524|NCT00279227|epicardial fat
1428525|NCT00279227|obesity
1428526|NCT00279201|diabetes
1428527|NCT00279201|type 2
1428528|NCT00279188|Bronchial hyperresponsiveness
1428529|NCT00279188|Atopy
1428530|NCT00279188|Inhaled steroids
1428531|NCT00279188|Exacerbations
1428532|NCT00279188|Lung function decline
1428533|NCT00279188|Prognosis
1428534|NCT00279175|Acute myocardial infarction
1428535|NCT00279149|Telemedicine
1428536|NCT00279149|TELESTROKE
1428537|NCT00279149|symptoms of ischemic stroke since less than 3 hours
1428538|NCT00279136|Bronchial hyperresponsiveness,
1428539|NCT00279136|lung function,
1428540|NCT00279136|airway inflammation,
1428541|NCT00279136|deep inspiration,
1428542|NCT00279136|bronchial biopsies
1428543|NCT00279136|airway smooth muscle
1428544|NCT00279110|HIV
1428545|NCT00279110|Antiretroviral therapy
1428546|NCT00279110|Heroin dependence
1428547|NCT00279110|Methadone
1428548|NCT00279110|Buprenorphine
1428549|NCT00279097|Intracranial pressure
1428550|NCT00279097|High Frequency Chest Wall Oscillation
1428551|NCT00279097|Neurosurgery
1428552|NCT00279084|Anaemia
1428553|NCT00279084|Chronic kidney disease
1428554|NCT00279084|Type 2 diabetes
1428555|NCT00279084|Randomized trial
1428556|NCT00279071|dystocia
1428557|NCT00279071|stimulation
1428558|NCT00279071|acupuncture
1428559|NCT00279071|oxytocin
1428560|NCT00279045|type 2 diabetes monotherapy treatment naive
1428561|NCT00279032|GW406381
1428562|NCT00279032|peripheral nerve injury
1428563|NCT00279032|patients
1428564|NCT00279032|allodynia
1428565|NCT00279032|hyperalgesia
1428566|NCT00279032|randomised
1428567|NCT00279032|placebo-controlled
1428568|NCT00279019|GSK233705
1428890|NCT00277966|Fluoroscopy time
1428569|NCT00279019|Chronic Obstructive Pulmonary Disease (COPD)
1428570|NCT00279019|COPD
1428571|NCT00279006|DES (drug eluting stents)
1428572|NCT00279006|CAD (cornary artery disease)
1428573|NCT00279006|stent retrieval
1428574|NCT00278993|Prostate cancer
1428575|NCT00278993|metastatic disease
1428576|NCT00278967|colonoscopy
1428577|NCT00278967|preparation
1428578|NCT00278954|Primary Antibody Deficiency
1428579|NCT00278954|Common variable hypogammaglobulinemia
1428580|NCT00278954|X-linked hypogammaglobulinemia
1428581|NCT00278954|Hypogammaglobulinemia
1428582|NCT00278954|Immunodeficiency with hyper-IgM
1428583|NCT00278954|Wiskott-Aldrich Syndrome
1428584|NCT00278941|Seroquel SR™
1428585|NCT00278941|Major Depressive Disorder
1428586|NCT00278928|Hypertriglyceridemia
1428587|NCT00278928|Infant, Premature
1428588|NCT00278915|Progressive Precocious Puberty
1428589|NCT00278915|PPP
1428590|NCT00278915|McCune-Albright Syndrome
1428591|NCT00278915|MAS
1428592|NCT00278902|ErbB2+ Breast Cancer
1428593|NCT00278902|HER2+ Breast Cancer
1428594|NCT00278889|Colorectal Cancer
1428595|NCT00278889|phase II
1428596|NCT00278889|metastatic colorectal cancer
1428597|NCT00278889|AZD2171
1428598|NCT00278889|RECENTIN
1428599|NCT00278876|GIST
1428600|NCT00278876|Imatinib
1428601|NCT00278876|Adjuvant therapy
1428602|NCT00278876|Kit mutation
1428603|NCT00278863|Stomach cancer
1428604|NCT00278863|Palliative chemotherapy
1428605|NCT00278863|Capecitabine
1428606|NCT00278863|S-1
1428607|NCT00278850|Vulvar vestibulitis
1428608|NCT00278850|Treatment
1428609|NCT00278850|Education
1428610|NCT00278837|Meditation
1428611|NCT00278837|Stress-reduction
1428612|NCT00278837|Cognitive-affective behavior learning
1428613|NCT00278824|Chronic Pain
1428614|NCT00278824|Pain
1428615|NCT00278811|Mental Health Services
1428616|NCT00278811|Suicide
1428617|NCT00278811|Suicide ideation
1428618|NCT00278798|tracehelectomy
1428619|NCT00278798|radical hysterectomy
1428620|NCT00278785|interviews
1428621|NCT00278785|brief intervention
1428622|NCT00278785|drinking
1428623|NCT00278785|alcohol
1428624|NCT00278785|injuries
1428625|NCT00278785|wounds
1428626|NCT00278785|intervention studies
1428627|NCT00278759|rapid viral diagnosis
1428628|NCT00278759|respiratory infection
1428629|NCT00278759|pediatric emergency department
1428630|NCT00278759|febrile respiratory infection
1428631|NCT00278746|zinc
1428632|NCT00278746|diarrhea
1428633|NCT00278746|cluster randomization
1428634|NCT00278746|hospitalization
1428635|NCT00278733|Randomized controlled trial
1428636|NCT00278733|brief intervention
1428637|NCT00278733|university students
1428638|NCT00278733|physician advice
1428639|NCT00278733|high risk drinking
1428640|NCT00278707|Canavan Disease
1428641|NCT00278707|Aspartoacylase Deficiency
1428642|NCT00278707|NAA
1428643|NCT00278707|Acetate
1428644|NCT00278707|Glyceryltriacetate
1428645|NCT00278694|Oxaliplatin, radiation
1428646|NCT00278681|zinc
1428647|NCT00278681|diarrhea
1428648|NCT00278681|hospitalization
1428649|NCT00278681|programme
1428650|NCT00278538|Stem cell, Autoimmune disease, Systemic Lupus Erythematosus
1428651|NCT00278473|Primarily Inattentive
1428652|NCT00278473|Hyperactive Impulsive Type
1428653|NCT00278473|Combined Type
1428654|NCT00278473|ADHD
1428655|NCT00278473|Adults
1428656|NCT00278473|Psychological
1428657|NCT00278473|Cognitive Behavioral Therapy
1428658|NCT00278473|CBT
1428659|NCT00278460|stage IIIB non-small cell lung cancer
1428660|NCT00278460|stage IV non-small cell lung cancer
1428661|NCT00278460|adenocarcinoma of the lung
1428662|NCT00278460|bronchoalveolar cell lung cancer
1428663|NCT00278460|large cell lung cancer
1428664|NCT00278460|recurrent non-small cell lung cancer
1428665|NCT00278460|squamous cell lung cancer
1428666|NCT00278447|Alcohol
1428667|NCT00278447|Alcohol use
1428668|NCT00278447|Alcohol dependence
1428669|NCT00278447|Drug
1428670|NCT00278447|Drug use
1428671|NCT00278447|Drug dependence
1428672|NCT00278447|Utilization
1428673|NCT00278447|Hospitalization
1428674|NCT00278447|Primary care
1428675|NCT00278447|Chronic disease management
1428676|NCT00278447|Care management
1428677|NCT00278447|Comorbidity
1428678|NCT00278434|cervical cancer
1428679|NCT00278434|cervical intraepithelial neoplasia grade 2
1428680|NCT00278434|cervical intraepithelial neoplasia grade 3
1428681|NCT00278421|contiguous stage II grade 3 follicular lymphoma
1428682|NCT00278421|noncontiguous stage II grade 3 follicular lymphoma
1428683|NCT00278421|stage I grade 3 follicular lymphoma
1428684|NCT00278421|contiguous stage II adult diffuse large cell lymphoma
1428685|NCT00278421|contiguous stage II adult diffuse mixed cell lymphoma
1428686|NCT00278421|noncontiguous stage II adult diffuse large cell lymphoma
1428687|NCT00278421|noncontiguous stage II adult diffuse mixed cell lymphoma
1428688|NCT00278421|stage I adult diffuse large cell lymphoma
1428689|NCT00278421|stage I adult diffuse mixed cell lymphoma
1428690|NCT00278421|nodal marginal zone B-cell lymphoma
1428691|NCT00278421|anaplastic large cell lymphoma
1428692|NCT00278421|contiguous stage II adult immunoblastic large cell lymphoma
1428693|NCT00278421|noncontiguous stage II adult immunoblastic large cell lymphoma
1428694|NCT00278421|stage I adult immunoblastic large cell lymphoma
1428695|NCT00278421|contiguous stage II adult Burkitt lymphoma
1428696|NCT00278421|contiguous stage II mantle cell lymphoma
1428697|NCT00278421|noncontiguous stage II adult Burkitt lymphoma
1428698|NCT00278421|noncontiguous stage II mantle cell lymphoma
1428699|NCT00278421|stage I adult Burkitt lymphoma
1428700|NCT00278421|stage I mantle cell lymphoma
1428701|NCT00278421|contiguous stage II marginal zone lymphoma
1428702|NCT00278421|noncontiguous stage II marginal zone lymphoma
1428703|NCT00278421|stage I marginal zone lymphoma
1428704|NCT00278421|stage III marginal zone lymphoma
1428705|NCT00278421|stage IV marginal zone lymphoma
1428706|NCT00278421|stage III adult Burkitt lymphoma
1428707|NCT00278421|stage III adult diffuse large cell lymphoma
1428708|NCT00278421|stage III adult diffuse mixed cell lymphoma
1428709|NCT00278421|stage III adult immunoblastic large cell lymphoma
1428710|NCT00278421|stage III grade 3 follicular lymphoma
1428711|NCT00278421|stage III mantle cell lymphoma
1428712|NCT00278421|stage IV adult Burkitt lymphoma
1428713|NCT00278421|stage IV adult diffuse large cell lymphoma
1428714|NCT00278421|stage IV adult diffuse mixed cell lymphoma
1428715|NCT00278421|stage IV adult immunoblastic large cell lymphoma
1428716|NCT00278421|stage IV grade 3 follicular lymphoma
1428717|NCT00278421|stage IV mantle cell lymphoma
1428718|NCT00278408|contiguous stage II grade 3 follicular lymphoma
1428719|NCT00278408|noncontiguous stage II grade 3 follicular lymphoma
1428720|NCT00278408|stage I grade 3 follicular lymphoma
1428721|NCT00278408|stage III grade 3 follicular lymphoma
1428722|NCT00278408|stage IV grade 3 follicular lymphoma
1428723|NCT00278408|contiguous stage II adult diffuse large cell lymphoma
1428724|NCT00278408|contiguous stage II adult diffuse mixed cell lymphoma
1428725|NCT00278408|noncontiguous stage II adult diffuse large cell lymphoma
1428726|NCT00278408|noncontiguous stage II adult diffuse mixed cell lymphoma
1428727|NCT00278408|stage I adult diffuse large cell lymphoma
1428728|NCT00278408|stage I adult diffuse mixed cell lymphoma
1428729|NCT00278408|stage III adult diffuse large cell lymphoma
1428730|NCT00278408|stage III adult diffuse mixed cell lymphoma
1428731|NCT00278408|stage IV adult diffuse large cell lymphoma
1428732|NCT00278408|stage IV adult diffuse mixed cell lymphoma
1428733|NCT00278408|nodal marginal zone B-cell lymphoma
1428734|NCT00278408|anaplastic large cell lymphoma
1428735|NCT00278408|contiguous stage II adult immunoblastic large cell lymphoma
1428736|NCT00278408|noncontiguous stage II adult immunoblastic large cell lymphoma
1428737|NCT00278408|stage I adult immunoblastic large cell lymphoma
1428738|NCT00278408|stage III adult immunoblastic large cell lymphoma
1428739|NCT00278408|stage IV adult immunoblastic large cell lymphoma
1428740|NCT00278408|contiguous stage II adult Burkitt lymphoma
1428741|NCT00278408|contiguous stage II mantle cell lymphoma
1428742|NCT00278408|noncontiguous stage II adult Burkitt lymphoma
1428743|NCT00278408|noncontiguous stage II mantle cell lymphoma
1428744|NCT00278408|stage I adult Burkitt lymphoma
1428745|NCT00278408|stage I mantle cell lymphoma
1428746|NCT00278408|stage III adult Burkitt lymphoma
1428747|NCT00278408|stage III mantle cell lymphoma
1428748|NCT00278408|stage IV adult Burkitt lymphoma
1428749|NCT00278408|stage IV mantle cell lymphoma
1428750|NCT00278408|contiguous stage II marginal zone lymphoma
1428751|NCT00278408|noncontiguous stage II marginal zone lymphoma
1428752|NCT00278408|stage I marginal zone lymphoma
1428753|NCT00278408|stage III marginal zone lymphoma
1428754|NCT00278408|stage IV marginal zone lymphoma
1428755|NCT00278369|recurrent renal cell cancer
1428756|NCT00278369|stage IV renal cell cancer
1428757|NCT00278369|clear cell renal cell carcinoma
1428758|NCT00278304|cervical adenocarcinoma
1428759|NCT00278304|cervical adenosquamous cell carcinoma
1428760|NCT00278304|cervical squamous cell carcinoma
1428761|NCT00278304|stage IB cervical cancer
1428762|NCT00278304|stage IIA cervical cancer
1428763|NCT00278304|stage IIB cervical cancer
1428764|NCT00278304|stage III cervical cancer
1428765|NCT00278304|stage IVA cervical cancer
1428766|NCT00278304|stage IVB cervical cancer
1428767|NCT00278278|untreated childhood brain stem glioma
1428768|NCT00278278|untreated childhood cerebellar astrocytoma
1428769|NCT00278278|childhood high-grade cerebral astrocytoma
1428770|NCT00278278|childhood spinal cord neoplasm
1428771|NCT00278265|T-cell large granular lymphocyte leukemia
1428772|NCT00278265|anemia
1428773|NCT00278265|neutropenia
1428774|NCT00278252|recurrent childhood ependymoma
1428775|NCT00278252|childhood infratentorial ependymoma
1428776|NCT00278252|childhood supratentorial ependymoma
1428777|NCT00278239|long-term effects secondary to cancer therapy in children
1428778|NCT00278239|psychosocial effects of cancer and its treatment
1428779|NCT00278239|cognitive/functional effects
1428780|NCT00278239|childhood supratentorial primitive neuroectodermal tumor
1428781|NCT00278226|unspecified adult solid tumor, protocol specific
1428782|NCT00278213|prolymphocytic leukemia
1428783|NCT00278213|refractory chronic lymphocytic leukemia
1428784|NCT00278213|stage I chronic lymphocytic leukemia
1428785|NCT00278213|stage II chronic lymphocytic leukemia
1428786|NCT00278213|stage III chronic lymphocytic leukemia
1428787|NCT00278213|stage IV chronic lymphocytic leukemia
1428788|NCT00278213|T-cell large granular lymphocyte leukemia
1428789|NCT00278200|post-transplant lymphoproliferative disorder
1428790|NCT00278187|stage IIIB non-small cell lung cancer
1428791|NCT00278187|stage IV non-small cell lung cancer
1428792|NCT00278187|recurrent non-small cell lung cancer
1428793|NCT00278174|stage IV renal cell cancer
1428794|NCT00278174|recurrent renal cell cancer
1428795|NCT00278174|clear cell renal cell carcinoma
1428796|NCT00278161|stage 0 chronic lymphocytic leukemia
1428797|NCT00278161|stage I chronic lymphocytic leukemia
1428798|NCT00278161|stage II chronic lymphocytic leukemia
1428799|NCT00278161|stage III chronic lymphocytic leukemia
1428800|NCT00278161|stage IV chronic lymphocytic leukemia
1428801|NCT00278161|small lymphocytic lymphoma
1428802|NCT00278161|stage I small lymphocytic lymphoma
1428803|NCT00278161|stage III small lymphocytic lymphoma
1428804|NCT00278161|stage IV small lymphocytic lymphoma
1428805|NCT00278161|B-cell chronic lymphocytic leukemia
1428806|NCT00278161|splenic marginal zone lymphoma
1428807|NCT00278161|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1428808|NCT00278161|nodal marginal zone B-cell lymphoma
1428809|NCT00278161|stage I grade 1 follicular lymphoma
1428810|NCT00278161|stage I grade 2 follicular lymphoma
1428811|NCT00278161|stage III grade 1 follicular lymphoma
1428812|NCT00278161|stage III grade 2 follicular lymphoma
1428813|NCT00278161|stage IV grade 1 follicular lymphoma
1428814|NCT00278161|stage IV grade 2 follicular lymphoma
1428815|NCT00278161|stage I mantle cell lymphoma
1428816|NCT00278161|stage III mantle cell lymphoma
1428817|NCT00278161|stage IV mantle cell lymphoma
1428818|NCT00278161|Waldenstrom macroglobulinemia
1428819|NCT00278161|prolymphocytic leukemia
1428820|NCT00278161|stage I marginal zone lymphoma
1428821|NCT00278161|contiguous stage II adult diffuse small cleaved cell lymphoma
1428822|NCT00278161|contiguous stage II grade 1 follicular lymphoma
1428823|NCT00278161|contiguous stage II grade 2 follicular lymphoma
1428824|NCT00278161|contiguous stage II mantle cell lymphoma
1428825|NCT00278161|contiguous stage II marginal zone lymphoma
1428826|NCT00278161|contiguous stage II small lymphocytic lymphoma
1428827|NCT00278161|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1428828|NCT00278161|noncontiguous stage II grade 1 follicular lymphoma
1428829|NCT00278161|noncontiguous stage II grade 2 follicular lymphoma
1428830|NCT00278161|noncontiguous stage II mantle cell lymphoma
1428831|NCT00278161|noncontiguous stage II marginal zone lymphoma
1428832|NCT00278161|noncontiguous stage II small lymphocytic lymphoma
1428833|NCT00278161|stage III marginal zone lymphoma
1428834|NCT00278161|recurrent grade 1 follicular lymphoma
1428835|NCT00278161|recurrent grade 2 follicular lymphoma
1428836|NCT00278161|recurrent mantle cell lymphoma
1428837|NCT00278161|recurrent marginal zone lymphoma
1428838|NCT00278161|recurrent small lymphocytic lymphoma
1428839|NCT00278161|refractory chronic lymphocytic leukemia
1428840|NCT00278161|stage IV marginal zone lymphoma
1428841|NCT00278148|stage IIIA non-small cell lung cancer
1428842|NCT00278148|stage IIIB non-small cell lung cancer
1428843|NCT00278135|Cognition
1428844|NCT00278135|Memory
1428845|NCT00278135|Nutrition
1428846|NCT00278135|Omega-3
1428847|NCT00278135|DHA
1428848|NCT00278122|stage III melanoma
1428849|NCT00278122|stage IV melanoma
1428850|NCT00278122|recurrent melanoma
1428851|NCT00278109|stage I breast cancer
1428852|NCT00278109|stage II breast cancer
1428853|NCT00278096|disability
1428854|NCT00278096|occupational therapy
1428855|NCT00278083|Pharmacology
1428856|NCT00278083|Asthma
1428857|NCT00278083|TNF-alpha
1428858|NCT00278070|Metronomic-therapy
1428859|NCT00278070|vinorelbine
1428860|NCT00278070|Recurrent Breast Cancer
1428861|NCT00278070|Recurrent Non Small Cell Lung Cancer
1428862|NCT00278070|Metastatic prostate cancer
1428863|NCT00278057|Blood pressure;
1428864|NCT00278057|chronic renal failure;
1428865|NCT00278057|diabetes mellitus;
1428866|NCT00278057|dialysis fluid; glucose;
1428867|NCT00278057|hemodialysis;
1428868|NCT00278057|hypertension;
1428869|NCT00278057|uremia.
1428870|NCT00278044|Search as text words in Annotation & Scope Note
1428871|NCT00278031|Retinoblastoma
1428872|NCT00278031|Quality of life
1428873|NCT00278005|pediatric
1428874|NCT00278005|DiGeorge Syndrome
1428875|NCT00278005|Congenital heart defects
1428876|NCT00278005|Infections
1428877|NCT00278005|Cardiac surgery
1428878|NCT00277992|Pediatric
1428879|NCT00277992|Cardiac
1428880|NCT00277992|Norwood operation modification
1428881|NCT00277992|GT/Nissen operation
1428882|NCT00277992|Po feed
1428883|NCT00277992|GT fed
1428884|NCT00277979|pediatric
1428885|NCT00277979|cardiac
1428886|NCT00277979|Infantile Pompe's Disease
1428887|NCT00277979|3D Echocardiography
1428888|NCT00277966|Pediatric
1428889|NCT00277966|Cardiac Catheterization
1428891|NCT00277953|Pediatric
1428892|NCT00277953|Cardiac
1428893|NCT00277953|Tracheal Dimensions
1428894|NCT00277953|MRI
1428895|NCT00277940|Pediatric
1428896|NCT00277940|Cardiac
1428897|NCT00277940|Neoaortic Elastic Properties
1428898|NCT00277940|Aortic Arch Reconstruction
1428899|NCT00277927|Pediatric
1428900|NCT00277927|Cardiac
1428901|NCT00277927|Valvar Pulmonary Stenosis
1428902|NCT00277901|cardiac
1428903|NCT00277901|pediatric
1428904|NCT00277901|MRI
1428905|NCT00277901|Tetralogy of Fallot TOF
1428906|NCT00277901|Aortic Coarctation
1428907|NCT00277888|Dialysis
1428908|NCT00277888|Hemodialysis
1428909|NCT00277888|Catheterization
1428910|NCT00277875|Cardiovascular
1428911|NCT00277875|Flow-Mediated Vasodilation (FMD)
1428912|NCT00277875|Pulse Perfusion-Mediated Vasodilation (PPMV)
1428913|NCT00277875|Endothelial Function
1428914|NCT00277875|Heart Failure
1428915|NCT00277875|Local Distensibility
1428916|NCT00277875|Arterial Stiffening
1428917|NCT00277875|Augmentation Index (AI)
1428918|NCT00277875|Aging
1428919|NCT00277875|Isolated Systolic Hypertension
1428920|NCT00277875|Advanced Glycation Endproducts
1428921|NCT00277875|Vascular Stiffness
1428922|NCT00277862|chronic hepatitis C;
1428923|NCT00277862|peg-interferon alfa-2b;
1428924|NCT00277862|ribavirin,
1428925|NCT00277862|rapid virologic response,
1428926|NCT00277862|sustained virological response
1428927|NCT00277849|Sickle
1428928|NCT00277849|Hemoglobinopathy
1428929|NCT00277849|Thalassemia
1428930|NCT00277849|G6PD
1428931|NCT00277849|Plasmodium
1428932|NCT00277849|Erythrocyte Variant
1428933|NCT00277849|Hemoglobin Variant
1428934|NCT00277849|Healthy Volunteer
1428935|NCT00277849|HV
1428936|NCT00277836|malignant tumor
1428937|NCT00277823|Depression
1428938|NCT00277823|Adult
1428939|NCT00277823|Outpatients
1428940|NCT00277810|Alzheimer's Disease
1428941|NCT00277810|Cholinesterase Inhibitors
1428942|NCT00277810|Outpatients
1428943|NCT00277797|Low Back Pain
1428944|NCT00277784|Age Related Macular Degeneration
1428945|NCT00277784|Ultrasound
1428946|NCT00277784|OCT
1428947|NCT00277784|Eye
1428948|NCT00277771|technology in weight loss
1428949|NCT00277771|standard behavioral therapy for obesity
1428950|NCT00277758|Interleukin-2
1428951|NCT00277745|periodontitis
1428952|NCT00277745|microfluidics
1428953|NCT00277745|saliva diagnostics
1428954|NCT00277706|periodontitis
1428955|NCT00277706|bone regeneration
1428956|NCT00277706|Parathyroid Hormone
1428957|NCT00277706|moderate to advanced periodontitis
1428958|NCT00277693|hemodialysis
1428959|NCT00277693|aldosterone
1428960|NCT00277693|heart failure
1428961|NCT00277693|spironolactone
1428962|NCT00277680|uterine fibroids
1428963|NCT00277680|leiomyoma
1428964|NCT00277680|laparoscopy
1428965|NCT00277680|menorrhagia
1428966|NCT00277667|currently experiencing hypomania or mild mania
1428967|NCT00277654|Bipolar Disorder with Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder
1428968|NCT00277641|Binge Eating Disorder Associated with Obesity
1428969|NCT00277615|Children
1428970|NCT00277615|Bladder volume
1428971|NCT00277615|Ultrasound
1428972|NCT00277576|DNA vaccine
1428973|NCT00277576|immunotherapy
1428974|NCT00277576|Hepatitis B Virus
1428975|NCT00277576|Particle Mediated Epidermal Delivery
1428976|NCT00277563|Carpal Tunnel Syndrome
1428977|NCT00277563|Neuropathic Pain
1428978|NCT00277563|Neuromodulation
1428979|NCT00277563|PEMF
1428980|NCT00277563|Magnetic Field Therapy
1428981|NCT00277563|Magnetotherapy
1428982|NCT00277550|Constipation, Tegaserod, Dyspepsia
1428983|NCT00277537|Mannitol
1428984|NCT00277524|Pacemaker
1428985|NCT00277524|Defibrillator
1428986|NCT00277524|Cardiac Resynchronization
1428987|NCT00277524|Dysynchrony
1428988|NCT00277524|Heart failure
1428989|NCT00277524|Arrhythmia
1428990|NCT00277524|Tachycardia
1428991|NCT00277524|Bradycardia
1428992|NCT00277472|Hypertension
1428993|NCT00277472|High blood pressure
1428994|NCT00277472|diuretics
1428995|NCT00277472|valsartan
1428996|NCT00277446|Asthma
1428997|NCT00277446|Soy isoflavones
1428998|NCT00277446|Eosinophils
1428999|NCT00277446|Exhaled nitric oxide
1429000|NCT00277433|Atopic Dermatitis
1429001|NCT00277433|Eczema
1429002|NCT00277433|Genetics
1429003|NCT00277433|Histamine
1429004|NCT00277407|NAET
1429005|NCT00277407|Chiropractic procedures
1429006|NCT00277407|Acupuncture/acupressure
1429007|NCT00277407|Treatment of Autism by holistic procedures
1429008|NCT00277407|Food and Vaccination allergy
1429009|NCT00277394|Acute, symptomatic and objectively confirmed DVT
1429010|NCT00277381|Adherence
1429011|NCT00277381|Hypertension
1429012|NCT00277381|Telemedicine
1429013|NCT00277368|Epilepsy
1429014|NCT00277368|Headache
1429015|NCT00277368|Seizure
1429016|NCT00277355|Study of Minocycline in Huntington's Disease
1429017|NCT00277342|lipid induced hepatic insulin resistance
1429018|NCT00277342|polymorphisms liver fatty-acid-binding-protein
1429019|NCT00277342|gluconeogenesis
1429020|NCT00277342|glycogenolysis
1429021|NCT00277342|endogenous glucose production
1429022|NCT00277316|Kidney cancer
1429023|NCT00277316|Metastatic
1429024|NCT00277303|Colon Cancer
1429025|NCT00277290|Cancer
1429026|NCT00277290|Recurrent
1429027|NCT00277290|Platinum-resistant
1429028|NCT00277290|Platinum-sensitive
1429029|NCT00277277|Telemedicine
1429030|NCT00277277|Biobehavioral weight loss program
1429031|NCT00277277|Body Mass Index
1429032|NCT00277277|Blood Glucose
1429033|NCT00277277|Diabetes Management
1429034|NCT00277251|Crohn's disease
1429035|NCT00277251|systemic-onset juvenile rheumatoid arthritis
1429036|NCT00277251|juvenile dermatomyositis
1429037|NCT00277251|systemic lupus erythematosus (SLE)
1429038|NCT00277251|Mixed connective tissue disease (MCTD)
1429039|NCT00277251|vasculitis
1429040|NCT00277238|HCV
1429041|NCT00277238|Hepatitis c virus
1429042|NCT00277238|Virus diseases
1429043|NCT00277238|Interferon-alpha
1429044|NCT00277238|Interferons
1429045|NCT00277238|Liver diseases
1429046|NCT00277212|Bipolar I Disorder with a recent manic or mixed episode
1429047|NCT00277186|Arthroplasty
1429048|NCT00277186|Health services research
1429049|NCT00277186|Intent to treat
1429050|NCT00277186|Randomized
1429051|NCT00277186|Controlled
1429052|NCT00277173|Medication Safety
1429053|NCT00277173|Adverse Drug Events
1429054|NCT00277173|Preventable Adverse Drug Events
1429055|NCT00277173|Culture of Safety
1429056|NCT00277173|Failure Modes and Effects Analysis
1429057|NCT00277173|Teambuilding
1429058|NCT00277147|Typhoid Fever
1429059|NCT00277147|Immunogenicity
1429060|NCT00277147|Safety
1429061|NCT00277147|Vaccine
1429062|NCT00277147|Conjugate
1429063|NCT00277147|Healthy Volunteer
1429064|NCT00277121|Lipid disorder
1429065|NCT00277121|Gene mutation
1429066|NCT00277108|postpartum depression
1429067|NCT00277108|postnatal depression
1429068|NCT00277108|PPD
1429069|NCT00277095|Urinary Incontinence
1429070|NCT00277082|Metastatic or Recurrent Cancer of the Endometrium or the Lung (NSCLC)
1429071|NCT00277082|Aerosolized Liposomal 9-Nitro 20
1429072|NCT00277082|Camptothecin (L9NC)
1429073|NCT00277069|Breast metastatic
1429074|NCT00277056|leukemia
1429075|NCT00277043|Taxane
1429076|NCT00277043|Test Dose
1429077|NCT00277030|Respiratory Distress Syndrome
1429078|NCT00277030|Surfactant
1429079|NCT00277030|Nasal CPAP
1429080|NCT00277017|Combination Therapy
1429081|NCT00277017|5-Fluorouracil
1429082|NCT00277017|Interferon-a Interleukin-2
1429083|NCT00277017|Thalidomide
1429084|NCT00277017|Renal Cell Carcinoma
1429085|NCT00276991|Prolonged Viral Suppression
1429086|NCT00276991|HIV Infections
1429087|NCT00276978|Therapy-resistant Depression
1429088|NCT00276978|add-on therapy depression
1429089|NCT00276965|Bipolar II Depression
1429090|NCT00276952|Gonyautoxins
1429091|NCT00276952|Tension-type Headache
1429092|NCT00276952|Human Treatment
1429093|NCT00276939|Diabetes Mellitus, Type 2
1429094|NCT00276939|Diet, Vegetarian
1429095|NCT00276939|Diet, Fat-Restricted
1429096|NCT00276939|Glycemic Index
1429097|NCT00276926|Hypereosinophilic Syndrome
1429098|NCT00276926|Eosinophilic leukemias
1429099|NCT00276926|STI571 (Gleevec)
1429100|NCT00276926|PDGF receptor alpha
1429101|NCT00276926|Familiar hypereosinophilia
1429102|NCT00276926|Myeloproliferative disorder (MPD) with eosinophilia
1429103|NCT00276926|myeloproliferative disorders/myelodysplastic syndromes
1429104|NCT00276900|Postpartum Depression
1429105|NCT00276900|Recurrent Depression
1429106|NCT00276887|Somatization Disorder
1429107|NCT00276887|Multiple Medically Unexplained Symptoms
1429108|NCT00276887|Cognitive Behavior Therapy
1429109|NCT00276887|Mental Health
1429110|NCT00276874|Cocaine Addiction
1429111|NCT00276874|Cocaine Dependence
1429112|NCT00276861|adenocarcinoma of the colon
1429113|NCT00276861|recurrent colon cancer
1429114|NCT00276861|stage IV colon cancer
1429115|NCT00276848|stage III chronic lymphocytic leukemia
1429116|NCT00276848|stage IV chronic lymphocytic leukemia
1429117|NCT00276835|recurrent renal cell cancer
1429118|NCT00276835|clear cell renal cell carcinoma
1429119|NCT00276835|stage IV renal cell cancer
1429120|NCT00276835|recurrent melanoma
1429121|NCT00276835|stage IV melanoma
1429122|NCT00276822|stage I breast cancer
1429123|NCT00276822|stage II breast cancer
1429124|NCT00276822|stage IIIA breast cancer
1429125|NCT00276822|stage IIIB breast cancer
1429126|NCT00276822|stage IIIC breast cancer
1429127|NCT00276822|stage IV breast cancer
1429128|NCT00276809|stage 0 chronic lymphocytic leukemia
1429129|NCT00276809|stage I chronic lymphocytic leukemia
1429130|NCT00276809|stage II chronic lymphocytic leukemia
1429131|NCT00276809|stage III chronic lymphocytic leukemia
1429132|NCT00276809|stage IV chronic lymphocytic leukemia
1429133|NCT00276796|cervical squamous cell carcinoma
1429134|NCT00276796|stage III cervical cancer
1429135|NCT00276796|recurrent cervical cancer
1429136|NCT00276796|cervical adenocarcinoma
1429137|NCT00276796|cervical adenosquamous cell carcinoma
1429138|NCT00276796|cervical small cell carcinoma
1429139|NCT00276796|stage IVA cervical cancer
1429140|NCT00276796|stage IVB cervical cancer
1429141|NCT00276783|primary central nervous system lymphoma
1429142|NCT00276783|tumors metastatic to brain
1429143|NCT00276783|recurrent adult brain tumor
1429144|NCT00276783|adult giant cell glioblastoma
1429145|NCT00276783|adult gliosarcoma
1429146|NCT00276783|adult mixed glioma
1429147|NCT00276783|adult anaplastic astrocytoma
1429148|NCT00276783|adult anaplastic oligodendroglioma
1429149|NCT00276783|adult glioblastoma
1429150|NCT00276770|adult anaplastic astrocytoma
1429151|NCT00276770|adult anaplastic ependymoma
1429152|NCT00276770|adult anaplastic oligodendroglioma
1429153|NCT00276770|adult diffuse astrocytoma
1429154|NCT00276770|adult glioblastoma
1429155|NCT00276770|adult giant cell glioblastoma
1429156|NCT00276770|adult gliosarcoma
1429157|NCT00276770|adult ependymoma
1429158|NCT00276770|adult oligodendroglioma
1429159|NCT00276770|recurrent adult brain tumor
1429160|NCT00276770|adult mixed glioma
1429161|NCT00276757|childhood Langerhans cell histiocytosis
1429162|NCT00276744|recurrent pancreatic cancer
1429163|NCT00276744|stage III pancreatic cancer
1429164|NCT00276744|adenocarcinoma of the pancreas
1429165|NCT00276744|stage I pancreatic cancer
1429166|NCT00276744|stage II pancreatic cancer
1429167|NCT00276731|localized resectable neuroblastoma
1429168|NCT00276731|localized unresectable neuroblastoma
1429169|NCT00276731|regional neuroblastoma
1429170|NCT00276718|childhood malignant ovarian germ cell tumor
1429171|NCT00276718|childhood malignant testicular germ cell tumor
1429172|NCT00276718|childhood central nervous system germ cell tumor
1429173|NCT00276718|childhood extragonadal germ cell tumor
1429174|NCT00276718|childhood teratoma
1429175|NCT00276705|adult primary hepatocellular carcinoma
1429176|NCT00276705|childhood hepatocellular carcinoma
1429177|NCT00276705|advanced adult primary liver cancer
1429178|NCT00276705|localized resectable adult primary liver cancer
1429179|NCT00276705|localized unresectable adult primary liver cancer
1429180|NCT00276705|stage I childhood liver cancer
1429181|NCT00276705|stage II childhood liver cancer
1429182|NCT00276705|stage III childhood liver cancer
1429183|NCT00276705|stage IV childhood liver cancer
1429184|NCT00276692|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1429185|NCT00276679|recurrent neuroblastoma
1429186|NCT00276679|disseminated neuroblastoma
1429187|NCT00276679|localized unresectable neuroblastoma
1429188|NCT00276666|untreated childhood medulloblastoma
1429189|NCT00276640|recurrent childhood brain stem glioma
1429190|NCT00276640|untreated childhood brain stem glioma
1429191|NCT00276640|recurrent childhood cerebellar astrocytoma
1429192|NCT00276640|untreated childhood cerebellar astrocytoma
1429193|NCT00276640|childhood low-grade cerebral astrocytoma
1429194|NCT00276640|recurrent childhood cerebral astrocytoma
1429195|NCT00276640|childhood oligodendroglioma
1429196|NCT00276640|recurrent childhood visual pathway and hypothalamic glioma
1429197|NCT00276640|untreated childhood visual pathway and hypothalamic glioma
1429198|NCT00276640|childhood spinal cord neoplasm
1429199|NCT00276627|unspecified adult solid tumor, protocol specific
1429200|NCT00276614|stage IV renal cell cancer
1429201|NCT00276614|recurrent renal cell cancer
1429202|NCT00276614|papillary renal cell carcinoma
1429203|NCT00276601|untreated adult acute myeloid leukemia
1429204|NCT00276601|untreated childhood acute myeloid leukemia and other myeloid malignancies
1429205|NCT00276601|adult acute promyelocytic leukemia (M3)
1429206|NCT00276601|childhood acute promyelocytic leukemia (M3)
1429207|NCT00276601|adult acute myeloid leukemia with t(15;17)(q22;q12)
1429208|NCT00276588|adenocarcinoma of the lung
1429209|NCT00276588|adenosquamous cell lung cancer
1429210|NCT00276588|large cell lung cancer
1429211|NCT00276588|recurrent non-small cell lung cancer
1429212|NCT00276588|squamous cell lung cancer
1429213|NCT00276588|stage IIIB non-small cell lung cancer
1429214|NCT00276588|stage IV non-small cell lung cancer
1429215|NCT00276575|unspecified adult solid tumor, protocol specific
1429216|NCT00276549|adenocarcinoma of the prostate
1429217|NCT00276549|stage IV prostate cancer
1429218|NCT00276536|stage IV melanoma
1429219|NCT00276536|unspecified adult solid tumor, protocol specific
1429220|NCT00276523|stage II squamous cell carcinoma of the lip and oral cavity
1429221|NCT00276523|stage III squamous cell carcinoma of the lip and oral cavity
1429222|NCT00276523|stage IV squamous cell carcinoma of the lip and oral cavity
1429223|NCT00276523|stage II squamous cell carcinoma of the oropharynx
1429224|NCT00276523|stage III squamous cell carcinoma of the oropharynx
1429225|NCT00276523|stage IV squamous cell carcinoma of the oropharynx
1429226|NCT00276523|stage II squamous cell carcinoma of the hypopharynx
1429227|NCT00276523|stage III squamous cell carcinoma of the hypopharynx
1429228|NCT00276523|stage IV squamous cell carcinoma of the hypopharynx
1429229|NCT00276523|stage II squamous cell carcinoma of the larynx
1429230|NCT00276523|stage III squamous cell carcinoma of the larynx
1429231|NCT00276523|stage IV squamous cell carcinoma of the larynx
1429232|NCT00276523|recurrent squamous cell carcinoma of the hypopharynx
1429233|NCT00276523|recurrent squamous cell carcinoma of the larynx
1429234|NCT00276523|recurrent squamous cell carcinoma of the lip and oral cavity
1429235|NCT00276523|recurrent squamous cell carcinoma of the oropharynx
1429236|NCT00276497|Impaired glucose tolerance
1429237|NCT00276497|Intervention
1429238|NCT00276497|Prevention
1429239|NCT00276445|allergy
1429240|NCT00276445|Allergy conjunctivitis
1429241|NCT00276445|beta-1-3glucan
1429242|NCT00276445|Th1/Th2
1429243|NCT00276341|cognitive impairment
1429244|NCT00276289|nephrolithiasis
1429245|NCT00276289|hypercalciuria
1429246|NCT00276289|hypokalemia
1429247|NCT00276289|thiazide diuretics
1429248|NCT00276276|relapsed
1429249|NCT00276276|lung cancer
1429250|NCT00276276|resistant
1429251|NCT00276276|small cel
1429252|NCT00276276|topotecan (HYCAMTIN)
1429253|NCT00276263|Schizophrenia prodrome
1429254|NCT00276263|Sarcosine
1429255|NCT00276263|Psychosis
1429256|NCT00276263|NMDA receptor
1429257|NCT00276263|Prevention
1429258|NCT00276237|Congenital Heart Disease
1429259|NCT00276237|Pulmonary Valve Replacement
1429260|NCT00276224|iron deficiency schistosomiasis soil transmitted helminths
1429261|NCT00276211|MRI diffusion mamma cancer
1429262|NCT00276198|Clinical trial, controlled
1429263|NCT00276198|Micronutrients
1429264|NCT00276198|Dietary Supplementation
1429265|NCT00276198|Infants
1429266|NCT00276185|spasticity ;
1429267|NCT00276185|Botulinum toxin ;
1429268|NCT00276185|Upper limb ;
1429269|NCT00276185|motor function.
1429270|NCT00276185|spastic hemiplegia after stoke
1429271|NCT00276159|Leukemia
1429272|NCT00276159|Lymphoma
1429273|NCT00276159|Myeloma
1429274|NCT00276159|Hematology
1429275|NCT00276159|852A
1429276|NCT00276159|IRM
1429277|NCT00276159|Oncology
1429278|NCT00276146|dipyridamole
1429279|NCT00276146|magnesium
1429280|NCT00276146|sickle cell
1429281|NCT00276146|anemia
1429282|NCT00276146|red blood cells
1429283|NCT00276133|small dense LDL
1429284|NCT00276120|Breast
1429285|NCT00276120|Cancer
1429286|NCT00276120|Young
1429287|NCT00276120|Women
1429288|NCT00276107|Vaccine
1429289|NCT00276107|Healthy Infants
1429290|NCT00276094|Urogenital atrophy
1429291|NCT00276094|Vaginal atrophy
1429292|NCT00276094|Vulvar and vaginal atrophy in postmenopausal women
1429293|NCT00276094|Menopausal symptoms
1429294|NCT00276081|Hot flashes
1429295|NCT00276081|postmenopausal
1429296|NCT00276081|climacteric symptoms
1429297|NCT00276081|hormone replacement therapy
1429298|NCT00276081|gabapentin
1429299|NCT00276068|Vulvar vestibulitis
1429300|NCT00276068|Vulvodynia
1429301|NCT00276068|Desipramine
1429302|NCT00276068|Lidocaine
1429303|NCT00276068|Genetics
1429304|NCT00276055|Soft Tissue Sarcoma
1429305|NCT00276055|Phase I
1429306|NCT00276055|Gemcitabine
1429307|NCT00276055|Docetaxel
1429308|NCT00276055|Bevacizumab
1429309|NCT00276055|vascular endothelial growth factor
1429310|NCT00276042|AOM
1429311|NCT00276029|Asthma
1429312|NCT00276029|Refractory
1429313|NCT00276003|Lymphoma-Non Hodgkins
1429314|NCT00276003|Phase II
1429315|NCT00276003|Gemcitabine
1429316|NCT00276003|Irinotecan
1429317|NCT00275990|coronary thrombectomy
1429318|NCT00275990|thrombectomy for acute myocardial infarction
1429319|NCT00275990|C14.280.647.500
1429320|NCT00275990|C14.907.553.355.500
1429321|NCT00275977|"Stem cell"
1429322|NCT00275977|"autologous bone marrow transplantation"
1429323|NCT00275977|"Myocardial infarction"
1429324|NCT00275951|Combination
1429325|NCT00275951|Chemotherapy
1429326|NCT00275951|Gastric cancer
1429327|NCT00275938|hepatitis B virus
1429328|NCT00275938|e antigen
1429329|NCT00275938|interferon
1429330|NCT00275938|ribavirin
1429331|NCT00275925|partial epilepsy, oxcarbazepine, adults
1429332|NCT00275834|obesity treatment
1429333|NCT00275834|weight loss
1429334|NCT00275834|antiobesity drugs
1429335|NCT00275834|zonisamide
1429336|NCT00275821|Age-related macular degeneration, ranibizumab
1429337|NCT00275795|NST-NAET testing
1429338|NCT00275795|Food Ssensitivities
1429339|NCT00275795|Eczema
1429340|NCT00275795|Acne
1429341|NCT00275795|Indigestion
1429342|NCT00275769|Arrhythmia
1429343|NCT00275769|Bradycardia
1429344|NCT00275769|Cardiac Pacemaker Artificial
1429345|NCT00275756|Ocular Physiology
1429346|NCT00275756|Brimonidine
1429347|NCT00275756|Timoptic
1429348|NCT00275756|Dorzolamide
1429349|NCT00275756|ocular blood flow
1429350|NCT00275756|Regional Blood Flow
1429351|NCT00275730|indometacine
1429352|NCT00275730|retinal blood flow
1429353|NCT00275730|choroidal blood flow
1429354|NCT00275561|Eosinophilic Esophagitis
1429355|NCT00275561|Fluticasone
1429356|NCT00275561|Dysphagia
1429357|NCT00275535|kidney transplantation
1429358|NCT00275535|immunosuppression
1429359|NCT00275535|calcineurin inhibitor
1429360|NCT00275535|sirolimus
1429361|NCT00275535|chronic allograft nephropathy
1429362|NCT00275509|kidney
1429363|NCT00275509|transplantation
1429364|NCT00275509|positive crossmatch
1429365|NCT00275509|antibody mediated rejection
1429366|NCT00275509|rejection
1429367|NCT00275509|induction
1429368|NCT00275509|therapy
1429369|NCT00275509|trial
1429370|NCT00275496|SLND
1429371|NCT00275496|Sentinel
1429372|NCT00275496|Melanoma
1429373|NCT00275496|Surgical
1429374|NCT00275431|cancer
1429375|NCT00275431|AT-101
1429376|NCT00275431|AT101
1429377|NCT00275431|B-cell malignancies
1429378|NCT00275431|Non-Hodgkin
1429379|NCT00275431|lymphoma
1429380|NCT00275431|lukemia
1429381|NCT00275418|Crohn's disease
1429382|NCT00275418|remission
1429383|NCT00275418|beta carotene
1429384|NCT00275405|Effects of Garlic
1429385|NCT00275392|Dizziness
1429386|NCT00275392|Geriatrics
1429387|NCT00275392|Rehabilitation
1429388|NCT00275392|Vestibular rehabilitation
1429389|NCT00275379|Cystitis
1429390|NCT00275366|cuff, rotator
1429391|NCT00275366|Rotator cuff
1429392|NCT00275340|Pain
1429393|NCT00275340|Depressive Symptoms
1429394|NCT00275340|Coronary Artery Bypass
1429395|NCT00275340|Convalescence
1429396|NCT00275340|Quality of Life
1429397|NCT00275340|Human Activities
1429398|NCT00275327|antibiotics
1429399|NCT00275314|transplantation
1429400|NCT00275301|Borderline Personality Disorder
1429401|NCT00275301|BPD
1429402|NCT00275301|PET
1429403|NCT00275301|olanzapine
1429404|NCT00275301|brain
1429405|NCT00275288|Borderline Personality Disorder
1429406|NCT00275288|BPD
1429407|NCT00275288|amygdala
1429408|NCT00275288|facial expression response
1429409|NCT00275288|MRI
1429410|NCT00275275|PD
1429411|NCT00275275|Parkinson's
1429412|NCT00275262|Bone marrow transplantation
1429413|NCT00275262|Hematopoietic stem cell transplantation
1429414|NCT00275262|Hodgkin's disease
1429415|NCT00275262|non-Hodgkin's lymphoma
1429416|NCT00275262|multiple myeloma
1429417|NCT00275249|Chronic Pain
1429418|NCT00275236|Idiopthic Restless Legs Syndrome
1429419|NCT00275223|adipose tissue
1429420|NCT00275223|adipocytokines
1429421|NCT00275210|Oxaliplatin
1429422|NCT00275210|Chemotherapy,adjuvant
1429423|NCT00275210|Colonic Neoplasms
1429424|NCT00275184|Bowel preparation
1429425|NCT00275184|capsule endoscopy
1429426|NCT00275184|randomised
1429427|NCT00275184|Citramag
1429428|NCT00275184|Senna
1429429|NCT00275184|Metoclopramide
1429430|NCT00275184|Patients referred for Capsule endoscopy
1429431|NCT00275184|occult/overt gastrointestinal bleeding
1429432|NCT00275184|other suspected small bowel pathology
1429433|NCT00275171|Nontoxic nodular goiter
1429434|NCT00275171|131I therapy
1429435|NCT00275171|thyroid radioiodine uptake
1429436|NCT00275171|optimal time-interval
1429437|NCT00275171|reduced 131I activity
1429438|NCT00275171|goiter reduction
1429439|NCT00275158|Pre-Eclampsia
1429440|NCT00275158|Glomerular Filtration Rate (GFR)
1429441|NCT00275158|Inulin clearance
1429442|NCT00275158|Hypertension
1429443|NCT00275158|L-Arginine
1429444|NCT00275158|Nitric Oxide
1429445|NCT00275158|cGMP
1429446|NCT00275158|Endothelin
1429447|NCT00275158|ADMA
1429448|NCT00275132|stage IIIB non-small cell lung cancer
1429449|NCT00275132|stage IV non-small cell lung cancer
1429450|NCT00275119|adenocarcinoma of the pancreas
1429451|NCT00275119|stage II pancreatic cancer
1429452|NCT00275119|stage III pancreatic cancer
1429453|NCT00275119|recurrent pancreatic cancer
1429454|NCT00275106|stage I childhood lymphoblastic lymphoma
1429455|NCT00275106|stage II childhood lymphoblastic lymphoma
1429456|NCT00275106|stage III childhood lymphoblastic lymphoma
1429457|NCT00275106|stage IV childhood lymphoblastic lymphoma
1429458|NCT00275067|adult anaplastic astrocytoma
1429459|NCT00275067|adult gliosarcoma
1429460|NCT00275067|adult anaplastic oligodendroglioma
1429461|NCT00275067|adult mixed glioma
1429462|NCT00275067|adult glioblastoma
1429463|NCT00275067|adult giant cell glioblastoma
1429464|NCT00275067|recurrent adult brain tumor
1429465|NCT00275054|stage 0 chronic lymphocytic leukemia
1429466|NCT00275054|B-cell chronic lymphocytic leukemia
1429467|NCT00275054|stage I chronic lymphocytic leukemia
1429468|NCT00275054|stage II chronic lymphocytic leukemia
1429469|NCT00275041|recurrent breast cancer
1429470|NCT00275041|stage IV breast cancer
1429471|NCT00275041|male breast cancer
1429472|NCT00275015|stage 0 chronic lymphocytic leukemia
1429473|NCT00275015|stage I chronic lymphocytic leukemia
1429474|NCT00275015|stage II chronic lymphocytic leukemia
1429475|NCT00275015|stage III chronic lymphocytic leukemia
1429476|NCT00275015|stage IV chronic lymphocytic leukemia
1429477|NCT00275015|refractory chronic lymphocytic leukemia
1429478|NCT00275002|recurrent childhood brain stem glioma
1429479|NCT00275002|recurrent childhood brain tumor
1429480|NCT00274989|B-cell chronic lymphocytic leukemia
1429481|NCT00274989|relapsed refractory chronic lymphocytic leukemia
1429482|NCT00274989|previously untreated chronic lymphocytic leukemia
1429483|NCT00274976|refractory chronic lymphocytic leukemia
1429484|NCT00274976|stage III chronic lymphocytic leukemia
1429485|NCT00274976|stage IV chronic lymphocytic leukemia
1429486|NCT00274963|B-cell chronic lymphocytic leukemia
1429487|NCT00274963|refractory chronic lymphocytic leukemia
1429488|NCT00274950|childhood extragonadal germ cell tumor
1429489|NCT00274950|childhood malignant ovarian germ cell tumor
1429490|NCT00274950|childhood malignant testicular germ cell tumor
1429491|NCT00274950|recurrent childhood malignant germ cell tumor
1429492|NCT00274950|childhood teratoma
1429493|NCT00274950|childhood extracranial germ cell tumor
1429494|NCT00274924|contiguous stage II adult diffuse large cell lymphoma
1429495|NCT00274924|noncontiguous stage II adult diffuse large cell lymphoma
1429496|NCT00274924|stage III adult diffuse large cell lymphoma
1429497|NCT00274924|stage IV adult diffuse large cell lymphoma
1429498|NCT00274911|untreated childhood supratentorial primitive neuroectodermal tumor
1429499|NCT00274898|stage II non-small cell lung cancer
1429500|NCT00274898|stage IIIA non-small cell lung cancer
1429501|NCT00274898|stage IIIB non-small cell lung cancer
1429502|NCT00274898|recurrent non-small cell lung cancer
1429503|NCT00274885|neurotoxicity
1429504|NCT00274885|carcinoma of the appendix
1429505|NCT00274885|recurrent anal cancer
1429506|NCT00274885|stage I anal cancer
1429507|NCT00274885|stage II anal cancer
1429508|NCT00274885|stage IIIA anal cancer
1429509|NCT00274885|stage IIIB anal cancer
1429510|NCT00274885|stage IV anal cancer
1429511|NCT00274885|localized extrahepatic bile duct cancer
1429512|NCT00274885|recurrent extrahepatic bile duct cancer
1429513|NCT00274885|unresectable extrahepatic bile duct cancer
1429514|NCT00274885|localized gallbladder cancer
1429515|NCT00274885|recurrent gallbladder cancer
1429516|NCT00274885|unresectable gallbladder cancer
1429517|NCT00274885|recurrent gastric cancer
1429518|NCT00274885|stage IV gastric cancer
1429519|NCT00274885|recurrent colon cancer
1429520|NCT00274885|recurrent rectal cancer
1429521|NCT00274885|recurrent esophageal cancer
1429522|NCT00274885|localized gastrointestinal carcinoid tumor
1429523|NCT00274885|metastatic gastrointestinal carcinoid tumor
1429524|NCT00274885|recurrent gastrointestinal carcinoid tumor
1429525|NCT00274885|regional gastrointestinal carcinoid tumor
1429526|NCT00274885|gastrointestinal stromal tumor
1429527|NCT00274885|advanced adult primary liver cancer
1429528|NCT00274885|localized resectable adult primary liver cancer
1429529|NCT00274885|localized unresectable adult primary liver cancer
1429530|NCT00274885|recurrent adult primary liver cancer
1429531|NCT00274885|recurrent pancreatic cancer
1429532|NCT00274885|stage I pancreatic cancer
1429533|NCT00274885|stage II pancreatic cancer
1429534|NCT00274885|stage III pancreatic cancer
1429535|NCT00274885|recurrent small intestine cancer
1429536|NCT00274885|small intestine adenocarcinoma
1429537|NCT00274885|small intestine leiomyosarcoma
1429538|NCT00274885|small intestine lymphoma
1429539|NCT00274885|stage IV pancreatic cancer
1429540|NCT00274885|metastatic extrahepatic bile duct cancer
1429541|NCT00274885|metastatic gallbladder cancer
1429542|NCT00274885|stage IA gastric cancer
1429543|NCT00274885|stage IB gastric cancer
1429544|NCT00274885|stage IIA gastric cancer
1429545|NCT00274885|stage IIB gastric cancer
1429546|NCT00274885|stage IIIA gastric cancer
1429547|NCT00274885|stage IIIB gastric cancer
1429548|NCT00274885|stage IIIC gastric cancer
1429549|NCT00274885|stage I colon cancer
1429550|NCT00274885|stage IIA colon cancer
1429551|NCT00274885|stage IIB colon cancer
1429552|NCT00274885|stage IIIA colon cancer
1429553|NCT00274885|stage IIIB colon cancer
1429554|NCT00274885|stage IIIC colon cancer
1429555|NCT00274885|stage IVA colon cancer
1429556|NCT00274885|stage IVB colon cancer
1429557|NCT00274885|stage I rectal cancer
1429558|NCT00274885|stage IIA rectal cancer
1429559|NCT00274885|stage IIB rectal cancer
1429560|NCT00274885|stage IIC rectal cancer
1429561|NCT00274885|stage IIIA rectal cancer
1429562|NCT00274885|stage IIIB rectal cancer
1429563|NCT00274885|stage IIIC rectal cancer
1429564|NCT00274885|stage IVA rectal cancer
1429565|NCT00274885|stage IVB rectal cancer
1429566|NCT00274885|stage IA esophageal cancer
1429567|NCT00274885|stage IB esophageal cancer
1429568|NCT00274885|stage IIA esophageal cancer
1429569|NCT00274885|stage IIB esophageal cancer
1429570|NCT00274885|stage IIIA esophageal cancer
1429571|NCT00274885|stage IIIB esophageal cancer
1429572|NCT00274885|stage IIIC esophageal cancer
1429573|NCT00274885|stage IV esophageal cancer
1429574|NCT00274872|recurrent rectal cancer
1429575|NCT00274872|stage IV rectal cancer
1429576|NCT00274872|recurrent colon cancer
1429577|NCT00274872|stage IV colon cancer
1429794|NCT00273910|gp 100:209-217 (210m)
1429578|NCT00274872|adenocarcinoma of the colon
1429579|NCT00274872|adenocarcinoma of the rectum
1429580|NCT00274859|unspecified adult solid tumor, protocol specific
1429581|NCT00274846|recurrent adult acute myeloid leukemia
1429582|NCT00274846|recurrent childhood acute myeloid leukemia
1429583|NCT00274846|secondary acute myeloid leukemia
1429584|NCT00274846|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1429585|NCT00274846|adult acute myeloid leukemia with inv(16)(p13;q22)
1429586|NCT00274846|adult acute myeloid leukemia with t(15;17)(q22;q12)
1429587|NCT00274846|adult acute myeloid leukemia with t(16;16)(p13;q22)
1429588|NCT00274846|adult acute myeloid leukemia with t(8;21)(q22;q22)
1429589|NCT00274833|adult glioblastoma
1429590|NCT00274833|adult giant cell glioblastoma
1429591|NCT00274833|adult gliosarcoma
1429592|NCT00274820|chronic idiopathic myelofibrosis
1429593|NCT00274820|chronic myelomonocytic leukemia
1429594|NCT00274820|atypical chronic myeloid leukemia
1429595|NCT00274820|myelodysplastic/myeloproliferative disease, unclassifiable
1429596|NCT00274820|de novo myelodysplastic syndromes
1429597|NCT00274820|previously treated myelodysplastic syndromes
1429598|NCT00274820|secondary myelodysplastic syndromes
1429599|NCT00274807|untreated adult acute myeloid leukemia
1429600|NCT00274807|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1429601|NCT00274807|adult acute myeloid leukemia with inv(16)(p13;q22)
1429602|NCT00274807|adult acute myeloid leukemia with t(15;17)(q22;q12)
1429603|NCT00274807|adult acute myeloid leukemia with t(16;16)(p13;q22)
1429604|NCT00274807|adult acute myeloid leukemia with t(8;21)(q22;q22)
1429605|NCT00274794|noncontiguous stage II adult Burkitt lymphoma
1429606|NCT00274794|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1429607|NCT00274794|nodal marginal zone B-cell lymphoma
1429608|NCT00274794|stage III adult Burkitt lymphoma
1429609|NCT00274794|stage IV adult Burkitt lymphoma
1429610|NCT00274794|noncontiguous stage II adult diffuse large cell lymphoma
1429611|NCT00274794|noncontiguous stage II adult diffuse mixed cell lymphoma
1429612|NCT00274794|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1429613|NCT00274794|recurrent adult diffuse large cell lymphoma
1429614|NCT00274794|recurrent adult diffuse mixed cell lymphoma
1429615|NCT00274794|recurrent adult diffuse small cleaved cell lymphoma
1429616|NCT00274794|stage III adult diffuse large cell lymphoma
1429617|NCT00274794|stage III adult diffuse mixed cell lymphoma
1429618|NCT00274794|stage III adult diffuse small cleaved cell lymphoma
1429619|NCT00274794|stage IV adult diffuse large cell lymphoma
1429620|NCT00274794|stage IV adult diffuse mixed cell lymphoma
1429621|NCT00274794|stage IV adult diffuse small cleaved cell lymphoma
1429622|NCT00274794|noncontiguous stage II adult immunoblastic large cell lymphoma
1429623|NCT00274794|recurrent adult immunoblastic large cell lymphoma
1429624|NCT00274794|stage III adult immunoblastic large cell lymphoma
1429625|NCT00274794|stage IV adult immunoblastic large cell lymphoma
1429626|NCT00274794|noncontiguous stage II adult lymphoblastic lymphoma
1429627|NCT00274794|recurrent adult lymphoblastic lymphoma
1429628|NCT00274794|stage III adult lymphoblastic lymphoma
1429629|NCT00274794|stage IV adult lymphoblastic lymphoma
1429630|NCT00274794|noncontiguous stage II grade 1 follicular lymphoma
1429631|NCT00274794|noncontiguous stage II grade 2 follicular lymphoma
1429632|NCT00274794|noncontiguous stage II grade 3 follicular lymphoma
1429633|NCT00274794|recurrent grade 1 follicular lymphoma
1429634|NCT00274794|recurrent grade 2 follicular lymphoma
1429635|NCT00274794|recurrent grade 3 follicular lymphoma
1429636|NCT00274794|stage III grade 1 follicular lymphoma
1429637|NCT00274794|stage III grade 2 follicular lymphoma
1429638|NCT00274794|stage III grade 3 follicular lymphoma
1429639|NCT00274794|stage IV grade 1 follicular lymphoma
1429640|NCT00274794|stage IV grade 2 follicular lymphoma
1429641|NCT00274794|stage IV grade 3 follicular lymphoma
1429642|NCT00274794|noncontiguous stage II mantle cell lymphoma
1429643|NCT00274794|recurrent mantle cell lymphoma
1429644|NCT00274794|stage III mantle cell lymphoma
1429645|NCT00274794|stage IV mantle cell lymphoma
1429646|NCT00274794|noncontiguous stage II marginal zone lymphoma
1429647|NCT00274794|recurrent marginal zone lymphoma
1429648|NCT00274794|splenic marginal zone lymphoma
1429649|NCT00274794|stage III marginal zone lymphoma
1429650|NCT00274794|stage IV marginal zone lymphoma
1429651|NCT00274794|noncontiguous stage II small lymphocytic lymphoma
1429652|NCT00274794|recurrent small lymphocytic lymphoma
1429653|NCT00274794|stage III small lymphocytic lymphoma
1429654|NCT00274794|stage IV small lymphocytic lymphoma
1429655|NCT00274781|refractory anemia with excess blasts in transformation
1429656|NCT00274781|refractory anemia with excess blasts
1429657|NCT00274781|chronic myelomonocytic leukemia
1429658|NCT00274781|secondary acute myeloid leukemia
1429659|NCT00274781|previously treated myelodysplastic syndromes
1429660|NCT00274781|secondary myelodysplastic syndromes
1429661|NCT00274781|de novo myelodysplastic syndromes
1429662|NCT00274768|stage IV breast cancer
1429663|NCT00274768|male breast cancer
1429664|NCT00274768|recurrent breast cancer
1429665|NCT00274755|adult anaplastic astrocytoma
1429666|NCT00274755|adult diffuse astrocytoma
1429667|NCT00274755|adult glioblastoma
1429668|NCT00274755|adult giant cell glioblastoma
1429669|NCT00274755|adult gliosarcoma
1429670|NCT00274755|adult pilocytic astrocytoma
1429671|NCT00274755|adult anaplastic ependymoma
1429672|NCT00274755|adult ependymoma
1429673|NCT00274755|adult myxopapillary ependymoma
1429674|NCT00274755|adult subependymoma
1429675|NCT00274755|adult anaplastic oligodendroglioma
1429676|NCT00274755|adult oligodendroglioma
1429677|NCT00274755|adult mixed glioma
1429678|NCT00274742|Non-Hodgkin's Lymphoma
1429679|NCT00274742|Cancer immunotherapy
1429680|NCT00274742|Monoclonal antibody
1429681|NCT00274742|anti-CD19
1429682|NCT00274742|anti-CD3
1429683|NCT00274742|BiTE
1429684|NCT00274742|Blinatumomab
1429685|NCT00274729|Dietary intervention
1429686|NCT00274729|High-carbohydrate diet
1429687|NCT00274729|High-fat diet
1429688|NCT00274729|Moderate-fat diet
1429689|NCT00274729|Obesity
1429690|NCT00274729|Weight maintenance
1429691|NCT00274729|Body composition
1429692|NCT00274729|Glucose metabolism
1429693|NCT00274729|Cardiovascular disease
1429694|NCT00274729|Appetite regulation
1429695|NCT00274729|Energy expenditure
1429696|NCT00274703|anti IL-5
1429697|NCT00274703|oesophagitis
1429698|NCT00274703|eosinophils
1429699|NCT00274703|mepolizumab
1429700|NCT00274703|adults
1429701|NCT00274690|Neurokinin-1 Receptor Antagonist
1429702|NCT00274690|GW679769
1429703|NCT00274690|Post-operative Nausea
1429704|NCT00274690|NK-1 Receptor Antagonist
1429705|NCT00274690|PONV
1429706|NCT00274690|Post-discharge Nausea and Vomiting
1429707|NCT00274690|PDNV
1429708|NCT00274690|Vomiting
1429709|NCT00274677|Bipolar Disorder
1429710|NCT00274664|Amblyopia
1429711|NCT00274664|Occlusion dose monitoring
1429712|NCT00274664|Refractive adaptation
1429713|NCT00274664|Dose-response
1429714|NCT00274651|CTCL
1429715|NCT00274651|PTCL
1429716|NCT00274651|lymphoma
1429717|NCT00274651|Non-Hodgkin's Lymphoma
1429718|NCT00274651|Cutaneous T-Cell Lymphomas (CTCL)
1429719|NCT00274651|Peripheral T-Cell Lymphomas (PTCL)
1429720|NCT00274651|Other Types of Non-Hodgkin's Lymphoma
1429721|NCT00274651|belinostat
1429722|NCT00274625|Biomaterials
1429723|NCT00274625|Bariatric Surgery
1429724|NCT00274625|Hernia, Prevention of
1429725|NCT00274625|Obesity
1429726|NCT00274625|Bypass Surgery
1429727|NCT00274625|Incisional Hernia
1429728|NCT00274625|Ventral Hernia
1429729|NCT00274495|Genotype 1
1429730|NCT00274495|Metabolic syndrome
1429731|NCT00274495|Insulin resistance
1429732|NCT00274469|oncology
1429733|NCT00274469|cancer
1429734|NCT00274469|breast cancer
1429735|NCT00274456|Metastatic breast cancer, nab paclitaxel, docetaxel,
1429736|NCT00274404|infectious mononucleosis
1429737|NCT00274404|Epstein-Barr virus
1429738|NCT00274404|valacyclovir
1429739|NCT00274404|quantitative PCR
1429740|NCT00274378|radius fracture
1429741|NCT00274378|fracture fixation
1429742|NCT00274378|homologous bone transplantation
1429743|NCT00274365|general practitioners, psychiatry, videoconference
1429744|NCT00274352|sarcoidosis
1429745|NCT00274352|adalimumab
1429746|NCT00274352|skin diseases
1429747|NCT00274339|Laryngopharyngeal Reflux
1429748|NCT00274339|Prevacid
1429749|NCT00274339|Lifestyle changes
1429750|NCT00274339|Reflux Finding Score
1429751|NCT00274339|Reflux Symptom Index
1429752|NCT00274339|Laryngoscopy
1429753|NCT00274326|Hyponatremia
1429754|NCT00274313|Cystic Fibrosis
1429755|NCT00274300|DNA vaccine
1429756|NCT00274300|immunotherapy
1429757|NCT00274300|Herpes Simplex Virus Type 2 (HSV2)
1429758|NCT00274300|Particle Mediated Epidermal Delivery
1429759|NCT00274261|contraception
1429760|NCT00274235|Malaria
1429761|NCT00274235|Prevention
1429762|NCT00274235|Pregnancy
1429763|NCT00274235|Low birthweight
1429764|NCT00274235|Anemia
1429765|NCT00274235|Africa
1429766|NCT00274222|COPD, nebulized budesonide, systemic corticosteroids
1429767|NCT00274209|Ulcerative colitis
1429768|NCT00274209|Crohn's disease
1429769|NCT00274209|Chromoendoscopy
1429770|NCT00274209|Dysplasia
1429771|NCT00274209|Neoplasia
1429772|NCT00274196|fractures, occult
1429773|NCT00274196|hip
1429774|NCT00274196|ultrasound examination
1429775|NCT00274196|MRI
1429776|NCT00274196|sensitivity
1429777|NCT00274196|specificity
1429778|NCT00274170|Migraine
1429779|NCT00274170|Octreotide
1429780|NCT00274170|Prochlorperazine
1429781|NCT00274157|Peripheral Vascular Disease
1429782|NCT00274157|Intermittent Claudication
1429783|NCT00274157|Catheter-based Arterial Revascularization
1429784|NCT00274157|Peripheral angioplasty
1429785|NCT00274157|Peripheral stenting
1429786|NCT00274157|Functional capacity
1429787|NCT00274157|Quality of life
1429788|NCT00273949|Lactulose
1429789|NCT00273949|Prebiotics
1429790|NCT00273949|Nosocomial infection
1429791|NCT00273949|children
1429792|NCT00273949|infants
1429793|NCT00273910|Disease Free Survival
1429795|NCT00273910|Immunologic Response
1429796|NCT00273910|Adjuvant Therapy
1429797|NCT00273910|Cutaneous Melanoma
1429798|NCT00273910|Melanoma
1429799|NCT00273897|Dementia Treatment
1429800|NCT00273897|Hand Function
1429801|NCT00273897|Clinical Trials
1429802|NCT00273897|Dementia
1429803|NCT00273897|Cortical Syndrome
1429804|NCT00273897|CBS
1429805|NCT00273897|Apraxia
1429806|NCT00273884|AML
1429807|NCT00273884|Secondary AML
1429808|NCT00273884|Leukemia
1429809|NCT00273871|kidney transplant
1429810|NCT00273858|Rheumatoid Arthritis
1429811|NCT00273858|Ankylosing Spondylitis
1429812|NCT00273858|Psoriatic Arthritis
1429813|NCT00273845|case management
1429814|NCT00273845|substance abuse treatment
1429815|NCT00273845|linkage
1429816|NCT00273832|Chest pain
1429817|NCT00273832|Angina pectoris
1429818|NCT00273832|Emergency medicine
1429819|NCT00273832|Spiral computed tomography
1429820|NCT00273832|Length of stay
1429821|NCT00273832|Cost analysis
1429822|NCT00273819|Congestive heart failure, LV dysfunction
1429823|NCT00273806|Behavioral risk factors
1429824|NCT00273806|Primary Care
1429825|NCT00273806|Health services research
1429826|NCT00273780|Patient compliance
1429827|NCT00273767|troponin T
1429828|NCT00273767|CK-MB
1429829|NCT00273767|protein S-100
1429830|NCT00273767|Cardiopulmonary Bypass
1429831|NCT00273767|Erythropoietin
1429832|NCT00273754|Obstructive Sleep Apnea (OSA)
1429833|NCT00273754|Tonsillectomy and Adenoidectomy (T&A)
1429834|NCT00273754|Postoperative Complications
1429835|NCT00273754|Recovery
1429836|NCT00273741|palliative care
1429837|NCT00273741|methylphenidate
1429838|NCT00273728|Hydroxyethyl Starch
1429839|NCT00273728|shock, septic
1429840|NCT00273728|infusion, intravenous
1429841|NCT00273728|mortality
1429842|NCT00273715|Comparative
1429843|NCT00273715|Randomized
1429844|NCT00273715|Suture
1429845|NCT00273715|Staples, surgical
1429846|NCT00273715|Skin
1429847|NCT00273715|Surgical procedures, operative
1429848|NCT00273715|Orthopedics
1429849|NCT00273715|Joint, hip
1429850|NCT00273715|Surgical procedures of Hip, Operative
1429851|NCT00273702|Gambling
1429852|NCT00273702|Gambler
1429853|NCT00273702|Gamble
1429854|NCT00273702|Pathological
1429855|NCT00273676|Community-acquired pneumonia
1429856|NCT00273676|Treatment
1429857|NCT00273676|Antibiotics
1429858|NCT00273663|cerebral blood flow
1429859|NCT00273663|electrical stimulation
1429860|NCT00273663|Computed Tomography Scanner, X-Ray
1429861|NCT00273663|Brain Mapping
1429862|NCT00273650|Autism
1429863|NCT00273650|Placebo
1429864|NCT00273650|B12
1429865|NCT00273650|Controlled
1429866|NCT00273650|Complementary Alternative Medicine
1429867|NCT00273650|Vitamin Supplement
1429868|NCT00273637|heart failure
1429869|NCT00273637|peripartum cardiomyopathy
1429870|NCT00273637|pregnancy-associated cardiomyopathy
1429871|NCT00273637|pregnancy complications
1429872|NCT00273637|nonischemic cardiomyopathy
1429873|NCT00273624|Therapy-resistant depression
1429874|NCT00273624|add-on therapy depression
1429875|NCT00273611|vitamin D deficiency
1429876|NCT00273611|geriatric patients
1429877|NCT00273598|Scoliosis
1429878|NCT00273598|spinal disease
1429879|NCT00273598|pediatrics
1429880|NCT00273598|Adolescents
1429881|NCT00273598|Universal Spinal Instrumentation System
1429882|NCT00273598|Moss Miami Spinal Instrumentation System
1429883|NCT00273598|Orthopedic Surgery
1429884|NCT00273585|Fecal occult blood testing
1429885|NCT00273585|Flexible sigmoidoscopy
1429886|NCT00273585|Colonoscopy
1429887|NCT00273585|Self-efficacy
1429888|NCT00273572|Obesity
1429889|NCT00273572|Women
1429890|NCT00273572|Arab
1429891|NCT00273572|Metabolic syndrome
1429892|NCT00273572|Lifestyle intervention
1429893|NCT00273572|Quality of life
1429894|NCT00273559|Renal Transplantation
1429895|NCT00273546|Head and Neck Cancer
1429896|NCT00273546|Induction
1429897|NCT00273546|Chemotherapy
1429898|NCT00273546|Chemoradiotherapy
1429899|NCT00273507|Non-small cell lung cancer
1429900|NCT00273507|neoadjuvant
1429901|NCT00273507|resection
1429902|NCT00273494|N2 disease
1429903|NCT00273494|Non-small cell lung cancer
1429904|NCT00273494|Surgery
1429905|NCT00273494|Neoadjuvant chemotherapy
1429906|NCT00273403|HIV
1429907|NCT00273403|Minority Groups
1429908|NCT00273403|Health Services Accessibility
1429909|NCT00273403|Quality of Life
1429910|NCT00273377|Anesthesia
1429911|NCT00273377|Oxygen
1429912|NCT00273377|Carbon dioxide
1429913|NCT00273377|Hypercapnia
1429914|NCT00273377|Hypercarbia
1429915|NCT00273377|Dexamethasone
1429916|NCT00273377|Steroid
1429917|NCT00273377|Postoperative nausea and vomiting (PONV)
1429918|NCT00273364|stem cell, autoimmune disease, multiple sclerosis
1429919|NCT00273351|Parkinson
1429920|NCT00273351|family history
1429921|NCT00273351|diagnosis
1429922|NCT00273338|Androgen-independent Prostate Cancer (AIPC)
1429923|NCT00273338|Prostate Cancer
1429924|NCT00273338|DN-101
1429925|NCT00273338|calcitriol
1429926|NCT00273338|Taxotere
1429927|NCT00273338|docetaxel
1429928|NCT00273325|NICHD Neonatal Research Network
1429929|NCT00273325|Very Low Birth Weight (VLBW)
1429930|NCT00273325|Extremely Low Birth Weight (ELBW)
1429931|NCT00273325|Prematurity
1429932|NCT00273325|Pneumococcal Vaccines
1429933|NCT00273325|Vaccines, Conjugate
1429934|NCT00273325|Immunogenicity
1429935|NCT00273325|Vaccine Response
1429936|NCT00273325|Heptavalent pneumococcal conjugate vaccine (PCV-7)
1429937|NCT00273325|pneumococcal polysaccharide, type 6B
1429938|NCT00273325|Pneumococcal polysaccharide, type 14
1429939|NCT00273325|Pneumococcal polysaccharide, type 19F,
1429940|NCT00273325|Pneumococcal polysaccharide, 23F
1429941|NCT00273325|Pneumococcal polysaccharide, 18C
1429942|NCT00273325|Pneumococcal polysaccharide, 4
1429943|NCT00273325|Pneumococcal polysaccharide, 9V
1429944|NCT00273312|Advanced unresectable metastatic hepatocellular carcinoma
1429945|NCT00273312|Liver cancer
1429946|NCT00273299|hypertension
1429947|NCT00273299|high blood pressure
1429948|NCT00273299|valsartan/hydrochlorozide
1429949|NCT00273299|severe hypertension
1429950|NCT00273286|Diabetes Mellitus, Insulin-Dependent
1429951|NCT00273286|Diabetes Mellitus, Juvenile-Onset
1429952|NCT00273286|IDDM
1429953|NCT00273286|Type 1 Diabetes Mellitus
1429954|NCT00273273|HIV
1429955|NCT00273273|Atazanavir
1429956|NCT00273273|ritonavir
1429957|NCT00273273|tenofovir
1429958|NCT00273273|Adolescent
1429959|NCT00273273|Treatment Experienced
1429960|NCT00273234|Venous
1429961|NCT00273234|Ulcer
1429962|NCT00273234|autologous
1429963|NCT00273234|platelet
1429964|NCT00273234|healing
1429965|NCT00273221|Glaucoma
1429966|NCT00273221|Cataract
1429967|NCT00273208|breast cancer
1429968|NCT00273208|fatigue
1429969|NCT00273195|Implantable Cardioverter Defibrillator, Anti-tachycardia pacing (ATP)
1429970|NCT00273182|Heart Failure
1429971|NCT00273182|Cardiomyopathy
1429972|NCT00273182|Cardiac pacing
1429973|NCT00273182|Cardiac resynchronization therapy
1429974|NCT00273130|transnasal gastroscopy, stress response, ischaemia
1429975|NCT00273117|transnasal gastroscopy
1429976|NCT00273117|tachycardia
1429977|NCT00273117|hypoxemia
1429978|NCT00273078|Speech,
1429979|NCT00273078|tongue,
1429980|NCT00273078|pressure,
1429981|NCT00273078|transducer,
1429982|NCT00273078|complete denture
1429983|NCT00273065|Local Anesthetic
1429984|NCT00273065|Neosaxitoxin
1429985|NCT00273052|hypertension
1429986|NCT00273039|Social Anxiety Disorder
1429987|NCT00273039|Anxiety
1429988|NCT00273039|Psychiatry
1429989|NCT00273026|Asthma Advair
1429990|NCT00273013|asthma
1429991|NCT00273013|allergen challenge
1429992|NCT00272987|trastuzumab
1429993|NCT00272987|ErbB2
1429994|NCT00272987|paclitaxel
1429995|NCT00272987|Herceptin
1429996|NCT00272987|Taxol
1429997|NCT00272987|ErbB1
1429998|NCT00272987|metastatic breast cancer
1429999|NCT00272987|Stage IV breast cancer
1430000|NCT00272987|lapatinib
1430001|NCT00272974|AE adverse event
1430002|NCT00272974|DCF data collection forms
1430003|NCT00272974|IRB Institutional Review Board
1430004|NCT00272974|SAE serious adverse event
1430005|NCT00272948|Venoocclusive disease
1430006|NCT00272948|Pediatric
1430007|NCT00272948|myeloablative conditioning
1430008|NCT00272948|stem cell transplant
1430009|NCT00272935|menopause
1430010|NCT00272935|vasomotor symptoms
1430011|NCT00272922|Biomaterials
1430012|NCT00272922|Paraesophageal Hernia
1430013|NCT00272922|Laparoscopy
1430014|NCT00272909|Acute Ischemic Stroke
1430015|NCT00272909|9-Hour window MRI
1430016|NCT00272909|Serotonin receptor agonist
1430017|NCT00272896|Migraine
1430018|NCT00272896|VIP
1430019|NCT00272896|Transcranial Doppler
1430020|NCT00272896|Headache
1430021|NCT00272883|central core
1430022|NCT00272883|centronuclear
1430023|NCT00272883|multiminicore
1430024|NCT00272883|multicore
1430025|NCT00272883|minicore
1430026|NCT00272883|congenital fiber type disproportion
1430027|NCT00272883|myotubular
1430028|NCT00272883|nemaline
1430029|NCT00272883|congenital myopathy
1430030|NCT00272883|neuromuscular
1430031|NCT00272883|rigid spine
1430032|NCT00272844|cholesterol
1430033|NCT00272844|Smith-Lemli-Opitz syndrome
1430034|NCT00272844|mental retardation
1430035|NCT00272844|sterols
1430036|NCT00272844|congenital anomalies
1430037|NCT00272831|Diabetic nephropathy
1430038|NCT00272831|Macroalbuminuria
1430039|NCT00272831|Pletaal
1430040|NCT00272818|Colitis
1430041|NCT00272818|Esophagitis
1430042|NCT00272818|CD23
1430043|NCT00272805|chronic heart failure
1430044|NCT00272805|left ventricular systolic dysfunction
1430045|NCT00272779|HIV
1430046|NCT00272779|Treatment Naive
1430047|NCT00272766|Ocular histoplasmosis
1430048|NCT00272766|Macugen
1430049|NCT00272766|Photodynamic therapy with Visudyne
1430050|NCT00272766|Best-corrected visual acuity scores between 20/40-20/200
1430051|NCT00272766|classic or occult choroidal neovascularization
1430052|NCT00272740|breast cancer
1430053|NCT00272740|fulvestrant
1430054|NCT00272740|Faslodex
1430055|NCT00272740|hormonotherapy
1430056|NCT00272740|aromatase inhibitor failure
1430057|NCT00272740|Advanced breast cancer
1430058|NCT00272727|Asthma
1430059|NCT00272727|dialog tool
1430060|NCT00272727|compliance
1430061|NCT00272714|breast pain, tenderness, benign breast conditions
1430062|NCT00272675|Nosocomial infection,
1430063|NCT00272675|Decontamination,
1430064|NCT00272675|Randomized placebo-controlled trial,
1430065|NCT00272675|Cardiac surgery,
1430066|NCT00272675|Chlorhexidine,
1430067|NCT00272675|Prevention
1430068|NCT00272662|anemia
1430069|NCT00272662|cancer
1430070|NCT00272662|chemotherapy
1430071|NCT00272662|chemotherapy induced anemia
1430072|NCT00272662|CIA
1430073|NCT00272662|hemoglobin
1430074|NCT00272662|Hb
1430075|NCT00272662|Hgb
1430076|NCT00272662|erythropoietin
1430077|NCT00272662|EPO
1430078|NCT00272662|erythropoiesis stimulating agent
1430079|NCT00272662|ESA
1430080|NCT00272662|Hematide
1430081|NCT00272662|Omontys
1430082|NCT00272662|peginesatide
1430083|NCT00272662|red blood cell
1430084|NCT00272662|red blood cell production
1430085|NCT00272649|Kidney cancer
1430086|NCT00272649|Renal cancer
1430087|NCT00272636|atrial fibrillation
1430088|NCT00272636|catheter ablation
1430089|NCT00272636|amiodarone
1430090|NCT00272636|cardioversion
1430091|NCT00272623|Catheter, Indwelling
1430092|NCT00272623|Indwelling Catheter
1430093|NCT00272623|Indwelling Catheters
1430094|NCT00272623|Implantable Catheters
1430095|NCT00272623|Catheter, Implantable
1430096|NCT00272623|Catheters, Implantable
1430097|NCT00272623|Implantable Catheter
1430098|NCT00272623|In-Dwelling Catheters
1430099|NCT00272623|Catheter, In-Dwelling
1430100|NCT00272623|Catheters, In-Dwelling
1430101|NCT00272623|In Dwelling Catheters
1430102|NCT00272623|In-Dwelling Catheter
1430103|NCT00272623|Venous Reservoirs
1430104|NCT00272623|Reservoir, Venous
1430105|NCT00272623|Reservoirs, Venous
1430106|NCT00272623|Venous Reservoir
1430107|NCT00272623|Vascular Access Ports
1430108|NCT00272623|Access Port, Vascular
1430109|NCT00272623|Access Ports, Vascular
1430110|NCT00272623|Port, Vascular Access
1430111|NCT00272623|Ports, Vascular Access
1430112|NCT00272623|Vascular Access Port
1430113|NCT00272610|Skin Aging
1430114|NCT00272610|Bateman's Purpura
1430115|NCT00272597|Psychosis
1430116|NCT00272597|schizophrenia
1430117|NCT00272597|schizoaffective
1430118|NCT00272597|risperidone
1430119|NCT00272584|Psychosis, schizophrenia, schizoaffective, clozapine, risperidone
1430120|NCT00272571|ECPT, endothelial progenitor cells
1430121|NCT00272558|Malignant Pleural Mesothelioma
1430122|NCT00272558|Chemotherapy
1430123|NCT00272545|Anorexia Nervosa
1430124|NCT00272545|Bulimia Nervosa
1430125|NCT00272545|Cognitive Behavioral Therapy
1430126|NCT00272519|HIV
1430127|NCT00272519|AIDS
1430128|NCT00272519|Adolescent
1430129|NCT00272519|HIV Positive
1430130|NCT00272493|Treatment Experienced
1430131|NCT00272493|Treatment Naive
1430132|NCT00272480|HAM/TSP
1430133|NCT00272480|HTLV-I-associated myelopathy
1430134|NCT00272480|zidovudine
1430135|NCT00272480|lamivudine
1430136|NCT00272480|antiretroviral therapy
1430137|NCT00272467|Helicobacter pylori
1430138|NCT00272467|Stomach ulcer
1430139|NCT00272467|Rebamipide
1430140|NCT00272467|Omeprazole
1430141|NCT00272454|cilostazol
1430142|NCT00272454|aspirin
1430143|NCT00272454|cerebral infarction
1430144|NCT00272428|Prevention trial
1430145|NCT00272428|Antioxydant vitamins and minerals
1430146|NCT00272428|Cancer
1430147|NCT00272428|Ischemic disease
1430148|NCT00272428|Mortality
1430149|NCT00272428|Health related quality of life
1430150|NCT00272415|INO4136g
1430151|NCT00272415|inotek
1430152|NCT00272415|Parp
1430153|NCT00272415|Temodar
1430154|NCT00272402|physician decision support
1430155|NCT00272402|diabetes mellitus
1430156|NCT00272402|electronic medical records
1430157|NCT00272402|office systems redesign
1430158|NCT00272376|Myopia
1430159|NCT00272376|Nearsightedness
1430160|NCT00272363|Glaucoma
1430161|NCT00272350|Brain
1430162|NCT00272350|Tumor
1430163|NCT00272350|Therapy
1430164|NCT00272350|Progression
1430165|NCT00272350|Antiangiogenesis
1430166|NCT00272350|Brain Tumor
1430167|NCT00272350|Malignant Glioma
1430168|NCT00272337|Cardiovascular diseases
1430169|NCT00272337|Aspirin
1430170|NCT00272337|Atherosclerosis
1430171|NCT00272337|Myocardial Infarction
1430172|NCT00272324|Colorectal neoplasms
1430173|NCT00272324|Adenomatous polyps
1430174|NCT00272311|Primary prevention
1430175|NCT00272311|Cardiovascular diseases
1430176|NCT00272311|Aspirin
1430177|NCT00272311|Metabolic Syndrome X
1430178|NCT00272311|Atherosclerosis
1430179|NCT00272285|Serotonin antagonists
1430180|NCT00272285|Randomized controlled trial
1430181|NCT00272285|Combination drug therapy
1430182|NCT00272285|Double-blind method
1430183|NCT00272272|Fall Prevention, Music Therapy, Geriatric, Nursing Home
1430184|NCT00272246|dystonia
1430185|NCT00272233|Inflammation Mediators [D23.469]
1430186|NCT00272233|Cardiovascular Physiologic Phenomena [G09.330.553]
1430187|NCT00272220|Acquired Immunodeficiency Syndrome
1430188|NCT00272220|Antiretroviral Therapy, Highly Active
1430189|NCT00272220|Randomized Controlled Trials
1430190|NCT00272220|Africa
1430191|NCT00272220|Adherence
1430192|NCT00272220|Treatment Naive
1430193|NCT00272207|Fibromyalgia
1430194|NCT00272207|Cannabinoids
1430195|NCT00272207|Nabilone
1430196|NCT00272207|Cesamet
1430197|NCT00272207|Pain
1430198|NCT00272194|Endotracheal Intubation
1430199|NCT00272194|Supraglottic Airway
1430200|NCT00272168|Cognitive behavioral therapy
1430201|NCT00272168|Social Skills training
1430202|NCT00272168|Vocational Rehabilitation
1430203|NCT00272142|mortality
1430204|NCT00272142|hospitalization
1430205|NCT00272142|diarrhea
1430206|NCT00272142|respiratory infection
1430207|NCT00272142|low birth weight
1430208|NCT00272142|morbidity
1430209|NCT00272116|zinc
1430210|NCT00272116|diarrhea
1430211|NCT00272116|severe diarrhea
1430212|NCT00272116|recurrent diarrhea
1430213|NCT00272116|acute lower respiratory infection
1430214|NCT00272116|pneumonia
1430215|NCT00272103|functional dyspepsia
1430216|NCT00272103|non ulcer dyspepsia
1430217|NCT00272103|drug treatment
1430218|NCT00272051|Neurotoxicity syndromes
1430219|NCT00272051|Paresthesia
1430220|NCT00272051|Oxaliplatin
1430221|NCT00272051|Xaliproden
1430222|NCT00272025|Bipolar Depression
1430223|NCT00272025|Escitalopram
1430224|NCT00272025|Mood Stabilizer
1430225|NCT00272025|Atypical Antipsychotic
1430226|NCT00271999|randomized controlled clinical trial
1430227|NCT00271999|hemodialysis
1430228|NCT00271999|End Stage Renal Disease
1430229|NCT00271986|Peritoneal microdialysis
1430230|NCT00271986|Low anterior resection
1430231|NCT00271986|Recto-sigmoid cancer
1430232|NCT00271986|Anastomotic leakage
1430233|NCT00271960|Pregnancy
1430234|NCT00271960|Birth Weight
1430235|NCT00271960|Gestational Age
1430236|NCT00271960|Preterm Delivery
1430237|NCT00271960|HIV Seronegativity
1430238|NCT00271921|eating disorders
1430239|NCT00271921|anorexia nervosa
1430240|NCT00271921|body fat distribution
1430241|NCT00271921|metabolic syndrome
1430242|NCT00271921|visceral adipose tissue
1430243|NCT00271908|HIV
1430244|NCT00271908|AIDS
1430245|NCT00271908|Adolescent
1430246|NCT00271908|Community
1430247|NCT00271908|Structural Changes
1430248|NCT00271908|HIV Seronegativity
1430249|NCT00271882|Adolescent Females
1430250|NCT00271882|HIV positive
1430251|NCT00271882|PTSD
1430252|NCT00271882|Sexual Abuse
1430253|NCT00271869|hematopoietic stem cell transplantation
1430254|NCT00271869|graft-versus-host disease
1430255|NCT00271869|treatment
1430256|NCT00271856|HIV
1430257|NCT00271856|Meditation
1430258|NCT00271856|Stress
1430259|NCT00271856|Randomized Controlled Trial
1430260|NCT00271856|Complementary Therapies
1430261|NCT00271856|MBSR
1430262|NCT00271856|Not on ART medications
1430263|NCT00271830|renal
1430264|NCT00271830|transplant
1430265|NCT00271830|sexual dysfunction
1430266|NCT00271830|male
1430267|NCT00271830|dialysis free
1430268|NCT00271804|Myelodysplastic syndrome
1430269|NCT00271804|Myelodysplasia
1430270|NCT00271804|MDS
1430271|NCT00271804|Velcade
1430272|NCT00271804|Thalidomide
1430273|NCT00271804|Bortezomib
1430274|NCT00271791|Vestibular Neuronitis
1430275|NCT00271791|Vestibular Function Tests
1430276|NCT00271791|Vestibular Adaptation
1430277|NCT00271791|Steroids
1430278|NCT00271778|Otitis media suppurative
1430279|NCT00271778|surgery ear
1430280|NCT00271765|Myocardial infarction
1430281|NCT00271765|Coronary angioplasty
1430282|NCT00271765|PARP inhibitor
1430283|NCT00271765|PARP inhibition
1430284|NCT00271765|Heart Attack
1430285|NCT00271752|Procalcitonin
1430286|NCT00271752|Sepsis
1430287|NCT00271752|Intensive Care Unit
1430288|NCT00271752|Sepsis and Complications
1430289|NCT00271752|Organ Failure
1430290|NCT00271739|Telemedicine
1430291|NCT00271739|Diabetes Mellitus
1430292|NCT00271726|distal radius fracture
1430293|NCT00271726|extraarticular Colles fracture
1430294|NCT00271713|bone structure
1430295|NCT00271713|ibandronate
1430296|NCT00271700|Diabetes Mellitus
1430297|NCT00271700|Outcome Assessment (Healthcare)
1430298|NCT00271700|Inpatients
1430299|NCT00271700|Hospital Information Systems
1430300|NCT00271700|Education
1430301|NCT00271687|exercise
1430302|NCT00271687|exercise therapy
1430303|NCT00271687|activities of daily living
1430304|NCT00271687|quality of life
1430305|NCT00271661|presbyopia; breast cancer survivors
1430306|NCT00271635|Charcot-Marie-Tooth Disease
1430307|NCT00271635|Hereditary Motor and Sensory Neuropathies
1430308|NCT00271635|Ascorbic Acid
1430309|NCT00271635|Vitamin C
1430310|NCT00271622|Screening
1430311|NCT00271622|Pediatric
1430312|NCT00271622|Pervasive Developmental Disorder
1430313|NCT00271622|Early Development
1430314|NCT00271622|Children
1430315|NCT00271622|Autism Spectrum Disorders
1430316|NCT00271622|Healthy Volunteer
1430317|NCT00271622|HV
1430318|NCT00271609|AVASTIN
1430319|NCT00271609|Recurrence
1430320|NCT00271609|Chemotherapy
1430321|NCT00271609|Anti-Angiogenesis
1430322|NCT00271609|Radiotherapy
1430323|NCT00271609|Brain Tumor
1430324|NCT00271609|Malignant Glioma
1430325|NCT00271596|Huntington Disease
1430326|NCT00271596|Citalopram
1430327|NCT00271596|Celexa
1430328|NCT00271596|Chorea
1430329|NCT00271596|Focus
1430330|NCT00271596|ADD
1430331|NCT00271596|ADHD
1430332|NCT00271596|HD
1430333|NCT00271596|SSRI
1430334|NCT00271583|emergency contraception
1430335|NCT00271583|antiprogestin
1430336|NCT00271557|Heart Failure
1430337|NCT00271557|Renal Dysfunction
1430338|NCT00271557|Cardiomyopathy
1430339|NCT00271557|Heart Decompensation
1430340|NCT00271557|Dyspnea Paroxysmal.
1430341|NCT00271544|heart failure
1430342|NCT00271544|cardiac pacing
1430343|NCT00271544|left ventricular lead
1430344|NCT00271544|cardiac resynchronization therapy
1430345|NCT00271531|bacterial infection, pneumonia, ventilation, children
1430346|NCT00271505|Non-Small Cell Lung Cancer
1430347|NCT00271505|Lung Cancer
1430348|NCT00271505|Bevacizumab
1430349|NCT00271505|Carboplatin
1430350|NCT00271505|Docetaxel
1430351|NCT00271505|Avastin
1430352|NCT00271505|NSCLC
1430353|NCT00271505|Anti-VEGF monoclonal antibody
1430354|NCT00271505|rhuMAb-VEGF
1430355|NCT00271505|Paraplatin®
1430356|NCT00271505|Taxotere
1430357|NCT00271479|Meningitis
1430358|NCT00271479|Dose-Response Relationship, Immunologic
1430359|NCT00271479|Neisseria meningitidis
1430360|NCT00271479|Outbreaks
1430361|NCT00271479|Vaccine
1430362|NCT00271479|Africa
1430363|NCT00271479|Uganda
1430364|NCT00271479|Prevention of Neisseria meningitidis infections
1430365|NCT00271479|In outbreak contexts in developing countries
1430366|NCT00271466|opioid
1430367|NCT00271466|fentanyl
1430368|NCT00271466|Duragesic
1430369|NCT00271466|transdermal
1430370|NCT00271466|chronic pain
1430371|NCT00271466|morphine
1430372|NCT00271453|chronic pain
1430373|NCT00271453|opioid
1430374|NCT00271453|fentanyl
1430375|NCT00271453|transdermal
1430376|NCT00271453|Durogesic
1430377|NCT00271453|morphine
1430378|NCT00271440|chlorhexidine
1430379|NCT00271440|neonatal
1430380|NCT00271440|skin flora
1430381|NCT00271440|skin cleansing
1430382|NCT00271440|bacterial colonization
1430383|NCT00271427|Thyroiditis
1430384|NCT00271427|Autoimmune
1430385|NCT00271427|Hashimoto's
1430386|NCT00271427|TPOAb
1430387|NCT00271427|Selenium
1430388|NCT00271414|chronic pain
1430389|NCT00271414|opioid
1430390|NCT00271414|fentanyl
1430391|NCT00271414|transdermal
1430392|NCT00271414|Duragesic
1430393|NCT00271414|morphine
1430394|NCT00271401|Stents
1430395|NCT00271401|Angioplasty, Transluminal, Percutaneous Coronary
1430396|NCT00271388|Galvanic Vestibular Stimulation
1430397|NCT00271388|Hemispatial Neglect
1430398|NCT00271388|Stroke
1430399|NCT00271375|Age
1430400|NCT00271375|Caregivers
1430401|NCT00271375|Family
1430402|NCT00271375|Intervention Studies
1430403|NCT00271362|Exercise
1430404|NCT00271362|Physical function
1430405|NCT00271362|Prosthetic mobility
1430406|NCT00271362|Rehabilitation
1430407|NCT00271349|Eosinophilic Esophagitis
1430408|NCT00271349|Budesonide
1430409|NCT00271336|NEC
1430410|NCT00271336|Premature Infants
1430411|NCT00271336|TNF
1430412|NCT00271336|Pentoxifylline
1430413|NCT00271297|pelvic floor
1430414|NCT00271297|exercise therapy
1430415|NCT00271297|prevention
1430416|NCT00271297|ultrasonography
1430417|NCT00271297|risk factors
1430418|NCT00271245|cirrhosis
1430419|NCT00271245|liver disease
1430420|NCT00271245|selenium
1430421|NCT00271245|selenoproteins
1430422|NCT00271245|selenoprotein P
1430423|NCT00271245|biomarkers
1430424|NCT00271232|Heart Failure, Cardiac Resynchronization
1430425|NCT00271219|opiate addiction
1430426|NCT00271219|opiate dependence
1430427|NCT00271219|substance abuse
1430428|NCT00271219|addiction
1430429|NCT00271219|substance addiction
1430430|NCT00271219|pregnancy
1430431|NCT00271219|buprenorphine
1430432|NCT00271219|methadone
1430433|NCT00271219|fetal
1430434|NCT00271219|neonatal
1430435|NCT00271219|post-partum
1430436|NCT00271206|Nicotine Dependence
1430437|NCT00271206|Tobacco Dependence
1430438|NCT00271180|Cardiac Pacing
1430439|NCT00271180|Implantable Cardioverter Defibrillator
1430440|NCT00271180|pacemaker
1430441|NCT00271180|Sinus Bradycardia
1430442|NCT00271167|Cardiac surgery
1430443|NCT00271167|PARP inhibitor
1430444|NCT00271167|PARP inhibition
1430445|NCT00271167|Bypass surgery
1430446|NCT00271167|CPB surgery
1430447|NCT00271167|Cardiopulmonary bypass
1430448|NCT00271167|Coronary revascularization
1430449|NCT00271167|Cardiac valve replacement
1430450|NCT00271154|Heart Failure
1430451|NCT00271154|Implantable Cardioverter Defibrillator
1430452|NCT00271154|Cardiac Resynchronization Therapy
1430453|NCT00271141|Parkinson's disease
1430454|NCT00271141|Oxidative stress
1430455|NCT00271141|Marker
1430456|NCT00271128|NT-proBNP
1430457|NCT00271128|Heart failure
1430458|NCT00271128|Dyspnea
1430459|NCT00271115|Kangaroo holding
1430460|NCT00271115|Kangaroo care
1430461|NCT00271115|Maternal stress levels
1430462|NCT00271115|Premature birth
1430463|NCT00271102|Cystocele, prolapse, anterior repair, colporrhaphy
1430464|NCT00271076|CAD
1430465|NCT00271076|CEA
1430466|NCT00271076|CAS
1430467|NCT00271076|IVUS
1430468|NCT00271076|symptomatic
1430469|NCT00271076|asymptomatic
1430470|NCT00271076|Cerebral Protection Device
1430471|NCT00271076|TIA
1430472|NCT00271076|Stroke
1430473|NCT00271076|plaque morphology
1430474|NCT00271063|Refractory or Relapsed Acute Lymphocytic Leukemia
1430475|NCT00271050|non-Hodgkin's lymphoma
1430476|NCT00271050|external beam radiotherapy (EBRT)
1430477|NCT00271050|radio-immunotherapy (RIT)
1430478|NCT00271050|Zevalin
1430479|NCT00271037|Pelvic organ prolapse
1430480|NCT00271037|Stress urinary incontinence
1430481|NCT00271037|Surgery
1430482|NCT00271037|Colpocleisis
1430483|NCT00271037|Urinary retention
1430484|NCT00271024|Smoking
1430485|NCT00271024|Smoking Cessation
1430486|NCT00270998|Stress urinary incontinence
1430487|NCT00270985|almonds
1430488|NCT00270985|pre-diabetes
1430489|NCT00270985|inflammatory
1430490|NCT00270985|CRP
1430491|NCT00270972|Venous leg ulcer
1430492|NCT00270972|Venous insufficiency
1430493|NCT00270972|OrCel
1430494|NCT00270959|PTSD
1430495|NCT00270946|Venous leg ulcer
1430496|NCT00270946|OrCel
1430497|NCT00270946|Compression therapy
1430498|NCT00270933|defibrillators
1430499|NCT00270933|LLECG
1430500|NCT00270933|ventricular tachycardia
1430501|NCT00270933|ventricular fibrillation
1430502|NCT00270920|Initiation, Maintenance, Breastfeeding
1430503|NCT00270907|Metastatic Breast Cancer
1430504|NCT00270907|Breast Cancer
1430505|NCT00270907|CT-2103
1430506|NCT00270907|Gemcitabine
1430507|NCT00270907|Xyotax
1430508|NCT00270907|Gemzar
1430509|NCT00270894|neoadjuvant chemotherapy
1430510|NCT00270894|HER2 positive breast cancer
1430511|NCT00270894|stage II - III breast cancer
1430512|NCT00270881|cord blood transplantation
1430513|NCT00270881|myeloablative regimen
1430514|NCT00270881|hematologic malignancies
1430515|NCT00270868|Double guide wire technique
1430516|NCT00270868|Difficult selective biliary cannulation
1430517|NCT00270868|ERCP
1430518|NCT00270868|Attempts of cannulation
1430519|NCT00270868|Post-ERCP complications.
1430520|NCT00270855|Body Composition
1430521|NCT00270855|Exercise
1430522|NCT00270855|Glucose Tolerance
1430523|NCT00270855|Insulin Sensitivity
1430524|NCT00270855|Functional Electric Stimulation
1430525|NCT00270842|Education
1430526|NCT00270842|Exercise
1430527|NCT00270842|Gait
1430528|NCT00270842|Peripheral Nervous System
1430529|NCT00270842|Postural Balance
1430530|NCT00270842|Self Efficacy
1430531|NCT00270842|Tai Chi Chuan
1430532|NCT00270829|renal function
1430533|NCT00270816|Multiple Sclerosis
1430534|NCT00270816|Interferon-ß-1b
1430535|NCT00270816|Therapy
1430536|NCT00270803|Marijuana, FDG, PET, maze, THC, motor coordination.
1430537|NCT00270790|Head and Neck cancer
1430538|NCT00270777|Controlled trial
1430539|NCT00270777|Snake bite
1430540|NCT00270777|Safety
1430541|NCT00270777|Antivenom
1430542|NCT00270764|HIV/AIDS
1430543|NCT00270764|Antiretroviral therapy
1430544|NCT00270764|Quality of life
1430545|NCT00270764|South Africa
1430546|NCT00270764|Treatment Naive
1430547|NCT00270751|Video-Assisted Thoracoscopic Surgery
1430548|NCT00270751|Spontaneous pneumothorax
1430549|NCT00270751|Pleurectomy
1430550|NCT00270751|Pleural abrasion
1430551|NCT00270751|Minocycline
1430552|NCT00270738|urinary incontinence
1430553|NCT00270738|transversus abdominis
1430554|NCT00270738|pelvic floor muscles
1430555|NCT00270738|randomized controlled trial
1430556|NCT00270725|HIV
1430557|NCT00270725|AIDS
1430558|NCT00270725|Labor productivity
1430559|NCT00270725|Antiretroviral therapy
1430560|NCT00270725|South Africa
1430561|NCT00270712|kidney
1430562|NCT00270712|transplant
1430563|NCT00270712|dysfunction
1430564|NCT00270712|chronic
1430565|NCT00270712|deterioration
1430566|NCT00270712|loss of function
1430567|NCT00270699|Dengue Vaccine
1430568|NCT00270699|Dengue Virus
1430569|NCT00270699|Dengue Hemorrhagic Fever
1430570|NCT00270699|Dengue Shock Syndrome
1430571|NCT00270686|Ehlers-Danlos Syndrome
1430572|NCT00270686|Stickler Syndrome
1430573|NCT00270686|Marfan Syndrome
1430574|NCT00270686|Genetics
1430575|NCT00270686|Aneurysm
1430576|NCT00270673|Lactate
1430577|NCT00270673|Tissue hypoxia
1430578|NCT00270673|Intensive care
1430579|NCT00270673|Goal- directed therapy
1430580|NCT00270660|retraction pockets ear
1430581|NCT00270660|unsafe otitis media
1430582|NCT00270660|otitis media complications
1430583|NCT00270647|cancer
1430584|NCT00270647|prostate cancer
1430585|NCT00270647|colorectal cancer
1430586|NCT00270647|cardiovascular disease
1430587|NCT00270647|eye disease
1430588|NCT00270647|cognitive decline
1430589|NCT00270634|Randomized Controlled Trials
1430590|NCT00270634|Immunosuppression
1430591|NCT00270634|Adult
1430592|NCT00270634|Kidney Transplantation
1430593|NCT00270634|Treatment Outcome
1430594|NCT00270608|Hypertension
1430595|NCT00270608|Peripheral vascular disease
1430596|NCT00270608|Diabetes
1430597|NCT00270608|Total body fat percentage
1430598|NCT00270556|Treatment Experienced
1430599|NCT00270543|Stomach Neoplasms
1430600|NCT00270530|Malaria
1430601|NCT00270530|Placental diseases
1430602|NCT00270530|Birth complications
1430603|NCT00270530|Plasmodium falciparum
1430604|NCT00270530|Zambia
1430605|NCT00270530|HIV-seropositive
1430606|NCT00270530|HIV
1430607|NCT00270504|Memokath
1430608|NCT00270504|Urethral stricture
1430609|NCT00270504|urethral stent
1430610|NCT00270504|Bulbar urethral stricture
1430611|NCT00270478|Erythropoietin Therapy
1430612|NCT00270478|Fetal Hemoglobin Induction
1430613|NCT00270478|Sickle Cell Disease
1430614|NCT00270478|Pulmonary Hypertension
1430615|NCT00270478|Chronic Kidney Disease
1430616|NCT00270478|SCD
1430617|NCT00270465|HIV-positive
1430618|NCT00270465|Treatment Interruption
1430619|NCT00270465|Therapeutic Vaccine
1430620|NCT00270465|HIV/AIDS
1430621|NCT00270465|Virologic Response
1430622|NCT00270465|HIV Positive
1430623|NCT00270452|Myelodyplastic Syndrome (MDS)
1430624|NCT00270452|Wilm's tumor-1
1430625|NCT00270452|Proteinase-3
1430626|NCT00270452|Vaccine Therapy
1430627|NCT00270452|Acute Myeloid Leukemia
1430628|NCT00270452|Chronic Myeloid Leukemias
1430629|NCT00270452|Myelodysplastic Syndrome
1430630|NCT00270452|MDS
1430631|NCT00270439|Obesity
1430632|NCT00270439|Omentectomy
1430633|NCT00270439|Diabetes Mellitus Type 2
1430634|NCT00270439|Laparoscopic
1430635|NCT00270439|Dyslipidemia
1430636|NCT00270426|Advanced Chronic Renal Insufficiency
1430637|NCT00270426|Benazepril
1430638|NCT00270413|breast cancer
1430639|NCT00270413|metastatic
1430640|NCT00270413|taxanes
1430641|NCT00270413|SU11248
1430642|NCT00270400|Heart Failure
1430643|NCT00270400|Renal Dysfunction
1430644|NCT00270400|Cardiomyopathy
1430645|NCT00270400|Heart Decompensation
1430646|NCT00270400|Dyspnea Paroxsymal.
1430647|NCT00270387|Acutely Decompensated Congestive Heart Failure
1430648|NCT00270387|Heart Failure
1430649|NCT00270387|Renal Impairment
1430650|NCT00270387|Kidney Failure
1430651|NCT00270387|Myocardial Infarction.
1430652|NCT00270374|Congestive heart failure
1430653|NCT00270374|CHF
1430654|NCT00270374|Left-sided heart failure
1430655|NCT00270374|Right-sided heart failure
1430656|NCT00270374|Systolic Heart Failure
1430657|NCT00270361|Heart Failure
1430658|NCT00270361|Renal Dysfunction
1430659|NCT00270361|Cardiomyopathy
1430660|NCT00270361|Heart Decompensation
1430661|NCT00270361|Dyspnea Paroxsymal
1430662|NCT00270361|Outpatient Therapy.
1430663|NCT00270348|Asthma
1430664|NCT00270348|Safety
1430665|NCT00270348|Pediatrics
1430666|NCT00270322|total knee replacement
1430667|NCT00270322|orthopedic surgery
1430668|NCT00270322|post operative analgesia
1430669|NCT00270322|continuous epidural
1430670|NCT00270322|patients controlled analgesia
1430671|NCT00270322|morphine
1430672|NCT00270322|combined spinal epidural anesthesia
1430673|NCT00270322|anesthesia
1430674|NCT00270322|analgesia
1430675|NCT00270322|epidural marcaine
1430676|NCT00270322|epidural fentanyl
1430677|NCT00270322|pain
1430678|NCT00270309|lower urinary tract symptoms, self-management
1430679|NCT00270296|Treatment Naive
1430680|NCT00270296|MTCT
1430681|NCT00270296|HIV Seronegativity
1430682|NCT00270283|Anemia
1430683|NCT00270283|AIDS
1430684|NCT00270283|erythropoietin
1430685|NCT00270283|epoetin alfa
1430686|NCT00270283|Quality of Life
1430687|NCT00270283|Zidovudine
1430688|NCT00270283|HIV
1430689|NCT00270270|erythropoietin
1430690|NCT00270270|Anemia
1430691|NCT00270270|Quality of Life
1430692|NCT00270270|epoetin alfa
1430693|NCT00270270|HIV
1430694|NCT00270270|Zidovudine
1430695|NCT00270270|AIDS
1430696|NCT00270257|HIV Seronegativity
1430697|NCT00270257|Opiate Addiction
1430698|NCT00270257|Opiate Dependence
1430699|NCT00270244|Major Depression
1430700|NCT00270244|Dysthymic Disorder
1430701|NCT00270244|Adjustment Disorder With Depressed Mood
1430702|NCT00270244|Depressive Disorder Not Otherwise Specified
1430703|NCT00270244|Adolescent
1430704|NCT00270244|Psychotherapy
1430705|NCT00270231|within-subjects, crossover, laboratory study
1430706|NCT00270231|Naltrexone vs. Placebo
1430707|NCT00270218|HIV Seronegativity
1430708|NCT00270218|Adenoviral Vector Vaccine
1430709|NCT00270218|DNA Plasmid Vaccine
1430710|NCT00270205|Treatment Experienced
1430711|NCT00270205|HIV Therapeutic Vaccine
1430712|NCT00270192|Breastfeeding
1430713|NCT00270192|exclusive
1430714|NCT00270192|education
1430715|NCT00270192|counseling
1430716|NCT00270179|Anemia
1430717|NCT00270179|blood transfusion
1430718|NCT00270179|epoetin alfa
1430719|NCT00270179|erythropoietin
1430720|NCT00270179|surgery
1430721|NCT00270179|self-blood donation
1430722|NCT00270166|cancer
1430723|NCT00270166|malignancy
1430724|NCT00270166|red cell transfusion
1430725|NCT00270166|epoetin alfa
1430726|NCT00270166|epoetin
1430727|NCT00270166|erythropoietin
1430728|NCT00270166|red blood cells
1430729|NCT00270153|renal transplant, ACE inhibitor
1430730|NCT00270140|anemia
1430731|NCT00270140|blood transfusion
1430732|NCT00270140|epoetin alfa
1430733|NCT00270140|erythropoietin
1430734|NCT00270140|surgery
1430735|NCT00270140|blood donation
1430736|NCT00270140|blood
1430737|NCT00270127|Anemia
1430738|NCT00270127|cancer
1430739|NCT00270127|quality of life
1430740|NCT00270127|chemotherapy
1430741|NCT00270127|hemoglobin
1430742|NCT00270127|transfusion
1430743|NCT00270127|epoetin alfa
1430744|NCT00270127|epoetin
1430745|NCT00270127|erythropoietin
1430746|NCT00270114|Anemia
1430747|NCT00270114|blood transfusion, autologous
1430748|NCT00270114|epoetin alfa
1430749|NCT00270114|epogen
1430750|NCT00270114|erythropoietin
1430751|NCT00270114|orthopedic procedures
1430752|NCT00270114|orthopedic surgery
1430753|NCT00270101|anemia
1430754|NCT00270101|cancer
1430755|NCT00270101|quality of life
1430756|NCT00270101|chemotherapy
1430757|NCT00270101|hemoglobin
1430758|NCT00270101|multiple myeloma
1430759|NCT00270101|transfusion
1430760|NCT00270101|epoetin alfa
1430761|NCT00270101|epoetin
1430762|NCT00270101|erythropoietin
1430763|NCT00270088|Anemia
1430764|NCT00270088|blood transfusion
1430765|NCT00270088|epoetin alfa
1430766|NCT00270088|epogen
1430767|NCT00270088|erythropoietin
1430768|NCT00270088|orthopedic procedures
1430769|NCT00270088|orthopedic surgery
1430770|NCT00270075|epogen
1430771|NCT00270075|erythropoietin
1430772|NCT00270075|orthopedic procedures
1430773|NCT00270075|orthopedic surgery
1430774|NCT00270075|cardiovascular surgical procedures
1430775|NCT00270075|Blood transfusion
1430776|NCT00270075|epoetin alfa
1430777|NCT00270062|anemia
1430778|NCT00270062|blood transfusion
1430779|NCT00270062|epoetin alfa
1430780|NCT00270062|erythropoietin
1430781|NCT00270062|surgery
1430782|NCT00270062|blood donation
1430783|NCT00270062|blood
1430784|NCT00270049|Anemia
1430785|NCT00270049|cancer
1430786|NCT00270049|leukemia
1430787|NCT00270049|chronic lymphocytic leukemia
1430788|NCT00270049|lymphocytic leukemia
1430789|NCT00270049|epoetin alfa
1430790|NCT00270049|erythropoietin
1430791|NCT00270049|red blood cells
1430792|NCT00270049|transfusions
1430793|NCT00270049|quality of life
1430794|NCT00270036|Blood transfusion
1430795|NCT00270036|epoetin alfa
1430796|NCT00270036|epogen
1430797|NCT00270036|erythropoietin
1430798|NCT00270036|orthopedic procedures
1430799|NCT00270036|orthopedic surgery
1430800|NCT00270023|Blood transfusion
1430801|NCT00270023|epoetin alfa
1430802|NCT00270023|epogen
1430803|NCT00270023|erythropoietin
1430804|NCT00270023|orthopedic procedures
1430805|NCT00270023|orthopedic surgery
1430806|NCT00270023|cardiovascular surgical procedures
1430807|NCT00270023|breast reduction
1430808|NCT00270010|Anemia
1430809|NCT00270010|AIDS
1430810|NCT00270010|HIV
1430811|NCT00270010|Zidovudine
1430812|NCT00270010|Quality of Life
1430813|NCT00270010|erythropoietin
1430814|NCT00270010|epoetin alfa
1430815|NCT00269997|Anemia
1430816|NCT00269997|chemotherapy
1430817|NCT00269997|epoetin alfa
1430818|NCT00269997|epogen
1430819|NCT00269997|erythropoietin
1430820|NCT00269997|neoplasms
1430821|NCT00269997|cancer
1430822|NCT00269984|Anemia
1430823|NCT00269984|Blood transfusion
1430824|NCT00269984|Epoetin alfa
1430825|NCT00269984|Erythropoietin
1430826|NCT00269984|Neoplasm
1430827|NCT00269984|Epogen
1430828|NCT00269984|Cancer
1430829|NCT00269971|hip replacement
1430830|NCT00269971|hip replacement surgery
1430831|NCT00269971|surgery
1430832|NCT00269971|anemia
1430833|NCT00269971|transfusions
1430834|NCT00269971|blood
1430835|NCT00269971|blood transfusions
1430836|NCT00269958|hip replacement
1430837|NCT00269958|hip replacement surgery
1430838|NCT00269958|surgery
1430839|NCT00269958|anemia
1430840|NCT00269958|transfusions
1430841|NCT00269958|blood transfusions
1430842|NCT00269945|Anemia
1430843|NCT00269945|AIDS
1430844|NCT00269945|HIV
1430845|NCT00269945|Zidovudine
1430846|NCT00269945|Quality of Life
1430847|NCT00269945|erythropoietin
1430848|NCT00269945|epoetin alfa
1430849|NCT00269932|Bronchitis
1430850|NCT00269932|chronic bronchitis
1430851|NCT00269932|lung diseases
1430852|NCT00269932|respiratory tract infections
1430853|NCT00269932|bronchial diseases
1430854|NCT00269932|antibacterial agents
1430855|NCT00269932|quinolones
1430856|NCT00269932|levofloxacin
1430857|NCT00269919|Schizophrenia
1430858|NCT00269919|Risperidone
1430859|NCT00269919|Risperidal Consta
1430860|NCT00269906|Angina, unstable
1430861|NCT00269906|Angioplasty, transluminal, percutaneous coronary
1430862|NCT00269906|Abciximab
1430863|NCT00269893|Abciximab
1430864|NCT00269893|Angina, unstable
1430865|NCT00269893|Angioplasty, transluminal, Percutaneous coronary
1430866|NCT00269880|Angioplasty, Transluminal, Percutaneous coronary
1430867|NCT00269867|Rheumatoid Arthritis
1430868|NCT00269867|infliximab
1430869|NCT00269867|methotrexate
1430870|NCT00269854|Crohn's Disease
1430871|NCT00269841|fistulae
1430872|NCT00269841|Crohn's Disease
1430873|NCT00269828|Non-small cell lung cancer
1430874|NCT00269828|NSCLC
1430875|NCT00269828|PS 2
1430876|NCT00269828|female
1430877|NCT00269828|chemotherapy
1430878|NCT00269815|ADHD
1430879|NCT00269815|Attention Deficit Hyperactivity Disorder
1430880|NCT00269815|OROS®
1430881|NCT00269815|children
1430882|NCT00269815|methylphenidate
1430883|NCT00269802|ADHD
1430884|NCT00269802|Attention Deficit Hyperactivity Disorder
1430885|NCT00269802|OROS®
1430886|NCT00269802|Ritalin®
1430887|NCT00269802|children
1430888|NCT00269802|methylphenidate
1430889|NCT00269789|Attention Deficit Hyperactivity Disorder
1430890|NCT00269789|OROS®
1430891|NCT00269789|Ritalin®
1430892|NCT00269789|children
1430893|NCT00269789|methylphenidate
1430894|NCT00269789|ADHD
1430895|NCT00269776|ADHD
1430896|NCT00269776|Attention Deficit Hyperactivity Disorder
1430897|NCT00269776|OROS
1430898|NCT00269776|children
1430899|NCT00269776|methylphenidate
1430900|NCT00269776|Ritalin
1430901|NCT00269763|patch
1430902|NCT00269763|pain
1430903|NCT00269763|fentanyl
1430904|NCT00269763|narcotic
1430905|NCT00269763|Cancer
1430906|NCT00269750|Ditropan®
1430907|NCT00269750|OROS®
1430908|NCT00269750|urge
1430909|NCT00269750|oxybutynin
1430910|NCT00269750|mixed urinary incontinence
1430911|NCT00269737|fentanyl
1430912|NCT00269737|pain
1430913|NCT00269737|Cancer
1430914|NCT00269737|patch
1430915|NCT00269724|urinary incontinence
1430916|NCT00269724|oxybutynin
1430917|NCT00269724|OROS®
1430918|NCT00269685|Septic shock
1430919|NCT00269685|catecholamine
1430920|NCT00269685|vasopressin
1430921|NCT00269685|tonometria
1430922|NCT00269685|lactate
1430923|NCT00269672|vaccine
1430924|NCT00269659|Left Bundle Branch Block
1430925|NCT00269659|Regional cardiac function
1430926|NCT00269659|Global cardiac function
1430927|NCT00269659|Mechanical asynchrony
1430928|NCT00269659|Echocardiography
1430929|NCT00269659|2D echocardiography
1430930|NCT00269659|Tissue Doppler Imaging
1430931|NCT00269659|Real-time 3D echocardiography
1430932|NCT00269659|Cardiovascular Magnetic Resonance Imaging-tagging
1430933|NCT00269646|Diet
1430934|NCT00269646|Low-carbohydrate
1430935|NCT00269646|Insulin
1430936|NCT00269646|Dietary fiber
1430937|NCT00269646|Diabetes
1430938|NCT00269646|Cardiovascular disease
1430939|NCT00269633|Seasonal Affective Disorder
1430940|NCT00269620|contraceptive vaginal ring
1430941|NCT00269620|contraceptive patch
1430942|NCT00269620|oral contraceptives
1430943|NCT00269620|acceptability
1430944|NCT00269607|Substance abuse
1430945|NCT00269607|Treatment
1430946|NCT00269607|Relapse prevention
1430947|NCT00269607|opioid antagonist
1430948|NCT00269594|Skin
1430949|NCT00269594|Picking
1430950|NCT00269594|Pick
1430951|NCT00269594|Neurotic Excoriation
1430952|NCT00269581|migraine
1430953|NCT00269581|tension headaches
1430954|NCT00269581|chronic daily headaches
1430955|NCT00269568|medical abortion
1430956|NCT00269568|mifepristone
1430957|NCT00269568|misoprostol
1430958|NCT00269555|Prostate
1430959|NCT00269555|Cancer
1430960|NCT00269555|Prostate Specific Antigen
1430961|NCT00269555|C04.588.945.440.770
1430962|NCT00269542|zinc supplementation
1430963|NCT00269542|hospitalisations
1430964|NCT00269542|children
1430965|NCT00269542|mortality
1430966|NCT00269542|iron folic acid
1430967|NCT00269529|postoperative pain
1430968|NCT00269529|knee arthroplasty
1430969|NCT00269529|analgesia
1430970|NCT00269529|infiltration
1430971|NCT00269529|femoral nerve block
1430972|NCT00269516|Parkinson's disease
1430973|NCT00269490|Post-Traumatic Stress Disorder
1430974|NCT00269490|Yoga Nidra
1430975|NCT00269477|Meningitis
1430976|NCT00269477|Meningococcal infection
1430977|NCT00269477|Neisseria meningitidis
1430978|NCT00269477|Menactra®
1430979|NCT00269477|Menomune®
1430980|NCT00269425|Cardiovascular disease
1430981|NCT00269425|Nutrition
1430982|NCT00269425|Mediterranean diet
1430983|NCT00269425|Low fat diet
1430984|NCT00269425|American Heart Association diet
1430985|NCT00269425|Monounsaturated fats
1430986|NCT00269425|Omega-3 fats
1430987|NCT00269425|Outcomes
1430988|NCT00269412|Irritable bowel syndrome
1430989|NCT00269399|Clostridium difficile-associated Diarrhea (CDAD)
1430990|NCT00269399|CDAD
1430991|NCT00269399|C diff
1430992|NCT00269386|Clarithromycin
1430993|NCT00269386|Crohn's
1430994|NCT00269373|Unknown primary tumor
1430995|NCT00269373|PET-CT
1430996|NCT00269360|Chiropractic
1430997|NCT00269360|Manual Therapies
1430998|NCT00269360|Exercise
1430999|NCT00269360|Randomized
1431000|NCT00269360|Clinical Trial
1431001|NCT00269360|Neck Pain
1431002|NCT00269347|Chiropractic
1431003|NCT00269347|Manual Therapy
1431004|NCT00269347|Exercise
1431005|NCT00269347|Randomized
1431006|NCT00269347|Clinical Trial
1431007|NCT00269347|Back Pain
1431008|NCT00269334|antidepressant,major depression,CYP2D6,CYP2C19,SSRI
1431009|NCT00269321|Randomized
1431010|NCT00269321|Clinical Trial
1431011|NCT00269321|Low Back Pain
1431012|NCT00269321|Chiropractic
1431013|NCT00269321|Manual Therapies
1431014|NCT00269321|Exercise
1431015|NCT00269308|Randomized
1431016|NCT00269308|Clinical Trial
1431017|NCT00269308|Neck Pain
1431018|NCT00269308|Chiropractic
1431019|NCT00269308|Manual Therapies
1431020|NCT00269308|Exercise
1431021|NCT00269295|Typhoid fever, S typhi, vaccine
1431022|NCT00269230|cardiac resynchronization therapy, left ventricular Lead, Heart Failure
1431023|NCT00269191|Arcoxia
1431024|NCT00269178|malaria
1431025|NCT00269178|knowledge attitudes and practice (KAP)
1431026|NCT00269178|bednets
1431027|NCT00269178|peer health education
1431028|NCT00269139|Behavioral crisis
1431029|NCT00269139|Perception of social crisis
1431030|NCT00269139|Repetition compulsion
1431031|NCT00269139|Intrusive mental events
1431032|NCT00269139|Uncontrollable urges
1431033|NCT00269126|COPD
1431034|NCT00269126|Chronic Bronchitis
1431035|NCT00269126|Emphysema
1431036|NCT00268658|Arthroplasty, Replacement, Hip
1431037|NCT00268658|Arthroplasty, Replacement, Knee
1431038|NCT00268658|Arthroscopy
1431039|NCT00269100|Debridement
1431040|NCT00269087|Chronic Bronchitis
1431041|NCT00269087|COPD
1431042|NCT00269087|Emphysema
1431043|NCT00269061|pioglitazone
1431044|NCT00269061|diabetes
1431045|NCT00269061|fluid
1431046|NCT00269048|CHD
1431047|NCT00269048|Lp-PLA2
1431048|NCT00269048|SB-480848
1431049|NCT00269035|SB-773812
1431050|NCT00269035|SPECT
1431051|NCT00269035|D2 RO
1431052|NCT00269035|pharmacokinetics
1431053|NCT00269035|schizophrenic patients
1431054|NCT00269035|5HT2A RO
1431055|NCT00269022|SB-705498 acute migraine single dose TRPV1 combination inpatient outpatient study
1431056|NCT00269009|Tobacco use
1431057|NCT00268996|Coronary artery disease
1431058|NCT00268996|Lipoprotein-associated Phospholipase A2
1431059|NCT00268996|palpography
1431060|NCT00268996|hs-CRP
1431061|NCT00268996|endothelial function
1431062|NCT00268996|intravascular ultrasound
1431063|NCT00268983|rituximab
1431064|NCT00268983|tositumomab and iodine I 131 tositumomab
1431065|NCT00268983|non-Hodgkins lymphoma
1431066|NCT00268983|radioimmunotherapy
1431067|NCT00268983|anti-B1 antibody
1431068|NCT00268983|Bexxar
1431069|NCT00268983|NHL
1431070|NCT00268983|Tositumomab
1431071|NCT00268970|Advanced non-small cell lung cancer (NSCLC)
1431072|NCT00268957|Chronic
1431073|NCT00268957|Hemodialysis
1431074|NCT00268957|Kidney
1431075|NCT00268957|Hyperphosphatemia
1431076|NCT00268957|Chronic kidney disease
1431077|NCT00268957|Chronic Renal Insufficiency
1431078|NCT00268944|Glycogen Storage Disease Type II
1431079|NCT00268944|GSD-II
1431080|NCT00268944|Pompe Disease
1431081|NCT00268931|premature birth
1431082|NCT00268931|motor skills
1431083|NCT00268931|learning
1431084|NCT00268931|reaching
1431085|NCT00268918|PTK787
1431086|NCT00268918|Metastatic breast cancer
1431087|NCT00268918|Refractory gynecological cancer
1431088|NCT00268892|Prostate Cancer
1431089|NCT00268892|Androgen ablation therapy
1431090|NCT00268879|Irritable bowel syndrome
1431091|NCT00268879|Constipation-predominant irritable bowel syndrome
1431092|NCT00268853|lymphoma
1431093|NCT00268853|NHL
1431094|NCT00268853|large cell
1431095|NCT00268853|phase II
1431096|NCT00268853|CHOP R
1431097|NCT00268853|CPOP R
1431098|NCT00268853|non Hodgkins
1431099|NCT00268840|Pancreas or biliary cancer
1431100|NCT00268827|Kaletra
1431101|NCT00268827|Comparison
1431102|NCT00268827|Quality of Life
1431103|NCT00268827|African American
1431104|NCT00268788|multifocal motor neuropathy
1431105|NCT00268788|subcutaneous
1431106|NCT00268788|IVIG
1431107|NCT00268788|gammaglobulin
1431108|NCT00268775|community pharmacy services
1431109|NCT00268775|patient care
1431110|NCT00268775|outcome assessment
1431111|NCT00268775|benzodiazepines therapeutic use
1431112|NCT00268762|stroke
1431113|NCT00268762|thrombin inhibition
1431114|NCT00268762|thrombolysis
1431115|NCT00268762|bleeding
1431116|NCT00268762|outcome
1431117|NCT00268697|Hyperlipidemia
1431118|NCT00268697|Drug Therapy
1431119|NCT00268606|fibromyalgia
1431120|NCT00268606|cognitive-behavioral therapy
1431121|NCT00268606|tailored treatment
1431122|NCT00268593|heparanase
1431123|NCT00268593|angiogenesis
1431124|NCT00268580|Asthma
1431125|NCT00268580|Care map
1431126|NCT00268580|Clinical pathway
1431127|NCT00268580|Education
1431128|NCT00268580|Emergency department
1431129|NCT00268554|adenosine
1431130|NCT00268554|caffeine
1431131|NCT00268554|dipyridamole
1431132|NCT00268541|exercise
1431133|NCT00268541|physical activity
1431134|NCT00268541|insulin resistance
1431135|NCT00268541|adipose tissue
1431136|NCT00268541|gene expression
1431137|NCT00268502|fatigue
1431138|NCT00268502|depression
1431139|NCT00268502|spiritual concerns
1431140|NCT00268502|sexual dysfunction
1431141|NCT00268502|sleep disorders
1431142|NCT00268502|cancer survivor
1431143|NCT00268502|stage IA breast cancer
1431144|NCT00268502|stage IB breast cancer
1431145|NCT00268502|stage II breast cancer
1431146|NCT00268502|stage IIIA breast cancer
1431147|NCT00268502|stage IIIB breast cancer
1431148|NCT00268502|stage IIIC breast cancer
1431149|NCT00268489|recurrent non-small cell lung cancer
1431150|NCT00268489|squamous cell lung cancer
1431151|NCT00268489|stage IIIB non-small cell lung cancer
1431152|NCT00268489|stage IV non-small cell lung cancer
1431153|NCT00268476|stage III prostate cancer
1431154|NCT00268476|stage IV prostate cancer
1431155|NCT00268476|recurrent prostate cancer
1431156|NCT00268476|adenocarcinoma of the prostate
1431157|NCT00268463|liver metastases
1431158|NCT00268463|stage IV colon cancer
1431159|NCT00268463|stage IV rectal cancer
1431160|NCT00268463|adenocarcinoma of the colon
1431161|NCT00268463|adenocarcinoma of the rectum
1431162|NCT00268450|transitional cell carcinoma of the bladder
1431163|NCT00268450|stage III bladder cancer
1431164|NCT00268450|stage II bladder cancer
1431165|NCT00268450|recurrent bladder cancer
1431166|NCT00268437|adenocarcinoma of the esophagus
1431167|NCT00268437|squamous cell carcinoma of the esophagus
1431168|NCT00268437|stage III esophageal cancer
1431169|NCT00268437|stage II esophageal cancer
1431170|NCT00268411|adenocarcinoma of the pancreas
1431171|NCT00268411|stage IV pancreatic cancer
1431172|NCT00268398|adenocarcinoma of the colon
1431173|NCT00268398|stage IV colon cancer
1431174|NCT00268398|adenocarcinoma of the rectum
1431175|NCT00268398|stage IV rectal cancer
1431176|NCT00268398|resectable metastases
1431177|NCT00268372|stage III squamous cell carcinoma of the oropharynx
1431178|NCT00268372|stage IV squamous cell carcinoma of the oropharynx
1431179|NCT00268359|adult anaplastic astrocytoma
1431180|NCT00268359|adult anaplastic oligodendroglioma
1431181|NCT00268359|adult glioblastoma
1431182|NCT00268359|adult gliosarcoma
1431183|NCT00268359|recurrent adult brain tumor
1431184|NCT00268359|adult giant cell glioblastoma
1431185|NCT00268346|adenocarcinoma of the esophagus
1431186|NCT00268346|recurrent esophageal cancer
1431187|NCT00268346|squamous cell carcinoma of the esophagus
1431188|NCT00268346|stage IV esophageal cancer
1431189|NCT00268333|adenocarcinoma of the colon
1431190|NCT00268333|adenocarcinoma of the rectum
1431191|NCT00268333|stage IV colon cancer
1431192|NCT00268333|stage III colon cancer
1431193|NCT00268333|stage III rectal cancer
1431194|NCT00268333|stage IV rectal cancer
1431195|NCT00268320|congestive heart failure, atrial arrhythmia, cardiac resynchronization therapy, implantable cardioverter defibrillator
1431196|NCT00268307|Cell therapy
1431197|NCT00268294|cardiac resynchronization therapy, atrial arrhythmia
1431198|NCT00268281|cardiac resynchronization therapy
1431199|NCT00268255|stage I non-small cell lung cancer
1431200|NCT00268255|stage II non-small cell lung cancer
1431201|NCT00268255|adenosquamous cell lung cancer
1431202|NCT00268255|bronchoalveolar cell lung cancer
1431203|NCT00268255|large cell lung cancer
1431204|NCT00268255|squamous cell lung cancer
1431205|NCT00268255|adenocarcinoma of the lung
1431206|NCT00268242|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1431207|NCT00268242|adult acute myeloid leukemia with inv(16)(p13;q22)
1431208|NCT00268242|adult acute myeloid leukemia with t(16;16)(p13;q22)
1431209|NCT00268242|adult acute myeloid leukemia with t(8;21)(q22;q22)
1431210|NCT00268242|recurrent adult acute myeloid leukemia
1431211|NCT00268242|adult acute minimally differentiated myeloid leukemia (M0)
1431212|NCT00268242|adult acute myeloblastic leukemia without maturation (M1)
1431213|NCT00268242|adult acute myeloblastic leukemia with maturation (M2)
1431214|NCT00268242|adult acute myelomonocytic leukemia (M4)
1431215|NCT00268242|adult acute monoblastic leukemia (M5a)
1431216|NCT00268242|adult acute monocytic leukemia (M5b)
1431217|NCT00268242|adult erythroleukemia (M6a)
1431218|NCT00268242|adult pure erythroid leukemia (M6b)
1431219|NCT00268242|adult acute megakaryoblastic leukemia (M7)
1431220|NCT00268229|recurrent adult acute myeloid leukemia
1431221|NCT00268229|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1431222|NCT00268229|adult acute myeloid leukemia with inv(16)(p13;q22)
1431223|NCT00268229|adult acute myeloid leukemia with t(16;16)(p13;q22)
1431224|NCT00268229|adult acute myeloid leukemia with t(8;21)(q22;q22)
1431225|NCT00268229|adult acute minimally differentiated myeloid leukemia (M0)
1431226|NCT00268229|adult acute megakaryoblastic leukemia (M7)
1431227|NCT00268229|adult acute monoblastic leukemia (M5a)
1431228|NCT00268229|adult acute monocytic leukemia (M5b)
1431229|NCT00268229|adult acute myeloblastic leukemia with maturation (M2)
1431230|NCT00268229|adult acute myeloblastic leukemia without maturation (M1)
1431231|NCT00268229|adult acute myelomonocytic leukemia (M4)
1431232|NCT00268229|adult erythroleukemia (M6a)
1431233|NCT00268229|adult pure erythroid leukemia (M6b)
1431234|NCT00268216|mortality
1431235|NCT00268216|TORCH
1431236|NCT00268216|SERETIDE
1431237|NCT00268216|ADVAIR
1431238|NCT00268216|COPD
1431239|NCT00268203|expanded access study
1431240|NCT00268203|refractory low-grade non-Hodgkin's Lymphoma
1431241|NCT00268203|Bexxar®
1431242|NCT00268203|Iodine I 131 Tositumomab
1431243|NCT00268203|EAP
1431244|NCT00268203|relapsed low-grade non-Hodgkin's lymphoma
1431245|NCT00268177|Airways
1431246|NCT00268177|Pulmonary
1431247|NCT00268177|Obstructive
1431248|NCT00268177|Chronic
1431249|NCT00268177|inflammation
1431250|NCT00268177|salmeterol/fluticasone propionate
1431251|NCT00268151|non-small cell lung cancer
1431252|NCT00268151|oxaliplatin
1431253|NCT00268151|capecitabine
1431254|NCT00268151|XELOX-RT
1431255|NCT00268138|amine fluoride
1431256|NCT00268138|white spot lesions
1431257|NCT00268138|qlf
1431258|NCT00268125|Breast Neoplasm
1431259|NCT00268125|FEC100
1431260|NCT00268125|Chemotherapy
1431261|NCT00268125|acupression
1431262|NCT00268125|bracelet
1431263|NCT00268125|nausea
1431264|NCT00268125|vomiting
1431265|NCT00268112|pediatric
1431266|NCT00268112|cardiac
1431267|NCT00268112|ALCAPA
1431268|NCT00268112|Tissue Doppler Imaging
1431269|NCT00268099|pediatric
1431270|NCT00268099|cardiac
1431271|NCT00268099|repair of right to left shunt lesions
1431272|NCT00268099|Tetralogy of Fallot defects
1431273|NCT00268086|constrictive pericarditis
1431274|NCT00268086|adult congenital patients
1431275|NCT00268086|pulmonary insufficiency
1431276|NCT00268073|Pediatric
1431277|NCT00268073|cardiac
1431278|NCT00268073|neo-aortic insufficience
1431279|NCT00268073|Norwood standard Stage I procedure
1431280|NCT00268073|Norwood Sano procedure
1431281|NCT00268060|pediatric
1431282|NCT00268060|cardiac
1431283|NCT00268060|Long QT Syndrome
1431284|NCT00268060|Pacemaker
1431285|NCT00268060|Herg mutation
1431286|NCT00268047|pediatric
1431287|NCT00268047|cardiac
1431288|NCT00268047|surgery
1431289|NCT00268047|transplantation
1431290|NCT00268047|pulmonary vascular resistance in Fontan patients
1431291|NCT00268034|pediatric
1431292|NCT00268034|cardiac
1431293|NCT00268034|aneurysms
1431294|NCT00268034|left ventricular aneurysms
1431295|NCT00268034|surgical repair for LV aneurysms
1431296|NCT00268021|pediatric
1431297|NCT00268021|biventricular pacemaker
1431298|NCT00268021|automated implantable cardioverter defibrillator
1431299|NCT00268021|AICD
1431300|NCT00268008|aortic valve replacement
1431301|NCT00268008|mitral valve replacement
1431302|NCT00268008|valvular stenosis
1431303|NCT00268008|Ross procedure
1431304|NCT00268008|Homograft valves
1431305|NCT00268008|Bio-prosthetic valves
1431306|NCT00268008|Mechanical valves
1431307|NCT00267995|Pediatric
1431308|NCT00267995|cardiac
1431309|NCT00267995|Ross procedure
1431310|NCT00267995|Aortic valve replacement
1431311|NCT00267995|Proximal buttressing technique
1431312|NCT00267982|pediatric
1431313|NCT00267982|cardiac
1431314|NCT00267982|Radiofrequency Ablation
1431315|NCT00267982|Ectopic Atrial Tachycardia
1431316|NCT00267969|Ustekinumab
1431317|NCT00267969|CNTO1275
1431318|NCT00267969|Plaque type Psoriasis
1431319|NCT00267969|Interleukin-23
1431320|NCT00267969|IL-23
1431321|NCT00267969|Psoriasis
1431322|NCT00267969|Interleukin 12
1431323|NCT00267969|IL-12
1431324|NCT00267956|Psoriatic arthritis
1431325|NCT00267956|CNTO 1275
1431326|NCT00267956|Ustekinumab
1431327|NCT00267956|Interleukin-23, IL-12, IL-23
1431328|NCT00267956|Monoclonal antibodies
1431329|NCT00267930|AFib
1431330|NCT00267930|AF
1431331|NCT00267904|Normal Physiology
1431332|NCT00267904|Catecholamines
1431333|NCT00267904|Catechols
1431334|NCT00267904|Healthy Volunteer
1431335|NCT00267904|HV
1431336|NCT00267891|Healthy Control Subjects
1431337|NCT00267891|Aggression
1431338|NCT00267891|Prefrontal Cortex Function
1431339|NCT00267891|Children and Adolescents
1431340|NCT00267891|Healthy Volunteer
1431341|NCT00267891|HV
1431342|NCT00267865|HIV
1431343|NCT00267865|AIDS-Related-Primary Central Nervous System Lymphoma
1431344|NCT00267865|High Dose Methotrexate
1431345|NCT00267865|Rituximab
1431346|NCT00267865|Highly Active Antiretroviral Therapy
1431347|NCT00267865|AIDS Related-Primary Central Nervous System Lymphoma
1431348|NCT00267865|AR-PCNSL
1431349|NCT00267852|Arthritis
1431350|NCT00267839|exercise
1431351|NCT00267839|intervention
1431352|NCT00267839|elderly woman
1431353|NCT00267839|risk factors
1431354|NCT00267839|health costs
1431355|NCT00267839|Osteoporosis
1431356|NCT00267839|cardiovascular diseases
1431357|NCT00267839|diabetes
1431358|NCT00267839|Higher Age
1431359|NCT00267826|Anti-CD20 antibody treatment
1431360|NCT00267826|Atopic dermatitis
1431361|NCT00267826|B cells
1431362|NCT00267826|Cytokines
1431363|NCT00267826|Immunopathology
1431364|NCT00267813|craving
1431365|NCT00267813|nicotine
1431366|NCT00267813|imaging
1431367|NCT00267813|FDG
1431368|NCT00267813|PET
1431369|NCT00267813|smoking
1431370|NCT00267813|Bupropion
1431371|NCT00267800|Lung disease, Interstitial
1431372|NCT00267800|Sarcoidosis
1431373|NCT00267800|Pulmonary fibrosis
1431374|NCT00267735|pregnancy
1431375|NCT00267735|repeat cesarean
1431376|NCT00267735|vaginal birth after cesarean
1431377|NCT00267696|ovarian cancer
1431378|NCT00267696|platinum sensitive cancer
1431379|NCT00267696|fallopian tube cancer
1431380|NCT00267696|peritoneal cancer
1431381|NCT00267670|Fatty Liver Disease
1431382|NCT00267670|Liver
1431383|NCT00267670|NASH
1431384|NCT00267670|Nonalcoholic Steatohepatitis
1431385|NCT00267670|Nonalcoholic Fatty Liver Disease (NAFLD)
1431386|NCT00267670|Pentoxifylline
1431387|NCT00267644|Children, dehydration, Ultrasound
1431388|NCT00267631|children, obesity, emergency medicine
1431389|NCT00267553|Atamestane
1431390|NCT00267553|Breast neoplasms
1431391|NCT00267553|Combined hormonal therapy
1431392|NCT00267553|Complete estrogen blockade
1431393|NCT00267553|Ductal breast carcinoma
1431394|NCT00267553|Estrogen blocker
1431395|NCT00267553|Fareston®
1431396|NCT00267553|Femara®
1431397|NCT00267553|First line therapy
1431398|NCT00267553|Letrozole
1431399|NCT00267553|Lobular breast carcinoma
1431400|NCT00267553|Locally advanced breast cancer
1431401|NCT00267553|Locally recurrent breast cancer
1431402|NCT00267553|Maximal estrogen inhibition
1431403|NCT00267553|Metastatic breast cancer
1431404|NCT00267553|Neoplasms, Hormone-dependent
1431405|NCT00267553|Receptor-positive
1431406|NCT00267553|Stage IIIA breast cancer
1431407|NCT00267553|Stage IIIB breast cancer
1431408|NCT00267553|Stage IV breast cancer
1431409|NCT00267553|Toremifene
1431410|NCT00267540|Vitamin D
1431411|NCT00267540|adolescent girls
1431412|NCT00267540|bone accretion
1431413|NCT00267540|bone turn over
1431414|NCT00267540|vitamin D status
1431415|NCT00267540|Vitamin D insufficiency in young girls
1431416|NCT00267527|Treatment Experienced
1431417|NCT00267527|HIV Visceral Obesity
1431418|NCT00267514|Hemodialysis
1431419|NCT00267501|Eosinophilic Disorders
1431420|NCT00267488|Hycamtin
1431421|NCT00267488|endometrial cancer
1431422|NCT00267488|topotecan
1431423|NCT00267475|eosinophilic esophagitis
1431424|NCT00267475|eosinophilic gastritis
1431425|NCT00267475|eosinophilic enteritis
1431426|NCT00267475|eosinophilic colitis
1431427|NCT00267475|eosinophilic gastroenteritis
1431428|NCT00267462|pediatric
1431429|NCT00267462|cardiac
1431430|NCT00267462|hypertrophic Myopathy
1431431|NCT00267449|Spectroscopy, Near-Infrared
1431432|NCT00267449|Mammography
1431433|NCT00267449|Breast Cancer
1431434|NCT00267436|adaptation
1431435|NCT00267436|HIV prevention
1431436|NCT00267436|HIV positive
1431437|NCT00267436|evidence based interventions
1431438|NCT00267436|HIV Seronegativity
1431439|NCT00267423|pediatric
1431440|NCT00267423|cardiac
1431441|NCT00267423|electrophysiology
1431442|NCT00267423|epicardial biventricular pacing
1431443|NCT00267410|HIV
1431444|NCT00267410|Adaptation
1431445|NCT00267410|Behavioral interventions
1431446|NCT00267410|Seropositive
1431447|NCT00267410|MSM
1431448|NCT00267410|HIV Seronegativity
1431449|NCT00267397|infant
1431450|NCT00267397|prenatal
1431451|NCT00267397|birth defects
1431452|NCT00267397|22Q11 deletion
1431453|NCT00267384|Aminoglycosides
1431454|NCT00267371|Migraine headache
1431455|NCT00267371|Patent Foramen Ovale
1431456|NCT00267371|Patent Foramen Ovale Closure
1431457|NCT00267332|Sedation
1431458|NCT00267332|Pain
1431459|NCT00267332|modafinil
1431460|NCT00267332|opioids
1431461|NCT00267293|fever treatment
1431462|NCT00267293|children
1431463|NCT00267241|ARDS
1431464|NCT00267241|ALI
1431465|NCT00267241|respiratory mechanics
1431466|NCT00267241|gas exchange
1431467|NCT00267241|assisted ventilation
1431468|NCT00267228|Anorexia Nervosa
1431469|NCT00267228|Eating disorder
1431470|NCT00267228|Quality of life
1431471|NCT00267215|Lumiracoxib
1431472|NCT00267215|osteoarthritis
1431473|NCT00267202|Allergic Asthma, IgE, immunotherapy, omalizumab
1431474|NCT00267189|Liver transplantation, everolimus, calcineurin inhibitor, renal function
1431475|NCT00267176|Osteoarthritis,
1431476|NCT00267176|hypertension,
1431477|NCT00267176|lumiracoxib,
1431478|NCT00267176|ibuprofen,
1431479|NCT00267176|24-hour blood pressure profile
1431480|NCT00267163|Alzheimer's disease
1431481|NCT00267163|Mild Cognitive Impairment
1431482|NCT00267150|Simultaneous Pancreas-Kidney Transplantation
1431483|NCT00267150|mycophenolate
1431484|NCT00267150|GI problems
1431485|NCT00267137|Pacemaker, Atrial Fibrillation/Therapy
1431486|NCT00267124|cognitive decline
1431487|NCT00267124|dementia
1431488|NCT00267124|neuroimaging
1431489|NCT00267111|Infant,newborn
1431490|NCT00267111|Topical anesthesia
1431491|NCT00267111|Intramuscular injection
1431492|NCT00267098|Atrioventricular block
1431493|NCT00267098|Cardiac Resynchronization Therapy
1431494|NCT00267098|Pacemaker
1431495|NCT00267098|Defibrillator
1431496|NCT00267098|NYHA Class I, II or III Heart failure
1431497|NCT00267085|Chronic Myeloid Leukemia
1431498|NCT00267085|Minimal Residual Disease
1431499|NCT00267085|Peptide Vaccine
1431500|NCT00267072|Ovarian Cancer
1431501|NCT00267059|Chronic Lymphocytic Leukemia
1431502|NCT00267059|Lenalidomide
1431503|NCT00267059|Revlimid
1431504|NCT00267059|CLL
1431505|NCT00267046|Sarcoma
1431506|NCT00267046|Soft Tissue Sarcoma
1431507|NCT00267046|Oral Mucositis
1431508|NCT00267046|Doxorubicin
1431509|NCT00267046|Adriamycin
1431510|NCT00267046|Ifosfamide
1431511|NCT00267046|Palifermin
1431512|NCT00267046|Vincristine
1431513|NCT00267046|Cisplatin
1431514|NCT00267046|Placebo
1431515|NCT00267033|Neoplasm Metastasis
1431516|NCT00267033|Bone Neoplasms
1431517|NCT00267033|Pain
1431518|NCT00267033|Radiotherapy
1431519|NCT00267033|Vertebroplasty
1431520|NCT00267033|Combined modality therapy
1431521|NCT00267007|Peripheral neuropathy
1431522|NCT00267007|Chemotherapy-induced
1431523|NCT00267007|Hemoglobin level
1431524|NCT00267007|Cancer
1431525|NCT00267007|Taxane
1431526|NCT00267007|Platinum-based chemotherapy
1431527|NCT00266994|Thrombosis
1431528|NCT00266968|pediatric
1431529|NCT00266968|cardiac
1431530|NCT00266968|single ventricle
1431531|NCT00266955|pediatric
1431532|NCT00266955|cardiac
1431533|NCT00266955|ADHD
1431534|NCT00266955|Adderall
1431535|NCT00266955|Straterra
1431536|NCT00266942|Fontan procedure
1431537|NCT00266942|single ventricle physiology
1431538|NCT00266942|intra-atrial
1431539|NCT00266942|extracardiac technique
1431540|NCT00266929|odontoid fx
1431541|NCT00266929|surgical intervention
1431542|NCT00266929|conservative treatment
1431543|NCT00266929|nonunion
1431544|NCT00266929|odontoid fractures
1431545|NCT00266929|surgical treatment
1431546|NCT00266916|adult
1431547|NCT00266916|congenital heart disease
1431548|NCT00266916|percutaneous occlusion
1431549|NCT00266916|percutaneous balloon valvotomy
1431550|NCT00266916|balloon angioplasty
1431551|NCT00266916|complex cyanotic congenital heart defects (CCHD)
1431552|NCT00266903|adult
1431553|NCT00266903|congenital heart disease
1431554|NCT00266903|Eisenmenger's Syndrome
1431555|NCT00266903|Bosentan
1431556|NCT00266903|Sitaxsetan
1431557|NCT00266903|Sildenafil
1431558|NCT00266877|Lung Cancer
1431559|NCT00266864|Spinal Cord Injury
1431560|NCT00266864|Testosterone Replacement Therapy
1431561|NCT00266864|Dual Energy X ray Absorptiometry
1431562|NCT00266864|Lean Tissue Mass
1431563|NCT00266851|Randomized clinical trial
1431564|NCT00266851|Asthma
1431565|NCT00266851|Adults
1431566|NCT00266851|Azithromycin
1431567|NCT00266838|Lacrimal Obstruction
1431568|NCT00266838|Epiphora
1431569|NCT00266812|temozolomide
1431570|NCT00266812|radiotherapy
1431571|NCT00266773|Chronic Pain
1431572|NCT00266773|Cognitive Therapy
1431573|NCT00266773|Cognitive Behavioral Therapy
1431574|NCT00266773|Recurrence
1431575|NCT00266773|Relapse Prevention
1431576|NCT00266773|Educational Technology
1431577|NCT00266773|CBT
1431578|NCT00266773|CST
1431579|NCT00266773|IVR
1431580|NCT00266773|TIVR
1431581|NCT00266747|Anxiety
1431582|NCT00266747|Anti-Anxiety Agents
1431583|NCT00266747|Controlled Clinical Trial
1431584|NCT00266734|Adenoviral conjunctivitis
1431585|NCT00266734|Viral conjunctivitis
1431586|NCT00266734|conjunctivitis
1431587|NCT00266721|Pancrelipase
1431588|NCT00266721|Abdominal bloating
1431589|NCT00266721|Abdominal pain
1431590|NCT00266721|Eructation
1431591|NCT00266708|renal transplant
1431592|NCT00266708|post-transplant osteoporosis
1431593|NCT00266682|Bradycardia
1431594|NCT00266669|Raynaud's Phenomenon
1431595|NCT00266669|Raynaud's Disease
1431596|NCT00266669|Scleroderma
1431597|NCT00266669|Raynaud's Disease Secondary to Scleroderma
1431598|NCT00266669|Raynaud's Disease Secondary to Other Autoimmune Disease
1431599|NCT00266617|Anemia
1431600|NCT00266617|chemotherapy
1431601|NCT00266617|epoetin alfa
1431602|NCT00266617|epogen
1431603|NCT00266617|erythropoietin
1431604|NCT00266617|neoplasms
1431605|NCT00266617|cancer
1431606|NCT00266604|Epilepsy
1431607|NCT00266604|seizures
1431608|NCT00266604|new-onset epilepsy
1431609|NCT00266604|epilepsy relapse
1431610|NCT00266604|epilepsy monotherapy
1431611|NCT00266591|Epilepsy
1431612|NCT00266591|Seizures
1431613|NCT00266591|Topiramate
1431614|NCT00266591|Prophylaxis
1431615|NCT00266591|Antiepileptic
1431616|NCT00266591|Epileptic seizures
1431617|NCT00266591|Partial seizure disorder
1431618|NCT00266591|Brain disease
1431619|NCT00266578|Eosinophilic Esophagitis
1431620|NCT00266552|conduct disorder
1431621|NCT00266552|oppositional defiant disorder
1431622|NCT00266552|disruptive behavior disorder not otherwise specified
1431623|NCT00266552|ADHD
1431624|NCT00266552|risperidone
1431625|NCT00266552|antipsychotropic agents
1431626|NCT00266552|children
1431627|NCT00266539|Postoperative pain
1431628|NCT00266539|patient-controlled analgesia
1431629|NCT00266526|Allergy
1431630|NCT00266526|Birch pollen
1431631|NCT00266526|Recombinant
1431632|NCT00266513|CD40 Ligand
1431633|NCT00266513|Nemo
1431634|NCT00266513|Genetics
1431635|NCT00266513|Hyper-IGM
1431636|NCT00266513|Ectodermal Dysplasia
1431637|NCT00266513|CVID
1431638|NCT00266513|Hyper-IgM Syndrome
1431639|NCT00266513|Primary Immune Deficiency Disorders
1431640|NCT00266513|Common Variable Immune Deficiency
1431641|NCT00266500|Adipose Tissue
1431642|NCT00266500|Weight Gain
1431643|NCT00266500|Overweight
1431644|NCT00266500|Thermogenesis
1431645|NCT00266500|Deep Body Temperature
1431646|NCT00266500|Adult
1431647|NCT00266500|Exercise
1431648|NCT00266487|Homocysteine
1431649|NCT00266487|B vitamins
1431650|NCT00266487|Folic acid
1431651|NCT00266487|Randomized trial
1431652|NCT00266487|Secondary prevention
1431653|NCT00266474|Cystic Fibrosis with Chronic Rhinosinusitis
1431654|NCT00266461|Postoperative Ileus
1431655|NCT00266448|MRSA
1431656|NCT00266448|eradication
1431657|NCT00266448|chlorhexidine
1431658|NCT00266435|Asymptomatic subjects
1431659|NCT00266435|Moderate to high risk for cardiovascular event
1431660|NCT00266396|Total Hip Arthroplasty
1431661|NCT00266396|THA
1431662|NCT00266396|Total Knee Arthroplasty
1431663|NCT00266396|TKA
1431664|NCT00266396|Total Hip Replacement
1431665|NCT00266396|THR
1431666|NCT00266396|Total Knee Replacement
1431667|NCT00266396|TKR
1431668|NCT00265382|Adolescent Subjects
1431669|NCT00265356|Positron Emission Tomography (PET)
1431670|NCT00265356|Diagnostic Investigation
1431671|NCT00265356|Colorectal cancer
1431672|NCT00265356|Liver metastases
1431673|NCT00265356|Liver surgery
1431674|NCT00265330|Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
1431675|NCT00265317|Non-small cell lung cancer
1431676|NCT00265317|sunitinib
1431677|NCT00265317|erlotinib
1431678|NCT00265317|Phase 2
1431679|NCT00265304|Osteoarthritis
1431680|NCT00265291|Depression
1431681|NCT00265291|mood disorders
1431682|NCT00265291|affective disorders
1431683|NCT00265291|pharmacogenetics
1431684|NCT00265291|pharmacogenomics
1431685|NCT00266331|Breast cancer
1431686|NCT00266331|Radiation skin protection
1431687|NCT00266318|Hepatitis C Nonresponder
1431688|NCT00266318|Genotype 1
1431689|NCT00266318|Interferon Alfacon-1
1431690|NCT00266318|Consensus Interferon
1431691|NCT00266318|CIFN
1431692|NCT00266318|Infergen
1431693|NCT00266318|Ribavirin
1431694|NCT00266305|n-3 LCPUFA
1431695|NCT00266305|Infant development
1431696|NCT00266305|Visual acuity
1431697|NCT00266305|Immune function
1431698|NCT00266305|Breast milk
1431699|NCT00266292|Fish oil
1431700|NCT00266292|Polyunsaturated fatty acid
1431701|NCT00266292|Immune function
1431702|NCT00266292|Endothelial function
1431703|NCT00266292|Cardiovascular risk factors
1431704|NCT00266266|Human Papilloma Virus
1431705|NCT00266214|lidocaine patch 5%
1431706|NCT00266214|Lidoderm
1431707|NCT00266214|carpal tunnel syndrome
1431708|NCT00266214|pain
1431709|NCT00266214|nerve compression injury
1431710|NCT00266214|topical analgesic
1431824|NCT00265850|stage III rectal cancer
1431711|NCT00266201|Heart Defects, Congenital
1431712|NCT00266201|Right Ventricular Dysfunction
1431713|NCT00266201|Low Cardiac Output
1431714|NCT00266201|Biochemical markers
1431715|NCT00266201|Neurohumoral activity
1431716|NCT00266188|Heart Defects, Congenital
1431717|NCT00266188|Tetralogy of Fallot
1431718|NCT00266188|Heart Septal Defects, Ventricular
1431719|NCT00266188|Pulmonary Valve Diseases
1431720|NCT00266188|Magnetic Resonance Imaging
1431721|NCT00266188|Heart Catheterization
1431722|NCT00266188|Echocardiography
1431723|NCT00266175|Pulmonary heart disease
1431724|NCT00266175|Pulmonary hypertension
1431725|NCT00266175|Stent implantation
1431726|NCT00266175|Balloon dilatation
1431727|NCT00266175|Surgery
1431728|NCT00266162|Heart Defects, Congenital
1431729|NCT00266162|Eisenmenger Complex
1431730|NCT00266162|Hypertension, Pulmonary
1431731|NCT00266162|Pulmonary Heart Disease
1431732|NCT00266162|Pulmonary Circulation
1431733|NCT00266162|Vascular Resistance
1431734|NCT00266149|Pharmacokinetics
1431735|NCT00266149|Lamotrigine
1431736|NCT00266149|Oral Contraceptives
1431737|NCT00266149|UGT
1431738|NCT00266149|Glucuronidation.
1431739|NCT00266136|AML treatment, de-novo, secondary, high-risk MDS, chemotherapy, autologous SCT, adult
1431740|NCT00266123|Kidney Failure
1431741|NCT00266123|Kidney Transplant
1431742|NCT00266110|stage IV breast cancer
1431743|NCT00266110|recurrent breast cancer
1431744|NCT00266097|stage III pancreatic cancer
1431745|NCT00266097|stage IV pancreatic cancer
1431746|NCT00266097|unresectable extrahepatic bile duct cancer
1431747|NCT00266097|unresectable gallbladder cancer
1431748|NCT00266097|adenocarcinoma of the extrahepatic bile duct
1431749|NCT00266097|adenocarcinoma of the gallbladder
1431750|NCT00266097|adenocarcinoma of the pancreas
1431751|NCT00266097|recurrent pancreatic cancer
1431752|NCT00266097|recurrent extrahepatic bile duct cancer
1431753|NCT00266097|recurrent gallbladder cancer
1431754|NCT00266084|Cervix
1431755|NCT00266084|Uterus
1431756|NCT00266084|Dysplasia
1431757|NCT00266084|Cancer
1431758|NCT00266084|Collector
1431759|NCT00266071|skin
1431760|NCT00266071|pressure
1431761|NCT00266071|age
1431762|NCT00266058|healthy
1431763|NCT00266058|controls
1431764|NCT00266058|research
1431765|NCT00266058|clinical
1431766|NCT00266058|study
1431767|NCT00266058|pharmacokinetic
1431768|NCT00266058|PK
1431769|NCT00266058|HIV
1431770|NCT00266058|malaria
1431771|NCT00266045|Deep Vein Thrombosis
1431772|NCT00266045|Pulmonary Embolism
1431773|NCT00266045|D-dimer
1431774|NCT00266045|Recurrence
1431775|NCT00266045|Duration of Anticoagulation
1431776|NCT00266045|Vitamin K Antagonists
1431777|NCT00266019|nonalcoholic steatohepatitis
1431778|NCT00266019|nonalcoholic fatty liver disease
1431779|NCT00266019|Fatty liver
1431780|NCT00266019|Cirrhosis
1431781|NCT00266019|Obesity
1431782|NCT00266019|Weight Reduction
1431783|NCT00266019|Weight Management
1431784|NCT00265980|Leptin
1431785|NCT00265980|Obesity
1431786|NCT00265980|Energy
1431787|NCT00265980|Autonomics
1431788|NCT00265980|Neuroendocrine
1431789|NCT00265941|stage III squamous cell carcinoma of the hypopharynx
1431790|NCT00265941|stage IV squamous cell carcinoma of the hypopharynx
1431791|NCT00265941|stage III squamous cell carcinoma of the larynx
1431792|NCT00265941|stage IV squamous cell carcinoma of the larynx
1431793|NCT00265941|stage III squamous cell carcinoma of the oropharynx
1431794|NCT00265941|stage IV squamous cell carcinoma of the oropharynx
1431795|NCT00265928|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1431796|NCT00265928|recurrent grade 1 follicular lymphoma
1431797|NCT00265928|recurrent grade 2 follicular lymphoma
1431798|NCT00265928|recurrent grade 3 follicular lymphoma
1431799|NCT00265928|recurrent mantle cell lymphoma
1431800|NCT00265928|recurrent marginal zone lymphoma
1431801|NCT00265928|recurrent small lymphocytic lymphoma
1431802|NCT00265928|splenic marginal zone lymphoma
1431803|NCT00265928|recurrent adult diffuse small cleaved cell lymphoma
1431804|NCT00265928|nodal marginal zone B-cell lymphoma
1431805|NCT00265928|Waldenstrom's macroglobulinemia
1431806|NCT00265915|B-cell chronic lymphocytic leukemia
1431807|NCT00265915|refractory chronic lymphocytic leukemia
1431808|NCT00265915|stage 0 chronic lymphocytic leukemia
1431809|NCT00265915|stage I chronic lymphocytic leukemia
1431810|NCT00265915|stage II chronic lymphocytic leukemia
1431811|NCT00265915|stage III chronic lymphocytic leukemia
1431812|NCT00265915|stage IV chronic lymphocytic leukemia
1431813|NCT00265902|Kaposi sarcoma
1431814|NCT00265889|recurrent adult Hodgkin lymphoma
1431815|NCT00265889|stage III adult Hodgkin lymphoma
1431816|NCT00265889|stage IV adult Hodgkin lymphoma
1431817|NCT00265876|adenocarcinoma of the pancreas
1431818|NCT00265876|stage III pancreatic cancer
1431819|NCT00265876|recurrent pancreatic cancer
1431820|NCT00265876|stage IV pancreatic cancer
1431821|NCT00265863|malignant ascites
1431822|NCT00265850|recurrent colon cancer
1431823|NCT00265850|stage III colon cancer
1431825|NCT00265850|stage IV colon cancer
1431826|NCT00265850|recurrent rectal cancer
1431827|NCT00265850|stage IV rectal cancer
1431828|NCT00265850|adenocarcinoma of the colon
1431829|NCT00265850|adenocarcinoma of the rectum
1431830|NCT00265837|graft versus host disease
1431831|NCT00265837|adult acute myeloid leukemia in remission
1431832|NCT00265837|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1431833|NCT00265837|adult acute myeloid leukemia with inv(16)(p13;q22)
1431834|NCT00265837|adult acute myeloid leukemia with t(15;17)(q22;q12)
1431835|NCT00265837|adult acute myeloid leukemia with t(16;16)(p13;q22)
1431836|NCT00265837|adult acute myeloid leukemia with t(8;21)(q22;q22)
1431837|NCT00265837|recurrent adult acute myeloid leukemia
1431838|NCT00265837|recurrent childhood acute myeloid leukemia
1431839|NCT00265837|childhood acute myeloid leukemia in remission
1431840|NCT00265837|adult acute lymphoblastic leukemia in remission
1431841|NCT00265837|recurrent adult acute lymphoblastic leukemia
1431842|NCT00265837|childhood acute lymphoblastic leukemia in remission
1431843|NCT00265837|recurrent childhood acute lymphoblastic leukemia
1431844|NCT00265837|accelerated phase chronic myelogenous leukemia
1431845|NCT00265837|blastic phase chronic myelogenous leukemia
1431846|NCT00265837|childhood chronic myelogenous leukemia
1431847|NCT00265837|chronic phase chronic myelogenous leukemia
1431848|NCT00265837|relapsing chronic myelogenous leukemia
1431849|NCT00265837|secondary acute myeloid leukemia
1431850|NCT00265837|de novo myelodysplastic syndromes
1431851|NCT00265837|previously treated myelodysplastic syndromes
1431852|NCT00265837|secondary myelodysplastic syndromes
1431853|NCT00265837|chronic myelomonocytic leukemia
1431854|NCT00265837|juvenile myelomonocytic leukemia
1431855|NCT00265837|atypical chronic myeloid leukemia
1431856|NCT00265837|myelodysplastic/myeloproliferative disease, unclassifiable
1431857|NCT00265837|Philadelphia chromosome negative chronic myelogenous leukemia
1431858|NCT00265837|stage I multiple myeloma
1431859|NCT00265837|stage II multiple myeloma
1431860|NCT00265837|stage III multiple myeloma
1431861|NCT00265837|refractory multiple myeloma
1431862|NCT00265837|stage III adult Hodgkin lymphoma
1431863|NCT00265837|stage IV adult Hodgkin lymphoma
1431864|NCT00265837|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1431865|NCT00265837|nodal marginal zone B-cell lymphoma
1431866|NCT00265837|noncontiguous stage II adult Burkitt lymphoma
1431867|NCT00265837|noncontiguous stage II adult diffuse large cell lymphoma
1431868|NCT00265837|noncontiguous stage II adult diffuse mixed cell lymphoma
1431869|NCT00265837|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1431870|NCT00265837|noncontiguous stage II adult immunoblastic large cell lymphoma
1431871|NCT00265837|noncontiguous stage II adult lymphoblastic lymphoma
1431872|NCT00265837|noncontiguous stage II grade 1 follicular lymphoma
1431873|NCT00265837|noncontiguous stage II grade 2 follicular lymphoma
1431874|NCT00265837|noncontiguous stage II grade 3 follicular lymphoma
1431875|NCT00265837|noncontiguous stage II mantle cell lymphoma
1431876|NCT00265837|noncontiguous stage II marginal zone lymphoma
1431877|NCT00265837|recurrent adult Hodgkin lymphoma
1431878|NCT00265837|recurrent adult Burkitt lymphoma
1431879|NCT00265837|recurrent adult diffuse large cell lymphoma
1431880|NCT00265837|recurrent adult diffuse mixed cell lymphoma
1431881|NCT00265837|recurrent adult diffuse small cleaved cell lymphoma
1431882|NCT00265837|recurrent adult immunoblastic large cell lymphoma
1431883|NCT00265837|recurrent adult lymphoblastic lymphoma
1431884|NCT00265837|recurrent/refractory childhood Hodgkin lymphoma
1431885|NCT00265837|recurrent childhood large cell lymphoma
1431886|NCT00265837|recurrent childhood lymphoblastic lymphoma
1431887|NCT00265837|recurrent childhood small noncleaved cell lymphoma
1431888|NCT00265837|recurrent grade 1 follicular lymphoma
1431889|NCT00265837|recurrent grade 2 follicular lymphoma
1431890|NCT00265837|recurrent grade 3 follicular lymphoma
1431891|NCT00265837|recurrent mantle cell lymphoma
1431892|NCT00265837|recurrent marginal zone lymphoma
1431893|NCT00265837|recurrent small lymphocytic lymphoma
1431894|NCT00265837|splenic marginal zone lymphoma
1431895|NCT00265837|stage III adult Burkitt lymphoma
1431896|NCT00265837|stage III adult diffuse large cell lymphoma
1431897|NCT00265837|stage III adult diffuse mixed cell lymphoma
1431898|NCT00265837|stage III adult diffuse small cleaved cell lymphoma
1431899|NCT00265837|stage IV adult diffuse large cell lymphoma
1431900|NCT00265837|stage IV adult diffuse mixed cell lymphoma
1431901|NCT00265837|stage IV adult diffuse small cleaved cell lymphoma
1431902|NCT00265837|stage III adult lymphoblastic lymphoma
1431903|NCT00265837|stage IV adult lymphoblastic lymphoma
1431904|NCT00265837|stage III grade 1 follicular lymphoma
1431905|NCT00265837|stage III grade 2 follicular lymphoma
1431906|NCT00265837|stage III grade 3 follicular lymphoma
1431907|NCT00265837|stage IV grade 1 follicular lymphoma
1431908|NCT00265837|stage IV grade 2 follicular lymphoma
1431909|NCT00265837|stage IV grade 3 follicular lymphoma
1431910|NCT00265837|stage III mantle cell lymphoma
1431911|NCT00265837|stage III marginal zone lymphoma
1431912|NCT00265837|stage IV mantle cell lymphoma
1431913|NCT00265837|stage IV marginal zone lymphoma
1431914|NCT00265837|stage III small lymphocytic lymphoma
1431915|NCT00265837|stage IV small lymphocytic lymphoma
1432161|NCT00264602|indocyanine green
1431916|NCT00265837|stage IV adult Burkitt lymphoma
1431917|NCT00265837|stage IV adult immunoblastic large cell lymphoma
1431918|NCT00265837|childhood myelodysplastic syndromes
1431919|NCT00265824|stage IV colon cancer
1431920|NCT00265824|stage IV rectal cancer
1431921|NCT00265824|adenocarcinoma of the colon
1431922|NCT00265824|adenocarcinoma of the rectum
1431923|NCT00265824|chemotherapy
1431924|NCT00265811|stage III colon cancer
1431925|NCT00265811|adenocarcinoma of the colon
1431926|NCT00265785|bronchoalveolar cell lung cancer
1431927|NCT00265785|stage IIIB non-small cell lung cancer
1431928|NCT00265785|stage IV non-small cell lung cancer
1431929|NCT00265785|recurrent non-small cell lung cancer
1431930|NCT00265772|enteral nutrition
1431931|NCT00265772|steroids
1431932|NCT00265772|mucosal healing
1431933|NCT00265759|stage II breast cancer
1431934|NCT00265759|stage IIIA breast cancer
1431935|NCT00265759|stage IIIB breast cancer
1431936|NCT00265759|stage IIIC breast cancer
1431937|NCT00265759|estrogen receptor-positive breast cancer
1431938|NCT00265746|metformin
1431939|NCT00265746|gestational diabetes
1431940|NCT00265746|lifestyle
1431941|NCT00265733|male breast cancer
1431942|NCT00265733|recurrent breast cancer
1431943|NCT00265733|stage IV breast cancer
1431944|NCT00265720|African Americans
1431945|NCT00265720|Colorectal Cancer Screening
1431946|NCT00265720|Colorectal Cancer
1431947|NCT00265720|Colorectal Cancer and African Americans
1431948|NCT00265720|Cancer Disparities
1431949|NCT00265707|Hypertension
1431950|NCT00265707|Hypotension
1431951|NCT00265681|smokeless tobacco cessation
1431952|NCT00265681|chewing tobacco
1431953|NCT00265681|oral tobacco
1431954|NCT00265681|smokeless tobacco
1431955|NCT00265681|telephone
1431956|NCT00265681|counseling
1431957|NCT00265642|Hepatitis C, Chronic
1431958|NCT00265642|irbesartan
1431959|NCT00265629|Atrial fibrillation
1431960|NCT00265616|Refractory status epilepticus,
1431961|NCT00265616|coma-induction,
1431962|NCT00265616|treatment,
1431963|NCT00265616|propofol,
1431964|NCT00265616|barbiturates,
1431965|NCT00265616|efficacy,
1431966|NCT00265616|safety.
1431967|NCT00265590|Aniridia
1431968|NCT00265590|PAX6
1431969|NCT00265590|Keratopathy
1431970|NCT00265590|Limbal Stem Cell Deficiency
1431971|NCT00265590|Molecular Genetics
1431972|NCT00265564|outcomes assessment
1431973|NCT00265564|substance use disorders
1431974|NCT00265564|stress disorders, post-traumatic
1431975|NCT00265564|screening
1431976|NCT00265551|Schizophrenia
1431977|NCT00265538|Hypertension
1431978|NCT00265538|Diuretics
1431979|NCT00265538|Drug Therapy
1431980|NCT00265538|Anti-Hypertensive Agents
1431981|NCT00265538|Patient Intervention
1431982|NCT00265525|Randomized Control Trial
1431983|NCT00265525|Exercise Intervention
1431984|NCT00265525|Prevention
1431985|NCT00265525|Rehabilitation
1431986|NCT00265512|Telemedicine
1431987|NCT00265512|Aftercare
1431988|NCT00265499|Coronary Artery Bypass
1431989|NCT00265499|Skeletonization
1431990|NCT00265499|Internal Thoracic Artery
1431991|NCT00265499|Flow
1431992|NCT00265499|Length
1431993|NCT00265499|Pain
1431994|NCT00265486|Divers
1431995|NCT00265486|Brain
1431996|NCT00265486|Flow
1431997|NCT00265486|Blood
1431998|NCT00265486|EPO
1431999|NCT00265486|Dive
1432000|NCT00265486|reflex
1432001|NCT00265460|smoking cessation,
1432002|NCT00265460|nicotine,
1432003|NCT00265460|smokeless tobacco,
1432004|NCT00265460|cigarettes
1432005|NCT00265447|knee osteoarthritis
1432006|NCT00265447|exercise
1432007|NCT00265447|aerobic exercise
1432008|NCT00265447|strengthening exercise
1432009|NCT00265447|exercise prescription
1432010|NCT00265447|rehabilitation
1432011|NCT00265447|physical disability
1432012|NCT00265447|physical function
1432013|NCT00265447|physical activity
1432014|NCT00265447|physical fitness
1432015|NCT00265421|Suture Techniques
1432016|NCT00265408|Cervicocephalic Arterial Dissection
1432017|NCT00265265|Cocaine Dependence
1432018|NCT00265252|osteonecrosis
1432019|NCT00265252|total hip replacement
1432020|NCT00265239|Edaravone
1432021|NCT00265239|Randomized Control Trial
1432022|NCT00265239|ST-Elevation Myocardial Infarction
1432023|NCT00265239|Coronary Angioplasty
1432024|NCT00265226|India
1432025|NCT00265226|Pulmonary Tuberculosis
1432026|NCT00265226|Category-II tuberculosis
1432027|NCT00265226|Immunomodulator
1432028|NCT00265226|Mycobacterium w
1432029|NCT00265226|Revised National Tuberculosis Control Programme
1432030|NCT00265226|Category-II Pulmonary Tuberculosis
1432031|NCT00265213|breast conservative surgery
1432032|NCT00265213|shoulder functional outcome questionnaire
1432033|NCT00265213|disability questionnaire
1432034|NCT00265200|Zometa
1432035|NCT00265200|bone metastasis
1432036|NCT00265200|lung cancer
1432162|NCT00264602|near infrared imaging
1432037|NCT00265200|non-small cell lung cancer
1432038|NCT00265200|small cell lung cancer
1432039|NCT00265200|bone metabolic markers
1432040|NCT00265200|tartrate resistant acid phosphatase
1432041|NCT00265187|child, bronchiolitis,
1432042|NCT00265174|SERUM DNA
1432043|NCT00265174|LOH
1432044|NCT00265174|METHYLATION
1432045|NCT00265174|GLIOMA
1432046|NCT00265174|MGMT
1432047|NCT00265161|influenza vaccine
1432048|NCT00265161|effectiveness
1432049|NCT00265161|health care worker
1432050|NCT00265161|OBSERVATIONAL STUDY
1432051|NCT00265148|rosiglitazone
1432052|NCT00265148|cognition
1432053|NCT00265148|cerebral glucose metabolism
1432054|NCT00265148|positron emission tomography (PET)
1432055|NCT00265148|Alzheimer's Disease
1432056|NCT00265135|Renal cell carcinoma
1432057|NCT00265135|CNTO 328
1432058|NCT00265135|Infusions
1432059|NCT00265135|Renal cell cancer
1432060|NCT00265122|Crohn Disease
1432061|NCT00265122|Biologic
1432062|NCT00265122|Infusion
1432063|NCT00265122|Injection
1432064|NCT00265122|CNTO 1275
1432065|NCT00265122|Ustekinumab
1432066|NCT00265122|C01275
1432067|NCT00265122|IL-12p40
1432068|NCT00265109|body dysmorphic disorder
1432069|NCT00265109|levetiracetam
1432070|NCT00265096|Psoriatic Arthritis
1432071|NCT00265096|Spondyloarthritis
1432072|NCT00265096|Spondyloarthropathy
1432073|NCT00265096|subcutaneous injection
1432074|NCT00265083|Spondylitis
1432075|NCT00265083|subcutaneous injection
1432076|NCT00265083|Bechterew's Disease
1432077|NCT00265083|Spondyloarthritis
1432078|NCT00265083|Spondyloarthropathy
1432079|NCT00265057|Cancer;
1432080|NCT00265057|Tumors;
1432081|NCT00265057|Neoplasms;
1432082|NCT00265057|Anticarcinogenic Agents;
1432083|NCT00265057|Antineoplastic Agents;
1432084|NCT00265057|Cadherins;
1432085|NCT00265057|Non-Small-Cell Lung Carcinoma;
1432086|NCT00265057|Ovarian Cancer
1432087|NCT00265044|Behavior Change
1432088|NCT00265044|patient Education
1432089|NCT00265031|Hodgkin´s Lymphoma
1432090|NCT00265031|advanced stages
1432091|NCT00265018|Hodgkin´s lymphoma
1432092|NCT00265018|early stages
1432093|NCT00265005|alteplase
1432094|NCT00265005|occluded central venous catheter
1432095|NCT00265005|occluded arterial catheter
1432096|NCT00265005|occluded PICC
1432097|NCT00265005|neonates
1432098|NCT00265005|infants
1432099|NCT00264992|embryo implantation, in vitro fertilization,
1432100|NCT00264992|cytokine expression
1432101|NCT00264979|Colorectal cancer
1432102|NCT00264979|Sequential or simultaneous surgery
1432103|NCT00264979|Synchronous hepatic metastases
1432104|NCT00264966|Mild asthma
1432105|NCT00264953|Hodgkin´s lymphoma
1432106|NCT00264953|intermediate stages
1432107|NCT00264927|Inappropriate ADH Syndrome
1432108|NCT00264927|Hyponatremia
1432109|NCT00264914|Inappropriate ADH Syndrome
1432110|NCT00264914|Hyponatremia
1432111|NCT00264888|Duchenne muscular dystrophy
1432112|NCT00264888|Nonsense mutation
1432113|NCT00264888|Premature stop codon
1432114|NCT00264849|Asthma
1432115|NCT00264849|omalizumab
1432116|NCT00264849|Severe persistent allergic asthma
1432117|NCT00264823|HIV
1432118|NCT00264823|Mental Illness
1432119|NCT00264810|Responsive Stimulation
1432120|NCT00264810|Brain Stimulator
1432121|NCT00264810|Epilepsy
1432122|NCT00264810|Seizures
1432123|NCT00264784|Streptococcus, Group A, Fiji, epidemiology
1432124|NCT00264771|Fiji, Group A streptococcus, rheumatic, glomerulonephritis
1432125|NCT00264758|randomized controlled clinical trial
1432126|NCT00264758|hemodialysis
1432127|NCT00264758|end stage renal disease
1432128|NCT00264745|Caregiver
1432129|NCT00264745|Stroke
1432130|NCT00264732|cervical lesions
1432131|NCT00264732|cervical dysplasia
1432132|NCT00264732|Human papilloma virus
1432133|NCT00264732|abnormal Pap
1432134|NCT00264732|High-grade cervical intraepithelial lesions (CIN 2/3)
1432135|NCT00264719|A drug is administered to initiate breastfeeding
1432136|NCT00264680|Validation of questionnaire
1432137|NCT00264680|qolie-10
1432138|NCT00264680|epilepsy
1432139|NCT00264680|lamotrigine
1432140|NCT00264680|quality of life
1432141|NCT00264667|Dyslipidaemia
1432142|NCT00264654|Social
1432143|NCT00264654|(SAD)
1432144|NCT00264654|Anxiety
1432145|NCT00264654|Disorder
1432146|NCT00264641|Hypoglycemia
1432147|NCT00264641|Cognitive impairment
1432148|NCT00264641|PET
1432149|NCT00264641|CalCAP
1432150|NCT00264628|NK1-antagonist
1432151|NCT00264628|Depression
1432152|NCT00264628|Fibromyalgia
1432153|NCT00264628|GW679769
1432154|NCT00264628|Outpatient
1432155|NCT00264615|once daily dosing
1432156|NCT00264615|seizure
1432157|NCT00264615|pharmacokinetics
1432158|NCT00264615|epilepsy
1432159|NCT00264602|Lymphatic mapping
1432160|NCT00264602|nodal targeting
1432163|NCT00264589|vascular function
1432164|NCT00264589|cardiac function
1432165|NCT00264589|individualized training
1432166|NCT00264589|ultrasonography
1432167|NCT00264589|body composition
1432168|NCT00264576|influenza
1432169|NCT00264576|flu
1432170|NCT00264550|Rheumatoid Arthritis
1432171|NCT00264550|Golimumab
1432172|NCT00264550|Methotrexate
1432173|NCT00264550|Fully Human anti-TNFa monoclonal antibody
1432174|NCT00264550|Simpony
1432175|NCT00264537|Rheumatoid Arthritis
1432176|NCT00264537|Methotrexate Naïve
1432177|NCT00264537|subcutaneous injection
1432178|NCT00264524|Rheumatic heart disease, HLA, Genetics, Taiwan
1432179|NCT00264511|Hyperbaric oxygen
1432180|NCT00264511|Crush injury
1432181|NCT00264511|Tibial fracture
1432182|NCT00264511|Gustillo 3
1432183|NCT00264511|soft tissue injury
1432184|NCT00264511|complications
1432185|NCT00264511|outcomes
1432186|NCT00264511|randomised controlled trial
1432187|NCT00264498|Non-Small-Cell Lung Cancer
1432188|NCT00264498|NSCLC
1432189|NCT00264498|Lung Cancer
1432190|NCT00264485|Postoperative pain
1432191|NCT00264485|patient-controlled analgesia
1432192|NCT00264472|Cancer
1432193|NCT00264472|Tumors
1432194|NCT00264472|Neoplasms
1432195|NCT00264472|Anticarcinogenic Agents
1432196|NCT00264472|Antineoplastic Agents
1432197|NCT00264472|Dihydrouracil Dehydrogenase (NADP)
1432198|NCT00264459|Sublingual immunotherapy
1432199|NCT00264459|Rhinoconjunctivitis
1432200|NCT00264459|Rhinitis
1432201|NCT00264459|Asthma
1432202|NCT00264446|Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents;
1432203|NCT00264446|Dihydrouracil dehydrogenase (NADP); Colorectal Carcinoma; Liver Cancer
1432204|NCT00264433|Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents
1432205|NCT00264433|Cadherins; Non-Small-Cell Lung Carcinoma; Esophageal Cancer; Gastric Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Adrenocortical Carcinoma
1432206|NCT00264420|bone metastases
1432207|NCT00264420|breast cancer
1432208|NCT00264420|lung cancer
1432209|NCT00264420|prostate cancer
1432210|NCT00264420|zoledronic acid
1432211|NCT00264420|radiation therapy
1432212|NCT00264407|Hearing Loss, Central
1432213|NCT00264407|Presbycusis
1432214|NCT00264407|Hearing Loss, Sensorineural
1432215|NCT00264407|Hearing Loss, Cochlear
1432216|NCT00264407|Hearing Loss, Bilateral
1432217|NCT00264407|Sex Steroid Hormones
1432218|NCT00264407|Estradiol
1432219|NCT00264394|Computer generated reminder system
1432220|NCT00264394|quality control
1432221|NCT00264394|dyslipidemia
1432222|NCT00264394|antiretroviral therapy
1432223|NCT00264394|HIV infection
1432224|NCT00264381|Superficial Thrombophlebitis
1432225|NCT00264381|STP
1432226|NCT00264381|Fragmin
1432227|NCT00264381|Ibuprofen
1432228|NCT00264381|Superficial Thrombus
1432229|NCT00264381|Superficial Phlebitis
1432230|NCT00264381|phlebitis
1432231|NCT00264368|Renal replacement therapy
1432232|NCT00264368|CMV disease
1432233|NCT00264355|cyclosporine
1432234|NCT00264355|metabolites
1432235|NCT00264355|metabolic pattern
1432236|NCT00264355|genotypes
1432237|NCT00264342|Smoking
1432238|NCT00264342|Tobacco
1432239|NCT00264342|Nicotine
1432240|NCT00264316|bone marrow cell transfer
1432241|NCT00264316|acute myocardial infarction
1432242|NCT00264316|left ventricular function
1432243|NCT00264303|Chronic Idiopathic Urticaria
1432244|NCT00264303|CUTE Levocetirizine Xyzal®
1432245|NCT00264290|HIV
1432246|NCT00264290|CMV
1432247|NCT00264290|T Cell activation
1432248|NCT00264290|Valganciclovir
1432249|NCT00264277|D-dimer
1432250|NCT00264277|Recurrence
1432251|NCT00264277|Venous Thromboembolism
1432252|NCT00264277|Anticoagulation
1432253|NCT00264277|Duration
1432254|NCT00264264|Closure device
1432255|NCT00264264|Stenting
1432256|NCT00264264|Percutaneous coronary intervention
1432257|NCT00264251|HIV
1432258|NCT00264251|Body composition
1432259|NCT00264251|Weight reduction
1432260|NCT00264251|Insulin resistance/sensitivity
1432261|NCT00264251|Exercise
1432262|NCT00264251|Diet
1432263|NCT00264251|Visceral adiposity
1432264|NCT00264225|osteoarthritis, pain
1432265|NCT00264199|Chronic Congestive heart failure
1432266|NCT00264199|Ischemic heart disease
1432267|NCT00264199|insulin resistance
1432268|NCT00264160|AMN107
1432269|NCT00264160|CML
1432270|NCT00264160|Bcr Abl
1432271|NCT00264160|cytogenetic response
1432272|NCT00264160|Chronic Myelogenous Leukemia (CML)
1432273|NCT00264160|imatinib mesylate
1432274|NCT00264147|Arcoxia
1432275|NCT00264134|Non-Small Cell Lung Cancer
1432276|NCT00264121|congenital, high scrotal
1432277|NCT00264108|Antineoplastic agents
1432278|NCT00264108|Chemotherapy
1432279|NCT00264108|Cost-effectiveness
1432280|NCT00264108|Epoetin alfa
1432281|NCT00264108|Darbepoetin alfa
1432282|NCT00264095|Anemia
1432283|NCT00264095|Blood loss
1432284|NCT00264095|Transfusion
1432285|NCT00264095|Blood transfusion
1432286|NCT00264095|Erythropoietin
1432287|NCT00264095|Surgery
1432288|NCT00264095|Surgical blood loss
1432289|NCT00264095|Tumor
1432290|NCT00264095|Cancer
1432291|NCT00264095|Surgical resection
1432292|NCT00264095|Tumor resection
1432293|NCT00264069|Adherence
1432294|NCT00264069|Compliance
1432295|NCT00264069|Schizophrenia
1432296|NCT00264069|Bipolar Disorder
1432297|NCT00264069|Depression
1432298|NCT00264069|Personality Disorders
1432299|NCT00264069|Registry
1432300|NCT00264056|malignant melanoma
1432301|NCT00264056|hyperthermia
1432302|NCT00264056|chemotherapy
1432303|NCT00264004|Advanced Solid Tumours
1432304|NCT00264004|phase II
1432305|NCT00264004|Hypertension
1432306|NCT00264004|RECENTIN
1432307|NCT00263978|Venous occlusive disease
1432308|NCT00263978|VOD
1432309|NCT00263952|Bee venom allergy
1432310|NCT00263952|Specific immunotherapy
1432311|NCT00263939|chronic disease
1432312|NCT00263939|patient education
1432313|NCT00263939|self-efficacy
1432314|NCT00263939|self-management
1432315|NCT00263926|Wasp venom allergy,
1432316|NCT00263926|specific immunotherapy
1432317|NCT00263900|Influenza A
1432318|NCT00263900|Influenza B
1432319|NCT00263900|RSV
1432320|NCT00263887|alpha 1 proteinase inhibitor
1432321|NCT00263887|alpha1 proteinase inhibitor
1432322|NCT00263887|congenital emphysema
1432323|NCT00263887|replacement therapy
1432324|NCT00263861|neurotoxicity
1432325|NCT00263861|unspecified adult solid tumor, protocol specific
1432326|NCT00263822|stage I ovarian epithelial cancer
1432327|NCT00263822|stage II ovarian epithelial cancer
1432328|NCT00263822|stage III ovarian epithelial cancer
1432329|NCT00263822|stage IV ovarian epithelial cancer
1432330|NCT00263822|primary peritoneal cavity cancer
1432331|NCT00263822|fallopian tube cancer
1432332|NCT00263731|lung cancer
1432333|NCT00263731|non-small cell lung cancer
1432334|NCT00263731|small cell lung cancer
1432335|NCT00263731|cancer metabolism
1432336|NCT00263640|House dust mite
1432337|NCT00263640|Bronchial Asthma
1432338|NCT00263640|Allergy
1432339|NCT00263640|House Dust Mite Allergy
1432340|NCT00263627|specific immunotherapy
1432341|NCT00263627|birch pollen allergy
1432342|NCT00263627|Allergovit
1432343|NCT00263601|Allergovit
1432344|NCT00263601|Grass pollen allergy
1432345|NCT00263588|breast cancer brain metastases ErbB2 positive HER2 positive
1432346|NCT00263575|EN3267
1432347|NCT00263575|Breakthrough Pain
1432348|NCT00263575|Safety Study
1432349|NCT00263575|Fentanyl Tablets
1432350|NCT00263562|Sickle cell disease
1432351|NCT00263562|vaso-occlusive crisis
1432352|NCT00263562|steroid treatment
1432353|NCT00263549|House dust mite,
1432354|NCT00263549|Allergy
1432355|NCT00263536|Obesity
1432356|NCT00263536|Adiposity
1432357|NCT00263536|Binge Eating
1432358|NCT00263536|Social Functioning
1432359|NCT00263536|Eating Disorders
1432360|NCT00263536|Prevention
1432361|NCT00263536|Adolescence
1432362|NCT00263536|Adolescent Weight Gain
1432363|NCT00263536|Overweight
1432364|NCT00263523|Serotonin
1432365|NCT00263523|Positron Emission Tomograhy
1432366|NCT00263523|Brain
1432367|NCT00263523|Neurochemistry
1432368|NCT00263523|Neurotransmitter
1432369|NCT00263523|Healthy Volunteer
1432370|NCT00263523|HV
1432371|NCT00263497|Postinjury chronic pain
1432372|NCT00263497|Transtibial amputation
1432373|NCT00263497|Physical rehabilitation
1432374|NCT00263497|Immediate temporary prosthesis
1432375|NCT00263484|Steroids, Fluorinated
1432376|NCT00263484|Thalidomide
1432377|NCT00263484|Bisphosphonates
1432378|NCT00263458|HIV
1432379|NCT00263458|acquired immunodeficiency syndrome
1432380|NCT00263458|buprenorphine
1432381|NCT00263458|opioid dependence
1432382|NCT00263458|opioid-related disorders
1432383|NCT00263458|integrated care
1432384|NCT00263458|primary care
1432385|NCT00263445|Growth hormone dosing
1432386|NCT00263445|IGF-I
1432387|NCT00263419|Diabetes Type 2
1432388|NCT00263419|Late Complications
1432389|NCT00263419|Stress relief management
1432390|NCT00263419|psychosocial stress
1432391|NCT00263393|Myocardial Infarction
1432392|NCT00263393|Angina Pectoris
1432393|NCT00263393|Cerebrovascular Accident
1432394|NCT00263393|Diabetes Mellitus
1432395|NCT00263393|Cluster randomized design
1432396|NCT00263393|Community-based intervention trial
1432397|NCT00263393|Primary Healthcare intervention
1432398|NCT00263393|Lifestyle advice
1432399|NCT00263380|COPD
1432400|NCT00263380|cytokines
1432401|NCT00263380|corticosteroids
1432402|NCT00263380|beta agonists
1432403|NCT00263380|synergistic effect
1432404|NCT00263367|Autism
1432405|NCT00263367|Oxidative Stress
1432406|NCT00263367|Hyperbaric Oxygen
1432407|NCT00263367|Reduced Glutathione
1432408|NCT00263367|Lipid Peroxides
1432409|NCT00263341|Contraceptive agents
1432410|NCT00263341|Female contraception
1432411|NCT00263341|Progestins
1432412|NCT00263328|immunosuppression
1432413|NCT00263328|JAK3 inhibitor
1432414|NCT00263328|kidney transplant
1432415|NCT00263328|tofacitinib
1432416|NCT00263328|Xeljanz
1432417|NCT00263328|CP-690
1432418|NCT00263328|550
1432419|NCT00263328|tacromilus
1432420|NCT00263328|mycophenolate mofetil
1432421|NCT00263315|aspergillosis
1432422|NCT00263315|mycosis
1432423|NCT00263315|neutropenia
1432424|NCT00263315|primary prevention
1432425|NCT00263315|hematologic diseases
1432426|NCT00263315|amphotericin B
1432427|NCT00263315|AmBisome
1432428|NCT00263315|liposomal amphotericin B
1432429|NCT00263302|dexamethasone, diuretic, congestive heart failure
1432430|NCT00263250|inguinal hernia
1432431|NCT00263250|asymptomatic
1432432|NCT00263250|watchful waiting
1432433|NCT00263250|tension-free hernia repair
1432434|NCT00263237|T Cell
1432435|NCT00263237|Lymphocyte
1432436|NCT00263237|Lamina Propria
1432437|NCT00263237|Malabsorption
1432438|NCT00263237|Colonoscopy
1432439|NCT00263237|Common Variable Immunodeficiency
1432440|NCT00263237|CVID
1432441|NCT00263237|Gastrointestinal Inflammation
1432442|NCT00263211|Breast Cancer
1432443|NCT00263211|Metastatic
1432444|NCT00263211|Platelet
1432445|NCT00263172|internet
1432446|NCT00263172|weight management
1432447|NCT00263172|behavior therapy
1432448|NCT00263172|self-help
1432449|NCT00263172|commercial program
1432450|NCT00263172|obesity
1432451|NCT00263133|Depression
1432452|NCT00263133|SSRI
1432453|NCT00263133|Sertraline
1432454|NCT00263133|synaptic plasticity
1432455|NCT00263133|visually evoked potentials
1432456|NCT00263107|telerounding
1432457|NCT00263107|minimally invasive surgery
1432458|NCT00263094|Fasting
1432459|NCT00263094|Headache
1432460|NCT00263094|Cox 2 Inhibitors
1432461|NCT00263094|Pain
1432462|NCT00263094|Prophylaxis
1432463|NCT00263081|Hyperlipidemia
1432464|NCT00263081|Dyslipidemia
1432465|NCT00263081|Drug Therapy
1432466|NCT00263068|IDIOPATHIC RESTLESS LEGS SYNDROME
1432467|NCT00263042|Myocardial infarction
1432468|NCT00263042|cerebrovascular accident
1432469|NCT00263042|obesity
1432470|NCT00262990|Epithelial ovarian cancer
1432471|NCT00262990|fallopian tube cancer
1432472|NCT00262990|peritoneal cancer
1432473|NCT00262990|primary cancer
1432474|NCT00262990|recurrent cancer
1432475|NCT00262990|doxorubicin
1432476|NCT00262990|taxane chemotherapy
1432477|NCT00262990|platinum chemotherapy
1432478|NCT00262990|Patupilone
1432479|NCT00262990|taxane platinum resistant
1432480|NCT00262977|diabetes mellitus
1432481|NCT00262977|cardiovascular diseases
1432482|NCT00262977|aspirin
1432483|NCT00262977|quality of healthcare
1432484|NCT00262964|non-alcoholic fatty liver disease
1432485|NCT00262964|obesity
1432486|NCT00262964|fatty liver disease
1432487|NCT00262951|stage I pancreatic cancer
1432488|NCT00262951|stage II pancreatic cancer
1432605|NCT00262340|Inflammation
1432489|NCT00262951|stage III pancreatic cancer
1432490|NCT00262951|adenocarcinoma of the pancreas
1432491|NCT00262938|stage I endometrial carcinoma
1432492|NCT00262938|stage II endometrial carcinoma
1432493|NCT00262938|weight changes
1432494|NCT00262925|MOAD
1432495|NCT00262925|Methotrexate
1432496|NCT00262925|Vincristine
1432497|NCT00262925|L-asparaginase
1432498|NCT00262925|Dexamethasone
1432499|NCT00262925|Subcutaneous Campath
1432500|NCT00262899|psychosocial effects of cancer and its treatment
1432501|NCT00262899|ductal breast carcinoma in situ
1432502|NCT00262899|breast cancer in situ
1432503|NCT00262899|stage IA breast cancer
1432504|NCT00262899|stage IB breast cancer
1432505|NCT00262899|stage II breast cancer
1432506|NCT00262899|stage IIIA breast cancer
1432507|NCT00262886|recurrent renal cell cancer
1432508|NCT00262886|stage IV renal cell cancer
1432509|NCT00262873|previously treated myelodysplastic syndromes
1432510|NCT00262873|refractory anemia with excess blasts
1432511|NCT00262873|refractory anemia with ringed sideroblasts
1432512|NCT00262873|refractory anemia
1432513|NCT00262873|secondary myelodysplastic syndromes
1432514|NCT00262873|de novo myelodysplastic syndromes
1432515|NCT00262860|recurrent adult Hodgkin lymphoma
1432516|NCT00262808|stage II colon cancer
1432517|NCT00262808|stage III colon cancer
1432518|NCT00262808|adenocarcinoma of the colon
1432519|NCT00262795|stage 0 chronic lymphocytic leukemia
1432520|NCT00262795|stage I chronic lymphocytic leukemia
1432521|NCT00262795|stage II chronic lymphocytic leukemia
1432522|NCT00262795|stage III chronic lymphocytic leukemia
1432523|NCT00262795|stage IV chronic lymphocytic leukemia
1432524|NCT00262782|B-cell chronic lymphocytic leukemia
1432525|NCT00262782|stage 0 chronic lymphocytic leukemia
1432526|NCT00262782|stage I chronic lymphocytic leukemia
1432527|NCT00262782|stage II chronic lymphocytic leukemia
1432528|NCT00262769|cholangiocarcinoma of the extrahepatic bile duct
1432529|NCT00262769|recurrent extrahepatic bile duct cancer
1432530|NCT00262769|unresectable extrahepatic bile duct cancer
1432531|NCT00262769|cholangiocarcinoma of the gallbladder
1432532|NCT00262769|recurrent gallbladder cancer
1432533|NCT00262769|unresectable gallbladder cancer
1432534|NCT00262769|metastatic extrahepatic bile duct cancer
1432535|NCT00262769|metastatic gallbladder cancer
1432536|NCT00262743|B-cell chronic lymphocytic leukemia
1432537|NCT00262743|stage 0 chronic lymphocytic leukemia
1432538|NCT00262743|stage I chronic lymphocytic leukemia
1432539|NCT00262743|stage II chronic lymphocytic leukemia
1432540|NCT00262730|adult glioblastoma
1432541|NCT00262730|adult giant cell glioblastoma
1432542|NCT00262730|adult gliosarcoma
1432543|NCT00262717|HIV drug resistance testing
1432544|NCT00262717|Treatment Experienced
1432545|NCT00262704|physician intervention
1432546|NCT00262704|diabetes mellitus
1432547|NCT00262704|primary care
1432548|NCT00262704|quality improvement
1432549|NCT00262704|disease management
1432550|NCT00262652|sodium pyruvate
1432551|NCT00262652|anti-inflammatory
1432552|NCT00262652|bronchodilation
1432553|NCT00262652|asthma
1432554|NCT00262652|asthmatics
1432555|NCT00262639|Alcoholism
1432556|NCT00262639|Alcohol Dependence
1432557|NCT00262639|Alcohol Withdrawal
1432558|NCT00262639|Treatment
1432559|NCT00262639|Pharmacotherapy
1432560|NCT00262613|Sodium Pyruvate
1432561|NCT00262613|COPD
1432562|NCT00262613|Chronic Obstructive Pulmonary Disease
1432563|NCT00262587|Sport
1432564|NCT00262587|Asthma
1432565|NCT00262587|Treatment
1432566|NCT00262587|Airway inflammation
1432567|NCT00262574|endothelial disfunction
1432568|NCT00262574|BNP
1432569|NCT00262574|PCI
1432570|NCT00262574|coronary artery disease
1432571|NCT00262561|Intermittent Claudication
1432572|NCT00262561|Aspirin resistance
1432573|NCT00262561|Clopidogrel resistance
1432574|NCT00262548|Obesity
1432575|NCT00262548|Menopause
1432576|NCT00262522|Human Immunodeficiency Virus Infections
1432577|NCT00262509|Rehabilitation
1432578|NCT00262509|Sensory Aid
1432579|NCT00262496|Botox
1432580|NCT00262496|Overactive bladder
1432581|NCT00262496|Incontinence
1432582|NCT00262496|Spinal Cord Injury
1432583|NCT00262470|tachycardia
1432584|NCT00262470|sinus tachycardia
1432585|NCT00262470|postural tachycardia syndrome (POTS)
1432586|NCT00262457|electrical stimulation
1432587|NCT00262457|Pressure Ulcers
1432588|NCT00262457|Spinal Cord Injury
1432589|NCT00262431|Tracheostomy
1432590|NCT00262431|Tracheostomy timing
1432591|NCT00262431|Ventilator associated pneumonia
1432592|NCT00262431|Mechanical ventilation
1432593|NCT00262392|heterotopic ossification,
1432594|NCT00262392|prevention,
1432595|NCT00262392|high risk,
1432596|NCT00262392|bisphosphonates,
1432597|NCT00262392|radiotherapy
1432598|NCT00262379|Chronic hepatitis C
1432599|NCT00262379|peginterferon
1432600|NCT00262379|ribavirin
1432601|NCT00262379|epoetin beta
1432602|NCT00262340|Asthma
1432603|NCT00262340|Pediatrics
1432604|NCT00262340|Airway
1432606|NCT00262327|antiangiogenesis
1432607|NCT00262327|endostatin
1432608|NCT00262327|adenovirus
1432609|NCT00262327|gene therapy
1432610|NCT00262327|cancer
1432611|NCT00262236|Hypertension, Aliskiren, Atenolol, Blood Pressure
1432612|NCT00262223|Co-morbid alcohol dependence and PTSD
1432613|NCT00262223|Alcohol and other drug use disorders
1432614|NCT00262223|Treatment outcome
1432615|NCT00262197|Diabetes mellitus
1432616|NCT00262197|Medical error rates
1432617|NCT00262197|Pharmacotherapy
1432618|NCT00262184|Post-Menopausal osteopenia
1432619|NCT00262158|smoking status
1432620|NCT00262158|cigarette consumption
1432621|NCT00262145|glucose
1432622|NCT00262145|lipid
1432623|NCT00262145|diabetes
1432624|NCT00262145|overweight
1432625|NCT00262119|Physiological pacing
1432626|NCT00262119|Antitachycardia pacing therapies
1432627|NCT00262106|Administration, intravaginal
1432628|NCT00262106|Anti-infective agents
1432629|NCT00262106|Double blind method
1432630|NCT00262106|Drug evaluation
1432631|NCT00262106|Female
1432632|NCT00262106|Gels
1432633|NCT00262106|HIV infections/prevention and control
1432634|NCT00262106|Microbicide
1432635|NCT00262106|Naphthalenesulfonates/administration and dosage
1432636|NCT00262106|Polymers/administration and dosage
1432637|NCT00262106|Sexual behavior
1432638|NCT00262106|Vaginal creams, foams and jellies
1432639|NCT00262106|HIV Seronegativity
1432640|NCT00262106|Genital Herpes Infections
1432641|NCT00262093|preeclampsia
1432642|NCT00262093|sFlt1
1432643|NCT00262093|PlGF
1432644|NCT00262093|parity
1432645|NCT00262093|angiogenesis
1432646|NCT00262054|coronary disease
1432647|NCT00261989|pulse oximetry readings
1432648|NCT00261989|pediatrics
1432649|NCT00261989|cardiac
1432650|NCT00261989|congenital heart disease
1432651|NCT00261976|Rheumatoid arthritis
1432652|NCT00261976|Crohn's disease
1432653|NCT00261976|Psoriasis
1432654|NCT00261950|Cinacalcet HCl, Cinacalcet, Amgen (AMG) 073, Sensipar, Mimpara, Calcimimetic
1432655|NCT00261924|Thrombocytopenic patients
1432656|NCT00261911|Meridia
1432657|NCT00261911|Sibutramine
1432658|NCT00261911|Obesity
1432659|NCT00261911|Adolescent
1432660|NCT00261911|BMI
1432661|NCT00261898|Sleep Deprivation
1432662|NCT00261898|Obesity
1432663|NCT00261898|Metabolic Syndrome
1432664|NCT00261898|Hormones
1432665|NCT00261898|Public Health
1432666|NCT00261898|Overweight
1432667|NCT00261898|Sleep
1432668|NCT00261872|Alcoholism
1432669|NCT00261872|Attention Deficit Disorder
1432670|NCT00261872|ADHD
1432671|NCT00261859|hazardous drinking
1432672|NCT00261846|Leukemia
1432673|NCT00261846|tyrosine kinase inhibitor
1432674|NCT00261846|philadelphia chromosome
1432675|NCT00261846|Myeloid
1432676|NCT00261846|Philadelphia Positive
1432677|NCT00261833|Alpha1-proteinase inhibitor deficiency
1432678|NCT00261833|Emphysema
1432679|NCT00261833|Chronic augmentation and maintenance therapy
1432680|NCT00261820|Kidney Transplant
1432681|NCT00261807|severe
1432682|NCT00261807|skin
1432683|NCT00261807|infections
1432684|NCT00261794|cognition
1432685|NCT00261794|schizophrenia
1432686|NCT00261794|treatment
1432687|NCT00261781|Treadmill
1432688|NCT00261781|Walking
1432689|NCT00261781|Exercise
1432690|NCT00261781|Automaticity
1432691|NCT00261781|Quality of Life
1432692|NCT00261768|Aging
1432693|NCT00261768|hearing aids
1432694|NCT00261768|hearing loss, sensorineural
1432695|NCT00261768|speech recognition
1432696|NCT00261755|Acupuncture
1432697|NCT00261755|pain relief
1432698|NCT00261755|labour
1432699|NCT00261755|randomized controlled trial
1432700|NCT00261755|TENS
1432701|NCT00261742|perianal
1432702|NCT00261742|dermatitis
1432703|NCT00261742|streptococcus pyogenes
1432704|NCT00261729|Paroxetine
1432705|NCT00261729|Prazosin
1432706|NCT00261729|Sleep Disorders
1432707|NCT00261729|Stress Disorders, Post-Traumatic
1432708|NCT00261716|clinical trial
1432709|NCT00261716|employment
1432710|NCT00261716|schizoaffective disorder
1432711|NCT00261716|schizophrenia
1432712|NCT00261690|Virtual Reality Distraction
1432713|NCT00261677|Anemia
1432714|NCT00261677|cancer
1432715|NCT00261677|solid tumor
1432716|NCT00261677|Hodgkin's Disease
1432717|NCT00261677|Acute Lymphocytic Leukemia (ALL)
1432718|NCT00261677|Non-Hodgkin's Lymphoma (NHL)
1432719|NCT00261677|Quality of Life
1432720|NCT00261677|hemoglobin
1432721|NCT00261677|Epoetin alfa
1432722|NCT00261638|Mental Health Promotion
1432723|NCT00261638|Mental Health Index
1432724|NCT00261638|Taiwan Mental Health Index scale
1432725|NCT00261638|psychophysical health
1432726|NCT00261638|education years over 9 years
1432727|NCT00261638|normal people, especially joining Mental Health Foundation Promotions
1432728|NCT00261625|peritoneal dialysis
1432729|NCT00261625|artery calcification
1432730|NCT00261625|bone mineral density
1432731|NCT00261612|relapsed or chemotherapy-refractory disease
1432732|NCT00261599|Colonoscopy
1432733|NCT00261599|Sedation
1432734|NCT00261599|AQUAVAN
1432735|NCT00261599|Fospropofol disodium
1432736|NCT00261599|Colon polyps
1432737|NCT00261599|Endoscopic outcomes
1432738|NCT00261599|Endoscopic sedation
1432739|NCT00261599|Endoscopy
1432740|NCT00261586|aspirin
1432741|NCT00261586|analgesics
1432742|NCT00261586|cyclooxygenase activity
1432743|NCT00261586|non-steroidal antiinflammatory drugs
1432744|NCT00261573|"Alzheimer's disease with cerebrovascular disease (mixed dementia)"
1432745|NCT00261573|probable vascular dementia
1432746|NCT00261573|galantamine
1432747|NCT00261560|ankle sprain
1432748|NCT00261560|acetaminophen extended release, ibuprofen
1432749|NCT00261547|Kidney transplantation
1432750|NCT00261547|HLA
1432751|NCT00261534|Chemotherapy
1432752|NCT00261521|Kidney failure, Chronic
1432753|NCT00261521|End-stage renal disease
1432754|NCT00261521|Kidney failure
1432755|NCT00261521|Anemia
1432756|NCT00261521|Dialysis
1432757|NCT00261521|Epoetin
1432758|NCT00261521|Erythropoetin
1432759|NCT00261521|Epoetin alfa
1432760|NCT00261508|Risperidone
1432761|NCT00261508|child development disorders
1432762|NCT00261508|pervasive development disorders
1432763|NCT00261508|autistic disorder
1432764|NCT00261508|autism
1432765|NCT00261508|developmental disabilities
1432766|NCT00261508|antipsychotropic agents
1432767|NCT00261495|chronic noncancer pain
1432768|NCT00261495|pain
1432769|NCT00261495|analgesia
1432770|NCT00261495|analgesic opioid
1432771|NCT00261495|oxycodone
1432772|NCT00261495|hydromorphone
1432773|NCT00261482|contraception
1432774|NCT00261482|female contraception
1432775|NCT00261482|hormonal contraception
1432776|NCT00261482|transdermal contraception
1432777|NCT00261482|EVRA
1432778|NCT00261482|estrogen
1432779|NCT00261482|progestin
1432780|NCT00261482|ethinyl estradiol
1432781|NCT00261482|norelgestromin
1432782|NCT00261469|Migraine
1432783|NCT00261469|Headache
1432784|NCT00261456|Prostate cancer
1432785|NCT00261456|BRCA1
1432786|NCT00261456|BRCA2
1432787|NCT00261456|prostate screening
1432788|NCT00261456|PSA
1432789|NCT00261456|prostate biopsy
1432790|NCT00261443|Bipolar I Disorder with a recent manic or mixed episode
1432791|NCT00261430|Schizophrenia
1432792|NCT00261430|acceptance
1432793|NCT00261430|motivational enhancement therapy
1432794|NCT00261430|long-acting risperidone
1432795|NCT00261430|intramuscular injection
1432796|NCT00261430|Treatment Guidebook
1432797|NCT00261430|GAIN Acceptance Approach
1432798|NCT00261391|Arteriovenous Malformation
1432799|NCT00261391|Lymphatic Malformation
1432800|NCT00261391|Gorham
1432801|NCT00261378|Hepatocellular Carcinoma (HCC)
1432802|NCT00261339|Gastroesophageal Reflux
1432803|NCT00261339|Gastroesophageal Reflux Disease
1432804|NCT00261339|Pantoprazole
1432805|NCT00261326|Simvastatin
1432806|NCT00261326|Optic Neuritis
1432807|NCT00261326|Multiple Sclerosis
1432808|NCT00261313|Breast cancer
1432809|NCT00261313|Doses dense chemotherapy
1432810|NCT00261313|Growth factor support
1432811|NCT00261313|Adjuvant Breast Cancer
1432812|NCT00261300|Gastric acid
1432813|NCT00261300|GERD
1432814|NCT00261300|Gastroesophageal reflux disease
1432815|NCT00261300|Pantoprazole
1432816|NCT00261300|Proton pump inhibitor
1432817|NCT00261287|Hay Fever
1432818|NCT00261287|Allergic Rhinitis
1432819|NCT00261287|Perennial Allergic Rhinitis
1432820|NCT00261287|Ciclesonide
1432821|NCT00261274|transfusion; red blood cells
1432822|NCT00261261|children
1432823|NCT00261261|anxiety
1432824|NCT00261261|behavioral preparation
1432825|NCT00261261|family
1432826|NCT00261261|surgery
1432827|NCT00261261|parents
1432828|NCT00261248|Phase 2
1432829|NCT00261248|Vaccine
1432830|NCT00261248|Urinary Tract Infection
1432831|NCT00261248|Vaginal Mucosal
1432832|NCT00261235|Rehabilitation, Vocational
1432833|NCT00261235|Virtues
1432834|NCT00261235|Employment, supported
1432835|NCT00261235|veterans
1432836|NCT00261235|Mentally Ill Persons
1432837|NCT00261222|Amodiaquine
1432838|NCT00261222|Efficacy
1432839|NCT00261222|Malaria
1432840|NCT00261222|Burkina Faso
1432841|NCT00261209|Flexor Tendon Adhesions
1432842|NCT00261209|Zone II of the Hand
1432843|NCT00261196|Frozen Shoulder
1432844|NCT00261170|smoking
1432845|NCT00261157|nephrectomy
1432846|NCT00261157|Safety
1432847|NCT00261157|Laparoscopy
1432848|NCT00261157|telerounding
1432849|NCT00261157|prostatectomy
1432850|NCT00261131|cerebral palsy
1432851|NCT00261131|spasticity
1432852|NCT00261131|diplegia
1432853|NCT00261118|colitis
1432854|NCT00261118|rituximab
1432855|NCT00261066|functional outcome
1432856|NCT00261066|orthopaedic surgery
1432857|NCT00261040|Osteoarthritis
1432858|NCT00261040|Total Hip Arthroplasty
1432859|NCT00261040|Minimally Invasive Surgery
1432860|NCT00261027|ovarian cancer
1432861|NCT00261014|Recurrent
1432862|NCT00261014|Idiopathic
1432863|NCT00261014|Deep Vein Thrombosis
1432864|NCT00261014|Pulmonary Embolism
1432865|NCT00261014|Clinical Prediction Rule
1432866|NCT00261014|Venous Thromboembolism
1432867|NCT00261014|Risk Factors
1432868|NCT00261001|Transcutaneous
1432869|NCT00261001|Vaccination
1432870|NCT00261001|Safety
1432871|NCT00261001|Immunogenicity
1432872|NCT00261001|HIV
1432873|NCT00261001|Treatment Experienced
1432874|NCT00260988|Prophylaxis
1432875|NCT00260988|Thromboembolic disease
1432876|NCT00260988|End stage renal disease
1432877|NCT00260988|Hemodialysis
1432878|NCT00260988|Pharmacokinetics
1432879|NCT00260988|Low Molecular Weight Heparin
1432880|NCT00260988|Innohep
1432881|NCT00260988|Tinzaparin
1432882|NCT00260988|Fragmin
1432883|NCT00260988|Dalteparin
1432884|NCT00260988|Anti Xa
1432885|NCT00260988|INR
1432886|NCT00260988|Oral anticoagulation
1432887|NCT00260988|warfarin
1432888|NCT00260988|Coumadin
1432889|NCT00260975|breast cancer
1432890|NCT00260975|chemotherapy
1432891|NCT00260975|hormonal therapy
1432892|NCT00260975|cognitive function
1432893|NCT00260975|chemo fog
1432894|NCT00260962|Pilot Project,
1432895|NCT00260962|Clinical Trial,
1432896|NCT00260962|Treatment Outcome,
1432897|NCT00260962|Psychopharmacology
1432898|NCT00260949|rotator cuff tear
1432899|NCT00260949|arthroscopic repair
1432900|NCT00260936|HIV
1432901|NCT00260936|AIDS
1432902|NCT00260936|Adolescent Males
1432903|NCT00260936|HIV positive
1432904|NCT00260936|Treatment Naive
1432905|NCT00260936|Treatment Experienced
1432906|NCT00260923|hypertension
1432907|NCT00260923|aliskiren
1432908|NCT00260923|blood pressure
1432909|NCT00260897|avascular necrosis of the femoral head
1432910|NCT00260897|genotyping
1432911|NCT00260897|linkage analysis
1432912|NCT00260897|pathogenesis
1432913|NCT00260897|therapy
1432914|NCT00260871|lung adenocarcinoma
1432915|NCT00260871|genetic epidemiology
1432916|NCT00260871|environmental factors
1432917|NCT00260871|genetic map
1432918|NCT00260871|coordination center
1432919|NCT00260858|Glycemic index
1432920|NCT00260858|Nutrition
1432921|NCT00260858|Carbohydrates
1432922|NCT00260858|Glycemic responses
1432923|NCT00260858|Methodology
1432924|NCT00260858|Healthy human subjects
1432925|NCT00260832|Acute Myeloid Leukemia
1432926|NCT00260832|Dacogen
1432927|NCT00260832|Decitabine
1432928|NCT00260832|Poor or intermediate-risk cytogenetics
1432929|NCT00260819|Hypoxia-induced pulmonary artery hypertension
1432930|NCT00260819|High-altitude pulmonary oedema
1432931|NCT00260819|ETA receptor antagonist
1432932|NCT00260793|Ropinirole
1432933|NCT00260793|Parkinson's disease
1432934|NCT00260793|dopamine agonist
1432935|NCT00260780|sexually transmitted diseases
1432936|NCT00260780|Risk Behavior
1432937|NCT00260754|Risk behavior
1432938|NCT00260754|Sexually transmitted diseases
1432939|NCT00260741|cannabis
1432940|NCT00260741|marijuana
1432941|NCT00260741|Multiple Sclerosis
1432942|NCT00260741|Spasticity
1432943|NCT00260728|vascular access
1432944|NCT00260728|hemodialysis
1432945|NCT00260715|Risk behavior
1432946|NCT00260715|Sexually Transmitted Diseases
1432947|NCT00260702|Phenotype
1432948|NCT00260702|Monoclonal
1432949|NCT00260702|Immunoglobulin
1432950|NCT00260702|Immunodeficiency
1432951|NCT00260702|Dermatitis
1432952|NCT00260702|Job's Syndrome
1432953|NCT00260702|Hyper-IgE Syndrome
1432954|NCT00260702|HIES
1432955|NCT00260689|Immunosuppression
1432956|NCT00260689|T-cells
1432957|NCT00260689|Hematopoiesis
1432958|NCT00260689|Autoimmunity
1432959|NCT00260689|Thrombocytopenia
1432960|NCT00260689|Severe Aplastic Anemia
1432961|NCT00260689|SAA
1432962|NCT00260676|brain death
1432963|NCT00260676|lung transplantation
1432964|NCT00260676|organ donors
1432965|NCT00260676|potential organ donors
1432966|NCT00260663|Hearing Impaired Rehabilitation
1432967|NCT00260663|Hearing Aids
1432968|NCT00260663|Randomized Controlled Trials
1432969|NCT00260663|Cost Effectiveness
1432970|NCT00260663|Quality of life
1432971|NCT00260663|Patient Compliance
1432972|NCT00260650|heart failure, congestive
1432973|NCT00260650|self-care
1432974|NCT00260650|quality of life
1432975|NCT00260650|health behavior
1432976|NCT00260637|Prostatitis
1432977|NCT00260624|agitation
1432978|NCT00260624|dementia
1432979|NCT00260624|Alzheimer's Disease
1432980|NCT00260611|prostate
1432981|NCT00260598|Non-small cell lung cancer
1432982|NCT00260598|Head and neck squamous cell cancer
1432983|NCT00260598|White light bronchoscopy
1432984|NCT00260598|Imaging Elastic Scattering Spectroscopy (IESS)
1432985|NCT00260598|Fluorescence Bronchoscopy
1432986|NCT00260598|COPD
1432987|NCT00260598|Helium-Cadmium Laser Bronchoscopy
1432988|NCT00260598|Autofluorescence spectra of dysplasia & cancer in situ (CIS)
1432989|NCT00260598|Severe Chronic Obstructive Pulmonary Disorders(COPD)
1432990|NCT00260585|gastroesophageal reflux disease
1432991|NCT00260585|GERD
1432992|NCT00260585|hiatal hernia
1432993|NCT00260585|achalasia
1432994|NCT00260585|Barrett's metaplasia
1432995|NCT00260585|Anti-Reflux Surgery
1432996|NCT00260585|Known/suspected esophageal/gastroesophageal junction tumor
1432997|NCT00260585|Esophageal disorders such as Barrett's metaplasia
1432998|NCT00260585|Symptomatic gastroesophageal reflux disease
1432999|NCT00260572|GERD
1433000|NCT00260572|nissen
1433001|NCT00260572|fundoplication
1433002|NCT00260572|reflux
1433003|NCT00260572|toupet
1433004|NCT00260572|QOL
1433005|NCT00260572|dyspepsia
1433006|NCT00260572|heartburn
1433007|NCT00260572|Patients with reflux symptoms for at least 6 months
1433008|NCT00260572|Patients scheduled for lap nissen or toupet fundoplication
1433009|NCT00260572|Reflux diagnosed by either endoscopy, upper GI, or 24hr. pH
1433010|NCT00260572|On or starting treatment with PPI or pro-motility agents
1433011|NCT00260559|Esophagectomy
1433012|NCT00260559|Esophageal Cancer
1433013|NCT00260559|Quality of Life
1433014|NCT00260559|Minimally Invasive Esophagectomy
1433015|NCT00260559|Laparoscopic Transhiatal Esophagectomy
1433016|NCT00260559|Open Esophagectomy
1433017|NCT00260559|Karnofsky Score
1433018|NCT00260559|Dysphagia score
1433019|NCT00260559|Heartburn Scale
1433020|NCT00260559|Nutrition Score
1433021|NCT00260546|Ventricular dyssynchrony
1433022|NCT00260520|Low molecular weight heparin
1433023|NCT00260520|Preeclampsia
1433024|NCT00260520|Fetal Growth Restriction
1433025|NCT00260520|Thrombophilia
1433026|NCT00260520|Factor V Leiden
1433027|NCT00260520|G20210A prothrombin gene mutation
1433028|NCT00260494|Cardiac Surgical Procedures
1433029|NCT00260494|open saphenous vein graft harvest wounds
1433030|NCT00260494|Postoperative Complications
1433031|NCT00260494|Surgical Wound Infection
1433032|NCT00260494|Surgical Wound Dehiscence
1433033|NCT00260481|Methamphetamine Dependence
1433034|NCT00260481|Pharmacotherapy
1433035|NCT00260468|Major depression
1433036|NCT00260468|Magnetic resonance imaging
1433037|NCT00260468|White matter lesions
1433038|NCT00260468|Perfusion
1433039|NCT00260468|Diffusion
1433040|NCT00260468|Magnetization transfer
1433041|NCT00260468|Vascular risk factors
1433042|NCT00260442|sarcopenia
1433043|NCT00260442|resistance training
1433044|NCT00260442|strength training
1433045|NCT00260442|skeletal muscle
1433046|NCT00260442|elderly
1433047|NCT00260442|cholesterol
1433048|NCT00260442|aging
1433049|NCT00260442|cardiovascular disease
1433050|NCT00260442|nutrition
1433051|NCT00260442|inflammation
1433052|NCT00260442|lipids
1433053|NCT00260429|Dupuytren's contracture
1433054|NCT00260429|fixed flexion contracture
1433055|NCT00260416|Acute myocardial infarction
1433056|NCT00260416|Symptom duration
1433057|NCT00260416|Primary angioplasty
1433058|NCT00260416|Infarct size
1433059|NCT00260416|Myocardial scintigraphy
1433060|NCT00260390|Dysthymic Disorder
1433061|NCT00260390|HPG hypofunctioning
1433062|NCT00260390|Testosterone replacement
1433063|NCT00260377|Aspirin treatment
1433064|NCT00260377|Aspirin resistance
1433065|NCT00260377|Coronary bypass surgery
1433066|NCT00260364|Recurrent carcinoma of the pancreas
1433067|NCT00260364|Adenocarcinoma of the pancreas
1433068|NCT00260364|Stage II carcinoma of the pancreas
1433069|NCT00260364|Stage III carcinoma of the pancreas
1433070|NCT00260364|Stage IVA carcinoma of the pancreas
1433071|NCT00260364|Stage IVB carcinoma of the pancreas
1433072|NCT00260351|rabies;
1433073|NCT00260351|rabies post-exposure;
1433074|NCT00260351|category III
1433075|NCT00260338|myocardial ischemia
1433076|NCT00260338|stem cell
1433077|NCT00260338|mesenchymal
1433078|NCT00260338|myocardial perfusion
1433079|NCT00260325|pretreatment
1433080|NCT00260325|healthy volunteers
1433081|NCT00260312|inactived
1433082|NCT00260312|polio
1433083|NCT00260312|vaccine
1433084|NCT00260312|cuba
1433085|NCT00260312|trial
1433086|NCT00260312|randomized
1433087|NCT00260312|eradication
1433088|NCT00260299|cholesterol defects
1433089|NCT00260299|Mevalonic Aciduria
1433090|NCT00260299|Mevalonate Kinase Deficiency
1433091|NCT00260299|HIDS
1433092|NCT00260299|Hyperimmunoglobulinemia with periodic fever syndrome
1433093|NCT00260299|MKD
1433094|NCT00260299|Lipid Metabolism, Inborn Errors
1433095|NCT00260299|Periodic Fever Syndromes, hereditary
1433096|NCT00260299|mevalonic acid
1433097|NCT00260299|mevalonate kinase
1433098|NCT00260299|cholesterol, dietary
1433099|NCT00260299|Hyper IgD
1433100|NCT00260299|Multiple malformations
1433101|NCT00260299|Fever
1433102|NCT00260286|LH pulsatility
1433103|NCT00260286|energy availability
1433104|NCT00260286|exercise
1433105|NCT00260286|diet
1433106|NCT00260286|gynecological age
1433107|NCT00260273|Preventive Therapy
1433108|NCT00260273|Psychoses
1433109|NCT00260273|Cognitive Behaviour Therapy
1433110|NCT00260247|CYP3A4
1433111|NCT00260247|Induction
1433112|NCT00260247|Oxcarbazepine
1433113|NCT00260247|Carbamazepine
1433114|NCT00260247|Quinidine
1433115|NCT00260247|Human
1433116|NCT00260247|In vivo
1433117|NCT00260234|Transplantation, Pancreatic Islets
1433118|NCT00260234|Diabetes Mellitus, Type 1
1433119|NCT00260234|Insulin Dependent
1433120|NCT00260234|Islet Transplant
1433121|NCT00260221|Virtual Reality Hypnosis
1433122|NCT00260208|Liver transplant, adults, hepatitis C, liver fibrosis, cyclosporine microemulsion, tacrolimus
1433123|NCT00260195|Trauma
1433124|NCT00260195|Violence
1433125|NCT00260195|Adolescent
1433126|NCT00260195|Schools
1433127|NCT00260195|Cognitive behavioral therapy
1433128|NCT00260182|Depressive Disorder
1433129|NCT00260182|Family
1433130|NCT00260182|Genetics
1433131|NCT00260169|Treatment Preferences
1433132|NCT00260169|Public sector
1433133|NCT00260169|Latino
1433134|NCT00260156|Type 2 diabetes
1433135|NCT00260156|vildagliptin
1433136|NCT00260143|HIV+ men
1433137|NCT00260143|Treatment Experienced
1433138|NCT00260130|obesity
1433139|NCT00260130|food intake
1433140|NCT00260130|human
1433141|NCT00260130|energy balance
1433142|NCT00260130|beverage
1433143|NCT00260117|Exercise
1433144|NCT00260117|Physical activity
1433145|NCT00260117|walking
1433146|NCT00260117|running
1433147|NCT00260091|Infertility
1433148|NCT00260091|Advanced maternal age
1433149|NCT00260091|Pregnancy
1433150|NCT00260091|Reproductive health
1433151|NCT00260091|Fertility treatment
1433152|NCT00260091|Reproduction
1433153|NCT00260078|Treatment Experienced
1433154|NCT00260078|Pharmacokinetics
1433155|NCT00260078|PK
1433156|NCT00260065|Myelodysplastic Syndrome
1433157|NCT00260065|Decitabine
1433158|NCT00260065|Dacogen
1433159|NCT00260065|MGI Pharma
1433160|NCT00260052|traumatic brain injury
1433161|NCT00260026|Lung Cancer
1433162|NCT00260013|chronic mental illness
1433163|NCT00260000|mild PKU
1433164|NCT00260000|Y414C
1433165|NCT00260000|5,6,7,8-tetrahydrobiopterin, BH4
1433166|NCT00260000|treatment without protein restriction
1433167|NCT00259987|relapsed adenocarcinoma
1433168|NCT00259987|esophagus
1433169|NCT00259987|tumors
1433170|NCT00259987|GE junction
1433171|NCT00259987|cancer
1433172|NCT00259987|lapatinib
1433173|NCT00259987|gastric cardia
1433174|NCT00259974|Anti-MAG monoclonal gammopathy
1433175|NCT00259974|Polyneuropathy
1433176|NCT00259974|Rituximab
1433177|NCT00259948|HR variability, CVA, Myocardial infarction, aerobic exercise training
1433178|NCT00259935|Any Solid Tumor
1433179|NCT00259922|constipation
1433180|NCT00259922|gastrointestinal
1433181|NCT00259922|opioids
1433182|NCT00259922|pain
1433183|NCT00259922|non-cancer pain
1433184|NCT00259922|opioid-induced
1433185|NCT00259922|bowel dysfunction
1433186|NCT00259909|Patient reported outcomes
1433187|NCT00259909|acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
1433188|NCT00259909|COPD
1433189|NCT00259896|exenatide
1433190|NCT00259896|pharmacokinetics
1433191|NCT00259896|pharmacodynamics
1433192|NCT00259883|depressive episodes
1433193|NCT00259883|paroxetine
1433194|NCT00259883|PAXIL
1433195|NCT00259883|depression
1433196|NCT00259883|benzodiazepine
1433197|NCT00259883|combination
1433198|NCT00259870|Schizophrenia
1433199|NCT00259870|PANSS
1433200|NCT00259870|Acute
1433201|NCT00259870|Cognition
1433202|NCT00259857|Fracture
1433203|NCT00259857|Bone Mineral Density
1433204|NCT00259857|DXA
1433205|NCT00259844|Colorectal
1433206|NCT00259844|Liver Metastases
1433207|NCT00259844|Vaccine
1433208|NCT00259844|Colorectal Liver Metastases
1433209|NCT00259831|cold
1433210|NCT00259831|influenza
1433211|NCT00259818|Refractory
1433212|NCT00259818|Solid Tumors
1433213|NCT00259805|encephalitis
1433214|NCT00259805|epilepsy
1433215|NCT00259805|Rasmussens
1433216|NCT00259805|rituximab
1433217|NCT00259805|autoimmune
1433218|NCT00259779|COPD
1433219|NCT00259753|Wet Age-Related Macular Degeneration
1433220|NCT00259740|Multiple Myeloma, Relapsed, Plateau-Phase
1433221|NCT00259727|Amprenavir
1433222|NCT00259727|Glucagon
1433223|NCT00259727|HIV Protease inhibitors
1433224|NCT00259727|Indinavir
1433225|NCT00259727|Lopinavir
1433226|NCT00259727|Ritonavir
1433227|NCT00259714|hypertension
1433228|NCT00259714|hemodialysis
1433229|NCT00259714|sodium
1433230|NCT00259714|dialysate
1433231|NCT00259714|hemodynamics
1433232|NCT00259701|endothelium
1433233|NCT00259701|iontophoresis
1433234|NCT00259701|acetylcholine
1433235|NCT00259701|nitroglycerin
1433236|NCT00259701|vasodilation
1433237|NCT00259688|Preeclampsia
1433238|NCT00259688|Sleep Apnea
1433239|NCT00259688|CPAP
1433240|NCT00259662|cancer--ovarian
1433241|NCT00259662|cancer--endometria
1433242|NCT00259662|deep vein thrombosis
1433243|NCT00259662|statin therapy in perioperative period
1433244|NCT00259623|Cardiac surgery
1433245|NCT00259623|Radiofrequency ablation
1433246|NCT00259623|Atrial fibrillation
1433247|NCT00259610|RA
1433248|NCT00259610|painful joints
1433249|NCT00259610|swollen joints
1433250|NCT00259597|nuclear morphology
1433251|NCT00259597|image analysis
1433252|NCT00259597|lipid peroxidation
1433253|NCT00259597|diet
1433254|NCT00259597|proliferative breast disease
1433255|NCT00259571|remission
1433256|NCT00259571|mesalazin
1433257|NCT00259571|non-inferiority study
1433258|NCT00259571|relapse
1433259|NCT00259558|Ulcerative Colitis
1433260|NCT00259558|Dose Finding
1433261|NCT00259558|Phosphatidylcholine
1433262|NCT00259545|retarded phosphatidylcholine
1433263|NCT00259545|chronic active
1433264|NCT00259545|steroid
1433265|NCT00259519|premature or preterm birth
1433266|NCT00259519|chorioamnionitis
1433267|NCT00259519|neonatal sepsis
1433268|NCT00259519|labour
1433269|NCT00259519|Cesarean Section
1433270|NCT00259519|delivery
1433271|NCT00259519|length of stay
1433272|NCT00259519|pregnancy
1433273|NCT00259506|Recurrent depression
1433274|NCT00259506|Mental Health
1433275|NCT00259493|Coronary Artery Disease
1433276|NCT00259493|Coronary Artery Bypass Graft Surgery
1433277|NCT00259493|Off-pump CABG
1433278|NCT00259493|Cardiac CT
1433279|NCT00259493|Bypass Graft CT angiography
1433280|NCT00259467|Activity, Dementia, Caregiving
1433281|NCT00259454|Caregivers
1433282|NCT00259454|in-home care occupational therapy
1433283|NCT00259441|Kidney failure
1433284|NCT00259441|Contrast media
1433285|NCT00259441|Prevention
1433286|NCT00259441|Simvastatin
1433287|NCT00259428|Atrial Fibrillation
1433288|NCT00259428|Atrial Flutter
1433289|NCT00259428|Arrhythmia
1433290|NCT00259428|Anti-Arrhythmia agents
1433291|NCT00259415|Support groups
1433292|NCT00259415|Alzheimer's Disease
1433293|NCT00259389|Treatment Experienced
1433294|NCT00259389|Adherence
1433295|NCT00259389|Compliance
1433296|NCT00259389|Directly Observed Therapy
1433297|NCT00259389|DOT
1433298|NCT00259389|Treatment Naive
1433299|NCT00259376|Atrial Fibrillation
1433300|NCT00259376|Atrial Flutter
1433301|NCT00259376|Arrhythmia
1433302|NCT00259376|Anti-Arrhythmia agents
1433303|NCT00259350|Central venous catheter
1433304|NCT00259350|Skin disinfection
1433305|NCT00259350|Antisepsis
1433306|NCT00259350|Nosocomial infection
1433307|NCT00259350|Catheter infection
1433308|NCT00259337|Diphteria
1433309|NCT00259337|Tetanus
1433310|NCT00259337|Polio
1433311|NCT00259337|Acellular Pertussis
1433312|NCT00259337|Hib
1433313|NCT00259337|Haemophilus influenzae type B
1433314|NCT00259259|Appetite regulation
1433315|NCT00259259|Hormones
1433316|NCT00259259|Energy intake
1433317|NCT00259220|Bleeding
1433318|NCT00259220|Endoscopy
1433319|NCT00259220|Gastric tube
1433320|NCT00259220|Erythromycin
1433321|NCT00259220|Randomized
1433322|NCT00259207|Pulmonary valve regurgitation
1433323|NCT00259207|Valve replacement
1433324|NCT00259207|Hybrid procedure
1433325|NCT00259194|Coronary angiography
1433326|NCT00259194|Complications
1433327|NCT00259194|Observation
1433328|NCT00259181|chlorhexidine gluconate
1433329|NCT00259181|polymethylmethacrylate
1433330|NCT00259181|Anti-Bacterial Agents
1433331|NCT00259168|Postprandial endothelial function
1433332|NCT00259155|Irritable bowel syndrome, Bacterial overgrowth
1433333|NCT00259142|home management of fever, malaria, Uganda
1433334|NCT00259116|Congestive heart failure
1433335|NCT00259116|Relaxin
1433336|NCT00259116|Cardiac hemodynamics
1433337|NCT00259103|relaxin
1433338|NCT00259103|pregnancy
1433339|NCT00259103|cervical ripening
1433340|NCT00259103|normal pregnancy at least at 40 weeks of gestation
1433341|NCT00259038|Carperitide
1433342|NCT00259038|Atrial Natriuretic Peptide
1433343|NCT00259038|Treatment efficacy
1433344|NCT00259038|Safety
1433345|NCT00259038|Heart failure, Congestive
1433346|NCT00259038|Pulmonary Artery Catheterization
1433347|NCT00259025|Renal failure, chronic
1433348|NCT00259025|Death, sudden, cardiac
1433349|NCT00259025|Heart rate variability
1433350|NCT00259025|Tachycardia, ventricular
1433351|NCT00259025|Ventricular premature complexes
1433352|NCT00259025|Ventricular repolarization
1433353|NCT00259025|Eicosapentaenoic acid
1433354|NCT00259025|Docosahexaenoic acid
1433355|NCT00259012|GERD
1433356|NCT00259012|Infant
1433357|NCT00258999|Skin Cholesterol
1433358|NCT00258999|Carotid Plaque
1433359|NCT00258999|Carotid Intima-Media Thickness
1433360|NCT00258986|Living donors
1433361|NCT00258986|Nephrectomy
1433362|NCT00258986|Kidney transplantation
1433363|NCT00258986|Randomized Controlled Trial
1433364|NCT00258986|Laparoscopy
1433365|NCT00258973|Hand held Ultrasound
1433366|NCT00258973|Office practice
1433367|NCT00258973|Atherosclerosis prevention
1433368|NCT00258973|Ultrasound training
1433369|NCT00258960|HER2 positive breast cancer
1433370|NCT00258960|Metastatic breast cancer
1433371|NCT00258947|Smallpox
1433372|NCT00258947|Orthopoxvirus
1433373|NCT00258947|Poxvirus
1433374|NCT00258947|Vaccina Virus
1433375|NCT00258947|LISTER Strain
1433376|NCT00258947|Bioterrorism
1433377|NCT00258934|Influenza
1433378|NCT00258934|Orthomyxoviruses
1433379|NCT00258934|Inactivated
1433380|NCT00258934|Split-virion influenza vaccine
1433381|NCT00258934|adults
1433382|NCT00258934|Myxovirus Infection
1433383|NCT00258934|Orthomyxovirus Infection
1433384|NCT00258908|ADACEL™
1433385|NCT00258908|Tetanus
1433386|NCT00258908|Diphteria
1433387|NCT00258908|Acellular pertussis
1433388|NCT00258895|DAPTACEL®
1433389|NCT00258895|Pentacel™
1433390|NCT00258895|Diphtheria
1433391|NCT00258895|Tetanus
1433392|NCT00258895|Pertussis
1433393|NCT00258895|Whooping cough
1433394|NCT00258895|Acellular Pertussis Vaccine Adsorbed
1433395|NCT00258882|Tetanus Toxoid,
1433396|NCT00258882|acellular pertussis,
1433397|NCT00258882|diphtheria toxoid
1433398|NCT00258869|prospective studies
1433399|NCT00258869|biological assay
1433400|NCT00258869|body weights and measures
1433401|NCT00258869|chemistry, analytical
1433402|NCT00258869|microchip analytical procedures
1433403|NCT00258869|spectrum analysis, mass
1433404|NCT00258869|molecular diagnostic techniques
1433405|NCT00258869|microbiological techniques
1433406|NCT00258869|drug administration schedule
1433407|NCT00258869|data collection
1433408|NCT00258869|statistics
1433409|NCT00258869|gene expression profiling
1433410|NCT00258869|sequence analysis
1433411|NCT00258869|human experimentation
1433412|NCT00258869|immunoassay
1433413|NCT00258869|Trauma severity indices
1433414|NCT00258869|Glasgow Coma score
1433415|NCT00258869|Outcome assessment
1433416|NCT00258869|mortality
1433417|NCT00258869|computer models
1433418|NCT00258869|decision modeling
1433419|NCT00258869|linear models
1433420|NCT00258869|logistic models
1433421|NCT00258869|immunologic model
1433422|NCT00258869|mathematical model
1433423|NCT00258869|non-linear models
1433424|NCT00258869|early diagnosis
1433425|NCT00258869|diagnosis, computer assisted
1433426|NCT00258869|medical informatics
1433427|NCT00258869|prognosis
1433428|NCT00258869|registries
1433429|NCT00258869|computational biology
1433430|NCT00258869|systems biology
1433431|NCT00258856|Meningitis
1433432|NCT00258856|Meningococcal infection
1433433|NCT00258856|Neisseria meningitidis
1433434|NCT00258856|Menactra®
1433435|NCT00258856|Menomune®
1433436|NCT00258843|IMOVAX;
1433437|NCT00258843|poliomyelitis
1433438|NCT00258830|Influenza vaccine
1433439|NCT00258817|Fluzone®
1433440|NCT00258817|Influenza Virus Vaccine
1433441|NCT00258791|Psychiatric disorders
1433442|NCT00258791|ECT
1433443|NCT00258791|Headache
1433444|NCT00258791|Ibuprofen
1433445|NCT00258765|zoledronic acid
1433446|NCT00258765|prostate cancer
1433447|NCT00258765|high risk
1433448|NCT00258765|PSA
1433449|NCT00258765|docetaxel
1433450|NCT00258752|Prevention
1433451|NCT00258752|Adolescent
1433452|NCT00258726|Measels, Mumps, Varicella, Rubella, vaccine, children
1433453|NCT00258713|Randomized Controlled Trials
1433454|NCT00258713|Immunosuppression
1433455|NCT00258713|Adult
1433456|NCT00258713|Chronic Disease
1433457|NCT00258713|Dermatologic Agents
1433458|NCT00258713|Female
1433459|NCT00258713|Humans
1433460|NCT00258713|Male
1433461|NCT00258713|Middle Aged
1433462|NCT00258713|Severity of Illness Index
1433463|NCT00258713|Treatment Outcome
1433464|NCT00258713|Quality of Life
1433465|NCT00258713|Double-Blind Method
1433466|NCT00258687|GVAX
1433467|NCT00258687|GM-CSF
1433468|NCT00258687|Adenoviral mediated gene transfer
1433469|NCT00258687|Pediatric Melanoma
1433470|NCT00258674|Diabetes
1433471|NCT00258674|Care coordination
1433472|NCT00258674|Case management
1433473|NCT00258674|Physician profiling
1433474|NCT00258661|Pneumonia
1433475|NCT00258661|Osteopathic
1433476|NCT00258661|Manipulation
1433477|NCT00258661|Multi-center
1433478|NCT00258661|Elderly
1433479|NCT00258635|Allergy
1433480|NCT00258635|Specific Immunotherapy
1433481|NCT00258622|Peripheral neuropathic pain
1433482|NCT00258622|Neuropathic pain
1433483|NCT00258622|Chronic pain
1433484|NCT00258609|Botulinum toxin type A,
1433485|NCT00258609|Dysport®,Dysport
1433486|NCT00258609|Migraine without aura,
1433487|NCT00258609|Migraine prophylaxis.
1433488|NCT00258596|drug-eluting stent
1433489|NCT00258596|chronic total occlusion
1433490|NCT00258596|sirolimus-eluting stent
1433491|NCT00258596|zotarolimus-eluting stent
1433492|NCT00258596|QCA
1433493|NCT00258583|"Lung[A04.400]"
1433494|NCT00258570|"Lung[A04.400]"
1433495|NCT00258557|HIV
1433496|NCT00258557|Anti-Retroviral agents
1433497|NCT00258557|HIV-1
1433498|NCT00258557|TMC114/r
1433499|NCT00258557|Treatment naïve patients
1433500|NCT00258544|Lung
1433501|NCT00258544|Fibrosis
1433502|NCT00258544|Idiopathic
1433503|NCT00258544|Microarray
1433504|NCT00258544|Tissue
1433505|NCT00258544|Biopsy
1433506|NCT00258518|Critically ill patients
1433507|NCT00258505|Spreading depression
1433508|NCT00258505|Seizures
1433509|NCT00258505|Blood-brain barrier
1433510|NCT00258492|Restless legs syndrome
1433511|NCT00258492|Insomnia
1433512|NCT00258492|Daytime sleepiness
1433513|NCT00258492|Exercise
1433514|NCT00258479|Nicotine Dependence
1433515|NCT00258479|Nicotine Use Disorder
1433516|NCT00258479|Tobacco Dependence
1433517|NCT00258466|adenocarcinoma of the prostate
1433518|NCT00258466|stage I prostate cancer
1433519|NCT00258466|stage II prostate cancer
1433520|NCT00258466|stage III prostate cancer
1433521|NCT00258453|psychosocial effects of cancer and its treatment
1433522|NCT00258453|long-term effects secondary to cancer therapy in children
1433523|NCT00258453|perioperative/postoperative complications
1433524|NCT00258453|weight changes
1433525|NCT00258453|childhood craniopharyngioma
1433526|NCT00258440|fatigue
1433527|NCT00258440|anemia
1433528|NCT00258440|unspecified adult solid tumor, protocol specific
1433529|NCT00258427|Fanconi anemia
1433530|NCT00258401|diarrhea
1433531|NCT00258401|radiation toxicity
1433532|NCT00258401|recurrent uterine sarcoma
1433533|NCT00258401|stage I uterine sarcoma
1433534|NCT00258401|stage II uterine sarcoma
1433535|NCT00258401|stage III uterine sarcoma
1433536|NCT00258401|stage IV uterine sarcoma
1433537|NCT00258401|recurrent prostate cancer
1433538|NCT00258401|stage I prostate cancer
1433539|NCT00258401|stage II prostate cancer
1433540|NCT00258401|stage III prostate cancer
1433541|NCT00258401|stage IV prostate cancer
1433542|NCT00258401|recurrent cervical cancer
1433543|NCT00258401|stage 0 cervical cancer
1433544|NCT00258401|stage IA cervical cancer
1433545|NCT00258401|stage IB cervical cancer
1433546|NCT00258401|stage IIA cervical cancer
1433547|NCT00258401|stage IIB cervical cancer
1433548|NCT00258401|stage III cervical cancer
1433549|NCT00258401|stage IVA cervical cancer
1433550|NCT00258401|stage IVB cervical cancer
1433551|NCT00258388|adenocarcinoma of the prostate
1433552|NCT00258388|recurrent prostate cancer
1433553|NCT00258388|stage IV prostate cancer
1433554|NCT00258375|stage IIIA breast cancer
1433555|NCT00258375|stage IIIB breast cancer
1433556|NCT00258375|stage IIIC breast cancer
1433557|NCT00258375|stage IV breast cancer
1433558|NCT00258375|recurrent breast cancer
1433559|NCT00258362|recurrent endometrial carcinoma
1433560|NCT00258362|stage III endometrial carcinoma
1433561|NCT00258362|stage IV endometrial carcinoma
1433562|NCT00258336|recurrent grade 1 follicular lymphoma
1433563|NCT00258336|recurrent grade 2 follicular lymphoma
1433564|NCT00258336|stage III grade 1 follicular lymphoma
1433565|NCT00258336|stage III grade 2 follicular lymphoma
1433566|NCT00258336|stage IV grade 1 follicular lymphoma
1433567|NCT00258336|stage IV grade 2 follicular lymphoma
1433568|NCT00258336|contiguous stage II grade 1 follicular lymphoma
1433569|NCT00258336|contiguous stage II grade 2 follicular lymphoma
1433570|NCT00258336|noncontiguous stage II grade 1 follicular lymphoma
1433571|NCT00258336|noncontiguous stage II grade 2 follicular lymphoma
1433572|NCT00258336|stage I grade 1 follicular lymphoma
1433573|NCT00258336|stage I grade 2 follicular lymphoma
1433574|NCT00258323|adenocarcinoma of the esophagus
1433575|NCT00258323|squamous cell carcinoma of the esophagus
1433576|NCT00258323|stage II esophageal cancer
1433577|NCT00258323|stage III esophageal cancer
1433578|NCT00258323|stage IV esophageal cancer
1433579|NCT00258310|stage I squamous cell carcinoma of the hypopharynx
1433580|NCT00258310|stage I squamous cell carcinoma of the larynx
1433581|NCT00258310|stage I squamous cell carcinoma of the lip and oral cavity
1433582|NCT00258310|stage I squamous cell carcinoma of the nasopharynx
1433583|NCT00258310|stage I squamous cell carcinoma of the oropharynx
1433584|NCT00258310|stage II squamous cell carcinoma of the hypopharynx
1433585|NCT00258310|stage II squamous cell carcinoma of the larynx
1433586|NCT00258310|stage II squamous cell carcinoma of the lip and oral cavity
1433587|NCT00258310|stage II squamous cell carcinoma of the nasopharynx
1433588|NCT00258310|stage II squamous cell carcinoma of the oropharynx
1433589|NCT00258310|stage III squamous cell carcinoma of the hypopharynx
1433590|NCT00258310|stage III squamous cell carcinoma of the larynx
1433591|NCT00258310|stage III squamous cell carcinoma of the lip and oral cavity
1433592|NCT00258310|stage III squamous cell carcinoma of the nasopharynx
1433593|NCT00258310|stage III squamous cell carcinoma of the oropharynx
1433594|NCT00258310|stage IV squamous cell carcinoma of the hypopharynx
1433595|NCT00258310|stage IV squamous cell carcinoma of the larynx
1433596|NCT00258310|stage IV squamous cell carcinoma of the lip and oral cavity
1433597|NCT00258310|stage IV squamous cell carcinoma of the nasopharynx
1433598|NCT00258310|stage IV squamous cell carcinoma of the oropharynx
1433599|NCT00258297|stage I esophageal cancer
1433600|NCT00258297|stage II esophageal cancer
1433601|NCT00258297|stage III esophageal cancer
1433602|NCT00258297|adenocarcinoma of the esophagus
1433603|NCT00258297|squamous cell carcinoma of the esophagus
1433604|NCT00258284|recurrent prostate cancer
1433605|NCT00258284|stage IV prostate cancer
1433606|NCT00258284|adenocarcinoma of the prostate
1433607|NCT00258271|recurrent adult acute myeloid leukemia
1433608|NCT00258271|adult acute basophilic leukemia
1433609|NCT00258271|adult acute eosinophilic leukemia
1433610|NCT00258271|adult acute megakaryoblastic leukemia (M7)
1433611|NCT00258271|adult acute myeloblastic leukemia with maturation (M2)
1433612|NCT00258271|adult acute myelomonocytic leukemia (M4)
1433613|NCT00258271|adult acute monoblastic leukemia (M5a)
1433614|NCT00258271|adult acute monocytic leukemia (M5b)
1433615|NCT00258271|adult acute myeloblastic leukemia without maturation (M1)
1433616|NCT00258271|adult erythroleukemia (M6a)
1433617|NCT00258271|adult pure erythroid leukemia (M6b)
1433618|NCT00258271|blastic phase chronic myelogenous leukemia
1433619|NCT00258271|relapsing chronic myelogenous leukemia
1433620|NCT00258258|refractory multiple myeloma
1433621|NCT00258245|stage II multiple myeloma
1433622|NCT00258245|stage III multiple myeloma
1433623|NCT00258245|refractory multiple myeloma
1433749|NCT00257699|Metronidazole
1433624|NCT00258245|stage I multiple myeloma
1433625|NCT00258232|adenocarcinoma of the colon
1433626|NCT00258232|adenocarcinoma of the rectum
1433627|NCT00258232|recurrent colon cancer
1433628|NCT00258232|recurrent rectal cancer
1433629|NCT00258232|stage IV colon cancer
1433630|NCT00258232|stage IV rectal cancer
1433631|NCT00258206|stage I multiple myeloma
1433632|NCT00258206|stage II multiple myeloma
1433633|NCT00258206|stage III multiple myeloma
1433634|NCT00258206|refractory multiple myeloma
1433635|NCT00258193|C-IBS
1433636|NCT00258193|IBS-C
1433637|NCT00258193|Constipation-predominant Irritable Bowel Syndrome
1433638|NCT00258193|Constipation Predominant Irritable Bowel Syndrome
1433639|NCT00258193|Irritable Bowel Syndrome
1433640|NCT00258193|IBS
1433641|NCT00258193|Transit
1433642|NCT00258193|Scintigraphy
1433643|NCT00258193|Gastroenterology
1433644|NCT00258193|Gastrointestinal
1433645|NCT00258193|GC
1433646|NCT00258193|MD-1100 Acetate
1433647|NCT00258193|MD-1100
1433648|NCT00258193|linaclotide
1433649|NCT00258193|linaclotide acetate
1433650|NCT00258180|unspecified childhood solid tumor, protocol specific
1433651|NCT00258180|gastrointestinal complications
1433652|NCT00258180|diarrhea
1433653|NCT00258167|Family members
1433654|NCT00258167|Illness burden
1433655|NCT00258167|Mental Disorders
1433656|NCT00258167|Family intervention
1433657|NCT00258115|Obesity
1433658|NCT00258115|Metabolic Syndrome
1433659|NCT00258115|Diabetes
1433660|NCT00258115|Inflammation
1433661|NCT00258102|levofloxacin
1433662|NCT00258102|urinary tract infections
1433663|NCT00258102|bacterial infections
1433664|NCT00258102|bacteriuria
1433665|NCT00258102|urinary anti-infective agents
1433666|NCT00258102|urinary infections
1433667|NCT00258102|quinolones
1433668|NCT00258089|levofloxacin
1433669|NCT00258089|urinary tract infections
1433670|NCT00258089|bacterial infections
1433671|NCT00258089|bacteriuria
1433672|NCT00258089|urinary anti-infective agents
1433673|NCT00258089|urinary infections
1433674|NCT00258089|quinolones
1433675|NCT00258076|Transdermal contraception
1433676|NCT00258076|contraceptive
1433677|NCT00258076|hormonal, steroid contraception
1433678|NCT00258076|ethinyl estradiol
1433679|NCT00258076|progesterone
1433680|NCT00258076|EVRA
1433681|NCT00258063|Transdermal contraception
1433682|NCT00258063|contraceptive
1433683|NCT00258063|hormonal, steroid contraception
1433684|NCT00258063|ethinyl estradiol
1433685|NCT00258063|progesterone
1433686|NCT00258063|EVRA
1433687|NCT00258063|CILEST
1433688|NCT00258063|ORTHO EVRA
1433689|NCT00258050|lapatinib
1433690|NCT00258050|midazolam
1433691|NCT00258050|pharmacokinetics
1433692|NCT00258037|Physiotherapy
1433693|NCT00258037|Stroke
1433694|NCT00258037|Urinary Incontinence
1433695|NCT00258037|quality of Life
1433696|NCT00258024|IPT-SP, pregnancy, malaria,Ghana
1433697|NCT00258011|MPS I Disease
1433698|NCT00257985|Familial hemiplegic migraine type 1 and 2
1433699|NCT00257985|GTN
1433700|NCT00257985|middle cerebral artery
1433701|NCT00257985|superficial temporal artery
1433702|NCT00257985|headache
1433703|NCT00257985|genotype
1433704|NCT00257972|Bipolar Mania
1433705|NCT00257946|Diaphragm
1433706|NCT00257946|Hernia
1433707|NCT00257946|Congenital
1433708|NCT00257933|Corticosteroids
1433709|NCT00257933|Treatment
1433710|NCT00257933|Pediatric
1433711|NCT00257920|Stage 5 Chronic Kidney Disease (CKD)
1433712|NCT00257907|Latent Tuberculosis
1433713|NCT00257907|PPD
1433714|NCT00257907|Antigen Specific T-Cells
1433715|NCT00257907|Lymphocyte Proliferation Assay
1433716|NCT00257907|HIV
1433717|NCT00257907|LPA
1433718|NCT00257894|Baclofen
1433719|NCT00257894|Conditioning, Classical
1433720|NCT00257894|Nicotine
1433721|NCT00257894|Smoking
1433722|NCT00257881|Tumor
1433723|NCT00257855|Secondary Progressive Multiple Sclerosis
1433724|NCT00257855|Neuroprotection
1433725|NCT00257855|Axonal loss
1433726|NCT00257855|Brain atrophy
1433727|NCT00257855|MRI
1433728|NCT00257855|Lamotrigine
1433729|NCT00257855|Sodium Channel Blockers
1433730|NCT00257829|Cervical Cancer
1433731|NCT00257816|Cervical Cancer
1433732|NCT00257803|Oxytocin, bolus, postpartum hemorrhage
1433733|NCT00257790|Fever
1433734|NCT00257790|Neutropenia
1433735|NCT00257790|Tobramycin
1433736|NCT00257790|Aminoglycoside
1433737|NCT00257790|Penicillin
1433738|NCT00257764|Swallowing disorder
1433739|NCT00257764|Stroke
1433740|NCT00257764|Standardized swallowing therapy
1433741|NCT00257764|Randomized controlled trial
1433742|NCT00257725|ADHD
1433743|NCT00257725|Attention-deficit/hyperactivity disorder (ADHD)
1433744|NCT00257712|Alzheimer's disease
1433745|NCT00257712|cognition disorders
1433746|NCT00257699|Crohn's Disease
1433747|NCT00257699|Randomized
1433748|NCT00257699|Ciprofloxacin
1433750|NCT00257699|Antibiotic
1433751|NCT00257686|Kowa
1433752|NCT00257686|Hypercholesterolemia
1433753|NCT00257686|combined
1433754|NCT00257686|dyslipidemia
1433755|NCT00257686|elderly
1433756|NCT00257686|pitavastatin
1433757|NCT00257686|NK-104
1433758|NCT00257673|Cognition
1433759|NCT00257673|Alzheimer's
1433760|NCT00257673|Cognitive impairment
1433761|NCT00257634|lateral epicondylitis
1433762|NCT00257634|iontophoresis
1433763|NCT00257634|dexamethasone
1433764|NCT00257621|HIV-1 protease inhibitor GW640385 ritonavir RTV
1433765|NCT00257608|NSCLC
1433766|NCT00257608|Lung Cancer
1433767|NCT00257608|ATLAS
1433768|NCT00257608|Avastin
1433769|NCT00257608|Tarceva
1433770|NCT00257595|Perennial Allergic Rhinitis pediatric
1433771|NCT00257582|cetirizine
1433772|NCT00257582|various type of cutaneous disease accompanied with Pruritus
1433773|NCT00257582|pediatrics
1433774|NCT00257569|Atopic
1433775|NCT00257569|Pediatric
1433776|NCT00257569|Dermatitis
1433777|NCT00257543|sickle cell disease
1433778|NCT00257543|bone marrow transplant
1433779|NCT00257517|Congenital heart disease
1433780|NCT00257517|Single ventricle
1433781|NCT00257517|Infant feeding
1433782|NCT00257478|Treatment Efficacy
1433783|NCT00257478|Treatment Effectiveness
1433784|NCT00257478|Disease Management
1433785|NCT00257478|Treatment
1433786|NCT00257478|Safety
1433787|NCT00257465|melanoma
1433788|NCT00257465|metastatic
1433789|NCT00257465|vaccine
1433790|NCT00257465|immunotherapy
1433791|NCT00257465|autologous
1433792|NCT00257439|Vitamin B12
1433793|NCT00257439|Folic Acid
1433794|NCT00257426|adult primary hepatocellular carcinoma
1433795|NCT00257426|advanced adult primary liver cancer
1433796|NCT00257426|localized unresectable adult primary liver cancer
1433797|NCT00257426|recurrent adult primary liver cancer
1433798|NCT00257400|major depressive disorder
1433799|NCT00257400|psychotherapy
1433800|NCT00257400|childhood sexual abuse
1433801|NCT00257400|trauma
1433802|NCT00257387|Kidney
1433803|NCT00257387|Kidney Transplant
1433804|NCT00257348|Advanced Cervical Carcinoma
1433805|NCT00257348|Recurrent Cervical Carcinoma
1433806|NCT00257335|Carcinoma of the head and neck
1433807|NCT00257322|Metastatic colon cancer
1433808|NCT00257322|Metastatic rectal cancer
1433809|NCT00257309|Acute myocardial infarction
1433810|NCT00257309|Elderly
1433811|NCT00257309|Thrombolysis
1433812|NCT00257309|Primary angioplasty
1433813|NCT00257309|Randomized trial
1433814|NCT00257309|Efficacy
1433815|NCT00257309|Safety
1433816|NCT00257283|Chronic renal failure
1433817|NCT00257283|Hemodialysis
1433818|NCT00257283|OMACOR (omega-3-acid ethyl ester 90)
1433819|NCT00257283|intervention study
1433820|NCT00257283|cardiovascular events
1433821|NCT00257283|mortality
1433822|NCT00257270|Chronic
1433823|NCT00257270|Tinnitus
1433824|NCT00257270|Acoustic trauma
1433825|NCT00257270|Psychophysics
1433826|NCT00257270|Loudness match
1433827|NCT00257270|gabapentin
1433828|NCT00257257|Type 2 diabetes mellitus
1433829|NCT00257244|Immunity, innate
1433830|NCT00257244|Inflammation
1433831|NCT00257244|Genomics
1433832|NCT00257244|Proteomics
1433833|NCT00257231|Immunity, innate
1433834|NCT00257231|Inflammation
1433835|NCT00257231|Genomics
1433836|NCT00257231|Proteomics
1433837|NCT00257192|Adolescent Subjects With Schizophrenia
1433838|NCT00257179|Tissue factor
1433839|NCT00257179|Lung cancer
1433840|NCT00257179|Tissue factor protein inhibitor
1433841|NCT00257179|Factor VII
1433842|NCT00257179|Factor X
1433843|NCT00257153|Acute myocardial infarction
1433844|NCT00257153|primary angioplasty
1433845|NCT00257153|myocardial reperfusion
1433846|NCT00257153|thrombus aspiration
1433847|NCT00257140|Bronchitis
1433848|NCT00257140|chronic bronchitis
1433849|NCT00257140|lung diseases
1433850|NCT00257140|respiratory tract infections
1433851|NCT00257140|bronchial diseases
1433852|NCT00257140|antibacterial agents
1433853|NCT00257140|quinolones
1433854|NCT00257140|levofloxacin
1433855|NCT00257127|Vaccination
1433856|NCT00257114|Multiple Myeloma
1433857|NCT00257114|Retreatment
1433858|NCT00257114|VELCADE
1433859|NCT00257088|development
1433860|NCT00257088|epidemiology
1433861|NCT00257088|risk factors
1433862|NCT00257088|randomized field trials
1433863|NCT00257075|risperidone
1433864|NCT00257075|antipsychotic agents
1433865|NCT00257075|bipolar disorders
1433866|NCT00257075|manic episode
1433867|NCT00257062|Infectious skin diseases
1433868|NCT00257062|skin diseases
1433869|NCT00257062|bacterial skin diseases
1433870|NCT00257062|antibacterial agents
1433871|NCT00257062|quinolones
1433872|NCT00257062|levofloxacin
1433873|NCT00257049|Pneumonia
1433874|NCT00257049|lung inflammation
1433875|NCT00257049|bacterial pneumonia
1433876|NCT00257049|lung diseases
1433877|NCT00257049|respiratory tract infections
1433878|NCT00257049|antibacterial agents
1433879|NCT00257049|quinolones
1433880|NCT00257049|levofloxacin
1433881|NCT00257036|Infectious skin diseases
1433882|NCT00257036|skin diseases
1433883|NCT00257036|bacterial skin diseases
1433884|NCT00257036|cellulitis
1433885|NCT00257036|quinolones
1433886|NCT00257036|levofloxacin
1433887|NCT00257023|Schizophrenia
1433888|NCT00257023|Risperidone
1433889|NCT00257023|Positive and Negative Syndrome Scale (PANSS)
1433890|NCT00257023|Clinical Global Impression (CGI)
1433891|NCT00257023|Positron Emission Tomography (PET)
1433892|NCT00257010|Migraine
1433893|NCT00257010|Almotriptan Malate
1433894|NCT00257010|Headache
1433895|NCT00257010|Triptan
1433896|NCT00256997|Schizophrenia
1433897|NCT00256997|Risperidone
1433898|NCT00256997|Risperdal Consta
1433899|NCT00256984|Obstructive Defecation Syndrome
1433900|NCT00256984|Colorectal Surgery
1433901|NCT00256984|Defecography
1433902|NCT00256984|Constipation
1433903|NCT00256984|Rectocele
1433904|NCT00256984|Intussusception
1433905|NCT00256984|Quality of Life
1433906|NCT00256945|biofilm formation
1433907|NCT00256945|dental plaque
1433908|NCT00256945|surface roughness
1433909|NCT00256945|dental restoration
1433910|NCT00256945|dental materials
1433911|NCT00256932|bowel dysfunction
1433912|NCT00256932|constipation
1433913|NCT00256932|gastrointestinal
1433914|NCT00256932|opioids
1433915|NCT00256932|pain
1433916|NCT00256932|non-cancer pain
1433917|NCT00256932|Opioid-induced
1433918|NCT00256919|GW856553
1433919|NCT00256919|biomarkers
1433920|NCT00256919|CRP
1433921|NCT00256919|rheumatoid arthritis
1433922|NCT00256906|lateral ventricles
1433923|NCT00256906|fetal ventriculomegaly
1433924|NCT00256893|pain intensity
1433925|NCT00256893|numerical rating scale
1433926|NCT00256893|fibromyalgia
1433927|NCT00256880|Pazopanib(GW786034)
1433928|NCT00256880|Solid Tumors
1433929|NCT00256880|Myeloma
1433930|NCT00256867|Type 2 diabetes Type II
1433931|NCT00256854|RLS
1433932|NCT00256854|Ropinirole
1433933|NCT00256854|Restless Legs Syndrome
1433934|NCT00256841|Hypofractionated Chest Radiation
1433935|NCT00256841|Taxotere
1433936|NCT00256841|5-FU
1433937|NCT00256828|HIV infection
1433938|NCT00256828|Highly active antiretroviral therapy
1433939|NCT00256828|Treatment Naive
1433940|NCT00256815|Hypofractionated chest radiation
1433941|NCT00256815|Oral Navelbine
1433942|NCT00256802|Headache
1433943|NCT00256802|migraine
1433944|NCT00256802|MR-angiography
1433945|NCT00256802|healthy volunteers
1433946|NCT00256802|GTN
1433947|NCT00256802|Middle cerebral artery
1433948|NCT00256789|NSCLC, Non-Small Cell Lung Cancer,Weekly Radiation, Taxotere
1433949|NCT00256776|Multiple Myeloma
1433950|NCT00256776|Velcade
1433951|NCT00256776|Autologous transplantation
1433952|NCT00256776|Relapse
1433953|NCT00256776|Disease progress
1433954|NCT00256737|Maintenance of healed erosive esophagitis
1433955|NCT00256724|hypotension
1433956|NCT00256724|hypovolemia
1433957|NCT00256724|dehydration
1433958|NCT00256724|sepsis
1433959|NCT00256724|blood loss
1433960|NCT00256711|Locally advanced or metastatic NSCLC.
1433961|NCT00256711|Stage IIIb or Stage IV lung cancer
1433962|NCT00256698|Hormone
1433963|NCT00256698|receptor
1433964|NCT00256698|positive
1433965|NCT00256698|breast
1433966|NCT00256698|cancer
1433967|NCT00256698|first
1433968|NCT00256698|relapse
1433969|NCT00256685|Menopause
1433970|NCT00256672|Spinal Cord Injury
1433971|NCT00256672|TLSO brace
1433972|NCT00256672|Spine curvature
1433973|NCT00256672|Child
1433974|NCT00256672|Effectiveness of bracing
1433975|NCT00256659|Medical inpatients
1433976|NCT00256659|Social Work
1433977|NCT00256659|Physical therapy
1433978|NCT00256659|Occupational therapy
1433979|NCT00256659|Psychiatry
1433980|NCT00256659|Early intervention
1433981|NCT00256659|Iatrogenic complications
1433982|NCT00256620|Cardiopulmonary bypass
1433983|NCT00256620|Coronary artery disease
1433984|NCT00256620|Cardiac morbidity
1433985|NCT00256620|Neurologic morbidity
1433986|NCT00256620|Neurocognitive function
1433987|NCT00256620|Autoregulation
1433988|NCT00256594|Medical Errors
1433989|NCT00256594|Medication Errors
1433990|NCT00256594|Prescriptions, Drug
1433991|NCT00256581|myocardial perfusion
1433992|NCT00256581|Imaging
1433993|NCT00256568|Medical Errors
1433994|NCT00256568|Medication Errors
1433995|NCT00256568|Prescriptions, Drug
1433996|NCT00256568|Pharmacies
1433997|NCT00256568|Ambulatory Care Facilities
1433998|NCT00256542|interstitial cystitis
1433999|NCT00256542|pelvic pain
1434000|NCT00256542|urgency
1434001|NCT00256542|frequency
1434002|NCT00256542|Pelvic Pain and/or Urgency of Bladder Origin
1434003|NCT00256529|dysphagia
1434004|NCT00256529|eosinophilic esophagitis
1434005|NCT00256516|Diet Therapy
1434006|NCT00256503|Primary Insomnia
1434007|NCT00256503|Insomnia
1434008|NCT00256503|Sleep
1434009|NCT00256490|Diffuse large B cells lymphoma
1434010|NCT00256490|PET/CT
1434011|NCT00256490|FDG
1434012|NCT00256464|PTSD
1434013|NCT00256451|Naltrexone
1434014|NCT00256451|Endophenotype
1434015|NCT00256438|Depression
1434016|NCT00256438|Transcranial Direct Current Stimulation
1434017|NCT00256425|glioma
1434018|NCT00256425|brain tumor
1434019|NCT00256425|cognit
1434020|NCT00256425|neuropsycholog
1434021|NCT00256425|attention
1434022|NCT00256425|memory
1434023|NCT00256425|executive function
1434024|NCT00256425|rehabilitation
1434025|NCT00256425|remediation
1434026|NCT00256425|training
1434027|NCT00256386|Baseline
1434028|NCT00256386|Laboratory
1434029|NCT00256386|Drug
1434030|NCT00256373|Low Back Pain
1434031|NCT00256373|Dynamic Back-Muscle exercise Treatment
1434032|NCT00256373|Interdisciplinary Treatment
1434033|NCT00256373|Roland Morris Disability Questionnaire
1434034|NCT00256373|SF-36
1434035|NCT00256373|Low Back Pain Rating Scale
1434036|NCT00256360|breast cancer
1434037|NCT00256360|adjuvant
1434038|NCT00256360|dose dense
1434039|NCT00256360|docetaxel
1434040|NCT00256360|pegfilgrastim
1434041|NCT00256334|Colon Cancer
1434042|NCT00256334|Resveratrol
1434043|NCT00256334|Clinical Trial
1434044|NCT00256334|WnT signaling
1434045|NCT00256334|Grapes
1434046|NCT00256334|Cancer prevention
1434047|NCT00256321|Gastric Carcinoma
1434048|NCT00256321|Gastroesophageal junction Carcinoma
1434049|NCT00256308|Head and Neck Cancer
1434050|NCT00256295|Cancer of the Head and Neck
1434051|NCT00256282|Metastatic Melanoma
1434052|NCT00256269|Esophageal Cancer
1434053|NCT00256269|Gastroesophageal junction cancer
1434054|NCT00256256|type 2 diabetes
1434055|NCT00256256|GLP-1
1434056|NCT00256256|PET
1434057|NCT00256256|brain
1434058|NCT00256256|heart
1434059|NCT00256204|Parkinson's
1434060|NCT00256204|Rasagiline Mesylate
1434061|NCT00256191|taxanes
1434062|NCT00256191|multidrug resistance
1434063|NCT00256191|mutant tubulin binding
1434064|NCT00256191|Hodgkin's or Non-Hodgkin's Lymphoma
1434065|NCT00256178|Hyperlipidemia
1434066|NCT00256178|Drug Therapy
1434067|NCT00256165|Aortic valve replacement
1434068|NCT00256152|Atrial fibrillation
1434069|NCT00256152|Pacemaker
1434070|NCT00256152|AF suppression pacing
1434071|NCT00256152|Indications for Pacemaker Implantation due to sinus node or atrio-ventricular node disease
1434072|NCT00256113|depression
1434073|NCT00256113|antidepressive agents
1434074|NCT00256113|controlled clinical trial
1434075|NCT00256087|Nosocomial rates in critically ill patients
1434076|NCT00256009|Late abortion
1434077|NCT00255983|bronchitis
1434078|NCT00255983|AECB
1434079|NCT00255970|Periodontal Treatment of Intraosseous Vertical Defects
1434080|NCT00255957|Stroke, HES, Coagulation, Kinetics, Hemorehology
1434081|NCT00255944|HIV Prevention
1434082|NCT00255944|Internet Intervention
1434083|NCT00255944|STDs
1434084|NCT00255931|Heart Failure
1434085|NCT00255931|Biofeedback-Relaxation
1434086|NCT00255931|Cognitive Behavioral Therapy
1434087|NCT00255918|Evoked Potentials
1434088|NCT00255918|3-(2,4-dimethoxybenzylidene)anabaseine
1434089|NCT00255918|DMXB-A
1434090|NCT00255918|Receptors, Nicotinic
1434091|NCT00255905|Depression
1434092|NCT00255905|Insomnia
1434093|NCT00255892|HIV
1434094|NCT00255879|Schizophrenia
1434095|NCT00255879|Neuroleptic
1434096|NCT00255879|Tardive dyskinesia
1434097|NCT00255866|Assisted Living Facilities
1434098|NCT00255866|Aged
1434099|NCT00255866|Elderly
1434100|NCT00255866|Caregivers
1434101|NCT00255840|Treatment Naive
1434102|NCT00255814|liver metastases
1434103|NCT00255801|stage I cutaneous T-cell non-Hodgkin lymphoma
1434104|NCT00255801|stage II cutaneous T-cell non-Hodgkin lymphoma
1434105|NCT00255801|stage III cutaneous T-cell non-Hodgkin lymphoma
1434106|NCT00255801|stage IV cutaneous T-cell non-Hodgkin lymphoma
1434107|NCT00255801|recurrent cutaneous T-cell non-Hodgkin lymphoma
1434108|NCT00255801|stage I mycosis fungoides/Sezary syndrome
1434109|NCT00255801|stage II mycosis fungoides/Sezary syndrome
1434110|NCT00255801|stage III mycosis fungoides/Sezary syndrome
1434111|NCT00255801|stage IV mycosis fungoides/Sezary syndrome
1434112|NCT00255801|recurrent mycosis fungoides/Sezary syndrome
1434113|NCT00255788|recurrent breast cancer
1434114|NCT00255788|stage IV breast cancer
1434115|NCT00255788|male breast cancer
1434116|NCT00255775|non-small cell lung cancer
1434117|NCT00255775|small cell lung cancer
1434118|NCT00255749|adult acute lymphoblastic leukemia in remission
1434119|NCT00255749|progressive hairy cell leukemia, initial treatment
1434120|NCT00255749|stage 0 chronic lymphocytic leukemia
1434121|NCT00255749|anemia
1434122|NCT00255749|extramedullary plasmacytoma
1434123|NCT00255749|isolated plasmacytoma of bone
1434124|NCT00255749|refractory multiple myeloma
1434125|NCT00255749|monoclonal gammopathy of undetermined significance
1434126|NCT00255749|primary systemic amyloidosis
1434127|NCT00255749|stage I multiple myeloma
1434128|NCT00255749|stage II multiple myeloma
1434129|NCT00255749|stage III multiple myeloma
1434130|NCT00255749|AIDS-related peripheral/systemic lymphoma
1434131|NCT00255749|AIDS-related primary CNS lymphoma
1434132|NCT00255749|anaplastic large cell lymphoma
1434133|NCT00255749|angioimmunoblastic T-cell lymphoma
1434134|NCT00255749|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1434135|NCT00255749|nodal marginal zone B-cell lymphoma
1434136|NCT00255749|recurrent adult Burkitt lymphoma
1434137|NCT00255749|recurrent adult diffuse large cell lymphoma
1434138|NCT00255749|recurrent adult diffuse mixed cell lymphoma
1434139|NCT00255749|recurrent adult diffuse small cleaved cell lymphoma
1434140|NCT00255749|recurrent adult Hodgkin lymphoma
1434141|NCT00255749|recurrent adult immunoblastic large cell lymphoma
1434142|NCT00255749|recurrent adult lymphoblastic lymphoma
1434143|NCT00255749|recurrent adult T-cell leukemia/lymphoma
1434144|NCT00255749|recurrent cutaneous T-cell non-Hodgkin lymphoma
1434145|NCT00255749|recurrent grade 1 follicular lymphoma
1434146|NCT00255749|recurrent grade 2 follicular lymphoma
1434147|NCT00255749|recurrent grade 3 follicular lymphoma
1434148|NCT00255749|recurrent mantle cell lymphoma
1434149|NCT00255749|recurrent marginal zone lymphoma
1434150|NCT00255749|recurrent mycosis fungoides/Sezary syndrome
1434151|NCT00255749|recurrent small lymphocytic lymphoma
1434152|NCT00255749|splenic marginal zone lymphoma
1434153|NCT00255749|stage III adult Burkitt lymphoma
1434154|NCT00255749|stage III adult diffuse large cell lymphoma
1434155|NCT00255749|stage III adult diffuse mixed cell lymphoma
1434156|NCT00255749|stage III adult diffuse small cleaved cell lymphoma
1434157|NCT00255749|stage III adult Hodgkin lymphoma
1434158|NCT00255749|stage III adult immunoblastic large cell lymphoma
1434159|NCT00255749|stage III adult lymphoblastic lymphoma
1434160|NCT00255749|stage III adult T-cell leukemia/lymphoma
1434161|NCT00255749|stage III cutaneous T-cell non-Hodgkin lymphoma
1434162|NCT00255749|stage III grade 1 follicular lymphoma
1434163|NCT00255749|stage III grade 2 follicular lymphoma
1434164|NCT00255749|stage III grade 3 follicular lymphoma
1434165|NCT00255749|stage III mantle cell lymphoma
1434166|NCT00255749|stage III marginal zone lymphoma
1434167|NCT00255749|stage III mycosis fungoides/Sezary syndrome
1434168|NCT00255749|stage III small lymphocytic lymphoma
1434169|NCT00255749|stage IV adult Burkitt lymphoma
1434170|NCT00255749|stage IV adult diffuse large cell lymphoma
1434171|NCT00255749|stage IV adult diffuse mixed cell lymphoma
1434172|NCT00255749|stage IV adult diffuse small cleaved cell lymphoma
1434173|NCT00255749|stage IV adult Hodgkin lymphoma
1434174|NCT00255749|stage IV adult immunoblastic large cell lymphoma
1434175|NCT00255749|stage IV adult lymphoblastic lymphoma
1434176|NCT00255749|stage IV adult T-cell leukemia/lymphoma
1434177|NCT00255749|stage IV cutaneous T-cell non-Hodgkin lymphoma
1434178|NCT00255749|stage IV grade 1 follicular lymphoma
1434179|NCT00255749|stage IV grade 2 follicular lymphoma
1434180|NCT00255749|stage IV grade 3 follicular lymphoma
1434473|NCT00255398|Kidney Disease
1434181|NCT00255749|stage IV mantle cell lymphoma
1434182|NCT00255749|stage IV marginal zone lymphoma
1434183|NCT00255749|stage IV mycosis fungoides/Sezary syndrome
1434184|NCT00255749|stage IV small lymphocytic lymphoma
1434185|NCT00255749|Waldenström macroglobulinemia
1434186|NCT00255749|contiguous stage II adult Burkitt lymphoma
1434187|NCT00255749|contiguous stage II adult diffuse large cell lymphoma
1434188|NCT00255749|contiguous stage II adult diffuse mixed cell lymphoma
1434189|NCT00255749|contiguous stage II adult diffuse small cleaved cell lymphoma
1434190|NCT00255749|contiguous stage II adult immunoblastic large cell lymphoma
1434191|NCT00255749|contiguous stage II adult lymphoblastic lymphoma
1434192|NCT00255749|contiguous stage II grade 1 follicular lymphoma
1434193|NCT00255749|contiguous stage II grade 2 follicular lymphoma
1434194|NCT00255749|contiguous stage II grade 3 follicular lymphoma
1434195|NCT00255749|contiguous stage II mantle cell lymphoma
1434196|NCT00255749|contiguous stage II marginal zone lymphoma
1434197|NCT00255749|contiguous stage II small lymphocytic lymphoma
1434198|NCT00255749|noncontiguous stage II adult Burkitt lymphoma
1434199|NCT00255749|noncontiguous stage II adult diffuse large cell lymphoma
1434200|NCT00255749|noncontiguous stage II adult diffuse mixed cell lymphoma
1434201|NCT00255749|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1434202|NCT00255749|noncontiguous stage II adult immunoblastic large cell lymphoma
1434203|NCT00255749|noncontiguous stage II adult lymphoblastic lymphoma
1434204|NCT00255749|noncontiguous stage II grade 1 follicular lymphoma
1434205|NCT00255749|noncontiguous stage II grade 2 follicular lymphoma
1434206|NCT00255749|noncontiguous stage II grade 3 follicular lymphoma
1434207|NCT00255749|noncontiguous stage II mantle cell lymphoma
1434208|NCT00255749|noncontiguous stage II marginal zone lymphoma
1434209|NCT00255749|noncontiguous stage II small lymphocytic lymphoma
1434210|NCT00255749|post-transplant lymphoproliferative disorder
1434211|NCT00255749|stage I adult Burkitt lymphoma
1434212|NCT00255749|stage I adult diffuse large cell lymphoma
1434213|NCT00255749|stage I adult diffuse mixed cell lymphoma
1434214|NCT00255749|stage I adult diffuse small cleaved cell lymphoma
1434215|NCT00255749|stage I adult Hodgkin lymphoma
1434216|NCT00255749|stage I adult immunoblastic large cell lymphoma
1434217|NCT00255749|stage I adult lymphoblastic lymphoma
1434218|NCT00255749|stage I adult T-cell leukemia/lymphoma
1434219|NCT00255749|stage I cutaneous T-cell non-Hodgkin lymphoma
1434220|NCT00255749|stage I grade 1 follicular lymphoma
1434221|NCT00255749|stage I grade 2 follicular lymphoma
1434222|NCT00255749|stage I grade 3 follicular lymphoma
1434223|NCT00255749|stage I mantle cell lymphoma
1434224|NCT00255749|stage I marginal zone lymphoma
1434225|NCT00255749|stage I small lymphocytic lymphoma
1434226|NCT00255749|stage II adult Hodgkin lymphoma
1434227|NCT00255749|stage II adult T-cell leukemia/lymphoma
1434228|NCT00255749|stage II cutaneous T-cell non-Hodgkin lymphoma
1434229|NCT00255749|stage I mycosis fungoides/Sezary syndrome
1434230|NCT00255749|stage II mycosis fungoides/Sezary syndrome
1434231|NCT00255749|recurrent adult acute lymphoblastic leukemia
1434232|NCT00255749|refractory chronic lymphocytic leukemia
1434233|NCT00255749|stage I chronic lymphocytic leukemia
1434234|NCT00255749|stage II chronic lymphocytic leukemia
1434235|NCT00255749|stage III chronic lymphocytic leukemia
1434236|NCT00255749|stage IV chronic lymphocytic leukemia
1434237|NCT00255749|refractory hairy cell leukemia
1434238|NCT00255749|prolymphocytic leukemia
1434239|NCT00255749|unspecified adult solid tumor, protocol specific
1434240|NCT00255749|T-cell large granular lymphocyte leukemia
1434241|NCT00255723|adult lymphocyte depletion Hodgkin lymphoma
1434242|NCT00255723|adult mixed cellularity Hodgkin lymphoma
1434243|NCT00255723|adult nodular sclerosis Hodgkin lymphoma
1434244|NCT00255723|recurrent adult Hodgkin lymphoma
1434245|NCT00255710|graft versus host disease
1434246|NCT00255710|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1434247|NCT00255710|adult acute myeloid leukemia with inv(16)(p13;q22)
1434248|NCT00255710|adult acute myeloid leukemia with t(15;17)(q22;q12)
1434249|NCT00255710|adult acute myeloid leukemia with t(16;16)(p13;q22)
1434250|NCT00255710|adult acute myeloid leukemia with t(8;21)(q22;q22)
1434251|NCT00255710|adult acute lymphoblastic leukemia in remission
1434252|NCT00255710|adult acute myeloid leukemia in remission
1434253|NCT00255710|chronic idiopathic myelofibrosis
1434254|NCT00255710|chronic myelomonocytic leukemia
1434255|NCT00255710|chronic phase chronic myelogenous leukemia
1434256|NCT00255710|myelodysplastic/myeloproliferative disease, unclassifiable
1434257|NCT00255710|previously treated myelodysplastic syndromes
1434258|NCT00255710|recurrent adult Burkitt lymphoma
1434259|NCT00255710|recurrent adult diffuse large cell lymphoma
1434260|NCT00255710|recurrent adult diffuse mixed cell lymphoma
1434261|NCT00255710|recurrent adult immunoblastic large cell lymphoma
1434262|NCT00255710|recurrent adult lymphoblastic lymphoma
1434263|NCT00255710|recurrent grade 3 follicular lymphoma
1434264|NCT00255710|recurrent mantle cell lymphoma
1434265|NCT00255710|stage II multiple myeloma
1434266|NCT00255710|stage III adult Hodgkin lymphoma
1434267|NCT00255710|stage III chronic lymphocytic leukemia
1434268|NCT00255710|stage III grade 1 follicular lymphoma
1434269|NCT00255710|stage III grade 2 follicular lymphoma
1434270|NCT00255710|stage III multiple myeloma
1434271|NCT00255710|stage III small lymphocytic lymphoma
1434272|NCT00255710|stage IV adult Hodgkin lymphoma
1434273|NCT00255710|stage IV chronic lymphocytic leukemia
1434274|NCT00255710|stage IV grade 1 follicular lymphoma
1434275|NCT00255710|stage IV grade 2 follicular lymphoma
1434276|NCT00255710|stage IV small lymphocytic lymphoma
1434277|NCT00255710|stage II mycosis fungoides/Sezary syndrome
1434278|NCT00255710|stage III mycosis fungoides/Sezary syndrome
1434279|NCT00255710|stage IV mycosis fungoides/Sezary syndrome
1434280|NCT00255710|refractory anemia with excess blasts in transformation
1434281|NCT00255710|refractory anemia with excess blasts
1434282|NCT00255710|refractory cytopenia with multilineage dysplasia
1434283|NCT00255710|primary systemic amyloidosis
1434284|NCT00255710|de novo myelodysplastic syndromes
1434285|NCT00255710|secondary acute myeloid leukemia
1434286|NCT00255710|secondary myelodysplastic syndromes
1434287|NCT00255710|atypical chronic myeloid leukemia
1434288|NCT00255697|psychosocial effects of cancer and its treatment
1434289|NCT00255697|unspecified adult solid tumor, protocol specific
1434290|NCT00255684|graft versus host disease
1434291|NCT00255684|adult acute myeloid leukemia in remission
1434292|NCT00255684|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1434293|NCT00255684|adult acute myeloid leukemia with t(16;16)(p13;q22)
1434294|NCT00255684|adult acute myeloid leukemia with t(8;21)(q22;q22)
1434295|NCT00255684|recurrent adult acute myeloid leukemia
1434296|NCT00255684|childhood acute myeloid leukemia in remission
1434297|NCT00255684|recurrent childhood acute myeloid leukemia
1434298|NCT00255684|adult acute lymphoblastic leukemia in remission
1434299|NCT00255684|recurrent adult acute lymphoblastic leukemia
1434300|NCT00255684|childhood acute lymphoblastic leukemia in remission
1434301|NCT00255684|recurrent childhood acute lymphoblastic leukemia
1434302|NCT00255684|acute undifferentiated leukemia
1434303|NCT00255684|accelerated phase chronic myelogenous leukemia
1434304|NCT00255684|chronic phase chronic myelogenous leukemia
1434305|NCT00255684|childhood chronic myelogenous leukemia
1434306|NCT00255684|refractory anemia with excess blasts
1434307|NCT00255684|refractory anemia
1434308|NCT00255684|chronic myelomonocytic leukemia
1434309|NCT00255684|atypical chronic myeloid leukemia, BCR-ABL1 negative
1434310|NCT00255684|juvenile myelomonocytic leukemia
1434311|NCT00255684|primary myelofibrosis
1434312|NCT00255684|refractory hairy cell leukemia
1434313|NCT00255684|stage I multiple myeloma
1434314|NCT00255684|stage II multiple myeloma
1434315|NCT00255684|stage III multiple myeloma
1434316|NCT00255684|refractory multiple myeloma
1434317|NCT00255684|refractory chronic lymphocytic leukemia
1434318|NCT00255684|stage III adult Hodgkin lymphoma
1434319|NCT00255684|stage IV adult Hodgkin lymphoma
1434320|NCT00255684|recurrent/refractory childhood Hodgkin lymphoma
1434321|NCT00255684|stage III adult Burkitt lymphoma
1434322|NCT00255684|stage IV adult Burkitt lymphoma
1434323|NCT00255684|stage III adult diffuse large cell lymphoma
1434324|NCT00255684|stage III adult diffuse mixed cell lymphoma
1434325|NCT00255684|stage III adult diffuse small cleaved cell lymphoma
1434326|NCT00255684|stage IV adult diffuse large cell lymphoma
1434327|NCT00255684|stage IV adult diffuse mixed cell lymphoma
1434328|NCT00255684|stage IV adult diffuse small cleaved cell lymphoma
1434329|NCT00255684|stage III adult immunoblastic large cell lymphoma
1434330|NCT00255684|stage IV adult immunoblastic large cell lymphoma
1434331|NCT00255684|stage III adult lymphoblastic lymphoma
1434332|NCT00255684|stage IV adult lymphoblastic lymphoma
1434333|NCT00255684|stage III grade 1 follicular lymphoma
1434334|NCT00255684|stage III grade 2 follicular lymphoma
1434335|NCT00255684|stage III grade 3 follicular lymphoma
1434336|NCT00255684|stage IV grade 1 follicular lymphoma
1434337|NCT00255684|stage IV grade 2 follicular lymphoma
1434338|NCT00255684|stage IV grade 3 follicular lymphoma
1434339|NCT00255684|stage III mantle cell lymphoma
1434340|NCT00255684|stage III marginal zone lymphoma
1434341|NCT00255684|stage IV mantle cell lymphoma
1434342|NCT00255684|stage IV marginal zone lymphoma
1434343|NCT00255684|stage III small lymphocytic lymphoma
1434344|NCT00255684|stage IV small lymphocytic lymphoma
1434345|NCT00255684|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1434346|NCT00255684|nodal marginal zone B-cell lymphoma
1434347|NCT00255684|splenic marginal zone lymphoma
1434348|NCT00255684|adult acute myeloid leukemia with inv(16)(p13;q22)
1434349|NCT00255684|adult acute myeloid leukemia with t(15;17)(q22;q12)
1434350|NCT00255684|de novo myelodysplastic syndromes
1434351|NCT00255684|recurrent mycosis fungoides/Sezary syndrome
1434352|NCT00255684|recurrent cutaneous T-cell non-Hodgkin lymphoma
1434353|NCT00255684|recurrent childhood large cell lymphoma
1434354|NCT00255684|recurrent childhood lymphoblastic lymphoma
1434355|NCT00255684|recurrent childhood small noncleaved cell lymphoma
1434356|NCT00255684|recurrent adult diffuse large cell lymphoma
1434357|NCT00255684|recurrent adult diffuse mixed cell lymphoma
1434358|NCT00255684|recurrent adult diffuse small cleaved cell lymphoma
1434359|NCT00255684|recurrent grade 1 follicular lymphoma
1434360|NCT00255684|recurrent grade 2 follicular lymphoma
1434361|NCT00255684|recurrent grade 3 follicular lymphoma
1434362|NCT00255684|recurrent marginal zone lymphoma
1434363|NCT00255684|recurrent small lymphocytic lymphoma
1434364|NCT00255684|recurrent adult Burkitt lymphoma
1434365|NCT00255684|recurrent adult immunoblastic large cell lymphoma
1434366|NCT00255684|recurrent adult lymphoblastic lymphoma
1434367|NCT00255684|recurrent mantle cell lymphoma
1434368|NCT00255684|relapsing chronic myelogenous leukemia
1434369|NCT00255684|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1434370|NCT00255684|previously treated myelodysplastic syndromes
1434371|NCT00255684|recurrent adult Hodgkin lymphoma
1434372|NCT00255684|secondary acute myeloid leukemia
1434373|NCT00255684|secondary myelodysplastic syndromes
1434374|NCT00255684|noncontiguous stage II adult Burkitt lymphoma
1434375|NCT00255684|noncontiguous stage II adult diffuse large cell lymphoma
1434376|NCT00255684|noncontiguous stage II adult diffuse mixed cell lymphoma
1434377|NCT00255684|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1434378|NCT00255684|noncontiguous stage II adult immunoblastic large cell lymphoma
1434379|NCT00255684|noncontiguous stage II adult lymphoblastic lymphoma
1434380|NCT00255684|noncontiguous stage II grade 1 follicular lymphoma
1434381|NCT00255684|noncontiguous stage II grade 2 follicular lymphoma
1434382|NCT00255684|noncontiguous stage II grade 3 follicular lymphoma
1434383|NCT00255684|noncontiguous stage II mantle cell lymphoma
1434384|NCT00255684|noncontiguous stage II marginal zone lymphoma
1434385|NCT00255684|noncontiguous stage II small lymphocytic lymphoma
1434386|NCT00255684|childhood myelodysplastic syndromes
1434387|NCT00255671|radiation toxicity
1434388|NCT00255671|tumors metastatic to brain
1434389|NCT00255671|adult anaplastic astrocytoma
1434390|NCT00255671|adult anaplastic ependymoma
1434391|NCT00255671|adult anaplastic meningioma
1434392|NCT00255671|adult anaplastic oligodendroglioma
1434393|NCT00255671|adult brain stem glioma
1434394|NCT00255671|adult central nervous system germ cell tumor
1434395|NCT00255671|adult choroid plexus tumor
1434396|NCT00255671|adult craniopharyngioma
1434397|NCT00255671|adult diffuse astrocytoma
1434398|NCT00255671|adult ependymoblastoma
1434399|NCT00255671|adult ependymoma
1434400|NCT00255671|adult giant cell glioblastoma
1434401|NCT00255671|adult gliosarcoma
1434402|NCT00255671|adult medulloblastoma
1434403|NCT00255671|adult melanocytic lesion
1434404|NCT00255671|adult meningeal hemangiopericytoma
1434405|NCT00255671|adult meningioma
1434406|NCT00255671|adult myxopapillary ependymoma
1434407|NCT00255671|adult oligodendroglioma
1434408|NCT00255671|adult papillary meningioma
1434409|NCT00255671|adult pineoblastoma
1434410|NCT00255671|adult pineocytoma
1434411|NCT00255671|adult subependymoma
1434412|NCT00255671|adult supratentorial primitive neuroectodermal tumor (PNET)
1434413|NCT00255671|adult grade I meningioma
1434414|NCT00255671|adult grade II meningioma
1434415|NCT00255671|adult grade III meningioma
1434416|NCT00255671|adult mixed glioma
1434417|NCT00255671|recurrent adult brain tumor
1434418|NCT00255671|adult pilocytic astrocytoma
1434419|NCT00255671|adult glioblastoma
1434420|NCT00255671|ACTH-producing pituitary tumor
1434421|NCT00255671|growth hormone-producing pituitary tumor
1434422|NCT00255671|nonfunctioning pituitary tumor
1434423|NCT00255671|prolactin-producing pituitary tumor
1434424|NCT00255671|recurrent pituitary tumor
1434425|NCT00255671|TSH producing pituitary tumor
1434426|NCT00255619|Continuous ambulatory peritoneal dialysis (CAPD)
1434427|NCT00255619|Peritonitis
1434428|NCT00255619|ANDY-disc® (Fresenius Medical care)
1434429|NCT00255619|Ultra® (Baxter)
1434430|NCT00255619|Twin bag System
1434431|NCT00255606|adenocarcinoma of the prostate
1434432|NCT00255606|stage IV prostate cancer
1434433|NCT00255606|recurrent prostate cancer
1434434|NCT00255593|Kidney
1434435|NCT00255593|Transplantation
1434436|NCT00255593|Immunosuppression
1434437|NCT00255593|Rituximab
1434438|NCT00255580|neuropathy
1434439|NCT00255580|cannabis
1434440|NCT00255580|marijuana
1434441|NCT00255580|HIV
1434442|NCT00255580|DSPN
1434443|NCT00255567|Visceral Leishmaniasis
1434444|NCT00255567|Combination
1434445|NCT00255554|Borderline Personality Disorder
1434446|NCT00255554|BPD
1434447|NCT00255554|Dialectical Behavior Therapy
1434448|NCT00255554|DBT
1434449|NCT00255554|Escitalopram
1434450|NCT00255554|Lexapro
1434451|NCT00255528|Pediatric hypertension
1434452|NCT00255502|Pediatric hypertension
1434453|NCT00255450|anemia
1434454|NCT00255411|Conversion Disorder
1434455|NCT00255411|Somatoform Disorder
1434456|NCT00255411|Involuntary Movement
1434457|NCT00255411|Childhood Abuse
1434458|NCT00255411|Depression
1434459|NCT00255411|Psychogenic Movement Disorder
1434460|NCT00255411|PMD
1434461|NCT00255411|Non-Epileptic Seizure
1434462|NCT00255411|NES
1434463|NCT00255411|Healthy Volunteer
1434464|NCT00255411|HV
1434465|NCT00255398|Focal Segmental Glomerulosclerosis
1434466|NCT00255398|Minimal Change Disease
1434467|NCT00255398|Diabetic Nephropathy
1434468|NCT00255398|Mass Spectrometry
1434469|NCT00255398|Proteinuria
1434470|NCT00255398|Idiopathic Nephrotic Syndrome
1434471|NCT00255398|Glomerular Disease
1434472|NCT00255398|FSG
1434474|NCT00255385|Zinc
1434475|NCT00255385|Iron
1434476|NCT00255385|Probiotics
1434477|NCT00255385|Prebiotics
1434478|NCT00255385|Child health
1434479|NCT00255385|Milk fortification
1434480|NCT00255385|Randomized controlled trial
1434481|NCT00255346|targeted therapy
1434482|NCT00255346|leukemia
1434483|NCT00255346|Acute myeloid leukemia (AML)
1434484|NCT00255346|Myelodysplastic syndrome (MDS)
1434485|NCT00255346|Agnogenic myeloid metaplasia - myelofibrosis (MMM)
1434486|NCT00255346|Hypereosinophilic syndrome (HES)
1434487|NCT00255346|Polycythemia vera (PV)
1434488|NCT00255346|Mastocytosis
1434489|NCT00255346|CMML
1434490|NCT00255320|healthy volunteers, headache, migraine, hemodynamics, VIP, SPECT, ultrasound
1434491|NCT00255307|cold
1434492|NCT00255307|flu
1434493|NCT00255307|respiratory tract infection
1434494|NCT00255255|Asthma
1434495|NCT00255242|Cystic Fibrosis
1434496|NCT00255242|Airway Inflammation
1434497|NCT00255242|Cytokines
1434498|NCT00255242|Simvastatin
1434499|NCT00255242|HMG-CoA reductase inhibitors
1434500|NCT00255242|Rho GTP-ase
1434501|NCT00255229|irinotecan
1434502|NCT00255229|5FU
1434503|NCT00255229|amino acids
1434504|NCT00255229|heat shock protein
1434505|NCT00255190|Gastroesophageal Reflux Disease
1434506|NCT00255177|Hepatitis C
1434507|NCT00255164|Erosive Esophagitis
1434508|NCT00255151|Erosive Esophagitis
1434509|NCT00255138|Cancer
1434510|NCT00255138|Cognitive Late Effects
1434511|NCT00255138|Stimulants
1434512|NCT00255138|Atomoxetine
1434513|NCT00255138|Attention
1434514|NCT00255138|Children
1434515|NCT00255125|Estrogen Receptor
1434516|NCT00255125|Isoflavones
1434517|NCT00255125|Prostate Neoplasm
1434518|NCT00255125|Soy Supplementation
1434519|NCT00255112|SAD
1434520|NCT00255112|treatment
1434521|NCT00255112|cognitive behavior therapy
1434522|NCT00255112|family
1434523|NCT00255112|children
1434524|NCT00255112|anxiety
1434525|NCT00255099|HIV
1434526|NCT00255099|HIV-1
1434527|NCT00255099|TMC125
1434528|NCT00255047|Pertussis
1434529|NCT00255047|Whooping cough
1434530|NCT00255047|Filamentous Haemagglutinin
1434531|NCT00255047|Fimbriae Types 2 and 3;
1434532|NCT00255047|Pertactin
1434533|NCT00255047|Diphtheria
1434534|NCT00255047|Tetanus
1434535|NCT00255047|Poliovirus Types 1, 2, and 3.
1434536|NCT00255034|chronic hepatitis C
1434537|NCT00255034|pegylated interferon alfa-2b
1434538|NCT00255034|ribavirin
1434539|NCT00255034|Australia
1434540|NCT00255021|Diphteria
1434541|NCT00255021|Tetanus
1434542|NCT00255021|Pertussis
1434543|NCT00255021|Poliomyelitis
1434544|NCT00255021|Haemophilus influenzae type b
1434545|NCT00255021|acellular
1434546|NCT00255008|chronic hepatitis C
1434547|NCT00255008|pegylated interferon alfa-2b
1434548|NCT00255008|ribavirin
1434549|NCT00255008|Asia
1434550|NCT00254995|Meningitis
1434551|NCT00254995|Meningococcal disease
1434552|NCT00254995|Menactra vaccine
1434553|NCT00254969|Diphteria
1434554|NCT00254969|tetanus
1434555|NCT00254969|haemophilus influenzae type b
1434556|NCT00254969|poliomyelitis
1434557|NCT00254969|pertussis
1434558|NCT00254956|Diseases
1434559|NCT00254956|respiratory tract diseases
1434560|NCT00254956|respiratory hypersensitivity
1434561|NCT00254956|asthma
1434562|NCT00254930|learning disorder
1434563|NCT00254930|children
1434564|NCT00254930|behaviour disorder
1434565|NCT00254930|risperidone
1434566|NCT00254917|Pentaxim
1434567|NCT00254904|advanced carcinoma, non-small cell lung, Phase III, Gemcitabine, Gemzar, Cisplatin, Platinol, PF-3512676, immunotherapy, immune modulator
1434568|NCT00254891|advanced carcinoma, non-small cell lung, Phase III, Paclitaxel, Taxol, Carboplatin, Paraplatin, PF-3512676, immunotherapy, immune modulator
1434569|NCT00254878|ADHD, Methylphenidate hydrochloride, modified-release
1434570|NCT00254865|Transdermal contraception
1434571|NCT00254865|contraceptive
1434572|NCT00254865|hormonal, steroid contraception
1434573|NCT00254865|ethinyl estradiol
1434574|NCT00254865|progesterone
1434575|NCT00254865|EVRA
1434576|NCT00254865|CILEST
1434577|NCT00254852|Primary lumbar fusion
1434578|NCT00254852|Demineralized Bone Matrix
1434579|NCT00254852|DBM
1434580|NCT00254852|Optecure
1434581|NCT00254852|Allograft
1434582|NCT00254852|Autograft
1434583|NCT00254852|Lumbar fusion
1434584|NCT00254852|Interbody fusion
1434585|NCT00254852|Instrumented fusion
1434586|NCT00254852|Non-instrumented fusion
1434587|NCT00254852|Exactech
1434588|NCT00254852|Spinal fusion
1434589|NCT00253864|shoulder surgery
1434590|NCT00253864|prospective database
1434591|NCT00253864|long term outcome
1434592|NCT00254839|Oral malodor
1434593|NCT00254839|Dental implants
1434594|NCT00254826|Yellow Fever Virus Vaccination
1434595|NCT00254813|Schizophrenia
1434596|NCT00254813|Schizoaffective disorder
1434597|NCT00254800|diabetes
1434598|NCT00254800|exenatide
1434599|NCT00254800|Amylin
1434600|NCT00254800|Lilly
1434601|NCT00254787|Schizophrenia
1434602|NCT00254774|Bipolar Disorder I or II with Rapid Cycling
1434603|NCT00254761|cannabis
1434604|NCT00254761|marijuana
1434605|NCT00254761|neuropathy
1434606|NCT00254761|antinociception
1434607|NCT00254761|mood
1434608|NCT00254761|cognition
1434609|NCT00254748|Borderline personality disorder
1434610|NCT00254735|Obsessive Compulsive Disorder (OCD)
1434611|NCT00254722|Traumatic Brain Injury
1434612|NCT00254722|Stem Cell
1434613|NCT00254709|kidney transplant
1434614|NCT00254709|elderly
1434615|NCT00254696|bacterial infection
1434616|NCT00254683|Rectal Cancer
1434617|NCT00254683|Positron Emission Tomography
1434618|NCT00254683|Fluorodeoxyglucose F18
1434619|NCT00254683|Computed Tomography
1434620|NCT00254683|Neoadjuvant Therapy
1434621|NCT00254683|Chemotherapy
1434622|NCT00254683|Radiotherapy
1434623|NCT00254670|Alcohol
1434624|NCT00254670|Naltrexone
1434625|NCT00254657|Fibromyalgia
1434626|NCT00254657|Fibro
1434627|NCT00254657|Keppra
1434628|NCT00254657|Levetiracetam
1434629|NCT00254644|phonological treatment
1434630|NCT00254644|language
1434631|NCT00254644|fMRI
1434632|NCT00254631|long bone fracture
1434633|NCT00254631|open fractures
1434634|NCT00254631|closed fractures
1434635|NCT00254631|trauma
1434636|NCT00254618|ulcerative colitis; pharmacokinetics; pediatrics
1434637|NCT00254605|imaging
1434638|NCT00254605|adaptive optics scanning laser ophthalmoscope
1434639|NCT00254605|optical coherence tomography
1434640|NCT00254605|electroretinography
1434641|NCT00254592|Inflammatory
1434642|NCT00254592|Breast Cancer
1434643|NCT00254592|Female
1434644|NCT00254592|Neo-adjuvant
1434645|NCT00254592|HER-2 positive
1434646|NCT00254592|Hormone receptor
1434647|NCT00254579|refractory melanoma
1434648|NCT00254579|malignant melanoma
1434649|NCT00254566|Azithromycin SR; Moxifloxacin; Acute exacerbation of chronic bronchitis (AECB)
1434650|NCT00254540|Ph2, RCC, SU011248, SUNITINIB
1434651|NCT00254527|Methicillin Resistant Staphylococcus aureus
1434652|NCT00254527|Children
1434653|NCT00254527|Colonization
1434654|NCT00254527|Risk Factor
1434655|NCT00254501|diabetes
1434656|NCT00254475|Valsartan
1434657|NCT00254475|simvastatin
1434658|NCT00254475|hypertension
1434659|NCT00254475|hypercholesterolemia
1434660|NCT00254475|angiotensin II receptor blocker
1434661|NCT00254462|ADHD
1434662|NCT00254462|Atomoxetine
1434663|NCT00254436|Epoetin Alfa
1434664|NCT00254436|Epogen
1434665|NCT00254436|Erythropoietin
1434666|NCT00254423|Chronic Myelogenous Leukemia
1434667|NCT00254423|CML
1434668|NCT00254423|Dasatinib
1434669|NCT00254423|BMS-354825
1434670|NCT00254410|Chronic Lymphocytic Leukemia
1434671|NCT00254410|Untreated
1434672|NCT00254410|Fludarabine
1434673|NCT00254410|Fludara
1434674|NCT00254410|Cyclophosphamide
1434675|NCT00254410|Cytoxan
1434676|NCT00254410|Mitoxantrone
1434677|NCT00254410|Novantrone
1434678|NCT00254410|Rituximab
1434679|NCT00254410|Rituxan
1434680|NCT00254410|Pegylated Filgrastim
1434681|NCT00254410|Neupogen
1434682|NCT00254397|Melanoma
1434683|NCT00254397|Uveal Melanoma
1434684|NCT00254397|Peptide Vaccine
1434685|NCT00254397|LHRH-agonist
1434686|NCT00254397|Leuprolide
1434687|NCT00254397|Lupron
1434688|NCT00254397|MAGE-3 Peptide
1434689|NCT00254397|MAGE-3
1434690|NCT00254397|GP100 Peptide
1434691|NCT00254397|Melanoma vaccines
1434692|NCT00254397|Tumor fighting immune cells
1434693|NCT00254397|T cells
1434694|NCT00254397|Skin Cancer
1434695|NCT00254397|Eye Cancer
1434696|NCT00254384|Non-Small Cell Lung Cancer
1434697|NCT00254384|Lung Cancer
1434698|NCT00254384|Cisplatin
1434699|NCT00254384|Platinol
1434700|NCT00254384|Platinol-AQ
1434701|NCT00254384|CDDP
1434702|NCT00254384|Docetaxel
1434703|NCT00254384|Taxotere
1434704|NCT00254384|Erlotinib
1434705|NCT00254384|Tarceva
1434706|NCT00254384|OSI-774
1434707|NCT00254384|NSCLC
1434708|NCT00254358|Nicotine
1434709|NCT00254358|Dopamine
1434710|NCT00254358|IBZM
1434711|NCT00254345|biofilm
1434712|NCT00254345|adhesion
1434713|NCT00254345|liquid polish
1434714|NCT00254345|bonding resin
1434715|NCT00254345|PMMA Polymethylmetacrylate
1434716|NCT00254345|provisional crown
1434717|NCT00254345|no antibiotics treatment three months prior to experiment
1434718|NCT00254345|no mouth rinse with oral solutions one month prior to experiment
1434719|NCT00254332|Cutaneous T-cell Lymphoma
1434720|NCT00254332|Sezary Syndrome
1434721|NCT00254332|Mycosis Fungoides
1434722|NCT00254332|Denileukin Diftitox
1434723|NCT00254306|Ecstasy
1434724|NCT00254306|D2 Dopamine Receptor
1434725|NCT00254306|IBZM
1434726|NCT00254306|MDMA
1434727|NCT00254280|Warts
1434728|NCT00254280|Intense pulsed light
1434729|NCT00254280|RCT
1434730|NCT00254280|Recalcitrant hand and foot warts
1434731|NCT00254267|Gastrointestinal Stromal Tumor, Imatinib Mesylate Resistance, Phase2 study, AMG 706
1434732|NCT00254254|diabetes
1434733|NCT00254254|adolescents
1434734|NCT00254254|exenatide
1434735|NCT00254254|Amylin
1434736|NCT00254254|Lilly
1434737|NCT00254241|Schizophrenia
1434738|NCT00254228|Balance
1434739|NCT00254228|Vestibular
1434740|NCT00254228|Electrotactile
1434741|NCT00254228|BrainPort
1434742|NCT00254228|Sensory substitution
1434743|NCT00254228|Tongue
1434744|NCT00254215|overweight
1434745|NCT00254215|obesity
1434746|NCT00254215|glycemic index
1434747|NCT00254215|glycemic load
1434748|NCT00254215|high protein diet
1434749|NCT00254215|blood cholesterol
1434750|NCT00254202|Schizophrenia
1434751|NCT00254202|Atypical antipsychotic
1434752|NCT00254202|psychosis
1434753|NCT00254189|Ovulation
1434754|NCT00254189|Oral Contraceptive
1434755|NCT00254176|Neonate
1434756|NCT00254176|Glutathione
1434757|NCT00254176|Cysteine
1434758|NCT00254176|Sepsis
1434759|NCT00254176|Stable Isotope
1434760|NCT00254137|capecitabine
1434761|NCT00254137|irinotecan
1434762|NCT00254137|cetuximab
1434763|NCT00254137|oxaliplatin
1434764|NCT00254137|colorectal cancer
1434765|NCT00254124|obesity
1434766|NCT00254124|type 2 diabetes mellitus
1434767|NCT00254124|portion control
1434768|NCT00254111|osteoarthritis
1434769|NCT00254111|hand
1434770|NCT00254111|laser
1434771|NCT00254111|device
1434772|NCT00254111|hand pain
1434773|NCT00254111|stiffness
1434774|NCT00254085|Type 2 diabtes
1434775|NCT00254085|Postprandial hyperglycemia
1434776|NCT00254085|Insulin treatment
1434777|NCT00254072|Morbid Obesity
1434778|NCT00254072|Laparoscopic Gastric Bypass
1434779|NCT00254072|Staple Line Hemorrhage
1434780|NCT00254059|OSAHS, OSA, CPAP, polysomnography, overnight oximetry, Obstructive sleep apnea, apnea hypopnea index, AHI, Obstructive Sleep Apnea Hypopnea Syndrome
1434781|NCT00254046|HIV
1434782|NCT00254046|HIV-1
1434783|NCT00254046|TMC125
1434784|NCT00254033|Alzheimer's Disease
1434785|NCT00254033|Apathy
1434786|NCT00254033|Brain Reward System
1434787|NCT00254033|Dopamine
1434788|NCT00254033|Dextroamphetamine Challenge
1434789|NCT00254033|Methylphenidate
1434790|NCT00254020|stroke
1434791|NCT00254020|depression
1434792|NCT00254020|cytokines
1434793|NCT00254020|serotonin
1434794|NCT00254020|citalopram
1434795|NCT00254007|depression
1434796|NCT00254007|traumatic brain injury
1434797|NCT00254007|serotonin transporter
1434798|NCT00254007|genetic polymorphisms
1434799|NCT00254007|citalopram
1434800|NCT00253981|Pain, Intractable
1434801|NCT00253981|Infrared Rays
1434802|NCT00253981|Leg
1434803|NCT00253968|Primary Insomnia
1434804|NCT00253968|Sleeplessness
1434805|NCT00253968|Early Awakening
1434806|NCT00253968|Chronic Insomnia
1434807|NCT00253929|adenosine
1434808|NCT00253929|polymorphisms
1434809|NCT00253929|blood flow
1434810|NCT00253929|adenosine A2a receptor
1434811|NCT00253929|AMP deaminase
1434812|NCT00253903|Primary Insomnia
1434813|NCT00253903|Sleeplessness
1434814|NCT00253903|Early Awakening
1434815|NCT00253903|Chronic Insomnia
1434816|NCT00253890|sleep quality
1434817|NCT00253890|methadone
1434818|NCT00253890|substance use
1434819|NCT00253877|osteoarthritis
1434820|NCT00253877|hip resurfacing
1434821|NCT00253851|DVT
1434822|NCT00253851|Osteoarthritis
1434823|NCT00253851|Total Knee Arthroplasty
1434824|NCT00253838|revision hip arthroplasty
1434825|NCT00253838|bone mineral density
1434826|NCT00253812|colonoscopy, sigmoidoscopy, chromoendoscopy, autofluorescence, narrow band imaging, colorectal cancer, polyp, adenoma,rectal remnant, FAP
1434827|NCT00253786|diabetes
1434828|NCT00253786|nephropathy
1434829|NCT00253773|sulfer amino acids
1434830|NCT00253773|redox status
1434831|NCT00253760|redox
1434832|NCT00253760|sulfur amino acids
1434833|NCT00253760|glutathione
1434834|NCT00253760|aging
1434835|NCT00253734|Influenza
1434836|NCT00253721|adult anaplastic astrocytoma
1434837|NCT00253721|adult brain stem glioma
1434838|NCT00253721|adult diffuse astrocytoma
1434839|NCT00253721|adult central nervous system germ cell tumor
1434840|NCT00253721|adult medulloblastoma
1434841|NCT00253721|adult supratentorial primitive neuroectodermal tumor (PNET)
1434842|NCT00253721|adult anaplastic oligodendroglioma
1434843|NCT00253721|adult oligodendroglioma
1434844|NCT00253721|adult pineoblastoma
1434845|NCT00253721|tumors metastatic to brain
1434846|NCT00253721|adult mixed glioma
1434847|NCT00253721|recurrent adult brain tumor
1434848|NCT00253721|primary central nervous system non-Hodgkin lymphoma
1434849|NCT00253708|depression
1434850|NCT00253708|nausea and vomiting
1434851|NCT00253708|pain
1434852|NCT00253708|psychosocial effects of cancer and its treatment
1434853|NCT00253708|stage IIIA non-small cell lung cancer
1434854|NCT00253708|stage IIIB non-small cell lung cancer
1434855|NCT00253708|stage IV non-small cell lung cancer
1434856|NCT00253708|extensive stage small cell lung cancer
1434857|NCT00253708|stage III gastric cancer
1434858|NCT00253708|stage III esophageal cancer
1434859|NCT00253708|localized unresectable adult primary liver cancer
1434860|NCT00253708|stage III colon cancer
1434861|NCT00253708|stage IV renal cell cancer
1434862|NCT00253708|stage IV bladder cancer
1434863|NCT00253708|stage IV prostate cancer
1434864|NCT00253708|stage IV breast cancer
1434865|NCT00253708|stage IV ovarian epithelial cancer
1434866|NCT00253708|advanced adult primary liver cancer
1434867|NCT00253708|stage IV melanoma
1434868|NCT00253708|stage IV ovarian germ cell tumor
1434869|NCT00253708|ovarian sarcoma
1434870|NCT00253708|ovarian stromal cancer
1434871|NCT00253708|recurrent small cell lung cancer
1434872|NCT00253708|recurrent adult primary liver cancer
1434873|NCT00253708|recurrent colon cancer
1434874|NCT00253708|recurrent esophageal cancer
1434875|NCT00253708|recurrent gastric cancer
1434876|NCT00253708|recurrent non-small cell lung cancer
1434877|NCT00253708|recurrent bladder cancer
1434878|NCT00253708|recurrent breast cancer
1434879|NCT00253708|recurrent ovarian epithelial cancer
1434880|NCT00253708|recurrent ovarian germ cell tumor
1434881|NCT00253708|recurrent prostate cancer
1434882|NCT00253708|recurrent renal cell cancer
1434883|NCT00253708|recurrent melanoma
1434884|NCT00253669|thromboembolism
1434885|NCT00253669|adult anaplastic astrocytoma
1434886|NCT00253669|adult anaplastic oligodendroglioma
1434887|NCT00253669|adult glioblastoma
1434888|NCT00253669|adult giant cell glioblastoma
1434889|NCT00253669|adult gliosarcoma
1434890|NCT00253643|prostate cancer
1434891|NCT00253643|precancerous condition
1434892|NCT00253591|stage I non-small cell lung cancer
1434893|NCT00253591|stage II non-small cell lung cancer
1434894|NCT00253591|stage IIIA non-small cell lung cancer
1434895|NCT00253591|stage IIIB non-small cell lung cancer
1434896|NCT00253565|unspecified adult solid tumor, protocol specific
1434897|NCT00253552|graft versus host disease
1434898|NCT00253552|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1434899|NCT00253552|adult acute myeloid leukemia with inv(16)(p13;q22)
1434900|NCT00253552|adult acute myeloid leukemia with t(15;17)(q22;q12)
1434901|NCT00253552|adult acute myeloid leukemia with t(16;16)(p13;q22)
1434902|NCT00253552|adult acute myeloid leukemia with t(8;21)(q22;q22)
1434903|NCT00253552|accelerated phase chronic myelogenous leukemia
1434904|NCT00253552|adult acute lymphoblastic leukemia in remission
1434905|NCT00253552|adult acute myeloid leukemia in remission
1434906|NCT00253552|atypical chronic myeloid leukemia
1434907|NCT00253552|blastic phase chronic myelogenous leukemia
1434908|NCT00253552|childhood acute lymphoblastic leukemia in remission
1434909|NCT00253552|childhood acute myeloid leukemia in remission
1434910|NCT00253552|childhood chronic myelogenous leukemia
1434911|NCT00253552|chronic eosinophilic leukemia
1434912|NCT00253552|chronic idiopathic myelofibrosis
1434913|NCT00253552|chronic myelomonocytic leukemia
1434914|NCT00253552|chronic neutrophilic leukemia
1434915|NCT00253552|chronic phase chronic myelogenous leukemia
1434916|NCT00253552|de novo myelodysplastic syndromes
1434917|NCT00253552|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1434918|NCT00253552|juvenile myelomonocytic leukemia
1434919|NCT00253552|myelodysplastic/myeloproliferative disease, unclassifiable
1434920|NCT00253552|nodal marginal zone B-cell lymphoma
1434921|NCT00253552|noncontiguous stage II adult Burkitt lymphoma
1434922|NCT00253552|noncontiguous stage II adult diffuse large cell lymphoma
1434923|NCT00253552|noncontiguous stage II adult diffuse mixed cell lymphoma
1434924|NCT00253552|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1434925|NCT00253552|noncontiguous stage II adult immunoblastic large cell lymphoma
1434926|NCT00253552|noncontiguous stage II adult lymphoblastic lymphoma
1434927|NCT00253552|noncontiguous stage II grade 1 follicular lymphoma
1434928|NCT00253552|noncontiguous stage II grade 2 follicular lymphoma
1434929|NCT00253552|noncontiguous stage II grade 3 follicular lymphoma
1434930|NCT00253552|noncontiguous stage II mantle cell lymphoma
1434931|NCT00253552|noncontiguous stage II marginal zone lymphoma
1434932|NCT00253552|noncontiguous stage II small lymphocytic lymphoma
1434933|NCT00253552|previously treated myelodysplastic syndromes
1434934|NCT00253552|recurrent adult acute lymphoblastic leukemia
1434935|NCT00253552|recurrent adult acute myeloid leukemia
1434936|NCT00253552|recurrent adult Burkitt lymphoma
1434937|NCT00253552|recurrent adult Hodgkin lymphoma
1434938|NCT00253552|recurrent adult diffuse large cell lymphoma
1434939|NCT00253552|recurrent adult diffuse mixed cell lymphoma
1434940|NCT00253552|recurrent adult diffuse small cleaved cell lymphoma
1434941|NCT00253552|recurrent adult immunoblastic large cell lymphoma
1434942|NCT00253552|recurrent adult lymphoblastic lymphoma
1434943|NCT00253552|recurrent/refractory childhood Hodgkin lymphoma
1435160|NCT00253162|manic episode
1434944|NCT00253552|recurrent childhood acute lymphoblastic leukemia
1434945|NCT00253552|recurrent childhood acute myeloid leukemia
1434946|NCT00253552|recurrent childhood large cell lymphoma
1434947|NCT00253552|recurrent childhood lymphoblastic lymphoma
1434948|NCT00253552|recurrent childhood rhabdomyosarcoma
1434949|NCT00253552|recurrent childhood small noncleaved cell lymphoma
1434950|NCT00253552|recurrent cutaneous T-cell non-Hodgkin lymphoma
1434951|NCT00253552|recurrent grade 1 follicular lymphoma
1434952|NCT00253552|recurrent grade 2 follicular lymphoma
1434953|NCT00253552|recurrent grade 3 follicular lymphoma
1434954|NCT00253552|recurrent mantle cell lymphoma
1434955|NCT00253552|recurrent marginal zone lymphoma
1434956|NCT00253552|recurrent mycosis fungoides/Sezary syndrome
1434957|NCT00253552|recurrent small lymphocytic lymphoma
1434958|NCT00253552|refractory chronic lymphocytic leukemia
1434959|NCT00253552|refractory hairy cell leukemia
1434960|NCT00253552|refractory multiple myeloma
1434961|NCT00253552|relapsing chronic myelogenous leukemia
1434962|NCT00253552|secondary acute myeloid leukemia
1434963|NCT00253552|secondary myelodysplastic syndromes
1434964|NCT00253552|splenic marginal zone lymphoma
1434965|NCT00253552|stage I multiple myeloma
1434966|NCT00253552|stage II multiple myeloma
1434967|NCT00253552|stage III adult Burkitt lymphoma
1434968|NCT00253552|stage III adult Hodgkin lymphoma
1434969|NCT00253552|stage III adult diffuse large cell lymphoma
1434970|NCT00253552|stage III adult diffuse mixed cell lymphoma
1434971|NCT00253552|stage III adult diffuse small cleaved cell lymphoma
1434972|NCT00253552|stage III adult immunoblastic large cell lymphoma
1434973|NCT00253552|stage III adult lymphoblastic lymphoma
1434974|NCT00253552|stage III chronic lymphocytic leukemia
1434975|NCT00253552|stage III grade 1 follicular lymphoma
1434976|NCT00253552|stage III grade 2 follicular lymphoma
1434977|NCT00253552|stage III grade 3 follicular lymphoma
1434978|NCT00253552|stage III mantle cell lymphoma
1434979|NCT00253552|stage III marginal zone lymphoma
1434980|NCT00253552|stage III multiple myeloma
1434981|NCT00253552|stage III small lymphocytic lymphoma
1434982|NCT00253552|stage IV adult Burkitt lymphoma
1434983|NCT00253552|stage IV adult Hodgkin lymphoma
1434984|NCT00253552|stage IV adult diffuse large cell lymphoma
1434985|NCT00253552|stage IV adult diffuse mixed cell lymphoma
1434986|NCT00253552|stage IV adult diffuse small cleaved cell lymphoma
1434987|NCT00253552|stage IV adult immunoblastic large cell lymphoma
1434988|NCT00253552|stage IV adult lymphoblastic lymphoma
1434989|NCT00253552|stage IV chronic lymphocytic leukemia
1434990|NCT00253552|stage IV grade 1 follicular lymphoma
1434991|NCT00253552|stage IV grade 2 follicular lymphoma
1434992|NCT00253552|stage IV grade 3 follicular lymphoma
1434993|NCT00253552|stage IV mantle cell lymphoma
1434994|NCT00253552|stage IV marginal zone lymphoma
1434995|NCT00253552|stage IV small lymphocytic lymphoma
1434996|NCT00253552|childhood myelodysplastic syndromes
1434997|NCT00253539|hereditary breast/ovarian cancer (BRCA1, BRCA2)
1434998|NCT00253539|breast cancer
1434999|NCT00253513|adult acute lymphoblastic leukemia in remission
1435000|NCT00253513|adult acute myeloid leukemia in remission
1435001|NCT00253513|childhood acute lymphoblastic leukemia in remission
1435002|NCT00253513|recurrent adult acute lymphoblastic leukemia
1435003|NCT00253513|recurrent adult acute myeloid leukemia
1435004|NCT00253513|recurrent childhood acute lymphoblastic leukemia
1435005|NCT00253513|recurrent childhood acute myeloid leukemia
1435006|NCT00253513|secondary acute myeloid leukemia
1435007|NCT00253513|myelodysplastic syndromes
1435008|NCT00253513|childhood myelodysplastic syndromes
1435009|NCT00253500|stage II breast cancer
1435010|NCT00253500|stage I breast cancer
1435011|NCT00253500|stage IIIA breast cancer
1435012|NCT00253500|stage IIIB breast cancer
1435013|NCT00253487|adult glioblastoma
1435014|NCT00253487|adult anaplastic astrocytoma
1435015|NCT00253487|childhood high-grade cerebral astrocytoma
1435016|NCT00253487|adult giant cell glioblastoma
1435017|NCT00253487|adult gliosarcoma
1435018|NCT00253474|neoplasm of uncertain malignant potential
1435019|NCT00253474|unspecified childhood solid tumor, protocol specific
1435020|NCT00253461|stage IV ovarian epithelial cancer
1435021|NCT00253461|stage IV ovarian germ cell tumor
1435022|NCT00253461|extensive stage small cell lung cancer
1435023|NCT00253461|recurrent small cell lung cancer
1435024|NCT00253461|unspecified adult solid tumor, protocol specific
1435025|NCT00253461|recurrent ovarian epithelial cancer
1435026|NCT00253461|recurrent ovarian germ cell tumor
1435027|NCT00253461|tumors metastatic to brain
1435028|NCT00253448|adult glioblastoma
1435029|NCT00253448|adult giant cell glioblastoma
1435030|NCT00253448|adult gliosarcoma
1435031|NCT00253435|recurrent neuroblastoma
1435032|NCT00253422|recurrent breast cancer
1435033|NCT00253422|stage IV breast cancer
1435034|NCT00253422|stage IIIB breast cancer
1435035|NCT00253422|stage IIIC breast cancer
1435036|NCT00253409|localized malignant mesothelioma
1435037|NCT00253396|warfarin
1435038|NCT00253396|clinical trial
1435039|NCT00253396|pain measurement
1435040|NCT00253396|heparin
1435041|NCT00253396|heparin, low-molecular-weight
1435042|NCT00253396|Anticoagulants
1435043|NCT00253383|transitional care planning
1435044|NCT00253383|stage IIIB non-small cell lung cancer
1435045|NCT00253383|stage IV non-small cell lung cancer
1435046|NCT00253383|extensive stage small cell lung cancer
1435047|NCT00253383|stage IV breast cancer
1435048|NCT00253383|recurrent breast cancer
1435049|NCT00253383|male breast cancer
1435050|NCT00253383|stage IIIB anal cancer
1435051|NCT00253383|stage IV anal cancer
1435052|NCT00253383|carcinoma of the appendix
1435053|NCT00253383|stage III colon cancer
1435054|NCT00253383|stage IV colon cancer
1435055|NCT00253383|stage III rectal cancer
1435056|NCT00253383|stage IV rectal cancer
1435057|NCT00253383|stage III esophageal cancer
1435058|NCT00253383|stage IV esophageal cancer
1435059|NCT00253383|unresectable extrahepatic bile duct cancer
1435060|NCT00253383|unresectable gallbladder cancer
1435061|NCT00253383|stage III gastric cancer
1435062|NCT00253383|stage IV gastric cancer
1435063|NCT00253383|metastatic gastrointestinal carcinoid tumor
1435064|NCT00253383|regional gastrointestinal carcinoid tumor
1435065|NCT00253383|gastrointestinal stromal tumor
1435066|NCT00253383|advanced adult primary liver cancer
1435067|NCT00253383|localized unresectable adult primary liver cancer
1435068|NCT00253383|stage III pancreatic cancer
1435069|NCT00253383|recurrent small intestine cancer
1435070|NCT00253383|small intestine adenocarcinoma
1435071|NCT00253383|small intestine leiomyosarcoma
1435072|NCT00253383|small intestine lymphoma
1435073|NCT00253383|stage IV bladder cancer
1435074|NCT00253383|stage IV renal cell cancer
1435075|NCT00253383|clear cell sarcoma of the kidney
1435076|NCT00253383|peripheral primitive neuroectodermal tumor of the kidney
1435077|NCT00253383|rhabdoid tumor of the kidney
1435078|NCT00253383|metastatic transitional cell cancer of the renal pelvis and ureter
1435079|NCT00253383|anterior urethral cancer
1435080|NCT00253383|posterior urethral cancer
1435081|NCT00253383|urethral cancer associated with invasive bladder cancer
1435082|NCT00253383|stage IV penile cancer
1435083|NCT00253383|stage IV prostate cancer
1435084|NCT00253383|stage III malignant testicular germ cell tumor
1435085|NCT00253383|stage IV endometrial carcinoma
1435086|NCT00253383|fallopian tube cancer
1435087|NCT00253383|ovarian sarcoma
1435088|NCT00253383|ovarian stromal cancer
1435089|NCT00253383|stage IV pancreatic cancer
1435090|NCT00253370|Sorafenib
1435091|NCT00253370|Docetaxel
1435092|NCT00253370|Cisplatin
1435093|NCT00253370|gastric cancer
1435094|NCT00253370|gastroesophageal junction adenocarcinoma
1435095|NCT00253357|Heart Failure
1435096|NCT00253357|Congestive Heart Failure
1435097|NCT00253357|Fluid overload
1435098|NCT00253357|Left sided heart failure
1435099|NCT00253357|Pacemaker
1435100|NCT00253357|Defibrillator
1435101|NCT00253344|unspecified adult solid tumor, protocol specific
1435102|NCT00253331|Raynaud's
1435103|NCT00253331|sclerderma
1435104|NCT00253331|systemic sclerosis
1435105|NCT00253331|autoimmune disease
1435106|NCT00253318|Neoplasm Metastasis
1435107|NCT00253318|Breast Cancer
1435108|NCT00253318|Docetaxel
1435109|NCT00253318|RAD001
1435110|NCT00253318|Taxotere
1435111|NCT00253305|tinea unguium
1435112|NCT00253305|onychomycosis
1435113|NCT00253292|Burns
1435114|NCT00253292|Trauma
1435115|NCT00253292|Outcomes
1435116|NCT00253292|Quality of Life
1435117|NCT00253279|Protein Synthesis Rate
1435118|NCT00253279|Burn Injury
1435119|NCT00253279|PET Scan
1435120|NCT00253266|Treatment resistant depression
1435121|NCT00253266|Augmentation
1435122|NCT00253266|Pharmacogenetics
1435123|NCT00253253|orchidopexy, long-term outcome, congenital
1435124|NCT00253227|Alzheimer's disease
1435125|NCT00253227|dementia
1435126|NCT00253227|brain disease
1435127|NCT00253227|memory loss
1435128|NCT00253227|galantamine
1435129|NCT00253227|placebo
1435130|NCT00253214|Alzheimer's disease
1435131|NCT00253214|dementia
1435132|NCT00253214|galantamine hydrobromide
1435133|NCT00253214|controlled-release
1435134|NCT00253214|once-daily dosing
1435135|NCT00253201|Alzheimer's disease
1435136|NCT00253201|dementia
1435137|NCT00253201|brain disease
1435138|NCT00253201|memory loss
1435139|NCT00253201|galantamine
1435140|NCT00253201|placebo
1435141|NCT00253201|caregiver
1435142|NCT00253201|quality of life
1435143|NCT00253201|resource utilization
1435144|NCT00253188|Alzheimer's disease
1435145|NCT00253188|dementia
1435146|NCT00253188|brain disease
1435147|NCT00253188|memory loss
1435148|NCT00253188|galantamine
1435149|NCT00253188|placebo
1435150|NCT00253188|caregiver
1435151|NCT00253188|quality of life
1435152|NCT00253188|resource utilization
1435153|NCT00253175|topiramate
1435154|NCT00253175|migraine headache
1435155|NCT00253175|migraine prevention
1435156|NCT00253175|migraine
1435157|NCT00253162|risperidone
1435158|NCT00253162|antipsychotic agents
1435159|NCT00253162|bipolar disorders
1435161|NCT00253149|risperidone
1435162|NCT00253149|antipsychotic agents
1435163|NCT00253149|bipolar disorders
1435164|NCT00253149|manic episode
1435165|NCT00253136|schizophrenia
1435166|NCT00253136|schizoaffective disorder
1435167|NCT00253136|psychotic disorder
1435168|NCT00253136|risperidone
1435169|NCT00253136|long-acting injectable
1435170|NCT00253136|intramuscular injection
1435171|NCT00253136|antipsychotic agents
1435172|NCT00253123|Dementia
1435173|NCT00253123|Alzheimer's disease
1435174|NCT00253123|vascular dementia
1435175|NCT00253123|mixed dementia
1435176|NCT00253123|risperidone
1435177|NCT00253123|nursing home
1435178|NCT00253110|Schizophrenia, Psychotic Disorders
1435179|NCT00253110|Haloperidol
1435180|NCT00253110|Risperidone
1435181|NCT00253110|Schizoaffective disorder
1435182|NCT00253097|stroke recurrence
1435183|NCT00253097|risk factors
1435184|NCT00253097|health behavior
1435185|NCT00253097|intervention
1435186|NCT00253097|tertiary prevention
1435187|NCT00253071|Prophylactic treatment
1435188|NCT00253071|Pharmacological treatment
1435189|NCT00253071|Psychological treatment
1435190|NCT00253058|Allergic
1435191|NCT00253058|pediatric
1435192|NCT00253058|Rhinitis
1435193|NCT00253058|Perennial
1435194|NCT00253045|Motivational Interviewing
1435195|NCT00253045|antiretroviral therapy
1435196|NCT00253045|medication adherence
1435197|NCT00253045|risk reduction behaviors
1435198|NCT00253045|women
1435199|NCT00253045|HIV
1435200|NCT00253045|AIDS
1435201|NCT00251966|Prevention of gastroduodenal lesions
1435202|NCT00251966|erosive oesophagitis
1435203|NCT00251966|upper GI symptoms
1435204|NCT00251927|Acid reflux disease
1435205|NCT00251927|Gastroesophageal Reflux Disease
1435206|NCT00251901|Gastroesophageal reflux disease
1435207|NCT00251901|GERD
1435208|NCT00251888|cervix cancer
1435209|NCT00251888|advanced cervix cancer
1435210|NCT00251888|radiochemotherapy
1435211|NCT00251888|pelvic radiotherapy
1435212|NCT00251888|campto
1435213|NCT00251888|cisplatin
1435214|NCT00251888|irinotecan
1435215|NCT00251888|cisplatyl
1435216|NCT00251888|maximum dose search
1435217|NCT00251875|patient portals
1435218|NCT00251875|electronic health records
1435219|NCT00251875|family history
1435220|NCT00251875|health maintenance
1435221|NCT00251875|medications
1435222|NCT00251875|diabetes
1435223|NCT00251862|Colorectal cancer screening
1435224|NCT00251862|Shared decision-making
1435225|NCT00251862|Decision aid
1435226|NCT00251849|Intermittent Claudication
1435227|NCT00251836|Kidney donation
1435228|NCT00251836|Organ Donation
1435229|NCT00251836|Vascular anatomy
1435230|NCT00251836|Adrenal Insufficiency
1435231|NCT00251823|ST-Elevation Myocardial Infarction
1435232|NCT00251810|general anaesthesia
1435233|NCT00251810|depth of hypnosis
1435234|NCT00251810|Cerebral State Monitor
1435235|NCT00251810|CSM
1435236|NCT00251810|Bispectral Index
1435237|NCT00251810|BIS
1435238|NCT00253019|birth control
1435239|NCT00253019|continuation
1435240|NCT00253019|abortion
1435241|NCT00253019|contraception
1435242|NCT00253006|NO
1435243|NCT00253006|mRNA-expression
1435244|NCT00253006|pathophysiology
1435245|NCT00253006|painful bladder syndrome
1435246|NCT00252993|Nausea
1435247|NCT00252993|Vomiting
1435248|NCT00252993|Chronic Functional Vomiting
1435249|NCT00252993|Functional Vomiting
1435250|NCT00252993|Cyclic Vomiting
1435251|NCT00252980|Cannabis
1435252|NCT00252980|Dependence
1435253|NCT00252980|Marijuana
1435254|NCT00252980|Substance Abuse Treatment
1435255|NCT00252980|Psychotherapy,
1435256|NCT00252967|Reactive Oxgen Speers
1435257|NCT00252967|Atrial Fibrillation
1435258|NCT00252967|Oxidative Stress
1435259|NCT00252967|Inflammation
1435260|NCT00252954|Spinal cord injury
1435261|NCT00252954|Neuropathic pain
1435262|NCT00252954|Spasms
1435263|NCT00252941|prostate cancer
1435264|NCT00252941|brachytherapy
1435265|NCT00252941|urethral stenting
1435266|NCT00252928|sodium dichloroisocyanurate
1435267|NCT00252928|water purification
1435268|NCT00252928|disinfection
1435269|NCT00252928|Ghana
1435270|NCT00252902|tobacco; emergency department; motivation; counseling
1435271|NCT00252889|Metastatic cancer
1435272|NCT00252889|Metastatic gastric and esophagus adenocarcinoma
1435273|NCT00252889|Unresectable pancreatic cancer
1435274|NCT00252889|Unresectable head and neck cancer
1435275|NCT00252889|Cancer of undetermined primary
1435276|NCT00252850|Parkinson's Disease
1435277|NCT00252850|Gene Transfer
1435278|NCT00252798|Non Small Cell Lung Cancer
1435279|NCT00252785|Asthma
1435280|NCT00252746|NSCLC
1435281|NCT00252746|Non Small Cell Lung Cancer
1435282|NCT00252733|Diabetes Mellitus, Insulin-Dependent
1435283|NCT00252720|Diabetes mellitus type 1
1435284|NCT00252694|Diabetes mellitus type 2
1435285|NCT00252681|randomized
1435286|NCT00252681|controlled
1435287|NCT00252681|trial
1435288|NCT00252681|necrotizing
1435289|NCT00252681|enterocolitis
1435290|NCT00252681|premature
1435291|NCT00252681|infants
1435292|NCT00252681|laparotomy
1435293|NCT00252681|peritoneal
1435294|NCT00252681|drainage
1435295|NCT00252668|Rheumatoid Arthritis
1435296|NCT00252642|Hepatitis C
1435297|NCT00252642|Interferon
1435298|NCT00252642|Cirrhosis
1435299|NCT00252642|Liver Disease
1435300|NCT00252642|Portal Hypertension
1435301|NCT00252642|Portal Pressure
1435302|NCT00252629|Fatigue
1435303|NCT00252629|Functional Somatic Syndrome
1435304|NCT00252629|Gulf War Syndrome
1435305|NCT00252629|Sleep apnea
1435306|NCT00252629|Upper Airway Resistance Syndrome
1435307|NCT00252616|Mechanical ventilation
1435308|NCT00252616|acute respiratory failure
1435309|NCT00252616|early nutrition
1435310|NCT00252603|Autism
1435311|NCT00252603|Childhood Autism
1435312|NCT00252590|Psychotherapy motivational intervention
1435313|NCT00252577|Lithium
1435314|NCT00252577|Pharmacogenetics
1435315|NCT00252551|spondylolisthesis, decompressive surgery, osteosynthesis
1435316|NCT00252538|Cortisol
1435317|NCT00252538|Depression
1435318|NCT00252538|Hepatitis C
1435319|NCT00252538|Interferon
1435320|NCT00252538|Polymorphism
1435321|NCT00252538|Serotonin
1435322|NCT00252538|Tryptophan
1435323|NCT00252512|Contingency management interventions
1435324|NCT00252512|Substance use disorders treatment
1435325|NCT00252512|Treatment effectiveness
1435326|NCT00252512|Randomized clinical trial
1435327|NCT00252512|Behavioral research
1435328|NCT00252499|beta cell function
1435329|NCT00252499|fenofibrate
1435330|NCT00252499|non-alcoholic steatohepatitis
1435331|NCT00252499|rosiglitazone
1435332|NCT00252499|insulin sensitivity
1435333|NCT00252486|Bipolar
1435334|NCT00252486|Omega-3 Fatty acids
1435335|NCT00252434|high-risk sexual behavior
1435336|NCT00252434|methamphetamine use
1435337|NCT00252434|drug craving
1435338|NCT00252434|addiction behaviors
1435339|NCT00252421|osteoporosis
1435340|NCT00252421|bone mineral density
1435341|NCT00252421|nitrates
1435342|NCT00252408|Fracture
1435343|NCT00252408|Osteoporosis
1435344|NCT00252408|Bone mineral density
1435345|NCT00252408|Hormone replacement therapy
1435346|NCT00252408|Estrogen
1435347|NCT00252408|Breast cancer
1435348|NCT00252395|medication error
1435349|NCT00252395|electronic prescribing
1435350|NCT00252395|patient safety
1435351|NCT00252382|Lung
1435352|NCT00252382|Squamous Cell
1435353|NCT00252382|Large Cell
1435354|NCT00252382|Adenocarcinoma
1435355|NCT00252382|Carcinoma
1435356|NCT00252382|Cancer
1435357|NCT00252356|major depressive disorder
1435358|NCT00252356|depression
1435359|NCT00252356|major depressive episode
1435360|NCT00252356|antidepressive agents
1435361|NCT00252343|anxiety disorder
1435362|NCT00252330|major depressive disorder
1435363|NCT00252330|depression
1435364|NCT00252330|major depressive episode
1435365|NCT00252330|antidepressive agents
1435366|NCT00252317|Aortic stenosis
1435367|NCT00252317|ACE-inhibitores
1435368|NCT00252304|Child, severe pneumonia, Zinc, Nepal, therapeutic
1435369|NCT00252291|bronchial
1435370|NCT00252291|hyperresponsiveness
1435371|NCT00252239|stroke
1435372|NCT00252239|tenecteplase
1435373|NCT00252239|TNK
1435374|NCT00252239|ischemic
1435375|NCT00252239|tissue plasminogen activator
1435376|NCT00252239|tPA
1435377|NCT00252226|Quetiapine
1435378|NCT00252226|bipolar spectrum disorders
1435379|NCT00252187|Heart failure
1435380|NCT00252187|Natriuretic peptides
1435381|NCT00252187|B-type natriuretic peptide
1435382|NCT00252187|Kidney
1435383|NCT00252187|Nesiritide
1435384|NCT00252187|Natrecor
1435385|NCT00252187|CHF
1435386|NCT00252174|MDMA
1435387|NCT00252174|cancer
1435388|NCT00252174|anxiety
1435389|NCT00252174|psychotherapy
1435390|NCT00252174|quality of life
1435391|NCT00252161|Neoadjuvant Therapy
1435392|NCT00252161|Stomach Neoplasms
1435393|NCT00252161|Cisplatin
1435394|NCT00252161|S-1(combination)
1435395|NCT00252148|HIV Preventive Vaccine
1435396|NCT00252135|Moderate to severe asthma
1435397|NCT00252109|HIV
1435398|NCT00252109|Seropositive
1435399|NCT00252109|MSM
1435400|NCT00252109|African American
1435401|NCT00252109|Popular Opinion Leader
1435402|NCT00252096|Diagnosis
1435403|NCT00252096|Chlamydia trachomatis
1435404|NCT00252096|Neisseria gonorrhoeae
1435405|NCT00252096|Nucleic acid amplification test
1435406|NCT00252096|Rectum
1435407|NCT00252096|Pharynx
1435408|NCT00252083|Seropositive
1435409|NCT00252083|MSM
1435410|NCT00252083|Hispanic
1435411|NCT00252083|Popular Opinion Leader
1435412|NCT00252083|HIV
1435413|NCT00252070|arthritis
1435414|NCT00252070|exercise
1435415|NCT00252070|function
1435416|NCT00252070|pain
1435417|NCT00252057|rehospitalization
1435418|NCT00252057|readmission
1435419|NCT00252057|adverse events
1435420|NCT00252057|discharge
1435421|NCT00252031|Borderline Personality Disorder
1435422|NCT00252031|BPD
1435423|NCT00252031|Dialectical Behavior Therapy
1435424|NCT00252031|DBT
1435425|NCT00252018|Nutritional supplement
1435426|NCT00252018|Prevention
1435427|NCT00252018|Endothelial function
1435428|NCT00252018|Flow mediated dilation
1435429|NCT00251797|Phase I
1435430|NCT00251797|Brain cancer
1435431|NCT00251797|Recurrent CNS tumors
1435432|NCT00251771|Thrombolytic therapy
1435433|NCT00251771|Postphlebitic syndrome
1435434|NCT00251771|Venous thrombosis
1435435|NCT00251758|Non-Erosive Gastroesophageal Reflux Disease(GERD),heartburn
1435436|NCT00251745|Non-Erosive Gastroesophageal Reflux Disease (GERD)
1435437|NCT00251745|Heartburn
1435438|NCT00251732|acid reflux studies
1435439|NCT00251732|efficacy of PPI therapy
1435440|NCT00251732|failing PPI therapy
1435441|NCT00251732|GERD
1435442|NCT00251732|Acid Reflux Disease
1435443|NCT00251719|Erosive Esophagitis
1435444|NCT00251706|atrial fibrillation
1435445|NCT00251706|atrial flutter
1435446|NCT00251706|amiodarone
1435447|NCT00251706|post-operative
1435448|NCT00251706|coronary artery bypass surgery
1435449|NCT00251706|valve replacement or repair
1435450|NCT00251693|Erosive Esophagitis
1435451|NCT00251680|Hyperlipidemia
1435452|NCT00251680|Drug Therapy
1435453|NCT00251654|complications
1435454|NCT00251654|adverse events
1435455|NCT00251654|regional anesthesia
1435456|NCT00251654|adverse effects
1435457|NCT00251628|Tonsils
1435458|NCT00251628|Tonsillectomy
1435459|NCT00251615|vascular surgery
1435460|NCT00251615|vascular aging
1435461|NCT00251615|arterial aging
1435462|NCT00251615|surgical tissue
1435463|NCT00251615|Aging
1435464|NCT00251602|heart rate variability
1435465|NCT00251602|gene response
1435466|NCT00251589|Relapsed Non-Small-Cell Lung Cancer
1435467|NCT00251589|Refractory Non-Small-Cell Lung Cancer
1435468|NCT00251563|Cancer,Risk factors
1435469|NCT00251537|Pilot study
1435470|NCT00251537|Randomized
1435471|NCT00251537|Placebo-controlled
1435472|NCT00251537|Double-blind
1435473|NCT00251537|Effect on viral load
1435474|NCT00251537|LTB4
1435475|NCT00251537|HIV-1 infection
1435476|NCT00251498|Metastatic 1st line NSCLC
1435477|NCT00251485|Metastatic 1st line colorectal cancer
1435478|NCT00251459|SAILOR
1435479|NCT00251459|CNV
1435480|NCT00251459|AMD
1435481|NCT00251459|CNV secondary to AMD
1435482|NCT00251433|ErbB1
1435483|NCT00251433|ErbB2
1435484|NCT00251433|trastuzumab (Herceptin)
1435485|NCT00251433|lapatinib
1435486|NCT00251433|Stage IV breast cancer
1435487|NCT00251433|metastatic breast cancer
1435488|NCT00251433|overexpression of ErbB2 receptors
1435489|NCT00251433|docetaxel (Taxotere)
1435490|NCT00251420|copd
1435491|NCT00251420|asthma
1435492|NCT00251420|QoL
1435493|NCT00251420|Perceived health status
1435494|NCT00251420|Trait anxiety
1435495|NCT00251407|Advanced solid tumor malignancy
1435496|NCT00251407|cisplatin
1435497|NCT00251407|CPT-11
1435498|NCT00251407|taxotere
1435499|NCT00251394|B-Cell follicular non-Hodgkin's lymphoma
1435500|NCT00251394|Rituxan
1435501|NCT00251394|Rituximab
1435502|NCT00251394|1018 ISS
1435503|NCT00251394|CD 20 +
1435504|NCT00251381|Oropharyngeal Neoplasms
1435505|NCT00251381|Cetuximab
1435506|NCT00251381|Concomitant-boost accelerated radiotherapy
1435507|NCT00251368|leukemia
1435508|NCT00251368|9-Aminocamptothecin
1435509|NCT00251368|AML
1435510|NCT00251368|ALL
1435511|NCT00251368|refractory leukemia
1435512|NCT00251368|relapsed leukemia
1435513|NCT00251355|gemcitabine
1435514|NCT00251355|5-fluorouracil
1435515|NCT00251355|5-FU
1435516|NCT00251355|unresectable pancreatic cancer
1435517|NCT00251355|non-metastatic pancreatic cancer
1435518|NCT00251342|Postnatal depression
1435519|NCT00251342|Randomized controlled trial
1435520|NCT00251342|Screening
1435521|NCT00251342|Outcome
1435522|NCT00251342|Edinburgh Postnatal Depression Scale
1435523|NCT00251329|Neoadjuvant
1435524|NCT00251329|Breast Cancer
1435525|NCT00251329|pCR
1435526|NCT00251329|Capecitabine
1435527|NCT00251329|Carboplatin
1435528|NCT00251329|Docetaxel
1435529|NCT00251316|Thyroid Neoplasm
1435530|NCT00251316|I-131
1435531|NCT00251316|Radiation Dose
1435532|NCT00251316|Radiation Effect
1435533|NCT00251316|Pharmaceutical Adjuvant
1435534|NCT00251316|Thyroid Cancer
1435535|NCT00251303|Clinical Trial
1435536|NCT00251303|Glutamate Antagonist
1435537|NCT00251303|Pediatrics
1435538|NCT00251303|Basal Ganglia
1435539|NCT00251303|Neuropsychological
1435540|NCT00251303|Obsessive Compulsive Disorder
1435541|NCT00251303|OCD
1435542|NCT00251303|Riluzole
1435543|NCT00251303|Rilutek
1435544|NCT00251290|transient ischemic attack
1435545|NCT00251290|sleep apnea
1435546|NCT00251277|Thrombotic Thrombocytopenic Purpura
1435547|NCT00251277|TTP
1435548|NCT00251277|Hematology
1435549|NCT00251264|Shoulder instability
1435550|NCT00251264|Traumatic
1435551|NCT00251264|Anterior
1435552|NCT00251264|Unidirectional
1435553|NCT00251264|Open stabilization
1435554|NCT00251264|Arthroscopic
1435555|NCT00251264|Bankart repair
1435556|NCT00251264|Shoulder instability, traumatic
1435557|NCT00251264|Anterior, unidirectional instability
1435558|NCT00251264|Bankart
1435559|NCT00251251|Congestive heart failure
1435560|NCT00251251|Multicentre randomized controlled trial
1435561|NCT00251251|Defibrillator
1435562|NCT00251251|Cardiac resynchronization
1435563|NCT00251251|Sudden death/mortality
1435564|NCT00251251|Hospitalization
1435565|NCT00251251|ICD indication
1435566|NCT00251251|NYHA Class II
1435567|NCT00251251|LVEF </equal to 30%
1435568|NCT00251251|QRS >/equal to 120 ms
1435569|NCT00251238|Raynaud´s phenomenon
1435570|NCT00251238|Vasospastic attacks
1435571|NCT00251238|Ginkgo biloba
1435572|NCT00251225|prostate
1435573|NCT00251212|Alcohol
1435574|NCT00251212|Violence
1435575|NCT00251212|Alcohol consumption
1435576|NCT00251212|Alcohol, drinking
1435577|NCT00251160|Multi-directional instability
1435578|NCT00251160|MDI
1435579|NCT00251160|Ligamentous laxity
1435580|NCT00251160|Multi-directional laxity
1435581|NCT00251160|MDL-AII
1435582|NCT00251160|Shoulder instability
1435583|NCT00251160|electrothermal capsulorrhaphy, ETAC
1435584|NCT00251160|inferior capsular shift, ICS
1435585|NCT00251160|capsular redundancy
1435586|NCT00251147|rotator cuff
1435587|NCT00251147|open
1435588|NCT00251147|arthroscopic
1435589|NCT00251147|mini-open
1435590|NCT00251147|acromioplasty
1435591|NCT00251147|quality of life
1435592|NCT00251147|shoulder
1435593|NCT00251134|myocardial infarction
1435594|NCT00251134|omega 3-fatty acids
1435595|NCT00251121|Electrophysiological study
1435596|NCT00251121|paroxysmal tachycardia
1435597|NCT00251108|'traumatic brain injury'
1435598|NCT00251108|'head injury'
1435599|NCT00251108|'brain injuries'
1435600|NCT00251108|'exercise therapy'
1435601|NCT00251108|'physical fitness'
1435602|NCT00251095|Metastatic Breast Cancer
1435603|NCT00251082|hormone replacement
1435604|NCT00251082|vasomotoric symptoms
1435605|NCT00251082|bleeding pattern
1435606|NCT00251069|glucosamine sulphate, osteoarthritis, cholesterol,
1435607|NCT00251043|Pregnancy
1435608|NCT00251043|Antepartum Depression
1435609|NCT00251043|Major Depression
1435610|NCT00251017|single nucleotide polymorphisms (SNPs)
1435611|NCT00251017|personalized medicines
1435612|NCT00251017|Subjects 16 years of age or older, of either sex.
1435613|NCT00251017|Subjects have a medication including vancomycin
1435614|NCT00251004|Renal transplantation, kidney, and organ transplant
1435615|NCT00251004|Renal transplant rejection
1435616|NCT00250991|stroke
1435617|NCT00250991|integrilin
1435618|NCT00250991|eptifibatide
1435619|NCT00250991|activase
1435620|NCT00250991|recombinant tissue plasminogen activator
1435621|NCT00250991|rt-PA
1435622|NCT00250991|recombinant t-PA
1435623|NCT00250991|SPOTRIAS
1435624|NCT00250978|Advanced Non Small Cell Lung Cancer
1435625|NCT00250952|Clinical Practice Variations
1435626|NCT00250939|Glycogen Storage Disease Type II
1435627|NCT00250939|GSD-II
1435628|NCT00250939|Pompe Disease
1435629|NCT00250926|bortezomib
1435630|NCT00250926|dexamethasone
1435631|NCT00250926|rituximab
1435632|NCT00250913|motor activity
1435633|NCT00250913|determinants
1435634|NCT00250913|psychology
1435635|NCT00250913|health care costs
1435636|NCT00250913|quality of life
1435637|NCT00250913|Angioplasty
1435638|NCT00250900|Otitis
1435639|NCT00250900|Antibiotic
1435640|NCT00250900|Prescription
1435641|NCT00250887|recurrent Glioblastoma, Gefitinib
1435642|NCT00250848|Lung Diseases
1435643|NCT00250848|Cancer
1435644|NCT00250835|Resectable Rectal Cancer
1435645|NCT00250835|Radiation
1435646|NCT00250835|Neoadjuvant
1435647|NCT00250835|Rectum
1435648|NCT00250835|GI - Colorectal Neoadjuvant
1435649|NCT00250835|Cancer
1435650|NCT00250822|Liver
1435651|NCT00250822|hepatocellular
1435652|NCT00250822|Gem-Ox
1435653|NCT00250822|Cancer
1435654|NCT00250796|Phase II
1435655|NCT00250796|Hepatocellular carcinoma
1435656|NCT00250783|Corpus Uteri
1435657|NCT00250783|Endometrium
1435658|NCT00250783|Cancer
1435659|NCT00250770|Corpus Uteri
1435660|NCT00250770|Endometrium
1435661|NCT00250770|Cancer
1435662|NCT00250757|prostate
1435663|NCT00250757|NMR Spectroscopy
1435664|NCT00250744|delayed nausea and vomiting
1435665|NCT00250744|Emetogenic Chemotherapy
1435666|NCT00250744|Pilot Trial
1435667|NCT00250731|diabetes
1435668|NCT00250731|relationship
1435669|NCT00250731|social support
1435670|NCT00250731|behavior change
1435671|NCT00250731|telemedicine
1435672|NCT00250718|Non Hodgkin's Lymphoma
1435673|NCT00250718|Phase II
1435674|NCT00250718|Lymphoid malignancies
1435675|NCT00250705|Aripiprazole
1435676|NCT00250679|COPD
1435677|NCT00250679|chronic bronchitis
1435678|NCT00250679|emphysema
1435679|NCT00250666|Biological Markers
1435680|NCT00250666|Procalcitonin
1435681|NCT00250666|Critical Care
1435682|NCT00250666|Diagnosis, Differential
1435683|NCT00250666|Prospective Study
1435684|NCT00250666|Sepsis
1435685|NCT00250666|Antibiotic stewardship
1435686|NCT00250666|Antimicrobial resistance
1435687|NCT00250653|depression
1435688|NCT00250653|antidepressive agents
1435689|NCT00250653|clinical trial
1435690|NCT00250640|Primary Pulmonary hypertension
1435691|NCT00250627|depression
1435692|NCT00250627|antidepressive agents
1435693|NCT00250627|controlled clinical trial
1435694|NCT00250614|depression
1435695|NCT00250614|antidepressive agents
1435696|NCT00250614|controlled clinical trial
1435697|NCT00250601|depression
1435698|NCT00250601|antidepressive agents
1435699|NCT00250601|controlled clinical trial
1435700|NCT00250588|Asthma
1435701|NCT00250588|Child
1435702|NCT00250588|Problem-solving
1435703|NCT00250588|Quality of Life
1435704|NCT00250588|Barriers to Care
1435705|NCT00250575|Schizophrenia, treatment-resistant, clozapine
1435706|NCT00250562|Hypertension
1435707|NCT00250562|Angiotensin II receptor blocker
1435708|NCT00250562|fixed combination
1435709|NCT00250562|diuretics
1435710|NCT00250549|HIV
1435711|NCT00250549|Prevention
1435712|NCT00250549|Rapid HIV testing
1435713|NCT00250523|trauma
1435714|NCT00250523|critical illness
1435715|NCT00250523|injury
1435716|NCT00250510|Obesity treatment
1435717|NCT00250510|Insurance reimbursement
1435718|NCT00250510|Health care utilization
1435719|NCT00250510|Health care costs
1435720|NCT00250497|Adolescent
1435721|NCT00250497|Girls
1435722|NCT00250497|Physical Activity
1435723|NCT00250497|Exercise
1435724|NCT00250497|Diet
1435725|NCT00250497|Body image
1435726|NCT00250484|analgesia
1435727|NCT00250484|electric stimulation therapy
1435728|NCT00250484|electric stimulation
1435729|NCT00250484|pain
1435730|NCT00250484|safety
1435731|NCT00250471|GP IIb/IIIa inhibitors
1435732|NCT00250471|eptifibatide
1435733|NCT00250471|Anti-thrombotic agents
1435734|NCT00250445|Arcoxia
1435735|NCT00250406|urolithiasis
1435736|NCT00250406|ureteral stent
1435737|NCT00250406|triclosan
1435738|NCT00250406|drug eluting
1435739|NCT00250393|Parkinson's disease
1435740|NCT00250393|monotherapy
1435741|NCT00250380|Aspirin
1435742|NCT00250380|Platelet Aggregation Inhibitors
1435743|NCT00250367|risperidone
1435744|NCT00250367|antipsychotic agents
1435745|NCT00250367|bipolar disorders
1435746|NCT00250367|manic episode
1435747|NCT00250354|conduct disorder
1435748|NCT00250354|oppositional deficit disorder
1435749|NCT00250354|disruptive behavior disorder not otherwise specified
1435750|NCT00250354|ADHD
1435751|NCT00250354|risperidone
1435752|NCT00250354|antipsychotropic agents
1435753|NCT00250354|children
1435754|NCT00249314|South Asians
1435755|NCT00249314|European Caucasians
1435756|NCT00249314|ethnic differences
1435757|NCT00249314|body composition
1435758|NCT00249314|body fat distribution
1435759|NCT00249314|adipose tissue
1435760|NCT00249314|visceral fat
1435761|NCT00249314|myocellular lipids
1435762|NCT00249314|skeletal muscle
1435763|NCT00249301|Breast Cancer
1435764|NCT00249301|Colon Cancer
1435765|NCT00249301|Pancreatic Cancer
1435766|NCT00249301|Bladder Cancer
1435767|NCT00249288|Schizophrenia
1435768|NCT00249288|Negative Symptoms
1435769|NCT00249288|Folate
1435770|NCT00249275|significant refractive errors
1435771|NCT00249275|children
1435772|NCT00249275|spectacles
1435773|NCT00249275|Africa
1435774|NCT00249249|hypercholesterolemia
1435775|NCT00249249|dyslipidemia
1435776|NCT00249249|kowa
1435777|NCT00249249|KRE
1435778|NCT00249249|pitavastatin
1435779|NCT00249249|NK-104
1435780|NCT00249236|risperidone
1435781|NCT00249236|antipsychotic agents
1435782|NCT00249236|bipolar disorders
1435783|NCT00249236|manic episode
1435784|NCT00249223|chronic schizophrenia, psychotic disorder, risperidone, long-acting injectable, intramuscular injection, antipsychotic agents
1435785|NCT00249210|Sinusitis
1435786|NCT00249210|respiratory tract diseases
1435787|NCT00249210|nose diseases
1435788|NCT00249210|respiratory tract infections
1435789|NCT00249210|paranasal sinus diseases
1435790|NCT00249210|antibacterial agents
1435791|NCT00249210|quinolones
1435792|NCT00249210|levofloxacin
1435793|NCT00249197|skin infection
1435794|NCT00249197|bacterial infection
1435795|NCT00249197|levofloxacin
1435796|NCT00249197|quinolones
1435797|NCT00249197|skin
1435798|NCT00249197|infection
1435799|NCT00249171|acute schizophrenia
1435800|NCT00249171|psychosis
1435801|NCT00249171|risperidone
1435802|NCT00249171|lorazepam, antipsychotic agents
1435803|NCT00249171|emergency treatment
1435804|NCT00249158|Dementia
1435805|NCT00249158|Alzheimer's Disease
1435806|NCT00249158|vascular dementia
1435807|NCT00249158|mixed dementia
1435808|NCT00249158|risperidone
1435809|NCT00249158|nursing home
1435810|NCT00249145|Dementia
1435811|NCT00249145|Alzheimer's Disease
1435812|NCT00249145|vascular dementia
1435813|NCT00249145|mixed dementia, risperidone
1435814|NCT00249145|nursing home
1435815|NCT00249132|chronic schizophrenia
1435816|NCT00249132|psychotic disorder
1435817|NCT00249132|risperidone
1435818|NCT00249132|antipsychotic agents
1435819|NCT00249119|chronic schizophrenia
1435820|NCT00249119|psychotic disorders
1435821|NCT00249119|risperidone
1435822|NCT00249119|antipsychotic agents
1435823|NCT00250289|malodor
1435824|NCT00250289|halitosis
1435825|NCT00250289|herbal formulation
1435826|NCT00250289|natural medicinals
1435827|NCT00250289|slow release delivery system
1435828|NCT00250263|rhinitis
1435829|NCT00250263|asthma
1435830|NCT00250263|atopy
1435831|NCT00250263|house dust mite
1435832|NCT00250263|immunotherapy
1435833|NCT00250263|SLIT
1435834|NCT00250237|Post-operative delirium
1435835|NCT00250237|hip fracture
1435836|NCT00250224|Radiotherapy
1435837|NCT00250224|image guided
1435838|NCT00250224|marker
1435839|NCT00250211|magnetic resonance imaging, functional
1435840|NCT00250211|radiation therapy
1435841|NCT00250211|temozolomide
1435842|NCT00250211|functional imaging
1435843|NCT00250211|concurrent chemoradiation
1435844|NCT00250198|T Cell
1435845|NCT00250198|Lymphocyte
1435846|NCT00250198|Lamina Propria
1435847|NCT00250198|Colonoscopy
1435848|NCT00250198|Placebo
1435849|NCT00250198|Crohn's Disease
1435850|NCT00250198|Crohns Disease
1435851|NCT00250185|Ischemia Tolerance
1435852|NCT00250185|Endothelial Function
1435853|NCT00250185|Forearm Blood Flow
1435854|NCT00250185|Muscle Recovery
1435855|NCT00250185|Inflammation
1435856|NCT00250185|Healthy Volunteer
1435857|NCT00250185|HV
1435858|NCT00250172|Dosimetry
1435859|NCT00250172|Pharmacokinetics
1435860|NCT00250172|Compartment Analysis
1435861|NCT00250172|Reproducibility
1435862|NCT00250172|Healthy Volunteer
1435863|NCT00250172|HV
1435864|NCT00250159|Congenital Adrenal Hyperplasia (CAH)
1435865|NCT00250159|Familial Male Precocious Puberty (FMPP)
1435866|NCT00250159|21-hydroxylast deficiency
1435867|NCT00250159|Congenital Adrenal Hyperplasia
1435868|NCT00250159|CAH
1435869|NCT00250159|Familial Male Precocious Puberty
1435870|NCT00250159|FMPP
1435871|NCT00250146|Celiac Disease
1435872|NCT00250146|Gluten
1435873|NCT00250146|Toxicity
1435874|NCT00250146|Small bowel morphometry
1435875|NCT00250133|selective decontamination of the digestive tract
1435876|NCT00250120|NSCLC
1435877|NCT00250120|L9NC
1435878|NCT00250120|Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin
1435879|NCT00250094|Phase I
1435880|NCT00250094|Ovarian Cancer
1435881|NCT00250094|Ovary
1435882|NCT00250094|Cancer
1435883|NCT00250081|Cerebral Palsy
1435884|NCT00250081|Tendon Transfer
1435885|NCT00250081|Botulinum Toxin Type A
1435886|NCT00250081|Occupational Therapy
1435887|NCT00250081|Child
1435888|NCT00250068|Phase II
1435889|NCT00250068|Aerosol Delivery
1435890|NCT00250068|NSCLC
1435891|NCT00250068|9-Nitrocamptothecin
1435892|NCT00250055|NIH
1435893|NCT00250055|Non-Invasive diagnosis of cervical tissue
1435894|NCT00250055|Los Alamos/NIH
1435895|NCT00250029|Colorectal Cancer
1435896|NCT00250029|Pilot Study
1435897|NCT00250029|Oxaliplatin
1435898|NCT00250016|Endometrium
1435899|NCT00250016|Tissue
1435900|NCT00250016|L9NC
1435901|NCT00250003|Elderly
1435902|NCT00250003|Preventive home visits
1435903|NCT00249990|Uterus
1435904|NCT00249990|Recurrent disease
1435905|NCT00249990|Treatment
1435906|NCT00249990|9-Nitrocamptothecin
1435907|NCT00249990|Endometrium
1435908|NCT00249977|Phase I
1435909|NCT00249977|solid tumors
1435910|NCT00249977|DNA repair
1435911|NCT00249964|Extensive or recurrent small cell lung cancer Phase I
1435912|NCT00249964|Paclitaxel, Carboplatin, Temozolomide
1435913|NCT00249951|nephrocalcinosis
1435914|NCT00249951|premature infants
1435915|NCT00249951|hypocitraturia
1435916|NCT00249951|alcaline citrate therapy
1435917|NCT00249951|Nephrocalcinosis in premature infants
1435918|NCT00249938|Antilipemic agents
1435919|NCT00249938|hyperlipidemia
1435920|NCT00249925|Home modification
1435921|NCT00249925|Occupational Therapy
1435922|NCT00249925|Physical Therapy
1435923|NCT00249925|Home care
1435924|NCT00249912|Hyperlipidemia
1435925|NCT00249912|Drug Therapy
1435926|NCT00249899|Hyperlipidemia
1435927|NCT00249899|Drug Therapy
1435928|NCT00249873|Atrial fibrillation
1435929|NCT00249873|Anticoagulant therapy
1435930|NCT00249873|Thromboembolic prevention
1435931|NCT00249860|Subjects with chronic hepatitis C who have never previously received interferon therapy.
1435932|NCT00249847|Hot flashes, vasomotor symptoms, estrogen, paroxetine
1435933|NCT00249834|Healthy female partners of infertile couples justifying Assisted Reproductive Technology (ART) treatment.
1435934|NCT00249808|Candidates for systemic therapy for psoriasis
1435935|NCT00249795|Atrial fibrillation
1435936|NCT00249795|Cardiovascular disease
1435937|NCT00249795|angiotensin II blocker
1435938|NCT00249782|rosacea, Papulopustular Rosacea,erythema, dapsone
1435939|NCT00249769|Japanese Encephalitis
1435940|NCT00249769|Japanese B Encephalitis
1435941|NCT00249769|Japanese B Viral Encephalitis
1435942|NCT00249769|Viral Encephalitis, Japanese B
1435943|NCT00249756|Criminal Justice
1435944|NCT00249743|fall prevention
1435945|NCT00249743|fall risk management
1435946|NCT00249743|RCT
1435947|NCT00249743|cost
1435948|NCT00249717|Contingency management
1435949|NCT00249717|Substance abuse treatment
1435950|NCT00249691|cocaine addiction
1435951|NCT00249691|cocaine dependence
1435952|NCT00249678|Behavior Therapy
1435953|NCT00249678|methamphetamine
1435954|NCT00249652|End stage liver disease
1435955|NCT00249652|End stage renal disease
1435956|NCT00249652|Substance-Related Disorders
1435957|NCT00249639|Contingency Management
1435958|NCT00249639|Substance Abuse Treatment
1435959|NCT00249626|Contingency management
1435960|NCT00249626|substance abuse treatment
1435961|NCT00249613|gender-responsive substance abuse treatment
1435962|NCT00249600|contingency management
1435963|NCT00249600|substance abuse
1435964|NCT00249574|heroin addiction
1435965|NCT00249548|contingency management
1435966|NCT00249548|substance abuse
1435967|NCT00249535|Substance Abuse
1435968|NCT00249535|Contingency Management
1435969|NCT00249522|contingency management
1435970|NCT00249522|substance abuse treatment
1435971|NCT00249509|marijuana dependence
1435972|NCT00249496|cocaine
1435973|NCT00249496|opioids
1435974|NCT00249496|contingency management
1435975|NCT00249496|sexual risk
1435976|NCT00249496|HIV
1435977|NCT00249483|Cocaine Addiction
1435978|NCT00249483|Cocaine Dependence
1435979|NCT00249470|HIV
1435980|NCT00249470|HIV risk behaviors
1435981|NCT00249470|Heroin
1435982|NCT00249470|Cocaine
1435983|NCT00249470|Methadone
1435984|NCT00249470|Opioid Dependence
1435985|NCT00249470|Cocaine Abuse
1435986|NCT00249470|Contingency management
1435987|NCT00249470|alcohol & drug use
1435988|NCT00249470|sexual risk behaviors
1435989|NCT00249457|Behavior Therapy
1435990|NCT00249457|Cocaine Abuse
1435991|NCT00249457|Cocaine Dependence
1435992|NCT00249457|Contingency Management
1435993|NCT00249457|Heroin Dependence
1435994|NCT00249457|Methadone
1435995|NCT00249457|Opioid Dependence
1435996|NCT00249418|Contingency Management
1435997|NCT00249418|Substance Abuse Treatment
1435998|NCT00249405|Clinical trial
1435999|NCT00249405|Alcoholism
1436000|NCT00249405|Alcohol
1436001|NCT00249405|Pharmacogenetics
1436002|NCT00249405|Citalopram
1436003|NCT00249405|Genotype
1436004|NCT00249405|Therapy compliance
1436005|NCT00249405|Serotonin inhibitor
1436006|NCT00249405|Alcoholism/alcohol abuse therapy
1436007|NCT00249392|ocular diseases
1436008|NCT00249392|risk factors
1436009|NCT00249392|genetic factors
1436010|NCT00249379|Alcohol dependence
1436011|NCT00249379|Acamprosate(drug)
1436012|NCT00249379|Drug Court
1436013|NCT00249379|Probation
1436014|NCT00249379|Parole
1436015|NCT00249379|Criminal justice
1436016|NCT00249366|Alcohol withdrawal
1436017|NCT00249366|Symptom-triggered therapy
1436018|NCT00249366|Fixed-schedule therapy
1436019|NCT00249366|CIWA-Ar
1436020|NCT00249366|Lorazepam (drug)
1436021|NCT00249353|Attention Deficit Hyperactivity Disorder
1436022|NCT00249353|ADHD
1436023|NCT00249353|Concerta
1436024|NCT00249340|behavioral weight loss treatment
1436025|NCT00249340|brief behavioral treatment
1436026|NCT00249340|commercial weight loss programs
1436027|NCT00249340|Weight Watchers
1436028|NCT00249327|HIV testing
1436029|NCT00249327|HIV disclosure
1436030|NCT00249327|HIV Seronegativity
1436031|NCT00249080|3T MRI
1436032|NCT00249080|neurodegenerative disease
1436033|NCT00249080|Alzheimer's disease
1436034|NCT00249080|spectroscopy
1436035|NCT00249080|Normal, healthy subject without memory complaint
1436036|NCT00249080|Not pregnant
1436037|NCT00249080|MR compatible
1436038|NCT00249067|Congestive Heart Failure, Left-to-Right Shunt
1436039|NCT00249041|Rheumatoid Arthritis, Enbrel liquid, antibodies
1436040|NCT00249015|aerobic exercise
1436041|NCT00249015|resistance exercise
1436042|NCT00249015|physical fitness
1436043|NCT00249015|body composition
1436044|NCT00249015|quality of life
1436045|NCT00249015|rehabilitation
1436046|NCT00249015|psychosocial oncology
1436047|NCT00249015|adherence
1436048|NCT00249002|Vascular Access Graft Failure
1436049|NCT00249002|Venous Neointimal Hyperplasia(VNH)
1436050|NCT00249002|Hemodialysis
1436051|NCT00248989|Skin aging
1436052|NCT00248989|Menopausal symptoms
1436053|NCT00248976|Angioplasty
1436054|NCT00248976|Motivating behavior change
1436055|NCT00248976|Reducing risk factors
1436056|NCT00248976|Enhancing quality of life
1436057|NCT00248976|Improving treatment outcomes
1436058|NCT00248963|Oral Contraceptive
1436059|NCT00248950|Angioplasty
1436060|NCT00248950|Behavior Change
1436061|NCT00248937|African-American
1436062|NCT00248937|Hypertension
1436063|NCT00248937|Medication adherence
1436064|NCT00248937|Risk reduction
1436065|NCT00248924|Social service intervention
1436066|NCT00248924|Social support
1436067|NCT00248924|Elderly
1436068|NCT00248924|Homebound
1436069|NCT00248924|Quality of life
1436070|NCT00248911|Breast cancer
1436071|NCT00248911|Gynecologic cancers
1436072|NCT00248911|Meditation
1436073|NCT00248911|Stress-reduction
1436074|NCT00248911|Cognitive-affective behavioral learning
1436075|NCT00248898|nonagenarians
1436076|NCT00248898|quality of life
1436077|NCT00248898|cardiothoracic surgery
1436078|NCT00248898|long term survival
1436079|NCT00248885|Coronary artery bypass graft surgery
1436080|NCT00248885|Perioperative complications
1436081|NCT00248885|Neurocognitive function
1436082|NCT00248885|Quality of life
1436083|NCT00248885|Blood pressure
1436084|NCT00248872|African-American
1436085|NCT00248872|Hypertension
1436086|NCT00248872|Medication adherence
1436087|NCT00248872|Risk reduction
1436088|NCT00248859|Coronary artery disease
1436089|NCT00248859|Depressive symptoms
1436090|NCT00248859|Latino American
1436091|NCT00248846|Angioplasty patients
1436092|NCT00248846|Behavior change
1436093|NCT00248846|Physical activity
1436094|NCT00248846|Risk reduction
1436095|NCT00248820|Contrast-enhanced Ultrasound
1436096|NCT00248820|Ultrasound Contrast agent, microbubbles
1436097|NCT00248820|Ovarian tumor
1436098|NCT00248820|vascularization
1436099|NCT00248807|Blood Pressure, Low
1436100|NCT00248807|Hypotension, Postural
1436101|NCT00248807|Injuries, Spinal Cord
1436102|NCT00248807|Spinal Cord Transection
1436103|NCT00248807|Spinal Cord Trauma
1436104|NCT00248794|Cognitive Impairment
1436105|NCT00248794|Rehabilitation
1436106|NCT00248781|Activities of daily living
1436107|NCT00248781|Aging
1436108|NCT00248781|Exercise
1436109|NCT00248781|Weight lifting
1436110|NCT00248768|Depression
1436111|NCT00248768|Parkinson Disease
1436112|NCT00248768|Transcranial Magnetic Stimulation
1436113|NCT00248755|cystic fibrosis
1436114|NCT00248755|mucociliary clearance
1436115|NCT00248755|nuclear medicine
1436116|NCT00248742|IBD, psychological, stress management
1436117|NCT00248703|Disseminating tumor cells,breast cancer,docetaxel,adjuvant
1436118|NCT00248690|Subarachnoid hemorrhage
1436119|NCT00248690|Intracranial hypertension
1436120|NCT00248690|Intracranial pressure
1436121|NCT00248690|Diagnostic techniques and procedures
1436122|NCT00248690|Compliance
1436123|NCT00248690|Treatment outcome
1436124|NCT00248690|Intensive care, surgical
1436125|NCT00248664|Cystitis, Interstitial
1436126|NCT00248664|Case-Control Studies
1436127|NCT00248664|Risk Factors
1436128|NCT00248651|Bloating
1436129|NCT00248651|Early Fullness
1436130|NCT00248651|Nausea
1436131|NCT00248651|Upper Abdominal Discomfort
1436132|NCT00248651|dyspepsia
1436133|NCT00248651|stomach pain
1436134|NCT00248651|stomach discomfort
1436135|NCT00248625|acute liver failure
1436136|NCT00248625|hepatic encephalopathy
1436137|NCT00248625|acetaminophen toxicity
1436138|NCT00248625|N-acetylcysteine
1436139|NCT00248612|Venlafaxine
1436140|NCT00248612|Alcoholism
1436141|NCT00248612|Anxiety Disorders
1436142|NCT00248612|Alcohol-Use Disorders
1436143|NCT00248612|Alcohol Abuse
1436144|NCT00248612|Alcohol Dependence
1436145|NCT00248612|Cognitive Behavioral Treatment
1436146|NCT00248560|recurrent squamous cell carcinoma of the hypopharynx
1436147|NCT00248560|stage IV squamous cell carcinoma of the hypopharynx
1436148|NCT00248560|recurrent squamous cell carcinoma of the larynx
1436149|NCT00248560|stage IV squamous cell carcinoma of the larynx
1436150|NCT00248560|recurrent squamous cell carcinoma of the lip and oral cavity
1436151|NCT00248560|stage IV squamous cell carcinoma of the lip and oral cavity
1436152|NCT00248560|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1436153|NCT00248560|recurrent metastatic squamous neck cancer with occult primary
1436154|NCT00248560|recurrent squamous cell carcinoma of the nasopharynx
1436155|NCT00248560|stage IV squamous cell carcinoma of the nasopharynx
1436156|NCT00248560|recurrent squamous cell carcinoma of the oropharynx
1436157|NCT00248560|stage IV squamous cell carcinoma of the oropharynx
1436158|NCT00248560|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1436159|NCT00248560|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1436160|NCT00248547|nausea and vomiting
1436161|NCT00248547|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1436162|NCT00248547|adult acute myeloid leukemia with inv(16)(p13;q22)
1436163|NCT00248547|adult acute myeloid leukemia with t(15;17)(q22;q12)
1436164|NCT00248547|adult acute myeloid leukemia with t(16;16)(p13;q22)
1436165|NCT00248547|adult acute myeloid leukemia with t(8;21)(q22;q22)
1436166|NCT00248547|accelerated phase chronic myelogenous leukemia
1436167|NCT00248547|adult acute lymphoblastic leukemia in remission
1436168|NCT00248547|adult acute myeloid leukemia in remission
1436169|NCT00248547|atypical chronic myeloid leukemia
1436170|NCT00248547|blastic phase chronic myelogenous leukemia
1436171|NCT00248547|chronic eosinophilic leukemia
1436172|NCT00248547|chronic idiopathic myelofibrosis
1436173|NCT00248547|chronic myelomonocytic leukemia
1436174|NCT00248547|chronic neutrophilic leukemia
1436175|NCT00248547|chronic phase chronic myelogenous leukemia
1436176|NCT00248547|de novo myelodysplastic syndromes
1436177|NCT00248547|disseminated neuroblastoma
1436178|NCT00248547|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1436179|NCT00248547|myelodysplastic/myeloproliferative disease, unclassifiable
1436180|NCT00248547|nodal marginal zone B-cell lymphoma
1436181|NCT00248547|noncontiguous stage II adult Burkitt lymphoma
1436182|NCT00248547|noncontiguous stage II adult diffuse large cell lymphoma
1436183|NCT00248547|noncontiguous stage II adult diffuse mixed cell lymphoma
1436184|NCT00248547|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1436185|NCT00248547|noncontiguous stage II adult immunoblastic large cell lymphoma
1436186|NCT00248547|noncontiguous stage II adult lymphoblastic lymphoma
1436187|NCT00248547|noncontiguous stage II grade 1 follicular lymphoma
1436188|NCT00248547|noncontiguous stage II grade 2 follicular lymphoma
1436189|NCT00248547|noncontiguous stage II grade 3 follicular lymphoma
1436190|NCT00248547|noncontiguous stage II mantle cell lymphoma
1436191|NCT00248547|noncontiguous stage II marginal zone lymphoma
1436192|NCT00248547|noncontiguous stage II small lymphocytic lymphoma
1436193|NCT00248547|poor prognosis metastatic gestational trophoblastic tumor
1436194|NCT00248547|previously treated myelodysplastic syndromes
1436195|NCT00248547|recurrent adult acute lymphoblastic leukemia
1436196|NCT00248547|recurrent adult acute myeloid leukemia
1436197|NCT00248547|recurrent adult Burkitt lymphoma
1436198|NCT00248547|recurrent adult Hodgkin lymphoma
1436199|NCT00248547|recurrent adult diffuse large cell lymphoma
1436200|NCT00248547|recurrent adult diffuse mixed cell lymphoma
1436201|NCT00248547|recurrent adult diffuse small cleaved cell lymphoma
1436202|NCT00248547|recurrent adult immunoblastic large cell lymphoma
1436203|NCT00248547|recurrent adult lymphoblastic lymphoma
1436204|NCT00248547|recurrent cutaneous T-cell non-Hodgkin lymphoma
1436205|NCT00248547|recurrent grade 1 follicular lymphoma
1436206|NCT00248547|recurrent grade 2 follicular lymphoma
1436207|NCT00248547|recurrent grade 3 follicular lymphoma
1436208|NCT00248547|recurrent mantle cell lymphoma
1436209|NCT00248547|recurrent marginal zone lymphoma
1436210|NCT00248547|recurrent mycosis fungoides/Sezary syndrome
1436211|NCT00248547|recurrent neuroblastoma
1436212|NCT00248547|recurrent ovarian epithelial cancer
1436213|NCT00248547|recurrent ovarian germ cell tumor
1436214|NCT00248547|recurrent small lymphocytic lymphoma
1436215|NCT00248547|recurrent malignant testicular germ cell tumor
1436216|NCT00248547|refractory chronic lymphocytic leukemia
1436217|NCT00248547|refractory hairy cell leukemia
1436218|NCT00248547|refractory multiple myeloma
1436219|NCT00248547|relapsing chronic myelogenous leukemia
1436220|NCT00248547|secondary acute myeloid leukemia
1436221|NCT00248547|secondary myelodysplastic syndromes
1436222|NCT00248547|splenic marginal zone lymphoma
1436223|NCT00248547|stage I multiple myeloma
1436224|NCT00248547|stage II multiple myeloma
1436225|NCT00248547|stage II ovarian epithelial cancer
1436226|NCT00248547|stage III adult Burkitt lymphoma
1436227|NCT00248547|stage III adult Hodgkin lymphoma
1436228|NCT00248547|stage III adult diffuse large cell lymphoma
1436229|NCT00248547|stage III adult diffuse mixed cell lymphoma
1436230|NCT00248547|stage III adult diffuse small cleaved cell lymphoma
1436231|NCT00248547|stage III adult immunoblastic large cell lymphoma
1436232|NCT00248547|stage III adult lymphoblastic lymphoma
1436233|NCT00248547|stage III chronic lymphocytic leukemia
1436234|NCT00248547|stage III grade 1 follicular lymphoma
1436235|NCT00248547|stage III grade 2 follicular lymphoma
1436236|NCT00248547|stage III grade 3 follicular lymphoma
1436237|NCT00248547|stage III mantle cell lymphoma
1436238|NCT00248547|stage III marginal zone lymphoma
1436239|NCT00248547|stage III multiple myeloma
1436240|NCT00248547|stage III ovarian epithelial cancer
1436241|NCT00248547|stage III small lymphocytic lymphoma
1436242|NCT00248547|stage III malignant testicular germ cell tumor
1436243|NCT00248547|stage IIIA breast cancer
1436244|NCT00248547|stage IIIB breast cancer
1436245|NCT00248547|stage IIIC breast cancer
1436246|NCT00248547|stage IV adult Burkitt lymphoma
1436247|NCT00248547|stage IV adult Hodgkin lymphoma
1436248|NCT00248547|stage IV adult diffuse large cell lymphoma
1436249|NCT00248547|stage IV adult diffuse mixed cell lymphoma
1436250|NCT00248547|stage IV adult diffuse small cleaved cell lymphoma
1436251|NCT00248547|stage IV adult immunoblastic large cell lymphoma
1436252|NCT00248547|stage IV adult lymphoblastic lymphoma
1436253|NCT00248547|stage IV breast cancer
1436254|NCT00248547|stage IV chronic lymphocytic leukemia
1436255|NCT00248547|stage IV grade 1 follicular lymphoma
1436256|NCT00248547|stage IV grade 2 follicular lymphoma
1436257|NCT00248547|stage IV grade 3 follicular lymphoma
1436258|NCT00248547|stage IV mantle cell lymphoma
1436259|NCT00248547|stage IV marginal zone lymphoma
1436260|NCT00248547|stage IV ovarian epithelial cancer
1436261|NCT00248547|stage IV small lymphocytic lymphoma
1436262|NCT00248547|unspecified adult solid tumor, protocol specific
1436263|NCT00248534|primary central nervous system non-Hodgkin lymphoma
1436264|NCT00248521|unspecified adult solid tumor, protocol specific
1436265|NCT00248495|stage IIIA non-small cell lung cancer
1436266|NCT00248495|stage IIIB non-small cell lung cancer
1436267|NCT00248495|stage II non-small cell lung cancer
1436268|NCT00248495|stage I non-small cell lung cancer
1436269|NCT00248482|extensive stage small cell lung cancer
1436270|NCT00248482|recurrent small cell lung cancer
1436271|NCT00248469|Community randomised trial
1436272|NCT00248469|Sexual behavior
1436273|NCT00248469|Intervention
1436274|NCT00248469|Evaluation
1436275|NCT00248469|Sexual health education
1436276|NCT00248469|Youth-friendly health services
1436277|NCT00248469|Adolescents
1436278|NCT00248469|Behavior change
1436279|NCT00248469|HIV Seronegativity
1436280|NCT00248469|HIV
1436281|NCT00248443|Haematology and cancer patients
1436282|NCT00248443|Acute respiratory failure
1436283|NCT00248443|Bronchoalveolar lavage
1436284|NCT00248443|Non invasive diagnostic tools
1436285|NCT00248443|Mechanical ventilation
1436286|NCT00248443|Intensive Care
1436287|NCT00248430|graft versus host disease
1436288|NCT00248430|stage II multiple myeloma
1436289|NCT00248430|stage III multiple myeloma
1436290|NCT00248430|refractory multiple myeloma
1436291|NCT00248430|refractory chronic lymphocytic leukemia
1436292|NCT00248430|stage III chronic lymphocytic leukemia
1436293|NCT00248430|stage IV chronic lymphocytic leukemia
1436294|NCT00248430|recurrent small lymphocytic lymphoma
1436295|NCT00248430|stage III small lymphocytic lymphoma
1436296|NCT00248430|stage IV small lymphocytic lymphoma
1436297|NCT00248430|recurrent mantle cell lymphoma
1436298|NCT00248430|stage III mantle cell lymphoma
1436299|NCT00248430|stage IV mantle cell lymphoma
1436300|NCT00248430|recurrent grade 1 follicular lymphoma
1436301|NCT00248430|recurrent grade 2 follicular lymphoma
1436302|NCT00248430|recurrent grade 3 follicular lymphoma
1436303|NCT00248430|stage III grade 1 follicular lymphoma
1436304|NCT00248430|stage III grade 2 follicular lymphoma
1436305|NCT00248430|stage III grade 3 follicular lymphoma
1436306|NCT00248430|stage IV grade 1 follicular lymphoma
1436307|NCT00248430|stage IV grade 2 follicular lymphoma
1436308|NCT00248430|stage IV grade 3 follicular lymphoma
1436309|NCT00248404|colorectal cancer
1436310|NCT00248404|ovarian cancer
1436311|NCT00248404|lung cancer
1436312|NCT00248404|breast cancer
1436313|NCT00248404|small bowel cancer
1436314|NCT00248404|Advanced, recurrent, or metastatic solid tumors of any type
1436315|NCT00248404|TS overexpression confirmed by fresh biopsy (RTPCR)
1436316|NCT00248404|Suitable for experimental monotherapy
1436317|NCT00248391|adenoid hypertrophy
1436318|NCT00248391|feeding position
1436319|NCT00248391|supine
1436320|NCT00248391|upright
1436321|NCT00248391|pneumonia
1436322|NCT00248391|wheezing
1436323|NCT00248391|otitis
1436324|NCT00248391|adenoid
1436325|NCT00248391|tonsil
1436326|NCT00248391|caries
1436327|NCT00248378|Multiple Sclerosis
1436328|NCT00248378|Cannabis
1436329|NCT00248378|Spasticity
1436330|NCT00248378|Tolerability
1436331|NCT00248365|Chronic GvHD
1436332|NCT00248365|Extensive chronic GvHD
1436333|NCT00248365|Resistant chronic GvHD
1436334|NCT00248352|Coronary Artery Disease
1436335|NCT00248352|Diabetes Mellitus
1436336|NCT00248352|Type 2
1436337|NCT00248352|Chronic Disease
1436338|NCT00248339|Hepatitis C
1436339|NCT00248339|Peginterferon
1436340|NCT00248339|Ribavirin
1436341|NCT00248339|Procrit
1436342|NCT00248339|Epoetin-alpha
1436343|NCT00248326|atrial fibrillation
1436344|NCT00248326|genetics
1436345|NCT00248326|genetic polymorphisms
1436346|NCT00248313|Kidney Disease
1436347|NCT00248300|ventilator-associated pneumonia
1436348|NCT00248300|hospital acquired pneumonia
1436349|NCT00248274|atrial fibrillation
1436350|NCT00248274|genetics
1436351|NCT00248261|ziprasidone, sertraline, PTSD
1436352|NCT00248248|Consolidation
1436353|NCT00248248|Ovarian cancer
1436354|NCT00248248|DOXIL
1436355|NCT00248248|Hand-foot syndrome
1436356|NCT00248235|exercise
1436357|NCT00248235|rehabilitation
1436358|NCT00248235|head and neck neoplasms
1436359|NCT00248222|Exercise
1436360|NCT00248222|Rehabilitation
1436361|NCT00248222|Aerobic training
1436362|NCT00248209|Female Orgasmic Disorder
1436363|NCT00248209|Female Sexual Dysfunction
1436364|NCT00248170|Breast cancer
1436365|NCT00248170|letrozole
1436366|NCT00248170|anastrozole
1436367|NCT00248170|adjuvant
1436368|NCT00248170|postmenopausal
1436369|NCT00248170|FACE
1436370|NCT00248157|Diabetic retinopathy
1436371|NCT00248157|Octreotide acetate in microspheres
1436372|NCT00248144|Herpes labialis
1436373|NCT00248131|Diabetic retinopathy, octreotide acetate in microspheres
1436374|NCT00248118|Randomized
1436375|NCT00248118|Double-blind
1436376|NCT00248118|Placebo-controlled
1436377|NCT00248105|Arthritis
1436378|NCT00248105|Physical Activity
1436379|NCT00248092|d-Amphetamine
1436380|NCT00248092|Diethylpropion
1436381|NCT00248092|Diethylpropion Hydrochloride
1436382|NCT00248092|Attention Deficit Hyperactivity Disorder
1436383|NCT00248092|Attention Deficit Disorders with Hyperactivity
1436384|NCT00248092|Attention Deficit Hyperactivity Disorders
1436385|NCT00248092|Amphetamine Abuse
1436386|NCT00248092|Amphetamine Dependence
1436387|NCT00248092|Amphetamine Addiction
1436388|NCT00248092|Amphetamine Users
1436389|NCT00248092|Drug Abuse
1436390|NCT00248092|Drug Addiction
1436391|NCT00248092|Drug Dependence
1436392|NCT00248092|Drug Habituation
1436393|NCT00248092|Drug Use Disorders
1436394|NCT00248092|Substance Abuse
1436395|NCT00248092|Substance Dependence
1436396|NCT00248092|Substance Use Disorders
1436397|NCT00248092|Drug Usage
1436398|NCT00248092|Substance Addiction
1436399|NCT00248079|Coronary Disease
1436400|NCT00248066|Coronary artery disease
1436401|NCT00248066|Restenosis
1436402|NCT00248066|Coronary stent restenosis
1436403|NCT00248053|Familial adenomatous polyposis patient with 5 or more adenomatous polyps in the colon or ileoanal pouch
1436404|NCT00248040|Kidney transplantation
1436405|NCT00248040|Reperfusion Injury
1436406|NCT00248040|Survival
1436407|NCT00248027|early intervention,program evaluation
1436408|NCT00248014|CLASS II
1436409|NCT00248014|FUNCTIONAL APPLIANCE
1436410|NCT00248014|MANDIBULAR ADVANCEMENT STABILITY
1436411|NCT00247988|Ovarian
1436412|NCT00247988|Relapsed
1436413|NCT00247975|L-carnitine
1436414|NCT00247975|Breast cancer
1436415|NCT00247975|Anthracycline Cardiotoxicity
1436416|NCT00247975|Primary prevention
1436417|NCT00247975|Anthracycline induced cardiotoxicity
1436418|NCT00247975|Left Ventricular Ejection Fraction
1436419|NCT00247962|Ankylosing Spondylitis (AS)
1436420|NCT00247949|carbon dioxide
1436421|NCT00247949|monitoring
1436422|NCT00247949|major surgery
1436423|NCT00247949|repeated blood gas testing
1436424|NCT00247949|carbon dioxide monitoring
1436425|NCT00247936|Adenocarcinoma, Esophagectomy
1436426|NCT00247923|Endometrial polyps.
1436427|NCT00247923|Angiogenesis.
1436428|NCT00247923|Asymptomatic.
1436429|NCT00247923|Symptoms.
1436430|NCT00247923|Malignancy.
1436431|NCT00247923|Treatment efficiency.
1436432|NCT00247923|Vaginal bleeding.
1436433|NCT00247910|hypertension, ambulatory BP, office resting BP, hydrochlorothiazide, stress reduction, self-help, psychotherapy, efficacy
1436434|NCT00247884|Injection drug users
1436435|NCT00247884|pegylated interferon
1436436|NCT00247884|ribavirin,
1436437|NCT00247884|HCV
1436438|NCT00247871|MRSA, USA300, CMRSA-10, CMRSA-6, soft tissue abscesses
1436439|NCT00247858|MRSA, USA300, CMRSA-10, CMRSA-6, soft tissue abscesses
1436440|NCT00247845|HIV
1436441|NCT00247845|Atazanavir
1436442|NCT00247845|quality of life
1436443|NCT00247845|Treatment Experienced
1436444|NCT00247832|Monitoring, early mobilization, motivation modality, visitation rate, step rates, anxiety, pain
1436445|NCT00247832|Elective lobectomy
1436446|NCT00247819|Substance abuse
1436447|NCT00247806|Pilot, pediatric, stem cell transplant, lactose intolerance
1436448|NCT00247793|immunonutrition
1436449|NCT00247793|preoperative optimization
1436450|NCT00247793|preoperative enteral nutritional supplement
1436451|NCT00247793|high risk
1436452|NCT00247793|cardiac surgery
1436453|NCT00247793|arginine
1436454|NCT00247793|omega-3 polyunsaturated fatty acids
1436455|NCT00247793|nucleotides
1436456|NCT00247793|glycine
1436457|NCT00247793|immune enhancing nutritional supplement
1436458|NCT00247793|immune enhancing formula
1436459|NCT00247780|Atrial fibrillation
1436460|NCT00247780|Pulmonary vein isolation
1436461|NCT00247780|Tissue Doppler echocardiography
1436462|NCT00247754|Anxiety
1436463|NCT00247754|Therapy
1436464|NCT00247754|Behaviour
1436465|NCT00247741|spinal anesthesia
1436466|NCT00247741|lidocaine
1436467|NCT00247741|articaine
1436468|NCT00247741|intrathecal
1436469|NCT00247728|PI-88
1436470|NCT00247728|post resection hepatoma
1436471|NCT00247728|adjuvant therapy
1436472|NCT00247728|hepatectomy
1436473|NCT00247728|hepatoma
1436474|NCT00247715|uninvestigated dyspepsia
1436475|NCT00247715|cost effectiveness
1436476|NCT00247715|acid suppressive medicine
1436477|NCT00247715|primary care
1436478|NCT00247715|gastrointestinal complaints
1436479|NCT00247715|Gastrointestinal drugs
1436480|NCT00247702|CYP2C9
1436481|NCT00247702|VKORC1
1436482|NCT00247702|polymorphism
1436483|NCT00247702|warfarin
1436484|NCT00247689|Ritalin
1436485|NCT00247689|Substance Abuse
1436486|NCT00247689|Allelic Variants
1436487|NCT00247689|Genotype
1436488|NCT00247689|Addiction-Associated Human Gene Variants
1436489|NCT00247689|Methylphenidate
1436490|NCT00247676|Liver neoplasms, sunitinib, Phase 2
1436491|NCT00247663|Aromatase inhibitor
1436492|NCT00247663|letrozole
1436493|NCT00247663|breast cancer
1436494|NCT00247650|neoadjuvant, postmenopausal women, breast cancer, hormonal therapy, bisphosphonate
1436495|NCT00247637|Mental Health
1436496|NCT00247637|Psychosis
1436497|NCT00247637|Genetics
1436498|NCT00247637|Heredity
1436499|NCT00247624|Depression
1436500|NCT00247624|Hypnotics
1436501|NCT00247624|Sleep
1436502|NCT00247624|Quality of Life
1436503|NCT00247624|Insomnia
1436504|NCT00247624|Suicide
1436505|NCT00247611|HIV
1436506|NCT00247611|AIDS
1436507|NCT00247611|Antiretroviral Medication Adherence
1436508|NCT00247585|Alcohol
1436509|NCT00247585|Alcohol abuse
1436510|NCT00247585|Alcohol consumption
1436511|NCT00247585|Unhealthy alcohol use
1436512|NCT00247585|Residual effects
1436513|NCT00247585|Sleep Stages
1436514|NCT00247585|Respiratory Physiology
1436515|NCT00247572|d-Amphetamine
1436516|NCT00247572|Attention Deficit Hyperactivity Disorder
1436517|NCT00247572|Attention Deficit Disorders with Hyperactivity
1436518|NCT00247572|Attention Deficit Hyperactivity Disorders
1436519|NCT00247572|Amphetamine Abuse
1436520|NCT00247572|Amphetamine Dependence
1436521|NCT00247572|Amphetamine Addiction
1436522|NCT00247572|Amphetamine Users
1436523|NCT00247572|Drug Abuse
1436524|NCT00247572|Drug Addiction
1436525|NCT00247572|Drug Dependence
1436526|NCT00247572|Drug Habituation
1436527|NCT00247572|Drug Use Disorders
1436528|NCT00247572|Substance Abuse
1436529|NCT00247572|Substance Dependence
1436530|NCT00247572|Substance Use Disorders
1436531|NCT00247572|Drug Usage
1436532|NCT00247572|Substance Addiction
1436533|NCT00247572|Drug Abuse, Intravenous
1436534|NCT00247572|Intravenous Drug Abuse
1436535|NCT00247559|crow's feet
1436536|NCT00247559|cosmesis
1436537|NCT00247559|ageing
1436538|NCT00247546|Falls
1436539|NCT00247546|Accidental falls
1436540|NCT00247546|Prevention
1436541|NCT00247546|Aged
1436542|NCT00247546|Multifactorial trial
1436543|NCT00247533|coronary disease
1436544|NCT00247533|cerebrovascular disorders
1436545|NCT00247533|angiography
1436546|NCT00247533|cerebral ischemia
1436547|NCT00247533|intracranial atherosclerosis
1436548|NCT00247533|Coronary artery disease
1436549|NCT00247533|cerebral artery stenosis
1436550|NCT00247533|percutaneous coronary balloon angioplasty
1436551|NCT00247533|coronary artery bypass surgery
1436552|NCT00247533|ischemic stroke
1436553|NCT00247533|electrocardiograph
1436554|NCT00247533|electroencephalograph
1436555|NCT00247533|Nuclear brain scan
1436556|NCT00247533|cognition decline
1436557|NCT00247533|atrial fibrillation
1436558|NCT00247533|undetermined ischemic stroke
1436559|NCT00247520|Seasonal allergic rhinitis (SAR), rhinoconjunctivitis, allergy
1436560|NCT00247507|Anemia
1436561|NCT00247507|atherosclerosis
1436562|NCT00247507|End-stage renal disease
1436563|NCT00247507|Erythropoietin
1436564|NCT00247507|Hemodialysis
1436565|NCT00247507|Oxidative stress
1436566|NCT00247507|Pro-inflammation
1436567|NCT00247494|HIV-1
1436568|NCT00247494|atherosclerosis
1436569|NCT00247494|immunomodulation
1436570|NCT00247481|Metastatic Breast Cancer
1436571|NCT00247455|Human nutrition
1436572|NCT00247455|Dietary fibre
1436573|NCT00247455|Insulin resistance
1436574|NCT00247455|Obesity
1436575|NCT00247455|Glucose
1436576|NCT00247455|Colonic fermentation
1436577|NCT00247455|Short chain fatty acids
1436578|NCT00247455|GLP-1
1436579|NCT00247455|Appetite
1436580|NCT00247455|Abdominal fat
1436581|NCT00247442|Mammography screening
1436582|NCT00247442|Breast cancer screening
1436583|NCT00247442|Screening outcomes
1436584|NCT00247442|Decision aid
1436585|NCT00247442|Decision support tool
1436586|NCT00247442|Informed choice
1436587|NCT00247429|depression
1436588|NCT00247429|anxiety
1436589|NCT00247429|elderly
1436590|NCT00247416|Untreated
1436591|NCT00247416|Lung
1436592|NCT00247416|Cancer
1436593|NCT00247416|non-small cell
1436594|NCT00247416|gemcitabine
1436595|NCT00247416|gemzar
1436596|NCT00247416|carboplatin
1436597|NCT00247416|dexamethasone
1436598|NCT00247403|Intracranial cancer
1436599|NCT00247403|Cancer
1436600|NCT00247403|2DG
1436601|NCT00247403|2-deoxyglucose
1436602|NCT00247403|Intracranial metastatic cancer
1436603|NCT00247390|Chronic Insomnia
1436604|NCT00247390|Sleep Initiation and Maintenance Disorder
1436605|NCT00247390|Drug Therapy
1436606|NCT00247377|Morbid Obesity
1436607|NCT00247377|Laparoscopic Gastric Bypass
1436608|NCT00247377|Laparoscopic Gastric Banding
1436609|NCT00247364|RLS
1436610|NCT00247338|parenteral nutrition
1436611|NCT00247338|low calorie
1436612|NCT00247338|low nitrogen
1436613|NCT00247338|gastrointestinal neoplasms
1436614|NCT00247338|gastrointestinal diseases
1436615|NCT00247338|gastrectomy
1436616|NCT00247338|colectomy
1436617|NCT00247338|rectectomy
1436618|NCT00247338|operations
1436619|NCT00247325|Kidney failure
1436620|NCT00247325|Contrast media
1436621|NCT00247325|Iodixanol
1436622|NCT00247325|Ioxaglate
1436623|NCT00247312|Prostate cancer
1436624|NCT00247312|brachytherapy
1436625|NCT00247312|palladium 103
1436626|NCT00247312|I-125
1436627|NCT00247299|Vascular lesions
1436628|NCT00247299|Intense pulse light
1436629|NCT00247299|phototermolysis
1436630|NCT00247299|wavelength
1436631|NCT00247299|filters
1436632|NCT00247299|non coherent
1436633|NCT00247286|urodynamic stress incontinence
1436634|NCT00247286|weighted vaginal cones
1436635|NCT00247286|pelvic floor biofeedback
1436636|NCT00247286|randomized controlled trial
1436637|NCT00247273|randomized controlled trial, osteoporosis, risedronate
1436638|NCT00247260|HCC
1436639|NCT00247260|Primary Liver Cancer
1436640|NCT00247221|Alcohol
1436641|NCT00247221|Substance abuse
1436642|NCT00247221|Adolescent
1436643|NCT00247221|Family functioning
1436644|NCT00247208|Coronary artery bypass
1436645|NCT00247208|Stents
1436646|NCT00247208|Angioplasty, Transluminal, Percutaneous Coronary
1436647|NCT00247208|Coronary Restenosis
1436648|NCT00247208|Paclitaxel
1436649|NCT00247195|Major Depression
1436650|NCT00247195|MDD
1436651|NCT00247195|Hispanic
1436652|NCT00247195|Primary Care
1436653|NCT00247195|Cultural Congruence
1436654|NCT00247182|Stepped Care
1436655|NCT00247182|Brief Motivational Intervention
1436656|NCT00247182|Minimal Intervention
1436657|NCT00247182|Treatment response
1436658|NCT00247182|College Students
1436659|NCT00247169|cervical intraepithelial neoplasia (CIN)
1436660|NCT00247169|progesterone
1436661|NCT00247156|Autism
1436662|NCT00247156|eye contact
1436663|NCT00247156|Noncommunicable
1436664|NCT00247143|Protease Inhibitor
1436665|NCT00247143|Antiretroviral Agents
1436666|NCT00247143|Treatment Experienced
1436667|NCT00247130|Omeprazole
1436668|NCT00247130|Ranitidine
1436669|NCT00247130|Endoscopic treatment
1436670|NCT00247130|Hemostasis
1436671|NCT00247130|Peptic ulcer
1436672|NCT00247117|non-alcoholic fatty liver disease
1436673|NCT00247117|insulin resistance
1436674|NCT00247117|metformin
1436675|NCT00247104|Urinary tract infection
1436676|NCT00247104|Endometritis
1436677|NCT00247104|Respiratory Distress Syndrome
1436678|NCT00247104|Necrotizing enterocolitis
1436679|NCT00247104|Intraventricular hemorrhage
1436680|NCT00247104|Latent period
1436681|NCT00247104|Neonatal infection
1436682|NCT00247091|HIV
1436683|NCT00247091|measles
1436684|NCT00247091|measles vaccine
1436685|NCT00247091|children
1436686|NCT00247091|Zambia
1436687|NCT00247078|black
1436688|NCT00247078|widow
1436689|NCT00247078|spider
1436690|NCT00247078|antivenom
1436691|NCT00247052|post operative pericardial effusion
1436692|NCT00247052|NSAID
1436693|NCT00247039|neutropenia
1436694|NCT00247039|fever
1436695|NCT00247039|garlic
1436696|NCT00247039|infection
1436697|NCT00247026|myelodysplasia
1436698|NCT00247026|curcumin
1436699|NCT00247026|coenzyme Q10
1436700|NCT00247026|cytopenia
1436701|NCT00247013|automated telephone system
1436702|NCT00247013|breast cancer
1436703|NCT00247013|cancer prevention
1436704|NCT00247013|intervention
1436705|NCT00247013|mammography
1436706|NCT00247013|screening
1436707|NCT00247000|Cardiovascular Diseases
1436708|NCT00247000|Heart Disease
1436709|NCT00247000|Heart Failure,Congestive
1436710|NCT00247000|Health Outcomes
1436711|NCT00247000|Disease Management
1436712|NCT00247000|Telehomecare
1436713|NCT00247000|Home Telehealth
1436714|NCT00246974|bladder cancer
1436715|NCT00246974|Transitionel cell cancer of the urothelium
1436716|NCT00246961|Adjuvant
1436717|NCT00246948|Physical therapy
1436718|NCT00246935|COPD
1436719|NCT00246935|Phosphodiesterase 4 inhibitor
1436720|NCT00246935|Roflumilast
1436721|NCT00246922|Asthma
1436722|NCT00246922|Roflumilast
1436723|NCT00246922|phosphodiesterase 4 inhibitor
1436724|NCT00246909|Gastroesophageal Reflux
1436725|NCT00246909|Gastroesophageal Reflux Disease
1436726|NCT00246909|Pantoprazole
1436727|NCT00246883|Endothelial Progenitor Cells
1436728|NCT00246883|Nitric Oxide
1436729|NCT00246883|Brachial Artery Reactivity
1436730|NCT00246883|Physical Fitness
1436731|NCT00246883|C-reactive Protein
1436732|NCT00246883|Exercise
1436733|NCT00246883|Vascular Function
1436734|NCT00246870|Seizures
1436735|NCT00246870|Development
1436736|NCT00246870|Pediatric
1436737|NCT00246870|Benzodiazepine Receptors
1436738|NCT00246870|Neurotransmission
1436739|NCT00246870|Succinic Semialdehyde Dehydrogenase
1436740|NCT00246870|Deficiency
1436741|NCT00246870|SSADH Deficiency
1436742|NCT00246870|Healthy Volunteer
1436743|NCT00246870|HV
1436744|NCT00246857|Apoptosis
1436745|NCT00246857|T-cell
1436746|NCT00246857|Autoimmunity
1436747|NCT00246857|Immunodeficiency
1436748|NCT00246857|B-Cell
1436749|NCT00246857|Inherited Lymphhocyte Homeostasis
1436750|NCT00246857|Genetic Disease
1436751|NCT00246844|Transplant
1436752|NCT00246844|Diabetes
1436753|NCT00246844|C-Peptide
1436754|NCT00246844|B Cell
1436755|NCT00246844|Immunosuppression
1436756|NCT00246844|Type 1 Diabetes
1436757|NCT00246844|Pancreas Transplant
1436758|NCT00246831|fMRI
1436759|NCT00246831|Self-Agency
1436760|NCT00246831|Functional Magnetic Resonance Imaging (fMRI)
1436761|NCT00246831|Voluntary Movement
1436762|NCT00246831|Healthy Volunteer
1436763|NCT00246831|HV
1436764|NCT00246818|Mind-Body
1436765|NCT00246818|Stress Reduction
1436766|NCT00246818|Complementary Medicine
1436767|NCT00246818|Quality of Life
1436768|NCT00246818|Well-being
1436769|NCT00246818|Psychoneuroimmunology
1436770|NCT00246818|Tai Chi
1436771|NCT00246818|Aerobic Exercise
1436772|NCT00246818|Cancer Survivor
1436773|NCT00246805|Permanent atrial fibrillation
1436774|NCT00246805|VVI(R) pacing
1436775|NCT00246805|rate regularization
1436776|NCT00246792|School-based intervention
1436777|NCT00246792|Learning disabilities
1436778|NCT00246792|ecological intervention
1436779|NCT00246779|transfusion
1436780|NCT00246779|cardiac surgery
1436781|NCT00246779|modified ultrafiltration
1436782|NCT00246779|Cardiopulmonary bypass
1436783|NCT00246766|Maternal's movements recorded by a specific sensor
1436784|NCT00246766|Parameters of fetal distress (umbilical and cerebral Doppler) and new-born parameters.
1436785|NCT00246753|adenocarcinoma of the prostate
1436786|NCT00246753|recurrent prostate cancer
1436787|NCT00246753|stage I prostate cancer
1436788|NCT00246753|stage II prostate cancer
1436789|NCT00246753|stage III prostate cancer
1436790|NCT00246753|stage IV prostate cancer
1436791|NCT00246740|Doxycycline
1436792|NCT00246740|coronary artery bypass grafting
1436793|NCT00246714|endotoxin tolerance
1436794|NCT00246714|humans
1436795|NCT00246714|cross-tolerance
1436796|NCT00246714|pro and anti-inflammatory cytokines
1436797|NCT00246701|omega-3-acid ethyl esters
1436798|NCT00246701|simvastatin
1436799|NCT00246701|Lovaza
1436800|NCT00246701|High triglycerides
1436801|NCT00246662|Leukemia
1436802|NCT00246662|Hematologic
1436803|NCT00246662|Blood
1436804|NCT00246662|Cancer
1436805|NCT00246662|Malignancy
1436806|NCT00246662|Myelodysplastic Syndromes
1436807|NCT00246649|Mafosfamide
1436808|NCT00246649|Growth Factor
1436809|NCT00246649|Stem Cell
1436810|NCT00246649|Bone Marrow
1436811|NCT00246636|Very high triglycerides
1436812|NCT00246636|omega-3-acid ethyl esters
1436813|NCT00246636|fenofibrate
1436814|NCT00246636|Lovaza
1436815|NCT00246610|Non-randomized open-label single-arm study of Nelfinavir plus Combivir in pregnant females infected with HIV-1 virus.
1436816|NCT00246597|Anemia
1436817|NCT00246597|Breast cancer
1436818|NCT00246597|Hemoglobin
1436819|NCT00246597|Quality of Life
1436820|NCT00246597|Adjuvant Chemotherapy
1436821|NCT00246597|Pure red cell aplasia (PRCA)
1436822|NCT00246597|Cognitive and executive function
1436823|NCT00246584|Hypertension
1436824|NCT00246584|angiotensin
1436825|NCT00246584|renin
1436826|NCT00246584|aliskiren
1436827|NCT00246558|Tight Achilles Tendon
1436828|NCT00246558|Hyperpronation of the foot
1436829|NCT00246519|hypertension
1436830|NCT00246519|pharmacogenetics
1436831|NCT00246519|pharmacogenomics
1436832|NCT00246519|beta-blocker
1436833|NCT00246519|atenolol
1436834|NCT00246519|diuretic
1436835|NCT00246519|hydrochlorothiazide
1436836|NCT00246519|blood pressure
1436837|NCT00246519|metabolic adverse effects
1436838|NCT00246506|Infertility
1436839|NCT00246506|Fertility
1436840|NCT00246506|Reproduction
1436841|NCT00246506|Advanced Maternal Age
1436842|NCT00246506|Reproductive Medicine
1436843|NCT00246506|Reproductive Techniques
1436844|NCT00246506|Pregnancy
1436845|NCT00246493|Coronary
1436846|NCT00246493|Endothelial
1436847|NCT00246493|Vascular
1436848|NCT00246493|Atherosclerosis
1436849|NCT00246493|Arterial
1436850|NCT00246480|Respiratory Syncytial Virus Infections, RSV, elderly
1436851|NCT00246467|plague
1436852|NCT00246454|circadian
1436853|NCT00246454|advanced sleep phase
1436854|NCT00246454|delayed sleep phase
1436855|NCT00246441|Pharmacotherapy
1436856|NCT00246441|Self medication
1436857|NCT00246428|Motivational Interviewing
1436858|NCT00246428|Alcohol Abuse
1436859|NCT00246428|Alcohol Dependence
1436860|NCT00246428|Emergency Care Setting
1436861|NCT00246415|Alcohol Dependence
1436862|NCT00246415|Alcohol Abuse
1436863|NCT00246415|Memantine
1436864|NCT00246415|Alcohol Treatment
1436865|NCT00246389|muscle spasm
1436866|NCT00246389|cyclobenzaprine hydrochloride
1436867|NCT00246363|HIV
1436868|NCT00246363|Hepatitis C
1436869|NCT00246350|Headaches
1436870|NCT00246350|Spinal manipulation
1436871|NCT00246350|Massage
1436872|NCT00246350|chiropractic
1436873|NCT00246298|Anemia
1436874|NCT00246298|erythropoetin
1436875|NCT00246298|Epoetin alfa
1436876|NCT00246298|erythropoietin recombinant
1436877|NCT00246298|HIV infection
1436878|NCT00246298|HIV
1436879|NCT00246298|AIDS
1436880|NCT00246285|schizophrenia
1436881|NCT00246285|antipsychotic agents
1436882|NCT00246285|risperidone
1436883|NCT00246285|adolescents
1436884|NCT00246272|risperidone
1436885|NCT00246272|schizophrenia
1436886|NCT00246272|rapidly-dissolving
1436887|NCT00246259|Schizophrenia
1436888|NCT00246259|Schizoaffective disorder
1437314|NCT00245375|umbilical hernia repair
1436889|NCT00246259|Schizophreniform disorder
1436890|NCT00246259|Risperidone
1436891|NCT00246259|Risperdal Consta
1436892|NCT00246246|risperidone
1436893|NCT00246246|long-acting injectable
1436894|NCT00246246|bipolar disorder
1436895|NCT00246246|intramuscular injection
1436896|NCT00246233|methylphenidate hydrochloride
1436897|NCT00246233|oral tablets
1436898|NCT00246233|Major Depressive Disorder
1436899|NCT00246220|Attention deficit/hyperactivity disorder
1436900|NCT00246220|methylphenidate
1436901|NCT00246220|central nervous system stimulants
1436902|NCT00246207|Attention Deficit Hyperactivity Disorder
1436903|NCT00246207|once-day oral tablets
1436904|NCT00246194|Schizophrenia
1436905|NCT00246194|Mental disorder
1436906|NCT00246194|DSM-IV
1436907|NCT00246194|RISPERDAL CONSTA
1436908|NCT00246194|Risperidone
1436909|NCT00246194|Long-acting risperidone
1436910|NCT00246194|Disorganized
1436911|NCT00246194|Catatonic
1436912|NCT00246194|Paranoid
1436913|NCT00246181|Lung cancer
1436914|NCT00246181|stereotactic body radiotherapy
1436915|NCT00246168|Rheumatoid arthritis
1436916|NCT00246168|NSAID add-on therapy
1436917|NCT00246168|tramadol
1436918|NCT00246168|acetaminophen
1436919|NCT00246155|chronic
1436920|NCT00246155|muscular
1436921|NCT00246129|Kidney Transplantation
1436922|NCT00246129|Kidney Disease
1436923|NCT00246129|Kidney Failure
1436924|NCT00246129|Graft Rejection
1436925|NCT00246116|Lung Cancer
1436926|NCT00246116|Radiation Oncology
1436927|NCT00246116|Treated with Stereostatic Body Radiation
1436928|NCT00246103|Valproic Acid
1436929|NCT00246103|Epirubicin
1436930|NCT00246103|Solid Tumor
1436931|NCT00246103|Malignancies
1436932|NCT00246077|chronic transfusion therapy
1436933|NCT00246077|quality of life
1436934|NCT00246064|Rheumatoid Arthritis
1436935|NCT00246064|Infliximab infusions
1436936|NCT00246064|Methotrexate
1436937|NCT00246064|Remicade
1436938|NCT00246051|Police
1436939|NCT00246051|Sleep
1436940|NCT00246051|Fatigue
1436941|NCT00246051|Work Hours
1436942|NCT00246051|Sleep disorder
1436943|NCT00246051|Performance
1436944|NCT00246038|Abdominal Aortic Aneurysm
1436945|NCT00246038|Aortic Aneurysm
1436946|NCT00246038|AAA
1436947|NCT00246038|Endovascular
1436948|NCT00246038|Stent Graft
1436949|NCT00246038|Endograft
1436950|NCT00246038|Vascular Prostheses
1436951|NCT00246012|Melanoma
1436952|NCT00246012|Neoplasm
1436953|NCT00246012|CNTO 95
1436954|NCT00246012|Dacarbazine
1436955|NCT00246012|Intetumumab
1436956|NCT00245986|Pharmacokinetics
1436957|NCT00245986|Cytochrome P450
1436958|NCT00245986|HIV Resistance
1436959|NCT00245986|Drug Interaction
1436960|NCT00245986|Non-Nucleoside Reverse Transcriptase Inhibitors
1436961|NCT00245986|HIV Positive
1436962|NCT00245986|Healthy Volunteer
1436963|NCT00245986|HV
1436964|NCT00245960|Psoriatic Arthritis
1436965|NCT00245960|Skin Disease
1436966|NCT00245960|Joint Disease
1436967|NCT00245947|Crohn's Disease
1436968|NCT00245947|Inflammation
1436969|NCT00245934|Rheumatoid Arthritis
1436970|NCT00245921|contraception
1436971|NCT00245908|Asthma
1436972|NCT00245908|Chlamydia pneumoniae
1436973|NCT00245908|Chlamydophila pneumoniae
1436974|NCT00245908|Azithromycin
1436975|NCT00245895|Anemia,
1436976|NCT00245895|Prostate Cancer
1436977|NCT00245882|Telehealth
1436978|NCT00245882|Veterans
1436979|NCT00245882|Glycemic control
1436980|NCT00245882|Active care management
1436981|NCT00245882|Care coordination
1436982|NCT00245869|Contrast-enhanced Ultrasound
1436983|NCT00245869|Ultrasound Contrast agents, microbubbles
1436984|NCT00245869|breast cancer
1436985|NCT00245869|chemotherapy
1436986|NCT00245869|vascularization
1436987|NCT00245856|Upper Extremity Deep-Vein Thrombosis
1436988|NCT00245856|DVT
1436989|NCT00245856|Fragmin
1436990|NCT00245856|Deep-Vein Thrombosis
1436991|NCT00245856|Thrombosis
1436992|NCT00245843|Premature birth
1436993|NCT00245843|moderate preterm
1436994|NCT00245843|late preterm
1436995|NCT00245843|Joint attention
1436996|NCT00245843|Social interaction
1436997|NCT00245843|Child development
1436998|NCT00245843|Parent
1436999|NCT00245843|infant
1437000|NCT00245830|Ischemia/reperfusion of the liver
1437001|NCT00245830|Ischemic Preconditioning
1437002|NCT00245830|Cadaver organ donor
1437003|NCT00245817|Anxiety. Depression. HRQOL. Psycho-educative intervention
1437004|NCT00245791|Complicated Urinary Infection
1437005|NCT00245115|adult acute myeloblastic leukemia without maturation (M1)
1437006|NCT00245115|childhood acute myeloblastic leukemia without maturation (M1)
1437007|NCT00245115|adult acute myeloblastic leukemia with maturation (M2)
1437008|NCT00245115|childhood acute myeloblastic leukemia with maturation (M2)
1437009|NCT00245115|adult acute promyelocytic leukemia (M3)
1437010|NCT00245115|childhood acute promyelocytic leukemia (M3)
1437011|NCT00245115|adult acute myelomonocytic leukemia (M4)
1437012|NCT00245115|childhood acute myelomonocytic leukemia (M4)
1437013|NCT00245115|adult acute monoblastic leukemia (M5a)
1437014|NCT00245115|adult acute monocytic leukemia (M5b)
1437015|NCT00245115|childhood acute monoblastic leukemia (M5a)
1437016|NCT00245115|childhood acute monocytic leukemia (M5b)
1437017|NCT00245115|adult erythroleukemia (M6a)
1437018|NCT00245115|adult pure erythroid leukemia (M6b)
1437019|NCT00245115|childhood acute erythroleukemia (M6)
1437020|NCT00245115|adult acute megakaryoblastic leukemia (M7)
1437021|NCT00245115|childhood acute megakaryocytic leukemia (M7)
1437022|NCT00245115|adult acute lymphoblastic leukemia in remission
1437023|NCT00245115|adult acute myeloid leukemia in remission
1437024|NCT00245115|childhood acute lymphoblastic leukemia in remission
1437025|NCT00245115|childhood acute myeloid leukemia in remission
1437026|NCT00245115|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1437027|NCT00245115|adult acute myeloid leukemia with inv(16)(p13;q22)
1437028|NCT00245115|adult acute myeloid leukemia with t(15;17)(q22;q12)
1437029|NCT00245115|adult acute myeloid leukemia with t(16;16)(p13;q22)
1437030|NCT00245115|adult acute myeloid leukemia with t(8;21)(q22;q22)
1437031|NCT00245115|secondary acute myeloid leukemia
1437032|NCT00245089|embryonal childhood rhabdomyosarcoma
1437033|NCT00245089|embryonal-botryoid childhood rhabdomyosarcoma
1437034|NCT00245089|previously untreated childhood rhabdomyosarcoma
1437035|NCT00245076|unspecified adult solid tumor, protocol specific
1437036|NCT00245050|drug/agent toxicity by tissue/organ
1437037|NCT00245050|fallopian tube cancer
1437038|NCT00245050|peritoneal cavity cancer
1437039|NCT00245050|recurrent ovarian epithelial cancer
1437040|NCT00245050|recurrent endometrial carcinoma
1437041|NCT00245050|stage III endometrial carcinoma
1437042|NCT00245050|stage IV endometrial carcinoma
1437043|NCT00245050|stage IV breast cancer
1437044|NCT00245050|male breast cancer
1437045|NCT00245050|recurrent breast cancer
1437046|NCT00245037|recurrent adult acute lymphoblastic leukemia
1437047|NCT00245037|recurrent adult acute myeloid leukemia
1437048|NCT00245037|de novo myelodysplastic syndromes
1437049|NCT00245037|previously treated myelodysplastic syndromes
1437050|NCT00245037|secondary myelodysplastic syndromes
1437051|NCT00245037|atypical chronic myeloid leukemia, breakpoint cluster region-Abelson (BCR-ABL) negative
1437052|NCT00245037|refractory chronic lymphocytic leukemia
1437053|NCT00245037|stage III chronic lymphocytic leukemia
1437054|NCT00245037|stage IV chronic lymphocytic leukemia
1437055|NCT00245037|accelerated phase chronic myelogenous leukemia
1437056|NCT00245037|blastic phase chronic myelogenous leukemia
1437057|NCT00245037|chronic phase chronic myelogenous leukemia
1437058|NCT00245037|relapsing chronic myelogenous leukemia
1437059|NCT00245037|stage II multiple myeloma
1437060|NCT00245037|stage III multiple myeloma
1437061|NCT00245037|primary systemic amyloidosis
1437062|NCT00245037|refractory multiple myeloma
1437063|NCT00245037|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1437064|NCT00245037|chronic eosinophilic leukemia
1437065|NCT00245037|primary myelofibrosis
1437066|NCT00245037|chronic neutrophilic leukemia
1437067|NCT00245037|essential thrombocythemia
1437068|NCT00245037|polycythemia vera
1437069|NCT00245037|chronic myelomonocytic leukemia
1437070|NCT00245037|acute undifferentiated leukemia
1437071|NCT00245037|extramedullary plasmacytoma
1437072|NCT00245037|isolated plasmacytoma of bone
1437073|NCT00245037|monoclonal gammopathy of undetermined significance
1437074|NCT00245037|stage I multiple myeloma
1437075|NCT00245037|secondary acute myeloid leukemia
1437076|NCT00245037|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1437077|NCT00245037|adult acute myeloid leukemia with inv(16)(p13;q22)
1437078|NCT00245037|adult acute myeloid leukemia with t(15;17)(q22;q12)
1437079|NCT00245037|adult acute myeloid leukemia with t(16;16)(p13;q22)
1437080|NCT00245037|adult acute myeloid leukemia with t(8;21)(q22;q22)
1437081|NCT00245037|nodal marginal zone B-cell lymphoma
1437082|NCT00245037|noncontiguous stage II adult Burkitt lymphoma
1437083|NCT00245037|noncontiguous stage II adult diffuse large cell lymphoma
1437084|NCT00245037|noncontiguous stage II adult diffuse mixed cell lymphoma
1437085|NCT00245037|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1437086|NCT00245037|noncontiguous stage II adult immunoblastic large cell lymphoma
1437087|NCT00245037|noncontiguous stage II adult lymphoblastic lymphoma
1437088|NCT00245037|noncontiguous stage II grade 1 follicular lymphoma
1437089|NCT00245037|noncontiguous stage II grade 2 follicular lymphoma
1437090|NCT00245037|noncontiguous stage II grade 3 follicular lymphoma
1437091|NCT00245037|noncontiguous stage II mantle cell lymphoma
1437092|NCT00245037|noncontiguous stage II marginal zone lymphoma
1437093|NCT00245037|noncontiguous stage II small lymphocytic lymphoma
1437094|NCT00245037|recurrent adult Burkitt lymphoma
1437095|NCT00245037|recurrent adult Hodgkin lymphoma
1437096|NCT00245037|recurrent adult diffuse large cell lymphoma
1437097|NCT00245037|recurrent adult diffuse mixed cell lymphoma
1437098|NCT00245037|recurrent adult diffuse small cleaved cell lymphoma
1437099|NCT00245037|recurrent adult immunoblastic large cell lymphoma
1437100|NCT00245037|recurrent adult lymphoblastic lymphoma
1437101|NCT00245037|recurrent cutaneous T-cell non-Hodgkin lymphoma
1437315|NCT00245362|cancer vaccine
1437102|NCT00245037|recurrent grade 1 follicular lymphoma
1437103|NCT00245037|recurrent grade 2 follicular lymphoma
1437104|NCT00245037|recurrent grade 3 follicular lymphoma
1437105|NCT00245037|recurrent mantle cell lymphoma
1437106|NCT00245037|recurrent marginal zone lymphoma
1437107|NCT00245037|recurrent small lymphocytic lymphoma
1437108|NCT00245037|splenic marginal zone lymphoma
1437109|NCT00245037|stage III adult Burkitt lymphoma
1437110|NCT00245037|stage III adult Hodgkin lymphoma
1437111|NCT00245037|stage III adult diffuse large cell lymphoma
1437112|NCT00245037|stage III adult diffuse mixed cell lymphoma
1437113|NCT00245037|stage III adult diffuse small cleaved cell lymphoma
1437114|NCT00245037|stage III adult immunoblastic large cell lymphoma
1437115|NCT00245037|stage III adult lymphoblastic lymphoma
1437116|NCT00245037|stage III grade 1 follicular lymphoma
1437117|NCT00245037|stage III grade 2 follicular lymphoma
1437118|NCT00245037|stage III grade 3 follicular lymphoma
1437119|NCT00245037|stage III mantle cell lymphoma
1437120|NCT00245037|stage III marginal zone lymphoma
1437121|NCT00245037|stage III small lymphocytic lymphoma
1437122|NCT00245037|stage IV adult Burkitt lymphoma
1437123|NCT00245037|stage IV adult Hodgkin lymphoma
1437124|NCT00245037|stage IV adult diffuse large cell lymphoma
1437125|NCT00245037|stage IV adult diffuse mixed cell lymphoma
1437126|NCT00245037|stage IV adult diffuse small cleaved cell lymphoma
1437127|NCT00245037|stage IV adult immunoblastic large cell lymphoma
1437128|NCT00245037|stage IV adult lymphoblastic lymphoma
1437129|NCT00245037|stage IV grade 1 follicular lymphoma
1437130|NCT00245037|stage IV grade 2 follicular lymphoma
1437131|NCT00245037|stage IV grade 3 follicular lymphoma
1437132|NCT00245037|stage IV mantle cell lymphoma
1437133|NCT00245037|stage IV marginal zone lymphoma
1437134|NCT00245037|stage IV small lymphocytic lymphoma
1437135|NCT00245037|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1437136|NCT00245024|breast cancer
1437137|NCT00245024|ductal breast carcinoma in situ
1437138|NCT00245024|lobular breast carcinoma in situ
1437139|NCT00245024|breast cancer in situ
1437140|NCT00245011|recurrent osteosarcoma
1437141|NCT00245011|metastatic osteosarcoma
1437142|NCT00245011|localized osteosarcoma
1437143|NCT00244998|adenocarcinoma of the prostate
1437144|NCT00244998|stage III prostate cancer
1437145|NCT00244998|stage IV prostate cancer
1437146|NCT00244985|recurrent grade 1 follicular lymphoma
1437147|NCT00244985|recurrent grade 2 follicular lymphoma
1437148|NCT00244985|recurrent grade 3 follicular lymphoma
1437149|NCT00244985|recurrent mantle cell lymphoma
1437150|NCT00244985|recurrent small lymphocytic lymphoma
1437151|NCT00244985|recurrent adult diffuse large cell lymphoma
1437152|NCT00244985|recurrent adult diffuse mixed cell lymphoma
1437153|NCT00244985|recurrent marginal zone lymphoma
1437154|NCT00244985|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1437155|NCT00244985|nodal marginal zone B-cell lymphoma
1437156|NCT00244985|splenic marginal zone lymphoma
1437157|NCT00244959|stage I breast cancer
1437158|NCT00244959|stage II breast cancer
1437159|NCT00244959|stage IIIA breast cancer
1437160|NCT00244959|stage IIIB breast cancer
1437161|NCT00244959|stage IIIC breast cancer
1437162|NCT00244959|ductal breast carcinoma in situ
1437163|NCT00244959|breast cancer in situ
1437164|NCT00244946|nodal marginal zone B-cell lymphoma
1437165|NCT00244946|recurrent adult Burkitt lymphoma
1437166|NCT00244946|recurrent adult diffuse large cell lymphoma
1437167|NCT00244946|recurrent adult diffuse mixed cell lymphoma
1437168|NCT00244946|recurrent adult diffuse small cleaved cell lymphoma
1437169|NCT00244946|recurrent adult immunoblastic large cell lymphoma
1437170|NCT00244946|recurrent adult lymphoblastic lymphoma
1437171|NCT00244946|recurrent grade 1 follicular lymphoma
1437172|NCT00244946|recurrent grade 2 follicular lymphoma
1437173|NCT00244946|recurrent grade 3 follicular lymphoma
1437174|NCT00244946|recurrent mantle cell lymphoma
1437175|NCT00244946|recurrent marginal zone lymphoma
1437176|NCT00244946|splenic marginal zone lymphoma
1437177|NCT00244946|stage III adult Burkitt lymphoma
1437178|NCT00244946|stage III adult diffuse large cell lymphoma
1437179|NCT00244946|stage III adult diffuse mixed cell lymphoma
1437180|NCT00244946|stage III adult diffuse small cleaved cell lymphoma
1437181|NCT00244946|stage III adult immunoblastic large cell lymphoma
1437182|NCT00244946|stage III adult lymphoblastic lymphoma
1437183|NCT00244946|stage III grade 1 follicular lymphoma
1437184|NCT00244946|stage III grade 2 follicular lymphoma
1437185|NCT00244946|stage III grade 3 follicular lymphoma
1437186|NCT00244946|stage III mantle cell lymphoma
1437187|NCT00244946|stage III marginal zone lymphoma
1437188|NCT00244946|stage IV adult Burkitt lymphoma
1437189|NCT00244946|stage IV adult diffuse large cell lymphoma
1437190|NCT00244946|stage IV adult diffuse mixed cell lymphoma
1437191|NCT00244946|stage IV adult diffuse small cleaved cell lymphoma
1437192|NCT00244946|stage IV adult immunoblastic large cell lymphoma
1437193|NCT00244946|stage IV adult lymphoblastic lymphoma
1437194|NCT00244946|stage IV grade 1 follicular lymphoma
1437195|NCT00244946|stage IV grade 2 follicular lymphoma
1437196|NCT00244946|stage IV grade 3 follicular lymphoma
1437197|NCT00244946|stage IV mantle cell lymphoma
1437198|NCT00244946|stage IV marginal zone lymphoma
1437199|NCT00244946|recurrent small lymphocytic lymphoma
1437200|NCT00244946|stage III small lymphocytic lymphoma
1437201|NCT00244946|stage IV small lymphocytic lymphoma
1437202|NCT00244946|noncontiguous stage II adult Burkitt lymphoma
1437203|NCT00244946|noncontiguous stage II adult diffuse large cell lymphoma
1437204|NCT00244946|noncontiguous stage II adult diffuse mixed cell lymphoma
1437205|NCT00244946|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1437206|NCT00244946|noncontiguous stage II adult immunoblastic large cell lymphoma
1437207|NCT00244946|noncontiguous stage II adult lymphoblastic lymphoma
1437208|NCT00244946|noncontiguous stage II grade 1 follicular lymphoma
1437209|NCT00244946|noncontiguous stage II grade 2 follicular lymphoma
1437210|NCT00244946|noncontiguous stage II grade 3 follicular lymphoma
1437211|NCT00244946|noncontiguous stage II mantle cell lymphoma
1437212|NCT00244946|noncontiguous stage II marginal zone lymphoma
1437213|NCT00244946|noncontiguous stage II small lymphocytic lymphoma
1437214|NCT00244933|stage IV breast cancer
1437215|NCT00244933|recurrent breast cancer
1437216|NCT00244920|adenocarcinoma of the prostate
1437217|NCT00244920|stage III prostate cancer
1437218|NCT00244907|Bone Resorption
1437219|NCT00244907|Phytoestrogens
1437220|NCT00244907|Calcium
1437221|NCT00244907|Genistein
1437222|NCT00244907|Equol
1437223|NCT00244894|fatigue
1437224|NCT00244894|recurrent prostate cancer
1437225|NCT00244894|stage II prostate cancer
1437226|NCT00244894|stage III prostate cancer
1437227|NCT00244894|stage IV prostate cancer
1437228|NCT00244894|hot flashes
1437229|NCT00244868|unspecified adult solid tumor, protocol specific
1437230|NCT00244868|metastatic cancer
1437231|NCT00244842|Randomized Controlled Trials
1437232|NCT00244842|Immunosuppression
1437233|NCT00244842|Adult
1437234|NCT00244842|Chronic Disease
1437235|NCT00244842|Dermatologic Agents
1437236|NCT00244842|Female
1437237|NCT00244842|Humans
1437238|NCT00244842|Male
1437239|NCT00244842|Middle Aged
1437240|NCT00244842|Severity of Illness Index
1437241|NCT00244842|Treatment Outcome
1437242|NCT00244842|Quality of Life
1437243|NCT00244842|Double-Blind Method
1437244|NCT00244829|accelerated phase chronic myelogenous leukemia
1437245|NCT00244829|blastic phase chronic myelogenous leukemia
1437246|NCT00244829|childhood chronic myelogenous leukemia
1437247|NCT00244829|chronic phase chronic myelogenous leukemia
1437248|NCT00244829|Philadelphia chromosome positive chronic myelogenous leukemia
1437249|NCT00244829|adult acute lymphoblastic leukemia in remission
1437250|NCT00244829|childhood acute lymphoblastic leukemia in remission
1437251|NCT00245765|chronic plaque psoriasis, anti TNFα
1437252|NCT00245765|CDP870, Cimzia
1437253|NCT00245752|post term pregnancy
1437254|NCT00245752|acupuncture
1437255|NCT00245752|induction
1437256|NCT00245739|HIV infections
1437257|NCT00245739|HIV-1
1437258|NCT00245739|TMC114
1437259|NCT00245739|Early access
1437260|NCT00245739|Highly antiretroviral treatment experienced patients
1437261|NCT00245739|Anti-retroviral agents
1437262|NCT00245713|Levetiracetam, adult, partial-onset epilepsy, antiepileptic
1437263|NCT00245687|feeding tube, nutrition, gastric, jejunal
1437264|NCT00245661|COPD
1437265|NCT00245661|respiratory
1437266|NCT00245661|sleep quality
1437267|NCT00245661|temazepam
1437268|NCT00245661|dyspnea
1437269|NCT00245635|Body Dysmorphic Disorder
1437270|NCT00245635|BDD
1437271|NCT00245635|BDD treatment
1437272|NCT00245635|delusionality variant
1437273|NCT00245635|OCD
1437274|NCT00245622|Phase 2b Tovaxin
1437275|NCT00245622|Clinically Isolated Syndrome (CIS)
1437276|NCT00245622|Relapse-Remitting Multiple Sclerosis (RR-MS)
1437277|NCT00245583|Pathological Gambling
1437278|NCT00245583|Compulsive Gambling
1437279|NCT00245583|Gambling
1437280|NCT00245583|topiramate
1437281|NCT00245557|Depression
1437282|NCT00245557|Geriatric
1437283|NCT00245557|MRI
1437284|NCT00245557|Sertraline
1437285|NCT00245531|endocrine abnormalities
1437286|NCT00245531|cognitive performance
1437287|NCT00245518|prostate cancer
1437288|NCT00245518|soy
1437289|NCT00245518|androgen deprivation
1437290|NCT00245518|quality of life
1437291|NCT00245518|isoflavones
1437292|NCT00245492|Colonoscopy
1437293|NCT00245492|Chromoscopy
1437294|NCT00245492|Prevention
1437295|NCT00245479|Primary nocturnal enuresis
1437296|NCT00245466|Prostate Cancer
1437297|NCT00245466|Androgen ablation therapy
1437298|NCT00245453|pneumonia
1437299|NCT00245453|Spneumoniae
1437300|NCT00245453|bronchitis
1437301|NCT00245453|telithromycin
1437302|NCT00245453|azithromycin
1437303|NCT00245440|S.pneumonia
1437304|NCT00245440|sinusitis
1437305|NCT00245440|ams
1437306|NCT00245440|azithromycin
1437307|NCT00245427|beta-lactam
1437308|NCT00245427|macrolide
1437309|NCT00245427|antibiotics
1437310|NCT00245388|Mixed Dyslipidemia
1437311|NCT00245375|Outpatient Surgery for:
1437312|NCT00245375|inguinal hernia repair
1437313|NCT00245375|abdominal hernia repair
1437316|NCT00245362|pancreatic cancer
1437317|NCT00245362|metastatic pancreatic cancer
1437318|NCT00245362|unresectable pancreatic cancer
1437319|NCT00245362|immunotherapy
1437320|NCT00245349|Head and Neck cancer
1437321|NCT00245349|Squamous cell carcinoma
1437322|NCT00245349|FLT
1437323|NCT00245349|Fluorothymidine
1437324|NCT00245349|F-18
1437325|NCT00245336|hemostasis
1437326|NCT00245336|surgery
1437327|NCT00245336|hemostatics
1437328|NCT00245336|randomized controlled trial
1437329|NCT00245336|phase 3
1437330|NCT00245323|smoking
1437331|NCT00245310|ICG clearance
1437332|NCT00245310|liver cirrhosis
1437333|NCT00245310|acute liver failure
1437334|NCT00245310|prognosis
1437335|NCT00245297|Bleeding disorder
1437336|NCT00245297|severe Haemophilia A
1437337|NCT00245297|Prophylaxis
1437338|NCT00245271|Knee
1437339|NCT00245271|Musculoskeletal System
1437340|NCT00245271|Ligament
1437341|NCT00245271|ACL reconstruction
1437342|NCT00245245|hemophilia A
1437343|NCT00245245|inhibitor
1437344|NCT00245245|treatment
1437345|NCT00245232|PTSD
1437346|NCT00245232|Cognitive therapy
1437347|NCT00245232|Rape
1437348|NCT00245206|Antipsychotic
1437349|NCT00245206|Diabetes
1437350|NCT00245206|Hyperlipidemia
1437351|NCT00245206|Stroke
1437352|NCT00245193|Major Depression
1437353|NCT00245154|stage IIIB non-small cell lung cancer
1437354|NCT00245154|stage IV non-small cell lung cancer
1437355|NCT00245141|embryonal childhood rhabdomyosarcoma
1437356|NCT00245141|embryonal-botryoid childhood rhabdomyosarcoma
1437357|NCT00245141|previously untreated childhood rhabdomyosarcoma
1437358|NCT00245128|chronic idiopathic myelofibrosis
1437359|NCT00245128|polycythemia vera
1437360|NCT00245128|essential thrombocythemia
1437361|NCT00244803|Human Immunodeficiency Virus
1437362|NCT00244803|FRAM 1
1437363|NCT00244790|glomerular hyperfiltration
1437364|NCT00244790|proteinuria
1437365|NCT00244777|Seizure
1437366|NCT00244777|Altered consciousness
1437367|NCT00244777|Hyponatraemia
1437368|NCT00244777|Diarrhoea
1437369|NCT00244777|Hypo osmolar ORS
1437370|NCT00244764|Angiogenesis
1437371|NCT00244764|Renal Cell Carcinoma
1437372|NCT00244764|Solid tumors
1437373|NCT00244764|Pazopanib(GW786034)
1437374|NCT00244751|Hepatitis C liver fibrosis
1437375|NCT00244738|pregnancy
1437376|NCT00244738|post-date
1437377|NCT00244738|induction of labor
1437378|NCT00244738|castor oil
1437379|NCT00244725|deep vein thrombosis
1437380|NCT00244725|total knee replacement
1437381|NCT00244725|PE
1437382|NCT00244725|Venous thromboembolism
1437383|NCT00244725|DVT
1437384|NCT00244725|pulmonary embolism
1437385|NCT00244725|VTE
1437386|NCT00244712|HEAT
1437387|NCT00244712|Antiretroviral-naive
1437388|NCT00244712|HIV
1437389|NCT00244712|EPZICOM
1437390|NCT00244712|TRUVADA
1437391|NCT00244712|KALETRA
1437392|NCT00244712|once-daily
1437393|NCT00244699|youth
1437394|NCT00244699|drug addiction
1437395|NCT00244699|substance abuse
1437396|NCT00244699|mindfulness
1437397|NCT00244699|motivational interviewing
1437398|NCT00244699|brief treatment
1437399|NCT00244699|skills training
1437400|NCT00244699|group therapy
1437401|NCT00244699|emotion regulation
1437402|NCT00244686|Hypereosinophilic Syndrome
1437403|NCT00244686|Mepo
1437404|NCT00244686|HES
1437405|NCT00244686|Compassionate Use
1437406|NCT00244686|Mepolizumab
1437407|NCT00244673|Vaccination
1437408|NCT00244673|DTP
1437409|NCT00244673|Child mortality
1437410|NCT00244673|Sex
1437411|NCT00244673|Non-specific effects
1437412|NCT00244647|restenosis
1437413|NCT00244647|in-stent restenosis
1437414|NCT00244621|Pediatric hypertension
1437415|NCT00244595|Pediatric hypertension
1437416|NCT00244595|Hypertension in children
1437417|NCT00244582|Central Nervous System
1437418|NCT00244582|Enzyme Replacement Therapy
1437419|NCT00244582|Convection
1437420|NCT00244582|Gaucher Disease
1437421|NCT00244582|Neuronopathic Gaucher Disease
1437422|NCT00244582|Type 2 Gaucher Disease
1437423|NCT00244569|Nonalcoholic Fatty Liver Disease
1437424|NCT00244569|Nonalcoholic Steatohepatitis
1437425|NCT00244569|Liver Function
1437426|NCT00244569|Metabolism
1437427|NCT00244569|Cirrhosis
1437428|NCT00244569|Fibrosis
1437429|NCT00244569|Liver
1437430|NCT00244556|Rheumatoid Arthritis
1437431|NCT00244543|ocular, allergic conjunctivitis, ophthalmic
1437432|NCT00244530|Preventive Therapy
1437433|NCT00244530|Calcium Channel Blockers
1437434|NCT00244530|Kidney Failure, Chronic
1437435|NCT00244530|Coronary Artery Bypass
1437436|NCT00244530|Heart Valve Prosthesis Implantation
1437437|NCT00244517|ventricular function
1437438|NCT00244517|diastolic function
1437439|NCT00244517|inhalative anaesthetics
1437440|NCT00244491|care transitions
1437441|NCT00244491|geriatric
1437442|NCT00244491|care coordination
1437443|NCT00244491|self-management
1437444|NCT00244491|chronic illness
1437445|NCT00244491|patient-centered care
1437446|NCT00244465|Narcolepsy
1437447|NCT00244465|Cataplexy
1437448|NCT00244465|Oxybate
1437449|NCT00244465|Xyrem
1437450|NCT00244465|Misuse
1437451|NCT00244465|Safety
1437452|NCT00244452|Endometriosis
1437453|NCT00244452|Cetrorelix
1437454|NCT00244452|Hormone
1437455|NCT00244452|Symptoms relief
1437456|NCT00244452|Safety
1437457|NCT00244452|Tolerability
1437458|NCT00244452|Pharmacodynamic
1437459|NCT00244452|Pharmacokinetic
1437460|NCT00244439|Head Lice
1437461|NCT00244439|Pediculosis capitis
1437462|NCT00244426|Prevention of thromboembolic events in patients with non valvular atrial fibrillation
1437463|NCT00244413|Myotonia
1437464|NCT00244413|Paramyotonia Congenita
1437465|NCT00244413|Thomsen's Disease
1437466|NCT00244400|Femur Head Necrosis
1437467|NCT00244400|CYP3A
1437468|NCT00244387|advanced stage idiopathic Parkinson's disease
1437469|NCT00244361|opsoclonus
1437470|NCT00244361|myoclonus
1437471|NCT00244348|hepatic artery infusion
1437472|NCT00244348|colorectal cancer
1437473|NCT00244348|liver metastasis
1437474|NCT00244348|oxaliplatin
1437475|NCT00244348|5 fluorouracil
1437476|NCT00244335|Post-Traumatic Stress Disorders
1437477|NCT00244335|PTSD
1437478|NCT00244309|brachytherapy
1437479|NCT00244309|urinary symptoms
1437480|NCT00244283|Myocardial preconditioning
1437481|NCT00244283|anesthetics
1437482|NCT00244283|epidural anesthesia
1437483|NCT00244283|sevoflurane
1437484|NCT00244283|NT proBNP
1437485|NCT00244270|totally implantable vascular access devices
1437486|NCT00244270|thromboembolism
1437487|NCT00244270|genetic susceptibility to venous thrombosis.
1437488|NCT00244257|idiopathic thrombocytopenia purpura
1437489|NCT00244231|Niacin
1437490|NCT00244231|Hyperlipidemia
1437491|NCT00244218|phenylketonuria
1437492|NCT00244218|hyperphenylalaninemia
1437493|NCT00244192|COPD
1437494|NCT00244192|infliximab
1437495|NCT00244192|Remicade
1437496|NCT00244192|inflammation
1437497|NCT00244192|cachexia
1437498|NCT00244192|fat-free mass
1437499|NCT00244192|health status
1437500|NCT00244192|exercise capacity
1437501|NCT00244179|reactive arthritis
1437502|NCT00244179|trial
1437503|NCT00244179|interferon-gamma
1437504|NCT00244179|infliximab
1437505|NCT00244179|chronic
1437506|NCT00244179|tnf-blocker
1437507|NCT00244166|treatment
1437508|NCT00244166|ankylosing spondylitis
1437509|NCT00244166|prednisolone
1437510|NCT00244166|trial
1437511|NCT00244166|steroid
1437512|NCT00244153|intraarticular morphine, steroids, arthroscopy
1437513|NCT00244140|Ultravist 370
1437514|NCT00244140|CECT
1437515|NCT00244140|CT Scan
1437516|NCT00244114|Hemophilia B
1437517|NCT00244114|Allergic Reaction
1437518|NCT00244101|Prematurity
1437519|NCT00244101|respiratory distress syndrome
1437520|NCT00244101|surfactant
1437521|NCT00244101|nasal continuous positive airway pressure
1437522|NCT00244088|Abdominal infection
1437523|NCT00244023|Erectile Dysfunction
1437524|NCT00244023|Testosterone
1437525|NCT00244023|Testosterone Therapy
1437526|NCT00244023|PDE V Inhibitor
1437527|NCT00244023|Tadalafil
1437528|NCT00244010|Aplastic anemia
1437529|NCT00244010|Amegakaryocytic thrombocytopenia
1437530|NCT00244010|Diamond-Blackfan Anemia
1437531|NCT00244010|Kostmann syndrome
1437532|NCT00244010|Allogeneic stem cell transplantation
1437533|NCT00244010|Haploidentical stem cell transplant
1437534|NCT00244010|T-cell depletion
1437535|NCT00244010|Partially matched family member donor transplant
1437536|NCT00244010|Refractory cytopenia
1437537|NCT00243997|parents
1437538|NCT00243997|fathers
1437539|NCT00243997|mothers
1437540|NCT00243984|metabolic syndrome
1437541|NCT00243984|type 2 diabetes
1437542|NCT00243984|topiramate
1437543|NCT00243984|weight loss
1437544|NCT00243971|EARLY-STAGE, IDIOPATHIC PARKINSON'S DISEASE
1437545|NCT00243932|amyotrophic lateral sclerosis
1437546|NCT00243932|ALS
1437547|NCT00243932|Lou Gehrig's disease
1437548|NCT00243932|CoQ10
1437549|NCT00243932|coenzyme Q10
1437550|NCT00243932|antioxidants
1437551|NCT00243932|free radicals
1437552|NCT00243932|mitochondrial dysfunction
1437553|NCT00243919|stroke
1437554|NCT00243919|locomotor
1437555|NCT00243919|exercise
1437556|NCT00243919|walking
1437557|NCT00243919|training program
1437558|NCT00243919|body weight support training
1437559|NCT00243919|physical therapy
1437560|NCT00243906|acute ischemic stroke
1437561|NCT00243906|stroke
1437562|NCT00243906|rt-PA
1437563|NCT00243906|thrombolytic
1437564|NCT00243906|recombinant tissue plasminogen activator
1437565|NCT00243893|giant aneurysms
1437566|NCT00243893|arteriovenous malformations
1437567|NCT00243893|minocycline
1437568|NCT00243893|doxycycline
1437569|NCT00243893|BAVM
1437570|NCT00243880|acute ischemic stroke
1437571|NCT00243880|lovastatin
1437572|NCT00243880|statin
1437573|NCT00243880|neuroprotection
1437574|NCT00243880|SPOTRIAS
1437575|NCT00243867|Advanced Non-Small Cell Lung Cancer
1437576|NCT00243854|Pancreatic Cancer
1437577|NCT00243854|Resectable Pancreatic Cancer
1437578|NCT00243854|adenocarcinoma of the pancreas
1437579|NCT00243828|Noninvasive Mechanical Ventilation
1437580|NCT00243828|Acute Respiratory Failure
1437581|NCT00243828|Intubation
1437582|NCT00243815|randomized controlled trial
1437583|NCT00243815|prophylactic nonsteroidal antiflammatory drug
1437584|NCT00243815|IUD removal
1437585|NCT00243802|Atrial Fibrillation
1437586|NCT00243802|Oxidative Stress
1437587|NCT00243802|Atrial Flutter
1437588|NCT00243789|Duchenne
1437589|NCT00243789|Genetic
1437590|NCT00243789|Muscular Dystrophy
1437591|NCT00243789|DMD
1437592|NCT00243763|Refractory Multiple Myeloma or
1437593|NCT00243763|Relapsed Multiple Myeloma
1437594|NCT00243750|ankylosing spondylitis
1437595|NCT00243750|trial
1437596|NCT00243750|methotrexate
1437597|NCT00243737|Malaria
1437598|NCT00243737|falciparum
1437599|NCT00243737|Mefloquine
1437600|NCT00243737|Artesunate
1437601|NCT00243737|Artemisinin
1437602|NCT00243724|immunohistochemical
1437603|NCT00243724|erosive esophagitis
1437604|NCT00243724|Acid reflux disease
1437605|NCT00243698|Contrast-enhanced Ultrasound Sonography
1437606|NCT00243698|Ultrasound Contrast agents, microbubbles
1437607|NCT00243698|Breast tumors
1437608|NCT00243685|Chemosensitivity
1437609|NCT00243685|Chemotherapy
1437610|NCT00243685|Lung cancer
1437611|NCT00243685|Ovarian Cancer
1437612|NCT00243685|Breast Cancer
1437613|NCT00243685|Sarcoma
1437614|NCT00243685|Apoptosis
1437615|NCT00243685|MiCK Assay
1437616|NCT00243685|New Technology
1437617|NCT00243685|Patients with pathological diagnoses of breast, lung, and ovarian adenocarcinomas and soft tissue sarcoma
1437618|NCT00243659|Hemophilia A
1437619|NCT00243659|bleeding disorder
1437620|NCT00243646|Radiation therapy
1437621|NCT00243646|Brachytherapy
1437622|NCT00243646|Prostatic neoplasm
1437623|NCT00243633|focal liver lesions
1437624|NCT00243633|contrast-enhanced ultrasound sonography
1437625|NCT00243633|cirrhosis
1437626|NCT00243633|suspected liver metastases
1437627|NCT00243633|suspected liver cirrhosis
1437628|NCT00243620|Chronic leg ulcers; wound healing; wound care; Vacuum Assisted Closure; topical negative Pressure
1437629|NCT00243607|climacteric symptoms
1437630|NCT00243607|breast cancer
1437631|NCT00243607|hydrotherapy
1437632|NCT00243594|Dendritic cells
1437633|NCT00243594|Immunotherapy
1437634|NCT00243594|Vaccination
1437635|NCT00243594|Melanoma
1437636|NCT00243594|Peptides
1437637|NCT00243594|MRI
1437638|NCT00243594|Scintigraphy
1437639|NCT00243594|Immune response
1437640|NCT00243568|HIV Infections
1437641|NCT00243568|Acquired Immunodeficiency Syndrome
1437642|NCT00243568|CCR5/CXCR4 mixed tropism
1437643|NCT00243568|R5/X4 mixed tropism
1437644|NCT00243568|CCR5 inhibitor
1437645|NCT00243568|vicriviroc
1437646|NCT00243568|treatment-experienced
1437647|NCT00243555|peanut hypersensitivity
1437648|NCT00243555|chemokines
1437649|NCT00243555|cytokines
1437650|NCT00243555|RNA,messenger
1437651|NCT00243555|monocytes
1437652|NCT00243542|Acne, G6PD deficiency, Dapsone
1437653|NCT00243529|Dendritic cells
1437654|NCT00243529|Melanoma
1437655|NCT00243529|Vaccine
1437656|NCT00243529|Immunotherapy
1437657|NCT00243529|RNA
1437658|NCT00243529|Peptides
1437659|NCT00243516|Acute Coronary Syndrome
1437660|NCT00243516|Emergency Department
1437661|NCT00243516|Chest Pain Evaluation Unit
1437662|NCT00243516|Overtesting
1437663|NCT00243516|Chest Pain Protocol
1437664|NCT00243516|Myocardial Infarction
1437665|NCT00243516|Medical Malpractice
1437666|NCT00243503|Breast Cancer Metastatic
1437667|NCT00243490|Photodynamic therapy
1437668|NCT00243490|Malignant glioma
1437669|NCT00243490|Photosan
1437670|NCT00243477|Coronary Artery Bypass
1437671|NCT00243477|Surgery
1437672|NCT00243425|Major Depressive Disorder;
1437673|NCT00243425|African Americans;
1437674|NCT00243425|Disparities;
1437675|NCT00243425|Quality Improvement;
1437676|NCT00243425|Patient Centered Care;
1437677|NCT00243425|Primary Care;
1437678|NCT00243425|Patient-Physician Relationship;
1437679|NCT00243412|Rituxan
1437680|NCT00243412|RA
1437681|NCT00243399|Fanconi anemia
1437682|NCT00243399|FA
1437683|NCT00243373|Patient safety
1437684|NCT00243373|Medication safety
1437685|NCT00243373|Barcode technology
1437686|NCT00243360|Urinary tract infections,
1437687|NCT00243360|antibiotic use,
1437688|NCT00243360|long term care facilities
1437689|NCT00243347|RECENTIN
1437690|NCT00243334|Ambulatory Care Information Systems
1437691|NCT00243334|Clinical Decision Support Systems
1437692|NCT00243334|Medication Systems
1437693|NCT00243334|Medication Errors
1437694|NCT00243334|Reminder Systems
1437695|NCT00243334|Drug Monitoring
1437696|NCT00243334|Preventive Health Services
1437697|NCT00243334|Time and Motion Studies
1437698|NCT00243334|Efficiency
1437699|NCT00243334|Cost-Benefit Analysis
1437700|NCT00243321|brachytherapy
1437701|NCT00243321|intensity-modulated radiation therapy
1437702|NCT00243321|prostate specific antigen
1437703|NCT00243308|Anti-inflammatory agents
1437704|NCT00243308|unstable plaque
1437705|NCT00243308|acute coronary syndrome
1437706|NCT00243295|osteoarthritis
1437707|NCT00243295|deformity of knee
1437708|NCT00243282|Complementary Therapies
1437709|NCT00243282|Dyspnea
1437710|NCT00243282|Palliative Care
1437711|NCT00243282|Meditation
1437712|NCT00243282|Quality of Life
1437713|NCT00243269|nausea, acupressure bands, relaxation
1437714|NCT00243243|Burns
1437715|NCT00243204|Stage IIIb/IV non-small cell lung cancer
1437716|NCT00243204|NSCLC
1437717|NCT00243204|Lung Cancer
1437718|NCT00243191|newly diagnosed or recurrent
1437719|NCT00243178|Atrial fibrillation
1437720|NCT00243178|Anticoagulant therapy
1437721|NCT00243178|Thromboembolic prevention
1437722|NCT00243165|breast cancer
1437723|NCT00243165|honey
1437724|NCT00243165|myelosuppression
1437725|NCT00243165|chemotherapy
1437726|NCT00243152|pain
1437727|NCT00243152|neuropathic
1437728|NCT00243152|face
1437729|NCT00243152|trigeminal
1437730|NCT00243139|Oral appliances
1437731|NCT00243139|Obstructive sleep apnea
1437732|NCT00243139|Epworth Sleepiness Scale
1437733|NCT00243139|SF-36
1437734|NCT00243126|HIV prevention
1437735|NCT00243126|HIV Seronegativity
1437736|NCT00243126|HIV negative
1437737|NCT00243113|stage II squamous cell carcinoma of the hypopharynx
1437738|NCT00243113|stage II squamous cell carcinoma of the larynx
1437739|NCT00243113|stage III squamous cell carcinoma of the hypopharynx
1437740|NCT00243113|stage III squamous cell carcinoma of the larynx
1437741|NCT00243087|stage IV adult diffuse large cell lymphoma
1437742|NCT00243087|recurrent adult diffuse large cell lymphoma
1437743|NCT00243087|recurrent adult Burkitt lymphoma
1437744|NCT00243087|stage IV adult Burkitt lymphoma
1437745|NCT00243087|stage IV grade 3 follicular lymphoma
1437746|NCT00243087|recurrent grade 3 follicular lymphoma
1437747|NCT00243087|stage IV mantle cell lymphoma
1437748|NCT00243087|recurrent mantle cell lymphoma
1437749|NCT00243087|recurrent adult immunoblastic large cell lymphoma
1437750|NCT00243087|stage IV adult immunoblastic large cell lymphoma
1437751|NCT00243087|anaplastic large cell lymphoma
1437752|NCT00243087|recurrent adult T-cell leukemia/lymphoma
1437753|NCT00243087|stage IV adult T-cell leukemia/lymphoma
1437754|NCT00243087|stage III adult Burkitt lymphoma
1437755|NCT00243087|stage III adult diffuse large cell lymphoma
1437756|NCT00243087|stage III adult immunoblastic large cell lymphoma
1437757|NCT00243087|stage III adult T-cell leukemia/lymphoma
1437758|NCT00243087|stage III grade 3 follicular lymphoma
1437759|NCT00243087|stage III mantle cell lymphoma
1437760|NCT00243048|stage I prostate cancer
1437761|NCT00243048|stage II prostate cancer
1437762|NCT00243022|cerebral edema
1437763|NCT00243022|adult glioblastoma
1437764|NCT00243022|adult giant cell glioblastoma
1437765|NCT00243022|adult gliosarcoma
1437766|NCT00243022|adult anaplastic astrocytoma
1437767|NCT00243022|adult anaplastic oligodendroglioma
1437768|NCT00243009|recurrent renal cell cancer
1437769|NCT00243009|stage IV renal cell cancer
1437770|NCT00243009|clear cell renal cell carcinoma
1437771|NCT00242996|recurrent adult diffuse large cell lymphoma
1437772|NCT00242983|adenocarcinoma of the lung
1437773|NCT00242983|large cell lung cancer
1437774|NCT00242983|recurrent non-small cell lung cancer
1437775|NCT00242983|squamous cell lung cancer
1437776|NCT00242983|stage IIIB non-small cell lung cancer
1437777|NCT00242983|stage IV non-small cell lung cancer
1437778|NCT00242957|HIV/AIDS
1437779|NCT00242957|Gender Based Violence
1437780|NCT00242957|Structural Interventions
1437781|NCT00242957|South Africa
1437782|NCT00242957|HIV Seronegativity
1437783|NCT00242944|Acute coronary syndrome
1437784|NCT00242944|Hypercholesterolemia
1437785|NCT00242944|Primary coronary intervention
1437786|NCT00242944|Hydroxymethylglutaryl-CoA reductase inhibitors
1437787|NCT00242944|coronary plaque
1437788|NCT00242944|Angioplasty, Transluminal, Percutaneous Coronary
1437789|NCT00242944|Ultrasonography, Interventional
1437790|NCT00242931|adenocarcinoma of the prostate
1437791|NCT00242931|recurrent prostate cancer
1437792|NCT00242931|stage IV prostate cancer
1437793|NCT00242918|High risk
1437794|NCT00242918|adenocarcinoma
1437795|NCT00242918|prostate cancer
1437796|NCT00242918|neoadjuvant
1437797|NCT00242905|Memory
1437798|NCT00242905|Epilepsy
1437799|NCT00242905|Children
1437800|NCT00242905|Magnetic resonance imaging
1437801|NCT00242905|Functional magnetic resonance imaging
1437802|NCT00242892|Deployment stent optimisation
1437803|NCT00242892|Fractional Flow Reserve
1437804|NCT00242892|Stent
1437805|NCT00242892|Restenosis
1437806|NCT00242892|Coronary
1437807|NCT00242879|treatment-experienced
1437808|NCT00242879|RTV
1437809|NCT00242879|protease inhibitor
1437810|NCT00242879|ritonavir
1437811|NCT00242879|GW640385
1437812|NCT00242879|HIV-1
1437813|NCT00242866|Productivity
1437814|NCT00242866|Efficacy
1437815|NCT00242866|without aura
1437816|NCT00242866|iNOS
1437817|NCT00242866|Safety
1437818|NCT00242866|Nitric Oxide
1437819|NCT00242866|Pharmacokinetics
1437820|NCT00242866|GW274150
1437821|NCT00242866|with aura
1437822|NCT00242866|Migraine
1437823|NCT00242866|Prophylaxis
1437824|NCT00242866|Quality of Life
1437825|NCT00242853|iNOS
1437826|NCT00242853|Rheumatoid arthritis
1437827|NCT00242853|Exhaled NO
1437828|NCT00242840|protease inhibitor
1437829|NCT00242840|ritonavir
1437830|NCT00242840|GW433908
1437831|NCT00242840|HIV-1
1437832|NCT00242840|fosamprenavir
1437833|NCT00242788|Colorectal Cancer
1437834|NCT00242775|Asthma
1437835|NCT00242762|Head and Neck Neoplasms
1437836|NCT00242762|Cancer of Head and Neck
1437837|NCT00242762|Head and Neck Cancer
1437838|NCT00242762|Head Cancer
1437839|NCT00242762|Neck Cancer
1437840|NCT00242749|Head and Neck Cancer Disease
1437841|NCT00242749|Head Cancer
1437842|NCT00242749|Neck Cancer
1437843|NCT00242749|Cancer of Head
1437844|NCT00242749|Cancer of Neck
1437845|NCT00242749|Cancer of the Head
1437846|NCT00242749|Cancer of the Head and Neck
1437847|NCT00242749|Cancer of the Neck
1437848|NCT00242749|Neoplasms, Head and Neck
1437849|NCT00242723|Lung Cancers
1437850|NCT00242723|Esophageal Cancer
1437851|NCT00242723|Malignant Pleural Mesothelioma
1437852|NCT00242723|Biopsy
1437853|NCT00242723|Staging Studies
1437854|NCT00242723|Lung Cancer
1437855|NCT00242710|Endometrium
1437856|NCT00242710|Uterus
1437857|NCT00242710|Menopause
1437858|NCT00242697|coronary artery bypass surgery
1437859|NCT00242697|anesthesia, general
1437860|NCT00242697|anesthesia, spinal
1437861|NCT00242697|heart-lung machine
1437862|NCT00242684|Aging
1437863|NCT00242684|Undernutrition
1437864|NCT00242684|Inflammation
1437865|NCT00242684|Frail Elderly
1437866|NCT00242671|general anesthesia, hyperventilation, carbon dioxide, isocapnic hyperponea
1437867|NCT00242658|Physical Activity
1437868|NCT00242658|Wellness Programs
1437869|NCT00242658|Health Promotion
1437870|NCT00242658|Blood Pressure, High
1437871|NCT00242645|Doctor-Patient relation
1437872|NCT00242645|Physician-Patient relation
1437873|NCT00242645|Diabetes
1437874|NCT00242645|Office visits
1437875|NCT00242645|Comparative Study
1437876|NCT00242645|Health behavior
1437877|NCT00242645|Randomized controlled trials
1437878|NCT00242645|Health Promotion
1437879|NCT00242645|Health Education
1437880|NCT00242645|Computer-tailor information
1437881|NCT00242606|Newly diagnosed epilepsy
1437882|NCT00242606|Initial monotherapy
1437883|NCT00242606|Levetiracetam
1437884|NCT00242606|Lamotrigine
1437885|NCT00242593|cognition disorders
1437886|NCT00242593|Alzheimer's disease
1437887|NCT00242593|memory
1437888|NCT00242580|AMD
1437889|NCT00242580|age-related macular degeneration
1437890|NCT00242580|choroidal neovascularization
1437891|NCT00242567|zoledronic acid
1437892|NCT00242567|bone metastases
1437893|NCT00242567|prostate cancer
1437894|NCT00242567|hormone-sensitive
1437895|NCT00242554|Prostate Cancer
1437896|NCT00242554|Bone Metastases
1437897|NCT00242554|Zoledronic acid
1437898|NCT00242541|microadenoma
1437899|NCT00242541|macroadenoma
1437900|NCT00242528|Bone Lesions
1437901|NCT00242528|Multiple Myeloma
1437902|NCT00242528|zoledronic acid
1437903|NCT00242515|High risk Myelodysplastic Syndrome (MDS)
1437904|NCT00242502|Hepatocellular Carcinoma
1437905|NCT00242502|Liver Cancer
1437906|NCT00242502|Bevacizumab
1437907|NCT00242502|Anti-VEGF monoclonal antibody
1437908|NCT00242502|rhuMAb-VEGF
1437909|NCT00242502|Erlotinib Hydrochloride
1437910|NCT00242502|OSI-774
1437911|NCT00242502|Tarceva
1437912|NCT00242502|Erlotinib
1437913|NCT00242502|Avastin
1437914|NCT00242489|Arcoxia
1437915|NCT00242463|malnutrition
1437916|NCT00242463|anabolic steroids
1437917|NCT00242463|intensive care unit
1437918|NCT00242463|rehabilitation
1437919|NCT00242450|metoclopramide
1437920|NCT00242450|feeding
1437921|NCT00242450|very low birthweightnewborn
1437922|NCT00242424|influenza vaccine
1437923|NCT00242424|infants
1437924|NCT00242424|safety
1437925|NCT00242424|immunogenicity
1437926|NCT00242398|Intensive care unit
1437927|NCT00242398|Patients with bleeding high risk
1437928|NCT00242398|Intermittent hemodialysis without anticoagulation
1437929|NCT00242398|Blood lost
1437930|NCT00242385|Severe congenital Alpha1-Proteinase Inhibitor (Alpha1-PI) deficiency
1437931|NCT00242372|Insulin dependent Type 2 diabetes
1437932|NCT00242346|Hypertension
1437933|NCT00242333|COPD
1437934|NCT00242333|COAD
1437935|NCT00242333|Chronic obstructive pulmonary disease
1437936|NCT00242333|emphysema
1437937|NCT00242333|chronic bronchitis
1437938|NCT00242320|COPD
1437939|NCT00242320|chronic obstructive pulmonary disease
1437940|NCT00242320|Roflumilast
1437941|NCT00242307|Asthma
1437942|NCT00242307|Roflumilast
1437943|NCT00242307|phosphodiesterase 4 inhibitor
1437944|NCT00242294|COPD
1437945|NCT00242294|Phosphodiesterase 4 inhibitor
1437946|NCT00242294|Roflumilast
1437947|NCT00242281|Sore Throat
1437948|NCT00242281|Pharyngitis
1437949|NCT00242281|Tonsillitis
1437950|NCT00242255|Histone
1437951|NCT00242255|Chromatin
1437952|NCT00242255|Epigenome
1437953|NCT00242255|Senescence
1437954|NCT00242255|Acetylation
1437955|NCT00242255|Aging
1437956|NCT00242255|Tissue Sample
1437957|NCT00242242|Stroke
1437958|NCT00242242|BCI
1437959|NCT00242242|Healthy Volunteer
1437960|NCT00242242|HV
1437961|NCT00242229|Depression
1437962|NCT00242216|HIV-1 infected people
1437963|NCT00242216|Antiretroviral treatment-naïve
1437964|NCT00242216|Atazanavir
1437965|NCT00242216|Fosamprenavir
1437966|NCT00242216|ARV Treatment Naive
1437967|NCT00242203|Breast Cancer
1437968|NCT00242203|Neoadjuvant
1437969|NCT00242203|Micrometastasis
1437970|NCT00242190|drug therapy
1437971|NCT00242190|radiotherapy
1437972|NCT00242190|clinical trial
1437973|NCT00242177|Multiple Sclerosis
1437974|NCT00242177|Relapsing, Remitting
1437975|NCT00242177|Autoimmune disease
1437976|NCT00242164|Hemodialysis
1437977|NCT00242164|Magnesium
1437978|NCT00242164|Arrhythmia
1437979|NCT00242164|QTc interval
1437980|NCT00242164|QT dispersion
1437981|NCT00242151|Delirium, Confusion, Cardiac Surgery, Organic Brain Injury, Diffusion Weighted Magnetic Resonance Imaging (DW-MRI)
1437982|NCT00242125|Primary biliary Cirrhosis
1437983|NCT00242125|genes
1437984|NCT00242125|DNA
1437985|NCT00242099|liver transplant
1437986|NCT00242099|HHV-6
1437987|NCT00242099|HHV-7
1437988|NCT00242099|Human Herpesvirus-6
1437989|NCT00242099|Human Herpesvirus-7
1437990|NCT00242047|Tuberculosis.
1437991|NCT00242047|Children.
1437992|NCT00242047|Vaccine.
1437993|NCT00242047|BCG.
1437994|NCT00242021|Satiety, ad libitum food intake, fatty acids, hormones
1437995|NCT00242008|IDIOPATHIC PARKINSON'S DISEASE
1437996|NCT00241982|rheumatoid arthritis
1437997|NCT00241982|long circulating liposomes
1437998|NCT00241969|nutrition therapy
1437999|NCT00241969|preschool children
1438000|NCT00241969|cystic fibrosis
1438001|NCT00241943|Hepatitis C
1438002|NCT00241943|Heroin
1438003|NCT00241943|Populations at risk
1438004|NCT00241943|testing
1438005|NCT00241943|vaccination
1438006|NCT00241930|Heroin
1438007|NCT00241930|HIV
1438008|NCT00241930|buprenorphine
1438009|NCT00241930|integration
1438010|NCT00241930|drug treatment
1438011|NCT00241917|hepatitis C
1438012|NCT00241917|heroin
1438013|NCT00241917|populations at risk
1438014|NCT00241917|testing
1438015|NCT00241917|vaccination
1438016|NCT00241722|bowel dysfunction
1438017|NCT00241722|constipation
1438018|NCT00241722|gastrointestinal
1438019|NCT00241722|opioids
1438020|NCT00241722|pain
1438021|NCT00241722|non-cancer pain
1438022|NCT00241722|opioid-induced
1438023|NCT00241644|Rotavirus gastroenteritis
1438024|NCT00241644|HRV vaccine
1438025|NCT00241618|Clinical trial
1438026|NCT00241618|Randomized
1438027|NCT00241618|Treatment
1438028|NCT00241618|Prospective
1438029|NCT00241618|Parallel Assignment
1438030|NCT00241618|Efficacy Safety Study
1438031|NCT00241605|Metformin
1438032|NCT00241605|AVANDAMET
1438033|NCT00241605|Type 2 diabetes
1438034|NCT00241592|Cannabis
1438035|NCT00241592|Marijuana
1438036|NCT00241592|Vaporization
1438037|NCT00241592|Volcano
1438038|NCT00241592|THC
1438039|NCT00241579|Pain
1438040|NCT00241579|Cannabis
1438041|NCT00241579|Analgesic
1438042|NCT00241566|Neuropathic pain
1438043|NCT00241566|Electric cortical stimulation
1438044|NCT00241566|Economic Medical evaluation
1438045|NCT00241540|NSAIDs
1438046|NCT00241540|Upper GI symptoms
1438047|NCT00241514|NSAIDs
1438048|NCT00241514|Upper GI symptoms
1438049|NCT00241475|Cancer of the Prostate
1438050|NCT00241462|Advanced Breast Cancer
1438051|NCT00241449|Locally advanced breast cancer or metastatic breast cancer
1438052|NCT00241423|exenatide
1438053|NCT00241423|diabetes
1438054|NCT00241423|Amylin
1438055|NCT00241423|Lilly
1438056|NCT00241410|Allergy
1438057|NCT00241410|Specific Immunotherapy
1438181|NCT00240864|acetaminophen
1438058|NCT00241410|Sublingual Immunotherapy
1438059|NCT00241397|pain
1438060|NCT00241397|depression
1438061|NCT00241397|anxiety disorder
1438062|NCT00241384|Prostatic Cancer
1438063|NCT00241384|Brachytherapy
1438064|NCT00241384|Prostatic neoplasm
1438065|NCT00241384|Radiation therapy
1438066|NCT00241371|Multiple Myeloma
1438067|NCT00241358|Plerixafor
1438068|NCT00241358|Stem cell transplantation
1438069|NCT00241358|Stem cells
1438070|NCT00241358|Mobilization
1438071|NCT00241345|post transplant
1438072|NCT00241345|Any patient receiving an allogeneic bone marrow or peripheral blood stem cell transplant at Washington University Medical Center
1438073|NCT00241332|pain
1438074|NCT00241332|hyperalgesia
1438075|NCT00241332|drug tolerance
1438076|NCT00241332|remifentanil
1438077|NCT00241332|fentanyl
1438078|NCT00241332|Anterior Cruciate Ligament
1438079|NCT00241332|Posterior Cruciate Ligament
1438080|NCT00241332|Medial Collateral Ligament, Knee
1438081|NCT00241319|ocular, allergic conjunctivitis, ophthalmic
1438082|NCT00241306|aging
1438083|NCT00241306|language
1438084|NCT00241306|gender
1438085|NCT00241293|language
1438086|NCT00241267|Pulmonary
1438087|NCT00241267|Neoplasms
1438088|NCT00241267|Endobronchial
1438089|NCT00241267|Ultrasonography
1438090|NCT00241267|Primary
1438091|NCT00241254|Multiple Sclerosis, Chronic Progressive
1438092|NCT00241254|Cyclophosphamide
1438093|NCT00241254|Methylprednisolone
1438094|NCT00241254|Randomized Controlled Trials
1438095|NCT00241254|Double-Blind Study
1438096|NCT00241241|myeloproliferative disorder
1438097|NCT00241241|polycythemia vera
1438098|NCT00241241|interferon
1438099|NCT00241228|Shock, Septic
1438100|NCT00241228|Renal Failure, Acute
1438101|NCT00241228|Venovenous Hemofiltration
1438102|NCT00241228|Randomized Controlled Trial
1438103|NCT00241228|Multicenter Study
1438104|NCT00241228|Mortality
1438105|NCT00241215|Botulinum toxin serotype A
1438106|NCT00241215|Cervicobrachial syndrome
1438107|NCT00241215|Myofascial pain
1438108|NCT00241215|Cervicothoracic myofascial pain
1438109|NCT00241215|Propulsion
1438110|NCT00241215|Postural abnormality
1438111|NCT00241202|signs and symptoms
1438112|NCT00241202|self care
1438113|NCT00241202|patient compliance
1438114|NCT00241202|quality of life
1438115|NCT00241189|Systemic sclerosis
1438116|NCT00241189|Scleroderma
1438117|NCT00241189|Rapamycin
1438118|NCT00241189|Methotrexate
1438119|NCT00241176|Psychiatric
1438120|NCT00241176|Clinical Trial
1438121|NCT00241176|Pediatrics
1438122|NCT00241176|Tourette's Disorder
1438123|NCT00241176|Tic Disorder
1438124|NCT00241150|valsartan
1438125|NCT00241150|hypertension
1438126|NCT00241150|metabolic syndrome
1438127|NCT00241150|endothelial function
1438128|NCT00241137|hypertension
1438129|NCT00241137|valsartan
1438130|NCT00241124|hypertension
1438131|NCT00241124|valsartan
1438132|NCT00241124|morning/evening dosing
1438133|NCT00241124|lisinopril
1438134|NCT00241111|Prostate
1438135|NCT00241111|cancer
1438136|NCT00241111|bone metastasis
1438137|NCT00241111|zoledronic acid
1438138|NCT00241098|HYPERTENSION
1438139|NCT00241098|HEART FAILURE
1438140|NCT00241098|PEPTIDE
1438141|NCT00241098|valsartan
1438142|NCT00241085|proteinuria
1438143|NCT00241085|hypertension
1438144|NCT00241085|valsartan
1438145|NCT00241085|type 2 diabetes
1438146|NCT00241059|Renal transplantation, maintenance patients, tolerability, EC-MPS
1438147|NCT00241046|Breast cancer
1438148|NCT00241046|Machine learning techniques
1438149|NCT00241046|Aromatase inhibitors
1438150|NCT00241046|1st line treatment
1438151|NCT00241046|2nd line treatment
1438152|NCT00241020|hepatocellular carcinoma
1438153|NCT00241020|Octreotide
1438154|NCT00241007|HYPERTENSION, VALSARTAN
1438155|NCT00240994|End stage renal disease
1438156|NCT00240994|Kidney transplantation
1438157|NCT00240994|Renal transplantation
1438158|NCT00240994|Kidney failure
1438159|NCT00240994|Pediatric renal transplant recipients
1438160|NCT00240994|Alemtuzumab
1438161|NCT00240994|Campath
1438162|NCT00240994|Mycophenolate mofetil
1438163|NCT00240994|MMF
1438164|NCT00240994|CellCept
1438165|NCT00240994|Tacrolimus
1438166|NCT00240994|Prograf
1438167|NCT00240994|Sirolimus
1438168|NCT00240994|Rapamycin
1438169|NCT00240981|Andropause
1438170|NCT00240981|frailty
1438171|NCT00240981|hormone replacement therapy
1438172|NCT00240981|Aging
1438173|NCT00240968|Avian influenza, vaccine, A/H5N1, sub-study
1438174|NCT00240955|Renal/Kidney, Transplantation, steroids, EC-MPS
1438175|NCT00240942|Endometriosis
1438176|NCT00240942|GnRH analog
1438177|NCT00240942|Aromataseinhibitor
1438178|NCT00240942|Letrozole
1438179|NCT00240903|revaccination, vaccination, influenza, H5N1 vaccine
1438180|NCT00240864|postoperative dental pain
1438182|NCT00240864|ibuprofen
1438183|NCT00240851|muscle ache
1438184|NCT00240851|pain
1438185|NCT00240851|soreness
1438186|NCT00240851|acetaminophen
1438187|NCT00240838|muscle soreness
1438188|NCT00240838|pain, acetaminophen
1438189|NCT00240838|ibuprofen
1438190|NCT00240825|postoperative dental pain
1438191|NCT00240825|acetaminophen
1438192|NCT00240825|ibuprofen
1438193|NCT00240812|nocturnal enuresis
1438194|NCT00240812|bedwetting
1438195|NCT00240812|ibuprofen
1438196|NCT00240799|osteoarthritis hip
1438197|NCT00240799|osteoarthritis knee
1438198|NCT00240799|acetaminophen
1438199|NCT00240786|osteoarthritis hip
1438200|NCT00240786|osteoarthritis knee
1438201|NCT00240786|acetaminophen
1438202|NCT00240773|osteoarthritis hip
1438203|NCT00240773|osteoarthritis knee
1438204|NCT00240773|acetaminophen, naproxen
1438205|NCT00240760|Memantine
1438206|NCT00240760|Down syndrome
1438207|NCT00240760|Dementia
1438208|NCT00240760|learning Disability
1438209|NCT00240760|Treatment of Dementia
1438210|NCT00240734|Anemia
1438211|NCT00240734|Chronic renal failure
1438212|NCT00240734|pre-dialysis
1438213|NCT00240734|diabetic
1438214|NCT00240721|topiramate
1438215|NCT00240721|bipolar disorders
1438216|NCT00240721|mood disorders
1438217|NCT00240721|manic state
1438218|NCT00240721|depression
1438219|NCT00240721|manic-depressive psychoses
1438220|NCT00240708|Schizophrenia
1438221|NCT00240708|intramuscular injection
1438222|NCT00240708|antipsychotic agents
1438223|NCT00240708|risperidone
1438224|NCT00240708|long-acting injectable
1438225|NCT00240695|Alzheimer's disease
1438226|NCT00240695|Dementia
1438227|NCT00240695|Brain Disease
1438228|NCT00240695|Memory Loss
1438229|NCT00240695|galantamine
1438230|NCT00240695|Nervous System Diseases
1438231|NCT00240695|open-label
1438232|NCT00240695|elderly
1438233|NCT00240682|Carcinoma, Squamous Cell
1438234|NCT00240682|Skin
1438235|NCT00240682|cetuximab
1438236|NCT00240682|epidermal growth factor receptor
1438237|NCT00240669|Maxillo facial surgery,
1438238|NCT00240669|osteosynthesis,
1438239|NCT00240669|resorbable device
1438240|NCT00240656|aldosterone antagonists, spironolactone, captopril carvedilol
1438241|NCT00240643|non valvular atrial fibrillation
1438242|NCT00240643|stroke
1438243|NCT00240643|aspirin
1438244|NCT00240630|acute migraine
1438245|NCT00240630|consistency of response
1438246|NCT00240630|satisfaction
1438247|NCT00240630|migraine
1438248|NCT00240630|early intervention
1438249|NCT00240617|consistency of response
1438250|NCT00240617|migraine
1438251|NCT00240617|satisfaction
1438252|NCT00240617|early intervention
1438253|NCT00240604|corticosteroid treatment
1438254|NCT00240604|inflammatory diseases
1438255|NCT00240591|BEXXAR
1438256|NCT00240591|Tositumomab
1438257|NCT00240591|Iodine I 131 Tositumomab
1438258|NCT00240591|low-grade follicular lymphomas
1438259|NCT00240578|Long-Term Follow-up
1438260|NCT00240578|BEXXAR
1438261|NCT00240578|Iodine I 131 Tositumomab
1438262|NCT00240578|Low-grade lymphoma
1438263|NCT00240565|BEXXAR
1438264|NCT00240565|non-Hodgkin's Lymphoma
1438265|NCT00240565|tositumomab
1438266|NCT00240565|I-131
1438267|NCT00240552|protease inhibitor
1438268|NCT00240552|Treatment Experienced
1438269|NCT00240552|amprenavir
1438270|NCT00240552|fosamprenavir
1438271|NCT00240552|GW433908
1438272|NCT00240552|HIV
1438273|NCT00240552|pro drug
1438274|NCT00240539|Hepatitis B
1438275|NCT00240526|Hepatitis B immunoglobulin
1438276|NCT00240526|Hepatitis B antibody persistence
1438277|NCT00240513|Acne
1438278|NCT00240500|Long-term follow-up
1438279|NCT00240500|Hepatitis B antibody persistence
1438280|NCT00240487|Acute Respiratory Distress Syndrome
1438281|NCT00240487|ARDS
1438282|NCT00240487|Nitric Oxide
1438283|NCT00240461|respiratory
1438284|NCT00240461|infection
1438285|NCT00240461|influenza
1438286|NCT00240396|fracture
1438287|NCT00240396|Tibia
1438288|NCT00240396|femur
1438289|NCT00240396|humerus
1438290|NCT00240396|narcotics
1438291|NCT00240396|bimodal
1438292|NCT00240396|analgesia
1438293|NCT00240396|long-bone
1438294|NCT00240396|NSAIDS
1438295|NCT00240344|High risk patients
1438296|NCT00240344|Crestor
1438297|NCT00240344|Rosuvastatin
1438298|NCT00240344|LDL cholesterol
1438299|NCT00240344|observational
1438300|NCT00240331|End Stage Renal Failure
1438301|NCT00240318|Coronary Artery Disease
1438302|NCT00240305|Metabolic Syndrome
1438303|NCT00240305|Dyslipidaemia
1438304|NCT00240292|Ischaemic or non-ischaemic systolic congestive heart failure
1438305|NCT00240279|high blood cholesterol levels
1438306|NCT00240266|Metabolic Syndrome
1438307|NCT00240266|Dyslipaemia
1438308|NCT00240253|diabetes
1438309|NCT00240253|Amylin
1438310|NCT00240253|Symlin
1438311|NCT00240253|pramlintide
1438312|NCT00240253|insulin glargine
1438313|NCT00240227|Alcoholism
1438314|NCT00240227|Cocaine Dependence
1438315|NCT00240227|Prazosin
1438316|NCT00240227|Substance use disorders
1438317|NCT00240214|Kidney transplants
1438318|NCT00240188|Hernia
1438319|NCT00240188|Incisional
1438320|NCT00240188|Laparoscopic
1438321|NCT00240188|Mesh
1438322|NCT00240188|Repair
1438323|NCT00240188|Ventral
1438324|NCT00240162|Myeloma
1438325|NCT00240162|PTK
1438326|NCT00240136|Early, severe
1438327|NCT00240123|ERCP
1438328|NCT00240123|EUS
1438329|NCT00240110|Bipolar
1438330|NCT00240110|Cocaine
1438331|NCT00240110|Comorbidity
1438332|NCT00240071|Breast cancer
1438333|NCT00240071|Metastatic breast cancer
1438334|NCT00240071|Hormonal therapy
1438335|NCT00240071|Bevacizumab
1438336|NCT00240058|Blood Pressure
1438337|NCT00240058|Nitric Oxide
1438338|NCT00240058|L-NMMA
1438339|NCT00240058|Phenylephrine
1438340|NCT00240058|Nitroprusside
1438341|NCT00240058|Vasoreactivity
1438342|NCT00240045|Hepatorenal syndrome
1438343|NCT00240045|Refractory ascites
1438344|NCT00240045|Midodrine
1438345|NCT00240045|Octreotide
1438346|NCT00240045|Albumin
1438347|NCT00240045|Cirrhosis
1438348|NCT00240006|Multiple Sclerosis
1438349|NCT00240006|Copaxone®
1438350|NCT00240006|Shared Solutions®
1438351|NCT00239980|antineoplastic agent
1438352|NCT00239980|ovarian cancer
1438353|NCT00239980|fragmin
1438354|NCT00239980|dalteparin
1438355|NCT00239967|dyslipidemia
1438356|NCT00239967|obesity
1438357|NCT00239928|Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
1438358|NCT00239902|Transplantation, kidney, and organ transplantation
1438359|NCT00239889|Forearm fracture
1438360|NCT00239889|Postmenopausal women
1438361|NCT00239889|Pain
1438362|NCT00239889|Grip strength
1438363|NCT00239889|Salmon calcitonin
1438364|NCT00239876|Transplantation, kidney, and organ transplant
1438365|NCT00239863|Transplantation, kidney,organ transplant
1438366|NCT00239850|obesity
1438367|NCT00239850|lifestyle
1438368|NCT00239850|treatment
1438369|NCT00239850|Complications
1438370|NCT00239850|endocrine changes
1438371|NCT00239850|Lipids
1438372|NCT00239850|C18.654.726.500.495
1438373|NCT00239837|Adolescent
1438374|NCT00239837|Foster Care
1438375|NCT00239837|Female
1438376|NCT00239824|urinary incontinence
1438377|NCT00239824|pelvic floor muscle training
1438378|NCT00239824|radical prostatectomy
1438379|NCT00239824|physiotherapy
1438380|NCT00239811|Transplantation, kidney, and organ transplant.
1438381|NCT00239798|Transplantation, kidney, organ transplant
1438382|NCT00239785|Transplantation, kidney, and organ transplant.
1438383|NCT00239772|Cognitive Therapy
1438384|NCT00239772|PTSD
1438385|NCT00239772|Females
1438386|NCT00239772|Rape
1438387|NCT00239772|Trauma
1438388|NCT00239759|Epidemiological study
1438389|NCT00239746|Nonsteroidal Anti-inflammatories
1438390|NCT00239746|NSAIDS
1438391|NCT00239733|HIV
1438392|NCT00239733|HCV
1438393|NCT00239733|Hepatitis C
1438394|NCT00239733|Thrombocytopenia
1438395|NCT00239720|Psoriatic Arthritis
1438396|NCT00239720|Arthritis
1438397|NCT00239720|Psoriasis
1438398|NCT00239720|Psoriatic
1438399|NCT00239720|PsA
1438400|NCT00239707|insulin sensitivity
1438401|NCT00239707|blood sugar
1438402|NCT00239694|Immune response
1438403|NCT00239694|Antibody response
1438404|NCT00239681|Primary prevention
1438405|NCT00239681|Cardiovascular disease
1438406|NCT00239681|Statin therapy
1438407|NCT00239681|C-reactive protein
1438408|NCT00239668|Burns
1438409|NCT00239668|Functional
1438410|NCT00239668|Psychosocial
1438411|NCT00239668|Recovery
1438412|NCT00239668|Long-term
1438413|NCT00239668|Pediatric
1438414|NCT00239668|Surgical
1438415|NCT00239668|Outcomes
1438416|NCT00239668|Benchmarking
1438417|NCT00239642|Iron
1438418|NCT00239642|Anemia
1438419|NCT00239642|CKD
1438420|NCT00239616|Anemia
1438421|NCT00239616|Pharmacokinetics
1438422|NCT00239603|OV-Watch
1438423|NCT00239603|fertility monitor
1438424|NCT00239603|ovulation induction
1438425|NCT00239603|clomiphene citrate
1438426|NCT00239603|anovulation
1438427|NCT00239603|infertility
1438428|NCT00239577|Dengue infection
1438429|NCT00239564|IPX054
1438430|NCT00239564|Parkinson disease
1438431|NCT00239564|Levodopa
1438432|NCT00239551|gastric stress ulcer
1438433|NCT00239551|Prevacid
1438434|NCT00239551|Prostaglandin
1438435|NCT00239525|Cerebrovascular Accident
1438436|NCT00239525|Intracranial Hypertension
1438437|NCT00239512|PDA
1438438|NCT00239512|VLBW infants
1438439|NCT00239512|Indomethacin
1438440|NCT00239512|Ibuprofen
1438441|NCT00239330|high blood cholesterol levels
1438442|NCT00239317|tamsulosin
1438443|NCT00239317|urinary tract diseases
1438444|NCT00239317|male
1438445|NCT00239304|Stage III Head and Neck Cancer
1438446|NCT00239304|Stage IV Head and Neck Cancer
1438447|NCT00239265|tamsulosin
1438448|NCT00239265|urinary tract diseases
1438449|NCT00239265|female
1438450|NCT00239252|Interferon alfacon-1
1438451|NCT00239252|Virus disease
1438452|NCT00239252|Hepatitis C
1438453|NCT00239239|Non-myeloid malignancy
1438454|NCT00239239|Chemotherapy-induced anemia
1438455|NCT00239239|Oncology
1438456|NCT00239239|Clinical Trials
1438457|NCT00239239|Pharmacokinetics
1438458|NCT00239239|Darbepoetin alfa
1438459|NCT00239239|Aranesp
1438460|NCT00239239|Amgen
1438461|NCT00239226|atrial fibrillation
1438462|NCT00239226|interatrial septum
1438463|NCT00239226|atrial pacing
1438464|NCT00239226|symptomatic sinus node dysfunction,
1438465|NCT00239226|pacemaker indication class I
1438466|NCT00239213|catechins
1438467|NCT00239213|gargling
1438468|NCT00239213|healthy volunteers
1438469|NCT00239187|Type 2 diabetes
1438470|NCT00239174|obesity
1438471|NCT00239161|Pyelonephritis
1438472|NCT00239148|Type 1 diabetes
1438473|NCT00239135|Actinic Keratosis
1438474|NCT00239135|Topical
1438475|NCT00239135|Maximum Tolerated Dose
1438476|NCT00239135|Solar Keratosis
1438477|NCT00239135|Sun Spots
1438478|NCT00239135|Dermatology
1438479|NCT00239122|Cognitive Therapy
1438480|NCT00239122|Psychotic Disorders
1438481|NCT00239122|Treatment Outcome
1438482|NCT00239096|alcoholic liver cirrhosis
1438483|NCT00239096|ascites
1438484|NCT00239096|sodium retention
1438485|NCT00239083|MYFORMS, Kidney Transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS), Cyclosporine microemulsion (CsA-ME)
1438486|NCT00239070|EC-MPS, renal transplantation, de novo patients
1438487|NCT00239057|Renal transplantation, EC-MPS
1438488|NCT00239044|Kidney transplant recipients; Enteric-coated Mycophenolate sodium (EC-MPS)
1438489|NCT00239031|Renal transplantation, EC-MPS
1438490|NCT00239018|Enteric-Coated Mycophenolate Sodium (EC-MPS), de novo, kidney transplantation, long-term safety.
1438491|NCT00239005|QoL
1438492|NCT00239005|GI Side Effects
1438493|NCT00239005|MPA
1438494|NCT00238992|Kidney, de novo transplant, steroid withdrawal, adults, EC-MPS and cyclosporine
1438495|NCT00238979|Renal transplantation, Enteric-coated mycophenolate sodium
1438496|NCT00238966|Renal transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS)
1438497|NCT00238953|Kidney transplantation
1438498|NCT00238953|enteric-coated mycophenolate sodium
1438499|NCT00238940|Renal transplantation, Enteric-Coated Mycophenolate Sodium (EC-MPS)
1438500|NCT00238927|asthma
1438501|NCT00238927|preschool
1438502|NCT00238927|viral
1438503|NCT00238927|upper respiratory track infection
1438504|NCT00238927|fluticasone
1438505|NCT00238927|inhaled corticosteroids
1438506|NCT00238927|placebo
1438507|NCT00238927|exacerbations
1438508|NCT00238927|severity
1438509|NCT00238927|safety
1438510|NCT00238927|growth
1438511|NCT00238927|bone mineral density
1438512|NCT00238927|adrenal function
1438513|NCT00238927|rescue beta2-agonists
1438514|NCT00238901|Liver transplant, HCV+, steroid free
1438515|NCT00238888|asthma
1438516|NCT00238888|children
1438517|NCT00238888|adolescent
1438518|NCT00238888|education
1438519|NCT00238888|medical review
1438520|NCT00238888|asthma control
1438521|NCT00238888|questionnaire
1438522|NCT00238888|quality of life
1438523|NCT00238888|emergency department visit
1438524|NCT00238888|use of medication
1438525|NCT00238888|adherence to treatment
1438526|NCT00238875|stereotactic body radiation therapy
1438527|NCT00238875|T1N0M0 non-small cell lung cancer
1438528|NCT00238875|radiotherapy
1438529|NCT00238862|Diabetes
1438530|NCT00238862|Corneal transplant
1438531|NCT00238862|Neurotrophic keratitis
1438532|NCT00238862|Post-bacterial keratitis
1438533|NCT00238862|Metaherpetic keratitis
1438534|NCT00238849|Non-small cell lung cancer
1438535|NCT00238823|cryoablation
1438536|NCT00238823|radiofrequency ablation
1438537|NCT00238823|pediatrics
1438538|NCT00238823|cardiology
1438539|NCT00238810|BNP
1438540|NCT00238810|Pediatrics
1438541|NCT00238810|Congenital heart disease
1438542|NCT00238810|b-type natriuretic peptide
1438543|NCT00238797|Glioblastoma multiforme
1438544|NCT00238797|Brain tumour
1438545|NCT00238758|Mood Disorder
1438546|NCT00238745|Postmenopausal Osteoporosis
1438547|NCT00238732|Vaginal Atrophy
1438548|NCT00238732|Postmenopause
1438549|NCT00238719|Social Anxiety
1438550|NCT00238719|Children Disorders
1438551|NCT00238706|Radiofrequency catheter ablation
1438552|NCT00238706|Atrial fibrillation
1438553|NCT00238706|Randomized trial
1438554|NCT00238693|transplant
1438555|NCT00238693|transplantation of liver, kidney, pancreas
1438556|NCT00238680|Overactive bladder
1438557|NCT00238680|Children
1438558|NCT00238680|Bladder rehabilitation
1438559|NCT00238667|Extracranial carotid artery dissection
1438560|NCT00238667|Dissection and stroke
1438561|NCT00238550|Diabetes
1438562|NCT00238550|Pain
1438563|NCT00238550|Peripheral neuropathy
1438564|NCT00238537|Stroke
1438565|NCT00238537|Thrombolysis
1438566|NCT00238537|MRI
1438567|NCT00238537|Echoplanar
1438568|NCT00238537|Penumbra
1438569|NCT00238524|painful distal diabetic neuropathy
1438570|NCT00238498|Type 2 diabetes
1438571|NCT00238498|vildagliptin
1438572|NCT00238498|HbA1c
1438573|NCT00238485|Bipolar I Disorder
1438574|NCT00238472|Type 2 diabetes
1438575|NCT00238472|nateglinide
1438576|NCT00238459|Immunity to HIV
1438577|NCT00238459|Acute Infection
1438578|NCT00238459|Treatment Naive
1438579|NCT00238459|Treatment Interruption
1438580|NCT00238459|Structured Treatment Interruption
1438581|NCT00238459|STI
1438582|NCT00238446|Enteric-coated mycophenolate sodium, heart transplant recipients, long term safety
1438583|NCT00238433|recurrent adult Hodgkin lymphoma
1438584|NCT00238433|recurrent adult diffuse small cleaved cell lymphoma
1438585|NCT00238433|stage III adult diffuse small cleaved cell lymphoma
1438586|NCT00238433|stage IV adult diffuse small cleaved cell lymphoma
1438587|NCT00238433|recurrent grade 3 follicular lymphoma
1438588|NCT00238433|stage III grade 3 follicular lymphoma
1438589|NCT00238433|stage IV grade 3 follicular lymphoma
1438590|NCT00238433|recurrent adult diffuse mixed cell lymphoma
1438591|NCT00238433|stage III adult diffuse mixed cell lymphoma
1438592|NCT00238433|stage IV adult diffuse mixed cell lymphoma
1438593|NCT00238433|recurrent adult diffuse large cell lymphoma
1438594|NCT00238433|stage III adult diffuse large cell lymphoma
1438595|NCT00238433|stage IV adult diffuse large cell lymphoma
1438596|NCT00238433|recurrent adult immunoblastic large cell lymphoma
1438597|NCT00238433|stage III adult immunoblastic large cell lymphoma
1438598|NCT00238433|stage IV adult immunoblastic large cell lymphoma
1438599|NCT00238433|recurrent adult lymphoblastic lymphoma
1438600|NCT00238433|stage III adult lymphoblastic lymphoma
1438601|NCT00238433|stage IV adult lymphoblastic lymphoma
1438602|NCT00238433|recurrent adult Burkitt lymphoma
1438603|NCT00238433|stage III adult Burkitt lymphoma
1438604|NCT00238433|stage IV adult Burkitt lymphoma
1438605|NCT00238433|recurrent mantle cell lymphoma
1438606|NCT00238433|stage III mantle cell lymphoma
1438607|NCT00238433|stage IV mantle cell lymphoma
1438608|NCT00238433|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1438609|NCT00238433|nodal marginal zone B-cell lymphoma
1438610|NCT00238433|recurrent marginal zone lymphoma
1438611|NCT00238433|splenic marginal zone lymphoma
1438612|NCT00238433|recurrent small lymphocytic lymphoma
1438613|NCT00238433|recurrent grade 1 follicular lymphoma
1438614|NCT00238433|recurrent grade 2 follicular lymphoma
1438615|NCT00238433|recurrent/refractory childhood Hodgkin lymphoma
1438616|NCT00238433|stage III childhood Hodgkin lymphoma
1438617|NCT00238433|stage IV childhood Hodgkin lymphoma
1438618|NCT00238433|recurrent childhood anaplastic large cell lymphoma
1438619|NCT00238433|stage III childhood anaplastic large cell lymphoma
1438620|NCT00238433|stage IV childhood anaplastic large cell lymphoma
1438621|NCT00238433|childhood grade III lymphomatoid granulomatosis
1438622|NCT00238433|recurrent childhood large cell lymphoma
1438623|NCT00238433|stage III childhood large cell lymphoma
1438624|NCT00238433|stage IV childhood large cell lymphoma
1438625|NCT00238433|recurrent childhood lymphoblastic lymphoma
1438626|NCT00238433|stage III childhood lymphoblastic lymphoma
1438627|NCT00238433|stage IV childhood lymphoblastic lymphoma
1438628|NCT00238433|recurrent childhood small noncleaved cell lymphoma
1438629|NCT00238433|stage III childhood small noncleaved cell lymphoma
1438630|NCT00238433|stage IV childhood small noncleaved cell lymphoma
1438631|NCT00238433|recurrent cutaneous T-cell non-Hodgkin lymphoma
1438632|NCT00238433|stage III cutaneous T-cell non-Hodgkin lymphoma
1438633|NCT00238433|stage IV cutaneous T-cell non-Hodgkin lymphoma
1438634|NCT00238407|adenocarcinoma of the esophagus
1438635|NCT00238407|squamous cell carcinoma of the esophagus
1438636|NCT00238407|stage III esophageal cancer
1438637|NCT00238407|stage IV esophageal cancer
1438638|NCT00238381|adenocarcinoma of the rectum
1438639|NCT00238381|stage 0 rectal cancer
1438640|NCT00238381|stage I rectal cancer
1438641|NCT00238381|stage II rectal cancer
1438642|NCT00238381|stage III rectal cancer
1438643|NCT00238381|stage IV rectal cancer
1438644|NCT00238381|recurrent rectal cancer
1438645|NCT00238368|contiguous stage II adult diffuse large cell lymphoma
1438646|NCT00238368|noncontiguous stage II adult diffuse large cell lymphoma
1438647|NCT00238368|stage I adult diffuse large cell lymphoma
1438648|NCT00238368|stage III adult diffuse large cell lymphoma
1438649|NCT00238368|stage IV adult diffuse large cell lymphoma
1438650|NCT00238368|contiguous stage II grade 3 follicular lymphoma
1438651|NCT00238368|noncontiguous stage II grade 3 follicular lymphoma
1438652|NCT00238368|stage I grade 3 follicular lymphoma
1438653|NCT00238368|stage III grade 3 follicular lymphoma
1438654|NCT00238368|stage IV grade 3 follicular lymphoma
1438655|NCT00238368|anaplastic large cell lymphoma
1438760|NCT00237874|prodrome
1438656|NCT00238368|stage I adult T-cell leukemia/lymphoma
1438657|NCT00238368|stage II adult T-cell leukemia/lymphoma
1438658|NCT00238368|stage III adult T-cell leukemia/lymphoma
1438659|NCT00238368|stage IV adult T-cell leukemia/lymphoma
1438660|NCT00238355|infection
1438661|NCT00238355|unspecified adult solid tumor, protocol specific
1438662|NCT00238342|stage I ovarian epithelial cancer
1438663|NCT00238342|stage II ovarian epithelial cancer
1438664|NCT00238342|stage III ovarian epithelial cancer
1438665|NCT00238342|stage IV ovarian epithelial cancer
1438666|NCT00238342|fallopian tube cancer
1438667|NCT00238342|ovarian clear cell cystadenocarcinoma
1438668|NCT00238342|ovarian endometrioid adenocarcinoma
1438669|NCT00238342|ovarian mucinous cystadenocarcinoma
1438670|NCT00238342|ovarian serous cystadenocarcinoma
1438671|NCT00238342|ovarian undifferentiated adenocarcinoma
1438672|NCT00238329|recurrent melanoma
1438673|NCT00238329|stage IV melanoma
1438674|NCT00238329|ciliary body and choroid melanoma, medium/large size
1438675|NCT00238329|extraocular extension melanoma
1438676|NCT00238329|iris melanoma
1438677|NCT00238329|recurrent intraocular melanoma
1438678|NCT00238316|breast cancer
1438679|NCT00238290|recurrent breast cancer
1438680|NCT00238290|stage IIIA breast cancer
1438681|NCT00238290|stage IIIB breast cancer
1438682|NCT00238290|stage IIIC breast cancer
1438683|NCT00238290|stage IV breast cancer
1438684|NCT00238277|adult glioblastoma
1438685|NCT00238277|adult giant cell glioblastoma
1438686|NCT00238277|adult gliosarcoma
1438687|NCT00238264|childhood oligodendroglioma
1438688|NCT00238264|recurrent childhood cerebellar astrocytoma
1438689|NCT00238264|recurrent childhood cerebral astrocytoma
1438690|NCT00238264|childhood low-grade cerebral astrocytoma
1438691|NCT00238264|recurrent childhood visual pathway and hypothalamic glioma
1438692|NCT00238264|untreated childhood cerebellar astrocytoma
1438693|NCT00238264|untreated childhood visual pathway and hypothalamic glioma
1438694|NCT00238251|stage IV non-small cell lung cancer
1438695|NCT00238251|recurrent non-small cell lung cancer
1438696|NCT00238251|tumors metastatic to brain
1438697|NCT00238238|recurrent grade 1 follicular lymphoma
1438698|NCT00238238|recurrent grade 2 follicular lymphoma
1438699|NCT00238238|recurrent grade 3 follicular lymphoma
1438700|NCT00238225|unspecified adult solid tumor, protocol specific
1438701|NCT00238199|stage III pancreatic cancer
1438702|NCT00238199|stage IV pancreatic cancer
1438703|NCT00238173|drug/agent toxicity by tissue/organ
1438704|NCT00238173|bone marrow suppression
1438705|NCT00238173|long-term effects secondary to cancer therapy in children
1438706|NCT00238173|recurrent childhood brain stem glioma
1438707|NCT00238173|untreated childhood brain stem glioma
1438708|NCT00238173|childhood central nervous system germ cell tumor
1438709|NCT00238173|recurrent childhood supratentorial primitive neuroectodermal tumor
1438710|NCT00238173|recurrent childhood visual pathway and hypothalamic glioma
1438711|NCT00238173|recurrent childhood brain tumor
1438712|NCT00238173|recurrent childhood cerebellar astrocytoma
1438713|NCT00238173|childhood high-grade cerebral astrocytoma
1438714|NCT00238173|childhood low-grade cerebral astrocytoma
1438715|NCT00238173|recurrent childhood cerebral astrocytoma
1438716|NCT00238173|recurrent childhood medulloblastoma
1438717|NCT00238173|childhood oligodendroglioma
1438718|NCT00238173|childhood infratentorial ependymoma
1438719|NCT00238173|childhood supratentorial ependymoma
1438720|NCT00238173|recurrent childhood ependymoma
1438721|NCT00238173|childhood central nervous system choriocarcinoma
1438722|NCT00238173|childhood central nervous system embryonal tumor
1438723|NCT00238173|childhood central nervous system germinoma
1438724|NCT00238173|childhood central nervous system mixed germ cell tumor
1438725|NCT00238173|childhood central nervous system teratoma
1438726|NCT00238173|childhood central nervous system yolk sac tumor
1438727|NCT00238173|recurrent childhood central nervous system embryonal tumor
1438728|NCT00238147|stage II esophageal cancer
1438729|NCT00238147|stage III esophageal cancer
1438730|NCT00238108|Sleep disorders
1438731|NCT00238108|High blood pressure
1438732|NCT00238082|COPD
1438733|NCT00238082|Chronic Obstructive Pulmonary Disease
1438734|NCT00238082|Emphysema
1438735|NCT00238082|Chronic Bronchitis
1438736|NCT00238069|Asthma
1438737|NCT00238069|Sleep Apnea
1438738|NCT00238069|Obesity
1438739|NCT00238069|CPAP
1438740|NCT00238056|Domperidone, QT, prematurity
1438741|NCT00238043|Biogeneric Epoetin treatment
1438742|NCT00238043|Renal anaemia
1438743|NCT00238043|Chronic Kidney Disease
1438744|NCT00238043|Pure Red Blood Cell Aplasia
1438745|NCT00238043|Hemodialysis
1438746|NCT00238030|organ donation
1438747|NCT00238030|thyroid replacement
1438748|NCT00238017|malaria, amodiaquine, artesunate, safety, efficacy
1438749|NCT00238004|Niacin
1438750|NCT00237965|Skin Self Examination
1438751|NCT00237965|Mole Mapping Diagram
1438752|NCT00237965|Melanoma
1438753|NCT00237926|Sleep
1438754|NCT00237926|Fatigue
1438755|NCT00237926|Exercise tolerance
1438756|NCT00237926|Quality of life
1438757|NCT00237926|Health status
1438758|NCT00237887|Psoriasis
1438759|NCT00237887|adalimumab
1438761|NCT00237874|ultra high risk
1438762|NCT00237874|aripiprazole
1438763|NCT00237822|Treatment Adherence
1438764|NCT00237822|Co-Occurring Disorders
1438765|NCT00237822|Motivational Enhancement Therapy
1438766|NCT00237822|Contingency Management
1438767|NCT00237822|MEMS Caps
1438768|NCT00237796|Behavioral
1438769|NCT00237796|Cognitive
1438770|NCT00237796|Functioning
1438771|NCT00237796|Older
1438772|NCT00237796|CBT
1438773|NCT00237796|Rehabilitation
1438774|NCT00237796|Schizophrenia
1438775|NCT00237796|Skills
1438776|NCT00237796|Social
1438777|NCT00237796|Training
1438778|NCT00237783|Renal dialysis
1438779|NCT00237783|Hypotension
1438780|NCT00237783|Dialysis solutions
1438781|NCT00237770|Blood Pressure
1438782|NCT00237770|Cardiovascular Autonomic Control
1438783|NCT00237770|Nitric Oxide
1438784|NCT00237770|NOS Inhibitor
1438785|NCT00237770|Orthostatic Hypotension
1438786|NCT00237770|Spinal Cord Injury
1438787|NCT00237770|Tetraplegia
1438788|NCT00237757|Patient Care Team
1438789|NCT00237757|Rehabilitation outcomes
1438790|NCT00237757|Treatment outcomes
1438791|NCT00237744|Motor Learning
1438792|NCT00237744|Rehabilitation
1438793|NCT00237744|Robotics
1438794|NCT00237744|Therapeutic Electric Stimulation
1438795|NCT00237731|Acute pain
1438796|NCT00237731|Morphine titration
1438797|NCT00237731|Analgesia
1438798|NCT00237731|Pre-hospital care
1438799|NCT00237705|Headache
1438800|NCT00237705|Concussion
1438801|NCT00237705|Post concussive syndrome
1438802|NCT00237705|Head trauma
1438803|NCT00237692|Telemedicine
1438804|NCT00237692|Adherence
1438805|NCT00237692|Tailored Nurse Intervention
1438806|NCT00237692|Home Blood Pressure Monitoring
1438807|NCT00237692|cardiovascular disease
1438808|NCT00237679|behavior therapy
1438809|NCT00237679|combination therapy
1438810|NCT00237679|gastrointestinal disorder chemotherapy
1438811|NCT00237679|human therapy evaluation
1438812|NCT00237679|larynx disorder
1438813|NCT00237679|middle childhood (6-11)
1438814|NCT00237679|lansoprazole
1438815|NCT00237679|reflux esophagitis
1438816|NCT00237679|quality of life
1438817|NCT00237679|clinical research
1438818|NCT00237679|human subject
1438819|NCT00237679|laryngoscopy
1438820|NCT00237679|patient oriented research
1438821|NCT00237679|questionnaire
1438822|NCT00237666|Bipolar II Disorder
1438823|NCT00237666|Major Depressive Episode
1438824|NCT00237653|Valganciclovir
1438825|NCT00237653|Cytomegalovirus
1438826|NCT00237653|Cryptogenic inflammatory bowel diseases
1438827|NCT00237653|Crohn Disease
1438828|NCT00237653|colitis, ulcerative
1438829|NCT00237640|Cinnamon
1438830|NCT00237640|Diabetes mellitus
1438831|NCT00237640|Hyperlipidemia
1438832|NCT00237640|Insulin Resistance
1438833|NCT00237627|stage IIIA breast cancer
1438834|NCT00237627|stage IIIB breast cancer
1438835|NCT00237627|stage IIIC breast cancer
1438836|NCT00237627|stage IV breast cancer
1438837|NCT00237627|male breast cancer
1438838|NCT00237627|recurrent ovarian epithelial cancer
1438839|NCT00237627|stage III ovarian epithelial cancer
1438840|NCT00237627|stage IV ovarian epithelial cancer
1438841|NCT00237627|recurrent adult acute lymphoblastic leukemia
1438842|NCT00237627|recurrent adult acute myeloid leukemia
1438843|NCT00237627|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1438844|NCT00237627|adult acute myeloid leukemia with inv(16)(p13;q22)
1438845|NCT00237627|adult acute myeloid leukemia with t(15;17)(q22;q12)
1438846|NCT00237627|adult acute myeloid leukemia with t(16;16)(p13;q22)
1438847|NCT00237627|adult acute myeloid leukemia with t(8;21)(q22;q22)
1438848|NCT00237627|secondary acute myeloid leukemia
1438849|NCT00237627|mast cell leukemia
1438850|NCT00237627|stage III chronic lymphocytic leukemia
1438851|NCT00237627|stage IV chronic lymphocytic leukemia
1438852|NCT00237627|refractory chronic lymphocytic leukemia
1438853|NCT00237627|T-cell large granular lymphocyte leukemia
1438854|NCT00237627|atypical chronic myeloid leukemia
1438855|NCT00237627|accelerated phase chronic myelogenous leukemia
1438856|NCT00237627|blastic phase chronic myelogenous leukemia
1438857|NCT00237627|chronic phase chronic myelogenous leukemia
1438858|NCT00237627|meningeal chronic myelogenous leukemia
1438859|NCT00237627|relapsing chronic myelogenous leukemia
1438860|NCT00237627|chronic myelomonocytic leukemia
1438861|NCT00237627|refractory hairy cell leukemia
1438862|NCT00237627|progressive hairy cell leukemia, initial treatment
1438863|NCT00237627|stage III adult T-cell leukemia/lymphoma
1438864|NCT00237627|stage IV adult T-cell leukemia/lymphoma
1438865|NCT00237627|recurrent adult T-cell leukemia/lymphoma
1438866|NCT00237627|stage III adult Hodgkin lymphoma
1438867|NCT00237627|stage IV adult Hodgkin lymphoma
1438868|NCT00237627|recurrent adult Hodgkin lymphoma
1438869|NCT00237627|anaplastic large cell lymphoma
1438870|NCT00237627|angioimmunoblastic T-cell lymphoma
1438871|NCT00237627|stage III cutaneous T-cell non-Hodgkin lymphoma
1438872|NCT00237627|stage IV cutaneous T-cell non-Hodgkin lymphoma
1438873|NCT00237627|stage III mycosis fungoides/Sezary syndrome
1438874|NCT00237627|stage IV mycosis fungoides/Sezary syndrome
1438875|NCT00237627|recurrent cutaneous T-cell non-Hodgkin lymphoma
1438876|NCT00237627|recurrent mycosis fungoides/Sezary syndrome
1438877|NCT00237627|adult grade III lymphomatoid granulomatosis
1438878|NCT00237627|adult nasal type extranodal NK/T-cell lymphoma
1438879|NCT00237627|Waldenstrom macroglobulinemia
1438880|NCT00237627|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1438881|NCT00237627|splenic marginal zone lymphoma
1438882|NCT00237627|stage III adult Burkitt lymphoma
1438883|NCT00237627|stage III adult diffuse large cell lymphoma
1438884|NCT00237627|stage III adult diffuse mixed cell lymphoma
1438885|NCT00237627|stage III adult diffuse small cleaved cell lymphoma
1438886|NCT00237627|stage III adult immunoblastic large cell lymphoma
1438887|NCT00237627|stage III adult lymphoblastic lymphoma
1438888|NCT00237627|stage III grade 1 follicular lymphoma
1438889|NCT00237627|stage III grade 2 follicular lymphoma
1438890|NCT00237627|stage III grade 3 follicular lymphoma
1438891|NCT00237627|stage III mantle cell lymphoma
1438892|NCT00237627|stage III marginal zone lymphoma
1438893|NCT00237627|stage III small lymphocytic lymphoma
1438894|NCT00237627|stage IV adult Burkitt lymphoma
1438895|NCT00237627|stage IV adult diffuse large cell lymphoma
1438896|NCT00237627|stage IV adult diffuse mixed cell lymphoma
1438897|NCT00237627|stage IV adult diffuse small cleaved cell lymphoma
1438898|NCT00237627|stage IV adult immunoblastic large cell lymphoma
1438899|NCT00237627|stage IV adult lymphoblastic lymphoma
1438900|NCT00237627|stage IV grade 1 follicular lymphoma
1438901|NCT00237627|stage IV grade 2 follicular lymphoma
1438902|NCT00237627|stage IV grade 3 follicular lymphoma
1438903|NCT00237627|stage IV mantle cell lymphoma
1438904|NCT00237627|stage IV marginal zone lymphoma
1438905|NCT00237627|stage IV small lymphocytic lymphoma
1438906|NCT00237627|recurrent adult Burkitt lymphoma
1438907|NCT00237627|recurrent adult diffuse large cell lymphoma
1438908|NCT00237627|recurrent adult diffuse mixed cell lymphoma
1438909|NCT00237627|recurrent adult diffuse small cleaved cell lymphoma
1438910|NCT00237627|recurrent adult grade III lymphomatoid granulomatosis
1438911|NCT00237627|recurrent adult immunoblastic large cell lymphoma
1438912|NCT00237627|recurrent adult lymphoblastic lymphoma
1438913|NCT00237627|recurrent grade 1 follicular lymphoma
1438914|NCT00237627|recurrent grade 2 follicular lymphoma
1438915|NCT00237627|recurrent grade 3 follicular lymphoma
1438916|NCT00237627|recurrent mantle cell lymphoma
1438917|NCT00237627|recurrent marginal zone lymphoma
1438918|NCT00237627|recurrent small lymphocytic lymphoma
1438919|NCT00237627|intraocular lymphoma
1438920|NCT00237627|primary central nervous system lymphoma
1438921|NCT00237627|stage III multiple myeloma
1438922|NCT00237627|stage II multiple myeloma
1438923|NCT00237627|refractory multiple myeloma
1438924|NCT00237627|cutaneous B-cell non-Hodgkin lymphoma
1438925|NCT00237627|recurrent ovarian germ cell tumor
1438926|NCT00237627|stage III ovarian germ cell tumor
1438927|NCT00237627|stage IV ovarian germ cell tumor
1438928|NCT00237627|unspecified adult solid tumor, protocol specific
1438929|NCT00237627|recurrent breast cancer
1438930|NCT00237627|nodal marginal zone B-cell lymphoma
1438931|NCT00237614|Contrast-induced nephropathy
1438932|NCT00237614|Acute myocardial infarction
1438933|NCT00237614|Primary coronary angioplasty
1438934|NCT00237601|Home birth
1438935|NCT00237601|Hospital birth
1438936|NCT00237601|Midwifery
1438937|NCT00237601|Effectivity
1438938|NCT00237601|Efficiency
1438939|NCT00237588|Angiotensin II Type I Receptor Blockers
1438940|NCT00237588|Amlodipine
1438941|NCT00237588|Calcium Channel Blockers
1438942|NCT00237588|Diabetes Mellitus
1438943|NCT00237588|Hypertension
1438944|NCT00237588|Insulin Resistance
1438945|NCT00237588|Losartan
1438946|NCT00237575|urothelial
1438947|NCT00237575|bladder
1438948|NCT00237575|gemcitabine
1438949|NCT00237575|cisplatin
1438950|NCT00237575|leukine
1438951|NCT00237575|neupogen
1438952|NCT00237575|filgrastim
1438953|NCT00237575|sargramostim
1438954|NCT00237575|metastatic
1438955|NCT00237575|Regionally Advanced
1438956|NCT00237575|Advanced
1438957|NCT00237549|Type 2 diabetes
1438958|NCT00237549|Screening
1438959|NCT00237549|Intensive treatment
1438960|NCT00237549|Polypharmacy
1438961|NCT00237549|Primary care
1438962|NCT00237536|Benign Prostatic Hyperplasia
1438963|NCT00237536|BPH
1438964|NCT00237536|Enlarged Prostate
1438965|NCT00237523|Breast pain
1438966|NCT00237523|Mastalgia
1438967|NCT00237523|Cyclic mastalgia
1438968|NCT00237523|Periodic mastalgia
1438969|NCT00237523|Non-cyclic mastalgia
1438970|NCT00237523|Fibrosis
1438971|NCT00237523|Nodularity
1438972|NCT00237523|Cysts
1438973|NCT00237523|Fibrocystic breast disease
1438974|NCT00237523|Fibrocystic breast condition
1438975|NCT00237523|Fibocystic breast syndrome
1438976|NCT00237510|Antidepressant induced excessive sweating
1438977|NCT00237497|Insomnia
1438978|NCT00237497|Center of Pressure
1438979|NCT00237497|Postural Sway
1438980|NCT00237497|Drug Therapy
1438981|NCT00237497|Balance and Stability
1438982|NCT00237484|pegylated interferon alfa-2b
1438983|NCT00237484|ribavirin
1438984|NCT00237484|infliximab
1438985|NCT00237484|chronic hepatitis C
1438986|NCT00237471|Acute Myocardial Infarction
1438987|NCT00237471|Hyperglycaemia
1438988|NCT00237471|Insulin Infusion
1438989|NCT00237419|Ankylosing spondylitis
1438990|NCT00237419|Long-term therapy with infliximab
1438991|NCT00237419|Radiographic progression
1438992|NCT00237406|IVR, methadone
1438993|NCT00237406|methadone maintenance
1438994|NCT00237393|PTSD
1438995|NCT00237393|Posttraumatic stress disorder
1438996|NCT00237393|Treatment
1438997|NCT00237393|Quetiapine
1438998|NCT00237380|Cystic fibrosis
1438999|NCT00237380|Nonsense mutation
1439000|NCT00237380|Premature stop codon
1439001|NCT00237367|Gastroesophageal Reflux
1439002|NCT00237367|GERD
1439003|NCT00237367|Nighttime heartburn
1439004|NCT00237367|heartburn
1439005|NCT00237367|esophagus
1439006|NCT00237367|esophageal acid exposure
1439007|NCT00237367|EAE
1439008|NCT00237367|Aciphex
1439009|NCT00237367|Pariet
1439010|NCT00237367|rabeprazole
1439011|NCT00237367|Protonix
1439012|NCT00237367|pantoprazole
1439013|NCT00237354|Recurrent soft tissue breast carcinoma
1439014|NCT00237341|chronic low back pain
1439015|NCT00237341|opioid
1439016|NCT00237341|fentanyl
1439017|NCT00237328|Heparin resistance
1439018|NCT00237328|Blood clotting
1439019|NCT00237328|Heart surgery
1439020|NCT00237328|Cardiopulmonary bypass
1439021|NCT00237315|Urea
1439022|NCT00237315|Inherited metabolic disorders
1439023|NCT00237302|pediatric migraine
1439024|NCT00237302|migraine headache
1439025|NCT00237302|migraine prophylaxis
1439026|NCT00237302|migraine prevention
1439027|NCT00237302|migraine
1439028|NCT00237289|Manic depression
1439029|NCT00237289|Mania
1439030|NCT00237289|Depression
1439031|NCT00237289|Bipolar disorder
1439032|NCT00237289|Psychosis
1439033|NCT00237276|colonoscopy, chromoendoscopy, autoflurescence, narrow band imaging, high definition endoscopy, colorectal cancer, colitis, polyp, DALM, adenoma, video
1439034|NCT00237263|Parkinson's disease, end-of -dose wearing-off, entacapone
1439035|NCT00237250|Pre-diabetes
1439036|NCT00237250|vildagliptin
1439037|NCT00237250|IGT
1439038|NCT00237237|Type 2 diabetes
1439039|NCT00237237|vildagliptin
1439040|NCT00237224|Breast Cancer, ER and/or PgR positive, Letrozole
1439041|NCT00237211|Aromatase inhibitor
1439042|NCT00237211|letrozole
1439043|NCT00237211|breast cancer
1439044|NCT00237198|Aromatase inhibitor
1439045|NCT00237198|letrozole
1439046|NCT00237198|breast cancer
1439047|NCT00237185|GIST
1439048|NCT00237185|c-kit
1439049|NCT00237185|imatinib mesylate
1439050|NCT00237172|GIST
1439051|NCT00237172|Imatinib
1439052|NCT00237172|STI571
1439053|NCT00237172|Gastrointestinal Stromal Tumors
1439054|NCT00237159|Prostate cancer
1439055|NCT00237159|Bone metastasis
1439056|NCT00237159|Skeletal related event
1439057|NCT00237146|Prostate cancer
1439058|NCT00237146|Zoledronic acid
1439059|NCT00237146|Bone metastasis
1439060|NCT00237133|Breast cancer,
1439061|NCT00237133|Letrozole,
1439062|NCT00237133|Hormonal receptors
1439063|NCT00237120|Chronic Myelogenous Leukemia
1439064|NCT00237120|Imatinib
1439065|NCT00237120|CML
1439066|NCT00237107|Cytoreduction Surgical Procedures
1439067|NCT00237107|Curretage
1439068|NCT00237107|Photochemotherapy
1439069|NCT00237094|Diabetes
1439070|NCT00237094|Self Management
1439071|NCT00237094|Interdisciplinary team
1439072|NCT00237081|Interstitial Cystitis
1439073|NCT00237081|Painful Bladder Syndrome
1439074|NCT00237081|Genetics
1439075|NCT00237081|Risk factors
1439076|NCT00237081|Family history
1439077|NCT00237068|Gastroesophageal Reflux
1439078|NCT00237055|Children
1439079|NCT00237055|Crohn's disease
1439080|NCT00237055|Inflammatory bowel disease
1439081|NCT00237055|Infectious agents
1439082|NCT00237055|Colonoscopy
1439083|NCT00237042|Temporomandibular Disorders
1439084|NCT00237042|TMJ Disorders
1439085|NCT00237003|women
1439086|NCT00237003|incarceration
1439087|NCT00237003|alcohol use
1439088|NCT00237003|motivational interviewing
1439089|NCT00236990|prostatitis
1439090|NCT00236990|Elmiron
1439091|NCT00236990|pentosan polysulfate sodium
1439092|NCT00236977|CKD
1439093|NCT00236977|iron
1439094|NCT00236977|anemia
1439095|NCT00236964|Anemia
1439096|NCT00236964|Chronic Kidney Disease
1439097|NCT00236951|Anemia
1439098|NCT00236951|Cancer
1439099|NCT00236951|Chemotherapy
1439100|NCT00236938|iron
1439101|NCT00236938|peritoneal dialysis
1439102|NCT00236938|anemia
1439103|NCT00236925|Fibromyalgia
1439104|NCT00236925|Cortisol
1439105|NCT00236925|Hydrocortisone
1439106|NCT00236925|Stress
1439107|NCT00236912|complicated appendicitis
1439108|NCT00236912|antibiotics
1439109|NCT00236912|appendicitis
1439110|NCT00236912|infection
1439111|NCT00236886|Epilepsy
1439112|NCT00236886|Partial Epilepsy
1439113|NCT00236886|Secondary Generalized Epilepsy
1439114|NCT00236886|Primary Generalized Epilepsy
1439115|NCT00236886|Tonic-Clonic Seizures
1439116|NCT00236886|Topiramate
1439117|NCT00236886|Weight Loss
1439118|NCT00236873|topiramate
1439119|NCT00236873|epilepsy
1439120|NCT00236873|partial epilepsies
1439121|NCT00236873|partial epilepsy
1439122|NCT00236873|seizures
1439123|NCT00236873|epileptic seizures
1439124|NCT00236873|partial seizure disorder
1439125|NCT00236873|brain diseases
1439126|NCT00236860|partial seizure disorder
1439127|NCT00236860|brain diseases
1439128|NCT00236860|topiramate
1439129|NCT00236860|epilepsy
1439130|NCT00236860|partial epilepsies
1439131|NCT00236860|partial epilepsy
1439132|NCT00236860|seizures
1439133|NCT00236860|epileptic seizures
1439134|NCT00236847|topiramate
1439135|NCT00236847|epilepsy
1439136|NCT00236847|partial epilepsy
1439137|NCT00236847|seizures
1439138|NCT00236847|epileptic seizures
1439139|NCT00236847|partial seizure disorder
1439140|NCT00236847|brain diseases
1439141|NCT00236834|respiratory tract diseases
1439142|NCT00236834|levofloxacin
1439143|NCT00236834|pneumonia
1439144|NCT00236834|quinolones, hospital-acquired pneumonia
1439145|NCT00236834|lung diseases
1439146|NCT00236821|respiratory tract diseases
1439147|NCT00236821|pneumonia
1439148|NCT00236821|levofloxacin
1439149|NCT00236821|community-acquired pneumonia
1439150|NCT00236821|lung diseases
1439151|NCT00236821|quinolones
1439152|NCT00236808|quinolones, ciprofloxacin
1439153|NCT00236808|levofloxacin
1439154|NCT00236808|chronic bacterial prostatitis
1439155|NCT00236808|inflammation
1439156|NCT00236808|chronic prostatitis
1439157|NCT00236808|prostatitis
1439158|NCT00236808|prostate
1439159|NCT00236808|antibiotic
1439160|NCT00236795|contraception
1439161|NCT00236795|hormonal contraception
1439162|NCT00236795|oral contraception
1439163|NCT00236795|steroid, ethinyl estradiol, horgestimate, levonorgestrel contraception
1439164|NCT00236795|transdermal.
1439165|NCT00236782|contraception
1439166|NCT00236782|hormonal contraception
1439167|NCT00236782|oral contraception
1439168|NCT00236782|steroid, ethinyl estradiol, progestin contraception
1439169|NCT00236782|transdermal.
1439170|NCT00236769|contraception
1439171|NCT00236769|transdermal contraception
1439172|NCT00236769|hormonal, steroidal contraception
1439173|NCT00236769|ethinyl estradiol
1439174|NCT00236769|progesterone
1439175|NCT00236756|Epilepsy
1439176|NCT00236756|Seizures
1439177|NCT00236756|Topiramate
1439178|NCT00236756|Prophylaxis
1439179|NCT00236756|Antiepileptic
1439180|NCT00236756|Lennox-Gastaut syndrome
1439181|NCT00236756|Seizures, tonic
1439182|NCT00236743|topiramate
1439183|NCT00236743|epilepsy
1439184|NCT00236743|partial epilepsies
1439185|NCT00236743|partial epilepsy
1439186|NCT00236743|seizures
1439187|NCT00236743|epileptic seizures
1439188|NCT00236743|partial seizure disorder
1439189|NCT00236743|children
1439190|NCT00236743|pediatric
1439191|NCT00236730|topiramate
1439192|NCT00236730|epilepsy
1439193|NCT00236730|partial epilepsies
1439194|NCT00236730|partial epilepsy
1439195|NCT00236730|seizures
1439196|NCT00236730|epileptic seizures
1439197|NCT00236730|partial seizure disorder
1439198|NCT00236730|brain diseases
1439199|NCT00236717|Epilepsy
1439200|NCT00236717|Seizures
1439201|NCT00236717|Topiramate
1439202|NCT00236717|Prophylaxis
1439203|NCT00236717|Antiepileptic
1439204|NCT00236704|Epilepsy
1439205|NCT00236704|Seizures
1439206|NCT00236704|Topiramate
1439207|NCT00236704|Prophylaxis
1439208|NCT00236704|Antiepileptic
1439209|NCT00236704|Tonic-clonic seizures
1439210|NCT00236704|Grand mal seizures
1439211|NCT00236691|topiramate
1439212|NCT00236691|epilepsy
1439213|NCT00236691|partial epilepsies
1439214|NCT00236691|partial epilepsy
1439215|NCT00236691|seizures
1439216|NCT00236691|epileptic seizures
1439217|NCT00236691|partial seizure disorder
1439218|NCT00236691|brain diseases
1439219|NCT00236678|Anemia
1439220|NCT00236678|Rheumatoid arthritis
1439221|NCT00236678|Hemoglobin level
1439222|NCT00236665|Obesity
1439223|NCT00236665|Essential Hypertension
1439224|NCT00236665|Mild Hypertension
1439225|NCT00236665|Moderate Hypertension
1439226|NCT00236665|High Blood Pressure
1439227|NCT00236652|Maxillary Sinusitis
1439228|NCT00236652|Infection
1439229|NCT00236639|Obesity
1439230|NCT00236639|Hypertension
1439231|NCT00236639|Hyperlipidemia
1439232|NCT00236639|Type 2 Diabetes Mellitus
1439233|NCT00236639|Body Mass Index
1439234|NCT00236626|Type 2 Diabetes
1439235|NCT00236626|Obesity
1439236|NCT00236626|Insulin Resistance
1439237|NCT00236626|Body Mass Index
1439238|NCT00236626|Hypertension
1439239|NCT00236626|Hyperlipidemia
1439240|NCT00236626|Sulfonylurea
1439241|NCT00236626|Topiramate
1439242|NCT00236626|Adult-Onset Diabetes Mellitus
1439243|NCT00236626|Metabolic Syndrome
1439244|NCT00236613|Obesity
1439245|NCT00236613|Hypertension
1439246|NCT00236613|Hyperlipidemia
1439247|NCT00236613|Body Mass Index
1439248|NCT00236600|Obesity
1439249|NCT00236600|Hypertension
1439250|NCT00236600|Hyperlipidemia
1439251|NCT00236600|Type 2 Diabetes
1439252|NCT00236600|Life style modification
1439253|NCT00236587|Schizophrenia
1439254|NCT00236587|Intramuscular injection
1439255|NCT00236587|Antipsychotic agents
1439256|NCT00236587|Long-acting risperidone
1439257|NCT00236574|Dementia
1439258|NCT00236574|Alzheimer disease
1439259|NCT00236574|Mild cognitive impairment
1439260|NCT00236574|Galantamine hydrobromide
1439261|NCT00236574|Memory disorder
1439262|NCT00236561|Migraine
1439263|NCT00236561|Common Migraine
1439264|NCT00236561|Classic Migraine
1439265|NCT00236561|Headache
1439266|NCT00236561|Topiramate
1439267|NCT00236561|Propranolol
1439268|NCT00236561|Prophylaxis
1439269|NCT00236561|Prevention
1439270|NCT00236548|Schizophrenia
1439271|NCT00236548|schizoaffective disorder
1439272|NCT00236548|patient compliance
1439273|NCT00236548|long-acting risperidone
1439274|NCT00236548|intramuscular injection
1439275|NCT00236548|Treatment Guidebook
1439276|NCT00236535|musculoskeletal
1439277|NCT00236535|Pain
1439278|NCT00236535|sprained ankle
1439279|NCT00236535|ligament
1439280|NCT00236535|sprain
1439281|NCT00236535|ankle
1439282|NCT00236522|sinus infection
1439283|NCT00236522|acute bacterial sinusitis
1439284|NCT00236522|sinusitis
1439285|NCT00236522|bacterial sinus infection
1439286|NCT00236509|Migraine
1439287|NCT00236509|Common Migraine
1439288|NCT00236509|Classic Migraine
1439289|NCT00236509|Headache
1439290|NCT00236509|Topiramate
1439291|NCT00236509|Prophylaxis
1439292|NCT00236496|tremor
1439293|NCT00236496|essential tremor
1439294|NCT00236483|Oral Surgery
1439295|NCT00236483|Analgesics
1439296|NCT00236483|Postoperative Pain
1439297|NCT00236483|dental
1439298|NCT00236470|Disruptive behavior disorder
1439299|NCT00236470|risperidone
1439300|NCT00236470|antipsychotropic agents
1439301|NCT00236470|child
1439302|NCT00236470|adolescent
1439303|NCT00236457|Schizophrenia
1439304|NCT00236457|Intramuscular injection
1439305|NCT00236457|Antipsychotic agents
1439306|NCT00236457|Long-acting risperidone
1439307|NCT00236457|Olanzapine
1439308|NCT00236444|Child
1439309|NCT00236444|adolescent
1439310|NCT00236444|disruptive behavior disorders
1439311|NCT00236444|risperidone
1439312|NCT00236444|antipsychotropic agents
1439313|NCT00236431|Mild cognitive impairment
1439314|NCT00236431|Galantamine hydrobromide
1439315|NCT00236431|Memory disorders
1439316|NCT00236418|Epilepsy
1439317|NCT00236418|Seizures
1439318|NCT00236418|Topiramate
1439319|NCT00236418|Prophylaxis
1439320|NCT00236418|Antiepileptic
1439321|NCT00236418|Tonic-clonic seizures
1439322|NCT00236418|Grand mal seizures
1439323|NCT00236405|Anemia
1439324|NCT00236405|erythropoetin
1439325|NCT00236405|quality-of-life outcomes
1439326|NCT00236392|Gastroesophageal reflux
1439327|NCT00236392|Heartburn
1439328|NCT00236392|Rabeprazole
1439329|NCT00236392|Anti-ulcer agents
1439330|NCT00236392|GERD
1439331|NCT00236392|Proton pump inhibitor
1439332|NCT00236392|GORD
1439333|NCT00236392|Non-Erosive Reflux Disease
1439334|NCT00236392|NERD
1439335|NCT00236379|schizophrenia
1439336|NCT00236379|blood glucose
1439337|NCT00236379|glucose metabolism
1439338|NCT00236379|diabetes mellitus
1439339|NCT00236379|risperidone
1439340|NCT00236379|olanzapine
1439341|NCT00236366|Fentanyl
1439342|NCT00236366|opioid analgesics
1439343|NCT00236366|osteoarthritis
1439344|NCT00236366|arthritis
1439345|NCT00236366|transdermal administration
1439346|NCT00236353|schizophrenia
1439347|NCT00236353|schizoaffective disorder
1439348|NCT00236353|long-acting risperidone
1439349|NCT00236353|intramuscular injection
1439350|NCT00236340|Amniodrainage
1439351|NCT00236340|Pregnancy
1439352|NCT00236340|Amniocentesis
1439353|NCT00236327|Fentanyl
1439354|NCT00236327|Analgesia
1439355|NCT00236327|Pain
1439356|NCT00236327|Cancer pain
1439357|NCT00236327|Opioid analgesia
1439358|NCT00236327|Transdermal fentanyl
1439359|NCT00236327|Patient-controlled analgesia
1439360|NCT00236301|Hormone
1439361|NCT00236301|Menopause
1439362|NCT00236301|Inflammation
1439363|NCT00236301|Dose effects
1439364|NCT00236301|Apoptosis
1439365|NCT00236288|Cancer treatment and tobacco abuse
1439366|NCT00236275|Comparison of imaging modalities
1439367|NCT00236275|predict the effectiveness of neoadjuvant chemotherapy
1439368|NCT00236262|SDRA
1439369|NCT00236262|Distress
1439370|NCT00236262|Expiratory
1439371|NCT00236262|Pressure
1439372|NCT00236262|Ventilatory
1439373|NCT00236249|Double blind method
1439374|NCT00236249|Prospective study
1439375|NCT00236249|Lidocaine/administration and dosage/therapeutic use
1439376|NCT00236249|Anaesthetics local/administration and dosage
1439377|NCT00236249|Opioids/administration and dosage
1439378|NCT00236249|Pain, postoperative
1439379|NCT00236249|Perioperative care
1439380|NCT00236249|Postoperative care
1439381|NCT00236249|Analgesia, Patient-controlled
1439382|NCT00236249|Length of stay
1439383|NCT00236249|Survival analysis
1439384|NCT00236249|Patient satisfaction
1439385|NCT00236249|Surgery
1439386|NCT00236249|Middle age
1439387|NCT00236249|Adult
1439388|NCT00236249|Aged
1439389|NCT00236223|Primary hip replacement
1439390|NCT00236223|Gabapentin
1439391|NCT00236223|Dexamethasone
1439392|NCT00236223|Ketamine
1439393|NCT00236223|Multimodal postoperative analgesia.
1439394|NCT00236210|Vascular Intervention Program
1439395|NCT00236210|Vascular Disease
1439396|NCT00236210|Coronary Artery Disease
1439397|NCT00236210|Diabetes
1439398|NCT00236210|Lifestyle Modification
1439399|NCT00236210|Modifiable Risk Factors
1439400|NCT00236197|Heartburn
1439401|NCT00236197|Rabeprazole
1439402|NCT00236171|topical therapy
1439403|NCT00236171|Psoriasis Plaque Test
1439404|NCT00236145|BTP
1439405|NCT00236145|Break through pain
1439406|NCT00236145|breakthrough pain
1439407|NCT00236093|Sickle Cell
1439408|NCT00236041|Breakthrough Pain
1439409|NCT00236041|Cancer
1439410|NCT00236041|Sickle Cell
1439411|NCT00236041|Severe Burns
1439412|NCT00236041|Children
1439413|NCT00236041|Adolescents
1439414|NCT00236041|Analgesia
1439415|NCT00236041|Sickle Cell Disease
1439416|NCT00236041|Non-Cancer
1439417|NCT00236028|Early Rheumatoid Arthritis
1439418|NCT00235989|Relapsing multiple sclerosis
1439419|NCT00235989|interferon beta 1b
1439420|NCT00235989|Betaferon
1439421|NCT00235989|Betaseron
1439422|NCT00235976|Neuromuscular Blocking Agent
1439423|NCT00235976|Anesthesia
1439424|NCT00235976|Succinylcholine
1439425|NCT00235976|Tracheal Intubation
1439426|NCT00235976|Adjunct for tracheal intubation
1439427|NCT00235950|Coronary Heart Disease
1439428|NCT00235950|Percutaeous Coronary Intervention (PCI)
1439429|NCT00235937|Premenopausal
1439430|NCT00235937|Advanced Breast Cancer
1439431|NCT00235937|Metastatic Breast Cancer
1439432|NCT00235924|menopause
1439433|NCT00235924|isoflavone
1439434|NCT00235924|endometrial safety
1439435|NCT00235924|breast innocuity assessment
1439436|NCT00235924|hot flushes
1439437|NCT00235885|Psoriatic Arthritis
1439438|NCT00235885|adalimumab
1439439|NCT00235872|Rheumatoid arthritis
1439440|NCT00235859|Rheumatoid Arthritis
1439441|NCT00235859|adalimumab
1439442|NCT00235846|Endoscopic vein harvesting
1439443|NCT00235846|Saphenous vein
1439444|NCT00235833|Rheumatoid Arthritis
1439445|NCT00235820|Psoriasis
1439446|NCT00235820|adalimumab
1439447|NCT00235807|Audiology
1439448|NCT00235807|Rehabilitation
1439449|NCT00235807|Tinnitus
1439450|NCT00235781|Kidney Transplantation
1439451|NCT00235781|Antilymphocyte Serum
1439452|NCT00235781|Induction
1439453|NCT00235781|Graft Rejection
1439454|NCT00235768|Ecstasy
1439455|NCT00235768|MDMA
1439456|NCT00235768|Cognition
1439457|NCT00235768|Brain function
1439458|NCT00235768|Neuroimaging
1439459|NCT00235755|Partial Seizures
1439460|NCT00235755|Complex Partial Seizures
1439461|NCT00235755|Epilepsy
1439462|NCT00235755|Potassium Channels
1439463|NCT00235755|Anticonvulsant
1439464|NCT00235729|Opiate addiction
1439465|NCT00235729|Opiate dependence
1439466|NCT00235729|Withdrawal symptoms
1439467|NCT00235716|Alzheimer's Disease
1439468|NCT00235716|clinical trial
1439469|NCT00235716|randomized controlled trial
1439470|NCT00235716|alpha-tocopherol
1439471|NCT00235716|vitamin E
1439472|NCT00235716|Namenda
1439473|NCT00235716|memantine
1439474|NCT00235677|Endoscopic antireflux treatment
1439475|NCT00235677|GERD
1439476|NCT00235677|Sham-controlled
1439477|NCT00235677|Endocinch
1439478|NCT00235664|liver transplant recipients
1439479|NCT00235664|intestinal transplant recipients
1439480|NCT00235664|multivisceral transplant recipients
1439481|NCT00235651|Lung transplant recipient
1439482|NCT00235625|Alternative Medicine
1439483|NCT00235625|Psoriasis
1439484|NCT00235625|Turmeric
1439485|NCT00235625|Curcumin
1439486|NCT00235625|Dermatology
1439487|NCT00235599|Growth
1439488|NCT00235599|Hormone
1439489|NCT00235599|Deficiency
1439490|NCT00235586|vitamin D deficiency postmenopausal women
1439491|NCT00235573|Vitamin B12 absorption
1439492|NCT00235573|Holo-transcobalamin
1439493|NCT00235560|AML
1439494|NCT00235560|Rapamycin
1439495|NCT00235560|Elderly
1439496|NCT00235560|Elderly patients not eligible for intensive chemotherapy
1439497|NCT00235547|abortion
1439498|NCT00235547|randomized
1439499|NCT00235547|contraception
1439500|NCT00235547|pregnancy
1439501|NCT00235547|compliance
1439502|NCT00235547|continuation
1439503|NCT00235547|contraceptive patch
1439504|NCT00235547|transdermal hormonal contraception
1439505|NCT00235534|abortion
1439506|NCT00235534|randomized
1439507|NCT00235534|contraception
1439508|NCT00235534|pregnancy
1439509|NCT00235534|compliance
1439510|NCT00235534|continuation
1439511|NCT00235534|oral contraceptive pills
1439512|NCT00235521|Pulmonary hypertension
1439513|NCT00235521|Cardiac Surgery
1439514|NCT00235521|Children
1439515|NCT00235521|Pediatric Patients
1439516|NCT00235521|Iloprost
1439517|NCT00235521|NO
1439518|NCT00235521|nitric oxide
1439519|NCT00235521|Pulmonary hypertension after cardiac surgery in pediatric patients, 0 - 2 years old
1439520|NCT00235508|Insomnia
1439521|NCT00235508|Anxiety
1439522|NCT00235508|Generalized Anxiety Disorder
1439523|NCT00235495|stroke
1439524|NCT00235469|PAINFUL DISTAL DIABETIC NEUROPATHY
1439525|NCT00235456|oxygen
1439526|NCT00235456|surgical complications
1439527|NCT00235456|colo-rectal resections
1439528|NCT00235443|Painful Distal Diabetic Neuropathy
1439529|NCT00235417|Bone Marrow Transplantation
1439530|NCT00235404|Treatment of elderly.
1439531|NCT00235404|Nursing home.
1439532|NCT00235404|Rehabilitation.
1439533|NCT00235404|Readmissions.
1439534|NCT00235391|Deferasirox
1439535|NCT00235391|Congenital Anemias
1439536|NCT00235391|Anemias
1439537|NCT00235391|Red Blood Cell Disorders
1439538|NCT00235391|Chronic Iron Overload
1439539|NCT00235391|Transfusional Iron Overload
1439540|NCT00235391|Iron Chelators
1439541|NCT00235391|Oral Iron Chelators
1439542|NCT00235391|Thalassemia
1439543|NCT00235391|Sickle Cell Disease
1439544|NCT00235391|Diamond Blackfan Anemia
1439545|NCT00235391|Myelofibrosis
1439546|NCT00235391|ICL670A
1439547|NCT00235378|Lupus
1439548|NCT00235378|SLE
1439549|NCT00235352|Schizphrenia
1439550|NCT00235352|Cognition
1439551|NCT00235352|Negative Symptoms
1439552|NCT00235339|Oxygen Consumption
1439553|NCT00235339|Exercise
1439554|NCT00235339|Rehabilitation
1439555|NCT00235326|residents of Walkerton ontario at outbreak
1439556|NCT00235313|Nicotine replacement therapies
1439557|NCT00235313|Smoking
1439558|NCT00235313|Smoking related diseases
1439559|NCT00235313|Saliva cotinine
1439560|NCT00235313|Dose adjustment
1439561|NCT00235313|Smoker; patients with smoking related disease conditions
1439562|NCT00235300|Anti-T cells antibodies
1439563|NCT00235300|Cadaveric Donor Renal Transplantation
1439564|NCT00235300|Acute Renal Allograft Rejection
1439565|NCT00235300|Induction Therapy
1439566|NCT00235287|Angiotensin-Converting Enzyme Inhibitors
1439567|NCT00235287|type 1 angiotensin receptor antagonists
1439568|NCT00235287|blood pressure
1439569|NCT00235274|Schizophrenia
1439570|NCT00235274|Secretin
1439571|NCT00235261|Total hip replacement
1439572|NCT00235261|Pregablin
1439573|NCT00235261|Dexamethasone
1439574|NCT00235261|Multimodal postoperative analgesia.
1439575|NCT00235248|TIA/Brain infarct
1439576|NCT00235248|and plaque>4mm in the aortic arch
1439577|NCT00235248|Or peripheral embolism
1439578|NCT00235248|and plaque>4 mm in the thoracic aorta
1439579|NCT00235222|Stavudine
1439580|NCT00235222|Reduced dose of stavudine
1439581|NCT00235222|Viral load
1439582|NCT00235222|Peripheral neuropathy
1439583|NCT00235222|Treatment Experienced
1439584|NCT00235183|plasma
1439585|NCT00235183|bleeding
1439586|NCT00235183|liver transplantation
1439587|NCT00235131|Peripheral Artery Occlusive Disease
1439588|NCT00235105|early ankylosing spondylitis
1439589|NCT00235105|spondyloarthritis
1439590|NCT00235105|trial
1439591|NCT00235105|adalimumab
1439592|NCT00235079|Pericarditis
1439593|NCT00235079|Recurrence
1439594|NCT00235079|Therapeutics
1439595|NCT00235079|Prevention
1439596|NCT00235079|Colchicine
1439597|NCT00235053|asthma
1439598|NCT00235053|candidiasis, oral
1439599|NCT00235053|voice disorders
1439600|NCT00235040|Upper Respiratory Infections
1439601|NCT00235040|Respiratory Tract Infections
1439602|NCT00235040|Tree Number C01.539.739
1439603|NCT00235040|Tree Number C08.730
1439604|NCT00235040|Unique ID D012141
1439605|NCT00235014|hypertension
1439606|NCT00235014|diabetes
1439607|NCT00235014|trandolapril
1439608|NCT00235014|verapamil
1439609|NCT00235014|albuminuria
1439610|NCT00235001|Hypertension
1439611|NCT00235001|Tarka
1439612|NCT00234988|Sibutramine
1439613|NCT00234988|Obesity
1439614|NCT00234975|Lopinavir
1439615|NCT00234975|Ritonavir
1439616|NCT00234975|Phase 4
1439617|NCT00234975|HIV
1439618|NCT00234962|HIV Infection
1439619|NCT00234962|HAART
1439620|NCT00234962|Lopinavir
1439621|NCT00234962|Ritonavir
1439622|NCT00234962|Treatment Experienced
1439623|NCT00234962|Treatment Naive
1439624|NCT00234949|Cefdinir
1439625|NCT00234949|Cephalexin
1439626|NCT00234949|Skin Infection
1439627|NCT00234936|rheumatoid arthritis
1439628|NCT00234936|adalimumab
1439629|NCT00234936|quality of life
1439630|NCT00234923|HIV Infection
1439631|NCT00234923|Kaletra
1439632|NCT00234923|Lopinavir
1439633|NCT00234923|Ritonavir
1439634|NCT00234923|Treatment Naive
1439635|NCT00234910|Lopinavir
1439636|NCT00234910|Ritonavir
1439637|NCT00234910|Kaletra
1439638|NCT00234910|Tenofovir
1439639|NCT00234910|HIV infection
1439640|NCT00234910|Treatment Naive
1439641|NCT00234897|adalimumab
1439642|NCT00234897|rheumatoid arthritis
1439643|NCT00234884|rheumatoid arthritis
1439644|NCT00234884|adalimumab
1439645|NCT00234871|Hypertension
1439646|NCT00234871|Diabetes
1439647|NCT00234871|Proteinuria
1439648|NCT00234871|Tarka
1439649|NCT00234871|Lotrel
1439650|NCT00234858|Hypertension
1439651|NCT00234858|Metabolic Syndrome
1439652|NCT00234858|Tarka
1439653|NCT00234858|Hyzaar
1439654|NCT00234832|Obesity
1439655|NCT00234832|Sibutramine
1439656|NCT00234819|Menopause
1439657|NCT00234806|telehealth
1439658|NCT00234806|telemedicine
1439659|NCT00234793|childhood cancer
1439660|NCT00234793|intervention
1439661|NCT00234793|maternal coping
1439662|NCT00234793|problem solving skills
1439663|NCT00234793|anxiety
1439664|NCT00234793|cope
1439665|NCT00234793|problem solving
1439666|NCT00234780|acute home care
1439667|NCT00234767|Acute Respiratory Distress Syndrome
1439668|NCT00234767|ARDS
1439669|NCT00234767|Acute Lung Injury
1439670|NCT00234767|ALI
1439671|NCT00234767|Cost-effectiveness
1439672|NCT00234767|Pharmacoeconomics
1439673|NCT00234767|Long-term follow-up
1439674|NCT00234754|Incontinence
1439675|NCT00234754|Surgery
1439676|NCT00234754|Trans-vaginal tape
1439677|NCT00234754|Trans-obturator tape
1439678|NCT00234728|psoriasis
1439679|NCT00234728|hydrogel
1439680|NCT00234728|occlusive dressing
1439681|NCT00234728|occlusion
1439682|NCT00234728|hydrocortisone
1439683|NCT00234728|tacrolimus
1439684|NCT00234728|Protopic
1439685|NCT00234728|triamcinolone
1439686|NCT00234728|calcipotriene
1439687|NCT00234728|Dovonex
1439688|NCT00234728|halobetasol
1439689|NCT00234728|Ultravate
1439690|NCT00234715|Breast Cancer
1439691|NCT00234715|Breast Cancer Risk
1439692|NCT00234715|Breast Cancer Risk Assessment
1439693|NCT00234715|Psychosocial
1439694|NCT00234715|Acceptance
1439695|NCT00234676|Parkinson disease
1439696|NCT00234676|women
1439697|NCT00234676|postmenopause
1439698|NCT00234676|estrogen replacement therapy
1439699|NCT00234676|clinical trials
1439700|NCT00234663|Cystic fibrosis
1439701|NCT00234663|Nonsense mutation
1439702|NCT00234663|Premature stop codon
1439703|NCT00234650|position change
1439704|NCT00234650|adenoma
1439705|NCT00234650|colonoscopy
1439706|NCT00234637|Alzheimer's disease,
1439707|NCT00234637|switch,
1439708|NCT00234637|rivastigmine,
1439709|NCT00234637|memantine
1439710|NCT00234598|Pneumonia
1439711|NCT00234598|Dental Health
1439712|NCT00234598|Critical Care
1439713|NCT00234559|Angiogenesis
1439714|NCT00234559|Post surgical dehisced wounds of the lower extremity
1439715|NCT00234533|growth
1439716|NCT00234533|child development
1439717|NCT00234533|growth hormone
1439718|NCT00234533|inadequate growth hormone secretion
1439719|NCT00234533|growth failure
1439720|NCT00234468|Locally Advanced Non Small Cell Lung Cancer (Stage IIIA and IIIB)
1439721|NCT00234442|Non symptomatic brain metastases
1439722|NCT00234442|Iressa
1439723|NCT00234429|Colorectal carcinoma advanced disease
1439724|NCT00234416|Pancreatic Cancer
1439725|NCT00234416|EGF-R
1439726|NCT00234403|Advanced breast cancer
1439727|NCT00234403|Metastatic breast cancer
1439728|NCT00234403|ER positive breast cancer
1439729|NCT00234403|PR positive breast cancer
1439730|NCT00234377|Schizophrenia
1439731|NCT00234364|Pergolide
1439732|NCT00234364|Ergotamine derivates
1439733|NCT00234364|Valvular heart disease
1439734|NCT00233610|Casodex monotherapy
1439735|NCT00233597|anemia
1439736|NCT00233597|iron
1439737|NCT00233584|Children of asthmatic mothers
1439738|NCT00233545|cutaneous
1439739|NCT00233545|leishmaniasis
1439740|NCT00233545|drug
1439741|NCT00233545|miltefosine
1439742|NCT00233532|Hypertension
1439743|NCT00233532|Trandolapril
1439744|NCT00233506|CpG 7909
1439745|NCT00233506|CLL
1439746|NCT00233493|dermatophytes
1439747|NCT00233480|Randomized Controlled Trial
1439748|NCT00233480|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1439749|NCT00233480|Sympathetic Nervous System
1439750|NCT00233480|Ventricular Remodeling
1439751|NCT00233480|Chemokines
1439752|NCT00233467|antipsychotics
1439753|NCT00233467|PTSD
1439754|NCT00233467|posttraumatic stress disorder
1439755|NCT00233441|Atrial Fibrillation
1439756|NCT00233441|Atrial Flutter
1439757|NCT00233441|Arrhythmia
1439758|NCT00233441|Anti-Arrhythmia Agents
1439759|NCT00233428|Healthy volunteers
1439760|NCT00233402|Bladder Cancer
1439761|NCT00233402|Hexvix
1439762|NCT00233402|Fluorescence
1439763|NCT00233402|Cystoscopy
1439764|NCT00233376|Decision support system
1439765|NCT00233376|Causal probabilistic network
1439766|NCT00233376|Antibiotics
1439767|NCT00233376|Antibiotic resistance
1439768|NCT00233376|Community-acquired infections
1439769|NCT00233376|Cross-infections
1439770|NCT00234338|Children
1439771|NCT00234338|Vaccine
1439772|NCT00234338|Prevenar
1439773|NCT00234312|Depressive Disorders
1439774|NCT00234299|Cancer
1439775|NCT00234299|Prostate
1439776|NCT00234299|Preventive Therapy
1439777|NCT00234286|Palliative Care
1439778|NCT00234286|Terminal Care
1439779|NCT00234286|Hospice Care
1439780|NCT00234286|Patient Care Planning
1439781|NCT00234286|Nursing Care Plans
1439782|NCT00234286|Quality of Health Care
1439783|NCT00234286|Inpatients
1439784|NCT00234286|Professional education
1439785|NCT00234286|Resuscitation orders
1439786|NCT00234286|Pastoral Care
1439787|NCT00234273|Adapted Physical Activity
1439788|NCT00234273|Quality of life
1439789|NCT00234273|cardiovascular risk
1439790|NCT00234273|teaching
1439791|NCT00234273|Directly Observed Therapy
1439792|NCT00234273|Physical activity
1439793|NCT00234260|Genetics
1439794|NCT00234234|Biologics
1439795|NCT00234208|Complicated parapneumonic effusion
1439796|NCT00234208|Pleural empyema
1439797|NCT00234208|Intervention
1439798|NCT00234208|Medical thoracoscopy
1439799|NCT00234208|Chest tube drainage
1439800|NCT00234195|Breast Cancer
1439801|NCT00234195|Major Depressive Disorder
1439802|NCT00234182|liver cancer
1439803|NCT00234182|hepatectomy
1439804|NCT00234182|survival
1439805|NCT00234182|recurrence
1439806|NCT00234169|Multiple Myeloma
1439807|NCT00234169|Lymphoma
1439808|NCT00234156|Fructose
1439809|NCT00234156|Lipogenesis
1439810|NCT00234156|Triglycerides
1439811|NCT00234156|Dialysis
1439812|NCT00234143|MDS
1439813|NCT00234143|EPO
1439814|NCT00234143|G-CSF
1439815|NCT00234143|REGiM
1439816|NCT00234130|Dialysis
1439817|NCT00234130|Cytokines
1439818|NCT00234130|Triglycerides
1439819|NCT00234130|Insulin
1439820|NCT00234104|OPC-41061
1439821|NCT00234104|Tolvaptan
1439822|NCT00234104|Heart Failure
1439823|NCT00234104|Edema
1439824|NCT00234104|Extracellular volume expansion
1439825|NCT00234091|Treatment Naive
1439826|NCT00234091|Treatment Initiation
1439827|NCT00234091|Infant
1439828|NCT00234091|Preschool Child
1439829|NCT00234091|Child
1439830|NCT00234091|Zidovudine
1439831|NCT00234091|AZT
1439832|NCT00234091|Retrovir
1439833|NCT00234091|3TC
1439834|NCT00234091|Lamivudine
1439835|NCT00234091|Epivir
1439836|NCT00234091|Nevirapine
1439837|NCT00234091|NVP
1439838|NCT00234091|Viramune
1439839|NCT00234091|Efavirenz
1439840|NCT00234091|EFV
1439841|NCT00234091|Sustiva
1439842|NCT00234091|Lopinavir/Ritonavir
1439843|NCT00234091|LPV/r
1439844|NCT00234091|Kaletra
1439845|NCT00234091|Nelfinavir
1439846|NCT00234091|NFV
1439847|NCT00234091|Viracept
1439848|NCT00234091|ABC
1439849|NCT00234091|Abacavir
1439850|NCT00234091|Ziagen
1439851|NCT00234078|OPC-12759
1439852|NCT00234078|Dry eye syndromes
1439853|NCT00234052|recurrent non-small cell lung cancer
1439854|NCT00234052|stage IIIB non-small cell lung cancer
1439855|NCT00234052|stage IV non-small cell lung cancer
1439856|NCT00234052|adenocarcinoma of the lung
1439857|NCT00234052|bronchoalveolar cell lung cancer
1439858|NCT00234052|large cell lung cancer
1439859|NCT00234039|recurrent bladder cancer
1439860|NCT00234039|stage 0 bladder cancer
1439861|NCT00234039|stage I bladder cancer
1439862|NCT00234039|transitional cell carcinoma of the bladder
1439863|NCT00234026|recurrent mantle cell lymphoma
1439864|NCT00234026|stage I mantle cell lymphoma
1439988|NCT00233077|adjuvant treatment
1439865|NCT00234026|contiguous stage II mantle cell lymphoma
1439866|NCT00234026|noncontiguous stage II mantle cell lymphoma
1439867|NCT00234026|stage III mantle cell lymphoma
1439868|NCT00234026|stage IV mantle cell lymphoma
1439869|NCT00234000|refractory anemia with excess blasts in transformation
1439870|NCT00234000|refractory anemia with excess blasts
1439871|NCT00234000|refractory anemia with ringed sideroblasts
1439872|NCT00234000|refractory anemia
1439873|NCT00234000|chronic myelomonocytic leukemia
1439874|NCT00234000|de novo myelodysplastic syndromes
1439875|NCT00234000|previously treated myelodysplastic syndromes
1439876|NCT00234000|secondary myelodysplastic syndromes
1439877|NCT00233987|recurrent adult Hodgkin lymphoma
1439878|NCT00233974|stage IIIA breast cancer
1439879|NCT00233974|stage IIIB breast cancer
1439880|NCT00233974|stage IIIC breast cancer
1439881|NCT00233974|stage IV breast cancer
1439882|NCT00233961|chronic phase chronic myelogenous leukemia
1439883|NCT00233922|orbit
1439884|NCT00233922|orbital
1439885|NCT00233922|trauma
1439886|NCT00233922|fractures
1439887|NCT00233922|facial
1439888|NCT00233909|Leukemia, Myeloid
1439889|NCT00233909|Relapse
1439890|NCT00233909|Chemotherapy
1439891|NCT00233909|Zosuquidar
1439892|NCT00233909|gemtuzumab ozogamicin (GO)
1439893|NCT00233896|Hematopoietic cell transplant
1439894|NCT00233896|Acute graft-vs.-host disease
1439895|NCT00233896|Gastrointestinal tract
1439896|NCT00233896|Randomized trial
1439897|NCT00233896|Topical corticosteroid
1439898|NCT00233896|Beclomethasone dipropionate
1439899|NCT00233896|Prednisone
1439900|NCT00233896|Survival
1439901|NCT00233857|Acute pain
1439902|NCT00233857|postoperative pain
1439903|NCT00233857|auricular acupuncture
1439904|NCT00233844|Acute pain
1439905|NCT00233844|pain on venipuncture
1439906|NCT00233844|"cough-trick"
1439907|NCT00233844|distraction
1439908|NCT00233831|Postoperative pain
1439909|NCT00233831|analgesia
1439910|NCT00233831|total knee arthroplasty
1439911|NCT00233753|Intracranial
1439912|NCT00233753|Wide-neck
1439913|NCT00233753|Saccular
1439914|NCT00233753|Aneurysms
1439915|NCT00233727|cervical cancer
1439916|NCT00233727|cervical intraepithelial neoplasia
1439917|NCT00233727|prevention
1439918|NCT00233727|cryotherapy
1439919|NCT00233727|HPV testing
1439920|NCT00233727|cytology
1439921|NCT00233701|NPH
1439922|NCT00233701|Hydrocephalus
1439923|NCT00233636|Squamous Cell Carcinoma of Head and Neck
1439924|NCT00233636|Inoperable locally advanced Squamous Cell Carcinoma of Head and Neck
1439925|NCT00233623|Metastatic Colorectal Cancer
1439926|NCT00233350|Neuronavigation
1439927|NCT00233350|Ultrasound
1439928|NCT00233350|Brain tumour surgery
1439929|NCT00233350|Biopsy
1439930|NCT00233350|Histopathology
1439931|NCT00233350|Intraoperative imaging
1439932|NCT00233350|3D ultrasound imaging
1439933|NCT00233337|Malaria, non-immune travelers
1439934|NCT00233324|NICHD Neonatal Research Network
1439935|NCT00233324|Extremely Low Birth Weight (ELBW)
1439936|NCT00233324|Very Low Birth Weight (VLBW)
1439937|NCT00233324|Prematurity
1439938|NCT00233324|Mechanical ventilation
1439939|NCT00233324|Surfactant
1439940|NCT00233324|Intubation
1439941|NCT00233324|Neurodevelopmental impairment
1439942|NCT00233324|Pulse oximetry
1439943|NCT00233324|Oxygen saturation
1439944|NCT00233324|Positive-Pressure Respiration
1439945|NCT00233311|high fat diet
1439946|NCT00233311|inflammation
1439947|NCT00233311|inflammatory markers
1439948|NCT00233311|C-reactive protein
1439949|NCT00233311|Aging
1439950|NCT00233298|Hypoglycemia
1439951|NCT00233298|Blood Sugar
1439952|NCT00233298|Blood Glucose Level
1439953|NCT00233298|Insulin Sensitivity
1439954|NCT00233298|Metabolism
1439955|NCT00233298|Type 2 Diabetes
1439956|NCT00233298|Healthy
1439959|NCT00233155|Analgesics
1439960|NCT00233155|Capsaicin
1439961|NCT00233155|Neuropathic pain
1439962|NCT00233155|Neuropathy
1439963|NCT00233155|PHN
1439964|NCT00233155|Shingles
1439965|NCT00233142|Diabetes
1439966|NCT00233142|Emotions
1439967|NCT00233142|Blood glucose
1439968|NCT00233142|Expressive Writing
1439969|NCT00233129|Day treatment
1439970|NCT00233129|executive function
1439971|NCT00233129|problem solving
1439972|NCT00233129|attention
1439973|NCT00233129|participation
1439974|NCT00233129|TBI
1439975|NCT00233129|brain injury
1439976|NCT00233129|traumatic brain injury
1439977|NCT00233103|Sertraline
1439978|NCT00233103|TBI
1439979|NCT00233103|depression
1439980|NCT00233103|SSRI
1439981|NCT00233103|brain injury
1439982|NCT00233090|Fatigue
1439983|NCT00233090|TBI
1439984|NCT00233090|brain injury
1439985|NCT00233090|Modafinil
1439986|NCT00233090|traumatic brain injury
1439987|NCT00233077|breast cancer
1439989|NCT00233077|racial disparities
1439990|NCT00233051|Chronic Obstructive Pulmonary Disease (COPD)
1439991|NCT00233051|Emphysema
1439992|NCT00233051|Chronic Bronchitis
1439993|NCT00233051|Inhaled Steroid
1439994|NCT00233051|Salmeterol
1439995|NCT00233038|Pancreatic cancer
1439996|NCT00233038|Pancreatic adenoma
1439997|NCT00233038|Ethanol
1439998|NCT00233038|Endoscopic ultrasound
1439999|NCT00233038|Cyst ablation
1440000|NCT00233012|Refractory partial-onset seizures
1440001|NCT00233012|Infants aged 1-24 months
1440002|NCT00233012|Pharmacokinetics
1440003|NCT00233012|Topiramate
1440004|NCT00232999|Allergic asthma
1440005|NCT00232999|Allergen challenge
1440006|NCT00232999|Bronchial hyperresponsiveness
1440007|NCT00232960|oral and oropharynx carcinoma
1440008|NCT00232960|surgery
1440009|NCT00232960|postoperative radiotherapy
1440010|NCT00232960|molecular analysis
1440011|NCT00232960|microsatellite instability
1440012|NCT00232947|vaccine
1440013|NCT00232947|elderly
1440014|NCT00232947|immunogenicity
1440015|NCT00232947|safety
1440016|NCT00232934|Myeloma
1440017|NCT00232934|Thalidomide
1440018|NCT00232934|Diagnosis
1440019|NCT00232934|Elderly patients
1440020|NCT00232882|Hypertension
1440021|NCT00232882|Blood pressure
1440022|NCT00232882|Antihypertensive drugs
1440023|NCT00232882|Clinical Pharmacology
1440024|NCT00232882|Autonomic nervous system
1440025|NCT00232882|Renin angiotensin system
1440026|NCT00232882|Oxidative stress
1440027|NCT00232882|Inflammatory markers
1440028|NCT00232843|Peripheral Artery Occlusive Disease
1440029|NCT00232817|Postoperative pain
1440030|NCT00232726|Malignant melanoma
1440031|NCT00232726|CP-4055
1440032|NCT00232726|Chemotherapy-naïve patients
1440033|NCT00232726|Phase II
1440034|NCT00232726|Chemotherapy-naive patients
1440035|NCT00232726|Metastatic malignant melanoma
1440036|NCT00232713|Birth Defects
1440037|NCT00232713|Pregnancy
1440038|NCT00232713|Uterine Fibroids
1440039|NCT00232713|Fibroids
1440040|NCT00232700|Major depressive disorder
1440041|NCT00232700|Repetitive transcranial magnetic stimulation
1440042|NCT00232674|Chronic Obstructive Pulmonary Disease
1440043|NCT00232635|RSV
1440044|NCT00232635|HSCT
1440045|NCT00232635|HEMATOPOIETIC STEM CELL TRANSPL
1440046|NCT00232622|Prosthetic valve thrombosis
1440047|NCT00232622|Fibrinolysis
1440048|NCT00232622|Streptokinase
1440049|NCT00232609|Wheelchair
1440050|NCT00232609|Exercise
1440051|NCT00232609|Cardiovascular Disease
1440052|NCT00232596|Partial Seizures
1440053|NCT00232596|Anticonvulsant
1440054|NCT00232596|Complex Partial Seizures
1440055|NCT00232596|Potassium Channels
1440056|NCT00232596|Epilepsy
1440057|NCT00232583|TYpe 2 diabetes mellitus
1440058|NCT00232583|Newly diagnosed
1440059|NCT00232583|Beta-cell function
1440060|NCT00232570|sleep disturbance
1440061|NCT00232570|dementia
1440062|NCT00232557|Asthma
1440063|NCT00232557|Disease Management
1440064|NCT00232557|Telecommunications
1440065|NCT00232557|Health Services
1440066|NCT00232557|Quality of Life
1440067|NCT00232557|Patient Compliance
1440068|NCT00232544|sleep apnea, obstructive
1440069|NCT00232544|Quality of Life
1440070|NCT00232544|Depression
1440071|NCT00232544|Patient Compliance
1440072|NCT00232518|immune system
1440073|NCT00232518|infection
1440074|NCT00232518|allergic rhinitis
1440075|NCT00232505|recurrent breast cancer
1440076|NCT00232505|stage IV breast cancer
1440077|NCT00232492|Wisdom
1440078|NCT00232492|Tooth
1440079|NCT00232492|Teeth
1440080|NCT00232492|Third
1440081|NCT00232492|Molar
1440082|NCT00232466|Vertebroplasty
1440083|NCT00232466|Vertebral fracture
1440084|NCT00232466|Actonel
1440085|NCT00232466|Osteoporotic
1440086|NCT00232466|vertebral
1440087|NCT00232466|fractures
1440088|NCT00232427|Liver cirrhosis
1440089|NCT00232427|Hemodynamics
1440090|NCT00232427|Fluid balance
1440091|NCT00232414|bipolar
1440092|NCT00232414|with acute depressive episode
1440093|NCT00232401|urine
1440094|NCT00232401|circadian rhythm
1440095|NCT00232388|Ejection Fraction <35%
1440096|NCT00232375|SPIDDM
1440097|NCT00232375|LADA
1440098|NCT00232375|GAD antibody
1440099|NCT00232375|Beta cell function
1440100|NCT00232375|Insulin
1440101|NCT00232349|schizophrenia
1440102|NCT00232349|galantamine
1440103|NCT00232349|cholinesterase inhibitors
1440104|NCT00232349|quality of life
1440105|NCT00232349|cognition
1440106|NCT00232336|cocaine
1440107|NCT00232336|drug
1440108|NCT00232336|substance
1440109|NCT00232336|abuse
1440110|NCT00232336|addiction
1440111|NCT00232336|dependence
1440112|NCT00232336|quetiapine
1440113|NCT00232336|antipsychotic
1440114|NCT00232336|treatment
1440115|NCT00232323|intensive care
1440116|NCT00232323|stress
1440117|NCT00232323|education
1440118|NCT00232323|simulation
1440119|NCT00232310|Atrial Fibrillation
1440120|NCT00232310|Atrial Flutter
1440121|NCT00232310|Electric Countershock
1440122|NCT00232297|Tachycardia, Ventricular
1440123|NCT00232297|Ventricular Fibrillation
1440124|NCT00232297|Defibrillators Implantable
1440125|NCT00232297|Arrhythmia
1440126|NCT00232297|Anti-arrhythmia agents
1440127|NCT00232258|NK1 Antagonist
1440128|NCT00232258|Inflammatory Bowel Disease
1440129|NCT00232258|Mesalamine
1440130|NCT00232232|Atrial mechanical stunning and
1440131|NCT00232232|atrial electrical remodeling
1440132|NCT00232206|NSCLC
1440133|NCT00232206|Lung
1440134|NCT00232206|Cancer
1440135|NCT00232206|Metastatic
1440136|NCT00232206|Neoadjuvant
1440137|NCT00232206|Stage IB Non-Small Cell Lung Cancer (NSCLC)
1440138|NCT00232206|IIA Non-Small Cell Lung Cancer (NSCLC)
1440139|NCT00232206|IIB Non-Small Cell Lung Cancer (NSCLC)
1440140|NCT00232206|Some IIIA Non-Small Cell Lung Cancer (NSCLC)
1440141|NCT00232193|Multiple Sclerosis
1440142|NCT00232193|Interferon Beta 1-a
1440143|NCT00232193|Pulsed steroids
1440144|NCT00232180|Open-label
1440145|NCT00232180|single arm mortality/morbidity trial eplerenone chronic systolic heart failure
1440146|NCT00232115|Perioral Dermatitis, pimecrolimus cream
1440147|NCT00232102|Dyspepsia, gastrointestinal, tegaserod
1440148|NCT00232089|Dyspepsia, gastrointestinal, tegaserod
1440149|NCT00232076|Atopic Dermatitis, Ciclosporin,
1440150|NCT00232063|Atopic Dermatitis, Ciclosporin,
1440151|NCT00232050|Asthma, IgE, Omalizumab
1440152|NCT00232037|Dyspepsia, gastrointestinal, tegaserod
1440153|NCT00232024|Dyspepsia, gastrointestinal, tegaserod
1440154|NCT00232011|Atopic dermatitis, ASM981, pimecrolimus
1440155|NCT00231998|Atopic dermatitis, ASM981, pimecrolimus
1440156|NCT00231985|Habit-reversal Therapy
1440157|NCT00231985|Behavior Therapy
1440158|NCT00231985|Supportive Therapy
1440159|NCT00231972|HIV
1440160|NCT00231972|MSM
1440161|NCT00231959|Depression, Treatment-Resistant
1440162|NCT00231946|gonadotropins
1440163|NCT00231946|hormone therapy
1440164|NCT00231946|HRT
1440165|NCT00231946|Antigonadotropin
1440166|NCT00231946|Leuprolide
1440167|NCT00231933|Person-centered Care
1440168|NCT00231933|Recovery
1440169|NCT00231933|Disparities
1440170|NCT00231933|Culturally Responsive Care
1440171|NCT00231933|Psychosis
1440172|NCT00231920|Influenza, Vaccine, Infants
1440173|NCT00231907|influenza, vaccine, TIV, LAIV, booster, children
1440174|NCT00231894|atypical antipsychotics
1440175|NCT00231894|hyperglycemia
1440176|NCT00231894|triglycerides
1440177|NCT00231894|HDL
1440178|NCT00231894|cholesterol
1440179|NCT00231894|insulin resistance
1440180|NCT00231894|schizophrenia
1440181|NCT00231894|verbal memory
1440182|NCT00231881|GORD – Oesophageal sensitivity- Oesophageal permeability
1440183|NCT00231868|Uterine Papillary Serous Carcinoma
1440184|NCT00231868|UPSC
1440185|NCT00231868|Radiation Therapy
1440186|NCT00231868|Chemotherapy
1440187|NCT00231855|Epithelial Ovarian Cancer
1440188|NCT00231855|Uterine Cancer
1440189|NCT00231855|Prior Therapy
1440190|NCT00231855|Chemotherapy
1440191|NCT00231855|Recurrence
1440192|NCT00231842|Mixed Mesodermal Tumor
1440193|NCT00231842|MMT
1440194|NCT00231842|Uterine Cancer
1440195|NCT00231842|Radiation Therapy
1440196|NCT00231842|Chemotherapy
1440197|NCT00231829|Treatment
1440198|NCT00231829|Uterine Papillary Serous Carcinoma
1440199|NCT00231829|Clear Cell Carcinoma
1440200|NCT00231829|COX-2 Inhibitors
1440201|NCT00231816|Prevention of Herpes Zoster
1440202|NCT00231764|Renal transplantation
1440203|NCT00231764|Immunosuppression
1440204|NCT00231764|Daclizumab
1440205|NCT00231764|GFR
1440206|NCT00231751|Hemophilia A
1440207|NCT00231751|Inhibitors
1440208|NCT00231738|Eicosapentaenoic acid
1440209|NCT00231738|Coronary artery disease
1440210|NCT00231712|prospective analysis of immune function,
1440211|NCT00231712|spectratype
1440212|NCT00231712|immunoscope
1440213|NCT00231712|TREC analysis
1440214|NCT00231712|solid tumor
1440215|NCT00231699|Prevention of Hypothermia
1440216|NCT00231699|Pediatric Patient
1440217|NCT00231699|Cotton
1440218|NCT00231699|Plastic wrap
1440219|NCT00231686|Lung function test
1440220|NCT00231686|Physical conditioning, human
1440221|NCT00231686|Physical fitness
1440222|NCT00231686|Quality of life
1440223|NCT00231673|Diabetic peripheral polyneuropathy
1440224|NCT00231673|Electrophysiology
1440225|NCT00231673|Nerve Conduction Study
1440226|NCT00231673|Neurological Examination
1440227|NCT00231673|Quantitative Sensory Testing
1440228|NCT00231673|Topiramate
1440229|NCT00231660|Type 2 Diabetes
1440230|NCT00231660|Obesity
1440231|NCT00231660|Metformin
1440232|NCT00231660|Hemoglobin A1c
1440233|NCT00231660|Adult-Onset Diabetes Mellitus (AODM)
1440234|NCT00231647|Obesity
1440235|NCT00231647|Type 2 Diabetes Mellitus
1440236|NCT00231647|Metformin
1440237|NCT00231647|Diabetic Diet
1440238|NCT00231647|Topiramate
1440239|NCT00231647|Adult-Onset Diabetes Mellitus (AODM)
1440240|NCT00231634|Obesity
1440241|NCT00231634|Type 2 Diabetes Mellitus
1440242|NCT00231634|HbA1c
1440243|NCT00231634|Sulfonylurea
1440244|NCT00231634|Topiramate
1440245|NCT00231634|Adult-Onset Diabetes Mellitus (AODM)
1440246|NCT00231621|Obesity
1440247|NCT00231621|Dyslipidemia
1440248|NCT00231621|Hyperlipidemia
1440249|NCT00231621|Triglyceride
1440250|NCT00231621|HDL
1440251|NCT00231621|LDL
1440252|NCT00231621|Diabetes
1440253|NCT00231608|Obesity
1440254|NCT00231608|Abdominal Obesity
1440255|NCT00231608|Visceral Fat
1440256|NCT00231608|Subcutaneous Fat
1440257|NCT00231608|Dislipidemia
1440258|NCT00231608|Hypertension
1440259|NCT00231608|Type 2 Diabetes Mellitus
1440260|NCT00231595|Migraine
1440261|NCT00231595|Common Migraine
1440262|NCT00231595|Classic Migraine
1440263|NCT00231595|Headache
1440264|NCT00231595|Topiramate
1440265|NCT00231595|Prophylaxis
1440266|NCT00231595|Prevention
1440267|NCT00231582|High-dose with autologous germ-cell tumors
1440268|NCT00231569|LDL-cholesterol
1440269|NCT00231569|apoB-100
1440270|NCT00231569|apoB-48
1440271|NCT00231556|Epilepsy
1440272|NCT00231556|Seizures
1440273|NCT00231556|Parital Epilepsies
1440274|NCT00231556|Generalized Epilepsy
1440275|NCT00231556|Tonic-Clonic Epilepsy
1440276|NCT00231556|Topiramate
1440277|NCT00231530|Type 2 Diabetes Mellitus
1440278|NCT00231530|Obesity
1440279|NCT00231530|Diabetic Diet
1440280|NCT00231530|Hypertension
1440281|NCT00231530|Hyperlipidemia
1440282|NCT00231530|Adult-Onset Diabetes Mellitus(AODM)
1440283|NCT00231504|Polymorphism P1
1440284|NCT00231504|Polymorphism P2
1440285|NCT00231504|FSH Receptor
1440286|NCT00231504|Antral follicle count
1440287|NCT00231504|FSH receptor polymorphism
1440288|NCT00231491|Overactive bladder
1440289|NCT00231491|Urgency
1440290|NCT00231491|Urge incontinence
1440291|NCT00231491|Botulinum toxin A
1440292|NCT00231491|Quality of life
1440293|NCT00231465|elderly
1440294|NCT00231465|malignant pleural effusion
1440295|NCT00231452|natural acquired immunity,
1440296|NCT00231452|clinical malaria,
1440297|NCT00231452|P. falciparum,
1440298|NCT00231452|age,
1440299|NCT00231452|exposure,
1440300|NCT00231452|neonatal immunology,
1440301|NCT00231452|infants
1440302|NCT00231439|Post-polio syndrome
1440303|NCT00231439|IvIg
1440304|NCT00231400|Glycogen Storage Disease Type II (GSD-II)
1440305|NCT00231400|GSD-II
1440306|NCT00231400|Pompe Disease
1440307|NCT00231400|Pompe Disease (late-onset)
1440308|NCT00231400|Acid Maltase Deficiency Disease
1440309|NCT00231400|Glycogenosis II
1440310|NCT00231387|diabetes rosiglitazone plaque
1440311|NCT00231374|cerebrospinal fluid
1440312|NCT00231374|pain in cervical spine
1440313|NCT00231374|pain in lumbar spine
1440314|NCT00231374|myelogram
1440315|NCT00231348|Social anxiety disorder
1440316|NCT00231348|social phobia
1440317|NCT00231348|positron emission tomography (PET
1440318|NCT00231348|regional cerebral blood flow (rCBF)
1440319|NCT00231348|nefazodone
1440320|NCT00231348|amygdala
1440321|NCT00231335|schizophrenia
1440322|NCT00231335|depression
1440323|NCT00231335|anxiety
1440324|NCT00231335|negative symptoms
1440325|NCT00231322|Schistosoma haematobium
1440326|NCT00231322|haematuria
1440327|NCT00231322|ultrasonography
1440328|NCT00231322|Uganda
1440329|NCT00231322|Vesical polyps
1440330|NCT00231309|G-CSF
1440331|NCT00231309|Bone Marrow
1440332|NCT00231309|Hematologic malignancies
1440333|NCT00231309|Non-malignancies
1440334|NCT00231309|Matched sibling donor
1440335|NCT00231309|Allogeneic BMT
1440336|NCT00231296|cryoablation
1440337|NCT00231296|atrial fibrillation
1440338|NCT00231218|vitamin c
1440339|NCT00231218|echinacea
1440340|NCT00231218|propolis
1440341|NCT00231218|upper respiratory tract infection
1440342|NCT00231218|common cold
1440343|NCT00231218|gastroenteritis
1440344|NCT00231218|dietary supplement
1440345|NCT00231218|herbal remedy
1440346|NCT00231205|viability
1440347|NCT00231205|myocardium
1440348|NCT00231205|preejection velocity
1440349|NCT00231205|CAD
1440350|NCT00231205|echocardiography
1440351|NCT00231205|tissue Doppler
1440352|NCT00231192|Diabetes
1440353|NCT00231192|Adolescents
1440354|NCT00231192|Cystic Fibrosis
1440355|NCT00231192|Insulin
1440356|NCT00231192|Repaglinide
1440357|NCT00231179|child, preschool
1440358|NCT00231179|intelligence
1440359|NCT00231179|environment
1440360|NCT00231179|home visiting
1440361|NCT00231166|dose-finding
1440362|NCT00231166|monoclonal antibody
1440363|NCT00231166|Multiple Myeloma
1440364|NCT00231153|catheter site infection
1440365|NCT00231153|catheter colonization
1440366|NCT00231153|catheter related blood stream infection
1440367|NCT00231153|patients with central venous catheters
1440368|NCT00231140|ALS, motor neuron disease
1440369|NCT00231127|COPD
1440370|NCT00231127|Osteoporosis
1440371|NCT00231127|Osteopenia
1440372|NCT00231127|Glucocorticoids
1440373|NCT00231127|GOLD
1440374|NCT00231127|BODE
1440375|NCT00231114|Asthma
1440376|NCT00231101|Smoking
1440377|NCT00231101|Schizophrenia
1440378|NCT00231075|Epithelial ovary cancer F.I.G.O. stages III or IV
1440379|NCT00231075|70 years or older
1440380|NCT00231062|sinusitis
1440381|NCT00231062|rhinitis
1440382|NCT00231062|sinus surgery
1440383|NCT00231062|maxillary
1440384|NCT00231062|ethmoid
1440385|NCT00231062|sphenoid
1440386|NCT00231062|frontal
1440387|NCT00231062|FESS
1440388|NCT00231062|sinuplasty
1440389|NCT00231049|Genital Herpes
1440390|NCT00231049|HSV-2 Seropositive
1440391|NCT00231049|Vaccine
1440392|NCT00231023|Anterior Subtenon
1440393|NCT00231023|Posterior Peribulbar
1440394|NCT00231023|Laser Photocoagulation
1440395|NCT00231023|Diabetes
1440396|NCT00231023|Diabetic Retinopathy
1440397|NCT00231023|Diabetic Macular Edema
1440398|NCT00231023|DME
1440399|NCT00231010|Retnitis Pigmentosa
1440400|NCT00231010|Retinal Degeneration
1440401|NCT00231010|Retinitis Pigmentosa
1440402|NCT00231010|RP
1440403|NCT00231010|Usher Syndrome
1440404|NCT00231010|USH
1440405|NCT00231010|Bietti Crystalline Dystrophy
1440406|NCT00231010|BCD
1440407|NCT00230997|Galantamine
1440408|NCT00230997|Dementia with Lewy Bodies
1440409|NCT00230997|Treatment
1440410|NCT00230984|Chronic Respiratory Failure
1440411|NCT00230984|Pulmonary Rehabilitation
1440412|NCT00230984|Nutritional Depletion
1440413|NCT00230984|Home
1440414|NCT00230984|COPD
1440415|NCT00230984|Oral Dietary Supplements
1440416|NCT00230984|Therapeutic Education
1440417|NCT00230984|Androgens
1440418|NCT00230984|Exacerbation
1440419|NCT00230984|Survival
1440420|NCT00230971|Intra-Abdominal Infections
1440421|NCT00230971|Abscess
1440422|NCT00230958|Viramidine
1440423|NCT00230958|Ribavirin
1440424|NCT00230958|Valeant
1440425|NCT00230958|Hepatitis C
1440426|NCT00230958|Pegylated interferon alfa-2b
1440427|NCT00230932|Veterans
1440428|NCT00230932|Pain
1440429|NCT00230932|Palliative Care
1440430|NCT00230932|Cardiology
1440431|NCT00230932|Reproducibility of Results
1440432|NCT00230932|Health Personnel
1440433|NCT00230932|Heart Failure, Congestive
1440434|NCT00230919|Obesity,
1440435|NCT00230919|weight loss,
1440436|NCT00230919|diet counseling
1440437|NCT00230919|low-glycemic load
1440438|NCT00228410|Skin Infections
1440439|NCT00228410|Skin Disease
1440440|NCT00230893|Antipsychotics
1440441|NCT00230893|PTSD
1440442|NCT00230893|Post Traumatic Stress Disorder
1440443|NCT00230893|monotherapy
1440444|NCT00230893|adjunct therapy
1440445|NCT00230880|Contraception behavior
1440446|NCT00230880|Condoms
1440447|NCT00230880|Unsafe sex
1440448|NCT00230880|Pregnancy unwanted
1440449|NCT00230880|Adolescent pregnancy
1440450|NCT00230880|Condom use
1440451|NCT00230880|Unprotected sex
1440452|NCT00230880|Unintended pregnancy
1440453|NCT00230867|herpes labialis
1440454|NCT00230867|cold sore
1440455|NCT00230867|acyclovir
1440456|NCT00230867|iontophoresis
1440457|NCT00230867|topical
1440458|NCT00230854|hepatitis C
1440459|NCT00230854|genotype 1
1440460|NCT00230854|non-responders
1440461|NCT00230854|viral hepatitis
1440462|NCT00230841|croup
1440463|NCT00230841|humidity therapy
1440464|NCT00230841|pediatrics
1440465|NCT00230815|Oligoanovulatory infertility
1440466|NCT00230815|Follitropin alfa
1440467|NCT00230815|Pen device
1440468|NCT00230815|Gonal-f®
1440469|NCT00230815|Recombinant Human Choriogonadotropin (r-hCG)
1440470|NCT00230815|Ovidrel®
1440471|NCT00230802|pregnancy
1440472|NCT00230802|hypothyroidism
1440473|NCT00230802|levothyroxine
1440474|NCT00230750|influenza, elderly, vaccine, H5N1, parent protocol
1440475|NCT00230737|Aged
1440476|NCT00230737|Sleep
1440477|NCT00230737|Insomnia
1440478|NCT00230737|Melatonin
1440479|NCT00230737|Neurobehavioral Manifestations
1440480|NCT00230737|Circadian Rhythms
1440481|NCT00230737|Human
1440482|NCT00230737|Polysomnography
1440483|NCT00230737|Elderly
1440484|NCT00230724|Exercise maintenance
1440485|NCT00230711|Physical activity
1440486|NCT00230711|Cancer follow-up care
1440487|NCT00230698|Epilepsy
1440488|NCT00230698|Partial Epilepsies
1440489|NCT00230698|Seizures
1440490|NCT00230698|Topiramate
1440491|NCT00230685|Pulmonary arteriovenous malformations
1440492|NCT00230646|cancer recovery
1440493|NCT00230646|physical activity
1440494|NCT00230607|alpha Galactosidase A
1440495|NCT00230607|aGAL
1440496|NCT00230607|rh aGAL
1440497|NCT00230607|Fabry
1440498|NCT00230607|GL3
1440499|NCT00230607|Fabrazyme
1440500|NCT00230607|Lysosomal Storage Disorder
1440501|NCT00230607|Enzyme Replacement Therapy (ERT)
1440502|NCT00230581|IBS-d, IBS
1440503|NCT00230568|Mild to Moderate Alzheimer's Disease
1440504|NCT00230568|Hispanic
1440505|NCT00230568|Latino
1440506|NCT00230568|Spanish-speaking
1440507|NCT00230555|child, preschool
1440508|NCT00230555|environment
1440509|NCT00230555|intelligence
1440510|NCT00230542|platinum-sensitive recurrence
1440511|NCT00230542|carboplatin
1440512|NCT00230542|pemetrexed
1440513|NCT00230529|Plaque-type Psoriasis
1440514|NCT00230529|infliximab
1440515|NCT00230529|Remicade
1440516|NCT00230529|biologics
1440517|NCT00230516|N/A this study is being conducted with healthy volunteers
1440518|NCT00230503|Hepatitis B, Chronic
1440519|NCT00230503|Hepatitis B Virus
1440520|NCT00230503|Pradefovir Mesylate
1440521|NCT00230503|Adefovir Dipivoxyl
1440522|NCT00230490|Hepatitis B, Chronic
1440523|NCT00230490|Hepatitis B Virus
1440524|NCT00230490|Pradefovir Mesylate
1440525|NCT00230490|Adefovir Dipivoxyl
1440526|NCT00230477|Hepatitis B
1440527|NCT00230464|diabetes
1440528|NCT00230464|rate of appearance of glucose
1440529|NCT00230464|insulin secretion
1440530|NCT00230464|glucagon
1440531|NCT00230425|Alcohol Abuse
1440532|NCT00230425|Anxiety Disorders
1440533|NCT00230425|Mood Disorders
1440534|NCT00230412|Kidney Failure, Acute
1440535|NCT00230412|Acute Renal Failure
1440536|NCT00230412|Kidney Failure
1440537|NCT00230412|Heat-Shock Proteins
1440538|NCT00230412|Children
1440539|NCT00230373|Localized scleroderma
1440540|NCT00230360|constipation
1440541|NCT00230360|fecal incontinence
1440542|NCT00230360|diagnosis
1440543|NCT00230360|children
1440544|NCT00230308|Head and Neck Cancer
1440545|NCT00228865|Pulsatile intravenous insulin
1440546|NCT00228865|Oral carbohydrate loading
1440547|NCT00228865|Mindstream testing
1440548|NCT00228865|Wechsler Memory Scale II
1440549|NCT00228865|Respiratory Quotients
1440550|NCT00228865|Hypoglycemia
1440551|NCT00228865|Diabetes Mellitus with cognitive impairment
1440552|NCT00228865|Diabetes Mellitus with complications
1440553|NCT00228852|Patients with severe T-cell immune deficiency diseases
1440554|NCT00228839|Recipients of an allogeneic hematopoietic stem cell transplant who have acute GVHD
1440555|NCT00228696|late effects
1440556|NCT00230243|Aspergillosis
1440557|NCT00230243|CandidiasisMucormycosis
1440558|NCT00230243|FusariosisCryptococcosis
1440559|NCT00230243|Endemic Fungal infections
1440560|NCT00230243|Phaeohyphomycosis
1440561|NCT00230217|Relapse
1440562|NCT00230217|Refracturing
1440563|NCT00230217|Leukemia
1440564|NCT00230217|Lymphoma
1440565|NCT00230217|Solid Tumor
1440566|NCT00230204|Multiple sclerosis
1440567|NCT00230204|Antibodies
1440568|NCT00230204|Serum
1440569|NCT00230204|Infectious agents
1440570|NCT00230204|Immunoglobulin G
1440571|NCT00230204|Immunoglobulin M
1440572|NCT00230191|Oral
1440573|NCT00230191|Mucositis
1440574|NCT00230191|Stomatitis
1440575|NCT00230191|Head and Neck Cancer
1440576|NCT00230178|Hyperuricemia
1440577|NCT00230178|Tumor lysis syndrome
1440578|NCT00230178|Leukemia
1440579|NCT00230178|Lymphoma
1440580|NCT00230178|Myelodysplastic Syndromes
1440581|NCT00230178|Solid tumor cancers
1440582|NCT00230178|Solid Tumor cancers with hyperuricemia Hyperuricemia (cancer patients only)
1440583|NCT00230178|Tumor lysis syndrome (cancer patients only)
1440584|NCT00230165|Platelets
1440585|NCT00230165|Erythrocytes
1440586|NCT00230165|Leukocytes
1440587|NCT00230165|Coagulation
1440588|NCT00230165|Thrombosis
1440589|NCT00230126|African Americans
1440590|NCT00230113|NAFLD
1440591|NCT00230113|NASH
1440592|NCT00230113|Fatty Liver Disease
1440593|NCT00230113|Omega-3 Fatty Acid
1440594|NCT00230113|Fish oil
1440595|NCT00230100|Gender differences
1440596|NCT00230100|Women
1440597|NCT00230100|Substance use disorders
1440598|NCT00230100|Alcohol use disorders
1440599|NCT00230100|Treatment outcomes
1440600|NCT00230100|Group therapy
1440601|NCT00230087|diabetes
1440602|NCT00230087|nafld
1440603|NCT00230087|nash
1440604|NCT00230087|phlebotomy
1440605|NCT00230074|Amyotrophic Lateral Sclerosis; ALS
1440606|NCT00230061|HIV
1440607|NCT00230009|child abuse, child neglect, substance use, violence exposure, brief intervention
1440608|NCT00229996|endometriosis
1440609|NCT00229996|pelvic pain
1440610|NCT00229996|treatment
1440611|NCT00229983|Substance use disorders
1440612|NCT00229983|Substance abuse
1440613|NCT00229983|Alcohol abuse
1440614|NCT00229983|Drug abuse
1440615|NCT00229957|Occupational therapy
1440616|NCT00229957|Physical therapy techniques
1440617|NCT00229957|Primary health care
1440618|NCT00229957|Chronic disease
1440619|NCT00229957|Rehabilitation
1440620|NCT00229957|Disease management
1440621|NCT00229957|Self care
1440622|NCT00229944|Azithromycin
1440623|NCT00229944|V. cholerae O1 / O139
1440624|NCT00229944|adults
1440625|NCT00229944|Bangladesh
1440626|NCT00229944|Clinical trial
1440627|NCT00229931|CATARACT EXTRACTION
1440628|NCT00229931|MACULAR EDEMA
1440629|NCT00229931|DIABETES
1440630|NCT00229931|FOCAL LASER
1440631|NCT00229931|TRIAMCINOLONE
1440632|NCT00229918|Diabetic macular edema
1440633|NCT00229918|Clinically significant macular edema
1440634|NCT00229905|pediatric health
1440635|NCT00229905|children
1440636|NCT00229905|single case study
1440637|NCT00229892|pediatric health
1440638|NCT00229892|cardiac
1440639|NCT00229892|small incisions
1440640|NCT00229892|operations
1440641|NCT00229892|minimally invasive
1440642|NCT00229879|pediatric health
1440643|NCT00229879|rare tumor
1440644|NCT00229879|children
1440645|NCT00229879|cardiac
1440646|NCT00229866|newborn
1440647|NCT00229866|pediatric health
1440648|NCT00229866|Feeding difficulty
1440649|NCT00229866|discharge with a NG tube
1440650|NCT00229866|G-tube placement
1440651|NCT00229866|Nissen fundoplication
1440652|NCT00229853|Children's Healthcare of Atlanta
1440653|NCT00229853|pediatric
1440654|NCT00229853|Thoracoscopic Vascular ring
1440655|NCT00229853|diverticulopexy
1440656|NCT00229853|Vascular Ring Division
1440657|NCT00229840|MRI, fMRI, Epilepsy, Pediatric
1440658|NCT00229827|pediatric health
1440659|NCT00229827|cardiac
1440660|NCT00229827|pediatric population
1440661|NCT00229827|congenital heart surgery
1440662|NCT00229827|left to right shunt lesions
1440663|NCT00229827|heart surgery
1440664|NCT00229827|Atrioventricular canal defects
1440665|NCT00229814|Tectal Plate Glioma
1440666|NCT00229814|Tumor
1440667|NCT00229814|Brain
1440668|NCT00229814|MRI
1440669|NCT00229814|Spectroscopy
1440670|NCT00229801|Renal Function, MRI
1440671|NCT00229788|orthotopic heart transplantation
1440672|NCT00229775|Plasmodium falciparum malaria
1440673|NCT00229775|malaria
1440674|NCT00229775|artemether lumafantrine
1440675|NCT00229775|chloroquine
1440676|NCT00229775|sulfadoxine pyrimethamine
1440677|NCT00229775|Coartem
1440678|NCT00229762|pneumococcal vaccination coverage with no disease or efficacy outcomes recorded
1440679|NCT00229749|HCV
1440680|NCT00229723|Head and Neck Squamous Cell Carcinoma
1440681|NCT00229723|Head and Neck Squamous Cell Cancer
1440682|NCT00229723|Squamous Cell Carcinoma
1440683|NCT00229723|Squamous Cell Cancer
1440684|NCT00229710|Diabetes Mellitus, Type II
1440685|NCT00229710|Type 2 Diabetes Mellitus
1440686|NCT00229697|Breast cancer
1440687|NCT00229697|metastatic breast cancer
1440688|NCT00229684|Type 2 Diabetes
1440689|NCT00229658|diabetes
1440690|NCT00229658|pramlintide
1440691|NCT00229658|Symlin
1440692|NCT00229658|Amylin
1440693|NCT00229658|phase 4
1440694|NCT00229645|Major Depression
1440695|NCT00229645|Anxiety
1440696|NCT00229632|Friedreich's Ataxia
1440697|NCT00229632|Idebenone
1440698|NCT00229632|Ataxia
1440699|NCT00229632|Drug Trial
1440700|NCT00229632|Randomized Trial
1440701|NCT00229632|Friedreich Ataxia
1440702|NCT00229632|FA
1440703|NCT00229619|rituxan
1440704|NCT00229619|Immunosuppression
1440705|NCT00229619|Bone Marrow Failure
1440706|NCT00229619|Monoclonal Antibody Therapy
1440707|NCT00229619|Diamond Blackfan Anemia (DBA)
1440708|NCT00229619|T -Cells
1440709|NCT00229619|B-Cells
1440710|NCT00229619|Hematopoiesis
1440711|NCT00229619|Moderate Aplastic Anemia (MAA)
1440712|NCT00229619|Diamond-Blackfan Anemia
1440713|NCT00229619|DBA
1440714|NCT00229619|Pure Red Cell Aplasia
1440715|NCT00229619|PRCA
1440716|NCT00229593|Male contraception
1440717|NCT00229593|Androgen
1440718|NCT00229593|Progestin
1440719|NCT00229593|Spermatogenesis
1440720|NCT00229593|Gonadotropin suppression
1440721|NCT00229593|Testosterone
1440722|NCT00229593|Nestorone
1440723|NCT00229580|Brief Intervention
1440724|NCT00229580|Motivational Interviewing
1440725|NCT00229580|Health Psychology
1440726|NCT00229580|Alcohol
1440727|NCT00229580|Hepatitis C
1440728|NCT00229580|Patient Education
1440729|NCT00229567|ketamine
1440730|NCT00229567|lidocaine
1440731|NCT00229567|postoperative ileus
1440732|NCT00229567|randomized controlled trial
1440733|NCT00229567|acute postoperative pain
1440734|NCT00229554|health surveys
1440735|NCT00229554|questionnaires
1440736|NCT00229541|Medical in-patient rehabilitation
1440737|NCT00229541|Gainfully employed
1440738|NCT00229541|Work incapacity
1440739|NCT00229515|Myocardial infarction
1440740|NCT00229515|Revascularization
1440741|NCT00229515|Stent
1440742|NCT00229515|ST segment elevation
1440743|NCT00229476|Depression
1440744|NCT00229476|EEG
1440745|NCT00229476|QEEG
1440746|NCT00229476|cordance
1440747|NCT00229476|Zoloft
1440748|NCT00229476|sertraline
1440749|NCT00229476|placebo
1440750|NCT00229476|electroencephalogram
1440751|NCT00229476|brain
1440752|NCT00229476|antidepressants
1440753|NCT00229463|Depression
1440754|NCT00229463|genetic
1440755|NCT00229463|gene
1440756|NCT00229463|antidepressant
1440757|NCT00229463|research
1440758|NCT00229450|depression
1440759|NCT00229450|menopause
1440760|NCT00229450|perimenopause
1440761|NCT00229450|mood
1440762|NCT00229450|memory
1440763|NCT00229450|perimenopausal
1440764|NCT00229450|antidepressant
1440765|NCT00229450|estrogen
1440766|NCT00229437|Diabetic Mononeuropathy
1440767|NCT00229437|Diabetic Neuralgia
1440768|NCT00229437|Mononeuropathy, Diabetic
1440769|NCT00229437|Neuralgia, Diabetic
1440770|NCT00229437|Diabetic Polyneuropathy
1440771|NCT00229437|Drug Therapy
1440772|NCT00229424|lafutidine
1440773|NCT00229424|reflux oesophagitis
1440774|NCT00229424|Gastroesophageal Reflux
1440775|NCT00229424|famotidine
1440776|NCT00229424|Double Blind
1440777|NCT00229424|Controlled Study
1440778|NCT00229424|H2 receptor antagonist
1440779|NCT00229424|H2-blocker
1440780|NCT00229411|intensive care
1440781|NCT00229411|teamwork
1440782|NCT00229411|medical errors
1440783|NCT00229411|education
1440784|NCT00229411|simulation
1440785|NCT00228670|Idiopathic Pulmonary Fibrosis
1440786|NCT00228670|herpesvirus
1440787|NCT00228670|lung biopsy
1440788|NCT00228670|Having diagnosed lung disease
1440789|NCT00228670|Scheduled to have a lung biopsy as part of the evaluation for your lung disease
1440790|NCT00228644|oxidative stress
1440791|NCT00228644|amino acids
1440792|NCT00228644|acetaminophen
1440793|NCT00228644|dietary requirements
1440794|NCT00228631|sickle
1440795|NCT00228631|cell
1440796|NCT00228618|oxidative stress
1440797|NCT00228618|amino acids
1440798|NCT00228618|dietary requirements
1440799|NCT00228605|Pain
1440800|NCT00228605|Sudden Pain
1440801|NCT00228605|Flares
1440802|NCT00228605|noncancer
1440803|NCT00228605|low back pain
1440804|NCT00228605|neuropathic pain
1440805|NCT00228605|osteoarthritis pain
1440806|NCT00228605|migraine
1440807|NCT00228605|chronic headache
1440808|NCT00228605|diabetic peripheral neuropathy
1440809|NCT00228579|diabetes
1440810|NCT00228579|insulin resistance
1440811|NCT00229333|Escitalopram
1440812|NCT00229333|Depression
1440813|NCT00229333|Dementia
1440814|NCT00229333|Treatment
1440815|NCT00229333|Depressive Syndrome in Alzheimer’s Disease
1440816|NCT00229333|Depressive Syndrome in Vascular Dementia
1440817|NCT00229333|Depressive Syndrome in Mixed Vascular and Alzheimer’s Dementia
1440818|NCT00229307|Post traumatic stress disorder
1440819|NCT00228488|advanced non-nasopharyngeal head and neck carcinoma
1440820|NCT00228462|Schizophrenia
1440821|NCT00228449|anemia
1440822|NCT00228449|chronic kidney disease
1440823|NCT00228449|CKD
1440824|NCT00228449|chronic renal failure
1440825|NCT00228449|CRF
1440826|NCT00228449|dialysis
1440827|NCT00228449|erythropoietin
1440828|NCT00228449|EPO
1440829|NCT00228449|erythropoiesis stimulating agent
1440830|NCT00228449|ESA
1440831|NCT00228449|Hematide™
1440832|NCT00228449|hemodialysis
1440833|NCT00228449|hemoglobin
1440834|NCT00228449|Hb
1440835|NCT00228449|Hgb
1440836|NCT00228449|Omontys
1440837|NCT00228449|peginesatide
1440838|NCT00228449|red blood cell
1440839|NCT00228449|red blood cell production
1440840|NCT00228436|anemia
1440841|NCT00228436|chronic kidney disease
1440842|NCT00228436|CKD
1440843|NCT00228436|chronic renal failure
1440844|NCT00228436|CRF
1440845|NCT00228436|dialysis
1440846|NCT00228436|erythropoietin
1440847|NCT00228436|EPO
1440848|NCT00228436|erythropoiesis stimulating agent
1440849|NCT00228436|ESA
1440850|NCT00228436|Hematide™
1440851|NCT00228436|hemoglobin
1440852|NCT00228436|Hb
1440853|NCT00228436|Hgb
1440854|NCT00228436|Omontys
1440855|NCT00228436|peginesatide
1440856|NCT00228436|red blood cell
1440857|NCT00228436|red blood cell production
1440858|NCT00228423|Saphenous vein
1440859|NCT00228423|Intimal hyperplasia
1440860|NCT00228423|Coronary artery bypass graft surgery
1440861|NCT00228423|Antiplatelet therapy
1440862|NCT00228423|Clopidogrel
1440863|NCT00228423|Saphenous vein graft disease
1440864|NCT00229268|Healthy Volunteers
1440865|NCT00229255|Non-Alcoholic hepatic steatosis
1440866|NCT00229242|Ambulatory blood pressure monitoring
1440867|NCT00229242|Echocardiography
1440868|NCT00229242|Diastolic function
1440869|NCT00229242|Left ventricular mass regression
1440870|NCT00229229|Obesity
1440871|NCT00229229|Cardiovascular Disease
1440872|NCT00229229|Metabolic Syndrome
1440873|NCT00229229|Canada Food Guide
1440874|NCT00229229|Glycemic Index
1440875|NCT00229229|Glycemic Load
1440876|NCT00229203|Myeloma
1440877|NCT00229203|Aplidin
1440878|NCT00229203|Plitidepsin
1440879|NCT00229203|PharmaMar
1440880|NCT00229190|Nasal lavage fluid
1440881|NCT00229190|Eosinophils
1440882|NCT00229190|Reproducibility of results
1440883|NCT00229177|ONO-2506
1440884|NCT00229177|stroke
1440885|NCT00229177|Acute ischemic stroke
1440886|NCT00229164|Primary Dysmenorrhea,
1440887|NCT00229164|Transcutaneous Electric Nerve Stimulation
1440888|NCT00229138|De novo kidney recipients,
1440889|NCT00229138|EC-MPS,
1440890|NCT00229138|tacrolimus,
1440891|NCT00229138|efficacy,
1440892|NCT00229138|safety,
1440893|NCT00229138|glomerular filtration rate
1440894|NCT00229138|Treatment in de novo kidney recipients
1440895|NCT00229125|Alcohol Withdrawal Syndrome
1440896|NCT00229125|CIWA-Ar
1440897|NCT00229125|Acoustic Startle Procedure
1440898|NCT00229125|Rebound Effect
1440899|NCT00229073|dapoxetine
1440900|NCT00229073|premature ejaculation
1440901|NCT00229073|ejaculation
1440902|NCT00229073|sexual dysfunction
1440903|NCT00229073|orgasmic disorder
1440904|NCT00229073|sexual intercourse
1440905|NCT00229060|Complicated Intra-Abdominal Infections
1440906|NCT00229060|Appendicitis
1440907|NCT00229060|Cholecystitis
1440908|NCT00229060|Peritonitis
1440909|NCT00229047|Ischemic Preconditioning
1440910|NCT00229047|Microvascular Perfusion
1440911|NCT00229047|Inflammation
1440912|NCT00229047|Ischemia and Reperfusion
1440913|NCT00229047|Chronic Limb Ischemia
1440914|NCT00229034|Systemic Inflammation
1440915|NCT00229034|Microvascular Perfusion
1440916|NCT00229034|Septic Shock
1440917|NCT00229021|Complicated Urinary Tract Infection
1440918|NCT00229021|Pyelonephritis
1440919|NCT00229008|Ceftobiprole medocaril
1440920|NCT00229008|Nosocomial Pneumonia
1440921|NCT00229008|Ventilator-Associated Pneumonia
1440922|NCT00229008|Cephalosporins
1440923|NCT00229008|Methicillin-Resistant Staphylococcus Aureus
1440924|NCT00228995|Anemia
1440925|NCT00228995|Subcutaneous injection
1440926|NCT00228995|PROCRIT
1440927|NCT00228995|Erythropoietin
1440928|NCT00228995|Epoetin Alfa
1440929|NCT00228995|Hemoglobin Level
1440930|NCT00228995|Elderly
1440931|NCT00228982|Complicated Skin Infections
1440932|NCT00228982|Infectious Skin Diseases
1440933|NCT00228982|Bacterial Skin Diseases
1440934|NCT00228982|Staphylococcal Skin Infections
1440935|NCT00228982|Cephalosporin
1440936|NCT00228956|Breast Cancer
1440937|NCT00228956|Aromatase Inhibitor
1440938|NCT00228956|Letrozole
1440939|NCT00228956|Exemestane
1440940|NCT00228943|Breast cancer survivorship
1440941|NCT00228943|Hot Flashes
1440942|NCT00228943|Serotonin
1440943|NCT00228930|Breast Cancer
1440944|NCT00228930|Tamoxifen
1440945|NCT00228930|Prevention
1440946|NCT00228917|Hib & Neisseria meningitidis serogroups A & C diseases
1440947|NCT00228904|Pulsatile intravenous insulin
1440948|NCT00228904|Oral carbohydrate loading
1440949|NCT00228904|Respiratory Quotients
1440950|NCT00228904|Hypoglycemia
1440951|NCT00228904|Diabetic Neuropathy
1440952|NCT00228904|Diabetes Mellitus, with complications
1440953|NCT00228891|Pulsatile intravenous insulin
1440954|NCT00228891|Oral carbohydrate loading
1440955|NCT00228891|Respiratory Quotients
1440956|NCT00228891|Hypoglycemia
1440957|NCT00228891|Diabetic Neuropathy
1440958|NCT00228878|Diabetes
1440959|NCT00228878|Pulsatile intravenous insulin
1440960|NCT00228878|Oral carbohydrate loading
1440961|NCT00228878|Respiratory Quotients
1440962|NCT00228878|Hypoglycemia
1440963|NCT00228878|Diabetes Mellitus, with complications
1440964|NCT00228397|Multiple Sclerosis
1440965|NCT00228371|Epilepsy
1440966|NCT00228371|deep brain stimulation
1440967|NCT00228371|Subthalamic nucleus
1440968|NCT00228371|Drug resistant epilepsy
1440969|NCT00228345|Idiopathic Axonal Polyneuropathy
1440970|NCT00228345|abnormal OGTT
1440971|NCT00228293|cardiac arrest
1440972|NCT00228293|CPR
1440973|NCT00228280|Apicoectomy
1440974|NCT00228280|Retrograde
1440975|NCT00228280|MTA
1440976|NCT00228267|Chronic Headache
1440977|NCT00228267|Analgesic Rebound Headache
1440978|NCT00228267|Chronic Daily Headache
1440979|NCT00228267|Headache, Intractable
1440980|NCT00228267|Randomised controlled trial
1440981|NCT00228267|Propofol
1440982|NCT00228254|acute respiratory infection
1440983|NCT00228254|acute lower respiratory infection
1440984|NCT00228254|diarrhea
1440985|NCT00228241|Sick sinus syndrome
1440986|NCT00228241|AV-block
1440987|NCT00228228|Multiple Sclerosis
1440988|NCT00228228|T-cell vaccination
1440989|NCT00228228|Autoreactive T cells
1440990|NCT00228215|sleep
1440991|NCT00228215|neonates
1440992|NCT00228215|mothers
1440993|NCT00228215|behavioural intervention
1440994|NCT00228202|cytomegalovirus
1440995|NCT00228202|CMV
1440996|NCT00228202|pregnancy
1440997|NCT00228202|amniotic fluid
1440998|NCT00228202|bone marrow
1440999|NCT00228202|transplantation
1441000|NCT00228202|viral load
1441001|NCT00228202|glycoprotein B
1441002|NCT00228202|genotyping
1441003|NCT00228202|PCR
1441004|NCT00228202|real-time PCR
1441005|NCT00228202|CMV disease
1441006|NCT00228202|Congenital CMV infection
1441007|NCT00228189|Dendritic cells
1441008|NCT00228189|Colorectal cancer
1441009|NCT00228189|Carcinoembryonic antigen
1441010|NCT00228189|Vaccine
1441011|NCT00228189|Immunotherapy
1441012|NCT00228176|Metabolic syndrome
1441013|NCT00228176|Carotid Atherosclerosis
1441014|NCT00228163|Multiple Sclerosis Relapsing Remitting
1441015|NCT00228163|Secondary Progressive
1441016|NCT00228163|Progressive Relapsing
1441017|NCT00228150|Parkinson Disease
1441018|NCT00228150|levodopa
1441019|NCT00228150|dopamine agonists
1441020|NCT00228124|Prostate cancer
1441021|NCT00228124|Continuous androgen suppression
1441022|NCT00228124|Intermittent androgen suppression
1441023|NCT00228124|Bone loss
1441024|NCT00228124|Osteoporosis
1441025|NCT00228111|Computed tomography
1441026|NCT00228111|wounds and injuries,non penetrating
1441027|NCT00228111|algorithms
1441028|NCT00228111|Blunt trauma of the thorax and abdomen
1441029|NCT00228072|Hyperhidrosis
1441030|NCT00228072|Axillary
1441031|NCT00228072|Excision
1441032|NCT00228072|Suction-curettage
1441033|NCT00228072|Outcome
1441034|NCT00228059|Bipolar disorder, manic episode/treatment/licarbazepine
1441035|NCT00228046|ADHD
1441036|NCT00228046|ODD
1441037|NCT00228046|Conduct Disorder
1441038|NCT00228046|CD
1441039|NCT00228033|Calcium
1441040|NCT00228033|Pregnancy
1441041|NCT00228033|Postpartum Depression
1441042|NCT00228033|Depression
1441043|NCT00228020|pediatric, kidney transplantation, basiliximab
1441044|NCT00228007|Injection Drug Use
1441045|NCT00228007|HIV Risk Behavior
1441046|NCT00228007|HIV Seronegativity
1441047|NCT00227994|Cholinesterase Inhibitors
1441048|NCT00227994|Elderly
1441049|NCT00227994|Stroke
1441050|NCT00227994|Cognition
1441051|NCT00227981|Depression Relapse
1441052|NCT00227981|Maintenance Therapy
1441053|NCT00227968|Manic-depressive psychosis
1441054|NCT00227968|Depression, bipolar
1441055|NCT00227955|Major depression
1441056|NCT00227942|Women
1441057|NCT00227942|Menopause
1441058|NCT00227942|Depression
1441059|NCT00227942|Hot flash
1441060|NCT00227942|Insomnia
1441061|NCT00227942|Sleep Disruption
1441062|NCT00227942|Estrogen Replacement Therapy
1441063|NCT00227929|Major Depressive Disorder
1441064|NCT00227929|MDD
1441065|NCT00227916|alcohol, marijuana
1441066|NCT00227890|substance abuse
1441067|NCT00227877|alcohol abuse
1441068|NCT00227877|substance abuse
1441069|NCT00227877|substance related disorders
1441070|NCT00227864|marijuana
1441071|NCT00227864|sexual risk
1441072|NCT00227838|substance abuse
1441073|NCT00227825|Behavioral Intervention
1441074|NCT00227812|cocaine dependence
1441075|NCT00227786|unspecified adult solid tumor, protocol specific
1441076|NCT00227786|tobacco use disorder
1441077|NCT00227773|localized gastrointestinal carcinoid tumor
1441078|NCT00227773|metastatic gastrointestinal carcinoid tumor
1441079|NCT00227773|recurrent gastrointestinal carcinoid tumor
1441080|NCT00227773|regional gastrointestinal carcinoid tumor
1441081|NCT00227773|recurrent islet cell carcinoma
1441082|NCT00227773|gastrinoma
1441083|NCT00227773|insulinoma
1441084|NCT00227773|WDHA syndrome
1441085|NCT00227773|glucagonoma
1441086|NCT00227773|pancreatic polypeptide tumor
1441087|NCT00227773|somatostatinoma
1441088|NCT00227747|adenocarcinoma of the rectum
1441089|NCT00227747|stage II rectal cancer
1441090|NCT00227747|stage III rectal cancer
1441091|NCT00227734|stage IV colon cancer
1441092|NCT00227734|stage IV rectal cancer
1441093|NCT00227734|recurrent colon cancer
1441094|NCT00227734|recurrent rectal cancer
1441095|NCT00227721|recurrent ovarian epithelial cancer
1441096|NCT00227721|peritoneal cavity cancer
1441097|NCT00227708|adenocarcinoma of the lung
1441098|NCT00227708|adenosquamous cell lung cancer
1441099|NCT00227708|large cell lung cancer
1441100|NCT00227708|squamous cell lung cancer
1441101|NCT00227708|stage IIIB non-small cell lung cancer
1441102|NCT00227708|stage IV non-small cell lung cancer
1441103|NCT00227708|recurrent non-small cell lung cancer
1441104|NCT00227695|stage I grade 1 follicular lymphoma
1441105|NCT00227695|stage I grade 2 follicular lymphoma
1441106|NCT00227695|stage I grade 3 follicular lymphoma
1441107|NCT00227695|stage III grade 1 follicular lymphoma
1441108|NCT00227695|stage III grade 2 follicular lymphoma
1441109|NCT00227695|stage III grade 3 follicular lymphoma
1441110|NCT00227695|stage IV grade 1 follicular lymphoma
1441111|NCT00227695|stage IV grade 2 follicular lymphoma
1441112|NCT00227695|stage IV grade 3 follicular lymphoma
1441113|NCT00227695|contiguous stage II grade 1 follicular lymphoma
1441114|NCT00227695|contiguous stage II grade 2 follicular lymphoma
1441115|NCT00227695|contiguous stage II grade 3 follicular lymphoma
1441116|NCT00227695|noncontiguous stage II grade 1 follicular lymphoma
1441117|NCT00227695|noncontiguous stage II grade 2 follicular lymphoma
1441118|NCT00227695|noncontiguous stage II grade 3 follicular lymphoma
1441119|NCT00227695|recurrent grade 1 follicular lymphoma
1441120|NCT00227695|recurrent grade 2 follicular lymphoma
1441121|NCT00227695|recurrent grade 3 follicular lymphoma
1441122|NCT00227682|refractory multiple myeloma
1441123|NCT00227669|uterine leiomyosarcoma
1441124|NCT00227669|stage III adult soft tissue sarcoma
1441125|NCT00227669|stage IV adult soft tissue sarcoma
1441126|NCT00227669|recurrent adult soft tissue sarcoma
1441127|NCT00227669|stage III uterine sarcoma
1441128|NCT00227669|stage IV uterine sarcoma
1441129|NCT00227669|recurrent uterine sarcoma
1441130|NCT00227669|adult leiomyosarcoma
1441131|NCT00227656|stage IV breast cancer
1441132|NCT00227656|recurrent breast cancer
1441133|NCT00227656|male breast cancer
1441134|NCT00227656|tumors metastatic to brain
1441135|NCT00227630|epithelial mesothelioma
1441136|NCT00227630|sarcomatous mesothelioma
1441137|NCT00227630|localized malignant mesothelioma
1441138|NCT00227630|recurrent malignant mesothelioma
1441139|NCT00227617|recurrent gastrointestinal carcinoid tumor
1441140|NCT00227617|regional gastrointestinal carcinoid tumor
1441141|NCT00227617|pulmonary carcinoid tumor
1441142|NCT00227617|gastrinoma
1441143|NCT00227617|insulinoma
1441144|NCT00227617|WDHA syndrome
1441145|NCT00227617|glucagonoma
1441146|NCT00227617|pancreatic polypeptide tumor
1441147|NCT00227617|somatostatinoma
1441148|NCT00227617|recurrent islet cell carcinoma
1441149|NCT00227617|metastatic gastrointestinal carcinoid tumor
1441150|NCT00227565|extensive stage small cell lung cancer
1441151|NCT00227539|stage I non-small cell lung cancer
1441152|NCT00227539|stage II non-small cell lung cancer
1441153|NCT00227539|stage IIIA non-small cell lung cancer
1441154|NCT00227539|stage IIIB non-small cell lung cancer
1441155|NCT00227526|Colon
1441156|NCT00227526|Surgery
1441157|NCT00227526|Prehabilitation
1441158|NCT00227526|Exercise
1441159|NCT00227500|Hyperlipidaemia
1441160|NCT00227500|Lipid metabolism
1441161|NCT00227500|Glucose metabolism
1441162|NCT00227500|HMG CoA reductase inhibitors
1441163|NCT00227500|Lipodystrophy
1441164|NCT00227500|Cardiovascular disease
1441165|NCT00227500|Treatment Experienced
1441166|NCT00227500|HIV
1441167|NCT00227487|autism
1441168|NCT00227487|intestine
1441169|NCT00227487|disaccharidases
1441170|NCT00227487|inflammation
1441171|NCT00227487|permeability
1441172|NCT00227474|stage IIIB breast cancer
1441173|NCT00227474|stage IIIC breast cancer
1441174|NCT00227474|stage IV breast cancer
1441175|NCT00227461|Aphasia
1441176|NCT00227461|Stroke
1441177|NCT00227448|Ischemic
1441178|NCT00227448|Stroke
1441179|NCT00227422|Neisseria meningitidis serogroups A & C diseases
1441180|NCT00227422|Hib diseases
1441181|NCT00227409|Repeated chelation therapy
1441182|NCT00227409|Progressive renal insufficiency
1441183|NCT00227409|Body lead burden
1441184|NCT00227409|Long-term outcome
1441185|NCT00227409|Glomerular filtration rate
1441186|NCT00227383|Diabetes
1441187|NCT00227383|gastroparesis
1441188|NCT00227383|electroacupuncture
1441189|NCT00227370|Acute rejection
1441190|NCT00227370|Non-CMV infections
1441191|NCT00227370|Resistance
1441192|NCT00227357|HIV
1441193|NCT00227357|AIDS
1441194|NCT00227357|Buprenorphine
1441195|NCT00227357|Methadone
1441196|NCT00227357|Primary care
1441197|NCT00227357|dual diagnosis
1441198|NCT00227357|ptsd
1441199|NCT00227331|Pneumonia
1441200|NCT00227305|Schizophrenia
1441201|NCT00227305|Bipolar I Disorder
1441202|NCT00227292|Low back pain
1441203|NCT00227292|Depression
1441204|NCT00227279|Grass pollen allergy
1441205|NCT00227279|Hayfever
1441206|NCT00227279|Allergen immunotherapy
1441207|NCT00227279|Specific immunotherapy
1441208|NCT00227266|Spinal Muscular Atrophy (SMA)
1441209|NCT00227266|SMA Type 2
1441210|NCT00227266|SMA Type 3
1441211|NCT00227253|Phenotype
1441212|NCT00227253|Growth
1441213|NCT00227253|Genotype
1441214|NCT00227253|Chromosome 18
1441215|NCT00227201|African-American
1441216|NCT00227201|Hypertension
1441217|NCT00227201|Complementary medicine
1441218|NCT00227201|Medication adherence
1441219|NCT00227175|African American
1441220|NCT00227175|Hypertension
1441221|NCT00227175|Medication adherence
1441222|NCT00227175|Risk reduction
1441223|NCT00227162|Asthma
1441224|NCT00227162|Behavior change
1441225|NCT00227162|Physical activity
1441226|NCT00227162|Risk reduction
1441227|NCT00227149|C06.552.380.705.440
1441228|NCT00227136|5Hydroxytryptamine
1441229|NCT00227136|Chromogranin A
1441230|NCT00227136|5HIAA
1441231|NCT00227136|carcinoid
1441232|NCT00227123|Bipolar, cocaine, methamphetamine,quetiapine,risperidone
1441233|NCT00227110|NASH, IGT, T2DM
1441234|NCT00227097|therapeutic education
1441235|NCT00227097|thrombi embolic disease
1441236|NCT00227084|Mammary glands
1441237|NCT00227084|hemostasis
1441238|NCT00227084|Mammaplasty
1441239|NCT00227071|accidental falls
1441240|NCT00227071|osteoporosis
1441241|NCT00227071|risk factors
1441242|NCT00227058|allergic rhinitis
1441243|NCT00227045|Kidney Transplantation
1441244|NCT00227032|adult giant cell glioblastoma
1441245|NCT00227032|adult gliosarcoma
1441246|NCT00227032|adult glioblastoma
1441247|NCT00227032|recurrent adult brain tumor
1441248|NCT00226915|ovarian neoplasms
1441249|NCT00226915|randomized controlled trial
1441250|NCT00226915|paclitaxel
1441251|NCT00226915|carboplatin
1441252|NCT00226902|Diabetes
1441253|NCT00226902|Hemoglobin
1441254|NCT00226902|Dialysis
1441255|NCT00226902|Vascular reactivity
1441256|NCT00226889|Scleroderma
1441257|NCT00226889|Fibrosis
1441258|NCT00226889|Therapy
1441259|NCT00226889|Bosentan
1441260|NCT00226889|Endothelin-1
1441261|NCT00226876|dreaming
1441262|NCT00226876|anaesthesia
1441263|NCT00226876|electroencephalography
1441264|NCT00226876|bispectral index
1441265|NCT00226876|awareness
1441266|NCT00226824|Tourette's disorder
1441267|NCT00226824|tic
1441268|NCT00226772|Anterior cruciate ligament reconstruction
1441269|NCT00226772|ACL reconstruction
1441270|NCT00226759|Anterior cruciate ligament reconstruction
1441271|NCT00226759|ACL reconstruction
1441272|NCT00226746|Pancreatic Cancer
1441273|NCT00226746|Hyperfractionated Radiation Therapy
1441274|NCT00226746|Gemcitabine
1441275|NCT00226746|Paclitaxel
1441276|NCT00226746|Carcinoma, Pancreatic Ductal
1441277|NCT00226733|Coronary Artery Bypass (E04.928.220.520.220)
1441278|NCT00226733|Exercise Test [E01.370.370.380.250]
1441279|NCT00226733|Echocardiography [E01.370.370.380.220]
1441280|NCT00226733|Quality of Life [K01.752.400.750]
1441281|NCT00226720|alcoholism
1441282|NCT00226720|Alcohol dependence
1441283|NCT00226720|Detoxification
1441284|NCT00226720|Abstinence maintain
1441285|NCT00226720|Efficacy
1441286|NCT00226720|Ambulatory detoxification
1441287|NCT00226707|Chronic hand dermatitis, pimecrolimus, dermatitis
1441288|NCT00226694|Alcoholism
1441289|NCT00226694|Stress
1441290|NCT00226694|Gender Differences
1441291|NCT00226694|Addiction
1441292|NCT00226694|Alcohol Dependence
1441293|NCT00226668|peritumoral brain edema
1441294|NCT00226668|edema
1441295|NCT00226668|malignant brain tumor
1441296|NCT00226668|astrocytoma
1441297|NCT00226668|brain tumor
1441298|NCT00226668|dexamethasone
1441299|NCT00226668|Decadron
1441300|NCT00226655|peritumoral brain edema
1441301|NCT00226655|edema
1441302|NCT00226655|malignant brain tumor
1441303|NCT00226655|astrocytoma
1441304|NCT00226655|brain tumor
1441305|NCT00226655|dexamethasone
1441306|NCT00226655|Decadron
1441307|NCT00226642|depression
1441308|NCT00226642|primary care
1441309|NCT00226616|Zinc
1441310|NCT00226616|cholera
1441311|NCT00226616|children
1441312|NCT00226616|Bangladesh
1441313|NCT00226603|groin injury
1441314|NCT00226603|football
1441315|NCT00226603|prevention
1441316|NCT00226603|traing programme
1441317|NCT00226603|cluster randomized study
1441318|NCT00226590|non-small cell lung cancer
1441319|NCT00226590|carcinoma
1441320|NCT00226590|unresectable
1441321|NCT00226590|Stage IIIA
1441322|NCT00226590|Stage IIIB
1441323|NCT00226590|thoracic radiation
1441324|NCT00226577|Non-Small-Cell Lung Cancer
1441325|NCT00226577|resectable
1441326|NCT00226577|NSCLC
1441327|NCT00225823|Seasonal Allergic Rhinitis Intranasal Corticosteroid
1441328|NCT00225797|chronic pain
1441329|NCT00225797|lower back
1441330|NCT00225797|opioid
1441331|NCT00225797|efficacy
1441332|NCT00225797|safety
1441333|NCT00225784|Stage I, II, III pancreatic adenocarcinoma
1441334|NCT00225784|Radiographically measurable disease
1441335|NCT00225758|breast cancer
1441336|NCT00225758|endocrine therapy
1441337|NCT00225758|drug resistance
1441338|NCT00225758|lapatinib
1441339|NCT00225758|epidermal growth factor receptor
1441340|NCT00225745|Ghrelin
1441341|NCT00225693|coronary artery
1441342|NCT00225693|restenosis
1441343|NCT00225693|patency
1441344|NCT00225693|drug eluting
1441345|NCT00225693|stent
1441346|NCT00225680|coronary artery
1441347|NCT00225680|stent
1441348|NCT00225680|drug eluting
1441349|NCT00225680|patency
1441350|NCT00225680|restenosis
1441351|NCT00225667|Atrial Fibrillation
1441352|NCT00225667|Arrhythmia
1441353|NCT00225667|Pacemaker, Artificial
1441354|NCT00225667|Atrial High Rate Episodes
1441355|NCT00225667|Electrophysiology
1441356|NCT00225667|Renin-Angiotensin System
1441357|NCT00225667|Hypertension
1441358|NCT00225667|Cardiac Remodeling
1441359|NCT00225654|coronary artery
1441360|NCT00225654|stent
1441361|NCT00225654|drug eluting
1441362|NCT00225654|patency
1441363|NCT00225654|restenosis
1441364|NCT00226525|Restenosis, skin metal allergy
1441365|NCT00226473|malignant Melanoma
1441366|NCT00226473|Chemotherapy
1441367|NCT00226473|Metastasis
1441368|NCT00226473|standard palliative care
1441369|NCT00226473|best supportive care
1441370|NCT00226447|Chronic Hepatitis B
1441371|NCT00226447|Pegylated Interferon
1441372|NCT00226447|Lamivudine
1441373|NCT00226434|HIV infection
1441374|NCT00226434|Tuberculosis
1441375|NCT00226434|Paradoxical reaction
1441376|NCT00226434|Treatment Naive
1441377|NCT00226421|opioid
1441378|NCT00226421|oxymorphone
1441379|NCT00226421|chronic pain
1441380|NCT00226421|randomized, double-blind trial
1441381|NCT00226421|low back pain
1441382|NCT00226408|melanoma,adjuvant therapy,stageIII Interferon
1441383|NCT00226408|high dose
1441384|NCT00226395|oxymorphone
1441385|NCT00226395|acute pain
1441386|NCT00226395|abdominal surgery
1441387|NCT00226395|opioids
1441388|NCT00226382|Chronic Hepatitis B
1441389|NCT00226382|Pegylated Interferon-alfa-2a
1441390|NCT00226382|Pegasys
1441391|NCT00226369|Pediatric
1441392|NCT00226369|Cardiopulmonary bypass
1441393|NCT00226369|Congenital heart disease
1441394|NCT00226369|Reperfusion injury
1441395|NCT00226330|Patients diagnosed with type 2 diabetes who have participated in and completed the randomized, double-blind, parallel-group, multi-center study GALLANT 6.
1441396|NCT00226304|Focal Brain Lesions
1441397|NCT00226304|AIDS
1441398|NCT00226304|Lymphoma
1441399|NCT00226304|EBV
1441400|NCT00226304|FDG-PET
1441401|NCT00226304|HIV Infection
1441402|NCT00226304|Brain Lesion
1441403|NCT00226291|EBM
1441404|NCT00226291|evidence based medicine
1441405|NCT00226291|informationist
1441406|NCT00226291|clinical medical librarian
1441407|NCT00226265|Cardiac surgery patients
1441408|NCT00226265|Quality of Life
1441409|NCT00226265|Recall bias
1441410|NCT00226265|Aortic valve replacement
1441411|NCT00226265|Mitral valve replacement
1441412|NCT00226265|Tricuspid valve replacement
1441413|NCT00226265|Coronary artery bypass graft surgery
1441414|NCT00226252|Wheelchair
1441415|NCT00226252|Propulsion
1441416|NCT00226252|Biomechanics
1441417|NCT00226239|head
1441418|NCT00226239|neck
1441419|NCT00226200|Allergic
1441420|NCT00226200|Non allergic
1441421|NCT00226187|Fatty acids
1441422|NCT00226187|Human milk
1441423|NCT00226187|Infant development
1441424|NCT00226187|Very low birthweight infants
1441425|NCT00226174|Curcuminoids
1441426|NCT00226174|Oral Lichen Planus
1441427|NCT00226148|Implant
1441428|NCT00226148|Immediate placement
1441429|NCT00226148|Molar tooth
1441430|NCT00226135|Bipolar disorder
1441431|NCT00226135|Treatment
1441432|NCT00226135|Long-term
1441433|NCT00226135|Lithium
1441434|NCT00226135|Lamotrigine
1441435|NCT00226135|Randomised Clinical Trial
1441436|NCT00226122|Enuresis
1441437|NCT00226122|Nocturnal
1441438|NCT00226122|Monosymptomatic
1441439|NCT00226122|DDAVP
1441440|NCT00226122|Indomethacin
1441441|NCT00226122|Randomized
1441442|NCT00226109|Alcoholism
1441443|NCT00226109|cardiomyopathy
1441444|NCT00226109|skeletal muscle
1441445|NCT00226109|spironolactone
1441446|NCT00226109|Na,K-pumps
1441447|NCT00226109|Magnesium
1441448|NCT00226096|Clinical Trial
1441449|NCT00226096|Blood Pressure
1441450|NCT00226096|CVA (Cerebrovascular Accident)
1441451|NCT00226070|selfrated health,
1441452|NCT00226070|SF-36,
1441453|NCT00226070|rehabilitation,
1441454|NCT00226070|total hip replacement,
1441455|NCT00226070|patients above 65
1441456|NCT00226057|Atopic dermatitis
1441457|NCT00226057|Raptiva
1441458|NCT00226044|Omeprazole, suppository, infants
1441459|NCT00226031|Osteoporosis
1441460|NCT00226031|Wrist fractures
1441461|NCT00226031|Knowledge translation
1441462|NCT00226031|Implementation
1441463|NCT00226031|Educational reminder
1441464|NCT00226005|pancreas
1441465|NCT00226005|adenocarcinoma
1441466|NCT00226005|cancer
1441467|NCT00226005|metastatic
1441468|NCT00226005|advanced cancer
1441469|NCT00226005|Phase II
1441470|NCT00226005|growth factor
1441471|NCT00226005|VEGF
1441472|NCT00226005|angiogenesis
1441473|NCT00225979|Acromegaly
1441474|NCT00225979|Untreated
1441475|NCT00225979|Newly diagnosed
1441476|NCT00225979|Octreotide LAR
1441477|NCT00225979|Pituitary surgery
1441478|NCT00225966|Urinary urgency-frequency
1441479|NCT00225927|invasive breast cancer
1441480|NCT00225927|in situ breast cancer
1441481|NCT00225927|radioguided seed localization
1441482|NCT00225927|nonpalpable tumour
1441483|NCT00225927|needle localization
1441484|NCT00225927|margin status
1441485|NCT00225914|Menopause
1441486|NCT00225914|Hormone Therapy
1441487|NCT00225914|Paxil
1441488|NCT00225914|Hot Flash
1441489|NCT00225914|Sleep Disturbance
1441490|NCT00225914|Night Sweats
1441491|NCT00225914|Antidepressants
1441492|NCT00225888|Diabetes
1441493|NCT00225888|Nutrition
1441494|NCT00225888|Digital photography
1441495|NCT00225888|Self-management
1441496|NCT00225875|Autoimmune thrombocytopenic purpura
1441497|NCT00225875|Rituximab
1441498|NCT00225862|RLS
1441499|NCT00225862|Restless Legs Syndrome
1441500|NCT00225849|Aspirin
1441501|NCT00225849|Primary prevention
1441502|NCT00225836|Dysmenorrhoea
1441503|NCT00225836|Women
1441504|NCT00225836|Pain
1441505|NCT00225836|TENS
1441506|NCT00225641|Follow-up
1441507|NCT00225628|Computerized clinical decision support
1441508|NCT00225628|Patient Safety
1441509|NCT00225628|Quality of Care
1441510|NCT00225628|Electronic Medical Records
1441511|NCT00225628|Chronic Disease Management
1441512|NCT00225628|Drug Monitoring
1441513|NCT00225628|Guideline Adherence
1441514|NCT00225628|Reminder Systems
1441515|NCT00225615|Phenylalanine Hydroxylase
1441516|NCT00225602|Schizophrenia
1441517|NCT00225602|Assertive community treatment
1441518|NCT00225589|Hypercholesteremia
1441519|NCT00225576|medication errors
1441520|NCT00225576|adverse drug events
1441521|NCT00225576|electronic health records
1441522|NCT00225563|Electronic medical records
1441523|NCT00225563|Electronic prescribing
1441524|NCT00225563|Quality measures
1441525|NCT00225550|Cancer;
1441526|NCT00225550|Tumors;
1441527|NCT00225550|Neoplasms;
1441528|NCT00225550|Anticarcinogenic Agents;
1441529|NCT00225550|Antineoplastic Agents;
1441530|NCT00225550|Cadherins
1441531|NCT00225537|hcv
1441532|NCT00225537|hbv
1441533|NCT00225537|methylumbelliferone
1441534|NCT00225537|liver
1441535|NCT00225537|hepatitis
1441536|NCT00225537|viral
1441537|NCT00225537|heparvit
1441538|NCT00225537|hiv
1441539|NCT00225537|aids
1441540|NCT00225524|Depression
1441541|NCT00225511|Depression
1441542|NCT00225485|Depression
1441543|NCT00225459|Religious psychology
1441544|NCT00225459|Anxiety disorder
1441545|NCT00225459|Mood disorder
1441546|NCT00225459|Suicide
1441547|NCT00225446|Orthognathic surgery.
1441548|NCT00225446|optic repositioning system.
1441549|NCT00225433|infertility
1441550|NCT00225433|in vitro fertilization
1441551|NCT00225420|adenocarcinoma of the prostate
1441552|NCT00225420|stage I prostate cancer
1441553|NCT00225420|stage II prostate cancer
1441554|NCT00225420|stage III prostate cancer
1441555|NCT00225420|stage IV prostate cancer
1441556|NCT00225407|Cannabis
1441557|NCT00225407|Tetrahydrocannabinol
1441558|NCT00225407|Pharmacokinetics
1441559|NCT00225407|Psychomotor tests
1441560|NCT00225407|Event related potentials
1441561|NCT00225394|CMV
1441562|NCT00225394|Kidney Transplant
1441563|NCT00225394|Pancreas Transplant
1441564|NCT00225394|Ganciclovir-resistance
1441565|NCT00225394|Valganciclovir
1441566|NCT00225394|CMV Disease
1441567|NCT00225381|Oxygen consumption
1441568|NCT00225381|CO2 production
1441569|NCT00225381|Indirect calorimetry
1441570|NCT00225381|Non steady state
1441571|NCT00225381|Anesthesia monitoring
1441572|NCT00225381|Critical events during anesthesia
1441573|NCT00225381|Acid base balance
1441574|NCT00225381|Metabolism during anesthesia
1441575|NCT00225368|Malaria
1441576|NCT00225368|All-cause mortality
1441577|NCT00225368|Africa
1441578|NCT00225368|Burkina Faso
1441579|NCT00225355|Angina pectoris
1441580|NCT00225355|Metabolic syndrome
1441581|NCT00225355|Ischaemic heart disease
1441582|NCT00225342|Angina
1441583|NCT00225342|Ischaemic heart disease
1441584|NCT00225342|Diabetes
1441585|NCT00225329|RCT
1441586|NCT00225329|intervention study
1441587|NCT00225329|labour management
1441588|NCT00225329|assessment
1441589|NCT00225316|RCT
1441590|NCT00225316|intervention study
1441591|NCT00225316|addiction
1441592|NCT00225316|substance use
1441593|NCT00225316|pregnancy
1441594|NCT00225303|HIV infection
1441595|NCT00225303|TMC125
1441596|NCT00225303|Non-Nucleoside reverse transcriptase inhibitor
1441597|NCT00225303|Protease inhibitor
1441598|NCT00225303|TMC125-C227
1441599|NCT00225290|Phase III
1441600|NCT00225290|Hepatocellular Carcinoma
1441601|NCT00225277|Glucose Metabolism Disorder
1441602|NCT00225277|Dysmetabolic Syndrome
1441603|NCT00225277|Type II Diabetes
1441604|NCT00225277|Diabetes Mellitus, Lipoatrophic
1441605|NCT00225277|Dyslipidemia
1441606|NCT00225277|Drug Therapy
1441607|NCT00225277|Atherosclerosis
1441608|NCT00225264|Glucose Metabolism Disorder
1441609|NCT00225264|Dysmetabolic Syndrome
1441610|NCT00225264|Type II Diabetes
1441611|NCT00225264|Diabetes Mellitus, Lipoatrophic
1441612|NCT00225264|Dyslipidemia
1441613|NCT00225264|Drug Therapy
1441614|NCT00225251|Dysthymic Disorder
1441615|NCT00225251|Dysthymia
1441616|NCT00225251|Depression
1441617|NCT00225251|Chronic Depression
1441618|NCT00225251|Wellbutrin XL
1441619|NCT00225238|colonoscopy prep
1441620|NCT00225212|non-Hodgkin's lymphoma
1441621|NCT00225212|diffuse large cell lymphoma
1441622|NCT00225212|mantle cell lymphoma
1441623|NCT00225212|transformed lymphoma
1441624|NCT00225212|other subtypes of B cell lymphoma
1441625|NCT00225212|recurrent lymphoma
1441626|NCT00225173|nodular sclerosis
1441627|NCT00225173|lymphocyte rich
1441628|NCT00225173|lymphocyte depleted
1441629|NCT00225173|mixed cellularity
1441630|NCT00225160|HIV
1441631|NCT00225160|poly neuropathy
1441632|NCT00225160|acetyl L-carnitine
1441633|NCT00225160|treatment naïve
1441634|NCT00225160|combination antiretroviral therapy
1441635|NCT00225160|Lipid abnormalities
1441636|NCT00225108|Deep vein thrombosis
1441637|NCT00225108|bleeding
1441638|NCT00225095|meniscectomy
1441639|NCT00225095|Chondrogen
1441640|NCT00225095|Mesenchymal Stem Cells
1441641|NCT00225095|Osiris
1441642|NCT00225082|Lipoatrophy
1441643|NCT00225082|Mitochondrial function
1441644|NCT00225082|Nucleoside analogue switch
1441645|NCT00225082|Treatment Experienced
1441646|NCT00225069|Facial blushing
1441647|NCT00225069|Sympathectomy
1441648|NCT00225017|Atazanavir
1441649|NCT00225017|Endothelial function
1441650|NCT00225017|Treatment Experienced
1441651|NCT00225004|Colles Fracture
1441652|NCT00225004|Osteoporosis
1441653|NCT00225004|BMD
1441654|NCT00225004|Quality assurance
1441655|NCT00224991|osteoporosis
1441656|NCT00224991|fall frequency
1441657|NCT00224991|medical treatment
1441658|NCT00224991|compliance
1441659|NCT00224991|quality of life
1441660|NCT00224991|systematic education
1441661|NCT00224965|nicotine dependence
1441662|NCT00224952|seizures
1441663|NCT00224952|Epilepsy
1441664|NCT00224926|Tinea Capitis
1441665|NCT00224913|osteoarthritis
1441666|NCT00224913|quadriceps
1441667|NCT00224913|inhibition
1441668|NCT00224913|functional outcome
1441669|NCT00224913|electrical stimulation
1441670|NCT00224900|Perinatally-acquired HIV infection
1441671|NCT00224900|Life Skills
1441672|NCT00224900|Focus Group
1441673|NCT00224900|Young adolescents
1441674|NCT00224900|Caregivers
1441675|NCT00224874|Acute Graft vs Host Disease
1441676|NCT00224874|GVHD
1441677|NCT00224822|Psychiatry
1441678|NCT00224822|Antipsychotic
1441679|NCT00224822|Psychopharmacology
1441680|NCT00224822|Clinical Trial
1441681|NCT00224822|Open Label
1441682|NCT00224822|Schizophrenia
1441683|NCT00224822|Schizoaffective Disorder
1441684|NCT00224822|Bipolar Disorder
1441685|NCT00224822|Metabolic Syndrome
1441686|NCT00224796|Wound closure
1441687|NCT00224796|Foot salvage
1441688|NCT00224796|Accelerated healing
1441689|NCT00224796|Amputation Wounds of the Diabetic Foot
1441690|NCT00224757|Echocardiography
1441691|NCT00224744|Vulvar Neoplasms
1441692|NCT00224744|Skin Neoplasms
1441693|NCT00224744|Ultracision
1441694|NCT00224744|Lymphadenectomy
1441695|NCT00224731|Attention disorder with hyperactivity
1441696|NCT00224731|sleep
1441697|NCT00224731|stimulants
1441698|NCT00224731|actigraphy
1441699|NCT00224718|Abdominal aortic aneurysm
1441700|NCT00224718|Endograft
1441701|NCT00224718|Open repair
1441702|NCT00224718|Endovascular repair
1441703|NCT00224718|AAA
1441704|NCT00224705|Albumin dialysis
1441705|NCT00224705|MARS system
1441706|NCT00224705|Extracorporeal artificial liver support
1441707|NCT00224705|Fulminant hepatitis
1441708|NCT00224705|Subfulminant hepatitis
1441709|NCT00224705|Acute liver failure
1441710|NCT00224692|Mucositis
1441711|NCT00224692|Pain
1441712|NCT00224692|Morphine
1441713|NCT00224692|Ketamine
1441714|NCT00224679|Colon cancer
1441715|NCT00224679|Aspirin
1441716|NCT00224679|Adenomas
1441717|NCT00224679|Prevention
1441718|NCT00224666|Cortex stimulation ,Rebel neuropathic pains
1441719|NCT00224653|Obesity.
1441720|NCT00224653|Respiration. Respiration, artificial.
1441721|NCT00224653|Ventilation. Pressure controlled. Volume controlled.
1441722|NCT00224640|Iron-chelating treatment
1441723|NCT00224627|Randomized study
1441724|NCT00224627|Capsule endoscopy
1441725|NCT00224627|Push enteroscopy
1441726|NCT00224627|Occult gastrointestinal bleeding
1441727|NCT00224627|Endoscopy
1441728|NCT00224614|stem cell transplantation
1441729|NCT00224614|reduced-intensity conditioning regimen
1441730|NCT00224614|acute myeloid leukemia
1441731|NCT00224601|Colorectal cancer
1441732|NCT00224601|HNPCC
1441733|NCT00224601|Diagnosis
1441734|NCT00224601|Coloscopy
1441735|NCT00224601|Chromoscopy
1441736|NCT00224601|Indigo carmine
1441737|NCT00224601|Colorectal Neoplasms
1441738|NCT00224601|Hereditary Nonpolyposis
1441739|NCT00224588|Ketamine
1441740|NCT00224588|Chronic post thoracotomy pain
1441741|NCT00224588|NMDA
1441742|NCT00224588|Post operative
1441743|NCT00224575|Veterans
1441744|NCT00224562|TNF alpha antagonists
1441745|NCT00224562|infections
1441746|NCT00224562|lymphoma
1441747|NCT00224562|safety
1441748|NCT00224549|Resistant hypertension
1441749|NCT00224549|Combined diuretic therapy
1441750|NCT00224549|Combined RAS blockers
1441751|NCT00224536|Myocardial infarction
1441752|NCT00224536|Bone marrow cells
1441753|NCT00224536|Intracoronary
1441754|NCT00224523|perennial allergic rhinitis
1441755|NCT00224523|nasal biopsy
1441756|NCT00224523|GW685698X
1441757|NCT00224510|bipolar disorder bipolar depression lamotrigine
1441758|NCT00224497|Alzheimer's disease
1441759|NCT00224497|cognition global functioning
1441760|NCT00224497|symptomatic
1441761|NCT00224497|B-742457
1441762|NCT00224484|Herpes Simplex vaccine
1441763|NCT00224484|Safety
1441764|NCT00224484|Adolescents
1441765|NCT00224484|Immunogenicity
1441766|NCT00224471|Adolescents
1441767|NCT00224471|Immunogenicity
1441768|NCT00224471|Safety
1441769|NCT00224471|Herpes Simplex vaccine
1441770|NCT00224458|Treatment Experienced
1441771|NCT00224458|HIV-1
1441772|NCT00224445|Treatment Naive
1441773|NCT00224445|HIV-1
1441774|NCT00224432|Atopic Dermatitis
1441775|NCT00224432|SCORAD
1441776|NCT00224432|probiotics
1441777|NCT00224432|cytokines
1441778|NCT00224432|Infant
1441779|NCT00224419|Smoking cessation
1441780|NCT00224419|Pregnancy
1441781|NCT00224419|Nicotine replacement therapy
1441782|NCT00224419|Motivational interviewing
1441783|NCT00224406|Lung transplantation
1441784|NCT00224406|Reperfusion Injury
1441785|NCT00224406|Survival
1441786|NCT00224393|Amyloidosis
1441787|NCT00224393|Enbrel
1441788|NCT00224380|Serious mental illness
1441789|NCT00224380|medication adherence
1441790|NCT00224367|fracture
1441791|NCT00224367|hip
1441792|NCT00224367|ambulation
1441793|NCT00224354|LYMPHOCYTIC
1441794|NCT00224354|B-LEUKEMIA
1441795|NCT00224354|B-CLL
1441796|NCT00224341|Pacemaker
1441797|NCT00224341|Atrial Fibrillation
1441798|NCT00224341|Prevention pacing
1441799|NCT00224341|Algorithms
1441800|NCT00224341|Sick sinus syndrome + Atrial Fibrillation
1441801|NCT00224328|Tissue Oxygen Saturation
1441802|NCT00224328|Peripheral Arterial Disease
1441803|NCT00224328|Critical Limb Ischemia
1441804|NCT00224328|Near-infrared Spectroscopy
1441805|NCT00224315|Schizophrenia,
1441806|NCT00224315|schizoaffective disorder,
1441807|NCT00224315|treatment resistancy
1441808|NCT00224315|clozapine,
1441809|NCT00224315|ziprasidone
1441810|NCT00224315|risperidone
1441811|NCT00224315|combination
1441812|NCT00224302|Schizophrenia,
1441813|NCT00224302|schizoaffective disorder,
1441814|NCT00224302|major depressive episode,
1441815|NCT00224302|combination,
1441816|NCT00224302|duloxetine
1441817|NCT00224289|Latanoprost
1441818|NCT00224289|Glaucoma
1441819|NCT00224289|Intraocular pressure
1441820|NCT00224263|Traditional Chinese Medicine
1441821|NCT00224263|Lingzhi
1441822|NCT00224237|Latino patients
1441823|NCT00224237|Health practices
1441824|NCT00224237|Culture influences
1441825|NCT00224224|Clinical performance
1441826|NCT00224224|Continuity of care
1441827|NCT00224224|Utilization of resources
1441828|NCT00224185|Healthy individuals
1441829|NCT00224185|smokers
1441830|NCT00224185|ex-smokers
1441831|NCT00224185|non-smokers
1441832|NCT00224172|Pre-hospitalization characteristics
1441833|NCT00224172|Post-hospitalization characteristics
1441834|NCT00224172|Psychosocial measures
1441835|NCT00224172|Predict re-hospitalization
1441836|NCT00224159|Statin therapy
1441837|NCT00224159|Dietary behavior
1441838|NCT00224159|Attitudes and beliefs
1441839|NCT00224159|Self efficacy
1441840|NCT00224146|Oxytrol(r)
1441841|NCT00224146|transdermal oxybutynin
1441842|NCT00224146|overactive bladder
1441843|NCT00224133|benign prostatic hyperplasia, alpha blocker
1441844|NCT00224120|Benign prostatic hyperplasia, alpha blocker
1441845|NCT00224107|Benign prostatic hyperplasia, BPH, alpha blocker
1441846|NCT00224094|Menopause
1441847|NCT00224094|Testosterone
1441848|NCT00224094|Androgens
1441849|NCT00224094|Sex Hormone Binding Globulin
1441850|NCT00224094|Thyroid function
1441851|NCT00224094|Cortisol
1441852|NCT00224081|iron deficiency anemia
1441853|NCT00224081|ferritin
1441854|NCT00224081|hemodialysis
1441855|NCT00224081|sodium ferric gluconate
1441856|NCT00224081|epoetin alfa
1441857|NCT00224068|Iron deficiency
1441858|NCT00224068|Sodium ferric gluconate
1441859|NCT00224068|anemia
1441860|NCT00224068|cancer chemotherapy
1441861|NCT00224068|epoetin alfa
1441862|NCT00224068|Anemia/drug therapy
1441863|NCT00224068|Anemia, Iron-Deficiency/drug therapy/etiology
1441864|NCT00224068|Hematinics/administration & dosage/pharmacology
1441865|NCT00224068|Antineoplastic Agents/adverse effects
1441866|NCT00224068|Erythropoietin, Recombinant/therapeutic use/adverse effects
1441867|NCT00224055|Iron deficiency
1441868|NCT00224055|Anemia
1441869|NCT00224055|Chronic kidney disease
1441870|NCT00224055|Sodium Ferric Gluconate
1441871|NCT00224055|Anemia, Iron-Deficiency/drug therapy/etiology
1441872|NCT00224055|Kidney Failure, Chronic/blood/complications/therapy
1441873|NCT00224042|Iron deficiency
1441874|NCT00224042|Anemia
1441875|NCT00224042|Chronic kidney disease
1441876|NCT00224042|Erythropoietic agents
1441877|NCT00224042|Sodium Ferric Gluconate
1441878|NCT00224042|Anemia, Iron-Deficiency/drug therapy/etiology
1441879|NCT00224042|Kidney Failure, Chronic/blood/complications/therapy
1441880|NCT00224042|Erythropoietin, Recombinant/adverse effects/therapeutic use
1441881|NCT00224003|Anemia
1441882|NCT00223990|Plasmodium
1441883|NCT00223990|falciparum
1441884|NCT00223990|malaria
1441885|NCT00223990|vaccine
1441886|NCT00223990|AS02A adjuvant
1441887|NCT00223990|FMP1
1441888|NCT00223990|Merozoite surface protein-1
1441889|NCT00223977|Anemia.
1441890|NCT00223964|Iron Deficiency
1441891|NCT00223964|Anemia in Pediatric Hemodialysis
1441892|NCT00223951|Healthy volunteers, safety, ocular, allergic conjunctivitis, ophthalmic
1441893|NCT00223925|Stem cell transplantation
1441894|NCT00223925|Allogeneic transplantation
1441895|NCT00223912|Cardiovascular Disease
1441896|NCT00223912|Exercise
1441897|NCT00223912|Functional electrical stimulation
1441898|NCT00223912|hemostasis
1441899|NCT00223912|Spinal cord injury
1441900|NCT00223899|Melanoma
1441901|NCT00223899|Electroporation
1441902|NCT00223899|IL-2
1441903|NCT00223873|Penile Vibratory Stimulation
1441904|NCT00223873|Muscles Spasticity
1441905|NCT00223873|Spasms
1441906|NCT00223873|Ferti Care Vibrator
1441907|NCT00223873|Antispasmotic treatment
1441908|NCT00223860|Hypogonadal
1441909|NCT00223860|Hypothalamus
1441910|NCT00223860|Pituitary
1441911|NCT00223860|Spinal Cord Injury
1441912|NCT00223860|Testes
1441913|NCT00223860|Testosterone
1441914|NCT00223847|Aphasia rehabilitation
1441915|NCT00223847|Aphasia therapy
1441916|NCT00223847|Constraint therapy
1441917|NCT00223847|Language therapy
1441918|NCT00223834|Counseling
1441919|NCT00223834|Motivation
1441920|NCT00223834|Psychotherapy, brief
1441921|NCT00223821|Behavior Therapy
1441922|NCT00223821|Behavioral Medicine
1441923|NCT00223821|Behavioral Research
1441924|NCT00223821|Behavioral Sciences
1441925|NCT00223821|Combined Modality Therapy
1441926|NCT00223821|Drug Therapy
1441927|NCT00223821|Overactive bladder
1441928|NCT00223821|Treatment Outcome
1441929|NCT00223821|Urge incontinence
1441930|NCT00223821|Urinary incontinence
1441931|NCT00223808|Rehabilitation
1441932|NCT00223808|Robotics
1441933|NCT00223795|Cane
1441934|NCT00223795|Gait
1441935|NCT00223795|Obesity
1441936|NCT00223795|Osteoarthritis
1441937|NCT00223795|Walking Aids
1441938|NCT00223782|Diabetes
1441939|NCT00223782|Peripheral Neuropathy
1441940|NCT00223782|Walking
1441941|NCT00223769|oxandrolone
1441942|NCT00223769|oxandrin
1441943|NCT00223769|lean body mass
1441944|NCT00223769|functional recovery
1441945|NCT00223769|resistance training
1441946|NCT00223756|Vision, Low
1441947|NCT00223743|essential tremor
1441948|NCT00223743|zonisamide
1441949|NCT00223743|clinical trial
1441950|NCT00223730|Peripheral Blood Stem Cell Transplant
1441951|NCT00223730|Bone Marrow Transplant
1441952|NCT00223730|Citrulline
1441953|NCT00223730|Urea Cycle
1441954|NCT00223730|Hepatic Injury
1441955|NCT00223730|Allogeneic PBSCT
1441956|NCT00223730|Matched-Unrelated PBSCT
1441957|NCT00223717|Supine Hypertension
1441958|NCT00223717|Hypertension
1441959|NCT00223717|Treatment
1441960|NCT00223717|Autonomic failure
1441961|NCT00223717|Pure autonomic failure
1441962|NCT00223717|Multiple System Atrophy
1441963|NCT00223717|Shy-Drager Syndrome
1441964|NCT00223704|Coronary Artery Bypass
1441965|NCT00223704|Blood Transfusion
1441966|NCT00223704|Bradykinin Receptor Antagonism
1441967|NCT00223704|Anti-Inflammatory Agents
1441968|NCT00223704|Antifibrinolytic Agents
1441969|NCT00223691|orthostatic hypotension
1441970|NCT00223691|autonomic failure
1441971|NCT00223665|Intermittent Hormone Therapy
1441972|NCT00223652|Cognitive-Behavioral Therapy
1441973|NCT00223652|Telephone psychotherapy
1441974|NCT00223652|Clinical Trial
1441975|NCT00223652|Primary Care Clinic
1441976|NCT00223652|Treatment for Depression
1441977|NCT00223639|alcoholism /alcohol abuse
1441978|NCT00223639|alcoholism antagonist
1441979|NCT00223639|anticonvulsant
1441980|NCT00223639|cognition
1441981|NCT00223639|neuropharmacology
1441982|NCT00223639|substance abuse related behavior
1441983|NCT00223639|craving
1441984|NCT00223639|euphoria
1441985|NCT00223639|relapse /recurrence
1441986|NCT00223639|patient oriented research
1441987|NCT00223626|Cocaine Addiction
1441988|NCT00223626|Cocaine Dependence
1441989|NCT00223613|diabetes
1441990|NCT00223613|juvenile diabetes
1441991|NCT00223613|insulin deficiency
1441992|NCT00223600|lipids
1441993|NCT00223600|lipoproproteins
1441994|NCT00223600|growth
1441995|NCT00223600|neurological development
1441996|NCT00223600|vascular wall
1441997|NCT00223600|blood pressure
1441998|NCT00223600|nutrient intake
1441999|NCT00223587|driving
1442000|NCT00223587|memory
1442001|NCT00223561|adult
1442002|NCT00223548|prophylaxis
1442003|NCT00223548|contrast-induced nephropathy
1442004|NCT00223548|mesna
1442005|NCT00223548|acute renal failure
1442006|NCT00223535|Schizophrenia
1442007|NCT00223535|Cognitive Remediation
1442008|NCT00223535|Social Skills Training
1442009|NCT00223535|Psychosocial
1442010|NCT00223522|Schizophrenia
1442011|NCT00223522|Schizoaffective
1442012|NCT00223522|MEMS
1442013|NCT00223522|adherence to antipsychotic medication
1442014|NCT00223509|mixed mania
1442015|NCT00223509|lamotrigine
1442016|NCT00223496|Bipolar Depression
1442017|NCT00223496|Refractory
1442018|NCT00223483|Hematologic Diseases
1442019|NCT00223483|Genomics
1442020|NCT00223483|Cytokines
1442021|NCT00223483|Chemokines
1442022|NCT00223483|Receptors
1442023|NCT00223470|pain
1442024|NCT00223457|multiple sclerosis
1442025|NCT00223457|compliance
1442026|NCT00223457|adherence
1442027|NCT00223457|disease modifying therapy
1442028|NCT00223457|depression
1442029|NCT00223457|hope
1442030|NCT00223457|quality of life
1442031|NCT00223444|alcohol
1442032|NCT00223444|GABA
1442033|NCT00223444|genetic variation
1442034|NCT00223418|aripiprazole
1442035|NCT00223418|olanzapine
1442036|NCT00223418|vocational
1442037|NCT00223418|learning
1442038|NCT00223418|cognition
1442039|NCT00223418|cognitive
1442040|NCT00223405|enamel wear against ceramic crowns
1442041|NCT00223379|Apical Periodontitis, Root Canal Therapy, Apical Preparation
1442042|NCT00223366|Pain in teeth
1442043|NCT00223353|Biomechanics
1442044|NCT00223353|Gait
1442045|NCT00223353|Balance
1442046|NCT00223340|patient activation
1442047|NCT00223340|primary care
1442048|NCT00223340|diabetes
1442049|NCT00223340|cardiovascular risk
1442050|NCT00223327|pain
1442051|NCT00223327|Normal pulp and normal periodontal status
1442052|NCT00223327|Chronic apical periodontitis of pulpal origin
1442053|NCT00223314|HIV
1442054|NCT00223314|Sexually Transmitted Diseases
1442055|NCT00223314|Pregnancy
1442056|NCT00223314|HIV Seronegativity
1442057|NCT00223275|Bipolar Disorder
1442058|NCT00223275|Alcohol Dependence
1442059|NCT00223275|Dual Diagnosis
1442060|NCT00223275|Naltrexone
1442061|NCT00223210|bipolar disorder
1442062|NCT00223210|cocaine dependence
1442063|NCT00223210|quetiapine
1442064|NCT00223197|Bipolar with depression
1442065|NCT00223197|Recurrent major depressive disorder
1442066|NCT00223197|substance abuse dependence
1442067|NCT00223171|Stage T3 T4
1442068|NCT00223171|PSA > 20
1442069|NCT00223171|Gleason Score > 7
1442070|NCT00223158|Thyroid cancer
1442071|NCT00223158|Hypothyroidism
1442072|NCT00223158|Whole Body Scintigraphy
1442073|NCT00223158|Liothyronine
1442074|NCT00223158|TSH elevation
1442075|NCT00223145|Prostate adenocarcinoma
1442076|NCT00223145|Gleason score <= 6 and PSA 10-20
1442077|NCT00223145|Gleason score = 7 and PSA <=20
1442078|NCT00223132|bariatric surgery
1442079|NCT00223132|body contouring
1442080|NCT00223132|skin laxity
1442081|NCT00223132|plastic surgery
1442082|NCT00223132|suture granuloma
1442083|NCT00223132|absorbable sutures
1442084|NCT00223119|perineal trauma
1442085|NCT00223119|perineal laceration
1442086|NCT00223119|persistent perineal pain
1442087|NCT00223106|urge incontinence
1442088|NCT00223106|urinary incontinence
1442089|NCT00223106|vault prolapse
1442090|NCT00223106|stess incontinence
1442091|NCT00223106|mixed incontinence
1442092|NCT00223106|urine leakage
1442093|NCT00223106|enterocele
1442094|NCT00223106|rectocele
1442095|NCT00223106|cystocele
1442096|NCT00223093|renal transplantation, TAIZ-moncytes
1442097|NCT00223080|HIV Seronegativity
1442098|NCT00223067|renal transplantation
1442099|NCT00223067|TAIZ
1442100|NCT00223054|cyclosporin A
1442101|NCT00223054|Tacrolimus
1442102|NCT00223054|Everolimus
1442103|NCT00223054|Sirolimus
1442104|NCT00223054|Fluvastatin
1442105|NCT00223041|renal transplantation
1442106|NCT00223041|cardiovasculary disease
1442107|NCT00223041|statin
1442108|NCT00223028|fluvastain
1442109|NCT00223028|sirolimus
1442110|NCT00223028|mycophenolat mofetil
1442111|NCT00223028|renal transplantation
1442112|NCT00223015|renal transplantation
1442113|NCT00223015|pharmacokinetics
1442114|NCT00223015|Fluvastatin
1442115|NCT00223015|Mycophenolat mofetil
1442116|NCT00223015|tacrolimus
1442117|NCT00222989|GERD
1442118|NCT00222989|PPI
1442119|NCT00222989|Functional heartburn
1442120|NCT00222963|Obesity
1442121|NCT00222963|Obstructive Sleep Apnea Syndrome
1442122|NCT00222963|Children
1442123|NCT00222963|Adolescents
1442124|NCT00222963|Adenotonsillectomy
1442125|NCT00222950|plant sterols, serum, aortic valve cusps
1442126|NCT00222937|Voice Problems
1442127|NCT00222937|Voice Disorders
1442128|NCT00222924|Mitochondria
1442129|NCT00222911|plantar fasciitis
1442130|NCT00222911|heel pain
1442131|NCT00222911|heel spur
1442132|NCT00222911|night splint
1442133|NCT00222911|arch support
1442134|NCT00222911|foot orthosis
1442135|NCT00222911|physical therapy
1442136|NCT00222898|Pancreatic Cyst
1442137|NCT00222898|PANDA Study
1442138|NCT00222885|PET imaging
1442139|NCT00222885|Skeletal muscle
1442140|NCT00222885|In vivo insulin-stimulated tissue perfusion
1442141|NCT00222885|Glucose transport
1442142|NCT00222885|Glucose phosphorylation
1442143|NCT00222872|Endocrine System Diseases
1442144|NCT00222872|MusculoSkeletal System Diseases
1442145|NCT00222872|Hormone
1442146|NCT00222872|Postmenopausal Women
1442147|NCT00222859|HIV
1442148|NCT00222859|HCV
1442149|NCT00222846|Clinical trial
1442150|NCT00222846|Behavioral research
1442151|NCT00222846|Patient compliance
1442152|NCT00222833|Schizophrenia
1442153|NCT00222833|Schizoaffective disorder
1442154|NCT00222833|Aripiprazole
1442155|NCT00222833|Obese
1442156|NCT00222833|Overweight
1442157|NCT00222833|Heart Health
1442158|NCT00222833|Antipsychotic
1442159|NCT00222833|Heart Health Factors
1442160|NCT00222833|Cardiovascular Health Indices
1442161|NCT00222833|Cardiovascular health
1442162|NCT00222807|schizophrenia, psychosis, type 2 diabetes mellitus
1442163|NCT00222794|Schizophrenia
1442164|NCT00222794|Schizo-Affective Disorder
1442165|NCT00222794|Negative Symptoms
1442166|NCT00222794|Atomoxetine
1442167|NCT00222794|Strattera
1442168|NCT00222781|Skeletal muscle
1442169|NCT00222781|Triple-tracer PET imaging
1442170|NCT00222768|Adipose tissue
1442171|NCT00222768|PET imaging
1442172|NCT00222755|Mood disorders-bipolar
1442173|NCT00222755|Disease management
1442174|NCT00222755|Quality of care
1442175|NCT00222742|hypothermia
1442176|NCT00222742|pediatric TBI
1442177|NCT00222729|head
1442178|NCT00222729|neck
1442179|NCT00222716|Treatment adherence
1442180|NCT00222716|HIV
1442181|NCT00222716|Self-efficacy
1442182|NCT00222716|Treatment Experienced
1442183|NCT00222703|nicotine addiction
1442184|NCT00222703|relapse
1442185|NCT00222703|smoking
1442186|NCT00222703|chronic disorders
1442187|NCT00222703|randomized controlled trial
1442188|NCT00222703|intervention
1442189|NCT00222690|qualitative interview
1442190|NCT00222690|symptom triggers
1442191|NCT00222690|activity and participation
1442192|NCT00222677|venous thromboembolism
1442193|NCT00222677|deep vein thrombosis
1442194|NCT00222677|pulmonary embolism
1442195|NCT00222677|antithrombotic agents
1442196|NCT00222664|hepatitis B
1442197|NCT00222664|hepatocellular carcinoma
1442198|NCT00222664|prevention
1442199|NCT00222664|vaccination
1442200|NCT00222651|pulmonary embolism
1442201|NCT00222651|right ventricular dysfunction
1442202|NCT00222651|thrombolysis
1442203|NCT00222651|echocardiography
1442204|NCT00222638|Oral anticoagulants
1442205|NCT00222638|Influenza virus
1442206|NCT00222638|Influenza vaccine
1442207|NCT00222638|Pharmacological interference
1442208|NCT00222625|Intracerebral Hemorrhage
1442209|NCT00222625|Oral Anticoagulants
1442210|NCT00222625|Antiplatelet Agents
1442211|NCT00222625|Recombinant Activated Factor VII
1442212|NCT00222573|clopidogrel
1442213|NCT00222573|metoprolol
1442214|NCT00222573|myocardial infarction
1442215|NCT00222573|randomised trial
1442216|NCT00222560|physical activity counselling
1442217|NCT00222560|physical activity behavior change intervention
1442218|NCT00222560|prevention
1442219|NCT00222560|collaborative health care
1442220|NCT00222560|physical inactivity
1442221|NCT00222560|motivation
1442222|NCT00222560|fitness
1442223|NCT00222560|randomized controlled trial
1442224|NCT00222534|Respiratory Insufficiency
1442225|NCT00222534|Alkalosis
1442226|NCT00222521|Cystic Fibrosis
1442227|NCT00222521|Diabetes
1442228|NCT00222508|Cystic Fibrosis
1442229|NCT00222508|Diabetes
1442230|NCT00222508|Complications
1442231|NCT00222495|Psychotic Disorders in adolescents
1442232|NCT00222495|Schizophrenia in adolescents
1442233|NCT00222495|Schizophreniform Disorders in adolescents
1442234|NCT00222495|Schizoaffective Disorders in adolescents
1442235|NCT00222482|Borderline Personality Disorder
1442236|NCT00222469|pancreatic cancer
1442237|NCT00222469|unresectable pancreatic cancer
1442238|NCT00222469|metastatic pancreatic cancer
1442239|NCT00222469|bevacizumab
1442240|NCT00222469|oxaliplatin
1442241|NCT00222469|gemcitabine
1442242|NCT00222469|1st line treatment
1442243|NCT00222469|first line treatment
1442244|NCT00222469|locally advanced (unresectable) pancreatic cancer
1442245|NCT00222456|preterm infants
1442246|NCT00222456|early intervention
1442247|NCT00222456|outcome
1442248|NCT00222456|behavioral problems
1442249|NCT00222456|parenting stress
1442250|NCT00222443|Recurrent solid tumors
1442251|NCT00222443|recurrent lymphomas
1442252|NCT00222443|Pediatrics
1442253|NCT00222443|Adolescents
1442254|NCT00222430|Fluoroscopy
1442255|NCT00222430|Femoral Artery
1442256|NCT00222430|Arterial Vascular Access
1442257|NCT00222404|Carcinoma, Non-Small-Cell Lung
1442258|NCT00222404|Pharmacogenomic
1442259|NCT00222378|Crohn's disease
1442260|NCT00222378|ulcerative colitis
1442261|NCT00222378|cytomegalovirus
1442262|NCT00222378|Epstein Bar Virus
1442263|NCT00222378|Human Herpes virus 6
1442264|NCT00222365|homeopathy
1442265|NCT00222365|assessment
1442266|NCT00222365|pain
1442267|NCT00222365|ligamentoplasty
1442268|NCT00222352|Unstable Angina
1442269|NCT00222352|Non-ST-segment Myocardial Infarction
1442270|NCT00222352|Myocardial Necrosis
1442271|NCT00222352|Troponin I
1442272|NCT00222339|Stroke
1442273|NCT00222339|Hand function
1442274|NCT00222339|Task-specific training
1442275|NCT00222326|Hysterectomy,
1442276|NCT00222326|Prolapse,
1442277|NCT00222326|Pelvic floor muscles,
1442278|NCT00222326|Bladder,
1442279|NCT00222326|Bowel.
1442280|NCT00222300|Total hip replacement
1442281|NCT00222300|Strength training
1442282|NCT00222300|Gait analysis
1442283|NCT00222287|Feldenkrais Method
1442284|NCT00222287|movement class
1442285|NCT00222287|balance
1442286|NCT00222287|Four square step test
1442287|NCT00222287|Activities Specific Balance Confidence Scale
1442288|NCT00222287|systems theory
1442289|NCT00222274|fibromyalgia
1442290|NCT00222274|pain
1442291|NCT00222274|biofeedback
1442292|NCT00222274|heart rate variability
1442293|NCT00222261|antiplatelet therapy
1442294|NCT00222261|aspirin non-responders
1442295|NCT00222261|aspirin resistance
1442296|NCT00222261|clopidogrel
1442297|NCT00222261|coronary heart disease
1442298|NCT00222261|stable angina pectoris
1442299|NCT00222248|Stress urinary incontinence
1442300|NCT00222248|Pelvic floor muscle training
1442301|NCT00222248|Bladder training
1442302|NCT00222248|Older women
1442303|NCT00222235|schizophrenia
1442304|NCT00222235|schizoaffective disorder
1442305|NCT00222235|negative symptoms
1442306|NCT00222235|cognitive impairments
1442307|NCT00222222|severe sepsis
1442308|NCT00222222|prognostic markers
1442309|NCT00222222|polymorphisms
1442310|NCT00222222|SIRS
1442311|NCT00222209|Experimental study
1442312|NCT00222209|chronic pain
1442313|NCT00222209|operant learning
1442314|NCT00222209|comorbidity
1442315|NCT00222209|stress
1442316|NCT00222209|Fibromyalgia w visceral hypersensitivity
1442317|NCT00222209|Fibromyalgia w/o visceral hypersensitivity
1442318|NCT00222196|atherosclerosis
1442319|NCT00222196|quality of life
1442320|NCT00222196|pain-score
1442321|NCT00222196|biomarkers
1442322|NCT00222183|Lupus erythematodes
1442323|NCT00222183|Elidel
1442324|NCT00222183|Pimecrolimus
1442325|NCT00222183|Chronic discoid lupus erythematosus (dLE)
1442326|NCT00222183|subacute cutaneous lupus erythematosus (scLE)
1442327|NCT00222131|Epigastric Pain
1442328|NCT00222131|Non-Ulcer Dyspepsia (NUD)
1442329|NCT00222092|post-ERCP pancreatitis
1442330|NCT00222092|prophylaxis
1442331|NCT00222092|prognosis
1442332|NCT00222092|natural course
1442333|NCT00222092|molecular markers
1442334|NCT00222066|Aspiration
1442335|NCT00222066|Fetal ovarian cyst
1442336|NCT00222066|Ovarian torsion
1442337|NCT00222053|Myeloma
1442338|NCT00222053|Autologous transplantation
1442339|NCT00222053|Maintenance therapy
1442340|NCT00222053|Thalidomide
1442341|NCT00222040|Stroke
1442342|NCT00222040|thrombolysis
1442343|NCT00222040|ultrasound
1442344|NCT00222040|microbubbles
1442345|NCT00222040|alteplase
1442346|NCT00222027|Acute lymphoblastic leukemia
1442347|NCT00222027|adult patient
1442348|NCT00222027|chemotherapy
1442349|NCT00222027|stem cell transplantation
1442350|NCT00222027|Young adult patients
1442351|NCT00222014|Refractory ascites
1442352|NCT00222014|Cirrhosis
1442353|NCT00222014|Paracentesesis
1442354|NCT00221988|Elderly
1442355|NCT00221988|Epilepsy
1442356|NCT00221988|Cognition
1442357|NCT00221988|Health Outcome
1442358|NCT00221962|ADHD
1442359|NCT00221923|Primary open angle glaucoma
1442360|NCT00221923|African American
1442361|NCT00221923|Glaucoma/pathology
1442362|NCT00221923|Glaucoma/ physiopathology
1442363|NCT00221923|Nerve Fibers/pathology
1442364|NCT00221923|Risk factor glaucoma
1442365|NCT00221897|Primary open angle glaucoma
1442366|NCT00221897|Glaucoma/pathology
1442367|NCT00221897|Glaucoma/physiopathology
1442368|NCT00221897|Nerve Fibers/pathology
1442369|NCT00221897|Risk factors glaucoma
1442370|NCT00221845|Ramipril
1442371|NCT00221845|Hypertension
1442372|NCT00221845|Chronic renal failure
1442373|NCT00221845|Disease progression
1442374|NCT00221845|Left ventricular hypertrophy
1442375|NCT00221845|Intima media thickness
1442376|NCT00221845|Cardiovascular disease
1442377|NCT00221845|Biomarkers
1442378|NCT00221845|Gene polymorphisms
1442379|NCT00221832|Long QT Syndrome
1442380|NCT00221832|Hypertrophic cardiomyopathy
1442381|NCT00221832|arrhythmogenic right ventricular dysplasia
1442382|NCT00221832|Short QT Syndrome
1442383|NCT00221832|Brugada Syndrome
1442384|NCT00221819|Humidification
1442385|NCT00221819|Heat and moisture exchanger
1442386|NCT00221819|Heated humidifier, non invasive ventilation
1442387|NCT00221806|Arteritis, femoro popliteal bypass, endothelialised prosthesis, saphenous vein graft, permeability, Doppler echography
1442388|NCT00221793|Parkinson
1442389|NCT00221793|deep subthalamic stimulation
1442390|NCT00221793|pharmacological treatment
1442391|NCT00221780|Heart failure
1442392|NCT00221780|Cardiomyopathy, dilated
1442393|NCT00221780|Coronary disease
1442394|NCT00221780|Cardiac Pacing, Artificial
1442395|NCT00221780|Hemodynamics
1442396|NCT00221780|Randomized Controlled Trials
1442397|NCT00221780|Single-Blind Study
1442398|NCT00221767|Neurogenic bladder
1442399|NCT00221767|electric stimulation therapy
1442400|NCT00221767|urinary tract infection
1442401|NCT00221767|urinary incontinence
1442402|NCT00221767|spinal cord injuries
1442403|NCT00221767|spinal nerve roots
1442404|NCT00221767|nonRandomized Controlled Trials
1442405|NCT00221767|open Study
1442406|NCT00221754|HIV,
1442407|NCT00221754|protease inhibitors
1442408|NCT00221754|pravastatin
1442409|NCT00221754|Treatment Experienced
1442410|NCT00221741|Heart surgery
1442411|NCT00221741|Blood Loss, Surgical
1442412|NCT00221741|Mortality
1442413|NCT00221741|Blood Transfusion
1442414|NCT00221741|Cohort Studies
1442415|NCT00221728|Kidney Neoplasms
1442416|NCT00221728|Surgery
1442417|NCT00221728|Catheter Ablation
1442418|NCT00221728|Randomized controlled trials
1442419|NCT00221728|Kidney Failure, Chronic
1442420|NCT00221715|arteritis
1442421|NCT00221715|lower limb ischemia
1442422|NCT00221715|femoropopliteal artery bypass
1442423|NCT00221715|blood vessel prothesis implantation
1442424|NCT00221715|saphenous vein
1442425|NCT00221715|vascular permeability
1442426|NCT00221715|doppler ultrasonography
1442553|NCT00221182|Pain
1442427|NCT00221715|randomized clinical trials
1442428|NCT00221715|efficacy study
1442429|NCT00221702|Melanoma
1442430|NCT00221702|Neoplasm metastasis
1442431|NCT00221702|Interferon alfa-2b
1442432|NCT00221702|Adjuvants
1442433|NCT00221702|Randomized clinical trial
1442434|NCT00221702|Disease-free survival time
1442435|NCT00221702|Safety
1442436|NCT00221702|Drug toxicity
1442437|NCT00221702|Quality of life
1442438|NCT00221689|Severe brain injury
1442439|NCT00221689|Coma
1442440|NCT00221689|Hypertonia
1442441|NCT00221689|Dysautonomia
1442442|NCT00221689|Baclofen
1442443|NCT00221689|Randomized Controlled Trials
1442444|NCT00221676|influenza vaccine
1442445|NCT00221676|general practitioner
1442446|NCT00221663|Cardiac surgery
1442447|NCT00221663|Aortic valve replacement
1442448|NCT00221663|Minimally invasive surgery
1442449|NCT00221663|Perioperative course
1442450|NCT00221650|Hepatitis C, Chronic
1442451|NCT00221650|HCV infection
1442452|NCT00221650|HIV infection
1442453|NCT00221650|Treatment Failure
1442454|NCT00221650|PEG interferon
1442455|NCT00221650|Interferons/therapeutic use
1442456|NCT00221650|Interferon Alfa-2a/adverse effects
1442457|NCT00221650|Ribavirin/therapeutic use
1442458|NCT00221650|Ribavirin/adverse effects
1442459|NCT00221650|Drug Therapy, Combination
1442460|NCT00221650|Treatment Experienced
1442461|NCT00221650|Treatment Naive
1442462|NCT00221637|Neuralgia
1442463|NCT00221637|Valproate
1442464|NCT00221637|Anticonvulsant Drugs
1442465|NCT00221637|Pain Measurement
1442466|NCT00221637|Randomized Controlled Trials
1442467|NCT00221624|Hepatitis C, chronic
1442468|NCT00221624|HCV infection
1442469|NCT00221624|Treatment failure
1442470|NCT00221624|PEG Interferon
1442471|NCT00221624|(Interferons/therapeutic use
1442472|NCT00221624|Interferon Alfa-2a/adverse effects)
1442473|NCT00221624|ribavirin
1442474|NCT00221624|(Ribavirin/therapeutic use
1442475|NCT00221624|Ribavirin/adverse effects)
1442476|NCT00221624|Amantadine
1442477|NCT00221624|Drug Therapy, Combination
1442478|NCT00221520|Sedation, mechanical ventilation
1442479|NCT00221507|Vaccination
1442480|NCT00221507|Prevention & Control
1442481|NCT00221494|depression
1442482|NCT00221481|Bipolar
1442483|NCT00221481|Alcohol
1442484|NCT00221468|Adolescents
1442485|NCT00221455|Diabetes Mellitus
1442486|NCT00221455|Chronic disease management
1442487|NCT00221455|Patient portal
1442488|NCT00221455|Patient empowerment
1442489|NCT00221442|Adults
1442490|NCT00221442|Binge eating disorder
1442491|NCT00221442|Blood draw
1442492|NCT00221442|E.Coli enterprotoxin
1442493|NCT00221442|Eating disorders
1442494|NCT00221442|Electrocardiogram
1442495|NCT00221442|Females
1442496|NCT00221442|Males
1442497|NCT00221442|Physical exam
1442498|NCT00221442|Psychiatric evaluation
1442499|NCT00221442|Questionnaire
1442500|NCT00221429|child
1442501|NCT00221429|adolescent
1442502|NCT00221416|child
1442503|NCT00221416|adolescent
1442504|NCT00221403|child
1442505|NCT00221403|adolescent
1442506|NCT00221403|bipolar disorder
1442507|NCT00221390|stroke
1442508|NCT00221390|Chronic stroke with hemiparesis
1442509|NCT00221377|intubation
1442510|NCT00221377|trachea
1442511|NCT00221377|tube
1442512|NCT00221377|cuff
1442513|NCT00221377|children
1442514|NCT00221364|Trachoma
1442515|NCT00221364|Chlamydia
1442516|NCT00221364|Azithromycin
1442517|NCT00221351|cough
1442518|NCT00221351|acute bronchitis
1442519|NCT00221351|upper respiratory tract infection
1442520|NCT00221351|pneumonia
1442521|NCT00221351|lower respiratory tract infection
1442522|NCT00221338|gabapentin
1442523|NCT00221338|pain
1442524|NCT00221338|surgery
1442525|NCT00221338|delirium
1442526|NCT00221338|cognitive decline
1442527|NCT00221325|Phase I Clinical Trial
1442528|NCT00221325|Pharmacokinetics
1442529|NCT00221325|Pharmacodynamics
1442530|NCT00221325|CNS Lymphoma
1442531|NCT00221325|Ocular Lymphoma
1442532|NCT00221312|Perimenopausal bone loss
1442533|NCT00221299|Osteoporosis
1442534|NCT00221299|Steroids
1442535|NCT00221299|Prednisone
1442536|NCT00221286|chronic hepatitis B
1442537|NCT00221286|human immunodeficiency virus
1442538|NCT00221286|pegylated interferon
1442539|NCT00221286|tenofovir DF
1442540|NCT00221286|emtricitabine
1442541|NCT00221260|Analgesia
1442542|NCT00221260|anesthesia
1442543|NCT00221247|cerebral palsy; acupuncture
1442544|NCT00221234|Diabetes
1442545|NCT00221234|Physical Activity
1442546|NCT00221221|breast cancer survivors
1442547|NCT00221221|physical activity
1442548|NCT00221221|health promotion
1442549|NCT00221208|Diabetes
1442550|NCT00221208|Resistance Training
1442551|NCT00221182|Angina
1442552|NCT00221182|Heart diseases
1442554|NCT00221182|Vascular diseases
1442555|NCT00221169|Non-small cell lung cancer
1442556|NCT00221169|Positron emission tomography
1442557|NCT00221169|Gross tumor volume
1442558|NCT00221169|Radiation therapy
1442559|NCT00221156|Abnormal Glucose Tolerance
1442560|NCT00221156|coronary artery disease
1442561|NCT00221156|diabetes mellitus
1442562|NCT00221156|clinical outcome
1442563|NCT00221143|Ulcer/ gangrene
1442564|NCT00221143|Leg diseases
1442565|NCT00221143|Pain
1442566|NCT00221143|Vascular diseases
1442567|NCT00221143|Chronic limb ischemia
1442568|NCT00221143|Peripheral artery disease
1442569|NCT00221130|Regenerative medicine
1442570|NCT00221130|Periodontal tissue
1442571|NCT00221117|Spinal Cord Injuries
1442572|NCT00221104|stroke
1442573|NCT00221104|brain ischemia
1442574|NCT00221104|cerebrovascular accident
1442575|NCT00221104|statin
1442576|NCT00221104|hydroxymethylglutaryl-CoA reductase inhibitors
1442577|NCT00221104|cholesterol
1442578|NCT00221104|hypercholesterolemia
1442579|NCT00221104|hyperlipidemia
1442580|NCT00221104|multicenter studies
1442581|NCT00221104|prospective studies
1442582|NCT00221104|endpoint determination
1442583|NCT00221104|randomized controlled trials
1442584|NCT00221104|recurrence
1442585|NCT00221104|pravastatin
1442586|NCT00221091|idiopathic normal pressure hydrocephalus
1442587|NCT00221091|shunt
1442588|NCT00221078|Cerebrovascular Accident
1442589|NCT00221078|Stroke
1442590|NCT00221065|Sleep Apnea Syndromes
1442591|NCT00221065|Cerebrovascular Accident
1442592|NCT00221039|ECP
1442593|NCT00221039|Photopheresis
1442594|NCT00221039|CTCL
1442595|NCT00221039|Cutaneous T Cell Lymphoma
1442596|NCT00221039|Mycosis Fungoides
1442597|NCT00221013|Acute Renal Failure
1442598|NCT00221013|Continuous Renal Replacement Therapy
1442599|NCT00221013|Continuous Veno-Venous Haemofiltration
1442600|NCT00221013|Continuous Veno-Venous Haemodiafiltration
1442601|NCT00221013|Renal Replacement Therapy
1442602|NCT00221000|Rheumatoid Arthritis
1442603|NCT00220987|Hyperglycemia in the critically ill patient
1442604|NCT00220987|Intensive Insulin Therapy
1442605|NCT00220987|Conventional insulin therapy
1442606|NCT00220987|Hypoglycaemia
1442607|NCT00220961|Impaired Glucose Tolerance
1442608|NCT00220961|Type 2 Diabetes
1442609|NCT00220961|Prevention
1442610|NCT00220961|Pioglitazone
1442611|NCT00220948|discogenic pain
1442612|NCT00220948|myoelectric activity
1442613|NCT00220935|Randomized controlled clinical trial
1442614|NCT00220922|Copaxone
1442615|NCT00220909|Gastric erosions
1442616|NCT00220909|Proton pump inhibitors
1442617|NCT00220896|Delirium
1442618|NCT00220896|Prevention
1442619|NCT00220896|Donepezil
1442620|NCT00220883|Functional Dyspepsia
1442621|NCT00220883|Electrogastrography
1442622|NCT00220870|schizophrenia
1442623|NCT00220870|shared decision making
1442624|NCT00220870|compliance
1442625|NCT00220870|maintenance therapy
1442626|NCT00220857|Rabeprazole
1442627|NCT00220857|Nonsteroidal Antiinflammatory Drugs
1442628|NCT00220857|Gastric erosions
1442629|NCT00220831|Diabetes
1442630|NCT00220831|MI
1442631|NCT00220831|CVD disease
1442632|NCT00220818|Pediatric GERD
1442633|NCT00220818|Pediatric Gastroesophageal Reflux Disease
1442634|NCT00220818|lansoprazole
1442635|NCT00220792|Primary breast cancer
1442636|NCT00220792|support groups
1442637|NCT00220792|mood disturbance
1442638|NCT00220766|Primary Immune Deficiency
1442639|NCT00220766|IGIV
1442640|NCT00220766|Immunoglobulin G
1442641|NCT00220753|Dog allergy
1442642|NCT00220753|Pet allergy
1442643|NCT00220753|Air cleaners
1442644|NCT00220753|HEPA filters
1442645|NCT00220753|Air filtration
1442646|NCT00220753|Can f1
1442647|NCT00220753|Asthma
1442648|NCT00220753|Children
1442649|NCT00220753|Adolescents
1442650|NCT00220753|Indoor environment
1442651|NCT00220753|Indoor allergy
1442652|NCT00220753|Perennial allergy
1442653|NCT00220740|Immunoglobulin G
1442654|NCT00220727|Idiopathic (Immune) Thrombocytopenic Purpura
1442655|NCT00220727|Immunoglobulin G
1442656|NCT00220714|schizophrenia
1442657|NCT00220714|first-episode
1442658|NCT00220714|patient compliance
1442659|NCT00220714|long-acting risperidone
1442660|NCT00220714|relapse
1442661|NCT00220701|Dysthymic Disorder
1442662|NCT00220701|Depression
1442663|NCT00220701|Chronic Depression
1442664|NCT00220701|Escitalopram
1442665|NCT00220688|nausea
1442666|NCT00220688|vomiting
1442667|NCT00220688|palliative
1442668|NCT00220688|acupressure
1442669|NCT00220675|Malignant extradural spinal cord compression
1442670|NCT00220675|Erythropoietin
1442671|NCT00220675|Neuroprotectant
1442672|NCT00220675|Radiotherapy
1442673|NCT00220675|Palliation
1442674|NCT00220662|anorexia nervosa
1442675|NCT00220662|bulimia nervosa
1442676|NCT00220662|readiness and motivation
1442677|NCT00220649|solid tumors or adenocarcinoma of the exocrine pancreas
1442678|NCT00220636|Major Depression
1442679|NCT00220636|Depression
1442680|NCT00220636|Unipolar Depression
1442681|NCT00220636|Treatment Resistant Depression
1442682|NCT00220636|Adjunctive treatment
1442683|NCT00220623|major depression
1442684|NCT00220623|psychotherapy
1442685|NCT00220623|antidepressant medications
1442686|NCT00220623|clincial trial
1442687|NCT00220597|group therapy
1442688|NCT00220597|sexual revictimization
1442689|NCT00220597|risky sex
1442690|NCT00220597|addiction
1442691|NCT00220571|AMI
1442692|NCT00220571|stent
1442693|NCT00220571|PTCA
1442694|NCT00220571|abciximab
1442695|NCT00220571|reteplase
1442696|NCT00220571|combo therapy
1442697|NCT00220558|Percutaneous Transluminal Coronary Angioplasty
1442698|NCT00220558|Bare metal stents
1442699|NCT00220558|drug eluting stents
1442700|NCT00220545|Polycystic ovarY
1442701|NCT00220545|Laparoscopic ovarian diathermy
1442702|NCT00220545|Induction of ovulation
1442703|NCT00220545|Clomiphene citrate
1442704|NCT00220532|Randomised placebo controlled intervention trial
1442705|NCT00220532|Folic acid
1442706|NCT00220532|Riboflavin
1442707|NCT00220532|cervical cancer
1442708|NCT00220506|provigil
1442709|NCT00220506|fatigue
1442710|NCT00220506|Multiple Sclerosis
1442711|NCT00220506|cognition
1442712|NCT00220493|MS
1442713|NCT00220493|RITALIN
1442714|NCT00220493|PASAT
1442715|NCT00220493|COGNITION
1442716|NCT00220493|ATTENTION
1442717|NCT00220493|Relapsing remitting
1442718|NCT00220493|Secondary progressive
1442719|NCT00220493|Primary progressive
1442720|NCT00220467|MCI
1442721|NCT00220467|aging
1442722|NCT00220467|cognition
1442723|NCT00220467|exercise
1442724|NCT00220467|aerobic
1442725|NCT00220467|insulin
1442726|NCT00220454|cognition
1442727|NCT00220454|estradiol
1442728|NCT00220454|cortisol
1442729|NCT00220454|postmenopause
1442730|NCT00220441|IGT
1442731|NCT00220441|exercise
1442732|NCT00220441|cognition
1442733|NCT00220441|insulin
1442734|NCT00220441|aging
1442735|NCT00220441|aerobic
1442736|NCT00220428|T cell
1442737|NCT00220350|arousal
1442738|NCT00220350|sex offender
1442739|NCT00220350|suppression of arousal
1442740|NCT00220350|pedohilia
1442741|NCT00220350|leuprolide acetate
1442742|NCT00220324|Contraception
1442743|NCT00220285|Antigen
1442744|NCT00220285|CD20
1442745|NCT00220272|Parkinson Disease
1442746|NCT00220272|5-fluorodopa
1442747|NCT00220259|Cystic Fibrosis, inhaled corticosteroids
1442748|NCT00220246|Hereditary colorectal cancer
1442749|NCT00220246|Microsatellite instability
1442750|NCT00220246|Chromosomal instability
1442751|NCT00220207|Diabetes
1442752|NCT00220207|Health Education
1442753|NCT00220207|Information Technology
1442754|NCT00220207|African Americans
1442755|NCT00220207|Disease Management
1442756|NCT00220207|Internet
1442757|NCT00220207|Patient Education
1442758|NCT00220181|Nutritional status
1442759|NCT00220181|Bowel symptoms
1442760|NCT00220181|Radical radiotherapy to pelvis
1442761|NCT00220181|Gynaecological, urological or rectal cancer
1442762|NCT00220090|Irritable Bowel Syndrome
1442763|NCT00220090|Cholecystokinin
1442764|NCT00220090|Dexloxiglumide
1442765|NCT00220090|Randomized/withdrawal
1442766|NCT00219999|Hepatitis
1442767|NCT00219999|Hepacivirus
1442768|NCT00219999|B Lymphocytes
1442769|NCT00219999|Chemokines
1442770|NCT00219999|Antibodies
1442771|NCT00219986|Treatment Experienced
1442772|NCT00219986|HIV
1442773|NCT00219973|venous thromboembolism
1442774|NCT00219973|deep vein thrombosis
1442775|NCT00219973|pulmonary embolism
1442776|NCT00219973|bleeding
1442777|NCT00219973|low-molecular-weight heparin
1442778|NCT00219973|cancer
1442779|NCT00219973|surgery
1442780|NCT00219960|Hypertension
1442781|NCT00219960|Blood Pressure
1442782|NCT00219960|Ambulatory Blood Pressure Monitoring
1442783|NCT00219960|Complementary and Alternative Medicine
1442784|NCT00219960|Herbal
1442785|NCT00219960|North American Ginseng
1442786|NCT00219960|Panax Quinquefolius
1442787|NCT00219947|HIV Infection
1442788|NCT00219947|Acute HIV Infection
1442789|NCT00219947|Primary HIV Infection
1442790|NCT00219947|Acute Seroconversion Syndrome
1442791|NCT00219934|New HIV Infection
1442792|NCT00219934|Acute HIV Infection
1442793|NCT00219934|Primary HIV Infection
1442794|NCT00219934|Acute Seroconversion Syndrome
1442795|NCT00219921|total hip replacement
1442796|NCT00219921|pain treatment
1442797|NCT00219908|Multiple sclerosis
1442798|NCT00219908|Mitoxantrone
1442799|NCT00219908|Methylprednisolone
1442800|NCT00219908|Interferon beta1b
1442801|NCT00219908|Relapse
1442802|NCT00219908|MRI
1442803|NCT00219908|EDSS
1442804|NCT00219895|Cystic Fibrosis
1442805|NCT00219895|Anti-inflammatory Agents
1442806|NCT00219895|Ibuprofen
1442807|NCT00219882|Cystic Fibrosis
1442808|NCT00219882|curcuminoids
1442809|NCT00219882|turmeric root extract
1442810|NCT00219882|nasal potential difference (NPD)
1442811|NCT00219882|sweat chloride
1442812|NCT00219869|Post
1442813|NCT00219869|Traumatic
1442814|NCT00219869|Headache
1442815|NCT00219869|Cognitive
1442816|NCT00219856|Propofol
1442817|NCT00219856|Hepatectomy
1442818|NCT00219856|Oxidative stress
1442819|NCT00219843|Stage III and IV melanoma
1442820|NCT00219830|Cardiac Rehabilitation
1442821|NCT00219830|Walking
1442822|NCT00219830|Acute Myocardial Infarction
1442823|NCT00219830|Secondary Prevention
1442824|NCT00219817|Anorexia
1442825|NCT00219817|Cachexia
1442826|NCT00219791|methotrexate
1442827|NCT00219791|delayed elimination
1442828|NCT00219791|renal insufficiency
1442829|NCT00219791|CPG2
1442830|NCT00219791|Voraxaze
1442831|NCT00219765|CML
1442832|NCT00219765|Acute Phase
1442833|NCT00219765|Imatinib mesylate
1442834|NCT00219765|Cytarabine
1442835|NCT00219765|Daunorubicine
1442836|NCT00219752|CML - ederly patients - Imatinib mesylate
1442837|NCT00219739|CML
1442838|NCT00219739|Imatinib
1442839|NCT00219739|Interferon
1442840|NCT00219739|Cytarabine
1442841|NCT00219726|CML
1442842|NCT00219726|Imatinib mesylate
1442843|NCT00219726|Stem cell transplantation
1442844|NCT00219713|Nitrous oxide and oxygen
1442845|NCT00219713|Pain
1442846|NCT00219713|Bone marrow biopsy
1442847|NCT00219713|Bone marrow aspiration
1442848|NCT00219700|NSAID-PC
1442849|NCT00219700|IBU-PC
1442850|NCT00219687|Heart arrest
1442851|NCT00219687|Cardiopulmonary resuscitation
1442852|NCT00219687|Dispatcher
1442853|NCT00219674|education
1442854|NCT00219674|training, defibrillators
1442855|NCT00219674|home defibrillators
1442856|NCT00219674|automated external defibrillators
1442857|NCT00219674|psychological adjustment
1442858|NCT00219661|randomised control trial
1442859|NCT00219661|intensive care unit
1442860|NCT00219661|mechanical ventilation
1442861|NCT00219661|ventilator-associated pneumonia
1442862|NCT00219661|drainage of subglottic secretions
1442863|NCT00219557|Randomized Phase 2 Study of AG-013736 in Combination with Gemcitabine versus Gemcitabine Alone in Advanced Pancreatic Cancer
1442864|NCT00219531|functional MRI
1442865|NCT00219531|pain perception
1442866|NCT00219531|anxiety
1442867|NCT00219531|brain-gut axis
1442868|NCT00219518|Defecography
1442869|NCT00219518|Pelvic floor dyssynergia
1442870|NCT00219518|Anismus
1442871|NCT00219505|Diarrhea-predominant irritable bowel syndrome
1442872|NCT00219505|Acupuncture
1442873|NCT00219505|abdominal pain
1442874|NCT00219492|NCCP, mast cell, esophagus
1442875|NCT00219479|seizure prophylaxis
1442876|NCT00219479|enteral nutrition
1442877|NCT00219453|Pilot Projects
1442878|NCT00219453|Injections, Jet
1442879|NCT00219453|Injections, Jet/instrumentation
1442880|NCT00219453|Equipment Contamination/prevention and control
1442881|NCT00219453|Blood-Borne Pathogens
1442882|NCT00219453|Disease Transmission, Horizontal
1442883|NCT00219427|Low vision
1442884|NCT00219401|Pneumococcal vaccine
1442885|NCT00219401|Antibody responses
1442886|NCT00219401|Cellular immunology
1442887|NCT00219401|Th1/Th2 immune responses
1442888|NCT00219401|Paediatric
1442889|NCT00219401|Neonatal
1442890|NCT00219401|Infectious diseases
1442891|NCT00219401|Papua New Guinea
1442892|NCT00219388|Safety
1442893|NCT00219388|Efficacy
1442894|NCT00219388|Levosimendan
1442895|NCT00219388|Dobutamine
1442896|NCT00219388|Intravenous
1442897|NCT00219388|Invasive hemodynamics
1442898|NCT00219388|Decompensated Heart Failure
1442899|NCT00219375|sivelestat sodium hydrate
1442900|NCT00219375|acute lung injury
1442901|NCT00219375|systemic inflammatory response syndrome
1442902|NCT00219375|Elaspol
1442903|NCT00219375|Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS)
1442904|NCT00219362|HIV-1 infection
1442905|NCT00219362|therapeutic vaccine
1442906|NCT00219362|Treatment Experienced
1442907|NCT00219349|Anxiety Disorders
1442908|NCT00219349|Anxiety Neuroses
1442909|NCT00219349|Behavior Therapy, Cognitive
1442910|NCT00219349|Escitalopram
1442911|NCT00219336|Prevent Alcohol Exposed Pregnancies
1442912|NCT00219336|Reduced Alcohol Used
1442913|NCT00219336|Self-Guided Motivational Intervention
1442914|NCT00219336|Effective Contraception
1442915|NCT00219336|Contraception
1442916|NCT00219336|College Students
1442917|NCT00219323|Asthma, IgE, Omalizumab
1442918|NCT00219310|Recurrent Genital Herpes (RGH), famciclovir, episodic treatment, suppressive treatment, Polymerase Chain Reaction (PCR).
1442919|NCT00219297|EPO
1442920|NCT00219297|EPO906
1442921|NCT00219297|Brain cancer
1442922|NCT00219297|Brain metastasis
1442923|NCT00219297|Lung cancer
1442924|NCT00219297|Lung metastasis
1442925|NCT00219297|Brain metastasis from non-small cell lung cancer
1442926|NCT00219284|Parkinson's disease, tremor
1442927|NCT00219271|Prostate cancer
1442928|NCT00219271|molecular staging
1442929|NCT00219271|antitumor potential
1442930|NCT00219245|Traumatic brain injury, head trauma, rivastigmine, cognitive deficits
1442931|NCT00219232|Alzheimer's disease
1442932|NCT00219232|Dementia
1442933|NCT00219219|zoledronic acid
1442934|NCT00219219|prostate cancer
1442935|NCT00219219|SRE
1442936|NCT00219193|Hypertension, aliskiren, blood pressure, valsartan, HCTZ
1442937|NCT00219180|Hypertension, Aliskiren
1442938|NCT00219167|hypertension
1442939|NCT00219167|aliskiren
1442940|NCT00219167|age
1442941|NCT00219128|Hypertension, aliskiren, blood pressure, placebo
1442942|NCT00219115|Hypertension, aliskiren, blood pressure, irbesartan, amlodipine, hydrochlorothiazide
1442943|NCT00219102|Hypertension,
1442944|NCT00219102|diabetes,
1442945|NCT00219102|aliskiren,
1442946|NCT00219102|blood pressure,
1442947|NCT00219102|valsartan,
1442948|NCT00219102|hydrochlorothiazide
1442949|NCT00219089|Hypertension, aliskiren, blood pressure, diabetes mellitus, ramipril
1442950|NCT00219076|Hypertension, aliskiren, blood pressure, amlodipine
1442951|NCT00219063|Hypertension, aliskiren, blood pressure, Ramipril, hydrochlorothiazide
1442952|NCT00219037|Hypertension, blood pressure, aliskiren
1442953|NCT00219024|Hypertension, aliskiren, blood pressure, hydrochlorothiazide (HCTZ).
1442954|NCT00219011|Aliskiren, heart failure,hypertension
1442955|NCT00218998|Exercise
1442956|NCT00218998|Exercise therapy
1442957|NCT00218985|Aerobic capacity
1442958|NCT00218985|Exercise training
1442959|NCT00218985|CABG
1442960|NCT00218985|Endothelial function
1442961|NCT00218972|Hypertension
1442962|NCT00218972|endurance training
1442963|NCT00218972|endothelial function
1442964|NCT00218972|left ventricular function
1442965|NCT00218972|Echocardiography
1442966|NCT00218972|Quality of life
1442967|NCT00218972|Essential hypertension grade 1 - 2
1442968|NCT00218959|PTSD
1442969|NCT00218959|trauma treatment
1442970|NCT00218959|refugees
1442971|NCT00218959|randomized controlled
1442972|NCT00218946|pain
1442973|NCT00218946|infant, premature
1442974|NCT00218946|intubation, gastrointestinal
1442975|NCT00218946|Neonatal nursing
1442976|NCT00218933|Interval training
1442977|NCT00218933|Endothelial dysfunction
1442978|NCT00218933|Aerobic capacity
1442979|NCT00218933|Exercise
1442980|NCT00218920|aerobic capacity
1442981|NCT00218920|endothelial function
1442982|NCT00218920|exercise
1442983|NCT00218907|HIV prevention
1442984|NCT00218907|HIV counseling
1442985|NCT00218907|HIV testing
1442986|NCT00218907|Emergency Medicine
1442987|NCT00218907|HIV Seronegativity
1442988|NCT00218894|Effect
1442989|NCT00218894|Balance
1442990|NCT00218894|Gait
1442991|NCT00218894|Falls
1442992|NCT00218881|HIV prevention
1442993|NCT00218881|HIV screening
1442994|NCT00218881|Emergency Medicine
1442995|NCT00218881|HIV counseling and Testing
1442996|NCT00218881|HIV Seronegativity
1442997|NCT00218868|Cytodiagnosis
1442998|NCT00218868|Skin Scrape
1442999|NCT00218868|Touch Imprint
1443000|NCT00218868|Papanicolaou
1443001|NCT00218868|May-Grunvald-Giemsa
1443002|NCT00218855|Multiple Myeloma
1443003|NCT00218855|Phase 3, randomised, double blind study
1443004|NCT00218855|thalidomide
1443005|NCT00218842|exercise
1443006|NCT00218842|functioning
1443007|NCT00218842|frail elderly
1443008|NCT00218829|Photodynamic treatment
1443009|NCT00218829|Basal cell carcinoma
1443010|NCT00218829|DMSO
1443011|NCT00218790|Sleep
1443012|NCT00218790|Renal failure
1443013|NCT00218790|Dialysis
1443014|NCT00218777|Chronic tic disorder
1443015|NCT00218777|Motor tics
1443016|NCT00218777|Vocal tics
1443017|NCT00218751|Child abuse
1443018|NCT00218751|Neglect
1443019|NCT00218751|Home Visitation
1443020|NCT00218751|Program Evaluation
1443021|NCT00218725|Cognitive Therapy
1443022|NCT00218725|Suicide
1443023|NCT00218725|Addictions
1443024|NCT00218725|Substance Abuse
1443025|NCT00218712|HIV
1443026|NCT00218712|AIDS
1443027|NCT00218712|MSM
1443028|NCT00218712|Cognitive-Behavioral
1443029|NCT00218712|HIV Seronegativity
1443030|NCT00218699|HIV
1443031|NCT00218699|MSM Men Who Have Sex with Men
1443032|NCT00218699|Men Who Have Sex With Men
1443033|NCT00218699|Cognitive-Behavioral
1443034|NCT00218699|HIV Counseling and Testing
1443035|NCT00218699|HIV Seronegativity
1443036|NCT00218686|HIV
1443037|NCT00218686|injection drug use
1443038|NCT00218686|social networks
1443039|NCT00218673|HIV
1443040|NCT00218673|injection drug use
1443041|NCT00218673|social networks
1443042|NCT00218621|Buprenorphine
1443043|NCT00218621|Methadone
1443044|NCT00218608|Cocaine Abuse
1443045|NCT00218582|12 step groups
1443046|NCT00218582|self help
1443047|NCT00218582|psychiatric day treatment
1443048|NCT00218582|co-occurring disorders
1443049|NCT00218582|dual diagnosis
1443050|NCT00218569|Alcohol Dependence
1443051|NCT00218569|Cocaine Dependence
1443052|NCT00218556|Hepatitis C, Depressive Symptoms
1443053|NCT00218543|ADHD
1443054|NCT00218543|Cocaine Abuse
1443055|NCT00218517|cannabis use disorder
1443056|NCT00218465|Drugs, Investigational
1443057|NCT00218465|Therapies for Relapse to Nicotine
1443058|NCT00218465|Relapse Prevention
1443059|NCT00218465|Nicotine Cessation Therapies
1443060|NCT00218465|Smoking Cessation
1443061|NCT00218465|Nicotine Dependence
1443062|NCT00218452|Tobacco use cessation
1443063|NCT00218439|Smoking
1443064|NCT00218413|Vaccine
1443065|NCT00218413|Immunogenicity
1443066|NCT00218413|Randomized Controlled Trial
1443067|NCT00218413|Addiction
1443068|NCT00218374|Opiate Addiction
1443069|NCT00218374|Opiate Dependence
1443070|NCT00218361|Behavioral economics
1443071|NCT00218361|Drug self administration
1443072|NCT00218361|Opioid
1443073|NCT00218348|Cocaine Abuse
1443074|NCT00218348|Dextro-Amphetamine Sulfate
1443075|NCT00218335|HIV prevention Intervention, injection drug user,peer-oriented, randomized controlled trial, social network
1443076|NCT00218309|opiate dependence
1443077|NCT00218296|Nicotine Dependence
1443078|NCT00218296|Tobacco Dependence
1443079|NCT00218283|Nicotine Dependence
1443080|NCT00218283|Tobacco Dependence
1443081|NCT00218270|Smokeless tobacco, harm reduction
1443082|NCT00218257|Cocaine
1443083|NCT00218244|Brand Switching, smokeless tobacco use
1443084|NCT00218231|schizophrenia
1443085|NCT00218231|tobacco dependence
1443086|NCT00218231|nicotine
1443087|NCT00218218|Nicotine Dependence
1443088|NCT00218218|Tobacco Dependence
1443089|NCT00218205|Epirubicin
1443090|NCT00218205|Estramustine Phosphate
1443091|NCT00218205|Celecoxib
1443092|NCT00218205|Hormone Refractory Prostate Cancer
1443093|NCT00218192|hepatitis c
1443094|NCT00218192|injection drug use
1443095|NCT00218179|Lung Cancer
1443096|NCT00218179|Cotinine
1443097|NCT00218179|NNAL
1443098|NCT00218179|Carcinogens
1443099|NCT00218179|Case-control
1443100|NCT00218179|SNPs
1443101|NCT00218166|cocaine
1443102|NCT00218166|tiagabine
1443103|NCT00218166|baclofen
1443104|NCT00218153|nicotine dependence
1443105|NCT00218140|tobacco
1443106|NCT00218127|Heroin dependence
1443107|NCT00218101|opioid dependence
1443108|NCT00218075|Cocaine addiction
1443109|NCT00218075|cocaine treatment
1443110|NCT00218036|Cocaine Abuse
1443111|NCT00218036|Opiate Abuse
1443112|NCT00218023|cocaine
1443113|NCT00218023|cocaine addiction
1443114|NCT00218023|cocaine abuse
1443115|NCT00218023|relapse prevention
1443116|NCT00218010|methadone
1443117|NCT00218010|lactation
1443118|NCT00218010|breastfeeding
1443119|NCT00218010|maternal opioid dependency
1443120|NCT00217997|cocaine abuse
1443121|NCT00217997|Cocaine-Related Disorders
1443122|NCT00217984|Tobacco use disorder
1443123|NCT00217984|Alcohol dependence
1443124|NCT00217971|cannabis dependence
1443125|NCT00217971|dronabinol
1443126|NCT00217971|treatment
1443127|NCT00217932|Behavioral Disorders
1443128|NCT00217854|asthma, corticosteroids
1443129|NCT00217841|MRSA
1443130|NCT00217763|Dementia
1443131|NCT00217763|Alzheimer's disease
1443132|NCT00217724|unspecified adult solid tumor, protocol specific
1443133|NCT00217724|pain
1443134|NCT00217711|stage III colon cancer
1443135|NCT00217711|stage IV colon cancer
1443136|NCT00217711|stage III rectal cancer
1443137|NCT00217711|stage IV rectal cancer
1443138|NCT00217698|recurrent non-small cell lung cancer
1443139|NCT00217698|stage IIIB non-small cell lung cancer
1443140|NCT00217698|stage IV non-small cell lung cancer
1443141|NCT00217698|adenocarcinoma of the lung
1443142|NCT00217698|large cell lung cancer
1443143|NCT00217698|squamous cell lung cancer
1443144|NCT00217672|stage IV breast cancer
1443145|NCT00217672|recurrent breast cancer
1443146|NCT00217659|male breast cancer
1443147|NCT00217659|recurrent breast cancer
1443148|NCT00217659|stage IV breast cancer
1443149|NCT00217620|adult angiosarcoma
1443150|NCT00217620|adult leiomyosarcoma
1443151|NCT00217620|adult liposarcoma
1443152|NCT00217620|adult malignant hemangiopericytoma
1443153|NCT00217620|recurrent adult soft tissue sarcoma
1443154|NCT00217620|stage III adult soft tissue sarcoma
1443155|NCT00217620|stage IV adult soft tissue sarcoma
1443156|NCT00217607|adult angiosarcoma
1443157|NCT00217607|recurrent adult soft tissue sarcoma
1443158|NCT00217607|stage III adult soft tissue sarcoma
1443159|NCT00217607|stage IV adult soft tissue sarcoma
1443160|NCT00217594|Immunosuppression
1443161|NCT00217594|T Cells
1443162|NCT00217594|Hematopoiesis
1443163|NCT00217594|Anti-CD52
1443164|NCT00217594|Monoclonal Antibody Therapy
1443165|NCT00217581|recurrent gastric cancer
1443166|NCT00217581|stage III gastric cancer
1443167|NCT00217581|stage IV gastric cancer
1443168|NCT00217581|recurrent esophageal cancer
1443169|NCT00217581|stage III esophageal cancer
1443170|NCT00217581|stage IV esophageal cancer
1443171|NCT00217581|adenocarcinoma of the stomach
1443172|NCT00217568|recurrent ovarian epithelial cancer
1443173|NCT00217568|stage III ovarian epithelial cancer
1443174|NCT00217568|stage IV ovarian epithelial cancer
1443175|NCT00217568|peritoneal cavity cancer
1443176|NCT00217555|recurrent ovarian epithelial cancer
1443177|NCT00217555|fallopian tube cancer
1443178|NCT00217555|peritoneal cavity cancer
1443179|NCT00217529|stage III ovarian epithelial cancer
1443180|NCT00217529|stage IV ovarian epithelial cancer
1443181|NCT00217529|peritoneal cavity cancer
1443182|NCT00217529|ovarian clear cell cystadenocarcinoma
1443183|NCT00217529|ovarian endometrioid adenocarcinoma
1443184|NCT00217529|ovarian undifferentiated adenocarcinoma
1443185|NCT00217529|ovarian mucinous cystadenocarcinoma
1443186|NCT00217529|ovarian serous cystadenocarcinoma
1443187|NCT00217529|Brenner tumor
1443188|NCT00217529|fallopian tube cancer
1443189|NCT00217529|ovarian mixed epithelial carcinoma
1443190|NCT00217516|adenocarcinoma of the prostate
1443191|NCT00217516|stage I prostate cancer
1443192|NCT00217516|stage II prostate cancer
1443193|NCT00217503|AIDS-related peripheral/systemic lymphoma
1443194|NCT00217490|unspecified adult solid tumor, protocol specific
1443195|NCT00217477|unspecified adult solid tumor, protocol specific
1443196|NCT00217464|adenocarcinoma of the prostate
1443197|NCT00217464|recurrent prostate cancer
1443198|NCT00217451|Malaria
1443199|NCT00217451|Fosmidomycin
1443200|NCT00217451|Clindamycin
1443201|NCT00217451|Gabon
1443202|NCT00217425|anaplastic large cell lymphoma
1443203|NCT00217425|stage I adult T-cell leukemia/lymphoma
1443204|NCT00217425|stage II adult T-cell leukemia/lymphoma
1443205|NCT00217425|stage III adult T-cell leukemia/lymphoma
1443206|NCT00217425|stage IV adult T-cell leukemia/lymphoma
1443207|NCT00217425|peripheral T-cell lymphoma
1443208|NCT00217386|de novo myelodysplastic syndromes
1443209|NCT00217386|previously treated myelodysplastic syndromes
1443210|NCT00217386|secondary myelodysplastic syndromes
1443211|NCT00217386|myelodysplastic/myeloproliferative disease, unclassifiable
1443212|NCT00217386|atypical chronic myeloid leukemia
1443213|NCT00217347|Gastroesophageal reflux
1443214|NCT00217347|Dyspepsia
1443215|NCT00217347|Esophageal Capsule Endoscopy
1443216|NCT00217334|Hypertension
1443217|NCT00217334|Cardiovascular diseases
1443218|NCT00217334|Randomized controlled trial
1443219|NCT00217334|Cluster randomization
1443220|NCT00217334|Primary care
1443221|NCT00217321|Parkinson's disease
1443222|NCT00217321|Parkinson disease
1443223|NCT00217321|Registry
1443224|NCT00217321|quality of life
1443225|NCT00217321|database
1443226|NCT00217295|Relapsing-remitting multiple sclerosis
1443227|NCT00217295|Brain atrophy
1443228|NCT00217295|Disease progression
1443229|NCT00217269|Restenosis
1443230|NCT00217256|Restenosis
1443231|NCT00217243|Pain
1443232|NCT00217243|Magnetoencephalography
1443233|NCT00217243|Median
1443234|NCT00217243|Ulnar
1443235|NCT00217243|Causalgia
1443236|NCT00217243|Complex regional pain syndrome
1443237|NCT00217243|Evoked fields
1443238|NCT00217243|Nerve injury
1443239|NCT00217243|Neuropathic pain
1443240|NCT00217217|non-pharmaceutical
1443241|NCT00217217|alternative
1443242|NCT00217217|imaging
1443243|NCT00217217|magnetic resonance imaging
1443244|NCT00217217|low field magnetic stimulation
1443245|NCT00217217|bipolar disorder
1443246|NCT00217217|depression
1443247|NCT00217217|bipolar depression
1443248|NCT00217204|Cystic fibrosis
1443249|NCT00217204|Pancreatic insufficiency
1443250|NCT00217204|Steatorrhea
1443251|NCT00217204|Fat malabsorption
1443252|NCT00217204|Pancrelipase
1443253|NCT00217191|Premature Infants
1443254|NCT00217191|Patent ductus arteriosus
1443255|NCT00217191|Renal function
1443256|NCT00217191|Ibuprofen
1443257|NCT00217178|Atherosclerosis
1443258|NCT00217178|CV Risk Factors
1443259|NCT00217178|Homocysteine
1443260|NCT00217178|CV disease
1443261|NCT00217178|Cardiovascular disease
1443262|NCT00217165|bipolar
1443263|NCT00217165|mania
1443264|NCT00217165|depression
1443265|NCT00217165|taurine
1443266|NCT00217165|alternative
1443267|NCT00217152|Kidney Transplant
1443268|NCT00217139|Hepatitis C
1443269|NCT00217139|Celgosivir
1443270|NCT00217139|HCV
1443271|NCT00217139|Genotype 1
1443272|NCT00217139|Non-responders
1443273|NCT00217139|Early Viral Response
1443274|NCT00217139|EVR
1443275|NCT00216099|Prostate Cancer
1443276|NCT00216086|Rectal Cancer
1443277|NCT00216073|Breast Cancer
1443278|NCT00216047|Breast Cancer
1443279|NCT00216034|Gastric Cancer
1443280|NCT00216034|TS-1
1443281|NCT00216034|PSK
1443282|NCT00216034|Disease-free survival
1443283|NCT00216034|Overall survival
1443284|NCT00216021|Breast Cancer
1443285|NCT00215995|esophageal cancer
1443286|NCT00215995|esophagogastric cancer
1443287|NCT00215995|gastric cancer
1443288|NCT00215982|advanced
1443289|NCT00215982|colon
1443290|NCT00215982|rectal
1443291|NCT00215969|Pre-eclampsia
1443292|NCT00215969|Pregnancy
1443293|NCT00215969|Hypercoagulation
1443294|NCT00215969|Screening
1443295|NCT00215969|Cardiovascular complications
1443296|NCT00215956|Topotecan
1443297|NCT00215956|Rectal Neoplasms
1443298|NCT00215956|Radiosensitizing
1443299|NCT00215943|hematologic malignancy
1443300|NCT00215930|malignant pleural effusion
1443301|NCT00215917|Schizophrenia
1443302|NCT00215917|NMDA
1443303|NCT00215917|D-serine
1443304|NCT00215891|Treatment Experienced
1443305|NCT00215852|Alferon LDO
1443306|NCT00215852|Low Dose Oral Interferon
1443307|NCT00215852|Alfa-n3
1443308|NCT00215852|Human Leukocyte Derived
1443309|NCT00215852|HIV
1443310|NCT00215852|Asymptomatic HIV
1443311|NCT00215852|Treatment Experienced
1443312|NCT00215839|Treatment Experienced
1443313|NCT00215826|SARS
1443314|NCT00215826|Alferon LDO
1443315|NCT00215826|Low Dose Oral Interferon ALFA-n3
1443316|NCT00215826|Human Leukocyte Derived
1443317|NCT00215826|Exposure to SARS
1443318|NCT00215826|Possible SARS
1443319|NCT00215813|Chronic Fatigue Syndrome
1443320|NCT00215813|CFS
1443321|NCT00215813|ME
1443322|NCT00215813|Ampligen
1443323|NCT00215813|poly I:poly C12U
1443324|NCT00215813|Rintatolimod
1443325|NCT00217035|parenteral nutrition
1443326|NCT00217035|burn injury
1443327|NCT00217035|stable isotopes
1443328|NCT00217035|Proline Metabolic Kinetics
1443329|NCT00217035|Ornithine Metabolic Kinetics
1443330|NCT00217035|Glutamate Metabolic Kinetics
1443331|NCT00217035|Glutamine Metabolic Kinetics
1443332|NCT00217022|Lymphocytic Colitis
1443333|NCT00217022|diarrhea
1443334|NCT00217022|budesonide
1443335|NCT00216996|parenteral nutrition
1443336|NCT00216996|burn injury
1443337|NCT00216996|stable isotopes
1443338|NCT00216996|Glutamate Metabolic Kinetics
1443339|NCT00216996|Glutamine Metabolic Kinetics
1443340|NCT00216983|parenteral nutrition
1443341|NCT00216983|burn injury
1443342|NCT00216983|stable isotopes
1443343|NCT00216983|Proline Metabolic Kinetics
1443344|NCT00216983|Ornithine Metabolic Kinetics
1443345|NCT00216983|Glutamate Metabolic Kinetics
1443346|NCT00216983|Glutamine Metabolic Kinetics
1443347|NCT00216970|parenteral nutrition
1443348|NCT00216970|burn injury
1443349|NCT00216970|stable isotopes
1443350|NCT00216970|Arginine Metabolic Kinetics
1443351|NCT00216970|Nitric Oxide Formation
1443352|NCT00216970|Glutamine Metabolic Kinetics
1443353|NCT00216944|Intubation
1443354|NCT00216944|premedication
1443355|NCT00216905|Patients with alcoholism according to ICD-10 after detoxification
1443356|NCT00216866|Embolism
1443357|NCT00216866|Thrombosis
1443358|NCT00216814|antiangiogenic effects of bcg treatment and prognosis
1443359|NCT00216801|Upper Tract Transitional Cell (TCC)
1443360|NCT00216788|Sucrose
1443361|NCT00216788|Barrett's esophagus
1443362|NCT00216788|Esophagitis
1443363|NCT00216788|GERD
1443364|NCT00216788|Reflux
1443365|NCT00216788|Esophagus
1443366|NCT00216788|Esomeprazole
1443367|NCT00216762|Urticaria
1443368|NCT00216762|Hives
1443369|NCT00216749|Cerebral Infarction Prevention
1443370|NCT00216749|Cilostazol
1443371|NCT00216736|Migraine
1443372|NCT00216736|Headache
1443373|NCT00216736|Rebound headache
1443374|NCT00216723|Aripiprazole
1443375|NCT00216723|Schizophrenia
1443376|NCT00216723|Bipolar Disorder
1443377|NCT00216710|Child abuse
1443378|NCT00216710|Neglect
1443379|NCT00216710|Home visitation
1443380|NCT00216710|Program evaluation
1443381|NCT00216697|Multiple myeloma
1443382|NCT00216697|Proteasome inhibitor
1443383|NCT00216697|Ubiquitin
1443384|NCT00216697|Boronic acids
1443385|NCT00216697|Bortezomib
1443386|NCT00216684|Fentanyl, Chronic intractable pain, Japanese patients
1443387|NCT00216671|Schizophrenia
1443388|NCT00216671|intramuscular injection
1443389|NCT00216671|antipsychotic agents
1443390|NCT00216671|long-acting risperidone
1443391|NCT00216658|Fentanyl
1443392|NCT00216658|Cancer pain
1443393|NCT00216658|Japanese patients
1443394|NCT00216645|Müllerian Carcinoma
1443395|NCT00216645|Doxil
1443396|NCT00216645|Japanese Patients
1443397|NCT00216632|Schizophrenia, Schizoaffective disorder
1443398|NCT00216632|antipsychotic agents
1443399|NCT00216632|long-acting risperidone
1443400|NCT00216632|intramuscular injection
1443401|NCT00216619|chronic migraine
1443402|NCT00216619|Topiramate
1443403|NCT00216619|migraine
1443404|NCT00216619|headache
1443405|NCT00216619|chronic headache
1443406|NCT00216606|Chronic migraine
1443407|NCT00216606|Migraine
1443408|NCT00216606|Headache
1443409|NCT00216606|Migraine headache
1443410|NCT00216606|Topiramate
1443411|NCT00216593|dementia
1443412|NCT00216593|cognition function
1443413|NCT00216593|Alzheimer disease
1443414|NCT00216593|behavioral symptoms
1443415|NCT00216593|galantamine hydrobromide
1443416|NCT00216580|Schizophrenia
1443417|NCT00216580|Intramuscular injection
1443418|NCT00216580|Antipsychotic agents
1443419|NCT00216580|Long-acting risperidone
1443420|NCT00216580|Schizophreniform disorders
1443421|NCT00216580|Schizoaffective disorder
1443422|NCT00216567|Benign rolandic epilepsy
1443423|NCT00216567|Topiramate
1443424|NCT00216554|Bipolar
1443425|NCT00216554|risperidone
1443426|NCT00216554|Adjunctive therapy
1443427|NCT00216541|Anemia
1443428|NCT00216541|cancer
1443429|NCT00216541|transfusion
1443430|NCT00216541|chemotherapy
1443431|NCT00216541|hemoglobin
1443432|NCT00216541|standard care
1443433|NCT00216541|epoetin alfa
1443434|NCT00216541|epoetin
1443435|NCT00216541|erythropoietin
1443436|NCT00216528|Schizophrenia
1443437|NCT00216528|risperidone
1443438|NCT00216528|Intramuscular injection, long-acting risperidone
1443439|NCT00216515|Alzheimer's disease
1443440|NCT00216515|galantamine
1443441|NCT00216515|attention
1443442|NCT00216515|executive function
1443443|NCT00216502|Alzheimer's disease
1443444|NCT00216502|Dementia
1443445|NCT00216502|galantamine
1443446|NCT00216502|placebo
1443447|NCT00216502|Caregiver
1443448|NCT00216502|Brain disease
1443449|NCT00216502|Memory loss
1443450|NCT00216489|gastroesophageal reflux
1443451|NCT00216489|heartburn
1443452|NCT00216489|rabeprazole
1443453|NCT00216489|GERD
1443454|NCT00216489|anti-ulcer agents
1443455|NCT00216489|proton pump inhibitor
1443456|NCT00216476|Schizophrenia, relapse prevention
1443457|NCT00216476|Antipsychotic agents
1443458|NCT00216476|Long-acting risperidone
1443459|NCT00216476|Quetiapine
1443460|NCT00216476|Aripiprazole
1443461|NCT00216463|LDL-cholesterol
1443462|NCT00216463|apoB-100
1443463|NCT00216463|apoB-48
1443464|NCT00216450|rabeprazole
1443465|NCT00216450|proton pump inhibitor
1443466|NCT00216450|Helicobacter infections
1443467|NCT00216450|Helicobacter pylori
1443468|NCT00216450|H pylori
1443469|NCT00216450|bacterial infections
1443470|NCT00216437|Liver cancer
1443471|NCT00216424|Colon cancer
1443472|NCT00216424|Rectal cancer
1443473|NCT00216398|acromegaly
1443474|NCT00216398|growth hormone
1443475|NCT00216385|Tuberculosis
1443476|NCT00216385|Treatment
1443477|NCT00216385|Quinolone
1443478|NCT00216385|Short course chemotherapy
1443479|NCT00216372|carcinomatosis
1443480|NCT00216359|Treatment Experienced
1443481|NCT00216333|tuberculosis
1443482|NCT00216333|fixed dose combination
1443483|NCT00216333|DOT
1443484|NCT00216333|shot-course chemotherapy
1443485|NCT00216320|electrical stimulation
1443486|NCT00216294|Obsessive Compulsive Disorder
1443487|NCT00216294|RG 1068 (Synthetic Human Secretin)
1443488|NCT00216281|Schizophrenia
1443489|NCT00216281|Clozapine
1443490|NCT00216281|Atomoxetine
1443491|NCT00216255|Persistent Developmental Stuttering
1443492|NCT00216242|influenza
1443493|NCT00216242|vaccine
1443494|NCT00216242|efficacy
1443495|NCT00216242|safety
1443496|NCT00216242|immunogenicity
1443497|NCT00216229|combined hepatitis A and B vaccine
1443498|NCT00216229|hepatitis B virus
1443499|NCT00216229|immunity
1443500|NCT00216203|Non-Small Cell Lung Cancer
1443501|NCT00216190|Sedation, ICU, Anesthesia, Dexmedetomidine, Midazolam
1443502|NCT00216164|Lymphoma
1443503|NCT00216151|Multiple Myeloma
1443504|NCT00216151|Bisphosphonates
1443505|NCT00216138|Head and Neck Cancer
1443506|NCT00216125|Non-Small Cell Lung Cancer
1443507|NCT00216112|Ovarian Cancer
1443508|NCT00215800|Chronic Fatigue Syndrome
1443509|NCT00215800|Myalgic Encephalomyelitis
1443510|NCT00215800|CFS
1443511|NCT00215800|Ampligen
1443512|NCT00215800|Poly I:ploy C12U
1443513|NCT00215787|Nasal polyps
1443514|NCT00215787|Gastroesophageal Reflux
1443515|NCT00215774|Atrial fibrillation
1443516|NCT00215761|Atrial fibrillation
1443517|NCT00215761|Preventive stimulation
1443518|NCT00215761|Pacemaker
1443519|NCT00215748|Elderly
1443520|NCT00215748|Weekly
1443521|NCT00215735|diabetes
1443522|NCT00215735|Ulcer
1443523|NCT00215735|APC
1443524|NCT00215709|elderly
1443525|NCT00215683|Prostate Cancer
1443526|NCT00215683|Androgen ablation therapy
1443527|NCT00215670|AMD
1443528|NCT00215670|Macugen
1443529|NCT00215670|Pharmacokinetics
1443530|NCT00215670|Age-Related Macular Degeneration
1443531|NCT00215670|PK
1443532|NCT00215644|Esophagus
1443533|NCT00215644|Gastric
1443534|NCT00215644|Adenocarcinoma
1443535|NCT00215644|EGFR
1443536|NCT00215644|matuzumab
1443537|NCT00215644|EMD 72000
1443538|NCT00215644|randomized
1443539|NCT00215644|Epirubicin
1443540|NCT00215644|cisplatin
1443541|NCT00215644|capecitabine
1443542|NCT00215644|Metastatic Esophago-Gastric cancer
1443543|NCT00215631|prostate cancer
1443544|NCT00215631|radiotherapy
1443545|NCT00215631|erectile dysfunction
1443546|NCT00215631|tadalafil
1443547|NCT00215605|Advanced Malignancies
1443548|NCT00215605|Solid Tumor
1443549|NCT00215605|Medullary Thyroid Cancer
1443550|NCT00215566|IBS
1443551|NCT00215566|IBS-c
1443552|NCT00215540|Double-blind
1443553|NCT00215540|Low Birth Weight
1443554|NCT00215540|Surfactant
1443555|NCT00215540|Placebo-Controlled
1443556|NCT00215540|Premature Birth
1443557|NCT00215527|mucopolysaccharidosis
1443558|NCT00215527|Hurler-Scheie
1443559|NCT00215527|Scheie
1443560|NCT00215527|laronidase
1443561|NCT00215527|spinal cord compression
1443562|NCT00215527|central nervous system
1443563|NCT00215527|enzyme replacement therapy
1443564|NCT00215527|intrathecal
1443565|NCT00215527|LA Biomed
1443566|NCT00215514|adjuvant chemoradiation
1443567|NCT00215514|GE junction
1443568|NCT00215514|epirubicin
1443569|NCT00215501|advanced solid tumor malignancy
1443570|NCT00215501|capecitabine
1443571|NCT00215501|continuous infusion
1443572|NCT00215501|5-FU
1443573|NCT00215501|irinotecan
1443574|NCT00215501|5-fluorouracil
1443575|NCT00215501|cisplatin
1443576|NCT00215462|gastric adenocarcinoma
1443577|NCT00215462|esophageal adenocarcinoma
1443578|NCT00215462|vinorelbine
1443579|NCT00215449|Chronic Obstructive Pulmonary Disease
1443580|NCT00215449|COPD
1443581|NCT00215449|formoterol
1443582|NCT00215449|formoterol fumarate
1443583|NCT00215436|Chronic Obstructive Pulmonary Disease
1443584|NCT00215436|COPD
1443585|NCT00215436|formoterol
1443586|NCT00215423|COPD
1443587|NCT00215423|Chronic Obstructive Pulmonary Disease
1443588|NCT00215423|Formoterol Fumarate
1443589|NCT00215423|Formoterol
1443590|NCT00215410|Asthma
1443591|NCT00215410|Formoterol
1443592|NCT00215410|Fumarate
1443593|NCT00215397|Asthma
1443594|NCT00215397|Formoterol
1443595|NCT00215397|Fumarate
1443596|NCT00215384|COPD
1443597|NCT00215384|formoterol
1443598|NCT00215371|Asthma
1443599|NCT00215371|Pediatric
1443600|NCT00215371|Formoterol Fumarate
1443601|NCT00215371|Foradil
1443602|NCT00215358|Asthma
1443603|NCT00215358|Formoterol
1443604|NCT00215358|Fumarate
1443605|NCT00215358|Foradil
1443606|NCT00215345|Celecoxib
1443607|NCT00215345|Taxotere
1443608|NCT00215345|Hormone Refractory Prostate Cancer
1443609|NCT00215332|arthroplasty
1443610|NCT00215332|lumbar
1443611|NCT00215332|disc
1443612|NCT00215319|Degenerative disc disease at up to 2 levels (L2-S1)
1443613|NCT00215306|arthroplasty
1443614|NCT00215306|lumbar
1443615|NCT00215306|spine
1443616|NCT00215293|fusion
1443617|NCT00215293|cervical
1443618|NCT00215293|spine
1443619|NCT00215280|Mansonella perstans
1443620|NCT00215280|microfilaraemia
1443621|NCT00215280|ivermectin
1443622|NCT00215280|albendazole
1443623|NCT00215280|Uganda
1443624|NCT00215267|Schistosoma mansoni
1443625|NCT00215267|hepatosplenomegaly
1443626|NCT00215267|malaria
1443627|NCT00215267|Uganda
1443628|NCT00215254|quetiapine
1443629|NCT00215254|social anxiety disorder
1443630|NCT00215254|antipsychotic
1443631|NCT00215254|pilot study
1443632|NCT00215241|PTSD
1443633|NCT00215241|sertraline
1443634|NCT00215241|risperidone
1443635|NCT00215241|antidepressant
1443636|NCT00215241|antipsychotic
1443637|NCT00215241|anxiety
1443638|NCT00215241|trauma
1443639|NCT00215215|Vagus Nerve Stimulation Therapy
1443640|NCT00215215|Epilepsies, Partial
1443641|NCT00215215|Seizures
1443642|NCT00215215|Antiepileptic Drugs
1443643|NCT00215215|Refractory Partial Seizures
1443644|NCT00215202|Adrenocortical Cancer
1443645|NCT00215202|Iressa
1443646|NCT00215202|Adrenal Cancer
1443647|NCT00215189|health
1443648|NCT00215189|mental illness
1443649|NCT00215189|fitness
1443650|NCT00215176|atypical depression
1443651|NCT00215176|psychostimulants
1443652|NCT00215176|modafinil
1443653|NCT00215163|PTSD
1443654|NCT00215163|Anxiety
1443655|NCT00215163|CBT
1443656|NCT00215163|Exposure
1443657|NCT00215163|Paroxetine
1443658|NCT00215163|Paroxetine-CR
1443659|NCT00215150|anxiety disorder
1443660|NCT00215150|SAD
1443661|NCT00215150|ziprasidone
1443662|NCT00215150|sertraline
1443663|NCT00215150|antidepressant
1443664|NCT00215150|antipsychotic
1443665|NCT00215137|OCD
1443666|NCT00215137|SSRI
1443667|NCT00215137|escitalopram
1443668|NCT00215137|relapse
1443669|NCT00215111|childhood obesity
1443670|NCT00215111|weight management
1443671|NCT00215111|dietary interventions
1443672|NCT00215111|cardiovascular disease risk factors
1443673|NCT00215098|pediatric health
1443674|NCT00215098|cardiac
1443675|NCT00215098|congenital heart surgery
1443676|NCT00215098|post-operative chylous effusions
1443677|NCT00215098|heart defects
1443678|NCT00215098|children
1443679|NCT00215085|pediatric health
1443680|NCT00215085|cardiac
1443681|NCT00215085|cardiac tumor
1443682|NCT00215085|children
1443683|NCT00215072|Death after heart surgery
1443684|NCT00215072|surgical mortality
1443685|NCT00215072|post-operative mortality
1443686|NCT00215072|pediatric health
1443687|NCT00215072|cardiac
1443688|NCT00215059|angiogenic related growth factor
1443689|NCT00215046|vinblastine
1443690|NCT00215046|methotrexate
1443691|NCT00215033|Epstein-Barr virus
1443692|NCT00215033|pediatric health
1443693|NCT00215033|cardiac
1443694|NCT00215033|heart transplant
1443695|NCT00215033|lymphoproliferative disease
1443696|NCT00215033|post-transplant
1443697|NCT00215033|pediatric transplant
1443698|NCT00215020|Isoprostanes
1443699|NCT00214981|ADHD
1443700|NCT00214981|Attention Deficit/Hyperactivity Disorder
1443701|NCT00214929|Pulmonary Embolism
1443702|NCT00214929|Therapy
1443703|NCT00214929|Home Nursing
1443704|NCT00214929|Economics
1443709|NCT00214903|Postmenopause
1443710|NCT00214903|HRT
1443711|NCT00214890|HIV
1443712|NCT00214890|nucleoside pharmacology
1443713|NCT00214890|drug-drug interaction
1443714|NCT00214890|Treatment Naive
1443715|NCT00214890|Drug resistance
1443716|NCT00214890|Drug pharmacokinetics
1443717|NCT00214877|methylene blue for cognitive dysfunction in bipolar disorder
1443718|NCT00214864|Metastatic Breast Cancer
1443719|NCT00214864|Taxotere (docetaxel)
1443720|NCT00214864|Xeloda (capecitabine)
1443721|NCT00214851|Familial Cold Urticaria
1443722|NCT00214851|Kineret (anakinra)
1443723|NCT00214851|Interleukin 1 beta
1443724|NCT00214851|C-Reactive Protein
1443725|NCT00214851|Serum Amyloid A protein
1443726|NCT00214838|cancer, atiprimod
1443727|NCT00214812|HIV Seronegativity
1443728|NCT00214812|HIV
1443729|NCT00214786|Diabetes Mellitus
1443730|NCT00214786|Hypoglycemia
1443731|NCT00214786|Hyperglycemia
1443732|NCT00214760|Hip prosthesis
1443733|NCT00214760|Centralizer
1443734|NCT00214760|Uncemented
1443735|NCT00214747|HIV Seronegativity
1443736|NCT00214747|HIV
1443737|NCT00214708|Tuberculosis
1443738|NCT00214708|Screening
1443739|NCT00214708|Heaf
1443740|NCT00214708|BCG
1443741|NCT00214682|Depression
1443742|NCT00214682|Cognition
1443743|NCT00214682|Depressive disorder
1443744|NCT00214682|Mental health literacy
1443745|NCT00214682|Older adults
1443746|NCT00214682|Randomzed controlled trial
1443747|NCT00214669|ethnicity
1443748|NCT00214669|primary care
1443749|NCT00214669|education
1443750|NCT00214656|Cardiac surgical procedures
1443751|NCT00214656|Surgical blood loss
1443752|NCT00214656|Surgical haemostasis
1443753|NCT00214656|Factor VIIa
1443754|NCT00214656|Anaesthesia
1443755|NCT00214643|Malaria
1443756|NCT00214643|Fosmidomycin
1443757|NCT00214643|Clindamycin
1443758|NCT00214643|Chemotherapy
1443759|NCT00214643|Gabon
1443764|NCT00214591|Type 2 diabetes
1443765|NCT00214578|Schizophrenia
1443766|NCT00214565|Type 2 diabetes
1443767|NCT00214552|GERD
1443768|NCT00214552|Gastroesophageal reflux disease
1443769|NCT00214552|Asthma symptoms
1443770|NCT00214539|Asthma
1443771|NCT00214539|Bronchial Thermoplasty
1443772|NCT00214526|Asthma
1443773|NCT00214526|Bronchial Thermoplasty
1443774|NCT00214526|Airway Hyperresponsiveness
1443775|NCT00214487|Myopia Progression
1443776|NCT00214487|Myopia Control
1443777|NCT00214487|Bifocal Contact Lenses
1443778|NCT00214487|Esophoria
1443779|NCT00214487|Fixation Disparity
1443780|NCT00214474|Disease Management
1443781|NCT00214474|Health Literacy
1443782|NCT00214474|Telephone Care
1443783|NCT00214474|Group Medical Visits
1443784|NCT00214474|Type 2 Diabetes
1443785|NCT00214474|Access to Care
1443786|NCT00214474|Technology
1443787|NCT00214474|Language Barriers
1443788|NCT00214461|Clostridium difficile
1443789|NCT00214448|Multiple genetic conditions will be studied
1443790|NCT00214435|HIV infection
1443791|NCT00214435|AIDS
1443792|NCT00214435|Adherence
1443793|NCT00214435|MEMS caps
1443794|NCT00214435|Treatment Experienced
1443799|NCT00214383|pediatric asthma
1443800|NCT00214370|pediatric
1443801|NCT00214370|acute leukemia/lymphoma
1443802|NCT00214344|dying
1443803|NCT00214227|patient who will undergo definitive radiotherapy
1443919|NCT00213746|Myocardial Hibernation
1443804|NCT00214175|low grade gliomas and benign CNS lesions
1443805|NCT00214045|Bladder cancer surveillance
1443806|NCT00214045|Voiding dysfunction
1443807|NCT00214045|Cystoscopy
1443808|NCT00214032|lymphedema of the arm in breast cancer survivors
1443809|NCT00213980|bone mineral density
1443810|NCT00213980|postmenopausal women
1443811|NCT00213967|Influenza vaccine
1443812|NCT00213954|Nerve block anaesthesia
1443813|NCT00213954|ultrasound-guidance
1443814|NCT00213941|transient tachypnoea of the newborn
1443815|NCT00213941|surfactant deficiency
1443816|NCT00213941|persistant pulmonary hypertension of the neonate
1443817|NCT00213941|lung maturity tests
1443818|NCT00213915|L-arginine
1443819|NCT00213915|exercise capacity
1443820|NCT00213915|renal function
1443821|NCT00213915|nitric oxide
1443822|NCT00213915|exercise capacity using a maximal exercise test
1443823|NCT00213915|urinary elimination of a saline load using blood and urinary samples
1443824|NCT00213902|Heart failure
1443825|NCT00213902|Diastolic
1443826|NCT00213902|functionClonidine
1443827|NCT00213902|Left ventricular diastolic dysfunction with preserved ejection fraction
1443828|NCT00213889|Facial clefting
1443829|NCT00213889|twist
1443830|NCT00213889|craniofacial development genes
1443831|NCT00213889|Human cleft lip and palate
1443832|NCT00213889|cleft lip and palate
1443833|NCT00213876|Brain tumours
1443834|NCT00213876|oligodendrogliomas
1443835|NCT00213876|allelotyping
1443836|NCT00213876|SAGE
1443837|NCT00213876|Presence of molecular abnormalities statistically linked to survival or response to chemotherapy
1443838|NCT00213863|porous titanium implants
1443839|NCT00213863|thyroplasty
1443840|NCT00213863|vocal cord paralysis
1443841|NCT00213863|male or female more than 18 years old
1443842|NCT00213850|Interrupter technique
1443843|NCT00213850|Respiratory resistance
1443844|NCT00213850|Normal adults
1443845|NCT00213837|porous titanium implants
1443846|NCT00213837|thyroplasty
1443847|NCT00213837|vocal cord paralysis
1443848|NCT00213837|male or female more than 18 years old
1443849|NCT00213824|Amyotrophic lateral sclerosis
1443850|NCT00213824|Nogo gene
1443851|NCT00213824|reticulon genes
1443852|NCT00213811|Bardet-Biedl syndrome, retinitis pigmentosa, obesity, genes
1443853|NCT00213798|Lung cancer
1443854|NCT00213798|plasma DNA
1443855|NCT00213798|allelotyping
1443856|NCT00213798|follow-up
1443857|NCT00213798|Prospective Study
1443858|NCT00213798|Non-Small Cell Lung Cancer
1443859|NCT00213798|Small Cell Lung Cancer
1443860|NCT00212706|ONO-8025, KRP-197, overactive bladder, antimuscarinic
1443861|NCT00212693|ONO-2506PO, Parkinson's disease
1443862|NCT00212680|ONO-1101,Landiolol Hydrochloride, Postoperative, Supraventricular Tachyarrhythmia
1443863|NCT00212667|ONO-5920, osteoporosis, bisphosphonate
1443864|NCT00212654|ONO-1101
1443865|NCT00212654|Landiolol Hydrochloride
1443866|NCT00212654|Postoperative
1443867|NCT00212654|supraventricular tachyarrhythmia
1443868|NCT00212628|ONO-5920
1443869|NCT00212628|osteoporosis
1443870|NCT00212628|bisphosphonate
1443871|NCT00212615|Colorectal neoplasm
1443872|NCT00212615|Capecitabine (Xeloda)
1443873|NCT00212615|Oxaliplatin (Eloxatin)
1443874|NCT00212615|Advanced disease
1443875|NCT00212615|Metastatic disease
1443876|NCT00212615|First-line treatment
1443877|NCT00212615|Phase II study
1443878|NCT00212602|ONO-7436, Aprepitant, Vomiting, Nausea
1443879|NCT00212589|Patients preference
1443880|NCT00212589|Colorectal cancer
1443881|NCT00212589|Capecitabine
1443882|NCT00212589|Fluorouracil + folinic acid
1443883|NCT00212589|Cross-over study
1443884|NCT00212576|Child development
1443885|NCT00212576|Language Development
1443886|NCT00212576|Parenting
1443887|NCT00212537|Asthma and normal
1443888|NCT00212485|Hemophilia
1443889|NCT00212485|Factor Deficiency
1443890|NCT00212485|synovitis
1443891|NCT00212485|sonogram
1443892|NCT00212459|Bleeding logs
1443893|NCT00212459|Factor Infusions
1443894|NCT00212446|Tocolysis
1443895|NCT00212446|Electrical Pacemaker
1443896|NCT00212433|colorectal neoplasia
1443897|NCT00212433|CT colonography
1443898|NCT00212433|faecal tagging
1443899|NCT00212420|fistula; enterocutaneous; nutrition;enteral; parenteral; TPN
1443900|NCT00212407|Cord blood transplantation
1443901|NCT00212407|bone marrow transplantation
1443902|NCT00213785|AreET1
1443903|NCT00213785|ANP
1443904|NCT00213785|BNP pronostic markers of stroke
1443905|NCT00213772|Porphyria cutanea tarda
1443906|NCT00213772|hepatitis C
1443907|NCT00213772|hemochromatosis
1443908|NCT00213759|neutropenia
1443909|NCT00213759|prematurity
1443910|NCT00213759|nosocomial infection
1443911|NCT00213759|G-CSF
1443912|NCT00213746|Coronary Arteriosclerosis
1443913|NCT00213746|Heart Failure, Congestive
1443914|NCT00213746|Myocardial Infarction
1443915|NCT00213746|Myocardial Revascularization
1443916|NCT00213746|Tomography, Emission-Computed, Single-Photon
1443917|NCT00213746|Dobutamine
1443918|NCT00213746|Myocardial Stunning
1443920|NCT00213733|Lung cancer patients
1443921|NCT00213733|non-small cell lung cancer
1443922|NCT00213733|molecular marker
1443923|NCT00213733|lymph node completed resected
1443924|NCT00213733|Lung cancer samples and paired lymph node resected
1443925|NCT00213720|Hyperthyroidism
1443926|NCT00213720|atrial fibrillation
1443927|NCT00213720|quality of life
1443928|NCT00213720|radioiodine treatment
1443929|NCT00213707|Dendritic cells
1443930|NCT00213707|liver transplantation
1443931|NCT00213707|hepatitis C virus
1443932|NCT00213707|quasispecies
1443933|NCT00213707|virological markers
1443934|NCT00213707|biochemical markers
1443935|NCT00213707|immunological markers
1443936|NCT00213707|clinical markers
1443937|NCT00213681|Pulmonary edema, respiratory failure, pressure support ventilation, continuous positive pressure
1443938|NCT00213668|glutamine
1443939|NCT00213668|premature neonate
1443940|NCT00213668|gastric emptying
1443941|NCT00213642|Technetium Tc 99m Mertiatide
1443942|NCT00213642|Radionuclide Imaging
1443943|NCT00213642|Cisplatin
1443944|NCT00213642|Kidney failure
1443945|NCT00213642|Drug Toxicity
1443946|NCT00213642|Cancer
1443947|NCT00213629|myositis
1443948|NCT00213629|cDNA arrays
1443949|NCT00213629|Genes, T-Cell Receptor beta
1443950|NCT00213616|bilateral vocal cord paralysis
1443951|NCT00213616|reinnervation
1443952|NCT00213616|phrenic nerve
1443953|NCT00213603|precancerous lesions
1443954|NCT00213603|Lung cancer
1443955|NCT00213603|Follow-up
1443956|NCT00213603|Randomized study
1443957|NCT00213603|Autofluorescence endoscopy
1443958|NCT00213603|precancerous conditions
1443959|NCT00213577|overactive neurogenic bladder
1443960|NCT00213499|Mechanical ventilation
1443961|NCT00213499|Weaning
1443962|NCT00213499|Noninvasive ventilation
1443963|NCT00213499|Acute on chronic respiratory failure
1443964|NCT00213473|acquired haemophilia
1443965|NCT00212394|Tourniquet
1443966|NCT00212394|paresis
1443967|NCT00212381|cervical dysplasia, diindolylmethane, pap smear
1443968|NCT00210665|Sarcoma
1443969|NCT00210665|Soft tissue sarcoma
1443970|NCT00210665|Standard care
1443971|NCT00210665|Trabectedin
1443972|NCT00210665|Antitumor agent
1443973|NCT00210665|Safety
1443974|NCT00210652|Epilepsy
1443975|NCT00210652|Refractory partial epilepsy
1443976|NCT00210652|seizure disorder
1443977|NCT00210652|antiepileptic drugs
1443978|NCT00213434|prospective
1443979|NCT00213434|randomized
1443980|NCT00213434|polysomnography
1443981|NCT00213434|orthodontic appliance, removable
1443982|NCT00213408|Arrhythmia
1443983|NCT00213408|atrial flutter
1443984|NCT00213408|catheter ablation
1443985|NCT00213395|Noninvasive ventilation
1443986|NCT00213395|Acute hypercapnic respiratory failure
1443987|NCT00213395|Cephalic mask
1443988|NCT00213395|Facial Mask
1443989|NCT00213382|swallowing
1443990|NCT00213382|ventilation
1443991|NCT00213382|pressure
1443992|NCT00213382|EMG
1443993|NCT00213382|cortical magnetic stimulation
1443994|NCT00213382|Brain Mapping
1443995|NCT00213369|aspiration
1443996|NCT00213369|stroke
1443997|NCT00213369|motor evoked potential
1443998|NCT00213369|cortical evoked potential
1443999|NCT00213369|neuromodulation
1444000|NCT00213356|spinal cord injuries - anal sphincter - evoked potentials
1444001|NCT00213343|aspiration
1444002|NCT00213343|phrenic nerve
1444003|NCT00213343|magnetic stimulation
1444004|NCT00213330|cerebral activity
1444005|NCT00213330|rectal distension
1444006|NCT00213330|colitis ulcerative
1444007|NCT00213330|irritable bowel syndrome
1444008|NCT00213330|magnetic resonance imaging
1444009|NCT00213317|sacral magnetic stimulation
1444010|NCT00213317|fecal incontinence
1444011|NCT00213317|constipation
1444012|NCT00213304|organ transplantation
1444013|NCT00213304|immunosuppression
1444014|NCT00213304|vaccine
1444015|NCT00213304|varicella
1444016|NCT00213304|pediatrics
1444017|NCT00213291|chronic kidney failure
1444018|NCT00213291|darbepoetin
1444019|NCT00213291|pediatrics
1444020|NCT00213291|anemia
1444021|NCT00213278|glioma
1444022|NCT00213278|brain tumour
1444023|NCT00213278|cancer
1444024|NCT00213278|pediatrics
1444025|NCT00213278|vinblastine sulfate
1444026|NCT00213265|organ transplantation
1444027|NCT00213265|immunosuppression
1444028|NCT00213265|vaccine
1444029|NCT00213265|pneumococcal conjugate vaccine
1444030|NCT00213265|pediatrics
1444031|NCT00213252|asthma, randomized trial, pediatrics
1444032|NCT00213239|spinal puncture
1444033|NCT00213239|remifentanil
1444034|NCT00213239|propofol
1444035|NCT00213239|anesthesia
1444036|NCT00213239|dose finding
1444037|NCT00213239|pediatrics
1444038|NCT00213226|bronchiolitis
1444039|NCT00213226|pediatrics
1444040|NCT00213226|corticosteroids
1444041|NCT00213213|sucrose
1444042|NCT00213213|analgesia
1444043|NCT00213213|pain
1444044|NCT00213213|neonates
1444045|NCT00213213|diabetes
1444046|NCT00213200|pain
1444047|NCT00213200|analgesia
1444048|NCT00213200|morphine
1444049|NCT00213200|amethocaine
1444050|NCT00213200|neonate
1444051|NCT00213187|Juvenile Rheumatoid Arthritis,
1444052|NCT00213187|Randomized Control Trial,
1444053|NCT00213187|attention placebo,
1444054|NCT00213187|exercise testing,
1444055|NCT00213187|aerobics,
1444056|NCT00213187|Qi Gong,
1444057|NCT00213187|exercise video,
1444058|NCT00213187|activities of daily living,
1444059|NCT00213187|quality of life,
1444060|NCT00213187|economy of walking,
1444061|NCT00213187|fitness
1444062|NCT00213187|pediatrics
1444063|NCT00213174|pediatrics
1444064|NCT00213174|injury
1444065|NCT00213174|arm fractures
1444066|NCT00213174|trauma
1444067|NCT00213174|playground surfaces
1444068|NCT00213174|fractures
1444069|NCT00213161|anemia
1444070|NCT00213161|iron deficiency
1444071|NCT00213161|iron drops
1444072|NCT00213161|iron supplement
1444073|NCT00213161|malnutrition
1444074|NCT00213161|pediatrics
1444202|NCT00212303|hypertension
1444075|NCT00213122|alpha-glucosidase inhibitor,Insulin
1444076|NCT00211666|Hypertension
1444077|NCT00211666|blood pressure
1444078|NCT00211666|self management
1444079|NCT00211666|nurse management
1444080|NCT00211666|racial disparities
1444081|NCT00211666|cardiovascular disease
1444082|NCT00211653|Kidney failure
1444083|NCT00211653|Thoracic surgery
1444084|NCT00211653|Acetylcysteine
1444085|NCT00210639|Musculoskeletal Diseases
1444086|NCT00210639|Musculoskeletal Disorders
1444087|NCT00210639|Childhood Disease
1444088|NCT00210639|Bone Diseases
1444089|NCT00210639|Joint Diseases
1444090|NCT00210639|Levofloxacin
1444091|NCT00210639|Quinolones
1444092|NCT00210639|Bacterial infections
1444093|NCT00210626|Anemia, erythropoetin, Epoetin alfa, erythropoetin recombinant, Critical care, critical illness, intensive care
1444094|NCT00213109|alpha-glucosidase inhibitor,Insulin
1444095|NCT00213096|Contraceptive agents
1444096|NCT00213096|female
1444097|NCT00213083|Microbicide
1444098|NCT00213083|HIV
1444099|NCT00213083|AIDS
1444100|NCT00213083|STIs
1444101|NCT00213083|STDs
1444102|NCT00213083|Efficacy
1444103|NCT00213083|HSV
1444104|NCT00213083|Women
1444105|NCT00213083|South Africa
1444106|NCT00213083|seroconversion
1444107|NCT00213083|condom
1444108|NCT00213083|safe-sex
1444109|NCT00213083|vaginal intercourse
1444110|NCT00213083|prevention
1444111|NCT00213083|HIV Seronegativity
1444112|NCT00213070|alpha-glucosidase inhibitor,Insulin
1444113|NCT00213057|Microbicides
1444114|NCT00213057|HIV prevention
1444115|NCT00213057|sexually transmitted infections
1444116|NCT00213057|carrageenan
1444117|NCT00213057|sero-concordant couples
1444118|NCT00213057|HIV Seronegativity
1444119|NCT00213057|HIV
1444120|NCT00213044|Microbicides
1444121|NCT00213044|HIV prevention
1444122|NCT00213044|HIV-positive women
1444123|NCT00213044|safety
1444124|NCT00213044|carrageenan
1444125|NCT00213044|HIV
1444126|NCT00213031|microbicides
1444127|NCT00213031|HIV prevention
1444128|NCT00213031|sexually transmitted infections
1444129|NCT00213031|female-initiated protection
1444130|NCT00213031|carrageenan
1444131|NCT00213031|expanded safety trial
1444132|NCT00213031|HIV Seronegativity
1444133|NCT00213031|HIV
1444134|NCT00213018|microbicides
1444135|NCT00213018|HIV prevention
1444136|NCT00213018|sexually transmitted infections
1444137|NCT00213018|female-initiated protection
1444138|NCT00213018|carrageenan
1444139|NCT00213018|expanded safety trial
1444140|NCT00213018|HIV Seronegativity
1444141|NCT00213018|HIV
1444142|NCT00213005|Microbicides
1444143|NCT00213005|HIV prevention
1444144|NCT00213005|HIV positive
1444145|NCT00213005|carrageenan
1444146|NCT00213005|safety trial
1444147|NCT00213005|Treatment Experienced
1444148|NCT00213005|HIV
1444149|NCT00212992|defibrillation
1444150|NCT00212992|ventricular fibrillation
1444151|NCT00212992|heart arrest
1444152|NCT00212979|glomerular filtration rate
1444153|NCT00212979|cystatin C
1444154|NCT00212979|creatinine
1444155|NCT00212966|psychosocial
1444156|NCT00212953|Chest Pain,
1444157|NCT00212953|Shortness of breath,
1444158|NCT00212953|Injury,
1444159|NCT00212953|Trauma
1444160|NCT00212940|Treatment Naive
1444161|NCT00212940|HIV
1444162|NCT00212901|Diabetes
1444163|NCT00212901|Proteinuria
1444164|NCT00212901|Angiotensin converting enzyme inhibitors
1444165|NCT00212901|Angiotensin receptor antagonists
1444166|NCT00212888|HIV
1444167|NCT00212888|Vaccination
1444168|NCT00212875|Chronic Kidney disease
1444169|NCT00212875|anemia
1444170|NCT00212862|Anemia
1444171|NCT00212862|Cancer
1444172|NCT00212862|Epoetin alfa
1444173|NCT00212862|Darbepoetin alfa
1444174|NCT00212862|Registry
1444175|NCT00212849|Articular Cartilage Lesions
1444176|NCT00212849|Patellar lesions
1444177|NCT00212849|Trochlear lesions
1444178|NCT00212849|Patellofemoral joint
1444179|NCT00212849|Carticel
1444180|NCT00212849|Autologous Chondrocyte Implantation
1444181|NCT00212823|Migraine
1444182|NCT00212810|Migraine
1444183|NCT00212810|Headache
1444184|NCT00212810|Migraine Headache
1444185|NCT00212758|Short stature
1444186|NCT00212758|children
1444187|NCT00212758|kidney failure, chronic
1444188|NCT00212758|Growth
1444189|NCT00212745|Behavior Therapy
1444190|NCT00212745|Relaxation Techniques
1444191|NCT00212732|ONO-8025, KRP-197, overactive bladder, antimuscarinic
1444192|NCT00212719|ONO-5920, osteoporosis, bisphosphonate
1444193|NCT00212329|Type 1 Diabetes
1444194|NCT00212329|Juvenile Onset Diabetes
1444195|NCT00212329|Insulin Dependent Diabetes
1444196|NCT00212329|T1D
1444197|NCT00212316|Huntington's Disease
1444198|NCT00212316|phenylbutyrate
1444199|NCT00212316|HDAC inhibitors
1444200|NCT00212316|transcription
1444201|NCT00212303|type 2 diabetes
1444203|NCT00212303|exercise training
1444204|NCT00212303|cardiac, peripheral
1444205|NCT00212303|body composition
1444206|NCT00212303|physical fitness
1444207|NCT00212303|inflammation
1444208|NCT00212290|impaired glucose tolerance
1444209|NCT00212264|urinary incontinence
1444210|NCT00212264|therapy
1444211|NCT00212264|prostatectomy
1444212|NCT00212264|prostate cancer
1444213|NCT00212251|obesity
1444214|NCT00212251|postpartum period
1444215|NCT00212251|exercise
1444216|NCT00212251|diet
1444217|NCT00212251|motivation
1444218|NCT00212238|obesity
1444219|NCT00212238|weight loss
1444220|NCT00212238|Internet
1444221|NCT00212238|cognitive behavior therapy
1444222|NCT00212238|computer assisted patient care
1444223|NCT00212238|human therapy evaluation
1444224|NCT00212238|physical activity
1444225|NCT00212238|clinical trial
1444226|NCT00212238|nutrient intake activity
1444227|NCT00212238|outcomes research
1444228|NCT00212238|personal log /diary
1444229|NCT00212238|reinforcer
1444230|NCT00212238|self care
1444231|NCT00212238|social support network
1444232|NCT00212238|weight control
1444233|NCT00212238|behavioral /social science research tag
1444234|NCT00212238|clinical research
1444235|NCT00212238|human subject
1444236|NCT00212238|questionnaire
1444237|NCT00212225|gastric disease
1444238|NCT00212225|H. pylori
1444239|NCT00212225|children
1444240|NCT00212225|Helicobacter pylori
1444241|NCT00212225|child
1444242|NCT00212225|epidemiology
1444243|NCT00212212|selenium supplements
1444244|NCT00212212|selenate
1444245|NCT00212212|selenomethionine
1444246|NCT00212212|biomarkers
1444247|NCT00212212|plasma selenium concentration
1444248|NCT00212212|plasma glutathione peroxidase
1444249|NCT00212212|selenoprotein P
1444250|NCT00212199|Obesity Treatment
1444251|NCT00212199|Effectiveness of weight management treatment
1444252|NCT00212199|Counseling for weight management
1444253|NCT00212173|Adolescent
1444254|NCT00212173|Weight Management
1444255|NCT00212173|Obesity Treatment
1444256|NCT00212173|Behavioral Treatment
1444257|NCT00212147|cobalamin
1444258|NCT00212147|anesthesia
1444259|NCT00212147|cognition
1444260|NCT00212134|cataract surgery
1444261|NCT00212134|intraocular lens
1444262|NCT00212134|contact lens
1444263|NCT00212134|infants
1444264|NCT00212134|aphakia
1444265|NCT00212121|breast cancer
1444266|NCT00212121|radiotherapy
1444267|NCT00212121|microarrays
1444268|NCT00212108|celecoxib, NPC, gefitinib
1444269|NCT00212095|breast cancer
1444270|NCT00212095|docetaxel
1444271|NCT00212095|gene expression
1444272|NCT00212095|proteomics
1444273|NCT00212082|breast cancer
1444274|NCT00212082|chemotherapy response
1444275|NCT00212082|gene expression profiles
1444276|NCT00212082|proteomics
1444277|NCT00212069|breast cancer
1444278|NCT00212069|serum proteomics
1444279|NCT00212069|gemcitabine
1444280|NCT00212069|carboplatin
1444281|NCT00212069|chemotherapy sensitivity
1444282|NCT00212056|Acute myocardial infarction
1444283|NCT00212056|Atrial natriuretic peptide
1444284|NCT00212056|Data mining
1444285|NCT00212056|Randomized clinical trial
1444286|NCT00212056|SNPs
1444287|NCT00212043|randomised phase II trial gemcitabine and carboplatin
1444288|NCT00212030|Acute myocardial infarction
1444289|NCT00212030|Data mining
1444290|NCT00212030|Nicorandil
1444291|NCT00212030|Randomized clinical trial
1444292|NCT00212030|SNPs
1444293|NCT00212017|IGT
1444294|NCT00212017|Myocardial Infarction
1444295|NCT00212017|alpha-glucosidase inhibitor
1444296|NCT00212017|re-infarction prevention
1444297|NCT00212004|diabetes mellitus
1444298|NCT00212004|myocardial infarction
1444299|NCT00212004|pioglitazone
1444300|NCT00211978|PhosLo (Calcium acetate)
1444301|NCT00211965|Knee replacement surgery
1444302|NCT00211965|hip replacement surgery
1444303|NCT00211965|nosocomial infections
1444304|NCT00211965|Arthroplasty
1444305|NCT00211939|PhosLo (Calcium acetate)
1444306|NCT00211939|Renagel (sevelamer, polyallylamine HCL)
1444307|NCT00211939|kidney dialysis
1444308|NCT00211939|hyperphosphatemia
1444309|NCT00211939|Kidney failure
1444310|NCT00211926|vaccine
1444311|NCT00211926|Staphylococcus aureus vaccine
1444312|NCT00211887|Multiple Sclerosis
1444313|NCT00211887|Clinical trial
1444314|NCT00211887|treatment trial
1444315|NCT00211887|autoimmune disease
1444316|NCT00211887|Relapsing Remitting
1444317|NCT00211887|MS Treatment
1444318|NCT00211887|interferon beta-1a
1444319|NCT00211887|glatiramer acetate
1444320|NCT00211874|Congestive heart failure
1444321|NCT00211874|nurse management
1444322|NCT00211874|effectiveness trial
1444323|NCT00211874|quality improvement
1444324|NCT00211874|minority communities
1444325|NCT00211874|disease management
1444326|NCT00211848|Chemical Compounds-drugs
1444327|NCT00211848|Human Subjects- adults
1444328|NCT00211848|Gastrointestinal System-liver
1444329|NCT00211848|Pathology
1444330|NCT00211835|TBI
1444331|NCT00211835|traumatic brain injury
1444332|NCT00211835|depression
1444333|NCT00211835|cognitive behavioral therapy
1444334|NCT00211835|supportive psychotherapy
1444335|NCT00211835|psychotherapy
1444336|NCT00211822|Pathological Gambling
1444337|NCT00211822|Obsessive-Compulsive Disorder
1444338|NCT00211822|Go No-go
1444339|NCT00211822|Monetary incentives delay
1444340|NCT00211822|fMRI
1444341|NCT00211809|Body Dysmorphic Disorder
1444342|NCT00211809|SRIs
1444343|NCT00211809|Cognitive Behavioral Therapy
1444344|NCT00211796|autism
1444345|NCT00211796|divalproex sodium ER
1444346|NCT00211796|aggression
1444347|NCT00211796|irritability
1444348|NCT00211783|autism
1444349|NCT00211783|fMRI
1444350|NCT00211783|response inhibition
1444351|NCT00211783|face processing
1444352|NCT00211783|linguistic processing
1444353|NCT00211770|Autism
1444354|NCT00211770|Functional Behavioral Assessment
1444355|NCT00211770|Citalopram
1444356|NCT00211757|autism
1444357|NCT00211757|aggression
1444358|NCT00211757|irritability
1444359|NCT00211757|divalproex sodium
1444360|NCT00211744|OCD
1444361|NCT00211744|Obsessive-Compulsive Disorder
1444362|NCT00211744|OCD treatment
1444363|NCT00211731|Acute stroke
1444364|NCT00211731|recurrent stroke preventive measures
1444365|NCT00211731|racial disparities
1444366|NCT00211718|shoulder pain
1444367|NCT00211718|arthritis
1444368|NCT00211718|intra-articular botulinum toxin a
1444369|NCT00211718|joint pain
1444370|NCT00211705|Hyperlipidemia
1444371|NCT00211705|coronary heart disease
1444372|NCT00211705|prevention
1444373|NCT00211705|stroke
1444374|NCT00211705|pravastatin
1444375|NCT00211692|Hepatitis C
1444376|NCT00211692|interferon alfa
1444377|NCT00211692|ribavirin
1444378|NCT00211692|interferon alfacon-1
1444379|NCT00211692|antiviral therapy
1444380|NCT00211679|Joint pain
1444381|NCT00211679|Knee Pain
1444382|NCT00211679|Arthritis
1444383|NCT00211679|Intra-articular Botulinum Toxin Type A
1444384|NCT00211614|Obstructive Sleep Apnea
1444385|NCT00211614|Gastroesophageal Reflux
1444386|NCT00211614|Proton Pump Inhibitor
1444387|NCT00211614|Lansoprazole (Prevacid)
1444388|NCT00211614|Quality of Life
1444389|NCT00211588|cognition
1444390|NCT00211562|weight gain
1444391|NCT00211562|weight gain supplementation
1444392|NCT00211562|antioxidants
1444393|NCT00211562|olanzapine
1444394|NCT00211549|Osteoarthritis
1444395|NCT00211536|Diabetes
1444396|NCT00211536|Implantable Insulin Pump
1444397|NCT00211536|Intraperitoneal Insulin Delivery
1444398|NCT00211523|acne
1444399|NCT00211523|acne vulgaris
1444400|NCT00211523|MBI 226
1444401|NCT00211523|Propionibacterium acnes
1444402|NCT00211523|lesion counts
1444403|NCT00211523|lesions
1444404|NCT00211523|inflammatory
1444405|NCT00211523|non-inflammatory
1444406|NCT00211523|topical
1444407|NCT00211510|Diabetes
1444408|NCT00211510|Continuous Glucose Monitoring
1444409|NCT00211510|Glycemic Control
1444410|NCT00211497|acne vulgaris
1444411|NCT00211497|acne
1444412|NCT00211497|Propionibacterium acnes
1444413|NCT00211497|topical
1444414|NCT00211497|inflammatory
1444415|NCT00211497|non-inflammatory
1444416|NCT00211497|lesion counts
1444417|NCT00211497|lesions
1444418|NCT00211458|Age-Related Macular Degeneration
1444419|NCT00211419|Exudative Age-Related Macular Degeneration
1444420|NCT00211419|AMD
1444421|NCT00211380|cognition
1444422|NCT00211380|schizophrenia
1444423|NCT00211380|schizoaffective disorder
1444424|NCT00211367|Radiation Retinopathy
1444425|NCT00211341|Pregnancy
1444426|NCT00211341|Mortality
1444427|NCT00211341|Maternal
1444428|NCT00211341|Vitamin A
1444429|NCT00211302|Cognition
1444430|NCT00211302|Schizophrenia
1444431|NCT00211302|Schizoaffective disorder
1444432|NCT00211289|Educational Interventions
1444433|NCT00211289|Heart Failure
1444434|NCT00211289|Compliance
1444435|NCT00211263|Bipolar Disorder
1444436|NCT00211250|Depakote Er and Valproic Acid
1444437|NCT00211237|Balloon Kyphoplasty
1444438|NCT00211237|Cancer
1444439|NCT00211237|Vertebral Compression Fracture
1444440|NCT00211237|Back Pain
1444441|NCT00211237|Spine
1444442|NCT00211224|multiple system atrophy
1444443|NCT00211224|progressive supranuclear palsy
1444444|NCT00211224|riluzole
1444445|NCT00211224|MSA
1444446|NCT00211224|PSP
1444447|NCT00211211|Osteopenia
1444448|NCT00211211|Osteoporosis
1444449|NCT00211211|Multiple Myeloma
1444450|NCT00211211|Osteolytic Metastatic Tumors
1444451|NCT00211211|Vertebral Compression Fracture
1444452|NCT00211211|Back Pain
1444453|NCT00211211|Spine
1444454|NCT00211198|Cutaneous
1444455|NCT00211198|T-cell lymphoma
1444456|NCT00211198|ONTAK
1444457|NCT00211198|CD25
1444458|NCT00211172|Acute Myocardial Infarction (AMI)
1444459|NCT00211172|Heart Attack
1444460|NCT00211172|Adherence
1444461|NCT00211172|Beta-blocker
1444462|NCT00211172|Behavior change
1444463|NCT00211159|Alzheimer's disease
1444464|NCT00211159|Omega-3 fatty acid
1444465|NCT00211159|Dietary supplementation
1444466|NCT00211159|Cognition
1444467|NCT00211159|Safety
1444468|NCT00211146|Anemia, erythropoetin, PROCRIT, deep vein thrombosis, thrombovascular event
1444469|NCT00211133|Anemia
1444470|NCT00211133|Breast Cancer
1444471|NCT00211133|Breast Tumor
1444472|NCT00211133|Quality of Life
1444473|NCT00211133|Women
1444474|NCT00211133|Female
1444475|NCT00211133|Chemotherapy
1444476|NCT00211133|Hemoglobin
1444477|NCT00211133|Survival
1444478|NCT00211133|Epoetin
1444479|NCT00211133|Epoetin alfa
1444480|NCT00211133|erythropoietin
1444481|NCT00211120|Anemia
1444482|NCT00211120|Low Blood Count
1444483|NCT00211120|Chronic Kidney Failure
1444484|NCT00211120|Chronic Kidney Disease
1444485|NCT00211107|dapoxetine
1444486|NCT00211107|rapid ejaculation
1444487|NCT00211107|premature ejaculation
1444488|NCT00211107|ejaculation
1444489|NCT00211107|sexual dysfunction
1444490|NCT00211107|orgasmic disorder
1444491|NCT00211107|sexual intercourse
1444492|NCT00211094|dapoxetine
1444493|NCT00211094|premature ejaculation
1444494|NCT00211094|ejaculation
1444495|NCT00211094|sexual dysfunction
1444496|NCT00211094|orgasmic disorder
1444497|NCT00211094|sexual intercourse
1444498|NCT00211081|Congenital Heart Disease
1444499|NCT00211081|Spironolactone
1444500|NCT00211081|>17 years old
1444501|NCT00211081|undergone Fontan procedure
1444502|NCT00211081|endothelial function
1444503|NCT00211068|Pure red-cell aplasia
1444504|NCT00211068|Chronic kidney failure
1444505|NCT00211068|Epoetin alfa (Eprex)
1444506|NCT00211068|Erythropoietin
1444507|NCT00211068|Kidney disease
1444508|NCT00211068|Anemia
1444509|NCT00211055|Critically Ill
1444510|NCT00211055|Intensive Care Unit
1444511|NCT00211055|Blood transfusion
1444512|NCT00211055|Blood loss
1444513|NCT00211055|Pediatric
1444514|NCT00211055|Children
1444515|NCT00211055|Anemia, Pediatric Intensive Care Unit
1444516|NCT00211055|Hemoglobin
1444517|NCT00211055|Transfusion
1444518|NCT00211042|Pure red-cell aplasia
1444519|NCT00211042|Anemia
1444520|NCT00211042|Red blood cells
1444521|NCT00211042|Epoetin alfa (Eprex)
1444522|NCT00211042|Anti-erythropoietin antibodies
1444523|NCT00211042|Recombinant human erythropoietin
1444524|NCT00211029|Anemia, Hemoglobin, Red Blood Cells, Epoetin alfa
1444525|NCT00211029|Epoetin
1444526|NCT00211029|erythropoietin
1444527|NCT00211029|Red Cell Aplasia, Pure Red Cell Aplasia
1444528|NCT00211029|Chronic Renal Failure
1444529|NCT00211029|Kidney Failure
1444530|NCT00211016|Ventilator-Associated Pneumonia
1444531|NCT00211003|Hospital-Acquired Pneumonia
1444532|NCT00211003|Mechanical Ventilation
1444533|NCT00210990|Complicated Urinary Tract Infections
1444534|NCT00210990|Pyelonephritis
1444535|NCT00210977|Anemia
1444536|NCT00210977|Erythropoietin
1444537|NCT00210977|Epoetin alfa
1444538|NCT00210977|Erythropoietin receptor agonist (ERA) therapy
1444539|NCT00210977|Anti-erythropoietin antibodies (anti-EPO Ab)
1444540|NCT00210977|Recombinant human erythropoietin
1444541|NCT00210977|Pure red cell aplasia
1444542|NCT00210977|Darbepoetin
1444543|NCT00210964|Ceftobiprole medocaril
1444544|NCT00210964|Nosocominal Pneumonia
1444545|NCT00210964|Ventilator-Associated Pneumonia
1444546|NCT00210964|Cephalosporins
1444674|NCT00210561|Acute Low Back Pain
1444547|NCT00210964|Methicillin-Resistant Staphylococcus Aureus
1444548|NCT00210951|Epoetin alfa
1444549|NCT00210951|Erythropoietin
1444550|NCT00210951|Red Cell Aplasia, Pure
1444551|NCT00210951|Chronic Renal Failure
1444552|NCT00210938|Complicated Intra-Abdominal Infections
1444553|NCT00210938|Appendicitis
1444554|NCT00210938|Cholecystitis
1444555|NCT00210938|Peritonitis
1444556|NCT00210925|alcoholism
1444557|NCT00210925|alcohol dependence
1444558|NCT00210925|medication treatment.
1444559|NCT00210912|prevention
1444560|NCT00210912|Migraine
1444561|NCT00210912|chronic
1444562|NCT00210912|headache
1444563|NCT00210899|Complicated Skin Infections
1444564|NCT00210899|Infectious Skin Diseases
1444565|NCT00210899|Bacterial Skin Diseases
1444566|NCT00210899|Staphylococcal Skin Infections
1444567|NCT00210899|Cephalosporin
1444568|NCT00210886|complicated urinary tract infection
1444569|NCT00210886|urinary tract infection
1444570|NCT00210886|acute pyelonephritis
1444571|NCT00210886|pyelonephritis
1444572|NCT00210886|kidney infection
1444573|NCT00210886|bladder infection
1444574|NCT00210873|Migraine
1444575|NCT00210873|headache
1444576|NCT00210873|chronic
1444577|NCT00210873|prevention
1444578|NCT00210860|chronic
1444579|NCT00210860|headache
1444580|NCT00210860|prevention
1444581|NCT00210860|Migraine
1444582|NCT00210847|peripheral neuropathy
1444583|NCT00210847|Diabetic neuropathy
1444584|NCT00210847|pain
1444585|NCT00210847|diabetes
1444586|NCT00210847|extremities
1444587|NCT00210847|neuropathy
1444588|NCT00210847|diabetic
1444589|NCT00210834|PROCRIT, Erythropoietin, Epoetin alfa, Hemoglobin level
1444590|NCT00210821|migraine
1444591|NCT00210821|headache
1444592|NCT00210821|analgesics
1444593|NCT00210821|prophylaxis
1444594|NCT00210821|prevention
1444595|NCT00210808|Binge-Eating Disorder
1444596|NCT00210808|medication treatment
1444597|NCT00210808|obesity
1444598|NCT00210808|bingeing
1444599|NCT00210795|Anemia
1444600|NCT00210795|Subcutaneous injection
1444601|NCT00210795|PROCRIT
1444602|NCT00210795|Erythropoietin
1444603|NCT00210795|Epoetin Alfa
1444604|NCT00210795|Hemoglobin Level
1444605|NCT00210795|Elderly
1444606|NCT00210782|epilepsy
1444607|NCT00210782|seizures
1444608|NCT00210782|epileptic seizures
1444609|NCT00210782|complex partial seizures
1444610|NCT00210782|generalized tonic-clonic seizures
1444611|NCT00210769|schizophrenia
1444612|NCT00210769|extended release
1444613|NCT00210769|oral administration
1444614|NCT00210769|antipsychotic agents
1444615|NCT00210769|dementia praecox
1444616|NCT00210769|mental disorders
1444617|NCT00210769|paliperidone
1444618|NCT00210769|PANSS
1444619|NCT00210756|Anemia
1444620|NCT00210756|pharmacokinetics
1444621|NCT00210756|erythropoetin
1444622|NCT00210756|Epoetin alfa
1444623|NCT00210756|erythropoetin recombinant
1444624|NCT00210756|Critical care
1444625|NCT00210756|critical illness, intensive care,
1444626|NCT00210743|Anemia
1444627|NCT00210743|chronic kidney disease
1444628|NCT00210743|erythropoetin, Epoetin alfa
1444629|NCT00210743|erythropoetin recombinant
1444630|NCT00210743|pre-dialysis
1444631|NCT00210730|Anemia
1444632|NCT00210730|Neoplasm
1444633|NCT00210730|Hemoglobin Level
1444634|NCT00210717|schizophrenia
1444635|NCT00210717|intramuscular injection
1444636|NCT00210717|antipsychotic agents
1444637|NCT00210717|risperidone
1444638|NCT00210717|paliperidone palmitate
1444639|NCT00210717|dementia praecox
1444640|NCT00210717|mental disorders
1444641|NCT00210717|PANSS
1444642|NCT00210704|dapoxetine
1444643|NCT00210704|premature ejaculation
1444644|NCT00210704|ejaculation
1444645|NCT00210704|sexual dysfunction
1444646|NCT00210704|orgasmic disorder
1444647|NCT00210704|sexual intercourse
1444648|NCT00210691|Schizophrenia
1444649|NCT00210691|intramuscular injection
1444650|NCT00210691|psychotropic agents
1444651|NCT00210691|long-acting risperidone
1444652|NCT00210678|Erectile Dysfunction
1444653|NCT00210678|Dapoxetine
1444654|NCT00210678|Premature ejaculation
1444655|NCT00210678|Ejaculation
1444656|NCT00210678|Sexual dysfunction
1444657|NCT00210678|Orgasmic disorder
1444658|NCT00210613|dapoxetine
1444659|NCT00210613|premature ejaculation
1444660|NCT00210613|sexual dysfunction
1444661|NCT00210613|orgasmic disorder
1444662|NCT00210613|sexual intercourse
1444663|NCT00210613|ejaculation
1444664|NCT00210600|Anemia
1444665|NCT00210600|Hemoglobin level
1444666|NCT00210587|Anemia
1444667|NCT00210587|Neoplasms
1444668|NCT00210587|hemoglobin level
1444669|NCT00210574|childhood absence epilepsy
1444670|NCT00210574|epilepsy
1444671|NCT00210574|seizures
1444672|NCT00210574|absence seizures
1444673|NCT00210561|Pain
1444675|NCT00210561|Back
1444676|NCT00210561|Lower back
1444677|NCT00210548|schizophrenia
1444678|NCT00210548|intramuscular injection
1444679|NCT00210548|antipsychotic agents
1444680|NCT00210548|dementia praecox
1444681|NCT00210548|paliperidone palmitate
1444682|NCT00210548|mental disorders
1444683|NCT00210548|PANSS.
1444684|NCT00210535|Topiramate
1444685|NCT00210535|Migraine
1444686|NCT00210535|Migraine headache
1444687|NCT00210535|Migraine prevention
1444688|NCT00210535|Pediatric
1444689|NCT00210522|RWJ-333369
1444690|NCT00210522|Anticonvulsants
1444691|NCT00210522|Epilepsy
1444692|NCT00210522|Refractory partial epilepsy
1444693|NCT00210522|Seizure disorder
1444694|NCT00210522|Antiepileptic drugs
1444695|NCT00210509|aura
1444696|NCT00210509|Migraine
1444697|NCT00210509|pain
1444698|NCT00210509|headache
1444699|NCT00210496|Migraine headache
1444700|NCT00210496|Topiramate, Almotriptan malate
1444701|NCT00210483|pain
1444702|NCT00210483|Migraine
1444703|NCT00210483|aura
1444704|NCT00210483|headache
1444705|NCT00210470|Head and Neck Cancer
1444706|NCT00210470|Immunotherapy
1444707|NCT00210470|IRX-2
1444708|NCT00210470|Mouth Cancer
1444709|NCT00210470|Throat Cancer
1444710|NCT00210418|Malnutrition
1444711|NCT00210418|Infant nutrition
1444712|NCT00210418|Food, fortified
1444713|NCT00210418|Growth
1444714|NCT00210418|Randomized controlled trials
1444715|NCT00210418|Evaluation studies
1444716|NCT00210418|Haiti
1444717|NCT00210405|Anemia
1444718|NCT00210405|Infant nutrition
1444719|NCT00210405|Dietary supplements
1444720|NCT00210405|Randomized controlled trials
1444721|NCT00210405|Evaluation studies
1444722|NCT00210405|Haiti
1444723|NCT00210301|MS
1444724|NCT00210301|cognition
1444725|NCT00210301|attention
1444726|NCT00210301|fatigue
1444727|NCT00210288|Healthy Volunteer
1444728|NCT00210288|Shigella
1444729|NCT00210288|Oral Vaccine
1444730|NCT00210288|Double Blind
1444731|NCT00210288|Placebo
1444732|NCT00210288|Immunogenicity
1444733|NCT00210288|Safety
1444734|NCT00210249|Cancer
1444735|NCT00210249|elderly
1444736|NCT00210249|geriatric evaluation
1444737|NCT00210249|safety
1444738|NCT00210249|chemotherapy
1444739|NCT00210236|Breast neoplasms
1444740|NCT00210236|Local recurrence
1444741|NCT00210236|Survival
1444742|NCT00210236|Surgery
1444743|NCT00210223|Radiofrequency
1444744|NCT00210223|Percutaneous technique
1444745|NCT00210223|breast cancer
1444746|NCT00210223|tolerance
1444747|NCT00210210|Post-operative-pain
1444748|NCT00210210|Breast cancer
1444749|NCT00210210|Morphine
1444750|NCT00210210|Analgesia
1444751|NCT00210197|Hypercoagulability
1444752|NCT00210197|Plasma coagulation parameters
1444753|NCT00210197|Breast cancer
1444754|NCT00210184|Chemotherapy
1444755|NCT00210184|gastric cancer
1444756|NCT00210184|geriatric evaluation
1444757|NCT00210184|efficacy
1444758|NCT00210184|safety
1444759|NCT00210171|Carcinoma
1444760|NCT00210171|Stage IIIA Non Small Cell Lung
1444761|NCT00210171|Stage IIIB Non-Small-Cell Lung
1444762|NCT00210171|Concomitant chemo-radiotherapy
1444763|NCT00210171|Consolidation chemotherapy
1444764|NCT00210158|Current opioid treatment
1444765|NCT00210158|Nitrous oxide
1444766|NCT00210158|Chronic pain
1444767|NCT00210158|Opioid therapy
1444768|NCT00210158|Postoperative hyperalgesia
1444769|NCT00210158|Acute opioid tolerance
1444770|NCT00210145|Aesthetic care,
1444771|NCT00210145|Mastectomy,
1444772|NCT00210145|Breast cancer,
1444773|NCT00210145|Quality of life,
1444774|NCT00210145|Body image,
1444775|NCT00210145|Psychological adjustment
1444776|NCT00210132|Thoracic surgery
1444777|NCT00210132|postoperative pain
1444778|NCT00210132|ropivacaine
1444779|NCT00210132|inter pleural analgesia
1444780|NCT00210119|Chronic myeloid leukemia
1444781|NCT00210119|imatinib mesylate
1444782|NCT00210119|zoledronate
1444783|NCT00210119|molecular response
1444784|NCT00210106|Radiofrequency ablation
1444785|NCT00210106|Colorectal cancer
1444786|NCT00210106|Liver metastases
1444787|NCT00210041|Genital Neoplasms, Male
1444788|NCT00210028|Breast Neoplasms
1444789|NCT00210028|Zarnestra
1444790|NCT00210028|Tamoxifen
1444791|NCT00210028|estrogen receptor
1444792|NCT00210028|progesterone receptor
1444793|NCT00210002|Neoplasms
1444794|NCT00210002|Solid
1444795|NCT00210002|Anemia
1444796|NCT00210002|darbepoetin alfa
1444797|NCT00210002|ferric saccharose
1444798|NCT00210002|Venofer®
1444799|NCT00210002|Aranesp®
1444800|NCT00209989|Glioblastoma Multiforme
1444801|NCT00209989|Zarnestra
1444802|NCT00209989|Radiation therapy
1444803|NCT00209963|Primary insomnia
1444804|NCT00209950|Primary insomnia
1444805|NCT00209573|Colonoscopy
1444806|NCT00209573|Sedation
1444807|NCT00209560|AQUAVAN® Injection
1444808|NCT00209560|Midazolam
1444809|NCT00209560|Minor surgical procedures
1444810|NCT00209560|Sedation
1444811|NCT00209937|Primary insomnia
1444812|NCT00209924|Primary insomnia
1444813|NCT00209911|atrial volume
1444814|NCT00209911|ventricular volume
1444815|NCT00209911|atrial function
1444816|NCT00209911|ventricular function
1444817|NCT00209911|magnetic resonance imaging
1444818|NCT00209911|cardioversion
1444819|NCT00209911|natriuretic peptides
1444820|NCT00209898|Chronic hepatits C
1444821|NCT00209898|peginterferon
1444822|NCT00209898|ribavirin
1444823|NCT00209898|inmate
1444824|NCT00209898|fast initiation procedure
1444825|NCT00209846|Primary insomnia
1444826|NCT00209820|low back pain
1444827|NCT00209820|randomized clinical trial
1444828|NCT00209820|Nordic walking
1444829|NCT00209820|supervision
1444830|NCT00209820|Advice to stay active
1444831|NCT00209807|major depression
1444832|NCT00209807|pain
1444833|NCT00209807|escitalopram
1444834|NCT00209807|reboxetine
1444835|NCT00209807|visceral sensitivity
1444836|NCT00209807|somatic sensitivity
1444837|NCT00209768|pediatric intensive care
1444838|NCT00209768|critically ill children
1444839|NCT00209768|in-line filtration
1444840|NCT00209768|prospective randomized study
1444841|NCT00209768|complications
1444842|NCT00209768|sepsis
1444843|NCT00209768|SIRS
1444844|NCT00209768|thrombosis
1444845|NCT00209768|organ failure
1444846|NCT00209755|chronic hepatitis C
1444847|NCT00209742|Colorectal Cancer,UFT,LV,Krestin,adjuvant therapy,phase III
1444848|NCT00209729|Docetaxel
1444849|NCT00209729|S-1
1444850|NCT00209729|Elderly Patients
1444851|NCT00209729|Gastric cancer
1444852|NCT00209664|Irinotecan, S-1, Phase II, gastric cancer
1444853|NCT00209651|Irinotecan, S-1, Phase II, colorectal cancer,
1444854|NCT00209638|Irinotecan,
1444855|NCT00209638|S-1,
1444856|NCT00209638|Phase I/II,
1444857|NCT00209638|gastric cancer
1444858|NCT00209625|Irinotecan, leucovorin, fluorouracil, PhaseI/II, colorectal cancer,
1444859|NCT00209599|Colonoscopy
1444860|NCT00209599|Seadation
1444861|NCT00209586|Bronchoscopy
1444862|NCT00209586|Sedation
1444863|NCT00209547|AQUAVAN® Injection
1444864|NCT00209547|Midazolam
1444865|NCT00209547|Angioplasty
1444866|NCT00209547|Coronary catheterization
1444867|NCT00209521|Coronary Artery Bypass Surgery
1444868|NCT00209521|AQUAVAN® Injection
1444869|NCT00209521|DISOPRIVAN® Injectable Emulsion.
1444870|NCT00209521|ischemic coronary artery disease
1444871|NCT00209508|Parkinson's Disease
1444872|NCT00209508|SPECT Scanning
1444873|NCT00209495|Abdominal hysterectomy
1444874|NCT00209495|Pregabalin
1444875|NCT00209495|Dexamethasone
1444876|NCT00209495|Multimodal postoperative analgesia
1444877|NCT00209456|Lewy Body Dementia
1444878|NCT00209456|non-DLB dementia
1444879|NCT00209456|Dopamine Transporter
1444880|NCT00209456|Striatal Uptake
1444881|NCT00209443|Aorto-iliac Stenosis
1444882|NCT00209443|Occlusion
1444883|NCT00209443|Diagnostic Imaging
1444884|NCT00209443|Omniscan
1444885|NCT00209443|Magnetic Resonance Angiography
1444886|NCT00209443|Contrast Media
1444887|NCT00209430|Iodixanol
1444888|NCT00209430|Iopamidol
1444889|NCT00209430|coronary angiography
1444890|NCT00209430|Contrast media-induced nephropathy
1444891|NCT00209417|Iodixanol
1444892|NCT00209417|Iopamidol
1444893|NCT00209417|computed tomography
1444894|NCT00209417|Patients with pre-existing renal impairment and diabetes
1444895|NCT00209404|MDCT
1444896|NCT00209404|Coronary Artery
1444897|NCT00209404|Heart Rate
1444898|NCT00209404|Image Quality
1444899|NCT00209404|Diagnostic Quality
1444900|NCT00209391|Renal Artery Stenosis
1444901|NCT00209391|Occlusion
1444902|NCT00209391|Diagnostic Imaging
1444903|NCT00209391|Omniscan
1444904|NCT00209391|Magnetic Resonance Angiography
1444905|NCT00209391|Contrast Media
1444906|NCT00209378|Continuous venovenous hemofiltration (CVVH)
1444907|NCT00209378|Continuous renal replacement therapy (CRRT)
1444908|NCT00209378|Acute Kidney Injury
1444909|NCT00209378|Regional citrate anticoagulation
1444910|NCT00209378|filter survival
1444911|NCT00209378|trisodium citrate
1444912|NCT00209378|bleeding complication
1444913|NCT00209378|Hemofiltration
1444914|NCT00209352|Varicella Zoster Virus Infection
1444915|NCT00209352|VZV infection
1444916|NCT00209352|Oral Acyclovir
1444917|NCT00209352|Allogeneic Bone Marrow Transplantation
1444918|NCT00209352|Allogeneic Hematopoietic Cell Transplantation
1444919|NCT00209339|Mitral Valve Insufficiency
1444920|NCT00209339|Mitral Valve Regurgitation
1444921|NCT00209339|Mitral Valve Incompetence
1444922|NCT00209339|Mitral Regurgitation
1444923|NCT00209339|Mitral Insufficiency
1444924|NCT00209339|Mitral Valve
1444925|NCT00209339|MR
1444926|NCT00209339|Mitral Valve Prolapse
1444927|NCT00209339|E2E - Edge to Edge
1444928|NCT00209339|Alfieri Technique
1444929|NCT00209339|MitraClip
1444930|NCT00209339|Functional MR
1444931|NCT00209339|Degenerative MR
1444932|NCT00209339|Echocardiogram
1444933|NCT00209339|CAD - Coronary Artery Disease
1444934|NCT00209339|Heart Failure
1444935|NCT00209339|Heart Attack
1444936|NCT00209339|EVEREST
1444937|NCT00209339|EVEREST I
1444938|NCT00209339|EVEREST II
1444939|NCT00209313|HIV-1
1444940|NCT00209313|HSV-2
1444941|NCT00209313|Coinfection
1444942|NCT00209313|Africa
1444943|NCT00209313|Cameroon
1444944|NCT00209300|Ulcerative Colitis for Maintenance of Remission
1444945|NCT00209287|Ulcerative Colitis for Maintenance of Remission
1444946|NCT00209274|Mitral Valve Insufficiency
1444947|NCT00209274|Mitral Valve Regurgitation
1444948|NCT00209274|Mitral Valve Incompetence
1444949|NCT00209274|Mitral Regurgitation
1444950|NCT00209274|Mitral Insufficiency
1444951|NCT00209274|Mitral Valve
1444952|NCT00209274|MR
1444953|NCT00209274|Mitral Valve Prolapse
1444954|NCT00209274|Edge to Edge (E2E)
1444955|NCT00209274|Alfieri Technique
1444956|NCT00209274|MitraClip
1444957|NCT00209274|Functional MR
1444958|NCT00209274|Degenerative MR
1444959|NCT00209274|Echocardiogram
1444960|NCT00209274|CAD - Coronary Artery Disease
1444961|NCT00209274|Heart Failure
1444962|NCT00209274|Heart Attack
1444963|NCT00209274|EVEREST
1444964|NCT00209274|EVEREST I
1444965|NCT00209274|EVEREST II
1444966|NCT00209274|REALISM
1444967|NCT00209235|Pseudohypoparathyroidism Type 1a (PHP 1a)
1444968|NCT00209235|Albright Hereditary Osteodystrophy
1444969|NCT00209235|Growth Hormone Deficiency
1444970|NCT00209222|Lymphoma, Mantle-Cell
1444971|NCT00209222|younger patients
1444972|NCT00209222|chemotherapy
1444973|NCT00209222|high dose therapy
1444974|NCT00209222|C04.557.386.480.300.725.500
1444975|NCT00209222|C15.604.515.569.480.300.725.500
1444976|NCT00209222|C20.683.515.761.480.300.725.500
1444977|NCT00209209|Lymphoma, Mantle-Cell
1444978|NCT00209209|Elderly patients
1444979|NCT00209209|Chemotherapy
1444980|NCT00209209|Maintenance therapy
1444981|NCT00209209|C04.557.386.480.300.725.500
1444982|NCT00209209|C15.604.515.569.480.300.725.500
1444983|NCT00209209|C20.683.515.761.480.300.725.500
1444984|NCT00209196|pediatric
1444985|NCT00209196|transplantation
1444986|NCT00209196|psychosocial
1444987|NCT00209196|kidney transplant recipient
1444988|NCT00209196|liver transplant recipient
1444989|NCT00209196|heart transplant recipient
1444990|NCT00209196|lung transplant recipient
1444991|NCT00209196|heart-lung transplant recipient
1444992|NCT00209144|Inflammation
1444993|NCT00209144|Thrombosis
1444994|NCT00209144|Hyperglycemia
1444995|NCT00209144|Myocardial Infarction
1444996|NCT00209144|Angioplasty
1444997|NCT00209131|urolithiasis
1444998|NCT00209118|Hepatitis C
1444999|NCT00209118|Interferon-alpha associated side effects
1445000|NCT00209118|Antidepressants
1445001|NCT00209118|Prevention
1445002|NCT00209105|Child Abuse
1445003|NCT00209105|Hypothalamic-Pituitary-Adrenal Axis
1445004|NCT00209105|Brain Imaging
1445005|NCT00209105|Depression
1445006|NCT00209092|Breast Cancer
1445007|NCT00209079|Gastric Adenocarcinoma
1445008|NCT00209066|Major Depressive Disorder
1445009|NCT00209066|Electroconvulsive Therapy
1445010|NCT00209066|Platelet Activation
1445011|NCT00209040|PTSD
1445012|NCT00209040|Acoustic startle
1445013|NCT00209027|schizophrenia
1445014|NCT00209027|reward
1445015|NCT00209027|fMRI
1445016|NCT00209014|B-Cell Lymphoma
1445017|NCT00209014|Hodgkin's Disease
1445018|NCT00209001|Breast Cancer
1445019|NCT00208988|Health literacy
1445020|NCT00208988|Physician-Patient Relationship
1445021|NCT00208988|Prostate Cancer
1445022|NCT00208975|Lymphoma
1445023|NCT00208962|Hematologic Diseases
1445024|NCT00208949|Hematologic Diseases
1445025|NCT00208936|Esophageal Diseases
1445026|NCT00208923|Hematologic Malignancies
1445027|NCT00208910|Anxiety
1445028|NCT00208910|Mental Health
1445029|NCT00208897|Early Life Stress
1445030|NCT00208897|HPA-axis
1445031|NCT00208897|CRF
1445032|NCT00208884|pediatric
1445033|NCT00208884|orthotopic heart transplantation
1445034|NCT00208884|graft failure
1445035|NCT00208871|Stereoscopic digital mammography
1445036|NCT00208871|Breast cancer detection
1445037|NCT00208871|Reduced rate of recall
1445038|NCT00208871|Focal abnormalities detection
1445039|NCT00208832|Medication Compliance
1445040|NCT00208832|Health Literacy
1445041|NCT00208819|Alzheimer's Disease
1445042|NCT00208819|Geriatric
1445043|NCT00208819|Dementia
1445044|NCT00208819|Agitation
1445045|NCT00208819|Behavioral Disturbances
1445046|NCT00208819|Psychosis
1445047|NCT00208806|Dilated Cardiomyopathy
1445048|NCT00208806|Pediatric
1445049|NCT00208806|Bi-ventricular Pacemaker
1445050|NCT00208793|colonic polyps
1445051|NCT00208793|adenomatous polyps
1445052|NCT00208793|colon cancer prevention
1445053|NCT00208793|dietary supplements
1445054|NCT00208780|Oxidative Stress
1445055|NCT00208780|Endothelium
1445056|NCT00208767|Angiotensin receptor blockade
1445057|NCT00208767|Oxidative stress
1445058|NCT00208767|Endothelial dysfunction
1445059|NCT00208754|heart defects
1445060|NCT00208754|cardiology
1445061|NCT00208754|adults who have congenital heart defects
1445062|NCT00208741|Social Anxiety Disorder
1445063|NCT00208741|Mental Health
1445064|NCT00208728|pediatric
1445065|NCT00208728|congenital heart disease
1445066|NCT00208728|cardiac surgery
1445067|NCT00208715|Depression
1445068|NCT00208702|Major Depressive Disorder
1445069|NCT00208702|Mental Health
1445070|NCT00208702|Depression
1445071|NCT00208689|pediatric
1445072|NCT00208689|congenital heart disease
1445073|NCT00208676|heart defects
1445074|NCT00208676|pediatrics
1445075|NCT00208650|pediatrics
1445076|NCT00208650|transplant
1445077|NCT00208650|cardiac
1445078|NCT00208637|Maori
1445079|NCT00208637|insulin sensitivity
1445080|NCT00208637|cardiovascular risk
1445081|NCT00208637|diabetes prevention
1445082|NCT00208637|diet modification
1445083|NCT00208624|arrhythmia
1445084|NCT00208624|pediatrics
1445085|NCT00208624|cardiac
1445086|NCT00208598|Maori
1445087|NCT00208598|Body Composition
1445088|NCT00208598|DEXA
1445089|NCT00208598|Cardiovascular disease
1445090|NCT00208598|Diabetes
1445091|NCT00208572|Traumatic Brain Injury; Anxiety Disorders; SRI Treatment
1445092|NCT00208559|Autism
1445093|NCT00208559|Pervasive Developmental Disorder
1445094|NCT00208559|Ziprasidone
1445095|NCT00208559|Adolescents
1445096|NCT00208546|capecitabine
1445097|NCT00208546|oxaliplatin
1445098|NCT00208546|bevacizumab
1445099|NCT00208546|cetuximab
1445100|NCT00208546|advanced colorectal cancer
1445101|NCT00208533|Autism
1445102|NCT00208533|Pervasive developmental disorder
1445103|NCT00208533|Aripiprazole
1445104|NCT00208533|Antipsychotic medication
1445105|NCT00208533|Adolescents
1445106|NCT00208520|Epilepsy
1445107|NCT00208520|Valproate
1445108|NCT00208520|Levetiracetam
1445109|NCT00208520|Lamotrigine
1445110|NCT00208520|Carbamazepine
1445111|NCT00208507|Joint Diseases
1445112|NCT00208507|Non-Inflammatory Degenerative Joint Disease
1445113|NCT00208494|Non-Inflammatory Degenerative Joint Disease
1445114|NCT00208468|Hip
1445115|NCT00208468|Cementless
1445116|NCT00208455|Arthroplasty
1445117|NCT00208455|Replacement
1445118|NCT00208455|Hip
1445119|NCT00208455|Conservative
1445120|NCT00208455|Anatomic
1445121|NCT00208455|Cementless
1445122|NCT00208442|Hip
1445123|NCT00208442|Cemented
1445126|NCT00208416|Hip
1445127|NCT00208416|Surgical Technique
1445128|NCT00208403|Hip
1445129|NCT00208403|Cement
1445130|NCT00208390|Hip
1445131|NCT00208390|Cementless
1445132|NCT00208377|Hip
1445133|NCT00208377|Conservative
1445134|NCT00208377|Metal-on-Metal
1445135|NCT00208377|Resurfacing
1445136|NCT00208364|Hip
1445137|NCT00208364|Cementless
1445138|NCT00208364|Metal-on-Metal
1445139|NCT00208351|Hip
1445140|NCT00208351|Cemented
1445141|NCT00208338|Rotator cuff tear repair
1445142|NCT00208312|Lexiscan
1445143|NCT00208312|Regadenoson
1445144|NCT00208312|Adenoscan®
1445145|NCT00208312|Adenosine
1445146|NCT00208312|SPECT Myocardial Perfusion Imaging
1445147|NCT00208312|Reversible Perfusion Defect
1445148|NCT00208299|Lexiscan
1445149|NCT00208299|Regadenoson
1445150|NCT00208299|Adenoscan®
1445151|NCT00208299|Adenosine
1445152|NCT00208299|SPECT Myocardial Perfusion Imaging
1445153|NCT00208299|Reversible Perfusion Defect
1445154|NCT00208273|Postmenopausal breast cancer, radiohormonotherapy sequences
1445155|NCT00208273|ER+ and/or PgR+,
1445156|NCT00208273|Postmenopausal Breast cancer,
1445157|NCT00208273|Adjuvant setting
1445158|NCT00208234|asthma
1445159|NCT00208221|Hypertension
1445160|NCT00208221|Diabetes
1445161|NCT00208221|Microalbuminuria
1445162|NCT00208221|Blood pressure
1445163|NCT00208208|Posttraumatic Stress Disorder
1445164|NCT00208208|Post-traumatic Stress Disorder
1445165|NCT00208208|PTSD
1445166|NCT00208208|Geodon
1445167|NCT00208208|Ziprasidone
1445168|NCT00208195|Bipolar Disorder
1445169|NCT00208195|Mania
1445170|NCT00208195|Substance Abuse
1445171|NCT00208195|Substance Dependence
1445172|NCT00208195|Comorbid
1445173|NCT00208169|Comorbid substance abuse/dependence
1445174|NCT00208169|Comorbid diagnoses
1445175|NCT00208169|Substance abuse and/or dependence
1445176|NCT00208156|Depression
1445177|NCT00208156|Major Depression
1445178|NCT00208156|Psychotic Major Depression
1445179|NCT00208156|PMD
1445180|NCT00208156|Psychosis
1445181|NCT00208143|Cocaine Abuse
1445182|NCT00208143|Cocaine Dependence
1445183|NCT00208143|Amphetamine Abuse
1445184|NCT00208143|Amphetamine Dependence
1445185|NCT00208143|Schizophrenia
1445186|NCT00208143|Comorbid
1445187|NCT00208143|Schizoaffective Disorder
1445188|NCT00208130|PTSD
1445189|NCT00208130|trauma
1445190|NCT00208117|depression
1445191|NCT00208117|inflammation
1445192|NCT00208117|heart disease
1445193|NCT00208117|randomized clinical trial
1445194|NCT00208117|sertraline
1445195|NCT00208117|simvastatin
1445196|NCT00208117|placebo
1445197|NCT00208104|Hypertension
1445198|NCT00208104|African Americans
1445199|NCT00208104|Adherence
1445200|NCT00208104|Motivational Interviewing
1445201|NCT00208091|Myloboc
1445202|NCT00208091|Botulinum Toxin Type B
1445203|NCT00208091|Focal Dystonia
1445204|NCT00208091|Musicians
1445205|NCT00208091|Muscle Relaxants
1445206|NCT00208091|Motor Impairments
1445207|NCT00208091|Motor Performance
1445208|NCT00208091|Tremor
1445209|NCT00208091|Abnormal Postures
1445210|NCT00208078|Hypercapnia
1445211|NCT00208078|Non-Invasive Ventilation
1445212|NCT00208065|migraine
1445213|NCT00208065|biological markers
1445214|NCT00208065|rhinosinusitis
1445215|NCT00208065|CGRP
1445216|NCT00208065|histamine
1445217|NCT00208065|VIP
1445218|NCT00208039|Prematurity
1445219|NCT00208039|Lung Disease
1445220|NCT00208039|Hyaline Membrane
1445221|NCT00208039|Surfactant
1445222|NCT00208013|resting energy expenditure
1445223|NCT00208013|cachexia
1445224|NCT00208013|advanced cancer
1445225|NCT00208013|advanced cancer patients
1445226|NCT00207987|controlled hypotension
1445227|NCT00207974|Hyperuricemia, Anserine, Pharmacokinetic
1445228|NCT00207948|Human Immunodeficiency Virus
1445229|NCT00207948|Protease Inhibitors
1445230|NCT00207948|Pharmacogenetics
1445231|NCT00207948|Genes, MDR1, Cytochrome P-450 enzymes
1445232|NCT00207948|Pharmacokinetics
1445233|NCT00207948|Pediatrics
1445234|NCT00207948|Treatment Experienced
1445235|NCT00207935|Seizures
1445236|NCT00207935|Depakote
1445237|NCT00207935|Developmental Delay
1445238|NCT00207935|Mental Retardation
1445239|NCT00207935|Swallow
1445240|NCT00207493|sexually transmitted disease
1445241|NCT00207493|structural intervention
1445242|NCT00207493|behavioral intervention
1445243|NCT00207467|patient-delivered partner treatment
1445244|NCT00207467|partner referral
1445245|NCT00207467|sexually transmitted diseases
1445246|NCT00207454|Partner Referral
1445247|NCT00207454|Social Cognitive Intervention
1445248|NCT00207454|Partner Delivered Medication
1445249|NCT00207441|arthritis
1445250|NCT00207441|chronic disease
1445251|NCT00207441|self management
1445252|NCT00207441|self efficacy
1445253|NCT00207428|Bronchial asthma
1445254|NCT00207428|Carbamazepine
1445255|NCT00207428|Efficacy
1445256|NCT00207415|arthritis
1445257|NCT00207415|self management
1445258|NCT00207402|Hepatitis C
1445259|NCT00207402|Insulin resistance
1445260|NCT00207389|Incretins:GIP , GLP-1
1445261|NCT00207389|Gastric bypass surgery
1445262|NCT00207389|Laparoscopic gastric bypass surgery
1445263|NCT00207389|Postprandial expression of GIP
1445264|NCT00207922|cytokine
1445265|NCT00207922|T-cell
1445266|NCT00207922|chemokine
1445267|NCT00207922|graft-versus-host disease
1445268|NCT00207909|Acute Renal Failure
1445269|NCT00207909|Contiuous Veno Venous Hemofiltration
1445270|NCT00207896|Pediatric Intensive Care
1445271|NCT00207896|Neuroendocrine Dysfunction
1445272|NCT00207883|Vascular Access
1445273|NCT00207883|Ultrasound
1445274|NCT00207883|Pediatric
1445275|NCT00207883|Pediatric intensive care patient
1445276|NCT00207870|Type II Supracondylar Fracture
1445277|NCT00207870|Orthopaedics
1445278|NCT00207857|Duchenne's Muscular Dystrophy
1445279|NCT00207857|Scoliosis
1445280|NCT00207844|Selenium
1445281|NCT00207844|Oxidative stress
1445282|NCT00207844|Septic shock
1445283|NCT00207844|Sodium selenite
1445284|NCT00207831|rectal cancer
1445285|NCT00207831|neoadjuvant therapy
1445286|NCT00207831|UFT
1445287|NCT00207831|radiochemotherapy
1445288|NCT00207818|tissue engineered wound dressing; autologous skin substitute; biological dressing; wound care
1445289|NCT00207792|Granulocyte colony stimulating factor
1445290|NCT00207779|central venous catheter
1445291|NCT00207779|catheter related bloodstream infection
1445292|NCT00207779|heparin
1445293|NCT00207766|Crohn's Disease
1445294|NCT00207766|infusions
1445295|NCT00207753|ascaris
1445296|NCT00207753|trichuris
1445297|NCT00207753|strongyloides
1445298|NCT00207753|hookworm
1445299|NCT00207753|head lice
1445300|NCT00207740|Asthma
1445301|NCT00207740|Severe Persistent Asthma
1445302|NCT00207740|Subcutaneous injections
1445303|NCT00207740|Immunology disorder
1445304|NCT00207740|Breathlesness
1445305|NCT00207727|Multiple Sclerosis
1445306|NCT00207714|Rheumatoid Arthritis
1445307|NCT00207714|CNTO 148
1445308|NCT00207714|Methotrexate
1445309|NCT00207714|Joint pain
1445310|NCT00207714|Arthritis
1445311|NCT00207701|Ankylosing Spondylitis
1445312|NCT00207701|infusion
1445313|NCT00207688|Ulcerative Colitis
1445314|NCT00207688|Infliximab
1445315|NCT00207688|Remicade
1445316|NCT00207688|Safety
1445317|NCT00207675|Crohn's Disease
1445318|NCT00207675|pediatric Crohn's Disease
1445319|NCT00207662|Crohn's Disease
1445320|NCT00207649|shared decision-making
1445321|NCT00207649|prostate cancer screening
1445322|NCT00207649|evidence-based medicine
1445323|NCT00207649|computer-assisted learning tools
1445324|NCT00207649|standardized patients
1445325|NCT00207649|randomized controlled trial
1445326|NCT00207649|educational intervention
1445327|NCT00207649|patient education
1445328|NCT00207649|physician education
1445329|NCT00207636|Computer-Assisted Decision Making
1445330|NCT00207636|Workplace
1445331|NCT00207636|Screening
1445332|NCT00207623|arthritis
1445333|NCT00207623|self management
1445334|NCT00207623|patient education
1445335|NCT00207610|Anemia
1445336|NCT00207610|Postpartum
1445337|NCT00207610|iron
1445338|NCT00207610|supplements
1445339|NCT00207571|computer
1445340|NCT00207571|video
1445341|NCT00207571|partner notification
1445342|NCT00207519|overweight
1445343|NCT00207519|obesity
1445344|NCT00207519|adolescent
1445345|NCT00207506|Latino
1445346|NCT00207506|Lay Health
1445347|NCT00207506|Access
1445348|NCT00207506|Prevention
1445349|NCT00207506|HIV Seronegativity
1445350|NCT00207506|HIV
1445351|NCT00207363|Hepatitis C
1445352|NCT00207350|Brain Tumor
1445353|NCT00207337|COPD (Chronic Obstructive Pulmonary Disease)
1445354|NCT00207337|Emphysema
1445355|NCT00207337|Minimally invasive
1445356|NCT00207311|Hepatitis C
1445357|NCT00207311|Fatty Liver
1445358|NCT00207311|NASH
1445359|NCT00207311|Steatohepatitis
1445360|NCT00207285|Police
1445361|NCT00207285|Sleep
1445362|NCT00207285|Fatigue
1445363|NCT00207285|Work Hours
1445364|NCT00207285|Sleep disorder
1445365|NCT00207285|Performance
1445366|NCT00207272|Hypocaloric MCT oil liquid diet
1445367|NCT00207272|Hypocaloric LCT oil liquid diet
1445368|NCT00207272|Visceral and omental adipose tissue
1445369|NCT00207272|Subcutaneous abdominal adipose tissue
1445370|NCT00207272|Gastric bypass surgery
1445371|NCT00207259|Prostate Cancer
1445372|NCT00207259|Reiki
1445373|NCT00207259|Relaxation Response
1445374|NCT00207259|Cognitive Restructuring
1445375|NCT00207259|Feasibility
1445376|NCT00207233|Weight loss
1445377|NCT00207233|MCT oil hypocaloric liquid diet
1445378|NCT00207233|LCT oil hypocaloric liquid diet
1445379|NCT00207233|Gastric Bypass
1445380|NCT00207220|heart failure
1445381|NCT00207220|preserved ejection fraction
1445382|NCT00207220|vascular stiffness
1445383|NCT00207207|Alternate Site
1445384|NCT00207207|Blood Glucose Testing
1445385|NCT00207207|Blood Sugar Testing
1445386|NCT00207207|Hemoglobin A1C
1445387|NCT00207181|Cancer prevention
1445388|NCT00207181|Physical activity
1445389|NCT00207181|Self-report
1445390|NCT00207181|Paper diary
1445391|NCT00207181|Electronic
1445392|NCT00207181|Computerized
1445393|NCT00207181|Measurement
1445394|NCT00207181|PDA
1445395|NCT00207181|Accelerometer
1445396|NCT00207142|Treatment Naive
1445397|NCT00207142|HIV-1 infected treatment naive patients
1445398|NCT00207116|Metastatic Non Small Cell Lung Cancer
1445399|NCT00207103|Advanced metastatic or solid tumors
1445400|NCT00207077|Advanced Solid Tumors
1445401|NCT00207064|first-episode
1445402|NCT00207064|altanserin
1445403|NCT00207064|5-HT2A receptors
1445404|NCT00207064|MRI
1445405|NCT00207064|fMRI
1445406|NCT00207064|PPI
1445407|NCT00207064|P300
1445408|NCT00207064|P50 gating
1445409|NCT00207064|endophenotypes
1445410|NCT00207064|vulnerability indicators
1445411|NCT00207064|quetiapine
1445412|NCT00207051|Advanced Gastrointestinal Malignancies
1445413|NCT00207038|Asthma
1445414|NCT00207038|Airway inflammation
1445415|NCT00207038|Sport
1445416|NCT00207025|Patients with advanced solid tumors
1445417|NCT00206999|Psychophysiology
1445418|NCT00206999|PPI
1445419|NCT00206999|P50 suppression
1445420|NCT00206999|Imipramine
1445421|NCT00206986|Schizophrenia
1445422|NCT00206986|Information processing
1445423|NCT00206986|PPI
1445424|NCT00206986|P50 gating
1445425|NCT00206986|P300
1445426|NCT00206986|mismatch negativity
1445427|NCT00206986|clonidine
1445428|NCT00206960|drug-naive
1445429|NCT00206960|epidepride
1445430|NCT00206960|single tomography
1445431|NCT00206960|D2 receptor
1445432|NCT00206960|information processing
1445433|NCT00206960|PPI
1445434|NCT00206960|antipsychotic treatment
1445435|NCT00206960|MRI
1445436|NCT00206960|fMRI
1445437|NCT00206960|cognitive disturbances
1445438|NCT00206947|Cognitive deficits
1445439|NCT00206947|Cholinergic Augmentation
1445440|NCT00206947|Schizophrenia
1445441|NCT00206934|PPI
1445442|NCT00206934|P50 suppression
1445443|NCT00206934|P300
1445444|NCT00206934|mismatch negativity
1445445|NCT00206934|escitalopram
1445446|NCT00206921|Telangiectasia
1445447|NCT00206921|Skin redness
1445448|NCT00206882|sunburn
1445449|NCT00206882|corticosteroids
1445450|NCT00206791|bone substitutes
1445451|NCT00206791|Bone Replacement Materials
1445452|NCT00206791|bone void filler
1445453|NCT00206791|Grafting, Bone
1445454|NCT00206791|Bone Cysts
1445455|NCT00206778|Mixed mania
1445456|NCT00206778|Bipolar Disorder
1445457|NCT00206765|panic
1445458|NCT00206739|Malaria
1445459|NCT00206739|Anemia
1445460|NCT00206739|IPTi
1445461|NCT00206739|Intermittent Preventive Treatment in Infants
1445462|NCT00206739|Sulfadoxine-Pyrimethamine
1445463|NCT00206739|Chemoprophylaxis
1445464|NCT00206739|Ghana
1445465|NCT00206713|Crohn Disease
1445466|NCT00206674|Morbus Crohn
1445467|NCT00206674|Sargramostim
1445468|NCT00206674|Phase III
1445469|NCT00206674|Placebo Controlled
1445470|NCT00206661|Crohn Disease
1445471|NCT00206609|Cancer
1445472|NCT00206609|palliative care
1445473|NCT00206609|dyspnoea
1445474|NCT00206609|oxygen
1445475|NCT00206570|Schizophrenia
1445476|NCT00206570|Gender differences
1445477|NCT00206570|Hormones
1445478|NCT00206570|Estradiol
1445479|NCT00206570|PANSS
1445480|NCT00206557|Schizophrenia
1445481|NCT00206557|Mental Illness
1445482|NCT00206557|Hormone Therapy
1445483|NCT00206557|Post-menopausal
1445484|NCT00206557|SERM
1445485|NCT00206557|Raloxifene
1445486|NCT00206544|Bipolar Affective Disorder
1445487|NCT00206544|Mania
1445488|NCT00206544|Anti-Estrogen
1445489|NCT00206544|Schizoaffective Disorder
1445490|NCT00206544|Mood
1445491|NCT00206531|HIV-1
1445492|NCT00206531|Naive T-cells
1445493|NCT00206531|CD31
1445494|NCT00206531|Treatment Naive
1445495|NCT00206518|Breast
1445496|NCT00206518|Cancer
1445497|NCT00206518|Taxotere
1445498|NCT00206518|AC
1445499|NCT00206518|Validation
1445500|NCT00206518|Neoadjuvant
1445501|NCT00206505|Breast
1445502|NCT00206505|Cancer
1445503|NCT00206505|Neoadjuvant
1445504|NCT00206505|Taxotere
1445505|NCT00206492|Breast
1445506|NCT00206492|Cancer
1445507|NCT00206492|Neoadjuvant
1445508|NCT00206492|HER2
1445509|NCT00206492|Overexpressing
1445510|NCT00206466|neoadjuvant
1445511|NCT00206466|chemosensitivity
1445512|NCT00206466|chemotherapy
1445513|NCT00206466|breast cancer
1445514|NCT00206466|tumor
1445515|NCT00206466|taxotere
1445516|NCT00206466|AC
1445517|NCT00206453|Breast
1445518|NCT00206453|Cancer
1445519|NCT00206453|Gene
1445520|NCT00206453|Expression
1445521|NCT00206453|Taxotere
1445522|NCT00206440|chemotherapy
1445523|NCT00206440|nausea
1445524|NCT00206440|vomiting
1445525|NCT00206440|breast cancer
1445526|NCT00206427|Advanced
1445527|NCT00206427|Breast
1445528|NCT00206427|Cancer
1445529|NCT00206427|Neoadjuvant
1445530|NCT00206427|HER2
1445531|NCT00206414|HORMONE RECEPTOR POSITIVE BREAST CANCER
1445532|NCT00206401|Adolescents
1445533|NCT00206401|Lantus
1445534|NCT00206388|NEUROBLASTOMA
1445535|NCT00206388|RECURRENT
1445536|NCT00206388|REFRACTORY
1445537|NCT00206388|CORTICAL
1445538|NCT00206388|BONE
1445539|NCT00206375|Hypothyroidism
1445540|NCT00206375|Growth hormone
1445541|NCT00206362|Depression
1445542|NCT00206362|Socioeconomic status
1445543|NCT00206362|Type 1 diabetes mellitus
1445544|NCT00206362|Children
1445545|NCT00206362|Adolescents
1445546|NCT00206349|Depression
1445547|NCT00206349|Socioeconomic status
1445548|NCT00206349|Type 1 diabetes mellitus
1445549|NCT00206349|Children
1445550|NCT00206349|Adolescents
1445551|NCT00206297|Type 1 diabetes
1445552|NCT00206297|hypoglycemia
1445553|NCT00206297|hyperglycemia
1445554|NCT00206284|GERD without erosive esophagitis
1445555|NCT00206271|whiplash injuries
1445556|NCT00206271|neck pain
1445557|NCT00206271|exercise movement techniques
1445558|NCT00206271|immobilisation
1445559|NCT00206258|type 1 diabetes
1445560|NCT00206258|hypoglycemia
1445561|NCT00206258|hyperglycemia
1445562|NCT00206245|GERD with erosive esophagitis
1445563|NCT00206232|Diastolic Heart Failure
1445564|NCT00206219|Squamous cell carcinoma of the head and neck
1445565|NCT00206193|termination of pregnancy
1445566|NCT00206141|Bipolar disorder
1445567|NCT00206141|bipolar depression
1445568|NCT00206141|depression
1445569|NCT00206128|Schizophrenia
1445570|NCT00206115|Schizophrenic disorder
1445571|NCT00206102|Schizophrenia
1445572|NCT00206102|Schizoaffective Disorder
1445573|NCT00206089|Prevention of venous thromboembolic events in patients undergoing elective hip replacement or hip fracture surgery
1445574|NCT00206076|Liver transplantation
1445575|NCT00206076|Calcineurin inhibitor withdraw
1445576|NCT00206076|mycophenolate mofetil
1445577|NCT00206076|Immunosuppression side effects
1445578|NCT00206076|Graft rejection
1445579|NCT00206037|Tibia osteotomy
1445580|NCT00206037|Bone healing
1445581|NCT00206037|Bone filler
1445582|NCT00206037|Equine Protein
1445583|NCT00206037|COLLOSS E
1445584|NCT00206037|TomoFix
1445585|NCT00206011|Condylar neck
1445586|NCT00206011|fractures
1445587|NCT00206011|endoscopic
1445588|NCT00206011|Helkimo Dysfunction index
1445589|NCT00205998|Locking Compression Plate
1445590|NCT00205998|Conservative treatment
1445591|NCT00205998|Surgical treatment
1445592|NCT00205998|Radius fractures
1445593|NCT00205998|AO 23
1445594|NCT00205985|Return to work
1445595|NCT00205985|Scaphoid fracture
1445596|NCT00205985|Operative treatment
1445597|NCT00205985|Activity level
1445598|NCT00205972|Fractures
1445599|NCT00205972|Humerus
1445600|NCT00205972|Conservative treatment
1445601|NCT00205972|Operative treatment
1445602|NCT00205959|Humerus
1445603|NCT00205959|Fractures
1445604|NCT00205959|Locking Plates
1445605|NCT00205959|Nail System
1445606|NCT00205946|Reward Processing
1445607|NCT00205946|Wellbutrin
1445608|NCT00205946|Bupropion
1445609|NCT00205933|Depression
1445610|NCT00205933|Bipolar Disorder
1445611|NCT00205933|Reward Processing
1445612|NCT00205920|emphysema
1445613|NCT00205920|pulmonary emphysema
1445614|NCT00205920|COPD
1445615|NCT00205920|COLD
1445616|NCT00205920|chronic obstructive pulmonary disease
1445617|NCT00205907|BLVR
1445618|NCT00205907|emphysema
1445619|NCT00205907|COPD
1445620|NCT00205907|COLD
1445621|NCT00205907|chronic obstructive pulmonary disease
1445622|NCT00205907|pulmonary emphysema
1445623|NCT00205894|Headache
1445624|NCT00205894|Chronic headache
1445625|NCT00205894|Migraine
1445626|NCT00205894|Pain
1445627|NCT00205894|Cluster headache
1445628|NCT00205881|HiResolution Bionic Ear
1445629|NCT00205881|severe to profound hearing loss
1445630|NCT00205881|bilateral implantation
1445631|NCT00205868|Back Pain
1445632|NCT00205868|Low Back Pain
1445633|NCT00205868|Chronic Pain
1445634|NCT00205868|Spinal Cord Stimulation
1445635|NCT00205855|Pain
1445636|NCT00205855|Chronic Pain
1445637|NCT00205855|Neurostimulation
1445638|NCT00205829|Chronic headaches
1445639|NCT00205829|greater occipital nerve stimulation
1445640|NCT00205816|Bacterial Infections
1445641|NCT00205803|Infant Vaccine
1445642|NCT00205777|Osteoporosis
1445643|NCT00205777|Postmenopause
1445644|NCT00205764|Multiple Myeloma
1445645|NCT00205764|first line tretment
1445646|NCT00205764|high dose chemotherapy
1445647|NCT00205764|stem cell transplantation
1445648|NCT00205764|maintenance therapy
1445649|NCT00205751|Multiple Myeloma
1445650|NCT00205751|first line treatment
1445651|NCT00205751|thalidomide
1445652|NCT00205751|melphalan
1445653|NCT00205738|Schizophrenia
1445654|NCT00205738|BMI
1445655|NCT00205738|T2DM
1445656|NCT00205725|Schizophrenia
1445657|NCT00205725|BMI
1445658|NCT00205725|T2DM
1445659|NCT00205712|NMDA antagonist-induced psychosis
1445660|NCT00205712|Children
1445661|NCT00205712|Memory Impairment
1445662|NCT00205712|Decreased cognitive function
1445663|NCT00205712|Increased memory impairment
1445664|NCT00205699|Antipsychotic treatment
1445665|NCT00205699|Insulin action/secretion
1445666|NCT00205699|Abdominal fat mass, total body fat
1445667|NCT00205699|Aggression
1445668|NCT00205699|Resting metabolic rates
1445669|NCT00205686|Aging, dhea, bone density, muscle mass, insulin action
1445670|NCT00205660|Schizophrenia
1445671|NCT00205660|Obesity
1445672|NCT00205660|Hyperglycemia
1445673|NCT00205660|Dyslipidemia
1445674|NCT00205660|Type 2 Diabetes Mellitus
1445675|NCT00205647|Chronic Bronchitis
1445676|NCT00205647|N-acetylcysteine (NAC)
1445677|NCT00205647|Quality of Life
1445678|NCT00205647|Mucus
1445679|NCT00205634|Cystic Fibrosis (CF)
1445680|NCT00205634|Macrolide antiobiotics
1445681|NCT00205634|airway inflammation
1445682|NCT00205621|Alzheimer's disease
1445683|NCT00205621|amyloid
1445684|NCT00205621|PET
1445685|NCT00205621|PIB
1445686|NCT00205621|FDDNP
1445687|NCT00205608|schizophrenia
1445688|NCT00205608|microglia
1445689|NCT00205608|PET
1445690|NCT00205595|microglia
1445691|NCT00205595|PET
1445692|NCT00205595|PK11195
1445693|NCT00205582|Traumatic Brain Injury
1445694|NCT00205582|PET
1445695|NCT00205582|microglia
1445696|NCT00205569|brain injury, acute rehabilitation
1445697|NCT00205556|online hemodiafiltration
1445698|NCT00205556|low flux hemodialysis
1445699|NCT00205556|cardiovascular disease
1445700|NCT00205556|endothelial dysfunction
1445701|NCT00205556|uremic toxicity
1445702|NCT00205556|quality of life
1445703|NCT00205556|nutritional status
1445704|NCT00205543|obstructive sleep apnea
1445705|NCT00205543|airway obstruction
1445706|NCT00205543|sleep-disordered breathing
1445707|NCT00205530|brain injury, family treatment
1445708|NCT00205504|Inflammatory markers, oral contraceptions, obesity, metabolic syndrome X
1445709|NCT00205491|depression after brain injury
1445710|NCT00205491|traumatic brain injury
1445711|NCT00205491|Venlafaxine
1445712|NCT00205426|Pulmonary hypertension in lung transplant recipients
1445713|NCT00205413|surveillance for lung cancer
1445714|NCT00205387|echocardiography
1445715|NCT00205387|cardiac elastography
1445716|NCT00205387|Normal volunteers
1445717|NCT00205309|intubated patients
1445718|NCT00205283|HIV
1445719|NCT00205270|Pre or post-lung transplant
1445720|NCT00205270|Healthy
1445721|NCT00205231|HIV
1445722|NCT00205192|Heart Failure
1445723|NCT00205192|Cardiac resynchronization
1445724|NCT00205192|echocardiography
1445725|NCT00205166|adenosine tracer scans
1445726|NCT00205166|coronary artery disease
1445727|NCT00205166|caffeine
1445728|NCT00205153|hypertension in African Americans
1445729|NCT00205127|Cardiac PET imaging
1445730|NCT00205127|Radiopharmaceutical tracers
1445731|NCT00205101|Transforaminal lumbar interbody fusion
1445732|NCT00205101|Posterior lumbar interbody fusion
1445733|NCT00205101|Isthmic spondylolisthesis, degenerative spondylolisthesis
1445734|NCT00205101|Pseudoarthritis
1445735|NCT00205101|Severe Foraminal Stenosis
1445736|NCT00205049|acute alcoholic hepatitis
1445737|NCT00204997|Cervical Cancer
1445738|NCT00204997|Squamous Cell
1445739|NCT00204997|Laparoscopy
1445740|NCT00204997|Ovarian Function
1445741|NCT00204984|arterial stiffness
1445742|NCT00204984|echocardiography
1445743|NCT00204984|nesiritide
1445744|NCT00204958|bone marrow transplant (BMT)
1445745|NCT00204958|hematopoietic stem cell transplant (HSCT)
1445746|NCT00204945|arterial stiffness
1445747|NCT00204945|echocardiography
1445748|NCT00204945|nesiritide
1445749|NCT00204945|high heart pressures
1445750|NCT00204945|cardiac catheterization
1445751|NCT00204919|osteoporosis
1445752|NCT00204919|vitamin D deficiency
1445753|NCT00204867|colorectal
1445754|NCT00204867|polyps
1445755|NCT00204763|manometry catheters
1445756|NCT00204763|diffuse esophageal spasm or hypertensive LES
1445757|NCT00204763|incontinence
1445758|NCT00204750|lower esophageal ring
1445759|NCT00204750|dysphagia
1445760|NCT00204750|electrosurgical incision
1445761|NCT00204750|bougie dilation
1445762|NCT00204750|GERD
1445763|NCT00204711|patients having outpatient surgery with sedation
1445764|NCT00204711|patients having procedures with sedation
1445765|NCT00204672|Asthma
1445766|NCT00204659|Rituximab
1445767|NCT00204659|CHOP
1445768|NCT00204659|DLBCL
1445769|NCT00204659|gastric lymphoma
1445770|NCT00204594|mRNA
1445771|NCT00204594|vaccination
1445772|NCT00204594|melanoma
1445773|NCT00204581|Melanoma
1445774|NCT00204581|Soft tissue metastases
1445775|NCT00204581|Interleukin-2
1445776|NCT00204555|nodular basal cell carcinoma
1445777|NCT00204555|Imiquimod
1445778|NCT00204555|topical treatment
1445779|NCT00204555|Adjuvants, Immunologic
1445780|NCT00204555|Antineoplastic Agents
1445781|NCT00204555|Interferon Inducers
1445782|NCT00204542|actinic keratosis
1445783|NCT00204542|diclofenac sodium
1445784|NCT00204529|malignant melanoma
1445785|NCT00204529|adjuvant therapy
1445786|NCT00204529|Adjuvants, Immunologic
1445787|NCT00204516|vaccination
1445788|NCT00204516|mRNA
1445789|NCT00204503|Bipolar I or II
1445790|NCT00204503|Depression
1445791|NCT00204503|Alcohol Abuse or Dependence
1445792|NCT00204503|Mental Health Issues
1445793|NCT00204490|soy
1445794|NCT00204490|isoflavones
1445795|NCT00204490|phytoestrogens
1445796|NCT00204490|prevention
1445797|NCT00204490|mammographic density
1445798|NCT00204490|bone density
1445799|NCT00204477|soy diet
1445800|NCT00204477|breast cancer
1445801|NCT00204477|ovarian hormones
1445802|NCT00204477|breast density
1445803|NCT00204477|prevention
1445804|NCT00204464|Amyotrophic Lateral Sclerosis
1445805|NCT00204464|Exercise
1445806|NCT00204451|emergency contraception
1445807|NCT00204451|follicle
1445808|NCT00204451|ovulation
1445809|NCT00204451|blood pressure
1445810|NCT00204451|Fertility Control
1445811|NCT00204451|Inhibition of fertilization
1445812|NCT00204438|female contraception
1445813|NCT00204438|oral contraceptive
1445814|NCT00204438|emergency contraceptive
1445815|NCT00204438|ovary
1445816|NCT00204438|follicle
1445817|NCT00204438|ovulation
1445818|NCT00204425|Osteoporosis
1445819|NCT00204425|Bone
1445820|NCT00204425|Exercise
1445821|NCT00204425|Soy
1445822|NCT00204425|Isoflavone
1445823|NCT00204425|Phytoestrogen
1445824|NCT00204425|Menopause
1445825|NCT00204425|Lipids
1445826|NCT00204412|Cholesterol
1445827|NCT00204412|High density lipoprotein
1445828|NCT00204412|Low density lipoprotein
1445829|NCT00204412|Triglyceride
1445830|NCT00204412|Glucose
1445831|NCT00204412|Exercise
1445832|NCT00204412|Fitness
1445833|NCT00204412|Flax
1445834|NCT00204412|Lignan
1445835|NCT00204412|Phytoestrogen
1445836|NCT00204412|bone
1445837|NCT00204386|Posttraumatic Stress Disorder
1445838|NCT00204360|epilepsy
1445839|NCT00204347|risperidone
1445840|NCT00204334|Kidney transplantation
1445841|NCT00204334|anemia
1445842|NCT00204334|vascular endothelium
1445843|NCT00204334|monocytes
1445844|NCT00204334|apoptosis
1445845|NCT00204321|rejection
1445846|NCT00204321|vesselwall function
1445847|NCT00204321|endothelial cell function
1445848|NCT00204321|monocytes
1445849|NCT00204308|HIV
1445850|NCT00204308|Pregnancy
1445851|NCT00204308|Mother-to-child transmission of HIV
1445852|NCT00204308|Drug resistance
1445853|NCT00204308|Nevirapine resistance
1445854|NCT00204308|NNRTI resistance
1445855|NCT00204295|Brain neoplasms
1445856|NCT00204295|Positron-Emission Tomography
1445857|NCT00204295|Amino Acids
1445858|NCT00204295|Magnetic Resonance Imaging
1445859|NCT00204282|Diabetes prevention
1445860|NCT00204269|Hypogonadism
1445861|NCT00204269|Testosterone
1445862|NCT00204269|Substitution
1445863|NCT00204256|chronic kidney disease
1445864|NCT00204256|anemia
1445865|NCT00204256|intravenous iron
1445866|NCT00204256|recombinant human erythropoetin
1445867|NCT00204243|naltrexone implant
1445868|NCT00204243|methadone
1445869|NCT00204243|inmates
1445870|NCT00204243|randomized controlled trial
1445871|NCT00204230|Kidney Failure, Chronic
1445872|NCT00204230|Kidney Transplantation
1445873|NCT00204217|cardiac arrest
1445874|NCT00204217|resuscitation
1445875|NCT00204217|ventilation
1445876|NCT00204217|impedance
1445877|NCT00204204|multiple trauma
1445878|NCT00204204|traffic accident
1445879|NCT00204204|outcome
1445880|NCT00204204|safety
1445881|NCT00204204|injury severity
1445882|NCT00204191|kidney transplantation
1445883|NCT00204191|Immunosuppression
1445884|NCT00204191|Cyclosporine
1445885|NCT00204191|Tacrolimus
1445886|NCT00204178|Kidney transplantation
1445887|NCT00204178|Reperfusion injury
1445888|NCT00204152|Early onset depression
1445889|NCT00204152|early adversity
1445890|NCT00204126|exercise testing
1445891|NCT00204126|treadmill
1445892|NCT00204126|incomplete spinal cord injury
1445893|NCT00204126|novel methods
1445894|NCT00204113|spinal cord injury
1445895|NCT00204113|standing
1445896|NCT00204113|balance
1445897|NCT00204113|functional electrical stimulation
1445898|NCT00204100|paraplegia
1445899|NCT00204100|spinal cord injury
1445900|NCT00204100|functional electrical stimulation
1445901|NCT00204100|cycling
1445902|NCT00204100|exercise
1445903|NCT00204100|cardiopulmonary fitness
1445904|NCT00204087|Schizophrenia
1445905|NCT00204087|Psychosis
1445906|NCT00204087|Prodrome
1445907|NCT00204087|Early Initial Prodromal State
1445908|NCT00204087|Early Intervention
1445909|NCT00204087|Cognitive Behavioral Therapy
1445910|NCT00204074|Migraine
1445911|NCT00204074|Menstrual cycle
1445912|NCT00204074|17 beta-estradiol
1445913|NCT00204074|Transdermal administration
1445914|NCT00204061|schizophrenia
1445915|NCT00204061|psychosis
1445916|NCT00204061|ultra high risk
1445917|NCT00204061|prodromal state
1445918|NCT00204061|early intervention
1445919|NCT00204061|amisulpride
1445920|NCT00204048|Hospitalists
1445921|NCT00204035|Training early achievers for careers in health
1445922|NCT00204022|Lupus nephritis
1445923|NCT00204022|Treatment
1445924|NCT00204022|Maintenance therapy
1445925|NCT00204022|Mycophenolate mofetil
1445926|NCT00204022|Azathioprine
1445927|NCT00204009|children and adolescents
1445928|NCT00204009|epidemiology
1445929|NCT00203996|polycystic ovary syndrome
1445930|NCT00203996|metabolic syndrome
1445931|NCT00203996|obstructive sleep apnea
1445932|NCT00203996|impaired glucose tolerance
1445933|NCT00203996|insulin resistance
1445934|NCT00203970|Thrombosis
1445935|NCT00203970|Low Molecular Weight Heparin
1445936|NCT00203957|Parkinson's Disease
1445937|NCT00203944|Adoption
1445938|NCT00203944|Stress Response
1445939|NCT00203944|Child Development
1445940|NCT00203931|Non-small cell lung cancer
1445941|NCT00203918|Prostate Cancer
1445942|NCT00203918|Cost-Effectiveness Analysis
1445943|NCT00203918|Utility Assessment
1445944|NCT00203905|Head and Neck Cancer
1445945|NCT00203892|Adenocarcinoma
1445946|NCT00203892|Pancreas
1445947|NCT00203879|metastatic melanoma
1445948|NCT00203866|Metastatic Renal Cell Carcinoma
1445949|NCT00203853|HIV
1445950|NCT00203853|HAART
1445951|NCT00203853|medication adherance
1445952|NCT00203853|pillbox
1445953|NCT00203853|wristwatch
1445954|NCT00203840|Sleep Disorders
1445955|NCT00203827|Sleep Disorders
1445956|NCT00203814|Malaria
1445957|NCT00203814|Efficacy
1445958|NCT00203814|Pharmacokinetic
1445959|NCT00203814|Gametocyte
1445960|NCT00203814|Molecular markers
1445961|NCT00203814|Sulfadoxine-pyrimethamine
1445962|NCT00203814|Artesunate
1445963|NCT00203814|Artemisinin
1445964|NCT00203801|Malaria
1445965|NCT00203801|Efficacy
1445966|NCT00203801|Pharmacokinetic
1445967|NCT00203801|Gametocyte
1445968|NCT00203801|Molecular markers
1445969|NCT00203801|Sulfadoxine-pyrimethamine
1445970|NCT00203801|Artesunate
1445971|NCT00203801|Artemisinin
1445972|NCT00203788|work outcome
1445973|NCT00203788|supported employment
1445974|NCT00203788|social skills training
1445975|NCT00203788|risperidone
1445976|NCT00203788|cognition
1445977|NCT00203788|first-episode schizophrenia
1445978|NCT00203762|Pragmatic cluster non-randomized controlled trial
1445979|NCT00203762|antiretroviral treatment
1445980|NCT00203762|tuberculosis
1445981|NCT00203762|childhood immunization
1445982|NCT00203762|primary care
1445983|NCT00203762|resource-restricted settings
1445984|NCT00203749|HIV
1445985|NCT00203749|Testing
1445986|NCT00203749|Counseling
1445987|NCT00203736|Malaria
1445988|NCT00203736|Efficacy
1445989|NCT00203736|Pharmacokinetic
1445990|NCT00203736|Gametocyte
1445991|NCT00203736|Molecular Markers
1445992|NCT00203736|Sulfadoxine-pyrimethamine
1445993|NCT00203736|Artesunate
1445994|NCT00203736|Artemisinin
1445995|NCT00203723|mood disorder
1445996|NCT00203723|affective disorder
1445997|NCT00203723|depression
1445998|NCT00203723|treatment-resistant
1445999|NCT00203710|Concentric Retriever Device
1446000|NCT00203710|embolectomy
1446001|NCT00203710|acute ischemic stroke
1446002|NCT00203710|treatment
1446003|NCT00203697|Eric Kleerup
1446004|NCT00203697|Idiopathic Pulmonary Fibrosis
1446005|NCT00203671|renal
1446006|NCT00203671|transplant
1446007|NCT00203671|kidney
1446008|NCT00203671|rejection
1446009|NCT00203671|MMF
1446010|NCT00203671|Mycophenolate Mofetil
1446011|NCT00203671|outcomes
1446012|NCT00203671|Kidney Transplantation
1446013|NCT00203645|Problem gambling
1446014|NCT00203645|Self-help manual
1446015|NCT00203645|Motivation enhancement
1446016|NCT00203645|Telephone support
1446017|NCT00203645|Treatment
1446018|NCT00203645|Pathological gambling
1446019|NCT00203632|diabetes mellitus
1446020|NCT00203632|endothelium
1446021|NCT00203632|thiazolidinediones
1446022|NCT00203632|atherosclerosis
1446023|NCT00203593|exercise
1446024|NCT00203593|total peripheral resistance
1446025|NCT00203593|venoconstriction
1446026|NCT00203593|blood volume expansion
1446027|NCT00203593|orthostatic tolerance
1446028|NCT00203580|venous thromboembolism
1446029|NCT00203580|low-molecular-weight heparin
1446030|NCT00203567|bipolar depression
1446031|NCT00203567|carbamazepine ER
1446032|NCT00203567|Equetro
1446033|NCT00203554|osteoporosis
1446034|NCT00203554|vertebra
1446035|NCT00203554|fracture
1446036|NCT00203554|pain
1446037|NCT00203554|percutaneous
1446038|NCT00203554|vertebroplasty
1446039|NCT00203554|polymethylmetacrylate
1446040|NCT00203528|divalproex sodium
1446041|NCT00203528|risperidone
1446042|NCT00203528|dual diagnosis
1446043|NCT00203528|substance use
1446044|NCT00203528|bipolar
1446045|NCT00203515|Urinary Catheterization
1446046|NCT00203502|Operable and Locally advanced Breast Cancer
1446047|NCT00203476|ezetimibe
1446048|NCT00203476|niacin
1446049|NCT00203476|colestipol
1446050|NCT00203476|hyperlipidemia
1446051|NCT00203476|adjunct therapy
1446052|NCT00203476|zetia
1446053|NCT00203463|topiramate
1446054|NCT00203463|PTSD
1446055|NCT00203463|posttraumatic stress disorder
1446056|NCT00203463|topamax
1446057|NCT00203450|obesity
1446058|NCT00203450|zonisamide
1446059|NCT00203450|zonegran
1446060|NCT00203450|psychotropic weight gain
1446061|NCT00203450|psychotropic
1446062|NCT00203385|divalproex sodium, depakote, ptsd, long-term ptsd treatments
1446063|NCT00203333|Epilepsy
1446064|NCT00203281|renal transplantation
1446065|NCT00203268|migraine
1446066|NCT00203268|cutaneous allodynia
1446067|NCT00203255|Menstrually-Associated Migraine
1446068|NCT00203229|Double-Blind
1446069|NCT00203229|Placebo-Controlled
1446070|NCT00203203|Autologous
1446071|NCT00203203|Cardiac
1446072|NCT00203203|Stem Cell
1446073|NCT00203203|Transplant
1446074|NCT00203047|Multiple Sclerosis
1446075|NCT00203047|brain atrophy
1446076|NCT00203047|Glatiramer Acetate
1446077|NCT00203047|Copaxone
1446078|NCT00203047|Steroids
1446079|NCT00203047|Prednisone
1446080|NCT00202969|Stomach cancer
1446081|NCT00202943|TCRFVR, LAUP, Snorer
1446082|NCT00202930|neuroblastoma
1446083|NCT00202930|Opsoclonus-myoclonus
1446084|NCT00202930|rituximab
1446085|NCT00202917|haploidentical transplantation
1446086|NCT00202917|immunomagnetic cell sorting
1446087|NCT00202917|allogeneic hematopoietic cell transplantation
1446088|NCT00202917|dose reduced conditioning
1446089|NCT00202904|ezetimibe
1446090|NCT00202904|atorvastatin
1446091|NCT00202904|hypercholesterolemia
1446092|NCT00202904|coronary heart disease
1446093|NCT00202891|pyoderma
1446094|NCT00202891|sisomicin
1446095|NCT00202891|nadifloxacin
1446096|NCT00202878|hypercholesterolemia
1446097|NCT00202878|myocardial infarction
1446098|NCT00202878|cholesterol
1446099|NCT00202878|randomized controlled trials
1446100|NCT00202878|acute coronary syndrome
1446101|NCT00202878|angina
1446102|NCT00202813|CVC
1446103|NCT00202813|central venous catheter
1446104|NCT00202813|infection
1446105|NCT00202813|bloodstream infection
1446106|NCT00202813|catheter infection
1446107|NCT00202813|pediatric
1446108|NCT00202813|children
1446109|NCT00202813|antibiotic impregnated catheters
1446110|NCT00202800|Pancreatic Cancer
1446111|NCT00202800|Gemcitabine/Etoposide
1446112|NCT00202800|Ras-mutation
1446113|NCT00202787|colorectal cancer
1446114|NCT00202787|cetuximab
1446115|NCT00202787|FOLFOX4
1446116|NCT00202774|colorectal cancer, capecitabine, oxaliplatin, 5-fluorouracil
1446117|NCT00202761|Cerebral palsy
1446118|NCT00202761|Functional training
1446119|NCT00202761|preschool children
1446120|NCT00202761|Gross Motor Functional Classification Level
1446121|NCT00202761|Gross motor functional Measure test
1446122|NCT00202761|Pediatric Evaluation of Disability Inventory
1446123|NCT00202761|Parental Stress Index
1446124|NCT00202748|metabolic syndrome
1446125|NCT00202748|lifestyle
1446126|NCT00202748|obesity
1446127|NCT00202735|shoulder dislocation
1446128|NCT00202735|anterior
1446129|NCT00202735|traumatic
1446130|NCT00202735|primary
1446131|NCT00202735|first time
1446132|NCT00202735|initial
1446133|NCT00202735|immobilization
1446134|NCT00202735|external
1446135|NCT00202735|rotation
1446136|NCT00202722|Remifentanil, parenteral opioids, obstetric analgesia, IVPCA
1446137|NCT00202709|Anxiety disorder
1446138|NCT00202709|Thought Field Therapy
1446139|NCT00202709|Psychotherapy
1446140|NCT00202709|Agoraphobia
1446141|NCT00202709|Social Phobia
1446142|NCT00202709|Post Traumatic Stress Disorder
1446143|NCT00202683|Altitude
1446144|NCT00202683|Anoxemia
1446145|NCT00202683|Mitochondria
1446146|NCT00202683|Reflex
1446147|NCT00202683|Genetic research
1446148|NCT00202670|coronary artery disease
1446149|NCT00202670|stress myocardial scintigraphy
1446150|NCT00202670|stress echocardiography
1446151|NCT00202657|parkinson's disease
1446152|NCT00202657|pergolide
1446153|NCT00202657|heart valve disease
1446154|NCT00202631|tetraplegia
1446155|NCT00202631|quadriplegia
1446156|NCT00202631|spinal cord injury
1446157|NCT00202631|functional electrical stimulation
1446158|NCT00202631|abdominal stimulation
1446159|NCT00202618|Hypertension
1446160|NCT00202618|Type 2 diabetes mellitus
1446161|NCT00202618|Microalbuminuria
1446162|NCT00202618|Amlodipine
1446163|NCT00202618|Calcium channel blocker
1446164|NCT00202618|Valsartan
1446165|NCT00202618|Angiotensin type 2 receptor blocker
1446166|NCT00202527|Sleep apnea
1446167|NCT00202527|Hypertension
1446168|NCT00202527|CPAP
1446169|NCT00202514|alcoholism
1446170|NCT00202514|alcohol related disorders
1446171|NCT00202514|mood disorders
1446172|NCT00202514|anticonvulsants
1446173|NCT00202514|divalproex sodium
1446174|NCT00202488|anemia, iron-deficiency
1446175|NCT00202488|Helicobacter pylori
1446176|NCT00202475|Dubble eerythrocytapheresis
1446177|NCT00202462|testosterone
1446178|NCT00202462|depression
1446179|NCT00202462|subsyndromal depression
1446180|NCT00202462|quality of life
1446181|NCT00202449|Prazosin
1446182|NCT00202449|Paroxetine
1446183|NCT00202449|Stress Disorders, Post-Traumatic
1446184|NCT00202449|Sleep Disorders
1446185|NCT00202423|Multiple sclerosis
1446186|NCT00202423|Cannabinoids
1446187|NCT00202423|Spasticity
1446188|NCT00202423|fMRI
1446189|NCT00202423|TMS
1446190|NCT00202410|Multiple Sclerosis
1446191|NCT00202410|Tuberculosis vaccine
1446192|NCT00202410|Therapy
1446193|NCT00202397|cerebellar ataxia
1446194|NCT00202397|deep cerebellar nuclei (DCN)
1446195|NCT00202397|small-conductance calcium-activated potassium(SK)channels
1446196|NCT00202397|riluzole
1446197|NCT00202397|Sporadic ataxia
1446198|NCT00202397|Multiple system atrophy type C
1446199|NCT00202384|Multiple Sclerosis
1446200|NCT00202384|microarrays
1446201|NCT00202371|MDS, Fatigue, RBC transfusion
1446202|NCT00202358|perioperative
1446203|NCT00202358|beta-blockers
1446204|NCT00202358|inflammation
1446205|NCT00202358|outcomes
1446206|NCT00202345|Creatinine Clearance
1446207|NCT00202345|Hemoglobin
1446208|NCT00202345|Iron sucrose
1446209|NCT00202345|Oral iron therapy
1446210|NCT00202345|Ferritin
1446211|NCT00202345|Transferrin saturation
1446212|NCT00202345|Iron
1446213|NCT00202319|sedation
1446214|NCT00202319|mechanical ventilation
1446215|NCT00202319|sedation protocols
1446216|NCT00202319|critical care
1446217|NCT00202319|intensive care outcomes
1446218|NCT00202319|staffing
1446219|NCT00202306|at risk mental state
1446220|NCT00202306|prodrome
1446221|NCT00202306|ultra high risk
1446222|NCT00202306|first episode psychosis
1446223|NCT00202306|schizophrenia
1446224|NCT00202306|bipolar disorder
1446225|NCT00202293|Bipolar
1446226|NCT00202293|Mania
1446227|NCT00202293|Drug treatment
1446228|NCT00202293|First episode
1446229|NCT00202293|Psychosis
1446230|NCT00202293|Therapy
1446231|NCT00202293|Antipsychotic
1446232|NCT00202267|leg ulcer, compression, bandage, APBI, venous insufficiency
1446233|NCT00202254|Mulitple Sclerosis
1446234|NCT00202254|MS
1446235|NCT00202241|HIV
1446236|NCT00202241|AIDS
1446237|NCT00202241|testosterone
1446238|NCT00202241|anabolic steroid
1446239|NCT00202241|body composition
1446240|NCT00202241|lipodystrophy
1446241|NCT00202241|MRI
1446242|NCT00202241|BIA
1446243|NCT00202241|skinfold measurements
1446244|NCT00202241|protease inhibitors
1446245|NCT00202228|HIV
1446246|NCT00202228|HIV/AIDS
1446247|NCT00202228|Lactic Acidosis
1446248|NCT00202228|Supplementation
1446249|NCT00202228|Lactate Clearance
1446250|NCT00202228|Mitochondrial Toxicity
1446251|NCT00202228|HAART
1446252|NCT00202215|Day hospital treatment
1446253|NCT00202202|personality disorder
1446254|NCT00202202|user satisfaction
1446255|NCT00202189|COPD
1446256|NCT00202189|Pulmicort
1446257|NCT00202189|Budesonide
1446258|NCT00202189|Chronic
1446259|NCT00202189|Obstructive
1446260|NCT00202189|Pulmonary
1446261|NCT00202189|Disease
1446262|NCT00202189|Exercise
1446263|NCT00202189|Emphysema
1446264|NCT00202176|Chronic
1446265|NCT00202176|Obstructive
1446266|NCT00202176|Pulmonary
1446267|NCT00202176|Disease
1446268|NCT00202176|COPD
1446269|NCT00202176|Atrovent
1446270|NCT00202176|Ipratropium
1446271|NCT00202176|Bromide
1446272|NCT00202176|Exercise
1446273|NCT00202176|Dyspnea
1446274|NCT00202163|ED
1446275|NCT00202163|DHEA
1446276|NCT00202163|testosterone
1446277|NCT00202150|Advanced chronic diseases
1446278|NCT00202150|Heart failure
1446279|NCT00202150|Chronic obstructive lung disease
1446280|NCT00202150|primary care
1446281|NCT00202150|Chronic Care
1446282|NCT00202137|Home Blood Pressure, Hypertension, Blood Pressure Control
1446283|NCT00202111|Clinical Trial
1446284|NCT00202111|Colonic Neoplasms
1446285|NCT00202111|Laparoscopic Surgery
1446286|NCT00202111|Morbidity
1446287|NCT00202111|Port Site Metastasis
1446288|NCT00202111|Disease-Free Survival
1446289|NCT00202098|ARDS
1446290|NCT00202098|mechanical ventilation
1446291|NCT00202098|variable ventilation
1446292|NCT00202098|chaotic ventilation
1446293|NCT00202072|lung
1446294|NCT00202072|airway
1446295|NCT00202072|pulmonary exacerbation
1446296|NCT00202072|mucus
1446297|NCT00202059|Breast cancer
1446298|NCT00202059|Bone mineral density
1446299|NCT00202059|Chemotherapy
1446300|NCT00202046|Breast cancer
1446301|NCT00202046|Lymphedema
1446302|NCT00202046|Quality of life
1446303|NCT00202033|referred to
1446304|NCT00202033|comprehensive
1446305|NCT00202033|diabetes
1446306|NCT00202033|education
1446307|NCT00202033|program
1446308|NCT00202020|Cerebral infarction
1446309|NCT00202020|Prevention
1446310|NCT00202020|Cilostazol
1446311|NCT00202020|Aspirin
1446312|NCT00202020|Stroke
1446313|NCT00202020|Clinical trial
1446314|NCT00202007|Aripiprazole
1446315|NCT00202007|Schizophrenia
1446316|NCT00202007|Clinical trial
1446317|NCT00202007|Risperidone
1446318|NCT00201994|Sodium
1446319|NCT00201994|SIADH
1446320|NCT00201994|Vasopressin
1446321|NCT00201994|CHF
1446322|NCT00201994|Cirrhosis
1446323|NCT00201994|salt
1446324|NCT00201994|water
1446325|NCT00201994|electrolyte
1446326|NCT00201981|dry eye
1446327|NCT00201981|keratoconjunctivitis sicca
1446328|NCT00201955|dry eye
1446329|NCT00201955|keratoconjunctivitis sicca
1446330|NCT00201942|Breast Cancer
1446331|NCT00201942|Diagnosis
1446332|NCT00201942|PET
1446333|NCT00201942|Positronic Emission Tomography
1446334|NCT00201942|fluorodeoxyglucose
1446335|NCT00201929|breast cancer
1446336|NCT00201929|decision aid
1446337|NCT00201929|Decision Board
1446338|NCT00201929|information transfer
1446339|NCT00201916|prostate cancer
1446340|NCT00201916|prostate specific antigen
1446341|NCT00201916|PSA
1446342|NCT00201916|radiation fractionation
1446343|NCT00201903|venous thromboembolism
1446344|NCT00201903|brain tumours
1446345|NCT00201903|glioma
1446346|NCT00201903|tissue factor
1446347|NCT00201903|blood coagulation
1446348|NCT00201903|tumour progression
1446349|NCT00201903|low molecular weight heparin
1446350|NCT00201890|Breast Cancer
1446351|NCT00201890|Lymphedema
1446352|NCT00201890|Treatment
1446353|NCT00201890|Massage
1446354|NCT00201890|Randomized
1446355|NCT00201890|DLT therapy
1446356|NCT00201890|Quality of Life
1446357|NCT00201890|Decongestive Therapy
1446358|NCT00201890|Breast Cancer related Lymphedema
1446359|NCT00201877|Relapsed/Refractory
1446360|NCT00201877|NHL
1446361|NCT00201877|Follicular
1446362|NCT00201877|Mantle Cell
1446363|NCT00201877|non-Hodgkin's lymphoma
1446364|NCT00201864|Postmenopausal
1446365|NCT00201864|Women
1446366|NCT00201851|Asian
1446367|NCT00201851|Premenopausal
1446368|NCT00201851|Women
1446369|NCT00201851|Oophorectomy
1446370|NCT00201838|Advanced Stage
1446371|NCT00201838|Chemotherapy Naive
1446372|NCT00201825|Previously Untreated
1446373|NCT00201825|Advanced
1446374|NCT00201812|Advanced Solid Tumors
1446375|NCT00201799|Hematopoietic Stem Cell Transplantation
1446376|NCT00201786|Corticosteroids
1446377|NCT00201773|Post-Menopause
1446378|NCT00201773|Neoadjuvant Therapy
1446379|NCT00201760|metastatic
1446380|NCT00201747|Advanced
1446381|NCT00201734|Adenocarcinoma
1446382|NCT00201721|Previously Untreated
1446383|NCT00201708|Adjuvant Trial
1446384|NCT00201708|Dose-Dense
1446385|NCT00201708|Axillary Node-Positive
1446386|NCT00201695|Untreated Patients
1446387|NCT00201695|Symptomatic
1446388|NCT00201682|Leukemia
1446389|NCT00201682|Lymphoma
1446390|NCT00201669|Aggressive
1446391|NCT00201669|Clofarabine
1446392|NCT00201656|PPROM
1446393|NCT00201656|Cerclage
1446394|NCT00201656|Preterm Premature Rupture of the Membranes with Cerclage
1446395|NCT00201643|Preterm Labor
1446396|NCT00201643|Preterm delivery
1446397|NCT00201630|Prostate
1446398|NCT00201630|cancer
1446399|NCT00201630|Brachytherapy
1446400|NCT00201630|Alpha Blocker
1446401|NCT00201617|Unilateral hearing loss
1446402|NCT00201617|Unilateral deafness
1446403|NCT00201617|Bone anchored hearing aid
1446404|NCT00201591|Coronary artery disease
1446405|NCT00201591|Exercise training
1446406|NCT00201591|Intensity
1446407|NCT00201591|Randomized
1446408|NCT00201591|echocardiography
1446409|NCT00201591|Aerobic Exercise
1446410|NCT00201578|Herbal Drugs
1446411|NCT00201578|Alternative medicine
1446412|NCT00201565|pulse wave velocity
1446413|NCT00201565|cardiovascular disease
1446414|NCT00201539|analgesics, opioid/pharmacokinetics
1446415|NCT00201539|humans
1446416|NCT00201539|morphine/therapeutic use*
1446417|NCT00201539|neoplasms
1446418|NCT00201539|pain/drugtherapy
1446419|NCT00201526|Bipolar Disorder
1446420|NCT00201513|Muscle, Skeletal
1446421|NCT00201513|Neuromuscular control
1446422|NCT00201513|Stability
1446423|NCT00201513|Exercise
1446424|NCT00201513|Anticipatory muscle control
1446425|NCT00201474|brief depressive episodes
1446426|NCT00201474|affective disorders
1446427|NCT00201474|EEG and QEEG
1446428|NCT00201474|epilepsy
1446429|NCT00201474|organic brain disorders
1446430|NCT00201474|acute psychiatry
1446431|NCT00201461|Patent Foramen Ovale
1446432|NCT00201461|STARFlex
1446433|NCT00201461|CLOSURE I
1446434|NCT00201461|Septal Closure System
1446435|NCT00201461|Stroke
1446436|NCT00201461|Cerebrovascular Accident
1446437|NCT00201461|Transient Ischemic Attack
1446438|NCT00201461|Heart Septal Defects, Atrial
1446439|NCT00201448|CMV, cytomegalovirus, vaccine, Towne strain
1446440|NCT00201435|Breast
1446441|NCT00201435|Cancer
1446442|NCT00201435|Paclitaxel
1446443|NCT00201435|Docetaxel
1446444|NCT00201435|Qulaity of life
1446445|NCT00201422|MALT lymphoma
1446446|NCT00201422|diffuse large B-cell lymphoma,
1446447|NCT00201422|stomach
1446448|NCT00201422|Helicobacter pylori
1446449|NCT00201422|antibiotic therapy
1446450|NCT00201396|A Multicenter Phase III Trial
1446451|NCT00201396|Induction Chemotherapy
1446452|NCT00201396|Concurrent Chemoradiotherapy
1446453|NCT00201396|Stage IV Nasopharyngeal Carcinoma (NPC)
1446454|NCT00201396|randomization
1446455|NCT00201396|disease-free survival
1446456|NCT00201370|cervical neoplasia;
1446457|NCT00201370|human papillomavirus,
1446458|NCT00201370|PCR,
1446459|NCT00201370|risk factors,
1446460|NCT00201370|Taiwan
1446461|NCT00201357|hormone-refractory prostate cancer
1446462|NCT00201357|thalidomide
1446463|NCT00201357|quality of life
1446464|NCT00201344|Radiotherapy
1446465|NCT00201344|Adjuvant chemotherapy
1446466|NCT00201344|Chemtherapy
1446467|NCT00201344|Nasopharyngeal Carcinoma
1446468|NCT00201292|Metabolic syndrome
1446469|NCT00201292|Diabetes
1446470|NCT00201292|Insulin resistance
1446471|NCT00201292|pharmacogenetics
1446472|NCT00201201|Older Adults
1446473|NCT00201201|Primary Care
1446474|NCT00201201|Hypertension
1446475|NCT00201201|Adherence
1446476|NCT00201136|Behavioral intervention
1446477|NCT00201136|Lifestyle modification
1446478|NCT00201136|Guidelines
1446479|NCT00201110|African Americans
1446480|NCT00201058|urban
1446481|NCT00201058|adolescents
1446482|NCT00201058|African American
1446483|NCT00201058|web-based
1446484|NCT00201058|computer tailoring
1446485|NCT00201058|school based
1446486|NCT00201045|Hypertension management
1446487|NCT00201045|Pharmacist management
1446488|NCT00201045|Physician pharmacist collaboration
1446489|NCT00201045|Blood pressure control
1446490|NCT00200954|prospective
1446491|NCT00200954|intervention
1446492|NCT00200954|randomised
1446493|NCT00200954|probiotics
1446494|NCT00200954|atopy
1446495|NCT00200941|Restless Legs Syndrome
1446496|NCT00200941|Topiramate
1446497|NCT00200941|Actigraphy
1446498|NCT00200941|Polysomnography
1446499|NCT00200928|prospective
1446500|NCT00200928|randomised
1446501|NCT00200928|intervention
1446502|NCT00200928|BCG
1446503|NCT00200928|atopy
1446504|NCT00200902|Major depressive disorder
1446505|NCT00200902|MDD
1446506|NCT00200902|Antidepressant
1446507|NCT00200889|Acupuncture
1446508|NCT00200889|Magnetic Resonance Imaging, Functional
1446509|NCT00200889|Brain Mapping
1446510|NCT00200889|normal volunteers
1446511|NCT00200876|Positron-Emission Tomography
1446512|NCT00200876|Endorphins
1446513|NCT00200876|Pain Relief
1446514|NCT00200876|Opioid Receptors
1446515|NCT00200876|Stress
1446516|NCT00200876|Analgesia
1446517|NCT00200863|light
1446518|NCT00200863|wavelength
1446519|NCT00200863|action spectrum
1446520|NCT00200863|circadian
1446521|NCT00200863|melatonin
1446522|NCT00200863|alertness
1446523|NCT00200863|performance
1446524|NCT00200863|arousal
1446525|NCT00200850|Breathing
1446526|NCT00200850|Allergy
1446527|NCT00200850|Mites, House Dust
1446528|NCT00200837|oral mucosal pain
1446529|NCT00200837|oral inflammations
1446530|NCT00200837|anisillo
1446531|NCT00200837|cordonsillo
1446532|NCT00200837|Piperaceae
1446533|NCT00200837|oral ulcers
1446534|NCT00200837|oral tumors
1446535|NCT00200837|mucosal pain
1446536|NCT00200837|mucosal inflammations
1446537|NCT00200837|cordoncillo
1446538|NCT00200824|isoflavones
1446539|NCT00200824|soy
1446540|NCT00200824|postmenopausal
1446541|NCT00200824|men
1446542|NCT00200824|prostate
1446543|NCT00200824|breast
1446544|NCT00200824|bone
1446545|NCT00200798|Milk Thistle
1446546|NCT00200798|Silymarin
1446547|NCT00200798|pharmacokinetics
1446548|NCT00200798|drug interactions
1446549|NCT00200798|Normal volunteers
1446550|NCT00200785|garlic
1446551|NCT00200759|Vaccinium macrocarpon
1446552|NCT00200759|Antioxidants
1446553|NCT00200759|Drug Interactions
1446554|NCT00200746|Hepatitis
1446555|NCT00200746|Liver Diseases
1446556|NCT00200746|Alcoholism
1446557|NCT00200746|Arginine
1446558|NCT00200733|acupuncture
1446559|NCT00200733|patient narratives
1446560|NCT00200733|qualitative methods
1446561|NCT00200720|Diet
1446562|NCT00200720|Carbohydrates
1446563|NCT00200720|Weight Loss
1446564|NCT00200707|Cell therapy
1446565|NCT00200707|bone marrow mononuclear cells
1446566|NCT00200707|myocardial infarction
1446567|NCT00200694|Proteinuria
1446568|NCT00200694|ACEI
1446569|NCT00200694|ARB
1446570|NCT00200694|diuretics
1446571|NCT00200694|blood pressure
1446572|NCT00200694|renal failure
1446573|NCT00200681|Secretory Multiple Myeloma
1446574|NCT00200681|First line treatment
1446575|NCT00200681|Velcade®
1446576|NCT00200681|autograft
1446577|NCT00200681|Newly diagnosed secretory Multiple Myeloma (MM)
1446708|NCT00199992|wounds
1446578|NCT00200642|Gastroesophageal reflux. PPI. Radiofrequency
1446579|NCT00200629|Women
1446580|NCT00200629|Diagnostic Testing
1446581|NCT00200629|Radionuclide Imaging
1446582|NCT00200629|Stress Testing
1446583|NCT00200629|Adenosine
1446584|NCT00200616|Urinary tract infection
1446585|NCT00200616|Vesico-renal reflux
1446586|NCT00200616|Child
1446587|NCT00200616|Antimicrobial prophylaxis
1446588|NCT00200616|Recurrence of urinary tract infection
1446589|NCT00200603|Calcium phosphate ceramic
1446590|NCT00200603|tibial osteotomy
1446591|NCT00200603|osteoarthritis
1446592|NCT00200590|prostaglandin
1446593|NCT00200590|analgesia
1446594|NCT00200590|congenital
1446595|NCT00200590|heart
1446596|NCT00200590|defect
1446597|NCT00200590|induced
1446598|NCT00200577|Adjuvant therapy
1446599|NCT00200577|immunotherapy
1446600|NCT00200577|TIL
1446601|NCT00200577|melanoma
1446602|NCT00200564|Pediatrics
1446603|NCT00200564|ketamine
1446604|NCT00200564|postoperative analgesia
1446605|NCT00200564|nalbuphine
1446606|NCT00200564|Postoperative analgesia in children
1446607|NCT00200538|frontotemporal dementia
1446608|NCT00200538|Mémantine
1446609|NCT00200538|Patients with frontotemporal dementia
1446610|NCT00200499|Nebivolol
1446611|NCT00200499|Hypertension
1446612|NCT00200499|Beta-Blocker
1446613|NCT00200486|genetic microarray
1446614|NCT00200486|head and neck cancer
1446615|NCT00200473|Nebivolol
1446616|NCT00200473|Hypertension
1446617|NCT00200473|Beta-Blockers
1446618|NCT00200460|Nebivolol
1446619|NCT00200460|Hypertension
1446620|NCT00200460|Beta-Blocker
1446621|NCT00200447|Parkinson
1446622|NCT00200447|brain imaging
1446623|NCT00200434|Nebivolol
1446624|NCT00200434|Beta-Blocker
1446625|NCT00200434|Hypertension
1446626|NCT00200421|Nebivolol
1446627|NCT00200421|Atenolol
1446628|NCT00200421|Exercise
1446629|NCT00200421|Hypertension
1446630|NCT00200408|cancer of head and neck
1446631|NCT00200408|smoking
1446632|NCT00200369|HIV
1446633|NCT00200369|Adherence
1446634|NCT00200369|Antiretroviral therapy
1446635|NCT00200369|Protease inhibitor
1446636|NCT00200369|Lopinavir
1446637|NCT00200343|Chronic hepatitis C, Ursodeoxycholic acid
1446638|NCT00200330|weight loss
1446639|NCT00200330|physical activity
1446640|NCT00200330|diet
1446641|NCT00200330|home environment
1446642|NCT00200317|Exercise
1446643|NCT00200317|Internet
1446644|NCT00200317|Print
1446645|NCT00200317|Randomized Controlled Trial
1446646|NCT00200317|Exercise Intervention
1446647|NCT00200304|Obesity
1446648|NCT00200304|Weight loss
1446649|NCT00200304|Internet
1446650|NCT00200278|Exercise
1446651|NCT00200278|Intervention studies
1446652|NCT00200278|Decision-making
1446653|NCT00200278|computer assisted Expert systems
1446654|NCT00200278|telephone
1446655|NCT00200252|oxytocin
1446656|NCT00200252|third stage
1446657|NCT00200252|dose
1446658|NCT00200252|route
1446659|NCT00200252|blood loss
1446660|NCT00200226|pain/discomfort
1446661|NCT00200226|cervical dilatation
1446662|NCT00200226|side effects
1446663|NCT00200200|BEVACIZUMAB (AVASTIN)
1446664|NCT00200200|DEXAMETHASONE
1446665|NCT00200200|FLOXURIDINE
1446666|NCT00200200|FLUOROURACIL
1446667|NCT00200200|IRINOTECAN (CPT-11) CAMPTOSAR
1446668|NCT00200200|LEUCOVORIN
1446669|NCT00200200|OXALIPLATIN
1446670|NCT00200200|Colon
1446671|NCT00200200|Rectal
1446672|NCT00200200|04-086
1446673|NCT00200200|Adjuvant postoperative chemo for CLM
1446674|NCT00200187|Prostatectomy
1446675|NCT00200187|Anesthesia
1446676|NCT00200187|Blood Loss
1446677|NCT00200174|Breast cancer
1446678|NCT00200174|estrogen
1446679|NCT00200174|postmenopausal
1446680|NCT00200148|Pancreaticoduodenectomy
1446681|NCT00200148|Hepatectomy
1446682|NCT00200148|Major Hepatic resection
1446683|NCT00200148|Acute Normovolemic Hemodilution
1446684|NCT00200135|motorcycle accident
1446685|NCT00200135|helmet
1446686|NCT00200135|traumatic brain injury
1446687|NCT00200135|financial burden
1446688|NCT00200096|Cancer
1446689|NCT00200096|Fatigue
1446690|NCT00200083|Obesity
1446691|NCT00200083|Morbid Obesity
1446692|NCT00200083|SHAPE
1446693|NCT00200083|IGS
1446694|NCT00200083|Implantable Gastric Stimulator
1446695|NCT00200070|Angina Pectoris Pain
1446696|NCT00200057|Fecal Incontinence
1446697|NCT00200057|InterStim
1446698|NCT00200044|GERD
1446699|NCT00200018|Obesity
1446700|NCT00200018|Morbid obesity
1446701|NCT00200018|Diabetes
1446702|NCT00200005|Slow transit constipation
1446703|NCT00200005|Fecal incontinence
1446704|NCT00200005|Constipation
1446705|NCT00200005|Idiopathic slow transit constipation
1446706|NCT00200005|Chronic constipation
1446707|NCT00199992|acute wounds
1446709|NCT00199992|platelets
1446710|NCT00199992|platelet gel
1446711|NCT00199979|Antiretroviral Therapy
1446712|NCT00199979|Nevirapine
1446713|NCT00199979|HIV Viral Load
1446714|NCT00199979|Adherence
1446715|NCT00199979|Quality of Life
1446716|NCT00199979|Resistance Mutations
1446717|NCT00199966|Bipolar Disorder; Pediatric Bipolar Disorder; Depakote ER
1446718|NCT00199953|Postnasal drainage
1446719|NCT00199953|Extraesophageal reflux
1446720|NCT00199940|Schizophrenia
1446721|NCT00199940|Pediatric psychotic disorders
1446722|NCT00199940|Ziprasidone
1446723|NCT00199914|Diathermy
1446724|NCT00199914|Short-wave therapy
1446725|NCT00199914|Osteoarthritis
1446726|NCT00199914|Knee
1446727|NCT00199901|Phase II
1446728|NCT00199901|Randomized Controlled Trial
1446729|NCT00199901|Double-Blind
1446730|NCT00199901|Cancer Vaccine
1446731|NCT00199901|NY-ESO-1 protein, human
1446732|NCT00199901|ISCOMATRIX, immunological adjuvant
1446733|NCT00199888|Kidney Cancer
1446734|NCT00199888|Renal Cancer
1446735|NCT00199888|Neoplasms, Kidney
1446736|NCT00199888|cG250
1446737|NCT00199888|antibody
1446738|NCT00199888|Iodine 124
1446739|NCT00199875|antibody
1446740|NCT00199875|renal cell carcinoma
1446741|NCT00199875|advanced renal cancer
1446742|NCT00199875|cG250
1446743|NCT00199875|90Y
1446744|NCT00199862|huA33
1446745|NCT00199862|antibody
1446746|NCT00199862|colorectal cancer
1446747|NCT00199862|Iodine 124
1446748|NCT00199862|124I
1446749|NCT00199862|03-124
1446750|NCT00199849|NY-ESO-1
1446751|NCT00199849|DNA
1446752|NCT00199836|cancer vaccine
1446753|NCT00199836|NY-ESO-1b peptide
1446754|NCT00199836|CpG 7909
1446755|NCT00199836|Montanide ISA-51
1446756|NCT00199836|LAGE-1
1446757|NCT00199836|immune response
1446758|NCT00199836|safety
1446759|NCT00199823|Myocardial infarction
1446760|NCT00199823|bone marrow cells
1446761|NCT00199823|cell transplantation
1446762|NCT00199810|Cardiac output
1446763|NCT00199810|Preeclamptic women
1446764|NCT00199810|systemic vascular resistance
1446765|NCT00199810|blood pressure
1446766|NCT00199797|Colorectal Cancer
1446767|NCT00199797|huA33
1446768|NCT00199797|antibody
1446769|NCT00199797|chemotherapy
1446770|NCT00199784|Hemodynamic
1446771|NCT00199784|Hypotension
1446772|NCT00199784|Spinal
1446773|NCT00199784|Anesthesia
1446774|NCT00199784|Healthy pregnant women for elective cesarean section
1446775|NCT00199771|Cardiac Surgery
1446776|NCT00199771|Infant
1446777|NCT00199771|Infant, Newborn
1446778|NCT00199771|Hypertonic Solutions
1446779|NCT00199771|Saline Solution, Hypertonic
1446780|NCT00199771|Capillary leak
1446781|NCT00199771|Inflammation Mediators
1446782|NCT00199758|Non small cell lung carcinoma
1446783|NCT00199758|Cisplatin
1446784|NCT00199758|Gemcitabine
1446785|NCT00199758|Paclitaxel
1446786|NCT00199745|statin
1446787|NCT00199745|statins
1446788|NCT00199745|statin therapy
1446789|NCT00199745|adverse events
1446790|NCT00199745|side effect
1446791|NCT00199745|Myotoxicity
1446792|NCT00199745|atorvastatin
1446793|NCT00199745|Atorvastatin Therapy
1446794|NCT00199732|Chronic hepatitis B
1446795|NCT00199732|CCC DNA kinetics
1446796|NCT00199732|Total HBV DNA kinetics
1446797|NCT00199732|Adefovir-Dipovixil
1446798|NCT00199732|Peg interferon alpha 2a
1446799|NCT00199719|drug monitoring
1446800|NCT00199719|ribavirin-pharmacokinetic
1446801|NCT00199719|pharmacodynamics
1446802|NCT00199719|chronic hepatitis C
1446803|NCT00199719|non 2 non 3 genotype
1446804|NCT00199706|Intracranial Pressure
1446805|NCT00199706|Intracranial Hypertension
1446806|NCT00199706|Hypertonic Solutions
1446807|NCT00199706|Saline Solutions, Hypertonic
1446808|NCT00199693|Hemodynamic and respiratory changes and pregnancy
1446809|NCT00199693|Healthy pregnant women
1446810|NCT00199680|PETscan, cervical cancer
1446811|NCT00199667|MMF, Monitoring, area under curve (AUC), kidney transplantation
1446812|NCT00199654|colorectal cancer stage II and III
1446813|NCT00199628|fetomaternal tissular alloimmunization
1446814|NCT00199628|Mothers having a child suffering from:
1446815|NCT00199628|neonatal membranous glomerulonephritis
1446816|NCT00199628|unexplained neonatal tubular defect
1446817|NCT00199628|unexplained thrombotic microangiopathy
1446818|NCT00199628|neonatal hemochromatosis
1446819|NCT00199615|lung cancer, 18 FDG, PET
1446820|NCT00199589|Spastic equinovarus
1446821|NCT00199589|Botox
1446822|NCT00199589|Ankle foot orthosis
1446823|NCT00199576|Corticosteroids
1446824|NCT00199576|Laryngotracheal injury
1446825|NCT00199576|Intubation-extubation
1446826|NCT00199563|Viagra
1446827|NCT00199563|sildenafil
1446828|NCT00199550|Transurethral Resection of Prostate
1446829|NCT00199550|TURP
1446830|NCT00199524|ureteroscopy
1446831|NCT00199524|stone free
1446832|NCT00199511|Brain Tumor
1446833|NCT00199511|Intracranial Pressure
1446834|NCT00199511|Osmolarity
1446835|NCT00199511|Seric
1446836|NCT00199511|Hypertonic Solution
1446837|NCT00199498|Permanent Pacemaker Implantation- Lead Position
1446838|NCT00199485|prostate cancer
1446839|NCT00199485|Luteinizing Hormone Releasing Hormone
1446840|NCT00199485|LHRH
1446841|NCT00199459|calculi
1446842|NCT00199459|proteomics
1446843|NCT00199446|Sleep -Sleep Disorder
1446844|NCT00199446|Sleep- Restless Legs Syndrome
1446845|NCT00199446|Clinical Trial
1446846|NCT00199433|Parkinson's Disease
1446847|NCT00199433|Movement Disorder
1446848|NCT00199433|Neurology,
1446849|NCT00199433|Clinical Trial
1446850|NCT00199420|levodopa
1446851|NCT00199420|end of dose wearing off
1446852|NCT00199420|OFF time
1446853|NCT00199407|Parkinson's disease
1446854|NCT00199407|levodopa
1446855|NCT00199407|end of dose wearing off
1446856|NCT00199407|OFF time
1446857|NCT00199394|KW-6002 (istradefylline)
1446858|NCT00199394|Entacapone
1446859|NCT00199394|Placebo
1446860|NCT00199394|Parkinson's Disease
1446861|NCT00199394|Motor Response Complications
1446862|NCT00199394|Levodopa Therapy
1446863|NCT00199381|Parkinson's Disease
1446864|NCT00199381|levodopa
1446865|NCT00199381|end of dose wearing off
1446866|NCT00199381|OFF time
1446867|NCT00199368|Parkinson's disease
1446868|NCT00199368|levodopa
1446869|NCT00199368|end of dose wearing off
1446870|NCT00199368|OFF time
1446871|NCT00199355|Parkinson's Disease
1446872|NCT00199355|levodopa
1446873|NCT00199355|end of dose wearing off
1446874|NCT00199355|OFF time
1446875|NCT00199342|Melanoma
1446876|NCT00199342|Monoclonal Antibody
1446877|NCT00199342|Anti-GD-3
1446878|NCT00199329|ondansetron
1446879|NCT00199329|PCA
1446880|NCT00199316|patient who recieve kidney surgery and Patient controlled anesthesia with spinal morphine, intrathecal
1446881|NCT00199303|NMDAreceptor antagonist, dextromethorphan
1446882|NCT00199303|pain, post-operative
1446883|NCT00199303|opioid consumption, morphine
1446884|NCT00199290|Trafermin
1446885|NCT00199290|Periodontitis
1446886|NCT00199264|antifungal oral therapy
1446887|NCT00199264|efficacy acute candidiasis vulvaginitis
1446888|NCT00199251|URTICARIA, WHEALS, FLARE, ANTIHISTAMINE, ANTIHISTAMINE
1446889|NCT00199238|ANTIHISTAMINE
1446890|NCT00199238|RUPATADINE
1446891|NCT00199238|WHEAL
1446892|NCT00199238|FLARE
1446893|NCT00199238|DERMATOLOGY
1446894|NCT00199225|Thorough study QT/QTc
1446895|NCT00199225|Cardiac repolarization
1446896|NCT00199225|QT prolongation
1446897|NCT00199212|HER-2 positive
1446898|NCT00199212|metastatic breast cancer patients
1446899|NCT00199173|colorectal cancer
1446900|NCT00199173|liver metastasis
1446901|NCT00199173|intraarterial hepatic injection
1446902|NCT00199173|yttrium loaded microspheres
1446903|NCT00199173|colorectal neoplasm metastatic to the liver
1446904|NCT00199160|local recurrence and or metastatic disease
1446905|NCT00199160|Previously treated with platinum
1446906|NCT00199160|carcinoma of the head and neck
1446907|NCT00199134|neoadjuvant treatment
1446908|NCT00199108|CNS relapse
1446909|NCT00199108|ALL
1446910|NCT00199108|Treatment
1446911|NCT00199095|ALL
1446912|NCT00199095|Elderly
1446913|NCT00199095|Chemotherapy
1446914|NCT00199082|High-grade NHL
1446915|NCT00199082|De novo
1446916|NCT00199082|Mature B-ALL
1446917|NCT00199082|Burkitt'S NHL
1446918|NCT00199082|Chemotherapy
1446919|NCT00199082|Rituximab
1446920|NCT00199082|Primary mediastinal diffuse large cell lymphoma
1446921|NCT00199082|B-precursor lymphoblastic lymphoma
1446922|NCT00199069|ALL
1446923|NCT00199069|Treatment
1446924|NCT00199069|De Novo
1446925|NCT00199069|Adult
1446926|NCT00199056|ALL
1446927|NCT00199056|Treatment
1446928|NCT00199056|De Novo
1446929|NCT00199056|Adult
1446930|NCT00199030|Relapse
1446931|NCT00199030|T-ALL
1446932|NCT00199030|T-LBL
1446933|NCT00199030|MabCampath
1446934|NCT00199030|Minimal residual disease
1446935|NCT00199030|Lymphoma, lymphoblastic, T-cell
1446936|NCT00199017|T-LBL
1446937|NCT00199017|Treatment
1446938|NCT00199017|De novo
1446939|NCT00199017|Chemotherapy
1446940|NCT00199017|Adult
1446941|NCT00199017|Lymphoma, lymphoblastic, T-cell
1446942|NCT00199004|ALL
1446943|NCT00199004|Treatment
1446944|NCT00199004|De novo
1446945|NCT00199004|Minimal residual disease
1446946|NCT00199004|Rituximab
1446947|NCT00199004|Adult
1446948|NCT00198991|ALL
1446949|NCT00198991|Treatment
1446950|NCT00198991|de novo
1446951|NCT00198991|Minimal residual disease
1446952|NCT00198991|Adult
1446953|NCT00198978|ALL
1446954|NCT00198978|Treatment
1446955|NCT00198978|Elderly
1446956|NCT00198978|De novo
1446957|NCT00198939|drug prevention
1446958|NCT00198939|adolescence
1446959|NCT00198939|middle school
1446960|NCT00198939|randomized trial
1446961|NCT00198939|family therapy
1446962|NCT00198939|cognitive-behavioral
1446963|NCT00198939|efficacy
1446964|NCT00198939|selected youth
1446965|NCT00198939|indicated youth
1446966|NCT00198887|newborn
1446967|NCT00198887|operations research
1446968|NCT00198887|newborn survival
1446969|NCT00198887|Neonatal illness/mortality
1446970|NCT00198887|Delivery complications
1446971|NCT00198874|drug abuse
1446972|NCT00198874|drug dependence
1446973|NCT00198874|treatment
1446974|NCT00198874|randomized trial
1446975|NCT00198874|stage II study
1446976|NCT00198874|adolescents
1446977|NCT00198874|young adults
1446978|NCT00198874|efficacy study
1446979|NCT00198861|HIV Epidemiology
1446980|NCT00198861|Neurology
1446981|NCT00198861|Neuropsychological
1446982|NCT00198861|HIV Risk Factors
1446983|NCT00198861|Cognitive Risk Factors
1446984|NCT00198861|HIV
1446985|NCT00198848|Iron deficiency anemia
1446986|NCT00198848|Adolescent girls
1446987|NCT00198848|India
1446988|NCT00198835|malnutrition
1446989|NCT00198835|anemia
1446990|NCT00198835|infants
1446991|NCT00198835|children
1446992|NCT00198835|India
1446993|NCT00198822|Maternal mortality
1446994|NCT00198822|Infant mortality
1446995|NCT00198822|Vitamin A
1446996|NCT00198822|Beta-carotene
1446997|NCT00198822|Micronutrients
1446998|NCT00198822|Bangladesh
1446999|NCT00198822|Neonatal mortality
1447000|NCT00198731|maternal health
1447001|NCT00198731|Bangladesh
1447002|NCT00198731|care seeking
1447003|NCT00198718|Vitamin A supplementation
1447004|NCT00198718|HIV
1447005|NCT00198718|Mother to child transmission of HIV
1447006|NCT00198718|Breastfeeding
1447007|NCT00198692|amputation
1447008|NCT00198692|depression
1447009|NCT00198692|pain
1447010|NCT00198692|anxiety
1447011|NCT00198692|self-management
1447012|NCT00198692|secondary conditions
1447013|NCT00198679|skin cleansing
1447014|NCT00198679|Bangladesh
1447015|NCT00198679|Skin Flora
1447016|NCT00198679|Newborn
1447017|NCT00198679|infectious disease
1447018|NCT00198679|chlorhexidine
1447019|NCT00198666|Pneumonia
1447020|NCT00198666|zinc
1447021|NCT00198653|Hypothermia
1447022|NCT00198653|Newborn
1447023|NCT00198653|India
1447024|NCT00198653|Maternal/Child Health
1447025|NCT00198653|Infant
1447026|NCT00198653|Kangaroo Mother Care
1447027|NCT00197145|HIV-1 GW873140 CCR5 antagonist experienced
1447028|NCT00197132|Insulin resistance vasodilatory response
1447029|NCT00197119|Hepatitis B
1447030|NCT00197119|TWINRIX™ Adult
1447031|NCT00197119|Hepatitis A
1447032|NCT00197119|TWINRIX™ Junior
1447033|NCT00198640|animal antibiotics
1447034|NCT00198640|human antibiotics
1447035|NCT00198627|Neonatal bacterial infection
1447036|NCT00198614|Adrenergic beta-Antagonists
1447037|NCT00198614|Carvedilol
1447038|NCT00198614|Metoprolol
1447039|NCT00198614|Coronary Artery Bypass
1447040|NCT00198614|Atrial Fibrillation
1447041|NCT00198601|meningitis
1447042|NCT00198601|neonatal deaths
1447043|NCT00198601|gentamicin
1447044|NCT00198601|Uniject
1447045|NCT00198601|aminoglycoside
1447046|NCT00198588|heparin-induced thrombocytopenia
1447047|NCT00198588|argatroban
1447048|NCT00198588|cardiac surgery
1447049|NCT00198588|acute coronary syndrome
1447050|NCT00198588|thrombosis
1447051|NCT00198588|amputation
1447052|NCT00198588|anticoagulation
1447053|NCT00198575|heparin-induced thrombocytopenia
1447054|NCT00198575|cardiovascular surgery
1447055|NCT00198575|percutaneous coronary intervention
1447056|NCT00198562|Antihypertensive therapy
1447057|NCT00198562|Home blood pressure
1447058|NCT00198562|Systolic blood pressure
1447059|NCT00198562|Morning blood pressure
1447060|NCT00198562|Calcium antagonist
1447061|NCT00198562|Angiotensin receptor antagonist
1447062|NCT00198549|Adjuvants, Anesthesia
1447063|NCT00198549|hyaluronate lyase
1447064|NCT00198523|Cataract Extraction
1447065|NCT00198523|Anti-Bacterial Agents
1447066|NCT00198523|Steroids
1447067|NCT00198484|Adjuvants, Anesthesia
1447068|NCT00198484|Spreading Factor
1447069|NCT00198445|Cataract Extraction
1447070|NCT00198445|Anti-Inflammatory Agents, Non-Steroidal
1447071|NCT00198393|stage IIIB/IV NSCLC
1447072|NCT00198393|patients with performance status 2 or 3.
1447073|NCT00198380|Adenocarcinoma, Bronchiolo-Alveolar
1447074|NCT00198367|operable and resectable stage IIIA (T1-3, N2) NSCLC
1447075|NCT00198341|Post-surgical Non-small cell lung cancer
1447076|NCT00198328|Squamous Cell Carcinoma
1447077|NCT00198328|carcinoma
1447078|NCT00198328|head and neck cancer
1447079|NCT00198328|larynx
1447080|NCT00198328|electroporation
1447081|NCT00198328|medpulser
1447082|NCT00198328|bleomycin
1447083|NCT00198328|cancer
1447206|NCT00196989|GW677954
1447207|NCT00196989|Pharmacodynamics
1447084|NCT00198328|Locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx, or larynx
1447085|NCT00198315|Squamous Cell Carcinoma
1447086|NCT00198315|Carcinoma
1447087|NCT00198315|Head and Neck Cancer
1447088|NCT00198315|Oral
1447089|NCT00198315|Soft Palate
1447090|NCT00198315|Cancer
1447091|NCT00198315|Medpulser
1447092|NCT00198315|Electroporation
1447093|NCT00198315|Local recurrent or second primary squamous cell carcinoma of anterior oral cavity, soft palate, or tonsil
1447094|NCT00198302|staphylococcus aureus
1447095|NCT00198302|bacteremia
1447096|NCT00198302|sepsis
1447097|NCT00198289|Cystic Fibrosis
1447098|NCT00198289|Staphylococcus aureus
1447099|NCT00198289|lungs
1447100|NCT00198276|cancer
1447101|NCT00198276|cutaneous
1447102|NCT00198276|subcutaneous
1447103|NCT00198276|MedPulser
1447104|NCT00198276|bleomycin
1447105|NCT00198276|electroporation
1447106|NCT00198276|Cutaneous or subcutaneous cancer
1447107|NCT00198263|head and neck cancer
1447108|NCT00198263|cancer
1447109|NCT00198263|bleomycin
1447110|NCT00198263|medpulser
1447111|NCT00198263|electroporation
1447112|NCT00198263|primary oral cavity, primary pharyngeal, primary laryngeal, salivary gland, limited recurrent and second primary tumors
1447113|NCT00198250|Breast cancer survivorship
1447114|NCT00198250|hot flashes
1447115|NCT00198250|treatment
1447116|NCT00198237|Breast Cancer
1447117|NCT00198237|Stage II Breast Cancer
1447118|NCT00198237|Stage III Breast Cancer
1447119|NCT00198224|immunosuppression
1447120|NCT00198185|Full Thickness Tendon Defect of Rotator Cuff
1447121|NCT00198172|Germ Cell Tumor
1447122|NCT00198172|Refractory Germ Cell Tumors
1447123|NCT00198172|Cisplatin plus Epirubicin Salvage Chemotherapy
1447124|NCT00198159|Refractory Germ Cell Tumors
1447125|NCT00198159|Germ Cell Tumors
1447126|NCT00198133|Thymoma
1447127|NCT00198133|Thymic Carcinoma
1447128|NCT00198120|Autistic Disorder
1447129|NCT00198120|cycloserine
1447130|NCT00198120|pharmacology
1447131|NCT00198120|glutamatergic agents
1447132|NCT00198120|communication
1447133|NCT00198120|social interaction
1447134|NCT00198120|Double-Blind Method
1447135|NCT00198107|Children
1447136|NCT00198107|Adolescents
1447137|NCT00198107|Aripiprazole
1447138|NCT00198107|Cycloserine
1447139|NCT00198107|Aggression
1447140|NCT00198107|Irritability
1447141|NCT00198107|Self-Injurious Behavior
1447142|NCT00198107|Social Interaction
1447143|NCT00198107|Antipsychotics
1447144|NCT00198107|Pharmacology
1447145|NCT00198107|Glutamatergic Agents
1447146|NCT00198081|celecoxib for pancreas lesions
1447147|NCT00198068|Pregnancy outcomes
1447148|NCT00198068|Systemic lupus erythematosus
1447149|NCT00198068|Antiphospholipid syndrome
1447150|NCT00198055|Aggression
1447151|NCT00198055|Behavioral symptoms
1447152|NCT00198042|ACL
1447153|NCT00198042|Tunnel
1447154|NCT00198042|Widening
1447155|NCT00198029|Osteoarthritis
1447156|NCT00198029|Hyaluronan
1447157|NCT00198029|Carpometacarpal
1447158|NCT00198029|Outcomes
1447159|NCT00198016|coronary fistulas.
1447160|NCT00198016|coils embolization.
1447161|NCT00198003|hip arthritis
1447162|NCT00198003|total hip arthroplasty
1447163|NCT00198003|expectations
1447164|NCT00198003|education
1447165|NCT00197990|total hip arthroplasty
1447166|NCT00197990|expectations
1447167|NCT00197990|satisfaction
1447168|NCT00197990|quality of life
1447169|NCT00197977|knee arthritis
1447170|NCT00197977|total knee arthroplasty
1447171|NCT00197977|expectations
1447172|NCT00197977|education
1447173|NCT00197964|Self-management
1447174|NCT00197964|Self-efficacy
1447175|NCT00197964|Quality of life
1447176|NCT00197964|Resource utilization
1447177|NCT00197951|Psychiatric symptoms associated to alcoholism recovery
1447178|NCT00197951|Alcoholism treatment
1447179|NCT00197951|Alcohol craving
1447180|NCT00197951|Relapse to heavy drinking
1447181|NCT00197951|Abuse of other substances during alcoholism recovery
1447182|NCT00197925|breast cancer
1447183|NCT00197925|dendritic cells
1447184|NCT00197925|vaccine
1447185|NCT00197912|dendritic cell
1447186|NCT00197912|cancer vaccine
1447187|NCT00197912|cyclophosphamide
1447188|NCT00197912|melanoma
1447189|NCT00197106|salmeterol/fluticasone combination
1447190|NCT00197106|Asthma
1447191|NCT00197106|bronchial hyperresponsiveness
1447192|NCT00197106|Children
1447193|NCT00197106|symptom control
1447194|NCT00197093|Schizophrenia
1447195|NCT00197093|safety
1447196|NCT00197093|tolerability
1447197|NCT00197093|pharmacokinetics
1447198|NCT00197080|Restless Legs Syndrome
1447199|NCT00197080|RLS
1447200|NCT00196989|Efficacy
1447201|NCT00196989|PPARpan
1447202|NCT00196989|Type 2 Diabetes Mellitus
1447203|NCT00196989|Phase IIb
1447204|NCT00196989|Safety
1447205|NCT00196989|Pharmacokinetics
1447208|NCT00196989|Tolerability
1447209|NCT00196989|Dose-Ranging
1447210|NCT00196976|Safety
1447211|NCT00196976|Meningococcal vaccine
1447212|NCT00196976|Dose selection
1447213|NCT00196976|Toddlers
1447214|NCT00196976|Immunogenicity
1447215|NCT00196976|Conjugate vaccine
1447216|NCT00196976|Reactogenicity
1447217|NCT00196976|Children
1447218|NCT00196937|HPV Vaccine Safety
1447219|NCT00196898|Parkinson´s disease
1447220|NCT00196898|fibrotic valvular heart fibrosis
1447221|NCT00196898|ergot dopamine agonists
1447222|NCT00196898|non-ergot dopamine agonists
1447223|NCT00196885|cancer cachexia
1447224|NCT00196885|muscle wasting
1447225|NCT00196885|weight loss
1447226|NCT00196885|proteolysis
1447227|NCT00196872|dose dense sequence
1447228|NCT00196872|dose dense combination
1447229|NCT00196872|node positive disease
1447230|NCT00196859|Early Breast Cancer in elderly Patients
1447231|NCT00196859|Ibandronate plus/minus Capecitabine in elderly patients
1447232|NCT00197873|colorectal cancer
1447233|NCT00197873|probiotics
1447234|NCT00197873|chemotherapy
1447235|NCT00197873|prevention
1447236|NCT00197873|adverse effects
1447237|NCT00197873|diarrhoea
1447238|NCT00197860|dendritic cell
1447239|NCT00197860|vaccine
1447240|NCT00197860|renal cell carcinoma
1447241|NCT00197834|Depakote
1447242|NCT00197834|Agitation
1447243|NCT00197834|Dementia
1447244|NCT00197834|Atypical antipsychotic
1447245|NCT00197834|Behavioral Symptoms
1447246|NCT00197834|Psychiatric Symptoms
1447247|NCT00197834|Psychological Symptoms
1447248|NCT00197834|Geriatric
1447249|NCT00197834|Behavioral and Psychological Symptoms
1447250|NCT00197808|Streptococcus pneumoniae
1447251|NCT00197808|Neisseria meningitidis
1447252|NCT00197756|HIV
1447253|NCT00197756|Breastfeeding
1447254|NCT00197756|Vitamins
1447255|NCT00197756|Tanzania
1447256|NCT00197756|Children
1447257|NCT00197743|HIV
1447258|NCT00197743|Multivitamins
1447259|NCT00197743|Pregnancy outcomes
1447260|NCT00197743|Tanzania
1447261|NCT00197743|Women
1447262|NCT00197730|Birth Outcomes
1447263|NCT00197730|Nutrition
1447264|NCT00197730|HIV
1447265|NCT00197730|AIDS
1447266|NCT00197730|Vitamins
1447267|NCT00197730|Multivitamins
1447268|NCT00197730|Maternal and child health outcomes
1447269|NCT00197730|Tanzania
1447270|NCT00197730|Africa
1447271|NCT00197704|Tuberculosis
1447272|NCT00197704|HIV
1447273|NCT00197704|Tanzania
1447274|NCT00197704|multivitamins
1447275|NCT00197691|HIV infected mothers
1447276|NCT00197691|Infants at risk of HIV-infection
1447277|NCT00197691|Infant lower respiratory tract disease
1447278|NCT00197691|Infant bloodstream infection
1447279|NCT00197678|HIV
1447280|NCT00197678|AIDS
1447281|NCT00197678|Multivitamins
1447282|NCT00197678|Pregnancy Outcomes
1447283|NCT00197678|Women
1447284|NCT00197678|Tanzania
1447285|NCT00197678|Africa
1447286|NCT00197652|Prevention of Mother-Infant HIV Transmission
1447287|NCT00197639|indinavir, HIV, ritonavir, pharmacokinetics, Thailand
1447288|NCT00197561|HIV
1447289|NCT00197561|Selenium
1447290|NCT00197561|Nutrition
1447291|NCT00197561|Women
1447292|NCT00197561|Pregnancy
1447293|NCT00197561|Tanzania
1447294|NCT00197561|Maternal and child health outcomes
1447295|NCT00197561|HIV/AIDS
1447296|NCT00197561|Pregnancy Outcome
1447297|NCT00197548|Women
1447298|NCT00197548|Pregnancy Outcomes
1447299|NCT00197548|Nutrition
1447300|NCT00197548|Vitamins
1447301|NCT00197548|Tanzania
1447302|NCT00197548|Maternal and Child Health Outcomes
1447303|NCT00197522|breast cancer
1447304|NCT00197522|vaccination
1447305|NCT00197522|dendritic cells
1447306|NCT00197522|HER-2
1447307|NCT00197522|CD34+ stem cells
1447308|NCT00197509|Long-Term Care
1447309|NCT00197509|Clinical Protocols
1447310|NCT00197509|Sit-To-Stand
1447311|NCT00197483|Pergolide
1447312|NCT00197483|Dopamine D1
1447313|NCT00197483|Schizophrenia
1447314|NCT00197483|Cognitive disturbance
1447315|NCT00197483|Negative symptoms
1447316|NCT00197444|esophageal cancer
1447317|NCT00197444|Nedaplatin
1447318|NCT00197444|5-FU
1447319|NCT00197444|chemotherapy
1447320|NCT00197444|radiation
1447321|NCT00197444|chemoradiotherapy
1447322|NCT00197418|H. pylori infection
1447323|NCT00197392|Ventriculostomy
1447324|NCT00197392|EVD
1447325|NCT00197379|androgenetic alopecia
1447326|NCT00197379|roxitromycin
1447327|NCT00197379|apoptosis
1447328|NCT00197366|pregnancy
1447329|NCT00197366|HIV-positive
1447330|NCT00197366|HIV resistance
1447331|NCT00197366|HIV
1447332|NCT00197353|Anesthesia, Epidural
1447333|NCT00197353|Pharmacology
1447334|NCT00197353|Dose-Response Relationship, Drug
1447335|NCT00197353|Sympathectomy
1447336|NCT00197353|Photoplethysmography
1447337|NCT00197340|Pre-Eclampsia
1447338|NCT00197340|Fetal Growth Retardation
1447339|NCT00197340|Anesthesia, Epidural
1447340|NCT00197340|Placental Circulation
1447341|NCT00197340|Dose-Response Relationship, Drug
1447342|NCT00197327|Labor Pain
1447343|NCT00197327|Analgesia, Obstetrical
1447344|NCT00197327|Pharmacology
1447345|NCT00197327|Treatment Outcome
1447346|NCT00197314|Urinary stress incontinence
1447347|NCT00197314|Randomized trial
1447348|NCT00197314|circular muscle training
1447349|NCT00197314|pelvic floor training
1447350|NCT00197314|bioequivalence
1447351|NCT00197301|Intranasal vaccination, Influenza
1447352|NCT00197288|Prophylaxis: Influenza virus infection
1447353|NCT00197275|Haemophilus influenzae type b
1447354|NCT00197275|diphtheria
1447355|NCT00197275|tetanus
1447356|NCT00197275|Prophylaxis diphtheria
1447357|NCT00197275|pertussis
1447358|NCT00197275|hepatitis B
1447359|NCT00197275|meningococcal serogroups A & C diseases
1447360|NCT00197262|Seasonal Allergic Rhinitis
1447361|NCT00197262|GW685698X
1447362|NCT00197262|allergic rhinitis
1447363|NCT00197262|Hayfever
1447364|NCT00197249|Hepatitis A & B
1447365|NCT00197249|Typhoid
1447366|NCT00197236|Hepatitis A
1447367|NCT00197197|HIV-1 GW873140 CCR5 antagonist treatment experienced
1447368|NCT00197184|Combined hepatitis A and B vaccine
1447369|NCT00197184|Twinrix™
1447370|NCT00196846|hormone insensitive breast cancer
1447371|NCT00196846|Prevention of Chemotherapy induced ovarian failure
1447372|NCT00196846|P.O.F.
1447373|NCT00196846|GnRH-Agonist Goserelin
1447374|NCT00196833|Breast Cancer in Pregnancy
1447375|NCT00196833|Prospective and Retrospective Register
1447376|NCT00196833|Study
1447377|NCT00196820|Metastatic breast cancer
1447378|NCT00196820|HER2 negative, medium-risk, metastatic breast cancer
1447379|NCT00196807|prostate cancer screening
1447380|NCT00196807|medical decision making
1447381|NCT00196807|informed decision making
1447382|NCT00196807|patient education
1447383|NCT00196807|male
1447384|NCT00196794|Pseudomembranous Colitis
1447385|NCT00196794|Clostridium difficile-associated diarrhea
1447386|NCT00196794|C. difficile
1447387|NCT00196794|CDAD
1447388|NCT00196781|prostate cancer treatment
1447389|NCT00196781|medical decision making
1447390|NCT00196781|informed decision making
1447391|NCT00196781|shared decision making
1447392|NCT00196781|decision aid
1447393|NCT00196781|patient education
1447394|NCT00196768|relapsed
1447395|NCT00196768|acute promyelocytic leukemia
1447396|NCT00196768|arsenic
1447397|NCT00196742|alpha Galactosidase A
1447398|NCT00196742|aGAL (alpha-galactosidase)
1447399|NCT00196742|Fabry
1447400|NCT00196742|GL3 (globotriaosylceramide)
1447401|NCT00196742|Anderson-Fabry Disease
1447402|NCT00196742|angiokeratomas
1447403|NCT00196742|GLA deficiency (gene deficiency)
1447404|NCT00196742|errors in metabolism
1447405|NCT00196716|alpha Galactosidase A
1447406|NCT00196716|aGAL
1447407|NCT00196716|rh aGAL
1447408|NCT00196716|Fabry
1447409|NCT00196716|GL3
1447410|NCT00196716|Fabrazyme
1447411|NCT00196703|Aphasia
1447412|NCT00196703|Memantine
1447413|NCT00196703|Constraint-induced language therapy
1447414|NCT00196703|Event-related potentials
1447415|NCT00196690|Aphasia
1447416|NCT00196690|Donepezil
1447417|NCT00196664|Chronic Hepatitis C
1447418|NCT00196664|Paroxetine
1447419|NCT00196664|Depression
1447420|NCT00196651|HIV infection
1447421|NCT00196651|AIDS Vaccines
1447422|NCT00196651|ALVAC vaccine
1447423|NCT00196651|Interleukin-2
1447424|NCT00196651|Antiretroviral Therapy, Highly Active
1447425|NCT00196638|HIV infections
1447426|NCT00196638|Primary acute infection
1447427|NCT00196638|Interferon-alpha
1447428|NCT00196625|HIV infections
1447429|NCT00196625|Salvage therapy
1447430|NCT00196625|Amprenavir
1447431|NCT00196625|Lopinavir
1447432|NCT00196625|Ritonavir
1447433|NCT00196612|HIV Infections
1447434|NCT00196612|Reverse Transcriptase Inhibitors
1447435|NCT00196612|Treatment simplification
1447436|NCT00196599|HIV infections
1447437|NCT00196599|Reverse Transcriptase Inhibitors
1447438|NCT00196586|Chronic Hepatitis C
1447439|NCT00196586|HIV infection
1447440|NCT00196586|Interleukin-2
1447441|NCT00196586|Pegylated interferon alpha 2 a
1447442|NCT00196586|ribavirin
1447443|NCT00196573|Rotator Cuff
1447444|NCT00196573|Tendinosis
1447445|NCT00196573|Impingement Syndrome
1447446|NCT00196573|Partial Thickness Tears
1447447|NCT00196573|Rotator Cuff Tendinosis
1447448|NCT00196573|Partial Thickness Rotator Cuff Tears
1447449|NCT00196560|Immobilization in External Rotation
1447450|NCT00196560|Acute primary anterior shoulder dislocation
1447451|NCT00196547|Asthma
1447452|NCT00196547|Respiratory viral infections
1447453|NCT00196547|Exacerbations
1447454|NCT00196547|Pediatric
1447455|NCT00196547|Leukotriene receptor antagonists
1447456|NCT00196547|School
1447457|NCT00196508|Childbirth
1447458|NCT00196482|growth
1447459|NCT00196482|oral feeding
1447460|NCT00196482|nutrition
1447461|NCT00196456|Photodynamic lasertherapy
1447462|NCT00196456|Periodontol disease
1447463|NCT00196417|heparin-induced thrombocytopenia
1447464|NCT00196417|HIT
1447465|NCT00196417|unfractionated heparin
1447466|NCT00196417|UFH
1447467|NCT00196417|low-molecular-weight heparin
1447468|NCT00196417|LMWH
1447469|NCT00196417|thrombosis prophylaxis
1447470|NCT00196417|HIT-antibody
1447471|NCT00196404|overactive bladder
1447472|NCT00196404|urge incontinence
1447473|NCT00196404|urinary incontinence
1447474|NCT00196391|secondary amenorrhea
1447475|NCT00196391|progesterone
1447476|NCT00196378|vaginal atrophy
1447477|NCT00196378|vaginal dryness
1447478|NCT00196378|vaginal itching
1447479|NCT00196378|vaginal pain
1447480|NCT00196378|dyspareunia
1447481|NCT00196365|cyclic pelvic pain
1447482|NCT00196365|dysmenorrhea
1447483|NCT00196352|oral contraceptives
1447484|NCT00196352|birth control
1447485|NCT00196352|ethinyl estradiol
1447486|NCT00196352|pregnancy prevention
1447487|NCT00196339|prostate cancer
1447488|NCT00196339|hot flashes
1447489|NCT00196339|hot flushes
1447490|NCT00196339|vasomotor symptoms
1447491|NCT00196326|pregnancy prevention
1447492|NCT00196326|oral contraceptives
1447493|NCT00196313|cyclic pelvic pain
1447494|NCT00196313|dysmenorrhea
1447495|NCT00196313|oral contraceptives
1447496|NCT00196300|Assessment, Risk
1447497|NCT00196300|Autonomic nervous system
1447498|NCT00196300|Aged
1447499|NCT00196287|Assessment, risk
1447500|NCT00196287|autonomic nervous system
1447501|NCT00196287|Gender
1447502|NCT00196274|AUTONOMIC NERVOUS SYSTEM
1447503|NCT00196274|Assessment, Risk
1447504|NCT00196261|Assessment, Risk
1447505|NCT00196261|Autonomic nervous system
1447506|NCT00196235|Assessment, Risk
1447507|NCT00196235|Diabetes mellitus
1447508|NCT00196235|Autonomic nervous system
1447509|NCT00196209|atrial fibrillation
1447510|NCT00196209|catheter ablation
1447511|NCT00196196|Hydrocephalus
1447512|NCT00196196|Codman Hakim Programmable Valve
1447513|NCT00196196|Programmable Valve
1447514|NCT00196196|Shunt System
1447515|NCT00196131|morphine
1447516|NCT00196131|head injury
1447517|NCT00196131|SAH
1447518|NCT00196118|Pulmonary Embolism
1447519|NCT00196118|Venous Thromboembolism
1447520|NCT00196118|Inferior Vena Cava Filter
1447521|NCT00196118|IVC
1447522|NCT00196118|PE
1447523|NCT00196105|Stents
1447524|NCT00196105|Stent-graft
1447525|NCT00196105|Minimally invasive
1447526|NCT00196105|Biliary Tract Cancer
1447527|NCT00196105|Pancreatic Cancer
1447528|NCT00196105|Jaundice
1447529|NCT00196105|Biliary Tract Neoplasms
1447530|NCT00196105|Pancreatic Neoplasms
1447531|NCT00196105|Jaundice, Obstructive
1447532|NCT00196105|Zilver
1447533|NCT00196079|coronary artery
1447534|NCT00196079|stenosis
1447535|NCT00196079|drug eluting stent
1447536|NCT00196079|stent
1447537|NCT00196053|Intrathecal pain management
1447538|NCT00196053|constant flow pump
1447539|NCT00196014|Registered Nurses
1447540|NCT00196014|Workload
1447541|NCT00196014|Clinical staff nurses that are currently working
1447542|NCT00196001|Adrenal sufficiency
1447543|NCT00196001|Low-dose ACTH stimulation
1447544|NCT00196001|G proteins
1447545|NCT00195988|immunosuppression,
1447546|NCT00195988|steroid avoidance,
1447547|NCT00195988|liver transplantation,
1447548|NCT00195988|children
1447549|NCT00195975|Abdominal Pain
1447550|NCT00195975|Functional Gastrointestinal Disorders
1447551|NCT00195975|Stress
1447552|NCT00195975|Anxiety
1447553|NCT00195975|Autonomic Nervous System
1447554|NCT00195962|Breastfeeding
1447555|NCT00195962|Post-partum mothers of healthy breast-fed newborns
1447556|NCT00195949|Pyloric Stenosis
1447557|NCT00195949|Laparoscopy
1447558|NCT00195949|Idiopathic Hypertrophic Pyloric Stenosis
1447559|NCT00195936|Cinacalcet
1447560|NCT00195936|PTH
1447561|NCT00195936|XLH
1447562|NCT00195936|children and adolescents with hypophosphatemic rickets (XLH)
1447563|NCT00195923|appendicitis
1447564|NCT00195923|perforation
1447565|NCT00195910|Acute
1447566|NCT00195910|Pain
1447567|NCT00195910|Emergency Department
1447568|NCT00195910|Morphine
1447569|NCT00195910|Hydromorphone
1447570|NCT00195910|Dilaudid
1447571|NCT00195897|Lymphoma
1447572|NCT00195897|Anthracyclines
1447573|NCT00195897|Heart Failure
1447574|NCT00195897|Radionuclide
1447575|NCT00195897|Magnetic Resonance Imaging
1447576|NCT00195897|Troponin
1447577|NCT00195897|Natriuretic Peptide, Brain
1447578|NCT00195884|Diabetes Mellitus
1447579|NCT00195884|Type 2 Diabetes
1447580|NCT00195884|Aerobic
1447581|NCT00195884|Resistance
1447582|NCT00195884|weight training
1447583|NCT00195884|Exercise
1447584|NCT00195871|Non-Hodgkin
1447585|NCT00195871|Lymphoma
1447586|NCT00195871|Lymphoblastic
1447587|NCT00195858|Youth
1447588|NCT00195858|Exercise
1447589|NCT00195858|Physical Activity
1447590|NCT00195858|Aerobic
1447591|NCT00195858|Resistance
1447592|NCT00195858|Overweight
1447593|NCT00195858|obese
1447594|NCT00195858|Canada
1447595|NCT00195858|Sigal
1447596|NCT00195819|ankylosing spondylitis
1447597|NCT00195819|adalimumab
1447598|NCT00195806|Migraine
1447599|NCT00195806|Depakote ER
1447600|NCT00195806|Divalproex sodium
1447601|NCT00195793|Hyperlipidemia
1447602|NCT00195793|fenofibrate
1447603|NCT00195793|ezetimibe
1447604|NCT00195793|atorvastatin
1447605|NCT00195780|Bipolar I Disorder
1447606|NCT00195780|Depakote
1447607|NCT00195767|Bipolar I Disorder
1447608|NCT00195767|Depakote ER
1447609|NCT00195767|divalproex sodium
1447610|NCT00195754|Migraines
1447611|NCT00195754|Depakote ER
1447612|NCT00195754|divalproex sodium
1447613|NCT00195741|Migraine
1447614|NCT00195741|Depakote ER
1447615|NCT00195728|Hydrocodone/Acetaminophen
1447616|NCT00195728|Vicodin CR
1447617|NCT00195702|Rheumatoid Arthritis
1447618|NCT00195663|Early Rheumatoid Arthritis
1447619|NCT00195650|Rheumatoid Arthritis
1447620|NCT00195637|GNE Gene
1447621|NCT00195637|Alpha-Dystroglycan
1447622|NCT00195637|Sialic Acid
1447623|NCT00195637|Glycosylation
1447624|NCT00195637|Dystroglycanopathy
1447625|NCT00195637|Hereditary Inclusion Body Myopathy
1447626|NCT00195637|Immune Globulin
1447627|NCT00195637|HIBM
1447628|NCT00195624|Immunosuppression
1447629|NCT00195624|Alemtuzumab/Campath
1447630|NCT00195624|Severe Aplastic Anemia
1447631|NCT00195624|T-cells
1447632|NCT00195624|Hematopoiesis
1447633|NCT00195624|Autoimmunity
1447634|NCT00195624|Thrombocytopenia
1447635|NCT00195624|Neutropenia
1447636|NCT00195624|SAA
1447637|NCT00195611|Middle Ear Infection
1447638|NCT00195598|Panic Disorders
1447639|NCT00195585|Colon Cancer
1447640|NCT00195572|Gastric Cancer
1447641|NCT00195572|Advanced/Recurrent Gastric Cancer
1447642|NCT00195559|Premenstrual Syndrome (PMS)
1447643|NCT00195559|Hormone Therapy
1447644|NCT00195546|Menopause
1447645|NCT00195533|Leukemia
1447646|NCT00195533|Lymphoma
1447647|NCT00195533|Myeloma
1447648|NCT00195520|Menopause
1447649|NCT00195520|Sleep Disorder
1447650|NCT00195520|Hot Flashes
1447651|NCT00195507|Psoriasis
1447652|NCT00195494|Rheumatoid Arthritis
1447653|NCT00195481|Kidney
1447654|NCT00195481|Transplant
1447655|NCT00195468|Kidney Failure
1447656|NCT00195468|Transplant
1447657|NCT00195455|Postmenopause
1447658|NCT00195442|Hemophilia A
1447659|NCT00195429|Kidney
1447660|NCT00195429|Transplant
1447661|NCT00195416|Ankylosing Spondylitis
1447662|NCT00195403|Rheumatoid Arthritis
1447663|NCT00195390|Vaccine
1447664|NCT00195390|heptavalent pneumococcal conjugate vaccine
1447665|NCT00195364|Rheumatoid Arthritis
1447666|NCT00195351|Complicated intra-abdominal infection
1447667|NCT00195351|Appendicitis with abscess
1447668|NCT00195351|Perforated diverticulitis
1447669|NCT00195351|Purulent peritonitis
1447670|NCT00195351|Complicated cholecystitis
1447671|NCT00195338|Rheumatoid Arthritis
1447672|NCT00195325|Advanced Malignant Solid Tumors
1447673|NCT00195312|HIV
1447674|NCT00195312|Vaccine
1447675|NCT00195312|Treatment Experienced
1447676|NCT00195299|Carcinoma
1447677|NCT00195299|Head
1447678|NCT00195299|Neck
1447679|NCT00195286|Urinary Infections
1447680|NCT00195273|Kidney
1447681|NCT00195273|Transplant
1447682|NCT00195260|Solid tumors
1447683|NCT00195247|Tumors
1447684|NCT00195247|Advanced malignant solid tumors
1447685|NCT00195234|HIV
1447686|NCT00195234|Treatment Experienced
1447687|NCT00195221|Hemophilia B
1447688|NCT00195208|Gastroesophageal Reflux Disease (GERD)
1447689|NCT00195195|Transplantation
1447690|NCT00195182|Hypertension
1447691|NCT00195182|African-American
1447692|NCT00195182|Perceived Racism
1447693|NCT00195182|Psychological Stress
1447694|NCT00195182|Medication Adherence
1447695|NCT00195169|Myocardial Infarction
1447696|NCT00195169|Social support
1447697|NCT00195156|Solid Tumor Malignancies
1447698|NCT00195143|Parkinson's disease
1447699|NCT00195143|GABA
1447700|NCT00195143|Subthalamic nucleus
1447701|NCT00195143|Adeno-associated virus
1447702|NCT00195143|AAV
1447703|NCT00195143|Gene therapy
1447704|NCT00195130|prognosis
1447705|NCT00195130|risk of death
1447706|NCT00195130|morbidity
1447707|NCT00195130|mortality
1447708|NCT00195130|quality of life
1447709|NCT00195117|Asthma
1447710|NCT00195117|Behavior change
1447711|NCT00195117|Physical activity
1447712|NCT00195117|Risk reduction
1447713|NCT00195104|Myelodysplastic Syndrome
1447714|NCT00195078|head and neck cancer
1447715|NCT00195078|squamous cell carcinoma of the oral cavity
1447716|NCT00195078|squamous cell carcinoma of the oropharynx
1447717|NCT00195078|squamous cell carcinoma of the larynx
1447718|NCT00195078|squamous cell carcinoma of the hypopharynx
1447719|NCT00195065|Asthma
1447720|NCT00195065|Behavior change
1447721|NCT00195065|Physical activity
1447722|NCT00195065|Risk reduction
1447723|NCT00195052|epilepsy
1447724|NCT00195052|optical imaging
1447725|NCT00195052|optical mapping
1447726|NCT00195039|Prostate Cancer
1447727|NCT00195000|Acute Myeloid Leukemia
1447728|NCT00195000|Myelodysplastic Syndrome
1447729|NCT00194987|Alloimmune thrombocytopenia
1447730|NCT00194987|Fetal alloimmune thrombocytopenia
1447731|NCT00194974|pregnancy
1447732|NCT00194974|chronic hypertension
1447733|NCT00194974|Toxemia
1447734|NCT00194974|Blood Pressure
1447735|NCT00194961|Chronic Kidney Disease
1447736|NCT00194961|Growth Failure
1447737|NCT00194961|Cytokines
1447738|NCT00194961|leptin
1447739|NCT00194935|Ovarian Cancer
1447740|NCT00194935|Cancer of the Ovary
1447741|NCT00194896|type 2 diabetes mellitus
1447742|NCT00194896|autoantibodies
1447743|NCT00194896|islet proteins
1447744|NCT00194896|rosiglitazone
1447745|NCT00194896|glyburide
1447746|NCT00194896|c-peptide
1447747|NCT00194883|Recombinant Human Growth Hormone
1447748|NCT00194883|Leptin
1447749|NCT00194883|Cytokines
1447750|NCT00194883|Chronic Renal Insufficiency
1447751|NCT00194883|Children
1447752|NCT00194870|EEG
1447753|NCT00194870|DBS
1447754|NCT00194857|anemia
1447755|NCT00194857|dose reduction
1447756|NCT00194857|neutropenia
1447757|NCT00194857|hepatitis C virus
1447758|NCT00194857|human immunodeficiency virus
1447759|NCT00194844|caring
1447760|NCT00194844|miscarriage
1447761|NCT00194844|grief
1447762|NCT00194844|couples
1447763|NCT00194844|counseling
1447764|NCT00194805|Internet
1447765|NCT00194805|Diabetes
1447766|NCT00194805|Education
1447767|NCT00194805|Social Support
1447768|NCT00194766|Breast cancer
1447769|NCT00194766|Soft tissue sarcoma
1447770|NCT00194753|Breast cancer
1447771|NCT00194740|Breast cancer
1447772|NCT00194727|Breast cancer
1447773|NCT00194701|heart failure
1447774|NCT00194701|sleep
1447775|NCT00194701|exercise
1447776|NCT00194701|heart rate variability
1447777|NCT00194688|ammonia
1447778|NCT00194675|androgen deficiency
1447779|NCT00194675|testosterone
1447780|NCT00194675|Benign Prostatic Hyperplasia
1447781|NCT00194675|hypogonadism
1447782|NCT00194675|prostate
1447783|NCT00194675|BPH
1447784|NCT00194649|Glycosphingolipids (GSL)
1447785|NCT00194636|Prostatitis
1447786|NCT00194636|Chronic Male Pelvic Pain Syndrome
1447787|NCT00194623|prostatitis
1447788|NCT00194597|Prostatitis
1447789|NCT00194584|children
1447790|NCT00194584|chronic illness
1447791|NCT00194584|parent education
1447792|NCT00194584|parent support
1447793|NCT00194571|breast cancer,
1447794|NCT00194571|child functioning,
1447795|NCT00194571|parenting,
1447796|NCT00194571|self-efficacy,
1447797|NCT00194571|psychoeducational intervention
1447798|NCT00194571|counseling
1447799|NCT00194558|Diabetes
1447800|NCT00194558|Health Education
1447801|NCT00194558|Information Technology
1447802|NCT00194558|Disease Management
1447803|NCT00194558|Internet
1447804|NCT00194558|Patient Education
1447805|NCT00194545|HIV-1
1447806|NCT00194545|pediatric adherence
1447807|NCT00194545|medication diaries
1447808|NCT00194545|HAART
1447809|NCT00194545|Treatment Naive
1447810|NCT00194532|UTI
1447811|NCT00194519|HIV infection
1447812|NCT00194519|HIV transmission
1447813|NCT00194519|genital herpes
1447814|NCT00194519|sexual intercourse
1447815|NCT00194519|sexual transmitted infection
1447816|NCT00194519|acyclovir
1447817|NCT00194519|HIV Seronegativity
1447818|NCT00194519|Treatment Naive
1447819|NCT00194519|HIV-discordant couples
1447820|NCT00194519|HIV serodiagnosis
1447821|NCT00194506|Diabetes
1447822|NCT00194506|Health Education
1447823|NCT00194506|Information Technology
1447824|NCT00194506|Disease Management
1447825|NCT00194506|Internet
1447826|NCT00194506|Patient Education
1447827|NCT00194493|Cancer
1447828|NCT00194493|Quality of Life
1447829|NCT00194493|Signs and Symptoms
1447830|NCT00194493|Computers
1447831|NCT00194493|Patient-Reported Outcomes
1447832|NCT00194480|Hepatitis C, peg-Interferon, drug abuse
1447833|NCT00194454|Depressive symptoms
1447834|NCT00194454|Behavior and behavior mechanisms
1447835|NCT00194454|Recovery
1447836|NCT00194441|cerebral circulation
1447837|NCT00194441|monitoring, physiologic
1447838|NCT00194441|informatics
1447839|NCT00194441|nursing care
1447840|NCT00194441|physiologic variability
1447841|NCT00194441|outcome
1447842|NCT00194441|quality adjusted life years
1447843|NCT00194428|Obesity,
1447844|NCT00194428|Metabolic Syndrome,
1447845|NCT00194428|BMI
1447846|NCT00194402|cholesterol
1447847|NCT00194402|dyslipidemia
1447848|NCT00194402|hypercholesterolemia
1447849|NCT00194402|C-reactive protein
1447850|NCT00194363|breast cancer
1447851|NCT00194363|breast cancer survivors
1447852|NCT00194363|lymphedema
1447853|NCT00194363|strength training
1447854|NCT00194363|breast cancer survivorship
1447855|NCT00194350|Infertility
1447856|NCT00194350|Factor V Leiden
1447857|NCT00194337|stage I breast cancer
1447858|NCT00194337|stage II breast cancer
1447859|NCT00194337|stage IIIA breast cancer
1447860|NCT00194337|stage IIIB breast cancer
1447861|NCT00194337|stage IIIC breast cancer
1447862|NCT00194337|stage IV breast cancer
1447863|NCT00194311|HPV
1447864|NCT00194311|Pregnancy
1447865|NCT00194298|diabetic foot disease
1447866|NCT00194298|osteomyelitis
1447867|NCT00194298|charcot
1447868|NCT00194298|neuropathy
1447869|NCT00194298|hypoxia
1447870|NCT00194298|[18 F] Fluorodeoxyglucose
1447871|NCT00194298|Positron Emission Tomography Imaging
1447872|NCT00194285|Prosthesis
1447873|NCT00194285|[18 F] Fluorodeoxyglucose
1447874|NCT00194285|Positron Emission Tomography Imaging
1447875|NCT00194272|Ectopic pregnancy
1447876|NCT00194272|Methotrexate
1447877|NCT00194233|Endometriosis
1447878|NCT00194220|Infertility
1447879|NCT00194220|Oxidative stress
1447880|NCT00194207|Ectopic pregnancy
1447881|NCT00194194|BMI
1447882|NCT00194194|RMR
1447883|NCT00194194|Personal Computer
1447884|NCT00194181|dialysis
1447885|NCT00194181|fibrin
1447886|NCT00194181|sheath
1447887|NCT00194181|clot
1447888|NCT00194181|tpa
1447889|NCT00194168|ectopic pregnancy
1447890|NCT00194155|cytomegalovirus
1447891|NCT00194155|pregnancy
1447892|NCT00194155|placenta
1447893|NCT00194142|Pregnancy
1447894|NCT00194142|Cytomegalovirus
1447895|NCT00194090|pain
1447896|NCT00194090|osteoarthritis
1447897|NCT00194051|obesity
1447898|NCT00194051|gait biomechanics
1447899|NCT00194051|knee osteoarthritis
1447900|NCT00194038|Bipolar Disorder
1447901|NCT00194038|Geriatric Psychiatry
1447902|NCT00194038|Aripiprazole
1447903|NCT00194025|Schizophrenia
1447904|NCT00194025|Anticonvulsants
1447905|NCT00194025|Valproic Acid
1447906|NCT00194025|Valproate
1447907|NCT00194012|bipolar disorder
1447908|NCT00193999|Nasogastric Tubes
1447909|NCT00193999|Nausea
1447910|NCT00193999|Vomiting
1447911|NCT00193999|Cardiac surgery
1447912|NCT00193986|Prepulse
1447913|NCT00193986|Defibrillator
1447914|NCT00193973|Lymphoma
1447915|NCT00193973|PCNSL
1447916|NCT00193973|Primary CNS lymphoma
1447917|NCT00193960|Seton surgery, glaucoma, Ahmed valve, intraocular pressure
1447918|NCT00193934|Women's Health
1447919|NCT00193934|Multidisciplinary, multicentre prospective study
1447920|NCT00193934|Cancer:mechanisms of growth, invasion, metastases
1447921|NCT00193934|Figo Stages cervical cancer
1447922|NCT00193934|Advances in diagnosis using radiological methods
1447923|NCT00193934|Quantitative Magnetic Resonance Imaging
1447924|NCT00193934|Patient Management Strategies
1447925|NCT00193934|Selecting patients for therapy
1447926|NCT00193921|Chemoradiotherapy
1447927|NCT00193921|High dose
1447928|NCT00193921|palliative radiotherapy
1447929|NCT00193921|Quality of life
1447930|NCT00193908|Skin care
1447931|NCT00193908|Radiotherapy
1447932|NCT00193895|Skin cancer
1447933|NCT00193895|radiotherapy
1447934|NCT00193895|chemotherapy
1447935|NCT00193895|surgery
1447936|NCT00193882|Oesophageal
1447937|NCT00193882|Dysphagia
1447938|NCT00193882|Palliation
1447939|NCT00193882|Quality of Life
1447940|NCT00193882|Radiotherapy
1447941|NCT00193882|Chemotherapy
1447942|NCT00193869|Radiotherapy
1447943|NCT00193869|Dose fractionation
1447944|NCT00193856|Prostate Cancer
1447945|NCT00193856|Androgen Deprivation
1447946|NCT00193856|Hormone Therapy
1447947|NCT00193856|RadiotherapyBisphosphonate
1447948|NCT00193856|Prostate Specific Antigen (PSA)
1447949|NCT00193843|Oral cancer
1447950|NCT00193843|Head and neck surgery
1447951|NCT00193843|Accelerated radiotherapy
1447952|NCT00193843|Chemo-radiotherapy
1447953|NCT00193830|Cervical Cancer
1447954|NCT00193830|High Dose Rate (HDR) Brachytherapy
1447955|NCT00193830|Low Dose Rate (LDR) Brachytherapy
1447956|NCT00193830|Acute Toxicities
1447957|NCT00193830|Late Radiation Sequelae
1447958|NCT00193817|Cancer
1447959|NCT00193817|Esophagus
1447960|NCT00193817|Lymphadenectomy
1447961|NCT00193804|Cervical Cancer
1447962|NCT00193804|FIGO STAGE IIB
1447963|NCT00193804|CHEMORADIATION
1447964|NCT00193804|Intensity Modulated Radiation Therapy(IMRT)
1447965|NCT00193804|Conventional Radiation Therapy
1447966|NCT00193804|Cancer of the Cervix
1447967|NCT00193804|Cervix Cancer
1447968|NCT00193791|Carcinoma Cervix
1447969|NCT00193791|FIGO Stage IIIB
1447970|NCT00193791|Radiation therapy
1447971|NCT00193791|Chemoradiation
1447972|NCT00193791|Treatment related toxicities
1447973|NCT00193791|Cervical Cancer
1447974|NCT00193791|Cervix Cancer
1447975|NCT00193778|Metastatic breast cancer
1447976|NCT00193778|Locoregional treatment
1447977|NCT00193778|Survival
1447978|NCT00193765|neck dissection
1447979|NCT00193765|survival
1447980|NCT00193765|early oral cancer
1447981|NCT00193765|Early oral cavity squamous cancer with node negative neck
1447982|NCT00193752|FDG-PET Imaging
1447983|NCT00193752|Cervical Cancer
1447984|NCT00193752|Post-treatment evaluation
1447985|NCT00193752|Para-aortic Nodal Staging
1447986|NCT00193752|Extended field Radiation
1447987|NCT00193752|Extended field IMRT
1447988|NCT00193752|Cancer of the Cervix
1447989|NCT00193739|Neoadjuvant chemotherapy
1447990|NCT00193739|Surgery
1447991|NCT00193739|Cervix cancer
1447992|NCT00193739|Concurrent chemoradiation
1447993|NCT00193726|Estrogen
1447994|NCT00193726|Priming
1447995|NCT00193726|Adjuvant chemotherapy
1447996|NCT00193726|Breast cancer
1447997|NCT00193713|double-blind study in the treatment of schizophrenia
1447998|NCT00193700|Hypogonadism
1447999|NCT00192556|tuberculosis
1448000|NCT00192556|nutrition
1448001|NCT00192556|directly observed therapy
1448002|NCT00192556|Timor Leste
1448003|NCT00192556|cost-effectiveness
1448004|NCT00192543|dialysis
1448005|NCT00192543|omega-3 fatty acids
1448006|NCT00192543|antioxidants
1448007|NCT00192543|cardiovascular markers
1448008|NCT00192543|Mortality
1448009|NCT00192543|End-stage renal disease
1448010|NCT00193687|open-label study in the treatment of schizophrenia
1448011|NCT00193674|Pregnancy
1448012|NCT00193674|Immunology
1448013|NCT00193674|Unexplained recurrent miscarriage
1448014|NCT00193661|Hypogonadism
1448015|NCT00193648|FSGS
1448016|NCT00193648|Pharmacokinetics
1448017|NCT00193648|Rosiglitazone
1448018|NCT00193648|PPAR-gamma agonist
1448019|NCT00193648|Adalimumab
1448020|NCT00193648|TNF-alpha antagonist
1448021|NCT00193648|Steroid and immunosuppressive drug resistance
1448022|NCT00193648|Resistant primary FSGS
1448023|NCT00193635|Congenital uropathies
1448024|NCT00193635|Mycophenolate mofetil
1448025|NCT00193635|GFR
1448026|NCT00193635|Iothalamate clearance
1448027|NCT00193635|Urine cytometry
1448028|NCT00193635|Children
1448029|NCT00193635|Congenital urological abnormalities which represent stuctural defects in the genitourinary system
1448030|NCT00193609|Neoplasms, Unknown Primary
1448031|NCT00193596|Neoplasms, Unknown Primary
1448032|NCT00193492|Lymphoma
1448033|NCT00193492|Bevacizumab
1448034|NCT00193492|Rituximab
1448035|NCT00193453|Lung Cancer
1448036|NCT00193336|NSCLC Lung Cancer
1448037|NCT00193336|Non Small Cell Lung Cancer
1448038|NCT00193297|Ovary Cancer
1448039|NCT00193258|Recurrent clear cell renal cell carcinoma
1448040|NCT00193258|Bevacizumab
1448041|NCT00193258|Erlotinib
1448042|NCT00193258|Imatinib
1448043|NCT00193219|Colon Cancer
1448044|NCT00193206|Locally Advanced Breast Cancer
1448045|NCT00193206|Inflammatory Breast Cancer
1448046|NCT00193206|Breast Cancer
1448047|NCT00193206|Abraxane
1448048|NCT00193206|nab Paclitaxel
1448049|NCT00193206|Epirubicin
1448050|NCT00193206|Gemcitabine
1448051|NCT00193206|Gemzar
1448052|NCT00193180|Breast Cancer
1448053|NCT00193154|Kidney Cancer
1448054|NCT00193128|Esophagus Cancer
1448055|NCT00193037|Breast Cancer
1448056|NCT00192998|Affective disorder
1448057|NCT00192998|Alzheimer dementia
1448058|NCT00192998|healthy controls
1448059|NCT00192972|Catheter ablation
1448060|NCT00192972|Atrial fibrillation
1448061|NCT00192959|Anaesthesia
1448062|NCT00192959|Surgery
1448063|NCT00192959|Postoperative
1448064|NCT00192959|Neuropsychological test
1448065|NCT00192946|Cardiac resynchronization
1448066|NCT00192946|Heart failure
1448067|NCT00192946|open heart surgery
1448068|NCT00192946|surgery
1448069|NCT00192881|Percutaneous coronary intervention
1448070|NCT00192881|Balloon angioplasty
1448071|NCT00192881|Restenosis
1448072|NCT00192881|Stents
1448073|NCT00192868|primary PCI
1448074|NCT00192868|distal protection
1448075|NCT00192868|drug eluting stent
1448076|NCT00192868|restenosis
1448077|NCT00192855|schizophrenia
1448078|NCT00192855|negative symptoms
1448079|NCT00192855|entacapone
1448080|NCT00192842|carcinoma
1448081|NCT00192842|pancreas
1448082|NCT00192842|gemcitabine
1448083|NCT00192842|curcumin
1448084|NCT00192829|Lung cancer
1448085|NCT00192829|Thrombosis
1448086|NCT00192829|Hypercoagulable
1448087|NCT00192803|niddm
1448088|NCT00192803|ace2
1448089|NCT00192803|NIDDM patients
1448090|NCT00192790|Therma,pain, Silent myocardial ischemia, catastrophizing
1448091|NCT00192777|Solid Tumors
1448092|NCT00192777|Bone Metastases
1448093|NCT00192777|Radiotherapy
1448094|NCT00192777|Xeloda
1448095|NCT00192777|Concurrent
1448096|NCT00192777|Radiosensitization
1448097|NCT00192764|large cell lymphoma
1448098|NCT00192764|CHOP
1448099|NCT00192764|cyclophosphamide
1448100|NCT00192764|high-dose
1448101|NCT00192751|Schizophrenia
1448102|NCT00192751|Major depression
1448103|NCT00192751|Bipolar disorder
1448104|NCT00192751|Compliance
1448105|NCT00192751|Relapse prevention
1448106|NCT00192738|telephone,
1448107|NCT00192738|internal medicine,
1448108|NCT00192738|readmission,
1448109|NCT00192738|patients' satisfaction
1448110|NCT00192725|bipolar disorder
1448111|NCT00192725|acute mania
1448112|NCT00192725|tryptophan depletion
1448113|NCT00192725|placebo controlled add-on
1448114|NCT00192725|Bipolar disorder- manic type
1448115|NCT00192712|carcinoma
1448116|NCT00192712|pancreas
1448117|NCT00192712|chemotherapy
1448118|NCT00192712|radiotherapy
1448119|NCT00192699|Osteoarthritis
1448120|NCT00192673|Asparaginase
1448121|NCT00192673|intramuscular administration
1448122|NCT00192673|Silent antibodies
1448123|NCT00192673|Childhood acute lymphoblastic leukemia
1448124|NCT00192673|Side effects
1448125|NCT00192673|5-year EFS
1448126|NCT00192660|HIV
1448127|NCT00192660|Metabolic abnormality
1448128|NCT00192660|Lipodystrophy
1448129|NCT00192660|Cardiovascular disease
1448130|NCT00192660|Treatment Naive
1448131|NCT00192660|Treatment Experienced
1448132|NCT00192660|HIV Infections
1448133|NCT00192634|HIV
1448134|NCT00192634|Antiretroviral therapy
1448135|NCT00192634|nucleoside analogue reverse transcriptase
1448136|NCT00192634|fixed dose combination
1448137|NCT00192634|Treatment Experienced
1448138|NCT00192621|HIV negative healthy subjects
1448139|NCT00192621|Lipid metabolism
1448140|NCT00192621|Glucose metabolism
1448141|NCT00192621|Metabolic abnormality
1448142|NCT00192621|Lipodystrophy
1448143|NCT00192621|Cardiovascular disease
1448144|NCT00192621|Treatment Naive
1448145|NCT00192621|HIV
1448146|NCT00192608|Pharmacokinetics, atazanavir, saquinavir, ritonavir, HIV
1448147|NCT00192595|Hepatitis B
1448148|NCT00192595|HIV
1448149|NCT00192595|Treatment Naive
1448150|NCT00192582|Motivational interview
1448151|NCT00192582|Care plan
1448152|NCT00192582|Relapse prevention
1448153|NCT00192582|Psychoeducation
1448154|NCT00192582|Indigenous mental health
1448155|NCT00192569|Acute Hepatitis C
1448156|NCT00191971|Transitional cell carcinoma of urothelium
1448157|NCT00191282|diabetes
1448158|NCT00191282|MI
1448159|NCT00191282|heart attack
1448160|NCT00191269|after
1448161|NCT00191269|anthracycline
1448162|NCT00191269|taxane
1448163|NCT00191269|regimen
1448164|NCT00191243|breast cancer
1448165|NCT00191113|syndrome
1448166|NCT00191113|Turner
1448167|NCT00191113|Turner's
1448168|NCT00191113|height
1448169|NCT00191113|growth
1448170|NCT00191113|growth hormone
1448171|NCT00191113|somatropin
1448172|NCT00191113|short stature
1448173|NCT00191113|short
1448174|NCT00191113|hearing
1448175|NCT00191113|glucose metabolism
1448176|NCT00190671|Advanced Breast Cancer
1448177|NCT00190580|CKD
1448178|NCT00190580|chronic kidney disease
1448179|NCT00190580|hypertension
1448180|NCT00190580|angiotensin II receptor blocker
1448181|NCT00190580|cardiovascular disease
1448182|NCT00190580|valsartan
1448183|NCT00190580|KVT
1448184|NCT00190554|esophageal cancer
1448185|NCT00190554|squamous cell carcinoma
1448186|NCT00190554|esophagectomy
1448187|NCT00190554|neoadjuvant chemotherapy
1448188|NCT00190554|esophageal squamous cell carcinoma
1448189|NCT00190541|Rectal Cancer
1448190|NCT00190541|Lymph Node Dissection
1448191|NCT00190541|Rectal Surgery
1448192|NCT00190541|Autonomic Nerves
1448193|NCT00190541|Stage II, III lower rectal cancer
1448194|NCT00190528|cervical cancer
1448195|NCT00190528|drug therapy
1448196|NCT00190528|cisplatin
1448197|NCT00190528|bleomycin
1448198|NCT00190528|mitomycin
1448199|NCT00190528|vincristine
1448200|NCT00190515|adjuvant chemotherapy
1448201|NCT00190515|Stage III colorectal cancer
1448202|NCT00190515|5-FU+l-LV
1448203|NCT00190515|UFT+LV
1448204|NCT00190515|randomized controlled trial
1448205|NCT00190502|Type 1 diabetes mellitus
1448206|NCT00190502|Immune intervention
1448207|NCT00190502|Polyclonal antibodies
1448208|NCT00190502|Type 1 diabetes of recent onset
1448209|NCT00190502|C-peptide level 0.3 pmol/l or higher
1448210|NCT00190502|Positivity of at least one marker of autoimmunity (diabetes)
1448337|NCT00190047|Cerebral Ischemia
1448211|NCT00190489|metastatic breast cancer
1448212|NCT00190489|drug therapy
1448213|NCT00190489|doxorubicin
1448214|NCT00190489|docetaxel
1448215|NCT00190476|Elderly
1448216|NCT00190476|advanced
1448217|NCT00190476|non-small-cell lung cancer
1448218|NCT00190476|cisplatin
1448219|NCT00190476|docetaxel
1448220|NCT00190476|weekly
1448221|NCT00190476|combination
1448222|NCT00190476|chemotherapy
1448223|NCT00190476|randomized trial
1448224|NCT00190463|aspergillosis
1448225|NCT00190463|antifungal therapy
1448226|NCT00190463|empirical antifungal treatment
1448227|NCT00190450|Huntington
1448228|NCT00190450|graft
1448229|NCT00190450|cellular therapy
1448230|NCT00190450|striatum
1448231|NCT00190437|Chronic Obstructive Lung Disease (COLD)
1448232|NCT00190437|Randomized Clinical Trial
1448233|NCT00190437|Antibiotics
1448234|NCT00190437|Acute Exacerbation
1448235|NCT00190437|Mechanical
1448236|NCT00190437|Ventilation
1448237|NCT00190437|Intensive Care
1448238|NCT00190437|Length of Stay
1448239|NCT00190437|Mortality
1448240|NCT00190424|Glioblastoma
1448241|NCT00190424|Immunotherapy
1448242|NCT00190411|Arteries
1448243|NCT00190411|ultrasonography
1448244|NCT00190411|Ehlers Danlos syndrome
1448245|NCT00190411|Cardiovascular disease
1448246|NCT00190411|beta adrenergic antagonists
1448247|NCT00190398|Prospective
1448248|NCT00190398|Randomised
1448249|NCT00190398|Open
1448250|NCT00190398|Blinded End-point
1448251|NCT00190398|PROBE Study
1448252|NCT00190398|Ischemic stroke
1448253|NCT00190385|Cirrhosis
1448254|NCT00190385|Hepatocellular carcinoma
1448255|NCT00190385|Screening
1448256|NCT00190385|Randomized
1448257|NCT00190385|HBV
1448258|NCT00190385|HCV
1448259|NCT00190385|alcohol
1448260|NCT00190385|hemochromatosis
1448261|NCT00190372|Alzheimer's disease training programme
1448262|NCT00190372|educational programme caregivers carers dementia treatment
1448263|NCT00190372|Dementia Cognitive disorder
1448264|NCT00190359|heart failure
1448265|NCT00190359|hormones
1448266|NCT00190359|growth substances
1448267|NCT00190346|Acute respiratory distress
1448268|NCT00190346|with hypercapnia
1448269|NCT00190346|with hypoxemia
1448270|NCT00190346|requiring NIV
1448271|NCT00190333|pulmonary hypertension
1448272|NCT00190333|6 minutes walking test
1448273|NCT00190333|serotonin
1448274|NCT00190333|primary or associated pulmonary hypertension
1448275|NCT00190320|Fetal macrosomia
1448276|NCT00190320|Neonatal traumatism
1448277|NCT00190320|Maternal morbidity
1448278|NCT00190307|Long term antiplatelet therapy
1448279|NCT00190307|Scheduled surgery
1448280|NCT00190294|Pregnancy Complications
1448281|NCT00190281|FUNCTIONAL STUDY
1448282|NCT00190281|CONTRAST-ENHANCED US
1448283|NCT00190281|PERFUSION
1448284|NCT00190268|multiple sclerosis
1448285|NCT00190268|fatigue
1448286|NCT00190268|3,4-diaminopyridine
1448287|NCT00190255|gastrointestinal haemorrhage
1448288|NCT00190255|stomach ulcer
1448289|NCT00190255|anti-inflammatory agents, non-steroidal
1448290|NCT00190255|CYP2C9 protein, human
1448291|NCT00190255|genotype
1448292|NCT00190255|pharmacogenetics
1448293|NCT00190242|HIV
1448294|NCT00190242|hepatitis A
1448295|NCT00190242|vaccine
1448296|NCT00190242|HBV and/or HCV co-infection
1448297|NCT00190229|Vasculitis
1448298|NCT00190229|Cyclophosphamide
1448299|NCT00190229|Renal failure
1448300|NCT00190216|Resistant depression
1448301|NCT00190216|Transcranial Magnetic Stimulation,
1448302|NCT00190216|Neuroimaging
1448303|NCT00190203|Malignant middle cerebral artery infarction
1448304|NCT00190203|Decompressive surgery
1448305|NCT00190203|Hemicraniectomy
1448306|NCT00190203|Brain edema
1448307|NCT00190190|Macular hole
1448308|NCT00190190|internal limiting membrane
1448309|NCT00190190|retina
1448310|NCT00190190|surgery
1448311|NCT00190164|Macular hole
1448312|NCT00190164|Vitrectomy
1448313|NCT00190164|positioning
1448314|NCT00190164|retina
1448315|NCT00190164|surgery
1448316|NCT00190151|ciprofloxacin
1448317|NCT00190151|commensal flora
1448318|NCT00190151|resistance
1448319|NCT00190151|Pharmacokinetic
1448320|NCT00190138|Bi-ventricular pacing
1448321|NCT00190138|ventricular resynchronization
1448322|NCT00190138|baroreflex sensitivity
1448323|NCT00190138|heart rate variability
1448324|NCT00190125|Hemodialysis
1448325|NCT00190125|Malnutrition
1448326|NCT00190125|Inflammation
1448327|NCT00190099|In-stent restenosis,
1448328|NCT00190099|Drug eluting stent,
1448329|NCT00190099|dexamethasone,
1448330|NCT00190099|Acute coronary syndrome
1448331|NCT00190073|Epidermal nerves;protein gene product 9.5; ethanol
1448332|NCT00190060|Frailty
1448333|NCT00190060|Muscle strength
1448334|NCT00190060|Physical performance
1448335|NCT00190060|Bone mineral density
1448336|NCT00190060|Quality of life
1448338|NCT00190047|Ischemic Brain Injury
1448339|NCT00190047|Brain Infarction
1448340|NCT00190047|Brain Ischemia
1448341|NCT00190034|Acetylcysteine
1448342|NCT00190034|cardiac surgery
1448343|NCT00190034|cardiopulmonary bypass
1448344|NCT00190034|acute renal insufficiency
1448345|NCT00190021|Alzheimer's type dementia
1448346|NCT00190021|donepezil
1448347|NCT00190021|double-blind
1448348|NCT00190008|tardive dyskinesia
1448349|NCT00190008|piracetam
1448350|NCT00189995|schizophrenia
1448351|NCT00189995|aggression
1448352|NCT00189995|clozapine
1448353|NCT00189995|efficacy
1448354|NCT00189995|double-blind
1448355|NCT00189982|Factor VIII Deficiency
1448356|NCT00189930|Treatment Experienced
1448357|NCT00189904|HIV
1448358|NCT00189878|chronic idiopathic urticaria
1448359|NCT00189878|methotrexate
1448360|NCT00189852|Telecare
1448361|NCT00189852|chronic
1448362|NCT00189852|older people
1448363|NCT00189852|heart failure
1448364|NCT00189839|Tacrolimus
1448365|NCT00189839|Kidney transplantation
1448366|NCT00189839|Transplantation, kidney
1448367|NCT00189839|Renal Transplantation
1448368|NCT00189839|Transplantation, renal
1448369|NCT00189826|Tacrolimus
1448370|NCT00189826|Liver transplantation
1448371|NCT00189813|Irritable Bowel Syndrome
1448372|NCT00189813|Diarrhea
1448373|NCT00189813|Nasea®
1448374|NCT00189813|Irribow®
1448375|NCT00189813|ramosetron
1448376|NCT00189800|Solifenacin
1448377|NCT00189800|tolterodine
1448378|NCT00189800|randomized controlled trial
1448379|NCT00189800|double-blind method
1448380|NCT00189787|Tacrolimus
1448381|NCT00189787|Immunosuppressant
1448382|NCT00189787|Anti-asthmatic drug
1448383|NCT00189787|Administration, inhalation
1448384|NCT00188500|epilepsy
1448385|NCT00188500|atkins diet
1448386|NCT00188253|Nasopharyngeal carcinoma
1448387|NCT00188253|PET scan
1448388|NCT00188253|MRI
1448389|NCT00188253|EBV virus
1448390|NCT00188240|hepatitis C
1448391|NCT00188240|insulin resistance
1448392|NCT00188240|antiviral therapy
1448393|NCT00188227|Bone marrow puncture
1448394|NCT00188227|Pain
1448395|NCT00188214|perfusion
1448396|NCT00188214|CT
1448397|NCT00188214|CAT
1448398|NCT00188214|non-small
1448399|NCT00188214|lung
1448400|NCT00188201|Hepatitis C
1448401|NCT00188201|neucognitive functions
1448402|NCT00188201|neuropsychological testing
1448403|NCT00188201|antiviral treatment
1448404|NCT00188188|Endothelial
1448405|NCT00188188|Dysfunction
1448406|NCT00188188|Systemic
1448407|NCT00188188|Lupus
1448408|NCT00189774|nateglinide
1448409|NCT00189774|pioglitazone
1448410|NCT00189774|combination drug therapy
1448411|NCT00189774|treatment
1448412|NCT00189761|Tacrolimus
1448413|NCT00189761|Immunosuppression
1448414|NCT00189761|Bone Marrow Transplantation
1448415|NCT00189761|Graft versus Host Disease
1448416|NCT00189748|Tacrolimus
1448417|NCT00189748|Immunosuppression
1448418|NCT00189748|Bone Marrow Transplantation
1448419|NCT00189748|Graft versus Host Disease
1448420|NCT00189735|Treatment Efficacy
1448421|NCT00189735|Treatment Effectiveness
1448422|NCT00189735|Anti-rejection therapy
1448423|NCT00189735|Immunosuppression
1448424|NCT00189735|Antirejection
1448425|NCT00189735|Malononitrilamide
1448426|NCT00189722|Tacrolimus
1448427|NCT00189722|Immunosuppressant
1448428|NCT00189722|Anti-asthmatic drug
1448429|NCT00189722|Administration, inhalation
1448430|NCT00189709|micafungin
1448431|NCT00189709|fluconazole
1448432|NCT00189709|invasive candidiasis
1448433|NCT00189709|candidemia
1448434|NCT00189696|Irritable Bowel Syndrome, Diarrhea
1448435|NCT00189618|Peripheral vascular disease
1448436|NCT00189618|Peripheral arterial disease
1448437|NCT00189618|Walking Capacity
1448438|NCT00189618|Aspirin
1448439|NCT00189618|Clopidogrel
1448440|NCT00189605|Plasma disc decompression
1448441|NCT00189605|Intradiscal Pressure
1448442|NCT00189605|Steroid Injection
1448443|NCT00189605|Epidural Steroid Injection
1448444|NCT00189605|Selective Nerve Root Injection
1448445|NCT00189605|Leg Pain
1448446|NCT00189605|Radicular Pain
1448447|NCT00189605|Coblation
1448448|NCT00189605|SNRI
1448449|NCT00189592|plantar fascia
1448450|NCT00189592|plantar fasciitis
1448451|NCT00189592|Coblation
1448452|NCT00189592|fasciotomy
1448453|NCT00189592|conventional surgical fasciotomy
1448454|NCT00189592|heel spur
1448455|NCT00189592|heel pain
1448456|NCT00189592|aponeurosis
1448457|NCT00189592|plasma based radiofrequency
1448458|NCT00189592|angiogenesis
1448459|NCT00189579|HERCEPTIN
1448460|NCT00189579|Carboplatin
1448461|NCT00189579|Paclitaxel
1448462|NCT00189579|Relapse
1448463|NCT00189566|Relapse within 6 months
1448464|NCT00189566|Previously received taxane derivative
1448465|NCT00189553|Extra-ovarian papillary serous tumors
1448466|NCT00189553|Relapse over 6 months
1448467|NCT00189553|Previously received taxane derivative
1448468|NCT00189540|Ischemic ulcers
1448469|NCT00189540|Critical Limb Ischemia
1448470|NCT00189514|obesity
1448471|NCT00189514|weight loss
1448472|NCT00189514|Amylin
1448473|NCT00189514|pramlintide
1448474|NCT00189501|Chronic Kidney Disease, CKD,
1448475|NCT00189501|Secondary Hyperparathyroidism, HPT
1448476|NCT00189488|Hematological Malignancies
1448477|NCT00189488|Graft-versus-host-disease
1448478|NCT00189488|Oral Mucositis
1448479|NCT00189488|Allogeneic Transplantation
1448480|NCT00189475|Cold
1448481|NCT00189475|Upper Respiratory Infection
1448482|NCT00189462|Ear Infections
1448483|NCT00189462|Otitis Media
1448484|NCT00189449|Allergic Rhinitis
1448485|NCT00189449|Allergy
1448486|NCT00189449|Growth
1448487|NCT00189436|Asthma
1448488|NCT00189423|Heart Arrest
1448489|NCT00189423|Cardiac Arrest
1448490|NCT00189423|Cardiopulmonary Resuscitation
1448491|NCT00189423|Impedance Threshold Device
1448492|NCT00189423|Active Compression Decompression
1448493|NCT00189423|ResQPOD
1448494|NCT00189423|ResQPump
1448495|NCT00189423|Survival
1448496|NCT00189423|Out-of-hospital
1448497|NCT00189423|Prehospital
1448498|NCT00189423|ResQCPR System
1448499|NCT00189397|Parthenium dermatitis
1448500|NCT00189384|Neonatal sepsis
1448501|NCT00189384|Neonatal pneumonia
1448502|NCT00189384|Bacterial infections
1448503|NCT00189384|Young infants
1448504|NCT00189384|Neonate
1448505|NCT00189384|Community
1448506|NCT00189384|Developing country
1448507|NCT00189358|cancer
1448508|NCT00189358|cancer alternative therapies
1448509|NCT00189358|ovarian cancer
1448510|NCT00189358|tyrosine kinase inhibitor
1448511|NCT00189345|Cancer
1448512|NCT00189345|Cancer alternative therapies
1448513|NCT00189345|ovarian cancer
1448514|NCT00189332|Oncology
1448515|NCT00189332|Melanoma
1448516|NCT00189319|Tambocor
1448517|NCT00189319|Paroxysmal Atrial Fibrillation
1448518|NCT00189319|Quality of Life
1448519|NCT00189306|Superficial Basal Cell Carcinoma
1448520|NCT00189306|Aldara
1448521|NCT00189293|External Ano-Genital Warts
1448522|NCT00189293|Ablative Therapy
1448523|NCT00189293|Aldara
1448524|NCT00189280|Aldara, sBCC
1448525|NCT00189267|Aldara
1448526|NCT00189267|Actinic Keratosis
1448527|NCT00189267|Graft Recipients
1448528|NCT00189254|1 year follow up
1448529|NCT00189241|Aldara
1448530|NCT00189241|Superficial Basal Cell Carcinoma
1448531|NCT00189241|Long-Term Study
1448532|NCT00189215|coronary artery disease
1448533|NCT00189215|cardiopulmonary bypass
1448534|NCT00189215|cognition disorders
1448535|NCT00189189|prevention
1448536|NCT00189189|oppositional defiant disorder
1448537|NCT00189189|conduct disorder
1448538|NCT00189163|Hepatitis C
1448539|NCT00189163|Genotype 1
1448540|NCT00189163|Insulin Resistance
1448541|NCT00189163|Pioglitazone
1448542|NCT00189150|Valganciclovir
1448543|NCT00189150|Mycophenolate Mofetil
1448544|NCT00189150|Pharmacokinetic
1448545|NCT00189150|Interaction
1448546|NCT00189150|MPA
1448547|NCT00189124|Systemic Lupus Erythematosus
1448548|NCT00189124|Dehydroepiandrosterone (DHEA)
1448549|NCT00189124|DHEA
1448550|NCT00189124|SLE
1448551|NCT00189124|Lupus
1448552|NCT00189111|peripheral arterial disease
1448553|NCT00189111|computed tomography
1448554|NCT00189111|cardiac asymptomatic
1448555|NCT00189111|dobutamine magnetic resonance imaging
1448556|NCT00189085|Metabolic syndrome
1448557|NCT00189072|gabapentin
1448558|NCT00189072|neuropathic pain
1448559|NCT00189072|driving
1448560|NCT00189072|attention
1448561|NCT00189059|neuropathic pain
1448562|NCT00189059|erp
1448563|NCT00189059|driving
1448564|NCT00189059|attention
1448565|NCT00189059|amitriptyline
1448566|NCT00189046|driving, chronic pain, attention
1448567|NCT00189033|Irritable Bowel Syndrome
1448568|NCT00189033|Diet Therapy
1448569|NCT00189033|Dietary Fiber
1448570|NCT00189033|Randomized Controlled Trial
1448571|NCT00189033|Family Practice
1448572|NCT00189020|pneumococcal conjugate vaccination
1448573|NCT00189020|nasopharyngeal carriage
1448574|NCT00189020|herd immunity
1448575|NCT00189020|antipneumococcal antibodies
1448576|NCT00189020|respiratory tract infections
1448577|NCT00189020|National infant vaccination program
1448578|NCT00189007|allopurinol
1448579|NCT00189007|neuroprotection
1448580|NCT00189007|reperfusion injury
1448581|NCT00189007|fetal hypoxia
1448582|NCT00189007|post hypoxic-ischemic reperfusion damage
1448583|NCT00188994|Myocardial Protection
1448584|NCT00188994|Myocardial Metabolism
1448585|NCT00188994|Ventricular Function
1448586|NCT00188994|Cardiovascular Disease
1448587|NCT00188994|Cardioplegic Additives
1448588|NCT00188981|psychosis
1448589|NCT00188981|high risk
1448590|NCT00188981|prodrome
1448591|NCT00188981|Multiple Complex Developmental Disorder
1448592|NCT00188968|Xanthines
1448593|NCT00188968|Reintubation
1448594|NCT00188968|Nasal Intermittent Ventilation
1448595|NCT00188968|Nasal continous positive airway pressure
1448596|NCT00188955|pediatric
1448597|NCT00188955|chronic allograft nephropathy
1448598|NCT00188955|chronic rejection
1448599|NCT00188955|interstitial fibrosis
1448600|NCT00188942|Magnetic Resonance Imaging
1448601|NCT00188942|Diagnostic Imaging
1448602|NCT00188942|Mood Disorders
1448603|NCT00188942|Major Depressive Disorder
1448604|NCT00188942|Antipsychotic
1448605|NCT00188942|Olanzapine
1448606|NCT00188942|Fluoxetine
1448607|NCT00188344|laparoscopic myotomy
1448608|NCT00188344|pneumatic dilatation
1448609|NCT00188344|motility disorder
1448610|NCT00188344|dysphasia
1448611|NCT00188344|health-related quality of life
1448612|NCT00188331|cognitive function
1448613|NCT00188331|fatigue
1448614|NCT00188331|colorectal cancer
1448615|NCT00188331|chemotherapy
1448616|NCT00188331|cognitive impairment
1448617|NCT00188305|Risk counselling
1448618|NCT00188305|Health education
1448619|NCT00188305|Prevention
1448620|NCT00188305|Behavioral
1448621|NCT00188305|Screening
1448622|NCT00188305|Intervention
1448623|NCT00188305|Telephone vs in person
1448624|NCT00188292|Human Papillomavirus
1448625|NCT00188292|Anal
1448626|NCT00188292|Cancer screening
1448627|NCT00188292|Immunodeficiency
1448628|NCT00188292|HIV
1448629|NCT00188279|ct
1448630|NCT00188279|scan
1448631|NCT00188279|lung
1448632|NCT00188279|follow-up
1448633|NCT00188916|Bronchial blockers
1448634|NCT00188916|Lung isolation
1448635|NCT00188916|Thoracic Anesthesia
1448636|NCT00188903|Cardiac Surgery
1448637|NCT00188903|Diastolic Dysfunction
1448638|NCT00188903|Atrial Fibrillation
1448639|NCT00188890|Lung Cancer
1448640|NCT00188890|Mesothelioma
1448641|NCT00188890|Asbestos
1448642|NCT00188890|Screening
1448643|NCT00188890|Early Diagnosis
1448644|NCT00188851|HIV
1448645|NCT00188851|salvage regimen
1448646|NCT00188851|virologic failure
1448647|NCT00188851|treatment interruption
1448648|NCT00188851|ARV experienced
1448649|NCT00188838|Bipolar Disorder
1448650|NCT00188838|Psychosocial Factors
1448651|NCT00188838|Mania
1448652|NCT00188838|Depression
1448653|NCT00188838|Social Adjustment
1448654|NCT00188838|Coping Skills
1448655|NCT00188825|Lung
1448656|NCT00188825|Transplant
1448657|NCT00188825|Rejection
1448658|NCT00188825|BOS
1448659|NCT00188812|dementia
1448660|NCT00188812|stroke
1448661|NCT00188773|n-acetylcysteine,
1448662|NCT00188773|free fatty acid,
1448663|NCT00188773|glucose stimulated insulin secretion,
1448664|NCT00188773|insulin resistance syndrome
1448665|NCT00188773|antioxidant therapy
1448666|NCT00188773|Insulin Resistance
1448667|NCT00188760|Breast Transillumination Spectroscopy
1448668|NCT00188760|Optical Transillumination Spectroscopy
1448669|NCT00188760|Breast Cancer Risk
1448670|NCT00188747|Coagulopathy
1448671|NCT00188747|Cardiac Surgery
1448672|NCT00188747|Point of Care
1448673|NCT00188747|Monitoring
1448674|NCT00188734|Lung Cancer
1448675|NCT00188734|Eary Diagnosis
1448676|NCT00188734|Screening
1448677|NCT00188721|Breast Cancer Risk
1448678|NCT00188721|Optical Transillumination Spectroscopy
1448679|NCT00188721|Transillumination Breast Spectroscopy
1448680|NCT00188682|Optical Transillumination Spectroscopy
1448681|NCT00188682|Transillumination Breast Spectroscopy
1448682|NCT00188682|Breast Cancer Risk
1448683|NCT00188643|Bipolar Disorder, Depression, Anticonvulsants, Antidepressants
1448684|NCT00188630|Cardiac Surgery
1448685|NCT00188630|Acute Renal Failure
1448686|NCT00188630|N-acetylcysteine
1448687|NCT00188630|Cardiopulmonary bypass
1448688|NCT00188617|LUNG CANCER
1448689|NCT00188617|IRESSA
1448690|NCT00188617|GEFITINIB
1448691|NCT00188617|STAGE 1A & 1B
1448692|NCT00188617|NEOADJUVANT
1448693|NCT00188617|PHASE 2
1448694|NCT00188591|Optical Transillumination Spectroscopy
1448695|NCT00188591|Breast Cancer Risk
1448696|NCT00188396|Major Depressive Disorder
1448697|NCT00188396|Women's Mental Health
1448698|NCT00188396|Hormones
1448699|NCT00188396|Citalopram
1448700|NCT00188396|Antidepressive agents
1448701|NCT00188396|Mental Health
1448702|NCT00188383|Hyperalgesia
1448703|NCT00188383|Quantitative Sensory Testing
1448704|NCT00188383|Pain
1448705|NCT00188383|Opioid use
1448706|NCT00188383|Elderly
1448707|NCT00188149|Hodgkin's Lymphoma
1448708|NCT00188149|Chemotherapy
1448709|NCT00188149|Radiation therapy
1448710|NCT00188149|PET
1448711|NCT00188136|AML, allogeneic transplantation, high-risk, karyotype
1448712|NCT00188123|Myocardial infarction
1448713|NCT00188123|MRI late enhancement
1448714|NCT00188123|Atrial fibrillation
1448715|NCT00188110|Water-Enema Computed Tomography
1448716|NCT00188110|colon tumor
1448717|NCT00188110|coloscopy
1448718|NCT00188110|suspicion of colon tumor
1448719|NCT00188110|coloscopy or surgery
1448720|NCT00188071|medical abortion
1448721|NCT00188071|analgesia
1448722|NCT00188058|Acute respiratory distress syndrome
1448723|NCT00188058|Positive end-expiratory pressure
1448724|NCT00188058|Acute lung injury
1448725|NCT00188058|Mechanical ventilation
1448726|NCT00188058|Randomized controlled trial
1448727|NCT00188045|Portal hypertension, alcoholic cirrhosis, Hepatic venous pressure gradient, hemodynamic, spironolactone, propranolol
1448728|NCT00188032|pulmonary embolism
1448729|NCT00188032|clinical practice
1448730|NCT00188032|quality of health care
1448731|NCT00188032|diagnostic criteria
1448732|NCT00188032|Computer-Assisted Decision Support
1448733|NCT00188032|reminders
1448734|NCT00188006|cardiopulmonary bypass, inflammatory response
1448735|NCT00188006|neurologic injury
1448736|NCT00188006|neurocognitive deficit
1448737|NCT00188006|biomaterials
1448738|NCT00188006|coronary artery bypass surgery
1448739|NCT00187993|growth hormone deficiency
1448740|NCT00187993|growth hormone
1448741|NCT00187993|energy expenditure
1448742|NCT00187993|body composition
1448743|NCT00187954|women
1448744|NCT00187954|chest pain
1448745|NCT00187954|microvascular dysfunction
1448746|NCT00187954|retinal photography
1448747|NCT00187954|Retinal vascular function
1448748|NCT00187941|transplant
1448749|NCT00187941|renal
1448750|NCT00187941|Cellcept
1448751|NCT00187941|therapeutic drug level
1448752|NCT00187941|MMF
1448753|NCT00187941|MPA
1448754|NCT00187941|immunosuppression
1448755|NCT00187928|Obsessive-Compulsive Disorder
1448756|NCT00187928|Obsessions
1448757|NCT00187928|Compulsions
1448758|NCT00187928|Adjunctive treatment
1448759|NCT00187915|Renal transplant
1448760|NCT00187915|Cellcept
1448761|NCT00187915|Therapeutic drug level
1448762|NCT00187915|Mycophenolate mofetil (MMF)
1448763|NCT00187915|Mycophenolate Acid (MPA)
1448764|NCT00187915|Oral Bioavailability
1448765|NCT00187915|Immunosuppression
1448766|NCT00187902|Sexually Transmitted Diseases
1448767|NCT00187902|Chlamydia trachomatis
1448768|NCT00187902|Neisseria gonorrhoeae
1448769|NCT00187889|Microvascular Disease
1448770|NCT00187889|Women
1448771|NCT00187889|Ischemic Heart Disease
1448772|NCT00187889|WISE
1448773|NCT00187850|Pulp capping
1448774|NCT00187850|partial pulpotomy
1448775|NCT00187850|Exposure of the pulp
1448776|NCT00187837|Stepwise excavation
1448777|NCT00187824|prospective
1448778|NCT00187824|observational
1448779|NCT00187824|hormonal
1448780|NCT00187824|inflammatory
1448781|NCT00187824|vioenergetic
1448782|NCT00187824|immune
1448783|NCT00187824|sepsis
1448784|NCT00187811|Angioplasty,
1448785|NCT00187811|Restenosis,
1448786|NCT00187811|Photodynamic therapy
1448787|NCT00187798|Healthy Control Twins
1448788|NCT00187785|Hispanic
1448789|NCT00187785|communication
1448790|NCT00187772|domestic violence
1448791|NCT00187772|preschoolers
1448792|NCT00187772|trauma
1448793|NCT00187772|intervention
1448794|NCT00187759|Abscess
1448795|NCT00187759|Antibitoics
1448796|NCT00187759|Methicillin-resistant Staphylococcus aureus
1448797|NCT00187746|Healthy Control
1448798|NCT00187733|L-carnitine
1448799|NCT00187720|Healthy Control
1448800|NCT00187681|Healthy controls
1448801|NCT00187668|Healthy Cohort
1448802|NCT00187655|Healthy volunteers willing to be dosed with cefotaxime
1448803|NCT00187616|adverse events
1448804|NCT00187616|clinical trial methodology
1448805|NCT00187603|tobacco
1448806|NCT00187603|cessation
1448807|NCT00187603|smoking
1448808|NCT00187603|smoking cessation
1448809|NCT00187590|HIV
1448810|NCT00187590|case management
1448811|NCT00187577|Alopecia areata
1448812|NCT00187577|Eyelash growth
1448813|NCT00187577|Latanoprost
1448814|NCT00187577|Bimatoprost
1448815|NCT00187564|Diabetes Mellitus, Type 1
1448816|NCT00187564|lipoic acid
1448817|NCT00187564|oxidative stress
1448818|NCT00187551|enfuvirtide
1448819|NCT00187551|T20
1448820|NCT00187551|Fuzeon
1448821|NCT00187551|Treatment
1448822|NCT00187551|Interruption
1448823|NCT00187551|Resistance
1448824|NCT00187551|HIV Drug Resistance
1448825|NCT00187551|Antiretroviral Agents
1448826|NCT00187551|Salvage Therapy
1448827|NCT00187551|Drug Resistance, Multiple
1448828|NCT00187551|Human Immunodeficiency virus
1448829|NCT00187512|HIV
1448830|NCT00187512|Antiretroviral Agents
1448831|NCT00187512|Drug Resistance, Multiple
1448832|NCT00187512|Long Term Non Progression
1448833|NCT00187512|Long Term Non Progressor
1448834|NCT00187512|Elite Suppression
1448835|NCT00187512|Elite Suppressor
1448836|NCT00187512|Natural History
1448837|NCT00187512|Observational
1448838|NCT00187499|Asthma
1448839|NCT00187499|Corticosteroid
1448840|NCT00187499|Gene expression
1448841|NCT00187486|Glioblastoma Multiforme
1448842|NCT00187486|Gliosarcoma
1448843|NCT00187486|GBM
1448844|NCT00187486|GS
1448845|NCT00187486|Tarceva
1448846|NCT00187486|Temodar
1448847|NCT00187486|Radiation
1448848|NCT00187486|Newly Diagnosed
1448849|NCT00187473|hepatitis C
1448850|NCT00187473|HCV
1448851|NCT00187473|natural history
1448852|NCT00187460|Acute myocardial infarction
1448853|NCT00187460|Congestive heart failure
1448854|NCT00187460|Quality of care
1448855|NCT00187460|Reperfusion
1448856|NCT00187460|Report cards
1448857|NCT00187460|Quality indicators
1448858|NCT00187447|prematurity
1448859|NCT00187447|chronic lung disease
1448860|NCT00187447|necrotizing enterocolitis
1448861|NCT00187447|indomethacin
1448862|NCT00187447|ductus arteriosus
1448863|NCT00187434|premature infant
1448864|NCT00187434|supporting extubation
1448865|NCT00187421|coronary disease
1448866|NCT00187421|angiography
1448867|NCT00187421|intraoperative care
1448868|NCT00187421|vascular patency
1448869|NCT00187408|Thrombosis
1448870|NCT00187408|Pulmonary Embolism
1448871|NCT00187408|Low Molecular Weight Heparin
1448872|NCT00187408|Tibial Fractures
1448873|NCT00187395|hypertension
1448874|NCT00187395|blood pressure
1448875|NCT00187395|pregnancy
1448876|NCT00187382|antenatal corticosteroids
1448877|NCT00187382|preterm birth
1448878|NCT00187382|multiple versus single doses
1448879|NCT00187382|follow-up
1448880|NCT00187369|twins
1448881|NCT00187369|twin births
1448882|NCT00187369|multiples
1448883|NCT00187356|Coronary Bypass Surgery
1448884|NCT00187356|Coronary Artery Disease
1448885|NCT00187356|Angiography
1448886|NCT00187356|Arterial Grafts
1448887|NCT00187356|Radial Artery
1448888|NCT00187356|Saphenous Vein
1448889|NCT00187343|Radiotherapy
1448890|NCT00187343|IMRT
1448891|NCT00187330|cardiopulmonary bypass
1448892|NCT00187330|renal insufficiency
1448893|NCT00187330|cardiac surgery
1448894|NCT00187330|n-acetylcysteine
1448895|NCT00187317|Exercise
1448896|NCT00187317|Rehabilitation
1448897|NCT00187317|Postural Balance
1448898|NCT00187317|Accidental Falls
1448899|NCT00187317|Geriatrics
1448900|NCT00187291|T-Wave Alternans
1448901|NCT00187291|ICD
1448902|NCT00187291|Primary Prevention
1448903|NCT00187278|Standard pacing indication
1448904|NCT00187252|Ventricular Dyssynchrony
1448905|NCT00187239|ICDs
1448906|NCT00187239|Ventricular pacing
1448907|NCT00187239|Patient has been implanted with a dual chamber SJM ICD with AICS for 1 month (± 2 weeks).
1448908|NCT00187239|At the time of enrollment, patient is paced in the RV ≤25% of the time as determined by the device diagnostics.
1448909|NCT00187239|Patient is medically stable.
1448910|NCT00187226|Brain neoplasm
1448911|NCT00187226|Brain cancer
1448912|NCT00187226|Neoplasm intracranial
1448913|NCT00187213|Ventricular Dyssynchrony
1448914|NCT00187174|Brain tumors
1448915|NCT00187174|Soft Tissue Sarcomas
1448916|NCT00187174|Refractory solid tumors
1448917|NCT00187174|Recurrent or Refractory Rhabdomyosarcomatous Soft Tissue and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
1448918|NCT00187161|Mature B-Cell Leukemia
1448919|NCT00187161|Non-Hodgkin Lymphoma
1448920|NCT00187161|Burkitt's lymphoma
1448921|NCT00187161|Small noncleaved cell non Hodgkin lymphoma
1448922|NCT00187161|Large cell lymphoma
1448923|NCT00187148|Vaccine
1448924|NCT00187148|Prevention
1448925|NCT00187148|HIV
1448926|NCT00187148|AIDS
1448927|NCT00187135|Pain Management
1448928|NCT00187135|Bone Marrow Aspiration
1448929|NCT00187122|Non-Hodgkin
1448930|NCT00187122|Lymphoma
1448931|NCT00187109|Thrombocytopenia
1448932|NCT00187109|Platelets
1448933|NCT00187109|Thrombopoietin
1448934|NCT00187096|Leukemia
1448935|NCT00187096|Myeloid
1448936|NCT00187096|Acute
1448937|NCT00187083|Leukemia
1448938|NCT00187083|Acute Lymphoblastic Leukemia
1448939|NCT00187083|Refractory Acute Lymphoblastic Leukemia
1448940|NCT00187083|Relapsed Acute Lymphoblastic Leukemia
1448941|NCT00187057|Ataxia
1448942|NCT00187057|alphafetoprotein
1448943|NCT00187044|Vaccine
1448944|NCT00187044|Prevention
1448945|NCT00187044|HIV
1448946|NCT00187044|AIDS
1448947|NCT00187031|Wilms Tumor
1448948|NCT00187018|Collagen Disease
1448949|NCT00187005|Leukemia
1448950|NCT00186992|Sarcoma
1448951|NCT00186992|radiation therapy
1448952|NCT00186992|Other musculoskeletal tumors
1448953|NCT00186979|Refractory Childhood Solid Tumors
1448954|NCT00186953|Ultrasound
1448955|NCT00186953|Abdominal tumors
1448956|NCT00186953|Pelvic tumors
1448957|NCT00186940|leukemia
1448958|NCT00186927|Vaccine
1448959|NCT00186927|Sendai virus vaccine
1448960|NCT00186914|Bone marrow transplant
1448961|NCT00186914|bone marrow stromal cells
1448962|NCT00186914|allogeneic transplant
1448963|NCT00186914|Osteodysplasia
1448964|NCT00186914|Osteogenesis imperfecta
1448965|NCT00186914|Gene marking
1448966|NCT00186914|Stromal cell
1448967|NCT00186901|Bone Density
1448968|NCT00186888|Cancer of the Eye
1448969|NCT00186888|Eye Enucleation
1448970|NCT00186875|Leukemia
1448971|NCT00186875|Lymphoblastic
1448972|NCT00186875|Acute
1448973|NCT00186875|Lymphoma
1448974|NCT00186875|Non-Hodgkin's
1448975|NCT00186862|Neuroblastoma
1448976|NCT00186862|Immunotherapy
1448977|NCT00186862|Gene therapy
1448978|NCT00186849|Neuroblastoma
1448979|NCT00186836|Hepatitis A
1448980|NCT00186836|Hepatitis B
1448981|NCT00186836|Hemodialysis
1448982|NCT00186836|Vaccine
1448983|NCT00186823|Haploidentical stem cell transplant
1448984|NCT00186823|Allogeneic stem cell transplant
1448985|NCT00186823|Mismatched family member stem cell donor transplant
1449111|NCT00185159|Microalbuminuria
1448986|NCT00186823|Bone marrow transplantHigh risk hematologic malignancies
1448987|NCT00186810|Anemia
1448988|NCT00186810|Sickle Cell
1448989|NCT00186797|Aplastic Anemia
1448990|NCT00186784|Repetitive Transcranial Magnetic Stimulation
1448991|NCT00186784|TMS
1448992|NCT00186771|Transcranial Magnetic Stimulation
1448993|NCT00186771|Paired Pulse
1448994|NCT00186758|Transcranial Magnetic Stimulation
1448995|NCT00186758|TMS
1448996|NCT00186745|Venous thrombosis
1448997|NCT00186745|Pulmonary embolism
1448998|NCT00186745|Kidney failure
1448999|NCT00186745|Anticoagulants
1449000|NCT00186745|Heparin, Low-Molecular-Weight
1449001|NCT00186732|wound closure
1449002|NCT00186732|Pfannenstiel incision
1449003|NCT00186732|surgical staples
1449004|NCT00186732|subcuticular suture
1449005|NCT00186719|Chronic Obstructive Pulmonary Disease
1449006|NCT00186719|Smoking Related Disease
1449007|NCT00186719|Immune System Changes
1449008|NCT00186706|Selenium
1449009|NCT00186706|Chronic Obstructive Pulmonaary Disease
1449010|NCT00186706|Cardiovascular Disease
1449011|NCT00186706|Anti-oxidant
1449012|NCT00186706|Pulmonary
1449013|NCT00186693|Airway remodeling
1449014|NCT00186693|Asthma
1449015|NCT00186693|Hyper-responsiveness
1449016|NCT00186641|chronic Graft vs Host Disease
1449017|NCT00186537|Insulin resistance
1449018|NCT00186537|Insulin resistance syndrome
1449019|NCT00186537|dyslipidemia
1449020|NCT00186537|atherogenic dyslipidemia
1449021|NCT00186537|triglyceride/HDL-C ratio
1449022|NCT00186420|Prostate Cancer
1449023|NCT00186420|Taxotere
1449024|NCT00186368|Prostate cancer
1449025|NCT00186368|Gene expression
1449026|NCT00186368|tumor markers
1449027|NCT00186368|microarray analysis
1449028|NCT00186329|Vasodilation
1449029|NCT00186329|Congestive heart failure
1449030|NCT00186329|Renal insufficiency
1449031|NCT00186329|Diuresis
1449032|NCT00186329|Serum creatinine
1449033|NCT00186199|voiding patterns
1449034|NCT00186199|flow rate
1449035|NCT00186199|ultrasound
1449036|NCT00186173|Obesity
1449037|NCT00186173|Physical activity
1449038|NCT00186134|Physical Activity
1449039|NCT00186134|Walking
1449040|NCT00186134|Primary Schools
1449041|NCT00186134|Transportation
1449042|NCT00186108|Oral Triamcinalone
1449043|NCT00186108|Prostate Cancer
1449044|NCT00186095|Amyloidosis
1449045|NCT00186095|nonmyeloablative
1449046|NCT00186095|hematopoietic
1449047|NCT00186095|cell transplantation
1449048|NCT00186030|HIV
1449049|NCT00186030|AIDS
1449050|NCT00186030|PTSD
1449051|NCT00186030|Prevention
1449052|NCT00185978|obesity prevention
1449053|NCT00185978|preadolescents
1449054|NCT00185978|schools
1449055|NCT00185965|non-Hodgkin
1449056|NCT00185965|lymphoma
1449057|NCT00185965|mycosis
1449058|NCT00185965|fungoides
1449059|NCT00185939|dog bites
1449060|NCT00185939|infection
1449061|NCT00185939|prophylactic antibiotics
1449062|NCT00185939|cost effectiveness
1449063|NCT00185783|Sepsis
1449064|NCT00185783|Adrenal Insufficiency
1449065|NCT00185783|Hydrocortisone
1449066|NCT00185783|Gene Expression
1449067|NCT00185783|Microarray
1449068|NCT00185783|RNA
1449069|NCT00185783|Critically Ill
1449070|NCT00185770|Obesity prevention
1449071|NCT00185770|Television
1449072|NCT00185770|Screen time
1449073|NCT00185770|Schools
1449074|NCT00185770|Preadolescents
1449075|NCT00185705|Insulin resistance
1449076|NCT00185705|obesity
1449077|NCT00185705|hypertension
1449078|NCT00185705|adolescents
1449079|NCT00185705|telmisartan
1449080|NCT00185705|lifestyle intervention
1449081|NCT00185562|Osteoarthritis
1449082|NCT00185549|Cystic Fibrosis;
1449083|NCT00185549|patient education,
1449084|NCT00185549|Internet
1449085|NCT00185536|Taste
1449086|NCT00185536|preschool children
1449087|NCT00185536|fast food
1449088|NCT00185484|Oral contraception
1449089|NCT00185445|Non Hodgkin Lymphoma
1449090|NCT00185393|Follicular Non Hodgkin lymphoma
1449091|NCT00185354|FC patch
1449092|NCT00185354|comparator study
1449093|NCT00185341|Endometriosis associated pelvic pain
1449094|NCT00185328|Postmenopause
1449095|NCT00185302|Non-resectable metastatic melanoma
1449096|NCT00185276|Structural abnormalities of the infrarenal aorta and peripheral arteries
1449097|NCT00185263|angina
1449098|NCT00185263|FGF-4
1449099|NCT00185263|angiogenesis
1449100|NCT00185263|adenovector
1449101|NCT00185263|growth factor
1449102|NCT00185263|myocardial ischemia
1449103|NCT00185263|revascularization
1449104|NCT00185250|Cardiomyopathy
1449105|NCT00185250|idiopathic chronic heart failure
1449106|NCT00185250|Adenovirus
1449107|NCT00185250|Enterovirus
1449108|NCT00185250|Parvovirus
1449109|NCT00185237|Menopause
1449110|NCT00185198|Partial androgen deficiency of aging males (PADAM)
1449112|NCT00185133|Treatment of high blood pressure in mild to severe hypertensive patients
1449113|NCT00185120|Hypertension
1449114|NCT00185120|angiotensin receptor blocker
1449115|NCT00185120|calcium channel blocker
1449116|NCT00185120|angiotensin converting enzyme inhibitor hydroclorothiazide
1449117|NCT00185107|Safety
1449118|NCT00185107|Efficacy
1449119|NCT00185107|WelChol®
1449120|NCT00185107|Zocor®
1449121|NCT00185107|Zetia®
1449122|NCT00185081|colon cancer
1449123|NCT00185081|radioimmunoscintigraphy
1449124|NCT00185081|colon-specific antigen,
1449125|NCT00185081|radioimmunotherapy,
1449126|NCT00185081|radioimmunodetection
1449127|NCT00185068|Systolic hypertension, Angiotensin receptor blocker
1449128|NCT00185055|olmesartan
1449129|NCT00185055|valsartan
1449130|NCT00185055|irbesartan
1449131|NCT00185055|renin-angiotensin-aldosterone system
1449132|NCT00185042|Atherosclerosis, intravascular ultrasound
1449133|NCT00185029|prostate
1449134|NCT00185029|ferumoxtran-10
1449135|NCT00185029|lymph nodes
1449136|NCT00185029|USPIO
1449137|NCT00185016|intimate partner abuse
1449138|NCT00185016|gender
1449139|NCT00185016|education
1449140|NCT00185016|attitude
1449141|NCT00185016|family doctor
1449142|NCT00185016|health care utilisation
1449143|NCT00185016|abused women
1449144|NCT00185003|Endotoxemia
1449145|NCT00185003|vascular potassium channels
1449146|NCT00185003|cytokine
1449147|NCT00185003|norepinephrine
1449148|NCT00185003|regional blood flow,
1449149|NCT00185003|inflammation,
1449150|NCT00185003|ion channels,
1449151|NCT00185003|nitric oxide synthase,
1449152|NCT00185003|pharmacology.
1449153|NCT00184990|Endotoxemia
1449154|NCT00184990|Aminoguanidine
1449155|NCT00184977|Pulmonary Disease, Chronic Obstructive
1449156|NCT00184977|Randomized Controlled Trial
1449157|NCT00184977|Family Practice
1449158|NCT00184977|Respiratory Function Tests
1449159|NCT00184977|Health Status
1449160|NCT00184951|HIV
1449161|NCT00184938|opioids
1449162|NCT00184938|ischemic preconditioning
1449163|NCT00184938|morphine
1449164|NCT00184899|free fatty acids
1449165|NCT00184899|vasodilation
1449166|NCT00184899|sympathetic activity
1449167|NCT00184873|randomized controlled trial
1449168|NCT00184873|health-counseling
1449169|NCT00184873|multi-center study
1449170|NCT00184847|acetylcholine
1449171|NCT00184847|adenosine
1449172|NCT00184847|caffeine
1449173|NCT00184847|ischemic preconditioning
1449174|NCT00184834|colorectal
1449175|NCT00184834|liver
1449176|NCT00184834|metastases
1449177|NCT00184834|health-related quality of life
1449178|NCT00184834|surgery
1449179|NCT00184821|Diabetes
1449180|NCT00184821|Ischemia
1449181|NCT00184821|Annexin A5 scintigraphy
1449182|NCT00184795|Hot flashes
1449183|NCT00184782|colorectal cancer
1449184|NCT00184782|liver metastases
1449185|NCT00184782|metabolic activity
1449186|NCT00184587|prophylactic
1449187|NCT00184587|episodic
1449188|NCT00184587|cluster
1449189|NCT00184587|candesartan
1449190|NCT00184587|angiotensin II receptor blocker
1449191|NCT00184587|randomized placebo controlled parallel study
1449192|NCT00184587|headache diary
1449193|NCT00184535|Low back pain
1449194|NCT00184535|Neuromuscular control
1449195|NCT00184535|Anticipatory motor control
1449196|NCT00184535|Musculoskeletal Physiologic Processes
1449197|NCT00184535|Muscle, Skeletal
1449198|NCT00184535|Ultrasonography
1449199|NCT00184535|Electromyography
1449200|NCT00184522|Gastroesophageal Reflux
1449201|NCT00184522|Esomeprazole
1449202|NCT00184522|Drug treatment
1449203|NCT00184509|schizophrenia
1449204|NCT00184509|psychosocial treatment
1449205|NCT00184509|outcome
1449206|NCT00184496|Analgesics, Opioid/pharmacokinetics
1449207|NCT00184496|Humans
1449208|NCT00184496|Methadone/therapeutic use
1449209|NCT00184496|Neoplasms/complications
1449210|NCT00184496|pain/drug therapy
1449211|NCT00184483|Surgery
1449212|NCT00184483|Lichtenstein
1449213|NCT00184483|Prolene Hernia System
1449214|NCT00184483|Postoperative pain
1449215|NCT00184483|Recurrence
1449216|NCT00184470|Adult
1449217|NCT00184470|Child
1449218|NCT00184470|Hospitalization/statistics & numerical data
1449219|NCT00184470|Retrospective studies
1449220|NCT00184457|Cardiac heart failure
1449221|NCT00184457|Leg press
1449222|NCT00184457|Maximal strength training
1449223|NCT00184457|Serum testosterone
1449224|NCT00184457|Work economy
1449225|NCT00184444|angina pectoris
1449226|NCT00184444|hyperoxia
1449227|NCT00184444|endurance training
1449228|NCT00184444|stroke volume
1449229|NCT00184444|cardiac perfusion
1449230|NCT00184431|Cerebrovascular Accident
1449231|NCT00184431|Physical Therapy Techniques
1449232|NCT00184431|Musculoskeletal Equilibrium
1449233|NCT00184431|Rehabilitation
1449234|NCT00184418|Immunity
1449235|NCT00184418|Immune System
1449236|NCT00184418|Cytokines
1449237|NCT00184418|Psychophysiology
1449238|NCT00184418|Psychoneuroimmunology
1449239|NCT00184405|Parents with psychiatric or addictive problems
1449240|NCT00184392|Sinus surgery
1449241|NCT00184392|endoscopic
1449242|NCT00184392|postoperative care
1449243|NCT00184392|debridement
1449244|NCT00184392|randomized
1449245|NCT00184392|acute recurrent rhinosinusitis
1449246|NCT00184392|chronic rhinosinusitis
1449247|NCT00184392|nasal polyps
1449248|NCT00184392|Chronic rhinosinusitis with nasal polyps
1449249|NCT00184392|Chronic rhinosinusitis without nasal polyps
1449250|NCT00184379|Relatives to
1449251|NCT00184379|patients
1449252|NCT00184379|with
1449253|NCT00184379|serious
1449254|NCT00184379|mental
1449255|NCT00184379|illness
1449256|NCT00184379|Psychoeducation
1449257|NCT00184366|drug therapy
1449258|NCT00184366|efalizumab
1449259|NCT00184353|brain metastasis
1449260|NCT00184353|signal to noise ratio
1449261|NCT00184353|spectral resolution
1449262|NCT00184340|eTherapy supplementary
1449263|NCT00184327|Severe and longstanding psychiatric symptoms in children
1449264|NCT00184301|Eating disorders
1449265|NCT00184301|Anorexia nervosa
1449266|NCT00184301|Bulimia nervosa
1449267|NCT00184301|Personality disorders
1449268|NCT00184301|In-patient treatment
1449269|NCT00184301|out-patient treatment
1449270|NCT00184301|group therapy
1449271|NCT00184288|Lipid
1449272|NCT00184288|choline
1449273|NCT00184288|metastasis
1449274|NCT00184288|magnetic resonance spectroscopy
1449275|NCT00184288|treatment response
1449276|NCT00184275|Brain metastasis
1449277|NCT00184275|HR MAS spectroscopy
1449278|NCT00184275|Tissue micro array
1449279|NCT00184275|DNA micro array
1449280|NCT00184249|Catheter ablation
1449281|NCT00184249|Heart/surgery
1449282|NCT00184249|Cardial surgical procedures
1449283|NCT00184236|Exercise Training
1449284|NCT00184236|Cardiovascular diseases
1449285|NCT00184236|Risk factors
1449286|NCT00184223|Motivational Interviewing
1449287|NCT00184223|Substance abuse
1449288|NCT00184223|Acuteley admitted psychiatric patients
1449289|NCT00184223|Emergency Services, Psychiatric
1449290|NCT00184210|Magnetic Resonance Spectroscopy
1449291|NCT00184197|Injection
1449292|NCT00184197|Headache
1449293|NCT00184197|Cervical muscles
1449294|NCT00184184|Emergency Services, Psychiatric
1449295|NCT00184184|Tobacco use cessation
1449296|NCT00184184|Coffee use cessation
1449297|NCT00184184|substance use detection
1449298|NCT00184184|Substance Abuse Detection
1449299|NCT00184171|Microscopic colitis
1449300|NCT00184171|Drug treatment
1449301|NCT00184171|Diarrhoea
1449302|NCT00184158|Cubital tunnel
1449303|NCT00184158|treatment
1449304|NCT00184158|nerve compression
1449305|NCT00184145|Specific (Animal) Phobia
1449306|NCT00184145|EMDR
1449307|NCT00184145|Exposure therapy
1449308|NCT00184132|Intensive care units
1449309|NCT00184132|Emergency services, psychiatric
1449310|NCT00184132|Interior Design and Furnishings
1449311|NCT00184132|Intensive Care
1449312|NCT00184119|Emergency services, psychiatric
1449313|NCT00184119|Intensive care units
1449314|NCT00184119|Hospitals, psychiatric
1449315|NCT00184119|Aggression
1449316|NCT00184119|Violence
1449317|NCT00184106|Phobic disorders
1449318|NCT00184106|Therapy, cognitive
1449319|NCT00184106|Paroxetine
1449320|NCT00184093|Cervical Carcinoma
1449321|NCT00183976|Diffuse mixed NHL
1449322|NCT00183976|Diffuse or follicular large B-cell NHL
1449323|NCT00183976|Immunoblastic NHL
1449324|NCT00183976|Burkitt or Burkitt-like lymphomas
1449325|NCT00183898|Gastroesophageal Junction Cancer
1449326|NCT00183872|Gastroesophageal cancer
1449327|NCT00183872|Gastric Adenocarcinoma
1449328|NCT00183872|Gastroesophageal Junction Adenocarcinoma
1449329|NCT00183859|solid tumor
1449330|NCT00183859|phase I
1449331|NCT00183859|phase one
1449332|NCT00183846|pancreas
1449333|NCT00183846|stomach
1449334|NCT00183846|common bile duct cancer
1449335|NCT00183846|ampulla of Vater cancer
1449336|NCT00183833|phase 1
1449337|NCT00183833|phase I
1449338|NCT00183833|phase one
1449339|NCT00183833|colon cancer
1449340|NCT00183833|colorectal cancer
1449341|NCT00183820|Testicular
1449342|NCT00183820|Extra gonadal germ cell neoplasm
1449343|NCT00183794|Primary Peritoneal
1449344|NCT00183781|HIV
1449345|NCT00183781|Telephone intervention
1449346|NCT00183768|Cognitive Behavioral Treatment For Depression
1449347|NCT00183768|Antidepressant Psychopharmacology
1449348|NCT00183768|HIV Risk Behavior
1449349|NCT00183768|Injection Drug Use
1449350|NCT00183755|Reward Processing
1449351|NCT00183755|Anhedonia
1449352|NCT00183755|Major Depressive Disorder
1449353|NCT00183755|Depression
1449354|NCT00183742|Phase 1
1449355|NCT00183742|Phase I
1449356|NCT00183742|Phase one
1449357|NCT00183742|Solid tumor
1449358|NCT00183729|Major depressive disorder
1449359|NCT00183729|Rehabilitating
1449360|NCT00183729|Elderly
1449361|NCT00183729|Apathy
1449362|NCT00183716|PTSD
1449363|NCT00183716|Physical Abuse
1449364|NCT00183716|Sexual Abuse
1449365|NCT00183716|Women
1449366|NCT00183716|Trauma
1449367|NCT00183716|Group Therapy
1449368|NCT00183716|Substance Abuse
1449369|NCT00183703|Depression, Bipolar
1449370|NCT00183703|Manic-Depressive Psychosis
1449371|NCT00183690|PTSD
1449372|NCT00183690|Anxiety Disorder
1449373|NCT00183690|Trauma
1449374|NCT00183690|Adolescents
1449375|NCT00183690|Cognitive Behavioral Therapy
1449376|NCT00183677|Brain Bioenergetic Metabolism
1449377|NCT00183677|Magnetic Resonance Spectroscopy
1449378|NCT00183677|Major Depressive Disorder
1449379|NCT00183677|Treatment Response
1449380|NCT00183651|Suicide
1449381|NCT00183651|Women
1449382|NCT00183651|Emotions
1449383|NCT00183651|Psychotherapy, Group
1449384|NCT00183638|Internet
1449385|NCT00183638|Interactive Computer Program
1449386|NCT00183638|HIV Prevention
1449387|NCT00183625|Antipsychotic Agents
1449388|NCT00183625|Employment
1449389|NCT00183612|Child
1449390|NCT00183612|Adolescent
1449391|NCT00183612|Mental Health
1449392|NCT00183612|Olanzapine
1449393|NCT00183612|Pharmacokinetics
1449394|NCT00183612|Pharmacology
1449395|NCT00183599|Brief interventions
1449396|NCT00183599|Motivational Enhancement Therapy
1449397|NCT00183599|Cognitive Behavioral Therapy
1449398|NCT00183586|Treatment outcomes study
1449399|NCT00183586|Anorexia
1449400|NCT00183586|Anorexia nervosa
1449401|NCT00183573|STDs
1449402|NCT00183573|Sexual Behavior
1449403|NCT00183573|Health Behavior
1449404|NCT00183573|HIV Seronegativity
1449405|NCT00183560|Depression Recurrence
1449406|NCT00183560|Drug Therapy
1449407|NCT00183560|Cognitive Therapy
1449408|NCT00183560|Relapse
1449409|NCT00183560|Antidepressants
1449410|NCT00183547|Postpartum Depression
1449411|NCT00183547|Postpartum Period
1449412|NCT00183547|Indians, North American
1449413|NCT00183547|Adolescent
1449414|NCT00183547|Female
1449415|NCT00183547|CBT
1449416|NCT00183521|Hyperventilation
1449417|NCT00183521|Breathing Exercises
1449418|NCT00183521|Carbon Dioxide
1449419|NCT00183521|Panic Attack
1449420|NCT00183508|PTSD
1449421|NCT00183508|Occupational Health
1449422|NCT00183508|Trauma
1449423|NCT00183508|Job
1449424|NCT00183508|CBT
1449425|NCT00183495|Depression, Bipolar
1449426|NCT00183495|Manic-Depressive Psychosis
1449427|NCT00183482|Parents
1449428|NCT00183482|Child
1449429|NCT00183482|Stress
1449430|NCT00183482|CBT
1449431|NCT00183469|Lamotrigine
1449432|NCT00183469|Divalproex
1449433|NCT00183469|Antidepressant
1449434|NCT00183456|Sex Education
1449435|NCT00183456|Peer Group
1449436|NCT00183456|Social Identity Theory
1449437|NCT00183456|HIV Seronegativity
1449438|NCT00183456|Intervention
1449439|NCT00183456|women
1449440|NCT00183456|Social Networks
1449441|NCT00183456|Peer Education
1449442|NCT00183443|Mania
1449443|NCT00183443|Manic-depressive
1449444|NCT00183443|Psychotic disorder
1449445|NCT00183430|Prazosin
1449446|NCT00183430|Sleep Disorders
1449447|NCT00183417|Adolescent
1449448|NCT00183417|CBT
1449449|NCT00183404|Drug Treatment
1449450|NCT00183404|Child
1449451|NCT00183404|Olanzapine
1449452|NCT00183391|ADHD
1449453|NCT00183391|Child
1449454|NCT00183391|Adolescent
1449455|NCT00183391|School
1449456|NCT00183378|Alzheimer's Disease
1449457|NCT00183378|Insomnia
1449458|NCT00183378|Sleep Problems
1449459|NCT00183378|Elderly
1449460|NCT00183378|Caregivers
1449461|NCT00183365|Family
1449462|NCT00183365|Parenting
1449463|NCT00183365|Depression
1449464|NCT00183365|Group Intervention
1449465|NCT00183352|Women
1449466|NCT00183352|Mood
1449467|NCT00183352|Menarche
1449468|NCT00183352|Menstruation
1449469|NCT00183339|Autism
1449470|NCT00183326|Posttraumatic Stress Disorder
1449471|NCT00183326|Domestic Violence
1449472|NCT00183326|Children
1449473|NCT00183326|Cognitive Behavioral Therapy
1449474|NCT00183326|CBT
1449475|NCT00183313|Mental Health
1449476|NCT00183313|Primary health care
1449477|NCT00183313|Case management
1449478|NCT00183300|Post-traumatic stress disorder
1449479|NCT00183300|PTSD
1449480|NCT00183300|Prolonged Exposure
1449481|NCT00183300|Cognitive-Behavior Therapy
1449482|NCT00183274|Generalized Anxiety Disorder
1449483|NCT00183274|Chronic Mediation Treatment
1449484|NCT00183274|Double-Blind
1449485|NCT00183274|Placebo Controlled
1449486|NCT00183274|Venlafaxine XR
1449487|NCT00183274|Relapse
1449488|NCT00183261|Treatment Interruption
1449489|NCT00183261|HIV Therapeutic Vaccine
1449490|NCT00183261|Acute Infection
1449491|NCT00183261|Acute Retroviral Syndrome
1449492|NCT00183248|kidney
1449493|NCT00183248|kidney transplant
1449494|NCT00183248|kidney transplantation
1449495|NCT00183248|transplant
1449496|NCT00183248|transplantation
1449497|NCT00183248|renal
1449498|NCT00183248|renal transplant
1449499|NCT00183248|renal transplantation
1449500|NCT00183248|kidney disease
1449501|NCT00183248|chronic
1449502|NCT00183248|renal failure
1449503|NCT00183248|kidney failure
1449504|NCT00183235|Alcohol dependence
1449505|NCT00183235|Alcoholism
1449506|NCT00183235|Craving
1449507|NCT00183222|Alcohol dependence
1449508|NCT00183222|Alcoholism
1449509|NCT00183222|Craving
1449510|NCT00183209|Substance use disorders
1449511|NCT00183209|Parent child relationship
1449512|NCT00183196|Alcohol dependence
1449513|NCT00183196|Alcoholism
1449514|NCT00183196|Heavy drinking
1449515|NCT00183183|Alcohol Abuse
1449516|NCT00183183|Harm Reduction
1449517|NCT00183183|Motivational Interviewing
1449518|NCT00183183|Emergency Department
1449519|NCT00183183|Risky Drinking
1449520|NCT00183183|Prevention
1449521|NCT00183170|Alcohol abuse
1449522|NCT00183170|Alcoholic beverages (beer)
1449523|NCT00183170|Residual effects
1449524|NCT00183170|Psychomotor performance
1449525|NCT00183170|Psychomotor vigilance test
1449526|NCT00183170|Neurobehavioral Evaluation System
1449527|NCT00183170|Family history of alcohol use
1449528|NCT00183170|Alcoholic Consumption
1449529|NCT00183170|Unhealthy alcohol use
1449530|NCT00183170|Alcohol
1449531|NCT00183157|High risk drinking
1449532|NCT00183157|Alcohol dependence
1449533|NCT00183157|Alcohol related injury
1449534|NCT00183144|contingency management
1449535|NCT00183144|reinforcement
1449536|NCT00183144|employment
1449537|NCT00183144|Therapeutic Workplace
1449538|NCT00183131|Alcohol
1449539|NCT00183131|Alcohol abuse
1449540|NCT00183131|Alcohol dependence
1449541|NCT00183131|Alcohol consumption
1449542|NCT00183131|Unhealthy alcohol use
1449543|NCT00183131|Screening
1449544|NCT00183131|Brief Intervention
1449545|NCT00183131|Effectiveness
1449546|NCT00183131|Electronic intervention
1449547|NCT00183131|Web-based intervention
1449548|NCT00183131|College students
1449549|NCT00183118|HIV
1449550|NCT00183118|Russia
1449551|NCT00183118|Prevention
1449552|NCT00183118|Behavioral intervention
1449553|NCT00183118|Alcohol dependence
1449554|NCT00183105|Alcohol
1449555|NCT00183105|Alcohol abuse
1449556|NCT00183105|Alcohol dependence
1449557|NCT00183105|Utilization
1449558|NCT00183105|Alcohol consumption
1449559|NCT00183105|Unhealthy alcohol use
1449560|NCT00183105|Hospitalization
1449561|NCT00183105|Screening
1449562|NCT00183105|Brief Intervention
1449563|NCT00183105|Motivational Interviewing
1449564|NCT00183105|Randomized trial
1449565|NCT00183105|Effectiveness
1449566|NCT00183105|Unhealthy alcohol use (Risky alcohol consumption amounts, problem alcohol use, hazardous alcohol use, alcohol abuse and alcohol dependence)
1449567|NCT00183092|dementia
1449568|NCT00183092|spongiform encephalopathy
1449569|NCT00183092|nervous system disorder
1449570|NCT00183092|acridine
1449571|NCT00183092|prion
1449572|NCT00183092|neuropharmacologic agent
1449573|NCT00183079|Depression
1449574|NCT00183079|Alcohol Use
1449575|NCT00183079|Motivational Interviewing
1449576|NCT00183053|Hospitalization
1449577|NCT00183053|Fall Risk
1449578|NCT00183053|Frailty
1449579|NCT00183040|andropause
1449580|NCT00183040|hormone therapy
1449581|NCT00183040|HRT
1449582|NCT00183027|Dietary restriction
1449583|NCT00183027|Caloric restriction
1449584|NCT00183014|behavior therapy
1449585|NCT00183014|exercise
1449586|NCT00183014|gait
1449587|NCT00183014|physical activity
1449588|NCT00183001|nutritional supplement
1449589|NCT00183001|dietary supplement
1449590|NCT00183001|vitamin therapy
1449591|NCT00183001|Vitamin K deficiency
1449592|NCT00183001|bone density
1449593|NCT00182988|communication behavior
1449594|NCT00182988|coping
1449595|NCT00182988|functional ability
1449596|NCT00182988|quality of life
1449597|NCT00182988|caregiving
1449598|NCT00182975|Metabolic syndrome
1449599|NCT00182962|Activities of Daily Living
1449600|NCT00182962|Low-income
1449601|NCT00182962|geriatric medicine
1449602|NCT00182962|computer assisted patient care
1449603|NCT00182949|Epidemiology
1449604|NCT00182949|Genetics
1449605|NCT00182949|Aging
1449606|NCT00182949|Sardinian Population
1449607|NCT00182949|Cardiovascular Diseases
1449608|NCT00182949|Personality Traits
1449609|NCT00182949|Frailty
1449610|NCT00182936|Cognition disorder
1449611|NCT00182936|organic brain syndrome
1449612|NCT00182936|patient care management
1449613|NCT00182936|long term care
1449614|NCT00182936|extended care facility
1449615|NCT00182923|Blood pressure
1449616|NCT00182923|genetics
1449617|NCT00182897|caregiver
1449618|NCT00182897|home health care
1449619|NCT00182897|coping
1449620|NCT00182884|Hospital acquired complications
1449621|NCT00182884|adverse effects
1449622|NCT00182884|Cognitive Impairment
1449623|NCT00182884|Aging
1449624|NCT00182871|geriatric medicine
1449625|NCT00182871|hormone therapy
1449626|NCT00182871|HT
1449627|NCT00182871|andropause
1449628|NCT00182858|Tissue
1449629|NCT00182858|Procurement
1449630|NCT00182858|Exploratory Methods
1449631|NCT00182858|Disease Correlation
1449632|NCT00182858|Sampling
1449633|NCT00182845|dementia
1449634|NCT00182845|MCI
1449635|NCT00182845|Aricept
1449636|NCT00182845|Adverse Effects
1449637|NCT00182845|Hospital Acquired Complications
1449638|NCT00182845|Cognitive Impairment
1449639|NCT00182845|Aging
1449640|NCT00182832|Physician Behavior
1449641|NCT00182832|Hospital Acquired Complications
1449642|NCT00182832|MCI
1449643|NCT00182832|Mild Cognitive Impairment
1449644|NCT00182819|adult oligodendroglioma
1449645|NCT00182819|adult diffuse astrocytoma
1449646|NCT00182819|adult mixed glioma
1449647|NCT00182806|recurrent non-small cell lung cancer
1449648|NCT00182806|stage IIIA non-small cell lung cancer
1449649|NCT00182806|stage IIIB non-small cell lung cancer
1449650|NCT00182806|stage IV non-small cell lung cancer
1449651|NCT00182793|stage IIIB breast cancer
1449652|NCT00182793|stage IIIC breast cancer
1449653|NCT00182793|stage IV breast cancer
1449654|NCT00182793|inflammatory breast cancer
1449655|NCT00182793|male breast cancer
1449656|NCT00182793|recurrent breast cancer
1449657|NCT00182793|invasive ductal breast carcinoma with predominant intraductal component
1449658|NCT00182793|invasive ductal breast carcinoma
1449659|NCT00182793|medullary ductal breast carcinoma with lymphocytic infiltrate
1449660|NCT00182793|mucinous ductal breast carcinoma
1449661|NCT00182793|Paget disease of the breast with invasive ductal carcinoma
1449662|NCT00182793|papillary ductal breast carcinoma
1449663|NCT00182793|tubular ductal breast carcinoma
1449664|NCT00182793|invasive lobular breast carcinoma with predominant in situ component
1449665|NCT00182793|invasive lobular breast carcinoma
1449666|NCT00182793|comedo ductal breast carcinoma
1449667|NCT00182780|fatigue
1449668|NCT00182780|unspecified adult solid tumor, protocol specific
1449669|NCT00182754|unspecified adult solid tumor, protocol specific
1449670|NCT00182754|malignant ascites
1449671|NCT00182741|recurrent prostate cancer
1449672|NCT00182741|stage IV prostate cancer
1449673|NCT00182728|invasive ductal breast carcinoma
1449674|NCT00182728|stage I breast cancer
1449675|NCT00182728|stage II breast cancer
1449676|NCT00182715|adenocarcinoma of the colon
1449677|NCT00182715|stage IV colon cancer
1449678|NCT00182715|adenocarcinoma of the rectum
1449679|NCT00182715|stage IV rectal cancer
1449680|NCT00182650|recurrent grade 1 follicular lymphoma
1449681|NCT00182650|recurrent grade 2 follicular lymphoma
1449682|NCT00182650|recurrent grade 3 follicular lymphoma
1449683|NCT00182637|recurrent mycosis fungoides/Sezary syndrome
1449684|NCT00182637|stage I mycosis fungoides/Sezary syndrome
1449685|NCT00182637|stage II mycosis fungoides/Sezary syndrome
1449686|NCT00182637|stage III mycosis fungoides/Sezary syndrome
1449687|NCT00182637|stage IV mycosis fungoides/Sezary syndrome
1449688|NCT00182637|stage I cutaneous T-cell non-Hodgkin lymphoma
1449689|NCT00182637|stage II cutaneous T-cell non-Hodgkin lymphoma
1449690|NCT00182637|stage III cutaneous T-cell non-Hodgkin lymphoma
1449691|NCT00182637|stage IV cutaneous T-cell non-Hodgkin lymphoma
1449692|NCT00182637|recurrent cutaneous T-cell non-Hodgkin lymphoma
1449693|NCT00182624|Prostate Cancer
1449694|NCT00182624|Magnetic Resonance Imaging
1449695|NCT00182624|Spectroscopy
1449696|NCT00182611|stage III gastric cancer
1449697|NCT00182611|adenocarcinoma of the stomach
1449698|NCT00182598|buprenorphine
1449699|NCT00182598|computer
1449700|NCT00182598|treatment
1449701|NCT00182598|opioid
1449702|NCT00182598|heroin
1449703|NCT00182585|HIV
1449704|NCT00182585|hepatitis
1449705|NCT00182585|STDs
1449706|NCT00182585|adolescents
1449707|NCT00182585|addiction
1449708|NCT00182585|treatment
1449709|NCT00182585|prevention
1449710|NCT00182585|HIV and related risk behavior among youth in drug treatment
1449711|NCT00182572|heroin
1449712|NCT00182572|opiate
1449713|NCT00182572|addiction
1449714|NCT00182572|adolescent
1449715|NCT00182572|treatment
1449716|NCT00182559|kidney
1449717|NCT00182559|transplantation
1449718|NCT00182559|tacrolimus
1449719|NCT00182559|cyclosporine
1449720|NCT00182559|conversion
1449721|NCT00182546|Pulmonary Embolism
1449722|NCT00182546|DVT
1449723|NCT00182546|Venous Thrombosis
1449724|NCT00182546|D dimer
1449725|NCT00182546|DD
1449726|NCT00182546|Thrombosis
1449727|NCT00182546|Diagnosis
1449728|NCT00182533|Generalized social phobia
1449729|NCT00182533|Comorbid panic disorder with agoraphobia
1449730|NCT00182533|Comorbid obsessive compulsive disorder
1449731|NCT00182533|Comorbid generalized anxiety disorder
1449732|NCT00182533|Comorbid major depressive disorder/Dysthymia
1449733|NCT00182520|Treatment Refractory Obsessive Compulsive Disorder
1449734|NCT00182494|Schizophrenia, Diabetes, Weight gain, Antipsychotic drugs
1449735|NCT00182481|asthma treatment
1449736|NCT00182481|induced sputum cell counts
1449737|NCT00182481|asthma exacerbations
1449738|NCT00182481|eosinophilic bronchitis
1449739|NCT00182481|non-eosinophilic bronchitis
1449740|NCT00182468|Domestic violence
1449741|NCT00182468|Spouse Abuse
1449742|NCT00182455|Treatment Refractory Generalized Social Phobia
1449743|NCT00182442|Cognitive deficits
1449744|NCT00182442|Psychosocial functioning
1449745|NCT00182442|Quality of Life
1449746|NCT00182429|Antibiotic associated diarrhea
1449747|NCT00182429|C. difficile
1449748|NCT00182429|Metronidazole
1449749|NCT00182429|Rifampin
1449750|NCT00182416|pacemakers
1449751|NCT00182416|atrial fibrillation
1449752|NCT00182416|stroke
1449753|NCT00182416|cardiovascular death
1449754|NCT00182403|Unfractionated Heparin
1449755|NCT00182403|Low Molecular Weight Heparin
1449756|NCT00182403|Venous Thromboembolism
1449757|NCT00182403|APTT
1449758|NCT00182403|Treatment
1449759|NCT00182390|ELBW premature infants
1449760|NCT00182390|neonatal transfusion
1449761|NCT00182390|bronchopulmonary dysplasia
1449762|NCT00182390|periventricular leukomalacia
1449763|NCT00182390|ventriculomegaly
1449764|NCT00182390|retinopathy of prematurity
1449765|NCT00182377|patients undergoing cardiac surgery requiring cardiopulmonary bypass
1449766|NCT00182364|Critically Ill
1449767|NCT00182364|Deep Venous Thrombosis
1449768|NCT00182364|Randomized Control Trial
1449769|NCT00182364|Pilot Study
1449770|NCT00182351|deep vein thrombosis
1449771|NCT00182351|d-dimer
1449772|NCT00182351|serial compression ultrasound
1449773|NCT00182338|cardiovascular outcomes
1449774|NCT00182338|congestive heart failure
1449775|NCT00182338|Peritoneal Membrane transport properties
1449776|NCT00182338|Arterial stiffening
1449777|NCT00182338|Inflammatory markers
1449778|NCT00182325|medical record
1449779|NCT00182325|pregnancy
1449780|NCT00182325|Internet
1449781|NCT00182312|preterm infants
1449782|NCT00182312|very low birthweight
1449783|NCT00182312|apnea of prematurity
1449784|NCT00182312|methylxanthines
1449785|NCT00182312|developmental disabilities
1449786|NCT00182286|Diabetes
1449787|NCT00182286|Continuity of Care
1449788|NCT00182286|Patient Perspective
1449789|NCT00182286|Health Service Organization
1449790|NCT00182273|Benign paroxysmal positional vertigo
1449791|NCT00182273|Canalith repositioning maneuver
1449792|NCT00182273|Dizziness
1449793|NCT00182273|Primary Care
1449794|NCT00182247|deep vein thrombosis
1449795|NCT00182247|DVT
1449796|NCT00182247|pulmonary embolism
1449797|NCT00182247|PE
1449798|NCT00182247|venous thromboembolism
1449799|NCT00182247|VTE
1449800|NCT00182247|d-dimer
1449801|NCT00182247|IPG
1449802|NCT00182234|unmet supportive care needs
1449803|NCT00182221|Pulmonary Embolism
1449804|NCT00182221|Deep Vein Thrombosis
1449805|NCT00182221|MDA D-Dimer Testing
1449806|NCT00182221|Diagnostic Algorithm
1449807|NCT00182208|PTS
1449808|NCT00182208|Post phlebitic Syndrome
1449809|NCT00182208|Activities of Daily Living
1449810|NCT00182208|Quality of Life
1449811|NCT00182182|Heart Failure
1449812|NCT00182182|Family physicians
1449813|NCT00182182|academic detailing
1449814|NCT00182182|process of care
1449815|NCT00182169|Severe heart failure
1449816|NCT00182169|Growth hormone
1449817|NCT00182169|exercise capacity
1449818|NCT00182169|quality of life
1449819|NCT00182169|cardiac function
1449820|NCT00182156|hemodialysis
1449821|NCT00182156|platelet function analyzer
1449822|NCT00182156|bioimpedance
1449823|NCT00182156|pulse wave velocity
1449824|NCT00182156|end stage renal disease
1449825|NCT00182143|Critically Ill
1449826|NCT00182143|Deep Venous ThromboEmbolism
1449827|NCT00182143|Randomized Controlled Trial
1449828|NCT00182130|rectal cancer
1449829|NCT00182130|surgery
1449830|NCT00182130|physician behaviour
1449831|NCT00182130|knowledge translation
1449832|NCT00182117|bleeding
1449833|NCT00182117|end stage renal disease
1449834|NCT00182117|antiplatelet therapy
1449835|NCT00182117|anticoagulant therapy
1449836|NCT00182117|hemodialysis
1449837|NCT00182104|Fontan procedure
1449838|NCT00182104|Anticoagulation
1449839|NCT00182104|Thrombosis
1449840|NCT00182104|Thromboembolism
1449841|NCT00182104|Prevention
1449842|NCT00182091|Acromegaly
1449843|NCT00182091|Growth Hormone Deficiency
1449844|NCT00182091|Cardiovascular Risk
1449845|NCT00182091|Pituitary
1449846|NCT00182091|Hypothalamic
1449847|NCT00182078|sertraline
1449848|NCT00182078|children
1449849|NCT00182078|adolescents
1449982|NCT00181623|Prolactin
1449850|NCT00182078|posttraumatic stress disorder
1449851|NCT00182078|depression
1449852|NCT00182078|prevention
1449853|NCT00182078|burns
1449854|NCT00182078|injuries
1449855|NCT00182065|Heart failure
1449856|NCT00182065|Functional decline
1449857|NCT00182065|Cognitive impairment
1449858|NCT00182065|Neuropsychiatric health
1449859|NCT00182065|Longitudinal
1449860|NCT00182065|Long-term care
1449861|NCT00182065|Elderly
1449862|NCT00182052|rosiglitazone
1449863|NCT00182052|Avandia
1449864|NCT00182052|androgen dependant prostate cancer
1449865|NCT00182039|randomized controlled trial
1449866|NCT00182039|blinded
1449867|NCT00182039|noncardiac surgery
1449868|NCT00182039|cardiovascular events
1449869|NCT00182026|diabetes
1449870|NCT00182026|community intervention
1449871|NCT00182026|self-management
1449872|NCT00182026|prevention
1449873|NCT00182000|OCD
1449874|NCT00181987|ADHD
1449875|NCT00181987|bipolar disorder
1449876|NCT00181987|children
1449877|NCT00181987|Concerta
1449878|NCT00181974|burns
1449879|NCT00181974|hemostasis
1449880|NCT00181974|skin graft
1449881|NCT00181974|Surgical Hemostasis
1449882|NCT00181974|Grafting, Skin
1449883|NCT00181961|antidepressant-induced sexual dysfunction
1449884|NCT00181948|ADHD
1449885|NCT00181948|children
1449886|NCT00181948|stimulant non-responders
1449887|NCT00181948|Strattera
1449888|NCT00181935|bipolar disorder
1449889|NCT00181935|preschoolers
1449890|NCT00181935|risperdal
1449891|NCT00181935|zyprexa
1449892|NCT00181922|bipolar disorder
1449893|NCT00181922|children
1449894|NCT00181922|ziprasidone
1449895|NCT00181922|mania
1449896|NCT00181909|Pregnancy
1449897|NCT00181909|Smoking cessation
1449898|NCT00181896|depression
1449899|NCT00181896|bipolar disorder
1449900|NCT00181896|children
1449901|NCT00181896|bupropion SR
1449902|NCT00181883|children
1449903|NCT00181883|bipolar disorder
1449904|NCT00181883|quetiapine
1449905|NCT00181883|preschoolers
1449906|NCT00181870|bipolar disorder
1449907|NCT00181870|children
1449908|NCT00181870|mania
1449909|NCT00181870|Equetro
1449910|NCT00181857|ADHD NOS
1449911|NCT00181857|familial risk
1449912|NCT00181857|children
1449913|NCT00181844|bipolar disorder
1449914|NCT00181844|lamotrigine
1449915|NCT00181844|children
1449916|NCT00181844|mania
1449917|NCT00181831|SPECT
1449918|NCT00181831|bipolar disorder
1449919|NCT00181831|ADHD
1449920|NCT00181831|children
1449921|NCT00181818|Smoking cessation
1449922|NCT00181818|Bupropion SR
1449923|NCT00181818|Hospital intervention
1449924|NCT00181818|Myocardial infarction
1449925|NCT00181818|Unstable angina
1449926|NCT00181805|GER
1449927|NCT00181792|ADHD
1449928|NCT00181792|smoking
1449929|NCT00181792|familial risk
1449930|NCT00181779|mania
1449931|NCT00181779|Abilify
1449932|NCT00181779|children
1449933|NCT00181779|bipolar disorder
1449934|NCT00181766|ADHD NOS
1449935|NCT00181766|Adults
1449936|NCT00181766|Strattera (atomoxetine)
1449937|NCT00181766|Open-Label
1449938|NCT00181753|glutamine metabolic kinetics
1449939|NCT00181753|glutamate metabolic kinetics
1449940|NCT00181753|enteral nutrition
1449941|NCT00181753|parenteral nutrition
1449942|NCT00181753|burn injury
1449943|NCT00181753|stable isotopes
1449944|NCT00181740|ADHD NOS
1449945|NCT00181740|Adults
1449946|NCT00181740|Concerta
1449947|NCT00181740|Open-Label
1449948|NCT00181727|bipolar disorder
1449949|NCT00181727|mania
1449950|NCT00181727|depakote ER
1449951|NCT00181727|children
1449952|NCT00181714|cigarette smoking
1449953|NCT00181714|ADHD
1449954|NCT00181714|adolescents
1449955|NCT00181714|Concerta
1449956|NCT00181701|Ovarian cancer
1449957|NCT00181701|Epithelial carcinoma of mullerian origin
1449958|NCT00181701|Intraperitoneal paclitaxel
1449959|NCT00181701|Intraperitoneal carboplatin
1449960|NCT00181701|Primary peritoneal carcinoma
1449961|NCT00181701|Tubal carcinoma
1449962|NCT00181688|Iressa
1449963|NCT00181688|ZD1839
1449964|NCT00181688|Anastrozole
1449965|NCT00181688|Arimidex
1449966|NCT00181675|Adult
1449967|NCT00181675|ADHD
1449968|NCT00181675|galantamine
1449969|NCT00181675|double-blind
1449970|NCT00181662|Curcumin
1449971|NCT00181662|Piperine
1449972|NCT00181662|Silybin
1449973|NCT00181662|Healthy volunteer
1449974|NCT00181662|Female
1449975|NCT00181649|Lactation
1449976|NCT00181649|Breastfeeding
1449977|NCT00181649|Adoptive mothers
1449978|NCT00181649|Prolactin
1449979|NCT00181649|Relative lactation insufficiency
1449980|NCT00181623|Lactation
1449981|NCT00181623|Breastfeeding
1449983|NCT00181623|Primary lactation insufficiency
1449984|NCT00181610|Lactation
1449985|NCT00181610|Breastfeeding
1449986|NCT00181610|Premature infants
1449987|NCT00181610|Prolactin
1449988|NCT00181610|Primary lactation insufficiency
1449989|NCT00181597|Trilostane
1449990|NCT00181597|Androgen-independent prostate cancer
1449991|NCT00181584|Androgen deprivation therapy
1449992|NCT00181584|bone loss
1449993|NCT00181584|prostate cancer
1449994|NCT00181584|Zoledronic Acid
1449995|NCT00181584|Zometa
1449996|NCT00181571|ADHD
1449997|NCT00181571|Adults
1449998|NCT00181571|Concerta
1449999|NCT00181571|Double-Blind
1450000|NCT00181558|Prostate Cancer
1450001|NCT00181558|bone metastases
1450002|NCT00181558|Atrasentan
1450003|NCT00181558|Zometa
1450004|NCT00181558|Androgen Independent Prostate Cancer
1450005|NCT00181545|Non-small cell lung carcinoma
1450006|NCT00181545|radiotherapy
1450007|NCT00181545|mean lung dose
1450008|NCT00181532|NSCLC
1450009|NCT00181532|cox-2-inhibitor
1450010|NCT00181532|radiosensitizer
1450011|NCT00181532|radiotherapy
1450012|NCT00181506|radiotherapy
1450013|NCT00181506|radiation dose
1450014|NCT00181506|lung cancer
1450015|NCT00181363|Breast cancer
1450016|NCT00181363|Breast conserving surgery
1450017|NCT00181363|Radiotherapy
1450018|NCT00181363|Pendulous breasts
1450019|NCT00181350|brain tumor
1450020|NCT00181350|fractionated stereotactic radiotherapy
1450021|NCT00181350|fixationsystems
1450022|NCT00181350|repositioning
1450023|NCT00181311|vaginal hysterectomy
1450024|NCT00181311|abdominal hysterectomy
1450025|NCT00181311|complications
1450026|NCT00181311|physical well being
1450027|NCT00181311|mental well being
1450028|NCT00181298|Memantine
1450029|NCT00181298|SLE
1450030|NCT00181298|Anti NR2
1450031|NCT00181298|ANAM
1450032|NCT00181298|Cognitive functioning
1450033|NCT00181272|chronic obstructive pulmonary disease (COPD)
1450034|NCT00181272|undifferentiated asthma/COPD
1450035|NCT00181246|Neuropathic pain
1450036|NCT00181246|Efficacy
1450037|NCT00181207|COPD
1450038|NCT00181194|Asthma
1450039|NCT00181181|Hypertension
1450040|NCT00181168|thyroid cancer
1450041|NCT00181168|PET scan
1450042|NCT00181168|recombinant thyrotropin
1450043|NCT00181168|thyroglobulin
1450044|NCT00181168|Thyroid cancer, differentiated epithelial
1450045|NCT00181155|metabolism
1450046|NCT00181155|congestive heart failure
1450047|NCT00181155|allopurinol
1450048|NCT00181155|Adenosine triphosphate (ATP)
1450049|NCT00181142|Induciton therapy, Daclizumab, Thymoglobulin, lung transplantation
1450050|NCT00181129|Fatigue
1450051|NCT00181129|Cancer treatment
1450052|NCT00181116|Epilepsy
1450053|NCT00181116|Benign rolandic
1450054|NCT00181116|Levetiracetam
1450055|NCT00181090|Epilepsy
1450056|NCT00181090|Ketosis
1450057|NCT00181090|Atkins
1450058|NCT00181090|seizures
1450059|NCT00181077|preeclampsia, hypertonic saline, diuresis
1450060|NCT00181064|headache
1450061|NCT00181064|Atkins
1450062|NCT00181064|ketosis
1450063|NCT00181064|intractable
1450064|NCT00181038|Oro-Pharyngeal Carcinoma Surgery
1450065|NCT00181025|Limbs’ girdle
1450066|NCT00181012|Cancer Related Visceral Pain Resistant to Morphinics
1450067|NCT00180947|Soft parts tissue
1450068|NCT00180921|Adenoid cystic carcinoma of the head and neck
1450069|NCT00180908|Osteosarcoma
1450070|NCT00180895|Burkitt lymphoma
1450071|NCT00180895|B-cell non Hodgkin lymphoma
1450072|NCT00180895|B-cell ALL
1450073|NCT00180895|Refractory
1450074|NCT00180895|Relapse
1450075|NCT00180895|Rituximab
1450076|NCT00180895|Children
1450077|NCT00180869|cancer
1450078|NCT00180869|peroperative transfusion
1450079|NCT00180869|allogeneic red blood cell concentrate
1450080|NCT00180869|leuko-reduced red blood cell concentrate
1450081|NCT00180856|Lung metastasis
1450082|NCT00180856|Lung cancer
1450083|NCT00180856|Radiofrequency ablation
1450084|NCT00180791|Brain PNET
1450085|NCT00180765|Leukocytes
1450086|NCT00180765|Eosinophils
1450087|NCT00180765|Neutrophils
1450088|NCT00180765|Chronic Obstructive Airway Disease
1450089|NCT00180765|Apoptosis
1450090|NCT00180765|Signal Transduction
1450091|NCT00180739|MR guided FUS
1450092|NCT00180739|Uterine Fibroids
1450093|NCT00180739|Fertility
1450094|NCT00180739|Pregnancy
1450095|NCT00180726|asthma, inflammatory, corticosteroid
1450096|NCT00180713|Pulmonary hypertension
1450097|NCT00180713|Simvastatin
1450098|NCT00180713|Statins
1450099|NCT00180700|HIV
1450100|NCT00180700|Stress
1450101|NCT00180700|Psychoneuroimmunology
1450102|NCT00180700|stress management
1450103|NCT00180700|hypnosis
1450104|NCT00180700|Johrei
1450105|NCT00180700|psychological intervention
1450106|NCT00180687|Pain
1450107|NCT00180687|Nebulisation
1450108|NCT00180687|Cholecystectomy
1450109|NCT00180687|Laparoscopic
1450110|NCT00180687|Bupivacaine
1450111|NCT00180687|Local Anaesthetic
1450112|NCT00180674|Hepatic fibrosis
1450113|NCT00180674|anticoagulation
1450114|NCT00180674|Coumarin
1450115|NCT00180674|Warfarin
1450116|NCT00180674|Chronic hepatitis C virus infection
1450117|NCT00180661|Severe asthma
1450118|NCT00180661|corticosteroid responsiveness
1450119|NCT00180648|Short Bowel Syndrome
1450120|NCT00180648|Intestinal Failure
1450121|NCT00180648|Glucagon Like Peptide 2
1450122|NCT00180648|Parenteral Nutrition
1450123|NCT00180518|Carotid artery disease
1450124|NCT00180518|High risk
1450125|NCT00180518|High surgical risk
1450126|NCT00180505|Peripheral Artery Disease
1450127|NCT00180505|Restenosis Rate
1450128|NCT00180505|Patency Rates
1450129|NCT00180505|Self-Expandable Nitinol Stents
1450130|NCT00180505|Stent Fractures
1450131|NCT00180492|Atherosclerotic disease
1450132|NCT00180479|Everolimus
1450133|NCT00180466|drug eluting stents
1450134|NCT00180466|stents
1450135|NCT00180466|angioplasty
1450136|NCT00180466|coronary artery disease
1450137|NCT00180466|total coronary occlusion
1450138|NCT00180466|coronary artery restenosis
1450139|NCT00180466|stent thrombosis
1450140|NCT00180466|vascular disease
1450141|NCT00180466|myocardial ischemia
1450142|NCT00180466|coronary artery stenosis
1450143|NCT00180453|Cardiovascular disease
1450144|NCT00180453|Ischemia
1450145|NCT00180414|heart failure
1450146|NCT00180388|cardiovascular system
1450147|NCT00180388|veins
1450148|NCT00180388|saphenous vein
1450149|NCT00180336|Heart Failure
1450150|NCT00180336|Tachycardia
1450151|NCT00180336|Atrial Fibrillation
1450152|NCT00180336|Atrial Flutter
1450153|NCT00180336|Ventricular Fibrillation
1450154|NCT00180310|drug eluting stents
1450155|NCT00180310|stents
1450156|NCT00180310|angioplasty
1450157|NCT00180310|coronary artery disease
1450158|NCT00180310|total coronary occlusion
1450159|NCT00180310|coronary artery restenosis
1450160|NCT00180310|stent thrombosis
1450161|NCT00180310|vascular disease
1450162|NCT00180310|myocardial ischemia
1450163|NCT00180310|coronary artery stenosis
1450164|NCT00180284|Pacemaker leads
1450165|NCT00180284|Electrodes, implantable
1450166|NCT00180284|Cardiac pacing, aritificial
1450167|NCT00180271|Defibrillator
1450168|NCT00180271|Cardiac Resynchronization Therapy
1450169|NCT00180271|MADIT
1450170|NCT00180258|Cardiac Resynchronization Therapy (CRT)
1450171|NCT00180258|Heart Failure
1450172|NCT00180258|Defibrillator
1450173|NCT00180258|Pacemaker
1450174|NCT00180245|Radiation therapy
1450175|NCT00180245|F-18-FDG
1450176|NCT00180219|G08.520.769.550.408
1450177|NCT00180219|G08.520.769.550.490
1450178|NCT00180219|G08.520.769.550.520
1450179|NCT00180206|Arthritis
1450180|NCT00180206|Hip
1450181|NCT00180206|Hip arthroplasty
1450182|NCT00180206|Hip resurfacing arthroplasty
1450183|NCT00180193|Radiotherapy
1450184|NCT00180193|F-18-OMFD
1450185|NCT00180180|head-and-neck cancer
1450186|NCT00180180|radiation therapy
1450187|NCT00180180|F-18-FMISO
1450188|NCT00180167|Chemotherapy
1450189|NCT00180167|elderly
1450190|NCT00180154|radiation therapy
1450191|NCT00180154|F-18-FDG
1450192|NCT00180154|NSCLC
1450193|NCT00180141|Atopic dermatitis on both lower arm.
1450194|NCT00180128|acute promyelocytic leukemia
1450195|NCT00180128|risk adapted therapy
1450196|NCT00180115|acute myeloid leukemia
1450197|NCT00180115|cytarabine postremission dosage
1450198|NCT00180115|risk adapted treatment strategy
1450199|NCT00180115|allogeneic stem cell transplantation
1450200|NCT00180115|autologous stem cell transplantation
1450201|NCT00180102|acute myeloid leukemia
1450202|NCT00180102|risk adapted treatment
1450203|NCT00180102|early allogeneic stem cell transplantation
1450204|NCT00180102|autologous stem cell transplantation
1450205|NCT00180089|graft-versus-host disease
1450206|NCT00180089|budesonide
1450207|NCT00180089|stem cell transplantation
1450208|NCT00180076|collagenous colitis
1450209|NCT00180076|microscopic colitis
1450210|NCT00180076|budesonide
1450211|NCT00180050|lymphocytic colitis
1450212|NCT00180050|microscopic colitis
1450213|NCT00180050|budesonide
1450214|NCT00180037|Parkinson's disease
1450215|NCT00180037|Coenzyme Q10
1450216|NCT00180037|Treatment
1450217|NCT00180037|Neuroprotection
1450218|NCT00180024|AT1-receptor
1450219|NCT00180024|AT2-receptor
1450220|NCT00180024|human pharmacology
1450221|NCT00180011|omalizumab
1450222|NCT00180011|severe asthma
1450223|NCT00180011|moderate asthma
1450224|NCT00180011|injectable asthma medication
1450225|NCT00180011|Xolair
1450226|NCT00179998|Cystic fibrosis
1450227|NCT00179998|Infants
1450228|NCT00179998|Children
1450229|NCT00179998|Pulmozyme
1450230|NCT00179998|Pulmonary function
1450231|NCT00179998|Computed tomography
1450232|NCT00179985|Developmental Care
1450233|NCT00179985|Neonatal Intensive Care Unit (NICU)
1450234|NCT00179972|Pulse oximetry
1450235|NCT00179972|Pulse oximetry sensors
1450236|NCT00179972|Skin Integrity
1450237|NCT00179972|Prematurity
1450238|NCT00179972|Neonatal Intensive Care Unit
1450239|NCT00179972|Infant, premature
1450240|NCT00179933|developmental care
1450241|NCT00179933|Neonatal Intensive Care Unit
1450242|NCT00179894|ADHD
1450243|NCT00179894|Attention Deficit Hyperactivity Disorder
1450244|NCT00179881|Brain stem glioma
1450245|NCT00179868|cancer
1450246|NCT00179868|leukemia
1450247|NCT00179868|stem cell transplant
1450248|NCT00179868|complications
1450249|NCT00179855|graft versus host disease
1450250|NCT00179855|ECP
1450251|NCT00179855|extracorporeal photopheresis
1450252|NCT00179855|allogeneic transplantation
1450253|NCT00179829|leukemia
1450254|NCT00179829|acute lymphocytic leukemia
1450255|NCT00179829|chronic myelogenous leukemia
1450256|NCT00179829|acute myelogenous leukemia
1450257|NCT00179816|wilm's tumor
1450258|NCT00179816|stem cell transplantation
1450259|NCT00179816|solid tumor
1450260|NCT00179803|brain tumor
1450261|NCT00179803|medulloblastoma
1450262|NCT00179803|germ cell tumor
1450263|NCT00179803|CNS tumor
1450264|NCT00179803|glioblastoma
1450265|NCT00179803|astrocytoma
1450266|NCT00179803|pineoblastoma
1450267|NCT00179803|rhabdoid tumor
1450268|NCT00179803|supratentorial PNET
1450269|NCT00179803|high grade astrocytoma
1450270|NCT00179790|cancer
1450271|NCT00179790|hemoglobinopathy
1450272|NCT00179790|immune deficiency
1450273|NCT00179790|photopheresis
1450274|NCT00179790|ECP
1450275|NCT00179790|extracorporeal photopheresis
1450276|NCT00179777|Diabetes Mellitus, Type 1
1450277|NCT00179777|Genetic Predisposition to Disease
1450278|NCT00179777|Infant Nutrition
1450279|NCT00179777|Primary Prevention
1450280|NCT00179764|Patients with recurrent solid tumors
1450281|NCT00179764|Patients with malignant melanoma
1450282|NCT00179764|Patients with hematological malignancies
1450283|NCT00179764|Acute lymphoblastic leukemia (ALL)
1450284|NCT00179764|Acute myelogenous leukemia (AML)
1450285|NCT00179751|cc-5013
1450286|NCT00179751|revlimid
1450287|NCT00179751|pancreatic cancer
1450288|NCT00179738|Androgen Independent Prostate Cancer
1450289|NCT00179725|cc-5013
1450290|NCT00179725|revlimid
1450291|NCT00179725|ovarian cancer
1450292|NCT00179725|celgene
1450293|NCT00179712|cc-5013
1450294|NCT00179712|revlimid
1450295|NCT00179712|ovarian cancer
1450296|NCT00179712|celgene
1450297|NCT00179699|cc-5013
1450298|NCT00179699|Non Small Cell Lung Cancer
1450299|NCT00179699|revlimid
1450300|NCT00179699|celgene
1450301|NCT00179699|cc5013
1450302|NCT00179686|celgene
1450303|NCT00179686|cc-5013
1450304|NCT00179686|NSCLC
1450305|NCT00179686|CC5013
1450306|NCT00179686|Revlimid
1450307|NCT00179686|Non-Small Cell Lung Cancer
1450308|NCT00179673|NHL
1450309|NCT00179673|CC5013
1450310|NCT00179673|Non-Hodgkins Lymphoma
1450311|NCT00179673|revlimid
1450312|NCT00179673|cc-5013
1450313|NCT00179673|celgene
1450314|NCT00179660|celgene
1450315|NCT00179660|cc-5013
1450316|NCT00179660|CC5013
1450317|NCT00179660|NHL
1450318|NCT00179660|Non-Hodgkins Lymphoma
1450319|NCT00179660|Revlimid
1450320|NCT00179647|Multiple Myeloma
1450321|NCT00179647|MM
1450322|NCT00179647|Revlimid
1450323|NCT00179647|CC5013
1450324|NCT00179647|celgene
1450325|NCT00179647|cc-5013
1450326|NCT00179647|relapsed/refractory
1450327|NCT00179647|lenalidomide
1450328|NCT00179647|dexamethasone
1450329|NCT00179647|Decadron
1450330|NCT00179634|Mastectomy
1450331|NCT00179634|Randomized Controlled Trial
1450332|NCT00179634|Imagery
1450333|NCT00179621|MDS
1450334|NCT00179621|transfusion dependent
1450335|NCT00179621|anaemia
1450336|NCT00179621|cytogenetic abnormality 5q-
1450337|NCT00179621|erythroid response
1450338|NCT00179621|leukaemia
1450339|NCT00179621|CC-5013
1450340|NCT00179621|Celgene
1450341|NCT00179621|revlimid
1450342|NCT00179621|lenalidomide
1450343|NCT00179608|CC-5013
1450344|NCT00179608|CC5013
1450345|NCT00179608|celgene
1450346|NCT00179608|Melanoma
1450347|NCT00179608|Revlimid
1450348|NCT00179608|Metastatic Malignant Melanoma
1450349|NCT00179608|Lenalidomide
1450350|NCT00179595|nitric oxide, volumetric oxygen consumption
1450351|NCT00179582|IBS
1450352|NCT00179582|Functional bowel disorder
1450353|NCT00179582|Diarrhea
1450354|NCT00179582|probiotic
1450355|NCT00179556|Hot flashes
1450356|NCT00179556|Menopausal symptoms
1450357|NCT00179556|Soybean germ
1450358|NCT00179556|Aglycones
1450359|NCT00179556|Menopause
1450360|NCT00179517|Seizure
1450361|NCT00179517|Epilepsy
1450362|NCT00179517|Testosterone
1450363|NCT00179517|Hormone
1450364|NCT00179517|Sexual Dysfunction
1450365|NCT00179517|Hypogonadism
1450366|NCT00179517|Men
1450367|NCT00179491|coronary artery bypass grafting surgery
1450368|NCT00179478|Multiple sclerosis
1450369|NCT00179478|Interferon Beta
1450370|NCT00179478|MRI
1450371|NCT00179478|Optic neuritis
1450372|NCT00179478|Transverse Myelitis
1450373|NCT00179465|Treatment
1450374|NCT00179465|fMRI
1450375|NCT00179465|Cognition
1450376|NCT00179465|Brain development
1450377|NCT00179452|epilepsy, yoga
1450378|NCT00179439|PSC
1450379|NCT00179439|IBD
1450380|NCT00179439|CFTR
1450381|NCT00179426|Seizure Disorder
1450382|NCT00179426|Hypogonadism
1450383|NCT00179426|Sexual Function
1450384|NCT00179426|Epilepsy
1450385|NCT00179413|hepatitis C
1450386|NCT00179413|cirrhosis
1450387|NCT00179413|interferon
1450388|NCT00179413|colchicine
1450389|NCT00179387|Neoplasms
1450390|NCT00179387|Needs Assessment
1450391|NCT00179387|Adaptation Psychological
1450392|NCT00179387|Minority Groups
1450393|NCT00179387|Psychotherapy, Group
1450394|NCT00179387|Program Evaluation
1450395|NCT00179387|Spirituality
1450396|NCT00179387|Spiritual Therapies
1450397|NCT00179374|Medication adherence
1450398|NCT00179374|Self-care behaviors
1450399|NCT00179374|Telephonic intervention
1450400|NCT00179374|Diabetes
1450401|NCT00179374|Nutrition
1450402|NCT00179374|Exercise
1450403|NCT00179335|Regular lopinavir/ritonavir or Efavirenz use
1450404|NCT00179335|Age >/= 55 y or </= 35 y
1450405|NCT00179335|HIV+
1450406|NCT00179322|Sleep Architecture
1450407|NCT00179322|Sleep Measures
1450408|NCT00179322|Speech Articulation
1450409|NCT00179322|Cerebral Perfusion
1450410|NCT00179322|Neuroimaging
1450411|NCT00179322|Healthy Volunteer
1450412|NCT00179322|HV
1450413|NCT00179309|CEA
1450414|NCT00179309|MUC-1
1450415|NCT00179309|Immunotherapy
1450416|NCT00179309|GM-CSF
1450417|NCT00179309|Vaccine
1450418|NCT00179309|Breast Cancer
1450419|NCT00179309|Metastatic Breast Cancer
1450420|NCT00179257|Failure to Escitalopram
1450421|NCT00179244|Treatment Resistant Depression
1450422|NCT00179192|End Stage Renal Disease
1450423|NCT00179192|ESRD
1450424|NCT00179192|Chronic Maintenance Hemodialysis
1450425|NCT00179127|Pediatrics
1450426|NCT00179127|Diabetes
1450427|NCT00179127|Emergency Care
1450428|NCT00179127|Endocrinology
1450429|NCT00179127|Critical Care
1450430|NCT00179114|Spasticity
1450431|NCT00179114|Developmental Disabilities
1450432|NCT00179114|Intrathecal baclofen (ITB)
1450433|NCT00179114|Botulinum Toxin Type A (Botox)
1450434|NCT00179101|Parkinson's Disease
1450435|NCT00179101|Depression
1450436|NCT00179101|Quality of Life
1450437|NCT00179101|Deep Brain Stimulation
1450438|NCT00179088|Weight-Bearing
1450439|NCT00179088|Total Hip Replacement
1450440|NCT00179088|Non-cemented
1450441|NCT00179088|Randomized
1450442|NCT00179088|Fiber-Metal-Taper-Stem
1450443|NCT00179088|Hip
1450444|NCT00179088|Osteoarthritis
1450445|NCT00179075|T-Lymphocyte Subsets
1450446|NCT00179062|major depression with psychotic features
1450447|NCT00179062|bipolar disorder with psychotic features
1450448|NCT00179049|T-Lymphocyte Subsets
1450449|NCT00179036|Blood supply
1450450|NCT00179036|Mesentery
1450451|NCT00179023|OBESITY
1450452|NCT00179023|RESTING ENERGY EXPENDITURE
1450453|NCT00179023|SYMPATHETIC NERVOUS SYSTEM
1450454|NCT00179023|HYPERTENSION
1450455|NCT00179023|AUTONOMIC FAILURE
1450456|NCT00179010|Adenosine
1450457|NCT00179010|AMP
1450458|NCT00179010|Microdialysis
1450459|NCT00179010|Blood Flow
1450460|NCT00178997|Blood supply
1450461|NCT00178997|Mesentery
1450462|NCT00178984|Blood supply
1450463|NCT00178984|Mesentery
1450464|NCT00178919|Endothelial Nitric Oxide
1450465|NCT00178919|L-NMMA
1450466|NCT00178919|Trimethaphan
1450467|NCT00178919|Autonomic Nervous System
1450468|NCT00178919|Nitric Oxide Inhibition
1450469|NCT00178906|depression
1450470|NCT00178906|suicide
1450471|NCT00178906|voice
1450472|NCT00178880|depression
1450473|NCT00178880|MRI
1450474|NCT00178880|imaging
1450475|NCT00178841|Cutaneous T-cell Lymphoma
1450476|NCT00178841|CTCL
1450477|NCT00178841|Mycosis Fungoides
1450478|NCT00178841|Sezary Syndrome
1450479|NCT00178841|Bexarotene
1450480|NCT00178841|Targretin
1450481|NCT00178841|Rosiglitazone
1450482|NCT00178841|Avandia
1450483|NCT00178828|Depression
1450484|NCT00178828|antidepressant
1450485|NCT00178828|SSRI
1450486|NCT00178802|breast cancer
1450487|NCT00178802|endometrial cancer
1450488|NCT00178802|cervical cancer
1450489|NCT00178802|ovarian cancer
1450490|NCT00178789|Deep Venous Thrombosis
1450491|NCT00178789|Blood Clot
1450492|NCT00178789|Lower Extremity
1450493|NCT00178789|Sonography
1450494|NCT00178776|Group
1450495|NCT00178776|Therapy
1450496|NCT00178776|Cocaine
1450497|NCT00178776|Drugs
1450498|NCT00178776|Trial
1450499|NCT00178776|Outcome
1450500|NCT00178776|Study
1450501|NCT00178776|Feasibility
1450502|NCT00178776|Transtheoretical
1450503|NCT00178776|Stages
1450504|NCT00178776|Motivation
1450505|NCT00178776|Change
1450506|NCT00178763|Cancer
1450507|NCT00178763|Pancreatic Cancer
1450508|NCT00178763|Pancreas
1450509|NCT00178763|Neoplasms
1450510|NCT00178750|Epidural placement
1450511|NCT00178750|CompuFlo®
1450512|NCT00178724|spinal cord injury
1450513|NCT00178724|SCI
1450514|NCT00178724|traumatic spinal cord injury
1450515|NCT00178724|acute spinal cord injury
1450516|NCT00178724|paralysis
1450517|NCT00178711|Traumatic Brain Injury
1450518|NCT00178711|Hypothermia
1450519|NCT00178698|thermochemotherapy
1450520|NCT00178698|fever range whole body
1450521|NCT00178698|cisplatin
1450522|NCT00178698|gemcitabine
1450523|NCT00178698|daily low dose interferon alpha
1450524|NCT00178685|Self-determination
1450525|NCT00178685|motivation
1450526|NCT00178685|adherence
1450527|NCT00178685|competence
1450528|NCT00178685|autonomy
1450529|NCT00178685|tobacco dependence
1450530|NCT00178685|Tobacco use and dependence
1450531|NCT00178685|Behavior change
1450532|NCT00178672|CVA
1450533|NCT00178672|TIA
1450534|NCT00178672|Carotid disease
1450535|NCT00178672|Stroke
1450536|NCT00178672|Neurology
1450537|NCT00178672|Carotid Stenting
1450538|NCT00178659|Traumatic Brain Injury
1450539|NCT00178659|TBI (Traumatic Brain Injury)
1450540|NCT00178659|Proteomics
1450541|NCT00178646|Stroke
1450542|NCT00178646|Brain Injuries
1450543|NCT00178646|Spasticity
1450544|NCT00178646|Botulinum Toxins
1450545|NCT00178633|Obesity
1450546|NCT00178633|Insulin Resistance
1450547|NCT00178633|Free Fatty Acids
1450548|NCT00178633|Heart Failure
1450549|NCT00178620|Heart Disease
1450550|NCT00178620|Heart Attack
1450551|NCT00178620|Myocardial Infarction
1450552|NCT00178620|Thrombolytic Therapy
1450553|NCT00178620|Emergency Medicine
1450554|NCT00178607|Inhibitors
1450555|NCT00178594|Hereditary Bleeding disorder
1450556|NCT00178594|Thrombotic Disorder
1450557|NCT00178581|Trauma
1450558|NCT00178581|Critical Illness
1450559|NCT00178581|Shock
1450560|NCT00178581|Enteral Nutrition
1450561|NCT00178581|Glutamine
1450562|NCT00178568|Caregiving
1450563|NCT00178568|Spousal
1450564|NCT00178568|Sleep disturbances
1450565|NCT00178568|Progressive dementia
1450566|NCT00178568|Stress
1450567|NCT00178568|Health outcomes
1450568|NCT00178568|Intervention
1450569|NCT00178568|Affective self-management
1450570|NCT00178568|Caregivers M01.526.485.200
1450571|NCT00178568|Spouses F01.829.263.500.660
1450572|NCT00178568|Alzheimer's disease C10.574.945.249
1450573|NCT00178568|Parkinson's disease C10.574.812
1450574|NCT00178568|Sleep disorder C10.886.425.800.800
1450575|NCT00178555|Endotracheal Intubation, Video Laryngoscopy
1450576|NCT00178542|von Willebrand Disease
1450577|NCT00178542|Healthy Women and Women with von Willebrand Disease
1450578|NCT00178529|Stroke
1450579|NCT00178529|Caregivers
1450580|NCT00178516|male
1450581|NCT00178516|infertility
1450582|NCT00178490|Neurocognitive Function
1450583|NCT00178464|sickle cell disease
1450584|NCT00178464|hemoglobin SS disease
1450585|NCT00178464|hemoglobin S Beta-0 Thalassemia
1450586|NCT00178464|silent infarction in sickle cell disease
1450587|NCT00178464|overt stroke in sickle cell disease
1450588|NCT00178464|aspirin
1450589|NCT00178464|transcranial Doppler ultrasound
1450590|NCT00178464|neurocognitive testing
1450717|NCT00177996|depression
1450591|NCT00178438|capsule endoscopy in small bowel
1450592|NCT00178425|mycophenolate mofetil hydrochloride
1450593|NCT00178425|pharmacokinetics
1450594|NCT00178425|tacrolimus
1450595|NCT00178412|Hospitalized elders
1450596|NCT00178412|Family caregivers
1450597|NCT00178412|Acute care
1450598|NCT00178386|cancer
1450599|NCT00178386|education
1450600|NCT00178386|learning
1450601|NCT00178386|brain tumor
1450602|NCT00178386|school
1450603|NCT00178373|cancer-related fatigue
1450604|NCT00178373|chemotherapy
1450605|NCT00178373|modafinil
1450606|NCT00178360|Huntington's Disease, Music Therapy, quality of life
1450607|NCT00178321|Sleep
1450608|NCT00178321|Criticall Ill
1450609|NCT00178321|Children
1450610|NCT00178321|Earplugs
1450611|NCT00177320|Rheumatic Disorders
1450612|NCT00177320|Computer Use
1450613|NCT00177307|colon
1450614|NCT00177307|rectum
1450615|NCT00177294|Elderly
1450616|NCT00177294|Remission
1450617|NCT00177294|Escitalopram
1450743|NCT00177788|liver transplant
1450618|NCT00177294|Interpersonal Psychotherapy
1450619|NCT00177294|Psychotherapy
1450620|NCT00177294|Caregiving
1450621|NCT00177294|Late-Life
1450622|NCT00177268|Cutaneous T-cell Lymphoma
1450623|NCT00177268|Sezary Syndrome
1450624|NCT00177268|Mycosis Fungoides
1450625|NCT00177268|Blood/tissue banking
1450626|NCT00177268|eczema
1450627|NCT00177268|atopic dermatitis
1450628|NCT00177255|gastric
1450629|NCT00177255|stomach
1450630|NCT00177255|esophagus
1450631|NCT00177255|esophageal
1450632|NCT00177242|pancreas
1450633|NCT00177242|pancreatic
1450634|NCT00177216|Primary Insomnia
1450635|NCT00177216|Insomnia
1450636|NCT00177216|Placebo-Controlled
1450637|NCT00177216|Double-Blind
1450638|NCT00177216|Polysomnography
1450639|NCT00177216|PET Studies
1450640|NCT00177216|Escitalopram
1450641|NCT00177216|Zolpidem
1450642|NCT00177203|Insomnia
1450643|NCT00177203|Sleep Disorders
1450644|NCT00177203|Sleeplessness
1450645|NCT00177203|Chronic Insomnia
1450646|NCT00177203|Sleep Studies
1450647|NCT00177203|Disorders of Initiating and Maintaining Sleep
1450648|NCT00177203|Primary Care
1450649|NCT00177190|Cutaneous T-cell Lymphoma
1450650|NCT00177190|Sezary Syndrome
1450651|NCT00177190|Mycosis Fungoides
1450652|NCT00177190|Immune Responses
1450653|NCT00177177|L-carnosine
1450654|NCT00177177|Schizophrenia
1450655|NCT00177177|Schizoaffective disorder
1450656|NCT00177177|Cognitive enhancement
1450657|NCT00177164|Bipolar I Disorder
1450658|NCT00177164|Risperidone Consta - Long Acting Injection
1450659|NCT00177164|Oral second generation antipsychotic agents
1450660|NCT00177138|Campath Study
1450661|NCT00177138|Pancreas After Kidney Transplantation
1450662|NCT00177138|Alemtuzumab
1450663|NCT00178217|Botulinum Toxin
1450664|NCT00178217|Music Therapy
1450665|NCT00178217|Cerebral Palsy
1450666|NCT00178217|Procedural Support
1450667|NCT00178204|delta sleep
1450668|NCT00178204|Cancer-related fatigue
1450669|NCT00178204|Sleep Disturbance
1450670|NCT00178204|chemotherapy
1450671|NCT00178178|anterior cruciate ligament reconstruction
1450672|NCT00178178|Pain Care 3000
1450673|NCT00178178|Catheter Placement
1450674|NCT00178178|Pain
1450675|NCT00178178|Breg, Inc
1450676|NCT00178165|Family Caregivers
1450677|NCT00178165|Dementia
1450678|NCT00178165|Alzheimer Disease
1450679|NCT00178165|Randomized Controlled Trial
1450680|NCT00178165|Intervention Studies
1450681|NCT00178139|Music Therapy
1450682|NCT00178139|Mechanical ventilation
1450683|NCT00178139|Weaning from mechanical ventilation
1450684|NCT00178139|complementary and alternative therapy
1450685|NCT00178126|pressure ulcer
1450686|NCT00178113|Prostatic Intraepithelial Neoplasia
1450687|NCT00178113|Prostate-Specific Antigen
1450688|NCT00178113|lycopene
1450689|NCT00178100|Depression
1450690|NCT00178100|Elderly
1450691|NCT00178100|Late Life
1450692|NCT00178087|late-life depression
1450693|NCT00178087|mild cognitive impairment
1450694|NCT00178087|dementia
1450695|NCT00178074|depression
1450696|NCT00178074|imaging
1450697|NCT00178074|PET
1450698|NCT00178074|elderly
1450699|NCT00178074|late life
1450700|NCT00178074|sleep deprivation
1450701|NCT00178048|primary insomnia
1450702|NCT00178048|insomnia
1450703|NCT00178048|depression
1450704|NCT00178048|late life
1450705|NCT00178048|elderly
1450706|NCT00178048|sleep disorders
1450707|NCT00178035|Depression
1450708|NCT00178035|Unipolar Depression
1450709|NCT00178035|Elderly depression
1450710|NCT00178035|Late-Life
1450711|NCT00178022|tbi
1450712|NCT00178022|intervention
1450713|NCT00178022|depression
1450714|NCT00178022|anxiety
1450715|NCT00178009|computer-assisted instruction
1450716|NCT00178009|instruction (video)
1450718|NCT00177996|anxiety
1450719|NCT00177983|Schizophrenia
1450720|NCT00177983|Relapse
1450721|NCT00177983|Psychological distress
1450722|NCT00177957|Gram negative bacteremia
1450723|NCT00177944|invasive fungal infection
1450724|NCT00177931|Liver transplant
1450725|NCT00177931|cefepime
1450726|NCT00177931|antibiotics
1450727|NCT00177918|Lung Transplant
1450728|NCT00177892|Sleep fragmentation
1450729|NCT00177892|Intermittent hypoxia
1450730|NCT00177892|Obstructive Sleep Apnea
1450731|NCT00177892|Metabolic Syndrome
1450732|NCT00177892|Insulin resistance
1450733|NCT00177879|website
1450734|NCT00177879|comparison
1450735|NCT00177853|Locally advanced pancreatic cancer
1450736|NCT00177853|invasion of major arteries and veins around pancreas
1450737|NCT00177853|No prior radiation or chemo
1450738|NCT00177840|cancer-related fatigue
1450739|NCT00177840|acupuncture
1450740|NCT00177840|breast cancer
1450741|NCT00177814|pipercillin
1450742|NCT00177814|gram negative bacteria infections
1450744|NCT00177788|voriconazole prophylaxis
1450745|NCT00177788|liver transplantation
1450746|NCT00177788|voriconazole
1450747|NCT00177749|invasive fungal infections
1450748|NCT00177736|ventilator associated pneumonia
1450749|NCT00177723|receiving antibiotic Linezolid clinically
1450750|NCT00177671|Depression
1450751|NCT00177671|Dementia
1450752|NCT00177671|Alzheimer's Disease
1450753|NCT00177671|Cognitive
1450754|NCT00177671|Donepezil
1450755|NCT00177671|Memory
1450756|NCT00177671|Function
1450757|NCT00177671|Elderly
1450758|NCT00177671|Late-Life
1450759|NCT00177658|Salmonella
1450760|NCT00177645|cystic fibrosis
1450761|NCT00177645|mucus clearance
1450762|NCT00177619|Prostatic neoplasms
1450763|NCT00177619|Bisphosphonates
1450764|NCT00177619|Hypogonadism
1450765|NCT00177606|withdrawal
1450766|NCT00177606|life-sustaining
1450767|NCT00177606|treatments
1450768|NCT00177606|UNOS
1450769|NCT00177606|organ donation
1450770|NCT00177580|schizophrenia
1450771|NCT00177580|schizoaffective disorder
1450772|NCT00177580|positive symptoms
1450773|NCT00177580|negative symptoms
1450774|NCT00177580|cognitive functioning
1450775|NCT00177580|pravastatin
1450776|NCT00177567|Bipolar Disorder
1450777|NCT00177567|Manic Depression
1450778|NCT00177567|Elderly
1450779|NCT00177567|Late-Life
1450780|NCT00177554|Non-Hodgkin Lymphoma
1450781|NCT00177541|urge incontinence
1450782|NCT00177541|biofeedback
1450783|NCT00177541|pelvic floor muscle training
1450784|NCT00177541|behavior modification
1450785|NCT00177528|Elderly
1450786|NCT00177515|emergency contraception
1450787|NCT00177515|folic acid
1450788|NCT00177515|education
1450789|NCT00177515|preventive health
1450790|NCT00177489|Family Caregivers
1450791|NCT00177489|Dementia
1450792|NCT00177489|Alzheimer Disease
1450793|NCT00177489|Randomized Controlled Trial
1450794|NCT00177489|Intervention Studies
1450795|NCT00177463|L-carnosine
1450796|NCT00177463|Bipolar I disorder
1450797|NCT00177463|Cognitive enhancement
1450798|NCT00177424|Rehabilitation
1450799|NCT00177411|Endocrine System Diseases
1450800|NCT00177411|MusculoSkeletal System Diseases
1450801|NCT00177411|Hormone
1450802|NCT00177411|Postmenopausal Women
1450803|NCT00177398|Type 2 diabetes
1450804|NCT00177398|Hyperglycemia
1450805|NCT00177398|Enteral nutrition
1450806|NCT00177385|Sleep
1450807|NCT00177385|Sleep Hygiene
1450808|NCT00177385|Modest sleep deprivation
1450809|NCT00177385|Healthy Aging and sleep
1450810|NCT00177385|Health Promotion
1450811|NCT00177359|gait impairment
1450812|NCT00177333|Abortion, Induced
1450813|NCT00177333|Doxycycline
1450814|NCT00177333|Antibiotic Prophylaxis
1450815|NCT00177333|Vomiting
1450816|NCT00177333|Abortion, Therapeutic
1450817|NCT00177112|Cystoscopy
1450818|NCT00177047|stem cell transplantation
1450819|NCT00177047|chemotherapy
1450820|NCT00177047|multiple myeloma
1450821|NCT00177047|autologous
1450822|NCT00177034|Keratinocyte
1450823|NCT00177008|Schizophrenia
1450824|NCT00177008|Schizoaffective Disorder
1450825|NCT00177008|Social Anxiety Disorder
1450826|NCT00176982|treatment of alopecia areata
1450827|NCT00176956|Post Pediatric Heart Transplant
1450828|NCT00176930|stem cell transplant
1450829|NCT00176930|chronic leukemia
1450830|NCT00176930|acute leukemia
1450831|NCT00176930|irradiation
1450832|NCT00176930|chemotherapy
1450833|NCT00176917|stem cell transplant
1450834|NCT00176917|storage disease
1450835|NCT00176917|errors of metabolism
1450836|NCT00176904|Inborn errors
1450837|NCT00176904|Storage disease
1450838|NCT00176904|errors of metabolism
1450839|NCT00176904|stem cell transplant
1450840|NCT00176891|Laronidase ERT
1450841|NCT00176891|Stem cell transplant
1450842|NCT00176891|storage disease
1450843|NCT00176891|inborn errors of metabolism
1450844|NCT00176891|hurler syndrome
1450845|NCT00176891|glycosaminoglycans
1450846|NCT00176891|enzyme replacement
1450847|NCT00176878|Stem cell transplant
1450848|NCT00176878|T-cell depletion
1450849|NCT00176878|TLI
1450850|NCT00176878|bone marrow failure disorders
1450851|NCT00176865|Stem cell transplant
1450852|NCT00176865|immunodeficiency
1450853|NCT00176865|donor lymphocyte infusion
1450854|NCT00176852|high risk hemoglobinopathy
1450855|NCT00176852|stem cell transplant
1450856|NCT00176852|donor lymphocyte infusion
1450857|NCT00176852|transfusion dependent
1450858|NCT00176852|stem cell donor
1450859|NCT00176852|cord blood
1450860|NCT00176852|marrow
1450861|NCT00176852|transfusion dependent non-malignant hematologic disorders
1450862|NCT00176839|Stem Cell transplant
1450863|NCT00176839|retransplant
1450864|NCT00176839|hematological malignancies
1450865|NCT00176826|Stem Cell Transplant
1450866|NCT00176826|T-cell depletion
1450867|NCT00176826|immune deficiencies
1450868|NCT00176826|Busulfan pharmacokinetics
1450869|NCT00176826|Non-Malignant Hematological Disorders
1450870|NCT00176722|Spine Surgery
1450871|NCT00176722|Intraocular Pressure
1450872|NCT00176722|lumbar or thoracic Spine Surgery in the prone position
1450873|NCT00176722|and its association with visual change
1450874|NCT00176696|general anesthesia
1450875|NCT00176696|pain
1450876|NCT00176696|depth of anesthesia
1450877|NCT00176683|intubation
1450878|NCT00176683|capnography
1450879|NCT00176670|presurgical anxiety, children,
1450880|NCT00176657|cardiac surgery
1450881|NCT00176657|transfusion
1450882|NCT00176644|prostate cancer
1450883|NCT00176631|adenocarcinoma of the prostate
1450884|NCT00176631|recurrent prostate cancer
1450885|NCT00176631|stage IV prostate cancer
1450886|NCT00176618|Aberrant Crypt Foci
1450887|NCT00176605|prostate cancer
1450888|NCT00176605|recurrent prostate cancer
1450889|NCT00176605|stage IV prostate cancer
1450890|NCT00176592|Multiple Sclerosis
1450891|NCT00176592|Brain
1450892|NCT00176592|Betaseron
1450893|NCT00176592|Copaxone
1450894|NCT00176592|MRI
1450895|NCT00176579|osteoporosis
1450896|NCT00176579|stage I prostate cancer
1450897|NCT00176566|oral leukoplakia
1450898|NCT00176553|methotrexate neurotoxicity
1450899|NCT00176540|unspecified adult solid tumor, protocol specific
1450900|NCT00176540|unspecified childhood solid tumor, protocol specific
1450901|NCT00176540|fatigue
1450902|NCT00176527|recurrent prostate cancer
1450903|NCT00176527|stage IV prostate cancer
1450904|NCT00176514|mucositis
1450905|NCT00176501|recurrent renal cell cancer
1450906|NCT00176501|clear cell renal cell carcinoma
1450907|NCT00176501|stage IV renal cell cancer
1450908|NCT00176488|recurrent breast cancer
1450909|NCT00176488|stage II breast cancer
1450910|NCT00176488|stage IIIA breast cancer
1450911|NCT00176488|stage IIIB breast cancer
1450912|NCT00176488|stage IV breast cancer
1450913|NCT00176488|male breast cancer
1450914|NCT00176475|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1450915|NCT00176475|nodal marginal zone B-cell lymphoma
1450916|NCT00176475|recurrent adult Burkitt lymphoma
1450917|NCT00176475|recurrent adult diffuse large cell lymphoma
1450918|NCT00176475|recurrent adult Hodgkin lymphoma
1450919|NCT00176475|recurrent adult lymphoblastic lymphoma
1450920|NCT00176475|recurrent adult acute lymphoblastic leukemia
1450921|NCT00176475|refractory chronic lymphocytic leukemia
1450922|NCT00176475|recurrent small lymphocytic lymphoma
1450923|NCT00176475|refractory hairy cell leukemia
1450924|NCT00176475|prolymphocytic leukemia
1450925|NCT00176475|recurrent marginal zone lymphoma
1450926|NCT00176475|recurrent grade 1 follicular lymphoma
1450927|NCT00176475|recurrent grade 2 follicular lymphoma
1450928|NCT00176475|recurrent grade 3 follicular lymphoma
1450929|NCT00176475|refractory multiple myeloma
1450930|NCT00176475|recurrent mantle cell lymphoma
1450931|NCT00176475|recurrent adult grade III lymphomatoid granulomatosis
1450932|NCT00176475|Waldenstrom macroglobulinemia
1450933|NCT00176475|splenic marginal zone lymphoma
1450934|NCT00176475|stage II multiple myeloma
1450935|NCT00176475|stage III multiple myeloma
1450936|NCT00176475|stage IV adult Burkitt lymphoma
1450937|NCT00176475|stage IV adult diffuse large cell lymphoma
1450938|NCT00176475|stage IV adult Hodgkin lymphoma
1450939|NCT00176475|stage IV adult lymphoblastic lymphoma
1450940|NCT00176475|stage III adult Burkitt lymphoma
1450941|NCT00176475|stage III adult diffuse large cell lymphoma
1450942|NCT00176475|stage III adult Hodgkin lymphoma
1450943|NCT00176475|stage III adult lymphoblastic lymphoma
1450944|NCT00176475|stage III grade 1 follicular lymphoma
1450945|NCT00176475|stage III grade 2 follicular lymphoma
1450946|NCT00176475|stage III grade 3 follicular lymphoma
1450947|NCT00176475|stage IV grade 1 follicular lymphoma
1450948|NCT00176475|stage IV grade 2 follicular lymphoma
1450949|NCT00176475|stage IV grade 3 follicular lymphoma
1450950|NCT00176475|stage III mantle cell lymphoma
1450951|NCT00176475|stage IV mantle cell lymphoma
1450952|NCT00176475|stage III marginal zone lymphoma
1450953|NCT00176475|stage IV marginal zone lymphoma
1450954|NCT00176475|stage III small lymphocytic lymphoma
1450955|NCT00176475|stage IV small lymphocytic lymphoma
1450956|NCT00176475|stage III chronic lymphocytic leukemia
1450957|NCT00176475|stage IV chronic lymphocytic leukemia
1450958|NCT00176475|progressive hairy cell leukemia, initial treatment
1450959|NCT00176462|Acute Lymphocytic Leukemia
1450960|NCT00176462|Leukemia
1450961|NCT00176449|Nicotine Dependence
1450962|NCT00176449|Nicotine Use Disorder
1450963|NCT00176449|Tobacco Dependence
1450964|NCT00176449|Tobacco-Use Disorder
1450965|NCT00176449|Smoking Cessation
1450966|NCT00176436|Weight loss
1450967|NCT00176436|Support group
1450968|NCT00176436|Exercise
1450969|NCT00176436|Atomoxetine
1450970|NCT00176423|schizophrenia
1450971|NCT00176423|acetylcholine
1450972|NCT00176423|cognitive impairments
1450973|NCT00176423|attention
1450974|NCT00176423|processing speed
1450975|NCT00176423|sensory gating
1450976|NCT00176423|eye-tracking
1450977|NCT00176410|aortic valve stenosis
1450978|NCT00176410|statin therapy
1450979|NCT00176397|left main coronary artery
1450980|NCT00176397|coronary artery disease
1450981|NCT00176384|chronic heart failure
1450982|NCT00176384|exercise training
1450983|NCT00176371|Physical fitness
1450984|NCT00176345|exercise training
1450985|NCT00176345|endothelial function
1450986|NCT00176332|chronic heart failure
1450987|NCT00176332|rosuvastatin
1450988|NCT00176332|endothelial function
1450989|NCT00176332|skeletal muscle
1450990|NCT00176319|heart failure
1450991|NCT00176319|ageing
1450992|NCT00176293|prostate
1450993|NCT00176293|prostate cancer
1450994|NCT00176293|doxil
1450995|NCT00176293|dexamethasone
1450996|NCT00176293|metastatic
1450997|NCT00176293|hormone refractory
1450998|NCT00176280|Renal
1450999|NCT00176280|Carcinoma
1451000|NCT00176280|Renal Cell Carcinoma
1451001|NCT00176280|RCC
1451002|NCT00176280|Leukine
1451003|NCT00176280|Dexamethasone
1451004|NCT00176280|Gemcitabine
1451005|NCT00176280|5 Fluorouracil
1451006|NCT00176280|5 FU
1451007|NCT00176280|Metastatic
1451008|NCT00176267|head and neck
1451009|NCT00176267|squamous cell carcinoma
1451010|NCT00176267|squamous cell
1451011|NCT00176267|carcinoma
1451012|NCT00176267|paclitaxel
1451013|NCT00176267|carboplatin
1451014|NCT00176267|radiotherapy
1451015|NCT00176267|induction therapy
1451016|NCT00176254|head and neck
1451017|NCT00176254|squamous cell carcinoma
1451018|NCT00176254|squamous cell
1451019|NCT00176254|carcinoma
1451020|NCT00176254|paclitaxel
1451021|NCT00176254|carboplatin
1451022|NCT00176254|radiotherapy
1451023|NCT00176254|induction therapy
1451024|NCT00176241|head and neck
1451025|NCT00176241|Gemcitabine
1451026|NCT00176241|Paclitaxel
1451027|NCT00176241|radiation
1451028|NCT00176241|low-dose radiation
1451029|NCT00176241|recurrent
1451030|NCT00176241|metastatic
1451031|NCT00176189|FPD, all-ceramic
1451032|NCT00176176|cerebral circulation
1451033|NCT00176163|Fibromyalgia
1451034|NCT00176163|Back pain
1451035|NCT00176163|Behavior Therapy
1451036|NCT00176163|Operant learning
1451037|NCT00176163|Tetrahydrocannabinol
1451038|NCT00176150|anorexia nervosa
1451039|NCT00176150|multidrug resistance
1451040|NCT00176150|cholesterol metabolism
1451041|NCT00176137|multimodality treatment
1451042|NCT00176124|leukocyte depletion, autologous transfusion,
1451043|NCT00176124|infection
1451044|NCT00176124|bacterial infection
1451045|NCT00176124|sepsis, antibiotics
1451046|NCT00176111|peripheral nerve stimulation
1451047|NCT00176111|saline
1451048|NCT00176111|local anesthestics
1451049|NCT00176111|regional anesthestia
1451050|NCT00176111|nerve damage
1451051|NCT00176098|Cataract surgery
1451052|NCT00176098|Hypnosis
1451053|NCT00176098|C11.510.245
1451054|NCT00176098|F04.754.424.771
1451055|NCT00176098|Suggestion
1451056|NCT00176059|immunoglobulins, intravenous
1451057|NCT00176059|kidney transplantation
1451058|NCT00176059|acute rejection
1451059|NCT00176059|chronic rejection
1451060|NCT00176059|regulatory autoantibodies
1451061|NCT00176059|Th1
1451062|NCT00176059|Th2
1451063|NCT00176059|B Cell
1451064|NCT00176059|Monokines
1451065|NCT00176059|Cytokine promoter gene polymorphisms
1451066|NCT00176046|breast cancer
1451067|NCT00176046|mistletoe
1451068|NCT00176046|complementary therapy
1451069|NCT00176046|quality of life
1451070|NCT00176046|immune function
1451071|NCT00176046|breast cancer (UICC stage I/II)
1451072|NCT00176033|ritonavir
1451073|NCT00176033|lopinavir
1451074|NCT00176033|HIV Infections
1451075|NCT00176020|nicotinic acid
1451076|NCT00176020|flush symptom
1451077|NCT00176020|pharmacodynamic
1451078|NCT00176020|pharmacokinetic
1451079|NCT00175994|voriconazole
1451080|NCT00175994|genotype
1451081|NCT00175994|bioavailability
1451082|NCT00175994|metabolic clearance
1451083|NCT00175955|Neuroleptic-induced tardive dyskinesia
1451084|NCT00175955|Keppra, Levetiracetam
1451085|NCT00175942|acute myocardial infarction
1451086|NCT00175942|ventricular fibrillation
1451087|NCT00175942|coagulation
1451088|NCT00175942|inflammation
1451089|NCT00175929|Epilepsy
1451090|NCT00175929|Focal Epilepsy
1451091|NCT00175929|Partial Onset Seizures
1451092|NCT00175929|Brivaracetam
1451093|NCT00175916|Brivaracetam
1451094|NCT00175916|Epilepsy
1451095|NCT00175916|long term
1451096|NCT00175903|Newly Diagnosed Epilepsy
1451097|NCT00175903|Levetiracetam
1451098|NCT00175903|Keppra
1451099|NCT00175903|Carbamazepine
1451100|NCT00175903|Valproate
1451101|NCT00175890|Partial Onset Seizure
1451102|NCT00175890|levetiracetam
1451103|NCT00175890|Video Electroencephalogram
1451104|NCT00175890|Keppra
1451105|NCT00175877|Rheumatoid Arthritis
1451106|NCT00175877|CDP870
1451107|NCT00175877|Certolizumab Pegol
1451108|NCT00175877|Cimzia
1451109|NCT00175864|Partial Onset, Primary Generalized Seizures, Seletracetam
1451110|NCT00175851|Partial onset, primary generalized seizures, seletracetam
1451111|NCT00175838|Primary Thrombocythmeia
1451112|NCT00175838|Hydroxyurea
1451113|NCT00175838|Randomised
1451114|NCT00175838|Thrombosis
1451115|NCT00175838|Haemorrhage
1451116|NCT00175825|Epilepsy: partial onset seizures
1451117|NCT00175825|brivaracetam
1451118|NCT00175812|Acute myelogenous leukemia
1451119|NCT00175812|Differentiation
1451120|NCT00175812|All trans retinoic acid
1451121|NCT00175812|Valproic acid
1451122|NCT00175812|Theophyllamin
1451123|NCT00175799|Observational study of physiological status at entry into PICU as a predictor of outcome, comparison of two commonly used scores (PRISM and PIM)
1451124|NCT00175799|Data from children admitted to a Paediatric Intensive Care unit
1451125|NCT00175786|Glaucoma
1451126|NCT00175786|Normal Tensions Glaucoma
1451127|NCT00175786|Neuroradiology
1451128|NCT00175786|Tumor
1451129|NCT00175786|MRI
1451130|NCT00175786|Magnetic Resonance Imaging
1451131|NCT00175786|Compressive Lesion
1451132|NCT00175773|Orthostatic stress
1451133|NCT00175760|TTG
1451134|NCT00175760|pediatric
1451135|NCT00175760|comparison study
1451136|NCT00175747|dysplasia
1451137|NCT00175747|lung cancer
1451138|NCT00175747|chemoprevention
1451139|NCT00175734|Vascular Reactivity
1451140|NCT00175734|Anemia Correction Therapy
1451141|NCT00175734|Hemodialysis patients
1451142|NCT00175734|Diabetic and non-diabetic patients
1451143|NCT00175734|Diabetes in Hemodialysis patients
1451144|NCT00175721|Combined Clinic
1451145|NCT00175721|Chronic Kidney Disease
1451146|NCT00175721|Diabetes
1451147|NCT00175708|Evaluation of an outcome tool
1451148|NCT00175708|clubfoot
1451149|NCT00175708|foot pressure profiles
1451150|NCT00175708|pedobarographs
1451151|NCT00175682|Autonomic Dysreflexia
1451152|NCT00175682|SCI
1451153|NCT00175682|Vibrostimulation
1451154|NCT00175682|Ejaculation
1451155|NCT00175669|Randomized control trial; placebo-control study
1451156|NCT00175656|Femur fracture
1451157|NCT00175656|titanium elastic nails
1451158|NCT00175643|actinic keratoses
1451159|NCT00175643|imiquimod
1451160|NCT00175643|pre-malignant
1451161|NCT00175643|squamous cell carcinoma
1451162|NCT00175643|immunosuppression
1451163|NCT00175630|ACL reconstruction
1451164|NCT00175630|morphine sparing
1451165|NCT00175630|preemptive analgesia
1451166|NCT00175630|Post-operative pain and post- operative opioid use
1451167|NCT00175604|Botox
1451168|NCT00175604|torticollis
1451169|NCT00175604|Congenital Muscular Torticollis (CMT)
1451170|NCT00175591|Femur fracture
1451171|NCT00175591|morphine sparing
1451172|NCT00175591|preemptive analgesia
1451173|NCT00175591|Post-operative pain and post- operative opioid use
1451174|NCT00175578|Early stage (0/I) non-small cell lung cancer
1451175|NCT00175565|inflammation
1451176|NCT00175565|trial
1451177|NCT00175565|fluticasone
1451178|NCT00175552|Depression
1451179|NCT00175552|Adolescents
1451180|NCT00175552|IPT
1451181|NCT00175552|Knowledge translation
1451182|NCT00175552|Psychotherapy
1451183|NCT00175539|sexual dysfunction
1451184|NCT00175539|group treatment
1451185|NCT00175513|Psychosis
1451186|NCT00175513|early psychosis
1451187|NCT00175513|first episode psychosis
1451188|NCT00175513|schizophrenia
1451189|NCT00175513|schizoaffective
1451190|NCT00175513|schizophreniform
1451191|NCT00175513|bipolar disorder
1451192|NCT00175513|valtrex
1451193|NCT00175513|valacyclovir.
1451194|NCT00175500|Post-Arthroplasty Hip Dislocation
1451195|NCT00175487|Osteoarthritis/Avascular Necrosis
1451196|NCT00175487|Hip
1451197|NCT00175435|Topical Immune Modulator
1451198|NCT00175435|resiquimod gel
1451199|NCT00175435|Hepatitis B booster response
1451200|NCT00175435|Vaccine Evaluation
1451201|NCT00175435|Prevention of Hepatitis B disease
1451202|NCT00175422|Prevention
1451203|NCT00175422|Randomized controlled trial
1451204|NCT00175422|Community education
1451205|NCT00175422|Shaken Baby Syndrome
1451206|NCT00175422|Crying
1451207|NCT00175422|Colic
1451208|NCT00175409|Pain Response
1451209|NCT00175396|ASCENDE-RT
1451210|NCT00175383|Prostate cancer, LHRH, hormone therapy, testosterone level
1451211|NCT00175370|Vancomycin
1451212|NCT00175370|Coagulase Negative Staphylococcus
1451213|NCT00175370|Central Venous Catheter
1451214|NCT00175370|Bloodstream infection
1451215|NCT00175370|CNS bloodstream infection
1451216|NCT00175357|Opiate addiction
1451217|NCT00175357|medical heroin
1451218|NCT00175357|methadoneRCT
1451219|NCT00175344|Breast cancer
1451220|NCT00175344|scar massage
1451221|NCT00175344|breast conserving surgery
1451222|NCT00175344|scar pain
1451223|NCT00175344|quality of life
1451224|NCT00175344|Breast cancer treated with breast conserving surgery with or without axillary dissection or sentinel node sampling.
1451225|NCT00175318|Motivational interviewing
1451226|NCT00175318|behavioural modification
1451227|NCT00175318|maternal counseling
1451228|NCT00175305|Prader-Willi Syndrome
1451229|NCT00175305|Somatostatin
1451230|NCT00175305|Ghrelin
1451231|NCT00175305|Obesity
1451232|NCT00175305|Hyperphagia
1451233|NCT00175305|Hyperphagia in Prader-Willi syndrome
1451234|NCT00175279|coronary disease
1451235|NCT00175279|heart failure
1451236|NCT00175279|quality improvement
1451237|NCT00175279|knowledge translation
1451238|NCT00175279|opinion leaders
1451239|NCT00175266|islet
1451240|NCT00175266|transplantation
1451241|NCT00175253|islet
1451242|NCT00175253|transplantation
1451243|NCT00175240|Coronary disease
1451244|NCT00175240|quality improvement
1451245|NCT00175240|knowledge translation
1451246|NCT00175227|contrast-induced nephropathy
1451247|NCT00175227|prevention
1451248|NCT00175227|renal failure
1451249|NCT00175227|cardiac angiogram
1451250|NCT00175214|osteoporosis
1451251|NCT00175214|wrist fractures
1451252|NCT00175214|quality improvement
1451253|NCT00175214|knowledge translation
1451254|NCT00175188|RSA
1451255|NCT00175188|DEXA
1451256|NCT00175188|Osteoarthritis
1451257|NCT00175188|Finger implant
1451258|NCT00175188|Micromotion
1451259|NCT00175188|Bone density
1451260|NCT00175188|Cement
1451261|NCT00175175|osteoporosis treatment
1451262|NCT00175175|osteoporosis testing
1451263|NCT00175175|hip fracture
1451264|NCT00175175|quality improvement
1451265|NCT00175162|RSA
1451266|NCT00175162|DEXA
1451267|NCT00175162|Genoarthrosis
1451268|NCT00175162|Knee Arthroplasty
1451269|NCT00175162|Micromotion of polyethylene liner
1451270|NCT00175162|Cement
1451271|NCT00175149|CKD 3-4
1451272|NCT00175136|RSA
1451273|NCT00175136|DEXA
1451274|NCT00175136|Gonarthrosis
1451275|NCT00175136|Knee Arthroplasty
1451276|NCT00175136|Micromotion of polyethylen liner
1451277|NCT00175136|Stem arthroplasty design
1451278|NCT00175123|Myelomeningocele
1451279|NCT00175123|Neurogenic Bladder
1451280|NCT00175123|Intervention
1451281|NCT00175123|Botulinum A toxin
1451282|NCT00175123|Oxybutynin
1451283|NCT00175110|pre-hypertension
1451284|NCT00175110|mild hypertension
1451285|NCT00175097|soy protein
1451286|NCT00175097|lipids
1451287|NCT00175097|lipoproteins
1451288|NCT00175097|apolipoproteins
1451289|NCT00175097|cholesterol
1451290|NCT00175097|endothelial function
1451291|NCT00175058|Heart Attack
1451292|NCT00175045|Intravenous
1451293|NCT00175045|gastric acid secretion
1451294|NCT00175045|Lansoprazole
1451295|NCT00175045|Esophagitis
1451296|NCT00175045|reflux
1451297|NCT00175032|Low dose aspirin
1451298|NCT00175032|Peptic Ulcer
1451299|NCT00175032|gastric ulcer
1451300|NCT00175032|duodenal ulcer
1451301|NCT00175032|NSAIDs
1451302|NCT00175019|uric acid
1451303|NCT00175019|xanthine oxidase
1451304|NCT00175019|hyperuricemia
1451305|NCT00175019|tophi
1451306|NCT00175019|Drug Therapy
1451307|NCT00175006|Hyperuricemia
1451308|NCT00175006|Tophi
1451309|NCT00175006|Tophus
1451310|NCT00175006|Drug Therapy
1451311|NCT00174993|Glucose Metabolism Disorder
1451312|NCT00174993|Dysmetabolic Syndrome
1451313|NCT00174993|Type II Diabetes; Diabetes Mellitus
1451314|NCT00174993|Lipoatrophic
1451315|NCT00174993|Dyslipidemia
1451316|NCT00174993|Drug Therapy
1451317|NCT00174980|Oxycyte
1451318|NCT00174980|perfluorocarbon oxygen carrier
1451319|NCT00174980|brain oxygen tension
1451320|NCT00174967|Uric Acid
1451321|NCT00174967|xanthine oxidase
1451322|NCT00174967|tophi
1451323|NCT00174967|Drug Therapy
1451324|NCT00174954|Gout
1451325|NCT00174954|Tophus
1451326|NCT00174954|MRI
1451327|NCT00174941|Uric acid
1451328|NCT00174941|xanthine oxidase
1451329|NCT00174941|tophi
1451330|NCT00174941|Drug Therapy
1451331|NCT00174928|Pediatric GERD
1451332|NCT00174928|Pediatric Gastroesophageal Reflux Disease
1451333|NCT00174928|Neonates
1451334|NCT00174928|lansoprazole
1451335|NCT00174915|Uric Acid, gout, xanthine oxidase, febuxostat, tophi
1451336|NCT00174902|Randomized controlled trial
1451337|NCT00174902|Blood platelets
1451338|NCT00174902|Hemostasis
1451339|NCT00174902|Stress, psychological
1451340|NCT00174902|Adrenergic beta-antagonists
1451341|NCT00174902|Aspirin
1451342|NCT00174902|Endothelium
1451343|NCT00174902|Arteriosclerosis
1451344|NCT00174889|Schizophrenia
1451345|NCT00174889|Pregnenolone
1451346|NCT00174889|Neurosteroids
1451347|NCT00174876|depression
1451348|NCT00174850|anxiety
1451349|NCT00174850|sexual dysfunction
1451350|NCT00174850|ssri
1451351|NCT00174837|Tirapazamine
1451352|NCT00174837|Head and Neck Cancer
1451353|NCT00174837|Cisplatin
1451354|NCT00174837|Radiation
1451355|NCT00174824|Diabetes
1451356|NCT00174824|Diabetic Retinopathy
1451357|NCT00174811|acute otitis media
1451358|NCT00174811|controlled clinical trial
1451359|NCT00174811|telithromycin
1451360|NCT00174811|cefuroxime axetil
1451361|NCT00174811|middle ear infections
1451362|NCT00174811|tympanocentecis
1451363|NCT00174798|Cystometry NK1 Antagonist SSR240600C
1451364|NCT00174785|Mortality, Hospitalization
1451365|NCT00174746|Glucocorticosteroid; Dose response; Bronchospasm
1451366|NCT00174733|Glucocorticosteroid. Bronchospasm
1451367|NCT00174720|Glucocorticosteroid. Bronchospasm
1451368|NCT00174603|depression
1451369|NCT00174603|psychosis
1451370|NCT00174590|depression
1451371|NCT00174538|codeine
1451372|NCT00174538|pain
1451373|NCT00174538|CYP2D6
1451374|NCT00174538|genotype
1451375|NCT00174538|morphine
1451376|NCT00174538|sickle cell
1451377|NCT00174538|pharmacokinetic
1451378|NCT00174525|Alzheimer's Caregivers
1451379|NCT00174525|Alzheimer disease
1451380|NCT00174499|Tooth stain
1451381|NCT00173810|stroke
1451382|NCT00173810|movement
1451383|NCT00173810|psychomterics
1451384|NCT00173797|depression
1451385|NCT00173797|psychometrics
1451386|NCT00173784|psychometrics
1451387|NCT00173784|activities of daily living
1451388|NCT00174213|iliotibial tract
1451389|NCT00174161|Premenstrual Syndrome,Health Related Quality of Life
1451390|NCT00174135|Sarcopenia
1451391|NCT00174135|exercise
1451392|NCT00174122|Emergency department
1451393|NCT00174122|Blood culture
1451394|NCT00174122|Antimicrobial therapy
1451395|NCT00174109|arecoline, oral cancer, MAP2, cell migration
1451396|NCT00174096|laryngeal cancer
1451397|NCT00174096|hypopharyngeal cancer
1451398|NCT00174096|CXCR4
1451399|NCT00174096|stromal-cell-derived factor-1(SDF-1)
1451400|NCT00174096|metastasis
1451401|NCT00174083|Tuberculosis, TB-ELISPOT, active tuberculosis latent infection interferon
1451402|NCT00174070|Respiratory failure
1451403|NCT00174070|Community
1451404|NCT00174057|Graves' ophthalmopathy
1451405|NCT00174057|real time PCR
1451406|NCT00174057|cytokines
1451407|NCT00174057|Tsh receptor
1451408|NCT00174031|baseball
1451409|NCT00174031|injury
1451410|NCT00174018|subacrominal space
1451411|NCT00174005|muscle
1451412|NCT00174005|tendon
1451413|NCT00173992|Stroke
1451414|NCT00173992|Balance
1451415|NCT00173992|Proactive control
1451416|NCT00173992|Reactive control
1451417|NCT00173992|Recovery
1451418|NCT00173992|Training
1451419|NCT00173992|Fall
1451420|NCT00173979|muscle
1451421|NCT00173979|tendon
1451422|NCT00173953|H. pylori、immune response、lymphocytic subsets、cytokine
1451423|NCT00173940|chronic diseases, such as hypertension, diabetes, obesity, chronic renal failure, and so on
1451424|NCT00173927|extracranial atherosclerosis
1451425|NCT00173927|imaging
1451426|NCT00173927|biomarkers
1451427|NCT00173914|1. Transplant vasculopathy
1451428|NCT00173914|2. Endothelial dysfunction
1451429|NCT00173914|3. Myocardial perfusion imaging
1451430|NCT00173914|4. Intravascular vascular ultrasound
1451431|NCT00173901|ceftazidime
1451432|NCT00173901|safety
1451433|NCT00173901|infection
1451434|NCT00173888|Combination, Chemotherapy,non-small cell lung cancer
1451435|NCT00173875|EGFR Non-small cell lung cancer
1451436|NCT00173862|Combination, Chemotherapy,transitional cell carcinoma
1451437|NCT00173849|oral cancer
1451438|NCT00173849|CXCR4
1451439|NCT00173849|stromal-cell-derived factor-1(SDF-1)
1451440|NCT00173849|metastasis
1451441|NCT00173836|Nasopharyngeal carcinoma
1451442|NCT00173836|Saliva
1451443|NCT00173836|Swallowing
1451444|NCT00173836|Videofluoroscopy
1451445|NCT00173836|Radiation
1451446|NCT00173771|stroke
1451447|NCT00173771|activities of daily living
1451448|NCT00173771|psychometrics
1451449|NCT00173758|IL-15
1451450|NCT00173758|IL-15 receptor
1451451|NCT00173758|decidual natural killer cells
1451452|NCT00173758|endometrium
1451453|NCT00173745|cerebral palsy
1451454|NCT00173745|drooling
1451455|NCT00173745|botulinum toxin
1451456|NCT00173732|Preimplantation genetic diagnosis (PGD)
1451457|NCT00173732|single cell
1451458|NCT00173732|Multiple displacement amplification (MDA)
1451459|NCT00173719|Hemiplegia
1451460|NCT00173719|Assisstive device
1451461|NCT00173719|Walking
1451462|NCT00173719|Dynamic equilibrium
1451463|NCT00173719|Reaction time
1451464|NCT00173719|Attention
1451465|NCT00173719|Dual task
1451466|NCT00173706|L-Carnitine
1451467|NCT00173706|hemodialysis
1451468|NCT00173706|cardiac complications
1451469|NCT00173706|impaired exercise and functional capacities
1451470|NCT00173706|muscle symptoms
1451471|NCT00173706|intradialytic hypotension
1451472|NCT00173706|erythropoietin-resistant anemia
1451719|NCT00172783|ELISPOT
1451473|NCT00173693|CEA, Osteoporosis, Fracture, Prevention, Exercise
1451474|NCT00173615|ECMO
1451475|NCT00173615|CPR
1451476|NCT00173602|Peritoneal Dialysis
1451477|NCT00173563|Immunology
1451478|NCT00173550|Menopause, premature
1451479|NCT00173550|Hysterectomy
1451480|NCT00173550|Ovariectomy
1451481|NCT00173550|Estrogen Replacement Therapy
1451482|NCT00173550|Knowledge
1451483|NCT00173550|Perception
1451484|NCT00173550|Attitude
1451485|NCT00173537|idiopathic pulmonary artery hypertension
1451486|NCT00173524|EGFR Non-small cell lung cancer
1451487|NCT00173498|atopic dermatitis, skin test
1451488|NCT00173485|peritonitis, peritoneal dialysis, dialysate
1451489|NCT00173472|colorectal cancer, MSI, TS, DPD, EGFR, chemotherapy.
1451490|NCT00173446|Normal part of the adrenal gland
1451491|NCT00173433|tuberculosis
1451492|NCT00173433|relapse
1451493|NCT00173433|reinfection
1451494|NCT00173433|reactivation
1451495|NCT00173433|dormancy
1451496|NCT00173433|tuberculin skin test
1451497|NCT00173420|Normal Controls
1451498|NCT00173407|Ovarian endometrioid carcinoma
1451499|NCT00173407|invasion
1451500|NCT00173407|IGFBP-3
1451501|NCT00173407|transfection
1451502|NCT00173407|signal transduction
1451503|NCT00173407|PTEN
1451504|NCT00173407|methylation
1451505|NCT00173394|ovarian cancer
1451506|NCT00173394|immunotherapy
1451507|NCT00173394|mesothelin
1451508|NCT00173394|normal volunteer
1451509|NCT00173381|lymphangiogenesis
1451510|NCT00173381|head and neck squamous cell carcinoma (HNSCC)
1451511|NCT00173381|vascular endothelial growth factor-C (VEGF-C)
1451512|NCT00173381|cyclooxygenase-2 (COX-2)
1451513|NCT00173381|interleukin-6 (IL-6)
1451514|NCT00173368|Sphincterotomy
1451515|NCT00173368|needle knife
1451516|NCT00173368|hemorrhage
1451517|NCT00173368|complication
1451518|NCT00173355|pediatric Dermatofibrosarcoma Protuberans
1451519|NCT00173342|Right bundle branch block
1451520|NCT00173342|Electrocardiography
1451521|NCT00173342|Ion channel
1451522|NCT00173329|HIV
1451523|NCT00173316|vascular endothelial growth factor-C
1451524|NCT00173316|VEGF-CR
1451525|NCT00173316|lymphangiogenesis
1451526|NCT00173316|host inflammatory responses
1451527|NCT00173316|oral carcinogenesis
1451528|NCT00173316|oral cancers
1451529|NCT00173316|oral premalignant lesions
1451530|NCT00173303|Breast neoplasms
1451531|NCT00173303|Breast radiography
1451532|NCT00173303|Cancer screening
1451533|NCT00173290|Cervical cancer
1451534|NCT00173290|Breast cancer
1451535|NCT00173290|T lymphocyte
1451536|NCT00173290|NK receptor
1451537|NCT00173277|colorectal cancer screening
1451538|NCT00173277|colonoscopy
1451539|NCT00173238|atherosclerosis
1451540|NCT00173238|optical coherence tomography
1451541|NCT00173238|polarization
1451542|NCT00173238|phase retardation
1451543|NCT00173238|birefringence
1451544|NCT00173225|nociceptin
1451545|NCT00173225|sunstance P
1451546|NCT00173225|asthma
1451547|NCT00173225|COPD
1451548|NCT00173225|cough
1451549|NCT00173212|adenomyosis
1451550|NCT00173212|cell proliferation
1451551|NCT00173212|Immunocytochemistry
1451552|NCT00173186|ventricular septal defect
1451553|NCT00173186|aortic regurgitation
1451554|NCT00173173|Gifted dance students
1451555|NCT00173173|eating disorders
1451556|NCT00173173|prevalence
1451557|NCT00173173|risk factors
1451558|NCT00173173|BITE
1451559|NCT00173160|Eating disorders
1451560|NCT00173160|risk factors
1451561|NCT00173160|prospective study
1451562|NCT00173160|case-controled study
1451563|NCT00173160|outcome
1451564|NCT00173160|gifted dance students
1451565|NCT00173134|diabetes
1451566|NCT00173134|erectile dysfunction
1451567|NCT00173134|erectile dysfunction related quality of life
1451568|NCT00173121|enterovirus, environment, aerosol, air
1451569|NCT00173108|Prematurity
1451570|NCT00173108|Early intervention
1451571|NCT00173108|Neurodevelopment
1451572|NCT00173108|Cost-effectiveness
1451573|NCT00173082|primary aldosteronism
1451574|NCT00173082|Insulin resistance
1451575|NCT00173082|Metabolic syndrome
1451576|NCT00173082|OGTT
1451577|NCT00173069|Schizophrenia
1451578|NCT00173069|PPI
1451579|NCT00173069|P50I
1451580|NCT00173069|MRS
1451581|NCT00173069|Niacin
1451582|NCT00173069|Candidate Genes
1451583|NCT00173056|Peritoneal dialysis
1451584|NCT00171743|Adults
1451585|NCT00171743|Post transplant diabetes
1451586|NCT00171730|Acromegaly
1451587|NCT00171730|Pasireotide
1451588|NCT00171730|GH
1451589|NCT00171730|IGF-1
1451590|NCT00171717|Cyclosporine, liver transplantation, maintenance, diabetes
1451591|NCT00171704|Breast Cancer
1451592|NCT00171704|Letrozole
1451593|NCT00171704|Bone Mineral Density
1451594|NCT00171704|Bone Markers
1451595|NCT00171704|Serum lipid
1451596|NCT00171704|Postmenopausal
1451597|NCT00171691|Knee osteoarthritis, Topical NSAID, Diclofenac sodium
1451598|NCT00171678|Knee osteoarthritis, Topical NSAID, Diclofenac sodium
1451599|NCT00171665|Hand osteoarthritis, Topical NSAID, Diclofenac sodium
1451600|NCT00171652|Hand osteoarthritis, Topical NSAID, Diclofenac sodium
1451601|NCT00171626|Knee osteoarthritis, Topical NSAID, Diclofenac sodium
1451602|NCT00171613|Obesity
1451603|NCT00171600|valsartan
1451604|NCT00171600|lisinopril
1451605|NCT00171600|albuminuria
1451606|NCT00171600|diabetic nephropathy
1451607|NCT00171587|Metastatic solid tumors
1451608|NCT00171587|PTK787/ZK 222584
1451609|NCT00171587|Vatalanib
1451610|NCT00171587|Capecitabine
1451611|NCT00171587|VEGF (vascular endothelial growth factor)
1451612|NCT00171587|Histologically confirmed metastatic solid tumors
1451613|NCT00171574|valsartan
1451614|NCT00171574|lisinopril
1451615|NCT00171574|antiproteinuric
1451616|NCT00171574|diabetic nephropathy
1451617|NCT00171561|hypertension
1451618|NCT00171561|diabetes
1451619|NCT00171561|albuminuria
1451620|NCT00171561|valsartan
1451621|NCT00171561|hydrochlorothiazide
1451622|NCT00171561|amlodipine
1451623|NCT00171548|Metabolic syndrome, cardiovascular risk reduction
1451624|NCT00171535|hypertension
1451625|NCT00171535|high blood pressure
1451626|NCT00171535|valsartan
1451627|NCT00171535|amlodipine
1451628|NCT00171522|Constipation
1451629|NCT00171522|Tegaserod
1451630|NCT00171522|Polyethylene Glycol 3350
1451631|NCT00171522|PEG
1451632|NCT00171509|Liver transplant, adults, once a day administration, Immunosuppressants
1451633|NCT00171496|Kidney transplant, adults, NODM, immunosuppressants
1451634|NCT00171483|GERD
1451635|NCT00171483|PPI
1451636|NCT00171483|heartburn
1451637|NCT00171483|regurgitation
1451638|NCT00173017|N95 mask
1451639|NCT00173017|medical staff
1451640|NCT00173017|hypoxemia
1451641|NCT00173017|hypercapnia
1451642|NCT00173017|neurological study
1451643|NCT00171470|dyspepsia
1451644|NCT00171470|hearburn
1451645|NCT00171470|female
1451646|NCT00171470|PPI
1451647|NCT00171457|functional heartburn
1451648|NCT00171457|dyspepsia
1451649|NCT00171457|male
1451650|NCT00171457|female
1451651|NCT00171457|visceral sensitivity
1451652|NCT00171444|hypertension,
1451653|NCT00171444|valsartan+hydrochlorothiazide
1451654|NCT00171431|IBS-C
1451655|NCT00171431|female
1451656|NCT00171418|GERD
1451657|NCT00171418|PPI
1451658|NCT00171405|hypertension
1451659|NCT00171405|aliskiren
1451660|NCT00171405|hydrochlorothiazide
1451661|NCT00171392|Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium, tacrolimus.
1451662|NCT00171379|Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium.
1451663|NCT00171366|amlodipine
1451664|NCT00171366|benazepril
1451665|NCT00171366|hypertension
1451666|NCT00171366|diastolic
1451667|NCT00171353|arterial hypertension
1451668|NCT00171353|albuminuria
1451669|NCT00171353|valsartan
1451670|NCT00171340|Bone Loss
1451671|NCT00171340|Osteopenia
1451672|NCT00171340|Breast cancer
1451673|NCT00171340|letrozole
1451674|NCT00171340|zoledronic acid
1451675|NCT00171340|postmenopausal
1451676|NCT00171327|arterial hypertension
1451677|NCT00171327|dyslipidemia
1451678|NCT00171327|valsartan
1451679|NCT00171327|fluvastatin
1451680|NCT00171314|breast cancer
1451681|NCT00171314|letrozole
1451682|NCT00171314|zoledronic acid
1451683|NCT00171314|adjuvant
1451684|NCT00171314|postmenopausal
1451685|NCT00172965|Optic coherence tomography
1451686|NCT00172965|oral cancer
1451687|NCT00172965|oral precancers
1451688|NCT00172952|high myopia, genomic
1451689|NCT00172926|Physical Constitution
1451690|NCT00172926|Disease Pattern
1451691|NCT00172926|Laboratory Data
1451692|NCT00172926|Integrative Chinese Medicine and Western Medicine
1451693|NCT00172913|Wavefront Aberration
1451694|NCT00172913|LASIK
1451695|NCT00172913|Contrast Sensitivity
1451696|NCT00172913|Visual Performance
1451697|NCT00172913|Ablation Profile
1451698|NCT00172900|Diffusion tensor imaging
1451699|NCT00172900|MR spectroscopy
1451700|NCT00172900|dementia
1451701|NCT00172900|white matter
1451702|NCT00172887|Psychiatrists
1451703|NCT00172874|cross-cultural,
1451704|NCT00172874|eating disorders,
1451705|NCT00172874|EDI,
1451706|NCT00172874|psychometrics
1451707|NCT00172861|gastric cancer, cyclooxygenase-2, microarray
1451708|NCT00172835|pleural effusion
1451709|NCT00172835|procalcitonin
1451710|NCT00172822|appendicitis
1451711|NCT00172809|Chronic Hepatitis C
1451712|NCT00172809|End stage renal disease
1451713|NCT00172809|Hemodialysis
1451714|NCT00172809|Interferon
1451715|NCT00172809|Pegylated interferon
1451716|NCT00172796|Metabolic syndrome
1451717|NCT00172783|TB
1451718|NCT00172783|PPD
1451720|NCT00172783|BCG
1451721|NCT00172757|MSI, TS, Colorectal Cancer, DM.
1451722|NCT00172744|stem cells
1451723|NCT00172744|periodontal cells
1451724|NCT00172744|mechanical stress
1451725|NCT00172744|differentiation
1451726|NCT00172744|periodontal ligament
1451727|NCT00171301|Transfusional hemosiderosis
1451728|NCT00171301|Beta-thalassemia major
1451729|NCT00171301|Deferasirox
1451730|NCT00171301|iron overload
1451731|NCT00171301|rare anemia
1451732|NCT00171301|iron overload due to transfusion
1451733|NCT00171288|Dyslipidemia, ezetimibe, inflammatory markers, fluvastatin
1451734|NCT00171275|Coronary disease
1451735|NCT00171275|Myocardial infarction
1451736|NCT00171275|Statins
1451737|NCT00171262|Dyslipidemia, chronic renal disease, fluvastatin
1451738|NCT00171249|Chronic Myelogenous Leukemia
1451739|NCT00171249|CML
1451740|NCT00171249|Philadelphia Chromosome
1451741|NCT00171249|Accelerated phase
1451742|NCT00171249|Acute Myelogenous Leukemia
1451743|NCT00171249|AML
1451744|NCT00171249|Acute Lymphoblastic Leukemia
1451745|NCT00171249|ALL
1451746|NCT00171249|Imatinib mesylate
1451747|NCT00169195|B-cell lymphoma
1451748|NCT00169195|Salvage Therapy
1451749|NCT00169195|rituximab
1451750|NCT00169195|oxaliplatine
1451751|NCT00169195|gemcitabine
1451752|NCT00169182|Larynx cancer
1451753|NCT00169182|Hypopharynx cancer
1451754|NCT00169182|Chemotherapy
1451755|NCT00169182|Randomized trial
1451756|NCT00169182|Larynx preservation
1451757|NCT00169169|Diffuse large B cell lymphoma
1451758|NCT00169169|Rituximab
1451759|NCT00169169|Autotransplant
1451760|NCT00169156|T-cell angioimmunoblastic lymphoma
1451761|NCT00169156|Rituximab
1451762|NCT00169143|Diffuse large B cell lymphoma
1451763|NCT00169143|Pegfilgrastim
1451764|NCT00169143|Autotransplant
1451765|NCT00169130|lymphoma
1451766|NCT00169130|autologous stem cell transplant
1451767|NCT00169130|chemotherapy
1451768|NCT00169130|BCL2
1451769|NCT00172692|Chewing efficiency,
1451770|NCT00172692|Gum chewing
1451771|NCT00172692|Chewing velocity
1451772|NCT00172692|Occlusal surface area
1451773|NCT00172692|EMG
1451774|NCT00172692|Jaw movement
1451775|NCT00172679|Tai Chi
1451776|NCT00172679|NK Cells
1451777|NCT00172679|T lymphocytes
1451778|NCT00172679|Exercise
1451779|NCT00172666|SLE
1451780|NCT00172666|healthy subjects
1451781|NCT00172653|shoulder, reliability, validity
1451782|NCT00172614|metabolic syndrome
1451783|NCT00172588|adenomyosis
1451784|NCT00172588|apoptosis
1451785|NCT00172588|flowcytometry
1451786|NCT00172575|Lung neoplasms
1451787|NCT00172575|Magnetic resonance imaging
1451788|NCT00172562|acute myeloid leukemia
1451789|NCT00172562|age and sex matched normal subjects
1451790|NCT00172562|dynamic MRI
1451791|NCT00172562|bone marrow perfusion
1451792|NCT00172562|tumor angiogenesis
1451793|NCT00172497|aggressive acts
1451794|NCT00172484|cerebrovascular accident
1451795|NCT00172484|stroke center
1451796|NCT00172484|stroke team
1451797|NCT00172484|intensive care of stroke
1451798|NCT00172484|rehabilitation of stroke
1451799|NCT00172419|statin, inflammation, FDG, positron emission tomography
1451800|NCT00172393|EV71,
1451801|NCT00172393|CNS,
1451802|NCT00172393|Outcome,
1451803|NCT00172393|Neurological,
1451804|NCT00172393|Psychiatric
1451805|NCT00172367|Urothelial carcinoma
1451806|NCT00172367|Lycopene
1451807|NCT00172367|uremia
1451808|NCT00172367|prevention
1451809|NCT00172367|biomarker
1451810|NCT00172367|progression
1451811|NCT00172367|anti-oxidant
1451812|NCT00172328|Hepatitis B
1451813|NCT00172328|vaccine
1451814|NCT00172315|acquired immunodeficiency syndrome
1451815|NCT00172315|lipodystrophy
1451816|NCT00172315|MR spectroscopy
1451817|NCT00172289|pulse wave velocity
1451818|NCT00172289|sympathetic nerve activity
1451819|NCT00172289|spinal cord injury
1451820|NCT00172289|cerebrovascular accident
1451821|NCT00172263|Immunology
1451822|NCT00172237|eye-head coordination
1451823|NCT00172237|proprioception
1451824|NCT00172237|cervical spine with degenerative disease
1451825|NCT00172237|degenerated cervical spine
1451826|NCT00172224|osteoporosis
1451827|NCT00172224|compression fracture
1451828|NCT00172224|bone marrow perfusion
1451829|NCT00172224|MR spectroscopy
1451830|NCT00172224|hormone therapy
1451831|NCT00172211|Physioneal
1451832|NCT00172211|Peritoneal dialysis
1451833|NCT00172211|Oxidative stress
1451834|NCT00172211|insulin resistance
1451835|NCT00172198|w-3 fish oil
1451836|NCT00172198|Nutrition
1451837|NCT00172198|immune
1451838|NCT00172198|intensive care
1451839|NCT00172198|patients
1451840|NCT00172185|Short Bowel Syndrome
1451841|NCT00172185|Parenteral Nutrition
1451842|NCT00172185|SBS
1451843|NCT00172185|Teduglutide
1451844|NCT00172172|Post-menopausal
1451845|NCT00172172|Osteoporosis
1451846|NCT00172172|Parathyroid Hormone
1451847|NCT00172172|PTH
1451848|NCT00172172|ALX1-11
1451849|NCT00172159|Colorectal cancer
1451850|NCT00172159|Chemotherapy
1451851|NCT00172159|Surgery
1451852|NCT00172159|Liver metastasis
1451853|NCT00172146|Hemiplegia
1451854|NCT00172146|Regular cane
1451855|NCT00172146|Volitional stepping
1451856|NCT00172146|Dynamic equilibrium
1451857|NCT00172146|Attention
1451858|NCT00172146|Dual task
1451859|NCT00172133|Post-menopausal
1451860|NCT00172133|Osteoporosis
1451861|NCT00172133|Parathyroid Hormone
1451862|NCT00172133|PTH
1451863|NCT00172133|ALX1-11
1451864|NCT00172120|Post-menopausal
1451865|NCT00172120|Osteoporosis
1451866|NCT00172120|Parathyroid Hormone
1451867|NCT00172120|PTH
1451868|NCT00172120|ALX1-11
1451869|NCT00172107|Post-menopausal
1451870|NCT00172107|Osteoporosis
1451871|NCT00172107|Parathyroid Hormone
1451872|NCT00172107|PTH
1451873|NCT00172107|ALX1-11
1451874|NCT00172094|Migraine
1451875|NCT00172081|Post-menopausal
1451876|NCT00172081|Osteoporosis
1451877|NCT00172081|Parathyroid Hormone
1451878|NCT00172081|PTH
1451879|NCT00172081|ALX1-11
1451880|NCT00172068|Primary breast cancer
1451881|NCT00172068|Bone metastases
1451882|NCT00172068|Minimal residual disease
1451883|NCT00172068|Bisphosphonates
1451884|NCT00172055|Zoledronic acid
1451885|NCT00172055|Zometa
1451886|NCT00172055|prostate cancer
1451887|NCT00172055|osteoporosis
1451888|NCT00172042|Non-Small-Cell Lung Cancer
1451889|NCT00172042|Bisphosphonates
1451890|NCT00172042|Zoledronic acid
1451891|NCT00172042|Bone metastases
1451892|NCT00172042|Prevention of bone metastases
1451893|NCT00172029|Zoledronic acid
1451894|NCT00172029|Radiotherapy
1451895|NCT00172029|Bone pain
1451896|NCT00172029|Breast cancer
1451897|NCT00172016|Zoledronic acid
1451898|NCT00172016|SRE
1451899|NCT00172016|Prostate cancer
1451900|NCT00172003|Renal Cell Cancer
1451901|NCT00172003|Bone metastasis
1451902|NCT00172003|Skeletal related event
1451903|NCT00172003|Renal Cell Cancer patients with bone metastasis
1451904|NCT00171990|genital herpes
1451905|NCT00171990|herpes
1451906|NCT00171990|famciclovir
1451907|NCT00171977|GIST
1451908|NCT00171977|Imatinib
1451909|NCT00171977|Postoperative Adjuvant
1451910|NCT00171964|Pain
1451911|NCT00171964|Bone metastasis
1451912|NCT00171964|Analgesic consumption
1451913|NCT00171964|Cancer patients
1451914|NCT00171964|Cancer patients with painful bone metastasis
1451915|NCT00171951|Cushing's disease
1451916|NCT00171951|ACTH
1451917|NCT00171951|Cortisol
1451918|NCT00171951|ACTH dependent Cushing's disease
1451919|NCT00171938|Glioblastoma
1451920|NCT00171938|Brain tumors
1451921|NCT00171938|Imatinib
1451922|NCT00171938|PDGFR
1451923|NCT00171925|Multiple Myeloma
1451924|NCT00171925|Stage I
1451925|NCT00171925|Zoledronic acid
1451926|NCT00171925|Progression
1451927|NCT00171912|Imatinib mesylate
1451928|NCT00171912|tyrosine kinases
1451929|NCT00171912|imatinib sensitivity
1451930|NCT00171912|Diverse malignancies either associated with
1451931|NCT00171912|or thought to be associated with
1451932|NCT00171912|activated tyrosine kinase enzymes
1451933|NCT00171912|including hypereosinophilic syndrome
1451934|NCT00171912|systemic mastocytosis
1451935|NCT00171912|chronic myelomonocytic leukaemia,
1451936|NCT00171912|dermatofibrosarcoma protuberans and other diseases.
1451937|NCT00171912|Not included:
1451938|NCT00171912|patients with chronic myeloid leukemia,
1451939|NCT00171912|some other types of leukemias (abl-mutated)
1451940|NCT00171912|some types of gastrointestinal stromal tumours (c-KIT-positive),
1451941|NCT00171912|some systemic mastocytosis (if c-KIT D816V mutation),
1451942|NCT00171912|brain,
1451943|NCT00171912|prostate,
1451944|NCT00171912|breast or lung cancers.
1451945|NCT00171899|Chronic Myelogenous Leukemia
1451946|NCT00171899|Complete cytogenetic response
1451947|NCT00171899|Imatinib mesylate
1451948|NCT00171899|Major molecular response
1451949|NCT00171899|Chronic phase Ph+ Chronic Myelogenous Leukemia
1451950|NCT00171886|Acromegaly
1451951|NCT00171886|Otreotide
1451952|NCT00171886|Tumor reduction
1451953|NCT00171873|Double blind
1451954|NCT00171873|Phase III
1451955|NCT00171873|Disease
1451956|NCT00171873|Clinical trial
1451957|NCT00171873|Octreotide
1451958|NCT00171873|Neuroendocrine tumor
1451959|NCT00171873|Cancer
1451960|NCT00171873|Tumor
1451961|NCT00171873|Midgut
1451962|NCT00171860|Hypereosinophilic syndrome
1451963|NCT00171860|Imatinib
1451964|NCT00171847|Breast cancer
1451965|NCT00171847|Metastatic
1451966|NCT00171847|Trastuzumab
1451967|NCT00171847|Letrozole
1451968|NCT00171834|EPO
1451969|NCT00171834|EPO906
1451970|NCT00171834|Brain metastasis
1451971|NCT00171834|Lung cancer
1451972|NCT00171834|Lung metastasis
1451973|NCT00171834|NSCLC
1451974|NCT00171821|Thalassemia
1451975|NCT00171821|Myelodysplastic Syndrome
1451976|NCT00171821|MDS
1451977|NCT00171821|Sickle cell
1451978|NCT00171821|Diamond-Blackfan anemia
1451979|NCT00171821|Transfusion
1451980|NCT00171821|Anemia
1451981|NCT00171821|Fanconi
1451982|NCT00171821|Chelation
1451983|NCT00171821|Deferasirox
1451984|NCT00171808|Endometrial Cancer
1451985|NCT00171808|Aromatase inhibitor
1451986|NCT00171808|Advanced or recurrent
1451987|NCT00171808|hormone receptor positive
1451988|NCT00171795|Traumatic brain injury,
1451989|NCT00171795|cognitive impairment,
1451990|NCT00171795|rivastigmine
1451991|NCT00171782|HYPERTENSION
1451992|NCT00171782|VALSARTAN
1451993|NCT00171782|VALSARTAN AND HYDROCHLOROTHIAZIDE
1451994|NCT00171782|RISK FACTORS
1451995|NCT00171756|hypertension
1451996|NCT00171756|valsartan
1451997|NCT00171236|Heterozygous familial hypercholesterolemia
1451998|NCT00171236|mixed dyslipidemia
1451999|NCT00171223|Chronic Myelogenous Leukemia
1452000|NCT00171223|CML
1452001|NCT00171223|Philadelphia Chromosome
1452002|NCT00171223|Accelerated phase
1452003|NCT00171223|Acute Myelogenous Leukemia
1452004|NCT00171223|AML
1452005|NCT00171223|Acute Lymphoblastic Leukemia
1452006|NCT00171223|ALL
1452007|NCT00171223|Imatinib mesylate
1452008|NCT00171210|β-thalassemia
1452009|NCT00171210|iron overload
1452010|NCT00171210|deferasirox
1452011|NCT00171184|Overactive bladder, Darifenacin, M3 muscarinic receptor antagonist, elderly population
1452012|NCT00171171|Thalassemia (beta-thal. major)
1452013|NCT00171171|Transfusional hemosiderosis
1452014|NCT00171171|Deferasirox
1452015|NCT00171171|Beta-thalassemia major patients
1452016|NCT00171171|Unable to be chelated with deferoxamine or deferiprone
1452017|NCT00171158|Chronic Myelogenous Leukemia
1452018|NCT00171158|CML
1452019|NCT00171158|Philadelphia Chromosome
1452020|NCT00171158|Blast crisis
1452021|NCT00171158|Imatinib mesylate
1452022|NCT00171145|Overactive Bladder, incontinence, antimuscarinic, warning time, darifenacin
1452023|NCT00171132|Postmenopausal
1452024|NCT00171132|women
1452025|NCT00171132|overweight
1452026|NCT00171132|hypertension
1452027|NCT00171132|impaired
1452028|NCT00171132|exercise
1452029|NCT00171132|capacity
1452030|NCT00171132|valsartan
1452031|NCT00171132|atenolol
1452032|NCT00171132|hydrochlorothiazide
1452033|NCT00171119|HYPERTENSION
1452034|NCT00171119|DIABETES MELLITUS TYPE II
1452035|NCT00171119|VALSARTAN
1452036|NCT00171119|BENAZAPRIL
1452037|NCT00171106|diastolic dysfunction
1452038|NCT00171106|heart failure
1452039|NCT00171106|exercise tolerance
1452040|NCT00171106|valsartan
1452041|NCT00171093|HYPERTENSION
1452042|NCT00171093|HYPERCHOLESTEROLEMIA
1452043|NCT00171093|BLOOD PRESSURE
1452044|NCT00171093|CHOLESTEROL
1452045|NCT00171093|VALSARTAN
1452046|NCT00171093|SIMVASTATIN
1452047|NCT00171080|Hypertension
1452048|NCT00171080|Valsartan
1452049|NCT00171080|Dialysis
1452050|NCT00171080|Renal Disease
1452051|NCT00171067|Microalbuminuria, urinary albumin excretion, urinary albumin creatinine ratio, hypertension, valsartan, lisinopril, combination
1452052|NCT00171054|hypertension
1452053|NCT00171054|postmenopausal
1452054|NCT00171054|valsartan
1452055|NCT00171054|amlodipine
1452056|NCT00171054|hydrochlorothiazide
1452057|NCT00171041|PEDIATRIC HYPERTENSION
1452058|NCT00171041|PEDIATRIC
1452059|NCT00171041|VALSARTAN
1452060|NCT00171028|PEDIATRIC HYPERTENSION
1452061|NCT00171028|PEDIATRIC
1452062|NCT00171028|VALSARTAN
1452063|NCT00171015|VALSARTAN
1452064|NCT00171015|HYDROCHLOROTHIAZIDE
1452065|NCT00171015|OLMESARTAN
1452066|NCT00171015|HYPERTENSION
1452067|NCT00171002|Hypertension, high blood pressure, valsartan, amlodipine
1452068|NCT00170989|hypertension
1452069|NCT00170989|high blood pressure
1452070|NCT00170989|valsartan
1452071|NCT00170989|hydrochlorothiazide
1452072|NCT00170976|HYPERTENSION, VALSARTAN, AMLODIPINE< SAFETY
1452073|NCT00170963|Hypertension, high blood pressure, valsartan, amlodipine
1452074|NCT00170950|cardiovascular morbidity
1452075|NCT00170950|cardiovascular mortality
1452076|NCT00170950|benazepril
1452077|NCT00170950|amlodipine
1452078|NCT00170950|high risk population
1452079|NCT00170937|METABOLIC SYNDROME, VALSARTAN, HYDROCHLOROTHIAZIDE, HYPERTENSION,
1452080|NCT00170924|Hypertension, High Blood Pressure, Diastolic Dysfunction,
1452081|NCT00170924|Heart Disease
1452082|NCT00170911|Osteoporosis
1452083|NCT00170911|Postmenopausal women
1452084|NCT00170911|Cathepsin K inhibitor
1452085|NCT00170898|Musculoskeletal pain
1452086|NCT00170898|cyclooxygenase-2 inhibitors
1452087|NCT00170898|lumiracoxib
1452088|NCT00170898|naproxen
1452089|NCT00170885|acute rejection
1452090|NCT00170885|renal function
1452091|NCT00170885|everolimus
1452092|NCT00170885|cyclosporine microemulsion
1452093|NCT00170872|Osteoarthritis
1452094|NCT00170872|Rheumatoid Arthritis
1452095|NCT00170872|Cox-2
1452096|NCT00170872|lumiracoxib
1452097|NCT00170859|everolimus
1452098|NCT00170859|cyclosporine microemulsion
1452099|NCT00170859|renal function
1452100|NCT00170846|Renal transplantation, everolimus, calcineurin inhibitors, GFR
1452101|NCT00170833|Renal/Kidney, transplantation, everolimus, calcineurin sparing
1452102|NCT00170820|Renal transplantation, maintenance, switch, everolimus, CNI-free
1452103|NCT00170794|cardiac transplantation, everolimus, cyclosporine microemulsion, GFR
1452104|NCT00170781|Pain, acute gout, arthritis, cyclooxygenase-2 inhibitors, lumiracoxib, indomethacin
1452105|NCT00170768|Darifenacin, oxybutynin, cognition, memory
1452106|NCT00170755|Overactive Bladder, incontinence, antimuscarinic, darifenacin, long-term treatment
1452107|NCT00170742|Open label,
1452108|NCT00170742|phase III,
1452109|NCT00170742|disease,
1452110|NCT00170742|clinical trial,
1452111|NCT00170742|octreotide,
1452112|NCT00170742|proliferative diabetic retinopathy, lasercoagulation
1452113|NCT00170729|Prednisolone acetate,
1452114|NCT00170729|efficacy,
1452115|NCT00170729|cataract,
1452116|NCT00170729|eye drops,
1452117|NCT00170729|tolerability,
1452118|NCT00170729|inflammation
1452119|NCT00170716|Motor Cortex Electrical Stimulation
1452120|NCT00170716|Ischemic Stroke
1452121|NCT00170716|Upper Extremity Hemiparesis
1452122|NCT00170716|Rehabilitation
1452123|NCT00170716|Motor Recovery
1452124|NCT00170716|Functional MRI
1452125|NCT00170703|Cortical Electrical Stimulation
1452126|NCT00170703|Ischemic Stroke
1452127|NCT00170703|Broca's Aphasia
1452128|NCT00170703|Speech Rehabilitation
1452129|NCT00170703|Functional MRI
1452130|NCT00170664|Ovarian neoplasms
1452131|NCT00170664|paclitaxel, carboplatin
1452132|NCT00170664|clinical trials, phase II
1452133|NCT00170664|first-line chemotherapy
1452134|NCT00170664|weekly therapy schedule
1452135|NCT00170638|Tuberculosis, children, infants
1452136|NCT00170625|platin-resistant
1452137|NCT00170612|Pneumococcal infections
1452138|NCT00170612|Fiji
1452139|NCT00170612|infants
1452140|NCT00170612|vaccine
1452141|NCT00170586|Underglove, polyvinylidene fluoride, acrylic polymer
1452142|NCT00170573|biweekly schedule of PLD - Ovarian cancer - pegylated liposomal doxorubicin -quality of life - Toxic skin reactions
1452143|NCT00170560|hospital, acquired, infections, mortality
1452144|NCT00170547|inactivated, trivalent, influenza, vaccine, Fluzone
1452145|NCT00170534|India, male, sexually transmitted infection, STI, STD
1452146|NCT00170521|group A streptococci, pharyngitis, epidemiology, Streptococcus pyogenes, children, Nicaragua
1452147|NCT00170508|Influenza, sub-study
1452148|NCT00170495|respiratory illness, influenza, bronchitis, pneumonia, cold
1452149|NCT00170482|influenza vaccine, Fluzone, inactivated, trivalent
1452150|NCT00170469|Anthrax
1452151|NCT00170456|Anthrax vaccine
1452152|NCT00170443|Influenza, Baculovirus, Immunogenicity, Geriatrics
1452153|NCT00170430|HIV-1, sexually transmitted diseases, females, Kenya
1452154|NCT00169390|smoking
1452155|NCT00169390|pregnancy
1452156|NCT00169390|newborns
1452157|NCT00169390|monoamine oxidases
1452158|NCT00169377|Obsessive compulsive disorder
1452159|NCT00169377|deep brain stimulation
1452160|NCT00169377|subthalamic nucleus
1452161|NCT00169364|Parkinson's disease
1452162|NCT00169364|parkin mutation
1452163|NCT00169364|Juvenile parkinson's disease
1452164|NCT00169364|positron emission tomography
1452165|NCT00169338|Dystonia
1452166|NCT00169338|deep brain stimulation
1452167|NCT00169338|globus pallidus
1452168|NCT00169338|Post-anoxic dystonia
1452169|NCT00169325|basal ganglia
1452170|NCT00169325|loss of psychic self-activation
1452171|NCT00169312|unspecified adult solid tumor, protocol specific
1452172|NCT00169299|Menopause
1452173|NCT00169299|Vasomotor
1452174|NCT00169299|Black cohosh
1452175|NCT00169299|Herbs
1452176|NCT00169299|Hot flashes
1452177|NCT00169299|HT
1452178|NCT00169299|CAM
1452179|NCT00169273|Obesity
1452180|NCT00169273|Depression
1452181|NCT00169273|Behavioral
1452182|NCT00169273|Cognitive
1452183|NCT00169273|Treatment
1452184|NCT00169260|smoking
1452185|NCT00169260|tobacco
1452186|NCT00169260|behavior therapy
1452187|NCT00169247|larynx cancer
1452188|NCT00169247|hypopharynx cancer
1452189|NCT00169247|larynx preservation
1452190|NCT00169247|concomitant radiochemotherapy
1452191|NCT00169247|cisplatin
1452192|NCT00169247|cetuximab
1452193|NCT00169247|randomized trial
1452194|NCT00169234|Pneumococcal disease
1452195|NCT00169234|Vaccination
1452196|NCT00169234|Immunization
1452197|NCT00169234|PPV23
1452198|NCT00169234|PCV7
1452199|NCT00169208|relapsed/refractory.
1452200|NCT00169208|lymphoma, follicular
1452201|NCT00169208|rituximab
1452202|NCT00169208|chemotherapy
1452203|NCT00170404|HIV Infections, Tuberculosis, Malnutrition, Tanzania
1452204|NCT00170391|Insomnia
1452205|NCT00170391|Sleep
1452206|NCT00170391|PSG
1452207|NCT00170391|Behavioural treatment
1452210|NCT00170365|Stress
1452211|NCT00170365|Yoga
1452212|NCT00170352|hyperbaric oxygen
1452213|NCT00170352|cerebral metabolism
1452214|NCT00170352|hyperoxia
1452215|NCT00170352|traumatic brain injury
1452216|NCT00170339|Opiate Dependence
1452217|NCT00170339|Methadone Maintenance
1452218|NCT00170339|Osteoporosis
1452219|NCT00170339|Hypogonadism
1452220|NCT00170326|Permanent Pacing artificial internal
1452221|NCT00170313|Heart Failure
1452222|NCT00170313|Primary Prevention of Sudden Cardiac Death
1452223|NCT00170313|Secondary Prevention of Sudden Cardiac Death
1452224|NCT00170313|Cardiac Desynchronization
1452225|NCT00170313|CRT-D
1452226|NCT00170313|Cardiac Dyssynchrony
1452227|NCT00170300|Cardiac resynchronisation therapy (CRT therapy),
1452228|NCT00170300|all-cause mortality,
1452229|NCT00170300|quality of life assesment,
1452230|NCT00170300|echocardiographic left ventricular function,
1452231|NCT00170300|CRT and neurohormonal activation,
1452232|NCT00170300|CRT and health economics
1452233|NCT00170287|Unstable Ventricular Tachycardia
1452234|NCT00170274|Indication for cardiac pacing
1452235|NCT00170274|Atrial Arrhythmia
1452236|NCT00170274|Indication for the implantation of a pacemaker according to the German guidelines
1452237|NCT00170274|Documented (ECG) atrial tachyarrhythmia within the last three months before enrollment
1452238|NCT00170261|Syncope of uncertain etiology
1452239|NCT00170261|Repeated presyncopes
1452240|NCT00170248|Asthma
1452241|NCT00170248|Primary Care
1452242|NCT00170248|Computer-Based Decision Support
1452243|NCT00170248|Outcome Evaluation
1452244|NCT00170235|Breast cancer
1452245|NCT00170235|Prehabilitation
1452246|NCT00170235|Rehabilitation
1452247|NCT00170235|Exercise
1452248|NCT00170222|Acute bronchitis
1452249|NCT00170222|antibiotics
1452250|NCT00170209|Tuberculosis
1452251|NCT00170209|Children
1452252|NCT00170196|pneumonia
1452253|NCT00170196|corticosteroids
1452254|NCT00170183|Heart failure
1452255|NCT00170183|Renal dysfunction
1452256|NCT00170170|cytomegalovirus
1452257|NCT00170105|Age 18 years or older
1452258|NCT00170105|No cognitive impairment or altered mental status
1452259|NCT00170105|Stable
1452260|NCT00170105|No aphasia
1452261|NCT00170105|English-speaking
1452262|NCT00170053|Kidney Transplantation
1452263|NCT00170001|supraesophageal reflux
1452264|NCT00170001|laryngopharyngeal symptoms
1452265|NCT00170001|pharynx
1452266|NCT00170001|esophagus
1452267|NCT00169988|clinical high risk
1452268|NCT00169988|attenuated positive symptoms
1452269|NCT00169988|attenuated negative symptoms
1452270|NCT00169988|cognition
1452271|NCT00169988|functional status
1452272|NCT00169988|prodromal psychosis
1452273|NCT00169962|acute disease
1452274|NCT00169949|early intervention
1452275|NCT00169949|social functioning
1452276|NCT00169949|role functioning
1452277|NCT00169949|cognition
1452278|NCT00169910|Renal Transplantation
1452279|NCT00169910|Calcineurin Inhibitor
1452280|NCT00169910|Mycophenolate Mofetil
1452281|NCT00169910|Cardiovascular Disease
1452282|NCT00169897|COPD
1452283|NCT00169897|Exercise
1452284|NCT00169897|Self-management
1452285|NCT00169897|Rehabilitation
1452286|NCT00169897|Quality of life
1452287|NCT00169897|Health economy
1452288|NCT00169897|Cost effectiveness
1452289|NCT00169897|Health care utilization
1452290|NCT00169884|Deliberate Self-Harm,
1452291|NCT00169884|cognitive-behavioural therapy,
1452292|NCT00169884|integrative approach
1452293|NCT00169858|Hepatitis B
1452294|NCT00169858|Vaccination
1452295|NCT00169858|Engerix-B
1452296|NCT00169858|Immunogenicity
1452297|NCT00169858|Long-term immunity
1452298|NCT00169858|Booster dose
1452299|NCT00169858|Safety
1452300|NCT00169845|chemoprevention trial
1452301|NCT00169845|antioxidant
1452302|NCT00169845|alpha-tocopherol
1452303|NCT00169845|beta-carotene
1452304|NCT00169845|second primary cancer
1452305|NCT00169845|head and neck cancer
1452306|NCT00169845|adverse effect of radiation therapy
1452307|NCT00169845|quality of life
1452308|NCT00169845|mortality
1452309|NCT00169845|cancer free survival
1452310|NCT00169845|cancer recurrence
1452311|NCT00169832|Atherosclerosis progression
1452312|NCT00169832|Ischemic heart disease
1452313|NCT00169832|Saphenous vein graft
1452314|NCT00169832|Metabolic risk factors
1452315|NCT00169832|Rosiglitazone
1452316|NCT00169819|Same day discharge
1452317|NCT00169819|Trans-radial
1452318|NCT00169819|Coronary artery stenting
1452319|NCT00169819|Abciximab bolus
1452320|NCT00169806|Randall's Plaque
1452321|NCT00169806|Kidney stones
1452322|NCT00169793|Obesity
1452323|NCT00169793|Nephrolithiasis
1452324|NCT00169780|Renal Calculi
1452325|NCT00169780|Radiology
1452326|NCT00169780|High Reslolution CT
1452327|NCT00169767|Enlarged Prostate
1452328|NCT00169767|BPH
1452329|NCT00169754|Nephrolithiasis
1452330|NCT00169754|Renal Calculi
1452331|NCT00169754|Perc
1452332|NCT00169754|Attached Stones
1452333|NCT00169741|Nephrolithiasis
1452334|NCT00169741|Renal Calculi
1452335|NCT00169728|allogeneic haematopoietic stem cell transplantation
1452336|NCT00169728|bone marrow transplantation
1452337|NCT00169728|children
1452338|NCT00169728|vaccination
1452339|NCT00169728|invasive pneumococcal disease
1452340|NCT00169728|tetanus
1452341|NCT00169728|diphtheria
1452342|NCT00169728|poliomyelitis
1452343|NCT00169728|pertussis
1452344|NCT00169728|Hepatitis B
1452345|NCT00169728|Haemophilus influenzae type B infection
1452346|NCT00169715|Kidney stones
1452347|NCT00169715|renal Calculi
1452348|NCT00169715|Tic
1452349|NCT00169715|Caliceal Diverticula
1452350|NCT00169702|Schizophrenia, weight management programme
1452351|NCT00169689|schizophrenia, rTMS
1452352|NCT00169676|Prostate Cancer
1452353|NCT00169663|Brushite Kidney Stones
1452354|NCT00169663|Nephrolithiasis
1452355|NCT00169650|UPJ Obstruction
1452356|NCT00169650|Renal Obstruction
1452357|NCT00169650|Delayed Renal Flow
1452358|NCT00169637|Short bowel syndrome
1452359|NCT00169637|Growth hormone
1452360|NCT00169637|Children
1452361|NCT00169624|Diabetes,
1452362|NCT00169624|coronary endothelial dysfunction,
1452363|NCT00169624|metformin,
1452364|NCT00169624|glyclazide,
1452365|NCT00169624|MRI.
1452366|NCT00169611|Neurofibromatosis type 1
1452367|NCT00169611|Attention deficit with hyperactivity disorder school difficulties
1452368|NCT00169611|methylphenidate
1452369|NCT00169598|Lymphoma
1452370|NCT00169598|positron emission tomography
1452371|NCT00169598|stem cell transplantation
1452372|NCT00169598|therapeutic impact
1452373|NCT00169585|diagnostic-therapeutic pathway
1452374|NCT00169585|PSA
1452375|NCT00169585|DRE
1452376|NCT00169585|Levofloxacin
1452377|NCT00169572|Nausea
1452378|NCT00169572|Vomiting
1452379|NCT00169572|Emesis
1452380|NCT00169572|Chemotherapy-induced Nausea and Vomiting
1452381|NCT00169572|CINV
1452382|NCT00169559|triglycerides
1452383|NCT00169559|Hypertriglyceridemia
1452384|NCT00169559|cholesterol
1452385|NCT00169559|LDL
1452386|NCT00169559|HDL
1452387|NCT00169546|Asthma
1452388|NCT00169546|inhaled corticosteroids
1452389|NCT00169533|safety
1452390|NCT00169533|tolerating lapatinib
1452391|NCT00169533|Lapatinib
1452392|NCT00169520|Safety
1452393|NCT00169520|tolerability
1452394|NCT00169520|dose limiting toxicity
1452395|NCT00169520|solid tumors
1452396|NCT00169520|docetaxel
1452397|NCT00169468|B Lymphoma
1452398|NCT00169468|Velcade
1452399|NCT00169468|Chemotherapy
1452400|NCT00169416|chicken pox
1452401|NCT00169416|varicella
1452402|NCT00169416|VZV
1452403|NCT00169416|pharmacokinetics
1452404|NCT00169403|Idiopathic dystonia
1452405|NCT00169403|deep brain stimulation
1452406|NCT00169403|globus pallidus
1452407|NCT00169403|generalised Idiopathic dystonia
1452408|NCT00169117|Mosquito nets
1452409|NCT00169117|Malaria prevention
1452410|NCT00169117|Songs
1452411|NCT00169117|Posters
1452412|NCT00169117|Net repair
1452413|NCT00169117|Bednets
1452414|NCT00169104|Breast cancer
1452415|NCT00169104|Her-2/neu
1452416|NCT00169104|Granulocyte Colony Stimulating Factor
1452417|NCT00169104|Trastuzumab
1452418|NCT00169104|Vinorelbine
1452419|NCT00169104|Antibody-dependent cellular cytotoxicity
1452420|NCT00169104|Effector cells
1452421|NCT00169091|Clozapine
1452422|NCT00169091|Haloperidol
1452423|NCT00169091|Schizophrenia
1452424|NCT00169078|Transmission intensity
1452425|NCT00169078|Insecticide-treated materials
1452426|NCT00169078|antimalarial drug resistance
1452427|NCT00169065|Clozapine
1452428|NCT00169065|olanzapine
1452429|NCT00169052|geriatric,
1452430|NCT00169052|older
1452431|NCT00169052|serious mental illness
1452432|NCT00169052|SMI
1452433|NCT00169039|Clozapine
1452434|NCT00169039|Chlorpromazine
1452435|NCT00169039|Schizophrenia
1452436|NCT00169039|Biochemistry
1452437|NCT00169026|Clozapine
1452438|NCT00169026|Atypical Antipsychotic
1452439|NCT00169026|Conventional antipsychotic
1452440|NCT00169026|Schizophrenia
1452441|NCT00169026|Dual Diagnosis
1452442|NCT00169026|Substance Abuse
1452443|NCT00169026|Alcohol Abuse
1452444|NCT00169000|breast cancer
1452445|NCT00169000|capecitabine
1452446|NCT00169000|docetaxel
1452447|NCT00169000|pharmacokinetic/pharmacodynamic
1452448|NCT00169000|bcl-2
1452449|NCT00169000|bax
1452450|NCT00168987|oral nutritional supplement
1452451|NCT00168987|eicosapentanoic acid
1452452|NCT00168987|gastroenterological tumors
1452453|NCT00168987|muscle function
1452454|NCT00168987|quality of life
1452455|NCT00168987|body composition
1452456|NCT00168961|liver cirrhosis Child B or C
1452457|NCT00168948|Intermittent preventive treatment
1452458|NCT00168948|IPTi
1452459|NCT00168948|Malaria control
1452460|NCT00168948|Ghana
1452461|NCT00168922|recurrent SCLC
1452462|NCT00168909|osteoporosis
1452463|NCT00168909|frailty
1452464|NCT00168909|falls
1452465|NCT00168896|SCLC
1452466|NCT00168883|NSCLC
1452467|NCT00168883|curative non-treatable NSCLC UICC stage IIIB and IV
1452468|NCT00168870|metastatic ocular melanoma
1452469|NCT00168766|Combination therapy for multiple sclerosis
1452470|NCT00168753|Extended dosing
1452471|NCT00168753|alefacept
1452472|NCT00168740|rituximab
1452473|NCT00168740|Rituxan
1452474|NCT00168740|B-cell lymphoma
1452475|NCT00168740|low-grade
1452476|NCT00168740|follicular
1452477|NCT00168740|anti-CD20 monoclonal antibody
1452478|NCT00168727|Radioimmunotherapy
1452479|NCT00168727|Antigens, CD20
1452480|NCT00168714|AVONEX
1452481|NCT00168714|Pregnancy
1452482|NCT00168701|Multiple Sclerosis
1452483|NCT00168701|MRI
1452484|NCT00168688|micronutrient supplementation
1452485|NCT00168688|pregnancy
1452486|NCT00168688|birth weight
1452487|NCT00168688|perinatal mortality
1452488|NCT00168662|Non-specific effects of vaccines
1452489|NCT00168662|Infant mortality
1452490|NCT00168662|Child mortality
1452491|NCT00168662|Mortality
1452492|NCT00168662|Morbidity
1452493|NCT00168662|Measles vaccine
1452494|NCT00168662|Measles
1452495|NCT00168662|Immunisation
1452496|NCT00168662|Low income country
1452497|NCT00168662|Guinea-Bissau
1452498|NCT00168662|Bandim Health Project
1452499|NCT00168662|Immunology
1452500|NCT00168649|Vitamin A
1452501|NCT00168649|Endotoxin
1452502|NCT00168649|TNF-alfa
1452503|NCT00168636|Vitamin A
1452504|NCT00168636|Mortality
1452505|NCT00168636|Morbidity
1452506|NCT00168636|OPV
1452507|NCT00168636|Sex
1452508|NCT00168623|Vitamin A
1452509|NCT00168623|Vaccines
1452510|NCT00168623|Mortality
1452511|NCT00168623|Morbidity
1452512|NCT00168610|Vitamin A
1452513|NCT00168610|BCG
1452514|NCT00168610|Infant mortality
1452515|NCT00168610|Morbidity
1452516|NCT00168610|Low-income country
1452517|NCT00168610|Mortality
1452518|NCT00168597|Vitamin A
1452519|NCT00168597|BCG
1452520|NCT00168597|Infant mortality
1452521|NCT00168597|Morbidity
1452522|NCT00168597|Low-income country
1452523|NCT00168584|Vitamin A
1452524|NCT00168584|Mortality
1452525|NCT00168584|Morbidity
1452526|NCT00168584|Doses
1452527|NCT00168584|OPV
1452528|NCT00168571|Measles vaccine
1452529|NCT00168571|Measles
1452530|NCT00168571|Measles antibodies
1452531|NCT00168571|Immunisation
1452532|NCT00168571|Low income country
1452533|NCT00168571|Guinea-Bissau
1452534|NCT00168571|Bandim Health Project
1452535|NCT00168571|Measles antibody level
1452536|NCT00168558|Non-specific effects of vaccines
1452537|NCT00168558|Infant mortality
1452538|NCT00168558|Child mortality
1452539|NCT00168558|Mortality
1452540|NCT00168558|Morbidity
1452541|NCT00168558|Diphtheria-tetanus-pertussis vaccine
1452542|NCT00168558|Measles vaccine
1452543|NCT00168558|Measles
1452544|NCT00168558|Immunisation
1452545|NCT00168558|Low income country
1452546|NCT00168558|Guinea-Bissau
1452547|NCT00168558|Bandim Health Project
1452548|NCT00168558|Immunology
1452549|NCT00168545|Non-specific effects of vaccines
1452550|NCT00168545|Immunology
1452551|NCT00168545|Cytokines
1452552|NCT00168545|Infant mortality
1452553|NCT00168545|Child mortality
1452554|NCT00168545|Mortality
1452555|NCT00168545|Morbidity
1452556|NCT00168545|Diphtheria-tetanus-pertussis vaccine
1452557|NCT00168545|Measles vaccine
1452558|NCT00168545|Measles
1452559|NCT00168545|Immunisation
1452560|NCT00168545|Low income country
1452561|NCT00168545|Guinea-Bissau
1452562|NCT00168545|Bandim Health Project
1452688|NCT00167102|Alopecia Areata
1452563|NCT00168545|Immunology of measles and DTP vaccination
1452564|NCT00168532|Prophylactic antibiotics
1452565|NCT00168532|Measles
1452566|NCT00168532|Pneumonia
1452567|NCT00168532|Post-measles pneumonia
1452568|NCT00168532|Low income country
1452569|NCT00168532|Guinea-Bissau
1452570|NCT00168532|Bandim Health Project
1452571|NCT00168519|Diabetes Mellitus, Type 2
1452572|NCT00168519|Blood Glucose
1452573|NCT00168519|Exercise
1452574|NCT00168519|Muscle Contraction
1452575|NCT00168519|Nitric Oxide
1452576|NCT00168519|Nitrates
1452577|NCT00168506|panic disorder
1452578|NCT00168506|cardiac risk
1452579|NCT00168493|Major Depression
1452580|NCT00168493|Cardiac disease
1452581|NCT00167440|cardiac index
1452582|NCT00167440|cardiac output
1452583|NCT00167440|indwelling central venous catheter
1452584|NCT00167440|indwelling arterial catheter
1452585|NCT00167414|conformal radiotherapy
1452586|NCT00167388|anemia
1452587|NCT00167388|prematurity
1452588|NCT00167388|blood flow velocity
1452589|NCT00167388|superior mesenteric artery
1452590|NCT00167388|intestinal blood flow in premature infants
1452591|NCT00167375|Insomnia
1452592|NCT00167375|polysomnography
1452593|NCT00167375|sleep onset
1452594|NCT00167375|time series analysis
1452595|NCT00167362|Schizophrenia
1452596|NCT00167362|Cognition
1452597|NCT00167362|Enhancement
1452598|NCT00167362|Randomized
1452599|NCT00167349|cardiac surgery
1452600|NCT00167349|cardiopulmonary bypass
1452601|NCT00167349|cytokines
1452602|NCT00167336|Computer
1452603|NCT00167336|Kinematics
1452604|NCT00167336|Instrument development
1452605|NCT00167336|Reliability
1452606|NCT00167336|Cumulative Trauma Disorder
1452607|NCT00167323|Bipolar
1452608|NCT00167323|Alcoholism
1452609|NCT00167310|Omega-3 fatty acids
1452610|NCT00167310|Statins
1452611|NCT00167310|Antipsychotic drug
1452612|NCT00167310|Antidepressant drug
1452613|NCT00167310|Antimanic drug
1452614|NCT00167310|Placebos
1452615|NCT00167310|Double-blind method
1452616|NCT00167310|Bipolar (depressed phase)
1452617|NCT00167297|atomoxetine
1452618|NCT00167297|cannabis dependence
1452619|NCT00167297|treatment
1452620|NCT00167284|chronic care model, diabetes, community, diabetes education
1452621|NCT00167271|Cognitive therapy
1452622|NCT00167245|Topiramate
1452623|NCT00167245|alcoholism
1452624|NCT00167245|cocaine dependence
1452625|NCT00167232|naltrexone
1452626|NCT00167232|cocaine dependence
1452627|NCT00167232|alcohol dependence
1452628|NCT00167232|psychosocial treatment
1452629|NCT00167219|Stem cell transplant
1452630|NCT00167219|long term survival
1452631|NCT00167219|retinoic acid
1452632|NCT00167206|Stem Cell Transplant
1452633|NCT00167206|Thymic Shielding
1452634|NCT00167206|Total Body Irradiation
1452635|NCT00167206|Chemotherapy
1452636|NCT00167180|donor lymphocyte infusions
1452637|NCT00167180|BMT
1452638|NCT00167180|bone marrow transplant
1452639|NCT00167167|Donor Lymphocyte Infusion
1452640|NCT00167167|relapse
1452641|NCT00167167|post-transplant
1452642|NCT00168402|Axillary Hyperhidrosis
1452643|NCT00168376|Transcranial Magnetic Stimulation
1452644|NCT00168376|Depression
1452645|NCT00168311|Transcranial Magnetic Stimulation
1452646|NCT00168311|Schizophrenia
1452647|NCT00168311|Negative Symptoms
1452648|NCT00168285|Exercise
1452649|NCT00168285|Pulmonary rehabilitation
1452650|NCT00168285|Idiopathic pulmonary fibrosis
1452651|NCT00168285|Connective tissue disorders
1452652|NCT00168272|Transcranial Magnetic Stimulation
1452653|NCT00168272|Depression
1452654|NCT00168259|Treatment Naive
1452655|NCT00168259|HIV
1452656|NCT00168246|HIV
1452657|NCT00168233|Treatment Naive
1452658|NCT00168233|HIV
1452659|NCT00168220|Treatment Experienced
1452660|NCT00168220|HIV
1452661|NCT00168207|Treatment Experienced
1452662|NCT00168207|HIV
1452663|NCT00168194|HIV
1452664|NCT00168181|salagen
1452665|NCT00168181|gland transfer
1452666|NCT00168181|randomized
1452667|NCT00168181|xerostomia
1452668|NCT00168168|G-CSF
1452669|NCT00168168|Filgrastim
1452670|NCT00168168|Engraftment time
1452671|NCT00168168|Autologus transplant
1452672|NCT00168155|resectable liver metastases
1452673|NCT00168155|colorectal adenocarcinoma
1452674|NCT00168155|survival
1452675|NCT00168155|neoadjuvant chemotherapy
1452676|NCT00167154|suicidality
1452677|NCT00167154|antipsychotic
1452678|NCT00167154|antidepressant
1452679|NCT00167154|treatment
1452680|NCT00167141|male fertility
1452681|NCT00167141|semen parameters
1452682|NCT00167128|Auditory Processing Disorder
1452683|NCT00167128|speech-in-noise intelligibility
1452684|NCT00167115|Alcohol
1452685|NCT00167115|Type 2 diabetes mellitus
1452686|NCT00167115|Plama glucose
1452687|NCT00167115|HDL cholesterol
1452689|NCT00167089|Stroke
1452690|NCT00167089|Hemiplegia
1452691|NCT00167089|Gait
1452692|NCT00167089|Ambulation training
1452693|NCT00167089|Neurologic physical therapy
1452694|NCT00167076|Stroke
1452695|NCT00167076|Foot pressure
1452696|NCT00167076|Walking speed
1452697|NCT00167076|Gait
1452698|NCT00167063|Stroke
1452699|NCT00167063|Fall
1452700|NCT00167063|Fall prediction
1452701|NCT00167063|Clinical manifestations
1452702|NCT00167063|Frequent faller
1452703|NCT00167037|Hemiplegia
1452704|NCT00167037|Waist pulling perturbation
1452705|NCT00167037|Reactive balance strategy
1452706|NCT00167037|Trajectory of center of pressure
1452707|NCT00167037|Parameters of center of pressure
1452708|NCT00167024|prostate cancer, DNA repair gene, genetic polymorphism
1452709|NCT00166023|pediatric
1452710|NCT00166023|cardiology
1452711|NCT00166010|drug
1452712|NCT00166010|pediatrics
1452713|NCT00166010|cardiac
1452714|NCT00166010|Children with Cardiac Ventricular Failure
1452715|NCT00165997|pediatrics
1452716|NCT00165997|cardiology
1452717|NCT00165997|Radiofrequency ablation
1452718|NCT00165997|structurally normal heart
1452719|NCT00168142|Helical tomotherapy
1452720|NCT00168142|Megavoltage imaging
1452721|NCT00168129|tomotherapy
1452722|NCT00168129|bone metastases
1452723|NCT00168129|radiotherapy
1452724|NCT00168129|intensity modulated
1452725|NCT00168116|nasopharynx
1452726|NCT00168116|xerostomia
1452727|NCT00168116|prevention
1452728|NCT00168103|C1 Inhibitor
1452729|NCT00168103|Hereditary angioedema
1452730|NCT00168103|Acute HAE attack
1452731|NCT00168090|von Willebrand Factor
1452732|NCT00168090|Blood Coagulation Disorders
1452733|NCT00168090|Factor VIII
1452734|NCT00168077|Prothrombin Complex Concentrate
1452735|NCT00168077|Anticoagulant reversal
1452736|NCT00168064|Mycosis Fungoides
1452737|NCT00168064|Nitrogen Mustard
1452738|NCT00168064|Cutaneous T-Cell Lymphoma
1452739|NCT00168064|CTCL - Mycosis Fungoides
1452740|NCT00168051|Hemophilia A
1452741|NCT00168038|Chronic Immune Thrombocytopenic Purpura
1452742|NCT00168038|Chronic Idiopathic Thrombocytopenic Purpura
1452743|NCT00168038|Werlhofs Disease
1452744|NCT00168038|Autoimmune Thrombocytopenia
1452745|NCT00168038|Immunglobulin Intravenous
1452746|NCT00168038|Chronic ITP
1452747|NCT00168038|Platelet count
1452748|NCT00168038|Thrombocytopenia
1452749|NCT00168025|Immunoglobulin Intravenous
1452750|NCT00168025|Agammaglobulinemia
1452751|NCT00168025|Hypogammaglobulinemia
1452752|NCT00168025|Common variable immunodeficiency
1452753|NCT00168025|Immunoglobulin G
1452754|NCT00168025|Children
1452755|NCT00168012|Immunoglobulin intravenous
1452756|NCT00168012|Agammaglobulinemia
1452757|NCT00168012|Hypogammaglobulinemia
1452758|NCT00168012|Common variable immunodeficiency
1452759|NCT00168012|Immunoglobulin G
1452760|NCT00168012|Children
1452761|NCT00167999|Bacterial Infections
1452762|NCT00167986|Bacterial Infections
1452763|NCT00167973|Hemophilia B
1452764|NCT00167960|Bacterial Infections
1452765|NCT00167947|Kidney
1452766|NCT00167947|Transplant
1452767|NCT00167934|Diabetes
1452768|NCT00167934|Metabolic
1452769|NCT00167895|osteoarthritis
1452770|NCT00167895|knee
1452771|NCT00167895|platelet concentrate
1452772|NCT00167882|Crohn's disease
1452773|NCT00167882|Ulcerative colitis
1452774|NCT00167882|Inflammatory bowel disease
1452775|NCT00167882|azathioprine
1452776|NCT00167882|6-mercaptopurine
1452777|NCT00167882|5-aminosalicylate
1452778|NCT00167882|metabolism
1452779|NCT00167869|hypertension
1452780|NCT00167869|blood pressure
1452781|NCT00167869|dairy peptides
1452782|NCT00167869|bioactive peptides
1452783|NCT00167869|randomized controlled trial
1452784|NCT00167856|Burning pain
1452785|NCT00167856|Clinical trial
1452786|NCT00167856|Effexor
1452787|NCT00167856|Pain
1452788|NCT00167856|Spinal cord injury
1452789|NCT00167856|Venalafaxine
1452790|NCT00167856|Neuropathic Pain
1452791|NCT00167843|Malaria
1452792|NCT00167843|Anemia
1452793|NCT00167843|Children
1452794|NCT00167843|Gabon
1452795|NCT00167843|Intermittent preventive treatment
1452796|NCT00167830|Pediatric Overweight,
1452797|NCT00167830|African American;
1452798|NCT00167830|Adolescent;
1452799|NCT00167830|Intervention,
1452800|NCT00167830|Teasing;
1452801|NCT00167830|Self-esteem
1452802|NCT00167830|Quality of Life
1452803|NCT00167830|Metabolic syndrome
1452804|NCT00167830|Insulin resistance
1452805|NCT00167830|Diabetes
1452806|NCT00167830|Nutrition
1452807|NCT00167830|Motivation
1452808|NCT00167830|Culture
1452809|NCT00167830|BMI
1452810|NCT00167830|Cardiorespiratory fitness
1452811|NCT00167830|Resistance Training
1452812|NCT00167830|Compliance
1452813|NCT00167817|Schizophrenia
1452814|NCT00167817|Smoking
1452815|NCT00167817|Metabolic
1452816|NCT00167817|Health
1452817|NCT00167817|Glucose
1452818|NCT00167817|Lipids
1452819|NCT00167804|Exposure Therapy
1452820|NCT00167804|Post Traumatic Stress Disorder
1452821|NCT00167804|Treatment Outcome
1452822|NCT00167804|Veterans
1452823|NCT00167804|Virtual Reality
1452824|NCT00167791|transplant
1452825|NCT00167791|desensitization
1452826|NCT00167791|kidney transplant
1452827|NCT00167778|Amputation
1452828|NCT00167778|Amputee
1452829|NCT00167778|Artificial limbs
1452830|NCT00167778|Gait
1452831|NCT00167778|Locomotion
1452832|NCT00167778|Walking
1452833|NCT00167765|stroke, ischemic
1452834|NCT00167765|acute ischemic stroke
1452835|NCT00167739|Malaria
1452836|NCT00167739|Quinine
1452837|NCT00167739|Sulfadoxine-pyrimethamine
1452838|NCT00167739|Gabon
1452839|NCT00167713|Malaria
1452840|NCT00167713|Fever
1452841|NCT00167713|Ibuprofen
1452842|NCT00167713|Gabon
1452843|NCT00167700|atopic disease
1452844|NCT00167700|probiotics
1452845|NCT00167700|gut microbiota
1452846|NCT00167700|allergy
1452847|NCT00167700|nutrition
1452848|NCT00167700|growth
1452849|NCT00167700|allergic rhinitis
1452850|NCT00167700|atopic sensitization
1452851|NCT00167700|risk-markers of life-style related diseases
1452852|NCT00167687|Alcoholism
1452853|NCT00167687|Randomized Controlled Trial
1452854|NCT00167674|breastmilk
1452855|NCT00167674|HIV-1
1452856|NCT00167674|antiretroviral
1452857|NCT00167674|mother-to-child
1452858|NCT00167674|transmission
1452859|NCT00167661|living or deceased donor renal transplant recipient
1452860|NCT00167635|Irritable Bowel Syndrome
1452861|NCT00167635|Cognitive-behavioral intervention
1452862|NCT00167635|Psychological distress
1452863|NCT00167635|Quality of life
1452864|NCT00167622|Guillain Barré
1452865|NCT00167622|Mechanical ventilation, invasive
1452866|NCT00167622|Mechanical ventilation, non invasive
1452867|NCT00167622|Pneumonia
1452868|NCT00167609|myotonic dystrophy
1452869|NCT00167609|hypersomnia
1452870|NCT00167609|dehydroepiandrosterone
1452871|NCT00167596|near infrared spectroscopy
1452872|NCT00167596|tissue oxygenation
1452873|NCT00167596|organ dysfunction
1452874|NCT00167596|mortality
1452875|NCT00167583|Ocular Behcet`s disease
1452876|NCT00167583|Panuveitis
1452877|NCT00167583|Posterior Uveitis
1452878|NCT00167583|Retinal vasculitis
1452879|NCT00167583|Treatment
1452880|NCT00167583|Interferon-alpha
1452881|NCT00167583|Cyclosporin A
1452882|NCT00167570|Artificial Limbs
1452883|NCT00167570|Amputees
1452884|NCT00167570|Computer-Aided Design
1452885|NCT00167557|Liver Transplantation
1452886|NCT00167544|Bronchopulmonary Dysplasia
1452887|NCT00167544|Encephalomalacia
1452888|NCT00167544|Brain injury
1452889|NCT00167544|Neurosensory impairment
1452890|NCT00167544|Corticosteroids
1452891|NCT00167544|Anti-Inflammatory Agents
1452892|NCT00167544|Extremely Low Birth Weight (ELBW) infants
1452893|NCT00167544|Premature Birth
1452894|NCT00167544|Magnetic Resonance Imaging
1452895|NCT00167531|Stroke
1452896|NCT00167531|health outcomes
1452897|NCT00167531|physiotherapy
1452898|NCT00167531|rehabilitation
1452899|NCT00167531|treadmill
1452900|NCT00167518|Diabetic macular oedema
1452901|NCT00167518|Triamcinolone acetate
1452902|NCT00167518|Intravitreal injection
1452903|NCT00167518|Clinical trial
1452904|NCT00167518|Laser treatment
1452905|NCT00167505|adolescents
1452906|NCT00167505|sexual health
1452907|NCT00167505|HIV
1452908|NCT00167505|STD
1452909|NCT00167505|pregnancy prevention
1452910|NCT00167505|abstinence education
1452911|NCT00167505|HIV Seronegativity
1452912|NCT00167505|human immunodeficiency virus
1452913|NCT00167479|Bipolar Anxiety
1452914|NCT00167479|Bipolar Disorder
1452915|NCT00167479|Anxiety
1452916|NCT00167479|Panic Disorder
1452917|NCT00167479|Generalized Anxiety Disorder
1452918|NCT00167479|GAD
1452919|NCT00167479|Risperidone
1452920|NCT00167479|Double-Blind
1452921|NCT00167479|Placebo Controlled
1452922|NCT00167466|periodontal disease
1452923|NCT00167466|toothbrush
1452924|NCT00167466|titanium dioxide semiconductor
1452925|NCT00167466|mild-to-moderate periodontal disease
1452926|NCT00167466|adult patients 18 to 70 years of age
1452927|NCT00167453|Nervous system disease
1452928|NCT00167453|movement disorder
1452929|NCT00167453|exercise
1452930|NCT00167453|balance
1452931|NCT00167453|education
1452932|NCT00167011|coronary artery
1452933|NCT00166998|Breast neoplasms
1452934|NCT00166998|diagnosis
1452935|NCT00166985|endometrial cancer, MRI, Doppler sonography, angiogenesis
1452936|NCT00166972|metastasis, survival, malignancy, female, trophinin
1452937|NCT00166959|Stroke patients
1452938|NCT00166959|Falls
1452939|NCT00166959|Reliability
1452940|NCT00166959|Validity
1452941|NCT00166933|minimal erythema dose
1452942|NCT00166933|UVB
1452943|NCT00166933|normal
1452944|NCT00166907|Stroke
1452945|NCT00166907|Balance
1452946|NCT00166907|Proactive control
1452947|NCT00166907|Reactive control
1452948|NCT00166907|Recovery
1452949|NCT00166907|Training
1452950|NCT00166907|Fall
1452951|NCT00166894|pleural effusion
1452952|NCT00166894|TREM-1
1452953|NCT00166881|Combination, Chemotherapy, Inoperable Gastric Cancer
1452954|NCT00166868|Biliary atresia, cholangitis, probiotics, prophylaxis
1452955|NCT00166855|angiogenesis
1452956|NCT00166855|bone marrow perfusion
1452957|NCT00166855|dynamic MRI
1452958|NCT00166855|multiple myeloma
1452959|NCT00166855|prognosis
1452960|NCT00166842|Pharmacokinetics
1452961|NCT00166842|Sirolimus
1452962|NCT00166842|Cyclosporine
1452963|NCT00166842|Tacrolimus
1452964|NCT00166842|Immunosuppressive Agents
1452965|NCT00166842|Immunosuppression
1452966|NCT00166842|Transplantation
1452967|NCT00166842|Kidney Transplantation
1452968|NCT00166829|Tacrolimus
1452969|NCT00166829|Sirolimus
1452970|NCT00166829|Mycophenolic acid
1452971|NCT00166829|Immunosuppressive Agents
1452972|NCT00166829|Immunosuppression
1452973|NCT00166829|Kidney Transplantation
1452974|NCT00166829|Transplantation
1452975|NCT00166816|Sirolimus
1452976|NCT00166816|Tacrolimus
1452977|NCT00166816|Cyclosporine
1452978|NCT00166816|Pharmacokinetics
1452979|NCT00166816|Immunosuppressive Agents
1452980|NCT00166816|Immunosuppression
1452981|NCT00166816|Kidney Transplantation
1452982|NCT00166816|Transplantation
1452983|NCT00166803|Diabetes Mellitus, PPARγ agonist, FDG PET
1452984|NCT00166790|Human Chorionic Gonadotropin
1452985|NCT00166790|Dual Polarization Interferometry,
1452986|NCT00166790|Gestational Trophoblastic Neoplasms
1452987|NCT00166764|Psychiatric Disorders
1452988|NCT00166764|Evaluation of Mental Health Index
1452989|NCT00166751|Videofluoroscopic examination,
1452990|NCT00166751|ultrasound
1452991|NCT00166751|laryngeal elevation
1452992|NCT00166751|dysphagia
1452993|NCT00166738|Schizophrenia
1452994|NCT00166738|multiple genes
1452995|NCT00166738|array-comparative genomic hybridization (CGH)
1452996|NCT00166738|genomic DNA
1452997|NCT00166738|Chinese Han People
1452998|NCT00166725|HRPC
1452999|NCT00166725|octreotide LAR
1453000|NCT00166725|CgA
1453001|NCT00166712|Kidney Transplant
1453002|NCT00166712|Living Donor Kidney Transplant Recipients
1453003|NCT00166699|ultrasonography
1453004|NCT00166699|obesity
1453005|NCT00166699|Cesarean Section
1453006|NCT00166699|Anesthesia
1453007|NCT00166699|Epidural
1453008|NCT00166686|Cancer
1453009|NCT00166686|Clonidine
1453010|NCT00166686|Neurocognitive sequelae
1453011|NCT00166673|Diabetes Mellitus, Insulin-Dependent
1453012|NCT00166673|Type 1 Diabetes
1453013|NCT00166673|Continuous Glucose Monitoring Devices
1453014|NCT00166673|Electronic Data Collection
1453015|NCT00166660|Preterm infants
1453016|NCT00166660|Developmental Care
1453017|NCT00166660|NIDCAP
1453018|NCT00166660|Fetal Growth Restriction
1453019|NCT00166660|Neurobehavior
1453020|NCT00166660|APIB
1453021|NCT00166660|MRI
1453022|NCT00166660|EEG
1453023|NCT00166660|Parent Stress
1453024|NCT00166647|Cancer
1453025|NCT00166647|Chemotherapy
1453026|NCT00166647|Hematological disorder
1453027|NCT00166634|Hypertension
1453028|NCT00166634|ABPM
1453029|NCT00166634|Ambulatory Blood Pressure Monitoring
1453030|NCT00166621|Autism
1453031|NCT00166621|Neuroplasticity
1453032|NCT00166608|acetaminophen toxicity
1453033|NCT00166608|liver damage
1453034|NCT00166608|tylenol overdose
1453035|NCT00166595|Risperidone
1453036|NCT00166595|Autism
1453037|NCT00166595|Pervasive Developmental Disorder (PDD)
1453038|NCT00166582|pediatric asthma, medication adherence, adolescents
1453039|NCT00166569|Polycystic Ovary Syndrome
1453040|NCT00166543|locally advanced breast carcinoma
1453041|NCT00166543|locally recurrent inoperable breast carcinoma
1453042|NCT00166543|progressive metastatic breast carcinoma
1453043|NCT00166517|Gastrointestinal Rotavirus
1453044|NCT00166439|C04.557.386
1453045|NCT00166387|Hemophilia
1453046|NCT00166387|Inhibitors
1453047|NCT00166361|Extrinsic ureteral obstruction
1453048|NCT00166361|Memokath 051 Ureteral Stent
1453049|NCT00166361|JJ Stent
1453050|NCT00166361|Stent
1453051|NCT00166348|Cognitive Rehabilitation
1453052|NCT00166322|IBZM-SPECT
1453053|NCT00166322|Amphetamine Challenge
1453054|NCT00166322|Schizophrenia
1453055|NCT00166322|dopaminergic neurotransmission
1453056|NCT00166322|Persons at risk for the development of schizophrenia
1453057|NCT00166322|healthy subjects
1453058|NCT00166309|Hemophilia A
1453059|NCT00166309|Inhibitors
1453060|NCT00166296|Major depressive disorder, chemically induced.
1453061|NCT00166296|Peginterferon alfa-2a.
1453062|NCT00166296|Escitalopram.
1453063|NCT00166296|Chronic hepatitis C, psychology.
1453064|NCT00166296|Prophylactic treatment.
1453065|NCT00166283|memory
1453066|NCT00166283|learning
1453067|NCT00166283|Multiple Sclerosis
1453068|NCT00166283|Cognition
1453069|NCT00166283|treatment
1453070|NCT00166283|therapy
1453071|NCT00166270|Fibroids
1453072|NCT00166270|ExAblate
1453073|NCT00166270|MrgFus
1453074|NCT00166270|Uterine Fibroids
1453075|NCT00166257|Paradoxical embolism, Patent foramen ovale,
1453076|NCT00166244|Mycophenolate mofetil
1453077|NCT00166244|Therapeutic Drug Monitoring
1453078|NCT00166244|Adult kidney transplantation
1453079|NCT00166244|Paediatric kidney transplantation
1453080|NCT00166231|Innocent heart murmurs
1453081|NCT00166231|Chest pain
1453082|NCT00166231|pediatric Cardiology
1453083|NCT00166231|Somatization
1453084|NCT00166231|life stress
1453085|NCT00166218|pediatrics
1453086|NCT00166218|cardiac defects
1453087|NCT00166205|Obesity, Morbid
1453088|NCT00166205|Obesity
1453089|NCT00166205|Body Weight
1453090|NCT00166192|Melasma
1453091|NCT00166192|Jessner's solution
1453092|NCT00166192|Trichloroacetic acid (TCA)
1453093|NCT00166179|CAD
1453094|NCT00166166|hyperlipidaemia
1453095|NCT00166166|EDHF
1453096|NCT00166166|FMD
1453097|NCT00166153|cardiac transplantation
1453098|NCT00166153|pediatrics
1453099|NCT00166153|cardiology
1453100|NCT00166153|drug metabolism
1453101|NCT00166140|pediatrics
1453102|NCT00166140|cardiac
1453103|NCT00166140|surgery
1453104|NCT00166127|heart failure
1453105|NCT00166127|cardiac surgery
1453106|NCT00166127|pharmacokinetics
1453107|NCT00166127|pharmacodynamics
1453108|NCT00166114|platelet function
1453109|NCT00166114|childhood abuse
1453110|NCT00166114|depression
1453111|NCT00166114|antidepressants
1453112|NCT00166114|immune function
1453113|NCT00166114|stress response
1453114|NCT00166101|pediatric
1453115|NCT00166101|cardiac surgery
1453116|NCT00166088|Oxidative Stress
1453117|NCT00166088|Diet, Mediterranean
1453118|NCT00166075|Suicidality
1453119|NCT00166075|PTSD
1453120|NCT00166075|depression
1453121|NCT00166062|intimate partner violence
1453122|NCT00166062|perpetration
1453123|NCT00166049|Heart failure
1453124|NCT00166049|Family partnership
1453125|NCT00166049|Patient family education
1453126|NCT00165984|cardiac
1453127|NCT00165984|hypoplastic
1453128|NCT00165984|pediatric
1453129|NCT00165984|hypoplastic heart ventricle
1453130|NCT00165971|Cognitive decline
1453131|NCT00165971|Inflammation
1453132|NCT00165971|Monitoring
1453133|NCT00165971|Recovery
1453134|NCT00165971|Bispectral index
1453135|NCT00165958|Epidermal cyst
1453136|NCT00165958|Epidermoid cyst
1453137|NCT00165958|Sebaceous cyst
1453138|NCT00165958|Pilar cyst
1453139|NCT00165945|pediatric, cardiology, diagnostic imaging using MRI
1453140|NCT00165932|tachycardia
1453141|NCT00165932|pediatrics
1453142|NCT00165919|Hepatitis C
1453143|NCT00165919|HIV
1453144|NCT00165919|Immunopathogenesis
1453145|NCT00165919|HIV-1
1453146|NCT00165906|neonates
1453147|NCT00165906|cardiac
1453148|NCT00165906|non-cardiac
1453149|NCT00165906|surgery
1453150|NCT00165906|anticoagulation
1453151|NCT00165893|low back pain
1453152|NCT00165893|DDD
1453153|NCT00165841|non-erosive symptomatic GERD
1453154|NCT00165841|GERD
1453155|NCT00165828|Epilepsy
1453156|NCT00165802|Cancer
1453157|NCT00165802|malignant tumors
1453158|NCT00165763|Vascular Dementia
1453159|NCT00165737|Dementia cerebrovascular disease
1453160|NCT00165698|Postmenopausal
1453161|NCT00165698|osteoporosis
1453162|NCT00165672|24-hour esophageal pH monitoring
1453163|NCT00165672|non-erosive gastroesophageal reflux disease
1453164|NCT00165672|NERD
1453165|NCT00165672|proton pump inhibitor
1453166|NCT00165672|rabeprazole
1453167|NCT00165646|non-erosive gastroesophageal reflux disease
1453168|NCT00165646|NERD
1453169|NCT00165646|proton pump inhibitor
1453170|NCT00165646|rabeprazole
1453171|NCT00165633|Hepatocellular
1453172|NCT00165633|Carcinoma
1453173|NCT00165633|Hepatitis C Virus
1453174|NCT00165633|Hepatitis B Virus
1453175|NCT00165633|recurrence
1453176|NCT00165633|Vitamin K2
1453177|NCT00165633|E0167
1453178|NCT00165594|gastric cancer
1453179|NCT00165594|Phase I
1453180|NCT00165594|Phase IIa
1453181|NCT00165594|E7070
1453182|NCT00165594|Indisulam
1453183|NCT00165594|Pharmacogenomic
1453184|NCT00165594|2C19
1453185|NCT00165581|Intracavitary brachytherapy
1453186|NCT00165581|radiation therapy
1453187|NCT00165581|Stage I breast cancer
1453188|NCT00165581|Stage II breast cancer
1453189|NCT00165568|Positron emission tomography
1453190|NCT00165568|PET
1453191|NCT00165568|bevacizumab
1453192|NCT00165568|5fluorouracil
1453193|NCT00165568|Metastatic colorectal cancer
1453194|NCT00165555|cisplatin
1453195|NCT00165555|pleurectomy
1453196|NCT00165555|decortication
1453197|NCT00165555|heated cisplatin
1453198|NCT00165542|A-protein level
1453199|NCT00165542|brain tumor
1453200|NCT00165516|Extrapleural pneumonectomy
1453201|NCT00165516|cisplatin
1453202|NCT00165516|heated cisplatin
1453203|NCT00165503|pleurectomy
1453204|NCT00165503|decortication
1453205|NCT00165503|cisplatin
1453206|NCT00165503|ALIMTA
1453207|NCT00165490|adenocarcinoma of esophagus
1453208|NCT00165490|squamous cell carcinoma of esophagus
1453209|NCT00165490|combination chemotherapy
1453210|NCT00165490|cisplatin
1453211|NCT00165490|irinotecan
1453212|NCT00165490|radiation therapy
1453213|NCT00165490|resectable esophageal cancer
1453214|NCT00165477|Glioblastoma
1453215|NCT00165477|Gliosarcoma
1453216|NCT00165477|Malignant Gliomas
1453217|NCT00165477|Radiation Therapy
1453218|NCT00165477|IMiD
1453219|NCT00165477|Lenalidomide
1453220|NCT00165464|Esophageal Cancer
1453221|NCT00165464|Gastric Cancer
1453222|NCT00165464|GE Junction
1453223|NCT00165464|Cisplatin
1453224|NCT00165464|Taxotere
1453225|NCT00165464|CPT-11
1453226|NCT00165464|Irinotecan
1453227|NCT00165451|Relapsed tumors
1453228|NCT00165451|Progressive Poor Prognosis Tumors
1453229|NCT00165451|Thalidomide
1453230|NCT00165451|Celecoxib
1453231|NCT00165451|Etoposide
1453232|NCT00165451|Cyclophosphamide
1453233|NCT00165438|Pulmonary function
1453234|NCT00165438|Bleomycin-based chemotherapy
1453235|NCT00165438|mediastinal irradiation
1453236|NCT00165425|Cardiac screening
1453237|NCT00165425|Cardiac stress test
1453238|NCT00165425|Echocardiogram
1453239|NCT00165412|Breast screening
1453240|NCT00165412|Breast MRI
1453241|NCT00165412|Mammogram
1453242|NCT00165412|Mammography
1453243|NCT00165399|Prostate cancer
1453244|NCT00165399|PSA level
1453245|NCT00165399|docetaxel
1453246|NCT00165399|estramustine
1453247|NCT00165399|hormone therapy
1453248|NCT00165399|androgen withdrawal
1453249|NCT00165386|MRI-guided bone marrow biopsy
1453250|NCT00165373|pediatric solid tumors
1453251|NCT00165373|rhEndostatin
1453252|NCT00165360|low-grade glioma
1453253|NCT00165360|astrocytoma
1453254|NCT00165360|oligodendroglioma
1453255|NCT00165360|oligoastrocytoma
1453256|NCT00165360|temozolomide
1453257|NCT00165360|mixed oligoastrocytoma
1453258|NCT00165347|Multiple myeloma
1453259|NCT00165347|PTK
1453260|NCT00165347|Relapsed multiple myeloma
1453261|NCT00165347|Refractory Multiple myeloma
1453262|NCT00165347|Myeloma
1453263|NCT00165334|Non-small cell lung cancer
1453264|NCT00165334|Cetuximab
1453265|NCT00165334|Vinorelbine
1453266|NCT00165334|Navelbine
1453267|NCT00165334|Previously untreated lung cancer
1453268|NCT00165308|Hodgkin's disease
1453269|NCT00165308|breast cancer prevention
1453270|NCT00165308|tamoxifen
1453271|NCT00165295|sildenafil citrate
1453272|NCT00165295|Viagra
1453273|NCT00165295|Waldenstrom's macroglobulinemia
1453274|NCT00165282|Meditation
1453275|NCT00165282|Mindfulness meditation
1453276|NCT00165282|Bone Marrow Transplant
1453277|NCT00165282|Stem Cell Transplant
1453278|NCT00165269|Hodgkin's Disease Stage IA-IIA
1453279|NCT00165269|mantle irradiation
1453280|NCT00165256|Ductal carcinoma in situ
1453281|NCT00165256|DCIS
1453282|NCT00165256|wide excision
1453283|NCT00165243|Axillary Dissection
1453284|NCT00165243|Tangential Radiation
1453285|NCT00165243|Breast Cancer
1453286|NCT00165230|thalidomide
1453287|NCT00165230|temodar
1453288|NCT00165230|metastatic neuroendocrine tumor
1453289|NCT00165230|unresectable neuroendocrine tumor
1453290|NCT00165217|capecitabine
1453291|NCT00165217|thalidomide
1453292|NCT00165217|colorectal cancer
1453293|NCT00165204|Tibolone
1453294|NCT00165204|High risk women
1453295|NCT00165204|Oophorectomy
1453296|NCT00165204|Breast Density
1453297|NCT00165204|Bone Density
1453298|NCT00165191|doxorubicin
1453299|NCT00165191|cisplatin
1453300|NCT00165191|5-fluorouracil
1453301|NCT00165191|stomach cancer
1453302|NCT00165191|esophagus cancer
1453303|NCT00165178|Acute lymphoblastic leukemia in children
1453304|NCT00165178|High Risk ALL
1453305|NCT00165178|Standard Risk ALL
1453306|NCT00165178|E. coli asparaginase
1453307|NCT00165152|Genetic testing
1453308|NCT00165152|BRCA1 gene
1453309|NCT00165152|BRCA2 gene
1453310|NCT00165152|Counseling interventions
1453311|NCT00165152|Genetic counseling
1453312|NCT00165139|Stem cell transplant
1453313|NCT00165139|High-risk pediatric tumors
1453314|NCT00165126|dosimetric analysis
1453315|NCT00165126|vaginal cuff brachytherapy
1453316|NCT00165100|DAT
1453317|NCT00165100|imaging modality
1453318|NCT00165087|childhood ALL
1453319|NCT00165087|standard risk
1453320|NCT00165087|high risk
1453321|NCT00165087|infant/high risk
1453322|NCT00165074|Prematurity
1453323|NCT00165074|Lung Disease
1453324|NCT00165074|Hyaline Membrane
1453325|NCT00165074|Surfactant
1453326|NCT00165035|Percutaneous coronary intervention (PCI)
1453327|NCT00165035|Drug eluting stent (DES)
1453328|NCT00165009|Bleeding Peptic Ulcer
1453329|NCT00165009|Endoscopic treatment
1453330|NCT00164996|upper endoscopy
1453331|NCT00164996|local pharyngeal anaesthesia
1453332|NCT00164996|ultrathin endoscope
1453333|NCT00164944|Colonoscopy
1453334|NCT00164944|First degree relatives
1453335|NCT00164931|Peptic ulcer hemorrhage
1453336|NCT00164931|Omeprazole
1453337|NCT00164931|Scheduled second endoscopy
1453338|NCT00164905|Peptic ulcer hemorrhage
1453339|NCT00164905|Doppler ultrasound
1453340|NCT00164879|Obstructing
1453341|NCT00164879|Left-sided
1453342|NCT00164879|Colorectal neoplasms
1453343|NCT00164879|Obstructing left-sided colorectal cancers
1453344|NCT00164866|Peptic ulcer
1453345|NCT00164866|IVPPI prior endoscopy
1453346|NCT00164840|GERD
1453347|NCT00164788|24 hours pH monitoring
1453348|NCT00164775|Functional dyspepsia, refractory, antidepressant
1453349|NCT00164762|HIV
1453350|NCT00164762|drug resistance
1453351|NCT00164762|nevirapine
1453352|NCT00164762|anti-retroviral drugs
1453353|NCT00164762|mother-to-child transmission
1453354|NCT00164762|Treatment Naive
1453355|NCT00164762|pregnancy
1453356|NCT00164749|dementia
1453357|NCT00164749|cognition
1453358|NCT00164749|memory
1453359|NCT00164749|neurodegenerative disease
1453360|NCT00164749|brain
1453361|NCT00164736|HIV
1453362|NCT00164736|Clinical trial
1453363|NCT00164736|breastfeeding
1453364|NCT00164736|mother-to-child-transmission
1453365|NCT00164736|nutrition
1453366|NCT00164736|HIV Seronegativity
1453367|NCT00164723|Capsule Endoscopy
1453368|NCT00164710|antimalarials
1453369|NCT00164697|Child Development
1453370|NCT00164697|Parenting
1453371|NCT00164697|Child Rearing
1453372|NCT00164697|Parent-Child Relations
1453373|NCT00164684|batterers
1453374|NCT00164684|prevention
1453375|NCT00164684|African American
1453376|NCT00164684|Latino
1453377|NCT00164671|Male condoms
1453378|NCT00164671|Female condoms
1453379|NCT00164671|Self-efficacy
1453380|NCT00164658|family history
1453381|NCT00164658|familial risk
1453382|NCT00164658|behavior change
1453383|NCT00164645|Emotional outcomes
1453384|NCT00164645|health outcomes
1453385|NCT00164645|traumatic brain injury
1453386|NCT00164645|caregiving
1453387|NCT00164619|controlled clinical trial
1453388|NCT00164619|behavioral intervention
1453389|NCT00164619|prevention intervention
1453390|NCT00164606|child maltreatment
1453391|NCT00164606|child abuse
1453392|NCT00164606|prevention
1453393|NCT00164593|Youth Violence
1453394|NCT00164593|Prevention
1453395|NCT00164580|Homosexuality, Male
1453396|NCT00164580|Adolescents
1453397|NCT00164580|Minority Groups
1453398|NCT00164580|Community Participation
1453399|NCT00164580|Community Surveys
1453400|NCT00164580|HIV Seronegativity
1453401|NCT00164580|HIV
1453402|NCT00164567|partner abuse
1453403|NCT00164567|screening
1453404|NCT00164567|intimate partner violence
1453405|NCT00164554|treatment
1453406|NCT00164554|control
1453407|NCT00164541|dating violence
1453408|NCT00164541|violence against women
1453409|NCT00164515|obesity, mobility limitations, women, physical activity
1453410|NCT00164463|tuberculosis
1453411|NCT00164463|TB
1453412|NCT00164450|tuberculosis
1453413|NCT00164450|TB
1453414|NCT00164450|pharmacokinetics
1453415|NCT00164450|children
1453416|NCT00164437|screening
1453417|NCT00164437|community healt education
1453418|NCT00164437|decision making
1453419|NCT00164437|computer-assisted decision making
1453420|NCT00164424|HSV2
1453421|NCT00164424|genital ulcer
1453422|NCT00164424|HIV
1453423|NCT00164424|South Africa
1453424|NCT00164424|Treatment
1453425|NCT00164424|Acyclovir
1453426|NCT00164424|Prevention
1453427|NCT00164411|Diptheria-Tetanus vaccine
1453428|NCT00164411|Pneumococcal vaccine
1453429|NCT00164411|Adverse events following vaccination
1453430|NCT00164411|Immunization
1453431|NCT00164411|Immunogenicity
1453432|NCT00164398|HIV
1453433|NCT00164385|HIV/AIDS
1453434|NCT00164372|IV Drug users
1453435|NCT00164372|HIV
1453436|NCT00164372|hepatitis C virus
1453437|NCT00164372|HIV Seronegativity
1453438|NCT00164359|malaria, falciparum
1453439|NCT00164359|antimalarials
1453440|NCT00164346|fetal alcohol syndrome (FAS)
1453441|NCT00164346|alcohol-related neurodevelopmental disorder (ARND)
1453442|NCT00164281|TB
1453443|NCT00164281|Tuberculosis
1453444|NCT00164281|INH
1453445|NCT00164281|Isoniazid
1453446|NCT00164281|Preventive therapy
1453447|NCT00164281|HIV
1453448|NCT00164281|AIDS
1453449|NCT00164281|Botswana
1453450|NCT00164281|LTBI
1453451|NCT00164281|Latent TB Infection
1453452|NCT00164268|Intimate partner violence
1453453|NCT00164268|Sexual violence
1453454|NCT00164268|Cultural intervention
1453455|NCT00164268|Native Hawaiian
1453456|NCT00164255|malaria
1453457|NCT00164255|birthweight
1453458|NCT00164255|placental malaria
1453459|NCT00164255|intermittent protective treatment
1453460|NCT00164255|sulfadoxine/ pyrimethamine
1453461|NCT00164255|artesuate
1453462|NCT00164255|combination therapy
1453463|NCT00164255|Pregnancy
1453464|NCT00164242|Tardive dyskinesia
1453465|NCT00164242|Galantamine
1453466|NCT00164242|Cholinesterase inhibitors
1453467|NCT00164229|treatment
1453468|NCT00164229|control
1453469|NCT00164216|malaria
1453470|NCT00164216|combination therapy
1453471|NCT00164216|mefloquine
1453472|NCT00164216|artesunate
1453473|NCT00164216|Peru
1453474|NCT00164216|malaria, uncomplicated
1453475|NCT00164190|Myocardial Infarction
1453476|NCT00164190|Thrombolysis
1453477|NCT00164190|Angioplasty
1453478|NCT00164190|ST Elevation Myocardial Infarction
1453479|NCT00164177|virtual colonoscopy
1453480|NCT00164177|colonoscopy preparation
1453481|NCT00164177|bowel prep
1453482|NCT00164164|colonoscopy preparation
1453483|NCT00164164|prep
1453484|NCT00164151|colonoscopy preparation
1453485|NCT00164151|prep
1453486|NCT00164138|Incontinence
1453487|NCT00164138|physiotherapy
1453488|NCT00164138|treatment
1453489|NCT00164138|pelvic floor muscle function
1453490|NCT00164138|coughing
1453491|NCT00164138|forced expirations
1453492|NCT00164138|lung disease
1453493|NCT00164112|Cooperstown Cocktail
1453494|NCT00164112|Drug Metabolizing Enzymes
1453495|NCT00164112|Drug Interactions
1453496|NCT00164112|Phenotyping
1453497|NCT00164099|Coronary Artery Bypass
1453498|NCT00164099|Postoperative Complications
1453499|NCT00164099|Probiotics
1453500|NCT00164099|Surgical Wound infection
1453501|NCT00164099|cystitis
1453502|NCT00164099|bacteremia
1453503|NCT00164099|pneumonia
1453504|NCT00164099|Enterocolitis, Pseudomembranous
1453505|NCT00164073|HCV and microarray
1453506|NCT00164073|HCV
1453507|NCT00164060|HCV
1453508|NCT00164060|HIV co-infection
1453509|NCT00164047|Nitrous Oxide
1453510|NCT00164047|Anaesthesia
1453511|NCT00164047|Anesthesia
1453512|NCT00164047|Recovery
1453513|NCT00164047|Quality
1453514|NCT00164034|Trauma
1453515|NCT00164034|Wounds
1453516|NCT00164034|Injuries
1453517|NCT00164021|gastroesophageal reflux, gastric reflux, acid reflux, lung transplantation, physiotherapy, anti-reflux medication
1453518|NCT00163995|Chronic Liver Disease
1453519|NCT00163982|HVPG > 12 mmHg
1453520|NCT00163969|Pain
1453521|NCT00163969|Wind-up
1453522|NCT00163969|opioid
1453523|NCT00163969|ketamine
1453524|NCT00163969|pre-emptive
1453525|NCT00163956|IVC filters
1453526|NCT00163956|failed retrieval
1453527|NCT00163943|Metabolic syndrome
1453528|NCT00163943|Sympathetic nervous system activity
1453529|NCT00163943|Insulin sensitivity
1453530|NCT00163943|weight loss
1453531|NCT00163943|aerobic exercise
1453532|NCT00163930|Uterine Fibroids
1453533|NCT00163930|embolisation
1453534|NCT00163930|pain management
1453535|NCT00163917|Hypnosis
1453536|NCT00163917|Analgesia
1453537|NCT00163904|Heart Failure
1453538|NCT00163904|Inflammatory mediators
1453539|NCT00163904|insulin sensitivity
1453540|NCT00163904|overweight
1453541|NCT00163904|high monounsaturated diet
1453542|NCT00163891|Respiratory Therapy
1453543|NCT00163891|Postoperative Care
1453544|NCT00163891|Treatment Outcome
1453545|NCT00163878|Sensory Stimulation Programs
1453546|NCT00163865|Boredom
1453547|NCT00163865|Adolescent
1453548|NCT00163865|Mental illness
1453549|NCT00163865|Depression
1453550|NCT00163865|Anxiety
1453551|NCT00163852|Cystic fibrosis
1453552|NCT00163852|Metabolic alkalosis
1453553|NCT00163852|Hypercapnia
1453554|NCT00163852|Salt replacement
1453555|NCT00163839|Dietary Intervention
1453556|NCT00163839|Pseudoallergen free diet
1453557|NCT00163826|cervical spine injury
1453558|NCT00163826|multiple trauma
1453559|NCT00163813|Mechanically-ventilated
1453560|NCT00163813|medical-surgical critically ill patients
1453561|NCT00163813|reduced gastric motility
1453562|NCT00163800|Outcome predictors
1453563|NCT00163800|Acute brain injury
1453564|NCT00163787|mobility
1453565|NCT00163787|falls
1453566|NCT00163787|activity level
1453567|NCT00163761|Lymphoma
1453568|NCT00163748|Lymphoma
1453569|NCT00163735|Food allergy
1453570|NCT00163735|wine
1453571|NCT00163735|milk allergy
1453572|NCT00163735|egg allergy
1453573|NCT00163735|nut allergy
1453574|NCT00163735|fish allergy
1453575|NCT00163709|Atrial natriuretic factor.
1453576|NCT00163709|Biochemistry.
1453577|NCT00163709|Cardiac failure.
1453578|NCT00163709|Randomised trials.
1453579|NCT00163709|Hormones.
1453580|NCT00163709|Systolic heart failure.
1453581|NCT00163709|Diastolic heart failure.
1453582|NCT00163709|Ischaemic cardiomyopathy.
1453583|NCT00163709|Ventricular hypertrophy.
1453584|NCT00163709|AMI
1453585|NCT00163696|MBNW
1453586|NCT00163696|Ventilation
1453587|NCT00163696|small airways
1453588|NCT00163696|Lung Transplant recipients (Bronchiolitis Obliterans syndrome)
1453589|NCT00163683|Dietary Intervention
1453590|NCT00163657|Hepatitis C Virus
1453591|NCT00163657|Immunosuppressive Agents
1453592|NCT00163644|Hematological malignancies.
1453593|NCT00163644|Bone- marrow/ haemopoetic transplant
1453594|NCT00163644|Exercise
1453595|NCT00163618|tick-borne encephalitis
1453596|NCT00163605|Sinus augmentation
1453597|NCT00163605|Alloplastic bone substitute
1453598|NCT00163605|Hydroxyl apatite
1453599|NCT00163592|Vascular reconstruction
1453600|NCT00163592|Polytetraflouroethylene (PTFE) prosthesis
1453601|NCT00163579|premature birth
1453602|NCT00163579|cerclage
1453603|NCT00163579|tocolysis
1453604|NCT00163579|drug therapy
1453605|NCT00163566|libido
1453606|NCT00163566|depression strength
1453607|NCT00163566|testosterone
1453608|NCT00163566|dihydrotestosterone
1453609|NCT00163553|spinal surgery
1453610|NCT00163553|pethidine
1453611|NCT00163553|analgesia
1453612|NCT00163540|tick-borne encephalitis
1453613|NCT00163527|Asthma
1453614|NCT00163527|Roflumilast
1453615|NCT00163527|Corticosteroids
1453616|NCT00163514|Allergy
1453617|NCT00163514|Perennial Allergic Rhinitis
1453618|NCT00163514|Allergic Rhinitis
1453619|NCT00163514|Hay Fever
1453620|NCT00163501|Allergy
1453621|NCT00163501|Perennial Allergic Rhinitis
1453622|NCT00163501|Allergic Rhinitis
1453623|NCT00163501|Hay Fever
1453624|NCT00163488|Allergy
1453625|NCT00163488|Perennial Allergic Rhinitis
1453626|NCT00163488|Allergic Rhinitis
1453627|NCT00163488|Hay Fever
1453628|NCT00163475|Asthma
1453629|NCT00163475|Roflumilast
1453630|NCT00163462|Asthma
1453631|NCT00163462|Ciclesonide
1453632|NCT00163462|Child
1453633|NCT00163462|Fluticasone propionate
1453634|NCT00163462|Pediatric
1453635|NCT00163449|Asthma
1453636|NCT00163449|Ciclesonide
1453637|NCT00163449|Child
1453638|NCT00163449|Pediatric
1453639|NCT00163436|Asthma
1453640|NCT00163436|Ciclesonide
1453641|NCT00163423|Asthma
1453642|NCT00163423|Ciclesonide
1453643|NCT00163423|Fluticasone propionate
1453644|NCT00163410|Asthma
1453645|NCT00163410|Ciclesonide
1453646|NCT00163410|Child
1453647|NCT00163410|Fluticasone propionate
1453648|NCT00163410|Pediatric
1453649|NCT00163397|Asthma
1453650|NCT00163397|Ciclesonide
1453651|NCT00163397|Budesonide
1453652|NCT00163384|Asthma
1453653|NCT00163384|Ciclesonide
1453654|NCT00163384|Budesonide
1453655|NCT00163371|Asthma
1453656|NCT00163371|Ciclesonide
1453657|NCT00163371|Child
1453658|NCT00163371|Fluticasone propionate
1453659|NCT00163371|HPA-axis
1453660|NCT00163371|Pediatric
1453661|NCT00163371|Linear growth rate
1453662|NCT00163358|Asthma
1453663|NCT00163358|Ciclesonide
1453664|NCT00163358|Fluticasone propionate
1453665|NCT00163358|Salmeterol
1453666|NCT00163345|Asthma
1453667|NCT00163345|Ciclesonide
1453668|NCT00163345|Small Airways
1453669|NCT00163332|Asthma
1453670|NCT00163332|Ciclesonide
1453671|NCT00163332|Fluticasone propionate
1453672|NCT00163319|Asthma
1453673|NCT00163319|Ciclesonide
1453674|NCT00163319|Fluticasone propionate
1453675|NCT00163306|Gastroesophageal Reflux
1453676|NCT00163306|Gastroesophageal Reflux Disease
1453677|NCT00163306|Pantoprazole
1453678|NCT00163293|Asthma
1453679|NCT00163293|Ciclesonide
1453680|NCT00163293|Exacerbation
1453681|NCT00163280|Mucositis
1453682|NCT00163280|Peripheral blood stem cell transplant
1453683|NCT00163267|peripheral arterial intervention
1453684|NCT00163267|atherosclerosis
1453685|NCT00163267|platelets
1453686|NCT00163267|Age above 18
1453687|NCT00163254|Chronic limb ischemia
1453688|NCT00163254|Intervention
1453689|NCT00163254|Restenosis
1453690|NCT00163254|Patients above 18 years
1453691|NCT00163228|C05.550.114.606.500
1453692|NCT00163228|C05.550.114.606.508
1453693|NCT00163176|cell proliferation
1453694|NCT00163176|PET
1453695|NCT00163176|radiotherapy
1453696|NCT00163124|chiropractic
1453697|NCT00163124|spinal manipulation
1453698|NCT00163124|low back pain
1453699|NCT00163072|transdermal
1453700|NCT00163072|Megace
1453701|NCT00163072|pharmacokinetics
1453702|NCT00163033|phase I study
1453703|NCT00163020|Preterm Birth
1453704|NCT00163020|Preterm Delivery
1453705|NCT00163020|Multiple gestation
1453706|NCT00163020|17-alpha-hydroxyprogesterone caproate
1453707|NCT00163020|Progesterone
1453708|NCT00162994|recurrent otitis media
1453709|NCT00162994|adenoidectomy
1453710|NCT00162994|tympanostomy
1453711|NCT00162994|young children
1453712|NCT00162994|prevention
1453713|NCT00162994|quality of life
1453714|NCT00162968|polyneuropathies
1453715|NCT00162968|pain
1453716|NCT00162968|drug effects
1453717|NCT00162968|escitalopram
1453718|NCT00162968|serotonin uptake inhibitors
1453719|NCT00162955|untreated adult Non-Hodgkin's Lymphoma
1453720|NCT00162955|CHOP protocol
1453721|NCT00162955|Angiotensin II Type 1 Receptor Blockers
1453722|NCT00162955|Cardiomyopathy
1453723|NCT00162942|Crohn's Disease
1453724|NCT00162929|metastatic breast cancer
1453725|NCT00162929|locally recurrent breast cancer
1453726|NCT00162916|Traumatic Brain Injury
1453727|NCT00162916|Depression
1453728|NCT00162916|Antidepressant medication
1453729|NCT00162916|Double-Blind Study
1453730|NCT00162916|Brain Injuries
1453731|NCT00162916|Antidepressive Agents
1453732|NCT00162916|Citalopram
1453733|NCT00162916|Double-Blind Method
1453734|NCT00162903|Preterm infant, Patent ductus arteriosus, Nitric oxide,Endothelin-1
1453735|NCT00162890|degenerated cervical spine
1453736|NCT00162890|assessment
1453737|NCT00162890|physical therapy
1453738|NCT00162877|rabeprazole, omeprazole, CYP2C19, H. pylori, PK/PD
1453739|NCT00162864|asthma
1453740|NCT00162864|COPD
1453741|NCT00162864|montelukast sodium
1453742|NCT00162864|leukotriene modifier
1453743|NCT00162864|older adults
1453744|NCT00162825|Psoriasis, T cell, inflammation, CD7, cytokine
1453745|NCT00162812|neoadjuvant chemotherapy
1453746|NCT00162812|early breast cancer
1453747|NCT00162812|inflammatory breast cancer
1453748|NCT00162799|insulin resistance and inflamation
1453749|NCT00162799|insulin sensitibity
1453750|NCT00162799|obesity-induced insuline resistence
1453751|NCT00162799|obesity-diabetes link
1453752|NCT00162799|salicylate
1453753|NCT00162799|insulin resistance in obesity health adults
1453754|NCT00162786|Driving performance
1453755|NCT00162786|Antihistamine
1453756|NCT00162773|asthma
1453757|NCT00162747|Pre-term infants
1453758|NCT00162747|skin infections
1453759|NCT00162747|infant skin
1453760|NCT00162747|Aquaphor
1453761|NCT00162747|sunflower seed oil
1453762|NCT00162747|nutrition
1453763|NCT00162747|skin care
1453764|NCT00162734|Chronic Hepatitis C
1453765|NCT00162734|Liver
1453766|NCT00162734|Pegylated
1453767|NCT00162734|Interferon
1453768|NCT00162734|Alpha
1453769|NCT00162734|Ribavirin
1453770|NCT00162734|Combination
1453771|NCT00162734|Nonresponder
1453772|NCT00162734|HCV
1453773|NCT00162734|Infergen
1453774|NCT00162734|SVR
1453775|NCT00162721|Uterine sarcoma non metastatic
1453776|NCT00162708|Head and neck squamous cell carcinoma
1453777|NCT00162708|Radiotherapy
1453778|NCT00162708|Chemotherapy
1453779|NCT00162682|HIV
1453780|NCT00162682|Highly Active Antiretroviral Therapy
1453781|NCT00162682|Monitoring
1453782|NCT00162682|Viral load
1453783|NCT00162682|CD4
1453784|NCT00162682|Thailand
1453785|NCT00162682|Future Drug Options
1453786|NCT00162682|Resistance
1453787|NCT00162682|Developing Country
1453788|NCT00162682|Acquired Immunodeficiency Syndrome
1453789|NCT00162669|Hepatocellular carcinoma, advanced, bevacizumab, phase II, VGEF, neovascularization
1453790|NCT00162656|B-Cell Lymphoma
1453791|NCT00162643|Acquired Immunodeficiency Syndrome
1453792|NCT00162643|Antiretroviral Therapy, Highly Active
1453793|NCT00162643|Protease Inhibitors
1453794|NCT00162643|Reverse Transcriptase Inhibitors
1453795|NCT00162630|Hip fracture, pain, regional anaesthesia, analgesia
1453796|NCT00162617|Hip fracture
1453797|NCT00162617|Rehabilitation
1453798|NCT00162617|Transfusion
1453799|NCT00162617|Outcome
1453800|NCT00162604|Prophylactic antibiotic
1453801|NCT00162604|Postoperative infections
1453802|NCT00162604|Uterine prolapse grade I - II
1453803|NCT00162604|cystocele
1453804|NCT00162604|rectocele
1453805|NCT00162604|enterocele
1453806|NCT00162604|defects of the perineal body
1453807|NCT00162591|Bispectral index
1453808|NCT00162591|sedation
1453809|NCT00162591|remifentanyl
1453810|NCT00162591|Bronchoalveolar lavage
1453811|NCT00162591|Intensive care
1453812|NCT00162591|Nociceptive stimuli
1453813|NCT00162591|Sedated patient
1453814|NCT00162591|BIS variation
1453815|NCT00162578|pneumococcal meningitis
1453816|NCT00162578|intensive care unit
1453817|NCT00162578|vancomycin
1453818|NCT00162578|dexamethasone
1453819|NCT00162578|drug diffusion in cerebrospinal fluid
1453820|NCT00162565|Heart Failure, Congestive
1453821|NCT00162565|beta-Adrenergic Blockers
1453822|NCT00162552|multicenter-randomized-trial
1453823|NCT00162552|pentoxifyllinE
1453824|NCT00162552|placebo
1453825|NCT00162552|cirrhosis
1453826|NCT00162552|liver failure
1453827|NCT00162552|cytokine
1453828|NCT00162539|foetal thyroid mensuration
1453829|NCT00162500|Metastatic solid tumors
1453830|NCT00162474|Healthy Volunteers
1453831|NCT00162461|Healthy Volunteers
1453832|NCT00162448|Patients requiring dual-chamber pacemakers or defibrillators
1453833|NCT00162396|Albuterol
1453834|NCT00162396|β2 Adrenergic receptor
1453835|NCT00162396|Polymorphism
1453836|NCT00162240|Metabolics Diabetes New Onset
1453837|NCT00162214|Advanced Solid Tumors
1453838|NCT00162123|ipilimumab
1453839|NCT00162123|previously treated
1453840|NCT00162019|Factor VIII Deficiency
1453841|NCT00162006|Chronic idiopathic thrombocytopenic purpura
1453842|NCT00161993|Gammaglobulin
1453843|NCT00161980|Axillary wound
1453844|NCT00161980|Seroma
1453845|NCT00161980|Fistulae
1453846|NCT00161967|tick-borne encephalitis
1453847|NCT00161954|Tick-Borne Encephalitis
1453848|NCT00161941|Meningococcal Vaccine
1453849|NCT00161941|Meningococcal Meningitis, Serogroup C
1453850|NCT00161941|Neisseria Meningitidis
1453851|NCT00161928|Meningococcal Vaccine
1453852|NCT00161928|Meningococcal Meningitis, Serogroup C
1453853|NCT00161928|Neisseria Meningitidis
1453854|NCT00161915|Liver cirrhosis
1453855|NCT00161902|Arthroplasty
1453856|NCT00161902|Hip Prosthesis
1453857|NCT00161902|Cement Free Hip Prosthesis
1453858|NCT00161902|Femur Head Necrosis
1453859|NCT00161902|Coxarthrosis
1453860|NCT00161876|tick-borne encephalitis
1453861|NCT00161837|Influenza
1453862|NCT00161837|Vaccine
1453863|NCT00161746|Tick-Borne Encephalitis
1453864|NCT00161733|Cardiopulmonary bypass
1453865|NCT00161733|Median sternotomy
1453866|NCT00161733|Fibrin sealant
1453867|NCT00161733|Clot
1453868|NCT00161733|Cardiac surgery
1453869|NCT00161720|Severe Congenital Protein C Deficiency
1453870|NCT00161694|pain control
1453871|NCT00161681|Levonorgestrel
1453872|NCT00161681|ethinyl estradiol
1453873|NCT00161681|premenstrual syndrome
1453874|NCT00161681|menstrual cycle related symptoms
1453875|NCT00161668|Leukemia
1453876|NCT00161655|Psoriasis
1453877|NCT00161655|Arthritis
1453878|NCT00161642|Malignant Tumors
1453879|NCT00161629|Distal Radius Fractures
1453880|NCT00161616|Open Diaphyseal Tibia Fractures
1453881|NCT00161603|Angioplasty
1453882|NCT00161603|Behavior change
1453883|NCT00161603|Physical activity
1453884|NCT00161603|Risk reduction
1453885|NCT00161590|NK cell lymphoma
1453886|NCT00161590|Null cell lymphoma
1453887|NCT00161577|Ketorolac
1453888|NCT00161564|Idiopathic Thrombocytopenic Purpura
1453889|NCT00161564|ITP
1453890|NCT00161564|Non-Malignant Hematology
1453891|NCT00161551|Cardiac Pacing, artificial
1453892|NCT00161551|Atrial Fibrillation
1453893|NCT00161551|Heart Failure
1453894|NCT00161551|Pacemaker leads
1453895|NCT00161551|Pacing Mode
1453896|NCT00161538|Cardiac Pacing, artificial
1453897|NCT00161538|Atrial fibrillation
1453898|NCT00161538|Pacemaker leads
1453899|NCT00161538|Lead positions
1453900|NCT00161525|Subretinal Hemorrhage, Perfluorocarbon gas
1453901|NCT00161486|Male contraception
1453902|NCT00161486|Prostate
1453903|NCT00161486|Acyline
1453904|NCT00161486|Androgen replacement
1453905|NCT00161473|double-blind
1453906|NCT00161473|treatment
1453907|NCT00161473|prazosin
1453908|NCT00161460|Colorectal cancer
1453909|NCT00161460|Mass screening
1453910|NCT00161447|Male contraception
1453911|NCT00161447|testosterone
1453912|NCT00161447|acyline
1453913|NCT00161434|HIV-1
1453914|NCT00161421|Male Contraception
1453915|NCT00161421|Testosterone
1453916|NCT00161421|Hypogonadism
1453917|NCT00161408|schizophrenia, first episode, cognitive behavioural therapy, psychoeducation
1453918|NCT00161395|fertility
1453919|NCT00161395|pregnancy
1453920|NCT00161382|HIV Seronegativity
1453921|NCT00161382|HIV
1453922|NCT00161369|homocysteine
1453923|NCT00161369|asymmetric dimethylarginine
1453924|NCT00161369|atherosclerosis
1453925|NCT00161369|cardiovascular event
1453926|NCT00161369|hemodialysis
1453927|NCT00161343|HIV
1453928|NCT00161343|Prevention Intervention
1453929|NCT00161343|Female
1453930|NCT00161343|Adolescents
1453931|NCT00161343|STD
1453932|NCT00161343|HIV Seronegativity
1453933|NCT00161330|urinary tract infection,
1453934|NCT00161330|antibiotic treatment
1453935|NCT00161330|childhood
1453936|NCT00161330|amoxicilline/clavulanic acid
1453937|NCT00161330|ceftriaxone
1453938|NCT00161330|renal ultrasonography
1453939|NCT00161330|renal scintigraphy
1453940|NCT00161291|Carcinoma of the breast
1453941|NCT00161291|Breast cancer
1453942|NCT00161252|Prostate Cancer
1453943|NCT00161239|T-Cell Lymphomas
1453944|NCT00161226|endometrial cancer
1453945|NCT00161213|recurrent pancreatic cancer
1453946|NCT00161213|stage IV pancreatic cancer
1453947|NCT00161213|stage III pancreatic cancer
1453948|NCT00161213|adenocarcinoma of the pancreas
1453949|NCT00161213|stage II pancreatic cancer
1453950|NCT00161200|Esophageal Metaplasia
1453951|NCT00161187|refractory chronic lymphocytic leukemia
1453952|NCT00161187|recurrent small lymphocytic lymphoma
1453953|NCT00161187|prolymphocytic leukemia
1453954|NCT00161187|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1453955|NCT00161187|nodal marginal zone B-cell lymphoma
1453956|NCT00161187|recurrent marginal zone lymphoma
1453957|NCT00161187|splenic marginal zone lymphoma
1453958|NCT00161187|recurrent grade 1 follicular lymphoma
1453959|NCT00161187|recurrent grade 2 follicular lymphoma
1453960|NCT00161187|recurrent grade 3 follicular lymphoma
1453961|NCT00161187|stage I multiple myeloma
1453962|NCT00161187|stage II multiple myeloma
1453963|NCT00161187|stage III multiple myeloma
1453964|NCT00161187|recurrent mantle cell lymphoma
1453965|NCT00161187|childhood diffuse large cell lymphoma
1453966|NCT00161187|recurrent adult diffuse large cell lymphoma
1453967|NCT00161187|recurrent adult Burkitt lymphoma
1453968|NCT00161187|recurrent adult grade III lymphomatoid granulomatosis
1453969|NCT00161187|recurrent childhood grade III lymphomatoid granulomatosis
1453970|NCT00161187|adult nasal type extranodal NK/T-cell lymphoma
1453971|NCT00161187|childhood nasal type extranodal NK/T-cell lymphoma
1453972|NCT00161187|recurrent mycosis fungoides/Sezary syndrome
1453973|NCT00161187|anaplastic large cell lymphoma
1453974|NCT00161187|angioimmunoblastic T-cell lymphoma
1453975|NCT00161187|recurrent adult T-cell leukemia/lymphoma
1453976|NCT00161187|recurrent adult Hodgkin lymphoma
1453977|NCT00161187|recurrent/refractory childhood Hodgkin lymphoma
1453978|NCT00161187|recurrent adult acute myeloid leukemia
1453979|NCT00161187|recurrent childhood acute myeloid leukemia
1453980|NCT00161187|childhood chronic myelogenous leukemia
1453981|NCT00161187|chronic phase chronic myelogenous leukemia
1453982|NCT00161187|relapsing chronic myelogenous leukemia
1453983|NCT00161187|recurrent renal cell cancer
1453984|NCT00161187|stage IV renal cell cancer
1453985|NCT00161187|recurrent bladder cancer
1453986|NCT00161187|stage IV bladder cancer
1453987|NCT00161187|recurrent prostate cancer
1453988|NCT00161187|stage IV prostate cancer
1453989|NCT00161187|recurrent malignant testicular germ cell tumor
1453990|NCT00161187|stage III malignant testicular germ cell tumor
1453991|NCT00161187|recurrent gastric cancer
1453992|NCT00161187|stage IV gastric cancer
1453993|NCT00161187|recurrent pancreatic cancer
1453994|NCT00161187|stage IV pancreatic cancer
1453995|NCT00161187|localized unresectable adult primary liver cancer
1453996|NCT00161187|recurrent adult primary liver cancer
1453997|NCT00161187|recurrent childhood liver cancer
1453998|NCT00161187|recurrent colon cancer
1453999|NCT00161187|stage IV colon cancer
1454000|NCT00161187|recurrent rectal cancer
1454001|NCT00161187|stage IV rectal cancer
1454002|NCT00161187|recurrent breast cancer
1454003|NCT00161187|stage IV breast cancer
1454004|NCT00161187|extensive stage small cell lung cancer
1454005|NCT00161187|recurrent non-small cell lung cancer
1454006|NCT00161187|recurrent small cell lung cancer
1454007|NCT00161187|stage IV non-small cell lung cancer
1454008|NCT00161187|recurrent ovarian epithelial cancer
1454009|NCT00161187|recurrent cervical cancer
1454010|NCT00161187|recurrent adult soft tissue sarcoma
1454011|NCT00161187|stage IV adult soft tissue sarcoma
1454012|NCT00161187|chondrosarcoma
1454013|NCT00161187|recurrent osteosarcoma
1454014|NCT00161187|previously treated childhood rhabdomyosarcoma
1454015|NCT00161187|recurrent childhood rhabdomyosarcoma
1454016|NCT00161187|ovarian sarcoma
1454017|NCT00161187|recurrent uterine sarcoma
1454018|NCT00161187|stage IV uterine sarcoma
1454019|NCT00161187|stage I small lymphocytic lymphoma
1454020|NCT00161187|contiguous stage II small lymphocytic lymphoma
1454021|NCT00161187|noncontiguous stage II small lymphocytic lymphoma
1454022|NCT00161187|stage III small lymphocytic lymphoma
1454023|NCT00161187|stage IV small lymphocytic lymphoma
1454024|NCT00161187|accelerated phase chronic myelogenous leukemia
1454025|NCT00161187|blastic phase chronic myelogenous leukemia
1454026|NCT00161187|recurrent childhood large cell lymphoma
1454027|NCT00161187|stage I childhood large cell lymphoma
1454028|NCT00161187|stage II childhood large cell lymphoma
1454029|NCT00161187|stage III childhood large cell lymphoma
1454030|NCT00161187|stage IV childhood large cell lymphoma
1454031|NCT00161187|adult primary hepatocellular carcinoma
1454032|NCT00161187|advanced adult primary liver cancer
1454033|NCT00161187|ovarian stromal cancer
1454034|NCT00161187|stage IA cervical cancer
1454035|NCT00161187|stage IB cervical cancer
1454036|NCT00161187|stage IIA cervical cancer
1454037|NCT00161187|stage IIB cervical cancer
1454038|NCT00161187|stage III cervical cancer
1454039|NCT00161187|stage IVA cervical cancer
1454040|NCT00161187|stage IVB cervical cancer
1454041|NCT00161187|recurrent adult acute lymphoblastic leukemia
1454042|NCT00161187|untreated adult acute lymphoblastic leukemia
1454043|NCT00161187|recurrent childhood acute lymphoblastic leukemia
1454044|NCT00161187|untreated childhood acute lymphoblastic leukemia
1454045|NCT00161187|recurrent endometrial carcinoma
1454046|NCT00161187|stage I endometrial carcinoma
1454047|NCT00161187|stage II endometrial carcinoma
1454048|NCT00161187|stage III endometrial carcinoma
1454049|NCT00161187|stage IV endometrial carcinoma
1454050|NCT00161187|childhood hepatocellular carcinoma
1454051|NCT00161187|stage III childhood liver cancer
1454052|NCT00161187|stage IV childhood liver cancer
1454053|NCT00161187|previously untreated childhood rhabdomyosarcoma
1454054|NCT00161187|metastatic childhood soft tissue sarcoma
1454055|NCT00161187|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1454056|NCT00161187|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1454057|NCT00161187|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1454058|NCT00161187|contiguous stage II grade 1 follicular lymphoma
1454059|NCT00161187|contiguous stage II grade 2 follicular lymphoma
1454060|NCT00161187|contiguous stage II grade 3 follicular lymphoma
1454061|NCT00161187|noncontiguous stage II grade 1 follicular lymphoma
1454062|NCT00161187|noncontiguous stage II grade 2 follicular lymphoma
1454063|NCT00161187|noncontiguous stage II grade 3 follicular lymphoma
1454064|NCT00161187|stage I grade 1 follicular lymphoma
1454065|NCT00161187|stage I grade 2 follicular lymphoma
1454066|NCT00161187|stage I grade 3 follicular lymphoma
1454067|NCT00161187|stage III grade 1 follicular lymphoma
1454068|NCT00161187|stage III grade 2 follicular lymphoma
1454069|NCT00161187|stage III grade 3 follicular lymphoma
1454070|NCT00161187|stage IV grade 1 follicular lymphoma
1454071|NCT00161187|stage IV grade 2 follicular lymphoma
1454072|NCT00161187|stage IV grade 3 follicular lymphoma
1454073|NCT00161187|contiguous stage II marginal zone lymphoma
1454074|NCT00161187|noncontiguous stage II marginal zone lymphoma
1454075|NCT00161187|stage I marginal zone lymphoma
1454076|NCT00161187|stage III marginal zone lymphoma
1454077|NCT00161187|stage IV marginal zone lymphoma
1454078|NCT00161187|localized osteosarcoma
1454079|NCT00161187|metastatic osteosarcoma
1454080|NCT00161187|stage I ovarian epithelial cancer
1454081|NCT00161187|stage II ovarian epithelial cancer
1454082|NCT00161187|stage III ovarian epithelial cancer
1454083|NCT00161187|stage IV ovarian epithelial cancer
1454084|NCT00161187|recurrent ovarian germ cell tumor
1454085|NCT00161187|stage I ovarian germ cell tumor
1454086|NCT00161187|stage II ovarian germ cell tumor
1454087|NCT00161187|stage III ovarian germ cell tumor
1454088|NCT00161187|stage IV ovarian germ cell tumor
1454089|NCT00161187|limited stage small cell lung cancer
1454090|NCT00161187|refractory multiple myeloma
1454091|NCT00161187|stage II malignant testicular germ cell tumor
1454092|NCT00161187|stage I adult soft tissue sarcoma
1454093|NCT00161187|stage II adult soft tissue sarcoma
1454094|NCT00161187|stage III adult soft tissue sarcoma
1454095|NCT00161187|stage I bladder cancer
1454096|NCT00161187|stage II bladder cancer
1454097|NCT00161187|stage III bladder cancer
1454098|NCT00161187|male breast cancer
1454099|NCT00161187|stage I breast cancer
1454100|NCT00161187|stage II breast cancer
1454101|NCT00161187|stage IIIA breast cancer
1454102|NCT00161187|stage IIIB breast cancer
1454103|NCT00161187|stage IIIC breast cancer
1454104|NCT00161187|stage I colon cancer
1454105|NCT00161187|stage II colon cancer
1454106|NCT00161187|stage III colon cancer
1454107|NCT00161187|stage I gastric cancer
1454108|NCT00161187|stage II gastric cancer
1454109|NCT00161187|stage III gastric cancer
1454110|NCT00161187|stage I non-small cell lung cancer
1454111|NCT00161187|stage II non-small cell lung cancer
1454112|NCT00161187|stage IIIA non-small cell lung cancer
1454113|NCT00161187|stage IIIB non-small cell lung cancer
1454114|NCT00161187|stage I pancreatic cancer
1454115|NCT00161187|stage II pancreatic cancer
1454116|NCT00161187|stage III pancreatic cancer
1454117|NCT00161187|stage I prostate cancer
1454118|NCT00161187|stage II prostate cancer
1454119|NCT00161187|stage III prostate cancer
1454120|NCT00161187|stage I rectal cancer
1454121|NCT00161187|stage II rectal cancer
1454122|NCT00161187|stage III rectal cancer
1454123|NCT00161187|stage I renal cell cancer
1454124|NCT00161187|stage II renal cell cancer
1454125|NCT00161187|stage III renal cell cancer
1454126|NCT00161187|stage I uterine sarcoma
1454127|NCT00161187|stage II uterine sarcoma
1454128|NCT00161187|stage III uterine sarcoma
1454129|NCT00161187|stage I chronic lymphocytic leukemia
1454130|NCT00161187|stage II chronic lymphocytic leukemia
1454131|NCT00161187|stage III chronic lymphocytic leukemia
1454132|NCT00161187|stage IV chronic lymphocytic leukemia
1454133|NCT00161187|contiguous stage II mantle cell lymphoma
1454134|NCT00161187|noncontiguous stage II mantle cell lymphoma
1454135|NCT00161187|stage I mantle cell lymphoma
1454136|NCT00161187|stage III mantle cell lymphoma
1454137|NCT00161187|stage IV mantle cell lymphoma
1454138|NCT00161187|Waldenstrom macroglobulinemia
1454139|NCT00161187|contiguous stage II adult diffuse large cell lymphoma
1454140|NCT00161187|noncontiguous stage II adult diffuse large cell lymphoma
1454141|NCT00161187|stage I adult diffuse large cell lymphoma
1454142|NCT00161187|stage III adult diffuse large cell lymphoma
1454143|NCT00161187|stage IV adult diffuse large cell lymphoma
1454144|NCT00161187|contiguous stage II adult Burkitt lymphoma
1454145|NCT00161187|noncontiguous stage II adult Burkitt lymphoma
1454146|NCT00161187|stage I adult Burkitt lymphoma
1454147|NCT00161187|stage III adult Burkitt lymphoma
1454148|NCT00161187|stage IV adult Burkitt lymphoma
1454149|NCT00161187|stage I mycosis fungoides/Sezary syndrome
1454150|NCT00161187|stage II mycosis fungoides/Sezary syndrome
1454151|NCT00161187|stage III mycosis fungoides/Sezary syndrome
1454152|NCT00161187|stage IV mycosis fungoides/Sezary syndrome
1454153|NCT00161187|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1454154|NCT00161187|adult acute myeloid leukemia with inv(16)(p13;q22)
1454155|NCT00161187|adult acute myeloid leukemia with t(15;17)(q22;q12)
1454156|NCT00161187|adult acute myeloid leukemia with t(16;16)(p13;q22)
1454157|NCT00161187|adult acute myeloid leukemia with t(8;21)(q22;q22)
1454158|NCT00161187|untreated adult acute myeloid leukemia
1454273|NCT00160875|esophagus
1454274|NCT00160875|irinotecan
1454159|NCT00161187|untreated childhood acute myeloid leukemia and other myeloid malignancies
1454160|NCT00161187|de novo myelodysplastic syndromes
1454161|NCT00161187|secondary myelodysplastic syndromes
1454162|NCT00161187|previously treated myelodysplastic syndromes
1454163|NCT00161187|nonmetastatic childhood soft tissue sarcoma
1454164|NCT00161187|recurrent childhood soft tissue sarcoma
1454165|NCT00161187|stage I childhood Hodgkin lymphoma
1454166|NCT00161187|stage II childhood Hodgkin lymphoma
1454167|NCT00161187|stage III childhood Hodgkin lymphoma
1454168|NCT00161187|stage IV childhood Hodgkin lymphoma
1454169|NCT00161187|stage I adult Hodgkin lymphoma
1454170|NCT00161187|stage II adult Hodgkin lymphoma
1454171|NCT00161187|stage III adult Hodgkin lymphoma
1454172|NCT00161187|stage IV adult Hodgkin lymphoma
1454173|NCT00161187|recurrent childhood small noncleaved cell lymphoma
1454174|NCT00161187|stage I childhood small noncleaved cell lymphoma
1454175|NCT00161187|stage II childhood small noncleaved cell lymphoma
1454176|NCT00161187|stage III childhood small noncleaved cell lymphoma
1454177|NCT00161187|stage IV childhood small noncleaved cell lymphoma
1454178|NCT00161187|Burkitt lymphoma
1454179|NCT00161187|stage I adult T-cell leukemia/lymphoma
1454180|NCT00161187|stage II adult T-cell leukemia/lymphoma
1454181|NCT00161187|stage III adult T-cell leukemia/lymphoma
1454182|NCT00161187|stage IV adult T-cell leukemia/lymphoma
1454183|NCT00161187|stage I malignant testicular germ cell tumor
1454184|NCT00161187|childhood myelodysplastic syndromes
1454185|NCT00161187|childhood renal cell carcinoma
1454186|NCT00161187|stage IA melanoma
1454187|NCT00161187|stage IB melanoma
1454188|NCT00161187|stage IIA melanoma
1454189|NCT00161187|stage IIB melanoma
1454190|NCT00161187|stage IIC melanoma
1454191|NCT00161187|stage IIIA melanoma
1454192|NCT00161187|stage IIIB melanoma
1454193|NCT00161187|stage IIIC melanoma
1454194|NCT00161187|stage IV melanoma
1454195|NCT00161187|recurrent melanoma
1454196|NCT00161174|testicular cancer
1454197|NCT00161174|cardiovascular morbidity
1454198|NCT00161174|cardiovascular risk factors
1454199|NCT00161174|pharmacogenomic determinants
1454200|NCT00161161|ADHD; MRI; genetics
1454201|NCT00161148|PSC
1454202|NCT00161148|Liver biochemistry
1454203|NCT00161148|Probiotics
1454204|NCT00161148|Pruritus
1454205|NCT00161135|MRI
1454206|NCT00161135|PDD-NOS, MCDD
1454207|NCT00161109|22q11.2 deletion syndrome
1454208|NCT00161109|Psychopathology
1454209|NCT00161109|Psychiatry
1454210|NCT00161109|Neuropsychology
1454211|NCT00161109|Psychiophysiology
1454212|NCT00161109|Autism
1454213|NCT00161109|Psychosis
1454214|NCT00161109|Deletion size
1454215|NCT00161109|Candidate genes
1454216|NCT00161109|Psychiatric symptoms
1454217|NCT00161109|Neuropsychological impairments
1454218|NCT00161109|Psychophysiological performance
1454219|NCT00161096|on-demand therapy
1454220|NCT00161096|pantoprazole
1454221|NCT00161096|gastro-oesophageal reflux disease
1454222|NCT00161096|proton pump inhibitor
1454223|NCT00161096|acid suppression
1454224|NCT00161096|intermittent
1454225|NCT00161083|ursodeoxycholic acid
1454226|NCT00161083|gallstone
1454227|NCT00161083|complications
1454228|NCT00161083|pancreatitis
1454229|NCT00161083|gallbladder motility
1454230|NCT00161083|colic
1454231|NCT00161070|secondary prevention
1454232|NCT00161070|TIA / minor stroke
1454233|NCT00161070|atherosclerotic origin
1454234|NCT00161070|TIA (Transient Ischemic Attack)
1454235|NCT00161070|prevention & control
1454236|NCT00161057|Schizophrenia
1454237|NCT00161057|Medication-naive
1454238|NCT00161057|Functional MRI
1454239|NCT00161057|Working memory
1454240|NCT00161057|Language lateralization
1454241|NCT00161057|schizoaffective disorder
1454242|NCT00161057|psychotic disorder Not Otherwise Specified
1454243|NCT00161005|Acute myocardial infarction
1454244|NCT00161005|Fibrinolysis
1454245|NCT00161005|Health effects /Quality of life
1454246|NCT00160992|Adoptive cell transfer
1454247|NCT00160992|peptide vaccination
1454248|NCT00160992|melanoma
1454249|NCT00160992|immunosuppression and homeostatic proliferation
1454250|NCT00160966|kidney transplantation
1454251|NCT00160966|polyoma virus associated transplant nephropathy
1454252|NCT00160966|tacrolimus
1454253|NCT00160966|mycophenolate mofetil
1454254|NCT00160966|everolimus
1454255|NCT00160966|cyclosporin A
1454256|NCT00160966|BK virus PCR
1454257|NCT00160966|viruria screening
1454258|NCT00160966|BK polyomavirus
1454259|NCT00160966|immunosuppression
1454260|NCT00160940|gene expression
1454261|NCT00160940|viral hepatitis
1454262|NCT00160940|autoimmune disease
1454263|NCT00160927|microcirculation
1454264|NCT00160927|Laser doppler flowmetry
1454265|NCT00160927|neuropathy
1454266|NCT00160927|endothelial function
1454267|NCT00160914|Childhood obesity
1454268|NCT00160901|Breast cancer
1454269|NCT00160901|Chemotherapy
1454270|NCT00160901|Phytotherapy
1454271|NCT00160901|Nutritional counseling
1454272|NCT00160875|esophageal
1454275|NCT00160875|CPT11
1454276|NCT00160875|cisplatin
1454277|NCT00160849|Treatment Experienced
1454278|NCT00160836|Tissue diagnosis
1454279|NCT00160823|Colon cleansing
1454280|NCT00160823|Quality
1454281|NCT00160823|Cost-effectiveness
1454282|NCT00160810|distal
1454283|NCT00160810|radius
1454284|NCT00160810|fractures
1454285|NCT00160745|endothelium, NO, renal, statins
1454286|NCT00160732|Islet Cell Transplant
1454287|NCT00160732|Human islet cell infusion
1454288|NCT00160732|Juvenile-onset diabetes
1454289|NCT00160693|Rheumatoid Arthritis
1454290|NCT00160693|America College of Rheumatology
1454291|NCT00160693|Disease modifying anti-rheumatic drug
1454292|NCT00160693|Certolizumab Pegol (CDP870)
1454293|NCT00160680|Persistent Allergic Rhinitis, HDM, Parietaria, sneezing, rhinorrhea, ocular pruritus, Rhinasthma, inflammatory cells, ICAM-1, ATAREAL, Xyzal, Levocetirizine
1454294|NCT00160667|Post-herpetic Neuralgia (PHN)
1454295|NCT00160667|Brivaracetam
1454296|NCT00160654|Epilepsy
1454297|NCT00160654|Partial Onset Seizures
1454298|NCT00160654|Keppra
1454299|NCT00160654|Levetiracetam
1454300|NCT00160641|Rheumatoid Arthritis
1454301|NCT00160641|CDP870
1454302|NCT00160641|Certolizumab Pegol
1454303|NCT00160641|Cimzia
1454304|NCT00160628|Epilepsy
1454305|NCT00160628|Partial Onset Seizures
1454306|NCT00160628|Keppra
1454307|NCT00160628|Levetiracetam
1454308|NCT00160615|Epilepsy, Partial,
1454309|NCT00160615|Keppra, levetiracetam
1454310|NCT00160602|Rheumatoid Arthritis
1454311|NCT00160602|Certolizumab Pegol, Cimzia
1454312|NCT00160589|Allergic Rhinits, Symptoms (sneezing, rhinorrhea, nasal/ocular pruritus, nasal congestion), LEADER, Xyzal, Levocetirizine
1454313|NCT00160576|Idiopathic Parkinson's Disease, levodopa induced dyskinesia,
1454314|NCT00160576|Levetiracetam, Keppra
1454315|NCT00160563|Pediatry
1454316|NCT00160563|EPAAC
1454317|NCT00160563|atopic Children
1454318|NCT00160563|prevention of asthma
1454319|NCT00160563|Levocetirizine
1454320|NCT00160563|Xyzal
1454321|NCT00160550|Idiopathic Generalized Epilepsy, tonic-clonic seizures
1454322|NCT00160550|Levetiracetam, Keppra
1454323|NCT00160537|Seasonal Allergic Rhinitis (SAR), Grass pollen, SAR Symptoms (sneezing, rhinorrhea, nasal / ocular pruritus, nasal congestion)
1454324|NCT00160537|POPULAR, Xyzal, Levocetirizine
1454325|NCT00160524|Certolizumab Pegol
1454326|NCT00160524|Cimzia
1454327|NCT00160524|CDP870
1454328|NCT00160524|CZP
1454329|NCT00160511|Postherpetic Neuralgia (PHN)
1454330|NCT00160511|Levetiracetam
1454331|NCT00160511|Keppra
1454332|NCT00160511|Nerve Pain
1454333|NCT00160498|Lercanidipine, calcium antagonist, hypertension, obesity
1454334|NCT00160485|Gestational Diabetes
1454335|NCT00160485|Pregnancy
1454336|NCT00160485|Glyburide
1454337|NCT00160485|Insulin
1454338|NCT00160472|vasopressin
1454339|NCT00160472|ovarian
1454340|NCT00160472|neoplasm
1454341|NCT00160459|Fibroid Uterus
1454342|NCT00160459|Leiomyoma
1454343|NCT00160459|Uterine Fibroids
1454344|NCT00160459|asoprisnil
1454345|NCT00160446|Pelvic pain
1454346|NCT00160446|Dysmenorrhea
1454347|NCT00160446|Dyspareunia
1454348|NCT00160446|Infertility
1454349|NCT00160446|Asoprisnil
1454350|NCT00160433|Pelvic pain
1454351|NCT00160433|Dysmenorrhea
1454352|NCT00160433|Dyspareunia
1454353|NCT00160433|Infertility
1454354|NCT00160433|asoprisnil
1454355|NCT00160420|Pelvic pain
1454356|NCT00160420|Dysmenorrhea
1454357|NCT00160420|Dyspareunia
1454358|NCT00160420|Infertility
1454359|NCT00160420|asoprisnil
1454360|NCT00160407|nonalcoholic steatohepatitis
1454361|NCT00160407|enzyme inhibitors
1454362|NCT00160407|lipase
1454363|NCT00160407|obesity
1454364|NCT00160407|insulin resistance
1454365|NCT00160394|Mild to Moderate
1454366|NCT00160381|Symptomatic Uterine Fibroids
1454367|NCT00160381|Excessive Uterine Bleeding
1454368|NCT00160381|Uterine Hemorrhage
1454369|NCT00160381|asoprisnil
1454370|NCT00160368|Hypertension, potassium salts
1454371|NCT00160355|Wiskott-Aldrich Syndrome
1454372|NCT00160355|Immunodeficiency
1454373|NCT00160355|Haploidentical transplantation
1454374|NCT00160342|Hormone replacement therapy, hot flushes, postmenopause
1454375|NCT00160303|Prolotherapy
1454376|NCT00160303|Lateral Epicondylitis
1454377|NCT00160303|Tennis Elbow
1454378|NCT00160303|Corticosteroid Therapy
1454379|NCT00160290|lactulose
1454380|NCT00160290|randomised clinical trial
1454381|NCT00160290|hemorrhoids
1454382|NCT00160290|anal fissures
1454383|NCT00160277|Efficacy and safety of moxonidine in Indian hypertensives
1454384|NCT00160264|lactulose; randomised clinical trial; osteopenia; postmenopause
1454385|NCT00160251|PEG-Intron
1454386|NCT00160251|Ribavirin
1454387|NCT00160251|Protease Inhibitor
1454388|NCT00160238|Meniere's disease
1454389|NCT00160238|Vestibular neurotomy
1454390|NCT00160225|blood pressure, diabetic nephropathy, proteinuria
1454391|NCT00160212|blood pressure
1454515|NCT00159354|COPD
1454392|NCT00160199|To collect additional data on 300 and 400 mg doses of PROMETRIUM in women with secondary amenorrhea
1454393|NCT00160173|Post menopausal vasomotor symptoms
1454394|NCT00160160|comparator trial
1454395|NCT00160160|hypertension
1454396|NCT00160160|diabetes
1454397|NCT00160160|blood pressure
1454398|NCT00160134|congestive heart failure, adenosine receptor blocker, cardiac hemodynamic
1454399|NCT00160095|larynx carcinoma
1454400|NCT00160095|Tumor hypoxia
1454401|NCT00160095|microregional imaging
1454402|NCT00160095|hypoxia modifying treatment
1454403|NCT00160082|Post Polio Syndrome
1454404|NCT00160082|PPS
1454405|NCT00160082|Poliomyelitis
1454406|NCT00160082|Paralylic Polio
1454407|NCT00160082|Late effects of polio
1454408|NCT00160082|Late onset polio sequele
1454409|NCT00160082|Xepol
1454410|NCT00160082|IvIg
1454411|NCT00160082|Intravenous Immunoglobuline
1454412|NCT00160069|Stage IIIB or stage IV non-small-cell lung cancer.
1454413|NCT00160056|Hypoglycemia unawareness
1454414|NCT00160056|Diabetes
1454415|NCT00160056|adrenal receptor
1454416|NCT00160056|adrenerg respons
1454417|NCT00160056|adrenergic beta-agonists
1454418|NCT00160056|salbutamol
1454419|NCT00160017|Quality assurance health care
1454420|NCT00160017|Diabetes
1454421|NCT00160017|Breakthrough collaborative (IHI)
1454422|NCT00160017|Evaluation
1454423|NCT00160004|Amyotrophic Lateral Sclerosis
1454424|NCT00160004|Exercise
1454425|NCT00160004|Fatigue
1454426|NCT00160004|Quality-of-life
1454427|NCT00159991|Coronary artery bypass grafting
1454428|NCT00159991|Total arterial revascularization
1454429|NCT00159991|Internal mammary artery grafting
1454430|NCT00159991|Radial artery grafting
1454431|NCT00159978|head and neck cancer
1454432|NCT00159978|hypoxia
1454433|NCT00159978|tumor cell proliferation
1454434|NCT00159978|PET
1454435|NCT00159965|nonepileptic seizure
1454436|NCT00159965|pseudoseizure
1454437|NCT00159965|conversion disorder
1454438|NCT00159965|psychogenic
1454439|NCT00159965|Depression
1454440|NCT00159965|Anxiety
1454441|NCT00159965|Abuse
1454442|NCT00159965|post-traumatic stress disorder
1454443|NCT00159965|sertraline
1454444|NCT00159965|serotonin
1454445|NCT00159965|randomized controlled trial
1454446|NCT00159952|Sepsis
1454447|NCT00159952|Septic shock
1454448|NCT00159952|Hyperglycemia
1454449|NCT00159952|Fibrinolysis
1454450|NCT00159952|PAI 1
1454451|NCT00159939|ARDS
1454452|NCT00159939|prone position
1454453|NCT00159926|systemic inflammatory response syndrome
1454454|NCT00159926|coronary artery bypass grafting
1454455|NCT00159926|cell saver
1454456|NCT00159926|interleukins
1454457|NCT00159926|tumor necrosis factor alfa
1454458|NCT00159900|Impotence
1454459|NCT00159874|children
1454460|NCT00159627|heart failure, congestive
1454461|NCT00159627|diuretic
1454462|NCT00159614|renal insufficiency
1454463|NCT00159614|diuretic
1454464|NCT00159614|heart failure, congestive
1454465|NCT00159601|Quality of Life
1454466|NCT00159601|Mental health
1454467|NCT00159601|Children
1454468|NCT00159601|Adolescents
1454469|NCT00159601|Normal population
1454470|NCT00159588|Medication-overuse headache
1454471|NCT00159588|preventative medication
1454472|NCT00159588|controls
1454473|NCT00159588|follow-up
1454474|NCT00159588|randomized
1454475|NCT00159588|abrupt withdrawal
1454476|NCT00159575|Polycystic ovarian syndrome
1454477|NCT00159575|Clinical pregnancy rate
1454478|NCT00159575|Oligo- or anovulation
1454479|NCT00159562|Bipolar Disorder
1454480|NCT00159562|Psycho-education
1454481|NCT00159549|Patient education
1454482|NCT00159536|PCOS
1454483|NCT00159536|metformin
1454484|NCT00159536|pregnancy
1454485|NCT00159536|preeclampsia
1454486|NCT00159536|diabetes
1454487|NCT00159536|preterm delivery
1454488|NCT00159523|Prevention
1454489|NCT00159523|Probiotics
1454490|NCT00159523|Allergy
1454491|NCT00159523|Hypersensitivity
1454492|NCT00159510|sepsis, methylene blue, nitric oxide, acute lung injury
1454493|NCT00159497|THA
1454494|NCT00159484|phase 1
1454495|NCT00159484|phase one
1454496|NCT00159484|phase I
1454497|NCT00159432|colorectal
1454498|NCT00159432|cancer
1454499|NCT00159419|Osteogenesis Imperfecta
1454500|NCT00159419|Fractures
1454501|NCT00159419|Pediatric
1454502|NCT00159419|Osteoporosis
1454503|NCT00159419|Juvenile Pagets
1454504|NCT00159406|BPH treatment
1454505|NCT00159406|Laser Prostatectomy
1454506|NCT00159406|Treatment of enlarged Prostates
1454507|NCT00159406|BPH
1454508|NCT00159393|Kidney stones
1454509|NCT00159393|nephrolithotripsy percutaneous
1454510|NCT00159380|Healthy Volunteers
1454511|NCT00159367|Neuromuscular electrical stimulation
1454512|NCT00159354|FDG−PET
1454513|NCT00159354|pulmonary inflammation,
1454514|NCT00159354|smoking,
1454516|NCT00159354|steroid intervention
1454517|NCT00159341|cigarette smoke
1454518|NCT00159341|nasal
1454519|NCT00159341|whole blood
1454520|NCT00159341|cytokines
1454521|NCT00159341|chemokines
1454522|NCT00159341|nasal fluid
1454523|NCT00159341|filter paper
1454524|NCT00159328|Magnetic Resonance Guided Focused Ultrasound
1454525|NCT00159328|Gonadotrophin Releasing Hormone Agonist
1454526|NCT00159328|Uterine Fibroids
1454527|NCT00159315|Healthy Volunteers (smokers)
1454528|NCT00159315|Healthy Volunteers (Non-smokers)
1454529|NCT00159315|Asthma Patients
1454530|NCT00159315|COPD Patients
1454531|NCT00159289|Mild to moderate Chronic Obstructive Pulmonary Disease (COPD)
1454532|NCT00159289|Volunteers (healthy non-smokers)
1454533|NCT00159289|Volunteers (current or ex-smokers)
1454534|NCT00159250|Duchenne muscular dystrophy;
1454535|NCT00159250|antisense oligonucleotides;
1454536|NCT00159250|gene restoration;
1454537|NCT00159250|deletion
1454538|NCT00159224|HIV
1454539|NCT00159224|Simplification
1454540|NCT00159224|Monotherapy
1454541|NCT00159224|Treatment Naive
1454542|NCT00159224|HIV-1 infection
1454543|NCT00159211|type 2 diabetes
1454544|NCT00159198|Amyotrophic lateral sclerosis
1454545|NCT00159198|Frontotemporal dementia
1454546|NCT00159198|Mutations spectrum
1454547|NCT00159198|Linkage studies
1454548|NCT00159198|Genetic epidemiology
1454549|NCT00159185|Arthroplasty, Replacement, Hip
1454550|NCT00159185|Epidemiology
1454551|NCT00159172|Advanced parkinson disease
1454552|NCT00159172|Stimulation
1454553|NCT00159172|Motor Cortex
1454554|NCT00159172|Parkinson disease C10.574.812
1454555|NCT00159172|Electric Stimulation Therapy E02.831.580.438
1454556|NCT00159172|Neuronavigation E05.873.249
1454557|NCT00159159|Cardiac Transplant
1454558|NCT00159159|ciclosporine
1454559|NCT00159159|immunosuppressive
1454560|NCT00159146|Major Depression
1454561|NCT00159146|Pindolol
1454562|NCT00159146|Venlafaxine
1454563|NCT00159146|Augmentation
1454564|NCT00159146|Major depression (DSM-IVR)
1454565|NCT00159133|Schizophrenia
1454566|NCT00159133|first episode
1454567|NCT00159133|prodrome based early intervention
1454568|NCT00159133|antipsychotics - benzodiazepine
1454569|NCT00159133|maintenance treatment
1454570|NCT00159133|drug discontinuation
1454571|NCT00159120|Schizophrenia
1454572|NCT00159120|first episode
1454573|NCT00159120|neuroleptic maintenance treatment
1454574|NCT00159120|drug discontinuation
1454575|NCT00159120|prodrome based early intervention
1454576|NCT00159107|alcoholism
1454577|NCT00159107|abstinence enhancement
1454578|NCT00159107|psychotherapy
1454579|NCT00159107|cognitive behavior therapy vs. supportive counseling
1454580|NCT00159107|Acamprosate vs. Placebo
1454581|NCT00159107|multi-center study
1454582|NCT00159081|Schizophrenia
1454583|NCT00159081|first episode
1454584|NCT00159081|long-term treatment
1454585|NCT00159081|typical vs. atypical neuroleptics
1454586|NCT00159003|drug metabolism and disposition enzymes
1454587|NCT00158990|major depression
1454588|NCT00158990|bipolar disorder
1454589|NCT00158990|unipolar depression
1454590|NCT00158990|sertraline
1454591|NCT00158990|triiodothyronine
1454592|NCT00158977|heart failure
1454593|NCT00158977|atrial fibrillation
1454594|NCT00158977|cardiac resynchronization therapy defibrillator
1454595|NCT00158964|left ventricular lead
1454596|NCT00158964|pacing
1454597|NCT00158964|heart failure
1454598|NCT00158951|Left Ventricular Lead
1454599|NCT00158951|Cardiac Resynchronization Therapy
1454600|NCT00158951|Congestive Heart Failure
1454601|NCT00158938|Artificial Cardiac Pacemaker
1454602|NCT00158938|Implanted Electrodes
1454603|NCT00158925|Artificial Cardiac Pacing
1454604|NCT00158925|Implanted Electrodes
1454605|NCT00158899|HDLc
1454606|NCT00158899|high-density lipoprotein
1454607|NCT00158899|Dyslipidemia
1454608|NCT00158886|oral topotecan rectal cancer pelvic radiation
1454609|NCT00158873|ICU mechanical ventilation analgesia sedation
1454610|NCT00158860|VALTREX®
1454611|NCT00158860|valaciclovir
1454612|NCT00158860|genital herpes
1454613|NCT00158860|HSV-2
1454614|NCT00158860|suppression
1454615|NCT00158847|COPD inflammation sputum lung function biopsy
1454616|NCT00158834|Children
1454617|NCT00158834|Asthma
1454618|NCT00158834|bronchial hyperresponsiveness
1454619|NCT00158834|symptoms
1454620|NCT00158821|HIV
1454621|NCT00158821|Antiretroviral
1454622|NCT00158821|Treatment Experienced
1454623|NCT00158821|HIV-1
1454624|NCT00158782|Cancer GW786034 Lapatinib Pazopanib
1454625|NCT00158769|Hepatic Impairment
1454626|NCT00158769|Emulsion
1454627|NCT00158769|GR270773
1454628|NCT00158756|Diphtheria
1454629|NCT00158756|Pertussis
1454630|NCT00158756|Prophylaxis
1454631|NCT00158756|Hepatitis B diseases
1454632|NCT00158756|Tetanus
1454633|NCT00158743|Pre-eclampsia
1454634|NCT00158743|Hypertension
1454635|NCT00158743|Endogenous digitalis-like factor
1454636|NCT00158743|Anti-digoxin antibody
1454637|NCT00158743|Digibind
1454638|NCT00158717|Chronic Hepatitis B
1454639|NCT00158704|Chronic Hepatitis B
1454640|NCT00158691|Head and Neck cancer
1454641|NCT00158691|Radiotherapy
1454642|NCT00158691|Xerostomia
1454643|NCT00158691|Randomized trial
1454644|NCT00158678|oral cancer
1454645|NCT00158678|oropharynx cancer
1454646|NCT00158678|hypopharynx cancer
1454647|NCT00158678|IMRT
1454648|NCT00158665|Influenza
1454649|NCT00158665|Vaccination
1454650|NCT00158665|Immunization
1454651|NCT00158665|Flu
1454652|NCT00158665|Immunogenicity
1454653|NCT00158652|Head and neck squamous cell carcinoma
1454654|NCT00158652|Radiotherapy
1454655|NCT00158652|Chemotherapy
1454656|NCT00158639|Blood Pressure Monitoring, home
1454657|NCT00158639|Pharmaceutical services
1454658|NCT00158639|Self care
1454659|NCT00158626|physical therapy
1454660|NCT00158626|physiotherapy
1454661|NCT00158626|pelvic organ prolapse
1454662|NCT00158600|Glycogen Storage Disease Type II
1454663|NCT00158600|GSD-II
1454664|NCT00158600|Pompe Disease
1454665|NCT00158587|Vivax
1454666|NCT00158587|Treatment
1454667|NCT00158587|Primaquine
1454668|NCT00158587|Asia
1454669|NCT00158574|intermittent preventive treatment
1454670|NCT00158574|malaria
1454671|NCT00158574|efficacy
1454672|NCT00158574|safety
1454673|NCT00158574|drug options
1454674|NCT00158561|vivax
1454675|NCT00158561|treatment
1454676|NCT00158561|Asia
1454677|NCT00158548|Falciparum
1454678|NCT00158548|Vivax
1454679|NCT00158548|Treatment
1454680|NCT00158548|Asia
1454681|NCT00158535|Liver Transplantation
1454682|NCT00158535|Hepatitis C
1454683|NCT00158535|HIV Infections
1454684|NCT00158522|Acute hepatitis C
1454685|NCT00158522|Genotype 4
1454686|NCT00158522|Pegylated Interferon
1454687|NCT00158522|Egypt
1454688|NCT00158509|Valacyclovir
1454689|NCT00158509|HIV-1
1454690|NCT00158509|HSV-2
1454691|NCT00158509|genital shedding
1454692|NCT00158509|herpes genitalis
1454693|NCT00158509|HIV infection
1454694|NCT00158496|Chronic Hepatitis C
1454695|NCT00158496|Genotype 4
1454696|NCT00158496|Pegylated Interferon
1454697|NCT00158496|Ribavirin
1454698|NCT00158496|Egypt
1454699|NCT00158483|Genital herpes
1454700|NCT00158483|Cofactors of sexual transmission
1454701|NCT00158483|Syndromic treatment
1454702|NCT00158483|Genital viral load
1454703|NCT00158483|Ulcer
1454704|NCT00158470|HIV infection
1454705|NCT00158470|injecting drug users
1454706|NCT00158470|HAART
1454707|NCT00158470|once daily regimen
1454708|NCT00158470|Treatment Naive
1454709|NCT00158457|Simplification regimen
1454710|NCT00158457|HIV infection
1454711|NCT00158457|Once a day
1454712|NCT00158457|Naive patients
1454713|NCT00158457|Sub-saharian Africa
1454714|NCT00158457|Treatment Naive
1454715|NCT00158444|arthroplasty
1454716|NCT00158444|Resurfacing
1454717|NCT00158444|implant
1454718|NCT00158431|osteoarthritis
1454719|NCT00158431|randomized trial
1454720|NCT00158431|knee
1454721|NCT00158431|quality of life
1454722|NCT00158418|osteoarthritis
1454723|NCT00158418|shoulder
1454724|NCT00158418|randomized trial
1454725|NCT00158418|cement
1454726|NCT00158405|HIV
1454727|NCT00158405|Structured treatment interruption
1454728|NCT00158405|HAART
1454729|NCT00158405|Sub-saharian africa
1454730|NCT00158405|Treatment Interruption
1454731|NCT00158405|Treatment Naive
1454732|NCT00158366|Weight Loss
1454733|NCT00158353|Mentors
1454734|NCT00158353|Self-esteem
1454735|NCT00158353|Adolescent
1454736|NCT00158353|Mental health
1454737|NCT00158353|Social support
1454738|NCT00158353|Substance use
1454739|NCT00158353|Violence
1454740|NCT00158353|Exercise
1454741|NCT00158353|Nutrition
1454742|NCT00158353|Sexual behavior
1454743|NCT00158353|Female
1454744|NCT00158340|Binge Eating
1454745|NCT00158340|Overeating
1454746|NCT00158340|Compulsive Eating
1454747|NCT00158340|Hyperphagia
1454748|NCT00158327|Primary Health Care
1454749|NCT00158314|Pathological gambling
1454750|NCT00158314|Gambler's anonymous
1454751|NCT00158314|Cognitive behavioral therapy
1454752|NCT00158314|CBT
1454753|NCT00158301|Child
1454754|NCT00158301|Adolescent
1454755|NCT00158301|CBT
1454756|NCT00158301|Drug Therapy
1454757|NCT00158288|Substance Use Disorders
1454758|NCT00158275|Cognitive behavioral therapy
1454759|NCT00158275|Problem solving therapy
1454760|NCT00158275|CBT
1454761|NCT00158262|Post-Traumatic Stress Disorder
1454762|NCT00158262|Prevention
1454763|NCT00158262|Propranolol
1454764|NCT00158262|Psychophysiology
1454765|NCT00158249|citicoline, drug abuse, marijuana
1454766|NCT00158236|Opiate Addiction
1454767|NCT00158236|Opiate Dependence
1454768|NCT00158223|Schizophrenia
1454769|NCT00158223|Clozapine
1454770|NCT00158223|Treatment
1454771|NCT00158223|Combination
1454772|NCT00158223|Unresponsive
1454773|NCT00158223|Schizoaffective Disorders
1454774|NCT00158197|Adherence
1454775|NCT00158197|Amphetamine-Related Disorders
1454776|NCT00158197|Behavior Therapy
1454777|NCT00158197|Contingency management
1454778|NCT00158197|Drug Counseling
1454779|NCT00158197|health behaviors
1454780|NCT00158197|methamphetamine
1454781|NCT00158197|sexual risk behaviors
1454782|NCT00158197|substance dependence
1454783|NCT00158171|smoking addiction
1454784|NCT00158158|smoking addiction
1454785|NCT00158132|cocaine
1454786|NCT00158119|strength training
1454787|NCT00158119|power training
1454788|NCT00158119|exercise training
1454789|NCT00158119|functional performance tasks
1454790|NCT00158106|functional communicative ability
1454791|NCT00158106|cost effectiveness
1454792|NCT00158106|service user preferences
1454793|NCT00158067|Epilepsy
1454794|NCT00158067|Neurostimulation
1454795|NCT00158054|depression
1454796|NCT00158054|acute coronary syndrome
1454797|NCT00158054|clinical trials
1454798|NCT00158041|Amifostine
1454799|NCT00158041|Mucositis
1454800|NCT00158041|Nausea
1454801|NCT00158041|Hypotension
1454802|NCT00158041|Rash
1454803|NCT00158028|Schizotypal Personality Disorder
1454804|NCT00158028|Risperidone
1454805|NCT00158028|Treatment
1454806|NCT00158028|Cognitive
1454807|NCT00158015|Echocardiography
1454808|NCT00158015|tissue Doppler Imaging
1454809|NCT00158015|Cardiac Resynchronization Therapy
1454810|NCT00158002|Basilar/Hemiplegic Migraine
1454811|NCT00158002|Prophylaxis
1454812|NCT00157989|Infant, Premature
1454813|NCT00157976|Macular Degeneration
1454814|NCT00157976|AMD
1454815|NCT00157976|Visual Acuity
1454816|NCT00157950|Human Papilloma Virus
1454817|NCT00157885|Falciparum
1454818|NCT00157885|Vivax
1454819|NCT00157885|Papua
1454820|NCT00157885|Amodiaquine
1454821|NCT00157885|Artekin
1454822|NCT00157885|Artemisinin Combination Therapy
1454823|NCT00157885|Dihydroartemisinin
1454824|NCT00157885|Piperaquine
1454825|NCT00157885|Lumefantrine
1454826|NCT00157885|Artemether
1454827|NCT00157859|Falciparum
1454828|NCT00157859|Vivax
1454829|NCT00157859|Papua
1454830|NCT00157859|Chloroquine
1454831|NCT00157859|Sulphadoxine-pyrimethamine
1454832|NCT00157846|Heart Failure
1454833|NCT00157846|LVEF < 35%
1454834|NCT00157846|Bradycardia
1454835|NCT00157833|Coartemether
1454836|NCT00157833|Artekin
1454837|NCT00157833|Papua
1454838|NCT00157833|Uncomplicated malaria
1454839|NCT00157820|Defibrillators, Implantable
1454840|NCT00157820|Atrial Fibrillation
1454841|NCT00157820|Ventricular Tachyarrhythmias
1454842|NCT00157820|Clinical Trial
1454843|NCT00157807|Persistent Atrial Fibrillation
1454844|NCT00157807|Permanent Atrial Fibrillation
1454845|NCT00157807|Mitral Valve Defect
1454846|NCT00157807|Tricuspid Valve Defect
1454847|NCT00157807|Aortic Valve Defect
1454848|NCT00157794|Sinus Node Disease
1454849|NCT00157794|Pacemaker
1454850|NCT00157794|Dual Chamber Pacemaker
1454851|NCT00157781|Atrial Fibrillation
1454852|NCT00157781|Atrial Tachyarrhythmia
1454853|NCT00157781|Pacing
1454854|NCT00157781|Electrophysiology
1454855|NCT00157768|Acute myocardial infarction
1454856|NCT00157768|Non-sustained ventricular tachycardia
1454857|NCT00157768|Left ventricular dysfunction
1454858|NCT00157768|Implantable cardioverter defibrillator
1454859|NCT00157768|ICD
1454860|NCT00157768|Risk-stratification
1454861|NCT00157755|Nausea and Vomiting
1454862|NCT00157742|Angina Pectoris
1454863|NCT00157742|Spinal Cord Stimulation (SCS)
1454864|NCT00157742|Percutaneous Myocardial Revascularisation (PMR)
1454865|NCT00157742|Refractory Angina Pectoris
1454866|NCT00157729|Hypertension
1454867|NCT00157729|antihypertensive agents
1454868|NCT00157729|diabetes mellitus type 2
1454869|NCT00157729|metabolic syndrome
1454870|NCT00157716|Coronary
1454871|NCT00157716|surgery
1454872|NCT00157716|ischemia
1454873|NCT00157716|reperfusion injury
1454874|NCT00157716|cardiac
1454875|NCT00157716|heart
1454876|NCT00157716|neurological
1454877|NCT00157716|cardiopulmonary bypass
1454878|NCT00157716|cardioprotection
1454879|NCT00157703|Malignant glioma
1454880|NCT00157703|Glioblastoma multiforme
1454881|NCT00157703|GBM
1454882|NCT00157703|Gliosarcoma
1454883|NCT00157703|Anaplastic astrocytoma
1454884|NCT00157703|Brain cancer
1454885|NCT00157703|Brain tumor
1454886|NCT00157703|Glioma
1454887|NCT00157703|recurrent/progressive malignant glioma
1454888|NCT00157690|Alendronate
1454889|NCT00157690|Bisphosphonates
1454890|NCT00157690|Cystic Fibrosis
1454891|NCT00157690|Osteoporosis
1454892|NCT00157677|deep vein thrombosis
1454893|NCT00157677|pulmonary embolism
1454894|NCT00157677|D-dimer testing
1454895|NCT00157651|end stage renal disease
1454896|NCT00157651|thrombosis
1454897|NCT00157651|bleeding
1454898|NCT00157638|pharmacist
1454899|NCT00157638|physician
1454900|NCT00157638|primary care
1454901|NCT00157638|collaboration
1454902|NCT00157638|therapeutics
1454903|NCT00157625|urinary infections, catheters, bacteriuria, trial
1454904|NCT00157612|pneumonia
1454905|NCT00157612|lower respiratory tract infection
1454906|NCT00157612|clinical pathway
1454907|NCT00157612|nursing home
1454908|NCT00157612|long-term care
1454909|NCT00157612|randomized control trial
1454910|NCT00157599|deep vein thrombosis
1454911|NCT00157599|DVT
1454912|NCT00157573|Asymptomatic
1454913|NCT00157573|Clinical trial
1454914|NCT00157573|Phase II
1454915|NCT00157573|GM-CSF
1454916|NCT00157573|Immunotherapy
1454917|NCT00157547|Depression
1454918|NCT00157547|Quantitative EEG (QEEG)
1454919|NCT00157547|Antidepressants
1454920|NCT00157534|Hepatitis C
1454921|NCT00157534|Celgosivir
1454922|NCT00157534|HCV
1454923|NCT00157534|Genotype 1
1454924|NCT00157378|first episode,
1454925|NCT00157378|schizophrenia,
1454926|NCT00157378|atypical neuroleptics,
1454927|NCT00157378|negative symptoms
1454928|NCT00157326|High Blood Pressure
1454929|NCT00157313|Schizophrenia
1454930|NCT00157313|First episode psychosis
1454931|NCT00157313|Psychosocial intervention
1454932|NCT00157300|erythropoietin
1454933|NCT00157300|kidney transplantation
1454934|NCT00157300|delayed graft function
1454935|NCT00157274|Alemtuzumab
1454936|NCT00157274|Mycosis fungoides
1454937|NCT00157274|Sezary
1454938|NCT00157222|Charcot
1454939|NCT00157222|Diabetic
1454940|NCT00157222|osteoporosis
1454941|NCT00157196|Carcinoma, Non-Small-Cell Lung, L-BLP25, Tecemotide
1454942|NCT00157183|cystic fibrosis
1454943|NCT00157183|hypoxia
1454944|NCT00157183|oxygen
1454945|NCT00157183|noninvasive ventilation
1454946|NCT00157183|quality of life
1454947|NCT00157170|exercise
1454948|NCT00157170|self efficacy
1454949|NCT00157170|quality of life
1454950|NCT00157170|HIV
1454951|NCT00157157|Factor VIII Deficiency
1454952|NCT00157144|Lung Transplantation
1454953|NCT00157144|Heart Transplantation
1454954|NCT00157131|autologous sheet skin grafts
1454955|NCT00157131|FS 4IU VH S/D
1454956|NCT00157131|skin grafts
1454957|NCT00157131|burn
1454958|NCT00157118|Severe congenital protein C deficiency
1454959|NCT00157079|PID
1454960|NCT00157079|Immune Thrombocytopenic Purpura (ITP)
1454961|NCT00157079|Kawasaki syndrome
1454962|NCT00157079|Immunodeficiency
1454963|NCT00157066|Latent tuberculosis infection
1454964|NCT00157066|Active tuberculosis infection
1454965|NCT00157053|Factor VIII Deficiency
1454966|NCT00157040|Factor VIII Deficiency
1454967|NCT00157027|Treatment Experienced
1454968|NCT00157027|HIV-1 Positive by ELISA Assay
1454969|NCT00157027|Confirmed by Western Blot
1454970|NCT00157027|Refractory or intolerant to HAART
1454971|NCT00157014|Antirejection
1454972|NCT00157014|Treatment Outcome
1454973|NCT00157014|Immunosuppression
1454974|NCT00157014|Treatment Effectiveness
1454975|NCT00157014|Anti-rejection therapy
1454976|NCT00156988|burns
1454977|NCT00156988|partial thickness
1454978|NCT00156988|cerium flamazine
1454979|NCT00156988|randomised clinical trial
1454980|NCT00156975|Oxaliplatin
1454981|NCT00156975|Capecitabine
1454982|NCT00156975|Chemotherapy
1454983|NCT00156975|Resection
1454984|NCT00156975|Liver metastases
1454985|NCT00156975|Liver resection
1454986|NCT00156975|Adjuvant
1454987|NCT00156962|Epogen
1454988|NCT00156962|Procrit
1454989|NCT00156962|Chronic Kidney Disease
1454990|NCT00156962|Anemia Treatment
1454991|NCT00156949|Epogen
1454992|NCT00156949|Procrit
1454993|NCT00156949|Chronic Kidney Disease
1454994|NCT00156949|Anemia Treatment for Dialysis Patients
1454995|NCT00156923|Alcohol dependence
1454996|NCT00156897|Non-insulin-dependent diabetes mellitus
1454997|NCT00156897|NIDDM
1454998|NCT00156897|Type II diabetes
1454999|NCT00156897|Obesity
1455000|NCT00156897|Lipase inhibitor
1455001|NCT00156884|prostate cancer
1455002|NCT00156884|cisplatin
1455003|NCT00156884|strontium-89
1455004|NCT00156884|phase II
1455005|NCT00156871|transplant
1455006|NCT00156871|fatigue
1455007|NCT00156871|exercise
1455008|NCT00156871|Malignant disease
1455009|NCT00156858|pharmacokinetics
1455010|NCT00156858|transplantation
1455011|NCT00156858|busulfan
1455012|NCT00156845|coronary artery disease
1455013|NCT00156845|ischemia
1455014|NCT00156845|echocardiography
1455015|NCT00156845|cardiac imaging
1455016|NCT00156845|heart disease
1455017|NCT00156845|myocardial contrast enhancement
1455018|NCT00156845|myocardial perfusion
1455019|NCT00156845|wall motion
1455020|NCT00156845|ultrasound contrast agent
1455021|NCT00156819|Asthma
1455022|NCT00156819|Asthma Control
1455023|NCT00156806|aloe
1455024|NCT00156806|radiation dermatitis
1455025|NCT00156806|radiation therapy
1455026|NCT00156793|coronary artery disease
1455027|NCT00156793|ischemia
1455028|NCT00156793|echocardiography
1455029|NCT00156793|cardiac imaging
1455030|NCT00156793|heart disease
1455031|NCT00156793|myocardial contrast enhancement
1455032|NCT00156793|myocardial perfusion
1455033|NCT00156793|wall motion
1455034|NCT00156793|ultrasound contrast agent
1455035|NCT00156780|ultrasound contrast agent
1455036|NCT00156780|pharmacokinetics
1455037|NCT00156780|congestive heart failure
1455038|NCT00156780|chronic obstructive pulmonary disease
1455039|NCT00156780|safety
1455040|NCT00156767|Critical Care
1455041|NCT00156767|Adrenal Insufficiency
1455042|NCT00156767|Septic Shock
1455043|NCT00156767|Cortrosyn
1455044|NCT00156767|Steroids
1455045|NCT00156767|Cortisol
1455046|NCT00156767|Critical Care Unit
1455047|NCT00156767|Adrenal Gland Function
1455048|NCT00156741|Refined ventricular pacing
1455049|NCT00156728|Pacemaker artificial, congestive heart failure and atrial fibrillation
1455050|NCT00156715|Quetiapine
1455051|NCT00156715|Seroquel
1455052|NCT00156715|Schizophrenia
1455053|NCT00156715|Dual Diagnosis
1455054|NCT00156715|Substance Abuse
1455055|NCT00156715|Alcohol Abuse
1455056|NCT00156702|Smoking
1455057|NCT00156702|Adolescents
1455058|NCT00156702|Motivational Interviewing
1455059|NCT00156689|polyneuropathy
1455060|NCT00156676|Disability
1455061|NCT00156676|Gait
1455062|NCT00156676|Multiple Sclerosis
1455063|NCT00156676|Rehabilitation
1455064|NCT00156676|Robot
1455065|NCT00156663|Women
1455066|NCT00156663|Veterans
1455067|NCT00156663|Delivery of Healthcare
1455068|NCT00156663|Intervention Studies
1455069|NCT00156663|United States Department of Veterans Affairs
1455070|NCT00156663|Women's Health
1455071|NCT00156650|Male contraception
1455072|NCT00156650|Testosterone
1455073|NCT00156637|schizophrenia
1455074|NCT00156637|quality of health care
1455075|NCT00156637|quality indicators
1455076|NCT00156637|intervention studies
1455077|NCT00156624|Intervention
1455078|NCT00156624|Peripheral Vascular Disease
1455079|NCT00156624|Drug
1455080|NCT00156624|Restenosis
1455081|NCT00156624|18 years and above
1455082|NCT00156611|peripheral vascular disease
1455083|NCT00156611|intervention
1455084|NCT00156611|restenosis
1455085|NCT00156611|Age above 18 years
1455086|NCT00156598|metal ion concentration
1455087|NCT00156585|cerebral metastases
1455088|NCT00156585|dynamic contrast enhanced magnetic resonance imaging
1455089|NCT00156585|DCE-MRI
1455090|NCT00156585|gamma knife
1455091|NCT00156559|immunization
1455092|NCT00156559|vaccine
1455093|NCT00156559|low birth weight infant
1455094|NCT00156559|premature infant
1455095|NCT00156546|Urinary tract infections
1455096|NCT00156546|Children
1455097|NCT00156546|Antibiotic prophylaxis
1455098|NCT00156546|Renal scintigraphy
1455099|NCT00156546|Vesico ureteral reflux
1455100|NCT00156533|Insomnia
1455101|NCT00156533|Sleep
1455102|NCT00156533|zolpidem
1455103|NCT00156533|Ambien
1455104|NCT00156533|Hypnotics
1455105|NCT00156455|Children
1455106|NCT00156455|Hypoplastic left heart syndrome
1455107|NCT00156455|Obstructive Sleep Apnea Syndrome
1455108|NCT00156455|Single Ventricle Physiology
1455109|NCT00156442|Obstructive Sleep Apnea Syndrome
1455110|NCT00156442|Cleft lip/palate
1455111|NCT00156442|Children
1455112|NCT00156429|genetic testing
1455113|NCT00156416|menopause
1455114|NCT00156416|hot flash
1455115|NCT00156416|night sweat
1455116|NCT00156416|meditation
1455117|NCT00156416|breast cancer
1455118|NCT00156403|pancreatitis, hereditary
1455119|NCT00156403|trypsinogen, cationic
1455120|NCT00156403|pilot study
1455121|NCT00156377|Mupirocin
1455122|NCT00156377|Staphylococcus aureus
1455123|NCT00156377|Nasal Cavity
1455124|NCT00156377|Preventive measures
1455125|NCT00156364|Diabetic Nephropathy
1455126|NCT00156364|Kidney Transplant
1455127|NCT00156364|Pancreas Transplant
1455128|NCT00156364|Renal Interstitium
1455129|NCT00156364|Diabetes Mellitus
1455130|NCT00156364|Cyclosporine
1455131|NCT00156364|Tacrolimus
1455132|NCT00156351|African Americans
1455133|NCT00156351|Women
1455134|NCT00156351|Internet
1455135|NCT00156351|Telephone Counseling
1455136|NCT00156338|Fluid therapy
1455137|NCT00156325|Bipolar Disorder
1455138|NCT00156325|Depression
1455139|NCT00156325|Hypomania
1455140|NCT00156325|Mood Stabilizer
1455141|NCT00156299|adult acute megakaryoblastic leukemia (M7)
1455142|NCT00156299|adult acute minimally differentiated myeloid leukemia (M0)
1455143|NCT00156299|adult acute monoblastic leukemia (M5a)
1455144|NCT00156299|adult acute monocytic leukemia (M5b)
1455145|NCT00156299|adult acute myeloblastic leukemia with maturation (M2)
1455146|NCT00156299|adult acute myeloblastic leukemia without maturation (M1)
1455147|NCT00156299|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1455148|NCT00156299|adult acute myeloid leukemia with inv(16)(p13;q22)
1455149|NCT00156299|adult acute myeloid leukemia with t(16;16)(p13;q22)
1455150|NCT00156299|adult acute myeloid leukemia with t(8;21)(q22;q22)
1455151|NCT00156299|adult acute myelomonocytic leukemia (M4)
1455152|NCT00156299|adult erythroleukemia (M6a)
1455153|NCT00156299|adult pure erythroid leukemia (M6b)
1455154|NCT00156299|untreated adult acute myeloid leukemia
1455155|NCT00156247|psoriasis
1455156|NCT00156247|etanercept
1455157|NCT00156247|acitretin
1455158|NCT00156221|Autism
1455159|NCT00156221|MRI
1455160|NCT00156221|Developmental Disorders
1455161|NCT00156208|Symptomatic Uterine Fibroids
1455162|NCT00156208|Excessive Uterine Bleeding
1455163|NCT00156208|Uterine Hemorrhage
1455164|NCT00156208|asoprisnil
1455165|NCT00156195|Symptomatic Uterine Fibroids
1455166|NCT00156195|Excessive Uterine Bleeding
1455167|NCT00156195|Uterine Hemorrhage
1455168|NCT00156195|asoprisnil
1455169|NCT00156182|Fibroid Uterus
1455170|NCT00156182|Leiomyoma
1455171|NCT00156182|Uterine Fibroids
1455172|NCT00156182|asoprisnil
1455173|NCT00156156|Symptomatic Uterine Fibroids
1455174|NCT00156156|Excessive Uterine Bleeding
1455175|NCT00156156|Uterine Hemorrhage
1455176|NCT00156130|Breast Cancer
1455177|NCT00156130|Lumpectomy
1455178|NCT00156130|Radiotherapy
1455179|NCT00156130|Hypofractionated Radiotherapy
1455180|NCT00156130|Long Term Outcomes
1455181|NCT00156052|Breast Cancer
1455182|NCT00156052|Hypofractionated Radiotherapy
1455183|NCT00156052|Lumpectomy
1455184|NCT00156039|Breast Cancer
1455185|NCT00156039|Follow-up Strategy
1455186|NCT00156039|Follow-up Care
1455187|NCT00156039|Family Physician
1455188|NCT00156039|Oncologist
1455189|NCT00156026|CIN 1
1455190|NCT00156026|cervical intraepithelial neoplasia
1455191|NCT00156026|cervix
1455192|NCT00156026|cancer
1455193|NCT00156026|loop electrosurgical excision procedure
1455194|NCT00156026|LEEP
1455195|NCT00156026|expectant management
1455196|NCT00156026|human papilloma virus
1455197|NCT00156026|HPV
1455198|NCT00156026|colposcopy
1455199|NCT00156013|B-Cell NHL
1455200|NCT00156000|Preterm Delivery
1455201|NCT00156000|Multifetal pregnancy
1455202|NCT00156000|Preterm Birth
1455203|NCT00156000|17-alpha Hydroxyprogesterone Caproate
1455204|NCT00156000|Markers of Preterm Birth
1455205|NCT00155987|Severe diffuse TBI refractory intracranial hypertension.
1455206|NCT00155974|Influenza
1455207|NCT00155974|Vaccination
1455208|NCT00155974|Hard-to-Reach Populations
1455209|NCT00155974|Urban
1455210|NCT00155974|Disadvantaged
1455211|NCT00155961|Androgens
1455212|NCT00155961|Metabolic syndrome
1455213|NCT00155961|Bone mineral density
1455214|NCT00155961|Body composition
1455215|NCT00155961|Questionnaire
1455216|NCT00155948|Ultrasonography
1455217|NCT00155948|Cervical Multifidus
1455218|NCT00155935|ovarian cancer
1455219|NCT00155935|immunotherapy
1455220|NCT00155935|folate receptor
1455221|NCT00155935|Chemotherapy
1455222|NCT00155922|Diabetes mellitus
1455223|NCT00155922|Monocyte
1455224|NCT00155922|Gene expression
1455225|NCT00155922|Monocyte gene expression
1455226|NCT00155909|Radiation Pneumonitis
1455227|NCT00155909|Radiotherapy Planning, Computer-Assisted
1455228|NCT00155896|BRCA1 gene, BRCA2 gene, DHPLC, genetic diagnosis
1455229|NCT00155870|laparoscopic assisted vaginal hysterectomy leiomyoma
1455230|NCT00155870|adenomyosis
1455231|NCT00155870|quality of life
1455232|NCT00155857|glaucoma, genetic
1455233|NCT00155831|Premature infants
1455234|NCT00155831|Kicking
1455235|NCT00155831|Stepping
1455236|NCT00155831|Walking
1455237|NCT00155831|Motor development
1455238|NCT00155831|Kinematics
1455239|NCT00155818|DISC1
1455240|NCT00155818|Schizophrenia
1455241|NCT00155818|Chromosome 1q
1455242|NCT00155818|Polymorphism detection
1455243|NCT00155818|Association study
1455244|NCT00155818|Balanced translocation
1455245|NCT00155818|DHPLC
1455246|NCT00155805|Gastroesophageal reflux disease
1455247|NCT00155805|reflux esophagitis
1455248|NCT00155805|nonerosive reflux disease
1455249|NCT00155805|Barrett’s esophagus
1455250|NCT00155805|hiatus hernia
1455251|NCT00155805|lower esophageal sphincter pressure
1455252|NCT00155805|24 hours esophageal pH monitor
1455253|NCT00155805|Helicobacter pylori
1455254|NCT00155792|ervical cancer, human papillomavirus, immunotherapy
1455255|NCT00155779|adult respiratory distress syndrome
1455256|NCT00155779|angiotensin-converting enzyme
1455257|NCT00155779|polymorphism
1455258|NCT00155766|cervical cancer, immunotherapy, DC
1455259|NCT00155753|pathological myopia, genomic
1455260|NCT00155740|ovarian cancer
1455261|NCT00155740|tumor marker
1455262|NCT00155740|mesothelin
1455263|NCT00155727|colorectal cancer, laparoscopic colectomy
1455264|NCT00155714|pulmonary arterial hypertension
1455265|NCT00155714|type-5 phosphodiesterase Inhibitors
1455266|NCT00155714|Sildenafil
1455267|NCT00155701|DISC1
1455268|NCT00155701|Schizophrenia
1455269|NCT00155701|Chromosome 1q
1455270|NCT00155701|Polymorphism detection
1455271|NCT00155701|Association study
1455272|NCT00155701|Balanced translocation
1455273|NCT00155701|DHPLC
1455274|NCT00155688|Schizophrenia
1455275|NCT00155688|linkage
1455276|NCT00155688|Taiwan
1455277|NCT00155688|Han Chinese population
1455278|NCT00155662|work hardening
1455279|NCT00155662|chronic low back pain over 3 months
1455280|NCT00155649|schizophrenia
1455281|NCT00155649|vulnerability gene
1455282|NCT00155649|positional cloning
1455283|NCT00155649|subtype definition
1455284|NCT00155649|endophenotype
1455285|NCT00155649|genetic marker
1455286|NCT00155649|genetic linkage
1455287|NCT00155649|candidate genes
1455288|NCT00155636|Schizophrenia
1455289|NCT00155623|H. pylori, 13C-urea breath test, serology, epidemiology
1455290|NCT00155610|diabetic cystopathy
1455291|NCT00155610|bladder
1455292|NCT00155610|voiding dysfunction
1455293|NCT00155610|current perception test
1455294|NCT00155597|physical therapy
1455295|NCT00155597|post surgery
1455296|NCT00155584|warts
1455297|NCT00155584|photodynamic therapy
1455298|NCT00155584|5-ALA
1455299|NCT00155571|betel nut
1455300|NCT00155571|periodontitis
1455301|NCT00155571|periodontal microbiology
1455302|NCT00155558|Colorectal Cancer, Maximum tolerated dose
1455303|NCT00155545|functional scoliosis
1455304|NCT00155545|idiopathic scoliosis
1455305|NCT00155545|leg length discrepancy
1455306|NCT00155545|motion analysis
1455307|NCT00155545|biomechanics
1455308|NCT00155532|Peripheral neuropathy;systemic lupus erythematosus
1455309|NCT00155519|Schizophrenia
1455310|NCT00155519|Latent Schizophrenia
1455311|NCT00155519|Schizotypal Disorder
1455312|NCT00155519|Psychopathology
1455313|NCT00155519|Neuropsychological Function
1455314|NCT00155519|Family History
1455315|NCT00155519|Nosology
1455316|NCT00155519|basic symptoms
1455317|NCT00155506|Schizophrenia
1455318|NCT00155506|Niacin
1455319|NCT00155506|Genotyping
1455320|NCT00155506|candidate gene
1455321|NCT00155506|one proband, normal parents and one normal sibling
1455322|NCT00155480|thoracic aorta
1455323|NCT00155480|finite element mesh
1455324|NCT00155467|CT
1455325|NCT00155467|children
1455326|NCT00155467|congenital
1455327|NCT00155454|Diabetic retinopathy
1455328|NCT00155454|Vitrectomy
1455329|NCT00155454|Postoperative vitreous hemorrahge
1455330|NCT00155454|Intravitreal gas injection
1455331|NCT00155441|sleep disorder
1455332|NCT00155441|peritoneal dialysis
1455333|NCT00155441|cognitive-behavioral therapy
1455334|NCT00155441|sleep disorder:C23.888.592.796
1455335|NCT00155441|peritoneal dialysis: F03.870.664
1455336|NCT00155428|biomodel
1455337|NCT00155428|rapid prototyping
1455338|NCT00155428|computed tomograpgy
1455339|NCT00155415|Colonoscopy
1455340|NCT00155415|Polyethylene glycol(PEG)
1455341|NCT00155415|Colon neoplasm
1455342|NCT00155415|Colon cleansing
1455343|NCT00155415|Timing
1455344|NCT00155402|fibrin glue
1455345|NCT00155402|corneal perforation
1455346|NCT00155402|pterygium
1455347|NCT00155402|conjunctiva
1455348|NCT00155402|corneal ulcer
1455349|NCT00155389|Helicobacter pylori
1455350|NCT00155389|Gastric cancer
1455351|NCT00155389|single nucleotide polymorphism
1455352|NCT00155350|atherosclerosis
1455353|NCT00155350|calcification
1455354|NCT00155350|coronary
1455355|NCT00155350|inflammation
1455356|NCT00155350|insulin
1455357|NCT00155350|plaque
1455358|NCT00155350|Coronary calcification
1455359|NCT00155350|Plaque vulnerability
1455360|NCT00154622|musculoskeletal disorder, work hardening, return to work
1455361|NCT00154596|etiology
1455362|NCT00154596|transmission
1455363|NCT00154596|vasculitis
1455364|NCT00154596|household
1455365|NCT00154596|etiology of disease
1455366|NCT00154583|cervical cancer
1455367|NCT00154583|human papillomavirus
1455368|NCT00154583|cancer vaccine
1455369|NCT00154583|normal volunteer
1455370|NCT00154570|reflux esophagitis
1455371|NCT00154570|24 hour esophageal pH
1455372|NCT00154570|electrogastrography (EGG)
1455373|NCT00154570|Running Spectral Analysis (RSA)
1455374|NCT00154557|Judo, Performance, Injury
1455375|NCT00154518|orthodontic tooth movement
1455376|NCT00154518|matrix metalloproteinase
1455377|NCT00154518|Orthodontics
1455378|NCT00154505|Scoliosis
1455379|NCT00154505|Spinal Cord Injury
1455380|NCT00154505|Lateral Trunk Support
1455381|NCT00154505|Radiography
1455382|NCT00154492|Active variceal bleeding in patients with advanced cirrhosis
1455383|NCT00154479|Cervical cancer
1455384|NCT00154479|Human papillomavirus
1455385|NCT00154479|Human leukocyte antigen
1455386|NCT00154479|immunologic response
1455387|NCT00154479|healthy volunteers
1455388|NCT00154466|Myocardial infarction, stem cell, cardiac rehabilitation
1455389|NCT00154453|Aging
1455390|NCT00154453|Orbicularis oculi
1455391|NCT00154453|Blepharoplasty
1455392|NCT00154453|Myosin heavy chain (MHC)
1455393|NCT00154440|primary gastric MALT lymphoma
1455394|NCT00154440|Helicobacter pylori
1455395|NCT00154440|eradication therapy
1455396|NCT00154440|radiation
1455397|NCT00154440|marginal zone B-cell lymphoma
1455398|NCT00154440|Mucosa-associated Lymphoid Tissue
1455399|NCT00154440|B-cell Non-Hodgkin's Lymphoma of the stomach
1455400|NCT00154440|primary gastric lymphoma
1455401|NCT00155337|leukoplakia
1455402|NCT00155337|erythroleukoplakia
1455403|NCT00155337|photodynamic therapy
1455404|NCT00155324|plantar fasciitis
1455405|NCT00155324|ultrasonographic examination
1455406|NCT00155311|orthodontic tooth movement
1455407|NCT00155311|OPG
1455408|NCT00155311|RANKL
1455409|NCT00155285|heart diseases
1455410|NCT00155285|congenital
1455411|NCT00155272|Hepatocellular Carcinoma
1455412|NCT00155272|Radiotherapy
1455413|NCT00155272|Thalidomide
1455414|NCT00155272|Dynamic contrast enhanced MRI
1455415|NCT00155259|Breast Cancer , Neoadjuvant Chemotherapy
1455416|NCT00155246|CKD, pentoxifylline
1455417|NCT00155233|analgeisa
1455418|NCT00155233|postoperatve
1455419|NCT00155233|side effects
1455420|NCT00155207|Schizophrenia
1455421|NCT00155207|endophenotype
1455422|NCT00155207|risk genetic mutation
1455423|NCT00155207|vulnerability genes
1455424|NCT00155207|affected sib-pairs
1455425|NCT00155207|case-control design
1455426|NCT00155207|animal model
1455427|NCT00155207|functional validity
1455428|NCT00155207|genetic epidemiological analysis
1455429|NCT00155181|Epstein-Barr virus
1455430|NCT00155181|Nasopharyngeal carcinoma
1455431|NCT00155181|Carcinogenesis
1455432|NCT00155168|Spinal muscular atrophy (SMA)
1455433|NCT00155168|SMN1/SMN2 gene
1455434|NCT00155168|denaturing high-performance liquid chromatography (DHPLC)
1455435|NCT00155168|multiplex PCR
1455436|NCT00155168|gene dose
1455437|NCT00155168|carrier test
1455438|NCT00155129|migraine
1455439|NCT00155129|CGRP
1455440|NCT00155129|nociceptin
1455441|NCT00155103|Hepatitis B
1455442|NCT00155103|Carcinoma, Hepatocellular
1455443|NCT00155103|Polymorphism, Genetic
1455444|NCT00155090|Magnetic resonance imaging,
1455445|NCT00155090|breast disease
1455446|NCT00155077|cervical cancer, chemoradiotherapy, angiogenesis
1455447|NCT00155064|Primary aldosteronism
1455448|NCT00155064|kallikrein
1455449|NCT00155064|aldosterone
1455450|NCT00155064|captopril
1455451|NCT00155038|Breast neoplasms
1455452|NCT00155038|breast radiography
1455453|NCT00155038|young women.
1455454|NCT00155025|Prostatic neoplasms
1455455|NCT00155025|Family history
1455456|NCT00154999|hyperbilirubinemia
1455457|NCT00154999|free radicals
1455458|NCT00154999|Health neonate
1455459|NCT00154986|invasion
1455460|NCT00154986|migration
1455461|NCT00154986|metastasis
1455462|NCT00154986|IGFBP-3
1455463|NCT00154986|transfection
1455464|NCT00154986|signal transduction.
1455465|NCT00154973|oral precancers
1455466|NCT00154973|oral cancer
1455467|NCT00154973|hypoxia-inducible factor
1455468|NCT00154960|Spinal muscular atrophy (SMA)
1455469|NCT00154960|SMN1/SMN2 gene
1455470|NCT00154960|denaturing high-performance liquid chromatography (DHPLC)
1455471|NCT00154960|multiplex PCR
1455472|NCT00154960|gene dose
1455473|NCT00154960|carrier test
1455474|NCT00154960|screen
1455475|NCT00154960|stool
1455476|NCT00154960|microsatellite
1455477|NCT00154895|minocycline
1455478|NCT00154895|pleurodesis
1455479|NCT00154895|thoracoscopy
1455596|NCT00154206|renal transplantation,
1455480|NCT00154895|primary spontaneous pneumothorax
1455481|NCT00154895|clinical trial
1455482|NCT00154882|Breast Cancer
1455483|NCT00154882|First-line
1455484|NCT00154869|Patients with dual chronic hepatitis B and C
1455485|NCT00154856|osteogenesis
1455486|NCT00154856|Ilizarov fixator
1455487|NCT00154856|motion analysis
1455488|NCT00154856|FEM
1455489|NCT00154856|bone stress
1455490|NCT00154843|Lycopene
1455491|NCT00154843|BPH
1455492|NCT00154843|PSA
1455493|NCT00154843|IPSS
1455494|NCT00154817|radiotherapy
1455495|NCT00154817|dynamic contrast enhanced MRI
1455496|NCT00154817|hepatocellular carcinoma
1455497|NCT00154804|Concurrent Chemoradiotherapy
1455498|NCT00154804|Esophageal Cancer
1455499|NCT00154791|Pancreatic adenocarcinoma
1455500|NCT00154791|Oxaliplatin
1455501|NCT00154791|Gemcitabine
1455502|NCT00154791|5-FU
1455503|NCT00154778|Combination,Chemotherapy,Advanced Gastric Cancer
1455504|NCT00154752|Rectal cancer, CCRT, Pelvic lymphadenoectomy.
1455871|NCT00152737|Surgery
1455505|NCT00154739|Combination, Chemotherapy,non-small cell lung cancer
1455506|NCT00154726|Paclitaxel-HDFL,Locally Advanced and Recurrent/Metastatic Gastric Cancer
1455507|NCT00154713|colorectal cancer
1455508|NCT00154713|dendritic cell
1455509|NCT00154713|CEA
1455510|NCT00154713|IL-2
1455511|NCT00154700|Combination,Chemotherapy,Esophageal Cancer
1455512|NCT00154687|Combination, Chemotherapy,transitional cell carcinoma
1455513|NCT00154661|glomerulonephritis
1455514|NCT00154648|MRA
1455515|NCT00154648|DSA
1455516|NCT00154648|gadovist
1455517|NCT00154648|angiography
1455518|NCT00154635|Alzheimer's disease
1455519|NCT00154635|Fo-ti
1455520|NCT00154635|Chinese herbs
1455521|NCT00154388|adenocarcinoma
1455522|NCT00154388|leiomyosarcoma
1455523|NCT00154388|angiosarcoma
1455524|NCT00154388|synovial sarcoma
1455525|NCT00154388|myelodysplastic syndrome/HES
1455526|NCT00154388|CMML
1455527|NCT00154388|multiple myeloma
1455528|NCT00154388|embryonal rhabdomyosarcoma
1455529|NCT00154388|endometrial sarcoma
1455530|NCT00154388|adenoid cystic carcinoma
1455531|NCT00154388|fibromatosis
1455532|NCT00154388|ductal invasive breast carcinoma
1455533|NCT00154388|chondrosarcoma
1455534|NCT00154388|pleural tumor
1455535|NCT00154388|brenner tumor
1455536|NCT00154388|ewing sarcoma
1455537|NCT00154388|round cell tumor
1455538|NCT00154388|seminoma
1455539|NCT00154388|thymic carcinoma
1455540|NCT00154388|malignant melanoma
1455541|NCT00154388|fibrosarcoma breast
1455542|NCT00154388|dermatofibrosarcoma protuberans
1455543|NCT00154388|DFSP
1455544|NCT00154388|ovarian stromal tumor
1455545|NCT00154388|osteosarcoma
1455546|NCT00154388|chorioideal melanoma
1455547|NCT00154388|hemangiopericytoma
1455548|NCT00154388|myelofibrosis
1455549|NCT00154388|liposarcoma
1455550|NCT00154388|SCLC
1455551|NCT00154388|small cell lung carcinoma
1455552|NCT00154388|hypereosinophilic syndrome
1455553|NCT00154388|chronic myelo-monocytic leukemia
1455554|NCT00154388|neurofibrosarcoma
1455555|NCT00154388|mesothelioma
1455556|NCT00154388|malignant mesenchymoma
1455557|NCT00154388|malignant schwannoma
1455558|NCT00154388|mast cell leukemia / mastocytosis
1455559|NCT00154388|renal cell carcinoma
1455560|NCT00154388|malignant histocytoma
1455561|NCT00154388|chordoma
1455562|NCT00154375|Open label
1455563|NCT00154375|Imatinib mesylate
1455564|NCT00154375|hydroxyurea
1455565|NCT00154375|temozolomide
1455566|NCT00154375|resistant
1455567|NCT00154375|protein tyrosine kinases
1455568|NCT00154375|adenocarcinoma
1455569|NCT00154375|glioblastoma multiforme
1455570|NCT00154375|astrocytoma
1455571|NCT00154375|brain tumor
1455572|NCT00154375|brain cancer
1455573|NCT00154362|Oxcarbazepine, conduct disorder, adolescents
1455574|NCT00154349|Ph+ALL
1455575|NCT00154349|imatinib mesylate
1455576|NCT00154336|Rheumatoid arthritis, imatinib, methotrexate
1455577|NCT00154323|Oxcarbazepine, bipolar disorder
1455578|NCT00154310|Renal transplantation, everolimus, immunosuppressants, CNI-free
1455579|NCT00154297|Renal transplantation
1455580|NCT00154297|everolimus
1455581|NCT00154297|immunosuppressants
1455582|NCT00154297|wound-healing
1455583|NCT00154284|Renal transplantation,
1455584|NCT00154284|everolimus,
1455585|NCT00154284|immunosuppressants,
1455586|NCT00154284|basiliximab,
1455587|NCT00154284|cyclosporine microemulsion discontinuation, cyclosporine microemulsion minimization
1455588|NCT00154271|Hypertension (HTN)
1455589|NCT00154271|High Sensitivity C-Reactive Protein
1455590|NCT00154258|Schizophrenia, treatment-resistant, clozapine
1455591|NCT00154245|Enteric-coated mycophenolate sodium, transplantation, de novo, cyclosporine
1455592|NCT00154232|Renal transplantation, DGF, basiliximab, EC-MPS, cyclosporine
1455593|NCT00154219|Osteoarthritis, Hip, Lumiracoxib, Efficacy, Safety
1455594|NCT00154206|Enteric-coated mycophenolate sodium,
1455595|NCT00154206|de novo,
1455597|NCT00154206|pediatric
1455598|NCT00154206|De novo pediatric renal transplantation
1455599|NCT00154193|Heart transplant, lung transplant, renal function, cyclosporine C2 Levels
1455600|NCT00154180|Perimenopause
1455601|NCT00154180|Coronary Disease
1455602|NCT00154180|Estrogen Replacement Therapy
1455603|NCT00154180|Hormone Replacement Therapy
1455604|NCT00154154|borderline personality disorder
1455605|NCT00154154|BPD
1455606|NCT00154154|treatment
1455607|NCT00154154|dialectical behavior therapy
1455608|NCT00154154|DBT
1455609|NCT00154154|general Psychiatric management
1455610|NCT00154154|GPM
1455611|NCT00154154|suicide
1455612|NCT00154154|parasuicide
1455613|NCT00154154|randomized control trials
1455614|NCT00154128|temporomandibular disorder
1455615|NCT00154128|craniomandibular disorder
1455616|NCT00154128|occlusal appliance
1455617|NCT00154128|clinical trial
1455618|NCT00154115|heart failure
1455619|NCT00154115|levosimendan
1455620|NCT00154115|cardiac surgery
1455872|NCT00152724|Physiology
1455621|NCT00154102|Metastatic colorectal cancer
1455622|NCT00154102|EGFR
1455623|NCT00154102|Irinotecan
1455624|NCT00154102|cetuximab
1455625|NCT00154102|first-line treatment
1455626|NCT00154089|cervical intraepithelial neoplasia
1455627|NCT00154089|CIN
1455628|NCT00154089|HPV
1455629|NCT00154050|restenosis
1455630|NCT00154050|intima hyperproliferation
1455631|NCT00154050|stent angioplasty
1455632|NCT00154050|pain-free walking distance
1455633|NCT00154037|vascular reactivity
1455634|NCT00154037|venodilation
1455635|NCT00154037|pulse wave velocity
1455636|NCT00154024|venoconstriction
1455637|NCT00154024|venodilation
1455638|NCT00154024|pleiotropic effects
1455639|NCT00154011|vascular reactivity, venodilation
1455640|NCT00153998|Cetuximab
1455641|NCT00153998|Oxaliplatin
1455642|NCT00153998|Irinotecan
1455643|NCT00153998|5-FU
1455644|NCT00153998|Chemotherapy
1455645|NCT00153998|Resection
1455646|NCT00153998|Liver resection
1455647|NCT00153998|Neoadjuvant
1455648|NCT00153985|Hemoglobinopathies
1455649|NCT00153985|Sickle cell anemia
1455650|NCT00153985|sickle cell-hemoglobin C disease
1455651|NCT00153985|sickle cell-B-thalassemia
1455652|NCT00153985|transfusion-dependant thalassemia
1455653|NCT00153985|allogeneic transplant
1455654|NCT00153985|nonmyeloablative transplant
1455655|NCT00153985|Stem cell transfusion
1455656|NCT00153985|graft vs. host disease
1455657|NCT00153972|Parkinson's disease
1455658|NCT00153972|Fluoro-Dopa-PET
1455659|NCT00153972|Dopamine agonists
1455660|NCT00153972|Cabergoline
1455661|NCT00153972|Surrogate marker
1455662|NCT00153972|Dopamine turnover
1455663|NCT00153946|Free Radical Scavenger
1455664|NCT00153946|Selective Thrombin Inhibitor
1455665|NCT00153946|Acute ischemic stroke (nonlacunar and noncardioembolic)
1455666|NCT00153933|Multiple Myeloma
1455667|NCT00153933|bortezomib
1455668|NCT00153933|Revlimid
1455669|NCT00153933|CC-5013
1455670|NCT00153920|multiple myeloma
1455671|NCT00153920|Velcade
1455672|NCT00153920|bortezomib
1455673|NCT00153907|Xeloda
1455674|NCT00153907|Navelbine
1455675|NCT00153907|capecitabine
1455676|NCT00153907|metastatic breast cancer
1455677|NCT00153894|Breast cancer survivor
1455678|NCT00153894|Insulin levels
1455679|NCT00153894|exercise regimen
1455680|NCT00153894|endurance training
1455681|NCT00153894|strength training
1455682|NCT00153881|Esophageal Cancer
1455683|NCT00153881|Trimodality
1455684|NCT00153881|Capecitabine
1455685|NCT00153881|Xeloda
1455686|NCT00153881|Gastro-esophageal Neoplasm
1455687|NCT00153881|Carcinoma of the Esophagus
1455688|NCT00153868|Anemia
1455689|NCT00153868|Cancer
1455690|NCT00153868|Quality of life
1455691|NCT00153868|Web-based
1455692|NCT00153868|Aranesp
1455693|NCT00153868|Darbepoetin alfa
1455694|NCT00153855|etiology
1455695|NCT00153855|pathology
1455696|NCT00153842|NSCLC
1455697|NCT00153842|Bexarotene
1455698|NCT00153842|Targretin
1455699|NCT00153829|Chronic Disease
1455700|NCT00153829|Quality of Life
1455701|NCT00153816|Colorectal neoplasms
1455702|NCT00153816|Adenomatous polyps
1455703|NCT00153803|Erlotinib
1455704|NCT00153803|Tarceva
1455705|NCT00153803|Web based
1455706|NCT00153803|Stage III NSCLC
1455707|NCT00153790|green tea
1455708|NCT00153790|weight
1455709|NCT00153790|women
1455710|NCT00153777|HIV prevention
1455711|NCT00153777|Randomized controlled trial
1455712|NCT00153777|Women
1455713|NCT00153777|Sexually transmitted infections
1455714|NCT00153777|HIV Seronegativity
1455715|NCT00153764|supplement
1455716|NCT00153764|omega-3 fatty acid
1455717|NCT00153764|Homocysteine
1455718|NCT00153764|LDL cholesterol
1455719|NCT00153751|Traditional Chinese Medicine
1455720|NCT00153738|LDL-C, phytosterol
1455721|NCT00153712|Non-NSAID
1455722|NCT00153712|Non-Hp Bleeding Peptic Ulcer
1455723|NCT00153699|Side effects
1455724|NCT00153699|Topiramate
1455725|NCT00153686|Capsule Endoscopy
1455726|NCT00153686|Mesenteric angiogram
1455727|NCT00153673|celecoxib
1455728|NCT00153673|arthritis
1455729|NCT00153673|ulcer healing
1455730|NCT00153634|Cystic fibrosis
1455731|NCT00153634|Antibiotic susceptibility testing
1455732|NCT00153634|Pseudomonas aeruginosa
1455733|NCT00153634|Chronic bronchitis
1455734|NCT00153634|Biofilms
1455735|NCT00153621|Pediatrics
1455736|NCT00153621|Chronic Kidney Failure
1455737|NCT00153621|HIV
1455738|NCT00153621|Acquired Immunodeficiency Syndrome
1455739|NCT00153621|AIDS-Associated Nephropathy
1455740|NCT00153595|Allergic rhinitis
1455741|NCT00153595|EWO1
1455742|NCT00153556|Haemophilus influenza type B
1455743|NCT00153556|Carrier state
1455744|NCT00153556|Bacterial Vaccines
1455745|NCT00153556|Anti-PRP antibody
1455746|NCT00153556|Antibody avidity
1455747|NCT00153556|Serum bacteriocidal antibody
1455748|NCT00153556|American Indians/Alaska Natives
1455749|NCT00153556|Case control study
1455750|NCT00153556|Adult vaccines
1455751|NCT00153530|primary central nervous system lymphoma
1455752|NCT00153517|Bacterial Vaginosis
1455753|NCT00153517|Metronidazole
1455754|NCT00153504|HIV
1455755|NCT00153504|AIDS
1455756|NCT00153504|Homeless
1455757|NCT00153504|Homelessness
1455758|NCT00153504|Housing
1455759|NCT00153504|HIV seropositive
1455760|NCT00153504|HIV risk behavior
1455761|NCT00153491|malaria
1455762|NCT00153491|artemether-lumefantrine
1455763|NCT00153491|co-artem
1455764|NCT00153491|Tanzania
1455765|NCT00153491|adherence
1455766|NCT00153478|Alcohol-Exposed Pregnancy
1455767|NCT00153478|Binge drinking
1455768|NCT00153478|Frequent drinking
1455769|NCT00153478|Unintended pregnancy
1455770|NCT00153478|Fetal Alcohol Syndrome
1455771|NCT00153465|Parent training
1455772|NCT00153465|Child maltreatment
1455773|NCT00153465|Motivation
1455774|NCT00153465|Program attrition
1455775|NCT00153439|parenting
1455776|NCT00153439|motivation
1455777|NCT00153439|child maltreatment
1455778|NCT00153439|program attrition
1455779|NCT00153400|CVD risk
1455780|NCT00153361|HIV Seronegativity
1455781|NCT00153361|HIV
1455782|NCT00153335|Health Risk Assessment
1455783|NCT00153335|Behavior Change
1455784|NCT00153335|Patient-Provider Interaction
1455785|NCT00153335|Employee Health
1455786|NCT00153335|Absenteeism
1455787|NCT00153335|Tobacco Use
1455788|NCT00153335|Substance Use
1455789|NCT00153335|Diet
1455790|NCT00153335|Exercise
1455791|NCT00153335|Medication Adherence
1455792|NCT00153322|Childhood Obesity
1455793|NCT00153322|Community-based Participatory Research
1455794|NCT00153322|School intervention
1455795|NCT00153322|Parental Involvement
1455796|NCT00153309|arthritis
1455797|NCT00153309|exercise
1455798|NCT00153309|physical activity
1455799|NCT00153309|physical function
1455800|NCT00153309|pain
1455801|NCT00153296|Bronchial asthma
1455802|NCT00153296|Carbamazepine
1455803|NCT00153296|Antiepileptic drugs
1455804|NCT00153296|Efficacy
1455805|NCT00153283|Bronchial asthma
1455806|NCT00153283|Gabapentin
1455807|NCT00153283|Antiepileptic drug
1455808|NCT00153283|Efficacy
1455809|NCT00153270|Bronchial asthma
1455810|NCT00153270|Sodium valproate
1455811|NCT00153270|Antiepileptic drug
1455812|NCT00153270|Efficacy
1455813|NCT00153244|Bronchial asthma
1455814|NCT00153244|Lamotrigine
1455815|NCT00153244|Antiepileptic drug
1455816|NCT00153244|Efficacy
1455817|NCT00153218|Metastatic Breast Cancer
1455818|NCT00153218|Her2neu
1455819|NCT00153218|trastuzumab
1455820|NCT00153205|medication errors
1455821|NCT00153205|medical records systems, computerized
1455822|NCT00153205|patient safety
1455823|NCT00153192|Marinol
1455824|NCT00153192|Dronabinol
1455825|NCT00153192|Cannabinoid
1455826|NCT00153192|Chronic Pain
1455827|NCT00153179|insulin resistance
1455828|NCT00153179|insulin signaling
1455829|NCT00153179|endothelium-dependent vasodilation
1455830|NCT00153166|peripheral arterial disease
1455831|NCT00153166|intermittent claudication
1455832|NCT00152945|intestinal lipoprotein
1455833|NCT00152945|very low density lipoprotein
1455834|NCT00152945|free fatty acids
1455835|NCT00152945|Apo B48 and Apo B100
1455836|NCT00152945|triglycerides
1455837|NCT00152945|Intestinal lipoprotein production
1455838|NCT00152932|Glaucoma
1455839|NCT00152932|Intraocular pressure
1455840|NCT00152932|Ocular blood flow
1455841|NCT00152932|Laser-Doppler Flowmetry
1455842|NCT00152893|HIV
1455843|NCT00152893|blood sugar > 6.1 mmol/l
1455844|NCT00152893|triglycerides > 2 mmol/l
1456085|NCT00151346|labor analgesia
1455845|NCT00152893|total cholesterol > 5.5 mmol/l or HDL < 0.9 mmol/l
1455846|NCT00152880|Hepatitis B, apoptosis
1455847|NCT00152867|quality of life
1455848|NCT00152867|dexamethasone
1455849|NCT00152867|emesis
1455850|NCT00152854|cancer pain
1455851|NCT00152854|acetaminophen
1455852|NCT00152854|opioids
1455853|NCT00152815|HIV
1455854|NCT00152815|non-alcoholic fatty liver disease
1455855|NCT00152802|liver transplant
1455856|NCT00152802|antibody response
1455857|NCT00152802|opsonophagocytic assay
1455858|NCT00152802|pneumococcal conjugate vaccine
1455859|NCT00152802|pneumococcal polysaccharide vaccine
1455860|NCT00152776|menopausal symptoms
1455861|NCT00152776|complementary medicine
1455862|NCT00152763|health anxiety
1455863|NCT00152750|Tourette's Syndrome
1455864|NCT00152750|Attention Deficit Hyperactivity Disorder
1455865|NCT00152750|Children
1455866|NCT00152750|Sleep disorders
1455867|NCT00152750|Aggression
1455868|NCT00152737|Intermittent Claudication
1455869|NCT00152737|Peripheral Vascular Diseases
1455870|NCT00152737|Blood Gas Monitoring, Transcutaneous
1455873|NCT00152724|Microcirculation
1455874|NCT00152724|Laser-Doppler Flowmetry
1455875|NCT00152659|Epilepsy
1455876|NCT00152659|Tumor
1455877|NCT00152659|Surgery
1455878|NCT00152659|Brain
1455879|NCT00152633|endothelium, hypertension, retina, AT1
1455880|NCT00152620|Inflammatory Bowel Disease (IBD)
1455881|NCT00152607|Liver Transplantation
1455882|NCT00152607|Living Donors
1455883|NCT00152607|End Stage Liver Disease
1455884|NCT00152581|HCV, genotype 1, treatment, HCV kinetics, T-cells
1455885|NCT00152568|Car Seat Check
1455886|NCT00152555|SLE,
1455887|NCT00152555|exercize,
1455888|NCT00152555|physical therapy,
1455889|NCT00152555|Systemic lupus erythematosus
1455890|NCT00152555|relaxation therapy
1455891|NCT00152542|Inhaled nitric oxide,
1455892|NCT00152542|Lung recruitment,
1455893|NCT00152542|Ventilatory approach,
1455894|NCT00152542|Neurodevelopmental outcomes,
1455895|NCT00152542|School age children
1455896|NCT00152529|Depression, educational site for depression
1455897|NCT00152516|Partial Onset Seizures
1455898|NCT00152516|levetiracetam
1455899|NCT00152516|Epilepsy
1455900|NCT00152516|Keppra
1455901|NCT00152503|Epilepsy, Partial Onset Seizures, Seletracetam
1455902|NCT00152490|Crohn's disease, CDP870, CDAI, clinical response, remission,
1455903|NCT00152490|Certolizumab Pegol, Cimzia
1455904|NCT00152477|Non-small-cell-lung cancer
1455905|NCT00152477|carboplatin
1455906|NCT00152477|paclitaxel
1455907|NCT00152477|VEGF
1455908|NCT00152477|monoclonal antibody
1455909|NCT00152464|EPAAC , atopic Children, asthma, XYZAL, levocetirizine
1455910|NCT00152451|Epilepsy: partial onset seizures, seletracetam
1455911|NCT00152438|Vasomotor symptoms
1455912|NCT00152438|Menopause
1455913|NCT00152425|Crohn's disease, CDP870, CDAI, clinical response, remission, Certolizumab Pegol, Cimzia
1455914|NCT00152412|Allergic Rhinitis, safety, levocetirizine, children
1455915|NCT00152412|Xyzal
1455916|NCT00152399|Peptic ulcer bleeding, upper intestinal bleeding, endoscopy, somatostatin
1455917|NCT00152386|Rheumatoid Arthritis, CDP870
1455918|NCT00152386|Certolizumab pegol, Cimzia
1455919|NCT00152373|Epilepsy, Partial Onset Seizures; Keppra; Levetiracetam
1455920|NCT00152360|Obesity
1455921|NCT00152360|weight loss
1455922|NCT00152360|cardiovascular risk factors
1455923|NCT00152360|Obesity and obesity related pathology
1455924|NCT00152334|Efficacy study
1455925|NCT00152334|assessment of patient outcomes following treatment
1455926|NCT00152321|osteoporosis
1455927|NCT00152321|wrist fractures
1455928|NCT00152321|quality improvement
1455929|NCT00152321|knowledge translation
1455930|NCT00152295|Postmenopausal
1455931|NCT00152295|Amenorrhea
1455932|NCT00152295|Hormone replacement therapy
1455933|NCT00152295|HRT
1455934|NCT00152295|asoprisnil
1455935|NCT00152295|Estrogen Replacement Therapy, postmenopause
1455936|NCT00152282|Postmenopausal
1455937|NCT00152282|Amenorrhea
1455938|NCT00152282|Hormone replacement therapy
1455939|NCT00152282|HRT
1455940|NCT00152282|asoprisnil
1455941|NCT00152269|Symptomatic Uterine Fibroids
1455942|NCT00152269|Excessive Uterine Bleeding
1455943|NCT00152269|Uterine Hemorrhage
1455944|NCT00152269|asoprisnil
1455945|NCT00152256|Symptomatic Uterine Fibroids
1455946|NCT00152256|Excessive Uterine Bleeding
1455947|NCT00152256|Uterine Hemorrhage
1455948|NCT00152243|Stomach Cancer
1455949|NCT00152230|Colorectal Cancer
1455950|NCT00152217|Stomach cancer
1455951|NCT00152204|Use-Effectiveness
1455952|NCT00152204|Cost Effectiveness
1455953|NCT00152204|Patient Acceptance of Health Care
1455954|NCT00152204|Drug Resistance
1455955|NCT00152204|Delivery of Health Care
1455956|NCT00152191|Breast Cancer
1455957|NCT00152178|Breast Cancer
1455958|NCT00152165|spinal motion
1455959|NCT00152165|tantalum beads
1455960|NCT00152165|DYNESYS Stabilization system
1455961|NCT00152165|spinal fusion
1455962|NCT00152165|Radiostereometric Analysis following spinal fusion
1455963|NCT00152165|Radiostereometric Analysis following surgery with DYNESYS Stabilization System
1455964|NCT00152152|spinal motion
1455965|NCT00152152|tantalum beads
1455966|NCT00152139|High risk hematologic malignancies
1455967|NCT00152139|Allogeneic stem cell transplant
1455968|NCT00152139|Matched unrelated donor transplantation
1455969|NCT00152139|Unmanipulated stem cell graft
1455970|NCT00152139|Bone marrow transplantation
1455971|NCT00152126|Autologous stem cell transplantation
1455972|NCT00152126|CD133 cell selection
1455973|NCT00152126|CliniMACS device
1455974|NCT00152126|Tumor marker
1455975|NCT00152126|Tumor purging
1455976|NCT00152113|Sickle Cell Anemia
1455977|NCT00152113|Stem Cell Transplantation
1455978|NCT00152113|Haploidentical stem cell transplant
1455979|NCT00152113|T cell depletion
1455980|NCT00152113|CliniMACS device
1455981|NCT00152100|Severe combined immunodeficiency
1455982|NCT00152100|Transplantation
1455983|NCT00152100|Haploidentical
1455984|NCT00152087|Liver cancer
1455985|NCT00152087|Brachytherapy
1455986|NCT00152074|Blood pressure
1455987|NCT00152074|Sodium
1455988|NCT00152074|Dietary
1455989|NCT00152074|Hypertension or prehypertension
1455990|NCT00152061|HIV
1455991|NCT00152061|Antiretroviral Drug Resistance
1455992|NCT00152061|Treatment Experienced
1455993|NCT00151905|bronchiolitis
1455994|NCT00151905|hypertonic saline
1455995|NCT00151879|partial seizures with or without secondary generalization
1455996|NCT00151866|Thrombopenia
1455997|NCT00151866|Platelet transfusion
1455998|NCT00151866|Increment
1455999|NCT00151866|Transfusion reactions
1456000|NCT00151866|Bleeding complication
1456001|NCT00151853|CPB
1456002|NCT00151853|oral anticoagulant therapy
1456003|NCT00151853|plasma
1456004|NCT00151853|PCC
1456005|NCT00151840|Purpura, Thrombocytopenic, Idiopathic
1456006|NCT00151840|ITP
1456007|NCT00151840|Immunoglobulin, Intravenous
1456008|NCT00151814|Olmesartan PK in children
1456009|NCT00151801|multiple sclerosis
1456010|NCT00151801|estroprogestins
1456011|NCT00151801|interferon-beta
1456012|NCT00151801|sex hormones
1456013|NCT00151801|MRI
1456014|NCT00151775|Treatment of hypertension or high blood pressure in children ages 1-16 years.
1456015|NCT00151762|Open label, Diabetes Mellitus
1456016|NCT00151762|Long term safety study, extension study
1456017|NCT00151749|Diabetes mellitus
1456018|NCT00151736|Chronic Lymphocytic Leukemia
1456019|NCT00151736|CLL
1456020|NCT00151736|Leukemia
1456021|NCT00151723|endogenous subclinical hyperthyroidism
1456022|NCT00151697|diabetes
1456023|NCT00151697|failing oral treatment
1456024|NCT00151697|weight gain
1456025|NCT00151684|Obesity
1456026|NCT00151684|Hyperinsulinism
1456027|NCT00151684|Diazoxide
1456028|NCT00151671|Surgery
1456029|NCT00151671|Liver Cancer
1456030|NCT00151671|Cirrhosis
1456031|NCT00151671|Nutrition
1456032|NCT00151658|Coronary complex lesions
1456033|NCT00151658|Restenosis
1456034|NCT00151658|Drug eluting stents
1456035|NCT00151645|Immunotherapy
1456036|NCT00151645|Renal cell carcinoma
1456037|NCT00151645|Metastasis
1456038|NCT00151645|Lymphokine activated killers
1456039|NCT00151645|Cell therapy
1456040|NCT00151632|Immunosuppression
1456041|NCT00151632|Liver transplantation
1456042|NCT00151632|Acute graft rejection
1456043|NCT00151632|Treatment combination
1456044|NCT00151619|Calcium channel blockers
1456045|NCT00151619|Heart failure
1456046|NCT00151619|Hemodynamics
1456047|NCT00151606|Infection prevention
1456048|NCT00151606|Isolation
1456049|NCT00151606|Resistant bacteria
1456050|NCT00151606|MRSA colonization
1456051|NCT00151593|Cold storage
1456052|NCT00151593|Liver transplantation
1456053|NCT00151593|Preservation solution
1456054|NCT00151580|Hepatitis C
1456055|NCT00151580|Viral recurrence
1456056|NCT00151580|Ribavirin / Interferon
1456057|NCT00151567|Ureterolithiasis
1456058|NCT00151567|Alpha1-blocker
1456059|NCT00151567|Lower ureteral stone
1456060|NCT00151554|Anxiety
1456061|NCT00151554|Intensive Care Unit (ICU)
1456062|NCT00151554|Preoperative Information
1456063|NCT00151554|Randomized Controlled Trial (RCT)
1456064|NCT00151554|Chronic heart disease
1456065|NCT00151541|Acne Vulgaris
1456066|NCT00151541|Acne
1456067|NCT00151541|Dermatology
1456068|NCT00151541|Dapsone
1456069|NCT00151541|Dapsone Topical Gel
1456070|NCT00151515|Alopecia, Balding
1456071|NCT00151476|Familial adenomatous polyposis
1456072|NCT00151476|celecoxib
1456073|NCT00151476|IRA
1456074|NCT00151476|IPAA
1456075|NCT00151411|Polycystic Ovary Syndrome (PCOS)
1456076|NCT00151411|Anovulation
1456077|NCT00151411|Elevated Testosterone
1456078|NCT00151346|Epidural
1456079|NCT00151346|Labour pain
1456080|NCT00151346|Pregnant women
1456081|NCT00151346|Epidural anesthesia
1456082|NCT00151346|Labour, Obstetric
1456083|NCT00151346|labor pain
1456084|NCT00151346|labor, obstetric
1456086|NCT00151320|diffuse large B cell
1456087|NCT00151320|mantle cell lymphoma
1456088|NCT00151307|Heart surgery
1456089|NCT00151307|Cerebral oxygen saturation
1456090|NCT00151307|Neuropsychological function
1456091|NCT00151294|Depression (mild to moderate)
1456092|NCT00151294|Affective symptoms
1456093|NCT00151294|Emotional lability
1456094|NCT00151294|Multiple Sclerosis
1456095|NCT00151281|relapsed mantle cell lymphoma
1456096|NCT00151268|Batten Disease
1456097|NCT00151268|Late Infantile Neuronal Lipofuscinosis
1456098|NCT00151268|LINCL
1456099|NCT00151255|age > 60 years
1456100|NCT00151229|isolated systolic hypertension
1456101|NCT00151229|valsartan
1456102|NCT00151229|target blood pressure
1456103|NCT00151216|Batten Disease
1456104|NCT00151216|Late Infantile Neuronal Ceroid Lipofuscinosis
1456105|NCT00151216|LINCL
1456106|NCT00151203|newly diagnosed multiple myeloma
1456107|NCT00151177|ischemic stroke
1456108|NCT00151177|CPAP ventilation
1456109|NCT00151164|transplantation tolerance
1456110|NCT00151164|thymus
1456111|NCT00151164|bone marrow
1456112|NCT00151164|pediatric heart transplantation
1456113|NCT00151151|pregnancy prevention
1456114|NCT00151151|STD prevention
1456115|NCT00151151|adolescents
1456116|NCT00151151|motivational interviewing
1456117|NCT00151151|abstinence
1456118|NCT00151151|contraception
1456119|NCT00151151|transtheoretical model
1456120|NCT00151151|sexual behavior
1456121|NCT00151138|cerebral blood flow, positron emission tomography, magnetic resonance imaging, neuropsychology
1456122|NCT00151125|Von Willebrand Disease
1456123|NCT00151125|Bleeding
1456124|NCT00151125|Coagulation
1456125|NCT00151125|Hemostatic agent
1456126|NCT00151112|nerve block
1456127|NCT00151112|regional anesthesia
1456128|NCT00151112|injuries
1456129|NCT00151112|diverse malformations
1456130|NCT00151099|preoperative nutrition
1456131|NCT00151099|postoperative nausea and vomiting
1456132|NCT00151099|Dysgnathia
1456133|NCT00151099|anesthesia
1456134|NCT00151073|Zometa
1456135|NCT00151073|Prostate Cancer
1456136|NCT00151073|Metastatic Prostate Cancer
1456137|NCT00151034|Urothelial Cancer
1456138|NCT00151034|Herceptin
1456139|NCT00151034|Advanced Urothelial Cancer
1456140|NCT00151021|Diabetes
1456141|NCT00151021|Pedometer
1456142|NCT00151021|Behavioral
1456143|NCT00151008|psoriasis
1456144|NCT00151008|bexarotene
1456145|NCT00151008|narrow band
1456146|NCT00151008|UVB
1456147|NCT00150982|psoriasis
1456148|NCT00150982|alefacept
1456149|NCT00150969|vitamin K
1456150|NCT00150969|bone mineral density
1456151|NCT00150969|post-menopausal women
1456152|NCT00150969|randomized double blind placebo controlled trial
1456153|NCT00150969|osteoporosis
1456154|NCT00150969|women's health
1456155|NCT00150943|Renal artery stenosis
1456156|NCT00150943|Stent
1456157|NCT00150943|Renal failure
1456158|NCT00150943|Atorvastatin
1456159|NCT00150943|Hypertension
1456160|NCT00150943|Atherosclerosis
1456161|NCT00150930|psoriasis
1456162|NCT00150930|ultraviolet
1456163|NCT00150930|UVB
1456164|NCT00150930|phototherapy
1456165|NCT00150930|home care
1456166|NCT00150930|narrowband
1456167|NCT00150917|Breast cancer
1456168|NCT00150917|Genetics
1456169|NCT00150917|Psychotherapy
1456170|NCT00150917|Group counselling
1456171|NCT00150917|Randomized control trial
1456172|NCT00150917|Risk counselling
1456173|NCT00150917|Women's mental health
1456174|NCT00150917|Familial breast cancer
1456175|NCT00150904|HIV
1456176|NCT00150904|hepatitis C
1456177|NCT00150904|virologic
1456178|NCT00150904|immunologic
1456179|NCT00150904|HIV / Hepatitis C coinfection
1456180|NCT00150891|Th1
1456181|NCT00150891|Th2
1456182|NCT00150891|B cell
1456183|NCT00150891|monokines
1456184|NCT00150891|kidney transplantation
1456185|NCT00150891|acute rejection
1456186|NCT00150891|chronic rejection
1456187|NCT00150878|Reduced-intensity conditioning
1456188|NCT00150878|Fludarabine
1456189|NCT00150878|Acute myeloid Leukemia
1456190|NCT00150878|Treatment-related mortality
1456191|NCT00150865|ropivacaine
1456192|NCT00150865|posterior lumbar plexus block
1456193|NCT00150865|hip arthroplasy
1456194|NCT00150865|analgesia
1456195|NCT00150865|postoperative
1456196|NCT00150852|Gastrostomy
1456197|NCT00150852|Wound infection
1456198|NCT00150852|Antibiotic prophylaxis
1456199|NCT00150839|Depressive Disorder, Major
1456200|NCT00150839|Venlafaxine
1456201|NCT00150839|Mirtazapine
1456202|NCT00150839|Double-blind RCT
1456203|NCT00150839|Magnetic resonance imaging
1456204|NCT00150839|Hippocampal volume
1456205|NCT00150826|microvascular disease
1456206|NCT00150826|women
1456207|NCT00150826|renin angiotensin system
1456208|NCT00150826|WISE
1456209|NCT00150826|ischemic heart disease
1456210|NCT00150813|Monotherapy, epilepsy
1456211|NCT00150813|Keppra, levetiracetam
1456212|NCT00150800|Brivaracetam
1456213|NCT00150800|Epilepsy
1456214|NCT00150800|Partial Onset Seizures
1456215|NCT00150800|open label
1456216|NCT00150787|Monotherapy, epilepsy
1456217|NCT00150787|Levetiracetam
1456218|NCT00150787|Keppra
1456219|NCT00150774|Idiopathic Generalized Epilepsy, Myoclonic seizures
1456220|NCT00150774|Keppra - Levetiracetam
1456221|NCT00150761|Nasal histamine provocation, facial thermography, levocetirizine, cetirizine,
1456222|NCT00150761|Xyzal, Zyrtec
1456223|NCT00150748|Generalized Epilepsy, Primary Generalized Seizures
1456224|NCT00150748|Keppra, Levetiracetam
1456225|NCT00150735|Monotherapy, epilepsy, Levetiracetam, Keppra.
1456226|NCT00150722|atherosclerosis
1456227|NCT00150722|endothelial function
1456228|NCT00150722|HDL
1456229|NCT00150722|Niacin
1456230|NCT00150722|statins
1456231|NCT00150722|Stable Atherosclerotic Vascular Disease
1456232|NCT00150709|Epilepsy, Pediatric , partial onset epilepsy,
1456233|NCT00150709|Levetiracetam (Keppra®)
1456234|NCT00150696|Osteoporosis
1456235|NCT00150696|Spinal Cord Injury
1456236|NCT00150683|Spinal Cord Injury.
1456237|NCT00150683|Osteoporosis.
1456238|NCT00150683|Standing.
1456239|NCT00150683|Vibration.
1456240|NCT00150670|Stomach cancer
1456241|NCT00150644|Fibroid Uterus
1456242|NCT00150644|Leiomyoma
1456243|NCT00150644|Uterine Fibroids
1456244|NCT00150644|Hysterectomy
1456245|NCT00150644|Asoprisnil
1456246|NCT00150631|Hypertension
1456247|NCT00150631|Prevention
1456248|NCT00150631|Offspring
1456249|NCT00150631|Prevent or delay development of hypertension
1456250|NCT00150527|antidepressive agents
1456251|NCT00150514|nasal biopsy grasspollen sublingual immunotherapy
1456252|NCT00150488|PBS
1456253|NCT00150488|Painful Bladder Syndrome
1456254|NCT00150488|Interstitial Cystitis
1456255|NCT00150488|chrondroitin sulfate
1456256|NCT00150475|Severe Acute Respiratory Syndrome
1456257|NCT00150462|Hematological
1456258|NCT00150462|Proteasome
1456259|NCT00150462|Myeloma
1456260|NCT00150462|Lymphoma
1456261|NCT00150371|(D006937)
1456262|NCT00150345|Neutropenia
1456263|NCT00150345|Fever of unknown origin
1456264|NCT00150345|Empirical treatment
1456265|NCT00150345|Voriconazole
1456266|NCT00150189|Pain
1456267|NCT00150189|Procedural Pain
1456268|NCT00150189|Sucrose
1456269|NCT00150189|Infant
1456270|NCT00150189|Newborn
1456271|NCT00150163|Androgens
1456272|NCT00150163|Bone
1456273|NCT00150163|Muscle
1456274|NCT00150163|Estrogens
1456275|NCT00150163|Fat
1456276|NCT00150163|Lipid and glucose metabolism
1456277|NCT00150150|Interventional ultrasound
1456278|NCT00150150|interstitial laser theraphy
1456279|NCT00150150|tumor ablation
1456280|NCT00150150|nodule reduction
1456281|NCT00150150|adverse effects
1456282|NCT00150150|patient satesfaction
1456283|NCT00150137|Radioiodine therapy
1456284|NCT00150137|Graves’ disease
1456285|NCT00150137|toxic nodular goiter
1456286|NCT00150137|antithyroid drugs
1456287|NCT00150137|radioprotection
1456288|NCT00150124|Radioiodine therapy
1456289|NCT00150124|Graves' disease
1456290|NCT00150124|toxic nodular goiter
1456291|NCT00150124|antithyroid drugs
1456292|NCT00150124|levothyroxine
1456293|NCT00150124|radioprotection
1456294|NCT00150111|Graves disease
1456295|NCT00150111|thyroid
1456296|NCT00150111|ophthalmopathy
1456297|NCT00150111|autoimmunity
1456298|NCT00150111|B lymphocyte depletion
1456299|NCT00150111|rituximab
1456300|NCT00150111|immunization
1456301|NCT00150098|HIV
1456302|NCT00150098|vaccines
1456303|NCT00150098|women
1456304|NCT00150098|substance use
1456305|NCT00150085|diabetes, glucose, tacrolimus, cyclosporine micro-emulsion, liver, kidney, renal
1456306|NCT00150072|chordoma
1456307|NCT00150072|imatinib
1456308|NCT00150072|PDGFR
1456309|NCT00150059|atopic dermatitis, eczema, mild to moderate, children, IGA
1456310|NCT00150046|Heart transplantation
1456311|NCT00150046|Everolimus
1456312|NCT00150046|Heart transplant recipient
1456313|NCT00150033|thyroid disease
1456314|NCT00150033|Quality of Life
1456315|NCT00150033|Patient reported outcome
1456316|NCT00150033|questionnaire
1456317|NCT00150033|Quality of Life measurement
1456318|NCT00150020|Renal/Kidney
1456319|NCT00150020|Transplantation
1456320|NCT00150020|MPA
1456321|NCT00150020|EC-MPS
1456322|NCT00150020|Renal Transplantation Patients with GI Intolerance with MMF
1456323|NCT00150007|Kidney, maintenance transplant, GI complaints, patient reported outcome
1456324|NCT00149994|Liver transplant, adults, C2 monitoring
1456325|NCT00149981|Kidney, heart, lung, liver, pancreas
1456326|NCT00149968|Renal transplantation
1456327|NCT00149968|MMF
1456328|NCT00149968|EC-MPS
1456329|NCT00149968|GI problems
1456330|NCT00149942|Enteric coated mycophenolate sodium
1456331|NCT00149942|transplantation
1456332|NCT00149942|gastrointestinal adverse events
1456333|NCT00149942|Kidney and liver transplantation patients experiencing GI AEs with current MMF treatment
1456334|NCT00149929|Renal Transplant, adults, immunosuppressant
1456335|NCT00149916|Renal Transplant, adults, immunosuppressants
1456336|NCT00149890|pediatric
1456337|NCT00149890|liver transplantation
1456338|NCT00149890|Simulect
1456339|NCT00149890|Basiliximab
1456340|NCT00149890|ciclosporin microemulsion
1456341|NCT00149890|steroid reduction
1456342|NCT00149890|pediatric liver transplantation
1456343|NCT00149877|Chronic constipation, tegaserod
1456344|NCT00149864|Renal Transplant, adults, immunosuppressant
1456345|NCT00149851|GERD, heartburn, regurgitation, reflux disease
1456346|NCT00149838|Electric Stimulation
1456347|NCT00149838|Magnetic Stimulation
1456348|NCT00149838|Prefrontal Cortex
1456349|NCT00149838|Brain
1456350|NCT00149825|Major Depressive Disorder
1456351|NCT00149825|Insomnia
1456352|NCT00149825|Sleep
1456353|NCT00149825|Mental Health
1456354|NCT00149812|Depression
1456355|NCT00149812|Child disruptive behavior
1456356|NCT00149812|Family functioning
1456357|NCT00149799|Body Dysmorphic Disorder
1456358|NCT00149799|Escitalopram
1456359|NCT00149799|Lexapro
1456360|NCT00149799|BDD
1456361|NCT00149799|Body Image
1456362|NCT00149786|Anorexia Nervosa
1456363|NCT00149786|Adolescents
1456364|NCT00149786|Family therapy
1456365|NCT00149786|Individual therapy
1456366|NCT00149773|Cognitive therapy
1456367|NCT00149773|Suicide
1456368|NCT00149773|Older men
1456369|NCT00149773|Death ideation
1456370|NCT00149773|Primary care
1456371|NCT00149760|Cognitive Behavior Therapy
1456372|NCT00149760|Treatment Outcome
1456373|NCT00149760|Health Care Utilization
1456374|NCT00149760|Somatization Disorder
1456375|NCT00149760|Somatoform Disorder
1456376|NCT00149747|Sleep
1456377|NCT00149747|Exercise
1456378|NCT00149747|Older Adults
1456379|NCT00149734|Schizophrenia
1456380|NCT00149734|Ondansetron
1456381|NCT00149734|P50 sensory gating
1456382|NCT00149734|Evoked potentials
1456383|NCT00149734|5-HT3 receptors
1456384|NCT00149734|Atypical antipsychotics
1456385|NCT00149721|hydrocephalus
1456386|NCT00149721|pituitary function
1456387|NCT00149721|shunting
1456388|NCT00149708|Growth hormone
1456389|NCT00149708|Deficiency
1456390|NCT00149708|Cardiovascular risk
1456391|NCT00149708|Body composition
1456392|NCT00149695|Obesity, beverages, weight loss, body mass index, diet
1456393|NCT00149682|Obesity
1456394|NCT00149656|Treatment Naive
1456395|NCT00149656|Multivitamins
1456396|NCT00149656|Selenium
1456397|NCT00149656|Supplementation
1456398|NCT00149656|HIV Disease Progression
1456399|NCT00149643|Cannabis
1456400|NCT00149643|MDD
1456401|NCT00149630|Opioid Dependence
1456402|NCT00149630|Substance Related Disorders
1456403|NCT00149617|Marijuana
1456404|NCT00149617|Mood Disorder
1456405|NCT00149604|metabolic syndrome
1456406|NCT00149604|hormone therapy
1456407|NCT00149604|abdominal adiposity
1456408|NCT00149604|lipolysis
1456409|NCT00149591|Myocardial infarction
1456410|NCT00149591|Viability
1456411|NCT00149591|Coronary angioplasty
1456412|NCT00149591|Prevention
1456413|NCT00149591|Prognosis
1456414|NCT00149578|pancreatic cancer
1456415|NCT00149578|gemcitabine
1456416|NCT00149578|oxaliplatin
1456417|NCT00149578|5-Fluorouracil
1456418|NCT00149578|radiation
1456419|NCT00149552|Treatment Naive
1456420|NCT00149552|Treatment Experienced
1456421|NCT00149461|Asthma Action Plans
1456422|NCT00149461|African Americans
1456423|NCT00149461|Latinos
1456424|NCT00149461|Health Literacy
1456425|NCT00149461|Asthma Education
1456426|NCT00149422|NT-proBNP
1456427|NCT00149396|Colorectal cancer metastases to liver
1456428|NCT00149396|Colorectal Cancer
1456429|NCT00149396|Colorectal Carcinoma
1456430|NCT00149396|Colorectal Tumors
1456431|NCT00149396|Colorectal Neoplasms
1456432|NCT00149396|Rectum Cancer
1456433|NCT00149396|Rectum tumors
1456434|NCT00149396|Rectum carcinoma
1456435|NCT00149396|Colon cancer
1456436|NCT00149396|Colon tumors
1456437|NCT00149396|Colon carcinoma
1456438|NCT00149396|Rectum Neoplasms
1456439|NCT00149396|Colon Neoplasms
1456440|NCT00149396|Liver Neoplasms
1456441|NCT00149396|Hepatic Neoplasms
1456442|NCT00149396|Liver Tumors
1456443|NCT00149396|Liver cancer
1456444|NCT00149396|Hepatic Cancer
1456445|NCT00149396|Hepatic tumors
1456446|NCT00149396|metastatic to the liver
1456447|NCT00149383|randomized controlled trial
1456448|NCT00149383|malaria
1456449|NCT00149383|Plasmodium falciparum
1456450|NCT00149383|thiazolidinediones
1456451|NCT00149383|rosiglitazone
1456452|NCT00149383|atovaquone-proguanil
1456453|NCT00149370|breast hypertrophy
1456454|NCT00149370|breast reduction surgery
1456455|NCT00149370|health-related quality of life
1456456|NCT00149370|Health Utilities Index
1456457|NCT00149370|HUI
1456458|NCT00149370|prospective
1456459|NCT00149370|SF-36
1456460|NCT00149370|quality-adjusted life years
1456461|NCT00149370|QALY
1456462|NCT00149357|venous thromboembolism
1456463|NCT00149357|VTE
1456464|NCT00149357|thrombophilia
1456465|NCT00149357|fetal loss
1456466|NCT00149344|cost-utility analysis;
1456467|NCT00149344|breast reduction;
1456468|NCT00149344|vertical scar mammoplasty;
1456469|NCT00149344|pedicle reduction mammoplasty
1456470|NCT00149331|Diabetes, Insulin, Education
1456471|NCT00149305|Gouty diathesis
1456472|NCT00149305|Acid uric nephrolithiasis
1456473|NCT00149279|stomach neoplasms
1456474|NCT00149279|lymph node excision
1456475|NCT00149279|abdominal aorta
1456476|NCT00149266|stomach neoplasms
1456477|NCT00149266|lymph node resection
1456478|NCT00149266|cardia
1456479|NCT00149266|thoracotomy
1456480|NCT00149253|Abdominal hysterectomy,
1456481|NCT00149253|Etoricoxib,
1456482|NCT00149253|morphine consumption,
1456483|NCT00149253|pre-emptive analgesia
1456484|NCT00149240|DYSPORT
1456485|NCT00149240|botulinum toxin A
1456486|NCT00149240|myofascial pain syndrome
1456487|NCT00149227|High risk hypertension
1456488|NCT00149227|Ischemic heart disease
1456489|NCT00149227|Angiotensin receptor blockers
1456490|NCT00149227|Cardiovascular mortality- morbidity
1456491|NCT00149227|KYOTO HEART Study
1456492|NCT00149201|gastric cancer
1456493|NCT00149201|peritoneal metastasis
1456494|NCT00149201|randomized trial
1456495|NCT00149201|5-FU
1456496|NCT00149201|MTX
1456497|NCT00149188|Growth Hormone
1456498|NCT00149175|Alzheimer's disease
1456499|NCT00149175|Dementia
1456500|NCT00149175|Phenotype-genotype correlations
1456501|NCT00149175|Candidate genes
1456502|NCT00149175|Related disorders
1456503|NCT00149162|Controlled
1456504|NCT00149162|Multicenter
1456505|NCT00149162|International
1456506|NCT00149162|Randomized study
1456507|NCT00149162|Direct individual benefit
1456508|NCT00149162|complete remission after chemotherapy
1456509|NCT00149162|non allogeneic transplanted
1456510|NCT00149149|Reduction in NSAID related gut damage
1456511|NCT00149136|Acute Lymphocytic Leukemia,
1456512|NCT00149136|Ph+,
1456513|NCT00149136|elderly patients,
1456514|NCT00149136|Imatinib
1456515|NCT00149123|Burn
1456516|NCT00149123|adrenal insufficiency
1456517|NCT00149123|hydrocortisone
1456518|NCT00149123|short corticotropin test
1456519|NCT00149110|Sleep deprivation
1456520|NCT00149110|Exercise
1456521|NCT00149110|Light therapy
1456522|NCT00149110|Major depression
1456523|NCT00149110|Bipolar depression
1456524|NCT00149110|Sleep-wake cycle
1456525|NCT00149084|The tailored H. pylori eradication therapy
1456526|NCT00149084|CYP2C19 genotype
1456527|NCT00149084|23S rRNA
1456528|NCT00149084|clarithromycin
1456529|NCT00149084|Lansoprazole
1456530|NCT00149084|Amoxicillin
1456531|NCT00149084|H. pylori infection
1456532|NCT00149071|Transcranial magnetic stimulation (TMS)
1456533|NCT00149071|Major depression
1456534|NCT00149071|treatment resistant major depression
1456535|NCT00149058|acute myocardial infarction
1456536|NCT00149058|primary angioplasty
1456537|NCT00149045|familial peripheral Neuropathy Anticipation
1456538|NCT00149032|Metastatic solid tumor
1456539|NCT00149006|Metastatic solid tumor
1456540|NCT00149006|Mismatch allogeneic cell mediated immunotherapy
1456541|NCT00148993|Tumor cell vaccine
1456542|NCT00148980|Myelodysplastic syndrome (MDS)
1456543|NCT00148980|Allogeneic stem cell transplantation
1456544|NCT00148980|Demineralized bone matrix (DBM)
1456545|NCT00148980|Bone marrow microenvironment
1456546|NCT00148967|right ventricular pacing
1456547|NCT00148967|implantable cardioverter defibrillator
1456548|NCT00148915|Osteoporosis
1456549|NCT00148915|bisphosphonates
1456550|NCT00148915|bone
1456551|NCT00147342|exercise
1456552|NCT00147342|hypoglycemia
1456553|NCT00147342|Diabetes Mellitus, Type I
1456554|NCT00147342|glucose monitoring
1456555|NCT00147316|acute stroke
1456556|NCT00147316|thrombolytic therapy
1456557|NCT00147316|tissue plasminogen activator
1456558|NCT00147290|ATP
1456559|NCT00147290|Tachycardia
1456560|NCT00147290|CRT-D
1456561|NCT00147277|ATP
1456562|NCT00147277|Thachy
1456563|NCT00147277|FVT
1456564|NCT00147264|insulin resistance, myocellular lipids, adipose tissue
1456565|NCT00147251|lowering LDL and BP below current targets
1456566|NCT00147251|LDL cholesterol treatment
1456567|NCT00147251|blood pressure treatment
1456568|NCT00147251|carotid intimal medial thickness
1456569|NCT00147251|prevent progression of CVD
1456570|NCT00147238|Bladder Cancer
1456571|NCT00147238|Genitourinary Cancer
1456572|NCT00147238|Prostate Cancer
1456573|NCT00147238|MR Lymphangiography
1456574|NCT00147238|Ferumoxtran-10
1456575|NCT00147238|SPIO
1456576|NCT00147238|Ultra-small superparamagnetic agent iron oxide
1456577|NCT00147225|Advanced Cancer
1456578|NCT00147225|Advanced Malignancy
1456579|NCT00147225|Solid Tumors
1456580|NCT00147225|Thrombocytopenia
1456581|NCT00147225|AMG 531
1456582|NCT00147225|Romiplostim
1456583|NCT00147225|Carboplatin
1456584|NCT00147225|Paraplatin
1456585|NCT00147225|Platelets
1456586|NCT00147225|Adriamycin
1456587|NCT00147225|Doxorubicin
1456588|NCT00147225|Rubex
1456589|NCT00147225|Ifosfamide
1456590|NCT00147225|Ifex
1456591|NCT00147212|Advanced Prostate Cancer
1456592|NCT00147212|Prostate Cancer
1456593|NCT00147212|Trabectedin
1456594|NCT00147212|ET 743
1456595|NCT00147212|Yondelis
1456596|NCT00147199|Pulmonary Arterial Hypertension
1456597|NCT00147147|gastric neoplasm
1456598|NCT00147147|gastrectomy
1456599|NCT00147147|adjuvant chemotherapy
1456600|NCT00147147|randomized trial
1456601|NCT00147147|T3 and T4 carcinoma of the stomach/Gastric Neoplasm
1456602|NCT00147134|colorectal cancer
1456603|NCT00147134|laparoscopic surgery
1456604|NCT00147134|randomized controlled trial
1456605|NCT00147134|oncological outcome
1456606|NCT00147121|Rituximab
1456607|NCT00147121|CHOP
1456608|NCT00147121|Bi-weekly
1456609|NCT00147121|low-grade B-cell lymphoma
1456610|NCT00147121|advanced stage
1456611|NCT00147121|follicular lymphoma
1456612|NCT00147121|G-CSF
1456613|NCT00147121|Untreated stage III/IV low-grade B-cell lymphoma
1456614|NCT00147108|Breast Cancer
1456615|NCT00147095|macrophages
1456616|NCT00147095|neutrophils
1456617|NCT00147095|lymphocytes
1456618|NCT00147082|chemokine
1456619|NCT00147082|chemokine receptor
1456620|NCT00147082|neutrophil
1456621|NCT00147082|lymphocyte
1456622|NCT00147082|monocyte
1456623|NCT00147069|sputum
1456624|NCT00147069|macrophage
1456625|NCT00147069|neutrophil
1456626|NCT00148902|tumor
1456627|NCT00148889|cervical dystonia
1456628|NCT00148889|torticollis
1456629|NCT00148889|deep brain stimulation
1456630|NCT00148889|pallidal stimulation
1456631|NCT00148889|globus pallidus internus
1456632|NCT00148876|Progression after treatment with Trastuzumab
1456633|NCT00148876|Metastatic Breast Cancer
1456634|NCT00148876|Palliative Study
1456635|NCT00148863|Hepatitis C, Chronic
1456636|NCT00148863|Interferon Alfa-2a
1456637|NCT00148863|Ribavirin
1456638|NCT00148863|Interferon-gamma, Recombinant
1456639|NCT00148850|HIV-Associated Lipodystrophy Syndrome
1456640|NCT00148850|pioglitazone
1456641|NCT00148850|HIV infections
1456642|NCT00148850|Treatment Experienced
1456643|NCT00148837|Hepatitis C, Chronic
1456644|NCT00148837|Fibrosis
1456645|NCT00148837|Interferon Alfa-2b
1456646|NCT00148837|Ribavirin
1456647|NCT00148837|Prazosin
1456648|NCT00148824|HIV infections
1456649|NCT00148824|Pneumococcal vaccines
1456650|NCT00148824|Treatment Experienced
1456651|NCT00148824|Treatment Naive
1456652|NCT00148798|Cetuximab
1456653|NCT00148798|Non small cell lung cancer
1456654|NCT00148798|Lung cancer
1456655|NCT00148798|Cisplatin/vinorelbine
1456656|NCT00148798|Monoclonal antibody
1456657|NCT00148798|Erbitux
1456658|NCT00148785|Antiretroviral drugs
1456659|NCT00148785|Pharmacokinetic
1456660|NCT00148785|Indinavir
1456661|NCT00148785|Ritonavir
1456662|NCT00148785|Fosamprenavir
1456663|NCT00148772|Prostate Cancer
1456664|NCT00148772|Rising PSA
1456665|NCT00148772|Erlotinib
1456666|NCT00148772|Tarceva
1456667|NCT00148772|Androgen Deprivation Therapy
1456668|NCT00148772|Hormone Therapy
1456669|NCT00148772|Rising Prostate Specific Antigen (PSA)
1456670|NCT00148772|Non-Metastatic Prostate Cancer
1456671|NCT00148759|Sex differences
1456672|NCT00148759|Pharmacokinetic
1456673|NCT00148759|Lopinavir/ritonavir
1456674|NCT00148759|Treatment Experienced
1456675|NCT00148759|HIV-infection
1456676|NCT00148746|atopic dermatitis, atopy
1456677|NCT00148733|Child
1456678|NCT00148733|pneumonia
1456679|NCT00148733|Zinc
1456680|NCT00148733|clinical trial
1456681|NCT00148733|Nepal
1456682|NCT00148733|nutrition
1456683|NCT00148733|therapeutic
1456684|NCT00148720|Invasive Breast Cancer
1456685|NCT00148720|Operable Breast Cancer
1456686|NCT00148720|Capecitabine
1456687|NCT00148707|Metastatic Breast Cancer
1456688|NCT00148707|HER2-negative Breast Cancer
1456689|NCT00148707|CT-2103
1456690|NCT00148707|Xyotax
1456691|NCT00148694|Cisplatin
1456692|NCT00148694|Early Stage Breast Cancer
1456693|NCT00148694|ER Negative Breast Cancer
1456694|NCT00148694|PR Negative Breast Cancer
1456695|NCT00148694|HER-2 Negative Breast Cancer
1456696|NCT00148681|HER-2 Positive breast cancer
1456697|NCT00148681|herceptin
1456698|NCT00148681|navelbine
1456699|NCT00148668|HER-2 Positive Breast Cancer
1456700|NCT00148668|herceptin
1456701|NCT00148668|navelbine
1456702|NCT00148668|taxotere
1456703|NCT00148668|carboplatin
1456704|NCT00148668|Early stage Breast Cancer
1456705|NCT00148655|educational intervention
1456706|NCT00148655|decision board
1456707|NCT00148655|DCIS
1456708|NCT00148642|ventilator-associated pneumonia
1456709|NCT00148642|nosocomial pneumonia
1456710|NCT00148629|Anemia
1456711|NCT00148629|Birth weight
1456712|NCT00148629|Neonatal Mortality
1456713|NCT00148629|Tanzania
1456714|NCT00148629|Pregnancy
1456715|NCT00148616|Memantine
1456716|NCT00148616|Negative Syndrome
1456717|NCT00148616|Schizophrenia
1456718|NCT00148616|Cognitive impairment
1456719|NCT00148603|dyspepsia
1456720|NCT00148603|eosinophilic gastroenteritis
1456721|NCT00148603|montelukast
1456722|NCT00148590|Memantine
1456723|NCT00148590|Negative syndrome
1456724|NCT00148590|Schizophrenia
1456725|NCT00148590|Cognitive impairment
1456726|NCT00148590|Glutamate
1456727|NCT00148577|Pain Relief, TENS, Acupuncture Points
1456728|NCT00148564|weight gain
1456729|NCT00148564|schizophrenia
1456730|NCT00148564|atypical antipsychotics
1456731|NCT00148551|AMD
1456732|NCT00148551|Triamcinolone
1456733|NCT00148551|Macular Degeneration
1456734|NCT00148538|Type 1 Diabetes
1456735|NCT00148538|Resistance Exercise
1456736|NCT00148538|Aerobic Exercise
1456737|NCT00148538|Exercise & Disease
1456738|NCT00148538|Exercise
1456739|NCT00148538|Diabetes
1456740|NCT00148525|automated telephony, cancer prevention, healthy diet
1456741|NCT00148473|Cervical ripening.
1456742|NCT00148473|Induction of labor.
1456743|NCT00148473|Misoprostol.
1456744|NCT00148447|negative symptoms
1456745|NCT00148447|depression
1456746|NCT00148447|ssri
1456747|NCT00148447|schizophrenia
1456748|NCT00148434|hypertension
1456749|NCT00148434|guidelines
1456750|NCT00148434|patient empowerment
1456751|NCT00148434|anxiety
1456752|NCT00148421|Non-myeloid malignancy
1456753|NCT00148421|Chemotherapy-induced anemia
1456754|NCT00148408|Asthma
1456755|NCT00148408|Placebo
1456756|NCT00148408|Education
1456757|NCT00148382|Obesity
1456758|NCT00148382|Pharmacokinetics
1456759|NCT00148382|Pharmacodynamics
1456760|NCT00148356|drug eluting stents
1456761|NCT00148356|stents
1456762|NCT00148356|angioplasty
1456763|NCT00148356|coronary artery disease
1456764|NCT00148356|total coronary occlusion
1456765|NCT00148356|coronary artery restenosis
1456766|NCT00148356|stent thrombosis
1456767|NCT00148356|vascular disease
1456768|NCT00148356|myocardial ischemia
1456769|NCT00148356|coronary artery stenosis
1456770|NCT00148343|hemiplegia
1456771|NCT00148343|hemiparesis
1456772|NCT00148343|stroke
1456773|NCT00148343|foot-drop
1456774|NCT00148343|electrical stimulation
1456775|NCT00148343|ankle-foot-orthosis
1456776|NCT00148330|Diabetic macular oedema
1456777|NCT00148330|Triamcinolone acetate
1456778|NCT00148330|Intravitreal injection
1456779|NCT00148330|Clinical trial
1456780|NCT00148330|Laser treatment
1456781|NCT00148304|Decision-making
1456782|NCT00148304|Insulin
1456783|NCT00148304|Preference
1456784|NCT00148304|Treatment Variation
1456785|NCT00148304|Provider
1456786|NCT00148304|Patient
1456787|NCT00148278|Catecholamines
1456788|NCT00148278|Septic shock
1456789|NCT00148265|Diabetic macular oedema
1456790|NCT00148265|Triamcinolone acetate
1456791|NCT00148265|Intravitreal injection
1456792|NCT00148265|Clinical trial
1456793|NCT00148265|Laser treatment
1456794|NCT00148252|Calcineurin
1456795|NCT00148252|reduction
1456796|NCT00148252|immunosuppression
1456797|NCT00148252|cyclosporine A
1456798|NCT00148252|mycophenolate mofetil
1456799|NCT00148239|SCI
1456800|NCT00148239|Caregiving
1456801|NCT00148239|Aging
1456802|NCT00148239|Disability
1456803|NCT00148239|Paralysis
1456804|NCT00148226|Decision Aid
1456805|NCT00148226|Faecal Occult Blood Test
1456806|NCT00148226|Colorectal Cancer Screening
1456807|NCT00148226|Informed Decision-making
1456808|NCT00148213|differentiated thyroid carcinoma
1456809|NCT00148213|thyroglobulin
1456810|NCT00148213|immunoassay
1456811|NCT00148213|thyroidectomy
1456812|NCT00148213|radioiodine therapy
1456813|NCT00148200|female sexual dysfunction
1456814|NCT00148200|desire
1456815|NCT00148200|arousal
1456816|NCT00148200|lubrification
1456817|NCT00148200|orgasm
1456818|NCT00148200|satisfaction
1456819|NCT00148200|pain
1456820|NCT00148187|Medication adherence
1456821|NCT00148187|Patient compliance
1456822|NCT00148187|Kidney transplant
1456823|NCT00148187|Organ rejection
1456824|NCT00148187|Allograft loss
1456825|NCT00148187|Drug monitoring
1456826|NCT00148174|Medication adherence
1456827|NCT00148174|Patient compliance
1456828|NCT00148174|Kidney transplant
1456829|NCT00148174|Organ rejection
1456830|NCT00148174|Allograft loss
1456831|NCT00148174|Drug monitoring
1456832|NCT00148161|Magnetoencephalography
1456833|NCT00148161|Auditory cortex
1456834|NCT00148161|Stuttering
1456835|NCT00148161|Non stuttering
1456836|NCT00148148|Hematopoietic Stem Cell Transplantation
1456837|NCT00148148|Caspofungin
1456838|NCT00148148|Liposomal Amphotericin B
1456839|NCT00148135|Carcinoma of Unknown Primary Site (CUP)
1456840|NCT00148122|Squamous cell cancer of the oral cavity and pharynx
1456841|NCT00148109|Unresectable/metastatic high grade soft tissue bony sarcoma
1456842|NCT00148096|asthma
1456843|NCT00148096|house dust mite
1456844|NCT00148096|allergy
1456845|NCT00148096|housing
1456846|NCT00148096|avoidance
1456847|NCT00148096|humidity
1456848|NCT00148083|Schizophrenia
1456849|NCT00148083|Cognition
1456850|NCT00148083|Clinical Trial
1456851|NCT00148057|Diet
1456852|NCT00148057|Dietary fat
1456853|NCT00148057|Breast cancer
1456854|NCT00148057|Prevention
1456855|NCT00147056|Brain tumor
1456856|NCT00147056|Brain Lesions
1456857|NCT00147056|Brain Cancer
1456858|NCT00147056|ExAblate
1456859|NCT00147043|Adult stem cells
1456860|NCT00147043|Liver disease
1456861|NCT00147043|CD34 positive cells
1456862|NCT00147030|Hypoxia
1456863|NCT00147030|Ischaemia
1456864|NCT00147030|Encephalopathy
1456865|NCT00147030|Neonatal
1456866|NCT00147030|Hypothermia
1456867|NCT00147030|Perinatal
1456868|NCT00147030|Cooling
1456869|NCT00147030|Whole/Total Body
1456870|NCT00147017|macrophage
1456871|NCT00147017|inflammation
1456872|NCT00147017|COPD
1456873|NCT00147004|Septic shock
1456874|NCT00147004|Steroids
1456875|NCT00147004|Hydrocortisone
1456876|NCT00147004|Mortality
1456877|NCT00147004|Reversal of shock
1456878|NCT00147004|Adrenal insufficiency
1456879|NCT00146952|Hemineglects
1456880|NCT00146926|Propofol
1456881|NCT00146926|pain
1456882|NCT00146926|general anesthesia
1456883|NCT00146926|prevention
1456884|NCT00146913|Chronic myeloid leukaemia
1456885|NCT00146913|resistant
1456886|NCT00146913|refractory
1456887|NCT00146913|Imatinib mesylate
1456888|NCT00146900|Traumatic Events
1456889|NCT00146900|Post-traumatic Stress Disorder
1456890|NCT00146900|Treatment (psychological)
1456891|NCT00146900|Treatment (pharmacological)
1456892|NCT00146900|Prevention
1456893|NCT00146900|SSRIs
1456894|NCT00148031|behavior modification
1456895|NCT00148031|health care service utilization
1456896|NCT00148031|hepatitis C,
1456897|NCT00148031|injection drug use
1456898|NCT00148031|therapy compliance
1456899|NCT00148031|alcoholism
1456900|NCT00148031|alcohol abuse
1456901|NCT00148031|prevention
1456902|NCT00148031|drug abuse
1456903|NCT00148031|liver disorder
1456904|NCT00148031|HCV
1456905|NCT00148031|methadone
1456906|NCT00148018|Hodgkin disease
1456907|NCT00148018|Bortezomib
1456908|NCT00148018|Relapse
1456909|NCT00148018|Lymphoma
1456910|NCT00147966|active disease despite concomitant methotrexate
1456911|NCT00147953|NHL
1456912|NCT00147953|Lymphoma
1456913|NCT00147953|Radiotherapy
1456914|NCT00147953|Rituximab
1456915|NCT00147953|Palliative treatment
1456916|NCT00147940|Allergy
1456917|NCT00147927|email
1456918|NCT00147927|internet
1456919|NCT00147927|health promotion
1456920|NCT00147927|behavior change
1456921|NCT00147927|health status
1456922|NCT00147927|work productivity
1456923|NCT00147927|healthcare cost
1456924|NCT00147927|employee
1456925|NCT00147914|Acute bacterial sinusitis
1456926|NCT00147901|CLL
1456927|NCT00147901|Immunochemotherapy
1456928|NCT00147888|Mucosal congestion
1456929|NCT00147888|Acoustic rhinometry
1456930|NCT00147888|Physiology
1456931|NCT00147875|Lymphoma
1456932|NCT00147875|Gemcitabine
1456933|NCT00147875|Advanced stages Hodgkin's lymphoma
1456934|NCT00147875|Elderly
1456935|NCT00147862|Tranexamic Acid
1456936|NCT00147862|Antifibrinolytic Agents
1456937|NCT00147862|Head and Neck Neoplasms
1456938|NCT00147862|Thromboelastography
1456939|NCT00147849|knowledge translation
1456940|NCT00147849|health care utilization
1456941|NCT00147849|economic analysis
1456942|NCT00147836|type 2 diabetes mellitus
1456943|NCT00147836|therapy
1456944|NCT00147836|sulfonylureas
1456945|NCT00147836|metformin
1456946|NCT00147836|insulin
1456947|NCT00147823|Bone formation
1456948|NCT00147823|Bone lesions
1456949|NCT00147823|Benign bone lesion
1456950|NCT00147810|telephone outreach
1456951|NCT00147810|asthma care
1456952|NCT00147797|Atherosclerosis
1456953|NCT00147797|intima media thickness
1456954|NCT00147797|aortic stiffness
1456955|NCT00147797|HIV infection
1456956|NCT00147797|Dyslipidemia
1456957|NCT00147797|Treatment Experienced
1456958|NCT00147784|Chronical Hepatitis C treatment
1456959|NCT00147784|Methadone Maintenance Treatment
1456960|NCT00147784|Pegylated Interferon and Ribavirin
1456961|NCT00147784|14 weeks treatment
1456962|NCT00147784|Genotype 2 and 3
1456963|NCT00147771|localized scleroderma
1456964|NCT00147771|morphea
1456965|NCT00147771|imiquimod
1456966|NCT00147771|pediatrics
1456967|NCT00147758|Diabetes Mellitus
1456968|NCT00147745|Mechanism of action insulin sensitivity
1456969|NCT00147732|larynx carcinoma
1456970|NCT00147732|radiotherapy
1456971|NCT00147732|carbogen
1456972|NCT00147732|nicotinamide
1456973|NCT00147719|Diabetes Mellitus
1456974|NCT00147706|Electronic Health Record
1456975|NCT00147706|Patient Portal
1456976|NCT00147706|Chronic Diseases
1456977|NCT00147693|Dementia
1456978|NCT00147693|Alzheimer Disease
1456979|NCT00147693|Lewy-Body
1456980|NCT00147693|Cost*
1456981|NCT00147693|Community (dwelling)
1456982|NCT00147693|Caregiver(s)
1456983|NCT00147693|Institutionalization
1456984|NCT00147693|Quality of life
1456985|NCT00147693|Randomized Control Trail
1456986|NCT00147693|Vascular dementia
1456987|NCT00147680|Uterine Papillary Serous Carcinoma (UPSC)
1456988|NCT00147667|COPD
1456989|NCT00147667|EXACERBATIONS
1456990|NCT00147667|AIRWAY INFLAMMATION
1456991|NCT00147537|non-small cell lung cancer
1456992|NCT00147537|chemotherapy
1456993|NCT00147537|figitumumab
1456994|NCT00147537|insulin-like growth 1 factor receptor
1456995|NCT00147537|IGF-IR
1456996|NCT00147537|monoclonal antibody
1456997|NCT00147498|oral JAK inhibitor
1456998|NCT00147498|clinical trial
1456999|NCT00147498|joint diseases
1457000|NCT00147498|anti-Inflammatory agents
1457001|NCT00147498|rheumatic diseases
1457002|NCT00147498|DMARD
1457003|NCT00147498|Antirheumatic Agents
1457004|NCT00147498|Autoimmune Diseases
1457005|NCT00147498|Immune System Diseases
1457006|NCT00147472|Head and neck
1457007|NCT00147472|Cancer
1457008|NCT00147472|Diagnosis
1457009|NCT00147472|Fluorodeoxyglucose
1457010|NCT00147472|Positron-Emission Tomography
1457011|NCT00147472|PET
1457012|NCT00147472|Oncology
1457013|NCT00147459|hepatitis B virus
1457014|NCT00147459|vaccine
1457015|NCT00147459|booster
1457016|NCT00147459|liver transplantation
1457017|NCT00147446|Stress
1457018|NCT00147446|Stress Management
1457019|NCT00147446|Behavioral Medicine
1457020|NCT00147446|Multiple Sclerosis
1457021|NCT00147446|Psychoneuroimmunology
1457022|NCT00147433|free thyroxine
1457023|NCT00147433|pregnancy
1457024|NCT00147433|fetal brain development
1457025|NCT00147433|thyroid stimulating hormone
1457026|NCT00147433|IQ
1457027|NCT00147420|Tibet
1457028|NCT00147420|Third Stage Labor
1457029|NCT00147420|Post Partum Hemorrhage
1457030|NCT00147420|Misoprostol
1457031|NCT00147420|Zhi Byed 11
1457032|NCT00147420|Global Network
1457033|NCT00147394|Risperidone
1457034|NCT00147394|Autism
1457035|NCT00147394|PDD
1457036|NCT00147394|Pervasive Developmental Disorder
1457037|NCT00147381|Campath-1H
1457038|NCT00147381|Alemtuzumab
1457039|NCT00147381|Tacrolimus
1457040|NCT00147381|renal transplantation
1457041|NCT00147381|immunosuppression
1457042|NCT00147381|prevention of acute rejection
1457043|NCT00147368|falciparum
1457044|NCT00147368|malaria
1457045|NCT00147368|arginine
1457046|NCT00147355|rIL-2-toxicity
1457047|NCT00147355|interleukin-2 therapy
1457048|NCT00147355|HIV
1457049|NCT00147355|Toxicity substudy of ESPRIT
1457050|NCT00146887|Coronary CT
1457051|NCT00146887|sensitivity
1457052|NCT00146887|specificity
1457053|NCT00146809|Multi-System-Atrophy
1457054|NCT00146809|Minocycline
1457055|NCT00146796|Malaria
1457056|NCT00146796|Diagnosis
1457057|NCT00146796|RDT
1457058|NCT00146796|Africa
1457059|NCT00146796|Tanzania
1457060|NCT00146783|intermittent preventive treatment
1457061|NCT00146783|malaria
1457062|NCT00146783|pregnancy
1457063|NCT00146783|efficacy
1457064|NCT00146783|safety
1457065|NCT00146731|malaria
1457066|NCT00146731|pregnancy
1457067|NCT00146731|treatment
1457068|NCT00146731|Africa
1457069|NCT00146731|Tanzania
1457070|NCT00146718|malaria
1457071|NCT00146718|drug resistance
1457072|NCT00146718|antimalarials
1457073|NCT00146705|chronic HBV
1457074|NCT00146705|Peginterferon
1457075|NCT00146705|long term follow-up
1457076|NCT00146692|Malaria
1457077|NCT00146692|Cost
1457078|NCT00146692|Treatment
1457079|NCT00146692|Diagnosis
1457080|NCT00146692|Africa
1457081|NCT00146692|Ghana
1457082|NCT00146679|Heart failure
1457083|NCT00146679|Ventricular arrhythmias
1457084|NCT00146679|ICD
1457085|NCT00146679|Psychoeducational intervention
1457086|NCT00146666|Peak walking time
1457087|NCT00146666|Absolute claudication distance
1457088|NCT00146666|Claudication onset time
1457089|NCT00146666|Initial claudication distance
1457090|NCT00146666|Intermittent compression
1457091|NCT00146653|pediatrics
1457092|NCT00146653|cardiopulmonary bypass
1457093|NCT00146653|surgery
1457094|NCT00146640|active disease
1457095|NCT00146640|morning stiffness of joints
1457096|NCT00146640|nighttime application of prednisone
1457097|NCT00146640|modified releae prednisone
1457098|NCT00146627|Human African Trypanosomiasis
1457099|NCT00146627|Combination
1457100|NCT00146627|Trypanosoma brucei gambiense Human African Trypanosomiasis
1457101|NCT00146614|Graft versus Host Disease
1457102|NCT00146614|GVHD
1457103|NCT00146614|Stem Cell Transplantation
1457104|NCT00146614|Tacrolimus
1457105|NCT00146614|Sirolimus
1457106|NCT00146614|Methotrexate
1457107|NCT00146614|allogeneic stem cell transplantation
1457108|NCT00146601|Fulvestrant
1457109|NCT00146601|Advanced breast cancer
1457110|NCT00146601|Invasive breast cancer
1457111|NCT00146601|Stage IV Breast Cancer
1457112|NCT00146601|Hormone Receptor-Positive Breast Cancer
1457113|NCT00146588|Breast cancer
1457114|NCT00146588|cytoxan
1457115|NCT00146588|epirubicin
1457116|NCT00146588|capecitabine
1457117|NCT00146562|adjuvant chemotherapy
1457118|NCT00146562|G-CSF
1457119|NCT00146562|pegfilgrastim
1457120|NCT00146562|darbepoetin alfa
1457121|NCT00146549|HER2-positive Breast cancer
1457122|NCT00146549|HER2 overexpressing
1457123|NCT00146549|trastuzumab
1457124|NCT00146549|Herceptin
1457125|NCT00146549|vinorelbine
1457126|NCT00146549|Navelbine
1457127|NCT00146549|Taxotere
1457128|NCT00146549|taxol
1457129|NCT00146536|ALH
1457130|NCT00146536|LCIS
1457131|NCT00146536|DCIS
1457132|NCT00146536|adjacent ipsilateral infiltrating carcinoma
1457133|NCT00146536|core needle biopsy
1457134|NCT00146536|Lobular neoplasia of the breast
1457135|NCT00146523|Psychotic Major Depression
1457136|NCT00146523|PMD
1457137|NCT00146523|Depression
1457138|NCT00146523|Major Depression
1457139|NCT00146523|Psychosis
1457140|NCT00146510|weight control
1457141|NCT00146510|compliance
1457142|NCT00146510|physical activity
1457143|NCT00146510|nutrition
1457144|NCT00146510|Health Behavior
1457145|NCT00146510|Patient Compliance
1457146|NCT00146497|Respiratory distress syndrome (RDS)
1457147|NCT00146497|Premature infants
1457148|NCT00146497|Chronic lung disease (CLD)
1457149|NCT00146497|Bronchoalveolar lavage fluid (BALF)
1457150|NCT00146497|Cytokines
1457151|NCT00146484|Diabetes Mellitus, Type 1
1457152|NCT00146484|Child
1457153|NCT00146484|Adolescent
1457154|NCT00146484|Disease Management
1457155|NCT00146484|Newly Diagnosed
1457156|NCT00146484|Hemoglobin A, Glycosylated
1457157|NCT00146471|alcohol withdrawal
1457158|NCT00146471|detoxification
1457159|NCT00146471|Inpatients
1457160|NCT00146471|alcohol dependence according to DSM-IV/ICD-10
1457161|NCT00146471|withdrawal symptoms
1457162|NCT00146458|Cervical cancer
1457163|NCT00146458|FDG-PET
1457164|NCT00146458|Lymph node metastasis
1457165|NCT00146458|Radiotherapy
1457166|NCT00146458|Chemotherapy
1457167|NCT00146445|IV drug users
1457168|NCT00146419|Treatment Experienced
1457169|NCT00146419|Treatment Naive
1457170|NCT00146406|Adolescent Health
1457171|NCT00146406|Sexually Transmitted Disease
1457172|NCT00146406|Sexual Behavior
1457173|NCT00146393|exercise
1457174|NCT00146393|physical activity
1457175|NCT00146393|physical conditioning
1457176|NCT00146393|pain
1457177|NCT00146393|physical function
1457178|NCT00146380|Prevention Mother-to-Child HIV transmission
1457179|NCT00146380|HIV Seronegativity
1457180|NCT00146367|arthritis
1457181|NCT00146367|osteoarthritis
1457182|NCT00146367|rheumatoid arthritis
1457183|NCT00146367|rheumatic disease
1457184|NCT00146367|exercise
1457185|NCT00146367|physical activity
1457186|NCT00146367|physical function
1457187|NCT00146367|disability
1457188|NCT00146354|Electronic Medical Record
1457189|NCT00146354|Electronic Results Tracking
1457190|NCT00146354|Patient Safety
1457191|NCT00146354|Post-Discharge Test Results
1457192|NCT00146315|Primary Health Care
1457193|NCT00146315|Family Practice
1457194|NCT00146315|Family Physician
1457195|NCT00146315|Exercise
1457196|NCT00146315|Coronary Heart Disease
1457197|NCT00146315|Randomized Controlled Trials
1457198|NCT00146315|Multicenter Studies
1457199|NCT00146302|Non-specific effects of vaccines
1457200|NCT00146302|Infant mortality
1457201|NCT00146302|Morbidity
1457202|NCT00146302|Low income country
1457203|NCT00146302|BCG
1457204|NCT00146302|Vaccine policy
1457205|NCT00146302|immunisation
1457206|NCT00146302|Low birth weight
1457207|NCT00146302|Tuberculin
1457208|NCT00146302|Mortality
1457209|NCT00146276|bladder cancer
1457210|NCT00146276|cystectomy
1457211|NCT00146276|gemcitabine
1457212|NCT00146276|adjuvant chemotherapy
1457213|NCT00146276|locally advanced bladder cancer
1457214|NCT00146263|mild cognitive impairment
1457215|NCT00146263|dementia
1457216|NCT00146263|Alzheimer's Disease
1457217|NCT00146263|cognitive training
1457218|NCT00146237|phenytoin
1457219|NCT00146237|SSRI failure
1457220|NCT00146237|depression
1457221|NCT00146224|anemia
1457222|NCT00146224|chronic kidney disease, CKD
1457223|NCT00146224|hemodialysis
1457224|NCT00146224|epoetin
1457225|NCT00146224|Epogen®
1457226|NCT00146211|Trial
1457227|NCT00146211|ethyl-EPA
1457228|NCT00146211|Miraxion™
1457229|NCT00146211|treating
1457230|NCT00146211|mild
1457231|NCT00146211|moderate
1457232|NCT00146211|Huntington's
1457233|NCT00146198|Postoperative pain
1457234|NCT00146198|Inguinal Hernia Repair
1457235|NCT00146198|Capsaicin
1457236|NCT00146185|Needlestick pain
1457237|NCT00146185|Venipuncture pain
1457238|NCT00146185|Procedural pain
1457239|NCT00146172|Tumors
1457240|NCT00146159|Multiple Sclerosis
1457241|NCT00146146|transsexualism
1457242|NCT00146146|testosterone
1457243|NCT00146146|dihydrotestosterone
1457244|NCT00146146|estradiol
1457245|NCT00146133|Obesity, Aging, Frailty, exercise, weight loss
1457246|NCT00146107|obesity
1457247|NCT00146107|aging
1457248|NCT00146107|exercise
1457249|NCT00146107|diet
1457250|NCT00146107|weight loss
1457251|NCT00146107|physical function
1457252|NCT00146107|Obesity in the Elderly
1457253|NCT00146094|Osteopenia
1457254|NCT00146094|osteoporosis
1457255|NCT00146094|bone mineral density
1457256|NCT00146094|HIV infection
1457257|NCT00146094|bone metabolism
1457258|NCT00146094|Treatment Naive
1457259|NCT00146081|African Americans
1457260|NCT00146081|weight control
1457261|NCT00146081|social support
1457262|NCT00146068|Clinically Isolated Syndrome
1457263|NCT00146029|Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer)
1457264|NCT00146016|Chronic Hepatitis C
1457265|NCT00146016|Amantadine
1457266|NCT00146016|Triple therapy
1457267|NCT00146003|eczema
1457268|NCT00146003|atopic dermatitis
1457269|NCT00146003|efalizumab
1457270|NCT00145990|methacholine PC20
1457271|NCT00145990|dosimeter
1457272|NCT00145990|asthma
1457273|NCT00145977|osteoporosis
1457274|NCT00145977|bone density
1457275|NCT00145977|women
1457276|NCT00145977|endocrine
1457277|NCT00145977|musculoskeletal
1457278|NCT00145977|metabolic
1457279|NCT00145964|Biliary Cirrhosis, Primary
1457280|NCT00145964|genes
1457281|NCT00145964|autoimmune disease
1457282|NCT00145938|Portopulmonary hypertension
1457283|NCT00145938|PTPH
1457284|NCT00145938|pulmonary hypertension
1457285|NCT00145938|high blood pressure in the pulmonary arteries
1457286|NCT00145925|Diabetes Mellitus, Type 2
1457287|NCT00145925|Blood Pressure
1457288|NCT00145925|Stroke
1457289|NCT00145925|MI
1457290|NCT00145912|Depression in adolescents and young adults, depression web-base activity
1457291|NCT00145886|low bone turnover; sclerosing bone disorders,
1457292|NCT00145886|osteopetrosis
1457293|NCT00145873|heart failure
1457294|NCT00145873|nesiritide
1457295|NCT00145873|heart disease
1457296|NCT00145873|cardiovascular disease
1457297|NCT00145860|Colorectal Cancer
1457298|NCT00145847|alcohol
1457299|NCT00145847|schizophrenia
1457300|NCT00145847|naltrexone
1457301|NCT00145834|psychosocial factors
1457302|NCT00145834|breastfeeding
1457303|NCT00145834|postnatal intervention
1457304|NCT00145834|health visitor
1457305|NCT00145808|Ulcerative colitis
1457306|NCT00145795|HIV
1457307|NCT00145795|HAART (Highly Active Anti-Retroviral Therapy) partial immune response
1457308|NCT00145795|no immune response
1457309|NCT00145795|Treatment Experienced
1457310|NCT00145782|multiphasic screening
1457311|NCT00145782|primary health care
1457312|NCT00145782|randomized controlled trial
1457313|NCT00145782|Risk factors
1457314|NCT00145769|rectal cancer
1457315|NCT00145769|radiotherapy
1457316|NCT00145769|chemotherapy
1457317|NCT00145769|chemoradiation
1457318|NCT00145769|adjuvant therapy
1457319|NCT00145756|Sodium Chloride
1457320|NCT00145756|Blood Pressure
1457321|NCT00145756|Cardiovascular Diseases
1457322|NCT00145756|Clinical Trial
1457323|NCT00145743|Quality of Life
1457324|NCT00145743|Breast Cancer
1457325|NCT00145743|Referee's Report
1457326|NCT00145743|Diagnostics
1457327|NCT00145743|Therapy
1457328|NCT00145730|osteoarthritis hip
1457329|NCT00145730|arthroplasty
1457330|NCT00145730|ectopic bone formation
1457331|NCT00145730|non-steroidal anti-inflammatory drugs
1457332|NCT00145730|disability
1457333|NCT00145717|Phytosterols
1457334|NCT00145717|Cholesterol
1457335|NCT00145717|China
1457336|NCT00145717|Randomized controlled trial
1457337|NCT00145704|osteopenia
1457338|NCT00145704|growth hormone deficiency
1457339|NCT00145704|pediatric malignancy
1457340|NCT00145678|borderline
1457341|NCT00145678|alcohol
1457342|NCT00145678|substance
1457343|NCT00145678|psychodynamic
1457344|NCT00145678|psychotherapy
1457345|NCT00145678|psychoanalytic
1457346|NCT00145665|FLT-PET
1457347|NCT00145665|colorectal liver metastases
1457348|NCT00145665|proliferation
1457349|NCT00145665|proliferation markers
1457350|NCT00145665|recurrence
1457351|NCT00145652|erythropoetin
1457352|NCT00145652|adjuvant iron therapy
1457353|NCT00145652|anemia
1457354|NCT00145652|cancer
1457355|NCT00145639|Osteosarcoma
1457356|NCT00145639|Treatment, Carboplatin
1457357|NCT00145626|Stem cell transplantation
1457358|NCT00145626|Stem cell transplant
1457359|NCT00145626|Haploidentical transplant
1457360|NCT00145613|Haploidentical stem cell transplant
1457361|NCT00145613|High risk hematologic malignancies
1457362|NCT00145613|Allogeneic stem cell transplant
1457363|NCT00145613|Mismatched family member stem cell donor
1457364|NCT00145600|Lymphoma
1457365|NCT00145600|Hodgkin Disease
1457366|NCT00145587|Osteopetrosis
1457367|NCT00145587|Autosomal recessive bone disease
1457368|NCT00145587|Haploidentical stem cell transplantation
1457369|NCT00145587|Allogeneic stem cell transplantation
1457370|NCT00145587|T-cell depletion methodology
1457371|NCT00145587|Miltenyi Biotec CliniMACS stem cell selection device
1457372|NCT00145574|Pediatric
1457373|NCT00145574|hypercholesterolemia
1457374|NCT00145574|colesevelam
1457375|NCT00145561|HIV
1457376|NCT00145548|COPD
1457377|NCT00145535|Glaucoma
1457378|NCT00145535|Glaucoma, open angle
1457379|NCT00145535|Intraocular Pressure
1457380|NCT00145535|Trabeculoplasty
1457381|NCT00145535|laser
1457382|NCT00145535|laser, surgery
1457383|NCT00145522|Menopause, IGF-1, HRT
1457384|NCT00145418|Non small Cell Lung Cancer Stage IIIb and IV
1457385|NCT00145405|Acromegaly
1457386|NCT00145405|somatostatin analogues
1457387|NCT00145405|lanreotide
1457388|NCT00145405|octreotide
1457389|NCT00145405|GH
1457390|NCT00145405|IGF-I
1457391|NCT00145405|injection site
1457392|NCT00145392|Polycystic ovary syndrome
1457393|NCT00145392|growth hormone
1457394|NCT00145392|insulin resistance
1457395|NCT00145392|overweight
1457396|NCT00145392|glucose metabolism
1457397|NCT00145379|type 1 diabetes mellitus
1457398|NCT00145379|insulin resistance
1457399|NCT00145379|metformin
1457400|NCT00145379|randomized, controlled study
1457401|NCT00145366|Benign nontoxic and toxic goiter
1457402|NCT00145366|rhTSH
1457403|NCT00145366|131I
1457404|NCT00145366|goiter reduction
1457405|NCT00145366|131I kinetic
1457406|NCT00145366|thyroid size
1457407|NCT00145366|patient satisfaction
1457408|NCT00145366|adverse effects
1457409|NCT00145366|BRT
1457410|NCT00145366|Graves' disease
1457411|NCT00145353|type 1 diabetes mellitus
1457412|NCT00145353|hypoglycaemia
1457413|NCT00145353|insulin profiles
1457414|NCT00145353|growth hormone
1457415|NCT00145353|cortisol
1457416|NCT00145353|glucagon
1457417|NCT00145340|polycystic ovary syndrome (PCOS)
1457418|NCT00145340|PPARgamma
1457419|NCT00145340|growth hormone
1457420|NCT00145340|insulin resistance
1457421|NCT00145340|pioglitazone
1457422|NCT00145340|glucose metabolism
1457423|NCT00145340|microarray
1457424|NCT00145327|Osteoporosis, Zoledronic Acid
1457425|NCT00145314|Metastatic colorectal cancer
1457426|NCT00145314|FLOX
1457427|NCT00145314|Cetuximab
1457428|NCT00145301|Osteoarthritis, lumiracoxib, retention on treatment, efficacy, safety
1457429|NCT00145288|hirsutism
1457430|NCT00145288|type 2 diabetes
1457431|NCT00145288|polycystic ovary syndrome
1457432|NCT00145288|metabolism
1457433|NCT00145275|zoledronic acid
1457434|NCT00145275|bisphosphonate
1457435|NCT00145275|Low bone mass
1457436|NCT00145262|critical limb ischemia
1457437|NCT00145262|bone marrow mononuclear cells
1457438|NCT00145262|angiogenesis
1457439|NCT00145262|vasculogenesis
1457440|NCT00145262|Arteriosclerosis Obliterans (ASO)
1457441|NCT00145262|Ischemic ulcers
1457442|NCT00145249|Bacterial infections, HIV infection, cryptococcal meningitis
1457443|NCT00145236|Nebivolol
1457444|NCT00145236|Beta-Blocker
1457445|NCT00145223|Wuchereria bancrofti, filariasis, Egypt
1457446|NCT00145210|Nebivolol
1457447|NCT00145197|breast cancer
1457448|NCT00145197|adjuvant treatment
1457449|NCT00145197|racial disparities
1457450|NCT00145197|Early-Stage Breast Cancer
1457451|NCT00145184|multivitamin, supplements, tuberculosis, Tanzania
1457452|NCT00145158|Melanoma
1457453|NCT00145158|Vaccine
1457454|NCT00145158|Peptide
1457455|NCT00145158|Montanide
1457456|NCT00145145|Melanoma
1457457|NCT00145145|Vaccine
1457458|NCT00145145|Peptide
1457459|NCT00145145|MAGE
1457460|NCT00145145|CpG
1457461|NCT00145132|depression
1457462|NCT00145132|β-CIT-SPECT
1457463|NCT00145132|SERT
1457464|NCT00145132|DAT
1457465|NCT00145132|neurophysiology
1457466|NCT00145132|LDAEP
1457467|NCT00145132|escitalopram
1457468|NCT00145132|SSRI
1457469|NCT00145119|Acute myocardial infarction
1457470|NCT00145119|Cardiac arrhythmias
1457471|NCT00145119|Left ventricular dysfunction
1457472|NCT00145119|Implantable loop recorder
1457473|NCT00145119|Risk stratifiers
1457474|NCT00145106|acne, tazarotene, minocycline, maintenance, retinoid, efficacy, combination
1457475|NCT00145093|Diabetes Mellitus, Type 2
1457476|NCT00145093|Chromium
1457477|NCT00145093|Saccharomyces cerevisiae
1457478|NCT00144378|gastric cancer
1457479|NCT00144378|metastatic
1457480|NCT00144378|irinotecan
1457481|NCT00144365|HIV
1457482|NCT00144365|Africa
1457483|NCT00144365|Adherence
1457484|NCT00144365|HIV viral load
1457485|NCT00144365|Sexual behavior
1457486|NCT00144365|Voluntary counseling and testing
1457487|NCT00144352|Malaria
1457488|NCT00144352|HIV
1457489|NCT00144352|AIDS
1457490|NCT00144352|drug efficacy
1457491|NCT00144352|Kenya
1457492|NCT00144352|Africa
1457493|NCT00144352|Sulfadoxine pyirmethamine
1457494|NCT00144352|fansidar
1457495|NCT00144313|vaccine
1457496|NCT00144313|hepatitis B
1457497|NCT00144313|immune memory
1457498|NCT00145028|Neoplasms
1457499|NCT00145028|Carboplatin
1457500|NCT00145028|optimal exposure
1457501|NCT00145028|AUC
1457502|NCT00145015|Intervention
1457503|NCT00145015|Adults
1457504|NCT00145015|Colorectal cancer
1457505|NCT00145015|Nutrition
1457506|NCT00145015|Fish
1457507|NCT00145015|n-3 fatty acids
1457508|NCT00145015|Apoptosis
1457509|NCT00145015|Ulcerative colitis
1457510|NCT00145015|Polyps
1457511|NCT00145015|Gastro-intestinal tract
1457512|NCT00145002|ATLL
1457513|NCT00145002|chemotherapy
1457514|NCT00145002|phase III study
1457515|NCT00145002|VCAP-AMP-VECP
1457516|NCT00145002|biweekly-CHOP
1457517|NCT00144989|Small-cell lung cancer
1457518|NCT00144989|Limited-Stage Small-Cell Lung Cancer
1457519|NCT00144989|Combined modality therapy
1457520|NCT00144989|chemotherapy
1457521|NCT00144989|radiotherapy
1457522|NCT00144989|Irinotecan
1457523|NCT00144989|Cisplatin
1457524|NCT00144976|Head and Neck Neoplasms
1457525|NCT00144976|Tarceva
1457526|NCT00144976|ENT
1457527|NCT00144911|exacerbations
1457528|NCT00144911|breathing
1457529|NCT00144911|chronic obstructive pulmonary disease
1457530|NCT00144898|Breast cancer
1457531|NCT00144898|sentinel node resection
1457532|NCT00144898|survival
1457533|NCT00144898|Breast cancer unifocal N0
1457534|NCT00144885|Endocarditis
1457535|NCT00144885|RMI
1457536|NCT00144885|Impact measure
1457537|NCT00144872|Absence Seizures
1457538|NCT00144872|EEG
1457539|NCT00144872|LTG
1457540|NCT00144872|Typical Absence Epilepsy
1457541|NCT00144872|Epilepsy
1457542|NCT00144872|LAMICTAL
1457543|NCT00144859|P38 map kinase
1457544|NCT00144859|CRP
1457545|NCT00144859|COPD
1457546|NCT00144859|safety
1457547|NCT00144846|wheezing
1457548|NCT00144846|bronchospasm
1457549|NCT00144846|albuterol sulfate HFA
1457550|NCT00144833|Protease inhibitors-experienced HIV-1 infected patients
1457551|NCT00144833|Highly-resistant HIV-1
1457552|NCT00144833|Dual boosted Pis
1457553|NCT00144833|fosamprenavir
1457554|NCT00144833|lopinavir
1457555|NCT00144820|Hyaluronan
1457556|NCT00144820|Gonarthrosis
1457557|NCT00144820|Osteoarthritis,knee
1457558|NCT00144820|Double-blinded
1457559|NCT00144820|Placebo controlled
1457560|NCT00144820|Randomised
1457561|NCT00144807|lymphoma, diffuse large B-cell
1457562|NCT00144807|rituximab
1457563|NCT00144807|chemotherapy
1457564|NCT00144807|autologous stem cell transplant
1457568|NCT00144755|lymphoma, diffuse large B-cell
1457569|NCT00144755|rituximab
1457570|NCT00144755|chemotherapy
1457571|NCT00144755|erythropoetin
1457572|NCT00144755|darbepoetin alfa
1457573|NCT00144716|Vector Control
1457574|NCT00144716|repellent
1457575|NCT00144716|ITN's
1457576|NCT00144716|malaria
1457577|NCT00144716|Amazon
1457578|NCT00144703|Graft versus host disease
1457579|NCT00144703|GVHD
1457580|NCT00144703|Stem cell transplantation
1457581|NCT00144703|sirolimus
1457582|NCT00144703|tacrolimus
1457583|NCT00144690|Epilepsy refractory partial seizures
1457584|NCT00144677|Graft versus Host Disease
1457585|NCT00144677|GVHD
1457586|NCT00144677|sirolimus
1457587|NCT00144677|tacrolimus
1457588|NCT00144677|Stem cell transplant
1457589|NCT00144443|Aerobiology
1457590|NCT00144443|Asthma
1457591|NCT00144443|Indoor Fungi
1457592|NCT00144443|Allergen
1457593|NCT00144443|Home Remediation
1457594|NCT00144430|chronic graft versus host disease
1457595|NCT00144430|graft
1457596|NCT00144430|host
1457597|NCT00144430|transplant
1457598|NCT00144430|stem cell
1457599|NCT00144430|pediatric
1457600|NCT00144430|GVH0313
1457601|NCT00144430|leukemia
1457602|NCT00144417|tuberculosis
1457603|NCT00144417|TB
1457604|NCT00144417|treatment
1457605|NCT00144417|efficacy
1457606|NCT00144417|safety
1457607|NCT00144144|Hypertension
1457608|NCT00144144|Diabetes Mellitus, Type 2
1457609|NCT00144144|Calcium Channel Blocker
1457610|NCT00144144|Angiotensin II type 1 Receptor Blocker
1457611|NCT00144131|Chemotherapy, Anemia
1457612|NCT00144131|Aranesp®, rHuEPO
1457613|NCT00144131|Chemotherapy Induced Anemia
1457614|NCT00144131|non-myeloid malignancy
1457615|NCT00144131|Non-Myeloid Malignancies
1457616|NCT00144131|Chemotherapy
1457617|NCT00144092|autologous and allogeneic stem cell transplantation
1457618|NCT00144092|low grade lymphoma
1457619|NCT00144092|mantle cell
1457620|NCT00144079|Differentiated thyroid carcinoma
1457621|NCT00144079|radiotherapy
1457622|NCT00144079|radioiodine therapy
1457623|NCT00144079|thyroidectomy
1457624|NCT00144040|Antibiotics
1457625|NCT00144040|Respiratory Infections
1457626|NCT00144040|Quality Assurance, Healthcare
1457627|NCT00144040|Professional Education
1457628|NCT00144040|Emergency Services, Medical
1457629|NCT00144040|Education, Patient
1457630|NCT00144027|patient non-adherence
1457631|NCT00144027|intervention studies
1457632|NCT00144014|Acute
1457633|NCT00144014|Ischaemic
1457634|NCT00144014|Stroke
1457635|NCT00144001|Epilepsy
1457636|NCT00144001|Pharmacoepidemiology
1457637|NCT00144001|Quality of Care
1457638|NCT00144001|Outcomes
1457639|NCT00143988|Blood Pressure
1457640|NCT00143988|Heart Rate
1457641|NCT00143988|Sexual Activity
1457642|NCT00143975|Acute myeloid leukemia
1457643|NCT00143975|gemtuzumab ozogamicin
1457644|NCT00143975|refractory disease
1457645|NCT00143962|Weight Loss
1457646|NCT00143949|diabetes
1457647|NCT00143949|nephropathy
1457648|NCT00143949|kidney
1457649|NCT00143949|retinopathy
1457650|NCT00143936|Weight Loss
1457651|NCT00143923|Cardiovascular Diseases
1457652|NCT00143923|Ethnic Groups
1457653|NCT00143923|Risk Factors
1457654|NCT00143923|Sleep disordered breathing
1457655|NCT00143923|Environmental exposures
1457656|NCT00143923|Cognitive Function
1457657|NCT00143910|Medication adherence
1457658|NCT00143910|Patient compliance
1457659|NCT00143910|Kidney transplant
1457660|NCT00143910|Organ rejection
1457661|NCT00143910|Allograft loss
1457662|NCT00143910|Drug monitoring
1457663|NCT00143858|Peripheral Pulse Volume
1457664|NCT00143832|fMRI
1457665|NCT00143819|psoriasis
1457666|NCT00143819|dry skin
1457667|NCT00143819|eczema
1457668|NCT00143819|atopic dermatitis
1457669|NCT00143806|psoriasis
1457670|NCT00143806|cyclosporine
1457671|NCT00143806|transition
1457672|NCT00143806|alefacept
1457673|NCT00143793|natruretic peptides
1457674|NCT00143793|NT-proBNP
1457675|NCT00143793|new biomarkers
1457676|NCT00143793|congestive heart failure
1457677|NCT00143793|atrial fibrillation
1457678|NCT00143793|acute myocardial infarction
1457679|NCT00143793|lung embolism
1457680|NCT00143780|Bone Marrow Transplant
1457681|NCT00143780|Pneumonia
1457682|NCT00143780|Vaccine
1457683|NCT00143780|Conjugate Vaccine
1457684|NCT00143780|Polysaccharide Vaccine
1457685|NCT00143767|Magnetic Resonance Imaging
1457686|NCT00143741|Kidney Disease, Lipitor, Atorvastatin, Allosensitization
1457687|NCT00143728|HIV
1457688|NCT00143728|Treatment Experienced
1457689|NCT00143715|Vitamin K1 (phytonadione)
1457690|NCT00143715|Randomized controlled trial
1457691|NCT00143715|Warfarin
1457692|NCT00143715|Coagulopathy
1457693|NCT00143715|Bleeding
1457694|NCT00143715|Thrombosis
1457695|NCT00143715|Warfarin associated coagulopathy defined as an INR of 4.5 and 10.0 (for entry into randomized tria) or greater than 10.0 (for entry into parallel cohort study
1457696|NCT00143715|Warfarin associated coagulopathy
1457697|NCT00143702|Elevated Lactic Acid
1457698|NCT00143676|Hyperlipidemia
1457699|NCT00143676|Dyslipidemia
1457700|NCT00143676|Drug Therapy
1457701|NCT00143663|Hypercholesterolemia
1457702|NCT00143663|Hyperlipidemia
1457703|NCT00143663|Drug Therapy
1457704|NCT00143650|Upper airway, irritation inflammation, discomfort, house dust, damp buildings, climate chamber, humans
1457705|NCT00143637|Office dust
1457706|NCT00143637|Glucan
1457707|NCT00143637|dose-response
1457708|NCT00143637|lung function
1457709|NCT00143637|peak expiratory flow
1457710|NCT00143637|inflammation
1457711|NCT00143637|perception
1457712|NCT00143624|Treatment Experienced
1457713|NCT00143624|HIV Metabolic Syndrome
1457714|NCT00143624|Atherosclerosis in HIV
1457715|NCT00143611|Shock, Septic
1457716|NCT00143611|Sepsis Syndrome
1457717|NCT00143611|Respiratory Insufficiency
1457718|NCT00143611|SIRS (Systemic Inflammatory Response Syndrome)
1457719|NCT00143611|Respiratory Failure
1457720|NCT00143611|Drug Therapy
1457721|NCT00143598|Postphlebitic Syndrome
1457722|NCT00143598|Post-Thrombotic Syndrome
1457723|NCT00143598|Elastic Stockings
1457724|NCT00143598|Stockings, Compression
1457725|NCT00143598|Randomized Controlled Trials
1457726|NCT00143598|Quality of Life
1457727|NCT00143585|angiogenesis
1457728|NCT00143585|VEGF
1457729|NCT00143572|Hematologic Diseases
1457730|NCT00143572|Anemia, Sickle Cell
1457731|NCT00143559|Allogeneic stem cell transplantation
1457732|NCT00143559|Haploidentical stem cell transplant
1457733|NCT00143559|Mismatched family member stem cell donor transplant
1457734|NCT00143559|Bone marrow transplant
1457735|NCT00143559|High risk hematological malignancies
1457736|NCT00143559|T-cell depletion methodology
1457737|NCT00143559|Miltenyi Biotec CliniMACS stem cell selection device
1457738|NCT00143546|Hepatic Veno-occlusive Disease
1457739|NCT00143533|Solid Tumors
1457740|NCT00143520|Placebo and active control dose response study of rivoglitazone in type 2 diabetics
1457741|NCT00143468|gas exchange
1457742|NCT00143468|respiratory mechanics
1457743|NCT00142454|Malignant melanoma
1457744|NCT00142454|Stages IIB-III
1457745|NCT00142441|Pulsed dye laser
1457746|NCT00142441|Keloids
1457747|NCT00142441|Hypertrophic scars
1457748|NCT00142441|Pulse width
1457749|NCT00142441|Pulse duration
1457750|NCT00142428|Hepatocellular carcinoma
1457751|NCT00142428|cetuximab
1457752|NCT00142428|Unresectable hepatocellular carcinoma
1457753|NCT00142428|Metastatic hepatocellular carcinoma
1457754|NCT00142415|Advanced Renal Cell Carcinoma
1457755|NCT00142415|Clear Cell Renal Cell Carcinoma (CCRCC)
1457756|NCT00142415|Lutetium-177
1457757|NCT00142415|177-Lu
1457758|NCT00142415|cG250
1457759|NCT00142415|DOTA-cG250
1457760|NCT00142415|Monoclonal Antibody
1457761|NCT00142402|Multiple Sclerosis
1457762|NCT00142402|Memory
1457763|NCT00142402|New Learning
1457764|NCT00142402|Fatigue
1457765|NCT00142389|gestational immunization,
1457766|NCT00142389|infant antibody,
1457767|NCT00142389|cord antibody
1457768|NCT00142363|Parkinson's disease
1457769|NCT00142363|Parkin
1457770|NCT00142363|Epilepsy
1457771|NCT00142363|Phenotype-genotype correlations
1457772|NCT00142363|Ionic channels
1457773|NCT00142350|gastric cancer
1457774|NCT00142350|5-fluorouracil
1457775|NCT00142350|irinotecan
1457776|NCT00142350|cisplatin
1457777|NCT00142350|S-1
1457778|NCT00142350|advanced or recurrent gastric cancer
1457779|NCT00142337|zidovudine
1457780|NCT00142337|didanosine
1457781|NCT00142337|Prevention of mother to child transmission of HIV
1457782|NCT00142337|nevirapine
1457783|NCT00142337|Thailand
1457784|NCT00142337|Resistance
1457785|NCT00142337|HIV
1457786|NCT00142337|Postpartum period
1457787|NCT00142324|Dementia
1457788|NCT00142311|Parkinson's disease
1457789|NCT00142311|Parkin mutations
1457790|NCT00142311|Metabolic explorations
1457791|NCT00142311|Clinics
1457792|NCT00142311|Genetics
1457793|NCT00142285|pneumonia
1457794|NCT00142285|zinc
1457795|NCT00142285|treatment
1457796|NCT00142285|efficacy
1457797|NCT00142285|children
1457798|NCT00143429|Primary Open Angle Glaucoma
1457799|NCT00143312|Invasive Fungal Infection, Allogenic Stem Cell Transplant, prophylaxis, leukemia, voriconazole
1457800|NCT00143130|phase 4, open label, seizures, epilepsy, add-on therapy, pregabalin, lyrica
1457801|NCT00143091|Major Depressive Disorder, Recurrent
1457802|NCT00143078|Obesity
1457803|NCT00143078|Reproduction
1457804|NCT00143078|Weight Loss
1457805|NCT00143078|Reproductive System
1457806|NCT00143065|Antigens, CD5
1457807|NCT00143065|Antigens, CD19
1457808|NCT00143065|Antigens, CD20
1457809|NCT00143052|Hirsutism
1457810|NCT00143052|Bone status
1457811|NCT00143052|Androgens
1457812|NCT00143052|insulin
1457813|NCT00143039|NIH
1457814|NCT00143039|Severe Symmetrical IUGR
1457815|NCT00143039|Tandem Mass Spectrometry
1457816|NCT00143039|Nonimmune Hydrops
1457817|NCT00143039|Severe Symmetrical Intrauterine Growth Restriction
1457818|NCT00143026|Parkinson's disease, levodopa, motor fluctuations
1457819|NCT00143013|type 2 diabetes
1457820|NCT00143013|microarray
1457821|NCT00143013|skeletal muscle
1457822|NCT00143013|bioinformatics
1457823|NCT00143000|Hepatitis C Virus
1457824|NCT00143000|Genotype 2
1457825|NCT00143000|Genotype 3
1457826|NCT00142987|Tegaserod, IBS-C, women, mixed bowel habit
1457827|NCT00142974|Diabetes, tegaserod, gastropathy
1457828|NCT00142961|cannabis abuse
1457829|NCT00142961|atomoxetine
1457830|NCT00142961|ADHD
1457831|NCT00142948|Heroin Abuse
1457832|NCT00142948|Heroin Addiction
1457833|NCT00142935|HIV Prevention
1457834|NCT00142935|Opioid-Related Disorders
1457835|NCT00142935|Medication Assisted Treatment
1457836|NCT00142935|Methadone
1457837|NCT00142922|Adherence
1457838|NCT00142922|self-care
1457839|NCT00142922|Behavioral intervention
1457840|NCT00142922|Diabetes
1457841|NCT00142909|Opioid dependence
1457842|NCT00142896|Opiate Addiction
1457843|NCT00142896|Opiate Dependence
1457844|NCT00142883|addiction, crack, cocaine
1457845|NCT00142870|marijuana
1457846|NCT00142870|treatment
1457847|NCT00142844|cocaine
1457848|NCT00142831|nicotine dependence
1457849|NCT00142818|Alcohol Abuse
1457850|NCT00142818|Cocaine Abuse
1457851|NCT00142805|ketones
1457852|NCT00142805|Apolipoprotein E
1457853|NCT00142805|ApoE genotype
1457854|NCT00142805|cognitive function
1457855|NCT00142805|glucose metabolism
1457856|NCT00142792|stroke
1457857|NCT00142792|recovery of function
1457858|NCT00142792|functional electrical stimulation (FES)
1457859|NCT00142779|Cocaine Addiction
1457860|NCT00142779|Cocaine Dependence
1457861|NCT00142779|Opiate Addiction
1457862|NCT00142779|Opiate Dependence
1457863|NCT00142766|Sedation
1457864|NCT00142766|Mechanical ventilation
1457865|NCT00142766|Critical illness
1457866|NCT00142766|Analgesic
1457867|NCT00142766|Opioid Withdrawal
1457868|NCT00142766|Benzodiazepine Withdrawal
1457869|NCT00142766|Nurse
1457870|NCT00142753|Hepatitis B vaccines
1457871|NCT00142753|HIV-infected adolescents
1457872|NCT00142753|Hepatitis B infection
1457873|NCT00142740|Hepatitis B vaccines
1457874|NCT00142740|HIV-infected adolescents
1457875|NCT00142740|Hepatitis B infection (negative)
1457876|NCT00142740|HIV vaccine trial
1457877|NCT00142714|sexual response
1457878|NCT00142714|sexual dysfunction in females
1457879|NCT00142714|spinal cord injury
1457880|NCT00142636|Chronic Kideny Disease
1457881|NCT00142636|Hypertension
1457882|NCT00142610|alpha tocopherol
1457883|NCT00142610|vitamin E
1457884|NCT00142610|ascorbate
1457885|NCT00142610|vitamin C
1457886|NCT00142610|antioxidant
1457887|NCT00142610|allergic
1457888|NCT00142610|asthma
1457889|NCT00142597|acupuncture
1457890|NCT00142597|analgesia
1457891|NCT00142597|pain
1457892|NCT00142597|fibromyalgia
1457893|NCT00142597|fMRI
1457894|NCT00142597|PET
1457895|NCT00142584|safety and tolerability study
1457896|NCT00142584|hypertension
1457897|NCT00142584|beta-blockers
1457898|NCT00142571|Sarcoma, Soft Tissue
1457899|NCT00142571|Gemcitabine
1457900|NCT00142571|Docetaxel
1457901|NCT00142558|Arcoxia
1457902|NCT00142532|Acupuncture
1457903|NCT00142532|Pain
1457904|NCT00142532|Lung Cancer
1457905|NCT00142532|Thoracotomy
1457906|NCT00142532|Surgery
1457907|NCT00142519|Pain
1457908|NCT00142519|Analgesics
1457909|NCT00142519|Retroperitoneal lymph node dissection
1457910|NCT00142506|Prostate Cancer
1457911|NCT00142506|Cancer of the Prostate
1457912|NCT00142506|Prostate Neoplasms
1457913|NCT00142506|Prostatic Cancer
1457914|NCT00142506|Viagra
1457915|NCT00142506|05-007
1457916|NCT00142493|Episodic Memory
1457917|NCT00142493|Amnesia
1457918|NCT00142493|Amnesia, Temporary
1457919|NCT00142480|locally advanced biliary adenocarcinoma
1457920|NCT00142480|unresectable biliary adenocarcinoma
1457921|NCT00142480|gallbladder adenocarcinoma
1457922|NCT00142480|capecitabine
1457923|NCT00142480|oxaliplatin
1457924|NCT00142480|bevacizumab
1457925|NCT00142480|Biliary tract adenocarcinoma
1457926|NCT00142467|Unresectable hepatocellular carcinoma
1457927|NCT00142467|Metastatic hepatocellular carcinoma
1457928|NCT00142467|gemcitabine
1457929|NCT00142467|oxaliplatin
1457930|NCT00142467|bevacizumab
1457931|NCT00142467|Avastin
1457932|NCT00142272|Ciprofloxacin
1457933|NCT00142272|children
1457934|NCT00142272|V.cholerae O1 and O139
1457935|NCT00142272|drug resistance
1457936|NCT00142272|Bangladesh
1457937|NCT00142259|deep brain stimulation
1457938|NCT00142259|internal globus pallidus
1457939|NCT00142259|dystonia
1457940|NCT00142246|malaria
1457941|NCT00142246|anaemia
1457942|NCT00142246|school performance
1457943|NCT00142246|education
1457944|NCT00142246|intermittent preventive treatment
1457945|NCT00142246|schools
1457946|NCT00142233|EUROPAC 2, ANTOX (vers)1.2, MGCT (Magnesiocard) Hereditary Pancreatitis, Idiopathic chronic pancreatitis.
1457947|NCT00142233|Hereditary Pancreatitis
1457948|NCT00142233|idiopathic chronic pancreatitis
1457949|NCT00142207|malaria
1457950|NCT00142207|pregnancy
1457951|NCT00142207|intermittent preventive treatment
1457952|NCT00142207|insecticide-treated nets
1457953|NCT00142194|Atrial Fibrillation
1457954|NCT00142194|Oxidative stress
1457955|NCT00142194|Cardiology
1457956|NCT00142181|Lymphoplasmacytic lymphoma
1457957|NCT00142181|Waldenstrom's Macroglobulinemia
1457958|NCT00142181|Antibody
1457959|NCT00142181|Campath-1H
1457960|NCT00142168|CC-5103 (lenalidomide)
1457961|NCT00142168|rituximab
1457962|NCT00142168|Waldenstrom's macroglobulinemia
1457963|NCT00142155|monoclonal antibody
1457964|NCT00142155|Fc gamma RIII receptor expression
1457965|NCT00142155|rituximab
1457966|NCT00142129|bortezomib
1457967|NCT00142129|Velcade
1457968|NCT00142129|Waldenstrom's macroglobulinemia
1457969|NCT00142116|thalidomide
1457970|NCT00142116|rituximab
1457971|NCT00142116|Waldenstrom's
1457972|NCT00142103|Hepatitis c virus
1457973|NCT00142103|HCV
1457974|NCT00142103|Liver
1457975|NCT00142090|Brain Concussion
1457976|NCT00142090|Post-Concussion Syndrome
1457977|NCT00142090|Closed Head Injury
1457978|NCT00142090|Traumatic Brain Injury
1457979|NCT00142090|Hypertonic Saline Solution
1457980|NCT00142077|Influenza
1457981|NCT00142077|Electronic health record
1457982|NCT00142077|Behavior modification
1457983|NCT00142064|Topical analgesia
1457984|NCT00142064|Urinary catheterization
1457985|NCT00142064|FlACC Pain Scale
1457986|NCT00142064|Lidocaine jelly
1457987|NCT00142051|sickle cell disease
1457988|NCT00142051|pain crisis
1457989|NCT00142051|vaso-occlusive crisis
1457990|NCT00142051|nitric oxide
1457991|NCT00142038|gastric cancer
1457992|NCT00142038|metastatic
1457993|NCT00142038|locally advanced
1457994|NCT00142038|docetaxel
1457995|NCT00142038|capecitabine
1457996|NCT00142025|Bronchial asthma
1457997|NCT00142025|Oxcarbazepine
1457998|NCT00142025|Antiepileptic drug
1457999|NCT00142025|Efficacy
1458000|NCT00142012|School-based
1458001|NCT00142012|Obesity
1458002|NCT00142012|Prevention
1458003|NCT00141999|vaccine
1458004|NCT00141999|hepatitis
1458005|NCT00141986|vitamin D
1458006|NCT00141986|type 1 diabetes
1458007|NCT00141986|prevention trial
1458008|NCT00141973|Procalcitonin
1458009|NCT00141973|Sepsis
1458010|NCT00141973|Corticosteroids
1458011|NCT00141960|Treatment efficacy
1458012|NCT00141960|Treatment effectiveness
1458013|NCT00141960|Gastrointestinal Diseases
1458014|NCT00141960|Reflux, Gastroesophageal
1458015|NCT00141960|GERD
1458016|NCT00141947|bexarotene
1458017|NCT00141947|schizophrenia
1458018|NCT00141947|psychopathology
1458019|NCT00141947|cognitive impairment
1458020|NCT00141947|quality of life
1458021|NCT00141947|open lable trial
1458022|NCT00141934|Rheumatoid Arthritis
1458023|NCT00141934|RA
1458024|NCT00141934|ACR20 endpoint
1458025|NCT00141934|Tender/swollen joints
1458026|NCT00141934|Improvement in pain
1458027|NCT00141934|Health assessment questionnaire
1458028|NCT00141934|Profile of mood states
1458034|NCT00141908|Hydroxyprogesterone Caproate, twins, preterm delivery
1458035|NCT00141895|Intrauterine fetal death, 2nd trimester, induction
1458036|NCT00141869|Sensory Processing
1458037|NCT00141869|Magnetoencephalogram
1458038|NCT00141869|Tourete Syndrome
1458039|NCT00141869|Trigeminal Nerve
1458040|NCT00141869|Tics
1458041|NCT00141869|TS
1458042|NCT00141869|Healthy Volunteer
1458043|NCT00141869|HV
1458044|NCT00141856|Dis Management
1458045|NCT00141856|Heart Decompensation
1458046|NCT00141856|Hearts
1458047|NCT00141856|Veteran (M01.930)
1458048|NCT00141843|Hemophilia A
1458049|NCT00141830|Rheumatoid Arthritis
1458050|NCT00141817|Gastrointestinal Reflux Disease
1458051|NCT00141804|renal transplantation
1458052|NCT00141804|immunosuppression
1458053|NCT00141804|prevention of acute rejection
1458054|NCT00141791|Asthma
1458055|NCT00141791|Anti-Asthmatic Agents
1458056|NCT00141791|Receptors
1458057|NCT00141791|Tumor Necrosis Factor
1458058|NCT00141778|atrial fibrillation
1458059|NCT00141778|cardiac surgery
1458060|NCT00141752|Cerebrovascular Accident
1458061|NCT00141752|Deglutition Disorders
1458062|NCT00141752|stroke
1458063|NCT00141752|dysphagia
1458064|NCT00141752|screening
1458065|NCT00141739|Stem Cell Transplantation
1458066|NCT00141739|Graft-Versus-Host Disease
1458067|NCT00141739|prophylaxis
1458068|NCT00141726|Enbrel
1458069|NCT00141726|Stem Cell Transplantation
1458070|NCT00141726|Lung Injury
1458071|NCT00141687|External cephalic version
1458072|NCT00141687|Cesarean section
1458073|NCT00141687|pregnancy
1458074|NCT00141687|labour
1458075|NCT00141687|Breech pregnancy
1458076|NCT00141674|Blood transfusion
1458077|NCT00141674|Age of blood
1458078|NCT00141674|Traumatic Brain Injury
1458079|NCT00141674|Cerebral Oxygen Extraction Ratio
1458080|NCT00141674|Age of transfused blood in traumatic brain injury
1458081|NCT00141661|Interventional, Alzheimer, Safety and Tolerability
1458082|NCT00141648|Osteolymphoma
1458083|NCT00141648|Chemotherapy
1458084|NCT00141648|Radiotherapy
1458085|NCT00141648|Lymphoma
1458086|NCT00141635|Quality of Life
1458087|NCT00141635|Breast Cancer
1458088|NCT00141635|Referee's Report
1458089|NCT00141635|Diagnostics
1458090|NCT00141635|Therapy
1458091|NCT00141622|Endothelial dysfunction
1458092|NCT00141622|ADMA
1458093|NCT00141622|DDAH
1458094|NCT00141622|Sodium
1458095|NCT00141609|End-stage renal failure
1458096|NCT00141609|Haemodialysis
1458097|NCT00141609|Sodium
1458098|NCT00141609|Blood Pressure
1458099|NCT00141596|Resistant Hypertension
1458100|NCT00141596|Extracellular Fluid Volume
1458101|NCT00141583|Renin-angiotensin system
1458102|NCT00141583|ACE Inhibitor
1458103|NCT00141583|Angiotensin Receptor Blocker
1458104|NCT00141570|Menopause; Postmenopause; Estrogen; Hormone Therapy
1458105|NCT00141557|Menopause; Postmenopause; Estrogen; Hormone Therapy
1458106|NCT00141544|Menopause; Postmenopause; Estrogen; Hormone Therapy
1458107|NCT00141531|Bladder cancer
1458108|NCT00141531|Superficial
1458109|NCT00141531|Carcinoma in situ
1458110|NCT00141531|Intravesical instillation
1458111|NCT00141531|Chemotherapy
1458112|NCT00141531|Adjuvant
1458113|NCT00141518|Health economics,Quality of life
1458114|NCT00141505|drug interaction
1458115|NCT00141505|pharmacokinetics
1458116|NCT00141505|valproate
1458117|NCT00141505|bipolar
1458118|NCT00141492|Type 2 diabetes
1458119|NCT00141492|hypogonadism
1458120|NCT00141492|testosterone
1458121|NCT00141492|glycosylated hemoglobin A1C
1458122|NCT00141479|Treatment interruption on reinitiation
1458123|NCT00141479|Schizophrenia
1458124|NCT00141479|Schizoaffective disorder
1458125|NCT00141466|Hereditary colorectal cancer
1458126|NCT00141466|Microsatellite instability
1458127|NCT00141466|Physician roles
1458128|NCT00141466|Health care implementation
1458129|NCT00141466|Intervention
1458130|NCT00141453|angiotensin II type I receptor blockers
1458131|NCT00141453|diabetic nephropathy
1458132|NCT00141453|end-stage renal disease
1458133|NCT00141453|renal failure
1458134|NCT00141453|type 2 diabetes
1458135|NCT00141453|olmesartan medoxomil
1458136|NCT00141440|gas exchange
1458137|NCT00141440|pressure support ventilation
1458138|NCT00141440|respiratory mechanics
1458139|NCT00141440|COPD patients
1458140|NCT00140374|Prostate
1458141|NCT00140374|Cancer
1458142|NCT00140374|Vaccine
1458143|NCT00140374|GVAX
1458144|NCT00140374|Allogeneic cells
1458145|NCT00140361|malaria
1458146|NCT00140361|sulfadoxine-pyrimethamine
1458147|NCT00140361|sulfadoxine-pyrimethamine plus artsunate
1458148|NCT00140361|lumefantrine plus artemether
1458149|NCT00140361|combination therapy
1458150|NCT00140348|Prostate
1458151|NCT00140348|Cancer
1458152|NCT00140348|Advanced Prostate Cancer
1458153|NCT00140348|Metastatic
1458154|NCT00140348|Hormone-refractory
1458155|NCT00140348|GVAX
1458156|NCT00140348|Vaccine
1458157|NCT00140348|Allogeneic cells
1458158|NCT00140335|handwashing
1458159|NCT00140335|communicable diseases
1458160|NCT00140335|health education
1458161|NCT00140322|falls
1458162|NCT00140322|injury
1458163|NCT00140322|elderly
1458164|NCT00140309|TB
1458165|NCT00140309|Pulmonary Tuberculosis
1458166|NCT00140309|Tuberculosis
1458167|NCT00140309|Pulmonary TB
1458168|NCT00140283|Effectiveness
1458169|NCT00140283|Educational intervention
1458170|NCT00140283|Primary health care
1458171|NCT00141297|Advanced cancer
1458172|NCT00141271|Bipolar I Disorder
1458173|NCT00141115|Substance-induced anxiety disorder
1458174|NCT00141102|GI events in high risk GI arthritis patients
1458175|NCT00141089|Male patients, chronic constipation, tegaserod
1458176|NCT00141076|obesity
1458177|NCT00141076|glycemic index
1458178|NCT00141076|insulin resistance
1458179|NCT00141076|cardiovascular disease
1458180|NCT00141076|diabetes
1458181|NCT00141063|ADHD, children
1458182|NCT00141050|ADHD, children
1458183|NCT00141037|Organ Rejection
1458184|NCT00141037|Corticosteroids
1458185|NCT00141037|Child
1458186|NCT00141037|Adolescent
1458187|NCT00141037|Immunosuppression
1458188|NCT00141037|Steroids
1458189|NCT00141024|HIV Seronegativity
1458190|NCT00141024|HIV Preventive Vaccine
1458191|NCT00141011|Stroke
1458192|NCT00141011|Fibrinogen
1458193|NCT00141011|Reperfusion
1458194|NCT00141011|Thrombolysis
1458195|NCT00140998|Turner syndrome
1458196|NCT00140998|Hypogonadism
1458197|NCT00140998|GH
1458198|NCT00140998|Estrogen
1458199|NCT00140998|Estrogen Patches
1458200|NCT00140998|IGF-I
1458201|NCT00140998|Body Composition
1458202|NCT00140998|Protein Metabolism
1458203|NCT00140998|Lipolysis
1458204|NCT00140972|Arcoxia
1458205|NCT00140894|Osteoarthritis
1458206|NCT00140894|Cancer Pain
1458207|NCT00140868|Colonic Pseudo-Obstruction
1458208|NCT00140868|Large bowel obstruction
1458209|NCT00140868|Stents
1458210|NCT00140868|Laparotomy
1458211|NCT00140868|Palliative Surgery
1458212|NCT00140868|Surgery, Palliative
1458213|NCT00140868|Palliative Therapy
1458214|NCT00140855|synovial sarcoma
1458215|NCT00140855|immunotherapy
1458216|NCT00140855|cancer-testis antigen
1458217|NCT00140855|cancer-germ cell antigen
1458218|NCT00140855|soft tissue sarcoma
1458219|NCT00140855|SYT-SSX chromosomal translocation
1458220|NCT00140842|Obesity, adolescent, ghrelin, growth hormone, cortisol
1458221|NCT00140829|Cerebellar ataxias
1458222|NCT00140829|Spastic paraplegias
1458223|NCT00140829|Mutations spectrum
1458224|NCT00140829|Linkage studies
1458225|NCT00140829|Genetic counselling
1458226|NCT00140790|Cardiorenal syndrome
1458227|NCT00140790|Renal dysfunction
1458228|NCT00140790|Cardiovascular events
1458229|NCT00140790|Valsartan
1458230|NCT00140764|Genitourinary symptoms
1458231|NCT00140751|HIV-1
1458232|NCT00140751|Treatment simplification
1458233|NCT00140751|Lopinavir/ritonavir
1458234|NCT00140751|Treatment Experienced
1458235|NCT00140751|HIV Seropositivity
1458236|NCT00140725|HBeAg-positive
1458237|NCT00140725|chronic
1458238|NCT00140725|Hepatitis B
1458239|NCT00140725|lamivudine
1458240|NCT00140725|seroconversion
1458241|NCT00140725|Chronic Hepatitis B
1458242|NCT00140712|Adolescent
1458243|NCT00140712|RLS
1458244|NCT00140712|Periodic Limb Movements of Sleep
1458245|NCT00140712|PLMS
1458246|NCT00140712|Ropinirole
1458247|NCT00140699|Children, Hearing loss, Balance control, Sensory inputs
1458248|NCT00140660|lymphoma, diffuse large B-cell
1458249|NCT00140660|rituximab
1458250|NCT00140660|chemotherapy
1458251|NCT00140647|atherosclerosis
1458252|NCT00140647|carotid artery
1458253|NCT00140647|ramipril
1458254|NCT00140647|rosiglitazone
1458255|NCT00140647|impaired glucose tolerance
1458256|NCT00140647|impaired fasting glucose
1458257|NCT00140647|diabetes prevention
1458258|NCT00140621|cardiac fabry disease
1458259|NCT00140608|sinus
1458260|NCT00140595|Lymphoma, diffuse large B-cell
1458261|NCT00140595|rituximab
1458262|NCT00140595|chemotherapy
1458263|NCT00140582|lymphoma
1458264|NCT00140582|follicular
1458265|NCT00140582|maintenance
1458266|NCT00140569|follicular lymphoma
1458267|NCT00140569|CHVP + interferon
1458268|NCT00140569|fludarabine
1458269|NCT00140569|autotransplant
1458270|NCT00140556|head and neck cancer
1458271|NCT00140556|targeted therapy
1458272|NCT00140556|bevacizumab
1458273|NCT00140556|erlotinib
1458274|NCT00140556|Tarceva
1458275|NCT00140556|radiotherapy
1458276|NCT00140556|concurrent chemotherapy
1458277|NCT00140556|pharynx cancer
1458278|NCT00140556|tonsil cancer
1458279|NCT00140556|hyperfractionation
1458280|NCT00140556|angiogenesis
1458281|NCT00140556|epidermal growth factor
1458282|NCT00140556|vascular endothelial growth factor
1458283|NCT00140556|magnetic resonance spectroscopy
1458284|NCT00140556|cancer of the head and neck
1458285|NCT00140556|upper aerodigestive tract neoplasms
1458286|NCT00140556|pharynx neoplasms
1458287|NCT00140543|simultaneous pancreas/kidney transplantation
1458288|NCT00140543|Immunosuppression
1458289|NCT00140517|Plasmodium falciparum
1458290|NCT00140517|malaria
1458291|NCT00140517|pregnancy
1458292|NCT00140517|resistance
1458293|NCT00140504|Adverse drug event
1458294|NCT00140504|Patient safety
1458295|NCT00140504|Internet portal
1458296|NCT00140504|PatientSite
1458297|NCT00140504|Preventive health
1458298|NCT00140504|Primary care
1458299|NCT00140491|Non-Arteritic Anterior Ischemic Optic Neuropathy
1458300|NCT00140491|Visual Field Defect
1458301|NCT00140491|Neuroplasticity
1458302|NCT00140491|Rehabilitation
1458303|NCT00140478|Androgen Independent Prostate Cancer
1458304|NCT00140478|Prostate Cancer
1458305|NCT00140478|Mifepristone
1458306|NCT00140478|RU-486
1458307|NCT00140452|ALS
1458308|NCT00140439|asthma
1458309|NCT00140439|emergency department
1458310|NCT00140439|compliance
1458311|NCT00140439|randomized clinical trial
1458312|NCT00140426|Anorexia Nervosa
1458313|NCT00140426|Risperidone
1458314|NCT00140426|Atypical Neuroleptics
1458315|NCT00140426|Dopamine
1458316|NCT00140426|Leptin
1458317|NCT00140426|Body Image
1458318|NCT00140426|Adolescents
1458319|NCT00140413|Optic Nerve Hypoplasia
1458320|NCT00140400|Prostate
1458321|NCT00140400|Cancer
1458322|NCT00140400|Advanced prostate cancer
1458323|NCT00140400|Metastatic
1458324|NCT00140400|Hormone-refractory
1458325|NCT00140400|GVAX
1458326|NCT00140400|Vaccine
1458327|NCT00140400|Allogeneic cells
1458328|NCT00140387|Prostate
1458329|NCT00140387|Cancer
1458330|NCT00140387|GVAX
1458331|NCT00140387|Metastatic
1458332|NCT00140387|Vaccine
1458333|NCT00140387|Allogeneic cells
1458334|NCT00140257|Myocardial Infarction
1458335|NCT00140244|leptin
1458336|NCT00140244|lipodystrophy
1458337|NCT00140244|insulin resistance
1458338|NCT00140244|hyperlipidemia
1458339|NCT00140244|metabolic syndrome
1458340|NCT00140231|leptin
1458341|NCT00140231|fasting
1458342|NCT00140231|reproductive
1458343|NCT00140231|neuroendocrine
1458344|NCT00140231|immune function
1458345|NCT00140231|energy deficiency associated with short-term fasting
1458346|NCT00140218|amyotrophic lateral sclerosis
1458347|NCT00140218|pramipexole
1458348|NCT00140218|oxidative stress
1458349|NCT00140218|neuroprotection
1458350|NCT00140205|leptin
1458351|NCT00140205|fasting
1458352|NCT00140205|pharmacokinetics
1458353|NCT00140192|creatine metabolism
1458354|NCT00140192|schizophrenia
1458355|NCT00140192|energy metabolism
1458356|NCT00140179|valnoctamide
1458357|NCT00140179|teratogenicity
1458358|NCT00140179|double-blind
1458359|NCT00140179|mania
1458360|NCT00140166|schizophrenia
1458361|NCT00140166|niacinamide
1458362|NCT00140153|androgel
1458363|NCT00140153|female sexuale dysfunction
1458364|NCT00140153|controlled double-blind
1458365|NCT00140153|testosterone
1458366|NCT00140140|Breast cancer
1458367|NCT00140114|Vaginal, sublingual, misoprostol, cervical ripening
1458368|NCT00140101|drug eluting stents
1458369|NCT00140101|stents
1458370|NCT00140101|angioplasty
1458371|NCT00140101|coronary artery disease
1458372|NCT00140101|total coronary occlusion
1458373|NCT00140101|coronary artery restenosis
1458374|NCT00140101|stent thrombosis
1458375|NCT00140101|vascular disease
1458376|NCT00140101|myocardial ischemia
1458377|NCT00140101|coronary artery stenosis
1458378|NCT00140088|Needlestick pain
1458379|NCT00140088|Venipuncture pain
1458380|NCT00140010|aneurysm
1458381|NCT00140010|autoregulation
1458382|NCT00140010|erythropoietion
1458383|NCT00140010|stroke
1458384|NCT00140010|subarachnoid hemorrhage
1458385|NCT00140010|vasospasm
1458386|NCT00139997|Major Depression
1458387|NCT00139997|Seasonal Affective Disorder (SAD)
1458388|NCT00139984|Hypertension
1458389|NCT00139984|Ambulatory blood pressure monitoring
1458390|NCT00139984|Blood pressure
1458391|NCT00139984|Risk assessment
1458392|NCT00139958|Acute coronary syndrome
1458393|NCT00139958|HIV infection
1458394|NCT00139958|Prognosis
1458395|NCT00139958|Coronary heart disease
1458396|NCT00139958|Revascularization
1458397|NCT00139919|Decreasing Titration Study
1458398|NCT00139919|Schizophrenia
1458399|NCT00139919|Bipolar
1458400|NCT00139919|Pharmacokinetic
1458401|NCT00139906|Titration Study
1458402|NCT00139906|Schizophrenia
1458403|NCT00139906|BID dosing
1458404|NCT00139906|Pharmacokinetic
1458405|NCT00139841|Lymphoma, Non-Hodgkin
1458406|NCT00139841|Rituximab Refractory
1458407|NCT00139841|Rituximab Failure
1458408|NCT00139841|Indolent Non-Hodgkins Lymphoma
1458409|NCT00139828|haemophilia B
1458410|NCT00139828|factor IX
1458411|NCT00139828|Product Surveillance, Postmarketing
1458412|NCT00139828|plasma products
1458413|NCT00139815|unstable angina
1458414|NCT00139815|acute coronary syndrome
1458415|NCT00139815|fondaparinux sodium
1458416|NCT00139815|non ST segment elevation myocardial infarction
1458417|NCT00139815|myocardial infarction
1458418|NCT00139776|Chronic treatment osteoarthritis, Celecoxib, Continuous Use, Intermittent Use
1458419|NCT00139737|Open-label extension Ziprasidone study in Schizophrenia
1458420|NCT00139633|esophageal cancer, chemotherapy, radiation
1458421|NCT00139620|advanced cancer, solid tumor
1458422|NCT00139594|Bipolar disorder, manic episode/treatment/licarbazepine
1458423|NCT00139581|Atopic dermatitis, children, infants, pimecrolimus, bid, od
1458424|NCT00139568|Chronic constipation
1458425|NCT00139568|5-HT,5-HT4,
1458426|NCT00139568|functional GI
1458427|NCT00139568|China
1458428|NCT00139568|tegaserod
1458429|NCT00139555|Hypertension
1458430|NCT00139555|Left ventricular hypertrophy
1458431|NCT00139542|human
1458432|NCT00139542|ventricular fibrillation
1458433|NCT00139542|out-of-hospital
1458434|NCT00139542|cardiac arrest
1458435|NCT00139542|automated external defibrillators (AED)
1458436|NCT00139542|defibrillators
1458437|NCT00139542|electrick countershock
1458438|NCT00139542|cardiopulmonary resuscitation
1458439|NCT00139490|Blood Pressure, High
1458440|NCT00139451|GH
1458441|NCT00139451|Delayed Growth
1458442|NCT00139451|Energy Expenditure
1458443|NCT00139451|Puberty
1458444|NCT00139451|Nutrition
1458445|NCT00139451|Short Stature
1458446|NCT00139399|Coronary artery bypass
1458447|NCT00139399|Coronary arteries
1458448|NCT00139399|Atherosclerosis
1458449|NCT00139399|Angiography
1458450|NCT00139399|Blood flow
1458451|NCT00139386|Drug-eluting stent
1458452|NCT00139386|Candesartan
1458453|NCT00139386|Randomized control study
1458454|NCT00139386|Coronary Angioplasty
1458455|NCT00139373|Progressive supranuclear palsy
1458456|NCT00139373|Frontal lobe
1458457|NCT00139373|Oculomotor testing
1458458|NCT00139373|Neuropsychological scores
1458459|NCT00139373|Motor disability (UPDRS)
1458460|NCT00139373|Distractibility
1458461|NCT00139321|Gait disorders
1458462|NCT00139321|Postural instability
1458463|NCT00139321|parkinsonian syndrome
1458464|NCT00139321|Gait initiation
1458465|NCT00139321|Parkinson's disease
1458466|NCT00139321|Adults
1458467|NCT00139308|Tourette's syndrome
1458468|NCT00139308|High frequency stimulation
1458469|NCT00139308|Globus pallidus
1458470|NCT00139308|Thalamus
1458471|NCT00139295|musculoskeletal
1458472|NCT00139295|osteoarthritis of the knee
1458473|NCT00139282|wet AMD
1458474|NCT00139282|macular degeneration
1458475|NCT00139269|Advanced Squamous Cell Carcinoma
1458476|NCT00139269|Squamous cell Carcinoma of Head and Neck
1458477|NCT00139269|SSCHN
1458478|NCT00139269|Docetaxel
1458479|NCT00139256|Glucocorticoid
1458480|NCT00139256|Antepartum Betamethasone Treatment
1458481|NCT00139256|Elective Cesarean Section
1458482|NCT00139256|Respiratory Distress in Infants
1458483|NCT00139243|squamous cell carcinoma
1458484|NCT00139243|Taxotere
1458485|NCT00139243|carcinoma of head/neck
1458486|NCT00139243|Cisplatin
1458487|NCT00139243|5-Fluorouracil
1458488|NCT00139243|Leucovorin
1458489|NCT00139230|Squamous Cell Carcinoma of Head and Neck
1458490|NCT00139230|Compressed TPFL
1458491|NCT00139230|Taxotere
1458492|NCT00139230|Growth Factor Support
1458493|NCT00139217|Persistent pulmonary hypertension
1458494|NCT00139217|Non-invasive inhaled nitric oxide
1458495|NCT00139217|iNO
1458496|NCT00139204|Prostate cancer
1458497|NCT00139204|Hormone-refractory prostate cancer
1458498|NCT00139204|PET scan
1458499|NCT00139204|C11-methionine
1458500|NCT00139204|positron emission tomography
1458501|NCT00139191|Prostate Cancer
1458502|NCT00139191|positron emission tomography
1458503|NCT00139191|carbon 11 acetate
1458504|NCT00139191|PET
1458505|NCT00139191|fatty acid synthase
1458506|NCT00139191|FAS
1458507|NCT00139165|Collagenous colitis
1458508|NCT00139165|Budesonide treatment
1458509|NCT00139165|Diarrhea
1458510|NCT00139152|moderate to severe allergic asthma
1458511|NCT00139139|hepatitis A
1458512|NCT00139139|hepatitis A vaccine
1458513|NCT00139139|immune globulin
1458514|NCT00139113|hepatitis A
1458515|NCT00139113|hepatitis A vaccine
1458516|NCT00139074|Bipolar I Disorder (DSM-IV 296.01, DSM-IV 296.4, DSM-IV 296.61)
1458517|NCT00139048|informed choice
1458518|NCT00139048|shared decision making
1458519|NCT00139048|decision aid
1458520|NCT00139048|mammography screening
1458521|NCT00139048|decision support
1458522|NCT00139035|glucose intolerance
1458523|NCT00139035|insulin
1458524|NCT00139035|microvascular function
1458525|NCT00139035|genotyping
1458526|NCT00139035|CYP3A5
1458527|NCT00139035|pharmacokinetics
1458528|NCT00139035|renal transplantation
1458529|NCT00139022|sleep apnea, home monitoring, CPAP
1458530|NCT00139009|intracellular concentration
1458531|NCT00139009|cyclosporine A
1458532|NCT00139009|renal biopsies
1458533|NCT00139009|heart biopsies
1458534|NCT00139009|Renal transplant recipients
1458535|NCT00138996|cardiac arrest
1458536|NCT00138996|resuscitation
1458537|NCT00138996|quality
1458538|NCT00138996|feedback
1458539|NCT00138996|training
1458540|NCT00138983|glucocorticoid-induced osteoporosis
1458541|NCT00138983|rheumatic diseases
1458542|NCT00138983|prevention
1458543|NCT00138983|randomized double-blind, double placebo controlled trial
1458544|NCT00138983|alendronate versus alfacalcidol
1458545|NCT00138970|Cadaveric donor
1458546|NCT00138970|Calcineurine free
1458547|NCT00138957|Laparoscopic parastomal hernia repair
1458548|NCT00138957|Intraperitoneally
1458549|NCT00138957|Mesh
1458550|NCT00138957|Quality of life
1458551|NCT00138957|Postoperative pain
1458552|NCT00138957|Recurrence
1458553|NCT00138944|Essential hypertension
1458554|NCT00138931|Cardiomyopathy
1458555|NCT00138931|Arrhythmia
1458556|NCT00138931|Muscular Dystrophy
1458557|NCT00138918|Prostate Cancer
1458558|NCT00138918|Clusterin
1458559|NCT00138918|Neoadjuvant
1458560|NCT00138918|Phase II
1458561|NCT00138905|Base station, EMF, human exposure study,Well-being,cognitive
1458562|NCT00138892|Quality of life
1458563|NCT00138892|waiting time
1458564|NCT00138892|total joint replacement
1458565|NCT00138879|Citrulline
1458566|NCT00138879|Parenteral Nutrition
1458567|NCT00138879|functioning intestinal mass
1458568|NCT00138879|small bowel permeability and absorption
1458569|NCT00138879|Granulomatous Enteritis
1458570|NCT00138866|Spinal cord injury
1458571|NCT00138853|RSA
1458572|NCT00138853|Genoarthrosis
1458573|NCT00138853|Knee arthroplasty
1458574|NCT00138853|Micromotion of polyethylene liner
1458575|NCT00138840|Crohn's disease
1458576|NCT00138840|Gastroenterology
1458577|NCT00138827|Radiotherapy
1458578|NCT00138827|Mucositis
1458579|NCT00138827|Xerostomia
1458580|NCT00138814|Neoplasm recurrence, local
1458581|NCT00138814|Radiotherapy dosage
1458582|NCT00138814|Cosmesis
1458583|NCT00138814|Mastectomy, segmental
1458584|NCT00138801|Neuroborreliosis
1458585|NCT00138788|Radiotherapy
1458586|NCT00138788|Qualify of life
1458587|NCT00138788|Neoplasm metastasis of the brain
1458588|NCT00138775|D-serine
1458589|NCT00138775|Negative symptoms
1458590|NCT00138775|Cognition
1458591|NCT00138775|Schizophrenia
1458592|NCT00138775|Amino acid
1458593|NCT00138736|MBL-deficient
1458594|NCT00138736|chemotherapy
1458595|NCT00138736|neutropenia
1458596|NCT00138736|chemotherapy-induced neutropenia
1458597|NCT00138710|obesity
1458598|NCT00138710|Hypogonadotrophic hypogonadism
1458599|NCT00138710|aromatase inhibition
1458600|NCT00138697|Agammaglobulinemia
1458601|NCT00138697|Hypogammaglobulinemia
1458602|NCT00138697|Immunoglobulins, Intravenous
1458603|NCT00138684|insulin resistance
1458604|NCT00138684|iron overload
1458605|NCT00138684|phlebotomy
1458606|NCT00138684|hepatic iron overload
1458607|NCT00138658|NSCLC
1458608|NCT00138658|custirsen sodium
1458609|NCT00138658|OGX-011
1458610|NCT00138658|Stage IIIB or IV advanced non-small cell lung cancer
1458611|NCT00138632|Wet Age-related macular degeneration
1458612|NCT00138632|PTK787
1458613|NCT00138619|Type 2 diabetes
1458614|NCT00138619|vildagliptin
1458615|NCT00138606|Type 2 diabetes
1458616|NCT00138606|vildagliptin
1458617|NCT00138593|Type 2 diabetes
1458618|NCT00138593|vildagliptin
1458619|NCT00138580|Type 2 diabetes
1458620|NCT00138580|vildagliptin
1458621|NCT00138567|Type 2 diabetes
1458622|NCT00138567|vildagliptin
1458623|NCT00138554|Type 2 diabetes
1458624|NCT00138554|vildagliptin
1458625|NCT00138541|type 2 diabetes
1458626|NCT00138541|vildagliptin
1458627|NCT00138528|Metabolic Syndrome, fluvastatin
1458628|NCT00138515|Type 2 diabetes
1458629|NCT00138515|vildagliptin
1458630|NCT00138502|Candidiasis, Funguria
1458631|NCT00138489|Malaria, Papua New Guinea, infants, children
1458632|NCT00138476|Norovirus, calicivirus, gastroenteritis, Norwalk virus, challenge
1458633|NCT00138463|West Nile Virus, Neuroinvasive Disease
1458634|NCT00138450|Schistosomiasis, S. haematobium, morbidity, Kenya
1458635|NCT00138437|leprosy
1458636|NCT00138437|Colombia
1458637|NCT00138424|Vistide®, Cidofovir, renal transplant, BK Virus Nephropathy
1458638|NCT00138411|anthrax, Bacillus anthracis, monoclonal antibody, ETI-204
1458639|NCT00138398|Influenza, T cell, vaccine, Congestive heart failure
1458640|NCT00138385|inactivated, attenuated, influenza vaccine, FluMist, Fluzone
1458641|NCT00138372|malaria
1458642|NCT00138372|immunity
1458643|NCT00138372|MSP-1
1458644|NCT00138372|Kenya
1458645|NCT00138372|infants
1458646|NCT00138359|T solium, cysticercus, pig triquina, solitaria, intestinal parasites, Niclosamide, tapeworms, Taeniasis
1458647|NCT00138346|hydatid disease, Echinococcus granulosus, tapeworm
1458648|NCT00138333|Thimerosal, mercury levels, low birth weight, Argentina
1458649|NCT00138320|Herpes Simplex, vaccine, antibodies, mother
1458650|NCT00138307|malaria, children, naturally acquired immunity, Ghana
1458651|NCT00138294|influenza vaccine
1458652|NCT00138294|live attenuated influenza vaccine (LAIV or FluMist)
1458653|NCT00138294|inactivated influenza vaccine (IIV)
1458654|NCT00138294|School-based influenza vaccination program
1458655|NCT00138294|children
1458656|NCT00138294|herd protection
1458657|NCT00138281|influenza, vaccine, respiratory virus, Fluzone, FluMist
1458658|NCT00138268|umbilical cord blood, vaccine, pregnant women
1458659|NCT00138242|stage I ovarian epithelial cancer
1458660|NCT00138242|stage II ovarian epithelial cancer
1458661|NCT00138242|stage III ovarian epithelial cancer
1458662|NCT00138242|stage IV ovarian epithelial cancer
1458663|NCT00138242|fallopian tube cancer
1458664|NCT00138242|primary peritoneal cavity cancer
1458665|NCT00138229|recurrent melanoma
1458666|NCT00138229|stage IV melanoma
1458667|NCT00138216|unspecified childhood solid tumor, protocol specific
1458668|NCT00138216|recurrent childhood cerebellar astrocytoma
1458669|NCT00138216|recurrent childhood cerebral astrocytoma
1458670|NCT00138216|recurrent childhood brain stem glioma
1458671|NCT00138216|recurrent childhood brain tumor
1458672|NCT00138216|recurrent childhood ependymoma
1458673|NCT00138216|recurrent childhood medulloblastoma
1458674|NCT00138216|recurrent childhood supratentorial primitive neuroectodermal tumor
1458675|NCT00138216|recurrent childhood visual pathway and hypothalamic glioma
1458676|NCT00138216|childhood oligodendroglioma
1458677|NCT00138216|childhood craniopharyngioma
1458678|NCT00138216|childhood choroid plexus tumor
1458679|NCT00138216|childhood infratentorial ependymoma
1458680|NCT00138216|childhood supratentorial ependymoma
1458681|NCT00138216|childhood high-grade cerebral astrocytoma
1458682|NCT00138216|childhood low-grade cerebral astrocytoma
1458683|NCT00138216|childhood central nervous system germ cell tumor
1458684|NCT00138216|childhood grade I meningioma
1458685|NCT00138216|childhood grade II meningioma
1458686|NCT00138216|childhood grade III meningioma
1458687|NCT00138216|recurrent childhood subependymal giant cell astrocytoma
1458688|NCT00138216|childhood atypical teratoid/rhabdoid tumor
1458689|NCT00138164|recurrent adult diffuse large cell lymphoma
1458690|NCT00138164|recurrent grade 1 follicular lymphoma
1458691|NCT00138164|recurrent grade 2 follicular lymphoma
1458692|NCT00138164|recurrent grade 3 follicular lymphoma
1458693|NCT00138164|recurrent small lymphocytic lymphoma
1458694|NCT00138151|recurrent cervical cancer
1458695|NCT00138151|stage IVB cervical cancer
1458696|NCT00138125|stage IV breast cancer
1458697|NCT00138125|recurrent breast cancer
1458698|NCT00138112|Streptococcal Sepsis
1458699|NCT00138112|Hematopoietic Stem Cell Transplantation
1458700|NCT00138112|Hematologic Malignancies
1458701|NCT00138112|Streptococci
1458702|NCT00138112|Transplant
1458703|NCT00138099|Critically ill patients (ICU)
1458704|NCT00138099|Deep Venous Thromboembolism prevention
1458705|NCT00138099|Renal Failure
1458706|NCT00138099|Critically ill
1458707|NCT00138086|lymphoma
1458708|NCT00138086|chemotherapy
1458709|NCT00138086|Zevalin ( Yttrium-90 Ibritumomab Tiuxetan)
1458710|NCT00138073|pulmonary artery catheter
1458711|NCT00138073|waveform interpretation
1458712|NCT00138073|computer-based learning
1458713|NCT00138073|medical education
1458714|NCT00138060|genotypic profile
1458715|NCT00138060|metastatic colorectal cancer
1458716|NCT00138047|zinc
1458717|NCT00138047|HIV
1458718|NCT00138047|children
1458719|NCT00138034|Open infarct-related artery within 72 hours of thrombolysis
1458720|NCT00138021|Serious mental illness
1458721|NCT00138021|Supported Employment
1458722|NCT00138021|Cognitive remediation
1458723|NCT00138021|Cognitive impairments
1458724|NCT00138008|prostate cancer
1458725|NCT00138008|radical prostatectomy
1458726|NCT00138008|PSA failure
1458727|NCT00138008|RCT
1458728|NCT00138008|radiation
1458729|NCT00138008|endocrinotherapy
1458730|NCT00137995|Lymphoma
1458731|NCT00137995|Chemotherapy
1458732|NCT00137995|rituximab
1458733|NCT00137982|Ectopic pregnancy
1458734|NCT00137982|Surgical treatment
1458735|NCT00137982|Medical treatment
1458736|NCT00137982|Fertility
1458737|NCT00137969|Rituxan
1458738|NCT00137969|SLE
1458739|NCT00137969|Lupus
1458740|NCT00137956|Endobronchial Valve
1458741|NCT00137956|Endobronchial Valve ProcedureEBV
1458742|NCT00137956|EBV Procedure
1458743|NCT00137956|Endobronchial Lung Volume Reduction
1458744|NCT00137956|Lung Volume Reduction
1458745|NCT00137943|Parent-child communication
1458746|NCT00137943|Primary prevention
1458747|NCT00137943|sexual risk prevention
1458748|NCT00137943|HIV
1458749|NCT00137930|Prophylaxis of rotavirus gastroenteritis
1458750|NCT00137917|Prophylaxis meningococcal serogroup B disease
1458751|NCT00137904|multiple sclerosis
1458752|NCT00137904|fatigue
1458753|NCT00137904|sleep disorders
1458754|NCT00137891|Multinodular goiter
1458755|NCT00137852|Esophageal Cancer
1458756|NCT00137852|Resectable Esophageal Cancer
1458757|NCT00137852|Radiation Therapy
1458758|NCT00137852|Celecoxib
1458759|NCT00137852|Irinotecan
1458760|NCT00137852|Cisplatin
1458761|NCT00137839|Tarceva
1458762|NCT00137839|Erlotinib
1458763|NCT00137839|OSI-774
1458764|NCT00137839|Adenocarcinoma
1458765|NCT00137839|Advanced Lung Cancer
1458766|NCT00137826|Mesothelioma
1458767|NCT00137826|Avastin
1458768|NCT00137826|Bevacizumab
1458769|NCT00137826|Tarceva
1458770|NCT00137826|OSI-774
1458771|NCT00137826|Erlotinib
1458772|NCT00137813|Bevacizumab
1458773|NCT00137813|Docetaxel
1458774|NCT00137813|AvaTax
1458775|NCT00137813|Metastatic Esophagogastric Cancer
1458776|NCT00137800|Non-Small Cell Lung Cancer
1458777|NCT00137800|Elderly Cancer Patients
1458778|NCT00137800|Tarceva
1458779|NCT00137800|Erlotinib
1458780|NCT00137800|OSI-774
1458781|NCT00137800|Stage IIIB or IV Non-Small Cell Lung Cancer
1458782|NCT00137787|febrile neutropenia
1458783|NCT00137787|hematologic disease
1458784|NCT00137774|Metastatic Neuroendocrine Tumor
1458785|NCT00137774|Advanced Neuroendocrine tumor
1458786|NCT00137774|Bevacizumab
1458787|NCT00137774|Temozolomide
1458788|NCT00137761|Pancreatic Carcinoma
1458789|NCT00137761|Iressa
1458790|NCT00137761|Docetaxel
1458791|NCT00137748|Lung transplantation
1458792|NCT00137735|carpal tunnel syndrome
1458793|NCT00137735|gabapentin
1458794|NCT00137722|Asthma
1458795|NCT00137722|Disease Management
1458796|NCT00137722|Outcomes
1458797|NCT00137722|Utilization
1458798|NCT00137709|epilepsy
1458799|NCT00137709|hormone
1458800|NCT00137696|polio
1458801|NCT00137696|vaccine
1458802|NCT00137696|immunogenicity
1458803|NCT00137683|screening
1458804|NCT00137683|prevention
1458805|NCT00137683|community health education
1458806|NCT00137670|Intervention studies
1458807|NCT00137670|HIV
1458808|NCT00137657|HIV
1458809|NCT00137657|malaria
1458810|NCT00137657|E. Coli
1458811|NCT00137657|S. pneumoniae
1458812|NCT00137657|drug resistance
1458813|NCT00137657|antifolate
1458814|NCT00137657|opportunistic infections
1458815|NCT00137657|Africa
1458816|NCT00137657|Kenya
1458817|NCT00137657|East Africa
1458818|NCT00137644|Adolescent
1458819|NCT00137644|*HIV Infections/ pc [Prevention & Control]
1458820|NCT00137644|Male
1458821|NCT00137644|Humans
1458822|NCT00137644|Risk-Taking
1458823|NCT00137644|Safe Sex
1458824|NCT00137644|Sexual Behavior
1458825|NCT00137644|HIV
1458826|NCT00137644|HIV Seronegativity
1458827|NCT00137631|Adult
1458828|NCT00137631|HIV Infections / pc [Prevention & Control]
1458829|NCT00137631|Homosexuality, Male
1458830|NCT00137631|Humans
1458831|NCT00137631|Male
1458832|NCT00137631|Risk-Taking
1458833|NCT00137631|Safe Sex
1458834|NCT00137631|Sexual Behavior
1458835|NCT00137631|HIV
1458836|NCT00137618|Prostatic neoplasm
1458837|NCT00137618|Prostate cancer
1458961|NCT00137163|Dermafill dressing
1458838|NCT00137618|Informed decision making
1458839|NCT00137618|Prostate cancer screening
1458840|NCT00137618|Prostate specific antigen
1458841|NCT00137605|HIV
1458842|NCT00137605|HIV Infections
1458843|NCT00137592|screening
1458844|NCT00137592|community health education
1458845|NCT00137579|Influenza Vaccines
1458846|NCT00137579|Acenocoumarol
1458847|NCT00137579|Drug Administration Routes
1458848|NCT00137579|Anticoagulants
1458849|NCT00137566|malaria
1458850|NCT00137566|treatment
1458851|NCT00137566|paracetamol
1458852|NCT00137566|chloroquine
1458853|NCT00137566|Guinea-Bissau
1458854|NCT00137566|children
1458855|NCT00137566|P.falciparum
1458856|NCT00137553|Children
1458857|NCT00137553|malaria
1458858|NCT00137553|sulfadoxine-pyrimethamine
1458859|NCT00137553|Guinea-Bissau
1458860|NCT00137553|treatment
1458861|NCT00137540|First line ablation therapy
1458862|NCT00137527|Cardiac Surgery
1458863|NCT00137527|Cardiopulmonary Bypass
1458864|NCT00137527|Cerebral Oxygenation
1458865|NCT00137527|Neurologic Dysfunction
1458866|NCT00137527|Neurocognitive Dysfunction
1458867|NCT00137527|Neurological manifestations
1458868|NCT00137527|Memory loss
1458869|NCT00137527|Delirium
1458870|NCT00137527|Coronary Artery Bypass
1458871|NCT00137514|malaria
1458872|NCT00137514|Plasmodium falciparum
1458873|NCT00137514|chloroquine
1458874|NCT00137514|amodiaquine
1458875|NCT00137514|treatment
1458876|NCT00137514|Guinea-Bissau
1458877|NCT00137514|children
1458878|NCT00137488|non-enhancing lesion
1458879|NCT00137488|low grade glioma
1458880|NCT00137488|high risk group selection
1458881|NCT00137475|IMRT
1458882|NCT00137475|head and neck cancer
1458883|NCT00137475|parotid sparing
1458884|NCT00137436|First-line treatment of metastatic hormone-refractory prostate cancer SUTENT in combination with docetaxel and prednisone
1458885|NCT00137384|Magnetoencephalogram
1458886|NCT00137384|Functional Connectivity
1458887|NCT00137384|Electroencephalogram (EEG)
1458888|NCT00137384|Focal Hand Dystonia
1458889|NCT00137384|Spectral Analysis
1458890|NCT00137384|Healthy Volunteer
1458891|NCT00137384|HV
1458892|NCT00137371|Postmenopause
1458893|NCT00137371|Vaginitis
1458894|NCT00137358|Cervical
1458895|NCT00137358|Uterine
1458896|NCT00137358|Para-aortic
1458897|NCT00137358|Nodes
1458898|NCT00137358|IMRT
1458899|NCT00137358|Cancer
1458900|NCT00137345|Randomized controlled trial
1458901|NCT00137345|Clinical Trial Phase III
1458902|NCT00137345|Drug therapy
1458903|NCT00137345|Immunosuppression
1458904|NCT00137345|Treatment outcome
1458905|NCT00137345|Kidney transplantation
1458906|NCT00137345|Kidney function tests
1458907|NCT00137332|Arrhythmia
1458908|NCT00137332|antiarrhythmic
1458909|NCT00137332|programmed electrical stimulation
1458910|NCT00137319|inspiratory impedance threshold device
1458911|NCT00137319|blood pressure regulation
1458912|NCT00137319|head-up tilt test
1458913|NCT00137319|tilt table testing
1458914|NCT00137319|burn injury
1458915|NCT00137319|Burns
1458916|NCT00137306|Guideline Adherence
1458917|NCT00137306|Quality Assurance, Health Care
1458918|NCT00137293|Arrhythmia, syncope, antiarrhythmic
1458919|NCT00137280|Randomized Controlled Trial
1458920|NCT00137280|Quality of Health Care
1458921|NCT00137280|Health Services Research
1458922|NCT00137280|Guidelines
1458923|NCT00137280|Medical Informatics Computing
1458924|NCT00137280|Services, Mental Health
1458925|NCT00137280|Medicine, Evidenced-Based
1458926|NCT00137280|Quality Assurance, Healthcare
1458927|NCT00137280|Quality Indicators, Health Care
1458928|NCT00137280|Veterans
1458929|NCT00137280|Unemployment
1458930|NCT00137280|Obesity
1458931|NCT00137280|Quality Improvement
1458932|NCT00137267|Schizophrenia / disorders w psychotic features
1458933|NCT00137267|Substance-related disorders
1458934|NCT00137267|Community Mental Health Services
1458935|NCT00137267|Case Management
1458936|NCT00137267|Health Education
1458937|NCT00137254|Severe burns
1458938|NCT00137254|Hyperinsulinemia
1458939|NCT00137254|Insulin
1458940|NCT00137254|Muscle protein kinetics
1458941|NCT00137254|Immune function
1458942|NCT00137254|Exercise
1458943|NCT00137241|health literacy
1458944|NCT00137241|screening
1458945|NCT00137241|cancer
1458946|NCT00137241|health disparities
1458947|NCT00137228|Hand Edema
1458948|NCT00137228|Figure of eight method
1458949|NCT00137228|Measuring edema in burn patients
1458950|NCT00137215|burns
1458951|NCT00137215|donor site care
1458952|NCT00137215|Silverlon dressing
1458953|NCT00137202|pruritus
1458954|NCT00137202|burn wound
1458955|NCT00137189|Motivation
1458956|NCT00137189|Music Therapy
1458957|NCT00137189|Psychotherapy
1458958|NCT00137176|Clinically Isolated Syndrome
1458959|NCT00137163|burns
1458960|NCT00137163|donor site care
1458962|NCT00137124|Essential hypertension
1458963|NCT00137111|Leukemia
1458964|NCT00137085|procedural sedation
1458965|NCT00136955|Weekly Irinotecan(60mg/sqm, D1, 8, 15) in combination with Cisplatin (60mg/sqm, D1), Squamous Cell Carcinoma Of The Uterine Cervix
1458966|NCT00136929|AMI
1458967|NCT00136929|MI
1458968|NCT00136929|Acute myocardial infarction (AMI), (MI)
1458969|NCT00136903|Graft vs Host Disease
1458970|NCT00136903|GVHD
1458971|NCT00136903|Graft Versus Host Disease
1458972|NCT00136903|Bone marrow transplant
1458973|NCT00136903|Stem cells
1458974|NCT00136903|Mesenchymal stem cells
1458975|NCT00136903|Adult stem cells
1458976|NCT00136903|Leukemia
1458977|NCT00136903|Lymphoma
1458978|NCT00136890|Positron-Emission Tomography
1458979|NCT00136890|PET Scan
1458980|NCT00136890|Lung Cancer
1458981|NCT00136890|Thoracic Surgery
1458982|NCT00136890|Diagnostic
1458983|NCT00136890|Randomized Controlled Trial
1458984|NCT00136890|Oncology
1458985|NCT00136877|recurrent tonsillitis
1458986|NCT00136877|streptococcus
1458987|NCT00136877|tonsillectomy
1458988|NCT00136877|prevention
1458989|NCT00136864|Positron-Emission Tomography
1458990|NCT00136864|PET Scan
1458991|NCT00136864|Non-Small-Cell Lung Carcinoma
1458992|NCT00136864|Diagnosis
1458993|NCT00136864|Radiation Oncology
1458994|NCT00136864|Lung Cancer
1458995|NCT00136864|Randomized Controlled Trial
1458996|NCT00136864|Oncology
1458997|NCT00136864|Radiation Planning
1458998|NCT00136851|Hypertension
1458999|NCT00136838|tobacco use
1459000|NCT00136825|cocaine
1459001|NCT00136825|treatment
1459002|NCT00136812|tobacco
1459003|NCT00136799|Mixed Dyslipidemia
1459004|NCT00136799|high cholesterol
1459005|NCT00136799|adults
1459006|NCT00136799|fluvastatin
1459007|NCT00136786|tobacco use
1459008|NCT00136773|Albuminuria
1459009|NCT00136773|Type 2 diabetes mellitus
1459010|NCT00136773|Hypertension
1459011|NCT00136760|tobacco
1459012|NCT00136747|tobacco use
1459013|NCT00136734|ADHD
1459014|NCT00136734|Cocaine dependence
1459015|NCT00136734|treatment
1459016|NCT00136734|methylphenidate
1459017|NCT00136721|Parkinson's disease
1459018|NCT00136721|phenotype-genotype correlations
1459019|NCT00136721|mutations spectrum
1459020|NCT00136721|candidate genes
1459021|NCT00136708|Global Network
1459022|NCT00136708|Neonatal mortality
1459023|NCT00136708|Asphyxia
1459024|NCT00136708|Maternal and child health
1459025|NCT00136708|International
1459026|NCT00136708|Zambia
1459027|NCT00136708|Pakistan
1459028|NCT00136708|India
1459029|NCT00136708|Democratic Republic of Congo
1459030|NCT00136708|Uruguay
1459031|NCT00136708|Guatemala
1459032|NCT00136708|Argentina
1459033|NCT00136708|Neonatal resuscitation
1459034|NCT00136695|Aging
1459035|NCT00136682|Major abdominal or pelvic surgery
1459036|NCT00136682|Patient-Controlled Epidural Analgesia (PCEA)
1459037|NCT00136682|Length of hospital stay after surgery
1459038|NCT00136669|Acupuncture
1459039|NCT00136669|Pain
1459040|NCT00136669|Pancreatic Neoplasms
1459041|NCT00136656|infant
1459042|NCT00136656|children
1459043|NCT00136656|pyelonephritis
1459044|NCT00136656|Renal scars
1459045|NCT00136656|DMSA scan
1459046|NCT00136643|microbicide
1459047|NCT00136643|Women
1459048|NCT00136643|Prevention
1459049|NCT00136643|HIV
1459050|NCT00136643|STIs
1459051|NCT00136643|HIV Seronegativity
1459052|NCT00136643|prevention of sexually transmitted infections including HIV.
1459053|NCT00136630|dominant spinocerebellar degenerations
1459054|NCT00136630|new rate scales
1459055|NCT00136630|natural history
1459056|NCT00136630|molecular biology
1459057|NCT00136630|candidate genes
1459058|NCT00136617|Short Alcohol Withdrawal Scale
1459059|NCT00136617|Documentation
1459060|NCT00136604|Prophylaxis diphtheria
1459061|NCT00136604|Hib & meningococcal serogroup A & C disease
1459062|NCT00136591|follicular lymphoma
1459063|NCT00136591|bortezomib
1459064|NCT00136591|relapse
1459065|NCT00136578|Safety
1459066|NCT00136578|tolerability
1459067|NCT00136578|dose limiting toxicity
1459068|NCT00136578|solid tumors
1459069|NCT00136578|carboplatin
1459070|NCT00136565|peripheral T-cell lymphomas
1459071|NCT00136565|bortezomib
1459072|NCT00136565|ACVBP regimen
1459073|NCT00136552|lymphoma
1459074|NCT00136552|follicular
1459075|NCT00136552|B-cell
1459076|NCT00136552|rituximab
1459077|NCT00136552|interferon
1459078|NCT00136539|Breast Cancer
1459079|NCT00136539|Early Stage Breast Cancer
1459080|NCT00136539|HER2-positive
1459081|NCT00136539|HER2-positive breast cancer
1459082|NCT00136539|Herceptin
1459083|NCT00136539|Taxol
1459084|NCT00136539|Stage II Breast Cancer
1459085|NCT00136539|Stage III Breast Cancer
1459086|NCT00136526|Prostate Cancer
1459087|NCT00136526|Hormone refractory prostate cancer
1459088|NCT00136526|Metastatic prostate cancer
1459089|NCT00136513|Safety
1459090|NCT00136513|tolerability
1459091|NCT00136513|dose limiting toxicity
1459092|NCT00136513|solid tumors
1459093|NCT00136500|genetics
1459094|NCT00136500|biomarkers
1459095|NCT00136500|pre-symptomatic
1459096|NCT00136500|natural history
1459097|NCT00136487|Prostate Cancer
1459098|NCT00136487|Cancer of Prostate
1459099|NCT00136487|Cancer of the Prostate
1459100|NCT00136487|Prostate-Specific Antigen
1459101|NCT00136474|Lymphoma
1459102|NCT00136474|Radiation therapy
1459103|NCT00136474|Amifostine
1459104|NCT00136461|AML
1459105|NCT00136461|acute myelogenous leukemia
1459106|NCT00136461|MDS
1459107|NCT00136461|myelodysplastic syndrome
1459108|NCT00136461|bryostatin 1
1459109|NCT00136461|all-trans retinoic acid
1459110|NCT00136461|ATRA
1459111|NCT00136448|AML
1459112|NCT00136448|acute myelogenous leukemia
1459113|NCT00136448|cytarabine
1459114|NCT00136448|interleukin-2
1459115|NCT00136435|ALL
1459116|NCT00136435|acute lymphoblastic leukemia
1459117|NCT00136435|chemotherapy
1459118|NCT00136435|asparaginase
1459119|NCT00136422|AML
1459120|NCT00136422|acute myelogenous leukemia
1459121|NCT00136422|MDS
1459122|NCT00136422|myelodysplasia
1459123|NCT00136422|vaccine
1459124|NCT00136409|myelofibrosis
1459125|NCT00136409|agnogenic myeloid metaplasia with myelofibrosis
1459126|NCT00136409|CMML
1459127|NCT00136409|chronic myelomonocytic leukemia
1459128|NCT00136409|imatinib mesylate
1459129|NCT00136409|Gleevec
1459130|NCT00136396|Steroid-refractory Chronic Graft vs. Host Disease
1459131|NCT00136396|Chronic Graft vs. Host Disease
1459132|NCT00136396|GVHD
1459133|NCT00136396|steroid-refractory
1459134|NCT00136396|rituximab
1459135|NCT00136370|Chlorhexidine
1459136|NCT00136370|Prevention
1459137|NCT00136370|Neonatal sepsis
1459138|NCT00136370|Peripartum infections
1459139|NCT00136357|posttraumatic stress
1459140|NCT00136357|mind-body techniques
1459141|NCT00136357|war
1459142|NCT00136357|adolescents
1459143|NCT00136344|cataract surgery
1459144|NCT00136344|phacoemulsification
1459145|NCT00136344|post-operative endophthalmitis
1459146|NCT00136331|Pandemic
1459147|NCT00136331|Influenza
1459148|NCT00136331|Prevention
1459149|NCT00136331|Vaccine
1459150|NCT00136331|Prevention of Pandemic Influenza
1459151|NCT00136318|Pegasys-Induced depression
1459152|NCT00136305|pediatric asthma
1459153|NCT00136305|asthma action plans
1459154|NCT00136305|patient education
1459155|NCT00136305|medication adherence
1459156|NCT00136292|Gram-Positive Infection
1459157|NCT00136279|adolescent behavior
1459158|NCT00136279|sexual behavior
1459159|NCT00136279|smoking
1459160|NCT00136279|parents
1459161|NCT00136279|communication
1459162|NCT00136279|health education
1459163|NCT00136279|schools
1459164|NCT00136279|Sexual initiation
1459165|NCT00136266|Adherence
1459166|NCT00136266|Supplements
1459167|NCT00136266|Iron
1459168|NCT00136266|Iron deficiency
1459169|NCT00136266|Anemia
1459170|NCT00136266|Vitamins
1459171|NCT00136266|Minerals
1459172|NCT00136227|screening,
1459173|NCT00136227|community health education,
1459174|NCT00136227|decision making,
1459175|NCT00136227|computer-assisted decision making
1459176|NCT00136201|Peritonitis
1459177|NCT00136201|Community-Acquired Infections
1459178|NCT00136201|Cross Infection
1459179|NCT00136188|Prediabetes
1459180|NCT00136188|Metabolic Syndrome
1459181|NCT00136188|Healthy Controls
1459182|NCT00136188|Endothelial function
1459183|NCT00136175|Neoadjuvant chemotherapy
1459184|NCT00136110|ALS
1459185|NCT00136110|Sodium Valproate
1459186|NCT00136110|randomised trial
1459187|NCT00136110|Amyotrophic Lateral Sclerosis (ALS)
1459188|NCT00135135|Cancer
1459189|NCT00135135|Childhood Tumor
1459190|NCT00135135|Neoplasms
1459191|NCT00135122|migraine
1459192|NCT00135122|analgesics
1459193|NCT00135122|tension type headache
1459194|NCT00135070|Diabetes Mellitus
1459195|NCT00136097|colonisation of the catheter
1459196|NCT00136084|Leukemia,Erythroblastic, Acute
1459197|NCT00136084|Erythroblastic Leukemia, Acute
1459198|NCT00136084|Leukemia, Myeloid, Acute
1459199|NCT00136084|Myeloid Leukemia, Acute
1459200|NCT00136071|Stress Urinary Incontinence,
1459201|NCT00136071|TOT,
1459202|NCT00136071|TVT-O
1459203|NCT00136058|osteoporosis
1459204|NCT00136058|hip fracture
1459205|NCT00136045|Idiopathic RLS
1459206|NCT00136032|Growth Hormone
1459207|NCT00136032|Cardiovascular risk
1459208|NCT00136032|Pituitary
1459209|NCT00136032|Hypothalamic
1459210|NCT00136032|GH Deficiency
1459211|NCT00136032|Pituitary Tumor
1459212|NCT00136032|Pituitary Disease
1459213|NCT00136019|Epilepsy with partial seizures
1459214|NCT00136006|Epidemiology
1459215|NCT00136006|Lung health
1459216|NCT00136006|lung function
1459217|NCT00136006|COPD
1459218|NCT00135993|Idiopathic Restless Leg syndrome
1459219|NCT00135967|membranous nephropathy
1459220|NCT00135967|mycophenolate mofetil
1459221|NCT00135967|cyclophosphamide
1459222|NCT00135967|prednisone
1459223|NCT00135954|membranous nephropathy
1459224|NCT00135954|cyclophosphamide
1459225|NCT00135954|prednisone
1459226|NCT00135941|Diabetes Mellitus, Type 2
1459227|NCT00135928|ST-elevation myocardial infarction
1459228|NCT00135928|granulocyte-colony stimulating factor angiogenesis
1459229|NCT00135928|stem cells
1459230|NCT00135902|Preterm birth
1459231|NCT00135902|Progesterone
1459232|NCT00135902|Omega-3 fatty acid
1459233|NCT00135902|Pregnancy
1459234|NCT00135889|Total Knee Arthroplasty secondary to osteoarthritis
1459235|NCT00135876|deep vein thrombosis
1459236|NCT00135876|pulmonary embolism
1459237|NCT00135876|glioma
1459238|NCT00135876|fragmin
1459239|NCT00135876|anticoagulant
1459240|NCT00135876|prophylaxis
1459241|NCT00135876|dalteparin
1459242|NCT00135850|Gene therapy
1459243|NCT00135850|VEGF
1459244|NCT00135850|Stem cells
1459245|NCT00135850|myocardial ischemia
1459246|NCT00135850|angiogenesis
1459247|NCT00135837|Age related Macula Degeneration,
1459248|NCT00135837|AMD,
1459249|NCT00135837|choroidal neovascularisation (CNV),
1459250|NCT00135837|occult CNV lesion,
1459251|NCT00135837|verteporfin for injection,
1459252|NCT00135837|photodynamic therapy (PDT)
1459253|NCT00135824|Artificial eye drops
1459254|NCT00135824|tolerability
1459255|NCT00135824|healthy volunteers
1459256|NCT00135824|povidone
1459257|NCT00135824|healthy subjects
1459258|NCT00135811|Focal Segmental Glomerulosclerosis
1459259|NCT00135798|Hepatitis C
1459260|NCT00135798|Ribavirin
1459261|NCT00135798|PegInterferon alfa2b
1459262|NCT00135772|nicotine dependence
1459263|NCT00135759|opiate dependence
1459264|NCT00135746|tobacco
1459265|NCT00135733|Lichen Planus
1459266|NCT00135733|Mucosal lichen planus
1459267|NCT00135733|Alefacept
1459268|NCT00135733|T-cell mediated
1459269|NCT00135733|subcutaneous medication
1459270|NCT00135733|Autoimmune disease
1459271|NCT00135720|Pemphigus Vulgaris
1459272|NCT00135720|Chronic Pemphigus
1459273|NCT00135720|Etanercept
1459274|NCT00135720|Enbrel
1459275|NCT00135720|anti-TNF-alpha
1459276|NCT00135720|TNF-alpha antagonist
1459277|NCT00135720|biologic
1459278|NCT00135720|immunomodulator
1459279|NCT00135720|subcutaneous medication
1459280|NCT00135707|Antioxidants
1459281|NCT00135707|Preeclampsia
1459282|NCT00135707|Pregnancy
1459283|NCT00135707|Hypertension
1459284|NCT00135694|hepatitis
1459285|NCT00135694|hepatitis C
1459286|NCT00135694|HCV
1459287|NCT00135694|liver
1459288|NCT00135694|liver disease
1459289|NCT00135694|liver transplant
1459290|NCT00135694|liver transplantation
1459291|NCT00135694|transplant
1459292|NCT00135694|hepatic
1459293|NCT00135694|hepatic transplantation
1459294|NCT00135694|immunosuppression
1459295|NCT00135694|rejection
1459296|NCT00135668|children
1459297|NCT00135668|sodium nitroprusside
1459298|NCT00135668|controlled hypotension
1459299|NCT00135668|dose-response
1459300|NCT00135668|pharmacokinetics
1459301|NCT00135668|pharmacodynamics
1459302|NCT00135668|safety
1459303|NCT00135668|efficacy
1459304|NCT00135655|macular edema
1459305|NCT00135655|post cataract extraction
1459306|NCT00135655|cystoid macular edema
1459307|NCT00135655|post cataract extraction macular edema
1459308|NCT00135642|Hayfever
1459309|NCT00135642|Subcutaneous Immunotherapy
1459310|NCT00135642|Grass pollen immunotherapy
1459311|NCT00135642|Seasonal Allergic Rhinoconjunctivitis
1459312|NCT00135629|Hayfever
1459313|NCT00135629|Sublingual Immunotherapy
1459314|NCT00135629|Grass pollen immunotherapy
1459315|NCT00135629|Late cutaneous response
1459316|NCT00135629|Intradermal allergen challenge
1459317|NCT00135629|Seasonal Allergic Rhinoconjunctivitis
1459318|NCT00135616|urinary incontinence
1459319|NCT00135616|stress incontinence
1459320|NCT00135616|urethra
1459321|NCT00135616|gynaecologic surgical procedures
1459322|NCT00135616|suburethral sling
1459323|NCT00135603|appendicitis.
1459324|NCT00135603|adult.
1459325|NCT00135603|treatment.
1459326|NCT00135603|antibiotic therapy.
1459327|NCT00135603|CT scanning.
1459328|NCT00135603|randomized trial
1459329|NCT00135603|safety
1459330|NCT00135590|Protein pulse-feeding
1459331|NCT00135590|Nutritional supplementation
1459332|NCT00135590|Protein-energy malnutrition
1459333|NCT00135590|Elderly subjects
1459334|NCT00135590|Body composition
1459335|NCT00135577|opioids
1459336|NCT00135577|constipation
1459337|NCT00135577|opioid-induced bowel dysfunction
1459461|NCT00134797|GFR
1459338|NCT00135564|Haemophilus Influenzae type b/Meningococcal (vaccine)
1459339|NCT00135564|Prophylaxis meningococcal serogroup C disease, Hib diseases
1459340|NCT00135551|Hypertension
1459341|NCT00135551|Multicenter clinical trial
1459342|NCT00135551|PROBE
1459343|NCT00135551|Combination therapy
1459344|NCT00135551|Benidipine
1459345|NCT00135551|Essential Hypertension
1459346|NCT00135538|Pulmonary Disease, Chronic Obstructive
1459347|NCT00135538|Intermittent Positive-Pressure Ventilation
1459348|NCT00135538|Rehabilitation
1459349|NCT00135525|Generalized Anxiety Disorder
1459351|NCT00135499|Lymphoma
1459352|NCT00135499|chemotherapy
1459353|NCT00135499|rituximab
1459354|NCT00135486|Haemophilus Influenzae type b/Meningococcal vaccine
1459355|NCT00135486|Prophylaxis meningococcal serogroup C disease, Hib diseases
1459356|NCT00135473|Severe sepsis
1459357|NCT00135473|septic shock
1459358|NCT00135473|volume substitution
1459359|NCT00135473|intensive insulin therapy
1459360|NCT00135473|colloids
1459361|NCT00135473|crystalloids
1459362|NCT00135473|outcome
1459363|NCT00135473|safety
1459364|NCT00135460|HIV
1459365|NCT00135460|Lipoatrophy
1459366|NCT00135460|Lipodystrophy
1459367|NCT00135460|Treatment Naive
1459368|NCT00135460|HIV Infections
1459369|NCT00135460|Hypercholesterolemia
1459370|NCT00135447|HIV/AIDS
1459371|NCT00135447|Treatment Experienced
1459372|NCT00135408|Unresectable Stage III or IV Malignant Melanoma
1459373|NCT00135395|HIV/AIDS
1459374|NCT00135395|Treatment Experienced
1459375|NCT00135382|HIV/AIDS
1459376|NCT00135369|HIV-AIDS
1459377|NCT00135356|HIV infections
1459378|NCT00135343|HIV/AIDS
1459379|NCT00135330|diabetes
1459380|NCT00135330|exenatide
1459381|NCT00135330|rosiglitazone
1459382|NCT00135330|Amylin
1459383|NCT00135330|Lilly
1459384|NCT00135317|oncology
1459385|NCT00135317|darbepoetin alfa
1459386|NCT00135317|Aranesp®
1459387|NCT00135317|Amgen
1459388|NCT00135317|Non-myeloid malignancy
1459389|NCT00135304|Vitamin D
1459390|NCT00135304|Sensipar®
1459391|NCT00135304|Cinacalcet HCl
1459392|NCT00135304|Chronic Kidney Disease
1459393|NCT00135291|transfusion-induced immunomodulation
1459394|NCT00135291|leukoreduction
1459395|NCT00135291|surgical site infections
1459396|NCT00135291|nosocomial infections
1459397|NCT00135291|transfusion
1459398|NCT00135291|Infection
1459399|NCT00135291|Sepsis
1459400|NCT00135291|Hemorrhage
1459401|NCT00135278|Neuroprotection
1459402|NCT00135278|inflammation
1459403|NCT00135278|cytokines
1459404|NCT00135278|CSF
1459405|NCT00135265|smoking cessation
1459406|NCT00135265|adolescents
1459407|NCT00135252|developing chronic lung disease
1459408|NCT00135239|back
1459409|NCT00135239|Lower Mechanical Back Pain
1459410|NCT00135239|Rehabilitation
1459411|NCT00135226|Diabetes Mellitus
1459412|NCT00135226|Cardiovascular Disease
1459413|NCT00135226|Aspirin
1459414|NCT00135226|Omega-3 fatty acids
1459415|NCT00135226|Primary prevention
1459416|NCT00135226|Randomized Controlled Trial
1459417|NCT00135226|Type 1 Diabetes Mellitus
1459418|NCT00135226|Type 2 Diabetes Mellitus
1459419|NCT00135213|passive smoking
1459420|NCT00135213|pediatric practice
1459421|NCT00135213|smoking cessation
1459422|NCT00135174|Pacemaker
1459423|NCT00135174|routine
1459424|NCT00135174|follow-up
1459425|NCT00135174|complications
1459426|NCT00135174|Quality of Life
1459427|NCT00135161|neoplasms (squamous cell carcinoma of the head and neck region)
1459428|NCT00135044|taurine
1459429|NCT00135044|intestinal failure
1459430|NCT00135044|HPN
1459431|NCT00135044|hepatobiliary complications
1459432|NCT00135044|chronic intestinal failure (CIF)
1459433|NCT00135005|GIST
1459434|NCT00135005|AMN107
1459435|NCT00135005|Gastrointestinal Stromal Tumors
1459436|NCT00134992|Prednisolone acetate
1459437|NCT00134992|eye drops
1459438|NCT00134992|tolerability
1459439|NCT00134992|Healthy volunteers
1459440|NCT00134979|COPD, formoterol,
1459441|NCT00134966|Parkinson's disease, levodopa, dyskinesia
1459442|NCT00134953|Mild cognitive impairment
1459443|NCT00134953|Alzheimer's disease
1459444|NCT00134953|Dementia
1459445|NCT00134953|Mild Cognitive Impairment (MCI)
1459446|NCT00134940|Transplantation, heart
1459447|NCT00134940|Organ transplant
1459448|NCT00134914|opiate dependence
1459449|NCT00134901|Cocaine dependence
1459450|NCT00134901|treatment
1459451|NCT00134901|memantine
1459452|NCT00134888|Opioid Dependence
1459453|NCT00134875|opioid dependence
1459454|NCT00134849|hypertension
1459455|NCT00134823|Parent Experience of Care
1459456|NCT00134823|Quality Improvement
1459457|NCT00134823|Medication Errors
1459458|NCT00134823|Abnormal Lab Values
1459459|NCT00134823|Guideline Adherence
1459460|NCT00134810|Myofascial pain syndrome
1459462|NCT00134797|serum creatinine
1459463|NCT00134784|parkinson
1459464|NCT00134784|brain imaging
1459465|NCT00134771|Infants whose birthweight is less than the 20th centile for gestational age (UK standards)
1459466|NCT00134771|Infants who are formula fed from birth
1459467|NCT00134771|Singletons
1459468|NCT00134771|Infants free from major congenital disease
1459469|NCT00134758|Treatment of adenomas of the duodenum in FAP patients.
1459470|NCT00134758|Adenoma
1459471|NCT00134745|Turner Syndrome
1459472|NCT00134745|Hormonal replacement therapy
1459473|NCT00134745|Bone mineralization
1459474|NCT00134745|Uterine size
1459475|NCT00134745|aortic root dilatation
1459476|NCT00134732|Prophylaxis of Rotavirus Gastroenteritis
1459477|NCT00134719|Invasive Hib & N. meningitidis diseases
1459478|NCT00134706|Prostate Cancer
1459479|NCT00134706|Cancer of the prostate
1459480|NCT00134706|Cancer of prostate
1459481|NCT00134706|Docetaxel
1459482|NCT00134706|Carboplatin
1459483|NCT00134693|SB-681323 rheumatoid arthritis CRP biomarkers
1459484|NCT00134680|estrogen receptor positive
1459485|NCT00134680|progesterone receptor positive
1459486|NCT00134680|ErbB2 positive
1459487|NCT00134680|metastatic breast cancer
1459488|NCT00134667|AMD
1459489|NCT00134667|Age-Related Macular Degeneration
1459490|NCT00134667|Macular Degeneration
1459491|NCT00134667|Macugen
1459492|NCT00134667|Photodynamic Therapy
1459493|NCT00134667|PDT
1459494|NCT00134667|Visudyne
1459495|NCT00134667|pegaptanib sodium
1459496|NCT00134667|verteporfin
1459497|NCT00134667|Predominantly Classic
1459498|NCT00134667|Age-Related Macular Degeneration (AMD)
1459499|NCT00134654|Androgen-independent prostate cancer
1459500|NCT00134654|Premarin
1459501|NCT00134654|conjugated estrogen
1459502|NCT00134641|soft tissue sarcoma
1459503|NCT00134641|metastatic soft tissue sarcoma
1459504|NCT00134641|gemcitabine
1459505|NCT00134641|vinorelbine
1459506|NCT00134628|Hyperbaric Oxygenation
1459507|NCT00134628|Radiation injuries
1459508|NCT00134628|Prophylaxis
1459509|NCT00134628|Proctitis
1459510|NCT00134628|Cystitis
1459511|NCT00134628|Enteritis
1459512|NCT00134628|Osteoradionecrosis
1459513|NCT00134615|decision-making
1459514|NCT00134615|patient activation
1459515|NCT00134615|empowerment
1459516|NCT00134615|mental health
1459517|NCT00134615|Depression
1459518|NCT00134615|Anxiety
1459519|NCT00134615|Other Psychiatric Disorder
1459520|NCT00134602|HIV infection, antiretroviral therapy, adherence, pediatric
1459521|NCT00134589|Academic Detailing
1459522|NCT00134589|Decision Aid
1459523|NCT00134589|Colorectal Cancer Screening
1459524|NCT00134589|RECTAL NEOPLASMS
1459525|NCT00134589|COLONIC POLYPS
1459526|NCT00134563|Multiple Sclerosis
1459527|NCT00134563|Relapsing Remitting
1459528|NCT00134563|Secondary Progressive
1459529|NCT00134563|Progressive Relapsing
1459530|NCT00134550|Diabetes Mellitus
1459531|NCT00134550|Foot ulcers
1459532|NCT00134550|Complication
1459533|NCT00134550|Foot Ulcer, Diabetic
1459534|NCT00134537|Degenerative Disc Disease of the lumbar spine
1459535|NCT00134524|Magnetics
1459536|NCT00134524|Electromagnetics
1459537|NCT00134524|Diabetic neuropathy
1459538|NCT00134524|Pain
1459539|NCT00134472|Hypothermia, induced
1459540|NCT00134472|Traumatic Brain injuries
1459541|NCT00134472|Anesthesia
1459542|NCT00134472|Neuro-intensive care
1459543|NCT00134472|neurochemistry
1459544|NCT00134459|Depression
1459545|NCT00134459|Bipolar Disorder
1459546|NCT00134446|post traumatic stress disorder
1459547|NCT00134446|PTSD
1459548|NCT00134446|trauma
1459549|NCT00134446|transcranial magnetic stimulation
1459550|NCT00134446|randomized clinical trial
1459551|NCT00134433|Coronary Artery Disease, Diffuse
1459552|NCT00134433|Coronary Artery Disease, Deemed Inoperable
1459553|NCT00134420|Growth Hormone
1459554|NCT00134420|Chromosomes, Human, Pair 18
1459555|NCT00134420|Child
1459556|NCT00134407|Nutrition
1459557|NCT00134407|Postoperative
1459558|NCT00134407|oral
1459559|NCT00134407|jejunal
1459560|NCT00134407|feeding
1459561|NCT00134407|Surgery
1459562|NCT00134407|major
1459563|NCT00134407|abdominal
1459564|NCT00134407|adult
1459565|NCT00134394|psoriasis
1459566|NCT00134394|tacrolimus
1459567|NCT00134394|etanercept
1459568|NCT00134381|Normal volunteer study
1459569|NCT00134368|vitiligo
1459570|NCT00134368|etanercept
1459571|NCT00134355|antiangiogenesis therapy
1459572|NCT00134355|vatalanib
1459573|NCT00134342|tuberculosis
1459574|NCT00134342|tuberculin test
1459575|NCT00134342|immunologic tests
1459576|NCT00134342|Latent tuberculosis
1459577|NCT00134342|end stage renal disease
1459578|NCT00134342|solid organ transplantation
1459579|NCT00134342|bone marrow transplantation
1459580|NCT00134342|rheumatologic disease
1459581|NCT00134316|sexual dysfunction
1459582|NCT00134251|Parkinson's disease
1459583|NCT00134251|adjunctive to L-dopa therapy
1459584|NCT00134251|Advanced stage Parkinson's disease
1459585|NCT00134225|Musculoskeletal abnormality
1459586|NCT00134225|Musculoskeletal physiology
1459587|NCT00134225|Musculoskeletal disease
1459588|NCT00134225|Musculoskeletal dysfunction
1459589|NCT00134212|Splanchnic perfusion, hepatic damage, oxidative stress.
1459590|NCT00134186|Kidney cancer
1459591|NCT00134186|Renal cell carcinoma
1459592|NCT00134186|Motexafin gadolinium
1459593|NCT00134160|Aged
1459594|NCT00134160|Hypertension
1459595|NCT00134160|Cardiovascular Diseases
1459596|NCT00134160|Angiotensin II Type 1 Receptor Blockers
1459597|NCT00134160|Calcium Channel Blockers
1459598|NCT00134160|Combination Drug Therapy
1459599|NCT00134160|Diabetes Mellitus Type 2
1459600|NCT00134134|hidradenitis suppurativa
1459601|NCT00134134|efalizumab
1459602|NCT00134134|biologic
1459603|NCT00134134|Raptiva
1459604|NCT00134095|adenocarcinoma of the stomach
1459605|NCT00134095|stage II gastric cancer
1459606|NCT00134095|stage III gastric cancer
1459607|NCT00134095|stage IV gastric cancer
1459608|NCT00134082|recurrent adult Hodgkin lymphoma
1459609|NCT00134056|adenocarcinoma of the prostate
1459610|NCT00134056|stage IV prostate cancer
1459611|NCT00134056|recurrent prostate cancer
1459612|NCT00134056|bone metastases
1459613|NCT00134017|adult acute myeloid leukemia in remission
1459614|NCT00134017|refractory anemia with excess blasts
1459615|NCT00134017|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1459616|NCT00134017|adult acute myeloid leukemia with inv(16)(p13;q22)
1459617|NCT00134017|adult acute myeloid leukemia with t(15;17)(q22;q12)
1459618|NCT00134017|adult acute myeloid leukemia with t(16;16)(p13;q22)
1459619|NCT00134017|adult acute myeloid leukemia with t(8;21)(q22;q22)
1459620|NCT00134017|childhood acute myeloid leukemia in remission
1459621|NCT00134017|recurrent adult acute myeloid leukemia
1459622|NCT00134017|recurrent childhood acute myeloid leukemia
1459623|NCT00134017|secondary acute myeloid leukemia
1459624|NCT00134017|de novo myelodysplastic syndromes
1459625|NCT00134017|adult acute lymphoblastic leukemia in remission
1459626|NCT00134017|childhood acute lymphoblastic leukemia in remission
1459627|NCT00134017|recurrent adult acute lymphoblastic leukemia
1459628|NCT00134017|recurrent childhood acute lymphoblastic leukemia
1459629|NCT00134017|accelerated phase chronic myelogenous leukemia
1459630|NCT00134017|blastic phase chronic myelogenous leukemia
1459631|NCT00134017|childhood chronic myelogenous leukemia
1459632|NCT00134017|chronic phase chronic myelogenous leukemia
1459633|NCT00134017|relapsing chronic myelogenous leukemia
1459634|NCT00134017|stage III chronic lymphocytic leukemia
1459635|NCT00134017|stage IV chronic lymphocytic leukemia
1459636|NCT00134017|chronic eosinophilic leukemia
1459637|NCT00134017|chronic idiopathic myelofibrosis
1459638|NCT00134017|chronic neutrophilic leukemia
1459639|NCT00134017|stage III adult Hodgkin lymphoma
1459640|NCT00134017|stage IV adult Hodgkin lymphoma
1459641|NCT00134017|stage II multiple myeloma
1459642|NCT00134017|stage III multiple myeloma
1459643|NCT00134017|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1459644|NCT00134017|nodal marginal zone B-cell lymphoma
1459645|NCT00134017|splenic marginal zone lymphoma
1459646|NCT00134017|noncontiguous stage II adult Burkitt lymphoma
1459647|NCT00134017|noncontiguous stage II adult diffuse large cell lymphoma
1459648|NCT00134017|noncontiguous stage II adult diffuse mixed cell lymphoma
1459649|NCT00134017|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1459650|NCT00134017|noncontiguous stage II adult immunoblastic large cell lymphoma
1459651|NCT00134017|noncontiguous stage II adult lymphoblastic lymphoma
1459652|NCT00134017|noncontiguous stage II grade 1 follicular lymphoma
1459653|NCT00134017|noncontiguous stage II grade 2 follicular lymphoma
1459654|NCT00134017|noncontiguous stage II grade 3 follicular lymphoma
1459655|NCT00134017|noncontiguous stage II mantle cell lymphoma
1459656|NCT00134017|noncontiguous stage II marginal zone lymphoma
1459657|NCT00134017|noncontiguous stage II small lymphocytic lymphoma
1459658|NCT00134017|previously treated myelodysplastic syndromes
1459659|NCT00134017|recurrent adult Burkitt lymphoma
1459660|NCT00134017|recurrent adult diffuse large cell lymphoma
1459661|NCT00134017|recurrent adult diffuse mixed cell lymphoma
1459662|NCT00134017|recurrent adult diffuse small cleaved cell lymphoma
1459663|NCT00134017|recurrent adult immunoblastic large cell lymphoma
1459664|NCT00134017|recurrent adult lymphoblastic lymphoma
1459665|NCT00134017|recurrent childhood large cell lymphoma
1459666|NCT00134017|recurrent childhood lymphoblastic lymphoma
1459667|NCT00134017|recurrent grade 1 follicular lymphoma
1459668|NCT00134017|recurrent grade 2 follicular lymphoma
1459669|NCT00134017|recurrent grade 3 follicular lymphoma
1459670|NCT00134017|recurrent mantle cell lymphoma
1459671|NCT00134017|recurrent childhood small noncleaved cell lymphoma
1459672|NCT00134017|recurrent/refractory childhood Hodgkin lymphoma
1459673|NCT00134017|recurrent adult Hodgkin lymphoma
1459674|NCT00134017|recurrent small lymphocytic lymphoma
1459675|NCT00134017|recurrent marginal zone lymphoma
1459676|NCT00134017|stage III adult Burkitt lymphoma
1459677|NCT00134017|stage III adult diffuse large cell lymphoma
1460004|NCT00132899|Crohn's Disease
1459678|NCT00134017|stage III adult diffuse mixed cell lymphoma
1459679|NCT00134017|stage III adult diffuse small cleaved cell lymphoma
1459680|NCT00134017|stage III adult immunoblastic large cell lymphoma
1459681|NCT00134017|stage III adult lymphoblastic lymphoma
1459682|NCT00134017|stage IV adult Burkitt lymphoma
1459683|NCT00134017|stage IV adult diffuse large cell lymphoma
1459684|NCT00134017|stage IV adult diffuse mixed cell lymphoma
1459685|NCT00134017|stage IV adult diffuse small cleaved cell lymphoma
1459686|NCT00134017|stage IV adult immunoblastic large cell lymphoma
1459687|NCT00134017|stage III grade 1 follicular lymphoma
1459688|NCT00134017|stage III grade 2 follicular lymphoma
1459689|NCT00134017|stage III grade 3 follicular lymphoma
1459690|NCT00134017|stage IV grade 1 follicular lymphoma
1459691|NCT00134017|stage IV grade 2 follicular lymphoma
1459692|NCT00134017|stage IV grade 3 follicular lymphoma
1459693|NCT00134017|stage III mantle cell lymphoma
1459694|NCT00134017|stage III marginal zone lymphoma
1459695|NCT00134017|stage IV mantle cell lymphoma
1459696|NCT00134017|stage IV marginal zone lymphoma
1459697|NCT00134017|stage III small lymphocytic lymphoma
1459698|NCT00134017|stage IV small lymphocytic lymphoma
1459699|NCT00134017|chronic myelomonocytic leukemia
1459700|NCT00134017|refractory chronic lymphocytic leukemia
1459701|NCT00134017|refractory multiple myeloma
1459702|NCT00134017|secondary myelodysplastic syndromes
1459703|NCT00134017|stage IV adult lymphoblastic lymphoma
1459704|NCT00134017|childhood myelodysplastic syndromes
1459705|NCT00134004|adult acute lymphoblastic leukemia in remission
1459706|NCT00134004|adult acute myeloid leukemia in remission
1459707|NCT00134004|childhood acute lymphoblastic leukemia in remission
1459708|NCT00134004|childhood acute myeloid leukemia in remission
1459709|NCT00134004|childhood chronic myelogenous leukemia
1459710|NCT00134004|chronic phase chronic myelogenous leukemia
1459711|NCT00134004|refractory chronic lymphocytic leukemia
1459712|NCT00134004|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1459713|NCT00134004|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1459714|NCT00134004|adult acute myeloid leukemia with inv(16)(p13;q22)
1459715|NCT00134004|adult acute myeloid leukemia with t(15;17)(q22;q12)
1459716|NCT00134004|adult acute myeloid leukemia with t(16;16)(p13;q22)
1459717|NCT00134004|adult acute myeloid leukemia with t(8;21)(q22;q22)
1459718|NCT00134004|chronic idiopathic myelofibrosis
1459719|NCT00134004|chronic myelomonocytic leukemia
1459720|NCT00134004|de novo myelodysplastic syndromes
1459721|NCT00134004|previously treated myelodysplastic syndromes
1459722|NCT00134004|noncontiguous stage II adult Burkitt lymphoma
1459723|NCT00134004|noncontiguous stage II adult diffuse large cell lymphoma
1459724|NCT00134004|noncontiguous stage II adult diffuse mixed cell lymphoma
1459725|NCT00134004|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1459726|NCT00134004|noncontiguous stage II adult immunoblastic large cell lymphoma
1459727|NCT00134004|noncontiguous stage II adult lymphoblastic lymphoma
1459728|NCT00134004|noncontiguous stage II grade 1 follicular lymphoma
1459729|NCT00134004|noncontiguous stage II grade 2 follicular lymphoma
1459730|NCT00134004|noncontiguous stage II grade 3 follicular lymphoma
1459731|NCT00134004|noncontiguous stage II mantle cell lymphoma
1459732|NCT00134004|noncontiguous stage II marginal zone lymphoma
1459733|NCT00134004|noncontiguous stage II small lymphocytic lymphoma
1459734|NCT00134004|recurrent adult Burkitt lymphoma
1459735|NCT00134004|recurrent adult diffuse large cell lymphoma
1459736|NCT00134004|recurrent adult diffuse mixed cell lymphoma
1459737|NCT00134004|recurrent adult diffuse small cleaved cell lymphoma
1459738|NCT00134004|recurrent adult Hodgkin lymphoma
1459739|NCT00134004|recurrent adult immunoblastic large cell lymphoma
1459740|NCT00134004|recurrent adult lymphoblastic lymphoma
1459741|NCT00134004|recurrent/refractory childhood Hodgkin lymphoma
1459742|NCT00134004|recurrent childhood large cell lymphoma
1459743|NCT00134004|recurrent childhood lymphoblastic lymphoma
1459744|NCT00134004|recurrent childhood small noncleaved cell lymphoma
1459745|NCT00134004|nodal marginal zone B-cell lymphoma
1459746|NCT00134004|recurrent grade 1 follicular lymphoma
1459747|NCT00134004|recurrent grade 2 follicular lymphoma
1459748|NCT00134004|recurrent grade 3 follicular lymphoma
1459749|NCT00134004|recurrent mantle cell lymphoma
1459750|NCT00134004|recurrent marginal zone lymphoma
1459751|NCT00134004|recurrent small lymphocytic lymphoma
1459752|NCT00134004|refractory multiple myeloma
1459753|NCT00134004|relapsing chronic myelogenous leukemia
1459754|NCT00134004|secondary myelodysplastic syndromes
1459755|NCT00134004|splenic marginal zone lymphoma
1459756|NCT00134004|stage I multiple myeloma
1459757|NCT00134004|stage II multiple myeloma
1459758|NCT00134004|stage III multiple myeloma
1459759|NCT00134004|stage III adult Burkitt lymphoma
1459760|NCT00134004|stage III adult diffuse large cell lymphoma
1459761|NCT00134004|stage III adult diffuse mixed cell lymphoma
1459762|NCT00134004|stage III adult diffuse small cleaved cell lymphoma
1459763|NCT00134004|stage III adult Hodgkin lymphoma
1459764|NCT00134004|stage III adult immunoblastic large cell lymphoma
1459765|NCT00134004|stage III adult lymphoblastic lymphoma
1459766|NCT00134004|stage III grade 1 follicular lymphoma
1459767|NCT00134004|stage III grade 2 follicular lymphoma
1459768|NCT00134004|stage III grade 3 follicular lymphoma
1459769|NCT00134004|stage III mantle cell lymphoma
1459770|NCT00134004|stage III marginal zone lymphoma
1459771|NCT00134004|polycythemia vera
1459772|NCT00134004|essential thrombocythemia
1459773|NCT00134004|stage III small lymphocytic lymphoma
1459774|NCT00134004|stage IV mantle cell lymphoma
1459775|NCT00134004|stage IV marginal zone lymphoma
1459776|NCT00134004|stage IV grade 1 follicular lymphoma
1459777|NCT00134004|stage IV grade 2 follicular lymphoma
1459778|NCT00134004|stage IV grade 3 follicular lymphoma
1459779|NCT00134004|stage IV adult Burkitt lymphoma
1459780|NCT00134004|stage IV adult diffuse large cell lymphoma
1459781|NCT00134004|stage IV adult diffuse mixed cell lymphoma
1459782|NCT00134004|stage IV adult diffuse small cleaved cell lymphoma
1459783|NCT00134004|stage IV adult immunoblastic large cell lymphoma
1459784|NCT00134004|stage IV adult lymphoblastic lymphoma
1459785|NCT00134004|stage IV small lymphocytic lymphoma
1459786|NCT00134004|stage IV adult Hodgkin lymphoma
1459787|NCT00134004|childhood myelodysplastic syndromes
1459788|NCT00133991|untreated adult acute lymphoblastic leukemia
1459789|NCT00133991|L3 adult acute lymphoblastic leukemia
1459790|NCT00133991|contiguous stage II adult Burkitt lymphoma
1459791|NCT00133991|noncontiguous stage II adult Burkitt lymphoma
1459792|NCT00133991|stage I adult Burkitt lymphoma
1459793|NCT00133991|stage III adult Burkitt lymphoma
1459794|NCT00133991|stage IV adult Burkitt lymphoma
1459795|NCT00133978|randomized trial
1459796|NCT00133978|antioxidants
1459797|NCT00133978|glutamine
1459798|NCT00133978|organ failure
1459799|NCT00133965|Advanced Cancer
1459800|NCT00133965|Dignity Care
1459801|NCT00133965|Supportive Care
1459802|NCT00133965|Quality of Life
1459803|NCT00133965|Psychotherapy
1459804|NCT00133965|Palliative Care
1459805|NCT00133939|Proportional assisted ventilation
1459806|NCT00133939|Pressure support ventilation
1459807|NCT00133939|Synchronism during mechanical ventilation
1459808|NCT00133939|Patients undergoing partial mechanical ventilation
1459809|NCT00133926|Periodontal disease
1459810|NCT00133926|Pregnancy
1459811|NCT00133926|Pre-term birth
1459812|NCT00133926|Fetal growth
1459813|NCT00133926|Pre-eclampsia
1459814|NCT00133926|Infant, Low Birth Weight
1459815|NCT00133913|metastatic colorectal cancer
1459816|NCT00133900|hormone refractory prostate cancer
1459817|NCT00133887|Squamous cell carcinoma
1459818|NCT00133887|kidney transplant recipients
1459819|NCT00133887|rapamycin
1459820|NCT00133887|Skin cancers in kidney transplant recipients
1459821|NCT00133874|topical antibacterial
1459822|NCT00133874|topical antibiotic
1459823|NCT00133874|impetigo
1459824|NCT00133861|cerebral palsy children
1459825|NCT00133861|Botulinum toxin
1459826|NCT00133848|impetigo
1459827|NCT00133848|topical antibacterial
1459828|NCT00133848|topical antibiotic
1459829|NCT00133835|Randomized controlled trial
1459830|NCT00133835|Lithotripsy
1459831|NCT00133835|Cholangiopancreatography, Endoscopic Retrograde
1459832|NCT00133835|Abdominal pain
1459833|NCT00133822|Post-Traumatic Stress Disorder
1459834|NCT00133822|Sertraline
1459835|NCT00133822|Risperidone
1459836|NCT00133809|Type 1 Diabetes
1459837|NCT00133809|Islet Transplantation
1459838|NCT00133809|Immunology
1459839|NCT00133796|Breast Cancer
1459840|NCT00133796|Advanced Breast Cancer
1459841|NCT00133783|Intermedin
1459842|NCT00133783|estradiol
1459843|NCT00133783|female hypertension
1459844|NCT00133783|Premenopausal and postmenopausal women
1459845|NCT00133783|Surgically-induced menopause women
1459846|NCT00133783|IVF treatment patients
1459847|NCT00133770|IV pantoprazole
1459848|NCT00133770|Esophagitis
1459849|NCT00133757|Tobacco
1459850|NCT00133757|Nicotine
1459851|NCT00133757|Bupropion
1459852|NCT00133757|Cue-reactivity
1459853|NCT00133757|Craving
1459854|NCT00133744|pregnancy
1459855|NCT00133744|vitamins
1459856|NCT00133744|minerals
1459857|NCT00133744|supplements
1459858|NCT00133744|mortality
1459859|NCT00133744|prenatal
1459860|NCT00133744|perinatal
1459861|NCT00133744|anemia
1459862|NCT00133744|birthweight
1459863|NCT00133744|preterm
1459864|NCT00133744|iron
1459865|NCT00133744|micronutrients
1459866|NCT00133744|Stillbirths
1459867|NCT00133744|Early neonatal deaths
1459868|NCT00133718|Type 2 diabetes mellitus
1459869|NCT00133718|Cardiovascular
1459870|NCT00133718|Coronary artery disease
1459871|NCT00133718|Glycemic control
1459872|NCT00133718|Treatment
1459873|NCT00133718|Diabetes Mellitus
1459874|NCT00133705|A benign tumor derived from smooth uterine muscle tissue.
1459875|NCT00133692|Hypertension
1459876|NCT00133692|Coronary Artery Disease
1459877|NCT00133692|INVEST
1459878|NCT00133692|Diabetes
1459879|NCT00133692|Verapamil SR
1459880|NCT00133692|Trandolapril
1459881|NCT00133692|Atenolol
1459882|NCT00133692|HCTZ
1459883|NCT00133679|Chronic lung disease
1459884|NCT00133679|Nitric oxide
1459885|NCT00133679|cyclic guanosine monophosphate
1459886|NCT00133679|phosphodiesterase inhibitor
1459887|NCT00133653|Hypertension; Job Strain; Marital Strain; Blood Pressure
1459888|NCT00133640|Vitamin D
1459889|NCT00133640|Elderly
1459890|NCT00133640|Hip fracture
1459891|NCT00133640|Falls
1459892|NCT00133640|Physical Therapy
1459893|NCT00133640|Disability
1459894|NCT00133627|Allergic
1459895|NCT00133627|Conjunctivitis
1459896|NCT00133627|Ketotifen
1459897|NCT00133627|Histamine
1459898|NCT00133588|influenza, vaccine, proteomic profiling, elderly
1459899|NCT00133575|MVA, smallpox, Acambis
1459900|NCT00133562|Malnutrition, pediatric, Brazil, alanyl-glutamine
1459901|NCT00133549|pneumococcal vaccine, 23-valent polysaccharide vaccine, elderly
1459902|NCT00133536|H5N1, Influenza, children
1459903|NCT00133523|FLU-VACS, influenza, vaccine
1459904|NCT00133510|children, immunocompromised, influenza, liver transplant
1459905|NCT00133497|cytomegalovirus, vaccine, women, children, parent protocol
1459906|NCT00133484|Anthrax, rPA
1459907|NCT00133471|Influenza, vaccine, A/H9N2, MF59, adjuvant
1459908|NCT00133458|Albenza, Subarachnoid cysticercosis
1459909|NCT00133445|Pentavalent vaccine, Pediarix, DTaP-Hep B-IPV vaccine
1459910|NCT00133432|Pneumonia, acute respiratory infections, zinc, Tanzania, children, infants, hospitalization
1459911|NCT00133419|micronutrient, supplementation, Africa, children, HIV
1459912|NCT00133406|Brazil, Child Nutrition Disorders, Deficiency Diseases
1459913|NCT00133367|Hematologic malignancy
1459914|NCT00133367|Cord blood transfusion
1459915|NCT00133367|Graft versus host disease
1459916|NCT00133367|tacrolimus
1459917|NCT00133367|sirolimus
1459918|NCT00133354|Puberty
1459919|NCT00133354|Growth hormone deficiency
1459920|NCT00133354|aromatase inhibitors
1459921|NCT00133354|estrogen
1459922|NCT00133354|bone mineral density
1459923|NCT00133354|short stature
1459924|NCT00133341|Allergic contact dermatitis,patch testing, dilution series
1459925|NCT00133328|stroke
1459926|NCT00133328|myocardial infarction
1459927|NCT00133328|angina
1459928|NCT00133328|renal damage
1459929|NCT00133302|Non-Hodgkin's lymphoma
1459930|NCT00133302|intermediate-grade lymphoma
1459931|NCT00133302|high-grade lymphoma
1459932|NCT00133302|CHOP protocol
1459933|NCT00133302|granulocyte-colony stimulating factor
1459934|NCT00133276|Hepatitis C
1459935|NCT00133276|Peg-interferon
1459936|NCT00133276|Psychiatric side-effects
1459937|NCT00133263|Randomized controlled trial
1459938|NCT00133263|Primary Care
1459939|NCT00133224|Advanced Prostate Cancer
1459940|NCT00133224|HRPC
1459941|NCT00133224|Prostate
1459942|NCT00133224|Cancer
1459943|NCT00133224|Metastatic
1459944|NCT00133224|Hormone-refractory
1459945|NCT00133224|GVAX
1459946|NCT00133224|Chemotherapy
1459947|NCT00133224|Taxotere
1459948|NCT00133224|Docetaxel
1459949|NCT00133224|Prednisone
1459950|NCT00133224|Vaccine
1459951|NCT00133224|Allogeneic cells
1459952|NCT00133211|Paroxysmal atrial fibrillation
1459953|NCT00133211|Heart arrhythmia
1459954|NCT00133211|Ablation
1459955|NCT00133211|Drug treatment
1459956|NCT00133172|Treatment Efficacy
1459957|NCT00133172|Treatment Effectiveness
1459958|NCT00133172|Anti-rejection therapy
1459959|NCT00133172|Immunosuppression
1459960|NCT00133172|Antirejection
1459961|NCT00133172|Renal Transplantation
1459962|NCT00133172|Transplantation, Renal
1459963|NCT00133172|Transplantation, Kidney
1459964|NCT00133172|Grafting, Kidney
1459965|NCT00133159|Allergy
1459966|NCT00133159|Specific Immunotherapy
1459967|NCT00133146|Allergy
1459968|NCT00133146|Specific Immunotherapy
1459969|NCT00133133|Postoperative pain
1459970|NCT00133133|Open cholecystectomy
1459971|NCT00133133|Capsaicin
1459972|NCT00133094|Hypercholesterolemia
1459973|NCT00133094|Decision Support Systems, Clinical
1459974|NCT00133081|epilepsy
1459975|NCT00133081|antiepileptic drugs
1459976|NCT00133081|side effects
1459977|NCT00133081|quality of life
1459978|NCT00133068|High Blood Pressure
1459979|NCT00133068|Health Behaviors
1459980|NCT00133068|Patient Compliance
1459981|NCT00133055|parenting
1459982|NCT00133055|sleep problems
1459983|NCT00133055|behavior problems
1459984|NCT00133055|brief intervention
1459985|NCT00133055|self-help
1459986|NCT00133055|preschool-age children
1459987|NCT00133055|psychosocial
1459988|NCT00133042|anti-IgE, omalizumab
1459989|NCT00133016|Induction of labor
1459990|NCT00132990|Cervical dystonia
1459991|NCT00132990|Deep brain stimulation
1459992|NCT00132977|Cardiac Resynchronization Therapy
1459993|NCT00132977|Heart Failure
1459994|NCT00132977|Mechanical Dyssynchrony
1459995|NCT00132964|pediatric
1459996|NCT00132964|ankle fractures
1459997|NCT00132964|randomized controlled trial
1459998|NCT00132964|management
1459999|NCT00132925|allergic rhinitis
1460000|NCT00132912|Platelets
1460001|NCT00132912|Platelet Aggregation Inhibitors
1460002|NCT00132912|Protease-Activated Receptor 1
1460003|NCT00132912|Hemorrhage
1460005|NCT00132899|multi-centre randomized placebo-controlled
1460006|NCT00132899|infliximab
1460007|NCT00132899|methotrexate
1460008|NCT00132899|inflammatory bowel disease
1460009|NCT00132873|Narcolepsy
1460010|NCT00132873|Cataplexy
1460011|NCT00132847|Child
1460012|NCT00132847|Adolescent
1460013|NCT00132847|Urban Health
1460014|NCT00132821|Nicotine dependence
1460015|NCT00132821|Sleep disorders
1460016|NCT00132821|smoking cessation
1460017|NCT00132821|Relapse
1460018|NCT00132808|Postmenopausal osteoporosis
1460019|NCT00132808|osteopenia
1460020|NCT00132808|zoledronic acid
1460021|NCT00132808|Osteopenia (osteoporosis prevention)
1460022|NCT00132795|Cognitive Therapy
1460023|NCT00132795|Recurrence
1460024|NCT00132795|Prevention
1460025|NCT00132795|Educational Technology
1460026|NCT00132756|Hormone Refractory
1460027|NCT00132756|Taxane Refractory
1460028|NCT00132704|Lung cancer metastases to the CNS (adenocarcinomas)
1460029|NCT00132704|Melanoma metastases to the CNS
1460030|NCT00132704|Breast cancer metastases to the CNS (ductal carcinomas)
1460031|NCT00132704|Central nervous system gliomas
1460032|NCT00132704|Colorectal cancers (adenocarcinomas)
1460033|NCT00132704|Ovarian cancers (papillary serous carcinomas)
1460034|NCT00132704|Endometrial cancers (endometrioid carcinomas)
1460035|NCT00132704|Cervical cancers (squamous cell carcinomas)
1460036|NCT00132704|Sarcomas (liposarcomas and leiomyosarcomas)
1460037|NCT00132704|Thoracic mesotheliomas
1460038|NCT00132704|Colorectal cancers metastatic to the liver
1460039|NCT00132704|Primary adenocarcinomas of the lung
1460040|NCT00132704|Primary squamous cell carcinomas of the lung
1460041|NCT00132704|Pancreatic Cancers-adenocarcinoma
1460042|NCT00132691|uveitis
1460043|NCT00132691|non-infectious intermediate uveitis
1460044|NCT00132691|non-infectious posterior uveitis
1460045|NCT00132691|non-infectious panuveitis
1460046|NCT00132678|Mood episodes
1460047|NCT00132678|Bipolar 1 disorder
1460048|NCT00132678|Intramuscular Injectable
1460049|NCT00132678|risperidone
1460050|NCT00132678|safety and efficacy
1460051|NCT00132665|non-small cell lung cancer
1460052|NCT00132665|elderly patients
1460053|NCT00132665|carboplatin
1460054|NCT00132665|chemoradiotherapy
1460055|NCT00132639|pulmonary neoplasm
1460056|NCT00132639|preoperative chemotherapy
1460057|NCT00132639|cisplatin, docetaxel
1460058|NCT00132639|randomized trial
1460059|NCT00132639|clinical stage IB or II nonsmall cell lung cancer
1460060|NCT00132626|parkinson
1460061|NCT00132626|diagnosis
1460062|NCT00132613|pulmonary neoplasm
1460063|NCT00132613|malignant pericardial effusion
1460064|NCT00132613|pericardial drainage
1460065|NCT00132613|randomized trial
1460066|NCT00132613|bleomycin
1460067|NCT00132613|intrapericardial instillation
1460068|NCT00132600|Allergic contact dermatitis
1460069|NCT00132600|Patch testing
1460070|NCT00132600|bacitracin
1460071|NCT00132587|Knee arthroplasty
1460072|NCT00132587|Femoral loosening
1460073|NCT00132587|Total Knee Arthroplasty
1460074|NCT00132574|acne, dairy
1460075|NCT00132548|Malaria
1460076|NCT00132548|Children
1460077|NCT00132548|Intermittent preventive treatment
1460078|NCT00132548|Senegal
1460079|NCT00132535|Malaria in pregnancy
1460080|NCT00132535|IPT
1460081|NCT00132535|Sulphadoxine-pyrimethamine
1460082|NCT00132535|Chloroquine
1460083|NCT00132535|HIV
1460084|NCT00132535|Viral load
1460085|NCT00132535|birth weight
1460086|NCT00132535|anaemia
1460087|NCT00132522|EpCAM
1460088|NCT00132522|monoclonal-antibody
1460089|NCT00132522|targeted therapy
1460090|NCT00132522|colorectal
1460091|NCT00132522|prostate
1460092|NCT00132522|non-small cell lung cancer
1460093|NCT00132522|ovarian
1460094|NCT00132522|solid tumor
1460095|NCT00132509|rt-PA
1460096|NCT00132509|thrombolysis
1460097|NCT00132509|Acute ischemic stroke
1460098|NCT00132496|GERD
1460099|NCT00132483|Physical activity
1460100|NCT00132483|cerebral infarct
1460101|NCT00132457|Chlamydia
1460102|NCT00132457|screening
1460103|NCT00132457|Sexually transmitted disease
1460104|NCT00132444|HIV
1460105|NCT00132444|topical microbicides
1460106|NCT00132431|calcimimetic
1460107|NCT00132431|cinacalcet
1460108|NCT00132431|hemodialysis
1460109|NCT00132431|secondary hyperparathyroidism
1460110|NCT00132431|chronic kidney disease
1460111|NCT00132418|rheumatoid arthritis and at least 1 qualifying comorbid condition (diabetes, chronic pulmonary disease, recent infection)
1460112|NCT00132418|RA
1460113|NCT00132418|rheumatoid arthritis
1460114|NCT00132405|Needlestick pain
1460115|NCT00132405|Venipuncture pain
1460116|NCT00132405|Procedural pain
1460117|NCT00132392|Arthroplasty
1460118|NCT00132392|Total knee arthroplasty
1460119|NCT00132392|Capsaicin
1460120|NCT00132392|Pain
1460121|NCT00132392|Analgesia
1460122|NCT00132366|Neurotransmission
1460123|NCT00132366|Cortical Excitability
1460124|NCT00132366|GABA
1460125|NCT00132366|Seizures
1460126|NCT00132366|Succinic Semialdehyde Dehydrogenase Deficiency
1460127|NCT00132366|SSADH
1460128|NCT00132366|Healthy Volunteer
1460129|NCT00132366|HV
1460130|NCT00132353|Magnetic Stimulation
1460131|NCT00132353|Single Fiber EMG
1460132|NCT00132353|Ultrasonography
1460133|NCT00132353|Quantitative Sensory Testing
1460134|NCT00132353|Near-nerve recording
1460135|NCT00132353|Neurological Disorders
1460136|NCT00132353|Neuromuscular Transmission Disorders
1460137|NCT00132353|Central Demyelinating Disorders
1460138|NCT00132353|Myelopathy
1460139|NCT00132353|Motor Neuron Disease
1460140|NCT00132353|Movement Disorders
1460141|NCT00132353|Healthy Volunteer
1460142|NCT00132340|Spasmodic Torticollis
1460143|NCT00132340|Treatment
1460144|NCT00132340|Physiology
1460145|NCT00132340|Surgery
1460146|NCT00132340|Cervical Dystonia
1460147|NCT00132327|Lyme Disease
1460148|NCT00132327|Borrelia Burgdorferi
1460149|NCT00132327|Inflammation
1460150|NCT00132327|Skin
1460151|NCT00132327|Host Response
1460152|NCT00132327|Erythema Migrans Rash
1460153|NCT00132327|Healthy Volunteer
1460154|NCT00132327|HV
1460155|NCT00132301|multi-site clinical trial
1460156|NCT00132301|prostate
1460157|NCT00132301|radical prostatectomy
1460158|NCT00132301|randomized
1460159|NCT00132288|Aging
1460160|NCT00132288|Frailty
1460161|NCT00132288|Sedentary
1460162|NCT00132288|Falls
1460163|NCT00132288|Physical Activity
1460164|NCT00132275|bacterial
1460165|NCT00132275|sinusitis
1460166|NCT00132275|treatment
1460167|NCT00132275|diagnosis
1460168|NCT00132275|guideline
1460169|NCT00132275|acute bacterial sinusitis
1460170|NCT00132262|Screening and Brief Intervention
1460171|NCT00132262|Ethnic Differences
1460172|NCT00132262|Trauma Center
1460173|NCT00132249|Traumatic Brain Injury
1460174|NCT00132249|Penetrating head wound
1460175|NCT00132249|Closed head trauma
1460176|NCT00132249|Vietnam Veteran
1460177|NCT00132236|smoking cessation
1460178|NCT00132236|nicotine sublingual tablets
1460179|NCT00132236|behaviour support
1460180|NCT00132236|smoking reduction
1460181|NCT00132236|quality of life
1460182|NCT00132236|COPD
1460183|NCT00132236|weight
1460184|NCT00132223|magnetic imaging
1460185|NCT00132223|angiography
1460186|NCT00132223|contrast agent
1460187|NCT00132223|signal/noise ratio
1460188|NCT00132223|contrast/noise ratio
1460189|NCT00132223|vessel
1460190|NCT00132210|acute hepatitis C
1460191|NCT00132210|HIV
1460192|NCT00132210|pegylated interferon
1460193|NCT00132197|Functional somatic symptoms
1460194|NCT00132197|Cognitive behavioral therapy
1460195|NCT00132197|somatization disorder
1460196|NCT00132197|SF-36
1460197|NCT00132197|cost-effectiveness
1460198|NCT00132197|Medically unexplained symptoms
1460199|NCT00132184|Vitamin D
1460200|NCT00132184|Crohns Disease
1460201|NCT00132171|Helicobacter pylori
1460202|NCT00132171|Eradication
1460203|NCT00132171|Sequential therapy
1460204|NCT00132171|Standard therapy
1460205|NCT00132145|Vascular diseases
1460206|NCT00132145|Computerized decision support systems
1460207|NCT00132145|Shared care
1460208|NCT00132145|Patient motivation
1460209|NCT00132145|Quality of care
1460210|NCT00132132|BMI
1460211|NCT00132132|obesity
1460212|NCT00132132|behavioral intervention
1460213|NCT00132132|longterm randomized controlled trial
1460214|NCT00132132|exercise
1460215|NCT00132132|empowerment
1460216|NCT00132132|nutrition
1460217|NCT00132093|Left ventricular remodelling
1460218|NCT00132093|Acute myocardial infarction
1460219|NCT00132093|Left ventricular dysfunction
1460220|NCT00132093|Eplerenone
1460221|NCT00132093|Cardiac Magnetic Resonance Imaging
1460222|NCT00132054|extensive stage small cell lung cancer
1460223|NCT00132054|recurrent small cell lung cancer
1460224|NCT00132041|adult primary hepatocellular carcinoma
1460225|NCT00132041|localized unresectable adult primary liver cancer
1460226|NCT00132015|Waldenström macroglobulinemia
1460227|NCT00132015|multicentric Castleman disease
1460228|NCT00132015|unicentric Castleman disease
1460229|NCT00132015|adult grade III lymphomatoid granulomatosis
1460230|NCT00132015|polycythemia vera
1460231|NCT00132015|essential thrombocythemia
1460232|NCT00132015|hairy cell leukemia
1460233|NCT00132015|monoclonal gammopathy of undetermined significance
1460234|NCT00132015|adult Burkitt lymphoma
1460235|NCT00132015|adult diffuse large cell lymphoma
1460236|NCT00132015|adult diffuse mixed cell lymphoma
1460237|NCT00132015|adult diffuse small cleaved cell lymphoma
1460238|NCT00132015|adult immunoblastic large cell lymphoma
1460239|NCT00132015|adult lymphoblastic lymphoma
1460240|NCT00132015|grade 1 follicular lymphoma
1460241|NCT00132015|grade 2 follicular lymphoma
1460242|NCT00132015|grade 3 follicular lymphoma
1460243|NCT00132015|mantle cell lymphoma
1460244|NCT00132015|marginal zone lymphoma
1460245|NCT00132015|small lymphocytic lymphoma
1460246|NCT00132015|precancerous condition
1460247|NCT00131963|stage One A (IA) breast cancer
1460248|NCT00131963|stage Two (II) breast cancer
1460249|NCT00131963|stage Three A (IIIA) breast cancer
1460250|NCT00131963|stage Three B(IIIB) breast cancer
1460251|NCT00131963|stage Three C(IIIC) breast cancer
1460252|NCT00131963|stage One B (IB) breast cancer
1460253|NCT00131950|breast cancer
1460254|NCT00131924|recurrent breast cancer
1460255|NCT00131924|stage IV breast cancer
1460256|NCT00131898|IMRT+Surgery versus Surgery For Sarcoma
1460257|NCT00131885|Menstruation
1460258|NCT00131885|Complementary Therapies
1460259|NCT00131885|Pharmacokinetics
1460260|NCT00131885|Hypericum
1460261|NCT00131885|St. John's wort
1460262|NCT00131885|Levonorgestrel
1460263|NCT00131885|Women
1460264|NCT00131872|vascular access graft
1460265|NCT00131872|hemodialysis
1460266|NCT00131872|dialysis
1460267|NCT00131872|end stage renal disease
1460268|NCT00131859|Perinatal brain injury
1460269|NCT00131859|Diffusion-tensor imaging
1460270|NCT00131846|Thiazide diuretics
1460271|NCT00131846|Essential hypertension
1460272|NCT00131846|Type 2 diabetes
1460273|NCT00131846|Randomized clinical trial
1460274|NCT00131846|Cost-effectiveness
1460275|NCT00131833|salmonella
1460276|NCT00131833|typhoid vaccine
1460277|NCT00131833|enteric fever
1460278|NCT00131820|Salmonella
1460279|NCT00131820|typhoid vaccine
1460280|NCT00131820|enteric fever
1460281|NCT00131820|socioeconomic costs
1460282|NCT00131807|Blood Pressure
1460283|NCT00131807|HIV
1460284|NCT00131807|Antiretroviral therapy
1460285|NCT00131794|Malaria
1460286|NCT00131794|BCG vaccine
1460287|NCT00131794|Guinea Bissau
1460288|NCT00131781|Borderline personality disorder
1460289|NCT00131781|Controlled trials
1460290|NCT00131781|Cognitive Therapy
1460291|NCT00131781|Supportive Therapy
1460292|NCT00131781|suicide
1460293|NCT00131781|impulsivity
1460294|NCT00131768|osteoarthritis of the ankle
1460295|NCT00131768|musculoskeletal
1460296|NCT00131755|type 1 diabetes
1460297|NCT00131755|beta cell rest
1460298|NCT00131755|diazoxide
1460299|NCT00131755|insulin secretion
1460300|NCT00131729|Amblyopia
1460301|NCT00131729|Occlusion therapy
1460302|NCT00131729|Compliance
1460303|NCT00131729|Risk factors
1460304|NCT00131716|prevention
1460305|NCT00131716|recurrence
1460306|NCT00131716|severe
1460307|NCT00131716|anaemia
1460308|NCT00131703|Screening
1460309|NCT00131703|Treatment
1460310|NCT00131703|Amodiaquine
1460311|NCT00131703|Sulphadoxine-pyrimethamine
1460312|NCT00131703|Malaria in pregnancy
1460313|NCT00131690|Caffeine
1460314|NCT00131690|Coffee
1460315|NCT00131690|Randomized
1460316|NCT00131690|Birth weight
1460317|NCT00131651|renal
1460318|NCT00131651|cancer
1460319|NCT00131651|advanced
1460320|NCT00131651|unresectable
1460321|NCT00131651|metastatic
1460322|NCT00131651|recurrent
1460323|NCT00131651|anti-angiogenic
1460324|NCT00131651|targeted
1460325|NCT00131651|ATN-161
1460326|NCT00131651|Recurrent renal cell cancer
1460327|NCT00131651|Renal clear cell carcinoma
1460328|NCT00131651|Advanced Renal Cell Cancer
1460329|NCT00131638|Oncology
1460330|NCT00131638|KGF
1460331|NCT00131638|Palifermin
1460332|NCT00131638|Oral mucositis
1460333|NCT00131638|Clinical Trial
1460334|NCT00131638|Amgen
1460335|NCT00131638|head and neck
1460336|NCT00131625|Exclusive breast-feeding
1460337|NCT00131625|Mortality
1460338|NCT00131625|Morbidity
1460339|NCT00131625|Nutrition
1460340|NCT00131625|Low income country
1460341|NCT00131612|adjuvant therapy
1460342|NCT00131612|epirubicin
1460343|NCT00131612|uridine glucuronosyl/transferase 2B7
1460344|NCT00131612|pharmacogenetics
1460345|NCT00131599|5-fluorouracil
1460346|NCT00131599|thymidylate synthase
1460347|NCT00131599|pharmacogenetics
1460348|NCT00131586|platinum analogues
1460349|NCT00131586|cisplatin, carboplatin, oxaliplatin
1460350|NCT00131586|proteomics
1460351|NCT00131586|hemoglobin
1460352|NCT00131573|Urgency-Frequency
1460353|NCT00131573|Syndrome
1460354|NCT00131573|Urinary
1460355|NCT00131573|Refractory
1460356|NCT00131573|Stimulation
1460357|NCT00131573|Nerve
1460358|NCT00131573|Neuromodulation
1460359|NCT00131573|Microstimulator
1460360|NCT00131573|bion
1460361|NCT00131573|Pudendal
1460362|NCT00131573|Overactive bladder
1460363|NCT00131560|HIV, gene therapy, leukapheresis, autologous CD4 T cell, lentivector
1460364|NCT00131547|Obesity
1460365|NCT00131547|Obstructive Sleep Apnea
1460366|NCT00131534|Complex trauma
1460367|NCT00131534|Trauma recovery
1460368|NCT00131534|Resiliency
1460369|NCT00131534|Posttraumatic stress
1460370|NCT00131534|Individual psychotherapy
1460371|NCT00131534|Group psychotherapy
1460372|NCT00131521|mucus obstruction, ventilator management
1460373|NCT00131508|Hemoglobin S Disease
1460374|NCT00131508|Sickle Cell Anemia
1460375|NCT00131495|Low Libido
1460376|NCT00131495|Low Desire
1460377|NCT00131495|Distress
1460378|NCT00131482|Chrysalin
1460379|NCT00131482|TP508
1460380|NCT00131482|Fracture
1460381|NCT00131482|Wrist
1460382|NCT00131482|Healing
1460383|NCT00131469|Osteogenesis Imperfecta
1460384|NCT00131469|Brittle Bone Disease
1460385|NCT00131469|Fragility Fractures
1460386|NCT00131456|cannabis dependence
1460387|NCT00131456|depression
1460388|NCT00131456|treatment
1460389|NCT00131456|venlafaxine
1460390|NCT00131443|Basilar/Hemiplegic Migraine
1460391|NCT00131443|Prophylaxis
1460392|NCT00131417|severe
1460393|NCT00131417|malnutrition
1460394|NCT00131417|ready-to-use-therapeutic-food
1460395|NCT00131417|children
1460396|NCT00131417|Uganda
1460397|NCT00131378|Visceral obesity
1460398|NCT00131378|Growth hormone
1460399|NCT00131378|Cardiovascular risk
1460400|NCT00131378|Insulin resistance
1460401|NCT00131365|fibroids
1460402|NCT00131365|Uterine Fibroids
1460403|NCT00131365|ExAblate
1460404|NCT00131365|MrgFUS
1460405|NCT00131352|Osteoarthritis of the knee
1460406|NCT00131352|Musculoskeletal
1460407|NCT00131339|panic disorder
1460408|NCT00131339|cognitive behavioral therapy
1460409|NCT00131339|D-cycloserine
1460410|NCT00131339|medication
1460411|NCT00131339|treatment trial
1460412|NCT00131339|placebo-controlled
1460413|NCT00131339|double-blind
1460414|NCT00131339|randomized
1460415|NCT00131326|osteoarthritis of the hip
1460416|NCT00131326|Musculoskeletal Diseases
1460417|NCT00131313|Leukemia
1460418|NCT00131313|Cancer
1460419|NCT00131313|Nipent
1460420|NCT00131313|Rituxan
1460421|NCT00131313|Cytoxan
1460422|NCT00131300|Osteoarthritis of the shoulder
1460423|NCT00131300|Musculoskeletal
1460424|NCT00131287|Agaricus Blazei Murill
1460425|NCT00131287|type II DM
1460426|NCT00131287|insulin index
1460427|NCT00131274|Pulmonary Fibrosis
1460428|NCT00131274|Respiratory Diseases
1460429|NCT00131274|Interstitial Lung Disease
1460430|NCT00131274|Usual Interstitial Pneumonia
1460431|NCT00131261|Multiple Myeloma
1460432|NCT00131261|Neoplasms
1460433|NCT00131235|Malaria
1460434|NCT00131235|STI
1460435|NCT00131235|Pregnancy
1460436|NCT00131235|Prevention
1460437|NCT00131235|Preterm birth
1460438|NCT00131235|Low birth weight
1460439|NCT00131235|Sub-Saharan Africa
1460440|NCT00131222|Infant
1460441|NCT00131222|Malnutrition
1460442|NCT00131222|Sub-Saharan Africa
1460443|NCT00131222|Treatment
1460444|NCT00131222|Growth
1460445|NCT00131222|Haemoglobin
1460446|NCT00131222|Fortified spread
1460447|NCT00131222|Food supplement
1460448|NCT00131209|Infant
1460449|NCT00131209|Sub-Saharan Africa
1460450|NCT00131209|Complementary feeding
1460451|NCT00131209|Malnutrition
1460452|NCT00131209|Growth
1460453|NCT00131209|Fortified spread
1460454|NCT00131209|Haemoglobin
1460455|NCT00131196|pneumonia
1460456|NCT00131196|peritonitis
1460457|NCT00131196|sepsis
1460458|NCT00131196|outcome
1460459|NCT00131196|genomics
1460460|NCT00131183|Angina Pectoris
1460461|NCT00131183|Arteriosclerosis
1460462|NCT00131183|Testosterone
1460463|NCT00131157|Pulmonary Disease, Chronic Obstructive
1460464|NCT00131157|Family Practice
1460465|NCT00131157|Spirometry
1460466|NCT00131157|Decision Support Systems
1460467|NCT00131157|Feedback
1460468|NCT00131144|Diabetic retinopathy,Octreotide Acetate in Microspheres
1460469|NCT00131131|physical activity
1460470|NCT00131131|cholelithiasis
1460471|NCT00131131|pregnancy complication
1460472|NCT00131118|Osteogenesis Imperfecta, Brittle bone disease, bisphosphonate, children
1460473|NCT00131105|Healthy
1460474|NCT00131105|Caregivers
1460475|NCT00131105|Aging
1460476|NCT00131092|exercise
1460477|NCT00131092|aging
1460478|NCT00131092|physical activity
1460479|NCT00131079|Primary Health Care
1460480|NCT00131079|Physicians, Family
1460481|NCT00131079|Family Practice
1460482|NCT00131079|Health Promotion
1460483|NCT00131079|Randomized Controlled Trials
1460484|NCT00131079|Multicenter Studies
1460485|NCT00131079|Physical Fitness
1460486|NCT00131079|Quality of Life
1460487|NCT00131066|Previously enrolled on a MEDI-507 for psoriasis
1460488|NCT00131053|acute lymphoblastic leukemia
1460489|NCT00131053|newly diagnosed
1460490|NCT00131053|BCR-ABL-negative
1460491|NCT00131040|Cardiopulmonary
1460492|NCT00131040|Surgery
1460493|NCT00131040|leukocyte
1460494|NCT00131040|inflammation
1460495|NCT00131040|Coronary Artery Bypass Grafting
1460496|NCT00131027|acute lymphoblastic leukemia
1460497|NCT00131027|newly diagnosed
1460498|NCT00131027|BCR-ABL-negative
1460499|NCT00131014|Non-Hodgkin's Lymphoma
1460500|NCT00131014|Hodgkin's disease
1460501|NCT00131014|Chronic Lymphocytic Leukemia
1460502|NCT00131014|Lymphoproliferative disorder
1460503|NCT00131014|Genetics
1460504|NCT00131001|Carotid artery stenosis
1460505|NCT00131001|cost effectiveness
1460506|NCT00131001|magnetic resonance angiography
1460507|NCT00131001|computed tomography angiography
1460508|NCT00131001|digital subtraction angiography
1460509|NCT00130988|Somatoform Disorders
1460510|NCT00130988|Medically unexplained symptoms
1460511|NCT00130988|Physician-Patient Relations
1460512|NCT00130988|Primary Health Care
1460513|NCT00130988|Family Physician
1460514|NCT00130988|psychosocial therapy
1460515|NCT00130988|re-attribution of symptoms
1460516|NCT00130988|cluster randomised controlled trial
1460517|NCT00130975|Atrial fibrillation.
1460518|NCT00130975|Cardioversion.
1460519|NCT00130975|Recurrence.
1460520|NCT00130975|Candesartan.
1460521|NCT00130962|Intermetatarsal neuroma
1460522|NCT00130962|Morton's neuroma
1460523|NCT00130962|ALGRX 4975
1460524|NCT00130962|capsaicin
1460525|NCT00130949|Acute lateral epicondylitis
1460526|NCT00130949|Tennis elbow
1460527|NCT00130949|Capsaicin
1460528|NCT00130936|phase I
1460529|NCT00130936|epirubicin
1460530|NCT00130936|solid tumors
1460531|NCT00130923|Risperidone
1460532|NCT00130923|Schizophrenia
1460533|NCT00130923|Substance Use Disorder
1460534|NCT00130923|Alcohol Use Disorder
1460535|NCT00130923|Treatment
1460536|NCT00130923|Schizoaffective Disorder
1460537|NCT00130910|HIV
1460538|NCT00130910|Helminthiasis
1460539|NCT00130910|Co-infection
1460540|NCT00130910|Intestinal immune activation
1460541|NCT00130910|Treatment Naive
1460542|NCT00130884|levosimendan
1460543|NCT00130884|chronic heart failure
1460544|NCT00130884|oral administration
1460545|NCT00130871|levosimendan
1460546|NCT00130871|weaning
1460547|NCT00130871|cardio-pulmonary bypass
1460548|NCT00130858|Sarcoma, Soft Tissue
1460549|NCT00130845|Diabetic retinopathy, Octreotide Acetate in Microspheres
1460550|NCT00130819|Drug Dependence
1460551|NCT00130819|Opiate Dependence
1460552|NCT00130819|Human Immunodeficiency Viruses
1460553|NCT00130819|Buprenorphine
1460554|NCT00130780|Multi-modality treatment for lung cancer
1460555|NCT00130780|Carcinoma, Squamous Cell
1460556|NCT00130780|Bevacizumab
1460557|NCT00130780|BEACON
1460558|NCT00130780|05-052
1460559|NCT00130767|Prostate
1460560|NCT00130767|apoptosis
1460561|NCT00130767|finasteride kinetics
1460562|NCT00130728|NSCLC
1460563|NCT00130728|Avastin
1460564|NCT00130728|Tarceva
1460565|NCT00130728|Lung Cancer
1460566|NCT00130715|Patients undergoing a variety of abdominal surgical procedures
1460567|NCT00130702|AML
1460568|NCT00130702|acute myelogenous leukemia
1460569|NCT00130702|gefitinib
1460570|NCT00130702|Iressa
1460571|NCT00130689|Esophageal Cancer
1460572|NCT00130689|Gastric Cancer
1460573|NCT00130689|Metastatic Esophageal Cancer
1460574|NCT00130689|Metastatic Gastric Cancer
1460575|NCT00130689|Cetuximab
1460576|NCT00130689|Metastatic Esophageal and Gastric Cancer
1460577|NCT00130676|PMD
1460578|NCT00130676|Psychotic Major Depression
1460579|NCT00130676|Depression
1460580|NCT00130676|Major Depression
1460581|NCT00130676|Psychosis
1460582|NCT00130650|IV
1460583|NCT00130650|cannulation
1460584|NCT00130650|Injections, Intravenous
1460585|NCT00130637|Anterior Uveitis
1460586|NCT00130637|Arthritis, Juvenile Idiopathic
1460587|NCT00130637|Daclizumab
1460588|NCT00130637|Iritis
1460589|NCT00130637|Immunosuppression
1460590|NCT00130637|Chronic Inflammatory Eye-Disease
1460591|NCT00130637|Juvenile Idiopathic Arthritis
1460592|NCT00130624|Falls
1460593|NCT00130624|Elderly
1460594|NCT00130624|multidisciplinary assessment
1460595|NCT00130611|heart failure
1460596|NCT00130611|cost effectiveness
1460597|NCT00130611|BNP
1460598|NCT00130611|private practice
1460599|NCT00130611|Acute dyspnoea
1460600|NCT00130598|contrast nephropathy
1460601|NCT00130598|contrast media
1460602|NCT00130598|renal dysfunction
1460603|NCT00130585|Folate
1460604|NCT00130585|Bioavailability
1460605|NCT00130585|Stable isotopes
1460606|NCT00130559|Respiratory failure
1460607|NCT00130559|BNP
1460608|NCT00130546|coronary artery disease
1460609|NCT00130546|coronary intervention
1460610|NCT00130546|drug eluting stent implantation
1460611|NCT00130546|Cypher - Stent
1460612|NCT00130546|Sirolimus
1460613|NCT00130546|Taxus - Stent
1460614|NCT00130546|Paclitaxel
1460619|NCT00130520|advanced ovarian cancer
1460620|NCT00130520|refractory ovarian cancer
1460621|NCT00130520|primary peritoneal cancer
1460622|NCT00130507|HER2 positive breast cancer.
1460623|NCT00130507|Progression to trastuzumab and taxanes.
1460624|NCT00130494|Non-symptomatic bone metastases.
1460625|NCT00130481|Diabetes
1460626|NCT00130481|Children
1460627|NCT00130481|Adolescents
1460628|NCT00130481|Arterial Compliance
1460629|NCT00130481|Physiology Cardiovascular Endothelium
1460630|NCT00130442|phase II
1460631|NCT00130442|metastatic melanoma
1460632|NCT00130442|dacarbazine
1460633|NCT00130442|combination
1460634|NCT00130442|PI-88
1460635|NCT00130429|dementia
1460636|NCT00130429|memory
1460637|NCT00130429|Hopkins verbal learning test
1460638|NCT00130429|paired associated learning
1460639|NCT00130416|behavior
1460640|NCT00130416|randomized trial
1460641|NCT00130416|communication
1460642|NCT00130416|patient
1460643|NCT00130416|internet
1460644|NCT00130416|coaching
1460645|NCT00130416|self-efficacy
1460646|NCT00130416|nurse
1460647|NCT00130416|primary care
1460648|NCT00130416|physician
1460649|NCT00130416|screening
1460650|NCT00130416|survey
1460651|NCT00130416|pain
1460652|NCT00130416|mobility
1460653|NCT00130416|disability
1460654|NCT00130416|depression
1460655|NCT00130390|Crohn's Disease
1460656|NCT00130377|Stem Cell
1460657|NCT00130377|Heart
1460658|NCT00130377|Lung
1460659|NCT00130377|Vascular
1460660|NCT00130377|cell therapy registry
1460661|NCT00130364|Atopic dermatitis
1460662|NCT00130364|T-cell
1460663|NCT00130364|pimecrolimus
1460664|NCT00130364|children
1460665|NCT00130364|facial
1460666|NCT00130364|Facial atopic dermatitis
1460667|NCT00130351|asthma, formoterol multi-dose dry powder inhaler (MDDPI)
1460668|NCT00130338|Dementia
1460669|NCT00130338|Vascular
1460670|NCT00130338|Rivastigmine
1460671|NCT00130338|Stroke
1460672|NCT00130338|Memory loss
1460673|NCT00130325|ELISPOT,
1460674|NCT00130325|tuberculosis,
1460675|NCT00130325|Mycobacterium tuberculosis
1460676|NCT00130325|Isoniazid
1460677|NCT00130325|Clinical trial
1460678|NCT00130312|Diabetes
1460679|NCT00130312|Diabetic Nephropathy
1460680|NCT00130312|Proteinuria
1460681|NCT00130286|Lipodystrophy
1460682|NCT00130286|HIV
1460683|NCT00130286|Growth hormone
1460684|NCT00130286|Rosiglitazone
1460685|NCT00130286|Visceral fat
1460686|NCT00130286|Metabolic syndrome
1460687|NCT00130286|Treatment Experienced
1460688|NCT00130286|Visceral fat accumulation
1460689|NCT00130286|fat accumulation
1460690|NCT00130286|HIV-Associated Metabolic Syndrome
1460691|NCT00130273|HIV
1460692|NCT00130273|AIDS
1460693|NCT00130273|Problem Solving
1460694|NCT00130273|Antiretroviral Therapy, Highly Active
1460695|NCT00130273|Patient Compliance
1460696|NCT00130260|Staphylococcus aureus
1460697|NCT00130260|Vaccine
1460698|NCT00130260|Randomized Controlled Trial
1460699|NCT00130247|Tuberculosis, Uganda, Brazil, Philippines
1460700|NCT00130234|urticaria
1460701|NCT00130234|hives
1460702|NCT00130234|Xolair
1460703|NCT00130221|Chlorhexidine
1460704|NCT00130221|Blood stream infections
1460705|NCT00130221|central venous catheter associated
1460706|NCT00130221|Nosocomial infection
1460707|NCT00130221|Bacteremia
1460708|NCT00130221|sepsis
1460709|NCT00130221|Pneumonia
1460710|NCT00130221|Urinary tract infection
1460711|NCT00130221|Clostridium Difficile
1460712|NCT00130221|intensive care unit
1460713|NCT00130221|catheter
1460714|NCT00130221|nosocomial pneumonia
1460715|NCT00130221|Infection control
1460716|NCT00130208|Diabetes
1460717|NCT00130208|Diabetes Mellitus, Type 2
1460718|NCT00130208|Albuminuria
1460719|NCT00130208|Diabetic Nephropathy
1460720|NCT00130195|acute lymphoblastic leukemia
1460721|NCT00130195|BCR-ABL
1460722|NCT00130195|Philadelphia-chromosome
1460723|NCT00130195|newly diagnosed
1460724|NCT00130182|lung disease
1460725|NCT00130169|Cancer
1460726|NCT00130169|malignant tumors
1460727|NCT00130156|Blood pressure
1460728|NCT00130156|SBP
1460729|NCT00130156|DBP
1460730|NCT00130117|leptin
1460731|NCT00130117|hypothalamic amenorrhea
1460732|NCT00130117|exercise-induced amenorrhea
1460733|NCT00130117|neuroendocrine function
1460734|NCT00130117|bone metabolism
1460735|NCT00130104|digital block
1460736|NCT00130104|regional anesthesia
1460737|NCT00130104|finger repair
1460738|NCT00130104|Fingers
1460739|NCT00130104|Anesthesia, Conduction
1460740|NCT00130091|unilateral
1460741|NCT00130091|hernia
1460742|NCT00130091|hydrocele
1460743|NCT00130091|pediatric
1460744|NCT00130091|clonidine
1460745|NCT00130091|nerve block
1460746|NCT00130078|HIV Seronegativity
1460747|NCT00130078|HIV transmission
1460748|NCT00130065|Malaria
1460749|NCT00130065|Pregnancy
1460750|NCT00130065|Sulfadoxine-pyrimethamine
1460751|NCT00130065|Folic acid
1460752|NCT00130065|Folate
1460753|NCT00130039|Infarction, Cerebral
1460754|NCT00130039|cilostazol
1460755|NCT00130039|stenosis
1460756|NCT00130039|atherosclerosis
1460757|NCT00130039|clopidogrel
1460758|NCT00130013|Children
1460759|NCT00130013|Non-severe pneumonia
1460760|NCT00130013|Oral amoxicillin
1460761|NCT00130000|h5g.1
1460762|NCT00130000|Paroxysmal Nocturnal Hemoglobinuria
1460763|NCT00130000|SHEPHERD
1460764|NCT00130000|PNH
1460765|NCT00129987|Asthma
1460766|NCT00129974|Lung cancer
1460767|NCT00129974|Phase II
1460768|NCT00129974|Drug Therapy
1460769|NCT00129961|Kidney
1460770|NCT00129961|Transplant
1460771|NCT00129961|Skin Cancer
1460772|NCT00129948|Acute myeloid leukemia
1460773|NCT00129948|AML
1460774|NCT00129948|refractory
1460775|NCT00129948|relapsed
1460776|NCT00129935|HER2 negative breast cancer
1460777|NCT00129935|Node positive breast cancer
1460778|NCT00129935|Adjuvant treatment
1460779|NCT00129935|Oral chemotherapy
1460780|NCT00129922|Axillary node positive breast cancer.
1460781|NCT00129922|Sequential drug administration.
1460782|NCT00129922|Weekly paclitaxel.
1460783|NCT00129909|hypertension
1460784|NCT00129909|family physicians
1460785|NCT00129909|fixed dose combination therapy
1460786|NCT00129909|cluster randomized controlled trial
1460787|NCT00129896|Her2neu positive breast cancer.
1460788|NCT00129896|Neoadjuvant treatment.
1460789|NCT00129883|quality of care
1460790|NCT00129883|antibiotic use
1460791|NCT00129883|intervention
1460792|NCT00129883|lower respiratory tract infections
1460793|NCT00129883|Community acquired Pneumonia
1460794|NCT00129883|Acute Exacerbation of Chronic Bronchitis or COPD
1460795|NCT00129844|Motexafin Gadolinium
1460796|NCT00129844|non-small cell, lung cancer
1460797|NCT00129844|Lung cancer
1460798|NCT00129844|cancer of the lung
1460799|NCT00129844|Carcinoma, Non-Small-Cell Lung
1460800|NCT00129831|COPD, indacaterol, PK
1460801|NCT00129818|Genital herpes
1460802|NCT00129818|viral shedding
1460803|NCT00129818|famciclovir
1460804|NCT00129818|Symptomatic genital herpes
1460805|NCT00129818|Asymptomatic genital herpes
1460806|NCT00129792|Blood Glucose
1460807|NCT00129792|Cholesterol
1460808|NCT00129792|Weight Loss
1460809|NCT00129792|Insulin
1460810|NCT00129792|Complementary Therapies
1460811|NCT00129779|COPD
1460812|NCT00129766|Respiratory Syncytial Virus (RSV)
1460813|NCT00129766|motavizumab
1460814|NCT00129766|palivizumab
1460815|NCT00129766|Synagis
1460816|NCT00129753|Campath-1H Monoclonal Antibody
1460817|NCT00129753|Alemtuzumab
1460818|NCT00129753|Campath
1460819|NCT00129753|Campath-1H
1460820|NCT00129753|Relapsed and Resistant Classical Hodgkin's Disease
1460821|NCT00129753|Lymphoma
1460822|NCT00129740|Chronic phase CML
1460823|NCT00129740|Newly diagnosed chronic phase CML
1460824|NCT00129740|AMN107
1460825|NCT00129727|Carboplatin
1460826|NCT00129727|Paclitaxel
1460827|NCT00129727|Bevacizumab
1460828|NCT00129727|Ovarian
1460829|NCT00129727|Cancer
1460830|NCT00129714|cervical radiculopathy conservative treatment
1460831|NCT00129688|febrile neutropenia
1460832|NCT00129688|once-daily
1460833|NCT00129688|amikacin
1460834|NCT00129688|cloxacillin
1460835|NCT00129688|children
1460836|NCT00129675|parkinson
1460837|NCT00129675|diagnosis
1460838|NCT00129610|Agoraphobia
1460839|NCT00129610|panic disorder
1460840|NCT00129610|Virtual Reality Therapy
1460841|NCT00129610|Cognitive Behavior Therapy
1460842|NCT00129610|cognition
1460843|NCT00129610|spatial cognition
1460844|NCT00129610|PANIC DISORDER WITH AGORAPHOBIA
1460845|NCT00129597|Ketalar
1460846|NCT00129597|NMDA
1460847|NCT00129597|mastectomy
1460848|NCT00129597|postoperative chronic pain
1460849|NCT00129597|Chronic pain after mastectomy for breast cancer
1460850|NCT00129584|Endobronchial Valve (EBV) Procedure
1460851|NCT00129584|Bronchoscopic Lung Volume Reduction
1460852|NCT00129545|Atrial Fibrillation
1460853|NCT00129545|AF
1460854|NCT00129545|A Fib
1460855|NCT00129545|Stroke
1460856|NCT00129545|Coumadin
1460857|NCT00129545|Warfarin
1460858|NCT00129545|Blood thinning medication
1460859|NCT00129545|transient ischemic attack (TIA)
1460860|NCT00129545|WATCHMAN
1460861|NCT00129545|Left atrial appendage
1460862|NCT00129545|LAA isolation
1460863|NCT00129545|LAA occlusion
1460864|NCT00129532|HIV transmission
1460865|NCT00129519|BCC curettage
1460866|NCT00129506|medical abortion
1460867|NCT00129506|methotrexate
1460868|NCT00129506|misoprostol
1460869|NCT00129493|Practice guidelines
1460870|NCT00129493|Hypertension
1460871|NCT00129493|Primary health care
1460872|NCT00129493|Patient-centered care
1460873|NCT00129493|Healthcare quality
1460874|NCT00129493|Office visits
1460875|NCT00129493|Self-efficacy
1460876|NCT00129493|Self care
1460877|NCT00129493|Guideline adherence
1460878|NCT00129493|Patient noncompliance
1460879|NCT00129480|veterans
1460880|NCT00129480|pain and chronic disease
1460881|NCT00129480|disease management
1460882|NCT00129480|depression
1460883|NCT00129480|primary health care
1460884|NCT00129480|practice guidelines
1460885|NCT00129480|guideline adherence
1460886|NCT00129480|narcotics
1460887|NCT00129480|patient compliance
1460888|NCT00129480|randomized controlled trial
1460889|NCT00129467|Depression
1460890|NCT00129467|Hospice Care
1460891|NCT00129467|Antidepressive Agents
1460892|NCT00129467|Methylphenidate
1460893|NCT00129467|Central Nervous System Stimulant
1460894|NCT00129467|Pain
1460895|NCT00129467|Caregiver Burden
1460896|NCT00129467|Cancer
1460897|NCT00129454|Telemedicine
1460898|NCT00129454|Cognitive Behavior Therapy
1460899|NCT00129454|Utilization
1460900|NCT00129454|Randomized Control Trial
1460901|NCT00129454|Gulf War Illness
1460902|NCT00129454|Symptom-Based Illness
1460903|NCT00129454|Multisymptom Illness
1460904|NCT00129454|High utilization
1460905|NCT00129441|schizophrenia
1460906|NCT00129428|UVB
1460907|NCT00129428|keloid
1460908|NCT00129428|scleroderma
1460909|NCT00129428|acne keloidalis nuchae
1460910|NCT00129428|scars
1460911|NCT00129428|granuloma annulare
1460912|NCT00129415|UVA1
1460913|NCT00129415|UVB
1460914|NCT00129415|atopic dermatitis
1460915|NCT00129415|psoriasis
1460916|NCT00129415|alopecia
1460917|NCT00129415|mycosis fungoides (CTCL)
1460918|NCT00129415|urticaria
1460919|NCT00129415|inflammatory dermatoses
1460920|NCT00129415|stretch marks
1460921|NCT00129402|cholesterol
1460922|NCT00129402|drugs
1460923|NCT00129402|hypercholesterolemia
1460924|NCT00129402|adolescent
1460925|NCT00129402|randomized controlled trials
1460926|NCT00129389|Node negative, high risk breast cancer.
1460927|NCT00129389|Prognostic gene profile.
1460928|NCT00129389|Saint Gallen high risk criteria.
1460929|NCT00129389|Weekly paclitaxel.
1460930|NCT00129376|Stage II and IIIA breast Cancer.
1460931|NCT00129376|Neoadjuvant chemotherapy.
1460932|NCT00129376|Weekly docetaxel.
1460933|NCT00129363|Adolescent
1460934|NCT00129363|Adrenergic alpha-Antagonists/therapeutic use
1460935|NCT00129363|Adrenergic alpha-Antagonists/pharmacokinetics
1460936|NCT00129363|Adrenergic alpha-Antagonists/administration & dosage
1460937|NCT00129363|Adrenergic beta-Antagonists/therapeutic use
1460938|NCT00129363|Adrenergic beta-Antagonists/pharmacokinetics
1460939|NCT00129363|Adrenergic beta-Antagonists/administration & dosage
1460940|NCT00129363|Age Factors
1460941|NCT00129363|Carbazoles/therapeutic use
1460942|NCT00129363|Carbazoles/administration & dosage
1460943|NCT00129363|Child
1460944|NCT00129363|Child, Preschool
1460945|NCT00129363|Drug Administration Schedule
1460946|NCT00129363|Female
1460947|NCT00129363|Heart Failure, Congestive/etiology
1460948|NCT00129363|Heart Failure, Congestive/drug therapy
1460949|NCT00129363|Heart Failure, Congestive/blood
1460950|NCT00129363|Human
1460951|NCT00129363|Infant
1460952|NCT00129363|Infant, Newborn
1460953|NCT00129363|Male
1460954|NCT00129363|Natriuretic Peptide, Brain/blood
1460955|NCT00129363|Placebos
1460956|NCT00129363|Propanolamines/therapeutic use
1460957|NCT00129363|Propanolamines/administration & dosage
1460958|NCT00129363|Prospective Studies
1460959|NCT00129363|Support, Non-U.S. Gov't
1460960|NCT00129363|Treatment Outcome
1460961|NCT00129363|Ventricular Dysfunction/drug therapy
1460962|NCT00129363|Ventricular Dysfunction/complications
1460963|NCT00129363|Ventricular Dysfunction/blood
1460964|NCT00129363|Ventricular Function/drug effects
1460965|NCT00129363|Ventricular Remodeling/drug effects
1460966|NCT00129350|End Stage Fibrotic Lung Disease
1460967|NCT00129337|monoclonal antibody
1460968|NCT00129337|phase 1
1460969|NCT00129337|solid tumor
1460970|NCT00129337|anti-angiogenesis
1460971|NCT00129337|refractory advanced solid tumor malignancy
1460972|NCT00129324|HOME
1460973|NCT00129324|Environmental Exposure
1460974|NCT00129324|Neurobehavior
1460975|NCT00129324|Child Development
1460976|NCT00129324|Lead Exposure
1460977|NCT00129324|Child Injury
1460978|NCT00129324|Adolescence
1460979|NCT00129324|Adiposity
1460980|NCT00129324|Neuroimaging
1460981|NCT00129311|Tobacco
1460982|NCT00129298|cocaine abuse
1460983|NCT00129298|opiate dependent
1460984|NCT00129298|tiagabine
1460985|NCT00129298|methadone
1460986|NCT00129285|cocaine
1460987|NCT00129272|adolescents, cigarettes, smoking, tobacco
1460988|NCT00129259|T1D
1460989|NCT00129259|type 1 diabetes
1460990|NCT00129259|type 1 diabetes mellitus
1460991|NCT00129259|juvenile diabetes
1460992|NCT00129259|autoimmune diabetes
1460993|NCT00129259|autoimmune
1460994|NCT00129259|anti-CD3 mAb
1460995|NCT00129259|mAb hOKT3g1(Ala-Ala)
1460996|NCT00129259|teplizumab
1460997|NCT00129246|Tobacco
1460998|NCT00129246|Smoking
1460999|NCT00129246|Weight
1461000|NCT00129246|Weight perception
1461001|NCT00129246|Naltrexone
1461002|NCT00129246|Bupropion
1461003|NCT00129233|cardiovascular disease
1461004|NCT00129233|rennin-angiotensin system
1461005|NCT00129233|calcium channel blocker
1461006|NCT00129233|impaired glucose tolerance
1461007|NCT00129220|Manic or mixed episode associated with bipolar I disorder
1461008|NCT00129207|pharmacokinetic
1461009|NCT00129207|pharmacodynamics
1461010|NCT00129207|VELCADE
1461011|NCT00129207|Ketoconazole
1461012|NCT00129207|CYP 3A4
1461013|NCT00129207|Solid Tumor
1461014|NCT00129207|Advanced Solid Tumors
1461015|NCT00129194|HIV
1461016|NCT00129194|Treatment Experienced
1461017|NCT00129181|parkinson
1461018|NCT00129181|brain imaging
1461019|NCT00129181|diagnosis
1461020|NCT00129168|Leukemia, Myeloid
1461021|NCT00129168|Relapse
1461022|NCT00129168|Chemotherapy
1461023|NCT00129168|Zosuquidar
1461024|NCT00129168|Daunorubicin
1461025|NCT00129168|Cytarabine
1461026|NCT00129168|Acute
1461027|NCT00129168|AML
1461028|NCT00129168|Adult AML
1461029|NCT00129155|Allogenic stem cell transplantation
1461030|NCT00129155|Treosulfan
1461031|NCT00129155|Haematological malignancies
1461032|NCT00129155|allogeneic stem cell transplantation in patients with hematological malignancies
1461033|NCT00129142|Prostate cancer
1461034|NCT00129142|Bone Loss
1461035|NCT00129142|Osteoporosis
1461036|NCT00129142|Fractures
1461037|NCT00129142|Androgen Deprivation Therapy
1461038|NCT00129129|Immunogenicity
1461039|NCT00129129|Primary & booster vaccination
1461040|NCT00129129|Infants
1461041|NCT00129129|Meningococcal vaccine
1461042|NCT00129129|Safety
1461043|NCT00129129|Children
1461044|NCT00129129|Hib disease
1461045|NCT00129129|Meningococcal disease
1461046|NCT00129116|Invasive bacterial disease caused by Hib
1461047|NCT00129116|Neisseria meningitidis serogroups C & Y
1461048|NCT00129077|Pediatric critical care
1461049|NCT00129077|neuromuscular blocking agents
1461050|NCT00129077|corneal abrasions
1461051|NCT00129064|Referrals
1461052|NCT00129064|Quality of care
1461053|NCT00129064|Ambulatory care
1461054|NCT00129064|Electronic medical record
1461055|NCT00129064|Referral communication
1461056|NCT00129051|tomotherapy
1461057|NCT00129051|metastatic carcinoma
1461058|NCT00129025|conformal hypofractionated radiotherapy
1461059|NCT00129025|localized prostate cancer
1461060|NCT00129012|radiation therapy
1461061|NCT00129012|carcinoma
1461062|NCT00129012|non-small cell lung
1461063|NCT00128999|radiation therapy
1461064|NCT00128986|radiotherapy
1461065|NCT00128986|brain
1461066|NCT00128973|CGD
1461067|NCT00128973|LAD
1461068|NCT00128973|XSCID
1461069|NCT00128973|cGVHD
1461070|NCT00128973|Infection
1461071|NCT00128973|Abnormal Immune Function
1461072|NCT00128973|Recurrent Infection
1461073|NCT00128973|Chronic Granulomatous Disease
1461074|NCT00128973|X-Linked Severe Combined Immune Deficiency (XSCID)
1461075|NCT00128973|Leukocyte Adhesion Deficiency 1
1461076|NCT00128973|Healthy Volunteer
1461077|NCT00128973|HV
1461078|NCT00128960|Allogeneic Hematopoietic Stem Cell Transplant
1461079|NCT00128960|Health Related Quality of Life
1461080|NCT00128960|Symptom Experience
1461081|NCT00128960|Fatigue
1461082|NCT00128960|Functional Status
1461083|NCT00128960|Survey
1461084|NCT00128960|Allogeneic Stem Cell Transplant
1461085|NCT00128947|Immunosuppresant
1461086|NCT00128947|Pharmacogenetics
1461087|NCT00128947|Glucuronidation
1461088|NCT00128947|Metabolism
1461089|NCT00128947|UGT
1461090|NCT00128934|Premenstrual Syndrome (PMS)
1461091|NCT00128934|Hormone Therapy
1461092|NCT00128921|Multiple Myeloma
1461093|NCT00128908|HIV-1
1461094|NCT00128908|HAART
1461095|NCT00128908|sequential HAART
1461096|NCT00128908|resistance
1461097|NCT00128908|salvage therapy
1461098|NCT00128908|Treatment Experienced
1461099|NCT00128895|Wegener's granulomatosis, ANCA, vasculitis, proteinase 3
1461100|NCT00128895|ANCA-associated vasculitis
1461101|NCT00128895|ANCA
1461102|NCT00128882|Idiopathic Thrombocytopenic Purpura
1461103|NCT00128882|Treatment
1461104|NCT00128882|Anti-D
1461105|NCT00128882|Subcutaneous
1461106|NCT00128882|Clinical evaluation
1461107|NCT00128882|Platelet count
1461108|NCT00128882|IVIG
1461109|NCT00128869|Manipulation
1461110|NCT00128869|Mobilization
1461111|NCT00128869|Neck Pain
1461112|NCT00128869|Physical Therapy
1461113|NCT00128856|Neoadjuvant chemotherapy.
1461114|NCT00128856|Stage III disease.
1461115|NCT00128843|Metastatic breast cancer
1461116|NCT00128843|First line of hormone treatment
1461117|NCT00128843|Postmenopausal women
1461118|NCT00128843|Positive hormone receptor tumours
1461119|NCT00128830|Human Immunodeficiency Virus Type 1
1461120|NCT00128830|HIV-1 infection
1461121|NCT00128830|TMC125
1461122|NCT00128830|Etravirine
1461123|NCT00128830|Enfuvirtide
1461124|NCT00128830|Antiretroviral therapy
1461125|NCT00128817|neoplasm
1461126|NCT00128817|larynx
1461127|NCT00128817|surgery
1461128|NCT00128817|radiotherapy
1461129|NCT00128817|chemotherapy
1461130|NCT00128804|vitamin A
1461131|NCT00128804|beta Carotene
1461132|NCT00128804|diet
1461133|NCT00128804|nutrition
1461134|NCT00128804|nutritional requirements
1461135|NCT00128791|myocardial infarction
1461136|NCT00128791|angioplasty
1461137|NCT00128791|nitric oxide
1461138|NCT00128791|prevention
1461139|NCT00128791|acute myocardial infarction
1461140|NCT00128778|Breast cancer
1461141|NCT00128778|Metastases
1461142|NCT00128778|Maintenance treatment
1461143|NCT00128765|chronic obstructive pulmonary disease (COPD)
1461144|NCT00128765|self-management
1461145|NCT00128765|practice nurse
1461146|NCT00128765|cost-effectiveness
1461147|NCT00128765|randomized controlled trial
1461148|NCT00128752|vitamin A
1461149|NCT00128752|beta Carotene
1461150|NCT00128752|diet
1461151|NCT00128752|nutrition
1461152|NCT00128752|nutritional requirements
1461153|NCT00128726|continuous combined oral contraceptive
1461154|NCT00128726|endometrial and ovarian suppression
1461155|NCT00128713|Blood Transfusion
1461156|NCT00128713|Blood Platelets
1461157|NCT00128700|adult glioblastoma
1461158|NCT00128700|adult giant cell glioblastoma
1461159|NCT00128700|adult gliosarcoma
1461160|NCT00128661|cervical intraepithelial neoplasia grade 2
1461161|NCT00128661|cervical cancer
1461162|NCT00128661|cervical intraepithelial neoplasia grade 3
1461163|NCT00128635|adult glioblastoma
1461164|NCT00128635|adult gliosarcoma
1461165|NCT00128635|adult giant cell glioblastoma
1461166|NCT00128635|recurrent adult brain tumor
1461167|NCT00128622|male breast cancer
1461168|NCT00128622|recurrent breast cancer
1461169|NCT00128622|stage IV breast cancer
1461170|NCT00128622|recurrent colon cancer
1461171|NCT00128622|stage IV colon cancer
1461172|NCT00128622|recurrent rectal cancer
1461173|NCT00128622|stage IV rectal cancer
1461174|NCT00128622|recurrent pancreatic cancer
1461175|NCT00128622|extensive stage small cell lung cancer
1461176|NCT00128622|recurrent non-small cell lung cancer
1461177|NCT00128622|recurrent small cell lung cancer
1461178|NCT00128622|stage IV non-small cell lung cancer
1461179|NCT00128622|unspecified adult solid tumor, protocol specific
1461180|NCT00128622|stage IV pancreatic cancer
1461181|NCT00128596|adult primary hepatocellular carcinoma
1461182|NCT00128596|advanced adult primary liver cancer
1461183|NCT00128596|recurrent adult primary liver cancer
1461184|NCT00128583|stage III melanoma
1461185|NCT00128570|unspecified adult solid tumor, protocol specific
1461186|NCT00128557|Vitamin A
1461187|NCT00128557|Newborn health
1461188|NCT00128557|Infant Mortality
1461189|NCT00128557|Supplementation
1461190|NCT00128557|Micronutrients
1461191|NCT00128557|Bangladesh
1461192|NCT00128531|Phase III
1461193|NCT00128531|open label
1461194|NCT00128531|multiple dose
1461195|NCT00128531|safety study
1461196|NCT00128531|pharmacokinetic study
1461197|NCT00128531|efficacy study
1461198|NCT00128518|Hypertension - Drugs - Blood pressure response - Responders - pharmacogenetics
1461199|NCT00128505|PMD
1461200|NCT00128505|Depression
1461201|NCT00128505|Psychosis
1461202|NCT00128505|Psychotic Major Depression
1461203|NCT00128505|Major Depression
1461204|NCT00128492|cystic fibrosis
1461205|NCT00128492|Pseudomonas aeruginosa
1461206|NCT00128479|PMD
1461207|NCT00128479|Psychotic Depression
1461208|NCT00128479|Psychosis
1461209|NCT00128479|Major Depression
1461210|NCT00128479|Depression
1461211|NCT00128479|Psychotic Major Depression
1461212|NCT00128466|bubonic plague
1461213|NCT00128466|pneumonic plague
1461214|NCT00128466|septicemic plague
1461215|NCT00128466|Yersinia pestis
1461216|NCT00128466|Pasteurella pestis
1461217|NCT00128453|Pericarditis
1461218|NCT00128453|Recurrence
1461219|NCT00128453|Therapeutics
1461220|NCT00128453|Prevention
1461221|NCT00128453|Colchicine
1461222|NCT00128427|Postpericardiotomy Syndrome
1461223|NCT00128427|Pericarditis
1461224|NCT00128427|Prevention
1461225|NCT00128427|Colchicine
1461226|NCT00128427|Recurrence
1461227|NCT00128414|Pericarditis
1461228|NCT00128414|Recurrence
1461229|NCT00128414|Therapeutics
1461230|NCT00128414|Prevention
1461231|NCT00128414|Colchicine
1461232|NCT00128401|Cognitive
1461233|NCT00128401|Behavioral
1461234|NCT00128401|Adolescent
1461235|NCT00128401|Therapy
1461236|NCT00128401|Extinction
1461237|NCT00128401|Social Phobia
1461238|NCT00128388|panic disorder,
1461239|NCT00128388|psychodynamic psychotherapy,
1461240|NCT00128388|efficacy trial
1461241|NCT00128375|Smoking Cessation
1461242|NCT00128375|Work-site
1461243|NCT00128375|Incentives
1461244|NCT00128375|Cost Effectiveness
1461245|NCT00128375|Health Behavior
1461246|NCT00128375|Smoking
1461247|NCT00128362|Sentinel node
1461248|NCT00128362|Axillary sampling
1461249|NCT00128362|Operable breast cancer
1461250|NCT00128336|Weight
1461251|NCT00128336|Diet
1461252|NCT00128336|exercise
1461253|NCT00128336|maintenance
1461254|NCT00128323|Children
1461255|NCT00128323|oropharyngeal candidiasis
1461256|NCT00128323|GV solution
1461257|NCT00128323|nystatin drops
1461258|NCT00128310|Drug-resistant metastatic breast cancer
1461259|NCT00128297|Breast cancer patients with symptomatic bone metastases
1461260|NCT00128284|gastroparesis
1461261|NCT00128284|Digestive
1461262|NCT00128284|Gastrointestinal
1461263|NCT00128284|Stomach
1461264|NCT00128284|Motility
1461265|NCT00128284|Non-Invasive
1461266|NCT00128284|Capsule
1461267|NCT00128284|GI
1461268|NCT00128284|Device
1461269|NCT00128284|Digestive System Diseases
1461270|NCT00128271|HCV
1461271|NCT00128271|monoclonal antibody
1461272|NCT00128271|phase 1
1461273|NCT00128258|Stem Cell
1461274|NCT00128258|Heart Failure
1461275|NCT00128258|Bone Marrow
1461276|NCT00128245|KCS
1461277|NCT00128245|dry eye
1461278|NCT00128245|pimecrolimus
1461279|NCT00128245|Keratoconjunctivitis sicca (dry eye syndrome)
1461280|NCT00128232|Acromegaly
1461281|NCT00128232|untreated
1461282|NCT00128232|newly diagnosed
1461283|NCT00128232|octreotide LAR
1461284|NCT00128219|Group B Streptococcus, women, vaccine
1461285|NCT00128206|LTBI, tuberculosis, rifampin, isoniazid, prisoners
1461286|NCT00128193|leprosy, Mycobacterium leprae, Hansen's Disease, skin test, Nepal
1461287|NCT00128180|hantaviruses, methylprednisolone, cardiopulmonary syndrome
1461288|NCT00128154|Chromium
1461289|NCT00128154|Chromium picolinate
1461290|NCT00128154|Blood Glucose
1461291|NCT00128154|Cholesterol
1461292|NCT00128154|Complementary Therapies
1461293|NCT00128128|Vaccinium macrocarpon
1461294|NCT00128128|Cranberry
1461295|NCT00128128|Complementary Therapies
1461296|NCT00128102|Advanced malignant pleural mesothelioma
1461297|NCT00128089|Obesity
1461298|NCT00128089|Dietary treatment
1461299|NCT00128089|Fasting as medical therapy
1461300|NCT00128076|shoulder surgery
1461301|NCT00128076|rotator cuff
1461302|NCT00128076|arthroscopic repair
1461303|NCT00128076|mini-open repair
1461304|NCT00128063|HIV-1
1461305|NCT00128063|succinylated human serum albumin
1461306|NCT00128063|Treatment Naive
1461307|NCT00128050|Spontaneous intracerebral hemorrhage
1461308|NCT00128050|ICH
1461309|NCT00128050|intracerebral rebleeding
1461310|NCT00128050|cerebral hematoma evacuation
1461311|NCT00128050|cerebral hematoma volume
1461312|NCT00128037|pulmonary neoplasm
1461313|NCT00128037|preoperative chemoradiotherapy
1461314|NCT00128037|surgical resection
1461315|NCT00128037|superior sulcus tumor
1461316|NCT00128037|chest wall invasion
1461317|NCT00128037|mytomicin C
1461318|NCT00128037|vindesine
1461319|NCT00128037|cisplatin
1461320|NCT00128024|randomized prospective study
1461321|NCT00128024|lipid-lowering therapy with any available statins
1461322|NCT00128024|multicenter study
1461323|NCT00128024|Japanese
1461324|NCT00128024|acute myocardial infarction
1461325|NCT00128024|primary percutaneous coronary intervention
1461326|NCT00128011|watery diarrhea
1461327|NCT00128011|cholera vaccine
1461328|NCT00127998|malaria
1461329|NCT00127998|Plasmodium falciparum
1461330|NCT00127998|drug resistance
1461331|NCT00127998|antimalarials
1461332|NCT00127998|genotype
1461333|NCT00127998|treatment outcome
1461334|NCT00127985|multiple organ dysfunction syndrome
1461335|NCT00127985|corticosteroids
1461336|NCT00127985|mortality
1461337|NCT00127972|nevirapine
1461338|NCT00127972|efavirenz
1461339|NCT00127972|hiv-1
1461340|NCT00127972|Treatment Experienced
1461341|NCT00127959|HIV-1
1461342|NCT00127959|HBV
1461343|NCT00127959|treatment
1461344|NCT00127959|tenofovir
1461345|NCT00127959|emtricitabine
1461346|NCT00127959|Treatment Naive
1461347|NCT00127959|HIV-1 infection
1461348|NCT00127959|Hepatitis B virus infection
1461349|NCT00127907|Out-of-hospital cardiac arrest - Vasopressin - Epinephrine
1461350|NCT00127881|Refractory or intolerant to Mycosis Fungoides and sezary syndrome
1461351|NCT00127881|Cutaneous T-cell Lymphoma
1461352|NCT00127881|To evaluate the efficacy and safety of zanolimumab in Mycosis Fungoides and sezary syndrome
1461353|NCT00127868|Tinea Capitis
1461354|NCT00127868|Children
1461355|NCT00127868|Pediatric
1461356|NCT00127868|Treatment
1461357|NCT00127868|Therapy
1461358|NCT00127868|Adjunctive
1461359|NCT00127868|Selenium Sulfide
1461360|NCT00127868|Ciclopirox
1461361|NCT00127868|Shampoo
1461362|NCT00127855|Invasive bacterial disease caused by Hib
1461363|NCT00127855|Neisseria meningitidis serogroups C & Y
1461364|NCT00127842|Psoriatic Arthritis
1461365|NCT00127842|PsA
1461366|NCT00127842|Commercial product
1461367|NCT00127842|American College of Rheumatology
1461368|NCT00127842|ACR/PASI
1461369|NCT00127829|Solid Tumors
1461370|NCT00127816|brachytherapy
1461371|NCT00127816|implant radiotherapy
1461372|NCT00127803|Clostridium difficile
1461373|NCT00127790|Insomnia
1461374|NCT00127790|Sleep
1461375|NCT00127790|Pain
1461376|NCT00127790|Pain, Chronic
1461377|NCT00127790|Behavior Therapy
1461378|NCT00127790|CBT
1461379|NCT00127790|CBT-I
1461380|NCT00127790|cognitive-behavioral
1461381|NCT00127777|HCV genotype 1
1461382|NCT00127777|peginterferon alfa-2a
1461383|NCT00127777|ribavirin
1461384|NCT00127777|amantadine
1461385|NCT00127777|treatment-naive
1461386|NCT00127764|pemphigus
1461387|NCT00127764|dexamethasone
1461388|NCT00127764|glucocorticoids
1461389|NCT00127764|pulse
1461390|NCT00127764|therapy
1461391|NCT00127764|randomised
1461392|NCT00127764|placebo-controlled
1461393|NCT00127751|Risk factor reduction
1461394|NCT00127751|cardiovascular disease prevention
1461395|NCT00127738|Hypertension
1461396|NCT00127738|Renal artery stenosis
1461397|NCT00127738|Kidney disease
1461398|NCT00127738|Renal vascular disease
1461399|NCT00127738|Atherosclerosis
1461400|NCT00127725|tibia
1461401|NCT00127725|fracture
1461402|NCT00127725|PEMF
1461403|NCT00127725|electromagnetic
1461404|NCT00127725|non-union
1461405|NCT00127725|revision
1461406|NCT00127725|Diaphyseal fractures of the tibia
1461407|NCT00127712|amiodarone
1461408|NCT00127712|atrial fibrillation
1461409|NCT00127712|surgical procedures, thoracic
1461410|NCT00127699|Umbilical cord
1461411|NCT00127699|Triple dye
1461412|NCT00127699|Infant care
1461413|NCT00127686|cough
1461414|NCT00127686|nocturnal cough
1461415|NCT00127686|upper respiratory tract infection
1461416|NCT00127686|sleep quality
1461417|NCT00127686|childhood cough
1461418|NCT00127686|Dextromethorphan
1461419|NCT00127686|Honey
1461420|NCT00127673|Antidepressants
1461421|NCT00127673|Cognitive behavior therapy
1461422|NCT00126672|angiomyolipoma
1461423|NCT00127660|Behavior
1461424|NCT00127621|ICU patients needing prolonged ventilatory support
1461425|NCT00127595|carcinoma of the urothelial tract
1461426|NCT00127582|Myotonic dystrophy type 1
1461427|NCT00127582|Sudden cardiac death
1461428|NCT00127582|Ventricular tachyarrhythmias
1461429|NCT00127582|Bradyarrhythmias
1461430|NCT00127569|HIV infections
1461431|NCT00127569|Giant Lymph Node Hyperplasia
1461432|NCT00127569|Herpesvirus 8, Human
1461433|NCT00127569|Rituximab (Mabthera)
1461434|NCT00127569|Antibodies, Monoclonal
1461435|NCT00127556|Transfusion
1461436|NCT00127556|Safety
1461437|NCT00127543|Medication Education
1461438|NCT00127543|Pediatric
1461439|NCT00127530|Walking Ability
1461440|NCT00127517|Oncology
1461441|NCT00127517|Palliative Care
1461442|NCT00127517|Advanced Cancer
1461443|NCT00127517|Palliative Cancer Care
1461444|NCT00127504|Onchocerciasis
1461445|NCT00127504|Wolbachia
1461446|NCT00127504|Therapy
1461447|NCT00127491|Acute Lung Injury
1461448|NCT00127491|Acute Respiratory Distress Syndrome
1461449|NCT00127491|Mechanical Ventilation
1461450|NCT00127491|Esophageal Pressures
1461451|NCT00127491|Randomized Controlled Trial
1461452|NCT00127478|Hormone Refractory Prostate Cancer
1461453|NCT00127478|Adenocarcinoma of the Prostate
1461454|NCT00127465|Medical Informatics
1461455|NCT00127465|Patient education
1461456|NCT00127465|Social support
1461457|NCT00127465|Cancer
1461458|NCT00127465|Anxiety
1461459|NCT00127452|alpha-linolenic acid
1461460|NCT00127452|cardiovascular diseases
1461461|NCT00127452|coronary heart disease
1461462|NCT00127452|coronary patients
1461463|NCT00127452|DHA
1461464|NCT00127452|dietary intervention
1461465|NCT00127452|dietary supplementation
1461466|NCT00127452|docosahexaenoic acid
1461467|NCT00127452|eicosapentaenoic acid
1461468|NCT00127452|EPA
1461469|NCT00127452|fish oil
1461470|NCT00127452|fish fatty acids
1461471|NCT00127452|human subjects
1461472|NCT00127452|ischaemic heart disease
1461473|NCT00127452|margarine
1461474|NCT00127452|marine fatty acids
1461475|NCT00127452|mortality
1461476|NCT00127452|myocardial infarction
1461477|NCT00127452|n-3 fatty acids
1461478|NCT00127452|n-3 polyunsaturated fatty acids
1461479|NCT00127452|n-3 PUFA
1461480|NCT00127452|omega-3 fatty acids
1461481|NCT00127452|omega-3 polyunsaturated fatty acids
1461482|NCT00127452|prevention
1461483|NCT00127452|randomized controlled trial
1461484|NCT00127452|secondary prevention
1461485|NCT00127439|Ambulatory Disability
1461486|NCT00127439|Disability Ambulation
1461487|NCT00127439|Locomotion Disorders
1461488|NCT00127439|Motor Activity
1461489|NCT00127439|Rehabilitation
1461490|NCT00127439|Spinal Cord Injury
1461491|NCT00127413|Chronic pain
1461492|NCT00127413|Co-morbid
1461493|NCT00127413|Intervention
1461494|NCT00127413|Posttraumatic Stress Disorder
1461495|NCT00127413|Treatment
1461496|NCT00127400|anger
1461497|NCT00127400|intermittent
1461498|NCT00127400|explosive
1461499|NCT00127387|Bone metastasis
1461500|NCT00127387|Radiation therapy
1461501|NCT00127387|Lung cancer
1461502|NCT00127387|Prostate cancer
1461503|NCT00127387|Advanced lung cancer receiving radiation therapy
1461504|NCT00127387|Advanced prostate cancer receiving radiation therapy
1461505|NCT00127387|Any cancer with bone mets receiving radiation therapy
1461506|NCT00127374|Overweight; self-esteem; depression
1461507|NCT00127361|doula
1461508|NCT00127361|caregivers
1461509|NCT00127361|labor support
1461510|NCT00127361|being with woman
1461511|NCT00127361|continuous labor support
1461512|NCT00127361|maternal outcomes
1461513|NCT00127361|Parturition
1461514|NCT00127335|rhabdomyolysis,
1461515|NCT00127335|myositis,
1461516|NCT00127335|myopathy,
1461517|NCT00127335|statin side effects,
1461518|NCT00127335|fatty acid oxidation
1461519|NCT00127335|Statin induced Muscle toxicity
1461520|NCT00127322|Heart Failure, Congestive
1461521|NCT00127322|survival
1461522|NCT00127322|patient admission
1461523|NCT00127309|hangover
1461524|NCT00127309|hangover symptoms
1461525|NCT00127270|OAB
1461526|NCT00127270|Overactive Bladder
1461527|NCT00127270|Bladder hyperactivity
1461528|NCT00127270|Urge Incontinence
1461529|NCT00127270|Incontinence
1461530|NCT00127270|Bladder
1461531|NCT00127257|Constipation
1461532|NCT00127257|Biofeedback
1461533|NCT00127257|Dyssynergia
1461534|NCT00127257|Pelvic floor dyssynergia
1461535|NCT00127257|Outlet dysfunction
1461536|NCT00127231|Controlled Clinical Trials, Randomized
1461537|NCT00127231|Alcohol Consumption
1461538|NCT00127231|Behavioral Research
1461539|NCT00127231|HIV
1461540|NCT00127231|Alcohol Abuse
1461541|NCT00127218|atherosclerotic plaque
1461542|NCT00127218|MRI
1461543|NCT00127218|inflammatory markers
1461544|NCT00127218|statins
1461545|NCT00127205|stage I breast cancer
1461546|NCT00127205|stage II breast cancer
1461547|NCT00127205|stage IIIA breast cancer
1461548|NCT00127205|stage IIIB breast cancer
1461549|NCT00127205|stage IIIC breast cancer
1461550|NCT00127127|Solid tumors
1461551|NCT00127114|Behavioral disturbance
1461552|NCT00127114|Frontotemporal dementia
1461553|NCT00127114|Dementia
1461554|NCT00127114|Amantadine
1461555|NCT00127114|Behavioral disturbance due to frontotemporal dementia
1461556|NCT00127088|Patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate
1461557|NCT00127075|Multiple sclerosis. Relapses. Post partum. Pregnancy. Delivery. Hormones. Progesterone. Estradiol. Clinical trial. Prevention.
1461558|NCT00127062|Exposure to Oxford Street
1461559|NCT00127062|Exposure to Hyde Park
1461560|NCT00127049|Patients with relapsed non-seminomatous germ-cell tumors (NSGCT)
1461561|NCT00127036|colon
1461562|NCT00127036|adenocarcinoma
1461563|NCT00127036|adenocarcinoma-colon
1461564|NCT00127036|adenocarcinoma-rectum
1461565|NCT00127023|Prophylaxis measles, mumps, rubella and chickenpox
1461566|NCT00127010|Prophylaxis measles, mumps, rubella and chickenpox
1461567|NCT00126997|Prophylaxis measles, mumps, rubella and chickenpox
1461568|NCT00126984|Safety
1461569|NCT00126984|Reactogenicity
1461570|NCT00126984|Immunogenicity
1461571|NCT00126984|Meningococcal vaccine
1461572|NCT00126984|Dose selection
1461573|NCT00126984|Conjugate vaccine
1461574|NCT00126971|malaria
1461575|NCT00126971|pregnancy
1461576|NCT00126971|Plasmodium falciparum
1461577|NCT00126971|antimalarials
1461578|NCT00126971|pharmacokinetics
1461579|NCT00126971|treatment outcome
1461580|NCT00126971|safety
1461581|NCT00126958|superficial urothelial cell carcinoma
1461582|NCT00126958|urinary analysis
1461583|NCT00126958|Loss of heterozygosity
1461584|NCT00126958|FGFR3 mutation
1461585|NCT00126958|follow-up
1461586|NCT00126945|Meningococcal serogroups A, C, W-135, Y disease
1461587|NCT00126906|Malaria
1461588|NCT00126906|Pregnancy
1461589|NCT00126906|HIV
1461590|NCT00126893|Leukemia
1461591|NCT00126893|AML
1461592|NCT00126893|CC401
1461593|NCT00126893|CC-401
1461594|NCT00126893|Celgene
1461595|NCT00126893|High Risk Myeloid Leukemia
1461596|NCT00126893|Myeloid Leukemia
1461597|NCT00126880|Human Immunodeficiency Virus
1461598|NCT00126880|anti-retroviral therapy
1461599|NCT00126880|nucleoside analogue
1461600|NCT00126880|reverse transcriptase
1461601|NCT00126880|lamivudine
1461602|NCT00126880|resistance mutation
1461603|NCT00126880|Treatment Experienced
1461604|NCT00126867|thymidylate synthase polymers
1461605|NCT00126867|rapecitabine
1461606|NCT00126867|adjuvant
1461607|NCT00126867|colon cancer
1461608|NCT00126867|toxicity
1461609|NCT00126867|Stage II colon cancer
1461610|NCT00126867|Stage III colon cancer
1461611|NCT00126867|adenocarcinoma of the colon
1461612|NCT00126854|brachytherapy
1461613|NCT00126854|magnetic resonance spectroscopy
1461614|NCT00126841|radiotherapy planning CT/MR fusion
1461615|NCT00126828|radiotherapy, conformal
1461616|NCT00126828|lung neoplasm
1461617|NCT00126828|radiotherapy dosage
1461618|NCT00126815|prostate cancer
1461619|NCT00126815|prostate specific antigen
1461620|NCT00126815|radiotherapy
1461621|NCT00126815|mathematical modeling
1461622|NCT00126802|tomotherapy
1461623|NCT00126802|MRSZ
1461624|NCT00126802|high risk prostate cancer
1461625|NCT00126789|Pain Cancer
1461626|NCT00126789|Chronic Pain
1461627|NCT00126776|chronic obstructive pulmonary disease
1461628|NCT00126776|case management
1461629|NCT00126776|self management
1461630|NCT00126763|Chronic Pain
1461631|NCT00126763|Pain
1461632|NCT00126750|Myocardial Infarction
1461633|NCT00126750|Comorbidities
1461634|NCT00126750|Guidelines
1461635|NCT00126750|Computer Assisted Instruction
1461636|NCT00126750|Physician Practice Instruction
1461637|NCT00126750|Online Systems
1461638|NCT00126737|Elderly
1461639|NCT00126737|Exercise
1461640|NCT00126737|lean body mass
1461641|NCT00126737|muscle strength
1461642|NCT00126737|Nutrition program
1461643|NCT00126737|Pain control
1461644|NCT00126737|stair climb
1461645|NCT00126737|walking distance
1461646|NCT00126737|weight loss
1461647|NCT00126724|tgAAC94
1461648|NCT00126724|Rheumatoid arthritis
1461649|NCT00126724|Inflammatory arthritis
1461650|NCT00126724|Arthritis
1461651|NCT00126724|Gene therapy
1461652|NCT00126724|AAV
1461653|NCT00126698|Bacteriuria
1461654|NCT00126698|Urinary Catheter
1461655|NCT00126698|Urinary tract infection
1461656|NCT00126698|Prophylaxis
1461657|NCT00126698|Urinary catheter removal
1461658|NCT00126685|stage IV melanoma
1461659|NCT00126685|recurrent melanoma
1461660|NCT00126646|B-cell chronic lymphocytic leukemia
1461661|NCT00126646|refractory chronic lymphocytic leukemia
1461662|NCT00126646|recurrent grade 1 follicular lymphoma
1461663|NCT00126646|recurrent grade 2 follicular lymphoma
1461664|NCT00126646|stage III grade 1 follicular lymphoma
1461665|NCT00126646|stage III grade 2 follicular lymphoma
1461666|NCT00126646|stage IV grade 1 follicular lymphoma
1461667|NCT00126646|stage IV grade 2 follicular lymphoma
1461668|NCT00126646|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1461669|NCT00126646|nodal marginal zone B-cell lymphoma
1461670|NCT00126646|recurrent marginal zone lymphoma
1461671|NCT00126646|splenic marginal zone lymphoma
1461672|NCT00126646|stage III marginal zone lymphoma
1461673|NCT00126646|stage IV marginal zone lymphoma
1461674|NCT00126646|recurrent mantle cell lymphoma
1461675|NCT00126646|stage III mantle cell lymphoma
1461676|NCT00126646|stage IV mantle cell lymphoma
1461677|NCT00126646|recurrent small lymphocytic lymphoma
1461678|NCT00126646|stage III small lymphocytic lymphoma
1461679|NCT00126646|stage IV small lymphocytic lymphoma
1461680|NCT00126646|recurrent adult diffuse small cleaved cell lymphoma
1461681|NCT00126646|stage III adult diffuse small cleaved cell lymphoma
1461682|NCT00126646|stage IV adult diffuse small cleaved cell lymphoma
1461683|NCT00126646|Waldenstrom macroglobulinemia
1461684|NCT00126646|prolymphocytic leukemia
1461685|NCT00126633|adenocarcinoma of the pancreas
1461686|NCT00126633|stage IV pancreatic cancer
1461687|NCT00126620|unspecified adult solid tumor, protocol specific
1461688|NCT00126581|A Phase II Randomized Study of OSI-774
1461689|NCT00126555|squamous cell carcinoma of the skin
1461690|NCT00126555|recurrent skin cancer
1461691|NCT00126555|non-melanomatous skin cancer
1461692|NCT00126555|Radiation
1461693|NCT00126555|ZD1839
1461694|NCT00126555|Iressa
1461695|NCT00126555|Gefitinib
1461696|NCT00126516|silent brain infarction
1461697|NCT00126516|cognitive decline
1461698|NCT00126516|Angiotensin II Type 1 Receptor Blockers
1461699|NCT00126516|Angiotensin-Converting Enzyme Inhibitors
1461700|NCT00126516|hypertension
1461701|NCT00126477|quality of life
1461702|NCT00126477|de novo myelodysplastic syndromes
1461703|NCT00126477|previously treated myelodysplastic syndromes
1461704|NCT00126477|secondary myelodysplastic syndromes
1461705|NCT00126477|juvenile myelomonocytic leukemia
1461706|NCT00126477|childhood Hodgkin lymphoma
1461707|NCT00126477|childhood lymphoblastic lymphoma
1461708|NCT00126477|childhood large cell lymphoma
1461709|NCT00126477|childhood small noncleaved cell lymphoma
1461710|NCT00126477|childhood acute lymphoblastic leukemia in remission
1461711|NCT00126477|childhood acute myeloid leukemia in remission
1461712|NCT00126477|childhood chronic myelogenous leukemia
1461713|NCT00126464|ductal breast carcinoma in situ
1461714|NCT00126464|breast cancer in situ
1461715|NCT00126438|Heart Failure
1461716|NCT00126438|nuclear cardiology
1461717|NCT00126438|sympathetic innervation
1461718|NCT00126438|123I-mIBG
1461719|NCT00126425|Heart Failure
1461720|NCT00126425|nuclear cardiology
1461721|NCT00126425|sympathetic innervation
1461722|NCT00126425|123I-mIBG
1461723|NCT00126412|Phaeochromocytoma
1461724|NCT00126412|Neuroblastoma
1461725|NCT00126412|diagnosis
1461726|NCT00126412|123I-mIBG
1461727|NCT00126399|rosacea
1461728|NCT00126399|acne rosacea
1461729|NCT00126386|tumor induced hypercalcemia
1461730|NCT00126386|malignant bone pain
1461731|NCT00126386|bisphosphonates
1461732|NCT00126386|cancer
1461733|NCT00126386|palliative
1461734|NCT00126386|Zometa
1461735|NCT00126386|palliative patient
1461736|NCT00126386|treatment in community
1461737|NCT00126373|Crohn disease
1461738|NCT00126373|TNF-alpha
1461739|NCT00126360|Breast Cancer
1461740|NCT00126360|Timing of Radiotherapy
1461741|NCT00126360|Local Control
1461742|NCT00126347|betaine
1461743|NCT00126347|serine
1461744|NCT00126347|folic acid
1461745|NCT00126347|methionine load
1461746|NCT00126347|homocysteine
1461747|NCT00126347|cardiovascular health
1461748|NCT00126347|vascular function
1461749|NCT00126347|human
1461750|NCT00126334|Myocardial Infarction
1461751|NCT00126334|Anemia
1461752|NCT00126334|Erythrocyte Transfusion
1461753|NCT00126321|AML, relapsed
1461754|NCT00126321|cladribine
1461755|NCT00126321|chemotherapy
1461756|NCT00126308|HIV
1461757|NCT00126308|Lipodystrophy
1461758|NCT00126308|Intervention
1461759|NCT00126308|Poly-L-lactic acid
1461760|NCT00126308|HIV facial lipoatrophy
1461761|NCT00126308|Treatment Experienced
1461762|NCT00126282|obsessive-compulsive disorder
1461763|NCT00126282|behavior therapy
1461764|NCT00126282|D-Cycloserine
1461765|NCT00126282|medication
1461766|NCT00126282|treatment trial
1461767|NCT00126282|placebo-controlled
1461768|NCT00126282|double-blind
1461769|NCT00126282|randomized
1461770|NCT00126269|Patients with Carcinoma of Unknown Primary and a Predicted Favorable Prognosis
1461771|NCT00126256|Colorectal cancer
1461772|NCT00126256|metastatic
1461773|NCT00126256|chemotherapy
1461774|NCT00126256|randomized trial
1461775|NCT00126243|AIDS related Lymphoma
1461776|NCT00126243|chemotherapy
1461777|NCT00126243|rituximab
1461778|NCT00126230|hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine
1461779|NCT00126217|Non-specific effects of vaccines
1461780|NCT00126217|Infant mortality
1461781|NCT00126217|Morbidity
1461782|NCT00126217|Low income country
1461783|NCT00126217|Malaria
1461784|NCT00126217|BCG
1461785|NCT00126217|immunisation
1461786|NCT00126217|BCG revaccination
1461787|NCT00126217|Tuberculin
1461788|NCT00126217|Mortality
1461789|NCT00126204|endoleak
1461790|NCT00126204|doxycycline
1461791|NCT00126204|matrix metalloproteinase
1461792|NCT00126204|inflammation
1461793|NCT00126204|endograft
1461794|NCT00126204|circulating markers
1461795|NCT00126191|Burkitt Lymphoma
1461796|NCT00126191|atypical Burkitt lymphoma
1461797|NCT00126191|Non-Hodgkin's Lymphoma
1461798|NCT00126191|rituximab
1461799|NCT00126178|Kidney Cancer
1461800|NCT00126178|Renal
1461801|NCT00126178|Immunotherapy
1461802|NCT00126178|Vaccine
1461803|NCT00126165|prostate cancer
1461804|NCT00126165|radiotherapy
1461805|NCT00126165|hypofraction
1461806|NCT00126165|radiosensitivity
1461807|NCT00126165|image-guidance
1461808|NCT00126152|Falls
1461809|NCT00126152|Exercise
1461810|NCT00126152|Fall Risk Factors
1461811|NCT00126152|Older Adults
1461812|NCT00126139|stroke, ischemic
1461813|NCT00126139|stenosis, internal carotid artery
1461814|NCT00126139|Acute ischemic stroke
1461815|NCT00126139|Stenosis of extracranial internal carotid artery
1461816|NCT00126126|Artificial Limbs
1461817|NCT00126126|Evidence based medicine
1461818|NCT00126126|Exercise
1461819|NCT00126126|Outcomes research
1461820|NCT00126126|Physical therapy
1461821|NCT00126113|Audiologic rehabilitation
1461822|NCT00126113|Counseling
1461823|NCT00126100|Stem Cells
1461824|NCT00126087|dopamine
1461825|NCT00126087|NMDA receptor
1461826|NCT00126087|brain imaging
1461827|NCT00126087|neuroplasticity
1461828|NCT00126087|learning
1461960|NCT00125619|locomotor therapy
1461829|NCT00126087|transcranial direct current stimulation
1461830|NCT00126087|rehabilitation
1461831|NCT00126087|aging
1461832|NCT00126074|Atrial fibrillation, atrial flutter, anti-arrhythmic agents, conversion to normal sinus rhythm
1461833|NCT00126061|Atrial fibrillation
1461834|NCT00126061|atrial flutter
1461835|NCT00126061|anti-arrhythmic agents
1461836|NCT00126061|conversion to normal sinus rhythm
1461837|NCT00126048|Atopy
1461838|NCT00126048|Statin
1461839|NCT00126048|Asthma
1461840|NCT00126048|methacholine
1461841|NCT00126048|FEV1
1461842|NCT00126035|Acute Migraine
1461843|NCT00126035|Device
1461844|NCT00126035|Migraid
1461845|NCT00126035|Treatment
1461846|NCT00126035|Aura
1461847|NCT00126022|Atrial fibrillation
1461848|NCT00126022|atrial flutter
1461849|NCT00126022|anti-arrhythmic agents
1461850|NCT00126022|conversion to normal sinus rhythm
1461851|NCT00125996|ANAEMIA
1461852|NCT00125996|Iron Deficiency
1461853|NCT00125983|Birth Control Pills
1461854|NCT00125983|Oral Contraceptives
1461855|NCT00125983|Contraceptive Patch
1461856|NCT00125983|Pharmacokinetics
1461857|NCT00125983|Antiretroviral Therapy, Highly Active
1461858|NCT00125983|Protease Inhibitor
1461859|NCT00125983|Treatment Experienced
1461860|NCT00125983|Treatment Naive
1461861|NCT00125983|Contraception
1461862|NCT00125970|HIV Seronegativity
1461863|NCT00125970|HIV Preventive Vaccine
1461864|NCT00125957|depression
1461865|NCT00125957|serotonin
1461866|NCT00125957|norepinephrine
1461867|NCT00125957|SSRI
1461868|NCT00125957|Wellbutrin
1461869|NCT00125957|bupropion
1461870|NCT00125957|executive function
1461871|NCT00125957|residual symptoms
1461872|NCT00125931|bipolar disorder
1461873|NCT00125931|mania
1461874|NCT00125931|manic state
1461875|NCT00125931|opiate
1461876|NCT00125931|kappa
1461877|NCT00125918|Hypertension, Pulmonary; Pulmonary Heart Disease
1461878|NCT00125905|Primary Care
1461879|NCT00125905|Smoking Cessation
1461880|NCT00125905|Stages of Change Model
1461881|NCT00125905|Health Education
1461882|NCT00125905|Clinical Practice guideline
1461883|NCT00125879|Glycogen Storage Disease Type II
1461884|NCT00125879|GSD-II
1461885|NCT00125879|Pompe Disease
1461886|NCT00125879|Pompe Disease (Late-onset)
1461887|NCT00125879|Acid Maltase Deficiency Disease
1461888|NCT00125879|Glycogenosis 2
1461889|NCT00125879|Glycogen Storage Disease Type II (GSD-II)
1461890|NCT00125866|randomised double blind trial
1461891|NCT00125866|blood pressure
1461892|NCT00125866|cocoa flavonoids
1461893|NCT00125853|blood pressure
1461894|NCT00125853|insulin sensitivity
1461895|NCT00125853|beta blockers
1461896|NCT00125853|randomised double blind crossover trial
1461897|NCT00125840|CLO151
1461898|NCT00125840|Clolar
1461899|NCT00125840|Pediatric ALL and AML
1461900|NCT00125840|Adult ALL and AML and MDS
1461901|NCT00125827|CLO152
1461902|NCT00125827|Clolar
1461903|NCT00125814|Interferon Alfa-2b
1461904|NCT00125814|HIV infections
1461905|NCT00125788|sickle cell disease
1461906|NCT00125788|sickle cell anemia
1461907|NCT00125788|L-glutamine
1461908|NCT00125788|Sickle Cell Anemia (homozygous)
1461909|NCT00125788|Sickle ß0-Thalassemia
1461910|NCT00125749|Dendritic
1461911|NCT00125749|Vaccine
1461912|NCT00125749|Melanoma
1461913|NCT00125749|Stage IV metastatic melanoma
1461914|NCT00125723|Phase 4 Clinical Trial
1461915|NCT00125723|Chemotherapy
1461916|NCT00125723|Neulasta®
1461917|NCT00125723|Oncology
1461918|NCT00125723|Malignancy
1461919|NCT00125710|cryogenic analysis
1461920|NCT00125710|oncogenes
1461921|NCT00125697|malignant glioma
1461922|NCT00125697|spectroscopy
1461923|NCT00125697|magnetic resonance
1461924|NCT00125684|transdermal morphine
1461925|NCT00125684|cancer
1461926|NCT00125684|pain
1461927|NCT00125684|bioavailability
1461928|NCT00125684|pharmacokinetics
1461929|NCT00125684|cancer related pain
1461930|NCT00125684|stable baseline pain
1461931|NCT00125684|currently taking opioids
1461932|NCT00125671|Warfarin and Antiplatelet Vascular Evaluation
1461933|NCT00125671|Peripheral vascular disease
1461934|NCT00125671|Atherosclerosis
1461935|NCT00125671|cardiovascular events
1461936|NCT00125671|Ischemia
1461937|NCT00125671|oral anticoagulants
1461938|NCT00125671|low ankle-brachial index
1461939|NCT00125671|moderate intensity warfarin
1461940|NCT00125671|International normalized ratio [INR]
1461948|NCT00125645|AMI
1461949|NCT00125645|Left ventricular function
1461950|NCT00125645|Myocardial performance index
1461951|NCT00125645|Acute myocardial infarction (AMI)
1461952|NCT00125632|Reading
1461953|NCT00125632|Rehabilitation
1461954|NCT00125632|Treatment Outcomes
1461955|NCT00125632|Low vision
1461956|NCT00125619|biomechanics
1461957|NCT00125619|stroke
1461958|NCT00125619|electromyography
1461959|NCT00125619|Gait disability stroke
1461961|NCT00125619|muscular weakness
1461962|NCT00125619|reflex variability stroke
1461963|NCT00125606|AML
1461964|NCT00125606|allogeneic HSCT
1461965|NCT00125606|reduced intensity conditioning
1461966|NCT00125606|randomized trail
1461967|NCT00125593|Kidney Disease, Chronic
1461968|NCT00125593|LDL cholesterol
1461969|NCT00125593|simvastatin
1461970|NCT00125593|ezetimibe
1461971|NCT00125593|cardiovascular disease
1461972|NCT00125593|atherosclerosis
1461973|NCT00125580|Obesity
1461974|NCT00125580|Childhood Obesity
1461975|NCT00125580|Infant Sleep
1461976|NCT00125580|Infant growth
1461977|NCT00125580|Infant feeding
1461978|NCT00125554|Clinical trial
1461979|NCT00125554|double-blind
1461980|NCT00125554|randomized placebo-controlled trial
1461981|NCT00125554|metyrapone
1461982|NCT00125554|Major Depression
1461983|NCT00125541|MeSH: angioneurotic edema, complement 1 inactivators
1461984|NCT00125541|Hereditary Angioedema Type I or II, Acquired Angioedema
1461985|NCT00125528|chronic pain
1461986|NCT00125528|low back pain
1461987|NCT00125528|D-cycloserine
1461988|NCT00125515|Heroin
1461989|NCT00125515|Opiates
1461990|NCT00125515|naltrexone
1461991|NCT00125515|memantine
1461992|NCT00125502|CMV, Cytomegalovirus, vaccine, women, postpartum
1461993|NCT00125489|chloroquine, malaria, sulfadoxine/pyrimethamine, Malawi
1461994|NCT00125476|Postmenopause
1461995|NCT00125463|Hypertension
1461996|NCT00125463|clinical trial
1461997|NCT00125463|Candesartan Antihypertensive Survival Evaluation in Japan trial
1461998|NCT00125463|candesartan cilexetil
1461999|NCT00125463|amlodipine besilate
1462000|NCT00125450|Acute Bronchiolitis
1462001|NCT00125450|Chest Physiotherapy
1462002|NCT00125450|Forced Expiratory Techniques
1462003|NCT00125450|Double Blind Trial
1462004|NCT00125450|Children
1462005|NCT00125450|Pediatric
1462006|NCT00125450|RESPIRATORY SYNCYTIAL VIRUS
1462007|NCT00125437|aldosterone antagonists
1462008|NCT00125437|spironolactone
1462009|NCT00125437|left ventricular remodeling
1462010|NCT00125424|Colonoscopy
1462011|NCT00125424|Sedation
1462012|NCT00125424|AQUAVAN
1462013|NCT00125424|(fospropofol disodium)
1462014|NCT00125424|Endoscopic sedation
1462015|NCT00125424|Endoscopic outcomes
1462016|NCT00125424|Endoscopy
1462017|NCT00125411|satraplatin
1462018|NCT00125411|docetaxel
1462019|NCT00125411|cancer
1462020|NCT00125411|Phase I
1462021|NCT00125411|advanced solid tumors
1462022|NCT00125398|AQUAVAN
1462023|NCT00125398|GPI 15715
1462024|NCT00125398|ICU
1462025|NCT00125398|Sedation
1462026|NCT00125385|IPF
1462027|NCT00125385|Idiopathic
1462028|NCT00125385|Pulmonary
1462029|NCT00125385|Fibrosis
1462030|NCT00125372|tarceva
1462031|NCT00125372|targretin
1462032|NCT00125372|non-small cell lung cancer
1462033|NCT00125372|carcinoma, non-small cell lung cancer
1462034|NCT00125372|nsclc
1462035|NCT00125359|tarceva
1462036|NCT00125359|targretin
1462037|NCT00125359|non-small cell lung cancer
1462038|NCT00125359|Carcinoma, non-small cell lung cancer
1462039|NCT00125359|NSCLC
1462040|NCT00125346|Tobramycin Inhalation Powder
1462041|NCT00125333|atopic dermatitis, eczema
1462042|NCT00125320|Treatment
1462043|NCT00125307|SLE
1462044|NCT00125307|glomerulonephritis
1462045|NCT00125307|immunosuppressive therapy
1462046|NCT00125307|type V (membranous) lupus nephritis
1462047|NCT00125294|cancer pain
1462048|NCT00125294|breakthrough pain
1462049|NCT00125294|methadone
1462050|NCT00125294|dose titration
1462051|NCT00125294|sublingual route of administration
1462052|NCT00125294|Cancer related pain
1462053|NCT00125294|currently taking narcotics
1462054|NCT00125281|Fatigue
1462055|NCT00125281|Cirrhosis
1462056|NCT00125281|S-Adenosyl Methionine
1462057|NCT00125281|Primary Biliary Cirrhosis
1462058|NCT00125281|Pruritus
1462059|NCT00125281|Symptomatic Releif
1462060|NCT00125281|Serum Liver-Related Enzymes
1462061|NCT00125281|PBC
1462062|NCT00125281|Liver Disease
1462063|NCT00125268|painful
1462064|NCT00125268|peripheral
1462065|NCT00125268|neuropathy
1462066|NCT00125268|light
1462067|NCT00125268|therapy
1462068|NCT00125242|Aphasia
1462069|NCT00125242|Language therapy
1462070|NCT00125242|Rehabilitation of speech and language disorders
1462071|NCT00125242|Speech-language pathology
1462072|NCT00125229|Hypertonic Saline
1462073|NCT00125229|Mannitol
1462074|NCT00125229|Intracranial hypertension
1462075|NCT00125229|Cerebral blood flow
1462076|NCT00125229|Traumatic brain injury
1462077|NCT00125216|Aphasia
1462078|NCT00125216|Language Therapy
1462079|NCT00125216|Rehabilitation of speech and language disorders
1462080|NCT00125216|Speech-language pathology
1462081|NCT00125203|ALS
1462082|NCT00125203|Lou Gehrig's Disease
1462083|NCT00125203|Motor Neuron Disease
1462084|NCT00125203|Amyotrophic Lateral Sclerosis
1462085|NCT00125203|Sialorrhea
1462086|NCT00125203|Hypersalivation
1462087|NCT00125203|Excessive Drooling
1462088|NCT00125203|Myobloc
1462089|NCT00125203|botulinum toxin type B
1462090|NCT00125203|Clostridium botulinum B toxin
1462091|NCT00125203|botulinum B toxin
1462092|NCT00125203|botulinum neurotoxin B
1462093|NCT00125203|NeuroBloc
1462094|NCT00125190|Primary IGF-1 Deficiency
1462095|NCT00125190|IGF-1
1462096|NCT00125177|pelvic muscle therapy
1462097|NCT00125177|urinary incontinence therapy
1462098|NCT00125177|stress incontinence intervention
1462099|NCT00125177|incontinence intervention
1462100|NCT00125177|Incontinence
1462101|NCT00125177|SUI
1462102|NCT00125177|Stress Incontinence
1462103|NCT00125164|Primary IGF-1 Deficiency
1462104|NCT00125151|MeSH: angioneurotic edema, complement 1 inactivators
1462105|NCT00125151|Hereditary angioedema type I or II, Acquired angioedema
1462106|NCT00125125|Dyslipidemia, adults, fluvastatin
1462107|NCT00125112|binge eating
1462108|NCT00125112|weight loss
1462109|NCT00125112|obesity
1462110|NCT00125099|Acute Infection
1462111|NCT00125099|Treatment Experienced
1462112|NCT00125099|Treatment Interruption
1462113|NCT00125099|HIV Therapeutic Vaccine
1462114|NCT00125086|wounds
1462115|NCT00125086|healing
1462116|NCT00125086|Acute wounds healing by secondary intention
1462117|NCT00125073|Standard Care
1462118|NCT00125073|Nutritional Counseling
1462119|NCT00125060|Aorta
1462120|NCT00125060|Atherosclerosis
1462121|NCT00125060|MRI
1462122|NCT00125060|statin
1462123|NCT00125060|inflammatory markers
1462124|NCT00125047|Salmonellosis
1462125|NCT00125047|typhoid vaccine
1462126|NCT00125047|enteric fever
1462127|NCT00125034|FOLFOX-4
1462128|NCT00125034|Cetuximab
1462129|NCT00125034|First-line mCRC
1462130|NCT00125034|EGFR positive
1462131|NCT00125034|metastatic CRC
1462132|NCT00125021|Second Line Therapy
1462133|NCT00125021|Gemcitabine Refractory
1462134|NCT00125021|Pancreatic Cancer
1462135|NCT00125021|Capecitabine
1462136|NCT00125021|Tarceva
1462137|NCT00125021|OSI-774
1462138|NCT00125021|Metastatic Pancreatic Cancer
1462139|NCT00125008|Salmonella
1462140|NCT00125008|Typhoid vaccine
1462141|NCT00125008|enteric fever
1462142|NCT00124969|End-stage renal disease, hemodialysis
1462143|NCT00124943|Prevention of Instent Restenosis
1462144|NCT00124930|olanzapine
1462145|NCT00124930|haldol
1462146|NCT00124930|cancer
1462147|NCT00124930|nausea
1462148|NCT00124930|second line treatment
1462149|NCT00124930|refractory nausea
1462150|NCT00124917|Prostate Cancer
1462151|NCT00124917|MRI
1462152|NCT00124917|Fiducial Marker
1462153|NCT00124917|IMRT
1462154|NCT00124904|Biofeedback
1462155|NCT00124904|Incontinence
1462156|NCT00124891|Arrhythmias
1462157|NCT00124878|HIV
1462158|NCT00124878|STDs
1462159|NCT00124878|Male circumcision
1462160|NCT00124878|HIV+ males
1462161|NCT00124878|HIV-negative males
1462162|NCT00124878|Female partners
1462163|NCT00124878|STDs such as the following:
1462164|NCT00124878|HPV
1462165|NCT00124878|HSV-2
1462166|NCT00124878|HIV Seronegativity
1462167|NCT00124865|Campylobacter
1462168|NCT00124865|Bacterial enteritis
1462169|NCT00124852|cognition
1462170|NCT00124852|depression
1462171|NCT00124852|elderly
1462172|NCT00124839|Dissociation
1462173|NCT00124839|Flashbacks
1462174|NCT00124839|Self-injurious behavior
1462175|NCT00124826|stroke
1462176|NCT00124826|cerebrovascular disease
1462177|NCT00124826|hyperglycemia
1462178|NCT00124826|magnetic resonance imaging
1462179|NCT00124826|acute ischemic stroke
1462180|NCT00124800|tinnitus
1462181|NCT00124774|hernia
1462182|NCT00124774|nucleoplasty
1462183|NCT00124774|radicular pain
1462184|NCT00124774|Contained lumbar herniated disc
1462185|NCT00124761|Radiosurgery
1462186|NCT00124761|Brain metastases
1462187|NCT00124761|Whole Brain Radiotherapy
1462188|NCT00124761|Neurosurgery
1462189|NCT00124761|Solitary Brain Metastases
1462190|NCT00124761|Adult Tumours Metastatic to Brain
1462191|NCT00124748|CML
1462192|NCT00124748|Philadelphia positive
1462193|NCT00124748|Bcr-abl
1462194|NCT00124748|imatinib mesylate
1462195|NCT00124748|Chronic myeloid leukemia (CML) in chronic phase
1462196|NCT00124709|Atopic, dermatitis, asthma, children, modification
1462197|NCT00124709|Atopic dermatitis/atopy
1462198|NCT00124696|cocaine dependence
1462199|NCT00124683|nicotine dependence
1462200|NCT00124657|adult anaplastic astrocytoma
1462201|NCT00124657|adult anaplastic oligodendroglioma
1462202|NCT00124657|adult glioblastoma
1462203|NCT00124657|adult giant cell glioblastoma
1462204|NCT00124657|adult gliosarcoma
1462205|NCT00124657|adult mixed glioma
1462206|NCT00124657|childhood mixed glioma
1462207|NCT00124657|untreated childhood cerebellar astrocytoma
1462208|NCT00124657|childhood high-grade cerebral astrocytoma
1462209|NCT00124657|childhood low-grade cerebral astrocytoma
1462210|NCT00124657|childhood oligodendroglioma
1462211|NCT00124657|childhood spinal cord neoplasm
1462212|NCT00124644|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1462213|NCT00124644|adult acute myeloid leukemia with t(16;16)(p13;q22)
1462214|NCT00124644|untreated adult acute myeloid leukemia
1462215|NCT00124644|secondary acute myeloid leukemia
1462216|NCT00124618|stage IIIA non-small cell lung cancer
1462217|NCT00124618|stage IIIB non-small cell lung cancer
1462218|NCT00124579|stage I multiple myeloma
1462219|NCT00124579|stage II multiple myeloma
1462220|NCT00124579|stage III multiple myeloma
1462221|NCT00124579|refractory multiple myeloma
1462222|NCT00124566|Irofulven
1462223|NCT00124566|Docetaxel
1462224|NCT00124566|Taxotere
1462225|NCT00124553|Type 2 diabetes
1462226|NCT00124553|cardiovascular risk
1462227|NCT00124553|glycaemic control
1462228|NCT00124553|dietary modification
1462229|NCT00124540|Misoprostol
1462230|NCT00124540|Active management
1462231|NCT00124540|Postpartum hemorrhage
1462232|NCT00124540|Maternal morbidity
1462233|NCT00124540|Anemia
1462234|NCT00124540|Developing countries
1462235|NCT00124527|Irofulven, Thyroid Cancer
1462236|NCT00124514|SLE
1462237|NCT00124514|Lupus
1462238|NCT00124514|Ovarian damage
1462239|NCT00124514|Menopause
1462240|NCT00124501|Biofeedback
1462241|NCT00124488|radiotherapy planning
1462242|NCT00124488|computer assisted radiotherapy
1462243|NCT00124488|conformal
1462244|NCT00124475|Chronic Hand Dermatitis
1462245|NCT00124436|Patients who have been enrolled in study protocol BAP089, and whose severe chronic hand dermatitis responded with mild or moderate disease, or who relapsed
1462246|NCT00124423|brachytherapy megavoltage CT imaging
1462247|NCT00124410|prostate cancer
1462248|NCT00124410|androgen suppression therapy (hormone therapy)
1462249|NCT00124410|osteoporosis
1462250|NCT00124384|primary insomnia, stimulants, cognitive behavioral therapy
1462251|NCT00124371|coronary artery bypass surgery
1462252|NCT00124371|risk factors
1462253|NCT00124371|nurse-led secondary prevention
1462254|NCT00124371|prehabilitation
1462255|NCT00124371|waiting period
1462256|NCT00124358|Drug Abuse
1462257|NCT00124358|Drug Addiction
1462258|NCT00124358|Drug Dependence
1462259|NCT00124358|Drug Use Disorders
1462260|NCT00124358|Drug Use Disorder
1462261|NCT00124358|Substance Abuse
1462262|NCT00124358|Substance Use Disorder
1462263|NCT00124358|Buprenorphine
1462264|NCT00124358|Opiate Addiction
1462265|NCT00124358|Substance-related disorders
1462266|NCT00124358|HIV
1462267|NCT00124345|temperature
1462268|NCT00124345|humidity
1462269|NCT00124345|non invasive mechanical ventilation
1462270|NCT00124319|Biomechanics
1462271|NCT00124319|Neuromuscular
1462272|NCT00124319|Lower limb
1462273|NCT00124319|Injury
1462274|NCT00124319|ACL
1462275|NCT00124319|Anterior Cruciate Ligament injury
1462276|NCT00124306|painful bladder syndrome
1462277|NCT00124306|interstitial cystitis
1462278|NCT00124306|newly diagnosed
1462279|NCT00124280|Lung cancer
1462280|NCT00124280|non-small cell
1462281|NCT00124280|everolimus
1462282|NCT00124280|Non-small cell lung cancer (NSCLC)
1462283|NCT00124267|Cerebral
1462284|NCT00124267|malaria
1462285|NCT00124267|intra-rectal
1462286|NCT00124267|quinine
1462287|NCT00124267|children
1462288|NCT00124267|Uganda
1462289|NCT00124267|efficacy
1462290|NCT00124267|safety
1462291|NCT00124254|Metacarpophalangeal Joint
1462292|NCT00124254|Arthroplasty
1462293|NCT00124254|Outcomes
1462294|NCT00124254|Michigan Hand Outcomes Questionnaire
1462295|NCT00124254|Joint Replacement
1462296|NCT00124228|Cirrhosis
1462297|NCT00124228|Infection
1462298|NCT00124228|Sepsis
1462299|NCT00124228|Renal failure
1462300|NCT00124215|Hepatitis
1462301|NCT00124215|HCV
1462302|NCT00124215|vaccine
1462303|NCT00124215|Hepatitis C Infection
1462304|NCT00124202|a fatty meal
1462305|NCT00124202|ERCP
1462306|NCT00124189|Chronic lymphocytic leukemia
1462307|NCT00124189|T-cell prolymphocytic leukemia
1462308|NCT00124189|Chronic lymphoproliferative diseases
1462309|NCT00124189|Telomerase
1462310|NCT00124189|Telomerase Inhibition
1462311|NCT00124176|Asthma
1462312|NCT00124176|Levalbuterol
1462313|NCT00124176|Albuterol
1462314|NCT00124176|Children
1462315|NCT00124163|CT Virtual Colonoscopy
1462316|NCT00124163|Optical Colonoscopy
1462317|NCT00124163|Stool Tagging
1462318|NCT00124163|Patient Preparation
1462319|NCT00124150|subarachnoid hemorrhage
1462320|NCT00124150|magnesium sulfate
1462321|NCT00124137|Ultrafiltration
1462322|NCT00124137|acute decompensated heart failure
1462323|NCT00124137|fluid overload
1462324|NCT00124137|pulmonary congestion
1462325|NCT00124111|clinical trial
1462326|NCT00124111|pegfilgrastim
1462327|NCT00124111|haematopoietic growth factor
1462328|NCT00124111|neutropenia
1462329|NCT00124111|CMF
1462330|NCT00124111|Cancer
1462331|NCT00124098|Chronic Kidney Disease (CKD)
1462332|NCT00124098|anemia, clinical trial
1462333|NCT00124098|darbepoetin alfa
1462334|NCT00124098|Aranesp®
1462335|NCT00124098|Amgen
1462336|NCT00124072|Myocardial infarction
1462337|NCT00124072|Coronary heart disease
1462338|NCT00124072|Cholesterol
1462339|NCT00124072|Stroke
1462340|NCT00124059|alcohol dependence
1462341|NCT00124046|Urinary Incontinence in Children
1462342|NCT00124046|Surgical Section of the Filum Terminale
1462343|NCT00124046|Occult Tethered Cord Syndrome
1462344|NCT00124046|Urodynamic Scale
1462345|NCT00124046|Enuresis-Specific Quality of Life Scale
1462346|NCT00124033|Cholecystectomy
1462347|NCT00124033|Cholangiopancreatography, Endoscopic Retrograde
1462348|NCT00124007|HIV Seronegativity
1462349|NCT00124007|HIV Preventive Vaccine
1462350|NCT00123994|TaiChi
1462351|NCT00123994|Hydrotherapy
1462352|NCT00123994|Exercise
1462353|NCT00123994|Joint pain
1462354|NCT00123994|Disability
1462355|NCT00123981|Off-pump Coronary Artery By-pass Grafting
1462356|NCT00123981|Randomization
1462357|NCT00123981|stroke
1462358|NCT00123981|myocardial infarction
1462359|NCT00123981|mortality
1462360|NCT00123981|graft patency
1462361|NCT00123981|quality of life
1462362|NCT00123968|HIV Seronegativity
1462363|NCT00123968|HIV Preventive Vaccine
1462364|NCT00123942|CD2+ Lymphoproliferative disorder
1462365|NCT00123929|breast cancer
1462366|NCT00123929|neoadjuvant chemotherapy
1462367|NCT00123929|genetic signature
1462368|NCT00123929|doxorubicin
1462369|NCT00123929|docetaxel
1462370|NCT00123916|Chagas Disease
1462371|NCT00123916|Trypanosomiasis
1462372|NCT00123916|Benznidazole
1462373|NCT00123916|Chronic Heart disease
1462374|NCT00123916|Trypanosoma Cruzi
1462375|NCT00123903|hypertension
1462376|NCT00123903|urine albumin:creatinine ratio
1462377|NCT00123903|microalbuminuria
1462378|NCT00123890|HIV-1 GW873140 CCR5 antagonist experienced
1462379|NCT00123877|Breast
1462380|NCT00123877|Cancer
1462381|NCT00123877|Metastasis
1462382|NCT00123864|intensity modulated radiation therapy
1462383|NCT00123864|parotid
1462384|NCT00123864|nasopharyngeal carcinoma
1462385|NCT00123851|Colorectal
1462386|NCT00123851|Metastatic Colorectal Cancer
1462387|NCT00123851|Oxaliplatin
1462388|NCT00123851|Tarceva
1462389|NCT00123851|Capecitabine
1462390|NCT00123851|Xeloda
1462391|NCT00123838|Prostate
1462392|NCT00123838|Cancer
1462393|NCT00123838|Radiotherapy
1462394|NCT00123838|Neoplasm
1462395|NCT00123838|Localization
1462396|NCT00123838|Tracking
1462397|NCT00123838|Cancer of Prostate
1462398|NCT00123838|Neoplasms, Prostate
1462399|NCT00123825|Gallbladder
1462400|NCT00123825|Biliary Tract
1462401|NCT00123825|Cholangiocarcinoma
1462402|NCT00123812|quality assurance
1462403|NCT00123812|frequency of port films
1462404|NCT00123799|positron emission tomography
1462405|NCT00123799|fluorodeoxyglucose F18
1462406|NCT00123799|sentinel lymph node biopsy
1462407|NCT00123786|positron emission tomography
1462408|NCT00123786|fluorodeoxyglucose F18
1462409|NCT00123786|tomography scanners, x-ray computed
1462410|NCT00123773|positron emission tomography
1462411|NCT00123773|fluorodeoxyglucose F18
1462412|NCT00123773|Tomography scanners, x-ray computed
1462413|NCT00123760|Positron-Emission Tomography
1462414|NCT00123760|Fluorodeoxyglucose F18
1462415|NCT00123760|Tomography scanners, X-Ray computed
1462416|NCT00123747|Positron Emission Tomography
1462417|NCT00123747|Fluorodeoxyglucose F18
1462418|NCT00123747|Tomography scanners, X-Ray Computed
1462419|NCT00123708|Spasticity
1462420|NCT00123708|Dystonia
1462421|NCT00123708|Movement Disorders
1462422|NCT00123708|Walking
1462423|NCT00123708|Muscle Weakness
1462424|NCT00123708|Resistance
1462425|NCT00123708|Gait
1462426|NCT00123708|Cerebral Palsy
1462427|NCT00123708|CP
1462428|NCT00123695|Subarachnoid hemorrhage
1462429|NCT00123695|Takotsubo cardiomyopathy
1462430|NCT00123695|Cardiac abnormalities
1462431|NCT00123695|outcome
1462432|NCT00123682|Smoking Cessation
1462433|NCT00123682|Care Management
1462434|NCT00123682|Substance Use Disorder QUERI
1462435|NCT00123682|Primary Care
1462436|NCT00123682|Regional Expansion
1462437|NCT00123682|Telephone
1462438|NCT00123669|Cancer of the Breast
1462439|NCT00123669|Neoplasm
1462440|NCT00123656|Eosinophilic esophagitis
1462441|NCT00123656|esomeprazole
1462442|NCT00123656|fluticasone
1462443|NCT00123643|thiazolidinedione
1462444|NCT00123643|sulfonylurea
1462445|NCT00123643|endothelial function
1462446|NCT00123630|eosinophilic esophagitis
1462447|NCT00123630|omalizumab
1462448|NCT00123617|Chest pain
1462449|NCT00123617|Women
1462450|NCT00123617|Syndrome X
1462451|NCT00123617|Cardiac rehabilitation
1462452|NCT00123617|Psychological morbidity
1462453|NCT00123617|Cardiovascular risk factors
1462454|NCT00123604|beta-blockers
1462455|NCT00123604|endothelial function
1462456|NCT00123565|Coronary Disease
1462457|NCT00123552|Uganda, malaria, combination antimalarial therapy
1462458|NCT00123487|Accelerated Phase Chronic Myeloid Leukemia
1462459|NCT00123487|Lymphoid Blast Phase Chronic Myeloid Leukemia
1462583|NCT00122941|Uganda
1462460|NCT00123487|Myeloid Blast Phase Chronic Myeloid Leukemia
1462461|NCT00123487|Philadelphia Positive Acute Lymphoblastic Leukemia
1462462|NCT00123474|Chronic Phase Chronic Myelogenous Leukemia
1462463|NCT00123448|Mirror Neurons
1462464|NCT00123448|fMRI
1462465|NCT00123448|Premotor Cortex
1462466|NCT00123448|gesture
1462467|NCT00123448|Healthy Volunteer
1462468|NCT00123448|HV
1462469|NCT00123435|Behavioral Research
1462470|NCT00123435|Nutritional management
1462471|NCT00123435|Physical activity
1462472|NCT00123435|Prevention
1462473|NCT00123435|Randomized control trial
1462474|NCT00123435|walking program
1462475|NCT00123435|Weight loss
1462476|NCT00123435|World wide web
1462477|NCT00123422|Breathing exercise
1462478|NCT00123422|Exercise Therapy
1462479|NCT00123422|Helium
1462480|NCT00123422|Oxygen inhalation therapy
1462481|NCT00123422|Pulmonary emphysema
1462482|NCT00123422|Pulmonary ventilation
1462483|NCT00123422|Rehabilitation
1462484|NCT00123409|Primary Care
1462485|NCT00123409|Telephone
1462486|NCT00123409|Quality of Life
1462487|NCT00123396|Bioterrorism
1462488|NCT00123396|Education, Medical, Continuing
1462489|NCT00123396|Internet
1462490|NCT00123383|Modafinil
1462491|NCT00123383|Cocaine Dependence
1462492|NCT00123383|Randomised placebo-controlled trial
1462493|NCT00123370|Modafinil
1462494|NCT00123370|Amphetamine Dependence
1462495|NCT00123370|Randomised placebo-controlled trial
1462496|NCT00123344|symptomatic bradycardia
1462497|NCT00123344|paroxysmal atrial fibrillation
1462498|NCT00123344|antitachycardia pacing therapies
1462499|NCT00123344|prevention algorithms
1462500|NCT00123331|Heart transplantation
1462501|NCT00123331|Renal failure
1462502|NCT00123331|Cyclosporine
1462503|NCT00123331|Rapamycin
1462504|NCT00123318|Gastric cancer
1462505|NCT00123318|Radiotherapy
1462506|NCT00123318|Chemotherapy
1462507|NCT00123318|Chemoradiation
1462508|NCT00123305|Stroke
1462509|NCT00123305|Acute Ischemic Stroke
1462510|NCT00123292|arterial occlusion
1462511|NCT00123292|thromboembolism
1462512|NCT00123292|Acute Peripheral Arterial Occlusion
1462513|NCT00123279|diabetic macular edema
1462514|NCT00123279|macular hole
1462515|NCT00123279|vitreomacular traction syndrome
1462516|NCT00123266|stroke
1462517|NCT00123266|vertebrobasilar
1462518|NCT00123266|basilar
1462519|NCT00123266|Acute vertebrobasilar artery occlusion
1462520|NCT00123253|HIV
1462521|NCT00123253|Lipodystrophy
1462522|NCT00123253|Abdominal fat accumulation
1462523|NCT00123253|Growth hormone releasing factor/Growth hormone releasing hormone
1462524|NCT00123253|Treatment Experienced
1462525|NCT00123240|overweight
1462526|NCT00123240|obese
1462527|NCT00123240|diet
1462528|NCT00123227|Randomised controlled trial
1462529|NCT00123227|Rosiglitazone
1462530|NCT00123227|Cardiovascular magnetic resonance
1462531|NCT00123227|Diabetes Mellitus
1462532|NCT00123227|Vascular Diseases
1462533|NCT00123227|Hypertension
1462534|NCT00123214|Diet
1462535|NCT00123214|Chronic sleep deprivation
1462536|NCT00123214|Weight
1462537|NCT00123214|Cognitive impairment
1462538|NCT00123214|Lipids
1462539|NCT00123214|Inflammation
1462540|NCT00123214|Resting metabolic rate
1462541|NCT00123214|Weight Gain
1462542|NCT00123214|Percent Body Fat
1462543|NCT00123214|Hyperlipidemia
1462544|NCT00123201|efficacy & safety, migraine headache, placebo-controlled
1462545|NCT00123201|migraine headache with or without aura
1462546|NCT00123175|Endometrial Hyperplasia without atypia
1462547|NCT00123162|Sildenafil
1462548|NCT00123149|Anemia
1462549|NCT00123149|Rheumatoid arthritis
1462550|NCT00123149|Hemoglobin level
1462551|NCT00123136|pulsed magnetic field therapy
1462552|NCT00123136|diabetic peripheral neuropathy
1462553|NCT00123136|neuromodulation
1462554|NCT00123136|diabetic peripheral neuropathic pain
1462555|NCT00123136|sleep benefit
1462556|NCT00123136|diabetic peripheral neuropathic functioning
1462557|NCT00123123|Ventilator-associated pneumonia
1462558|NCT00123097|Facial Neoplasms
1462559|NCT00123097|Head and Neck Neoplasms
1462560|NCT00123097|Head Injuries, Penetrating
1462561|NCT00123097|Birth Injuries
1462562|NCT00123084|Parkinson's disease
1462563|NCT00123084|Swallowing difficulties
1462564|NCT00123084|speech
1462565|NCT00123084|voice
1462566|NCT00123058|Hypertension
1462567|NCT00123058|Cariovascular Diseases
1462568|NCT00123058|Health Illiteracy
1462569|NCT00122980|Blood Diseases
1462570|NCT00122954|Fatty Acids, Omega-3
1462571|NCT00122954|Fish Oils
1462572|NCT00122954|Complementary Therapies
1462573|NCT00122941|multiple
1462574|NCT00122941|micronutrients
1462575|NCT00122941|supplementation
1462576|NCT00122941|HIV
1462577|NCT00122941|children
1462578|NCT00122941|randomised
1462579|NCT00122941|trial
1462580|NCT00122941|mortality
1462581|NCT00122941|morbidity
1462582|NCT00122941|growth
1462584|NCT00122928|Worksite
1462585|NCT00122928|Workplace
1462586|NCT00122928|Return on Investment
1462587|NCT00122928|Financial Impact
1462588|NCT00122915|Motor Cortex Stimulation
1462589|NCT00122915|Pain treatment
1462590|NCT00122915|Central post-stroke pain (CPSP)
1462591|NCT00122915|Trigeminal neuropathic pain (TGN)
1462592|NCT00122915|Facial pain
1462593|NCT00122915|Neurostimuation
1462594|NCT00122915|Cortical lead
1462595|NCT00122915|Neuropathic pain
1462596|NCT00122902|HIV
1462597|NCT00122902|AIDS
1462598|NCT00122902|Spirituality
1462599|NCT00122889|Drug Interactions
1462600|NCT00122889|Pharmacokinetics
1462601|NCT00122889|Garlic
1462602|NCT00122889|Complementary Therapies
1462603|NCT00122889|Complementary and Alternative Medicine
1462604|NCT00122876|Hepatocellular Carcinoma
1462605|NCT00122876|HCC
1462606|NCT00122876|Photodynamic therapy
1462607|NCT00122876|Talaporfin Sodium (LS11)
1462608|NCT00122876|Light emitting diodes (LEDs)
1462609|NCT00122876|Litx
1462610|NCT00122876|Light Infusion Technology
1462611|NCT00122811|Aged
1462612|NCT00122811|Hypertension
1462613|NCT00122811|Stroke
1462614|NCT00122798|Stroke, stroke treatment, atrial fibrillation, medication, rehabilitation
1462615|NCT00122785|bronchiolitis
1462616|NCT00122785|wheezing
1462617|NCT00122785|dexamethasone
1462618|NCT00122785|young children
1462619|NCT00122759|Mechanical ventilation
1462620|NCT00122759|Agitation
1462621|NCT00122746|Cervical Cancer
1462622|NCT00122746|AIDS
1462623|NCT00122746|External Beam Radiotherapy
1462624|NCT00122746|Brachytherapy
1462625|NCT00122746|Cisplatin
1462626|NCT00122733|Mechanical ventilation
1462627|NCT00122733|Agitation
1462628|NCT00122733|Difficult weaning
1462629|NCT00122720|colorectal cancer
1462630|NCT00122720|erythropoietin
1462631|NCT00122720|rehabilitation
1462632|NCT00122720|physical capacity
1462633|NCT00122707|catheter-related infection
1462634|NCT00122707|mechanical complications of catheters
1462635|NCT00122694|carbon monoxide
1462636|NCT00122694|COPD
1462637|NCT00122694|inflammation
1462638|NCT00122694|sputum induction
1462639|NCT00122694|stable COPD
1462640|NCT00122668|HIV Protease Inhibitors
1462641|NCT00122668|HIV-Associated Lipodystrophy Syndrome
1462642|NCT00122668|HIV infections
1462643|NCT00122655|HIV infections
1462644|NCT00122655|HIV Lipodystrophy Syndrome
1462645|NCT00122642|catheterization
1462646|NCT00122642|Catheters, Indwelling
1462647|NCT00122629|Hepatitis C, Chronic
1462648|NCT00122629|peginterferon alfa-2b
1462649|NCT00122629|ribavirin
1462650|NCT00122629|Amantadine
1462651|NCT00122616|HIV infections
1462652|NCT00122616|peginterferon alfa-2a
1462653|NCT00122616|Treatment Failure
1462654|NCT00122616|Hepatitis C, Chronic
1462655|NCT00122616|Treatment Experienced
1462656|NCT00122603|HIV Protease Inhibitors
1462657|NCT00122603|HIV infections
1462658|NCT00122603|Atazanavir
1462659|NCT00122603|Saquinavir
1462660|NCT00122603|Fosamprenavir
1462661|NCT00122603|ritonavir
1462662|NCT00122603|Treatment Naive
1462663|NCT00122590|protease inhibitors
1462664|NCT00122590|nelfinavir
1462665|NCT00122590|lopinavir
1462666|NCT00122590|indinavir
1462667|NCT00122590|Pharmacokinetics
1462668|NCT00122577|HIV infections
1462669|NCT00122577|Treatment Failure
1462670|NCT00122577|tenofovir
1462671|NCT00122577|atazanavir
1462672|NCT00122564|HIV Vaccines
1462673|NCT00122564|HIV Seronegativity
1462674|NCT00122551|HIV infections
1462675|NCT00122538|HAART
1462676|NCT00122538|once-daily
1462677|NCT00122538|child
1462678|NCT00122538|africa
1462679|NCT00122538|HIV
1462680|NCT00122538|AIDS
1462681|NCT00122538|Treatment Naive
1462682|NCT00122525|HIV
1462683|NCT00122525|Male circumcision
1462684|NCT00122525|Prevention
1462685|NCT00122525|HSV-2
1462686|NCT00122525|Africa
1462687|NCT00122525|Sexual behavior
1462688|NCT00122512|AE adverse event
1462689|NCT00122512|AIDS acquired immunodeficiency syndrome
1462690|NCT00122512|ALT (SGPT) alanine aminotransferase
1462691|NCT00122512|ART antiretroviral therapy
1462692|NCT00122512|AST (SGOT) aspartate aminotransferase
1462693|NCT00122512|DCF data collection forms
1462694|NCT00122512|DMC Data Monitoring Committee
1462695|NCT00122512|FDA (U.S.) Food and Drug Administration
1462696|NCT00122512|GCP Good Clinical Practice guidelines
1462697|NCT00122512|HB sAg Hepatitis B surface antigen
1462698|NCT00122512|ICH International Conference of Harmonisation
1462817|NCT00122174|Bioinstrumentation
1462699|NCT00122512|IND Investigational New Drug Application
1462700|NCT00122512|IRB Institutional Review Board
1462701|NCT00122512|IU international units
1462702|NCT00122512|mg milligram(s)
1462703|NCT00122512|mm3 cubic millimeter(s)
1462704|NCT00122512|PCR polymerase chain reaction
1462705|NCT00122512|SAE serious adverse event
1462706|NCT00122512|TDF tenofovir disoproxil fumarate, GS-4331-05, PMPA prodrug
1462707|NCT00122512|µg microgram
1462708|NCT00122512|ULN upper limit of the normal range
1462709|NCT00122512|WB Western Blot
1462710|NCT00122512|Human Immunodeficiency Virus
1462711|NCT00122512|HIV Seronegativity
1462712|NCT00122499|Prostate cancer
1462713|NCT00122499|Radiotherapy
1462714|NCT00122499|Erectile dysfunction
1462715|NCT00122499|Tadalafil
1462716|NCT00122486|AE adverse event
1462717|NCT00122486|AIDS acquired immunodeficiency syndrome
1462718|NCT00122486|ALT (SGPT) alanine aminotransferase
1462719|NCT00122486|ART antiretroviral therapy
1462720|NCT00122486|AST (SGOT) aspartate aminotransferase
1462721|NCT00122486|DCF data collection forms
1462722|NCT00122486|DMC Data Monitoring Committee
1462723|NCT00122486|FDA (U.S.) Food and Drug Administration
1462724|NCT00122486|GCP Good Clinical Practice guidelines
1462725|NCT00122486|HB sAg Hepatitis B surface antigen
1462726|NCT00122486|ICH International Conference of Harmonisation
1462727|NCT00122486|IND Investigational New Drug Application
1462728|NCT00122486|IRB Institutional Review Board
1462729|NCT00122486|IU international units
1462730|NCT00122486|mg milligram(s)
1462731|NCT00122486|mm3 cubic millimeter(s)
1462732|NCT00122486|PCR polymerase chain reaction
1462733|NCT00122486|SAE serious adverse event
1462734|NCT00122486|µg microgram
1462735|NCT00122486|ULN upper limit of the normal range
1462736|NCT00122486|WB Western Blot
1462737|NCT00122486|Human Immunodeficiency Virus
1462738|NCT00122473|Dermatofibrosarcoma
1462739|NCT00122473|Imatinib
1462740|NCT00122473|Tyrosine Kinase Inhibitor
1462741|NCT00122460|Head and Neck Cancer
1462742|NCT00122447|Prediabetic state
1462743|NCT00122447|Cardiovascular disease
1462744|NCT00122447|Diabetes
1462745|NCT00122447|Glucose intolerance
1462746|NCT00122421|diabetes
1462747|NCT00122421|quality of care
1462748|NCT00122421|pharmacist recommendations
1462749|NCT00122408|ventilator-associated pneumonia
1462750|NCT00122408|probiotic
1462751|NCT00122408|mechanical ventilation
1462752|NCT00122408|intensive care
1462753|NCT00122395|Domestic violence
1462754|NCT00122395|Screening
1462755|NCT00122395|Emergency department
1462756|NCT00122382|abatacept, methotrexate, erosive RA
1462757|NCT00122369|Breast
1462758|NCT00122369|Biopsy
1462759|NCT00122369|Hypnosis
1462760|NCT00122369|Relaxation
1462761|NCT00122369|Anxiety
1462762|NCT00122369|Pain
1462763|NCT00122369|Medical and Surgical Procedures
1462764|NCT00122343|Endometrial
1462765|NCT00122343|Cancer
1462766|NCT00122317|Transfusion dependent, hemolytic paroxysmal nocturnal hemoglobinuria
1462767|NCT00122291|preoperative
1462768|NCT00122291|chemotherapy
1462769|NCT00122291|radiation therapy
1462770|NCT00122291|rectal cancer
1462771|NCT00122291|transmural rectal wall invasion
1462772|NCT00122291|nodal metastasis
1462773|NCT00122278|migraine, emergency department, dexamethasone
1462774|NCT00122278|Migraine with or without aura or probable migraine without aura as defined by ICHD, 2nd edition
1462775|NCT00122265|prostate cancer
1462776|NCT00122265|radiotherapy
1462777|NCT00122265|radiation toxicity
1462778|NCT00122265|single nucleotide polymorphism
1462779|NCT00122252|prostate cancer
1462780|NCT00122252|radiotherapy
1462781|NCT00122252|biological imaging
1462782|NCT00122239|radiotherapy
1462783|NCT00122239|radiation toxicity
1462784|NCT00122239|single nucleotide polymorphism
1462785|NCT00122239|breast carcinoma
1462786|NCT00122239|prostate carcinoma
1462787|NCT00122239|squamous cell carcinoma of the head and neck
1462788|NCT00122239|lung carcinoma (non-small cell)
1462789|NCT00122226|HIV
1462790|NCT00122226|HIV-associated lipodystrophy syndrome
1462791|NCT00122213|Prevention
1462792|NCT00122213|Retirement
1462793|NCT00122213|Physical activity
1462794|NCT00122213|Diet
1462795|NCT00122213|Weight gain
1462796|NCT00122213|Body composition
1462797|NCT00122187|cancer
1462798|NCT00122187|colonoscopy
1462799|NCT00122187|mass screening
1462800|NCT00122187|colorectal cancer
1462801|NCT00122187|colorectal carcinoma
1462802|NCT00122187|reminder systems
1462803|NCT00122187|rectal cancers
1462804|NCT00122187|colorectal tumor
1462805|NCT00122187|guidelines
1462806|NCT00122187|CRC secondary prevention
1462807|NCT00122187|colorectal neoplasms
1462808|NCT00122187|colonic neoplasms
1462809|NCT00122187|colonic diseases
1462810|NCT00122187|hemoccult testing
1462811|NCT00122174|Caregivers
1462812|NCT00122174|Stress
1462813|NCT00122174|Coping
1462814|NCT00122174|Immune
1462815|NCT00122174|Relaxation
1462816|NCT00122174|Biofeedback
1462818|NCT00122174|Homecare
1462819|NCT00122161|Drug therapy
1462820|NCT00122161|Practice guidelines
1462821|NCT00122161|Reminder systems
1462822|NCT00122161|Ambulatory care
1462823|NCT00122161|Hypertension
1462824|NCT00122161|Clinical protocols
1462825|NCT00122161|Quality Assurance, Health Care
1462826|NCT00122148|Quality of health care
1462827|NCT00122148|Feedback
1462828|NCT00122135|end-of-life care
1462829|NCT00122135|clinical decision-making
1462830|NCT00122135|values inventory
1462831|NCT00122135|racial disparities
1462832|NCT00122109|Posttraumatic Stress Disorder
1462833|NCT00122109|Anger Management
1462834|NCT00122109|Telemedicine modality
1462835|NCT00122096|neurosurgery
1462836|NCT00122096|COX-2
1462837|NCT00122096|inflammation
1462838|NCT00122096|pain
1462839|NCT00122083|Depression
1462840|NCT00122083|Students
1462841|NCT00122083|Health education
1462842|NCT00122070|Borderline Personality Disorder
1462843|NCT00122070|Personality Disorder
1462844|NCT00122070|Quetiapine
1462845|NCT00122070|Atypical Antipsychotics
1462846|NCT00122070|Seroquel
1462847|NCT00122070|Antipsychotics
1462848|NCT00122057|ventilator-associated tracheobronchitis
1462849|NCT00122057|nosocomial tracheobronchitis
1462850|NCT00122044|childhood
1462851|NCT00122044|cerebral palsy
1462852|NCT00122044|dystonia
1462853|NCT00122044|secondary
1462854|NCT00122044|trihexyphenidyl
1462855|NCT00122044|pediatric dystonia
1462856|NCT00122031|Major Depression
1462857|NCT00122031|Treatment Refractory Major Depression
1462858|NCT00122018|Kidney failure
1462859|NCT00122018|Cardiac Surgery
1462860|NCT00122018|Fenoldopam
1462861|NCT00122018|N-acetylcysteine
1462862|NCT00122005|Metastatic
1462863|NCT00122005|Prostate
1462864|NCT00122005|Advanced
1462865|NCT00122005|Cancer
1462866|NCT00122005|GVAX
1462867|NCT00122005|Vaccine
1462868|NCT00121992|High risk node negative breast cancer
1462869|NCT00121992|Disease-Free survival
1462870|NCT00121992|Quality of life
1462871|NCT00121979|HIV
1462872|NCT00121979|treatment-experienced
1462873|NCT00121979|lamivudine
1462874|NCT00121979|3TC
1462875|NCT00121966|Type 2 diabetes
1462876|NCT00121966|Insulin Aspart
1462877|NCT00121966|Insulin NPH
1462878|NCT00121966|Metformin
1462879|NCT00121966|Rosiglitazone
1462880|NCT00121953|Endometriosis
1462881|NCT00121953|Peritoneal fluid
1462882|NCT00121953|Cytokines
1462883|NCT00121953|Peroxisome Proliferator-Activated Receptors
1462884|NCT00121940|Chronic Disease
1462885|NCT00121940|Nurses
1462886|NCT00121940|Caregivers
1462887|NCT00121940|Support Groups
1462888|NCT00121927|intractable
1462889|NCT00121927|ketogenic
1462890|NCT00121927|ketosis
1462891|NCT00121927|Atkins
1462892|NCT00121914|Carcinoma, Hepatocellular,
1462893|NCT00121914|percutaneous ethanol instillation
1462894|NCT00121914|long-acting somatostatin
1462895|NCT00121901|Pancreatitis
1462896|NCT00121901|Cholangiopancreatograpy, Endoscopic Retrograde/adverse
1462897|NCT00121901|Nitroglycerin
1462898|NCT00121901|Randomized Controlled Trial,
1462899|NCT00121888|post traumatic stress disorder
1462900|NCT00121888|Prolonged Exposure Therapy
1462901|NCT00121888|pharmacotherapy
1462902|NCT00121888|double-blind
1462903|NCT00121888|Anxiety Disorder
1462904|NCT00121875|short stature
1462905|NCT00121875|insulin resistance
1462906|NCT00121875|body composition
1462907|NCT00121875|Turner syndrome
1462908|NCT00121875|intramyocellular lipid
1462909|NCT00121875|glucose tolerance
1462910|NCT00121862|Leishmaniasis
1462911|NCT00121862|Subunit Vaccine
1462912|NCT00121862|Prevention
1462913|NCT00121862|T cell
1462914|NCT00121849|Leishmaniasis,
1462915|NCT00121849|Subunit Vaccine,
1462916|NCT00121849|Prevention,
1462917|NCT00121849|T cell
1462918|NCT00121823|Malaria
1462919|NCT00121823|PCR
1462920|NCT00121823|Vaccines
1462921|NCT00121823|Acceptability
1462922|NCT00121797|Postpartum Period
1462923|NCT00121771|Malaria
1462924|NCT00121771|Vaccines
1462925|NCT00121771|Safety
1462926|NCT00121771|Immunogenicity
1462927|NCT00121758|HIV Vaccines
1462928|NCT00121758|HIV Seronegativity
1462929|NCT00121745|gene transfer
1462930|NCT00121745|cell cycle control
1462931|NCT00121745|cancer gene therapy
1462932|NCT00121745|pathotropic targeting
1462933|NCT00121745|tumor targeted retroviral vector
1462934|NCT00121719|Resistant and refractory solid tumors
1462935|NCT00121719|lymphomas
1462936|NCT00121719|hodgkins disease
1462937|NCT00121719|non-hodgkins lymphoma
1462938|NCT00121719|neoplasms
1462939|NCT00121693|Fall prevention
1462940|NCT00121693|posturography
1462941|NCT00121693|music therapy
1462942|NCT00121680|cancer
1462943|NCT00121654|Angina pectoris
1462944|NCT00121654|Spinal cord stimulation
1462945|NCT00121654|Refractory angina pectoris
1462946|NCT00121628|Thyroid cancer
1462947|NCT00121628|Advanced thyroid cancer
1462948|NCT00121628|Metastatic thyroid cancer
1462949|NCT00121628|Medullary thyroid cancer
1462950|NCT00121628|Follicular thyroid cancer
1462951|NCT00121628|Papillary thyroid cancer
1462952|NCT00121628|Hurthle cell thyroid cancer
1462953|NCT00121628|Thyroid cancer treatments
1462954|NCT00121628|Differentiated thyroid cancer and medullary thyroid cancer
1462955|NCT00121615|Clinical Trials
1462956|NCT00121602|Hemodialysis
1462957|NCT00121602|Darbepoetin Alfa
1462958|NCT00121602|Clinical Trials
1462959|NCT00121602|Nephrology
1462960|NCT00121602|Amgen
1462961|NCT00121602|Chronic Kidney Disease (CKD)
1462962|NCT00121589|AMD
1462963|NCT00121589|Macular Pigment
1462964|NCT00121589|Serum Lutein Levels
1462965|NCT00121589|Vitamin Supplementation
1462966|NCT00121589|Carotenoids
1462967|NCT00121589|Lutein
1462968|NCT00121589|Zeaxanthin
1462969|NCT00121589|DHA
1462970|NCT00121589|Age Related Macular Degeneration
1462971|NCT00121563|Cytokines
1462972|NCT00121563|Inflammation
1462973|NCT00121563|Pain
1462974|NCT00121563|Injury
1462975|NCT00121563|Peripheral
1462976|NCT00121563|Wisdom Teeth
1462977|NCT00121563|Third Molar Extraction
1462978|NCT00121550|Coronary heart disease
1462979|NCT00121550|Clarithromycin
1462980|NCT00121550|Macrolides
1462981|NCT00121550|Cardiovascular mortality
1462982|NCT00121550|Chlamydia pneumoniae
1462983|NCT00121537|wounds-open
1462984|NCT00121524|cardiac arrest
1462985|NCT00121524|resuscitation
1462986|NCT00121524|epinephrine
1462987|NCT00121524|intravenous
1462988|NCT00121524|survival
1462989|NCT00121511|photoaging
1462990|NCT00121511|Actinic Keratoses
1462991|NCT00121511|Efudex
1462992|NCT00121511|5 fluorouracil
1462993|NCT00121498|Pain
1462994|NCT00121498|Hysterectomy
1462995|NCT00121498|Preemptive
1462996|NCT00121498|Lidocaine
1462997|NCT00121485|Heart-assist devices
1462998|NCT00121472|Heart-assist devices
1462999|NCT00121459|Diaphragm
1463000|NCT00121459|HIV prevention
1463001|NCT00121459|Southern/South Africa, Zimbabwe
1463002|NCT00121459|female-controlled methods
1463003|NCT00121459|Replens
1463004|NCT00121459|STI prevention
1463005|NCT00121459|HIV Seronegativity
1463006|NCT00121446|Heart Attack
1463007|NCT00121446|ST Elevation Myocardial Infarction
1463008|NCT00121446|fibrinolytic therapy
1463009|NCT00121446|percutaneous coronary intervention
1463010|NCT00121446|Acute Myocardial Infarction
1463011|NCT00121420|Brain Neoplasms/secondary
1463012|NCT00121420|Brain neoplasms/radiotherapy
1463013|NCT00121420|Brain metastasis
1463014|NCT00121420|Neoplasm metastasis
1463015|NCT00121420|Cranial irradiation
1463016|NCT00121420|Radiosurgery
1463017|NCT00121420|Lung Neoplasms
1463018|NCT00121420|Breast Neoplasms
1463019|NCT00121420|Kidney Neoplasms
1463020|NCT00121420|Melanoma
1463021|NCT00121420|Radiotherapy
1463022|NCT00121420|Carcinoma, non-small cell lung
1463023|NCT00121407|Age Related Macular Degeneration (AMD)
1463024|NCT00121407|Photodynamic Therapy (PDT)
1463025|NCT00121407|Visudyne
1463026|NCT00121394|Chlorhexidine
1463027|NCT00121394|Vaginal wash
1463028|NCT00121394|Neonatal mortality
1463029|NCT00121394|Sepsis
1463030|NCT00121394|Global Network
1463031|NCT00121394|Maternal and child health
1463032|NCT00121394|Women's Health
1463033|NCT00121394|International
1463034|NCT00121394|Pakistan
1463035|NCT00121381|Atopic dermatitis
1463036|NCT00121381|T-cell
1463037|NCT00121381|pimecrolimus
1463038|NCT00121381|children
1463039|NCT00121381|topical corticosteroids
1463040|NCT00121368|Global Network
1463041|NCT00121368|Maternal and child health
1463042|NCT00121368|International
1463043|NCT00121368|Women's health
1463044|NCT00121368|Tobacco
1463045|NCT00121368|Smoking
1463046|NCT00121368|Africa
1463047|NCT00121368|Latin America
1463048|NCT00121368|South America
1463049|NCT00121368|Guatemala
1463050|NCT00121368|Zambia
1463051|NCT00121368|India
1463052|NCT00121368|Argentina
1463053|NCT00121368|Democratic Republic of the Congo
1463054|NCT00121329|Pain with procedures
1463055|NCT00121316|Atopic dermatitis
1463056|NCT00121316|pimecrolimus
1463057|NCT00121303|adult acute monocytic leukemia (M5b)
1463058|NCT00121303|adult erythroleukemia (M6a)
1463059|NCT00121303|adult pure erythroid leukemia (M6b)
1463060|NCT00121303|adult acute megakaryoblastic leukemia (M7)
1463061|NCT00121303|adult acute myeloblastic leukemia with maturation (M2)
1463062|NCT00121303|adult acute myeloblastic leukemia without maturation (M1)
1463063|NCT00121303|adult acute myelomonocytic leukemia (M4)
1463064|NCT00121303|adult acute monoblastic leukemia (M5a)
1463065|NCT00121303|refractory anemia with excess blasts in transformation
1463066|NCT00121303|refractory anemia with excess blasts
1463067|NCT00121303|secondary acute myeloid leukemia
1463068|NCT00121303|untreated adult acute myeloid leukemia
1463069|NCT00121303|de novo myelodysplastic syndromes
1463070|NCT00121303|adult acute minimally differentiated myeloid leukemia (M0)
1463071|NCT00121303|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1463191|NCT00120796|Hepatitis B
1463072|NCT00121303|adult acute myeloid leukemia with inv(16)(p13;q22)
1463073|NCT00121303|adult acute myeloid leukemia with t(16;16)(p13;q22)
1463074|NCT00121303|adult acute myeloid leukemia with t(8;21)(q22;q22)
1463075|NCT00121303|secondary myelodysplastic syndromes
1463076|NCT00121277|unspecified adult solid tumor, protocol specific
1463077|NCT00121212|stage I prostate cancer
1463078|NCT00121212|stage IIB prostate cancer
1463079|NCT00121212|stage IIA prostate cancer
1463080|NCT00121212|stage III prostate cancer
1463081|NCT00121186|recurrent adult Hodgkin lymphoma
1463082|NCT00121186|recurrent small lymphocytic lymphoma
1463083|NCT00121186|recurrent mantle cell lymphoma
1463084|NCT00121186|recurrent grade 1 follicular lymphoma
1463085|NCT00121186|recurrent grade 2 follicular lymphoma
1463086|NCT00121186|recurrent grade 3 follicular lymphoma
1463087|NCT00121186|recurrent adult diffuse large cell lymphoma
1463088|NCT00121173|cervical cancer
1463089|NCT00121173|cervical intraepithelial neoplasia grade 2
1463090|NCT00121173|cervical intraepithelial neoplasia grade 3
1463091|NCT00121160|immune response to vaccines
1463092|NCT00121160|stress management
1463093|NCT00121160|breast cancer
1463094|NCT00121147|glaucoma
1463095|NCT00121147|pseudoexfoliation
1463096|NCT00121134|Bevacizumab
1463097|NCT00121134|Metronomic Chemotherapy
1463098|NCT00121134|Breast Cancer Stages II-III
1463099|NCT00121134|Invasive breast cancer stages II-III
1463100|NCT00121121|HIV Vaccines
1463101|NCT00121121|HIV Seronegativity
1463102|NCT00121095|prostate cancer
1463103|NCT00121069|specific phobia
1463104|NCT00121069|anxiety
1463105|NCT00121069|SSRI
1463106|NCT00121069|clinical trial
1463107|NCT00121069|escitalopram
1463108|NCT00121043|Rheumatoid Arthritis, Inflammation
1463109|NCT00121043|Interleukin-1 (IL-1), r-metHuIL-1ra
1463110|NCT00121043|Autoimmune, Kineret®
1463111|NCT00121043|Anakinra, Immunex
1463112|NCT00121043|Amgen, Clinical Trials
1463113|NCT00121030|uterine cancer
1463114|NCT00121030|ovarian cancer
1463115|NCT00121030|darbepoetin alfa
1463116|NCT00121030|Amgen
1463117|NCT00121030|Gynecological Malignancies
1463118|NCT00121017|HCV Infection
1463119|NCT00121017|Treatment Naive
1463120|NCT00121004|Advance Directive
1463121|NCT00121004|Living Will
1463122|NCT00121004|Terminal Illness
1463123|NCT00120991|Coronary artery bypass grafting
1463124|NCT00120991|OPCAB
1463125|NCT00120978|Clinical Trial; C-reactive protein; fluticasone; salmeterol
1463126|NCT00120965|Cardiac arrest
1463127|NCT00120965|OOH-cardiac arrest
1463128|NCT00120965|CPR
1463129|NCT00120965|Chest compressions
1463130|NCT00120965|Chest compression device
1463131|NCT00120952|RSA
1463132|NCT00120952|Osteoarthritis
1463133|NCT00120952|Hip arthroplasty
1463134|NCT00120952|DEXA
1463135|NCT00120952|Titanium
1463136|NCT00120952|Cobalt chromium
1463137|NCT00120952|Bone cement
1463138|NCT00120939|Lung Cancer
1463139|NCT00120939|Breast Cancer
1463140|NCT00120939|Prostate Cancer
1463141|NCT00120939|Ovarian Cancer
1463142|NCT00120939|Head and Neck Cancer
1463143|NCT00120939|Gastrointestinal Cancer
1463144|NCT00120939|Metastatic Cancer
1463145|NCT00120939|Advanced Cancer
1463146|NCT00120939|Genitourinary Cancer
1463147|NCT00120939|Glioblastoma Multiforme
1463148|NCT00120939|Recurrent Cancer
1463149|NCT00120939|Colon Cancer
1463150|NCT00120939|Gastric Cancer
1463151|NCT00120939|Stomach Cancer
1463152|NCT00120939|Pancreatic Cancer
1463153|NCT00120939|Esophageal Cancer
1463154|NCT00120939|Throat Cancer
1463155|NCT00120939|Bladder Cancer
1463156|NCT00120939|Kidney Cancer
1463157|NCT00120939|Renal Cancer
1463158|NCT00120939|Cervical Cancer
1463159|NCT00120939|Endometrial Cancer
1463160|NCT00120939|Colorectal Cancer
1463161|NCT00120926|Premature neonate
1463162|NCT00120926|Parenteral nutrition
1463163|NCT00120926|Growth
1463164|NCT00120926|Amino Acids
1463165|NCT00120926|Nutrition
1463166|NCT00120913|Breakthrough bleeding while taking continuously dosed oral contraceptives
1463167|NCT00120900|COX-2 inhibitor
1463168|NCT00120900|Knee osteoarthritis
1463169|NCT00120887|Atherosclerosis, SLE, statins
1463170|NCT00120874|Alzheimer's disease
1463171|NCT00120874|caregiver training
1463172|NCT00120874|caregiver counseling
1463173|NCT00120874|individualized management
1463174|NCT00120874|memantine
1463175|NCT00120874|dementia
1463176|NCT00120861|Genotype-1
1463177|NCT00120861|Previously failed treatment
1463178|NCT00120848|HPV vaccine efficacy
1463179|NCT00120848|Prophylaxis HPV 16/18 infections
1463180|NCT00120835|Genotype-1
1463181|NCT00120835|Treatment-Naive
1463182|NCT00120822|Malaria
1463183|NCT00120822|Pregnancy
1463184|NCT00120822|Folic acid
1463185|NCT00120822|Sulfadoxine-pyrimethamine
1463186|NCT00120809|Malaria
1463187|NCT00120809|Pregnancy
1463188|NCT00120809|Multigravidae
1463189|NCT00120809|Intermittent preventative treatment
1463190|NCT00120809|Sulfadoxine-pyrimethamine
1463192|NCT00120796|Hepatitis B Vaccines
1463193|NCT00120796|Lamivudine
1463194|NCT00120783|Treatment Failure
1463195|NCT00120783|HIV infections
1463196|NCT00120770|AE adverse event
1463197|NCT00120770|AIDS acquired immunodeficiency syndrome
1463198|NCT00120770|ALT (SGPT) alanine aminotransferase
1463199|NCT00120770|ART antiretroviral therapy
1463200|NCT00120770|AST (SGOT) aspartate aminotransferase
1463201|NCT00120770|DCF data collection forms
1463202|NCT00120770|DMC Data Monitoring Committee
1463203|NCT00120770|FDA (U.S.) Food and Drug Administration
1463204|NCT00120770|GCP Good Clinical Practice guidelines
1463205|NCT00120770|HB sAg Hepatitis B surface antigen
1463206|NCT00120770|ICH International Conference of Harmonisation
1463207|NCT00120770|IND Investigational New Drug Application
1463208|NCT00120770|IRB Institutional Review Board
1463209|NCT00120770|IU international units
1463210|NCT00120770|mg milligram(s)
1463211|NCT00120770|mm3 cubic millimeter(s)
1463212|NCT00120770|PCR polymerase chain reaction
1463213|NCT00120770|SAE serious adverse event
1463214|NCT00120770|µg microgram
1463215|NCT00120770|ULN upper limit of the normal range
1463216|NCT00120770|WB Western Blot
1463217|NCT00120770|Human Immunodeficiency Virus
1463218|NCT00120770|Neisseria gonorrhoeae
1463219|NCT00120770|Chlamydia trachomatis
1463220|NCT00120770|HIV Seronegativity
1463221|NCT00120757|Osteoporosis
1463222|NCT00120731|Recurrent nephrolithiasis
1463223|NCT00120731|Potassium Citrate
1463224|NCT00120731|Hypercalciuria
1463225|NCT00120731|Distal Renal Tubular Acidosis
1463226|NCT00120731|Nephrolithiasis in children
1463227|NCT00120705|anemia
1463228|NCT00120705|darbepoetin alfa
1463229|NCT00120705|Amgen
1463230|NCT00120705|Non-myeloid Malignancies
1463231|NCT00120692|breast cancer
1463232|NCT00120692|darbepoetin alfa
1463233|NCT00120692|Amgen
1463234|NCT00120679|non-small cell lung cancer
1463235|NCT00120679|darbepoetin alfa
1463236|NCT00120679|Amgen
1463237|NCT00120666|Exercise
1463238|NCT00120666|Stimulation
1463239|NCT00120666|Nerve
1463240|NCT00120666|Electrical
1463241|NCT00120666|Muscle
1463242|NCT00120666|Healthy Volunteer
1463243|NCT00120666|HV
1463244|NCT00120653|Reglan
1463245|NCT00120653|Prolactin
1463246|NCT00120653|MDS
1463247|NCT00120653|Metoclopramide
1463248|NCT00120653|Myelodysplastic Syndrome
1463249|NCT00120640|Premature birth
1463250|NCT00120640|Premature labor
1463251|NCT00120640|Progesterone
1463252|NCT00120627|Randomized Controlled Trial
1463253|NCT00120627|Intervention Study
1463254|NCT00120627|Mindfulness
1463255|NCT00120627|Complementary Therapy
1463256|NCT00120627|Mind-Body Relations (Metaphysics)
1463257|NCT00120627|Spiritual Therapy
1463258|NCT00120627|Meditation
1463259|NCT00120627|Qualitative Analysis
1463260|NCT00120614|Premature Infant
1463261|NCT00120614|Premature Birth
1463262|NCT00120614|Parenting Interventions
1463263|NCT00120614|NICU Interventional studies
1463264|NCT00120614|Parental coping
1463265|NCT00120614|Low birthweight infant
1463266|NCT00120614|Coping Behavior
1463267|NCT00120614|Infant, Premature
1463268|NCT00120601|treatment
1463269|NCT00120601|alcohol
1463270|NCT00120601|dependence
1463271|NCT00120601|medication
1463272|NCT00120588|brain protection
1463273|NCT00120588|white matter injury
1463274|NCT00120588|neurodevelopmental sequelae
1463275|NCT00120588|magnesium sulfate
1463276|NCT00120588|intraventricular hemorrhage
1463277|NCT00120575|Hemofiltration
1463278|NCT00120575|Pediatrics
1463279|NCT00120562|weight loss surgery
1463280|NCT00120562|gastric bypass surgery
1463281|NCT00120549|Assisted Hatching
1463282|NCT00120549|Cleavage Stage, Ovum
1463283|NCT00120549|Embryo Transfer
1463284|NCT00120549|Pregnancy
1463285|NCT00120549|Embryo Implantation
1463286|NCT00120536|Type 2 diabetes
1463287|NCT00120536|vildagliptin
1463288|NCT00120523|Atopic dermatitis, children, infants, pimecrolimus
1463289|NCT00120510|Treatment Naive
1463290|NCT00120510|TB
1463291|NCT00120497|short stature
1463292|NCT00120497|intrauterine growth restriction
1463293|NCT00120497|insulin resistance
1463294|NCT00120497|intramyocellular lipid
1463295|NCT00120497|small for gestational age
1463296|NCT00120497|glucose tolerance
1463297|NCT00120484|Circadian Rhythm
1463298|NCT00120484|Biological Clock
1463299|NCT00120484|Complementary and Alternative Medicine
1463300|NCT00120471|Perinatal Transmission
1463301|NCT00120471|MTCT
1463302|NCT00120471|HIV Seronegativity
1463303|NCT00120458|Black Cohosh
1463304|NCT00120458|Cimicifuga
1463305|NCT00120458|Anxiety
1463306|NCT00120458|Women
1463307|NCT00120458|Complementary and Alternative Medicine
1463308|NCT00120445|retinal detachment
1463309|NCT00120445|pneumatic retinopexy
1463310|NCT00120432|single dose
1463311|NCT00120432|mydriatic drug
1463312|NCT00120432|pupillary dilation
1463313|NCT00120419|HIV-1 infection
1463314|NCT00120419|immunomodulatory therapy
1463315|NCT00120419|Treatment Naive
1463316|NCT00120406|Peripheral Arterial Disease (PAD)
1463317|NCT00120406|Peripheral Vascular Disease
1463318|NCT00120406|Drug-Eluting Stent
1463319|NCT00120406|Drug-Coated Stent
1463320|NCT00120393|Treatment Experienced
1463321|NCT00120380|Idiopathic pulmonary arterial hypertension
1463322|NCT00120367|Leukoencephalopathy, Progressive Multifocal
1463323|NCT00120367|HIV infections
1463324|NCT00120367|HIV Fusion Inhibitors
1463325|NCT00120354|Hepatitis B Virus
1463326|NCT00120354|Antiviral Resistance
1463327|NCT00120354|Drug Withdrawal
1463328|NCT00120354|Immune Response
1463329|NCT00120354|Hepatitis B Surface Antigen
1463330|NCT00120354|Liver Biopsy
1463331|NCT00120354|Hepatitis B
1463332|NCT00120328|serum creatinine
1463333|NCT00120328|end stage renal disease
1463334|NCT00120328|cardiovascular mortality
1463335|NCT00120328|cardiovascular morbidity
1463336|NCT00120328|non-cardiovascular mortality
1463337|NCT00120328|non-cardiovascular morbidity
1463338|NCT00120315|dyspepsia
1463339|NCT00120315|discontinuation
1463340|NCT00120315|Primary health care
1463341|NCT00120315|Helicobacter pylori
1463342|NCT00120315|Proton Pump Inhibitor
1463343|NCT00120315|Histamine-2-receptor-antagonist
1463344|NCT00120302|Randomised
1463345|NCT00120302|Placebo-controlled
1463346|NCT00120302|Elidel
1463347|NCT00120302|Quality of Life
1463348|NCT00120302|Atopic Eczema
1463349|NCT00120276|Functional Mitral Regurgitation (FMR)
1463350|NCT00120276|Ischemic Mitral Regurgitation
1463351|NCT00120276|Less invasive repair
1463352|NCT00120276|Surgical MV repair
1463353|NCT00120276|Mitral Valve Repair
1463354|NCT00120276|Heart Failure
1463355|NCT00120276|Left Ventricular Dysfunction
1463356|NCT00120263|Plasma Exchange
1463357|NCT00120263|Myeloma
1463358|NCT00120263|Acute renal failure
1463359|NCT00120263|Light Chains
1463360|NCT00120263|Bence Jones Proteins
1463361|NCT00120263|Kidney Function
1463362|NCT00120250|PTSD
1463363|NCT00120250|Sleep disturbance
1463364|NCT00120250|Eszopiclone
1463365|NCT00120250|Double-blind
1463366|NCT00120250|Crossover
1463367|NCT00120237|Postpartum hemorrhage
1463368|NCT00120237|Misoprostol
1463369|NCT00120237|Maternal morbidity
1463370|NCT00120237|Developing countries
1463371|NCT00120237|Traditional birth attendants
1463372|NCT00120224|Mifepristone
1463373|NCT00120224|Medical abortion
1463374|NCT00120224|Ultrasound
1463375|NCT00120198|NHL
1463376|NCT00120198|elderly
1463377|NCT00120185|HIV Infections
1463378|NCT00120185|Interleukin-2
1463379|NCT00120172|colorectal
1463380|NCT00120172|metastatic
1463381|NCT00120172|elderly
1463382|NCT00120172|metastatic colorectal cancer
1463383|NCT00120159|Necrotizing Enterocolitis
1463384|NCT00120133|Osteoporosis
1463385|NCT00120133|Bisphosphonates
1463386|NCT00120133|Atorvastatin
1463387|NCT00120120|Radiculopathy
1463388|NCT00120120|Back Pain
1463389|NCT00120120|Lumbar Pain
1463390|NCT00120120|CC-5013
1463391|NCT00120120|Revlimid
1463392|NCT00120120|Lenalidomide
1463393|NCT00120094|Syncope
1463394|NCT00120094|Electrocardiographic monitoring
1463395|NCT00120081|Vaccine
1463396|NCT00120081|Hookworm
1463397|NCT00120081|Phase 1
1463398|NCT00120081|Human Hookworm Infection
1463399|NCT00120081|Na-ASP-2
1463400|NCT00120042|Abortion
1463401|NCT00120042|Retained placenta
1463402|NCT00120042|Hemorrhage
1463403|NCT00120042|Postpartum ultrasound
1463404|NCT00120029|weight loss
1463405|NCT00120029|survivorship
1463406|NCT00120029|breast ductal lavage
1463407|NCT00120029|exercise
1463408|NCT00120029|diet
1463409|NCT00120016|cancer prevention
1463410|NCT00120016|diet
1463411|NCT00120016|nutrition
1463412|NCT00120016|polyunsaturated fat
1463413|NCT00120016|olive oil
1463414|NCT00120003|Acute stroke
1463415|NCT00120003|Elevated blood pressure
1463416|NCT00120003|Blood pressure lowering treatment
1463417|NCT00119990|vasopressin
1463418|NCT00119990|icodextrin
1463419|NCT00119990|cardiac output
1463420|NCT00119977|cartilage thickness
1463421|NCT00119977|RSA
1463422|NCT00119977|DEXA
1463423|NCT00119977|ultra sound
1463424|NCT00119977|MRI
1463425|NCT00119977|osteoarthritis
1463426|NCT00119977|periacetabular osteotomy
1463427|NCT00119951|Behavioral
1463428|NCT00119938|Disease management
1463429|NCT00119938|Patient access to records
1463430|NCT00119938|Medical records systems, computerized
1463431|NCT00119938|Questionnaires
1463432|NCT00119938|Physician-patient relations
1463433|NCT00119938|Medical records
1463434|NCT00119925|infertility
1463435|NCT00119925|guideline
1463436|NCT00119925|health care implementation
1463437|NCT00119925|intervention
1463438|NCT00119925|gynecology
1463439|NCT00119912|screening
1463440|NCT00119912|flexible sigmoidoscopy
1463441|NCT00119912|fecal occult blood
1463442|NCT00119912|cancer
1463443|NCT00119912|colon
1463444|NCT00119912|rectum
1463445|NCT00119899|Colorectal Cancer;
1463446|NCT00119899|Liver;
1463447|NCT00119899|Metastases;
1463448|NCT00119899|Resection;
1463449|NCT00119899|Fluorodeoxyglucose;
1463450|NCT00119899|Tomography;
1463451|NCT00119899|Positron-Emission
1463452|NCT00119873|HIV Preventive Vaccine
1463453|NCT00119873|AIDS Vaccines
1463454|NCT00119873|Adenoviridae
1463455|NCT00119834|Heart Failure
1463456|NCT00119834|Intermacs
1463457|NCT00119834|Pedimacs
1463458|NCT00119834|Mechanical Circulatory Support
1463459|NCT00119834|Ventricular Assist Device
1463460|NCT00119769|HIV
1463461|NCT00119769|immune stimulation
1463462|NCT00119769|lipodystrophy
1463463|NCT00119769|growth hormone
1463464|NCT00119769|recombinant growth hormone
1463465|NCT00119769|Treatment Experienced
1463466|NCT00119756|Schizophrenia
1463467|NCT00119756|Intramuscular injection
1463468|NCT00119756|Deltoid muscle
1463469|NCT00119756|Gluteus muscle
1463470|NCT00119756|Paliperidone palmitate
1463471|NCT00119743|Prophylaxis pneumococcal vaccine
1463472|NCT00119730|Fludarabine
1463473|NCT00119730|Mitoxantrone
1463474|NCT00119730|Rituximab
1463475|NCT00119730|Zevalin
1463476|NCT00119730|Mantle Cell Lymphoma
1463477|NCT00119730|Relapsed Mantle Cell Lymphoma
1463478|NCT00119717|acute
1463479|NCT00119717|ischemic
1463480|NCT00119717|stroke
1463481|NCT00119717|randomized
1463482|NCT00119717|device
1463483|NCT00119717|treatment
1463484|NCT00119678|SLE
1463485|NCT00119665|Postmenopausal symptoms
1463486|NCT00119665|Hot Flashes
1463487|NCT00119665|Postmenopausal Hot Flashes
1463488|NCT00119652|Bipolar disorder
1463489|NCT00119652|bipolar depression
1463490|NCT00119652|depression
1463491|NCT00119626|Stroke, Acute
1463492|NCT00119626|Cerebrovascular Stroke
1463493|NCT00119613|Oncology
1463494|NCT00119613|Clinical Trial
1463495|NCT00119613|Hemoglobin
1463496|NCT00119613|Darbepoetin alfa
1463497|NCT00119613|Survival
1463498|NCT00119613|Carboplatin
1463499|NCT00119613|Cisplatin
1463500|NCT00119613|Etoposide
1463501|NCT00119613|Extensive Stage Small Cell Lung Cancer
1463502|NCT00119600|Non-myeloid malignancy
1463503|NCT00119600|Clinical Trial
1463504|NCT00119587|Hemodialysis
1463505|NCT00119587|darbepoetin alfa
1463506|NCT00119587|Clinical Trial
1463507|NCT00119587|Amgen
1463508|NCT00119574|Randomized Controlled Trial
1463509|NCT00119574|Quality of Health Care
1463510|NCT00119574|Health Services Research
1463511|NCT00119574|Guidelines
1463512|NCT00119574|Medical Informatics Computing
1463513|NCT00119574|Services, Mental Health
1463514|NCT00119574|Medicine, Evidence-Based
1463515|NCT00119574|Quality Assurance, Healthcare
1463516|NCT00119574|Quality Indicators, Health Care
1463517|NCT00119574|Veterans
1463518|NCT00119561|Caregiver
1463519|NCT00119561|Dementia
1463520|NCT00119561|Alzheimer Disease
1463521|NCT00119561|Telephone
1463522|NCT00119561|Randomized Controlled Trials
1463523|NCT00119548|HIV Rapid Testing
1463524|NCT00119548|Cost-effectiveness
1463525|NCT00119548|HIV Seronegativity
1463526|NCT00119535|Diabetes mellitus
1463527|NCT00119535|Diabetic retinopathy
1463528|NCT00119535|Organizational change
1463529|NCT00119535|Quality improvement
1463530|NCT00119535|Quasi-experimental
1463531|NCT00119522|wheelchairs
1463532|NCT00119522|falls
1463533|NCT00119522|spinal cord injury
1463534|NCT00119522|accidental falls
1463535|NCT00119522|safety
1463536|NCT00119509|Cervix Neoplasms
1463537|NCT00119509|Vaginal smears
1463538|NCT00119509|Papillomavirus - Human
1463539|NCT00119496|Corticosteroid
1463540|NCT00119496|Rosiglitazone
1463541|NCT00119496|Theophylline
1463542|NCT00119496|Beclomethasone
1463543|NCT00119496|Inflammation
1463544|NCT00119496|Asthma
1463545|NCT00119496|Smoking
1463546|NCT00119496|Pulmonary
1463547|NCT00119483|Men
1463548|NCT00119483|testosterone
1463549|NCT00119483|hypogonadal
1463550|NCT00119483|aging
1463551|NCT00119483|body composition
1463552|NCT00119483|quality og life
1463553|NCT00119483|Muscle strength
1463554|NCT00119483|Aging male
1463555|NCT00119457|antithrombotic agents
1463556|NCT00119457|anticoagulants
1463557|NCT00119457|prophylaxis
1463558|NCT00119457|embolism
1463559|NCT00119457|deep vein thrombosis
1463560|NCT00119457|hip fracture
1463561|NCT00119444|PET
1463562|NCT00119444|Periacetabular osteotomy
1463563|NCT00119431|Hereditary angioedema type I (MeSH: angioneurotic edema, complement 1 inactivators)
1463564|NCT00119418|hot flash
1463565|NCT00119418|menopause
1463566|NCT00119418|herbal medicine
1463567|NCT00119418|kampo
1463568|NCT00119418|alternative medicine
1463569|NCT00119405|Lipoatrophy
1463570|NCT00119405|Mitochondria
1463571|NCT00119405|Treatment Naive
1463572|NCT00119379|lipoatrophy
1463573|NCT00119379|mitochondria
1463574|NCT00119379|HIV
1463575|NCT00119379|treatment experienced
1463576|NCT00119340|accelerated phase chronic myelogenous leukemia
1463577|NCT00119340|Philadelphia chromosome positive chronic myelogenous leukemia
1463578|NCT00119340|relapsing chronic myelogenous leukemia
1463579|NCT00119340|chronic phase chronic myelogenous leukemia
1463580|NCT00119314|newly diagnosed carcinoma of unknown primary
1463581|NCT00119314|recurrent carcinoma of unknown primary
1463582|NCT00119301|recurrent osteosarcoma
1463583|NCT00119210|Tobacco use cessation
1463584|NCT00119210|Bupropion
1463585|NCT00119210|Zyban
1463586|NCT00119210|Puerperium
1463587|NCT00119197|watery diarrhea
1463588|NCT00119197|cholera vaccine
1463589|NCT00119184|anesthesia
1463590|NCT00119184|breech
1463591|NCT00119184|external cephalic version
1463592|NCT00119184|spinal
1463593|NCT00119184|success
1463594|NCT00119184|anesthesia,spinal
1463595|NCT00119171|Safety
1463596|NCT00119171|tolerability
1463597|NCT00119171|dose limiting toxicity
1463598|NCT00119171|solid tumors
1463599|NCT00119171|capecitabine
1463600|NCT00119158|THerapy for acute moderate to severe flares
1463601|NCT00119145|antimalarial drugs
1463602|NCT00119145|efficacy
1463603|NCT00119145|safety
1463604|NCT00119145|trial
1463605|NCT00119132|intermittent preventive treatment
1463606|NCT00119132|effectiveness
1463607|NCT00119132|malaria
1463608|NCT00119119|Hepatitis C
1463609|NCT00119119|Liver Cirrhosis
1463610|NCT00119119|Tocopherols
1463611|NCT00119106|HIV
1463612|NCT00119106|Prevention
1463613|NCT00119106|Tenofovir
1463614|NCT00119106|HIV Seronegativity
1463615|NCT00119093|Antiretroviral therapy
1463616|NCT00119093|HIV
1463617|NCT00119093|Adherence
1463618|NCT00119093|Viral Load
1463619|NCT00119093|Opportunistic illness
1463620|NCT00119080|Meningococcal carriage
1463621|NCT00119080|Conjugate vaccine
1463622|NCT00119067|Anthrax
1463623|NCT00119067|Vaccine
1463624|NCT00119067|Immunogenicity
1463625|NCT00119067|Reactogenicity
1463626|NCT00119054|Hypertension
1463627|NCT00119054|Diabetes Mellitus
1463628|NCT00119054|Telemedicine
1463629|NCT00119054|Nursing Care
1463630|NCT00119041|Diabetes Mellitus
1463631|NCT00119041|Telemedicine
1463632|NCT00119041|Referral
1463633|NCT00119041|Consultation
1463634|NCT00119028|Quality Improvement
1463635|NCT00119028|Cluster Randomized Trial
1463636|NCT00119028|Care Model
1463637|NCT00119015|perennial allergic rhinitis
1463638|NCT00119002|randomized clinical trial
1463639|NCT00119002|placebo-controlled
1463640|NCT00119002|double-blind
1463641|NCT00119002|double-masked
1463642|NCT00119002|infant
1463643|NCT00119002|dexamethasone
1463644|NCT00119002|wheezing
1463645|NCT00118989|Curcumin
1463646|NCT00118989|chemoprevention
1463647|NCT00118989|adenomatous polyps
1463648|NCT00118989|colorectal cancer
1463649|NCT00118976|diabetic nephropathy
1463650|NCT00118976|type 1 diabetes
1463651|NCT00118976|albuminuria
1463652|NCT00118976|hypertension
1463653|NCT00118924|Dengue Vaccine
1463654|NCT00118924|Tick-Borne Illnesses
1463655|NCT00118924|Flavivirus
1463656|NCT00118911|Adult
1463657|NCT00118911|ADHD
1463658|NCT00118911|ADD
1463659|NCT00118911|CBT
1463660|NCT00118911|Relaxation Techniques
1463661|NCT00118911|Education
1463662|NCT00118898|Treatment Naive
1463663|NCT00118885|Shingles
1463664|NCT00118885|depression
1463665|NCT00118885|varicella zoster virus
1463666|NCT00118885|alternative medicine
1463667|NCT00118885|psychoneuroimmunology
1463668|NCT00118872|Growth and Development
1463669|NCT00118872|Pakistan
1463670|NCT00118872|Weaning
1463671|NCT00118872|Probiotics
1463672|NCT00118872|Infant
1463673|NCT00118872|Lactobacillus GG
1463674|NCT00118859|Back Pain
1463675|NCT00118859|Integrative Care
1463676|NCT00118859|Acupuncture
1463677|NCT00118859|Chiropractic
1463678|NCT00118859|Exercise
1463679|NCT00118859|Massage Therapy
1463680|NCT00118859|Mind-Body Therapy
1463681|NCT00118859|Nutritional Counseling
1463682|NCT00118859|Complementary Therapies
1463683|NCT00118859|Complementary and Alternative Medicine
1463684|NCT00118846|Women
1463685|NCT00118846|Complementary and Alternative Medicine
1463686|NCT00118846|CAM
1463687|NCT00118833|Social Anxiety Disorder
1463688|NCT00118833|Social Phobia
1463689|NCT00118833|Generalized Anxiety Disorder
1463690|NCT00118833|Hypericum
1463691|NCT00118833|St. John's wort
1463692|NCT00118833|Medicine, Herbal
1463693|NCT00118833|Complementary Therapies
1463694|NCT00118820|Dry socket
1463695|NCT00118820|Third molar
1463696|NCT00118820|Infection
1463697|NCT00118820|postop-infection
1463698|NCT00118820|Antibiotic efficacy
1463699|NCT00118820|Infection characterized by pus,erythema,edema and pain
1463700|NCT00118807|malaria treatment
1463701|NCT00118807|artemisinin based combination therapy
1463702|NCT00118807|Plasmodium falciparum
1463703|NCT00118807|pragmatic trial
1463704|NCT00118807|effectiveness
1463705|NCT00118794|uncomplicated malaria
1463706|NCT00118794|G6PD deficiency
1463707|NCT00118794|haemolytic anaemia
1463708|NCT00118794|Lapdap
1463709|NCT00118794|Artemsinin based combination treatment
1463710|NCT00118794|compliance
1463711|NCT00118794|pragmatic trials
1463712|NCT00118781|ventilator-associated pneumonia
1463713|NCT00118781|VAP
1463714|NCT00118781|pneumonia
1463715|NCT00118781|ICU infection
1463716|NCT00118768|Genotype-1, Chronic Hepatitis C
1463717|NCT00118729|Ragweed
1463718|NCT00118729|GW685698X
1463719|NCT00118729|seasonal allergic rhinitis
1463720|NCT00118729|onset
1463721|NCT00118716|asthma
1463722|NCT00118716|bronchospasm
1463723|NCT00118703|nonallergic rhinitis
1463724|NCT00118703|GW685698X
1463725|NCT00118703|VMR
1463726|NCT00118703|vasomotor rhinitis
1463727|NCT00118690|bronchospasm
1463728|NCT00118690|asthma
1463729|NCT00118677|HIV Infections
1463730|NCT00118664|Septic Shock
1463731|NCT00118664|Thrombocytopenia
1463732|NCT00118664|Multiple Organ Failure
1463733|NCT00118664|Pediatric
1463734|NCT00118651|pneumonia
1463735|NCT00118651|chest x-ray
1463736|NCT00118651|diagnosis
1463737|NCT00118638|Non-myeloid malignancy
1463738|NCT00118638|Darbepoetin alfa
1463739|NCT00118638|Clinical Trial
1463740|NCT00118625|Allergy
1463741|NCT00118625|Specific Immunotherapy
1463742|NCT00118625|Adjuvant
1463743|NCT00118625|Allergy Vaccination
1463744|NCT00118625|Allergenicity
1463745|NCT00118612|Allergy
1463746|NCT00118612|Specific Immunotherapy
1463747|NCT00118612|Allergy Vaccination
1463748|NCT00118612|Allergenicity
1463749|NCT00118586|Neuroanatomy
1463750|NCT00118586|Brain Damage
1463751|NCT00118586|Dystonia
1463752|NCT00118586|Pathology
1463753|NCT00118586|Brain Imaging
1463754|NCT00118586|Spasmodic Dysphonia
1463755|NCT00118586|SD
1463756|NCT00118586|Focal Dystonia
1463757|NCT00118586|Healthy Volunteer
1463758|NCT00118586|HV
1463759|NCT00118573|abdominal aortic aneurysm
1463760|NCT00118573|randomized controlled trial
1463761|NCT00118573|endovascular aneurysm repair
1463762|NCT00118560|Collateral Circulation
1463763|NCT00118560|Exercise Therapy
1463764|NCT00118560|Microcirculation
1463765|NCT00118560|Oxygen
1463766|NCT00118560|Positron-emission tomography
1463767|NCT00118560|Walking
1463768|NCT00118547|Adherence
1463769|NCT00118547|Medication
1463770|NCT00118547|Multiple Sclerosis
1463771|NCT00118534|addictive disorders
1463772|NCT00118534|clinical trial
1463773|NCT00118534|cost effectiveness
1463774|NCT00118534|mental health
1463775|NCT00118534|military or environmental exposure
1463776|NCT00118534|multi-site trial
1463777|NCT00118534|nicotine
1463778|NCT00118534|nicotine replacement
1463779|NCT00118534|post traumatic stress
1463780|NCT00118534|post traumatic stress disorder
1463781|NCT00118534|psychiatric
1463782|NCT00118534|psychological
1463783|NCT00118534|PTSD
1463784|NCT00118534|smoking cessation
1463785|NCT00118534|smoking cessation medications
1463786|NCT00118534|substance abuse
1463787|NCT00118521|Anterior Knee Pain
1463788|NCT00118495|female sexual dysfunction
1463789|NCT00118495|FSD
1463790|NCT00118495|arousal
1463791|NCT00118495|orgasm
1463792|NCT00118495|desire
1463793|NCT00118495|Zestra
1463794|NCT00118495|Mixed FSD
1463795|NCT00118495|Hypoactive sexual desire disorder
1463796|NCT00118495|Sexual arousal disorder
1463797|NCT00118495|Orgasmic disorder
1463798|NCT00118482|vasovagal syncope
1463799|NCT00118482|randomized clinical trial
1463800|NCT00118482|quality of life
1463801|NCT00118469|Adolescent
1463802|NCT00118469|CBT
1463803|NCT00118469|Parents
1463804|NCT00118456|Advanced cancers
1463805|NCT00118456|EGFR
1463806|NCT00118456|Her2
1463807|NCT00118456|VEGFR
1463808|NCT00118443|Suicide Prevention
1463809|NCT00118443|Depression
1463810|NCT00118443|Adolescent
1463811|NCT00118443|Students
1463812|NCT00118443|School Teachers
1463813|NCT00118430|Back Pain
1463814|NCT00118430|Knee Pain
1463815|NCT00118430|Hip Pain
1463816|NCT00118430|Stepped Care
1463817|NCT00118430|Antidepressant
1463818|NCT00118430|Relaxation Techniques
1463819|NCT00118430|Exercise
1463820|NCT00118417|Selective serotonin reuptake inhibitor
1463821|NCT00118417|Anxiety
1463822|NCT00118417|Pharmacotherapy
1463823|NCT00118417|Cognitive behavioral therapy
1463824|NCT00118417|CBT
1463825|NCT00118404|Cognitive therapy
1463826|NCT00118404|Antidepressants
1463827|NCT00118404|Psychotherapy
1463828|NCT00118391|Pathological Gambling
1463829|NCT00118391|CBT
1463830|NCT00118391|CM
1463831|NCT00118378|HIV
1463832|NCT00118378|AIDS
1463833|NCT00118378|Modafinil
1463834|NCT00118378|Depression
1463835|NCT00118339|oral complications
1463836|NCT00118339|drug/agent toxicity by tissue/organ
1463837|NCT00118339|stage I multiple myeloma
1463838|NCT00118339|stage II multiple myeloma
1463839|NCT00118339|stage III multiple myeloma
1463840|NCT00118326|de novo myelodysplastic syndromes
1463841|NCT00118326|disseminated neuroblastoma
1463842|NCT00118326|previously treated myelodysplastic syndromes
1463843|NCT00118326|recurrent neuroblastoma
1463844|NCT00118326|secondary myelodysplastic syndromes
1463845|NCT00118326|childhood acute myeloid leukemia in remission
1463846|NCT00118326|childhood acute lymphoblastic leukemia in remission
1463847|NCT00118326|childhood chronic myelogenous leukemia
1463848|NCT00118326|juvenile myelomonocytic leukemia
1463849|NCT00118326|previously treated childhood rhabdomyosarcoma
1463850|NCT00118326|recurrent Wilms tumor and other childhood kidney tumors
1463851|NCT00118326|recurrent/refractory childhood Hodgkin lymphoma
1463852|NCT00118326|recurrent childhood acute lymphoblastic leukemia
1463853|NCT00118326|recurrent childhood acute myeloid leukemia
1463854|NCT00118326|recurrent childhood large cell lymphoma
1463855|NCT00118326|recurrent childhood lymphoblastic lymphoma
1463856|NCT00118326|recurrent childhood rhabdomyosarcoma
1463857|NCT00118326|recurrent childhood small noncleaved cell lymphoma
1463858|NCT00118326|untreated childhood acute lymphoblastic leukemia
1463859|NCT00118326|untreated childhood acute myeloid leukemia and other myeloid malignancies
1463860|NCT00118313|stage II melanoma
1463861|NCT00118313|stage III melanoma
1463862|NCT00118313|stage IV melanoma
1463863|NCT00118300|stage III cervical cancer
1463864|NCT00118300|stage IVA cervical cancer
1463865|NCT00118300|recurrent cervical cancer
1463866|NCT00118300|stage III endometrial carcinoma
1463867|NCT00118300|recurrent endometrial carcinoma
1463868|NCT00118300|stage III ovarian epithelial cancer
1463869|NCT00118300|recurrent ovarian epithelial cancer
1463870|NCT00118300|stage III ovarian germ cell tumor
1463871|NCT00118300|recurrent ovarian germ cell tumor
1463872|NCT00118300|stage III vaginal cancer
1463873|NCT00118300|stage IVA vaginal cancer
1463874|NCT00118300|recurrent vaginal cancer
1463875|NCT00118300|ovarian sarcoma
1463876|NCT00118300|ovarian stromal cancer
1463877|NCT00118300|stage IV endometrial carcinoma
1463878|NCT00118300|stage IB cervical cancer
1463879|NCT00118300|stage IIA cervical cancer
1463880|NCT00118300|stage IIB cervical cancer
1463881|NCT00118300|stage II vaginal cancer
1463882|NCT00118300|stage I vaginal cancer
1463883|NCT00118274|stage II melanoma
1463884|NCT00118274|stage III melanoma
1463885|NCT00118274|stage IV melanoma
1463886|NCT00118261|stage IV rectal cancer
1463887|NCT00118261|stage IV colon cancer
1463888|NCT00118261|recurrent rectal cancer
1463889|NCT00118261|recurrent colon cancer
1463890|NCT00118222|adult mixed glioma
1463891|NCT00118222|adult anaplastic astrocytoma
1463892|NCT00118222|recurrent adult brain tumor
1463893|NCT00118222|adult giant cell glioblastoma
1463894|NCT00118222|adult gliosarcoma
1463895|NCT00118196|de novo myelodysplastic syndromes
1463896|NCT00118196|previously treated myelodysplastic syndromes
1463897|NCT00118196|secondary myelodysplastic syndromes
1463898|NCT00118196|chronic myelomonocytic leukemia
1463899|NCT00118131|stage IIIB non-small cell lung cancer
1463900|NCT00118131|stage IV non-small cell lung cancer
1463901|NCT00118131|recurrent non-small cell lung cancer
1463902|NCT00118105|recurrent colon cancer
1463903|NCT00118105|stage IV colon cancer
1463904|NCT00118105|recurrent rectal cancer
1463905|NCT00118105|stage IV rectal cancer
1463906|NCT00118105|liver metastases
1463907|NCT00118066|prostate cancer
1463908|NCT00118066|high grade prostatic intraepithelial neoplasia
1463909|NCT00118053|inflammatory breast cancer
1463910|NCT00118053|stage II breast cancer
1463911|NCT00118053|stage IIIA breast cancer
1463912|NCT00118053|stage IIIB breast cancer
1463913|NCT00118053|stage IIIC breast cancer
1463914|NCT00118027|Malaria in pregnancy
1463915|NCT00118027|Anaemia
1463916|NCT00118027|Low birth weight
1463917|NCT00118014|Trichotillomania
1463918|NCT00118014|Habit Reversal Training
1463919|NCT00118014|Sertraline
1463920|NCT00118014|Zoloft
1463921|NCT00118001|Psychotherapy
1463922|NCT00118001|Generalized Anxiety Disorder
1463923|NCT00118001|randomized-controlled trial
1463924|NCT00118001|worry exposure
1463925|NCT00118001|applied relaxation
1463926|NCT00117975|contiguous stage II grade 1 follicular lymphoma
1463927|NCT00117975|contiguous stage II grade 2 follicular lymphoma
1463928|NCT00117975|noncontiguous stage II grade 1 follicular lymphoma
1463929|NCT00117975|noncontiguous stage II grade 2 follicular lymphoma
1463930|NCT00117975|noncontiguous stage II grade 3 follicular lymphoma
1463931|NCT00117975|stage III grade 1 follicular lymphoma
1463932|NCT00117975|stage III grade 2 follicular lymphoma
1463933|NCT00117975|stage III grade 3 follicular lymphoma
1463934|NCT00117975|stage IV grade 1 follicular lymphoma
1463935|NCT00117975|stage IV grade 2 follicular lymphoma
1463936|NCT00117975|stage IV grade 3 follicular lymphoma
1463937|NCT00117975|contiguous stage II grade 3 follicular lymphoma
1463938|NCT00117962|stage IIIA non-small cell lung cancer
1463939|NCT00117962|stage IIIB non-small cell lung cancer
1463940|NCT00117962|squamous cell lung cancer
1463941|NCT00117962|large cell lung cancer
1463942|NCT00117962|adenocarcinoma of the lung
1463943|NCT00117962|bronchoalveolar cell lung cancer
1463944|NCT00117949|Prostate Cancer
1463945|NCT00117949|Androgen ablation therapy
1463946|NCT00117936|Angiogenesis
1463947|NCT00117936|No-option heart patients
1463948|NCT00117936|Blocked coronary artery
1463949|NCT00117936|Revascularization
1463950|NCT00117936|FGF-1
1463951|NCT00117936|growth factor
1463952|NCT00117923|Warts
1463953|NCT00117923|Adults
1463954|NCT00117923|Common Warts
1463955|NCT00117923|Resiquimod
1463956|NCT00117910|Aged, Granulocyte Colony-Stimulating Factor
1463957|NCT00117910|Combined Modality Therapy, Neutropenia
1463958|NCT00117910|pegfilgrastim, Neulasta®
1463959|NCT00117910|FEC-100, Antineoplastic Agents
1463960|NCT00117910|Breast Cancer, Female
1463961|NCT00117897|non-Hodgkin's lymphoma
1463962|NCT00117897|R-CHOP-14
1463963|NCT00117897|pegfilgrastim
1463964|NCT00117897|neutropenia, clinical trial
1463965|NCT00117897|haematopoietic growth factor
1463966|NCT00117884|Papillomavirus infections;
1463967|NCT00117884|Cervix Dysplasia
1463968|NCT00117871|Warts
1463969|NCT00117871|Adults
1463970|NCT00117871|Common Warts
1463971|NCT00117871|Resiquimod
1463972|NCT00117858|Frontal Lobe
1463973|NCT00117858|Language
1463974|NCT00117858|Behavior
1463975|NCT00117858|Degenerative Diseases
1463976|NCT00117858|Pick's Disease
1463977|NCT00117858|Frontotemporal Dementia
1463978|NCT00117858|FTP
1463979|NCT00117845|Denileukin Diftitox (Ontak)
1463980|NCT00117845|Recombinant Immunotoxin
1463981|NCT00117845|Human T-Cell Lymphotropic Virus (HTLV1)
1463982|NCT00117845|CD25 Positive
1463983|NCT00117845|IL-2R
1463984|NCT00117845|ATL
1463985|NCT00117845|Ontak
1463986|NCT00117845|Adult T-Cell Leukemia
1463987|NCT00117845|Lymphoproliferative Disorders
1463988|NCT00117832|allergic rhinitis
1463989|NCT00117819|parkinson
1463990|NCT00117819|family history
1463991|NCT00117819|diagnosis
1463992|NCT00117806|Adult
1463993|NCT00117806|Depression
1463994|NCT00117806|Employment, supported
1463995|NCT00117806|Health Service/ut
1463996|NCT00117806|Humans
1463997|NCT00117806|Outcomes
1463998|NCT00117806|Quality of life
1463999|NCT00117806|Veterans/rh (rehabilitation)
1464000|NCT00117806|Workplace
1464001|NCT00117806|Spinal Cord Injuries
1464002|NCT00117793|Amputee
1464003|NCT00117793|Artificial limbs
1464004|NCT00117793|Gait
1464005|NCT00117793|Walking
1464006|NCT00117767|Terbinafine, Tinea capitis, pediatric, antifungal
1464007|NCT00117754|Terbinafine, Tinea capitis, pediatric, antifungal
1464008|NCT00117741|Opiate Dependence
1464009|NCT00117741|DBT
1464010|NCT00117741|Dialectical Behavior Therapy
1464011|NCT00117741|Drug Counseling
1464012|NCT00117741|Therapy, Cognitive Behavior
1464013|NCT00117728|Non-nucleoside reverse transcriptase inhibitor
1464014|NCT00117728|Drug Resistance
1464015|NCT00117728|HIV Seronegativity
1464016|NCT00117728|Treatment Naive
1464017|NCT00117715|Developmental regulation of CYPs 1A2, 2D6, 3A4
1464018|NCT00117715|Ontogeny
1464019|NCT00117715|pharmacokinetics
1464020|NCT00117715|drug biotransformation
1464021|NCT00117715|enzymatic biotransformation of drugs
1464022|NCT00117702|GvHD
1464023|NCT00117702|Tacrolimus
1464024|NCT00117702|Everolimus
1464025|NCT00117702|Stem cell transplantation
1464026|NCT00117689|Anti-T cell antibodies
1464027|NCT00117689|Primary Liver Transplantation and Renal Dysfunction
1464028|NCT00117689|Liver Transplant Rejection
1464029|NCT00117689|Induction Therapy with reduction of Calcineurin inhibitors
1464030|NCT00117689|Primary Liver Transplantation
1464031|NCT00117689|Primary Transplant Rejection
1464032|NCT00117689|Transplantation, Liver
1464033|NCT00117689|Rejection, Transplant
1464034|NCT00117676|tenofovir
1464035|NCT00117676|adefovir
1464036|NCT00117676|hepatitis B virus
1464037|NCT00117676|HBeAg Negative
1464038|NCT00117663|Randomized controlled trial
1464039|NCT00117663|Mammography
1464040|NCT00117663|health care setting
1464041|NCT00117663|hormone replacement therapy
1464042|NCT00117663|breast density
1464043|NCT00117663|mammography performance
1464044|NCT00117663|Breast Carcinoma
1464045|NCT00117650|leg pain
1464046|NCT00117650|gene transfer
1464047|NCT00117650|angiogenesis
1464048|NCT00117650|Phase 2
1464049|NCT00117650|Genzyme
1464050|NCT00117650|peripheral arterial disease
1464051|NCT00117637|Renal Cell Cancer
1464052|NCT00117637|RCC
1464053|NCT00117637|Cancer
1464054|NCT00117624|Non-myeloid malignancy
1464055|NCT00117624|Darbepoetin alfa
1464056|NCT00117624|Clinical Trial
1464057|NCT00117611|chronic sinusitis
1464058|NCT00117598|Lymphoma
1464059|NCT00117585|Aging
1464060|NCT00117585|Blood pressure
1464061|NCT00117585|Hypotension
1464062|NCT00117585|Orthostatic
1464063|NCT00117585|Rehabilitation
1464064|NCT00117572|Cancer of the Pharynx (Nasopharynx, Oropharynx, Hypopharynx)
1464065|NCT00117572|Cancer of the Nasal Cavity and Paranasal Sinuses
1464066|NCT00117559|Psychotherapy,group
1464067|NCT00117559|Rehabilitation
1464068|NCT00117559|Telecommunications
1464069|NCT00117546|CAPACITY trial
1464070|NCT00117546|preeclampsia
1464071|NCT00117546|plasma volume
1464072|NCT00117546|sympathetic activity
1464073|NCT00117546|hypertension
1464074|NCT00117546|cardiovascular system
1464075|NCT00117533|chronic hepatitis B;
1464076|NCT00117533|chronic hepatitis delta;
1464077|NCT00117533|treatment;
1464078|NCT00117533|pegylated interferon alfa-2b;
1464079|NCT00117533|ribavirin
1464080|NCT00117520|caffeine, endurance, postural stability, elderly
1464081|NCT00117507|MDS
1464082|NCT00117507|Myelodysplastic Syndrome
1464083|NCT00117507|ICL-670
1464084|NCT00117507|ICL-670 and Myelodysplastic Syndrome
1464085|NCT00117494|Hyperlipidemia
1464086|NCT00117494|HIV infections
1464087|NCT00117494|STATINS, HMG-COA
1464088|NCT00117494|Protease Inhibitor
1464089|NCT00117494|Treatment Experienced
1464090|NCT00117481|endometriosis
1464091|NCT00117481|pelvic pain
1464092|NCT00117481|hormonal treatment
1464093|NCT00117468|luteal phase replacement
1464094|NCT00117468|oocyte donation
1464095|NCT00117468|infertility
1464096|NCT00117468|progesterone
1464097|NCT00117455|ICE
1464098|NCT00117455|BEAM
1464099|NCT00117455|PBPC transplant
1464100|NCT00117442|solid tumour
1464101|NCT00117442|unknown primary tumour
1464102|NCT00117442|carboplatin
1464103|NCT00117442|paclitaxel
1464104|NCT00117429|HIV-1
1464105|NCT00117429|therapeutic vaccination
1464106|NCT00117429|cellular immunity
1464107|NCT00117429|humoral immunity
1464108|NCT00117429|HAART
1464109|NCT00117429|chronic HIV-1 infection
1464110|NCT00117429|Treatment Experienced
1464111|NCT00117429|HIV Therapeutic Vaccine
1464112|NCT00117403|dementia
1464113|NCT00117403|anti-oxidant
1464114|NCT00117403|biomarkers
1464115|NCT00117403|alpha-tocopherol
1464116|NCT00117403|CoQ
1464117|NCT00117377|Atopic dermatitis, pimecrolimus, cellular, molecular
1464118|NCT00117364|chronic ulcer
1464119|NCT00117364|poor healing
1464120|NCT00117364|The patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study
1464121|NCT00117351|Adenocarcinoma
1464122|NCT00117351|Bronchiolo-Alveolar
1464123|NCT00117351|Carcinoma, Bronchioloalveolar
1464124|NCT00117351|Carcinoma, Non-Small-Cell Lung
1464125|NCT00117351|Carcinoma, Bronchiolo-Alveolar
1464126|NCT00117325|Vasomotor Rhinitis
1464127|NCT00117325|VMR
1464128|NCT00117325|nonallergic rhinitis
1464129|NCT00117325|GW685698X
1464130|NCT00117312|Prostate Cancer
1464131|NCT00117312|Androgen ablation therapy
1464132|NCT00117299|Gastrointestinal stromal tumor
1464133|NCT00117299|GIST
1464134|NCT00117299|Sarcoma
1464135|NCT00117299|PTK787
1464136|NCT00117299|ZK 222584
1464137|NCT00117299|Tyrosine kinase inhibitor
1464138|NCT00117299|Tyrosine kinase
1464139|NCT00117299|VEGF
1464140|NCT00117299|Vascular endothelial growth factor
1464141|NCT00117299|VEGFR
1464142|NCT00117299|Vascular endothelial growth factor receptor
1464143|NCT00117299|KDR
1464144|NCT00117299|KIT
1464145|NCT00117299|c-KIT
1464146|NCT00117299|Platelet derived growth factor receptor
1464147|NCT00117299|PDGFR
1464148|NCT00117286|Prostate Cancer
1464149|NCT00117286|Androgen ablation therapy
1464150|NCT00117260|osteopenia
1464151|NCT00117260|bone mineral density
1464152|NCT00117260|amenorrhea
1464153|NCT00117260|adolescents
1464154|NCT00117247|Heart Failure
1464155|NCT00117234|chronic heart failure
1464156|NCT00117234|congestive heart failure
1464157|NCT00117234|low hemoglobin
1464158|NCT00117234|anemia
1464159|NCT00117234|CHF
1464160|NCT00117234|Symptomatic Congestive Heart Failure (CHF)
1464161|NCT00117221|Magnetic Resonance Imaging
1464162|NCT00117221|Functional Imaging
1464163|NCT00117221|Cerebral Blood Flow
1464164|NCT00117221|BOLD Effect
1464165|NCT00117221|Sleep
1464166|NCT00117208|cystic fibrosis
1464167|NCT00117195|parkinson
1464168|NCT00117195|diagnosis
1464169|NCT00117195|screening
1464170|NCT00117169|Pulmonary embolism
1464171|NCT00117169|multi-detector helical computed tomography clinical probability
1464172|NCT00117169|clinical score
1464173|NCT00117156|Fludarabine
1464174|NCT00117156|Rituximab
1464175|NCT00117156|Marginal Zone Lymphoma
1464176|NCT00117156|MALT lymphoma
1464177|NCT00117143|Immune Thrombocytopenic Purpura
1464178|NCT00117143|Idiopathic Thrombocytopenic Purpura
1464179|NCT00117143|ITP
1464180|NCT00117143|Thrombocytopenia
1464181|NCT00117130|Kidney disease, Renal, CKD (Chronic Kidney Disease)
1464182|NCT00117130|CRI (Chronic Renal Insufficiency), Pre-dialysis, Amgen
1464183|NCT00117130|Aranesp®, Darbepoetin alfa, QW dosing
1464184|NCT00117130|Q2W dosing, Q4W dosing
1464185|NCT00117130|Patient preference, Subject preference
1464186|NCT00117117|Chemotherapy induced anemia
1464187|NCT00117117|Amgen
1464188|NCT00117117|Aranesp®
1464189|NCT00117117|darbepoetin alfa
1464190|NCT00117104|End Stage Renal Disease (ESRD)
1464191|NCT00117104|Kidney Disease, Dialysis
1464192|NCT00117104|Aranesp®, rHuEPO
1464193|NCT00117104|Anemia, Hemoglobin
1464194|NCT00117104|Dosing, Amgen
1464195|NCT00117091|Rheumatoid Arthritis
1464196|NCT00117091|RA
1464197|NCT00117091|Anakinra (Kineret®)
1464198|NCT00117078|Kidney disease, Renal, CKD (Chronic Kidney Disease)
1464199|NCT00117078|CRI (Chronic Renal Insufficiency), Pre-dialysis, Amgen
1464200|NCT00117078|Aranesp®, Darbepoetin alfa, QW dosing
1464201|NCT00117078|Q2W dosing, Q4W dosing
1464202|NCT00117078|Patient preference, Subject preference
1464203|NCT00117065|Kidney transplant, Renal transplant
1464204|NCT00117065|Aranesp®, Darbepoetin alfa
1464205|NCT00117065|Amgen, Q2W dosing, Q4W dosing
1464206|NCT00117052|Clinical trial
1464207|NCT00117052|Amgen
1464208|NCT00117052|Secondary HyperParaThyroidism (SHPT)
1464209|NCT00117052|Dialysis
1464210|NCT00117052|End Stage Renal Disease (ESRD)
1464211|NCT00117052|KDOQI
1464212|NCT00117052|Cinacalcet
1464213|NCT00117039|anemia
1464214|NCT00117039|fatigue
1464215|NCT00117039|Aranesp®
1464216|NCT00117039|clinical trial
1464217|NCT00117026|Diabetes Complications
1464218|NCT00117026|benfotiamine
1464219|NCT00117026|type 1 diabetes
1464220|NCT00117026|elevated urinary albumin excretion
1464221|NCT00117026|nerve function
1464222|NCT00117026|advanced glycation end products
1464223|NCT00117013|Phase I
1464224|NCT00117013|Antiangiogenesis
1464225|NCT00117013|Targeted Therapy
1464226|NCT00117013|Chronic Schedule
1464227|NCT00117013|VEGF
1464228|NCT00117013|Cancer
1464229|NCT00117013|Metastatic Solid Tumor
1464230|NCT00117000|testosterone
1464231|NCT00117000|food, formulated
1464232|NCT00117000|malnutrition
1464233|NCT00117000|undernutrition
1464234|NCT00117000|aging
1464235|NCT00117000|aged
1464236|NCT00117000|aged, 80 and over
1464237|NCT00117000|frail elderly
1464238|NCT00116987|physiologic pacing
1464239|NCT00116987|ventricular pacing
1464240|NCT00116987|hospitalizations
1464241|NCT00116974|Dental scaling
1464242|NCT00116948|Osteoarthrosis
1464243|NCT00116948|RSA
1464244|NCT00116948|DEXA
1464245|NCT00116948|Hip arthroplasty
1464246|NCT00116948|Metal ion
1464247|NCT00116948|Inflammatory response
1464248|NCT00116948|Gait analysis
1464249|NCT00116935|Gastrointestinal stromal tumor
1464250|NCT00116935|GIST
1464251|NCT00116935|Sarcoma
1464252|NCT00116935|Imatinib
1464253|NCT00116935|Adjuvant therapy
1464254|NCT00116935|KIT
1464255|NCT00116935|PDGFRA
1464256|NCT00116935|Receptor tyrosine kinase
1464257|NCT00116935|Tyrosine kinase inhibitor
1464258|NCT00116922|Diabetes
1464259|NCT00116922|Prevention.
1464260|NCT00116922|Rosiglitazone
1464261|NCT00116922|Metformin
1464262|NCT00116922|Lifestyle
1464263|NCT00116922|Impaired glucose Tolerance
1464264|NCT00116883|GW685698X
1464265|NCT00116883|perennial allergic rhinitis
1464266|NCT00116883|pediatric
1464267|NCT00116883|intranasal corticosteroid
1464268|NCT00116883|HPA axis function
1464269|NCT00116870|CAD
1464270|NCT00116870|familial hypercholesterolemia
1464271|NCT00116844|viral shedding
1464272|NCT00116844|Recurrent
1464273|NCT00116844|herpes
1464274|NCT00116844|genital herpes
1464275|NCT00116831|atheroma
1464276|NCT00116831|IVUS
1464277|NCT00116831|Intravascular ultrasound
1464278|NCT00116831|atherosclerosis
1464279|NCT00116818|perennial allergic rhinitis
1464280|NCT00116818|intranasal corticosteroid
1464281|NCT00116818|HPA axis function
1464282|NCT00116818|GW685698X
1464283|NCT00116805|tenofovir
1464284|NCT00116805|adefovir
1464285|NCT00116805|hepatitis B
1464286|NCT00116805|HBeAg Positive
1464287|NCT00116792|CAD
1464288|NCT00116792|Diabetes Mellitus
1464289|NCT00116792|Restenosis
1464290|NCT00116792|ppar gamma
1464291|NCT00116792|glitazone
1464292|NCT00116779|Prostate Cancer
1464293|NCT00116779|Androgen ablation therapy
1464294|NCT00116766|mosquitoes
1464295|NCT00116766|malaria
1464296|NCT00116766|vector control
1464297|NCT00116766|plant-based
1464298|NCT00116753|Prostate Cancer
1464299|NCT00116753|Androgen ablation therapy
1464300|NCT00116740|Serotonin
1464301|NCT00116740|5-HT2c
1464302|NCT00116740|Satiety
1464303|NCT00116740|Obesity
1464304|NCT00116740|Appetite suppressant
1464305|NCT00116740|Weight Loss
1464306|NCT00116740|Overweight
1464307|NCT00116727|Rheumatoid Arthritis
1464308|NCT00116727|DMARD
1464309|NCT00116714|rheumatoid arthritis
1464310|NCT00116714|RA
1464311|NCT00116714|DMARD
1464312|NCT00116701|Chronic Kidney Disease (CKD)
1464313|NCT00116701|Haemoglobin (Hb)
1464314|NCT00116701|Erthropoetin (EPO)
1464315|NCT00116701|End Stage Renal Disease (ESRD)
1464316|NCT00116701|Recombinant Human Erthropoetic (rHuEPO)
1464317|NCT00116701|Anaemia
1464318|NCT00116701|Darbepoetin Alfa, Aranesp®
1464319|NCT00116701|Haemodialysis
1464320|NCT00116701|Clinical Trial
1464321|NCT00116688|Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
1464322|NCT00116688|Thrombocytopenic
1464323|NCT00116675|Common Wart(s)
1464324|NCT00116675|Pediatric
1464325|NCT00116675|Wart(s)
1464326|NCT00116675|Children
1464327|NCT00116675|3M Pharmaceuticals
1464328|NCT00116675|Resiquimod
1464329|NCT00116662|Wart(s)
1464330|NCT00116662|Common Wart(s)
1464331|NCT00116662|Children
1464332|NCT00116662|Pediatric
1464333|NCT00116662|3M Pharmaceuticals
1464334|NCT00116662|Resiquimod
1464335|NCT00116649|actinic keratosis lesions large head torso extremities
1464336|NCT00116649|actinic keratosis
1464337|NCT00116636|HIV
1464338|NCT00116636|Treatment Naive
1464339|NCT00116610|small cell lung cancer
1464340|NCT00116610|resistant
1464341|NCT00116610|refractory
1464342|NCT00116610|platinum
1464343|NCT00116610|chemotherapy
1464344|NCT00116610|second-line
1464345|NCT00116610|relapse
1464346|NCT00116610|sensitive
1464347|NCT00116597|Active Specific Immunotherapy
1464348|NCT00116597|Intranodal
1464349|NCT00116597|Cancer
1464350|NCT00116597|Melanoma stages IIb to IV
1464351|NCT00116597|Gene Therapy
1464352|NCT00116597|Recombinant Vaccinia virus
1464353|NCT00116597|HLA-A2
1464354|NCT00116597|Mart-1/Melan-A, Gp-100, tyrosinase
1464355|NCT00116597|Clinical Trial
1464356|NCT00116597|Phase I/II
1464357|NCT00116584|heliox
1464358|NCT00116584|bronchiolitis
1464359|NCT00116584|racemic epinephrine
1464360|NCT00116571|Benign Prostatic Hyperplasia (BPH)
1464361|NCT00116571|Photodynamic Therapy (PDT)
1464362|NCT00116571|Lower Urinary Tract Symptoms (LUTS)
1464363|NCT00116558|amyotrophic lateral sclerosis
1464364|NCT00116558|ALS
1464365|NCT00116558|Lou Gehrig's disease
1464366|NCT00116558|nutrition
1464367|NCT00116558|NIPPV
1464368|NCT00116558|non-invasive positive pressure ventilation
1464369|NCT00116558|percutaneous endoscopic gastrostomy
1464370|NCT00116558|PEG
1464371|NCT00116545|IDDM
1464372|NCT00116545|Insulin
1464373|NCT00116545|cardiovascular disease
1464374|NCT00116532|Obsessive Compulsive Disorder
1464375|NCT00116532|Escitalopram
1464376|NCT00116532|SSRI
1464377|NCT00116532|Open Label
1464378|NCT00116506|Metastatic Colorectal Cancer
1464379|NCT00116506|Bevacizumab
1464380|NCT00116506|Erlotinib
1464381|NCT00116506|FOLFOX
1464382|NCT00116493|severe anemia
1464383|NCT00116493|anthelminthic
1464384|NCT00116493|multivitamins
1464385|NCT00116493|pregnancy
1464386|NCT00116493|children
1464387|NCT00116493|Pakistan
1464388|NCT00116480|Postpartum Haemorrhage
1464389|NCT00116480|Misoprostol
1464390|NCT00116467|AML
1464391|NCT00116467|Acute Myelogenous Leukemia
1464392|NCT00116467|GVAX
1464393|NCT00116467|Vaccine
1464394|NCT00116467|Stem Cell Transplant
1464395|NCT00116467|Autologous
1464396|NCT00116454|Carcinoma, Hepatocellular
1464397|NCT00116454|Viral Hepatitis, Alcoholic Hepatitis
1464398|NCT00116441|Multiple Myeloma
1464399|NCT00116441|Cancer
1464400|NCT00116441|PSCT
1464401|NCT00116441|Peripheral Stem Cell Transplant
1464402|NCT00116441|Chemotherapy
1464403|NCT00116441|GVAX
1464404|NCT00116428|Atrial Fibrillation
1464405|NCT00116428|Paroxysmal Atrial Fibrillation
1464406|NCT00116415|HIV/AIDS
1464407|NCT00116402|COPD
1464408|NCT00116402|Chronic Obstructive
1464409|NCT00116402|Pulmonary Disease
1464410|NCT00116402|Inhaled Corticosteroids
1464411|NCT00116402|Airway Inflammation
1464412|NCT00116402|Bronchoscopy
1464413|NCT00116389|pancreatic cancer
1464414|NCT00116389|cancer of the pancreas
1464415|NCT00116389|adenocarcinoma of the pancreas
1464416|NCT00116389|pancreatic neoplasms
1464417|NCT00116389|Metastatic pancreatic cancer (Stage IV)
1464418|NCT00116389|Stage IV Adenocarcinoma of the Pancreas
1464419|NCT00116376|GBM
1464420|NCT00116376|recurrent/relapse
1464421|NCT00116376|EGFR
1464422|NCT00116376|VEGFR
1464423|NCT00116363|gene therapy
1464424|NCT00116363|melanoma
1464425|NCT00116363|adenovirus
1464426|NCT00116363|in-transit melanoma
1464427|NCT00116363|metastatic melanoma
1464428|NCT00116350|Postpartum hemorrhage
1464429|NCT00116350|Misoprostol
1464430|NCT00116350|Developing countries
1464431|NCT00116350|Maternal morbidity
1464432|NCT00116350|Randomized controlled trial
1464433|NCT00116337|spinal cord injury
1464434|NCT00116337|paralysis
1464435|NCT00116337|cough
1464436|NCT00116337|cervical spinal cord injury
1464437|NCT00116337|thoracic spinal cord injury
1464438|NCT00116324|Asthma
1464439|NCT00116324|Leukotriene receptor antagonist
1464440|NCT00116324|Hypertonic saline challenge
1464441|NCT00116311|Adenosine receptors
1464442|NCT00116311|asthma
1464443|NCT00116311|sputum
1464444|NCT00116311|peripheral blood
1464445|NCT00116311|healthy
1464446|NCT00116298|Antivirals
1464447|NCT00116298|HIV
1464448|NCT00116285|allergy
1464449|NCT00116285|skin prick test
1464450|NCT00116285|allergoid
1464451|NCT00116285|allergenicity
1464452|NCT00116285|specific immunotherapy
1464453|NCT00116272|pregnancy
1464454|NCT00116272|Autoimmune Disease
1464455|NCT00116259|clinical trial
1464456|NCT00116259|aripiprazole
1464457|NCT00116259|Bipolar Disorder
1464458|NCT00116259|Attention-Deficit Hyperactivity Disorder
1464459|NCT00116259|ADHD
1464460|NCT00116246|Labour
1464461|NCT00116246|vaginal delivery
1464462|NCT00116246|primigravida
1464463|NCT00116246|McRobert's Manoeuvre
1464464|NCT00116246|operative delivery
1464465|NCT00116233|post operative adhesions
1464466|NCT00116220|Prostate Cancer
1464467|NCT00116220|Total Androgen Suppression
1464468|NCT00116220|endorectal coil MRI
1464469|NCT00116220|External Beam Radiation Therapy
1464470|NCT00116220|Prostate Cancer- High Risk, clinically Organ-Confined
1464471|NCT00116207|Type 1 Diabetes
1464472|NCT00116207|Oxidative Stress
1464473|NCT00116207|Diabetic Complications
1464474|NCT00116207|Neuropathy
1464475|NCT00116194|exercise
1464476|NCT00116194|activities of daily living
1464477|NCT00116194|ADL
1464478|NCT00116194|loss of mobility
1464479|NCT00116194|risk of disability
1464480|NCT00116194|physical activity
1464481|NCT00116194|mobility disability
1464482|NCT00116155|Hormone Refractory Metastatic Prostate Cancer
1464483|NCT00116142|Prostate Cancer
1464484|NCT00116142|Hormone Refractory
1464485|NCT00116142|Metastatic
1464486|NCT00116142|Localized
1464487|NCT00116142|Locally Advanced
1464488|NCT00116142|Prostate Cancer - High Risk Localized or Locally Advanced
1464489|NCT00116129|Fibromyalgia
1464490|NCT00116129|Treatment
1464491|NCT00116129|Growth hormone
1464492|NCT00116129|IGF-1
1464493|NCT00116129|MK-0677
1464494|NCT00116129|Oral growth hormone secretagogue
1464495|NCT00116116|HIV/AIDS
1464496|NCT00116103|Treatment Effectiveness
1464497|NCT00116103|Treatment Efficacy
1464498|NCT00116103|Investigational, Therapies
1464499|NCT00116103|Asthma
1464500|NCT00116103|Antiasthmatics
1464501|NCT00116103|Antiasthmatic agents
1464502|NCT00116090|Uveitis
1464503|NCT00116090|Immunosuppression
1464504|NCT00116090|Cancer
1464505|NCT00116090|Infections
1464506|NCT00116090|Mortality
1464507|NCT00116090|Ocular Inflammatory Disease
1464508|NCT00116090|Scleritis
1464509|NCT00116090|Mucous Membranes Pemphigoid
1464510|NCT00116077|PET
1464511|NCT00116077|[C-11] NNC-112
1464512|NCT00116077|[F-18] Fallypride
1464513|NCT00116077|Dopamine Receptors
1464514|NCT00116077|Mood Disorders
1464515|NCT00116077|DA Receptors
1464516|NCT00116077|Major Depressive Disorder
1464517|NCT00116077|Bipolar Disorder
1464518|NCT00116077|MDD
1464519|NCT00116077|Bipolar Depression
1464520|NCT00116077|Healthy Volunteer
1464521|NCT00116077|HV
1464522|NCT00116064|intranasal
1464523|NCT00116064|lorazepam
1464524|NCT00116064|paediatric
1464525|NCT00116064|convulsions
1464526|NCT00116051|RSA
1464527|NCT00116051|DEXA
1464528|NCT00116051|Osteoarthritis
1464529|NCT00116051|Hip arthroplasty
1464530|NCT00116038|RSA
1464531|NCT00116038|Osteoarthritis
1464532|NCT00116038|Hip arthroplasty
1464533|NCT00116038|DEXA
1464534|NCT00116012|acute coronary syndrome
1464535|NCT00116012|rNAPc2
1464536|NCT00116012|unstable angina
1464537|NCT00116012|Non-STE myocardial infarction
1464538|NCT00116012|ST elevation
1464539|NCT00116012|cardiac enzymes
1464540|NCT00116012|acute coronary syndromes
1464541|NCT00116012|factor VIIa
1464542|NCT00116012|tissue factor
1464543|NCT00116012|nematode anticoagulant protein c2
1464544|NCT00116012|anticoagulants
1464545|NCT00116012|thrombin inhibitors
1464546|NCT00116012|thrombosis
1464547|NCT00115999|PAO
1464548|NCT00115999|acute peripheral arterial occlusion
1464549|NCT00115999|thrombolysis
1464550|NCT00115999|blood clot
1464551|NCT00115999|leg attack
1464552|NCT00115999|alfimeprase
1464553|NCT00115999|thrombus
1464554|NCT00115999|embolism
1464555|NCT00115999|thromboembolism
1464556|NCT00115999|claudication
1464557|NCT00115999|thrombolytic
1464558|NCT00115999|thrombosis
1464559|NCT00115999|plasminogen activator
1464560|NCT00115999|arterial flow
1464561|NCT00115986|A/H5N1, Influenza, Vaccine, parent protocol
1464562|NCT00115973|Pump
1464563|NCT00115973|Diabetes
1464564|NCT00115960|IL-12
1464565|NCT00115960|IL-15
1464566|NCT00115960|HIV Seronegativity
1464567|NCT00115960|HIV Preventive Vaccine
1464568|NCT00115921|Home-based care
1464569|NCT00115921|Malaria
1464570|NCT00115921|Africa
1464571|NCT00115908|Hepatitis C
1464572|NCT00115895|radioiodine
1464573|NCT00115895|serum thyroglobulin
1464574|NCT00115895|whole body radioiodine scanning
1464575|NCT00115882|Adolescent
1464576|NCT00115882|smoking
1464577|NCT00115882|smoking cessation
1464578|NCT00115882|counseling
1464579|NCT00115869|smoking prevention
1464580|NCT00115869|tobacco use prevention
1464581|NCT00115869|adolescent tobacco use
1464582|NCT00115869|prevention intervention
1464583|NCT00115856|Arterial Disease
1464584|NCT00115843|Atrial fibrillation
1464585|NCT00115843|Arrhythmia
1464586|NCT00115843|Tachycardia
1464587|NCT00115804|Fibromyalgia
1464588|NCT00115804|Juvenile
1464589|NCT00115791|Atrial Flutters
1464590|NCT00115791|Atrial Fibrillations
1464591|NCT00115791|RSD1235
1464592|NCT00115778|Hypogammaglobulinemia
1464593|NCT00115778|Lung Transplantation
1464594|NCT00115765|Panitumumab Advanced Colorectal Cancer Evaluation Study (PACCE Study)
1464595|NCT00115765|Colorectal, Colon, Rectal Cancer, Metastatic Colorectal
1464596|NCT00115765|Cancer
1464597|NCT00115765|EGFr, Clinical Trial
1464598|NCT00115765|Panitumumab, ABX-EGF
1464599|NCT00115765|Immunex, Abgenix, Amgen
1464600|NCT00115765|Metastatic Colorectal Cancer
1464601|NCT00115765|Oncology
1464602|NCT00115752|Single Nucleotide Polymorphism
1464603|NCT00115752|Analgesic Efficacy
1464604|NCT00115752|Oral Surgery Model
1464605|NCT00115752|Cyclooxygenase Inhibitor
1464606|NCT00115752|Gene Expression Profile
1464607|NCT00115752|Wisdom Teeth
1464608|NCT00115752|Third Molar Extraction
1464609|NCT00115739|Anaplastic Thyroid Cancer
1464610|NCT00115726|anesthesia
1464611|NCT00115726|hypotension
1464612|NCT00115726|furosemide
1464613|NCT00115726|blood pressure
1464614|NCT00115726|peripheral edema
1464615|NCT00115726|diuretic
1464616|NCT00115726|surgery
1464617|NCT00115726|congestive heart failure
1464618|NCT00115713|Aerobic Exercise
1464619|NCT00115713|Weight Lifting
1464620|NCT00115713|Breast Cancer
1464621|NCT00115713|Quality of Life
1464622|NCT00115700|Radiotherapy
1464623|NCT00115700|Chemotherapy
1464624|NCT00115700|Rituximab
1464625|NCT00115700|Randomised Trial
1464626|NCT00115700|Stage I-II low grade follicular lymphoma
1464627|NCT00115687|nicotine addiction
1464628|NCT00115661|Peroxisome Proliferator-Activated Receptors
1464629|NCT00115661|treatment of endometriosis
1464630|NCT00115648|HIV
1464631|NCT00115648|MTCT
1464632|NCT00115648|Infants
1464633|NCT00115648|africa
1464634|NCT00115648|HIV Seronegativity
1464635|NCT00115635|Hormonal refractory, chemotherapy, docetaxel, gemcitabine
1464636|NCT00115622|GW685698X
1464637|NCT00115622|once daily
1464638|NCT00115622|mountain cedar
1464639|NCT00115622|allergic rhinitis
1464640|NCT00115622|fluticasone furoate
1464641|NCT00115609|HIV infections
1464642|NCT00115609|tuberculosis
1464643|NCT00115609|tuberculosis agents
1464644|NCT00115609|Anti HIV agents
1464645|NCT00115609|Treatment Naive
1464646|NCT00115596|Procedure
1464647|NCT00115596|Training
1464648|NCT00115596|Simulation
1464649|NCT00115596|Pediatrics
1464650|NCT00115596|Curriculum
1464651|NCT00115596|Evaluation
1464652|NCT00115570|Diabetes,Insulin-Dependent, pediatric,rapid acting injection
1464653|NCT00115557|translational research
1464654|NCT00115557|prevention
1464655|NCT00115557|primary care
1464656|NCT00115557|practice-based research network
1464657|NCT00115544|neonatal
1464658|NCT00115544|jaundice
1464659|NCT00115544|hyperbilirubinemia
1464660|NCT00115531|Elderly, influenza, vaccine, parent protocol
1464661|NCT00115505|stage IA breast cancer
1464662|NCT00115505|stage II breast cancer
1464663|NCT00115505|stage IB breast cancer
1464664|NCT00115505|estrogen receptor-negative breast cancer
1464665|NCT00115505|estrogen receptor-positive breast cancer
1464666|NCT00115505|progesterone receptor-negative breast cancer
1464667|NCT00115505|progesterone receptor-positive breast cancer
1464668|NCT00115492|Breathing
1464669|NCT00115492|Exacerbation
1464670|NCT00115492|Chronic Obstructive Pulmonary Disease
1464671|NCT00115479|critical illness
1464672|NCT00115479|intensive care
1464673|NCT00115479|outcome
1464674|NCT00115479|insulin
1464675|NCT00115479|blood glucose
1464676|NCT00115466|ASCs (adult stem cells derived from adipose tissue)
1464677|NCT00115466|Fistula
1464678|NCT00115466|Cell Therapy
1464679|NCT00115466|Complex perianal fistula
1464680|NCT00115453|glioblastoma
1464681|NCT00115453|boron neutron capture therapy
1464682|NCT00115453|boronophenylalanine
1464683|NCT00115453|brain tumor
1464684|NCT00115440|glioblastoma
1464685|NCT00115440|anaplastic astrocytoma
1464686|NCT00115440|boron neutron capture therapy
1464687|NCT00115440|radiation therapy
1464688|NCT00115440|boronophenylalanine
1464689|NCT00115427|Bilateral, Idiopathic Parkinson's Disease
1464690|NCT00115414|Neulasta®
1464691|NCT00115414|Chemotherapy
1464692|NCT00115414|TAC
1464693|NCT00115414|Amgen
1464694|NCT00115401|Walking
1464695|NCT00115401|Compensation
1464696|NCT00115401|Leg Weakness
1464697|NCT00115401|Orthotics
1464698|NCT00115401|Joint Impairment
1464699|NCT00115401|Healthy Volunteer
1464700|NCT00115401|HV
1464701|NCT00115401|Joint Inmpairment
1464702|NCT00115388|Pelvic inflammatory disease
1464703|NCT00115388|Chlamydia trachomatis
1464704|NCT00115388|Screening
1464705|NCT00115375|THROMBOSIS
1464706|NCT00115375|PLATELET AGGREGATION
1464707|NCT00115375|Pediatrics
1464708|NCT00115362|functional dyspepsia;
1464709|NCT00115362|Serotonin Uptake Inhibitors;
1464710|NCT00115362|Antidepressive Agents.
1464711|NCT00115336|Blood Diseases
1464712|NCT00115336|Sickle Cell Anemia
1464713|NCT00115310|dermal assessment
1464714|NCT00115310|pain measurement
1464715|NCT00115310|diary
1464716|NCT00115310|PHN
1464717|NCT00115310|shingles
1464718|NCT00115310|neuropathy
1464719|NCT00115310|analgesics
1464720|NCT00115310|capsaicin
1464721|NCT00115310|postherpetic neuralgia
1464722|NCT00115284|Asthma
1464723|NCT00115284|Education, Medical, Continuing
1464724|NCT00115284|American Board of Internal Medicine
1464725|NCT00115284|Recertification
1464726|NCT00115284|Continuous Professional Development
1464727|NCT00115284|Practice improvement
1464728|NCT00115271|Micronutrients
1464729|NCT00115271|Supplementation
1464730|NCT00115271|Pregnancy
1464731|NCT00115271|Birth weight
1464732|NCT00115271|Infant mortality
1464733|NCT00115258|Nutrition, Parenteral
1464734|NCT00115258|Body Composition
1464735|NCT00115258|Energy Expenditure
1464736|NCT00115232|cardiovascular disease
1464737|NCT00115232|metabolic syndrome
1464738|NCT00115232|hypercholesterolemia
1464739|NCT00115232|child
1464740|NCT00115232|family history
1464741|NCT00115232|inflammation
1464742|NCT00115219|Rheumatoid Arthritis, RA
1464743|NCT00115219|Enbrel® (etanercept)
1464744|NCT00115219|Clinical Trials, Amgen
1464745|NCT00115219|Immunex, Methotrexate (MTX)
1464746|NCT00115219|Rheumatoid Arthritis (RA)
1464747|NCT00115206|Non Small Cell Lung Cancer
1464748|NCT00115206|NSCLC
1464749|NCT00115206|Fever
1464750|NCT00115206|Neutropenia
1464751|NCT00115206|Neulasta®
1464752|NCT00115206|Quality of Life
1464753|NCT00115206|Chemotherapy
1464754|NCT00115206|Amgen
1464755|NCT00115193|Oncology
1464756|NCT00115193|NHL
1464757|NCT00115193|Mantle cell
1464758|NCT00115193|Diffuse large B-cell
1464759|NCT00115193|Chemotherapy
1464760|NCT00115193|RCHOP
1464761|NCT00115193|Neulasta®
1464762|NCT00115193|Neutropenia
1464763|NCT00115193|Pegfilgrastim
1464764|NCT00115193|Amgen
1464765|NCT00115180|analgesia
1464766|NCT00115180|adult
1464767|NCT00115180|opioid
1464768|NCT00115180|Long Bone Fractures
1464769|NCT00115167|Oncology
1464770|NCT00115167|Cancer-related anemia
1464771|NCT00115154|Actinic Keratosis
1464772|NCT00115154|AK
1464773|NCT00115154|3M Pharmaceuticals
1464774|NCT00115154|Aldara
1464775|NCT00115154|Imiquimod
1464776|NCT00115154|Actinic Keratosis (AK)
1464777|NCT00115141|Wart(s)
1464778|NCT00115141|Adults
1464779|NCT00115141|Common Wart(s)
1464780|NCT00115128|normal PBPC donors
1464781|NCT00115115|Donor dopamine
1464782|NCT00115115|Immediate graft function
1464783|NCT00115115|Kidney transplantation
1464784|NCT00115102|Atypical odontalgia
1464785|NCT00115102|capsaicin
1464786|NCT00115102|pain
1464787|NCT00115102|neuropathic pain
1464788|NCT00115089|Allergic Rhinitis
1464789|NCT00115089|Nasal Spray
1464790|NCT00115089|Seasonal Allergic Rhinitis
1464791|NCT00115076|skin
1464792|NCT00115076|psoriasis
1464793|NCT00115063|obesity
1464794|NCT00115063|Low Calorie Diet
1464795|NCT00115063|Obesity Pharmacotherapy
1464796|NCT00115063|Pragmatic Clinical Trial
1464797|NCT00115050|HIV infections
1464798|NCT00115050|Antiretroviral
1464799|NCT00115050|TMC114
1464800|NCT00115050|Ritonavir
1464801|NCT00115050|Safety, TMC114-C209
1464802|NCT00115037|Alcoholism
1464803|NCT00115037|alcohol abuse
1464804|NCT00115037|therapy
1464805|NCT00115037|drug resistance
1464806|NCT00115037|naltrexone
1464807|NCT00115037|patient care management
1464808|NCT00115037|human subject
1464809|NCT00115024|cardiovascular disease
1464810|NCT00115024|CVD
1464811|NCT00115024|estrogen
1464812|NCT00115024|cholesterol
1464813|NCT00115024|LDL
1464814|NCT00115024|lipids
1464815|NCT00115024|postmenopausal
1464816|NCT00115011|Skin Picking
1464817|NCT00115011|Escitalopram
1464818|NCT00115011|Lexapro
1464819|NCT00115011|Body Focused Repetitive Behaviors
1464820|NCT00115011|Obsessive Compulsive Spectrum Disorders
1464821|NCT00114985|Total Androgen Suppression
1464822|NCT00114985|Simulation
1464823|NCT00114985|3-D Conformal External Beam Radiation Therapy
1464824|NCT00114985|Intra-rectal immobilization device
1464825|NCT00114985|Quality of Life Assessment Questionnaire
1464826|NCT00114985|Rectal Bleeding
1464827|NCT00114985|Late effects
1464828|NCT00114972|Three-vessel coronary artery disease
1464829|NCT00114972|Left main coronary artery disease
1464830|NCT00114959|ChemGenex Pharmaceuticals, Ltd
1464831|NCT00114959|ChemGenex Pharmaceuticals
1464832|NCT00114959|ChemGenex
1464833|NCT00114959|Chronic Myeloid Leukemia
1464834|NCT00114959|Myeloid Leukemia, Chronic
1464835|NCT00114959|Leukemia
1464836|NCT00114959|Myeloid Leukemia
1464837|NCT00114959|Chronic Phase
1464838|NCT00114959|Accelerated Phase
1464839|NCT00114959|Blast Phase
1464840|NCT00114959|Myeloid, Leukemia, Chronic, Accelerated Phase
1464841|NCT00114959|Myeloid, Leukemia, Chronic
1464842|NCT00114959|Leukemia, Myeloid, Chronic
1464843|NCT00114959|Leukemia, Myeloid, Chronic-Phase
1464844|NCT00114959|Leukemia, Myeloid, Chronic Phase
1464845|NCT00114959|Leukemia, Myeloid, Accelerated-Phase
1464846|NCT00114959|Myeloid, Leukemia, Chronic, Chronic Phase
1464847|NCT00114959|Leukemia, Myeloid, Accelerated Phase
1464848|NCT00114959|Homoharringtonine
1464849|NCT00114959|Omacetaxine
1464850|NCT00114946|Metastatic Colorectal Cancer OASIS
1464851|NCT00114933|HIV
1464852|NCT00114933|AIDS
1464853|NCT00114933|Treatment Experienced
1464854|NCT00114920|Wart(s)
1464855|NCT00114920|Adults
1464856|NCT00114920|Common Wart(s)
1464857|NCT00114907|Tea
1464858|NCT00114907|Oxidative stress markers
1464859|NCT00114907|cardiovascular disease
1464860|NCT00114907|polyphenolics
1464861|NCT00114907|double blind
1464862|NCT00114907|Ischaemic cardiac disease
1464863|NCT00114894|Jellyfish
1464864|NCT00114894|Stings
1464865|NCT00114894|Marine
1464866|NCT00114894|Envenomation
1464867|NCT00114894|Jellyfish stings
1464868|NCT00114881|Children
1464869|NCT00114881|Urban Health
1464870|NCT00114881|Pregnancy
1464871|NCT00114881|Asthma
1464872|NCT00114868|vitamin A
1464873|NCT00114868|mortality
1464874|NCT00114868|newborn
1464875|NCT00114868|liveborn infants
1464876|NCT00114855|Hypocol
1464877|NCT00114855|Red yeast rice
1464878|NCT00114855|Patients with mild Type IIa, Type IIb or IV hyperlipidaemia (LDL-cholesterol >3.0 mmol/L< 6.0 mmol/L.
1464879|NCT00114855|Mildly elevated blood glucose
1464880|NCT00114842|colorectal polyps
1464881|NCT00114842|colorectal cancer
1464882|NCT00114842|Virtual colonoscopy
1464883|NCT00114842|Fecal tagging
1464884|NCT00114842|MR colonography
1464885|NCT00114829|Colorectal cancer
1464886|NCT00114829|Colorectal tumor
1464887|NCT00114829|Dynamic contrast uptake
1464888|NCT00114829|MR colonography
1464889|NCT00114816|breast cancer
1464890|NCT00114816|chemotherapy
1464891|NCT00114816|adjuvant
1464892|NCT00114816|capecitabine
1464893|NCT00114816|docetaxel
1464894|NCT00114803|bone mineral density
1464895|NCT00114803|osteoporosis
1464896|NCT00114803|osteopenia
1464897|NCT00114803|children
1464898|NCT00114803|adolescents
1464899|NCT00114803|DXA
1464900|NCT00114790|head and neck cancer
1464901|NCT00114790|boron neutron capture therapy
1464902|NCT00114790|radiation therapy
1464903|NCT00114790|boronophenylalanine
1464904|NCT00114764|Acute myeloid leukaemia
1464905|NCT00114764|Pegfilgrastim
1464906|NCT00114764|Neulasta®
1464907|NCT00114764|Neutropenia
1464908|NCT00114764|Induction chemotherapy
1464909|NCT00114764|Consolidation
1464910|NCT00114738|Proteasome Inhibition
1464911|NCT00114738|NF-Kappa-B
1464912|NCT00114738|Gene Expression Signature
1464913|NCT00114738|Cyclin D1
1464914|NCT00114738|Translational Studies
1464915|NCT00114738|Lymphoma
1464916|NCT00114738|Mantle Cell Lymphoma
1464917|NCT00114738|MCL
1464918|NCT00114725|In Vitro Fertilization
1464919|NCT00114725|Intracytoplasmic Sperm Injection
1464920|NCT00114725|Oocytes
1464921|NCT00114725|Zona Pellucida
1464922|NCT00114725|Oolemma
1464923|NCT00114725|Fertilization
1464924|NCT00114725|Preimplantation Embryo Development
1464925|NCT00114712|Birth Defects
1464926|NCT00114712|Pregnancy
1464927|NCT00114712|Ribavirin
1464928|NCT00114712|Hepatitis C
1464929|NCT00114699|HIV
1464930|NCT00114699|Treatment Naive
1464931|NCT00114686|Bipolar I Disorder
1464932|NCT00114686|Alcohol Dependency
1464933|NCT00114673|Uneven skin color
1464934|NCT00114673|Wrinkles
1464935|NCT00114673|Wrinkles and uneven skin color in the area around the eyes
1464936|NCT00114660|striae gravidarum
1464937|NCT00114660|stretch marks
1464938|NCT00114660|cocoa butter
1464939|NCT00114660|prevention
1464940|NCT00114647|Plasmapheresis
1464941|NCT00114647|Leukapheresis
1464942|NCT00114647|Lymphocytes
1464943|NCT00114647|Apheresis
1464944|NCT00114634|SLOS
1464945|NCT00114634|RSH syndrome
1464946|NCT00114634|ABC Checklist
1464947|NCT00114634|Cholesterol supplementation
1464948|NCT00114634|Egg yolk
1464949|NCT00114634|Smith-Lemli-Opitz Syndrome
1464950|NCT00114621|PA
1464951|NCT00114621|Phase I
1464952|NCT00114621|Phase 2
1464953|NCT00114621|Safety
1464954|NCT00114621|Immunogenicity
1464955|NCT00114608|Electrical foot stimulation
1464956|NCT00114608|Intermittent pneumatic compression
1464957|NCT00114608|Venous thromboembolism
1464958|NCT00114608|Immobilization
1464959|NCT00114608|Total hip replacement
1464960|NCT00114608|Prolonged travel
1464961|NCT00114608|Venous thromboembolic disease (VTE)
1464962|NCT00114608|Deep vein thrombosis (DVT)
1464963|NCT00114608|Pulmonary embolism (PE)
1464964|NCT00114595|eicosapentaenoic acid
1464965|NCT00114595|tardive dyskinesia
1464966|NCT00114595|omega-3
1464967|NCT00114595|schizophrenia
1464968|NCT00114582|family style dinner
1464969|NCT00114582|quality of life
1464970|NCT00114582|nutritional status
1464971|NCT00114582|nursing home residents
1464972|NCT00114569|children
1464973|NCT00114569|status epilepticus
1464974|NCT00114569|lorazepam
1464975|NCT00114569|safety
1464976|NCT00114569|pharmacokinetics
1464977|NCT00114569|status epilepticus in children
1464978|NCT00114556|osteoporosis
1464979|NCT00114556|liver transplantation
1464980|NCT00114543|NICHD Neonatal Research Network
1464981|NCT00114543|Bilirubin
1464982|NCT00114543|Phototherapy
1464983|NCT00114543|Very Low Birth Weight (VLBW)
1464984|NCT00114543|Extremely Low Birth Weight (ELBW)
1464985|NCT00114543|Prematurity
1464986|NCT00114543|Neurodevelopmental outcome
1464987|NCT00114530|autoimmune disease
1464988|NCT00114517|atherosclerosis
1464989|NCT00114517|CAD
1464990|NCT00114517|cardiac computed tomography
1464991|NCT00114517|cardiovascular disease
1464992|NCT00114517|carotid artery intima-media thickness
1464993|NCT00114517|cognitive function
1464994|NCT00114517|computed tomography
1464995|NCT00114517|coronary artery calcium
1464996|NCT00114517|coronary artery disease
1464997|NCT00114517|coronary artery lesions
1464998|NCT00114517|CVD
1464999|NCT00114517|estrogen
1465000|NCT00114517|estrogen therapy
1465001|NCT00114517|hormone therapy
1465002|NCT00114517|postmenopausal
1465003|NCT00114517|subclinical vascular disease
1465004|NCT00114517|timing hypothesis
1465005|NCT00114517|ultrasonography
1465006|NCT00114504|atherosclerosis
1465007|NCT00114504|inflammation
1465008|NCT00114504|statins
1465009|NCT00114504|PET
1465010|NCT00114504|carotid ultrasonography
1465011|NCT00114491|Aortic Stenosis
1465012|NCT00114491|Statins
1465013|NCT00114491|Hypercholesterolemia
1465014|NCT00114478|Bronchiolitis
1465015|NCT00114478|disposition
1465016|NCT00114478|pediatric
1465017|NCT00114478|epinephrine
1465018|NCT00114478|albuterol
1465019|NCT00114465|Randomized
1465020|NCT00114465|Double-Blind
1465021|NCT00114465|Probiotic
1465022|NCT00114465|Remission
1465023|NCT00114465|Crohn's Disease
1465024|NCT00114452|Acute Myocardial Infarction
1465025|NCT00114452|Heart Attack
1465026|NCT00114452|Cardiovascular Disease
1465027|NCT00114452|Stem cells
1465028|NCT00114452|Congestive Heart Failure
1465029|NCT00114452|Heart Attack Repair
1465030|NCT00114439|cannabis withdrawal
1465031|NCT00114439|lithium
1465032|NCT00114439|Cannabis withdrawal syndrome
1465033|NCT00114426|randomized controlled trial; COPD
1465034|NCT00114413|Exhaled Nitric Oxide
1465035|NCT00114413|Lung
1465036|NCT00114413|Urban Health
1465037|NCT00114413|Child
1465038|NCT00114413|Adolescent
1465039|NCT00114400|cardiovascular disease
1465040|NCT00114400|CVD
1465041|NCT00114387|vitamin E
1465042|NCT00114374|Acute Stress Disorder
1465150|NCT00114049|Cox-2 inhibitor
1465043|NCT00114374|Posttraumatic Stress Disorder
1465044|NCT00114374|Escitalopram
1465045|NCT00114374|Double-Blind
1465046|NCT00114361|HBeAg-negative
1465047|NCT00114361|chronic
1465048|NCT00114361|hepatitis B
1465049|NCT00114361|viral
1465050|NCT00114348|non-B ALL
1465051|NCT00114348|relapse
1465052|NCT00114348|treatment
1465053|NCT00114348|Relapsed non-B ALL or non-B non-Hodgkin lymphoma
1465054|NCT00114335|low molecular weight heparin
1465055|NCT00114335|unfractionated heparin
1465056|NCT00114309|High grade recurrent glioma
1465057|NCT00114309|Phase II
1465058|NCT00114309|Multi-Center
1465059|NCT00114309|Open label
1465060|NCT00114309|Multiple dose
1465061|NCT00114309|Brain Cancer
1465062|NCT00114309|Brain Tumor
1465063|NCT00114309|GBM
1465064|NCT00114309|glioma
1465065|NCT00114296|breast cancer
1465066|NCT00114270|breast cancer
1465067|NCT00114270|osteoporosis
1465068|NCT00114257|recurrent adult acute lymphoblastic leukemia
1465069|NCT00114257|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1465070|NCT00114257|adult acute myeloid leukemia with inv(16)(p13;q22)
1465071|NCT00114257|adult acute myeloid leukemia with t(15;17)(q22;q12)
1465072|NCT00114257|adult acute myeloid leukemia with t(16;16)(p13;q22)
1465073|NCT00114257|adult acute myeloid leukemia with t(8;21)(q22;q22)
1465074|NCT00114257|recurrent adult acute myeloid leukemia
1465075|NCT00114257|secondary acute myeloid leukemia
1465076|NCT00114257|untreated adult acute myeloid leukemia
1465077|NCT00114257|adult acute promyelocytic leukemia (M3)
1465078|NCT00114257|relapsing chronic myelogenous leukemia
1465079|NCT00114257|refractory chronic lymphocytic leukemia
1465080|NCT00114257|de novo myelodysplastic syndromes
1465081|NCT00114257|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1465082|NCT00114257|previously treated myelodysplastic syndromes
1465083|NCT00114257|secondary myelodysplastic syndromes
1465084|NCT00114257|atypical chronic myeloid leukemia, BCR-ABL1 negative
1465085|NCT00114257|chronic myelomonocytic leukemia
1465086|NCT00114257|chronic eosinophilic leukemia
1465087|NCT00114257|primary myelofibrosis
1465088|NCT00114257|chronic neutrophilic leukemia
1465089|NCT00114257|essential thrombocythemia
1465090|NCT00114257|polycythemia vera
1465091|NCT00114257|Philadelphia chromosome negative chronic myelogenous leukemia
1465092|NCT00114257|chronic myelogenous leukemia, BCR-ABL1 positive
1465093|NCT00114257|adult acute minimally differentiated myeloid leukemia (M0)
1465094|NCT00114257|adult acute myeloblastic leukemia without maturation (M1)
1465095|NCT00114257|adult acute myeloblastic leukemia with maturation (M2)
1465096|NCT00114257|adult acute myelomonocytic leukemia (M4)
1465097|NCT00114257|adult acute monoblastic leukemia (M5a)
1465098|NCT00114257|adult acute monocytic leukemia (M5b)
1465099|NCT00114257|adult erythroleukemia (M6a)
1465100|NCT00114257|adult pure erythroid leukemia (M6b)
1465101|NCT00114257|adult acute megakaryoblastic leukemia (M7)
1465102|NCT00114257|adult acute basophilic leukemia
1465103|NCT00114257|adult acute eosinophilic leukemia
1465104|NCT00114231|adenocarcinoma of the rectum
1465105|NCT00114231|stage I rectal cancer
1465106|NCT00114205|malignant pleural effusion
1465107|NCT00114192|recurrent non-small cell lung cancer
1465108|NCT00114192|stage IIIA non-small cell lung cancer
1465109|NCT00114192|stage IIIB non-small cell lung cancer
1465110|NCT00114192|stage IV non-small cell lung cancer
1465111|NCT00114166|recurrent ovarian epithelial cancer
1465112|NCT00114166|fallopian tube cancer
1465113|NCT00114166|primary peritoneal cavity cancer
1465114|NCT00114153|stage III squamous cell carcinoma of the hypopharynx
1465115|NCT00114153|stage III squamous cell carcinoma of the lip and oral cavity
1465116|NCT00114153|stage III squamous cell carcinoma of the oropharynx
1465117|NCT00114153|stage IV squamous cell carcinoma of the hypopharynx
1465118|NCT00114153|stage IV squamous cell carcinoma of the lip and oral cavity
1465119|NCT00114153|stage IV squamous cell carcinoma of the oropharynx
1465120|NCT00114140|adult diffuse astrocytoma
1465121|NCT00114140|adult oligodendroglioma
1465122|NCT00114140|adult mixed glioma
1465123|NCT00114127|social anxiety disorder
1465124|NCT00114127|social phobia
1465125|NCT00114127|duloxetine
1465126|NCT00114127|serotonin norepinephrine reuptake inhibitor
1465127|NCT00114127|SNRI
1465128|NCT00114127|double blind
1465129|NCT00114114|Testosterone
1465130|NCT00114114|Bone turnover
1465131|NCT00114114|Aging
1465132|NCT00114114|Body composition
1465133|NCT00114114|Hypogonadism
1465134|NCT00114114|Sexual function
1465135|NCT00114088|Hysterectomy,
1465136|NCT00114088|Endometrial ablation,
1465137|NCT00114088|Ovulatory dysfunctional uterine bleeding,
1465138|NCT00114088|Anovulatory dysfucntional uterine bleeding,
1465139|NCT00114088|DUB
1465140|NCT00114088|Dysfunctional uterine bleeding
1465141|NCT00114075|gait
1465142|NCT00114075|walking
1465143|NCT00114075|orthopedic surgery
1465144|NCT00114075|orthopaedic surgery
1465145|NCT00114062|uveitis
1465146|NCT00114062|macular edema
1465147|NCT00114062|uveitis associated macular edema
1465148|NCT00114049|Dental Pain
1465149|NCT00114049|Dental Surgery
1465151|NCT00114036|Antibiotic prophylaxis
1465152|NCT00114036|Surgical wound infections
1465153|NCT00114023|AK
1465154|NCT00114023|Imiquimod 5% cream
1465155|NCT00114023|3M Pharmaceuticals
1465156|NCT00114023|Aldara
1465157|NCT00114023|Actinic Keratosis
1465158|NCT00114010|B Cells
1465159|NCT00114010|T Cells
1465160|NCT00114010|Erythrocyte Stage
1465161|NCT00114010|Antibody
1465162|NCT00114010|Immunogenicity
1465163|NCT00114010|Healthy Volunteer
1465164|NCT00113997|Anticoagulant
1465165|NCT00113997|Antidote
1465166|NCT00113997|Pharmacokinetics
1465167|NCT00113997|Pharmacodynamics
1465168|NCT00113997|Healthy Volunteer
1465169|NCT00113997|HV
1465170|NCT00113984|Monoclonal Antibody
1465171|NCT00113984|Vaccine
1465172|NCT00113984|Cytokines
1465173|NCT00113984|Immunotherapy
1465174|NCT00113984|Elispot Assay
1465175|NCT00113984|Prostate Cancer
1465176|NCT00113984|Metastatic Prostate Cancer
1465177|NCT00113971|study of epratuzumab in systemic lupus erythematosus
1465178|NCT00113971|systemic lupus erythematosus
1465179|NCT00113971|SLE
1465180|NCT00113958|End Stage Renal Disease (ESRD)
1465181|NCT00113958|secondary hyperparathyroidism (SHPT)
1465182|NCT00113958|hemodialysis
1465183|NCT00113958|biPTH
1465184|NCT00113958|AMG 073, Amgen
1465185|NCT00113945|End Stage Renal Disease (ESRD)
1465186|NCT00113945|secondary hyperparathyroidism
1465187|NCT00113945|hemodialysis, biPTH
1465188|NCT00113945|AMG 073, Amgen
1465189|NCT00113932|Myeloma
1465190|NCT00113919|Myeloma, MM
1465191|NCT00113906|melatonin,
1465192|NCT00113906|fatigue,
1465193|NCT00113906|sleep quality,
1465194|NCT00113906|circadian,
1465195|NCT00113906|postoperative
1465196|NCT00113906|Postoperative fatigue
1465197|NCT00113906|postoperative sleep disturbance
1465198|NCT00113906|general wellbeing
1465199|NCT00113893|Myelodysplastic syndromes
1465200|NCT00113893|p38 MAP kinase
1465201|NCT00113893|Bone marrow diseases
1465202|NCT00113893|SCIO-469
1465203|NCT00113867|IVF
1465204|NCT00113867|in vitro fertilization
1465205|NCT00113867|hormones
1465206|NCT00113867|stress
1465207|NCT00113867|memory
1465208|NCT00113867|Cognitive Function
1465209|NCT00113867|adoption
1465210|NCT00113854|cerebral
1465211|NCT00113854|malaria
1465212|NCT00113854|children
1465213|NCT00113854|mannitol
1465214|NCT00113854|adjunct
1465215|NCT00113854|therapy
1465216|NCT00113854|Uganda
1465217|NCT00113841|Multiple Myeloma
1465218|NCT00113841|Diferuloylmethane Derivative
1465219|NCT00113841|Curcumin
1465220|NCT00113841|Bioperine
1465221|NCT00113828|Non-Myeloablative
1465222|NCT00113828|Stem Cell Transplantation
1465223|NCT00113828|T-cell Depletion
1465224|NCT00113828|HLA-Matched
1465225|NCT00113815|Partial seizure disorder
1465226|NCT00113815|Topiramate
1465227|NCT00113815|Epilepsy
1465228|NCT00113815|Infants
1465229|NCT00113802|Epratuzumab (hLL2- anti-CD22 humanized antibody)
1465230|NCT00113802|Waldenstrom's Macroglobulinemia
1465231|NCT00113802|Waldenstrom Macroglobulinemia
1465232|NCT00113802|Hematologic Disease
1465233|NCT00113802|Hematologic Diseases
1465234|NCT00113802|Paraproteinemias
1465235|NCT00113802|Vascular Hemostatic Disorders
1465236|NCT00113802|Lymphoproliferative Disorders
1465237|NCT00113789|ovarian cancer
1465238|NCT00113789|topotecan
1465239|NCT00113789|neutropenia
1465240|NCT00113789|Neulasta®
1465241|NCT00113776|Metastatic Colorectal Cancer, Colon
1465242|NCT00113776|Colorectal, Rectal Cancer, EGFr
1465243|NCT00113776|Metastatic, Cancer, ABX-EGF
1465244|NCT00113776|Panitumumab, Clinical Trial
1465245|NCT00113776|Immunex, Abgenix, Amgen
1465246|NCT00113763|Metastatic Colorectal Cancer, Colon
1465247|NCT00113763|Colorectal, Rectal Cancer, Cancer
1465248|NCT00113763|Metastatic, EGFr, Clinical Trial
1465249|NCT00113763|Panitumumab, ABX-EGF
1465250|NCT00113763|Immunex, Abgenix, Amgen
1465251|NCT00113750|Allergy
1465252|NCT00113750|Allergoid
1465253|NCT00113750|Specific Immunotherapy
1465254|NCT00113724|taxane
1465255|NCT00113724|multi-drug resistance
1465256|NCT00113724|mutant tubulin binding
1465257|NCT00113724|Advanced malignancies
1465258|NCT00113724|Hodgkin's or Non-Hodgkin's Lymphoma
1465259|NCT00113659|Asthma
1465260|NCT00113659|Probiotics
1465261|NCT00113659|Prevention
1465262|NCT00113659|Eczema
1465263|NCT00113646|Non-Myeloablative
1465264|NCT00113646|T-cell Depleted
1465265|NCT00113646|Mismatched
1465266|NCT00113646|Stem Cell Transplantation
1465267|NCT00113633|Asthma
1465268|NCT00113633|Emergency
1465269|NCT00113633|Primary Care
1465270|NCT00113633|Children
1465271|NCT00113620|distal symmetrical
1465272|NCT00113620|pain
1465273|NCT00113620|lower extremities
1465274|NCT00113620|dextromethorphan
1465275|NCT00113607|Ovarian cancer
1465276|NCT00113607|Trabectedin
1465277|NCT00113607|Yondelis
1465278|NCT00113607|Advanced Relapsed Ovarian Cancer
1465279|NCT00113607|DOXIL
1465280|NCT00113607|CAELYX
1465281|NCT00113581|EMD 72000
1465282|NCT00113581|matuzumab
1465283|NCT00113581|Esophageal adenocarcinoma
1465284|NCT00113581|Gastric adenocarcinoma
1465285|NCT00113568|Menorrhagia
1465286|NCT00113568|Heavy Menstrual Bleeding
1465287|NCT00113555|urinary incontinence
1465288|NCT00113542|Psoriasis
1465289|NCT00113542|Tetrathiomolybdate
1465290|NCT00113516|Lung Neoplasms
1465291|NCT00113503|Inflammatory Bowel Disease, Crohn's disease, Crohn's Colitis
1465292|NCT00113490|motavizumab, palivizumab, synagis
1465293|NCT00113490|Rezield, MEDI-524
1465294|NCT00113477|Q10
1465295|NCT00113477|CoQ10
1465296|NCT00113477|Coenzyme Q10
1465297|NCT00113477|selen
1465298|NCT00113477|selenoprotein
1465299|NCT00113477|selenoproteins
1465300|NCT00113477|adverse events
1465301|NCT00113477|adverse effects
1465302|NCT00113477|AE
1465303|NCT00113477|myalgia
1465304|NCT00113477|muscle
1465305|NCT00113477|statin therapy
1465306|NCT00113477|Indication for statin therapy
1465307|NCT00113464|SCID (Severe Combined Immunodeficiency)
1465308|NCT00113464|TREC (T cell Receptor Excision Circle)
1465309|NCT00113464|Bone Marrow Transplant
1465310|NCT00113464|Dried Blood Spots
1465311|NCT00113464|Early Detection
1465312|NCT00113464|T Cell Immunodeficiency Diseases
1465313|NCT00113464|Immunodeficiency Diseases
1465314|NCT00113464|Primary Immunodeficiency
1465315|NCT00113464|T Cell Immunodeficiency Disease
1465316|NCT00113464|Severe Combined Immunodeficiency
1465317|NCT00113464|SCID
1465318|NCT00113451|radial artery
1465319|NCT00113451|angina pectoris
1465320|NCT00113451|infarction
1465321|NCT00113451|bypass
1465322|NCT00113451|angiography
1465323|NCT00113438|cancer
1465324|NCT00113438|tumor
1465325|NCT00113438|imageable
1465326|NCT00113438|CA4P
1465327|NCT00113438|Combretastatin
1465328|NCT00113438|Combretastatin A4 Phosphate
1465329|NCT00113438|Combretastatin A-4 Phosphate
1465330|NCT00113438|Carboplatin
1465331|NCT00113438|Paclitaxel
1465332|NCT00113438|carbo
1465333|NCT00113438|taxol
1465334|NCT00113425|non-ablative laser
1465335|NCT00113425|acne
1465336|NCT00113425|photosensitizer
1465337|NCT00113425|photodynamic therapy
1465338|NCT00113412|HIV
1465339|NCT00113412|Treatment Experienced
1465340|NCT00113399|recurrent squamous cell carcinoma of the hypopharynx
1465341|NCT00113399|recurrent squamous cell carcinoma of the larynx
1465342|NCT00113399|recurrent squamous cell carcinoma of the lip and oral cavity
1465343|NCT00113399|recurrent squamous cell carcinoma of the oropharynx
1465344|NCT00113399|recurrent metastatic squamous neck cancer with occult primary
1465345|NCT00113399|recurrent lymphoepithelioma of the oropharynx
1465346|NCT00113386|stage IIIA non-small cell lung cancer
1465347|NCT00113386|adenocarcinoma of the lung
1465348|NCT00113386|large cell lung cancer
1465349|NCT00113386|squamous cell lung cancer
1465350|NCT00113386|bronchoalveolar cell lung cancer
1465351|NCT00113360|Neuroendocrine Carcinoma
1465352|NCT00113360|Low Grade Neuroendocrine Carcinoma
1465353|NCT00113360|Neuroendocrine Carcinoid
1465354|NCT00113360|Islet Cell Carcinoma
1465355|NCT00113360|RAD001
1465356|NCT00113360|Everolimus
1465357|NCT00113360|Octreotide Depot
1465358|NCT00113360|Sandostatin LAR
1465359|NCT00113360|Octreotide long-acting release (LAR)
1465360|NCT00113360|Octreotide LAR
1465361|NCT00113347|Head and Neck Cancer
1465362|NCT00113347|Squamous Cell Carcinoma
1465363|NCT00113347|Erlotinib
1465364|NCT00113347|Docetaxel
1465365|NCT00113347|Radiation
1465366|NCT00113347|Radiotherapy
1465367|NCT00113347|Concomitant Boost Radiation
1465368|NCT00113334|Head and Neck Cancer
1465369|NCT00113334|Thrombospondin Analogue
1465370|NCT00113334|ABT-510
1465371|NCT00113334|Antiangiogenic agent
1465372|NCT00113334|Lung
1465373|NCT00113334|Skin
1465374|NCT00113334|Thyroid
1465375|NCT00113321|Myelodysplastic Syndrome
1465376|NCT00113321|Chronic Myelomonocytic Leukemia
1465377|NCT00113321|Azacytidine Failure
1465378|NCT00113321|Decitabine
1465379|NCT00113308|Rheumatoid Arthritis
1465380|NCT00113308|COX-2 Inhibitor
1465381|NCT00113295|generalized anxiety disorder
1465382|NCT00113295|pharmacotherapy
1465383|NCT00113295|treatment refractory
1465384|NCT00113295|double-blind
1465385|NCT00113282|Treatment failure
1465386|NCT00113282|Acquired Immunodeficiency Syndrome
1465387|NCT00113282|Interleukin-2
1465388|NCT00113282|Treatment Experienced
1465389|NCT00113269|Treatment Effectiveness
1465390|NCT00113269|Treatment Efficacy
1465391|NCT00113269|Anti-rejection therapy
1465392|NCT00113269|Immunosuppression
1465393|NCT00113269|Therapy, antirejection
1465394|NCT00113269|Renal Transplantation
1465395|NCT00113269|Transplantation, Kidney
1465396|NCT00113269|Transplantation, Renal
1465397|NCT00113269|Grafting, Kidney
1465398|NCT00113256|rubitecan
1465399|NCT00113256|Orathecin
1465400|NCT00113256|9-nitrocamptothecin
1465401|NCT00113256|gemcitabine
1465402|NCT00113256|Gemzar
1465403|NCT00113256|pancreatic cancer
1465404|NCT00113256|adenocarcinoma
1465405|NCT00113256|RFS 2000
1465406|NCT00113230|Rectal Cancer
1465407|NCT00113230|Bevacizumab
1465408|NCT00113230|RHUMAB VEGF
1465409|NCT00113230|Avastin
1465410|NCT00113230|Capecitabine
1465411|NCT00113230|Neoadjuvant Concurrent Capecitabine
1465412|NCT00113230|Xeloda
1465413|NCT00113230|Radiation
1465414|NCT00113230|Radiotherapy
1465415|NCT00113230|Radiation Therapy
1465416|NCT00113230|XRT
1465417|NCT00113217|Renal Cell Carcinoma
1465418|NCT00113217|Kidney Cancer
1465419|NCT00113217|Bevacizumab
1465420|NCT00113217|Avastin
1465421|NCT00113217|RCC
1465422|NCT00113204|Multiple myeloma
1465423|NCT00113204|Relapsed
1465424|NCT00113204|Relapsed refractory
1465425|NCT00113204|Hematologic cancer
1465426|NCT00113204|hematologic disease
1465427|NCT00113204|plasma cells
1465428|NCT00113191|late onset sepsis
1465429|NCT00113191|premature infants
1465430|NCT00113191|staphylococcus
1465431|NCT00113191|candida
1465432|NCT00113191|prevention
1465433|NCT00113178|atrial flutter
1465434|NCT00113178|cryoablation
1465435|NCT00113165|partial seizures
1465436|NCT00113165|Epilepsy
1465437|NCT00113165|antiepileptic drugs
1465438|NCT00113165|anticonvulsants
1465439|NCT00113165|LAMICTAL
1465440|NCT00113165|seizures
1465441|NCT00113165|lamotrigine
1465442|NCT00113152|Cardiac Arrhythmias
1465443|NCT00113152|Diastolic Dysfunction
1465444|NCT00113152|Pulmonary Hypertension
1465445|NCT00113152|Sickle Cell Anemia
1465446|NCT00113152|Sudden Death
1465447|NCT00113152|Thalassemia
1465448|NCT00113126|Scheduled treatment interruptions
1465449|NCT00113126|STI
1465450|NCT00113113|rubitecan
1465451|NCT00113113|Orathecin
1465452|NCT00113113|9-nitrocamptothecin
1465453|NCT00113113|solid tumors
1465454|NCT00113113|organ dysfunction
1465455|NCT00113113|renal dysfunction
1465456|NCT00113113|hepatic dysfunction
1465457|NCT00113113|RFS 2000
1465458|NCT00113100|skin
1465459|NCT00113100|estrogen
1465460|NCT00113100|sun damage
1465461|NCT00113100|Photodamaged Skin
1465462|NCT00113061|Coronary Heart Disease Risk Reduction
1465463|NCT00113048|CD52 Expressing Hematologic Malignancies
1465464|NCT00113035|Glycogen Storage Disease Type II
1465465|NCT00113035|GSD-II
1465466|NCT00113035|Pompe Disease
1465467|NCT00113035|Pompe Disease (Late-Onset)
1465468|NCT00113035|Glycogen Storage Disease Type II (GSD-II)
1465469|NCT00113035|Acid Maltase Deficiency
1465470|NCT00113035|Glycogenosis 2
1465471|NCT00113022|Depression
1465472|NCT00113022|Glutamate
1465473|NCT00113022|Ampakine
1465474|NCT00113022|Treatment
1465475|NCT00113022|Memory
1465476|NCT00113022|Major Depressive Disorder
1465477|NCT00113022|AMPA Receptor Activation
1465478|NCT00113022|BDNF
1465479|NCT00113009|Peripheral arterial disease
1465480|NCT00112996|neurotoxicity
1465481|NCT00112996|unspecified adult solid tumor, protocol specific
1465482|NCT00112996|unspecified childhood solid tumor, protocol specific
1465483|NCT00112983|adult acute lymphoblastic leukemia
1465484|NCT00112983|adult acute myeloid leukemia
1465485|NCT00112957|fallopian tube cancer
1465486|NCT00112957|stage II ovarian epithelial cancer
1465487|NCT00112957|stage III ovarian epithelial cancer
1465488|NCT00112957|stage IV ovarian epithelial cancer
1465489|NCT00112957|peritoneal cavity cancer
1465490|NCT00112931|stage III grade 1 follicular lymphoma
1465491|NCT00112931|stage III grade 2 follicular lymphoma
1465492|NCT00112931|stage III grade 3 follicular lymphoma
1465493|NCT00112931|stage IV grade 1 follicular lymphoma
1465494|NCT00112931|stage IV grade 2 follicular lymphoma
1465495|NCT00112931|stage IV grade 3 follicular lymphoma
1465496|NCT00112931|noncontiguous stage II grade 1 follicular lymphoma
1465497|NCT00112931|noncontiguous stage II grade 2 follicular lymphoma
1465498|NCT00112931|noncontiguous stage II grade 3 follicular lymphoma
1465499|NCT00112931|contiguous stage II grade 1 follicular lymphoma
1465500|NCT00112931|contiguous stage II grade 2 follicular lymphoma
1465501|NCT00112931|contiguous stage II grade 3 follicular lymphoma
1465502|NCT00112918|stage II colon cancer
1465503|NCT00112918|stage III colon cancer
1465504|NCT00112892|unspecified adult solid tumor, protocol specific
1465505|NCT00112775|chronic phase chronic myelogenous leukemia
1465506|NCT00112775|chronic myelogenous leukemia, BCR-ABL1 positive
1465507|NCT00112775|relapsing chronic myelogenous leukemia
1465508|NCT00112749|stage I breast cancer
1465509|NCT00112749|stage II breast cancer
1465510|NCT00112749|breast cancer in situ
1465511|NCT00112749|fatigue
1465512|NCT00112710|stage IIIB non-small cell lung cancer
1465513|NCT00112710|stage IV non-small cell lung cancer
1465514|NCT00112697|adenocarcinoma of the pancreas
1465515|NCT00112697|stage IV pancreatic cancer
1465516|NCT00112658|adenocarcinoma of the pancreas
1465517|NCT00112658|stage IV pancreatic cancer
1465518|NCT00112645|unspecified childhood solid tumor, protocol specific
1465519|NCT00112645|recurrent neuroblastoma
1465612|NCT00112515|depression
1465520|NCT00112645|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1465521|NCT00112645|recurrent childhood rhabdomyosarcoma
1465522|NCT00112632|gastrointestinal stromal tumor
1465523|NCT00112619|AIDS-related diffuse large cell lymphoma
1465524|NCT00112619|AIDS-related diffuse mixed cell lymphoma
1465525|NCT00112619|AIDS-related diffuse small cleaved cell lymphoma
1465526|NCT00112619|AIDS-related immunoblastic large cell lymphoma
1465527|NCT00112619|AIDS-related lymphoblastic lymphoma
1465528|NCT00112619|AIDS-related peripheral/systemic lymphoma
1465529|NCT00112619|AIDS-related primary CNS lymphoma
1465530|NCT00112619|AIDS-related small noncleaved cell lymphoma
1465531|NCT00112619|HIV-associated Hodgkin lymphoma
1465532|NCT00112619|stage IV childhood Hodgkin lymphoma
1465533|NCT00112619|stage IV childhood large cell lymphoma
1465534|NCT00112619|stage IV childhood lymphoblastic lymphoma
1465535|NCT00112619|stage IV childhood small noncleaved cell lymphoma
1465536|NCT00112619|primary central nervous system non-Hodgkin lymphoma
1465537|NCT00112619|primary central nervous system Hodgkin lymphoma
1465538|NCT00112619|recurrent childhood acute lymphoblastic leukemia
1465539|NCT00112619|recurrent childhood acute myeloid leukemia
1465540|NCT00112619|unspecified childhood solid tumor, protocol specific
1465541|NCT00112619|childhood grade I meningioma
1465542|NCT00112619|childhood grade II meningioma
1465543|NCT00112619|childhood grade III meningioma
1465544|NCT00112619|recurrent childhood cerebellar astrocytoma
1465545|NCT00112619|recurrent childhood cerebral astrocytoma
1465546|NCT00112619|childhood high-grade cerebral astrocytoma
1465547|NCT00112619|childhood low-grade cerebral astrocytoma
1465548|NCT00112619|childhood choroid plexus tumor
1465549|NCT00112619|childhood craniopharyngioma
1465550|NCT00112619|childhood infratentorial ependymoma
1465551|NCT00112619|childhood supratentorial ependymoma
1465552|NCT00112619|recurrent childhood ependymoma
1465553|NCT00112619|recurrent childhood medulloblastoma
1465554|NCT00112619|childhood oligodendroglioma
1465555|NCT00112619|recurrent childhood supratentorial primitive neuroectodermal tumor
1465556|NCT00112619|leptomeningeal metastases
1465557|NCT00112619|recurrent carcinoma of unknown primary
1465558|NCT00112619|childhood central nervous system germ cell tumor
1465559|NCT00112619|childhood chronic myelogenous leukemia
1465560|NCT00112619|juvenile myelomonocytic leukemia
1465561|NCT00112619|recurrent/refractory childhood Hodgkin lymphoma
1465562|NCT00112619|recurrent childhood grade III lymphomatoid granulomatosis
1465563|NCT00112619|recurrent childhood visual pathway and hypothalamic glioma
1465564|NCT00112619|childhood atypical teratoid/rhabdoid tumor
1465565|NCT00112619|recurrent childhood large cell lymphoma
1465566|NCT00112619|recurrent childhood lymphoblastic lymphoma
1465567|NCT00112619|recurrent childhood small noncleaved cell lymphoma
1465568|NCT00112619|relapsing chronic myelogenous leukemia
1465569|NCT00112619|recurrent childhood pineoblastoma
1465570|NCT00112619|recurrent childhood subependymal giant cell astrocytoma
1465571|NCT00112619|meningeal leukemia
1465572|NCT00112619|secondary central nervous system Hodgkin lymphoma
1465573|NCT00112619|secondary central nervous system non-Hodgkin lymphoma
1465574|NCT00112593|HIV
1465575|NCT00112593|Lymphoma
1465576|NCT00112593|Leukemia
1465577|NCT00112580|recurrent pancreatic cancer
1465578|NCT00112580|adenocarcinoma of the pancreas
1465579|NCT00112580|stage IV pancreatic cancer
1465580|NCT00112567|recurrent childhood acute lymphoblastic leukemia
1465581|NCT00112567|childhood myelodysplastic syndromes
1465582|NCT00112567|childhood acute lymphoblastic leukemia in remission
1465583|NCT00112567|recurrent childhood acute myeloid leukemia
1465584|NCT00112567|childhood acute myeloid leukemia in remission
1465585|NCT00112567|secondary acute myeloid leukemia
1465586|NCT00112567|accelerated phase chronic myelogenous leukemia
1465587|NCT00112567|blastic phase chronic myelogenous leukemia
1465588|NCT00112567|childhood chronic myelogenous leukemia
1465589|NCT00112567|relapsing chronic myelogenous leukemia
1465590|NCT00112567|de novo myelodysplastic syndromes
1465591|NCT00112567|secondary myelodysplastic syndromes
1465592|NCT00112567|previously treated myelodysplastic syndromes
1465593|NCT00112554|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1465594|NCT00112554|adult acute myeloid leukemia with inv(16)(p13;q22)
1465595|NCT00112554|adult acute myeloid leukemia with t(16;16)(p13;q22)
1465596|NCT00112554|adult acute myeloid leukemia with t(8;21)(q22;q22)
1465597|NCT00112554|recurrent adult acute myeloid leukemia
1465598|NCT00112554|adult acute basophilic leukemia
1465599|NCT00112554|adult acute eosinophilic leukemia
1465600|NCT00112554|adult erythroleukemia (M6a)
1465601|NCT00112554|adult pure erythroid leukemia (M6b)
1465602|NCT00112554|adult acute megakaryoblastic leukemia (M7)
1465603|NCT00112554|adult acute minimally differentiated myeloid leukemia (M0)
1465604|NCT00112554|adult acute monoblastic leukemia (M5a)
1465605|NCT00112554|adult acute monocytic leukemia (M5b)
1465606|NCT00112554|adult acute myeloblastic leukemia with maturation (M2)
1465607|NCT00112554|adult acute myeloblastic leukemia without maturation (M1)
1465608|NCT00112554|adult acute myelomonocytic leukemia (M4)
1465609|NCT00112528|duct cell adenocarcinoma of the pancreas
1465610|NCT00112528|recurrent pancreatic cancer
1465611|NCT00112528|stage IV pancreatic cancer
1465613|NCT00112515|cognitive/functional effects
1465614|NCT00112515|fatigue
1465615|NCT00112515|unspecified adult solid tumor, protocol specific
1465616|NCT00112502|adult giant cell glioblastoma
1465617|NCT00112502|adult gliosarcoma
1465618|NCT00112502|adult glioblastoma
1465619|NCT00112489|recurrent uterine sarcoma
1465620|NCT00112489|stage III uterine sarcoma
1465621|NCT00112489|stage IV uterine sarcoma
1465622|NCT00112489|uterine carcinosarcoma
1465623|NCT00112424|Superior cavo-pulmonary anastomosis
1465624|NCT00112424|Glenn operation
1465625|NCT00112424|Congenital heart defects
1465626|NCT00112424|Cardiac magnetic resonance imaging
1465627|NCT00112398|Head injuries
1465628|NCT00112398|Prehospital
1465629|NCT00112398|Advanced Interventions
1465630|NCT00112385|dermatomyositis
1465631|NCT00112385|etanercept
1465632|NCT00112385|tumor necrosis factor alpha
1465633|NCT00112372|unresectable
1465634|NCT00112372|metastatic
1465635|NCT00112372|cancer
1465636|NCT00112372|recurrent
1465637|NCT00112372|malignancies
1465638|NCT00112372|progressive
1465639|NCT00112359|Cystic Fibrosis
1465640|NCT00112359|Pseudomonas aeruginosa
1465641|NCT00112359|Pulmonary Cystic Fibrosis
1465642|NCT00112346|Non-Small Lung Cancer
1465643|NCT00112333|Dyspepsia, fMRI
1465644|NCT00112320|Pulmonary Valve Regurgitation
1465645|NCT00112320|Right Ventricular Dysfunction
1465646|NCT00112320|Heart Diseases
1465647|NCT00112307|MRI
1465648|NCT00112307|Brachytherapy
1465649|NCT00112307|Carcinoma
1465650|NCT00112307|Cervix
1465651|NCT00112307|Uterus
1465652|NCT00112307|Vagina
1465653|NCT00112307|Vulva
1465654|NCT00112307|Carcinoma of the cervix
1465655|NCT00112307|Carcinoma of the uterus
1465656|NCT00112307|Carcinoma of the vagina
1465657|NCT00112307|Carcinoma of the vulva
1465658|NCT00112294|Non-Small Cell Lung Cancer
1465659|NCT00112281|"shock, cardiogenic, myocardial infarction"
1465660|NCT00112268|randomized controlled trial
1465661|NCT00112268|primary health care
1465662|NCT00112268|smoking cessation
1465663|NCT00112255|Chlamydia trachomatis
1465664|NCT00112255|Chlamydia infections
1465665|NCT00112255|Randomized controlled trials
1465666|NCT00112255|Contact tracing
1465667|NCT00112255|Family practice
1465668|NCT00112242|Immunotherapy
1465669|NCT00112242|Vaccination
1465670|NCT00112242|Melanoma
1465671|NCT00112242|Melan-A/Mart-1 peptide
1465672|NCT00112242|MAGE-A10 peptide
1465673|NCT00112242|NY-ESO-1 peptide
1465674|NCT00112242|Montanide
1465675|NCT00112229|Immunotherapy
1465676|NCT00112229|Vaccination
1465677|NCT00112229|Melanoma
1465678|NCT00112229|Melan-A/Mart-1 peptide
1465679|NCT00112229|Tyrosinase peptide
1465680|NCT00112229|CpG
1465681|NCT00112229|Montanide
1465682|NCT00112216|Immunotherapy
1465683|NCT00112216|Vaccination
1465684|NCT00112216|Melanoma
1465685|NCT00112216|Melan-A/Mart-1 peptide
1465686|NCT00112216|Flu peptide
1465687|NCT00112216|Mage-A10 peptide
1465688|NCT00112216|SB AS-2 adjuvant
1465689|NCT00112216|Montanide adjuvant
1465690|NCT00112203|Abdominal Symptom Relief
1465691|NCT00112203|Fullness
1465692|NCT00112203|Bloating
1465693|NCT00112203|Indigestion
1465694|NCT00112203|Functional dyspepsia
1465695|NCT00112190|Functional dyspepsia
1465696|NCT00112190|Abdominal Symptom relief
1465697|NCT00112190|Fullness
1465698|NCT00112190|Bloating
1465699|NCT00112190|Indigestion
1465700|NCT00112177|Functional dyspepsia
1465701|NCT00112177|Abdominal Symptom relief
1465702|NCT00112177|Fullness
1465703|NCT00112177|Bloating
1465704|NCT00112177|Indigestion
1465705|NCT00112164|Acute Respiratory Distress Syndrome
1465706|NCT00112151|andropause
1465707|NCT00112151|hypogonadism
1465708|NCT00112151|AndroGel
1465709|NCT00112151|exercise
1465710|NCT00112151|PRT
1465711|NCT00112151|Testosterone
1465712|NCT00112151|T supplementation
1465713|NCT00112138|gabapentin
1465714|NCT00112138|hot flashes or flushes
1465715|NCT00112138|menopause
1465716|NCT00112125|cardiac contractility modulation
1465717|NCT00112125|heart failure
1465718|NCT00112125|cardiopulmonary exercise test
1465719|NCT00112125|chronic heart disease
1465720|NCT00112112|cancer, pediatric, influenza, vaccine
1465721|NCT00112099|gastric neoplasm
1465722|NCT00112099|gastrectomy
1465723|NCT00112099|splenectomy
1465724|NCT00112099|randomized trial
1465725|NCT00112099|T2, T3 and T4 carcinoma in the proximal third of the stomach
1465726|NCT00112086|ovarian neoplasms
1465727|NCT00112086|laparoscopy
1465728|NCT00112086|neoadjuvant therapy
1465729|NCT00112086|interval cytoreductive surgery
1465730|NCT00112073|Alzheimer's disease
1465731|NCT00112073|immunotherapy
1465732|NCT00112073|beta amyloid
1465733|NCT00112060|Talotrexin
1465734|NCT00112060|PT-523
1465735|NCT00112060|Non-Small Cell Lung Carcinoma (NSCLC)
1465736|NCT00112047|Human Immunodeficiency Virus
1465737|NCT00112034|Multiple Sclerosis
1465738|NCT00112034|Relapsing-Remitting
1465739|NCT00112034|AVONEX
1465740|NCT00112034|Combination
1465741|NCT00112034|Methotrexate
1465742|NCT00112034|IV Methylprednisolone
1465743|NCT00112034|IVMP
1465744|NCT00112034|ACT
1465745|NCT00112034|MTX
1465746|NCT00112021|obesity
1465747|NCT00112021|weight loss
1465748|NCT00112021|Amylin
1465749|NCT00112021|pramlintide
1465750|NCT00112021|Symlin
1465751|NCT00112008|Anemia
1465752|NCT00111995|Chronic Renal Failure (CRF)
1465753|NCT00111995|Anemia
1465754|NCT00111982|bilateral, idiopathic Parkinson's Disease
1465755|NCT00111969|Heart failure
1465756|NCT00111969|Immune modulation therapy
1465757|NCT00111969|Inflammation
1465758|NCT00111969|Chronic systolic heart failure
1465759|NCT00111956|TNF
1465760|NCT00111956|metabolic syndrome
1465761|NCT00111956|inflammation
1465762|NCT00111956|CRP
1465763|NCT00111956|adiponectin
1465764|NCT00111943|Anti-Infective Agents, Local
1465765|NCT00111943|HIV Seronegativity
1465766|NCT00111943|Tenofovir
1465767|NCT00111943|Vaginal gel
1465768|NCT00111943|Microbicide
1465769|NCT00111943|Vaginal Microbicide
1465770|NCT00111943|PMPA
1465771|NCT00111930|dehydroepiandrosterone
1465772|NCT00111930|DHEAS
1465773|NCT00111930|bone mineral density
1465774|NCT00111930|body composition
1465775|NCT00111930|lean mass
1465776|NCT00111930|fat mass
1465777|NCT00111930|bone mass
1465778|NCT00111930|decreased DHEAS levels
1465779|NCT00111917|Chronic Beryllium Disease
1465780|NCT00111917|Berylliosis
1465781|NCT00111917|Beryllium Disease
1465782|NCT00111917|CBD
1465783|NCT00111917|Infliximab
1465784|NCT00111904|stage III pancreatic cancer
1465785|NCT00111904|recurrent pancreatic cancer
1465786|NCT00111904|stage IV pancreatic cancer
1465787|NCT00111878|Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3)
1465788|NCT00111865|physical exercise
1465789|NCT00111865|quality of life
1465790|NCT00111865|lymphoma
1465791|NCT00111852|Desmoteplase
1465792|NCT00111852|Acute Ischemic Stroke
1465793|NCT00111852|Stroke, Acute
1465794|NCT00111839|Lung cancer
1465795|NCT00111826|Intermittent Claudication
1465796|NCT00111826|Peripheral Arterial Disease
1465797|NCT00111826|Immune modulation therapy
1465798|NCT00111826|Inflammation
1465799|NCT00111800|NIDDM
1465800|NCT00111787|breast cancer
1465801|NCT00111774|Colon Cancer, Rectal Cancer
1465802|NCT00111774|Colorectal Carcinoma, EGFr
1465803|NCT00111774|Metastatic Cancer, ABX-EGF
1465804|NCT00111774|Panitumumab, Abgenix
1465805|NCT00111774|Clinical Trial, Immunex, Amgen
1465806|NCT00111774|Metastatic Colorectal
1465807|NCT00111761|Immunex
1465808|NCT00111761|Panitumumab
1465809|NCT00111761|ABX-EGF
1465810|NCT00111761|Abgenix
1465811|NCT00111748|Myeloma
1465812|NCT00111683|Myelodysplastic Syndrome[Refractory Anemia with
1465813|NCT00111683|Excess Blasts-1 or 2 (WHO Classification)]
1465814|NCT00111683|Chronic Myelogenous Leukemia in blast crisis
1465815|NCT00111657|Gout
1465816|NCT00111657|Tophi
1465817|NCT00111657|Tophaceous gout
1465818|NCT00111657|Allergy to allopurinol
1465819|NCT00111657|Post-transplant gout
1465820|NCT00111618|vascular disrupting agent
1465821|NCT00111618|safety
1465822|NCT00111618|tolerability
1465823|NCT00111618|efficacy
1465824|NCT00111618|hormone refractory prostate cancer
1465825|NCT00111605|AIDS Vaccines
1465826|NCT00111605|HIV Vaccines
1465827|NCT00111605|HIV Preventive Vaccine
1465828|NCT00111605|HIV Seronegativity
1465829|NCT00111592|BPH
1465830|NCT00111592|benign prostatic hyperplasia
1465831|NCT00111566|Percutaneous Coronary Intervention (PCI)
1465832|NCT00111566|Glycoprotein IIb/IIIa blockade
1465833|NCT00111566|Ischemic complications following PCI
1465834|NCT00111553|Leishmaniasis
1465835|NCT00111553|Subunit vaccine
1465836|NCT00111553|Therapeutic
1465837|NCT00111553|T cell
1465838|NCT00111553|Antimony
1465839|NCT00111540|exenatide
1465840|NCT00111540|diabetes
1465841|NCT00111540|Amylin
1465842|NCT00111540|exendin-4
1465843|NCT00111527|Heart failure
1465844|NCT00111527|Atrial fibrillation
1465845|NCT00111527|Cardiac resynchronization
1465846|NCT00111527|Cardiac pacing
1465847|NCT00111527|Catheter ablation
1465848|NCT00111527|Quality of life
1465849|NCT00111527|Echocardiography
1465850|NCT00111514|Leishmaniasis
1465851|NCT00111514|Subunit vaccine
1465852|NCT00111514|therapeutic
1465853|NCT00111514|T-cell
1465854|NCT00111514|pentavalent antimony
1465855|NCT00111501|smoking
1465856|NCT00111501|tobacco
1465857|NCT00111488|atrial fibrillation
1465858|NCT00111475|Immune Thrombocytopenic Purpura
1465859|NCT00111475|Idiopathic Thrombocytopenic Purpura
1465860|NCT00111475|Thrombocytopenic
1465861|NCT00111475|Thrombocytopenia
1465862|NCT00111475|ITP
1465863|NCT00111462|non-myeloid malignancy
1465864|NCT00111462|chemotherapy-induced anemia
1465865|NCT00111449|Psoriasis, adults
1465866|NCT00111449|skin, Phase 3
1465867|NCT00111449|clinical trial, Amgen
1465868|NCT00111449|etanercept, Enbrel®
1465869|NCT00111449|moderate, severe
1465870|NCT00111436|Psoriasis, adults, skin
1465871|NCT00111436|Phase 3, clinical trial
1465872|NCT00111436|Amgen, etanercept
1465873|NCT00111436|Enbrel®, moderate
1465874|NCT00111436|severe, extension
1465875|NCT00111423|Rheumatoid Arthritis, Inflammation
1465876|NCT00111423|Pegsunercept, PEG sTNF-RI
1465877|NCT00111423|Autoimmune, Amgen
1465878|NCT00111423|Clinical Trials
1465879|NCT00111410|Rheumatoid Arthritis, Inflammation
1465880|NCT00111410|Interleukin-1 (IL-1), r-metHuIL-1ra
1465881|NCT00111410|Autoimmune, Kineret®
1465882|NCT00111410|Anakinra, Immunex
1465883|NCT00111410|Amgen, Clinical Trials
1465884|NCT00111397|Mycobacterial
1465885|NCT00111397|Interferon
1465886|NCT00111397|GM-CSF
1465887|NCT00111397|Microarray
1465888|NCT00111397|Proteomics
1465889|NCT00111397|Mycobacterium Avium Complex Infection
1465890|NCT00111397|MAC
1465891|NCT00111384|Phenotype
1465892|NCT00111384|NF1-associated tumors
1465893|NCT00111384|NF1
1465894|NCT00111384|EQTL
1465895|NCT00111384|Modifier Genes
1465896|NCT00111384|Neurofibroma
1465897|NCT00111384|Neurofibromatosis Type 1
1465898|NCT00111371|artificial grammar learning
1465899|NCT00111371|dyslexia
1465900|NCT00111371|healthy subjects
1465901|NCT00111371|levodopa
1465902|NCT00111371|drug
1465903|NCT00111371|treatment
1465904|NCT00111371|intervention
1465905|NCT00111358|HIV, AIDS, metabolic syndrome
1465906|NCT00111345|Acute
1465907|NCT00111345|myeloid
1465908|NCT00111345|leukemia
1465909|NCT00111345|Acute myeloid leukemia
1465910|NCT00111319|Front Line
1465911|NCT00111319|Multiple Myeloma
1465912|NCT00111319|Untreated
1465913|NCT00111306|Lupus
1465914|NCT00111306|Antibody
1465915|NCT00111306|B-cell immunotherapy
1465916|NCT00111293|Attention
1465917|NCT00111293|Executive Function
1465918|NCT00111293|Vision
1465919|NCT00111293|fMRI
1465920|NCT00111293|Top-Down
1465921|NCT00111293|Visual Processing
1465922|NCT00111293|Lesion
1465923|NCT00111293|Prefrontal
1465924|NCT00111293|Parietal
1465925|NCT00111293|Focal Brain Lesion
1465926|NCT00111293|Healthy Volunteer
1465927|NCT00111280|HIV infection
1465928|NCT00111280|TMC125
1465929|NCT00111280|Nucleoside reverse transcriptase inhibitors (NRTIs)
1465930|NCT00111280|roll-over trial
1465931|NCT00111280|antiretrovirals (ARVs)
1465932|NCT00111267|vitamin B12
1465933|NCT00111267|cognitive function
1465934|NCT00111267|oral supplementation
1465935|NCT00111267|elderly
1465936|NCT00111254|microdermabrasion
1465937|NCT00111254|skin
1465938|NCT00111254|wrinkles
1465939|NCT00111254|collagen
1465940|NCT00111254|photoaging
1465941|NCT00111254|wrinkled skin
1465942|NCT00111241|bone fracture
1465943|NCT00111241|cartilage
1465944|NCT00111241|osteoporosis
1465945|NCT00111241|breast cancer
1465946|NCT00111241|aromatase inhibitors
1465947|NCT00111241|knee articular cartilage volume
1465948|NCT00111228|Diabetes
1465949|NCT00111215|Menorrhagia
1465950|NCT00111215|Von Willebrand's Disease
1465951|NCT00111215|Platelet Disorder
1465952|NCT00111202|Genetic counseling
1465953|NCT00111202|Genetic counselling
1465954|NCT00111202|Genetics
1465955|NCT00111202|Schizophrenia
1465956|NCT00111189|Schizophrenia
1465957|NCT00111189|Paliperidone palmitate
1465958|NCT00111189|R092670
1465959|NCT00111189|antipsychotic
1465960|NCT00111189|recurrence prevention
1465961|NCT00111176|Thoracic Aortic Aneurysm
1465962|NCT00111176|Descending
1465963|NCT00111176|minimally invasive
1465964|NCT00111176|endovascular
1465965|NCT00111176|rupture
1465966|NCT00111176|back pain
1465967|NCT00111176|stent graft
1465968|NCT00111176|endovascular aneurysm repair
1465969|NCT00111176|aortic aneurysm
1465970|NCT00111176|thoracic
1465971|NCT00111163|malaria
1465972|NCT00111163|anemia
1465973|NCT00111163|Plasmodium falciparum
1465974|NCT00111163|infants
1465975|NCT00111163|prevention
1465976|NCT00111163|safety
1465977|NCT00111163|efficacy
1465978|NCT00111163|antimalarials
1465979|NCT00111150|HIV incidence
1465980|NCT00111150|HIV prevention
1465981|NCT00111137|darbepoetin alfa
1465982|NCT00111137|anemia
1465983|NCT00111137|Amgen
1465984|NCT00111137|Chemotherapy
1465985|NCT00111124|psoriasis
1465986|NCT00111124|arthritis
1465987|NCT00111124|Enbrel®
1465988|NCT00111124|etanercept
1465989|NCT00111111|Psoriasis
1465990|NCT00111098|Anemia
1465991|NCT00111098|Chronic Kidney Disease (CKD)
1465992|NCT00111085|aneurysmal subarachnoid hemorrhage (aSAH)
1465993|NCT00111085|vasospasm
1465994|NCT00111085|delayed ischemic neurological deficits (DIND)
1465995|NCT00111085|computer tomography scan (CT scan)
1465996|NCT00111085|digital subtraction angiography (DSA)
1465997|NCT00111085|endothelin A receptor
1465998|NCT00111085|clazosentan
1465999|NCT00111072|Mucosal Disease
1466000|NCT00111072|Topical Steroids
1466001|NCT00111072|Salivary Diagnostics
1466002|NCT00111072|Oral Pain
1466003|NCT00111072|Quality of Life Indicators
1466004|NCT00111072|Oral Lichen Planus
1466005|NCT00111059|obesity
1466006|NCT00111059|cardiovascular disease
1466007|NCT00111059|depression
1466008|NCT00111059|stress
1466009|NCT00111046|Pain Relief
1466010|NCT00111046|Choroidal melanoma
1466011|NCT00111046|plaque radiotherapy
1466012|NCT00110981|psoriasis
1466013|NCT00110981|dermatology
1466014|NCT00110981|plaque psoriasis
1466015|NCT00110981|skin
1466016|NCT00110981|etanercept
1466017|NCT00110981|ENBREL
1466018|NCT00110981|NB-UVB, narrow-band UVB, phototherapy
1466019|NCT00110981|combination therapy, 50 mg prefilled syringes
1466020|NCT00110968|Abdominal Symptom relief
1466021|NCT00110968|Fullness
1466022|NCT00110968|Bloating
1466023|NCT00110968|Indigestion
1466024|NCT00110968|Functional dyspepsia
1466025|NCT00110955|Non-myeloid malignancy
1466026|NCT00110955|Chemotherapy-induced anemia
1466027|NCT00110942|Intra-articular
1466028|NCT00110942|Osteoarthritis
1466029|NCT00110942|OA
1466030|NCT00110942|anakinra
1466031|NCT00110942|Amgen
1466032|NCT00110929|Sensipar®
1466033|NCT00110929|Secondary HPT
1466034|NCT00110929|Mimpara®
1466035|NCT00110929|Cinacalcet
1466036|NCT00110929|calcimimetic
1466037|NCT00110929|End-Stage Renal Disease (ESRD)
1466038|NCT00110916|Intra-articular
1466039|NCT00110916|Osteoarthritis
1466040|NCT00110916|OA
1466041|NCT00110916|anakinra
1466042|NCT00110916|Amgen
1466043|NCT00110903|Rheumatoid arthritis
1466044|NCT00110903|RA
1466045|NCT00110903|etanercept
1466046|NCT00110903|Immunex
1466047|NCT00110903|Amgen
1466048|NCT00110890|Secondary HyperParaThyroidism (SHPT)
1466049|NCT00110890|Dialysis, End Stage Renal Disease (ESRD)
1466050|NCT00110890|KDOQI, Cinacalcet
1466051|NCT00110890|Clinical Trial, Amgen
1466052|NCT00110877|Human Immunodeficiency Virus
1466053|NCT00110877|Treatment Experienced
1466054|NCT00110877|TMC114-C214
1466055|NCT00110864|diabetes, type 2
1466056|NCT00110851|diabetes, type 2
1466057|NCT00110838|fish oil
1466058|NCT00110838|n-3 fatty acids
1466059|NCT00110838|n-3 PUFA
1466060|NCT00110838|omega-3 fatty acids
1466061|NCT00110838|arrhythmia
1466062|NCT00110838|ICD
1466063|NCT00110838|human
1466064|NCT00110838|Patients with an implantable cardioverter defibrillator
1466065|NCT00110812|Treatment Naive
1466066|NCT00110812|IL-2
1466067|NCT00110812|rIL-2
1466068|NCT00110799|thrombopoietin
1466069|NCT00110799|platelets
1466070|NCT00110799|Hepatitis C-related thrombocytopenia
1466071|NCT00110799|Hepatitis C
1466072|NCT00110786|Allergy
1466073|NCT00110786|Specific Immunotherapy
1466074|NCT00110786|Ragweed
1466075|NCT00110786|Environmental Exposure Chamber
1466076|NCT00110721|colorectal cancer
1466077|NCT00110721|DAVANAT
1466078|NCT00110721|5-fluorouracil
1466079|NCT00110708|autism
1466080|NCT00110708|gastrointestinal dysfunction
1466081|NCT00110708|autistic disorder
1466082|NCT00110708|diarrhea
1466083|NCT00110708|constipation
1466084|NCT00110708|abdominal pain
1466085|NCT00110708|gastrointestinal problems associated with autism
1466086|NCT00110708|immune globulin
1466087|NCT00110708|immunoglobulin
1466088|NCT00110708|Immunoglobulins, Intravenous
1466089|NCT00110708|Intestinal Mucosa/immunology/pathology
1466090|NCT00110708|Administration, Oral
1466091|NCT00110708|Autistic Disorder/*drug therapy
1466092|NCT00110708|Child Behavior/*drug effects
1466093|NCT00110708|Constipation/drug therapy
1466094|NCT00110708|Diarrhea/drug therapy
1466095|NCT00110708|Gastrointestinal Agents/*therapeutic use
1466096|NCT00110695|NSABP
1466097|NCT00110695|Abraxis
1466098|NCT00110695|Abraxane
1466099|NCT00110695|Locally advanced breast cancer
1466100|NCT00110695|Fluorouracil
1466101|NCT00110695|Epirubicin
1466102|NCT00110695|Cyclophosphamide
1466103|NCT00110695|FEC
1466104|NCT00110682|Actinic Keratosis
1466105|NCT00110682|Cryotherapy
1466106|NCT00110682|Imiquimod
1466107|NCT00110669|Muscular dystrophy, Duchenne and Beckers
1466108|NCT00110669|Beckers Muscular dystrophy
1466109|NCT00110656|Kidney transplant
1466110|NCT00110643|Acne
1466111|NCT00110643|laser
1466112|NCT00110630|nicotine dependence
1466113|NCT00110617|Sickle Cell Disease
1466114|NCT00110617|Iron Overload from Repeated Blood Transfusions
1466115|NCT00110617|Iron Overload
1466116|NCT00110617|Blood Transfusions
1466117|NCT00110604|Folic acid
1466118|NCT00110604|Atherosclerosis
1466119|NCT00110604|Cognitive function
1466120|NCT00110604|Hearing
1466121|NCT00110604|Inflammation
1466122|NCT00110604|Hemostasis
1466123|NCT00110604|Arterial stiffness
1466124|NCT00110578|Treatment Naive
1466125|NCT00110578|Treatment Experienced
1466126|NCT00110565|Magnetics
1466127|NCT00110565|Pulsed Magnetic Pad
1466128|NCT00110565|Magnetic Field
1466129|NCT00110565|Electromagnetic Field
1466130|NCT00110565|Women
1466131|NCT00110565|Pulsed Magnetic Field
1466132|NCT00110539|Medicine, Herbal
1466133|NCT00110539|Dietary Supplements
1466134|NCT00110539|Complementary and Alternative Medicine
1466135|NCT00110539|Physicians
1466136|NCT00110526|Prostate Cancer
1466137|NCT00110526|Radiation Therapy
1466138|NCT00110526|Local recurrence
1466139|NCT00110526|Gene Therapy
1466140|NCT00110513|Antithrombin Deficiency, Congenital or Hereditary
1466141|NCT00110513|Antithrombin III Deficiency
1466142|NCT00110513|ATIII
1466143|NCT00110513|Hereditary Antithrombin Deficiency (HD)
1466144|NCT00110500|Diabetes
1466145|NCT00110500|Neuropathy
1466146|NCT00110487|Endometriosis
1466147|NCT00110474|Glucosamine sulfate
1466148|NCT00110474|Osteoarthritis
1466149|NCT00110474|Acetaminophen
1466150|NCT00110474|Paracetamol
1466151|NCT00110474|Clinical trial
1466152|NCT00110461|Aripiprazole
1466153|NCT00110461|Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features
1466154|NCT00110448|type 2 diabetes
1466155|NCT00110448|coronary heart diseases
1466156|NCT00110448|primary prevention
1466157|NCT00110448|atherosclerosis
1466158|NCT00110448|aspirin
1466159|NCT00110422|Metabolic Syndrome
1466160|NCT00110396|Multiple Sclerosis
1466161|NCT00110396|Relapsing forms of multiple sclerosis
1466162|NCT00110344|Cancer
1466163|NCT00110331|Encephalopathy
1466164|NCT00110331|Neuroimaging
1466165|NCT00110331|Cognition
1466166|NCT00110331|Neuroinflammation
1466167|NCT00110331|Opportunistic Infections
1466168|NCT00110331|HIV
1466169|NCT00110331|Central Nervous System Disease
1466170|NCT00110331|Bipolar Disorder
1466171|NCT00110331|Attention Deficit Hyperactivity Disorder
1466172|NCT00110331|ADHD
1466173|NCT00110331|Major Depression
1466174|NCT00110331|Psychosis
1466175|NCT00110318|Tennis Elbow
1466176|NCT00110318|Physical Therapy Techniques
1466177|NCT00110318|Evidence-Based Medicine
1466178|NCT00110318|Primary Health Care
1466179|NCT00110305|Human Immunodeficiency Virus Type 1
1466180|NCT00110305|Human immunodeficiency virus (HIV)
1466181|NCT00110305|Antiretroviral
1466182|NCT00110305|Antiviral
1466183|NCT00110305|ARV
1466184|NCT00110305|TMC278
1466185|NCT00110305|Efavirenz
1466186|NCT00110305|Combivir
1466187|NCT00110305|Truvada
1466188|NCT00110305|Zidovudine
1466189|NCT00110305|Lamivudine
1466190|NCT00110305|Tenofovir disoproxil fumarate
1466191|NCT00110305|Emtricitabine
1466192|NCT00110292|Public health
1466193|NCT00110292|Primary care
1466194|NCT00110292|Parenting education
1466195|NCT00110292|Child rearing
1466196|NCT00110292|Parenting newsletters
1466197|NCT00110292|Child development
1466198|NCT00110292|Language delay
1466199|NCT00110279|Bird Flu
1466200|NCT00110266|ICL670
1466201|NCT00110266|Deferasirox
1466202|NCT00110266|Iron chelation
1466203|NCT00110266|Chelator
1466204|NCT00110266|Desferal
1466205|NCT00110240|Type 2 diabetes
1466206|NCT00110240|vildagliptin
1466207|NCT00110227|Complementary Therapies
1466208|NCT00110227|Tai Chi
1466209|NCT00110201|Acute renal failure
1466210|NCT00110201|Nesiritide
1466211|NCT00110201|Cardiovascular surgery
1466212|NCT00110188|prostate
1466213|NCT00110188|cancer
1466214|NCT00110175|Cortical Reorganization
1466215|NCT00110175|Motor Function
1466216|NCT00110175|Somatosensory Stimulation
1466217|NCT00110175|Rehabilitation
1466218|NCT00110175|Transcranial Direct Current Stimulation (tDCS)
1466219|NCT00110175|Direct Current Stimulation
1466220|NCT00110175|Stroke
1466221|NCT00110175|Healthy Volunteer
1466222|NCT00110162|adenocarcinoma of the prostate
1466223|NCT00110162|stage I prostate cancer
1466224|NCT00110162|stage IIB prostate cancer
1466225|NCT00110162|stage IIA prostate cancer
1466226|NCT00110162|stage III prostate cancer
1466227|NCT00110162|stage IV prostate cancer
1466228|NCT00110162|recurrent prostate cancer
1466229|NCT00110149|contiguous stage II grade 1 follicular lymphoma
1466230|NCT00110149|noncontiguous stage II grade 1 follicular lymphoma
1466231|NCT00110149|stage I grade 1 follicular lymphoma
1466232|NCT00110149|stage III grade 1 follicular lymphoma
1466233|NCT00110149|stage IV grade 1 follicular lymphoma
1466234|NCT00110149|contiguous stage II grade 2 follicular lymphoma
1466235|NCT00110149|noncontiguous stage II grade 2 follicular lymphoma
1466618|NCT00109707|Gleevec resistance
1466236|NCT00110149|stage I grade 2 follicular lymphoma
1466237|NCT00110149|stage III grade 2 follicular lymphoma
1466238|NCT00110149|stage IV grade 2 follicular lymphoma
1466239|NCT00110149|contiguous stage II marginal zone lymphoma
1466240|NCT00110149|noncontiguous stage II marginal zone lymphoma
1466241|NCT00110149|splenic marginal zone lymphoma
1466242|NCT00110149|stage I marginal zone lymphoma
1466243|NCT00110149|stage III marginal zone lymphoma
1466244|NCT00110149|stage IV marginal zone lymphoma
1466245|NCT00110149|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1466246|NCT00110149|nodal marginal zone B-cell lymphoma
1466247|NCT00110149|contiguous stage II small lymphocytic lymphoma
1466248|NCT00110149|noncontiguous stage II small lymphocytic lymphoma
1466249|NCT00110149|stage I small lymphocytic lymphoma
1466250|NCT00110149|stage III small lymphocytic lymphoma
1466251|NCT00110149|stage IV small lymphocytic lymphoma
1466252|NCT00110136|recurrent breast cancer
1466253|NCT00110136|stage I breast cancer
1466254|NCT00110136|stage II breast cancer
1466255|NCT00110136|stage IIIA breast cancer
1466256|NCT00110136|stage IIIB breast cancer
1466257|NCT00110136|breast cancer in situ
1466258|NCT00110136|ductal breast carcinoma in situ
1466259|NCT00110136|hot flashes
1466260|NCT00110123|liver metastases
1466261|NCT00110123|ciliary body and choroid melanoma, medium/large size
1466262|NCT00110123|iris melanoma
1466263|NCT00110123|extraocular extension melanoma
1466264|NCT00110123|recurrent intraocular melanoma
1466265|NCT00110123|metastatic intraocular melanoma
1466266|NCT00110110|intraocular retinoblastoma
1466267|NCT00110084|recurrent breast cancer
1466268|NCT00110084|stage IV breast cancer
1466269|NCT00110058|accelerated phase chronic myelogenous leukemia
1466270|NCT00110058|childhood chronic myelogenous leukemia
1466271|NCT00110058|chronic phase chronic myelogenous leukemia
1466272|NCT00110058|Philadelphia chromosome positive chronic myelogenous leukemia
1466273|NCT00110058|relapsing chronic myelogenous leukemia
1466274|NCT00110045|infection
1466275|NCT00110045|ataxia-telangiectasia
1466276|NCT00110045|accelerated phase chronic myelogenous leukemia
1466277|NCT00110045|acute undifferentiated leukemia
1466278|NCT00110045|blastic phase chronic myelogenous leukemia
1466279|NCT00110045|meningeal chronic myelogenous leukemia
1466280|NCT00110045|relapsing chronic myelogenous leukemia
1466281|NCT00110045|chronic eosinophilic leukemia
1466282|NCT00110045|primary myelofibrosis
1466283|NCT00110045|chronic neutrophilic leukemia
1466284|NCT00110045|essential thrombocythemia
1466285|NCT00110045|polycythemia vera
1466286|NCT00110045|adult acute lymphoblastic leukemia in remission
1466287|NCT00110045|recurrent adult acute lymphoblastic leukemia
1466288|NCT00110045|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1466289|NCT00110045|adult acute myeloid leukemia with inv(16)(p13;q22)
1466290|NCT00110045|adult acute myeloid leukemia with t(15;17)(q22;q12)
1466291|NCT00110045|adult acute myeloid leukemia with t(16;16)(p13;q22)
1466292|NCT00110045|adult acute myeloid leukemia with t(8;21)(q22;q22)
1466293|NCT00110045|adult acute myeloid leukemia in remission
1466294|NCT00110045|recurrent adult T-cell leukemia/lymphoma
1466295|NCT00110045|stage I adult T-cell leukemia/lymphoma
1466296|NCT00110045|stage II adult T-cell leukemia/lymphoma
1466297|NCT00110045|stage III adult T-cell leukemia/lymphoma
1466298|NCT00110045|stage IV adult T-cell leukemia/lymphoma
1466299|NCT00110045|refractory chronic lymphocytic leukemia
1466300|NCT00110045|stage 0 chronic lymphocytic leukemia
1466301|NCT00110045|stage I chronic lymphocytic leukemia
1466302|NCT00110045|stage II chronic lymphocytic leukemia
1466303|NCT00110045|stage III chronic lymphocytic leukemia
1466304|NCT00110045|stage IV chronic lymphocytic leukemia
1466305|NCT00110045|progressive hairy cell leukemia, initial treatment
1466306|NCT00110045|refractory hairy cell leukemia
1466307|NCT00110045|prolymphocytic leukemia
1466308|NCT00110045|recurrent adult Hodgkin lymphoma
1466309|NCT00110045|stage I adult Hodgkin lymphoma
1466310|NCT00110045|stage II adult Hodgkin lymphoma
1466311|NCT00110045|stage III adult Hodgkin lymphoma
1466312|NCT00110045|stage IV adult Hodgkin lymphoma
1466313|NCT00110045|anaplastic large cell lymphoma
1466314|NCT00110045|angioimmunoblastic T-cell lymphoma
1466315|NCT00110045|recurrent mycosis fungoides/Sezary syndrome
1466316|NCT00110045|stage I mycosis fungoides/Sezary syndrome
1466317|NCT00110045|stage II mycosis fungoides/Sezary syndrome
1466318|NCT00110045|stage III mycosis fungoides/Sezary syndrome
1466319|NCT00110045|stage IV mycosis fungoides/Sezary syndrome
1466320|NCT00110045|recurrent cutaneous T-cell non-Hodgkin lymphoma
1466321|NCT00110045|stage I cutaneous T-cell non-Hodgkin lymphoma
1466322|NCT00110045|stage II cutaneous T-cell non-Hodgkin lymphoma
1466323|NCT00110045|stage III cutaneous T-cell non-Hodgkin lymphoma
1466324|NCT00110045|stage IV cutaneous T-cell non-Hodgkin lymphoma
1466325|NCT00110045|adult grade III lymphomatoid granulomatosis
1466326|NCT00110045|recurrent adult grade III lymphomatoid granulomatosis
1466327|NCT00110045|Waldenstrom macroglobulinemia
1466328|NCT00110045|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1466329|NCT00110045|nodal marginal zone B-cell lymphoma
1466330|NCT00110045|recurrent adult Burkitt lymphoma
1466331|NCT00110045|recurrent adult diffuse large cell lymphoma
1466332|NCT00110045|recurrent adult diffuse mixed cell lymphoma
1466333|NCT00110045|recurrent adult diffuse small cleaved cell lymphoma
1466334|NCT00110045|recurrent adult immunoblastic large cell lymphoma
1466335|NCT00110045|recurrent adult lymphoblastic lymphoma
1466336|NCT00110045|recurrent grade 3 follicular lymphoma
1466337|NCT00110045|recurrent mantle cell lymphoma
1466338|NCT00110045|recurrent grade 1 follicular lymphoma
1466339|NCT00110045|recurrent grade 2 follicular lymphoma
1466340|NCT00110045|recurrent marginal zone lymphoma
1466341|NCT00110045|recurrent small lymphocytic lymphoma
1466342|NCT00110045|contiguous stage II adult Burkitt lymphoma
1466343|NCT00110045|noncontiguous stage II adult Burkitt lymphoma
1466344|NCT00110045|stage I adult Burkitt lymphoma
1466345|NCT00110045|stage III adult Burkitt lymphoma
1466346|NCT00110045|stage IV adult Burkitt lymphoma
1466347|NCT00110045|contiguous stage II adult diffuse large cell lymphoma
1466348|NCT00110045|noncontiguous stage II adult diffuse large cell lymphoma
1466349|NCT00110045|stage I adult diffuse large cell lymphoma
1466350|NCT00110045|stage III adult diffuse large cell lymphoma
1466351|NCT00110045|stage IV adult diffuse large cell lymphoma
1466352|NCT00110045|contiguous stage II adult diffuse mixed cell lymphoma
1466353|NCT00110045|noncontiguous stage II adult diffuse mixed cell lymphoma
1466354|NCT00110045|stage I adult diffuse mixed cell lymphoma
1466355|NCT00110045|stage III adult diffuse mixed cell lymphoma
1466356|NCT00110045|stage IV adult diffuse mixed cell lymphoma
1466357|NCT00110045|contiguous stage II adult immunoblastic large cell lymphoma
1466358|NCT00110045|noncontiguous stage II adult immunoblastic large cell lymphoma
1466359|NCT00110045|stage I adult immunoblastic large cell lymphoma
1466360|NCT00110045|stage III adult immunoblastic large cell lymphoma
1466361|NCT00110045|stage IV adult immunoblastic large cell lymphoma
1466362|NCT00110045|contiguous stage II adult lymphoblastic lymphoma
1466363|NCT00110045|noncontiguous stage II adult lymphoblastic lymphoma
1466364|NCT00110045|stage I adult lymphoblastic lymphoma
1466365|NCT00110045|stage III adult lymphoblastic lymphoma
1466366|NCT00110045|stage IV adult lymphoblastic lymphoma
1466367|NCT00110045|contiguous stage II grade 1 follicular lymphoma
1466368|NCT00110045|noncontiguous stage II grade 1 follicular lymphoma
1466369|NCT00110045|stage I grade 1 follicular lymphoma
1466370|NCT00110045|stage III grade 1 follicular lymphoma
1466371|NCT00110045|stage IV grade 1 follicular lymphoma
1466372|NCT00110045|contiguous stage II grade 2 follicular lymphoma
1466373|NCT00110045|noncontiguous stage II grade 2 follicular lymphoma
1466374|NCT00110045|stage I grade 2 follicular lymphoma
1466375|NCT00110045|stage III grade 2 follicular lymphoma
1466376|NCT00110045|stage IV grade 2 follicular lymphoma
1466377|NCT00110045|contiguous stage II grade 3 follicular lymphoma
1466378|NCT00110045|noncontiguous stage II grade 3 follicular lymphoma
1466379|NCT00110045|stage I grade 3 follicular lymphoma
1466380|NCT00110045|stage III grade 3 follicular lymphoma
1466381|NCT00110045|stage IV grade 3 follicular lymphoma
1466382|NCT00110045|contiguous stage II mantle cell lymphoma
1466383|NCT00110045|noncontiguous stage II mantle cell lymphoma
1466384|NCT00110045|stage I mantle cell lymphoma
1466385|NCT00110045|stage III mantle cell lymphoma
1466386|NCT00110045|stage IV mantle cell lymphoma
1466387|NCT00110045|contiguous stage II marginal zone lymphoma
1466388|NCT00110045|noncontiguous stage II marginal zone lymphoma
1466389|NCT00110045|stage I marginal zone lymphoma
1466390|NCT00110045|stage III marginal zone lymphoma
1466391|NCT00110045|stage IV marginal zone lymphoma
1466392|NCT00110045|splenic marginal zone lymphoma
1466393|NCT00110045|contiguous stage II small lymphocytic lymphoma
1466394|NCT00110045|noncontiguous stage II small lymphocytic lymphoma
1466395|NCT00110045|stage I small lymphocytic lymphoma
1466396|NCT00110045|stage III small lymphocytic lymphoma
1466397|NCT00110045|stage IV small lymphocytic lymphoma
1466398|NCT00110045|intraocular lymphoma
1466399|NCT00110045|primary central nervous system non-Hodgkin lymphoma
1466400|NCT00110045|post-transplant lymphoproliferative disorder
1466401|NCT00110045|extramedullary plasmacytoma
1466402|NCT00110045|isolated plasmacytoma of bone
1466403|NCT00110045|monoclonal gammopathy of undetermined significance
1466404|NCT00110045|stage I multiple myeloma
1466405|NCT00110045|stage II multiple myeloma
1466406|NCT00110045|stage III multiple myeloma
1466407|NCT00110045|primary systemic amyloidosis
1466408|NCT00110045|refractory multiple myeloma
1466409|NCT00110045|de novo myelodysplastic syndromes
1466410|NCT00110045|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1466411|NCT00110045|previously treated myelodysplastic syndromes
1466412|NCT00110045|secondary myelodysplastic syndromes
1466413|NCT00110045|atypical chronic myeloid leukemia, BCR-ABL1 negative
1466414|NCT00110045|chronic myelomonocytic leukemia
1466415|NCT00110045|disseminated neuroblastoma
1466416|NCT00110045|high risk metastatic gestational trophoblastic tumor
1466417|NCT00110045|recurrent neuroblastoma
1466418|NCT00110045|recurrent ovarian epithelial cancer
1466419|NCT00110045|stage II ovarian epithelial cancer
1466420|NCT00110045|stage III ovarian epithelial cancer
1466421|NCT00110045|stage IV ovarian epithelial cancer
1466422|NCT00110045|recurrent ovarian germ cell tumor
1466423|NCT00110045|recurrent malignant testicular germ cell tumor
1466619|NCT00109707|Gleevec intolerant
1466424|NCT00110045|stage III malignant testicular germ cell tumor
1466425|NCT00110045|secondary acute myeloid leukemia
1466426|NCT00110045|stage IIIA breast cancer
1466427|NCT00110045|stage IIIB breast cancer
1466428|NCT00110045|stage IIIC breast cancer
1466429|NCT00110045|stage IV breast cancer
1466430|NCT00110045|chronic phase chronic myelogenous leukemia
1466431|NCT00110045|contiguous stage II adult diffuse small cleaved cell lymphoma
1466432|NCT00110045|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1466433|NCT00110045|recurrent adult acute myeloid leukemia
1466434|NCT00110045|stage I adult diffuse small cleaved cell lymphoma
1466435|NCT00110045|stage III adult diffuse small cleaved cell lymphoma
1466436|NCT00110045|stage IV adult diffuse small cleaved cell lymphoma
1466437|NCT00110045|T-cell large granular lymphocyte leukemia
1466438|NCT00110006|contiguous stage II grade 3 follicular lymphoma
1466439|NCT00110006|noncontiguous stage II grade 3 follicular lymphoma
1466440|NCT00110006|stage I grade 3 follicular lymphoma
1466441|NCT00110006|stage III grade 3 follicular lymphoma
1466442|NCT00110006|stage IV grade 3 follicular lymphoma
1466443|NCT00110006|contiguous stage II adult diffuse large cell lymphoma
1466444|NCT00110006|noncontiguous stage II adult diffuse large cell lymphoma
1466445|NCT00110006|stage I adult diffuse large cell lymphoma
1466446|NCT00110006|stage III adult diffuse large cell lymphoma
1466447|NCT00110006|stage IV adult diffuse large cell lymphoma
1466448|NCT00110006|contiguous stage II mantle cell lymphoma
1466449|NCT00110006|noncontiguous stage II mantle cell lymphoma
1466450|NCT00110006|stage I mantle cell lymphoma
1466451|NCT00110006|stage III mantle cell lymphoma
1466452|NCT00110006|stage IV mantle cell lymphoma
1466453|NCT00110006|anaplastic large cell lymphoma
1466454|NCT00109993|graft versus host disease
1466455|NCT00109993|accelerated phase chronic myelogenous leukemia
1466456|NCT00109993|adult acute lymphoblastic leukemia in remission
1466457|NCT00109993|adult acute myeloid leukemia in remission
1466458|NCT00109993|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1466459|NCT00109993|adult acute myeloid leukemia with inv(16)(p13;q22)
1466460|NCT00109993|adult acute myeloid leukemia with t(15;17)(q22;q12)
1466461|NCT00109993|adult acute myeloid leukemia with t(16;16)(p13;q22)
1466462|NCT00109993|adult acute myeloid leukemia with t(8;21)(q22;q22)
1466463|NCT00109993|atypical chronic myeloid leukemia
1466464|NCT00109993|blastic phase chronic myelogenous leukemia
1466465|NCT00109993|chronic eosinophilic leukemia
1466466|NCT00109993|chronic idiopathic myelofibrosis
1466467|NCT00109993|chronic myelomonocytic leukemia
1466468|NCT00109993|chronic neutrophilic leukemia
1466469|NCT00109993|chronic phase chronic myelogenous leukemia
1466470|NCT00109993|de novo myelodysplastic syndromes
1466471|NCT00109993|disseminated neuroblastoma
1466472|NCT00109993|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1466473|NCT00109993|myelodysplastic/myeloproliferative disease, unclassifiable
1466474|NCT00109993|nodal marginal zone B-cell lymphoma
1466475|NCT00109993|noncontiguous stage II adult Burkitt lymphoma
1466476|NCT00109993|noncontiguous stage II adult diffuse large cell lymphoma
1466477|NCT00109993|noncontiguous stage II adult diffuse mixed cell lymphoma
1466478|NCT00109993|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1466479|NCT00109993|noncontiguous stage II adult immunoblastic large cell lymphoma
1466480|NCT00109993|noncontiguous stage II adult lymphoblastic lymphoma
1466481|NCT00109993|noncontiguous stage II grade 1 follicular lymphoma
1466482|NCT00109993|noncontiguous stage II grade 2 follicular lymphoma
1466483|NCT00109993|noncontiguous stage II grade 3 follicular lymphoma
1466484|NCT00109993|noncontiguous stage II mantle cell lymphoma
1466485|NCT00109993|noncontiguous stage II marginal zone lymphoma
1466486|NCT00109993|noncontiguous stage II small lymphocytic lymphoma
1466487|NCT00109993|poor prognosis metastatic gestational trophoblastic tumor
1466488|NCT00109993|previously treated myelodysplastic syndromes
1466489|NCT00109993|recurrent adult acute lymphoblastic leukemia
1466490|NCT00109993|recurrent adult acute myeloid leukemia
1466491|NCT00109993|recurrent adult Burkitt lymphoma
1466492|NCT00109993|recurrent adult diffuse large cell lymphoma
1466493|NCT00109993|recurrent adult diffuse mixed cell lymphoma
1466494|NCT00109993|recurrent adult diffuse small cleaved cell lymphoma
1466495|NCT00109993|recurrent adult Hodgkin lymphoma
1466496|NCT00109993|recurrent adult immunoblastic large cell lymphoma
1466497|NCT00109993|recurrent adult lymphoblastic lymphoma
1466498|NCT00109993|recurrent grade 1 follicular lymphoma
1466499|NCT00109993|recurrent grade 2 follicular lymphoma
1466500|NCT00109993|recurrent grade 3 follicular lymphoma
1466501|NCT00109993|recurrent cutaneous T-cell non-Hodgkin lymphoma
1466502|NCT00109993|recurrent mantle cell lymphoma
1466503|NCT00109993|recurrent mycosis fungoides/Sezary syndrome
1466504|NCT00109993|recurrent marginal zone lymphoma
1466505|NCT00109993|recurrent neuroblastoma
1466506|NCT00109993|recurrent ovarian epithelial cancer
1466507|NCT00109993|recurrent ovarian germ cell tumor
1466508|NCT00109993|recurrent small lymphocytic lymphoma
1466509|NCT00109993|recurrent malignant testicular germ cell tumor
1466510|NCT00109993|refractory chronic lymphocytic leukemia
1466511|NCT00109993|refractory multiple myeloma
1466512|NCT00109993|refractory hairy cell leukemia
1466513|NCT00109993|relapsing chronic myelogenous leukemia
1466514|NCT00109993|secondary acute myeloid leukemia
1466515|NCT00109993|secondary myelodysplastic syndromes
1466516|NCT00109993|splenic marginal zone lymphoma
1466517|NCT00109993|stage I multiple myeloma
1466518|NCT00109993|stage III adult Burkitt lymphoma
1466519|NCT00109993|stage III adult diffuse large cell lymphoma
1466520|NCT00109993|stage III adult diffuse mixed cell lymphoma
1466521|NCT00109993|stage III adult diffuse small cleaved cell lymphoma
1466522|NCT00109993|stage III adult immunoblastic large cell lymphoma
1466523|NCT00109993|stage III adult lymphoblastic lymphoma
1466524|NCT00109993|stage II ovarian epithelial cancer
1466525|NCT00109993|stage III chronic lymphocytic leukemia
1466526|NCT00109993|stage III grade 1 follicular lymphoma
1466527|NCT00109993|stage III grade 2 follicular lymphoma
1466528|NCT00109993|stage III grade 3 follicular lymphoma
1466529|NCT00109993|stage III mantle cell lymphoma
1466530|NCT00109993|stage III marginal zone lymphoma
1466531|NCT00109993|stage III multiple myeloma
1466532|NCT00109993|stage III ovarian epithelial cancer
1466533|NCT00109993|stage III small lymphocytic lymphoma
1466534|NCT00109993|stage III malignant testicular germ cell tumor
1466535|NCT00109993|stage IIIA breast cancer
1466536|NCT00109993|stage IIIB breast cancer
1466537|NCT00109993|stage IIIC breast cancer
1466538|NCT00109993|stage IV adult Burkitt lymphoma
1466539|NCT00109993|stage IV adult diffuse large cell lymphoma
1466540|NCT00109993|stage IV adult diffuse mixed cell lymphoma
1466541|NCT00109993|stage IV adult diffuse small cleaved cell lymphoma
1466542|NCT00109993|stage IV adult immunoblastic large cell lymphoma
1466543|NCT00109993|stage IV adult lymphoblastic lymphoma
1466544|NCT00109993|stage IV breast cancer
1466545|NCT00109993|stage IV chronic lymphocytic leukemia
1466546|NCT00109993|stage IV grade 1 follicular lymphoma
1466547|NCT00109993|stage IV grade 2 follicular lymphoma
1466548|NCT00109993|stage IV grade 3 follicular lymphoma
1466549|NCT00109993|stage IV mantle cell lymphoma
1466550|NCT00109993|stage IV marginal zone lymphoma
1466551|NCT00109993|stage IV ovarian epithelial cancer
1466552|NCT00109993|stage IV small lymphocytic lymphoma
1466553|NCT00109980|Complementary Therapies
1466554|NCT00109980|Plants, Medicinal
1466555|NCT00109980|Dominican Republic
1466556|NCT00109980|Hispanic Americans
1466557|NCT00109954|adult primary hepatocellular carcinoma
1466558|NCT00109954|advanced adult primary liver cancer
1466559|NCT00109954|localized unresectable adult primary liver cancer
1466560|NCT00109954|recurrent adult primary liver cancer
1466561|NCT00109941|recurrent pancreatic cancer
1466562|NCT00109941|stage III pancreatic cancer
1466563|NCT00109941|stage IV pancreatic cancer
1466564|NCT00109928|stage III adult diffuse mixed cell lymphoma
1466565|NCT00109928|stage IV adult diffuse mixed cell lymphoma
1466566|NCT00109928|contiguous stage II adult diffuse mixed cell lymphoma
1466567|NCT00109928|noncontiguous stage II adult diffuse mixed cell lymphoma
1466568|NCT00109928|contiguous stage II adult diffuse large cell lymphoma
1466569|NCT00109928|noncontiguous stage II adult diffuse large cell lymphoma
1466570|NCT00109928|stage III adult diffuse large cell lymphoma
1466571|NCT00109928|stage IV adult diffuse large cell lymphoma
1466572|NCT00109928|anaplastic large cell lymphoma
1466573|NCT00109889|extramedullary plasmacytoma
1466574|NCT00109889|isolated plasmacytoma of bone
1466575|NCT00109876|stage I non-small cell lung cancer
1466576|NCT00109863|recurrent melanoma
1466577|NCT00109863|stage IV melanoma
1466578|NCT00109850|adenocarcinoma of the esophagus
1466579|NCT00109850|squamous cell carcinoma of the esophagus
1466580|NCT00109850|stage III esophageal cancer
1466581|NCT00109837|L1 adult acute lymphoblastic leukemia
1466582|NCT00109837|L2 adult acute lymphoblastic leukemia
1466583|NCT00109837|untreated adult acute lymphoblastic leukemia
1466584|NCT00109798|primary central nervous system non-Hodgkin lymphoma
1466585|NCT00109798|primary central nervous system Hodgkin lymphoma
1466586|NCT00109785|stage IIIA breast cancer
1466587|NCT00109785|stage IIIB breast cancer
1466588|NCT00109785|stage IIIC breast cancer
1466589|NCT00109785|male breast cancer
1466590|NCT00109772|CRPS
1466591|NCT00109772|RSDS
1466592|NCT00109772|Pain
1466593|NCT00109772|CC-5013
1466594|NCT00109772|Revlimid
1466595|NCT00109772|Complex Regional Pain Syndrome
1466596|NCT00109772|Reflex Sympathy Dystrophy Syndrome
1466597|NCT00109772|Lenalidomide
1466598|NCT00109772|CRPS Type I
1466599|NCT00109772|Celgene
1466600|NCT00109759|allergy
1466601|NCT00109759|allergoid
1466602|NCT00109759|specific immunotherapy
1466603|NCT00109759|ragweed
1466604|NCT00109746|HIV
1466605|NCT00109746|Treatment Experienced
1466606|NCT00109746|Anti-Retroviral Agents
1466607|NCT00109746|Antiretroviral Therapy, Highly Active
1466608|NCT00109746|Picolinic acid
1466609|NCT00109746|Dietary Supplements
1466737|NCT00109382|Stroke
1466610|NCT00109733|Childhood-onset growth hormone deficiency (COGHD)
1466611|NCT00109733|Saizen®
1466612|NCT00109720|Diabetes
1466613|NCT00109720|Self Management
1466614|NCT00109720|Type 2 diabetes
1466615|NCT00109707|CML in blast crisis
1466616|NCT00109707|CML in chronic phase
1466617|NCT00109707|CML in accelerated phase
1466620|NCT00109707|Gleevec and CML
1466621|NCT00109707|imatinib resistance
1466622|NCT00109707|imatinib intolerant
1466623|NCT00109707|Hypereosinophilic Syndrome
1466624|NCT00109707|Systemic Mastocytosis
1466625|NCT00109707|Chronic eosinophilic syndrome
1466626|NCT00109707|Philadelphia chromosome positive acute lymphoblastic leukemia
1466627|NCT00109707|HES
1466628|NCT00109707|CEL
1466629|NCT00109707|CML
1466630|NCT00109707|SM
1466631|NCT00109707|Ph+ ALL refractory to standard therapy
1466632|NCT00109707|Ph+ALL relapsed
1466633|NCT00109707|AMN107A
1466634|NCT00109681|ACTIVE
1466635|NCT00109681|iloprost
1466636|NCT00109681|idiopathic pulmonary fibrosis
1466637|NCT00109681|pulmonary arterial hypertension
1466638|NCT00109655|Superficial Transitional Cell Carcinoma
1466639|NCT00109655|Bacillus Calmette-Guerin (BCG)
1466640|NCT00109655|Superficial Bladder Cancer
1466641|NCT00109655|Gene Therapy
1466642|NCT00109655|Vaccine
1466643|NCT00109655|Adenovirus
1466644|NCT00109655|Carcinoma in situ
1466645|NCT00109642|Amygdala
1466646|NCT00109642|Orbitofrontal Cortex
1466647|NCT00109642|Yohimbine
1466648|NCT00109642|Emotion
1466649|NCT00109642|Guanfacine
1466650|NCT00109642|Norepinephrine
1466651|NCT00109642|Healthy Volunteer
1466652|NCT00109629|HIV-Negative
1466653|NCT00109629|Healthy
1466654|NCT00109629|Immunity
1466655|NCT00109629|Preventive
1466656|NCT00109629|Virus
1466657|NCT00109629|Healthy Volunteer
1466658|NCT00109616|neonatal mortality
1466659|NCT00109616|chlorhexidine
1466660|NCT00109616|newborn cleansing
1466661|NCT00109616|umbilical cord care
1466662|NCT00109616|community-based trial
1466663|NCT00109616|prevention trial
1466664|NCT00109616|omphalitis
1466665|NCT00109603|Treatment Experienced
1466666|NCT00109603|TDF
1466667|NCT00109590|HIV Seronegativity
1466668|NCT00109590|Treatment Naive
1466669|NCT00109590|Pregnancy
1466670|NCT00109590|Perinatal Transmission
1466671|NCT00109590|Vertical Transmission
1466672|NCT00109590|Mother-To-Child Transmission
1466673|NCT00109590|MTCT
1466674|NCT00109577|bipolar disorder
1466675|NCT00109577|mood disorders
1466676|NCT00109577|manic depression
1466677|NCT00109577|nutrition
1466678|NCT00109564|AAMI
1466679|NCT00109564|Memory Impairment
1466680|NCT00109564|Decline in Cognitive Function
1466681|NCT00109564|Age Associated Memory Impairment
1466682|NCT00109551|zinc
1466683|NCT00109551|child mortality
1466684|NCT00109551|child morbidity
1466685|NCT00109551|community trial
1466686|NCT00109551|prevention trial
1466687|NCT00109551|dietary supplement
1466688|NCT00109538|Lonafarnib
1466689|NCT00109525|NICHD Neonatal Research Network
1466690|NCT00109525|Fungal Infection
1466691|NCT00109525|Mycosis
1466692|NCT00109525|Extremely Low Birth Weight (ELBW)
1466693|NCT00109525|Prematurity
1466694|NCT00109525|Clinical Judgement
1466695|NCT00109525|Polymerase chain reaction (PCR) testing
1466696|NCT00109525|Beta-glucan assay
1466697|NCT00109525|Mass Spectrometry
1466698|NCT00109525|Lumbar puncture
1466699|NCT00109512|endometriosis
1466700|NCT00109512|pelvic pain
1466701|NCT00109512|painful periods
1466702|NCT00109512|dysmenorrhea
1466703|NCT00109512|painful menstruation
1466704|NCT00109512|GnRH
1466705|NCT00109512|agonist
1466706|NCT00109512|antagonist
1466707|NCT00109512|menstrual pain
1466708|NCT00109499|Wet Age-Related Macular Degeneration
1466709|NCT00109499|Age-Related Maculopathies
1466710|NCT00109486|GW685698X
1466711|NCT00109486|seasonal allergic rhinitis
1466712|NCT00109486|perennial allergic rhinitis
1466713|NCT00109486|knemometry
1466714|NCT00109486|children
1466715|NCT00109473|Pediatric Crohn's disease
1466716|NCT00109473|Pediatric
1466717|NCT00109473|Crohn's Disease
1466718|NCT00109460|Tobacco
1466719|NCT00109434|exercise
1466720|NCT00109434|hypoglycemia
1466721|NCT00109434|Diabetes Mellitus, Type I
1466722|NCT00109434|glucose monitoring
1466723|NCT00109421|adolescent
1466724|NCT00109421|female
1466725|NCT00109421|community-based
1466726|NCT00109421|social network
1466727|NCT00109421|HIV/STI intervention
1466728|NCT00109421|High HIV-risk African American adolescent females
1466729|NCT00109395|Lorazepam
1466730|NCT00109395|Midazolam
1466731|NCT00109395|Best Pharmaceuticals for Children Act
1466732|NCT00109395|Critically ill
1466733|NCT00109395|pediatrics
1466734|NCT00109395|mechanical ventilation
1466735|NCT00109395|sedation
1466736|NCT00109382|Transient Ischemic Attack
1466738|NCT00109382|Stroke Prevention
1466739|NCT00109382|Recurrence
1466740|NCT00109382|Neuroprotection
1466741|NCT00109382|Antiplatelet Therapy
1466742|NCT00109382|Statins
1466743|NCT00109369|Chronic Disease
1466744|NCT00109369|Multi-Hospital Information Systems
1466871|NCT00108901|black, African-American
1466745|NCT00109369|Clinical Decision Support Systems
1466746|NCT00109369|Reminder Systems
1466747|NCT00109369|Registries
1466748|NCT00109369|Quality of Healthcare
1466749|NCT00109369|Guideline Adherence
1466750|NCT00109369|Outcome and Process Assessment (Health Care)
1466751|NCT00109369|Technology Assessment, Biomedical
1466752|NCT00109369|Primary Health Care
1466753|NCT00109369|Hypercholesterolemia
1466754|NCT00109369|Hypertension
1466755|NCT00109369|Hyperglycemia
1466756|NCT00109356|Non-Hodgkin's Lymphoma
1466757|NCT00109356|Chronic Lymphocytic Leukemia
1466758|NCT00109356|Small Lymphocytic Leukemia
1466759|NCT00109330|Prevention of Diphtheria, Tetanus, Pertussis
1466760|NCT00109317|Moderate Plaque Psoriasis
1466761|NCT00109317|Severe Plaque Psoriasis
1466762|NCT00109317|Topical
1466763|NCT00109304|Venezuelan Equine Encephalitis
1466764|NCT00109304|VEE
1466765|NCT00109304|Vaccine
1466766|NCT00109304|Provide protective immunity against VEE subtypes IA/B
1466767|NCT00109291|anemia
1466768|NCT00109291|chronic kidney disease
1466769|NCT00109291|CKD
1466770|NCT00109291|chronic renal failure
1466771|NCT00109291|CRF
1466772|NCT00109291|dialysis
1466773|NCT00109291|erythropoietin
1466774|NCT00109291|EPO
1466775|NCT00109291|erythropoiesis stimulating agent
1466776|NCT00109291|ESA
1466777|NCT00109291|Hematide™
1466778|NCT00109291|hemoglobin
1466779|NCT00109291|Hb
1466780|NCT00109291|Hgb
1466781|NCT00109291|Omontys
1466782|NCT00109291|peginesatide
1466783|NCT00109291|red blood cell
1466784|NCT00109291|red blood cell production
1466785|NCT00109278|Prevention of Measles
1466786|NCT00109265|Advanced Breast Cancer
1466787|NCT00109265|Metastatic Breast Cancer
1466788|NCT00109265|Cancer
1466789|NCT00109252|Plaque Psoriasis
1466790|NCT00109252|Topical
1466791|NCT00109239|Metastatic Breast Cancer
1466792|NCT00109239|Metastatic
1466793|NCT00109239|Cancer
1466794|NCT00109226|Metastatic Colorectal Cancer
1466795|NCT00109226|Cancer
1466796|NCT00109213|Spinal Stenosis
1466797|NCT00109213|Lumbar Spine
1466798|NCT00109213|Decompression
1466799|NCT00109213|Fusion
1466800|NCT00109213|Spondylolisthesis
1466801|NCT00109213|Prospective, randomized clinical trial
1466802|NCT00109200|Allergic Asthma
1466803|NCT00109200|Severe Allergic Asthma
1466804|NCT00109187|Moderate Persistent Asthma
1466805|NCT00109187|Severe Persistent Asthma
1466806|NCT00109174|Glutamate
1466807|NCT00109174|Excitatory Amino Acid
1466808|NCT00109174|Neurochemistry
1466809|NCT00109174|GABA
1466810|NCT00109174|Magnetic Resonance Spectroscopy
1466811|NCT00109161|Multiple Sclerosis, MS, CNS, Daclizumab
1466812|NCT00109148|Obesity and obesity-related medical conditions
1466813|NCT00109083|Migraine
1466814|NCT00109083|Headaches
1466815|NCT00109083|Migraine headaches
1466816|NCT00109083|Head pain
1466817|NCT00109070|Metastatic
1466818|NCT00109057|Cancer
1466819|NCT00109057|Advanced malignancies
1466820|NCT00109044|Depression
1466821|NCT00109044|Major Depressive Disorder
1466822|NCT00109044|Escitalopram
1466823|NCT00109031|Cancer
1466824|NCT00109031|Oncology
1466825|NCT00109018|Risk Assessment
1466826|NCT00109018|Coronary Heart Disease
1466827|NCT00109018|Vascular Function
1466828|NCT00109018|Nitric Oxide Metabolites
1466829|NCT00109018|Blood Tests
1466830|NCT00109018|Nitrite
1466831|NCT00109018|Flow-Mediated Dilation
1466832|NCT00109018|Biomarker
1466833|NCT00109018|Endothelial Dysfunction
1466834|NCT00109018|Coronary Artery Disease
1466835|NCT00109018|CAD
1466836|NCT00109018|Coronary Artery Disease At Risk
1466837|NCT00109018|Healthy Volunteer
1466838|NCT00109005|Response Rate
1466839|NCT00109005|Toxicity
1466840|NCT00109005|Progression-Free Survival
1466841|NCT00109005|Overall Survival
1466842|NCT00109005|Pharmacokinetic
1466843|NCT00109005|Ocular Melanoma
1466844|NCT00108992|topical NSAID
1466845|NCT00108992|topical diclofenac
1466846|NCT00108979|Depression
1466847|NCT00108979|Major Depressive Disorder
1466848|NCT00108979|Escitalopram
1466849|NCT00108953|Cancer
1466850|NCT00108953|Liver Cancer
1466851|NCT00108953|Hepatocellular carcinoma
1466852|NCT00108953|HCC
1466853|NCT00108940|stroke
1466854|NCT00108940|ischemic stroke
1466855|NCT00108940|siblings
1466856|NCT00108927|Clinical trial
1466857|NCT00108927|Diabetes
1466858|NCT00108927|Quality Improvement
1466859|NCT00108914|Perennial allergic rhinitis
1466860|NCT00108914|pediatric
1466861|NCT00108901|prevention
1466862|NCT00108901|children
1466863|NCT00108901|diabetes
1466864|NCT00108901|overweight
1466865|NCT00108901|obesity
1466866|NCT00108901|metabolic syndrome
1466867|NCT00108901|exercise
1466868|NCT00108901|insulin resistance
1466869|NCT00108901|female
1466870|NCT00108901|male
1466872|NCT00108901|white, Caucasian
1466873|NCT00108901|cognition
1466874|NCT00108901|executive function
1466875|NCT00108875|Peptide vaccine therapy
1466876|NCT00108875|Survivin
1466877|NCT00108862|Treatment Naive
1466878|NCT00108862|TB
1466879|NCT00108862|HIV
1466880|NCT00108862|Antiretroviral Agents
1466881|NCT00108862|Strategy Study
1466882|NCT00108836|GAD
1466883|NCT00108836|Anxiety
1466884|NCT00108836|XBD173
1466885|NCT00108836|Generalized Anxiety Disorder
1466886|NCT00108810|Pain
1466887|NCT00108810|Osteoarthritis
1466888|NCT00108810|OA
1466889|NCT00108810|Mild to Moderate Osteoarthritis (OA) Pain of the Knee
1466890|NCT00108784|reduced-energy-density diet
1466891|NCT00108784|fat-restricted diet
1466892|NCT00108784|fruit
1466893|NCT00108784|vegetables
1466894|NCT00108784|ad libitum intake
1466895|NCT00108784|weight loss
1466896|NCT00108784|obesity
1466897|NCT00108771|Pain
1466898|NCT00108771|Chronic Pain
1466899|NCT00108771|Osteoarthritis Pain
1466900|NCT00108771|Osteoarthritis
1466901|NCT00108706|Acute Stroke
1466902|NCT00108706|Cerebrovascular Accident
1466903|NCT00108706|Ischaemic Stroke
1466904|NCT00108706|Candesartan
1466905|NCT00108706|Angiotensin Receptor Blocker
1466906|NCT00108680|Hemiparesis
1466907|NCT00108680|Rehabilitation
1466908|NCT00108680|Reaching
1466909|NCT00108680|Interlimb Coupling
1466910|NCT00108680|Cortical Excitability
1466911|NCT00108680|Stroke
1466912|NCT00108667|Parkinson's Disease
1466913|NCT00108667|AMPA Antagonist
1466914|NCT00108667|Dyskinesias
1466915|NCT00108667|Glutamate Antagonist
1466916|NCT00108667|Parkinson Disease
1466917|NCT00108667|PD
1466918|NCT00108654|HIV-Negative
1466919|NCT00108654|Healthy
1466920|NCT00108654|Immunity
1466921|NCT00108654|Preventive
1466922|NCT00108654|Virus
1466923|NCT00108654|Healthy Volunteer
1466924|NCT00108628|Imagery
1466925|NCT00108628|Nightmares
1466926|NCT00108628|Post-Traumatic Stress Disorder
1466927|NCT00108628|Psychotherapy
1466928|NCT00108602|sleep apnea
1466929|NCT00108602|stroke
1466930|NCT00108602|ventilatory control
1466931|NCT00108589|s-adenosylmethionine
1466932|NCT00108589|fatty liver
1466933|NCT00108589|obesity
1466934|NCT00108589|Non-alcoholic steatohepatitis
1466935|NCT00108576|anticonvulsant
1466936|NCT00108576|anxiety
1466937|NCT00108576|divalproex
1466938|NCT00108576|PTSD
1466939|NCT00108563|Hepatitis C
1466940|NCT00108563|Depression
1466941|NCT00108563|Interferon-alpha
1466942|NCT00108563|Citalopram
1466943|NCT00108563|ribavirin
1466944|NCT00108563|antidepressive agents
1466945|NCT00108550|analgesia
1466946|NCT00108550|antidepressant agents
1466947|NCT00108550|back pain
1466948|NCT00108550|pain
1466949|NCT00108537|smoking
1466950|NCT00108537|nicotine
1466951|NCT00108537|drug therapy
1466952|NCT00108537|smoking cessation
1466953|NCT00108524|anti-obesity agents
1466954|NCT00108524|diet therapy
1466955|NCT00108524|diet, reducing
1466956|NCT00108524|obesity
1466957|NCT00108524|overweight
1466958|NCT00108524|risk factors
1466959|NCT00108524|weight loss
1466960|NCT00108511|hypertriglyceridemia
1466961|NCT00108511|lipoproteins
1466962|NCT00108511|triglycerides
1466963|NCT00108511|serum GPI-PLD (glycosylphosphatidylinositol-specific phospholipase D)
1466964|NCT00108498|sleep apnea
1466965|NCT00108498|mirtazapine
1466966|NCT00108498|sleep
1466967|NCT00108485|Diabetes Mellitus, Type 2
1466968|NCT00108485|Kidney Failure, Chronic
1466969|NCT00108485|Hyperlipidemia
1466970|NCT00108485|Randomized Controlled Trials
1466971|NCT00108459|Obesity
1466972|NCT00108459|Type 2 Diabetes
1466973|NCT00108459|Hyperlipidemia
1466974|NCT00108459|Insulin resistance
1466975|NCT00108446|Irritable Bowel Syndrome
1466976|NCT00108446|visceral hypersensitivity
1466977|NCT00108446|cutaneous hypersensitivity
1466978|NCT00108446|lidocaine
1466979|NCT00108420|Prazosin
1466980|NCT00108420|Stress Disorders, Post-traumatic
1466981|NCT00108407|Alcohol Abuse/Dependence
1466982|NCT00108407|Alcohol Use Disorders
1466983|NCT00108407|Cannabis Abuse/Dependence
1466984|NCT00108407|Depression
1466985|NCT00108407|Dual diagnosis
1466986|NCT00108407|Dysthymia
1466987|NCT00108407|Stimulant Abuse/Dependence
1466988|NCT00108407|Substance Use Disorders
1466989|NCT00108394|Uremia
1466990|NCT00108394|Dialysis
1466991|NCT00108394|Clinical Trials
1466992|NCT00108394|Bone Diseases, Metabolic
1466993|NCT00108394|adynamic bone disease
1466994|NCT00108394|low bone turnover
1466995|NCT00108381|chronic back pain
1466996|NCT00108381|cognitive-behavioral
1466997|NCT00108381|pain
1466998|NCT00108381|stages of change
1466999|NCT00108368|schizophrenia
1467000|NCT00108368|cognition
1467001|NCT00108368|antipsychotic medication
1467002|NCT00108368|information processing
1467003|NCT00108368|social cognition
1467004|NCT00108368|Psychotic
1467005|NCT00108355|albumin
1467006|NCT00108355|ascites
1467007|NCT00108355|paracentesis
1467008|NCT00108342|nicotine
1467009|NCT00108342|drug therapy
1467010|NCT00108342|Smoking Cessation
1467011|NCT00108329|aging
1467012|NCT00108329|exercise
1467013|NCT00108329|metabolic syndrome
1467014|NCT00108329|insulin resistance
1467015|NCT00108316|Depressive Disorder
1467016|NCT00108316|DNA
1467017|NCT00108316|Serotonin
1467018|NCT00108303|schizophrenia
1467019|NCT00108290|Prostate cancer
1467020|NCT00108290|chemotherapy
1467021|NCT00108290|hormone therapy
1467022|NCT00108290|surgery
1467023|NCT00108290|PSA
1467024|NCT00108290|Gleason score
1467025|NCT00108277|Anxiety
1467026|NCT00108277|Breathing Training
1467027|NCT00108277|Respiratory Dysregulation
1467028|NCT00108264|Prostatic Neoplasms
1467029|NCT00108264|Neoplasm Metastasis
1467030|NCT00108264|Immunotherapy
1467031|NCT00108264|Active
1467032|NCT00108264|Dendritic Cells
1467033|NCT00108251|controlled clinical trial
1467034|NCT00108251|Diastole
1467035|NCT00108251|Echocardiography
1467036|NCT00108251|exercise tolerance
1467037|NCT00108251|Heart Failure, Congestive
1467038|NCT00108251|Receptors, Aldosterone
1467039|NCT00108238|endothelial function
1467040|NCT00108238|hormone replacement therapy
1467041|NCT00108238|coronary flow reserve
1467042|NCT00108238|posmenopausal women
1467043|NCT00108238|women's cardiovascular heatlh
1467044|NCT00108225|Cholesterol
1467045|NCT00108225|Creatinine Clearance
1467046|NCT00108225|Diabetes
1467047|NCT00108225|Glycohemoglobin
1467048|NCT00108225|High Protein Diet
1467049|NCT00108212|Diet
1467050|NCT00108212|triglyceride
1467051|NCT00108212|inflammation
1467052|NCT00108212|Genetic polymorphism
1467053|NCT00107172|stage I non-small cell lung cancer
1467054|NCT00107159|recurrent melanoma
1467055|NCT00107159|stage III melanoma
1467056|NCT00107159|stage IV melanoma
1467057|NCT00107120|Major Depressive Disorder
1467058|NCT00107120|Depression
1467059|NCT00107120|Adolescents
1467060|NCT00107120|Escitalopram
1467061|NCT00107120|Pediatrics
1467062|NCT00107107|Diabetes
1467063|NCT00107107|Amylin
1467064|NCT00107107|pramlintide
1467065|NCT00107107|Symlin
1467066|NCT00107094|Breast Cancer
1467067|NCT00107094|Adriamycin
1467068|NCT00107094|Cyclophosphamide
1467069|NCT00107094|Abraxane
1467070|NCT00107081|children
1467071|NCT00107081|oral antibiotics
1467072|NCT00107081|outpatient treatment
1467073|NCT00107081|fever and neutropenia
1467074|NCT00107068|Stroke
1467075|NCT00107068|Exercise
1467076|NCT00107068|Aerobic
1467077|NCT00107068|PRT
1467078|NCT00107068|Walking ability
1467079|NCT00107055|Herniated nucleus pulposus
1467080|NCT00107055|Lumbosacral radiculopathy
1467081|NCT00107055|Anti-TNF alpha
1467082|NCT00107055|Tumor necrosis factor alpha
1467083|NCT00107042|Hepatitis B
1467084|NCT00107042|HIV vaccine trial
1467085|NCT00107029|HIV infection
1467086|NCT00107029|CD8+ T-cells
1467087|NCT00107029|HIV-1 genotype
1467088|NCT00107016|Breast Cancer
1467089|NCT00107016|Cancer of the Breast
1467090|NCT00107016|Neo-adjuvant
1467091|NCT00107016|Primary breast cancer
1467092|NCT00107016|postmenopausal
1467093|NCT00107016|pre-operative
1467094|NCT00107003|Brain
1467095|NCT00107003|Tumor
1467096|NCT00107003|Surgery
1467097|NCT00107003|Therapy
1467098|NCT00107003|Trial
1467099|NCT00107003|Brain Tumor
1467100|NCT00107003|Glioblastoma Multiforme
1467101|NCT00107003|GBM
1467102|NCT00107003|Gliosarcoma
1467103|NCT00107003|GS
1467104|NCT00106977|Craniosynostosis
1467105|NCT00106977|Hearing Loss
1467106|NCT00106977|Genectic Disorders
1467107|NCT00106977|Muenke Syndrome
1467108|NCT00106964|Hepatitis B vaccines
1467109|NCT00106964|HIV-infected adolescents
1467110|NCT00106964|Hepatitis B infection (negative)
1467111|NCT00106951|Surveillance
1467112|NCT00106951|coronary heart disease
1467113|NCT00106951|neighborhood SES
1467114|NCT00106938|Carotid stenting
1467115|NCT00106938|Carotid endarterectomy
1467116|NCT00106938|Carotid artery disease with severe narrowing of the artery
1467117|NCT00106938|Stroke prevention
1467118|NCT00106925|Peripheral Blood Stem Cells
1467119|NCT00106925|Graft-Versus Leukemia/Myeloma
1467120|NCT00106925|Graft-Versus-Host Disease
1467121|NCT00106925|Whole Body Irradiation
1467122|NCT00106925|Leukemic Relapse
1467123|NCT00106925|Allogeneic Stem Cell Transplantation Recipient
1467124|NCT00106912|Genetic
1467125|NCT00106912|Stroke
1467126|NCT00106912|Heart
1467127|NCT00106912|Lysosomal
1467128|NCT00106912|Glycolipid
1467129|NCT00106912|Fabry Disease
1467130|NCT00106899|neuroimaging
1467131|NCT00106899|brain metabolism
1467132|NCT00106899|biomarkers
1467133|NCT00106899|cognition disorder
1467134|NCT00106899|Mild Cognitive Impairment
1467135|NCT00108199|Schizophrenia
1467136|NCT00108199|vocational rehabilitation
1467137|NCT00108199|neuropsychology
1467138|NCT00108186|cyclooxygenase 2
1467139|NCT00108186|lung cancer
1467140|NCT00108186|lymphocytes
1467141|NCT00108186|non small cell
1467142|NCT00108186|therapeutics
1467143|NCT00108173|Position Emission Tomography (PET)
1467144|NCT00108173|Nicotine dependence
1467145|NCT00108173|functional magnetic resonance imaging
1467146|NCT00108173|cigarette cues
1467147|NCT00108160|mupirocin
1467148|NCT00108160|prevention and control
1467149|NCT00108160|s. aureus
1467150|NCT00108147|Aged
1467151|NCT00108147|Congestive Heart Failure
1467152|NCT00108147|Exercise
1467153|NCT00108134|Superficial basal cell carcinoma
1467154|NCT00108134|basal cell carcinoma
1467155|NCT00108134|sBCC
1467156|NCT00108134|BCC
1467157|NCT00108134|PEP005
1467158|NCT00108134|Topical
1467159|NCT00108134|Dermatology
1467160|NCT00108121|Nodular basal cell carcinoma
1467161|NCT00108121|basal cell carcinoma
1467162|NCT00108121|nBCC
1467163|NCT00108121|BCC
1467164|NCT00108121|PEP005
1467165|NCT00108121|Topical
1467166|NCT00108121|Dermatology
1467167|NCT00108108|Lymphocytic Leukemia
1467168|NCT00108095|emesis
1467169|NCT00108095|nausea
1467170|NCT00108095|post operative nausea and vomiting
1467171|NCT00108095|vomiting
1467172|NCT00108095|PONV
1467173|NCT00108082|left ventricular hypertrophy (LVH)
1467174|NCT00108082|echocardiogram
1467175|NCT00108082|left ventricular mass regression
1467176|NCT00108082|cardiac MRI
1467177|NCT00108082|left ventricular mass index (LVMI)hypertension
1467178|NCT00108069|Brain
1467179|NCT00108069|Tumor
1467180|NCT00108069|Malignant
1467181|NCT00108069|Therapy
1467182|NCT00108069|Progression
1467183|NCT00108069|Chemotherapy
1467184|NCT00108069|Antiangiogenesis
1467185|NCT00108069|Radiation
1467186|NCT00108069|Malignant Brain Tumor
1467187|NCT00108069|Malignant Glioma
1467188|NCT00108069|Glioma
1467189|NCT00108056|Brain
1467190|NCT00108056|Tumor
1467191|NCT00108056|Malignant
1467192|NCT00108056|Therapy
1467193|NCT00108056|Progression
1467194|NCT00108056|Malignant Brain Tumor
1467195|NCT00108056|Malignant Glioma
1467196|NCT00108056|Glioma
1467197|NCT00108043|Functional Electrical Stimulation
1467198|NCT00108043|Gait
1467199|NCT00108043|Blood pressure
1467200|NCT00108043|Orthostatic Hypotension
1467201|NCT00108043|Cardiovascular responses
1467202|NCT00108043|Near-infra red spectroscopy
1467203|NCT00108030|PBWST training
1467204|NCT00108030|Strength training
1467205|NCT00108030|6-min walking endurance
1467206|NCT00108030|Cardiovascular fitness
1467207|NCT00108030|Psychosocial attributes
1467208|NCT00108017|Ocular hypertension (excessive pressure in the eye)
1467209|NCT00108004|Diabetes
1467210|NCT00108004|Amylin
1467211|NCT00108004|Symlin
1467212|NCT00108004|pramlintide acetate
1467213|NCT00107991|clinical trial; efficacy; etanercept; hidradenitis suppurativa; quality of life; safety; tnf
1467214|NCT00107978|cSSSI (complicated Skin and Skin Structure Infections)
1467215|NCT00107978|Staph (Staphylococcus)
1467216|NCT00107978|MRSA (Methicillin-resistant Staphylococcus Aureus)
1467217|NCT00107965|Actinic Keratosis
1467218|NCT00107965|Solar Keratosis
1467219|NCT00107965|AK
1467220|NCT00107965|Sun spots
1467221|NCT00107965|PEP005
1467222|NCT00107965|Topical
1467223|NCT00107965|Dermatology
1467224|NCT00107952|Nosocomial pneumonia
1467225|NCT00107952|MRSA
1467226|NCT00107939|bipolar disorder
1467227|NCT00107939|manic episode
1467228|NCT00107939|treatment
1467229|NCT00107939|licarbazepine
1467230|NCT00107926|bipolar disorder
1467231|NCT00107926|manic episode
1467232|NCT00107926|treatment
1467233|NCT00107926|licarbazepine
1467234|NCT00107913|Immune Thrombocytopenic Purpura
1467235|NCT00107900|Deep Vein Thrombosis,
1467236|NCT00107900|Anticoagulant,
1467237|NCT00107900|Venous thromboembolic
1467238|NCT00107887|TST
1467239|NCT00107887|isoniazid
1467240|NCT00107887|HAART
1467241|NCT00107887|Brazil
1467242|NCT00107887|HIV
1467243|NCT00107874|Maternal
1467244|NCT00107874|morbidity
1467245|NCT00107874|mortality
1467246|NCT00107874|pregnancy
1467247|NCT00107874|postpartum hemorrhage
1467248|NCT00107874|Cesarean Section
1467249|NCT00107848|Pediatric Narcolepsy
1467250|NCT00107848|Pediatric OSA
1467251|NCT00107848|CPAP
1467252|NCT00107848|Pediatric Narcolepsy or OSAHS
1467253|NCT00107835|Pain
1467254|NCT00107822|Pain
1467255|NCT00107809|Pediatric Obstructive sleep Apnea
1467256|NCT00107809|Excessive sleepiness
1467257|NCT00107809|CPAP
1467258|NCT00107809|Pediatric OSAHS
1467259|NCT00107796|Pediatric Narcolepsy
1467260|NCT00107796|Excessive sleepiness
1467261|NCT00107783|Arthritis
1467262|NCT00107783|Homogentisic Acid
1467263|NCT00107783|Corneal Damage
1467264|NCT00107783|Tyrosine
1467265|NCT00107783|Alkaptonuria
1467266|NCT00107783|Photophobia
1467267|NCT00107783|Nitisinone
1467268|NCT00107770|ALS
1467269|NCT00107770|histone deacetylase inhibition
1467270|NCT00107770|open label
1467271|NCT00107770|safety study
1467272|NCT00107770|sodium phenylbutyrate
1467273|NCT00107757|pediatric
1467274|NCT00107757|Seasonal allergic rhinitis
1467275|NCT00107744|Blood Pressure; Lipids; Dietary Protein
1467276|NCT00107731|Bipolar I Disorder
1467277|NCT00107731|Manic Depressive Disorder
1467278|NCT00107731|Manic Depression
1467279|NCT00107718|IL-18
1467280|NCT00107718|Phase 2
1467281|NCT00107718|melanoma
1467282|NCT00107718|treatment naive
1467283|NCT00107705|allergy
1467284|NCT00107705|skin prick test
1467285|NCT00107705|allergoid
1467286|NCT00107705|allergenicity
1467287|NCT00107705|specific immunotherapy
1467288|NCT00107692|Child Obesity
1467289|NCT00107692|Physical activity
1467290|NCT00107692|community intervention study
1467291|NCT00107692|competence
1467292|NCT00107692|diet and nutrition
1467293|NCT00107692|Nutrition
1467294|NCT00107679|Treatment Experienced
1467295|NCT00107679|HIV
1467296|NCT00107679|HPV
1467297|NCT00107679|Antiretroviral Therapy, Highly Active
1467298|NCT00107679|Papillomavirus, Human
1467299|NCT00107666|Coronary artery bypass grafting
1467300|NCT00107666|Heart valve prosthesis implantation
1467301|NCT00107666|Cardiopulmonary bypass
1467302|NCT00107666|Oxidative stress
1467303|NCT00107666|Inflammation
1467304|NCT00107666|Endotoxemia
1467305|NCT00107640|At-risk drinking
1467306|NCT00107640|Alcohol education
1467307|NCT00107640|Effectiveness
1467308|NCT00107640|Cost-effectiveness
1467309|NCT00107627|Gynaecological Cancer
1467310|NCT00107627|Surgical Staples
1467311|NCT00107627|Subcuticular Sutures
1467312|NCT00107614|Waldenstrom
1467313|NCT00107601|Glucose
1467314|NCT00107601|Glucose Control
1467315|NCT00107601|Insulin
1467316|NCT00107601|Insulin therapy
1467317|NCT00107601|Critically ill
1467318|NCT00107601|Intensive Care
1467319|NCT00107588|marijuana dependence
1467320|NCT00107588|self-efficacy
1467321|NCT00107588|coping skills
1467322|NCT00107588|attendance
1467323|NCT00107588|marijuana abstinence
1467324|NCT00107575|tobacco
1467325|NCT00107575|alcohol
1467326|NCT00107562|risk behavior
1467327|NCT00107562|social networks
1467328|NCT00107562|behavior
1467329|NCT00107549|Treatment Experienced
1467330|NCT00107549|HIV Therapeutic Vaccine
1467331|NCT00107523|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1467332|NCT00107523|adult acute myeloid leukemia with inv(16)(p13;q22)
1467333|NCT00107523|adult acute myeloid leukemia with t(15;17)(q22;q12)
1467334|NCT00107523|adult acute myeloid leukemia with t(16;16)(p13;q22)
1467335|NCT00107523|adult acute myeloid leukemia with t(8;21)(q22;q22)
1467336|NCT00107523|recurrent adult acute myeloid leukemia
1467337|NCT00107523|untreated adult acute myeloid leukemia
1467338|NCT00107510|stage II breast cancer
1467339|NCT00107510|stage IIIA breast cancer
1467340|NCT00107510|stage IIIB breast cancer
1467341|NCT00107510|stage IIIC breast cancer
1467342|NCT00107510|male breast cancer
1467343|NCT00107497|stage I breast cancer
1467344|NCT00107497|stage II breast cancer
1467345|NCT00107484|stage IV breast cancer
1467346|NCT00107484|stage I breast cancer
1467347|NCT00107484|stage II breast cancer
1467348|NCT00107484|stage IIIA breast cancer
1467349|NCT00107484|stage IIIB breast cancer
1467350|NCT00107484|stage IIIC breast cancer
1467351|NCT00107484|male breast cancer
1467352|NCT00107471|untreated childhood brain stem glioma
1467353|NCT00107458|recurrent childhood brain stem glioma
1467354|NCT00107458|recurrent childhood brain tumor
1467355|NCT00107458|recurrent childhood cerebellar astrocytoma
1467356|NCT00107458|recurrent childhood cerebral astrocytoma
1467357|NCT00107458|recurrent childhood ependymoma
1467358|NCT00107458|recurrent childhood medulloblastoma
1467359|NCT00107458|recurrent childhood supratentorial primitive neuroectodermal tumor
1467360|NCT00107458|unspecified childhood solid tumor, protocol specific
1467361|NCT00107458|recurrent childhood visual pathway and hypothalamic glioma
1467362|NCT00107458|childhood high-grade cerebral astrocytoma
1467363|NCT00107458|childhood low-grade cerebral astrocytoma
1467364|NCT00107458|childhood infratentorial ependymoma
1467365|NCT00107458|childhood supratentorial ependymoma
1467366|NCT00107458|childhood spinal cord neoplasm
1467367|NCT00107458|childhood grade I meningioma
1467368|NCT00107458|childhood grade II meningioma
1467369|NCT00107458|childhood grade III meningioma
1467370|NCT00107458|childhood craniopharyngioma
1467484|NCT00106717|Narrative medicine
1467371|NCT00107458|childhood central nervous system germ cell tumor
1467372|NCT00107419|chondrosarcoma
1467373|NCT00107393|recurrent breast cancer
1467374|NCT00107393|stage IV breast cancer
1467375|NCT00107380|contiguous stage II adult diffuse large cell lymphoma
1467376|NCT00107380|noncontiguous stage II adult diffuse large cell lymphoma
1467377|NCT00107380|stage III adult diffuse large cell lymphoma
1467378|NCT00107380|stage IV adult diffuse large cell lymphoma
1467379|NCT00107367|tumors metastatic to brain
1467380|NCT00107354|recurrent adult acute lymphoblastic leukemia
1467381|NCT00107354|recurrent adult acute myeloid leukemia
1467382|NCT00107354|recurrent childhood acute lymphoblastic leukemia
1467383|NCT00107354|recurrent childhood acute myeloid leukemia
1467384|NCT00107354|secondary acute myeloid leukemia
1467385|NCT00107354|refractory anemia with excess blasts in transformation
1467386|NCT00107354|refractory anemia with excess blasts
1467387|NCT00107354|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1467388|NCT00107354|adult acute myeloid leukemia with inv(16)(p13;q22)
1467389|NCT00107354|adult acute myeloid leukemia with t(15;17)(q22;q12)
1467390|NCT00107354|adult acute myeloid leukemia with t(16;16)(p13;q22)
1467391|NCT00107354|adult acute myeloid leukemia with t(8;21)(q22;q22)
1467392|NCT00107354|de novo myelodysplastic syndromes
1467393|NCT00107354|previously treated myelodysplastic syndromes
1467394|NCT00107354|secondary myelodysplastic syndromes
1467395|NCT00107354|T-cell adult acute lymphoblastic leukemia
1467396|NCT00107354|T-cell childhood acute lymphoblastic leukemia
1467397|NCT00107354|B-cell adult acute lymphoblastic leukemia
1467398|NCT00107354|B-cell childhood acute lymphoblastic leukemia
1467399|NCT00107354|childhood myelodysplastic syndromes
1467400|NCT00107341|adenocarcinoma of the esophagus
1467401|NCT00107341|stage IV esophageal cancer
1467402|NCT00107341|recurrent esophageal cancer
1467403|NCT00107315|recurrent colon cancer
1467404|NCT00107315|stage IV colon cancer
1467405|NCT00107315|recurrent rectal cancer
1467406|NCT00107315|stage IV rectal cancer
1467407|NCT00107289|metastatic pheochromocytoma
1467408|NCT00107289|recurrent pheochromocytoma
1467409|NCT00107289|regional pheochromocytoma
1467410|NCT00107289|recurrent neuroblastoma
1467411|NCT00107289|04-148
1467412|NCT00107276|stage IV breast cancer
1467413|NCT00107276|recurrent breast cancer
1467414|NCT00107263|osteoporosis
1467415|NCT00107263|stage I breast cancer
1467416|NCT00107263|stage II breast cancer
1467417|NCT00107263|stage IIIA breast cancer
1467418|NCT00107250|recurrent non-small cell lung cancer
1467419|NCT00107250|stage IIIB non-small cell lung cancer
1467420|NCT00107250|stage IV non-small cell lung cancer
1467421|NCT00107250|stage IV colon cancer
1467422|NCT00107250|stage IV rectal cancer
1467423|NCT00107250|unspecified adult solid tumor, protocol specific
1467424|NCT00107237|adult glioblastoma
1467425|NCT00107237|recurrent adult brain tumor
1467426|NCT00107237|adult giant cell glioblastoma
1467427|NCT00107237|adult gliosarcoma
1467428|NCT00107211|ductal breast carcinoma in situ
1467429|NCT00107211|breast cancer in situ
1467430|NCT00107185|childhood high-grade cerebral astrocytoma
1467431|NCT00107185|recurrent childhood cerebral astrocytoma
1467432|NCT00107185|childhood oligodendroglioma
1467433|NCT00106886|homocysteine
1467434|NCT00106886|folic acid
1467435|NCT00106886|micronutrients
1467436|NCT00106886|multivitamins
1467437|NCT00106886|vitamin supplements
1467438|NCT00106860|Anxiety
1467439|NCT00106860|Generalized Anxiety Disorder
1467440|NCT00106847|plaque-type psoriasis
1467441|NCT00106847|psoriasis
1467442|NCT00106847|drug safety
1467443|NCT00106847|drug efficacy
1467444|NCT00106847|maintenance therapy
1467445|NCT00106847|induction therapy
1467446|NCT00106847|remicade
1467447|NCT00106834|Psoriasis
1467448|NCT00106834|Infliximab
1467449|NCT00106834|Remicade
1467450|NCT00106808|Type 2 Diabetes
1467451|NCT00106795|Antiretrovirals
1467452|NCT00106795|Adipocytes
1467453|NCT00106795|Skeletal Muscle
1467454|NCT00106795|Fatigue
1467455|NCT00106795|HIV
1467456|NCT00106795|AIDS
1467457|NCT00106795|Lymphocytes
1467458|NCT00106795|Lipodystrophy
1467459|NCT00106795|HIV Positive
1467460|NCT00106795|Healthy Volunteer
1467461|NCT00106795|HV
1467462|NCT00106782|Electrical
1467463|NCT00106782|Stimulation
1467464|NCT00106782|Dystonia
1467465|NCT00106782|Brain
1467466|NCT00106782|Focal Hand Dystonia
1467467|NCT00106782|FHD
1467468|NCT00106769|Flavivirus
1467469|NCT00106769|Mosquito
1467470|NCT00106769|Immunity
1467471|NCT00106769|Preventive
1467472|NCT00106769|Virus
1467473|NCT00106769|West Nile Fever
1467474|NCT00106769|Healthy Volunteer
1467475|NCT00106769|HV
1467476|NCT00106756|Exudation
1467477|NCT00106756|Avascular Retina
1467478|NCT00106756|Retina Fold
1467479|NCT00106743|Usher Syndrome
1467480|NCT00106743|Retinitis Pigmentosa
1467481|NCT00106743|Congenital Deafness
1467482|NCT00106717|Cancer pain
1467483|NCT00106717|Quality of life
1467485|NCT00106717|Pain relief
1467486|NCT00106691|neoplasia
1467487|NCT00106691|chemoprevention
1467488|NCT00106691|cancer
1467489|NCT00106691|premalignant
1467490|NCT00106691|precancerous
1467491|NCT00106691|Chemoprophylaxis
1467492|NCT00106691|Intraepithelial Prostatic Neoplasia
1467493|NCT00106691|Neoplasia, Prostatic Intraepithelial
1467494|NCT00106678|HIV
1467495|NCT00106678|Antiretroviral therapy (ART)
1467496|NCT00106678|HAART
1467497|NCT00106678|Adherence
1467498|NCT00106678|Barriers
1467499|NCT00106665|ICU acquired weakness
1467500|NCT00106665|Critical care polyneuropathy
1467501|NCT00106665|Critical care myopathy
1467502|NCT00106652|autism
1467503|NCT00106652|neurodevelopment
1467504|NCT00106652|neurotoxicology
1467505|NCT00106652|perinatology
1467506|NCT00106652|teratology
1467507|NCT00106639|tofacitinib
1467508|NCT00106639|CP-690550
1467509|NCT00106639|kidney transplant
1467510|NCT00106626|Advanced solid tumors including MPM and NSCLC
1467511|NCT00106613|Renal Cell Carcinoma
1467512|NCT00106613|Metastatic Cancer
1467513|NCT00106613|Metastatic Renal Cell Carcinoma
1467514|NCT00106600|Relapsed
1467515|NCT00106600|Refractory
1467516|NCT00106587|in stent restenosis
1467517|NCT00106587|paclitaxel coated balloon catheter
1467518|NCT00106587|paccocath
1467519|NCT00106587|drug eluting balloon
1467520|NCT00106561|spironolactone
1467521|NCT00106561|proteinuria
1467522|NCT00106561|angiotensin converting enzyme inhibitor
1467523|NCT00106561|angiotensin receptor blocker
1467524|NCT00106561|renin angiotensin aldosterone system
1467525|NCT00106561|aldosterone
1467526|NCT00106509|Clostridium Enterocolitis
1467527|NCT00106509|Pseudomembranous Colitis
1467528|NCT00106509|Clostridium difficile-associated diarrhea
1467529|NCT00106509|C. difficile
1467530|NCT00106509|CDAD
1467531|NCT00106496|Treatment Effectiveness
1467532|NCT00106496|Treatment Efficacy
1467533|NCT00106496|Immunomodulator, Topical
1467534|NCT00106496|Tacrolimus, Topical
1467535|NCT00106496|Dermatitis, Atopic
1467536|NCT00106496|Eczema, Atopic
1467537|NCT00106496|Atopic Dermatitis
1467538|NCT00106483|Cardiovascular Diseases
1467539|NCT00106483|Coronary Disease
1467540|NCT00106483|Heart Diseases
1467541|NCT00106470|Chronic Obstructive Pulmonary Disease
1467542|NCT00106431|romidepsin
1467543|NCT00106418|Prostate Cancer
1467544|NCT00106418|Androgen independent metastatic prostate cancer patients with rising PSA
1467545|NCT00106418|romidepsin
1467546|NCT00106405|Bipolar I Disorder
1467547|NCT00106405|Mania
1467548|NCT00106405|Memantine HCl
1467549|NCT00106392|Treatment effectiveness
1467550|NCT00106392|Treatment efficacy
1467551|NCT00106392|Investigational, Therapies
1467552|NCT00106392|Immunosuppressant
1467553|NCT00106392|Erectile dysfunction
1467554|NCT00106392|Prostatectomy
1467555|NCT00106379|HIV-1
1467556|NCT00106379|Treatment Naive
1467557|NCT00106379|Treatment Experienced
1467558|NCT00106366|Diabetes, Type 2
1467559|NCT00106353|Pediatric Tumors
1467560|NCT00106340|type 2 diabetes
1467561|NCT00106340|vildagliptin
1467562|NCT00106314|Dehydroepiandrosterone
1467563|NCT00106314|DHEA
1467564|NCT00106314|Crohn's disease
1467565|NCT00106314|C-reactive protein
1467566|NCT00106314|CRP
1467567|NCT00106314|Crohn's Disease Activity Index
1467568|NCT00106314|CDAI
1467569|NCT00106314|Inflammatory Bowel Disease Questionnaire
1467570|NCT00106314|IBDQ
1467571|NCT00106301|FK228
1467572|NCT00106301|Hormone Refractory Prostate Cancer
1467573|NCT00106288|Candidaemia
1467574|NCT00106288|Micafungin
1467575|NCT00106275|Fibromyalgia
1467576|NCT00106275|Meditation
1467577|NCT00106275|Stress, Psychological
1467578|NCT00106275|Monitoring, Ambulatory
1467579|NCT00106275|Electrocardiographie, Ambulatory
1467580|NCT00106275|Psychophysiology
1467581|NCT00106262|advanced cervical cancer
1467582|NCT00106262|metastatic cervical cancer
1467583|NCT00106249|TMS, Supplementary Motor Area, Obsessive-Compulsive Disorder
1467584|NCT00106236|Exercise
1467585|NCT00106236|Fitness Club
1467586|NCT00106236|Randomized Controlled Trial
1467587|NCT00106236|Cardiovascular Risk Factor
1467588|NCT00106236|Overweight
1467589|NCT00106236|Inactivity
1467590|NCT00106223|Cognitive Behavioral Therapy
1467591|NCT00106223|CBT
1467592|NCT00106223|BDD
1467593|NCT00106223|Body dysmorphic disorder
1467594|NCT00106210|Child
1467595|NCT00106197|Sleep, REM
1467596|NCT00106197|Antidepressant
1467597|NCT00106197|Adolescent
1467598|NCT00106197|Cortisol
1467599|NCT00106184|rituximab
1467600|NCT00106184|myositis
1467601|NCT00106184|dermatomyositis
1467602|NCT00106184|polymyositis
1467603|NCT00106184|refractory
1467604|NCT00106184|Juvenile Dermatomyositis
1467605|NCT00106171|HIV
1467606|NCT00106171|Acute/Early Seroconverters
1467607|NCT00106171|Acute Infection
1467608|NCT00106171|Treatment Naive
1467609|NCT00106171|Primary HIV Infection
1467610|NCT00106158|cancer/testis antigen
1467611|NCT00106158|cancer vaccine
1467612|NCT00106158|recombinant protein
1467613|NCT00106145|Advanced Breast Cancer
1467614|NCT00106145|Solid Tumors
1467615|NCT00106145|Advanced Solid Tumors
1467616|NCT00106132|Macular Edema
1467617|NCT00106132|Steroid
1467618|NCT00106132|Fluorescein Angiogram
1467619|NCT00106132|Ocular Coherence Tomography
1467620|NCT00106132|Laser
1467621|NCT00106132|Retinal Vein Occlusion
1467622|NCT00106119|Levothyroxine
1467623|NCT00106119|Liothyronine
1467624|NCT00106119|Lipid Metabolism
1467625|NCT00106119|Gluconeogensis
1467626|NCT00106119|Thyrotropin Releasing Hormone
1467627|NCT00106119|Deiodinase
1467628|NCT00106119|Replacement Thyroid Hormone Therapy
1467629|NCT00106119|Thyroidectomy
1467630|NCT00106119|Near Total Thyroidectomy
1467631|NCT00106106|Alcoholism
1467632|NCT00106106|Acamprosate
1467633|NCT00106106|Withdrawal
1467634|NCT00106106|Glutamate
1467635|NCT00106106|Magnetic Resonance Spectroscopy
1467636|NCT00106106|Alcohol Dependence
1467637|NCT00106106|Healthy Volunteer
1467638|NCT00106106|HV
1467639|NCT00106093|Alcohol
1467640|NCT00106093|Alcohol Treatment
1467641|NCT00106093|DNA
1467642|NCT00106093|Treatment
1467643|NCT00106093|Alcohol Dependence
1467644|NCT00106093|Alcoholism
1467645|NCT00106093|Alcohol Drinking Related Problems
1467646|NCT00106080|Communication
1467647|NCT00106080|Palliative Care
1467648|NCT00106067|aging
1467649|NCT00106067|behavioral research
1467650|NCT00106067|quality of life
1467651|NCT00106067|end of life
1467652|NCT00106067|family relations
1467653|NCT00106067|supportive care
1467654|NCT00106067|advanced care
1467655|NCT00106067|bereavement
1467656|NCT00106041|end of life care
1467657|NCT00106041|evaluation studies
1467658|NCT00106041|quality of death and dying
1467659|NCT00106041|palliative care
1467660|NCT00106041|coordination of care
1467661|NCT00106041|satisfaction with care
1467662|NCT00106041|healthcare cost
1467663|NCT00106041|utilization of healthcare resources
1467664|NCT00106041|caregivers
1467665|NCT00106041|veterans
1467666|NCT00106028|Primary disease: Osteogenesis Imperfecta
1467667|NCT00106015|inherited pure red cell aplasia
1467668|NCT00105963|abuse
1467669|NCT00105950|ErbB2 overexpressing
1467670|NCT00105950|ErbB1 expressing
1467671|NCT00105950|relapsed breast cancer
1467672|NCT00105950|refractory inflammatory breast cancer
1467673|NCT00105937|Cancer
1467674|NCT00105937|Pain
1467675|NCT00105911|Cognitive Behavioral Therapy
1467676|NCT00105898|Diabetes mellitus
1467677|NCT00105898|Hypertension
1467678|NCT00105898|Telemedicine
1467679|NCT00105898|Case management
1467680|NCT00105885|Telephone
1467681|NCT00105885|Telemedicine
1467682|NCT00105885|Psychopharmacology
1467683|NCT00105872|insomnia
1467684|NCT00105872|cognitive behavior therapy
1467685|NCT00105820|Evaluation
1467686|NCT00105820|Quality improvement
1467687|NCT00105820|Cluster randomized trial
1467688|NCT00105820|Care model
1467689|NCT00105820|Collaborative care
1467690|NCT00105820|Informatics
1467691|NCT00105794|advance directives
1467692|NCT00105794|advance directive adherence
1467693|NCT00105794|patient-centered care
1467694|NCT00105794|patient satisfaction
1467695|NCT00105794|coercion
1467696|NCT00105794|informed consent
1467697|NCT00105794|commitment of mentally ill
1467698|NCT00105794|physician-patient relations
1467699|NCT00105781|Nurses
1467700|NCT00105781|Telephone
1467701|NCT00105781|Counseling
1467702|NCT00105781|Exercise
1467703|NCT00105755|Activity Cycles
1467704|NCT00105755|Amputation
1467705|NCT00105755|Prevention
1467706|NCT00105755|Temperature
1467707|NCT00105729|Self-help groups
1467708|NCT00105729|Referral and consultation
1467709|NCT00105716|hypertension
1467710|NCT00105716|adherence
1467711|NCT00105716|cardiovascular diseases
1467712|NCT00105703|Nurse practitioners
1467713|NCT00105703|Case management
1467714|NCT00105677|Racial/ethnic health disparities
1467715|NCT00105677|Attitudes
1467716|NCT00105677|Osteoarthritis Management
1467717|NCT00105677|Patient Perceptions
1467718|NCT00105664|Outcomes Assessment
1467719|NCT00105664|Primary Health Care
1467720|NCT00105664|Group Process
1467721|NCT00105638|Intervention studies
1467722|NCT00105638|Health Care Costs
1467723|NCT00105638|Telephone
1467724|NCT00105638|Caregivers
1467725|NCT00105625|Geriatrics
1467726|NCT00105625|Nutrition
1467727|NCT00105625|Immune function
1467728|NCT00105625|Infection
1467729|NCT00105625|Rehabilitation
1467730|NCT00105625|Inpatient
1467731|NCT00105612|Informed Consent
1467732|NCT00105612|Memory Aid
1467733|NCT00105586|Anxiety
1467734|NCT00105586|Elderly
1467735|NCT00105586|Aged
1467736|NCT00105586|Serotonin Reuptake Inhibitors
1467737|NCT00105586|SSRI
1467738|NCT00105586|SERT
1467739|NCT00105573|Mother-Child Relations
1467740|NCT00105573|Infant
1467741|NCT00105573|Child Development
1467742|NCT00105573|Poverty
1467743|NCT00105560|long-term effects secondary to cancer therapy in children
1467744|NCT00105560|untreated childhood medulloblastoma
1467745|NCT00105560|untreated childhood pineoblastoma
1467746|NCT00105547|Alzheimer's
1467747|NCT00105547|Dementia
1467748|NCT00105547|Dementia of Alzheimer Type
1467749|NCT00105534|Bacterial Conjunctivitis
1467750|NCT00105534|Pink Eye
1467751|NCT00105534|Conjunctivitis
1467752|NCT00105534|Eye Infection
1467753|NCT00105534|Eye Discharge
1467754|NCT00105521|Parkinson's Disease
1467755|NCT00105521|Dyskinesia
1467756|NCT00105521|Dyskinesia associated with dopaminergic treatment
1467757|NCT00105508|Parkinson's Disease
1467758|NCT00105508|Dyskinesia
1467759|NCT00105508|Dyskinesia associated with dopaminergic treatment
1467760|NCT00105495|Iron Overload
1467761|NCT00105495|Thalassemia
1467762|NCT00105495|Haemosiderosis
1467763|NCT00105495|Cardiac
1467764|NCT00105495|Deferiprone
1467765|NCT00105495|Chelation
1467766|NCT00105482|Tobacco
1467767|NCT00105482|Smoking
1467768|NCT00105482|Weight
1467769|NCT00105482|Weight perception
1467770|NCT00105482|Naltrexone
1467771|NCT00105469|Bacterial Conjunctivitis
1467772|NCT00105469|Pink Eye
1467773|NCT00105469|Conjunctivitis
1467774|NCT00105469|Eye Infection
1467775|NCT00105456|HER2-Positive Metastatic Breast Cancer
1467776|NCT00105456|HER2
1467777|NCT00105443|Liver Cancer
1467778|NCT00105443|Cancer
1467779|NCT00105430|Surgery
1467780|NCT00105430|Treatment
1467781|NCT00105430|Physiology
1467782|NCT00105430|Pediatric
1467783|NCT00105430|Neurosurgery
1467784|NCT00105430|Generalized Primary Dystonia
1467785|NCT00105417|Immune Reconstitution
1467786|NCT00105417|Thymus
1467787|NCT00105417|Cytokines
1467788|NCT00105417|HIV
1467789|NCT00105404|Steroid
1467790|NCT00105404|Diabetic Macular Edema
1467791|NCT00105404|DME
1467792|NCT00105378|health care services research
1467793|NCT00105378|frail elderly
1467794|NCT00105378|intermediate care
1467795|NCT00105378|patient centered care
1467796|NCT00105378|comprehensive health care
1467797|NCT00105378|geriatric nursing
1467798|NCT00105378|Behavioral symptoms
1467799|NCT00105365|lateral wedge inserts
1467800|NCT00105365|shoe inserts
1467801|NCT00105352|Type 1 Diabetes Study Group
1467802|NCT00105352|TrialNet
1467803|NCT00105352|type 1 diabetes
1467804|NCT00105352|juvenile onset diabetes
1467805|NCT00105339|consent form, vaccine trial
1467806|NCT00105339|Simplified consent form
1467807|NCT00105326|Schizophrenia
1467808|NCT00105326|Schizophrenia-related insomnia
1467809|NCT00105326|insomnia
1467810|NCT00105326|paliperidone
1467811|NCT00105326|placebo
1467812|NCT00105326|polysomnography
1467813|NCT00105287|cancer
1467814|NCT00105287|pain
1467815|NCT00105287|Breakthrough Pain in cancer patients
1467816|NCT00105274|Velocardiofacial Syndrome
1467817|NCT00105274|Susceptibility Genes
1467818|NCT00105274|Neuroimaging
1467819|NCT00105274|22q11.2
1467820|NCT00105274|Psychosis
1467821|NCT00105274|Mircodeletion
1467822|NCT00105274|DiGeorge Syndrome
1467823|NCT00105274|22q11.2 Syndrome
1467824|NCT00105248|acute repiratory infections
1467825|NCT00105248|antibiotic therapy
1467826|NCT00105248|patient-centred communication
1467827|NCT00105248|randomized controlled trial
1467828|NCT00105235|transplantation
1467829|NCT00105235|liver transplant
1467830|NCT00105235|rejection
1467831|NCT00105235|tolerance
1467832|NCT00105235|antibody induction
1467833|NCT00105222|Cycle Ergometer
1467834|NCT00105222|Exercise Physiology
1467835|NCT00105222|Nitric Oxide
1467836|NCT00105222|Sodium Nitrite
1467837|NCT00105222|Healthy Volunteers
1467838|NCT00105222|Normal Volunteer
1467839|NCT00105222|Healthy Volunteer
1467840|NCT00105222|HV
1467841|NCT00105209|Platelets
1467842|NCT00105196|Single or recurrent
1467843|NCT00105196|non-psychotic episode of Major Depressive Disorder
1467844|NCT00105183|pulmonary transplantation
1467845|NCT00105183|Pulmonary Allograft Rejection
1467846|NCT00105170|Monoclonal antibody
1467847|NCT00105170|Advanced solid tumors
1467848|NCT00105170|Tumors
1467849|NCT00105170|hCBE-11
1467850|NCT00105144|Treatment Effectiveness
1467851|NCT00105144|Treatment Efficacy
1467852|NCT00105144|Investigational, Therapies
1467853|NCT00105144|Antifungal, Systemic
1467854|NCT00105144|Antibiotics, Antifungal
1467855|NCT00105144|Micafungin
1467856|NCT00105131|Parkinson's Disease
1467857|NCT00105131|Movement Disorders
1467858|NCT00105131|Tremor
1467859|NCT00105131|Alpha-Synuclein
1467860|NCT00105131|Lewy Bodies
1467861|NCT00105131|Parkinson Disease
1467862|NCT00105131|PD
1467863|NCT00105131|Movement Disorder
1467864|NCT00105131|Healthy Volunteer
1467865|NCT00105131|HV
1467866|NCT00105118|Cognition
1467867|NCT00105118|Alpha
1467868|NCT00105118|Schizophrenia
1467869|NCT00105118|Functional Connectivity
1467870|NCT00105118|Oscillatory Potential
1467871|NCT00105105|Alzheimers
1467872|NCT00105105|cognition
1467873|NCT00105105|acetyl cholinesterase inhibitor
1467874|NCT00105105|GR-II antagonist
1467875|NCT00105066|Metabolic Syndrome
1467876|NCT00105066|triglycerides
1467877|NCT00105066|HDL
1467878|NCT00105066|LDL
1467879|NCT00105066|High Blood Pressure
1467880|NCT00105066|High Cholesterol
1467881|NCT00105066|High Blood Sugar
1467882|NCT00105040|Partial onset seizures
1467883|NCT00105040|epilepsy
1467884|NCT00105040|levetiracetam
1467885|NCT00105040|Keppra
1467886|NCT00105040|cognition
1467887|NCT00105040|behavior
1467888|NCT00105040|pediatry
1467889|NCT00105027|macular edema
1467890|NCT00105027|central retinal vein occlusion (CRVO)
1467891|NCT00105027|branch retinal vein occlusion (BRVO)
1467892|NCT00104988|stage IV melanoma
1467893|NCT00104975|accelerated phase chronic myelogenous leukemia
1467894|NCT00104975|recurrent adult Burkitt lymphoma
1467895|NCT00104975|stage IV adult Burkitt lymphoma
1467896|NCT00104975|recurrent adult lymphoblastic lymphoma
1467897|NCT00104975|stage IV adult lymphoblastic lymphoma
1467898|NCT00104975|recurrent adult immunoblastic large cell lymphoma
1467899|NCT00104975|stage IV adult immunoblastic large cell lymphoma
1467900|NCT00104975|refractory anemia with excess blasts in transformation
1467901|NCT00104975|refractory anemia with excess blasts
1467902|NCT00104975|secondary myelodysplastic syndromes
1467903|NCT00104975|chronic myelomonocytic leukemia
1467904|NCT00104975|blastic phase chronic myelogenous leukemia
1467905|NCT00104975|chronic eosinophilic leukemia
1467906|NCT00104975|primary myelofibrosis
1467907|NCT00104975|chronic neutrophilic leukemia
1467908|NCT00104975|essential thrombocythemia
1467909|NCT00104975|polycythemia vera
1467910|NCT00104975|adult acute myeloid leukemia in remission
1467911|NCT00104975|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1467912|NCT00104975|adult acute myeloid leukemia with inv(16)(p13;q22)
1467913|NCT00104975|adult acute myeloid leukemia with t(15;17)(q22;q12)
1467914|NCT00104975|adult acute myeloid leukemia with t(16;16)(p13;q22)
1467915|NCT00104975|adult acute myeloid leukemia with t(8;21)(q22;q22)
1467916|NCT00104975|recurrent adult acute myeloid leukemia
1467917|NCT00104975|refractory chronic lymphocytic leukemia
1467918|NCT00104975|stage III chronic lymphocytic leukemia
1467919|NCT00104975|stage IV chronic lymphocytic leukemia
1467920|NCT00104975|stage III adult Burkitt lymphoma
1467921|NCT00104975|stage III adult immunoblastic large cell lymphoma
1467922|NCT00104975|stage III adult lymphoblastic lymphoma
1467923|NCT00104975|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1467924|NCT00104975|de novo myelodysplastic syndromes
1467925|NCT00104975|previously treated myelodysplastic syndromes
1467926|NCT00104975|atypical chronic myeloid leukemia, BCR-ABL1 negative
1467927|NCT00104949|adult synovial sarcoma
1467928|NCT00104949|recurrent adult soft tissue sarcoma
1467929|NCT00104949|stage III adult soft tissue sarcoma
1467930|NCT00104949|stage IV adult soft tissue sarcoma
1467931|NCT00104936|adult grade I meningioma
1467932|NCT00104923|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1467933|NCT00104923|adult acute myeloid leukemia with inv(16)(p13;q22)
1467934|NCT00104923|adult acute myeloid leukemia with t(15;17)(q22;q12)
1467935|NCT00104923|adult acute myeloid leukemia with t(16;16)(p13;q22)
1467936|NCT00104923|adult acute myeloid leukemia with t(8;21)(q22;q22)
1467937|NCT00104923|recurrent grade 1 follicular lymphoma
1467938|NCT00104923|recurrent grade 2 follicular lymphoma
1467939|NCT00104923|recurrent grade 3 follicular lymphoma
1467940|NCT00104923|recurrent small lymphocytic lymphoma
1467941|NCT00104923|recurrent mantle cell lymphoma
1467942|NCT00104923|Waldenstrom macroglobulinemia
1467943|NCT00104923|adult grade III lymphomatoid granulomatosis
1467944|NCT00104923|recurrent adult grade III lymphomatoid granulomatosis
1467945|NCT00104923|secondary acute myeloid leukemia
1467946|NCT00104923|recurrent adult Burkitt lymphoma
1467947|NCT00104923|recurrent adult immunoblastic large cell lymphoma
1467948|NCT00104923|refractory chronic lymphocytic leukemia
1467949|NCT00104923|recurrent adult lymphoblastic lymphoma
1467950|NCT00104923|recurrent adult Hodgkin lymphoma
1467951|NCT00104923|refractory multiple myeloma
1467952|NCT00104923|recurrent adult acute lymphoblastic leukemia
1467953|NCT00104923|relapsing chronic myelogenous leukemia
1467954|NCT00104923|chronic eosinophilic leukemia
1467955|NCT00104923|primary myelofibrosis
1467956|NCT00104923|chronic neutrophilic leukemia
1467957|NCT00104923|essential thrombocythemia
1467958|NCT00104923|polycythemia vera
1467959|NCT00104923|stage II multiple myeloma
1467960|NCT00104923|stage III multiple myeloma
1467961|NCT00104923|recurrent adult diffuse large cell lymphoma
1467962|NCT00104923|recurrent adult diffuse mixed cell lymphoma
1467963|NCT00104923|recurrent adult diffuse small cleaved cell lymphoma
1467964|NCT00104923|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1467965|NCT00104923|nodal marginal zone B-cell lymphoma
1467966|NCT00104923|recurrent marginal zone lymphoma
1467967|NCT00104923|splenic marginal zone lymphoma
1467968|NCT00104923|recurrent adult acute myeloid leukemia
1467969|NCT00104897|recurrent melanoma
1467970|NCT00104897|stage IV melanoma
1467971|NCT00104884|stage III melanoma
1467972|NCT00104884|stage IV melanoma
1467973|NCT00104884|Depsipeptide
1467974|NCT00104871|National Thyroid Cancer Treatment Cooperative Study Group
1467975|NCT00104871|NTCTCSG
1467976|NCT00104871|bortezomib
1467977|NCT00104871|velcade
1467978|NCT00104871|metastatic differentiated thyroid carcinoma
1467979|NCT00104871|Differentiated thyroid carcinoma
1467980|NCT00104871|follicular epithelial thyroid cells
1467981|NCT00104871|papillary
1467982|NCT00104871|oxyphilic cell
1467983|NCT00104871|Hurthle cell
1467984|NCT00104871|insular cell
1467985|NCT00104871|columnar cell
1467986|NCT00104871|tall cell
1467987|NCT00104845|stage II melanoma
1467988|NCT00104845|stage III melanoma
1467989|NCT00104845|stage IV melanoma
1467990|NCT00104845|recurrent melanoma
1467991|NCT00104819|recurrent grade 1 follicular lymphoma
1467992|NCT00104819|recurrent grade 2 follicular lymphoma
1467993|NCT00104819|recurrent grade 3 follicular lymphoma
1467994|NCT00104806|de novo myelodysplastic syndromes
1467995|NCT00104806|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1467996|NCT00104806|previously treated myelodysplastic syndromes
1467997|NCT00104806|secondary myelodysplastic syndromes
1467998|NCT00104806|refractory anemia with excess blasts in transformation
1467999|NCT00104806|refractory anemia with excess blasts
1468000|NCT00104806|refractory anemia
1468001|NCT00104806|refractory anemia with ringed sideroblasts
1468002|NCT00104806|refractory cytopenia with multilineage dysplasia
1468003|NCT00104806|chronic myelomonocytic leukemia
1468004|NCT00104806|childhood myelodysplastic syndromes
1468005|NCT00104793|extensive stage small cell lung cancer
1468006|NCT00104780|recurrent non-small cell lung cancer
1468007|NCT00104780|stage IIIB non-small cell lung cancer
1468008|NCT00104780|stage IV non-small cell lung cancer
1468009|NCT00104767|stage IIIB non-small cell lung cancer
1468010|NCT00104767|stage IV non-small cell lung cancer
1468011|NCT00104767|recurrent non-small cell lung cancer
1468012|NCT00104754|extensive stage small cell lung cancer
1468013|NCT00104754|limited stage small cell lung cancer
1468014|NCT00104754|recurrent small cell lung cancer
1468015|NCT00104741|stage IIB prostate cancer
1468016|NCT00104741|stage IIA prostate cancer
1468017|NCT00104741|stage III prostate cancer
1468018|NCT00104728|stage II non-small cell lung cancer
1468019|NCT00104728|stage IIIA non-small cell lung cancer
1468020|NCT00104728|stage IA non-small cell lung cancer
1468021|NCT00104728|stage IB non-small cell lung cancer
1468022|NCT00104715|adenocarcinoma of the prostate
1468023|NCT00104715|recurrent prostate cancer
1468024|NCT00104715|stage IV prostate cancer
1468025|NCT00104702|stage I breast cancer
1468026|NCT00104702|stage II breast cancer
1468027|NCT00104689|stage IV colon cancer
1468028|NCT00104689|stage IV rectal cancer
1468029|NCT00104689|adenocarcinoma of the colon
1468030|NCT00104689|adenocarcinoma of the rectum
1468031|NCT00104676|stage II malignant testicular germ cell tumor
1468032|NCT00104676|stage III malignant testicular germ cell tumor
1468033|NCT00104676|testicular choriocarcinoma and embryonal carcinoma
1468034|NCT00104676|testicular choriocarcinoma and teratoma
1468035|NCT00104676|testicular choriocarcinoma and yolk sac tumor
1468036|NCT00104676|testicular choriocarcinoma
1468037|NCT00104676|testicular embryonal carcinoma and teratoma
1468038|NCT00104676|testicular embryonal carcinoma and yolk sac tumor
1468039|NCT00104676|testicular embryonal carcinoma
1468040|NCT00104676|testicular yolk sac tumor and teratoma
1468041|NCT00104676|testicular yolk sac tumor
1468042|NCT00104676|stage II extragonadal non-seminomatous germ cell tumor
1468043|NCT00104676|stage III extragonadal non-seminomatous germ cell tumor
1468044|NCT00104676|testicular immature teratoma
1468045|NCT00104676|testicular mature teratoma
1468046|NCT00104676|adult teratoma
1468047|NCT00104663|Creutzfeldt-Jakob disease
1468048|NCT00104663|inherited
1468049|NCT00104663|sporadic
1468050|NCT00104663|acquired
1468051|NCT00104663|new variant CJD
1468052|NCT00104650|Bone Metastases
1468053|NCT00104650|AMG 162
1468054|NCT00104650|Bisphosphonates
1468055|NCT00104650|Solid Tumor Carcinomas
1468056|NCT00104650|Advanced
1468057|NCT00104637|Chronic Obstructive Pulmonary Disease
1468058|NCT00104637|Emphysema
1468059|NCT00104637|Phosphodiesterase inhibitors
1468060|NCT00104637|Sildenafil
1468061|NCT00104637|Exercise testing
1468062|NCT00104637|Quality of life
1468063|NCT00104624|stage IV breast cancer
1468064|NCT00104624|recurrent breast cancer
1468065|NCT00104611|Major Depressive Disorder
1468066|NCT00104611|Repetitive Transcranial Magnetic Stimulation
1468067|NCT00104611|rTMS
1468068|NCT00104611|Non-invasive Neuromodulation
1468069|NCT00104611|Antidepressant
1468070|NCT00104585|Parkinson's disease
1468071|NCT00104585|PD
1468072|NCT00104585|gene
1468073|NCT00104585|environment
1468074|NCT00104585|early-onset Parkinson's disease
1468075|NCT00104572|Estrogen
1468076|NCT00104572|Glucose Tolerance
1468077|NCT00104572|Bone Density
1468078|NCT00104572|Quality-of-Life
1468079|NCT00104572|Sarcopenia
1468080|NCT00104559|HIV
1468081|NCT00104559|Informed Consent
1468082|NCT00104546|Dysmenorrhea
1468083|NCT00104546|Acupuncture
1468084|NCT00104546|Vitamin K
1468085|NCT00104546|Medicine, Chinese Traditional
1468086|NCT00104546|Women
1468087|NCT00104546|Menstruation
1468088|NCT00104546|Pain, Menstrual
1468089|NCT00104546|China
1468090|NCT00104533|Static magnetic therapy
1468091|NCT00104533|Pain
1468092|NCT00104533|Analgesia
1468093|NCT00104533|Opioids
1468094|NCT00104520|Cystic Fibrosis
1468095|NCT00104520|Pseudomonas aeruginosa
1468096|NCT00104520|Pulmonary Cystic Fibrosis
1468097|NCT00104507|Serotonin
1468098|NCT00104507|5-HT2c
1468099|NCT00104507|Satiety
1468100|NCT00104507|Obesity
1468101|NCT00104507|Appetite suppressant
1468102|NCT00104507|Weight Loss
1468103|NCT00104507|Overweight
1468104|NCT00104494|Cystic Fibrosis
1468105|NCT00104494|Zinc supplementation
1468106|NCT00104494|Nutrition
1468107|NCT00104494|Zinc absorption
1468108|NCT00104494|Zinc excretion
1468109|NCT00104494|Zinc status
1468110|NCT00104481|cognitive behavior therapy
1468111|NCT00104481|coping
1468112|NCT00104481|smoking cessation
1468113|NCT00104481|acceptance
1468114|NCT00104481|expectancies
1468115|NCT00104481|quit smoking
1468116|NCT00104481|quitting smoking
1468117|NCT00104468|Single-arm, open-label, multi-center, dose escalation, continuous infusion, multi-dose, acute myeloid leukemia
1468118|NCT00104468|Acute myelogenous leukemia (AML) that has been refractory to prior therapy and/or is unlikely to benefit from known therapies
1468119|NCT00104455|rFVIIa
1468120|NCT00104455|Punch Biopsy
1468121|NCT00104455|Dose Response
1468122|NCT00104455|Healthy People Programs
1468123|NCT00104442|Alzheimer's disease
1468124|NCT00104442|memory loss
1468125|NCT00104442|dementia
1468126|NCT00104442|senility
1468127|NCT00104442|forgetful
1468128|NCT00104442|geriatric
1468129|NCT00104442|behavior
1468130|NCT00104442|mood swings
1468131|NCT00104429|HIV infections
1468132|NCT00104429|therapy naive
1468133|NCT00104416|antiepileptic drugs
1468134|NCT00104416|seizures
1468135|NCT00104416|primary generalized tonic-clonic seizures
1468136|NCT00104416|Epilepsy
1468137|NCT00104416|lamotrigine
1468138|NCT00104416|anticonvulsants
1468139|NCT00104416|LAMICTAL
1468140|NCT00104403|Vomiting
1468141|NCT00104403|CINV
1468142|NCT00104403|Emesis
1468143|NCT00104403|Nausea
1468144|NCT00104403|Chemotherapy-Induced Nausea and Vomiting
1468145|NCT00104390|allergy
1468146|NCT00104390|skin prick test
1468147|NCT00104390|allergoid
1468148|NCT00104390|allergenicity
1468149|NCT00104390|specific immunotherapy
1468150|NCT00104377|Allergy
1468151|NCT00104377|Allergoid
1468152|NCT00104377|Specific Immunotherapy
1468153|NCT00104338|Investigational Therapies
1468154|NCT00104338|Treatment Effectiveness
1468155|NCT00104338|Treatment Efficacy
1468156|NCT00104338|Immunosuppressant
1468157|NCT00104338|BK Nephropathy
1468158|NCT00104338|Polyomavirus, BK
1468159|NCT00104338|Human Polyomavirus BK
1468160|NCT00104338|Polyomavirus hominis 1
1468161|NCT00104325|Cytapheresis
1468162|NCT00104325|Blood Collection
1468163|NCT00104325|Volunteer Donor
1468164|NCT00104325|White Blood Cells
1468165|NCT00104312|Knee Osteoarthritis
1468166|NCT00104312|Muscle
1468167|NCT00104312|Cytokine
1468168|NCT00104312|Mobility
1468169|NCT00104312|Function
1468170|NCT00104299|ANCA
1468171|NCT00104299|Vasculitis
1468172|NCT00104299|Wegener's Granulomatosis
1468173|NCT00104299|microscopic polyangiitis
1468174|NCT00104299|ANCA-positive
1468175|NCT00104299|ANCA-associated
1468176|NCT00104299|ANCA-associated vasculitis
1468177|NCT00104299|MPA
1468178|NCT00104273|Dementia, Alzheimer's Disease
1468179|NCT00104247|Phenylalanine Hydroxylase
1468180|NCT00104195|Anxiety
1468181|NCT00104195|Adolescence
1468182|NCT00104195|Generalized Anxiety Disorder
1468183|NCT00104169|Anemia
1468184|NCT00104169|Frailty
1468185|NCT00104169|Epoetin
1468186|NCT00104169|Erythropoietin
1468187|NCT00104169|EPO
1468188|NCT00104156|Knee pain
1468189|NCT00104156|Arthritis
1468190|NCT00104156|Qigong
1468191|NCT00104156|Qi
1468192|NCT00104156|Meditation
1468193|NCT00104156|Breathing Exercises
1468194|NCT00104130|prostate
1468195|NCT00104104|Z-MAX, multiple myeloma, zoledronic acid, bone metastases
1468196|NCT00104091|Gross Total Resection
1468197|NCT00104091|Convection Enhanced Delivery
1468198|NCT00104091|Recurrent Glioblastoma Multiforme
1468199|NCT00104065|oral mucositis
1468200|NCT00104065|oncology - supportive care
1468201|NCT00104065|mouth diseases
1468202|NCT00104039|Amygdala
1468203|NCT00104039|Orbital Frontal Cortex
1468204|NCT00104039|Serotonin
1468205|NCT00104039|Orbitofrontal Cortex
1468206|NCT00104039|Attention Deficit Hyperactivity Disorder
1468207|NCT00104039|ADHD
1468208|NCT00104039|Anti-Social Behavior
1468209|NCT00104039|Healthy Volunteer
1468210|NCT00104039|HV
1468211|NCT00104026|Periodontal Disease
1468212|NCT00104026|Dilantin
1468213|NCT00104026|Cyclosporin
1468214|NCT00104026|Calcium-Channel Blockers
1468215|NCT00104026|Genetics
1468216|NCT00104026|Hereditary Gingival Fibromatosis
1468217|NCT00104026|HGF
1468218|NCT00104026|Gingival Overgrowth
1468219|NCT00104026|Gum Overgrowth
1468220|NCT00104000|Neuromuscular
1468221|NCT00104000|Elevation
1468222|NCT00104000|Current
1468223|NCT00104000|Videofluoroscopy
1468224|NCT00104000|Nasoendoscopy
1468225|NCT00104000|Healthy Volunteer
1468226|NCT00104000|HV
1468227|NCT00103987|Panic Disorder
1468228|NCT00103987|Norepinephrine
1468229|NCT00103987|Yohimbine
1468230|NCT00103987|Genes
1468231|NCT00103987|Pathophysiology
1468232|NCT00103987|Noradrenergic Mechanisms
1468233|NCT00103987|PET Imaging
1468234|NCT00103987|PD
1468235|NCT00103987|Healthy Volunteer
1468236|NCT00103987|HV
1468237|NCT00103974|multiple sclerosis
1468238|NCT00103974|relapsing-remitting
1468239|NCT00103974|secondary progressive
1468240|NCT00103961|Acute Infection
1468241|NCT00103961|HIV
1468242|NCT00103961|AIDS
1468243|NCT00103961|Acute HIV
1468244|NCT00103961|Early HIV
1468245|NCT00103935|diabetes
1468246|NCT00103935|exenatide
1468247|NCT00103935|long acting release
1468248|NCT00103935|Amylin
1468249|NCT00103935|Lilly
1468250|NCT00103922|smokers cough
1468251|NCT00103896|High-risk youth
1468252|NCT00103896|HIV infected youth
1468253|NCT00103896|Community mobilization
1468254|NCT00103896|HIV serosurveys
1468255|NCT00103883|HIV
1468256|NCT00103883|Detuned Assay
1468257|NCT00103883|Enzyme Immunoassay (EIA)
1468258|NCT00103883|HIV Incidence
1468259|NCT00103883|Laboratory assay
1468260|NCT00103883|Sensitive/Less sensitive Assay
1468261|NCT00103883|Acute Infection
1468262|NCT00103870|Music Therapy
1468263|NCT00103870|Electric Stimulation
1468264|NCT00103870|Electric Shock
1468265|NCT00103870|Analgesics
1468266|NCT00103870|Distraction
1468267|NCT00103844|Chronic Phase Philadelphia chromosome Positive (Ph+) chronic myeloid leukemia
1468268|NCT00103831|NSCLC - non-small cell lung cancer
1468269|NCT00103805|language acquisition
1468270|NCT00103805|plasticity
1468271|NCT00103805|stroke recovery
1468272|NCT00103805|associative learning
1468273|NCT00103792|Induction therapy
1468274|NCT00103792|ANCA-associated vasculitis
1468275|NCT00103792|Wegener's granulomatosis
1468276|NCT00103792|microscopic polyangiitis
1468277|NCT00103792|mycophenolate mofetil
1468278|NCT00103792|cyclophosphamide
1468279|NCT00103779|Antigens, CD40
1468280|NCT00103779|Antibody, Monoclonal
1468281|NCT00103779|Lymphoma, Non-Hodgkin
1468282|NCT00103779|Lymphoma, B-Cell
1468283|NCT00103779|Hematologic Diseases
1468284|NCT00103779|Immunoproliferative Disorders
1468285|NCT00103779|Lymphatic Diseases
1468286|NCT00103779|Lymphoproliferative Disorders
1468287|NCT00103779|Lymphoma
1468288|NCT00103766|Alteplase
1468289|NCT00103766|Empyema
1468290|NCT00103766|Complicated Parapneumonic Effusion
1468291|NCT00103753|Randomized Controlled Trial
1468292|NCT00103753|Deferiprone
1468293|NCT00103753|Deferoxamine
1468294|NCT00103753|Iron chelation
1468295|NCT00103753|Beta Thalassemia Major
1468296|NCT00103740|Zoledronic acid, risedronate, Paget's disease of bone
1468297|NCT00103727|paranoid
1468298|NCT00103727|catatonic
1468299|NCT00103727|undifferentiated types
1468300|NCT00103727|disorganized
1468301|NCT00103714|lung disease
1468302|NCT00103701|Chronic myelogenous leukemia (CML) chronic, accelerated, blast phase
1468303|NCT00103701|Philadelphia chromosome positive acute (Ph+ALL)
1468304|NCT00103675|Acupuncture
1468305|NCT00103636|Phlebitis/etiology
1468306|NCT00103636|Infusions
1468307|NCT00103636|Intravenous/adverse effects
1468308|NCT00103636|Randomised controlled trial
1468309|NCT00103636|Phlebitis/prevention
1468310|NCT00103636|Adult
1468311|NCT00103636|Time factors
1468312|NCT00103623|Advanced
1468313|NCT00103623|Symptomatic
1468314|NCT00103623|Prostate
1468315|NCT00103623|Cancer
1468316|NCT00103623|Advanced Symptomatic Prostate Cancer
1468317|NCT00103610|Non-Hodgkin's lymphoma
1468318|NCT00103610|Stem cell mobilization
1468319|NCT00103597|Orthostatic hypotension
1468320|NCT00103597|Parkinson's Disease
1468321|NCT00103545|Ovarian Cancer
1468322|NCT00103545|ACA 125
1468323|NCT00103545|6 or 9 vaccinations
1468324|NCT00103545|immune response
1468325|NCT00103545|Fallopian tube cancer
1468326|NCT00103545|Peritoneal cancer
1468327|NCT00103532|motivational enhancement
1468328|NCT00103532|health behaviors
1468329|NCT00103532|risk behaviors
1468330|NCT00103519|Heart Failure, DITPA
1468331|NCT00103506|Multiple Myeloma
1468332|NCT00103506|Doxil
1468333|NCT00103506|Caelyx
1468334|NCT00103506|Doxorubicin
1468335|NCT00103506|Velcade
1468336|NCT00103506|Bortezomib
1468337|NCT00103454|allergic rhinitis
1468338|NCT00103454|GW685698X
1468339|NCT00103454|Perennial Allergic Rhinitis
1468340|NCT00103428|chemotherapy
1468341|NCT00103428|prostate cancer
1468342|NCT00103428|cancer
1468343|NCT00103428|metastatic
1468344|NCT00103428|hormone refractory
1468345|NCT00103428|chemotherapy naive
1468346|NCT00103428|dose escalation
1468347|NCT00103415|Depression
1468348|NCT00103415|Exercise
1468349|NCT00103415|Job
1468350|NCT00103402|Prostatitis
1468351|NCT00103402|Non-bacterial Prostatitis
1468352|NCT00103402|Prostatodynia
1468353|NCT00103402|Alfuzosin
1468354|NCT00103402|Alpha-adrenergic blocker
1468355|NCT00103389|recurrent non-small cell lung cancer
1468356|NCT00103389|stage IIIB non-small cell lung cancer
1468357|NCT00103389|stage IV non-small cell lung cancer
1468358|NCT00103376|adenocarcinoma of the prostate
1468359|NCT00103376|recurrent prostate cancer
1468360|NCT00103363|non-small cell lung cancer
1468361|NCT00103363|small cell lung cancer
1468362|NCT00103350|myocardial infarction
1468363|NCT00103350|infarct size
1468364|NCT00103350|angioplasty
1468365|NCT00103350|percutaneous coronary intervention
1468366|NCT00103350|Acute Myocardial Infarction
1468367|NCT00103298|recurrent colon cancer
1468368|NCT00103298|stage IV colon cancer
1468369|NCT00103298|recurrent rectal cancer
1468370|NCT00103298|stage IV rectal cancer
1468371|NCT00103298|liver metastases
1468372|NCT00103246|skin cancer
1468373|NCT00103246|squamous cell carcinoma of the skin
1468374|NCT00103246|basal cell carcinoma of the skin
1468375|NCT00103246|recurrent skin cancer
1468376|NCT00103246|recurrent mycosis fungoides/Sezary syndrome
1468377|NCT00103246|stage I mycosis fungoides/Sezary syndrome
1468378|NCT00103246|stage II mycosis fungoides/Sezary syndrome
1468379|NCT00103246|actinic keratosis
1468380|NCT00103246|recurrent cutaneous T-cell non-Hodgkin lymphoma
1468381|NCT00103246|stage I cutaneous T-cell non-Hodgkin lymphoma
1468382|NCT00103246|stage II cutaneous T-cell non-Hodgkin lymphoma
1468383|NCT00103233|stage IV breast cancer
1468384|NCT00103233|recurrent breast cancer
1468385|NCT00103207|bronchioalveolar carcinoma (BAC)
1468386|NCT00103207|adenocarcinoma with BAC features
1468387|NCT00103207|stage IIIB non-small cell lung cancer
1468388|NCT00103207|stage IV non-small cell lung cancer
1468389|NCT00103207|recurrent non-small cell lung cancer
1468390|NCT00103207|cetuximab
1468391|NCT00103181|stage II breast cancer
1468392|NCT00103181|ductal breast carcinoma in situ
1468393|NCT00103181|breast cancer in situ
1468394|NCT00103181|stage IA breast cancer
1468395|NCT00103181|stage IB breast cancer
1468396|NCT00103168|gastrointestinal stromal tumor
1468397|NCT00103155|stage I papillary thyroid cancer
1468398|NCT00103142|liver metastases
1468399|NCT00103142|adenocarcinoma of the colon
1468400|NCT00103142|recurrent colon cancer
1468401|NCT00103142|stage IV colon cancer
1468402|NCT00103142|adenocarcinoma of the rectum
1468403|NCT00103142|recurrent rectal cancer
1468404|NCT00103142|stage IV rectal cancer
1468405|NCT00103142|lung metastases
1468406|NCT00103116|stage I non-small cell lung cancer
1468407|NCT00103116|stage II non-small cell lung cancer
1468408|NCT00103116|stage IIIA non-small cell lung cancer
1468409|NCT00103116|stage IIIB non-small cell lung cancer
1468410|NCT00103116|bronchoalveolar cell lung cancer
1468411|NCT00103103|recurrent gastric cancer
1468412|NCT00103103|stage IV gastric cancer
1468413|NCT00103103|adenocarcinoma of the stomach
1468414|NCT00103090|recurrent squamous cell carcinoma of the hypopharynx
1468415|NCT00103090|stage III squamous cell carcinoma of the hypopharynx
1468416|NCT00103090|stage IV squamous cell carcinoma of the hypopharynx
1468417|NCT00103090|recurrent squamous cell carcinoma of the larynx
1468418|NCT00103090|stage III squamous cell carcinoma of the larynx
1468419|NCT00103090|stage IV squamous cell carcinoma of the larynx
1468420|NCT00103090|recurrent squamous cell carcinoma of the lip and oral cavity
1468421|NCT00103090|stage III squamous cell carcinoma of the lip and oral cavity
1468422|NCT00103090|stage IV squamous cell carcinoma of the lip and oral cavity
1468543|NCT00102700|cancer of the pancreas
1468423|NCT00103090|recurrent squamous cell carcinoma of the nasopharynx
1468424|NCT00103090|stage III squamous cell carcinoma of the nasopharynx
1468425|NCT00103090|stage IV squamous cell carcinoma of the nasopharynx
1468426|NCT00103090|recurrent squamous cell carcinoma of the oropharynx
1468427|NCT00103090|stage III squamous cell carcinoma of the oropharynx
1468428|NCT00103090|stage IV squamous cell carcinoma of the oropharynx
1468554|NCT00102635|apoptotic activity
1468429|NCT00103090|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1468430|NCT00103090|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1468431|NCT00103090|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1468432|NCT00103090|recurrent salivary gland cancer
1468433|NCT00103090|salivary gland squamous cell carcinoma
1468434|NCT00103090|stage III salivary gland cancer
1468435|NCT00103090|stage IV salivary gland cancer
1468436|NCT00103090|recurrent metastatic squamous neck cancer with occult primary
1468437|NCT00103090|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1468438|NCT00103051|stage IIIA non-small cell lung cancer
1468439|NCT00103025|Vasodilation
1468440|NCT00103025|Hypotension
1468441|NCT00103025|Hypertension
1468442|NCT00103025|EDRF
1468443|NCT00103025|Methemoglobinemia
1468444|NCT00103025|Healthy Volunteer
1468445|NCT00103025|HV
1468446|NCT00103012|Antiretrovirals
1468447|NCT00103012|Protease Inhibitors
1468448|NCT00103012|Herbal Supplements
1468449|NCT00103012|Drug Interactions
1468450|NCT00103012|Metabolism
1468451|NCT00103012|Healthy Volunteer
1468452|NCT00103012|HV
1468453|NCT00102999|Learning
1468454|NCT00102999|PAS
1468455|NCT00102999|Upper Limb
1468456|NCT00102999|TMS
1468457|NCT00102999|Somatosensory
1468458|NCT00102999|Dystonia
1468459|NCT00102999|Upper Limb Dystonia
1468460|NCT00102999|Healthy Volunteer
1468461|NCT00102999|HV
1468462|NCT00102986|Kaletra
1468463|NCT00102986|Treatment Experienced
1468464|NCT00102973|Ovary
1468465|NCT00102960|Infant
1468466|NCT00102960|Perinatal
1468467|NCT00102960|HIV
1468468|NCT00102960|Disease Transmission, Vertical
1468469|NCT00102960|Anti-Retroviral Agents
1468470|NCT00102960|Treatment Interruption
1468471|NCT00102960|Treatment Naive
1468472|NCT00102960|Acute Infection
1468473|NCT00102960|Mother-to-Child Transmission
1468474|NCT00102947|renal impairment
1468475|NCT00102947|daptomycin
1468476|NCT00102947|Cubist
1468477|NCT00102947|complicated skin and skin structure infections
1468478|NCT00102934|HIV
1468479|NCT00102934|Drug Resistance
1468480|NCT00102934|Viral Fitness
1468481|NCT00102934|HIV Specific Immunity
1468482|NCT00102934|T Cell Activation
1468483|NCT00102934|Drug Resistant Viremia
1468484|NCT00102934|Treatment Experienced
1468485|NCT00102921|Crohn Disease
1468486|NCT00102921|oral medication
1468487|NCT00102908|Bone Metabolism
1468488|NCT00102908|Osteopenia
1468489|NCT00102908|Osteoporosis
1468490|NCT00102908|Treatment Experienced
1468491|NCT00102882|genotype
1468492|NCT00102882|Salmeterol
1468493|NCT00102882|ADVAIR
1468494|NCT00102869|language acquisition
1468495|NCT00102869|plasticity
1468496|NCT00102869|stroke recovery
1468497|NCT00102869|aphasia treatment
1468498|NCT00102869|naming
1468499|NCT00102869|levodopa
1468500|NCT00102869|stroke
1468501|NCT00102856|language acquisition
1468502|NCT00102856|plasticity
1468503|NCT00102856|stroke recovery
1468504|NCT00102856|associative learning
1468505|NCT00102843|folic acid
1468506|NCT00102843|betaine
1468507|NCT00102843|homocysteine
1468508|NCT00102843|cardiovascular disease prevention
1468509|NCT00102843|human
1468510|NCT00102843|Cardiovascular health
1468511|NCT00102830|Solid Tumor
1468512|NCT00102830|Metastatic Cancer
1468513|NCT00102830|Advanced Solid Tumors
1468514|NCT00102817|Growth Hormone Disorder
1468515|NCT00102791|Sickle Cell Anemia
1468516|NCT00102778|HIV infected
1468517|NCT00102778|therapy-naive subjects
1468518|NCT00102765|asthma exacerbation
1468519|NCT00102765|asthma
1468520|NCT00102752|Pancreas
1468521|NCT00102752|Cancer
1468522|NCT00102752|Metastatic
1468523|NCT00102752|Glufosfamide
1468524|NCT00102752|Advanced
1468525|NCT00102752|Solid
1468526|NCT00102752|Tumor
1468527|NCT00102752|Advanced Solid Tumors
1468528|NCT00102752|Pancreatic Adenocarcinoma
1468529|NCT00102739|thrombopoietin
1468530|NCT00102739|immune thrombocytopenic purpura
1468531|NCT00102739|platelets
1468532|NCT00102739|chronic thrombocytopenia
1468533|NCT00102726|chemotherapy
1468534|NCT00102726|thrombopoietin
1468535|NCT00102726|platelets
1468536|NCT00102726|chemotherapy induced
1468537|NCT00102713|Partial Seizures
1468538|NCT00102700|cancer
1468539|NCT00102700|solid tumor
1468540|NCT00102700|advanced solid tumor
1468541|NCT00102700|pancreas
1468542|NCT00102700|pancreatic cancer
1468544|NCT00102674|cangrelor
1468545|NCT00102674|clopidogrel
1468546|NCT00102648|Glioblastoma Multiforme
1468547|NCT00102648|Gliosarcoma
1468548|NCT00102648|Brain Tumors
1468549|NCT00102648|Sarasar
1468550|NCT00102648|Temodar
1468551|NCT00102648|Temozolomide
1468552|NCT00102648|Lonafarnib
1468553|NCT00102648|SCH 66336
1468555|NCT00102635|4-HPR
1468556|NCT00102635|FTI
1468557|NCT00102635|Fenretinide
1468558|NCT00102635|SCH66336
1468559|NCT00102635|Farnesyl Transferase Inhibitor
1468560|NCT00102635|HNC
1468561|NCT00102622|Ovary
1468562|NCT00102622|ovarian cancer
1468563|NCT00102622|biologic therapy
1468564|NCT00102622|platinum-resistant
1468565|NCT00102622|platinum-refractory ovarian cancer
1468566|NCT00102622|platinum-resistant ovarian cancer
1468567|NCT00102622|paclitaxel
1468568|NCT00102622|tgDCC-E1A
1468569|NCT00102622|E1A
1468570|NCT00102622|Taxol
1468571|NCT00102609|Doxorubicin
1468572|NCT00102609|Adriamycin
1468573|NCT00102609|Trabectedin
1468574|NCT00102609|Yondelis
1468575|NCT00102609|Ecteinascidin 743
1468576|NCT00102609|Filgrastim, Antineoplastic
1468577|NCT00102609|Antineoplastic Agents
1468578|NCT00102609|Pharmacologic Actions
1468579|NCT00102609|Alkylating Agents
1468580|NCT00102596|Ethanol
1468581|NCT00102596|Alcohol Responsive
1468582|NCT00102596|Movement Disorder
1468583|NCT00102596|Gas Chromatography
1468584|NCT00102596|Bioavailability
1468585|NCT00102596|Pharmacokinetics
1468586|NCT00102596|Essential Tremor
1468587|NCT00102583|Dry Eye
1468588|NCT00102583|Lacrimal Gland
1468589|NCT00102583|Tear Deficiency
1468590|NCT00102583|Keratitis Sicca
1468591|NCT00102583|GVHD
1468592|NCT00102583|Ocular GVHD
1468593|NCT00102583|Ocular Graft Vs Host Disease
1468594|NCT00102570|Pediatric
1468595|NCT00102570|Atopic
1468596|NCT00102570|Asthma
1468597|NCT00102570|Rhinitis
1468598|NCT00102570|Outpatient
1468599|NCT00102570|Allergy
1468600|NCT00102570|Pediatric Allergy
1468601|NCT00102570|Food Allergy
1468602|NCT00102570|Stinging Insect Allergy
1468603|NCT00102570|Atopic Dermatitis
1468604|NCT00102570|Insect Sting
1468605|NCT00102557|Vesiculobullous
1468606|NCT00102557|Mucosal Lesions
1468607|NCT00102557|Oral Health
1468608|NCT00102557|Dermatology
1468609|NCT00102557|Plaquenil
1468610|NCT00102557|Oral Lichen Planus
1468611|NCT00102557|Mouth Lesions
1468612|NCT00102557|Oral Lesions
1468618|NCT00102531|Osteosarcoma
1468619|NCT00102531|relapsed
1468620|NCT00102531|progressive
1468621|NCT00102531|metastatic
1468622|NCT00102531|lung
1468623|NCT00102518|Open Label
1468624|NCT00102518|Aripiprazole
1468625|NCT00102518|Bipolar I Disorder, Manic or Mixed Episode
1468626|NCT00102505|Non-Small Cell Lung Cancer
1468627|NCT00102505|Lung Cancer
1468628|NCT00102505|Metastatic lung cancer
1468629|NCT00102505|Inoperable lung cancer
1468630|NCT00102505|Advanced lung cancer
1468631|NCT00102505|Large-cell lung cancer
1468632|NCT00102505|Adenocarcinoma, lung
1468633|NCT00102505|Squamous cell carcinoma, lung
1468634|NCT00102505|Squamous cell lung cancer
1468635|NCT00102505|Large cell carcinoma, lung
1468636|NCT00102505|Bronchogenic
1468637|NCT00102492|Major Depressive Disorder
1468638|NCT00102492|Major Depression
1468639|NCT00102492|Mood Disorders
1468640|NCT00102492|Major Depressive Episode
1468641|NCT00102479|Pharmacokinetics,
1468642|NCT00102479|Aripiprazole
1468643|NCT00102479|acute mania in pediatric populations
1468644|NCT00102466|type 2 diabetes
1468645|NCT00102466|vildagliptin
1468646|NCT00102453|Duchenne
1468647|NCT00102453|Genetics
1468648|NCT00102440|uric Acid
1468649|NCT00102440|xanthine oxidase
1468650|NCT00102440|tophi
1468651|NCT00102440|Drug Therapy
1468652|NCT00102427|Anxiety
1468653|NCT00102427|Panic
1468654|NCT00102427|Generalized Anxiety Disorder
1468655|NCT00102414|Ovarian cancer
1468656|NCT00102414|Recurrence or progression
1468657|NCT00102414|Gemcitabine plus Carboplatin vs Carboplatin
1468658|NCT00102401|Chronic obstructive pulmonary disease
1468659|NCT00102401|Pulmonary Disease, chronic obstructive
1468660|NCT00102401|Lung disease, obstructive
1468661|NCT00102401|Self-care
1468662|NCT00102401|Self-management
1468663|NCT00102401|Patient education
1468664|NCT00102388|type 2 diabetes
1468665|NCT00102388|vildagliptin
1468666|NCT00102375|Ovarian Cancer
1468667|NCT00102375|first-line
1468668|NCT00102375|Topotecan
1468669|NCT00102362|behavioral intervention
1468670|NCT00102349|behavioral intervention
1468671|NCT00102336|immune (idiopathic) thrombocytopenic purpura
1468672|NCT00102336|pre-splenectomy
1468673|NCT00102336|ITP
1468674|NCT00102336|Thrombopenia
1468675|NCT00102323|immune (idiopathic) thrombocytopenic purpura
1468676|NCT00102323|post-splenectomy
1468677|NCT00102323|ITP
1468678|NCT00102323|Thrombopenia
1468679|NCT00102310|Nausea
1468680|NCT00102310|Indigestion
1468681|NCT00102310|Bloating
1468682|NCT00102310|Functional Dyspepsia
1468683|NCT00102310|Fullness after Meals
1468684|NCT00102297|Incipient Nephropathy
1468685|NCT00102297|Type 1 or Type 2 Diabetes
1468686|NCT00102284|language acquisition
1468687|NCT00102284|plasticity
1468688|NCT00102284|stroke recovery
1468689|NCT00102284|associative learning
1468690|NCT00102271|Sodium Nitrite
1468691|NCT00102271|Oxypurinol
1468692|NCT00102271|Ascorbic Acid
1468693|NCT00102271|Hypoxic Gas
1468694|NCT00102271|Forearm Blood Flow
1468695|NCT00102271|Healthy Volunteer
1468696|NCT00102271|HV
1468697|NCT00102258|Short Stature
1468698|NCT00102258|Constitutional Delay of Growth and Development
1468699|NCT00102258|Body Composition
1468700|NCT00102258|Energy Expenditure
1468701|NCT00102258|Dietary Supplements
1468702|NCT00102258|Constitutional Delay of Growth
1468703|NCT00102258|CDGM
1468704|NCT00102245|Hemoglobin
1468705|NCT00102245|Hemoglobinapathies
1468706|NCT00102245|Human Genome
1468707|NCT00102245|Recombinant DNA Technology
1468708|NCT00102245|Sequencing
1468709|NCT00102245|Erythrocyte
1468710|NCT00102232|phosphatidylcholine
1468711|NCT00102232|choline
1468712|NCT00102232|homocysteine
1468713|NCT00102232|cardiovascular disease prevention
1468714|NCT00102232|human
1468715|NCT00102232|cardiovascular health
1468716|NCT00102206|Treatment Experienced
1468717|NCT00102206|Child
1468718|NCT00102193|Ulcerative Colitis, Apheresis
1468719|NCT00102141|Postmenopausal
1468720|NCT00102141|vasomotor symptoms
1468721|NCT00102141|essential hypertension
1468722|NCT00102115|Macular disease
1468723|NCT00102115|Wet AMD
1468724|NCT00102115|AMD
1468725|NCT00102115|Age-Related Macular Disease
1468726|NCT00102115|PDT
1468727|NCT00102115|Photodynamic Therapy
1468728|NCT00102102|Substance P
1468729|NCT00102102|Neurokinin
1468730|NCT00102102|Tachykinin
1468731|NCT00102102|Anxiety
1468732|NCT00102102|Neuroreceptor Imaging
1468733|NCT00102102|Post-Traumatic Stress Disorder
1468734|NCT00102102|PTSD
1468735|NCT00102102|Healthy Volunteer
1468736|NCT00102102|HV
1468737|NCT00102089|HIV-Negative
1468738|NCT00102089|Healthy
1468739|NCT00102089|Immunity
1468740|NCT00102089|Preventive
1468741|NCT00102089|Virus
1468742|NCT00102089|Healthy Volunteer
1468743|NCT00102089|HV
1468744|NCT00102076|Minimal
1468745|NCT00102076|Risk
1468746|NCT00102076|Regulations
1468747|NCT00102076|Parents
1468748|NCT00102076|IRB
1468749|NCT00102076|Surgery
1468750|NCT00102076|Assent Requirement
1468751|NCT00102063|Schizophrenia
1468752|NCT00102063|Aripiprazole
1468753|NCT00102050|NM-702 tablets
1468754|NCT00102050|intermittent claudication
1468755|NCT00102050|peripheral
1468756|NCT00102050|arterial
1468757|NCT00102050|vascular
1468758|NCT00102050|peripheral arterial disease
1468759|NCT00102024|Metastatic Colorectal Adenocarcinoma
1468760|NCT00102024|Anti TAG-72
1468761|NCT00102024|Monoclonal Antibody
1468762|NCT00102011|colon cancer
1468763|NCT00102011|rectal cancer
1468764|NCT00101998|OBD (Induced Bowel Dysfunction)
1468765|NCT00101998|cancer pain
1468766|NCT00101998|pain medication
1468767|NCT00101998|constipation
1468768|NCT00101998|bowel
1468769|NCT00101998|bowel dysfunction
1468770|NCT00101985|Quality of Life
1468771|NCT00101985|Irritable bowel syndrome
1468772|NCT00101985|IBS
1468773|NCT00101985|SB223412
1468774|NCT00101985|Qol
1468775|NCT00101972|adenocarcinoma of the bladder
1468776|NCT00101972|adenocarcinoma of the colon
1468777|NCT00101972|adenocarcinoma of the esophagus
1468778|NCT00101972|adenocarcinoma of the extrahepatic bile duct
1468779|NCT00101972|adenocarcinoma of the gallbladder
1468780|NCT00101972|adenocarcinoma of the lung
1468781|NCT00101972|adenocarcinoma of the pancreas
1468782|NCT00101972|adenocarcinoma of the prostate
1468783|NCT00101972|adenocarcinoma of the rectum
1468784|NCT00101972|adenocarcinoma of the stomach
1468785|NCT00101972|adenocarcinoma with squamous metaplasia of the gallbladder
1468786|NCT00101972|cervical adenocarcinoma
1468787|NCT00101972|endometrial adenocarcinoma
1468788|NCT00101972|ovarian endometrioid adenocarcinoma
1468789|NCT00101972|ovarian undifferentiated adenocarcinoma
1468790|NCT00101972|salivary gland adenocarcinoma
1468791|NCT00101972|small intestine adenocarcinoma
1468792|NCT00101972|vaginal adenocarcinoma
1468793|NCT00101972|vaginal clear cell adenocarcinoma
1468794|NCT00101972|ovarian clear cell cystadenocarcinoma
1468795|NCT00101972|ovarian mucinous cystadenocarcinoma
1468796|NCT00101972|ovarian serous cystadenocarcinoma
1468797|NCT00101972|stage IV bladder cancer
1468798|NCT00101972|stage IV breast cancer
1468799|NCT00101972|stage IV colon cancer
1468800|NCT00101972|stage IV endometrial carcinoma
1468801|NCT00101972|stage IV esophageal cancer
1468802|NCT00101972|stage IV gastric cancer
1468803|NCT00101972|stage IV non-small cell lung cancer
1468925|NCT00101582|Concurrent Chemotherapy
1468804|NCT00101972|stage IV ovarian epithelial cancer
1468805|NCT00101972|stage IV prostate cancer
1468806|NCT00101972|stage IV rectal cancer
1468807|NCT00101972|stage IV renal cell cancer
1468808|NCT00101972|stage IV salivary gland cancer
1468809|NCT00101972|stage IVA cervical cancer
1468810|NCT00101972|stage IVA vaginal cancer
1468811|NCT00101972|stage IVB cervical cancer
1468812|NCT00101972|stage IVB vaginal cancer
1468813|NCT00101972|recurrent bladder cancer
1468814|NCT00101972|recurrent breast cancer
1468815|NCT00101972|recurrent cervical cancer
1468816|NCT00101972|recurrent colon cancer
1468817|NCT00101972|recurrent endometrial carcinoma
1468818|NCT00101972|recurrent esophageal cancer
1468819|NCT00101972|recurrent extrahepatic bile duct cancer
1468820|NCT00101972|recurrent gallbladder cancer
1468821|NCT00101972|recurrent gastric cancer
1468822|NCT00101972|recurrent non-small cell lung cancer
1468823|NCT00101972|recurrent ovarian epithelial cancer
1468824|NCT00101972|recurrent pancreatic cancer
1468825|NCT00101972|recurrent prostate cancer
1468826|NCT00101972|recurrent rectal cancer
1468827|NCT00101972|recurrent renal cell cancer
1468828|NCT00101972|recurrent salivary gland cancer
1468829|NCT00101972|recurrent small intestine cancer
1468830|NCT00101972|recurrent vaginal cancer
1468831|NCT00101972|unresectable extrahepatic bile duct cancer
1468832|NCT00101972|unresectable gallbladder cancer
1468833|NCT00101972|stage IV pancreatic cancer
1468834|NCT00101946|CD
1468835|NCT00101946|Crohn's Disease
1468836|NCT00101933|Direct brain stimulation, SANTE
1468837|NCT00101907|Advanced Cancer
1468838|NCT00101907|AMG 706
1468839|NCT00101907|Panitumumab
1468840|NCT00101907|Gemcitabine-Cisplatin
1468841|NCT00101894|AMG 706
1468842|NCT00101894|Panitumumab
1468843|NCT00101881|Cardiac arrest
1468844|NCT00101881|Defibrillation
1468845|NCT00101881|Biphasic defibrillation
1468846|NCT00101881|Monophasic defibrillation
1468847|NCT00101881|Ventricular fibrillation
1468848|NCT00101868|Aged
1468849|NCT00101868|Hospitalists
1468850|NCT00101868|Outcome and process assessment (health care)
1468851|NCT00101868|Human
1468852|NCT00101868|Hospitals, teaching
1468853|NCT00101868|Physicians, family
1468854|NCT00101868|Medical records
1468855|NCT00101868|Quality assurance, health care
1468856|NCT00101868|Medical errors
1468857|NCT00101855|prevention
1468858|NCT00101855|internet
1468859|NCT00101855|quality of care
1468860|NCT00101829|Autoimmune Diseases
1468861|NCT00101816|Myeloid blast phase Chronic Myeloid Leukemia (CML)
1468862|NCT00101803|type 2 diabetes
1468863|NCT00101803|vildagliptin
1468864|NCT00101790|low back pain
1468865|NCT00101790|pamidronate
1468866|NCT00101777|Anxiety
1468867|NCT00101777|Ventilation
1468868|NCT00101777|Panic Disorder
1468869|NCT00101777|Children
1468870|NCT00101777|Healthy Volunteer
1468871|NCT00101777|HV
1468872|NCT00101777|Normal Control
1468873|NCT00101764|AMD
1468874|NCT00101764|CRVO
1468875|NCT00101764|BRVO
1468876|NCT00101764|Uveitis
1468877|NCT00101764|Choroidal Neovascularization
1468878|NCT00101764|Age-Related Macular Degeneration (AMD)
1468879|NCT00101764|Macular Edema
1468880|NCT00101764|Central Retinal Vein Occlusion
1468881|NCT00101764|Branch Retinal Vein Occlusion
1468882|NCT00101764|Inflammation
1468883|NCT00101764|Age Related Macular Degeneration
1468884|NCT00101764|Retinal Disorder
1468885|NCT00101738|MPA
1468886|NCT00101738|Kidney Transplantation
1468887|NCT00101738|Acute rejection
1468888|NCT00101738|Kidney function
1468889|NCT00101725|Diarrhea
1468890|NCT00101725|IBS
1468891|NCT00101725|Irritable Bowel Syndrome
1468892|NCT00101725|Abdominal pain
1468893|NCT00101712|type 2 diabetes
1468894|NCT00101712|vildagliptin
1468895|NCT00101699|Women
1468896|NCT00101699|Soy Foods
1468897|NCT00101699|Middle Aged
1468898|NCT00101673|type 2 diabetes
1468899|NCT00101673|vildagliptin
1468900|NCT00101660|Chronic phase Philadelphia chromosome chronic myeloid leukemia (Ph+CML)
1468901|NCT00101647|Chronic myelogenous leukemia (CML): Accelerated phase
1468902|NCT00101634|Schizophrenia
1468903|NCT00101634|Paliperidone palmitate
1468904|NCT00101634|R092670
1468905|NCT00101634|antipsychotic
1468906|NCT00101621|cancer
1468907|NCT00101621|pain
1468908|NCT00101621|Cancers, Pain
1468909|NCT00101608|urothelium
1468910|NCT00101595|Lymphoid blast phase chronic myeloid leukemia
1468911|NCT00101595|Philadelphia chromosome positive acute lymphoblastic leukemia
1468912|NCT00101582|SCCHN
1468913|NCT00101582|Palifermin
1468914|NCT00101582|Mucositis
1468915|NCT00101582|Oral Cavity
1468916|NCT00101582|Oropharynx
1468917|NCT00101582|Nasopharynx
1468918|NCT00101582|Hypopharynx
1468919|NCT00101582|Larynx
1468920|NCT00101582|Mouth Pain
1468921|NCT00101582|Mouth Sores
1468922|NCT00101582|Radiation Therapy
1468923|NCT00101582|Radiotherapy
1468924|NCT00101582|Radiochemotherapy
1468926|NCT00101582|Xerostomia
1468927|NCT00101582|Stomatitis
1468928|NCT00101582|Mucosa
1468929|NCT00101582|KGF
1468930|NCT00101582|rHuKGF
1468931|NCT00101582|Keratinocyte Growth Factor
1468932|NCT00101582|HNC
1468933|NCT00101582|Head and Neck Cancer
1468934|NCT00101582|Oral Mucositis
1468935|NCT00101543|Gait Training
1468936|NCT00101543|Motor learning
1468937|NCT00101543|Electrical stimulation
1468938|NCT00101543|Body Weight supported Treadmill Training
1468939|NCT00101543|Cerebrovascular Accident
1468940|NCT00101465|Heart Failure
1468941|NCT00101452|Depression
1468942|NCT00101452|Antidepressive Agents
1468943|NCT00101452|Complementary Therapies
1468944|NCT00101439|Primary Hypercholesterolemia
1468945|NCT00101426|Diabetic sensorimotor polyneuropathy
1468946|NCT00101426|Diabetic Neuropathy
1468947|NCT00101413|NSCLC
1468948|NCT00101400|Cancer
1468949|NCT00101387|Aged
1468950|NCT00101387|Acupuncture
1468951|NCT00101374|Immunomodulatory Drug
1468952|NCT00101374|Antiviral
1468953|NCT00101374|Ki67+
1468954|NCT00101374|Immune Activation
1468955|NCT00101374|T Cell Proliferation
1468956|NCT00101374|HIV
1468957|NCT00101374|Activated CD4+T-cell
1468958|NCT00101374|Proliferation
1468959|NCT00101361|dermatologic
1468960|NCT00101361|skin
1468961|NCT00101361|clinical trial
1468962|NCT00101361|androgen/anabolic
1468963|NCT00101335|hypopharyngeal cancer
1468964|NCT00101335|lip and oral cavity cancer
1468965|NCT00101335|nasopharyngeal cancer
1468966|NCT00101335|oropharyngeal cancer
1468967|NCT00101335|tongue cancer
1468968|NCT00101335|oral leukoplakia
1468969|NCT00101309|recurrent neuroblastoma
1468970|NCT00101309|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1468971|NCT00101283|advanced malignant mesothelioma
1468972|NCT00101283|recurrent malignant mesothelioma
1468973|NCT00101257|recurrent ovarian epithelial cancer
1468974|NCT00101257|stage III ovarian epithelial cancer
1468975|NCT00101257|stage IV ovarian epithelial cancer
1468976|NCT00101257|peritoneal cavity cancer
1468977|NCT00101192|recurrent cervical cancer
1468978|NCT00101192|cervical adenocarcinoma
1468979|NCT00101192|cervical adenosquamous cell carcinoma
1468980|NCT00101192|cervical small cell carcinoma
1468981|NCT00101192|cervical squamous cell carcinoma
1468982|NCT00101192|stage III cervical cancer
1468983|NCT00101192|stage IVA cervical cancer
1468984|NCT00101192|stage IVB cervical cancer
1468985|NCT00101166|recurrent melanoma
1468986|NCT00101166|stage III melanoma
1468987|NCT00101166|stage IV melanoma
1468988|NCT00101153|adult acute basophilic leukemia
1468989|NCT00101153|adult acute eosinophilic leukemia
1468990|NCT00101153|adult acute megakaryoblastic leukemia (M7)
1468991|NCT00101153|adult acute minimally differentiated myeloid leukemia (M0)
1468992|NCT00101153|adult acute monoblastic leukemia (M5a)
1468993|NCT00101153|adult acute monocytic leukemia (M5b)
1468994|NCT00101153|adult acute myeloblastic leukemia with maturation (M2)
1468995|NCT00101153|adult acute myeloblastic leukemia without maturation (M1)
1468996|NCT00101153|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1468997|NCT00101153|adult acute myeloid leukemia with inv(16)(p13;q22)
1468998|NCT00101153|adult acute myeloid leukemia with t(16;16)(p13;q22)
1468999|NCT00101153|adult acute myeloid leukemia with t(8;21)(q22;q22)
1469000|NCT00101153|adult acute myelomonocytic leukemia (M4)
1469001|NCT00101153|adult erythroleukemia (M6a)
1469002|NCT00101153|adult pure erythroid leukemia (M6b)
1469003|NCT00101153|untreated adult acute myeloid leukemia
1469004|NCT00101140|adult erythroleukemia (M6a)
1469005|NCT00101140|adult acute megakaryoblastic leukemia (M7)
1469006|NCT00101140|adult acute minimally differentiated myeloid leukemia (M0)
1469007|NCT00101140|adult acute monocytic leukemia (M5b)
1469008|NCT00101140|adult acute myeloblastic leukemia with maturation (M2)
1469009|NCT00101140|adult acute myeloblastic leukemia without maturation (M1)
1469010|NCT00101140|adult acute myeloid leukemia in remission
1469011|NCT00101140|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1469012|NCT00101140|adult acute myeloid leukemia with inv(16)(p13;q22)
1469013|NCT00101140|adult acute myeloid leukemia with t(16;16)(p13;q22)
1469014|NCT00101140|adult acute myeloid leukemia with t(8;21)(q22;q22)
1469015|NCT00101140|adult acute myelomonocytic leukemia (M4)
1469016|NCT00101127|recurrent uterine sarcoma
1469017|NCT00101127|stage III uterine sarcoma
1469018|NCT00101127|stage IV uterine sarcoma
1469019|NCT00101127|uterine leiomyosarcoma
1469020|NCT00101101|recurrent mantle cell lymphoma
1469021|NCT00101101|contiguous stage II mantle cell lymphoma
1469022|NCT00101101|noncontiguous stage II mantle cell lymphoma
1469023|NCT00101101|stage III mantle cell lymphoma
1469024|NCT00101101|stage IV mantle cell lymphoma
1469025|NCT00101075|high-grade salivary gland mucoepidermoid carcinoma
1469026|NCT00101075|low-grade salivary gland mucoepidermoid carcinoma
1469027|NCT00101075|salivary gland acinic cell tumor
1469028|NCT00101075|salivary gland adenocarcinoma
1469029|NCT00101075|salivary gland adenoid cystic carcinoma
1469030|NCT00101075|salivary gland malignant mixed cell type tumor
1469031|NCT00101075|salivary gland poorly differentiated carcinoma
1469032|NCT00101075|salivary gland squamous cell carcinoma
1469033|NCT00101075|recurrent salivary gland cancer
1469034|NCT00101075|stage III salivary gland cancer
1469035|NCT00101075|stage IV salivary gland cancer
1469036|NCT00101062|stage IIIA breast cancer
1469037|NCT00101062|stage IIIB breast cancer
1469038|NCT00101062|stage IIIC breast cancer
1469039|NCT00101062|stage IV breast cancer
1469040|NCT00101062|recurrent breast cancer
1469041|NCT00101010|contiguous stage II adult diffuse large cell lymphoma
1469042|NCT00101010|noncontiguous stage II adult diffuse large cell lymphoma
1469043|NCT00101010|stage III adult diffuse large cell lymphoma
1469044|NCT00101010|stage IV adult diffuse large cell lymphoma
1469045|NCT00100997|chronic myelogenous leukemia, BCR-ABL1 positive
1469046|NCT00100997|chronic phase chronic myelogenous leukemia
1469047|NCT00100997|relapsing chronic myelogenous leukemia
1469048|NCT00100971|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1469049|NCT00100971|adult acute myeloid leukemia with inv(16)(p13;q22)
1469050|NCT00100971|adult acute myeloid leukemia with t(15;17)(q22;q12)
1469051|NCT00100971|adult acute myeloid leukemia with t(16;16)(p13;q22)
1469052|NCT00100971|adult acute myeloid leukemia with t(8;21)(q22;q22)
1469053|NCT00100971|secondary acute myeloid leukemia
1469054|NCT00100958|unspecified adult solid tumor, protocol specific
1469055|NCT00100945|adenocarcinoma of the esophagus
1469056|NCT00100945|stage II esophageal cancer
1469057|NCT00100919|Kinesithesia
1469058|NCT00100919|Sensorimotor Function
1469059|NCT00100919|Somatosensory
1469060|NCT00100919|Muscle Spindles
1469061|NCT00100919|Sensory Feedback
1469062|NCT00100919|Healthy Volunteer
1469063|NCT00100919|HV
1469064|NCT00100906|stage IV renal cell cancer
1469065|NCT00100906|recurrent renal cell cancer
1469066|NCT00100906|clear cell renal cell carcinoma
1469067|NCT00100893|breast cancer
1469068|NCT00100867|Perinatal Transmission
1469069|NCT00100867|Mother-to-Child Transmission
1469070|NCT00100854|stage IIIB non-small cell lung cancer
1469071|NCT00100854|stage IV non-small cell lung cancer
1469072|NCT00100854|recurrent non-small cell lung cancer
1469073|NCT00100828|thyroid gland medullary carcinoma
1469074|NCT00100828|recurrent thyroid cancer
1469075|NCT00100815|adenocarcinoma of the pancreas
1469076|NCT00100815|recurrent pancreatic cancer
1469077|NCT00100815|stage IV pancreatic cancer
1469078|NCT00100802|childhood high-grade cerebral astrocytoma
1469079|NCT00100802|childhood spinal cord neoplasm
1469080|NCT00100789|Recurrent
1469081|NCT00100789|stage IV
1469082|NCT00100789|squamous cell carcinoma
1469083|NCT00100789|hypopharynx
1469084|NCT00100789|larynx
1469085|NCT00100789|lip
1469086|NCT00100789|oral cavity
1469087|NCT00100789|nasopharynx
1469088|NCT00100789|oropharynx
1469089|NCT00100789|paranasal
1469090|NCT00100789|nasal cavity
1469091|NCT00100789|metastatic
1469092|NCT00100789|neck cancer
1469093|NCT00100737|non-hodgkins lymphoma
1469094|NCT00100737|interleukin-2
1469095|NCT00100737|rituximab
1469096|NCT00100737|CD20+ follicular B-cell non-hodgkins lymphoma (grade I, II,III)
1469097|NCT00100724|Anthrax
1469098|NCT00100724|rPA102
1469099|NCT00100724|vaccine
1469100|NCT00100711|Chronic Lymphocytic Leukemia
1469101|NCT00100711|Small Lymphocytic Lymphoma
1469102|NCT00100711|Leukemia
1469103|NCT00100711|Lymphoma
1469104|NCT00100711|Motexafin Gadolinium
1469105|NCT00100711|Relapsed Chronic Lymphocytic Leukemia
1469106|NCT00100711|Relapsed Chronic Lymphocycic Lymphoma
1469107|NCT00100711|Refractory Chronic Lymphocytic Leukemia
1469108|NCT00100711|Refractory Small Lymphocytic Lymphoma
1469109|NCT00100698|HIV
1469110|NCT00100698|lipodystrophy
1469111|NCT00100698|growth hormone
1469112|NCT00100698|visceral fat
1469113|NCT00100698|IGF-I
1469114|NCT00100698|Treatment Experienced
1469115|NCT00100685|Kidney
1469116|NCT00100685|renal
1469117|NCT00100685|cancer
1469118|NCT00100685|carcinoma
1469119|NCT00100685|cell
1469120|NCT00100685|metastatic
1469121|NCT00100685|metastatic renal cell carcinoma
1469122|NCT00100685|RCC
1469123|NCT00100672|LErafAON-ETU
1469124|NCT00100672|Signal transduction
1469125|NCT00100672|Neoplasm
1469126|NCT00100672|Cancer
1469127|NCT00100672|NeoPharm
1469128|NCT00100672|Liposomes
1469129|NCT00100672|Antisense
1469130|NCT00100672|Anti-cancer
1469131|NCT00100672|Advanced neoplasm
1469132|NCT00100672|Advanced cancer
1469133|NCT00100672|Chemotherapy
1469134|NCT00100672|Refractory cancer
1469135|NCT00100672|Metastatic cancer
1469136|NCT00100659|pediatric
1469137|NCT00100659|hepatitis
1469138|NCT00100659|children
1469139|NCT00100659|HCV
1469140|NCT00100659|PEG
1469141|NCT00100659|PEG-2a
1469142|NCT00100659|peginterferon alfa-2a
1469143|NCT00100659|Pegylated Interferon
1469144|NCT00100659|RV
1469145|NCT00100659|ribavirin
1469146|NCT00100659|Pegasys
1469147|NCT00100659|CHC
1469148|NCT00100659|chronic hepatitis C
1469149|NCT00100659|chronic hepatitis C virus
1469150|NCT00100659|hepatitis c
1469151|NCT00100659|pediatric hepatitis
1469152|NCT00100659|pediatric HCV
1469153|NCT00100646|Treatment Interruption
1469154|NCT00100646|Treatment Naive
1469155|NCT00100633|Hepatitis B Vaccine
1469156|NCT00100633|Treatment Experienced
1469157|NCT00100633|Treatment Naive
1469158|NCT00100620|Corticosteroid induced osteoporosis
1469159|NCT00100620|prevention
1469160|NCT00100620|treatment
1469161|NCT00100620|zoledronic acid
1469162|NCT00100607|osteoporosis/osteopenia, BMD, postmenopausal
1469163|NCT00100594|Treatment Naive
1469164|NCT00100581|Treatment Naive
1469165|NCT00100568|Treatment Naive
1469166|NCT00100555|Osteoporosis, osteopenia, post-menopausal, zoledronic acid
1469167|NCT00100542|Treatment Experienced
1469168|NCT00100542|Treatment Naive
1469169|NCT00100542|Psychopathology
1469170|NCT00100542|Anti-Retroviral Agents
1469171|NCT00100542|Child
1469172|NCT00100542|Adolescent
1469173|NCT00100529|Facial Imaging
1469174|NCT00100529|Genetics
1469175|NCT00100529|Growth
1469176|NCT00100529|Development
1469177|NCT00100529|Diagnostics
1469178|NCT00100529|Craniofacial Dysmorphologies
1469179|NCT00100529|Facial Features
1469180|NCT00100516|Renal
1469181|NCT00100516|Allografts
1469182|NCT00100516|Nephrectomy
1469183|NCT00100516|Pneumoperitoneum
1469184|NCT00100516|LaparoscopIC
1469185|NCT00100516|Kidney Donation
1469186|NCT00100503|Rehabilitation
1469187|NCT00100503|Forced Use
1469188|NCT00100503|Hemiplegia
1469189|NCT00100503|Magnetic Resonance Imaging
1469190|NCT00100503|TMS
1469191|NCT00100503|Cerebral Palsy
1469192|NCT00100503|Spastic Hemiplegia
1469193|NCT00100503|Healthy Volunteer
1469194|NCT00100503|HV
1469195|NCT00100477|Multiple Myeloma
1469196|NCT00100477|Lymphoma
1469197|NCT00100477|Leukemia
1469198|NCT00100477|Etoposide
1469199|NCT00100477|Drug Therapy
1469200|NCT00100477|Clinical Trials
1469201|NCT00100464|Serotonin
1469202|NCT00100464|Sleep Apnea Syndrome
1469203|NCT00100464|Pharyngeal Muscles
1469204|NCT00100451|Adipose tissue
1469205|NCT00100451|Aging
1469206|NCT00100451|Exercise
1469207|NCT00100451|Lipolysis
1469208|NCT00100451|Estrogens
1469209|NCT00100425|Irritable Bowel Syndrome
1469210|NCT00100425|Visceral Hypersensitivity
1469211|NCT00100425|Visceral Pain
1469212|NCT00100399|influenza, flu, Fluarix, vaccine, GSK, immunogenicity
1469213|NCT00100386|Hand hygiene, antibiotic resistance, contact precautions
1469214|NCT00100373|Respiratory Syncytial Virus Infections
1469215|NCT00100360|Gonadal Steroids
1469216|NCT00100360|GnRH Agonist
1469217|NCT00100360|Depression
1469218|NCT00100360|Menstrual Cycle
1469219|NCT00100360|Menstrually Related Mood Disorder
1469220|NCT00100360|MRMD
1469221|NCT00100360|Healthy Volunteer
1469222|NCT00100360|HV
1469223|NCT00100347|non-Hodgkin lymphoma
1469224|NCT00100347|non-Hodgkin’s lymphoma
1469225|NCT00100347|NHL
1469226|NCT00100347|MetAP2
1469227|NCT00100347|Solid Tumors
1469228|NCT00100334|Alzheimer's Disease
1469229|NCT00100321|Tumor Antigen Identification
1469230|NCT00100321|Standard Treatment
1469231|NCT00100321|Tissue Acquisition
1469232|NCT00100321|Surgery
1469233|NCT00100321|Adjuvant Chemotherapy
1469234|NCT00100321|Pancreatic Cancer
1469235|NCT00100321|Pancreatic Tumor
1469236|NCT00100308|sepsis
1469237|NCT00100308|Randomized clinical trial
1469238|NCT00100308|Heparin
1469239|NCT00100308|Therapy
1469240|NCT00100295|Adolescent
1469241|NCT00100295|Child
1469242|NCT00100295|Phytotherapy
1469243|NCT00100282|Mild-moderate Alzheimer's disease
1469244|NCT00100269|Male infertility
1469245|NCT00100269|sperm
1469246|NCT00100269|pregnancy
1469247|NCT00100269|IVF (in vitro fertilisation)
1469248|NCT00100269|oxidative stress
1469249|NCT00100269|free radicals
1469250|NCT00100269|DNA damage
1469251|NCT00100256|Advanced or recurrent stage IIIb or IV non small cell lung cancer
1469252|NCT00100256|Disseminated or recurrent small cell lung cancer
1469253|NCT00100243|androgen-independent
1469254|NCT00100243|prostate cancer
1469255|NCT00100230|retina
1469256|NCT00100230|electroretinography
1469257|NCT00100230|clinical trial
1469258|NCT00100230|docosahexaenoic acid
1469259|NCT00100230|omega-3 fatty acid
1469260|NCT00100230|x-linked inheritance
1469261|NCT00100217|Training
1469262|NCT00100217|Critical Care
1469263|NCT00100217|Heart Failure
1469264|NCT00100217|Pulmonary Hypertension
1469265|NCT00100217|Infectious Diseases
1469266|NCT00100204|Head and Neck Radiation
1469267|NCT00100204|Diabetes
1469268|NCT00100204|Sarcoidosis
1469269|NCT00100204|Sjogren's Syndrome
1469270|NCT00100204|Caries
1469271|NCT00100204|Healthy Volunteer
1469272|NCT00100204|HV
1469273|NCT00100204|Saliva Sample
1469274|NCT00100191|hysterectomy
1469275|NCT00100191|fibroids
1469276|NCT00100191|uterine artery embolization
1469277|NCT00100191|therapeutic embolization
1469278|NCT00100191|uterus
1469279|NCT00100191|menorrhagia
1469280|NCT00100178|immunosuppressive therapy
1469281|NCT00100178|Type 1 Diabetes TrialNet
1469282|NCT00100178|TrialNet
1469283|NCT00100178|POPPII
1469284|NCT00100178|POPPII-1
1469285|NCT00100165|Schizophrenia
1469286|NCT00100152|Relapsed or refractory T-cell ALL acute lymphoblastic/leukemia
1469287|NCT00100152|Relapsed/refractory T-cell acute Lymphoblastic/leukemia
1469288|NCT00100152|Acute/chronic myelogenous leukemia
1469289|NCT00100152|Poor-risk myelodysplasia
1469290|NCT00100139|Neoplasm
1469291|NCT00100139|Cancer
1469292|NCT00100139|NeoPharm
1469293|NCT00100139|Liposomes
1469294|NCT00100139|Taxol
1469295|NCT00100139|Paclitaxel
1469296|NCT00100139|Anti-cancer
1469297|NCT00100139|Advanced neoplasm
1469298|NCT00100139|Advanced cancer
1469299|NCT00100139|Chemotherapy
1469300|NCT00100139|Refractory cancer
1469301|NCT00100139|Metastatic cancer
1469302|NCT00100126|Pharyngitis
1469303|NCT00100126|Strep throat
1469304|NCT00100113|cocaine dependence
1469305|NCT00100100|cocaine dependence
1469306|NCT00100087|macular degeneration
1469307|NCT00100087|brachytherapy
1469308|NCT00100087|choroidal neovascularization
1469309|NCT00100087|retinal degeneration
1469310|NCT00100087|retinal diseases
1469311|NCT00100061|Cranberry
1469312|NCT00100061|Vaccinium macrocarpon
1469313|NCT00100035|Caregivers
1469314|NCT00100035|Complementary Therapies
1469315|NCT00100009|Steroid
1469316|NCT00100009|Inflammation
1469317|NCT00100009|Choroidal Neovascularization
1469318|NCT00100009|Intravitreal Injection
1469319|NCT00100009|Verteporfin
1469320|NCT00100009|Age-Related Macular Degeneration
1469321|NCT00100009|Photodynamic Therapy
1469322|NCT00100009|Age Related Macular Degeneration
1469323|NCT00100009|AMD
1469324|NCT00099996|Sitosterolemia
1469325|NCT00099996|Sitosterol
1469326|NCT00099996|Ezetimibe
1469327|NCT00099996|Absorption
1469328|NCT00099996|Intestine
1469329|NCT00099996|Cholesterol
1469330|NCT00099996|Atherosclerosis
1469331|NCT00099996|Homozygous Sitosterolemia
1469332|NCT00099983|PTSD
1469333|NCT00099970|Solid tumors
1469334|NCT00099970|Metastatic melanoma
1469335|NCT00099957|type 2 diabetes
1469336|NCT00099957|vildagliptin
1469337|NCT00099944|type 2 diabetes
1469338|NCT00099944|vildagliptin
1469339|NCT00099931|type 2 diabetes
1469340|NCT00099931|vildagliptin
1469341|NCT00099918|type 2 diabetes
1469342|NCT00099918|vildagliptin
1469343|NCT00099905|type 2 diabetes
1469344|NCT00099905|vildagliptin
1469345|NCT00099892|type 2 diabetes
1469346|NCT00099892|vildagliptin
1469347|NCT00099866|type 2 diabetes
1469348|NCT00099866|vildagliptin
1469349|NCT00099853|type 2 diabetes
1469350|NCT00099853|vildagliptin
1469351|NCT00099840|common cold
1469352|NCT00099840|pharyngitis
1469353|NCT00099840|tonsillitis
1469354|NCT00099840|rhinosinusitis
1469355|NCT00099840|tracheo-bronchitis
1469356|NCT00099840|otitis media
1469357|NCT00099840|acute exacerbations of asthma
1469358|NCT00099840|acute exacerbations of chronic pulmonary disease
1469359|NCT00099840|community acquired pneumonia
1469360|NCT00099827|Depression
1469361|NCT00099814|tooth movement
1469362|NCT00099814|orthodontics
1469363|NCT00099814|force
1469364|NCT00099814|humans
1469365|NCT00099814|clinical trial
1469366|NCT00099801|Kidney, Transplantation, Rejection, Immunosuppression
1469367|NCT00099788|Acute Coronary Syndrome
1469368|NCT00099788|Myocardial Infarction
1469369|NCT00099788|Heart Attack
1469370|NCT00099788|Angina
1469371|NCT00099788|Chest pain
1469372|NCT00099788|Ischemia
1469373|NCT00099788|Non-ST Elevation Acute Coronary Syndrome
1469374|NCT00099775|Mycoses
1469375|NCT00099775|Candida
1469376|NCT00099775|Echinocandin
1469377|NCT00099775|Immunocompromised Host
1469378|NCT00099775|Invasive Fungal Infection
1469379|NCT00099775|Fungal Infection
1469380|NCT00099762|Tumor Induced Osteomalacia
1469381|NCT00099762|FGF-23
1469382|NCT00099762|Phosphatonin
1469383|NCT00099762|Hypophosphatemia
1469384|NCT00099762|Oncogenic Osteomalacia
1469385|NCT00099762|Phosphaturic Mesenchymal Tumor
1469386|NCT00099762|TIO
1469387|NCT00099762|Osteogenic Osteomalacia
1469388|NCT00099762|OOM
1469389|NCT00099749|Kidney, immunosuppression, transplant, rejection
1469390|NCT00099736|Kidney, transplantation, rejection, immunosuppression
1469391|NCT00099723|Hepatic steatosis
1469392|NCT00099723|adult-onset diabetes
1469393|NCT00099723|Non-alcoholic fatty liver disease
1469394|NCT00099710|Curcumin
1469395|NCT00099710|Turmeric
1469396|NCT00099710|Curry
1469397|NCT00099710|NSAID
1469398|NCT00099710|anti-inflammatory
1469399|NCT00099710|Cholesterol
1469400|NCT00099710|anti-oxidant
1469401|NCT00099697|abdominal fat
1469402|NCT00099697|dehydroepiandrosterone
1469403|NCT00099697|Insulin sensitivity
1469404|NCT00099684|Treatment Experienced
1469405|NCT00099671|Treatment Experienced
1469406|NCT00099658|MTCT
1469407|NCT00099645|Mifepristone
1469408|NCT00099645|Mifeprex
1469409|NCT00099645|RU486
1469410|NCT00099645|VGX-410
1469411|NCT00099645|Abortion Pill
1469412|NCT00099645|Investigational Drug
1469413|NCT00099632|Treatment Naive
1469414|NCT00099619|exenatide
1469415|NCT00099619|exendin-4
1469416|NCT00099619|diabetes
1469417|NCT00099619|Amylin
1469418|NCT00099619|Lilly
1469419|NCT00099593|Cutaneous T-cell lymphoma (CTCL)
1469420|NCT00099593|Sezary Syndrome
1469421|NCT00099593|Mycosis Fungoides
1469422|NCT00099593|Vaccine
1469423|NCT00099580|Congestive Heart Failure
1469424|NCT00099580|AC2592
1469425|NCT00099580|GLP-1
1469426|NCT00099580|Amylin
1469427|NCT00099580|metabolic abnormality
1469428|NCT00099567|Metabolic Syndrome
1469429|NCT00099567|Alzheimer's Disease
1469430|NCT00099567|Cognitive Impairment
1469431|NCT00099567|Inflammation
1469432|NCT00099541|Lung Cancer
1469433|NCT00099541|Bone Metastases
1469434|NCT00099541|Bone Markers
1469435|NCT00099541|NTX
1469436|NCT00099541|zoledronic acid
1469437|NCT00099541|Registry
1469438|NCT00099541|Unresectable Stage IV Non Small-cell Lung Cancer (NSCLC)
1469439|NCT00099541|Unresectable Stage IIIB NSCLC with Pleural Effusion
1469440|NCT00099528|Post-herpetic neuralgia
1469441|NCT00099528|Shingles
1469442|NCT00099528|Herpes Zoster
1469443|NCT00099528|Neuropathic pain
1469444|NCT00099528|Neuralgia
1469445|NCT00099528|Anti-TNF agents
1469446|NCT00099528|Inflammatory cytokines
1469447|NCT00099528|Hyperalgesia
1469448|NCT00099528|Allodynia
1469449|NCT00099528|Irritable nociceptor
1469450|NCT00099502|Relapsing multiple sclerosis
1469451|NCT00099502|interferon beta 1b
1469452|NCT00099502|Betaferon
1469453|NCT00099502|Betaseron
1469454|NCT00099489|Chronic Inflammatory Demyelinating Polyradiculoneuropathy
1469455|NCT00099489|CIDP
1469456|NCT00099489|IVIg
1469457|NCT00099489|AVONEX
1469458|NCT00099476|Epicatechin
1469459|NCT00099476|Polyphenols
1469460|NCT00099476|Chocolate
1469461|NCT00099476|Insulin Resistance
1469462|NCT00099476|Endothelial Dysfunction
1469463|NCT00099476|Hypertension
1469464|NCT00099463|Coronavirus
1469465|NCT00099463|Healthy
1469466|NCT00099463|Immunity
1469467|NCT00099463|Preventive
1469468|NCT00099463|Virus
1469469|NCT00099463|Healthy Volunteer
1469470|NCT00099463|HV
1469471|NCT00099450|bleeding
1469472|NCT00099450|blood transfusion
1469473|NCT00099450|surgeries
1469474|NCT00099437|Advanced Breast Cancer
1469475|NCT00099437|Metastatic Breast Cancer
1469476|NCT00099424|exercise training
1469477|NCT00099424|resistance training
1469478|NCT00099424|endurance training
1469479|NCT00099424|Boeck's Sarcoid
1469480|NCT00099424|Besnier-Boeck Disease
1469481|NCT00099385|social development
1469482|NCT00099385|risk behaviors
1469483|NCT00099385|social emotional education
1469484|NCT00099385|classroom instruction
1469485|NCT00099372|sacrocolpopexy
1469486|NCT00099372|abdominal sacrocolpopexy
1469487|NCT00099372|surgical procedure, prolapse
1469488|NCT00099372|pelvic organ prolapse
1469489|NCT00099372|urinary incontinence
1469490|NCT00099372|stress urinary incontinence
1469491|NCT00099359|HIV
1469492|NCT00099359|Perinatal
1469493|NCT00099359|Prevention
1469494|NCT00099359|Transmission
1469495|NCT00099359|Nevirapine
1469496|NCT00099359|Epivir
1469497|NCT00099359|Zidovudine
1469498|NCT00099359|Nelfinavir
1469499|NCT00099359|ZDV
1469500|NCT00099359|NVP
1469501|NCT00099359|3TC
1469502|NCT00099359|NFV
1469503|NCT00099359|Viracept
1469504|NCT00099359|Viramune
1469505|NCT00099359|HIV Seronegativity
1469506|NCT00099359|Treatment Naive
1469507|NCT00099333|exenatide
1469508|NCT00099333|exendin-4
1469509|NCT00099333|Amylin
1469510|NCT00099333|Eli Lilly
1469511|NCT00099333|diabetes
1469512|NCT00099320|exenatide
1469513|NCT00099320|exendin-4
1469514|NCT00099320|diabetes
1469515|NCT00099320|Amylin
1469516|NCT00099320|Lilly
1469517|NCT00099307|White Matter
1469518|NCT00099307|Grey Matter
1469519|NCT00099307|Brain
1469520|NCT00099307|Disability
1469521|NCT00099307|Lesions
1469522|NCT00099307|Multiple Sclerosis
1469523|NCT00099307|MS
1469524|NCT00099307|Healthy Volunteer
1469525|NCT00099307|HV
1469526|NCT00099294|Pancreas
1469527|NCT00099294|Cancer
1469528|NCT00099294|Pancreatic Adenocarcinoma
1469529|NCT00099294|Metastatic
1469530|NCT00099294|Glufosfamide
1469531|NCT00099281|Metastatic breast cancer
1469532|NCT00099268|Parkinson's disease, levodopa therapy, dyskinesia
1469533|NCT00099255|Keyword?
1469534|NCT00099255|Primary Cutaneous Anaplastic Large Cell Lymphoma
1469535|NCT00099255|Large Cell Transformation of Mycosis Fungoides
1469536|NCT00099255|Lymphomatoid Papulosis
1469537|NCT00099242|Alzheimer's Disease
1469538|NCT00099242|Dementia
1469539|NCT00099229|bipolar disorder
1469540|NCT00099229|manic episode
1469541|NCT00099229|treatment
1469542|NCT00099229|licarbazepine
1469543|NCT00099216|Dementia,vascular,rivastigmine,stroke,memory loss
1469544|NCT00099190|cancer
1469545|NCT00099190|solid tumor
1469546|NCT00099190|advanced solid tumor
1469547|NCT00099164|preterm birth
1469548|NCT00099164|pregnancy
1469549|NCT00099164|multifetal
1469550|NCT00099164|Progesterone
1469551|NCT00099151|Longevity
1469552|NCT00099151|Dietary restriction
1469553|NCT00099151|Physical activity
1469554|NCT00099151|Weight Loss
1469555|NCT00099151|Diabetes
1469556|NCT00099138|Diet
1469557|NCT00099138|Caloric Restriction
1469558|NCT00099138|Exercise
1469559|NCT00099138|Energy Metabolism
1469560|NCT00099138|Primary Aging
1469561|NCT00099138|Secondary Aging
1469562|NCT00099125|adult giant cell glioblastoma
1469563|NCT00099125|adult gliosarcoma
1469564|NCT00099125|adult glioblastoma
1469565|NCT00099112|basal cell carcinoma of the skin
1469566|NCT00099112|squamous cell carcinoma of the skin
1469567|NCT00099112|actinic keratosis
1469568|NCT00099099|Longevity
1469569|NCT00099099|Calorie restriction
1469570|NCT00099099|Physical activity
1469571|NCT00099099|Weight loss
1469572|NCT00099086|adenocarcinoma of the prostate
1469573|NCT00099086|stage IIB prostate cancer
1469574|NCT00099086|stage IIA prostate cancer
1469575|NCT00099086|stage III prostate cancer
1469576|NCT00099086|stage IV prostate cancer
1469577|NCT00099060|adult giant cell glioblastoma
1469578|NCT00099060|adult gliosarcoma
1469579|NCT00099060|recurrent adult brain tumor
1469580|NCT00099008|breast cancer
1469581|NCT00099008|endometrial cancer
1469582|NCT00098995|stage IB cervical cancer
1469583|NCT00098995|stage IIA cervical cancer
1469584|NCT00098995|stage IIB cervical cancer
1469585|NCT00098995|stage III cervical cancer
1469586|NCT00098995|stage IVA cervical cancer
1469587|NCT00098995|cervical adenocarcinoma
1469588|NCT00098995|cervical adenosquamous cell carcinoma
1469589|NCT00098995|cervical squamous cell carcinoma
1469590|NCT00098982|stage III colon cancer
1469591|NCT00098982|stage IV colon cancer
1469592|NCT00098982|stage III rectal cancer
1469593|NCT00098982|stage IV rectal cancer
1469594|NCT00098982|recurrent colon cancer
1469595|NCT00098982|recurrent rectal cancer
1469596|NCT00098969|unspecified adult solid tumor, protocol specific
1469597|NCT00098943|unspecified adult solid tumor, protocol specific
1469598|NCT00098943|stage IV renal cell cancer
1469599|NCT00098943|recurrent renal cell cancer
1469600|NCT00098943|stage IV colon cancer
1469601|NCT00098943|recurrent colon cancer
1469602|NCT00098943|anaplastic thyroid cancer
1469603|NCT00098943|insular thyroid cancer
1469604|NCT00098943|thyroid gland medullary carcinoma
1469605|NCT00098943|stage IV follicular thyroid cancer
1469606|NCT00098943|stage IV papillary thyroid cancer
1469607|NCT00098943|recurrent thyroid cancer
1469608|NCT00098943|recurrent squamous cell carcinoma of the hypopharynx
1469609|NCT00098943|recurrent squamous cell carcinoma of the larynx
1469610|NCT00098943|recurrent squamous cell carcinoma of the lip and oral cavity
1469611|NCT00098943|recurrent squamous cell carcinoma of the nasopharynx
1469612|NCT00098943|recurrent squamous cell carcinoma of the oropharynx
1469613|NCT00098943|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1469614|NCT00098943|stage IV squamous cell carcinoma of the hypopharynx
1469615|NCT00098943|stage IV squamous cell carcinoma of the larynx
1469616|NCT00098943|stage IV squamous cell carcinoma of the lip and oral cavity
1469617|NCT00098943|stage IV squamous cell carcinoma of the nasopharynx
1469618|NCT00098943|stage IV squamous cell carcinoma of the oropharynx
1469619|NCT00098943|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1469620|NCT00098943|recurrent verrucous carcinoma of the larynx
1469621|NCT00098943|recurrent verrucous carcinoma of the oral cavity
1469622|NCT00098943|stage IV verrucous carcinoma of the oral cavity
1469623|NCT00098943|stage IV verrucous carcinoma of the larynx
1469624|NCT00098943|recurrent adenoid cystic carcinoma of the oral cavity
1469625|NCT00098943|stage IV adenoid cystic carcinoma of the oral cavity
1469626|NCT00098943|recurrent basal cell carcinoma of the lip
1469627|NCT00098943|stage IV basal cell carcinoma of the lip
1469628|NCT00098943|recurrent mucoepidermoid carcinoma of the oral cavity
1469629|NCT00098943|stage IV mucoepidermoid carcinoma of the oral cavity
1469630|NCT00098943|recurrent lymphoepithelioma of the nasopharynx
1469631|NCT00098943|recurrent lymphoepithelioma of the oropharynx
1469632|NCT00098943|stage IV lymphoepithelioma of the nasopharynx
1469851|NCT00098007|Everolimus
1469633|NCT00098943|stage IV lymphoepithelioma of the oropharynx
1469634|NCT00098943|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1469635|NCT00098943|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1469636|NCT00098943|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1469637|NCT00098943|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1469638|NCT00098943|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1469639|NCT00098943|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1469640|NCT00098943|metastatic parathyroid cancer
1469641|NCT00098943|recurrent parathyroid cancer
1469642|NCT00098943|recurrent salivary gland cancer
1469643|NCT00098943|stage IV salivary gland cancer
1469644|NCT00098917|stage I non-small cell lung cancer
1469645|NCT00098917|stage II non-small cell lung cancer
1469646|NCT00098917|stage IIIA non-small cell lung cancer
1469647|NCT00098878|stage I ovarian epithelial cancer
1469648|NCT00098878|stage II ovarian epithelial cancer
1469649|NCT00098878|stage III ovarian epithelial cancer
1469650|NCT00098878|stage IV ovarian epithelial cancer
1469651|NCT00098878|fallopian tube cancer
1469652|NCT00098878|primary peritoneal cavity cancer
1469653|NCT00098852|recurrent thyroid cancer
1469654|NCT00098852|stage II follicular thyroid cancer
1469655|NCT00098852|stage IV follicular thyroid cancer
1469656|NCT00098852|stage II papillary thyroid cancer
1469657|NCT00098852|stage IV papillary thyroid cancer
1469658|NCT00098800|ovarian epithelial cancer
1469659|NCT00098800|BRCA1 mutation carrier
1469660|NCT00098800|BRCA2 mutation carrier
1469661|NCT00098787|recurrent colon cancer
1469662|NCT00098787|stage IV colon cancer
1469663|NCT00098787|recurrent rectal cancer
1469664|NCT00098787|stage IV rectal cancer
1469665|NCT00098787|adenocarcinoma of the colon
1469666|NCT00098787|adenocarcinoma of the rectum
1469667|NCT00098774|primary central nervous system non-Hodgkin lymphoma
1469668|NCT00098761|recurrent childhood brain stem glioma
1469669|NCT00098761|recurrent childhood visual pathway and hypothalamic glioma
1469670|NCT00098761|recurrent childhood cerebellar astrocytoma
1469671|NCT00098761|recurrent childhood cerebral astrocytoma
1469672|NCT00098761|recurrent childhood ependymoma
1469673|NCT00098761|recurrent childhood medulloblastoma
1469674|NCT00098761|recurrent childhood supratentorial primitive neuroectodermal tumor
1469675|NCT00098761|childhood central nervous system germ cell tumor
1469676|NCT00098761|childhood choroid plexus tumor
1469677|NCT00098761|childhood craniopharyngioma
1469678|NCT00098761|childhood infratentorial ependymoma
1469679|NCT00098761|childhood grade I meningioma
1469680|NCT00098761|childhood grade II meningioma
1469681|NCT00098761|childhood grade III meningioma
1469682|NCT00098761|childhood high-grade cerebral astrocytoma
1469683|NCT00098761|childhood low-grade cerebral astrocytoma
1469684|NCT00098735|Kidney,Transplantation, rejection, immunosuppression
1469685|NCT00098709|pregnancy
1469686|NCT00098709|labor, obstetric
1469687|NCT00098709|fetal monitoring
1469688|NCT00098709|oximetry
1469689|NCT00098709|fetal heart rate
1469690|NCT00098709|cardiotocography
1469691|NCT00098683|refractory anemia with excess blasts
1469692|NCT00098683|refractory anemia
1469693|NCT00098683|refractory anemia with ringed sideroblasts
1469694|NCT00098683|de novo myelodysplastic syndromes
1469695|NCT00098683|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1469696|NCT00098683|refractory cytopenia with multilineage dysplasia
1469697|NCT00098566|quality of life
1469698|NCT00098566|recurrent adult Burkitt lymphoma
1469699|NCT00098566|recurrent adult diffuse large cell lymphoma
1469700|NCT00098566|recurrent adult diffuse mixed cell lymphoma
1469701|NCT00098566|recurrent adult diffuse small cleaved cell lymphoma
1469702|NCT00098566|recurrent adult immunoblastic large cell lymphoma
1469703|NCT00098566|recurrent adult lymphoblastic lymphoma
1469704|NCT00098566|recurrent grade 1 follicular lymphoma
1469705|NCT00098566|recurrent grade 2 follicular lymphoma
1469706|NCT00098566|recurrent grade 3 follicular lymphoma
1469707|NCT00098566|recurrent small lymphocytic lymphoma
1469708|NCT00098566|recurrent mantle cell lymphoma
1469709|NCT00098566|recurrent marginal zone lymphoma
1469710|NCT00098566|Waldenstrom macroglobulinemia
1469711|NCT00098566|recurrent adult grade III lymphomatoid granulomatosis
1469712|NCT00098566|splenic marginal zone lymphoma
1469713|NCT00098566|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1469714|NCT00098566|nodal marginal zone B-cell lymphoma
1469715|NCT00098553|stage IV melanoma
1469716|NCT00098553|recurrent melanoma
1469717|NCT00098514|unspecified adult solid tumor, protocol specific
1469718|NCT00098462|recurrent non-small cell lung cancer
1469719|NCT00098462|stage IIIB non-small cell lung cancer
1469720|NCT00098462|stage IV non-small cell lung cancer
1469721|NCT00098436|recurrent adult acute myeloid leukemia
1469722|NCT00098436|recurrent adult acute lymphoblastic leukemia
1469723|NCT00098436|blastic phase chronic myelogenous leukemia
1469724|NCT00098436|relapsing chronic myelogenous leukemia
1469725|NCT00098436|secondary acute myeloid leukemia
1469726|NCT00098436|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1469727|NCT00098436|adult acute myeloid leukemia with inv(16)(p13;q22)
1469728|NCT00098436|adult acute myeloid leukemia with t(15;17)(q22;q12)
1469729|NCT00098436|adult acute myeloid leukemia with t(16;16)(p13;q22)
1469730|NCT00098436|adult acute myeloid leukemia with t(8;21)(q22;q22)
1469731|NCT00098384|Travelers’ diarrhea
1469732|NCT00098384|rifaximin
1469733|NCT00098384|prophylaxis
1469734|NCT00098384|enterotoxigenic E. coli
1469735|NCT00098358|Leukotrienes
1469736|NCT00098358|inflammation
1469737|NCT00098345|Caprelsa (vandetanib)
1469738|NCT00098345|ZD6474
1469739|NCT00098332|recurrent cutaneous T-cell non-Hodgkin lymphoma
1469740|NCT00098332|stage II cutaneous T-cell non-Hodgkin lymphoma
1469741|NCT00098332|stage III cutaneous T-cell non-Hodgkin lymphoma
1469742|NCT00098332|stage IV cutaneous T-cell non-Hodgkin lymphoma
1469743|NCT00098332|recurrent mycosis fungoides/Sezary syndrome
1469744|NCT00098332|stage II mycosis fungoides/Sezary syndrome
1469745|NCT00098332|stage III mycosis fungoides/Sezary syndrome
1469746|NCT00098332|stage IV mycosis fungoides/Sezary syndrome
1469747|NCT00098319|Cleft palate
1469748|NCT00098319|Cleft lip
1469749|NCT00098319|Folic acid
1469750|NCT00098319|Global Network
1469751|NCT00098319|Maternal and child health
1469752|NCT00098319|International
1469753|NCT00098319|Women's health
1469754|NCT00098319|Brazil
1469755|NCT00098319|Brasil
1469756|NCT00098319|Latin America
1469757|NCT00098319|ECLAMC
1469758|NCT00098319|Congenital defects
1469759|NCT00098319|Pregnancy
1469760|NCT00098293|Aids
1469761|NCT00098293|HIV
1469762|NCT00098280|H5g1
1469763|NCT00098280|PNH
1469764|NCT00098280|TRIUMPH
1469765|NCT00098280|Paroxysmal Nocturnal Hemoglobinuria
1469766|NCT00098267|Bacteria
1469767|NCT00098267|Biofilm Formation
1469768|NCT00098267|Secretory Antibodies
1469769|NCT00098267|Teeth
1469770|NCT00098267|Health and Disease
1469771|NCT00098254|Non-Small Cell
1469772|NCT00098254|Molecular
1469773|NCT00098254|Targeted
1469774|NCT00098254|Therapies
1469775|NCT00098254|Cancer
1469776|NCT00098254|Non-Small Cell Lung Cancer
1469777|NCT00098254|NSCLC
1469778|NCT00098241|pediatric
1469779|NCT00098241|renal
1469780|NCT00098241|transplant recipients
1469781|NCT00098241|de novo
1469782|NCT00098241|De novo renal pediatric transplant
1469783|NCT00098228|COPD, adults, QAB149
1469784|NCT00098215|Residency training
1469785|NCT00098202|Global Network
1469786|NCT00098202|Micronutrients
1469787|NCT00098202|Zinc
1469788|NCT00098202|Maternal and child health
1469789|NCT00098202|Women's health
1469790|NCT00098202|International
1469791|NCT00098202|Guatemala
1469792|NCT00098202|Nutrition
1469793|NCT00098202|Corn
1469794|NCT00098202|Maize
1469795|NCT00098189|Safety, psoriasis, adverse event, SAE, extension
1469796|NCT00098163|HIV Seronegativity
1469797|NCT00098163|HIV Preventive Vaccine
1469798|NCT00098150|Safety, atopic dermatitis, adverse event, SAE, extension
1469799|NCT00098137|atrial fibrillation
1469800|NCT00098137|angiotensin II
1469801|NCT00098137|angiotensin receptor antagonist
1469802|NCT00098137|drug
1469803|NCT00098137|controlled clinical trial
1469804|NCT00098124|NSRI
1469805|NCT00098124|milnacipran
1469806|NCT00098124|fibromyalgia
1469807|NCT00098111|Crohn's disease
1469808|NCT00098111|inflammatory bowel disease
1469809|NCT00098111|IMURAN
1469810|NCT00098111|azathioprine
1469811|NCT00098098|Botulinum
1469812|NCT00098098|Recombinant Botulinum Vaccine
1469813|NCT00098098|botulinum neurotoxins
1469814|NCT00098085|Lung cancer
1469815|NCT00098085|Non-small cell lung cancer
1469816|NCT00098085|Pulmonary
1469817|NCT00098085|Immunotherapy
1469818|NCT00098085|Vaccine
1469819|NCT00098072|Cytometry
1469820|NCT00098072|Genes
1469821|NCT00098072|Hypertension
1469822|NCT00098072|Lung
1469823|NCT00098072|Proteomics
1469824|NCT00098072|Primary Pulmonary Hypertenion
1469825|NCT00098072|PPH
1469826|NCT00098072|Healthy Volunteers
1469827|NCT00098072|HV
1469828|NCT00098059|herpes simplex
1469829|NCT00098059|cold sores
1469830|NCT00098059|fever blisters
1469831|NCT00098059|children
1469832|NCT00098059|Famvir
1469833|NCT00098059|famciclovir
1469834|NCT00098046|chickenpox
1469835|NCT00098046|herpes zoster
1469836|NCT00098046|children
1469837|NCT00098046|Famvir
1469838|NCT00098046|varicella zoster virus
1469839|NCT00098033|clinical
1469840|NCT00098033|pharmacodynamics
1469841|NCT00098033|investigational drug clofarabine
1469842|NCT00098033|AML, ALL, CML-accelerated phase, CML-blastic phase
1469843|NCT00098033|Chronic Myelogenous Leukemia - accelerated phase
1469844|NCT00098033|Chronic Myelogenous Leukemia - blastic phase
1469845|NCT00098020|Glomerulosclerosis
1469846|NCT00098020|Proteinuria
1469847|NCT00098020|Fibrosis
1469848|NCT00098020|Chronic Kidney Disease
1469849|NCT00098020|Nephrotic Syndrome
1469850|NCT00098007|Heart transplantation
1469852|NCT00098007|De novo heart transplant patients
1469853|NCT00097994|Menopause
1469854|NCT00097994|Quality of Life
1469855|NCT00097994|Health Services
1469856|NCT00097994|Complementary Therapies
1469857|NCT00097981|Multiple myeloma
1469858|NCT00097981|Newly diagnosed multiple myeloma
1469859|NCT00097981|Thalidomide
1469860|NCT00097981|Dexamethasone
1469861|NCT00097981|DOXIL
1469862|NCT00097981|Pegylated liposomal hydrochloride doxorubicin injection
1469863|NCT00097968|transplant, heart, adult, everolimus
1469864|NCT00097968|allograft rejection
1469865|NCT00097955|diabetes
1469866|NCT00097955|nephropathy
1469867|NCT00097955|hypertension
1469868|NCT00097955|aliskiren
1469869|NCT00097955|losartan
1469870|NCT00097942|memantine
1469871|NCT00097942|adjunctive therapy
1469872|NCT00097942|schizophrenia
1469873|NCT00097929|Relapsed Diffuse Large B-cell Lymphoma
1469874|NCT00097916|memantine HCl
1469875|NCT00097916|Dementia
1469876|NCT00097916|Agitation
1469877|NCT00097916|Alzheimer Disease
1469878|NCT00097903|Carcinoma, Non-Small-Cell Lung
1469879|NCT00097903|Solid Tumors
1469880|NCT00097903|Oral
1469881|NCT00097890|Lysosomes
1469882|NCT00097890|Storage
1469883|NCT00097890|Glycolipid
1469884|NCT00097890|Fabry Disease
1469885|NCT00097890|Stroke
1469886|NCT00097877|Type 2 Diabetes
1469887|NCT00097851|second-line
1469888|NCT00097851|combination
1469889|NCT00097851|chemotherapy
1469890|NCT00097851|anti-angiogenic
1469891|NCT00097838|HIV Seronegativity
1469892|NCT00097838|HIV Preventive Vaccine
1469893|NCT00097825|Male Osteoporosis
1469894|NCT00097812|osteoporosis, osteopenia, post-menopausal, zoledronic acid
1469895|NCT00097786|Prevention
1469896|NCT00097786|Diabetes type 2
1469897|NCT00097786|valsartan
1469898|NCT00097786|nateglinide
1469899|NCT00097773|Lung Diseases
1469900|NCT00097773|Chronic Obstructive Pulmonary Disease
1469901|NCT00097760|Multiple Sclerosis
1469902|NCT00097760|MS
1469903|NCT00097747|anemia
1469904|NCT00097747|chronic kidney disease
1469905|NCT00097747|CKD
1469906|NCT00097747|chronic renal failure
1469907|NCT00097747|CRF
1469908|NCT00097747|erythropoietin
1469909|NCT00097747|EPO
1469910|NCT00097747|erythropoiesis stimulating agent
1469911|NCT00097747|ESA
1469912|NCT00097747|Hematide™
1469913|NCT00097747|hemoglobin
1469914|NCT00097747|Hb
1469915|NCT00097747|Hgb
1469916|NCT00097747|Omontys
1469917|NCT00097747|peginesatide
1469918|NCT00097747|red blood cell
1469919|NCT00097747|red blood cell production
1469920|NCT00097734|diverticulitis
1469921|NCT00097734|Invanz
1469922|NCT00097734|Ertapenem
1469923|NCT00097734|acute attacks
1469924|NCT00097734|sigmoid diverticulitis
1469925|NCT00097734|Acute attacks of sigmoid diverticulitis
1469926|NCT00097721|breast neoplasm
1469927|NCT00097721|breast cancer
1469928|NCT00097721|breast tumor
1469929|NCT00097708|Double Blind, Placebo controlled, Safety and Efficacy
1469930|NCT00097708|Generalized Anxiety Disorder
1469931|NCT00097695|Hereditary Angioedema
1469932|NCT00097695|C1 inhibitor deficiency
1469933|NCT00097695|HAE
1469934|NCT00097695|Icatibant
1469935|NCT00097695|Bradykinin antagonist
1469936|NCT00097695|acute attack
1469937|NCT00097695|subcutaneous
1469938|NCT00097682|Financial Ties
1469939|NCT00097682|Institution
1469940|NCT00097682|Research Doctor
1469941|NCT00097682|Oncology
1469942|NCT00097682|Attitudes
1469943|NCT00097682|Cancer
1469944|NCT00097682|Survey
1469945|NCT00097669|VITATOPS
1469946|NCT00097669|stroke
1469947|NCT00097669|prevention
1469948|NCT00097669|multivitamins
1469949|NCT00097669|homocysteine
1469950|NCT00097643|exercise
1469951|NCT00097643|health promotion
1469952|NCT00097643|independent living
1469953|NCT00097643|affective aspects
1469954|NCT00097630|mechanical ventilation
1469955|NCT00097630|delirium
1469956|NCT00097630|sedation scoring
1469957|NCT00097630|cognitive impairment
1469958|NCT00097630|ventilation weaning
1469959|NCT00097604|Sleep
1469960|NCT00097604|Aged
1469961|NCT00097604|Valerian
1469962|NCT00097604|Complementary Therapies
1469963|NCT00097604|Medicine, Herbal
1469964|NCT00097565|Follicular Non-Hodgkin's Lymphoma
1469965|NCT00097539|Pediatric growth disorders
1469966|NCT00097526|Growth Hormone Deficiency
1469967|NCT00097513|Pubertal Growth Hormone Deficiency
1469968|NCT00097500|diabetes
1469969|NCT00097500|exenatide
1469970|NCT00097500|exendin-4
1469971|NCT00097500|Amylin
1469972|NCT00097500|Lilly
1469973|NCT00097487|Metastatic Breast Cancer
1469974|NCT00097474|Cortisol
1469975|NCT00097474|Travel
1469976|NCT00097474|Saliva
1469977|NCT00097474|Body Clock
1469978|NCT00097474|Sleep
1469979|NCT00097474|Healthy Volunteer
1469980|NCT00097474|HV
1469981|NCT00097474|Jet Lag
1469982|NCT00097461|Employee Health
1469983|NCT00097461|Insurance Benefit
1469984|NCT00097461|Fringe Benefit
1469985|NCT00097461|Health Status
1469986|NCT00097461|Socioeconomic Factors
1469987|NCT00097448|sudden hearing loss
1469988|NCT00097448|unilateral sudden sensorineural hearing loss
1469989|NCT00097448|sudden sensorineural hearing loss
1469990|NCT00097448|sudden unilateral hearing loss
1469991|NCT00097422|CDAD, diarrhea
1469992|NCT00097422|Clostridium difficile-Associated Diarrhea
1469993|NCT00097409|ovarian cancer
1469994|NCT00097409|platinum/taxane-refractory chemotherapy
1469995|NCT00097409|Persistent
1469996|NCT00097409|Recurrent
1469997|NCT00097396|plague
1469998|NCT00097396|recombinant plague vaccine
1469999|NCT00097396|vaccine
1470000|NCT00097396|plague vaccine
1470001|NCT00097396|Protection against pneumonic plague
1470002|NCT00097370|Mepolizumab
1470003|NCT00097370|Open-label
1470004|NCT00097370|Anti-IL-5
1470005|NCT00097370|Hypereosinophilic Syndrome
1470006|NCT00097370|Hypereosinophilia
1470007|NCT00097357|Prevention of deep vein thrombosis and pulmonary embolism
1470008|NCT00097357|Preventive therapy
1470009|NCT00097344|Aromatase inhibitor
1470010|NCT00097344|Atamestane
1470011|NCT00097344|Breast neoplasms
1470012|NCT00097344|Combined hormonal therapy
1470013|NCT00097344|Complete estrogen blockade
1470014|NCT00097344|Ductal breast carcinoma
1470015|NCT00097344|Estrogen blocker
1470016|NCT00097344|Fareston®
1470017|NCT00097344|Femara®
1470018|NCT00097344|First line therapy
1470019|NCT00097344|Letrozole
1470020|NCT00097344|Lobular breast carcinoma
1470021|NCT00097344|Locally advanced breast cancer
1470022|NCT00097344|Locally recurrent breast cancer
1470023|NCT00097344|Maximal estrogen inhibition
1470024|NCT00097344|Metastatic breast cancer
1470025|NCT00097344|Neoplasms, Hormone-dependent
1470026|NCT00097344|Receptor-positive
1470027|NCT00097344|Stage IIIA breast cancer
1470028|NCT00097344|Stage IIIB breast cancer
1470029|NCT00097344|Stage IV breast cancer
1470030|NCT00097344|Toremifene
1470031|NCT00097331|multiple sclerosis
1470032|NCT00097331|relapsing
1470033|NCT00097331|remitting
1470034|NCT00097331|Relapsing-Remitting MS (RRMS)
1470035|NCT00097318|Ischemic
1470036|NCT00097318|Brain
1470037|NCT00097318|Inflammation
1470038|NCT00097318|Clinical Trial
1470039|NCT00097318|Stroke
1470040|NCT00097305|Mental Health
1470041|NCT00097305|Psychotherapy
1470042|NCT00097292|"at risk for developing type 1 diabetes"
1470043|NCT00097292|T1DM
1470044|NCT00097292|T1D
1470045|NCT00097292|juvenile diabetes
1470046|NCT00097292|Type 1 Diabetes TrialNet
1470047|NCT00097292|TrialNet
1470048|NCT00097266|Bipolar Mania
1470049|NCT00097253|Aromatherapy
1470050|NCT00097253|Smell
1470051|NCT00097240|FOLLOW
1470052|NCT00097240|Psoriasis
1470053|NCT00097240|Pregnancy
1470054|NCT00097227|NSCLC
1470055|NCT00097227|non-small
1470056|NCT00097227|lung
1470057|NCT00097227|IIIb
1470058|NCT00097227|IV
1470059|NCT00097227|Carboplatin
1470060|NCT00097227|Paclitaxel
1470061|NCT00097227|Cetuximab
1470062|NCT00097227|Stage IIIB Non-Small Cell Lung Cancer
1470063|NCT00097227|Stage IV Non-Small Cell Lung Cancer
1470064|NCT00097214|NSCLC
1470065|NCT00097214|Non-small
1470066|NCT00097214|Lung
1470067|NCT00097214|IIIB
1470068|NCT00097214|IV
1470069|NCT00097214|Carboplatin
1470070|NCT00097214|Cetuximab
1470071|NCT00097214|Stage IIIB non-small cell lung cancer
1470072|NCT00097214|Stage IV non-small cell lung cancer
1470073|NCT00097188|Relapsing remitting multiple sclerosis
1470074|NCT00097175|Major Depressive Disorder
1470075|NCT00097175|Serotonin
1470076|NCT00097175|Functional MRI
1470077|NCT00097175|Genotype
1470078|NCT00097175|Negative Affect
1470079|NCT00097175|MDD
1470080|NCT00097175|Healthy Volunteer
1470081|NCT00097175|HV
1470082|NCT00097162|Anisometropia
1470083|NCT00097162|Strabismus
1470084|NCT00097162|Cortical Suppression
1470085|NCT00097162|Impaired Vision
1470086|NCT00097162|Cortical Plasticity
1470087|NCT00097162|Amblyopia
1470088|NCT00097162|Adult Amblyopia
1470089|NCT00097149|Congenital birth defects
1470090|NCT00097149|Cleft lip
1470091|NCT00097149|Cleft palate
1470092|NCT00097149|Global Network
1470093|NCT00097149|Neurodevelopmental outcome
1470094|NCT00097149|Maternal and child health
1470095|NCT00097149|International
1470096|NCT00097149|Women's health
1470097|NCT00097149|Brazil
1470098|NCT00097149|Brasil
1470099|NCT00097149|Latin America
1470100|NCT00097149|ECLAMC
1470101|NCT00097149|Argentina
1470102|NCT00097149|Bolivia
1470103|NCT00097149|Chile
1470104|NCT00097149|Colombia
1470105|NCT00097149|Ecuador
1470106|NCT00097149|Venezuela
1470107|NCT00097123|Acute postpartum hemorrhage
1470108|NCT00097123|PPH
1470109|NCT00097123|Misoprostol
1470110|NCT00097123|Global Network
1470111|NCT00097123|Uterotonics
1470112|NCT00097123|India
1470113|NCT00097123|Maternal and child health
1470114|NCT00097123|International
1470115|NCT00097123|Women's health
1470116|NCT00097110|Vitamin C
1470117|NCT00097110|Vitamin E
1470118|NCT00097110|Preeclampsia
1470119|NCT00097110|Antioxidants
1470120|NCT00097110|Global Network
1470121|NCT00097110|Preterm birth
1470122|NCT00097110|Low birth weight infants
1470123|NCT00097110|Brazil
1470124|NCT00097110|Brasil
1470125|NCT00097110|Maternal and child health
1470126|NCT00097110|International
1470127|NCT00097110|Women's health
1470128|NCT00097097|Asphyxia
1470129|NCT00097097|Neonatal mortality
1470130|NCT00097097|Neonatal morbidity
1470131|NCT00097097|Hypoxic ischemic encephalopathy
1470132|NCT00097097|Neurodevelopmental impairment
1470133|NCT00097097|Neonatal resuscitation
1470134|NCT00097097|Global Network
1470135|NCT00097097|Zambia
1470136|NCT00097097|Africa
1470137|NCT00097097|Cerebral palsy
1470138|NCT00097097|Child health
1470139|NCT00097097|International
1470140|NCT00097071|Diabetes, Type 1
1470141|NCT00097058|Aging
1470142|NCT00097058|Menopause
1470143|NCT00097058|Estrogen Replacement Therapy
1470144|NCT00097058|Cognitive Decline
1470145|NCT00097045|Hepatitis C
1470146|NCT00097045|HCV
1470147|NCT00097045|Omega Interferon
1470148|NCT00097045|Interferon
1470149|NCT00097045|HCV genotype 1
1470150|NCT00097032|Bipolar I Disorder
1470151|NCT00097032|risperidone
1470152|NCT00097032|quetiapine
1470153|NCT00097032|sedation
1470154|NCT00097032|cognition
1470155|NCT00097019|Recurrent ovarian cancer
1470156|NCT00097019|Refractory ovarian cancer
1470157|NCT00096993|Omnitarg
1470158|NCT00096993|Cancer
1470159|NCT00096993|Platinum-Resistant
1470160|NCT00096967|Metastatic breast cancer
1470161|NCT00096967|Metastatic colorectal cancer
1470162|NCT00096954|Omalizumab (Xolair)
1470163|NCT00096954|Atopic Asthma
1470164|NCT00096941|Advanced solid cancers
1470165|NCT00096941|HER2
1470166|NCT00096941|EGFR
1470167|NCT00096928|Plaque Psoriasis
1470168|NCT00096928|RESPONSE
1470169|NCT00096928|Raptiva
1470170|NCT00096928|efalizumab
1470171|NCT00096915|chronic kidney disease, CKD
1470172|NCT00096915|renal failure
1470173|NCT00096915|anemia
1470174|NCT00096915|hemodialysis
1470175|NCT00096915|peritoneal dialysis
1470176|NCT00096915|Aranesp®, Darbepoetin Alfa
1470177|NCT00096902|Orthostatic Intolerance
1470178|NCT00096902|Hypnosis
1470179|NCT00096902|Cold Pressor
1470180|NCT00096902|Isometric Exercise
1470181|NCT00096902|Behavior
1470182|NCT00096902|Neurocardiogenic Syncope
1470183|NCT00096876|Parkinsonian syndrome
1470184|NCT00096863|Delirium
1470185|NCT00096863|Cognition Disorders
1470186|NCT00096863|Antipsychotics
1470187|NCT00096863|Mechanical Ventilation
1470188|NCT00096863|Critical Illness
1470189|NCT00096850|HIV Seronegativity
1470190|NCT00096850|Antitubercular agents
1470191|NCT00096837|Myeloma
1470192|NCT00096837|Multiple Myeloma
1470193|NCT00096837|Relapsed Multiple Myeloma
1470194|NCT00096837|Refractory Multiple Myeloma
1470195|NCT00096824|Acute Infection
1470196|NCT00096824|Treatment Naive
1470197|NCT00096798|Fatty Acids, Omega-3
1470198|NCT00096798|Antidepressive Agents
1470199|NCT00096798|Eicosapentanoic Acid
1470200|NCT00096785|chronic hepatitis B infection
1470201|NCT00096772|Genetic Testing
1470202|NCT00096772|Genomics
1470203|NCT00096772|Human Genetic Factors
1470204|NCT00096759|Arthritis
1470205|NCT00096759|Tai Chi
1470206|NCT00096759|Meditation
1470207|NCT00096759|Relaxation Techniques
1470208|NCT00096746|Treatment Experienced
1470209|NCT00096733|Living donors
1470210|NCT00096733|Organ procurement
1470211|NCT00096733|Liver transplantation
1470212|NCT00096733|Hepatitis C
1470213|NCT00096733|Hepatocellular carcinoma
1470214|NCT00096733|Hepatectomy
1470215|NCT00096733|Liver regeneration
1470216|NCT00096733|Graft rejection
1470217|NCT00096733|Quality of life
1470218|NCT00096733|Informed consent
1470219|NCT00096720|parkinson
1470220|NCT00096720|brain imaging
1470221|NCT00096720|diagnosis
1470222|NCT00096707|advanced solid tumors
1470223|NCT00096707|cancer
1470224|NCT00096707|docetaxel
1470225|NCT00096707|2-deoxy-D-glucose (2DG)
1470226|NCT00096707|phase 1
1470227|NCT00096694|Intrauterine Device
1470228|NCT00096694|IUD
1470229|NCT00096694|Contraceptive
1470230|NCT00096694|Levonorgestrel
1470231|NCT00096668|Breast cancer
1470232|NCT00096668|TOCOSOL Paclitaxel
1470233|NCT00096655|Ulcerative colitis
1470234|NCT00096655|Infliximab
1470235|NCT00096655|Remicade
1470236|NCT00096642|cognitive behavioral therapy
1470237|NCT00096642|depression
1470238|NCT00096642|group therapy
1470239|NCT00096642|parenting
1470240|NCT00096642|children and adolescents
1470241|NCT00096629|recurrent renal cell cancer
1470242|NCT00096629|stage I renal cell cancer
1470243|NCT00096629|stage II renal cell cancer
1470244|NCT00096629|stage III renal cell cancer
1470245|NCT00096629|stage IV renal cell cancer
1470246|NCT00095550|Moderate Hypertension
1470247|NCT00095537|Solid tumors
1470248|NCT00095537|cancer
1470249|NCT00095537|HER-2-expressing tumors
1470250|NCT00095524|Patient weight change
1470251|NCT00095524|changes in metabolic status
1470252|NCT00095511|Bipolar Mania
1470253|NCT00095498|arthritis
1470254|NCT00095498|joint pain
1470255|NCT00095498|Methotrexate
1470256|NCT00095485|Activity Level
1470257|NCT00095485|Musculoskeletal
1470258|NCT00095485|Healthy Volunteer
1470259|NCT00095485|Physical Activity
1470260|NCT00095472|Blood Flow
1470261|NCT00095472|Nitric Oxide
1470262|NCT00095472|Vascular Function
1470263|NCT00095472|Vasodilation
1470264|NCT00095472|Vaso-Occlusive Pain Crisis
1470265|NCT00095472|Sickle Cell Disease
1470266|NCT00095459|Raf-Kinase Inhibitor
1470267|NCT00095459|Combinatorial Therapy
1470268|NCT00095459|Pathway Profiling
1470269|NCT00095459|VEGFR
1470270|NCT00095459|Bevacizumab
1470271|NCT00095459|Sorafenib
1470272|NCT00095459|Advanced Solid Tumors
1470273|NCT00095459|Angiogenesis
1470274|NCT00095459|Targeted Therapy
1470275|NCT00095459|VEGF
1470276|NCT00095459|Cancer
1470277|NCT00095459|Solid Tumor
1470278|NCT00095459|Metastatic Uresectable Solid Tumors
1470279|NCT00095446|Diabetes Mellitus
1470280|NCT00095446|Diabetes
1470281|NCT00095433|AMD
1470282|NCT00095433|Neovascular age-related macular degeneration
1470283|NCT00095420|Interpersonal Relationships
1470284|NCT00095420|Child
1470285|NCT00095407|Social Cognition
1470286|NCT00095407|Semantic Memory
1470287|NCT00095407|Prefrontal Cortex
1470288|NCT00095407|Temporal Cortex
1470289|NCT00095407|Conceptual Self
1470290|NCT00095394|Severe Hypertension
1470291|NCT00095381|Leukemia, Lymphocytic, T-Cell
1470292|NCT00095381|Entry Term Lymphocytic Leukemia, T-Cell
1470293|NCT00095381|T-Cell Leukemia
1470294|NCT00095381|T-Lymphocytic Leukemia
1470295|NCT00095381|Leukemia, Lymphocytic, T Cell
1470296|NCT00095381|T Lymphocytic Leukemia
1470297|NCT00095381|BCX-1777
1470298|NCT00095381|forodesine hydrochloride
1470299|NCT00095381|BioCryst
1470300|NCT00095368|Pharyngitis
1470301|NCT00095368|Tonsillitis
1470302|NCT00095355|BDNF
1470303|NCT00095355|Lithium
1470304|NCT00095355|Divalproex
1470305|NCT00095355|Huntington Disease
1470306|NCT00095355|HD
1470307|NCT00095329|relapsing-remitting MS
1470308|NCT00095329|nonresponsive to standard of care MS
1470309|NCT00095329|sirolimus
1470310|NCT00095316|candidiasis, caspofungin, fungal infection, prophylaxis
1470311|NCT00095303|BSFT
1470312|NCT00095303|Family Therapy
1470313|NCT00095303|Adolescents
1470314|NCT00095303|Substance Abuse
1470315|NCT00096603|Moderate to severe plaque psoriasis
1470316|NCT00096590|thromboembolism
1470317|NCT00096590|unspecified adult solid tumor, protocol specific
1470318|NCT00096564|Mirror Neuron
1470319|NCT00096564|Urge
1470320|NCT00096564|Statistical Parametric Mapping
1470321|NCT00096564|Healthy Volunteer
1470322|NCT00096564|HV
1470323|NCT00096551|Biochemical Failure
1470324|NCT00096551|Immunotherapy
1470325|NCT00096551|TRICOM
1470326|NCT00096551|Pox-virus
1470327|NCT00096551|Fowlpox
1470328|NCT00096551|Prostate Cancer
1470329|NCT00096538|classic Kaposi sarcoma
1470330|NCT00096538|recurrent Kaposi sarcoma
1470331|NCT00096525|recurrent renal cell cancer
1470332|NCT00096525|stage III renal cell cancer
1470333|NCT00096525|stage IV renal cell cancer
1470334|NCT00096486|recurrent non-small cell lung cancer
1470335|NCT00096486|stage IIIB non-small cell lung cancer
1470336|NCT00096486|stage IV non-small cell lung cancer
1470337|NCT00096473|Alzheimer's Disease
1470338|NCT00096473|dementia
1470339|NCT00096473|acetylcholinesterase
1470340|NCT00096473|donepezil
1470341|NCT00096473|Aricept
1470342|NCT00096473|memory loss
1470343|NCT00096473|Severe dementia of the Alzheimer's type
1470344|NCT00096421|Critical illness
1470345|NCT00096421|Critical care
1470346|NCT00096421|Hyperglycemia
1470347|NCT00096421|Intensive care
1470348|NCT00096421|Intensive Care Units
1470349|NCT00096421|Insulin resistance
1470350|NCT00096421|Intensive insulin therapy
1470351|NCT00096421|Conventional insulin therapy
1470352|NCT00096408|Endometrial
1470353|NCT00096408|Endometrium
1470354|NCT00096408|Uterus
1470355|NCT00096408|Cancer
1470356|NCT00096408|Carcinoma
1470357|NCT00096408|Adenocarcinoma
1470358|NCT00096408|Stage 1
1470359|NCT00096408|Hysterectomy
1470360|NCT00096408|Laparoscopy
1470361|NCT00096408|Abdominal
1470362|NCT00096408|Total
1470363|NCT00096408|Surgery
1470364|NCT00096408|Quality of Life
1470365|NCT00096408|Disease-free survival
1470366|NCT00096382|stage IV melanoma
1470367|NCT00096382|recurrent melanoma
1470368|NCT00096369|breast cancer
1470369|NCT00096369|lobular breast carcinoma in situ
1470370|NCT00096369|breast cancer in situ
1470371|NCT00096356|fatigue
1470372|NCT00096356|stage I breast cancer
1470373|NCT00096356|stage II breast cancer
1470374|NCT00096356|stage IIIA breast cancer
1470375|NCT00096356|stage IIIB breast cancer
1470376|NCT00096356|stage IIIC breast cancer
1470377|NCT00096356|stage IV breast cancer
1470378|NCT00096343|invasive ductal breast carcinoma
1470379|NCT00096343|invasive lobular breast carcinoma
1470380|NCT00096343|stage II breast cancer
1470381|NCT00096343|stage IIIA breast cancer
1470382|NCT00096343|stage IIIB breast cancer
1470383|NCT00096343|inflammatory breast cancer
1470384|NCT00096330|colon cancer
1470385|NCT00096330|rectal cancer
1470386|NCT00096317|unspecified adult solid tumor, protocol specific
1470387|NCT00096304|adenocarcinoma of the prostate
1470388|NCT00096304|recurrent prostate cancer
1470389|NCT00096304|stage IV prostate cancer
1470390|NCT00096291|stage II breast cancer
1470391|NCT00096291|stage IIIA breast cancer
1470392|NCT00096291|stage IIIB breast cancer
1470393|NCT00096291|stage IIIC breast cancer
1470394|NCT00096239|recurrent ovarian epithelial cancer
1470395|NCT00096239|primary peritoneal cavity cancer
1470396|NCT00096239|fallopian tube cancer
1470397|NCT00096226|stage IIIA non-small cell lung cancer
1470398|NCT00096226|stage IIIB non-small cell lung cancer
1470399|NCT00096213|chondrosarcoma
1470400|NCT00096187|low risk metastatic gestational trophoblastic tumor
1470401|NCT00096187|recurrent gestational trophoblastic tumor
1470402|NCT00096187|nonmetastatic gestational trophoblastic tumor
1470403|NCT00096174|stage IV squamous cell carcinoma of the hypopharynx
1470404|NCT00096174|stage IV squamous cell carcinoma of the larynx
1470405|NCT00096174|stage IV squamous cell carcinoma of the lip and oral cavity
1470406|NCT00096174|stage IV squamous cell carcinoma of the oropharynx
1470407|NCT00096135|recurrent childhood acute lymphoblastic leukemia
1470408|NCT00096135|B-cell childhood acute lymphoblastic leukemia
1470409|NCT00096135|T-cell childhood acute lymphoblastic leukemia
1470410|NCT00096135|TdT positive childhood acute lymphoblastic leukemia
1470411|NCT00096096|graft versus host disease
1470412|NCT00096096|accelerated phase chronic myelogenous leukemia
1470413|NCT00096096|relapsing chronic myelogenous leukemia
1470414|NCT00096096|recurrent adult Hodgkin lymphoma
1470415|NCT00096096|refractory multiple myeloma
1470416|NCT00096096|recurrent adult Burkitt lymphoma
1470417|NCT00096096|chronic idiopathic myelofibrosis
1470418|NCT00096096|recurrent adult diffuse large cell lymphoma
1470419|NCT00096096|recurrent adult diffuse mixed cell lymphoma
1470420|NCT00096096|recurrent adult diffuse small cleaved cell lymphoma
1470421|NCT00096096|recurrent adult immunoblastic large cell lymphoma
1470422|NCT00096096|recurrent mantle cell lymphoma
1470423|NCT00096096|recurrent grade 1 follicular lymphoma
1470424|NCT00096096|recurrent grade 2 follicular lymphoma
1470425|NCT00096096|recurrent grade 3 follicular lymphoma
1470426|NCT00096096|recurrent adult lymphoblastic lymphoma
1470427|NCT00096096|secondary acute myeloid leukemia
1470428|NCT00096096|secondary myelodysplastic syndromes
1470429|NCT00096096|adult acute lymphoblastic leukemia in remission
1470430|NCT00096096|de novo myelodysplastic syndromes
1470431|NCT00096096|previously treated myelodysplastic syndromes
1470432|NCT00096096|chronic myelomonocytic leukemia
1470433|NCT00096096|refractory anemia with excess blasts in transformation
1470434|NCT00096096|refractory anemia with excess blasts
1470435|NCT00096096|refractory anemia with ringed sideroblasts
1470436|NCT00096096|refractory hairy cell leukemia
1470437|NCT00096096|juvenile myelomonocytic leukemia
1470438|NCT00096096|chronic eosinophilic leukemia
1470439|NCT00096096|chronic neutrophilic leukemia
1470440|NCT00096096|chronic phase chronic myelogenous leukemia
1470441|NCT00096096|recurrent adult acute lymphoblastic leukemia
1470442|NCT00096096|recurrent adult acute myeloid leukemia
1470443|NCT00096096|recurrent childhood acute lymphoblastic leukemia
1470444|NCT00096096|recurrent childhood acute myeloid leukemia
1470445|NCT00096096|recurrent childhood large cell lymphoma
1470446|NCT00096096|recurrent childhood lymphoblastic lymphoma
1470447|NCT00096096|recurrent childhood small noncleaved cell lymphoma
1470448|NCT00096096|recurrent cutaneous T-cell non-Hodgkin lymphoma
1470449|NCT00096096|recurrent marginal zone lymphoma
1470450|NCT00096096|recurrent small lymphocytic lymphoma
1470451|NCT00096096|recurrent/refractory childhood Hodgkin lymphoma
1470452|NCT00096096|recurrent mycosis fungoides/Sezary syndrome
1470453|NCT00096096|refractory chronic lymphocytic leukemia
1470454|NCT00096096|refractory cytopenia with multilineage dysplasia
1470455|NCT00096096|stage III adult Hodgkin lymphoma
1470456|NCT00096096|stage IV adult Hodgkin lymphoma
1470457|NCT00096096|adult acute myeloid leukemia in remission
1470458|NCT00096096|childhood acute myeloid leukemia in remission
1470459|NCT00096096|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1470460|NCT00096096|adult acute myeloid leukemia with inv(16)(p13;q22)
1470461|NCT00096096|adult acute myeloid leukemia with t(15;17)(q22;q12)
1470462|NCT00096096|adult acute myeloid leukemia with t(16;16)(p13;q22)
1470463|NCT00096096|adult acute myeloid leukemia with t(8;21)(q22;q22)
1470464|NCT00096096|childhood acute lymphoblastic leukemia in remission
1470465|NCT00096096|childhood chronic myelogenous leukemia
1470466|NCT00096096|blastic phase chronic myelogenous leukemia
1470467|NCT00096096|stage I multiple myeloma
1470468|NCT00096096|stage II multiple myeloma
1470469|NCT00096096|stage III multiple myeloma
1470470|NCT00096096|myelodysplastic/myeloproliferative disease, unclassifiable
1470471|NCT00096096|nodal marginal zone B-cell lymphoma
1470472|NCT00096096|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1470473|NCT00096096|splenic marginal zone lymphoma
1470474|NCT00096096|atypical chronic myeloid leukemia
1470475|NCT00096096|stage III childhood large cell lymphoma
1470476|NCT00096096|stage IV childhood large cell lymphoma
1470477|NCT00096096|stage III childhood lymphoblastic lymphoma
1470478|NCT00096096|stage IV childhood lymphoblastic lymphoma
1470479|NCT00096096|stage III childhood small noncleaved cell lymphoma
1470480|NCT00096096|stage IV childhood small noncleaved cell lymphoma
1470481|NCT00096096|stage III chronic lymphocytic leukemia
1470482|NCT00096096|stage IV chronic lymphocytic leukemia
1470483|NCT00096096|stage III adult Burkitt lymphoma
1470484|NCT00096096|stage III adult diffuse large cell lymphoma
1470485|NCT00096096|stage III adult diffuse mixed cell lymphoma
1470486|NCT00096096|stage III adult diffuse small cleaved cell lymphoma
1470487|NCT00096096|stage III adult immunoblastic large cell lymphoma
1470488|NCT00096096|stage III adult lymphoblastic lymphoma
1470489|NCT00096096|stage III grade 1 follicular lymphoma
1470490|NCT00096096|stage III grade 2 follicular lymphoma
1470491|NCT00096096|stage III grade 3 follicular lymphoma
1470492|NCT00096096|stage IV adult Burkitt lymphoma
1470493|NCT00096096|stage IV adult diffuse large cell lymphoma
1470494|NCT00096096|stage IV adult diffuse mixed cell lymphoma
1470495|NCT00096096|stage IV adult diffuse small cleaved cell lymphoma
1470496|NCT00096096|stage IV adult immunoblastic large cell lymphoma
1470497|NCT00096096|stage IV adult lymphoblastic lymphoma
1470498|NCT00096096|stage IV grade 1 follicular lymphoma
1470499|NCT00096096|stage IV grade 2 follicular lymphoma
1470500|NCT00096096|stage IV grade 3 follicular lymphoma
1470501|NCT00096096|stage III marginal zone lymphoma
1470502|NCT00096096|stage IV marginal zone lymphoma
1470503|NCT00096096|stage III small lymphocytic lymphoma
1470504|NCT00096096|stage IV small lymphocytic lymphoma
1470505|NCT00096096|childhood myelodysplastic syndromes
1470506|NCT00096083|advanced adult primary liver cancer
1470507|NCT00096083|localized unresectable adult primary liver cancer
1470508|NCT00096083|recurrent adult primary liver cancer
1470509|NCT00096083|liver metastases
1470510|NCT00096083|adenocarcinoma of the colon
1470511|NCT00096083|adenocarcinoma of the esophagus
1470512|NCT00096083|adenocarcinoma of the extrahepatic bile duct
1470513|NCT00096083|adenocarcinoma of the gallbladder
1470514|NCT00096083|adenocarcinoma of the pancreas
1470515|NCT00096083|adenocarcinoma of the rectum
1470516|NCT00096083|adenocarcinoma of the stomach
1470517|NCT00096083|carcinoma of the appendix
1470518|NCT00096083|recurrent gallbladder cancer
1470519|NCT00096083|unresectable gallbladder cancer
1470520|NCT00096083|recurrent colon cancer
1470521|NCT00096083|stage IV colon cancer
1470522|NCT00096083|recurrent esophageal cancer
1470523|NCT00096083|stage IV esophageal cancer
1470524|NCT00096083|recurrent extrahepatic bile duct cancer
1470525|NCT00096083|unresectable extrahepatic bile duct cancer
1470526|NCT00096083|recurrent gastric cancer
1470527|NCT00096083|stage IV gastric cancer
1470528|NCT00096083|recurrent rectal cancer
1470529|NCT00096083|stage IV rectal cancer
1470530|NCT00096083|small intestine adenocarcinoma
1470531|NCT00096083|recurrent small intestine cancer
1470532|NCT00096083|recurrent islet cell carcinoma
1470533|NCT00096083|recurrent pheochromocytoma
1470534|NCT00096083|metastatic pheochromocytoma
1470535|NCT00096083|pulmonary carcinoid tumor
1470536|NCT00096083|thyroid gland medullary carcinoma
1470537|NCT00096083|metastatic gastrointestinal carcinoid tumor
1470538|NCT00096083|recurrent gastrointestinal carcinoid tumor
1470539|NCT00096083|recurrent pancreatic cancer
1470540|NCT00096083|insulinoma
1470541|NCT00096083|WDHA syndrome
1470542|NCT00096083|glucagonoma
1470543|NCT00096083|pancreatic polypeptide tumor
1470544|NCT00096083|somatostatinoma
1470545|NCT00096083|stage IV pancreatic cancer
1470546|NCT00096083|intraocular melanoma
1470547|NCT00096083|conjunctival melanoma
1470548|NCT00096083|iris melanoma
1470549|NCT00096083|recurrent melanoma
1470550|NCT00096083|stage IV melanoma
1470551|NCT00096057|recurrent breast cancer
1470552|NCT00096057|stage IIIA breast cancer
1470553|NCT00096057|stage IIIB breast cancer
1470554|NCT00096057|stage IIIC breast cancer
1470555|NCT00096057|stage IV breast cancer
1470556|NCT00096044|refractory chronic lymphocytic leukemia
1470557|NCT00096031|adenocarcinoma of the esophagus
1470558|NCT00096031|recurrent esophageal cancer
1470559|NCT00096031|stage IV esophageal cancer
1470560|NCT00096018|stage I chronic lymphocytic leukemia
1470561|NCT00096018|stage II chronic lymphocytic leukemia
1470562|NCT00096018|stage III chronic lymphocytic leukemia
1470563|NCT00096018|stage IV chronic lymphocytic leukemia
1470564|NCT00096018|B-cell chronic lymphocytic leukemia
1470565|NCT00095992|adult primary hepatocellular carcinoma
1470566|NCT00095992|advanced adult primary liver cancer
1470567|NCT00095992|localized unresectable adult primary liver cancer
1470568|NCT00095992|recurrent adult primary liver cancer
1470569|NCT00095953|recurrent melanoma
1470570|NCT00095953|stage IV melanoma
1470571|NCT00095927|radiation toxicity
1470572|NCT00095927|chemotherapeutic agent toxicity
1470573|NCT00095927|mucositis
1470574|NCT00095927|xerostomia
1470575|NCT00095927|stage II squamous cell carcinoma of the lip and oral cavity
1470576|NCT00095927|stage III squamous cell carcinoma of the lip and oral cavity
1470577|NCT00095927|stage IV squamous cell carcinoma of the lip and oral cavity
1470578|NCT00095927|stage II squamous cell carcinoma of the oropharynx
1470579|NCT00095927|stage III squamous cell carcinoma of the oropharynx
1470580|NCT00095927|stage IV squamous cell carcinoma of the oropharynx
1470581|NCT00095927|stage II squamous cell carcinoma of the hypopharynx
1470582|NCT00095927|stage III squamous cell carcinoma of the hypopharynx
1470583|NCT00095927|stage IV squamous cell carcinoma of the hypopharynx
1470584|NCT00095927|stage II squamous cell carcinoma of the larynx
1470585|NCT00095927|stage III squamous cell carcinoma of the larynx
1470586|NCT00095927|stage IV squamous cell carcinoma of the larynx
1470587|NCT00095927|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1470588|NCT00095927|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1470589|NCT00095927|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1470590|NCT00095927|untreated metastatic squamous neck cancer with occult primary
1470591|NCT00095927|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1470592|NCT00095914|unspecified adult solid tumor, protocol specific
1470593|NCT00095901|recurrent squamous cell carcinoma of the nasopharynx
1470594|NCT00095901|stage IV squamous cell carcinoma of the nasopharynx
1470595|NCT00095901|stage III squamous cell carcinoma of the nasopharynx
1470596|NCT00095901|stage II squamous cell carcinoma of the nasopharynx
1470597|NCT00095875|stage III squamous cell carcinoma of the hypopharynx
1470598|NCT00095875|stage III squamous cell carcinoma of the larynx
1470599|NCT00095875|stage III squamous cell carcinoma of the lip and oral cavity
1470600|NCT00095875|stage III squamous cell carcinoma of the oropharynx
1470601|NCT00095875|stage IV squamous cell carcinoma of the hypopharynx
1470602|NCT00095875|stage IV squamous cell carcinoma of the larynx
1470603|NCT00095875|stage IV squamous cell carcinoma of the lip and oral cavity
1470604|NCT00095875|stage IV squamous cell carcinoma of the oropharynx
1470605|NCT00095862|recurrent breast cancer
1470606|NCT00095862|stage IV breast cancer
1470607|NCT00095862|male breast cancer
1470608|NCT00095862|unspecified adult solid tumor, protocol specific
1470609|NCT00095836|recurrent thyroid cancer
1470610|NCT00095836|stage III follicular thyroid cancer
1470611|NCT00095836|stage III papillary thyroid cancer
1470612|NCT00095836|stage IV follicular thyroid cancer
1470613|NCT00095836|stage IV papillary thyroid cancer
1470614|NCT00095836|anaplastic thyroid cancer
1470615|NCT00095836|thyroid gland medullary carcinoma
1470616|NCT00095810|Psychosis, Parkinson's Disease
1470617|NCT00095771|untreated childhood brain stem glioma
1470618|NCT00095771|childhood high-grade cerebral astrocytoma
1470619|NCT00095732|Pancreatic Insufficiency
1470620|NCT00095732|Cystic Fibrosis
1470621|NCT00095732|Enzymes
1470622|NCT00095719|Acute agitation in patients diagnosed with Dementia
1470623|NCT00095706|Metastatic breast cancer
1470624|NCT00095706|HER2
1470625|NCT00095706|Trastuzumab
1470626|NCT00095706|Herceptin
1470627|NCT00095706|VEGF
1470628|NCT00095706|Bevacizumab
1470629|NCT00095706|Avastin
1470630|NCT00095680|Multiple Myeloma
1470631|NCT00095680|SCIO-469
1470632|NCT00095680|Bortezomib
1470633|NCT00095680|p38 MAP kinase
1470634|NCT00095654|diabetes prevention
1470635|NCT00095654|ramipril
1470636|NCT00095654|rosiglitazone
1470637|NCT00095654|impaired glucose tolerance
1470638|NCT00095654|isolated impaired fasting glucose
1470639|NCT00095654|Isolated Impaired Glucose Tolerance
1470640|NCT00095589|bladder cancer
1470641|NCT00095589|stage 0 bladder cancer
1470642|NCT00095589|stage I bladder cancer
1470643|NCT00095589|transitional cell carcinoma of the bladder
1470644|NCT00095290|Albuminuria
1470645|NCT00095290|Hypertension
1470646|NCT00095290|Elevated Cardiovascular Risk
1470647|NCT00095290|Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk
1470648|NCT00095277|non-myeloid malignancies
1470649|NCT00095277|myeloma
1470650|NCT00095277|Anemia of Cancer
1470651|NCT00095264|Myelodysplastic Syndrome
1470652|NCT00095251|Delirium
1470653|NCT00095251|Hypnotics and Sedatives
1470775|NCT00094783|Cardiovascular Disease
1470654|NCT00095251|Adrenergic alpha-Agonists
1470655|NCT00095251|efficacy of sedation
1470656|NCT00095251|cognitive impairment
1470657|NCT00095225|Recurrent or refractory non-small cell lung cancer
1470658|NCT00095212|HIV
1470659|NCT00095212|women
1470660|NCT00095212|androgen
1470661|NCT00095212|Treatment Experienced
1470662|NCT00095199|Recurrent or Progressive Non-Small Cell Lung Cancer
1470663|NCT00095199|Second-line therapy
1470664|NCT00095199|Docetaxel
1470665|NCT00095199|Pemetrexed
1470666|NCT00095199|Cetuximab
1470667|NCT00095199|Failed platinum-based therapy
1470668|NCT00095199|NSCLC
1470669|NCT00095186|Cancer
1470670|NCT00095186|Metastatic
1470671|NCT00095186|Kidney
1470672|NCT00095186|Refractive
1470673|NCT00095186|Lactoferrin
1470674|NCT00095186|Oral
1470675|NCT00095173|Juvenile Idiopathic Arthritis
1470676|NCT00095160|Solid Organ Tumors
1470677|NCT00095121|Hepatitis B
1470678|NCT00095121|Children
1470679|NCT00095121|Pediatric
1470680|NCT00095121|Adefovir Dipivoxil
1470681|NCT00095108|Metastatic Melanoma
1470682|NCT00095108|Metastatic Renal Cell Carcinoma
1470683|NCT00095095|Spine
1470684|NCT00095095|Lumbar spine
1470685|NCT00095095|Spinal fusion
1470686|NCT00095095|Low back pain
1470687|NCT00095095|Fusion cage
1470688|NCT00095095|Posterior lumbar interbody fusion
1470689|NCT00095095|Bioresorbable
1470690|NCT00095095|Peek
1470691|NCT00095082|Diabetes Mellitus, Type I
1470692|NCT00095056|Type 2 Diabetes Mellitus and Chronic Renal Insufficiency
1470693|NCT00095030|Diabetes
1470694|NCT00095017|Arcoxia
1470695|NCT00094991|Type 2 diabetes
1470696|NCT00094978|Apoptosis
1470697|NCT00094978|Toxicity
1470698|NCT00094978|Pharmacokinetic
1470699|NCT00094978|Gene Induction
1470700|NCT00094978|Maximally Tolerated Dose
1470701|NCT00094978|Small Cell Lung Cancer
1470702|NCT00094978|SCLC
1470703|NCT00094978|Non-Small Cell Lung Cancer
1470704|NCT00094978|NSCLC
1470705|NCT00094978|Esophageal Cancer
1470706|NCT00094978|Pleural Mesothelioma
1470707|NCT00094965|Advanced Gastrointestinal tumors and normal to severely abnormal renal function
1470708|NCT00094952|Mild Cognitive Impairment
1470709|NCT00094952|Alzheimer's disease
1470710|NCT00094952|magnetic resonance imaging
1470711|NCT00094952|cerebrospinal fluid (CSF) biomarkers
1470712|NCT00094939|mild cognitive impairment
1470713|NCT00094939|Alzheimer disease
1470714|NCT00094939|magnetic resonance imaging
1470715|NCT00094939|CSF tau protein
1470716|NCT00094939|Hippocampus
1470717|NCT00094926|Risperidal CONSTA
1470718|NCT00094926|Bipolar disorder
1470719|NCT00094926|mood episodes
1470720|NCT00094926|Safety and efficacy, adjuvant therapy
1470721|NCT00094913|Aging
1470722|NCT00094913|Mild Cognitive Impairment
1470723|NCT00094913|Alzheimer disease, preclinical
1470724|NCT00094913|Hippocampal formation
1470725|NCT00094913|Glucose metabolism
1470726|NCT00094900|Muckle Wells Syndrome
1470727|NCT00094900|NOMID
1470728|NCT00094900|Adult Stills Disease
1470729|NCT00094900|Familial Mediterranean
1470730|NCT00094900|Treatment Trial/Fever
1470731|NCT00094900|Autoinflammatory Disease
1470732|NCT00094887|Blood Flow
1470733|NCT00094887|Nitric Oxide
1470734|NCT00094887|Pain Crisis
1470735|NCT00094887|Sickle Cell Anemia
1470736|NCT00094887|Vaso-Occlusive Crisis
1470737|NCT00094887|Sickle Cell Disease
1470738|NCT00094887|SCD
1470739|NCT00094874|pelvic pain, bladder pain, urgency, frequency, nocturia
1470740|NCT00094861|dysphagia
1470741|NCT00094861|palifermin, KGF
1470742|NCT00094861|chemoradiotherapy
1470743|NCT00094861|NSCLC, non-small cell lung cancer
1470744|NCT00094861|lung cancer
1470745|NCT00094861|supportive care
1470746|NCT00094861|clinical trial
1470747|NCT00094861|consolidation chemotherapy
1470748|NCT00094861|radiotherapy
1470749|NCT00094835|Lung cancer, Non-small cell lung cancer, NSCLC
1470750|NCT00094835|Clinical Trial, Panitumumab, AMG 706
1470751|NCT00094835|Anti-angiogenesis
1470752|NCT00094835|Immunex, Abgenix, Amgen
1470753|NCT00094835|Stage IIIB, Stage IV, Unresectable
1470754|NCT00094822|Metastatic Cancer
1470755|NCT00094822|Neulasta®
1470756|NCT00094822|pegfilgrastim
1470757|NCT00094809|Neulasta®
1470758|NCT00094809|pegfilgrastim
1470759|NCT00094809|Advanced
1470760|NCT00094809|Chemotherapy
1470761|NCT00094796|Insulin Resistance
1470762|NCT00094796|Brachial Artery Reactivity
1470763|NCT00094796|Endothelial Progenitor Cells
1470764|NCT00094796|Metabolic Stress Test
1470765|NCT00094796|Mitochondrial Function
1470766|NCT00094796|Type 2 Diabetes
1470767|NCT00094796|T2DM
1470768|NCT00094796|Pre-Diabetes
1470769|NCT00094783|Magnetic Resonance Imaging
1470770|NCT00094783|Interventional MRI
1470771|NCT00094783|Arterial Stenosis
1470772|NCT00094783|Revascularization
1470773|NCT00094783|Lllac Artery Stenosis
1470774|NCT00094783|Peripheral Arterial Disease
1470776|NCT00094731|Aging
1470777|NCT00094731|Memory
1470778|NCT00094731|Mental Recall
1470779|NCT00094731|Mental Processes
1470780|NCT00094718|Chimeric Virus Vaccine
1470781|NCT00094718|West Nile Virus
1470782|NCT00094718|Dengue Virus
1470783|NCT00094705|Dengue Vaccine
1470784|NCT00094705|Dengue Virus
1470785|NCT00094705|Dengue Hemorrhagic Fever
1470786|NCT00094705|Dengue Shock Syndrome
1470787|NCT00094692|Amblyopia
1470788|NCT00094692|Patching
1470789|NCT00094692|Spectacles
1470790|NCT00094653|melanoma
1470791|NCT00094653|metastatic melanoma
1470792|NCT00094653|skin cancer
1470793|NCT00094601|Positron Emission Tomograhy
1470794|NCT00094601|[18F] FDOPA
1470795|NCT00094601|[11C] NNC-112
1470796|NCT00094601|Dopamine
1470797|NCT00094601|Molecular Imaging
1470798|NCT00094601|Dopamine D1 Receptor
1470799|NCT00094601|PET
1470800|NCT00094601|Parkinson's Disease
1470801|NCT00094601|Cognition
1470802|NCT00094601|Parkinson Disease
1470803|NCT00094601|PD
1470804|NCT00094601|Healthy Volunteer
1470805|NCT00094601|HV
1470806|NCT00094575|Abdominal
1470807|NCT00094575|Aortic Aneurysm
1470808|NCT00094575|cost of AAA repair
1470809|NCT00094575|Endovascular Repair
1470810|NCT00094575|Grafts
1470811|NCT00094575|Long-term survival
1470812|NCT00094575|secondary outcomes
1470813|NCT00094562|Cancer
1470814|NCT00094562|Cancer Cachexia
1470815|NCT00094562|Weight Loss
1470816|NCT00094562|Chronic Obstructive Pulmonary Disease
1470817|NCT00094562|Chronic Heart Failure
1470818|NCT00094562|Rheumatoid Arthritis
1470819|NCT00094536|Menorrhagia
1470820|NCT00094536|Excessive Uterine Bleeding
1470821|NCT00094536|Cryoablation
1470822|NCT00094536|Menstrual disorder
1470823|NCT00094536|Endometrial ablation
1470824|NCT00094536|Abnormal uterine bleeding
1470825|NCT00094536|Dysfunctional uterine bleeding
1470826|NCT00094523|fosamprenavir LEXIVA non-inferiority safety tolerability
1470827|NCT00094510|Prefrontal GABA
1470828|NCT00094510|Stress
1470829|NCT00094510|Emotion Recognition
1470830|NCT00094510|Differential Reward
1470831|NCT00094510|Gabapentin
1470832|NCT00094510|GABA
1470833|NCT00094510|Prefrontal Cortex
1470834|NCT00094510|Emotional Processing
1470835|NCT00094510|Healthy Humans
1470836|NCT00094510|Healthy Volunteer
1470837|NCT00094510|HV
1470838|NCT00094484|Sensipar®
1470839|NCT00094484|Mimpara®
1470840|NCT00094484|Cinacalcet
1470841|NCT00094484|Calcimimetic
1470842|NCT00094484|Chronic Kidney Disease
1470843|NCT00094458|Crohn's Disease
1470844|NCT00094458|infliximab
1470845|NCT00094458|azathioprine
1470846|NCT00094458|Remicade
1470847|NCT00094458|SONIC
1470848|NCT00094445|Pancreatic Cancer
1470849|NCT00094445|Adenocarcinoma of the pancreas
1470850|NCT00094445|Alternative therapy
1470851|NCT00094445|Pancreas
1470852|NCT00094445|Pancreatic Neoplasm
1470853|NCT00094445|Cancer of the pancreas
1470854|NCT00094432|depressed
1470855|NCT00094419|Complementary Therapies
1470856|NCT00094406|Lung Permeability
1470857|NCT00094406|Endotoxin Tolerance
1470858|NCT00094406|Bronchoscopy
1470859|NCT00094406|Carbon Monoxide Inhalation
1470860|NCT00094393|Ageing
1470861|NCT00094393|Atherosclerosis
1470862|NCT00094393|Lamin A
1470863|NCT00094393|Lipodystrophy
1470864|NCT00094393|Growth Impairment
1470865|NCT00094393|Premature Aging
1470866|NCT00094393|Hutchinson-Gilford Progeria Syndrome
1470867|NCT00094393|HGPS
1470868|NCT00094380|SLE
1470869|NCT00094380|Lupus
1470870|NCT00094380|Systemic Lupus Erythematosus
1470871|NCT00094380|Lupus Nephritis
1470872|NCT00094367|1592U89
1470873|NCT00094367|GR109714
1470874|NCT00094367|abacavir
1470875|NCT00094367|lamivudine
1470876|NCT00094367|fixed-dose combination
1470877|NCT00094367|once-daily
1470878|NCT00094367|twice-daily
1470879|NCT00094367|HIV infection
1470880|NCT00094367|naive
1470881|NCT00094354|HIV infected former Plasma Donors
1470882|NCT00094354|Needs assessment
1470883|NCT00094354|HIV-related stigma and discrimination
1470884|NCT00094354|In-depth interview
1470885|NCT00094354|Focus Groups
1470886|NCT00094341|Arthritis
1470887|NCT00094341|Rheumatology
1470888|NCT00094328|Testotoxicosis
1470889|NCT00094328|Familial Male-limited Precocious Puberty (FMPP)
1470890|NCT00094302|Heart Failure
1470891|NCT00094302|Diastolic Heart Failure
1470892|NCT00094302|Preserved Ejection Fraction
1470893|NCT00094172|Early Multiple Sclerosis
1470894|NCT00094172|MS
1470895|NCT00094172|Clinically Isolated Syndrome
1470896|NCT00094146|Primary Insulin Hypersecretion
1470897|NCT00094146|PIH
1470898|NCT00094146|Obesity
1470899|NCT00094133|cancer survivor
1470900|NCT00094133|stage IA breast cancer
1470901|NCT00094133|stage IB breast cancer
1470902|NCT00094133|stage II breast cancer
1470903|NCT00094133|stage IIIA breast cancer
1471472|NCT00091286|stage IIB rectal cancer
1470904|NCT00094133|stage IIIB breast cancer
1470905|NCT00094133|stage IIIC breast cancer
1470906|NCT00094133|stage IV breast cancer
1470907|NCT00094133|breast cancer in situ
1470908|NCT00094133|inflammatory breast cancer
1470909|NCT00094133|hot flashes
1470910|NCT00094120|Age-Related Macular Degeneration - Wet Type
1470911|NCT00094107|melanoma
1470912|NCT00094107|antiangiogenesis
1470913|NCT00094081|squamous cell carcinoma
1470914|NCT00094081|oropharynx
1470915|NCT00094081|oral cavity
1470916|NCT00094081|larynx
1470917|NCT00094081|hypopharynx
1470918|NCT00094068|Gray Matter
1470919|NCT00094068|White Matter
1470920|NCT00094068|Cerebral Blood Flow
1470921|NCT00094068|Cerebral Blood Volume
1470922|NCT00094068|Lesion
1470923|NCT00094068|MRI
1470924|NCT00094068|Multiple Sclerosis
1470925|NCT00094068|Perfusion
1470926|NCT00094068|Imaging
1470927|NCT00094068|Sildenafil
1470928|NCT00094068|MS
1470929|NCT00094068|Healthy Volunteer
1470930|NCT00094068|HV
1470931|NCT00094042|Socioeconomic Factors
1470932|NCT00094042|Dietary Supplementation
1470933|NCT00094003|Liver metastases
1470934|NCT00094003|Colorectal cancer
1470935|NCT00094003|Gastric cancer
1470936|NCT00094003|Esophagus cancer
1470937|NCT00094003|Breast cancer
1470938|NCT00094003|Lung cancer
1470939|NCT00094003|Skin cancer
1470940|NCT00094003|Renal Cancer
1470941|NCT00094003|Liver metastasis
1470942|NCT00093990|Myeloid leukemia acute disease
1470943|NCT00093990|Tipifarnib
1470944|NCT00093990|Bone marrow aspirate
1470945|NCT00093977|Chronic Kidney Disease
1470946|NCT00093977|Dialysis
1470947|NCT00093977|Anemia
1470948|NCT00093977|Nephrology
1470949|NCT00093964|brain cancer
1470950|NCT00093964|brain tumor
1470951|NCT00093951|Alzheimer disease
1470952|NCT00093951|memory
1470953|NCT00093951|cognition
1470954|NCT00093951|GABA(B)receptor antagonist
1470955|NCT00093938|Vaccinium macrocarpon
1470956|NCT00093938|Asymptomatic Bacteriuria
1470957|NCT00093925|Postoperative hypertension
1470958|NCT00093912|Perioperative Hypertension
1470959|NCT00093899|Mixed Hyperlipidemia
1470960|NCT00093886|Preoperative hypertension
1470961|NCT00093873|Cancer
1470962|NCT00093873|antiangiogenesis
1470963|NCT00093873|Solid Tumors
1470964|NCT00093860|Adrenaline
1470965|NCT00093860|Norepinephrine
1470966|NCT00093860|Sympathetic Nervous System
1470967|NCT00093860|Fainting
1470968|NCT00093860|Hypotension
1470969|NCT00093860|Beta-Adrenoceptors
1470970|NCT00093860|Neurocardiogenic Syncope
1470971|NCT00093860|Chronic Orthostatic Intolerance
1470972|NCT00093860|Sympathoadrenal Imbalance
1470973|NCT00093860|SAI
1470974|NCT00093860|Children
1470975|NCT00093847|Selective Serotonin Reuptake Inhibitors
1470976|NCT00093847|S-adenosyl Methionine
1470977|NCT00093847|SSRI
1470978|NCT00093847|SAMe
1470979|NCT00093834|stage IV breast cancer
1470980|NCT00093834|recurrent breast cancer
1470981|NCT00093808|recurrent breast cancer
1470982|NCT00093808|stage IV breast cancer
1470983|NCT00093808|male breast cancer
1470984|NCT00093795|stage II breast cancer
1470985|NCT00093795|stage IIIA breast cancer
1470986|NCT00093795|stage IIIC breast cancer
1470987|NCT00093769|recurrent grade 1 follicular lymphoma
1470988|NCT00093769|recurrent grade 2 follicular lymphoma
1470989|NCT00093769|recurrent grade 3 follicular lymphoma
1470990|NCT00093769|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1470991|NCT00093769|nodal marginal zone B-cell lymphoma
1470992|NCT00093769|recurrent marginal zone lymphoma
1470993|NCT00093769|splenic marginal zone lymphoma
1470994|NCT00093730|unspecified adult solid tumor, protocol specific
1470995|NCT00093704|recurrent adult Hodgkin lymphoma
1470996|NCT00093704|recurrent adult Burkitt lymphoma
1470997|NCT00093704|post-transplant lymphoproliferative disorder
1470998|NCT00093704|recurrent adult grade III lymphomatoid granulomatosis
1470999|NCT00093704|angioimmunoblastic T-cell lymphoma
1471000|NCT00093704|adult grade III lymphomatoid granulomatosis
1471001|NCT00093678|pain
1471002|NCT00093678|cachexia
1471003|NCT00093678|unspecified adult solid tumor, protocol specific
1471004|NCT00093678|recurrent uterine sarcoma
1471005|NCT00093678|stage III uterine sarcoma
1471006|NCT00093678|stage IV uterine sarcoma
1471007|NCT00093678|ovarian sarcoma
1471008|NCT00093678|recurrent adult soft tissue sarcoma
1471009|NCT00093678|stage III adult soft tissue sarcoma
1471010|NCT00093678|stage IV adult soft tissue sarcoma
1471011|NCT00093678|recurrent melanoma
1471012|NCT00093678|stage III melanoma
1471013|NCT00093678|stage IV melanoma
1471014|NCT00093678|chondrosarcoma
1471015|NCT00093678|metastatic osteosarcoma
1471016|NCT00093678|recurrent osteosarcoma
1471017|NCT00093678|classic Kaposi sarcoma
1471018|NCT00093678|AIDS-related Kaposi sarcoma
1471221|NCT00093002|neoadjuvant therapy
1471019|NCT00093678|recurrent Kaposi sarcoma
1471020|NCT00093678|stage III adult Burkitt lymphoma
1471021|NCT00093678|stage III adult diffuse large cell lymphoma
1471022|NCT00093678|stage III adult diffuse mixed cell lymphoma
1471023|NCT00093678|stage III adult diffuse small cleaved cell lymphoma
1471024|NCT00093678|stage III adult immunoblastic large cell lymphoma
1471025|NCT00093678|stage III adult lymphoblastic lymphoma
1471026|NCT00093678|stage III grade 1 follicular lymphoma
1471027|NCT00093678|stage III grade 2 follicular lymphoma
1471028|NCT00093678|stage III grade 3 follicular lymphoma
1471029|NCT00093678|stage III mantle cell lymphoma
1471030|NCT00093678|stage III marginal zone lymphoma
1471031|NCT00093678|stage III small lymphocytic lymphoma
1471032|NCT00093678|stage IV adult Burkitt lymphoma
1471033|NCT00093678|stage IV adult diffuse large cell lymphoma
1471034|NCT00093678|stage IV adult diffuse mixed cell lymphoma
1471035|NCT00093678|stage IV adult diffuse small cleaved cell lymphoma
1471036|NCT00093678|stage IV adult immunoblastic large cell lymphoma
1471037|NCT00093678|stage IV adult lymphoblastic lymphoma
1471038|NCT00093678|stage IV grade 1 follicular lymphoma
1471039|NCT00093678|stage IV grade 2 follicular lymphoma
1471040|NCT00093678|stage IV grade 3 follicular lymphoma
1471041|NCT00093678|stage IV mantle cell lymphoma
1471042|NCT00093678|stage IV marginal zone lymphoma
1471043|NCT00093678|stage IV small lymphocytic lymphoma
1471044|NCT00093678|intraocular lymphoma
1471045|NCT00093678|recurrent adult Burkitt lymphoma
1471046|NCT00093678|recurrent adult diffuse large cell lymphoma
1471047|NCT00093678|recurrent adult diffuse mixed cell lymphoma
1471048|NCT00093678|recurrent adult diffuse small cleaved cell lymphoma
1471049|NCT00093678|recurrent adult immunoblastic large cell lymphoma
1471050|NCT00093678|recurrent adult lymphoblastic lymphoma
1471051|NCT00093678|recurrent grade 1 follicular lymphoma
1471052|NCT00093678|recurrent grade 2 follicular lymphoma
1471053|NCT00093678|recurrent grade 3 follicular lymphoma
1471054|NCT00093678|recurrent mantle cell lymphoma
1471055|NCT00093678|recurrent marginal zone lymphoma
1471056|NCT00093678|recurrent small lymphocytic lymphoma
1471057|NCT00093678|primary central nervous system lymphoma
1471058|NCT00093678|recurrent adult Hodgkin lymphoma
1471059|NCT00093678|stage III adult Hodgkin lymphoma
1471060|NCT00093678|stage IV adult Hodgkin lymphoma
1471061|NCT00093678|recurrent cutaneous T-cell non-Hodgkin lymphoma
1471062|NCT00093678|stage III cutaneous T-cell non-Hodgkin lymphoma
1471063|NCT00093678|stage IV cutaneous T-cell non-Hodgkin lymphoma
1471064|NCT00093678|anaplastic large cell lymphoma
1471065|NCT00093678|angioimmunoblastic T-cell lymphoma
1471066|NCT00093678|Waldenstrom macroglobulinemia
1471067|NCT00093678|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1471068|NCT00093678|nodal marginal zone B-cell lymphoma
1471069|NCT00093678|splenic marginal zone lymphoma
1471070|NCT00093678|adult grade III lymphomatoid granulomatosis
1471071|NCT00093678|recurrent adult grade III lymphomatoid granulomatosis
1471072|NCT00093678|recurrent mycosis fungoides/Sezary syndrome
1471073|NCT00093678|stage III mycosis fungoides/Sezary syndrome
1471074|NCT00093678|stage IV mycosis fungoides/Sezary syndrome
1471075|NCT00093678|recurrent adult T-cell leukemia/lymphoma
1471076|NCT00093678|stage III adult T-cell leukemia/lymphoma
1471077|NCT00093678|stage IV adult T-cell leukemia/lymphoma
1471078|NCT00093678|AIDS-related peripheral/systemic lymphoma
1471079|NCT00093678|AIDS-related primary CNS lymphoma
1471080|NCT00093678|immunosuppressive treatment related Kaposi sarcoma
1471081|NCT00093665|stage II lymphoepithelioma of the nasopharynx
1471082|NCT00093665|stage III lymphoepithelioma of the nasopharynx
1471083|NCT00093665|stage IV lymphoepithelioma of the nasopharynx
1471084|NCT00093665|stage II squamous cell carcinoma of the nasopharynx
1471085|NCT00093665|stage III squamous cell carcinoma of the nasopharynx
1471086|NCT00093665|stage IV squamous cell carcinoma of the nasopharynx
1471087|NCT00093652|adenocarcinoma of the esophagus
1471088|NCT00093652|recurrent esophageal cancer
1471089|NCT00093652|stage II esophageal cancer
1471090|NCT00093652|stage III esophageal cancer
1471091|NCT00093652|stage IV esophageal cancer
1471092|NCT00093652|squamous cell carcinoma of the esophagus
1471093|NCT00093639|chronic phase chronic myelogenous leukemia
1471094|NCT00093639|chronic myelogenous leukemia, BCR-ABL1 positive
1471095|NCT00093600|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1471096|NCT00093600|adult acute myeloid leukemia with inv(16)(p13;q22)
1471097|NCT00093600|adult acute myeloid leukemia with t(15;17)(q22;q12)
1471098|NCT00093600|adult acute myeloid leukemia with t(16;16)(p13;q22)
1471099|NCT00093600|adult acute myeloid leukemia with t(8;21)(q22;q22)
1471100|NCT00093600|untreated adult acute myeloid leukemia
1471101|NCT00093587|graft versus host disease
1471102|NCT00093587|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1471103|NCT00093587|adult acute myeloid leukemia with inv(16)(p13;q22)
1471104|NCT00093587|adult acute myeloid leukemia with t(15;17)(q22;q12)
1471105|NCT00093587|adult acute myeloid leukemia with t(16;16)(p13;q22)
1471106|NCT00093587|adult acute myeloid leukemia with t(8;21)(q22;q22)
1471107|NCT00093587|secondary acute myeloid leukemia
1471108|NCT00093587|adult acute lymphoblastic leukemia in remission
1471109|NCT00093587|adult acute myeloid leukemia in remission
1471110|NCT00093561|prostate cancer
1471111|NCT00093548|adult primary hepatocellular carcinoma
1471112|NCT00093548|advanced adult primary liver cancer
1471113|NCT00093548|localized resectable adult primary liver cancer
1471114|NCT00093548|localized unresectable adult primary liver cancer
1471115|NCT00093522|recurrent renal cell cancer
1471116|NCT00093522|stage IV renal cell cancer
1471117|NCT00093509|stage I adult soft tissue sarcoma
1471118|NCT00093509|stage II adult soft tissue sarcoma
1471119|NCT00093509|stage III adult soft tissue sarcoma
1471120|NCT00093509|stage IV adult soft tissue sarcoma
1471121|NCT00093483|adult acute basophilic leukemia
1471122|NCT00093483|adult acute eosinophilic leukemia
1471123|NCT00093483|adult erythroleukemia (M6a)
1471124|NCT00093483|adult pure erythroid leukemia (M6b)
1471125|NCT00093483|adult acute megakaryoblastic leukemia (M7)
1471126|NCT00093483|adult acute minimally differentiated myeloid leukemia (M0)
1471127|NCT00093483|adult acute monoblastic leukemia (M5a)
1471128|NCT00093483|adult acute monocytic leukemia (M5b)
1471129|NCT00093483|adult acute myeloblastic leukemia with maturation (M2)
1471130|NCT00093483|adult acute myeloblastic leukemia without maturation (M1)
1471131|NCT00093483|adult acute myelomonocytic leukemia (M4)
1471132|NCT00093483|adult acute myeloid leukemia with t(8;21)(q22;q22)
1471133|NCT00093483|adult acute myeloid leukemia with t(16;16)(p13;q22)
1471134|NCT00093483|adult acute myeloid leukemia with inv(16)(p13;q22)
1471135|NCT00093483|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1471136|NCT00093483|untreated adult acute myeloid leukemia
1471137|NCT00093483|secondary acute myeloid leukemia
1471138|NCT00093470|Leukemia
1471139|NCT00093470|Acute Myeloid Leukemia
1471140|NCT00093470|AML
1471141|NCT00093470|Farnesyl Transferase Inhibitor
1471142|NCT00093470|R115777
1471143|NCT00093457|recurrent prostate cancer
1471144|NCT00093457|stage IV prostate cancer
1471145|NCT00093457|adenocarcinoma of the prostate
1471146|NCT00093444|advanced adult primary liver cancer
1471147|NCT00093444|liver metastases
1471148|NCT00093444|localized unresectable adult primary liver cancer
1471149|NCT00093444|recurrent adult primary liver cancer
1471150|NCT00093405|recurrent renal cell cancer
1471151|NCT00093405|stage IV renal cell cancer
1471152|NCT00093405|clear cell renal cell carcinoma
1471153|NCT00093379|stage II anal cancer
1471154|NCT00093379|stage IIIA anal cancer
1471155|NCT00093379|stage IIIB anal cancer
1471156|NCT00093379|squamous cell carcinoma of the anus
1471157|NCT00093379|Capecitabine
1471158|NCT00093379|Xeloda
1471159|NCT00093379|Oxaliplatin
1471160|NCT00093379|Eloxatin
1471161|NCT00093379|Radiotherapy
1471162|NCT00093379|XRT
1471163|NCT00093366|de novo myelodysplastic syndromes
1471164|NCT00093366|previously treated myelodysplastic syndromes
1471165|NCT00093366|secondary myelodysplastic syndromes
1471166|NCT00093366|myelodysplastic/myeloproliferative disease, unclassifiable
1471167|NCT00093366|atypical chronic myeloid leukemia
1471168|NCT00093366|chronic myelomonocytic leukemia
1471169|NCT00093353|diarrhea
1471170|NCT00093353|drug/agent toxicity by tissue/organ
1471171|NCT00093353|disseminated neuroblastoma
1471172|NCT00093353|recurrent neuroblastoma
1471173|NCT00093314|Chronic Lymphocytic Leukemia
1471174|NCT00093314|B-cell Lymphoma
1471175|NCT00093301|Shock
1471176|NCT00093301|Levosimendan
1471177|NCT00093301|Inotropes
1471178|NCT00093301|Dobutamine
1471179|NCT00093301|Heart failure
1471180|NCT00093301|Sepsis
1471181|NCT00093288|MDD
1471182|NCT00093288|bupropion
1471183|NCT00093288|Depression
1471184|NCT00093262|Postoperative Hypertension
1471185|NCT00093249|Pre-operative hypertension
1471186|NCT00093223|In-Stent Restenosis
1471187|NCT00093184|ST-Segment Elevation
1471188|NCT00093184|Acute Myocardial Infarction
1471189|NCT00093184|PCI
1471190|NCT00093184|Percutaneous Coronary Intervention
1471191|NCT00093158|Acute Coronary Syndromes
1471192|NCT00093145|Advanced Breast Cancer
1471193|NCT00093132|Non-Small Cell Lung Cancer (stage II or III)
1471194|NCT00093132|NSCLC
1471195|NCT00093132|Squamous Cell Lung Cancer
1471196|NCT00093132|adenocarcinoma of the lung
1471197|NCT00093132|adenosquamous cell lung cancer
1471198|NCT00093132|bronchoalveolar cell lung cancer
1471199|NCT00093132|carcinoma, non-small cell lung
1471200|NCT00093119|Metastatic Melanoma
1471201|NCT00093093|Viramidine
1471202|NCT00093093|Ribavirin
1471203|NCT00093093|Valeant
1471204|NCT00093093|Hepatitis C
1471205|NCT00093093|Pegylated interferon alfa-2a
1471206|NCT00093080|Metastatic and/or unresectable soft tissue or
1471207|NCT00093067|Gram-positive bacterial infections
1471208|NCT00093067|Staph Aureus
1471209|NCT00093067|endocarditis
1471210|NCT00093067|bacteremia
1471211|NCT00093067|Cubist
1471212|NCT00093054|Vaccinium macrocarpon
1471213|NCT00093041|Head and neck cancer
1471214|NCT00093041|squamous cell carcinoma of the head and neck
1471215|NCT00093028|Myeloma
1471216|NCT00093028|Revlimid
1471217|NCT00093028|bortezomib
1471218|NCT00093028|CC-5013
1471219|NCT00093028|Dexamethasone
1471220|NCT00093002|Early Breast Cancer
1471222|NCT00093002|hormonal treatment
1471223|NCT00093002|newly diagnosed breast cancer
1471224|NCT00093002|Estrogen Receptor Positive Breast Cancer
1471225|NCT00093002|treatment naïve
1471226|NCT00093002|neoadjuvant treatment
1471227|NCT00093002|neoadjuvant setting
1471228|NCT00093002|invasive breast cancer
1471229|NCT00092976|Hemophilia A
1471230|NCT00092950|Exercise
1471231|NCT00092950|Pedometer
1471232|NCT00092950|Physician Prescription
1471233|NCT00092950|Biomarkers
1471234|NCT00092950|Compliance
1471235|NCT00092950|Breast Cancer Survivor
1471236|NCT00092950|Breast Cancer Risk
1471237|NCT00092937|Chronic Granulomatous Disease
1471238|NCT00092937|Nonmyeloablative
1471239|NCT00092937|CD34 Positive Cells
1471240|NCT00092937|Donor Engraftment
1471241|NCT00092937|Myeloid Chimerism
1471242|NCT00092898|Sitosterolemia
1471243|NCT00091858|Cancer-related anemia
1471244|NCT00091845|West Nile Fever Myelitis
1471245|NCT00091845|West Nile Fever Encephalitis
1471246|NCT00091845|West Nile Fever Meningitis
1471247|NCT00091845|West Nile Fever Meningoencephalitis
1471248|NCT00091832|Breast Cancer
1471249|NCT00091832|Cancer
1471250|NCT00091819|staph
1471251|NCT00091819|MRSA
1471252|NCT00091819|cSSSI
1471253|NCT00091806|Targeted Therapy
1471254|NCT00091806|Solid tumors
1471255|NCT00091806|ABX-EGF, panitumumab
1471256|NCT00091806|EGFr
1471257|NCT00091806|Immunex, Abgenix, Amgen
1471258|NCT00091806|Monoclonal Antibody
1471259|NCT00091793|Osteoporosis
1471260|NCT00091793|Postmenopausal
1471261|NCT00091741|HIV
1471262|NCT00091741|Treatment Experienced
1471263|NCT00091741|Complementary Therapies
1471264|NCT00091728|epidemiology
1471265|NCT00091728|relative risk
1471266|NCT00091728|cervical ectopy
1471267|NCT00091728|hormonal contraceptives
1471268|NCT00091728|sexually transmitted infections
1471269|NCT00091715|Pulmonary arterial hypertension
1471270|NCT00091715|PAH
1471271|NCT00091715|PPH
1471272|NCT00091715|bosentan
1471273|NCT00091715|early
1471274|NCT00091702|FluMist
1471275|NCT00091702|Influenza Vaccine
1471276|NCT00091702|Adolescent
1471277|NCT00091702|Treatment Experienced
1471278|NCT00091689|Advanced Metastatic Melanoma
1471279|NCT00091676|follicular
1471280|NCT00091676|lymphoma
1471281|NCT00091676|Non-Hodgkins
1471282|NCT00091676|idiotype
1471283|NCT00091676|vaccine
1471284|NCT00091676|indolent follicular Non-Hodgkins Lymphoma
1471285|NCT00091676|tumor-derived
1471286|NCT00091676|B-cell
1471287|NCT00091676|cancer
1471288|NCT00091663|Advanced non-small cell lung cancer
1471289|NCT00092846|High Blood Cholesterol Levels
1471290|NCT00092820|Homozygous Sitosterolemia
1471291|NCT00092807|Homozygous Sitosterolemia
1471292|NCT00092781|Arcoxia
1471293|NCT00092768|Arcoxia
1471294|NCT00092755|Arcoxia
1471295|NCT00092742|Arcoxia
1471296|NCT00092703|Arcoxia
1471297|NCT00092664|Primary hypercholesterolemia
1471298|NCT00092651|Primary hypercholesterolemia
1471299|NCT00092638|Elevated Cholesterol
1471300|NCT00092625|Elevated Cholesterol
1471301|NCT00092612|Elevated Cholesterol
1471302|NCT00092599|Elevated Cholesterol
1471303|NCT00092573|Mixed hyperlipidemia (high cholesterol and high triglycerides)
1471304|NCT00092560|mixed hyperlipidemia
1471305|NCT00092560|high cholesterol
1471306|NCT00092560|high triglycerides
1471307|NCT00092508|Ulcerative Colitis Remission
1471308|NCT00092508|ulcerative
1471309|NCT00092508|colitis
1471310|NCT00092508|remission
1471311|NCT00092508|relapse
1471312|NCT00092508|Asacol®
1471313|NCT00092508|maintain
1471314|NCT00092508|maintenance
1471315|NCT00092508|flare
1471316|NCT00092508|rectal
1471317|NCT00092508|bleeding
1471318|NCT00092508|bowel
1471319|NCT00092378|Bunionectomy
1471320|NCT00092339|dental surgery
1471321|NCT00092339|molar removal
1471322|NCT00092326|dental surgery
1471323|NCT00092326|molar removal
1471324|NCT00092313|dental surgery
1471325|NCT00092313|molar removal
1471326|NCT00092300|dental surgery
1471327|NCT00092300|molar removal
1471328|NCT00092287|Carcinoid Syndrome
1471329|NCT00092287|Neuroendocrine Tumuors
1471330|NCT00092274|Follicular Lymphoma
1471331|NCT00092274|Non Hodgkin´s Lymphoma
1471337|NCT00092222|HHV-8
1471338|NCT00092222|HIV
1471339|NCT00092222|Malignancy
1471340|NCT00092222|Lymphoproliferation
1471341|NCT00092222|Lymph Node Hyperplasia
1471342|NCT00092222|Multicentric Castleman DIsease
1471343|NCT00092222|MCD
1471344|NCT00092222|KSHV-MCD
1471345|NCT00092222|KSHV Associated MCD
1471346|NCT00092222|HIV Infections
1471347|NCT00092222|Herpes Viruses
1471348|NCT00092196|Chemotherapy-Induced Nausea and Vomiting
1471349|NCT00092183|Chemotherapy-Induced Nausea and Vomiting
1471350|NCT00092170|Intra-abdominal infections
1471351|NCT00092170|Acute pelvic infections
1471352|NCT00092157|High cholesterol
1471353|NCT00092105|Rhinitis, Allergic
1471354|NCT00092053|Postmenopausal
1471355|NCT00092053|Osteoporosis
1471356|NCT00092001|Non-small cell lung cancer, carcinoma, sunitinib, Phase 2
1471357|NCT00091988|Urinary Incontinence
1471358|NCT00091988|Weight Loss
1471359|NCT00091988|Obesity
1471360|NCT00091988|Motivation
1471361|NCT00091975|Chronic Kidney Disease
1471362|NCT00091949|stroke
1471363|NCT00091949|heart attack
1471364|NCT00091949|diabetes
1471365|NCT00091949|pioglitazone
1471366|NCT00091949|insulin resistance
1471367|NCT00091936|Treatment Naive
1471368|NCT00091936|Directly Observed Therapy
1471369|NCT00091936|DOT
1471370|NCT00091936|TB
1471371|NCT00091910|Anemia
1471372|NCT00091910|Epoetin alfa
1471373|NCT00091910|Erythropoietin
1471374|NCT00091910|Blood transfusion
1471375|NCT00091910|Intensive care units
1471376|NCT00091897|RITUXAN
1471377|NCT00091897|GABA
1471378|NCT00091897|B Cells
1471379|NCT00091897|Humanized Monoclonal Antibodies
1471380|NCT00091897|GAD
1471381|NCT00091897|Stiff Person Syndrome
1471382|NCT00091897|SPS
1471383|NCT00091884|HIV
1471384|NCT00091884|Immune Recovery
1471385|NCT00091884|Reactivation
1471386|NCT00091884|Anti-Viral Medication
1471387|NCT00091884|HAART
1471388|NCT00091884|CMV Retinitis
1471389|NCT00091884|Retinal Disease
1471390|NCT00091871|Genetic
1471391|NCT00091871|Eosinophils
1471392|NCT00091871|Familial Hypereosinophilia
1471393|NCT00091871|Hypereosinophilia
1471394|NCT00091871|FE
1471395|NCT00091624|CC-5013
1471396|NCT00091624|CC5013
1471397|NCT00091624|Revlimid
1471398|NCT00091624|Lenalidomide
1471399|NCT00091624|Multiple myeloma
1471400|NCT00091611|Clinical Response
1471401|NCT00091611|Intravenous
1471402|NCT00091611|Intra-Arterial
1471403|NCT00091611|Lymphodepletion
1471404|NCT00091611|Traffic of Cells
1471405|NCT00091611|T-Cell Transfer
1471406|NCT00091611|Renal Cell Carcinoma
1471407|NCT00091611|Metastatic Renal Cell Cancer
1471408|NCT00091598|Pulmonary Arterial Hypertension
1471409|NCT00091572|Metastatic Melanoma
1471410|NCT00091559|CTCL
1471411|NCT00091533|fMRI
1471412|NCT00091533|Mirror Neuron System
1471413|NCT00091533|Bimodal Neurons
1471414|NCT00091533|Somatosensory Cortex
1471415|NCT00091533|Rehabilitation
1471416|NCT00091533|Healthy Volunteer
1471417|NCT00091533|HV
1471418|NCT00091520|Congestive heart failure
1471419|NCT00091520|Nesiritide
1471420|NCT00091507|Acute Coronary Syndrome
1471421|NCT00091481|Stage V Chronic Kidney Disease
1471422|NCT00091468|Age-Related Memory Loss
1471423|NCT00091468|Nicotine
1471424|NCT00091468|Mild Cognitive Impairment (MCI)
1471425|NCT00091442|Breast Cancer
1471426|NCT00091442|Advanced breast cancer
1471427|NCT00091442|Breast Tumors
1471428|NCT00091442|Cancer of Breast
1471429|NCT00091442|Human Mammary Carcinoma
1471430|NCT00091442|Mammary Neoplasms, Human
1471431|NCT00091442|DOXIL
1471432|NCT00091442|Docetaxel
1471433|NCT00091429|Angina
1471434|NCT00091429|Chest Pain
1471435|NCT00091429|Coronary Artery Disease
1471436|NCT00091429|Heart Disease
1471437|NCT00091416|HIV Seronegativity
1471438|NCT00091416|HIV Preventive Vaccine
1471439|NCT00091390|adenocarcinoma of the prostate
1471440|NCT00091390|stage IIB prostate cancer
1471441|NCT00091390|stage IIA prostate cancer
1471442|NCT00091390|stage III prostate cancer
1471443|NCT00091377|recurrent ovarian epithelial cancer
1471444|NCT00091377|fallopian tube cancer
1471445|NCT00091377|primary peritoneal cavity cancer
1471446|NCT00091351|adult alveolar soft-part sarcoma
1471447|NCT00091351|adult angiosarcoma
1471448|NCT00091351|adult epithelioid sarcoma
1471449|NCT00091351|adult fibrosarcoma
1471450|NCT00091351|adult leiomyosarcoma
1471451|NCT00091351|adult liposarcoma
1471452|NCT00091351|adult neurofibrosarcoma
1471453|NCT00091351|adult synovial sarcoma
1471454|NCT00091351|adult malignant fibrous histiocytoma
1471455|NCT00091351|stage I adult soft tissue sarcoma
1471456|NCT00091351|stage II adult soft tissue sarcoma
1471457|NCT00091351|stage III adult soft tissue sarcoma
1471458|NCT00091338|recurrent melanoma
1471459|NCT00091338|stage IV melanoma
1471460|NCT00091325|unspecified adult solid tumor, protocol specific
1471461|NCT00091312|stage II colon cancer
1471462|NCT00091312|adenocarcinoma of the colon
1471463|NCT00091299|unspecified adult solid tumor, protocol specific
1471464|NCT00091286|recurrent colon cancer
1471465|NCT00091286|stage IIB colon cancer
1471466|NCT00091286|stage IIIA colon cancer
1471467|NCT00091286|stage IIIB colon cancer
1471468|NCT00091286|stage IIIC colon cancer
1471469|NCT00091286|stage IVA colon cancer
1471470|NCT00091286|stage IVB colon cancer
1471471|NCT00091286|recurrent rectal cancer
1471473|NCT00091286|stage IIIA rectal cancer
1471474|NCT00091286|stage IIIB rectal cancer
1471475|NCT00091286|stage IIIC rectal cancer
1471476|NCT00091286|stage IVA rectal cancer
1471477|NCT00091286|stage IVB rectal cancer
1471478|NCT00091273|stage I ovarian epithelial cancer
1471479|NCT00091273|stage II ovarian epithelial cancer
1471480|NCT00091273|stage III ovarian epithelial cancer
1471481|NCT00091273|stage IV ovarian epithelial cancer
1471482|NCT00091273|primary peritoneal cavity cancer
1471483|NCT00091260|primary systemic amyloidosis
1471484|NCT00091247|unspecified adult solid tumor, protocol specific
1471485|NCT00091234|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1471486|NCT00091234|adult acute myeloid leukemia with inv(16)(p13;q22)
1471487|NCT00091234|adult acute myeloid leukemia with t(16;16)(p13;q22)
1471488|NCT00091234|adult acute myeloid leukemia with t(8;21)(q22;q22)
1471489|NCT00091234|untreated adult acute myeloid leukemia
1471490|NCT00091234|secondary acute myeloid leukemia
1471491|NCT00091234|adult acute basophilic leukemia
1471492|NCT00091234|adult acute eosinophilic leukemia
1471493|NCT00091234|adult erythroleukemia (M6a)
1471494|NCT00091234|adult pure erythroid leukemia (M6b)
1471495|NCT00091234|adult acute megakaryoblastic leukemia (M7)
1471496|NCT00091234|adult acute minimally differentiated myeloid leukemia (M0)
1471497|NCT00091234|adult acute monoblastic leukemia (M5a)
1471498|NCT00091234|adult acute monocytic leukemia (M5b)
1471499|NCT00091234|adult acute myeloblastic leukemia with maturation (M2)
1471500|NCT00091234|adult acute myeloblastic leukemia without maturation (M1)
1471501|NCT00091234|adult acute myelomonocytic leukemia (M4)
1471502|NCT00091169|fatigue
1471503|NCT00091169|unspecified adult solid tumor, protocol specific
1471504|NCT00091169|levocarnitine
1471505|NCT00091169|depression
1471506|NCT00091169|pain
1471507|NCT00091169|carnitine deficiency
1471508|NCT00091156|stage IIIB non-small cell lung cancer
1471509|NCT00091156|stage IV non-small cell lung cancer
1471510|NCT00091143|recurrent melanoma
1471511|NCT00091143|stage III melanoma
1471512|NCT00091143|stage IV melanoma
1471513|NCT00091104|stage IV melanoma
1471514|NCT00091104|recurrent melanoma
1471515|NCT00091091|long-term effects secondary to cancer therapy in children
1471516|NCT00091091|stage I childhood Hodgkin lymphoma
1471517|NCT00091091|stage II childhood Hodgkin lymphoma
1471518|NCT00091091|stage III childhood Hodgkin lymphoma
1471519|NCT00091091|stage IV childhood Hodgkin lymphoma
1471520|NCT00091052|unspecified adult solid tumor, protocol specific
1471521|NCT00091039|stage IIIA non-small cell lung cancer
1471522|NCT00091039|stage IIIB non-small cell lung cancer
1471523|NCT00090987|AIDS-related Kaposi sarcoma
1471524|NCT00090987|recurrent Kaposi sarcoma
1471525|NCT00090974|stage I breast cancer
1471526|NCT00090974|stage II breast cancer
1471527|NCT00090974|stage IIIA breast cancer
1471528|NCT00090961|pulmonary complications
1471529|NCT00090961|stage IIIA non-small cell lung cancer
1471530|NCT00090961|stage IIIB non-small cell lung cancer
1471531|NCT00090961|squamous cell lung cancer
1471532|NCT00090961|large cell lung cancer
1471533|NCT00090961|adenocarcinoma of the lung
1471534|NCT00090961|bronchoalveolar cell lung cancer
1471535|NCT00090961|limited stage small cell lung cancer
1471536|NCT00090909|recurrent adult Hodgkin lymphoma
1471537|NCT00090896|recurrent melanoma
1471538|NCT00090896|stage III melanoma
1471539|NCT00090896|stage IV melanoma
1471540|NCT00090870|stage IV renal cell cancer
1471541|NCT00090857|breast cancer
1471542|NCT00090857|stage I breast cancer
1471543|NCT00090857|stage II breast cancer
1471544|NCT00090857|stage IIIA breast cancer
1471545|NCT00090857|stage IIIB breast cancer
1471546|NCT00090857|stage IIIC breast cancer
1471547|NCT00090857|stage IV breast cancer
1471548|NCT00090857|breast cancer in situ
1471549|NCT00090857|ductal breast carcinoma in situ
1471550|NCT00090844|drug/agent toxicity by tissue/organ
1471551|NCT00090844|hormone changes
1471552|NCT00090844|stage I breast cancer
1471553|NCT00090844|stage II breast cancer
1471554|NCT00090831|Emotional Learning
1471555|NCT00090831|Neurotransmitter
1471556|NCT00090831|Neural Systems
1471557|NCT00090831|Response Control
1471558|NCT00090831|Orbitofrontal Cortex
1471559|NCT00090831|Amygdala
1471560|NCT00090831|Serotonin
1471561|NCT00090831|Healthy Volunteer
1471562|NCT00090831|HV
1471563|NCT00090818|Dental Abnormalities
1471564|NCT00090818|Lichen Planus
1471565|NCT00090818|Oral Mucosal Disease
1471566|NCT00090818|Genetic Disease
1471567|NCT00090818|Amelogensis Imperfecta
1471568|NCT00090818|Maxillofacial Abnormalities
1471569|NCT00090818|Craniofacial Abnormalities
1471570|NCT00090818|Craniofacial Genetic Abnormalities
1471571|NCT00090779|Acute Infection
1471572|NCT00090779|Treatment Naive
1471573|NCT00090727|diffuse
1471574|NCT00090727|follicular
1471575|NCT00090727|chronic lymphocytic leukemia
1471576|NCT00090727|colorectal cancer
1471577|NCT00090727|pancreatic cancer
1471578|NCT00090727|acute myelogenous leukemia
1471579|NCT00090727|head and neck cancer
1471580|NCT00090727|breast cancer
1471581|NCT00090727|prostate cancer
1471582|NCT00090727|ovarian cancer
1471583|NCT00090727|bladder cancer
1471584|NCT00090727|hypoxia
1471585|NCT00090727|refractory
1471586|NCT00090727|metastatic
1471587|NCT00090714|DNA
1471588|NCT00090714|Circular
1471589|NCT00090714|Gene Therapy
1471590|NCT00090688|diarrhea
1471595|NCT00090623|Subfoveal neovascular
1471596|NCT00090623|Age-related macular degeneration
1471597|NCT00090623|AMD
1471598|NCT00090623|Wet AMD
1471599|NCT00090610|Relapsed ovarian cancer
1471600|NCT00090584|Urge urinary incontinence (UUI)
1471601|NCT00090584|Drug/Behavior treatment
1471602|NCT00090571|JRA ASPs
1471603|NCT00090571|Genomics
1471604|NCT00090558|Atherosclerosis
1471605|NCT00090558|Bone Marrow
1471606|NCT00090558|Exercise
1471607|NCT00090558|Endothelium
1471608|NCT00090558|Nitroglycerin
1471609|NCT00090558|Coronary Artery Disease
1471610|NCT00090558|CAD
1471611|NCT00090545|Hormone-Refractory
1471612|NCT00090545|Proteomics
1471613|NCT00090545|Angiogenesis
1471614|NCT00090545|VEGFR
1471615|NCT00090545|Prostate Cancer
1471616|NCT00090545|Metastatic Prostate Cancer
1471617|NCT00090506|Yoga
1471618|NCT00090506|Meditation
1471619|NCT00090493|Myeloma
1471620|NCT00090493|Mage-A3
1471621|NCT00090493|Transplant
1471622|NCT00090493|Peptide
1471623|NCT00090493|DTPACE
1471624|NCT00090493|vaccines
1471625|NCT00090493|Immunotherapy
1471626|NCT00090493|NY-ESO-1
1471627|NCT00090480|Cancer
1471628|NCT00090428|Autism
1471629|NCT00090428|Applied Behavioral Analysis
1471630|NCT00090428|Gluten
1471631|NCT00090428|Casein
1471632|NCT00090415|Autism
1471633|NCT00090415|Developmental Delay Disorders
1471634|NCT00090402|Fish Oils
1471635|NCT00090402|Thioctic Acid
1471636|NCT00090402|Antioxidants
1471637|NCT00090402|Dietary Supplements
1471638|NCT00090389|Acupuncture
1471639|NCT00090389|Medicine, Chinese Traditional
1471640|NCT00090376|Erectile Dysfunction
1471641|NCT00090376|Impotence
1471642|NCT00090376|Prostate Cancer
1471643|NCT00090376|Prostatectomy
1471644|NCT00090363|rising PSA
1471645|NCT00090363|bone metastases
1471646|NCT00090363|Clinical study
1471647|NCT00090363|pain-free or mildly symptomatic
1471648|NCT00090337|pain
1471649|NCT00090337|recurrent squamous cell carcinoma of the hypopharynx
1471650|NCT00090337|stage I squamous cell carcinoma of the hypopharynx
1471651|NCT00090337|stage II squamous cell carcinoma of the hypopharynx
1471652|NCT00090337|stage III squamous cell carcinoma of the hypopharynx
1471653|NCT00090337|stage IV squamous cell carcinoma of the hypopharynx
1471654|NCT00090337|recurrent squamous cell carcinoma of the larynx
1471655|NCT00090337|recurrent verrucous carcinoma of the larynx
1471656|NCT00090337|stage I squamous cell carcinoma of the larynx
1471657|NCT00090337|stage I verrucous carcinoma of the larynx
1471658|NCT00090337|stage II squamous cell carcinoma of the larynx
1471659|NCT00090337|stage II verrucous carcinoma of the larynx
1471660|NCT00090337|stage III squamous cell carcinoma of the larynx
1471661|NCT00090337|stage III verrucous carcinoma of the larynx
1471662|NCT00090337|stage IV squamous cell carcinoma of the larynx
1471663|NCT00090337|stage IV verrucous carcinoma of the larynx
1471664|NCT00090337|recurrent squamous cell carcinoma of the lip and oral cavity
1471665|NCT00090337|stage I squamous cell carcinoma of the lip and oral cavity
1471666|NCT00090337|stage II squamous cell carcinoma of the lip and oral cavity
1471667|NCT00090337|stage III squamous cell carcinoma of the lip and oral cavity
1471668|NCT00090337|stage IV squamous cell carcinoma of the lip and oral cavity
1471669|NCT00090337|recurrent basal cell carcinoma of the lip
1471670|NCT00090337|stage I basal cell carcinoma of the lip
1471671|NCT00090337|stage II basal cell carcinoma of the lip
1471672|NCT00090337|stage III basal cell carcinoma of the lip
1471673|NCT00090337|stage IV basal cell carcinoma of the lip
1471674|NCT00090337|recurrent adenoid cystic carcinoma of the oral cavity
1471675|NCT00090337|recurrent mucoepidermoid carcinoma of the oral cavity
1471676|NCT00090337|recurrent verrucous carcinoma of the oral cavity
1471677|NCT00090337|stage I adenoid cystic carcinoma of the oral cavity
1471678|NCT00090337|stage I mucoepidermoid carcinoma of the oral cavity
1471679|NCT00090337|stage I verrucous carcinoma of the oral cavity
1471680|NCT00090337|stage II adenoid cystic carcinoma of the oral cavity
1471681|NCT00090337|stage II mucoepidermoid carcinoma of the oral cavity
1471682|NCT00090337|stage II verrucous carcinoma of the oral cavity
1471683|NCT00090337|stage III adenoid cystic carcinoma of the oral cavity
1471684|NCT00090337|stage III mucoepidermoid carcinoma of the oral cavity
1471685|NCT00090337|stage III verrucous carcinoma of the oral cavity
1471686|NCT00090337|stage IV adenoid cystic carcinoma of the oral cavity
1471687|NCT00090337|stage IV mucoepidermoid carcinoma of the oral cavity
1471688|NCT00090337|stage IV verrucous carcinoma of the oral cavity
1471911|NCT00089557|Dermal assessment
1471689|NCT00090337|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1471690|NCT00090337|recurrent metastatic squamous neck cancer with occult primary
1471691|NCT00090337|recurrent lymphoepithelioma of the nasopharynx
1471692|NCT00090337|recurrent squamous cell carcinoma of the nasopharynx
1471693|NCT00090337|stage I lymphoepithelioma of the nasopharynx
1471694|NCT00090337|stage I squamous cell carcinoma of the nasopharynx
1471695|NCT00090337|stage II lymphoepithelioma of the nasopharynx
1471696|NCT00090337|stage II squamous cell carcinoma of the nasopharynx
1471697|NCT00090337|stage III lymphoepithelioma of the nasopharynx
1471698|NCT00090337|stage III squamous cell carcinoma of the nasopharynx
1471699|NCT00090337|stage IV lymphoepithelioma of the nasopharynx
1471700|NCT00090337|stage IV squamous cell carcinoma of the nasopharynx
1471701|NCT00090337|recurrent lymphoepithelioma of the oropharynx
1471702|NCT00090337|recurrent squamous cell carcinoma of the oropharynx
1471703|NCT00090337|stage I lymphoepithelioma of the oropharynx
1471704|NCT00090337|stage I squamous cell carcinoma of the oropharynx
1471705|NCT00090337|stage II lymphoepithelioma of the oropharynx
1471706|NCT00090337|stage II squamous cell carcinoma of the oropharynx
1471707|NCT00090337|stage III lymphoepithelioma of the oropharynx
1471708|NCT00090337|stage III squamous cell carcinoma of the oropharynx
1471709|NCT00090337|stage IV lymphoepithelioma of the oropharynx
1471710|NCT00090337|stage IV squamous cell carcinoma of the oropharynx
1471711|NCT00090337|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1471712|NCT00090337|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1471713|NCT00090337|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1471714|NCT00090337|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1471715|NCT00090337|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1471716|NCT00090337|stage I inverted papilloma of the paranasal sinus and nasal cavity
1471717|NCT00090337|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1471718|NCT00090337|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1471719|NCT00090337|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1471720|NCT00090337|stage II inverted papilloma of the paranasal sinus and nasal cavity
1471721|NCT00090337|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1471722|NCT00090337|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1471723|NCT00090337|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1471724|NCT00090337|stage III inverted papilloma of the paranasal sinus and nasal cavity
1471725|NCT00090337|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1471726|NCT00090337|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1471727|NCT00090337|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1471728|NCT00090337|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1471729|NCT00090337|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1471730|NCT00090337|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1471731|NCT00090337|recurrent salivary gland cancer
1471732|NCT00090337|stage I salivary gland cancer
1471733|NCT00090337|stage II salivary gland cancer
1471734|NCT00090337|stage III salivary gland cancer
1471735|NCT00090337|stage IV salivary gland cancer
1471736|NCT00090324|Schizophrenia
1471737|NCT00090311|Bipolar I Mania
1471738|NCT00090285|anogenital warts
1471739|NCT00090194|Kidney Transplantation
1471740|NCT00090194|Transplantation, Homologous
1471741|NCT00090194|HLA Antigens
1471742|NCT00090194|Autoantibodies
1471743|NCT00090194|Immunoglobulins, Intravenous
1471744|NCT00090194|Living Donors
1471745|NCT00090194|Dose-Response Relationship, Immunologic
1471746|NCT00090181|Arcoxia
1471747|NCT00090129|Psoriatic Arthritis
1471748|NCT00090129|Moderate plaque psoriasis
1471749|NCT00090129|severe plaque psoriasis
1471750|NCT00090129|Onercept
1471751|NCT00090129|Placebo
1471752|NCT00090116|Neramexane
1471753|NCT00090116|NMDA receptor antagonist
1471754|NCT00090116|Memory Loss
1471755|NCT00090116|Alzheimer Disease
1471756|NCT00090103|Combination Therapy
1471757|NCT00090103|dutasteride
1471758|NCT00090103|BPH
1471759|NCT00090077|GW695634G
1471760|NCT00090077|GW695634X
1471761|NCT00090077|GW678248X
1471762|NCT00090077|pharmacokinetics
1471763|NCT00090077|NNRTI
1471764|NCT00090077|HIV
1471765|NCT00090064|MDMA
1471766|NCT00090064|Methylenedioxymethamphetamine
1471767|NCT00090064|PTSD
1471768|NCT00090064|psychotherapy
1471769|NCT00090025|Advanced Biliary Cancer
1471770|NCT00090025|Cholangiocarcinoma
1471771|NCT00090025|Gall bladder tumor
1471772|NCT00090025|Gall bladder cancer
1471773|NCT00090025|Bile duct tumor
1471774|NCT00090025|Tumor of biliary tree
1471775|NCT00089999|lapatinib
1471776|NCT00089999|advanced
1471777|NCT00089999|metastatic breast cancer
1471778|NCT00089999|GW572016
1471779|NCT00089999|ErbB2
1471780|NCT00089986|severe sepsis
1471781|NCT00089986|septic shock
1471782|NCT00089986|Gram-negative infection
1471783|NCT00089986|phospholipid emulsion
1471784|NCT00089973|breast cancer
1471785|NCT00089960|GIST
1471786|NCT00089947|Anti-T cell antibodies
1471787|NCT00089947|Living Donor Renal Transplantation
1471788|NCT00089947|Acute Renal Allograft Rejection
1471789|NCT00089947|Induction Therapy with Reduction of Calcineurin inhibitors
1471790|NCT00089921|Rheumatoid Arthritis
1471791|NCT00089921|DMARDs
1471792|NCT00089921|Methotrexate
1471793|NCT00089921|p38 kinase
1471794|NCT00089908|Dengue Vaccine
1471795|NCT00089908|Dengue Virus
1471796|NCT00089908|Dengue Hemorrhagic Fever
1471797|NCT00089908|Dengue Shock Syndrome
1471798|NCT00089895|myocardial infarction
1471799|NCT00089895|acute coronary syndrome
1471800|NCT00089895|non-ST-segment elevation
1471801|NCT00089895|eptifibatide
1471802|NCT00089895|Integrilin
1471803|NCT00089895|glycoprotein IIb/IIIa inhibitor (GP IIb/IIIa)
1471804|NCT00089895|percutaneous coronary intervention (PCI)
1471805|NCT00089895|coronary artery bypass graph surgery (CABG)
1471806|NCT00089895|catheterization
1471807|NCT00089895|angina
1471808|NCT00089895|ischemia
1471809|NCT00089895|cardiac ischemia
1471810|NCT00089895|cardiovascular disease
1471811|NCT00089882|Alzheimer disease
1471812|NCT00089882|Apolipoproteins E (APOE)
1471813|NCT00089882|Genetic susceptibility testing
1471814|NCT00089856|Prostate
1471815|NCT00089856|Cancer
1471816|NCT00089856|Metastatic
1471817|NCT00089856|Hormone-refractory
1471818|NCT00089856|GVAX
1471819|NCT00089856|Chemotherapy
1471820|NCT00089856|Taxotere
1471821|NCT00089856|Docetaxel
1471822|NCT00089856|Prednisone
1471823|NCT00089856|Vaccine
1471824|NCT00089856|Allogeneic cells
1471825|NCT00089856|Advanced Prostate Cancer
1471826|NCT00089843|Eating Disorders
1471827|NCT00089843|Osteopenia
1471828|NCT00089830|Subfoveal Choroidal Neovascularization
1471829|NCT00089830|Squalamine Lactate
1471830|NCT00089804|Lupus
1471831|NCT00089804|Nephritis
1471832|NCT00089804|Kidney
1471833|NCT00089804|SLE
1471834|NCT00089804|Systemic Lupus Erythematosus
1471835|NCT00089804|Nephritis, Lupus
1471836|NCT00089791|Postmenopausal Osteoporosis
1471837|NCT00089778|Clinical Response
1471838|NCT00089778|Toxicity
1471839|NCT00089778|Immunologic Response
1471840|NCT00089778|Adjuvant
1471841|NCT00089778|IL-2
1471842|NCT00089778|Renal Cancer
1471843|NCT00089765|Retinal Angioma
1471844|NCT00089765|Tumor
1471845|NCT00089765|Anti-VEGF
1471846|NCT00089765|Monoclonal Antibody
1471847|NCT00089765|Macular Edema
1471848|NCT00089765|Von Hippel-Lindau Disease
1471849|NCT00089765|VEGF
1471850|NCT00089765|Ranibizumab
1471851|NCT00089765|VHL
1471852|NCT00089739|Uveitis
1471853|NCT00089739|Suppressor of Cytokine Secretion
1471854|NCT00089739|GITR
1471855|NCT00089739|Immunosuppression
1471856|NCT00089739|GITR Ligand
1471857|NCT00089739|Intraocular Inflammation
1471858|NCT00089726|cancer vaccine
1471859|NCT00089726|NSCLC
1471860|NCT00089726|immunotherapy
1471861|NCT00089713|antihypertensive agents/therapeutic use
1471862|NCT00089713|hypertension/drug therapy
1471863|NCT00089713|blood pressure
1471864|NCT00089700|HIV
1471865|NCT00089700|AIDS
1471866|NCT00089700|Treatment Experienced
1471867|NCT00089700|Optimized Background Therapy
1471868|NCT00089700|HIV-1
1471869|NCT00089674|Prostate Cancer
1471870|NCT00089674|Bone Loss with Prostate Cancer
1471871|NCT00089674|Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).
1471872|NCT00089661|Breast Cancer
1471873|NCT00089661|Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic BC
1471874|NCT00089661|osteopenia
1471875|NCT00089661|Low bone density
1471876|NCT00089635|Colon, Rectal Cancer
1471877|NCT00089635|ABX-EGF, Panitumumab, EGFr
1471878|NCT00089635|Immunex, Abgenix, Amgen
1471879|NCT00089635|Metastatic Colorectal Cancer
1471880|NCT00089635|Vectibix
1471881|NCT00089622|Parkinson's Disease
1471882|NCT00089622|Motor Fluctuations
1471883|NCT00089622|Intravenous Levodopa
1471884|NCT00089622|Antiparkinsonian Response
1471885|NCT00089622|Lisuride Patch
1471886|NCT00089622|Parkinson Disease
1471887|NCT00089622|PD
1471888|NCT00089609|Hormones
1471889|NCT00089609|Angiogenesis
1471890|NCT00089609|Markers
1471891|NCT00089609|Tumor
1471892|NCT00089609|Prostate Cancer
1471893|NCT00089596|umbilical cord blood
1471894|NCT00089596|transplant
1471895|NCT00089596|ALL
1471896|NCT00089596|AML
1471897|NCT00089596|MDS
1471898|NCT00089596|NHL
1471899|NCT00089596|CML
1471900|NCT00089583|antiretroviral therapy
1471901|NCT00089583|pediatrics
1471902|NCT00089583|AGENERASE
1471903|NCT00089583|amprenavir
1471904|NCT00089583|fosamprenavir
1471905|NCT00089583|HIV Infection
1471906|NCT00089583|ritonavir
1471907|NCT00089583|protease inhibitor
1471908|NCT00089583|LEXIVA
1471909|NCT00089570|hepatorenal syndrome
1471910|NCT00089570|terlipressin
1471912|NCT00089557|Pain assessment
1471913|NCT00089557|Diary
1471914|NCT00089557|Analgesics
1471915|NCT00089557|Capsaicin
1471916|NCT00089557|Herpes zoster
1471917|NCT00089557|Neuralgia
1471918|NCT00089557|Pain
1471919|NCT00089557|HIV Infections
1471920|NCT00089557|Peripheral Nervous System Diseases
1471921|NCT00089557|Diabetic Neuropathies
1471922|NCT00089557|Diabetes Mellitus
1471923|NCT00089557|Polyneuropathies
1471924|NCT00089557|Complementary Therapies
1471925|NCT00089531|Healthy
1471926|NCT00089531|Virus
1471927|NCT00089531|T-Cells
1471928|NCT00089531|HIV-Negative
1471929|NCT00089531|Immunity
1471930|NCT00089531|Healthy Volunteer
1471931|NCT00089531|HV
1471932|NCT00089531|HIV Preventive Vaccine
1471933|NCT00089531|HIV Seronegativity
1471934|NCT00089518|Treatment Experienced
1471935|NCT00089505|Treatment Experienced
1471936|NCT00089505|Treatment Naive
1471937|NCT00089505|MTCT
1471938|NCT00089505|HIV Seronegativity
1471939|NCT00089466|Entry Inhibitors
1471940|NCT00089466|CXCR4 Entry Inhibitors
1471941|NCT00089466|Treatment Experienced
1471942|NCT00089466|Treatment Naive
1471943|NCT00089453|Myeloma
1471944|NCT00089453|Transplant
1471945|NCT00089453|Relapsed
1471946|NCT00089453|Donor
1471947|NCT00089453|Stem Cell
1471948|NCT00089453|Thalidomide
1471949|NCT00089453|Dexamethasone
1471950|NCT00089453|Cisplatin
1471951|NCT00089453|Adriamycin
1471952|NCT00089453|Cyclophosphamide
1471953|NCT00089453|Etoposide
1471954|NCT00089453|Melphalan
1471955|NCT00089427|brain tumor
1471956|NCT00089427|malignant glioma
1471957|NCT00089427|brain neoplasm
1471958|NCT00089427|central nervous system
1471959|NCT00089427|surgery
1471960|NCT00089427|resection
1471961|NCT00089427|temozolomide
1471962|NCT00089427|infusion
1471963|NCT00089427|glioblastoma multiforme
1471964|NCT00089427|anaplastic astrocytoma
1471965|NCT00089427|oligoastrocytoma
1471966|NCT00089427|Temodar
1471967|NCT00089427|radiation
1471968|NCT00089427|convection-enhanced delivery
1471969|NCT00089427|GBM
1471970|NCT00089414|Depression
1471971|NCT00089414|Menstrual Cycle
1471972|NCT00089414|Gonadal Steroids
1471973|NCT00089414|Ethinyl Estradiol
1471974|NCT00089414|Drospirenone
1471975|NCT00089414|Menstrually Related Mood Disorder
1471976|NCT00089414|MRMD
1471977|NCT00089401|recurrent colon cancer
1471978|NCT00089401|stage IV colon cancer
1471979|NCT00089401|recurrent rectal cancer
1471980|NCT00089401|stage IV rectal cancer
1471981|NCT00089401|liver metastases
1471982|NCT00089323|stage IA breast cancer
1471983|NCT00089323|stage II breast cancer
1471984|NCT00089323|stage IIIA breast cancer
1471985|NCT00089323|male breast cancer
1471986|NCT00089323|stage IB breast cancer
1471987|NCT00089310|stage I non-small cell lung cancer
1471988|NCT00089297|Stage III head and neck cancer
1471989|NCT00089297|Stage IV head and neck cancer
1471990|NCT00089297|Cetuximab
1471991|NCT00089297|Paclitaxel
1471992|NCT00089297|Carboplatin
1471993|NCT00089258|localized unresectable neuroblastoma
1471994|NCT00089258|disseminated neuroblastoma
1471995|NCT00089258|regional neuroblastoma
1471996|NCT00089258|stage 4S neuroblastoma
1471997|NCT00089258|recurrent neuroblastoma
1471998|NCT00089245|leptomeningeal metastases
1471999|NCT00089245|recurrent neuroblastoma
1472000|NCT00089245|disseminated neuroblastoma
1472001|NCT00089245|recurrent adult brain tumor
1472002|NCT00089245|recurrent childhood medulloblastoma
1472003|NCT00089245|recurrent childhood rhabdomyosarcoma
1472004|NCT00089245|recurrent childhood soft tissue sarcoma
1472005|NCT00089245|recurrent osteosarcoma
1472006|NCT00089245|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1472007|NCT00089245|childhood atypical teratoid/rhabdoid tumor
1472008|NCT00089245|adult medulloblastoma
1472009|NCT00089245|previously treated childhood rhabdomyosarcoma
1472010|NCT00089245|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1472011|NCT00089245|metastatic osteosarcoma
1472012|NCT00089245|childhood desmoplastic small round cell tumor
1472013|NCT00089245|metastatic childhood soft tissue sarcoma
1472014|NCT00089245|adult rhabdomyosarcoma
1472015|NCT00089245|recurrent adult soft tissue sarcoma
1472016|NCT00089245|stage IV adult soft tissue sarcoma
1472017|NCT00089219|stage III melanoma
1472018|NCT00089219|stage IV melanoma
1472019|NCT00089219|recurrent melanoma
1472020|NCT00089219|ciliary body and choroid melanoma, medium/large size
1472021|NCT00089219|extraocular extension melanoma
1472022|NCT00089219|iris melanoma
1472023|NCT00089219|recurrent intraocular melanoma
1472024|NCT00089206|stage III melanoma
1472025|NCT00089206|stage IV melanoma
1472026|NCT00089206|recurrent melanoma
1472027|NCT00089206|recurrent intraocular melanoma
1472028|NCT00089206|iris melanoma
1472029|NCT00089206|extraocular extension melanoma
1472030|NCT00089206|ciliary body and choroid melanoma, medium/large size
1472031|NCT00089193|stage II melanoma
1472032|NCT00089193|stage III melanoma
1472033|NCT00089193|stage IV melanoma
1472034|NCT00089193|recurrent melanoma
1472035|NCT00089167|primary systemic amyloidosis
1472036|NCT00089141|graft versus host disease
1472037|NCT00089141|accelerated phase chronic myelogenous leukemia
1472443|NCT00088413|CEA
1472038|NCT00089141|adult acute lymphoblastic leukemia in remission
1472039|NCT00089141|adult acute myeloid leukemia in remission
1472040|NCT00089141|childhood acute lymphoblastic leukemia in remission
1472041|NCT00089141|childhood acute myeloid leukemia in remission
1472042|NCT00089141|atypical chronic myeloid leukemia
1472043|NCT00089141|blastic phase chronic myelogenous leukemia
1472044|NCT00089141|childhood chronic myelogenous leukemia
1472045|NCT00089141|chronic eosinophilic leukemia
1472046|NCT00089141|chronic idiopathic myelofibrosis
1472047|NCT00089141|chronic myelomonocytic leukemia
1472048|NCT00089141|chronic neutrophilic leukemia
1472049|NCT00089141|chronic phase chronic myelogenous leukemia
1472050|NCT00089141|de novo myelodysplastic syndromes
1472051|NCT00089141|disseminated neuroblastoma
1472052|NCT00089141|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1472053|NCT00089141|juvenile myelomonocytic leukemia
1472054|NCT00089141|myelodysplastic/myeloproliferative disease, unclassifiable
1472055|NCT00089141|nodal marginal zone B-cell lymphoma
1472056|NCT00089141|noncontiguous stage II adult Burkitt lymphoma
1472057|NCT00089141|noncontiguous stage II adult diffuse large cell lymphoma
1472058|NCT00089141|noncontiguous stage II adult diffuse mixed cell lymphoma
1472059|NCT00089141|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1472060|NCT00089141|noncontiguous stage II adult immunoblastic large cell lymphoma
1472061|NCT00089141|noncontiguous stage II adult lymphoblastic lymphoma
1472062|NCT00089141|noncontiguous stage II grade 1 follicular lymphoma
1472063|NCT00089141|noncontiguous stage II grade 2 follicular lymphoma
1472064|NCT00089141|noncontiguous stage II grade 3 follicular lymphoma
1472065|NCT00089141|noncontiguous stage II mantle cell lymphoma
1472066|NCT00089141|noncontiguous stage II marginal zone lymphoma
1472067|NCT00089141|noncontiguous stage II small lymphocytic lymphoma
1472068|NCT00089141|poor prognosis metastatic gestational trophoblastic tumor
1472069|NCT00089141|previously treated childhood rhabdomyosarcoma
1472070|NCT00089141|previously treated myelodysplastic syndromes
1472071|NCT00089141|secondary acute myeloid leukemia
1472072|NCT00089141|secondary myelodysplastic syndromes
1472073|NCT00089141|splenic marginal zone lymphoma
1472074|NCT00089141|stage I multiple myeloma
1472075|NCT00089141|stage II multiple myeloma
1472076|NCT00089141|stage II ovarian epithelial cancer
1472077|NCT00089141|stage III adult Burkitt lymphoma
1472078|NCT00089141|stage III adult diffuse large cell lymphoma
1472079|NCT00089141|stage III adult diffuse mixed cell lymphoma
1472080|NCT00089141|stage III adult diffuse small cleaved cell lymphoma
1472081|NCT00089141|stage III adult immunoblastic large cell lymphoma
1472082|NCT00089141|stage III adult lymphoblastic lymphoma
1472083|NCT00089141|stage III chronic lymphocytic leukemia
1472084|NCT00089141|stage III grade 1 follicular lymphoma
1472085|NCT00089141|stage III grade 2 follicular lymphoma
1472086|NCT00089141|stage III grade 3 follicular lymphoma
1472087|NCT00089141|stage III mantle cell lymphoma
1472088|NCT00089141|stage III marginal zone lymphoma
1472089|NCT00089141|stage III multiple myeloma
1472090|NCT00089141|stage III ovarian epithelial cancer
1472091|NCT00089141|stage III small lymphocytic lymphoma
1472092|NCT00089141|stage III malignant testicular germ cell tumor
1472093|NCT00089141|stage IIIA breast cancer
1472094|NCT00089141|stage IIIB breast cancer
1472095|NCT00089141|stage IIIC breast cancer
1472096|NCT00089141|stage IV adult Burkitt lymphoma
1472097|NCT00089141|stage IV adult diffuse large cell lymphoma
1472098|NCT00089141|stage IV adult diffuse mixed cell lymphoma
1472099|NCT00089141|stage IV adult diffuse small cleaved cell lymphoma
1472100|NCT00089141|stage IV adult immunoblastic large cell lymphoma
1472101|NCT00089141|stage IV adult lymphoblastic lymphoma
1472102|NCT00089141|stage IV breast cancer
1472103|NCT00089141|stage IV chronic lymphocytic leukemia
1472104|NCT00089141|stage IV grade 1 follicular lymphoma
1472105|NCT00089141|stage IV grade 2 follicular lymphoma
1472106|NCT00089141|stage IV grade 3 follicular lymphoma
1472107|NCT00089141|stage IV mantle cell lymphoma
1472108|NCT00089141|stage IV marginal zone lymphoma
1472109|NCT00089141|stage IV ovarian epithelial cancer
1472110|NCT00089141|stage IV small lymphocytic lymphoma
1472111|NCT00089141|childhood myelodysplastic syndromes
1472112|NCT00089128|transitional cell carcinoma of the bladder
1472113|NCT00089128|recurrent bladder cancer
1472114|NCT00089128|stage III bladder cancer
1472115|NCT00089128|stage IV bladder cancer
1472116|NCT00089115|contiguous stage II grade 1 follicular lymphoma
1472117|NCT00089115|contiguous stage II grade 2 follicular lymphoma
1472118|NCT00089115|contiguous stage II grade 3 follicular lymphoma
1472119|NCT00089115|noncontiguous stage II grade 1 follicular lymphoma
1472120|NCT00089115|noncontiguous stage II grade 2 follicular lymphoma
1472121|NCT00089115|noncontiguous stage II grade 3 follicular lymphoma
1472122|NCT00089115|stage I grade 1 follicular lymphoma
1472123|NCT00089115|stage I grade 2 follicular lymphoma
1472124|NCT00089115|stage I grade 3 follicular lymphoma
1472125|NCT00089115|stage III grade 1 follicular lymphoma
1472126|NCT00089115|stage III grade 2 follicular lymphoma
1472127|NCT00089115|stage III grade 3 follicular lymphoma
1472128|NCT00089115|stage IV grade 1 follicular lymphoma
1472129|NCT00089115|stage IV grade 2 follicular lymphoma
1472130|NCT00089115|stage IV grade 3 follicular lymphoma
1472131|NCT00089115|recurrent grade 1 follicular lymphoma
1472132|NCT00089115|recurrent grade 2 follicular lymphoma
1472133|NCT00089115|recurrent grade 3 follicular lymphoma
1472134|NCT00089102|recurrent renal cell cancer
1472135|NCT00089102|stage III renal cell cancer
1472136|NCT00089102|stage IV renal cell cancer
1472137|NCT00089050|recurrent adult acute myeloid leukemia
1472138|NCT00089050|adult acute minimally differentiated myeloid leukemia (M0)
1472139|NCT00089050|adult acute myeloblastic leukemia without maturation (M1)
1472140|NCT00089050|adult acute myeloblastic leukemia with maturation (M2)
1472141|NCT00089050|adult acute myelomonocytic leukemia (M4)
1472142|NCT00089050|adult acute monoblastic leukemia (M5a)
1472143|NCT00089050|adult acute monocytic leukemia (M5b)
1472144|NCT00089050|adult erythroleukemia (M6a)
1472145|NCT00089050|adult pure erythroid leukemia (M6b)
1472146|NCT00089050|adult acute megakaryoblastic leukemia (M7)
1472147|NCT00089050|adult acute basophilic leukemia
1472148|NCT00089050|adult acute eosinophilic leukemia
1472149|NCT00089050|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1472150|NCT00089050|adult acute myeloid leukemia with inv(16)(p13;q22)
1472151|NCT00089050|adult acute myeloid leukemia with t(16;16)(p13;q22)
1472152|NCT00089050|adult acute myeloid leukemia with t(8;21)(q22;q22)
1472153|NCT00089037|graft versus host disease
1472154|NCT00089037|accelerated phase chronic myelogenous leukemia
1472155|NCT00089037|atypical chronic myeloid leukemia
1472156|NCT00089037|blastic phase chronic myelogenous leukemia
1472157|NCT00089037|chronic eosinophilic leukemia
1472158|NCT00089037|chronic idiopathic myelofibrosis
1472159|NCT00089037|chronic myelomonocytic leukemia
1472160|NCT00089037|chronic neutrophilic leukemia
1472161|NCT00089037|myelodysplastic/myeloproliferative disease, unclassifiable
1472162|NCT00089037|previously treated myelodysplastic syndromes
1472163|NCT00089037|recurrent adult acute lymphoblastic leukemia
1472164|NCT00089037|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1472165|NCT00089037|nodal marginal zone B-cell lymphoma
1472166|NCT00089037|de novo myelodysplastic syndromes
1472167|NCT00089037|adult acute lymphoblastic leukemia in remission
1472168|NCT00089037|adult acute myeloid leukemia in remission
1472169|NCT00089037|childhood acute lymphoblastic leukemia in remission
1472170|NCT00089037|childhood acute myeloid leukemia in remission
1472171|NCT00089037|recurrent adult acute myeloid leukemia
1472172|NCT00089037|recurrent adult Burkitt lymphoma
1472173|NCT00089037|recurrent adult diffuse large cell lymphoma
1472174|NCT00089037|recurrent adult diffuse mixed cell lymphoma
1472175|NCT00089037|recurrent adult diffuse small cleaved cell lymphoma
1472176|NCT00089037|recurrent adult Hodgkin lymphoma
1472177|NCT00089037|recurrent adult immunoblastic large cell lymphoma
1472178|NCT00089037|recurrent adult lymphoblastic lymphoma
1472179|NCT00089037|recurrent grade 1 follicular lymphoma
1472180|NCT00089037|recurrent grade 2 follicular lymphoma
1472181|NCT00089037|recurrent grade 3 follicular lymphoma
1472182|NCT00089037|recurrent mantle cell lymphoma
1472183|NCT00089037|recurrent mycosis fungoides/Sezary syndrome
1472184|NCT00089037|recurrent small lymphocytic lymphoma
1472185|NCT00089037|refractory chronic lymphocytic leukemia
1472186|NCT00089037|refractory hairy cell leukemia
1472187|NCT00089037|refractory multiple myeloma
1472188|NCT00089037|relapsing chronic myelogenous leukemia
1472189|NCT00089037|secondary acute myeloid leukemia
1472190|NCT00089037|secondary myelodysplastic syndromes
1472191|NCT00089037|noncontiguous stage II adult Burkitt lymphoma
1472192|NCT00089037|stage III adult Burkitt lymphoma
1472193|NCT00089037|stage IV adult Burkitt lymphoma
1472194|NCT00089037|noncontiguous stage II adult diffuse large cell lymphoma
1472195|NCT00089037|noncontiguous stage II adult diffuse mixed cell lymphoma
1472196|NCT00089037|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1472197|NCT00089037|noncontiguous stage II adult immunoblastic large cell lymphoma
1472198|NCT00089037|noncontiguous stage II adult lymphoblastic lymphoma
1472199|NCT00089037|noncontiguous stage II grade 1 follicular lymphoma
1472200|NCT00089037|noncontiguous stage II grade 2 follicular lymphoma
1472201|NCT00089037|noncontiguous stage II grade 3 follicular lymphoma
1472202|NCT00089037|noncontiguous stage II mantle cell lymphoma
1472203|NCT00089037|noncontiguous stage II marginal zone lymphoma
1472204|NCT00089037|noncontiguous stage II small lymphocytic lymphoma
1472205|NCT00089037|stage III adult diffuse large cell lymphoma
1472206|NCT00089037|stage III adult diffuse mixed cell lymphoma
1472207|NCT00089037|stage III adult diffuse small cleaved cell lymphoma
1472208|NCT00089037|stage IV adult diffuse large cell lymphoma
1472209|NCT00089037|stage IV adult diffuse mixed cell lymphoma
1472210|NCT00089037|stage IV adult diffuse small cleaved cell lymphoma
1472211|NCT00089037|stage III adult immunoblastic large cell lymphoma
1472212|NCT00089037|stage IV adult immunoblastic large cell lymphoma
1472213|NCT00089037|stage III grade 1 follicular lymphoma
1472214|NCT00089037|stage III grade 2 follicular lymphoma
1472215|NCT00089037|stage III grade 3 follicular lymphoma
1472216|NCT00089037|stage IV grade 1 follicular lymphoma
1472217|NCT00089037|stage IV grade 2 follicular lymphoma
1472218|NCT00089037|stage IV grade 3 follicular lymphoma
1472219|NCT00089037|stage III mantle cell lymphoma
1472444|NCT00088413|Vaccine
1472220|NCT00089037|stage IV mantle cell lymphoma
1472221|NCT00089037|stage III small lymphocytic lymphoma
1472222|NCT00089037|stage IV small lymphocytic lymphoma
1472223|NCT00089037|stage III marginal zone lymphoma
1472224|NCT00089037|stage IV marginal zone lymphoma
1472225|NCT00089037|childhood chronic myelogenous leukemia
1472226|NCT00089037|recurrent childhood acute lymphoblastic leukemia
1472227|NCT00089037|recurrent childhood acute myeloid leukemia
1472228|NCT00089037|recurrent childhood large cell lymphoma
1472229|NCT00089037|recurrent childhood lymphoblastic lymphoma
1472230|NCT00089037|recurrent childhood small noncleaved cell lymphoma
1472231|NCT00089037|untreated childhood acute lymphoblastic leukemia
1472232|NCT00089037|untreated childhood acute myeloid leukemia and other myeloid malignancies
1472233|NCT00089037|recurrent/refractory childhood Hodgkin lymphoma
1472234|NCT00089037|juvenile myelomonocytic leukemia
1472235|NCT00089037|splenic marginal zone lymphoma
1472236|NCT00089037|untreated adult acute lymphoblastic leukemia
1472237|NCT00089037|untreated adult acute myeloid leukemia
1472238|NCT00089037|stage III chronic lymphocytic leukemia
1472239|NCT00089037|stage IV chronic lymphocytic leukemia
1472240|NCT00089037|stage I multiple myeloma
1472241|NCT00089037|stage II multiple myeloma
1472242|NCT00089037|stage III multiple myeloma
1472243|NCT00089037|refractory cytopenia with multilineage dysplasia
1472244|NCT00089037|recurrent cutaneous T-cell non-Hodgkin lymphoma
1472245|NCT00089037|recurrent marginal zone lymphoma
1472246|NCT00089024|adenocarcinoma of the pancreas
1472247|NCT00089024|stage II pancreatic cancer
1472248|NCT00089024|stage III pancreatic cancer
1472249|NCT00088998|male breast cancer
1472250|NCT00088998|recurrent breast cancer
1472251|NCT00088998|stage IV breast cancer
1472252|NCT00088985|recurrent breast cancer
1472253|NCT00088985|stage IIIB breast cancer
1472254|NCT00088985|stage IIIC breast cancer
1472255|NCT00088985|stage IV breast cancer
1472256|NCT00088972|breast cancer
1472257|NCT00088972|breast cancer in situ
1472258|NCT00088972|lobular breast carcinoma in situ
1472259|NCT00088972|ductal breast carcinoma
1472260|NCT00088946|transitional cell carcinoma of the bladder
1472261|NCT00088946|stage 0 bladder cancer
1472262|NCT00088946|stage I bladder cancer
1472263|NCT00088907|docetaxel
1472264|NCT00088907|gefitinib
1472265|NCT00088907|head and neck cancer
1472266|NCT00088868|unspecified adult solid tumor, protocol specific
1472267|NCT00088868|anaplastic large cell lymphoma
1472268|NCT00088868|intraocular lymphoma
1472269|NCT00088868|recurrent grade 1 follicular lymphoma
1472270|NCT00088868|recurrent grade 2 follicular lymphoma
1472271|NCT00088868|recurrent grade 3 follicular lymphoma
1472272|NCT00088868|recurrent mantle cell lymphoma
1472273|NCT00088868|recurrent marginal zone lymphoma
1472274|NCT00088868|recurrent small lymphocytic lymphoma
1472275|NCT00088868|stage III adult Burkitt lymphoma
1472276|NCT00088868|stage III adult diffuse large cell lymphoma
1472277|NCT00088868|stage III adult diffuse mixed cell lymphoma
1472278|NCT00088868|stage III adult diffuse small cleaved cell lymphoma
1472279|NCT00088868|stage III adult Hodgkin lymphoma
1472280|NCT00088868|stage III adult immunoblastic large cell lymphoma
1472281|NCT00088868|stage III adult lymphoblastic lymphoma
1472282|NCT00088868|stage III grade 1 follicular lymphoma
1472283|NCT00088868|stage III grade 2 follicular lymphoma
1472284|NCT00088868|stage III grade 3 follicular lymphoma
1472285|NCT00088868|stage III mantle cell lymphoma
1472286|NCT00088868|stage III marginal zone lymphoma
1472287|NCT00088868|stage III small lymphocytic lymphoma
1472288|NCT00088868|stage IV adult Burkitt lymphoma
1472289|NCT00088868|stage IV adult diffuse large cell lymphoma
1472290|NCT00088868|stage IV adult diffuse mixed cell lymphoma
1472291|NCT00088868|stage IV adult diffuse small cleaved cell lymphoma
1472292|NCT00088868|stage IV adult Hodgkin lymphoma
1472293|NCT00088868|stage IV adult immunoblastic large cell lymphoma
1472294|NCT00088868|stage IV adult lymphoblastic lymphoma
1472295|NCT00088868|stage IV grade 1 follicular lymphoma
1472296|NCT00088868|stage IV grade 2 follicular lymphoma
1472297|NCT00088868|stage IV grade 3 follicular lymphoma
1472298|NCT00088868|stage IV mantle cell lymphoma
1472299|NCT00088868|stage IV marginal zone lymphoma
1472300|NCT00088868|stage IV small lymphocytic lymphoma
1472301|NCT00088868|recurrent mycosis fungoides/Sezary syndrome
1472302|NCT00088868|stage III mycosis fungoides/Sezary syndrome
1472303|NCT00088868|stage IV mycosis fungoides/Sezary syndrome
1472304|NCT00088868|recurrent adult Burkitt lymphoma
1472305|NCT00088868|recurrent adult diffuse large cell lymphoma
1472306|NCT00088868|recurrent adult diffuse mixed cell lymphoma
1472307|NCT00088868|recurrent adult diffuse small cleaved cell lymphoma
1472308|NCT00088868|recurrent adult Hodgkin lymphoma
1472309|NCT00088868|recurrent adult immunoblastic large cell lymphoma
1472310|NCT00088868|recurrent adult lymphoblastic lymphoma
1472311|NCT00088868|angioimmunoblastic T-cell lymphoma
1472312|NCT00088868|small intestine lymphoma
1472313|NCT00088868|Waldenström macroglobulinemia
1472314|NCT00088868|recurrent cutaneous T-cell non-Hodgkin lymphoma
1472315|NCT00088868|stage III cutaneous T-cell non-Hodgkin lymphoma
1472316|NCT00088868|stage IV cutaneous T-cell non-Hodgkin lymphoma
1472445|NCT00088413|Immunotherapy
1472317|NCT00088868|recurrent adult T-cell leukemia/lymphoma
1472318|NCT00088868|stage III adult T-cell leukemia/lymphoma
1472319|NCT00088868|stage IV adult T-cell leukemia/lymphoma
1472320|NCT00088868|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1472321|NCT00088868|nodal marginal zone B-cell lymphoma
1472322|NCT00088868|splenic marginal zone lymphoma
1472323|NCT00088829|stage II breast cancer
1472324|NCT00088829|stage IIIA breast cancer
1472325|NCT00088829|stage IIIB breast cancer
1472326|NCT00088829|stage IIIC breast cancer
1472327|NCT00088829|stage IV breast cancer
1472328|NCT00088829|stage IA breast cancer
1472329|NCT00088829|stage IB breast cancer
1472330|NCT00088829|HER2-negative breast cancer
1472331|NCT00088829|HER2-positive breast cancer
1472332|NCT00088816|stage IV gastric cancer
1472333|NCT00088816|adenocarcinoma of the stomach
1472334|NCT00088803|recurrent Wilms tumor and other childhood kidney tumors
1472335|NCT00088803|stage I Wilms tumor
1472336|NCT00088803|stage II Wilms tumor
1472337|NCT00088803|stage III Wilms tumor
1472338|NCT00088803|stage IV Wilms tumor
1472339|NCT00088803|stage V Wilms tumor
1472340|NCT00088790|advanced, solid, malignancies
1472341|NCT00088764|Stress
1472342|NCT00088764|Coping
1472343|NCT00088764|Expressive Writing
1472344|NCT00088764|Self-Efficacy
1472345|NCT00088764|Disclosure
1472346|NCT00088751|Frontotemporal Dementia
1472347|NCT00088751|Alzheimer's Disease
1472348|NCT00088751|Atypical Antipsychotic
1472349|NCT00088751|Stimulant
1472350|NCT00088751|Apathy
1472351|NCT00088751|Disinhibition
1472352|NCT00088751|Antipsychotic
1472353|NCT00088751|Biomarkers
1472354|NCT00088751|Dementia
1472355|NCT00088751|FTD
1472356|NCT00088738|Tachykinin
1472357|NCT00088738|Anxiety
1472358|NCT00088738|Neuroreceptor
1472359|NCT00088738|Internalization
1472360|NCT00088738|Carbon Dioxide
1472361|NCT00088738|Healthy Volunteer
1472362|NCT00088738|HV
1472363|NCT00088738|Panic Disorder
1472364|NCT00088712|Behavior and Neurocognition
1472365|NCT00088712|Functional Brian Activity
1472366|NCT00088712|Visual Perception
1472367|NCT00088712|Selective Attention
1472368|NCT00088712|Information Processing
1472369|NCT00088712|Age Differences
1472370|NCT00088712|Childhood Growth and Development
1472371|NCT00088712|Cognitive Development
1472372|NCT00088712|Brain Connectivity
1472373|NCT00088712|Healthy Volunteer
1472374|NCT00088712|HV
1472375|NCT00088699|Depression
1472376|NCT00088699|NMDA Antagonist
1472377|NCT00088699|Treatment Resistant
1472378|NCT00088699|Glutamatergic System
1472379|NCT00088699|Bipolar Disorder
1472380|NCT00088699|Major Depression
1472381|NCT00088686|Preemptive Analgesia
1472382|NCT00088686|Vanilloid
1472383|NCT00088686|Capsaicin
1472384|NCT00088686|Acute Pain
1472385|NCT00088686|Orofacial
1472386|NCT00088686|Vanilloid Receptor (VR)
1472387|NCT00088686|Visual Analog Scale (VAS)
1472388|NCT00088686|Wisdom Teeth
1472389|NCT00088686|Third Molar Extraction
1472390|NCT00088673|Alzheimer Disease
1472391|NCT00088660|Metastatic
1472392|NCT00088647|advanced malignant solid tumors
1472393|NCT00088647|breast cancer
1472394|NCT00088634|Schizophrenia
1472395|NCT00088634|Latuda
1472396|NCT00088634|Lurasidone
1472397|NCT00088621|Schizophrenia
1472398|NCT00088621|Latuda
1472399|NCT00088621|Lurasidone
1472400|NCT00088595|SOM230
1472401|NCT00088595|Sandostatin
1472402|NCT00088595|Carcinoid syndrome
1472403|NCT00088582|Acromegaly
1472404|NCT00088582|SOM230
1472405|NCT00088582|Sandostatin
1472406|NCT00088569|Frontal Lobe
1472407|NCT00088569|Working Memory
1472408|NCT00088569|Treatment
1472409|NCT00088569|Transcranial
1472410|NCT00088569|Electrical
1472411|NCT00088569|Healthy Volunteer
1472412|NCT00088569|HV
1472413|NCT00088556|Non-small cell lung cancer
1472414|NCT00088543|Acute myelogenous leukemia (AML)
1472415|NCT00088543|Acute lymphocytic leukemia (ALL)
1472416|NCT00088543|Anti-T cell antibodies
1472417|NCT00088543|Allogenic stem cell transplant
1472418|NCT00088543|Graft vs. Host Disease (GvHD)
1472419|NCT00088530|Pixantrone
1472420|NCT00088530|Non-Hodgkins lymphoma
1472421|NCT00088517|Biodistribution
1472422|NCT00088517|MIRD
1472423|NCT00088517|Radiation Absorbed Dose
1472424|NCT00088517|Healthy
1472425|NCT00088517|Prefrontal Cortex
1472426|NCT00088517|Radiation Exposure
1472427|NCT00088517|PET
1472428|NCT00088517|Dopamine D1 Receptor
1472429|NCT00088517|(11C)NNC-112
1472430|NCT00088517|Healthy Volunteer
1472431|NCT00088517|HV
1472432|NCT00088504|Hepatitis
1472433|NCT00088452|childhood absence epilepsy
1472434|NCT00088452|CAE
1472435|NCT00088452|petit mal epilepsy
1472436|NCT00088452|epilepsy
1472437|NCT00088452|seizures
1472438|NCT00088452|ethosuximide
1472439|NCT00088452|lamotrigine
1472440|NCT00088452|valproic acid
1472446|NCT00088413|MUC-1
1472447|NCT00088413|Cancer
1472448|NCT00088413|Adenocarcinoma
1472449|NCT00088413|Metastatic Adenocarcinoma
1472450|NCT00088400|Transferrin
1472451|NCT00088400|Brain Tumor
1472452|NCT00088400|Convection
1472453|NCT00088400|Immunotherapy
1472454|NCT00088400|Targeted Protein Toxin
1472455|NCT00088400|Glioblastoma Multiforme
1472456|NCT00088400|GBM
1472457|NCT00088387|Tau
1472458|NCT00088387|T181
1472459|NCT00088387|T231
1472460|NCT00088387|Amyloid Beta
1472461|NCT00088387|Beta-Catenin
1472462|NCT00088387|Alzheimer Disease
1472463|NCT00088387|AD
1472464|NCT00088374|Kidney Cancer
1472465|NCT00088374|VHL
1472466|NCT00088374|17 AAG
1472467|NCT00088374|Chemotherapy
1472468|NCT00088374|Von Hippel Lindau Disease
1472469|NCT00088374|Renal Tumor
1472470|NCT00088361|Reconstruction
1472471|NCT00088361|PET Artifacts
1472472|NCT00088361|PET/CT Motion Artifacts
1472473|NCT00088361|Liver
1472474|NCT00088361|Heart
1472475|NCT00088361|Respiratory Motion
1472476|NCT00088348|Cornea
1472477|NCT00088348|Conjunctiva
1472478|NCT00088348|Keratitis
1472479|NCT00088348|Ocular Surface
1472480|NCT00088348|Inflammation
1472481|NCT00088348|Evaluation
1472482|NCT00088348|Screening
1472483|NCT00088348|Ocular Surface Disease
1472484|NCT00088348|Eye
1472485|NCT00088348|Ocular Disease
1472486|NCT00088348|Anterior Segment Disease
1472487|NCT00088335|Parkinsonism
1472488|NCT00088335|Biomarker
1472489|NCT00088335|Proteomics
1472490|NCT00088335|Parkinson's Disease
1472491|NCT00088335|Neurodegenerative Disorders
1472492|NCT00088335|Parkinson Disease
1472493|NCT00088335|PD
1472494|NCT00088309|Drug Resistance
1472495|NCT00088309|HAART
1472496|NCT00088309|Pamidronate
1472497|NCT00088309|Osteopenia
1472498|NCT00088309|Pediatric
1472499|NCT00088309|HIV
1472500|NCT00088309|Pediatrics
1472501|NCT00088309|Treatment Experienced
1472502|NCT00088296|Osteoarthritis
1472503|NCT00088296|MS Contin
1472504|NCT00088296|Placebo
1472505|NCT00088296|Cortisol
1472506|NCT00088296|Testosterone
1472507|NCT00088296|Degenerative Joint Disease
1472508|NCT00088296|OA
1472509|NCT00088296|Arthritis
1472510|NCT00088296|Joint Pain
1472511|NCT00088296|Arthritic Pain
1472512|NCT00088296|Opioid
1472513|NCT00088283|CRVO
1472514|NCT00088283|Central Retinal Vein Occlusion
1472515|NCT00088283|RVO
1472516|NCT00088283|Retinal Vein Occlusion
1472517|NCT00088231|Acute Myelogenous Leukemia (AML)
1472518|NCT00088231|Agnogenic Myeloid Metaplasia (AMM)
1472519|NCT00088231|Chronic Myelogenous Leukemia-Blastic Phase (CML-BP)
1472520|NCT00088218|Acute Myeloid Leukemia
1472521|NCT00088218|AML
1472522|NCT00088218|High-Risk Myelodysplastic Syndrome
1472523|NCT00088218|MDS
1472524|NCT00088218|Clofarabine
1472525|NCT00088218|Cytarabine
1472526|NCT00088218|ara-C
1472527|NCT00088192|AMD
1472528|NCT00088192|Age-Related Macular Degeneration
1472529|NCT00088192|Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization
1472530|NCT00088179|CABG
1472531|NCT00088179|CPB
1472532|NCT00088166|peritumoral brain edema
1472533|NCT00088166|edema
1472534|NCT00088166|malignant brain tumor
1472535|NCT00088166|astrocytoma
1472536|NCT00088166|brain tumor
1472537|NCT00088166|dexamethasone
1472538|NCT00088166|Decadron
1472539|NCT00088153|Anorexia Nervosa
1472540|NCT00088153|Amenorrhea
1472541|NCT00088153|Bone Mass
1472542|NCT00088153|Growth hormone
1472543|NCT00088101|Hematological Malignancies
1472544|NCT00088101|Leukemia
1472545|NCT00088101|Lymphoma
1472546|NCT00088101|Metastatic
1472547|NCT00088101|Unresectable solid tumors
1472548|NCT00088075|Schizophrenia
1472549|NCT00088075|Risperidone
1472550|NCT00088075|Adolescents
1472551|NCT00088062|Crohn's Disease
1472552|NCT00088023|Solid tumors
1472553|NCT00087997|sarcoma
1472554|NCT00087984|Kidney cancer
1472555|NCT00087984|Renal cancer
1472556|NCT00087958|Metastatic breast cancer
1472557|NCT00087945|Treatment Experienced
1472558|NCT00087932|Complementary Therapies
1472559|NCT00087880|smoking cessation
1472560|NCT00087867|Multiple Myeloma
1472561|NCT00087867|SCIO-469
1472562|NCT00087867|p38 MAP kinase
1472563|NCT00087867|myeloma
1472564|NCT00087867|bone marrow
1472565|NCT00087841|Hypnosis
1472566|NCT00087841|Analgesia
1472567|NCT00087841|Embolization, Therapeutic
1472568|NCT00087841|Chemoembolization, Therapeutic
1472569|NCT00087828|Vaccinium macrocarpon
1472570|NCT00087815|cognitive/functional effects
1472571|NCT00087815|radiation toxicity
1472572|NCT00087815|adult brain tumor
1472573|NCT00087815|childhood brain tumor
1472574|NCT00087789|Alzheimer's Disease
1472575|NCT00087789|Gene Transfer
1472576|NCT00087763|AMD
1472577|NCT00087763|Age Related Macular Degeneration
1472578|NCT00087763|Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization
1472579|NCT00087685|Recurrent Endometrial Cancer
1472580|NCT00087685|Endometrial
1472581|NCT00087685|Endometrioid
1472582|NCT00087685|RAD001
1472583|NCT00087685|Uterine Cancer
1472584|NCT00087672|Myelofibrosis
1472585|NCT00087672|Philadelphia negative myeloproliferative disorder
1472586|NCT00087672|CC-5013
1472587|NCT00087672|Lenalidomide
1472588|NCT00087672|Revlimid
1472589|NCT00087672|Antiangiogenesis
1472590|NCT00087659|ADT, BMD, US63, H014
1472591|NCT00087555|Fibromyalgia
1472592|NCT00087555|Pain
1472593|NCT00087542|Hallucinosis/Psychosis
1472594|NCT00087529|PPMS
1472595|NCT00087529|Primary progressive MS
1472596|NCT00087529|Primary progressive multiple sclerosis
1472597|NCT00087529|Rituxan
1472598|NCT00087529|MS
1472599|NCT00087477|Malignant Melanoma, Pivanex, Histone deacetylases inhibitor
1472600|NCT00087464|Acute Infection
1472601|NCT00087464|Treatment Naive
1472602|NCT00087464|Treatment Interruption
1472603|NCT00087451|Progressive or recurrent malignant glioma
1472604|NCT00087438|stage I non-small cell lung cancer
1472605|NCT00087438|stage II non-small cell lung cancer
1472606|NCT00087438|squamous cell lung cancer
1472607|NCT00087438|large cell lung cancer
1472608|NCT00087438|adenocarcinoma of the lung
1472609|NCT00087438|bronchoalveolar cell lung cancer
1472610|NCT00087425|contiguous stage II adult diffuse small cleaved cell lymphoma
1472611|NCT00087425|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1472612|NCT00087425|recurrent adult diffuse small cleaved cell lymphoma
1472613|NCT00087425|stage III adult diffuse small cleaved cell lymphoma
1472614|NCT00087425|stage IV adult diffuse small cleaved cell lymphoma
1472615|NCT00087425|contiguous stage II grade 1 follicular lymphoma
1472616|NCT00087425|noncontiguous stage II grade 1 follicular lymphoma
1472617|NCT00087425|recurrent grade 1 follicular lymphoma
1472618|NCT00087425|stage III grade 1 follicular lymphoma
1472619|NCT00087425|stage IV grade 1 follicular lymphoma
1472620|NCT00087425|contiguous stage II grade 2 follicular lymphoma
1472621|NCT00087425|noncontiguous stage II grade 2 follicular lymphoma
1472622|NCT00087425|recurrent grade 2 follicular lymphoma
1472623|NCT00087425|stage III grade 2 follicular lymphoma
1472624|NCT00087425|stage IV grade 2 follicular lymphoma
1472625|NCT00087425|contiguous stage II marginal zone lymphoma
1472626|NCT00087425|noncontiguous stage II marginal zone lymphoma
1472627|NCT00087425|recurrent marginal zone lymphoma
1472628|NCT00087425|stage III marginal zone lymphoma
1472629|NCT00087425|stage IV marginal zone lymphoma
1472630|NCT00087425|refractory chronic lymphocytic leukemia
1472631|NCT00087425|Waldenström macroglobulinemia
1472632|NCT00087425|contiguous stage II small lymphocytic lymphoma
1472633|NCT00087425|noncontiguous stage II small lymphocytic lymphoma
1472634|NCT00087425|recurrent small lymphocytic lymphoma
1472635|NCT00087425|stage III small lymphocytic lymphoma
1472636|NCT00087425|stage IV small lymphocytic lymphoma
1472637|NCT00087399|breast cancer
1472638|NCT00087399|hot flashes
1472639|NCT00087360|colon cancer
1472640|NCT00087360|rectal cancer
1472641|NCT00087347|recurrent prostate cancer
1472642|NCT00087347|stage I prostate cancer
1472643|NCT00087347|stage IIB prostate cancer
1472644|NCT00087347|stage IIA prostate cancer
1472645|NCT00087347|stage III prostate cancer
1472646|NCT00087347|stage IV prostate cancer
1472647|NCT00087347|stage I breast cancer
1472648|NCT00087347|stage II breast cancer
1472649|NCT00087347|stage IIIA breast cancer
1472650|NCT00087347|stage IIIB breast cancer
1472651|NCT00087347|stage IIIC breast cancer
1472652|NCT00087347|stage IV breast cancer
1472653|NCT00087347|recurrent breast cancer
1472654|NCT00087334|recurrent colon cancer
1472655|NCT00087334|stage IV colon cancer
1472656|NCT00087334|recurrent rectal cancer
1472657|NCT00087334|stage IV rectal cancer
1472658|NCT00087295|recurrent bladder cancer
1472659|NCT00087295|stage IV bladder cancer
1472660|NCT00087295|transitional cell carcinoma of the bladder
1472661|NCT00087295|metastatic transitional cell cancer of the renal pelvis and ureter
1472662|NCT00087295|recurrent transitional cell cancer of the renal pelvis and ureter
1472663|NCT00087295|anterior urethral cancer
1472664|NCT00087295|posterior urethral cancer
1472665|NCT00087295|recurrent urethral cancer
1472666|NCT00087295|urethral cancer associated with invasive bladder cancer
1472667|NCT00087282|adult primary hepatocellular carcinoma
1472668|NCT00087282|advanced adult primary liver cancer
1472669|NCT00087282|recurrent adult primary liver cancer
1472670|NCT00087256|stage I colon cancer
1472671|NCT00087256|adenocarcinoma of the colon
1472672|NCT00087178|stage I breast cancer
1472673|NCT00087178|stage II breast cancer
1472674|NCT00087165|adenocarcinoma of the prostate
1472675|NCT00087165|recurrent prostate cancer
1472676|NCT00087152|stage IV breast cancer
1472677|NCT00087152|recurrent breast cancer
1472678|NCT00087126|recurrent cervical cancer
1472679|NCT00087126|cervical squamous cell carcinoma
1472794|NCT00086541|Chronic Hepatitis C
1472680|NCT00087113|cervical squamous cell carcinoma
1472681|NCT00087113|recurrent cervical cancer
1472682|NCT00087113|stage III cervical cancer
1472683|NCT00087113|stage IVA cervical cancer
1472684|NCT00087113|stage IVB cervical cancer
1472685|NCT00087100|recurrent endometrial carcinoma
1472686|NCT00087100|endometrial adenocarcinoma
1472687|NCT00087100|stage III endometrial carcinoma
1472688|NCT00087100|stage IV endometrial carcinoma
1472689|NCT00087087|recurrent ovarian epithelial cancer
1472690|NCT00087087|primary peritoneal cavity cancer
1472691|NCT00087061|adult anaplastic oligodendroglioma
1472692|NCT00087061|recurrent adult brain tumor
1472693|NCT00087061|adult glioblastoma
1472694|NCT00087061|adult anaplastic astrocytoma
1472695|NCT00087061|adult giant cell glioblastoma
1472696|NCT00087061|adult gliosarcoma
1472697|NCT00087048|extensive stage small cell lung cancer
1472698|NCT00087048|recurrent small cell lung cancer
1472699|NCT00087035|adenocarcinoma of the prostate
1472700|NCT00087035|recurrent prostate cancer
1472701|NCT00087022|clear cell renal cell carcinoma
1472702|NCT00087022|stage I renal cell cancer
1472703|NCT00087022|stage II renal cell cancer
1472704|NCT00087022|stage III renal cell cancer
1472705|NCT00087022|stage IV renal cell cancer
1472706|NCT00087009|post-transplant lymphoproliferative disorder
1472707|NCT00087009|recurrent childhood acute lymphoblastic leukemia
1472708|NCT00087009|recurrent childhood large cell lymphoma
1472709|NCT00087009|recurrent childhood lymphoblastic lymphoma
1472710|NCT00087009|recurrent childhood small noncleaved cell lymphoma
1472711|NCT00087009|recurrent/refractory childhood Hodgkin lymphoma
1472712|NCT00087009|AIDS-related peripheral/systemic lymphoma
1472713|NCT00087009|AIDS-related primary CNS lymphoma
1472714|NCT00086996|adenocarcinoma of the esophagus
1472715|NCT00086996|stage II esophageal cancer
1472716|NCT00086996|stage III esophageal cancer
1472717|NCT00086957|stage IV breast cancer
1472718|NCT00086957|male breast cancer
1472719|NCT00086957|recurrent breast cancer
1472720|NCT00086931|adenocarcinoma of the rectum
1472721|NCT00086931|stage III rectal cancer
1472722|NCT00086931|stage II rectal cancer
1472723|NCT00086892|recurrent ovarian epithelial cancer
1472724|NCT00086892|primary peritoneal cavity cancer
1472725|NCT00086879|adult glioblastoma
1472726|NCT00086879|recurrent adult brain tumor
1472727|NCT00086879|adult giant cell glioblastoma
1472728|NCT00086879|adult gliosarcoma
1472729|NCT00086866|stage III melanoma
1472730|NCT00086866|stage IV melanoma
1472731|NCT00086866|recurrent melanoma
1472732|NCT00086801|stage I adult Hodgkin lymphoma
1472733|NCT00086801|stage II adult Hodgkin lymphoma
1472734|NCT00086775|refractory chronic lymphocytic leukemia
1472735|NCT00086775|B-cell chronic lymphocytic leukemia
1472736|NCT00086762|nausea and vomiting
1472737|NCT00086762|unspecified adult solid tumor, protocol specific
1472738|NCT00086762|mindfulness relaxation
1472739|NCT00086749|breast cancer
1472740|NCT00086749|stage I breast cancer
1472741|NCT00086749|stage II breast cancer
1472742|NCT00086749|stage IIIA breast cancer
1472743|NCT00086749|stage IIIB breast cancer
1472744|NCT00086749|stage IIIC breast cancer
1472745|NCT00086736|stage I prostate cancer
1472746|NCT00086736|stage IIB prostate cancer
1472747|NCT00086736|stage IIA prostate cancer
1472748|NCT00086736|stage III prostate cancer
1472749|NCT00086723|unspecified adult solid tumor, protocol specific
1472750|NCT00086684|Interstitial Cystitis
1472751|NCT00086684|Urinary Bladder Pain
1472752|NCT00086658|Hypereosinophilic Syndrome Hypereosinophilia
1472753|NCT00086658|mepolizumab
1472754|NCT00086658|anti IL-5
1472755|NCT00086645|Autism
1472756|NCT00086645|Asperger Syndrome
1472757|NCT00086645|Pervasive Developmental Disorder
1472758|NCT00086645|PDD
1472759|NCT00086645|Rituals
1472760|NCT00086645|Compulsions
1472761|NCT00086645|Stereotypy
1472762|NCT00086645|Routines
1472763|NCT00086645|Repetitive behavior
1472764|NCT00086645|SSRI
1472765|NCT00086645|Serotonin
1472766|NCT00086632|oregovomab
1472767|NCT00086632|ovarex
1472768|NCT00086632|ovarian cancer
1472769|NCT00086632|ovary
1472770|NCT00086632|ovarian carcinoma
1472771|NCT00086632|front-line
1472772|NCT00086619|Osteoporosis
1472773|NCT00086619|Parathyroid hormone
1472774|NCT00086619|Teriparatide
1472775|NCT00086619|Bone formation
1472776|NCT00086619|Bone resorption
1472777|NCT00086606|Peanut
1472778|NCT00086593|adjunctive
1472779|NCT00086593|atypical antipsychotics
1472780|NCT00086593|add-on
1472781|NCT00086593|Schizophrenia
1472782|NCT00086593|psychosis
1472783|NCT00086567|Blood
1472784|NCT00086567|Testing
1472785|NCT00086567|Gynecologic
1472786|NCT00086567|Urine
1472787|NCT00086567|CA125
1472788|NCT00086567|Epithelial Ovarian Cancer
1472789|NCT00086567|Peritoneal Cancer
1472790|NCT00086567|Fallopian Tube Cancer
1472791|NCT00086554|Surgery
1472792|NCT00086554|Intestinal Resection
1472793|NCT00086554|Blood Sample
1472795|NCT00086541|Liver
1472796|NCT00086541|Pegylated
1472797|NCT00086541|Interferon
1472798|NCT00086541|Alpha
1472799|NCT00086541|Ribavirin
1472800|NCT00086541|Combination
1472801|NCT00086541|Nonresponder
1472802|NCT00086541|HCV
1472803|NCT00086541|Infergen
1472804|NCT00086541|SVR
1472805|NCT00086528|Solid Tumors
1472806|NCT00086515|Type 2 Diabetes Mellitus
1472807|NCT00086489|metastatic melanoma
1472808|NCT00086489|multiple dose
1472809|NCT00086476|Gray Platelet Syndrome
1472810|NCT00086476|Hermansky-Pudlak Syndrome
1472811|NCT00086476|Storage Pool Deficiency
1472812|NCT00086476|Organelle Formation
1472813|NCT00086476|Megakaryocyte Development
1472814|NCT00086476|Megakaryocytes
1472815|NCT00086476|Platelets
1472816|NCT00086476|Dense Granules
1472817|NCT00086476|Alpha Granules
1472818|NCT00086476|Lysosome-related Organelles
1472819|NCT00086476|GPS
1472820|NCT00086476|HPS
1472821|NCT00086476|Griscelli Disease
1472822|NCT00086476|Chediak Higashi Syndrome
1472823|NCT00086476|Wiskott Aldrich Syndrome
1472824|NCT00086476|Platelet
1472825|NCT00086476|Congenital Bleeding Disorders
1472826|NCT00086476|SAC
1472827|NCT00086476|Vesicle
1472828|NCT00086463|STEP
1472829|NCT00086463|PAH
1472830|NCT00086463|iloprost
1472831|NCT00086463|inhalation
1472832|NCT00086463|prostacyclin
1472833|NCT00086411|light smokers, smoking cessation treatment programs
1472834|NCT00086385|Smoking cessation
1472835|NCT00086385|Tobacco
1472836|NCT00086372|Acute Infection
1472837|NCT00086372|Treatment Experienced
1472838|NCT00086372|Treatment Naive
1472839|NCT00086359|Treatment Naive
1472840|NCT00086359|Perinatal Transmission
1472841|NCT00086359|Mother-to-Child Transmission
1472842|NCT00086359|MTCT
1472843|NCT00086359|Treatment Experienced
1472844|NCT00086346|Liver
1472845|NCT00086346|Transplant
1472846|NCT00086333|Carcinoma, Non-Small-Cell Lung
1472847|NCT00086333|Taxotere
1472848|NCT00086333|docetaxel
1472849|NCT00086333|taxanes
1472850|NCT00086320|Schizophrenia
1472851|NCT00086320|paliperidone
1472852|NCT00086320|Risperidone
1472853|NCT00086307|Pramipexole
1472854|NCT00086307|Escitalopran
1472855|NCT00086307|Antidepressant
1472856|NCT00086307|Dopaminergic Receptor Agonist
1472857|NCT00086307|Depression
1472858|NCT00086307|Major Depression
1472859|NCT00086294|Non-Dopaminergic
1472860|NCT00086294|Dyskinesias
1472861|NCT00086294|Fluctuations
1472862|NCT00086294|Inverse Agonist
1472863|NCT00086294|ACP-103
1472864|NCT00086294|Parkinson Disease
1472865|NCT00086294|PD
1472866|NCT00086281|Sleep-disordered breathing
1472867|NCT00086281|Obstructive sleep apnea syndrome
1472868|NCT00086268|lung cancer
1472869|NCT00086268|ZPACT
1472870|NCT00086268|US75
1472871|NCT00086268|Bone Metastases
1472872|NCT00086255|cocaine dependence
1472873|NCT00086242|psychosocial effects of cancer and its treatment
1472874|NCT00086242|stage IA cervical cancer
1472875|NCT00086242|stage IB cervical cancer
1472876|NCT00086242|stage IIA cervical cancer
1472877|NCT00086242|stage IIB cervical cancer
1472878|NCT00086242|stage III cervical cancer
1472879|NCT00086229|Complementary Therapies
1472880|NCT00086216|Multiple myeloma
1472881|NCT00086190|Parkinson disease
1472882|NCT00086190|depression
1472883|NCT00086190|Parkinson's disease
1472884|NCT00086190|paroxetine
1472885|NCT00086190|venlafaxine
1472886|NCT00086190|antidepressant
1472887|NCT00086177|Pregnancy,
1472888|NCT00086177|prevention of preterm birth,
1472889|NCT00086177|prevention of preterm labor,
1472890|NCT00086164|edifoligide
1472891|NCT00086164|E2F Decoy
1472892|NCT00086164|Chronic Renal failure
1472893|NCT00086164|hemodialysis
1472894|NCT00086164|AV Graft
1472895|NCT00086164|neointimal hyperplasia
1472896|NCT00086138|Alzheimer's disease
1472897|NCT00086138|Depression
1472898|NCT00086125|Relapsed or refractory hematologic malignancies
1472899|NCT00086112|Anxiety
1472900|NCT00086112|antipsychotic
1472901|NCT00086086|Symptomatic Congestive Heart Failure
1472902|NCT00086086|CHF
1472903|NCT00086086|Anaemia
1472904|NCT00086086|Anemia
1472905|NCT00086073|Parkinson disease
1472906|NCT00086073|Parkinson's disease
1472907|NCT00086073|PD
1472908|NCT00086073|genetics
1472909|NCT00086073|genes
1472910|NCT00086073|siblings
1472911|NCT00086073|family
1472912|NCT00086060|Internal-External Control
1472913|NCT00086060|Magnetic Resonance Imaging
1472914|NCT00086060|fMRI
1472915|NCT00086060|Exercise
1472916|NCT00086060|Relaxation
1472917|NCT00086047|Juvenile Fibromyalgia Syndrome
1472918|NCT00086047|JPFS
1472919|NCT00086047|Fibromyalgia
1472920|NCT00086047|Chronic Pain
1472921|NCT00086047|Pediatric Pain
1472922|NCT00086047|Juvenile Fibromyalgia
1472923|NCT00086034|Lymphoma
1472924|NCT00086034|Non-Hodgkin's Lymphoma
1472925|NCT00086034|Indolent lymphoma
1472926|NCT00086034|Relapsed lymphoma
1472927|NCT00086034|Refractory lymphoma
1472928|NCT00086034|Motexafin gadolinium
1472929|NCT00086021|Headache
1472930|NCT00086021|Acupuncture
1472931|NCT00085995|Syndesmophyte
1472932|NCT00085995|Ankylosing Spondylitis
1472933|NCT00085995|AS
1472934|NCT00085995|Spondyloarthropathy
1472935|NCT00085995|Spondyloarthritis
1472936|NCT00085982|Rabson Mendenhall
1472937|NCT00085982|Type B Insulin Resistance
1472938|NCT00085982|Type A Insulin Resistance
1472939|NCT00085982|Diabetes
1472940|NCT00085969|diabetes
1472941|NCT00085969|exenatide
1472942|NCT00085969|Amylin
1472943|NCT00085969|Lilly
1472944|NCT00085943|ritonavir
1472945|NCT00085943|abacavir
1472946|NCT00085943|HIV
1472947|NCT00085943|lopinavir
1472948|NCT00085943|lamivudine
1472949|NCT00085943|fosamprenavir
1472950|NCT00085943|Epzicom
1472951|NCT00085930|Neuroblastoma
1472952|NCT00085917|Pegasys
1472953|NCT00085917|Ribavirin
1472954|NCT00085917|Early Virological Response
1472955|NCT00085917|Hepatitis C
1472956|NCT00085917|HIV
1472957|NCT00085904|Advanced cancer
1472958|NCT00085904|IL-18
1472959|NCT00085904|repeat dosing
1472960|NCT00085904|Phase 1
1472961|NCT00085904|pharmacokinetics
1472962|NCT00085904|oncology
1472963|NCT00085891|Schizophrenia
1472964|NCT00085891|Schizophrenic disorder
1472965|NCT00085878|IL-18
1472966|NCT00085878|subcutaneous
1472967|NCT00085878|pharmacokinetics
1472968|NCT00085878|Phase 1
1472969|NCT00085865|5 HT
1472970|NCT00085865|Neuroreceptors
1472971|NCT00085865|Radiotracer
1472972|NCT00085865|Neuroimaging
1472973|NCT00085865|Serotonin Transporter
1472974|NCT00085865|Alcoholism
1472975|NCT00085865|PET
1472976|NCT00085865|Healthy Volunteer
1472977|NCT00085865|HV
1472978|NCT00085852|emphysema
1472979|NCT00085852|chronic obstructive pulmonary disease
1472980|NCT00085852|lung volume reduction
1472981|NCT00085852|bronchoscopic
1472982|NCT00085852|bronchoscopy
1472983|NCT00085852|bronchoscope
1472984|NCT00085839|Tarceva
1472985|NCT00085839|NSCLC
1472986|NCT00085839|EGFR
1472987|NCT00085839|ECOG Performance Status 2
1472988|NCT00085839|erlotinib
1472989|NCT00085839|Non-Small Cell Lung Cancer
1472990|NCT00085839|OSI-774
1472991|NCT00085826|Lung Cancer
1472992|NCT00085826|NSCLC
1472993|NCT00085826|Non-small Cell Lung Cancer
1472994|NCT00085813|Platinum-Refractory
1472995|NCT00085813|Platinum-Relapsed
1472996|NCT00085813|Non-Small Cell Lung Cancer
1472997|NCT00085774|albuterol
1472998|NCT00085774|aerosol inhaler
1472999|NCT00085774|metered-dose inhaler
1473000|NCT00085774|breath-actuated inhaler
1473001|NCT00085774|exercise-induced bronchospasm
1473002|NCT00085761|Dermal assessment
1473003|NCT00085761|Pain measurement
1473004|NCT00085761|Diary
1473005|NCT00085761|Neuropathy
1473006|NCT00085761|Analgesics/*therapeutic use
1473007|NCT00085761|Capsaicin/*administration & dosage/adverse effects
1473008|NCT00085761|HIV Infections/*complications/*drug therapy
1473009|NCT00085761|Pain
1473010|NCT00085761|Complementary Therapies
1473011|NCT00085748|schizophrenia
1473012|NCT00085748|geriatric
1473013|NCT00085748|elderly
1473014|NCT00085722|Injection Therapy
1473015|NCT00085709|untreated adult acute myeloid leukemia
1473016|NCT00085709|adult acute eosinophilic leukemia
1473017|NCT00085709|adult acute basophilic leukemia
1473018|NCT00085709|adult acute monocytic leukemia (M5b)
1473019|NCT00085709|adult acute erythroid leukemia (M6)
1473020|NCT00085709|adult acute megakaryoblastic leukemia (M7)
1473021|NCT00085709|adult acute minimally differentiated myeloid leukemia (M0)
1473022|NCT00085709|adult acute myeloblastic leukemia with maturation (M2)
1473023|NCT00085709|adult acute myeloblastic leukemia without maturation (M1)
1473024|NCT00085709|adult acute myelomonocytic leukemia (M4)
1473025|NCT00085709|adult acute monoblastic leukemia (M5a)
1473026|NCT00085709|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1473027|NCT00085709|adult acute myeloid leukemia with inv(16)(p13;q22)
1473028|NCT00085709|adult acute myeloid leukemia with t(16;16)(p13;q22)
1473029|NCT00085709|adult acute myeloid leukemia with t(8;21)(q22;q22)
1473030|NCT00085696|Lymphoma
1473031|NCT00085696|Non-Hodgkin's
1473032|NCT00085696|NHL
1473033|NCT00085696|B-Cell
1473034|NCT00085696|Indolent
1473035|NCT00085683|Magnetic Resonance Spectroscopy
1473036|NCT00085683|Lumbar Puncture
1473037|NCT00085683|Healthy Control Subjects
1473038|NCT00085683|Mesial Temporal Sclerosis
1473039|NCT00085683|Neuroexcitotoxicity
1473040|NCT00085683|Seizure Disorder
1473041|NCT00085683|Epilepsy
1473042|NCT00085683|Healthy Volunteer
1473043|NCT00085683|HV
1473044|NCT00085670|Tumor Necrosis Factor Alpha (TNF-Alpha)
1473045|NCT00085670|Interferon-Gamma (IFN-Gamma)
1473046|NCT00085670|Transforming Growth Factor Beta 1 (TGF-B1)
1473047|NCT00085670|Interleukin-10 (IL-10)
1473048|NCT00085670|Interleukin-1 Receptor Antagonist (IL-1 Ra)
1473049|NCT00085670|Vitamin D Receptor (VitD R)
1473050|NCT00085670|Interleukin-6 (IL-6)
1473051|NCT00085670|Bone Marrow Failure
1473052|NCT00085670|Aplastic Anemia
1473053|NCT00085670|Myelodysplastic Syndrome
1473054|NCT00085670|MDS
1473055|NCT00085670|Pure Red Cell Aplasia
1473056|NCT00085670|PRCA
1473057|NCT00085657|Direct Current Stimulation
1473058|NCT00085657|Cortical Reorganization
1473059|NCT00085657|Rehabilitation
1473060|NCT00085657|Acute Stroke
1473061|NCT00085657|Stroke
1473062|NCT00085631|stage IA cervical cancer
1473063|NCT00085631|stage IB cervical cancer
1473064|NCT00085631|stage IIA cervical cancer
1473065|NCT00085631|stage IIB cervical cancer
1473066|NCT00085631|stage III cervical cancer
1473067|NCT00085631|stage IVA cervical cancer
1473068|NCT00085631|cervical adenocarcinoma
1473069|NCT00085631|cervical adenosquamous cell carcinoma
1473070|NCT00085631|cervical squamous cell carcinoma
1473071|NCT00085579|stage III melanoma
1473072|NCT00085579|stage IV melanoma
1473073|NCT00085566|adult glioblastoma
1473074|NCT00085566|recurrent prostate cancer
1473075|NCT00085566|recurrent adult brain tumor
1473076|NCT00085566|stage IV prostate cancer
1473077|NCT00085566|adult giant cell glioblastoma
1473078|NCT00085566|adult gliosarcoma
1473079|NCT00085527|recurrent ovarian epithelial cancer
1473080|NCT00085527|stage III ovarian epithelial cancer
1473081|NCT00085527|stage IV ovarian epithelial cancer
1473082|NCT00085501|recurrent non-small cell lung cancer
1473083|NCT00085501|stage IIIB non-small cell lung cancer
1473084|NCT00085501|stage IV non-small cell lung cancer
1473085|NCT00085501|adenocarcinoma of the lung
1473086|NCT00085501|squamous cell lung cancer
1473087|NCT00085501|large cell lung cancer
1473088|NCT00085488|recurrent melanoma
1473089|NCT00085488|stage III melanoma
1473090|NCT00085488|stage IV melanoma
1473091|NCT00085475|recurrent adult soft tissue sarcoma
1473092|NCT00085475|stage III adult soft tissue sarcoma
1473093|NCT00085475|stage IV adult soft tissue sarcoma
1473094|NCT00085475|adult fibrosarcoma
1473095|NCT00085475|adult malignant fibrous histiocytoma
1473096|NCT00085462|recurrent melanoma
1473097|NCT00085462|stage IV melanoma
1473098|NCT00085449|recurrent adult acute myeloid leukemia
1473099|NCT00085449|adult acute myeloid leukemia in remission
1473100|NCT00085449|recurrent adult acute lymphoblastic leukemia
1473101|NCT00085449|adult acute lymphoblastic leukemia in remission
1473102|NCT00085449|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1473103|NCT00085449|previously treated myelodysplastic syndromes
1473104|NCT00085449|atypical chronic myeloid leukemia, BCR-ABL1 negative
1473105|NCT00085449|chronic myelomonocytic leukemia
1473106|NCT00085449|recurrent adult Burkitt lymphoma
1473107|NCT00085449|recurrent grade 1 follicular lymphoma
1473108|NCT00085449|recurrent grade 2 follicular lymphoma
1473109|NCT00085449|recurrent grade 3 follicular lymphoma
1473110|NCT00085449|recurrent adult diffuse small cleaved cell lymphoma
1473111|NCT00085449|recurrent adult immunoblastic large cell lymphoma
1473112|NCT00085449|recurrent small lymphocytic lymphoma
1473113|NCT00085449|recurrent marginal zone lymphoma
1473114|NCT00085449|recurrent mantle cell lymphoma
1473115|NCT00085449|recurrent adult lymphoblastic lymphoma
1473116|NCT00085449|accelerated phase chronic myelogenous leukemia
1473117|NCT00085449|chronic phase chronic myelogenous leukemia
1473118|NCT00085449|recurrent adult diffuse mixed cell lymphoma
1473119|NCT00085449|recurrent adult diffuse large cell lymphoma
1473120|NCT00085449|refractory chronic lymphocytic leukemia
1473121|NCT00085449|stage III chronic lymphocytic leukemia
1473122|NCT00085449|stage IV chronic lymphocytic leukemia
1473123|NCT00085449|refractory multiple myeloma
1473124|NCT00085449|secondary myelodysplastic syndromes
1473125|NCT00085449|de novo myelodysplastic syndromes
1473126|NCT00085449|adult acute myeloid leukemia with t(8;21)(q22;q22)
1473127|NCT00085449|adult acute myeloid leukemia with t(16;16)(p13;q22)
1473128|NCT00085449|adult acute myeloid leukemia with inv(16)(p13;q22)
1473129|NCT00085449|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1473130|NCT00085449|adult acute myeloid leukemia with t(15;17)(q22;q12)
1473131|NCT00085436|recurrent renal cell cancer
1473132|NCT00085436|stage IV renal cell cancer
1473133|NCT00085423|recurrent melanoma
1473134|NCT00085423|stage IV melanoma
1473135|NCT00085397|recurrent melanoma
1473136|NCT00085397|stage III melanoma
1473137|NCT00085397|stage IV melanoma
1473138|NCT00085384|recurrent ovarian epithelial cancer
1473139|NCT00085384|peritoneal cavity cancer
1473140|NCT00085384|fallopian tube cancer
1473141|NCT00085332|recurrent endometrial carcinoma
1473142|NCT00085332|stage III endometrial carcinoma
1473143|NCT00085332|stage IV endometrial carcinoma
1473144|NCT00085306|recurrent melanoma
1473145|NCT00085306|stage IV melanoma
1473146|NCT00085306|iris melanoma
1473147|NCT00085306|ciliary body and choroid melanoma, medium/large size
1473148|NCT00085306|extraocular extension melanoma
1473149|NCT00085306|recurrent intraocular melanoma
1473150|NCT00085228|adenocarcinoma of the prostate
1473151|NCT00085228|recurrent prostate cancer
1473152|NCT00085228|stage IV prostate cancer
1473153|NCT00085202|untreated childhood medulloblastoma
1473154|NCT00085202|untreated childhood supratentorial primitive neuroectodermal tumor
1473155|NCT00085202|childhood atypical teratoid/rhabdoid tumor
1473156|NCT00085202|untreated childhood pineoblastoma
1473157|NCT00085176|long-term effects secondary to cancer therapy in children
1473158|NCT00085176|neurotoxicity
1473159|NCT00085176|psychosocial effects of cancer and its treatment
1473160|NCT00085176|childhood acute lymphoblastic leukemia in remission
1473161|NCT00085163|adenocarcinoma of the colon
1473162|NCT00085163|stage III colon cancer
1473163|NCT00085150|recurrent adult T-cell leukemia/lymphoma
1473164|NCT00085150|recurrent childhood acute lymphoblastic leukemia
1473165|NCT00085150|childhood Burkitt lymphoma
1473166|NCT00085150|recurrent childhood acute myeloid leukemia
1473167|NCT00085150|recurrent childhood large cell lymphoma
1473168|NCT00085150|recurrent childhood lymphoblastic lymphoma
1473169|NCT00085150|recurrent mycosis fungoides/Sezary syndrome
1473170|NCT00085150|recurrent cutaneous T-cell non-Hodgkin lymphoma
1473171|NCT00085150|recurrent/refractory childhood Hodgkin lymphoma
1473172|NCT00085150|relapsing chronic myelogenous leukemia
1473173|NCT00085150|acute undifferentiated leukemia
1473174|NCT00085098|childhood central nervous system germ cell tumor
1473175|NCT00085059|stage IV melanoma
1473176|NCT00085059|recurrent melanoma
1473177|NCT00085020|stage IV breast cancer
1473178|NCT00085020|male breast cancer
1473179|NCT00085020|recurrent breast cancer
1473180|NCT00084942|cholangiocarcinoma of the gallbladder
1473181|NCT00084942|recurrent gallbladder cancer
1473182|NCT00084942|unresectable gallbladder cancer
1473183|NCT00084942|cholangiocarcinoma of the extrahepatic bile duct
1473184|NCT00084942|recurrent extrahepatic bile duct cancer
1473185|NCT00084942|unresectable extrahepatic bile duct cancer
1473186|NCT00084929|colon cancer
1473187|NCT00084929|rectal cancer
1473188|NCT00084903|cervical cancer
1473189|NCT00084903|cervical intraepithelial neoplasia
1473190|NCT00084890|stage IVB cervical cancer
1473191|NCT00084890|recurrent cervical cancer
1473192|NCT00084890|cervical squamous cell carcinoma
1473193|NCT00084864|adenocarcinoma of the prostate
1473194|NCT00084864|stage II prostate cancer
1473195|NCT00084864|stage III prostate cancer
1473196|NCT00084838|childhood atypical teratoid/rhabdoid tumor
1473197|NCT00084825|adenocarcinoma of the prostate
1473198|NCT00084825|recurrent prostate cancer
1473199|NCT00084825|stage IV prostate cancer
1473200|NCT00084825|bone metastases
1473201|NCT00084812|unspecified adult solid tumor, protocol specific
1473202|NCT00084799|recurrent small cell lung cancer
1473203|NCT00084786|unspecified adult solid tumor, protocol specific
1473204|NCT00084773|recurrent rectal cancer
1473205|NCT00084773|stage II rectal cancer
1473206|NCT00084773|stage III rectal cancer
1473207|NCT00084773|adenocarcinoma of the rectum
1473208|NCT00084747|stage II multiple myeloma
1473209|NCT00084747|stage III multiple myeloma
1473210|NCT00084734|unspecified adult solid tumor, protocol specific
1473211|NCT00084721|diarrhea
1473212|NCT00084721|recurrent colon cancer
1473213|NCT00084721|stage IV colon cancer
1473214|NCT00084721|recurrent rectal cancer
1473215|NCT00084721|stage IV rectal cancer
1473216|NCT00084721|stage III colon cancer
1473217|NCT00084721|stage III rectal cancer
1473218|NCT00084708|unspecified adult solid tumor, protocol specific
1473219|NCT00084695|childhood myelodysplastic syndromes
1473220|NCT00084695|recurrent childhood rhabdomyosarcoma
1473221|NCT00084695|unspecified childhood solid tumor, protocol specific
1473222|NCT00084695|previously treated childhood rhabdomyosarcoma
1473223|NCT00084695|previously untreated childhood rhabdomyosarcoma
1473224|NCT00084695|disseminated neuroblastoma
1473225|NCT00084695|regional neuroblastoma
1473226|NCT00084695|recurrent neuroblastoma
1473227|NCT00084695|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1473228|NCT00084695|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1473229|NCT00084695|recurrent childhood acute lymphoblastic leukemia
1473230|NCT00084695|juvenile myelomonocytic leukemia
1473231|NCT00084695|childhood acute lymphoblastic leukemia in remission
1473232|NCT00084695|childhood Burkitt lymphoma
1473233|NCT00084695|recurrent childhood lymphoblastic lymphoma
1473234|NCT00084695|stage III childhood lymphoblastic lymphoma
1473235|NCT00084695|stage IV childhood lymphoblastic lymphoma
1473236|NCT00084695|recurrent childhood small noncleaved cell lymphoma
1473237|NCT00084695|stage III childhood small noncleaved cell lymphoma
1473238|NCT00084695|stage IV childhood small noncleaved cell lymphoma
1473239|NCT00084695|recurrent childhood large cell lymphoma
1473240|NCT00084695|stage III childhood large cell lymphoma
1473241|NCT00084695|stage IV childhood large cell lymphoma
1473242|NCT00084695|stage III childhood Hodgkin lymphoma
1473243|NCT00084695|stage IV childhood Hodgkin lymphoma
1473244|NCT00084695|previously treated myelodysplastic syndromes
1473245|NCT00084695|Fanconi anemia
1473350|NCT00084292|Spastic Hemiplegia
1473246|NCT00084695|de novo myelodysplastic syndromes
1473247|NCT00084695|secondary myelodysplastic syndromes
1473248|NCT00084695|childhood chronic myelogenous leukemia
1473249|NCT00084695|chronic phase chronic myelogenous leukemia
1473250|NCT00084695|relapsing chronic myelogenous leukemia
1473251|NCT00084695|childhood Langerhans cell histiocytosis
1473252|NCT00084695|recurrent childhood acute myeloid leukemia
1473253|NCT00084695|recurrent/refractory childhood Hodgkin lymphoma
1473254|NCT00084669|hot flashes
1473255|NCT00084669|sleep disorders
1473256|NCT00084669|ductal breast carcinoma in situ
1473257|NCT00084669|breast cancer in situ
1473258|NCT00084669|lobular breast carcinoma in situ
1473259|NCT00084669|lobular breast carcinoma
1473260|NCT00084669|recurrent breast cancer
1473261|NCT00084669|stage I breast cancer
1473262|NCT00084669|stage II breast cancer
1473263|NCT00084669|stage IIIA breast cancer
1473264|NCT00084669|stage IIIB breast cancer
1473265|NCT00084669|stage IIIC breast cancer
1473266|NCT00084669|stage IV breast cancer
1473267|NCT00084656|stage III melanoma
1473268|NCT00084656|stage IV melanoma
1473269|NCT00084656|ciliary body and choroid melanoma, medium/large size
1473270|NCT00084656|extraocular extension melanoma
1473271|NCT00084656|iris melanoma
1473272|NCT00084656|recurrent melanoma
1473273|NCT00084656|recurrent intraocular melanoma
1473274|NCT00084656|metastatic intraocular melanoma
1473275|NCT00084591|stage II rectal cancer
1473276|NCT00084591|stage III rectal cancer
1473277|NCT00084591|adenocarcinoma of the rectum
1473278|NCT00084578|stage 0 bladder cancer
1473279|NCT00084578|stage I bladder cancer
1473280|NCT00084578|stage II bladder cancer
1473281|NCT00084578|stage III bladder cancer
1473282|NCT00084578|stage IV bladder cancer
1473283|NCT00084578|transitional cell carcinoma of the bladder
1473284|NCT00084565|stage IV prostate cancer
1473285|NCT00084565|adenocarcinoma of the prostate
1473286|NCT00084552|sexual dysfunction
1473287|NCT00084552|sexuality and reproductive issues
1473288|NCT00084552|adenocarcinoma of the prostate
1473289|NCT00084552|stage IIB prostate cancer
1473290|NCT00084552|stage IIA prostate cancer
1473291|NCT00084539|stage I breast cancer
1473292|NCT00084539|stage II breast cancer
1473293|NCT00084539|breast cancer in situ
1473294|NCT00084526|recurrent prostate cancer
1473295|NCT00084526|stage I prostate cancer
1473296|NCT00084526|stage II prostate cancer
1473297|NCT00084526|stage III prostate cancer
1473298|NCT00084526|stage IV prostate cancer
1473299|NCT00084513|unspecified adult solid tumor, protocol specific
1473300|NCT00084448|recurrent ovarian epithelial cancer
1473301|NCT00084448|primary peritoneal cavity cancer
1473302|NCT00084435|stage III squamous cell carcinoma of the lip and oral cavity
1473303|NCT00084435|stage IV squamous cell carcinoma of the lip and oral cavity
1473304|NCT00084435|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1473305|NCT00084435|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1473306|NCT00084435|stage III salivary gland cancer
1473307|NCT00084435|stage IV salivary gland cancer
1473308|NCT00084435|stage III squamous cell carcinoma of the hypopharynx
1473309|NCT00084435|stage IV squamous cell carcinoma of the hypopharynx
1473310|NCT00084435|stage III squamous cell carcinoma of the larynx
1473311|NCT00084435|stage IV squamous cell carcinoma of the larynx
1473312|NCT00084435|stage III squamous cell carcinoma of the oropharynx
1473313|NCT00084435|stage IV squamous cell carcinoma of the oropharynx
1473314|NCT00084435|salivary gland squamous cell carcinoma
1473315|NCT00084422|recurrent neuroblastoma
1473316|NCT00084409|non-small cell lung cancer
1473317|NCT00084409|squamous lung dysplasia
1473318|NCT00084396|stage II breast cancer
1473319|NCT00084396|stage IIIA breast cancer
1473320|NCT00084396|stage IIIB breast cancer
1473321|NCT00084383|stage I pancreatic cancer
1473322|NCT00084383|stage II pancreatic cancer
1473323|NCT00084383|duct cell adenocarcinoma of the pancreas
1473324|NCT00084370|ovarian epithelial cancer
1473325|NCT00084370|BRCA1 mutation carrier
1473326|NCT00084370|BRCA2 mutation carrier
1473327|NCT00084344|breast cancer
1473328|NCT00084318|stage III squamous cell carcinoma of the hypopharynx
1473329|NCT00084318|stage IV squamous cell carcinoma of the hypopharynx
1473330|NCT00084318|stage III squamous cell carcinoma of the oropharynx
1473331|NCT00084318|stage IV squamous cell carcinoma of the oropharynx
1473332|NCT00084318|stage III squamous cell carcinoma of the larynx
1473333|NCT00084318|stage IV squamous cell carcinoma of the larynx
1473334|NCT00084318|stage III lymphoepithelioma of the oropharynx
1473335|NCT00084318|stage IV lymphoepithelioma of the oropharynx
1473336|NCT00084305|Bronchoscopy
1473337|NCT00084305|Pulmonary Fibrosis
1473338|NCT00084305|Lung Biopsy (Clinically-Indicated)
1473339|NCT00084305|Hereditary Pulmonary Fibrosis
1473340|NCT00084305|Healthy Volunteer
1473341|NCT00084305|HV
1473342|NCT00084292|Ischemia
1473343|NCT00084292|Pediatric
1473344|NCT00084292|Etiology
1473345|NCT00084292|Treatment
1473346|NCT00084292|Outcome
1473347|NCT00084292|Childhood Stroke
1473348|NCT00084292|Pediatric Stroke
1473349|NCT00084292|Ischemic Stroke
1473351|NCT00084292|Hemiplegic cerebral palsy
1473352|NCT00084279|Chronic Hepatitis C
1473353|NCT00084279|Liver
1473354|NCT00084279|Pegylated
1473355|NCT00084279|Interferon
1473356|NCT00084279|Alpha
1473357|NCT00084279|Gamma
1473358|NCT00084279|Ribavirin
1473359|NCT00084279|Combination
1473360|NCT00084279|Nonresponder
1473361|NCT00084279|Pegasys
1473362|NCT00084279|PegIntron
1473363|NCT00084266|Staphylococcal pneumonia
1473364|NCT00084266|Methicillin-resistant staphylococcal pneumonia
1473365|NCT00084266|healthcare-associated pneumonia
1473366|NCT00084253|HIV
1473367|NCT00084253|Treatment Naive
1473368|NCT00084214|metastatic
1473369|NCT00084214|increased antitumor effect
1473370|NCT00084201|Vaccinium macrocarpon
1473371|NCT00084188|behavioral intervention
1473372|NCT00084175|behavioral intervention
1473373|NCT00084162|PET
1473374|NCT00084162|Heart Rate Variability
1473375|NCT00084162|N-Back Task
1473376|NCT00084162|Isometric Handgrip
1473377|NCT00084162|MRI
1473378|NCT00084162|Depression
1473379|NCT00084162|MDD
1473380|NCT00084162|Heart
1473381|NCT00084149|Acute Infection
1473382|NCT00084149|Treatment Naive
1473383|NCT00084136|Treatment Naive
1473384|NCT00084136|Adherence
1473385|NCT00084136|Drug Resistance
1473386|NCT00084136|Treatment Failure
1473387|NCT00084123|Relaxation Techniques
1473388|NCT00084123|Radiation
1473389|NCT00084123|Drug Therapy
1473390|NCT00084123|Healing Touch
1473391|NCT00084110|Aged
1473392|NCT00084110|Mexican Americans
1473393|NCT00084110|Complementary Therapies
1473394|NCT00084097|Allergy
1473395|NCT00084097|IgE
1473396|NCT00084097|Eosinophil
1473397|NCT00084097|Monoclonal Antibody
1473398|NCT00084097|Eosinophilic Gastroenteritis
1473399|NCT00084097|EG
1473400|NCT00084084|Lysosomes
1473401|NCT00084084|Storage
1473402|NCT00084084|Glycolipid
1473403|NCT00084084|Fabry disease
1473404|NCT00084084|Stroke
1473405|NCT00084084|Children
1473406|NCT00084084|Pediatrics
1473407|NCT00084058|Dose Intensification
1473408|NCT00084058|Pharmacokinetic Sampling
1473409|NCT00084058|Treatment Experienced
1473410|NCT00084058|Child
1473411|NCT00084045|HIV Seronegativity
1473412|NCT00084045|Treatment Naive
1473413|NCT00084045|Pediatric HIV
1473414|NCT00084045|Perinatal Transmission
1473415|NCT00084032|Acute Infection
1473416|NCT00084032|Treatment Interruption
1473417|NCT00084032|Treatment Naive
1473418|NCT00084032|Primary HIV Infection
1473419|NCT00084032|PHI
1473420|NCT00084019|Treatment Experienced
1473421|NCT00083993|Breast Cancer
1473422|NCT00083980|Kava
1473423|NCT00083980|Complementary Therapies
1473424|NCT00083980|Medicine, Herbal
1473425|NCT00083967|rhegmatogenous retinal detachment
1473426|NCT00083967|detached retina
1473427|NCT00083967|retinal tear
1473428|NCT00083967|retinal break
1473429|NCT00083954|Bipolar I Disorder
1473430|NCT00083941|Renal Cell Cancer
1473431|NCT00083941|Requiring IL-2 treatment
1473432|NCT00083941|Stage IV Renal Cell Cancer
1473433|NCT00083928|Asymptomatic
1473434|NCT00083928|subcutaneous
1473435|NCT00083928|CA125 Progression
1473436|NCT00083928|Angstrom
1473437|NCT00083928|Ångstrom
1473438|NCT00083928|ovarian cancer
1473439|NCT00083915|Multiple Myeloma
1473440|NCT00083915|DTPACE
1473441|NCT00083915|Tandem Transplant
1473442|NCT00083915|Cisplatin
1473443|NCT00083915|Cyclophosphamide
1473444|NCT00083915|Dexamethasone
1473445|NCT00083915|Doxorubicin
1473446|NCT00083915|Etoposide
1473447|NCT00083915|Sargramostim
1473448|NCT00083915|Thalidomide
1473449|NCT00083915|Melphalan
1473450|NCT00083902|Myeloma
1473451|NCT00083902|Thalidomide
1473452|NCT00083902|Dexamethasone
1473453|NCT00083876|Multiple Myeloma
1473454|NCT00083876|D.T. PACE
1473455|NCT00083876|Melphalan
1473456|NCT00083876|Transplant
1473457|NCT00083876|Thalidomide
1473458|NCT00083876|Dexamethasone
1473459|NCT00083876|Cisplatin
1473460|NCT00083876|Cyclophosphamide
1473461|NCT00083876|Doxorubicin
1473462|NCT00083876|Etoposide
1473463|NCT00083876|Filgrastim
1473464|NCT00083876|Interferon-alpha 2b
1473465|NCT00083876|Sargramostim
1473466|NCT00083772|Heart failure
1473467|NCT00083772|Diastolic heart failure
1473468|NCT00083772|Congestive heart failure
1473469|NCT00083772|Nesiritide
1473470|NCT00083772|Natrecor
1473471|NCT00083772|Left ventricular (LV) diastolic function
1473472|NCT00083772|Fatigue
1473473|NCT00083772|Shortness of breath
1473474|NCT00083772|Edema
1473475|NCT00083772|Heart disease
1473476|NCT00083733|Gene Expression
1473477|NCT00083733|Microarray
1473478|NCT00083733|Stem Cell
1473479|NCT00083733|Proteomics
1473480|NCT00083733|Metastases
1473481|NCT00083733|Breast Tissue
1473482|NCT00083733|Normal Breast Tissue
1473483|NCT00083733|Breast Cancer
1473484|NCT00083720|EGFR-undetectable
1473485|NCT00083720|Metastatic Colorectal Cancer
1473486|NCT00083707|Macroglobulinemia
1473487|NCT00083707|Waldenstrom
1473488|NCT00083707|Thalidomide
1473489|NCT00083694|Leukemia
1473490|NCT00083694|Thalidomide
1473491|NCT00083694|relapsed
1473492|NCT00083681|Multiple Myeloma
1473493|NCT00083681|Thalidomide
1473494|NCT00083681|G-CSF
1473495|NCT00083681|Cisplatin
1473496|NCT00083681|Etoposide
1473497|NCT00083681|Dexamethasone
1473498|NCT00083681|Cytoxan
1473499|NCT00083681|DCEP
1473500|NCT00083681|Relapse
1473501|NCT00083668|Schizophrenia
1473502|NCT00083668|Paliperidone
1473503|NCT00083668|Olanzapine
1473504|NCT00083668|PANSS
1473505|NCT00083668|Extended release
1473506|NCT00083668|Atypical neuroleptic
1473507|NCT00083642|Brain Plasticity
1473508|NCT00083642|Functional MRI
1473509|NCT00083642|Finger Movement
1473510|NCT00083642|Rehabilitation
1473511|NCT00083642|Improvement
1473512|NCT00083642|Stroke
1473513|NCT00083642|Motor Recovery
1473514|NCT00083642|Observation
1473515|NCT00083642|fMRI
1473516|NCT00083642|Healthy Volunteer
1473517|NCT00083642|HV
1473518|NCT00083629|[18F]FECNT
1473519|NCT00083629|Biodistribution
1473520|NCT00083629|Dosimetry
1473521|NCT00083629|Dopamine Transporter
1473522|NCT00083629|MIRD
1473523|NCT00083629|Kinetic Analysis
1473524|NCT00083629|Compartment Analysis
1473525|NCT00083629|Healthy Volunteer
1473526|NCT00083629|HV
1473527|NCT00083616|EGFr
1473528|NCT00083616|Clinical Trial
1473529|NCT00083616|Panitumumab
1473530|NCT00083616|ABX-EGF
1473531|NCT00083616|Immunex
1473532|NCT00083616|Metastatic Cancer
1473533|NCT00083616|Vectibix
1473534|NCT00083616|Abgenix
1473535|NCT00083616|Amgen
1473536|NCT00083603|HIV Seronegativity
1473537|NCT00083603|HIV Preventive Vaccine
1473538|NCT00083603|Vaccinia vector
1473539|NCT00083603|Pox vector
1473540|NCT00083590|Alzheimer disease
1473541|NCT00083590|Cholinesterase inhibitor
1473542|NCT00083577|Multiple Myeloma
1473543|NCT00083577|Thalidomide
1473544|NCT00083577|Anti-Angiogenesis
1473545|NCT00083564|Multiple myeloma
1473546|NCT00083564|Primary refractory multiple myeloma
1473547|NCT00083564|STR
1473548|NCT00083564|Skeletal Targeted Radiotherapy
1473549|NCT00083564|Holmium-166
1473550|NCT00083564|166-Ho-DOTMP
1473551|NCT00083551|Multiple Myeloma
1473552|NCT00083551|Cancer
1473553|NCT00083551|Therapy
1473554|NCT00083551|Thalidomide
1473555|NCT00083551|DTPACE
1473556|NCT00083551|Transplant
1473557|NCT00083551|VAD
1473558|NCT00083551|DCEP
1473559|NCT00083551|CAD
1473560|NCT00083551|Consolidation
1473561|NCT00083551|Melphalan
1473562|NCT00083538|Multiple Myeloma
1473563|NCT00083538|DTPACE
1473564|NCT00083538|Dexamethasone
1473565|NCT00083538|Thalidomide
1473566|NCT00083538|Cisplatin
1473567|NCT00083538|Cytoxan
1473568|NCT00083538|Doxorubicin
1473569|NCT00083538|Etoposide
1473570|NCT00083538|Dendritic Cell Vaccination
1473571|NCT00083538|Leukapheresis
1473572|NCT00083512|Blood
1473573|NCT00083512|Urine
1473574|NCT00083512|GBM
1473575|NCT00083512|Radiation
1473576|NCT00083512|Glioblastoma Multiforme
1473577|NCT00083499|Pental of Cantrell
1473578|NCT00083499|TAS Syndrome
1473579|NCT00083499|Midline Defects
1473580|NCT00083499|Contractile Proteins
1473581|NCT00083499|Herniation
1473582|NCT00083499|Nonmuscle Myosin IIC
1473583|NCT00083499|Pentalogy of Cantrell
1473584|NCT00083499|Non-muscle Myosin Heavy Chain Genes
1473585|NCT00083473|Leukemia Lymphocytic Chronic,
1473586|NCT00083473|Pivanex,
1473587|NCT00083473|Histone deacetylase inhibitor
1473588|NCT00083460|Multiple Myeloma
1473589|NCT00083460|Thalidomide
1473590|NCT00083460|Velcade
1473591|NCT00083460|PS-341
1473592|NCT00083460|Refractory
1473593|NCT00083460|Bortezomid
1473594|NCT00083447|brain tumor
1473595|NCT00083447|GBM
1473596|NCT00083447|glioblastoma
1473597|NCT00083447|glioblastoma multiforme
1473598|NCT00083447|brain cancer
1473599|NCT00083447|treatment
1473600|NCT00083434|Anemia
1473601|NCT00083434|Cancer
1473602|NCT00083408|Multiple Myeloma
1473603|NCT00083408|Pamidronate
1473604|NCT00083408|Thalidomide
1473605|NCT00083408|refractory myeloma
1473606|NCT00083408|bisphosphonates
1473607|NCT00083408|Aredia
1473608|NCT00083395|ARVC/ARVD
1473609|NCT00083395|Genetics
1473610|NCT00083395|Sudden Death
1473611|NCT00083395|Heart
1473612|NCT00083395|MRI
1473613|NCT00083395|Cardiomyopathy
1473614|NCT00083395|Arrhythmogenic Right Ventricular
1473615|NCT00083395|ARVC
1473616|NCT00083395|Healthy Volunteer
1473617|NCT00083395|HV
1473618|NCT00083382|Myeloma
1473619|NCT00083382|Thalidomide
1473620|NCT00083382|Pamidronate
1473621|NCT00083382|Aredia
1473622|NCT00083382|Bisphosphonate
1473623|NCT00083382|Anti-Angiogenesis
1473624|NCT00083382|Smoldering/Indolent Myeloma
1473625|NCT00083382|Zometa
1473626|NCT00083356|Pain
1473627|NCT00083356|Kinins
1473628|NCT00083356|Inflammation
1473629|NCT00083356|Gene Expression
1473630|NCT00083356|Oral Surgey
1473631|NCT00083356|Bradykinin B1 Receptors
1473632|NCT00083356|Acute Peripheral Inflammation
1473633|NCT00083356|Inflammatory Gene Expression
1473634|NCT00083356|Wisdom Teeth
1473635|NCT00083356|Third Molar Extraction
1473636|NCT00083330|Healthy
1473637|NCT00083330|T Cells
1473638|NCT00083330|Immunity
1473639|NCT00083330|Healthy Volunteer
1473640|NCT00083330|HV
1473641|NCT00083317|PFC
1473642|NCT00083317|Competition
1473643|NCT00083317|Bargaining Games
1473644|NCT00083317|Hyper-Brain Scanning
1473645|NCT00083317|fMRI
1473646|NCT00083317|Healthy Volunteer
1473647|NCT00083317|HV
1473648|NCT00083304|Breast
1473649|NCT00083304|Brain
1473650|NCT00083304|RSR13
1473651|NCT00083304|efaproxiral
1473652|NCT00083304|Whole Brain Radiation Therapy
1473653|NCT00083304|Brain metastases
1473654|NCT00083304|Metastatic breast cancer
1473655|NCT00083291|Dry Eyes
1473656|NCT00083291|Conjunctiva
1473657|NCT00083291|Infection
1473658|NCT00083291|Antibodies
1473659|NCT00083291|Inflammation
1473660|NCT00083291|Ocular Surface Disease
1473661|NCT00083291|Helicobacter Pylori
1473662|NCT00083278|Breast Cancer
1473663|NCT00083278|Stage IV adenocarcinoma of the breast
1473664|NCT00083265|Adenosine Receptor
1473665|NCT00083265|Panic Disorder
1473666|NCT00083265|Polymorphism
1473667|NCT00083265|Challenge Study
1473668|NCT00083265|Caffeine
1473669|NCT00083265|Healthy Volunteer
1473670|NCT00083265|HV
1473671|NCT00083226|doxorubicin
1473672|NCT00083226|doxorubicin hydrochloride
1473673|NCT00083226|bortezomib
1473674|NCT00083226|hepatocellular carcinoma
1473675|NCT00083213|recurrent grade 1 follicular lymphoma
1473676|NCT00083213|stage IV grade 1 follicular lymphoma
1473677|NCT00083213|recurrent grade 2 follicular lymphoma
1473678|NCT00083213|stage IV grade 2 follicular lymphoma
1473679|NCT00083213|recurrent grade 3 follicular lymphoma
1473680|NCT00083213|stage IV grade 3 follicular lymphoma
1473681|NCT00083213|recurrent adult diffuse small cleaved cell lymphoma
1473682|NCT00083213|stage IV adult diffuse small cleaved cell lymphoma
1473683|NCT00083213|recurrent adult diffuse large cell lymphoma
1473684|NCT00083213|stage IV adult diffuse large cell lymphoma
1473685|NCT00083213|stage IV adult diffuse mixed cell lymphoma
1473686|NCT00083213|recurrent adult diffuse mixed cell lymphoma
1473687|NCT00083213|recurrent adult immunoblastic large cell lymphoma
1473688|NCT00083213|stage IV adult immunoblastic large cell lymphoma
1473689|NCT00083213|recurrent adult Burkitt lymphoma
1473690|NCT00083213|stage IV adult Burkitt lymphoma
1473691|NCT00083213|recurrent mantle cell lymphoma
1473692|NCT00083213|stage IV mantle cell lymphoma
1473693|NCT00083213|recurrent adult lymphoblastic lymphoma
1473694|NCT00083213|stage IV adult lymphoblastic lymphoma
1473695|NCT00083213|unspecified adult solid tumor, protocol specific
1473696|NCT00083213|recurrent adult soft tissue sarcoma
1473697|NCT00083213|recurrent adult primary liver cancer
1473698|NCT00083213|advanced adult primary liver cancer
1473699|NCT00083213|recurrent cervical cancer
1473700|NCT00083213|stage IVA cervical cancer
1473701|NCT00083213|stage IVB cervical cancer
1473702|NCT00083213|fallopian tube cancer
1473703|NCT00083213|ovarian sarcoma
1473704|NCT00083213|recurrent ovarian epithelial cancer
1473705|NCT00083213|stage IV ovarian epithelial cancer
1473706|NCT00083213|recurrent endometrial carcinoma
1473707|NCT00083213|stage IV endometrial carcinoma
1473708|NCT00083213|recurrent uterine sarcoma
1473709|NCT00083213|stage IV uterine sarcoma
1473710|NCT00083213|recurrent ovarian germ cell tumor
1473711|NCT00083213|stage IV ovarian germ cell tumor
1473712|NCT00083213|ovarian stromal cancer
1473713|NCT00083213|recurrent vaginal cancer
1473714|NCT00083213|stage IVA vaginal cancer
1473715|NCT00083213|stage IVB vaginal cancer
1473716|NCT00083213|recurrent prostate cancer
1473717|NCT00083213|stage IV prostate cancer
1473718|NCT00083213|recurrent penile cancer
1473719|NCT00083213|stage IV penile cancer
1473720|NCT00083213|recurrent malignant testicular germ cell tumor
1473721|NCT00083213|stage III malignant testicular germ cell tumor
1473722|NCT00083213|recurrent bladder cancer
1473723|NCT00083213|stage IV bladder cancer
1473724|NCT00083213|recurrent vulvar cancer
1473725|NCT00083213|stage IVB vulvar cancer
1473726|NCT00083213|distal urethral cancer
1473727|NCT00083213|proximal urethral cancer
1473728|NCT00083213|recurrent urethral cancer
1473729|NCT00083213|urethral cancer associated with invasive bladder cancer
1473730|NCT00083213|primary peritoneal cavity cancer
1473731|NCT00083213|recurrent marginal zone lymphoma
1473732|NCT00083213|recurrent small lymphocytic lymphoma
1473733|NCT00083213|stage IV small lymphocytic lymphoma
1473734|NCT00083213|stage IV marginal zone lymphoma
1473735|NCT00083213|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1473736|NCT00083213|nodal marginal zone B-cell lymphoma
1473737|NCT00083213|splenic marginal zone lymphoma
1473738|NCT00083213|stage IV adult soft tissue sarcoma
1473739|NCT00083187|recurrent adult acute myeloid leukemia
1473740|NCT00083187|untreated adult acute myeloid leukemia
1473741|NCT00083187|atypical chronic myeloid leukemia, BCR-ABL1 negative
1473742|NCT00083187|chronic myelomonocytic leukemia
1473743|NCT00083187|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1473744|NCT00083187|secondary myelodysplastic syndromes
1473745|NCT00083187|de novo myelodysplastic syndromes
1473746|NCT00083187|adult acute myeloid leukemia with t(8;21)(q22;q22)
1473747|NCT00083187|adult acute myeloid leukemia with t(16;16)(p13;q22)
1473748|NCT00083187|adult acute myeloid leukemia with inv(16)(p13;q22)
1473749|NCT00083187|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1473750|NCT00083187|adult acute myeloid leukemia with t(15;17)(q22;q12)
1473751|NCT00083174|breast cancer
1473752|NCT00083161|extensive stage small cell lung cancer
1473753|NCT00083161|recurrent small cell lung cancer
1473754|NCT00083148|recurrent breast cancer
1473755|NCT00083148|stage IV breast cancer
1473756|NCT00083135|recurrent neuroblastoma
1473757|NCT00083096|recurrent adult brain tumor
1473758|NCT00083096|adult mixed glioma
1473759|NCT00083096|adult anaplastic astrocytoma
1473760|NCT00083096|adult anaplastic oligodendroglioma
1473761|NCT00083096|adult glioblastoma
1473762|NCT00083096|adult pilocytic astrocytoma
1473763|NCT00083096|adult anaplastic ependymoma
1473764|NCT00083096|adult subependymoma
1473765|NCT00083096|adult myxopapillary ependymoma
1473766|NCT00083096|adult oligodendroglioma
1473767|NCT00083096|adult giant cell glioblastoma
1473768|NCT00083096|adult gliosarcoma
1473769|NCT00083096|adult diffuse astrocytoma
1473770|NCT00083096|adult subependymal giant cell astrocytoma
1473771|NCT00083096|adult pineal gland astrocytoma
1473772|NCT00083083|stage II non-small cell lung cancer
1473773|NCT00083083|stage IIIA non-small cell lung cancer
1473774|NCT00083083|stage IIIB non-small cell lung cancer
1473775|NCT00083070|recurrent childhood acute lymphoblastic leukemia
1473776|NCT00083070|recurrent childhood acute myeloid leukemia
1473777|NCT00083070|relapsing chronic myelogenous leukemia
1473778|NCT00083070|childhood acute promyelocytic leukemia (M3)
1473779|NCT00083070|blastic phase chronic myelogenous leukemia
1473780|NCT00083057|stage III squamous cell carcinoma of the lip and oral cavity
1473781|NCT00083057|stage IV squamous cell carcinoma of the lip and oral cavity
1473782|NCT00083057|recurrent squamous cell carcinoma of the lip and oral cavity
1473783|NCT00083057|stage III squamous cell carcinoma of the hypopharynx
1473784|NCT00083057|stage IV squamous cell carcinoma of the hypopharynx
1473785|NCT00083057|recurrent squamous cell carcinoma of the hypopharynx
1473786|NCT00083057|stage III squamous cell carcinoma of the oropharynx
1473787|NCT00083057|stage IV squamous cell carcinoma of the oropharynx
1473788|NCT00083057|recurrent squamous cell carcinoma of the oropharynx
1473789|NCT00083057|recurrent squamous cell carcinoma of the nasopharynx
1473790|NCT00083057|stage III squamous cell carcinoma of the nasopharynx
1473791|NCT00083057|stage IV squamous cell carcinoma of the nasopharynx
1473792|NCT00083057|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1473793|NCT00083057|recurrent squamous cell carcinoma of the larynx
1473794|NCT00083057|stage III squamous cell carcinoma of the larynx
1473795|NCT00083057|stage IV squamous cell carcinoma of the larynx
1473796|NCT00083044|breast cancer
1473797|NCT00083044|breast cancer in situ
1473798|NCT00083044|stage I breast cancer
1473799|NCT00083044|lobular breast carcinoma in situ
1473800|NCT00083044|ductal breast carcinoma in situ
1473801|NCT00083031|recurrent breast cancer
1473802|NCT00083031|stage IV breast cancer
1473803|NCT00083018|stage II breast cancer
1473804|NCT00083018|stage IIIA breast cancer
1473805|NCT00083018|stage IIIB breast cancer
1473806|NCT00083018|stage IIIC breast cancer
1473807|NCT00083018|stage IA breast cancer
1473808|NCT00083018|stage IB breast cancer
1473809|NCT00083005|adenocarcinoma of the prostate
1473810|NCT00083005|recurrent prostate cancer
1473811|NCT00083005|stage IV prostate cancer
1473812|NCT00082979|breast cancer
1473813|NCT00082940|B-cell chronic lymphocytic leukemia
1473814|NCT00082940|refractory chronic lymphocytic leukemia
1473815|NCT00082927|stage IV prostate cancer
1473816|NCT00082927|bone metastases
1473817|NCT00082927|pain
1473818|NCT00082927|recurrent prostate cancer
1473819|NCT00082914|recurrent renal cell cancer
1473820|NCT00082914|stage IV renal cell cancer
1473821|NCT00082914|recurrent melanoma
1473822|NCT00082914|stage IV melanoma
1473823|NCT00082862|stage II pancreatic cancer
1473824|NCT00082862|stage III pancreatic cancer
1473825|NCT00082862|recurrent pancreatic cancer
1473826|NCT00082862|stage IV pancreatic cancer
1473827|NCT00082836|primary central nervous system non-Hodgkin lymphoma
1473828|NCT00082823|recurrent grade 1 follicular lymphoma
1473829|NCT00082823|stage IV grade 1 follicular lymphoma
1473830|NCT00082823|recurrent grade 2 follicular lymphoma
1473831|NCT00082823|stage IV grade 2 follicular lymphoma
1473832|NCT00082823|recurrent grade 3 follicular lymphoma
1473833|NCT00082823|stage IV grade 3 follicular lymphoma
1473834|NCT00082823|recurrent adult diffuse small cleaved cell lymphoma
1473835|NCT00082823|stage IV adult diffuse small cleaved cell lymphoma
1473836|NCT00082823|recurrent adult diffuse large cell lymphoma
1473837|NCT00082823|stage IV adult diffuse large cell lymphoma
1473838|NCT00082823|recurrent adult diffuse mixed cell lymphoma
1473839|NCT00082823|stage IV adult diffuse mixed cell lymphoma
1473840|NCT00082823|recurrent adult immunoblastic large cell lymphoma
1473841|NCT00082823|stage IV adult immunoblastic large cell lymphoma
1473842|NCT00082823|recurrent adult Burkitt lymphoma
1473843|NCT00082823|stage IV adult Burkitt lymphoma
1473844|NCT00082823|recurrent mantle cell lymphoma
1473845|NCT00082823|stage IV mantle cell lymphoma
1473846|NCT00082823|recurrent adult lymphoblastic lymphoma
1473847|NCT00082823|stage IV adult lymphoblastic lymphoma
1473848|NCT00082823|unspecified adult solid tumor, protocol specific
1473849|NCT00082823|recurrent adult soft tissue sarcoma
1473850|NCT00082823|advanced adult primary liver cancer
1473851|NCT00082823|recurrent adult primary liver cancer
1473852|NCT00082823|recurrent cervical cancer
1473853|NCT00082823|stage IVA cervical cancer
1473854|NCT00082823|stage IVB cervical cancer
1473855|NCT00082823|fallopian tube cancer
1473856|NCT00082823|ovarian sarcoma
1473857|NCT00082823|recurrent ovarian epithelial cancer
1473858|NCT00082823|stage IV ovarian epithelial cancer
1473859|NCT00082823|recurrent endometrial carcinoma
1473860|NCT00082823|stage IV endometrial carcinoma
1473861|NCT00082823|recurrent uterine sarcoma
1473862|NCT00082823|stage IV uterine sarcoma
1473863|NCT00082823|recurrent ovarian germ cell tumor
1473864|NCT00082823|stage IV ovarian germ cell tumor
1473865|NCT00082823|ovarian stromal cancer
1473866|NCT00082823|recurrent vaginal cancer
1473867|NCT00082823|stage IVA vaginal cancer
1473868|NCT00082823|stage IVB vaginal cancer
1473869|NCT00082823|recurrent prostate cancer
1473870|NCT00082823|stage IV prostate cancer
1473871|NCT00082823|recurrent penile cancer
1473872|NCT00082823|stage IV penile cancer
1473873|NCT00082823|recurrent malignant testicular germ cell tumor
1473874|NCT00082823|stage III malignant testicular germ cell tumor
1473875|NCT00082823|recurrent bladder cancer
1473876|NCT00082823|stage IV bladder cancer
1473877|NCT00082823|recurrent vulvar cancer
1473878|NCT00082823|stage IVB vulvar cancer
1473879|NCT00082823|distal urethral cancer
1473880|NCT00082823|proximal urethral cancer
1473881|NCT00082823|recurrent urethral cancer
1473882|NCT00082823|urethral cancer associated with invasive bladder cancer
1473883|NCT00082823|primary peritoneal cavity cancer
1473884|NCT00082823|recurrent marginal zone lymphoma
1473885|NCT00082823|recurrent small lymphocytic lymphoma
1473886|NCT00082823|stage IV small lymphocytic lymphoma
1473887|NCT00082823|stage IV marginal zone lymphoma
1473888|NCT00082823|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1473889|NCT00082823|nodal marginal zone B-cell lymphoma
1473890|NCT00082823|splenic marginal zone lymphoma
1473891|NCT00082823|stage IV adult soft tissue sarcoma
1473892|NCT00082797|adult glioblastoma
1473893|NCT00082797|adult giant cell glioblastoma
1473894|NCT00082797|adult gliosarcoma
1473895|NCT00082758|recurrent neuroblastoma
1473896|NCT00082732|stage I prostate cancer
1473897|NCT00082732|stage II prostate cancer
1473898|NCT00082732|adenocarcinoma of the prostate
1473899|NCT00082719|stage II bladder cancer
1473900|NCT00082719|stage III bladder cancer
1473901|NCT00082719|stage IV bladder cancer
1473902|NCT00082719|localized transitional cell cancer of the renal pelvis and ureter
1473903|NCT00082719|regional transitional cell cancer of the renal pelvis and ureter
1473904|NCT00082719|metastatic transitional cell cancer of the renal pelvis and ureter
1473905|NCT00082719|anterior urethral cancer
1473906|NCT00082719|posterior urethral cancer
1473907|NCT00082719|urethral cancer associated with invasive bladder cancer
1473908|NCT00082706|adenocarcinoma of the bladder
1473909|NCT00082706|recurrent bladder cancer
1473910|NCT00082706|stage IV bladder cancer
1473911|NCT00082706|recurrent urethral cancer
1473912|NCT00082706|anterior urethral cancer
1473913|NCT00082706|posterior urethral cancer
1473914|NCT00082706|urethral cancer associated with invasive bladder cancer
1473915|NCT00082706|stage III bladder cancer
1473916|NCT00082667|breast cancer in situ
1473917|NCT00082667|ductal breast carcinoma in situ
1473918|NCT00082654|psychosocial effects of cancer and its treatment
1473919|NCT00082654|accelerated phase chronic myelogenous leukemia
1473920|NCT00082654|adult acute lymphoblastic leukemia in remission
1473921|NCT00082654|adult acute myeloid leukemia in remission
1473922|NCT00082654|atypical chronic myeloid leukemia
1473923|NCT00082654|blastic phase chronic myelogenous leukemia
1473924|NCT00082654|chronic eosinophilic leukemia
1473925|NCT00082654|chronic idiopathic myelofibrosis
1473926|NCT00082654|chronic myelomonocytic leukemia
1473927|NCT00082654|chronic neutrophilic leukemia
1473928|NCT00082654|chronic phase chronic myelogenous leukemia
1473929|NCT00082654|de novo myelodysplastic syndromes
1473930|NCT00082654|disseminated neuroblastoma
1473931|NCT00082654|myelodysplastic/myeloproliferative disease, unclassifiable
1473932|NCT00082654|noncontiguous stage II adult Burkitt lymphoma
1473933|NCT00082654|noncontiguous stage II adult diffuse large cell lymphoma
1473934|NCT00082654|noncontiguous stage II adult diffuse mixed cell lymphoma
1473935|NCT00082654|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1473936|NCT00082654|noncontiguous stage II adult immunoblastic large cell lymphoma
1473937|NCT00082654|noncontiguous stage II adult lymphoblastic lymphoma
1473938|NCT00082654|noncontiguous stage II grade 1 follicular lymphoma
1473939|NCT00082654|noncontiguous stage II grade 2 follicular lymphoma
1473940|NCT00082654|noncontiguous stage II grade 3 follicular lymphoma
1473941|NCT00082654|noncontiguous stage II mantle cell lymphoma
1473942|NCT00082654|poor prognosis metastatic gestational trophoblastic tumor
1473943|NCT00082654|previously treated myelodysplastic syndromes
1473944|NCT00082654|recurrent adult acute lymphoblastic leukemia
1473945|NCT00082654|recurrent adult acute myeloid leukemia
1473946|NCT00082654|recurrent adult Burkitt lymphoma
1473947|NCT00082654|recurrent adult diffuse large cell lymphoma
1473948|NCT00082654|recurrent adult diffuse mixed cell lymphoma
1473949|NCT00082654|recurrent adult diffuse small cleaved cell lymphoma
1473950|NCT00082654|recurrent adult Hodgkin lymphoma
1473951|NCT00082654|recurrent adult immunoblastic large cell lymphoma
1473952|NCT00082654|recurrent adult lymphoblastic lymphoma
1473953|NCT00082654|recurrent cutaneous T-cell non-Hodgkin lymphoma
1473954|NCT00082654|recurrent grade 1 follicular lymphoma
1473955|NCT00082654|recurrent grade 2 follicular lymphoma
1473956|NCT00082654|recurrent grade 3 follicular lymphoma
1473957|NCT00082654|recurrent mantle cell lymphoma
1473958|NCT00082654|recurrent mycosis fungoides/Sezary syndrome
1473959|NCT00082654|recurrent neuroblastoma
1473960|NCT00082654|recurrent ovarian epithelial cancer
1473961|NCT00082654|recurrent ovarian germ cell tumor
1473962|NCT00082654|recurrent malignant testicular germ cell tumor
1473963|NCT00082654|refractory chronic lymphocytic leukemia
1473964|NCT00082654|refractory hairy cell leukemia
1473965|NCT00082654|refractory multiple myeloma
1473966|NCT00082654|relapsing chronic myelogenous leukemia
1473967|NCT00082654|secondary acute myeloid leukemia
1473968|NCT00082654|secondary myelodysplastic syndromes
1473969|NCT00082654|stage I multiple myeloma
1473970|NCT00082654|stage II multiple myeloma
1473971|NCT00082654|stage II ovarian epithelial cancer
1473972|NCT00082654|stage III adult Burkitt lymphoma
1473973|NCT00082654|stage III adult diffuse large cell lymphoma
1473974|NCT00082654|stage III adult diffuse mixed cell lymphoma
1473975|NCT00082654|stage III adult diffuse small cleaved cell lymphoma
1473976|NCT00082654|stage III adult immunoblastic large cell lymphoma
1473977|NCT00082654|stage III adult lymphoblastic lymphoma
1473978|NCT00082654|stage III chronic lymphocytic leukemia
1473979|NCT00082654|stage III grade 1 follicular lymphoma
1473980|NCT00082654|stage III grade 2 follicular lymphoma
1473981|NCT00082654|stage III grade 3 follicular lymphoma
1473982|NCT00082654|stage III mantle cell lymphoma
1473983|NCT00082654|stage III multiple myeloma
1473984|NCT00082654|stage III ovarian epithelial cancer
1473985|NCT00082654|stage III malignant testicular germ cell tumor
1473986|NCT00082654|stage IIIA breast cancer
1473987|NCT00082654|stage IIIB breast cancer
1473988|NCT00082654|stage IIIC breast cancer
1473989|NCT00082654|stage IV adult Burkitt lymphoma
1473990|NCT00082654|stage IV adult diffuse large cell lymphoma
1473991|NCT00082654|stage IV adult diffuse mixed cell lymphoma
1473992|NCT00082654|stage IV adult diffuse small cleaved cell lymphoma
1473993|NCT00082654|stage IV adult immunoblastic large cell lymphoma
1473994|NCT00082654|stage IV adult lymphoblastic lymphoma
1473995|NCT00082654|stage IV breast cancer
1473996|NCT00082654|stage IV chronic lymphocytic leukemia
1473997|NCT00082654|stage IV grade 1 follicular lymphoma
1473998|NCT00082654|stage IV grade 2 follicular lymphoma
1473999|NCT00082654|stage IV grade 3 follicular lymphoma
1474000|NCT00082654|stage IV mantle cell lymphoma
1474001|NCT00082654|stage IV ovarian epithelial cancer
1474002|NCT00082654|untreated adult acute lymphoblastic leukemia
1474003|NCT00082654|untreated adult acute myeloid leukemia
1474004|NCT00082654|noncontiguous stage II small lymphocytic lymphoma
1474005|NCT00082654|noncontiguous stage II marginal zone lymphoma
1474006|NCT00082654|recurrent marginal zone lymphoma
1474007|NCT00082654|recurrent small lymphocytic lymphoma
1474008|NCT00082654|stage III small lymphocytic lymphoma
1474009|NCT00082654|stage III marginal zone lymphoma
1474010|NCT00082654|stage IV small lymphocytic lymphoma
1474011|NCT00082654|stage IV marginal zone lymphoma
1474012|NCT00082654|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1474013|NCT00082654|nodal marginal zone B-cell lymphoma
1474014|NCT00082654|splenic marginal zone lymphoma
1474015|NCT00082654|adult acute myeloid leukemia with t(8;21)(q22;q22)
1474016|NCT00082654|adult acute myeloid leukemia with t(16;16)(p13;q22)
1474017|NCT00082654|adult acute myeloid leukemia with inv(16)(p13;q22)
1474018|NCT00082654|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1474019|NCT00082654|adult acute myeloid leukemia with t(15;17)(q22;q12)
1474020|NCT00082641|stage IIIA breast cancer
1474021|NCT00082641|stage IIIB breast cancer
1474022|NCT00082628|growth hormone
1474023|NCT00082628|Serostim®
1474024|NCT00082628|Human Adipose Redistribution Syndrome
1474025|NCT00082628|Human Immunodeficiency Virus lipodystrophy
1474026|NCT00082628|Treatment Experienced
1474027|NCT00082615|Movement Disorders
1474028|NCT00082615|Recovery Cycle
1474029|NCT00082615|Blink Reflex
1474030|NCT00082615|Cervical Dystonia
1474031|NCT00082615|Blepharospasm
1474032|NCT00082615|Dystonia
1474033|NCT00082615|Craniofacial Dystonia
1474034|NCT00082615|Healthy Volunteer
1474035|NCT00082615|HV
1474036|NCT00082602|galantamine
1474037|NCT00082602|Alzheimer's disease
1474038|NCT00082550|Genetics
1474039|NCT00082550|Serotonin Transporter
1474040|NCT00082550|Brain Imaging
1474041|NCT00082550|Neurotransmitter
1474042|NCT00082550|OCD
1474043|NCT00082550|Obsessive-Compulsive Disorder
1474044|NCT00082550|PET
1474045|NCT00082550|Obsessive Compulsive Disorder
1474046|NCT00082550|Healthy Volunteer
1474047|NCT00082550|HV
1474048|NCT00082511|Lupus
1474049|NCT00082511|Systemic Lupus Erythematosus
1474050|NCT00082511|SLE
1474051|NCT00082511|Bone Loss
1474052|NCT00082511|DHEA
1474053|NCT00082498|SCH-D
1474054|NCT00082498|Schering D
1474055|NCT00082498|Treatment Experienced
1474056|NCT00082498|Entry Inhibitors
1474057|NCT00082498|Fusion Inhibitors
1474058|NCT00082498|Vicriviroc
1474059|NCT00082485|Cocaine Dependence
1474060|NCT00082472|NSCLC
1474061|NCT00082472|Metastatic
1474062|NCT00082472|Unresectable
1474063|NCT00082472|No Prior Chemotherapy
1474064|NCT00082459|Kidney Cancer
1474065|NCT00082459|Renal
1474066|NCT00082459|Tumor
1474067|NCT00082459|Immunotherapy
1474068|NCT00082446|Smallpox, vaccine
1474069|NCT00082420|Vitamin A malnutrition
1474070|NCT00082420|low vitamin A status
1474071|NCT00082407|diabetes
1474072|NCT00082407|exendin
1474073|NCT00082407|Amylin
1474074|NCT00082407|Lilly
1474075|NCT00082407|insulin aspart
1474076|NCT00082394|safety
1474077|NCT00082394|drug efficacy
1474078|NCT00082394|TRIZIVIR
1474079|NCT00082394|tolerability
1474080|NCT00082394|COMBIVIR
1474081|NCT00082394|HIV
1474082|NCT00082394|atazanavir
1474083|NCT00082381|Diabetes
1474084|NCT00082381|Insulin glargine
1474085|NCT00082381|comparator
1474086|NCT00082381|Amylin
1474087|NCT00082381|Lilly
1474088|NCT00082368|Tariquidar
1474089|NCT00082368|PET
1474090|NCT00082368|Sestamibi
1474091|NCT00082368|Cancer
1474092|NCT00082355|r-tPA
1474093|NCT00082355|Thrombolysis
1474094|NCT00082355|Clot
1474095|NCT00082355|Anticoagulation
1474096|NCT00082355|Fibrinolysis
1474097|NCT00082355|Deep Vein Thrombosis
1474098|NCT00082355|DVT
1474099|NCT00082342|Human Brain
1474100|NCT00082342|Electrical Stimulation
1474101|NCT00082342|Parkinson Disease
1474102|NCT00082342|PD
1474103|NCT00082329|Hematopoietic Stem Cells
1474104|NCT00082329|PBSC's
1474105|NCT00082329|Mobilization
1474106|NCT00082329|Alloreactivity
1474107|NCT00082329|T Cell Polarization
1474108|NCT00082329|Dendritic Cells
1474109|NCT00082329|CXCR4
1474110|NCT00082329|Plerixafor
1474111|NCT00082329|Healthy Volunteer (HV)
1474112|NCT00082316|Dermal assessment
1474113|NCT00082316|Pain assessment
1474114|NCT00082316|Diary
1474115|NCT00082316|Analgesics
1474116|NCT00082316|Capsaicin
1474117|NCT00082316|Herpes zoster
1474118|NCT00082316|Neuralgia
1474119|NCT00082316|HIV Infections
1474120|NCT00082316|Peripheral Nervous System Diseases
1474121|NCT00082316|Diabetic Neuropathies
1474122|NCT00082316|Diabetes Mellitus
1474123|NCT00082316|Polyneuropathies
1474124|NCT00082316|Complementary Therapies
1474125|NCT00082303|Music Therapy
1474126|NCT00082303|Anxiety
1474127|NCT00082303|Depression
1474128|NCT00082290|unspecified adult solid tumor, protocol specific
1474129|NCT00082290|pain
1474130|NCT00082277|hormone-receptor positive, breast cancer
1474131|NCT00082277|Osteopenia
1474132|NCT00082277|Osteoporosis
1474133|NCT00082277|risk of fracture
1474134|NCT00082277|bone loss
1474135|NCT00082251|Dyslipidemia
1474136|NCT00082251|High Blood Cholesterol
1474137|NCT00082251|Coronary Heart Disease
1474138|NCT00082251|Hypertension
1474139|NCT00082251|National Cholesterol Education Program
1474140|NCT00082251|Adult Treatment Panel III
1474141|NCT00082251|Niacin
1474142|NCT00082251|Simvastatin
1474143|NCT00082251|Diabetes
1474144|NCT00082251|Peripheral Vascular Disease
1474145|NCT00082251|Cerebrovascular disease
1474146|NCT00082251|Stroke
1474147|NCT00082251|High-Density Lipoprotein Cholesterol
1474148|NCT00082251|Hydroxymethyl Glutaryl Coenzyme A
1474149|NCT00082251|High-Sensitivity C-Reactive Protein
1474150|NCT00082251|Low-Density Lipoprotein Cholesterol
1474151|NCT00082251|Lipoprotein (a)
1474152|NCT00082251|Lipoprotein A-I
1474153|NCT00082251|Total Cholesterol
1474154|NCT00082251|Triglycerides
1474155|NCT00082225|Hodgkins
1474156|NCT00082225|Non-Hodgkins
1474157|NCT00082225|Lymphoma
1474158|NCT00082212|ovarian
1474159|NCT00082212|primary peritoneal cancer
1474160|NCT00082212|Persistent or Recurrent Ovarian Cancer
1474161|NCT00082212|Primary Peritoneal Carcinoma
1474162|NCT00082160|Meditation
1474163|NCT00082160|Relaxation
1474168|NCT00082134|Prostate cancer
1474169|NCT00082134|Hormone-refractory prostate cancer
1474170|NCT00082134|HRPC
1474171|NCT00082134|Prostate
1474172|NCT00082134|Docetaxel
1474173|NCT00082134|PSA progression
1474174|NCT00082134|PSA progressed
1474175|NCT00082121|cardiac bypass
1474176|NCT00082121|CABG
1474177|NCT00082121|complement activation
1474178|NCT00082108|Registry
1474179|NCT00082108|FSHD
1474180|NCT00082108|DM
1474181|NCT00082108|Muscular Dystrophy
1474182|NCT00082108|Facioscapulohumeral Myotonic Dystrophy
1474183|NCT00082108|Myotonic Dystrophy
1474184|NCT00082108|DM1
1474185|NCT00082108|DM2
1474186|NCT00082108|FSH
1474187|NCT00082108|MMD
1474188|NCT00082095|Metastatic breast cancer
1474189|NCT00082095|Breast Cancer
1474190|NCT00082095|Pegylated Liposomal Doxorubicin
1474191|NCT00082095|Capecitabine
1474192|NCT00082095|DOXIL
1474193|NCT00082095|Xeloda
1474194|NCT00082069|Shigella
1474195|NCT00082069|diarrhea
1474196|NCT00082043|Neurosteroids
1474197|NCT00082043|5 Alpha-Reductase Inhibitor
1474198|NCT00082043|Depression
1474199|NCT00082043|Menstrual Cycle
1474200|NCT00082043|Gonadal Steroids
1474201|NCT00082043|Menstrual Cycle Related Mood Disorder
1474202|NCT00082043|MRMD
1474203|NCT00082043|Healthy Volunteer
1474204|NCT00082030|Depression
1474205|NCT00082030|PET
1474206|NCT00082030|fMRI
1474207|NCT00082030|Dopamine
1474208|NCT00082030|Norepinephrine Depletion
1474209|NCT00082030|Emotional Stimuli
1474210|NCT00082030|Anhedonia
1474211|NCT00082030|Norepinephrine
1474212|NCT00082030|Dopamine Depletion
1474213|NCT00082030|Major Depressive Disorder
1474214|NCT00082030|MDD
1474215|NCT00082030|Healthy Volunteer
1474216|NCT00082030|HV
1474217|NCT00082017|Protein Kinase Inhibition
1474218|NCT00082017|Soluble Tac
1474219|NCT00082017|Gene Expression Profiling
1474220|NCT00082017|ALK Expression
1474221|NCT00082017|Apoptosis
1474222|NCT00082017|Lymphoma
1474223|NCT00082017|Anaplastic Large Cell Lymphoma
1474224|NCT00082017|ALCL
1474225|NCT00082017|T-Cell Lymphoma
1474226|NCT00081991|Cataract
1474227|NCT00081991|Blindness
1474228|NCT00081991|Clinical
1474229|NCT00081991|Human Aging
1474230|NCT00081991|Dynamic Light Scattering (DLS)
1474231|NCT00081991|Aging-Related Lens Changes
1474232|NCT00081991|Early Cataract
1474233|NCT00081991|Lens
1474234|NCT00081991|AREDS Grading
1474235|NCT00081991|In Vivo
1474236|NCT00081991|Healthy Volunteer
1474237|NCT00081978|HIV infection
1474238|NCT00081978|TMC125
1474239|NCT00081978|Non-nucleoside reverse transcriptase inhibitor, TMC125-C223
1474240|NCT00081965|breast cancer in situ
1474241|NCT00081965|stage I breast cancer
1474242|NCT00081965|stage II breast cancer
1474243|NCT00081965|stage IIIA breast cancer
1474244|NCT00081965|stage IIIB breast cancer
1474245|NCT00081965|stage IV breast cancer
1474246|NCT00081965|recurrent breast cancer
1474247|NCT00081965|stage IIIC breast cancer
1474248|NCT00081965|hot flashes
1474249|NCT00081952|Postmenopause
1474250|NCT00081926|CML
1474251|NCT00081926|Chronic Myelogenous Leukemia
1474252|NCT00081926|RIGHT Trial
1474253|NCT00081926|US177
1474254|NCT00081926|CSTI571
1474255|NCT00081913|Apheresis
1474256|NCT00081913|Cell Transfer
1474257|NCT00081913|Chest Pain
1474258|NCT00081913|Adult Stem Cell Therapy
1474259|NCT00081900|Carcinoma, Hepatocellular
1474260|NCT00081887|Chronic Lymphocytic Leukemia
1474261|NCT00081887|CLL
1474262|NCT00081887|Leukemia
1474263|NCT00081887|Clofarabine
1474264|NCT00081887|Clofarex
1474265|NCT00081887|Clolar
1474266|NCT00081874|Leukemia
1474267|NCT00081874|Mantle cell lymphoma
1474268|NCT00081874|Myelofibrosis
1474269|NCT00081874|Relapsed or Refractory Acute Myeloid Leukemia
1474270|NCT00081874|Acute Lymphocytic Leukemia
1474271|NCT00081874|Chronic Myeloid Leukemia in Blastic-Phase
1474272|NCT00081874|Agnogenic Myeloid Metaplasia
1474273|NCT00081874|Chronic Lymphocytic Leukemia
1474274|NCT00081874|T-Cell Leukemia
1474275|NCT00081874|RAD001
1474276|NCT00081874|Everolimus
1474277|NCT00081874|Afinitor
1474278|NCT00081861|Non-Hodgkin's Lymphoma
1474279|NCT00081861|B-Cell Lymphoma
1474280|NCT00081861|Lymphoma
1474281|NCT00081861|Avastin
1474282|NCT00081861|Bevacizumab
1474283|NCT00081861|Rituximab
1474284|NCT00081861|Rituxan
1474285|NCT00081848|Colon Cancer
1474286|NCT00081848|Gastrointestinal Cancer
1474287|NCT00081848|Cytokines
1474288|NCT00081848|Immunotherapy
1474289|NCT00081848|Cancer
1474290|NCT00081848|Solid Tumor
1474291|NCT00081848|Liver Metastasis
1474292|NCT00081835|Smallpox
1474293|NCT00081835|Cowpox
1474294|NCT00081835|Corneal Ulcer
1474295|NCT00081835|Keratitis
1474296|NCT00081835|Immune Response, Vaccine
1474297|NCT00081835|Cornea
1474298|NCT00081835|Vaccinia
1474299|NCT00081835|Vaccinia Immune Globulin (VIG)
1474300|NCT00081835|Conjunctivitis
1474301|NCT00081835|Vaccinia Vaccination
1474302|NCT00081835|Smallpox Vaccination
1474303|NCT00081822|Foran
1474304|NCT00081822|clofarabine
1474305|NCT00081822|cytosine arabinoside
1474306|NCT00081822|acute myeloid leukemia
1474307|NCT00081809|non-Hodgkin's lymphoma
1474308|NCT00081809|Brill-Symmers Disease
1474309|NCT00081809|Follicular Lymphoma
1474310|NCT00081809|Lymphoma, Giant Follicular
1474311|NCT00081809|Lymphoma, Nodular
1474312|NCT00081809|Follicular Lymphoma, Giant
1474313|NCT00081809|Giant Follicular Lymphoma
1474314|NCT00081809|Lymphocytic Lymphoma, Diffuse, Well-Differentiated
1474315|NCT00081809|Lymphocytic Lymphoma, Well-Differentiated
1474316|NCT00081809|Lymphoma, Lymphocytic, Diffuse, Well-Differentiated
1474317|NCT00081809|Lymphoma, Lymphocytic, Well-Differentiated
1474318|NCT00081809|Lymphoma, Lymphoplasmacytoid, CLL
1474319|NCT00081809|Lymphoma, Small Lymphocytic, Plasmacytoid
1474320|NCT00081809|Lymphoplasmacytoid Lymphoma, CLL
1474321|NCT00081809|Diffuse Well-Differentiated Lymphocytic Lymphoma
1474322|NCT00081809|Lymphocytic Lymphoma, Diffuse, Well Differentiated
1474323|NCT00081809|Lymphocytic Lymphoma, Well Differentiated
1474324|NCT00081809|Lymphoma, Lymphocytic, Diffuse, Well Differentiated
1474325|NCT00081809|Lymphoma, Lymphocytic, Well Differentiated
1474326|NCT00081809|Lymphoma, Mucosa-Associated Lymphoid Tissue
1474327|NCT00081809|MALT Lymphoma
1474328|NCT00081809|Lymphoma of Mucosa-Associated Lymphoid Tissue
1474329|NCT00081809|Mucosa-Associated Lymphoid Tissue Lymphoma
1474330|NCT00081809|Monocytoid B-cell lymphoma
1474331|NCT00081809|Waldenstrom's macroglobulinemia
1474332|NCT00081809|Marginal zone lymphoma
1474333|NCT00081796|Metastatic Breast Cancer
1474334|NCT00081783|T Cells
1474335|NCT00081783|Immunotherapy
1474336|NCT00081783|NHL
1474337|NCT00081783|Xcellerated T Cells
1474338|NCT00081757|Advanced
1474339|NCT00081757|Refractory
1474340|NCT00081757|Plasmacytoma
1474341|NCT00081757|Myeloma Proteins
1474342|NCT00081744|Bacterial Infections
1474343|NCT00081640|HIV Seronegativity
1474344|NCT00081640|Vaginal Microbicide
1474345|NCT00081614|Metastatic renal cell carcinoma
1474346|NCT00081601|prostate cancer
1474347|NCT00081601|prostate specific antigen
1474348|NCT00081601|PSA
1474349|NCT00081588|TMC114-C215
1474350|NCT00081588|Ritonavir
1474351|NCT00081588|HIV infections
1474352|NCT00081588|TMC114-C202
1474353|NCT00081588|TMC114-C213
1474354|NCT00081575|Bacterial Pneumonia
1474355|NCT00081549|Pancreatic Cancer
1474356|NCT00081549|Neoplasms Pancreatic
1474357|NCT00081549|Pancreas Cancer
1474358|NCT00081549|Pancreas Neoplasms
1474359|NCT00081549|Pancreatic Tumor
1474360|NCT00081549|Pancreas Tumor
1474361|NCT00081549|Unresectable
1474362|NCT00081549|Metastatic
1474363|NCT00081549|Refractory
1474364|NCT00081536|Colorectal Neoplasms
1474365|NCT00081536|Colorectal Cancer
1474366|NCT00081536|Colorectal Carcinoma
1474367|NCT00081536|Colorectal Tumor
1474368|NCT00081536|Neoplasms, Colorectal
1474369|NCT00081536|Unresectable
1474370|NCT00081536|Metastatic
1474371|NCT00081536|Refractory
1474372|NCT00081523|Hemoglobin
1474373|NCT00081523|Pain Crisis
1474374|NCT00081523|Treatment Options
1474375|NCT00081523|Sickle Cell Disease
1474376|NCT00081523|Sickle Cell Trait
1474377|NCT00081523|Red Blood Cell Disorder
1474378|NCT00081523|Thalassemia
1474379|NCT00081523|Paroxysmal Nocturnal Hemoglobinuria
1474380|NCT00081523|Hemolytic Disorders
1474381|NCT00081497|alpha-galactosidase A
1474382|NCT00081497|a-GAL
1474383|NCT00081497|r-haGAL
1474384|NCT00081497|Fabry
1474385|NCT00081497|GL-3
1474386|NCT00081497|Fabrazyme
1474387|NCT00081458|Short Bowel Syndrome
1474388|NCT00081458|Parenteral Nutrition
1474389|NCT00081458|SBS
1474390|NCT00081432|Seizures
1474391|NCT00081432|Language
1474392|NCT00081432|Memory
1474393|NCT00081432|Brain
1474394|NCT00081432|Imaging
1474395|NCT00081432|Epilepsy
1474396|NCT00081432|Temporal Lobe Epilepsy
1474397|NCT00081419|Bereitschaftspotential
1474398|NCT00081419|Timing of Volition
1474399|NCT00081419|Urge
1474400|NCT00081419|Conscious Will
1474401|NCT00081419|Libet's Clock
1474402|NCT00081419|Tourette Syndrome
1474403|NCT00081419|Tic Disorder
1474404|NCT00081419|Healthy Volunteer
1474405|NCT00081419|HV
1474406|NCT00081380|Bipolar I Disorder
1474407|NCT00081380|Manic Depressive Disorder
1474408|NCT00081380|Manic Depression, Mixed
1474409|NCT00081367|Minority Groups
1474420|NCT00081315|- Non-Small cell lung cancer
1474421|NCT00081302|stage IIIA non-small cell lung cancer
1474422|NCT00081302|stage IIIB non-small cell lung cancer
1474423|NCT00081302|squamous cell lung cancer
1474424|NCT00081302|large cell lung cancer
1474425|NCT00081302|adenocarcinoma of the lung
1474426|NCT00081302|bronchoalveolar cell lung cancer
1474427|NCT00081289|stage III rectal cancer
1474428|NCT00081289|adenocarcinoma of the rectum
1474429|NCT00081289|stage II rectal cancer
1474430|NCT00081250|unspecified adult solid tumor, protocol specific
1474431|NCT00081250|cachexia
1474432|NCT00081250|anorexia
1474433|NCT00081250|weight changes
1474434|NCT00081237|recurrent colon cancer
1474435|NCT00081237|stage III colon cancer
1474436|NCT00081237|stage IV colon cancer
1474437|NCT00081237|recurrent rectal cancer
1474438|NCT00081237|stage III rectal cancer
1474439|NCT00081237|stage IV rectal cancer
1474440|NCT00081224|adenocarcinoma of the rectum
1474441|NCT00081224|stage II rectal cancer
1474442|NCT00081224|stage III rectal cancer
1474443|NCT00081172|adenocarcinoma of the prostate
1474444|NCT00081172|recurrent prostate cancer
1474445|NCT00081172|stage IV prostate cancer
1474446|NCT00081159|recurrent prostate cancer
1474447|NCT00081159|stage IV prostate cancer
1474448|NCT00081159|bone metastases
1474449|NCT00081133|accelerated phase chronic myelogenous leukemia
1474450|NCT00081133|blastic phase chronic myelogenous leukemia
1474451|NCT00081133|recurrent adult acute lymphoblastic leukemia
1474452|NCT00081133|untreated adult acute lymphoblastic leukemia
1474453|NCT00081107|recurrent non-small cell lung cancer
1474454|NCT00081107|stage IIIB non-small cell lung cancer
1474455|NCT00081107|stage IV non-small cell lung cancer
1474456|NCT00081094|adult primary hepatocellular carcinoma
1474457|NCT00081094|recurrent adult primary liver cancer
1474458|NCT00081094|localized resectable adult primary liver cancer
1474459|NCT00081068|Waldenström macroglobulinemia
1474460|NCT00081055|graft versus host disease
1474461|NCT00081055|adult acute lymphoblastic leukemia in remission
1474462|NCT00081055|recurrent adult acute lymphoblastic leukemia
1474463|NCT00081055|adult acute myeloid leukemia in remission
1474464|NCT00081055|recurrent adult acute myeloid leukemia
1474465|NCT00081055|accelerated phase chronic myelogenous leukemia
1474466|NCT00081055|chronic phase chronic myelogenous leukemia
1474467|NCT00081055|refractory anemia
1474468|NCT00081055|refractory anemia with excess blasts
1474469|NCT00081055|refractory anemia with ringed sideroblasts
1474470|NCT00081055|de novo myelodysplastic syndromes
1474471|NCT00081055|previously treated myelodysplastic syndromes
1474472|NCT00081055|secondary myelodysplastic syndromes
1474473|NCT00081055|adult acute myeloid leukemia with t(8;21)(q22;q22)
1474474|NCT00081055|adult acute myeloid leukemia with t(16;16)(p13;q22)
1474475|NCT00081055|adult acute myeloid leukemia with inv(16)(p13;q22)
1474476|NCT00081055|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1474477|NCT00081055|adult acute myeloid leukemia with t(15;17)(q22;q12)
1474478|NCT00081042|recurrent melanoma
1474479|NCT00081042|stage III melanoma
1474480|NCT00081042|stage IV melanoma
1474481|NCT00081029|xerostomia
1474482|NCT00081029|radiation toxicity
1474483|NCT00081029|stage I squamous cell carcinoma of the hypopharynx
1474484|NCT00081029|stage I squamous cell carcinoma of the oropharynx
1474485|NCT00081029|stage II squamous cell carcinoma of the hypopharynx
1474486|NCT00081029|stage II squamous cell carcinoma of the oropharynx
1474487|NCT00081029|stage III squamous cell carcinoma of the hypopharynx
1474488|NCT00081029|stage III squamous cell carcinoma of the oropharynx
1474489|NCT00081029|stage IV squamous cell carcinoma of the hypopharynx
1474490|NCT00081029|stage IV squamous cell carcinoma of the oropharynx
1474491|NCT00081003|breast cancer
1474709|NCT00080431|Immunosuppression
1474492|NCT00080977|recurrent renal cell cancer
1474493|NCT00080977|stage IV renal cell cancer
1474494|NCT00080951|stage IV colon cancer
1474495|NCT00080951|stage IV rectal cancer
1474496|NCT00080951|adenocarcinoma of the colon
1474497|NCT00080951|adenocarcinoma of the rectum
1474498|NCT00080938|recurrent non-small cell lung cancer
1474499|NCT00080938|stage IV non-small cell lung cancer
1474500|NCT00080938|squamous cell lung cancer
1474501|NCT00080938|adenocarcinoma of the lung
1474502|NCT00080938|large cell lung cancer
1474503|NCT00080938|bronchoalveolar cell lung cancer
1474504|NCT00080938|adenosquamous cell lung cancer
1474505|NCT00080938|tumors metastatic to brain
1474506|NCT00080925|prolymphocytic leukemia
1474507|NCT00080925|accelerated phase chronic myelogenous leukemia
1474508|NCT00080925|chronic phase chronic myelogenous leukemia
1474509|NCT00080925|relapsing chronic myelogenous leukemia
1474510|NCT00080925|refractory chronic lymphocytic leukemia
1474511|NCT00080925|de novo myelodysplastic syndromes
1474512|NCT00080925|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1474513|NCT00080925|previously treated myelodysplastic syndromes
1474514|NCT00080925|secondary myelodysplastic syndromes
1474515|NCT00080925|secondary acute myeloid leukemia
1474516|NCT00080925|recurrent adult Hodgkin lymphoma
1474517|NCT00080925|refractory anemia with excess blasts
1474518|NCT00080925|refractory multiple myeloma
1474519|NCT00080925|primary myelofibrosis
1474520|NCT00080925|recurrent adult diffuse large cell lymphoma
1474521|NCT00080925|recurrent adult diffuse mixed cell lymphoma
1474522|NCT00080925|recurrent adult diffuse small cleaved cell lymphoma
1474523|NCT00080925|recurrent adult immunoblastic large cell lymphoma
1474524|NCT00080925|recurrent adult lymphoblastic lymphoma
1474525|NCT00080925|recurrent grade 1 follicular lymphoma
1474526|NCT00080925|recurrent grade 2 follicular lymphoma
1474527|NCT00080925|recurrent grade 3 follicular lymphoma
1474528|NCT00080925|recurrent adult Burkitt lymphoma
1474529|NCT00080925|recurrent mantle cell lymphoma
1474530|NCT00080925|adult acute lymphoblastic leukemia in remission
1474531|NCT00080925|adult acute myeloid leukemia in remission
1474532|NCT00080925|chronic myelomonocytic leukemia
1474533|NCT00080925|polycythemia vera
1474534|NCT00080925|essential thrombocythemia
1474535|NCT00080925|stage II multiple myeloma
1474536|NCT00080925|stage III multiple myeloma
1474537|NCT00080925|recurrent marginal zone lymphoma
1474538|NCT00080925|recurrent small lymphocytic lymphoma
1474539|NCT00080925|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1474540|NCT00080925|nodal marginal zone B-cell lymphoma
1474541|NCT00080925|splenic marginal zone lymphoma
1474542|NCT00080925|adult acute myeloid leukemia with t(8;21)(q22;q22)
1474543|NCT00080925|adult acute myeloid leukemia with t(16;16)(p13;q22)
1474544|NCT00080925|adult acute myeloid leukemia with inv(16)(p13;q22)
1474545|NCT00080925|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1474546|NCT00080925|adult acute myeloid leukemia with t(15;17)(q22;q12)
1474547|NCT00080912|bone metastases
1474548|NCT00080912|pain
1474549|NCT00080886|recurrent adult Burkitt lymphoma
1474550|NCT00080886|recurrent adult diffuse large cell lymphoma
1474551|NCT00080886|recurrent adult diffuse mixed cell lymphoma
1474552|NCT00080886|recurrent adult diffuse small cleaved cell lymphoma
1474553|NCT00080886|recurrent adult immunoblastic large cell lymphoma
1474554|NCT00080886|recurrent adult lymphoblastic lymphoma
1474555|NCT00080886|recurrent grade 1 follicular lymphoma
1474556|NCT00080886|recurrent grade 2 follicular lymphoma
1474557|NCT00080886|recurrent grade 3 follicular lymphoma
1474558|NCT00080886|recurrent mantle cell lymphoma
1474559|NCT00080886|recurrent marginal zone lymphoma
1474560|NCT00080886|recurrent small lymphocytic lymphoma
1474561|NCT00080886|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1474562|NCT00080886|nodal marginal zone B-cell lymphoma
1474563|NCT00080886|splenic marginal zone lymphoma
1474564|NCT00080873|oral complications
1474565|NCT00080873|disseminated neuroblastoma
1474566|NCT00080873|previously treated childhood rhabdomyosarcoma
1474567|NCT00080873|recurrent Wilms tumor and other childhood kidney tumors
1474568|NCT00080873|recurrent/refractory childhood Hodgkin lymphoma
1474569|NCT00080873|recurrent childhood acute lymphoblastic leukemia
1474570|NCT00080873|recurrent childhood acute myeloid leukemia
1474571|NCT00080873|recurrent childhood large cell lymphoma
1474572|NCT00080873|recurrent childhood lymphoblastic lymphoma
1474573|NCT00080873|recurrent childhood rhabdomyosarcoma
1474574|NCT00080873|recurrent childhood small noncleaved cell lymphoma
1474575|NCT00080873|untreated childhood acute lymphoblastic leukemia
1474576|NCT00080873|untreated childhood acute myeloid leukemia and other myeloid malignancies
1474577|NCT00080873|childhood acute lymphoblastic leukemia in remission
1474578|NCT00080873|childhood acute myeloid leukemia in remission
1474579|NCT00080873|childhood chronic myelogenous leukemia
1474580|NCT00080873|juvenile myelomonocytic leukemia
1474581|NCT00080873|recurrent neuroblastoma
1474582|NCT00080860|stage II breast cancer
1474583|NCT00080860|stage IIIA breast cancer
1474584|NCT00080860|stage IIIB breast cancer
1474585|NCT00080860|stage IIIC breast cancer
1474586|NCT00080860|stage IV breast cancer
1474587|NCT00080834|adenocarcinoma of the colon
1474588|NCT00080834|adenocarcinoma of the rectum
1474589|NCT00080834|recurrent colon cancer
1474590|NCT00080834|recurrent rectal cancer
1474591|NCT00080834|stage III colon cancer
1474592|NCT00080834|stage IV colon cancer
1474593|NCT00080834|stage III rectal cancer
1474594|NCT00080834|stage IV rectal cancer
1474595|NCT00080808|perioperative/postoperative complications
1474596|NCT00080808|sexual dysfunction and infertility
1474597|NCT00080808|sexuality and reproductive issues
1474598|NCT00080808|adenocarcinoma of the prostate
1474599|NCT00080808|stage I prostate cancer
1474600|NCT00080808|stage II prostate cancer
1474601|NCT00080808|prostaglandin E1
1474602|NCT00080808|papaverine
1474603|NCT00080808|phentolamine
1474604|NCT00080808|Nerve-sparing radical prostatectomy
1474605|NCT00080808|nerve grafting
1474606|NCT00080795|stage III bladder cancer
1474607|NCT00080795|regional transitional cell cancer of the renal pelvis and ureter
1474608|NCT00080795|anterior urethral cancer
1474609|NCT00080795|posterior urethral cancer
1474610|NCT00080795|urethral cancer associated with invasive bladder cancer
1474611|NCT00080782|recurrent prostate cancer
1474612|NCT00080782|stage IV prostate cancer
1474613|NCT00080782|bone metastases
1474614|NCT00080782|Progressive Androgen-Independent Prostate Cancer
1474615|NCT00080782|Metastron
1474616|NCT00080782|Sr-89
1474617|NCT00080782|Strontium-89
1474618|NCT00080782|strontium chloride Sr 89
1474619|NCT00080782|Celecoxib
1474620|NCT00080782|Celebrex
1474621|NCT00080782|Doxorubicin
1474622|NCT00080782|Rubex
1474623|NCT00080782|Adriamycin
1474624|NCT00080756|breast cancer
1474625|NCT00080756|BRCA1 mutation carrier
1474626|NCT00080756|BRCA2 mutation carrier
1474627|NCT00080743|recurrent breast cancer
1474628|NCT00080743|stage IV breast cancer
1474629|NCT00080678|adenocarcinoma of the prostate
1474630|NCT00080678|recurrent prostate cancer
1474631|NCT00080678|stage IV prostate cancer
1474632|NCT00080678|bone metastases
1474633|NCT00080665|male breast cancer
1474634|NCT00080665|stage IIIB breast cancer
1474635|NCT00080665|stage IIIC breast cancer
1474636|NCT00080665|stage IV breast cancer
1474637|NCT00080665|recurrent breast cancer
1474638|NCT00080639|ovarian epithelial cancer
1474639|NCT00080626|stage I breast cancer
1474640|NCT00080626|stage II breast cancer
1474641|NCT00080626|stage IIIA breast cancer
1474642|NCT00080626|stage IIIB breast cancer
1474643|NCT00080626|stage IIIC breast cancer
1474644|NCT00080626|stage IV breast cancer
1474645|NCT00080600|Post Polio Syndrome
1474646|NCT00080600|Magnetic Stimulation
1474647|NCT00080600|Fatigue
1474648|NCT00080600|Exercise
1474649|NCT00080600|Weakness
1474650|NCT00080600|Transcranial Magnetic Stimulation
1474651|NCT00080600|Post-Exercise Fatigue
1474652|NCT00080600|Motor Neuron Disease
1474653|NCT00080600|Cortical Reorganization
1474654|NCT00080600|Intracortical Facilitation
1474655|NCT00080600|Polio
1474656|NCT00080600|Healthy Volunteer
1474657|NCT00080600|HV
1474658|NCT00080587|Intravascular Ultrasound
1474659|NCT00080587|Magnetic Resonance Imaging
1474660|NCT00080587|Hyperlipidemia
1474661|NCT00080587|Cholesterol
1474662|NCT00080587|Coronary Artery Disease
1474663|NCT00080574|Pharmacokinetics
1474664|NCT00080574|Drug Metabolism
1474665|NCT00080574|Levothyroxine
1474666|NCT00080574|Hypothyroidism
1474667|NCT00080574|Hyperthyroidism
1474668|NCT00080574|Drug Interactions
1474669|NCT00080574|Cytochrome P450
1474670|NCT00080574|P-Glycoprotein
1474671|NCT00080574|Drug Transport Proteins
1474672|NCT00080574|Thyroid Hormone
1474673|NCT00080574|Thyroid Cancer
1474674|NCT00080548|Bereitschafts Potential
1474675|NCT00080548|Timing of Volition
1474676|NCT00080548|Somatic Passivity Phenomenon
1474677|NCT00080548|Conscious Will
1474678|NCT00080548|Libet's Clock
1474679|NCT00080548|Schizophrenia
1474680|NCT00080548|Healthy Volunteer
1474681|NCT00080548|HV
1474682|NCT00080535|LMB-2
1474683|NCT00080535|Cutaneous T Cell Lymphoma
1474684|NCT00080535|CTCL
1474685|NCT00080535|Immunotoxin
1474686|NCT00080535|Oncology
1474687|NCT00080522|Treatment Naive
1474688|NCT00080522|Resource Poor Setting
1474689|NCT00080522|Drug Delivery
1474690|NCT00080522|Household
1474691|NCT00080522|South Africa
1474692|NCT00080496|Pneumonia
1474693|NCT00080470|Incontinence
1474694|NCT00080470|Refractory
1474695|NCT00080470|Urinary
1474696|NCT00080470|Urge
1474697|NCT00080470|Stimulation
1474698|NCT00080470|Nerve
1474699|NCT00080470|Microstimulator
1474700|NCT00080470|Neuromodulation
1474701|NCT00080457|Primary or secondary pulmonary arterial hypertension
1474702|NCT00080457|Scleroderma
1474703|NCT00080457|Connective tissue disease
1474704|NCT00080457|Congenital heart defects
1474705|NCT00080457|Lupus
1474706|NCT00080457|Pulmonary Arterial Hypertension
1474707|NCT00080431|Reservoir
1474708|NCT00080431|Viral Load
1474710|NCT00080431|Activation
1474711|NCT00080431|Latency
1474712|NCT00080431|HIV
1474713|NCT00080431|HAART
1474714|NCT00080431|Immunosuppressive Drug
1474715|NCT00080431|Viral Reservoirs
1474716|NCT00080418|neoplasm
1474717|NCT00080418|cancer
1474718|NCT00080418|NeoPharm
1474719|NCT00080418|liposomes
1474720|NCT00080418|Taxol
1474721|NCT00080418|paclitaxel
1474722|NCT00080418|anti-cancer
1474723|NCT00080418|advanced neoplasm
1474724|NCT00080418|advanced cancer
1474725|NCT00080418|chemotherapy
1474726|NCT00080418|refractory cancer
1474727|NCT00080418|metastatic cancer
1474728|NCT00080405|Relapsed
1474729|NCT00080405|Multiple Myeloma
1474730|NCT00080405|Pharmacokinetic
1474731|NCT00080405|Pharmacodynamic
1474732|NCT00080392|Gene Transfer
1474733|NCT00080392|Therapeutic Angiogenesis
1474734|NCT00080392|Peripheral Arterial Disease
1474735|NCT00080392|Perfusion
1474736|NCT00080392|Magnetic Resonance Imaging
1474737|NCT00080392|Peripheral Vascular Disease
1474738|NCT00080392|Claudication
1474739|NCT00080392|PAD
1474740|NCT00080392|Leg Claudication
1474741|NCT00080392|Intermittent Claudication
1474742|NCT00080366|Essential Tremor
1474743|NCT00080366|Cross over Design
1474744|NCT00080366|Accelerometry
1474745|NCT00080366|Placebo
1474746|NCT00080366|Alcohol Responsive
1474747|NCT00080366|Double Blind
1474748|NCT00080366|1-Octanol
1474749|NCT00080353|Complete Tumor Regression
1474750|NCT00080353|Cell Survival
1474751|NCT00080353|Chemotherapy Preparative Regimen
1474752|NCT00080353|IL-2
1474753|NCT00080353|Toxicity
1474754|NCT00080353|Metastatic Melanoma
1474755|NCT00080314|Bipolar 1 Disorder, depressed
1474756|NCT00080301|Metastatic Breast Cancer
1474757|NCT00080288|Excessive Sleepiness
1474758|NCT00080288|Chronic Shift Work Sleep Disorder
1474759|NCT00080288|Chronic SWSD
1474760|NCT00080288|Circadian Rhythm Disorder
1474761|NCT00080288|Shift Worker
1474762|NCT00080288|Cephalon
1474763|NCT00080288|Cephalon, Inc
1474764|NCT00080288|Nuvigil
1474765|NCT00080275|Niacin
1474766|NCT00080275|Statin
1474767|NCT00080275|Zocor
1474768|NCT00080275|Simvastatin
1474769|NCT00080275|Coronary Heart Disease
1474770|NCT00080275|Dyslipidemia
1474771|NCT00080275|Atherosclerosis
1474772|NCT00080275|Hypercholesterolemia
1474773|NCT00080275|Stroke
1474774|NCT00080275|High-Density Lipoprotein Cholesterol
1474775|NCT00080275|Low-Density Lipoprotein Cholesterol
1474776|NCT00080275|Lipoprotein
1474777|NCT00080275|Lipid
1474778|NCT00080275|Niacin ER/simvastatin
1474779|NCT00080275|Total Cholesterol
1474780|NCT00080275|Triglycerides
1474781|NCT00080262|Metastatic Breast Cancer
1474782|NCT00080236|Liver Transplantation
1474783|NCT00080223|pulmonary fibrosis
1474784|NCT00080223|respiratory diseases
1474785|NCT00080210|elevated uric acid
1474786|NCT00080210|Elevated serum uric acid level
1474787|NCT00080210|Symptomatic gout
1474788|NCT00080197|Breast Cancer
1474789|NCT00080197|Cancer of the Breast
1474790|NCT00080184|Fibromyalgia
1474791|NCT00080184|Electroencephalograph (EEG) biofeedback
1474792|NCT00080184|Electromagnetic stimulation
1474793|NCT00080184|Neurofeedback
1474794|NCT00080184|Neurotherapy
1474795|NCT00080184|Complementary and Alternative Medicine
1474796|NCT00080171|Osteoarthritis
1474797|NCT00080171|Knee Pain
1474798|NCT00080171|Knee Health
1474799|NCT00080158|Dysthymic Disorder
1474800|NCT00080158|Adolescent
1474801|NCT00080145|Autistic Disorder
1474802|NCT00080145|Asperger Syndrome
1474803|NCT00080132|HTG
1474804|NCT00080132|Hypertriglyceridemia, Fredrickson Type I
1474805|NCT00080132|Hypertriglyceridemia, Fredrickson Type V
1474806|NCT00080119|Treatment Naive
1474807|NCT00080119|INH Prophylaxis
1474808|NCT00080119|HIV Seronegativity
1474809|NCT00080106|HIV Therapeutic Vaccine
1474810|NCT00080106|Treatment Experienced
1474811|NCT00080106|Treatment Interruption
1474812|NCT00080106|Adenovirus Vector
1474813|NCT00080093|Condom
1474814|NCT00080093|HIV Seronegativity
1474815|NCT00080093|HIV Prevention
1474816|NCT00080093|Behavioral Intervention
1474817|NCT00080067|Movement
1474818|NCT00080067|Anticipation
1474819|NCT00080067|Stimulation
1474820|NCT00080067|Timing
1474821|NCT00080067|Execution
1474822|NCT00080067|Perception
1474823|NCT00080067|Rhythm
1474824|NCT00080067|Healthy Volunteer
1474825|NCT00080067|HV
1474826|NCT00080054|Malignant Glioma
1474827|NCT00080054|Glioblastoma multiforme
1474828|NCT00080054|GBM
1474829|NCT00080054|Anaplastic astrocytoma
1474830|NCT00080054|AA
1474831|NCT00080054|Anaplastic oligodendroglioma
1474832|NCT00080054|Anaplastic mixed glioma
1474833|NCT00080054|Brain tumor
1474834|NCT00080054|Brain neoplasm
1474835|NCT00080054|Glioma
1474962|NCT00079612|RCC
1474836|NCT00080041|Antineoplastic Combined Chemotherapy Protocols
1474837|NCT00080028|Head and Neck Cancer
1474838|NCT00080028|SCCHN
1474839|NCT00080028|Oropharynx Cancer
1474840|NCT00080028|Hypopharynx Cancer
1474841|NCT00080028|Larynx Cancer
1474842|NCT00080028|Soft palate Cancer
1474843|NCT00080028|Tonsil Cancer
1474844|NCT00080028|Base of tongue Cancer
1474845|NCT00080028|Supraglottic Cancer
1474846|NCT00080028|Glottic Cancer
1474847|NCT00080028|Pyriform Sinus Cancer
1474848|NCT00080028|Pharyngeal wall Cancer
1474849|NCT00080028|Throat cancer
1474850|NCT00080002|cancer
1474851|NCT00080002|gastric
1474852|NCT00080002|gastroesophageal junction
1474853|NCT00080002|neoplasms
1474854|NCT00080002|gastric cancer
1474855|NCT00080002|gastric neoplasms
1474856|NCT00079989|Bacterial Infections
1474857|NCT00079976|Staphylococcus aureus
1474858|NCT00079976|Bacterial Infections
1474859|NCT00079950|soft
1474860|NCT00079950|sarcoma
1474861|NCT00079950|metastatic
1474862|NCT00079937|allergic
1474863|NCT00079937|asthma
1474864|NCT00079937|atopic
1474865|NCT00079937|omalizumab
1474866|NCT00079937|immunoglobulin E
1474867|NCT00079937|IgE
1474868|NCT00079937|anti-IgE
1474869|NCT00079911|Herpes
1474870|NCT00079911|Genital Herpes
1474871|NCT00079911|HIV
1474872|NCT00079911|HSV
1474873|NCT00079885|Bacterial Pneumonia
1474874|NCT00079859|Heterozygous Familial Hypercholesterolemia (HeFH)
1474875|NCT00079846|Homozygous Familial Hypercholesterolemia (HoFH)
1474876|NCT00079833|gastric acid hypersecretory conditions
1474877|NCT00079833|Idiopathic Hypersecretion
1474878|NCT00079833|Excessive Gastric Acid secretion
1474879|NCT00079820|Smallpox
1474880|NCT00079820|Smallpox Vaccine
1474881|NCT00079820|Variola virus
1474882|NCT00079820|Smallpox Virus
1474883|NCT00079820|MODIFIED VACCINIA ANKARA
1474884|NCT00079820|MVA
1474885|NCT00079820|Dryvax
1474886|NCT00079820|Dryvax vaccine
1474887|NCT00079820|Protection against smallpox
1474888|NCT00079807|HIV
1474889|NCT00079807|Peripheral neuropathy
1474890|NCT00079807|Alpha-Lipoic Acid
1474891|NCT00079807|ALA
1474892|NCT00079807|Complementary Therapies
1474893|NCT00079794|lung cancer
1474894|NCT00079794|herbal medicine
1474895|NCT00079794|non-small cell cancer
1474896|NCT00079794|Iscar
1474897|NCT00079794|mistletoe
1474898|NCT00079781|Responsive Stimulation
1474899|NCT00079781|Brain Stimulator
1474900|NCT00079781|Epilepsy
1474901|NCT00079781|Seizures
1474902|NCT00079768|Inflammation
1474903|NCT00079768|Myositis
1474904|NCT00079768|Humanized Monoclonal Antibody
1474905|NCT00079768|Cytotoxic T Cells
1474906|NCT00079768|Endomysial T Cells
1474907|NCT00079768|Alemtuzumab
1474908|NCT00079768|Monoclonal Antibodies
1474909|NCT00079768|IBM
1474910|NCT00079768|Anti-CD 52
1474911|NCT00079768|Inclusion Body Myositis
1474912|NCT00079755|Anaplastic Large-Cell Lymphoma
1474913|NCT00079755|Lymphoma
1474914|NCT00079755|antigens, CD30
1474915|NCT00079755|Monoclonal Antibody
1474916|NCT00079742|Growth restriction in children with cystic fibrosis
1474917|NCT00079729|Treatment Experienced
1474918|NCT00079716|Antigens, CD40
1474919|NCT00079716|Antibody, Monoclonal
1474920|NCT00079716|Blood Coagulation Disorders
1474921|NCT00079716|Hematologic Diseases
1474922|NCT00079716|Hemorrhagic Disorders
1474923|NCT00079716|Hemostatic Disorders
1474924|NCT00079716|Immunoproliferative Disorders
1474925|NCT00079716|Lymphoproliferative Disorders
1474926|NCT00079716|Paraproteinemias
1474927|NCT00079716|Vascular Diseases
1474928|NCT00079716|Antibody-Dependent Cell Cytotoxicity
1474929|NCT00079677|Excessive Sleepiness
1474930|NCT00079677|Obstructive Sleep Apnea
1474931|NCT00079677|Obstructive Sleep Hypopnea
1474932|NCT00079677|nCPAP
1474933|NCT00079677|Cephalon
1474934|NCT00079677|Cephalon, Inc
1474935|NCT00079677|Nuvigil
1474936|NCT00079664|Tai Ji
1474937|NCT00079651|Aged
1474938|NCT00079651|Nursing Homes
1474939|NCT00079651|Assisted Living Facilities
1474940|NCT00079638|Niaspan
1474941|NCT00079638|Niacin
1474942|NCT00079638|Statin
1474943|NCT00079638|Cholesterol
1474944|NCT00079638|Triglycerides
1474945|NCT00079638|Lipid-Modifying Therapies
1474946|NCT00079638|Dyslipidemia
1474947|NCT00079638|Coronary Heart Disease
1474948|NCT00079638|Atherosclerosis
1474949|NCT00079638|Stroke
1474950|NCT00079638|VA-HIT
1474951|NCT00079638|Niacin Statin Combination Threrapy
1474952|NCT00079638|High Density Lipoprotein
1474953|NCT00079638|Low Density Lipoprotein
1474954|NCT00079638|Hypertension
1474955|NCT00079638|Diabetes
1474956|NCT00079638|Adult Treatment Panel III
1474957|NCT00079625|Engraftment
1474958|NCT00079625|Graft-Versus-Host Disease
1474959|NCT00079625|Metastatic Breast Cancer
1474960|NCT00079625|MBC
1474961|NCT00079612|Renal Cell Cancer
1474963|NCT00079612|Cancer
1474964|NCT00079599|Carnitine Deficiency
1474965|NCT00079599|Fatigue
1474966|NCT00079599|Complementary Therapies
1474967|NCT00079573|Weight Loss
1474968|NCT00079573|Obesity
1474969|NCT00079573|Overweight
1474970|NCT00079573|Premenopausal women
1474971|NCT00079573|Diet
1474972|NCT00079560|HIV
1474973|NCT00079560|Marijuana
1474974|NCT00079560|Marinol
1474975|NCT00079560|Oral THC
1474976|NCT00079560|Appetite
1474977|NCT00079560|Complementary Therapies
1474978|NCT00079547|Weight Loss
1474979|NCT00079534|AIDS
1474980|NCT00079534|HIV
1474981|NCT00079534|Prayer
1474982|NCT00079534|Healing
1474983|NCT00079534|Complementary Therapies
1474984|NCT00079521|Bone Metabolism
1474985|NCT00079521|Therapeutic Touch
1474986|NCT00079508|Heparin-induced Thrombocytopenia
1474987|NCT00079508|Heparin-induced Thrombocytopenia/Thrombosis Syndrome
1474988|NCT00079508|HIT/HITTS
1474989|NCT00079508|Heparin anti-body positive
1474990|NCT00079495|MS
1474991|NCT00079495|Autoimmune disease
1474992|NCT00079495|relapsing
1474993|NCT00079495|progressive
1474994|NCT00079495|Myelin
1474995|NCT00079495|Myelin Basic Protein
1474996|NCT00079495|MBP
1474997|NCT00079495|acute fulminating
1474998|NCT00079495|chronic progressive
1474999|NCT00079495|Altered Peptide Ligand
1475000|NCT00079495|APL
1475001|NCT00079495|Neurocrine
1475002|NCT00079495|NBI-5788
1475003|NCT00079495|Relapse
1475004|NCT00079482|AML
1475005|NCT00079469|cancer survivor
1475006|NCT00079469|unspecified adult solid tumor, protocol specific
1475007|NCT00079391|Chronic Myelogenous Leukemia (CML)
1475008|NCT00079391|Acute Lymphoblastic Leukemia (ALL)
1475009|NCT00079391|Acute Myelogenous Leukemia (AML)
1475010|NCT00079391|Chronic Lymphocytic Leukemia (CLL)
1475011|NCT00079391|Myelodysplastic Syndromes (MDS)
1475012|NCT00079391|Peripheral Blood Stem Cells
1475013|NCT00079391|Graft-Versus Leukemia/Myeloma
1475014|NCT00079391|Graft-Versus-Host Disease (GVHD)
1475015|NCT00079391|Cyclosporine
1475016|NCT00079391|Fludarabine
1475017|NCT00079391|Leukemia
1475018|NCT00079391|Myelodysplastic Syndrome
1475019|NCT00079391|Myeloproliferative Syndrome
1475020|NCT00079391|Non-Hodgkin Lymphoma
1475021|NCT00079365|adenocarcinoma of the pancreas
1475022|NCT00079365|stage II pancreatic cancer
1475023|NCT00079365|stage III pancreatic cancer
1475024|NCT00079365|stage IV pancreatic cancer
1475025|NCT00079313|CMML
1475026|NCT00079313|CML
1475027|NCT00079313|Gleevec
1475028|NCT00079313|Glivec
1475029|NCT00079313|STI-571
1475030|NCT00079313|Tyrosine Kinase Inhibitor
1475031|NCT00079313|Chronic Myelogenous Leukemia
1475032|NCT00079313|Atypical Chronic Myelogenous Leukemia
1475033|NCT00079313|Chronic Myelomoncytic Leukemia
1475034|NCT00079313|Leukemia
1475035|NCT00079300|basal cell carcinoma of the skin
1475036|NCT00079287|adenocarcinoma of the lung
1475037|NCT00079287|large cell lung cancer
1475038|NCT00079287|recurrent non-small cell lung cancer
1475039|NCT00079287|squamous cell lung cancer
1475040|NCT00079287|stage IIIB non-small cell lung cancer
1475041|NCT00079287|stage IV non-small cell lung cancer
1475042|NCT00079261|contiguous stage II grade 3 follicular lymphoma
1475043|NCT00079261|noncontiguous stage II grade 3 follicular lymphoma
1475044|NCT00079261|stage III grade 3 follicular lymphoma
1475045|NCT00079261|stage IV grade 3 follicular lymphoma
1475046|NCT00079261|contiguous stage II adult diffuse large cell lymphoma
1475047|NCT00079261|noncontiguous stage II adult diffuse large cell lymphoma
1475048|NCT00079261|stage III adult diffuse large cell lymphoma
1475049|NCT00079261|stage IV adult diffuse large cell lymphoma
1475050|NCT00079261|anaplastic large cell lymphoma
1475051|NCT00079261|angioimmunoblastic T-cell lymphoma
1475052|NCT00079261|adult grade III lymphomatoid granulomatosis
1475053|NCT00079261|small intestine lymphoma
1475054|NCT00079248|osteoporosis
1475055|NCT00079248|stage I breast cancer
1475056|NCT00079248|stage II breast cancer
1475057|NCT00079248|menopausal symptoms
1475058|NCT00079248|hot flashes
1475059|NCT00079222|infection
1475060|NCT00079222|adult acute lymphoblastic leukemia in remission
1475061|NCT00079222|adult acute myeloid leukemia in remission
1475062|NCT00079222|childhood acute lymphoblastic leukemia in remission
1475063|NCT00079222|childhood acute myeloid leukemia in remission
1475064|NCT00079222|recurrent adult acute lymphoblastic leukemia
1475065|NCT00079222|recurrent adult acute myeloid leukemia
1475066|NCT00079222|recurrent childhood acute lymphoblastic leukemia
1475067|NCT00079222|recurrent childhood acute myeloid leukemia
1475068|NCT00079222|untreated adult acute lymphoblastic leukemia
1475069|NCT00079222|untreated adult acute myeloid leukemia
1475070|NCT00079222|untreated childhood acute lymphoblastic leukemia
1475071|NCT00079222|untreated childhood acute myeloid leukemia and other myeloid malignancies
1475072|NCT00079222|refractory chronic lymphocytic leukemia
1475073|NCT00079222|stage III chronic lymphocytic leukemia
1475074|NCT00079222|stage IV chronic lymphocytic leukemia
1475075|NCT00079222|accelerated phase chronic myelogenous leukemia
1475076|NCT00079222|atypical chronic myeloid leukemia
1475077|NCT00079222|blastic phase chronic myelogenous leukemia
1475078|NCT00079222|childhood chronic myelogenous leukemia
1475079|NCT00079222|chronic myelomonocytic leukemia
1475080|NCT00079222|chronic phase chronic myelogenous leukemia
1475081|NCT00079222|relapsing chronic myelogenous leukemia
1475082|NCT00079222|secondary acute myeloid leukemia
1475083|NCT00079222|secondary myelodysplastic syndromes
1475084|NCT00079222|de novo myelodysplastic syndromes
1475085|NCT00079222|myelodysplastic/myeloproliferative disease, unclassifiable
1475086|NCT00079222|previously treated myelodysplastic syndromes
1475087|NCT00079222|chronic eosinophilic leukemia
1475088|NCT00079222|primary myelofibrosis
1475089|NCT00079222|chronic neutrophilic leukemia
1475090|NCT00079222|stage I multiple myeloma
1475091|NCT00079222|stage II multiple myeloma
1475092|NCT00079222|stage III multiple myeloma
1475093|NCT00079222|refractory hairy cell leukemia
1475094|NCT00079222|refractory multiple myeloma
1475095|NCT00079222|recurrent adult Burkitt lymphoma
1475096|NCT00079222|recurrent adult diffuse large cell lymphoma
1475097|NCT00079222|recurrent adult diffuse mixed cell lymphoma
1475098|NCT00079222|recurrent adult diffuse small cleaved cell lymphoma
1475099|NCT00079222|recurrent adult Hodgkin lymphoma
1475100|NCT00079222|recurrent adult immunoblastic large cell lymphoma
1475101|NCT00079222|recurrent adult lymphoblastic lymphoma
1475102|NCT00079222|recurrent childhood large cell lymphoma
1475103|NCT00079222|recurrent childhood lymphoblastic lymphoma
1475104|NCT00079222|recurrent childhood small noncleaved cell lymphoma
1475105|NCT00079222|recurrent cutaneous T-cell non-Hodgkin lymphoma
1475106|NCT00079222|recurrent grade 1 follicular lymphoma
1475107|NCT00079222|recurrent grade 2 follicular lymphoma
1475108|NCT00079222|recurrent grade 3 follicular lymphoma
1475109|NCT00079222|recurrent mantle cell lymphoma
1475110|NCT00079222|recurrent/refractory childhood Hodgkin lymphoma
1475111|NCT00079222|noncontiguous stage II adult Burkitt lymphoma
1475112|NCT00079222|noncontiguous stage II adult diffuse large cell lymphoma
1475113|NCT00079222|noncontiguous stage II adult diffuse mixed cell lymphoma
1475114|NCT00079222|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1475115|NCT00079222|noncontiguous stage II adult immunoblastic large cell lymphoma
1475116|NCT00079222|noncontiguous stage II adult lymphoblastic lymphoma
1475117|NCT00079222|noncontiguous stage II grade 1 follicular lymphoma
1475118|NCT00079222|noncontiguous stage II grade 2 follicular lymphoma
1475119|NCT00079222|noncontiguous stage II grade 3 follicular lymphoma
1475120|NCT00079222|noncontiguous stage II mantle cell lymphoma
1475121|NCT00079222|stage III adult Burkitt lymphoma
1475122|NCT00079222|stage III adult diffuse large cell lymphoma
1475123|NCT00079222|stage III adult diffuse mixed cell lymphoma
1475124|NCT00079222|stage III adult diffuse small cleaved cell lymphoma
1475125|NCT00079222|stage III adult immunoblastic large cell lymphoma
1475126|NCT00079222|stage III adult lymphoblastic lymphoma
1475127|NCT00079222|stage III grade 1 follicular lymphoma
1475128|NCT00079222|stage III grade 2 follicular lymphoma
1475129|NCT00079222|stage III grade 3 follicular lymphoma
1475130|NCT00079222|stage III mantle cell lymphoma
1475131|NCT00079222|stage IV adult Burkitt lymphoma
1475132|NCT00079222|stage IV adult diffuse large cell lymphoma
1475133|NCT00079222|stage IV adult diffuse mixed cell lymphoma
1475134|NCT00079222|stage IV adult diffuse small cleaved cell lymphoma
1475135|NCT00079222|stage IV adult immunoblastic large cell lymphoma
1475136|NCT00079222|stage IV adult lymphoblastic lymphoma
1475137|NCT00079222|stage IV grade 1 follicular lymphoma
1475138|NCT00079222|stage IV grade 2 follicular lymphoma
1475139|NCT00079222|stage IV grade 3 follicular lymphoma
1475140|NCT00079222|stage IV mantle cell lymphoma
1475141|NCT00079222|recurrent mycosis fungoides/Sezary syndrome
1475142|NCT00079222|recurrent malignant testicular germ cell tumor
1475143|NCT00079222|stage III malignant testicular germ cell tumor
1475144|NCT00079222|recurrent ovarian epithelial cancer
1475145|NCT00079222|stage II ovarian epithelial cancer
1475146|NCT00079222|stage III ovarian epithelial cancer
1475147|NCT00079222|stage IV ovarian epithelial cancer
1475148|NCT00079222|poor prognosis metastatic gestational trophoblastic tumor
1475149|NCT00079222|disseminated neuroblastoma
1475150|NCT00079222|recurrent neuroblastoma
1475151|NCT00079222|recurrent ovarian germ cell tumor
1475152|NCT00079222|previously treated childhood rhabdomyosarcoma
1475153|NCT00079222|recurrent childhood rhabdomyosarcoma
1475154|NCT00079222|recurrent Wilms tumor and other childhood kidney tumors
1475155|NCT00079222|stage IIIA breast cancer
1475156|NCT00079222|stage IIIB breast cancer
1475157|NCT00079222|stage IIIC breast cancer
1475158|NCT00079222|stage IV breast cancer
1475159|NCT00079222|juvenile myelomonocytic leukemia
1475160|NCT00079222|noncontiguous stage II small lymphocytic lymphoma
1475161|NCT00079222|noncontiguous stage II marginal zone lymphoma
1475162|NCT00079222|recurrent marginal zone lymphoma
1475163|NCT00079222|recurrent small lymphocytic lymphoma
1475164|NCT00079222|stage III small lymphocytic lymphoma
1475165|NCT00079222|stage III marginal zone lymphoma
1475166|NCT00079222|stage IV small lymphocytic lymphoma
1475167|NCT00079222|stage IV marginal zone lymphoma
1475168|NCT00079222|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1475169|NCT00079222|nodal marginal zone B-cell lymphoma
1475170|NCT00079222|splenic marginal zone lymphoma
1475171|NCT00079222|adult acute myeloid leukemia with t(8;21)(q22;q22)
1475172|NCT00079222|adult acute myeloid leukemia with t(16;16)(p13;q22)
1475173|NCT00079222|adult acute myeloid leukemia with inv(16)(p13;q22)
1475174|NCT00079222|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1475175|NCT00079222|adult acute myeloid leukemia with t(15;17)(q22;q12)
1475176|NCT00079222|childhood myelodysplastic syndromes
1475177|NCT00079170|male breast cancer
1475178|NCT00079170|recurrent breast cancer
1475179|NCT00079170|stage IIIA breast cancer
1475180|NCT00079170|stage IIIB breast cancer
1475181|NCT00079170|stage IIIC breast cancer
1475182|NCT00079170|stage IV breast cancer
1475183|NCT00079157|recurrent breast cancer
1475184|NCT00079157|stage IV breast cancer
1475185|NCT00079144|recurrent melanoma
1475186|NCT00079144|stage IV melanoma
1475187|NCT00079118|stage IV breast cancer
1475188|NCT00079118|recurrent breast cancer
1475189|NCT00079118|male breast cancer
1475190|NCT00079105|stage I adult Hodgkin lymphoma
1475191|NCT00079105|stage II adult Hodgkin lymphoma
1475192|NCT00079105|stage III adult Hodgkin lymphoma
1475193|NCT00079105|stage IV adult Hodgkin lymphoma
1475194|NCT00079092|recurrent adult brain tumor
1475195|NCT00079092|adult anaplastic astrocytoma
1475196|NCT00079092|adult anaplastic oligodendroglioma
1475197|NCT00079092|adult glioblastoma
1475198|NCT00079092|adult mixed glioma
1475199|NCT00079092|adult giant cell glioblastoma
1475200|NCT00079092|adult gliosarcoma
1475201|NCT00079079|stage II salivary gland cancer
1475202|NCT00079079|stage III salivary gland cancer
1475203|NCT00079079|stage IV salivary gland cancer
1475204|NCT00079079|recurrent salivary gland cancer
1475205|NCT00079079|salivary gland acinic cell tumor
1475206|NCT00079079|salivary gland adenoid cystic carcinoma
1475207|NCT00079079|salivary gland poorly differentiated carcinoma
1475208|NCT00079079|high-grade salivary gland mucoepidermoid carcinoma
1475209|NCT00079079|low-grade salivary gland mucoepidermoid carcinoma
1475210|NCT00079079|salivary gland malignant mixed cell type tumor
1475211|NCT00079079|salivary gland adenocarcinoma
1475212|NCT00079079|salivary gland anaplastic carcinoma
1475213|NCT00079079|salivary gland squamous cell carcinoma
1475214|NCT00079066|quality of life
1475215|NCT00079066|stage IV colon cancer
1475216|NCT00079066|recurrent colon cancer
1475217|NCT00079066|recurrent rectal cancer
1475218|NCT00079066|stage IV rectal cancer
1475219|NCT00079053|stage III squamous cell carcinoma of the hypopharynx
1475220|NCT00079053|stage III squamous cell carcinoma of the larynx
1475221|NCT00079053|stage III squamous cell carcinoma of the lip and oral cavity
1475222|NCT00079053|stage III squamous cell carcinoma of the nasopharynx
1475223|NCT00079053|stage III squamous cell carcinoma of the oropharynx
1475224|NCT00079053|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1475225|NCT00079053|stage IV squamous cell carcinoma of the hypopharynx
1475226|NCT00079053|stage IV squamous cell carcinoma of the larynx
1475227|NCT00079053|stage IV squamous cell carcinoma of the lip and oral cavity
1475228|NCT00079053|stage IV squamous cell carcinoma of the nasopharynx
1475229|NCT00079053|stage IV squamous cell carcinoma of the oropharynx
1475230|NCT00079053|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1475231|NCT00079053|salivary gland squamous cell carcinoma
1475232|NCT00079053|stage III salivary gland cancer
1475233|NCT00079053|stage IV salivary gland cancer
1475234|NCT00079027|advanced adult primary liver cancer
1475235|NCT00079027|adult primary hepatocellular carcinoma
1475236|NCT00079001|adenocarcinoma of the prostate
1475237|NCT00079001|recurrent prostate cancer
1475238|NCT00079001|stage IV prostate cancer
1475239|NCT00079001|bone metastases
1475240|NCT00078988|childhood high-grade cerebral astrocytoma
1475241|NCT00078988|recurrent childhood cerebellar astrocytoma
1475242|NCT00078988|recurrent childhood cerebral astrocytoma
1475243|NCT00078975|adenocarcinoma of the pancreas
1475244|NCT00078975|recurrent pancreatic cancer
1475245|NCT00078975|stage II pancreatic cancer
1475246|NCT00078975|stage III pancreatic cancer
1475247|NCT00078975|stage IV pancreatic cancer
1475248|NCT00078949|anaplastic large cell lymphoma
1475249|NCT00078949|recurrent adult Burkitt lymphoma
1475250|NCT00078949|recurrent adult diffuse large cell lymphoma
1475251|NCT00078949|angioimmunoblastic T-cell lymphoma
1475252|NCT00078923|stage I prostate cancer
1475253|NCT00078923|stage II prostate cancer
1475254|NCT00078923|adenocarcinoma of the prostate
1475255|NCT00078910|adenocarcinoma of the prostate
1475256|NCT00078910|stage IIB prostate cancer
1475257|NCT00078910|stage IIA prostate cancer
1475258|NCT00078910|stage III prostate cancer
1475259|NCT00078897|colon cancer
1475260|NCT00078897|rectal cancer
1475261|NCT00078897|colorectal cancer
1475262|NCT00078897|adenomatous polyp
1475263|NCT00078845|neurotoxicity
1475264|NCT00078845|unspecified adult solid tumor, protocol specific
1475265|NCT00078845|recurrent prostate cancer
1475266|NCT00078845|stage I prostate cancer
1475267|NCT00078845|stage IIB prostate cancer
1475268|NCT00078845|stage IIA prostate cancer
1475269|NCT00078845|stage III prostate cancer
1475270|NCT00078845|stage IV prostate cancer
1475271|NCT00078845|recurrent non-small cell lung cancer
1475272|NCT00078845|stage I non-small cell lung cancer
1475273|NCT00078845|stage II non-small cell lung cancer
1475274|NCT00078845|stage IIIA non-small cell lung cancer
1475275|NCT00078845|stage IIIB non-small cell lung cancer
1475276|NCT00078845|stage IV non-small cell lung cancer
1475277|NCT00078845|limited stage small cell lung cancer
1475278|NCT00078845|extensive stage small cell lung cancer
1475279|NCT00078845|recurrent small cell lung cancer
1475280|NCT00078845|recurrent breast cancer
1475281|NCT00078845|stage I breast cancer
1475282|NCT00078845|stage II breast cancer
1475283|NCT00078845|stage IIIA breast cancer
1475284|NCT00078845|stage IIIB breast cancer
1475285|NCT00078845|stage IIIC breast cancer
1475286|NCT00078845|stage IV breast cancer
1475287|NCT00078845|recurrent ovarian epithelial cancer
1475288|NCT00078845|stage I ovarian epithelial cancer
1475289|NCT00078845|stage II ovarian epithelial cancer
1475290|NCT00078845|stage III ovarian epithelial cancer
1475291|NCT00078845|stage IV ovarian epithelial cancer
1475292|NCT00078832|breast cancer, chemoprevention
1475293|NCT00078819|Pediatric Psoriasis
1475294|NCT00078806|Systemic Onset Juvenile Rheumatoid Arthiritis
1475295|NCT00078806|SOJRA
1475296|NCT00078806|Fever
1475297|NCT00078806|Rash
1475298|NCT00078806|Joint Pain
1475299|NCT00078793|JRA
1475300|NCT00078793|Registry
1475301|NCT00078767|PTSD
1475302|NCT00078767|Depression
1475303|NCT00078767|Anxiety
1475304|NCT00078741|Psychotic Disorders
1475305|NCT00078728|Anxiety
1475306|NCT00078715|Yohimbine
1475307|NCT00078715|Sleep Deprivation
1475308|NCT00078715|Depression
1475309|NCT00078715|Mood Disorder
1475310|NCT00078715|Fast
1475311|NCT00078715|Affective Disorder
1475312|NCT00078715|Rapid Onset
1475313|NCT00078715|Major Depression
1475314|NCT00078715|MDD
1475315|NCT00078689|Sirolimus
1475316|NCT00078689|Daclizumab
1475317|NCT00078689|Inflammation
1475318|NCT00078689|Induce Tolerance
1475319|NCT00078689|Uveitis
1475320|NCT00078689|Immune Tolerance
1475321|NCT00078689|T Cell
1475322|NCT00078663|Oral Care
1475323|NCT00078663|ICU
1475324|NCT00078663|Pneumonia
1475325|NCT00078663|Pathogens
1475326|NCT00078663|Intubation
1475327|NCT00078663|Intubated
1475328|NCT00078663|Oral Hygiene
1475329|NCT00078663|Intensive Care
1475330|NCT00078624|Osteoarthritis
1475331|NCT00078624|Knee Joint
1475332|NCT00078624|Joint Stability
1475333|NCT00078624|Motor Control
1475334|NCT00078624|Exercise Therapy
1475335|NCT00078611|Crohn's disease
1475336|NCT00078611|Inflammatory Bowel Disease
1475337|NCT00078611|IBD
1475338|NCT00078611|Gastroenterology
1475339|NCT00078611|Regional Enteritis
1475340|NCT00078611|Colitis
1475341|NCT00078598|Relapsed
1475342|NCT00078598|Follicular
1475343|NCT00078572|XELODA
1475344|NCT00078572|Metastatic
1475345|NCT00078572|Breast Cancer
1475346|NCT00078572|Advanced
1475347|NCT00078572|HERCEPTIN
1475348|NCT00078559|Immunosuppression
1475349|NCT00078559|Renal Failure
1475350|NCT00078546|EBV
1475351|NCT00078546|NASOPHARYNGEAL
1475352|NCT00078546|CARCINOMA
1475353|NCT00078546|EBV POSITIVE NASOPHARYNGEAL CARCINOMA
1475354|NCT00078533|Allogeneic
1475355|NCT00078533|Transplant
1475356|NCT00078533|CMV
1475357|NCT00078533|Stem Cell
1475358|NCT00078533|Donor
1475359|NCT00078533|Allogeneic stem cell recipients at risk for CMV reactivation
1475360|NCT00078520|Leukemia
1475361|NCT00078507|Outcome and Process Assessment (Health Care)
1475362|NCT00078507|Behavior Control
1475363|NCT00078507|Sensation
1475364|NCT00078507|Randomized Controlled Trials
1475365|NCT00078507|Adolescent
1475366|NCT00078507|Adult
1475367|NCT00078494|Immunization
1475368|NCT00078494|Vaccine
1475369|NCT00078494|Nasopharyngeal Cancer
1475370|NCT00078494|Immunotherapy
1475371|NCT00078494|Cancer
1475372|NCT00078494|NPC
1475373|NCT00078481|Neurodegeneration
1475374|NCT00078481|Anti-Oxidant
1475375|NCT00078481|Neuropathy
1475376|NCT00078481|Hereditary
1475377|NCT00078481|Spinocerebellar
1475378|NCT00078481|Friedreich Ataxia
1475379|NCT00078481|FRDA
1475380|NCT00078455|NSCLC
1475381|NCT00078455|Non-small Cell Lung Cancer
1475382|NCT00078455|Non-small Cell Lung Carcinoma
1475383|NCT00078455|Locally Advanced NSCLC
1475384|NCT00078455|Metastatic NSCLC
1475385|NCT00078442|Treatment Experienced
1475386|NCT00078442|Treatment Interruption
1475387|NCT00078442|Treatment Naive
1475388|NCT00078403|Treatment Experienced
1475389|NCT00078390|Lung cancer
1475390|NCT00078390|Lung carcinoma
1475391|NCT00078390|Non small cell lung cancer
1475392|NCT00078390|Stage IIIA non small cell lung cancer
1475393|NCT00078390|Stage IIIB non small cell lung cancer
1475394|NCT00078390|NSCLC
1475395|NCT00078390|Stage III
1475396|NCT00078390|chemotherapy
1475397|NCT00078390|radiation
1475398|NCT00078390|chemoradiation
1475399|NCT00078390|matrix metalloproteinases
1475400|NCT00078390|neovascularization
1475401|NCT00078390|antiangiogenesis
1475402|NCT00078390|type IV collagenases
1475403|NCT00078390|Unresectable locally advanced non-small cell lung cancer
1475404|NCT00078377|Narcolepsy
1475405|NCT00078377|Excessive Sleepiness
1475406|NCT00078377|Cataplexy
1475407|NCT00078377|Sleep Attacks
1475408|NCT00078377|Excessive Sleepiness associated with Narcolepsy
1475409|NCT00078377|Cephalon
1475410|NCT00078377|Cephalon, Inc
1475411|NCT00078377|Nuvigil
1475412|NCT00078364|MRI
1475413|NCT00078364|NSAID Analgesia
1475414|NCT00078364|Pain Mechanisms
1475415|NCT00078364|SNP's
1475416|NCT00078364|Acute Pain
1475417|NCT00078364|Wisdom Teeth
1475418|NCT00078364|Third Molar Extraction
1475419|NCT00078364|Third Molar Impaction
1475420|NCT00078351|Chronic Pain
1475421|NCT00078351|Synvisc
1475422|NCT00078351|Temporomandibular Joint
1475423|NCT00078351|Osteoarthritis
1475424|NCT00078351|TMD
1475425|NCT00078351|Temporomandibular Joint Osteoarthritis
1475426|NCT00078351|TMJ OA
1475427|NCT00078351|Temporomandibular Joint Disease
1475428|NCT00078351|TMJ
1475429|NCT00078325|Excessive Sleepiness
1475430|NCT00078325|Obstructive Sleep Apnea
1475431|NCT00078325|Obstructive Sleep Hypopnea
1475432|NCT00078325|nCPAP
1475433|NCT00078325|Cephalon
1475434|NCT00078325|Cephalon, Inc
1475435|NCT00078325|NUVIGIL
1475436|NCT00078312|Excessive Sleepiness
1475437|NCT00078312|Narcolepsy
1475438|NCT00078312|Cataplexy
1475439|NCT00078312|Sleep Attacks
1475440|NCT00078312|Obstructive Sleep Apnea
1475441|NCT00078312|Obstructive Sleep Hypopnea
1475442|NCT00078312|nCPAP
1475443|NCT00078312|Chronic Shift Work Sleep Disorder
1475444|NCT00078312|Chronic SWSD
1475445|NCT00078312|Circadian Rhythm Disorder
1475446|NCT00078312|Shift Worker
1475447|NCT00078312|Cepahlon
1475448|NCT00078312|Cephalon, Inc
1475449|NCT00078312|Nuvigil
1475450|NCT00078299|Cortical
1475451|NCT00078299|Nuclear Sclerosis
1475452|NCT00078299|Posterior Subcapsular
1475453|NCT00078299|Photographic Methods
1475454|NCT00078299|Reproducibility (intra and interobserver)
1475455|NCT00078299|Cataract
1475456|NCT00078299|Agreement
1475457|NCT00078299|Grading System
1475458|NCT00078286|Antidepressive Agents
1475459|NCT00078273|Gambling
1475460|NCT00078273|Pathological Gambling
1475461|NCT00078273|Problem Gambling
1475462|NCT00078273|College Students
1475463|NCT00078273|Prevention
1475464|NCT00078247|Antiretroviral Therapy
1475465|NCT00078247|Africa
1475466|NCT00078234|CLL
1475467|NCT00078234|Leukemia
1475468|NCT00078234|Chronic
1475469|NCT00078234|Cancer
1475470|NCT00078234|Adult
1475471|NCT00078234|Lymphocytic
1475472|NCT00078234|Genasense
1475473|NCT00078234|G3139
1475474|NCT00078234|Genta
1475475|NCT00078234|Bcl-2
1475476|NCT00078234|Antisense
1475477|NCT00078234|Oligonucleotide
1475478|NCT00078234|oblimersen
1475479|NCT00078221|Dry AMD
1475480|NCT00078221|Age-related Macular Degeneration
1475481|NCT00078221|Rheopheresis
1475482|NCT00078208|Pediatric
1475483|NCT00078208|Non-Invasive
1475484|NCT00078208|Anti-Inflammatory
1475485|NCT00078208|pH
1475486|NCT00078208|Mediators
1475487|NCT00078208|Asthma
1475488|NCT00078208|Childhood Asthma
1475489|NCT00078208|Healthy Volunteer
1475490|NCT00078208|HV
1475491|NCT00078195|Ragweed
1475492|NCT00078195|Immunotherapy
1475493|NCT00078195|Rush Immunotherapy
1475494|NCT00078195|RIT
1475495|NCT00078195|Hayfever
1475496|NCT00078195|Seasonal Allergic Rhinitis
1475497|NCT00078182|HIV Prevention
1475498|NCT00078169|behavioral intervention
1475499|NCT00078156|behavioral intervention
1475500|NCT00078143|behavioral intervention
1475501|NCT00078130|opioid dependence
1475502|NCT00078130|behavioral intervention
1475503|NCT00078117|opiate dependence
1475504|NCT00078104|Prostanoid
1475505|NCT00078104|Cyclooxygenase (COX)
1475506|NCT00078104|Selective Cox Inhibitor
1475507|NCT00078104|Acute Peripheral Inflammation
1475508|NCT00078104|Neuronal Expression of COX
1475509|NCT00078104|Pain
1475510|NCT00078104|Coxibs
1475511|NCT00078104|Wisdom Teeth
1475512|NCT00078104|Third Molar Extraction
1475513|NCT00078104|Third Molar Impaction
1475514|NCT00078091|Obesity
1475515|NCT00078091|Retinopathy
1475516|NCT00078091|Dyslipidemia
1475517|NCT00078091|Insulin Resistance
1475518|NCT00078091|Hypogonadism
1475519|NCT00078091|Polydactyly
1475520|NCT00078091|Bardet-Biedl Syndrome
1475521|NCT00078091|BBS
1475522|NCT00078078|Vitamin B12
1475523|NCT00078078|Methylmalonic Acidemia
1475524|NCT00078078|Hyperhomocysteinemia
1475525|NCT00078078|MMA
1475526|NCT00078078|Metabolic Disease
1475527|NCT00078065|multiple myeloma
1475528|NCT00078065|fludarabine
1475529|NCT00078065|Xcellerated T Cells
1475530|NCT00078039|Schizophrenia, paliperidone
1475531|NCT00078026|Apomine
1475532|NCT00078026|Osteoporosis
1475533|NCT00078026|Bone Mass
1475534|NCT00078026|Postmenopausal
1475535|NCT00078013|AMI
1475536|NCT00078013|STEMI
1475537|NCT00078013|Infarct
1475538|NCT00078013|acute myocardial infarction with ST segment elevation
1475539|NCT00077961|Non-Hodgkin's Lymphoma
1475540|NCT00077961|NHL
1475541|NCT00077961|CAMPATH
1475542|NCT00077961|alemtuzumab
1475543|NCT00077948|positive inotrope
1475544|NCT00077948|enoximone
1475545|NCT00077948|beta-blocker
1475546|NCT00077948|intolerant
1475547|NCT00077922|LMB-2
1475548|NCT00077922|Chronic Lymphocytic Leukemia
1475549|NCT00077922|CLL
1475550|NCT00077922|Immunotoxin
1475551|NCT00077922|Oncology
1475552|NCT00077922|Lymphocytes
1475553|NCT00077922|Hematological Disease
1475554|NCT00077922|Monoclonal Antibody
1475555|NCT00077922|Neutralizing Antibodies
1475556|NCT00077909|Proteomics
1475557|NCT00077909|Infection
1475558|NCT00077909|Pneumonia
1475559|NCT00077909|Mass Spectrometry
1475560|NCT00077909|BAL
1475561|NCT00077909|Lung
1475562|NCT00077909|Pulmonary Disease
1475563|NCT00077909|Lung Infiltrates
1475564|NCT00077896|Treatment
1475565|NCT00077896|Transcranial Stimulation
1475566|NCT00077896|Frontal Lobe
1475567|NCT00077896|Pick's Disease
1475568|NCT00077896|Cognitive Impairment
1475569|NCT00077896|Dementia
1475570|NCT00077896|Frontotemporal Dementia
1475571|NCT00077896|FTD
1475572|NCT00077870|Moderate to severe rheumatoid arthritis
1475573|NCT00077792|Receiving fibrinolytic therapy
1475574|NCT00077727|Schizophrenia
1475575|NCT00077727|cognitive impairment
1475576|NCT00077727|galantamine
1475577|NCT00077727|acetylcholinesterase inhibitors
1475578|NCT00077727|antipsychotic drugs
1475579|NCT00077727|BACS
1475580|NCT00077714|Schizophrenia
1475581|NCT00077714|Paliperidone
1475582|NCT00077675|Abscess
1475583|NCT00077675|Burns
1475584|NCT00077675|Cellulitis
1475585|NCT00077675|Ulcer
1475586|NCT00077675|Wound infections
1475587|NCT00077662|Pompe Disease
1475588|NCT00077662|Glycogen Storage Disease Type II
1475589|NCT00077662|GSD-II
1475590|NCT00077662|Acid Maltase Deficiency Disease
1475591|NCT00077662|Glycogenosis 2
1475592|NCT00077584|Scleroderma
1475593|NCT00077584|Finger Ulcers
1475594|NCT00077584|Digital Ulcers
1475595|NCT00077584|Systemic Sclerosis
1475596|NCT00077558|accelerated phase chronic myelogenous leukemia
1475597|NCT00077558|blastic phase chronic myelogenous leukemia
1475598|NCT00077558|relapsing chronic myelogenous leukemia
1475599|NCT00077558|previously treated myelodysplastic syndromes
1475600|NCT00077558|secondary myelodysplastic syndromes
1475601|NCT00077558|refractory chronic lymphocytic leukemia
1475602|NCT00077558|recurrent adult acute lymphoblastic leukemia
1475603|NCT00077558|prolymphocytic leukemia
1475604|NCT00077558|refractory anemia with excess blasts
1475605|NCT00077558|chronic myelomonocytic leukemia
1475606|NCT00077558|recurrent adult acute myeloid leukemia
1475607|NCT00077558|secondary acute myeloid leukemia
1475608|NCT00077558|adult acute minimally differentiated myeloid leukemia (M0)
1475609|NCT00077558|adult acute monocytic leukemia (M5b)
1475610|NCT00077558|adult acute erythroid leukemia (M6)
1475611|NCT00077558|adult acute megakaryoblastic leukemia (M7)
1475612|NCT00077558|adult acute myeloblastic leukemia with maturation (M2)
1475613|NCT00077558|adult acute myeloblastic leukemia without maturation (M1)
1475614|NCT00077558|adult acute myelomonocytic leukemia (M4)
1475615|NCT00077558|adult acute monoblastic leukemia (M5a)
1475616|NCT00077558|adult acute promyelocytic leukemia (M3)
1475617|NCT00077558|adult acute eosinophilic leukemia
1475618|NCT00077558|adult acute basophilic leukemia
1475619|NCT00077558|atypical chronic myeloid leukemia
1475620|NCT00077558|myelodysplastic/myeloproliferative disease, unclassifiable
1475621|NCT00077558|adult acute myeloid leukemia with t(8;21)(q22;q22)
1475622|NCT00077558|adult acute myeloid leukemia with t(16;16)(p13;q22)
1475623|NCT00077558|adult acute myeloid leukemia with inv(16)(p13;q22)
1475624|NCT00077558|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1475625|NCT00077558|adult acute myeloid leukemia with t(15;17)(q22;q12)
1475626|NCT00077532|stage IV melanoma
1475627|NCT00077532|recurrent melanoma
1475628|NCT00077519|stage II pancreatic cancer
1475629|NCT00077519|stage III pancreatic cancer
1475630|NCT00077519|recurrent pancreatic cancer
1475631|NCT00077493|recurrent childhood acute lymphoblastic leukemia
1475632|NCT00077493|Burkitt lymphoma
1475633|NCT00077493|recurrent childhood large cell lymphoma
1475634|NCT00077493|recurrent childhood lymphoblastic lymphoma
1475635|NCT00077493|childhood non-Hodgkin lymphoma
1475636|NCT00077415|recurrent non-small cell lung cancer
1475637|NCT00077415|stage IIIA non-small cell lung cancer
1475638|NCT00077415|stage IIIB non-small cell lung cancer
1475639|NCT00077415|stage IV non-small cell lung cancer
1475640|NCT00077415|adenocarcinoma of the lung
1475641|NCT00077415|bronchoalveolar cell lung cancer
1475642|NCT00077415|large cell lung cancer
1475643|NCT00077415|squamous cell lung cancer
1475644|NCT00077402|recurrent prostate cancer
1475645|NCT00077402|stage III prostate cancer
1475646|NCT00077402|stage IV prostate cancer
1475647|NCT00077402|adenocarcinoma of the prostate
1475648|NCT00077389|childhood hepatoblastoma
1475649|NCT00077389|stage IV childhood liver cancer
1475650|NCT00077337|recurrent colon cancer
1475651|NCT00077337|stage III colon cancer
1475652|NCT00077337|stage IV colon cancer
1475653|NCT00077337|recurrent rectal cancer
1475654|NCT00077337|stage III rectal cancer
1475655|NCT00077337|stage IV rectal cancer
1475656|NCT00077324|stage I non-small cell lung cancer
1475657|NCT00077311|drug/agent toxicity by tissue/organ
1475658|NCT00077311|anemia
1475659|NCT00077311|neutropenia
1475660|NCT00077311|stage IV non-small cell lung cancer
1475661|NCT00077311|stage IIIB non-small cell lung cancer
1475662|NCT00077311|recurrent non-small cell lung cancer
1475663|NCT00077311|squamous cell lung cancer
1475664|NCT00077311|large cell lung cancer
1475665|NCT00077311|adenocarcinoma of the lung
1475666|NCT00077311|bronchoalveolar cell lung cancer
1475667|NCT00077311|adenosquamous cell lung cancer
1475668|NCT00077285|previously untreated childhood rhabdomyosarcoma
1475669|NCT00077285|embryonal childhood rhabdomyosarcoma
1475670|NCT00077285|alveolar childhood rhabdomyosarcoma
1475671|NCT00077285|adult rhabdomyosarcoma
1475672|NCT00077285|stage IV adult soft tissue sarcoma
1475673|NCT00077285|metastatic childhood soft tissue sarcoma
1475674|NCT00077285|nonmetastatic childhood soft tissue sarcoma
1475675|NCT00077285|childhood malignant mesenchymoma
1475676|NCT00077285|adult malignant mesenchymoma
1475677|NCT00077285|stage III adult soft tissue sarcoma
1475678|NCT00077285|stage II adult soft tissue sarcoma
1475679|NCT00077285|stage I adult soft tissue sarcoma
1475680|NCT00077259|recurrent colon cancer
1475681|NCT00077259|recurrent rectal cancer
1475682|NCT00077259|stage III colon cancer
1475683|NCT00077259|stage III rectal cancer
1475684|NCT00077259|stage IV colon cancer
1475685|NCT00077259|stage IV rectal cancer
1475686|NCT00077259|adenocarcinoma of the colon
1475687|NCT00077259|adenocarcinoma of the rectum
1475688|NCT00077246|stage IV non-small cell lung cancer
1475689|NCT00077246|recurrent non-small cell lung cancer
1475690|NCT00077233|adenocarcinoma of the colon
1475691|NCT00077233|adenocarcinoma of the rectum
1475692|NCT00077233|recurrent colon cancer
1475693|NCT00077233|recurrent rectal cancer
1475694|NCT00077233|stage IV colon cancer
1475695|NCT00077233|stage IV rectal cancer
1475696|NCT00077220|stage II non-small cell lung cancer
1475697|NCT00077220|stage IIIA non-small cell lung cancer
1475698|NCT00077220|stage IIIB non-small cell lung cancer
1475699|NCT00077207|untreated childhood cerebellar astrocytoma
1475700|NCT00077207|untreated childhood visual pathway and hypothalamic glioma
1475701|NCT00077207|childhood spinal cord neoplasm
1475702|NCT00077207|childhood oligodendroglioma
1475703|NCT00077207|childhood low-grade cerebral astrocytoma
1475704|NCT00077194|recurrent adult diffuse large cell lymphoma
1475705|NCT00077194|recurrent mantle cell lymphoma
1475706|NCT00077194|recurrent adult Burkitt lymphoma
1475707|NCT00077168|ductal breast carcinoma in situ
1475708|NCT00077168|breast cancer in situ
1475709|NCT00077142|advanced adult primary liver cancer
1475710|NCT00077142|recurrent adult primary liver cancer
1475711|NCT00077142|adult primary hepatocellular carcinoma
1475712|NCT00077142|localized unresectable adult primary liver cancer
1475713|NCT00077142|Oral TAC-101
1475714|NCT00077129|stage III renal cell cancer
1475715|NCT00077129|stage IV renal cell cancer
1475716|NCT00077129|recurrent renal cell cancer
1475717|NCT00077116|untreated adult acute myeloid leukemia
1475718|NCT00077116|refractory anemia with excess blasts
1475719|NCT00077116|refractory anemia with excess blasts in transformation
1475720|NCT00077116|chronic myelomonocytic leukemia
1475721|NCT00077116|de novo myelodysplastic syndromes
1475722|NCT00077116|secondary myelodysplastic syndromes
1475723|NCT00077116|adult acute myeloid leukemia with t(8;21)(q22;q22)
1475724|NCT00077116|adult acute myeloid leukemia with t(16;16)(p13;q22)
1475725|NCT00077116|adult acute myeloid leukemia with inv(16)(p13;q22)
1475726|NCT00077116|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1475727|NCT00077116|adult acute myeloid leukemia with t(15;17)(q22;q12)
1475728|NCT00077116|childhood myelodysplastic syndromes
1475729|NCT00077103|anaplastic thyroid cancer
1475730|NCT00077090|lymphedema
1475731|NCT00077090|radiation fibrosis
1475732|NCT00077090|perioperative/postoperative complications
1475733|NCT00077090|stage I breast cancer
1475734|NCT00077090|stage II breast cancer
1475735|NCT00077090|stage IIIA breast cancer
1475736|NCT00077077|unspecified adult solid tumor, protocol specific
1475737|NCT00077064|radiation fibrosis
1475738|NCT00077064|pulmonary complications
1475739|NCT00077064|limited stage small cell lung cancer
1475740|NCT00077064|stage II non-small cell lung cancer
1475741|NCT00077064|stage IIIA non-small cell lung cancer
1475742|NCT00077064|stage IIIB non-small cell lung cancer
1475743|NCT00077064|stage I non-small cell lung cancer
1475744|NCT00077051|stage III squamous cell carcinoma of the lip and oral cavity
1475745|NCT00077051|stage III squamous cell carcinoma of the oropharynx
1475746|NCT00077051|stage IV squamous cell carcinoma of the lip and oral cavity
1475747|NCT00077051|stage IV squamous cell carcinoma of the oropharynx
1475748|NCT00077038|Visual Feedback
1475749|NCT00077038|Cortical Connectivity
1475750|NCT00077038|Magnetoencephalography
1475751|NCT00077038|Eye Tracking
1475752|NCT00077038|Healthy Volunteer
1475753|NCT00077038|HV
1475754|NCT00077025|metastatic breast cancer
1475755|NCT00077012|BPH
1475756|NCT00076986|brain tumor
1475757|NCT00076986|recurrent malignant glioma
1475758|NCT00076986|brain neoplasm
1475759|NCT00076986|central nervous system
1475760|NCT00076986|surgery
1475761|NCT00076986|resection
1475762|NCT00076986|GLIADEL
1475763|NCT00076986|infusion
1475764|NCT00076986|glioblastoma multiforme
1475765|NCT00076986|convection-enhanced delivery
1475766|NCT00076986|first recurrence
1475767|NCT00076986|recurrent GBM
1475768|NCT00076986|GBM
1475769|NCT00076986|supratentorial GBM
1475770|NCT00076973|RSV Bronchiolitis
1475771|NCT00076960|hyperbilirubinemia
1475772|NCT00076960|jaundice
1475773|NCT00076960|tin-mesoporphyrin
1475774|NCT00076960|stannsoporfin
1475775|NCT00076960|exchange transfusion
1475776|NCT00076960|neonatal hyperbilirubinemia
1475777|NCT00076947|HIV Preventive Vaccine
1475778|NCT00076947|HIV Seronegativity
1475779|NCT00076947|Protein
1475780|NCT00076934|Ataxia
1475781|NCT00076934|MRI
1475782|NCT00076934|MS
1475783|NCT00076934|CTLA4-IgG4m
1475784|NCT00076934|Costimulatory Signals
1475785|NCT00076934|Autoimmune Disorders
1475786|NCT00076869|Definite or probable Invasive Aspergillosis either refractory or intolerant to prior antifungal treatment.
1475787|NCT00076843|Interleukin-15
1475788|NCT00076843|CD8+ T-cells
1475789|NCT00076843|HAM/TSP
1475790|NCT00076843|HTLV-1
1475791|NCT00076843|HTLV-1 Associated Myelopathy
1475792|NCT00076843|Tropical Spastic Paraparesis
1475793|NCT00076830|Errors of Bone Matrix and Metabolism
1475794|NCT00076830|Connective Tissue Disorders
1475795|NCT00076817|HIV Preventive Vaccine
1475796|NCT00076817|ALVAC Vaccine
1475797|NCT00076817|Immunization Site
1475798|NCT00076817|Deltoid
1475799|NCT00076817|Groin
1475800|NCT00076817|Targeted Inguinal Lymph Node
1475801|NCT00076817|TILN
1475802|NCT00076804|Directly Observed Therapy
1475803|NCT00076804|DOT
1475804|NCT00076791|HIV Seronegativity
1475805|NCT00076752|Refractory SLE
1475806|NCT00076752|Immunoablation
1475807|NCT00076752|Immunological Recovery
1475808|NCT00076752|Efficacy
1475809|NCT00076752|Mechanism of Disease
1475810|NCT00076752|Lupus
1475811|NCT00076752|Systemic Lupus Erythematosus
1475812|NCT00076752|SLE
1475813|NCT00076739|Prefrontal Cortex
1475814|NCT00076739|Semantic Memory
1475815|NCT00076739|Semantic Relations
1475816|NCT00076739|Priming Paradigm
1475817|NCT00076739|fMRI
1475818|NCT00076739|Healthy Volunteer
1475819|NCT00076739|HV
1475820|NCT00076726|Giant Cell Arteritis
1475821|NCT00076726|infliximab
1475822|NCT00076713|Antiphospholipid
1475823|NCT00076700|Cross-Modal Plasticity
1475824|NCT00076700|Functional MRI
1475825|NCT00076700|Behavior
1475826|NCT00076700|Memory
1475827|NCT00076700|Blind
1475828|NCT00076700|Blindness
1475829|NCT00076700|Healthy Volunteer
1475830|NCT00076700|HV
1475831|NCT00076674|Parkinson's Disease
1475832|NCT00076674|Keppra
1475833|NCT00076674|Motor Fluctuations
1475834|NCT00076674|Intravenous Levodopa
1475835|NCT00076674|Antiparkinsonian Response
1475836|NCT00076674|Parkinson Disease
1475837|NCT00076674|PD
1475838|NCT00076635|Idiopathic
1475839|NCT00076635|Pulmonary
1475840|NCT00076635|Fibrosis
1475841|NCT00076635|IPF
1475842|NCT00076635|Lung
1475843|NCT00076635|Actimmune
1475844|NCT00076635|Interferon
1475845|NCT00076635|Gamma
1475846|NCT00076635|InterMune
1475847|NCT00076622|Antidepressant drugs
1475848|NCT00076622|Nursing Homes
1475849|NCT00076609|hepatocellular carcinoma
1475850|NCT00076609|advanced
1475851|NCT00076609|unresectable
1475852|NCT00076609|liver cancer
1475853|NCT00076609|systemic chemotherapy
1475854|NCT00076609|botanical
1475855|NCT00076609|herbal
1475856|NCT00076609|alternative and complementary medicine
1475857|NCT00076609|capecitabine
1475858|NCT00076609|PHY906
1475859|NCT00076609|oral
1475860|NCT00076609|HCC
1475861|NCT00076609|traditional chinese medicine
1475862|NCT00076609|tcm
1475863|NCT00076609|QOL
1475864|NCT00076609|quality of life
1475865|NCT00076596|Corticospinal Tracts
1475866|NCT00076596|Spastic Hemiplegia
1475867|NCT00076596|Spastic Diplegia
1475868|NCT00076596|Cortical Re-Organization
1475869|NCT00076596|Functional Outcome
1475870|NCT00076596|Cerebral Palsy
1475871|NCT00076583|Motor Learning
1475872|NCT00076583|Co-contraction
1475873|NCT00076583|Reciprocal Inhibition
1475874|NCT00076583|Spinal Plasticity
1475875|NCT00076583|Rhythmic Movement
1475876|NCT00076583|Healthy Volunteer
1475877|NCT00076583|HV
1475878|NCT00076570|Tolerance
1475879|NCT00076570|Kidney
1475880|NCT00076570|Transplant
1475881|NCT00076570|Polyclonal
1475882|NCT00076570|Antibody
1475883|NCT00076570|Kidney Transplant
1475884|NCT00076557|Hemophilia B
1475885|NCT00076557|Factor IX
1475886|NCT00076557|Gene Transfer
1475887|NCT00076557|Adeno-Associated Virus (AAV)
1475888|NCT00076544|Intrathecal
1475889|NCT00076531|Prostate
1475890|NCT00076531|Cancer
1475891|NCT00076531|PSA
1475892|NCT00076531|Leuprolide
1475893|NCT00076518|Treatment Experienced
1475894|NCT00076505|Mitochondria
1475895|NCT00076505|Proteasome
1475896|NCT00076505|Lipid
1475897|NCT00076505|Polymorphism
1475898|NCT00076505|Genetic
1475899|NCT00076505|Parkinson's Disease
1475900|NCT00076505|Parkinson Disease
1475901|NCT00076505|PD
1475902|NCT00076505|Heredity
1475903|NCT00076505|Parkinson Disease At Risk
1475904|NCT00076505|Healthy Volunteer
1475905|NCT00076505|HV
1475906|NCT00076492|Parkinson's disease
1475907|NCT00076492|Parkinson disease
1475908|NCT00076492|CoQ10
1475909|NCT00076492|GPI 1485
1475910|NCT00076479|Aphasia
1475911|NCT00076479|Rehabilitation
1475912|NCT00076479|Neuroplasticity
1475913|NCT00076479|Picture Naming
1475914|NCT00076479|Transcranial Magnetic
1475915|NCT00076479|Stroke
1475916|NCT00076479|Healthy Volunteer
1475917|NCT00076479|HV
1475918|NCT00076466|Brain Excitability
1475919|NCT00076466|Reaction Time
1475920|NCT00076466|Plasticity
1475921|NCT00076466|Motor Evoked Potential
1475922|NCT00076466|Transcranial Magnetic Stimulation
1475923|NCT00076466|Healthy Volunteer
1475924|NCT00076466|HV
1475925|NCT00076453|Knee Pain
1475926|NCT00076453|Degenerative Arthritis
1475927|NCT00076453|Cartilage Disease
1475928|NCT00076453|Non-drug Therapy
1475929|NCT00076440|Alzheimer disease
1475930|NCT00076427|Immunity
1475931|NCT00076427|Liver
1475932|NCT00076427|Apheresis
1475933|NCT00076427|Cytokine
1475934|NCT00076427|Virology
1475935|NCT00076427|Hepatitis C
1475936|NCT00076427|HCV
1475937|NCT00076427|Hepatitis C co-infection
1475938|NCT00076414|Endothelial Function
1475939|NCT00076414|Lopinavir/Ritonavir
1475940|NCT00076414|HIV
1475941|NCT00076414|Blood Flow Studies
1475942|NCT00076414|Flow-Mediated Vasodilatation
1475943|NCT00076414|Healthy Volunteer
1475944|NCT00076414|HV
1475945|NCT00076401|CLL
1475946|NCT00076401|chronic lymphocytic leukemia
1475947|NCT00076401|relapsed chronic lymphocytic leukemia
1475948|NCT00076401|refractory chronic lymphocytic leukemia
1475949|NCT00076401|Leukemia
1475950|NCT00076401|Motexafin gadolinium
1475951|NCT00076401|Chronic leukemia
1475952|NCT00076401|Lymphocytic leukemia, chronic
1475953|NCT00076388|Non-Small-Cell Lung Cancer
1475954|NCT00076375|Atopic Dermatitis
1475955|NCT00076375|Eczema
1475956|NCT00076349|Non-Hodgkin's Lymphoma
1475957|NCT00076349|NHL
1475958|NCT00076349|Rituxan
1475959|NCT00076349|Mantle Cell
1475960|NCT00076349|mabs
1475961|NCT00076323|G6PD
1475962|NCT00076323|Favism
1475963|NCT00076323|G6PD Deficiency
1475964|NCT00076323|hemolysis
1475965|NCT00076323|drug reaction
1475966|NCT00076323|drug-induced hemolysis
1475967|NCT00076310|Head and Neck Cancer
1475968|NCT00076310|Squamous Cell Cancer
1475969|NCT00076310|OSI-774
1475970|NCT00076310|Cisplatin
1475971|NCT00076310|Platinol®-AQ
1475972|NCT00076310|Platinol®
1475973|NCT00076310|CDDP
1475974|NCT00076310|Docetaxel
1475975|NCT00076310|Taxotere
1475976|NCT00076310|Tarceva
1475977|NCT00076310|HNSCC
1475978|NCT00076310|Erlotinib Hydrochloride
1475979|NCT00076284|CCR5 Antagonist
1475980|NCT00076284|Coreceptor Inhibitor
1475981|NCT00076284|Fusion Inhibitor
1475982|NCT00076284|Entry Inhibitor
1475983|NCT00076284|Antiretroviral
1475984|NCT00076284|HIV
1475985|NCT00076271|Strabismus
1475986|NCT00076271|Cataract, Pediatric
1475987|NCT00076271|Optic Nerve Anomaly
1475988|NCT00076271|Coloboma
1475989|NCT00076271|Evaluation and Treatment
1475990|NCT00076271|Pediatric Ophthalmology
1475991|NCT00076271|Genetic Eye Disease
1475992|NCT00076271|Nystagmus
1475993|NCT00076271|Pediatric Eye Disease
1475994|NCT00076271|Developmental Eye Condition
1475995|NCT00076271|Cataract
1475996|NCT00076271|Juvenile Glaucoma
1475997|NCT00076271|Eye Movement Disorder
1475998|NCT00076258|Exercise therapy
1475999|NCT00076258|Complementary Therapies
1476000|NCT00076245|Phototherapy
1476001|NCT00076232|HIV Seronegativity
1476002|NCT00076219|Acute Renal Failure
1476003|NCT00076219|Renal Replacement Therapy
1476004|NCT00076219|multi-site randomization trial
1476005|NCT00076219|Hemodialysis
1476006|NCT00076219|Hemofiltration
1476007|NCT00076219|Critical Illness
1476008|NCT00076219|Hemodiafiltration
1476009|NCT00076180|cytotoxic activity against T-LGL cells
1476010|NCT00076180|chronic lymphoproliferative disorder
1476011|NCT00076180|T-LGL Leukemia
1476012|NCT00076180|Natural Killer Cells
1476013|NCT00076180|Leukemia
1476014|NCT00076180|Lymphocytic Leukemia
1476015|NCT00076180|T-LGL
1476016|NCT00076154|ALS
1476017|NCT00076141|relatively healthy male
1476018|NCT00076115|Bipolar
1476019|NCT00076115|Mania
1476020|NCT00076115|Manic
1476021|NCT00076115|Depressive
1476022|NCT00076115|Manic Depressive
1476023|NCT00076115|Bipolar mania
1476024|NCT00076115|risperidone
1476025|NCT00076115|adolescents
1476026|NCT00076115|children
1476027|NCT00076102|Side Effect
1476028|NCT00076102|Oral Administration
1476029|NCT00076102|Nerve Sheath Tumor
1476030|NCT00076102|Antifibrotic Agent
1476031|NCT00076102|Volumetric Tumor Measurement
1476032|NCT00076102|Plexiform Neurofibroma
1476033|NCT00076102|Neurofibromatosis Type 1
1476034|NCT00076102|Volumetric MRI Analysis
1476035|NCT00076102|Time to Progression
1476036|NCT00076102|NF1
1476037|NCT00076089|Roflumilast
1476038|NCT00076089|Chronic obstructive pulmonary disease
1476039|NCT00076089|COPD
1476040|NCT00076076|Roflumilast
1476041|NCT00076076|Asthma
1476042|NCT00076063|HIV Seronegativity
1476043|NCT00076063|ALVAC-HIV vCP1452
1476044|NCT00076063|ALVAC Vaccine
1476045|NCT00076063|HIV-1
1476046|NCT00076063|Normal Values
1476047|NCT00076063|HIV Preventive Vaccine
1476048|NCT00076037|HIV Preventive Vaccine
1476049|NCT00076037|Granulocyte-Macrophage Colony-Stimulating Factor
1476050|NCT00076037|AIDS Vaccines
1476051|NCT00076037|HIV-1
1476052|NCT00076037|HIV Seronegativity
1476053|NCT00076037|Injections, Intramuscular
1476054|NCT00076037|RC529
1476055|NCT00076037|Epitopes
1476056|NCT00076037|T-Lymphocytes, Cytotoxic
1476057|NCT00076024|metastatic breast cancer
1476058|NCT00075998|Idiopathic
1476059|NCT00075998|Pulmonary
1476060|NCT00075998|Fibrosis
1476061|NCT00075998|IPF
1476062|NCT00075998|Lung
1476063|NCT00075998|Interferon
1476064|NCT00075998|Gamma
1476065|NCT00075998|Actimmune
1476066|NCT00075998|INSPIRE
1476067|NCT00075998|InterMune
1476068|NCT00075959|Stroke
1476069|NCT00075959|cerebral vascular accident
1476070|NCT00075959|CVA
1476071|NCT00075959|Hemorrhage
1476072|NCT00075959|Intracerebral Hemorrhage (ICH)
1476073|NCT00075959|Brain Attack
1476074|NCT00075959|Cataplexy
1476075|NCT00075946|stage III grade 1 follicular lymphoma
1476076|NCT00075946|stage III grade 2 follicular lymphoma
1476077|NCT00075946|stage IV grade 1 follicular lymphoma
1476078|NCT00075946|stage IV grade 2 follicular lymphoma
1476079|NCT00075946|stage III small lymphocytic lymphoma
1476080|NCT00075946|stage III marginal zone lymphoma
1476081|NCT00075946|stage IV small lymphocytic lymphoma
1476082|NCT00075946|stage IV marginal zone lymphoma
1476083|NCT00075946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1476084|NCT00075946|nodal marginal zone B-cell lymphoma
1476085|NCT00075946|splenic marginal zone lymphoma
1476086|NCT00075920|Heart
1476087|NCT00075920|Function
1476088|NCT00075920|Ultrasound
1476089|NCT00075920|MRI
1476090|NCT00075920|Left Ventricle
1476091|NCT00075920|Healthy Volunteer
1476092|NCT00075920|HV
1476093|NCT00075920|Heart Disease
1476094|NCT00075907|Acute Infection
1476095|NCT00075907|Treatment Experienced
1476096|NCT00075907|Treatment Naive
1476097|NCT00075894|adult anaplastic oligodendroglioma
1476098|NCT00075894|adult anaplastic astrocytoma
1476099|NCT00075894|adult glioblastoma
1476100|NCT00075894|recurrent adult brain tumor
1476101|NCT00075894|adult giant cell glioblastoma
1476102|NCT00075894|adult gliosarcoma
1476103|NCT00075868|radiation enteritis
1476104|NCT00075868|drug/agent toxicity by tissue/organ
1476105|NCT00075868|stage I rectal cancer
1476106|NCT00075868|stage II rectal cancer
1476107|NCT00075868|stage III rectal cancer
1476108|NCT00075868|stage IIIA anal cancer
1476109|NCT00075868|stage IIIB anal cancer
1476110|NCT00075868|recurrent anal cancer
1476111|NCT00075868|stage I anal cancer
1476112|NCT00075868|stage II anal cancer
1476113|NCT00075868|recurrent rectal cancer
1476114|NCT00075855|sexual dysfunction
1476115|NCT00075855|unspecified adult solid tumor, protocol specific
1476116|NCT00075855|sexuality and reproductive issues
1476117|NCT00075855|cancer survivor
1476118|NCT00075842|sleep disorders
1476119|NCT00075842|unspecified adult solid tumor, protocol specific
1476120|NCT00075842|fatigue
1476121|NCT00075829|Stage II Multiple Myeloma
1476122|NCT00075829|Stage III Multiple Myeloma
1476123|NCT00075829|Refractory Plasma Cell Neoplasm
1476124|NCT00075803|Myelodysplastic and Myeloproliferative Diseases
1476125|NCT00075777|recurrent Kaposi sarcoma
1476126|NCT00075777|AIDS-related Kaposi sarcoma
1476127|NCT00075764|stage IV breast cancer
1476128|NCT00075764|recurrent breast cancer
1476129|NCT00075738|stage IV esophageal cancer
1476130|NCT00075738|recurrent esophageal cancer
1476131|NCT00075725|untreated childhood acute lymphoblastic leukemia
1476132|NCT00075725|B-cell childhood acute lymphoblastic leukemia
1476133|NCT00075725|untreated adult acute lymphoblastic leukemia
1476134|NCT00075725|B-cell adult acute lymphoblastic leukemia
1476135|NCT00075712|stage IV ovarian epithelial cancer
1476136|NCT00075712|stage IIIA fallopian tube cancer
1476137|NCT00075712|stage IIIB fallopian tube cancer
1476138|NCT00075712|stage IIIC fallopian tube cancer
1476139|NCT00075712|stage IV fallopian tube cancer
1476140|NCT00075712|stage IIIA primary peritoneal cavity cancer
1476141|NCT00075712|stage IIIB primary peritoneal cavity cancer
1476142|NCT00075712|stage IIIC primary peritoneal cavity cancer
1476143|NCT00075712|stage IV primary peritoneal cavity cancer
1476144|NCT00075712|stage IIIA ovarian epithelial cancer
1476145|NCT00075712|stage IIIB ovarian epithelial cancer
1476146|NCT00075712|stage IIIC ovarian epithelial cancer
1476147|NCT00075699|epithelial mesothelioma
1476148|NCT00075699|localized malignant mesothelioma
1476149|NCT00075699|advanced malignant mesothelioma
1476150|NCT00075686|adenocarcinoma of the pancreas
1476151|NCT00075686|stage III pancreatic cancer
1476152|NCT00075686|stage IV pancreatic cancer
1476153|NCT00075673|recurrent breast cancer
1476154|NCT00075673|stage IV breast cancer
1476155|NCT00075660|recurrent renal cell cancer
1476156|NCT00075660|stage III renal cell cancer
1476157|NCT00075660|stage IV renal cell cancer
1476158|NCT00075621|primary systemic amyloidosis
1476159|NCT00075608|primary systemic amyloidosis
1476160|NCT00075595|stage IV colon cancer
1476161|NCT00075595|stage IV rectal cancer
1476162|NCT00075595|recurrent colon cancer
1476163|NCT00075595|recurrent rectal cancer
1476164|NCT00075595|adenocarcinoma of the colon
1476165|NCT00075595|adenocarcinoma of the rectum
1476166|NCT00075569|cervical cancer
1476167|NCT00075569|cervical intraepithelial neoplasia grade 3
1476168|NCT00075556|stage III colon cancer
1476169|NCT00075556|stage IV colon cancer
1476170|NCT00075556|stage III rectal cancer
1476171|NCT00075556|stage IV rectal cancer
1476172|NCT00075556|adenocarcinoma of the rectum
1476173|NCT00075556|adenocarcinoma of the colon
1476174|NCT00075543|recurrent ovarian epithelial cancer
1476175|NCT00075543|stage III ovarian epithelial cancer
1476176|NCT00075543|stage IV ovarian epithelial cancer
1476177|NCT00075517|stage IIIB non-small cell lung cancer
1476178|NCT00075517|stage IV non-small cell lung cancer
1476179|NCT00075517|adenocarcinoma of the lung
1476180|NCT00075517|large cell lung cancer
1476181|NCT00075517|squamous cell lung cancer
1476182|NCT00075465|adenocarcinoma of the stomach
1476183|NCT00075465|stage III gastric cancer
1476184|NCT00075465|stage IV gastric cancer
1476185|NCT00075452|adenocarcinoma of the pancreas
1476186|NCT00075452|stage II pancreatic cancer
1476187|NCT00075452|stage III pancreatic cancer
1476188|NCT00075452|stage IV pancreatic cancer
1476189|NCT00075426|stage IIIA non-small cell lung cancer
1476190|NCT00075426|stage IIIB non-small cell lung cancer
1476191|NCT00075426|stage IV non-small cell lung cancer
1476192|NCT00075426|recurrent non-small cell lung cancer
1476193|NCT00075413|stage IIIB breast cancer
1476194|NCT00075413|stage IIIC breast cancer
1476195|NCT00075413|stage IV breast cancer
1476196|NCT00075413|recurrent breast cancer
1476197|NCT00075413|stage IIIA breast cancer
1476198|NCT00075374|stage IIIB non-small cell lung cancer
1476199|NCT00075374|stage IV non-small cell lung cancer
1476200|NCT00075374|recurrent non-small cell lung cancer
1476201|NCT00075348|renal cell carcinoma
1476202|NCT00075348|von Hippel-Lindau syndrome
1476203|NCT00075335|Hematopoietic Stem Cells
1476204|NCT00075335|Mobilization
1476205|NCT00075335|Alloreactivity
1476206|NCT00075335|T Cell Polarization
1476207|NCT00075335|Dendritic Cells
1476208|NCT00075335|Plerixafor
1476209|NCT00075335|Mozobil
1476210|NCT00075335|Healthy Volunteer
1476211|NCT00075335|HV
1476212|NCT00075296|Major Depressive Disorder
1476213|NCT00075296|Bipolar Disorder
1476214|NCT00075296|Negative Feedback
1476215|NCT00075296|Cognitive Performance
1476216|NCT00075296|Negative Affect
1476217|NCT00075296|Depression
1476218|NCT00075296|Major Depression
1476219|NCT00075296|MDD
1476220|NCT00075296|Healthy Volunteer
1476221|NCT00075296|HV
1476222|NCT00075283|Physical Therapy
1476223|NCT00075283|Locomotion therapy
1476224|NCT00075283|Gait training
1476225|NCT00075283|Stroke
1476226|NCT00075283|Robotics
1476227|NCT00075283|Rehabilitation
1476228|NCT00075283|Treadmill
1476229|NCT00075283|Hemiparetic stroke
1476230|NCT00075283|Unilateral brain lesion
1476231|NCT00075270|metastatic breast cancer
1476232|NCT00075270|ErbB1
1476233|NCT00075270|kinase inhibitor
1476234|NCT00075270|ErbB2
1476235|NCT00075270|EGFR
1476236|NCT00075270|lapatinib
1476237|NCT00075270|Her2-neu
1476238|NCT00075244|Lysosomes
1476239|NCT00075244|Storage
1476240|NCT00075244|Glycolipid
1476241|NCT00075244|Fabry Disease
1476242|NCT00075244|Stroke
1476243|NCT00075231|Treatment Naive
1476244|NCT00075205|Alcohol Consumption
1476245|NCT00075205|Alcohol Treatment
1476246|NCT00075205|Medication Trial
1476247|NCT00075205|Craving
1476248|NCT00075205|Cannabinoids
1476249|NCT00075205|CB 1 Receptor Antagonist
1476250|NCT00075205|SR141716
1476251|NCT00075205|Alcoholism
1476252|NCT00075179|Pulmonary hypertension
1476253|NCT00075179|cancer
1476254|NCT00075179|lung cancer
1476255|NCT00075179|lung disease
1476256|NCT00075179|cardiothoracic surgery
1476257|NCT00075179|Nesiritide
1476258|NCT00075179|Natrecor
1476259|NCT00075179|CV Surgery
1476260|NCT00075179|Lung Tumor
1476261|NCT00075166|Stereotactic
1476262|NCT00075166|Carcinoma
1476263|NCT00075166|Melanoma
1476264|NCT00075166|Surgical Resection
1476265|NCT00075166|Metastases
1476266|NCT00075166|Metastatic Brain Tumor
1476267|NCT00075166|Surgery
1476268|NCT00075166|Radiosurgery
1476269|NCT00075166|Treatment
1476270|NCT00075153|ADOLESCENCE
1476271|NCT00075153|HIV INFECTION
1476272|NCT00075153|PEDIATRIC AIDS
1476273|NCT00075153|QUALITY OF LIFE
1476274|NCT00075153|HIV
1476275|NCT00075140|Patient Care Management
1476276|NCT00075140|Family
1476277|NCT00075140|Huntington's Disease
1476278|NCT00075114|Self Care
1476279|NCT00075114|Behavior Modification
1476280|NCT00075101|Drug Adverse Effect
1476281|NCT00075101|Pediatric Cancer
1476282|NCT00075088|Telemedicine
1476283|NCT00075088|Emergency Care
1476284|NCT00075088|Cardiac
1476285|NCT00075075|Infliximab
1476286|NCT00075075|Scleritis
1476287|NCT00075075|Intraocular Inflammatory Disease
1476288|NCT00075075|Corticosteroids
1476289|NCT00075075|Immunosuppressives
1476290|NCT00075049|malaria
1476291|NCT00075036|Health Disparities
1476292|NCT00075036|Transplantation
1476293|NCT00075036|Trust
1476294|NCT00075036|Interview
1476295|NCT00075036|Ethnic Bias
1476296|NCT00075023|Stomatitis
1476297|NCT00075023|Oropharyngeal pain
1476298|NCT00075023|TNF-alpha
1476299|NCT00075023|Allogeneic hematopoietic stem cell transplant
1476300|NCT00075023|Inflammation
1476301|NCT00075023|Thalidomide
1476302|NCT00075023|Oral chronic graft-versus-host disease
1476303|NCT00075010|Relapsed/Refractory Leukemia
1476304|NCT00075010|Myelodysplastic Syndromes
1476305|NCT00074997|Gene Therapy
1476306|NCT00074997|Anti-HIV-1 Ribozyme
1476307|NCT00074997|OZ1
1476308|NCT00074997|HIV-1 Infections
1476309|NCT00074984|a-Galactosidase A
1476310|NCT00074984|aGAL
1476311|NCT00074984|r-haGAL
1476312|NCT00074984|Fabry
1476313|NCT00074984|GL-3
1476314|NCT00074984|Fabrazyme
1476315|NCT00074971|a-Galactosidase A
1476316|NCT00074971|aGAL
1476317|NCT00074971|r-haGAL
1476318|NCT00074971|Fabry
1476319|NCT00074971|GL-3
1476320|NCT00074971|Fabrazyme
1476321|NCT00074958|a-Galactosidase A
1476322|NCT00074958|aGal
1476323|NCT00074958|r-haGAL
1476324|NCT00074958|Fabry
1476325|NCT00074958|GL-3
1476326|NCT00074958|Fabrazyme
1476327|NCT00074945|Obesity
1476328|NCT00074945|Resting Energy Expenditure
1476329|NCT00074945|Metabolic Rate
1476330|NCT00074945|Visceral Fat
1476331|NCT00074945|Body Fat Distribution
1476332|NCT00074932|Glycogen Storage Disease Type II
1476333|NCT00074932|GSD-II
1476334|NCT00074932|Pompe Disease
1476335|NCT00074932|Acid Maltase Deficiency Disease
1476336|NCT00074919|Glycogen Storage Disease Type II
1476337|NCT00074919|GSD-II
1476338|NCT00074919|Pompe Disease
1476339|NCT00074919|Acid Maltase Deficiency Disease
1476340|NCT00074906|Aspiration of gastric contents
1476341|NCT00074893|Repetitive Strain Injuries
1476342|NCT00074893|Vibration Damping
1476343|NCT00074893|Protective Brace
1476344|NCT00074893|Piezoelectric
1476345|NCT00074893|SmartWear
1476346|NCT00074880|Cardiac Hypertrophy
1476347|NCT00074880|Diastolic Dysfunction
1476348|NCT00074880|Cardiac Glycosides
1476349|NCT00074880|Cardiac Fibrosis
1476350|NCT00074880|Atrial Systole
1476351|NCT00074841|MALARIA
1476352|NCT00074841|INDIA
1476353|NCT00074841|CHLOROQUINE
1476354|NCT00074841|PLASMODIUM FALCIPARUM
1476355|NCT00074841|SULFADOXINE-PYRIMETHAMINE
1476356|NCT00074828|elective
1476357|NCT00074828|primary unilateral
1476358|NCT00074815|Child
1476359|NCT00074815|Adolescent
1476360|NCT00074802|Social Phobia
1476361|NCT00074789|Early Head Start Program
1476362|NCT00074776|Bipolar Depression
1476363|NCT00074763|Leukemia
1476364|NCT00074763|Lymphoma
1476365|NCT00074763|ALL
1476366|NCT00074763|CLL
1476367|NCT00074763|AML
1476368|NCT00074763|CML
1476369|NCT00074763|MDS
1476370|NCT00074763|Remission
1476371|NCT00074763|Hematologic Disorder
1476372|NCT00074763|Transfusion
1476373|NCT00074763|Thrombosol
1476374|NCT00074763|Autologous Platelet Transfusion
1476375|NCT00074763|Platelet Transfusion
1476376|NCT00074763|Single donor platelet apheresis
1476377|NCT00074763|Cryopreservation
1476378|NCT00074763|Thrombocytopenia
1476379|NCT00074750|AML
1476380|NCT00074750|CMML
1476381|NCT00074737|Refractory or Relapsed Acute Myelogenous Leukemia (AML)
1476382|NCT00074737|Antisense
1476383|NCT00074711|Bone Mineral Density
1476384|NCT00074711|Calcium
1476385|NCT00074698|Idiopathic pulmonary fibrosis
1476386|NCT00074698|IPF
1476387|NCT00074698|Pulmonary fibrosis
1476388|NCT00074698|Respiratory disease
1476389|NCT00074685|Congenital
1476390|NCT00074685|Epidermal nevus
1476391|NCT00074685|Erythroderma
1476392|NCT00074685|Darier
1476393|NCT00074685|Hailey-Hailey
1476394|NCT00074685|Harlequin
1476395|NCT00074685|Ichthyosiform
1476396|NCT00074685|Ichthyosiform erythroderma
1476397|NCT00074685|Keratoderma
1476398|NCT00074685|Keratosis
1476399|NCT00074685|Pachyonychia
1476400|NCT00074685|Sjogren-Larsson
1476401|NCT00074672|Prepulse Inhibition
1476402|NCT00074672|PPI
1476403|NCT00074672|Dopamine
1476404|NCT00074672|Sensorimotor Integration
1476405|NCT00074672|Dopaminergic
1476406|NCT00074646|CC-8490
1476407|NCT00074646|CC8490
1476408|NCT00074646|Glio
1476409|NCT00074646|Glioblastoma
1476410|NCT00074646|Malignant Gliomas
1476411|NCT00074633|Type 2 Diabetes
1476412|NCT00074633|Self-Esteem
1476413|NCT00074620|Haemodialysis
1476414|NCT00074620|PEG-Hirudin
1476415|NCT00074620|Vascular graft occlusion
1476416|NCT00074620|Renal replacement therapy
1476417|NCT00074620|Hemodialysis
1476418|NCT00074607|Neoplastic meningitis
1476419|NCT00074581|HIV Infections
1476420|NCT00074581|HIV Seronegativity
1476421|NCT00074568|Genetic Study
1476422|NCT00074568|Transmission Dysequilibrium Testing
1476423|NCT00074568|Genome Wide Scan
1476424|NCT00074568|Family Study
1476425|NCT00074555|African American, Rheumatoid Arthritis
1476426|NCT00074542|Crohn's
1476427|NCT00074542|colon
1476428|NCT00074542|small bowel
1476429|NCT00074542|inflammation
1476430|NCT00074542|steroid therapy
1476431|NCT00074542|free fatty acids
1476432|NCT00074516|Immunosuppression
1476433|NCT00074516|Kidney
1476434|NCT00074516|Cysteamine
1476435|NCT00074516|Steroid-Free
1476436|NCT00074516|Outcomes
1476437|NCT00074503|Positron Emission Tomography
1476438|NCT00074503|Phospholipids
1476439|NCT00074503|Alcoholism
1476440|NCT00074503|[11C]Docosahexaenoate
1476441|NCT00074503|[150]Water
1476442|NCT00074503|Brain
1476443|NCT00074503|Fatty Acids
1476444|NCT00074503|Blood Flow
1476445|NCT00074503|Healthy
1476446|NCT00074490|Leukemia
1476447|NCT00074490|Lymphoma
1476448|NCT00074490|Multiple Myeloma
1476449|NCT00074490|Bone Marrow Transplantation
1476450|NCT00074490|Immune Therapy
1476451|NCT00074477|Schizophrenia
1476452|NCT00074477|Paliperidone palmitate
1476453|NCT00074477|R092670
1476454|NCT00074477|antipsychotic
1476455|NCT00074438|Rituxan
1476456|NCT00074438|RA
1476457|NCT00074425|HIV Seronegativity
1476458|NCT00074425|Anti-Infective Agents, Local
1476459|NCT00074425|BufferGel
1476460|NCT00074425|PRO 2000
1476461|NCT00074425|Vagina
1476462|NCT00074425|Risk Factors
1476463|NCT00074412|HIV Seronegativity
1476464|NCT00074412|Treatment Experienced
1476465|NCT00074412|Treatment Naive
1476466|NCT00074399|Maternal/Infant Transmisson
1476467|NCT00074399|Vertical Transmission
1476468|NCT00074399|Pregnancy
1476469|NCT00074399|HIV Seronegativity
1476470|NCT00074386|HIV
1476471|NCT00074386|Transplant
1476472|NCT00074386|Liver
1476473|NCT00074386|Kidney
1476474|NCT00074386|Organ
1476475|NCT00074386|Treatment Experienced
1476476|NCT00074386|Kidney Transplant
1476477|NCT00074386|Liver Transplant
1476478|NCT00074373|Anti-SSA/Ro Antibodies
1476479|NCT00074373|Anti-SSB/La Antibodies
1476480|NCT00074360|Ethanol
1476481|NCT00074360|fMRI
1476482|NCT00074360|Blood Flow
1476483|NCT00074360|Conditioning
1476484|NCT00074360|Reinforcement
1476485|NCT00074334|childhood high-grade cerebral astrocytoma
1476486|NCT00074334|recurrent childhood cerebral astrocytoma
1476487|NCT00074334|childhood oligodendroglioma
1476488|NCT00074334|childhood supratentorial ependymoma
1476489|NCT00074334|recurrent childhood ependymoma
1476490|NCT00074334|recurrent childhood brain tumor
1476491|NCT00074295|bronchoalveolar cell lung cancer
1476492|NCT00074295|stage IIIB non-small cell lung cancer
1476493|NCT00074295|stage IV non-small cell lung cancer
1476494|NCT00074295|recurrent non-small cell lung cancer
1476495|NCT00074282|refractory chronic lymphocytic leukemia
1476496|NCT00074282|B-cell chronic lymphocytic leukemia
1476497|NCT00074269|recurrent breast cancer
1476498|NCT00074269|stage IV breast cancer
1476499|NCT00074243|adult anaplastic astrocytoma
1476500|NCT00074243|adult anaplastic oligodendroglioma
1476501|NCT00074243|adult glioblastoma
1476502|NCT00074243|adult mixed glioma
1476503|NCT00074243|adult brain stem glioma
1476504|NCT00074243|recurrent adult brain tumor
1476505|NCT00074243|adult giant cell glioblastoma
1476506|NCT00074243|adult gliosarcoma
1476507|NCT00074230|stage IV melanoma
1476508|NCT00074230|recurrent melanoma
1476509|NCT00074204|stage IIIB non-small cell lung cancer
1476510|NCT00074204|stage IV non-small cell lung cancer
1476511|NCT00074204|recurrent non-small cell lung cancer
1476512|NCT00074191|intraocular lymphoma
1476513|NCT00074191|primary central nervous system lymphoma
1476514|NCT00074178|primary central nervous system lymphoma
1476515|NCT00074178|intraocular lymphoma
1476516|NCT00074165|drug/agent toxicity by tissue/organ
1476517|NCT00074165|thrombocytopenia
1476518|NCT00074165|intraocular lymphoma
1476519|NCT00074165|primary central nervous system non-Hodgkin lymphoma
1476520|NCT00074165|primary central nervous system Hodgkin lymphoma
1476521|NCT00074152|recurrent breast cancer
1476522|NCT00074152|stage I breast cancer
1476523|NCT00074152|stage II breast cancer
1476524|NCT00074152|stage IIIA breast cancer
1476525|NCT00074152|stage IIIB breast cancer
1476526|NCT00074152|stage IIIC breast cancer
1476527|NCT00074139|stage IIIA breast cancer
1476528|NCT00074139|recurrent breast cancer
1476529|NCT00074139|stage IIIB breast cancer
1476530|NCT00074139|stage IIIC breast cancer
1476531|NCT00074139|stage IV breast cancer
1476532|NCT00074100|stage IV breast cancer
1476533|NCT00074100|recurrent breast cancer
1476534|NCT00074087|stage II mycosis fungoides/Sezary syndrome
1476535|NCT00074087|stage IV mycosis fungoides/Sezary syndrome
1476536|NCT00074087|recurrent mycosis fungoides/Sezary syndrome
1476537|NCT00074087|stage IV cutaneous T-cell non-Hodgkin lymphoma
1476538|NCT00074087|stage II cutaneous T-cell non-Hodgkin lymphoma
1476539|NCT00074087|recurrent cutaneous T-cell non-Hodgkin lymphoma
1476540|NCT00074074|refractory anemia with excess blasts
1476541|NCT00074074|refractory anemia with ringed sideroblasts
1476542|NCT00074074|refractory anemia
1476543|NCT00074074|de novo myelodysplastic syndromes
1476544|NCT00074074|secondary myelodysplastic syndromes
1476545|NCT00074074|previously treated myelodysplastic syndromes
1476546|NCT00074048|refractory hairy cell leukemia
1476547|NCT00074009|recurrent gastric cancer
1476548|NCT00074009|stage III gastric cancer
1476549|NCT00074009|stage IV gastric cancer
1476550|NCT00074009|adenocarcinoma of the stomach
1476551|NCT00073983|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1476552|NCT00073983|chondrosarcoma
1476553|NCT00073983|recurrent osteosarcoma
1476554|NCT00073970|recurrent prostate cancer
1476555|NCT00073970|stage I prostate cancer
1476556|NCT00073970|stage II prostate cancer
1476557|NCT00073970|adenocarcinoma of the prostate
1476558|NCT00073957|recurrent adult diffuse large cell lymphoma
1476559|NCT00073957|recurrent adult immunoblastic large cell lymphoma
1476560|NCT00073957|anaplastic large cell lymphoma
1476561|NCT00073944|acute undifferentiated leukemia
1476562|NCT00073944|anaplastic large cell lymphoma
1476563|NCT00073944|angioimmunoblastic T-cell lymphoma
1476564|NCT00073944|atypical chronic myeloid leukemia, BCR-ABL1 negative
1476565|NCT00073944|chronic eosinophilic leukemia
1476566|NCT00073944|primary myelofibrosis
1476567|NCT00073944|chronic myelomonocytic leukemia
1476568|NCT00073944|chronic neutrophilic leukemia
1476569|NCT00073944|essential thrombocythemia
1476570|NCT00073944|intraocular lymphoma
1476571|NCT00073944|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1476572|NCT00073944|polycythemia vera
1476573|NCT00073944|previously treated myelodysplastic syndromes
1476574|NCT00073944|primary central nervous system non-Hodgkin lymphoma
1476575|NCT00073944|prolymphocytic leukemia
1476576|NCT00073944|recurrent adult acute lymphoblastic leukemia
1476577|NCT00073944|recurrent adult acute myeloid leukemia
1476578|NCT00073944|recurrent adult T-cell leukemia/lymphoma
1476579|NCT00073944|recurrent adult diffuse large cell lymphoma
1476580|NCT00073944|recurrent adult diffuse mixed cell lymphoma
1476581|NCT00073944|recurrent adult diffuse small cleaved cell lymphoma
1476582|NCT00073944|recurrent adult Burkitt lymphoma
1476583|NCT00073944|recurrent adult Hodgkin lymphoma
1476584|NCT00073944|recurrent adult immunoblastic large cell lymphoma
1476585|NCT00073944|recurrent adult lymphoblastic lymphoma
1476586|NCT00073944|recurrent grade 1 follicular lymphoma
1476587|NCT00073944|recurrent grade 2 follicular lymphoma
1476588|NCT00073944|recurrent grade 3 follicular lymphoma
1476589|NCT00073944|recurrent mantle cell lymphoma
1476590|NCT00073944|recurrent mycosis fungoides/Sezary syndrome
1476591|NCT00073944|refractory chronic lymphocytic leukemia
1476592|NCT00073944|refractory hairy cell leukemia
1476593|NCT00073944|refractory multiple myeloma
1476594|NCT00073944|relapsing chronic myelogenous leukemia
1476595|NCT00073944|secondary acute myeloid leukemia
1476596|NCT00073944|secondary myelodysplastic syndromes
1476597|NCT00073944|Waldenström macroglobulinemia
1476598|NCT00073944|adenocarcinoma of the colon
1476599|NCT00073944|adenocarcinoma of the esophagus
1476600|NCT00073944|adenocarcinoma of the pancreas
1476601|NCT00073944|adenocarcinoma of the rectum
1476602|NCT00073944|recurrent adult brain tumor
1476603|NCT00073944|recurrent adult primary liver cancer
1476604|NCT00073944|recurrent colon cancer
1476605|NCT00073944|recurrent esophageal cancer
1476606|NCT00073944|recurrent gastric cancer
1476607|NCT00073944|recurrent melanoma
1476608|NCT00073944|recurrent ovarian epithelial cancer
1476609|NCT00073944|recurrent pancreatic cancer
1476610|NCT00073944|recurrent rectal cancer
1476611|NCT00073944|adenocarcinoma of the stomach
1476612|NCT00073944|adult anaplastic astrocytoma
1476613|NCT00073944|adult glioblastoma
1476614|NCT00073944|adult pilocytic astrocytoma
1476615|NCT00073944|adult subependymoma
1476616|NCT00073944|adenocarcinoma of the extrahepatic bile duct
1476617|NCT00073944|recurrent extrahepatic bile duct cancer
1476618|NCT00073944|recurrent cutaneous T-cell non-Hodgkin lymphoma
1476619|NCT00073944|de novo myelodysplastic syndromes
1476620|NCT00073944|recurrent marginal zone lymphoma
1476621|NCT00073944|recurrent small lymphocytic lymphoma
1476622|NCT00073944|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1476623|NCT00073944|nodal marginal zone B-cell lymphoma
1476624|NCT00073944|splenic marginal zone lymphoma
1476625|NCT00073944|adult acute myeloid leukemia with t(8;21)(q22;q22)
1476626|NCT00073944|adult acute myeloid leukemia with t(16;16)(p13;q22)
1476627|NCT00073944|adult acute myeloid leukemia with inv(16)(p13;q22)
1476628|NCT00073944|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1476629|NCT00073944|adult acute myeloid leukemia with t(15;17)(q22;q12)
1476630|NCT00073944|adult diffuse astrocytoma
1476631|NCT00073944|adult giant cell glioblastoma
1476632|NCT00073944|adult gliosarcoma
1476633|NCT00073944|T-cell large granular lymphocyte leukemia
1476634|NCT00073931|recurrent adult diffuse large cell lymphoma
1476635|NCT00073931|recurrent adult diffuse mixed cell lymphoma
1476636|NCT00073931|recurrent adult diffuse small cleaved cell lymphoma
1476637|NCT00073931|recurrent adult Burkitt lymphoma
1476638|NCT00073931|recurrent adult immunoblastic large cell lymphoma
1476639|NCT00073931|recurrent adult lymphoblastic lymphoma
1476640|NCT00073931|recurrent grade 1 follicular lymphoma
1476641|NCT00073931|recurrent grade 2 follicular lymphoma
1476642|NCT00073931|recurrent grade 3 follicular lymphoma
1476643|NCT00073931|recurrent mantle cell lymphoma
1476644|NCT00073905|unresectable gallbladder cancer
1476645|NCT00073905|adenocarcinoma of the gallbladder
1476646|NCT00073905|adenocarcinoma of the extrahepatic bile duct
1476647|NCT00073905|unresectable extrahepatic bile duct cancer
1476648|NCT00073905|pain
1476649|NCT00073905|recurrent gallbladder cancer
1476650|NCT00073905|recurrent extrahepatic bile duct cancer
1476651|NCT00073905|localized unresectable adult primary liver cancer
1476652|NCT00073905|advanced adult primary liver cancer
1476653|NCT00073905|recurrent adult primary liver cancer
1476654|NCT00073892|unspecified adult solid tumor, protocol specific
1476655|NCT00073892|stage IV melanoma
1476656|NCT00073892|recurrent melanoma
1476657|NCT00073879|stage IV renal cell cancer
1476658|NCT00073879|recurrent renal cell cancer
1476659|NCT00073866|recurrent non-small cell lung cancer
1476660|NCT00073866|stage IIIB non-small cell lung cancer
1476661|NCT00073866|stage IV non-small cell lung cancer
1476662|NCT00073853|paraplegia
1476663|NCT00073853|quadraplegia
1476664|NCT00073853|tetraplegia
1476665|NCT00073853|paralysis
1476666|NCT00073853|nerve regeneration
1476667|NCT00073853|Acute, Complete SCI
1476668|NCT00073840|levalbuterol
1476669|NCT00073840|asthma
1476670|NCT00073840|bronchoconstriction
1476671|NCT00073840|adolescent
1476672|NCT00073840|adult
1476673|NCT00073827|adolescent
1476674|NCT00073827|adult
1476675|NCT00073827|asthma
1476676|NCT00073827|levalbuterol
1476677|NCT00073827|bronchoconstriction
1476678|NCT00073814|levalbuterol
1476679|NCT00073814|pediatric
1476680|NCT00073814|asthma
1476681|NCT00073801|Neuromusculoskeletal Pain
1476682|NCT00073801|Laparoscopy
1476683|NCT00073801|Cytokines
1476684|NCT00073801|HPA Axis
1476685|NCT00073801|Neuroimmune
1476686|NCT00073801|Endometriosis
1476687|NCT00073801|Surgical Excision
1476688|NCT00073801|Inflammatory Cytokines
1476689|NCT00073749|B-Cell
1476690|NCT00073749|Non-Hodgkin's
1476691|NCT00073749|Lymphoma
1476692|NCT00073736|Hepatocellular
1476693|NCT00073736|Carcinoma
1476694|NCT00073736|Liver
1476695|NCT00073736|Cancer
1476696|NCT00073723|Non-Small Cell Lung Cancer
1476697|NCT00073723|Taxol
1476698|NCT00073723|Advanced Non-Small Cell Lung Cancer
1476699|NCT00073710|secondary hyperparathyroidism
1476700|NCT00073697|Psychotherapy
1476701|NCT00073697|Depressive disorder
1476702|NCT00073697|Antidepressive agents
1476703|NCT00073697|Citalopram
1476704|NCT00073684|Stress Disorders, Post-Traumatic
1476705|NCT00073684|Depression
1476706|NCT00073684|Anxiety
1476707|NCT00073671|Adolescent
1476708|NCT00073658|Alzheimer disease
1476709|NCT00073658|Aggression
1476710|NCT00073658|Delusions
1476711|NCT00073658|Paranoid behavior
1476712|NCT00073619|Violence
1476713|NCT00073619|School based
1476714|NCT00073619|Urban Youth
1476715|NCT00073619|Prevention
1476716|NCT00073619|Community
1476717|NCT00073606|Spinal Reflexes
1476718|NCT00073606|Locomotion
1476719|NCT00073606|Motor Practice
1476720|NCT00073606|Healthy Volunteer
1476721|NCT00073606|HV
1476722|NCT00073593|Off-Pump Coronary Artery Bypass Graft Surgery
1476723|NCT00073593|CABG
1476724|NCT00073593|OPCAB
1476725|NCT00073593|Heparin
1476726|NCT00073593|Patients requiring off-pump CABG
1476727|NCT00073580|HIT
1476728|NCT00073580|HITTS
1476729|NCT00073580|Heparin-antibodies
1476730|NCT00073580|Coronary artery bypass surgery
1476731|NCT00073580|CABG
1476732|NCT00073580|Heparin-induced thrombocytopenia
1476733|NCT00073580|Heparin-induced thrombocytopenia and thrombosis syndrome
1476734|NCT00073541|EGFR; HER-1; monoclonal antibody; targeted therapy
1476735|NCT00073528|metastatic
1476736|NCT00073528|advanced breast cancer
1476737|NCT00073528|breast cancer
1476738|NCT00073515|central venous access device
1476739|NCT00073515|thrombosis
1476740|NCT00073515|central venous catheter
1476741|NCT00073515|thrombolysis
1476742|NCT00073515|fibrinolysis
1476743|NCT00073489|chronic leukemia
1476744|NCT00073489|leukemia
1476745|NCT00073489|CLL
1476746|NCT00073463|Gene Transfer
1476747|NCT00073463|Pulmonary function
1476748|NCT00073450|Squamous Cell Carcinoma of the Head & Neck
1476749|NCT00073437|Sarcoidosis
1476750|NCT00073437|Infliximab
1476751|NCT00073437|Pulmonary involvement
1476752|NCT00073437|Remicade
1476753|NCT00073424|Treatment Experienced
1476754|NCT00073398|Anti-tumor Vaccination
1476755|NCT00073398|Alpha (1,3) Galactosyltransferase
1476756|NCT00073398|Allogeneic Tumor Cells
1476757|NCT00073398|Hyperacute Lung
1476758|NCT00073398|NSCLC
1476759|NCT00073398|Lung Cancer
1476760|NCT00073398|Non-Small Cell Lung Cancer
1476761|NCT00073385|Lung cancer, Docetaxel, Histone deacetylase inhibitor
1476762|NCT00073372|Acute ischemic stroke
1476763|NCT00073372|abciximab
1476764|NCT00073372|ReoPro
1476765|NCT00073372|drug safety
1476766|NCT00073372|drug efficacy
1476767|NCT00073372|intracranial hemorrhage
1476768|NCT00073372|stroke
1476769|NCT00073359|Adolescent
1476770|NCT00073346|Compulsive Hoarding
1476771|NCT00073333|Phobic Disorders
1476772|NCT00073320|Schizophrenia
1476773|NCT00073320|Paliperidone palmitate
1476774|NCT00073320|R092670
1476775|NCT00073320|antipsychotic
1476776|NCT00073307|Renal Cell Cancer (RCC)
1476777|NCT00073307|Cancer
1476778|NCT00073294|diabetes
1476779|NCT00073281|diabetes
1476780|NCT00073281|autoimmunity
1476781|NCT00073268|diabetes
1476782|NCT00073268|adolescent
1476783|NCT00073242|leptin
1476784|NCT00073242|obesity
1476785|NCT00073229|AIDS
1476786|NCT00073229|Vertical Transmission
1476787|NCT00073229|Acute Infection
1476788|NCT00073216|HIV Seronegativity
1476789|NCT00073216|HIV Preventive Vaccine
1476790|NCT00073190|Patient Education
1476791|NCT00073190|Physician Education
1476792|NCT00073125|Advanced histologically documented renal cell carcinoma
1476793|NCT00073099|Dry Eye
1476794|NCT00073099|Lissamine Green
1476795|NCT00073099|Fluorescein
1476796|NCT00073099|Conjunctiva
1476797|NCT00073099|Cornea
1476798|NCT00073099|Digital Photography
1476799|NCT00073099|Corneal and Conjunctival Staining
1476800|NCT00073086|Coronavirus
1476801|NCT00073086|Pneumonia
1476802|NCT00073086|Asia
1476803|NCT00073086|China
1476804|NCT00073086|Severe Acut Respiratory Syndrome
1476805|NCT00073086|SARS
1476806|NCT00073086|Suspected SARS
1476807|NCT00073073|Chemoprevention
1476808|NCT00073073|Mammographic Density
1476809|NCT00073073|Bone Mineral Density
1476810|NCT00073073|Biomarkers
1476811|NCT00073073|Safety
1476812|NCT00073073|Breast Cancer
1476813|NCT00073073|Postmenopausal
1476814|NCT00073060|Plateletpheresis
1476815|NCT00073060|Lymphocytapheresis
1476816|NCT00073060|Apheresis
1476817|NCT00073060|Citrate
1476818|NCT00073060|Bone Density
1476819|NCT00073060|Healthy Volunteer
1476820|NCT00073060|HV
1476821|NCT00073047|Ulcerative Colitis
1476822|NCT00073047|Inflammatory Bowel Disease
1476823|NCT00073047|Gastrointestinal
1476824|NCT00073047|Humanized Monoclonal antibody
1476825|NCT00073034|Neuropathic Pain
1476826|NCT00073034|Diabetic Neuropathy
1476827|NCT00073008|EGFR
1476828|NCT00073008|ErbB1
1476829|NCT00073008|ErbB2
1476830|NCT00073008|metastatic
1476831|NCT00073008|lapatinib
1476832|NCT00073008|Her-2/neu
1476833|NCT00073008|protein kinase inhibitor
1476834|NCT00073008|BAC
1476835|NCT00073008|GW572016
1476836|NCT00073008|Advanced
1476837|NCT00073008|NSCLC
1476838|NCT00072982|Fish oil
1476839|NCT00072982|Borage oil
1476840|NCT00072969|Immunosuppression
1476841|NCT00072969|Myelodysplastic Syndrome
1476842|NCT00072969|MDS
1476843|NCT00072956|Transcranial Magnetic Stimulation
1476844|NCT00072956|Torticollis
1476845|NCT00072956|Cervical Dystonia
1476846|NCT00072956|Surround Inhibition
1476847|NCT00072956|Sensory Tricks
1476848|NCT00072943|Crohn's Disease
1476849|NCT00072943|Colitis
1476850|NCT00072943|Monoclonal antibody therapy
1476851|NCT00072943|anti-interferon gamma
1476852|NCT00072917|obesity
1476853|NCT00072917|thinness
1476854|NCT00072917|weight gain
1476855|NCT00072917|physical activity
1476856|NCT00072917|diet
1476857|NCT00072917|fat oxidation
1476858|NCT00072917|hunger
1476859|NCT00072917|feeding behavior
1476860|NCT00072917|overfeeding
1476861|NCT00072904|Cystic Fibrosis Related Diabetes
1476862|NCT00072904|Diabetes without Fasting Hyperglycemia
1476863|NCT00072891|Diabetes
1476864|NCT00072826|3-hydroxy-3-methlglutaryl (HMG)
1476865|NCT00072826|Inhibitors
1476866|NCT00072826|Endothelial Function
1476867|NCT00072826|Leukocyte Gene Expression
1476868|NCT00072826|Statins
1476869|NCT00072826|Atorvastatin
1476870|NCT00072826|Sickle Cell Disease
1476871|NCT00072813|Genetics
1476872|NCT00072813|Seizures
1476873|NCT00072813|Brain Imaging
1476874|NCT00072813|Diffusion
1476875|NCT00072813|Temporal Lobe
1476876|NCT00072800|Reliability
1476877|NCT00072800|Muscle Tone Abnormality
1476878|NCT00072800|Spasticity
1476879|NCT00072800|Dystonia
1476880|NCT00072800|Rigidity
1476881|NCT00072800|Cerebral Palsy
1476882|NCT00072800|CP
1476883|NCT00072800|Children
1476884|NCT00072787|gastric cancer
1476885|NCT00072787|phase 2 clinical trial
1476886|NCT00072774|Depressive Disorder, Major
1476887|NCT00072774|Melancholia, Involutional
1476888|NCT00072774|Depression, Involutional
1476889|NCT00072761|silent cerebral infarct
1476890|NCT00072761|silent stroke
1476891|NCT00072761|sickle cell anemia
1476892|NCT00072761|stroke
1476893|NCT00072761|transfusion therapy
1476894|NCT00072748|Advanced Colorectal Cancer
1476895|NCT00072748|Colorectal Carcinoma
1476896|NCT00072748|Colorectal Tumors
1476897|NCT00072748|Neoplasms, Colorectal
1476898|NCT00072735|Use Dependent Plasticity
1476899|NCT00072735|Cortical Reorganization
1476900|NCT00072735|Rehabilitation
1476901|NCT00072735|Somatosensory Nerve
1476902|NCT00072735|Amphetamine
1476903|NCT00072735|Stroke
1476904|NCT00072735|Healthy Volunteer
1476905|NCT00072735|HV
1476906|NCT00072722|Prostate Cancer
1476907|NCT00072722|Metastatic Hormone Refractory Prostate Cancer
1476908|NCT00072722|CC4047
1476909|NCT00072722|CC-4047
1476910|NCT00072722|Prostate Carcinoma
1476911|NCT00072722|Celgene
1476912|NCT00072709|ALS
1476913|NCT00072709|Lou Gehrig's disease
1476914|NCT00072683|Sodium
1476915|NCT00072683|SIADH
1476916|NCT00072683|Vasopressin
1476917|NCT00072683|CHF
1476918|NCT00072683|Cirrhosis
1476919|NCT00072683|salt
1476920|NCT00072683|water
1476921|NCT00072683|electrolyte
1476922|NCT00072670|Prostate cancer
1476923|NCT00072670|Advanced prostate cancer
1476924|NCT00072670|Metastatic prostate cancer
1476925|NCT00072670|Trabectedin
1476926|NCT00072670|Yondelis
1476927|NCT00072670|ET-743
1476928|NCT00072657|Arthritis
1476929|NCT00072657|Pain
1476930|NCT00072657|Meditation
1476931|NCT00072657|Tai Chi
1476932|NCT00072657|Chronic Illness
1476933|NCT00072657|Depression
1476934|NCT00072644|HIV
1476935|NCT00072644|Osteonecrosis
1476936|NCT00072644|Drug Interaction
1476937|NCT00072644|P-Glycoprotein
1476938|NCT00072644|Cytochrome P 450
1476939|NCT00072644|Healthy Volunteer
1476940|NCT00072644|HV
1476941|NCT00072631|Tarceva
1476942|NCT00072631|erlotinib
1476943|NCT00072631|NSCLC
1476944|NCT00072631|Non-Small Cell Lung Cancer
1476945|NCT00072631|EGFR
1476946|NCT00072631|OSI-774
1476947|NCT00072605|Healthy
1476948|NCT00072605|T Cells
1476949|NCT00072605|Immunity
1476950|NCT00072605|Hemorrhagic Fever
1476951|NCT00072605|Healthy Volunteer
1476952|NCT00072605|HV
1476953|NCT00072592|ANCA
1476954|NCT00072592|B Lymphocyte
1476955|NCT00072592|Vasculitis
1476956|NCT00072592|Treatment
1476957|NCT00072592|Remission
1476958|NCT00072592|Wegener Granulomatosis
1476959|NCT00072592|WG
1476960|NCT00072579|chronic phase chronic myelogenous leukemia
1476961|NCT00072579|chronic myelogenous leukemia, BCR-ABL1 positive
1476962|NCT00072553|stage IV rectal cancer
1476963|NCT00072553|stage IV colon cancer
1476964|NCT00072553|adenocarcinoma of the colon
1476965|NCT00072553|adenocarcinoma of the rectum
1476966|NCT00072553|recurrent rectal cancer
1476967|NCT00072553|recurrent colon cancer
1476968|NCT00072527|limited stage small cell lung cancer
1476969|NCT00072501|breast cancer
1476970|NCT00072488|disseminated neuroblastoma
1476971|NCT00072488|localized resectable neuroblastoma
1476972|NCT00072488|localized unresectable neuroblastoma
1476973|NCT00072488|regional neuroblastoma
1476974|NCT00072488|stage 4S neuroblastoma
1476975|NCT00072488|previously untreated childhood rhabdomyosarcoma
1476976|NCT00072488|stage I childhood Hodgkin lymphoma
1476977|NCT00072488|stage I childhood large cell lymphoma
1476978|NCT00072488|stage I childhood lymphoblastic lymphoma
1476979|NCT00072488|stage I childhood small noncleaved cell lymphoma
1476980|NCT00072488|stage II childhood Hodgkin lymphoma
1476981|NCT00072488|stage II childhood large cell lymphoma
1476982|NCT00072488|stage II childhood lymphoblastic lymphoma
1476983|NCT00072488|stage II childhood small noncleaved cell lymphoma
1476984|NCT00072488|stage III childhood Hodgkin lymphoma
1476985|NCT00072488|stage III childhood large cell lymphoma
1476986|NCT00072488|stage III childhood lymphoblastic lymphoma
1476987|NCT00072488|stage III childhood small noncleaved cell lymphoma
1476988|NCT00072488|stage IV childhood Hodgkin lymphoma
1476989|NCT00072488|stage IV childhood large cell lymphoma
1476990|NCT00072488|stage IV childhood lymphoblastic lymphoma
1476991|NCT00072488|stage IV childhood small noncleaved cell lymphoma
1476992|NCT00072488|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1476993|NCT00072488|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1476994|NCT00072488|previously treated childhood rhabdomyosarcoma
1476995|NCT00072475|refractory anemia with excess blasts
1476996|NCT00072475|refractory anemia with ringed sideroblasts
1476997|NCT00072475|refractory cytopenia with multilineage dysplasia
1476998|NCT00072475|chronic myelomonocytic leukemia
1476999|NCT00072475|de novo myelodysplastic syndromes
1477000|NCT00072475|secondary myelodysplastic syndromes
1477001|NCT00072475|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1477002|NCT00072475|refractory anemia
1477003|NCT00072475|previously treated myelodysplastic syndromes
1477004|NCT00072462|ductal breast carcinoma in situ
1477005|NCT00072462|breast cancer in situ
1477006|NCT00072449|primary central nervous system non-Hodgkin lymphoma
1477007|NCT00072410|recurrent ovarian epithelial cancer
1477008|NCT00072410|stage III ovarian epithelial cancer
1477009|NCT00072358|disseminated neuroblastoma
1477010|NCT00072358|localized unresectable neuroblastoma
1477011|NCT00072358|recurrent neuroblastoma
1477012|NCT00072358|regional neuroblastoma
1477013|NCT00072358|stage 4S neuroblastoma
1477014|NCT00072345|stage III melanoma
1477015|NCT00072345|stage IV melanoma
1477016|NCT00072345|recurrent melanoma
1477017|NCT00072345|iris melanoma
1477018|NCT00072345|ciliary body and choroid melanoma, medium/large size
1477019|NCT00072345|ciliary body and choroid melanoma, small size
1477020|NCT00072345|extraocular extension melanoma
1477021|NCT00072345|recurrent intraocular melanoma
1477022|NCT00072332|unspecified adult solid tumor, protocol specific
1477023|NCT00072332|stage IV esophageal cancer
1477024|NCT00072332|stage IV gastric cancer
1477025|NCT00072319|stage I breast cancer
1477026|NCT00072319|stage II breast cancer
1477027|NCT00072319|stage IIIA breast cancer
1477028|NCT00072319|stage IIIB breast cancer
1477029|NCT00072319|stage IIIC breast cancer
1477030|NCT00072319|inflammatory breast cancer
1477031|NCT00072293|stage IA breast cancer
1477032|NCT00072293|stage IB breast cancer
1477033|NCT00072293|stage II breast cancer
1477034|NCT00072293|estrogen receptor-negative breast cancer
1477035|NCT00072293|estrogen receptor-positive breast cancer
1477036|NCT00072293|progesterone receptor-negative breast cancer
1477037|NCT00072293|progesterone receptor-positive breast cancer
1477038|NCT00072280|childhood fibrosarcoma
1477039|NCT00072280|nonmetastatic childhood soft tissue sarcoma
1477040|NCT00072267|stage IV ovarian epithelial cancer
1477041|NCT00072267|recurrent ovarian epithelial cancer
1477042|NCT00072267|primary peritoneal cavity cancer
1477043|NCT00072267|fallopian tube cancer
1477044|NCT00072267|stage III ovarian epithelial cancer
1477045|NCT00072215|recurrent malignant testicular germ cell tumor
1477046|NCT00072215|stage III malignant testicular germ cell tumor
1477047|NCT00072215|testicular choriocarcinoma and embryonal carcinoma
1477048|NCT00072215|testicular choriocarcinoma and seminoma
1477049|NCT00072215|testicular choriocarcinoma and teratoma
1477050|NCT00072215|testicular choriocarcinoma and yolk sac tumor
1477051|NCT00072215|testicular choriocarcinoma
1477052|NCT00072215|testicular embryonal carcinoma and seminoma
1477053|NCT00072215|testicular embryonal carcinoma and teratoma with seminoma
1477054|NCT00072215|testicular embryonal carcinoma and teratoma
1477055|NCT00072215|testicular embryonal carcinoma and yolk sac tumor with seminoma
1477056|NCT00072215|testicular embryonal carcinoma and yolk sac tumor
1477057|NCT00072215|testicular embryonal carcinoma
1477058|NCT00072215|testicular seminoma
1477059|NCT00072215|testicular yolk sac tumor and teratoma with seminoma
1477060|NCT00072215|testicular yolk sac tumor and teratoma
1477061|NCT00072215|testicular yolk sac tumor
1477062|NCT00072215|recurrent extragonadal non-seminomatous germ cell tumor
1477063|NCT00072215|recurrent extragonadal seminoma
1477064|NCT00072215|stage IV extragonadal non-seminomatous germ cell tumor
1477065|NCT00072215|stage IV extragonadal seminoma
1477066|NCT00072215|testicular immature teratoma
1477067|NCT00072215|testicular mature teratoma
1477068|NCT00072215|recurrent extragonadal germ cell tumor
1477069|NCT00072124|stage IV melanoma
1477070|NCT00072124|recurrent melanoma
1477071|NCT00072111|unspecified adult solid tumor, protocol specific
1477072|NCT00072098|stage IV colon cancer
1477073|NCT00072098|stage IV rectal cancer
1477074|NCT00072098|liver metastases
1477075|NCT00072098|recurrent rectal cancer
1477076|NCT00072098|recurrent colon cancer
1477077|NCT00072085|stage IV melanoma
1477078|NCT00072085|recurrent melanoma
1477079|NCT00072072|recurrent non-small cell lung cancer
1477080|NCT00072072|stage IIIB non-small cell lung cancer
1477081|NCT00072072|stage IV non-small cell lung cancer
1477082|NCT00072059|anemia
1477083|NCT00072059|stage IIIB non-small cell lung cancer
1477084|NCT00072059|stage IV non-small cell lung cancer
1477085|NCT00072059|recurrent non-small cell lung cancer
1477086|NCT00072046|stage IV renal cell cancer
1477087|NCT00072046|clear cell renal cell carcinoma
1477088|NCT00072046|recurrent renal cell cancer
1477089|NCT00072033|stage II esophageal cancer
1477090|NCT00072033|stage III esophageal cancer
1477091|NCT00072033|adenocarcinoma of the esophagus
1477092|NCT00072033|squamous cell carcinoma of the esophagus
1477093|NCT00072020|bone metastases
1477094|NCT00072020|stage II breast cancer
1477095|NCT00072020|stage IIIA breast cancer
1477096|NCT00072020|stage IIIB breast cancer
1477097|NCT00072020|stage IIIC breast cancer
1477098|NCT00072007|B-cell chronic lymphocytic leukemia
1477099|NCT00072007|refractory chronic lymphocytic leukemia
1477100|NCT00072007|stage II chronic lymphocytic leukemia
1477101|NCT00072007|stage III chronic lymphocytic leukemia
1477102|NCT00072007|stage I chronic lymphocytic leukemia
1477103|NCT00072007|stage IV chronic lymphocytic leukemia
1477104|NCT00071981|stage IV melanoma
1477105|NCT00071981|recurrent melanoma
1477106|NCT00071968|adenocarcinoma of the prostate
1477107|NCT00071968|stage IIB prostate cancer
1477108|NCT00071968|stage IIA prostate cancer
1477109|NCT00071968|stage I prostate cancer
1477110|NCT00071955|recurrent grade 1 follicular lymphoma
1477111|NCT00071955|recurrent grade 2 follicular lymphoma
1477112|NCT00071955|recurrent grade 3 follicular lymphoma
1477113|NCT00071955|stage III grade 1 follicular lymphoma
1477114|NCT00071955|stage III grade 2 follicular lymphoma
1477115|NCT00071955|stage III grade 3 follicular lymphoma
1477116|NCT00071955|stage IV grade 1 follicular lymphoma
1477117|NCT00071955|stage IV grade 2 follicular lymphoma
1477118|NCT00071955|stage IV grade 3 follicular lymphoma
1477119|NCT00071929|recurrent endometrial carcinoma
1477120|NCT00071916|Hepatitis C, African Americans, ribavirin
1477121|NCT00071903|Thrombophilia
1477122|NCT00071903|Idiopathic Intracranial Hypertension
1477123|NCT00071903|Kidney Involvement
1477124|NCT00071903|Lysosomal Storage Disorder
1477125|NCT00071903|Cystine
1477126|NCT00071903|Pseudotumor Cerebri
1477127|NCT00071903|Susceptibility to Thrombosis
1477128|NCT00071903|Nephropathic Cystinosis
1477129|NCT00071903|PTC
1477130|NCT00071903|Intracranial Hypertension
1477131|NCT00071890|Interleukin 2
1477132|NCT00071890|Treatment Interruption
1477133|NCT00071890|HIV
1477134|NCT00071877|Lysosomal Disease
1477135|NCT00071877|Hypohidrosis
1477136|NCT00071877|Pain
1477137|NCT00071877|Neuropathy
1477138|NCT00071877|X-Linked
1477139|NCT00071877|Fabry Disease
1477140|NCT00071877|Children
1477141|NCT00071851|HIV Seronegativity
1477142|NCT00071851|HIV Preventive Vaccine
1477143|NCT00071838|Neuroimmunology
1477144|NCT00071838|Therapy
1477145|NCT00071838|Demyelinating Disease
1477146|NCT00071838|Immunological Mechanism
1477147|NCT00071838|MRI
1477148|NCT00071838|Multiple Sclerosis
1477149|NCT00071838|MS
1477150|NCT00071812|RA
1477151|NCT00071786|Bipolar Mood Disorder
1477152|NCT00071786|Migraine
1477153|NCT00071786|Behavior Genetics
1477154|NCT00071786|Genetic Epidemiology
1477155|NCT00071786|Family Study
1477156|NCT00071773|diabetic macular edema
1477157|NCT00071773|laser photocoagulation
1477158|NCT00071773|etdrs
1477159|NCT00071773|macular grid photocoagulation
1477160|NCT00071773|DME
1477161|NCT00071760|pediatrics
1477162|NCT00071760|ritonavir
1477163|NCT00071760|amprenavir
1477164|NCT00071760|AGENERASE
1477165|NCT00071760|HIV
1477166|NCT00071760|Lexiva
1477167|NCT00071760|protease inhibitors
1477168|NCT00071760|HIV Infection
1477169|NCT00071760|fosamprenavir
1477170|NCT00071747|schizophrenia
1477171|NCT00071747|lamotrigine
1477172|NCT00071734|fMRI
1477173|NCT00071734|Auditory Feedback
1477174|NCT00071734|Motor Control
1477175|NCT00071734|Adult
1477176|NCT00071734|BOLD
1477177|NCT00071734|Healthy Volunteer
1477178|NCT00071734|HV
1477179|NCT00071721|Alzheimer disease
1477180|NCT00071721|Agitation
1477181|NCT00071721|Psychosis
1477182|NCT00071682|herbal medicine
1477183|NCT00071682|alternative medicines
1477184|NCT00071682|anticoagulation
1477185|NCT00071682|side effects
1477186|NCT00071682|bleeding
1477187|NCT00071682|clotting
1477188|NCT00071669|Mood Disorder
1477189|NCT00071669|Acupuncture
1477190|NCT00071643|Stroke
1477191|NCT00071630|Adolescent
1477192|NCT00071617|Suicide
1477193|NCT00071617|Adolescence
1477194|NCT00071578|Psychotherapy
1477195|NCT00071578|Treatment
1477196|NCT00071565|familial intracranial aneurysm
1477197|NCT00071565|intracranial aneurysm
1477198|NCT00071565|brain aneurysm
1477199|NCT00071565|aneurysm
1477200|NCT00071565|subarachnoid hemorrhage
1477201|NCT00071565|stroke
1477202|NCT00071552|Poorly Controlled Asthma
1477203|NCT00071539|gross total resection
1477204|NCT00071526|Vitamin C
1477205|NCT00071526|Diabetes Mellitus
1477206|NCT00071526|Proteinuria
1477207|NCT00071526|Renal Threshold
1477208|NCT00071526|Healthy Volunteer
1477209|NCT00071513|Adolescent
1477210|NCT00071513|Substance Abuse
1477211|NCT00071513|At-risk
1477212|NCT00071500|Compliance
1477213|NCT00071500|Adherence
1477214|NCT00071500|Computerized
1477215|NCT00071500|Electronic Pillbox
1477216|NCT00071500|Treatment Experienced
1477217|NCT00071487|SLE
1477218|NCT00071474|temporomandibular disroders
1477219|NCT00071474|shamanism
1477220|NCT00071474|chronic pain
1477221|NCT00071461|Idiopathic pulmonary fibrosis
1477222|NCT00071461|Interstitial lung disease
1477223|NCT00071461|Bosentan
1477224|NCT00071461|BUILD
1477225|NCT00071435|EEG
1477226|NCT00071435|Voluntary Movement
1477227|NCT00071435|Motor Cortex
1477228|NCT00071435|Reaction Time
1477229|NCT00071435|Corticospinal
1477230|NCT00071435|Primary Lateral Sclerosis
1477231|NCT00071435|PLS
1477232|NCT00071435|Healthy Volunteer
1477233|NCT00071435|HV
1477234|NCT00071422|Type 2 diabetes
1477235|NCT00071409|Type 1 diabetes
1477236|NCT00071396|Chronic Lymphocytic Leukemia
1477237|NCT00071396|CD-52 and CD-20 Positive
1477238|NCT00071396|Refractory
1477239|NCT00071396|Relapsed
1477240|NCT00071383|Herceptin
1477241|NCT00071383|Trastuzumab
1477242|NCT00071383|Microdissection
1477243|NCT00071383|Proteomics
1477244|NCT00071383|Microarrays
1477245|NCT00071383|Metastatic Brain Tumor
1477246|NCT00071383|Breast Cancer
1477247|NCT00071383|Brain
1477248|NCT00071383|Carcinoma
1477249|NCT00071383|Genomics
1477250|NCT00071383|Metastatic Breast Cancer
1477251|NCT00071383|Metastatic Breast Tumor
1477252|NCT00071370|Magnetoencephalography
1477253|NCT00071370|Electroencephalogram (EEG)
1477254|NCT00071370|Interictal Epileptiform Discharges
1477255|NCT00071370|Epilepsy
1477256|NCT00071370|Sleep Deprivation
1477257|NCT00071370|Seizure
1477258|NCT00071357|Microarray
1477259|NCT00071357|Herceptin
1477260|NCT00071357|Trastuzumab
1477261|NCT00071357|Carcinoma
1477262|NCT00071357|Proteomics
1477263|NCT00071357|Breast Cancer
1477264|NCT00071357|Metastatic Breast Cancer
1477265|NCT00071357|Metastatic Breast Tumor
1477266|NCT00071344|Microarray
1477267|NCT00071344|Genomics
1477268|NCT00071344|Trastuzumab
1477269|NCT00071344|Carcinoma
1477270|NCT00071344|Non-Small Cell Lung Cancer
1477271|NCT00071344|Metastatic Brain Tumor
1477272|NCT00071344|Brain
1477273|NCT00071344|Microarrays
1477274|NCT00071344|Microdissection
1477275|NCT00071344|Lung Cancer
1477276|NCT00071344|NSCLC
1477277|NCT00071331|chronic heart failure
1477278|NCT00071331|heart failure
1477279|NCT00071305|Magnetoencephalography
1477280|NCT00071305|Electroencephalography
1477281|NCT00071305|Epilepsy
1477282|NCT00071305|Dipole Modeling
1477283|NCT00071305|Surgery
1477284|NCT00071292|rheumatoid arthritis
1477285|NCT00071292|stress reduction
1477286|NCT00071292|meditation
1477287|NCT00071292|mindfulness
1477288|NCT00071292|MBSR
1477289|NCT00071292|mindfulness-based stress reduction
1477290|NCT00071292|mind-body skills
1477291|NCT00071266|Intermittent Claudication
1477292|NCT00071266|Peripheral Arterial Disease
1477293|NCT00071266|Atherosclerosis
1477294|NCT00071266|Niacin
1477295|NCT00071266|Lovastatin
1477296|NCT00071266|PAD
1477297|NCT00071266|IC
1477298|NCT00071253|Bipolar Disorder - Mania
1477299|NCT00071240|Growth Hormone
1477300|NCT00071240|HIV
1477301|NCT00071240|AIDS
1477302|NCT00071240|Thymus
1477303|NCT00071240|CD4 Cell
1477304|NCT00071240|Immune System
1477305|NCT00071240|Treatment Experienced
1477306|NCT00071227|Age Related Macular Degeneration
1477307|NCT00071227|Macular Edema
1477308|NCT00071227|Inflammation
1477309|NCT00071227|Choroidal Neovascularization
1477310|NCT00071227|CRVO
1477311|NCT00071227|Diabetic Retinopathy
1477312|NCT00071227|Age Related Macular Edema
1477313|NCT00071227|AMD
1477314|NCT00071214|Staphylococcal infection
1477315|NCT00071214|Gram positive bacteria
1477316|NCT00071214|Staphylococcus
1477317|NCT00071214|Staphylococcus aureus
1477318|NCT00071214|Staphylococcus aureus infection
1477319|NCT00071188|Non-Small-Cell Lung Carcinoma
1477320|NCT00071175|Lupus
1477321|NCT00071175|Genetics
1477322|NCT00071162|Pain
1477323|NCT00071162|Fatigue
1477324|NCT00071162|Sleep
1477325|NCT00071162|Depression
1477326|NCT00071162|Irritable Bowel Syndrome
1477327|NCT00071162|Chronic Fatigue Syndrome
1477328|NCT00071149|Rheumatoid Arthritis
1477329|NCT00071149|TCM
1477330|NCT00071149|Diagnosis
1477331|NCT00071149|Traditional Chinese Medicine
1477332|NCT00071149|Complementary Therapies
1477333|NCT00071123|fMRI
1477334|NCT00071123|Habituation
1477335|NCT00071123|Extinction
1477336|NCT00071123|Amygdala
1477337|NCT00071123|Emotion
1477338|NCT00071123|Major Depressive Disorder
1477339|NCT00071123|Medial Prefrontal Cortex
1477340|NCT00071123|Backward Masking
1477341|NCT00071123|Depression
1477342|NCT00071123|MDD
1477343|NCT00071123|Healthy Volunteer
1477344|NCT00071123|HV
1477345|NCT00071110|Acupuncture
1477346|NCT00071110|Electroacupuncture
1477347|NCT00071110|Alternative therapy
1477348|NCT00071097|HIV
1477349|NCT00071097|TMC114
1477350|NCT00071097|Ritonavir
1477351|NCT00071097|Tolerability
1477352|NCT00071097|Safety and efficacy
1477353|NCT00071097|TMC114-C211
1477354|NCT00071084|Skin cancer
1477355|NCT00071084|Lymphoma
1477356|NCT00071084|Mycosis fungoides
1477357|NCT00071084|Sezary syndrome
1477358|NCT00071071|Skin cancer
1477359|NCT00071071|Lymphoma
1477360|NCT00071071|Mycosis fungoides
1477361|NCT00071071|Sezary syndrome
1477362|NCT00071058|P-glycoprotein Inhibition
1477363|NCT00071058|Drug Resistance Reversal
1477364|NCT00071058|Pharmacodynamics
1477365|NCT00071058|Molecular Target
1477366|NCT00071058|Endocrine Cancer
1477367|NCT00071058|Adrenocortical Cancer
1477368|NCT00071058|ACC
1477369|NCT00071058|Adrenocortical Tumor
1477377|NCT00071032|Blood Disease
1477378|NCT00071032|blood transfusion
1477379|NCT00070993|ALS
1477380|NCT00070993|Creatine
1477381|NCT00070980|Complementary Therapies
1477382|NCT00070967|Acupuncture
1477383|NCT00070967|Quality of Life
1477384|NCT00070967|Complementary Therapies
1477385|NCT00070967|TCM
1477386|NCT00070967|Traditional Chinese Medicine
1477387|NCT00070954|ECT
1477388|NCT00070954|Memory
1477389|NCT00070954|Ginkgo biloba
1477390|NCT00070941|Parkinsons Disease
1477391|NCT00070941|Depression
1477392|NCT00070941|SAM-e
1477393|NCT00070928|Sleep
1477394|NCT00070902|Spinal Manipulation
1477395|NCT00070902|Chiropractic
1477396|NCT00070902|Zygapophysial Joints
1477397|NCT00070889|Complementary Therapies
1477398|NCT00070876|Child
1477399|NCT00070876|Adolescent
1477400|NCT00070850|Screening
1477401|NCT00070850|Prenatal
1477402|NCT00070850|Amniocentesis
1477403|NCT00070824|Acupuncture
1477404|NCT00070824|SPECT
1477405|NCT00070824|f-MRI
1477406|NCT00070824|Functional brain imaging
1477407|NCT00070824|RCT
1477408|NCT00070811|Facial form
1477409|NCT00070811|Facial animation
1477410|NCT00070811|Lip muscle reconstruction
1477411|NCT00070811|Lip form
1477412|NCT00070811|Lip function
1477413|NCT00070785|Nasopharyngeal Cancer
1477414|NCT00070785|EBV Virus
1477415|NCT00070785|Epitope Mapping
1477416|NCT00070785|Epstein-Barr Virus
1477417|NCT00070785|Latent Protein-2
1477418|NCT00070785|Healthy Volunteer
1477419|NCT00070785|HV
1477420|NCT00070759|Daclizumab
1477421|NCT00070759|Uveitis
1477422|NCT00070759|Active
1477423|NCT00070759|Acute
1477424|NCT00070746|Perinatal mortality [PNM]
1477425|NCT00070746|Neonatal mortality
1477426|NCT00070746|Low birth weight [LBW]
1477427|NCT00070746|Spontaneous preterm delivery [SPTD]
1477428|NCT00070746|Premature rupture of membranes [PROM]
1477429|NCT00070746|Histological chorioamnionitis
1477430|NCT00070746|Global Network
1477431|NCT00070746|Pakistan
1477432|NCT00070746|Maternal and child health
1477433|NCT00070746|International
1477434|NCT00070746|Women's health
1477435|NCT00070733|Testosterone
1477436|NCT00070733|5-alpha Reductase
1477437|NCT00070733|Muscle Strength
1477438|NCT00070733|Libido
1477439|NCT00070733|Sexual Function
1477440|NCT00070733|Muscle Mass
1477441|NCT00070733|Testosterone 5-alpha-Reductase
1477442|NCT00070720|Behavior change
1477443|NCT00070720|Change in practitioner behavior
1477444|NCT00070720|Episiotomy
1477445|NCT00070720|Active management of third stage of labor
1477446|NCT00070720|Global Network
1477447|NCT00070720|Latin America
1477448|NCT00070720|Uruguay
1477449|NCT00070720|Argentina
1477450|NCT00070720|Maternal and child health
1477451|NCT00070720|International
1477452|NCT00070720|Women's health
1477453|NCT00070707|Seasonal Allergic Rhinitis
1477454|NCT00070707|Concomitant Asthma
1477455|NCT00070694|Affective Disorders
1477456|NCT00070694|Refractory
1477457|NCT00070694|Augmentation
1477458|NCT00070694|Polysomogram
1477459|NCT00070694|Combination Therapy
1477460|NCT00070694|Affective Disorder
1477461|NCT00070694|Depression
1477462|NCT00070694|Major Depression
1477463|NCT00070642|Immunotherapy, skin cancer
1477464|NCT00070629|Immunotherapy
1477465|NCT00070629|lung cancer
1477466|NCT00070616|mucositis
1477467|NCT00070616|chemotherapy
1477468|NCT00070616|radiation therapy
1477469|NCT00070590|Scleroderma
1477470|NCT00070590|Fibrosing alveolitis
1477471|NCT00070590|Build
1477472|NCT00070590|bosentan
1477473|NCT00070577|Alcohol Clamp
1477474|NCT00070577|Pharmacokinetics
1477475|NCT00070577|Pharmacodynamics
1477476|NCT00070577|Alcohol
1477477|NCT00070577|Metabolism
1477478|NCT00070577|Response
1477479|NCT00070577|Age
1477480|NCT00070577|Sex
1477481|NCT00070577|Healthy Volunteer
1477482|NCT00070577|HV
1477483|NCT00070564|stage II breast cancer
1477484|NCT00070564|stage IA breast cancer
1477485|NCT00070564|stage IB breast cancer
1477486|NCT00070564|stage IIIC breast cancer
1477487|NCT00070564|male breast cancer
1477488|NCT00070564|HER2-positive breast cancer
1477489|NCT00070564|estrogen receptor-negative breast cancer
1477490|NCT00070564|estrogen receptor-positive breast cancer
1477491|NCT00070564|progesterone receptor-negative breast cancer
1477492|NCT00070564|progesterone receptor-positive breast cancer
1477493|NCT00070538|recurrent adult acute lymphoblastic leukemia
1477494|NCT00070538|blastic phase chronic myelogenous leukemia
1477495|NCT00070538|relapsing chronic myelogenous leukemia
1477496|NCT00070538|chronic myelomonocytic leukemia
1477497|NCT00070538|refractory anemia with excess blasts in transformation
1477498|NCT00070538|refractory anemia with excess blasts
1477499|NCT00070538|recurrent adult acute myeloid leukemia
1477500|NCT00070538|untreated adult acute myeloid leukemia
1477501|NCT00070538|untreated adult acute lymphoblastic leukemia
1477502|NCT00070538|de novo myelodysplastic syndromes
1477503|NCT00070538|previously treated myelodysplastic syndromes
1477504|NCT00070538|secondary myelodysplastic syndromes
1477505|NCT00070538|adult acute myeloid leukemia with t(8;21)(q22;q22)
1477506|NCT00070538|adult acute myeloid leukemia with t(16;16)(p13;q22)
1477507|NCT00070538|adult acute myeloid leukemia with inv(16)(p13;q22)
1477508|NCT00070538|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1477509|NCT00070538|adult acute myeloid leukemia with t(15;17)(q22;q12)
1477510|NCT00070486|stage IV non-small cell lung cancer
1477511|NCT00070486|adenocarcinoma of the lung
1477512|NCT00070486|squamous cell lung cancer
1477513|NCT00070486|large cell lung cancer
1477514|NCT00070486|stage IIIB non-small cell lung cancer
1477515|NCT00070473|unspecified childhood solid tumor, protocol specific
1477516|NCT00070447|contiguous stage II mantle cell lymphoma
1477517|NCT00070447|noncontiguous stage II mantle cell lymphoma
1477518|NCT00070447|stage III mantle cell lymphoma
1477519|NCT00070447|stage IV mantle cell lymphoma
1477520|NCT00070434|stage II rectal cancer
1477521|NCT00070434|stage III rectal cancer
1477522|NCT00070434|adenocarcinoma of the rectum
1477523|NCT00070421|psychosocial effects of cancer and its treatment
1477524|NCT00070421|unspecified childhood solid tumor, protocol specific
1477525|NCT00070421|childhood acute lymphoblastic leukemia in remission
1477526|NCT00070421|childhood acute myeloid leukemia in remission
1477527|NCT00070421|recurrent childhood acute lymphoblastic leukemia
1477528|NCT00070421|recurrent childhood acute myeloid leukemia
1477529|NCT00070421|recurrent childhood large cell lymphoma
1477530|NCT00070421|recurrent childhood lymphoblastic lymphoma
1477531|NCT00070421|recurrent childhood small noncleaved cell lymphoma
1477938|NCT00069498|Tissue Viral Load
1477532|NCT00070421|stage I childhood Hodgkin lymphoma
1477533|NCT00070421|stage I childhood large cell lymphoma
1477534|NCT00070421|stage I childhood lymphoblastic lymphoma
1477535|NCT00070421|stage I childhood small noncleaved cell lymphoma
1477536|NCT00070421|stage II childhood Hodgkin lymphoma
1477537|NCT00070421|stage II childhood large cell lymphoma
1477538|NCT00070421|stage II childhood lymphoblastic lymphoma
1477539|NCT00070421|stage II childhood small noncleaved cell lymphoma
1477540|NCT00070421|stage III childhood Hodgkin lymphoma
1477541|NCT00070421|stage III childhood large cell lymphoma
1477542|NCT00070421|stage III childhood lymphoblastic lymphoma
1477543|NCT00070421|stage III childhood small noncleaved cell lymphoma
1477544|NCT00070421|stage IV childhood Hodgkin lymphoma
1477545|NCT00070421|stage IV childhood large cell lymphoma
1477546|NCT00070421|stage IV childhood lymphoblastic lymphoma
1477547|NCT00070421|stage IV childhood small noncleaved cell lymphoma
1477548|NCT00070421|recurrent/refractory childhood Hodgkin lymphoma
1477549|NCT00070382|anemia
1477550|NCT00070382|unspecified adult solid tumor, protocol specific
1477551|NCT00070382|Waldenstrom macroglobulinemia
1477552|NCT00070382|monoclonal gammopathy of undetermined significance
1477553|NCT00070382|extramedullary plasmacytoma
1477554|NCT00070382|isolated plasmacytoma of bone
1477555|NCT00070382|refractory multiple myeloma
1477556|NCT00070382|primary systemic amyloidosis
1477557|NCT00070382|stage I multiple myeloma
1477558|NCT00070382|stage II multiple myeloma
1477559|NCT00070382|stage III multiple myeloma
1477560|NCT00070382|post-transplant lymphoproliferative disorder
1477561|NCT00070382|angioimmunoblastic T-cell lymphoma
1477562|NCT00070382|anaplastic large cell lymphoma
1477563|NCT00070382|stage I cutaneous T-cell non-Hodgkin lymphoma
1477564|NCT00070382|stage II cutaneous T-cell non-Hodgkin lymphoma
1477565|NCT00070382|stage III cutaneous T-cell non-Hodgkin lymphoma
1477566|NCT00070382|stage IV cutaneous T-cell non-Hodgkin lymphoma
1477567|NCT00070382|recurrent adult T-cell leukemia/lymphoma
1477568|NCT00070382|stage I adult T-cell leukemia/lymphoma
1477569|NCT00070382|stage II adult T-cell leukemia/lymphoma
1477570|NCT00070382|stage III adult T-cell leukemia/lymphoma
1477571|NCT00070382|stage IV adult T-cell leukemia/lymphoma
1477572|NCT00070382|recurrent cutaneous T-cell non-Hodgkin lymphoma
1477573|NCT00070382|recurrent mycosis fungoides/Sezary syndrome
1477574|NCT00070382|stage I mycosis fungoides/Sezary syndrome
1477575|NCT00070382|stage II mycosis fungoides/Sezary syndrome
1477576|NCT00070382|stage III mycosis fungoides/Sezary syndrome
1477577|NCT00070382|stage IV mycosis fungoides/Sezary syndrome
1477578|NCT00070382|recurrent adult Hodgkin lymphoma
1477579|NCT00070382|stage I adult Hodgkin lymphoma
1477580|NCT00070382|stage II adult Hodgkin lymphoma
1477581|NCT00070382|stage III adult Hodgkin lymphoma
1477582|NCT00070382|stage IV adult Hodgkin lymphoma
1477583|NCT00070382|T-cell large granular lymphocyte leukemia
1477584|NCT00070382|refractory chronic lymphocytic leukemia
1477585|NCT00070382|stage 0 chronic lymphocytic leukemia
1477586|NCT00070382|stage I chronic lymphocytic leukemia
1477587|NCT00070382|stage II chronic lymphocytic leukemia
1477588|NCT00070382|stage III chronic lymphocytic leukemia
1477589|NCT00070382|stage IV chronic lymphocytic leukemia
1477590|NCT00070382|prolymphocytic leukemia
1477591|NCT00070382|recurrent grade 1 follicular lymphoma
1477592|NCT00070382|recurrent grade 2 follicular lymphoma
1477593|NCT00070382|recurrent grade 3 follicular lymphoma
1477594|NCT00070382|stage I grade 1 follicular lymphoma
1477595|NCT00070382|stage I grade 2 follicular lymphoma
1477596|NCT00070382|stage I grade 3 follicular lymphoma
1477597|NCT00070382|stage III grade 1 follicular lymphoma
1477598|NCT00070382|stage III grade 2 follicular lymphoma
1477599|NCT00070382|stage III grade 3 follicular lymphoma
1477600|NCT00070382|stage IV grade 1 follicular lymphoma
1477601|NCT00070382|stage IV grade 2 follicular lymphoma
1477602|NCT00070382|stage IV grade 3 follicular lymphoma
1477603|NCT00070382|contiguous stage II adult diffuse large cell lymphoma
1477604|NCT00070382|contiguous stage II adult diffuse mixed cell lymphoma
1477605|NCT00070382|contiguous stage II adult diffuse small cleaved cell lymphoma
1477606|NCT00070382|noncontiguous stage II adult diffuse large cell lymphoma
1477607|NCT00070382|noncontiguous stage II adult diffuse mixed cell lymphoma
1477608|NCT00070382|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1477609|NCT00070382|recurrent adult diffuse large cell lymphoma
1477610|NCT00070382|recurrent adult diffuse mixed cell lymphoma
1477611|NCT00070382|recurrent adult diffuse small cleaved cell lymphoma
1477612|NCT00070382|stage I adult diffuse large cell lymphoma
1477613|NCT00070382|stage I adult diffuse mixed cell lymphoma
1477614|NCT00070382|stage I adult diffuse small cleaved cell lymphoma
1477615|NCT00070382|stage III adult diffuse large cell lymphoma
1477616|NCT00070382|stage III adult diffuse mixed cell lymphoma
1477617|NCT00070382|stage III adult diffuse small cleaved cell lymphoma
1477618|NCT00070382|stage IV adult diffuse large cell lymphoma
1477619|NCT00070382|stage IV adult diffuse mixed cell lymphoma
1477620|NCT00070382|stage IV adult diffuse small cleaved cell lymphoma
1477621|NCT00070382|contiguous stage II adult immunoblastic large cell lymphoma
1477622|NCT00070382|noncontiguous stage II adult immunoblastic large cell lymphoma
1477623|NCT00070382|recurrent adult immunoblastic large cell lymphoma
1477624|NCT00070382|stage I adult immunoblastic large cell lymphoma
1477625|NCT00070382|stage III adult immunoblastic large cell lymphoma
1477626|NCT00070382|stage IV adult immunoblastic large cell lymphoma
1477627|NCT00070382|contiguous stage II mantle cell lymphoma
1477628|NCT00070382|noncontiguous stage II mantle cell lymphoma
1477629|NCT00070382|recurrent mantle cell lymphoma
1477630|NCT00070382|stage I mantle cell lymphoma
1477631|NCT00070382|stage III mantle cell lymphoma
1477632|NCT00070382|stage IV mantle cell lymphoma
1477633|NCT00070382|contiguous stage II grade 1 follicular lymphoma
1477634|NCT00070382|contiguous stage II grade 2 follicular lymphoma
1477635|NCT00070382|contiguous stage II grade 3 follicular lymphoma
1477636|NCT00070382|noncontiguous stage II grade 1 follicular lymphoma
1477637|NCT00070382|noncontiguous stage II grade 2 follicular lymphoma
1477638|NCT00070382|noncontiguous stage II grade 3 follicular lymphoma
1477639|NCT00070343|stage IV melanoma
1477640|NCT00070343|stage III melanoma
1477641|NCT00070304|recurrent/refractory childhood Hodgkin lymphoma
1477642|NCT00070304|childhood lymphocyte predominant Hodgkin lymphoma
1477643|NCT00070304|childhood lymphocyte depletion Hodgkin lymphoma
1477644|NCT00070304|childhood nodular sclerosis Hodgkin lymphoma
1477645|NCT00070304|childhood mixed cellularity Hodgkin lymphoma
1477646|NCT00070291|angioimmunoblastic T-cell lymphoma
1477647|NCT00070278|stage II breast cancer
1477648|NCT00070278|stage IIIA breast cancer
1477649|NCT00070278|stage IIIB breast cancer
1477650|NCT00070278|stage IIIC breast cancer
1477651|NCT00070213|adenocarcinoma of the colon
1477652|NCT00070213|adenocarcinoma of the rectum
1477653|NCT00070213|stage IV rectal cancer
1477654|NCT00070213|stage IV colon cancer
1477655|NCT00070213|recurrent rectal cancer
1477656|NCT00070213|recurrent colon cancer
1477657|NCT00070200|recurrent neuroblastoma
1477658|NCT00070200|stage 4S neuroblastoma
1477659|NCT00070200|localized unresectable neuroblastoma
1477660|NCT00070200|localized resectable neuroblastoma
1477661|NCT00070200|regional neuroblastoma
1477662|NCT00070200|disseminated neuroblastoma
1477663|NCT00070187|recurrent adult Hodgkin lymphoma
1477664|NCT00070187|recurrent/refractory childhood Hodgkin lymphoma
1477665|NCT00070174|untreated childhood acute myeloid leukemia and other myeloid malignancies
1477666|NCT00070174|childhood acute monocytic leukemia (M5b)
1477667|NCT00070174|childhood acute megakaryocytic leukemia (M7)
1477668|NCT00070174|childhood acute minimally differentiated myeloid leukemia (M0)
1477669|NCT00070174|childhood acute myeloblastic leukemia with maturation (M2)
1477670|NCT00070174|childhood acute myeloblastic leukemia without maturation (M1)
1477671|NCT00070174|childhood acute myelomonocytic leukemia (M4)
1477672|NCT00070174|childhood acute monoblastic leukemia (M5a)
1477673|NCT00070174|childhood acute erythroleukemia (M6)
1477674|NCT00070161|radiation toxicity
1477675|NCT00070161|adult mixed glioma
1477676|NCT00070161|adult central nervous system germ cell tumor
1477677|NCT00070161|adult brain stem glioma
1477678|NCT00070161|adult craniopharyngioma
1477679|NCT00070161|adult medulloblastoma
1477680|NCT00070161|adult meningioma
1477681|NCT00070161|adult choroid plexus tumor
1477682|NCT00070161|adult tumors metastatic to brain
1477683|NCT00070161|adult anaplastic oligodendroglioma
1477684|NCT00070161|adult anaplastic astrocytoma
1477685|NCT00070161|adult pilocytic astrocytoma
1477686|NCT00070161|adult subependymoma
1477687|NCT00070161|adult meningeal hemangiopericytoma
1477688|NCT00070161|adult ependymoblastoma
1477689|NCT00070161|adult anaplastic ependymoma
1477690|NCT00070161|adult pineoblastoma
1477691|NCT00070161|adult pineocytoma
1477692|NCT00070161|adult myxopapillary ependymoma
1477693|NCT00070161|adult glioblastoma
1477694|NCT00070161|adult grade III meningioma
1477695|NCT00070161|adult oligodendroglioma
1477696|NCT00070161|adult giant cell glioblastoma
1477697|NCT00070161|adult gliosarcoma
1477698|NCT00070161|adult ependymoma
1477699|NCT00070148|weight changes
1477700|NCT00070148|unspecified adult solid tumor, protocol specific
1477701|NCT00070135|adult acute myeloid leukemia in remission
1477702|NCT00070135|secondary acute myeloid leukemia
1477703|NCT00070135|adult acute monocytic leukemia (M5b)
1477704|NCT00070135|adult acute erythroid leukemia (M6)
1477705|NCT00070135|adult acute megakaryoblastic leukemia (M7)
1477706|NCT00070135|adult acute minimally differentiated myeloid leukemia (M0)
1477707|NCT00070135|adult acute myeloblastic leukemia with maturation (M2)
1477708|NCT00070135|adult acute myeloblastic leukemia without maturation (M1)
1477709|NCT00070135|adult acute myelomonocytic leukemia (M4)
1477710|NCT00070135|adult acute monoblastic leukemia (M5a)
1477711|NCT00070135|adult acute myeloid leukemia with t(8;21)(q22;q22)
1477712|NCT00070135|adult acute myeloid leukemia with t(16;16)(p13;q22)
1477713|NCT00070135|adult acute myeloid leukemia with inv(16)(p13;q22)
1477714|NCT00070135|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1477715|NCT00070096|stage IV ovarian germ cell tumor
1477716|NCT00070096|recurrent ovarian germ cell tumor
1477717|NCT00070096|adult central nervous system germ cell tumor
1477718|NCT00070096|recurrent malignant testicular germ cell tumor
1477719|NCT00070096|stage III malignant testicular germ cell tumor
1477720|NCT00070096|testicular seminoma
1477721|NCT00070096|testicular choriocarcinoma and embryonal carcinoma
1477722|NCT00070096|testicular choriocarcinoma and seminoma
1477723|NCT00070096|testicular choriocarcinoma and teratoma
1477724|NCT00070096|testicular choriocarcinoma and yolk sac tumor
1477725|NCT00070096|testicular choriocarcinoma
1477726|NCT00070096|testicular embryonal carcinoma and seminoma
1477727|NCT00070096|testicular embryonal carcinoma and teratoma with seminoma
1477728|NCT00070096|testicular embryonal carcinoma and teratoma
1477729|NCT00070096|testicular embryonal carcinoma and yolk sac tumor with seminoma
1477730|NCT00070096|testicular embryonal carcinoma and yolk sac tumor
1477731|NCT00070096|testicular embryonal carcinoma
1477732|NCT00070096|testicular yolk sac tumor and teratoma with seminoma
1477733|NCT00070096|testicular yolk sac tumor and teratoma
1477734|NCT00070096|testicular yolk sac tumor
1477735|NCT00070096|recurrent extragonadal non-seminomatous germ cell tumor
1477736|NCT00070096|recurrent extragonadal seminoma
1477737|NCT00070096|stage IV extragonadal non-seminomatous germ cell tumor
1477738|NCT00070096|stage IV extragonadal seminoma
1477739|NCT00070096|recurrent extragonadal germ cell tumor
1477740|NCT00070096|testicular immature teratoma
1477741|NCT00070096|testicular mature teratoma
1477742|NCT00070083|contiguous stage II adult diffuse large cell lymphoma
1477743|NCT00070083|noncontiguous stage II adult diffuse large cell lymphoma
1477744|NCT00070083|stage III adult diffuse large cell lymphoma
1477745|NCT00070083|stage IV adult diffuse large cell lymphoma
1477746|NCT00070070|transitional cell carcinoma of the bladder
1477747|NCT00070070|stage I bladder cancer
1477748|NCT00070031|recurrent breast cancer
1477749|NCT00070031|stage IIIA breast cancer
1477750|NCT00070031|stage IIIB breast cancer
1477751|NCT00070031|stage IIIC breast cancer
1477752|NCT00070031|stage IV breast cancer
1477753|NCT00070018|stage I mantle cell lymphoma
1477754|NCT00070018|stage I adult diffuse large cell lymphoma
1477755|NCT00070018|stage I adult Burkitt lymphoma
1477756|NCT00070018|anaplastic large cell lymphoma
1477757|NCT00070018|contiguous stage II adult diffuse large cell lymphoma
1477758|NCT00070018|contiguous stage II adult Burkitt lymphoma
1477759|NCT00070018|contiguous stage II mantle cell lymphoma
1477760|NCT00070018|noncontiguous stage II adult diffuse large cell lymphoma
1477761|NCT00070018|noncontiguous stage II adult Burkitt lymphoma
1477762|NCT00070018|noncontiguous stage II mantle cell lymphoma
1477763|NCT00070005|perioperative/postoperative complications
1477764|NCT00070005|stage I rectal cancer
1477765|NCT00070005|stage II rectal cancer
1477766|NCT00070005|stage III rectal cancer
1477767|NCT00070005|adenocarcinoma of the rectum
1477768|NCT00069992|polycythemia vera
1477769|NCT00069992|essential thrombocythemia
1477770|NCT00069992|de novo myelodysplastic syndromes
1477771|NCT00069992|previously treated myelodysplastic syndromes
1477772|NCT00069992|secondary myelodysplastic syndromes
1477773|NCT00069992|primary myelofibrosis
1477774|NCT00069992|chronic myelogenous leukemia
1477775|NCT00069992|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1477776|NCT00069992|adult acute myeloid leukemia with inv(16)(p13;q22)
1477777|NCT00069992|adult acute myeloid leukemia with t(15;17)(q22;q12)
1477778|NCT00069992|adult acute myeloid leukemia with t(16;16)(p13;q22)
1477779|NCT00069992|adult acute myeloid leukemia with t(8;21)(q22;q22)
1477780|NCT00069992|childhood myelodysplastic syndromes
1477781|NCT00069966|recurrent adult diffuse large cell lymphoma
1477782|NCT00069966|anaplastic large cell lymphoma
1477783|NCT00069966|recurrent adult diffuse mixed cell lymphoma
1477784|NCT00069966|recurrent adult immunoblastic large cell lymphoma
1477785|NCT00069966|recurrent grade 3 follicular lymphoma
1477786|NCT00069966|recurrent adult Burkitt lymphoma
1477787|NCT00069953|adenocarcinoma of the esophagus
1477788|NCT00069953|squamous cell carcinoma of the esophagus
1477789|NCT00069953|stage II esophageal cancer
1477790|NCT00069953|stage III esophageal cancer
1477791|NCT00069940|adult glioblastoma
1477792|NCT00069940|stage III adult soft tissue sarcoma
1477793|NCT00069940|stage IV adult soft tissue sarcoma
1477794|NCT00069940|adult synovial sarcoma
1477795|NCT00069940|childhood synovial sarcoma
1477796|NCT00069940|childhood leiomyosarcoma
1477797|NCT00069940|adult leiomyosarcoma
1477798|NCT00069940|adult liposarcoma
1477799|NCT00069940|childhood liposarcoma
1477800|NCT00069940|gastrointestinal stromal tumor
1477801|NCT00069940|recurrent childhood brain tumor
1477802|NCT00069940|recurrent adult brain tumor
1477803|NCT00069940|metastatic childhood soft tissue sarcoma
1477804|NCT00069940|recurrent childhood soft tissue sarcoma
1477805|NCT00069940|recurrent adult soft tissue sarcoma
1477806|NCT00069940|adult giant cell glioblastoma
1477807|NCT00069940|adult gliosarcoma
1477808|NCT00069940|adult anaplastic astrocytoma
1477809|NCT00069940|adult oligodendroglioma
1477810|NCT00069940|adult anaplastic oligodendroglioma
1477811|NCT00069940|adult diffuse astrocytoma
1477812|NCT00069940|adult mixed glioma
1477813|NCT00069940|adult myxopapillary ependymoma
1477814|NCT00069940|adult anaplastic ependymoma
1477815|NCT00069940|childhood high-grade cerebral astrocytoma
1477816|NCT00069940|recurrent childhood cerebral astrocytoma
1477817|NCT00069940|untreated childhood cerebellar astrocytoma
1477818|NCT00069940|recurrent childhood cerebellar astrocytoma
1477819|NCT00069940|childhood infratentorial ependymoma
1477820|NCT00069940|newly diagnosed childhood ependymoma
1477821|NCT00069940|recurrent childhood ependymoma
1477822|NCT00069940|childhood oligodendroglioma
1477823|NCT00069927|unspecified childhood solid tumor, protocol specific
1477824|NCT00069927|depression
1477825|NCT00069927|neurotoxicity
1477826|NCT00069914|Immunization
1477827|NCT00069914|Immune Activation
1477828|NCT00069914|Flu
1477829|NCT00069914|Antibodies
1477830|NCT00069914|Titers
1477831|NCT00069914|HIV
1477832|NCT00069914|Healthy Volunteer
1477833|NCT00069914|HV
1477834|NCT00069901|ovarian cancer
1477835|NCT00069901|paclitaxel
1477836|NCT00069901|carboplatin
1477837|NCT00069862|Beta Thalassemia
1477838|NCT00069836|AVANDAMET insulin type 2 diabetes
1477839|NCT00069784|Impaired Fasting Glucose (IFG)
1477840|NCT00069784|Impaired Glucose Tolerance (IGT)
1477841|NCT00069758|NHL, indolent NHL, non-Hodgkin's lymphoma, lymphoma
1477842|NCT00069745|Prostatic Neoplasms
1477843|NCT00069745|Cancer Treatment Protocols
1477844|NCT00069745|Antineoplastic protocols
1477845|NCT00069745|One Prior Cytotoxic Chemotherapy Regimen
1477846|NCT00069732|Overweight
1477847|NCT00069732|Weight loss maintenance
1477848|NCT00069732|CAM therapy
1477849|NCT00069732|Qigong
1477850|NCT00069732|Acupressure
1477851|NCT00069732|Traditional Chinese Medicine
1477852|NCT00069719|open-angle
1477853|NCT00069719|glaucoma
1477854|NCT00069719|ocular
1477855|NCT00069719|hypertension
1477856|NCT00069719|POAG
1477857|NCT00069706|open-angle
1477858|NCT00069706|glaucoma
1477859|NCT00069706|ocular
1477860|NCT00069706|hypertension
1477861|NCT00069706|POAG
1477862|NCT00069693|Dysautonomia
1477863|NCT00069693|Sympathetic Nervous System
1477864|NCT00069693|Autonomic Nervous System
1477865|NCT00069693|Syncope
1477866|NCT00069693|Post Tachycardia Syndrome
1477867|NCT00069693|POTS
1477868|NCT00069693|Neurocardiogenic Syncope
1477869|NCT00069693|Baroreflex
1477870|NCT00069693|Norepinephrine
1477871|NCT00069693|Epinephrine
1477872|NCT00069693|Neurocardiology
1477873|NCT00069693|Chronic Orthostatic Intolerance
1477874|NCT00069693|COI
1477875|NCT00069693|Healthy Volunteer
1477876|NCT00069693|HV
1477877|NCT00069680|Gene Identification
1477878|NCT00069680|Linkage Analysis
1477879|NCT00069680|Homozygosity Mapping
1477880|NCT00069680|Gray Platelet Syndrome
1477881|NCT00069680|GPS
1477882|NCT00069680|Platelet Function Defect
1477883|NCT00069680|Bleeding Disorder
1477884|NCT00069654|Endothelium
1477885|NCT00069654|Atherosclerosis
1477886|NCT00069654|Vasodilation
1477887|NCT00069654|Ischemia
1477888|NCT00069654|Exercise
1477889|NCT00069654|Coronary Artery Disease
1477890|NCT00069654|CAD
1477891|NCT00069641|Mucopolysaccharidosis II
1477892|NCT00069641|MPS II
1477893|NCT00069641|Hunter Syndrome
1477894|NCT00069641|iduronate-2-sulfatase
1477895|NCT00069641|I2S
1477896|NCT00069641|Iduronate-2-sulfatase deficiency
1477897|NCT00069628|Diabetes Mellitus, Insulin-Dependent
1477898|NCT00069628|Type 1 Diabetes
1477899|NCT00069628|Diabetes in Children
1477900|NCT00069628|Continuous Glucose Monitoring Devices
1477901|NCT00069615|Diabetes Mellitus, Insulin-Dependent
1477902|NCT00069615|Type 1 Diabetes
1477903|NCT00069615|Continuous Glucose Monitoring Devices
1477904|NCT00069615|Electronic Data Collection
1477905|NCT00069602|Continuous Glucose Monitoring Devices
1477906|NCT00069602|Blood glucose profiles in normal children
1477907|NCT00069602|Blood glucose profiles in non-diabetic children
1477908|NCT00069589|Baldness
1477909|NCT00069589|Autoimmunity
1477910|NCT00069589|Hair
1477911|NCT00069589|Alopecia Areata
1477912|NCT00069589|Alopecia Partialis
1477913|NCT00069589|Alopecia Totalis
1477914|NCT00069589|Alopecia Universalis
1477915|NCT00069589|Autoimmune Hair Loss
1477916|NCT00069576|Mild gestational diabetes mellitus
1477917|NCT00069576|Maternal Fetal Medicine Units Network
1477918|NCT00069563|Internalizing psychopathology
1477919|NCT00069563|Externalizing psychopathology
1477920|NCT00069550|Glutamate/NMDA receptors
1477921|NCT00069550|Cholinergic upregulation
1477922|NCT00069550|Dextromethorphan
1477923|NCT00069550|Donepezil hydrochloride
1477924|NCT00069550|Aricept
1477925|NCT00069537|Diabetes Mellitus, Insulin-Dependent
1477926|NCT00069537|Type 1 Diabetes
1477927|NCT00069537|Diabetes in Children
1477928|NCT00069537|Continuous Glucose Monitoring Devices
1477929|NCT00069524|Highly active antiretroviral therapy (HAART)
1477930|NCT00069524|Ritonavir
1477931|NCT00069524|Oyster mushrooms
1477932|NCT00069524|Non-HDL cholesterol
1477933|NCT00069524|Complementary Therapies
1477934|NCT00069524|Treatment Experienced
1477935|NCT00069511|Hepatitis C
1477936|NCT00069498|Mucosa
1477937|NCT00069498|Inflammation
1477939|NCT00069498|Anti-inflammatory
1477940|NCT00069498|HIV-related diarrhea
1477941|NCT00069498|Mucosal Inflammation
1477942|NCT00069498|Treatment Experienced
1477943|NCT00069485|HIV Seronegativity
1477944|NCT00069472|Genetics
1477945|NCT00069459|Winter depression, winter blues, depression, seasonal depression, seasonal affective disorder
1477946|NCT00069446|Diabetes
1477947|NCT00069446|Diabetic
1477948|NCT00069446|Diabetic Foot Ulcer
1477949|NCT00069433|Psychotic Disorders
1477950|NCT00069407|Bipolar Disorder
1477951|NCT00069368|Healthy
1477952|NCT00069355|PTSD
1477953|NCT00069355|Catecholamines
1477954|NCT00069355|Conditioning
1477955|NCT00069355|Memory
1477956|NCT00069355|Psychophysiology
1477957|NCT00069355|Acute Stress Disorder
1477958|NCT00069355|Post-Traumatic Stress Disorder
1477959|NCT00069342|Chronic Pain
1477960|NCT00069342|Pain
1477961|NCT00069342|Rheumatoid Arthritis
1477962|NCT00069342|Depression
1477963|NCT00069342|Function
1477964|NCT00069342|Rheumatic Disease
1477965|NCT00069329|Central Nervous System
1477966|NCT00069329|Abnormalities
1477967|NCT00069329|Arthropathy
1477968|NCT00069329|Urticaria
1477969|NCT00069329|Papilledema
1477970|NCT00069329|Auto-Inflammation
1477971|NCT00069329|Inflammatory Disease
1477972|NCT00069329|Neonatal Onset Multisystem Inflammatory Disease
1477973|NCT00069329|NOMID
1477974|NCT00069329|CINCA Syndrome
1477975|NCT00069316|West Nile Virus
1477976|NCT00069316|Encephalitis
1477977|NCT00069316|Virus
1477978|NCT00069316|Mosquito
1477979|NCT00069316|Fever
1477980|NCT00069316|WNV
1477981|NCT00069316|Myelitis
1477982|NCT00069303|West Nile Virus
1477983|NCT00069303|Encephalitis
1477984|NCT00069303|Virus
1477985|NCT00069303|Mosquito
1477986|NCT00069303|Fever
1477987|NCT00069303|WNV
1477988|NCT00069303|Myelitis
1477989|NCT00069277|Cancer, tumors
1477990|NCT00069264|Metastatic Tumors
1477991|NCT00069264|Advanced Solid Tumors
1477992|NCT00069264|Stage IV Tumors
1477993|NCT00069264|Solid Tumors
1477994|NCT00069264|Recurrent Solid Tumors
1477995|NCT00069251|amphetamine dependence
1477996|NCT00069238|Lymphoma
1477997|NCT00069238|T-Cell Lymphoma
1477998|NCT00069238|NK -Cell Lymphoma
1477999|NCT00069225|fMRI
1478000|NCT00069225|Prolonged Exposure
1478001|NCT00069225|Brain Activation
1478002|NCT00069225|Conditioning
1478003|NCT00069225|Paroxetine
1478004|NCT00069225|PTSD
1478005|NCT00069225|Differential Fear Conditioning
1478006|NCT00069225|Masked Faces
1478007|NCT00069225|Amygdala
1478008|NCT00069225|Hippocampus
1478009|NCT00069225|Post-Traumatic Stress Disorder
1478010|NCT00069212|Post-Traumatic Stress Disorder
1478011|NCT00069212|Neural Circuits
1478012|NCT00069212|Fear
1478013|NCT00069212|Emotional Regulation
1478014|NCT00069212|Reward
1478015|NCT00069212|PTSD
1478016|NCT00069199|Reproducibility
1478017|NCT00069199|Macular Edema
1478018|NCT00069199|OCT2
1478019|NCT00069199|OCT3
1478020|NCT00069199|Retina
1478021|NCT00069186|Amyotrophic Lateral Sclerosis
1478022|NCT00069186|ALS
1478023|NCT00069186|Creatine
1478024|NCT00069186|Creatine Monohydrate
1478025|NCT00069186|Muscle Strength
1478026|NCT00069173|Females
1478027|NCT00069173|Sedentary
1478028|NCT00069173|School-based
1478029|NCT00069160|Pharmacokinetics
1478030|NCT00069160|Pharmacodynamics
1478031|NCT00069160|Multidrug Resistance Reversal
1478032|NCT00069160|Molecular Target
1478033|NCT00069160|P-Glycoprotein Inhibition
1478034|NCT00069160|Lung Cancer
1478035|NCT00069160|Ovarian Cancer
1478036|NCT00069160|Cervical Cancer
1478037|NCT00069160|Renal Cancer
1478038|NCT00069134|glutathione kinetics
1478039|NCT00069134|oxidant damage
1478040|NCT00069134|anti-oxidant capacity
1478041|NCT00069134|oxidative stress
1478042|NCT00069134|cysteine kinetics
1478043|NCT00069134|severe childhood malnutrition
1478044|NCT00069082|Headache
1478045|NCT00069082|Cluster
1478046|NCT00069082|EC
1478047|NCT00069082|Episodic Cluster
1478048|NCT00069069|Stroke
1478049|NCT00069069|TIA
1478050|NCT00069056|Grid Laser
1478051|NCT00069056|Focal Laser
1478052|NCT00069056|Glycemic Control
1478053|NCT00069056|Diabetes
1478054|NCT00069056|Diabetic Macular Edema
1478055|NCT00069056|Macular Edema
1478056|NCT00069030|HIV Seronegativity
1478057|NCT00069030|HIV Preventive Vaccine
1478058|NCT00069030|HIV-1
1478059|NCT00069030|AIDS Vaccines
1478060|NCT00069030|Vaccines, DNA
1478061|NCT00069030|Dose-Response Relationship, Immunologic
1478062|NCT00069030|Cytokines
1478063|NCT00069030|Plasmids
1478064|NCT00069030|Adjuvants, Immunologic
1478065|NCT00069030|Drug Administration Schedule
1478066|NCT00069030|Interleukin
1478067|NCT00069030|IL2
1478068|NCT00069030|Ig
1478069|NCT00069030|IL@/Ig
1478070|NCT00069004|HIV-Associated Lipodystrophy Syndrome
1478071|NCT00069004|HIV Lipodystrophy Syndrome
1478072|NCT00069004|Treatment Experienced
1478073|NCT00069004|Lipodystrophy
1478074|NCT00069004|Dyslipidemia
1478075|NCT00069004|Osteoporosis
1478076|NCT00069004|Osteopenia
1478077|NCT00068991|Behavioral Intervention Study
1478078|NCT00068991|Randomized Prevention Trial
1478079|NCT00068991|China
1478080|NCT00068991|Condom Use
1478081|NCT00068991|STDs
1478082|NCT00068991|Sexual Partners
1478083|NCT00068991|HIV Seronegativity
1478084|NCT00068978|HIV Seronegativity
1478085|NCT00068978|HIV Preventive Vaccine
1478086|NCT00068978|HIV Therapeutic Vaccine
1478087|NCT00068926|Biodefense
1478088|NCT00068926|Prevention
1478089|NCT00068926|Emergent
1478090|NCT00068926|Virus
1478091|NCT00068926|Immune Response
1478092|NCT00068926|Healthy Volunteer
1478093|NCT00068926|HV
1478094|NCT00068913|Lactic Acidosis
1478095|NCT00068913|Mitochondrial Disorder
1478096|NCT00068913|Stroke
1478097|NCT00068913|Seizure
1478098|NCT00068887|type 2 diabetes
1478099|NCT00068887|some studies - family history of type 2 diabetes
1478100|NCT00068874|African American
1478101|NCT00068874|Adolescent
1478102|NCT00068874|Coping
1478103|NCT00068874|Adjustment
1478104|NCT00068874|Quality of Life
1478105|NCT00068848|Oral Contraceptives
1478106|NCT00068848|Initiation
1478107|NCT00068848|Continuation
1478108|NCT00068835|Reading
1478109|NCT00068835|Brain imaging
1478110|NCT00068822|Vertebroplasty
1478111|NCT00068822|Crushed Vertebrae
1478112|NCT00068822|Back Pain
1478113|NCT00068822|Structurally Unstable Vertebrae
1478114|NCT00068822|polymethylmethacrylate
1478115|NCT00068822|INVEST
1478116|NCT00068822|PMMA
1478117|NCT00068822|RDQ
1478118|NCT00068809|Treatment experienced
1478119|NCT00068809|Treatment interruption
1478120|NCT00068770|adult glioblastoma
1478121|NCT00068770|adult giant cell glioblastoma
1478122|NCT00068770|adult gliosarcoma
1478123|NCT00068757|recurrent breast cancer
1478124|NCT00068757|stage IIIB breast cancer
1478125|NCT00068757|stage IIIC breast cancer
1478126|NCT00068757|stage IV breast cancer
1478127|NCT00068757|male breast cancer
1478128|NCT00068757|HER2-positive breast cancer
1478129|NCT00068744|squamous cell carcinoma of the anus
1478130|NCT00068744|stage II anal cancer
1478131|NCT00068744|stage IIIA anal cancer
1478132|NCT00068744|stage IIIB anal cancer
1478133|NCT00068731|stage IV prostate cancer
1478134|NCT00068731|recurrent prostate cancer
1478135|NCT00068666|stage IV melanoma
1478136|NCT00068666|recurrent melanoma
1478137|NCT00068666|tumors metastatic to brain
1478138|NCT00068653|recurrent non-small cell lung cancer
1478139|NCT00068614|stage IV breast cancer
1478140|NCT00068614|stage II breast cancer
1478141|NCT00068614|stage IIIA breast cancer
1478142|NCT00068614|stage IIIB breast cancer
1478143|NCT00068614|stage IIIC breast cancer
1478144|NCT00068601|infertility
1478145|NCT00068601|menopausal symptoms
1478146|NCT00068601|stage II breast cancer
1478147|NCT00068601|stage IIIA breast cancer
1478148|NCT00068601|stage IA breast cancer
1478149|NCT00068601|stage IB breast cancer
1478150|NCT00068601|estrogen receptor-negative breast cancer
1478151|NCT00068601|progesterone receptor-negative breast cancer
1478152|NCT00068575|stage I pancreatic cancer
1478153|NCT00068575|stage II pancreatic cancer
1478154|NCT00068575|stage III pancreatic cancer
1478155|NCT00068575|adenocarcinoma of the pancreas
1478156|NCT00068523|refractory multiple myeloma
1478157|NCT00068523|accelerated phase chronic myelogenous leukemia
1478158|NCT00068523|adult acute lymphoblastic leukemia in remission
1478159|NCT00068523|adult acute myeloid leukemia in remission
1478160|NCT00068523|blastic phase chronic myelogenous leukemia
1478161|NCT00068523|recurrent adult acute lymphoblastic leukemia
1478162|NCT00068523|recurrent adult acute myeloid leukemia
1478163|NCT00068523|refractory chronic lymphocytic leukemia
1478164|NCT00068523|relapsing chronic myelogenous leukemia
1478165|NCT00068523|de novo myelodysplastic syndromes
1478166|NCT00068523|previously treated myelodysplastic syndromes
1478167|NCT00068523|recurrent adult diffuse large cell lymphoma
1478168|NCT00068523|recurrent adult diffuse mixed cell lymphoma
1478169|NCT00068523|recurrent adult diffuse small cleaved cell lymphoma
1478170|NCT00068523|recurrent adult Burkitt lymphoma
1478171|NCT00068523|recurrent adult immunoblastic large cell lymphoma
1478172|NCT00068523|recurrent adult lymphoblastic lymphoma
1478173|NCT00068523|recurrent grade 1 follicular lymphoma
1478174|NCT00068523|recurrent grade 2 follicular lymphoma
1478175|NCT00068523|recurrent grade 3 follicular lymphoma
1478176|NCT00068523|recurrent mantle cell lymphoma
1478177|NCT00068523|refractory anemia with excess blasts in transformation
1478178|NCT00068523|refractory anemia with excess blasts
1478179|NCT00068523|secondary myelodysplastic syndromes
1478180|NCT00068523|Philadelphia chromosome negative chronic myelogenous leukemia
1478181|NCT00068523|chronic idiopathic myelofibrosis
1478182|NCT00068523|B-cell chronic lymphocytic leukemia
1478183|NCT00068523|T-cell large granular lymphocyte leukemia
1478184|NCT00068523|chronic phase chronic myelogenous leukemia
1478185|NCT00068523|recurrent adult Hodgkin lymphoma
1478186|NCT00068523|recurrent adult T-cell leukemia/lymphoma
1478187|NCT00068523|stage III chronic lymphocytic leukemia
1478188|NCT00068523|stage IV chronic lymphocytic leukemia
1478189|NCT00068523|recurrent cutaneous T-cell non-Hodgkin lymphoma
1478190|NCT00068523|recurrent mycosis fungoides/Sezary syndrome
1478191|NCT00068523|secondary acute myeloid leukemia
1478192|NCT00068523|atypical chronic myeloid leukemia
1478193|NCT00068523|myelodysplastic/myeloproliferative disease, unclassifiable
1478194|NCT00068523|recurrent marginal zone lymphoma
1478195|NCT00068523|recurrent small lymphocytic lymphoma
1478196|NCT00068523|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1478197|NCT00068523|nodal marginal zone B-cell lymphoma
1478198|NCT00068523|splenic marginal zone lymphoma
1478199|NCT00068523|adult acute myeloid leukemia with t(8;21)(q22;q22)
1478200|NCT00068523|adult acute myeloid leukemia with t(16;16)(p13;q22)
1478201|NCT00068523|adult acute myeloid leukemia with inv(16)(p13;q22)
1478202|NCT00068523|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1478203|NCT00068523|adult acute myeloid leukemia with t(15;17)(q22;q12)
1478204|NCT00068510|adult glioblastoma
1478205|NCT00068510|adult anaplastic astrocytoma
1478206|NCT00068510|adult brain tumor
1478207|NCT00068510|adult giant cell glioblastoma
1478208|NCT00068510|adult gliosarcoma
1478209|NCT00068510|adult anaplastic oligodendroglioma
1478210|NCT00068471|infection
1478211|NCT00068471|neutropenia
1478212|NCT00068471|unspecified childhood solid tumor, protocol specific
1478213|NCT00068458|weight changes
1478214|NCT00068458|depression
1478215|NCT00068458|stage I breast cancer
1478216|NCT00068458|stage II breast cancer
1478217|NCT00068458|stage IIIA breast cancer
1478218|NCT00068445|neurotoxicity
1478219|NCT00068445|pain
1478220|NCT00068445|unspecified adult solid tumor, protocol specific
1478221|NCT00068432|recurrent pancreatic cancer
1478222|NCT00068432|stage IV pancreatic cancer
1478223|NCT00068406|squamous cell carcinoma of the vulva
1478224|NCT00068406|stage III vulvar cancer
1478225|NCT00068406|stage IVB vulvar cancer
1478226|NCT00068393|Sarcomatoid
1478227|NCT00068393|Gemcitabine
1478228|NCT00068393|Doxorubicin
1478229|NCT00068393|Renal cell cancer
1478230|NCT00068393|Kidney cancer
1478231|NCT00068367|adult neurofibrosarcoma
1478232|NCT00068367|stage III adult soft tissue sarcoma
1478233|NCT00068367|recurrent adult soft tissue sarcoma
1478234|NCT00068367|stage II adult soft tissue sarcoma
1478235|NCT00068367|stage IV adult soft tissue sarcoma
1478236|NCT00068341|stage IIIA breast cancer
1478237|NCT00068341|stage IIIB breast cancer
1478238|NCT00068341|stage IIIC breast cancer
1478239|NCT00068341|stage II breast cancer
1478240|NCT00068328|psychosocial effects of cancer and its treatment
1478241|NCT00068328|stage II breast cancer
1478242|NCT00068328|stage IIIA breast cancer
1478243|NCT00068328|stage IIIB breast cancer
1478244|NCT00068328|stage IIIC breast cancer
1478245|NCT00068328|stage IA breast cancer
1478246|NCT00068328|stage IB breast cancer
1478247|NCT00068328|estrogen receptor-negative breast cancer
1478248|NCT00068328|estrogen receptor-positive breast cancer
1478249|NCT00068302|recurrent childhood lymphoblastic lymphoma
1478250|NCT00068302|recurrent childhood small noncleaved cell lymphoma
1478251|NCT00068302|recurrent childhood large cell lymphoma
1478252|NCT00068302|recurrent childhood acute myeloid leukemia
1478253|NCT00068302|recurrent childhood acute lymphoblastic leukemia
1478254|NCT00068289|extensive stage small cell lung cancer
1478255|NCT00068289|recurrent small cell lung cancer
1478256|NCT00068276|previously treated myelodysplastic syndromes
1478257|NCT00068276|de novo myelodysplastic syndromes
1478258|NCT00068276|secondary myelodysplastic syndromes
1478259|NCT00068276|atypical chronic myeloid leukemia, BCR-ABL1 negative
1478260|NCT00068276|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1478261|NCT00068276|childhood myelodysplastic syndromes
1478262|NCT00068263|stage I breast cancer
1478263|NCT00068263|stage II breast cancer
1478264|NCT00068250|primary central nervous system non-Hodgkin lymphoma
1478265|NCT00068250|primary central nervous system Hodgkin lymphoma
1478266|NCT00068237|xerostomia
1478267|NCT00068237|radiation toxicity
1478268|NCT00068237|stage II squamous cell carcinoma of the oropharynx
1478269|NCT00068237|stage III squamous cell carcinoma of the oropharynx
1478270|NCT00068237|stage I squamous cell carcinoma of the hypopharynx
1478271|NCT00068237|stage II squamous cell carcinoma of the hypopharynx
1478272|NCT00068237|stage III squamous cell carcinoma of the hypopharynx
1478273|NCT00068237|stage III squamous cell carcinoma of the larynx
1478274|NCT00068237|untreated metastatic squamous neck cancer with occult primary
1478275|NCT00068237|stage IV squamous cell carcinoma of the larynx
1478276|NCT00068237|stage IV squamous cell carcinoma of the hypopharynx
1478277|NCT00068237|stage IV squamous cell carcinoma of the oropharynx
1478278|NCT00068224|Caroli's Syndrome
1478279|NCT00068224|Congenital Hepatic Fibrosis
1478280|NCT00068224|Ductal Plate Malformation
1478281|NCT00068224|Ciliopathy
1478282|NCT00068224|Polycystic Kidney
1478283|NCT00068224|Polycystic Liver
1478284|NCT00068224|Nephronophthisis
1478285|NCT00068224|Molar Tooth Sign
1478286|NCT00068224|Dandy-Walker Malformation
1478287|NCT00068224|Retinopathy
1478288|NCT00068224|Situs Inversus
1478289|NCT00068224|Heterotaxia
1478290|NCT00068224|Cerebellar Vermis Hypoplasia
1478291|NCT00068224|Autosomal Recessive Polycystic Kidney Disease
1478292|NCT00068224|ARPKD
1478293|NCT00068224|Kidney
1478294|NCT00068224|Liver
1478295|NCT00068211|Metastatic Melanoma
1478296|NCT00068211|Melanoma
1478297|NCT00068211|Inoperable Locally Advanced Melanoma
1478298|NCT00068185|Black cohosh
1478299|NCT00068185|Pharmacokinetics
1478300|NCT00068185|Alternative therapies
1478301|NCT00068185|Natural product
1478302|NCT00068159|Hereditary Disease
1478303|NCT00068159|Diastolic Dysfunction
1478304|NCT00068159|Exercise Tolerance
1478305|NCT00068159|Exercise Stress Echocardiography
1478306|NCT00068159|MRI
1478307|NCT00068159|Hereditary Hemochromatosis
1478308|NCT00068159|HH
1478309|NCT00068159|Iron Overload
1478310|NCT00068146|Adenopathy
1478311|NCT00068146|Genetic Disorder
1478312|NCT00068146|Apoptosis
1478313|NCT00068146|Diagnostic Imaging
1478314|NCT00068146|Hodgkins
1478315|NCT00068146|Autoimmune Lymphoproliferative
1478316|NCT00068146|Syndrome
1478317|NCT00068146|ALPS
1478318|NCT00068146|ALPS-Associated Lymphoma
1478319|NCT00068120|Urinary tract infection
1478320|NCT00068107|Lysosomal Storage
1478321|NCT00068107|Renal Insufficiency
1478322|NCT00068107|Stroke
1478323|NCT00068107|Hypohidrosis
1478324|NCT00068107|Peripheral Neuropathy
1478325|NCT00068107|Fabry Disease
1478326|NCT00068094|Probiotics
1478327|NCT00068094|Bacteria
1478328|NCT00068081|Dermal assessment
1478329|NCT00068081|Pain measurement
1478330|NCT00068081|Diary
1478331|NCT00068081|Analgesics/*therapeutic use
1478332|NCT00068081|Capsaicin/*administration & dosage/adverse effects
1478333|NCT00068081|Herpes zoster/*complication/drug therapy
1478334|NCT00068081|Neuralgia/*drug therapy/etiology
1478335|NCT00068081|Pain
1478336|NCT00068081|Peripheral nervous system diseases/*complications
1478337|NCT00068068|Photodynamic therapy
1478338|NCT00068068|Liver metastases
1478339|NCT00068068|Colorectal cancer
1478340|NCT00068068|Litx™
1478341|NCT00068068|Light Infusion Technology™
1478342|NCT00068068|Talaporfin sodium
1478343|NCT00068068|LS11
1478344|NCT00068068|Liver mets
1478345|NCT00068068|Metastatic colorectal cancer
1478346|NCT00068068|Light emittting diodes (LED)
1478347|NCT00068068|Tumor ablation
1478348|NCT00068068|Combination therapy
1478349|NCT00068055|West Nile Virus, encephalitis, myelitis, immunoglobulin G
1478355|NCT00067990|chronic allograft nephropathy
1478356|NCT00067990|post transplant proteinuria
1478357|NCT00067951|Hyperglycemia
1478358|NCT00067951|HbA1c
1478359|NCT00067951|Hemoglobin A1c
1478360|NCT00067951|Type 2 diabetes mellitus
1478361|NCT00067938|bipolar disorder
1478362|NCT00067938|lamotrigine
1478363|NCT00067925|Weight-bearing physical activity
1478364|NCT00067925|Calcium intake
1478365|NCT00067925|School-based health education
1478366|NCT00067925|Adolescent girls
1478367|NCT00067925|Child nutrition
1478368|NCT00067925|Diet
1478369|NCT00067899|cigarette smoking
1478370|NCT00067899|tocopherol
1478371|NCT00067899|bioavailability
1478372|NCT00067899|metabolism
1478373|NCT00067899|oxidative stress
1478374|NCT00067847|obesity
1478375|NCT00067847|food policy
1478376|NCT00067847|physical fitness (Respiratory Burst)
1478377|NCT00067847|academic achievement
1478378|NCT00067834|Electromagnetic Fields
1478379|NCT00067834|Bone
1478380|NCT00067834|Forelimb
1478381|NCT00067834|Radius
1478382|NCT00067821|Brain Tumor
1478383|NCT00067821|Children
1478384|NCT00067821|Metabolic
1478385|NCT00067821|Spectroscopy
1478386|NCT00067821|PET
1478387|NCT00067808|Myelodysplastic Syndrome
1478388|NCT00067808|Chronic Myelomonocytic Leukemia
1478389|NCT00067808|MDS
1478390|NCT00067808|Decitabine
1478391|NCT00067808|Dacogen
1478392|NCT00067808|Methylation
1478393|NCT00067795|Treatment Experienced
1478394|NCT00067795|Antiretroviral Therapy, Highly Active
1478395|NCT00067795|HIV Antigens
1478396|NCT00067795|Cohort Studies
1478397|NCT00067795|Immunity, Cellular
1478398|NCT00067795|T-Lymphocytes
1478399|NCT00067782|HIV
1478400|NCT00067782|Treatment Experienced
1478401|NCT00067769|Encopresis
1478402|NCT00067769|Internet
1478403|NCT00067769|Web
1478404|NCT00067769|Treatment
1478405|NCT00067769|Intervention
1478406|NCT00067756|Pulmonary Disease
1478407|NCT00067756|Liver Disease
1478408|NCT00067743|Pain
1478409|NCT00067743|Pain syndrome
1478410|NCT00067743|Reflex sympathetic dystrophy
1478411|NCT00067743|CC-5013
1478412|NCT00067743|CC5013
1478413|NCT00067743|Revlimid
1478414|NCT00067743|Celgene
1478415|NCT00067743|CRPS
1478416|NCT00067717|breast reconstruction surgery
1478417|NCT00067717|prayer
1478418|NCT00067717|distance healing
1478419|NCT00067717|wound healing
1478420|NCT00067704|Complementary Therapies
1478421|NCT00067691|Lung cancer
1478422|NCT00067691|Breast cancer
1478423|NCT00067691|Shortness of breath
1478424|NCT00067691|Dyspnea
1478425|NCT00067691|Metastasis
1478426|NCT00067691|Breathlessness
1478427|NCT00067691|Acupuncture
1478428|NCT00067678|diabetic nephropathy
1478429|NCT00067678|nephropathy
1478430|NCT00067678|diabetes
1478431|NCT00067678|diabetes mellitus
1478432|NCT00067678|type I diabetes
1478433|NCT00067678|soy protein
1478434|NCT00067665|hemodialysis
1478435|NCT00067639|Multiple Myeloma
1478436|NCT00067639|PBSC mobilization
1478437|NCT00067639|Pegfilgrastim
1478438|NCT00067639|Neulasta
1478439|NCT00067639|PEG-G-CSF
1478440|NCT00067626|glucose tolerance test
1478441|NCT00067626|minerals
1478442|NCT00067626|chromium
1478443|NCT00067626|complementary and alternative medicine
1478444|NCT00067613|NICHD Neonatal Research Network
1478445|NCT00067613|Extremely Low Birth Weight (ELBW)
1478446|NCT00067613|Very Low Birth Weight (VLBW)
1478447|NCT00067613|Prematurity
1478448|NCT00067613|Mechanical ventilation
1478449|NCT00067613|Benchmarking
1478450|NCT00067613|Chronic Lung Disease (CLD)
1478451|NCT00067587|Treatment experienced
1478452|NCT00067587|Treatment naive
1478453|NCT00067574|Structured treatment interruption
1478454|NCT00067574|Treatment experienced
1478455|NCT00067561|Dose-ranging
1478456|NCT00067561|Diarrhea-Predominant Irritable Bowel Syndrome
1478457|NCT00067561|d-IBS
1478458|NCT00067561|IBS
1478459|NCT00067561|Irritable Bowel Syndrome
1478460|NCT00067548|Advanced Non-Small Cell Lung Cancer
1478461|NCT00067535|cocaine dependence
1478462|NCT00067522|Family Planning
1478463|NCT00067522|Sexually Transmitted Diseases
1478464|NCT00067522|HIV
1478465|NCT00067522|Africa
1478466|NCT00067522|Zambia
1478467|NCT00067522|AIDS
1478468|NCT00067522|Contraception
1478469|NCT00067522|HIV Prevention
1478470|NCT00067509|Female
1478471|NCT00067496|Pain
1478472|NCT00067496|Weakness
1478473|NCT00067496|Depression
1478474|NCT00067496|Poliomyelitis
1478475|NCT00067496|Sleep Apnea
1478476|NCT00067496|Post-Polio Syndrome
1478477|NCT00067496|PPS
1478478|NCT00067483|Cataract
1478479|NCT00067483|Pre-Senile
1478480|NCT00067483|Dynamic Light Scattering (DLS)
1478481|NCT00067483|Light Scattering
1478482|NCT00067483|Lens
1478483|NCT00067483|Cataracts
1478484|NCT00067457|PRN
1478485|NCT00067457|Diarrhea-Predominant Irritable Bowel Syndrome
1478486|NCT00067457|Irritable Bowel Syndrome (IBS)
1478487|NCT00067444|Elderly
1478488|NCT00067444|Major Depressive Disorder
1478489|NCT00067444|MDD
1478490|NCT00067431|Partial Seizures
1478491|NCT00067418|Glioma
1478492|NCT00067418|Brain Tumor
1478493|NCT00067418|Spectroscopy
1478494|NCT00067405|Fibromyalgia
1478495|NCT00067405|Intravenous micronutrient therapy
1478496|NCT00067405|IVMT
1478497|NCT00067405|alternative medicine
1478498|NCT00067405|complementary medicine
1478499|NCT00067405|vitamins
1478500|NCT00067405|vitamin supplements
1478501|NCT00067392|Partial edentulism
1478502|NCT00067392|Bone atrophy
1478503|NCT00067392|Bone healing
1478504|NCT00067353|Early Childhood Caries
1478505|NCT00067327|Relapsing remitting multiple sclerosis
1478506|NCT00067327|Multiple sclerosis
1478507|NCT00067327|Peroxynitrite
1478508|NCT00067327|Uric acid
1478509|NCT00067327|Inosine
1478510|NCT00067301|depression
1478511|NCT00067301|citalopram
1478512|NCT00067301|Celexa
1478513|NCT00067301|Polyunsaturated Fatty Acids
1478514|NCT00067301|omega-3
1478515|NCT00067301|EPA
1478516|NCT00067301|antidepressants
1478517|NCT00067288|Stage 3 cancer;
1478518|NCT00067288|Stage 4 cancer;
1478519|NCT00067288|solid tumor cancer;
1478520|NCT00067288|Non-Hodgkin's Lymphoma;
1478521|NCT00067288|solid tumors;
1478522|NCT00067288|end-stage cancer;
1478523|NCT00067288|group psychotherapy;
1478524|NCT00067288|psychotherapy;
1478525|NCT00067288|emotional support;
1478526|NCT00067288|support groups
1478527|NCT00067275|Stroke
1478528|NCT00067275|Motor Training
1478529|NCT00067275|Positron Emission Tomograhy
1478530|NCT00067275|Plasticity
1478531|NCT00067275|Transcranial Magnetic Stimulation
1478532|NCT00067275|Healthy Volunteer
1478533|NCT00067275|HV
1478534|NCT00067262|Bipolar Disorder Type 1 (manic or mixed type)
1478535|NCT00067249|Race
1478536|NCT00067249|Ethnicity
1478537|NCT00067249|Complementary and Alternative Medicine
1478538|NCT00067249|Women's health
1478539|NCT00067249|Social determinants of Health
1478540|NCT00067223|Transcranial Magnetic Stimulation (TMS)
1478541|NCT00067223|Unilateral Finger Movement
1478542|NCT00067223|Interhemispheric Inhibition
1478543|NCT00067223|Motor Training
1478544|NCT00067223|Plasticity
1478545|NCT00067223|Healthy Volunteer
1478546|NCT00067223|HV
1478547|NCT00067210|Brain
1478548|NCT00067210|Epilepsy
1478549|NCT00067210|Core
1478550|NCT00067210|Temperature
1478551|NCT00067197|Transcranial Direct Current Stimulation (tDCS)
1478552|NCT00067197|Cortical Reorganization
1478553|NCT00067197|Rehabilitation
1478554|NCT00067197|Motor Learning
1478555|NCT00067197|Activity of Daily Living (ADL)
1478556|NCT00067197|Stroke
1478557|NCT00067197|Healthy Volunteer
1478558|NCT00067197|HV
1478559|NCT00067184|methadone
1478560|NCT00067184|fetus
1478561|NCT00067171|behavioral intervention
1478562|NCT00067158|nicotine dependence
1478563|NCT00067119|Graft Failure
1478564|NCT00067119|Access Blood Flow Monitoring
1478565|NCT00067119|Clinical Trial Vascular Access
1478566|NCT00067119|Fistula Failure
1478567|NCT00067119|Hemodialysis
1478568|NCT00067119|Vascular Access
1478569|NCT00067106|HIV
1478570|NCT00067106|Women
1478571|NCT00067106|Genital tract
1478572|NCT00067106|Treatment experienced
1478573|NCT00067106|Drug resistance
1478574|NCT00067080|Sickle cell disease
1478575|NCT00067080|iron overload
1478576|NCT00067080|deferoxamine
1478577|NCT00067080|hemosiderosis
1478578|NCT00067067|Glioma
1478579|NCT00067067|Brain Tumor
1478580|NCT00067067|Endothelial Progenitor Cells
1478581|NCT00067054|Volunteer
1478582|NCT00067054|Plasmapheresis
1478583|NCT00067054|Leukapheresis
1478584|NCT00067054|Immunology
1478585|NCT00067054|Leukocyte
1478586|NCT00067054|Healthy Volunteer
1478587|NCT00067054|HV
1478588|NCT00067041|Critical Limb Ischemia
1478589|NCT00067041|Autogenous Bypass Graft
1478590|NCT00067041|CLI
1478591|NCT00067028|Chronic Myeloid Leukemia
1478592|NCT00067028|CML Myeloid Blast Phase
1478593|NCT00067028|Acute Myeloid Leukemia
1478594|NCT00067028|Myelodysplastic Syndrome
1478595|NCT00067028|Clofarabine
1478596|NCT00067028|Clofarex
1478597|NCT00067028|Clolar
1478598|NCT00067028|Ara-C
1478599|NCT00067028|Cytarabine
1478600|NCT00067028|Cytosar
1478601|NCT00067028|DepoCyt
1478602|NCT00067028|Cytosine arabinosine hydrochloride
1478603|NCT00067028|Idarubicin
1478604|NCT00067028|Idamycin
1478605|NCT00067015|adenocarcinoma of the prostate
1478606|NCT00067015|stage III prostate cancer
1478607|NCT00067002|ALL
1478608|NCT00067002|Leukemia, Lymphocytic, Acute
1478609|NCT00067002|AML
1478610|NCT00067002|Leukemia, Myelocytic, Acute
1478611|NCT00067002|CML
1478612|NCT00067002|Leukemia, Myeloid, Chronic
1478613|NCT00067002|NHL
1478614|NCT00067002|Lymphoma, Non-Hodgkin
1478615|NCT00067002|double cord blood transplant
1478616|NCT00067002|expanded cord blood transplant
1478617|NCT00067002|Rituxan
1478618|NCT00067002|Rituximab
1478619|NCT00067002|Melphalan
1478620|NCT00067002|Alkeran
1478621|NCT00067002|Thiotepa
1478622|NCT00067002|Fludarabine
1478623|NCT00067002|Fludarabine phosphate
1478624|NCT00067002|Fludara
1478625|NCT00067002|Cyclophosphamide
1478626|NCT00067002|Cytoxan
1478627|NCT00067002|Neosar
1478628|NCT00067002|Mesna
1478629|NCT00067002|Mesnex
1478630|NCT00066989|Staphylococcal infection
1478631|NCT00066989|Gram positive bacteria
1478632|NCT00066989|Staphylococcus
1478633|NCT00066989|Staphylococcus aureus
1478634|NCT00066976|Prenatal
1478635|NCT00066976|Respiration
1478636|NCT00066976|Ultrasound
1478637|NCT00066976|Prematurity
1478638|NCT00066976|Diagnoses
1478639|NCT00066976|Fetal Breathing-Movement
1478640|NCT00066976|Doppler Sonography
1478641|NCT00066976|Amniotic Fluid
1478642|NCT00066976|Oligohydraminos
1478643|NCT00066976|Polyhydraminos
1478644|NCT00066976|Pregnancy
1478645|NCT00066963|Early Childhood Caries
1478646|NCT00066950|Early childhood caries
1478647|NCT00066924|spirituality
1478648|NCT00066924|religiosity
1478649|NCT00066924|immune functioning
1478650|NCT00066924|psychoneuroimmunology
1478651|NCT00066924|cytokines
1478652|NCT00066924|cancer
1478653|NCT00066924|death
1478654|NCT00066924|depression
1478655|NCT00066911|Functional Magnetic Resonance Imaging
1478656|NCT00066911|Vocalization
1478657|NCT00066911|Spasmodic Dysphonia
1478658|NCT00066911|Muscular Tension Dysphonia
1478659|NCT00066911|Topical Lidocaine
1478660|NCT00066911|Voice Disorders
1478661|NCT00066911|Vocal Tremor
1478662|NCT00066911|Healthy Volunteer
1478663|NCT00066911|HV
1478664|NCT00066898|succinobucol
1478665|NCT00066898|AGI-1067
1478666|NCT00066898|coronary artery disease
1478667|NCT00066885|DN101
1478668|NCT00066885|Calcitriol
1478669|NCT00066885|Lung Cancer
1478670|NCT00066885|NSCLC
1478671|NCT00066885|Taxotere
1478672|NCT00066872|basal cell carcinoma of the skin
1478673|NCT00066859|depression
1478674|NCT00066859|unspecified adult solid tumor, protocol specific
1478675|NCT00066846|adenocarcinoma of the colon
1478676|NCT00066846|adenocarcinoma of the rectum
1478677|NCT00066846|stage IV rectal cancer
1478678|NCT00066846|recurrent rectal cancer
1478679|NCT00066846|stage IV colon cancer
1478680|NCT00066846|recurrent colon cancer
1478681|NCT00066807|stage IIIA breast cancer
1478682|NCT00066807|stage I breast cancer
1478683|NCT00066807|stage II breast cancer
1478684|NCT00066794|adult acute monocytic leukemia (M5b)
1478685|NCT00066794|adult acute megakaryoblastic leukemia (M7)
1478686|NCT00066794|adult acute minimally differentiated myeloid leukemia (M0)
1478687|NCT00066794|adult acute myeloblastic leukemia with maturation (M2)
1478688|NCT00066794|adult acute myeloblastic leukemia without maturation (M1)
1478689|NCT00066794|adult acute myelomonocytic leukemia (M4)
1478690|NCT00066794|adult acute monoblastic leukemia (M5a)
1478691|NCT00066794|untreated adult acute myeloid leukemia
1478692|NCT00066794|adult acute myeloid leukemia with t(8;21)(q22;q22)
1478693|NCT00066794|adult acute myeloid leukemia with t(16;16)(p13;q22)
1478694|NCT00066794|adult acute myeloid leukemia with inv(16)(p13;q22)
1478695|NCT00066794|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1478696|NCT00066794|adult pure erythroid leukemia (M6b)
1478697|NCT00066794|adult erythroleukemia (M6a)
1478698|NCT00066781|adenocarcinoma of unknown primary
1478699|NCT00066781|newly diagnosed carcinoma of unknown primary
1478700|NCT00066781|squamous cell carcinoma of unknown primary
1478701|NCT00066781|undifferentiated carcinoma of unknown primary
1478702|NCT00066729|stage II ovarian epithelial cancer
1478703|NCT00066729|stage III ovarian epithelial cancer
1478704|NCT00066729|stage IV ovarian epithelial cancer
1478705|NCT00066729|primary peritoneal cavity cancer
1478706|NCT00066729|fallopian tube cancer
1478707|NCT00066716|adenocarcinoma of the esophagus
1478708|NCT00066716|squamous cell carcinoma of the esophagus
1478709|NCT00066716|stage I esophageal cancer
1478710|NCT00066716|stage II esophageal cancer
1478711|NCT00066716|stage III esophageal cancer
1478712|NCT00066716|stage IV esophageal cancer (lymph node metastasis only)
1478713|NCT00066703|stage II breast cancer
1478714|NCT00066703|stage IIIA breast cancer
1478715|NCT00066703|estrogen receptor-positive breast cancer
1478716|NCT00066703|progesterone receptor-positive breast cancer
1478717|NCT00066703|stage IA breast cancer
1478718|NCT00066703|stage IB breast cancer
1478719|NCT00066690|tamoxifen
1478720|NCT00066690|ovarian function suppression + tamoxifen
1478721|NCT00066690|ovarian function suppression + exemestane
1478722|NCT00066677|adenocarcinoma of the pancreas
1478723|NCT00066677|recurrent pancreatic cancer
1478724|NCT00066677|stage IV pancreatic cancer
1478725|NCT00066664|recurrent cutaneous T-cell non-Hodgkin lymphoma
1478726|NCT00066664|stage I cutaneous T-cell non-Hodgkin lymphoma
1478727|NCT00066664|stage II cutaneous T-cell non-Hodgkin lymphoma
1478728|NCT00066664|stage III cutaneous T-cell non-Hodgkin lymphoma
1478729|NCT00066664|stage IV cutaneous T-cell non-Hodgkin lymphoma
1478730|NCT00066664|recurrent mycosis fungoides/Sezary syndrome
1478731|NCT00066664|stage I mycosis fungoides/Sezary syndrome
1478732|NCT00066664|stage II mycosis fungoides/Sezary syndrome
1478733|NCT00066664|stage III mycosis fungoides/Sezary syndrome
1478734|NCT00066664|stage IV mycosis fungoides/Sezary syndrome
1478735|NCT00066651|ovarian carcinosarcoma
1478736|NCT00066651|ovarian clear cell cystadenocarcinoma
1478737|NCT00066651|ovarian endometrioid adenocarcinoma
1478738|NCT00066651|ovarian mixed epithelial carcinoma
1478739|NCT00066651|ovarian serous cystadenocarcinoma
1478740|NCT00066651|ovarian undifferentiated adenocarcinoma
1478741|NCT00066651|recurrent ovarian epithelial cancer
1478742|NCT00066651|Brenner tumor
1478743|NCT00066651|primary peritoneal cavity cancer
1478744|NCT00066651|fallopian tube cancer
1478745|NCT00066651|epithelial mesothelioma
1478746|NCT00066651|recurrent malignant mesothelioma
1478747|NCT00066651|recurrent pancreatic cancer
1478748|NCT00066651|cervical squamous cell carcinoma
1478749|NCT00066651|recurrent cervical cancer
1478750|NCT00066651|recurrent non-small cell lung cancer
1478751|NCT00066651|squamous cell lung cancer
1478752|NCT00066651|recurrent squamous cell carcinoma of the lip and oral cavity
1478753|NCT00066651|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1478754|NCT00066651|recurrent metastatic squamous neck cancer with occult primary
1478755|NCT00066651|recurrent salivary gland cancer
1478756|NCT00066651|salivary gland squamous cell carcinoma
1478757|NCT00066651|recurrent squamous cell carcinoma of the hypopharynx
1478758|NCT00066651|recurrent squamous cell carcinoma of the larynx
1478759|NCT00066651|recurrent squamous cell carcinoma of the oropharynx
1479057|NCT00066053|Angina
1478760|NCT00066651|recurrent squamous cell carcinoma of the nasopharynx
1478761|NCT00066612|recurrent bladder cancer
1478762|NCT00066612|stage IV bladder cancer
1478763|NCT00066612|metastatic transitional cell cancer of the renal pelvis and ureter
1478764|NCT00066612|recurrent transitional cell cancer of the renal pelvis and ureter
1478765|NCT00066612|regional transitional cell cancer of the renal pelvis and ureter
1478766|NCT00066612|transitional cell carcinoma of the bladder
1478767|NCT00066612|anterior urethral cancer
1478768|NCT00066612|posterior urethral cancer
1478769|NCT00066612|recurrent urethral cancer
1478770|NCT00066612|urethral cancer associated with invasive bladder cancer
1478771|NCT00066599|neutropenia
1478772|NCT00066599|recurrent childhood lymphoblastic lymphoma
1478773|NCT00066599|stage I childhood lymphoblastic lymphoma
1478774|NCT00066599|stage II childhood lymphoblastic lymphoma
1478775|NCT00066599|stage III childhood lymphoblastic lymphoma
1478776|NCT00066599|stage IV childhood lymphoblastic lymphoma
1478777|NCT00066599|recurrent childhood small noncleaved cell lymphoma
1478778|NCT00066599|stage I childhood small noncleaved cell lymphoma
1478779|NCT00066599|stage II childhood small noncleaved cell lymphoma
1478780|NCT00066599|stage III childhood small noncleaved cell lymphoma
1478781|NCT00066599|stage IV childhood small noncleaved cell lymphoma
1478782|NCT00066599|recurrent childhood large cell lymphoma
1478783|NCT00066599|stage I childhood large cell lymphoma
1478784|NCT00066599|stage II childhood large cell lymphoma
1478785|NCT00066599|stage III childhood large cell lymphoma
1478786|NCT00066599|stage IV childhood large cell lymphoma
1478787|NCT00066599|childhood acute myeloid leukemia in remission
1478788|NCT00066599|recurrent childhood acute myeloid leukemia
1478789|NCT00066599|untreated childhood acute myeloid leukemia and other myeloid malignancies
1478790|NCT00066599|recurrent/refractory childhood Hodgkin lymphoma
1478791|NCT00066599|stage I childhood Hodgkin lymphoma
1478792|NCT00066599|stage II childhood Hodgkin lymphoma
1478793|NCT00066599|stage III childhood Hodgkin lymphoma
1478794|NCT00066599|stage IV childhood Hodgkin lymphoma
1478795|NCT00066599|childhood acute promyelocytic leukemia (M3)
1478796|NCT00066599|previously treated childhood rhabdomyosarcoma
1478797|NCT00066599|recurrent Wilms tumor and other childhood kidney tumors
1478798|NCT00066599|recurrent childhood rhabdomyosarcoma
1478799|NCT00066599|childhood chronic myelogenous leukemia
1478800|NCT00066599|accelerated phase chronic myelogenous leukemia
1478801|NCT00066599|blastic phase chronic myelogenous leukemia
1478802|NCT00066599|chronic phase chronic myelogenous leukemia
1478803|NCT00066599|meningeal chronic myelogenous leukemia
1478804|NCT00066599|relapsing chronic myelogenous leukemia
1478805|NCT00066599|anaplastic large cell lymphoma
1478806|NCT00066599|angioimmunoblastic T-cell lymphoma
1478807|NCT00066599|intraocular lymphoma
1478808|NCT00066599|primary central nervous system non-Hodgkin lymphoma
1478809|NCT00066599|recurrent adult T-cell leukemia/lymphoma
1478810|NCT00066599|acute undifferentiated leukemia
1478811|NCT00066599|childhood acute lymphoblastic leukemia in remission
1478812|NCT00066599|recurrent childhood acute lymphoblastic leukemia
1478813|NCT00066599|secondary acute myeloid leukemia
1478814|NCT00066599|untreated childhood acute lymphoblastic leukemia
1478815|NCT00066599|disseminated neuroblastoma
1478816|NCT00066599|de novo myelodysplastic syndromes
1478817|NCT00066599|previously treated myelodysplastic syndromes
1478818|NCT00066599|secondary myelodysplastic syndromes
1478819|NCT00066599|stage I multiple myeloma
1478820|NCT00066599|stage II multiple myeloma
1478821|NCT00066599|stage III multiple myeloma
1478822|NCT00066599|refractory multiple myeloma
1478823|NCT00066599|stage I cutaneous T-cell non-Hodgkin lymphoma
1478824|NCT00066599|stage II cutaneous T-cell non-Hodgkin lymphoma
1478825|NCT00066599|stage III cutaneous T-cell non-Hodgkin lymphoma
1478826|NCT00066599|stage IV cutaneous T-cell non-Hodgkin lymphoma
1478827|NCT00066599|recurrent neuroblastoma
1478828|NCT00066599|atypical chronic myeloid leukemia, BCR-ABL1 negative
1478829|NCT00066599|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1478830|NCT00066586|breast cancer
1478831|NCT00066573|stage IIIA breast cancer
1478832|NCT00066573|stage I breast cancer
1478833|NCT00066573|stage II breast cancer
1478834|NCT00066547|recurrent breast cancer
1478835|NCT00066547|stage IIIA breast cancer
1478836|NCT00066547|stage IIIB breast cancer
1478837|NCT00066547|stage IIIC breast cancer
1478838|NCT00066547|stage IV breast cancer
1478839|NCT00066508|recurrent adult diffuse large cell lymphoma
1478840|NCT00066482|childhood teratoma
1478841|NCT00066482|childhood extragonadal germ cell tumor
1478842|NCT00066469|post-transplant lymphoproliferative disorder
1478843|NCT00066443|stage IIIA breast cancer
1478844|NCT00066443|stage IIIB breast cancer
1478845|NCT00066443|stage IIIC breast cancer
1478846|NCT00066443|inflammatory breast cancer
1478847|NCT00066430|anal cancer
1478848|NCT00066430|high-grade squamous intraepithelial lesion
1478849|NCT00066417|essential thrombocythemia
1478850|NCT00066417|polycythemia vera
1478851|NCT00066417|blastic phase chronic myelogenous leukemia
1478852|NCT00066417|secondary myelodysplastic syndromes
1478853|NCT00066417|previously treated myelodysplastic syndromes
1479183|NCT00065663|wounds
1478854|NCT00066417|adult acute myeloid leukemia in remission
1478855|NCT00066417|childhood acute myeloid leukemia in remission
1478856|NCT00066417|de novo myelodysplastic syndromes
1478857|NCT00066417|secondary acute myeloid leukemia
1478858|NCT00066417|accelerated phase chronic myelogenous leukemia
1478859|NCT00066417|childhood chronic myelogenous leukemia
1478860|NCT00066417|adult acute lymphoblastic leukemia in remission
1478861|NCT00066417|childhood acute lymphoblastic leukemia in remission
1478862|NCT00066417|recurrent adult acute myeloid leukemia
1478863|NCT00066417|relapsing chronic myelogenous leukemia
1478864|NCT00066417|recurrent childhood acute myeloid leukemia
1478865|NCT00066417|chronic idiopathic myelofibrosis
1478866|NCT00066417|atypical chronic myeloid leukemia
1478867|NCT00066417|myelodysplastic/myeloproliferative disease, unclassifiable
1478868|NCT00066417|adult acute myeloid leukemia with t(8;21)(q22;q22)
1478869|NCT00066417|adult acute myeloid leukemia with t(16;16)(p13;q22)
1478870|NCT00066417|adult acute myeloid leukemia with inv(16)(p13;q22)
1478871|NCT00066417|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1478872|NCT00066417|adult acute myeloid leukemia with t(15;17)(q22;q12)
1478873|NCT00066404|advanced malignant mesothelioma
1478874|NCT00066404|male breast cancer
1478875|NCT00066404|localized malignant mesothelioma
1478876|NCT00066404|recurrent bladder cancer
1478877|NCT00066404|recurrent renal cell cancer
1478878|NCT00066404|recurrent urethral cancer
1478879|NCT00066404|recurrent breast cancer
1478880|NCT00066404|recurrent penile cancer
1478881|NCT00066404|recurrent prostate cancer
1478882|NCT00066404|recurrent anal cancer
1478883|NCT00066404|recurrent colon cancer
1478884|NCT00066404|recurrent esophageal cancer
1478885|NCT00066404|recurrent gastric cancer
1478886|NCT00066404|recurrent pancreatic cancer
1478887|NCT00066404|recurrent rectal cancer
1478888|NCT00066404|recurrent gastrointestinal carcinoid tumor
1478889|NCT00066404|recurrent small intestine cancer
1478890|NCT00066404|recurrent gallbladder cancer
1478891|NCT00066404|recurrent extrahepatic bile duct cancer
1478892|NCT00066404|recurrent adult primary liver cancer
1478893|NCT00066404|recurrent non-small cell lung cancer
1478894|NCT00066404|recurrent small cell lung cancer
1478895|NCT00066404|recurrent thymoma and thymic carcinoma
1478896|NCT00066404|recurrent melanoma
1478897|NCT00066404|recurrent malignant mesothelioma
1478898|NCT00066404|recurrent malignant testicular germ cell tumor
1478899|NCT00066404|recurrent cervical cancer
1478900|NCT00066404|recurrent ovarian epithelial cancer
1478901|NCT00066404|fallopian tube cancer
1478902|NCT00066404|recurrent vulvar cancer
1478903|NCT00066404|recurrent vaginal cancer
1478904|NCT00066404|recurrent gestational trophoblastic tumor
1478905|NCT00066404|recurrent endometrial carcinoma
1478906|NCT00066404|recurrent ovarian germ cell tumor
1478907|NCT00066404|malignant pleural effusion
1478908|NCT00066391|penile squamous cell carcinoma
1478909|NCT00066391|stage III penile cancer
1478910|NCT00066391|stage IV penile cancer
1478911|NCT00066378|recurrent breast cancer
1478912|NCT00066378|stage IIIA breast cancer
1478913|NCT00066378|stage IIIB breast cancer
1478914|NCT00066378|stage IIIC breast cancer
1478915|NCT00066378|stage IV breast cancer
1478916|NCT00066365|metastatic osteosarcoma
1478917|NCT00066365|recurrent osteosarcoma
1478918|NCT00066365|lung metastases
1478919|NCT00066352|recurrent bladder cancer
1478920|NCT00066352|stage IV bladder cancer
1478921|NCT00066352|metastatic transitional cell cancer of the renal pelvis and ureter
1478922|NCT00066352|recurrent transitional cell cancer of the renal pelvis and ureter
1478923|NCT00066352|regional transitional cell cancer of the renal pelvis and ureter
1478924|NCT00066352|transitional cell carcinoma of the bladder
1478925|NCT00066339|stage IV breast cancer
1478926|NCT00066339|recurrent breast cancer
1478927|NCT00066326|blastic phase chronic myelogenous leukemia
1478928|NCT00066326|Philadelphia chromosome positive chronic myelogenous leukemia
1478929|NCT00066326|chronic phase chronic myelogenous leukemia
1478930|NCT00066326|accelerated phase chronic myelogenous leukemia
1478931|NCT00066326|relapsing chronic myelogenous leukemia
1478932|NCT00066313|extensive stage small cell lung cancer
1478933|NCT00066313|limited stage small cell lung cancer
1478934|NCT00066274|stage IV colon cancer
1478935|NCT00066274|stage IV rectal cancer
1478936|NCT00066248|cachexia
1478937|NCT00066248|unspecified childhood solid tumor
1478938|NCT00066248|childhood spinal cord neoplasm
1478939|NCT00066248|recurrent childhood medulloblastoma
1478940|NCT00066248|untreated childhood medulloblastoma
1478941|NCT00066248|childhood high-grade cerebral astrocytoma
1478942|NCT00066248|childhood low-grade cerebral astrocytoma
1478943|NCT00066248|recurrent childhood cerebellar astrocytoma
1478944|NCT00066248|recurrent childhood cerebral astrocytoma
1478945|NCT00066248|untreated childhood cerebellar astrocytoma
1478946|NCT00066248|childhood oligodendroglioma
1478947|NCT00066248|recurrent childhood brain stem glioma
1478948|NCT00066248|recurrent childhood visual pathway glioma
1478949|NCT00066248|hypothalamic glioma
1478950|NCT00066248|untreated childhood brain stem glioma
1478951|NCT00066248|untreated childhood visual pathway
1479184|NCT00065663|diabetic
1478952|NCT00066248|childhood supratentorial primitive neuroectodermal tumor
1478953|NCT00066248|childhood craniopharyngioma
1478954|NCT00066248|childhood infratentorial ependymoma
1478955|NCT00066248|childhood supratentorial ependymoma
1478956|NCT00066248|newly diagnosed childhood ependymoma
1478957|NCT00066248|recurrent childhood ependymoma
1478958|NCT00066248|childhood choroid plexus tumor
1478959|NCT00066248|childhood central nervous system germ cell tumor
1478960|NCT00066248|childhood acute lymphoblastic leukemia in remission
1478961|NCT00066248|recurrent childhood acute lymphoblastic leukemia
1478962|NCT00066248|untreated childhood acute lymphoblastic leukemia
1478963|NCT00066248|childhood acute myeloid leukemia in remission
1478964|NCT00066248|recurrent childhood acute myeloid leukemia
1478965|NCT00066248|untreated childhood acute myeloid leukemia
1478966|NCT00066248|other myeloid malignancies
1478967|NCT00066248|refractory chronic lymphocytic leukemia
1478968|NCT00066248|stage I chronic lymphocytic leukemia
1478969|NCT00066248|stage II chronic lymphocytic leukemia
1478970|NCT00066248|stage III chronic lymphocytic leukemia
1478971|NCT00066248|stage IV chronic lymphocytic leukemia
1478972|NCT00066248|accelerated phase chronic myelogenous leukemia
1478973|NCT00066248|blastic phase chronic myelogenous leukemia
1478974|NCT00066248|chronic phase chronic myelogenous leukemia
1478975|NCT00066248|meningeal chronic myelogenous leukemia
1478976|NCT00066248|relapsing chronic myelogenous leukemia
1478977|NCT00066248|juvenile myelomonocytic leukemia
1478978|NCT00066248|recurrent/refractory childhood Hodgkin lymphoma
1478979|NCT00066248|stage I childhood Hodgkin lymphoma
1478980|NCT00066248|stage II childhood Hodgkin lymphoma
1478981|NCT00066248|stage III childhood Hodgkin lymphoma
1478982|NCT00066248|stage IV childhood Hodgkin lymphoma
1478983|NCT00066248|AIDS-related peripheral/systemic lymphoma
1478984|NCT00066248|AIDS-related primary CNS lymphoma
1478985|NCT00066248|progressive hairy cell leukemia, initial treatment
1478986|NCT00066248|refractory hairy cell leukemia
1478987|NCT00066248|untreated hairy cell leukemia
1478988|NCT00066248|recurrent childhood lymphoblastic lymphoma
1478989|NCT00066248|stage I childhood lymphoblastic lymphoma
1478990|NCT00066248|stage II childhood lymphoblastic lymphoma
1478991|NCT00066248|stage III childhood lymphoblastic lymphoma
1478992|NCT00066248|stage IV childhood lymphoblastic lymphoma
1478993|NCT00066248|recurrent childhood small noncleaved cell lymphoma
1478994|NCT00066248|stage I childhood small noncleaved cell lymphoma
1478995|NCT00066248|stage II childhood small noncleaved cell lymphoma
1478996|NCT00066248|stage III childhood small noncleaved cell lymphoma
1478997|NCT00066248|stage IV childhood small noncleaved cell lymphoma
1478998|NCT00066248|recurrent childhood large cell lymphoma
1478999|NCT00066248|stage I childhood large cell lymphoma
1479000|NCT00066248|stage II childhood large cell lymphoma
1479001|NCT00066248|stage III childhood large cell lymphoma
1479002|NCT00066248|stage IV childhood large cell lymphoma
1479003|NCT00066248|recurrent childhood brain tumor
1479004|NCT00066248|atypical chronic myeloid leukemia
1479005|NCT00066248|myelodysplastic/myeloproliferative disease
1479006|NCT00066248|childhood chronic myelogenous leukemia
1479007|NCT00066248|de novo myelodysplastic syndromes
1479008|NCT00066248|previously treated myelodysplastic syndromes
1479009|NCT00066248|secondary myelodysplastic syndromes
1479010|NCT00066248|chronic myelomonocytic leukemia
1479011|NCT00066222|limited stage small cell lung cancer
1479012|NCT00066209|Inflammation
1479013|NCT00066209|Coronavirus
1479014|NCT00066209|Immunity
1479015|NCT00066209|Interferon
1479016|NCT00066209|Cytokine
1479017|NCT00066209|Severe Acute Respiratory Syndrome
1479018|NCT00066209|SARS
1479019|NCT00066209|Healthy Volunteer
1479020|NCT00066209|HV
1479021|NCT00066183|Fibroblast Growth Factor 23
1479022|NCT00066183|FGF-23
1479023|NCT00066183|Hypophosphatemia
1479024|NCT00066183|Phosphaturia
1479025|NCT00066183|Phosphorus
1479026|NCT00066183|Phosphorus Metabolism
1479027|NCT00066170|Narcolepsy
1479028|NCT00066170|Daytime Sleepiness
1479029|NCT00066170|Daytime sleepiness in narcolepsy
1479030|NCT00066157|Alzheimer disease
1479031|NCT00066157|Hormone replacement therapy
1479032|NCT00066157|Postmenopausal women
1479033|NCT00066144|menopause
1479034|NCT00066144|hot flashes
1479035|NCT00066144|red clover
1479036|NCT00066144|black cohosh
1479037|NCT00066144|sexual dysfunction
1479038|NCT00066118|neurologic
1479039|NCT00066118|nerve conduction
1479040|NCT00066118|neurobehavioral
1479041|NCT00066118|renal disease
1479042|NCT00066092|PBPC transplant
1479043|NCT00066092|Hodgkin's Disease
1479044|NCT00066092|Non-Hodgkin's Lymphoma
1479045|NCT00066092|NHL
1479046|NCT00066092|mobilization
1479047|NCT00066079|Sickle Cell Pain
1479048|NCT00066079|Sickle Cell Disease
1479049|NCT00066079|Chronic Pain
1479050|NCT00066079|Alternative Medicine/Therapy
1479051|NCT00066079|Complementary Medicine
1479052|NCT00066079|Massage Therapy
1479053|NCT00066079|Relaxation Technique
1479054|NCT00066079|Home-based Therapy
1479055|NCT00066053|Heart attacks
1479056|NCT00066053|Stroke
1479058|NCT00066040|mutans streptococci infections
1479059|NCT00066027|periodontitis, metabolic bone diseases, doxycycline
1479060|NCT00066014|Dental Implantation-Osseointegrated
1479061|NCT00066014|Dentures
1479062|NCT00066014|Dental Prostheses
1479063|NCT00066014|Denture, Implant-Supported
1479064|NCT00065975|chronic low back pain
1479065|NCT00065975|acupuncture
1479066|NCT00065975|chiropractic
1479067|NCT00065975|massage therapy
1479068|NCT00065975|CAM therapies
1479069|NCT00065962|Pervasive Developmental Disorders
1479070|NCT00065962|Secretin, synthetic porcine
1479071|NCT00065962|Secretin, biological porcine
1479072|NCT00065962|Autism Diagnostic Observation Schedule - Generic (ADOS-G)
1479073|NCT00065962|Rimland Questionnaire
1479074|NCT00065962|Expressive Vocabulary Test
1479075|NCT00065962|MacArthur Communication Inventory
1479076|NCT00065962|Aberrant Behavior Checklist
1479077|NCT00065949|Low birthweight infants
1479078|NCT00065949|Magnesium supplementation
1479079|NCT00065949|Intracranial hemorrhage
1479080|NCT00065949|Cystic periventricular leukomalacia
1479081|NCT00065949|Mental retardation
1479082|NCT00065936|Intractable self-injurious behavior
1479083|NCT00065936|Naltrexone
1479084|NCT00065936|Transcutaneous electrical nerve stimulation
1479085|NCT00065936|Substance P
1479086|NCT00065936|Met-enkephalin
1479087|NCT00065936|Cortisol
1479088|NCT00065923|Prader-Willi Syndrome
1479089|NCT00065923|Self-Injurious Behavior
1479090|NCT00065910|Joint attention
1479091|NCT00065910|Developmental delay
1479092|NCT00065910|Caregiver interaction
1479093|NCT00065897|Amniocentesis
1479094|NCT00065897|Transabdominal chorionic villus sampling
1479095|NCT00065897|Fluorescence in situ hybridization
1479096|NCT00065897|Alpha fetoprotein
1479097|NCT00065897|Acetylcholinesterase
1479098|NCT00065897|Prenatal testing
1479099|NCT00065897|Prenatal diagnosis
1479100|NCT00065884|Adolescents
1479101|NCT00065871|Pharmacist prescribers
1479102|NCT00065871|Increased access
1479103|NCT00065871|Hormonal contraception
1479104|NCT00065871|Birth control pills
1479105|NCT00065871|Birth control patch
1479106|NCT00065871|Vaginal contraceptive ring
1479107|NCT00065858|Contraception
1479108|NCT00065858|Nonoxynol 9
1479109|NCT00065858|Microbicide
1479110|NCT00065858|Spermicide
1479111|NCT00065845|Urinary incontinence
1479112|NCT00065845|Pelvic organ prolapse
1479113|NCT00065845|Stress incontinence
1479114|NCT00065845|Sacrocolpopexy
1479115|NCT00065845|Burch urethropexy
1479116|NCT00065845|Surgical Trials
1479117|NCT00065832|Reading disabilities
1479118|NCT00065832|Inner-city
1479119|NCT00065832|Urban
1479120|NCT00065819|HIV
1479121|NCT00065819|African American
1479122|NCT00065819|Symptom Management
1479123|NCT00065806|Pediatric lupus
1479124|NCT00065806|Atherosclerosis
1479125|NCT00065806|SLE
1479126|NCT00065806|HMG CoA reductase inhibitor
1479127|NCT00065767|Alzheimer disease
1479128|NCT00065767|Postmenopausal women
1479129|NCT00065767|Hormone therapy
1479130|NCT00065754|Placebo
1479131|NCT00065754|Analgesia
1479132|NCT00065754|Pain
1479133|NCT00065754|Brain mechanism
1479134|NCT00065754|Expectation
1479135|NCT00065741|Milk thistle
1479136|NCT00065741|silymarin
1479137|NCT00065741|piperine
1479138|NCT00065741|glucarate
1479139|NCT00065741|zidovudine
1479140|NCT00065741|abacavir
1479141|NCT00065741|mycophenolate mofetil
1479142|NCT00065741|HIV
1479143|NCT00065741|pharmacokinetics
1479144|NCT00065741|interaction
1479145|NCT00065741|glucuronidation
1479146|NCT00065741|Healthy
1479147|NCT00065741|Complementary Therapies
1479148|NCT00065728|AMD
1479149|NCT00065728|age-related macular degeneration
1479150|NCT00065728|Anecortave
1479151|NCT00065728|Acetate
1479152|NCT00065728|Wet form of age-related macular degeneration
1479153|NCT00065728|CNV
1479154|NCT00065728|Anecortave Acetate
1479155|NCT00065715|head cold
1479156|NCT00065715|common cold
1479157|NCT00065715|echinacea
1479158|NCT00065715|placebo
1479159|NCT00065702|fibromyalgia
1479160|NCT00065702|homeopathy
1479161|NCT00065702|EEG
1479162|NCT00065702|EKG
1479163|NCT00065702|chronic pain
1479164|NCT00065689|Alzheimer's disease
1479165|NCT00065689|light therapy
1479166|NCT00065689|long-term care
1479167|NCT00065689|depression
1479168|NCT00065689|sleep
1479169|NCT00065689|agitation
1479170|NCT00065676|Hyperglycemia
1479171|NCT00065676|Hyperinsulinemia
1479172|NCT00065676|OGTT
1479173|NCT00065676|GLUT2
1479174|NCT00065676|Post-Prandial
1479175|NCT00065676|Type 2 Diabetes
1479176|NCT00065676|Obesity
1479177|NCT00065663|gene transfer
1479178|NCT00065663|adenovirus
1479179|NCT00065663|platelet-derived growth factor-B
1479180|NCT00065663|collagen
1479181|NCT00065663|diabetic ulcer
1479182|NCT00065663|foot
1479185|NCT00065663|ulcers
1479186|NCT00065650|Diabetes Mellitus Type 2
1479187|NCT00065650|Vedic medicine
1479188|NCT00065650|Ayurveda
1479189|NCT00065650|Transcendental Meditation
1479190|NCT00065624|Lipoic acid
1479191|NCT00065624|F2-isoprostanes
1479192|NCT00065624|endothelial dysfunction
1479193|NCT00065624|natural product
1479194|NCT00065611|Steroids
1479195|NCT00065611|Osteoporosis
1479196|NCT00065611|Proteinuria
1479197|NCT00065611|Minimal Change Disease
1479198|NCT00065611|Focal Segmental Glomerulosclerosis
1479199|NCT00065611|FSGS
1479200|NCT00065611|MCD
1479201|NCT00065611|Kidney Disease
1479202|NCT00065585|low back pain
1479203|NCT00065585|acupuncture
1479204|NCT00065572|Kidney Cancer
1479205|NCT00065572|Metastatic
1479206|NCT00065572|Newly diagnosed renal cell carcinoma
1479207|NCT00065507|hepatic decompensation
1479208|NCT00065468|Advanced Renal Cell Carcinoma
1479209|NCT00065468|Kidney Cancer
1479210|NCT00065455|Retinitis Pigmentosa
1479211|NCT00065455|Vitamin A
1479212|NCT00065455|ERG
1479213|NCT00065455|RP
1479214|NCT00065442|prostate cancer
1479215|NCT00065442|prostate
1479216|NCT00065442|AIPC
1479217|NCT00065442|androgen-independent
1479218|NCT00065442|androgen independent
1479219|NCT00065442|hormone insensitive
1479220|NCT00065442|hormone-insensitive
1479221|NCT00065442|PSA
1479222|NCT00065442|prostatic adenocarcinoma
1479223|NCT00065442|hormone-refractory
1479224|NCT00065442|hormone refractory
1479225|NCT00065442|HRPC
1479226|NCT00065442|LHRH
1479227|NCT00065442|immune therapy
1479228|NCT00065442|immunotherapy
1479229|NCT00065442|vaccine
1479230|NCT00065442|dendritic cells
1479231|NCT00065442|antigen-presenting cells
1479232|NCT00065442|antigen presenting cells
1479233|NCT00065442|cancer vaccine
1479234|NCT00065442|therapeutic vaccine
1479235|NCT00065442|therapeutic cancer vaccine
1479236|NCT00065442|recombinant
1479237|NCT00065442|biological
1479238|NCT00065442|biopharmaceutical
1479239|NCT00065442|biotechnology
1479240|NCT00065442|biotech
1479241|NCT00065416|neck pain
1479242|NCT00065416|cervicalgia
1479243|NCT00065416|massage
1479244|NCT00065403|Irritable Bowel Syndrome
1479245|NCT00065403|Acupuncture
1479246|NCT00065390|ALPS
1479247|NCT00065390|Pyrimethamine
1479248|NCT00065390|Folinic Acid
1479249|NCT00065390|Lymphadenopathy
1479250|NCT00065390|Splenomegaly
1479251|NCT00065390|Autoimmune Lymphoproliferative Syndrome
1479252|NCT00065377|Diabetes
1479253|NCT00065377|Insulin Resistance
1479254|NCT00065377|Capillary Blood Flow
1479255|NCT00065377|Osteoarthritis
1479256|NCT00065377|Endothelial Dysfunction
1479257|NCT00065377|Obesity
1479258|NCT00065377|Healthy Volunteer
1479259|NCT00065377|HV
1479260|NCT00065364|Preterm infant
1479261|NCT00065364|Premature infant
1479262|NCT00065364|Developmental care
1479263|NCT00065364|MRI
1479264|NCT00065364|qEEG
1479265|NCT00065364|Neurodevelopment
1479266|NCT00065364|Behavior
1479267|NCT00065364|Infants
1479268|NCT00065364|NICU
1479269|NCT00065351|Multiple Myeloma
1479270|NCT00065351|CC-5013
1479271|NCT00065351|Revlimid
1479272|NCT00065351|MM
1479273|NCT00065351|CC5013
1479274|NCT00065351|relapsed and refractory multiple myeloma
1479275|NCT00065338|Physical activity
1479276|NCT00065325|Locally advanced breast cancer
1479277|NCT00065325|metastatic breast cancer
1479278|NCT00065325|Breast Cancer
1479279|NCT00065325|Cancer of Breast
1479280|NCT00065325|Cancer of the Breast
1479281|NCT00065312|Type 2 diabetes
1479282|NCT00065299|Hyperphenylalaninemia
1479283|NCT00065299|PKU
1479284|NCT00065299|Maternal PKU
1479285|NCT00065299|Pregnancy outcome
1479286|NCT00065299|Phenylalanine restricted diet
1479287|NCT00065299|Tyrosine supplementation
1479288|NCT00065299|Maternal hyperphenylalanemia during pregnancy
1479289|NCT00065286|Akathisia
1479290|NCT00065286|Mental retardation
1479291|NCT00065286|Schizophrenia
1479292|NCT00065286|Neuroleptic medication
1479293|NCT00065286|Tardive dyskinesia
1479294|NCT00065286|Brief Psychiatric Rating Scale
1479295|NCT00065286|Barnes test
1479296|NCT00065286|Stereotypy Checklist Test
1479297|NCT00065286|DISCUS Tardive Dyskinesia test
1479298|NCT00065273|Severe aberrant behavior
1479299|NCT00065273|Risperidone
1479300|NCT00065273|Clozapine
1479301|NCT00065273|Haloperidol
1479302|NCT00065273|Laboratory operant tasks
1479303|NCT00065273|Simple acquisition procedures
1479304|NCT00065273|Matching to sample task
1479305|NCT00065273|Lag sequential analysis
1479306|NCT00065260|Alemtuzumab (Campath-1H)
1479307|NCT00065260|Rabbit ATG
1479308|NCT00065260|Severe Aplastic Anemia
1479309|NCT00065260|Cyclosporine
1479310|NCT00065260|Thrombocytopenia
1479311|NCT00065260|Leukopenia
1479312|NCT00065260|Neutropenia
1479313|NCT00065260|Autoimmunity
1479314|NCT00065260|Relapse
1479315|NCT00065260|Anemia
1479316|NCT00065247|Bone
1479317|NCT00065247|Children
1479318|NCT00065247|After-school program
1479319|NCT00065247|Osteoporosis
1479320|NCT00065247|Calcium
1479321|NCT00065247|Physical activity
1479322|NCT00065234|Colostomy
1479323|NCT00065234|Ileostomy
1479324|NCT00065221|Ginger
1479325|NCT00065221|Plant preparation
1479326|NCT00065221|Herbal medicine
1479327|NCT00065221|Chemotherapy
1479328|NCT00065221|Nausea
1479329|NCT00065208|Prostate cancer
1479330|NCT00065208|Reiki
1479331|NCT00065208|Energy Healing
1479332|NCT00065195|Massage
1479333|NCT00065195|Palliative Care
1479334|NCT00065195|Hospices
1479335|NCT00065195|Cancer
1479336|NCT00065182|Stage IIIB/IV
1479337|NCT00065182|topotecan
1479338|NCT00065182|docetaxel
1479339|NCT00065182|TAXOTERE
1479340|NCT00065182|HYCAMTIN
1479341|NCT00065182|non-small cell lung cancer
1479342|NCT00065182|Advanced
1479343|NCT00065182|NSCLC
1479344|NCT00065156|MDS
1479345|NCT00065156|CC-5013
1479346|NCT00065156|Revlimid
1479347|NCT00065156|Celgene
1479348|NCT00065143|Newly diagnosed and previously untreated acute myeloid leukemia (AML)
1479349|NCT00065143|High-risk myelodysplastic syndrome (MDS) (>/= 10% bone marrow blasts)
1479350|NCT00065143|Acute Myeloid Leukemia (AML)
1479351|NCT00065143|Myelodysplastic Syndrome (MDS)
1479352|NCT00065117|metastatic
1479353|NCT00065117|colorectal
1479354|NCT00065117|first-line
1479355|NCT00065117|adjuvant
1479356|NCT00065117|cancer
1479357|NCT00065117|Colorectal Cancer
1479358|NCT00065117|Colorectal Carcinoma
1479359|NCT00065117|Colorectal Tumors
1479360|NCT00065117|Neoplasms, Colorectal
1479361|NCT00065104|HIV
1479362|NCT00065104|DHEA
1479363|NCT00065104|immune system
1479364|NCT00065104|hormones
1479365|NCT00065104|body composition
1479366|NCT00065104|quality of life
1479367|NCT00065078|Home-visits
1479368|NCT00065078|Community nurse
1479369|NCT00065078|Unintended pregnancy
1479370|NCT00065065|Rosiglitazone
1479371|NCT00065065|Ulcerative
1479372|NCT00065065|Colitis
1479373|NCT00065052|physical activity
1479374|NCT00065052|television
1479375|NCT00065052|child obesity
1479376|NCT00065052|Reduce TV
1479377|NCT00065052|Usual control
1479378|NCT00065013|obesity
1479379|NCT00065013|gastric bypass
1479380|NCT00065013|obesity surgery
1479381|NCT00065013|bariatric surgery
1479382|NCT00065013|exercise
1479383|NCT00064272|nausea and vomiting
1479384|NCT00064272|unspecified adult solid tumor, protocol specific
1479385|NCT00064233|chronic phase chronic myelogenous leukemia
1479386|NCT00064233|relapsing chronic myelogenous leukemia
1479387|NCT00064233|Philadelphia chromosome positive chronic myelogenous leukemia
1479388|NCT00064220|adult leiomyosarcoma
1479389|NCT00064220|adult malignant fibrous histiocytoma
1479390|NCT00064220|adult liposarcoma
1479391|NCT00064220|adult rhabdomyosarcoma
1479392|NCT00064220|adult synovial sarcoma
1479393|NCT00064220|adult fibrosarcoma
1479394|NCT00064220|adult angiosarcoma
1479395|NCT00064220|adult malignant hemangiopericytoma
1479396|NCT00064220|stage IV adult soft tissue sarcoma
1479397|NCT00064220|recurrent adult soft tissue sarcoma
1479398|NCT00064207|adenocarcinoma of the pancreas
1479399|NCT00064207|stage I pancreatic cancer
1479400|NCT00064207|stage II pancreatic cancer
1479401|NCT00064207|stage III pancreatic cancer
1479402|NCT00064194|prostate cancer
1479403|NCT00064194|high grade prostatic intraepithelial neoplasia
1479404|NCT00064181|adenocarcinoma of the colon
1479405|NCT00064181|adenocarcinoma of the rectum
1479406|NCT00064181|stage IV colon cancer
1479407|NCT00064181|stage IV rectal cancer
1479408|NCT00064116|stage I adult diffuse large cell lymphoma
1479409|NCT00064116|contiguous stage II adult diffuse large cell lymphoma
1479410|NCT00064116|noncontiguous stage II adult diffuse large cell lymphoma
1479411|NCT00064116|stage III adult diffuse large cell lymphoma
1479412|NCT00064116|stage IV adult diffuse large cell lymphoma
1479413|NCT00064090|recurrent adult acute lymphoblastic leukemia
1479414|NCT00064090|recurrent adult acute myeloid leukemia
1479415|NCT00064090|blastic phase chronic myelogenous leukemia
1479416|NCT00064090|refractory chronic lymphocytic leukemia
1479417|NCT00064090|relapsing chronic myelogenous leukemia
1479418|NCT00064090|chronic myelomonocytic leukemia
1479419|NCT00064090|refractory anemia with excess blasts in transformation
1479420|NCT00064090|refractory anemia with excess blasts
1479421|NCT00064090|previously treated myelodysplastic syndromes
1479422|NCT00064090|atypical chronic myeloid leukemia, BCR-ABL1 negative
1479423|NCT00064090|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1479424|NCT00064090|adult acute myeloid leukemia with t(8;21)(q22;q22)
1479425|NCT00064090|adult acute myeloid leukemia with t(16;16)(p13;q22)
1479426|NCT00064090|adult acute myeloid leukemia with inv(16)(p13;q22)
1479554|NCT00064623|Diary
1479427|NCT00064090|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1479428|NCT00064090|adult acute myeloid leukemia with t(15;17)(q22;q12)
1479429|NCT00064987|Male reproduction hormones
1479430|NCT00064987|Hypogonadotropic hypogonadism
1479431|NCT00064987|FSH
1479432|NCT00064987|LH
1479433|NCT00064987|GnRH
1479434|NCT00064974|MDS
1479435|NCT00064974|CC-5013
1479436|NCT00064974|Revlimid
1479437|NCT00064974|Celgene
1479438|NCT00064961|Smoking Cessation
1479439|NCT00064935|Endometrium
1479440|NCT00064935|Luteal phase
1479441|NCT00064935|Endometrial biopsy
1479442|NCT00064922|nicotine dependence
1479443|NCT00064909|Multiple Sclerosis
1479444|NCT00064909|MRI
1479445|NCT00064909|Perfusion
1479446|NCT00064909|Imaging
1479447|NCT00064909|Cerebral Blood Flow
1479448|NCT00064909|Cerebral Blood Volume
1479449|NCT00064909|CO2 Inhalation
1479450|NCT00064909|Contrast Agent
1479451|NCT00064909|Healthy Volunteer
1479452|NCT00064909|HV
1479453|NCT00064896|Blood Flow
1479454|NCT00064896|Revascularization
1479455|NCT00064896|Image Fusion
1479456|NCT00064896|Fluoroscopy
1479457|NCT00064896|MRI
1479458|NCT00064896|Chronic Total Occlusion of Arteries
1479459|NCT00064896|Claudication
1479460|NCT00064896|Safety
1479461|NCT00064896|Atherosclerosis
1479462|NCT00064896|Cardiovascular Disease
1479463|NCT00064883|Radiation Therapy
1479464|NCT00064883|Children
1479465|NCT00064883|Cancer
1479466|NCT00064883|Late Effects
1479467|NCT00064883|Natural History
1479468|NCT00064883|Radiation
1479469|NCT00064870|Alzheimer disease
1479470|NCT00064870|Late Onset Alzheimer disease risk factor genes
1479471|NCT00064870|Genetics
1479472|NCT00064870|Initiative
1479473|NCT00064870|Dementia
1479474|NCT00064857|lymphedema
1479475|NCT00064857|breast
1479476|NCT00064857|cancer
1479477|NCT00064857|plant preparation
1479478|NCT00064857|herbal preparation
1479479|NCT00064857|pine bark extract
1479480|NCT00064844|Smoking
1479481|NCT00064844|Alcoholism
1479482|NCT00064831|estrogen stimulation
1479483|NCT00064831|relief of hot flashes
1479484|NCT00064831|nipple aspirate fluid
1479485|NCT00064831|body fluid levels of black cohosh
1479486|NCT00064818|connective tissue
1479487|NCT00064818|ultrasound
1479488|NCT00064818|acupuncture
1479489|NCT00064805|Cognitive therapy
1479490|NCT00064805|Aphasia therapy
1479491|NCT00064805|Alexia
1479492|NCT00064805|Acquired dyslexia
1479493|NCT00064805|Phonological deficits
1479494|NCT00064805|Orthographic deficits
1479495|NCT00064805|Brain disorders
1479496|NCT00064805|Brain injury
1479497|NCT00064805|Stroke
1479498|NCT00064792|Cholesterol
1479499|NCT00064792|SLOS
1479500|NCT00064792|HMG-COA Reductase Inhibitor
1479501|NCT00064792|Malformation Syndrome
1479502|NCT00064792|Mental Retardation
1479503|NCT00064792|Smith-Lemli-Opitz Syndrome
1479504|NCT00064779|CNS neoplasms
1479505|NCT00064779|Brain neoplasms
1479506|NCT00064779|neurosurgery
1479507|NCT00064779|intralesional infusion
1479508|NCT00064779|recombinant proteins
1479509|NCT00064779|immunotoxins
1479510|NCT00064766|Norplant
1479511|NCT00064766|Periodontal disease
1479512|NCT00064766|Endometrial bleeding
1479513|NCT00064766|Progestin-induced endometrial bleeding
1479514|NCT00064753|homocysteine
1479515|NCT00064753|multi-vitamin
1479516|NCT00064753|cardiovascular disease
1479517|NCT00064753|renal transplant recipients
1479518|NCT00064740|Human Immunodeficiency Viruses
1479519|NCT00064740|Relaxation
1479520|NCT00064740|Acupuncture
1479521|NCT00064740|Complementary therapies
1479522|NCT00064727|Ventricular Contractile Function
1479523|NCT00064727|Diastolic Dysfunction
1479524|NCT00064727|PPAR gamma
1479525|NCT00064727|Gene Expression Patterns
1479526|NCT00064727|Insulin Sensitization
1479527|NCT00064727|Glucose Intolerance
1479528|NCT00064727|Intolerance
1479529|NCT00064714|Type 1 Diabetes Mellitus (T1DM)
1479530|NCT00064714|Beta-Cell
1479531|NCT00064714|C-Peptide
1479532|NCT00064714|Immunosuppression
1479533|NCT00064714|Insulin
1479534|NCT00064714|Islet
1479535|NCT00064714|Function
1479536|NCT00064714|AC2993 (Synthetic Exendin-4)
1479537|NCT00064714|Diabetes Mellitus
1479538|NCT00064714|Type I Diabetes Mellitus
1479539|NCT00064714|T1DM
1479540|NCT00064701|De Novo Kidney Transplant
1479541|NCT00064701|cyclosporine
1479542|NCT00064701|Prograf®
1479543|NCT00064701|mycophenolate mofetil
1479544|NCT00064701|tacrolimus
1479545|NCT00064662|Stress urinary incontinence
1479546|NCT00064662|Surgery
1479547|NCT00064649|prostate
1479548|NCT00064649|benign disease
1479549|NCT00064649|TUNA
1479550|NCT00064649|TUMT
1479551|NCT00064649|medical therapy
1479552|NCT00064623|Dermal assessment
1479553|NCT00064623|Pain measurement
1479555|NCT00064623|Analgesics/*therapeutic use
1479556|NCT00064623|Capsaicin/*administration & dosage/adverse effects
1479557|NCT00064623|HIV Infections/*complications/*drug therapy
1479558|NCT00064623|Peripheral Nervous System Diseases/*complications/diagnosis/*therapy
1479559|NCT00064623|Peripheral Nervous System Diseases/drug therapy/*etiology/physiopathology
1479560|NCT00064610|Advanced androgen-independent prostate cancer
1479561|NCT00064597|Fetal cells
1479562|NCT00064597|Prenatal diagnosis
1479563|NCT00064597|Cytogenetic disorders
1479564|NCT00064597|Chromosomal disorders
1479565|NCT00064597|Single gene mutation detection
1479566|NCT00064597|Abnormal serum marker profile
1479567|NCT00064597|Fluorescence activated cell sorting (FACS)
1479568|NCT00064597|Magnetic activated cell sorting (MACS)
1479569|NCT00064597|Fluorescence in situ hybridization (FISH)
1479570|NCT00064597|Chromosomal disorders of the fetus
1479571|NCT00064597|Single gene defects of the fetus
1479572|NCT00064571|unilateral vocal fold paralysis
1479573|NCT00064467|lethargic
1479574|NCT00064467|decreased interest
1479575|NCT00064467|decreased motivation
1479576|NCT00064467|depression
1479577|NCT00064454|Ulcerative Colitis
1479578|NCT00064441|Ulcerative Colitis
1479579|NCT00064428|ST-segment elevation myocardial infarction
1479580|NCT00064428|fondaparinux
1479581|NCT00064428|Acute Myocardial Infarction
1479582|NCT00064428|acute coronary syndrome
1479583|NCT00064376|de novo myelodysplastic syndromes
1479781|NCT00063661|Overlearned
1479584|NCT00064376|previously treated myelodysplastic syndromes
1479585|NCT00064376|secondary myelodysplastic syndromes
1479586|NCT00064376|refractory anemia with excess blasts in transformation
1479587|NCT00064376|refractory anemia with excess blasts
1479588|NCT00064376|refractory anemia with ringed sideroblasts
1479589|NCT00064376|refractory anemia
1479590|NCT00064376|chronic myelomonocytic leukemia
1479591|NCT00064363|recurrent adult brain tumor
1479592|NCT00064363|adult anaplastic astrocytoma
1479593|NCT00064363|adult glioblastoma
1479594|NCT00064363|adult anaplastic oligodendroglioma
1479595|NCT00064363|adult mixed glioma
1479596|NCT00064363|adult giant cell glioblastoma
1479597|NCT00064363|adult gliosarcoma
1479598|NCT00064363|adult brain stem glioma
1479599|NCT00064350|recurrent non-small cell lung cancer
1479600|NCT00064350|stage IIIB non-small cell lung cancer
1479601|NCT00064350|stage IV non-small cell lung cancer
1479602|NCT00064350|sorafenib
1479603|NCT00064337|primary systemic amyloidosis
1479604|NCT00064337|stage II multiple myeloma
1479605|NCT00064337|stage III multiple myeloma
1479606|NCT00064311|infection
1479607|NCT00064311|recurrent cutaneous T-cell non-Hodgkin lymphoma
1479608|NCT00064311|recurrent adult diffuse large cell lymphoma
1479609|NCT00064311|recurrent adult diffuse mixed cell lymphoma
1479610|NCT00064311|recurrent adult diffuse small cleaved cell lymphoma
1479611|NCT00064311|recurrent adult Burkitt lymphoma
1479612|NCT00064311|recurrent adult Hodgkin lymphoma
1479613|NCT00064311|recurrent adult immunoblastic large cell lymphoma
1479614|NCT00064311|recurrent adult lymphoblastic lymphoma
1479615|NCT00064311|recurrent grade 1 follicular lymphoma
1479616|NCT00064311|recurrent grade 2 follicular lymphoma
1479617|NCT00064311|recurrent grade 3 follicular lymphoma
1479618|NCT00064311|recurrent mantle cell lymphoma
1479619|NCT00064311|noncontiguous stage II adult diffuse large cell lymphoma
1479620|NCT00064311|noncontiguous stage II adult diffuse mixed cell lymphoma
1479621|NCT00064311|noncontiguous stage II adult Burkitt lymphoma
1479622|NCT00064311|noncontiguous stage II adult immunoblastic large cell lymphoma
1479623|NCT00064311|noncontiguous stage II adult lymphoblastic lymphoma
1479624|NCT00064311|noncontiguous stage II grade 3 follicular lymphoma
1479625|NCT00064311|noncontiguous stage II mantle cell lymphoma
1479626|NCT00064311|stage III adult diffuse large cell lymphoma
1479627|NCT00064311|stage III adult diffuse mixed cell lymphoma
1479628|NCT00064311|stage III adult Burkitt lymphoma
1479629|NCT00064311|stage III adult immunoblastic large cell lymphoma
1479630|NCT00064311|stage III adult lymphoblastic lymphoma
1479631|NCT00064311|stage III grade 3 follicular lymphoma
1479632|NCT00064311|stage III mantle cell lymphoma
1479633|NCT00064311|stage IV grade 3 follicular lymphoma
1479634|NCT00064311|stage IV adult diffuse large cell lymphoma
1479635|NCT00064311|stage IV adult diffuse mixed cell lymphoma
1479636|NCT00064311|stage IV adult Burkitt lymphoma
1479637|NCT00064311|stage IV adult immunoblastic large cell lymphoma
1479638|NCT00064311|stage IV adult lymphoblastic lymphoma
1479639|NCT00064311|stage IV mantle cell lymphoma
1479640|NCT00064311|refractory chronic lymphocytic leukemia
1479641|NCT00064311|stage III chronic lymphocytic leukemia
1479642|NCT00064311|stage IV chronic lymphocytic leukemia
1479643|NCT00064311|accelerated phase chronic myelogenous leukemia
1479644|NCT00064311|blastic phase chronic myelogenous leukemia
1479645|NCT00064311|chronic phase chronic myelogenous leukemia
1479646|NCT00064311|meningeal chronic myelogenous leukemia
1479647|NCT00064311|relapsing chronic myelogenous leukemia
1479648|NCT00064311|refractory hairy cell leukemia
1479649|NCT00064311|de novo myelodysplastic syndromes
1479650|NCT00064311|previously treated myelodysplastic syndromes
1479651|NCT00064311|secondary myelodysplastic syndromes
1479652|NCT00064311|stage I multiple myeloma
1479653|NCT00064311|stage II multiple myeloma
1479654|NCT00064311|stage III multiple myeloma
1479655|NCT00064311|recurrent malignant testicular germ cell tumor
1479656|NCT00064311|stage III malignant testicular germ cell tumor
1479657|NCT00064311|disseminated neuroblastoma
1479658|NCT00064311|recurrent neuroblastoma
1479659|NCT00064311|stage II ovarian epithelial cancer
1479660|NCT00064311|recurrent ovarian epithelial cancer
1479661|NCT00064311|stage III ovarian epithelial cancer
1479662|NCT00064311|stage IV ovarian epithelial cancer
1479663|NCT00064311|recurrent ovarian germ cell tumor
1479664|NCT00064311|stage IIIA breast cancer
1479665|NCT00064311|stage IIIB breast cancer
1479666|NCT00064311|stage IV breast cancer
1479667|NCT00064311|high risk metastatic gestational trophoblastic tumor
1479668|NCT00064311|primary myelofibrosis
1479669|NCT00064311|recurrent adult acute lymphoblastic leukemia
1479670|NCT00064311|adult acute lymphoblastic leukemia in remission
1479671|NCT00064311|recurrent adult acute myeloid leukemia
1479672|NCT00064311|adult acute myeloid leukemia in remission
1479673|NCT00064311|secondary acute myeloid leukemia
1479674|NCT00064311|atypical chronic myeloid leukemia, BCR-ABL1 negative
1479675|NCT00064311|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1479676|NCT00064311|stage IIIC breast cancer
1479677|NCT00064311|recurrent marginal zone lymphoma
1479678|NCT00064311|recurrent small lymphocytic lymphoma
1479782|NCT00063661|Dual-Task
1479679|NCT00064311|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1479680|NCT00064311|nodal marginal zone B-cell lymphoma
1479681|NCT00064311|splenic marginal zone lymphoma
1479682|NCT00064311|adult acute myeloid leukemia with t(8;21)(q22;q22)
1479683|NCT00064311|adult acute myeloid leukemia with t(16;16)(p13;q22)
1479684|NCT00064311|adult acute myeloid leukemia with inv(16)(p13;q22)
1479685|NCT00064311|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1479686|NCT00064311|adult acute myeloid leukemia with t(15;17)(q22;q12)
1479687|NCT00064298|stage I squamous cell carcinoma of the hypopharynx
1479688|NCT00064298|stage I squamous cell carcinoma of the larynx
1479689|NCT00064298|stage I squamous cell carcinoma of the lip and oral cavity
1479690|NCT00064298|stage I squamous cell carcinoma of the oropharynx
1479691|NCT00064298|stage II squamous cell carcinoma of the hypopharynx
1479692|NCT00064298|stage II squamous cell carcinoma of the larynx
1479693|NCT00064298|stage II squamous cell carcinoma of the lip and oral cavity
1479694|NCT00064298|stage II squamous cell carcinoma of the oropharynx
1479695|NCT00064298|stage III squamous cell carcinoma of the hypopharynx
1479696|NCT00064298|stage III squamous cell carcinoma of the larynx
1479697|NCT00064298|stage III squamous cell carcinoma of the lip and oral cavity
1479698|NCT00064298|stage III squamous cell carcinoma of the oropharynx
1479699|NCT00064298|stage IV squamous cell carcinoma of the hypopharynx
1479700|NCT00064298|stage IV squamous cell carcinoma of the larynx
1479701|NCT00064298|stage IV squamous cell carcinoma of the lip and oral cavity
1479702|NCT00064298|stage IV squamous cell carcinoma of the oropharynx
1479703|NCT00064285|chronic phase chronic myelogenous leukemia
1479704|NCT00064285|blastic phase chronic myelogenous leukemia
1479705|NCT00064285|accelerated phase chronic myelogenous leukemia
1479706|NCT00064285|recurrent adult acute myeloid leukemia
1479707|NCT00064285|untreated adult acute myeloid leukemia
1479708|NCT00064285|adult acute myeloid leukemia in remission
1479709|NCT00064285|adult acute lymphoblastic leukemia in remission
1479710|NCT00064285|recurrent adult acute lymphoblastic leukemia
1479711|NCT00064285|untreated adult acute lymphoblastic leukemia
1479712|NCT00064285|relapsing chronic myelogenous leukemia
1479713|NCT00064285|adult acute myeloid leukemia with t(8;21)(q22;q22)
1479714|NCT00064285|adult acute myeloid leukemia with t(16;16)(p13;q22)
1479715|NCT00064285|adult acute myeloid leukemia with inv(16)(p13;q22)
1479716|NCT00064285|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1479717|NCT00064285|adult acute myeloid leukemia with t(15;17)(q22;q12)
1479718|NCT00064064|recurrent non-small cell lung cancer
1479719|NCT00064064|stage IV non-small cell lung cancer
1479720|NCT00064051|stage II pancreatic cancer
1479721|NCT00064051|stage III pancreatic cancer
1479722|NCT00064051|recurrent pancreatic cancer
1479723|NCT00064051|stage IV pancreatic cancer
1479724|NCT00064038|stage I multiple myeloma
1479725|NCT00064038|stage II multiple myeloma
1479726|NCT00064038|stage III multiple myeloma
1479727|NCT00064012|stage IIIB non-small cell lung cancer
1479728|NCT00064012|stage IV non-small cell lung cancer
1479729|NCT00064012|recurrent non-small cell lung cancer
1479730|NCT00063986|esophageal cancer
1479731|NCT00063986|minimally invasive esophagectomy (MIE)
1479732|NCT00063960|stage IV colon cancer
1479733|NCT00063960|adenocarcinoma of the colon
1479734|NCT00063960|adenocarcinoma of the rectum
1479735|NCT00063960|stage IV rectal cancer
1479736|NCT00063960|liver metastases
1479737|NCT00063882|stage IIB prostate cancer
1479738|NCT00063882|stage IIA prostate cancer
1479739|NCT00063882|adenocarcinoma of the prostate
1479740|NCT00063869|Idiopathic Pulmonary Fibrosis
1479741|NCT00063869|Fibrosis, Pulmonary
1479742|NCT00063869|Pulmonary Fibroses
1479743|NCT00063869|Fibroses, Pulmonary
1479744|NCT00063856|Smallpox, wetvax
1479745|NCT00063843|Bacillus anthracis (anthrax)
1479746|NCT00063830|Ulcerative Colitis
1479747|NCT00063817|Renal Disease
1479748|NCT00063817|End-stage renal disease
1479749|NCT00063817|Renal Transplant
1479750|NCT00063817|Bone Marrow Transplant
1479751|NCT00063817|Tolerance, Chimerism
1479752|NCT00063817|Immune Tolerance
1479753|NCT00063817|ESRD
1479754|NCT00063804|HIV Seronegativity
1479755|NCT00063804|CXCR4
1479756|NCT00063804|AMD11070
1479757|NCT00063791|Relapsed or Refractory
1479758|NCT00063778|HIV Seronegativity
1479759|NCT00063778|HIV Preventive Vaccine
1479760|NCT00063778|AIDS Vaccines
1479761|NCT00063778|Gene Products, gag
1479762|NCT00063778|HIV-1
1479763|NCT00063778|Dose-Response Relationship, Immunologic
1479764|NCT00063778|Injections, Subcutaneous
1479765|NCT00063765|NT-501
1479766|NCT00063765|CNTF
1479767|NCT00063765|Retinitis Pigmentosa
1479768|NCT00063765|RP
1479769|NCT00063726|Relapsed Multiple Myeloma
1479770|NCT00063726|Refractory Multiple Myeloma
1479771|NCT00063700|obesity in school aged children
1479772|NCT00063674|exercise
1479773|NCT00063674|eating
1479774|NCT00063674|dance
1479775|NCT00063674|health education
1479776|NCT00063674|obesity prevention
1479777|NCT00063674|diabetes prevention
1479778|NCT00063674|children
1479779|NCT00063661|fMRI
1479780|NCT00063661|Brain Activity
1479783|NCT00063661|Mechanism
1479784|NCT00063661|Parkinson Disease
1479785|NCT00063661|PD
1479786|NCT00063648|PTLD
1479787|NCT00063648|CTL Therapy
1479788|NCT00063648|Post-transplant lymphoproliferative disorder
1479789|NCT00063635|Non alcoholic fatty liver disease
1479790|NCT00063622|Non alcoholic steatohepatitis
1479791|NCT00063622|Steatohepatitis
1479792|NCT00063609|Prostate Cancer
1479793|NCT00063609|Bone Loss
1479794|NCT00063609|Osteoporosis
1479795|NCT00063609|Bone Mineral Density
1479796|NCT00063609|Androgen Deprivation Therapy
1479797|NCT00063596|Vitamin A
1479798|NCT00063596|Hepatitis B vaccine
1479799|NCT00063596|Immune responses
1479800|NCT00063596|T-cell subsets
1479801|NCT00063596|Chronic lung disease
1479802|NCT00063596|Cytokines, intracytoplasmic
1479803|NCT00063596|Antibodies, hepatitis B and tetanus toxoid
1479804|NCT00063583|Kidney disease
1479805|NCT00063570|Cancer of Breast
1479806|NCT00063570|Cancer of the Breast
1479807|NCT00063479|Osteogenesis Imperfecta
1479808|NCT00063479|OI
1479809|NCT00063479|bone markers
1479810|NCT00063479|fracture
1479811|NCT00063479|bone loss
1479812|NCT00063479|pediatric
1479813|NCT00063479|bisphosphonate
1479814|NCT00063479|brittle bone disease
1479815|NCT00063479|pamidronate
1479816|NCT00063427|Colorectal Cancer
1479817|NCT00063427|Colorectal Carcinoma
1479818|NCT00063427|Colorectal Tumors
1479819|NCT00063427|Neoplasms, Colorectal
1479820|NCT00063427|Colorectal Neoplasms
1479821|NCT00063401|ovarian
1479822|NCT00063401|primary peritoneal cancer
1479823|NCT00063401|fallopian tube cancer
1479824|NCT00063388|Non
1479825|NCT00063388|Small
1479826|NCT00063388|Cell
1479827|NCT00063388|Lung
1479828|NCT00063388|Cancer
1479829|NCT00063362|Depression
1479830|NCT00063323|Maintenance treatment
1479831|NCT00063323|Smoking relapse
1479832|NCT00063323|Bupropion
1479833|NCT00063323|Nicotine replacement
1479834|NCT00063310|Alzheimer disease
1479835|NCT00063310|Aging Women
1479836|NCT00063310|Hormone therapy
1479837|NCT00063297|schizophrenia with negative symptoms
1479838|NCT00063284|Electrical Stimulation
1479839|NCT00063284|Human Brain
1479840|NCT00063284|Parkinson Disease
1479841|NCT00063284|PD
1479842|NCT00063258|Non-Small Cell Lung Cancer
1479843|NCT00063258|Lung Cancer
1479844|NCT00063258|OSI-774
1479845|NCT00063258|Tarceva
1479846|NCT00063258|Carboplatin
1479847|NCT00063258|Paclitaxel
1479848|NCT00063258|NSCLC
1479849|NCT00063245|Motor Cortex
1479850|NCT00063245|Mood
1479851|NCT00063245|Reward
1479852|NCT00063245|Transcranial Magnetic Stimulation
1479853|NCT00063245|Magnetic Coil
1479854|NCT00063245|Healthy Volunteer
1479855|NCT00063245|HV
1479856|NCT00063232|Insulin
1479857|NCT00063232|Obesity
1479858|NCT00063232|Fatty Liver
1479859|NCT00063232|Diabetes
1479860|NCT00063232|Cirrhosis
1479861|NCT00063232|Metformin
1479862|NCT00063232|Insulin Resistance
1479863|NCT00063232|Nonalcoholic Steatohepatitis
1479864|NCT00063232|Hepatitis
1479865|NCT00063232|NASH
1479866|NCT00063219|Non-Small-Cell Lung Carcinoma
1479867|NCT00063219|Lung Cancer
1479868|NCT00063219|Cancer of Lung
1479869|NCT00063206|Depressive Disorder, Major
1479870|NCT00063206|Depression, Involutional
1479871|NCT00063193|Parkinson's disease
1479872|NCT00063193|minocycline
1479873|NCT00063193|creatine
1479874|NCT00063193|neuroprotection
1479875|NCT00063180|Diaschisis
1479876|NCT00063180|Glucose
1479877|NCT00063180|GABA
1479878|NCT00063180|N-Acetylaspartate
1479879|NCT00063180|Glutamate
1479880|NCT00063180|Stroke
1479881|NCT00063180|Healthy Volunteer
1479882|NCT00063180|HV
1479883|NCT00063154|Lung cancer
1479884|NCT00063115|Praxis Movements
1479885|NCT00063115|Pantomime
1479886|NCT00063115|Statistical Parametric Mapping
1479887|NCT00063115|Functional Connectivity
1479888|NCT00063115|Path Analysis
1479889|NCT00063115|Ideomotor Apraxia
1479890|NCT00063115|Healthy Volunteer
1479891|NCT00063115|HV
1479892|NCT00063089|Staphylococcal infection
1479893|NCT00063089|Gram positive bacteria
1479894|NCT00063089|Staphylococcus
1479895|NCT00063089|Staphylococcus aureus
1479896|NCT00063076|Alopecia Areata
1479897|NCT00063076|Alopecia Totalis
1479898|NCT00063076|Alopecia Universalis
1479899|NCT00063076|Targretin Gel
1479900|NCT00063063|NICHD Neonatal Research Network
1479901|NCT00063063|Extremely Low Birth Weight (ELBW)
1479902|NCT00063063|Prematurity
1479903|NCT00063050|Bone density
1479904|NCT00063050|Children
1479905|NCT00063050|Adolescents
1479906|NCT00063050|Behavior
1479907|NCT00063050|Health education
1479908|NCT00063050|Health promotion
1479909|NCT00063050|Physical fitness
1479910|NCT00063050|Diet
1479911|NCT00063050|Parent training
1479912|NCT00063050|Injury control
1479913|NCT00063037|Bone mass
1479914|NCT00063037|Calcium intake
1479915|NCT00063037|Prevention of osteoporosis
1479916|NCT00063037|Optimizing peak bone mass
1479917|NCT00063037|Bone mineral density
1479918|NCT00063024|Bone health
1479919|NCT00063024|Weight-bearing physical activity
1479920|NCT00063024|Calcium
1479921|NCT00063011|Weight-bearing exercise
1479922|NCT00063011|Calcium-rich diet
1479923|NCT00063011|Adolescents
1479924|NCT00063011|Females
1479925|NCT00063011|Bone mass
1479926|NCT00063011|Osteopenia
1479927|NCT00061880|recurrent cutaneous T-cell non-Hodgkin lymphoma
1479928|NCT00061880|stage I cutaneous T-cell non-Hodgkin lymphoma
1479929|NCT00061880|stage II cutaneous T-cell non-Hodgkin lymphoma
1479930|NCT00061880|stage III cutaneous T-cell non-Hodgkin lymphoma
1479931|NCT00061880|stage IV cutaneous T-cell non-Hodgkin lymphoma
1479932|NCT00061880|recurrent mycosis fungoides/Sezary syndrome
1479933|NCT00061880|stage I mycosis fungoides/Sezary syndrome
1479934|NCT00061880|stage II mycosis fungoides/Sezary syndrome
1479935|NCT00061880|stage III mycosis fungoides/Sezary syndrome
1479936|NCT00061880|stage IV mycosis fungoides/Sezary syndrome
1479937|NCT00062985|obesity treatment
1479938|NCT00062985|weight management
1479939|NCT00062985|managed care
1479940|NCT00062972|Multiple Sclerosis
1479941|NCT00062972|Cognitive Dysfunction
1479942|NCT00062972|Treatment Interventions
1479943|NCT00062972|Verbal memory deficits
1479944|NCT00062959|Adolescence
1479945|NCT00062959|Parenting
1479946|NCT00062959|School
1479947|NCT00062959|Primary Prevention
1479948|NCT00062959|School-based intervention
1479949|NCT00062946|Thalamus
1479950|NCT00062946|Cerebral Cortices
1479951|NCT00062946|Quantification
1479952|NCT00062946|Reproducibility
1479953|NCT00062946|Dopamine Release
1479954|NCT00062946|(18F) Fallypride
1479955|NCT00062946|D-Amphetamine
1479956|NCT00062946|Alpha-Methyl-Para-Tyrosine (AMPT)
1479957|NCT00062946|PET
1479958|NCT00062946|Dopamine D2 Receptor
1479959|NCT00062946|Healthy Volunteer
1479960|NCT00062946|HV
1479961|NCT00062933|Clinical Response
1479962|NCT00062933|Duration of Response
1479963|NCT00062933|Quality of Life
1479964|NCT00062933|Hyperthermia
1479965|NCT00062933|Survival
1479966|NCT00062933|Melanoma
1479967|NCT00062933|Ocular Melanoma
1479968|NCT00062933|Eye Cancer
1479969|NCT00062894|Iodine I 131 Tositumomab
1479970|NCT00062894|BEXXAR
1479971|NCT00062894|non-Hodgkin's lymphoma
1479972|NCT00062881|Cancer
1479973|NCT00062881|Leukemia
1479974|NCT00062881|Lymphoma
1479975|NCT00062881|Solid Tumor
1479976|NCT00062868|Lymphoma
1479977|NCT00062868|EBV-T/NK lymphoproliferative disease
1479978|NCT00062868|Severe Chronic EBV
1479979|NCT00062868|LMP1/2
1479980|NCT00062868|CTL
1479981|NCT00062868|EBV
1479982|NCT00062868|Relapse
1479983|NCT00062855|GENE MODIFIED AUTOLOGOUS NEUROBLASTOMA CELLS
1479984|NCT00062855|Gene Therapy
1479985|NCT00062829|Teen driving
1479986|NCT00062829|Adolescent risk behavior
1479987|NCT00062829|Parenting
1479988|NCT00062829|Checkpoints Program
1479989|NCT00062829|Health Education
1479990|NCT00062816|Hepatitis
1479991|NCT00062816|Chronic
1479992|NCT00062790|Testosterone
1479993|NCT00062790|DHT
1479994|NCT00062790|TURP
1479995|NCT00062777|Genetics
1479996|NCT00062777|Populations
1479997|NCT00062777|CVD Risk
1479998|NCT00062777|Gene Mapping
1479999|NCT00062777|Epidemiology
1480000|NCT00062777|Framingham Study
1480001|NCT00062777|Vascular Diseases
1480002|NCT00062764|Insulin Resistance
1480003|NCT00062764|Obesity
1480004|NCT00062764|Fatty Liver
1480005|NCT00062764|Cirrhosis
1480006|NCT00062764|Diabetes
1480007|NCT00062764|Pioglitazone
1480008|NCT00062764|Thiazolidinediones
1480009|NCT00062764|Peroxisome Proliferator-Advanced Receptor Gamma
1480010|NCT00062764|PPAR Gama
1480011|NCT00062764|Nonalcoholic Steatohepatitis
1480012|NCT00062764|Hepatitis
1480013|NCT00062764|Non-Alcoholic Steatohepatitis
1480014|NCT00062764|NASH
1480015|NCT00062751|breast
1480016|NCT00062751|neoplasms
1480017|NCT00062738|Parkinson's disease
1480018|NCT00062738|Parkinson disease
1480019|NCT00062738|depression
1480020|NCT00062738|antidepressants
1480021|NCT00062738|nortriptyline
1480022|NCT00062738|paroxetine
1480023|NCT00062712|Immunosuppression
1480024|NCT00062712|Transplant
1480025|NCT00062712|Kidney Transplant
1480026|NCT00062686|Lapatinib
1480027|NCT00062686|Metastatic Breast Cancer
1480028|NCT00062686|HERCEPTIN refractory
1480029|NCT00062634|Female condom use
1480030|NCT00062634|Male condom use
1480031|NCT00062634|AIDS education
1480032|NCT00062634|AIDS prevention
1480033|NCT00062634|HIV Seronegativity
1480034|NCT00062621|Immune tolerance
1480035|NCT00062621|Graft vs host disease
1480036|NCT00062621|Kidney Failure
1480037|NCT00062621|Kidney diseases
1480038|NCT00062621|End Stage Renal Disease
1480039|NCT00062621|Multiple Myeloma
1480040|NCT00062621|Bone Marrow Transplant
1480041|NCT00062621|Kidney Transplant
1480042|NCT00062621|Renal Transplant
1480043|NCT00062621|Tolerance
1480044|NCT00062621|Chimerism
1480045|NCT00062621|ESRD
1480046|NCT00062608|Abdominal
1480047|NCT00062595|Menopause
1480048|NCT00062595|Vitamin K
1480049|NCT00062595|Bone turnover
1480050|NCT00062595|Bone Density
1480051|NCT00062582|Roflumilast
1480052|NCT00062582|Chronic Obstructive Pulmonary Disease
1480053|NCT00062582|COPD
1480054|NCT00062569|Alzheimer disease
1480055|NCT00062569|Resistiveness to baths
1480056|NCT00062569|Caregiver stress
1480057|NCT00062569|Bathing support intervention
1480058|NCT00062569|Reminiscence
1480059|NCT00062569|Agitated behavior
1480060|NCT00062569|Resistiveness to care
1480061|NCT00062556|Intermittent Claudication
1480062|NCT00062556|Peripheral Arterial Disease
1480063|NCT00062556|Atherosclerosis
1480064|NCT00062556|Niacin
1480065|NCT00062556|Lovastatin
1480066|NCT00062556|PAD
1480067|NCT00062556|IC
1480068|NCT00062543|Severe hepatic dysfunction post stem cell transplantation
1480069|NCT00062543|Stem Cell Transplantation
1480070|NCT00062543|Hepatic Artery Infusion
1480071|NCT00062543|Liver Diseases
1480072|NCT00062543|CD34+ Cells
1480073|NCT00062543|SCT
1480074|NCT00062530|AIDS
1480075|NCT00062530|HIV seronegativity
1480076|NCT00062530|HIV preventive vaccine
1480077|NCT00062517|Amygdala
1480078|NCT00062517|Generalized Anxiety Disorder
1480079|NCT00062517|Anxiety Disorder
1480080|NCT00062517|GAD
1480081|NCT00062517|Social Anxiety Disorder
1480082|NCT00062517|SAD
1480083|NCT00062465|DMARD
1480084|NCT00062465|Clinical Trial
1480085|NCT00062465|Thunder God Vine
1480086|NCT00062465|Chinese Herb
1480087|NCT00062465|Rheumatoid Arthritis
1480088|NCT00062465|RA
1480089|NCT00062452|Esophageal
1480090|NCT00062452|Airway
1480091|NCT00062439|stage II non-small cell lung cancer
1480092|NCT00062439|stage IIIA non-small cell lung cancer
1480093|NCT00062439|stage IIIB non-small cell lung cancer
1480094|NCT00062426|adenocarcinoma of the colon
1480095|NCT00062426|adenocarcinoma of the rectum
1480096|NCT00062426|recurrent colon cancer
1480097|NCT00062426|stage IV colon cancer
1480098|NCT00062426|recurrent rectal cancer
1480099|NCT00062426|stage IV rectal cancer
1480100|NCT00062400|sexual dysfunction and infertility
1480101|NCT00062400|sexuality and reproductive issues
1480102|NCT00062400|psychosocial effects of cancer and its treatment
1480103|NCT00062400|stage II breast cancer
1480104|NCT00062400|stage IA breast cancer
1480105|NCT00062400|stage IB breast cancer
1480106|NCT00062387|stage IV squamous cell carcinoma of the hypopharynx
1480107|NCT00062387|stage IV squamous cell carcinoma of the larynx
1480108|NCT00062387|stage IV squamous cell carcinoma of the lip and oral cavity
1480109|NCT00062387|stage IV squamous cell carcinoma of the nasopharynx
1480110|NCT00062387|stage IV squamous cell carcinoma of the oropharynx
1480111|NCT00062387|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1480112|NCT00062387|recurrent squamous cell carcinoma of the hypopharynx
1480113|NCT00062387|recurrent squamous cell carcinoma of the larynx
1480114|NCT00062387|recurrent squamous cell carcinoma of the lip and oral cavity
1480115|NCT00062387|recurrent squamous cell carcinoma of the nasopharynx
1480116|NCT00062387|recurrent squamous cell carcinoma of the oropharynx
1480117|NCT00062387|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1480118|NCT00062387|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1480119|NCT00062387|recurrent metastatic squamous neck cancer with occult primary
1480120|NCT00062387|recurrent salivary gland cancer
1480121|NCT00062387|salivary gland squamous cell carcinoma
1480122|NCT00062387|stage IV salivary gland cancer
1480123|NCT00062348|recurrent squamous cell carcinoma of the hypopharynx
1480124|NCT00062348|recurrent squamous cell carcinoma of the larynx
1480125|NCT00062348|recurrent squamous cell carcinoma of the lip and oral cavity
1480126|NCT00062348|recurrent squamous cell carcinoma of the nasopharynx
1480127|NCT00062348|recurrent squamous cell carcinoma of the oropharynx
1480128|NCT00062348|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1480129|NCT00062348|stage IV squamous cell carcinoma of the hypopharynx
1480130|NCT00062348|stage IV squamous cell carcinoma of the larynx
1480131|NCT00062348|stage IV squamous cell carcinoma of the lip and oral cavity
1480132|NCT00062348|stage IV squamous cell carcinoma of the nasopharynx
1480133|NCT00062348|stage IV squamous cell carcinoma of the oropharynx
1480134|NCT00062348|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1480135|NCT00062348|untreated metastatic squamous neck cancer with occult primary
1480136|NCT00062348|recurrent thyroid cancer
1480137|NCT00062348|stage IV follicular thyroid cancer
1480138|NCT00062348|stage IV papillary thyroid cancer
1480139|NCT00062348|stage IVA colon cancer
1480140|NCT00062348|stage IVB colon cancer
1480141|NCT00062348|recurrent colon cancer
1480142|NCT00062348|adenocarcinoma of the colon
1480143|NCT00062348|recurrent rectal cancer
1480144|NCT00062348|stage IVA rectal cancer
1480145|NCT00062348|stage IVB rectal cancer
1480146|NCT00062348|adenocarcinoma of the rectum
1480147|NCT00062348|anaplastic thyroid cancer
1480148|NCT00062348|insular thyroid cancer
1480149|NCT00062348|thyroid gland medullary carcinoma
1480150|NCT00062348|liver metastases
1480151|NCT00062348|stage I squamous cell carcinoma of the hypopharynx
1480152|NCT00062348|stage I squamous cell carcinoma of the larynx
1480153|NCT00062348|stage I squamous cell carcinoma of the lip and oral cavity
1480154|NCT00062348|stage I squamous cell carcinoma of the nasopharynx
1480155|NCT00062348|stage I squamous cell carcinoma of the oropharynx
1480156|NCT00062348|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1480157|NCT00062348|stage II squamous cell carcinoma of the hypopharynx
1480158|NCT00062348|stage II squamous cell carcinoma of the larynx
1480159|NCT00062348|stage II squamous cell carcinoma of the lip and oral cavity
1480160|NCT00062348|stage II squamous cell carcinoma of the nasopharynx
1480161|NCT00062348|stage II squamous cell carcinoma of the oropharynx
1480162|NCT00062348|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1480163|NCT00062348|stage III squamous cell carcinoma of the hypopharynx
1480164|NCT00062348|stage III squamous cell carcinoma of the larynx
1480165|NCT00062348|stage III squamous cell carcinoma of the lip and oral cavity
1480166|NCT00062348|stage III squamous cell carcinoma of the nasopharynx
1480167|NCT00062348|stage III squamous cell carcinoma of the oropharynx
1480168|NCT00062348|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1480169|NCT00062348|stage I papillary thyroid cancer
1480170|NCT00062348|stage II papillary thyroid cancer
1480171|NCT00062348|stage III papillary thyroid cancer
1480172|NCT00062348|stage I follicular thyroid cancer
1480173|NCT00062348|stage II follicular thyroid cancer
1480174|NCT00062348|stage III follicular thyroid cancer
1480175|NCT00062348|recurrent metastatic squamous neck cancer with occult primary
1480176|NCT00062348|recurrent salivary gland cancer
1480177|NCT00062348|salivary gland squamous cell carcinoma
1480178|NCT00062348|stage I salivary gland cancer
1480179|NCT00062348|stage II salivary gland cancer
1480180|NCT00062348|stage III salivary gland cancer
1480181|NCT00062348|stage IV salivary gland cancer
1480182|NCT00062348|tongue cancer
1480183|NCT00062335|stage I non-small cell lung cancer
1480184|NCT00062335|stage II non-small cell lung cancer
1480185|NCT00062335|stage IIIA non-small cell lung cancer
1480186|NCT00062322|limited stage small cell lung cancer
1480187|NCT00062309|stage II prostate cancer
1480188|NCT00062309|stage III prostate cancer
1480189|NCT00062309|adenocarcinoma of the prostate
1480190|NCT00062296|B-cell chronic lymphocytic leukemia
1480191|NCT00062296|refractory chronic lymphocytic leukemia
1480192|NCT00062296|recurrent adult diffuse large cell lymphoma
1480193|NCT00062296|recurrent adult diffuse mixed cell lymphoma
1480194|NCT00062296|recurrent adult diffuse small cleaved cell lymphoma
1480195|NCT00062296|recurrent adult Burkitt lymphoma
1480196|NCT00062296|recurrent adult immunoblastic large cell lymphoma
1480197|NCT00062296|recurrent grade 1 follicular lymphoma
1480198|NCT00062296|recurrent grade 2 follicular lymphoma
1480199|NCT00062296|recurrent grade 3 follicular lymphoma
1480200|NCT00062296|recurrent mantle cell lymphoma
1480201|NCT00062296|recurrent adult lymphoblastic lymphoma
1480202|NCT00062296|recurrent marginal zone lymphoma
1480203|NCT00062296|recurrent small lymphocytic lymphoma
1480204|NCT00062296|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1480205|NCT00062296|nodal marginal zone B-cell lymphoma
1480206|NCT00062296|splenic marginal zone lymphoma
1480207|NCT00062283|advanced malignant mesothelioma
1480208|NCT00062283|recurrent malignant mesothelioma
1480209|NCT00062283|metastatic osteosarcoma
1480210|NCT00062283|recurrent osteosarcoma
1480211|NCT00062283|recurrent adult soft tissue sarcoma
1480212|NCT00062283|stage IV adult soft tissue sarcoma
1480213|NCT00062283|chondrosarcoma
1480214|NCT00062283|recurrent non-small cell lung cancer
1480215|NCT00062283|stage IIIB non-small cell lung cancer
1480216|NCT00062283|stage IV non-small cell lung cancer
1480217|NCT00062283|adenocarcinoma of the pancreas
1480218|NCT00062283|recurrent pancreatic cancer
1480219|NCT00062283|stage III adult soft tissue sarcoma
1480220|NCT00062283|stage II adult soft tissue sarcoma
1480221|NCT00062283|stage IV pancreatic cancer
1480222|NCT00062270|stage IIIA non-small cell lung cancer
1480223|NCT00062270|stage IIIB non-small cell lung cancer
1480224|NCT00062257|recurrent gastric cancer
1480225|NCT00062257|stage IV gastric cancer
1480226|NCT00062257|adenocarcinoma of the stomach
1480227|NCT00062231|infection
1480228|NCT00062231|neutropenia
1480229|NCT00062231|fever, sweats, and hot flashes
1480230|NCT00062231|unspecified adult solid tumor, protocol specific
1480231|NCT00062231|stage I adult Hodgkin lymphoma
1480232|NCT00062231|stage II adult Hodgkin lymphoma
1480233|NCT00062231|stage III adult Hodgkin lymphoma
1480234|NCT00062231|stage IV adult Hodgkin lymphoma
1480235|NCT00062231|monoclonal gammopathy of undetermined significance
1480236|NCT00062231|recurrent adult Hodgkin lymphoma
1480237|NCT00062231|stage I cutaneous T-cell non-Hodgkin lymphoma
1480238|NCT00062231|stage II cutaneous T-cell non-Hodgkin lymphoma
1480239|NCT00062231|stage III cutaneous T-cell non-Hodgkin lymphoma
1480240|NCT00062231|stage IV cutaneous T-cell non-Hodgkin lymphoma
1480241|NCT00062231|recurrent cutaneous T-cell non-Hodgkin lymphoma
1480242|NCT00062231|isolated plasmacytoma of bone
1480243|NCT00062231|extramedullary plasmacytoma
1480244|NCT00062231|refractory multiple myeloma
1480245|NCT00062231|stage 0 chronic lymphocytic leukemia
1480246|NCT00062231|Waldenstrom macroglobulinemia
1480247|NCT00062231|stage I multiple myeloma
1480248|NCT00062231|stage II multiple myeloma
1480249|NCT00062231|stage III multiple myeloma
1480250|NCT00062231|stage I chronic lymphocytic leukemia
1480251|NCT00062231|stage II chronic lymphocytic leukemia
1480252|NCT00062231|stage III chronic lymphocytic leukemia
1480253|NCT00062231|stage IV chronic lymphocytic leukemia
1480254|NCT00062231|recurrent adult acute lymphoblastic leukemia
1480255|NCT00062231|relapsing chronic myelogenous leukemia
1480256|NCT00062231|refractory chronic lymphocytic leukemia
1480257|NCT00062231|accelerated phase chronic myelogenous leukemia
1480258|NCT00062231|blastic phase chronic myelogenous leukemia
1480259|NCT00062231|chronic phase chronic myelogenous leukemia
1480260|NCT00062231|meningeal chronic myelogenous leukemia
1480261|NCT00062231|adult acute myeloid leukemia in remission
1480262|NCT00062231|polycythemia vera
1480263|NCT00062231|primary myelofibrosis
1480264|NCT00062231|essential thrombocythemia
1480265|NCT00062231|progressive hairy cell leukemia, initial treatment
1480266|NCT00062231|refractory hairy cell leukemia
1480267|NCT00062231|contiguous stage II grade 1 follicular lymphoma
1480268|NCT00062231|contiguous stage II grade 2 follicular lymphoma
1480269|NCT00062231|contiguous stage II grade 3 follicular lymphoma
1480270|NCT00062231|noncontiguous stage II grade 1 follicular lymphoma
1480271|NCT00062231|noncontiguous stage II grade 2 follicular lymphoma
1480272|NCT00062231|noncontiguous stage II grade 3 follicular lymphoma
1480273|NCT00062231|recurrent grade 1 follicular lymphoma
1480274|NCT00062231|recurrent grade 2 follicular lymphoma
1480275|NCT00062231|recurrent grade 3 follicular lymphoma
1480276|NCT00062231|stage I grade 1 follicular lymphoma
1480277|NCT00062231|stage I grade 2 follicular lymphoma
1480278|NCT00062231|stage I grade 3 follicular lymphoma
1480279|NCT00062231|stage III grade 1 follicular lymphoma
1480280|NCT00062231|stage III grade 2 follicular lymphoma
1480281|NCT00062231|stage III grade 3 follicular lymphoma
1480282|NCT00062231|stage IV grade 1 follicular lymphoma
1480283|NCT00062231|stage IV grade 2 follicular lymphoma
1480284|NCT00062231|stage IV grade 3 follicular lymphoma
1480285|NCT00062231|contiguous stage II adult diffuse large cell lymphoma
1480286|NCT00062231|contiguous stage II adult diffuse mixed cell lymphoma
1480287|NCT00062231|contiguous stage II adult diffuse small cleaved cell lymphoma
1480288|NCT00062231|contiguous stage II adult Burkitt lymphoma
1480289|NCT00062231|noncontiguous stage II adult diffuse large cell lymphoma
1480290|NCT00062231|noncontiguous stage II adult diffuse mixed cell lymphoma
1480291|NCT00062231|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1480292|NCT00062231|noncontiguous stage II adult Burkitt lymphoma
1480293|NCT00062231|recurrent adult diffuse large cell lymphoma
1480294|NCT00062231|recurrent adult diffuse mixed cell lymphoma
1480295|NCT00062231|recurrent adult diffuse small cleaved cell lymphoma
1480296|NCT00062231|recurrent adult Burkitt lymphoma
1480297|NCT00062231|stage I adult diffuse large cell lymphoma
1480298|NCT00062231|stage I adult diffuse mixed cell lymphoma
1480299|NCT00062231|stage I adult diffuse small cleaved cell lymphoma
1480300|NCT00062231|stage I adult Burkitt lymphoma
1480301|NCT00062231|stage III adult diffuse large cell lymphoma
1480606|NCT00061360|Bone Marrow Failure
1480302|NCT00062231|stage III adult diffuse mixed cell lymphoma
1480303|NCT00062231|stage III adult diffuse small cleaved cell lymphoma
1480304|NCT00062231|stage III adult Burkitt lymphoma
1480305|NCT00062231|stage IV adult diffuse large cell lymphoma
1480306|NCT00062231|stage IV adult diffuse mixed cell lymphoma
1480307|NCT00062231|stage IV adult diffuse small cleaved cell lymphoma
1480308|NCT00062231|stage IV adult Burkitt lymphoma
1480309|NCT00062231|stage I adult immunoblastic large cell lymphoma
1480310|NCT00062231|stage I adult lymphoblastic lymphoma
1480311|NCT00062231|chronic myelomonocytic leukemia
1480312|NCT00062231|T-cell large granular lymphocyte leukemia
1480313|NCT00062231|acute undifferentiated leukemia
1480314|NCT00062231|stage III adult immunoblastic large cell lymphoma
1480315|NCT00062231|stage IV adult immunoblastic large cell lymphoma
1480316|NCT00062231|recurrent adult immunoblastic large cell lymphoma
1480317|NCT00062231|stage III adult lymphoblastic lymphoma
1480318|NCT00062231|stage IV adult lymphoblastic lymphoma
1480319|NCT00062231|recurrent adult lymphoblastic lymphoma
1480320|NCT00062231|recurrent adult T-cell leukemia/lymphoma
1480321|NCT00062231|stage I adult T-cell leukemia/lymphoma
1480322|NCT00062231|stage II adult T-cell leukemia/lymphoma
1480323|NCT00062231|stage III adult T-cell leukemia/lymphoma
1480324|NCT00062231|stage IV adult T-cell leukemia/lymphoma
1480325|NCT00062231|de novo myelodysplastic syndromes
1480326|NCT00062231|previously treated myelodysplastic syndromes
1480327|NCT00062231|secondary myelodysplastic syndromes
1480328|NCT00062231|prolymphocytic leukemia
1480329|NCT00062231|primary systemic amyloidosis
1480330|NCT00062231|intraocular lymphoma
1480331|NCT00062231|stage I mantle cell lymphoma
1480332|NCT00062231|stage III mantle cell lymphoma
1480333|NCT00062231|stage IV mantle cell lymphoma
1480334|NCT00062231|contiguous stage II mantle cell lymphoma
1480335|NCT00062231|noncontiguous stage II mantle cell lymphoma
1480336|NCT00062231|recurrent mantle cell lymphoma
1480337|NCT00062231|anaplastic large cell lymphoma
1480338|NCT00062231|angioimmunoblastic T-cell lymphoma
1480339|NCT00062231|recurrent mycosis fungoides/Sezary syndrome
1480340|NCT00062231|stage I mycosis fungoides/Sezary syndrome
1480341|NCT00062231|stage II mycosis fungoides/Sezary syndrome
1480342|NCT00062231|stage III mycosis fungoides/Sezary syndrome
1480343|NCT00062231|stage IV mycosis fungoides/Sezary syndrome
1480344|NCT00062231|chronic eosinophilic leukemia
1480345|NCT00062231|chronic neutrophilic leukemia
1480346|NCT00062231|recurrent adult acute myeloid leukemia
1480347|NCT00062231|adult acute lymphoblastic leukemia in remission
1480348|NCT00062231|contiguous stage II adult lymphoblastic lymphoma
1480349|NCT00062231|noncontiguous stage II adult lymphoblastic lymphoma
1480350|NCT00062231|contiguous stage II adult immunoblastic large cell lymphoma
1480351|NCT00062231|noncontiguous stage II adult immunoblastic large cell lymphoma
1480352|NCT00062231|atypical chronic myeloid leukemia, BCR-ABL1 negative
1480353|NCT00062231|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1480354|NCT00062231|contiguous stage II small lymphocytic lymphoma
1480355|NCT00062231|contiguous stage II marginal zone lymphoma
1480356|NCT00062231|noncontiguous stage II small lymphocytic lymphoma
1480357|NCT00062231|noncontiguous stage II marginal zone lymphoma
1480358|NCT00062231|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1480359|NCT00062231|nodal marginal zone B-cell lymphoma
1480360|NCT00062231|splenic marginal zone lymphoma
1480361|NCT00062231|recurrent marginal zone lymphoma
1480362|NCT00062231|recurrent small lymphocytic lymphoma
1480363|NCT00062231|stage I marginal zone lymphoma
1480364|NCT00062231|stage I small lymphocytic lymphoma
1480365|NCT00062231|stage III small lymphocytic lymphoma
1480366|NCT00062231|stage III marginal zone lymphoma
1480367|NCT00062231|stage IV small lymphocytic lymphoma
1480368|NCT00062231|stage IV marginal zone lymphoma
1480369|NCT00062231|adult acute myeloid leukemia with t(8;21)(q22;q22)
1480370|NCT00062231|adult acute myeloid leukemia with t(16;16)(p13;q22)
1480371|NCT00062231|adult acute myeloid leukemia with inv(16)(p13;q22)
1480372|NCT00062231|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1480373|NCT00062231|adult acute myeloid leukemia with t(15;17)(q22;q12)
1480374|NCT00062205|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1480375|NCT00062179|stage IIIA non-small cell lung cancer
1480376|NCT00062166|Imaging Studies
1480377|NCT00062166|Rate of Tumor Growth
1480378|NCT00062166|Familial Cancer Syndrome
1480379|NCT00062166|Surgical Resection
1480380|NCT00062140|recurrent adult diffuse large cell lymphoma
1480381|NCT00062140|recurrent adult diffuse mixed cell lymphoma
1480382|NCT00062140|recurrent adult diffuse small cleaved cell lymphoma
1480383|NCT00062140|recurrent adult Burkitt lymphoma
1480384|NCT00062140|recurrent adult Hodgkin lymphoma
1480385|NCT00062140|recurrent adult immunoblastic large cell lymphoma
1480386|NCT00062140|recurrent adult lymphoblastic lymphoma
1480387|NCT00062140|recurrent cutaneous T-cell non-Hodgkin lymphoma
1480388|NCT00062140|recurrent grade 1 follicular lymphoma
1480389|NCT00062140|recurrent grade 2 follicular lymphoma
1480390|NCT00062140|recurrent grade 3 follicular lymphoma
1480391|NCT00062140|recurrent mantle cell lymphoma
1480392|NCT00062140|noncontiguous stage II adult diffuse large cell lymphoma
1480393|NCT00062140|noncontiguous stage II adult diffuse mixed cell lymphoma
1480394|NCT00062140|noncontiguous stage II adult Burkitt lymphoma
1480395|NCT00062140|noncontiguous stage II adult immunoblastic large cell lymphoma
1480396|NCT00062140|noncontiguous stage II adult lymphoblastic lymphoma
1480397|NCT00062140|noncontiguous stage II grade 3 follicular lymphoma
1480398|NCT00062140|noncontiguous stage II mantle cell lymphoma
1480399|NCT00062140|stage III adult lymphoblastic lymphoma
1480400|NCT00062140|stage IV adult lymphoblastic lymphoma
1480401|NCT00062140|stage III adult Burkitt lymphoma
1480402|NCT00062140|stage IV adult Burkitt lymphoma
1480403|NCT00062140|recurrent adult acute myeloid leukemia
1480404|NCT00062140|untreated adult acute myeloid leukemia
1480405|NCT00062140|accelerated phase chronic myelogenous leukemia
1480406|NCT00062140|blastic phase chronic myelogenous leukemia
1480407|NCT00062140|chronic phase chronic myelogenous leukemia
1480408|NCT00062140|meningeal chronic myelogenous leukemia
1480409|NCT00062140|relapsing chronic myelogenous leukemia
1480410|NCT00062140|de novo myelodysplastic syndromes
1480411|NCT00062140|previously treated myelodysplastic syndromes
1480412|NCT00062140|secondary myelodysplastic syndromes
1480413|NCT00062140|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1480414|NCT00062140|noncontiguous stage II grade 1 follicular lymphoma
1480415|NCT00062140|noncontiguous stage II grade 2 follicular lymphoma
1480416|NCT00062140|recurrent mycosis fungoides/Sezary syndrome
1480417|NCT00062140|secondary acute myeloid leukemia
1480418|NCT00062140|stage III grade 1 follicular lymphoma
1480419|NCT00062140|stage III grade 2 follicular lymphoma
1480420|NCT00062140|stage III adult diffuse small cleaved cell lymphoma
1480421|NCT00062140|stage III grade 3 follicular lymphoma
1480422|NCT00062140|stage III adult diffuse large cell lymphoma
1480423|NCT00062140|stage III adult diffuse mixed cell lymphoma
1480424|NCT00062140|stage III adult immunoblastic large cell lymphoma
1480425|NCT00062140|stage III mantle cell lymphoma
1480426|NCT00062140|stage IV grade 3 follicular lymphoma
1480427|NCT00062140|stage IV adult diffuse large cell lymphoma
1480428|NCT00062140|stage IV adult diffuse mixed cell lymphoma
1480429|NCT00062140|stage IV adult immunoblastic large cell lymphoma
1480430|NCT00062140|stage IV mantle cell lymphoma
1480431|NCT00062140|stage IV adult diffuse small cleaved cell lymphoma
1480432|NCT00062140|stage IV grade 1 follicular lymphoma
1480433|NCT00062140|stage IV grade 2 follicular lymphoma
1480434|NCT00062140|recurrent adult acute lymphoblastic leukemia
1480435|NCT00062140|untreated adult acute lymphoblastic leukemia
1480436|NCT00062140|atypical chronic myeloid leukemia
1480437|NCT00062140|myelodysplastic/myeloproliferative disease, unclassifiable
1480438|NCT00062140|noncontiguous stage II small lymphocytic lymphoma
1480439|NCT00062140|noncontiguous stage II marginal zone lymphoma
1480440|NCT00062140|recurrent marginal zone lymphoma
1480441|NCT00062140|recurrent small lymphocytic lymphoma
1480442|NCT00062140|stage III small lymphocytic lymphoma
1480443|NCT00062140|stage III marginal zone lymphoma
1480444|NCT00062140|stage IV small lymphocytic lymphoma
1480445|NCT00062140|stage IV marginal zone lymphoma
1480446|NCT00062140|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1480447|NCT00062140|nodal marginal zone B-cell lymphoma
1480448|NCT00062140|splenic marginal zone lymphoma
1480449|NCT00062140|adult acute myeloid leukemia with t(8;21)(q22;q22)
1480450|NCT00062140|adult acute myeloid leukemia with t(16;16)(p13;q22)
1480451|NCT00062140|adult acute myeloid leukemia with inv(16)(p13;q22)
1480452|NCT00062140|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1480453|NCT00062140|adult acute myeloid leukemia with t(15;17)(q22;q12)
1480454|NCT00062114|recurrent adult diffuse large cell lymphoma
1480455|NCT00062114|recurrent adult diffuse mixed cell lymphoma
1480456|NCT00062114|recurrent adult immunoblastic large cell lymphoma
1480457|NCT00062062|stage IV non-small cell lung cancer
1480458|NCT00062062|stage IIIB non-small cell lung cancer
1480459|NCT00062049|unspecified adult solid tumor, protocol specific
1480460|NCT00062036|stage IV melanoma
1480461|NCT00062036|recurrent melanoma
1480462|NCT00062023|colorectal cancer
1480463|NCT00062023|stage I colon cancer
1480464|NCT00062023|stage II colon cancer
1480465|NCT00062023|stage III colon cancer
1480466|NCT00062023|stage IV colon cancer
1480467|NCT00062010|recurrent small cell lung cancer
1480468|NCT00061997|non-small cell lung cancer
1480469|NCT00061997|small cell lung cancer
1480470|NCT00061997|precancerous condition
1480471|NCT00061984|adult angiosarcoma
1480472|NCT00061984|adult epithelioid sarcoma
1480473|NCT00061984|adult fibrosarcoma
1480474|NCT00061984|adult leiomyosarcoma
1480475|NCT00061984|adult liposarcoma
1480476|NCT00061984|adult rhabdomyosarcoma
1480477|NCT00061984|adult synovial sarcoma
1480478|NCT00061984|stage III adult soft tissue sarcoma
1480479|NCT00061984|adult malignant fibrous histiocytoma
1480480|NCT00061984|adult neurofibrosarcoma
1480481|NCT00061984|stage II adult soft tissue sarcoma
1480482|NCT00061984|stage IV adult soft tissue sarcoma
1480483|NCT00061919|extensive stage small cell lung cancer
1480484|NCT00061919|limited stage small cell lung cancer
1480485|NCT00061906|insular thyroid cancer
1480486|NCT00061906|recurrent thyroid cancer
1480487|NCT00061906|stage II follicular thyroid cancer
1480488|NCT00061906|stage II papillary thyroid cancer
1480489|NCT00061906|stage IV follicular thyroid cancer
1480490|NCT00061906|stage IV papillary thyroid cancer
1480491|NCT00061893|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1480492|NCT00061867|adenocarcinoma of the prostate
1480493|NCT00061867|stage III prostate cancer
1480494|NCT00061867|stage IV prostate cancer
1480495|NCT00061854|stage IIIA non-small cell lung cancer
1480496|NCT00061854|stage IIIB non-small cell lung cancer
1480497|NCT00061854|stage IV non-small cell lung cancer
1480498|NCT00061854|recurrent non-small cell lung cancer
1480499|NCT00061789|Schizophrenia
1480500|NCT00061789|SPECT
1480501|NCT00061789|Nicotinic Acetylcholine Receptors
1480502|NCT00061789|Cigarette Smoking
1480503|NCT00061789|Cognitive Dysfunction
1480504|NCT00061789|Reproducibility
1480505|NCT00061789|Quantification
1480506|NCT00061789|Healthy Volunteer
1480507|NCT00061789|HV
1480508|NCT00061776|Dermal assessment
1480509|NCT00061776|Pain measurement
1480510|NCT00061776|Diary
1480511|NCT00061776|Shingles
1480512|NCT00061776|Neuropathy
1480513|NCT00061776|Analgesics/*therapeutic use
1480514|NCT00061776|Capsaicin/*administration & dosage/adverse effects
1480515|NCT00061776|Herpes Zoster/*complications/drug therapy
1480516|NCT00061776|Neuralgia/*drug therapy/etiology
1480517|NCT00061776|Pain
1480518|NCT00061776|Peripheral Nervous System Diseases/*complications
1480519|NCT00061763|beta-thalassemia
1480520|NCT00061763|iron overload
1480521|NCT00061763|deferoxamine
1480522|NCT00061763|Myelodysplastic Syndromes
1480523|NCT00061763|Fanconi Syndrome
1480524|NCT00061763|Anemia, Diamond-Blackfan
1480525|NCT00061763|Anemia, Aplastic
1480526|NCT00061750|Thalassemia, iron overload, deferoxamine, hemosiderosis
1480527|NCT00061737|Pediatric IBD
1480528|NCT00061737|Inflammatory
1480529|NCT00061737|Bowel
1480530|NCT00061724|Esophageal
1480531|NCT00061724|Reflux
1480532|NCT00061672|Non-Hodgkin's Lymphoma (NHL)
1480533|NCT00061672|Hodgkin's Lymphoma (HL)
1480534|NCT00061659|high grade locally advanced/metastatic soft tissue sarcoma
1480535|NCT00061646|Stage IIIb with pleural effusion or IV NSCLC
1480536|NCT00061620|Investigational
1480537|NCT00061620|Chemotherapy
1480538|NCT00061620|Hematologic Malignancies
1480539|NCT00061620|Nucleoside analogue
1480540|NCT00061607|Motor Neuron Disease
1480541|NCT00061607|Neuromuscular Disease
1480542|NCT00061607|Histone Deacytelase Inhibitors
1480543|NCT00061607|Spinal Muscular Atrophy
1480544|NCT00061607|SMA
1480545|NCT00061594|Neovascular age-related macular degeneration
1480557|NCT00061568|Stem Cell Transplant
1480558|NCT00061568|Low Dose Radiation
1480559|NCT00061568|Alemtuzumab (Campath)
1480560|NCT00061568|Sirolimus (Rapamune)
1480561|NCT00061568|Donor Apheresis
1480562|NCT00061568|Graft-Versus-Host Disease
1480563|NCT00061568|Graft-Versus-Marrow
1480564|NCT00061568|Host-Donor Chimerism
1480565|NCT00061568|Peripheral Blood Stem Cells
1480566|NCT00061568|Low Dose Irradiation
1480567|NCT00061568|Sickle Cell Anemia
1480568|NCT00061568|SCA
1480569|NCT00061568|Thalassemia
1480570|NCT00061568|Diamond-Blackfan Anemia
1480571|NCT00061568|DBA
1480572|NCT00061542|Glaucoma
1480573|NCT00061542|Ocular Hypertension
1480574|NCT00061529|Open-Angle Glaucoma
1480575|NCT00061529|Ocular Hypertension
1480576|NCT00061516|Glaucoma
1480577|NCT00061516|Ocular Hypertension
1480578|NCT00061503|Glaucoma
1480579|NCT00061503|Ocular Hypertension
1480580|NCT00061490|Osteoarthritis
1480581|NCT00061490|Arthritis
1480582|NCT00061490|Weight Loss
1480583|NCT00061438|non-infected necrotizing pancreatitis
1480584|NCT00061438|pancreatic infection
1480585|NCT00061438|peripancreatic infection
1480586|NCT00061425|NHL
1480587|NCT00061425|recurrent B-cell lymphoma
1480588|NCT00061412|Low reading and writing achievement
1480589|NCT00061412|At-risk students
1480590|NCT00061412|Reading Disability
1480591|NCT00061412|Writing Disability
1480592|NCT00061399|TBI
1480593|NCT00061399|Prospective memory
1480594|NCT00061386|Postpartum
1480595|NCT00061386|Low income
1480596|NCT00061386|Diet
1480597|NCT00061386|Physical activity
1480598|NCT00061373|Alteplase
1480599|NCT00061373|Recombinant tissue plasminogen activator
1480600|NCT00061373|Reperfusion therapy
1480601|NCT00061373|Magnetic Resonance Imaging
1480602|NCT00061373|Clinical Trial
1480603|NCT00061373|Tinzaparin
1480604|NCT00061373|Eptifibatide
1480605|NCT00061373|Ischemic Stroke
1480607|NCT00061360|Cyclosporine
1480608|NCT00061360|Anti Thymocyte Globulin
1480609|NCT00061360|Severe Aplastic Anemia
1480610|NCT00061347|Fiducial Marker
1480611|NCT00061347|MRI
1480612|NCT00061347|Prostate Cancer
1480613|NCT00061347|Radiation
1480614|NCT00061334|Attitudes
1480615|NCT00061334|fMRI
1480616|NCT00061334|Development
1480617|NCT00061334|Stereotypes
1480618|NCT00061334|Memory
1480619|NCT00061334|Healthy Volunteer
1480620|NCT00061334|HV
1480621|NCT00061321|Nevirapine
1480622|NCT00061321|Pregnancy
1480623|NCT00061321|Maternal to Infant transmission
1480624|NCT00061321|Infant
1480625|NCT00061321|Breastfeeding
1480626|NCT00061321|HIV Seronegativity
1480627|NCT00061308|Ovarian cancer
1480628|NCT00061308|peritoneal cancer
1480629|NCT00061308|cancer
1480630|NCT00061308|Fallopian cancer
1480631|NCT00061295|Locomotion
1480632|NCT00061295|Spinal Cord Injury
1480633|NCT00061295|Body Weight Supported Walking
1480634|NCT00061282|Pouchitis
1480635|NCT00061282|Colitis
1480636|NCT00061282|Ileitis
1480637|NCT00061269|Infected pancreatic necrosis
1480638|NCT00061256|Bone Mineral Density
1480639|NCT00061256|Lumbar Vertebrae
1480640|NCT00061256|Treatment Experienced
1480641|NCT00061243|HIV
1480642|NCT00061243|Vaccine
1480643|NCT00061243|DNA prime
1480644|NCT00061243|Protein boost
1480645|NCT00061243|HIV Seronegativity
1480646|NCT00061243|HIV preventive vaccine
1480647|NCT00061230|Relaxation training
1480648|NCT00061217|Transtibial amputees
1480649|NCT00061217|Rectified sockets
1480650|NCT00061217|Unrectified sockets
1480651|NCT00061217|Gait
1480652|NCT00061217|Energy expenditure
1480653|NCT00061217|Prosthetic evaluation questionnaire
1480654|NCT00061204|fMRI
1480655|NCT00061204|Susceptibility Artifacts
1480656|NCT00061204|Prefrontal Cortex
1480657|NCT00061204|Temporal Lobes
1480658|NCT00061204|Methodology
1480659|NCT00061204|Healthy Volunteer
1480660|NCT00061204|HV
1480661|NCT00061165|obesity
1480662|NCT00061165|overweight
1480663|NCT00061165|children
1480664|NCT00061165|adolescents
1480665|NCT00061165|African American
1480666|NCT00061165|diet
1480667|NCT00061165|nutrition
1480668|NCT00061165|physical activity
1480669|NCT00061165|Chicago
1480670|NCT00061152|Pain Measurement
1480671|NCT00061152|Diary
1480672|NCT00061152|Painful HIV Neuropathy
1480673|NCT00061152|HIV Neuropathy
1480674|NCT00061152|Capsaicin
1480675|NCT00061152|Analgesics/*therapeutic use
1480676|NCT00061152|Capsaicin/*administration & dosage/adverse effects
1480677|NCT00061152|Peripheral Nervous System Diseases/*complications/diagnosis/*therapy
1480678|NCT00061152|Peripheral Nervous System Diseases/drug therapy/*etiology/physiopathology
1480679|NCT00061152|Pain
1480680|NCT00061139|Cerebral palsy
1480681|NCT00061139|Hemiparesis
1480682|NCT00061139|Pediatric CI therapy
1480683|NCT00061139|Upper extremity
1480684|NCT00061139|Training
1480685|NCT00061139|Limb restraint
1480686|NCT00061126|Prostate Cancer
1480687|NCT00061126|PSA
1480688|NCT00061126|Hormone refractory
1480689|NCT00061126|Rising PSA
1480690|NCT00061113|alcohol dependence
1480691|NCT00061113|marijuana dependence
1480692|NCT00061100|HIV
1480693|NCT00061100|methadone maintenance
1480694|NCT00061087|ADHD
1480695|NCT00061087|Cocaine
1480696|NCT00061087|Treatment
1480697|NCT00061087|Methadone
1480698|NCT00061074|Smoking
1480699|NCT00061061|Tobacco Cessation
1480700|NCT00061061|Postmenopausal Women
1480701|NCT00061048|Monoclonal Antibody
1480702|NCT00061048|HTLV-1
1480703|NCT00061048|CD52
1480704|NCT00061048|Flow Cytometry
1480705|NCT00061048|Antibody Saturation
1480706|NCT00061048|Adult T-Cell Leukemia (ATL)
1480707|NCT00061048|ATL
1480708|NCT00061035|Prostate Cancer; Immunotherapy
1480709|NCT00061022|Stroke
1480710|NCT00061022|cerebral vascular accident
1480711|NCT00061022|CVA
1480712|NCT00061022|Ischemia
1480713|NCT00061022|Hemorrhage
1480714|NCT00061022|TIA
1480715|NCT00061022|Transient Ischemic Attack
1480716|NCT00061022|Brain Attack
1480717|NCT00061022|Cataplexy
1480718|NCT00061009|Chronic Orthostatic Intolerance
1480719|NCT00061009|Dysautonomia
1480720|NCT00061009|Postural Tachycardia Syndrome
1480721|NCT00061009|Neurocardiogenic
1480722|NCT00061009|Syncope
1480723|NCT00061009|Neurocardiogenic Syncope
1480724|NCT00061009|COI
1480725|NCT00061009|POTS
1480726|NCT00061009|Neurocardogenic Syncope
1480727|NCT00061009|NCS
1480728|NCT00061009|Healthy Volunteer
1480729|NCT00061009|HV
1480730|NCT00060996|Critical Limb Ischemia
1480731|NCT00060996|Peripheral Vascular Disease
1480732|NCT00060996|UT-15
1480733|NCT00060996|Remodulin
1480734|NCT00060996|treprostinil
1480735|NCT00060983|Locomotion
1480736|NCT00060983|Spinal Cord Injury, ASIA C
1480737|NCT00060983|Body weight support (BWS)
1480738|NCT00060983|Functional electrical stimulation (FES)
1480739|NCT00060983|Gait
1480740|NCT00060983|Treadmill training
1480741|NCT00060983|Physical Therapy
1480742|NCT00060970|Disuse atrophy
1480743|NCT00060970|Ankle fracture
1480744|NCT00060970|Exercise, therapy
1480745|NCT00060970|Cast immobilization
1480746|NCT00060970|Deconditioning
1480747|NCT00060970|Sarcopenia
1480748|NCT00060957|Cerebral Palsy
1480749|NCT00060957|Spasticity
1480750|NCT00060957|Botulinum toxin
1480751|NCT00060957|BOTOX
1480752|NCT00060944|Trabectedin
1480753|NCT00060944|Yondelis
1480754|NCT00060944|ET-743
1480755|NCT00060944|Ecteinascidin
1480756|NCT00060944|Anthracycline
1480757|NCT00060944|Ifosfamide
1480758|NCT00060944|Dexamethasone
1480759|NCT00060944|Intravenous
1480760|NCT00060944|Cancer
1480761|NCT00060944|Malignant
1480762|NCT00060944|Metastatic
1480763|NCT00060931|hypertension
1480764|NCT00060931|beta-blockers
1480765|NCT00060931|Type 2 diabetes
1480766|NCT00060918|Type 2 diabetes
1480767|NCT00060918|hypertension
1480768|NCT00060918|beta-blockers
1480769|NCT00060905|Bipolar Disorder (manic or mixed type)
1480770|NCT00060892|Critical Limb Ischemia
1480771|NCT00060866|Beta-Adrenoceptors
1480772|NCT00060866|Beta-Adrenoceptor Blocker
1480773|NCT00060866|Neurocardiogenic Syncope
1480774|NCT00060866|Chronic Orthostatic Intolerance
1480775|NCT00060866|Neurocardiogenic
1480776|NCT00060866|Dysautonomia
1480777|NCT00060866|Autonomic Nervous System
1480778|NCT00060866|Nurocardiogenic Syncope
1480779|NCT00060866|NCS
1480780|NCT00060866|Sympathoadrenal Imbalance
1480781|NCT00060866|SAI
1480782|NCT00060866|Orthostatic Intolerance
1480783|NCT00060853|Amygdala
1480784|NCT00060853|Orbitofrontal Cortex
1480785|NCT00060853|Emotion
1480786|NCT00060853|Cognition
1480787|NCT00060853|Theory of Mind
1480788|NCT00060853|Healthy Volunteer
1480789|NCT00060853|HV
1480790|NCT00060840|Left Ventricular Assist Device Implantation
1480791|NCT00060840|Progressive Left Ventricular Failure
1480792|NCT00060827|Mild traumatic brain injury
1480793|NCT00060801|Cystic Fibrosis
1480794|NCT00060801|BIIL 284
1480795|NCT00060801|Boehringer Ingelheim
1480796|NCT00060788|Antisocial behavior
1480797|NCT00060788|Mauritius Child Health Project
1480798|NCT00060788|Intergenerational transmission
1480799|NCT00060775|Magnetic Resonance Imaging
1480800|NCT00060775|fMRI
1480801|NCT00060775|Emotion
1480802|NCT00060775|Children
1480803|NCT00060775|Adolescence
1480804|NCT00060775|Affective Neuroscience
1480805|NCT00060775|Neuroimaging
1480806|NCT00060775|Behavioral Inhibition
1480807|NCT00060775|Depression
1480808|NCT00060775|Anxiety
1480809|NCT00060775|Normal Volunteers
1480810|NCT00060775|Healthy Volunteer
1480811|NCT00060775|HV
1480812|NCT00060762|Weight Loss
1480813|NCT00060749|Stargardt
1480814|NCT00060749|Macular Dystrophy
1480815|NCT00060749|ELOVL4
1480816|NCT00060749|DHA
1480817|NCT00060749|Stargardt's Disease
1480818|NCT00060749|Autosomal Dominant Macular Dystrophy
1480819|NCT00060749|Autosomal Recessive Macular Dystrophy
1480820|NCT00060736|Hormone Replacement
1480821|NCT00060736|Gonadal Steroids
1480822|NCT00060736|Estrogen
1480823|NCT00060736|Major Depression
1480824|NCT00060736|Minor Depression
1480825|NCT00060736|Perimenopause
1480826|NCT00060736|Estradiol
1480827|NCT00060736|Depression
1480828|NCT00060736|Perimenopausal Depression
1480829|NCT00060723|Polysomnography
1480830|NCT00060723|Sleep-disordered breathing
1480831|NCT00060723|Sleep apnea, obstructive
1480832|NCT00060723|Hyperactivity
1480833|NCT00060723|Sleep
1480834|NCT00060723|Child
1480835|NCT00060710|melanoma
1480836|NCT00060697|Sexual risk taking
1480837|NCT00060697|Mother-child communication
1480838|NCT00060697|Problem behaviors
1480839|NCT00060684|Pixantrone
1480840|NCT00060684|BBR 2778
1480841|NCT00060684|chemotherapy
1480842|NCT00060684|DNA Intercalator
1480843|NCT00060684|mitoxantrone
1480844|NCT00060684|fludarabine
1480845|NCT00060684|dexamethasone
1480846|NCT00060684|Rituximab
1480847|NCT00060684|Rituxan
1480848|NCT00060684|Mabthera
1480849|NCT00060684|monoclonal antibody
1480850|NCT00060684|antibody
1480851|NCT00060684|NHL
1480852|NCT00060684|Non-Hodgkin's lymphoma
1480853|NCT00060684|indolent
1480854|NCT00060684|low grade
1480855|NCT00060684|Novuspharma
1480856|NCT00060671|Pixantrone
1480857|NCT00060671|BBR 2778
1480858|NCT00060671|chemotherapy
1480859|NCT00060671|DNA Intercalator
1480860|NCT00060671|Anthracycline
1480861|NCT00060671|Rituximab
1480862|NCT00060671|Rituxan
1480863|NCT00060671|Mabthera
1480864|NCT00060671|monoclonal antibody
1480865|NCT00060671|antibody
1480866|NCT00060671|NHL
1480867|NCT00060671|Non-Hodgkin's lymphoma
1480868|NCT00060671|indolent
1480869|NCT00060671|low grade
1480870|NCT00060671|Novuspharma
1480871|NCT00060658|Prefrontal Cortex
1480872|NCT00060658|Calculation
1480873|NCT00060658|Mathematician
1480874|NCT00060658|Cognition
1480875|NCT00060658|Brain Mapping
1480876|NCT00060658|Healthy Volunteer
1480877|NCT00060658|HV
1480878|NCT00060645|Advanced, refractory or recurrent solid tumors
1480879|NCT00060632|Advanced, refractory or recurrent solid tumors
1480880|NCT00060619|Migraine
1480881|NCT00060619|Functional abdominal pain
1480882|NCT00060619|Biofeedback
1480883|NCT00060619|Psychological assessment
1480891|NCT00060593|Balance
1480892|NCT00060593|Functional Connectivity
1480893|NCT00060593|Healthy Volunteer
1480894|NCT00060593|HV
1480895|NCT00060580|Retinal Measurements
1480896|NCT00060580|Lutein in Vivo
1480897|NCT00060580|Raman Spectroscopy
1480898|NCT00060580|Retinal Measurements of Lutein in Vivo in the Human Eye
1480899|NCT00060580|Healthy Volunteer
1480900|NCT00060580|HV
1480901|NCT00060567|E7070
1480902|NCT00060567|Irinotecan
1480903|NCT00060567|hydrochloride
1480904|NCT00060567|gastrointestinal
1480905|NCT00060567|cancer
1480906|NCT00060554|Elective PCI
1480907|NCT00060554|Heart catherization
1480908|NCT00060554|Acute coronary syndromes
1480909|NCT00060541|Brain Tumor
1480910|NCT00060541|Epilepsy
1480911|NCT00060541|Pituitary Adenoma
1480912|NCT00060541|Parkinson's Disease
1480913|NCT00060541|Vascular Malformation
1480914|NCT00060541|Neurosurgery
1480915|NCT00060541|Glioblastoma
1480916|NCT00060541|Astrocytoma
1480917|NCT00060541|Oligodendroglioma
1480918|NCT00060541|Spinal Arteriovenous Malformation
1480919|NCT00060541|Oncogenes
1480920|NCT00060541|Proteomics
1480921|NCT00060528|Immunotherapy
1480922|NCT00060528|Cytokines
1480923|NCT00060528|Immune Assays
1480924|NCT00060528|Prostate Cancer
1480925|NCT00060502|cachexia
1480926|NCT00060502|pancreatic cancer
1480927|NCT00060502|infliximab
1480928|NCT00060502|anorexia
1480929|NCT00060502|anemia
1480930|NCT00060502|Remicade.
1480931|NCT00060489|Bipolar Depression
1480932|NCT00060463|Emergency contraceptive pills
1480933|NCT00060463|Pregnancy
1480934|NCT00060463|Sexually transmitted infection
1480935|NCT00060463|Chlamydia
1480936|NCT00060463|Gonorrhea
1480937|NCT00060463|Trichomonas
1480938|NCT00060463|Contraception
1480939|NCT00060450|Ischemia-reperfusion lung injury
1480940|NCT00060450|IRLI
1480941|NCT00060437|stage IV prostate cancer
1480942|NCT00060437|recurrent prostate cancer
1480943|NCT00060437|adenocarcinoma of the prostate
1480944|NCT00060398|recurrent prostate cancer
1480945|NCT00060398|anemia
1480946|NCT00060398|fatigue
1480947|NCT00060385|stage I adult T-cell leukemia/lymphoma
1480948|NCT00060385|stage I cutaneous T-cell non-Hodgkin lymphoma
1480949|NCT00060385|stage II adult T-cell leukemia/lymphoma
1480950|NCT00060385|stage II cutaneous T-cell non-Hodgkin lymphoma
1480951|NCT00060385|stage III adult T-cell leukemia/lymphoma
1480952|NCT00060385|stage III cutaneous T-cell non-Hodgkin lymphoma
1480953|NCT00060385|stage IV adult T-cell leukemia/lymphoma
1480954|NCT00060385|stage IV cutaneous T-cell non-Hodgkin lymphoma
1480955|NCT00060385|stage I mycosis fungoides/Sezary syndrome
1480956|NCT00060385|stage II mycosis fungoides/Sezary syndrome
1480957|NCT00060385|stage III mycosis fungoides/Sezary syndrome
1480958|NCT00060385|stage IV mycosis fungoides/Sezary syndrome
1480959|NCT00060385|contiguous stage II adult diffuse large cell lymphoma
1480960|NCT00060385|noncontiguous stage II adult diffuse large cell lymphoma
1480961|NCT00060385|stage I adult diffuse large cell lymphoma
1480962|NCT00060385|stage III adult diffuse large cell lymphoma
1480963|NCT00060385|stage IV adult diffuse large cell lymphoma
1480964|NCT00060346|Waldenstrom macroglobulinemia
1480965|NCT00060346|Rituximab
1480966|NCT00060346|CHOP
1480967|NCT00060333|recurrent melanoma
1480968|NCT00060333|stage I melanoma
1480969|NCT00060333|stage II melanoma
1480970|NCT00060333|stage III melanoma
1480971|NCT00060320|stage IV breast cancer
1480972|NCT00060320|stage I breast cancer
1480973|NCT00060320|stage II breast cancer
1480974|NCT00060320|stage IIIA breast cancer
1480975|NCT00060320|stage IIIB breast cancer
1480976|NCT00060320|stage IIIC breast cancer
1480977|NCT00060320|hot flashes
1480978|NCT00060294|Waldenström macroglobulinemia
1480979|NCT00060268|recurrent esophageal cancer
1480980|NCT00060268|stage I esophageal cancer
1480981|NCT00060268|stage II esophageal cancer
1480982|NCT00060268|stage III esophageal cancer
1480983|NCT00060268|stage IV esophageal cancer
1480984|NCT00060255|stage IV breast cancer
1480985|NCT00060255|male breast cancer
1480986|NCT00060255|recurrent malignant testicular germ cell tumor
1480987|NCT00060255|Waldenstrom macroglobulinemia
1480988|NCT00060255|childhood acute lymphoblastic leukemia in remission
1480989|NCT00060255|adult acute lymphoblastic leukemia in remission
1480990|NCT00060255|recurrent adult acute myeloid leukemia
1480991|NCT00060255|adult acute myeloid leukemia in remission
1480992|NCT00060255|recurrent childhood acute myeloid leukemia
1480993|NCT00060255|childhood acute myeloid leukemia in remission
1480994|NCT00060255|chronic phase chronic myelogenous leukemia
1480995|NCT00060255|accelerated phase chronic myelogenous leukemia
1480996|NCT00060255|blastic phase chronic myelogenous leukemia
1480997|NCT00060255|refractory chronic lymphocytic leukemia
1480998|NCT00060255|recurrent adult diffuse large cell lymphoma
1480999|NCT00060255|recurrent adult diffuse mixed cell lymphoma
1481000|NCT00060255|recurrent adult diffuse small cleaved cell lymphoma
1481001|NCT00060255|recurrent adult Burkitt lymphoma
1481002|NCT00060255|recurrent adult Hodgkin lymphoma
1481003|NCT00060255|recurrent adult immunoblastic large cell lymphoma
1481004|NCT00060255|recurrent childhood large cell lymphoma
1481005|NCT00060255|recurrent childhood lymphoblastic lymphoma
1481006|NCT00060255|recurrent childhood small noncleaved cell lymphoma
1481007|NCT00060255|recurrent grade 1 follicular lymphoma
1481008|NCT00060255|recurrent grade 2 follicular lymphoma
1481009|NCT00060255|recurrent grade 3 follicular lymphoma
1481010|NCT00060255|recurrent mantle cell lymphoma
1481011|NCT00060255|recurrent/refractory childhood Hodgkin lymphoma
1481012|NCT00060255|unspecified adult solid tumor, protocol specific
1481013|NCT00060255|unspecified childhood solid tumor, protocol specific
1481014|NCT00060255|stage IIIA breast cancer
1481015|NCT00060255|stage IIIB breast cancer
1481016|NCT00060255|stage IIIC breast cancer
1481017|NCT00060255|recurrent breast cancer
1481018|NCT00060255|primary systemic amyloidosis
1481019|NCT00060255|refractory multiple myeloma
1481020|NCT00060255|childhood chronic myelogenous leukemia
1481021|NCT00060255|atypical chronic myeloid leukemia
1481022|NCT00060255|recurrent marginal zone lymphoma
1481023|NCT00060255|recurrent small lymphocytic lymphoma
1481024|NCT00060255|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1481025|NCT00060255|nodal marginal zone B-cell lymphoma
1481026|NCT00060255|splenic marginal zone lymphoma
1481027|NCT00060255|adult acute myeloid leukemia with t(8;21)(q22;q22)
1481028|NCT00060255|adult acute myeloid leukemia with t(16;16)(p13;q22)
1481029|NCT00060255|adult acute myeloid leukemia with inv(16)(p13;q22)
1481030|NCT00060255|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1481031|NCT00060255|adult acute myeloid leukemia with t(15;17)(q22;q12)
1481032|NCT00060242|anaplastic thyroid cancer
1481033|NCT00060242|recurrent thyroid cancer
1481034|NCT00060203|stage III multiple myeloma
1481035|NCT00060203|refractory multiple myeloma
1481036|NCT00060151|unspecified adult solid tumor, protocol specific
1481037|NCT00060138|hypercalcemia of malignancy
1481038|NCT00060138|stage IV breast cancer
1481039|NCT00060138|recurrent breast cancer
1481040|NCT00060138|bone metastases
1481041|NCT00060138|pain
1481042|NCT00060099|cervical intraepithelial neoplasia grade 2
1481043|NCT00060099|cervical intraepithelial neoplasia grade 3
1481044|NCT00060099|human papilloma virus infection
1481045|NCT00060086|adenocarcinoma of the prostate
1481046|NCT00060086|recurrent prostate cancer
1481047|NCT00060021|oral complications
1481048|NCT00060021|pain
1481049|NCT00060021|accelerated phase chronic myelogenous leukemia
1481050|NCT00060021|blastic phase chronic myelogenous leukemia
1481051|NCT00060021|chronic eosinophilic leukemia
1481052|NCT00060021|primary myelofibrosis
1481053|NCT00060021|chronic neutrophilic leukemia
1481054|NCT00060021|chronic phase chronic myelogenous leukemia
1481055|NCT00060021|de novo myelodysplastic syndromes
1481056|NCT00060021|disseminated neuroblastoma
1481057|NCT00060021|meningeal chronic myelogenous leukemia
1481058|NCT00060021|noncontiguous stage II adult diffuse large cell lymphoma
1481059|NCT00060021|noncontiguous stage II adult diffuse mixed cell lymphoma
1481060|NCT00060021|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1481061|NCT00060021|noncontiguous stage II adult Burkitt lymphoma
1481062|NCT00060021|noncontiguous stage II adult immunoblastic large cell lymphoma
1481063|NCT00060021|noncontiguous stage II adult lymphoblastic lymphoma
1481064|NCT00060021|noncontiguous stage II grade 1 follicular lymphoma
1481065|NCT00060021|noncontiguous stage II grade 2 follicular lymphoma
1481066|NCT00060021|noncontiguous stage II grade 3 follicular lymphoma
1481067|NCT00060021|noncontiguous stage II mantle cell lymphoma
1481068|NCT00060021|ovarian choriocarcinoma
1481069|NCT00060021|ovarian embryonal carcinoma
1481070|NCT00060021|ovarian yolk sac tumor
1481071|NCT00060021|ovarian immature teratoma
1481072|NCT00060021|ovarian mature teratoma
1481073|NCT00060021|ovarian monodermal and highly specialized teratoma
1481074|NCT00060021|ovarian polyembryoma
1481075|NCT00060021|ovarian mixed germ cell tumor
1481076|NCT00060021|high risk metastatic gestational trophoblastic tumor
1481077|NCT00060021|previously treated myelodysplastic syndromes
1481078|NCT00060021|recurrent adult acute lymphoblastic leukemia
1481079|NCT00060021|recurrent adult diffuse large cell lymphoma
1481080|NCT00060021|recurrent adult diffuse mixed cell lymphoma
1481081|NCT00060021|recurrent adult diffuse small cleaved cell lymphoma
1481082|NCT00060021|recurrent adult Burkitt lymphoma
1481083|NCT00060021|recurrent adult Hodgkin lymphoma
1481084|NCT00060021|recurrent adult immunoblastic large cell lymphoma
1481085|NCT00060021|recurrent adult lymphoblastic lymphoma
1481086|NCT00060021|recurrent cutaneous T-cell non-Hodgkin lymphoma
1481087|NCT00060021|recurrent grade 1 follicular lymphoma
1481088|NCT00060021|recurrent grade 2 follicular lymphoma
1481089|NCT00060021|recurrent grade 3 follicular lymphoma
1481090|NCT00060021|recurrent mantle cell lymphoma
1481091|NCT00060021|recurrent mycosis fungoides/Sezary syndrome
1481092|NCT00060021|recurrent neuroblastoma
1481093|NCT00060021|recurrent ovarian epithelial cancer
1481094|NCT00060021|recurrent ovarian germ cell tumor
1481095|NCT00060021|recurrent malignant testicular germ cell tumor
1481096|NCT00060021|refractory chronic lymphocytic leukemia
1481097|NCT00060021|relapsing chronic myelogenous leukemia
1481098|NCT00060021|refractory hairy cell leukemia
1481099|NCT00060021|refractory multiple myeloma
1481100|NCT00060021|secondary acute myeloid leukemia
1481101|NCT00060021|secondary myelodysplastic syndromes
1481102|NCT00060021|stage I multiple myeloma
1481103|NCT00060021|stage II multiple myeloma
1481104|NCT00060021|stage III multiple myeloma
1481105|NCT00060021|stage II ovarian epithelial cancer
1481106|NCT00060021|stage III adult diffuse large cell lymphoma
1481107|NCT00060021|stage III adult diffuse mixed cell lymphoma
1481108|NCT00060021|stage III adult diffuse small cleaved cell lymphoma
1481109|NCT00060021|stage III adult Burkitt lymphoma
1481110|NCT00060021|stage III adult immunoblastic large cell lymphoma
1481111|NCT00060021|stage III adult lymphoblastic lymphoma
1481112|NCT00060021|stage III chronic lymphocytic leukemia
1481113|NCT00060021|stage III grade 1 follicular lymphoma
1481114|NCT00060021|stage III grade 2 follicular lymphoma
1481115|NCT00060021|stage III grade 3 follicular lymphoma
1481116|NCT00060021|stage III mantle cell lymphoma
1481117|NCT00060021|stage III ovarian epithelial cancer
1481118|NCT00060021|stage III malignant testicular germ cell tumor
1481119|NCT00060021|stage IIIA breast cancer
1481120|NCT00060021|stage IIIB breast cancer
1481121|NCT00060021|stage IIIC breast cancer
1481122|NCT00060021|stage IV adult diffuse large cell lymphoma
1481123|NCT00060021|stage IV adult diffuse mixed cell lymphoma
1481124|NCT00060021|stage IV adult diffuse small cleaved cell lymphoma
1481125|NCT00060021|stage IV adult Burkitt lymphoma
1481126|NCT00060021|stage IV adult immunoblastic large cell lymphoma
1481127|NCT00060021|stage IV adult lymphoblastic lymphoma
1481128|NCT00060021|stage IV breast cancer
1481129|NCT00060021|stage IV chronic lymphocytic leukemia
1481130|NCT00060021|stage IV grade 1 follicular lymphoma
1481131|NCT00060021|stage IV grade 2 follicular lymphoma
1481132|NCT00060021|stage IV grade 3 follicular lymphoma
1481133|NCT00060021|stage IV mantle cell lymphoma
1481134|NCT00060021|stage IV ovarian epithelial cancer
1481135|NCT00060021|testicular choriocarcinoma and embryonal carcinoma
1481136|NCT00060021|testicular choriocarcinoma and seminoma
1481137|NCT00060021|testicular choriocarcinoma and teratoma
1481138|NCT00060021|testicular choriocarcinoma and yolk sac tumor
1481139|NCT00060021|testicular embryonal carcinoma and seminoma
1481140|NCT00060021|testicular embryonal carcinoma and teratoma with seminoma
1481141|NCT00060021|testicular embryonal carcinoma and teratoma
1481142|NCT00060021|testicular embryonal carcinoma and yolk sac tumor with seminoma
1481143|NCT00060021|testicular embryonal carcinoma and yolk sac tumor
1481144|NCT00060021|testicular embryonal carcinoma
1481145|NCT00060021|testicular teratoma
1481146|NCT00060021|testicular yolk sac tumor and teratoma with seminoma
1481147|NCT00060021|testicular yolk sac tumor and teratoma
1481148|NCT00060021|testicular yolk sac tumor
1481149|NCT00060021|recurrent adult acute myeloid leukemia
1481150|NCT00060021|testicular choriocarcinoma
1481151|NCT00060021|atypical chronic myeloid leukemia, BCR-ABL1 negative
1481152|NCT00060021|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1481153|NCT00060021|noncontiguous stage II small lymphocytic lymphoma
1481154|NCT00060021|noncontiguous stage II marginal zone lymphoma
1481155|NCT00060021|recurrent marginal zone lymphoma
1481156|NCT00060021|recurrent small lymphocytic lymphoma
1481157|NCT00060021|stage III small lymphocytic lymphoma
1481158|NCT00060021|stage III marginal zone lymphoma
1481159|NCT00060021|stage IV small lymphocytic lymphoma
1481160|NCT00060021|stage IV marginal zone lymphoma
1481161|NCT00060021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1481162|NCT00060021|nodal marginal zone B-cell lymphoma
1481163|NCT00060021|splenic marginal zone lymphoma
1481164|NCT00060008|neurofibromatosis type 1
1481165|NCT00060008|plexiform neurofibroma
1481166|NCT00059995|recurrent adult Hodgkin lymphoma
1481167|NCT00059995|recurrent/refractory childhood Hodgkin lymphoma
1481168|NCT00059995|anaplastic large cell lymphoma
1481169|NCT00059995|recurrent adult diffuse large cell lymphoma
1481170|NCT00059995|recurrent childhood large cell lymphoma
1481171|NCT00059995|recurrent cutaneous T-cell non-Hodgkin lymphoma
1481172|NCT00059982|adenocarcinoma of the pancreas
1481173|NCT00059982|stage II pancreatic cancer
1481174|NCT00059982|stage III pancreatic cancer
1481175|NCT00059982|stage IV pancreatic cancer
1481176|NCT00059943|stage IV breast cancer
1481177|NCT00059943|stage IV non-small cell lung cancer
1481178|NCT00059943|recurrent non-small cell lung cancer
1481179|NCT00059943|recurrent breast cancer
1481180|NCT00059943|stage IV prostate cancer
1481181|NCT00059943|recurrent prostate cancer
1481182|NCT00059930|liver metastases
1481183|NCT00059930|stage IV colon cancer
1481184|NCT00059930|stage IV rectal cancer
1481185|NCT00059930|adenocarcinoma of the colon
1481186|NCT00059930|adenocarcinoma of the rectum
1481187|NCT00059930|recurrent colon cancer
1481188|NCT00059930|recurrent rectal cancer
1481189|NCT00059917|unspecified adult solid tumor, protocol specific
1481190|NCT00059904|recurrent adult diffuse large cell lymphoma
1481191|NCT00059904|recurrent adult diffuse mixed cell lymphoma
1481192|NCT00059904|recurrent adult immunoblastic large cell lymphoma
1481193|NCT00059891|perioperative/postoperative complications
1481194|NCT00059891|stage II anal cancer
1481195|NCT00059891|stage I anal cancer
1481196|NCT00059891|stage III anal cancer
1481197|NCT00059891|stage I rectal cancer
1481198|NCT00059891|stage II rectal cancer
1481199|NCT00059891|stage III rectal cancer
1481200|NCT00059878|infection
1481201|NCT00059878|unspecified adult solid tumor, protocol specific
1481202|NCT00059865|advanced adult primary liver cancer
1481203|NCT00059865|unresectable gallbladder cancer
1481204|NCT00059865|unresectable extrahepatic bile duct cancer
1481205|NCT00059865|adult primary cholangiocellular carcinoma
1481206|NCT00059852|male breast cancer
1481207|NCT00059852|recurrent breast cancer
1481208|NCT00059852|stage IV breast cancer
1481209|NCT00059839|anaplastic large cell lymphoma
1481210|NCT00059826|stage I pancreatic cancer
1481211|NCT00059826|stage II pancreatic cancer
1481212|NCT00059826|stage III pancreatic cancer
1481213|NCT00059826|adenocarcinoma of the pancreas
1481214|NCT00059800|recurrent melanoma
1481215|NCT00059800|stage 0 melanoma
1481216|NCT00059800|stage I melanoma
1481217|NCT00059800|stage II melanoma
1481218|NCT00059800|stage III melanoma
1481219|NCT00059800|stage IV melanoma
1481220|NCT00059761|limited stage small cell lung cancer
1481221|NCT00059748|Central Nervous System Abnormalities
1481222|NCT00059748|Arthropathy
1481223|NCT00059748|Urticaria
1481224|NCT00059748|Papilledema
1481225|NCT00059748|Autoinflammation
1481226|NCT00059748|Neonatal Onset Multisystem Imflammatory
1481227|NCT00059748|Disease
1481228|NCT00059748|NOMID
1481229|NCT00059735|kidney cancer
1481230|NCT00059735|kidney neoplasms
1481231|NCT00059735|renal cell cancer
1481232|NCT00059722|NSCLC
1481233|NCT00059722|locally advanced or metastatic
1481234|NCT00059722|second-line
1481235|NCT00059709|Conflict Resolution training
1481236|NCT00059709|Children
1481237|NCT00059696|Constraint-Induced Movement Therapy
1481238|NCT00059696|CI therapy
1481239|NCT00059696|Rehabilitation
1481240|NCT00059696|Cerebrovascular accident
1481241|NCT00059696|Upper extremity
1481242|NCT00059696|Concentrated, extended practice
1481243|NCT00059696|Limb restraint
1481244|NCT00059696|Motor Deficits
1481245|NCT00059683|Preterm Birth
1481246|NCT00059683|Premature Birth
1481247|NCT00059683|Cervical cerclage
1481248|NCT00059683|Vaginal ultrasound
1481249|NCT00059683|Cervical length
1481250|NCT00059670|UES
1481251|NCT00059670|Dysphagia
1481252|NCT00059657|Ecraprost in lipid emulsion
1481253|NCT00059657|CLI
1481254|NCT00059657|peripheral, vascular
1481255|NCT00059657|amputation
1481256|NCT00059657|Angioplasty
1481257|NCT00059657|by-pass
1481258|NCT00059657|Critical Limb Ischemia due to peripheral arterial disease
1481259|NCT00059644|Ecraprost in lipid emulsion
1481260|NCT00059644|CLI
1481261|NCT00059644|peripheral
1481262|NCT00059644|vascular
1481263|NCT00059644|amputation
1481264|NCT00059644|Critical Limb Ischemia due to peripheral arterial disease
1481265|NCT00059631|Prostate Cancer
1481266|NCT00059631|Advanced Androgen-Independent Prostate Cancer
1481267|NCT00059631|AI-PCa
1481268|NCT00059631|Advanced Prostate Cancer
1481269|NCT00059631|Novantrone
1481270|NCT00059631|Mitoxantrone
1481271|NCT00059631|PS-341
1481272|NCT00059631|Bortezomib
1481273|NCT00059631|Velcade
1481274|NCT00059631|LDP-341
1481275|NCT00059631|MLN341
1481276|NCT00059631|20S proteasome
1481277|NCT00059618|Platinum Resistant
1481278|NCT00059618|Taxane Resistant
1481279|NCT00059618|Ovarian Cancer
1481280|NCT00059618|Primary Peritoneal Cancer
1481281|NCT00059618|Fallopian Tube Cancer
1481282|NCT00059618|Bortezomib
1481283|NCT00059618|PS-341
1481284|NCT00059618|Velcade
1481285|NCT00059618|LDP-341
1481286|NCT00059618|MLN341
1481287|NCT00059618|Carboplatin
1481288|NCT00059618|Paraplatin
1481289|NCT00059605|Non-Small Cell Lung Cancer
1481290|NCT00059605|Small Cell Lung Cancer
1481291|NCT00059605|Lung Cancer
1481292|NCT00059605|NSCLC
1481293|NCT00059605|SCLC
1481294|NCT00059605|DOTAP:Chol-fus1
1481295|NCT00059605|gene
1481296|NCT00059605|gene transfer
1481297|NCT00059579|Reward
1481298|NCT00059579|Cortex
1481299|NCT00059579|Dopamine
1481300|NCT00059579|Neuroimaging
1481301|NCT00059579|Strirtum
1481302|NCT00059579|Major Depressive Disorder (MDD)
1481303|NCT00059579|Melancholic Features
1481304|NCT00059579|Brain Imaging
1481305|NCT00059579|Functional Magnetic Resonance Imaging (fMRI)
1481306|NCT00059579|Dopaminergic Mechanisms
1481307|NCT00059579|Anhedonia
1481308|NCT00059579|Depression
1481309|NCT00059579|Major Depressive Disorder
1481310|NCT00059579|MDD
1481311|NCT00059579|Healthy Volunteer
1481312|NCT00059579|HV
1481313|NCT00059553|spinal cord injury
1481314|NCT00059553|walking
1481315|NCT00059553|training
1481316|NCT00059553|treadmill
1481317|NCT00059553|incomplete spinal cord injury
1481318|NCT00059540|NICHD Neonatal Research Network
1481319|NCT00059540|Maternal Lifestyle Study
1481320|NCT00059540|Cocaine abuse
1481321|NCT00059540|Cocaine dependence
1481322|NCT00059540|Opiate abuse
1481323|NCT00059540|Opiate dependence
1481324|NCT00059540|Follow-up
1481325|NCT00059540|Neurodevelopmental outcome
1481326|NCT00059540|Substance-related disorders
1481327|NCT00059527|Physical Activity
1481328|NCT00059527|Nutrition
1481329|NCT00059527|Self Efficacy
1481330|NCT00059527|Middle School
1481331|NCT00059527|Intervention
1481332|NCT00059514|Youth
1481333|NCT00059514|Adolescents
1481334|NCT00059514|Smoking cessation
1481335|NCT00059514|Smoking prevention
1481336|NCT00059514|Risk factors
1481337|NCT00059514|Arab Americans
1481338|NCT00059501|Postural Stability
1481339|NCT00059501|EEG
1481340|NCT00059501|Aging
1481341|NCT00059501|Falls
1481342|NCT00059501|Healthy Volunteer
1481343|NCT00059501|HV
1481344|NCT00059475|Adjuvant Therapy
1481345|NCT00059475|MART-1 Peptides
1481346|NCT00059475|GP100 Peptide
1481347|NCT00059475|Immunologic Response
1481348|NCT00059475|Melanoma
1481349|NCT00059462|Treatment experienced
1481350|NCT00059449|Enterocolitis
1481351|NCT00059436|Muscle strengthening
1481352|NCT00059436|Skeletal muscle Contractions
1481353|NCT00059436|Rehabilitative exercise
1481354|NCT00059423|Leukapheresis
1481355|NCT00059423|G-CSF
1481356|NCT00059423|Dexamethasone
1481357|NCT00059423|mRNA
1481358|NCT00059423|Benign Ethnic Neutropenia
1481359|NCT00059423|BEN
1481360|NCT00059423|Healthy Volunteer
1481361|NCT00059423|HV
1481362|NCT00059410|Alzheimer disease
1481363|NCT00059410|Caregivers
1481364|NCT00059410|African Americans
1481365|NCT00059410|Perceptions
1481366|NCT00059410|Cultural Competency
1481367|NCT00059397|Hepatitis C
1481368|NCT00059384|Treatment experienced
1481369|NCT00059384|Therapeutic Drug Monitoring
1481370|NCT00059371|Male circumcision
1481371|NCT00059371|HIV acquisition
1481372|NCT00059371|Sexually transmitted infection
1481373|NCT00059371|HIV Seronegativity
1481374|NCT00059358|HIV
1481375|NCT00059358|HCV
1481376|NCT00059358|Ribavirin
1481377|NCT00059358|Interferon
1481378|NCT00059358|Co-infection
1481379|NCT00059358|Treatment experienced
1481380|NCT00059345|Acupuncture
1481381|NCT00059345|Arthritis
1481382|NCT00059332|stroke
1481383|NCT00059332|brain attack
1481384|NCT00059332|magnesium sulfate
1481385|NCT00059332|neuroprotection
1481386|NCT00059332|prehospital care
1481387|NCT00059332|emergency medical services
1481388|NCT00059319|coronary artery bypass graft surgery
1481389|NCT00059319|CABG surgery
1481390|NCT00059319|neurobehavioral impairment
1481391|NCT00059319|aorta clamping
1481392|NCT00059319|aorta manipulation
1481393|NCT00059319|microemboli
1481394|NCT00059306|stroke
1481395|NCT00059306|hypertension
1481396|NCT00059306|high blood pressure
1481397|NCT00059306|lacunar stroke
1481398|NCT00059306|subcortical stroke
1481399|NCT00059306|aspirin
1481400|NCT00059306|clopidogrel
1481401|NCT00059280|Pompe disease
1481402|NCT00059280|Glycogen storage disease type II
1481403|NCT00059280|GSD-II
1481404|NCT00059280|Acid maltase deficiency disease
1481405|NCT00059280|Glycogenosis 2
1481406|NCT00059254|fatty acids
1481407|NCT00059254|oleic acid
1481408|NCT00059254|palmitic acid
1481409|NCT00059254|fat oxidation
1481410|NCT00059254|energy expenditure
1481411|NCT00059254|body composition
1481412|NCT00059254|monounsaturated fat
1481413|NCT00059254|human
1481414|NCT00059241|Early sexual initiation
1481415|NCT00059241|Prevention of early sexual activity
1481416|NCT00059241|Middle childhood
1481417|NCT00059228|Pregnancy
1481418|NCT00059228|Gonadal Steroids
1481419|NCT00059228|Antidepressants
1481420|NCT00059228|Puerperium
1481421|NCT00059228|Depression
1481422|NCT00059228|Postpartum
1481423|NCT00059228|Estradiol
1481424|NCT00059228|Estrogen Response Element
1481425|NCT00059228|Postpartum Depression
1481426|NCT00059202|Urso
1481427|NCT00059202|PSC
1481428|NCT00059189|Occipital Cortex
1481429|NCT00059189|Prefrontal Cortex
1481430|NCT00059189|Transcranial Magnetic Stimulation
1481431|NCT00059189|Inhibition
1481432|NCT00059189|Cortical Excitability
1481433|NCT00059189|Blindness
1481434|NCT00059189|Healthy Volunteer
1481435|NCT00059189|HV
1481436|NCT00059137|Gating
1481437|NCT00059137|Respiratory Misregistration
1481438|NCT00059137|Abdominal Belt
1481439|NCT00059137|Percutaneous
1481440|NCT00059137|CT Guided Biopsy
1481441|NCT00059137|Respiratory Cycle
1481442|NCT00059137|Needle Biopsy
1481443|NCT00059046|Neuroreceptors
1481444|NCT00059046|PET Measurements
1481445|NCT00059046|Kinetic Analysis
1481446|NCT00059046|Test/Retest
1481447|NCT00059046|Healthy Volunteer
1481448|NCT00059046|HV
1481456|NCT00059020|Glioma
1481457|NCT00059020|Brain Tumor
1481458|NCT00059020|Epidermal Growth Factor
1481459|NCT00059020|Polymorphisms
1481460|NCT00058994|AMD
1481461|NCT00058994|anecortave acetate
1481462|NCT00058994|wet AMD
1481463|NCT00058994|age-related macular degeneration
1481464|NCT00058994|Macular Degeneration
1481465|NCT00058994|Maculopathy, Age-Related
1481466|NCT00058994|Age-Related Maculopathies
1481467|NCT00058994|Age-Related Maculopathy
1481468|NCT00058994|Maculopathies, Age-Related
1481469|NCT00058981|Diabetes
1481470|NCT00058981|LADA
1481471|NCT00058981|latent autoimmune diabetes in adults
1481472|NCT00058968|neuropathy
1481473|NCT00058968|pain
1481474|NCT00058968|diabetes
1481475|NCT00058968|chronic pain
1481476|NCT00058968|persistent pain
1481477|NCT00058968|leg pain
1481478|NCT00058968|peripheral neuropathy
1481479|NCT00058968|foot pain
1481480|NCT00058968|painful neuropathy
1481481|NCT00058968|diabetic neuropathy
1481482|NCT00058955|ghb
1481483|NCT00058955|Xyrem
1481484|NCT00058955|triazolam
1481485|NCT00058955|pentobarbital
1481486|NCT00058955|sedative
1481487|NCT00058955|abuse
1481488|NCT00058942|Drinking Water
1481489|NCT00058903|Cholestatic
1481490|NCT00058903|Pruritus
1481491|NCT00058903|Sertraline
1481492|NCT00058903|primary biliary cirrhosis
1481493|NCT00058903|hepatitis C
1481494|NCT00058890|itching
1481495|NCT00058890|pruritus
1481496|NCT00058890|cholestasis
1481497|NCT00058890|liver disease
1481498|NCT00058890|hepatitis
1481499|NCT00058890|cirrhosis
1481500|NCT00058851|Manual lymph drainage
1481501|NCT00058851|Combined physiotherapy
1481502|NCT00058825|Campath
1481503|NCT00058825|stem cell transplant
1481504|NCT00058812|Cytotoxic T Lymphocytes
1481505|NCT00058812|bone marrow transplant
1481506|NCT00058812|EBV+ lymphoproliferative disease
1481507|NCT00058773|Hodgkin disease
1481508|NCT00058773|non-Hodgkins Lymphoma
1481509|NCT00058773|bone marrow transplant
1481510|NCT00058760|Prevention of early sexual behavior
1481511|NCT00058760|NIA intervention
1481512|NCT00058747|Granulocytic Leukemia, Chronic
1481513|NCT00058747|Leukemia, Granulocytic, Chronic
1481514|NCT00058747|Leukemia, Myelocytic, Chronic
1481515|NCT00058747|Leukemia, Myelogenous, Chronic
1481516|NCT00058747|Myelocytic Leukemia, Chronic
1481517|NCT00058747|Myelogenous Leukemia, Chronic
1481518|NCT00058747|Myeloid Leukemia, Chronic
1481519|NCT00058734|Dendritic Cell
1481520|NCT00058734|Immunotherapy
1481521|NCT00058734|Acute HIV
1481522|NCT00058734|Human Immunodeficiency Virus
1481523|NCT00058734|AIDS
1481524|NCT00058734|HIV Therapeutic Vaccine
1481525|NCT00058734|Treatment Experienced
1481526|NCT00058734|Treatment Interruption
1481527|NCT00058721|Dementia
1481528|NCT00058721|Feasibility
1481529|NCT00058721|Dopamine
1481530|NCT00058721|Lewy Body
1481531|NCT00058721|Parkinson Disease
1481532|NCT00058721|PD
1481533|NCT00058721|Healthy Volunteer
1481534|NCT00058721|HV
1481535|NCT00058695|Macualar Degeneration
1481536|NCT00058695|AMD
1481537|NCT00058695|Healthy Volunteer
1481538|NCT00058695|HV
1481539|NCT00058682|Fungal Infection
1481540|NCT00058682|Mycoses
1481541|NCT00058682|Candida Species
1481542|NCT00058682|Candidiasis
1481543|NCT00058656|Immunotherapy
1481544|NCT00058656|T Cell Therapy
1481545|NCT00058656|Adoptive immunotherapy
1481546|NCT00058656|Xcellerate
1481547|NCT00058656|Xcellerated
1481548|NCT00058617|EBV Positive Hodgkin's Lymphoma
1481549|NCT00058617|EBV Positive Non-Hodgkin's Lymphoma
1481550|NCT00058617|EBV Specific Cytotoxic T-Lymphocytes
1481551|NCT00058552|Advanced, refractory, or recurrent ovarian cancer
1481552|NCT00058526|dHER2-AS15 ASCI
1481553|NCT00058526|Immunotherapeutic
1481554|NCT00058526|Dose escalation
1481555|NCT00058526|Breast cancer
1481556|NCT00058487|adult primary hepatocellular carcinoma
1481557|NCT00058487|advanced adult primary liver cancer
1481558|NCT00058487|localized unresectable adult primary liver cancer
1481559|NCT00058487|recurrent adult primary liver cancer
1481560|NCT00058474|stage II rectal cancer
1481561|NCT00058474|stage III rectal cancer
1481562|NCT00058474|adenocarcinoma of the rectum
1481563|NCT00058448|stage II penile cancer
1481564|NCT00058448|stage III penile cancer
1481565|NCT00058448|stage IV penile cancer
1481566|NCT00058435|stage II ovarian epithelial cancer
1481567|NCT00058435|stage III ovarian epithelial cancer
1481568|NCT00058435|stage IV ovarian epithelial cancer
1481569|NCT00058435|recurrent ovarian epithelial cancer
1481570|NCT00058435|fallopian tube cancer
1481571|NCT00058435|primary peritoneal cavity cancer
1481572|NCT00058422|noncontiguous stage II adult diffuse large cell lymphoma
1481573|NCT00058422|stage III adult diffuse large cell lymphoma
1481574|NCT00058422|stage IV adult diffuse large cell lymphoma
1481575|NCT00058396|refractory chronic lymphocytic leukemia
1481576|NCT00058396|stage I chronic lymphocytic leukemia
1481577|NCT00058396|stage II chronic lymphocytic leukemia
1481578|NCT00058396|stage III chronic lymphocytic leukemia
1481579|NCT00058396|stage IV chronic lymphocytic leukemia
1481580|NCT00058396|noncontiguous stage II small lymphocytic lymphoma
1481581|NCT00058396|recurrent small lymphocytic lymphoma
1481582|NCT00058396|stage I small lymphocytic lymphoma
1481583|NCT00058396|stage III small lymphocytic lymphoma
1481584|NCT00058396|stage IV small lymphocytic lymphoma
1481585|NCT00058396|contiguous stage II small lymphocytic lymphoma
1481586|NCT00058370|adult medulloblastoma
1481587|NCT00058370|untreated childhood medulloblastoma
1481588|NCT00058357|unspecified adult solid tumor, protocol specific
1481589|NCT00058357|pain
1481590|NCT00058318|stage IV renal cell cancer
1481591|NCT00058318|stage III renal cell cancer
1481592|NCT00058292|recurrent grade 1 follicular lymphoma
1481593|NCT00058292|recurrent grade 2 follicular lymphoma
1481594|NCT00058292|recurrent grade 3 follicular lymphoma
1481595|NCT00058292|recurrent adult diffuse large cell lymphoma
1481596|NCT00058292|recurrent adult diffuse mixed cell lymphoma
1481597|NCT00058292|recurrent adult Burkitt lymphoma
1481598|NCT00058292|recurrent adult immunoblastic large cell lymphoma
1481599|NCT00058292|recurrent mantle cell lymphoma
1481600|NCT00058292|recurrent adult lymphoblastic lymphoma
1481601|NCT00058292|recurrent adult diffuse small cleaved cell lymphoma
1481602|NCT00058292|recurrent marginal zone lymphoma
1481603|NCT00058292|recurrent small lymphocytic lymphoma
1481604|NCT00058292|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1481605|NCT00058292|nodal marginal zone B-cell lymphoma
1481606|NCT00058292|splenic marginal zone lymphoma
1481607|NCT00058279|stage IV melanoma
1481608|NCT00058279|extraocular extension melanoma
1481609|NCT00058279|recurrent melanoma
1481610|NCT00058279|iris melanoma
1481611|NCT00058279|ciliary body and choroid melanoma, medium/large size
1481612|NCT00058279|ciliary body and choroid melanoma, small size
1481613|NCT00058279|recurrent intraocular melanoma
1481614|NCT00058266|stage I prostate cancer
1481615|NCT00058266|stage II prostate cancer
1481616|NCT00058201|acinar cell adenocarcinoma of the pancreas
1481617|NCT00058201|duct cell adenocarcinoma of the pancreas
1481618|NCT00058201|stage I pancreatic cancer
1481619|NCT00058201|stage II pancreatic cancer
1481620|NCT00058201|stage III pancreatic cancer
1481621|NCT00058201|stage IV pancreatic cancer
1481622|NCT00058188|osteoporosis
1481623|NCT00058188|stage III prostate cancer
1481624|NCT00058188|stage IV prostate cancer
1481625|NCT00058149|stage II pancreatic cancer
1481626|NCT00058149|stage III pancreatic cancer
1481627|NCT00058149|adenocarcinoma of the pancreas
1481628|NCT00058149|stage IV pancreatic cancer
1481629|NCT00058123|adult anaplastic astrocytoma
1481630|NCT00058123|adult mixed glioma
1481631|NCT00058123|adult anaplastic oligodendroglioma
1481632|NCT00058123|recurrent adult brain tumor
1481633|NCT00058123|adult anaplastic ependymoma
1481634|NCT00058071|peripheral neuropathy
1481635|NCT00058071|neurotoxicity
1481636|NCT00058071|hydatidiform mole
1481637|NCT00058071|unspecified adult solid tumor, protocol specific
1481638|NCT00058058|ductal breast carcinoma in situ
1481639|NCT00058058|invasive ductal breast carcinoma
1481640|NCT00058058|invasive lobular breast carcinoma
1481641|NCT00058058|breast cancer in situ
1481642|NCT00058058|stage I breast cancer
1481643|NCT00058058|stage II breast cancer
1481644|NCT00058058|stage IIIA breast cancer
1481645|NCT00058058|stage IIIB breast cancer
1481646|NCT00058058|stage IIIC breast cancer
1481647|NCT00058058|stage IV breast cancer
1481648|NCT00058045|AIDS-related peripheral/systemic lymphoma
1481649|NCT00058032|ovarian epithelial cancer
1481650|NCT00058006|stage I non-small cell lung cancer
1481651|NCT00058006|stage I squamous cell carcinoma of the hypopharynx
1481652|NCT00058006|stage I squamous cell carcinoma of the larynx
1481653|NCT00058006|stage I squamous cell carcinoma of the lip and oral cavity
1481654|NCT00058006|stage I squamous cell carcinoma of the nasopharynx
1481655|NCT00058006|stage I squamous cell carcinoma of the oropharynx
1481656|NCT00058006|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1481657|NCT00058006|stage II squamous cell carcinoma of the hypopharynx
1481658|NCT00058006|stage II squamous cell carcinoma of the larynx
1481659|NCT00058006|stage II squamous cell carcinoma of the lip and oral cavity
1481660|NCT00058006|stage II squamous cell carcinoma of the nasopharynx
1481661|NCT00058006|stage II squamous cell carcinoma of the oropharynx
1481662|NCT00058006|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1481663|NCT00058006|salivary gland squamous cell carcinoma
1481664|NCT00058006|stage I salivary gland cancer
1481665|NCT00058006|stage II salivary gland cancer
1481666|NCT00057993|stage IV breast cancer
1481667|NCT00057993|stage IIIA breast cancer
1481668|NCT00057993|stage IIIB breast cancer
1481669|NCT00057993|stage IIIC breast cancer
1481670|NCT00057980|advanced adult primary liver cancer
1481671|NCT00057980|localized unresectable adult primary liver cancer
1481672|NCT00057980|adult primary hepatocellular carcinoma
1481673|NCT00057967|recurrent mycosis fungoides/Sezary syndrome
1481674|NCT00057967|stage I mycosis fungoides/Sezary syndrome
1481675|NCT00057967|stage II mycosis fungoides/Sezary syndrome
1481676|NCT00057967|stage III mycosis fungoides/Sezary syndrome
1481677|NCT00057967|stage IV mycosis fungoides/Sezary syndrome
1481678|NCT00057967|recurrent cutaneous T-cell non-Hodgkin lymphoma
1481679|NCT00057967|stage I cutaneous T-cell non-Hodgkin lymphoma
1481680|NCT00057967|stage II cutaneous T-cell non-Hodgkin lymphoma
1481681|NCT00057967|stage III cutaneous T-cell non-Hodgkin lymphoma
1481682|NCT00057967|stage IV cutaneous T-cell non-Hodgkin lymphoma
1481683|NCT00057954|recurrent adult Hodgkin lymphoma
1481684|NCT00057954|recurrent adult diffuse large cell lymphoma
1481685|NCT00057954|recurrent adult diffuse mixed cell lymphoma
1481686|NCT00057954|recurrent adult diffuse small cleaved cell lymphoma
1481687|NCT00057954|recurrent adult Burkitt lymphoma
1481688|NCT00057954|recurrent adult immunoblastic large cell lymphoma
1481689|NCT00057954|recurrent adult lymphoblastic lymphoma
1481690|NCT00057954|recurrent grade 1 follicular lymphoma
1481691|NCT00057954|recurrent grade 2 follicular lymphoma
1481692|NCT00057954|recurrent grade 3 follicular lymphoma
1481693|NCT00057954|recurrent mantle cell lymphoma
1481694|NCT00057954|recurrent mycosis fungoides/Sezary syndrome
1481695|NCT00057954|recurrent adult T-cell leukemia/lymphoma
1481696|NCT00057954|anaplastic large cell lymphoma
1481697|NCT00057954|recurrent marginal zone lymphoma
1481698|NCT00057954|recurrent small lymphocytic lymphoma
1481699|NCT00057954|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1481700|NCT00057954|nodal marginal zone B-cell lymphoma
1481701|NCT00057954|splenic marginal zone lymphoma
1481702|NCT00057928|recurrent cervical cancer
1481703|NCT00057928|stage IVB cervical cancer
1481704|NCT00057915|unspecified adult solid tumor, protocol specific
1481705|NCT00057889|clear cell renal cell carcinoma
1481706|NCT00057889|stage IV renal cell cancer
1481707|NCT00057889|recurrent renal cell cancer
1481708|NCT00057876|stage III pancreatic cancer
1481709|NCT00057876|adenocarcinoma of the pancreas
1481710|NCT00057850|recurrent squamous cell carcinoma of the hypopharynx
1481711|NCT00057850|recurrent squamous cell carcinoma of the larynx
1481712|NCT00057850|recurrent squamous cell carcinoma of the lip and oral cavity
1481713|NCT00057850|recurrent squamous cell carcinoma of the oropharynx
1481714|NCT00057850|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1481715|NCT00057850|stage IV squamous cell carcinoma of the hypopharynx
1481716|NCT00057850|stage IV squamous cell carcinoma of the larynx
1481717|NCT00057850|stage IV squamous cell carcinoma of the lip and oral cavity
1481718|NCT00057850|stage IV squamous cell carcinoma of the oropharynx
1481719|NCT00057850|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1481720|NCT00057850|recurrent salivary gland cancer
1481721|NCT00057850|salivary gland squamous cell carcinoma
1481722|NCT00057850|stage IV salivary gland cancer
1481723|NCT00057837|extensive stage small cell lung cancer
1481724|NCT00057837|Topotecan
1481725|NCT00057837|Etoposide
1481726|NCT00057837|Cisplatin
1481727|NCT00057837|Irinotecan
1481728|NCT00057798|stage I non-small cell lung cancer
1481729|NCT00057798|stage II non-small cell lung cancer
1481730|NCT00057798|stage IIIA non-small cell lung cancer
1481731|NCT00057798|stage IIIB non-small cell lung cancer
1481732|NCT00057785|oral complications of radiation therapy
1481733|NCT00057785|radiation toxicity
1481734|NCT00057785|stage I squamous cell carcinoma of the nasopharynx
1481735|NCT00057785|stage II squamous cell carcinoma of the nasopharynx
1481736|NCT00057785|stage III squamous cell carcinoma of the nasopharynx
1481737|NCT00057785|stage IV squamous cell carcinoma of the nasopharynx
1481738|NCT00057759|sexual dysfunction
1481739|NCT00057759|sexuality and reproductive issues
1481740|NCT00057759|radiation toxicity
1481741|NCT00057759|stage IIB prostate cancer
1481742|NCT00057759|stage IIA prostate cancer
1481743|NCT00057759|stage III prostate cancer
1481744|NCT00057759|psychosocial effects of cancer and its treatment
1481745|NCT00057746|limited stage small cell lung cancer
1481746|NCT00057733|anxiety disorder
1481747|NCT00057733|depression
1481748|NCT00057733|unspecified adult solid tumor, protocol specific
1481749|NCT00057720|ovary
1481750|NCT00057707|Catecholamines
1481751|NCT00057707|Dopamine
1481752|NCT00057707|fMRI
1481753|NCT00057707|Working Memory
1481754|NCT00057707|Clinical Trial
1481755|NCT00057707|Stabilization
1481756|NCT00057707|Inpatients
1481757|NCT00057707|Placebo
1481758|NCT00057707|Modafinil
1481759|NCT00057707|Normal Volunteers
1481760|NCT00057707|Schizophrenia
1481761|NCT00057707|Schizoaffective Disorder
1481762|NCT00057707|Healthy Volunteer
1481763|NCT00057707|HV
1481764|NCT00057694|Qualitative
1481765|NCT00057694|Telephone Interviews
1481766|NCT00057694|Genetic Counseling
1481767|NCT00057694|Family History
1481768|NCT00057694|Health Information
1481769|NCT00057694|Adult Adoptees
1481770|NCT00057694|Adult Adoptee
1481771|NCT00057694|Interview
1481772|NCT00057681|Mania
1481773|NCT00057655|Social Welfare
1481774|NCT00057655|Mentally Ill Persons
1481775|NCT00057655|Mental Health Services
1481776|NCT00057642|Hispanic Americans
1481777|NCT00057629|Rape
1481778|NCT00057629|Sex Offenses
1481779|NCT00057616|Metastatic Melanoma
1481780|NCT00057616|Melanoma
1481781|NCT00057616|Revimid
1481782|NCT00057616|CC5013
1481783|NCT00057564|Newly Diagnosed Multiple Myeloma
1481784|NCT00057564|Multiple Myeloma
1481785|NCT00057538|HIV
1481786|NCT00057538|Randomized Trial
1481787|NCT00057538|Stress
1481788|NCT00057538|Spirituality
1481789|NCT00057538|Quality of Life
1481790|NCT00057538|Complementary Therapies
1481791|NCT00057525|Anthrax
1481792|NCT00057499|Juvenile diabetes
1481793|NCT00057499|Diabetes
1481794|NCT00057499|Insulin
1481795|NCT00057499|Vaccine
1481796|NCT00057499|Type 1 Diabetes
1481797|NCT00057499|Diabetes Mellitus
1481798|NCT00057486|Chronic Diarrhea
1481799|NCT00057486|Interleukin 12
1481800|NCT00057473|unspecified childhood solid tumor, protocol specific
1481801|NCT00057460|Antiepileptic Drug
1481802|NCT00057460|Neuroprotection
1481803|NCT00057460|Seizure Disorder
1481804|NCT00057460|TMS Stimulation
1481805|NCT00057460|EEG
1481806|NCT00057460|AMPA Antagonist
1481807|NCT00057460|Dosing
1481808|NCT00057460|Transcranial Magnetic Stimulation
1481809|NCT00057460|Healthy Volunteer
1481810|NCT00057460|HV
1481811|NCT00057447|lymphoma
1481812|NCT00057434|Vitamin A
1481813|NCT00057421|Tuberculosis
1481814|NCT00057421|HIV infection
1481815|NCT00057421|Prednisolone
1481816|NCT00057421|Safety
1481817|NCT00057421|Immune activation
1481818|NCT00057408|Autism
1481819|NCT00057408|Pervasive Developmental Disorder
1481820|NCT00057408|Treatment
1481821|NCT00057408|Olanzapine
1481822|NCT00057408|Antipsychotic
1481823|NCT00057395|Esophageal Neoplasms
1481824|NCT00057395|Esophagus Neoplasm
1481825|NCT00057395|Esophagus Cancer
1481826|NCT00057395|Esophageal Cancer
1481827|NCT00057395|Esophageal Tumors
1481828|NCT00057395|Esophagus Tumors
1481829|NCT00057395|Neoplasms, Esophageal
1481830|NCT00057395|Hepatocellular Carcinoma
1481831|NCT00057395|Carcinoma, Hepatocellular
1481832|NCT00057395|Hepatoma
1481833|NCT00057395|Colorectal Neoplasms
1481834|NCT00057395|Colorectal Cancer
1481835|NCT00057395|Colorectal Carcinoma
1481836|NCT00057395|Colorectal Tumor
1481837|NCT00057395|Neoplasms, Colorectal
1481838|NCT00057395|Ovarian Neoplasms
1481839|NCT00057395|Ovary Neoplasms
1481840|NCT00057395|Ovary Cancer
1481841|NCT00057395|Ovary Carcinoma
1481842|NCT00057395|Ovarian Cancer
1481843|NCT00057395|Ovarian Carcinoma
1481844|NCT00057395|Neoplasms, Ovarian
1481845|NCT00057395|Pancreatic Neoplasms
1481846|NCT00057395|Pancreatic Cancer
1481847|NCT00057395|Pancreas Neoplasms
1481848|NCT00057395|Pancreas Cancer
1481849|NCT00057395|Neoplasms, Pancreatic
1481850|NCT00057395|Neoplasms, Pancreas
1481851|NCT00057395|and other solid tumors
1481852|NCT00057382|liver cancer
1481853|NCT00057356|Chronic Heart Failure
1481854|NCT00057356|YM078
1481855|NCT00057291|Orphanage
1481856|NCT00057291|Caregiving
1481857|NCT00057291|Training
1481858|NCT00057291|Child development
1481859|NCT00057278|Gabapentin
1481860|NCT00057252|Diagnostic Radiology
1481861|NCT00057252|Imaging
1481862|NCT00057252|Algorithms
1481863|NCT00057252|Healthy Volunteer
1481864|NCT00057252|HV
1481865|NCT00057239|GW353162
1481866|NCT00057239|Major Depressive Disorder
1481867|NCT00057239|MDD
1481868|NCT00057226|GW353162,
1481869|NCT00057226|Major depressive disorder,
1481870|NCT00057226|flexible
1481871|NCT00057213|Major Depressive Disorder (MDD),
1481872|NCT00057213|Flexible
1481873|NCT00057213|GW353162,
1481874|NCT00057200|Home Care
1481875|NCT00057174|Proton pump inhibitor
1481876|NCT00057148|massage therapy
1481877|NCT00057148|pain management
1481878|NCT00057148|post-surgical
1481879|NCT00057148|complementary therapy
1481880|NCT00057135|Schizophrenia
1481881|NCT00057135|Treatment Refusal
1481882|NCT00057135|Drug Packaging
1481883|NCT00057135|Reminder Systems
1481884|NCT00057135|Antipsychotic Agents
1481885|NCT00057122|Preventive therapy
1481886|NCT00057083|Telemedicine
1481887|NCT00057083|Remote consultation
1481888|NCT00057083|Patient Satisfaction
1481889|NCT00057083|Physician patient relations
1481890|NCT00057083|Provider satisfaction
1481891|NCT00057083|Doctor-patient relations
1481892|NCT00057031|myelodysplastic syndrome
1481893|NCT00057031|MDS
1481894|NCT00057018|stroke
1481895|NCT00057018|cerebrovascular accident
1481896|NCT00057018|upper extremity
1481897|NCT00057018|physical therapy
1481898|NCT00057018|constraint-induced therapy
1481899|NCT00057005|LEUKEMIA
1481900|NCT00056979|Metabolic diseases
1481901|NCT00056966|Acute myeloid leukemia
1481902|NCT00056966|Acute lymphoblastic leukemia
1481903|NCT00056966|Chronic myeloid leukemia
1481904|NCT00056966|Non-Hodgkin's lymphoma
1481905|NCT00056966|Hodgkin's disease
1481906|NCT00056966|Myelodysplastic syndrome
1481907|NCT00056966|Myeloproliferative disorders
1481908|NCT00056966|Multiple myeloma
1481909|NCT00056966|Severe aplastic anemia
1481910|NCT00056953|health behavior
1481911|NCT00056953|adolescent behavior
1481912|NCT00056953|peer mentoring
1481913|NCT00056940|Prevention
1481914|NCT00056940|Parenting strategies
1481915|NCT00056940|Media use
1481916|NCT00056940|Discipline
1481917|NCT00056940|Firearm storage
1481918|NCT00056927|Smoking
1481919|NCT00056927|Primary Prevention
1481920|NCT00056927|Health Education
1481921|NCT00056927|Child
1481922|NCT00056927|Parents
1481923|NCT00056927|Parenting Education
1481924|NCT00056927|Communication
1481925|NCT00056914|Magnetic Resonance Imaging
1481926|NCT00056914|Functional Imaging
1481927|NCT00056914|Cerebral Blood Flow
1481928|NCT00056914|Parallel Imaging
1481929|NCT00056914|BOLD Effect
1481930|NCT00056914|Spectroscopic Imaging
1481931|NCT00056914|Healthy Volunteer
1481932|NCT00056914|HV
1481933|NCT00056901|Puerperium
1481934|NCT00056901|Pregnancy
1481935|NCT00056901|Mood Disorders
1481936|NCT00056901|Estradiol
1481937|NCT00056901|Progesterone
1481938|NCT00056901|Mood
1481939|NCT00056901|Behavior
1481940|NCT00056901|Cognition
1481941|NCT00056901|Perimenopause
1481942|NCT00056901|Menopause
1481943|NCT00056901|Post Partum Depression
1481944|NCT00056901|PPD
1481945|NCT00056901|Healthy Volunteer
1481946|NCT00056901|HV
1481947|NCT00056888|Electroencephalogram
1481948|NCT00056888|Functional (BOLD) MRI
1481949|NCT00056888|Startle Reflex
1481950|NCT00056888|Electromyogram
1481951|NCT00056888|Psychogenic
1481952|NCT00056888|Paroxysmal
1481953|NCT00056888|Dyskinesia
1481954|NCT00056888|Kinesiogenic
1481955|NCT00056888|EEG
1481956|NCT00056888|Movement-Related Potential
1481957|NCT00056888|Movement Disorder
1481958|NCT00056888|Paroxysmal Hyperkinetic Movement
1481959|NCT00056888|Disorder
1481960|NCT00056888|Paroxysmal Dyskinesia
1481961|NCT00056875|graft versus host disease
1481962|NCT00056875|bone marrow transplant
1481963|NCT00056875|alternative donor
1481964|NCT00056862|Hepatitis C Virus
1481965|NCT00056862|Antiviral Agents
1481966|NCT00056862|Hemolysis
1481967|NCT00056862|Neutropenia
1481968|NCT00056862|Cirrhosis
1481969|NCT00056862|Hemolytic Anemia
1481970|NCT00056862|Viral Hepatitis
1481971|NCT00056862|Ribavirin
1481972|NCT00056862|Alfa Interferon
1481973|NCT00056862|Pegylated Interferon
1481974|NCT00056862|Hepatitis C
1481975|NCT00056862|HCV
1481976|NCT00056849|Arthritis
1481977|NCT00056849|Spondyloarthropathy
1481978|NCT00056849|Spine
1481979|NCT00056849|Hereditary
1481980|NCT00056849|Disability
1481981|NCT00056849|Ankylosing Spondylitis
1481982|NCT00056849|AS
1481983|NCT00056849|Spondyloarthritis
1481984|NCT00056836|AMD
1481985|NCT00056836|Neovascular age-related macular degeneration
1481986|NCT00056823|AMD
1481987|NCT00056810|Guillain Barre Syndrome
1481988|NCT00056810|4-aminopyridine
1481989|NCT00056797|HIV Therapeutic vaccine
1481990|NCT00056797|IL-2
1481991|NCT00056797|Structured Treatment Interruption
1481992|NCT00056797|Treatment Experienced
1481993|NCT00056784|TGF-Beta
1481994|NCT00056784|Kidney
1481995|NCT00056784|Transplantation
1481996|NCT00056784|Rejection
1481997|NCT00056784|Immunosuppression
1481998|NCT00056784|Kidney Transplant
1481999|NCT00056784|Chronic Allograft Nephropathy
1482000|NCT00056784|CAN
1482001|NCT00056771|Cataract
1482002|NCT00056771|Congenital Cataracts
1482003|NCT00056771|Hereditary Cataracts
1482004|NCT00056758|HIV-1
1482005|NCT00056758|HAART
1482006|NCT00056758|Therapeutic immunization
1482007|NCT00056758|HIV Therapeutic Vaccine
1482008|NCT00056758|Treatment Experienced
1482009|NCT00056745|HIV seronegativity
1482010|NCT00056745|HIV preventive vaccine
1482011|NCT00056719|Arthritis
1482012|NCT00056719|Spondylarthropathy
1482013|NCT00056719|Spine
1482014|NCT00056719|Hereditary
1482015|NCT00056719|Disability
1482016|NCT00056719|Ankylosing Spondylitis
1482017|NCT00056719|Spondyloarthropathy
1482018|NCT00056719|Spondyloarthritis
1482019|NCT00056719|AS
1482020|NCT00056706|Motor Deficit
1482021|NCT00056706|Somatosensory Deficit
1482022|NCT00056706|Cortical Reorganization
1482023|NCT00056706|Disinhibition
1482024|NCT00056706|Rehabilitation
1482025|NCT00056706|Plasticity
1482026|NCT00056706|Stroke
1482027|NCT00056693|Neuroendocrine tumor, advanced disease, sunitinib, Phase 2
1482028|NCT00056680|Prematurity
1482029|NCT00056680|low birthweight
1482030|NCT00056680|parenting
1482031|NCT00056680|intervention
1482032|NCT00056667|Treatment
1482033|NCT00056667|Pain
1482034|NCT00056667|Relaxation Response
1482035|NCT00056667|Cognitive Behavioral Therapy
1482036|NCT00056654|Leuprolide
1482037|NCT00056654|Prostatic Neoplasms
1482038|NCT00056654|Testosterone
1482039|NCT00056654|Prostate-specific Antigen
1482040|NCT00056654|Pharmacokinetics
1482041|NCT00056654|luprolide acetate
1482042|NCT00056628|Alzheimer disease
1482043|NCT00056628|Dementia
1482044|NCT00056628|Ventriculoperitoneal shunt
1482045|NCT00056628|Tau
1482046|NCT00056628|ABeta
1482047|NCT00056602|Utility
1482048|NCT00056602|Health Status
1482049|NCT00056602|Preferences
1482050|NCT00056602|Response Criteria
1482051|NCT00056602|Treatment
1482052|NCT00056602|Rheumatoid Arthritis
1482053|NCT00056602|RA
1482054|NCT00056576|Monotherapy
1482055|NCT00056576|Complex Partial Seizures
1482056|NCT00056576|Epilepsy
1482057|NCT00056576|anti-epilepsy drug
1482058|NCT00056576|AED
1482059|NCT00056563|Parkinson's disease
1482060|NCT00056563|levo-dopa
1482061|NCT00056563|tremor
1482062|NCT00056563|dyskinesia
1482063|NCT00056563|subthalamic nucleus
1482064|NCT00056563|globus pallidus
1482065|NCT00056550|Antithrombin Deficiency, Congenital
1482066|NCT00056550|Antithrombin III Deficiency
1482067|NCT00056524|ALS
1482068|NCT00056524|MS
1482069|NCT00056524|CNS
1482070|NCT00056524|AD
1482071|NCT00056524|TBI
1482072|NCT00056524|Dextromethorphan
1482073|NCT00056524|IEED
1482074|NCT00056524|Emotional
1482075|NCT00056511|Garlic
1482076|NCT00056511|Supplements
1482077|NCT00056511|Adults
1482078|NCT00056511|Hypercholesterolemics
1482079|NCT00056511|Randomized Clinical Trial
1482080|NCT00056485|Nursing homes
1482081|NCT00056485|Aging
1482082|NCT00056472|Major depressive disorder with psychotic features
1482083|NCT00056472|Delusional Depression
1482084|NCT00056472|Randomized Trial
1482085|NCT00056472|Combination Treatment
1482086|NCT00056472|SSRI
1482087|NCT00056472|Atypical Antipsychotic
1482088|NCT00056459|Colorectal Cancer
1482089|NCT00056459|PTK787
1482090|NCT00056459|Vatalanib
1482091|NCT00056459|VEGF inhibitor
1482092|NCT00056459|Oxaliplatin
1482093|NCT00056459|Angiogenesis
1482094|NCT00056459|Rectal Cancer
1482095|NCT00056459|Colon Cancer
1482096|NCT00056459|Colorectal Carcinoma
1482097|NCT00056459|Colorectal Tumor
1482098|NCT00056446|Colorectal Cancer
1482099|NCT00056446|Oxaliplatin
1482100|NCT00056446|VEGF inhibitor
1482101|NCT00056446|Vatalanib
1482102|NCT00056446|PTK787
1482103|NCT00056446|Colon Cancer
1482104|NCT00056446|Colorectal Carcinoma
1482105|NCT00056446|Rectal Cancer
1482106|NCT00056446|Colorectal Tumor
1482107|NCT00056433|Fetal Hemoglobin Induction
1482108|NCT00056433|L-Arginine
1482109|NCT00056433|Nitric Oxide Therapy
1482110|NCT00056433|Sickle Cell Disease
1482111|NCT00056433|Sildenafil (Viagra)
1482112|NCT00056433|Sickle Cell Anemia
1482113|NCT00056420|Tourette's Syndrome
1482114|NCT00056420|Tic Disorder
1482115|NCT00056420|(EEG) Electroencephalography
1482116|NCT00056420|Event-Related Desynchronization/Synchronization
1482117|NCT00056420|Coherence
1482118|NCT00056420|Tourette's
1482119|NCT00056420|Tourette Syndrome
1482120|NCT00056420|Healthy Volunteer
1482121|NCT00056420|HV
1482122|NCT00056407|Prostate cancer prevention
1482123|NCT00056407|prostate
1482124|NCT00056407|BPH
1482125|NCT00056407|enlarged prostate
1482126|NCT00056407|PSA
1482127|NCT00056407|prostate cancer
1482128|NCT00056394|Early Rheumatoid Arthritis
1482129|NCT00056394|Coping Skills Training
1482130|NCT00056394|Pain
1482131|NCT00056394|Physical Disability
1482132|NCT00056394|Psychological Disability
1482133|NCT00056394|Daily Diary Measures
1482134|NCT00056381|neutropenia
1482135|NCT00056381|fever
1482136|NCT00056381|febrile neutropenia
1482137|NCT00056368|Candida blood stream infections
1482138|NCT00056368|Candida infections
1482139|NCT00056368|Candidemia
1482140|NCT00056368|Invasive Candidiasis
1482141|NCT00056355|Pheresis
1482142|NCT00056355|Cytokine
1482143|NCT00056355|Lymphocyte
1482144|NCT00056355|Remission
1482145|NCT00056355|Ultraviolet A Light
1482146|NCT00056355|Crohn's Disease
1482147|NCT00056355|Crohn Disease
1482148|NCT00056329|Aging Persons
1482149|NCT00056329|Down Syndrome
1482150|NCT00056329|Vitamin E
1482151|NCT00056329|Alzheimer disease
1482152|NCT00056316|Caregiving
1482153|NCT00056316|Dementia
1482154|NCT00056316|Alzheimer's
1482155|NCT00056316|Depression
1482156|NCT00056316|Technology
1482157|NCT00056316|Treatment
1482158|NCT00056303|Attachment
1482159|NCT00056303|Intervention
1482160|NCT00056303|Prevention
1482161|NCT00056290|Diabetes Mellitus
1482162|NCT00056290|Neuropathy
1482163|NCT00056290|Peripheral Artery Disease
1482164|NCT00056264|Chronic obstructive pulmonary disease
1482165|NCT00056264|COPD
1482166|NCT00056264|Infliximab
1482167|NCT00056264|Remicade
1482168|NCT00056251|Interstitial Cystitis
1482169|NCT00056251|Bladder
1482170|NCT00056238|Neurologic Diseases (General)
1482171|NCT00056238|Hemorrhagic Stroke
1482172|NCT00056238|Cerebral Amyloid Angiopathy
1482173|NCT00056238|Cerebrovascular Accident
1482174|NCT00056225|homocysteine
1482175|NCT00056199|Vision Loss
1482176|NCT00056199|Optic Nerve Tumors
1482177|NCT00056199|Macular Edema
1482178|NCT00056199|Von Hippel-Lindau Disease
1482179|NCT00056199|VEGF
1482180|NCT00056199|EYE001
1482181|NCT00056199|VHL
1482182|NCT00056186|Adaptation
1482183|NCT00056186|Neurodegenerative
1482184|NCT00056186|Health Care Provider
1482185|NCT00056186|Psychosocial
1482186|NCT00056186|Chronic Illness/Disability
1482187|NCT00056186|Friedreich's Ataxia
1482188|NCT00056186|Friedreich Ataxia
1482189|NCT00056186|FA
1482190|NCT00056173|Metastatic Renal Cell Carcinoma
1482191|NCT00056160|Multiple Myeloma
1482192|NCT00056160|Refractory and Relapsed
1482193|NCT00056160|Revlimid
1482194|NCT00056160|CC5013
1482195|NCT00056147|cystic fibrosis
1482196|NCT00056134|recurrent melanoma
1482197|NCT00056134|stage IV melanoma
1482198|NCT00056134|stage IIIA melanoma
1482199|NCT00056134|stage IIIB melanoma
1482200|NCT00056134|stage IIIC melanoma
1482201|NCT00056095|recurrent renal cell cancer
1482202|NCT00056095|stage IV renal cell cancer
1482203|NCT00056082|breast cancer
1482204|NCT00056069|psychosocial effects of cancer and its treatment
1482205|NCT00056069|childhood acute lymphoblastic leukemia
1482206|NCT00056056|stage I mycosis fungoides/Sezary syndrome
1482207|NCT00056056|stage II mycosis fungoides/Sezary syndrome
1482208|NCT00056056|recurrent mycosis fungoides/Sezary syndrome
1482209|NCT00056030|liver metastases
1482210|NCT00056030|stage IV colon cancer
1482211|NCT00056030|stage IV rectal cancer
1482212|NCT00056030|adenocarcinoma of the colon
1482213|NCT00056030|adenocarcinoma of the rectum
1482214|NCT00056004|non-small cell lung cancer
1482215|NCT00056004|small cell lung cancer
1482216|NCT00056004|stage I non-small cell lung cancer
1482217|NCT00056004|stage I squamous cell carcinoma of the hypopharynx
1482218|NCT00056004|stage I squamous cell carcinoma of the larynx
1482219|NCT00056004|stage I squamous cell carcinoma of the lip and oral cavity
1482220|NCT00056004|stage I squamous cell carcinoma of the nasopharynx
1482221|NCT00056004|stage I squamous cell carcinoma of the oropharynx
1482222|NCT00056004|stage II squamous cell carcinoma of the hypopharynx
1482223|NCT00056004|stage II squamous cell carcinoma of the larynx
1482224|NCT00056004|stage II squamous cell carcinoma of the lip and oral cavity
1482225|NCT00056004|stage II squamous cell carcinoma of the nasopharynx
1482226|NCT00056004|stage II squamous cell carcinoma of the oropharynx
1482227|NCT00055991|breast cancer
1482228|NCT00055978|non-small cell lung cancer
1482229|NCT00055978|stage I non-small cell lung cancer
1482230|NCT00055965|stage IIIA non-small cell lung cancer
1482231|NCT00055965|stage IIIB non-small cell lung cancer
1482232|NCT00055965|stage IV non-small cell lung cancer
1482233|NCT00055952|childhood desmoplastic small round cell tumor
1482234|NCT00055952|metastatic childhood soft tissue sarcoma
1482235|NCT00055952|nonmetastatic childhood soft tissue sarcoma
1482458|NCT00055185|Treatment Experienced
1482236|NCT00055952|recurrent childhood soft tissue sarcoma
1482237|NCT00055952|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1482238|NCT00055952|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1482239|NCT00055952|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1482240|NCT00055939|previously treated childhood rhabdomyosarcoma
1482241|NCT00055939|recurrent childhood rhabdomyosarcoma
1482242|NCT00055926|recurrent breast cancer
1482243|NCT00055926|stage IV breast cancer
1482244|NCT00055926|male breast cancer
1482245|NCT00055887|stage IIIB non-small cell lung cancer
1482246|NCT00055887|stage IIIA non-small cell lung cancer
1482247|NCT00055887|adenocarcinoma of the lung
1482248|NCT00055887|squamous cell lung cancer
1482249|NCT00055887|large cell lung cancer
1482250|NCT00055874|chronic phase chronic myelogenous leukemia
1482251|NCT00055874|childhood chronic myelogenous leukemia
1482252|NCT00055874|chronic myelogenous leukemia, BCR-ABL1 positive
1482253|NCT00055848|adenocarcinoma of the colon
1482254|NCT00055848|stage I colon cancer
1482255|NCT00055848|stage II colon cancer
1482256|NCT00055848|stage III colon cancer
1482257|NCT00055848|stage IV colon cancer
1482258|NCT00055835|recurrent bladder cancer
1482259|NCT00055835|stage III bladder cancer
1482260|NCT00055835|squamous cell carcinoma of the bladder
1482261|NCT00055835|stage II bladder cancer
1482262|NCT00055835|recurrent urethral cancer
1482263|NCT00055835|urethral cancer associated with invasive bladder cancer
1482264|NCT00055835|distal urethral cancer
1482265|NCT00055835|proximal urethral cancer
1482266|NCT00055835|stage IV bladder cancer
1482267|NCT00055835|transitional cell carcinoma of the bladder
1482268|NCT00055822|adenocarcinoma of the colon
1482269|NCT00055822|recurrent colon cancer
1482270|NCT00055822|stage III colon cancer
1482271|NCT00055822|stage IV colon cancer
1482272|NCT00055822|adenocarcinoma of the rectum
1482273|NCT00055822|recurrent rectal cancer
1482274|NCT00055822|stage III rectal cancer
1482275|NCT00055822|stage IV rectal cancer
1482276|NCT00055783|recurrent adult Hodgkin lymphoma
1482277|NCT00055731|stage III prostate cancer
1482278|NCT00055731|stage IIB prostate cancer
1482279|NCT00055731|stage IIA prostate cancer
1482280|NCT00055718|drug/agent toxicity by tissue/organ
1482281|NCT00055718|childhood acute lymphoblastic leukemia
1482282|NCT00055705|recurrent ovarian epithelial cancer
1482283|NCT00055705|stage IV ovarian epithelial cancer
1482284|NCT00055705|fallopian tube cancer
1482285|NCT00055705|primary peritoneal cavity cancer
1482286|NCT00055705|recurrent colon cancer
1482287|NCT00055705|stage IV colon cancer
1482288|NCT00055705|ovarian sarcoma
1482289|NCT00055705|recurrent ovarian germ cell tumor
1482290|NCT00055705|stage IV ovarian germ cell tumor
1482291|NCT00055705|recurrent endometrial carcinoma
1482292|NCT00055705|stage IV endometrial carcinoma
1482293|NCT00055705|recurrent uterine sarcoma
1482294|NCT00055705|stage IV uterine sarcoma
1482295|NCT00055705|ovarian stromal cancer
1482296|NCT00055705|recurrent rectal cancer
1482297|NCT00055705|stage IV rectal cancer
1482298|NCT00055705|metastatic gastrointestinal carcinoid tumor
1482299|NCT00055705|recurrent gastrointestinal carcinoid tumor
1482300|NCT00055705|gastrointestinal stromal tumor
1482301|NCT00055705|advanced malignant mesothelioma
1482302|NCT00055705|recurrent malignant mesothelioma
1482303|NCT00055705|recurrent gastric cancer
1482304|NCT00055705|stage IV gastric cancer
1482305|NCT00055705|carcinoma of the appendix
1482306|NCT00055705|small intestine adenocarcinoma
1482307|NCT00055705|small intestine leiomyosarcoma
1482308|NCT00055705|small intestine lymphoma
1482309|NCT00055705|recurrent small intestine cancer
1482310|NCT00055705|recurrent gallbladder cancer
1482311|NCT00055705|unresectable gallbladder cancer
1482312|NCT00055705|advanced adult primary liver cancer
1482313|NCT00055705|localized unresectable adult primary liver cancer
1482314|NCT00055705|recurrent adult primary liver cancer
1482315|NCT00055679|stage I breast cancer
1482316|NCT00055666|graft versus host disease
1482317|NCT00055653|refractory anemia with excess blasts in transformation
1482318|NCT00055653|refractory anemia with excess blasts
1482319|NCT00055653|refractory anemia with ringed sideroblasts
1482320|NCT00055653|refractory anemia
1482321|NCT00055653|chronic myelomonocytic leukemia
1482322|NCT00055653|childhood acute myeloid leukemia in remission
1482323|NCT00055653|recurrent childhood acute myeloid leukemia
1482324|NCT00055653|secondary acute myeloid leukemia
1482325|NCT00055653|childhood acute lymphoblastic leukemia in remission
1482326|NCT00055653|recurrent childhood acute lymphoblastic leukemia
1482327|NCT00055653|accelerated phase chronic myelogenous leukemia
1482328|NCT00055653|blastic phase chronic myelogenous leukemia
1482329|NCT00055653|chronic phase chronic myelogenous leukemia
1482330|NCT00055653|acute undifferentiated leukemia
1482331|NCT00055653|recurrent/refractory childhood Hodgkin lymphoma
1482332|NCT00055653|recurrent childhood large cell lymphoma
1482333|NCT00055653|recurrent childhood lymphoblastic lymphoma
1482334|NCT00055653|recurrent childhood small noncleaved cell lymphoma
1482335|NCT00055653|untreated childhood acute lymphoblastic leukemia
1482456|NCT00055198|Bacterial and fungal infections
1482336|NCT00055653|untreated childhood acute myeloid leukemia and other myeloid malignancies
1482337|NCT00055653|de novo myelodysplastic syndromes
1482338|NCT00055653|previously treated myelodysplastic syndromes
1482339|NCT00055653|secondary myelodysplastic syndromes
1482340|NCT00055653|atypical chronic myeloid leukemia
1482341|NCT00055653|myelodysplastic/myeloproliferative disease, unclassifiable
1482342|NCT00055640|stage I adult diffuse large cell lymphoma
1482343|NCT00055640|contiguous stage II adult diffuse large cell lymphoma
1482344|NCT00055640|stage III adult diffuse large cell lymphoma
1482345|NCT00055640|noncontiguous stage II adult diffuse large cell lymphoma
1482346|NCT00055640|stage IV adult diffuse large cell lymphoma
1482347|NCT00055614|stage III ovarian epithelial cancer
1482348|NCT00055614|stage IV ovarian epithelial cancer
1482349|NCT00055614|fallopian tube cancer
1482350|NCT00055614|primary peritoneal cavity cancer
1482351|NCT00055601|stage II bladder cancer
1482352|NCT00055601|stage III bladder cancer
1482353|NCT00055588|Spinal Reflexes
1482354|NCT00055588|Motor Practice
1482355|NCT00055588|Spinal Cord Injury
1482356|NCT00055588|Locomotion
1482357|NCT00055588|Healthy Volunteer
1482358|NCT00055588|HV
1482359|NCT00055575|Scopolamine
1482360|NCT00055575|Depression
1482361|NCT00055575|fMRI
1482362|NCT00055575|Cognition
1482363|NCT00055575|Emotion
1482364|NCT00055575|Brain
1482365|NCT00055575|Bipolar Disorder
1482366|NCT00055575|Major Depressive Disorder
1482367|NCT00055575|MDD
1482368|NCT00055575|Healthy Volunteer
1482369|NCT00055575|HV
1482370|NCT00055562|Metastatic Melanoma
1482371|NCT00055562|Metastatic Malignant Melanoma
1482372|NCT00055562|Revimid
1482373|NCT00055562|CC5013
1482374|NCT00055549|Dextromethorphan
1482375|NCT00055549|Sensorimotor Modulation
1482376|NCT00055549|Spasmodic Dysphonia
1482377|NCT00055549|Muscular Tension Dysphonia
1482378|NCT00055549|Voice Tremor
1482379|NCT00055549|Lorazepam
1482380|NCT00055549|Dysphonia
1482381|NCT00055549|Macular Tension Dysphonia
1482382|NCT00055510|BO-653
1482383|NCT00055510|Coronary restenosis
1482384|NCT00055510|Stent restenosis
1482385|NCT00055510|LDL oxidative inhibitor
1482386|NCT00055510|Antioxidant
1482387|NCT00055484|Migraine Headache
1482388|NCT00055484|prophylaxis
1482389|NCT00055484|AED
1482390|NCT00055484|migraine prophylaxis
1482391|NCT00055471|prostate cancer
1482392|NCT00055471|Metastatic prostate cancer
1482393|NCT00055471|bone metastases
1482394|NCT00055445|Complementary Therapies
1482395|NCT00055445|IdB 1016
1482396|NCT00055445|Silybin
1482397|NCT00055445|Antioxidant
1482398|NCT00055445|Hepatitis C Virus
1482399|NCT00055445|Phosphatidylcholine
1482400|NCT00055432|recurrent ovarian cancer
1482401|NCT00055432|platinum-resistant
1482402|NCT00055432|platinum-sensitive
1482403|NCT00055432|folate receptor antagonist
1482404|NCT00055419|Stage IV colorectal cancer
1482405|NCT00055380|Molecular Targets
1482406|NCT00055380|Keratinocytes
1482407|NCT00055380|Cell Cycle
1482408|NCT00055380|Small Molecule
1482409|NCT00055380|Gene Expression
1482410|NCT00055380|Pharmacodynamics
1482411|NCT00055380|Surrogate Markers
1482412|NCT00055380|Targeted Therapy
1482413|NCT00055380|Buccal Mucosa
1482414|NCT00055380|Pharmacogenomics
1482415|NCT00055380|Oral Mucosa
1482416|NCT00055354|Acupuncture
1482417|NCT00055354|Medicine, Chinese Traditional
1482418|NCT00055302|vaginal bleeding
1482419|NCT00055302|advanced bone age
1482420|NCT00055302|fibrous dysplasia
1482421|NCT00055302|MAS
1482422|NCT00055302|McCune-Albright Syndrome
1482423|NCT00055289|Transcranial Magnetic Stimulation
1482424|NCT00055289|Counting
1482425|NCT00055289|Sensorimotor Integration
1482426|NCT00055289|Superior Temporal Cortex
1482427|NCT00055289|Dorsal Premotor Cortex
1482428|NCT00055289|Healthy Volunteer
1482429|NCT00055289|HV
1482430|NCT00055263|advanced solid tumor malignancies
1482431|NCT00055237|Angiogenesis
1482432|NCT00055237|Cancer
1482433|NCT00055237|HHV-8
1482434|NCT00055237|KSHV
1482435|NCT00055237|Skin
1482436|NCT00055237|Kaposi Sarcoma
1482437|NCT00055237|KS
1482438|NCT00055224|Anxiety Disorder
1482439|NCT00055224|Fear
1482440|NCT00055224|Aversive Conditioning
1482441|NCT00055224|Psychophysiology
1482442|NCT00055224|Predictability
1482443|NCT00055224|Startle
1482444|NCT00055224|Context Conditioning
1482445|NCT00055224|Fear Conditioning
1482446|NCT00055224|Agoraphobia
1482447|NCT00055224|Panic Disorder
1482448|NCT00055224|Generalized Anxiety Disorder
1482449|NCT00055224|GAD
1482450|NCT00055224|Healthy Volunteer
1482451|NCT00055224|HV
1482452|NCT00055198|Gram positive bacterial infections
1482453|NCT00055198|expanded access program
1482454|NCT00055198|resistant infections
1482455|NCT00055198|bacteremia
1482457|NCT00055198|bacterial infections
1482459|NCT00055172|Cytokines
1482460|NCT00055172|Mutation
1482461|NCT00055172|DNA
1482462|NCT00055172|Phenotype
1482463|NCT00055172|T Cell
1482464|NCT00055172|Immunodeficiency
1482465|NCT00055172|Inherited Immunodeficiency
1482466|NCT00055159|RT PA
1482467|NCT00055159|Blood Clots
1482468|NCT00055159|Catheter Directed Thrombolytic Therapy
1482469|NCT00055159|Alteplase
1482470|NCT00055159|Deep Vein Thrombosis
1482471|NCT00055159|DVT
1482472|NCT00055133|rheumatoid arthritis
1482473|NCT00055133|Paxceed
1482474|NCT00055133|Micellar Paclitaxel
1482475|NCT00055120|Anti-HIV Agents
1482476|NCT00055120|Disease Progression
1482477|NCT00055120|Drug Administration Schedule
1482478|NCT00055120|Viral Load
1482479|NCT00055120|HIV-1
1482480|NCT00055120|Treatment Outcome
1482481|NCT00055120|Survival Analysis
1482482|NCT00055120|Treatment Naive
1482483|NCT00055107|Nitazoxanide
1482484|NCT00055107|Antiprotozoal Agents
1482485|NCT00055107|Cryptosporidiosis
1482486|NCT00055107|Cryptosporidium parvum
1482487|NCT00055107|AIDS-Related Opportunistic Infections
1482488|NCT00055107|Pharmacokinetics
1482489|NCT00055107|Drug Adminstration Schedule
1482490|NCT00055094|Immune system
1482491|NCT00055094|Helper T-Cells
1482492|NCT00055094|Acute Infection
1482493|NCT00055094|Treatment naive
1482494|NCT00055081|Homeless Persons
1482495|NCT00055055|Autoimmunity Pathogenesis
1482496|NCT00055055|Microarray Analyses
1482497|NCT00055055|Microchimerism
1482498|NCT00055055|Genetic and Environmental Risk Factors
1482499|NCT00055055|Adult and Pediatric Disease
1482500|NCT00055055|Rheumatoid Arthritis
1482501|NCT00055055|Systemic Lupus Erythematosus
1482502|NCT00055055|Systemic Sclerosis
1482503|NCT00055055|Idiopathic Inflammatory Myopathies
1482504|NCT00055055|Inflammatory Myopathies
1482505|NCT00055055|Dermatomyositis
1482506|NCT00055055|Scleroderma
1482507|NCT00055055|SLE
1482508|NCT00055055|Lupus
1482509|NCT00055055|Rheumatic Disease
1482510|NCT00055055|RA
1482511|NCT00055055|Healthy Volunteer
1482512|NCT00055055|HV
1482513|NCT00055042|Types 1 and 2 Diabetes
1482514|NCT00055042|Diode Laser Photocoagulation
1482515|NCT00055042|Vitamin E
1482516|NCT00055042|Elevated Low-Density Lipoprotein (LDL-C) Cholesterol
1482517|NCT00055042|Diabetes Type I
1482518|NCT00055042|Diabetes Type II
1482519|NCT00055042|Diabetic Macular Edema
1482520|NCT00055029|Retinoschisis
1482521|NCT00055029|Genomic DNA
1482522|NCT00055029|Pedigree Analysis
1482523|NCT00055029|Genetic Analysis
1482524|NCT00055029|Macular Degeneration
1482525|NCT00055029|Juvenile Retinoschisis
1482526|NCT00055029|X-Linked Juvenile Retinoschisis
1482527|NCT00055029|XLRS
1482528|NCT00055016|Lysosomal Disease
1482529|NCT00055016|Renal Function
1482530|NCT00055016|Stroke
1482531|NCT00055016|Cardiac Disease
1482532|NCT00055016|Natural History
1482533|NCT00055016|Fabry Disease
1482534|NCT00055003|Amygdala
1482535|NCT00055003|Medial Prefrontal Cortex
1482536|NCT00055003|Orbitofrontal Cortex
1482537|NCT00055003|Cortisol
1482538|NCT00055003|Memory
1482539|NCT00055003|Glucocorticoid
1482540|NCT00055003|Hydrocortisone
1482541|NCT00055003|Stress
1482542|NCT00055003|Perception
1482543|NCT00055003|Affect
1482544|NCT00055003|Healthy Volunteer
1482545|NCT00055003|HV
1482546|NCT00054990|Antiepileptic Drugs
1482547|NCT00054990|Cortical Excitability
1482548|NCT00054990|Transcranial Magnetic Stimulation
1482549|NCT00054990|Epilepsy
1482550|NCT00054990|TMS
1482551|NCT00054990|Healthy Volunteer
1482552|NCT00054990|HV
1482553|NCT00054977|cancer
1482554|NCT00054977|tumor
1482555|NCT00054951|Hepatoma
1482556|NCT00054951|Liver Cancer
1482557|NCT00054938|SLE
1482558|NCT00054938|Accelerated Atherosclerosis
1482559|NCT00054938|Cholesterol
1482560|NCT00054912|vaccine
1482561|NCT00054912|colon
1482562|NCT00054912|cancer
1482563|NCT00054912|colorectal
1482564|NCT00054912|neoplasm
1482565|NCT00054912|Colonic Cancer
1482566|NCT00054912|Colon Cancer
1482567|NCT00054912|Cancer of the Colon
1482568|NCT00054899|vaccine
1482569|NCT00054899|lung
1482570|NCT00054899|cancer
1482571|NCT00054899|Carcinoma, Large Cell
1482572|NCT00054899|Non-Small-Cell Lung Carcinoma
1482573|NCT00054873|Adenocarcinoma of the esophagus or stomach
1482574|NCT00054860|HIV Preventive Vaccine
1482575|NCT00054860|HIV Seronegativity
1482576|NCT00054860|HIV-1
1482577|NCT00054860|AIDS Vaccines
1482578|NCT00054860|Vaccines, DNA
1482579|NCT00054860|Dose-Response Relationship, Immunologic
1482580|NCT00054860|CD4-Positive T-Lymphocytes
1482581|NCT00054860|CD8-Positive T-Lymphocytes
1482582|NCT00054860|Epitopes
1482583|NCT00054847|CABG
1482584|NCT00054847|cardiovascular
1482585|NCT00054847|chronic diseases
1482586|NCT00054847|clinical trial
1482587|NCT00054847|heart
1482588|NCT00054847|multi-site trial
1482589|NCT00054847|prospective
1482590|NCT00054821|Osteoarthritis, Ankle
1482591|NCT00054821|Ankle Distraction
1482592|NCT00054808|Gallium Nitrate
1482593|NCT00054808|Ganite
1482594|NCT00054808|NHL
1482595|NCT00054808|Relapsed
1482596|NCT00054795|Brain Neoplasms/radiotherapy
1482597|NCT00054795|Neoplasms/complications/prevention & control,
1482598|NCT00054795|Neuropsychological Tests,
1482599|NCT00054795|Metalloporphyrins/therapeutic use,
1482600|NCT00054795|Combined Modality Therapy,
1482601|NCT00054795|Drug therapy,
1482602|NCT00054795|Quality of Life,
1482603|NCT00054795|Cranial Irradiation,
1482604|NCT00054795|Radiotherapy/Targeted,
1482605|NCT00054795|Prospective Studies,
1482606|NCT00054795|Neoplasm Recurrence/Local,
1482607|NCT00054795|Treatment Outcome
1482608|NCT00054795|Brain metastases
1482609|NCT00054795|Brain Neoplasms/secondary
1482610|NCT00054795|Non-small cell lung cancer
1482611|NCT00054769|Pediatrics
1482612|NCT00054769|Polymerase Chain Reaction
1482613|NCT00054756|Hypothalamic Releasing Factor
1482614|NCT00054756|Neuropeptide
1482615|NCT00054756|Diagnostic Testing
1482616|NCT00054756|Pituitary Tumors
1482617|NCT00054756|Central Hypothyroidism
1482618|NCT00054756|Pituitary Disorder
1482619|NCT00054756|Thyroid Disorder
1482620|NCT00054756|Healthy Volunteer
1482621|NCT00054756|HV
1482622|NCT00054743|Race
1482623|NCT00054743|Ethnicity
1482624|NCT00054743|Pharmacogenetics
1482625|NCT00054743|Cytochrome P450
1482626|NCT00054743|Population Pharmacokinetics
1482627|NCT00054743|HIV
1482628|NCT00054730|Fragile X Syndrome
1482629|NCT00054730|Autism
1482630|NCT00054704|Riluzole
1482631|NCT00054704|Neuroprotective
1482632|NCT00054704|Open-Label Study
1482633|NCT00054704|Glutamate Dysfunction
1482634|NCT00054704|Bipolar Mood Disorder
1482635|NCT00054704|Bipolar Disorder
1482636|NCT00054704|Mood Disorder
1482637|NCT00054691|Skin Cancer
1482638|NCT00054691|Squamous Cell Carcinoma of the Skin
1482639|NCT00054691|Gefitinib
1482640|NCT00054691|ZD1839
1482641|NCT00054691|Iressa
1482642|NCT00054691|Epidermal Growth Factor Receptor
1482643|NCT00054691|EGFR
1482644|NCT00054678|Myocardial infarction
1482645|NCT00054678|Heart disease
1482646|NCT00054678|Endoventricular
1482647|NCT00054678|Cardiovascular
1482648|NCT00054678|Interventional
1482649|NCT00054678|ICD
1482650|NCT00054678|Heart failure
1482651|NCT00054678|Implantable Cardioverter Defibrillator
1482652|NCT00054665|BCL-2
1482653|NCT00054665|NFK-B
1482654|NCT00054665|Drug Resistance
1482655|NCT00054665|Translational
1482656|NCT00054665|Lymphoma
1482657|NCT00054665|Large B-Cell Lymphoma
1482658|NCT00054652|Geste Antagoniste
1482659|NCT00054652|TMS
1482660|NCT00054652|Sensorimotor Integration
1482661|NCT00054652|Writer's Cramp
1482662|NCT00054652|Sensory Input
1482663|NCT00054652|Focal Dystonia
1482664|NCT00054626|stage II bladder cancer
1482665|NCT00054626|stage III bladder cancer
1482666|NCT00054626|stage IV bladder cancer
1482667|NCT00054626|transitional cell carcinoma of the bladder
1482668|NCT00054613|Graft-versus-Host Disease
1482669|NCT00054613|Extracorporeal Photopheresis
1482670|NCT00054600|Extracorporeal Photopheresis
1482671|NCT00054600|Graft-versus-Host Disease
1482672|NCT00054587|stage II breast cancer
1482673|NCT00054587|stage IIIA breast cancer
1482674|NCT00054574|recurrent prostate cancer
1482675|NCT00054574|stage I prostate cancer
1482676|NCT00054574|stage II prostate cancer
1482677|NCT00054574|stage III prostate cancer
1482678|NCT00054561|stage III squamous cell carcinoma of the lip and oral cavity
1482679|NCT00054561|stage IV squamous cell carcinoma of the lip and oral cavity
1482680|NCT00054561|stage III squamous cell carcinoma of the oropharynx
1482681|NCT00054561|stage IV squamous cell carcinoma of the oropharynx
1482682|NCT00054561|stage III squamous cell carcinoma of the larynx
1482683|NCT00054561|stage IV squamous cell carcinoma of the larynx
1482684|NCT00054561|stage III squamous cell carcinoma of the hypopharynx
1482685|NCT00054561|stage IV squamous cell carcinoma of the hypopharynx
1482686|NCT00054535|stage IV melanoma
1482687|NCT00054535|recurrent melanoma
1482688|NCT00054522|adenocarcinoma of the prostate
1482689|NCT00054522|recurrent prostate cancer
1482690|NCT00054496|adult glioblastoma
1482691|NCT00054496|recurrent adult brain tumor
1482692|NCT00054496|adult giant cell glioblastoma
1482693|NCT00054496|adult gliosarcoma
1482694|NCT00054470|stage IV breast cancer
1482695|NCT00054470|recurrent breast cancer
1482696|NCT00054470|male breast cancer
1482697|NCT00054457|adenocarcinoma of the stomach
1482698|NCT00054457|adenocarcinoma of the esophagus
1482699|NCT00054457|stage IV gastric cancer
1482700|NCT00054457|recurrent gastric cancer
1482701|NCT00054457|stage IV esophageal cancer
1482702|NCT00054457|recurrent esophageal cancer
1482703|NCT00054418|osteoporosis
1482704|NCT00054418|stage I breast cancer
1482705|NCT00054418|stage II breast cancer
1482706|NCT00054418|stage IIIA breast cancer
1482707|NCT00054418|stage IIIB breast cancer
1482708|NCT00054392|adenosquamous cell lung cancer
1482709|NCT00054392|bronchoalveolar cell lung cancer
1482710|NCT00054392|large cell lung cancer
1482711|NCT00054392|recurrent non-small cell lung cancer
1482712|NCT00054392|squamous cell lung cancer
1482713|NCT00054392|stage IIIB non-small cell lung cancer
1482714|NCT00054392|stage IV non-small cell lung cancer
1482715|NCT00054392|adenocarcinoma of the lung
1482716|NCT00054340|graft versus host disease
1482717|NCT00054340|polycythemia vera
1482718|NCT00054340|chronic idiopathic myelofibrosis
1482719|NCT00054340|essential thrombocythemia
1482720|NCT00054340|untreated adult acute myeloid leukemia
1482721|NCT00054340|recurrent adult acute myeloid leukemia
1482722|NCT00054340|recurrent childhood acute myeloid leukemia
1482723|NCT00054340|untreated childhood acute myeloid leukemia and other myeloid malignancies
1482724|NCT00054340|de novo myelodysplastic syndromes
1482725|NCT00054340|previously treated myelodysplastic syndromes
1482726|NCT00054340|secondary myelodysplastic syndromes
1482727|NCT00054340|chronic eosinophilic leukemia
1482728|NCT00054340|chronic neutrophilic leukemia
1482729|NCT00054340|myelodysplastic/myeloproliferative disease, unclassifiable
1482730|NCT00054340|adult acute myeloid leukemia with t(8;21)(q22;q22)
1482731|NCT00054340|adult acute myeloid leukemia with t(16;16)(p13;q22)
1482732|NCT00054340|adult acute myeloid leukemia with inv(16)(p13;q22)
1482733|NCT00054340|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1482734|NCT00054340|adult acute myeloid leukemia with t(15;17)(q22;q12)
1482735|NCT00054340|childhood myelodysplastic syndromes
1482736|NCT00054327|adult acute myeloid leukemia in remission
1482737|NCT00054327|childhood acute myeloid leukemia in remission
1482738|NCT00054327|recurrent adult acute myeloid leukemia
1482739|NCT00054327|recurrent childhood acute myeloid leukemia
1482740|NCT00054327|adult acute lymphoblastic leukemia in remission
1482741|NCT00054327|childhood acute lymphoblastic leukemia in remission
1482742|NCT00054327|refractory anemia with excess blasts in transformation
1482743|NCT00054327|refractory anemia with excess blasts
1482744|NCT00054327|recurrent adult diffuse large cell lymphoma
1482745|NCT00054327|recurrent adult diffuse mixed cell lymphoma
1482746|NCT00054327|recurrent adult diffuse small cleaved cell lymphoma
1482747|NCT00054327|recurrent adult Burkitt lymphoma
1482748|NCT00054327|recurrent adult immunoblastic large cell lymphoma
1482749|NCT00054327|recurrent adult lymphoblastic lymphoma
1482750|NCT00054327|recurrent grade 3 follicular lymphoma
1482751|NCT00054327|secondary acute myeloid leukemia
1482752|NCT00054327|accelerated phase chronic myelogenous leukemia
1482753|NCT00054327|blastic phase chronic myelogenous leukemia
1482754|NCT00054327|chronic phase chronic myelogenous leukemia
1482755|NCT00054327|recurrent childhood large cell lymphoma
1482756|NCT00054327|recurrent childhood lymphoblastic lymphoma
1482757|NCT00054327|recurrent childhood small noncleaved cell lymphoma
1482758|NCT00054327|recurrent mantle cell lymphoma
1482759|NCT00054327|refractory anemia with ringed sideroblasts
1482760|NCT00054327|refractory anemia
1482761|NCT00054327|chronic myelomonocytic leukemia
1482762|NCT00054327|refractory cytopenia with multilineage dysplasia
1482763|NCT00054327|previously treated myelodysplastic syndromes
1482764|NCT00054327|de novo myelodysplastic syndromes
1482765|NCT00054327|secondary myelodysplastic syndromes
1482766|NCT00054327|relapsing chronic myelogenous leukemia
1482767|NCT00054327|childhood chronic myelogenous leukemia
1482768|NCT00054327|atypical chronic myeloid leukemia
1482769|NCT00054327|myelodysplastic/myeloproliferative disease, unclassifiable
1482770|NCT00054327|juvenile myelomonocytic leukemia
1482771|NCT00054327|adult acute myeloid leukemia with t(8;21)(q22;q22)
1482772|NCT00054327|adult acute myeloid leukemia with t(16;16)(p13;q22)
1482773|NCT00054327|adult acute myeloid leukemia with inv(16)(p13;q22)
1482774|NCT00054327|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1482775|NCT00054327|adult acute myeloid leukemia with t(15;17)(q22;q12)
1482776|NCT00054327|childhood myelodysplastic syndromes
1482777|NCT00054314|recurrent non-small cell lung cancer
1482778|NCT00054301|stage I breast cancer
1482779|NCT00054301|stage II breast cancer
1482780|NCT00054301|stage IIIA breast cancer
1482781|NCT00054301|ductal breast carcinoma in situ
1482782|NCT00054301|breast cancer in situ
1482783|NCT00054288|unspecified adult solid tumor, protocol specific
1482784|NCT00054275|recurrent breast cancer
1482785|NCT00054275|stage IV breast cancer
1482786|NCT00054275|male breast cancer
1482787|NCT00054262|localized unresectable adult primary liver cancer
1482788|NCT00054262|advanced adult primary liver cancer
1482789|NCT00054262|adult primary hepatocellular carcinoma
1482790|NCT00054249|recurrent gastric cancer
1482791|NCT00054236|refractory anemia with excess blasts in transformation
1482792|NCT00054236|refractory anemia with excess blasts
1482793|NCT00054236|adult acute myeloid leukemia in remission
1482794|NCT00054236|childhood acute myeloid leukemia in remission
1482795|NCT00054236|recurrent adult acute myeloid leukemia
1482796|NCT00054236|recurrent childhood acute myeloid leukemia
1482797|NCT00054236|adult erythroleukemia (M6a)
1482798|NCT00054236|childhood acute erythroleukemia (M6)
1482799|NCT00054236|adult acute minimally differentiated myeloid leukemia (M0)
1482800|NCT00054236|childhood acute minimally differentiated myeloid leukemia (M0)
1482801|NCT00054236|adult acute megakaryoblastic leukemia (M7)
1482802|NCT00054236|childhood acute megakaryocytic leukemia (M7)
1482803|NCT00054236|adult acute lymphoblastic leukemia in remission
1482804|NCT00054236|childhood acute lymphoblastic leukemia in remission
1482805|NCT00054236|recurrent adult acute lymphoblastic leukemia
1482806|NCT00054236|recurrent childhood acute lymphoblastic leukemia
1482807|NCT00054236|accelerated phase chronic myelogenous leukemia
1482808|NCT00054236|chronic phase chronic myelogenous leukemia
1482809|NCT00054236|previously treated myelodysplastic syndromes
1482810|NCT00054236|refractory chronic lymphocytic leukemia
1482811|NCT00054236|stage I multiple myeloma
1482812|NCT00054236|stage II multiple myeloma
1482813|NCT00054236|stage III multiple myeloma
1482814|NCT00054236|recurrent/refractory childhood Hodgkin lymphoma
1482815|NCT00054236|polycythemia vera
1482816|NCT00054236|primary myelofibrosis
1482817|NCT00054236|essential thrombocythemia
1482818|NCT00054236|refractory multiple myeloma
1482819|NCT00054236|recurrent grade 1 follicular lymphoma
1482820|NCT00054236|recurrent grade 2 follicular lymphoma
1482821|NCT00054236|recurrent grade 3 follicular lymphoma
1482822|NCT00054236|recurrent adult diffuse large cell lymphoma
1482823|NCT00054236|recurrent adult diffuse mixed cell lymphoma
1482824|NCT00054236|recurrent adult diffuse small cleaved cell lymphoma
1482825|NCT00054236|recurrent adult Burkitt lymphoma
1482826|NCT00054236|recurrent adult immunoblastic large cell lymphoma
1482827|NCT00054236|recurrent adult lymphoblastic lymphoma
1482828|NCT00054236|recurrent mantle cell lymphoma
1482829|NCT00054236|recurrent childhood large cell lymphoma
1482830|NCT00054236|recurrent childhood lymphoblastic lymphoma
1482831|NCT00054236|recurrent childhood small noncleaved cell lymphoma
1482832|NCT00054236|childhood diffuse large cell lymphoma
1482833|NCT00054236|childhood immunoblastic large cell lymphoma
1482834|NCT00054236|Burkitt lymphoma
1482835|NCT00054236|anaplastic large cell lymphoma
1482836|NCT00054236|recurrent adult Hodgkin lymphoma
1482837|NCT00054236|childhood chronic myelogenous leukemia
1482838|NCT00054236|chronic eosinophilic leukemia
1482839|NCT00054236|chronic neutrophilic leukemia
1482840|NCT00054236|myelodysplastic/myeloproliferative disease, unclassifiable
1482841|NCT00054236|atypical chronic myeloid leukemia
1482842|NCT00054236|recurrent marginal zone lymphoma
1482843|NCT00054236|recurrent small lymphocytic lymphoma
1482844|NCT00054236|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1482845|NCT00054236|nodal marginal zone B-cell lymphoma
1482846|NCT00054236|splenic marginal zone lymphoma
1482847|NCT00054236|adult acute myeloid leukemia with t(8;21)(q22;q22)
1482848|NCT00054236|adult acute myeloid leukemia with t(16;16)(p13;q22)
1482849|NCT00054236|adult acute myeloid leukemia with inv(16)(p13;q22)
1482850|NCT00054236|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1482851|NCT00054236|adult acute myeloid leukemia with t(15;17)(q22;q12)
1482852|NCT00054236|childhood myelodysplastic syndromes
1482853|NCT00054223|psychosocial effects of cancer and its treatment
1482854|NCT00054223|unspecified adult solid tumor, protocol specific
1482855|NCT00054210|recurrent non-small cell lung cancer
1482856|NCT00054210|stage IIIB non-small cell lung cancer
1482857|NCT00054210|stage IV non-small cell lung cancer
1482858|NCT00054197|recurrent non-small cell lung cancer
1482859|NCT00054197|stage IIIB non-small cell lung cancer
1482860|NCT00054197|stage IV non-small cell lung cancer
1482861|NCT00054184|recurrent non-small cell lung cancer
1482862|NCT00054184|stage IV non-small cell lung cancer
1482863|NCT00054184|stage IIIB non-small cell lung cancer
1482864|NCT00054171|B-cell chronic lymphocytic leukemia
1482865|NCT00054171|stage I cutaneous T-cell non-Hodgkin lymphoma
1482866|NCT00054171|stage I mycosis fungoides/Sezary syndrome
1482867|NCT00054171|stage 0 chronic lymphocytic leukemia
1482868|NCT00054171|stage I chronic lymphocytic leukemia
1482869|NCT00054158|stage I multiple myeloma
1482870|NCT00054158|stage II multiple myeloma
1482871|NCT00054158|stage III multiple myeloma
1482872|NCT00054145|male breast cancer
1482873|NCT00054145|recurrent breast cancer
1482874|NCT00054145|stage IV breast cancer
1482875|NCT00054145|stage IIIA breast cancer
1482876|NCT00054145|stage IIIB breast cancer
1482877|NCT00054145|stage IIIC breast cancer
1482878|NCT00054106|adenocarcinoma of the prostate
1482879|NCT00054106|stage III prostate cancer
1482880|NCT00054106|stage II prostate cancer
1482881|NCT00054067|cervical adenocarcinoma
1482882|NCT00054067|cervical adenosquamous cell carcinoma
1482883|NCT00054067|cervical squamous cell carcinoma
1482884|NCT00054067|stage IB cervical cancer
1482885|NCT00054054|stage III squamous cell carcinoma of the hypopharynx
1482886|NCT00054054|stage III squamous cell carcinoma of the larynx
1482887|NCT00054054|stage III squamous cell carcinoma of the oropharynx
1482888|NCT00054054|stage IV squamous cell carcinoma of the hypopharynx
1482889|NCT00054054|stage IV squamous cell carcinoma of the larynx
1482890|NCT00054054|stage IV squamous cell carcinoma of the oropharynx
1482891|NCT00054015|recurrent prostate cancer
1482892|NCT00054015|stage IV prostate cancer
1482893|NCT00054002|localized malignant mesothelioma
1482894|NCT00054002|recurrent malignant mesothelioma
1482895|NCT00054002|epithelial mesothelioma
1482896|NCT00054002|sarcomatous mesothelioma
1482897|NCT00053989|accelerated phase chronic myelogenous leukemia
1482898|NCT00053989|chronic myelomonocytic leukemia
1482899|NCT00053989|primary myelofibrosis
1482900|NCT00053989|de novo myelodysplastic syndromes
1482901|NCT00053989|chronic phase chronic myelogenous leukemia
1482902|NCT00053989|relapsing chronic myelogenous leukemia
1482903|NCT00053989|refractory anemia with excess blasts
1482904|NCT00053989|stage I multiple myeloma
1482905|NCT00053989|stage II multiple myeloma
1482906|NCT00053989|stage III multiple myeloma
1482907|NCT00053989|Waldenstrom macroglobulinemia
1482908|NCT00053989|stage III adult lymphoblastic lymphoma
1482909|NCT00053989|stage IV adult lymphoblastic lymphoma
1482910|NCT00053989|noncontiguous stage II adult Burkitt lymphoma
1482911|NCT00053989|stage III adult Burkitt lymphoma
1482912|NCT00053989|stage IV adult Burkitt lymphoma
1482913|NCT00053989|recurrent adult Hodgkin lymphoma
1482914|NCT00053989|adult acute myeloid leukemia in remission
1482915|NCT00053989|secondary acute myeloid leukemia
1482916|NCT00053989|recurrent childhood acute lymphoblastic leukemia
1482917|NCT00053989|recurrent adult acute myeloid leukemia
1482918|NCT00053989|childhood acute lymphoblastic leukemia in remission
1482919|NCT00053989|adult acute lymphoblastic leukemia in remission
1482920|NCT00053989|noncontiguous stage II adult lymphoblastic lymphoma
1482921|NCT00053989|refractory multiple myeloma
1482922|NCT00053989|refractory anemia
1482923|NCT00053989|refractory chronic lymphocytic leukemia
1482924|NCT00053989|previously treated myelodysplastic syndromes
1482925|NCT00053989|secondary myelodysplastic syndromes
1482926|NCT00053989|grade 1 follicular lymphoma
1482927|NCT00053989|grade 2 follicular lymphoma
1482928|NCT00053989|recurrent/refractory childhood Hodgkin lymphoma
1482929|NCT00053989|recurrent adult acute lymphoblastic leukemia
1482930|NCT00053989|recurrent childhood acute myeloid leukemia
1482931|NCT00053989|childhood acute myeloid leukemia in remission
1482932|NCT00053989|childhood chronic myelogenous leukemia
1482933|NCT00053989|atypical chronic myeloid leukemia
1482934|NCT00053989|myelodysplastic/myeloproliferative disease, unclassifiable
1482935|NCT00053989|recurrent marginal zone lymphoma
1483035|NCT00053742|Adults
1482936|NCT00053989|recurrent small lymphocytic lymphoma
1482937|NCT00053989|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1482938|NCT00053989|nodal marginal zone B-cell lymphoma
1482939|NCT00053989|splenic marginal zone lymphoma
1482940|NCT00053989|adult acute myeloid leukemia with t(8;21)(q22;q22)
1482941|NCT00053989|adult acute myeloid leukemia with t(16;16)(p13;q22)
1482942|NCT00053989|adult acute myeloid leukemia with inv(16)(p13;q22)
1482943|NCT00053989|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1482944|NCT00053989|adult acute myeloid leukemia with t(15;17)(q22;q12)
1482945|NCT00053989|childhood myelodysplastic syndromes
1482946|NCT00053976|graft versus host disease
1482947|NCT00053937|plexiform neurofibroma
1482948|NCT00053937|neurofibromatosis type 1
1482949|NCT00053924|recurrent pancreatic cancer
1482950|NCT00053924|stage II pancreatic cancer
1482951|NCT00053924|adenocarcinoma of the pancreas
1482952|NCT00053924|stage III pancreatic cancer
1482953|NCT00053924|stage IV pancreatic cancer
1482954|NCT00053911|recurrent breast cancer
1482955|NCT00053911|stage I breast cancer
1482956|NCT00053911|stage II breast cancer
1482957|NCT00053911|stage IIIA breast cancer
1482958|NCT00053898|breast cancer in situ
1482959|NCT00053898|ductal breast carcinoma in situ
1482960|NCT00053885|advanced malignant mesothelioma
1482961|NCT00053885|epithelial mesothelioma
1482962|NCT00053885|recurrent malignant mesothelioma
1482963|NCT00053885|sarcomatous mesothelioma
1482964|NCT00053872|untreated childhood medulloblastoma
1482965|NCT00053846|dyspnea
1482966|NCT00053846|pulmonary complications
1482967|NCT00053846|unspecified adult solid tumor, protocol specific
1482968|NCT00053833|recurrent ovarian epithelial cancer
1482969|NCT00053833|fallopian tube cancer
1482970|NCT00053833|primary peritoneal cavity cancer
1482971|NCT00053833|stage III ovarian epithelial cancer
1482972|NCT00053833|stage IV ovarian epithelial cancer
1482973|NCT00053820|stage IV renal cell cancer
1482974|NCT00053807|stage III renal cell cancer
1482975|NCT00053807|stage IV renal cell cancer
1482976|NCT00053794|adult alveolar soft-part sarcoma
1482977|NCT00053794|adult angiosarcoma
1482978|NCT00053794|adult fibrosarcoma
1482979|NCT00053794|adult leiomyosarcoma
1482980|NCT00053794|adult liposarcoma
1482981|NCT00053794|adult synovial sarcoma
1482982|NCT00053794|endometrial stromal sarcoma
1482983|NCT00053794|uterine leiomyosarcoma
1482984|NCT00053794|adult malignant hemangiopericytoma
1482985|NCT00053794|stage III adult soft tissue sarcoma
1482986|NCT00053794|stage III uterine sarcoma
1482987|NCT00053794|stage IV uterine sarcoma
1482988|NCT00053794|recurrent adult soft tissue sarcoma
1482989|NCT00053794|recurrent uterine sarcoma
1482990|NCT00053794|adult malignant fibrous histiocytoma
1482991|NCT00053794|adult neurofibrosarcoma
1482992|NCT00053794|adult rhabdomyosarcoma
1482993|NCT00053794|stage IV adult soft tissue sarcoma
1482994|NCT00053781|recurrent melanoma
1482995|NCT00053781|stage IV melanoma
1482996|NCT00053768|contiguous stage II grade 3 follicular lymphoma
1482997|NCT00053768|noncontiguous stage II grade 3 follicular lymphoma
1482998|NCT00053768|stage I grade 3 follicular lymphoma
1482999|NCT00053768|stage III grade 3 follicular lymphoma
1483000|NCT00053768|stage IV grade 3 follicular lymphoma
1483001|NCT00053768|contiguous stage II adult diffuse mixed cell lymphoma
1483002|NCT00053768|noncontiguous stage II adult diffuse mixed cell lymphoma
1483003|NCT00053768|stage I adult diffuse mixed cell lymphoma
1483004|NCT00053768|stage III adult diffuse mixed cell lymphoma
1483005|NCT00053768|stage IV adult diffuse mixed cell lymphoma
1483006|NCT00053768|contiguous stage II adult diffuse large cell lymphoma
1483007|NCT00053768|contiguous stage II adult Burkitt lymphoma
1483008|NCT00053768|noncontiguous stage II adult diffuse large cell lymphoma
1483009|NCT00053768|noncontiguous stage II adult Burkitt lymphoma
1483010|NCT00053768|stage I adult diffuse large cell lymphoma
1483011|NCT00053768|stage I adult Burkitt lymphoma
1483012|NCT00053768|stage III adult diffuse large cell lymphoma
1483013|NCT00053768|stage III adult Burkitt lymphoma
1483014|NCT00053768|stage IV adult diffuse large cell lymphoma
1483015|NCT00053768|stage IV adult Burkitt lymphoma
1483016|NCT00053768|contiguous stage II adult immunoblastic large cell lymphoma
1483017|NCT00053768|noncontiguous stage II adult immunoblastic large cell lymphoma
1483018|NCT00053768|stage I adult immunoblastic large cell lymphoma
1483019|NCT00053768|stage III adult immunoblastic large cell lymphoma
1483020|NCT00053768|stage IV adult immunoblastic large cell lymphoma
1483021|NCT00053768|contiguous stage II adult lymphoblastic lymphoma
1483022|NCT00053768|noncontiguous stage II adult lymphoblastic lymphoma
1483023|NCT00053768|stage I adult lymphoblastic lymphoma
1483024|NCT00053768|stage III adult lymphoblastic lymphoma
1483025|NCT00053768|stage IV adult lymphoblastic lymphoma
1483026|NCT00053768|contiguous stage II mantle cell lymphoma
1483027|NCT00053768|noncontiguous stage II mantle cell lymphoma
1483028|NCT00053768|stage I mantle cell lymphoma
1483029|NCT00053768|stage III mantle cell lymphoma
1483030|NCT00053768|stage IV mantle cell lymphoma
1483031|NCT00053742|Smallpox
1483032|NCT00053742|Vaccine
1483033|NCT00053742|Vaccination
1483034|NCT00053742|Variola
1483036|NCT00053742|Healthy Volunteer
1483037|NCT00053742|HV
1483038|NCT00053742|Smallpox Vaccine
1483039|NCT00053716|Angioplasty & PGE1 Treatment of Peripheral Vascular Disease
1483040|NCT00053703|Psychotic Disorders
1483041|NCT00053703|Schizophreniform Disorder
1483042|NCT00053690|Comorbidity
1483043|NCT00053690|Schizophrenia
1483044|NCT00053690|Bipolar Disorder
1483045|NCT00053690|Depression
1483046|NCT00053677|Impulse Control Disorders
1483047|NCT00053638|HIV-1 Efavirenz Tenofovir
1483048|NCT00053625|Parkinson's disease
1483049|NCT00053625|PD
1483050|NCT00053625|deep brain stimulation
1483051|NCT00053625|DBS
1483052|NCT00053612|HIV-1
1483053|NCT00053612|Women
1483054|NCT00053612|Vitamin A
1483055|NCT00053612|Shedding
1483056|NCT00053599|Cholesterol-lowering drug
1483057|NCT00053599|Mild to Moderate Alzheimer disease
1483058|NCT00053573|Glycogen Storage Disease Type II
1483059|NCT00053573|GSD-II
1483060|NCT00053573|Pompe Disease
1483061|NCT00053560|lupus
1483062|NCT00053560|systemic lupus erythematosus
1483063|NCT00053560|SLE
1483064|NCT00053560|bone loss
1483065|NCT00053560|DHEA
1483066|NCT00053495|Smallpox
1483067|NCT00053482|Smallpox vaccines
1483068|NCT00053482|Dryvax®
1483069|NCT00053482|Orthopoxvirus
1483070|NCT00053482|Vaccinia virus
1483071|NCT00053482|ACAM2000
1483072|NCT00053469|Cognitive Development
1483073|NCT00053469|Motor Planning
1483074|NCT00053469|Categorization
1483075|NCT00053469|Perception
1483076|NCT00053469|Adaptation
1483077|NCT00053456|Endothelium
1483078|NCT00053456|Nitric Oxide
1483079|NCT00053456|Myocardial Ischemia
1483080|NCT00053456|Exercise
1483081|NCT00053456|Endothelial Progenitor Cells
1483082|NCT00053443|Adherence
1483083|NCT00053443|Treatment Experienced
1483084|NCT00053430|Immune Modulation
1483085|NCT00053430|Thalidomide
1483086|NCT00053430|Immune reconstitution
1483087|NCT00053430|Treatment Experienced
1483088|NCT00053417|Walking Ability
1483089|NCT00053417|Muscle strength
1483090|NCT00053417|Spasticity
1483091|NCT00053404|Treatment Experienced
1483092|NCT00053404|Drug Resistance
1483093|NCT00053391|stage III melanoma
1483094|NCT00053391|stage IV melanoma
1483095|NCT00053391|recurrent melanoma
1483096|NCT00053378|hypocalcemia, ionized calcium, intensive care
1483097|NCT00053300|extensive stage small cell lung cancer
1483098|NCT00053287|adult acute promyelocytic leukemia (M3)
1483099|NCT00053287|refractory anemia with excess blasts in transformation
1483100|NCT00053287|refractory anemia with excess blasts
1483101|NCT00053287|de novo myelodysplastic syndromes
1483102|NCT00053287|recurrent adult acute myeloid leukemia
1483103|NCT00053287|secondary acute myeloid leukemia
1483104|NCT00053287|untreated adult acute myeloid leukemia
1483105|NCT00053287|blastic phase chronic myelogenous leukemia
1483106|NCT00053287|relapsing chronic myelogenous leukemia
1483107|NCT00053287|previously treated myelodysplastic syndromes
1483108|NCT00053287|secondary myelodysplastic syndromes
1483109|NCT00053287|atypical chronic myeloid leukemia
1483110|NCT00053287|myelodysplastic/myeloproliferative disease, unclassifiable
1483111|NCT00053287|adult acute myeloid leukemia with t(8;21)(q22;q22)
1483112|NCT00053287|adult acute myeloid leukemia with t(16;16)(p13;q22)
1483113|NCT00053287|adult acute myeloid leukemia with inv(16)(p13;q22)
1483114|NCT00053287|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1483115|NCT00053287|adult acute myeloid leukemia with t(15;17)(q22;q12)
1483116|NCT00053261|sexuality and reproductive issues
1483117|NCT00053261|stage IB cervical cancer
1483118|NCT00053248|chronic phase chronic myelogenous leukemia
1483119|NCT00053248|Philadelphia chromosome positive chronic myelogenous leukemia
1483120|NCT00053222|recurrent pancreatic cancer
1483121|NCT00053222|stage II pancreatic cancer
1483122|NCT00053222|stage III pancreatic cancer
1483123|NCT00053222|adenocarcinoma of the pancreas
1483124|NCT00053222|stage IV pancreatic cancer
1483125|NCT00053209|metastatic transitional cell cancer of the renal pelvis and ureter
1483126|NCT00053209|recurrent transitional cell cancer of the renal pelvis and ureter
1483127|NCT00053209|regional transitional cell cancer of the renal pelvis and ureter
1483128|NCT00053209|transitional cell carcinoma of the bladder
1483129|NCT00053209|recurrent bladder cancer
1483130|NCT00053209|stage III bladder cancer
1483131|NCT00053209|stage IV bladder cancer
1483132|NCT00053209|anterior urethral cancer
1483133|NCT00053209|posterior urethral cancer
1483134|NCT00053209|recurrent urethral cancer
1483135|NCT00053209|urethral cancer associated with invasive bladder cancer
1483136|NCT00053196|refractory chronic lymphocytic leukemia
1483137|NCT00053196|prolymphocytic leukemia
1483138|NCT00053196|recurrent adult Hodgkin lymphoma
1483139|NCT00053196|stage I multiple myeloma
1483140|NCT00053196|stage II multiple myeloma
1483141|NCT00053196|stage III multiple myeloma
1483142|NCT00053196|refractory multiple myeloma
1483143|NCT00053196|previously treated myelodysplastic syndromes
1483144|NCT00053196|recurrent adult diffuse large cell lymphoma
1483145|NCT00053196|recurrent adult diffuse mixed cell lymphoma
1483146|NCT00053196|recurrent adult diffuse small cleaved cell lymphoma
1483147|NCT00053196|recurrent adult Burkitt lymphoma
1483148|NCT00053196|recurrent adult immunoblastic large cell lymphoma
1483149|NCT00053196|recurrent grade 1 follicular lymphoma
1483150|NCT00053196|recurrent grade 2 follicular lymphoma
1483151|NCT00053196|recurrent grade 3 follicular lymphoma
1483152|NCT00053196|secondary myelodysplastic syndromes
1483153|NCT00053196|de novo myelodysplastic syndromes
1483154|NCT00053196|recurrent adult acute myeloid leukemia
1483155|NCT00053196|recurrent childhood acute myeloid leukemia
1483156|NCT00053196|recurrent childhood large cell lymphoma
1483157|NCT00053196|recurrent childhood lymphoblastic lymphoma
1483158|NCT00053196|recurrent childhood small noncleaved cell lymphoma
1483159|NCT00053196|recurrent/refractory childhood Hodgkin lymphoma
1483160|NCT00053196|atypical chronic myeloid leukemia, BCR-ABL negative
1483161|NCT00053196|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1483162|NCT00053196|recurrent marginal zone lymphoma
1483163|NCT00053196|recurrent small lymphocytic lymphoma
1483164|NCT00053196|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1483165|NCT00053196|nodal marginal zone B-cell lymphoma
1483166|NCT00053196|splenic marginal zone lymphoma
1483167|NCT00053196|adult acute myeloid leukemia with t(8;21)(q22;q22)
1483168|NCT00053196|adult acute myeloid leukemia with t(16;16)(p13;q22)
1483169|NCT00053196|adult acute myeloid leukemia with inv(16)(p13;q22)
1483170|NCT00053196|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1483171|NCT00053196|adult acute myeloid leukemia with t(15;17)(q22;q12)
1483172|NCT00053196|childhood myelodysplastic syndromes
1483173|NCT00053183|adult glioblastoma
1483174|NCT00053183|adult giant cell glioblastoma
1483175|NCT00053183|adult gliosarcoma
1483176|NCT00053157|graft versus host disease
1483177|NCT00053157|accelerated phase chronic myelogenous leukemia
1483178|NCT00053157|chronic phase chronic myelogenous leukemia
1483179|NCT00053157|primary myelofibrosis
1483180|NCT00053157|childhood acute myeloid leukemia/other myeloid malignancies
1483181|NCT00053157|childhood acute promyelocytic leukemia (M3)
1483182|NCT00053157|recurrent childhood acute lymphoblastic leukemia
1483183|NCT00053157|recurrent childhood acute myeloid leukemia
1483184|NCT00053157|recurrent childhood large cell lymphoma
1483185|NCT00053157|recurrent childhood lymphoblastic lymphoma
1483186|NCT00053157|recurrent childhood small noncleaved cell lymphoma
1483187|NCT00053157|recurrent/refractory childhood Hodgkin lymphoma
1483188|NCT00053157|de novo myelodysplastic syndromes
1483189|NCT00053157|previously treated myelodysplastic syndromes
1483190|NCT00053157|secondary myelodysplastic syndromes
1483191|NCT00053157|meningeal chronic myelogenous leukemia
1483192|NCT00053157|noncontiguous stage II adult diffuse large cell lymphoma
1483571|NCT00052273|protocol specific
1483193|NCT00053157|noncontiguous stage II adult diffuse mixed cell lymphoma
1483194|NCT00053157|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1483195|NCT00053157|noncontiguous stage II adult Burkitt lymphoma
1483196|NCT00053157|noncontiguous stage II adult immunoblastic large cell lymphoma
1483197|NCT00053157|noncontiguous stage II adult lymphoblastic lymphoma
1483198|NCT00053157|noncontiguous stage II grade 1 follicular lymphoma
1483199|NCT00053157|noncontiguous stage II grade 2 follicular lymphoma
1483200|NCT00053157|noncontiguous stage II grade 3 follicular lymphoma
1483201|NCT00053157|noncontiguous stage II mantle cell lymphoma
1483202|NCT00053157|recurrent adult diffuse large cell lymphoma
1483203|NCT00053157|recurrent adult diffuse mixed cell lymphoma
1483204|NCT00053157|recurrent adult diffuse small cleaved cell lymphoma
1483205|NCT00053157|recurrent adult Burkitt lymphoma
1483206|NCT00053157|recurrent adult immunoblastic large cell lymphoma
1483207|NCT00053157|recurrent adult lymphoblastic lymphoma
1483208|NCT00053157|recurrent adult acute lymphoblastic leukemia
1483209|NCT00053157|recurrent adult acute myeloid leukemia
1483210|NCT00053157|recurrent adult Hodgkin lymphoma
1483211|NCT00053157|recurrent cutaneous T-cell non-Hodgkin lymphoma
1483212|NCT00053157|recurrent grade 1 follicular lymphoma
1483213|NCT00053157|recurrent grade 2 follicular lymphoma
1483214|NCT00053157|recurrent grade 3 follicular lymphoma
1483215|NCT00053157|recurrent mantle cell lymphoma
1483216|NCT00053157|relapsing chronic myelogenous leukemia
1483217|NCT00053157|secondary acute myeloid leukemia
1483218|NCT00053157|refractory chronic lymphocytic leukemia
1483219|NCT00053157|stage III adult diffuse large cell lymphoma
1483220|NCT00053157|stage III adult diffuse mixed cell lymphoma
1483221|NCT00053157|stage III adult diffuse small cleaved cell lymphoma
1483222|NCT00053157|stage III adult Burkitt lymphoma
1483223|NCT00053157|stage III adult immunoblastic large cell lymphoma
1483224|NCT00053157|stage III adult lymphoblastic lymphoma
1483225|NCT00053157|stage III grade 1 follicular lymphoma
1483226|NCT00053157|stage III grade 2 follicular lymphoma
1483227|NCT00053157|stage III grade 3 follicular lymphoma
1483228|NCT00053157|stage III mantle cell lymphoma
1483229|NCT00053157|stage III chronic lymphocytic leukemia
1483230|NCT00053157|stage IV adult diffuse large cell lymphoma
1483231|NCT00053157|stage IV adult diffuse mixed cell lymphoma
1483232|NCT00053157|stage IV adult diffuse small cleaved cell lymphoma
1483233|NCT00053157|stage IV adult Burkitt lymphoma
1483234|NCT00053157|stage IV adult immunoblastic large cell lymphoma
1483235|NCT00053157|stage IV adult lymphoblastic lymphoma
1483236|NCT00053157|stage IV grade 1 follicular lymphoma
1483237|NCT00053157|stage IV grade 2 follicular lymphoma
1483238|NCT00053157|stage IV grade 3 follicular lymphoma
1483239|NCT00053157|stage IV mantle cell lymphoma
1483240|NCT00053157|stage IV chronic lymphocytic leukemia
1483241|NCT00053157|untreated adult acute lymphoblastic leukemia
1483242|NCT00053157|untreated adult acute myeloid leukemia
1483243|NCT00053157|untreated childhood acute lymphoblastic leukemia
1483244|NCT00053157|untreated childhood acute myeloid leukemia and other myeloid malignancies
1483245|NCT00053157|childhood chronic myelogenous leukemia
1483246|NCT00053157|chronic eosinophilic leukemia
1483247|NCT00053157|chronic neutrophilic leukemia
1483248|NCT00053157|atypical chronic myeloid leukemia, BCR-ABL1 negative
1483249|NCT00053157|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1483250|NCT00053157|noncontiguous stage II small lymphocytic lymphoma
1483251|NCT00053157|noncontiguous stage II marginal zone lymphoma
1483252|NCT00053157|recurrent marginal zone lymphoma
1483253|NCT00053157|recurrent small lymphocytic lymphoma
1483254|NCT00053157|stage III small lymphocytic lymphoma
1483255|NCT00053157|stage III marginal zone lymphoma
1483256|NCT00053157|stage IV small lymphocytic lymphoma
1483257|NCT00053157|stage IV marginal zone lymphoma
1483258|NCT00053157|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1483259|NCT00053157|nodal marginal zone B-cell lymphoma
1483260|NCT00053157|splenic marginal zone lymphoma
1483261|NCT00053157|adult acute myeloid leukemia with t(8;21)(q22;q22)
1483262|NCT00053157|adult acute myeloid leukemia with t(16;16)(p13;q22)
1483263|NCT00053157|adult acute myeloid leukemia with inv(16)(p13;q22)
1483264|NCT00053157|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1483265|NCT00053157|adult acute myeloid leukemia with t(15;17)(q22;q12)
1483266|NCT00053157|childhood myelodysplastic syndromes
1483267|NCT00053144|recurrent adult acute myeloid leukemia
1483268|NCT00053144|Philadelphia chromosome positive chronic myelogenous leukemia
1483269|NCT00053144|secondary acute myeloid leukemia
1483270|NCT00053144|blastic phase chronic myelogenous leukemia
1483271|NCT00053144|relapsing chronic myelogenous leukemia
1483272|NCT00053144|adult acute monocytic leukemia (M5b)
1483273|NCT00053144|adult acute erythroid leukemia (M6)
1483274|NCT00053144|adult acute megakaryoblastic leukemia (M7)
1483275|NCT00053144|adult acute minimally differentiated myeloid leukemia (M0)
1483276|NCT00053144|adult acute myeloblastic leukemia with maturation (M2)
1483277|NCT00053144|adult acute myeloblastic leukemia without maturation (M1)
1483278|NCT00053144|adult acute myelomonocytic leukemia (M4)
1483279|NCT00053144|adult acute monoblastic leukemia (M5a)
1483280|NCT00053144|adult acute promyelocytic leukemia (M3)
1483281|NCT00053131|recurrent adult acute myeloid leukemia
1483694|NCT00051766|adherence
1483282|NCT00053131|recurrent childhood acute myeloid leukemia
1483283|NCT00053131|recurrent adult acute lymphoblastic leukemia
1483284|NCT00053131|recurrent childhood acute lymphoblastic leukemia
1483285|NCT00053118|childhood central nervous system germ cell tumor
1483286|NCT00053118|childhood choroid plexus tumor
1483287|NCT00053118|childhood craniopharyngioma
1483288|NCT00053118|childhood grade I meningioma
1483289|NCT00053118|childhood grade II meningioma
1483290|NCT00053118|childhood grade III meningioma
1483291|NCT00053118|recurrent childhood brain stem glioma
1483292|NCT00053118|recurrent childhood cerebellar astrocytoma
1483293|NCT00053118|recurrent childhood cerebral astrocytoma
1483294|NCT00053118|recurrent childhood ependymoma
1483295|NCT00053118|recurrent childhood medulloblastoma
1483296|NCT00053118|recurrent childhood supratentorial primitive neuroectodermal tumor
1483297|NCT00053118|recurrent neuroblastoma
1483298|NCT00053118|recurrent retinoblastoma
1483299|NCT00053118|childhood visual pathway and hypothalamic glioma
1483300|NCT00053118|childhood atypical teratoid/rhabdoid tumor
1483301|NCT00053118|primary central nervous system non-Hodgkin lymphoma
1483302|NCT00053105|recurrent adult diffuse large cell lymphoma
1483303|NCT00053105|recurrent grade 3 follicular lymphoma
1483304|NCT00053105|recurrent cutaneous T-cell non-Hodgkin lymphoma
1483305|NCT00053105|recurrent adult immunoblastic large cell lymphoma
1483306|NCT00053092|contiguous stage II mantle cell lymphoma
1483307|NCT00053092|noncontiguous stage II mantle cell lymphoma
1483308|NCT00053092|stage I mantle cell lymphoma
1483309|NCT00053092|stage III mantle cell lymphoma
1483310|NCT00053092|stage IV mantle cell lymphoma
1483311|NCT00053053|unspecified adult solid tumor, protocol specific
1483312|NCT00053053|cachexia
1483313|NCT00053053|recurrent adult diffuse large cell lymphoma
1483314|NCT00053053|recurrent adult diffuse mixed cell lymphoma
1483315|NCT00053053|recurrent adult diffuse small cleaved cell lymphoma
1483316|NCT00053053|recurrent adult Hodgkin lymphoma
1483317|NCT00053053|recurrent adult immunoblastic large cell lymphoma
1483318|NCT00053053|recurrent adult lymphoblastic lymphoma
1483319|NCT00053053|recurrent cutaneous T-cell non-Hodgkin lymphoma
1483320|NCT00053053|recurrent grade 1 follicular lymphoma
1483321|NCT00053053|recurrent grade 2 follicular lymphoma
1483322|NCT00053053|recurrent grade 3 follicular lymphoma
1483323|NCT00053053|recurrent mantle cell lymphoma
1483625|NCT00052026|Support, Non-U.S. Gov't
1483324|NCT00053053|stage III adult diffuse large cell lymphoma
1483325|NCT00053053|stage III adult diffuse mixed cell lymphoma
1483326|NCT00053053|stage III adult diffuse small cleaved cell lymphoma
1483327|NCT00053053|stage III adult Burkitt lymphoma
1483328|NCT00053053|stage III adult Hodgkin lymphoma
1483329|NCT00053053|stage III adult immunoblastic large cell lymphoma
1483330|NCT00053053|stage III adult lymphoblastic lymphoma
1483331|NCT00053053|stage III cutaneous T-cell non-Hodgkin lymphoma
1483332|NCT00053053|stage III grade 1 follicular lymphoma
1483333|NCT00053053|stage III grade 2 follicular lymphoma
1483334|NCT00053053|stage III grade 3 follicular lymphoma
1483335|NCT00053053|stage III mantle cell lymphoma
1483336|NCT00053053|stage IV adult diffuse large cell lymphoma
1483337|NCT00053053|stage IV adult diffuse mixed cell lymphoma
1483338|NCT00053053|stage IV adult diffuse small cleaved cell lymphoma
1483339|NCT00053053|stage IV adult Burkitt lymphoma
1483340|NCT00053053|stage IV adult Hodgkin lymphoma
1483341|NCT00053053|stage IV adult immunoblastic large cell lymphoma
1483342|NCT00053053|stage IV adult lymphoblastic lymphoma
1483343|NCT00053053|stage IV cutaneous T-cell non-Hodgkin lymphoma
1483344|NCT00053053|stage IV grade 1 follicular lymphoma
1483345|NCT00053053|stage IV grade 2 follicular lymphoma
1483346|NCT00053053|stage IV grade 3 follicular lymphoma
1483347|NCT00053053|stage IV mantle cell lymphoma
1483348|NCT00053053|intraocular lymphoma
1483349|NCT00053053|AIDS-related peripheral/systemic lymphoma
1483350|NCT00053053|recurrent adult Burkitt lymphoma
1483351|NCT00053053|anaplastic large cell lymphoma
1483352|NCT00053053|post-transplant lymphoproliferative disorder
1483353|NCT00053053|recurrent marginal zone lymphoma
1483354|NCT00053053|recurrent small lymphocytic lymphoma
1483355|NCT00053053|stage III small lymphocytic lymphoma
1483356|NCT00053053|stage III marginal zone lymphoma
1483357|NCT00053053|stage IV small lymphocytic lymphoma
1483358|NCT00053053|stage IV marginal zone lymphoma
1483359|NCT00053053|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1483360|NCT00053053|nodal marginal zone B-cell lymphoma
1483361|NCT00053053|splenic marginal zone lymphoma
1483362|NCT00053040|recurrent childhood brain tumor
1483363|NCT00053027|contiguous stage II mantle cell lymphoma
1483364|NCT00053027|noncontiguous stage II mantle cell lymphoma
1483365|NCT00053027|stage I mantle cell lymphoma
1483366|NCT00053027|stage III mantle cell lymphoma
1483367|NCT00053027|stage IV mantle cell lymphoma
1483368|NCT00053014|adult acute myeloid leukemia in remission
1483369|NCT00053014|adult acute myeloid leukemia with t(8;21)(q22;q22)
1483370|NCT00053014|adult acute myeloid leukemia with t(16;16)(p13;q22)
1483371|NCT00053014|adult acute myeloid leukemia with inv(16)(p13;q22)
1483372|NCT00053014|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1483373|NCT00053001|de novo myelodysplastic syndromes
1483374|NCT00053001|secondary myelodysplastic syndromes
1483695|NCT00051766|intervention
1483375|NCT00053001|previously treated myelodysplastic syndromes
1483376|NCT00053001|anemia
1483377|NCT00053001|atypical chronic myeloid leukemia, BCR-ABL1 negative
1483378|NCT00053001|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1483379|NCT00053001|childhood myelodysplastic syndromes
1483380|NCT00052962|Appendiceal Cancer
1483381|NCT00052962|Regional Therapy
1483382|NCT00052962|Carcinomatosis
1483383|NCT00052962|Hyperthermia
1483384|NCT00052936|anaplastic large cell lymphoma
1483385|NCT00052936|angioimmunoblastic T-cell lymphoma
1483386|NCT00052936|stage III grade 1 follicular lymphoma
1483387|NCT00052936|stage III grade 3 follicular lymphoma
1483388|NCT00052936|stage III grade 2 follicular lymphoma
1483389|NCT00052936|stage I adult T-cell leukemia/lymphoma
1483390|NCT00052936|stage II adult T-cell leukemia/lymphoma
1483391|NCT00052936|stage III adult T-cell leukemia/lymphoma
1483392|NCT00052936|stage IV adult T-cell leukemia/lymphoma
1483393|NCT00052936|contiguous stage II adult lymphoblastic lymphoma
1483394|NCT00052936|noncontiguous stage II adult lymphoblastic lymphoma
1483395|NCT00052936|stage I adult lymphoblastic lymphoma
1483396|NCT00052936|stage III adult lymphoblastic lymphoma
1483397|NCT00052936|stage IV adult lymphoblastic lymphoma
1483398|NCT00052936|contiguous stage II adult diffuse large cell lymphoma
1483399|NCT00052936|noncontiguous stage II adult diffuse large cell lymphoma
1483400|NCT00052936|stage I adult diffuse large cell lymphoma
1483401|NCT00052936|stage III adult diffuse large cell lymphoma
1483402|NCT00052936|stage IV adult diffuse large cell lymphoma
1483403|NCT00052936|contiguous stage II mantle cell lymphoma
1483404|NCT00052936|noncontiguous stage II mantle cell lymphoma
1483405|NCT00052936|stage I mantle cell lymphoma
1483406|NCT00052936|stage III mantle cell lymphoma
1483407|NCT00052936|stage IV mantle cell lymphoma
1483408|NCT00052936|contiguous stage II adult Burkitt lymphoma
1483409|NCT00052936|noncontiguous stage II adult Burkitt lymphoma
1483410|NCT00052936|stage I adult Burkitt lymphoma
1483411|NCT00052936|stage III adult Burkitt lymphoma
1483412|NCT00052936|stage IV adult Burkitt lymphoma
1483413|NCT00052936|contiguous stage II marginal zone lymphoma
1483414|NCT00052936|noncontiguous stage II marginal zone lymphoma
1483415|NCT00052936|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1483416|NCT00052936|nodal marginal zone B-cell lymphoma
1483417|NCT00052936|splenic marginal zone lymphoma
1483418|NCT00052936|stage I marginal zone lymphoma
1483419|NCT00052936|stage III marginal zone lymphoma
1483420|NCT00052936|stage IV marginal zone lymphoma
1483421|NCT00052923|recurrent adult diffuse large cell lymphoma
1483422|NCT00052910|stage I gastric cancer
1483423|NCT00052910|stage II gastric cancer
1483424|NCT00052910|stage III gastric cancer
1483425|NCT00052910|adenocarcinoma of the stomach
1483426|NCT00052910|adenocarcinoma of the esophagus
1483427|NCT00052910|stage I esophageal cancer
1483428|NCT00052910|stage II esophageal cancer
1483429|NCT00052910|stage III esophageal cancer
1483430|NCT00052897|anal cancer
1483431|NCT00052884|drug/agent toxicity by tissue/organ
1483432|NCT00052884|primary systemic amyloidosis
1483433|NCT00052845|adenocarcinoma of the prostate
1483434|NCT00052845|recurrent prostate cancer
1483435|NCT00052845|stage IV prostate cancer
1483436|NCT00052832|chronic myelomonocytic leukemia
1483437|NCT00052832|previously treated myelodysplastic syndromes
1483438|NCT00052832|secondary myelodysplastic syndromes
1483439|NCT00052832|de novo myelodysplastic syndromes
1483440|NCT00052832|atypical chronic myeloid leukemia
1483441|NCT00052832|myelodysplastic/myeloproliferative disease, unclassifiable
1483442|NCT00052754|adult synovial sarcoma
1483443|NCT00052754|stage III adult soft tissue sarcoma
1483444|NCT00052754|recurrent adult soft tissue sarcoma
1483445|NCT00052754|stage IV adult soft tissue sarcoma
1483446|NCT00052728|stage IV breast cancer
1483447|NCT00052728|recurrent breast cancer
1483448|NCT00052715|adult glioblastoma
1483449|NCT00052715|adult giant cell glioblastoma
1483450|NCT00052715|adult gliosarcoma
1483451|NCT00052676|stage I breast cancer
1483452|NCT00052676|stage II breast cancer
1483453|NCT00052637|bladder cancer
1483454|NCT00052637|recurrent bladder cancer
1483455|NCT00052637|stage 0 bladder cancer
1483456|NCT00052624|recurrent childhood cerebral astrocytoma
1483457|NCT00052611|lip and oral cavity cancer
1483458|NCT00052611|paranasal sinus and nasal cavity cancer
1483459|NCT00052611|hypopharyngeal cancer
1483460|NCT00052611|laryngeal cancer
1483461|NCT00052611|oropharyngeal cancer
1483462|NCT00052611|nasopharyngeal cancer
1483463|NCT00052611|salivary gland cancer
1483464|NCT00052572|refractory chronic lymphocytic leukemia
1483465|NCT00052572|B-cell chronic lymphocytic leukemia
1483466|NCT00052572|recurrent grade 1 follicular lymphoma
1483467|NCT00052572|recurrent grade 2 follicular lymphoma
1483468|NCT00052572|recurrent grade 3 follicular lymphoma
1483469|NCT00052572|Waldenström macroglobulinemia
1483470|NCT00052572|recurrent marginal zone lymphoma
1483471|NCT00052572|recurrent small lymphocytic lymphoma
1483472|NCT00052572|recurrent mantle cell lymphoma
1483473|NCT00052572|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1483474|NCT00052572|nodal marginal zone B-cell lymphoma
1483475|NCT00052572|splenic marginal zone lymphoma
1483476|NCT00052507|stage IV colon cancer
1483477|NCT00052507|stage IV rectal cancer
1483478|NCT00052507|adenocarcinoma of the colon
1483479|NCT00052507|adenocarcinoma of the rectum
1483480|NCT00052507|recurrent colon cancer
1483481|NCT00052507|recurrent rectal cancer
1483482|NCT00052494|extensive stage small cell lung cancer
1483483|NCT00052494|recurrent small cell lung cancer
1483484|NCT00052481|stage IIB prostate cancer
1483485|NCT00052481|stage IIA prostate cancer
1483486|NCT00052481|adenocarcinoma of the prostate
1483487|NCT00052468|stage I ovarian epithelial cancer
1483488|NCT00052468|stage II ovarian epithelial cancer
1483489|NCT00052468|stage III ovarian epithelial cancer
1483490|NCT00052468|stage IV ovarian epithelial cancer
1483491|NCT00052468|fallopian tube cancer
1483492|NCT00052455|adult glioblastoma
1483493|NCT00052455|adult anaplastic astrocytoma
1483494|NCT00052455|recurrent adult brain tumor
1483495|NCT00052455|adult giant cell glioblastoma
1483496|NCT00052455|adult gliosarcoma
1483497|NCT00052442|recurrent adult diffuse large cell lymphoma
1483498|NCT00052442|recurrent adult diffuse mixed cell lymphoma
1483499|NCT00052442|recurrent adult Burkitt lymphoma
1483500|NCT00052442|recurrent adult immunoblastic large cell lymphoma
1483501|NCT00052442|recurrent adult lymphoblastic lymphoma
1483502|NCT00052442|recurrent mantle cell lymphoma
1483503|NCT00052442|recurrent adult Hodgkin lymphoma
1483504|NCT00052442|recurrent grade 3 follicular lymphoma
1483505|NCT00052429|stage II lymphoepithelioma of the nasopharynx
1483506|NCT00052429|stage II squamous cell carcinoma of the nasopharynx
1483507|NCT00052429|stage III lymphoepithelioma of the nasopharynx
1483508|NCT00052429|stage III squamous cell carcinoma of the nasopharynx
1483509|NCT00052429|stage IV lymphoepithelioma of the nasopharynx
1483510|NCT00052429|stage IV squamous cell carcinoma of the nasopharynx
1483511|NCT00052416|B-cell chronic lymphocytic leukemia
1483512|NCT00052416|stage 0 chronic lymphocytic leukemia
1483513|NCT00052416|stage I chronic lymphocytic leukemia
1483514|NCT00052416|stage II chronic lymphocytic leukemia
1483515|NCT00052416|stage III chronic lymphocytic leukemia
1483516|NCT00052416|stage IV chronic lymphocytic leukemia
1483517|NCT00052416|stage I grade 1 follicular lymphoma
1483518|NCT00052416|stage III grade 1 follicular lymphoma
1483519|NCT00052416|stage IV grade 1 follicular lymphoma
1483520|NCT00052416|contiguous stage II grade 1 follicular lymphoma
1483521|NCT00052416|noncontiguous stage II grade 1 follicular lymphoma
1483522|NCT00052416|contiguous stage II grade 2 follicular lymphoma
1483523|NCT00052416|noncontiguous stage II grade 2 follicular lymphoma
1483524|NCT00052416|stage I grade 2 follicular lymphoma
1483525|NCT00052416|stage III grade 2 follicular lymphoma
1483526|NCT00052416|stage IV grade 2 follicular lymphoma
1483527|NCT00052416|Waldenström macroglobulinemia
1483528|NCT00052416|contiguous stage II marginal zone lymphoma
1483529|NCT00052416|contiguous stage II small lymphocytic lymphoma
1483530|NCT00052416|noncontiguous stage II small lymphocytic lymphoma
1483531|NCT00052416|noncontiguous stage II marginal zone lymphoma
1483532|NCT00052416|stage I marginal zone lymphoma
1483533|NCT00052416|stage I small lymphocytic lymphoma
1483534|NCT00052416|stage III small lymphocytic lymphoma
1483535|NCT00052416|stage III marginal zone lymphoma
1483536|NCT00052416|stage IV small lymphocytic lymphoma
1483537|NCT00052416|stage IV marginal zone lymphoma
1483538|NCT00052416|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1483539|NCT00052416|nodal marginal zone B-cell lymphoma
1483540|NCT00052416|splenic marginal zone lymphoma
1483541|NCT00052390|recurrent adult soft tissue sarcoma
1483542|NCT00052390|stage III adult soft tissue sarcoma
1483543|NCT00052390|stage IV adult soft tissue sarcoma
1483544|NCT00052351|stage II breast cancer
1483545|NCT00052351|stage IIIA breast cancer
1483546|NCT00052351|stage IIIB breast cancer
1483547|NCT00052325|stage IV non-small cell lung cancer
1483548|NCT00052325|stage IIIB non-small cell lung cancer
1483549|NCT00052312|recurrent endometrial carcinoma
1483550|NCT00052312|stage III endometrial carcinoma
1483551|NCT00052312|stage IV endometrial carcinoma
1483552|NCT00052312|endometrial papillary serous carcinoma
1483553|NCT00052299|adult acute monocytic leukemia (M5b)
1483554|NCT00052299|adult acute erythroid leukemia (M6)
1483555|NCT00052299|adult acute megakaryoblastic leukemia (M7)
1483556|NCT00052299|adult acute minimally differentiated myeloid leukemia (M0)
1483557|NCT00052299|adult acute myeloblastic leukemia with maturation (M2)
1483558|NCT00052299|adult acute myeloblastic leukemia without maturation (M1)
1483559|NCT00052299|adult acute myelomonocytic leukemia (M4)
1483560|NCT00052299|adult acute monoblastic leukemia (M5a)
1483561|NCT00052299|untreated adult acute myeloid leukemia
1483562|NCT00052299|secondary acute myeloid leukemia
1483563|NCT00052299|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1483564|NCT00052299|adult acute myeloid leukemia with inv(16)(p13;q22)
1483565|NCT00052299|adult acute myeloid leukemia with t(16;16)(p13;q22)
1483566|NCT00052299|adult acute myeloid leukemia with t(8;21)(q22;q22)
1483567|NCT00052286|adult brain tumor
1483568|NCT00052286|fatigue
1483569|NCT00052286|cognitive/functional effects
1483570|NCT00052273|unspecified adult solid tumor
1483572|NCT00052221|unspecified adult solid tumor, protocol specific
1483573|NCT00052221|fatigue
1483574|NCT00052195|Mycobacterium vaccae
1483575|NCT00052195|BCG
1483576|NCT00052195|Disseminated tuberculosis
1483577|NCT00052195|SRL-172
1483578|NCT00052195|DAR-901
1483579|NCT00052182|HIV Therapeutic Vaccine
1483580|NCT00052182|CTL Epitope
1483581|NCT00052182|Treatment Experienced
1483582|NCT00052169|metastatic breast cancer
1483583|NCT00052169|docetaxel
1483584|NCT00052169|Taxotere
1483585|NCT00052169|ZD 1839
1483586|NCT00052169|gefitinib
1483587|NCT00052169|NSABP
1483588|NCT00052169|advanced breast cancer
1483589|NCT00052169|AstraZeneca
1483590|NCT00052143|Huntington's disease
1483591|NCT00052143|HD
1483592|NCT00052143|Huntington disease
1483593|NCT00052091|Geriatrics
1483594|NCT00052078|Phobic Disorders
1483595|NCT00052078|Anxiety, Separation
1483596|NCT00052052|idiopathic pulmonary fibrosis
1483597|NCT00052052|IPF
1483598|NCT00052039|idiopathic pulmonary fibrosis
1483599|NCT00052026|Adolescent
1483600|NCT00052026|Adrenergic alpha-Antagonists/therapeutic use
1483601|NCT00052026|Adrenergic alpha-Antagonists/pharmacokinetics
1483602|NCT00052026|Adrenergic alpha-Antagonists/administration & dosage
1483603|NCT00052026|Adrenergic beta-Antagonists/therapeutic use
1483604|NCT00052026|Adrenergic beta-Antagonists/pharmacokinetics
1483605|NCT00052026|Adrenergic beta-Antagonists/administration & dosage
1483606|NCT00052026|Age Factors
1483607|NCT00052026|Carbazoles/therapeutic use
1483608|NCT00052026|Carbazoles/administration & dosage
1483609|NCT00052026|Child
1483610|NCT00052026|Child, Preschool
1483611|NCT00052026|Drug Administration Schedule
1483612|NCT00052026|Female
1483613|NCT00052026|Heart Failure, Congestive/etiology
1483614|NCT00052026|Heart Failure, Congestive/drug therapy
1483615|NCT00052026|Heart Failure, Congestive/blood
1483616|NCT00052026|Human
1483617|NCT00052026|Infant
1483618|NCT00052026|Infant, Newborn
1483619|NCT00052026|Male
1483620|NCT00052026|Natriuretic Peptide, Brain/blood
1483621|NCT00052026|Placebos
1483622|NCT00052026|Propanolamines/therapeutic use
1483623|NCT00052026|Propanolamines/administration & dosage
1483624|NCT00052026|Prospective Studies
1483626|NCT00052026|Treatment Outcome
1483627|NCT00052026|Ventricular Dysfunction/drug therapy
1483628|NCT00052026|Ventricular Dysfunction/complications
1483629|NCT00052026|Ventricular Dysfunction/blood
1483630|NCT00052026|Ventricular Function/drug effects
1483631|NCT00052026|Ventricular Remodeling/drug effects
1483632|NCT00052013|von Hippel-Lindau disease,
1483633|NCT00052013|CNS,
1483634|NCT00052013|hemangioblastoma,
1483635|NCT00052013|retinal
1483636|NCT00051961|Dopamine
1483637|NCT00051961|Spinal Physiology
1483638|NCT00051961|Flexor Reflex
1483639|NCT00051961|Ropinirole
1483640|NCT00051961|Motor Control
1483641|NCT00051961|Dopaminergic
1483642|NCT00051961|Restless Legs
1483643|NCT00051935|Glycogen Storage Disease Type II
1483644|NCT00051935|GSD-II
1483645|NCT00051935|Pompe Disease
1483646|NCT00051922|HIV Preventive Vaccine
1483647|NCT00051922|HIV Seronegativity
1483648|NCT00051909|Alzheimer's Disease
1483649|NCT00051870|Verbal Memory
1483650|NCT00051870|Inhibition
1483651|NCT00051870|Transcranial Magnetic Stimulation
1483652|NCT00051870|Cortical Excitability
1483653|NCT00051870|Nonverbal Memory
1483654|NCT00051857|Magnetic Resonance Imaging
1483655|NCT00051857|Muscle
1483656|NCT00051857|Bone
1483657|NCT00051857|Dynamics
1483658|NCT00051857|Visualization
1483659|NCT00051844|HIV
1483660|NCT00051844|NNRTI Failure
1483661|NCT00051844|HIV Infections
1483662|NCT00051831|Treatment Naive
1483663|NCT00051831|HIV-1
1483664|NCT00051831|Virus Replication
1483665|NCT00051831|CD4-Positive T-Lymphocytes
1483666|NCT00051831|Immunologic Memory
1483667|NCT00051831|Pentafuside
1483668|NCT00051831|Anti-HIV Agents
1483669|NCT00051831|Drug Therapy, Combination
1483670|NCT00051831|Saquinavir
1483671|NCT00051831|Ritonavir
1483672|NCT00051831|Tenofovir Disoproxil Fumarate
1483673|NCT00051831|RNA, Viral
1483674|NCT00051831|Viral Load
1483675|NCT00051831|Fusion Inhibitors
1483676|NCT00051831|Entry Inhibitors
1483677|NCT00051818|chronic HIV infection
1483678|NCT00051818|treatment interruption
1483679|NCT00051818|HIV-specific immune response
1483680|NCT00051818|immune response
1483681|NCT00051818|virological response
1483682|NCT00051818|treatment experienced
1483683|NCT00051805|Patient Compliance
1483684|NCT00051805|Adherence
1483685|NCT00051805|Treatment Experienced
1483686|NCT00051779|CAL
1483687|NCT00051779|Parathyroid hormone-related protein (PTHrP)
1483688|NCT00051779|Breast Cancer
1483689|NCT00051779|Bone Metastasis
1483690|NCT00051779|Hypercalcemia
1483691|NCT00051766|compliance
1483692|NCT00051766|medication
1483693|NCT00051766|antiretroviral
1483696|NCT00051766|treatment experienced
1483697|NCT00051753|Otitis Media
1483698|NCT00051753|Acute Otitis Media
1483699|NCT00051753|ear infection
1483700|NCT00051753|levofloxacin
1483701|NCT00051753|amoxicillin
1483702|NCT00051753|clavulanate
1483703|NCT00051714|Social Behavior Disorders
1483704|NCT00051701|Non-Hodgkins lymphoma
1483705|NCT00051701|NHL
1483706|NCT00051701|Campath
1483707|NCT00051701|alemtuzumab
1483708|NCT00051675|adenocarcinoma
1483709|NCT00051675|monoclonal antibody
1483710|NCT00051636|Bisphosphonate
1483711|NCT00051636|SAP
1483712|NCT00051636|SAP excess
1483713|NCT00051636|non-inferiority
1483714|NCT00051636|therapeutic response
1483715|NCT00051636|extended observation period
1483716|NCT00051623|Psoriatic arthritis
1483717|NCT00051623|Infliximab
1483718|NCT00051623|Remicade
1483719|NCT00051571|Carcinoma, Non-Small-Cell Lung
1483720|NCT00051545|liver
1483721|NCT00051545|cancer
1483722|NCT00051545|hepatocellular
1483723|NCT00051545|carcinoma
1483724|NCT00051532|hepatocellular
1483725|NCT00051532|carcinoma
1483726|NCT00051532|liver
1483727|NCT00051532|cancer
1483728|NCT00051519|HIV
1483729|NCT00051519|AIDS
1483730|NCT00051519|Vaccine
1483731|NCT00051519|HIV-positive
1483732|NCT00051519|Therapy
1483733|NCT00051493|Non-Small Cell Lung Cancer
1483734|NCT00051493|Lung Cancer
1483735|NCT00051493|NSCLC
1483736|NCT00051493|Advanced Non-Small Cell Lung Cancer
1483737|NCT00051454|HIV Seronegativity
1483738|NCT00051454|HIV Preventive Vaccine
1483739|NCT00051441|stomatitis
1483740|NCT00051441|radiation effects
1483741|NCT00051428|Fibromyalgia, Reiki, Energy Medicine
1483742|NCT00051415|Flaxseed
1483743|NCT00051415|Cholesterol
1483744|NCT00051402|Postmenopausal
1483745|NCT00051402|Memory Loss
1483746|NCT00051402|Cognition
1483747|NCT00051402|Phytoestrogens
1483748|NCT00051363|Obstructive Sleep Apnea
1483749|NCT00051337|Kinesiogenic
1483750|NCT00051337|Psychogenic
1483751|NCT00051337|Channelopathy
1483752|NCT00051337|Ictal
1483753|NCT00051337|Paroxysmal Dyskinesia
1483754|NCT00051337|Psychogenic Movement Disorders
1483755|NCT00051337|Single Photon Emission
1483756|NCT00051337|Computed Tomography (SPECT)
1483757|NCT00051324|Huntington's disease
1483758|NCT00051324|Huntington disease
1483759|NCT00051324|HD
1483760|NCT00051311|Lymphoma
1483761|NCT00051311|Leukemia
1483762|NCT00051311|Hodgkin's Disease
1483763|NCT00051311|Multiple Myeloma
1483764|NCT00051311|Immunotherapy
1483765|NCT00051285|CHF
1483766|NCT00051285|heart
1483767|NCT00051285|failure
1483768|NCT00051285|congestive
1483769|NCT00051285|enoximone
1483770|NCT00051285|phosphodiesterase
1483771|NCT00051285|inhibitor
1483772|NCT00051272|depression, sexual dysfunction, orgasm disorder, MDD
1483773|NCT00051259|depression
1483774|NCT00051259|MDD
1483775|NCT00051259|sexual dysfunction
1483776|NCT00051259|orgasm disorder
1483777|NCT00051207|Mood Disorders
1483778|NCT00051207|Psychotherapy
1483779|NCT00051207|Comorbidity
1483780|NCT00051194|Glaucoma
1483781|NCT00051194|POAG
1483782|NCT00051194|OAG
1483783|NCT00051194|OHT
1483784|NCT00050778|Multiple Sclerosis
1483785|NCT00050778|Active Relapsing-Remitting Multiple Sclerosis
1483786|NCT00050765|Myocardial Infarction
1483787|NCT00050765|Heart disease
1483788|NCT00050765|Coronary bypass graft (CABG) surgery
1483789|NCT00050765|Implantable Cardioverter Defibrillator (ICD)
1483790|NCT00050765|CABG
1483791|NCT00050765|ICD
1483792|NCT00050765|Heart failure
1483793|NCT00050752|Renal Cancer
1483794|NCT00050752|Hereditary Leiomyomatosis
1483795|NCT00050752|Uterine Fibroid
1483796|NCT00050752|Cutaneous Leiomyoma
1483797|NCT00050726|Interleukin-2
1483798|NCT00050726|Immunotherapy
1483799|NCT00050726|HIV
1483800|NCT00050726|IL-2
1483801|NCT00050713|Kidney Disease
1483802|NCT00050713|Glomerulonephritis
1483803|NCT00050713|Lupus Nephritis
1483804|NCT00050713|Nephrotic Syndrome
1483805|NCT00050713|Hyperlipidemia
1483806|NCT00050700|PET
1483807|NCT00050700|[18F]FP-TZTP
1483808|NCT00050700|Bipolar Disorder
1483809|NCT00050700|Major Depressive Disorder
1483810|NCT00050700|Muscarinic 2 Receptors
1483811|NCT00050674|lung cancer, oncology, neutropenia, chemotherapy, filgrastim
1483812|NCT00050661|psoriasis
1483813|NCT00050661|Cyclosporine
1483814|NCT00050661|Daclizamub
1483815|NCT00050661|anti-TAC
1483816|NCT00050661|dermatology
1483817|NCT00050661|skin
1483818|NCT00050661|lesions
1483819|NCT00050648|psoriasis
1483820|NCT00050648|Daclizumab
1483821|NCT00050648|Cyclosporin
1483822|NCT00050648|anti-TAC
1483823|NCT00050648|dermatology
1483824|NCT00050648|skin
1483825|NCT00050635|chemotherapy induced diarrhea
1483826|NCT00050635|diarrhea
1483827|NCT00050635|CTID
1483828|NCT00050635|colorectal cancer
1483829|NCT00050635|Sandostatin LAR Depot
1483830|NCT00050635|Sandostatin
1483831|NCT00050635|adverse events
1483832|NCT00050635|side effects
1483833|NCT00050531|Chronic Myelogenous Leukemia
1483834|NCT00050531|CML
1483835|NCT00050531|Early Chronic Phase Chronic Myelogenous Leukemia
1483836|NCT00050531|Imatinib Mesylate
1483837|NCT00050531|Gleevec
1483838|NCT00050531|Peg-Alpha Interferon
1483839|NCT00050531|Peg-Intron
1483840|NCT00050531|Sargramostim
1483841|NCT00050531|GM-CSF
1483842|NCT00051181|Glaucoma
1483843|NCT00051181|POAG
1483844|NCT00051181|OAG
1483845|NCT00051181|OHT
1483846|NCT00051168|Glaucoma
1483847|NCT00051168|POAG
1483848|NCT00051168|OAG
1483849|NCT00051168|OHT
1483850|NCT00051155|Glaucoma
1483851|NCT00051155|POAG
1483852|NCT00051155|OAG
1483853|NCT00051155|OHT
1483854|NCT00051142|Glaucoma
1483855|NCT00051142|POAG
1483856|NCT00051142|OAG
1483857|NCT00051142|OHT
1483858|NCT00051129|AMD
1483859|NCT00051129|anecortave acetate
1483860|NCT00051129|wet AMD
1483861|NCT00051129|age-related macular degeneration
1483862|NCT00051129|Macular Degeneration
1483863|NCT00051129|Maculopathy, Age-Related
1483864|NCT00051129|Age-Related Maculopathies
1483865|NCT00051129|Age-Related Maculopathy
1483866|NCT00051129|Maculopathies, Age-Related
1483867|NCT00051116|Multiple Myeloma
1483868|NCT00051116|Revimid
1483869|NCT00051116|CC5013
1483870|NCT00051116|CC-5013
1483871|NCT00051103|Refractory
1483872|NCT00051090|Hepatitis B
1483873|NCT00051090|Antiretroviral Therapy, Highly-Active
1483874|NCT00051090|HIV Infections
1483875|NCT00051090|Lamivudine
1483876|NCT00051090|Reverse Transcriptase Inhibitors
1483877|NCT00051090|Antiviral Agents
1483878|NCT00051090|Drug Therapy, Combination
1483879|NCT00051090|Treatment Naive
1483880|NCT00051077|HIV Infections
1483881|NCT00051077|Hepatitis B
1483882|NCT00051077|Hepatitis C
1483883|NCT00051077|Interferon Alfa-2a
1483884|NCT00051077|Adefovir dipivoxil
1483885|NCT00051077|Ribavirin
1483886|NCT00051077|Antiviral Agents
1483887|NCT00051077|Drug Resistance, Viral
1483888|NCT00051077|Treatment Experienced
1483889|NCT00050986|Brain Neoplasms
1483890|NCT00050986|CNS Diseases
1483891|NCT00050986|Glioblastoma Multiforme
1483892|NCT00050986|Temozolomide
1483893|NCT00050986|Temodar
1483894|NCT00050986|R115777
1483895|NCT00050986|Zarnestra
1483896|NCT00050973|NSCLC
1483897|NCT00050973|Targretin
1483898|NCT00050973|Retinoid
1483899|NCT00050973|Bexarotene
1483900|NCT00050960|NSCLC
1483901|NCT00050960|Targretin
1483902|NCT00050960|Retinoid
1483903|NCT00050960|Bexarotene
1483904|NCT00050947|partial seizures
1483905|NCT00050934|partial seizures
1483906|NCT00050921|HIV Infections
1483907|NCT00050921|CD4 Lymphocyte Count
1483908|NCT00050921|Antiretroviral Therapy, Highly Active
1483909|NCT00050921|Growth Hormone
1483910|NCT00050921|Cell Division
1483911|NCT00050921|CD4-Positive T-Lymphocytes
1483912|NCT00050921|Treatment Experienced
1483913|NCT00050908|Brachial Artery
1483914|NCT00050908|Endothelium, Vascular
1483915|NCT00050908|Vasodilation
1483916|NCT00050908|Nitroglycerin
1483917|NCT00050908|Reverse Transcriptase Inhibitors
1483918|NCT00050908|HIV Protease Inhibitors
1483919|NCT00050908|Drug Therapy, Combination
1483920|NCT00050908|Ritonavir
1483921|NCT00050908|efavirenz
1483922|NCT00050908|lopinavir
1483923|NCT00050908|stavudine
1483924|NCT00050908|lamivudine
1483925|NCT00050908|zidovudine
1483926|NCT00050908|Treatment Naive
1483927|NCT00050895|Reverse Transcriptase Inhibitors
1483928|NCT00050895|HIV Protease Inhibitors
1483929|NCT00050895|Drug Therapy, Combination
1483930|NCT00050895|Delayed Action Preparations
1483931|NCT00050895|Treatment Naive
1483932|NCT00050895|HIV-1
1483933|NCT00050882|GM-611
1483934|NCT00050882|Diabetic gastroparesis
1483935|NCT00050882|Bloating
1483936|NCT00050882|Delayed gastric emptying
1483937|NCT00050882|Mitemcinal
1483938|NCT00050869|Mirror Neurons
1483939|NCT00050869|Performance
1483940|NCT00050869|Use-Dependent Plasticity
1483941|NCT00050869|Attention
1483942|NCT00050869|Premotor Cortex
1483943|NCT00050856|Antiretrovial Therapy
1483944|NCT00050856|Salvage
1483945|NCT00050856|CD4+Lymphocyte Count
1483946|NCT00050856|HIV-1 RNA Level
1483947|NCT00050856|Subcutaneous Injection
1483948|NCT00050817|Embolism
1483949|NCT00050804|Acute Stress Disorder
1483950|NCT00050804|PTSD
1483951|NCT00050804|Treatment
1483952|NCT00050804|SSRI
1483953|NCT00050804|Startle
1483954|NCT00050804|Psychophysiology
1483955|NCT00050804|Trauma
1483956|NCT00050804|Anxiety
1483957|NCT00050804|Emotion
1483958|NCT00050791|Obesity
1483959|NCT00050791|Weightloss
1483960|NCT00050791|Leptin
1483961|NCT00050791|Diet
1483962|NCT00050791|Reducing
1483963|NCT00050791|Overweight
1483964|NCT00050791|Fat
1483965|NCT00050518|Smallpox
1483966|NCT00050518|Aventis Pasteur
1483967|NCT00050518|Vaccine
1483968|NCT00050505|smallpox, Dryvax, vaccine, dilution
1483969|NCT00050492|Ocular
1483970|NCT00050492|Cytokine
1483971|NCT00050492|Chemokine
1483972|NCT00050492|Viruses
1483973|NCT00050492|Autoantibody
1483974|NCT00050492|Retina
1483975|NCT00050492|Vasculitis
1483976|NCT00050492|Adhesion Molecules
1483977|NCT00050479|Types 1 and 2 diabetes
1483978|NCT00050479|Diode Laser Photocoagulation
1483979|NCT00050479|Elevated Low-Density Lipoprotein (LDL-C) Cholesterol
1483980|NCT00050466|Normal Volunteers
1483981|NCT00050466|Dynamic Light Scattering (DLS)
1483982|NCT00050466|Corneal Opacities
1483983|NCT00050466|Cornea
1483984|NCT00050466|Transparency
1483985|NCT00050466|Vision
1483986|NCT00050440|Endometrial
1483987|NCT00050440|Cancer
1483988|NCT00050440|Carcinoma
1483989|NCT00050440|Trabectedin
1483990|NCT00050440|Ecteinascidin 743
1483991|NCT00050440|ET743
1483992|NCT00050440|Antineoplastic Agents
1483993|NCT00050440|Alkylating Agents
1483994|NCT00050440|Molecular Mechanisms of Pharmacological Action
1483995|NCT00050427|Trabectedin
1483996|NCT00050427|Yondelis
1483997|NCT00050427|ET743
1483998|NCT00050427|Advanced breast cancer
1483999|NCT00050427|Breast
1484000|NCT00050427|Cancer
1484001|NCT00050427|Antineoplastic Agents, Alkylating Agents
1484002|NCT00050427|Molecular Mechanisms of Pharmacological Action
1484003|NCT00050414|Ovarian cancer
1484004|NCT00050414|Ovary
1484005|NCT00050414|Cancer
1484006|NCT00050414|Trabectedin
1484007|NCT00050414|Yondelis
1484008|NCT00050414|ET743
1484009|NCT00050414|Ecteinascidin 743
1484010|NCT00050414|Antineoplastic Agents, Alkylating
1484011|NCT00050414|Alkylating Agents
1484012|NCT00050401|ventilator-associated
1484013|NCT00050401|nosocomial
1484014|NCT00050388|Cancer
1484015|NCT00050388|Carcinoma
1484016|NCT00050388|Neoplasm
1484017|NCT00050388|Head cancer
1484018|NCT00050388|Neck cancer
1484019|NCT00050388|Tongue cancer
1484020|NCT00050388|Lip cancer
1484021|NCT00050388|Oral Cavity
1484022|NCT00050388|Oropharynx
1484023|NCT00050388|Pharynx
1484024|NCT00050388|Larynx
1484025|NCT00050388|Squamous Cell
1484026|NCT00050388|Salivary Glands
1484027|NCT00050388|Tumor
1484028|NCT00050388|Lesion
1484029|NCT00050388|Cancer treatment
1484030|NCT00050388|Clinical trial
1484031|NCT00050388|Allovectin-7®
1484032|NCT00050388|Otorhinolaryngologic Neoplasm
1484033|NCT00050388|Otolaryngologic Cancer
1484034|NCT00050388|Gene therapy
1484035|NCT00050388|Immunotherapy
1484036|NCT00050388|Cancer research
1484037|NCT00050388|Cancer vaccine
1484038|NCT00050388|Cancer cells
1484039|NCT00050375|OvaRex
1484040|NCT00050375|ovarian
1484041|NCT00050375|CA125
1484042|NCT00050375|murine
1484043|NCT00050375|antibody
1484044|NCT00050375|immunotherapy
1484045|NCT00050362|Pain
1484046|NCT00050362|NSAID
1484047|NCT00050362|Oral Surgery
1484048|NCT00050362|Hyperalgesia
1484049|NCT00050362|Preemptive Analgesia
1484050|NCT00050349|cancer
1484051|NCT00050349|tumor
1484052|NCT00050349|tumour
1484053|NCT00050349|neoplasm
1484054|NCT00050349|carcinoma
1484055|NCT00050349|carcinoid
1484056|NCT00050349|neuroendocrine
1484057|NCT00050349|Islet cell
1484058|NCT00050349|Gastrinoma
1484059|NCT00050349|VIPoma
1484060|NCT00050349|metastatic
1484061|NCT00050349|intravenous
1484062|NCT00050349|epothilone
1484063|NCT00050336|Stage 3b or 4 (metastatic) non-small cell lung cancer
1484064|NCT00050323|Stage IV Renal Cell Carcinoma
1484065|NCT00050323|Kidney Cancer
1484066|NCT00050323|Cancer (General)
1484067|NCT00050310|Confirmed
1484068|NCT00050310|Suspected
1484069|NCT00050310|Pathogenesis
1484070|NCT00050310|Bronchoscopy
1484071|NCT00050310|Cultures
1484072|NCT00050310|Anthrax
1484073|NCT00050310|Natural History
1484074|NCT00050310|Vaccinated Healthy Volunteer
1484075|NCT00050284|Treatment Experienced
1484076|NCT00050284|Disease Progression
1484077|NCT00050284|Anti-HIV Agents
1484078|NCT00050284|Treatment Interruption
1484079|NCT00050271|Acetylcarnitine
1484080|NCT00050271|Dideoxynucleosides
1484081|NCT00050271|Epidermis
1484082|NCT00050271|Biopsy
1484083|NCT00050271|Immunohistochemistry
1484084|NCT00050271|Nerve Fibers
1484085|NCT00050271|Treatment Experienced
1484086|NCT00050245|Neuropathy
1484087|NCT00050245|B Cells
1484088|NCT00050245|Anti-MAG
1484089|NCT00050245|Demyelination
1484090|NCT00050245|MAG
1484091|NCT00050245|RITUXAN
1484092|NCT00050245|Monoclonal Antibodies
1484093|NCT00050245|Retuximab
1484094|NCT00050245|Demyelinating Neuropathy
1484095|NCT00050232|Pseudobulbar Affect
1484096|NCT00050232|Uncontrolled
1484097|NCT00050232|Laughing
1484098|NCT00050232|Crying
1484099|NCT00050219|Raclopride
1484100|NCT00050219|D2 Receptors
1484101|NCT00050219|Striatum
1484102|NCT00050219|Low-Response
1484103|NCT00050219|Alcoholism
1484104|NCT00050219|Alcohol
1484105|NCT00050219|Dopamine
1484106|NCT00050219|Response
1484107|NCT00050193|Children
1484108|NCT00050193|Mast Cells
1484109|NCT00050193|Urticaria Pigmentosa
1484110|NCT00050193|Bone Marrow
1484111|NCT00050193|Severe
1484112|NCT00050193|Mastocytosis
1484113|NCT00050193|Pediatric Mastocytosis
1484114|NCT00050180|P-Glycoprotein
1484115|NCT00050180|Protease Inhibitor
1484116|NCT00050180|Antiretrovirals
1484117|NCT00050180|Cytochrome P450
1484118|NCT00050180|Drug Transporters
1484119|NCT00050180|Healthy Volunteer
1484120|NCT00050180|HV
1484121|NCT00050167|Breast Cancer
1484122|NCT00050167|Capecitabine
1484123|NCT00050167|Docetaxel
1484124|NCT00050167|Paclitaxel
1484125|NCT00050167|Taxotere
1484126|NCT00050167|Taxol
1484127|NCT00050167|Xeloda
1484128|NCT00050167|Taxanes
1484129|NCT00050167|Operable Breast Cancer
1484130|NCT00050154|R115777
1484131|NCT00050154|Myelodysplastic syndromes
1484132|NCT00050154|Tipifarnib
1484133|NCT00050154|Zarnestra
1484134|NCT00050141|Breast cancer
1484135|NCT00050141|ZARNESTRA
1484136|NCT00050141|tipifarnib
1484137|NCT00050141|R115777
1484138|NCT00050141|Estrogen receptor positive
1484139|NCT00050141|Progesterone receptor positive
1484140|NCT00050141|Anti-estrogen therapy
1484141|NCT00050128|Rehabilitation
1484142|NCT00050128|Plasticity
1484143|NCT00050128|Frequency
1484144|NCT00050128|Inhibition
1484145|NCT00050128|Pinch
1484146|NCT00050128|Stroke
1484147|NCT00050115|Bone Marrow Failure
1484148|NCT00050115|Seronegative Hepatitis
1484149|NCT00050115|Fulminate Hepatitis
1484150|NCT00050115|Hepatitis
1484151|NCT00050115|Aplastic Anemia
1484152|NCT00050115|Hepatitis Associated Aplastic Anemia
1484153|NCT00050089|AIDS
1484154|NCT00050089|antiretrovirals
1484155|NCT00050089|ART
1484156|NCT00050089|drug-free period
1484157|NCT00050089|HAART
1484158|NCT00050089|HIV
1484159|NCT00050089|human immunodeficiency virus
1484160|NCT00050089|randomized
1484161|NCT00050089|structured treatment interruptions
1484162|NCT00050076|Congestive Heart Failure
1484163|NCT00050076|Cardiac Failure
1484164|NCT00050076|Heart Decompensation
1484165|NCT00050076|Drug Therapy
1484166|NCT00050063|HIV Therapeutic Vaccine
1484167|NCT00050063|Treatment Experienced
1484168|NCT00050063|AIDS Vaccines
1484169|NCT00050063|Treatment Interruption
1484170|NCT00050063|Viral Load
1484171|NCT00050063|T-Lymphocytes, Cytotoxic
1484172|NCT00050063|T-Lymphocytes, Helper-Inducer
1484173|NCT00050050|Adult
1484174|NCT00050050|ADHD
1484175|NCT00050050|ADD
1484176|NCT00050024|TMS
1484177|NCT00050024|Afferent Stimulation
1484178|NCT00050024|Motor Cortex
1484179|NCT00050024|Writer's Cramp
1484180|NCT00050024|Surround Inhibition
1484181|NCT00050024|Heterotopic Inhibition
1484182|NCT00050024|Focal Dystonia
1484183|NCT00050024|Writer Cramp
1484184|NCT00050011|cancer-treatment related bone loss
1484185|NCT00050011|postmenopausal women
1484186|NCT00050011|breast cancer
1484187|NCT00050011|hormone receptor positive breast cancer
1484188|NCT00050011|adjuvant therapy
1484189|NCT00050011|hormonal therapy
1484190|NCT00050011|bone loss
1484191|NCT00050011|bisphosphonates
1484192|NCT00050011|ZFAST
1484193|NCT00050011|Letrozole
1484194|NCT00050011|Zoledronic Acid
1484195|NCT00050011|US32
1484196|NCT00049998|Nonsmall Cell Lung cancer
1484197|NCT00049998|advanced
1484198|NCT00049998|Second-line
1484199|NCT00049998|topotecan
1484200|NCT00049998|Hycamtin
1484201|NCT00049998|oral
1484202|NCT00049998|docetaxel
1484203|NCT00049972|Major Depressive Disorder Open-label discontinued
1484204|NCT00049959|Verteporfin PDT
1484205|NCT00049959|multiple basal cell carcinoma
1484206|NCT00049959|nevoid basal cell carcinoma syndrome
1484207|NCT00049946|Talnetant
1484208|NCT00049946|schizophrenia
1484209|NCT00049946|NK3 receptor antagonist
1484210|NCT00049946|psychosis
1484211|NCT00049829|Bisphosphonate,BMD,Height loss, Hip protectors,HRT,
1484212|NCT00049829|Osteoporosis
1484213|NCT00049816|knee
1484214|NCT00049816|aerobic exercise
1484215|NCT00049816|walking
1484216|NCT00049816|cycling
1484217|NCT00049816|gait
1484218|NCT00049816|MRI
1484219|NCT00049803|Narcolepsy
1484220|NCT00049803|Sodium Oxybate
1484221|NCT00049803|Cataplexy
1484222|NCT00049803|Excessive Daytime Sleepiness
1484223|NCT00049803|GHB
1484224|NCT00049803|Gamma Hydroxybutyric Acid
1484225|NCT00049803|Orphan Medical
1484226|NCT00049803|Orphan Drug
1484227|NCT00049790|Advanced non-small cell lung cancer
1484228|NCT00049738|Psychosis
1484229|NCT00049738|Childhood Onset Schizophrenia
1484230|NCT00049738|Schizophrenia
1484231|NCT00049738|Schizoaffective
1484232|NCT00049738|Psychotic Disorder
1484233|NCT00049738|Multidimensionally Impaired Syndrome
1484234|NCT00049725|Autoimmune Disease
1484235|NCT00049725|Monoclonal Antibody Therapy
1484236|NCT00049725|Anti-IL2 Receptor
1484237|NCT00049725|Platelets
1484238|NCT00049725|Monoclonal Antibody
1484239|NCT00049725|Immune Thrombocytopenia
1484240|NCT00049725|ITP
1484241|NCT00049712|anaplastic large cell lymphoma
1484242|NCT00049712|angioimmunoblastic T-cell lymphoma
1484243|NCT00049712|intraocular lymphoma
1484244|NCT00049712|primary central nervous system lymphoma
1484245|NCT00049712|recurrent adult diffuse large cell lymphoma
1484246|NCT00049712|recurrent adult diffuse mixed cell lymphoma
1484247|NCT00049712|recurrent adult diffuse small cleaved cell lymphoma
1484248|NCT00049712|recurrent adult Burkitt lymphoma
1484249|NCT00049712|recurrent adult Hodgkin lymphoma
1484250|NCT00049712|recurrent adult immunoblastic large cell lymphoma
1484251|NCT00049712|recurrent adult lymphoblastic lymphoma
1484252|NCT00049712|recurrent adult T-cell leukemia/lymphoma
1484253|NCT00049712|recurrent cutaneous T-cell non-Hodgkin lymphoma
1484254|NCT00049712|recurrent grade 1 follicular lymphoma
1484255|NCT00049712|recurrent grade 2 follicular lymphoma
1484256|NCT00049712|recurrent grade 3 follicular lymphoma
1484257|NCT00049712|recurrent mantle cell lymphoma
1484258|NCT00049712|recurrent mycosis fungoides/Sezary syndrome
1484259|NCT00049712|small intestine lymphoma
1484260|NCT00049712|stage IV adult diffuse large cell lymphoma
1484261|NCT00049712|stage IV adult diffuse mixed cell lymphoma
1484262|NCT00049712|stage IV adult diffuse small cleaved cell lymphoma
1484263|NCT00049712|stage IV adult Burkitt lymphoma
1484264|NCT00049712|stage IV adult Hodgkin lymphoma
1484265|NCT00049712|stage IV adult immunoblastic large cell lymphoma
1484266|NCT00049712|stage IV adult T-cell leukemia/lymphoma
1484267|NCT00049712|stage IV cutaneous T-cell non-Hodgkin lymphoma
1484268|NCT00049712|stage IV grade 1 follicular lymphoma
1484269|NCT00049712|stage IV grade 2 follicular lymphoma
1484270|NCT00049712|stage IV grade 3 follicular lymphoma
1484271|NCT00049712|stage IV mantle cell lymphoma
1484272|NCT00049712|stage IV mycosis fungoides/Sezary syndrome
1484273|NCT00049712|unspecified adult solid tumor, protocol specific
1484274|NCT00049712|stage IV adult lymphoblastic lymphoma
1484275|NCT00049712|stage III adult diffuse large cell lymphoma
1484276|NCT00049712|stage III adult diffuse mixed cell lymphoma
1484277|NCT00049712|stage III adult diffuse small cleaved cell lymphoma
1484278|NCT00049712|stage III adult Burkitt lymphoma
1484279|NCT00049712|stage III adult Hodgkin lymphoma
1484280|NCT00049712|stage III adult immunoblastic large cell lymphoma
1484281|NCT00049712|stage III adult lymphoblastic lymphoma
1484282|NCT00049712|stage III cutaneous T-cell non-Hodgkin lymphoma
1484283|NCT00049712|stage III grade 1 follicular lymphoma
1484284|NCT00049712|stage III grade 2 follicular lymphoma
1484285|NCT00049712|stage III grade 3 follicular lymphoma
1484286|NCT00049712|stage III mantle cell lymphoma
1484287|NCT00049712|stage III mycosis fungoides/Sezary syndrome
1484288|NCT00049712|stage III adult T-cell leukemia/lymphoma
1484289|NCT00049712|recurrent marginal zone lymphoma
1484290|NCT00049712|recurrent small lymphocytic lymphoma
1484291|NCT00049712|stage III small lymphocytic lymphoma
1484292|NCT00049712|stage III marginal zone lymphoma
1484293|NCT00049712|stage IV small lymphocytic lymphoma
1484294|NCT00049712|stage IV marginal zone lymphoma
1484295|NCT00049712|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1484296|NCT00049712|nodal marginal zone B-cell lymphoma
1484297|NCT00049712|splenic marginal zone lymphoma
1484298|NCT00049699|anaplastic large cell lymphoma
1484299|NCT00049699|angioimmunoblastic T-cell lymphoma
1484300|NCT00049699|intraocular lymphoma
1484301|NCT00049699|primary central nervous system non-Hodgkin lymphoma
1484302|NCT00049699|recurrent adult diffuse large cell lymphoma
1484303|NCT00049699|recurrent adult diffuse mixed cell lymphoma
1484304|NCT00049699|recurrent adult diffuse small cleaved cell lymphoma
1484305|NCT00049699|recurrent adult Burkitt lymphoma
1484306|NCT00049699|recurrent adult Hodgkin lymphoma
1484307|NCT00049699|recurrent adult immunoblastic large cell lymphoma
1484308|NCT00049699|recurrent adult lymphoblastic lymphoma
1484309|NCT00049699|recurrent adult T-cell leukemia/lymphoma
1484310|NCT00049699|recurrent cutaneous T-cell non-Hodgkin lymphoma
1484311|NCT00049699|recurrent grade 1 follicular lymphoma
1484312|NCT00049699|recurrent grade 2 follicular lymphoma
1484313|NCT00049699|recurrent grade 3 follicular lymphoma
1484314|NCT00049699|recurrent mantle cell lymphoma
1484315|NCT00049699|recurrent mycosis fungoides/Sezary syndrome
1484316|NCT00049699|small intestine lymphoma
1484317|NCT00049699|stage IV adult diffuse large cell lymphoma
1484318|NCT00049699|stage IV adult diffuse mixed cell lymphoma
1484319|NCT00049699|stage IV adult diffuse small cleaved cell lymphoma
1484320|NCT00049699|stage IV adult Burkitt lymphoma
1484321|NCT00049699|stage IV adult Hodgkin lymphoma
1484322|NCT00049699|stage IV adult immunoblastic large cell lymphoma
1484323|NCT00049699|stage IV adult lymphoblastic lymphoma
1484324|NCT00049699|stage IV adult T-cell leukemia/lymphoma
1484325|NCT00049699|stage IV cutaneous T-cell non-Hodgkin lymphoma
1484326|NCT00049699|stage IV grade 1 follicular lymphoma
1484327|NCT00049699|stage IV grade 2 follicular lymphoma
1484328|NCT00049699|stage IV grade 3 follicular lymphoma
1484329|NCT00049699|stage IV mantle cell lymphoma
1484330|NCT00049699|stage IV mycosis fungoides/Sezary syndrome
1484331|NCT00049699|unspecified adult solid tumor, protocol specific
1484332|NCT00049699|recurrent marginal zone lymphoma
1484333|NCT00049699|recurrent small lymphocytic lymphoma
1484334|NCT00049699|stage IV small lymphocytic lymphoma
1484335|NCT00049699|stage IV marginal zone lymphoma
1484336|NCT00049699|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1484337|NCT00049699|nodal marginal zone B-cell lymphoma
1484338|NCT00049699|splenic marginal zone lymphoma
1484339|NCT00049686|acute undifferentiated leukemia
1484340|NCT00049686|chronic myelomonocytic leukemia
1484341|NCT00049686|previously treated myelodysplastic syndromes
1484342|NCT00049686|prolymphocytic leukemia
1484343|NCT00049686|recurrent adult acute lymphoblastic leukemia
1484344|NCT00049686|recurrent adult acute myeloid leukemia
1484345|NCT00049686|refractory chronic lymphocytic leukemia
1484346|NCT00049686|refractory anemia with excess blasts
1484347|NCT00049686|refractory cytopenia with multilineage dysplasia
1484348|NCT00049686|refractory hairy cell leukemia
1484349|NCT00049686|relapsing chronic myelogenous leukemia
1484350|NCT00049686|secondary acute myeloid leukemia
1484351|NCT00049686|secondary myelodysplastic syndromes
1484352|NCT00049686|atypical chronic myeloid leukemia, BCR-ABL1 negative
1484353|NCT00049686|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1484354|NCT00049673|stage I multiple myeloma
1484355|NCT00049673|stage II multiple myeloma
1484356|NCT00049673|stage III multiple myeloma
1484357|NCT00049660|stage IV breast cancer
1484358|NCT00049634|chronic myelomonocytic leukemia
1484359|NCT00049634|de novo myelodysplastic syndromes
1484360|NCT00049634|essential thrombocythemia
1484361|NCT00049634|polycythemia vera
1484362|NCT00049634|previously treated myelodysplastic syndromes
1484363|NCT00049634|refractory anemia with excess blasts
1484364|NCT00049634|refractory anemia with excess blasts in transformation
1484365|NCT00049634|secondary acute myeloid leukemia
1484366|NCT00049634|secondary myelodysplastic syndromes
1484367|NCT00049634|chronic eosinophilic leukemia
1484368|NCT00049634|chronic neutrophilic leukemia
1484369|NCT00049634|atypical chronic myeloid leukemia
1484370|NCT00049634|myelodysplastic/myeloproliferative disease, unclassifiable
1484371|NCT00049608|male breast cancer
1484372|NCT00049608|recurrent breast cancer
1484373|NCT00049608|recurrent colon cancer
1484374|NCT00049608|recurrent non-small cell lung cancer
1484375|NCT00049608|recurrent pancreatic cancer
1484376|NCT00049608|recurrent rectal cancer
1484377|NCT00049608|stage III colon cancer
1484378|NCT00049608|stage III pancreatic cancer
1484379|NCT00049608|stage III rectal cancer
1484380|NCT00049608|stage IIIA breast cancer
1484381|NCT00049608|stage IIIB breast cancer
1484382|NCT00049608|stage IIIC breast cancer
1484383|NCT00049608|stage IV breast cancer
1484384|NCT00049608|stage IV colon cancer
1484385|NCT00049608|stage IV non-small cell lung cancer
1484386|NCT00049608|stage IV rectal cancer
1484387|NCT00049608|stage IIIA non-small cell lung cancer
1484388|NCT00049608|stage IIIB non-small cell lung cancer
1484389|NCT00049608|stage IV pancreatic cancer
1484390|NCT00049595|adult lymphocyte depletion Hodgkin lymphoma
1484391|NCT00049595|adult mixed cellularity Hodgkin lymphoma
1484392|NCT00049595|adult nodular sclerosis Hodgkin lymphoma
1484393|NCT00049595|stage III adult Hodgkin lymphoma
1484394|NCT00049595|stage IV adult Hodgkin lymphoma
1484395|NCT00049556|fallopian tube cancer
1484396|NCT00049556|borderline ovarian surface epithelial-stromal tumor
1484397|NCT00049556|primary peritoneal cavity cancer
1484398|NCT00049556|recurrent cervical cancer
1484399|NCT00049556|recurrent ovarian epithelial cancer
1484400|NCT00049530|recurrent melanoma
1484401|NCT00049530|stage IV melanoma
1484402|NCT00049517|acute myeloid leukemia
1484403|NCT00049517|autologous transplantation
1484404|NCT00049517|gemtuzumab ozogamicin
1484405|NCT00049465|depression
1484406|NCT00049465|fatigue
1484407|NCT00049465|menopausal symptoms
1484408|NCT00049465|transitional care planning
1484409|NCT00049465|psychosocial effects of cancer and its treatment
1484410|NCT00049465|accelerated phase chronic myelogenous leukemia
1484411|NCT00049465|chronic idiopathic myelofibrosis
1484412|NCT00049465|blastic phase chronic myelogenous leukemia
1484413|NCT00049465|chronic phase chronic myelogenous leukemia
1484414|NCT00049465|de novo myelodysplastic syndromes
1484415|NCT00049465|disseminated neuroblastoma
1484416|NCT00049465|meningeal chronic myelogenous leukemia
1484608|NCT00049296|adult medulloblastoma
1484417|NCT00049465|noncontiguous stage II adult diffuse large cell lymphoma
1484418|NCT00049465|noncontiguous stage II adult diffuse mixed cell lymphoma
1484419|NCT00049465|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1484420|NCT00049465|noncontiguous stage II adult Burkitt lymphoma
1484421|NCT00049465|noncontiguous stage II adult immunoblastic large cell lymphoma
1484422|NCT00049465|noncontiguous stage II adult lymphoblastic lymphoma
1484423|NCT00049465|noncontiguous stage II grade 1 follicular lymphoma
1484424|NCT00049465|noncontiguous stage II grade 2 follicular lymphoma
1484425|NCT00049465|noncontiguous stage II grade 3 follicular lymphoma
1484426|NCT00049465|noncontiguous stage II mantle cell lymphoma
1484427|NCT00049465|ovarian choriocarcinoma
1484428|NCT00049465|ovarian embryonal carcinoma
1484429|NCT00049465|ovarian yolk sac tumor
1484430|NCT00049465|ovarian immature teratoma
1484431|NCT00049465|ovarian mature teratoma
1484432|NCT00049465|ovarian monodermal and highly specialized teratoma
1484433|NCT00049465|ovarian polyembryoma
1484434|NCT00049465|ovarian mixed germ cell tumor
1484435|NCT00049465|poor prognosis metastatic gestational trophoblastic tumor
1484436|NCT00049465|previously treated myelodysplastic syndromes
1484437|NCT00049465|recurrent adult acute lymphoblastic leukemia
1484438|NCT00049465|recurrent adult acute myeloid leukemia
1484439|NCT00049465|recurrent adult diffuse large cell lymphoma
1484440|NCT00049465|recurrent adult diffuse mixed cell lymphoma
1484441|NCT00049465|recurrent adult diffuse small cleaved cell lymphoma
1484442|NCT00049465|recurrent adult Burkitt lymphoma
1484443|NCT00049465|recurrent adult Hodgkin lymphoma
1484444|NCT00049465|recurrent adult immunoblastic large cell lymphoma
1484445|NCT00049465|recurrent adult lymphoblastic lymphoma
1484446|NCT00049465|recurrent cutaneous T-cell non-Hodgkin lymphoma
1484447|NCT00049465|recurrent grade 1 follicular lymphoma
1484448|NCT00049465|recurrent grade 2 follicular lymphoma
1484449|NCT00049465|recurrent grade 3 follicular lymphoma
1484450|NCT00049465|recurrent mantle cell lymphoma
1484451|NCT00049465|recurrent mycosis fungoides/Sezary syndrome
1484452|NCT00049465|recurrent neuroblastoma
1484453|NCT00049465|recurrent ovarian epithelial cancer
1484454|NCT00049465|recurrent ovarian germ cell tumor
1484455|NCT00049465|recurrent malignant testicular germ cell tumor
1484456|NCT00049465|refractory chronic lymphocytic leukemia
1484457|NCT00049465|refractory hairy cell leukemia
1484458|NCT00049465|refractory multiple myeloma
1484459|NCT00049465|relapsing chronic myelogenous leukemia
1484460|NCT00049465|secondary acute myeloid leukemia
1484461|NCT00049465|secondary myelodysplastic syndromes
1484462|NCT00049465|stage I multiple myeloma
1484463|NCT00049465|stage II multiple myeloma
1484464|NCT00049465|stage II ovarian epithelial cancer
1484465|NCT00049465|stage III adult diffuse large cell lymphoma
1484466|NCT00049465|stage III adult diffuse mixed cell lymphoma
1484467|NCT00049465|stage III adult diffuse small cleaved cell lymphoma
1484468|NCT00049465|stage III adult Burkitt lymphoma
1484469|NCT00049465|stage III adult immunoblastic large cell lymphoma
1484470|NCT00049465|stage III adult lymphoblastic lymphoma
1484471|NCT00049465|stage III chronic lymphocytic leukemia
1484472|NCT00049465|stage III grade 1 follicular lymphoma
1484473|NCT00049465|stage III grade 2 follicular lymphoma
1484474|NCT00049465|stage III grade 3 follicular lymphoma
1484475|NCT00049465|stage III mantle cell lymphoma
1484476|NCT00049465|stage III ovarian epithelial cancer
1484477|NCT00049465|stage III malignant testicular germ cell tumor
1484478|NCT00049465|stage IIIA breast cancer
1484479|NCT00049465|stage IIIB breast cancer
1484480|NCT00049465|stage IIIC breast cancer
1484481|NCT00049465|stage IV adult diffuse large cell lymphoma
1484482|NCT00049465|stage IV adult diffuse mixed cell lymphoma
1484483|NCT00049465|stage IV adult diffuse small cleaved cell lymphoma
1484484|NCT00049465|stage IV adult Burkitt lymphoma
1484485|NCT00049465|stage IV adult immunoblastic large cell lymphoma
1484486|NCT00049465|stage IV adult lymphoblastic lymphoma
1484487|NCT00049465|stage IV breast cancer
1484488|NCT00049465|stage IV chronic lymphocytic leukemia
1484489|NCT00049465|stage IV grade 1 follicular lymphoma
1484490|NCT00049465|stage IV grade 2 follicular lymphoma
1484491|NCT00049465|stage IV grade 3 follicular lymphoma
1484492|NCT00049465|stage IV mantle cell lymphoma
1484493|NCT00049465|stage IV ovarian epithelial cancer
1484494|NCT00049465|testicular choriocarcinoma and embryonal carcinoma
1484495|NCT00049465|testicular choriocarcinoma and seminoma
1484496|NCT00049465|testicular choriocarcinoma and teratoma
1484497|NCT00049465|testicular choriocarcinoma and yolk sac tumor
1484498|NCT00049465|testicular choriocarcinoma
1484499|NCT00049465|testicular embryonal carcinoma and seminoma
1484500|NCT00049465|testicular embryonal carcinoma and teratoma with seminoma
1484501|NCT00049465|testicular embryonal carcinoma and teratoma
1484502|NCT00049465|testicular embryonal carcinoma and yolk sac tumor with seminoma
1484503|NCT00049465|testicular embryonal carcinoma and yolk sac tumor
1484504|NCT00049465|testicular embryonal carcinoma
1484505|NCT00049465|testicular teratoma
1484506|NCT00049465|testicular yolk sac tumor and teratoma with seminoma
1484507|NCT00049465|testicular yolk sac tumor and teratoma
1484508|NCT00049465|testicular yolk sac tumor
1484509|NCT00049465|stage III multiple myeloma
1484510|NCT00049465|chronic eosinophilic leukemia
1484511|NCT00049465|chronic neutrophilic leukemia
1484512|NCT00049465|atypical chronic myeloid leukemia
1484513|NCT00049465|myelodysplastic/myeloproliferative disease, unclassifiable
1484514|NCT00049465|noncontiguous stage II small lymphocytic lymphoma
1484515|NCT00049465|noncontiguous stage II marginal zone lymphoma
1484516|NCT00049465|recurrent marginal zone lymphoma
1484517|NCT00049465|recurrent small lymphocytic lymphoma
1484518|NCT00049465|stage III small lymphocytic lymphoma
1484519|NCT00049465|stage III marginal zone lymphoma
1484520|NCT00049465|stage IV small lymphocytic lymphoma
1484521|NCT00049465|stage IV marginal zone lymphoma
1484522|NCT00049465|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1484523|NCT00049465|nodal marginal zone B-cell lymphoma
1484524|NCT00049465|splenic marginal zone lymphoma
1484525|NCT00049452|osteoporosis
1484526|NCT00049452|stage I breast cancer
1484527|NCT00049452|stage II breast cancer
1484528|NCT00049439|AIDS-related diffuse large cell lymphoma
1484529|NCT00049439|AIDS-related diffuse mixed cell lymphoma
1484530|NCT00049439|AIDS-related diffuse small cleaved cell lymphoma
1484531|NCT00049439|AIDS-related immunoblastic large cell lymphoma
1484532|NCT00049439|AIDS-related lymphoblastic lymphoma
1484533|NCT00049439|AIDS-related small noncleaved cell lymphoma
1484534|NCT00049413|B-cell chronic lymphocytic leukemia
1484535|NCT00049413|refractory chronic lymphocytic leukemia
1484536|NCT00049413|stage I chronic lymphocytic leukemia
1484537|NCT00049413|stage II chronic lymphocytic leukemia
1484538|NCT00049413|stage III chronic lymphocytic leukemia
1484539|NCT00049413|stage IV chronic lymphocytic leukemia
1484540|NCT00049413|contiguous stage II small lymphocytic lymphoma
1484541|NCT00049413|noncontiguous stage II small lymphocytic lymphoma
1484542|NCT00049413|recurrent small lymphocytic lymphoma
1484543|NCT00049413|stage I small lymphocytic lymphoma
1484544|NCT00049413|stage III small lymphocytic lymphoma
1484545|NCT00049413|stage IV small lymphocytic lymphoma
1484546|NCT00049400|unspecified adult solid tumor, protocol specific
1484547|NCT00049400|anaplastic large cell lymphoma
1484548|NCT00049400|angioimmunoblastic T-cell lymphoma
1484549|NCT00049400|intraocular lymphoma
1484550|NCT00049400|primary central nervous system lymphoma
1484551|NCT00049400|recurrent adult diffuse large cell lymphoma
1484552|NCT00049400|recurrent adult Hodgkin lymphoma
1484553|NCT00049400|recurrent adult immunoblastic large cell lymphoma
1484554|NCT00049400|recurrent adult T-cell leukemia/lymphoma
1484555|NCT00049400|recurrent cutaneous T-cell non-Hodgkin lymphoma
1484556|NCT00049400|recurrent grade 1, 2, or 3 follicular lymphoma
1484557|NCT00049400|recurrent mantle cell lymphoma
1484558|NCT00049400|small intestine lymphoma
1484559|NCT00049400|stage IV adult diffuse large cell or mixed cell lymphoma
1484560|NCT00049400|stage IV adult diffuse small cleaved cell lymphoma
1484561|NCT00049400|stage IV adult Burkitt lymphoma or Hodgkin lymphoma
1484562|NCT00049400|stage IV adult immunoblastic large cell lymphoma
1484563|NCT00049400|stage IV adult lymphoblastic lymphoma
1484564|NCT00049400|stage IV adult T-cell leukemia/lymphoma
1484565|NCT00049400|stage IV cutaneous T-cell non-Hodgkin lymphoma
1484566|NCT00049400|stage IV grade 1, 2, or 3 follicular lymphoma
1484567|NCT00049400|stage IV mantle cell lymphoma
1484568|NCT00049400|recurrent marginal zone lymphoma
1484569|NCT00049400|recurrent small lymphocytic lymphoma
1484570|NCT00049400|stage IV small lymphocytic lymphoma
1484571|NCT00049400|stage IV marginal zone lymphoma
1484572|NCT00049400|extranodal marginal zone B-cell lymphoma of MALT
1484573|NCT00049400|nodal marginal zone B-cell lymphoma
1484574|NCT00049400|splenic marginal zone lymphoma
1484575|NCT00049400|recurrent adult Burkitt lymphoma
1484576|NCT00049400|recurrent adult lymphoblastic lymphoma
1484577|NCT00049400|recurrent adult diffuse small cleaved cell lymphoma
1484578|NCT00049400|recurrent adult diffuse mixed cell lymphoma
1484579|NCT00049374|refractory multiple myeloma
1484580|NCT00049361|adult tumors metastatic to brain
1484581|NCT00049361|unspecified adult solid tumor, protocol specific
1484582|NCT00049348|adenocarcinoma of the pancreas
1484583|NCT00049348|stage II pancreatic cancer
1484584|NCT00049348|stage III pancreatic cancer
1484585|NCT00049335|recurrent colon cancer
1484586|NCT00049335|stage IV colon cancer
1484587|NCT00049335|recurrent rectal cancer
1484588|NCT00049335|stage IV rectal cancer
1484589|NCT00049322|localized unresectable adult primary liver cancer
1484590|NCT00049322|recurrent adult primary liver cancer
1484591|NCT00049322|adult primary hepatocellular carcinoma
1484592|NCT00049309|stage I prostate cancer
1484593|NCT00049309|stage IIB prostate cancer
1484594|NCT00049309|stage IIA prostate cancer
1484595|NCT00049309|stage III prostate cancer
1484596|NCT00049296|adult anaplastic astrocytoma
1484597|NCT00049296|male breast cancer
1484598|NCT00049296|adult anaplastic oligodendroglioma
1484599|NCT00049296|adult meningeal hemangiopericytoma
1484600|NCT00049296|adult brain stem glioma
1484601|NCT00049296|adult central nervous system germ cell tumor
1484602|NCT00049296|adult choroid plexus tumor
1484603|NCT00049296|adult craniopharyngioma
1484604|NCT00049296|adult ependymoblastoma
1484605|NCT00049296|adult glioblastoma
1484606|NCT00049296|adult pilocytic astrocytoma
1484607|NCT00049296|adult anaplastic ependymoma
1484609|NCT00049296|adult meningioma
1484610|NCT00049296|adult pineoblastoma
1484611|NCT00049296|adult pineocytoma
1484612|NCT00049296|adult subependymoma
1484613|NCT00049296|adult myxopapillary ependymoma
1484614|NCT00049296|advanced adult primary liver cancer
1484615|NCT00049296|anterior urethral cancer
1484616|NCT00049296|carcinoma of the appendix
1484617|NCT00049296|chondrosarcoma
1484618|NCT00049296|classic Kaposi sarcoma
1484619|NCT00049296|AIDS-related Kaposi sarcoma
1484620|NCT00049296|immunosuppressive treatment related Kaposi sarcoma
1484621|NCT00049296|recurrent Kaposi sarcoma
1484622|NCT00049296|clear cell sarcoma of the kidney
1484623|NCT00049296|disseminated neuroblastoma
1484624|NCT00049296|extensive stage small cell lung cancer
1484625|NCT00049296|gastrointestinal stromal tumor
1484626|NCT00049296|metastatic gastrointestinal carcinoid tumor
1484627|NCT00049296|metastatic osteosarcoma
1484628|NCT00049296|metastatic transitional cell cancer of the renal pelvis and ureter
1484629|NCT00049296|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1484630|NCT00049296|adult mixed glioma
1484631|NCT00049296|ovarian sarcoma
1484632|NCT00049296|posterior urethral cancer
1484633|NCT00049296|primary central nervous system lymphoma
1484634|NCT00049296|pulmonary carcinoid tumor
1484635|NCT00049296|recurrent adenoid cystic carcinoma of the oral cavity
1484636|NCT00049296|recurrent adult brain tumor
1484637|NCT00049296|recurrent adult diffuse large cell lymphoma
1484638|NCT00049296|recurrent adult diffuse mixed cell lymphoma
1484639|NCT00049296|recurrent adult diffuse small cleaved cell lymphoma
1484640|NCT00049296|recurrent adult Burkitt lymphoma
1484641|NCT00049296|recurrent adult immunoblastic large cell lymphoma
1484642|NCT00049296|recurrent adult lymphoblastic lymphoma
1484643|NCT00049296|recurrent adult primary liver cancer
1484644|NCT00049296|recurrent adult soft tissue sarcoma
1484645|NCT00049296|recurrent anal cancer
1484646|NCT00049296|recurrent basal cell carcinoma of the lip
1484647|NCT00049296|recurrent bladder cancer
1484648|NCT00049296|recurrent breast cancer
1484649|NCT00049296|recurrent colon cancer
1484650|NCT00049296|recurrent esophageal cancer
1484651|NCT00049296|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1484652|NCT00049296|recurrent extrahepatic bile duct cancer
1484653|NCT00049296|recurrent gallbladder cancer
1484654|NCT00049296|recurrent gastric cancer
1484655|NCT00049296|recurrent gastrointestinal carcinoid tumor
1484656|NCT00049296|recurrent grade 1 follicular lymphoma
1484657|NCT00049296|recurrent grade 2 follicular lymphoma
1484658|NCT00049296|recurrent grade 3 follicular lymphoma
1484659|NCT00049296|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1484660|NCT00049296|recurrent lymphoepithelioma of the nasopharynx
1484661|NCT00049296|recurrent lymphoepithelioma of the oropharynx
1484662|NCT00049296|recurrent mantle cell lymphoma
1484663|NCT00049296|recurrent melanoma
1484664|NCT00049296|recurrent metastatic squamous neck cancer with occult primary
1484665|NCT00049296|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1484666|NCT00049296|recurrent mucoepidermoid carcinoma of the oral cavity
1484667|NCT00049296|recurrent neuroblastoma
1484668|NCT00049296|recurrent non-small cell lung cancer
1484669|NCT00049296|recurrent osteosarcoma
1484670|NCT00049296|recurrent pancreatic cancer
1484671|NCT00049296|recurrent rectal cancer
1484672|NCT00049296|recurrent renal cell cancer
1484673|NCT00049296|recurrent small cell lung cancer
1484674|NCT00049296|recurrent small intestine cancer
1484675|NCT00049296|recurrent squamous cell carcinoma of the hypopharynx
1484676|NCT00049296|recurrent squamous cell carcinoma of the larynx
1484677|NCT00049296|recurrent squamous cell carcinoma of the lip and oral cavity
1484678|NCT00049296|recurrent squamous cell carcinoma of the nasopharynx
1484679|NCT00049296|recurrent squamous cell carcinoma of the oropharynx
1484680|NCT00049296|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1484681|NCT00049296|recurrent transitional cell cancer of the renal pelvis and ureter
1484682|NCT00049296|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1484683|NCT00049296|recurrent urethral cancer
1484684|NCT00049296|recurrent uterine sarcoma
1484685|NCT00049296|recurrent verrucous carcinoma of the larynx
1484686|NCT00049296|recurrent verrucous carcinoma of the oral cavity
1484687|NCT00049296|refractory multiple myeloma
1484688|NCT00049296|rhabdoid tumor of the kidney
1484689|NCT00049296|small intestine adenocarcinoma
1484690|NCT00049296|small intestine leiomyosarcoma
1484691|NCT00049296|small intestine lymphoma
1484692|NCT00049296|stage II esophageal cancer
1484693|NCT00049296|stage II pancreatic cancer
1484694|NCT00049296|stage III esophageal cancer
1484695|NCT00049296|stage III multiple myeloma
1484696|NCT00049296|stage III pancreatic cancer
1484697|NCT00049296|stage IV adenoid cystic carcinoma of the oral cavity
1484698|NCT00049296|stage IV adult diffuse large cell lymphoma
1484699|NCT00049296|stage IV adult diffuse mixed cell lymphoma
1484700|NCT00049296|stage IV adult diffuse small cleaved cell lymphoma
1484701|NCT00049296|stage IV adult Burkitt lymphoma
1484702|NCT00049296|stage IV adult immunoblastic large cell lymphoma
1484703|NCT00049296|stage IV adult lymphoblastic lymphoma
1484704|NCT00049296|stage IV anal cancer
1484705|NCT00049296|stage IV basal cell carcinoma of the lip
1484706|NCT00049296|stage IV bladder cancer
1484707|NCT00049296|stage IV breast cancer
1484708|NCT00049296|stage IV colon cancer
1484709|NCT00049296|stage IV esophageal cancer
1484710|NCT00049296|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1484711|NCT00049296|stage IV gastric cancer
1484712|NCT00049296|stage IV grade 1 follicular lymphoma
1484713|NCT00049296|stage IV grade 2 follicular lymphoma
1484714|NCT00049296|stage IV grade 3 follicular lymphoma
1484715|NCT00049296|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1484716|NCT00049296|stage IV lymphoepithelioma of the nasopharynx
1484717|NCT00049296|stage IV lymphoepithelioma of the oropharynx
1484718|NCT00049296|stage IV mantle cell lymphoma
1484719|NCT00049296|stage IV melanoma
1484720|NCT00049296|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1484721|NCT00049296|stage IV mucoepidermoid carcinoma of the oral cavity
1484722|NCT00049296|stage IV non-small cell lung cancer
1484723|NCT00049296|stage IV rectal cancer
1484724|NCT00049296|stage IV renal cell cancer
1484725|NCT00049296|stage IV squamous cell carcinoma of the hypopharynx
1484726|NCT00049296|stage IV squamous cell carcinoma of the larynx
1484727|NCT00049296|stage IV squamous cell carcinoma of the lip and oral cavity
1484728|NCT00049296|stage IV squamous cell carcinoma of the nasopharynx
1484729|NCT00049296|stage IV squamous cell carcinoma of the oropharynx
1484730|NCT00049296|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1484731|NCT00049296|stage IV uterine sarcoma
1484732|NCT00049296|stage IV verrucous carcinoma of the larynx
1484733|NCT00049296|stage IV verrucous carcinoma of the oral cavity
1484734|NCT00049296|unresectable extrahepatic bile duct cancer
1484735|NCT00049296|unresectable gallbladder cancer
1484736|NCT00049296|unspecified adult solid tumor, protocol specific
1484737|NCT00049296|urethral cancer associated with invasive bladder cancer
1484738|NCT00049296|recurrent salivary gland cancer
1484739|NCT00049296|stage IV salivary gland cancer
1484740|NCT00049296|recurrent marginal zone lymphoma
1484741|NCT00049296|recurrent small lymphocytic lymphoma
1484742|NCT00049296|stage IV small lymphocytic lymphoma
1484743|NCT00049296|stage IV marginal zone lymphoma
1484744|NCT00049296|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1484745|NCT00049296|nodal marginal zone B-cell lymphoma
1484746|NCT00049296|splenic marginal zone lymphoma
1484747|NCT00049296|stage IV adult soft tissue sarcoma
1484748|NCT00049296|adult grade III meningioma
1484749|NCT00049296|adult oligodendroglioma
1484750|NCT00049296|adult giant cell glioblastoma
1484751|NCT00049296|adult gliosarcoma
1484752|NCT00049296|stage IV pancreatic cancer
1484753|NCT00049257|adenocarcinoma of the prostate
1484754|NCT00049257|recurrent prostate cancer
1484755|NCT00049257|stage IV prostate cancer
1484756|NCT00049244|recurrent breast cancer
1484757|NCT00049244|stage IV breast cancer
1484758|NCT00049231|cervical adenocarcinoma
1484759|NCT00049231|cervical adenosquamous cell carcinoma
1484760|NCT00049231|cervical squamous cell carcinoma
1484761|NCT00049231|stage IIB cervical cancer
1484762|NCT00049231|stage III cervical cancer
1484763|NCT00049231|stage IVA cervical cancer
1484764|NCT00049218|extensive stage small cell lung cancer
1484765|NCT00049179|adult acute monocytic leukemia (M5b)
1484766|NCT00049179|adult acute erythroid leukemia (M6)
1484767|NCT00049179|adult acute megakaryoblastic leukemia (M7)
1484768|NCT00049179|adult acute myeloblastic leukemia with maturation (M2)
1484769|NCT00049179|adult acute myeloblastic leukemia without maturation (M1)
1484770|NCT00049179|adult acute myelomonocytic leukemia (M4)
1484771|NCT00049179|adult acute monoblastic leukemia (M5a)
1484772|NCT00049179|recurrent adult acute myeloid leukemia
1484773|NCT00049179|secondary acute myeloid leukemia
1484774|NCT00049179|adult acute myeloid leukemia with t(8;21)(q22;q22)
1484775|NCT00049179|adult acute myeloid leukemia with t(16;16)(p13;q22)
1484776|NCT00049179|adult acute myeloid leukemia with inv(16)(p13;q22)
1484777|NCT00049179|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1484778|NCT00049140|stage I squamous cell carcinoma of the hypopharynx
1484779|NCT00049140|stage I squamous cell carcinoma of the larynx
1484780|NCT00049140|stage I squamous cell carcinoma of the lip and oral cavity
1484781|NCT00049140|stage I squamous cell carcinoma of the nasopharynx
1484782|NCT00049140|stage I squamous cell carcinoma of the oropharynx
1484783|NCT00049140|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1484784|NCT00049140|stage II squamous cell carcinoma of the hypopharynx
1484785|NCT00049140|stage II squamous cell carcinoma of the larynx
1484786|NCT00049140|stage II squamous cell carcinoma of the lip and oral cavity
1484787|NCT00049140|stage II squamous cell carcinoma of the nasopharynx
1484788|NCT00049140|stage II squamous cell carcinoma of the oropharynx
1484789|NCT00049140|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1484790|NCT00049140|stage III squamous cell carcinoma of the hypopharynx
1484791|NCT00049140|stage III squamous cell carcinoma of the larynx
1484792|NCT00049140|stage III squamous cell carcinoma of the lip and oral cavity
1484793|NCT00049140|stage III squamous cell carcinoma of the nasopharynx
1484794|NCT00049140|stage III squamous cell carcinoma of the oropharynx
1484795|NCT00049140|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1484796|NCT00049140|stage IV squamous cell carcinoma of the hypopharynx
1484797|NCT00049140|stage IV squamous cell carcinoma of the larynx
1484798|NCT00049140|stage IV squamous cell carcinoma of the lip and oral cavity
1484799|NCT00049140|stage IV squamous cell carcinoma of the nasopharynx
1484800|NCT00049140|stage IV squamous cell carcinoma of the oropharynx
1484801|NCT00049140|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1484802|NCT00049140|stage I salivary gland cancer
1484803|NCT00049140|stage II salivary gland cancer
1484804|NCT00049140|stage III salivary gland cancer
1484805|NCT00049140|stage IV salivary gland cancer
1484806|NCT00049140|salivary gland squamous cell carcinoma
1484807|NCT00049101|recurrent colon cancer
1484808|NCT00049101|stage IV colon cancer
1484809|NCT00049101|recurrent rectal cancer
1484810|NCT00049101|stage IV rectal cancer
1484811|NCT00049075|B-cell chronic lymphocytic leukemia
1484812|NCT00049075|stage I chronic lymphocytic leukemia
1484813|NCT00049075|stage II chronic lymphocytic leukemia
1484814|NCT00049075|stage III chronic lymphocytic leukemia
1484815|NCT00049075|stage IV chronic lymphocytic leukemia
1484816|NCT00049062|recurrent breast cancer
1484817|NCT00049062|stage IIIB breast cancer
1484818|NCT00049062|stage IIIC breast cancer
1484819|NCT00049062|stage IV breast cancer
1484820|NCT00049023|childhood grade III meningioma
1484821|NCT00049023|disseminated neuroblastoma
1484822|NCT00049023|localized unresectable neuroblastoma
1484823|NCT00049023|metastatic pheochromocytoma
1484824|NCT00049023|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1484825|NCT00049023|recurrent childhood brain tumor
1484826|NCT00049023|recurrent childhood medulloblastoma
1484827|NCT00049023|recurrent neuroblastoma
1484828|NCT00049023|recurrent pheochromocytoma
1484829|NCT00049023|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1484830|NCT00049023|regional neuroblastoma
1484831|NCT00049023|regional pheochromocytoma
1484832|NCT00049023|unspecified childhood solid tumor, protocol specific
1484833|NCT00049023|recurrent childhood ependymoma
1484834|NCT00049023|childhood infratentorial ependymoma
1484835|NCT00049023|childhood supratentorial ependymoma
1484836|NCT00049023|recurrent islet cell carcinoma
1484837|NCT00049023|gastrinoma
1484838|NCT00049023|insulinoma
1484839|NCT00049023|metastatic gastrointestinal carcinoid tumor
1484840|NCT00049023|recurrent gastrointestinal carcinoid tumor
1484841|NCT00049023|regional gastrointestinal carcinoid tumor
1484842|NCT00049010|stage I melanoma
1484843|NCT00049010|stage II melanoma
1484844|NCT00048997|stage IIIA non-small cell lung cancer
1484845|NCT00048997|stage IIIB non-small cell lung cancer
1484846|NCT00048971|adenocarcinoma of the colon
1484847|NCT00048971|stage III colon cancer
1484848|NCT00048971|diarrhea
1484849|NCT00048971|neutropenia
1484850|NCT00048906|Pharmacokinetics
1484851|NCT00048906|Enzyme
1484852|NCT00048906|Lysosomal
1484853|NCT00048906|Kidney
1484854|NCT00048906|Stroke
1484855|NCT00048906|Fabry Disease
1484856|NCT00048906|Fabrys
1484857|NCT00048906|Fabry's
1484858|NCT00048893|CEA vaccine
1484859|NCT00048893|Metastatic Breast Cancer
1484860|NCT00048893|T- Cell Repertoire
1484861|NCT00048893|High-dose Chemotherapy
1484862|NCT00048893|Breast Cancer
1484863|NCT00048880|Anaplastic Large Cell Lymphoma
1484864|NCT00048880|Monoclonal Antibody
1484865|NCT00048880|CD30
1484866|NCT00048880|Antibody Saturation
1484867|NCT00048880|Apoptosis
1484868|NCT00048880|Flow Cytometry
1484869|NCT00048880|Cancer
1484870|NCT00048841|Male
1484871|NCT00048841|Osteoporosis
1484872|NCT00048841|Prostate cancer
1484873|NCT00048841|Hypogonadism
1484874|NCT00048841|Bisphosphonates
1484875|NCT00048841|Bone mineral density
1484876|NCT00048802|Adolescence
1484877|NCT00048789|Psoralen
1484878|NCT00048789|Refractory
1484879|NCT00048789|Transplantation
1484880|NCT00048789|Stem Cell
1484881|NCT00048789|UVA
1484882|NCT00048789|Graft-versus-host Disease
1484883|NCT00048789|GVHD
1484884|NCT00048776|Secondary Raynaud's
1484885|NCT00048776|circulatory
1484886|NCT00048776|vascular
1484887|NCT00048776|scleroderma
1484888|NCT00048776|lupus
1484889|NCT00048776|mixed connective tissue disease
1484890|NCT00048763|circulatory
1484891|NCT00048763|vascular
1484892|NCT00048763|idiopathic
1484893|NCT00048750|Anti-Fungal Therapy
1484894|NCT00048750|Preemptive Anti-Fungal Therapy
1484895|NCT00048750|Invasive Fungal Infection
1484896|NCT00048750|Micafungin
1484897|NCT00048750|ICU
1484898|NCT00048737|Leukemia
1484899|NCT00048737|Lymphoma
1484900|NCT00048737|Lymphoid Malignancy
1484901|NCT00048737|Cyclophosphamide
1484902|NCT00048737|Cytoxan
1484903|NCT00048737|Neosar
1484904|NCT00048737|Fludarabine
1484905|NCT00048737|Fludarabine Phosphate
1484906|NCT00048737|Fludara
1484907|NCT00048737|Rituximab
1484908|NCT00048737|Rituxan
1484909|NCT00048737|Zevalin
1484910|NCT00048737|Indium Zevalin
1484911|NCT00048737|90Y Zevalin
1484912|NCT00048737|CD-20-positive
1484913|NCT00048737|B-cell Lymphoma
1484914|NCT00048737|CD-20-positive B-cell Lymphoma
1484915|NCT00048737|NHL
1484916|NCT00048737|CLL
1484917|NCT00048737|Chronic Lymphocytic Leukemia
1484918|NCT00048737|Allogeneic Stem Cell Transplantation
1484919|NCT00048737|ASCT
1484920|NCT00048724|Hepatitis C; Cirrhosis
1484921|NCT00048698|Frontal Lobe
1484922|NCT00048698|Motor Cortex
1484923|NCT00048698|Dementia
1484924|NCT00048698|Cognition
1484925|NCT00048698|Healthy Volunteer
1484926|NCT00048698|HV
1484927|NCT00048685|Caries
1484928|NCT00048685|Bacteria
1484929|NCT00048685|Saliva
1484930|NCT00048685|Teeth
1484931|NCT00048685|Autoimmune
1484932|NCT00048685|Dry Mouth
1484933|NCT00048685|Salivary Gland Dysfunction
1484934|NCT00048685|Sjogren's Syndrome
1484935|NCT00048672|Early Chronic Phase Chronic Myelogenous Leukemia
1484936|NCT00048672|Leukemia
1484937|NCT00048672|Gleevec
1484938|NCT00048672|STI571
1484939|NCT00048672|Imatinib mesylate
1484940|NCT00048659|Androgen-independent prostate cancer
1484941|NCT00048646|TBI
1484942|NCT00048646|ProTECT
1484943|NCT00048633|Chemotherapy resistance advanced breast cancer
1484944|NCT00048542|Polyarticular Juvenile Idiopathic Arthritis
1484945|NCT00048529|adenocarcinoma of the esophagus
1484946|NCT00048503|Zarnestra
1484947|NCT00048503|Acute myeloid leukemia
1484948|NCT00048503|Tipifarnib
1484949|NCT00048490|Seizures
1484950|NCT00048490|Magnetism
1484951|NCT00048490|Brain
1484952|NCT00048490|Stimulation
1484953|NCT00048490|Therapy
1484954|NCT00048490|Epilepsy
1484955|NCT00048477|Endothelium
1484956|NCT00048477|Vasodilation
1484957|NCT00048477|Exercise
1484958|NCT00048477|Hemoglobin
1484959|NCT00048477|Blood Flow
1484960|NCT00048477|Healthy Volunteer
1484961|NCT00048477|HV
1484962|NCT00048464|Immunotherapy
1484963|NCT00048464|T Cell Therapy
1484964|NCT00048464|Peripheral Blood Stem Cell Transplant
1484965|NCT00048464|Bone marrow transplant
1484966|NCT00048464|Adoptive immunotherapy
1484967|NCT00048464|Xcellerate
1484968|NCT00048425|Decompensated chronic heart failure
1484969|NCT00048373|LANGERHANS
1484970|NCT00048373|HISTIOCYTOSIS
1484971|NCT00048360|ADD
1484972|NCT00048360|ADHD
1484973|NCT00048360|attention deficit
1484974|NCT00048360|hyperactivity
1484975|NCT00048347|Lymphocyte
1484976|NCT00048347|Monocyte
1484977|NCT00048347|Inflammation
1484978|NCT00048347|Th2
1484979|NCT00048347|Colonoscopy
1484980|NCT00048347|Ulcerative Colitis
1484981|NCT00048334|Histone Acetylation
1484982|NCT00048334|Cancer
1484983|NCT00048308|CABG
1484984|NCT00048282|Incidence
1484985|NCT00048282|HIV Seroprevalence
1484986|NCT00048282|Vagina
1484987|NCT00048282|Anti-Infective Agents
1484988|NCT00048282|Administration, Topical
1484989|NCT00048282|Gels
1484990|NCT00048282|HIV Seronegativity
1484991|NCT00048256|Cancer
1484992|NCT00048256|Personality Assessment
1484993|NCT00048256|Coping Styles
1484994|NCT00048256|Psychological Distress
1484995|NCT00048256|Bone Marrow Transplants
1484996|NCT00048256|Bone Marrow Transplant
1484997|NCT00048230|Relapsed Multiple Myeloma
1484998|NCT00048230|Refractory Multiple Myeloma
1484999|NCT00048217|Treatment Experienced
1485000|NCT00048204|Depression
1485001|NCT00048204|Psychiatry
1485002|NCT00048204|Major Depressive Disorder
1485003|NCT00048113|Crohn's
1485004|NCT00048100|Dendritic cells
1485005|NCT00048100|Lymphocytes
1485006|NCT00048100|AML
1485007|NCT00048087|Non-small cell lung cancer
1485008|NCT00047983|Kidney Transplantation
1485009|NCT00047983|Fatty Acids, Omega-3
1485010|NCT00047983|Erythrocyte Membrane
1485011|NCT00047983|Graft Survival
1485012|NCT00047970|Breast Cancer
1485013|NCT00047970|Sisters
1485014|NCT00047957|Transcranial
1485015|NCT00047957|Magnetic
1485016|NCT00047957|Stimulation
1485017|NCT00047957|Motor
1485018|NCT00047957|Cortex
1485019|NCT00047957|Motor Cortex
1485020|NCT00047957|Afferent Stimulation
1485021|NCT00047957|Transcranial Magnetic Stimulation
1485022|NCT00047957|Healthy Volunteer
1485023|NCT00047957|HV
1485024|NCT00047944|Attention
1485025|NCT00047944|Emotion
1485026|NCT00047944|Amygdala
1485027|NCT00047944|Prefrontal Cortex
1485028|NCT00047944|Facial Expression
1485029|NCT00047944|Magnetic Resonance Imaging
1485030|NCT00047944|fMRI
1485031|NCT00047944|Depression
1485032|NCT00047944|Anxiety
1485033|NCT00047944|Adolescence
1485034|NCT00047944|Children
1485035|NCT00047931|Healthy
1485036|NCT00047931|HIV-Negative
1485037|NCT00047931|Placebo-Controlled
1485038|NCT00047931|Volunteer
1485039|NCT00047931|Dose-Escalation
1485040|NCT00047931|HIV Seronegativity
1485041|NCT00047931|Healthy Volunteer
1485042|NCT00047931|HV
1485043|NCT00047918|Mast Cells
1485044|NCT00047918|Bone Marrow
1485045|NCT00047918|Flushing
1485046|NCT00047918|Mutations
1485047|NCT00047918|Mastocytosis
1485048|NCT00047918|Anaphylaxis
1485049|NCT00047905|Qualitative
1485050|NCT00047905|Communication Analysis
1485051|NCT00047905|RIAS
1485052|NCT00047905|Counseling Models
1485053|NCT00047905|Videotaping
1485054|NCT00047905|Prenatal Genetic Counselors
1485055|NCT00047905|Counseling Process
1485056|NCT00047905|Video Tape Study
1485057|NCT00047905|Simulated Clients
1485058|NCT00047905|Prenatal Genetic Counseling
1485059|NCT00047879|Brain Tumors
1485060|NCT00047879|Experimental
1485061|NCT00047879|Toxicities
1485062|NCT00047879|Efficacy
1485063|NCT00047879|Progression-Free
1485064|NCT00047879|Brain Tumor
1485065|NCT00047879|Glioma
1485066|NCT00047866|Limbic System
1485067|NCT00047866|Amphetamine
1485068|NCT00047866|Dopamine
1485069|NCT00047866|Brain Imaging
1485070|NCT00047866|Cerebral Blood Flow
1485071|NCT00047866|Cerebral Blood Volume
1485072|NCT00047866|Alcoholism
1485073|NCT00047866|Tyrosine Depletion
1485074|NCT00047866|Amino Acids
1485075|NCT00047866|Affect
1485076|NCT00047866|Healthy Volunteer
1485077|NCT00047866|HV
1485078|NCT00047853|Anxiety
1485079|NCT00047853|Neuroimaging
1485080|NCT00047853|Affective Neuroscience
1485081|NCT00047853|Healthy Volunteer
1485082|NCT00047853|HV
1485083|NCT00047827|Aspergillus
1485084|NCT00047827|Aspergillosis
1485085|NCT00047827|Anti-Fungal
1485086|NCT00047827|AmBisome
1485087|NCT00047827|Micafungin
1485088|NCT00047814|HCV
1485089|NCT00047788|Relapsed Multiple Myeloma
1485090|NCT00047749|pain
1485091|NCT00047749|ziconotide
1485092|NCT00047749|Prialt
1485093|NCT00047749|intrathecal
1485094|NCT00047749|Synchromed
1485095|NCT00047736|Non-small cell lung cancer
1485096|NCT00047723|ALS
1485097|NCT00047723|amyotrophic lateral sclerosis
1485098|NCT00047723|minocycline
1485099|NCT00047710|pancreatic cancer
1485100|NCT00047710|pancreas cancer
1485101|NCT00047710|pancreas
1485102|NCT00047684|Child Abuse, Sexual
1485103|NCT00047671|Depressive Disorder
1485104|NCT00047645|lung
1485105|NCT00047645|IPF
1485106|NCT00047632|ovarian
1485107|NCT00047632|carcinoma
1485108|NCT00047632|peritoneal
1485109|NCT00047632|cancer
1485110|NCT00047632|ovary
1485111|NCT00047632|interferon gamma
1485112|NCT00047619|Decubitus Ulcers
1485113|NCT00047619|Pulsatile Lavage
1485114|NCT00047619|SCI
1485115|NCT00047619|Spinal Cord Injury
1485116|NCT00047619|Wound healing
1485117|NCT00047619|pressure ulcer
1485118|NCT00047606|open-angle
1485119|NCT00047606|glaucoma
1485120|NCT00047606|ocular
1485121|NCT00047606|hypertension
1485122|NCT00047606|POAG
1485123|NCT00047606|Iris
1485124|NCT00047606|Pigmentation
1485125|NCT00047606|Japanese
1485126|NCT00047593|open-angle
1485127|NCT00047593|glaucoma
1485128|NCT00047593|ocular
1485129|NCT00047593|hypertension
1485130|NCT00047593|POAG
1485131|NCT00047593|Iris
1485132|NCT00047593|Pigmentation
1485133|NCT00047593|Japanese
1485134|NCT00047580|Spasticity
1485135|NCT00047580|spasticity secondary to Multiple Sclerosis
1485136|NCT00047580|Spinal Cord Injury
1485137|NCT00047580|Stroke
1485138|NCT00046436|AIDS Serodiagnosis
1485139|NCT00046436|Pregnancy Complications, Infectious
1485140|NCT00046436|Anti-HIV Agents
1485141|NCT00046436|Disease Transmission, Vertical
1485142|NCT00046423|Cancer
1485143|NCT00046423|solid tumor
1485144|NCT00046423|Advanced malignancy
1485145|NCT00046423|Taxane therapy
1485146|NCT00046423|Biopsy-proven diagnosis of advanced malignancy
1485147|NCT00046423|Various solid tumors which are refractory
1485148|NCT00046410|MRI
1485149|NCT00046410|Diffusion
1485150|NCT00046410|Cognitive
1485151|NCT00046410|Stroke
1485152|NCT00046410|Heart
1485153|NCT00046410|Coronary Artery Disease
1485154|NCT00046410|Heart Disease
1485155|NCT00046397|Smallpox
1485156|NCT00046397|Vaccine
1485157|NCT00046397|Vaccination
1485158|NCT00046397|Variola
1485159|NCT00046397|Adults
1485160|NCT00046397|Smallpox Vaccine
1485161|NCT00046397|Healthy Volunteer
1485162|NCT00046397|Small Pox
1485163|NCT00046371|Cancer Vaccines
1485164|NCT00046371|Aromatase
1485165|NCT00046371|Receptors, Estrogen
1485166|NCT00046371|Receptors, Progesterone
1485167|NCT00046358|Cerebrospinal Fluid
1485168|NCT00046358|Cholesterol
1485169|NCT00046358|Statin
1485170|NCT00046358|NSAID
1485171|NCT00046358|Antiinflammatory
1485172|NCT00046358|Dementia
1485173|NCT00046358|Alzheimer's Disease
1485174|NCT00046358|Nonsteroidal Antiinflammatory
1485175|NCT00046358|Healthy Volunteer
1485176|NCT00046345|treatment experienced
1485177|NCT00046332|Integrase inhibitors
1485178|NCT00046332|Monotherapy
1485179|NCT00046332|HIV-1 infection
1485180|NCT00046319|Pulmonary Arterial Hypertension
1485181|NCT00046319|Primary Pulmonary Hypertension
1485182|NCT00046306|Oxidative Stress
1485183|NCT00046306|Cardiovascular Disease
1485184|NCT00046306|Cancer
1485185|NCT00046293|Stroke
1485186|NCT00046293|Abciximab
1485187|NCT00046293|Retavase
1485188|NCT00046293|MRI
1485189|NCT00046293|Cerebral Blood Flow
1485190|NCT00046267|Delayed-Action Preparations
1485191|NCT00046267|Blood Glucose
1485192|NCT00046267|Insulin
1485193|NCT00046267|Alanine Transaminase
1485194|NCT00046267|Aspartate Aminotransferases
1485195|NCT00046267|Fructosamine
1485196|NCT00046267|Glucose Tolerance Test
1485197|NCT00046267|Treatment Experienced
1485198|NCT00046254|hip fracture
1485199|NCT00046254|recurrent fracture
1485200|NCT00046254|fracture
1485201|NCT00046254|bone loss
1485202|NCT00046254|bisphosphonate
1485203|NCT00046254|bone mineral density
1485204|NCT00046254|osteoporosis
1485205|NCT00046254|zoledronic acid
1485206|NCT00046254|geriatrics
1485207|NCT00046254|rehabilitation
1485208|NCT00046254|elderly
1485209|NCT00046254|nursing home
1485210|NCT00046254|orthopedic
1485211|NCT00046241|seasonal depression winter blues winter depression
1485212|NCT00046228|Myocardial infarction
1485213|NCT00046228|percutaneous coronary intervention
1485214|NCT00046228|abciximab
1485215|NCT00046228|reteplase
1485216|NCT00046228|safety and efficacy
1485217|NCT00047567|ZONISAMIDE
1485218|NCT00047567|BIPOLAR
1485219|NCT00047554|open-angle
1485220|NCT00047554|glaucoma
1485221|NCT00047554|ocular
1485222|NCT00047554|hypertension
1485223|NCT00047554|primary open-angle glaucoma
1485224|NCT00047554|iris
1485225|NCT00047554|pigmentation
1485226|NCT00047541|open-angle
1485227|NCT00047541|glaucoma
1485228|NCT00047541|ocular
1485229|NCT00047541|hypertension
1485230|NCT00047541|POAG
1485231|NCT00047528|open-angle
1485232|NCT00047528|glaucoma
1485233|NCT00047528|ocular
1485234|NCT00047528|hypertension
1485235|NCT00047528|POAG
1485236|NCT00047515|open-angle
1485237|NCT00047515|glaucoma
1485238|NCT00047515|ocular
1485239|NCT00047515|hypertension
1485240|NCT00047515|POAG
1485241|NCT00047476|neurobehavioral function
1485242|NCT00047476|chemobrain
1485243|NCT00047476|chemo brain
1485244|NCT00047476|fatigue
1485245|NCT00047476|memory loss
1485246|NCT00047476|exhausted
1485247|NCT00047476|trouble concentrating
1485248|NCT00047463|epilepsy
1485249|NCT00047463|sleep apnea
1485250|NCT00047463|obstructive sleep apnea
1485251|NCT00047463|continuous positive airway pressure
1485252|NCT00047463|CPAP
1485253|NCT00047450|Psychotic Disorders
1485254|NCT00047411|CPR, AED
1485255|NCT00047385|small cell lung cancer
1485256|NCT00047385|non-small cell lung cancer
1485257|NCT00047320|childhood central nervous system germ cell tumor
1485258|NCT00047320|childhood teratoma
1485259|NCT00047320|recurrent childhood malignant germ cell tumor
1485260|NCT00047320|childhood central nervous system choriocarcinoma
1485261|NCT00047320|childhood central nervous system embryonal tumor
1485262|NCT00047320|childhood central nervous system germinoma
1485263|NCT00047320|childhood central nervous system mixed germ cell tumor
1485264|NCT00047320|childhood central nervous system teratoma
1485265|NCT00047320|childhood central nervous system yolk sac tumor
1485266|NCT00047320|recurrent childhood central nervous system embryonal tumor
1485267|NCT00047294|adult mixed glioma
1485268|NCT00047294|adult glioblastoma
1485269|NCT00047294|adult giant cell glioblastoma
1485270|NCT00047294|adult gliosarcoma
1485271|NCT00047281|adult anaplastic astrocytoma
1485272|NCT00047281|adult anaplastic oligodendroglioma
1485273|NCT00047281|adult glioblastoma
1485274|NCT00047281|adult mixed glioma
1485275|NCT00047281|recurrent adult brain tumor
1485276|NCT00047281|adult giant cell glioblastoma
1485277|NCT00047281|adult gliosarcoma
1485278|NCT00047268|juvenile myelomonocytic leukemia
1485279|NCT00047268|childhood myelodysplastic syndromes
1485280|NCT00047268|atypical chronic myeloid leukemia, BCR-ABL1 negative
1485281|NCT00047268|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1485282|NCT00047268|chronic myelomonocytic leukemia
1485283|NCT00047255|stage IIIB breast cancer
1485284|NCT00047255|stage IIIC breast cancer
1485285|NCT00047255|stage IV breast cancer
1485286|NCT00047255|recurrent breast cancer
1485287|NCT00047242|unspecified adult solid tumor, protocol specific
1485288|NCT00047229|adult primary hepatocellular carcinoma
1485289|NCT00047229|advanced adult primary liver cancer
1485290|NCT00047229|localized unresectable adult primary liver cancer
1485291|NCT00047229|recurrent adult primary liver cancer
1485292|NCT00047216|recurrent bladder cancer
1485293|NCT00047216|stage 0 bladder cancer
1485294|NCT00047216|stage I bladder cancer
1485295|NCT00047216|transitional cell carcinoma of the bladder
1485296|NCT00047177|recurrent childhood medulloblastoma
1485297|NCT00047177|recurrent childhood supratentorial primitive neuroectodermal tumor
1485298|NCT00047177|recurrent childhood ependymoma
1485299|NCT00047177|childhood atypical teratoid/rhabdoid tumor
1485300|NCT00047164|recurrent grade 1 follicular lymphoma
1485301|NCT00047164|recurrent grade 2 follicular lymphoma
1485302|NCT00047164|contiguous stage II adult lymphoblastic lymphoma
1485303|NCT00047164|noncontiguous stage II adult lymphoblastic lymphoma
1485304|NCT00047164|recurrent adult lymphoblastic lymphoma
1485305|NCT00047164|stage I adult lymphoblastic lymphoma
1485306|NCT00047164|stage III adult lymphoblastic lymphoma
1485307|NCT00047164|stage IV adult lymphoblastic lymphoma
1485308|NCT00047164|noncontiguous stage II grade 3 follicular lymphoma
1485309|NCT00047164|recurrent grade 3 follicular lymphoma
1485310|NCT00047164|stage I grade 3 follicular lymphoma
1485311|NCT00047164|stage III grade 3 follicular lymphoma
1485312|NCT00047164|stage IV grade 3 follicular lymphoma
1485313|NCT00047164|contiguous stage II grade 3 follicular lymphoma
1485314|NCT00047164|contiguous stage II grade 2 follicular lymphoma
1485315|NCT00047164|contiguous stage II grade 1 follicular lymphoma
1485316|NCT00047164|contiguous stage II adult diffuse mixed cell lymphoma
1485317|NCT00047164|noncontiguous stage II adult diffuse mixed cell lymphoma
1485318|NCT00047164|recurrent adult diffuse mixed cell lymphoma
1485319|NCT00047164|stage I adult diffuse mixed cell lymphoma
1485320|NCT00047164|stage III adult diffuse mixed cell lymphoma
1485321|NCT00047164|stage IV adult diffuse mixed cell lymphoma
1485322|NCT00047164|contiguous stage II adult diffuse large cell lymphoma
1485323|NCT00047164|noncontiguous stage II adult diffuse large cell lymphoma
1485324|NCT00047164|recurrent adult diffuse large cell lymphoma
1485325|NCT00047164|stage I adult diffuse large cell lymphoma
1485326|NCT00047164|stage III adult diffuse large cell lymphoma
1485327|NCT00047164|stage IV adult diffuse large cell lymphoma
1485328|NCT00047164|contiguous stage II adult immunoblastic large cell lymphoma
1485329|NCT00047164|noncontiguous stage II adult immunoblastic large cell lymphoma
1485330|NCT00047164|recurrent adult immunoblastic large cell lymphoma
1485331|NCT00047164|stage I adult immunoblastic large cell lymphoma
1485332|NCT00047164|stage III adult immunoblastic large cell lymphoma
1485333|NCT00047164|stage IV adult immunoblastic large cell lymphoma
1485334|NCT00047164|contiguous stage II adult Burkitt lymphoma
1485335|NCT00047164|noncontiguous stage II adult Burkitt lymphoma
1485336|NCT00047164|recurrent adult Burkitt lymphoma
1485337|NCT00047164|stage I adult Burkitt lymphoma
1485338|NCT00047164|stage III adult Burkitt lymphoma
1485339|NCT00047164|stage IV adult Burkitt lymphoma
1485340|NCT00047164|contiguous stage II mantle cell lymphoma
1485341|NCT00047164|noncontiguous stage II mantle cell lymphoma
1485342|NCT00047164|recurrent mantle cell lymphoma
1485343|NCT00047164|stage I mantle cell lymphoma
1485344|NCT00047164|stage III mantle cell lymphoma
1485345|NCT00047164|stage IV mantle cell lymphoma
1485346|NCT00047164|recurrent adult Hodgkin lymphoma
1485347|NCT00047164|stage I adult Hodgkin lymphoma
1485348|NCT00047164|stage II adult Hodgkin lymphoma
1485349|NCT00047164|stage III adult Hodgkin lymphoma
1485350|NCT00047164|stage IV adult Hodgkin lymphoma
1485351|NCT00047164|recurrent adult diffuse small cleaved cell lymphoma
1485352|NCT00047164|stage I adult diffuse small cleaved cell lymphoma
1485353|NCT00047164|stage II adult diffuse small cleaved cell lymphoma
1485354|NCT00047164|stage III adult diffuse small cleaved cell lymphoma
1485355|NCT00047164|stage IV adult diffuse small cleaved cell lymphoma
1485356|NCT00047164|contiguous stage II marginal zone lymphoma
1485357|NCT00047164|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1485358|NCT00047164|nodal marginal zone B-cell lymphoma
1485359|NCT00047164|noncontiguous stage II marginal zone lymphoma
1485360|NCT00047164|recurrent marginal zone lymphoma
1485361|NCT00047164|splenic marginal zone lymphoma
1485362|NCT00047164|stage I marginal zone lymphoma
1485363|NCT00047164|stage III marginal zone lymphoma
1485364|NCT00047164|stage IV marginal zone lymphoma
1485365|NCT00047164|contiguous stage II small lymphocytic lymphoma
1485366|NCT00047164|noncontiguous stage II small lymphocytic lymphoma
1485367|NCT00047164|recurrent small lymphocytic lymphoma
1485368|NCT00047164|stage I small lymphocytic lymphoma
1485369|NCT00047164|stage III small lymphocytic lymphoma
1485370|NCT00047164|stage IV small lymphocytic lymphoma
1485371|NCT00047164|recurrent adult T-cell leukemia/lymphoma
1485372|NCT00047164|recurrent cutaneous T-cell non-Hodgkin lymphoma
1485373|NCT00047164|stage I adult T-cell leukemia/lymphoma
1485374|NCT00047164|stage I cutaneous T-cell non-Hodgkin lymphoma
1485375|NCT00047164|stage II adult T-cell leukemia/lymphoma
1485376|NCT00047164|stage II cutaneous T-cell non-Hodgkin lymphoma
1485377|NCT00047164|stage III adult T-cell leukemia/lymphoma
1485378|NCT00047164|stage III cutaneous T-cell non-Hodgkin lymphoma
1485379|NCT00047164|stage IV adult T-cell leukemia/lymphoma
1485380|NCT00047164|stage IV cutaneous T-cell non-Hodgkin lymphoma
1485381|NCT00047138|blastema predominant Wilms tumor
1485382|NCT00047138|epithelial predominant Wilms tumor
1485383|NCT00047138|mixed cell type Wilms tumor
1485384|NCT00047138|stage I Wilms tumor
1485385|NCT00047138|stage II Wilms tumor
1485386|NCT00047138|stage III Wilms tumor
1485387|NCT00047138|stage IV Wilms tumor
1485388|NCT00047138|stage V Wilms tumor
1485389|NCT00047138|stromal predominant Wilms tumor
1485390|NCT00047125|newly diagnosed carcinoma of unknown primary
1485391|NCT00047125|squamous cell carcinoma of unknown primary
1485392|NCT00047112|adenocarcinoma of the esophagus
1485393|NCT00047112|squamous cell carcinoma of the esophagus
1485394|NCT00047112|stage I esophageal cancer
1485395|NCT00047112|stage II esophageal cancer
1485396|NCT00047099|stage II breast cancer
1485397|NCT00047099|stage IIIA breast cancer
1485398|NCT00047099|stage IIIB breast cancer
1485399|NCT00047073|recurrent adult brain tumor
1485400|NCT00047073|adult glioblastoma
1485401|NCT00047073|adult giant cell glioblastoma
1485402|NCT00047073|adult gliosarcoma
1485403|NCT00047060|Cutaneous T Cell Lymphoma
1485404|NCT00047060|Allogeneic PBSCT
1485405|NCT00047060|Low Intensity Regimen
1485406|NCT00047060|Mycosis Fungoides
1485407|NCT00047060|Sezary Syndrome
1485408|NCT00047060|CTCL
1485409|NCT00047021|accelerated phase chronic myelogenous leukemia
1485410|NCT00047021|blastic phase chronic myelogenous leukemia
1485411|NCT00047021|recurrent adult acute lymphoblastic leukemia
1485412|NCT00047021|recurrent adult acute myeloid leukemia
1485413|NCT00047021|recurrent adult diffuse large cell lymphoma
1485414|NCT00047021|recurrent adult diffuse mixed cell lymphoma
1485415|NCT00047021|recurrent adult diffuse small cleaved cell lymphoma
1485416|NCT00047021|recurrent adult Burkitt lymphoma
1485417|NCT00047021|recurrent adult Hodgkin lymphoma
1485418|NCT00047021|recurrent adult immunoblastic large cell lymphoma
1485419|NCT00047021|recurrent adult lymphoblastic lymphoma
1485420|NCT00047021|recurrent childhood acute lymphoblastic leukemia
1485421|NCT00047021|recurrent childhood acute myeloid leukemia
1485422|NCT00047021|recurrent childhood large cell lymphoma
1485423|NCT00047021|recurrent childhood lymphoblastic lymphoma
1485424|NCT00047021|recurrent childhood small noncleaved cell lymphoma
1485425|NCT00047021|recurrent grade 1 follicular lymphoma
1485426|NCT00047021|recurrent grade 2 follicular lymphoma
1485528|NCT00046735|solid tumors
1485427|NCT00047021|recurrent grade 3 follicular lymphoma
1485428|NCT00047021|recurrent mantle cell lymphoma
1485429|NCT00047021|recurrent/refractory childhood Hodgkin lymphoma
1485430|NCT00047021|relapsing chronic myelogenous leukemia
1485431|NCT00047021|secondary acute myeloid leukemia
1485432|NCT00047021|childhood chronic myelogenous leukemia
1485433|NCT00047021|atypical chronic myeloid leukemia
1485434|NCT00047021|recurrent marginal zone lymphoma
1485435|NCT00047021|recurrent small lymphocytic lymphoma
1485436|NCT00047021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1485437|NCT00047021|nodal marginal zone B-cell lymphoma
1485438|NCT00047021|splenic marginal zone lymphoma
1485439|NCT00047021|adult acute myeloid leukemia with t(8;21)(q22;q22)
1485440|NCT00047021|adult acute myeloid leukemia with t(16;16)(p13;q22)
1485441|NCT00047021|adult acute myeloid leukemia with inv(16)(p13;q22)
1485442|NCT00047021|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1485443|NCT00047021|adult acute myeloid leukemia with t(15;17)(q22;q12)
1485444|NCT00047008|stage III squamous cell carcinoma of the hypopharynx
1485445|NCT00047008|stage III squamous cell carcinoma of the larynx
1485446|NCT00047008|stage III squamous cell carcinoma of the lip and oral cavity
1485447|NCT00047008|stage III squamous cell carcinoma of the oropharynx
1485448|NCT00047008|stage IV squamous cell carcinoma of the hypopharynx
1485449|NCT00047008|stage IV squamous cell carcinoma of the larynx
1485450|NCT00047008|stage IV squamous cell carcinoma of the lip and oral cavity
1485451|NCT00047008|stage IV squamous cell carcinoma of the oropharynx
1485452|NCT00046995|adenocarcinoma of the colon
1485453|NCT00046995|stage IIB colon cancer
1485454|NCT00046995|stage IIIA colon cancer
1485455|NCT00046995|stage IIIB colon cancer
1485456|NCT00046995|stage IIIC colon cancer
1485457|NCT00046969|anemia
1485458|NCT00046969|stage IIB cervical cancer
1485459|NCT00046969|stage III cervical cancer
1485460|NCT00046969|stage IVA cervical cancer
1485461|NCT00046969|cervical adenosquamous cell carcinoma
1485462|NCT00046969|cervical squamous cell carcinoma
1485463|NCT00046969|cervical adenocarcinoma
1485464|NCT00046943|adenocarcinoma of the prostate
1485465|NCT00046943|recurrent prostate cancer
1485466|NCT00046943|stage IIB prostate cancer
1485467|NCT00046943|stage IIA prostate cancer
1485468|NCT00046943|stage III prostate cancer
1485469|NCT00046943|stage IV prostate cancer
1485470|NCT00046930|adult acute monocytic leukemia (M5b)
1485471|NCT00046930|adult acute erythroid leukemia (M6)
1485472|NCT00046930|adult acute megakaryoblastic leukemia (M7)
1485473|NCT00046930|adult acute myeloblastic leukemia with maturation (M2)
1485474|NCT00046930|adult acute myeloblastic leukemia without maturation (M1)
1485475|NCT00046930|adult acute myelomonocytic leukemia (M4)
1485476|NCT00046930|adult acute monoblastic leukemia (M5a)
1485477|NCT00046930|refractory anemia with excess blasts in transformation
1485478|NCT00046930|refractory anemia with excess blasts
1485479|NCT00046930|secondary acute myeloid leukemia
1485480|NCT00046930|untreated adult acute myeloid leukemia
1485481|NCT00046930|de novo myelodysplastic syndromes
1485482|NCT00046930|adult acute minimally differentiated myeloid leukemia (M0)
1485483|NCT00046930|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1485484|NCT00046930|adult acute myeloid leukemia with inv(16)(p13;q22)
1485485|NCT00046930|adult acute myeloid leukemia with t(16;16)(p13;q22)
1485486|NCT00046930|adult acute myeloid leukemia with t(8;21)(q22;q22)
1485487|NCT00046904|unspecified adult solid tumor, protocol specific
1485488|NCT00046904|anorexia
1485489|NCT00046904|cachexia
1485490|NCT00046891|neurotoxicity
1485491|NCT00046891|stage I breast cancer
1485492|NCT00046891|stage II breast cancer
1485493|NCT00046891|stage IIIA breast cancer
1485494|NCT00046891|stage IIIB breast cancer
1485495|NCT00046891|stage IIIC breast cancer
1485496|NCT00046878|adult glioblastoma
1485497|NCT00046878|adult giant cell glioblastoma
1485498|NCT00046878|adult gliosarcoma
1485499|NCT00046865|nausea and vomiting
1485500|NCT00046865|stage I breast cancer
1485501|NCT00046865|stage II breast cancer
1485502|NCT00046865|stage IIIA breast cancer
1485503|NCT00046865|stage IIIB breast cancer
1485504|NCT00046865|stage IIIC breast cancer
1485505|NCT00046865|stage IV breast cancer
1485506|NCT00046852|infection
1485507|NCT00046852|refractory multiple myeloma
1485508|NCT00046852|stage I multiple myeloma
1485509|NCT00046852|stage II multiple myeloma
1485510|NCT00046852|stage III multiple myeloma
1485511|NCT00046839|stage II non-small cell lung cancer
1485512|NCT00046839|stage IIIA non-small cell lung cancer
1485513|NCT00046839|stage IIIB non-small cell lung cancer
1485514|NCT00046826|adenocarcinoma of the prostate
1485515|NCT00046826|stage IV prostate cancer
1485516|NCT00046826|recurrent prostate cancer
1485517|NCT00046800|Ovarian Cancer
1485518|NCT00046787|Small Cell Lung Cancer
1485519|NCT00046774|Safety
1485520|NCT00046774|Nephritis
1485521|NCT00046774|Biologic Therapy
1485522|NCT00046774|Lymphocytes
1485523|NCT00046774|Response
1485524|NCT00046774|Lupus
1485525|NCT00046774|Systemic Lupus Erythematosus
1485526|NCT00046774|SLE
1485527|NCT00046761|Acute Ischemic Stroke
1485529|NCT00046735|Revimid
1485530|NCT00046735|CC5013
1485531|NCT00046735|CC-5013
1485532|NCT00046722|treatment experienced
1485533|NCT00046722|complementary therapies
1485534|NCT00046722|Neuropathy
1485535|NCT00046722|Peripheral Neuropathy
1485536|NCT00046722|HIV-Related Peripheral Neuropathy
1485537|NCT00046722|HIV
1485538|NCT00046709|Cancer pain
1485539|NCT00046709|All types of cancer except lung cancer
1485540|NCT00046696|Cancer
1485541|NCT00046696|Cancer Alternative Therapies
1485542|NCT00046696|Living with Cancer
1485543|NCT00046683|Adult acute leukemia
1485544|NCT00046683|Adult chronic leukemia
1485545|NCT00046683|Childhood leukemia
1485546|NCT00046683|Campath
1485547|NCT00046683|Alemtuzumab
1485548|NCT00046631|built environment
1485549|NCT00046631|parks
1485550|NCT00046631|retail outlets
1485551|NCT00046631|adolescent girls
1485552|NCT00046631|physical activity
1485553|NCT00046553|Cortisol
1485554|NCT00046553|CRH
1485555|NCT00046553|HPA Axis
1485556|NCT00046553|Hypothalamus
1485557|NCT00046553|Hippocampus
1485558|NCT00046553|Post-Traumatic Stress Disorder
1485559|NCT00046553|PTSD
1485560|NCT00046553|Healthy Volunteer
1485561|NCT00046540|Liposome-Encapsulated SN38
1485562|NCT00046540|Irinotecan
1485563|NCT00046540|CPT-11
1485564|NCT00046540|Malignant Tumors
1485565|NCT00046527|Metastatic breast cancer
1485566|NCT00046527|Taxol
1485567|NCT00046527|Taxane
1485568|NCT00046514|Metastatic Breast Cancer
1485569|NCT00046514|Taxol
1485570|NCT00046488|Chronic Lymphoblastic Leukemia
1485571|NCT00046488|Leukemia, Lymphoblastic, Chronic
1485572|NCT00046488|Chronic Lymphocytic Leukemia
1485573|NCT00046488|CLL
1485574|NCT00046215|Virtual Lesion Study
1485575|NCT00046215|Motor Imagery
1485576|NCT00046215|Primary Motor Cortex
1485577|NCT00046215|Motor Inhibition
1485578|NCT00046215|Motor Execution
1485579|NCT00046215|Healthy Volunteer
1485580|NCT00046202|Smith-Lemli-Opitz Syndrome
1485581|NCT00046202|Sterol
1485582|NCT00046202|Mutations
1485583|NCT00046202|Dysmorphology
1485584|NCT00046202|Mental Retardation
1485585|NCT00046202|Inborn Errors of Cholesterol Synthesis
1485586|NCT00046202|Smith-Lemli-Optiz Syndrome
1485587|NCT00046202|Lathosterolosis
1485588|NCT00046202|Desmosterols
1485589|NCT00046202|CHILD Syndrome
1485590|NCT00046202|Greenberg Dysplasia
1485591|NCT00046202|X Linked Dominant Chrondrodysplasia
1485592|NCT00046189|Sun Exposure
1485593|NCT00046189|Xeroderma Pigmentosum
1485594|NCT00046189|Skin Cancer
1485595|NCT00046189|Family History
1485596|NCT00046189|HETEROZYGOTE
1485597|NCT00046189|XP
1485598|NCT00046176|HIV-1 Abacavir Lamivudine Antiretroviral-experienced
1485599|NCT00046163|Neurology
1485600|NCT00046163|Cardiology
1485601|NCT00046111|oral
1485602|NCT00046111|Bioequivalence
1485603|NCT00046111|Hycamtin
1485604|NCT00046111|Topotecan
1485605|NCT00046085|Schizophrenia
1485606|NCT00046085|Family
1485607|NCT00046085|Psychoeducation
1485608|NCT00046085|Internet
1485609|NCT00046072|Sepsis
1485610|NCT00046072|Shock
1485611|NCT00046072|Septic
1485612|NCT00046072|Sepsis Syndrome
1485613|NCT00046072|Septicemia
1485614|NCT00046072|Endotoxins
1485615|NCT00046072|Endotoxemia
1485616|NCT00046072|Infection
1485617|NCT00046059|Linkage
1485618|NCT00046059|Gene Identification
1485619|NCT00046059|ADHD
1485620|NCT00046059|Hyperactivity
1485621|NCT00046059|Attention Deficit Hyperactivity Disorder
1485622|NCT00046033|Dose-Relationship, Drug
1485623|NCT00046033|HIV Protease Inhibitors
1485624|NCT00046033|Salvage Therapy
1485625|NCT00046033|Viral Load
1485626|NCT00046033|RNA, Viral
1485627|NCT00046033|Drug Therapy, Combination
1485628|NCT00046020|Depression
1485629|NCT00045994|cardiovascular
1485630|NCT00045994|aged
1485631|NCT00045994|antihypertensive agents/therapeutic use
1485632|NCT00045994|hypertension/*drug therapy
1485633|NCT00045994|blood pressure
1485634|NCT00045981|cardiovascular
1485635|NCT00045981|aged
1485636|NCT00045981|antihypertensive agents/therapeutic use
1485637|NCT00045981|hypertension/*drug therapy
1485638|NCT00045981|blood pressure
1485639|NCT00045968|oncology
1485640|NCT00045968|neurology
1485641|NCT00045968|glioma
1485642|NCT00045968|brain tumor
1485643|NCT00045968|brain cancer
1485644|NCT00045968|glioblastoma multiforme
1485645|NCT00045968|glioblastoma
1485646|NCT00045968|newly diagnosed glioblastoma
1485647|NCT00045968|immunotherapy
1485648|NCT00045968|dendritic cells
1485649|NCT00045968|immune therapy
1485650|NCT00045968|GBM
1485651|NCT00045968|Brain cancer, primary
1485652|NCT00045968|tumor vaccine
1485653|NCT00045968|grade IV astrocytoma
1485654|NCT00045968|DCVax
1485655|NCT00045968|Grade IV brain cancer
1485656|NCT00045942|AML
1485657|NCT00045942|MDS
1485658|NCT00045942|high risk myelodysplastic syndrome
1485659|NCT00045916|Electroconvulsive therapy
1485660|NCT00045916|Antidepressive Agents
1485661|NCT00045903|Cognitive Behavioral Therapy
1485662|NCT00045877|Low-Grade or Follicular Non-Hodgkin's Lymphoma
1485663|NCT00045864|Intermediate and High-Grade Non-Hodgkin's Lymphoma
1485664|NCT00045838|Healthy
1485665|NCT00045838|HIV-Negative
1485666|NCT00045838|Placebo Controlled
1485667|NCT00045838|Volunteer
1485668|NCT00045838|Dose-Escalation
1485669|NCT00045838|Healthy Volunteers
1485670|NCT00045838|HV
1485671|NCT00045838|HIV Seronegativity
1485672|NCT00045838|HIV Preventive Vaccine
1485673|NCT00045812|Cholesterol
1485674|NCT00045812|Sitosterol
1485675|NCT00045812|Atherosclerosis
1485676|NCT00045812|Intestine
1485677|NCT00045812|Absorption
1485678|NCT00045812|Homozygous Sitosterolemia
1485679|NCT00045812|Sterol Metabolism
1485680|NCT00045786|myelodysplastic syndrome
1485681|NCT00045747|adenocarcinoma of the pancreas
1485682|NCT00045747|recurrent pancreatic cancer
1485683|NCT00045747|stage IV pancreatic cancer
1485684|NCT00045721|recurrent childhood cerebral astrocytoma
1485685|NCT00045695|Waldenstrom macroglobulinemia
1485686|NCT00045669|recurrent salivary gland cancer
1485687|NCT00045669|salivary gland adenoid cystic carcinoma
1485688|NCT00045669|stage III salivary gland cancer
1485689|NCT00045669|stage IV salivary gland cancer
1485690|NCT00045630|anterior urethral cancer
1485691|NCT00045630|localized transitional cell cancer of the renal pelvis and ureter
1485692|NCT00045630|posterior urethral cancer
1485693|NCT00045630|stage II bladder cancer
1485694|NCT00045630|stage III bladder cancer
1485695|NCT00045630|transitional cell carcinoma of the bladder
1485696|NCT00045630|urethral cancer associated with invasive bladder cancer
1485697|NCT00045630|regional transitional cell cancer of the renal pelvis and ureter
1485698|NCT00045617|limited stage small cell lung cancer
1485699|NCT00045604|extensive stage small cell lung cancer
1485700|NCT00045591|recurrent breast cancer
1485701|NCT00045591|stage IV breast cancer
1485702|NCT00045539|primary central nervous system non-Hodgkin lymphoma
1485703|NCT00045513|refractory chronic lymphocytic leukemia
1485704|NCT00045513|recurrent small lymphocytic lymphoma
1485705|NCT00045500|anaplastic large cell lymphoma
1485706|NCT00045500|angioimmunoblastic T-cell lymphoma
1485707|NCT00045500|intraocular lymphoma
1485708|NCT00045500|primary central nervous system non-Hodgkin lymphoma
1485709|NCT00045500|recurrent adult Hodgkin lymphoma
1485710|NCT00045500|recurrent adult T-cell leukemia/lymphoma
1485711|NCT00045500|recurrent adult diffuse large cell lymphoma
1485712|NCT00045500|recurrent adult diffuse mixed cell lymphoma
1485713|NCT00045500|recurrent adult diffuse small cleaved cell lymphoma
1485714|NCT00045500|recurrent adult immunoblastic large cell lymphoma
1486085|NCT00045006|male breast cancer
1485715|NCT00045500|recurrent adult lymphoblastic lymphoma
1485716|NCT00045500|recurrent cutaneous T-cell non-Hodgkin lymphoma
1485717|NCT00045500|recurrent grade 1 follicular lymphoma
1485718|NCT00045500|recurrent grade 2 follicular lymphoma
1485719|NCT00045500|recurrent mantle cell lymphoma
1485720|NCT00045500|unspecified adult solid tumor, protocol specific
1485721|NCT00045500|recurrent adult Burkitt lymphoma
1485722|NCT00045500|recurrent grade 3 follicular lymphoma
1485723|NCT00045500|recurrent marginal zone lymphoma
1485724|NCT00045500|recurrent small lymphocytic lymphoma
1485725|NCT00045500|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1485726|NCT00045500|nodal marginal zone B-cell lymphoma
1485727|NCT00045500|splenic marginal zone lymphoma
1485728|NCT00045487|recurrent renal cell cancer
1485729|NCT00045487|stage III renal cell cancer
1485730|NCT00045487|stage IV renal cell cancer
1485731|NCT00045474|adult anaplastic astrocytoma
1485732|NCT00045474|adult anaplastic oligodendroglioma
1485733|NCT00045474|adult glioblastoma
1485734|NCT00045474|recurrent adult brain tumor
1485735|NCT00045474|adult giant cell glioblastoma
1485736|NCT00045474|adult gliosarcoma
1485737|NCT00045461|recurrent ovarian epithelial cancer
1485738|NCT00045461|recurrent fallopian tube cancer
1485739|NCT00045461|stage IIIA fallopian tube cancer
1485740|NCT00045461|stage IIIB fallopian tube cancer
1485741|NCT00045461|stage IIIC fallopian tube cancer
1485742|NCT00045461|stage IV fallopian tube cancer
1485743|NCT00045461|recurrent primary peritoneal cavity cancer
1485744|NCT00045461|stage IIIA primary peritoneal cavity cancer
1485745|NCT00045461|stage IIIB primary peritoneal cavity cancer
1485746|NCT00045461|stage IIIC primary peritoneal cavity cancer
1485747|NCT00045461|stage IV primary peritoneal cavity cancer
1485748|NCT00045461|stage IIIA ovarian epithelial cancer
1485749|NCT00045461|stage IIIB ovarian epithelial cancer
1485750|NCT00045461|stage IIIC ovarian epithelial cancer
1485751|NCT00045461|stage IV ovarian epithelial cancer
1485752|NCT00045448|unspecified adult solid tumor, protocol specific
1485753|NCT00045422|chronic myelogenous leukemia, BCR-ABL1 positive
1485754|NCT00045422|chronic phase chronic myelogenous leukemia
1485755|NCT00045422|childhood chronic myelogenous leukemia
1485756|NCT00045370|recurrent renal cell cancer
1485757|NCT00045370|stage III renal cell cancer
1485758|NCT00045370|stage IV renal cell cancer
1485759|NCT00045357|recurrent melanoma
1485760|NCT00045357|stage IV melanoma
1485761|NCT00045331|recurrent prostate cancer
1485762|NCT00045331|stage I prostate cancer
1485763|NCT00045331|stage IIB prostate cancer
1485764|NCT00045331|stage IIA prostate cancer
1485765|NCT00045331|stage III prostate cancer
1485766|NCT00045331|stage IV prostate cancer
1485767|NCT00045318|unspecified adult solid tumor, protocol specific
1485768|NCT00045305|chronic myelomonocytic leukemia
1485769|NCT00045305|de novo myelodysplastic syndromes
1485770|NCT00045305|previously treated myelodysplastic syndromes
1485771|NCT00045305|refractory anemia
1485772|NCT00045305|refractory anemia with excess blasts
1485773|NCT00045305|refractory anemia with ringed sideroblasts
1485774|NCT00045305|secondary myelodysplastic syndromes
1485775|NCT00045305|atypical chronic myeloid leukemia, BCR-ABL1 negative
1485776|NCT00045305|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1485777|NCT00045292|infection
1485778|NCT00045292|accelerated phase chronic myelogenous leukemia
1485779|NCT00045292|blastic phase chronic myelogenous leukemia
1485780|NCT00045292|childhood chronic myelogenous leukemia
1485781|NCT00045292|chronic phase chronic myelogenous leukemia
1485782|NCT00045292|relapsing chronic myelogenous leukemia
1485783|NCT00045292|adult acute lymphoblastic leukemia in remission
1485784|NCT00045292|childhood acute lymphoblastic leukemia in remission
1485785|NCT00045292|recurrent adult acute lymphoblastic leukemia
1485786|NCT00045292|recurrent childhood acute lymphoblastic leukemia
1485787|NCT00045292|untreated adult acute lymphoblastic leukemia
1485788|NCT00045292|untreated childhood acute lymphoblastic leukemia
1485789|NCT00045292|adult acute myeloid leukemia in remission
1485790|NCT00045292|childhood acute myeloid leukemia in remission
1485791|NCT00045292|recurrent adult acute myeloid leukemia
1485792|NCT00045292|recurrent childhood acute myeloid leukemia
1485793|NCT00045292|secondary acute myeloid leukemia
1485794|NCT00045292|untreated adult acute myeloid leukemia
1485795|NCT00045292|untreated childhood acute myeloid leukemia and other myeloid malignancies
1485796|NCT00045292|atypical chronic myeloid leukemia
1485797|NCT00045292|chronic eosinophilic leukemia
1485798|NCT00045292|chronic idiopathic myelofibrosis
1485799|NCT00045292|chronic neutrophilic leukemia
1485800|NCT00045292|chronic myelomonocytic leukemia
1485801|NCT00045292|juvenile myelomonocytic leukemia
1485802|NCT00045292|de novo myelodysplastic syndromes
1485803|NCT00045292|myelodysplastic/myeloproliferative disease, unclassifiable
1485804|NCT00045292|previously treated myelodysplastic syndromes
1485805|NCT00045292|secondary myelodysplastic syndromes
1485806|NCT00045292|disseminated neuroblastoma
1485807|NCT00045292|recurrent neuroblastoma
1485808|NCT00045292|noncontiguous stage II adult diffuse large cell lymphoma
1485809|NCT00045292|recurrent adult diffuse large cell lymphoma
1486086|NCT00044993|male breast cancer
1485810|NCT00045292|stage III adult diffuse large cell lymphoma
1485811|NCT00045292|stage IV adult diffuse large cell lymphoma
1485812|NCT00045292|noncontiguous stage II adult Burkitt lymphoma
1485813|NCT00045292|recurrent adult Burkitt lymphoma
1485814|NCT00045292|stage III adult Burkitt lymphoma
1485815|NCT00045292|stage IV adult Burkitt lymphoma
1485816|NCT00045292|noncontiguous stage II adult diffuse mixed cell lymphoma
1485817|NCT00045292|recurrent adult diffuse mixed cell lymphoma
1485818|NCT00045292|stage III adult diffuse mixed cell lymphoma
1485819|NCT00045292|stage IV adult diffuse mixed cell lymphoma
1485820|NCT00045292|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1485821|NCT00045292|recurrent adult diffuse small cleaved cell lymphoma
1485822|NCT00045292|stage III adult diffuse small cleaved cell lymphoma
1485823|NCT00045292|stage IV adult diffuse small cleaved cell lymphoma
1485824|NCT00045292|noncontiguous stage II adult immunoblastic large cell lymphoma
1485825|NCT00045292|recurrent adult immunoblastic large cell lymphoma
1485826|NCT00045292|stage III adult immunoblastic large cell lymphoma
1485827|NCT00045292|stage IV adult immunoblastic large cell lymphoma
1485828|NCT00045292|noncontiguous stage II adult lymphoblastic lymphoma
1485829|NCT00045292|recurrent adult lymphoblastic lymphoma
1485830|NCT00045292|recurrent childhood lymphoblastic lymphoma
1485831|NCT00045292|stage III adult lymphoblastic lymphoma
1485832|NCT00045292|stage IV adult lymphoblastic lymphoma
1485833|NCT00045292|noncontiguous stage II grade 1 follicular lymphoma
1485834|NCT00045292|noncontiguous stage II grade 2 follicular lymphoma
1485835|NCT00045292|noncontiguous stage II grade 3 follicular lymphoma
1485836|NCT00045292|recurrent grade 1 follicular lymphoma
1485837|NCT00045292|recurrent grade 2 follicular lymphoma
1485838|NCT00045292|recurrent grade 3 follicular lymphoma
1485839|NCT00045292|stage III grade 1 follicular lymphoma
1485840|NCT00045292|stage III grade 2 follicular lymphoma
1485841|NCT00045292|stage III grade 3 follicular lymphoma
1485842|NCT00045292|stage IV grade 1 follicular lymphoma
1485843|NCT00045292|stage IV grade 2 follicular lymphoma
1485844|NCT00045292|stage IV grade 3 follicular lymphoma
1485845|NCT00045292|noncontiguous stage II mantle cell lymphoma
1485846|NCT00045292|recurrent mantle cell lymphoma
1485847|NCT00045292|stage III mantle cell lymphoma
1485848|NCT00045292|stage IV mantle cell lymphoma
1486130|NCT00044928|Abdominal Infections
1485849|NCT00045292|poor prognosis metastatic gestational trophoblastic tumor
1485850|NCT00045292|previously treated childhood rhabdomyosarcoma
1485851|NCT00045292|recurrent Wilms tumor and other childhood kidney tumors
1485852|NCT00045292|recurrent adult Hodgkin lymphoma
1485853|NCT00045292|recurrent/refractory childhood Hodgkin lymphoma
1485854|NCT00045292|recurrent childhood rhabdomyosarcoma
1485855|NCT00045292|recurrent childhood large cell lymphoma
1485856|NCT00045292|recurrent childhood small noncleaved cell lymphoma
1485857|NCT00045292|recurrent cutaneous T-cell non-Hodgkin lymphoma
1485858|NCT00045292|recurrent mycosis fungoides/Sezary syndrome
1485859|NCT00045292|recurrent ovarian epithelial cancer
1485860|NCT00045292|recurrent ovarian germ cell tumor
1485861|NCT00045292|stage II ovarian epithelial cancer
1485862|NCT00045292|stage III ovarian epithelial cancer
1485863|NCT00045292|stage IV ovarian epithelial cancer
1485864|NCT00045292|recurrent malignant testicular germ cell tumor
1485865|NCT00045292|stage III malignant testicular germ cell tumor
1485866|NCT00045292|refractory chronic lymphocytic leukemia
1485867|NCT00045292|stage III chronic lymphocytic leukemia
1485868|NCT00045292|stage IV chronic lymphocytic leukemia
1485869|NCT00045292|refractory hairy cell leukemia
1485870|NCT00045292|refractory multiple myeloma
1485871|NCT00045292|stage I multiple myeloma
1485872|NCT00045292|stage II multiple myeloma
1485873|NCT00045292|stage III multiple myeloma
1485874|NCT00045292|stage IIIA breast cancer
1485875|NCT00045292|stage IIIB breast cancer
1485876|NCT00045292|stage IIIC breast cancer
1485877|NCT00045292|stage IV breast cancer
1485878|NCT00045292|noncontiguous stage II small lymphocytic lymphoma
1485879|NCT00045292|noncontiguous stage II marginal zone lymphoma
1485880|NCT00045292|recurrent marginal zone lymphoma
1485881|NCT00045292|recurrent small lymphocytic lymphoma
1485882|NCT00045292|stage III small lymphocytic lymphoma
1485883|NCT00045292|stage III marginal zone lymphoma
1485884|NCT00045292|stage IV small lymphocytic lymphoma
1485885|NCT00045292|stage IV marginal zone lymphoma
1485886|NCT00045292|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1485887|NCT00045292|nodal marginal zone B-cell lymphoma
1485888|NCT00045292|splenic marginal zone lymphoma
1485889|NCT00045292|childhood myelodysplastic syndromes
1485890|NCT00045279|stage IV renal cell cancer
1485891|NCT00045266|recurrent adult diffuse large cell lymphoma
1485892|NCT00045266|recurrent adult diffuse mixed cell lymphoma
1485893|NCT00045266|recurrent adult diffuse small cleaved cell lymphoma
1485894|NCT00045266|recurrent adult Burkitt lymphoma
1485895|NCT00045266|recurrent adult immunoblastic large cell lymphoma
1485896|NCT00045266|recurrent adult lymphoblastic lymphoma
1485897|NCT00045266|recurrent grade 1 follicular lymphoma
1485898|NCT00045266|recurrent grade 2 follicular lymphoma
1485899|NCT00045266|recurrent grade 3 follicular lymphoma
1485900|NCT00045266|recurrent mantle cell lymphoma
1485901|NCT00045266|stage IV adult diffuse large cell lymphoma
1485902|NCT00045266|stage IV adult diffuse mixed cell lymphoma
1485903|NCT00045266|stage IV adult diffuse small cleaved cell lymphoma
1485904|NCT00045266|stage IV adult Burkitt lymphoma
1485905|NCT00045266|stage IV adult immunoblastic large cell lymphoma
1485906|NCT00045266|stage IV adult lymphoblastic lymphoma
1485907|NCT00045266|stage IV grade 1 follicular lymphoma
1485908|NCT00045266|stage IV grade 2 follicular lymphoma
1485909|NCT00045266|stage IV grade 3 follicular lymphoma
1485910|NCT00045266|stage IV mantle cell lymphoma
1485911|NCT00045266|unspecified adult solid tumor, protocol specific
1485912|NCT00045266|recurrent marginal zone lymphoma
1485913|NCT00045266|recurrent small lymphocytic lymphoma
1485914|NCT00045266|stage IV small lymphocytic lymphoma
1485915|NCT00045266|stage IV marginal zone lymphoma
1485916|NCT00045266|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1485917|NCT00045266|nodal marginal zone B-cell lymphoma
1485918|NCT00045266|splenic marginal zone lymphoma
1485919|NCT00045227|adenocarcinoma of the prostate
1485920|NCT00045227|recurrent prostate cancer
1485921|NCT00045227|stage IV prostate cancer
1485922|NCT00045175|primary peritoneal cavity cancer
1485923|NCT00045175|recurrent ovarian epithelial cancer
1485924|NCT00045175|fallopian tube cancer
1485925|NCT00045162|extensive stage small cell lung cancer
1485926|NCT00045149|recurrent melanoma
1485927|NCT00045149|stage IV melanoma
1485928|NCT00045136|refractory multiple myeloma
1485929|NCT00045136|stage I multiple myeloma
1485930|NCT00045136|stage II multiple myeloma
1485931|NCT00045136|stage III multiple myeloma
1485932|NCT00045123|adenocarcinoma of the prostate
1485933|NCT00045123|recurrent prostate cancer
1485934|NCT00045097|male breast cancer
1485935|NCT00045097|recurrent breast cancer
1485936|NCT00045097|stage IIIB breast cancer
1485937|NCT00045097|stage IIIC breast cancer
1485938|NCT00045097|stage IV breast cancer
1485939|NCT00045045|stage I malignant testicular germ cell tumor
1485940|NCT00045045|testicular choriocarcinoma
1485941|NCT00045045|testicular choriocarcinoma and embryonal carcinoma
1485942|NCT00045045|testicular choriocarcinoma and seminoma
1485943|NCT00045045|testicular choriocarcinoma and teratoma
1485944|NCT00045045|testicular choriocarcinoma and yolk sac tumor
1486375|NCT00044239|Basal Ganglia
1485945|NCT00045045|testicular embryonal carcinoma and seminoma
1485946|NCT00045045|testicular embryonal carcinoma and teratoma with seminoma
1485947|NCT00045045|testicular embryonal carcinoma and teratoma
1485948|NCT00045045|testicular embryonal carcinoma and yolk sac tumor with seminoma
1485949|NCT00045045|testicular embryonal carcinoma and yolk sac tumor
1485950|NCT00045045|testicular embryonal carcinoma
1485951|NCT00045045|testicular teratoma
1485952|NCT00045045|testicular yolk sac tumor and teratoma with seminoma
1485953|NCT00045045|testicular yolk sac tumor and teratoma
1485954|NCT00045045|testicular yolk sac tumor
1485955|NCT00045019|unspecified adult solid tumor, protocol specific
1485956|NCT00045006|acute undifferentiated leukemia
1485957|NCT00045006|de novo myelodysplastic syndromes
1485958|NCT00045006|borderline ovarian surface epithelial-stromal tumor
1485959|NCT00045006|ovarian sarcoma
1485960|NCT00045006|ovarian stromal cancer
1485961|NCT00045006|previously treated myelodysplastic syndromes
1485962|NCT00045006|prolymphocytic leukemia
1485963|NCT00045006|recurrent adult Hodgkin lymphoma
1485964|NCT00045006|recurrent adult T-cell leukemia/lymphoma
1485965|NCT00045006|recurrent adult acute lymphoblastic leukemia
1485966|NCT00045006|recurrent adult acute myeloid leukemia
1485967|NCT00045006|recurrent adult diffuse large cell lymphoma
1485968|NCT00045006|recurrent adult diffuse small cleaved cell lymphoma
1485969|NCT00045006|recurrent adult diffuse mixed cell lymphoma
1485970|NCT00045006|recurrent bladder cancer
1485971|NCT00045006|recurrent breast cancer
1485972|NCT00045006|recurrent cutaneous T-cell non-Hodgkin lymphoma
1485973|NCT00045006|recurrent grade 1 follicular lymphoma
1485974|NCT00045006|recurrent grade 2 follicular lymphoma
1485975|NCT00045006|recurrent grade 3 follicular lymphoma
1485976|NCT00045006|recurrent metastatic squamous neck cancer with occult primary
1485977|NCT00045006|recurrent mycosis fungoides/Sezary syndrome
1485978|NCT00045006|recurrent non-small cell lung cancer
1485979|NCT00045006|recurrent ovarian epithelial cancer
1485980|NCT00045006|recurrent ovarian germ cell tumor
1485981|NCT00045006|recurrent prostate cancer
1485982|NCT00045006|recurrent renal cell cancer
1485983|NCT00045006|refractory chronic lymphocytic leukemia
1485984|NCT00045006|refractory hairy cell leukemia
1485985|NCT00045006|refractory multiple myeloma
1485986|NCT00045006|relapsing chronic myelogenous leukemia
1485987|NCT00045006|secondary acute myeloid leukemia
1485988|NCT00045006|secondary myelodysplastic syndromes
1485989|NCT00045006|stage III multiple myeloma
1485990|NCT00045006|stage III mycosis fungoides/Sezary syndrome
1485991|NCT00045006|stage III ovarian germ cell tumor
1485992|NCT00045006|stage IV mycosis fungoides/Sezary syndrome
1485993|NCT00045006|stage IV ovarian germ cell tumor
1485994|NCT00045006|unspecified adult solid tumor, protocol specific
1485995|NCT00045006|stage III adult Hodgkin lymphoma
1485996|NCT00045006|stage IV adult Hodgkin lymphoma
1485997|NCT00045006|stage III adult T-cell leukemia/lymphoma
1485998|NCT00045006|stage IV adult T-cell leukemia/lymphoma
1485999|NCT00045006|stage III adult diffuse large cell lymphoma
1486000|NCT00045006|stage III adult diffuse mixed cell lymphoma
1486001|NCT00045006|stage III adult diffuse small cleaved cell lymphoma
1486002|NCT00045006|stage IV adult diffuse large cell lymphoma
1486003|NCT00045006|stage IV adult diffuse mixed cell lymphoma
1486004|NCT00045006|stage IV adult diffuse small cleaved cell lymphoma
1486005|NCT00045006|stage III bladder cancer
1486006|NCT00045006|stage IV bladder cancer
1486007|NCT00045006|stage IIIA breast cancer
1486008|NCT00045006|stage IIIB breast cancer
1486009|NCT00045006|stage IIIC breast cancer
1486010|NCT00045006|stage IV breast cancer
1486011|NCT00045006|stage III cutaneous T-cell non-Hodgkin lymphoma
1486012|NCT00045006|stage IV cutaneous T-cell non-Hodgkin lymphoma
1486013|NCT00045006|stage III grade 1 follicular lymphoma
1486014|NCT00045006|stage III grade 2 follicular lymphoma
1486015|NCT00045006|stage III grade 3 follicular lymphoma
1486016|NCT00045006|stage IV grade 1 follicular lymphoma
1486017|NCT00045006|stage IV grade 2 follicular lymphoma
1486018|NCT00045006|stage IV grade 3 follicular lymphoma
1486019|NCT00045006|stage IIIA non-small cell lung cancer
1486020|NCT00045006|stage IIIB non-small cell lung cancer
1486021|NCT00045006|stage IV non-small cell lung cancer
1486022|NCT00045006|stage III oropharyngeal cancer
1486023|NCT00045006|stage IV oropharyngeal cancer
1486024|NCT00045006|stage III ovarian epithelial cancer
1486025|NCT00045006|stage IV ovarian epithelial cancer
1486026|NCT00045006|stage III prostate cancer
1486027|NCT00045006|stage IV prostate cancer
1486028|NCT00045006|stage III renal cell cancer
1486029|NCT00045006|stage IV renal cell cancer
1486030|NCT00045006|stage III chronic lymphocytic leukemia
1486031|NCT00045006|stage IV chronic lymphocytic leukemia
1486032|NCT00045006|recurrent salivary gland cancer
1486033|NCT00045006|stage IV salivary gland cancer
1486034|NCT00045006|stage III salivary gland cancer
1486035|NCT00045006|recurrent squamous cell carcinoma of the hypopharynx
1486036|NCT00045006|stage III squamous cell carcinoma of the hypopharynx
1486037|NCT00045006|stage IV squamous cell carcinoma of the hypopharynx
1486038|NCT00045006|recurrent squamous cell carcinoma of the larynx
1486039|NCT00045006|recurrent verrucous carcinoma of the larynx
1486513|NCT00043862|topotecan
1486040|NCT00045006|stage III squamous cell carcinoma of the larynx
1486041|NCT00045006|stage III verrucous carcinoma of the larynx
1486042|NCT00045006|stage IV squamous cell carcinoma of the larynx
1486043|NCT00045006|stage IV verrucous carcinoma of the larynx
1486044|NCT00045006|recurrent squamous cell carcinoma of the lip and oral cavity
1486045|NCT00045006|stage III squamous cell carcinoma of the lip and oral cavity
1486046|NCT00045006|stage IV squamous cell carcinoma of the lip and oral cavity
1486047|NCT00045006|recurrent lymphoepithelioma of the nasopharynx
1486048|NCT00045006|recurrent squamous cell carcinoma of the nasopharynx
1486049|NCT00045006|stage III lymphoepithelioma of the nasopharynx
1486050|NCT00045006|stage III squamous cell carcinoma of the nasopharynx
1486051|NCT00045006|stage IV lymphoepithelioma of the nasopharynx
1486052|NCT00045006|stage IV squamous cell carcinoma of the nasopharynx
1486053|NCT00045006|recurrent lymphoepithelioma of the oropharynx
1486054|NCT00045006|recurrent squamous cell carcinoma of the oropharynx
1486055|NCT00045006|stage III lymphoepithelioma of the oropharynx
1486056|NCT00045006|stage III squamous cell carcinoma of the oropharynx
1486057|NCT00045006|stage IV lymphoepithelioma of the oropharynx
1486058|NCT00045006|stage IV squamous cell carcinoma of the oropharynx
1486059|NCT00045006|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1486060|NCT00045006|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1486061|NCT00045006|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1486062|NCT00045006|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1486063|NCT00045006|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1486064|NCT00045006|stage III inverted papilloma of the paranasal sinus and nasal cavity
1486065|NCT00045006|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1486066|NCT00045006|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1486067|NCT00045006|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1486068|NCT00045006|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1486069|NCT00045006|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1486070|NCT00045006|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1486071|NCT00045006|recurrent basal cell carcinoma of the lip
1486072|NCT00045006|stage III basal cell carcinoma of the lip
1486073|NCT00045006|stage IV basal cell carcinoma of the lip
1486074|NCT00045006|recurrent mucoepidermoid carcinoma of the oral cavity
1486075|NCT00045006|stage III mucoepidermoid carcinoma of the oral cavity
1486076|NCT00045006|stage IV mucoepidermoid carcinoma of the oral cavity
1486077|NCT00045006|recurrent adenoid cystic carcinoma of the oral cavity
1486078|NCT00045006|stage III adenoid cystic carcinoma of the oral cavity
1486079|NCT00045006|stage IV adenoid cystic carcinoma of the oral cavity
1486080|NCT00045006|recurrent verrucous carcinoma of the oral cavity
1486081|NCT00045006|stage III verrucous carcinoma of the oral cavity
1486082|NCT00045006|stage IV verrucous carcinoma of the oral cavity
1486083|NCT00045006|atypical chronic myeloid leukemia, BCR-ABL1 negative
1486084|NCT00045006|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1486087|NCT00044993|stage IIIA breast cancer
1486088|NCT00044993|stage IIIB breast cancer
1486089|NCT00044993|stage IIIC breast cancer
1486090|NCT00044993|stage IV breast cancer
1486091|NCT00044980|malnutrition
1486092|NCT00044980|stage I prostate cancer
1486093|NCT00044980|stage II B prostate cancer
1486094|NCT00044980|stage II A prostate cancer
1486095|NCT00044967|stage I colon cancer
1486096|NCT00044967|stage II colon cancer
1486097|NCT00044967|stage III colon cancer
1486098|NCT00044967|stage I rectal cancer
1486099|NCT00044967|stage II rectal cancer
1486100|NCT00044967|stage III rectal cancer
1486101|NCT00044967|adenocarcinoma of the colon
1486102|NCT00044967|adenocarcinoma of the rectum
1486103|NCT00044954|recurrent adult Hodgkin lymphoma
1486104|NCT00044954|stage I multiple myeloma
1486105|NCT00044954|stage II multiple myeloma
1486106|NCT00044954|stage III multiple myeloma
1486107|NCT00044954|chronic phase chronic myelogenous leukemia
1486108|NCT00044954|accelerated phase chronic myelogenous leukemia
1486109|NCT00044954|adult acute myeloid leukemia in remission
1486110|NCT00044954|recurrent grade 3 follicular lymphoma
1486111|NCT00044954|recurrent adult diffuse large cell lymphoma
1486112|NCT00044954|de novo myelodysplastic syndromes
1486113|NCT00044954|previously treated myelodysplastic syndromes
1486114|NCT00044954|secondary myelodysplastic syndromes
1486115|NCT00044954|recurrent mantle cell lymphoma
1486116|NCT00044954|stage III mantle cell lymphoma
1486117|NCT00044954|stage IV mantle cell lymphoma
1486118|NCT00044954|refractory multiple myeloma
1486119|NCT00044954|stage I mantle cell lymphoma
1486120|NCT00044954|contiguous stage II mantle cell lymphoma
1486121|NCT00044954|noncontiguous stage II mantle cell lymphoma
1486122|NCT00044954|atypical chronic myeloid leukemia
1486123|NCT00044954|myelodysplastic/myeloproliferative disease, unclassifiable
1486124|NCT00044954|refractory chronic lymphocytic leukemia
1486125|NCT00044954|adult acute myeloid leukemia with t(8;21)(q22;q22)
1486126|NCT00044954|adult acute myeloid leukemia with t(16;16)(p13;q22)
1486127|NCT00044954|adult acute myeloid leukemia with inv(16)(p13;q22)
1486128|NCT00044954|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1486129|NCT00044954|adult acute myeloid leukemia with t(15;17)(q22;q12)
1486131|NCT00044915|Acute Ischemic Stroke Without Hemorrhage
1486132|NCT00043303|hepatitis C
1486133|NCT00043303|liver fibrosis
1486134|NCT00043303|liver cirrhosis
1486135|NCT00043277|neonates
1486136|NCT00043277|thrombosis
1486137|NCT00043277|bivalirudin
1486138|NCT00043277|direct thrombin inhibitor
1486139|NCT00043238|PCBs
1486140|NCT00043238|Thyroid
1486141|NCT00043238|Hyperactivity
1486142|NCT00043238|School Performance
1486143|NCT00043238|Mohawk Tribe
1486144|NCT00043225|Type III Secretion Pathways
1486145|NCT00043225|Exotoxin A Polymorphisms
1486146|NCT00043225|Cystic Fibrosis and Pseudomonas Aeruginosa
1486147|NCT00043225|Adenosine Deaminase Deficiency
1486148|NCT00043225|Severe Combined Immune Deficiency
1486149|NCT00043225|SCID
1486150|NCT00043225|ADA-SCID
1486151|NCT00043225|Immune Deficiency
1486152|NCT00043212|prostate cancer
1486153|NCT00043212|oncology
1486154|NCT00043212|urology
1486155|NCT00043212|hormone refractory prostate cancer
1486156|NCT00043199|Colorectal Neoplasms
1486157|NCT00043199|Colorectal Cancer
1486158|NCT00043199|Colorectal Carcinoma
1486159|NCT00043199|Colorectal Tumor
1486160|NCT00043199|Neoplasms, Colorectal
1486161|NCT00043199|Unresectable
1486162|NCT00043199|Metastatic
1486163|NCT00043199|Refractory
1486164|NCT00043186|bone loss
1486165|NCT00043186|osteoporosis
1486166|NCT00043147|graft versus host disease
1486167|NCT00043134|chronic myelomonocytic leukemia
1486168|NCT00043134|de novo myelodysplastic syndromes
1486169|NCT00043134|previously treated myelodysplastic syndromes
1486170|NCT00043134|refractory anemia
1486171|NCT00043134|refractory anemia with excess blasts
1486172|NCT00043134|refractory anemia with excess blasts in transformation
1486173|NCT00043134|refractory anemia with ringed sideroblasts
1486174|NCT00043134|refractory cytopenia with multilineage dysplasia
1486175|NCT00043134|secondary myelodysplastic syndromes
1486176|NCT00043134|atypical chronic myeloid leukemia, BCR-ABL negative
1486177|NCT00043134|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1486178|NCT00043108|stage II non-small cell lung cancer
1486179|NCT00043108|stage IIIA non-small cell lung cancer
1486180|NCT00043108|stage IIIB non-small cell lung cancer
1486181|NCT00043095|unspecified adult solid tumor, protocol specific
1486182|NCT00043082|peritoneal cavity cancer
1486183|NCT00043082|recurrent ovarian epithelial cancer
1486184|NCT00043082|stage III ovarian epithelial cancer
1486185|NCT00043082|stage IV ovarian epithelial cancer
1486186|NCT00043069|osteoporosis
1486187|NCT00043069|stage I prostate cancer
1486188|NCT00043069|stage IIB prostate cancer
1486189|NCT00043069|stage IIA prostate cancer
1486190|NCT00043069|stage III prostate cancer
1486191|NCT00043043|colorectal cancer
1486192|NCT00043030|psychosocial effects of cancer and its treatment
1486193|NCT00043030|unspecified adult solid tumor, protocol specific
1486194|NCT00044889|CLO221
1486195|NCT00044889|clolar
1486196|NCT00044876|Endometrium
1486197|NCT00044876|Progesterone
1486198|NCT00044876|Estrogen
1486199|NCT00044876|Leiomyoma
1486200|NCT00044876|Uterine Leiomyoma
1486201|NCT00044876|Uterine Fibroids
1486202|NCT00044876|Fibroids
1486203|NCT00044863|EGFr
1486204|NCT00044863|Metastatic Colorectal Carcinoma
1486205|NCT00044837|Lopinavir
1486206|NCT00044837|HIV-1
1486207|NCT00044837|HIV Protease Inhibitors
1486208|NCT00044837|Ritonavir
1486209|NCT00044837|Postmenopause
1486210|NCT00044837|Reverse Transcriptase Inhibitors
1486211|NCT00044837|Pharmacokinetics
1486212|NCT00044837|Area Under Curve
1486213|NCT00044837|Hormone Replacement Therapy
1486214|NCT00044837|efavirenz
1486215|NCT00044837|estradiol
1486216|NCT00044798|Aged
1486217|NCT00044785|colorectal cancer
1486218|NCT00044785|gastric cancer
1486219|NCT00044785|breast cancer
1486220|NCT00044772|Panic
1486221|NCT00044772|Disorder
1486222|NCT00044759|Hematologic
1486223|NCT00044759|Neoplasms
1486224|NCT00044746|Diabetes
1486225|NCT00044733|Leukemia
1486226|NCT00044733|Stem Cell Transplant
1486227|NCT00044720|Kidney Transplant
1486228|NCT00044707|Diabetes Mellitus, Type 2
1486229|NCT00044694|Diabetes Mellitus, Type 2
1486230|NCT00044681|Risperidone
1486231|NCT00044681|depression
1486232|NCT00044681|melancholia
1486233|NCT00044681|depressive disorder
1486234|NCT00044681|antipsychotic agents
1486235|NCT00044668|exenatide
1486236|NCT00044668|exendin-4
1486237|NCT00044668|diabetes
1486238|NCT00044668|Amylin
1486239|NCT00044668|Lilly
1486240|NCT00044642|Anxiety
1486241|NCT00044629|Sleep Deprivation
1486242|NCT00044629|Insomnia
1486243|NCT00044629|Sleep Disorders
1486244|NCT00044603|Pregnancy
1486245|NCT00044590|Parkinson's disease
1486246|NCT00044590|Pesticides
1486247|NCT00044590|Genetic susceptibility
1486248|NCT00044590|Polymorphisms
1486514|NCT00043849|Psychosis
1486249|NCT00044577|HIV-1 Abacavir Lamivudine Tenofovir
1486250|NCT00044564|Taxane
1486251|NCT00044564|Renal Cell Carcinoma
1486252|NCT00044564|Advanced Renal Cell Carcinoma
1486253|NCT00044551|Taxane
1486254|NCT00044551|Lymphoma
1486255|NCT00044551|Non-Hodgkin's Lymphoma
1486256|NCT00044538|Taxane
1486257|NCT00044538|Lung cancer, non-small cell
1486258|NCT00044538|NSCLC
1486259|NCT00044525|Taxane
1486260|NCT00044525|Breast Cancer
1486261|NCT00044525|Metastasis
1486262|NCT00044512|Cancer
1486263|NCT00044512|Liver Cancer
1486264|NCT00044512|Hepatocellular carcinoma (HCC)
1486265|NCT00044486|Prophylaxis
1486266|NCT00044486|neutropenia
1486267|NCT00044486|AML
1486268|NCT00044486|MDS
1486269|NCT00044486|fungal infections
1486270|NCT00044486|Acute Myelogenous Leukemia
1486271|NCT00044486|Anticipated prolonged profound neutropenia
1486272|NCT00044473|Otitis Media
1486273|NCT00044473|Ear Diaeases
1486274|NCT00044473|Levofloxacin
1486275|NCT00044473|Quinolones
1486276|NCT00044460|Type 2 diabetes drug-naive
1486277|NCT00044382|Revimid
1486278|NCT00044382|CC5013
1486279|NCT00044382|CC-5013
1486280|NCT00044369|Varicocele
1486281|NCT00044369|environmental toxins
1486282|NCT00044369|male infertility
1486283|NCT00044369|cadmium
1486284|NCT00044356|Melanoma
1486285|NCT00044356|Metastatic Melanoma
1486286|NCT00044356|Malignant Melanoma
1486287|NCT00044356|Skin Cancer
1486288|NCT00044356|Tumor
1486289|NCT00044356|Experimental Treatment
1486290|NCT00044356|Clinical Trial
1486291|NCT00044356|Gene Therapy
1486292|NCT00044356|Gene Delivery
1486293|NCT00044356|Gene Transfer
1486294|NCT00044356|Immunotherapy
1486295|NCT00044356|Cancer
1486296|NCT00044356|Neoplasm
1486297|NCT00044356|Lesion
1486298|NCT00044356|Metastasis
1486299|NCT00044356|Cancerous mole
1486300|NCT00044356|Melanoma vaccine
1486301|NCT00044356|Cancer research
1486302|NCT00044356|Cancer cells
1486303|NCT00044356|Allovectin-7®
1486304|NCT00044343|colorectal cancer
1486305|NCT00044343|EGFR inhibitor
1486306|NCT00044343|lapatinib
1486307|NCT00044343|metastatic
1486308|NCT00043017|stage IIIA breast cancer
1486309|NCT00043017|stage IIIB breast cancer
1486310|NCT00043017|stage IIIC breast cancer
1486311|NCT00043004|liver metastases
1486312|NCT00043004|stage IV colon cancer
1486313|NCT00043004|stage IV rectal cancer
1486314|NCT00042965|recurrent renal cell cancer
1486315|NCT00042965|stage IV renal cell cancer
1486316|NCT00042939|pancreatic cancer
1486317|NCT00042939|metastatic pancreatic cancer
1486318|NCT00042939|EGF-r
1486319|NCT00042939|irinotecan
1486320|NCT00042939|docetaxel
1486321|NCT00042939|cetuximab
1486322|NCT00042926|stage I squamous cell carcinoma of the lip and oral cavity
1486323|NCT00042926|stage II squamous cell carcinoma of the lip and oral cavity
1486324|NCT00042913|recurrent adult diffuse large cell lymphoma
1486325|NCT00044317|FEV
1486326|NCT00044317|Smoking
1486327|NCT00044317|antioxidents
1486328|NCT00044317|lung growth
1486329|NCT00044304|Treatment
1486330|NCT00044304|Eosinophil
1486331|NCT00044304|Tyrosine Kinase Inhibitor
1486332|NCT00044304|Hypereosinophilia
1486333|NCT00044304|Biologicals
1486334|NCT00044304|Chemotherapy
1486335|NCT00044304|Gleevec
1486336|NCT00044304|Eosinophils
1486337|NCT00044304|Hypereosinophilic Syndrome
1486338|NCT00044304|HES
1486339|NCT00044291|Atamestane
1486340|NCT00044291|Toremifene
1486341|NCT00044291|Letrozole
1486342|NCT00044291|Aromatase inhibitor
1486343|NCT00044291|Receptor-positive
1486344|NCT00044291|First line therapy
1486345|NCT00044291|Estrogen blocker
1486346|NCT00044291|Metastatic breast cancer
1486347|NCT00044291|Locally advanced breast cancer
1486348|NCT00044291|Locally recurrent breast cancer
1486349|NCT00044291|stage IV breast cancer
1486350|NCT00044291|ductal breast carcinoma
1486351|NCT00044291|lobular breast carcinoma
1486352|NCT00044291|stage IIIA breast cancer
1486353|NCT00044291|stage IIIB breast cancer
1486354|NCT00044291|recurrent breast cancer
1486355|NCT00044278|epilepsy
1486356|NCT00044278|pediatric
1486357|NCT00044278|partial seizures
1486358|NCT00044265|ACE inhibitor
1486359|NCT00044265|high blood pressure
1486360|NCT00044265|pediatric
1486361|NCT00044252|Neurosteroids
1486362|NCT00044252|Complex Partial Seizure
1486363|NCT00044252|Menstrual Cycle
1486364|NCT00044252|Allopregnanolone
1486365|NCT00044252|Catamenial Epilepsy
1486366|NCT00044252|Seizures
1486367|NCT00044252|Epilepsy
1486368|NCT00044252|Healthy Volunteer
1486369|NCT00044252|HV
1486370|NCT00044252|Normal Control
1486371|NCT00044239|Tic Disorders
1486372|NCT00044239|Neurophyschological
1486373|NCT00044239|Immunology
1486374|NCT00044239|Magnetic Resonance Imaging
1486376|NCT00044239|Obsessive-Compulsive Disorder
1486377|NCT00044239|Children
1486378|NCT00044239|Adolescents
1486379|NCT00044239|Magnetic Resonance Spectroscopy
1486380|NCT00044239|PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated d
1486381|NCT00044239|Obsessive Compulsive Disorder
1486382|NCT00044239|OCD
1486383|NCT00044239|Healthy Volunteers
1486384|NCT00044239|HV
1486385|NCT00044226|BPH
1486386|NCT00044226|Benign Prostatic Hyperplasia
1486387|NCT00044226|Benign Prostatic Hypertrophy
1486388|NCT00044226|Enlarged Prostate
1486389|NCT00044200|Phospholipase A2
1486390|NCT00044200|Arachidonic Acid
1486391|NCT00044200|Blood Flow
1486392|NCT00044200|Coupling
1486393|NCT00044200|Neurotransmission
1486394|NCT00044200|PET
1486395|NCT00044200|Signal Transduction
1486396|NCT00044200|Activation
1486397|NCT00044200|Brain
1486398|NCT00044200|[15O]H20
1486399|NCT00044187|schizoaffective disorder
1486400|NCT00044187|schizophreniform disorder
1486401|NCT00044187|bipolar I disorder
1486402|NCT00044174|Depression
1486403|NCT00044174|Mother-Infant Interaction
1486404|NCT00044174|Still-face
1486405|NCT00044174|Socioemotional Development
1486406|NCT00044174|Cognitive Development
1486407|NCT00044174|Healthy
1486408|NCT00044174|Mothers
1486409|NCT00044174|Postpartum
1486410|NCT00044174|Postpartum Depression
1486411|NCT00044148|Persistent Albuminuria
1486412|NCT00044135|clevudine
1486413|NCT00044135|hepatitis B
1486419|NCT00044109|Pain
1486420|NCT00044109|Low Back
1486421|NCT00044109|Radiculopathy
1486422|NCT00044109|Electromagnetic Treatment
1486423|NCT00044109|Back Device
1486424|NCT00044109|Sciatica
1486425|NCT00044109|Low Back Pain
1486426|NCT00044096|SSRI
1486427|NCT00044096|Anxiety
1486428|NCT00044096|Stress
1486429|NCT00044096|Citalopram
1486430|NCT00044096|Benadryl
1486431|NCT00044096|Diphenhydramine
1486432|NCT00044096|Startle
1486433|NCT00044096|Fear-Potentiated Startle
1486434|NCT00044096|Fear
1486435|NCT00044096|Normal Volunteers
1486436|NCT00044096|Healthy Volunteers
1486437|NCT00044096|HV
1486438|NCT00044083|Catecholamines
1486439|NCT00044083|Dopamine
1486440|NCT00044083|Clinical Trial
1486441|NCT00044083|fMRI
1486442|NCT00044083|PFC
1486443|NCT00044083|Vitamin B2
1486444|NCT00044083|Riboflavin
1486445|NCT00044083|Tolcapone
1486446|NCT00044083|Placebo
1486447|NCT00044083|Normal Volunteers
1486448|NCT00044083|Schizophrenia
1486449|NCT00044083|Healthy Volunteers
1486450|NCT00044083|HV
1486451|NCT00044070|ARTIST
1486452|NCT00044070|Acute ischemic stroke
1486453|NCT00044057|ARTIST
1486454|NCT00044044|Schizophrenia
1486455|NCT00044044|Latuda
1486456|NCT00044044|Lurasidone
1486457|NCT00044031|pancreatic cancer
1486458|NCT00044031|G17DT
1486459|NCT00044031|gemcitabine
1486460|NCT00044018|Revimid
1486461|NCT00044018|CC5013
1486462|NCT00044005|Schizophrenia
1486463|NCT00044005|Latuda
1486464|NCT00044005|Lurasidone
1486465|NCT00043992|Asthma
1486466|NCT00043992|Allergens
1486467|NCT00043979|Ewing's Sarcoma
1486468|NCT00043979|Rhabdomyosarcoma
1486469|NCT00043979|Desmoplastic Small Round Cell Tumor
1486470|NCT00043979|Sarcoma
1486471|NCT00043979|Ewing Sarcoma
1486472|NCT00043966|treatment naive
1486473|NCT00043953|treatment naive
1486474|NCT00043940|thrombosis
1486475|NCT00043940|bivalirudin
1486476|NCT00043940|direct thrombin inhibitor
1486477|NCT00043940|HIT
1486478|NCT00043940|HITTS
1486479|NCT00043940|HIT/HITTS
1486480|NCT00043927|Chemotherapy-naive
1486481|NCT00043927|Small Cell Lung Cancer
1486482|NCT00043927|SCLC
1486483|NCT00043927|Extensive disease
1486484|NCT00043927|ED
1486485|NCT00043927|topotecan
1486486|NCT00043927|Hycamtin
1486487|NCT00043927|oral
1486488|NCT00043914|epilepsy
1486489|NCT00043914|monotherapy conversion
1486490|NCT00043901|PGTC
1486491|NCT00043901|Lamotrigine
1486492|NCT00043901|epilepsy
1486493|NCT00043901|seizures
1486494|NCT00043901|primary generalized tonic-clonic
1486495|NCT00043888|fosamprenavir
1486496|NCT00043888|ritonavir
1486497|NCT00043888|COMBIVIR
1486498|NCT00043888|TRIZIVIR
1486499|NCT00043888|abacavir
1486500|NCT00043888|lamivudine
1486501|NCT00043888|zidovudine
1486502|NCT00043888|HIV
1486503|NCT00043888|protease inhibitors
1486504|NCT00043875|partial seizures
1486505|NCT00043875|pediatric
1486506|NCT00043875|epilepsy
1486507|NCT00043862|Hycamtin
1486508|NCT00043862|oral
1486509|NCT00043862|Radiation Sensitization
1486510|NCT00043862|Small Cell Lung Cancer
1486511|NCT00043862|newly diagnosed
1486512|NCT00043862|limited stage
1486515|NCT00043849|Agitation, Psychomotor
1486516|NCT00043836|ejection fraction
1486517|NCT00043836|exercise tolerance
1486518|NCT00043836|heart failure, congestive
1486519|NCT00043836|quality of life
1486520|NCT00043823|Non-Small Cell Lung Cancer
1486521|NCT00043823|NSCLC
1486522|NCT00043823|Lung Cancer
1486523|NCT00043823|Avastin
1486524|NCT00043823|Bevacizumab
1486525|NCT00043823|rhuMAb VEGF
1486526|NCT00043823|Anti-VEGF monoclonal antibody
1486527|NCT00043823|Tarceva
1486528|NCT00043823|OSI-774
1486529|NCT00043823|Erlotinib Hydrocholoride
1486530|NCT00043810|AML
1486531|NCT00043810|MDS
1486532|NCT00043810|Gelonin
1486533|NCT00043810|Purging
1486534|NCT00043810|Transplant
1486535|NCT00043810|Peripheral Stem Cell
1486536|NCT00043797|ARI
1486537|NCT00043797|Diabetic polyneuropathy
1486538|NCT00043797|Diabetic complications
1486539|NCT00043784|Acute coronary syndromes
1486540|NCT00043784|non-ST-segment elevation
1486541|NCT00043771|CHF
1486542|NCT00043758|CHF
1486543|NCT00043745|soy
1486544|NCT00043745|isoflavones
1486545|NCT00043745|alternative hormone therapy
1486546|NCT00043745|bone loss
1486547|NCT00043732|Rheumatoid arthritis
1486548|NCT00043732|Scio-469
1486549|NCT00043719|Human Female
1486550|NCT00043719|Osteoporosis
1486551|NCT00043719|Postmenopausal
1486552|NCT00043719|Nitric Oxide
1486553|NCT00043719|Nitroglycerin
1486554|NCT00043719|Calcium
1486555|NCT00043719|Vitamin D
1486556|NCT00043693|Psychotic Disorders
1486557|NCT00043693|Schizoaffective Disorder
1486558|NCT00043693|Substance Abuse
1486559|NCT00043680|Classic
1486560|NCT00043680|Occult
1486561|NCT00043680|Neovascular
1486562|NCT00043680|Celecoxib
1486563|NCT00043680|Age-Related Macular Degeneration
1486564|NCT00043680|Photodynamic Therapy
1486565|NCT00043680|Choroidal Neovascularization
1486566|NCT00043680|Cyclooxygenase 2
1486567|NCT00043680|Macular Degeneration
1486568|NCT00043680|AMD
1486569|NCT00043680|Age Related Macular Degeneration
1486570|NCT00043667|Interleukin 2
1486571|NCT00043667|IL-2 Receptor
1486572|NCT00043667|Anti-CD25
1486573|NCT00043667|Anti-Tac
1486574|NCT00043667|Anti-IL-2R
1486575|NCT00043667|Uveitis
1486576|NCT00043667|Daclizumab
1486577|NCT00043667|Inflammatory Eye DIsease
1486578|NCT00043654|Antidepressant
1486579|NCT00043654|Manic-Depressive Disorder
1486580|NCT00043654|Cortisol
1486581|NCT00043654|Neuroendocrine
1486582|NCT00043654|Cognition
1486583|NCT00043654|Bipolar
1486584|NCT00043654|Bipolar Disorder
1486585|NCT00043654|BPD
1486586|NCT00043654|HV
1486587|NCT00043641|RT PCR
1486588|NCT00043641|Antiretrovial Therapy
1486589|NCT00043641|Drug Intensification
1486590|NCT00043641|Ultra-low
1486591|NCT00043641|Sequence
1486592|NCT00043641|HIV
1486593|NCT00043641|Treatment Experienced
1486594|NCT00043628|Progenitor Cells
1486595|NCT00043628|MRI
1486596|NCT00043628|Coronary Blood Flow
1486597|NCT00043628|Hematopoiesis
1486598|NCT00043628|Myocardial Contractility
1486599|NCT00043628|Coronary Artery Disease
1486600|NCT00043628|CAD
1486601|NCT00043628|Heart Disease
1486602|NCT00043615|Angiogenesis
1486603|NCT00043615|Drug Resistance
1486604|NCT00043615|Signal Transduction
1486605|NCT00043615|EGFR
1486606|NCT00043615|Survival Factors
1486607|NCT00043615|Malignancy
1486608|NCT00043615|Pre-Cancer Condition
1486609|NCT00043615|Cancer Risk
1486610|NCT00043589|Memory
1486611|NCT00043576|Prostate Cancer
1486612|NCT00043576|Androgen Independent Prostate Cancer
1486613|NCT00043563|Cognitive-behavior Therapy
1486614|NCT00043563|Minimal Attention Control
1486615|NCT00043550|Major Depressive Disorder
1486616|NCT00043537|Phobic Disorders
1486617|NCT00043537|Mutism
1486618|NCT00043511|Injections, Intramuscular
1486619|NCT00043511|HIV Seronegativity
1486620|NCT00043511|Plasmids
1486621|NCT00043511|Vaccines, DNA
1486622|NCT00043511|HIV Preventive Vaccine
1486623|NCT00043498|Pollutants
1486624|NCT00043472|Screening
1486625|NCT00043472|Oophorectomy
1486626|NCT00043472|Hereditary
1486627|NCT00043472|Genetics
1486628|NCT00043472|Cancer
1486629|NCT00043472|Ovarian Cancer
1486630|NCT00043472|Ovarian Cancer Risk
1486631|NCT00043459|NHL
1486632|NCT00043433|HCC
1486633|NCT00043420|immunotherapy, lymphoma
1486634|NCT00043407|Renal Cell Carcinoma, Phase I, Phase II, Immunotherapy
1486635|NCT00043394|CpG 7909 subcutaneous injection combination with Herceptin® metastatic breast cancer.
1486636|NCT00043381|myelodysplastic syndrome
1486637|NCT00043381|MDS
1486638|NCT00043381|chronic myelomonocytic leukemia
1486639|NCT00043381|CMML
1486640|NCT00043381|decitabine
1486641|NCT00043381|5-aza-2'deoxycytidine
1486642|NCT00043368|CPG 7909 continuation study
1486643|NCT00043355|pulmonary
1486644|NCT00043355|mycobacterium avium complex infection
1486645|NCT00043355|MAC
1486646|NCT00043355|nontuberculous
1486647|NCT00043355|mycobacteria
1486648|NCT00043355|lung
1486649|NCT00043342|cystic fibrosis
1486650|NCT00043342|pulmonary impairment
1486651|NCT00043329|Registry
1486652|NCT00043329|Actimmune
1486653|NCT00043329|osteopetrosis
1486654|NCT00043316|cystic fibrosis
1486655|NCT00043316|pulmonary impairment
1486656|NCT00042900|AIDS-related peripheral/systemic lymphoma
1486657|NCT00042900|AIDS-related primary CNS lymphoma
1486658|NCT00042900|T-cell large granular lymphocyte leukemia
1486659|NCT00042900|Waldenström macroglobulinemia
1486660|NCT00042900|accelerated phase chronic myelogenous leukemia
1486661|NCT00042900|acute undifferentiated leukemia
1486662|NCT00042900|adult acute lymphoblastic leukemia in remission
1486663|NCT00042900|adult acute myeloid leukemia in remission
1486664|NCT00042900|primary myelofibrosis
1486665|NCT00042900|anaplastic large cell lymphoma
1486666|NCT00042900|angioimmunoblastic T-cell lymphoma
1486667|NCT00042900|blastic phase chronic myelogenous leukemia
1486668|NCT00042900|chronic myelomonocytic leukemia
1486669|NCT00042900|chronic phase chronic myelogenous leukemia
1486670|NCT00042900|de novo myelodysplastic syndromes
1486671|NCT00042900|essential thrombocythemia
1486672|NCT00042900|extramedullary plasmacytoma
1486673|NCT00042900|intraocular lymphoma
1486674|NCT00042900|isolated plasmacytoma of bone
1486675|NCT00042900|meningeal chronic myelogenous leukemia
1486676|NCT00042900|monoclonal gammopathy of undetermined significance
1486677|NCT00042900|polycythemia vera
1486678|NCT00042900|previously treated myelodysplastic syndromes
1486679|NCT00042900|primary central nervous system non-Hodgkin lymphoma
1486680|NCT00042900|primary systemic amyloidosis
1486681|NCT00042900|progressive hairy cell leukemia, initial treatment
1486682|NCT00042900|prolymphocytic leukemia
1486683|NCT00042900|recurrent adult Hodgkin lymphoma
1486684|NCT00042900|recurrent adult T-cell leukemia/lymphoma
1486685|NCT00042900|recurrent adult acute lymphoblastic leukemia
1486686|NCT00042900|recurrent adult acute myeloid leukemia
1486687|NCT00042900|recurrent adult diffuse large cell lymphoma
1486688|NCT00042900|recurrent adult diffuse mixed cell lymphoma
1486689|NCT00042900|recurrent adult diffuse small cleaved cell lymphoma
1486690|NCT00042900|recurrent adult Burkitt lymphoma
1486691|NCT00042900|recurrent adult immunoblastic large cell lymphoma
1486692|NCT00042900|recurrent adult lymphoblastic lymphoma
1486693|NCT00042900|recurrent cutaneous T-cell non-Hodgkin lymphoma
1486694|NCT00042900|recurrent grade 1 follicular lymphoma
1486695|NCT00042900|recurrent grade 2 follicular lymphoma
1486696|NCT00042900|recurrent grade 3 follicular lymphoma
1486697|NCT00042900|recurrent mantle cell lymphoma
1486698|NCT00042900|recurrent mycosis fungoides/Sezary syndrome
1486699|NCT00042900|refractory chronic lymphocytic leukemia
1486700|NCT00042900|refractory hairy cell leukemia
1486701|NCT00042900|refractory multiple myeloma
1486702|NCT00042900|relapsing chronic myelogenous leukemia
1486703|NCT00042900|secondary acute myeloid leukemia
1486704|NCT00042900|secondary myelodysplastic syndromes
1486705|NCT00042900|small intestine lymphoma
1486706|NCT00042900|stage III adult Hodgkin lymphoma
1486707|NCT00042900|stage III adult T-cell leukemia/lymphoma
1486708|NCT00042900|stage III adult diffuse mixed cell lymphoma
1486709|NCT00042900|stage III adult diffuse large cell lymphoma
1486710|NCT00042900|stage III adult diffuse small cleaved cell lymphoma
1486711|NCT00042900|stage III adult Burkitt lymphoma
1486712|NCT00042900|stage III adult immunoblastic large cell lymphoma
1486713|NCT00042900|stage III adult lymphoblastic lymphoma
1486714|NCT00042900|stage III chronic lymphocytic leukemia
1486715|NCT00042900|stage III cutaneous T-cell non-Hodgkin lymphoma
1486716|NCT00042900|stage III grade 1 follicular lymphoma
1486717|NCT00042900|stage III grade 2 follicular lymphoma
1486718|NCT00042900|stage III grade 3 follicular lymphoma
1486719|NCT00042900|stage III mantle cell lymphoma
1486720|NCT00042900|stage III multiple myeloma
1486721|NCT00042900|stage III mycosis fungoides/Sezary syndrome
1486722|NCT00042900|stage IV adult diffuse large cell lymphoma
1486723|NCT00042900|stage IV adult diffuse mixed cell lymphoma
1486724|NCT00042900|stage IV adult diffuse small cleaved cell lymphoma
1486725|NCT00042900|stage IV adult Burkitt lymphoma
1486726|NCT00042900|stage IV adult immunoblastic large cell lymphoma
1486727|NCT00042900|stage IV adult lymphoblastic lymphoma
1486728|NCT00042900|stage IV chronic lymphocytic leukemia
1486729|NCT00042900|stage IV cutaneous T-cell non-Hodgkin lymphoma
1486730|NCT00042900|stage IV grade 1 follicular lymphoma
1486731|NCT00042900|stage IV grade 2 follicular lymphoma
1486732|NCT00042900|stage IV grade 3 follicular lymphoma
1486733|NCT00042900|stage IV mantle cell lymphoma
1486734|NCT00042900|stage IV mycosis fungoides/Sezary syndrome
1486735|NCT00042900|untreated adult acute lymphoblastic leukemia
1486736|NCT00042900|untreated adult acute myeloid leukemia
1486737|NCT00042900|untreated hairy cell leukemia
1486738|NCT00042900|stage IV adult Hodgkin lymphoma
1486739|NCT00042900|stage IV adult T-cell leukemia/lymphoma
1486740|NCT00042900|unspecified adult solid tumor, protocol specific
1486854|NCT00040521|Active Crohns Disease
1486741|NCT00042900|recurrent marginal zone lymphoma
1486742|NCT00042900|recurrent small lymphocytic lymphoma
1486743|NCT00042900|stage III small lymphocytic lymphoma
1486744|NCT00042900|stage III marginal zone lymphoma
1486745|NCT00042900|stage IV small lymphocytic lymphoma
1486746|NCT00042900|stage IV marginal zone lymphoma
1486747|NCT00042900|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1486748|NCT00042900|nodal marginal zone B-cell lymphoma
1486749|NCT00042900|splenic marginal zone lymphoma
1486750|NCT00042887|stage 0 bladder cancer
1486751|NCT00042887|stage I bladder cancer
1486752|NCT00042887|recurrent bladder cancer
1486753|NCT00042887|transitional cell carcinoma of the bladder
1486754|NCT00042861|unspecified adult solid tumor, protocol specific
1486755|NCT00042848|fatigue
1486756|NCT00042848|unspecified adult solid tumor, protocol specific
1486757|NCT00042822|recurrent adult acute myeloid leukemia
1486758|NCT00042822|refractory anemia with excess blasts
1486759|NCT00042822|refractory anemia with excess blasts in transformation
1486760|NCT00042822|chronic myelomonocytic leukemia
1486761|NCT00042822|recurrent grade 3 follicular lymphoma
1486762|NCT00042822|previously treated myelodysplastic syndromes
1486763|NCT00042822|secondary myelodysplastic syndromes
1486764|NCT00042822|untreated adult acute myeloid leukemia
1486765|NCT00042822|recurrent grade 1 follicular lymphoma
1486766|NCT00042822|recurrent grade 2 follicular lymphoma
1486767|NCT00042822|recurrent adult diffuse large cell lymphoma
1486768|NCT00042822|recurrent adult diffuse mixed cell lymphoma
1486769|NCT00042822|recurrent adult diffuse small cleaved cell lymphoma
1486770|NCT00042822|atypical chronic myeloid leukemia, BCR-ABL1 negative
1486771|NCT00042822|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1486772|NCT00042822|adult acute myeloid leukemia with t(8;21)(q22;q22)
1486773|NCT00042822|adult acute myeloid leukemia with t(16;16)(p13;q22)
1486774|NCT00042822|adult acute myeloid leukemia with inv(16)(p13;q22)
1486775|NCT00042822|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1486776|NCT00042822|adult acute myeloid leukemia with t(15;17)(q22;q12)
1486777|NCT00042783|stage IV melanoma
1486778|NCT00042783|recurrent melanoma
1486779|NCT00042770|malignant pleural effusion
1486780|NCT00042770|pulmonary complications
1486781|NCT00042731|stage I prostate cancer
1486782|NCT00042731|stage IIB prostate cancer
1486783|NCT00042731|stage IIA prostate cancer
1486784|NCT00042718|Chronic Bronchitis
1486785|NCT00042718|Acute Bacterial Exacerbation of Chronic Bronchitis
1486786|NCT00042705|asthma
1486787|NCT00042705|indoor allergens
1486788|NCT00042692|catechol thioethers
1486789|NCT00042692|Parkinson's disease
1486790|NCT00042692|neurodegenerative disease
1486791|NCT00042679|Non-Small-Cell Lung Cancer
1486792|NCT00042679|Adenocarcinoma
1486793|NCT00042679|Carcinoma Squamous
1486794|NCT00042679|Adult Lung Cancer
1486795|NCT00042627|Cataracts
1486796|NCT00042627|Granulocytapheresis
1486797|NCT00042627|Granulocyte Donors
1486798|NCT00042614|Genes
1486799|NCT00042614|Heart
1486800|NCT00042614|Lymphocytes
1486801|NCT00042614|Proteomics
1486802|NCT00042614|Transplant
1486803|NCT00042614|Heart Transplant
1486804|NCT00042614|Healthy Volunteer
1486805|NCT00042614|HV
1486806|NCT00042614|Normal Control
1486807|NCT00042588|Safety and Efficacy
1486808|NCT00042588|Community-Acquired Pneumonia, Sepsis
1486809|NCT00042575|Sad, blue, lack of energy, depressed, hopelessness, guilt
1486810|NCT00042562|Depressed
1486811|NCT00042562|blues
1486812|NCT00042562|sadness
1486813|NCT00042562|feelings of guilt
1486814|NCT00042562|hopelessness
1486815|NCT00042562|lack of energy
1486816|NCT00042549|Gallstones
1486817|NCT00042549|Gallstone
1486818|NCT00042549|Biliary stones
1486819|NCT00042549|Gallbladder stones
1486820|NCT00042549|Gallbladder
1486821|NCT00042549|Lithotripsy
1486822|NCT00042549|Cholelithiasis
1486823|NCT00042549|ESWL
1486824|NCT00042549|Shock wave
1486825|NCT00042549|Shock waves
1486826|NCT00042549|shockwaves
1486827|NCT00042549|shockwave
1486828|NCT00042536|Yohimbine
1486829|NCT00042536|Naltrexone
1486830|NCT00042536|Sexual Function
1486831|NCT00042536|Erectile Dysfunction
1486832|NCT00042536|Alpha-2 Adrenoreceptor
1486833|NCT00042536|Opiate Receptor
1486834|NCT00042536|Male Impotence
1486835|NCT00042536|ED
1486836|NCT00042536|Healthy Volunteer
1486837|NCT00042536|HV
1486838|NCT00042536|Normal Control
1486839|NCT00042523|Autoantibody
1486840|NCT00042523|Anti-DNA Antibody
1486841|NCT00042523|Cross-Reactivity
1486842|NCT00042523|Neuron Loss
1486843|NCT00042523|Imaging
1486844|NCT00042523|Lupus
1486845|NCT00042523|SLE
1486846|NCT00042523|Systemic Lupus Erythematosus
1486847|NCT00042510|Gastroesophageal cancer
1486848|NCT00042510|Gastric cancer
1486849|NCT00040560|Lung Cancer
1486850|NCT00040560|Metastatic Brain Cancer
1486851|NCT00040547|Cancer-Advanced Solid Tumors
1486852|NCT00040534|Advanced Cancer
1486853|NCT00040521|Crohn's Disease
1486855|NCT00040508|Proteinuria
1486856|NCT00040508|Renal Failure
1486857|NCT00040508|Fibrosis
1486858|NCT00040508|Rapamycin
1486859|NCT00040508|Immunosuppression
1486860|NCT00040508|Focal Segmental Glomerulosclerosis
1486861|NCT00040508|FSGS
1486862|NCT00040495|Peptic
1486863|NCT00040495|Ulcer
1486864|NCT00040495|Hemorrhage
1486865|NCT00042484|Asthma
1486866|NCT00042484|Children's Health
1486867|NCT00042484|Community Based Research
1486868|NCT00042445|Neoplasm
1486869|NCT00042445|Petrochemical
1486870|NCT00042445|Leukemia
1486871|NCT00042445|Taiwan
1486872|NCT00042419|Industrial Injuries
1486873|NCT00042419|Tendonitis
1486874|NCT00042419|Assembly Line
1486875|NCT00042393|Hepatitis B, Chronic
1486876|NCT00042380|Antidepressant
1486877|NCT00042380|Anxiety
1486878|NCT00042380|Dopamine
1486879|NCT00042380|Tyrosine Kinase Inhibitor
1486880|NCT00042380|Affective Disorder
1486881|NCT00042380|Phytoestrogen
1486882|NCT00042380|Genistein
1486883|NCT00042380|Major Depression
1486884|NCT00042380|Depression
1486885|NCT00042354|CLO222
1486886|NCT00042354|clolar
1486887|NCT00042354|Pediatric Acute Myelogenous Leukemia
1486888|NCT00042341|CLO212
1486889|NCT00042341|clolar
1486890|NCT00042341|pediatric ALL
1486891|NCT00042341|Leukemia, Lymphoblastic, Acute - pediatric
1486892|NCT00042328|Cancer
1486893|NCT00042289|Pregnancy
1486894|NCT00042289|Pharmacokinetics
1486895|NCT00042289|Treatment Experienced
1486896|NCT00042276|Pressure Pain Threshold
1486897|NCT00042276|MTrP
1486898|NCT00042276|Musculoskeletal Pain
1486899|NCT00042276|Soft Tissue Pain
1486900|NCT00042276|Pathophysiology
1486901|NCT00042276|Myofascial Pain
1486902|NCT00042276|Microdialysis
1486903|NCT00042276|Myofascial Trigger Points
1486904|NCT00042276|Rehabilitation
1486905|NCT00042276|Muscle Pain
1486906|NCT00042276|Neck Pain
1486907|NCT00042276|Healthy Volunteer
1486908|NCT00042276|HV
1486909|NCT00042276|Normal Control
1486910|NCT00040456|Hemoglobin SC disease
1486911|NCT00040456|sickle cell-hemoglobin
1486912|NCT00040443|Mild Cognitive Impairment
1486913|NCT00040443|Memory Loss
1486914|NCT00040443|Alzheimer's Disease
1486915|NCT00040443|Brain Aging
1486916|NCT00040443|Ampalex®
1486917|NCT00040443|CX516
1486918|NCT00040404|Parkinson's disease
1486919|NCT00040404|Idiopathic Parkinson's disease
1486920|NCT00040404|Idiopathic Parkinson disease
1486921|NCT00040404|Parkinson's disease, idiopathic
1486922|NCT00040391|Pharmacia
1486923|NCT00040378|Alzheimer Disease
1486924|NCT00040378|Vitamin E
1486925|NCT00040378|Selenium
1486926|NCT00040365|Prostate Cancer
1486927|NCT00040365|Radiation Therapy
1486928|NCT00040365|Rectal Toxicity
1486929|NCT00040365|Amifostine
1486930|NCT00040365|Radioprotector
1486931|NCT00040352|Genetics
1486932|NCT00040352|Risk Factors
1486933|NCT00040352|Natural History
1486934|NCT00040352|Melanoma Precursors
1486935|NCT00040352|Skin Cancer
1486936|NCT00040352|Melanoma
1486937|NCT00040339|brain injury
1486938|NCT00040339|hypothermia
1486939|NCT00040339|body cooling
1486940|NCT00040339|body temperature
1486941|NCT00040326|epilepsy
1486942|NCT00040326|mesial temporal lobe epilepsy
1486943|NCT00040326|temporal lobe epilepsy
1486944|NCT00040326|MTLE
1486945|NCT00040326|seizures
1486946|NCT00040326|anteromesial temporal resection
1486947|NCT00040326|surgery
1486948|NCT00040326|antiepileptic drugs
1486949|NCT00040326|hippocampal sclerosis
1486950|NCT00042263|health disparities
1486951|NCT00042263|social environment
1486952|NCT00042263|physical environment
1486953|NCT00042263|racial health disparities
1486954|NCT00042250|Cell Cycle Interphase
1486955|NCT00042250|G0
1486956|NCT00042250|G1
1486957|NCT00042250|G2
1486958|NCT00042250|S Phase
1486959|NCT00042237|Child Abuse, Sexual
1486960|NCT00042224|Electroconvulsive Therapy
1486961|NCT00042211|Depressive Disorder
1486962|NCT00042211|Blindness
1486963|NCT00042211|Aged
1486964|NCT00042198|Cognitive therapy
1486965|NCT00042198|Relaxation techniques
1486966|NCT00042185|Adolescence
1486967|NCT00042185|Prevention and Control
1486968|NCT00042185|Bulimia
1486969|NCT00042172|Cognition
1486970|NCT00042172|Memory
1486971|NCT00042159|Auditory hallucinations (voices)
1486972|NCT00042146|Insomnia
1486973|NCT00042146|Sleep Disorders
1486974|NCT00042146|Sleep Deprivation
1486975|NCT00042133|aging
1486976|NCT00042133|disability
1486977|NCT00042133|longitudinal studies
1486978|NCT00042133|neighborhood factors
1486979|NCT00042133|socio-economic status
1486980|NCT00042133|race
1486981|NCT00042120|Parkinson's disease
1486982|NCT00042120|Movement Disorders
1486983|NCT00042120|Epidemiological Study
1486984|NCT00042107|Parkinson Disease
1486985|NCT00042107|Neurodegenerative
1486986|NCT00042094|Smallpox
1486987|NCT00042094|Smallpox Vaccine
1486988|NCT00042094|Vaccinia
1486989|NCT00042081|CABG
1486990|NCT00042081|coronary artery bypass surgery
1486991|NCT00042081|coronary artery disease
1486992|NCT00042081|coronary arteriosclerosis
1486993|NCT00042081|coronary stenosis
1486994|NCT00042081|coronary occlusion
1486995|NCT00042055|Crohn's Disease
1486996|NCT00042055|Inflammatory Bowel Disease
1486997|NCT00042016|Chronic myelogenous leukemia
1486998|NCT00042016|CML
1486999|NCT00042016|CML-CP
1487000|NCT00042016|Chronic phase
1487001|NCT00042016|Decitabine
1487002|NCT00042016|5-aza-2'deoxycytidine
1487003|NCT00042016|Methylation
1487004|NCT00042016|STI 571
1487005|NCT00042016|Imatinib mesylate
1487006|NCT00042016|Gleevec
1487007|NCT00042016|BCR/ABL
1487008|NCT00042003|Chronic myelogenous leukemia
1487009|NCT00042003|CML
1487010|NCT00042003|CML-BP
1487011|NCT00042003|Blast phase
1487012|NCT00042003|Decitabine
1487013|NCT00042003|5-aza-2'deoxycytidine
1487014|NCT00042003|Methylation
1487015|NCT00042003|STI 571
1487016|NCT00042003|Imatinib mesylate
1487017|NCT00042003|Gleevec
1487018|NCT00042003|BCR/ABL
1487019|NCT00041990|Chronic myelogenous leukemia
1487020|NCT00041990|CML
1487021|NCT00041990|CML-AP
1487022|NCT00041990|Accelerated phase
1487023|NCT00041990|Decitabine
1487024|NCT00041990|5-aza-2'deoxycytidine
1487025|NCT00041990|Methylation
1487026|NCT00041990|STI 571
1487027|NCT00041990|Imatinib mesylate
1487028|NCT00041990|Gleevec
1487029|NCT00041990|BCR/ABL
1487030|NCT00041977|Rosacea
1487031|NCT00041964|Lopinavir
1487032|NCT00041964|Pregnancy Trimester, Third
1487033|NCT00041964|Pregnancy Complications, Infectious
1487034|NCT00041964|HIV Protease Inhibitors
1487035|NCT00041964|Ritonavir
1487036|NCT00041964|Nelfinavir
1487037|NCT00041964|Viral Load
1487038|NCT00041964|puerperium
1487039|NCT00041951|Childhood Absence Epilepsy
1487040|NCT00041951|CAE
1487041|NCT00041951|Petit Mal
1487042|NCT00041951|Epilepsy
1487043|NCT00041951|Seizures
1487044|NCT00041951|Genes
1487045|NCT00041951|Inheritance
1487046|NCT00041951|Genetics
1487047|NCT00041951|Genetic Linkage
1487048|NCT00041938|heart disease
1487049|NCT00041938|stroke
1487050|NCT00041938|ischemic heart disease
1487051|NCT00041938|myocardial infarction
1487052|NCT00041938|atrial fibrillation
1487053|NCT00041938|low ejection fraction
1487054|NCT00041938|cardiac failure
1487055|NCT00041938|aspirin
1487056|NCT00041938|Warfarin
1487057|NCT00041938|anticoagulant
1487058|NCT00041925|atherosclerotic vascular disease
1487059|NCT00041925|chronic critical limb ischemia
1487060|NCT00041925|neointimal hyperplasia
1487061|NCT00041925|peripheral vein bypass
1487062|NCT00041925|infra-inguinal bypass grafting surgery
1487063|NCT00041925|graft stenosis
1487064|NCT00041925|occluded grafts
1487065|NCT00041899|Progesterone
1487066|NCT00041899|Cortisol
1487067|NCT00041899|Menstrual Cycle
1487068|NCT00041899|Formulation
1487069|NCT00041899|Endometrium
1487070|NCT00041899|Estrogen
1487071|NCT00041886|Minimally Invasive Surgery
1487072|NCT00041886|Percutaneous
1487073|NCT00041886|Radiofrequency Ablation
1487074|NCT00041886|Soft Tissue Metastases
1487075|NCT00041886|Thermal Ablation
1487076|NCT00041886|Soft Tissue Neoplasm
1487077|NCT00041886|Tumor
1487078|NCT00041860|Benzene
1487079|NCT00041860|Air pollution
1487080|NCT00041847|gene
1487081|NCT00041847|environment
1487082|NCT00041847|occupation
1487083|NCT00041847|diet
1487084|NCT00041847|interaction
1487085|NCT00041834|childhood asthma
1487086|NCT00041834|traffic
1487087|NCT00041821|rhinitis
1487088|NCT00041821|irritation
1487089|NCT00041821|trigeminal
1487090|NCT00041808|Metastatic liver cancer
1487091|NCT00041808|Cholangiocarcinoma
1487092|NCT00041808|colorectal cancer
1487093|NCT00041808|esophageal cancer
1487094|NCT00041808|gastric cancer
1487095|NCT00041808|pancreatic cancer
1487096|NCT00041808|breast cancer
1487097|NCT00041808|malignant melanoma
1487098|NCT00041808|sarcoma
1487099|NCT00041808|GIST
1487100|NCT00041808|gastrointestinal stromal tumor
1487101|NCT00041808|lung cancer
1487102|NCT00041808|liver cancer
1487103|NCT00041782|Deep Vein Thrombosis
1487104|NCT00041769|Drug Therapy, Combination
1487105|NCT00041769|HIV Protease Inhibitors
1487106|NCT00041769|Salvage Therapy
1487107|NCT00041769|Viral Load
1487108|NCT00041769|Treatment Experienced
1487109|NCT00041756|Primary Disease: Knee Primary Osteoarthritis
1487110|NCT00041730|lymphoma
1487111|NCT00041730|vaccine
1487112|NCT00041730|idiotype
1487113|NCT00041730|KLH
1487114|NCT00041730|GM-CSF
1487115|NCT00041730|FavId
1487116|NCT00041717|spinal cord injury
1487117|NCT00041717|muscle spasticity
1487118|NCT00041704|Azole-Refractory Mucosal Candidiasis
1487119|NCT00041704|Mucosal Candidiasis
1487120|NCT00041691|Colorectal Cancer
1487121|NCT00041691|Colon Cancer
1487122|NCT00041691|Rectal Cancer
1487123|NCT00041691|Colorectal Neoplasms
1487124|NCT00041691|Colorectal Carcinoma
1487125|NCT00041691|Colorectal Tumor
1487126|NCT00039884|Cervical cancer
1487127|NCT00039858|heparin-induced thrombocytopenia
1487128|NCT00039858|heparin-induced thrombocytopenia and thrombosis
1487129|NCT00039858|HIT
1487130|NCT00039858|HITTS
1487131|NCT00039858|anticoagulation
1487132|NCT00039845|Brain
1487133|NCT00039845|Imaging
1487134|NCT00039845|Pediatrics
1487135|NCT00039845|Mapping
1487136|NCT00039845|Development
1487137|NCT00039845|fMRI
1487138|NCT00039845|Children
1487139|NCT00039845|Language
1487140|NCT00039845|Healthy Volunteer
1487141|NCT00039845|HV
1487142|NCT00039845|Normal Control
1487143|NCT00039832|Stroke
1487144|NCT00039832|Abciximab
1487145|NCT00039832|Reteplase
1487146|NCT00039832|MRI
1487147|NCT00039832|Cerebral Blood Flow
1487148|NCT00039819|Spinal Cord
1487149|NCT00039819|Sensory Stimulation
1487150|NCT00039819|Locomotion
1487151|NCT00039819|Magnetic Stimulation
1487152|NCT00039819|Reflexes
1487153|NCT00039819|Healthy Volunteer
1487154|NCT00039819|HV
1487155|NCT00039819|Normal Control
1487156|NCT00039793|Cancer-related fatigue
1487157|NCT00039793|alternative medicine
1487158|NCT00039793|cancer rehabilitation /care
1487159|NCT00039793|fatigue
1487160|NCT00039793|human therapy evaluation
1487161|NCT00039793|physical therapy
1487162|NCT00039793|neoplasm /cancer chemotherapy
1487163|NCT00039793|neoplasm /cancer palliative treatment
1487164|NCT00039780|Breast
1487165|NCT00039780|Cancer
1487166|NCT00039780|Metastatic
1487167|NCT00039780|Paclitaxel
1487168|NCT00039780|Peripheral
1487169|NCT00039780|Taxol
1487170|NCT00039780|Neuropathy
1487171|NCT00039780|Neurotoxicity
1487172|NCT00039780|Paresthesias
1487173|NCT00039780|Weekly
1487174|NCT00039780|BNP7787
1487175|NCT00039780|7787
1487176|NCT00039780|Tavocept
1487177|NCT00039780|Prevention
1487178|NCT00039767|Fibrin Sleeves
1487179|NCT00039767|Anticoagulants
1487180|NCT00039767|Catheters
1487181|NCT00039767|Thrombosis
1487182|NCT00039767|Hirudin
1487183|NCT00039767|Lepirudin
1487184|NCT00039754|Multiple myeloma
1487185|NCT00039754|Transplant
1487186|NCT00039754|Skeletal Targeted Radiotherapy
1487187|NCT00039754|Holmium
1487188|NCT00041678|Psychosis Associated with Dementia of the Alzheimer's Type
1487189|NCT00041652|Colorectal Cancer
1487190|NCT00041652|Colon Cancer
1487191|NCT00041652|Rectal Cancer
1487192|NCT00041652|Colorectal Neoplasms
1487193|NCT00041652|Colorectal Carcinoma
1487194|NCT00041652|Breast Cancer
1487195|NCT00041652|Breast Neoplasms
1487196|NCT00041639|Pancreatic Cancer
1487197|NCT00041639|Pancreatic Carcinoma
1487198|NCT00041639|Pancreatic Neoplasms
1487199|NCT00041639|Pancreas Cancer
1487200|NCT00041639|Pancreatic Tumor
1487201|NCT00041626|Recurrent Squamous Cell Carcinoma of the Head and Neck
1487202|NCT00041613|Refractory Squamous Cell Carcinoma of the Head and Neck
1487203|NCT00041600|epilepsy
1487204|NCT00041600|seizures
1487205|NCT00041600|disorders of human cognition
1487206|NCT00041600|neuronal migration
1487207|NCT00041600|neuronal migration disorders
1487208|NCT00041600|lissencephaly
1487209|NCT00041600|schizencephaly
1487210|NCT00041600|polymicrogyria
1487211|NCT00041600|agenesis of the corpus callosum
1487212|NCT00041600|heterotopia
1487213|NCT00041587|Cancer
1487214|NCT00041587|Recurrent resectable supratentorial malignant glioma
1487215|NCT00041561|Acute hypoxemic respiratory failure
1487216|NCT00041535|Eye Movements
1487217|NCT00041535|Saccades
1487218|NCT00041535|Metabolic
1487219|NCT00041535|Lysosomal
1487220|NCT00041535|Myoclonus
1487221|NCT00041535|Gaucher Disease
1487222|NCT00041535|Neuronopathic Gaucher Disease
1487223|NCT00041509|venous thromboembolism
1487224|NCT00041509|thromboembolism
1487225|NCT00041509|pulmonary embolism
1487226|NCT00041509|deep vein thrombosis
1487227|NCT00041496|symptomatic atrial fibrillation
1487228|NCT00041496|persistent atrial fibrillation
1487229|NCT00041483|AMD
1487230|NCT00041483|age-related macular degeneration
1487231|NCT00041483|Anecortave
1487232|NCT00041483|Acetate
1487233|NCT00041483|Wet form of age-related macular degeneration
1487234|NCT00041379|Waldenström macroglobulinemia
1487235|NCT00041353|ductal breast carcinoma in situ
1487236|NCT00041353|lobular breast carcinoma in situ
1487237|NCT00041327|stage I adult T-cell leukemia/lymphoma
1487238|NCT00041327|stage II adult T-cell leukemia/lymphoma
1487239|NCT00041327|stage III adult T-cell leukemia/lymphoma
1487240|NCT00041327|stage IV adult T-cell leukemia/lymphoma
1487241|NCT00041314|recurrent non-small cell lung cancer
1487242|NCT00041314|stage IIIB non-small cell lung cancer
1487243|NCT00041314|stage IV non-small cell lung cancer
1487244|NCT00041301|stage I prostate cancer
1487245|NCT00041301|stage IIB prostate cancer
1487246|NCT00041301|stage IIA prostate cancer
1487247|NCT00041301|stage III prostate cancer
1487248|NCT00041301|stage IV prostate cancer
1487249|NCT00041288|Waldenstrom macroglobulinemia
1487250|NCT00041288|refractory chronic lymphocytic leukemia
1487251|NCT00041288|recurrent grade 1 follicular lymphoma
1487252|NCT00041288|recurrent grade 2 follicular lymphoma
1487253|NCT00041288|recurrent adult diffuse small cleaved cell lymphoma
1487254|NCT00041288|recurrent small lymphocytic lymphoma
1487255|NCT00041275|localized unresectable adult primary liver cancer
1487256|NCT00041275|advanced adult primary liver cancer
1487257|NCT00041275|adult primary hepatocellular carcinoma
1487258|NCT00041262|stage IIB esophageal cancer
1487259|NCT00041262|stage IIIA esophageal cancer
1487260|NCT00041262|stage IIIB esophageal cancer
1487261|NCT00041262|adenocarcinoma of the esophagus
1487262|NCT00041249|adult angiosarcoma
1487263|NCT00041249|adult fibrosarcoma
1487264|NCT00041249|adult leiomyosarcoma
1487265|NCT00041249|adult liposarcoma
1487266|NCT00041249|adult neurofibrosarcoma
1487267|NCT00041249|adult synovial sarcoma
1487268|NCT00041249|stage III adult soft tissue sarcoma
1487269|NCT00041249|recurrent adult soft tissue sarcoma
1487270|NCT00041249|adult malignant fibrous histiocytoma
1487271|NCT00041249|adult malignant hemangiopericytoma
1487272|NCT00041249|adult rhabdomyosarcoma
1487273|NCT00041249|gastrointestinal stromal tumor
1487274|NCT00041249|stage IV adult soft tissue sarcoma
1487275|NCT00041236|adult angiosarcoma
1487276|NCT00041236|adult fibrosarcoma
1487277|NCT00041236|adult leiomyosarcoma
1487278|NCT00041236|adult liposarcoma
1487279|NCT00041236|adult neurofibrosarcoma
1487280|NCT00041236|adult synovial sarcoma
1487281|NCT00041236|stage IV adult soft tissue sarcoma
1487282|NCT00041236|recurrent adult soft tissue sarcoma
1487283|NCT00041236|adult malignant fibrous histiocytoma
1487284|NCT00041236|adult malignant hemangiopericytoma
1487285|NCT00041236|adult rhabdomyosarcoma
1487286|NCT00041236|stage IV uterine sarcoma
1487287|NCT00041236|recurrent uterine sarcoma
1487288|NCT00041236|uterine leiomyosarcoma
1487289|NCT00041223|radiation fibrosis
1487290|NCT00041223|stage I breast cancer
1487291|NCT00041223|stage II breast cancer
1487292|NCT00041223|stage IIIA breast cancer
1487293|NCT00041210|stage I adult Hodgkin lymphoma
1487294|NCT00041210|stage II adult Hodgkin lymphoma
1487295|NCT00041210|stage III adult Hodgkin lymphoma
1487296|NCT00041210|stage IV adult Hodgkin lymphoma
1487297|NCT00041210|adult lymphocyte predominant Hodgkin lymphoma
1487298|NCT00041210|adult lymphocyte depletion Hodgkin lymphoma
1487299|NCT00041210|adult nodular sclerosis Hodgkin lymphoma
1487300|NCT00041210|adult mixed cellularity Hodgkin lymphoma
1487301|NCT00041171|stage IV breast cancer
1487302|NCT00041171|stage IIIA breast cancer
1487303|NCT00041171|recurrent breast cancer
1487304|NCT00041171|stage IIIB breast cancer
1487305|NCT00041171|recurrent non-small cell lung cancer
1487306|NCT00041171|extensive stage small cell lung cancer
1487307|NCT00041171|recurrent small cell lung cancer
1487308|NCT00041171|stage III bladder cancer
1487309|NCT00041171|recurrent bladder cancer
1487310|NCT00041171|stage IV bladder cancer
1487311|NCT00041171|stage III prostate cancer
1487312|NCT00041171|stage IV prostate cancer
1487313|NCT00041171|recurrent prostate cancer
1487314|NCT00041171|stage IIIA non-small cell lung cancer
1487315|NCT00041171|stage IIIB non-small cell lung cancer
1487316|NCT00041171|stage IV non-small cell lung cancer
1487317|NCT00041171|unspecified adult solid tumor, protocol specific
1487318|NCT00041171|untreated metastatic squamous neck cancer with occult primary
1487319|NCT00041171|recurrent metastatic squamous neck cancer with occult primary
1487320|NCT00041171|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1487321|NCT00041171|stage III squamous cell carcinoma of the lip and oral cavity
1487322|NCT00041171|stage III basal cell carcinoma of the lip
1487323|NCT00041171|stage III verrucous carcinoma of the oral cavity
1487324|NCT00041171|stage III mucoepidermoid carcinoma of the oral cavity
1487325|NCT00041171|stage III adenoid cystic carcinoma of the oral cavity
1487326|NCT00041171|stage IV squamous cell carcinoma of the lip and oral cavity
1487327|NCT00041171|stage IV basal cell carcinoma of the lip
1487328|NCT00041171|stage IV verrucous carcinoma of the oral cavity
1487329|NCT00041171|stage IV mucoepidermoid carcinoma of the oral cavity
1487330|NCT00041171|stage IV adenoid cystic carcinoma of the oral cavity
1487331|NCT00041171|recurrent squamous cell carcinoma of the lip and oral cavity
1487332|NCT00041171|recurrent basal cell carcinoma of the lip
1487333|NCT00041171|recurrent verrucous carcinoma of the oral cavity
1487334|NCT00041171|recurrent mucoepidermoid carcinoma of the oral cavity
1487335|NCT00041171|recurrent adenoid cystic carcinoma of the oral cavity
1487336|NCT00041171|stage III squamous cell carcinoma of the oropharynx
1487337|NCT00041171|stage III lymphoepithelioma of the oropharynx
1487338|NCT00041171|stage IV squamous cell carcinoma of the oropharynx
1487339|NCT00041171|stage IV lymphoepithelioma of the oropharynx
1487340|NCT00041171|recurrent squamous cell carcinoma of the oropharynx
1487341|NCT00041171|recurrent lymphoepithelioma of the oropharynx
1487342|NCT00041171|stage III squamous cell carcinoma of the nasopharynx
1487343|NCT00041171|stage III lymphoepithelioma of the nasopharynx
1487344|NCT00041171|stage IV squamous cell carcinoma of the nasopharynx
1487345|NCT00041171|stage IV lymphoepithelioma of the nasopharynx
1487346|NCT00041171|recurrent squamous cell carcinoma of the nasopharynx
1487347|NCT00041171|recurrent lymphoepithelioma of the nasopharynx
1487348|NCT00041171|stage III squamous cell carcinoma of the hypopharynx
1487349|NCT00041171|stage IV squamous cell carcinoma of the hypopharynx
1487350|NCT00041171|recurrent squamous cell carcinoma of the hypopharynx
1487351|NCT00041171|stage III squamous cell carcinoma of the larynx
1487352|NCT00041171|stage III verrucous carcinoma of the larynx
1487353|NCT00041171|stage IV squamous cell carcinoma of the larynx
1487354|NCT00041171|stage IV verrucous carcinoma of the larynx
1487355|NCT00041171|recurrent squamous cell carcinoma of the larynx
1487356|NCT00041171|recurrent verrucous carcinoma of the larynx
1487357|NCT00041171|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1487358|NCT00041171|stage III inverting papilloma of the paranasal sinus and nasal cavity
1487359|NCT00041171|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1487360|NCT00041171|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1487361|NCT00041171|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1487362|NCT00041171|stage IV inverting papilloma of the paranasal sinus and nasal cavity
1487363|NCT00041171|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1487364|NCT00041171|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1487365|NCT00041171|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1487366|NCT00041171|recurrent inverting papilloma of the paranasal sinus and nasal cavity
1487367|NCT00041171|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1487368|NCT00041171|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1487369|NCT00041171|recurrent salivary gland cancer
1487370|NCT00041171|stage III salivary gland cancer
1487371|NCT00041171|stage IV salivary gland cancer
1487372|NCT00041132|stage III mantle cell lymphoma
1487373|NCT00041132|stage IV mantle cell lymphoma
1487374|NCT00041132|contiguous stage II mantle cell lymphoma
1487375|NCT00041132|noncontiguous stage II mantle cell lymphoma
1487376|NCT00041119|stage IB breast cancer
1487377|NCT00041119|stage II breast cancer
1487378|NCT00041067|stage IV breast cancer
1487379|NCT00041067|recurrent breast cancer
1487380|NCT00041054|extensive stage small cell lung cancer
1487381|NCT00041028|stage I non-small cell lung cancer
1487382|NCT00041028|stage II non-small cell lung cancer
1487383|NCT00041028|stage IIIA non-small cell lung cancer
1487384|NCT00041028|stage IIIB non-small cell lung cancer
1487385|NCT00041015|extensive stage small cell lung cancer
1487386|NCT00041015|recurrent small cell lung cancer
1487387|NCT00040950|recurrent grade 1 follicular lymphoma
1487388|NCT00040950|recurrent grade 2 follicular lymphoma
1487389|NCT00040950|recurrent grade 3 follicular lymphoma
1487390|NCT00040950|recurrent adult diffuse small cleaved cell lymphoma
1487391|NCT00040950|recurrent adult diffuse mixed cell lymphoma
1487392|NCT00040950|recurrent adult diffuse large cell lymphoma
1487393|NCT00040950|recurrent adult immunoblastic large cell lymphoma
1487394|NCT00040950|recurrent adult lymphoblastic lymphoma
1487395|NCT00040950|recurrent adult Burkitt lymphoma
1487396|NCT00040950|recurrent mantle cell lymphoma
1487397|NCT00040950|recurrent marginal zone lymphoma
1487398|NCT00040950|recurrent small lymphocytic lymphoma
1487399|NCT00040950|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1487400|NCT00040950|nodal marginal zone B-cell lymphoma
1487401|NCT00040950|splenic marginal zone lymphoma
1487402|NCT00040937|stage I multiple myeloma
1487403|NCT00040937|stage II multiple myeloma
1487404|NCT00040937|stage III multiple myeloma
1487405|NCT00040911|nausea and vomiting
1487406|NCT00040911|localized osteosarcoma
1487407|NCT00040911|metastatic osteosarcoma
1487408|NCT00040911|nonmetastatic childhood soft tissue sarcoma
1487409|NCT00040911|metastatic childhood soft tissue sarcoma
1487410|NCT00040911|previously untreated childhood rhabdomyosarcoma
1487411|NCT00040911|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1487412|NCT00040911|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1487413|NCT00040911|childhood teratoma
1487414|NCT00040911|childhood extragonadal germ cell tumor
1487415|NCT00040911|childhood malignant testicular germ cell tumor
1487416|NCT00040911|childhood malignant ovarian germ cell tumor
1487417|NCT00040911|childhood central nervous system germ cell tumor
1487418|NCT00040911|localized resectable neuroblastoma
1487419|NCT00040911|localized unresectable neuroblastoma
1487420|NCT00040911|disseminated neuroblastoma
1487421|NCT00040911|regional neuroblastoma
1487422|NCT00040911|stage 4S neuroblastoma
1487423|NCT00040911|stage I lymphoepithelioma of the nasopharynx
1487424|NCT00040911|stage I squamous cell carcinoma of the nasopharynx
1487425|NCT00040911|stage II lymphoepithelioma of the nasopharynx
1487426|NCT00040911|stage II squamous cell carcinoma of the nasopharynx
1487427|NCT00040911|stage III lymphoepithelioma of the nasopharynx
1487428|NCT00040911|stage III squamous cell carcinoma of the nasopharynx
1487429|NCT00040911|stage IV lymphoepithelioma of the nasopharynx
1487430|NCT00040911|stage IV squamous cell carcinoma of the nasopharynx
1487431|NCT00040911|stage I adult Hodgkin lymphoma
1487432|NCT00040911|stage I childhood Hodgkin lymphoma
1487433|NCT00040911|stage II adult Hodgkin lymphoma
1487434|NCT00040911|stage II childhood Hodgkin lymphoma
1487435|NCT00040911|stage III adult Hodgkin lymphoma
1487436|NCT00040911|stage III childhood Hodgkin lymphoma
1487437|NCT00040911|stage IV adult Hodgkin lymphoma
1487438|NCT00040911|stage IV childhood Hodgkin lymphoma
1487439|NCT00040898|localized unresectable adult primary liver cancer
1487440|NCT00040898|advanced adult primary liver cancer
1487441|NCT00040898|recurrent adult primary liver cancer
1487442|NCT00040898|adult primary hepatocellular carcinoma
1487443|NCT00040885|recurrent non-small cell lung cancer
1487444|NCT00040885|stage IIIA non-small cell lung cancer
1487445|NCT00040885|stage IIIB non-small cell lung cancer
1487446|NCT00040885|stage IV non-small cell lung cancer
1487447|NCT00040885|fatigue
1487448|NCT00040885|anorexia
1487449|NCT00040885|cachexia
1487450|NCT00040872|regional neuroblastoma
1487451|NCT00040872|disseminated neuroblastoma
1487452|NCT00040872|recurrent neuroblastoma
1487453|NCT00040872|localized unresectable neuroblastoma
1487454|NCT00040859|stage IV gastric cancer
1487455|NCT00040859|recurrent gastric cancer
1487456|NCT00040859|stage III esophageal cancer
1487457|NCT00040859|stage IV esophageal cancer
1487458|NCT00040859|recurrent esophageal cancer
1487459|NCT00040859|adenocarcinoma of the stomach
1487460|NCT00040859|adenocarcinoma of the esophagus
1487461|NCT00040833|stage III pancreatic cancer
1487462|NCT00040833|recurrent pancreatic cancer
1487463|NCT00040833|pain
1487464|NCT00040833|stage IV pancreatic cancer
1487465|NCT00040820|stage III colon cancer
1487466|NCT00040820|stage IV colon cancer
1487467|NCT00040820|stage III rectal cancer
1487468|NCT00040820|stage IV rectal cancer
1487469|NCT00040820|recurrent colon cancer
1487470|NCT00040820|recurrent rectal cancer
1487471|NCT00040820|adenocarcinoma of the colon
1487472|NCT00040820|adenocarcinoma of the rectum
1487473|NCT00040807|recurrent metastatic squamous neck cancer with occult primary
1487474|NCT00040807|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1487475|NCT00040807|stage IV squamous cell carcinoma of the lip and oral cavity
1487476|NCT00040807|recurrent squamous cell carcinoma of the lip and oral cavity
1487477|NCT00040807|stage IV squamous cell carcinoma of the oropharynx
1487478|NCT00040807|recurrent squamous cell carcinoma of the oropharynx
1487479|NCT00040807|stage IV squamous cell carcinoma of the nasopharynx
1487480|NCT00040807|recurrent squamous cell carcinoma of the nasopharynx
1487481|NCT00040807|stage IV squamous cell carcinoma of the hypopharynx
1487482|NCT00040807|recurrent squamous cell carcinoma of the hypopharynx
1487483|NCT00040807|stage IV squamous cell carcinoma of the larynx
1487484|NCT00040807|recurrent squamous cell carcinoma of the larynx
1487485|NCT00040807|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1487486|NCT00040807|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1487487|NCT00040807|recurrent salivary gland cancer
1487488|NCT00040807|salivary gland squamous cell carcinoma
1487489|NCT00040807|stage IV salivary gland cancer
1487490|NCT00040742|nausea
1487491|NCT00040742|vomiting
1487492|NCT00040729|unspecified adult solid tumor, protocol specific
1487493|NCT00040690|untreated adult acute lymphoblastic leukemia
1487494|NCT00040690|L3 adult acute lymphoblastic leukemia
1487495|NCT00040690|stage I adult Burkitt lymphoma
1487496|NCT00040690|stage III adult Burkitt lymphoma
1487497|NCT00040690|stage IV adult Burkitt lymphoma
1487498|NCT00040690|contiguous stage II adult Burkitt lymphoma
1487499|NCT00040690|noncontiguous stage II adult Burkitt lymphoma
1487500|NCT00040677|sickle cell anemia
1487501|NCT00040677|sickle cell disease
1487502|NCT00040677|anemia
1487503|NCT00040677|ICA-17043
1487504|NCT00040677|senicapoc
1487505|NCT00040664|pediatrics
1487506|NCT00040664|HIV
1487507|NCT00040664|protease inhibitors
1487508|NCT00040664|ritonavir
1487509|NCT00040664|fosamprenavir
1487510|NCT00040664|LEXIVA
1487511|NCT00040664|AGENERASE
1487512|NCT00040664|amprenavir
1487513|NCT00040651|Systemic Sclerosis
1487514|NCT00040651|Chemotherapy
1487515|NCT00040651|Cyclophosphamide
1487516|NCT00040651|Fludarabine
1487517|NCT00040651|Leukapheresis
1487518|NCT00040651|Mesna
1487519|NCT00040651|Stem Cell
1487520|NCT00040651|T-Cell
1487521|NCT00040651|Thymoglobulin
1487522|NCT00040651|Scleroderma
1487523|NCT00040599|Colon Cancer
1487524|NCT00040599|Rectal Cancer
1487525|NCT00040599|Colorectal Neoplasms
1487526|NCT00040599|Colorectal Carcinoma
1487527|NCT00040599|Colorectal Tumor
1487528|NCT00040586|hormone-refractory
1487529|NCT00040573|Brain neoplasm
1487530|NCT00040573|Clinical trial, phase I/II
1487531|NCT00040300|treatment experienced
1487532|NCT00040300|HIV
1487533|NCT00040300|Phase I
1487534|NCT00040300|Combination Therapy
1487535|NCT00040287|smoking
1487536|NCT00040287|obesity
1487537|NCT00040287|weight loss
1487538|NCT00040287|smoking cessation
1487539|NCT00040287|weight control
1487540|NCT00040274|HIV
1487541|NCT00040274|Phase I
1487542|NCT00040261|Antiglutamatergic
1487543|NCT00040261|Neuroprotective
1487544|NCT00040261|Unipolar Depression
1487545|NCT00040261|Treatment
1487546|NCT00040261|Antidepressant
1487547|NCT00040261|Depression
1487548|NCT00040261|Glutamate
1487549|NCT00040261|Memantine
1487550|NCT00040261|Pathophysiology
1487551|NCT00040261|Positron Emission Tomography
1487552|NCT00040261|Major Depression
1487553|NCT00040248|Relapse
1487554|NCT00040248|Monoclonal Antibody
1487555|NCT00040248|Biologic Agent
1487556|NCT00040248|Anti-CD25
1487557|NCT00040248|Activated Lymphocyte
1487558|NCT00040248|Wegener Granulomatosis
1487559|NCT00040248|Wegener's Granulomatosis
1487560|NCT00040248|WG
1487561|NCT00040235|Leukapheresis
1487562|NCT00040235|Hypomagnesemia
1487563|NCT00040235|Plateletpheresis
1487564|NCT00040235|Hypocalcemia
1487565|NCT00040235|Citrate
1487566|NCT00040235|Healthy Volunteer
1487567|NCT00040235|HV
1487568|NCT00040235|Normal Control
1487569|NCT00040222|Counseling/behavioral/psychosocial
1487570|NCT00040222|Gene discovery
1487571|NCT00040222|Cancer prevention
1487572|NCT00040222|Risk-reduction
1487573|NCT00040222|Hereditary
1487574|NCT00040222|Breast Cancer
1487575|NCT00040222|Ovarian Cancer
1487576|NCT00040222|Cowden Syndrome
1487577|NCT00040222|Peutz-Jegher Syndrome
1487578|NCT00040222|Li-Fraumeni Syndrome
1487579|NCT00040209|JP 1730
1487580|NCT00040209|Dyskinesias
1487581|NCT00040209|Levodopa Infusion
1487582|NCT00040209|Apomorphine Infusion
1487583|NCT00040209|Clinical Trial
1487584|NCT00040209|Parkinson Disease
1487585|NCT00040209|PD
1487586|NCT00040196|Parkinson's Disease
1487587|NCT00040196|Levodopa
1487588|NCT00040196|Perfusion fMRI
1487589|NCT00040196|Aging
1487590|NCT00040196|Motor Control
1487591|NCT00040196|PD
1487592|NCT00040196|Healthy Volunteer
1487593|NCT00040196|HV
1487594|NCT00040196|Normal Control
1487595|NCT00040183|Tarceva, EGFR, erlotinib, OSI-774
1487596|NCT00040170|Adenocarcinoma of the prostate
1487597|NCT00040157|treatment experienced,
1487598|NCT00040157|Stable triple anti-retroviral combination therapy in HIV-infected,
1487599|NCT00040157|Achillion
1487600|NCT00040144|E-Antigen positive,
1487601|NCT00040144|Lamivudine-Resistant Chronic Hepatitis B,
1487602|NCT00040144|Achillion
1487603|NCT00040105|Chronic Myelogenous Leukemia, Chronic Phase
1487604|NCT00040105|R115777
1487605|NCT00040105|Zarnestra
1487606|NCT00040105|Tipifarnib
1487607|NCT00040105|Imatinib Mesylate
1487608|NCT00040105|Gleevec
1487609|NCT00040105|Imatinib
1487610|NCT00040105|STI571
1487611|NCT00040105|NSC-716051
1487612|NCT00040092|Virulizin
1487613|NCT00040092|Immunotherapy
1487614|NCT00040092|Pancreas
1487615|NCT00040092|Pancreatic Cancer
1487616|NCT00040092|clinical trial
1487617|NCT00040053|amphetamine dependence
1487618|NCT00040027|hepatitis C
1487619|NCT00040027|hepatitis C, chronic
1487620|NCT00039988|Treatment Outcome
1487621|NCT00039988|Multiple Sclerosis
1487622|NCT00039988|Albuterol
1487623|NCT00039988|Copolymer 1
1487624|NCT00039975|Drug Interactions
1487625|NCT00039975|HIV Protease Inhibitors
1487626|NCT00039975|Ritonavir
1487627|NCT00039975|Indinavir
1487628|NCT00039975|Calcium Channel Blockers
1487629|NCT00039975|Pharmacokinetics
1487630|NCT00039975|Diltiazem
1487631|NCT00039975|Amlodipine
1487632|NCT00039962|hepatitis C
1487633|NCT00039962|hepatitis C, chronic
1487634|NCT00039962|cirrhosis, liver
1487635|NCT00039936|Binge Eating
1487636|NCT00039936|Obesity
1487637|NCT00039936|Cognitive
1487638|NCT00039936|Behavior
1487639|NCT00039923|Hemolysis
1487640|NCT00039923|CD55
1487641|NCT00039923|CD59
1487642|NCT00039923|Transfusion
1487643|NCT00039923|Paroxysmal Nocturnal Hemoglobinuria
1487644|NCT00039923|PNH
1487645|NCT00039741|Drug Therapy, Combination
1487646|NCT00039741|HIV Protease Inhibitors
1487647|NCT00039741|Reverse Transcriptase Inhibitors
1487648|NCT00039741|Viral Load
1487649|NCT00039741|Treatment Naive
1487650|NCT00039715|Glucocorticoid Receptor
1487651|NCT00039715|Traumatic Reminders
1487652|NCT00039715|Stress
1487653|NCT00039715|Hippocampus
1487654|NCT00039715|Flashbacks
1487655|NCT00039715|PTSD
1487656|NCT00039715|Type II GR Receptor
1487657|NCT00039715|Hydrocortisone
1487658|NCT00039715|Memory
1487659|NCT00039715|Major Depression
1487660|NCT00039715|Post-Traumatic Stress Disorder
1487661|NCT00039715|Healthy Volunteer
1487662|NCT00039715|HV
1487663|NCT00039715|Normal Control
1487664|NCT00039702|Nicotinic Acetylcholine Receptors
1487665|NCT00039702|Alzheimer's Disease
1487666|NCT00039702|SPECT
1487667|NCT00039702|AD
1487668|NCT00039702|Healthy Volunteer
1487669|NCT00039702|HV
1487670|NCT00039702|Normal Control
1487671|NCT00039689|Primary HIV Infection
1487672|NCT00039689|Chronic HIV Infection
1487673|NCT00039689|Antiretroviral Therapy
1487674|NCT00039689|Innate Immunity
1487675|NCT00039689|B Cell
1487676|NCT00039689|HIV Infection
1487677|NCT00039689|Acute Infection
1487678|NCT00039689|Treatment Naive
1487685|NCT00039663|Hyperlipidemia
1487686|NCT00039663|Insulin Resistance
1487687|NCT00039663|Coronary Artery Disease
1487688|NCT00039663|Lipodystrophy
1487689|NCT00039663|Antiretroviral Therapy
1487690|NCT00039663|HIV Infection
1487691|NCT00039663|Treatment Experienced
1487692|NCT00039650|Granulocyte Colony-Stimulating Factor
1487693|NCT00039650|T Cells
1487694|NCT00039650|Peripheral Blood Stem Cells
1487695|NCT00039650|Apheresis
1487696|NCT00039650|Hematopoietic Progenitor Cell Transplantation
1487697|NCT00039650|Healthy Volunteer
1487698|NCT00039650|HV
1487699|NCT00039650|Normal Control
1487700|NCT00039624|Radiation Therapy
1487701|NCT00039624|Prostate
1487702|NCT00039624|MRI
1487703|NCT00039624|Brachytherapy
1487704|NCT00039624|Phase II
1487705|NCT00039624|Prostate Cancer
1487706|NCT00039611|stage III colon cancer
1487707|NCT00039611|stage IV colon cancer
1487708|NCT00039611|stage III rectal cancer
1487709|NCT00039611|stage IV rectal cancer
1487710|NCT00039611|recurrent colon cancer
1487711|NCT00039611|recurrent rectal cancer
1487712|NCT00039585|recurrent ovarian epithelial cancer
1487713|NCT00039585|fallopian tube cancer
1487714|NCT00039585|primary peritoneal cavity cancer
1487715|NCT00039585|borderline ovarian surface epithelial-stromal tumor
1487716|NCT00039572|adult glioblastoma
1487717|NCT00039572|stage IV melanoma
1487718|NCT00039572|tumors metastatic to brain
1487719|NCT00039572|adult giant cell glioblastoma
1487720|NCT00039572|adult gliosarcoma
1487721|NCT00039559|ovarian epithelial cancer
1487722|NCT00039546|stage I breast cancer
1487723|NCT00039546|stage II breast cancer
1487724|NCT00039520|stage IV breast cancer
1487725|NCT00039520|recurrent breast cancer
1487726|NCT00039507|stage I non-small cell lung cancer
1487727|NCT00039507|stage II non-small cell lung cancer
1487728|NCT00039468|adult glioblastoma
1487729|NCT00039468|recurrent adult brain tumor
1487730|NCT00039468|adult giant cell glioblastoma
1487731|NCT00039468|adult gliosarcoma
1487732|NCT00039429|stage IV renal cell cancer
1487733|NCT00039429|recurrent renal cell cancer
1487734|NCT00039364|recurrent adult brain tumor
1487735|NCT00039364|adult glioblastoma
1487736|NCT00039364|adult anaplastic astrocytoma
1487737|NCT00039364|adult anaplastic oligodendroglioma
1487738|NCT00039364|adult mixed glioma
1487739|NCT00039364|adult pilocytic astrocytoma
1487740|NCT00039364|adult subependymoma
1487741|NCT00039364|adult giant cell glioblastoma
1487742|NCT00039364|adult gliosarcoma
1487743|NCT00039364|adult diffuse astrocytoma
1487744|NCT00039351|stage I adult diffuse large cell lymphoma
1487745|NCT00039351|stage III adult diffuse large cell lymphoma
1487746|NCT00039351|stage IV adult diffuse large cell lymphoma
1487747|NCT00039351|contiguous stage II adult diffuse large cell lymphoma
1487748|NCT00039351|noncontiguous stage II adult diffuse large cell lymphoma
1487749|NCT00039351|angioimmunoblastic T-cell lymphoma
1487750|NCT00039338|stage IB cervical cancer
1487751|NCT00039338|stage IIB cervical cancer
1487752|NCT00039338|stage IIA cervical cancer
1487753|NCT00039338|cervical squamous cell carcinoma
1487754|NCT00039338|cervical adenocarcinoma
1487755|NCT00039338|cervical adenosquamous cell carcinoma
1487756|NCT00039325|stage IV melanoma
1487757|NCT00039325|recurrent melanoma
1487758|NCT00039312|cervical cancer
1487759|NCT00039299|adenocarcinoma of the prostate
1487760|NCT00039299|recurrent prostate cancer
1487761|NCT00039286|stage II breast cancer
1487762|NCT00039286|stage IIIA breast cancer
1487763|NCT00039286|recurrent breast cancer
1487764|NCT00039273|stage IV colon cancer
1487765|NCT00039273|stage IV rectal cancer
1487766|NCT00039273|recurrent colon cancer
1487767|NCT00039273|recurrent rectal cancer
1487768|NCT00039234|stage IV melanoma
1487769|NCT00039234|recurrent melanoma
1487770|NCT00039234|liver metastases
1487771|NCT00039208|stage III colon cancer
1487772|NCT00039208|stage IV colon cancer
1487773|NCT00039208|stage III rectal cancer
1487774|NCT00039208|stage IV rectal cancer
1487775|NCT00039208|recurrent colon cancer
1487776|NCT00039208|recurrent rectal cancer
1487777|NCT00039195|stage I adult diffuse large cell lymphoma
1487778|NCT00039195|stage III adult diffuse large cell lymphoma
1487779|NCT00039195|stage IV adult diffuse large cell lymphoma
1487780|NCT00039195|contiguous stage II adult diffuse large cell lymphoma
1487781|NCT00039195|noncontiguous stage II adult diffuse large cell lymphoma
1487782|NCT00039169|stage III renal cell cancer
1487783|NCT00039169|stage IV renal cell cancer
1487784|NCT00039169|recurrent renal cell cancer
1487785|NCT00039156|recurrent grade 3 follicular lymphoma
1487786|NCT00039156|recurrent adult diffuse mixed cell lymphoma
1487787|NCT00039156|recurrent adult diffuse large cell lymphoma
1487788|NCT00039156|recurrent adult immunoblastic large cell lymphoma
1487789|NCT00039156|recurrent adult lymphoblastic lymphoma
1487790|NCT00039156|recurrent adult Burkitt lymphoma
1487791|NCT00039156|recurrent mantle cell lymphoma
1487792|NCT00039130|untreated adult acute lymphoblastic leukemia
1487793|NCT00039130|L3 adult acute lymphoblastic leukemia
1487794|NCT00039130|stage I adult Burkitt lymphoma
1487795|NCT00039130|stage III adult Burkitt lymphoma
1487796|NCT00039130|stage IV adult Burkitt lymphoma
1487797|NCT00039130|contiguous stage II adult Burkitt lymphoma
1487798|NCT00039130|noncontiguous stage II adult Burkitt lymphoma
1487799|NCT00039078|localized unresectable adult primary liver cancer
1487800|NCT00039078|recurrent adult primary liver cancer
1487801|NCT00039078|adult primary hepatocellular carcinoma
1487802|NCT00039052|stage IV breast cancer
1487803|NCT00039052|recurrent breast cancer
1487804|NCT00039052|recurrent non-small cell lung cancer
1487805|NCT00039052|stage IV renal cell cancer
1487806|NCT00039052|recurrent renal cell cancer
1487807|NCT00039052|stage IV non-small cell lung cancer
1487808|NCT00039052|male breast cancer
1487809|NCT00039039|recurrent non-small cell lung cancer
1487810|NCT00039039|stage IIIA non-small cell lung cancer
1487811|NCT00039039|stage IIIB non-small cell lung cancer
1487812|NCT00039026|Type 2 Diabetes Mellitis
1487813|NCT00039000|Immunotherapy, Cancer, Melanoma, Skin Cancer, tumor
1487814|NCT00038987|Smallpox
1487815|NCT00038987|APSV
1487816|NCT00038987|Aventis Pasteur Smallpox Vaccine
1487817|NCT00038987|vaccinia-naive
1487818|NCT00038974|Hepatitis C
1487819|NCT00038974|Interferon
1487820|NCT00038974|Ribavirin
1487821|NCT00038974|Efficacy
1487822|NCT00038974|Viral load
1487823|NCT00038974|Genetics
1487824|NCT00038974|Cytokines
1487825|NCT00038974|Immunology
1487826|NCT00038961|fondaparinux sodium
1487827|NCT00038961|DVT Prevention
1487828|NCT00038961|abdominal surgery
1487829|NCT00038961|VTE prevention
1487830|NCT00038961|venous thromboembolism
1487831|NCT00038961|pulmonary embolism
1487832|NCT00038948|Renal
1487833|NCT00038948|Allograft
1487834|NCT00038948|Recipients
1487835|NCT00038935|Hemophilia
1487836|NCT00038922|Left-Sided
1487837|NCT00038922|Ulcerative
1487838|NCT00038922|Colitis
1487839|NCT00038896|Panic
1487840|NCT00038896|Disorder
1487841|NCT00038883|Lymphoid Malignancies
1487842|NCT00038883|Chronic Lymphocytic Leukemia
1487843|NCT00038883|Acute Lymphoblastic Leukemia
1487844|NCT00038883|Low grade Lymphoma
1487845|NCT00038883|B and T cell Lymphoma of the intermediate and high grade
1487846|NCT00038870|AML
1487847|NCT00038870|CML
1487848|NCT00038870|Dendritic Cells
1487849|NCT00038857|Acute Myelogenous Leukemia
1487850|NCT00038857|Acute Lymphocytic Leukemia
1487851|NCT00038857|Myelodysplastic Syndrome
1487852|NCT00038857|Chronic Lymphocytic Leukemia
1487853|NCT00038857|Leukemia
1487854|NCT00038857|Lymphoma
1487855|NCT00038857|Non Hodgkin's Lymphoma
1487856|NCT00038857|T cell depletion
1487857|NCT00038857|CD34 selected progenitors cell
1487858|NCT00038857|GVHD
1487859|NCT00038844|Lymphoma
1487860|NCT00038844|Leukemia
1487861|NCT00038844|Campath-1 H
1487862|NCT00038844|Campath
1487863|NCT00038844|Alemtuzumab
1487864|NCT00038844|Fludarabine
1487865|NCT00038844|Fludarabine Phosphate
1487866|NCT00038844|Fludara
1487867|NCT00038844|Cyclophosphamide
1487868|NCT00038844|Cytoxan
1487869|NCT00038844|Neosar
1487870|NCT00038844|Rituxan
1487871|NCT00038844|Rituximab
1487872|NCT00038831|Acute Myelogenous leukemia
1487873|NCT00038831|AML
1487874|NCT00038831|Myelodysplastic Syndrome
1487875|NCT00038831|MDS
1487876|NCT00038831|Chronic Lymphocytic Leukemia
1487877|NCT00038831|CML
1487878|NCT00038831|Mylotarg
1487879|NCT00038831|Gemtuzumab
1487880|NCT00038831|Gemtuzumab ozogamicin
1487881|NCT00038831|Melphalan
1487882|NCT00038831|Alkeran
1487883|NCT00038831|Fludarabine Phosphate
1487884|NCT00038831|Fludarabine
1487885|NCT00038831|Fludara
1487886|NCT00038831|Anti-thymocyte globulin
1487887|NCT00038831|ATG
1487888|NCT00038831|Allogeneic Bone Marrow
1487889|NCT00038831|Peripheral Blood Stem Cell Transplantation
1487890|NCT00038831|Allo PBSCT
1487891|NCT00038831|Allogeneic transplantation
1487892|NCT00038818|CML
1487893|NCT00038818|MM
1487894|NCT00038818|NHL
1487895|NCT00038818|HD
1487896|NCT00038818|CLL
1487897|NCT00038818|CD8 Depleted
1487898|NCT00038818|Donor Lymphocyte
1487899|NCT00038805|High Risk Acute Myeloid Leukemia
1487900|NCT00038805|Acute Lymphocytic Leukemia
1487901|NCT00038805|Chronic Myeloid Leukemia
1487902|NCT00038805|Myelodysplastic Syndrome
1487903|NCT00038805|ALL
1487904|NCT00038805|AML
1487905|NCT00038805|MDS
1487906|NCT00038805|CML
1487907|NCT00038805|CMML
1487908|NCT00038805|Nonmyeloablative Preparative Regimen
1487909|NCT00038805|Mylotarg
1487910|NCT00038805|CMA-676
1487911|NCT00038792|Acute Graft Versus Host Disease
1487912|NCT00038792|Refractory
1487913|NCT00038779|Lymphoma
1487914|NCT00038779|CML
1487915|NCT00038779|CLL
1487916|NCT00038779|AML
1487917|NCT00038779|ALL
1487918|NCT00038779|MDS
1487919|NCT00038779|AA
1487920|NCT00038766|Inflammatory Bowel Disease
1487921|NCT00038753|vision screening
1487922|NCT00038727|DPP
1487923|NCT00038727|IGT
1487924|NCT00038727|Prediabetes
1487925|NCT00038727|Type 2 diabetes
1487926|NCT00038727|Macrovascular disease
1487927|NCT00038727|Microvascular disease
1487928|NCT00038714|HPV
1487929|NCT00038714|Papilloma
1487930|NCT00038701|Metastatic Pancreas Cancer
1487931|NCT00038688|Health Education
1487932|NCT00038688|Substance Abuse, Intravenous
1487933|NCT00038688|Program Evaluation
1487934|NCT00038688|Peer Group
1487935|NCT00038688|Risk-Taking
1487936|NCT00038688|HIV Seronegativity
1487937|NCT00038688|Substance-related Disorders
1487938|NCT00038675|Leukemia
1487939|NCT00038675|Chronic Myelomonocytic Leukemia
1487940|NCT00038675|Chronic Myeloid Leukemia
1487941|NCT00038675|Polycythemia Vera
1487942|NCT00038675|Hypereosinophilic Syndrome
1487943|NCT00038675|Mastocytosis
1487944|NCT00038675|Imatinib Mesylate
1487945|NCT00038675|Gleevec
1487946|NCT00038649|Philadelphia chromosome positive
1487947|NCT00038649|early chronic phase (diagnosis < 12 months)
1487948|NCT00038649|Chronic Myelogenous Leukemia, Chronic Phase
1487949|NCT00038649|Chronic Myelogenous Leukemia
1487950|NCT00038649|CML
1487951|NCT00038649|Gleevec
1487952|NCT00038649|STI571
1487953|NCT00038636|HIV
1487954|NCT00038623|Relapsed/Refractory Mantle Cell Lymphoma
1487955|NCT00038623|Yttrium-Ibritumomab
1487956|NCT00038623|Zevalin
1487957|NCT00038610|Leukemia
1487958|NCT00038610|Lymphoblastic
1487959|NCT00038610|Acute
1487960|NCT00038610|Philadelphia-Positive
1487961|NCT00038610|Imatinib Mesylate
1487962|NCT00038610|Gleevec
1487963|NCT00038610|Glivec
1487964|NCT00038610|Imatinib
1487965|NCT00038610|STI571
1487966|NCT00038610|STI-571
1487967|NCT00038610|CGP-57148B
1487968|NCT00038610|NSC-716051
1487969|NCT00038610|Cyclophosphamide
1487970|NCT00038610|Cytoxan®,
1487971|NCT00038610|Neosar®
1487972|NCT00038610|Doxorubicin
1487973|NCT00038610|Adriamycin ®
1487974|NCT00038610|Rubex ®
1487975|NCT00038610|Adriamycin PFS
1487976|NCT00038610|Adriamycin RDF
1487977|NCT00038610|Vincristine
1487978|NCT00038610|Dexamethasone
1487979|NCT00038610|Decadron
1487980|NCT00038610|Methotrexate
1487981|NCT00038610|Cytarabine
1487982|NCT00038610|Ara-C
1487983|NCT00038610|Cytosar
1487984|NCT00038610|DepoCyt
1487985|NCT00038610|Cytosine Arabinosine Hydrochloride
1487986|NCT00038610|Mesna
1487987|NCT00038610|Mesnex
1487988|NCT00038610|G-CSF
1487989|NCT00038610|Filgrastim
1487990|NCT00038610|Neupogen
1487991|NCT00038597|Philadelphia chromosome positive CML
1487992|NCT00038597|Myelogenous Leukemia, Chronic, Chronic Phase
1487993|NCT00038597|Myelogenous Leukemia, Chronic, Accelerated Phase
1487994|NCT00038571|Cancer
1487995|NCT00038571|Relapsed
1487996|NCT00038571|Refractory
1487997|NCT00038571|B cell lymphoma
1487998|NCT00038571|Proteasome Inhibitor
1487999|NCT00038571|PS-341
1488000|NCT00038558|Hodgkin's lymphoma
1488001|NCT00038558|Dacarbazine
1488002|NCT00038558|DTIC
1488003|NCT00038558|DTIC-Dome
1488004|NCT00038558|Vinblastine
1488005|NCT00038558|Velban
1488006|NCT00038558|Bleomycin sulfate
1488007|NCT00038558|Blenoxane
1488008|NCT00038558|BLM
1488009|NCT00038558|Doxorubicin Hydrochloride
1488010|NCT00038558|Adriamycin
1488011|NCT00038558|Filgrastim
1488012|NCT00038558|G-CSF
1488013|NCT00038558|Neupogen
1488014|NCT00038558|Pegfilgrastim
1488015|NCT00038558|granulocyte colony-stimulating factor
1488016|NCT00038545|LYMPHOMA
1488017|NCT00038545|NON-HODGKINS
1488018|NCT00038545|AGGRESSIVE
1488019|NCT00038545|RELAPSED AND REFRACTORY
1488020|NCT00038532|treatment experienced
1488021|NCT00038532|HIV
1488022|NCT00038519|treatment experienced
1488023|NCT00038519|HIV
1488024|NCT00038506|HIV-1 TRIZIVIR Tenofovir
1488025|NCT00038493|GBM
1488026|NCT00038493|Glioma
1488027|NCT00038493|Brain Tumor
1488028|NCT00038480|Lopinavir
1488029|NCT00038480|HIV-1
1488030|NCT00038480|Drug Therapy, Combination
1488031|NCT00038480|HIV Protease Inhibitors
1488032|NCT00038480|Ritonavir
1488033|NCT00038480|Reverse Transcriptase Inhibitors
1488034|NCT00038454|Oxygen Therapeutics
1488035|NCT00038454|CABG
1488036|NCT00038454|Transfusion
1488037|NCT00038441|Malignant Glioma
1488038|NCT00038415|Chronic Lymphocytic Leukemia
1488039|NCT00038415|CLL
1488040|NCT00038415|Binet Stage A
1488041|NCT00038415|Vaccination
1488042|NCT00038415|Idiotypic
1488043|NCT00038415|Genetic
1488044|NCT00038415|Deoxyribonucleic acid
1488045|NCT00038415|DNA
1488046|NCT00038402|Breast Cancer
1488047|NCT00038402|Non-Inflammatory Breast Cancer
1488048|NCT00038402|Operable Breast Cancer
1488049|NCT00038402|Herceptin
1488050|NCT00038402|Taxol
1488051|NCT00038402|FEC
1488052|NCT00038402|Fluorouracil
1488053|NCT00038402|Cyclophosphamide
1488054|NCT00038402|Epirubicin
1488055|NCT00038402|Trastuzumab
1488056|NCT00038402|Paclitaxel
1488057|NCT00038402|Neosar
1488058|NCT00038389|Brain Stem Tumor
1488059|NCT00038376|T-cell lymphoma
1488060|NCT00038376|accutane
1488061|NCT00038376|isotretinoin
1488062|NCT00038376|mycosis fungoides
1488063|NCT00038376|T-cell malignancies
1488064|NCT00038363|Frail
1488065|NCT00038363|Disable
1488066|NCT00038363|Disabled Persons
1488067|NCT00038363|Physically disabled
1488068|NCT00038363|Elderly
1488069|NCT00038363|Rehabilitation
1488070|NCT00038363|Subacute care
1488071|NCT00038350|Age
1488072|NCT00038350|Dysphagia
1488073|NCT00038350|Swallowing
1488074|NCT00038337|Health Literacy
1488075|NCT00038337|Visual
1488076|NCT00038337|Cognitive
1488077|NCT00038285|Amputation
1488078|NCT00038285|Cardiovascular Disease
1488079|NCT00038285|PVD
1488080|NCT00038272|Placebos
1488081|NCT00038272|Drug Therapy, Combination
1488082|NCT00038272|Anti-HIV Agents
1488083|NCT00038272|Mycophenolate Mofetil
1488084|NCT00038272|2,6-diaminopurine dioxolane
1488085|NCT00038272|Treatment Experienced
1488086|NCT00038272|DAPD
1488087|NCT00038272|MMF
1488088|NCT00038259|Interleukin-2
1488089|NCT00038259|Drug Administration Schedule
1488090|NCT00038259|CD4 Lymphocyte Count
1488091|NCT00038259|Anti-HIV Agents
1488092|NCT00038259|Viral Load
1488093|NCT00038259|Treatment Interruption
1488094|NCT00038259|Treatment Experienced
1488095|NCT00038259|STI
1488096|NCT00038246|Prostate Cancer
1488097|NCT00038233|myeloma
1488098|NCT00038220|HIV
1488099|NCT00038207|soft tissue sarcoma
1488100|NCT00038207|Bone sarcomas
1488101|NCT00038194|Prostate Cancer
1488102|NCT00038194|bone metastasis
1488103|NCT00038181|Prostate Cancer
1488104|NCT00038168|Prostate Cancer
1488105|NCT00038155|Ambulation
1488106|NCT00038155|Difficulties in ambulation
1488107|NCT00038155|Geriatric
1488108|NCT00038155|Rehabilitation
1488109|NCT00038142|Ewing's Sarcoma
1488110|NCT00038142|Vincristine
1488111|NCT00038142|Doxorubicin
1488112|NCT00038142|Adriamycin
1488113|NCT00038142|Rubex
1488114|NCT00038142|Cyclophosphamide
1488115|NCT00038142|Dexrazoxane
1488116|NCT00038142|Zinecard
1488117|NCT00038142|VACdxr
1488118|NCT00038142|ImmTher
1488119|NCT00038116|Parkinson's disease
1488120|NCT00038116|PD
1488121|NCT00038116|dopamine
1488122|NCT00038116|embryonic dopamine cell implant surgery
1488123|NCT00038116|tissue implants
1488124|NCT00038090|Myeloma
1488125|NCT00038090|Thalidomide
1488126|NCT00038090|Thalomid
1488127|NCT00038090|Dexamethasone
1488128|NCT00038090|Decadron
1488129|NCT00038064|anemia of cancer/chemotherapy
1488130|NCT00038064|non-myeloid malignancies
1488131|NCT00038064|Drug Therapy
1488132|NCT00038051|Acute Myeloid Leukemia
1488133|NCT00038051|AML
1488134|NCT00038051|Chronic Myelomonocytic Leukemia
1488135|NCT00038051|CMML
1488136|NCT00038051|Myeloproliferative Disorders
1488137|NCT00038051|Refractory Anemia with Excess of Blasts
1488138|NCT00038051|RAEB-t
1488139|NCT00038051|RAEB
1488140|NCT00038051|Hum-195/rGel
1488141|NCT00038038|Squamous cell carcinoma of head and neck
1488142|NCT00038025|Mycosis Fungoides
1488143|NCT00038025|Lymphoma
1488144|NCT00038025|Chronic lymphocytic leukemia
1488145|NCT00038025|Deoxycoformycin
1488146|NCT00038025|Pentostatin
1488147|NCT00038025|All other lymphomas
1488148|NCT00038025|Nucleoside analogue
1488149|NCT00038025|Adenosine deaminase inhibitor
1488150|NCT00038025|T-cells
1488151|NCT00038012|Dose-intensified carboplatin
1488152|NCT00038012|autologous cryopreserved platelets
1488153|NCT00038012|thrombopoietin
1488154|NCT00038012|Gynecologic malignancy
1488155|NCT00037999|Muscle strength
1488156|NCT00037999|Testosterone
1488157|NCT00037999|Rehabilitation
1488158|NCT00037999|Impaired muscle strength
1488159|NCT00037986|Audiology
1488160|NCT00037986|Hearing
1488161|NCT00037986|Hearing Aids
1488162|NCT00037986|Quality of Life
1488163|NCT00037973|COPD
1488164|NCT00037973|Ventilation
1488165|NCT00037960|Constrained Induced
1488166|NCT00037960|CI therapy
1488167|NCT00037960|CVA
1488168|NCT00037960|Strokes
1488169|NCT00037947|Multiple Sclerosis
1488170|NCT00037947|MS
1488171|NCT00037947|Hearing
1488172|NCT00037934|Robot
1488173|NCT00037934|Stroke
1488174|NCT00037934|Upper Extremity
1488175|NCT00037921|SCI
1488176|NCT00037921|UTI
1488177|NCT00037908|Stroke
1488178|NCT00037908|Hemiparesis
1488179|NCT00037908|Upper limb function
1488180|NCT00037908|Strength training
1488181|NCT00037895|Stroke
1488182|NCT00037895|Ambulation Training
1488183|NCT00037895|Rehabilitation
1488184|NCT00037895|Treadmill
1488185|NCT00037882|Chronic Myelogenous Leukemia
1488186|NCT00037882|Interferon alpha
1488187|NCT00037882|Roferon
1488188|NCT00037882|Intron
1488189|NCT00037882|Chronic Myelogenous Leukemia-Philadelphia positive
1488190|NCT00037869|Metastatic neuroendocrine tumors
1488191|NCT00037843|adrenal diseases
1488192|NCT00037830|Parkinson's disease
1488193|NCT00037830|PD
1488194|NCT00037830|GM1 Ganglioside
1488195|NCT00037830|Sygen
1488196|NCT00037817|Toxicity Evaluation
1488197|NCT00037817|Pharmacokinetics
1488198|NCT00037817|Apoptosis
1488199|NCT00037817|Gene Induction
1488200|NCT00037817|Gene Expression
1488201|NCT00037817|Lung Cancer
1488202|NCT00037817|Small Cell Lung Cancer
1488203|NCT00037817|Non-Small Cell Lung Cancer
1488204|NCT00037817|Pleural Mesothelioma
1488205|NCT00037804|Pharmacia
1488206|NCT00037713|LD Small Cell Lung Cancer
1488207|NCT00037713|BEC2, vaccine
1488208|NCT00037713|adjuvant, monoclonal antibody
1488209|NCT00037713|LD Small Cell Lung Cancer (VA Classification, Zelen, 1973)
1488210|NCT00037687|Severe sepsis
1488211|NCT00037687|Platelet-activating factor acetylhydrolase
1488212|NCT00037674|Bipolar Disorder
1488213|NCT00037674|Bipolar
1488214|NCT00037674|Mania
1488215|NCT00037674|Topiramate
1488216|NCT00037674|Lithium
1488217|NCT00037661|dry eye
1488342|NCT00036959|recurrent Wilms tumor and other childhood kidney tumors
1488218|NCT00037622|E-antigen positive, treatment naïve chronic HBV infected, lamivudine resistant chronic Hepatitis B, Achillion
1488219|NCT00037609|Metastatic breast cancer
1488220|NCT00037583|Acute
1488221|NCT00037583|Myeloid
1488222|NCT00037583|Leukemia
1488223|NCT00037570|Peptic
1488224|NCT00037570|Ulcer
1488225|NCT00037570|Hemorrhage
1488226|NCT00037557|Hemophilia B
1488227|NCT00037544|Severe
1488228|NCT00037544|Hemophilia
1488229|NCT00037544|A
1488230|NCT00037531|Transplant
1488231|NCT00037531|Kidney
1488232|NCT00037518|Severe primary hyperparathyroidism
1488233|NCT00037518|Parathyroid carcinoma
1488234|NCT00037492|stroke
1488235|NCT00037492|recovery
1488236|NCT00037479|neurologic Lyme disease
1488237|NCT00037479|Lyme disease
1488238|NCT00037479|ceftriaxone
1488239|NCT00037479|Rocephin
1488240|NCT00037479|PET scans
1488241|NCT00037479|Lyme encephalopathy
1488242|NCT00037479|neuroborreliosis
1488243|NCT00037479|borreliosis
1488244|NCT00037219|Anidulafungin
1488245|NCT00037219|Candidemia
1488246|NCT00037219|Invasive Candidiasis
1488247|NCT00037206|Invasive Aspergillosis
1488248|NCT00037167|Fall-Prevention
1488249|NCT00037167|Balance
1488250|NCT00037167|Musculoskeletal Systems
1488251|NCT00037167|Protective Devices
1488252|NCT00037167|Gait
1488253|NCT00037167|Equilibrium
1488254|NCT00037167|Accidental Falls
1488255|NCT00037167|Frail Elderly
1488256|NCT00037154|Benign Prostatic Hyperplasia
1488257|NCT00037154|Herbal Therapies
1488258|NCT00037154|Complementary and Alternative Medicine
1488259|NCT00037154|Men's Health
1488260|NCT00037141|Prostate
1488261|NCT00037141|BPH
1488262|NCT00037141|Prostatitis
1488263|NCT00037128|Lupus
1488264|NCT00037128|SLE
1488265|NCT00037128|DHEA
1488266|NCT00037128|GL701
1488267|NCT00037115|Demyelinating
1488268|NCT00037115|Multiple Sclerosis
1488269|NCT00037115|Myelitis
1488270|NCT00037115|Neuritis
1488271|NCT00037115|Optic Neuritis
1488272|NCT00037115|AVONEX
1488273|NCT00037115|methotrexate
1488274|NCT00037115|methylprednisolone
1488275|NCT00037115|interferon beta 1a
1488276|NCT00037115|demyelination
1488277|NCT00037115|central nervous system
1488278|NCT00037115|brain
1488279|NCT00037115|nerve
1488280|NCT00037115|lesions
1488281|NCT00037115|enhancement
1488282|NCT00037115|enhancing
1488283|NCT00037102|Multiple Sclerosis
1488284|NCT00037102|Relapsing
1488285|NCT00037102|Methotrexate
1488286|NCT00037102|AVONEX
1488287|NCT00037102|interferon beta 1a
1488288|NCT00037102|demyelinating
1488289|NCT00037102|autoimmune
1488290|NCT00037076|HIV Seropositivity
1488291|NCT00037076|Hepatitis C
1488292|NCT00037076|Polymerase Chain Reaction
1488293|NCT00037076|RNA, Viral
1488294|NCT00037076|Prevalence
1488295|NCT00037076|Disease Transmission, Vertical
1488296|NCT00037076|Hepacivirus
1488297|NCT00037076|Enzyme Immunoassay
1488298|NCT00037076|GB virus C
1488299|NCT00037063|Pilot Projects
1488300|NCT00037063|Recurrence
1488301|NCT00037063|Antioxidants
1488302|NCT00037063|Reverse Transcriptase Inhibitors
1488303|NCT00037063|Anti-HIV Agents
1488304|NCT00037063|Ascorbic Acid
1488305|NCT00037063|Alpha-Tocopherol
1488306|NCT00037063|Riboflavin
1488307|NCT00037063|Thiamine
1488308|NCT00037063|Lactic Acid
1488309|NCT00037037|stage III melanoma
1488310|NCT00037037|stage IV melanoma
1488311|NCT00037037|recurrent melanoma
1488312|NCT00037024|stage I breast cancer
1488313|NCT00037024|stage II breast cancer
1488314|NCT00037024|stage I prostate cancer
1488315|NCT00037024|stage II B prostate cancer
1488316|NCT00037024|stage II A prostate cancer
1488317|NCT00037024|male breast cancer
1488318|NCT00037024|fatigue
1488319|NCT00037024|malnutrition
1488320|NCT00037024|psychosocial effects of cancer and its treatment
1488321|NCT00037024|depression
1488322|NCT00037011|disseminated neuroblastoma
1488323|NCT00037011|recurrent neuroblastoma
1488324|NCT00036998|stage I breast cancer
1488325|NCT00036998|stage II breast cancer
1488326|NCT00036985|stage IIIA breast cancer
1488327|NCT00036972|recurrent adult brain tumor
1488328|NCT00036972|adult glioblastoma
1488329|NCT00036972|adult anaplastic astrocytoma
1488330|NCT00036972|adult mixed glioma
1488331|NCT00036972|adult giant cell glioblastoma
1488332|NCT00036972|adult gliosarcoma
1488333|NCT00036959|metastatic osteosarcoma
1488334|NCT00036959|childhood infratentorial ependymoma
1488335|NCT00036959|recurrent childhood rhabdomyosarcoma
1488336|NCT00036959|childhood supratentorial ependymoma
1488337|NCT00036959|childhood craniopharyngioma
1488338|NCT00036959|disseminated neuroblastoma
1488339|NCT00036959|recurrent neuroblastoma
1488340|NCT00036959|recurrent childhood liver cancer
1488341|NCT00036959|stage IV childhood liver cancer
1488343|NCT00036959|stage IV Wilms tumor
1488344|NCT00036959|childhood central nervous system germ cell tumor
1488345|NCT00036959|recurrent osteosarcoma
1488346|NCT00036959|unspecified childhood solid tumor, protocol specific
1488347|NCT00036959|childhood germ cell tumor
1488348|NCT00036959|metastatic childhood soft tissue sarcoma
1488349|NCT00036959|recurrent childhood soft tissue sarcoma
1488350|NCT00036959|childhood high-grade cerebral astrocytoma
1488351|NCT00036959|childhood oligodendroglioma
1488352|NCT00036959|childhood choroid plexus tumor
1488353|NCT00036959|childhood grade I meningioma
1488354|NCT00036959|childhood grade II meningioma
1488355|NCT00036959|childhood grade III meningioma
1488356|NCT00036959|recurrent childhood cerebellar astrocytoma
1488357|NCT00036959|recurrent childhood cerebral astrocytoma
1488358|NCT00036959|recurrent childhood medulloblastoma
1488359|NCT00036959|recurrent childhood visual pathway and hypothalamic glioma
1488360|NCT00036959|previously treated childhood rhabdomyosarcoma
1488361|NCT00036959|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1488362|NCT00036959|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1488363|NCT00036959|recurrent childhood ependymoma
1488364|NCT00036959|childhood teratoma
1488365|NCT00036959|childhood malignant testicular germ cell tumor
1488366|NCT00036959|childhood malignant ovarian germ cell tumor
1488367|NCT00036959|childhood extragonadal germ cell tumor
1488368|NCT00036959|recurrent childhood malignant germ cell tumor
1488369|NCT00036946|unspecified adult solid tumor, protocol specific
1488370|NCT00036946|stage IV grade 1 follicular lymphoma
1488371|NCT00036946|stage IV grade 2 follicular lymphoma
1488372|NCT00036946|stage IV grade 3 follicular lymphoma
1488373|NCT00036946|stage IV adult diffuse small cleaved cell lymphoma
1488374|NCT00036946|stage IV adult diffuse mixed cell lymphoma
1488375|NCT00036946|stage IV adult diffuse large cell lymphoma
1488376|NCT00036946|stage IV adult immunoblastic large cell lymphoma
1488377|NCT00036946|stage IV adult lymphoblastic lymphoma
1488378|NCT00036946|stage IV adult Burkitt lymphoma
1488379|NCT00036946|recurrent grade 1 follicular lymphoma
1488380|NCT00036946|recurrent grade 2 follicular lymphoma
1488381|NCT00036946|recurrent grade 3 follicular lymphoma
1488382|NCT00036946|recurrent adult diffuse small cleaved cell lymphoma
1488383|NCT00036946|recurrent adult diffuse mixed cell lymphoma
1488384|NCT00036946|recurrent adult diffuse large cell lymphoma
1488385|NCT00036946|recurrent adult immunoblastic large cell lymphoma
1488386|NCT00036946|recurrent adult lymphoblastic lymphoma
1488387|NCT00036946|recurrent adult Burkitt lymphoma
1488388|NCT00036946|stage IV mantle cell lymphoma
1488389|NCT00036946|recurrent mantle cell lymphoma
1488390|NCT00036946|recurrent marginal zone lymphoma
1488391|NCT00036946|recurrent small lymphocytic lymphoma
1488392|NCT00036946|stage IV small lymphocytic lymphoma
1488393|NCT00036946|stage IV marginal zone lymphoma
1488394|NCT00036946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1488395|NCT00036946|nodal marginal zone B-cell lymphoma
1488396|NCT00036946|splenic marginal zone lymphoma
1488397|NCT00036933|stage III prostate cancer
1488398|NCT00036933|recurrent prostate cancer
1488399|NCT00036920|recurrent non-small cell lung cancer
1488400|NCT00036920|squamous cell lung cancer
1488401|NCT00036920|large cell lung cancer
1488402|NCT00036920|stage IIIB non-small cell lung cancer
1488403|NCT00036920|stage IV non-small cell lung cancer
1488404|NCT00036920|adenocarcinoma of the lung
1488405|NCT00036920|adenosquamous cell lung cancer
1488406|NCT00036920|bronchoalveolar cell lung cancer
1488407|NCT00036894|recurrent adult brain tumor
1488408|NCT00036894|adult glioblastoma
1488409|NCT00036894|adult anaplastic astrocytoma
1488410|NCT00036894|adult anaplastic oligodendroglioma
1488411|NCT00036894|adult mixed glioma
1488412|NCT00036894|adult ependymoblastoma
1488413|NCT00036894|adult anaplastic ependymoma
1488414|NCT00036894|adult myxopapillary ependymoma
1488415|NCT00036894|adult meningioma
1488416|NCT00036894|adult meningeal hemangiopericytoma
1488417|NCT00036894|adult brain stem glioma
1488418|NCT00036894|adult grade III meningioma
1488419|NCT00036894|adult giant cell glioblastoma
1488420|NCT00036894|adult gliosarcoma
1488421|NCT00036868|stage IV breast cancer
1488422|NCT00036868|recurrent breast cancer
1488423|NCT00036842|recurrent malignant testicular germ cell tumor
1488424|NCT00036842|extragonadal germ cell tumor
1488425|NCT00036829|unspecified adult solid tumor, protocol specific
1488426|NCT00036829|pain
1488427|NCT00036816|ciliary body and choroid melanoma, medium/large size
1488428|NCT00036790|stage III adult Hodgkin lymphoma
1488429|NCT00036790|stage IV adult Hodgkin lymphoma
1488430|NCT00036790|recurrent adult Hodgkin lymphoma
1488431|NCT00036790|stage III cutaneous T-cell non-Hodgkin lymphoma
1488432|NCT00036790|stage IV cutaneous T-cell non-Hodgkin lymphoma
1488433|NCT00036790|recurrent cutaneous T-cell non-Hodgkin lymphoma
1488434|NCT00036790|isolated plasmacytoma of bone
1488435|NCT00036790|extramedullary plasmacytoma
1488436|NCT00036790|refractory multiple myeloma
1488437|NCT00036790|Waldenstrom macroglobulinemia
1488438|NCT00036790|stage III multiple myeloma
1488439|NCT00036790|stage III chronic lymphocytic leukemia
1488440|NCT00036790|stage IV chronic lymphocytic leukemia
1488648|NCT00036517|chinese herbal medicine
1488441|NCT00036790|recurrent adult acute myeloid leukemia
1488442|NCT00036790|recurrent adult acute lymphoblastic leukemia
1488443|NCT00036790|relapsing chronic myelogenous leukemia
1488444|NCT00036790|refractory chronic lymphocytic leukemia
1488445|NCT00036790|small intestine lymphoma
1488446|NCT00036790|unspecified adult solid tumor, protocol specific
1488447|NCT00036790|chronic phase chronic myelogenous leukemia
1488448|NCT00036790|accelerated phase chronic myelogenous leukemia
1488449|NCT00036790|blastic phase chronic myelogenous leukemia
1488450|NCT00036790|meningeal chronic myelogenous leukemia
1488451|NCT00036790|untreated adult acute lymphoblastic leukemia
1488452|NCT00036790|untreated adult acute myeloid leukemia
1488453|NCT00036790|refractory hairy cell leukemia
1488454|NCT00036790|chronic myelomonocytic leukemia
1488455|NCT00036790|T-cell large granular lymphocyte leukemia
1488456|NCT00036790|acute undifferentiated leukemia
1488457|NCT00036790|stage III grade 1 follicular lymphoma
1488458|NCT00036790|stage III grade 2 follicular lymphoma
1488459|NCT00036790|stage III grade 3 follicular lymphoma
1488460|NCT00036790|stage III adult diffuse small cleaved cell lymphoma
1488461|NCT00036790|stage III adult diffuse mixed cell lymphoma
1488462|NCT00036790|stage III adult diffuse large cell lymphoma
1488463|NCT00036790|stage III adult immunoblastic large cell lymphoma
1488464|NCT00036790|stage III adult lymphoblastic lymphoma
1488465|NCT00036790|stage III adult Burkitt lymphoma
1488466|NCT00036790|stage IV grade 1 follicular lymphoma
1488467|NCT00036790|stage IV grade 2 follicular lymphoma
1488468|NCT00036790|stage IV grade 3 follicular lymphoma
1488469|NCT00036790|stage IV adult diffuse small cleaved cell lymphoma
1488470|NCT00036790|stage IV adult diffuse mixed cell lymphoma
1488471|NCT00036790|stage IV adult diffuse large cell lymphoma
1488472|NCT00036790|stage IV adult immunoblastic large cell lymphoma
1488473|NCT00036790|stage IV adult lymphoblastic lymphoma
1488474|NCT00036790|stage IV adult Burkitt lymphoma
1488475|NCT00036790|recurrent grade 1 follicular lymphoma
1488476|NCT00036790|recurrent grade 2 follicular lymphoma
1488477|NCT00036790|recurrent grade 3 follicular lymphoma
1488478|NCT00036790|recurrent adult diffuse small cleaved cell lymphoma
1488479|NCT00036790|recurrent adult diffuse mixed cell lymphoma
1488480|NCT00036790|recurrent adult diffuse large cell lymphoma
1488481|NCT00036790|recurrent adult immunoblastic large cell lymphoma
1488482|NCT00036790|recurrent adult lymphoblastic lymphoma
1488483|NCT00036790|recurrent adult Burkitt lymphoma
1488484|NCT00036790|stage III adult T-cell leukemia/lymphoma
1488485|NCT00036790|stage IV adult T-cell leukemia/lymphoma
1488486|NCT00036790|recurrent adult T-cell leukemia/lymphoma
1488487|NCT00036790|secondary acute myeloid leukemia
1488488|NCT00036790|prolymphocytic leukemia
1488489|NCT00036790|stage III mantle cell lymphoma
1488490|NCT00036790|stage IV mantle cell lymphoma
1488491|NCT00036790|recurrent mantle cell lymphoma
1488492|NCT00036790|angioimmunoblastic T-cell lymphoma
1488493|NCT00036790|anaplastic large cell lymphoma
1488494|NCT00036790|stage III mycosis fungoides/Sezary syndrome
1488495|NCT00036790|stage IV mycosis fungoides/Sezary syndrome
1488496|NCT00036790|recurrent mycosis fungoides/Sezary syndrome
1488497|NCT00036790|chronic eosinophilic leukemia
1488498|NCT00036790|chronic neutrophilic leukemia
1488499|NCT00036790|recurrent non-small cell lung cancer
1488500|NCT00036790|recurrent small cell lung cancer
1488501|NCT00036790|stage IIIA non-small cell lung cancer
1488502|NCT00036790|stage IIIB non-small cell lung cancer
1488503|NCT00036790|stage IV non-small cell lung cancer
1488504|NCT00036790|extensive stage small cell lung cancer
1488505|NCT00036790|limited stage small cell lung cancer
1488506|NCT00036790|recurrent breast cancer
1488507|NCT00036790|stage IIIA breast cancer
1488508|NCT00036790|stage IIIB breast cancer
1488509|NCT00036790|stage IIIC breast cancer
1488510|NCT00036790|stage IV breast cancer
1488511|NCT00036790|recurrent colon cancer
1488512|NCT00036790|stage III colon cancer
1488513|NCT00036790|stage IV colon cancer
1488514|NCT00036790|recurrent prostate cancer
1488515|NCT00036790|stage III prostate cancer
1488516|NCT00036790|stage IV prostate cancer
1488517|NCT00036790|recurrent lip and oral cavity cancer
1488518|NCT00036790|stage III lip and oral cavity cancer
1488519|NCT00036790|stage IV lip and oral cavity cancer
1488520|NCT00036790|recurrent paranasal sinus and nasal cavity cancer
1488521|NCT00036790|stage III paranasal sinus and nasal cavity cancer
1488522|NCT00036790|stage IV paranasal sinus and nasal cavity cancer
1488523|NCT00036790|recurrent metastatic squamous neck cancer with occult primary
1488524|NCT00036790|recurrent hypopharyngeal cancer
1488525|NCT00036790|stage III hypopharyngeal cancer
1488526|NCT00036790|stage IV hypopharyngeal cancer
1488527|NCT00036790|recurrent laryngeal cancer
1488528|NCT00036790|stage III laryngeal cancer
1488529|NCT00036790|stage IV laryngeal cancer
1488530|NCT00036790|recurrent oropharyngeal cancer
1488531|NCT00036790|stage III oropharyngeal cancer
1488532|NCT00036790|stage IV oropharyngeal cancer
1488533|NCT00036790|recurrent nasopharyngeal cancer
1488534|NCT00036790|stage III nasopharyngeal cancer
1488535|NCT00036790|stage IV nasopharyngeal cancer
1488536|NCT00036790|atypical chronic myeloid leukemia
1488537|NCT00036790|myelodysplastic/myeloproliferative disease, unclassifiable
1488538|NCT00036790|recurrent marginal zone lymphoma
1488539|NCT00036790|recurrent small lymphocytic lymphoma
1488540|NCT00036790|stage III small lymphocytic lymphoma
1488541|NCT00036790|stage III marginal zone lymphoma
1488542|NCT00036790|stage IV small lymphocytic lymphoma
1488543|NCT00036790|stage IV marginal zone lymphoma
1488544|NCT00036790|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1488545|NCT00036790|nodal marginal zone B-cell lymphoma
1488546|NCT00036790|splenic marginal zone lymphoma
1488547|NCT00036790|adult acute myeloid leukemia with t(8;21)(q22;q22)
1488548|NCT00036790|adult acute myeloid leukemia with t(16;16)(p13;q22)
1488549|NCT00036790|adult acute myeloid leukemia with inv(16)(p13;q22)
1488550|NCT00036790|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1488551|NCT00036790|adult acute myeloid leukemia with t(15;17)(q22;q12)
1488552|NCT00036712|recurrent childhood acute lymphoblastic leukemia
1488553|NCT00036712|refractory multiple myeloma
1488554|NCT00036712|recurrent childhood rhabdomyosarcoma
1488555|NCT00036712|disseminated neuroblastoma
1488556|NCT00036712|recurrent neuroblastoma
1488557|NCT00036712|recurrent Wilms tumor and other childhood kidney tumors
1488558|NCT00036712|recurrent childhood lymphoblastic lymphoma
1488559|NCT00036712|stage III chronic lymphocytic leukemia
1488560|NCT00036712|stage IV chronic lymphocytic leukemia
1488561|NCT00036712|recurrent childhood acute myeloid leukemia
1488562|NCT00036712|relapsing chronic myelogenous leukemia
1488563|NCT00036712|refractory chronic lymphocytic leukemia
1488564|NCT00036712|chronic phase chronic myelogenous leukemia
1488565|NCT00036712|accelerated phase chronic myelogenous leukemia
1488566|NCT00036712|blastic phase chronic myelogenous leukemia
1488567|NCT00036712|primary myelofibrosis
1488568|NCT00036712|childhood acute promyelocytic leukemia (M3)
1488569|NCT00036712|refractory hairy cell leukemia
1488570|NCT00036712|oral complications
1488571|NCT00036712|recurrent/refractory childhood Hodgkin lymphoma
1488572|NCT00036712|de novo myelodysplastic syndromes
1488573|NCT00036712|previously treated myelodysplastic syndromes
1488574|NCT00036712|secondary myelodysplastic syndromes
1488575|NCT00036712|pain
1488576|NCT00036712|recurrent childhood small noncleaved cell lymphoma
1488577|NCT00036712|recurrent childhood large cell lymphoma
1488578|NCT00036712|previously treated childhood rhabdomyosarcoma
1488579|NCT00036712|childhood malignant ovarian germ cell tumor
1488580|NCT00036712|childhood chronic myelogenous leukemia
1488581|NCT00036712|atypical chronic myeloid leukemia, BCR-ABL1 negative
1488582|NCT00036712|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1488583|NCT00036712|childhood myelodysplastic syndromes
1488584|NCT00036686|stage I breast cancer
1488585|NCT00036686|stage II breast cancer
1488586|NCT00036686|stage IIIA breast cancer
1488587|NCT00036686|stage IIIB breast cancer
1488588|NCT00036686|stage IIIC breast cancer
1488589|NCT00036686|recurrent breast cancer
1488590|NCT00036686|stage IV breast cancer
1488591|NCT00036660|recurrent adult brain tumor
1488592|NCT00036660|adult glioblastoma
1488593|NCT00036660|adult anaplastic astrocytoma
1488594|NCT00036660|adult giant cell glioblastoma
1488595|NCT00036660|adult gliosarcoma
1488596|NCT00036647|Non-Small Cell Lung Cancer
1488597|NCT00036647|Tarceva
1488598|NCT00036647|EGFR
1488599|NCT00036647|erlotinib
1488600|NCT00036634|treatment naive
1488601|NCT00036595|Subdural
1488602|NCT00036595|Epilepsy
1488603|NCT00036595|Motor Function
1488604|NCT00036595|Desynchronization
1488605|NCT00036595|Coherence
1488606|NCT00036595|Motor Control
1488607|NCT00036582|Psychophysiology
1488608|NCT00036582|Structural MRI
1488609|NCT00036582|Genetics
1488610|NCT00036582|Bipolar Disorder
1488611|NCT00036582|Children and Adolescents
1488612|NCT00036582|Clozapine
1488613|NCT00036582|Placebo
1488614|NCT00036582|Treatment-Refractory
1488615|NCT00036582|Bipolar
1488616|NCT00036582|Healthy Volunteer
1488617|NCT00036582|HV
1488618|NCT00036582|BPD
1488619|NCT00036582|Normal Control
1488620|NCT00036569|Brainstem Glioma
1488621|NCT00036569|Pediatric
1488622|NCT00036569|Interferon
1488623|NCT00036569|MR Imaging
1488624|NCT00036569|Angiogenesis
1488625|NCT00036569|Brain Tumor
1488626|NCT00036569|Glioma
1488627|NCT00036569|Pediatric Brain Tumor
1488628|NCT00036556|Hormone-Refractory Prostate Cancer
1488629|NCT00036543|Hormone-Refractory, Prostate Cancer
1488630|NCT00036517|Stage III and Stage IV colorectal cancer
1488631|NCT00036517|diarrhea
1488632|NCT00036517|reduce
1488633|NCT00036517|alleviate
1488634|NCT00036517|modulate
1488635|NCT00036517|Saltz regimen
1488636|NCT00036517|CPT-11
1488637|NCT00036517|irinotecan
1488638|NCT00036517|camptosar
1488639|NCT00036517|5-fluorouracil
1488640|NCT00036517|leucovorin
1488641|NCT00036517|5-FU
1488642|NCT00036517|LV
1488643|NCT00036517|chemotherapy
1488644|NCT00036517|side effect
1488645|NCT00036517|toxicity
1488646|NCT00036517|botanical drug
1488647|NCT00036517|herbal medicine
1488649|NCT00036517|traditional chinese medicine
1488650|NCT00036517|TCM
1488651|NCT00036517|oral dose
1488652|NCT00036517|oral administration
1488653|NCT00036517|concomitant use
1488654|NCT00036504|Diabetes mellitus, insulin deficiency, hyperglycemia
1488655|NCT00036491|Systemic Lupus Erythematosus
1488656|NCT00036491|SLE
1488657|NCT00036491|B-Lymphocytes
1488658|NCT00036491|anti-CD20
1488659|NCT00036491|rituximab
1488660|NCT00036478|Pilot Projects
1488661|NCT00036478|Exercise
1488662|NCT00036478|Phosphorus Isotopes
1488663|NCT00036478|Mitochondria
1488664|NCT00036478|Lactates
1488665|NCT00036478|Magnetic Resonance Spectroscopy
1488666|NCT00036465|Pilot Projects
1488667|NCT00036465|HIV-1
1488668|NCT00036465|RNA, Viral
1488669|NCT00036465|Genotype
1488670|NCT00036465|Viral Load
1488671|NCT00036465|Antiretroviral Therapy, Highly Active
1488672|NCT00036465|Treatment Experienced
1488673|NCT00036452|Lopinavir
1488674|NCT00036452|HIV-1
1488675|NCT00036452|Drug Administration Schedule
1488676|NCT00036452|Stavudine
1488677|NCT00036452|HIV Protease Inhibitors
1488678|NCT00036452|Ritonavir
1488679|NCT00036452|Reverse Transcriptase Inhibitors
1488680|NCT00036452|Self Care
1488681|NCT00036452|Viral Load
1488682|NCT00036452|Emtricitabine
1488683|NCT00036452|Directly Observed Therapy
1488684|NCT00036452|Tenofovir Disoproxil Fumarate
1488685|NCT00036452|Treatment Naive
1488686|NCT00036439|ulcerative colitis
1488687|NCT00036439|infliximab
1488688|NCT00036439|Remicade
1488689|NCT00036439|infusion
1488690|NCT00036426|lymphoma
1488691|NCT00036426|vaccine
1488692|NCT00036426|idiotype
1488693|NCT00036426|KLH
1488694|NCT00036426|GM-CSF
1488695|NCT00036413|(ALS)
1488696|NCT00036400|Anemia
1488697|NCT00036400|Gastric Cancer
1488698|NCT00036400|Rectal Cancer
1488699|NCT00036400|Epoetin Alfa
1488700|NCT00036387|Rheumatoid arthritis
1488701|NCT00036387|infliximab
1488702|NCT00036387|anti-TNF
1488703|NCT00036387|methotrexate
1488704|NCT00036387|safety and efficacy
1488705|NCT00036387|Remicade
1488706|NCT00036374|Juvenile rheumatoid arthritis
1488707|NCT00036374|Infliximab
1488708|NCT00036374|Methotrexate
1488709|NCT00036374|remicade
1488710|NCT00036348|Bipolar I disorder
1488711|NCT00036335|depression
1488712|NCT00036335|pain
1488713|NCT00036335|blues
1488714|NCT00036335|sadness
1488715|NCT00036335|aches
1488716|NCT00036309|Major Depressive Disorder
1488839|NCT00035815|amyotrophic lateral sclerosis
1488840|NCT00035815|ALS
1488717|NCT00036309|Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features
1488718|NCT00036296|Involuntary Movements
1488719|NCT00036296|Abnormal Movements
1488720|NCT00036296|Advanced Parkinson's disease
1488721|NCT00036296|Levodopa induced dyskinesia
1488722|NCT00036257|Chronic Lymphocytic Leukemia
1488723|NCT00036257|Leukemia
1488724|NCT00036257|CLL
1488725|NCT00034489|metastatic breast cancer
1488726|NCT00034489|combination therapy
1488727|NCT00034489|Alimta
1488728|NCT00034476|Sepsis, sPLA2 Inhibitor
1488729|NCT00034463|metastatic cancer
1488730|NCT00034463|chemotherapy
1488731|NCT00034450|Terminal Cancer
1488732|NCT00034437|Normal Volunteer
1488733|NCT00034437|Phlebotomy
1488734|NCT00034437|Cytomegalovirus
1488735|NCT00034437|CMV
1488736|NCT00034437|CMV Seropositve
1488737|NCT00034424|Genetics
1488738|NCT00034424|Hereditary
1488739|NCT00034424|Screening
1488740|NCT00034424|Behavioral
1488741|NCT00034424|Familial Testicular Germ Cell Tumor
1488742|NCT00034424|Testicular Cancer
1488743|NCT00034398|Basal Ganglia
1488744|NCT00034398|Neuroimaging
1488745|NCT00034398|Inhibitory Neurons
1488746|NCT00034398|Disinhibition
1488747|NCT00034398|Tics
1488748|NCT00034398|Tourette's Syndrome
1488749|NCT00034398|Tourette Syndrome
1488750|NCT00034398|Healthy Volunteer
1488751|NCT00034398|HV
1488752|NCT00034398|Normal Control
1488753|NCT00034385|Cytomegalovirus
1488754|NCT00034385|Prophylaxis
1488755|NCT00034385|Renal Transplant
1488756|NCT00034385|Valcyte
1488757|NCT00034385|Kidney Transplant
1488758|NCT00034372|immunotherapy
1488759|NCT00034372|monoclonal
1488760|NCT00034372|antibody
1488761|NCT00034372|Stage III ovarian epithelial cancer
1488762|NCT00034372|Stage IV ovarian epithelial cancer
1488763|NCT00034359|E-antigen positive
1488764|NCT00034359|Treatment Naive Chronic Hepatitis B, Achillion
1488765|NCT00034346|Advanced
1488766|NCT00034346|Non-Small-Cell
1488767|NCT00034346|Lung
1488768|NCT00034346|Cancer
1488769|NCT00034346|NSCLC
1488770|NCT00034346|Carcinoma
1488771|NCT00034346|Advanced Non-Small-Cell Lung Cancer (NSCLC)
1488772|NCT00034333|Hepatoma
1488773|NCT00034333|Unresectable adult primary liver cancer
1488774|NCT00034333|liver cancer
1488775|NCT00034333|HCC
1488776|NCT00034333|Hepatocellular Carcinoma
1488777|NCT00034294|C. difficile-associated diarrhea
1488778|NCT00034294|CDAD
1488779|NCT00034294|Clostridium difficile-Associated Diarrhea
1488780|NCT00034294|Clostridium enterocolitis
1488781|NCT00034294|antibiotic-associated diarrhea
1488782|NCT00034294|clostridium difficile colitis
1488783|NCT00034294|infectious diarrhea
1488784|NCT00034294|chronic diarrhea
1488785|NCT00034294|antibiotic-associated colitis
1488786|NCT00036179|Candidemia
1488787|NCT00036179|Anti-Fungal
1488788|NCT00036166|Aspergillus
1488789|NCT00036166|Anti-Fungal
1488790|NCT00036153|Tacrolimus, Prograf®, FK506
1488791|NCT00036140|Pharmacia
1488792|NCT00036127|agitated schizophrenic patients
1488793|NCT00036114|Psychosis associated with dementia of the Alzheimer's type
1488794|NCT00036101|Bipolar I Disorder
1488795|NCT00036075|prostate cancer
1488796|NCT00036075|prostate
1488797|NCT00036062|Sivelestat
1488798|NCT00036062|acute lung injury
1488799|NCT00036036|renal
1488800|NCT00036036|renal cell cancer
1488801|NCT00036036|renal cell carcinoma
1488802|NCT00036036|kidney cancer
1488803|NCT00035997|Hormone-sensitive Prostate Cancer
1488804|NCT00035997|Prostate Cancer
1488805|NCT00035997|Bone Metastasis
1488806|NCT00035984|Type 2 Diabetes Mellitis
1488807|NCT00035958|Juvenile Dermatomyositis
1488808|NCT00035958|Pediatric
1488809|NCT00035958|Randomized Clinical Trial
1488810|NCT00035958|Pediatric Rheumatology
1488811|NCT00035919|Colon cancer
1488812|NCT00035919|Targeted Injectable Vector
1488813|NCT00035919|Gene Transfer
1488814|NCT00035919|Gene Therapy
1488815|NCT00035919|Retroviral vector
1488816|NCT00035906|Diabetes
1488817|NCT00035906|Macular Edema
1488818|NCT00035906|Diabetic Macular Edema
1488819|NCT00035906|Diabetic Retinopathy
1488820|NCT00035906|Cystoid Macular Edema
1488821|NCT00035906|Uveitis
1488822|NCT00035906|Vision
1488823|NCT00035906|Eye
1488824|NCT00035906|Retina
1488825|NCT00035906|Retinal Vein Occlusion
1488826|NCT00035906|Irvine-Gass Syndrome
1488827|NCT00035893|treatment interruption
1488828|NCT00035893|HIV Infections
1488829|NCT00035880|Acute graft versus host disease
1488830|NCT00035880|Stem Cell Transplantation
1488831|NCT00035854|Pharmacia
1488832|NCT00035854|Drug Resistance, Microbial
1488833|NCT00035828|COPD
1488834|NCT00035828|Chronic bronchitis
1488835|NCT00035828|Chronic obstructive pulmonary disease
1488836|NCT00035828|Shortness of breath
1488837|NCT00035828|Dyspnea
1488838|NCT00035828|Bronchitis
1488841|NCT00035815|progressive weakness
1488842|NCT00035815|insulin-like growth factor-1
1488843|NCT00035815|IGF-I
1488844|NCT00035815|Myotrophin
1488845|NCT00035802|Bipolar
1488846|NCT00035802|Mania
1488847|NCT00035802|Pediatric
1488848|NCT00035802|Children
1488849|NCT00035802|Adolescent
1488850|NCT00035802|Topiramate
1488851|NCT00035802|Anticonvulsants
1488852|NCT00035802|Central Nervous System Agents
1488853|NCT00035802|Protective Agents
1488854|NCT00035802|Neuroprotectiive Agents
1488855|NCT00035620|Bone cancer
1488856|NCT00035620|Sarcoma
1488857|NCT00035620|Neutropenia
1488858|NCT00035620|Chemotherapy
1488859|NCT00035594|Breast cancer
1488860|NCT00035594|Neutropenia
1488861|NCT00035594|Chemotherapy
1488862|NCT00035581|treatment experienced
1488863|NCT00035581|HIV Infections
1488864|NCT00035581|HIV
1488865|NCT00035581|HAART
1488866|NCT00035581|early virologic failure
1488867|NCT00035568|Type 2 Diabetes Mellitus
1488868|NCT00035555|kidney
1488869|NCT00035555|transplant
1488870|NCT00035555|rejection
1488871|NCT00035542|Diabetes Mellitus, Type II
1488872|NCT00035529|MS
1488873|NCT00035438|obsessive compulsive disorder
1488874|NCT00035438|ocd
1488875|NCT00035438|Anxiety
1488876|NCT00035438|St. John’s Wort
1488877|NCT00035438|Wisconsin
1488878|NCT00035438|Psychiatric
1488879|NCT00035438|Mental health
1488880|NCT00035412|Social phobia
1488881|NCT00035412|Social anxiety
1488882|NCT00035412|Anxiety
1488883|NCT00035412|St. John’ Wort
1488884|NCT00035412|Wisconsin
1488885|NCT00035412|Psychiatric
1488886|NCT00035412|Mental health
1488887|NCT00035399|acupressure /acupuncture
1488888|NCT00035399|alternative medicine
1488889|NCT00035399|arthritis therapy
1488890|NCT00035399|combination therapy
1488891|NCT00035399|human therapy evaluation
1488892|NCT00035399|knee
1488893|NCT00035399|osteoarthritis
1488894|NCT00035399|physical therapy
1488895|NCT00035399|chronic pain
1488896|NCT00035399|clinical trial
1488897|NCT00035399|functional ability
1488898|NCT00035386|Outflow Obstruction
1488899|NCT00035386|ICE
1488900|NCT00035386|HCM
1488901|NCT00035386|Hypertrophic Cardiomyopathy
1488902|NCT00035386|OHC
1488903|NCT00035386|Obstructive HCM
1488904|NCT00035386|Cardiomyopathy
1488905|NCT00035373|Tumor
1488906|NCT00035373|Brain
1488907|NCT00035373|Chemotherapy
1488908|NCT00035373|Anti-Angiogenesis
1488909|NCT00035373|Radiation Therapy
1488910|NCT00035373|CNS Tumor
1488911|NCT00035360|PEG-Intron
1488912|NCT00035360|treatment experienced
1488913|NCT00035334|Familial Mediterranean Fever
1488914|NCT00035334|Amyloidosis
1488915|NCT00035334|Secondary (AA) Amyloidosis
1488916|NCT00035334|Nephrotic Syndrome
1488917|NCT00035308|Immunologic Diseases
1488918|NCT00035308|Autoimmune Diseases
1488919|NCT00035308|Systemic Lupus Erythematosus
1488920|NCT00035308|SLE
1488921|NCT00035308|Lupus Nephritis
1488922|NCT00035308|Lupus Glomerulonephritis
1488923|NCT00035269|Pharmacia
1488924|NCT00035243|kidney cancer
1488925|NCT00035243|renal cancer
1488926|NCT00035243|cancer
1488927|NCT00035243|tumor
1488928|NCT00035243|tumour
1488929|NCT00035243|neoplasm
1488930|NCT00035243|carcinoma
1488931|NCT00035243|clear cell
1488932|NCT00035243|sarcomatoid
1488933|NCT00035243|papillary
1488934|NCT00035243|medullary
1488935|NCT00035243|collecting duct
1488936|NCT00035243|chromophobe
1488937|NCT00035243|intravenous
1488938|NCT00035243|epothilone
1488939|NCT00035230|Bipolar disorders
1488940|NCT00035230|Bipolar
1488941|NCT00035230|mania
1488942|NCT00035230|Topiramate
1488943|NCT00035230|Lithium
1488944|NCT00034281|Gene, HER2
1488945|NCT00034281|Clinical Trial, Phase I
1488946|NCT00034281|Breast neoplasm
1488947|NCT00034281|Pancreatic neoplasm
1488948|NCT00034281|Ovarian neoplasm
1488949|NCT00034281|Colorectal neoplasm
1488950|NCT00034281|Renal neoplasm
1488951|NCT00034281|Prostate neoplasm
1488952|NCT00034281|Cancer
1488953|NCT00034268|non-small cell lung cancer
1488954|NCT00034268|Stage IIIB or IV non-small cell lung cancer (NSCLC)
1488955|NCT00035204|Donepezil
1488956|NCT00035204|Alzheimer's
1488957|NCT00035204|Dementia
1488958|NCT00035204|Cognitive impairment
1488959|NCT00035204|Aricept
1488960|NCT00035204|Alzheimer's disease
1488961|NCT00035204|Razadyne
1488962|NCT00035204|Galantamine
1488963|NCT00035191|Dementia
1488964|NCT00035191|vascular dementia
1488965|NCT00035191|cerebral vascular disease
1488966|NCT00035178|ESRD
1488967|NCT00035178|End-stage renal disease
1488968|NCT00035178|Hemodialysis
1488969|NCT00035165|melanoma
1488970|NCT00035165|cancer
1488971|NCT00035165|tumor
1488972|NCT00035165|tumour
1488973|NCT00035165|malignant
1488974|NCT00035165|metastatic
1488975|NCT00035165|intravenous
1488976|NCT00035165|epothilone
1488977|NCT00035139|pediatric traumatic brain injury
1488978|NCT00035126|breast
1488979|NCT00035126|cancer
1488980|NCT00035126|tumor
1488981|NCT00035126|tumour
1488982|NCT00035126|intravenous
1488983|NCT00035126|epothilone
1488984|NCT00035126|taxane
1488985|NCT00035126|anthracycline
1488986|NCT00035113|prostate cancer
1488987|NCT00035113|prostate
1488988|NCT00035113|androgen independent
1488989|NCT00035113|cancer
1488990|NCT00035113|tumor
1488991|NCT00035113|tumour
1488992|NCT00035113|neoplasm
1488993|NCT00035113|carcinoma
1488994|NCT00035113|intravenous
1488995|NCT00035113|epothilone
1488996|NCT00035100|ovarian
1488997|NCT00035100|ovary
1488998|NCT00035100|peritoneal cancer
1488999|NCT00035100|fallopian cancer
1489000|NCT00035100|cancer
1489001|NCT00035100|tumor
1489002|NCT00035100|tumour
1489003|NCT00035100|neoplasm
1489004|NCT00035100|carcinoma
1489005|NCT00035100|intravenous
1489006|NCT00035100|epothilone
1489007|NCT00035087|colon
1489008|NCT00035087|rectum
1489009|NCT00035087|colorectal
1489010|NCT00035087|rectal
1489011|NCT00035087|cancer
1489012|NCT00035087|tumor
1489013|NCT00035087|tumour
1489014|NCT00035087|neoplasm
1489015|NCT00035087|carcinoma
1489016|NCT00035087|intravenous
1489017|NCT00035087|epothilone
1489018|NCT00035061|Bladder Cancer
1489019|NCT00035061|Metastatic
1489020|NCT00035061|Recurrent
1489021|NCT00035061|Transitional cell carcinoma of the urothelium
1489022|NCT00035035|Pancreas
1489023|NCT00035035|Cancer
1489024|NCT00035035|Unresectable or Metastatic Cancer of the Pancreas
1489025|NCT00035035|Alimta
1489026|NCT00035022|Leukemia, Lymphoma, T-Cell
1489027|NCT00034970|alternative medicine
1489028|NCT00034970|art
1489029|NCT00034970|cancer
1489030|NCT00034970|combination cancer therapy
1489031|NCT00034970|creative-expression
1489032|NCT00034970|group therapy
1489033|NCT00034970|holistic
1489034|NCT00034970|human therapy evaluation
1489035|NCT00034970|meditation
1489036|NCT00034970|neoplasm /cancer chemotherapy
1489037|NCT00034970|coping
1489038|NCT00034970|gender difference
1489039|NCT00034970|outcomes research
1489040|NCT00034970|psychological aspect of cancer
1489041|NCT00034970|psychological stressor
1489042|NCT00034970|quality of life
1489043|NCT00034970|racial /ethnic difference
1489044|NCT00034970|stress management
1489045|NCT00034970|support
1489046|NCT00034970|behavioral /social science research
1489047|NCT00034970|patient oriented research
1489048|NCT00034957|Pharmacia
1489049|NCT00034918|Metastatic breast cancer
1489050|NCT00034879|Locally advanced and/or metastatic non-operable
1489051|NCT00034879|non-small cell lung cancer (stage III or IV)
1489052|NCT00034879|patients who have failed standard therapy.
1489053|NCT00034866|HIV
1489054|NCT00034866|treatment experienced
1489055|NCT00034866|Boehringer
1489056|NCT00034866|tipranavir
1489057|NCT00034866|ritonavir
1489058|NCT00034840|hypertension
1489059|NCT00034840|telmisartan
1489060|NCT00034840|valsartan
1489061|NCT00034840|boehringer
1489062|NCT00034801|Depression
1489063|NCT00034801|Comorbid Depression
1489064|NCT00034801|Schizophrenia
1489065|NCT00034801|Schizoaffective Disorder
1489066|NCT00034788|Regranex
1489067|NCT00034788|Foot ulcers
1489068|NCT00034788|Diabetes
1489069|NCT00034788|Diabetes mellitus
1489070|NCT00034788|Diabetic foot
1489071|NCT00034775|Schizophrenia
1489072|NCT00034775|intramuscular injection
1489073|NCT00034775|antipsychotic agents
1489074|NCT00034775|risperidone
1489075|NCT00034762|Alzheimer's disease
1489076|NCT00034762|psychosis
1489077|NCT00034762|elderly
1489078|NCT00034762|dementia
1489079|NCT00034762|risperidone
1489080|NCT00034762|antipsychotic agents
1489081|NCT00034749|Adolescents
1489082|NCT00034749|Schizophrenia
1489083|NCT00034749|risperidone
1489084|NCT00034736|Pneumonia
1489085|NCT00034736|Bacterial pneumonia
1489086|NCT00034736|Community acquired pneumonia
1489087|NCT00034736|Lung Inflammation
1489088|NCT00034736|Quinolones
1489089|NCT00034736|Levofloxacin
1489090|NCT00034736|Ceftriaxone
1489091|NCT00034736|Erythromycin
1489092|NCT00034736|Clarithromycin
1489093|NCT00034723|DTI
1489094|NCT00034723|MRSI
1489095|NCT00034723|MTR
1489096|NCT00034723|NAWN
1489097|NCT00034723|Fiber-Tract
1489098|NCT00034723|Normal Control
1489099|NCT00034723|Healthy Volunteer
1489100|NCT00034723|HV
1489101|NCT00034723|HTLV-1 Associated Myelopathy
1489102|NCT00034723|Tropical Spastic Paraparesis
1489103|NCT00034723|HAM/TSP
1489104|NCT00034710|Analgesics/*therapeutic use
1489105|NCT00034710|Capsaicin/*administration & dosage/adverse effects
1489106|NCT00034710|Herpes Zoster/*complications/drug therapy
1489107|NCT00034710|Neuralgia/*drug therapy/etiology
1489108|NCT00034710|Pain
1489109|NCT00034710|Capsicum
1489110|NCT00034710|Pepper
1489111|NCT00034710|Dermal assessment
1489112|NCT00034710|Pain measurement
1489113|NCT00034710|Diary
1489114|NCT00034710|PHN
1489115|NCT00034710|Postherpetic Neuralgia
1489116|NCT00034710|allodynia
1489117|NCT00034710|hyperalgesia
1489118|NCT00034710|shingles
1489119|NCT00034710|varicella
1489120|NCT00034697|Brain mets
1489121|NCT00034697|non-small cell lung cancer
1489122|NCT00034684|Leukemia
1489123|NCT00034684|Myelodysplastic Syndromes
1489124|NCT00034684|Leukemia, Myeloid
1489125|NCT00034684|Leukemia, Lymphocytic
1489126|NCT00034671|Aspergillosis, Candidiasis, Mucormycosis, Cryptococcosis
1489127|NCT00034671|Invasive Fungal Infections
1489128|NCT00034658|Aspergillosis, Candidiasis, Cryptococcosis,
1489129|NCT00034645|Allogenic Stem cell transplantation
1489130|NCT00034645|Fungal infections
1489131|NCT00034632|Aspergillosis, Candidiasis, Cryptococcosis, Phaeohyphomycosis
1489132|NCT00034632|Invasive Fungal Infections
1489133|NCT00034606|Lung cancer
1489134|NCT00034606|cancer
1489135|NCT00034606|neoplasm
1489136|NCT00034606|non-small
1489137|NCT00034606|chemotherapy
1489138|NCT00034593|Bladder cancer
1489139|NCT00034593|metastatic
1489140|NCT00034593|transitional cell carcinoma of the urothelium
1489141|NCT00034580|Bipolar I Disorder
1489142|NCT00034567|Prevention
1489143|NCT00034554|AJCC stage III or stage IV malignant melanoma
1489144|NCT00034554|melanoma
1489145|NCT00034554|gp75
1489146|NCT00034554|DNA vaccine
1489147|NCT00034541|cetuximab
1489148|NCT00034541|epidermal growth factor receptor
1489149|NCT00034541|antibody
1489150|NCT00034541|non-small cell lung cancer
1489151|NCT00034541|carboplatin
1489152|NCT00034541|paclitaxel
1489153|NCT00034242|Ataxia
1489154|NCT00034242|Treatment
1489155|NCT00034242|IVIG
1489156|NCT00034242|SCA
1489157|NCT00034242|Cerebellar Degeneration
1489158|NCT00034242|Cerebellar Ataxia
1489159|NCT00034242|Cerebellum
1489160|NCT00034229|Antidepressant
1489161|NCT00034229|Anti-Glutamatergic
1489162|NCT00034229|Bipolar Disorder
1489163|NCT00034229|Depression
1489164|NCT00034229|Treatment Refractory
1489165|NCT00034229|Felbamate
1489166|NCT00034229|Glutamate
1489167|NCT00034229|Treatment-Resistant
1489168|NCT00034229|Bipolar
1489169|NCT00034229|BPD
1489170|NCT00034229|Bipolar Depression
1489171|NCT00034216|Suppressor Cells
1489172|NCT00034216|T-cells
1489173|NCT00034216|CD4+/CD25+ Cells
1489174|NCT00034216|Cancer
1489175|NCT00034216|Malignancy
1489176|NCT00034216|Blood Sample
1489177|NCT00034177|Locally Advanced, Metastatic, or Recurrent Transitional Cell Carcinoma of the Urothelium
1489178|NCT00034138|immunotherapy
1489179|NCT00034138|monoclonal
1489180|NCT00034138|antibody
1489181|NCT00034138|Stage III ovarian epithelial cancer
1489182|NCT00034138|Stage IV ovarian epithelial cancer
1489183|NCT00034125|cancer
1489184|NCT00034125|metastatic breast cancer
1489185|NCT00034125|hormonal therapy
1489186|NCT00034112|chronic obstructive pulmonary disease
1489187|NCT00034112|combination therapy,
1489188|NCT00034112|emphysema
1489189|NCT00034112|exercise
1489190|NCT00034112|human therapy evaluation
1489191|NCT00034112|rehabilitation
1489192|NCT00034112|respiratory disease /disorder therapy
1489193|NCT00034112|respiratory function
1489194|NCT00034112|biomechanics
1489195|NCT00034112|body movement
1489196|NCT00034112|diaphragm
1489197|NCT00034112|dyspnea
1489198|NCT00034112|muscle tension
1489199|NCT00034112|musculoskeletal system
1489200|NCT00034112|outcomes research
1489201|NCT00034112|quality of life
1489202|NCT00034112|somatic reflex
1489203|NCT00034086|Lopinavir
1489204|NCT00034086|OspA Protein
1489205|NCT00034086|HIV-1
1489206|NCT00034086|HIV Protease Inhibitors
1489207|NCT00034086|CD4 Lymphocyte Count
1489208|NCT00034086|Ritonavir
1489209|NCT00034086|Haemophilus Vaccines
1489210|NCT00034086|HAART
1489211|NCT00034086|Pneumococcal Vaccines
1489212|NCT00034086|tenofovir disoproxil
1489213|NCT00034073|Imaging
1489214|NCT00034073|Pediatrics
1489215|NCT00034073|Brain
1489216|NCT00034073|Mapping
1489217|NCT00034073|Development
1489218|NCT00034073|Healthy Volunteer
1489219|NCT00034073|HV
1489220|NCT00034073|Normal Control
1489221|NCT00034060|Cytokines
1489222|NCT00034060|Exanercept
1489223|NCT00034060|Cachexia
1489224|NCT00034060|Body Composition
1489225|NCT00034060|Vascular Endothelial System
1489226|NCT00034060|Rheumatoid Arthritis
1489227|NCT00034060|RA
1489228|NCT00034060|Women
1489229|NCT00034060|Healthy Volunteer
1489230|NCT00034060|HV
1489231|NCT00034060|Normal Control
1489232|NCT00034047|Endometriosis
1489233|NCT00034047|Pelvic pain
1489234|NCT00034047|Acupuncture
1489235|NCT00034047|Chinese herbs
1489236|NCT00034047|Hormone therapy
1489237|NCT00034047|Nafarelin
1489238|NCT00034034|Advanced colorectal cancer
1489239|NCT00034034|acupressure /acupuncture
1489240|NCT00034034|anxiety
1489241|NCT00034034|colorectal neoplasm
1489242|NCT00034034|human therapy evaluation
1489243|NCT00034034|neoplasm /cancer palliative treatment
1489244|NCT00034034|quality of life
1489245|NCT00034034|terminal patient care
1489246|NCT00034034|hypothalamic pituitary adrenal axis
1489247|NCT00034034|pain
1489248|NCT00034034|psychological aspect of cancer
1489249|NCT00034034|stress management
1489250|NCT00034034|alternative medicine
1489251|NCT00034034|behavioral /social science research tag
1489252|NCT00034034|human subject
1489253|NCT00034034|patient oriented research
1489254|NCT00034021|Female Sexual Arousal Disorder
1489255|NCT00034021|Female Orgasmic Disorder
1489256|NCT00034021|ginkgo biloba
1489257|NCT00034021|human therapy evaluation
1489258|NCT00034021|sex behavior
1489259|NCT00034021|antidepressant
1489260|NCT00034021|blood flow
1489261|NCT00034021|clinical trial
1489262|NCT00034021|drug adverse effect
1489263|NCT00034021|mental disorder chemotherapy
1489264|NCT00034021|relaxation
1489265|NCT00034021|smooth muscle
1489266|NCT00034021|alternative medicine
1489267|NCT00034021|blood flow measurement
1489268|NCT00034021|female
1489269|NCT00034021|placebo
1489270|NCT00034021|women's health
1489271|NCT00034021|Secondary to either to fluoxetine, sertraline, or paroxetine use.
1489272|NCT00034008|Energy Medicine
1489273|NCT00034008|Healing Touch
1489274|NCT00034008|CAM Research
1489275|NCT00034008|Neonates
1489276|NCT00034008|Stress
1489277|NCT00034008|Conditions resulting from stress
1489278|NCT00034008|Neonatal intensive care
1489279|NCT00034008|Healing of stress and prevention of negative
1489280|NCT00034008|Developmental outcomes – physical and behavioral
1489281|NCT00034008|Therapeutic Touch
1489282|NCT00034008|Touch therapies
1489283|NCT00034008|Energy therapies
1489284|NCT00034008|Infant touch
1489285|NCT00034008|Infant stimulation
1489286|NCT00033995|Tics
1489287|NCT00033995|Basal Ganglia
1489288|NCT00033995|Neuroimaging
1489289|NCT00033995|Sleep
1489290|NCT00033995|Suppression of Tics
1489291|NCT00033995|Tourette Syndrome
1489292|NCT00033995|Tourette's Syndrome
1489293|NCT00033995|Tic Disorder
1489294|NCT00033995|Healthy Volunteer
1489295|NCT00033995|HV
1489296|NCT00033995|Normal Control
1489297|NCT00033982|Triazole
1489298|NCT00033982|Refractory
1489299|NCT00033982|Antifungal
1489300|NCT00033982|Fungal Infection
1489301|NCT00033969|CRPS
1489302|NCT00033969|RSD
1489303|NCT00033969|Causalgia
1489304|NCT00033969|Chronic Pain
1489305|NCT00033969|Neuropathic Pain
1489306|NCT00033969|Normal Control
1489307|NCT00033969|Complex Regional Pain Syndrome
1489308|NCT00033969|Healthy Volunteer
1489309|NCT00033969|HV
1489310|NCT00033956|Metastatic Melanoma
1489311|NCT00033956|Renal Cell Carcinoma
1489312|NCT00033956|IL-2
1489313|NCT00033956|Interleukin-2
1489314|NCT00033956|Hypotension
1489315|NCT00033917|intraventricular hemorrhage (IVH)
1489316|NCT00033917|bleeding in the brain
1489317|NCT00033917|indomethacin
1489318|NCT00033917|prematurity
1489319|NCT00033917|very low birth weight infants
1489320|NCT00033904|Kidney Cancer, renal, immunotherapy, tumor,
1489321|NCT00033891|Muscle Weakness
1489322|NCT00033891|Muscle Biopsy
1489323|NCT00033891|Gene Expression Profiling
1489324|NCT00033891|MRI
1489325|NCT00033891|Inflammation
1489326|NCT00033891|Polymyositis
1489327|NCT00033891|Dermatomyositis
1489328|NCT00033878|Advanced Cancer
1489329|NCT00033865|Insomnia
1489330|NCT00033865|Yoga
1489331|NCT00033865|Meditation
1489332|NCT00033865|Behavioral treatment
1489333|NCT00033852|complementary therapies
1489334|NCT00033852|Depression
1489335|NCT00033852|HIV
1489336|NCT00033852|Massage Therapy
1489337|NCT00033852|Alternative Treatments
1489338|NCT00033839|Headache
1489339|NCT00033839|Cluster
1489340|NCT00033839|EC
1489341|NCT00033839|Episodic Cluster
1489342|NCT00033826|Vitamin D
1489343|NCT00033826|Adipose tissue
1489344|NCT00033826|Metabolism
1489345|NCT00033813|Duchenne
1489346|NCT00033813|muscular
1489347|NCT00033813|dystrophy
1489348|NCT00033813|controlled clinical trial
1489349|NCT00033813|CINRG
1489350|NCT00033787|Depression
1489351|NCT00033787|Tryptophan Depletion
1489352|NCT00033787|PET
1489353|NCT00033787|Serotonin
1489354|NCT00033787|Pathophysiology
1489355|NCT00033787|Emotional Stimuli
1489356|NCT00033787|GABA MRS
1489357|NCT00033787|MDD
1489358|NCT00033787|Healthy Volunteer
1489359|NCT00033787|HV
1489360|NCT00033787|Normal Control
1489361|NCT00033774|Leukapheresis
1489362|NCT00033774|G-CSF
1489363|NCT00033774|Mobilization
1489364|NCT00033774|Stem Cells
1489365|NCT00033774|Adult
1489366|NCT00033774|Healthy Volunteer
1489367|NCT00033774|HV
1489368|NCT00033774|Normal Control
1489369|NCT00033748|stage IV colon cancer
1489370|NCT00033748|stage IV rectal cancer
1489371|NCT00033748|recurrent colon cancer
1489372|NCT00033748|recurrent rectal cancer
1489373|NCT00033748|liver metastases
1489374|NCT00033735|recurrent pancreatic cancer
1489375|NCT00033735|duct cell adenocarcinoma of the pancreas
1489376|NCT00033722|recurrent non-small cell lung cancer
1489377|NCT00033722|squamous cell lung cancer
1489378|NCT00033722|large cell lung cancer
1489379|NCT00033722|stage IIIB non-small cell lung cancer
1489380|NCT00033722|stage IV non-small cell lung cancer
1489381|NCT00033722|adenocarcinoma of the lung
1489382|NCT00033722|adenosquamous cell lung cancer
1489383|NCT00033709|adult leiomyosarcoma
1489384|NCT00033709|stage III adult soft tissue sarcoma
1489385|NCT00033709|recurrent adult soft tissue sarcoma
1489386|NCT00033709|stage III uterine sarcoma
1489387|NCT00033709|stage IV uterine sarcoma
1489388|NCT00033709|recurrent uterine sarcoma
1489389|NCT00033709|uterine leiomyosarcoma
1489390|NCT00033709|stage IV adult soft tissue sarcoma
1489391|NCT00033696|limited stage small cell lung cancer
1489392|NCT00033683|stage I breast cancer
1489393|NCT00033683|stage II breast cancer
1489394|NCT00033657|stage I gastric cancer
1489395|NCT00033657|stage II gastric cancer
1489396|NCT00033657|stage III gastric cancer
1489397|NCT00033657|stage IV gastric cancer
1489398|NCT00033657|stage I esophageal cancer
1489399|NCT00033657|stage II esophageal cancer
1489400|NCT00033657|stage III esophageal cancer
1489401|NCT00033657|stage IV esophageal cancer
1489402|NCT00033657|adenocarcinoma of the stomach
1489403|NCT00033657|adenocarcinoma of the esophagus
1489404|NCT00033644|stage IV uterine sarcoma
1489405|NCT00033644|recurrent uterine sarcoma
1489406|NCT00033644|uterine leiomyosarcoma
1489407|NCT00033631|adenocarcinoma of the prostate
1489408|NCT00033631|stage IIB prostate cancer
1489409|NCT00033631|stage IIA prostate cancer
1489410|NCT00033592|non-small cell lung cancer
1489411|NCT00033592|small cell lung cancer
1489412|NCT00033566|unspecified adult solid tumor, protocol specific
1489413|NCT00033553|squamous cell lung cancer
1489414|NCT00033553|large cell lung cancer
1489415|NCT00033553|stage IIIA non-small cell lung cancer
1489416|NCT00033553|stage IIIB non-small cell lung cancer
1489417|NCT00033553|adenocarcinoma of the lung
1489418|NCT00033553|bronchoalveolar cell lung cancer
1489419|NCT00033540|unresectable gallbladder cancer
1489420|NCT00033540|recurrent gallbladder cancer
1489421|NCT00033540|unresectable extrahepatic bile duct cancer
1489422|NCT00033540|recurrent extrahepatic bile duct cancer
1489423|NCT00033540|adenocarcinoma of the gallbladder
1489424|NCT00033540|adenocarcinoma with squamous metaplasia of the gallbladder
1489425|NCT00033540|squamous cell carcinoma of the gallbladder
1489426|NCT00033540|adenocarcinoma of the extrahepatic bile duct
1489427|NCT00033540|cholangiocarcinoma of the gallbladder
1489428|NCT00033540|cholangiocarcinoma of the extrahepatic bile duct
1489429|NCT00033527|non-small cell lung cancer
1489430|NCT00033527|small cell lung cancer
1489431|NCT00033514|stage IV breast cancer
1489432|NCT00033514|recurrent breast cancer
1489433|NCT00033488|ovarian epithelial cancer
1489434|NCT00033475|post-transplant lymphoproliferative disorder
1489435|NCT00033436|stage I bladder cancer
1489436|NCT00033436|stage II bladder cancer
1489437|NCT00033436|stage III bladder cancer
1489438|NCT00033436|transitional cell carcinoma of the bladder
1489439|NCT00033423|recurrent grade 1 follicular lymphoma
1489440|NCT00033423|recurrent grade 2 follicular lymphoma
1489441|NCT00033423|recurrent grade 3 follicular lymphoma
1489442|NCT00033423|recurrent marginal zone lymphoma
1489443|NCT00033423|recurrent small lymphocytic lymphoma
1489444|NCT00033423|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1489445|NCT00033423|nodal marginal zone B-cell lymphoma
1489446|NCT00033423|splenic marginal zone lymphoma
1489447|NCT00033410|stage II non-small cell lung cancer
1489448|NCT00033410|squamous cell lung cancer
1489449|NCT00033410|large cell lung cancer
1489450|NCT00033410|stage IIIA non-small cell lung cancer
1489451|NCT00033410|stage IIIB non-small cell lung cancer
1489452|NCT00033410|adenocarcinoma of the lung
1489453|NCT00033397|stage II breast cancer
1489454|NCT00033397|stage IV breast cancer
1489455|NCT00033397|stage IIIA breast cancer
1489456|NCT00033397|stage IIIB breast cancer
1489457|NCT00033397|stage IIIC breast cancer
1489458|NCT00033397|inflammatory breast cancer
1489459|NCT00033384|stage III colon cancer
1489460|NCT00033384|stage IV colon cancer
1489461|NCT00033384|stage IV breast cancer
1489462|NCT00033384|stage IIIA breast cancer
1489463|NCT00033384|recurrent breast cancer
1489464|NCT00033384|stage IIIB breast cancer
1489465|NCT00033384|recurrent non-small cell lung cancer
1489466|NCT00033384|stage II pancreatic cancer
1489467|NCT00033384|stage III pancreatic cancer
1489468|NCT00033384|recurrent pancreatic cancer
1489469|NCT00033384|recurrent colon cancer
1489470|NCT00033384|stage IIIA non-small cell lung cancer
1489471|NCT00033384|stage IIIB non-small cell lung cancer
1489472|NCT00033384|stage IV non-small cell lung cancer
1489473|NCT00033384|duct cell adenocarcinoma of the pancreas
1489474|NCT00033384|stage IV pancreatic cancer
1489475|NCT00033345|breast cancer
1489476|NCT00033332|stage I multiple myeloma
1489477|NCT00033332|stage II multiple myeloma
1489478|NCT00033332|stage III multiple myeloma
1489479|NCT00033319|colon cancer
1489480|NCT00033319|rectal cancer
1489481|NCT00033306|stage IV colon cancer
1489482|NCT00033306|stage IV rectal cancer
1489483|NCT00033306|recurrent colon cancer
1489484|NCT00033306|recurrent rectal cancer
1489485|NCT00033306|adenocarcinoma of the colon
1489486|NCT00033306|adenocarcinoma of the rectum
1489487|NCT00033280|adult anaplastic oligodendroglioma
1489488|NCT00033280|adult mixed glioma
1489489|NCT00033241|stage II pancreatic cancer
1489490|NCT00033241|stage III pancreatic cancer
1489491|NCT00033241|recurrent pancreatic cancer
1489492|NCT00033241|unspecified adult solid tumor, protocol specific
1489493|NCT00033241|stage IV pancreatic cancer
1489494|NCT00033228|stage IV melanoma
1489495|NCT00033228|recurrent melanoma
1489496|NCT00033215|neovascularization
1489497|NCT00033215|matrix metalloproteinases
1489498|NCT00033215|antiangiogenesis
1489499|NCT00033215|type IV collagenases
1489500|NCT00033202|Solid Tumor
1489501|NCT00033202|Camptothecin
1489502|NCT00033202|Pharmacokinetics
1489503|NCT00033189|duchenne
1489504|NCT00033189|dystrophy
1489505|NCT00033189|DMD
1489506|NCT00033189|clinical trial
1489507|NCT00033189|CINRG
1489508|NCT00033176|complementary therapies
1489509|NCT00033176|Immune restoration
1489510|NCT00033176|HIV infection
1489511|NCT00033176|AIDS
1489512|NCT00033176|HAART non-responsiveness
1489513|NCT00033176|glutathione restoration
1489514|NCT00033176|lipoic acid
1489515|NCT00033176|dithiol
1489516|NCT00033163|Antiviral Agents
1489517|NCT00033163|Hepatitis B
1489518|NCT00033163|Drug Resistance, Microbial
1489519|NCT00033163|Lamivudine
1489520|NCT00033163|DNA, Viral
1489521|NCT00033163|Hepatitis B Virus
1489522|NCT00033163|Adefovir dipivoxil
1489523|NCT00033163|Tenofovir disoproxil fumarate
1489524|NCT00033163|Treatment Experienced
1489525|NCT00033150|Specific Language Impairment
1489526|NCT00033150|Fast ForWord
1489527|NCT00033150|Language therapy
1489528|NCT00033150|Auditory processing
1489529|NCT00033137|Pneumothorax
1489530|NCT00033137|Kidney
1489531|NCT00033137|Fibrofolliculoma
1489532|NCT00033137|BHD
1489533|NCT00033137|Neoplasms
1489534|NCT00033137|Kidney Cancer
1489535|NCT00033137|Birt Hogg Dube Syndrome
1489536|NCT00033137|Skin Papules
1489537|NCT00033085|cocaine dependence
1489538|NCT00033033|cocaine dependence
1489539|NCT00033020|substance use disorders
1489540|NCT00033007|substance use disorders
1489541|NCT00032994|substance use disorders
1489542|NCT00032981|substance use disorder
1489543|NCT00032968|opiate dependence
1489544|NCT00032955|opiate addiction
1489545|NCT00032955|morphine addiction
1489546|NCT00032942|opiate dependence
1489547|NCT00032929|Cocaine Dependence
1489548|NCT00032903|Malignant Glioma, Camptothecin, Pharmacokinetics
1489549|NCT00032890|osteoarthritis
1489550|NCT00032890|knee pain
1489551|NCT00032877|Linkage Study
1489552|NCT00032877|Gene Identification Study
1489553|NCT00032877|Diaphragmatic Hernia
1489554|NCT00032877|Fraser Syndrome
1489555|NCT00032877|Cryptophthalmos
1489556|NCT00032877|Fryns Syndrome
1489557|NCT00032877|Hydrolethalus Syndrome
1489558|NCT00032877|Positional Cloning
1489559|NCT00032864|amputations, diabetes,
1489560|NCT00032838|Hydrocortisone
1489561|NCT00032838|Yohimbine
1489562|NCT00032838|Cognition
1489563|NCT00032838|Norepinephrine
1489564|NCT00032838|Cortisol
1489565|NCT00032838|Emotion
1489566|NCT00032838|Healthy Volunteer
1489567|NCT00032838|HV
1489568|NCT00032838|Normal Control
1489569|NCT00032825|Combination
1489570|NCT00032825|Microtubule
1489571|NCT00032825|Hormonal
1489572|NCT00032825|Chemotherapy
1489573|NCT00032825|Pharmacokinetics
1489574|NCT00032825|Prostate Cancer
1489575|NCT00032825|Prostate
1489576|NCT00032812|Motor Learning
1489577|NCT00032812|Sequencing
1489578|NCT00032812|Functional Imaging
1489579|NCT00032812|Raclopride
1489580|NCT00032812|Connectivity
1489581|NCT00032812|Parkinson Disease
1489582|NCT00032812|Parkinson's Disease
1489583|NCT00032812|PD
1489584|NCT00032812|Healthy Volunteer
1489585|NCT00032812|HV
1489586|NCT00032812|Normal Control
1489587|NCT00032773|acute graft versus host disease
1489588|NCT00032773|aGVHD
1489589|NCT00032773|allogeneic hematopoietic stem cell transplantation
1489590|NCT00032773|peripheral blood stem cell transplantation
1489591|NCT00032773|cord blood transplant
1489592|NCT00032773|pentostatin
1489593|NCT00032773|Nipent
1489594|NCT00032773|deoxycoformycin
1489595|NCT00032760|binge eating disorder
1489596|NCT00032760|human therapy evaluation
1489597|NCT00032760|meditation
1489598|NCT00032760|obesity
1489599|NCT00032760|nutrition education
1489600|NCT00032760|psychotherapy
1489601|NCT00032760|racial /ethnic difference
1489602|NCT00032760|adult human
1489603|NCT00032760|alternative medicine
1489604|NCT00032760|patient oriented research
1489605|NCT00032747|Chronic Heart Failure
1489606|NCT00032747|Heart Disease
1489607|NCT00032734|Low Blood Sodium (Hyponatremia)
1489608|NCT00032734|SIADH
1489609|NCT00032734|Inappropriate ADH Syndrome
1489610|NCT00032721|complementary therapies
1489611|NCT00032721|Alternative medicine
1489612|NCT00032721|Complementary and alternative medicine
1489613|NCT00032721|Subtle energy therapy
1489614|NCT00032721|Reiki
1489615|NCT00032721|HIV/AIDS
1489616|NCT00032695|myelopathy
1489617|NCT00032695|AIDS-myelopathy
1489618|NCT00032695|AIDS vacuolar myelopathy
1489619|NCT00032695|methionine
1489620|NCT00032682|Bowel Movement
1489621|NCT00032682|Children
1489622|NCT00032682|Stool
1489623|NCT00032682|Symptom Management
1489624|NCT00032682|Cancer
1489625|NCT00032682|Constipation
1489626|NCT00032669|Antiretrovirals
1489627|NCT00032669|Adherence
1489628|NCT00032669|Dose Adjustments
1489629|NCT00032669|Genotypic Resistance
1489630|NCT00032669|Phenotypic Resistance
1489631|NCT00032656|Adolescents
1489632|NCT00032656|Alternative and complimentary medication use
1489633|NCT00032656|Health services utilization
1489634|NCT00032656|Communication
1489635|NCT00032656|Quality of care
1489636|NCT00032617|PTSD
1489637|NCT00032617|Stress Disorder
1489638|NCT00032617|Trauma
1489639|NCT00032591|AF
1489640|NCT00032591|Mechanical heart valve (MHV)
1489641|NCT00032539|Informed Consent
1489642|NCT00032513|Herpesvirus
1489643|NCT00032513|Hemophagocytosis
1489644|NCT00032513|Lymphoproliferative
1489645|NCT00032513|Epstein-Barr
1489646|NCT00032513|Mononucleosis
1489647|NCT00032513|EBV
1489648|NCT00032513|CAEBV
1489649|NCT00032513|Chronic Active Epstein-Barr Virus
1489650|NCT00032513|Virus
1489651|NCT00032500|common cold
1489652|NCT00032500|Echinacea
1489653|NCT00032487|DM
1489654|NCT00032487|glycemic control
1489655|NCT00032487|insulin
1489656|NCT00032487|type 2 diabetes mellitus
1489657|NCT00032474|Ginkgo biloba
1489658|NCT00032474|type 2 diabetes
1489659|NCT00032474|platelet function
1489660|NCT00032474|antioxidant
1489661|NCT00032461|chronic fatigue syndrome
1489662|NCT00032461|fibromyalgia
1489663|NCT00032461|post-traumatic stress disorder
1489664|NCT00032461|neurologic abnormalities
1489665|NCT00032448|Hernia
1489666|NCT00032448|laparoscopic herniorrhaphy
1489667|NCT00032448|tension-free herniorrhaphy
1489668|NCT00032435|folate
1489669|NCT00032435|pyridoxine
1489670|NCT00032435|vitamin B6
1489671|NCT00032435|cyanocobalamin
1489672|NCT00032435|homoc
1489673|NCT00032422|Acupuncture
1489674|NCT00032422|Heart Failure
1489675|NCT00032422|Autonomic nervous system
1489676|NCT00032409|Music Therapy
1489677|NCT00032409|Relaxation Therapy
1489678|NCT00032409|Stress Reduction
1489679|NCT00032409|Bone Marrow Transplantation
1489680|NCT00032409|Stem Cell Transplantation
1489681|NCT00032396|AMD
1489682|NCT00032396|ARMD
1489683|NCT00032396|Age-Related Macular Degeneration
1489684|NCT00032396|Subfoveal Choroidal Neovascularization
1489685|NCT00032396|CNV
1489686|NCT00032383|Rehabilitation
1489687|NCT00032383|Tai Chi
1489688|NCT00032370|myocardial infarction
1489689|NCT00032370|Prophylactic coronary artery revascularization
1489690|NCT00032357|Ferritin reduction
1489691|NCT00032357|Peripheral Vascular Disease (PVD)
1489692|NCT00032357|phlebotomy
1489693|NCT00032357|Reduction of Total Body Iron Storage(TBIS)
1489694|NCT00032357|Total Body Iron Storage(TBIS)
1489695|NCT00032344|large (>1 cm) adenomas
1489696|NCT00032331|PET imaging, benign and malignant solitary pulmonary nodules
1489697|NCT00032305|Colitis
1489698|NCT00032305|Gastrointestinal Disease
1489699|NCT00032305|Digestive System Disease
1489700|NCT00032305|Intestinal Disease
1489701|NCT00032305|Colonic Disease
1489702|NCT00032240|Biomechanics
1489703|NCT00032227|Carpal Tunnel Release
1489704|NCT00032227|MR Nerve Imaging
1489705|NCT00032227|Wrist MRI
1489706|NCT00032201|Surgery
1489707|NCT00032201|Tissue Sample
1489708|NCT00032201|Gene Expression Profiling
1489709|NCT00032201|Tissue Array Gene Expression
1489710|NCT00032201|Comparative Genomic Hybridization
1489711|NCT00032201|Breast Cancer
1489712|NCT00032201|Breast Cancer Risk
1489713|NCT00032201|Breast
1489714|NCT00032175|stage III pancreatic cancer
1489715|NCT00032175|duct cell adenocarcinoma of the pancreas
1489716|NCT00032175|stage IV pancreatic cancer
1489717|NCT00032162|stage III cervical cancer
1489718|NCT00032162|recurrent cervical cancer
1489719|NCT00032162|stage IB cervical cancer
1489720|NCT00032162|stage IIB cervical cancer
1489721|NCT00032162|stage IVB cervical cancer
1489722|NCT00032162|stage IA cervical cancer
1489723|NCT00032162|stage IIA cervical cancer
1489724|NCT00032162|stage IVA cervical cancer
1489725|NCT00032162|stage I endometrial carcinoma
1489726|NCT00032162|stage II endometrial carcinoma
1489727|NCT00032162|stage III endometrial carcinoma
1489728|NCT00032162|stage IV endometrial carcinoma
1489729|NCT00032162|recurrent endometrial carcinoma
1489730|NCT00032162|fallopian tube cancer
1489731|NCT00032162|stage I uterine sarcoma
1489732|NCT00032162|stage II uterine sarcoma
1489733|NCT00032162|stage III uterine sarcoma
1489734|NCT00032162|stage IV uterine sarcoma
1489735|NCT00032162|recurrent uterine sarcoma
1489736|NCT00032162|ovarian sarcoma
1489737|NCT00032162|ovarian carcinosarcoma
1489738|NCT00032149|AIDS-related peripheral/systemic lymphoma
1489739|NCT00032149|AIDS-related primary CNS lymphoma
1489740|NCT00032149|AIDS-related diffuse large cell lymphoma
1489741|NCT00032149|AIDS-related immunoblastic large cell lymphoma
1489742|NCT00032149|AIDS-related small noncleaved cell lymphoma
1489743|NCT00032149|AIDS-related diffuse mixed cell lymphoma
1489744|NCT00032149|AIDS-related diffuse small cleaved cell lymphoma
1489745|NCT00032149|AIDS-related lymphoblastic lymphoma
1489746|NCT00032136|stage I breast cancer
1489747|NCT00032136|stage II breast cancer
1489748|NCT00032123|stage IV gastric cancer
1489749|NCT00032123|stage IV esophageal cancer
1489750|NCT00032123|adenocarcinoma of the stomach
1489751|NCT00032123|adenocarcinoma of the esophagus
1489752|NCT00032123|recurrent esophageal cancer
1489753|NCT00032123|recurrent gastric cancer
1489754|NCT00032097|adult glioblastoma
1489755|NCT00032097|adult giant cell glioblastoma
1489756|NCT00032097|adult gliosarcoma
1489757|NCT00032084|non-small cell lung cancer
1489758|NCT00032084|stage I non-small cell lung cancer
1489759|NCT00032084|stage II non-small cell lung cancer
1489760|NCT00032058|adenocarcinoma of the prostate
1489761|NCT00032058|stage I prostate cancer
1489762|NCT00032058|stage IIB prostate cancer
1489763|NCT00032058|stage IIA prostate cancer
1489764|NCT00032045|iris melanoma
1489765|NCT00032045|ciliary body and choroid melanoma, small size
1489766|NCT00032045|ciliary body and choroid melanoma, medium/large size
1489767|NCT00032045|extraocular extension melanoma
1489768|NCT00032045|recurrent intraocular melanoma
1489769|NCT00032045|stage IV melanoma
1489770|NCT00032045|recurrent melanoma
1489771|NCT00032032|stage I non-small cell lung cancer
1489772|NCT00032032|stage II non-small cell lung cancer
1489773|NCT00032032|stage IIIA non-small cell lung cancer
1489774|NCT00032032|stage IIIB non-small cell lung cancer
1489775|NCT00032019|stage III adult diffuse large cell lymphoma
1489776|NCT00032019|stage III adult immunoblastic large cell lymphoma
1489777|NCT00032019|stage IV adult diffuse large cell lymphoma
1489778|NCT00032019|stage IV adult immunoblastic large cell lymphoma
1489779|NCT00032019|contiguous stage II adult immunoblastic large cell lymphoma
1489780|NCT00032019|contiguous stage II adult diffuse large cell lymphoma
1489781|NCT00032019|noncontiguous stage II adult immunoblastic large cell lymphoma
1489782|NCT00032019|noncontiguous stage II adult diffuse large cell lymphoma
1489783|NCT00032006|adenocarcinoma of the prostate
1489784|NCT00032006|stage I prostate cancer
1489785|NCT00032006|stage IIB prostate cancer
1489786|NCT00032006|stage IIA prostate cancer
1489787|NCT00032006|recurrent prostate cancer
1489788|NCT00031980|stage I chronic lymphocytic leukemia
1489789|NCT00031980|stage II chronic lymphocytic leukemia
1489790|NCT00031980|stage III chronic lymphocytic leukemia
1489791|NCT00031980|stage IV chronic lymphocytic leukemia
1489792|NCT00031980|T-cell large granular lymphocyte leukemia
1489793|NCT00031980|anemia
1489794|NCT00031980|neutropenia
1489795|NCT00031980|thrombocytopenia
1489796|NCT00031967|unspecified adult solid tumor, protocol specific
1489797|NCT00031967|tumors metastatic to brain
1489798|NCT00031967|radiation toxicity
1489799|NCT00031954|stage II ovarian epithelial cancer
1489800|NCT00031954|stage I ovarian epithelial cancer
1489801|NCT00031954|stage III ovarian epithelial cancer
1489802|NCT00031954|stage IV ovarian epithelial cancer
1489803|NCT00031954|fallopian tube cancer
1489804|NCT00031954|primary peritoneal cavity cancer
1489805|NCT00031941|stage IV adult Hodgkin lymphoma
1489806|NCT00031941|recurrent adult Hodgkin lymphoma
1489807|NCT00031941|stage IV cutaneous T-cell non-Hodgkin lymphoma
1489808|NCT00031941|recurrent cutaneous T-cell non-Hodgkin lymphoma
1489809|NCT00031941|unspecified adult solid tumor, protocol specific
1489810|NCT00031941|stage IV grade 1 follicular lymphoma
1489811|NCT00031941|stage IV grade 2 follicular lymphoma
1489812|NCT00031941|stage IV grade 3 follicular lymphoma
1489813|NCT00031941|stage IV adult diffuse small cleaved cell lymphoma
1489814|NCT00031941|stage IV adult diffuse mixed cell lymphoma
1489815|NCT00031941|stage IV adult diffuse large cell lymphoma
1489816|NCT00031941|stage IV adult immunoblastic large cell lymphoma
1489817|NCT00031941|stage IV adult lymphoblastic lymphoma
1489818|NCT00031941|stage IV adult Burkitt lymphoma
1489819|NCT00031941|recurrent grade 1 follicular lymphoma
1489820|NCT00031941|recurrent grade 2 follicular lymphoma
1489821|NCT00031941|recurrent grade 3 follicular lymphoma
1489822|NCT00031941|recurrent adult diffuse small cleaved cell lymphoma
1489823|NCT00031941|recurrent adult diffuse mixed cell lymphoma
1489824|NCT00031941|recurrent adult diffuse large cell lymphoma
1489825|NCT00031941|recurrent adult immunoblastic large cell lymphoma
1489826|NCT00031941|recurrent adult lymphoblastic lymphoma
1489827|NCT00031941|recurrent adult Burkitt lymphoma
1489828|NCT00031941|stage IV adult T-cell leukemia/lymphoma
1489829|NCT00031941|recurrent adult T-cell leukemia/lymphoma
1489830|NCT00031941|stage IV mantle cell lymphoma
1489831|NCT00031941|recurrent mantle cell lymphoma
1489832|NCT00031941|angioimmunoblastic T-cell lymphoma
1489833|NCT00031941|anaplastic large cell lymphoma
1489834|NCT00031941|recurrent mycosis fungoides/Sezary syndrome
1489835|NCT00031941|stage IV mycosis fungoides/Sezary syndrome
1489836|NCT00031941|small intestine lymphoma
1489837|NCT00031941|recurrent marginal zone lymphoma
1489838|NCT00031941|recurrent small lymphocytic lymphoma
1489839|NCT00031941|stage IV small lymphocytic lymphoma
1489840|NCT00031941|stage IV marginal zone lymphoma
1489841|NCT00031941|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1489842|NCT00031941|nodal marginal zone B-cell lymphoma
1489843|NCT00031941|splenic marginal zone lymphoma
1489844|NCT00031928|leptomeningeal metastases
1489845|NCT00031915|metastatic osteosarcoma
1489846|NCT00031915|recurrent childhood rhabdomyosarcoma
1489847|NCT00031915|recurrent osteosarcoma
1489848|NCT00031915|embryonal childhood rhabdomyosarcoma
1489849|NCT00031915|alveolar childhood rhabdomyosarcoma
1489850|NCT00031915|pleomorphic childhood rhabdomyosarcoma
1489851|NCT00031915|metastatic childhood soft tissue sarcoma
1489852|NCT00031915|recurrent childhood soft tissue sarcoma
1489853|NCT00031915|childhood fibrosarcoma
1489854|NCT00031915|childhood synovial sarcoma
1489855|NCT00031915|childhood liposarcoma
1489856|NCT00031915|childhood alveolar soft-part sarcoma
1489857|NCT00031915|childhood neurofibrosarcoma
1489858|NCT00031915|childhood angiosarcoma
1489859|NCT00031915|childhood malignant fibrous histiocytoma of bone
1489860|NCT00031915|previously treated childhood rhabdomyosarcoma
1489861|NCT00031915|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1489862|NCT00031915|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1489863|NCT00031915|fibrosarcomatous osteosarcoma
1489864|NCT00031902|AIDS-related peripheral/systemic lymphoma
1489865|NCT00031902|AIDS-related diffuse large cell lymphoma
1489866|NCT00031902|AIDS-related immunoblastic large cell lymphoma
1489867|NCT00031902|AIDS-related small noncleaved cell lymphoma
1489868|NCT00031902|AIDS-related diffuse mixed cell lymphoma
1489869|NCT00031902|AIDS-related diffuse small cleaved cell lymphoma
1489870|NCT00031902|AIDS-related lymphoblastic lymphoma
1489871|NCT00031889|adenocarcinoma of the prostate
1489872|NCT00031889|stage IV prostate cancer
1489873|NCT00031889|recurrent prostate cancer
1489874|NCT00031876|stage IV breast cancer
1489875|NCT00031876|recurrent breast cancer
1489876|NCT00031863|stage II colon cancer
1489877|NCT00031863|stage III colon cancer
1489878|NCT00031863|stage II rectal cancer
1489879|NCT00031863|stage III rectal cancer
1489880|NCT00031850|breast cancer
1489881|NCT00031837|thromboembolism
1489882|NCT00031837|stage III pancreatic cancer
1489883|NCT00031837|recurrent pancreatic cancer
1489884|NCT00031837|adenocarcinoma of the pancreas
1489885|NCT00031837|stage IV pancreatic cancer
1489886|NCT00031824|graft versus host disease
1489887|NCT00031811|stage I breast cancer
1489888|NCT00031811|stage II breast cancer
1489889|NCT00031811|stage IIIA breast cancer
1489890|NCT00031811|stage IIIB breast cancer
1489891|NCT00031811|osteoporosis
1489892|NCT00031811|menopausal symptoms
1489893|NCT00031798|fatigue
1489894|NCT00031798|depression
1489895|NCT00031798|quality of life
1489896|NCT00031798|cognitive/functional effects
1489897|NCT00031798|recurrent adult brain tumor
1489898|NCT00031798|adult brain stem glioma
1489899|NCT00031798|adult glioblastoma
1489900|NCT00031798|adult tumors metastatic to brain
1489901|NCT00031798|adult anaplastic astrocytoma
1489902|NCT00031798|adult anaplastic oligodendroglioma
1489903|NCT00031798|adult mixed glioma
1489904|NCT00031798|adult meningioma
1489905|NCT00031798|adult anaplastic ependymoma
1489906|NCT00031798|adult myxopapillary ependymoma
1489907|NCT00031798|adult ependymoblastoma
1489908|NCT00031798|adult pilocytic astrocytoma
1489909|NCT00031798|adult subependymoma
1489910|NCT00031798|adult grade III meningioma
1490022|NCT00031369|Movement Disorder
1489911|NCT00031798|adult giant cell glioblastoma
1489912|NCT00031798|adult gliosarcoma
1489913|NCT00031798|adult grade II meningioma
1489914|NCT00031785|stage I non-small cell lung cancer
1489915|NCT00031785|stage II non-small cell lung cancer
1489916|NCT00031785|limited stage small cell lung cancer
1489917|NCT00031785|stage IIIA non-small cell lung cancer
1489918|NCT00031785|stage IIIB non-small cell lung cancer
1489919|NCT00031785|anorexia
1489920|NCT00031785|cachexia
1489921|NCT00031772|recurrent breast cancer
1489922|NCT00031772|psychosocial effects of cancer and its treatment
1489923|NCT00031759|cervical cancer
1489924|NCT00031759|cervical intraepithelial neoplasia grade 1
1489925|NCT00031759|cervical intraepithelial neoplasia grade 2
1489926|NCT00031759|cervical intraepithelial neoplasia grade 3
1489927|NCT00031746|prostate cancer
1489928|NCT00031733|iris melanoma
1489929|NCT00031733|ciliary body and choroid melanoma, small size
1489930|NCT00031733|ciliary body and choroid melanoma, medium/large size
1489931|NCT00031733|extraocular extension melanoma
1489932|NCT00031733|recurrent intraocular melanoma
1489933|NCT00031733|stage II melanoma
1489934|NCT00031733|stage III melanoma
1489935|NCT00031733|stage IV melanoma
1489936|NCT00031733|recurrent melanoma
1489937|NCT00031720|lobular breast carcinoma in situ
1489938|NCT00031720|stage I breast cancer
1489939|NCT00031720|stage II breast cancer
1489940|NCT00031720|stage IIIA breast cancer
1489941|NCT00031720|recurrent breast cancer
1489942|NCT00031720|ductal breast carcinoma in situ
1489943|NCT00031720|hot flashes
1489944|NCT00031707|anorexia
1489945|NCT00031707|cachexia
1489946|NCT00031668|Waldenstrom macroglobulinemia
1489947|NCT00031668|recurrent adult diffuse large cell lymphoma
1489948|NCT00031668|recurrent adult Burkitt lymphoma
1489949|NCT00031668|recurrent adult T-cell leukemia/lymphoma
1489950|NCT00031668|anaplastic large cell lymphoma
1489951|NCT00031642|recurrent grade 1 follicular lymphoma
1489952|NCT00031642|recurrent grade 2 follicular lymphoma
1489953|NCT00031642|recurrent grade 3 follicular lymphoma
1489954|NCT00031642|recurrent adult diffuse small cleaved cell lymphoma
1489955|NCT00031642|recurrent adult diffuse mixed cell lymphoma
1489956|NCT00031642|recurrent adult diffuse large cell lymphoma
1490081|NCT00031174|Myositis
1489957|NCT00031642|recurrent adult immunoblastic large cell lymphoma
1489958|NCT00031642|recurrent adult Burkitt lymphoma
1489959|NCT00031642|recurrent mantle cell lymphoma
1489960|NCT00031642|recurrent marginal zone lymphoma
1489961|NCT00031642|recurrent small lymphocytic lymphoma
1489962|NCT00031642|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1489963|NCT00031642|nodal marginal zone B-cell lymphoma
1489964|NCT00031642|splenic marginal zone lymphoma
1489965|NCT00031616|stage IV colon cancer
1489966|NCT00031616|stage IV rectal cancer
1489967|NCT00031616|recurrent colon cancer
1489968|NCT00031616|recurrent rectal cancer
1489969|NCT00031616|adenocarcinoma of the colon
1489970|NCT00031616|adenocarcinoma of the rectum
1489971|NCT00031590|untreated childhood medulloblastoma
1489972|NCT00031590|PNET
1489973|NCT00031590|craniospinal radiotherapy
1489974|NCT00031577|untreated childhood brain stem glioma
1489975|NCT00031564|stage IV
1489976|NCT00031564|renal cell carcinoma
1489977|NCT00031551|Stomatitis
1489978|NCT00031551|Oropharyngeal pain
1489979|NCT00031551|TNF
1489980|NCT00031551|Etanercept
1489981|NCT00031551|Bone marrow transplantation
1489982|NCT00031551|Chemotherapy
1489983|NCT00031551|Cancer
1489984|NCT00031551|Oral cavity
1489985|NCT00031551|Oral mucous membranes
1489986|NCT00031551|Randomized controlled clinical trial
1489987|NCT00031551|Inflammation
1489988|NCT00031538|Brain Tumor
1489989|NCT00031538|Surgery
1489990|NCT00031538|Molecular
1489991|NCT00031538|Glioma
1489992|NCT00031538|Intraoperative
1489993|NCT00031538|Gliomas
1489994|NCT00031512|enterovirus, enteroviral sepsis, Pleconaril, infants
1489995|NCT00031499|Azithromycin, Syphilis, Penicillin
1489996|NCT00031486|encephalitis, herpes simplex, valacyclovir
1489997|NCT00031473|Ribavirin
1489998|NCT00031473|RSV
1489999|NCT00031460|acyclovir, central nervous system, Herpes Simplex Virus
1490000|NCT00031447|Herpes Simplex, Acyclovir, Infants
1490001|NCT00031434|Valganciclovir, congenital cytomegalovirus, ganciclovir
1490002|NCT00031421|CMV, cytomegalovirus, children, ganciclovir
1490003|NCT00031408|Specimen Handling
1490004|NCT00031408|Blood
1490005|NCT00031408|Informed Consent
1490006|NCT00031408|Genetic Screening
1490007|NCT00031395|Attention Deficit Hyperactivity Disorder
1490008|NCT00031395|ADHD
1490009|NCT00031395|clonidine
1490010|NCT00031395|methylphenidate
1490011|NCT00031395|MPH
1490012|NCT00031382|Functional MRI
1490013|NCT00031382|Dual Task
1490014|NCT00031382|Neural Activation
1490015|NCT00031382|Basal Ganglia
1490016|NCT00031382|Cerebellum
1490017|NCT00031382|Healthy Volunteer
1490018|NCT00031382|HV
1490019|NCT00031382|Normal Control
1490020|NCT00031369|MRI
1490021|NCT00031369|Writer's Cramp
1490023|NCT00031369|Gray Matter
1490024|NCT00031369|Brain Morphology
1490025|NCT00031369|Dystonia
1490026|NCT00031369|Focal Hand Dystonia
1490027|NCT00031369|Healthy Volunteer
1490028|NCT00031369|HV
1490029|NCT00031369|Normal Control
1490030|NCT00031343|Liver Disease
1490031|NCT00031343|Virologic Response
1490032|NCT00031343|Immune Mechanisms
1490033|NCT00031343|Eradication
1490034|NCT00031343|Antiviral Therapy
1490035|NCT00031343|HIV
1490036|NCT00031343|Hepatitis C
1490037|NCT00031343|HCV
1490038|NCT00031343|Coinfection
1490039|NCT00031317|Depression
1490040|NCT00031317|Treatment
1490041|NCT00031317|Antidepressant
1490042|NCT00031317|Benzodiazepine (clonazepam)
1490043|NCT00031317|SSRI (paroxetine)
1490044|NCT00031317|Combined Treatment
1490045|NCT00031317|Panic Disorder (PD)
1490046|NCT00031317|Panic Disorder
1490047|NCT00031317|PD
1490048|NCT00031304|HIV
1490049|NCT00031304|AIDS
1490050|NCT00031304|Vaccine
1490051|NCT00031304|Screening
1490052|NCT00031304|Prevention
1490053|NCT00031304|HV
1490054|NCT00031304|Healthy Volunteer
1490055|NCT00031304|Volunteer
1490056|NCT00031304|HIV Seronegativity
1490057|NCT00031304|HIV Preventive Vaccine
1490058|NCT00031291|Anthrax
1490059|NCT00031291|Immune Globulin
1490060|NCT00031291|Plasmapheresis
1490061|NCT00031291|Vaccine
1490062|NCT00031278|Metastatic
1490063|NCT00031278|Breast
1490064|NCT00031278|Cancer
1490065|NCT00031278|immunotherapy
1490066|NCT00031278|CPG 7909
1490067|NCT00031265|stroke
1490068|NCT00031265|telephone
1490069|NCT00031265|intervention
1490070|NCT00031187|Prostate
1490071|NCT00031187|Lewis Blood-Group System
1490072|NCT00031187|Antibodies, Monoclonal
1490073|NCT00031187|Antigens, Neoplasm
1490074|NCT00031187|Antineoplastic Agents
1490075|NCT00031174|Apheresis
1490076|NCT00031174|Healthy Volunteer
1490077|NCT00031174|Rheumatoid Disease
1490078|NCT00031174|Rheumatic Disease
1490079|NCT00031174|Lupus
1490080|NCT00031174|Rheumatoid Arthritis
1490082|NCT00031174|HV
1490083|NCT00031174|Normal Control
1490084|NCT00031161|Tyrosine
1490085|NCT00031161|Diet
1490086|NCT00031161|2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
1490087|NCT00031161|4-Hydroxyphenylpyruvate Dioxygenase
1490088|NCT00031161|Enzyme Inhibitors
1490089|NCT00031148|Keratinocyte growth factor
1490090|NCT00031148|Bone Marrow Transplantation
1490091|NCT00031148|Hematopoietic Stem Cell Transplantation
1490092|NCT00031148|HLA Antigens
1490093|NCT00031148|Transplantation, Homologous
1490094|NCT00031148|Recombinant Proteins
1490095|NCT00031135|Parenteral Nutrition, Total
1490096|NCT00031135|Lipotropic Agents
1490097|NCT00031135|Choline
1490098|NCT00031122|Genetic Predisposition to Disease
1490099|NCT00031122|Environmental Exposure
1490100|NCT00031122|Chromosome Mapping
1490101|NCT00031122|Data Collection
1490102|NCT00031109|HIV Antibodies
1490103|NCT00031109|HIV-1
1490104|NCT00031109|HIV Envelope Protein gp160
1490105|NCT00031109|Adjuvants, Immunologic
1490106|NCT00031109|AIDS Vaccines
1490107|NCT00031109|CD4 Lymphocyte Count
1490108|NCT00031109|Disease Models, Animal
1490109|NCT00031109|Antibody Formation
1490110|NCT00031109|Macaca
1490111|NCT00031109|Neutralization Tests
1490112|NCT00031109|Viral Load
1490113|NCT00031109|aluminum hydroxide
1490114|NCT00031109|HIV Preventive Vaccine
1490115|NCT00031096|Acne Vulgaris
1490116|NCT00031096|Propionibacterium acnes
1490117|NCT00031083|Glioma
1490118|NCT00031083|Brain Tumor
1490119|NCT00031083|Adenovirus
1490120|NCT00031083|Gene Therapy
1490121|NCT00031083|Biogen
1490122|NCT00031070|Zidovudine
1490123|NCT00031070|CD4 Lymphocyte Count
1490124|NCT00031070|Lamivudine
1490125|NCT00031070|Cyclosporine
1490126|NCT00031070|Hepatitis A Vaccine
1490127|NCT00031070|Rabies Vaccine
1490128|NCT00031070|abacavir
1490129|NCT00031070|Antiretroviral Therapy, Highly Active
1490130|NCT00031070|efavirenz
1490131|NCT00031070|Treatment Naive
1490132|NCT00031057|Administration, Oral
1490133|NCT00031057|Blood
1490134|NCT00031057|Reverse Transcriptase Inhibitors
1490135|NCT00031057|Riboflavin
1490136|NCT00031057|Thiamine
1490137|NCT00031057|Vitamin B Complex
1490138|NCT00031057|Lactic Acid
1490139|NCT00031044|HIV-1
1490140|NCT00031044|Drug Therapy, Combination
1490141|NCT00031044|RNA, Viral
1490142|NCT00031044|Salvage Therapy
1490143|NCT00031044|Anti-HIV Agents
1490144|NCT00031044|Viral Load
1490145|NCT00031044|Purines
1490146|NCT00031044|T-20 Peptide
1490147|NCT00031044|ABT 378
1490148|NCT00031044|Treatment Experienced
1490149|NCT00031031|MTD
1490150|NCT00031031|Safety
1490151|NCT00031031|Pharmacokinetics
1490152|NCT00031031|Efficacy
1490153|NCT00031018|Inflammation
1490154|NCT00031018|immunosenescence
1490155|NCT00031018|autoimmunity
1490156|NCT00031018|atherosclerosis
1490157|NCT00031018|pro-inflammatory cytokines
1490158|NCT00031018|Hayflick phenomenon
1490159|NCT00031005|Non-Myeloablative
1490160|NCT00031005|Campath 1-H
1490161|NCT00031005|Fludarabine
1490162|NCT00031005|Immunodeficiency
1490163|NCT00031005|Infection
1490164|NCT00031005|Leukocyte Adhesion Deficiency
1490165|NCT00031005|LAD
1490166|NCT00030992|Epothilone B
1490167|NCT00030992|Ixabepilone
1490168|NCT00030992|Renal Cell Carcinoma
1490169|NCT00030992|Kidney Cancer
1490170|NCT00030979|Mild Dementia
1490171|NCT00030979|Acetylcholine
1490172|NCT00030979|Memory
1490173|NCT00030979|Hallucinations
1490174|NCT00030979|Washout
1490175|NCT00030979|Parkinson Disease
1490176|NCT00030979|Parkinson's Disease
1490177|NCT00030979|PD
1490178|NCT00030979|Dementia
1490179|NCT00030966|Multiple Sclerosis
1490180|NCT00030966|MS
1490181|NCT00030953|Tourette's Syndrome
1490182|NCT00030953|GABA
1490183|NCT00030953|NAA
1490184|NCT00030953|Choline
1490185|NCT00030953|Creatine
1490186|NCT00030953|Tourette Syndrome
1490187|NCT00030953|Healthy Volunteer
1490188|NCT00030953|HV
1490189|NCT00030953|Normal Control
1490190|NCT00030940|Antigenic Epitopes
1490191|NCT00030940|Glutamic Acid Decarboxylase (GAD)
1490192|NCT00030940|Auto-antibodies
1490193|NCT00030940|Stiffness Index
1490194|NCT00030940|SPS
1490195|NCT00030940|Anti-GAD
1490196|NCT00030940|MR Spectroscopy
1490197|NCT00030940|GAD
1490198|NCT00030940|Stiff Person Syndrome
1490199|NCT00030914|hot flashes
1490200|NCT00030901|prostate cancer
1490201|NCT00030901|high grade prostatic intraepithelial neoplasia
1490202|NCT00030888|stage III renal cell cancer
1490203|NCT00030888|stage IV renal cell cancer
1490204|NCT00030888|recurrent renal cell cancer
1490205|NCT00030875|stage I mantle cell lymphoma
1490206|NCT00030875|contiguous stage II mantle cell lymphoma
1490207|NCT00030875|noncontiguous stage II mantle cell lymphoma
1490208|NCT00030875|stage III mantle cell lymphoma
1490209|NCT00030875|stage IV mantle cell lymphoma
1490210|NCT00030875|recurrent mantle cell lymphoma
1490211|NCT00030862|stage II esophageal cancer
1490212|NCT00030862|stage III esophageal cancer
1490213|NCT00030862|stage IV esophageal cancer
1490214|NCT00030862|squamous cell carcinoma of the esophagus
1490215|NCT00030862|adenocarcinoma of the esophagus
1490216|NCT00030849|stage I cutaneous T-cell non-Hodgkin lymphoma
1490217|NCT00030849|stage II cutaneous T-cell non-Hodgkin lymphoma
1490218|NCT00030849|stage III cutaneous T-cell non-Hodgkin lymphoma
1490219|NCT00030849|stage IV cutaneous T-cell non-Hodgkin lymphoma
1490220|NCT00030849|recurrent cutaneous T-cell non-Hodgkin lymphoma
1490221|NCT00030823|stage I breast cancer
1490222|NCT00030823|stage II breast cancer
1490223|NCT00030823|stage IV breast cancer
1490224|NCT00030823|stage IIIA breast cancer
1490225|NCT00030823|recurrent breast cancer
1490226|NCT00030823|stage IIIB breast cancer
1490227|NCT00030823|stage IIIC breast cancer
1490228|NCT00030823|male breast cancer
1490229|NCT00030810|squamous cell lung cancer
1490230|NCT00030810|large cell lung cancer
1490231|NCT00030810|stage IIIB non-small cell lung cancer
1490232|NCT00030810|adenosquamous cell lung cancer
1490233|NCT00030797|stage III colon cancer
1490234|NCT00030797|stage IV colon cancer
1490235|NCT00030797|stage III rectal cancer
1490236|NCT00030797|stage IV rectal cancer
1490237|NCT00030784|adult angiosarcoma
1490238|NCT00030784|adult fibrosarcoma
1490239|NCT00030784|adult leiomyosarcoma
1490240|NCT00030784|adult liposarcoma
1490241|NCT00030784|adult neurofibrosarcoma
1490242|NCT00030784|adult synovial sarcoma
1490243|NCT00030784|stage III adult soft tissue sarcoma
1490244|NCT00030784|adult alveolar soft-part sarcoma
1490245|NCT00030784|adult epithelioid sarcoma
1490246|NCT00030784|adult malignant fibrous histiocytoma
1490247|NCT00030784|adult malignant hemangiopericytoma
1490248|NCT00030784|adult malignant mesenchymoma
1490249|NCT00030784|adult rhabdomyosarcoma
1490250|NCT00030784|stage IV adult soft tissue sarcoma
1490251|NCT00030771|squamous cell lung cancer
1490252|NCT00030771|large cell lung cancer
1490253|NCT00030771|stage IIIA non-small cell lung cancer
1490254|NCT00030771|adenosquamous cell lung cancer
1490255|NCT00030758|neutropenia
1490256|NCT00030758|stage I breast cancer
1490257|NCT00030758|stage II breast cancer
1490258|NCT00030745|stage IA malignant mesothelioma
1490259|NCT00030745|stage IB malignant mesothelioma
1490260|NCT00030745|stage II malignant mesothelioma
1490261|NCT00030745|stage III malignant mesothelioma
1490262|NCT00030732|stage III pancreatic cancer
1490263|NCT00030732|recurrent pancreatic cancer
1490264|NCT00030732|adenocarcinoma of the pancreas
1490265|NCT00030732|stage IV pancreatic cancer
1490266|NCT00030719|regional neuroblastoma
1490267|NCT00030719|disseminated neuroblastoma
1490268|NCT00030719|stage 4S neuroblastoma
1490269|NCT00030719|localized unresectable neuroblastoma
1490270|NCT00030706|stage III ovarian epithelial cancer
1490271|NCT00030706|stage IV ovarian epithelial cancer
1490272|NCT00030706|recurrent ovarian epithelial cancer
1490273|NCT00030706|peritoneal cavity cancer
1490274|NCT00030680|desmoid tumor
1490275|NCT00030654|adenocarcinoma of the prostate
1490276|NCT00030654|stage IIB prostate cancer
1490277|NCT00030654|stage IIA prostate cancer
1490278|NCT00030654|stage III prostate cancer
1490279|NCT00030654|stage IV prostate cancer
1490280|NCT00030654|recurrent prostate cancer
1490281|NCT00030641|recurrent non-small cell lung cancer
1490282|NCT00030641|stage IIIB non-small cell lung cancer
1490283|NCT00030641|stage IV non-small cell lung cancer
1490284|NCT00030628|tumors metastatic to brain
1490285|NCT00030602|adenocarcinoma of the prostate
1490286|NCT00030602|recurrent prostate cancer
1490287|NCT00030589|stage I cutaneous T-cell non-Hodgkin lymphoma
1490288|NCT00030589|stage II cutaneous T-cell non-Hodgkin lymphoma
1490289|NCT00030589|recurrent cutaneous T-cell non-Hodgkin lymphoma
1490290|NCT00030589|stage I mycosis fungoides/Sezary syndrome
1490291|NCT00030589|stage II mycosis fungoides/Sezary syndrome
1490292|NCT00030589|recurrent mycosis fungoides/Sezary syndrome
1490293|NCT00030576|recurrent metastatic squamous neck cancer occult primary
1490294|NCT00030576|neck cancer with occult primary squamous carcinoma
1490295|NCT00030576|stage IV squamous cell carcinoma of the lip and oral cavity
1490296|NCT00030576|recurrent squamous cell carcinoma of the lip and oral cavity
1490297|NCT00030576|stage IV squamous cell carcinoma of the oropharynx
1490298|NCT00030576|recurrent squamous cell carcinoma of the oropharynx
1490299|NCT00030576|stage IV squamous cell carcinoma of the nasopharynx
1490300|NCT00030576|recurrent squamous cell carcinoma of the nasopharynx
1490301|NCT00030576|stage IV squamous cell carcinoma of the hypopharynx
1490302|NCT00030576|recurrent squamous cell carcinoma of the hypopharynx
1490303|NCT00030576|stage IV squamous cell carcinoma of the larynx
1490304|NCT00030576|recurrent squamous cell carcinoma of the larynx
1490305|NCT00030576|squamous cell carcinoma of paranasal sinus and nasal cavity
1490306|NCT00030576|recurrent squamous cell carcinoma of sinus and nasal cavity
1490307|NCT00030563|liver metastases
1490308|NCT00030563|stage IV colon cancer
1490309|NCT00030563|stage IV rectal cancer
1490310|NCT00030563|adenocarcinoma of the colon
1490311|NCT00030563|adenocarcinoma of the rectum
1490312|NCT00030563|recurrent colon cancer
1490313|NCT00030563|recurrent rectal cancer
1490314|NCT00030550|refractory anemia
1490315|NCT00030550|refractory anemia with ringed sideroblasts
1490316|NCT00030550|refractory anemia with excess blasts
1490317|NCT00030550|de novo myelodysplastic syndromes
1490318|NCT00030550|chronic myelomonocytic leukemia
1490319|NCT00030550|previously treated myelodysplastic syndromes
1490320|NCT00030550|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1490321|NCT00030550|atypical chronic myeloid leukemia, BCR-ABL1 negative
1490322|NCT00030537|stage IV breast cancer
1490323|NCT00030537|recurrent breast cancer
1490324|NCT00030537|stage IIIB breast cancer
1490325|NCT00030537|male breast cancer
1490326|NCT00030524|stage III colon cancer
1490327|NCT00030524|stage IV colon cancer
1490328|NCT00030524|stage III rectal cancer
1490329|NCT00030524|stage IV rectal cancer
1490330|NCT00030524|recurrent colon cancer
1490331|NCT00030524|recurrent rectal cancer
1490332|NCT00030524|adenocarcinoma of the colon
1490333|NCT00030524|adenocarcinoma of the rectum
1490334|NCT00030511|localized resectable adult primary liver cancer
1490335|NCT00030511|recurrent adult primary liver cancer
1490336|NCT00030511|localized extrahepatic bile duct cancer
1490337|NCT00030511|recurrent extrahepatic bile duct cancer
1490338|NCT00030485|stage IV endometrial carcinoma
1490339|NCT00030485|recurrent endometrial carcinoma
1490340|NCT00030485|endometrial adenocarcinoma
1490341|NCT00030485|endometrial adenosquamous cell carcinoma
1490342|NCT00030472|recurrent cervical cancer
1490343|NCT00030472|stage IVB cervical cancer
1490344|NCT00030472|cervical squamous cell carcinoma
1490345|NCT00030459|localized malignant mesothelioma
1490346|NCT00030459|advanced malignant mesothelioma
1490347|NCT00030459|recurrent malignant mesothelioma
1490348|NCT00030446|recurrent ovarian epithelial cancer
1490349|NCT00030446|fallopian tube cancer
1490350|NCT00030446|peritoneal cavity cancer
1490351|NCT00030433|extensive stage small cell lung cancer
1490352|NCT00030420|recurrent non-small cell lung cancer
1490353|NCT00030420|stage IIIA non-small cell lung cancer
1490354|NCT00030420|stage IIIB non-small cell lung cancer
1490355|NCT00030420|stage IV non-small cell lung cancer
1490356|NCT00030407|stage IIIB non-small cell lung cancer
1490357|NCT00030407|stage IV non-small cell lung cancer
1490358|NCT00030355|recurrent childhood acute myeloid leukemia
1490359|NCT00030355|recurrent adult acute myeloid leukemia
1490360|NCT00030355|adult acute promyelocytic leukemia (M3)
1490361|NCT00030355|childhood acute promyelocytic leukemia (M3)
1490362|NCT00030355|adult acute myeloid leukemia with t(15;17)(q22;q12)
1490363|NCT00030342|stage IV colon cancer
1490364|NCT00030342|stage IV rectal cancer
1490365|NCT00030342|recurrent colon cancer
1490366|NCT00030342|recurrent rectal cancer
1490367|NCT00030342|stage IV renal cell cancer
1490368|NCT00030342|recurrent renal cell cancer
1490369|NCT00030303|chronic phase chronic myelogenous leukemia
1490370|NCT00030303|chronic myelogenous leukemia, BCR-ABL1 positive
1490371|NCT00030290|stage I prostate cancer
1490372|NCT00030290|stage IIB prostate cancer
1490373|NCT00030290|stage IIA prostate cancer
1490374|NCT00030277|stage I prostate cancer
1490375|NCT00030277|stage IIB prostate cancer
1490376|NCT00030277|stage IIA prostate cancer
1490377|NCT00030277|recurrent prostate cancer
1490378|NCT00030264|plexiform neurofibroma
1490379|NCT00030264|neurofibromatosis type 1
1490380|NCT00030238|Body Fat
1490381|NCT00030238|Weight Gain
1490382|NCT00030238|Adult
1490383|NCT00030238|Hypertension
1490384|NCT00030238|Dietary Supplements
1490385|NCT00030238|Healthy Volunteer
1490386|NCT00030238|HIV
1490387|NCT00030238|Body Weight
1490388|NCT00030225|Fulminant Hepatic Failure
1490389|NCT00030212|T Cell
1490390|NCT00030212|IBM
1490391|NCT00030212|Inflammatory Myopathies
1490392|NCT00030212|Antigenic Epitopes
1490393|NCT00030212|Endomysial T Lymphocytes
1490394|NCT00030212|Myositis
1490395|NCT00030212|Inclusion Body Myositis
1490396|NCT00030212|Inflammatory Myopathy
1490397|NCT00030199|Transcranial Magnetic Stimuli
1490398|NCT00030199|Eletromyography
1490399|NCT00030199|Needle Electrode
1490400|NCT00030199|Facial Muscles
1490401|NCT00030199|Blink Reflex
1490402|NCT00030199|Motor Cortex
1490403|NCT00030199|Transcranial Magnetic Stimulation
1490404|NCT00030199|Healthy Volunteer
1490405|NCT00030199|HV
1490406|NCT00030199|Normal Control
1490407|NCT00030186|AML
1490408|NCT00030186|FLT-3 mutation
1490409|NCT00030173|Epothilone D
1490410|NCT00030173|tubulin polymerization
1490411|NCT00030160|Obesity
1490412|NCT00030160|Prevention
1490413|NCT00030160|Exercise
1490414|NCT00030147|Gonadal Steroids
1490415|NCT00030147|Estrogen Receptor
1490416|NCT00030147|Mood Disorders
1490417|NCT00030147|Perimenopause
1490418|NCT00030147|Estradiol
1490419|NCT00030147|Depression
1490420|NCT00030147|Estrogen Response Element
1490421|NCT00030147|Perimenopausal
1490422|NCT00030147|Perimenopausal Depression
1490423|NCT00030134|Natural History
1490424|NCT00030134|Female Carrier
1490425|NCT00030134|Alpha-Galactosidase
1490426|NCT00030134|Lysosomal Disease
1490427|NCT00030134|X-Linked
1490428|NCT00030134|Fabry
1490429|NCT00030134|Fabry Disease
1490430|NCT00030121|Acute Respiratory Distress
1490431|NCT00030121|Acute Lung Injury
1490432|NCT00030108|recurrent childhood rhabdomyosarcoma
1490433|NCT00030108|childhood craniopharyngioma
1490434|NCT00030108|recurrent neuroblastoma
1490435|NCT00030108|recurrent childhood liver cancer
1490436|NCT00030108|recurrent Wilms tumor and other childhood kidney tumors
1490437|NCT00030108|childhood central nervous system germ cell tumor
1490438|NCT00030108|recurrent osteosarcoma
1490439|NCT00030108|unspecified childhood solid tumor, protocol specific
1490440|NCT00030108|childhood germ cell tumor
1490441|NCT00030108|recurrent childhood soft tissue sarcoma
1490442|NCT00030108|childhood oligodendroglioma
1490443|NCT00030108|childhood choroid plexus tumor
1490444|NCT00030108|childhood grade I meningioma
1490445|NCT00030108|childhood grade II meningioma
1490446|NCT00030108|childhood grade III meningioma
1490447|NCT00030108|recurrent childhood cerebellar astrocytoma
1490448|NCT00030108|recurrent childhood cerebral astrocytoma
1490449|NCT00030108|recurrent childhood medulloblastoma
1490450|NCT00030108|recurrent childhood visual pathway and hypothalamic glioma
1490451|NCT00030108|previously treated childhood rhabdomyosarcoma
1490452|NCT00030108|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1490453|NCT00030108|recurrent childhood ependymoma
1490454|NCT00030108|childhood teratoma
1490455|NCT00030108|childhood malignant testicular germ cell tumor
1490456|NCT00030108|childhood malignant ovarian germ cell tumor
1490457|NCT00030108|childhood extragonadal germ cell tumor
1490458|NCT00030108|recurrent childhood malignant germ cell tumor
1490459|NCT00030108|B-cell childhood acute lymphoblastic leukemia
1490460|NCT00030108|childhood acute basophilic leukemia
1490461|NCT00030108|childhood acute eosinophilic leukemia
1490462|NCT00030108|childhood acute lymphoblastic leukemia
1490463|NCT00030108|childhood acute myeloid leukemia in remission
1490464|NCT00030108|childhood acute promyelocytic leukemia (M3)
1490465|NCT00030108|L1 childhood acute lymphoblastic leukemia
1490466|NCT00030108|L2 childhood acute lymphoblastic leukemia
1490467|NCT00030108|L3 childhood acute lymphoblastic leukemia
1490468|NCT00030108|non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
1490469|NCT00030108|non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
1490470|NCT00030108|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
1490471|NCT00030108|recurrent childhood acute lymphoblastic leukemia
1490472|NCT00030108|recurrent childhood acute myeloid leukemia
1490473|NCT00030108|TdT negative childhood acute lymphoblastic leukemia
1490474|NCT00030108|TdT positive childhood acute lymphoblastic leukemia
1490475|NCT00030108|chronic myelogenous leukemia, BCR-ABL1 positive
1490476|NCT00030108|childhood chronic myelogenous leukemia
1490477|NCT00030095|unspecified adult solid tumor, protocol specific
1490478|NCT00030082|localized unresectable adult primary liver cancer
1490479|NCT00030082|advanced adult primary liver cancer
1490480|NCT00030082|recurrent adult primary liver cancer
1490481|NCT00030082|liver metastases
1490482|NCT00030069|Hematopoiesis
1490483|NCT00030069|Apoptosis
1490484|NCT00030069|Cell Differentiation
1490485|NCT00030069|Bone Marrow Cells
1490486|NCT00030056|Sargramostim
1490487|NCT00030056|Injections, Subcutaneous
1490488|NCT00030043|Electric Stimulation
1490489|NCT00030043|Implants, Artificial
1490490|NCT00030043|Brainstem
1490491|NCT00030043|Electrodes
1490492|NCT00030043|Speech Perception
1490493|NCT00029991|Leg pain
1490494|NCT00029991|Peripheral angiopathies
1490495|NCT00029991|Vascular Diseases, peripheral
1490496|NCT00029965|Tay-Sachs
1490497|NCT00029965|Lysosomal Storage Disease
1490498|NCT00029965|Sandhoff
1490499|NCT00029965|GM1 Gangliosidosis
1490500|NCT00029965|GM2 Gangliosidosis
1490501|NCT00029965|Lysosomal Storage Disorder
1490502|NCT00029965|Gaucher
1490503|NCT00029952|Cortisol
1490504|NCT00029952|Bone Density
1490505|NCT00029952|Cushing Syndrome
1490506|NCT00029952|Postoperative
1490507|NCT00029939|Preparation
1490508|NCT00029939|Subconscious
1490509|NCT00029939|Healthy Volunteer
1490510|NCT00029939|HV
1490511|NCT00029939|Normal Control
1490512|NCT00029926|Imaging
1490513|NCT00029926|Immune System
1490514|NCT00029926|Autoimmune Disease
1490515|NCT00029926|Lymphonodes
1490516|NCT00029926|Spleen
1490517|NCT00029926|Systemic Lupus Erythematosus
1490518|NCT00029926|Lupus
1490519|NCT00029926|SLE
1490520|NCT00029913|Placebos
1490521|NCT00029913|AIDS Vaccines
1490522|NCT00029913|CD4 Lymphocyte Count
1490523|NCT00029913|Disease Progression
1490524|NCT00029913|Viral Load
1490525|NCT00029913|HIV Preventive Vaccine
1490526|NCT00029900|Dose-Response Relationship, Drug
1490527|NCT00029900|Polyethylene Glycol
1490528|NCT00029900|Arginine Deiminase
1490529|NCT00029874|Tetracyclines
1490530|NCT00029874|Dose-Response Relationship, Drug
1490531|NCT00029861|Weight Loss
1490532|NCT00029861|Obesity
1490533|NCT00029861|Weight Reduction
1490534|NCT00029861|Overweight
1490535|NCT00029848|Diabetes
1490536|NCT00029848|Obesity
1490537|NCT00029835|Obesity
1490538|NCT00029822|Acute Urinary Retention
1490539|NCT00029822|AUR
1490540|NCT00029822|Benign Prostatic Hyperplasia
1490541|NCT00029822|Benign Prostatic Hypertrophy
1490542|NCT00029822|BPH
1490543|NCT00029822|Enlarged Prostate
1490544|NCT00029809|Parkinsons Disease
1490545|NCT00029809|Chinese exercise
1490546|NCT00029783|Glioblastoma
1490547|NCT00029783|Brain tumor
1490548|NCT00029783|Distant healing
1490549|NCT00029783|Distance healing
1490550|NCT00029757|Surgical menopause
1490551|NCT00029744|AIDS Vaccines
1490552|NCT00029744|Clinical Protocols
1490553|NCT00029744|HIV Seronegativity
1490554|NCT00029744|Patient Selection
1490555|NCT00029744|Patient Acceptance of Health Care
1490556|NCT00029744|Demography
1490557|NCT00029744|HIV Preventive Vaccine
1490558|NCT00029731|Nitric Oxide
1490559|NCT00029731|Administration, Oral
1490560|NCT00029718|Chronic Stroke
1490561|NCT00029718|Transcallosal Inhibition
1490562|NCT00029718|Motor Cortex
1490563|NCT00029718|Motor Control
1490564|NCT00029718|Motor Recovery
1490565|NCT00029718|Healthy Volunteer
1490566|NCT00029718|HV
1490567|NCT00029718|Normal Control
1490568|NCT00029666|Motor Cortex
1490569|NCT00029666|Sham Stimulation
1490570|NCT00029666|Prefrontal Cortex
1490571|NCT00029666|Brain Stimulation
1490572|NCT00029666|Gait
1490573|NCT00029666|Parkinson
1490574|NCT00029666|Parkinson's
1490575|NCT00029666|PD
1490576|NCT00029653|Frontal Lobe
1490577|NCT00029653|Reaction Time
1490578|NCT00029653|Movement Preparation
1490579|NCT00029653|Motor Threshold
1490580|NCT00029653|Transcranial Magnetic Stimulation
1490581|NCT00029653|Motor Cortex
1490582|NCT00029653|Healthy Volunteer
1490583|NCT00029653|Normal Control
1490584|NCT00029653|HV
1490585|NCT00029640|MRI
1490586|NCT00029640|MRS
1490587|NCT00029640|SSRI
1490588|NCT00029640|Children
1490589|NCT00029640|Depression
1490590|NCT00029640|Augmentation
1490591|NCT00029640|Magnetic Resonance Imaging
1490592|NCT00029640|Major Depression
1490593|NCT00029640|MDD
1490594|NCT00029627|Alpha2-Adrenoreceptors
1490595|NCT00029627|Polymorphisms
1490596|NCT00029627|Challenge Study
1490597|NCT00029627|Yohimbine
1490598|NCT00029627|Clonidine
1490599|NCT00029627|Subtypes
1490600|NCT00029627|Normal Control
1490601|NCT00029627|HV
1490602|NCT00029627|Healthy Volunteer
1490603|NCT00029614|ADHD
1490604|NCT00029614|Substance Use
1490605|NCT00029601|Magnetic Stimulation
1490606|NCT00029601|Intracortical Inhibition
1490607|NCT00029601|Intracortical Facilitation
1490608|NCT00029601|Motor Evoked Potential
1490609|NCT00029601|Reaction Time
1490610|NCT00029601|Transcranial Magnetic Stimulation
1490611|NCT00029601|Dystonia
1490612|NCT00029601|Focal Dystonia
1490613|NCT00029601|Healthy Volunteer
1490614|NCT00029601|HV
1490615|NCT00029601|Normal Control
1490616|NCT00029588|fMRI
1490617|NCT00029588|Adolescents and Adults
1490618|NCT00029588|Depression
1490619|NCT00029588|Anxiety
1490620|NCT00029588|Anxiety Disorder
1490621|NCT00029588|GAD
1490622|NCT00029588|Adolescents
1490623|NCT00029588|Healthy Volunteer
1490624|NCT00029588|HV
1490625|NCT00029588|Normal Control
1490626|NCT00029575|Atherosclerotic
1490627|NCT00029575|Plaque
1490628|NCT00029575|Resolution
1490629|NCT00029575|Adventitia
1490630|NCT00029575|Ultrasound
1490631|NCT00029575|Cardiac Catheterization
1490632|NCT00029575|Arteriosclerosis
1490633|NCT00029575|Coronary Artery Disease
1490634|NCT00029536|Epilepsy
1490635|NCT00029536|Seizure
1490636|NCT00029536|Hormone
1490637|NCT00029536|Progesterone
1490638|NCT00029536|Catamenial
1490639|NCT00029523|neoplastic
1490640|NCT00029523|meningitis
1490641|NCT00029523|cerebrospinal fluid
1490642|NCT00029523|CSF
1490643|NCT00029523|meningeal
1490644|NCT00029523|meninges
1490645|NCT00029523|CNS
1490646|NCT00029523|Leptomeningeal Neoplasms
1490647|NCT00029458|Placebo Controlled
1490648|NCT00029458|Atypical Anti-Psychotic
1490649|NCT00029458|Bipolar Mood Disorder
1490650|NCT00029458|Positron Emission Tomography
1490651|NCT00029458|Dopamine Receptor Blockade
1490652|NCT00029458|Antimanic
1490653|NCT00029458|Mania
1490654|NCT00029458|Pathophysiology
1490655|NCT00029458|Treatment-Resistant
1490656|NCT00029458|Mood Disorder
1490657|NCT00029458|BPD
1490658|NCT00029458|Bipolar
1490659|NCT00029445|HLA B5701
1490660|NCT00029445|LTNP
1490661|NCT00029445|Neutralizing Antibodies
1490662|NCT00029445|CTL
1490663|NCT00029445|Virus Restriction
1490664|NCT00029445|HIV
1490665|NCT00029445|HIV-Infected Long Term Nonprogressors
1490666|NCT00029341|Drug Therapy, Combination
1490667|NCT00029341|Drug Administration Schedule
1490668|NCT00029341|Drug Resistance, Microbial
1490669|NCT00029341|Genotype
1490670|NCT00029341|Reverse Transcriptase Inhibitors
1490671|NCT00029341|Anti-HIV Agents
1490672|NCT00029341|Viral Load
1490673|NCT00029341|Pharmacokinetics
1490674|NCT00029341|Efavirenz
1490675|NCT00029341|Treatment Interruption
1490676|NCT00029328|TNFR-Fc fusion protein
1490677|NCT00029328|Stem Cell Transplantation
1490678|NCT00029328|Transplantation, Homologous
1490679|NCT00029328|Respiratory Function Tests
1490680|NCT00029315|Intraventricular hemorrhage
1490681|NCT00029315|Subarachnoid hemorrhage
1490682|NCT00029315|Intracerebral hemorrhage
1490683|NCT00029315|Pharmacokinetics
1490684|NCT00029315|Recombinant Proteins
1490685|NCT00029315|Anticoagulants
1490686|NCT00029315|Tissue Plasminogen Activator
1490687|NCT00029315|Pharmacology
1490688|NCT00029315|Catheters, Indwelling
1490689|NCT00029315|Cerebral Ventricles
1490690|NCT00029302|fMRI
1490691|NCT00029302|Voluntary Movement
1490692|NCT00029302|Healthy Volunteer
1490693|NCT00029302|HV
1490694|NCT00029302|Normal Control
1490695|NCT00029276|Parkinson's
1490696|NCT00029276|Depression
1490697|NCT00029276|Magnetic Stimulation
1490698|NCT00029250|complementary therapies
1490699|NCT00029250|garlic
1490700|NCT00029250|Allium sativum
1490701|NCT00029250|metabolic diseases
1490702|NCT00029250|HAART
1490703|NCT00029250|Protease inhibitors
1490704|NCT00029237|Behavioral intervention
1490705|NCT00029237|Psychoneuroimmunology
1490706|NCT00029237|Complementary therapy
1490707|NCT00029237|Stress and coping
1490708|NCT00029237|complementary therapies
1490709|NCT00029224|bone lesions
1490710|NCT00029224|breast cancer
1490711|NCT00029224|multiple myeloma
1490712|NCT00029224|prostate cancer
1490713|NCT00029224|bone metastases
1490714|NCT00029224|pain
1490715|NCT00029198|Massage Therapy
1490716|NCT00029198|Preterm Infants
1490717|NCT00029198|Weight Gain
1490718|NCT00029198|Vagal Tone
1490719|NCT00029198|IGF-1
1490720|NCT00029198|Oxytocin
1490721|NCT00029198|Brazelton
1490722|NCT00029185|Corneal Erosion
1490723|NCT00029185|Dextrans
1490724|NCT00029185|Administration, Topical
1490725|NCT00029185|Ophthalmic Solutions
1490726|NCT00029185|Thimerosal
1490727|NCT00029172|stroke
1490728|NCT00029172|depression
1490729|NCT00029159|Turner syndrome
1490730|NCT00029159|estrogen
1490731|NCT00029159|androgen
1490732|NCT00029159|growth hormone
1490733|NCT00029146|stroke
1490734|NCT00029146|transient ischemic attack (TIA)
1490735|NCT00029146|carotid arteries
1490736|NCT00029146|cerebral infarction
1490737|NCT00029133|aneurysm
1490738|NCT00029133|hypothermia
1490739|NCT00029133|subarachnoid intracranial hemorrhage
1490740|NCT00029120|Alzheimer's Disease
1490741|NCT00029120|Spectroscopy
1490742|NCT00029120|Longitudinal
1490743|NCT00029120|Perfusion
1490744|NCT00029120|Hippocampus
1490745|NCT00029120|N-acetylaspartic Acid
1490746|NCT00029120|Cerebral Blood Flow
1490747|NCT00029120|Aging
1490748|NCT00029120|Dementia
1490749|NCT00029120|Alzheimer's
1490750|NCT00029120|Memory Disorder
1490751|NCT00029120|Memory
1490752|NCT00029120|Healthy Volunteer
1490753|NCT00029120|HV
1490754|NCT00029120|Normal Control
1490755|NCT00029107|Hepatitis
1490756|NCT00029107|Vasculitis
1490757|NCT00029107|Rituximab
1490758|NCT00029107|Cryoglobulinemia
1490759|NCT00029107|Hepatitis C
1490760|NCT00029107|HcV-cV
1490761|NCT00029107|Cryoglobulinemic Vasculitis
1490762|NCT00029068|Neurophysiology
1490763|NCT00029068|Tourette Syndrome
1490764|NCT00029068|Anorexia
1490765|NCT00029068|SRIs
1490766|NCT00029068|Personality
1490767|NCT00029068|Obsessive-Compulsive Disorder (OCD)
1490768|NCT00029068|Cortical Excitability
1490769|NCT00029068|Motor Cortex
1490770|NCT00029068|Transcranial Magnetic Stimulation
1490771|NCT00029068|OCD Spectrum Disorders
1490772|NCT00029068|Obsessive Compulsive
1490773|NCT00029068|OCD
1490774|NCT00029068|Healthy Volunteer
1490775|NCT00029068|Normal Control
1490776|NCT00029068|HV
1490777|NCT00029042|MRI
1490778|NCT00029042|Inflammation
1490779|NCT00029042|Joint Disability
1490780|NCT00029042|Imaging
1490781|NCT00029042|Biologic Therapy
1490782|NCT00029042|Rheumatoid Arthritis
1490783|NCT00029042|Juvenile Rheumatoid Arthritis
1490784|NCT00029042|JRA
1490785|NCT00029042|Children
1490786|NCT00029042|Joints
1490787|NCT00029042|Joint Inflammation
1490788|NCT00029029|bone metastases
1490789|NCT00029029|pain
1490790|NCT00028990|stage IV breast cancer
1490791|NCT00028990|recurrent breast cancer
1490792|NCT00028990|male breast cancer
1490793|NCT00028977|stage IV breast cancer
1490794|NCT00028977|recurrent breast cancer
1490795|NCT00028964|stage I breast cancer
1490796|NCT00028964|stage II breast cancer
1490797|NCT00028964|stage IIIA breast cancer
1490798|NCT00028964|recurrent breast cancer
1490799|NCT00028964|drug/agent toxicity by tissue/organ
1490800|NCT00028951|lymphedema
1490801|NCT00028951|perioperative/postoperative complications
1490802|NCT00028951|stage I vulvar cancer
1490803|NCT00028951|stage II vulvar cancer
1490804|NCT00028951|stage III vulvar cancer
1490805|NCT00028951|stage IVB vulvar cancer
1490806|NCT00028938|squamous cell lung cancer
1490807|NCT00028938|large cell lung cancer
1490808|NCT00028938|stage IIIA non-small cell lung cancer
1490809|NCT00028938|stage IIIB non-small cell lung cancer
1490810|NCT00028938|adenocarcinoma of the lung
1490811|NCT00028938|bronchoalveolar cell lung cancer
1490812|NCT00028925|extensive stage small cell lung cancer
1490813|NCT00028912|recurrent ovarian epithelial cancer
1490814|NCT00028912|primary peritoneal cavity cancer
1490815|NCT00028912|fallopian tube cancer
1490816|NCT00028899|recurrent childhood acute myeloid leukemia
1490817|NCT00028899|secondary acute myeloid leukemia
1490818|NCT00028899|previously treated myelodysplastic syndromes
1490819|NCT00028886|stage II multiple myeloma
1490820|NCT00028886|stage III multiple myeloma
1490821|NCT00028873|stage IV breast cancer
1490822|NCT00028873|recurrent breast cancer
1490823|NCT00028860|stage III bladder cancer
1490824|NCT00028860|stage IV bladder cancer
1490825|NCT00028860|transitional cell carcinoma of the bladder
1490826|NCT00028860|localized transitional cell cancer of the renal pelvis and ureter
1490827|NCT00028860|regional transitional cell cancer of the renal pelvis and ureter
1490828|NCT00028847|chronic phase chronic myelogenous leukemia
1490829|NCT00028847|chronic myelogenous leukemia, BCR-ABL1 positive
1490830|NCT00028795|childhood brain stem glioma
1490831|NCT00028795|childhood high-grade cerebral astrocytoma
1490832|NCT00028795|childhood spinal cord neoplasm
1490833|NCT00028795|untreated childhood brain stem glioma
1490834|NCT00028769|adenocarcinoma of the prostate
1490835|NCT00028769|stage IV prostate cancer
1490836|NCT00028769|recurrent prostate cancer
1490837|NCT00028743|stage II ovarian epithelial cancer
1490838|NCT00028743|stage III ovarian epithelial cancer
1490839|NCT00028743|stage IV ovarian epithelial cancer
1490840|NCT00028743|fallopian tube cancer
1490841|NCT00028743|peritoneal cavity cancer
1490842|NCT00028730|recurrent childhood lymphoblastic lymphoma
1490843|NCT00028730|chronic phase chronic myelogenous leukemia
1490844|NCT00028730|childhood acute myeloid leukemia in remission
1490945|NCT00028431|Antibodies
1490845|NCT00028730|childhood acute lymphoblastic leukemia in remission
1490846|NCT00028730|secondary acute myeloid leukemia
1490847|NCT00028730|de novo myelodysplastic syndromes
1490848|NCT00028730|previously treated myelodysplastic syndromes
1490849|NCT00028730|secondary myelodysplastic syndromes
1490850|NCT00028730|recurrent childhood small noncleaved cell lymphoma
1490851|NCT00028730|recurrent childhood large cell lymphoma
1490852|NCT00028730|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1490853|NCT00028717|stage I grade 3 follicular lymphoma
1490854|NCT00028717|stage I adult diffuse large cell lymphoma
1490855|NCT00028717|stage III grade 3 follicular lymphoma
1490856|NCT00028717|stage III adult diffuse large cell lymphoma
1490857|NCT00028717|stage IV grade 3 follicular lymphoma
1490858|NCT00028717|stage IV adult diffuse large cell lymphoma
1490859|NCT00028717|stage I mantle cell lymphoma
1490860|NCT00028717|contiguous stage II grade 3 follicular lymphoma
1490861|NCT00028717|contiguous stage II mantle cell lymphoma
1490862|NCT00028717|contiguous stage II adult diffuse large cell lymphoma
1490863|NCT00028717|noncontiguous stage II grade 3 follicular lymphoma
1490864|NCT00028717|noncontiguous stage II mantle cell lymphoma
1490865|NCT00028717|noncontiguous stage II adult diffuse large cell lymphoma
1490866|NCT00028717|stage III mantle cell lymphoma
1490867|NCT00028717|stage IV mantle cell lymphoma
1490868|NCT00028704|stage II breast cancer
1490869|NCT00028704|stage IIIA breast cancer
1490870|NCT00028704|stage IIIB breast cancer
1490871|NCT00028704|inflammatory breast cancer
1490872|NCT00028691|stage III grade 1 follicular lymphoma
1490873|NCT00028691|stage III grade 2 follicular lymphoma
1490874|NCT00028691|stage III grade 3 follicular lymphoma
1490875|NCT00028691|stage IV grade 1 follicular lymphoma
1490876|NCT00028691|stage IV grade 2 follicular lymphoma
1490877|NCT00028691|stage IV grade 3 follicular lymphoma
1490878|NCT00028678|adult glioblastoma
1490879|NCT00028678|adult giant cell glioblastoma
1490880|NCT00028678|adult gliosarcoma
1490881|NCT00028665|stage III grade 1 follicular lymphoma
1490882|NCT00028665|stage III grade 2 follicular lymphoma
1490883|NCT00028665|stage III grade 3 follicular lymphoma
1490884|NCT00028665|stage III adult diffuse small cleaved cell lymphoma
1490885|NCT00028665|stage III adult diffuse mixed cell lymphoma
1490886|NCT00028665|stage III adult diffuse large cell lymphoma
1490887|NCT00028665|stage III adult immunoblastic large cell lymphoma
1490888|NCT00028665|stage III adult lymphoblastic lymphoma
1490889|NCT00028665|stage IV grade 1 follicular lymphoma
1490890|NCT00028665|stage IV grade 2 follicular lymphoma
1490891|NCT00028665|stage IV grade 3 follicular lymphoma
1490892|NCT00028665|stage IV adult diffuse small cleaved cell lymphoma
1490893|NCT00028665|stage IV adult diffuse mixed cell lymphoma
1490894|NCT00028665|stage IV adult diffuse large cell lymphoma
1490895|NCT00028665|stage IV adult immunoblastic large cell lymphoma
1490896|NCT00028665|stage IV adult lymphoblastic lymphoma
1490897|NCT00028665|recurrent grade 1 follicular lymphoma
1490898|NCT00028665|recurrent grade 2 follicular lymphoma
1490899|NCT00028665|recurrent grade 3 follicular lymphoma
1490900|NCT00028665|recurrent adult diffuse small cleaved cell lymphoma
1490901|NCT00028665|recurrent adult diffuse mixed cell lymphoma
1490902|NCT00028665|recurrent adult diffuse large cell lymphoma
1490903|NCT00028665|recurrent adult immunoblastic large cell lymphoma
1490904|NCT00028665|stage III mantle cell lymphoma
1490905|NCT00028665|stage IV mantle cell lymphoma
1490906|NCT00028665|recurrent mantle cell lymphoma
1490907|NCT00028652|skin metastases
1490908|NCT00028639|stage IV breast cancer
1490909|NCT00028639|recurrent breast cancer
1490910|NCT00028626|liver metastases
1490911|NCT00028626|adenocarcinoma of the colon
1490912|NCT00028626|recurrent colon cancer
1490913|NCT00028626|stage IV colon cancer
1490914|NCT00028626|adenocarcinoma of the rectum
1490915|NCT00028626|recurrent rectal cancer
1490916|NCT00028626|stage IV rectal cancer
1490917|NCT00028613|recurrent adult diffuse large cell lymphoma
1490918|NCT00028600|refractory multiple myeloma
1490919|NCT00028600|stage I multiple myeloma
1490920|NCT00028600|stage II multiple myeloma
1490921|NCT00028600|stage III multiple myeloma
1490922|NCT00028574|stage I prostate cancer
1490923|NCT00028574|stage IIB prostate cancer
1490924|NCT00028574|stage IIA prostate cancer
1490925|NCT00028574|stage III prostate cancer
1490926|NCT00028574|stage IV prostate cancer
1490927|NCT00028574|recurrent prostate cancer
1490928|NCT00028574|hot flashes
1490929|NCT00028548|unspecified adult solid tumor, protocol specific
1490930|NCT00028509|neurotoxicity
1490931|NCT00028509|long-term effects secondary to cancer therapy in children
1490932|NCT00028483|stage IV breast cancer
1490933|NCT00028483|recurrent breast cancer
1490934|NCT00028431|Stage III melanoma
1490935|NCT00028431|Stage IV melanoma
1490936|NCT00028431|Interleukin-12
1490937|NCT00028431|Cancer Vaccines
1490938|NCT00028431|Antineoplastic Agents, Combined
1490939|NCT00028431|Incomplete Freund's adjuvant
1490940|NCT00028431|Monophenol Monooxygenase
1490941|NCT00028431|Mannitol
1490942|NCT00028431|Adjuvants, Immunologic
1490943|NCT00028431|Melan-A Protein
1490944|NCT00028431|Antigens, Neoplasm
1490946|NCT00028431|Melanocyte lineage-specific antigen gp100
1490947|NCT00028431|CTLA-4
1490948|NCT00028418|Acute Leukemia
1490949|NCT00028418|Chronic Lymphocytic Leukemia
1490950|NCT00028418|Antineoplastic Agents
1490951|NCT00028418|Nucleosides
1490952|NCT00028418|Dose-Response Relationship, Drug
1490953|NCT00028418|Cladribine
1490954|NCT00028418|Fludarabine
1490955|NCT00028405|Photodynamic Therapy
1490956|NCT00028405|Bulky Tumor
1490957|NCT00028405|Refractory Tumor
1490958|NCT00028405|Head and Neck Cancer
1490959|NCT00028405|Breast Cancer
1490960|NCT00028405|Pelvic Tumors
1490961|NCT00028405|Liver Metastasis
1490962|NCT00028405|Colorectal Cancer
1490963|NCT00028405|Sarcoma
1490964|NCT00028405|Anal Cancer
1490965|NCT00028405|Oral Cancer
1490966|NCT00028405|Recurrent
1490967|NCT00028405|Lymphadenopathy
1490968|NCT00028405|Ovarian Cancer
1490969|NCT00028405|Cervical Cancer
1490970|NCT00028379|Plasticity
1490971|NCT00028379|Motor Cortex
1490972|NCT00028379|Stroke
1490973|NCT00028379|Somatosensory
1490974|NCT00028379|Hemiparesis
1490975|NCT00028366|HIV-1
1490976|NCT00028366|Drug Therapy, Combination
1490977|NCT00028366|HIV Protease Inhibitors
1490978|NCT00028366|Ritonavir
1490979|NCT00028366|RNA, Viral
1490980|NCT00028366|Reverse Transcriptase Inhibitors
1490981|NCT00028366|Viral Load
1490982|NCT00028366|ABT 378
1490983|NCT00028366|tenofovir disoproxil
1490984|NCT00028366|VX-175
1490985|NCT00028366|Treatment Experienced
1490986|NCT00028353|PIN
1490987|NCT00028353|High Grade Prostate Intraepithelial Neoplasia (PIN)
1490994|NCT00028327|AIDS-Related Opportunistic Infections
1490995|NCT00028327|Zidovudine
1490996|NCT00028327|HIV Protease Inhibitors
1490997|NCT00028327|CD4 Lymphocyte Count
1490998|NCT00028327|Lamivudine
1490999|NCT00028327|Pneumonia
1491000|NCT00028327|Nelfinavir
1491001|NCT00028327|Reverse Transcriptase Inhibitors
1491002|NCT00028327|Antiretroviral Therapy, Highly Active
1491003|NCT00028327|Efavirenz
1491004|NCT00028327|Intensive Care Units
1491005|NCT00028327|Sepsis
1491006|NCT00028314|HIV-1
1491007|NCT00028314|Abacavir
1491008|NCT00028314|Nevirapine
1491009|NCT00028314|Ritonavir
1491010|NCT00028314|RNA, Viral
1491011|NCT00028314|HIV Protease Inhibitors
1491012|NCT00028314|Reverse Transcriptase Inhibitors
1491013|NCT00028314|Anti-HIV Agents
1491014|NCT00028314|Viral Load
1491015|NCT00028314|HIV Wasting Syndrome
1491016|NCT00028314|ABT 378
1491017|NCT00028314|Treatment Experienced
1491018|NCT00028301|HIV Protease Inhibitors
1491019|NCT00028301|RNA, Viral
1491020|NCT00028301|Reverse Transcriptase Inhibitors
1491021|NCT00028301|Anti-HIV Agents
1491022|NCT00028301|Viral Load
1491023|NCT00028301|Lipids
1491024|NCT00028301|ABT 378
1491025|NCT00028301|Antiretroviral Therapy, Highly Active
1491026|NCT00028301|Lipoproteins, LDL Cholesterol
1491027|NCT00028288|Asthma
1491028|NCT00028288|Daclizumab
1491029|NCT00028288|anti-Tac monoclonal antibody
1491030|NCT00028288|anti-IL-2
1491031|NCT00028288|Zenapax
1491032|NCT00028275|Hepatitis C Virus
1491033|NCT00028275|Cirrhosis
1491034|NCT00028275|Antiviral Agents
1491035|NCT00028275|Viral Resistance
1491036|NCT00028275|Alpha Interferon
1491037|NCT00028275|Hepatitis C
1491038|NCT00028275|Hepatitis
1491039|NCT00028262|Palmitoyl-Protein Thioesterase
1491040|NCT00028262|Lysosomes
1491041|NCT00028262|Batten Disease
1491042|NCT00028262|Encephalopathy
1491043|NCT00028262|Progressive Neurodegeneration
1491044|NCT00028262|CLN 1
1491045|NCT00028262|Infantile Neuronal Ceroid Lipofuscinosis
1491046|NCT00028262|Cystagon
1491047|NCT00028249|Patient Satisfaction
1491048|NCT00028249|Self Efficacy
1491049|NCT00028249|Social Support
1491050|NCT00028249|Symptom Management
1491051|NCT00028249|Advanced Malignancies
1491052|NCT00028249|Pain Intervention
1491053|NCT00028236|Peripheral Blood Stem Cells
1491054|NCT00028236|Common Gamma Chain (GC)
1491055|NCT00028236|Immune Reconstitution
1491056|NCT00028236|T Lymphocytes
1491057|NCT00028236|B Lymphocytes
1491058|NCT00028236|X-Linked Severe Combined Immune Deficiency (XSCID)
1491059|NCT00028236|Gene Therapy
1491060|NCT00028236|NK Cell
1491061|NCT00028236|Bone Marrow Transplantation
1491062|NCT00028236|Engraftment
1491063|NCT00028236|XSCID
1491064|NCT00028236|Immune Deficiency
1491065|NCT00028236|Immune System
1491066|NCT00028210|Amputee
1491067|NCT00028210|Plasticity
1491068|NCT00028210|Somatosensory
1491069|NCT00028210|Upper Limb Amputation
1491070|NCT00028210|Tactile Performance
1491071|NCT00028210|Cortical Reorganization
1491072|NCT00028210|Healthy Volunteer
1491073|NCT00028210|HV
1491074|NCT00028210|Normal Control
1491075|NCT00028197|Voluntary Movement
1491076|NCT00028197|Functional MRI
1491077|NCT00028197|Sensorimotor Integration
1491078|NCT00028197|Superior Parietal Lobe
1491079|NCT00028197|Supplementary Motor Area
1491080|NCT00028197|Normal Control
1491081|NCT00028197|HV
1491082|NCT00028197|Healthy Volunteer
1491083|NCT00028184|Chronic Stroke
1491084|NCT00028184|Ipsilateral Motor Cortex
1491085|NCT00028184|Motor Control
1491086|NCT00028184|Motor Recovery
1491087|NCT00028184|Stroke
1491088|NCT00028184|Healthy Volunteer
1491089|NCT00028184|HV
1491090|NCT00028184|Healthy Control
1491091|NCT00028158|Antineoplastic agents
1491092|NCT00028158|Herpes virus
1491093|NCT00028158|Brain tumor
1491094|NCT00028158|Oncolytic virs
1491095|NCT00028145|Women's Health
1491096|NCT00028145|Disease Transmission, Vertical
1491097|NCT00028145|Preventive Medicine
1491098|NCT00028145|Treatment Experienced
1491099|NCT00028132|Risk Factors
1491100|NCT00028132|Mucous Membrane
1491101|NCT00028132|Anti-Infective Agents
1491102|NCT00028132|Cervix Uteri
1491103|NCT00028132|Vagina
1491104|NCT00028132|Anti-HIV Agents
1491105|NCT00028132|Pharmacokinetics
1491106|NCT00028132|Vulva
1491107|NCT00028132|9-(2-phosphonylmethoxypropyl)adenine
1491108|NCT00028132|HIV Seronegativity
1491109|NCT00028119|Clinical Trials
1491110|NCT00028119|Sexual Partners
1491111|NCT00028119|Risk Factors
1491112|NCT00028119|Incidence
1491113|NCT00028119|HIV Seronegativity
1491114|NCT00028119|India
1491115|NCT00028119|Patient Compliance
1491116|NCT00028119|Preventive Health Services
1491117|NCT00028106|Cancer
1491118|NCT00028106|Metastasis
1491119|NCT00028106|Fluorodopamine
1491120|NCT00028106|PET
1491121|NCT00028106|Methylprednisolone
1491122|NCT00028106|Catecholamines
1491123|NCT00028106|Metanephrines
1491124|NCT00028106|Alpha-Methyl-Para-Tyrosine
1491125|NCT00028106|Retinoic Acid
1491126|NCT00028106|Carbidopa
1491127|NCT00028093|Chronic Hepatitis
1491128|NCT00028093|Cirrhosis
1491129|NCT00028093|Hepatitis C Virus
1491130|NCT00028093|Hemolysis
1491131|NCT00028093|Ribavirin
1491132|NCT00028093|Alpha Interferon
1491133|NCT00028093|Peginterferon
1491134|NCT00028093|Antiviral Agents
1491135|NCT00028093|Viral Hepatitis
1491136|NCT00028093|Hemolytic Anemia
1491137|NCT00028093|Renal Failure
1491138|NCT00028093|Renal Dialysis
1491139|NCT00028093|Hepatitis
1491140|NCT00028093|Hepatitis C
1491141|NCT00028080|Borrelia Burgdorferi
1491142|NCT00028080|Lyme Disease
1491143|NCT00028080|Infection
1491144|NCT00028080|Therapy
1491145|NCT00028080|Lyme
1491146|NCT00028067|Drug Therapy, Combination
1491147|NCT00028067|HIV Protease Inhibitors
1491148|NCT00028067|RNA, Viral
1491149|NCT00028067|Reverse Transcriptase Inhibitors
1491150|NCT00028067|Viral Load
1491151|NCT00028067|BMS 232632
1491152|NCT00028015|stage IV colon cancer
1491153|NCT00028015|stage IV rectal cancer
1491154|NCT00028015|recurrent colon cancer
1491155|NCT00028015|recurrent rectal cancer
1491156|NCT00027989|stage IV breast cancer
1491157|NCT00027976|actinic keratosis
1491158|NCT00027963|neurotoxicity
1491159|NCT00027963|pain
1491160|NCT00027937|stage I adult Hodgkin lymphoma
1491161|NCT00027937|stage II adult Hodgkin lymphoma
1491162|NCT00027937|stage III adult Hodgkin lymphoma
1491163|NCT00027937|stage IV adult Hodgkin lymphoma
1491164|NCT00027937|recurrent adult Hodgkin lymphoma
1491165|NCT00027937|unspecified childhood solid tumor, protocol specific
1491166|NCT00027937|unspecified adult solid tumor, protocol specific
1491167|NCT00027937|stage II childhood Hodgkin lymphoma
1491168|NCT00027937|stage I childhood Hodgkin lymphoma
1491169|NCT00027937|stage III childhood Hodgkin lymphoma
1491170|NCT00027937|stage IV childhood Hodgkin lymphoma
1491171|NCT00027937|recurrent/refractory childhood Hodgkin lymphoma
1491172|NCT00027937|stage I grade 1 follicular lymphoma
1491173|NCT00027937|stage I grade 2 follicular lymphoma
1491174|NCT00027937|stage I grade 3 follicular lymphoma
1491175|NCT00027937|stage I adult diffuse small cleaved cell lymphoma
1491176|NCT00027937|stage I adult diffuse mixed cell lymphoma
1491177|NCT00027937|stage I adult diffuse large cell lymphoma
1491178|NCT00027937|stage I adult immunoblastic large cell lymphoma
1491179|NCT00027937|stage I adult lymphoblastic lymphoma
1491180|NCT00027937|stage I adult Burkitt lymphoma
1491181|NCT00027937|stage III grade 1 follicular lymphoma
1491182|NCT00027937|stage III grade 2 follicular lymphoma
1491183|NCT00027937|stage III grade 3 follicular lymphoma
1491184|NCT00027937|stage III adult diffuse small cleaved cell lymphoma
1491185|NCT00027937|stage III adult diffuse mixed cell lymphoma
1491186|NCT00027937|stage III adult diffuse large cell lymphoma
1491187|NCT00027937|stage III adult immunoblastic large cell lymphoma
1491188|NCT00027937|stage III adult lymphoblastic lymphoma
1491189|NCT00027937|stage III adult Burkitt lymphoma
1491190|NCT00027937|stage IV grade 1 follicular lymphoma
1491191|NCT00027937|stage IV grade 2 follicular lymphoma
1491192|NCT00027937|stage IV grade 3 follicular lymphoma
1491193|NCT00027937|stage IV adult diffuse small cleaved cell lymphoma
1491194|NCT00027937|stage IV adult diffuse mixed cell lymphoma
1491195|NCT00027937|stage IV adult diffuse large cell lymphoma
1491196|NCT00027937|stage IV adult immunoblastic large cell lymphoma
1491197|NCT00027937|stage IV adult lymphoblastic lymphoma
1491198|NCT00027937|stage IV adult Burkitt lymphoma
1491199|NCT00027937|recurrent grade 1 follicular lymphoma
1491200|NCT00027937|recurrent grade 2 follicular lymphoma
1491201|NCT00027937|recurrent grade 3 follicular lymphoma
1491202|NCT00027937|recurrent adult diffuse small cleaved cell lymphoma
1491203|NCT00027937|recurrent adult diffuse mixed cell lymphoma
1491204|NCT00027937|recurrent adult diffuse large cell lymphoma
1491205|NCT00027937|recurrent adult immunoblastic large cell lymphoma
1491206|NCT00027937|recurrent adult lymphoblastic lymphoma
1491207|NCT00027937|recurrent adult Burkitt lymphoma
1491208|NCT00027937|stage I childhood small noncleaved cell lymphoma
1491209|NCT00027937|stage I childhood large cell lymphoma
1491210|NCT00027937|stage II childhood small noncleaved cell lymphoma
1491211|NCT00027937|stage II childhood large cell lymphoma
1491212|NCT00027937|stage III childhood small noncleaved cell lymphoma
1491213|NCT00027937|stage III childhood large cell lymphoma
1491214|NCT00027937|stage IV childhood small noncleaved cell lymphoma
1491215|NCT00027937|stage IV childhood large cell lymphoma
1491216|NCT00027937|recurrent childhood small noncleaved cell lymphoma
1491217|NCT00027937|recurrent childhood large cell lymphoma
1491218|NCT00027937|stage I mantle cell lymphoma
1491219|NCT00027937|contiguous stage II grade 1 follicular lymphoma
1491220|NCT00027937|contiguous stage II grade 2 follicular lymphoma
1491221|NCT00027937|contiguous stage II grade 3 follicular lymphoma
1491222|NCT00027937|contiguous stage II adult diffuse small cleaved cell lymphoma
1491223|NCT00027937|contiguous stage II mantle cell lymphoma
1491224|NCT00027937|contiguous stage II adult diffuse mixed cell lymphoma
1491225|NCT00027937|contiguous stage II adult immunoblastic large cell lymphoma
1491226|NCT00027937|contiguous stage II adult diffuse large cell lymphoma
1491227|NCT00027937|contiguous stage II adult Burkitt lymphoma
1491228|NCT00027937|contiguous stage II adult lymphoblastic lymphoma
1491229|NCT00027937|noncontiguous stage II grade 1 follicular lymphoma
1491230|NCT00027937|noncontiguous stage II grade 2 follicular lymphoma
1491231|NCT00027937|noncontiguous stage II grade 3 follicular lymphoma
1491232|NCT00027937|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1491233|NCT00027937|noncontiguous stage II mantle cell lymphoma
1491234|NCT00027937|noncontiguous stage II adult diffuse mixed cell lymphoma
1491235|NCT00027937|noncontiguous stage II adult immunoblastic large cell lymphoma
1491236|NCT00027937|noncontiguous stage II adult diffuse large cell lymphoma
1491237|NCT00027937|noncontiguous stage II adult Burkitt lymphoma
1491238|NCT00027937|noncontiguous stage II adult lymphoblastic lymphoma
1491239|NCT00027937|stage III mantle cell lymphoma
1491240|NCT00027937|stage IV mantle cell lymphoma
1491241|NCT00027937|recurrent mantle cell lymphoma
1491242|NCT00027937|noncontiguous stage II small lymphocytic lymphoma
1491243|NCT00027937|noncontiguous stage II marginal zone lymphoma
1491244|NCT00027937|recurrent marginal zone lymphoma
1491245|NCT00027937|recurrent small lymphocytic lymphoma
1491246|NCT00027937|stage I marginal zone lymphoma
1491247|NCT00027937|stage I small lymphocytic lymphoma
1491248|NCT00027937|stage III small lymphocytic lymphoma
1491249|NCT00027937|stage III marginal zone lymphoma
1491250|NCT00027937|stage IV small lymphocytic lymphoma
1491251|NCT00027937|stage IV marginal zone lymphoma
1491252|NCT00027937|contiguous stage II marginal zone lymphoma
1491253|NCT00027937|contiguous stage II small lymphocytic lymphoma
1491254|NCT00027937|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1491255|NCT00027937|nodal marginal zone B-cell lymphoma
1491256|NCT00027937|splenic marginal zone lymphoma
1491257|NCT00027924|relapsing chronic myelogenous leukemia
1491258|NCT00027924|chronic phase chronic myelogenous leukemia
1491259|NCT00027924|accelerated phase chronic myelogenous leukemia
1491260|NCT00027924|blastic phase chronic myelogenous leukemia
1491261|NCT00027924|meningeal chronic myelogenous leukemia
1491262|NCT00027924|Philadelphia chromosome positive chronic myelogenous leukemia
1491263|NCT00027924|refractory anemia
1491264|NCT00027924|refractory anemia with ringed sideroblasts
1491265|NCT00027924|refractory anemia with excess blasts
1491266|NCT00027924|refractory anemia with excess blasts in transformation
1491267|NCT00027924|chronic myelomonocytic leukemia
1491268|NCT00027924|secondary acute myeloid leukemia
1491269|NCT00027924|de novo myelodysplastic syndromes
1491270|NCT00027924|previously treated myelodysplastic syndromes
1491271|NCT00027924|secondary myelodysplastic syndromes
1491272|NCT00027924|childhood myelodysplastic syndromes
1491273|NCT00027911|adult synovial sarcoma
1491274|NCT00027911|stage III adult soft tissue sarcoma
1491275|NCT00027911|recurrent adult soft tissue sarcoma
1491276|NCT00027911|stage IV adult soft tissue sarcoma
1491277|NCT00027911|stage II adult soft tissue sarcoma
1491278|NCT00027885|stage IV breast cancer
1491279|NCT00027885|stage IIIA breast cancer
1491280|NCT00027885|stage IIIB breast cancer
1491281|NCT00027885|stage IIIC breast cancer
1491282|NCT00027885|male breast cancer
1491283|NCT00027859|adenocarcinoma of the prostate
1491284|NCT00027859|stage III prostate cancer
1491285|NCT00027846|childhood supratentorial ependymoma
1491286|NCT00027846|newly diagnosed childhood ependymoma
1491287|NCT00027846|childhood infratentorial ependymoma
1491288|NCT00027833|stage IV colon cancer
1491289|NCT00027833|stage IV rectal cancer
1491290|NCT00027833|adenocarcinoma of the colon
1491291|NCT00027833|adenocarcinoma of the rectum
1491292|NCT00027807|stage IV breast cancer
1491293|NCT00027807|recurrent breast cancer
1491294|NCT00027807|ductal breast carcinoma
1491295|NCT00027794|adenocarcinoma of the prostate
1491296|NCT00027794|stage III prostate cancer
1491297|NCT00027781|adenocarcinoma of the prostate
1491298|NCT00027781|recurrent prostate cancer
1491299|NCT00027768|localized resectable adult primary liver cancer
1491300|NCT00027768|adult primary hepatocellular carcinoma
1491301|NCT00027742|iris melanoma
1491302|NCT00027742|extraocular extension melanoma
1491303|NCT00027742|recurrent intraocular melanoma
1491304|NCT00027742|stage III melanoma
1491305|NCT00027742|stage IV melanoma
1491306|NCT00027742|recurrent melanoma
1491307|NCT00027729|recurrent colon cancer
1491308|NCT00027729|recurrent rectal cancer
1491309|NCT00027716|metastatic osteosarcoma
1491310|NCT00027716|recurrent adult soft tissue sarcoma
1491311|NCT00027716|recurrent osteosarcoma
1491312|NCT00027716|adult rhabdomyosarcoma
1491313|NCT00027716|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1491314|NCT00027716|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1491315|NCT00027716|stage IV adult soft tissue sarcoma
1491316|NCT00027677|unspecified adult solid tumor, protocol specific
1491317|NCT00027664|stage IV renal cell cancer
1491318|NCT00027638|metastatic gastrointestinal carcinoid tumor
1491319|NCT00027638|recurrent gastrointestinal carcinoid tumor
1491320|NCT00027638|gastrinoma
1491321|NCT00027638|insulinoma
1491322|NCT00027638|recurrent islet cell carcinoma
1491323|NCT00027638|WDHA syndrome
1491324|NCT00027638|somatostatinoma
1491325|NCT00027638|pancreatic polypeptide tumor
1491326|NCT00027638|glucagonoma
1491327|NCT00027638|pulmonary carcinoid tumor
1491328|NCT00027625|recurrent adult brain tumor
1491329|NCT00027625|adult glioblastoma
1491330|NCT00027625|adult anaplastic astrocytoma
1491331|NCT00027625|adult anaplastic oligodendroglioma
1491332|NCT00027625|adult mixed glioma
1491333|NCT00027625|adult giant cell glioblastoma
1491334|NCT00027625|adult gliosarcoma
1491335|NCT00027612|adult glioblastoma
1491336|NCT00027612|adult giant cell glioblastoma
1491337|NCT00027612|adult gliosarcoma
1491338|NCT00027599|adenocarcinoma of the prostate
1491339|NCT00027599|stage I prostate cancer
1491340|NCT00027599|stage IIB prostate cancer
1491341|NCT00027599|stage IIA prostate cancer
1491342|NCT00027599|stage III prostate cancer
1491343|NCT00027599|stage IV prostate cancer
1491344|NCT00027599|recurrent prostate cancer
1491345|NCT00027586|stage IV melanoma
1491346|NCT00027586|recurrent melanoma
1491347|NCT00027586|Imatinib Mesylate
1491348|NCT00027586|Gleevec
1491349|NCT00027586|protein tyrosine kinases
1491350|NCT00027586|PTK
1491351|NCT00027586|Gleevec targets
1491352|NCT00027586|metastatic melanoma
1491353|NCT00027573|stage IV renal cell cancer
1491354|NCT00027573|recurrent renal cell cancer
1491355|NCT00027573|clear cell renal cell carcinoma
1491356|NCT00027573|papillary renal cell carcinoma
1491357|NCT00027560|recurrent childhood acute lymphoblastic leukemia
1491358|NCT00027560|recurrent adult Hodgkin lymphoma
1491359|NCT00027560|refractory multiple myeloma
1491360|NCT00027560|stage II multiple myeloma
1491361|NCT00027560|stage III multiple myeloma
1491362|NCT00027560|recurrent childhood lymphoblastic lymphoma
1491363|NCT00027560|recurrent childhood acute myeloid leukemia
1491364|NCT00027560|recurrent adult acute myeloid leukemia
1491365|NCT00027560|recurrent adult acute lymphoblastic leukemia
1491366|NCT00027560|relapsing chronic myelogenous leukemia
1491367|NCT00027560|refractory chronic lymphocytic leukemia
1491368|NCT00027560|recurrent/refractory childhood Hodgkin lymphoma
1491369|NCT00027560|recurrent grade 1 follicular lymphoma
1491370|NCT00027560|recurrent grade 2 follicular lymphoma
1491371|NCT00027560|recurrent grade 3 follicular lymphoma
1491372|NCT00027560|recurrent adult diffuse small cleaved cell lymphoma
1491373|NCT00027560|recurrent adult diffuse mixed cell lymphoma
1491374|NCT00027560|recurrent adult diffuse large cell lymphoma
1491375|NCT00027560|recurrent adult immunoblastic large cell lymphoma
1491376|NCT00027560|recurrent adult lymphoblastic lymphoma
1491377|NCT00027560|recurrent adult Burkitt lymphoma
1491378|NCT00027560|previously treated myelodysplastic syndromes
1491379|NCT00027560|recurrent childhood small noncleaved cell lymphoma
1491380|NCT00027560|recurrent childhood large cell lymphoma
1491381|NCT00027560|recurrent mantle cell lymphoma
1491382|NCT00027560|Waldenström macroglobulinemia
1491383|NCT00027560|childhood chronic myelogenous leukemia
1491384|NCT00027560|atypical chronic myeloid leukemia, BCR-ABL1 negative
1491385|NCT00027560|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1491386|NCT00027560|recurrent marginal zone lymphoma
1491387|NCT00027560|recurrent small lymphocytic lymphoma
1491500|NCT00027339|Phenotype
1491388|NCT00027560|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1491389|NCT00027560|nodal marginal zone B-cell lymphoma
1491390|NCT00027560|splenic marginal zone lymphoma
1491391|NCT00027560|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1491392|NCT00027560|childhood myelodysplastic syndromes
1491393|NCT00027547|adult acute lymphoblastic leukemia in remission
1491394|NCT00027547|childhood acute lymphoblastic leukemia in remission
1491395|NCT00027534|recurrent colon cancer
1491396|NCT00027534|stage III colon cancer
1491397|NCT00027534|stage IV colon cancer
1491398|NCT00027534|recurrent breast cancer
1491399|NCT00027534|stage IIIA breast cancer
1491400|NCT00027534|stage IIIB breast cancer
1491401|NCT00027534|stage IIIC breast cancer
1491402|NCT00027534|stage IV breast cancer
1491403|NCT00027534|recurrent gastric cancer
1491404|NCT00027534|stage III gastric cancer
1491405|NCT00027534|stage IV gastric cancer
1491406|NCT00027534|recurrent pancreatic cancer
1491407|NCT00027534|stage II pancreatic cancer
1491408|NCT00027534|stage III pancreatic cancer
1491409|NCT00027534|recurrent rectal cancer
1491410|NCT00027534|stage III rectal cancer
1491411|NCT00027534|stage IV rectal cancer
1491412|NCT00027534|advanced adult primary liver cancer
1491413|NCT00027534|recurrent adult primary liver cancer
1491414|NCT00027534|recurrent gallbladder cancer
1491415|NCT00027534|unresectable gallbladder cancer
1491416|NCT00027534|thyroid gland medullary carcinoma
1491417|NCT00027534|recurrent salivary gland cancer
1491418|NCT00027534|stage III salivary gland cancer
1491419|NCT00027534|stage IV salivary gland cancer
1491420|NCT00027534|Paget disease of the breast with intraductal carcinoma
1491421|NCT00027534|Paget disease of the breast with invasive ductal carcinoma
1491422|NCT00027534|adult primary hepatocellular carcinoma
1491423|NCT00027534|diffuse adenocarcinoma of the stomach
1491424|NCT00027534|intestinal adenocarcinoma of the stomach
1491425|NCT00027534|mixed adenocarcinoma of the stomach
1491426|NCT00027534|adenocarcinoma of the colon
1491427|NCT00027534|adenocarcinoma of the gallbladder
1491428|NCT00027534|adenocarcinoma of the rectum
1491552|NCT00027183|Lung Injury
1491429|NCT00027534|recurrent malignant testicular germ cell tumor
1491430|NCT00027534|stage II malignant testicular germ cell tumor
1491431|NCT00027534|stage III malignant testicular germ cell tumor
1491432|NCT00027534|male breast cancer
1491433|NCT00027534|adenocarcinoma of the pancreas
1491434|NCT00027534|cholangiocarcinoma of the gallbladder
1491435|NCT00027534|salivary gland adenocarcinoma
1491436|NCT00027534|ovarian endometrioid adenocarcinoma
1491437|NCT00027534|stage IV pancreatic cancer
1491438|NCT00027521|stage III pancreatic cancer
1491439|NCT00027521|adenocarcinoma of the pancreas
1491440|NCT00027508|advanced malignant mesothelioma
1491441|NCT00027508|recurrent malignant mesothelioma
1491442|NCT00027495|colon cancer
1491443|NCT00027482|T Cell
1491444|NCT00027482|B Cell
1491445|NCT00027482|Flow Cytometry
1491446|NCT00027482|Cell-Mediated Immunity
1491447|NCT00027482|Thymus
1491448|NCT00027482|HIV
1491449|NCT00027482|Immunity
1491450|NCT00027482|Lymphocytes
1491451|NCT00027482|Monocytes
1491452|NCT00027482|Healthy Volunteer
1491453|NCT00027482|HV
1491454|NCT00027482|Normal Control
1491455|NCT00027469|Atheroembolism
1491456|NCT00027469|Atherosclerosis
1491457|NCT00027469|MRI
1491458|NCT00027469|Renal Artery Stenosis
1491459|NCT00027469|Renovascular Hypertension
1491460|NCT00027469|ARAS
1491461|NCT00027469|Renovascular Disease
1491462|NCT00027469|Renal Artery Stenting
1491463|NCT00027469|PTRAS
1491464|NCT00027456|Insulin Resistance
1491465|NCT00027456|Diabetes Mellitus
1491466|NCT00027456|Adipocytes
1491467|NCT00027456|Rabson Mendenhall Syndrome
1491468|NCT00027456|Leprechaunism
1491469|NCT00027456|Leptin
1491470|NCT00027443|Giant Cell Myocarditis
1491471|NCT00027417|Congenital heart defects
1491472|NCT00027417|Hypoplastic left heart syndrome
1491473|NCT00027417|Complete atrioventricular canal defect
1491474|NCT00027417|Triostat
1491475|NCT00027417|Cardiac surgery
1491476|NCT00027404|Adult, Autism
1491477|NCT00027391|Muscle Weakness, Muscular Dystrophy
1491478|NCT00027378|fluoxetine,
1491479|NCT00027378|adolescents,
1491480|NCT00027378|alcohol dependence,
1491481|NCT00027378|major depression
1491482|NCT00027378|Alcoholism
1491483|NCT00027365|HIV Seronegativity
1491484|NCT00027365|HIV Preventive Vaccine
1491485|NCT00027365|Injections, Intramuscular
1491486|NCT00027365|HIV Antibodies
1491487|NCT00027365|HIV-1
1491488|NCT00027365|HIV Envelope Protein gp120
1491489|NCT00027365|Gene Products, tat
1491490|NCT00027365|AIDS Vaccines
1491491|NCT00027365|Neutralization Tests
1491492|NCT00027365|Vaccines, Combined
1491493|NCT00027365|AIDS Seronegativity
1491494|NCT00027365|Gene Products, nef
1491495|NCT00027352|Physician's Practice Patterns
1491496|NCT00027352|Anti-HIV Agents
1491497|NCT00027339|HIV-1
1491498|NCT00027339|HIV Protease Inhibitors
1491499|NCT00027339|RNA, Viral
1491501|NCT00027339|Viral Load
1491502|NCT00027339|Pharmacokinetics
1491503|NCT00027339|Treatment Experienced
1491504|NCT00027326|Blood
1491505|NCT00027326|Samples
1491506|NCT00027326|Radiation
1491507|NCT00027326|Urine
1491508|NCT00027326|Cancer
1491509|NCT00027326|Radiation Therapy
1491510|NCT00027300|Relapsing Remitting Multiple Sclerosis
1491511|NCT00027287|Type I Diabetes
1491512|NCT00027287|Type 2 Diabetes
1491513|NCT00027287|Diode Laser Photocoagulation
1491514|NCT00027287|Vitamin E
1491515|NCT00027287|Elevated Low-Density Lipoprotein (LDL-C) Cholesterol
1491516|NCT00027287|Diabetic Retinopathy
1491517|NCT00027287|Macular Edema
1491518|NCT00027287|Type II Diabetes
1491519|NCT00027274|Fanconi's Anemia
1491520|NCT00027274|Diamond Blackfan Anemia
1491521|NCT00027274|Dyskeratosis Congenita
1491522|NCT00027274|Shwachman-Diamond Syndrome
1491523|NCT00027274|Hereditary
1491524|NCT00027274|Bone Marrow
1491525|NCT00027274|Inherited Bone Marrow Failure Syndromes
1491526|NCT00027274|IBMFS
1491527|NCT00027274|Familial Cancer
1491528|NCT00027261|Vaccines, Synthetic
1491529|NCT00027261|HIV-1
1491530|NCT00027261|AIDS Vaccines
1491531|NCT00027261|CD8-Positive T-Lymphocytes
1491532|NCT00027261|HIV Seronegativity
1491533|NCT00027261|Avipoxvirus
1491534|NCT00027261|Dose-Response Relationship, Immunologic
1491535|NCT00027261|HIV Preventive Vaccine
1491536|NCT00027248|central venous catheter
1491537|NCT00027248|bloodstream infection
1491538|NCT00027248|CVC
1491539|NCT00027248|catheter colonization
1491540|NCT00027248|local catheter site infection
1491541|NCT00027209|seizures
1491542|NCT00027209|epilepsy
1491543|NCT00027209|menopause
1491544|NCT00027196|Genetics
1491545|NCT00027196|Cardiac Diseases
1491546|NCT00027196|Cardiac Hypertrophy
1491547|NCT00027196|Sudden Death
1491548|NCT00027196|Arrhythmias
1491549|NCT00027183|Cystic Fibrosis
1491550|NCT00027183|Effector Proteins
1491551|NCT00027183|Cytotoxin
1491553|NCT00027183|Genetic Screen
1491561|NCT00027157|Coronary Spasm
1491562|NCT00027157|Endothelial-Derived-Relaxation Factor
1491563|NCT00027157|Nitric Oxide Synthase
1491564|NCT00027157|Susceptibility Genes
1491565|NCT00027157|Tetrahydrobiopterin
1491566|NCT00027144|Leukemia
1491567|NCT00027144|Vaccine
1491568|NCT00027131|vaccine
1491569|NCT00027131|immunotherapy
1491570|NCT00027118|Shoulder
1491571|NCT00027118|Breast Cancer
1491572|NCT00027118|Physical Therapy
1491573|NCT00027118|Lymphedema
1491574|NCT00027118|Quality of Life
1491575|NCT00027118|Breast Cancer Surgery
1491576|NCT00027118|Healthy Volunteer
1491577|NCT00027118|HV
1491578|NCT00027118|Normal Control
1491579|NCT00027105|Fatigue
1491580|NCT00027105|Shoulder function
1491581|NCT00027105|Lymphedema
1491582|NCT00027105|Breast Cancer
1491583|NCT00027105|Breast Cancer Surgery
1491584|NCT00027105|Quality of Life
1491585|NCT00027092|Infusions, Intravenous
1491586|NCT00027092|Testosterone
1491587|NCT00027092|Insulin Resistance
1491588|NCT00027092|Hormone Replacement Therapy
1491589|NCT00027092|Glucose Tolerance Test
1491590|NCT00027066|stroke
1491591|NCT00027066|aspirin
1491592|NCT00027066|warfarin
1491593|NCT00027053|alcoholism
1491594|NCT00027053|alcohol dependence
1491595|NCT00027053|trazadone
1491596|NCT00027053|sleep
1491597|NCT00027040|AIDS Dementia Complex
1491598|NCT00027040|Selegiline
1491599|NCT00027040|Oxidative Stress
1491600|NCT00027040|Cognition
1491601|NCT00027040|Neuroprotective Agents
1491602|NCT00027040|Brain Injuries
1491603|NCT00027040|Magnetic Resonance Spectroscopy
1491604|NCT00027040|Protons
1491605|NCT00027014|opioid
1491606|NCT00027014|St. John's wort
1491607|NCT00027014|analgesia
1491608|NCT00027014|metabolism
1491609|NCT00027014|transporter
1491610|NCT00027001|Qigong, exercise, circulatory assist devices
1491611|NCT00026988|Huntington's disease
1491612|NCT00026988|creatine
1491613|NCT00026988|energy depletion
1491614|NCT00026975|Laryngeal Cancer
1491615|NCT00026975|Laryngectomy
1491616|NCT00026975|Tissue Oxygenation
1491617|NCT00026975|Irradiated Tissue
1491618|NCT00026975|Hyperbaric Oxygen
1491619|NCT00026975|Angiogenesis
1491620|NCT00026975|EF5
1491621|NCT00026962|Breast
1491622|NCT00026962|Hormones
1491623|NCT00026962|Prevention
1491624|NCT00026962|Saliva
1491625|NCT00026962|Serum
1491626|NCT00026949|Etoposide
1491627|NCT00026949|Breast Cancer
1491628|NCT00026949|Pharmacokinetics
1491629|NCT00026936|External Beam Radiotherapy
1491630|NCT00026936|TCP
1491631|NCT00026936|DVH
1491632|NCT00026936|NTCP
1491633|NCT00026936|3-D Programming
1491634|NCT00026923|Laparoscopy
1491635|NCT00026923|Telemedicine
1491636|NCT00026923|Surgery
1491637|NCT00026923|Endoscopy
1491638|NCT00026910|Cell-Cycle
1491639|NCT00026910|Apoptosis
1491640|NCT00026910|Molecular Prognosis
1491641|NCT00026897|Adoptive Immunotherapy
1491642|NCT00026897|Cellular Therapy
1491643|NCT00026897|Lymphocyte Migration
1491644|NCT00026897|Tumor Imaging
1491645|NCT00026884|Serum
1491646|NCT00026884|Collection of Tissue
1491647|NCT00026884|Malignant Disease
1491648|NCT00026884|Molecular Basis
1491649|NCT00026884|Genome Sequencing
1491650|NCT00026871|Non-Therapeutic
1491651|NCT00026871|Radiation Therapy
1491652|NCT00026871|Dosimetry
1491653|NCT00026871|Dose-Rate
1491654|NCT00026871|Fiberoptic
1491655|NCT00026858|Bone Marrow Transplantation
1491656|NCT00026858|Leukemia
1491657|NCT00026858|Breast Cancer
1491658|NCT00026858|Multiple Myeloma
1491659|NCT00026858|Total Body Irradiation
1491660|NCT00026832|PET
1491661|NCT00026832|Major Depression
1491662|NCT00026832|MRI
1491663|NCT00026832|Cerebral Blood Flow
1491664|NCT00026832|Neuroendocrine
1491665|NCT00026832|Bipolar Disorder
1491666|NCT00026832|Serotonin1A
1491667|NCT00026832|Mood Disorder
1491668|NCT00026832|Major Depressive Disorder
1491669|NCT00026832|MDD
1491670|NCT00026832|Depression
1491671|NCT00026832|Healthy Volunteer
1491672|NCT00026832|HV
1491673|NCT00026832|Normal Control
1491674|NCT00026819|NSAID
1491675|NCT00026819|Acute Pain Model
1491676|NCT00026819|Hyperalgesia
1491677|NCT00026819|Central Sensitization
1491678|NCT00026819|Wisdom Teeth
1491679|NCT00026819|Wisdom Teeth Extraction
1491680|NCT00026819|Third Molar
1491681|NCT00026806|HIV Infection
1491682|NCT00026806|Mental Health
1491683|NCT00026806|Risk Behaviors
1491684|NCT00026806|Post-Traumatic Stress Disorder
1491685|NCT00026806|Youth
1491686|NCT00026806|HIV
1491687|NCT00026806|Long Term Survivor
1491688|NCT00026793|Kaposi Sarcoma
1491689|NCT00026793|Doppler
1491690|NCT00026793|Infrared
1491691|NCT00026793|HIV
1491692|NCT00026793|Imaging
1491693|NCT00026793|Kaposi's Sarcoma
1491694|NCT00026793|Laser Imaging
1491695|NCT00026793|Infrared Imaging
1491696|NCT00026780|CT Scan
1491697|NCT00026780|MRI Scan
1491698|NCT00026780|Childhood Cancer
1491699|NCT00026780|Eligibility Screening
1491700|NCT00026780|Tissue Procurement
1491701|NCT00026780|Pediatric
1491702|NCT00026780|Children
1491703|NCT00026780|Screening
1491704|NCT00026767|Risk Factors
1491705|NCT00026767|Epidemiology
1491706|NCT00026767|BMT/SCT
1491707|NCT00026767|Fungal Infection
1491708|NCT00026767|Bone Marrow Stem Cell Transplant
1491709|NCT00026767|Organ Transplant
1491717|NCT00026741|Cytokine
1491718|NCT00026741|Inflammation
1491719|NCT00026741|Lymphocyte
1491720|NCT00026741|T Cell
1491721|NCT00026741|Migration
1491722|NCT00026741|Healthy Volunteer
1491723|NCT00026741|Skin Biopsy
1491724|NCT00026728|Human Herpesvirus B
1491725|NCT00026728|NHANES
1491726|NCT00026728|Epidemiology
1491727|NCT00026728|Population-Based Study
1491728|NCT00026728|Kaposi's Sarcoma Herpes Virus
1491729|NCT00026715|Renal Function
1491730|NCT00026715|Iothalamate
1491731|NCT00026702|Acute Renal Failure
1491732|NCT00026702|Biomarkers
1491733|NCT00026689|Evaluation
1491734|NCT00026689|Screening
1491735|NCT00026689|Cancer
1491736|NCT00026689|Radiation
1491737|NCT00026689|Eligibility
1491738|NCT00026676|Surrogate Markers
1491739|NCT00026676|Genotypic Resistance
1491740|NCT00026676|Phenotypic Resistance
1491741|NCT00026676|Selenium
1491742|NCT00026663|Assays
1491743|NCT00026663|Resistance
1491744|NCT00026663|Biopsy Samples
1491745|NCT00026663|Specimen Acquisition
1491746|NCT00026663|Cancer Cells
1491747|NCT00026650|Late Effects
1491748|NCT00026650|Radiation Therapy
1491749|NCT00026650|Cancer
1491750|NCT00026637|depression
1491751|NCT00026637|epilepsy
1491752|NCT00026637|seizures
1491753|NCT00026624|Virus Replication
1491754|NCT00026624|Injections, Subcutaneous
1491755|NCT00026624|HIV-1
1491756|NCT00026624|AIDS Vaccines
1491757|NCT00026624|Dendritic Cells
1491758|NCT00026624|Adoptive Transfer
1491759|NCT00026624|Keyhole-Limpet Hemocyanin
1491760|NCT00026624|HIV Therapeutic Vaccine
1491761|NCT00026611|Vaccine prophylaxis
1491762|NCT00026598|Basal Ganglia
1491763|NCT00026598|Cerebral Cortex
1491764|NCT00026598|Functional Neuroanatomy
1491765|NCT00026598|Bradykinesia
1491766|NCT00026598|Bradyphrenia
1491767|NCT00026598|Parkinson's Disease
1491768|NCT00026598|Parkinson Disease
1491769|NCT00026598|PD
1491770|NCT00026598|Healthy Volunteer
1491771|NCT00026598|HV
1491772|NCT00026598|Normal Control
1491773|NCT00026585|Bipolar Disorder
1491774|NCT00026585|Antimanic
1491775|NCT00026585|Placebo Controlled
1491776|NCT00026585|Randomized
1491777|NCT00026585|Cytochrome P450
1491778|NCT00026585|Mania
1491779|NCT00026585|PKC Inhibitor
1491780|NCT00026585|Tamoxifen
1491781|NCT00026585|Bipolar
1491782|NCT00026585|Manic
1491783|NCT00026585|BPD
1491784|NCT00026559|Classical Conditioning
1491785|NCT00026559|Fear Conditioning
1491786|NCT00026559|Stress
1491787|NCT00026559|Anxiety
1491788|NCT00026559|Learning
1491789|NCT00026559|Normal Volunteers
1491790|NCT00026559|Adults
1491791|NCT00026559|Healthy Volunteer
1491792|NCT00026559|Normal Control
1491793|NCT00026546|Stop Task
1491794|NCT00026546|Functional (BOLD) MRI
1491795|NCT00026546|Developmental
1491796|NCT00026546|Inhibitory Control
1491797|NCT00026546|Attention Deficit Hyperactivity Disorder
1491798|NCT00026546|ADHD
1491799|NCT00026546|Impulsivity
1491800|NCT00026546|Healthy Volunteer
1491801|NCT00026546|Normal Volunteer
1491802|NCT00026546|HV
1491803|NCT00026533|stage IV papillary thyroid cancer
1491804|NCT00026533|stage IV follicular thyroid cancer
1491805|NCT00026533|thyroid gland medullary carcinoma
1491806|NCT00026533|recurrent thyroid cancer
1491807|NCT00026533|insular thyroid cancer
1491808|NCT00026520|stage IV melanoma
1491809|NCT00026520|recurrent melanoma
1491810|NCT00026494|tumors metastatic to brain
1491811|NCT00026468|colon cancer
1491812|NCT00026468|rectal cancer
1491813|NCT00026468|small intestine cancer
1491814|NCT00026442|stage IV breast cancer
1491815|NCT00026442|stage IIIA breast cancer
1491816|NCT00026442|stage IIIB breast cancer
1491817|NCT00026442|stage IIIC breast cancer
1491818|NCT00026429|stage I chronic lymphocytic leukemia
1491819|NCT00026429|stage II chronic lymphocytic leukemia
1491820|NCT00026429|stage III chronic lymphocytic leukemia
1491821|NCT00026429|stage IV chronic lymphocytic leukemia
1491822|NCT00026429|refractory chronic lymphocytic leukemia
1491823|NCT00026429|B-cell chronic lymphocytic leukemia
1491824|NCT00026429|stage I grade 1 follicular lymphoma
1491825|NCT00026429|stage I grade 2 follicular lymphoma
1491826|NCT00026429|stage I grade 3 follicular lymphoma
1491827|NCT00026429|stage I adult diffuse small cleaved cell lymphoma
1491828|NCT00026429|stage I adult diffuse mixed cell lymphoma
1491829|NCT00026429|stage I adult diffuse large cell lymphoma
1491830|NCT00026429|stage III grade 1 follicular lymphoma
1491831|NCT00026429|stage III grade 2 follicular lymphoma
1491832|NCT00026429|stage III grade 3 follicular lymphoma
1491833|NCT00026429|stage III adult diffuse small cleaved cell lymphoma
1491834|NCT00026429|stage III adult diffuse mixed cell lymphoma
1491835|NCT00026429|stage III adult diffuse large cell lymphoma
1491836|NCT00026429|stage IV grade 1 follicular lymphoma
1491837|NCT00026429|stage IV grade 2 follicular lymphoma
1491838|NCT00026429|stage IV grade 3 follicular lymphoma
1491839|NCT00026429|stage IV adult diffuse small cleaved cell lymphoma
1491840|NCT00026429|stage IV adult diffuse mixed cell lymphoma
1491841|NCT00026429|stage IV adult diffuse large cell lymphoma
1491842|NCT00026429|recurrent grade 1 follicular lymphoma
1491843|NCT00026429|recurrent grade 2 follicular lymphoma
1491844|NCT00026429|recurrent grade 3 follicular lymphoma
1491845|NCT00026429|recurrent adult diffuse small cleaved cell lymphoma
1491846|NCT00026429|recurrent adult diffuse mixed cell lymphoma
1491847|NCT00026429|recurrent adult diffuse large cell lymphoma
1491848|NCT00026429|stage I mantle cell lymphoma
1491849|NCT00026429|contiguous stage II grade 1 follicular lymphoma
1491850|NCT00026429|contiguous stage II grade 2 follicular lymphoma
1491851|NCT00026429|contiguous stage II grade 3 follicular lymphoma
1491852|NCT00026429|contiguous stage II adult diffuse small cleaved cell lymphoma
1491853|NCT00026429|contiguous stage II mantle cell lymphoma
1491854|NCT00026429|contiguous stage II adult diffuse mixed cell lymphoma
1491855|NCT00026429|contiguous stage II adult diffuse large cell lymphoma
1491856|NCT00026429|noncontiguous stage II grade 1 follicular lymphoma
1491857|NCT00026429|noncontiguous stage II grade 2 follicular lymphoma
1491858|NCT00026429|noncontiguous stage II grade 3 follicular lymphoma
1491859|NCT00026429|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1491860|NCT00026429|noncontiguous stage II mantle cell lymphoma
1491861|NCT00026429|noncontiguous stage II adult diffuse mixed cell lymphoma
1491862|NCT00026429|noncontiguous stage II adult diffuse large cell lymphoma
1491863|NCT00026429|stage III mantle cell lymphoma
1491864|NCT00026429|stage IV mantle cell lymphoma
1491865|NCT00026429|recurrent mantle cell lymphoma
1491866|NCT00026429|noncontiguous stage II small lymphocytic lymphoma
1491867|NCT00026429|noncontiguous stage II marginal zone lymphoma
1491868|NCT00026429|recurrent marginal zone lymphoma
1491869|NCT00026429|recurrent small lymphocytic lymphoma
1491870|NCT00026429|stage I marginal zone lymphoma
1491871|NCT00026429|stage I small lymphocytic lymphoma
1491872|NCT00026429|stage III small lymphocytic lymphoma
1491873|NCT00026429|stage III marginal zone lymphoma
1491874|NCT00026429|stage IV small lymphocytic lymphoma
1491875|NCT00026429|stage IV marginal zone lymphoma
1491876|NCT00026429|contiguous stage II marginal zone lymphoma
1491877|NCT00026429|contiguous stage II small lymphocytic lymphoma
1491878|NCT00026429|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1491879|NCT00026416|stage III adult soft tissue sarcoma
1491880|NCT00026416|localized osteosarcoma
1491881|NCT00026416|metastatic osteosarcoma
1491882|NCT00026416|stage II adult soft tissue sarcoma
1491883|NCT00026416|stage IV adult soft tissue sarcoma
1491884|NCT00026403|stage III pancreatic cancer
1491885|NCT00026403|adenocarcinoma of the pancreas
1491886|NCT00026403|stage IV pancreatic cancer
1491887|NCT00026377|adenocarcinoma of the prostate
1491888|NCT00026377|stage IIB prostate cancer
1491889|NCT00026377|stage IIA prostate cancer
1491890|NCT00026377|stage III prostate cancer
1491891|NCT00026377|stage IV prostate cancer
1491892|NCT00026364|stage IV colon cancer
1491893|NCT00026364|stage IV rectal cancer
1491894|NCT00026364|recurrent colon cancer
1491895|NCT00026364|recurrent rectal cancer
1491896|NCT00026364|adenocarcinoma of the colon
1491897|NCT00026364|adenocarcinoma of the rectum
1491898|NCT00026351|stage I chronic lymphocytic leukemia
1491899|NCT00026351|stage II chronic lymphocytic leukemia
1491900|NCT00026351|stage III chronic lymphocytic leukemia
1491901|NCT00026351|stage IV chronic lymphocytic leukemia
1491902|NCT00026351|refractory chronic lymphocytic leukemia
1491903|NCT00026351|B-cell chronic lymphocytic leukemia
1491904|NCT00026351|stage I grade 1 follicular lymphoma
1491905|NCT00026351|stage I grade 2 follicular lymphoma
1491906|NCT00026351|stage I grade 3 follicular lymphoma
1491907|NCT00026351|stage III grade 1 follicular lymphoma
1491908|NCT00026351|stage III grade 2 follicular lymphoma
1491909|NCT00026351|stage III grade 3 follicular lymphoma
1491910|NCT00026351|stage IV grade 1 follicular lymphoma
1491911|NCT00026351|stage IV grade 2 follicular lymphoma
1491912|NCT00026351|stage IV grade 3 follicular lymphoma
1491913|NCT00026351|recurrent grade 1 follicular lymphoma
1491914|NCT00026351|recurrent grade 2 follicular lymphoma
1491915|NCT00026351|recurrent grade 3 follicular lymphoma
1491916|NCT00026351|prolymphocytic leukemia
1491917|NCT00026351|contiguous stage II grade 1 follicular lymphoma
1491918|NCT00026351|contiguous stage II grade 2 follicular lymphoma
1491919|NCT00026351|contiguous stage II grade 3 follicular lymphoma
1491920|NCT00026351|noncontiguous stage II grade 1 follicular lymphoma
1491921|NCT00026351|noncontiguous stage II grade 2 follicular lymphoma
1491922|NCT00026351|noncontiguous stage II grade 3 follicular lymphoma
1491923|NCT00026351|noncontiguous stage II small lymphocytic lymphoma
1491924|NCT00026351|noncontiguous stage II marginal zone lymphoma
1491925|NCT00026351|recurrent marginal zone lymphoma
1491926|NCT00026351|recurrent small lymphocytic lymphoma
1491927|NCT00026351|stage I marginal zone lymphoma
1491928|NCT00026351|stage I small lymphocytic lymphoma
1491929|NCT00026351|stage III small lymphocytic lymphoma
1491930|NCT00026351|stage III marginal zone lymphoma
1491931|NCT00026351|stage IV small lymphocytic lymphoma
1491932|NCT00026351|stage IV marginal zone lymphoma
1491933|NCT00026351|contiguous stage II marginal zone lymphoma
1491934|NCT00026351|contiguous stage II small lymphocytic lymphoma
1491935|NCT00026351|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1491936|NCT00026338|stage III pancreatic cancer
1491937|NCT00026338|adenocarcinoma of the pancreas
1491938|NCT00026338|stage IV pancreatic cancer
1491939|NCT00026299|stage IV colon cancer
1491940|NCT00026299|stage IV rectal cancer
1491941|NCT00026299|recurrent colon cancer
1491942|NCT00026299|recurrent rectal cancer
1491943|NCT00026299|adenocarcinoma of the colon
1491944|NCT00026299|adenocarcinoma of the rectum
1491945|NCT00026286|stage I breast cancer
1491946|NCT00026286|stage II breast cancer
1491947|NCT00026286|breast cancer in situ
1491948|NCT00026286|ductal breast carcinoma
1491949|NCT00026286|hot flashes
1491950|NCT00026286|menopausal symptoms
1491951|NCT00026273|stage III colon cancer
1491952|NCT00026273|stage III rectal cancer
1491953|NCT00026273|adenocarcinoma of the colon
1491954|NCT00026273|adenocarcinoma of the rectum
1491955|NCT00026260|recurrent cervical cancer
1491956|NCT00026260|cervical squamous cell carcinoma
1491957|NCT00026247|bone metastases
1491958|NCT00026247|pain
1491959|NCT00026247|unspecified adult solid tumor, protocol specific
1491960|NCT00026195|unspecified adult solid tumor, protocol specific
1491961|NCT00026156|recurrent non-small cell lung cancer
1491962|NCT00026156|squamous cell lung cancer
1491963|NCT00026156|large cell lung cancer
1491964|NCT00026156|stage IIIB non-small cell lung cancer
1491965|NCT00026156|stage IV non-small cell lung cancer
1491966|NCT00026156|adenocarcinoma of the lung
1491967|NCT00026130|stage II pancreatic cancer
1491968|NCT00026130|stage III pancreatic cancer
1491969|NCT00026130|adenocarcinoma of the pancreas
1491970|NCT00026117|stage IV colon cancer
1491971|NCT00026117|stage IV breast cancer
1491972|NCT00026117|recurrent breast cancer
1491973|NCT00026117|stage IV rectal cancer
1491974|NCT00026117|recurrent colon cancer
1491975|NCT00026117|recurrent rectal cancer
1491976|NCT00026117|male breast cancer
1491977|NCT00026078|stage IV breast cancer
1491978|NCT00026078|recurrent breast cancer
1491979|NCT00026065|Hypertension
1491980|NCT00026065|BIofeedback
1492113|NCT00025831|Healthy Volunteer
1491981|NCT00026065|Non-pharmacological treatment
1491982|NCT00026065|Prediction
1491983|NCT00026052|Riluzole
1491984|NCT00026052|Neuroprotective
1491985|NCT00026052|Open-Label Study
1491986|NCT00026052|Glutamate Dysfunction
1491987|NCT00026052|Unipolar Depression
1491988|NCT00026052|Antidepressant
1491989|NCT00026052|Depression
1491990|NCT00026052|Major Depression
1491991|NCT00026039|stroke
1491992|NCT00026039|estrogen
1491993|NCT00026026|Human tooth agenesis
1491994|NCT00026013|contraception
1491995|NCT00026013|hormonal contraception
1491996|NCT00026013|herbal remedies
1491997|NCT00026013|hypericum perforatum
1491998|NCT00026013|contraceptive effectiveness
1491999|NCT00026000|Voluntary Movement
1492000|NCT00026000|Basal Ganglia
1492001|NCT00026000|Frontal Lobe
1492002|NCT00026000|Motor Cortex
1492003|NCT00026000|Motor Tic Disorder
1492004|NCT00026000|Tourette's Syndrome
1492005|NCT00026000|Vocal Tic Disorder
1492006|NCT00026000|Tic
1492007|NCT00026000|Healthy Volunteer
1492008|NCT00026000|HV
1492009|NCT00026000|Normal Control
1492010|NCT00025987|Brain
1492011|NCT00025987|Temperature
1492012|NCT00025987|Lower
1492013|NCT00025987|Tympanic
1492014|NCT00025987|Rectal
1492015|NCT00025987|Cooling of the Head and Neck
1492016|NCT00025987|Control
1492017|NCT00025987|Epilepsy
1492018|NCT00025987|Healthy Volunteer
1492019|NCT00025987|HV
1492020|NCT00025974|PET
1492021|NCT00025974|5-HT1A Receptors
1492022|NCT00025974|Benzodiazepine Receptors
1492023|NCT00025974|Panic Disorder
1492024|NCT00025974|PTSD
1492025|NCT00025974|Serotonin Type 1A Receptors
1492026|NCT00025974|Post-Traumatic Stress Disorder
1492027|NCT00025974|Major Depression
1492028|NCT00025974|Anxiety
1492029|NCT00025974|Depression
1492030|NCT00025974|Healthy Volunteer
1492031|NCT00025974|HV
1492032|NCT00025974|Normal Control
1492033|NCT00025935|Mood Disorders
1492034|NCT00025935|Bipolar Disorder
1492035|NCT00025935|Neuroimaging
1492036|NCT00025935|Psychophysiology
1492037|NCT00025935|Frustration
1492038|NCT00025935|Emotional Dysregulation
1492039|NCT00025935|Lithium
1492040|NCT00025935|Conduct Disorder
1492041|NCT00025935|Children and Adolescents
1492042|NCT00025935|Affective Neuroscience
1492043|NCT00025935|Behavioral Dysregulation
1492044|NCT00025935|Mood Disorder
1492045|NCT00025935|Behavior
1492046|NCT00025935|Children
1492047|NCT00025935|Adolescent
1492048|NCT00025935|Healthy Volunteer
1492049|NCT00025935|HV
1492050|NCT00025935|Normal Control
1492051|NCT00025922|Immunization
1492052|NCT00025922|Titers
1492053|NCT00025922|Immune Activation
1492054|NCT00025922|Antibody
1492055|NCT00025922|CD4 Cell Count
1492056|NCT00025922|HIV
1492057|NCT00025909|Therapy
1492058|NCT00025909|Antiretrovirals
1492059|NCT00025909|Interruption
1492060|NCT00025909|CD4+ T Cell
1492061|NCT00025909|Plasma Viremia
1492062|NCT00025909|HIV
1492063|NCT00025909|Treatment Experienced
1492064|NCT00025909|Treatment Interuption
1492065|NCT00025883|Lipoatrophic Diabetes
1492066|NCT00025883|Diabetes Mellitus
1492067|NCT00025883|Hypertriglyceridemia
1492068|NCT00025883|NASH
1492069|NCT00025883|Lipodystrophy
1492070|NCT00025883|Leptin
1492071|NCT00025883|Diabetes
1492072|NCT00025870|Genetics
1492073|NCT00025870|Metabolic
1492074|NCT00025870|Dysmorphology
1492075|NCT00025870|Training
1492076|NCT00025870|DNA
1492077|NCT00025870|DNA Testing
1492078|NCT00025870|Dysmorphic Syndromes
1492079|NCT00025870|Developmental Delay
1492080|NCT00025870|Genetic Counseling
1492081|NCT00025870|Molecular Genetics
1492082|NCT00025857|fMRI
1492083|NCT00025857|Depression
1492084|NCT00025857|PTSD
1492085|NCT00025857|Emotion
1492086|NCT00025857|Magnetic Resonance Imaging
1492087|NCT00025857|Anxiety
1492088|NCT00025857|Normal Volunteers
1492089|NCT00025857|Adolescence
1492090|NCT00025857|Memory
1492091|NCT00025857|Physical/Sexual Abuse History
1492092|NCT00025857|Post-Traumatic Stress Disorder
1492093|NCT00025857|Adolescent
1492094|NCT00025857|Healthy Volunteer
1492095|NCT00025857|HV
1492096|NCT00025857|Normal Control
1492097|NCT00025844|Stress
1492098|NCT00025844|Anxiety
1492099|NCT00025844|Adults
1492100|NCT00025844|Fear Conditioning
1492101|NCT00025844|Normal Volunteers
1492102|NCT00025844|Associative Learning
1492103|NCT00025844|Virtual Reality
1492104|NCT00025844|Context Conditioning
1492105|NCT00025844|Healthy Volunteer
1492106|NCT00025844|HV
1492107|NCT00025844|Normal Control
1492108|NCT00025831|Buccal
1492109|NCT00025831|DNA
1492110|NCT00025831|Pooling
1492111|NCT00025831|Genotyping
1492112|NCT00025831|Mouthwash
1492114|NCT00025831|HV
1492115|NCT00025831|Normal Control
1492116|NCT00025818|dry eyes
1492117|NCT00025818|rheumatoid arthritis
1492118|NCT00025818|Lupus
1492119|NCT00025818|Sjogren's syndrome
1492120|NCT00025818|myositis
1492121|NCT00025818|scleroderma
1492122|NCT00025818|autoimmune disorder
1492123|NCT00025805|Cytokines
1492124|NCT00025805|Th1 Th2 Response
1492125|NCT00025805|Inflammatory Bowel Dx
1492126|NCT00025805|Lymphocyte
1492127|NCT00025805|Colonoscopy
1492128|NCT00025805|Crohn's Disease
1492129|NCT00025805|Crohn's
1492130|NCT00025792|Pramipexole
1492131|NCT00025792|Neuroprotective
1492132|NCT00025792|Placebo Controlled
1492133|NCT00025792|Depression
1492134|NCT00025792|Brain Imaging
1492135|NCT00025792|Antidepressant
1492136|NCT00025792|Bipolar Disorder
1492137|NCT00025792|Bipolar
1492138|NCT00025792|BPD
1492139|NCT00025792|Bipolar Depression
1492140|NCT00025779|Hyperactivity
1492141|NCT00025779|Distractibility
1492142|NCT00025779|Impulsiveness
1492143|NCT00025779|Pervasive Development Disorders
1492144|NCT00025740|SSRI (paroxetine)
1492145|NCT00025740|Benzodiazepine (clonazepam)
1492146|NCT00025740|Post-Traumatic Stress Disorder (PTSD)
1492147|NCT00025740|Combined Treatment
1492148|NCT00025740|Rapid Treatment
1492149|NCT00025740|Post-Traumatic Stress Disorder
1492150|NCT00025740|PTSD
1492151|NCT00025727|HIV-1
1492152|NCT00025727|HIV Protease Inhibitors
1492153|NCT00025727|Ritonavir
1492154|NCT00025727|RNA, Viral
1492155|NCT00025727|Anti-HIV Agents
1492156|NCT00025727|Viral Load
1492157|NCT00025727|ABT 378
1492158|NCT00025727|VX-175
1492159|NCT00025714|Serotonin Receptor
1492160|NCT00025714|Cell Culture
1492161|NCT00025714|Temporal Lobe
1492162|NCT00025714|Endothelial Cells
1492163|NCT00025714|Superficial Temporal Artery
1492164|NCT00025714|Magnetic Resonance Imaging (MRI)
1492165|NCT00025714|Epilepsy
1492166|NCT00025714|Intractable Epilepsy
1492167|NCT00025701|Cortex
1492168|NCT00025701|Inhibition
1492169|NCT00025701|Motor Control
1492170|NCT00025701|Event-Related Synchronization
1492171|NCT00025701|Event-Related Desynchronization
1492172|NCT00025701|Focal Hand Dystonia
1492173|NCT00025701|Focal Dystonia
1492174|NCT00025701|Dystonia
1492175|NCT00025701|Hand
1492176|NCT00025701|Healthy Volunteer
1492177|NCT00025701|HV
1492178|NCT00025688|stage IV breast cancer
1492179|NCT00025688|recurrent breast cancer
1492180|NCT00025675|recurrent adult brain tumor
1492181|NCT00025675|adult meningioma
1492182|NCT00025675|adult glioblastoma
1492183|NCT00025675|adult anaplastic astrocytoma
1492184|NCT00025675|adult anaplastic oligodendroglioma
1492185|NCT00025675|adult pilocytic astrocytoma
1492186|NCT00025675|adult subependymoma
1492187|NCT00025675|adult mixed glioma
1492188|NCT00025675|adult meningeal hemangiopericytoma
1492189|NCT00025675|adult grade III meningioma
1492190|NCT00025675|adult giant cell glioblastoma
1492191|NCT00025675|adult gliosarcoma
1492192|NCT00025675|adult grade I meningioma
1492193|NCT00025675|adult grade II meningioma
1492194|NCT00025662|Peripheral Blood Stem Cell
1492195|NCT00025662|Melphalan
1492196|NCT00025662|Fludarabine
1492197|NCT00025662|Donor Apheresis
1492198|NCT00025662|Non-Myeloablative
1492199|NCT00025662|MDS
1492200|NCT00025662|Chronic Myeloid Leukemia
1492201|NCT00025662|CML
1492202|NCT00025662|Chronic Lymphocytic Leukemia
1492203|NCT00025662|CLL
1492204|NCT00025662|Lymphoma
1492205|NCT00025662|Non-Hodgkin's Lymphoma
1492206|NCT00025662|Hodgkin's Disease
1492207|NCT00025662|Mantle Cell Lymphoma
1492208|NCT00025662|Acute Myelogenous Leukemia (AML)
1492209|NCT00025662|Chronic Myeloid Leukemia (CML)
1492210|NCT00025662|Chronic Lymphocytic Leukemia (CLL)
1492211|NCT00025662|Myelodysplasia (MDS)
1492212|NCT00025662|Acute Lymphoblastic Leukemia (ALL)
1492213|NCT00025662|Bone Marrow Transplant
1492214|NCT00025649|localized resectable neuroblastoma
1492215|NCT00025649|regional neuroblastoma
1492216|NCT00025649|disseminated neuroblastoma
1492217|NCT00025649|stage 4S neuroblastoma
1492218|NCT00025649|localized unresectable neuroblastoma
1492219|NCT00025636|recurrent adult Hodgkin lymphoma
1492220|NCT00025623|disseminated neuroblastoma
1492221|NCT00025610|disseminated neuroblastoma
1492222|NCT00025610|stage 4S neuroblastoma
1492223|NCT00025597|localized unresectable neuroblastoma
1492224|NCT00025571|squamous cell lung cancer
1492225|NCT00025571|large cell lung cancer
1492226|NCT00025571|adenocarcinoma of the lung
1492227|NCT00025571|stage I non-small cell lung cancer
1492228|NCT00025571|stage II non-small cell lung cancer
1492229|NCT00025558|childhood central nervous system germ cell tumor
1492230|NCT00025558|recurrent adult brain tumor
1492231|NCT00025558|adult medulloblastoma
1492232|NCT00025558|adult glioblastoma
1492233|NCT00025558|adult anaplastic astrocytoma
1492438|NCT00024986|HIV
1492234|NCT00025558|adult anaplastic oligodendroglioma
1492235|NCT00025558|adult mixed glioma
1492236|NCT00025558|adult central nervous system germ cell tumor
1492237|NCT00025558|adult pineoblastoma
1492238|NCT00025558|recurrent childhood supratentorial primitive neuroectodermal tumor
1492239|NCT00025558|recurrent childhood medulloblastoma
1492240|NCT00025558|recurrent childhood ependymoma
1492241|NCT00025558|adult giant cell glioblastoma
1492242|NCT00025558|adult gliosarcoma
1492243|NCT00025558|adult anaplastic ependymoma
1492244|NCT00025558|adult supratentorial primitive neuroectodermal tumor (PNET)
1492245|NCT00025545|recurrent childhood acute lymphoblastic leukemia
1492246|NCT00025545|recurrent childhood acute myeloid leukemia
1492247|NCT00025545|recurrent adult acute myeloid leukemia
1492248|NCT00025545|recurrent adult acute lymphoblastic leukemia
1492249|NCT00025545|adult acute lymphoblastic leukemia in remission
1492250|NCT00025545|childhood acute lymphoblastic leukemia in remission
1492251|NCT00025545|acute undifferentiated leukemia
1492252|NCT00025545|secondary acute myeloid leukemia
1492253|NCT00025532|stage III colon cancer
1492254|NCT00025532|stage IV colon cancer
1492255|NCT00025532|stage III gastric cancer
1492256|NCT00025532|stage IV gastric cancer
1492257|NCT00025532|recurrent gastric cancer
1492258|NCT00025532|stage III pancreatic cancer
1492259|NCT00025532|recurrent pancreatic cancer
1492260|NCT00025532|stage III rectal cancer
1492261|NCT00025532|stage IV rectal cancer
1492262|NCT00025532|recurrent colon cancer
1492263|NCT00025532|recurrent rectal cancer
1492264|NCT00025532|stage III esophageal cancer
1492265|NCT00025532|stage IV esophageal cancer
1492266|NCT00025532|recurrent esophageal cancer
1492267|NCT00025532|adenocarcinoma of the stomach
1492268|NCT00025532|adenocarcinoma of the esophagus
1492269|NCT00025532|adenocarcinoma of the colon
1492270|NCT00025532|adenocarcinoma of the rectum
1492271|NCT00025532|adenocarcinoma of the pancreas
1492272|NCT00025532|stage IV pancreatic cancer
1492273|NCT00025519|stage IV renal cell cancer
1492274|NCT00025519|recurrent renal cell cancer
1492275|NCT00025519|clear cell renal cell carcinoma
1492276|NCT00025493|stage IV breast cancer
1492277|NCT00025493|recurrent breast cancer
1492278|NCT00025480|stage IIIA non-small cell lung cancer
1492279|NCT00025480|stage IIIB non-small cell lung cancer
1492280|NCT00025454|unspecified adult solid tumor, protocol specific
1492281|NCT00025441|chondrosarcoma
1492282|NCT00025441|small intestine leiomyosarcoma
1492283|NCT00025441|fibrosarcomatous osteosarcoma
1492284|NCT00025441|embryonal childhood rhabdomyosarcoma
1492285|NCT00025441|alveolar childhood rhabdomyosarcoma
1492286|NCT00025441|pleomorphic childhood rhabdomyosarcoma
1492287|NCT00025441|mixed childhood rhabdomyosarcoma
1492288|NCT00025441|embryonal-botryoid childhood rhabdomyosarcoma
1492289|NCT00025441|metastatic childhood soft tissue sarcoma
1492290|NCT00025441|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
1492291|NCT00025441|childhood fibrosarcoma
1492292|NCT00025441|childhood synovial sarcoma
1492293|NCT00025441|childhood malignant hemangiopericytoma
1492294|NCT00025441|childhood liposarcoma
1492295|NCT00025441|childhood alveolar soft-part sarcoma
1492296|NCT00025441|childhood leiomyosarcoma
1492297|NCT00025441|childhood angiosarcoma
1492298|NCT00025441|childhood epithelioid sarcoma
1492299|NCT00025441|childhood malignant mesenchymoma
1492300|NCT00025441|stage IV uterine sarcoma
1492301|NCT00025441|uterine leiomyosarcoma
1492302|NCT00025441|ovarian sarcoma
1492303|NCT00025441|previously untreated childhood rhabdomyosarcoma
1492304|NCT00025441|childhood desmoplastic small round cell tumor
1492305|NCT00025428|localized unresectable neuroblastoma
1492306|NCT00025402|chronic phase chronic myelogenous leukemia
1492307|NCT00025402|chronic myelogenous leukemia, BCR-ABL1 positive
1492308|NCT00025402|Philadelphia chromosome negative chronic myelogenous leukemia
1492309|NCT00025402|childhood chronic myelogenous leukemia
1492310|NCT00025402|atypical chronic myeloid leukemia, BCR-ABL1 negative
1492311|NCT00025389|stage I non-small cell lung cancer
1492312|NCT00025389|stage II non-small cell lung cancer
1492313|NCT00025389|stage IIIA non-small cell lung cancer
1492314|NCT00025376|stage IV renal cell cancer
1492315|NCT00025376|recurrent renal cell cancer
1492316|NCT00025350|stage IV colon cancer
1492317|NCT00025350|stage IV rectal cancer
1492318|NCT00025350|recurrent colon cancer
1492319|NCT00025350|recurrent rectal cancer
1492320|NCT00025350|adenocarcinoma of the colon
1492321|NCT00025350|adenocarcinoma of the rectum
1492322|NCT00025324|childhood central nervous system germ cell tumor
1492323|NCT00025324|adult central nervous system germ cell tumor
1492324|NCT00025311|leptomeningeal metastases
1492325|NCT00025298|stage II nasopharyngeal cancer
1492326|NCT00025298|stage III nasopharyngeal cancer
1492327|NCT00025298|stage IV nasopharyngeal cancer
1492328|NCT00025298|oral complications
1492329|NCT00025298|drug/agent toxicity by tissue/organ
1492330|NCT00025298|radiation toxicity
1492331|NCT00025285|squamous cell lung cancer
1492332|NCT00025285|large cell lung cancer
1492333|NCT00025285|stage IIIB non-small cell lung cancer
1492334|NCT00025285|stage IV non-small cell lung cancer
1492335|NCT00025285|adenocarcinoma of the lung
1492336|NCT00025285|adenosquamous cell lung cancer
1492337|NCT00025285|bronchoalveolar cell lung cancer
1492338|NCT00025272|extensive stage small cell lung cancer
1492339|NCT00025194|adenocarcinoma of the prostate
1492340|NCT00025194|stage IV prostate cancer
1492341|NCT00025194|recurrent prostate cancer
1492342|NCT00025181|iris melanoma
1492343|NCT00025181|ciliary body and choroid melanoma, small size
1492344|NCT00025181|ciliary body and choroid melanoma, medium/large size
1492345|NCT00025181|extraocular extension melanoma
1492346|NCT00025181|recurrent intraocular melanoma
1492347|NCT00025181|stage III melanoma
1492348|NCT00025181|stage IV melanoma
1492349|NCT00025181|recurrent melanoma
1492350|NCT00025168|stage III pancreatic cancer
1492351|NCT00025142|stage IV colon cancer
1492352|NCT00025142|stage IV rectal cancer
1492353|NCT00025142|recurrent colon cancer
1492354|NCT00025142|recurrent rectal cancer
1492355|NCT00025142|adenocarcinoma of the colon
1492356|NCT00025142|adenocarcinoma of the rectum
1492357|NCT00025129|stage IV adult Hodgkin lymphoma
1492358|NCT00025129|recurrent adult Hodgkin lymphoma
1492359|NCT00025129|stage IV cutaneous T-cell non-Hodgkin lymphoma
1492360|NCT00025129|recurrent cutaneous T-cell non-Hodgkin lymphoma
1492361|NCT00025129|small intestine lymphoma
1492362|NCT00025129|unspecified adult solid tumor, protocol specific
1492363|NCT00025129|stage IV grade 1 follicular lymphoma
1492364|NCT00025129|stage IV grade 2 follicular lymphoma
1492365|NCT00025129|stage IV grade 3 follicular lymphoma
1492477|NCT00024791|Corticospinal Tracts
1492366|NCT00025129|stage IV adult diffuse small cleaved cell lymphoma
1492367|NCT00025129|stage IV adult diffuse mixed cell lymphoma
1492368|NCT00025129|stage IV adult diffuse large cell lymphoma
1492369|NCT00025129|stage IV adult immunoblastic large cell lymphoma
1492370|NCT00025129|stage IV adult lymphoblastic lymphoma
1492371|NCT00025129|stage IV adult Burkitt lymphoma
1492372|NCT00025129|recurrent grade 1 follicular lymphoma
1492373|NCT00025129|recurrent grade 2 follicular lymphoma
1492374|NCT00025129|recurrent grade 3 follicular lymphoma
1492375|NCT00025129|recurrent adult diffuse small cleaved cell lymphoma
1492376|NCT00025129|recurrent adult diffuse mixed cell lymphoma
1492377|NCT00025129|recurrent adult diffuse large cell lymphoma
1492378|NCT00025129|recurrent adult immunoblastic large cell lymphoma
1492379|NCT00025129|recurrent adult lymphoblastic lymphoma
1492380|NCT00025129|recurrent adult Burkitt lymphoma
1492381|NCT00025129|stage IV adult T-cell leukemia/lymphoma
1492382|NCT00025129|recurrent adult T-cell leukemia/lymphoma
1492383|NCT00025129|primary central nervous system non-Hodgkin lymphoma
1492384|NCT00025129|intraocular lymphoma
1492385|NCT00025129|stage IV mantle cell lymphoma
1492386|NCT00025129|recurrent mantle cell lymphoma
1492387|NCT00025129|angioimmunoblastic T-cell lymphoma
1492388|NCT00025129|anaplastic large cell lymphoma
1492389|NCT00025129|stage IV mycosis fungoides/Sezary syndrome
1492390|NCT00025129|recurrent mycosis fungoides/Sezary syndrome
1492391|NCT00025129|recurrent marginal zone lymphoma
1492392|NCT00025129|recurrent small lymphocytic lymphoma
1492393|NCT00025129|stage IV small lymphocytic lymphoma
1492394|NCT00025129|stage IV marginal zone lymphoma
1492395|NCT00025129|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1492396|NCT00025129|nodal marginal zone B-cell lymphoma
1492397|NCT00025129|splenic marginal zone lymphoma
1492398|NCT00025116|adenocarcinoma of the prostate
1492399|NCT00025116|recurrent prostate cancer
1492400|NCT00025103|recurrent Wilms tumor and other childhood kidney tumors
1492401|NCT00025103|clear cell sarcoma of the kidney
1492402|NCT00025090|stage I anal cancer
1492403|NCT00025090|stage II anal cancer
1492404|NCT00025090|stage IIIA anal cancer
1492405|NCT00025090|stage IIIB anal cancer
1492406|NCT00025090|squamous cell carcinoma of the anus
1492407|NCT00025090|cloacogenic carcinoma of the anus
1492408|NCT00025090|basaloid carcinoma of the anus
1492409|NCT00025077|recurrent childhood supratentorial primitive neuroectodermal tumor
1492410|NCT00025077|recurrent childhood medulloblastoma
1492411|NCT00025064|stage II childhood Hodgkin lymphoma
1492412|NCT00025064|stage I childhood Hodgkin lymphoma
1492413|NCT00025064|stage III childhood Hodgkin lymphoma
1492414|NCT00025064|stage IV childhood Hodgkin lymphoma
1492415|NCT00025064|recurrent/refractory childhood Hodgkin lymphoma
1492416|NCT00025051|basal cell carcinoma of the skin
1492417|NCT00025051|squamous cell carcinoma of the skin
1492418|NCT00025025|colon cancer
1492419|NCT00025025|rectal cancer
1492420|NCT00025012|basal cell carcinoma of the skin
1492421|NCT00025012|squamous cell carcinoma of the skin
1492422|NCT00025012|melanoma
1492423|NCT00024999|Movement
1492424|NCT00024999|Coordination
1492425|NCT00024999|Correlation
1492426|NCT00024999|Coherence
1492427|NCT00024999|Parietofrontal Circuitry
1492428|NCT00024999|Apraxia
1492429|NCT00024999|Ideomotor Apraxia
1492430|NCT00024999|Healthy Volunteer
1492431|NCT00024999|HV
1492432|NCT00024999|Normal Control
1492433|NCT00024986|HAART
1492434|NCT00024986|Genotypic Resistance
1492435|NCT00024986|Phenotypic Resistance
1492436|NCT00024986|Immune Reconstitution
1492437|NCT00024986|Bone Density
1492439|NCT00024986|Children
1492440|NCT00024986|Pediatric HIV Infection
1492441|NCT00024960|Speech
1492442|NCT00024960|Motor Control
1492443|NCT00024960|Phenotype
1492444|NCT00024960|Dysfluency
1492445|NCT00024960|Fluency
1492446|NCT00024960|Stuttering
1492447|NCT00024960|Healthy Volunteer
1492448|NCT00024960|HV
1492449|NCT00024960|Normal Control
1492450|NCT00024934|Immunodeficiency
1492451|NCT00024934|Primary
1492452|NCT00024934|Cancer
1492453|NCT00024934|Genetics
1492454|NCT00024934|IGA Deficiency
1492455|NCT00024934|Immune Deficiency
1492456|NCT00024908|Cognition
1492457|NCT00024908|Frontal Lobes
1492458|NCT00024908|Frontotemporal Dementia
1492459|NCT00024908|Focal Lesions
1492460|NCT00024908|Executive Functions
1492461|NCT00024908|Frontotemporal Lobe Dementia
1492462|NCT00024908|Frontal Lobe
1492463|NCT00024908|Frontal Lobe Dementia
1492464|NCT00024908|Healthy Volunteer
1492465|NCT00024908|HV
1492466|NCT00024908|Normal Control
1492472|NCT00024791|Cerebral Palsy
1492473|NCT00024791|Pediatric
1492474|NCT00024791|Cognition
1492475|NCT00024791|Motor Learning
1492476|NCT00024791|Visuomotor Integration
1492478|NCT00024791|Cortical Re-Organization
1492479|NCT00024791|Spastic Hemiplegia
1492480|NCT00024791|Spastic Diplegia
1492481|NCT00024791|Functional Outcome
1492482|NCT00024791|Children
1492483|NCT00024791|Healthy Volunteer
1492484|NCT00024791|HV
1492485|NCT00024791|Normal Control
1492486|NCT00024687|SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin
1492487|NCT00024687|advanced malignancy
1492488|NCT00024674|SS1(dsFv)-PE38
1492489|NCT00024674|SS1P
1492490|NCT00024674|anti-mesothelin immunotoxin
1492491|NCT00024674|advanced malignancy
1492492|NCT00024661|recurrent solid tumors
1492493|NCT00024661|liposomes containing AON to c-raf protein (LErafAON)
1492494|NCT00024648|advanced malignancy
1492495|NCT00024648|liposomes containing AON to c-raf messenger RNA
1492496|NCT00024648|antisense oligodeoxynucleotide (AON)
1492497|NCT00024648|LErafAON
1492498|NCT00024635|Screening
1492499|NCT00024635|Psychiatric History
1492500|NCT00024635|Medical History
1492501|NCT00024635|Diagnostic Evaluation
1492502|NCT00024635|Natural History
1492503|NCT00024635|Anxiety
1492504|NCT00024635|HV
1492505|NCT00024635|Healthy Volunteer
1492506|NCT00024635|Normal Control
1492507|NCT00024635|Mood Disorder
1492508|NCT00024635|PTSD
1492509|NCT00024635|Post-Traumatic Stress Disorder
1492510|NCT00024622|Familial
1492511|NCT00024622|Genetic
1492512|NCT00024622|Symptomatic
1492513|NCT00024622|Equivocally Affected
1492514|NCT00024622|18F-Fluoro-L-dopa
1492515|NCT00024622|O-15 Labelled Water
1492516|NCT00024622|Carbidopa
1492517|NCT00024622|Adult
1492518|NCT00024622|Schizophrenia
1492519|NCT00024622|Parkinson's Disease
1492520|NCT00024622|PD
1492521|NCT00024622|Parkinson
1492522|NCT00024622|Healthy Control
1492523|NCT00024622|HV
1492524|NCT00024622|Normal Control
1492525|NCT00024570|neurosurgery, craniotomy
1492526|NCT00024570|convection-enhanced delivery
1492527|NCT00024570|CNS interstitial infusion
1492528|NCT00024570|recombinant toxins
1492529|NCT00024570|malignant glioma, recurrent
1492530|NCT00024570|catheter, stereotaxic
1492531|NCT00024570|intratumoral therapy
1492532|NCT00024570|positive pressure microinfusion
1492533|NCT00024557|neurosurgery, craniotomy
1492534|NCT00024557|convection-enhanced delivery
1492535|NCT00024557|CNS interstitial infusion
1492536|NCT00024557|recombinant toxins
1492537|NCT00024557|malignant glioma, recurrent
1492538|NCT00024557|intratumoral therapy
1492539|NCT00024557|positive pressure microinfusion
1492540|NCT00024544|asthma
1492541|NCT00024544|anti-IL-4 monoclonal antibody
1492542|NCT00024544|pascolizumab
1492543|NCT00024531|Alzheimer disease
1492544|NCT00024531|Cholesterol-lowering drugs
1492545|NCT00024518|Diabetes
1492546|NCT00024518|Immunotherapy
1492547|NCT00024518|Study Drug
1492548|NCT00024518|Insulin Dependent Diabetes
1492549|NCT00024518|Diabetes Mellitus
1492550|NCT00024518|TIBM
1492551|NCT00024492|Liposome Encapsulated Mitoxantrone (LEM)
1492552|NCT00024492|solid tumors
1492553|NCT00024479|Minorities
1492554|NCT00024479|Rheumatic Disease
1492555|NCT00024479|Community Based
1492556|NCT00024479|Ethnicity
1492557|NCT00024479|Health Disparities
1492558|NCT00024466|stage I multiple myeloma
1492559|NCT00024466|stage II multiple myeloma
1492560|NCT00024466|stage III multiple myeloma
1492561|NCT00024453|infection
1492562|NCT00024440|refractory chronic lymphocytic leukemia
1492563|NCT00024440|B-cell chronic lymphocytic leukemia
1492564|NCT00024427|drug/agent toxicity by tissue/organ
1492565|NCT00024427|stage II pancreatic cancer
1492566|NCT00024427|stage III pancreatic cancer
1492567|NCT00024427|recurrent pancreatic cancer
1492568|NCT00024427|adenocarcinoma of the pancreas
1492569|NCT00024427|stage IV pancreatic cancer
1492570|NCT00024414|adenocarcinoma of the prostate
1492571|NCT00024414|stage IV prostate cancer
1492572|NCT00024414|recurrent prostate cancer
1492573|NCT00024401|stage IV colon cancer
1492574|NCT00024401|stage IV rectal cancer
1492575|NCT00024401|recurrent colon cancer
1492576|NCT00024401|recurrent rectal cancer
1492577|NCT00024388|stage III renal cell cancer
1492578|NCT00024388|stage IV renal cell cancer
1492579|NCT00024388|recurrent renal cell cancer
1492580|NCT00024375|recurrent pancreatic cancer
1492581|NCT00024375|stage IV pancreatic cancer
1492582|NCT00024362|stage III pancreatic cancer
1492583|NCT00024362|adenocarcinoma of the pancreas
1492584|NCT00024362|stage IV pancreatic cancer
1492585|NCT00024349|stage II bladder cancer
1492586|NCT00024349|stage III bladder cancer
1492587|NCT00024349|transitional cell carcinoma of the bladder
1492588|NCT00024349|squamous cell carcinoma of the bladder
1492589|NCT00024349|adenocarcinoma of the bladder
1492590|NCT00024336|untreated childhood brain stem glioma
1492591|NCT00024323|unspecified adult solid tumor, protocol specific
1492592|NCT00024310|unspecified adult solid tumor, protocol specific
1492593|NCT00024310|drug/agent toxicity by tissue/organ
1492594|NCT00024297|thromboembolism
1492595|NCT00024284|unspecified childhood solid tumor, protocol specific
1492596|NCT00024271|localized malignant mesothelioma
1492597|NCT00024271|advanced malignant mesothelioma
1492598|NCT00024271|recurrent malignant mesothelioma
1492599|NCT00024258|metastatic osteosarcoma
1492600|NCT00024258|recurrent childhood rhabdomyosarcoma
1492601|NCT00024258|regional neuroblastoma
1492602|NCT00024258|disseminated neuroblastoma
1492603|NCT00024258|stage 4S neuroblastoma
1492604|NCT00024258|recurrent neuroblastoma
1492605|NCT00024258|stage III childhood liver cancer
1492606|NCT00024258|stage IV childhood liver cancer
1492607|NCT00024258|recurrent childhood liver cancer
1492608|NCT00024258|childhood hepatoblastoma
1492609|NCT00024258|stage III Wilms tumor
1492610|NCT00024258|stage IV Wilms tumor
1492611|NCT00024258|stage V Wilms tumor
1492612|NCT00024258|recurrent Wilms tumor and other childhood kidney tumors
1492613|NCT00024258|intraocular retinoblastoma
1492614|NCT00024258|extraocular retinoblastoma
1492615|NCT00024258|recurrent retinoblastoma
1492616|NCT00024258|recurrent osteosarcoma
1492617|NCT00024258|childhood germ cell tumor
1492618|NCT00024258|metastatic childhood soft tissue sarcoma
1492619|NCT00024258|recurrent childhood soft tissue sarcoma
1492620|NCT00024258|localized unresectable neuroblastoma
1492621|NCT00024258|previously untreated childhood rhabdomyosarcoma
1492622|NCT00024258|childhood desmoplastic small round cell tumor
1492623|NCT00024258|untreated childhood medulloblastoma
1492624|NCT00024258|recurrent childhood medulloblastoma
1492625|NCT00024258|previously treated childhood rhabdomyosarcoma
1492626|NCT00024258|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1492627|NCT00024258|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1492628|NCT00024258|childhood teratoma
1492629|NCT00024258|childhood malignant testicular germ cell tumor
1492630|NCT00024258|childhood malignant ovarian germ cell tumor
1492631|NCT00024258|childhood extragonadal germ cell tumor
1492632|NCT00024258|recurrent childhood malignant germ cell tumor
1492633|NCT00024245|unspecified adult solid tumor, protocol specific
1492634|NCT00024232|stage IV prostate cancer
1492635|NCT00024232|recurrent prostate cancer
1492636|NCT00024193|stage 4S neuroblastoma
1492637|NCT00024180|Waldenström macroglobulinemia
1492638|NCT00024180|recurrent adult acute myeloid leukemia
1492639|NCT00024180|recurrent adult acute lymphoblastic leukemia
1492640|NCT00024180|refractory chronic lymphocytic leukemia
1492641|NCT00024180|untreated adult acute lymphoblastic leukemia
1492642|NCT00024180|untreated adult acute myeloid leukemia
1492643|NCT00024180|recurrent small lymphocytic lymphoma
1492644|NCT00024167|adenocarcinoma of the prostate
1492645|NCT00024167|stage IV prostate cancer
1492646|NCT00024167|recurrent prostate cancer
1492647|NCT00024167|Strontium-89
1492648|NCT00024167|Induction Chemotherapy
1492649|NCT00024167|Androgen-Independent Prostate Cancer
1492650|NCT00024141|unspecified adult solid tumor, protocol specific
1492651|NCT00024128|AIDS-related peripheral/systemic lymphoma
1492652|NCT00024128|HIV-associated Hodgkin lymphoma
1492653|NCT00024115|refractory chronic lymphocytic leukemia
1492654|NCT00024115|B-cell chronic lymphocytic leukemia
1492655|NCT00024115|stage III grade I follicular small cleaved cell lymphoma
1492656|NCT00024115|stage III grade II follicular mixed cell lymphoma
1492657|NCT00024115|stage III adult diffuse small cleaved cell lymphoma
1492658|NCT00024115|stage IV grade I follicular small cleaved cell lymphoma
1492659|NCT00024115|stage IV grade II follicular mixed cell lymphoma
1492660|NCT00024115|stage IV adult diffuse small cleaved cell lymphoma
1492661|NCT00024115|recurrent grade I follicular small cleaved cell lymphoma
1492662|NCT00024115|recurrent grade II follicular mixed cell lymphoma
1492663|NCT00024115|recurrent grade III follicular large cell lymphoma
1492664|NCT00024115|recurrent adult diffuse small cleaved cell lymphoma
1492665|NCT00024115|recurrent adult diffuse mixed cell lymphoma
1492666|NCT00024115|recurrent adult diffuse large cell lymphoma
1492667|NCT00024115|recurrent adult immunoblastic large cell lymphoma
1492668|NCT00024115|recurrent adult lymphoblastic lymphoma
1492669|NCT00024115|recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma
1492670|NCT00024115|prolymphocytic leukemia
1492671|NCT00024115|contiguous stage II grade I follicular small cleaved cell lymphoma
1492672|NCT00024115|contiguous stage II grade II follicular mixed cell lymphoma
1492673|NCT00024115|contiguous stage II adult diffuse small cleaved cell lymphoma
1492674|NCT00024115|noncontiguous stage II grade I follicular small cleaved cell lymphoma
1492675|NCT00024115|noncontiguous stage II grade II follicular mixed cell lymphoma
1492676|NCT00024115|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1492677|NCT00024115|stage III diffuse small lymphocytic/marginal zone lymphoma
1492678|NCT00024115|contiguous stage II diffuse small lymphocytic/marginal zone lymphoma
1492679|NCT00024115|noncontiguous stage II diffuse small lymphocytic/marginal zone lymphoma
1492680|NCT00024115|stage IV diffuse small lymphocytic/marginal zone lymphoma
1492681|NCT00024115|recurrent diffuse small lymphocytic/marginal zone lymphoma
1492682|NCT00024115|recurrent mantle cell lymphoma
1492683|NCT00024102|stage I breast cancer
1492684|NCT00024102|stage II breast cancer
1492685|NCT00024102|stage IIIA breast cancer
1492686|NCT00024102|stage IIIB breast cancer
1492687|NCT00024102|stage IIIC breast cancer
1492688|NCT00024089|recurrent metastatic squamous neck cancer with occult primary
1492689|NCT00024089|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1492690|NCT00024089|stage IV squamous cell carcinoma of the lip and oral cavity
1492691|NCT00024089|recurrent squamous cell carcinoma of the lip and oral cavity
1492692|NCT00024089|stage IV squamous cell carcinoma of the oropharynx
1492693|NCT00024089|recurrent squamous cell carcinoma of the oropharynx
1492694|NCT00024089|stage IV squamous cell carcinoma of the nasopharynx
1492695|NCT00024089|recurrent squamous cell carcinoma of the nasopharynx
1492696|NCT00024089|stage IV squamous cell carcinoma of the hypopharynx
1492697|NCT00024089|recurrent squamous cell carcinoma of the hypopharynx
1492698|NCT00024089|stage IV squamous cell carcinoma of the larynx
1492699|NCT00024089|recurrent squamous cell carcinoma of the larynx
1492700|NCT00024089|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1492701|NCT00024089|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1492702|NCT00024089|salivary gland squamous cell carcinoma
1492703|NCT00024076|recurrent non-small cell lung cancer
1492704|NCT00024076|recurrent small cell lung cancer
1492705|NCT00024076|recurrent malignant mesothelioma
1492706|NCT00024076|recurrent thymoma and thymic carcinoma
1492707|NCT00024076|stage IIIB non-small cell lung cancer
1492708|NCT00024076|stage IV non-small cell lung cancer
1492709|NCT00024076|pulmonary carcinoid tumor
1492710|NCT00024076|lung metastases
1492711|NCT00024063|stage III colon cancer
1492712|NCT00024063|stage IV colon cancer
1492713|NCT00024063|stage IV breast cancer
1492714|NCT00024063|stage IIIA breast cancer
1492715|NCT00024063|recurrent breast cancer
1492716|NCT00024063|stage III gastric cancer
1492717|NCT00024063|stage IV gastric cancer
1492718|NCT00024063|recurrent gastric cancer
1492719|NCT00024063|stage IIIB breast cancer
1492720|NCT00024063|recurrent non-small cell lung cancer
1492721|NCT00024063|stage II pancreatic cancer
1492722|NCT00024063|stage III pancreatic cancer
1492723|NCT00024063|recurrent pancreatic cancer
1492724|NCT00024063|stage III rectal cancer
1492725|NCT00024063|stage IV rectal cancer
1492726|NCT00024063|recurrent colon cancer
1492727|NCT00024063|recurrent rectal cancer
1492728|NCT00024063|refractory multiple myeloma
1492729|NCT00024063|stage III renal cell cancer
1492730|NCT00024063|stage IV renal cell cancer
1492731|NCT00024063|recurrent renal cell cancer
1492732|NCT00024063|stage III multiple myeloma
1492733|NCT00024063|stage III prostate cancer
1492734|NCT00024063|stage IV prostate cancer
1492735|NCT00024063|recurrent prostate cancer
1492736|NCT00024063|stage IIIA non-small cell lung cancer
1492737|NCT00024063|stage IIIB non-small cell lung cancer
1492738|NCT00024063|stage IV non-small cell lung cancer
1492739|NCT00024063|male breast cancer
1492740|NCT00024063|stage IV pancreatic cancer
1492741|NCT00024050|refractory anemia
1492742|NCT00024050|refractory anemia with ringed sideroblasts
1492743|NCT00024050|de novo myelodysplastic syndromes
1492744|NCT00024050|previously treated myelodysplastic syndromes
1492745|NCT00024050|secondary myelodysplastic syndromes
1492746|NCT00024050|childhood myelodysplastic syndromes
1492747|NCT00024037|oral complications
1492748|NCT00024024|AIDS-related Kaposi sarcoma
1492749|NCT00024024|recurrent Kaposi sarcoma
1492750|NCT00023985|stage I non-small cell lung cancer
1492751|NCT00023985|stage II non-small cell lung cancer
1492752|NCT00023985|stage IIIA non-small cell lung cancer
1492753|NCT00023972|stage III pancreatic cancer
1492754|NCT00023972|stage IV pancreatic cancer
1492755|NCT00023907|recurrent ovarian epithelial cancer
1492756|NCT00023907|primary peritoneal cavity cancer
1492757|NCT00023894|recurrent endometrial carcinoma
1492758|NCT00023881|relapsing chronic myelogenous leukemia
1492759|NCT00023881|chronic phase chronic myelogenous leukemia
1492760|NCT00023881|accelerated phase chronic myelogenous leukemia
1492761|NCT00023881|chronic myelogenous leukemia, BCR-ABL1 positive
1492762|NCT00023868|stage IV colon cancer
1492763|NCT00023868|stage IV rectal cancer
1492764|NCT00023868|recurrent colon cancer
1492765|NCT00023868|recurrent rectal cancer
1492766|NCT00023868|adenocarcinoma of the colon
1492767|NCT00023868|adenocarcinoma of the rectum
1492768|NCT00023868|liver metastases
1492769|NCT00023855|unspecified adult solid tumor, protocol specific
1492770|NCT00023842|stage 0 bladder cancer
1492771|NCT00023842|recurrent bladder cancer
1492772|NCT00023842|transitional cell carcinoma of the bladder
1492773|NCT00023829|stage III prostate cancer
1492774|NCT00023829|stage IIB prostate cancer
1492775|NCT00023829|stage IIA prostate cancer
1492776|NCT00023816|stage IV adult Hodgkin lymphoma
1492777|NCT00023816|recurrent adult Hodgkin lymphoma
1492778|NCT00023816|stage IV cutaneous T-cell non-Hodgkin lymphoma
1492779|NCT00023816|recurrent cutaneous T-cell non-Hodgkin lymphoma
1492780|NCT00023816|unspecified adult solid tumor, protocol specific
1492781|NCT00023816|stage IV grade 1 follicular lymphoma
1492782|NCT00023816|stage IV grade 2 follicular lymphoma
1492783|NCT00023816|stage IV grade 3 follicular lymphoma
1492784|NCT00023816|stage IV adult diffuse small cleaved cell lymphoma
1492992|NCT00023309|Liver
1492785|NCT00023816|stage IV adult diffuse mixed cell lymphoma
1492786|NCT00023816|stage IV adult diffuse large cell lymphoma
1492787|NCT00023816|stage IV adult immunoblastic large cell lymphoma
1492788|NCT00023816|stage IV adult lymphoblastic lymphoma
1492789|NCT00023816|stage IV adult Burkitt lymphoma
1492790|NCT00023816|recurrent grade 1 follicular lymphoma
1492791|NCT00023816|recurrent grade 2 follicular lymphoma
1492792|NCT00023816|recurrent grade 3 follicular lymphoma
1492793|NCT00023816|recurrent adult diffuse small cleaved cell lymphoma
1492794|NCT00023816|recurrent adult diffuse mixed cell lymphoma
1492795|NCT00023816|recurrent adult diffuse large cell lymphoma
1492796|NCT00023816|recurrent adult immunoblastic large cell lymphoma
1492797|NCT00023816|recurrent adult lymphoblastic lymphoma
1492798|NCT00023816|recurrent adult Burkitt lymphoma
1492799|NCT00023816|stage IV adult T-cell leukemia/lymphoma
1492800|NCT00023816|recurrent adult T-cell leukemia/lymphoma
1492801|NCT00023816|primary central nervous system non-Hodgkin lymphoma
1492802|NCT00023816|AIDS-related peripheral/systemic lymphoma
1492803|NCT00023816|AIDS-related primary CNS lymphoma
1492804|NCT00023816|intraocular lymphoma
1492805|NCT00023816|stage IV mantle cell lymphoma
1492806|NCT00023816|recurrent mantle cell lymphoma
1492807|NCT00023816|anaplastic large cell lymphoma
1492808|NCT00023816|stage IV mycosis fungoides/Sezary syndrome
1492809|NCT00023816|recurrent mycosis fungoides/Sezary syndrome
1492810|NCT00023816|recurrent marginal zone lymphoma
1492811|NCT00023816|recurrent small lymphocytic lymphoma
1492812|NCT00023816|stage IV small lymphocytic lymphoma
1492813|NCT00023816|stage IV marginal zone lymphoma
1492814|NCT00023816|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1492815|NCT00023816|nodal marginal zone B-cell lymphoma
1492816|NCT00023816|splenic marginal zone lymphoma
1492817|NCT00023790|stage IV breast cancer
1492818|NCT00023790|recurrent breast cancer
1492819|NCT00023790|stage I cutaneous T-cell non-Hodgkin lymphoma
1492820|NCT00023790|stage II cutaneous T-cell non-Hodgkin lymphoma
1492821|NCT00023790|stage IV cutaneous T-cell non-Hodgkin lymphoma
1492822|NCT00023790|recurrent cutaneous T-cell non-Hodgkin lymphoma
1492823|NCT00023790|basal cell carcinoma of the skin
1492824|NCT00023790|squamous cell carcinoma of the skin
1492825|NCT00023790|recurrent skin cancer
1492826|NCT00023790|classic Kaposi sarcoma
1492827|NCT00023790|immunosuppressive treatment related Kaposi sarcoma
1492828|NCT00023790|AIDS-related Kaposi sarcoma
1492829|NCT00023790|recurrent Kaposi sarcoma
1492830|NCT00023790|stage IV squamous cell carcinoma of the lip and oral cavity
1492831|NCT00023790|stage IV basal cell carcinoma of the lip
1492832|NCT00023790|stage IV verrucous carcinoma of the oral cavity
1492833|NCT00023790|stage IV mucoepidermoid carcinoma of the oral cavity
1492834|NCT00023790|stage IV adenoid cystic carcinoma of the oral cavity
1492835|NCT00023790|recurrent squamous cell carcinoma of the lip and oral cavity
1492836|NCT00023790|recurrent basal cell carcinoma of the lip
1492837|NCT00023790|recurrent verrucous carcinoma of the oral cavity
1492838|NCT00023790|recurrent mucoepidermoid carcinoma of the oral cavity
1492839|NCT00023790|recurrent adenoid cystic carcinoma of the oral cavity
1492840|NCT00023790|stage IV squamous cell carcinoma of the oropharynx
1492841|NCT00023790|stage IV lymphoepithelioma of the oropharynx
1492842|NCT00023790|recurrent squamous cell carcinoma of the oropharynx
1492843|NCT00023790|recurrent lymphoepithelioma of the oropharynx
1492844|NCT00023790|stage IV squamous cell carcinoma of the nasopharynx
1492845|NCT00023790|stage IV lymphoepithelioma of the nasopharynx
1492846|NCT00023790|recurrent squamous cell carcinoma of the nasopharynx
1492847|NCT00023790|recurrent lymphoepithelioma of the nasopharynx
1492848|NCT00023790|stage IV squamous cell carcinoma of the hypopharynx
1492849|NCT00023790|recurrent squamous cell carcinoma of the hypopharynx
1492850|NCT00023790|stage IV squamous cell carcinoma of the larynx
1492851|NCT00023790|stage IV verrucous carcinoma of the larynx
1492957|NCT00023413|tuberculosis
1492852|NCT00023790|recurrent squamous cell carcinoma of the larynx
1492853|NCT00023790|recurrent verrucous carcinoma of the larynx
1492854|NCT00023790|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1492855|NCT00023790|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1492856|NCT00023790|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1492857|NCT00023790|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1492858|NCT00023790|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1492859|NCT00023790|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1492860|NCT00023790|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1492861|NCT00023790|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1492862|NCT00023790|skin metastases
1492863|NCT00023790|stage I mycosis fungoides/Sezary syndrome
1492864|NCT00023790|stage II mycosis fungoides/Sezary syndrome
1492865|NCT00023790|stage IV mycosis fungoides/Sezary syndrome
1492866|NCT00023790|recurrent mycosis fungoides/Sezary syndrome
1492867|NCT00023790|male breast cancer
1492868|NCT00023777|untreated adult acute myeloid leukemia
1492869|NCT00023777|adult acute erythroid leukemia (M6)
1492870|NCT00023777|adult acute myeloblastic leukemia without maturation (M1)
1492871|NCT00023777|adult acute myeloblastic leukemia with maturation (M2)
1492872|NCT00023777|adult acute myelomonocytic leukemia (M4)
1492873|NCT00023777|adult acute monoblastic leukemia (M5a)
1492874|NCT00023777|adult acute eosinophilic leukemia
1492875|NCT00023777|adult acute basophilic leukemia
1492876|NCT00023777|adult acute megakaryoblastic leukemia (M7)
1492877|NCT00023777|adult acute monocytic leukemia (M5b)
1492878|NCT00023777|adult acute minimally differentiated myeloid leukemia (M0)
1492879|NCT00023751|stage I rectal cancer
1492880|NCT00023751|adenocarcinoma of the rectum
1492881|NCT00023738|stage III adult soft tissue sarcoma
1492882|NCT00023738|recurrent adult soft tissue sarcoma
1492883|NCT00023738|stage II adult soft tissue sarcoma
1492884|NCT00023725|stage I adult soft tissue sarcoma
1492885|NCT00023699|recurrent ovarian epithelial cancer
1492886|NCT00023699|primary peritoneal cavity cancer
1492887|NCT00023686|adenocarcinoma of the prostate
1492888|NCT00023686|stage IIB prostate cancer
1492889|NCT00023686|stage IIA prostate cancer
1492890|NCT00023673|squamous cell lung cancer
1492891|NCT00023673|large cell lung cancer
1492892|NCT00023673|stage IIIA non-small cell lung cancer
1492893|NCT00023673|stage IIIB non-small cell lung cancer
1492894|NCT00023673|adenocarcinoma of the lung
1492895|NCT00023673|adenosquamous cell lung cancer
1492896|NCT00023660|stage III cervical cancer
1492897|NCT00023660|stage IB cervical cancer
1492898|NCT00023660|stage IIB cervical cancer
1492899|NCT00023660|stage IIA cervical cancer
1492900|NCT00023660|stage IVA cervical cancer
1492901|NCT00023660|cervical squamous cell carcinoma
1492902|NCT00023660|cervical adenocarcinoma
1492903|NCT00023660|cervical adenosquamous cell carcinoma
1492904|NCT00023647|stage IV melanoma
1492905|NCT00023647|recurrent melanoma
1492906|NCT00023634|stage II gastric cancer
1492907|NCT00023634|stage III gastric cancer
1492908|NCT00023634|stage IV gastric cancer
1492909|NCT00023634|recurrent gastric cancer
1492910|NCT00023634|adenocarcinoma of the prostate
1492911|NCT00023634|stage II ovarian epithelial cancer
1492912|NCT00023634|stage III ovarian epithelial cancer
1492913|NCT00023634|stage IV ovarian epithelial cancer
1492914|NCT00023634|recurrent adult brain tumor
1492915|NCT00023634|stage IV prostate cancer
1492916|NCT00023634|recurrent prostate cancer
1492917|NCT00023634|adult anaplastic astrocytoma
1492918|NCT00023621|basal cell carcinoma of the skin
1492919|NCT00023582|Syphilis
1492920|NCT00023582|Herpes Genitalis
1492921|NCT00023582|Risk Factors
1492922|NCT00023582|Incidence
1492923|NCT00023582|Prevalence
1492924|NCT00023582|Homosexuality, Male
1492925|NCT00023582|Informed Consent
1492926|NCT00023582|Peru
1492927|NCT00023582|HIV Seronegativity
1492928|NCT00023569|TMS
1492929|NCT00023569|Conjoint Movement
1492930|NCT00023569|Chronic Hemiplegia
1492931|NCT00023569|Brain Plasticity
1492932|NCT00023569|Electrical Stimulation
1492933|NCT00023569|Stroke
1492934|NCT00023569|CVA
1492935|NCT00023504|Immunization
1492936|NCT00023504|Antibody
1492937|NCT00023504|Immunodeficiency
1492938|NCT00023504|Pneumococcal Vaccines
1492939|NCT00023504|Phi-X 174
1492940|NCT00023504|Primary Immune Disorders
1492941|NCT00023491|Sjogren's Syndrome
1492942|NCT00023491|Peripheral Blood Stem Cell
1492943|NCT00023491|Tissue Regeneration
1492944|NCT00023491|Graft-versus-host Disease
1492945|NCT00023491|Head and Neck Cancer
1492946|NCT00023491|Salivary Gland
1492947|NCT00023491|Saliva Gland
1492948|NCT00023491|Salivary Gland Dysfunction
1492949|NCT00023452|Latent TB infection
1492950|NCT00023439|tuberculosis
1492951|NCT00023439|TB
1492952|NCT00023426|tuberculosis
1492953|NCT00023426|tb
1492954|NCT00023426|rifapentine
1492955|NCT00023426|safety
1492956|NCT00023426|dose
1492958|NCT00023413|TB
1492959|NCT00023400|tuberculosis
1492960|NCT00023400|TB
1492961|NCT00023374|tuberculosis
1492962|NCT00023374|TB
1492963|NCT00023374|isoniazid resistance
1492964|NCT00023374|isoniazid intolerance
1492965|NCT00023374|treatment
1492966|NCT00023374|efficacy
1492967|NCT00023374|toxicity
1492968|NCT00023361|tuberculosis
1492969|NCT00023361|TB
1492970|NCT00023348|Tuberculosis
1492971|NCT00023348|TB
1492972|NCT00023322|Cirrhosis
1492973|NCT00023322|Chronic Hepatitis
1492974|NCT00023322|Alpha Interferon
1492975|NCT00023322|Hepatitis D Virus
1492976|NCT00023322|Delta Hepatitis
1492977|NCT00023322|Viral Hepatitis
1492978|NCT00023322|Antiviral Agents
1492979|NCT00023322|Hepatitis D
1492980|NCT00023322|HDV
1492981|NCT00023322|Liver
1492982|NCT00023322|Hepatitis
1492983|NCT00023309|Adefovir Dipivoxil
1492984|NCT00023309|Lamivudine
1492985|NCT00023309|Nucleoside/Nucleotide Analogue
1492986|NCT00023309|Chronic Hepatitis B
1492987|NCT00023309|Hepatitis B Mutants
1492988|NCT00023309|Liver Biopsy
1492989|NCT00023309|Hepatitis B
1492990|NCT00023309|Hepatitis
1492991|NCT00023309|HBV
1492993|NCT00023296|Acute Chest Syndrome
1492994|NCT00023296|Blood Flow
1492995|NCT00023296|Nitric Oxide
1492996|NCT00023296|NO Therapy
1492997|NCT00023296|Vaso-Occlusive Crisis
1492998|NCT00023296|Sickle Cell Anemia
1492999|NCT00023296|Sickle Cell
1493000|NCT00023296|ACS
1493001|NCT00023296|Pulmonary Hypertension
1493002|NCT00023218|Liver
1493003|NCT00023218|HIV-1
1493004|NCT00023218|HIV Protease Inhibitors
1493005|NCT00023218|Ritonavir
1493006|NCT00023218|Biopsy
1493007|NCT00023218|Reverse Transcriptase Inhibitors
1493008|NCT00023218|Anti-HIV Agents
1493009|NCT00023218|ABT 378
1493010|NCT00023218|Acidosis, Lactic
1493011|NCT00023218|efavirenz
1493012|NCT00023218|Alanine Transaminase
1493013|NCT00023205|Arthritis
1493014|NCT00023205|Health literacy
1493015|NCT00023205|Patient education
1493016|NCT00023205|Self-efficacy
1493017|NCT00023192|Campath 1-H
1493018|NCT00023192|T-Cell Depletion
1493019|NCT00023192|Therapy
1493020|NCT00023192|Stem Cell Transplantation
1493021|NCT00023192|Chronic Granulomatous Disease
1493022|NCT00023192|CGD
1493023|NCT00023166|Phase I
1493024|NCT00023166|Open label
1493025|NCT00023166|Safety/efficacy
1493026|NCT00023166|Lymphomas
1493027|NCT00023166|Advanced primary and/or metastatic solid tumors
1493028|NCT00023166|Neoplasms
1493029|NCT00023166|Neoplasm metastasis
1493030|NCT00023153|Drug Resistance
1493031|NCT00023153|Viral Load
1493032|NCT00023153|Liver
1493033|NCT00023153|Immunology
1493034|NCT00023153|Liver Histology
1493035|NCT00023153|Hepatitis B
1493036|NCT00023153|HBV
1493037|NCT00023153|HIV
1493038|NCT00023140|biomarkers
1493039|NCT00023140|exposure
1493040|NCT00023140|adducts
1493041|NCT00023140|metabolites
1493042|NCT00023140|butadiene
1493043|NCT00023127|Asthma
1493044|NCT00023127|Allergen
1493045|NCT00023127|Cockroach
1493046|NCT00023114|lung function
1493047|NCT00023114|smoking
1493048|NCT00023114|metabolism
1493049|NCT00023101|lead
1493050|NCT00023101|endocrine dysfunction
1493051|NCT00023088|Rehabilitation
1493052|NCT00023088|Functional Level
1493053|NCT00023088|Activity of Daily Living
1493054|NCT00023088|Mobility
1493055|NCT00023088|Normal Volunteer
1493056|NCT00023075|MRI
1493057|NCT00023075|Neuromuscular Disease
1493058|NCT00023075|N-Acetyl Aspartate
1493059|NCT00023075|Choline
1493060|NCT00023075|Creatine
1493061|NCT00023075|Spasms
1493062|NCT00023075|Spasticity
1493063|NCT00023075|Primary Lateral Sclerosis
1493064|NCT00023075|Hereditary Spastic Paraplegia
1493065|NCT00023075|Spastic Paraparesis
1493066|NCT00023075|Healthy Volunteer
1493067|NCT00023075|HV
1493068|NCT00023075|Normal Control
1493069|NCT00023062|Natural History
1493070|NCT00023062|Motor Cortex
1493071|NCT00023062|Behavior
1493072|NCT00023062|Healthy Volunteers
1493073|NCT00023062|Motor Control
1493074|NCT00023062|Parkinson Disease
1493075|NCT00023062|Parkinson's
1493076|NCT00023062|Healthy Volunteer
1493077|NCT00023062|HV
1493078|NCT00023062|Normal Control
1493079|NCT00023049|Deafness
1493080|NCT00023049|Genes
1493081|NCT00023049|Impairment
1493082|NCT00023049|Auditory
1493083|NCT00023049|Vestibular
1493084|NCT00023049|Hereditary Hearing Disorder
1493085|NCT00023049|Hearing Impairment
1493086|NCT00023049|Sensorineural Hearing Loss
1493087|NCT00023049|Vestibular Dysfunction
1493088|NCT00023049|SNHL
1493099|NCT00023023|Hepatitis
1493100|NCT00023023|Blood Bank
1493101|NCT00023023|Viruses
1493102|NCT00023023|Blood Donors
1493103|NCT00023023|Blood Recipients
1493104|NCT00023010|CD18
1493105|NCT00023010|Retrovirus
1493106|NCT00023010|RCR
1493107|NCT00023010|Stem Cell
1493108|NCT00023010|Gene Transfer
1493109|NCT00023010|Leukocyte Adhesion Deficiency
1493110|NCT00023010|LAD
1493111|NCT00022997|Phenylthiocarbamide
1493112|NCT00022997|Phlebotomy
1493113|NCT00022997|Chemoreceptors
1493114|NCT00022997|Population Associations
1493115|NCT00022997|Non-Tasters
1493116|NCT00022997|Taste
1493117|NCT00022997|Healthy Volunteer
1493118|NCT00022997|HV
1493119|NCT00022997|Normal Control
1493120|NCT00022984|Attitudes Towards Technology
1493121|NCT00022984|Cardiovascular Disease
1493122|NCT00022984|Illness Representation
1493123|NCT00022984|Implantable Cardioverter Defibrillator
1493124|NCT00022984|Symptom Distress
1493125|NCT00022984|Heart Disease
1493126|NCT00022984|ICD
1493127|NCT00022971|Monoclonal Antibody
1493128|NCT00022971|Lymphoma
1493129|NCT00022971|Rituximab
1493130|NCT00022971|Hu1D10
1493131|NCT00022971|Non-Hodgkin's Lymphoma
1493132|NCT00022971|NHL
1493133|NCT00022971|Chronic Lymphocytic Leukemia
1493134|NCT00022971|CLL
1493135|NCT00022971|Leukemia
1493136|NCT00022958|Non-Hodgkin's Lymphoma
1493137|NCT00022958|Radioimmunotherapy
1493138|NCT00022958|Monoclonal Antibody
1493139|NCT00022958|Corixa
1493140|NCT00022958|Bexxar
1493141|NCT00022958|Anti-B1 Antibody
1493142|NCT00022958|Tositumomab
1493143|NCT00022958|Iodine -131 Anti-B1 Antibody
1493144|NCT00022958|Iodine I 131 Tositumomab
1493145|NCT00022945|Mantle Cell Lymphoma
1493146|NCT00022945|Radioimmunotherapy
1493147|NCT00022945|Monoclonal Antibody
1493148|NCT00022945|Corixa
1493149|NCT00022945|Bexxar
1493150|NCT00022945|Anti-B1 Antibody
1493151|NCT00022945|Tositumomab
1493152|NCT00022945|Iodine -131 Anti-B1 Antibody
1493153|NCT00022945|Iodine I 131 Tositumomab
1493154|NCT00022932|Non-Hodgkin's Lymphoma
1493155|NCT00022932|Radioimmunotherapy
1493156|NCT00022932|Monoclonal Antibody
1493157|NCT00022932|Corixa
1493158|NCT00022932|Bexxar
1493159|NCT00022932|Anti-B1 Antibody
1493160|NCT00022932|Tositumomab
1493161|NCT00022932|Iodine -131 Anti-B1 Antibody
1493162|NCT00022932|Iodine I 131 Tositumomab
1493163|NCT00022919|Microdissection
1493164|NCT00022919|Chromosome
1493165|NCT00022919|Karyotype
1493166|NCT00022919|Tumor
1493167|NCT00022919|Malignancy
1493168|NCT00022919|Prostate Adenocarcinoma
1493169|NCT00022919|Prostate Intraepithelial Neoplasia
1493170|NCT00022919|Prostate Cancer
1493171|NCT00022919|Prostate
1493172|NCT00022906|Non-Hodgkin's Lymphoma
1493173|NCT00022906|Radioimmunotherapy
1493174|NCT00022906|Monoclonal Antibody
1493175|NCT00022906|Corixa
1493176|NCT00022906|Bexxar
1493177|NCT00022906|Anti-B1 Antibody
1493178|NCT00022906|Tositumomab
1493179|NCT00022906|Iodine -131 Anti-B1 Antibody
1493180|NCT00022906|Iodine I 131 Tositumomab
1493181|NCT00022893|Non-Hodgkin's Lymphoma
1493182|NCT00022893|Radioimmunotherapy
1493183|NCT00022893|Monoclonal Antibody
1493184|NCT00022893|Corixa
1493185|NCT00022893|Bexxar
1493186|NCT00022893|Anti-B1 Antibody
1493187|NCT00022893|Tositumomab
1493188|NCT00022893|Iodine -131 Anti-B1 Antibody
1493189|NCT00022893|Iodine I 131 Tositumomab
1493190|NCT00022880|Chronic Lymphocytic Leukemia
1493191|NCT00022880|Dose-Escalation
1493192|NCT00022880|Radioimmunotherapy
1493193|NCT00022880|Monoclonal Antibody
1493194|NCT00022880|Corixa
1493195|NCT00022880|Bexxar
1493196|NCT00022880|Anti-B1 Antibody
1493197|NCT00022880|Tositumomab
1493198|NCT00022880|Iodine -131 Anti-B1 Antibody
1493199|NCT00022880|Iodine I 131 Tositumomab
1493200|NCT00022867|Bone growth
1493201|NCT00022867|Calcium
1493202|NCT00022867|Children
1493203|NCT00022867|Diet
1493204|NCT00022867|Puberty
1493205|NCT00022854|ACL
1493206|NCT00022854|Nerve block
1493207|NCT00022854|Knee
1493208|NCT00022854|Outcome survey
1493209|NCT00022854|Anesthesia
1493210|NCT00022854|Analgesia
1493211|NCT00022854|Pain
1493212|NCT00022841|Bone mineral density (BMD)
1493213|NCT00022841|Children
1493214|NCT00022841|Glucocorticoids
1493215|NCT00022841|Osteoporosis
1493216|NCT00022841|Pediatric
1493217|NCT00022841|Pamidronate
1493218|NCT00022841|Steroids
1493219|NCT00022828|Laser
1493220|NCT00022828|Cervical
1493221|NCT00022828|Spinal
1493222|NCT00022828|Spine
1493223|NCT00022828|Neck
1493224|NCT00022828|Illinois
1493225|NCT00022815|Compartment syndrome
1493226|NCT00022815|Tissue ultrafiltration
1493227|NCT00022815|Reperfusion injury
1493228|NCT00022815|Ischemia
1493229|NCT00022802|Biomedical equipment development
1493230|NCT00022802|Computer assisted patient care
1493231|NCT00022802|Digital imaging
1493232|NCT00022802|Hip surgery
1493233|NCT00022802|Orthopedics
1493234|NCT00022802|Trauma
1493235|NCT00022802|Radiography
1493236|NCT00022802|Biomedical imaging
1493237|NCT00022789|Sleep-Disordered Breathing
1493238|NCT00022776|Human therapy evaluation
1493239|NCT00022776|Orthopedics
1493240|NCT00022776|Physical therapy
1493241|NCT00022776|Nonsurgical treatment
1493242|NCT00022776|Surgical decompression
1493243|NCT00022776|Surgery
1493244|NCT00022776|Lumbar
1493245|NCT00022776|Spine disorder
1493246|NCT00022776|Spinal stenosis
1493247|NCT00022776|Gender difference
1493248|NCT00022776|Medical rehabilitation
1493249|NCT00022763|Anti-HIV Agents
1493250|NCT00022763|pentafuside
1493251|NCT00022750|Type 2 Diabetes Mellitus
1493252|NCT00022750|Nurse Case Manager
1493253|NCT00022750|Community Health Worker
1493254|NCT00022750|Behavioral Interventions
1493255|NCT00022750|Cost-effectiveness
1493256|NCT00022750|Randomized trial
1493257|NCT00022724|recurrent adult brain tumor
1493258|NCT00022724|adult glioblastoma
1493259|NCT00022724|adult anaplastic astrocytoma
1493260|NCT00022724|adult anaplastic oligodendroglioma
1493261|NCT00022724|adult mixed glioma
1493262|NCT00022724|adult giant cell glioblastoma
1493263|NCT00022724|adult gliosarcoma
1493264|NCT00022711|recurrent small cell lung cancer
1493265|NCT00022711|intermediate type small cell lung cancer
1493266|NCT00022698|stage III colon cancer
1493267|NCT00022698|stage IV colon cancer
1493268|NCT00022698|stage III rectal cancer
1493269|NCT00022698|stage IV rectal cancer
1493270|NCT00022698|recurrent colon cancer
1493271|NCT00022698|recurrent rectal cancer
1493272|NCT00022698|adenocarcinoma of the colon
1493273|NCT00022698|adenocarcinoma of the rectum
1493274|NCT00022685|recurrent grade 1 follicular lymphoma
1493275|NCT00022685|recurrent grade 2 follicular lymphoma
1493276|NCT00022646|stage IIIB non-small cell lung cancer
1493277|NCT00022646|stage IV non-small cell lung cancer
1493278|NCT00022633|recurrent bladder cancer
1493279|NCT00022633|stage IV bladder cancer
1493280|NCT00022633|transitional cell carcinoma of the bladder
1493281|NCT00022633|squamous cell carcinoma of the bladder
1493282|NCT00022633|adenocarcinoma of the bladder
1493283|NCT00022633|recurrent urethral cancer
1493284|NCT00022633|anterior urethral cancer
1493285|NCT00022633|posterior urethral cancer
1493286|NCT00022633|urethral cancer associated with invasive bladder cancer
1493287|NCT00022633|metastatic transitional cell cancer of the renal pelvis and ureter
1493288|NCT00022633|regional transitional cell cancer of the renal pelvis and ureter
1493289|NCT00022633|recurrent transitional cell cancer of the renal pelvis and ureter
1493290|NCT00022620|recurrent endometrial carcinoma
1493291|NCT00022620|endometrial papillary serous carcinoma
1493292|NCT00022607|refractory multiple myeloma
1493293|NCT00022607|stage I multiple myeloma
1493294|NCT00022607|stage II multiple myeloma
1493295|NCT00022607|stage III multiple myeloma
1493296|NCT00022594|recurrent metastatic squamous neck cancer with occult primary
1493297|NCT00022594|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1493298|NCT00022594|stage III squamous cell carcinoma of the lip and oral cavity
1493299|NCT00022594|stage IV squamous cell carcinoma of the lip and oral cavity
1493300|NCT00022594|recurrent squamous cell carcinoma of the lip and oral cavity
1493301|NCT00022594|stage III squamous cell carcinoma of the oropharynx
1493302|NCT00022594|stage IV squamous cell carcinoma of the oropharynx
1493303|NCT00022594|recurrent squamous cell carcinoma of the oropharynx
1493304|NCT00022594|stage III squamous cell carcinoma of the hypopharynx
1493305|NCT00022594|stage IV squamous cell carcinoma of the hypopharynx
1493306|NCT00022594|recurrent squamous cell carcinoma of the hypopharynx
1493307|NCT00022594|stage III squamous cell carcinoma of the larynx
1493308|NCT00022594|stage IV squamous cell carcinoma of the larynx
1493309|NCT00022594|recurrent squamous cell carcinoma of the larynx
1493310|NCT00022568|stage IV melanoma
1493311|NCT00022568|recurrent melanoma
1493312|NCT00022516|stage IA breast cancer
1493313|NCT00022516|stage II breast cancer
1493314|NCT00022516|stage IIIA breast cancer
1493315|NCT00022516|stage IIIB breast cancer
1493316|NCT00022516|stage IB breast cancer
1493317|NCT00022516|estrogen receptor-negative breast cancer
1493318|NCT00022516|progesterone receptor-negative breast cancer
1493319|NCT00022516|triple-negative breast cancer
1493320|NCT00022516|low-dose maintenance chemotherapy
1493321|NCT00022516|stroma
1493322|NCT00022516|angiogenesis
1493323|NCT00022490|chronic phase chronic myelogenous leukemia
1493324|NCT00022490|Philadelphia chromosome positive chronic myelogenous leukemia
1493325|NCT00022477|stage IV colon cancer
1493326|NCT00022477|stage IV rectal cancer
1493327|NCT00022477|recurrent colon cancer
1493328|NCT00022477|recurrent rectal cancer
1493329|NCT00022477|adenocarcinoma of the colon
1493330|NCT00022477|adenocarcinoma of the rectum
1493331|NCT00022464|stage IV melanoma
1493332|NCT00022464|recurrent melanoma
1493333|NCT00022451|recurrent childhood acute lymphoblastic leukemia
1493334|NCT00022451|recurrent childhood acute myeloid leukemia
1493335|NCT00022451|relapsing chronic myelogenous leukemia
1493336|NCT00022451|blastic phase chronic myelogenous leukemia
1493337|NCT00022451|chronic myelogenous leukemia, BCR-ABL1 positive
1493338|NCT00022451|childhood acute promyelocytic leukemia (M3)
1493339|NCT00022451|acute undifferentiated leukemia
1493340|NCT00022451|juvenile myelomonocytic leukemia
1493341|NCT00022451|childhood chronic myelogenous leukemia
1493342|NCT00022438|stage IV melanoma
1493343|NCT00022438|recurrent melanoma
1493344|NCT00022425|recurrent breast cancer
1493345|NCT00022412|adenocarcinoma of the prostate
1493346|NCT00022412|stage I prostate cancer
1493347|NCT00022412|stage II prostate cancer
1493348|NCT00022399|stage I prostate cancer
1493349|NCT00022399|stage IIB prostate cancer
1493350|NCT00022399|stage IIA prostate cancer
1493351|NCT00022399|adenocarcinoma of the prostate
1493352|NCT00022386|stage I breast cancer
1493353|NCT00022386|stage II breast cancer
1493354|NCT00022386|stage IIIA breast cancer
1493355|NCT00022386|stage IIIB breast cancer
1493356|NCT00022386|anemia
1493357|NCT00022386|fatigue
1493358|NCT00022373|stage I nasopharyngeal cancer
1493359|NCT00022373|stage II nasopharyngeal cancer
1493360|NCT00022373|stage III nasopharyngeal cancer
1493361|NCT00022373|stage IV nasopharyngeal cancer
1493362|NCT00022373|stage I salivary gland cancer
1493363|NCT00022373|stage II salivary gland cancer
1493364|NCT00022373|stage III salivary gland cancer
1493365|NCT00022373|stage IV salivary gland cancer
1493366|NCT00022373|recurrent salivary gland cancer
1493367|NCT00022373|untreated metastatic squamous neck cancer with occult primary
1493368|NCT00022373|recurrent metastatic squamous neck cancer with occult primary
1493369|NCT00022373|stage I lip and oral cavity cancer
1493370|NCT00022373|stage II lip and oral cavity cancer
1493371|NCT00022373|stage III lip and oral cavity cancer
1493372|NCT00022373|stage IV lip and oral cavity cancer
1493373|NCT00022373|stage I hypopharyngeal cancer
1493374|NCT00022373|stage II hypopharyngeal cancer
1493375|NCT00022373|stage III hypopharyngeal cancer
1493376|NCT00022373|stage IV hypopharyngeal cancer
1493377|NCT00022373|stage I oropharyngeal cancer
1493378|NCT00022373|stage II oropharyngeal cancer
1493379|NCT00022373|stage III oropharyngeal cancer
1493380|NCT00022373|stage IV oropharyngeal cancer
1493381|NCT00022373|radiation toxicity
1493382|NCT00022373|oral complications of radiation therapy
1493383|NCT00022360|recurrent adult brain tumor
1493384|NCT00022360|adult glioblastoma
1493385|NCT00022360|adult anaplastic astrocytoma
1493386|NCT00022360|adult giant cell glioblastoma
1493387|NCT00022360|adult gliosarcoma
1493388|NCT00022347|stage IV ovarian epithelial cancer
1493389|NCT00022347|recurrent ovarian epithelial cancer
1493390|NCT00022347|ovarian undifferentiated adenocarcinoma
1493391|NCT00022347|ovarian mixed epithelial carcinoma
1493392|NCT00022347|ovarian serous cystadenocarcinoma
1493393|NCT00022347|ovarian mucinous cystadenocarcinoma
1493394|NCT00022347|ovarian endometrioid adenocarcinoma
1493395|NCT00022347|ovarian clear cell cystadenocarcinoma
1493396|NCT00022347|fallopian tube cancer
1493397|NCT00022347|primary peritoneal cavity cancer
1493398|NCT00022334|localized resectable adult primary liver cancer
1493399|NCT00022334|localized unresectable adult primary liver cancer
1493400|NCT00022334|advanced adult primary liver cancer
1493401|NCT00022334|recurrent adult primary liver cancer
1493402|NCT00022334|adult primary hepatocellular carcinoma
1493403|NCT00022321|refractory anemia
1493404|NCT00022321|refractory anemia with ringed sideroblasts
1493405|NCT00022321|refractory anemia with excess blasts
1493406|NCT00022321|refractory anemia with excess blasts in transformation
1493407|NCT00022321|de novo myelodysplastic syndromes
1493408|NCT00022308|stage II non-small cell lung cancer
1493409|NCT00022308|recurrent non-small cell lung cancer
1493410|NCT00022308|stage IIIA non-small cell lung cancer
1493411|NCT00022308|stage IIIB non-small cell lung cancer
1493412|NCT00022295|unspecified adult solid tumor, protocol specific
1493413|NCT00022282|refractory multiple myeloma
1493414|NCT00022256|adult glioblastoma
1493415|NCT00022256|adult giant cell glioblastoma
1493416|NCT00022256|adult gliosarcoma
1493417|NCT00022243|recurrent non-small cell lung cancer
1493418|NCT00022243|stage IIIA non-small cell lung cancer
1493419|NCT00022243|stage IIIB non-small cell lung cancer
1493420|NCT00022243|stage IV non-small cell lung cancer
1493421|NCT00022230|stage II breast cancer
1493422|NCT00022230|stage IIIA breast cancer
1493423|NCT00022230|stage IIIB breast cancer
1493424|NCT00022230|stage IIIC breast cancer
1493425|NCT00022217|recurrent salivary gland cancer
1493426|NCT00022217|salivary gland squamous cell carcinoma
1493427|NCT00022217|salivary gland anaplastic carcinoma
1493428|NCT00022217|recurrent squamous cell carcinoma of the lip and oral cavity
1493429|NCT00022217|recurrent verrucous carcinoma of the oral cavity
1493430|NCT00022217|recurrent squamous cell carcinoma of the oropharynx
1493431|NCT00022217|recurrent lymphoepithelioma of the oropharynx
1493432|NCT00022217|recurrent squamous cell carcinoma of the nasopharynx
1493433|NCT00022217|recurrent lymphoepithelioma of the nasopharynx
1493434|NCT00022217|recurrent squamous cell carcinoma of the hypopharynx
1493435|NCT00022217|recurrent squamous cell carcinoma of the larynx
1493436|NCT00022217|recurrent verrucous carcinoma of the larynx
1493437|NCT00022217|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1493438|NCT00022204|stage I breast cancer
1493439|NCT00022204|stage II breast cancer
1493440|NCT00022204|stage IIIA breast cancer
1493441|NCT00022204|lymphedema
1493442|NCT00022204|male breast cancer
1493443|NCT00022191|stage IV bladder cancer
1493444|NCT00022191|transitional cell carcinoma of the bladder
1493445|NCT00022191|urethral cancer associated with invasive bladder cancer
1493446|NCT00022191|metastatic transitional cell cancer of the renal pelvis and ureter
1493447|NCT00022191|regional transitional cell cancer of the renal pelvis and ureter
1493448|NCT00022178|adenocarcinoma of unknown primary
1493449|NCT00022178|squamous cell carcinoma of unknown primary
1493450|NCT00022178|undifferentiated carcinoma of unknown primary
1493567|NCT00021749|Antisense
1493451|NCT00022178|newly diagnosed carcinoma of unknown primary
1493452|NCT00022165|unspecified adult solid tumor, protocol specific
1493453|NCT00022152|stage IV breast cancer
1493454|NCT00022152|recurrent breast cancer
1493455|NCT00022139|stage III gastric cancer
1493456|NCT00022139|stage II esophageal cancer
1493457|NCT00022139|stage III esophageal cancer
1493458|NCT00022139|adenocarcinoma of the stomach
1493459|NCT00022139|squamous cell carcinoma of the esophagus
1493460|NCT00022139|adenocarcinoma of the esophagus
1493461|NCT00022126|untreated childhood acute lymphoblastic leukemia
1493462|NCT00022126|L1 childhood acute lymphoblastic leukemia
1493463|NCT00022126|L2 childhood acute lymphoblastic leukemia
1493464|NCT00022126|acute undifferentiated leukemia
1493465|NCT00022087|osteoporosis
1493466|NCT00022087|stage I breast cancer
1493467|NCT00022087|stage II breast cancer
1493468|NCT00022087|stage IV breast cancer
1493469|NCT00022087|stage IIIA breast cancer
1493470|NCT00022087|stage IIIB breast cancer
1493471|NCT00022087|stage IIIC breast cancer
1493472|NCT00022074|stage I breast cancer
1493473|NCT00022074|stage II breast cancer
1493474|NCT00022074|stage IV breast cancer
1493475|NCT00022074|stage IIIA breast cancer
1493476|NCT00022074|recurrent breast cancer
1493477|NCT00022074|stage IIIB breast cancer
1493478|NCT00022074|stage IIIC breast cancer
1493479|NCT00022074|anxiety disorder
1493480|NCT00022074|depression
1493481|NCT00022074|hot flashes
1493482|NCT00022048|refractory anemia
1493483|NCT00022048|refractory anemia with ringed sideroblasts
1493484|NCT00022048|refractory anemia with excess blasts
1493485|NCT00022048|refractory anemia with excess blasts in transformation
1493486|NCT00022048|chronic myelomonocytic leukemia
1493487|NCT00022048|de novo myelodysplastic syndromes
1493488|NCT00022048|previously treated myelodysplastic syndromes
1493489|NCT00022048|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1493490|NCT00022048|atypical chronic myeloid leukemia, BCR-ABL1 negative
1493491|NCT00022035|childhood acute lymphoblastic leukemia in remission
1493492|NCT00022035|infection
1493493|NCT00022022|recurrent non-small cell lung cancer
1493494|NCT00022022|stage IIIB non-small cell lung cancer
1493495|NCT00022022|stage IV non-small cell lung cancer
1493496|NCT00022009|stage IIIA non-small cell lung cancer
1493497|NCT00022009|stage IIIB non-small cell lung cancer
1493498|NCT00022009|stage IV non-small cell lung cancer
1493499|NCT00021996|unspecified adult solid tumor, protocol specific
1493500|NCT00021996|pain
1493501|NCT00021983|refractory hairy cell leukemia
1493502|NCT00021866|epilepsy
1493503|NCT00021866|seizure
1493504|NCT00021866|pregnancy
1493505|NCT00021866|antiepileptic
1493506|NCT00021866|AED
1493507|NCT00021866|carbamazepine
1493508|NCT00021866|phenytoin
1493509|NCT00021866|valproate
1493510|NCT00021866|lamotrigine
1493511|NCT00021866|child
1493512|NCT00021866|behavior
1493513|NCT00021853|Individualized
1493514|NCT00021853|Finger
1493515|NCT00021853|Training
1493516|NCT00021853|Splinting
1493517|NCT00021853|TMS
1493518|NCT00021853|Dystonia
1493519|NCT00021853|Focal Dystonia
1493520|NCT00021853|Movement Disorder
1493521|NCT00021853|Focal Hand Dystonia
1493522|NCT00021853|Writer's Cramp
1493523|NCT00021827|parathyroid hormone-related protein
1493524|NCT00021827|parathyroid hormone
1493525|NCT00021827|anabolic skeletal therapy
1493526|NCT00021827|postmenopausal women
1493527|NCT00021814|BPH progression
1493528|NCT00021814|Medical Therapy
1493529|NCT00021814|Finasteride
1493530|NCT00021814|Doxazosin
1493531|NCT00021814|Randomized
1493532|NCT00021814|Multi-center
1493533|NCT00021814|Clinical Trial
1493534|NCT00021814|Proscar
1493535|NCT00021814|Cardura
1493536|NCT00021801|Type I Diabetes Mellitus
1493537|NCT00021801|Immunosuppression
1493538|NCT00021801|Islet Cell Transplant
1493539|NCT00021801|Percutaneous Transhepatic Portal
1493540|NCT00021788|Type I Diabetes Mellitus
1493541|NCT00021788|Immunosuppression
1493542|NCT00021788|Islet Cell Transplantation
1493543|NCT00021788|PercutaneousTranshepaticPortalVein Catheterization
1493544|NCT00021775|Risk Factors
1493545|NCT00021775|Incidence
1493546|NCT00021775|Patient Selection
1493547|NCT00021775|HIV Seronegativity
1493548|NCT00021762|Virus Replication
1493549|NCT00021762|HIV-1
1493550|NCT00021762|Drug Administration Schedule
1493551|NCT00021762|AIDS Vaccines
1493552|NCT00021762|RNA, Viral
1493553|NCT00021762|Viral Load
1493554|NCT00021762|HIV-1 immunogen, incomplete Freund's adjuvant
1493555|NCT00021762|Treatment Interruption
1493556|NCT00021762|HIV Therapeutic Vaccine
1493557|NCT00021749|CLL
1493558|NCT00021749|Leukemia
1493559|NCT00021749|Chronic
1493560|NCT00021749|Cancer
1493561|NCT00021749|Adult
1493562|NCT00021749|Lymphocytic
1493563|NCT00021749|Genasense
1493564|NCT00021749|G3139
1493565|NCT00021749|Genta
1493566|NCT00021749|Bcl-2
1493568|NCT00021749|Oligonucleotide
1493569|NCT00021749|oblimerson
1493570|NCT00021736|choroidal neovascularization (CNV)
1493571|NCT00021736|subretinal neovascularization
1493572|NCT00021723|Alzheimer's
1493573|NCT00021723|AN-1792
1493574|NCT00021723|AIP-001
1493575|NCT00021710|Stroke
1493576|NCT00021710|Learning
1493577|NCT00021710|Plasticity
1493578|NCT00021710|Motor
1493579|NCT00021710|Rehabilitation
1493580|NCT00021710|Premotor
1493581|NCT00021710|Normal Control
1493582|NCT00021710|Healthy Volunteer
1493583|NCT00021710|HV
1493584|NCT00021710|Motor Learning
1493585|NCT00021697|AVP-923
1493586|NCT00021697|Dextromethorphan
1493587|NCT00021697|Quinidine
1493588|NCT00021697|Pseudobulbar Affect
1493589|NCT00021671|Drug Therapy, Combination
1493590|NCT00021671|Ampicillin
1493591|NCT00021671|Nevirapine
1493592|NCT00021671|Disease Transmission, Vertical
1493593|NCT00021671|Anti-Infective Agents
1493594|NCT00021671|Erythromycin
1493595|NCT00021671|Reverse Transcriptase Inhibitors
1493596|NCT00021671|Metronidazole
1493597|NCT00021671|Anti-HIV Agents
1493598|NCT00021671|Chorioamnionitis
1493599|NCT00021671|HIV Seronegativity
1493600|NCT00021658|Epidemiology
1493601|NCT00021658|pesticide
1493602|NCT00021658|asthma
1493603|NCT00021658|children
1493604|NCT00021658|exposure
1493605|NCT00021645|Corticosteroids
1493606|NCT00021645|Immunosuppressives
1493607|NCT00021645|Intraocular Inflammatory Disease
1493608|NCT00021645|Uveitis
1493609|NCT00021645|Macular Edema
1493610|NCT00021632|Ribavirin
1493611|NCT00021632|Drug Interactions
1493612|NCT00021632|Drug Therapy, Combination
1493613|NCT00021632|Zidovudine
1493614|NCT00021632|Stavudine
1493615|NCT00021632|Reverse Transcriptase Inhibitors
1493616|NCT00021632|Anti-HIV Agents
1493617|NCT00021632|Pharmacokinetics
1493618|NCT00021632|Area Under Curve
1493619|NCT00021567|Pneumonia
1493620|NCT00021567|Cytokine
1493621|NCT00021567|Aerosol
1493622|NCT00021567|Therapy
1493623|NCT00021567|Mycobacteria
1493624|NCT00021567|Mycobacterium Avium Complex
1493625|NCT00021567|MAC
1493626|NCT00021567|Pulmonary Infection
1493627|NCT00021567|Lung Infection
1493628|NCT00021554|HIV-1
1493629|NCT00021554|Drug Therapy, Combination
1493630|NCT00021554|HIV Protease Inhibitors
1493631|NCT00021554|RNA, Viral
1493632|NCT00021554|Reverse Transcriptase Inhibitors
1493633|NCT00021554|Anti-HIV Agents
1493634|NCT00021554|Viral Load
1493635|NCT00021554|pentafuside
1493636|NCT00021541|Surrogate Markers
1493637|NCT00021541|3-Dimensional Magnetic Resonance Imaging (MRI)
1493638|NCT00021541|Natural History of Neurofibromatosis Type 1 (NF1)
1493639|NCT00021541|Tumor Tissue Bank
1493640|NCT00021541|Neurofibromatosis
1493641|NCT00021541|NF1
1493642|NCT00021541|Neurofibromatosis Type 1
1493643|NCT00021541|Plexiform Neurofibroma
1493644|NCT00021541|Neurofibroma
1493645|NCT00021528|Sequential Treatment
1493646|NCT00021528|Major Depression
1493647|NCT00021528|Treatment Resistant Depression
1493648|NCT00021502|Pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)
1493649|NCT00021502|Systemic Inflammatory Response Syndrome (SIRS)
1493650|NCT00021502|Nitric oxide (NO)
1493651|NCT00021502|Shock
1493652|NCT00021489|Placebos
1493653|NCT00021489|Drug Therapy, Combination
1493654|NCT00021489|Reverse Transcriptase Inhibitors
1493655|NCT00021489|Anti-HIV Agents
1493656|NCT00021489|abacavir
1493657|NCT00021489|mycophenolate mofetil
1493658|NCT00021476|Whiplash
1493659|NCT00021476|Chronic pain
1493660|NCT00021476|Motor vehicle accidents
1493661|NCT00021463|Nevirapine
1493662|NCT00021463|Reverse Transcriptase Inhibitors
1493663|NCT00021463|Anti-HIV Agents
1493664|NCT00021463|Triglycerides
1493665|NCT00021463|abacavir
1493666|NCT00021463|efavirenz
1493667|NCT00021463|Lipoproteins, LDL Cholesterol
1493668|NCT00021450|stage IIB prostate cancer
1493669|NCT00021450|stage IIA prostate cancer
1493670|NCT00021437|Bloom syndrome protein
1493767|NCT00021138|laryngeal cancer
1493671|NCT00021424|stage IV squamous cell carcinoma of the lip and oral cavity
1493672|NCT00021424|recurrent squamous cell carcinoma of the lip and oral cavity
1493673|NCT00021424|stage IV squamous cell carcinoma of the oropharynx
1493674|NCT00021424|recurrent squamous cell carcinoma of the oropharynx
1493675|NCT00021424|skin metastases
1493676|NCT00021398|stage II rectal cancer
1493677|NCT00021398|stage III rectal cancer
1493678|NCT00021398|adenocarcinoma of the rectum
1493679|NCT00021385|stage III ovarian epithelial cancer
1493680|NCT00021385|stage IV ovarian epithelial cancer
1493681|NCT00021385|recurrent ovarian epithelial cancer
1493682|NCT00021385|ovarian stromal cancer
1493683|NCT00021385|stage III ovarian germ cell tumor
1493684|NCT00021385|stage IV ovarian germ cell tumor
1493685|NCT00021385|recurrent ovarian germ cell tumor
1493686|NCT00021385|borderline ovarian surface epithelial-stromal tumor
1493687|NCT00021385|ovarian sarcoma
1493688|NCT00021372|recurrent grade 1 follicular lymphoma
1493689|NCT00021372|recurrent grade 2 follicular lymphoma
1493690|NCT00021372|recurrent grade 3 follicular lymphoma
1493691|NCT00021372|recurrent adult diffuse small cleaved cell lymphoma
1493692|NCT00021372|recurrent adult diffuse mixed cell lymphoma
1493693|NCT00021372|recurrent adult diffuse large cell lymphoma
1493694|NCT00021372|recurrent adult immunoblastic large cell lymphoma
1493695|NCT00021372|recurrent adult lymphoblastic lymphoma
1493696|NCT00021372|recurrent adult Burkitt lymphoma
1493697|NCT00021372|recurrent mantle cell lymphoma
1493698|NCT00021372|recurrent marginal zone lymphoma
1493699|NCT00021372|recurrent small lymphocytic lymphoma
1493700|NCT00021372|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1493701|NCT00021372|nodal marginal zone B-cell lymphoma
1493702|NCT00021372|splenic marginal zone lymphoma
1493703|NCT00021359|stage I multiple myeloma
1493704|NCT00021359|stage II multiple myeloma
1493705|NCT00021359|stage III multiple myeloma
1493706|NCT00021346|unspecified adult solid tumor, protocol specific
1493707|NCT00021333|recurrent non-small cell lung cancer
1493708|NCT00021333|recurrent small cell lung cancer
1493709|NCT00021333|recurrent thyroid cancer
1493710|NCT00021333|recurrent salivary gland cancer
1493711|NCT00021333|recurrent squamous cell carcinoma of the lip and oral cavity
1493712|NCT00021333|recurrent basal cell carcinoma of the lip
1493713|NCT00021333|recurrent verrucous carcinoma of the oral cavity
1493714|NCT00021333|recurrent mucoepidermoid carcinoma of the oral cavity
1493715|NCT00021333|recurrent adenoid cystic carcinoma of the oral cavity
1493716|NCT00021333|recurrent squamous cell carcinoma of the oropharynx
1493717|NCT00021333|recurrent lymphoepithelioma of the oropharynx
1493718|NCT00021333|recurrent squamous cell carcinoma of the nasopharynx
1493719|NCT00021333|recurrent lymphoepithelioma of the nasopharynx
1493720|NCT00021333|recurrent squamous cell carcinoma of the hypopharynx
1493721|NCT00021333|recurrent squamous cell carcinoma of the larynx
1493722|NCT00021333|recurrent verrucous carcinoma of the larynx
1493723|NCT00021333|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1493724|NCT00021333|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1493725|NCT00021333|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1493726|NCT00021333|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1493727|NCT00021320|stage 0 esophageal cancer
1493728|NCT00021320|stage I esophageal cancer
1493729|NCT00021320|stage II esophageal cancer
1493730|NCT00021320|stage III esophageal cancer
1493731|NCT00021320|squamous cell carcinoma of the esophagus
1493732|NCT00021320|adenocarcinoma of the esophagus
1493733|NCT00021307|recurrent adult brain tumor
1493734|NCT00021307|adult glioblastoma
1493735|NCT00021307|adult giant cell glioblastoma
1493736|NCT00021307|adult gliosarcoma
1493737|NCT00021294|basal cell carcinoma of the skin
1493738|NCT00021294|squamous cell carcinoma of the skin
1493739|NCT00021294|actinic keratosis
1493740|NCT00021281|stage IV colon cancer
1493741|NCT00021281|stage IV rectal cancer
1493742|NCT00021281|recurrent colon cancer
1493743|NCT00021281|recurrent rectal cancer
1493744|NCT00021281|adenocarcinoma of the colon
1493745|NCT00021281|adenocarcinoma of the rectum
1493746|NCT00021268|stage IV colon cancer
1493747|NCT00021268|stage IV rectal cancer
1493748|NCT00021268|recurrent colon cancer
1493749|NCT00021268|recurrent rectal cancer
1493750|NCT00021242|recurrent childhood acute lymphoblastic leukemia
1493751|NCT00021242|recurrent childhood acute myeloid leukemia
1493752|NCT00021242|childhood acute promyelocytic leukemia (M3)
1493753|NCT00021229|childhood central nervous system germ cell tumor
1493754|NCT00021229|childhood high-grade cerebral astrocytoma
1493755|NCT00021229|untreated childhood brain stem glioma
1493756|NCT00021229|recurrent childhood brain stem glioma
1493757|NCT00021229|recurrent childhood cerebral astrocytoma
1493758|NCT00021164|stage IV melanoma
1493759|NCT00021164|recurrent melanoma
1493760|NCT00021164|unspecified adult solid tumor, protocol specific
1493761|NCT00021151|refractory chronic lymphocytic leukemia
1493762|NCT00021151|prolymphocytic leukemia
1493763|NCT00021138|non-small cell lung cancer
1493764|NCT00021138|small cell lung cancer
1493765|NCT00021138|esophageal cancer
1493766|NCT00021138|hypopharyngeal cancer
1493768|NCT00021138|nasopharyngeal cancer
1493769|NCT00021138|oropharyngeal cancer
1493770|NCT00021138|lip and oral cavity cancer
1493771|NCT00021138|paranasal sinus and nasal cavity cancer
1493772|NCT00021138|tongue cancer
1493773|NCT00021125|squamous cell carcinoma of the skin
1493774|NCT00021125|stage I squamous cell carcinoma of the lip and oral cavity
1493775|NCT00021125|stage II squamous cell carcinoma of the lip and oral cavity
1493776|NCT00021125|stage III squamous cell carcinoma of the lip and oral cavity
1493777|NCT00021125|stage IV squamous cell carcinoma of the lip and oral cavity
1493778|NCT00021125|stage I squamous cell carcinoma of the oropharynx
1493779|NCT00021125|stage II squamous cell carcinoma of the oropharynx
1493780|NCT00021125|stage III squamous cell carcinoma of the oropharynx
1493781|NCT00021125|stage IV squamous cell carcinoma of the oropharynx
1493782|NCT00021125|stage I squamous cell carcinoma of the hypopharynx
1493783|NCT00021125|stage II squamous cell carcinoma of the hypopharynx
1493784|NCT00021125|stage III squamous cell carcinoma of the hypopharynx
1493785|NCT00021125|stage IV squamous cell carcinoma of the hypopharynx
1493786|NCT00021125|stage I squamous cell carcinoma of the larynx
1493787|NCT00021125|stage II squamous cell carcinoma of the larynx
1493788|NCT00021125|stage III squamous cell carcinoma of the larynx
1493789|NCT00021125|stage IV squamous cell carcinoma of the larynx
1493790|NCT00021125|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1493791|NCT00021125|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1493792|NCT00021125|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1493793|NCT00021125|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1493794|NCT00021125|salivary gland squamous cell carcinoma
1493795|NCT00021125|stage I salivary gland cancer
1493796|NCT00021125|stage II salivary gland cancer
1493797|NCT00021125|stage III salivary gland cancer
1493798|NCT00021125|stage IV salivary gland cancer
1493799|NCT00021112|stage IIIB non-small cell lung cancer
1493800|NCT00021047|stage IV gastric cancer
1493801|NCT00021047|recurrent gastric cancer
1493802|NCT00021047|stage II esophageal cancer
1493803|NCT00021047|stage III esophageal cancer
1493804|NCT00021047|stage IV esophageal cancer
1493805|NCT00021047|recurrent esophageal cancer
1493806|NCT00021047|advanced adult primary liver cancer
1493807|NCT00021047|recurrent adult primary liver cancer
1493808|NCT00021047|unresectable extrahepatic bile duct cancer
1493809|NCT00021047|recurrent extrahepatic bile duct cancer
1493810|NCT00021047|unspecified adult solid tumor, protocol specific
1493811|NCT00021047|untreated metastatic squamous neck cancer with occult primary
1493812|NCT00021047|recurrent metastatic squamous neck cancer with occult primary
1493813|NCT00021047|stage IV squamous cell carcinoma of the lip and oral cavity
1493814|NCT00021047|stage IV basal cell carcinoma of the lip
1493815|NCT00021047|stage IV verrucous carcinoma of the oral cavity
1493816|NCT00021047|stage IV mucoepidermoid carcinoma of the oral cavity
1493817|NCT00021047|stage IV adenoid cystic carcinoma of the oral cavity
1493818|NCT00021047|recurrent squamous cell carcinoma of the lip and oral cavity
1493819|NCT00021047|recurrent basal cell carcinoma of the lip
1493820|NCT00021047|recurrent verrucous carcinoma of the oral cavity
1493821|NCT00021047|recurrent mucoepidermoid carcinoma of the oral cavity
1493822|NCT00021047|recurrent adenoid cystic carcinoma of the oral cavity
1493823|NCT00021047|stage IV squamous cell carcinoma of the oropharynx
1493824|NCT00021047|stage IV lymphoepithelioma of the oropharynx
1493825|NCT00021047|recurrent squamous cell carcinoma of the oropharynx
1493826|NCT00021047|recurrent lymphoepithelioma of the oropharynx
1493827|NCT00021047|stage IV squamous cell carcinoma of the nasopharynx
1493828|NCT00021047|stage IV lymphoepithelioma of the nasopharynx
1493829|NCT00021047|recurrent squamous cell carcinoma of the nasopharynx
1493830|NCT00021047|recurrent lymphoepithelioma of the nasopharynx
1493831|NCT00021047|stage IV squamous cell carcinoma of the hypopharynx
1493832|NCT00021047|recurrent squamous cell carcinoma of the hypopharynx
1493833|NCT00021047|stage IV squamous cell carcinoma of the larynx
1493834|NCT00021047|stage IV verrucous carcinoma of the larynx
1493835|NCT00021047|recurrent squamous cell carcinoma of the larynx
1493836|NCT00021047|recurrent verrucous carcinoma of the larynx
1493837|NCT00021047|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1493838|NCT00021047|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1493839|NCT00021047|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1493840|NCT00021047|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1493841|NCT00021047|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1493842|NCT00021047|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1493843|NCT00021047|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1493844|NCT00021047|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1493845|NCT00021047|recurrent salivary gland cancer
1493846|NCT00021047|stage IV salivary gland cancer
1493847|NCT00021034|stage II ovarian epithelial cancer
1493848|NCT00021034|stage III ovarian epithelial cancer
1493849|NCT00021034|stage IV ovarian epithelial cancer
1493850|NCT00021034|recurrent ovarian epithelial cancer
1493851|NCT00021034|fallopian tube cancer
1493852|NCT00021034|primary peritoneal cavity cancer
1493853|NCT00021021|stage IV renal cell cancer
1493854|NCT00021021|clear cell renal cell carcinoma
1493855|NCT00021008|recurrent non-small cell lung cancer
1493856|NCT00021008|stage IIIB non-small cell lung cancer
1493857|NCT00021008|stage IV non-small cell lung cancer
1493858|NCT00020995|adenocarcinoma of the prostate
1493859|NCT00020995|stage I prostate cancer
1493860|NCT00020995|stage IIB prostate cancer
1493861|NCT00020995|stage IIA prostate cancer
1493862|NCT00020995|stage III prostate cancer
1493863|NCT00020995|stage IV prostate cancer
1493864|NCT00020969|refractory anemia
1493865|NCT00020969|refractory anemia with ringed sideroblasts
1493866|NCT00020969|refractory anemia with excess blasts
1493867|NCT00020969|refractory anemia with excess blasts in transformation
1493868|NCT00020969|chronic myelomonocytic leukemia
1493869|NCT00020969|de novo myelodysplastic syndromes
1493870|NCT00020969|previously treated myelodysplastic syndromes
1493871|NCT00020969|secondary myelodysplastic syndromes
1493872|NCT00020969|atypical chronic myeloid leukemia, BCR-ABL1 negative
1493873|NCT00020969|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1493874|NCT00020943|stage I mantle cell lymphoma
1493875|NCT00020943|contiguous stage II mantle cell lymphoma
1493876|NCT00020943|noncontiguous stage II mantle cell lymphoma
1493877|NCT00020943|stage III mantle cell lymphoma
1493878|NCT00020943|stage IV mantle cell lymphoma
1493879|NCT00020930|stage IV colon cancer
1493880|NCT00020930|stage IV rectal cancer
1493881|NCT00020930|recurrent colon cancer
1493882|NCT00020930|recurrent rectal cancer
1493883|NCT00020917|stage IV colon cancer
1493884|NCT00020917|stage IV rectal cancer
1493885|NCT00020904|stage IV breast cancer
1493886|NCT00020904|recurrent breast cancer
1493887|NCT00020891|stage I prostate cancer
1493888|NCT00020891|stage IIB prostate cancer
1493889|NCT00020891|stage IIA prostate cancer
1493890|NCT00020891|stage III prostate cancer
1493891|NCT00020891|stage IV prostate cancer
1493892|NCT00020891|recurrent prostate cancer
1493893|NCT00020878|non-small cell lung cancer
1493894|NCT00020865|stage I adult Hodgkin lymphoma
1493895|NCT00020865|stage II adult Hodgkin lymphoma
1493896|NCT00020865|stage III adult Hodgkin lymphoma
1493897|NCT00020865|stage IV adult Hodgkin lymphoma
1493898|NCT00020865|recurrent adult Hodgkin lymphoma
1493899|NCT00020865|stage I cutaneous T-cell non-Hodgkin lymphoma
1493900|NCT00020865|stage II cutaneous T-cell non-Hodgkin lymphoma
1493901|NCT00020865|stage III cutaneous T-cell non-Hodgkin lymphoma
1493902|NCT00020865|stage IV cutaneous T-cell non-Hodgkin lymphoma
1493903|NCT00020865|recurrent cutaneous T-cell non-Hodgkin lymphoma
1493904|NCT00020865|stage 0 chronic lymphocytic leukemia
1493905|NCT00020865|stage I chronic lymphocytic leukemia
1493906|NCT00020865|stage II chronic lymphocytic leukemia
1493907|NCT00020865|stage III chronic lymphocytic leukemia
1493908|NCT00020865|stage IV chronic lymphocytic leukemia
1493909|NCT00020865|recurrent adult acute myeloid leukemia
1493910|NCT00020865|recurrent adult acute lymphoblastic leukemia
1493911|NCT00020865|relapsing chronic myelogenous leukemia
1493912|NCT00020865|refractory chronic lymphocytic leukemia
1493913|NCT00020865|unspecified adult solid tumor, protocol specific
1493914|NCT00020865|chronic phase chronic myelogenous leukemia
1493915|NCT00020865|accelerated phase chronic myelogenous leukemia
1493916|NCT00020865|blastic phase chronic myelogenous leukemia
1493917|NCT00020865|meningeal chronic myelogenous leukemia
1493918|NCT00020865|adult acute myeloid leukemia in remission
1493919|NCT00020865|adult acute lymphoblastic leukemia in remission
1493920|NCT00020865|fever, sweats, and hot flashes
1493921|NCT00020865|progressive hairy cell leukemia, initial treatment
1493922|NCT00020865|refractory hairy cell leukemia
1493923|NCT00020865|stage I grade 1 follicular lymphoma
1493924|NCT00020865|stage I grade 2 follicular lymphoma
1493925|NCT00020865|stage I grade 3 follicular lymphoma
1493926|NCT00020865|stage I adult diffuse small cleaved cell lymphoma
1493927|NCT00020865|stage I adult diffuse mixed cell lymphoma
1493928|NCT00020865|stage I adult diffuse large cell lymphoma
1493929|NCT00020865|stage I adult immunoblastic large cell lymphoma
1493930|NCT00020865|stage I adult lymphoblastic lymphoma
1493931|NCT00020865|stage I adult Burkitt lymphoma
1493932|NCT00020865|chronic myelomonocytic leukemia
1493933|NCT00020865|T-cell large granular lymphocyte leukemia
1493934|NCT00020865|acute undifferentiated leukemia
1493935|NCT00020865|stage III grade 1 follicular lymphoma
1493936|NCT00020865|stage III grade 2 follicular lymphoma
1493937|NCT00020865|stage III grade 3 follicular lymphoma
1493938|NCT00020865|stage III adult diffuse small cleaved cell lymphoma
1493939|NCT00020865|stage III adult diffuse mixed cell lymphoma
1493940|NCT00020865|stage III adult diffuse large cell lymphoma
1493941|NCT00020865|stage III adult immunoblastic large cell lymphoma
1493942|NCT00020865|stage III adult lymphoblastic lymphoma
1493943|NCT00020865|stage III adult Burkitt lymphoma
1493944|NCT00020865|stage IV grade 1 follicular lymphoma
1493945|NCT00020865|stage IV grade 2 follicular lymphoma
1493946|NCT00020865|stage IV grade 3 follicular lymphoma
1493947|NCT00020865|stage IV adult diffuse small cleaved cell lymphoma
1493948|NCT00020865|stage IV adult diffuse mixed cell lymphoma
1493949|NCT00020865|stage IV adult diffuse large cell lymphoma
1493950|NCT00020865|stage IV adult immunoblastic large cell lymphoma
1493951|NCT00020865|stage IV adult lymphoblastic lymphoma
1493952|NCT00020865|stage IV adult Burkitt lymphoma
1493953|NCT00020865|recurrent grade 1 follicular lymphoma
1493954|NCT00020865|recurrent grade 2 follicular lymphoma
1493955|NCT00020865|recurrent grade 3 follicular lymphoma
1493956|NCT00020865|recurrent adult diffuse small cleaved cell lymphoma
1493957|NCT00020865|recurrent adult diffuse mixed cell lymphoma
1493958|NCT00020865|recurrent adult diffuse large cell lymphoma
1493959|NCT00020865|recurrent adult immunoblastic large cell lymphoma
1493960|NCT00020865|recurrent adult lymphoblastic lymphoma
1493961|NCT00020865|recurrent adult Burkitt lymphoma
1493962|NCT00020865|stage I adult T-cell leukemia/lymphoma
1493963|NCT00020865|stage II adult T-cell leukemia/lymphoma
1493964|NCT00020865|stage III adult T-cell leukemia/lymphoma
1493965|NCT00020865|stage IV adult T-cell leukemia/lymphoma
1493966|NCT00020865|recurrent adult T-cell leukemia/lymphoma
1493967|NCT00020865|secondary acute myeloid leukemia
1493968|NCT00020865|primary central nervous system non-Hodgkin lymphoma
1493969|NCT00020865|neutropenia
1493970|NCT00020865|infection
1493971|NCT00020865|prolymphocytic leukemia
1493972|NCT00020865|AIDS-related peripheral/systemic lymphoma
1493973|NCT00020865|AIDS-related primary CNS lymphoma
1493974|NCT00020865|intraocular lymphoma
1493975|NCT00020865|stage I mantle cell lymphoma
1493976|NCT00020865|contiguous stage II grade 1 follicular lymphoma
1493977|NCT00020865|contiguous stage II grade 2 follicular lymphoma
1493978|NCT00020865|contiguous stage II grade 3 follicular lymphoma
1493979|NCT00020865|contiguous stage II adult diffuse small cleaved cell lymphoma
1493980|NCT00020865|contiguous stage II mantle cell lymphoma
1493981|NCT00020865|contiguous stage II adult diffuse mixed cell lymphoma
1493982|NCT00020865|contiguous stage II adult immunoblastic large cell lymphoma
1493983|NCT00020865|contiguous stage II adult diffuse large cell lymphoma
1493984|NCT00020865|contiguous stage II adult Burkitt lymphoma
1493985|NCT00020865|contiguous stage II adult lymphoblastic lymphoma
1493986|NCT00020865|noncontiguous stage II grade 1 follicular lymphoma
1493987|NCT00020865|noncontiguous stage II grade 2 follicular lymphoma
1493988|NCT00020865|noncontiguous stage II grade 3 follicular lymphoma
1493989|NCT00020865|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1493990|NCT00020865|noncontiguous stage II mantle cell lymphoma
1493991|NCT00020865|noncontiguous stage II adult diffuse mixed cell lymphoma
1493992|NCT00020865|noncontiguous stage II adult immunoblastic large cell lymphoma
1493993|NCT00020865|noncontiguous stage II adult diffuse large cell lymphoma
1493994|NCT00020865|noncontiguous stage II adult Burkitt lymphoma
1493995|NCT00020865|noncontiguous stage II adult lymphoblastic lymphoma
1493996|NCT00020865|stage III mantle cell lymphoma
1493997|NCT00020865|stage IV mantle cell lymphoma
1493998|NCT00020865|recurrent mantle cell lymphoma
1493999|NCT00020865|angioimmunoblastic T-cell lymphoma
1494000|NCT00020865|anaplastic large cell lymphoma
1494001|NCT00020865|stage I mycosis fungoides/Sezary syndrome
1494002|NCT00020865|stage II mycosis fungoides/Sezary syndrome
1494003|NCT00020865|stage III mycosis fungoides/Sezary syndrome
1494004|NCT00020865|stage IV mycosis fungoides/Sezary syndrome
1494005|NCT00020865|recurrent mycosis fungoides/Sezary syndrome
1494006|NCT00020865|noncontiguous stage II small lymphocytic lymphoma
1494007|NCT00020865|noncontiguous stage II marginal zone lymphoma
1494008|NCT00020865|recurrent marginal zone lymphoma
1494009|NCT00020865|recurrent small lymphocytic lymphoma
1494010|NCT00020865|stage I marginal zone lymphoma
1494011|NCT00020865|stage I small lymphocytic lymphoma
1494012|NCT00020865|stage III small lymphocytic lymphoma
1494013|NCT00020865|stage III marginal zone lymphoma
1494014|NCT00020865|stage IV small lymphocytic lymphoma
1494015|NCT00020865|stage IV marginal zone lymphoma
1494016|NCT00020865|contiguous stage II marginal zone lymphoma
1494017|NCT00020865|contiguous stage II small lymphocytic lymphoma
1494018|NCT00020865|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1494019|NCT00020865|nodal marginal zone B-cell lymphoma
1494020|NCT00020865|splenic marginal zone lymphoma
1494021|NCT00020852|stage I breast cancer
1494022|NCT00020852|stage II breast cancer
1494023|NCT00020839|stage IV melanoma
1494024|NCT00020839|recurrent melanoma
1494025|NCT00020839|tumors metastatic to brain
1494026|NCT00020826|adenocarcinoma of the stomach
1494027|NCT00020800|Waldenström macroglobulinemia
1494028|NCT00020787|stage IV gastric cancer
1494029|NCT00020787|recurrent gastric cancer
1494030|NCT00020787|stage IV esophageal cancer
1494031|NCT00020787|recurrent esophageal cancer
1494032|NCT00020787|adenocarcinoma of the stomach
1494033|NCT00020787|adenocarcinoma of the esophagus
1494034|NCT00020774|localized resectable adult primary liver cancer
1494035|NCT00020774|recurrent adult primary liver cancer
1494036|NCT00020774|adult primary hepatocellular carcinoma
1494037|NCT00020774|adult primary cholangiocellular carcinoma
1494038|NCT00020761|stage IV gastric cancer
1494039|NCT00020761|recurrent gastric cancer
1494040|NCT00020761|stage IV esophageal cancer
1494041|NCT00020761|recurrent esophageal cancer
1494042|NCT00020761|adenocarcinoma of the stomach
1494043|NCT00020761|adenocarcinoma of the esophagus
1494044|NCT00020748|unspecified adult solid tumor, protocol specific
1494045|NCT00020735|adenocarcinoma of the prostate
1494046|NCT00020735|stage I prostate cancer
1494047|NCT00020735|stage II prostate cancer
1494048|NCT00020722|stage IV breast cancer
1494049|NCT00020722|recurrent breast cancer
1494050|NCT00020696|recurrent ovarian epithelial cancer
1494051|NCT00020696|primary peritoneal cavity cancer
1494056|NCT00020657|nausea and vomiting
1494057|NCT00020657|unspecified adult solid tumor, protocol specific
1494058|NCT00020644|unspecified adult solid tumor, protocol specific
1494059|NCT00020631|radiation fibrosis
1494060|NCT00020618|unspecified adult solid tumor, protocol specific
1494061|NCT00020618|pain
1494062|NCT00020605|unspecified adult solid tumor, protocol specific
1494063|NCT00020605|constipation, impaction, and bowel obstruction
1494064|NCT00020579|stage IV cutaneous T-cell non-Hodgkin lymphoma
1494065|NCT00020579|recurrent cutaneous T-cell non-Hodgkin lymphoma
1494066|NCT00020579|small intestine lymphoma
1494067|NCT00020579|stage IV grade 1 follicular lymphoma
1494068|NCT00020579|stage IV grade 2 follicular lymphoma
1494069|NCT00020579|stage IV grade 3 follicular lymphoma
1494070|NCT00020579|stage IV adult diffuse small cleaved cell lymphoma
1494071|NCT00020579|stage IV adult diffuse mixed cell lymphoma
1494072|NCT00020579|stage IV adult diffuse large cell lymphoma
1494073|NCT00020579|stage IV adult immunoblastic large cell lymphoma
1494074|NCT00020579|stage IV adult lymphoblastic lymphoma
1494075|NCT00020579|stage IV adult Burkitt lymphoma
1494076|NCT00020579|recurrent grade 1 follicular lymphoma
1494077|NCT00020579|recurrent grade 2 follicular lymphoma
1494078|NCT00020579|recurrent grade 3 follicular lymphoma
1494079|NCT00020579|recurrent adult diffuse small cleaved cell lymphoma
1494080|NCT00020579|recurrent adult diffuse mixed cell lymphoma
1494081|NCT00020579|recurrent adult diffuse large cell lymphoma
1494082|NCT00020579|recurrent adult immunoblastic large cell lymphoma
1494083|NCT00020579|recurrent adult lymphoblastic lymphoma
1494084|NCT00020579|recurrent adult Burkitt lymphoma
1494085|NCT00020579|stage IV adult T-cell leukemia/lymphoma
1494086|NCT00020579|recurrent adult T-cell leukemia/lymphoma
1494087|NCT00020579|primary central nervous system non-Hodgkin lymphoma
1494088|NCT00020579|intraocular lymphoma
1494089|NCT00020579|stage IV mantle cell lymphoma
1494090|NCT00020579|recurrent mantle cell lymphoma
1494091|NCT00020579|angioimmunoblastic T-cell lymphoma
1494092|NCT00020579|anaplastic large cell lymphoma
1494093|NCT00020579|stage IV mycosis fungoides/Sezary syndrome
1494094|NCT00020579|recurrent mycosis fungoides/Sezary syndrome
1494095|NCT00020579|recurrent marginal zone lymphoma
1494096|NCT00020579|recurrent small lymphocytic lymphoma
1494097|NCT00020579|stage IV small lymphocytic lymphoma
1494098|NCT00020579|stage IV marginal zone lymphoma
1494099|NCT00020579|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1494100|NCT00020579|nodal marginal zone B-cell lymphoma
1494101|NCT00020579|splenic marginal zone lymphoma
1494102|NCT00020579|male breast cancer
1494103|NCT00020579|stage IIIA breast cancer
1494104|NCT00020579|stage IIIB breast cancer
1494105|NCT00020579|stage IIIC breast cancer
1494106|NCT00020579|stage IV breast cancer
1494107|NCT00020579|recurrent pancreatic cancer
1494108|NCT00020579|stage III pancreatic cancer
1494109|NCT00020579|recurrent colon cancer
1494110|NCT00020579|stage III colon cancer
1494111|NCT00020579|stage IV colon cancer
1494112|NCT00020579|recurrent rectal cancer
1494113|NCT00020579|stage III rectal cancer
1494114|NCT00020579|stage IV rectal cancer
1494115|NCT00020579|recurrent ovarian epithelial cancer
1494116|NCT00020579|recurrent ovarian germ cell tumor
1494117|NCT00020579|stage III ovarian epithelial cancer
1494118|NCT00020579|stage III ovarian germ cell tumor
1494119|NCT00020579|stage IV ovarian epithelial cancer
1494120|NCT00020579|stage IV ovarian germ cell tumor
1494121|NCT00020579|recurrent malignant testicular germ cell tumor
1494122|NCT00020579|stage III malignant testicular germ cell tumor
1494123|NCT00020579|recurrent cervical cancer
1494124|NCT00020579|stage III cervical cancer
1494125|NCT00020579|stage IVA cervical cancer
1494126|NCT00020579|stage IVB cervical cancer
1494127|NCT00020579|recurrent endometrial carcinoma
1494128|NCT00020579|stage III endometrial carcinoma
1494129|NCT00020579|stage IV endometrial carcinoma
1494130|NCT00020579|fallopian tube cancer
1494131|NCT00020579|primary peritoneal cavity cancer
1494132|NCT00020579|recurrent uterine sarcoma
1494133|NCT00020579|stage III uterine sarcoma
1494134|NCT00020579|stage IV uterine sarcoma
1494135|NCT00020579|recurrent vaginal cancer
1494136|NCT00020579|stage III vaginal cancer
1494137|NCT00020579|stage IVA vaginal cancer
1494138|NCT00020579|stage IVB vaginal cancer
1494139|NCT00020579|recurrent vulvar cancer
1494140|NCT00020579|stage III vulvar cancer
1494141|NCT00020579|stage IV vulvar cancer
1494142|NCT00020579|recurrent anal cancer
1494143|NCT00020579|stage IIIA anal cancer
1494144|NCT00020579|stage IIIB anal cancer
1494145|NCT00020579|stage IV anal cancer
1494146|NCT00020579|recurrent esophageal cancer
1494147|NCT00020579|stage III esophageal cancer
1494148|NCT00020579|stage IV esophageal cancer
1494149|NCT00020579|recurrent gastric cancer
1494150|NCT00020579|stage III gastric cancer
1494151|NCT00020579|stage IV gastric cancer
1494152|NCT00020579|recurrent extrahepatic bile duct cancer
1494153|NCT00020579|unresectable extrahepatic bile duct cancer
1494154|NCT00020579|advanced adult primary liver cancer
1494155|NCT00020579|localized unresectable adult primary liver cancer
1494156|NCT00020579|recurrent adult primary liver cancer
1494157|NCT00020579|recurrent squamous cell carcinoma of the larynx
1494158|NCT00020579|recurrent verrucous carcinoma of the larynx
1494159|NCT00020579|stage III squamous cell carcinoma of the larynx
1494160|NCT00020579|stage III verrucous carcinoma of the larynx
1494161|NCT00020579|stage IV squamous cell carcinoma of the larynx
1494162|NCT00020579|stage IV verrucous carcinoma of the larynx
1494163|NCT00020579|recurrent basal cell carcinoma of the lip
1494164|NCT00020579|recurrent squamous cell carcinoma of the lip and oral cavity
1494165|NCT00020579|stage III basal cell carcinoma of the lip
1494166|NCT00020579|stage III squamous cell carcinoma of the lip and oral cavity
1494167|NCT00020579|stage IV basal cell carcinoma of the lip
1494168|NCT00020579|stage IV squamous cell carcinoma of the lip and oral cavity
1494169|NCT00020579|recurrent lymphoepithelioma of the oropharynx
1494170|NCT00020579|recurrent squamous cell carcinoma of the oropharynx
1494171|NCT00020579|stage III lymphoepithelioma of the oropharynx
1494172|NCT00020579|stage III squamous cell carcinoma of the oropharynx
1494173|NCT00020579|stage IV lymphoepithelioma of the oropharynx
1494174|NCT00020579|stage IV squamous cell carcinoma of the oropharynx
1494175|NCT00020579|recurrent lymphoepithelioma of the nasopharynx
1494176|NCT00020579|recurrent squamous cell carcinoma of the nasopharynx
1494177|NCT00020579|stage III lymphoepithelioma of the nasopharynx
1494178|NCT00020579|stage III squamous cell carcinoma of the nasopharynx
1494179|NCT00020579|stage IV lymphoepithelioma of the nasopharynx
1494180|NCT00020579|stage IV squamous cell carcinoma of the nasopharynx
1494181|NCT00020579|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1494182|NCT00020579|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1494183|NCT00020579|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1494184|NCT00020579|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1494185|NCT00020579|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1494186|NCT00020579|stage III inverted papilloma of the paranasal sinus and nasal cavity
1494187|NCT00020579|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1494188|NCT00020579|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1494189|NCT00020579|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1494190|NCT00020579|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1494191|NCT00020579|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1494192|NCT00020579|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1494193|NCT00020579|metastatic parathyroid cancer
1494194|NCT00020579|recurrent parathyroid cancer
1494195|NCT00020579|recurrent salivary gland cancer
1494196|NCT00020579|stage III salivary gland cancer
1494197|NCT00020579|stage IV salivary gland cancer
1494198|NCT00020579|recurrent bladder cancer
1494199|NCT00020579|recurrent gallbladder cancer
1494200|NCT00020579|stage III bladder cancer
1494201|NCT00020579|stage IV bladder cancer
1494202|NCT00020579|unresectable gallbladder cancer
1494203|NCT00020579|recurrent renal cell cancer
1494204|NCT00020579|stage III renal cell cancer
1494205|NCT00020579|stage IV renal cell cancer
1494206|NCT00020579|stage III Wilms tumor
1494207|NCT00020579|stage IV Wilms tumor
1494208|NCT00020579|stage V Wilms tumor
1494209|NCT00020579|metastatic transitional cell cancer of the renal pelvis and ureter
1494210|NCT00020579|recurrent transitional cell cancer of the renal pelvis and ureter
1494211|NCT00020579|regional transitional cell cancer of the renal pelvis and ureter
1494212|NCT00020579|anterior urethral cancer
1494213|NCT00020579|posterior urethral cancer
1494214|NCT00020579|recurrent urethral cancer
1494215|NCT00020579|recurrent penile cancer
1494216|NCT00020579|stage III penile cancer
1494217|NCT00020579|stage IV penile cancer
1494218|NCT00020579|recurrent prostate cancer
1494219|NCT00020579|stage III prostate cancer
1494220|NCT00020579|stage IV prostate cancer
1494221|NCT00020579|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1494222|NCT00020579|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1494223|NCT00020579|metastatic osteosarcoma
1494224|NCT00020579|recurrent osteosarcoma
1494225|NCT00020579|recurrent adult soft tissue sarcoma
1494226|NCT00020579|stage III adult soft tissue sarcoma
1494227|NCT00020579|stage IV adult soft tissue sarcoma
1494228|NCT00020579|classic Kaposi sarcoma
1494229|NCT00020579|AIDS-related Kaposi sarcoma
1494230|NCT00020579|recurrent Kaposi sarcoma
1494231|NCT00020579|stage III cutaneous T-cell non-Hodgkin lymphoma
1494232|NCT00020579|ciliary body and choroid melanoma, medium/large size
1494233|NCT00020579|ciliary body and choroid melanoma, small size
1494234|NCT00020579|extraocular extension melanoma
1494235|NCT00020579|iris melanoma
1494236|NCT00020579|recurrent intraocular melanoma
1494237|NCT00020579|recurrent melanoma
1494238|NCT00020579|stage III melanoma
1494239|NCT00020579|stage IV melanoma
1494240|NCT00020579|extensive stage small cell lung cancer
1494241|NCT00020579|recurrent non-small cell lung cancer
1494242|NCT00020579|recurrent small cell lung cancer
1494243|NCT00020579|stage IIIA non-small cell lung cancer
1494244|NCT00020579|stage IIIB non-small cell lung cancer
1494245|NCT00020579|stage IV non-small cell lung cancer
1494246|NCT00020579|recurrent thymoma and thymic carcinoma
1494247|NCT00020579|advanced malignant mesothelioma
1494248|NCT00020579|recurrent malignant mesothelioma
1494249|NCT00020579|recurrent adrenocortical carcinoma
1494250|NCT00020579|stage III adrenocortical carcinoma
1494251|NCT00020579|stage IV adrenocortical carcinoma
1494252|NCT00020579|metastatic gastrointestinal carcinoid tumor
1494253|NCT00020579|recurrent gastrointestinal carcinoid tumor
1494254|NCT00020579|regional gastrointestinal carcinoid tumor
1494255|NCT00020579|desmoid tumor
1494256|NCT00020579|newly diagnosed carcinoma of unknown primary
1494257|NCT00020579|recurrent carcinoma of unknown primary
1494258|NCT00020579|undifferentiated carcinoma of unknown primary
1494259|NCT00020579|carcinoma of the appendix
1494260|NCT00020579|recurrent metastatic squamous neck cancer with occult primary
1494261|NCT00020579|untreated metastatic squamous neck cancer with occult primary
1494262|NCT00020579|recurrent pituitary tumor
1494263|NCT00020579|adult anaplastic astrocytoma
1494264|NCT00020579|adult astrocytic tumors
1494265|NCT00020579|adult diffuse astrocytoma
1494266|NCT00020579|adult pilocytic astrocytoma
1494267|NCT00020579|adult anaplastic oligodendroglioma
1494268|NCT00020579|adult brain stem glioma
1494269|NCT00020579|adult oligodendroglioma
1494270|NCT00020579|adult mixed glioma
1494271|NCT00020579|adult central nervous system germ cell tumor
1494272|NCT00020579|adult choroid plexus tumor
1494273|NCT00020579|adult craniopharyngioma
1494274|NCT00020579|adult anaplastic ependymoma
1494275|NCT00020579|adult subependymoma
1494276|NCT00020579|adult medulloblastoma
1494277|NCT00020579|adult supratentorial primitive neuroectodermal tumor (PNET)
1494278|NCT00020579|adult ependymoblastoma
1494279|NCT00020579|adult ependymoma
1494280|NCT00020579|adult myxopapillary ependymoma
1494281|NCT00020579|adult anaplastic meningioma
1494282|NCT00020579|adult meningeal hemangiopericytoma
1494283|NCT00020579|adult meningioma
1494284|NCT00020579|adult papillary meningioma
1494285|NCT00020579|adult grade I meningioma
1494286|NCT00020579|adult grade II meningioma
1494287|NCT00020579|adult grade III meningioma
1494288|NCT00020579|adult pineal parenchymal tumor
1494289|NCT00020579|recurrent adult brain tumor
1494290|NCT00020579|stage IV pancreatic cancer
1494291|NCT00020579|stage III thymoma
1494292|NCT00020579|stage IVA thymoma
1494293|NCT00020579|stage IVB thymoma
1494294|NCT00020566|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1494295|NCT00020566|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1494296|NCT00020553|psychosocial effects of cancer and its treatment
1494297|NCT00020540|stage IV renal cell cancer
1494298|NCT00020540|recurrent renal cell cancer
1494299|NCT00020540|stage IV melanoma
1494300|NCT00020540|recurrent melanoma
1494301|NCT00020527|recurrent childhood acute lymphoblastic leukemia
1494302|NCT00020527|recurrent childhood rhabdomyosarcoma
1494303|NCT00020527|disseminated neuroblastoma
1494304|NCT00020527|recurrent neuroblastoma
1494305|NCT00020527|recurrent Wilms tumor and other childhood kidney tumors
1494306|NCT00020527|recurrent childhood lymphoblastic lymphoma
1494307|NCT00020527|recurrent childhood acute myeloid leukemia
1494308|NCT00020527|fever, sweats, and hot flashes
1494309|NCT00020527|childhood acute promyelocytic leukemia (M3)
1494310|NCT00020527|recurrent/refractory childhood Hodgkin lymphoma
1494311|NCT00020527|neutropenia
1494312|NCT00020527|infection
1494313|NCT00020527|recurrent childhood small noncleaved cell lymphoma
1494314|NCT00020527|recurrent childhood large cell lymphoma
1494315|NCT00020527|previously treated childhood rhabdomyosarcoma
1494316|NCT00020501|stage IV colon cancer
1494317|NCT00020501|stage IV rectal cancer
1494318|NCT00020501|recurrent colon cancer
1494319|NCT00020501|recurrent rectal cancer
1494320|NCT00020501|liver metastases
1494321|NCT00020488|unspecified adult solid tumor, protocol specific
1494322|NCT00020475|adult solid tumor
1494323|NCT00020475|body system/site cancer
1494324|NCT00020475|cancer
1494325|NCT00020475|extraocular extension melanoma
1494326|NCT00020475|eye cancer
1494327|NCT00020475|intraocular melanoma
1494328|NCT00020475|recurrent intraocular melanoma
1494329|NCT00020475|solid tumor
1494330|NCT00020475|stage, intraocular melanoma
1494331|NCT00020462|stage III grade 1 follicular lymphoma
1494332|NCT00020462|stage III grade 2 follicular lymphoma
1494333|NCT00020462|stage III grade 3 follicular lymphoma
1494334|NCT00020462|stage IV grade 1 follicular lymphoma
1494335|NCT00020462|stage IV grade 2 follicular lymphoma
1494336|NCT00020462|stage IV grade 3 follicular lymphoma
1494337|NCT00020462|recurrent grade 1 follicular lymphoma
1494338|NCT00020462|recurrent grade 2 follicular lymphoma
1494339|NCT00020462|recurrent grade 3 follicular lymphoma
1494340|NCT00020449|AIDS-related Kaposi sarcoma
1494341|NCT00020449|recurrent Kaposi sarcoma
1494342|NCT00020410|stage IV breast cancer
1494343|NCT00020410|recurrent breast cancer
1494344|NCT00020410|male breast cancer
1494345|NCT00020397|recurrent melanoma
1494346|NCT00020397|stage IV melanoma
1494347|NCT00020371|adult solid tumor
1494348|NCT00020371|bone marrow suppression
1494349|NCT00020371|cancer
1494350|NCT00020371|cancer-related problem/condition
1494351|NCT00020371|neutropenia
1494352|NCT00020371|solid tumor
1494353|NCT00020371|unspecified adult solid tumor, protocol specific
1494354|NCT00020358|stage I melanoma
1494355|NCT00020358|stage II melanoma
1494356|NCT00020358|stage III melanoma
1494357|NCT00020358|stage IV melanoma
1494358|NCT00020358|recurrent melanoma
1494359|NCT00020345|adenocarcinoma of the pancreas
1494360|NCT00020345|adult solid tumor
1494361|NCT00020345|body system/site cancer
1494362|NCT00020345|cancer
1494363|NCT00020345|cellular diagnosis, pancreatic cancer
1494364|NCT00020345|gastrointestinal cancer
1494365|NCT00020345|pancreatic cancer
1494366|NCT00020345|solid tumor
1494367|NCT00020345|stage III pancreatic cancer
1494368|NCT00020345|stage IV pancreatic cancer
1494369|NCT00020345|stage IVA pancreatic cancer
1494370|NCT00020345|stage, pancreatic cancer
1494371|NCT00020332|stage IV breast cancer
1494372|NCT00020332|stage IIIA breast cancer
1494373|NCT00020332|recurrent breast cancer
1494374|NCT00020332|stage IIIB breast cancer
1494375|NCT00020332|male breast cancer
1494376|NCT00020267|Ewing's family of tumors
1494377|NCT00020267|adult soft tissue sarcoma
1494378|NCT00020267|adult solid tumor
1494379|NCT00020267|body system/site cancer
1494380|NCT00020267|bone cancer
1494381|NCT00020267|breast cancer
1494382|NCT00020267|cancer
1494383|NCT00020267|childhood cancer
1494384|NCT00020267|childhood solid tumor
1494385|NCT00020267|ciliary body and choroid melanoma, medium/large size
1494386|NCT00020267|colon cancer
1494387|NCT00020267|colorectal cancer
1494388|NCT00020267|extraocular extension melanoma
1494389|NCT00020267|eye cancer
1494390|NCT00020267|female reproductive cancer
1494391|NCT00020267|gastrointestinal cancer
1494392|NCT00020267|genetic condition
1494393|NCT00020267|intraocular melanoma
1494394|NCT00020267|lung cancer
1494395|NCT00020267|male breast cancer
1494396|NCT00020267|melanoma
1494397|NCT00020267|metastatic osteosarcoma
1494398|NCT00020267|metastatic tumors of the Ewing's family
1494399|NCT00020267|muscle cancer
1494400|NCT00020267|musculoskeletal cancer
1494401|NCT00020267|non-small cell lung cancer
1494402|NCT00020267|osteosarcoma
1494403|NCT00020267|osteosarcoma/malignant fibrous histiocytoma of bone
1494404|NCT00020267|ovarian sarcoma
1494405|NCT00020267|rectal cancer
1494406|NCT00020267|recurrent adult soft tissue sarcoma
1494407|NCT00020267|recurrent breast cancer
1494408|NCT00020267|recurrent colon cancer
1494409|NCT00020267|recurrent intraocular melanoma
1494410|NCT00020267|recurrent melanoma
1494411|NCT00020267|recurrent non-small cell lung cancer
1494412|NCT00020267|recurrent osteosarcoma
1494413|NCT00020267|recurrent rectal cancer
1494414|NCT00020267|recurrent tumors of the Ewing's family
1494415|NCT00020267|recurrent uterine sarcoma
1494416|NCT00020267|skin tumor
1494417|NCT00020267|solid tumor
1494418|NCT00020267|stage IIIB, IV, recurrent, and metastatic breast cancer
1494419|NCT00020267|stage IV adult soft tissue sarcoma
1494420|NCT00020267|stage IV breast cancer
1494421|NCT00020267|stage IV colon cancer
1494422|NCT00020267|stage IV melanoma
1494423|NCT00020267|stage IV non-small cell lung cancer
1494424|NCT00020267|stage IV rectal cancer
1494425|NCT00020267|stage IV uterine sarcoma
1494426|NCT00020267|stage IVA adult soft tissue sarcoma
1494427|NCT00020267|stage IVB adult soft tissue sarcoma
1494428|NCT00020267|stage, Ewing's family of tumors
1494429|NCT00020267|stage, adult soft tissue sarcoma
1494430|NCT00020267|stage, breast cancer
1494431|NCT00020267|stage, colon cancer
1494432|NCT00020267|stage, intraocular melanoma
1494433|NCT00020267|stage, melanoma
1494434|NCT00020267|stage, non-small cell lung cancer
1494435|NCT00020267|stage, osteosarcoma
1494436|NCT00020267|stage, rectal cancer
1494437|NCT00020267|stage, uterine sarcoma
1494438|NCT00020267|thorax/respiratory cancer
1494439|NCT00020267|uterine sarcoma
1494440|NCT00020254|adenocarcinoma of the prostate
1494441|NCT00020254|recurrent prostate cancer
1494442|NCT00020202|adult solid tumor
1494443|NCT00020202|body system/site cancer
1494444|NCT00020202|cancer
1494445|NCT00020202|extensive stage small cell lung cancer
1494446|NCT00020202|genetic condition
1494447|NCT00020202|lung cancer
1494448|NCT00020202|non-small cell lung cancer
1494449|NCT00020202|recurrent non-small cell lung cancer
1494450|NCT00020202|recurrent small cell lung cancer
1494451|NCT00020202|small cell lung cancer
1494452|NCT00020202|solid tumor
1494453|NCT00020202|stage III non-small cell lung cancer
1494454|NCT00020202|stage IIIA non-small cell lung cancer
1494455|NCT00020202|stage IIIB non-small cell lung cancer
1494456|NCT00020202|stage IV non-small cell lung cancer
1494457|NCT00020202|stage, non-small cell lung cancer
1494458|NCT00020202|stage, small cell lung cancer
1494459|NCT00020202|thorax/respiratory cancer
1494460|NCT00020189|thromboembolism
1494461|NCT00020189|untreated metastatic squamous neck cancer with occult primary
1494462|NCT00020189|recurrent metastatic squamous neck cancer with occult primary
1494463|NCT00020189|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1494464|NCT00020189|stage IV squamous cell carcinoma of the lip and oral cavity
1494465|NCT00020189|recurrent squamous cell carcinoma of the lip and oral cavity
1494466|NCT00020189|stage IV squamous cell carcinoma of the oropharynx
1494467|NCT00020189|recurrent squamous cell carcinoma of the oropharynx
1494468|NCT00020189|stage IV squamous cell carcinoma of the hypopharynx
1494469|NCT00020189|recurrent squamous cell carcinoma of the hypopharynx
1494470|NCT00020189|stage IV squamous cell carcinoma of the larynx
1494471|NCT00020189|recurrent squamous cell carcinoma of the larynx
1494472|NCT00020189|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1494473|NCT00020189|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1494474|NCT00020189|recurrent salivary gland cancer
1494475|NCT00020189|salivary gland squamous cell carcinoma
1494476|NCT00020189|stage IV salivary gland cancer
1494477|NCT00020176|stage IV breast cancer
1494478|NCT00020176|recurrent breast cancer
1494479|NCT00020176|male breast cancer
1494480|NCT00020150|recurrent childhood rhabdomyosarcoma
1494481|NCT00020150|childhood craniopharyngioma
1494482|NCT00020150|recurrent childhood brain tumor
1494483|NCT00020150|recurrent neuroblastoma
1494484|NCT00020150|recurrent childhood liver cancer
1494485|NCT00020150|recurrent Wilms tumor and other childhood kidney tumors
1494486|NCT00020150|childhood central nervous system germ cell tumor
1494487|NCT00020150|recurrent osteosarcoma
1494488|NCT00020150|unspecified childhood solid tumor, protocol specific
1494489|NCT00020150|childhood germ cell tumor
1494490|NCT00020150|recurrent childhood soft tissue sarcoma
1494491|NCT00020150|childhood oligodendroglioma
1494492|NCT00020150|childhood choroid plexus tumor
1494493|NCT00020150|childhood grade I meningioma
1494494|NCT00020150|childhood grade II meningioma
1494495|NCT00020150|childhood grade III meningioma
1494496|NCT00020150|recurrent childhood cerebellar astrocytoma
1494497|NCT00020150|recurrent childhood cerebral astrocytoma
1494498|NCT00020150|recurrent childhood medulloblastoma
1494499|NCT00020150|recurrent childhood visual pathway and hypothalamic glioma
1494500|NCT00020150|previously treated childhood rhabdomyosarcoma
1494501|NCT00020150|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1494502|NCT00020150|recurrent childhood ependymoma
1494503|NCT00020150|childhood teratoma
1494504|NCT00020150|childhood malignant testicular germ cell tumor
1494505|NCT00020150|childhood extragonadal germ cell tumor
1494506|NCT00020150|childhood malignant ovarian germ cell tumor
1494507|NCT00020150|recurrent childhood malignant germ cell tumor
1494508|NCT00020124|recurrent non-small cell lung cancer
1494509|NCT00020124|extensive stage small cell lung cancer
1494510|NCT00020124|recurrent small cell lung cancer
1494511|NCT00020124|advanced malignant mesothelioma
1494512|NCT00020124|recurrent malignant mesothelioma
1494513|NCT00020124|stage IIIB non-small cell lung cancer
1494514|NCT00020124|stage IV non-small cell lung cancer
1494515|NCT00020124|pulmonary carcinoid tumor
1494516|NCT00020124|lung metastases
1494517|NCT00020111|recurrent childhood acute myeloid leukemia
1494518|NCT00020111|childhood acute promyelocytic leukemia (M3)
1494519|NCT00020111|recurrent childhood acute lymphoblastic leukemia
1494520|NCT00020111|recurrent childhood large cell lymphoma
1494521|NCT00020111|recurrent childhood lymphoblastic lymphoma
1494522|NCT00020111|recurrent childhood small noncleaved cell lymphoma
1494523|NCT00020111|recurrent/refractory childhood Hodgkin lymphoma
1494524|NCT00020111|childhood chronic myelogenous leukemia
1494525|NCT00020111|atypical chronic myeloid leukemia, BCR-ABL1 negative
1494526|NCT00020098|breast cancer
1494527|NCT00020072|cutaneous T-cell non-Hodgkin lymphoma
1494528|NCT00020072|mycosis fungoides/Sezary syndrome
1494529|NCT00020046|adenocarcinoma of the prostate
1494530|NCT00020046|adult solid tumor
1494531|NCT00020046|body system/site cancer
1494532|NCT00020046|cancer
1494533|NCT00020046|cellular diagnosis, prostate cancer
1494534|NCT00020046|genetic condition
1494535|NCT00020046|male reproductive cancer
1494536|NCT00020046|prostate cancer
1494537|NCT00020046|recurrent prostate cancer
1494538|NCT00020046|solid tumor
1494539|NCT00020046|stage IV prostate cancer
1494540|NCT00020046|stage, prostate cancer
1494541|NCT00020007|recurrent non-small cell lung cancer
1494542|NCT00020007|limited stage small cell lung cancer
1494543|NCT00020007|extensive stage small cell lung cancer
1494544|NCT00020007|recurrent small cell lung cancer
1494545|NCT00020007|stage IIIA non-small cell lung cancer
1494546|NCT00020007|stage IIIB non-small cell lung cancer
1494547|NCT00020007|stage IV non-small cell lung cancer
1494548|NCT00020007|lung metastases
1494549|NCT00020007|bronchoalveolar cell lung cancer
1494550|NCT00020007|pulmonary carcinoid tumor
1494551|NCT00019994|stage IV melanoma
1494552|NCT00019994|recurrent melanoma
1494553|NCT00019968|adult soft tissue sarcoma
1494554|NCT00019968|adult solid tumor
1494555|NCT00019968|body system/site cancer
1494556|NCT00019968|cancer
1494557|NCT00019968|muscle cancer
1494558|NCT00019968|musculoskeletal cancer
1494559|NCT00019968|recurrent adult soft tissue sarcoma
1494560|NCT00019968|solid tumor
1494561|NCT00019968|stage IA, IB, and IIA adult soft tissue sarcoma
1494562|NCT00019968|stage II adult soft tissue sarcoma
1494563|NCT00019968|stage IIB adult soft tissue sarcoma
1494564|NCT00019968|stage IIB, IIC, and III adult soft tissue sarcoma
1494565|NCT00019968|stage IIC adult soft tissue sarcoma
1494676|NCT00019747|recurrent rectal cancer
1494566|NCT00019968|stage III adult soft tissue sarcoma
1494567|NCT00019968|stage IV adult soft tissue sarcoma
1494568|NCT00019968|stage IVA adult soft tissue sarcoma
1494569|NCT00019968|stage IVB adult soft tissue sarcoma
1494570|NCT00019968|stage, adult soft tissue sarcoma
1494571|NCT00019955|stage I renal cell cancer
1494572|NCT00019955|stage II renal cell cancer
1494573|NCT00019929|stage IIIA non-small cell lung cancer
1494574|NCT00019929|stage IIIB non-small cell lung cancer
1494575|NCT00019916|stage IV breast cancer
1494576|NCT00019916|recurrent breast cancer
1494577|NCT00019916|recurrent ovarian epithelial cancer
1494578|NCT00019916|stage IV ovarian epithelial cancer
1494579|NCT00019890|adult solid tumor
1494580|NCT00019890|body system/site cancer
1494581|NCT00019890|cancer
1494582|NCT00019890|melanoma
1494583|NCT00019890|recurrent melanoma
1494584|NCT00019890|skin tumor
1494585|NCT00019890|solid tumor
1494586|NCT00019890|stage III melanoma
1494587|NCT00019890|stage IV melanoma
1494588|NCT00019890|stage, melanoma
1494589|NCT00019864|cardiac toxicity
1494590|NCT00019864|localized osteosarcoma
1494591|NCT00019864|metastatic osteosarcoma
1494592|NCT00019864|recurrent osteosarcoma
1494593|NCT00019838|Waldenström macroglobulinemia
1494594|NCT00019838|refractory chronic lymphocytic leukemia
1494595|NCT00019838|refractory hairy cell leukemia
1494596|NCT00019838|recurrent grade 1 follicular lymphoma
1494597|NCT00019838|recurrent grade 2 follicular lymphoma
1494598|NCT00019838|recurrent mantle cell lymphoma
1494599|NCT00019838|recurrent marginal zone lymphoma
1494600|NCT00019838|recurrent small lymphocytic lymphoma
1494601|NCT00019838|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1494602|NCT00019838|nodal marginal zone B-cell lymphoma
1494603|NCT00019838|splenic marginal zone lymphoma
1494604|NCT00019825|recurrent non-small cell lung cancer
1494605|NCT00019825|stage II esophageal cancer
1494606|NCT00019825|stage III esophageal cancer
1494607|NCT00019825|stage IV esophageal cancer
1494608|NCT00019825|recurrent esophageal cancer
1494609|NCT00019825|extensive stage small cell lung cancer
1494610|NCT00019825|recurrent small cell lung cancer
1494611|NCT00019825|advanced malignant mesothelioma
1494612|NCT00019825|recurrent malignant mesothelioma
1494613|NCT00019825|stage IIIB non-small cell lung cancer
1494614|NCT00019825|stage IV non-small cell lung cancer
1494615|NCT00019825|malignant pleural effusion
1494616|NCT00019812|stage IV breast cancer
1494617|NCT00019812|male breast cancer
1494618|NCT00019786|stage IV colon cancer
1494619|NCT00019786|stage IV rectal cancer
1494620|NCT00019786|recurrent colon cancer
1494621|NCT00019786|recurrent rectal cancer
1494622|NCT00019786|localized unresectable adult primary liver cancer
1494623|NCT00019786|recurrent adult primary liver cancer
1494624|NCT00019786|recurrent islet cell carcinoma
1494625|NCT00019786|adult primary hepatocellular carcinoma
1494626|NCT00019786|adenocarcinoma of the colon
1494627|NCT00019786|adenocarcinoma of the rectum
1494628|NCT00019786|liver metastases
1494629|NCT00019786|adult primary cholangiocellular carcinoma
1494630|NCT00019786|advanced adult primary liver cancer
1494631|NCT00019786|recurrent childhood liver cancer
1494632|NCT00019786|childhood hepatocellular carcinoma
1494633|NCT00019786|stage III childhood liver cancer
1494634|NCT00019786|stage IV childhood liver cancer
1494635|NCT00019786|neuroendocrine carcinoma
1494636|NCT00019773|stage I colon cancer
1494637|NCT00019773|stage II colon cancer
1494638|NCT00019773|stage III colon cancer
1494639|NCT00019773|stage IV colon cancer
1494640|NCT00019773|stage 0 colon cancer
1494641|NCT00019773|stage 0 rectal cancer
1494642|NCT00019773|stage I rectal cancer
1494643|NCT00019773|stage II rectal cancer
1494644|NCT00019773|stage III rectal cancer
1494645|NCT00019773|stage IV rectal cancer
1494646|NCT00019773|recurrent colon cancer
1494647|NCT00019773|recurrent rectal cancer
1494648|NCT00019773|small intestine adenocarcinoma
1494649|NCT00019773|small intestine lymphoma
1494650|NCT00019773|small intestine leiomyosarcoma
1494651|NCT00019773|recurrent small intestine cancer
1494652|NCT00019773|carcinoma of the appendix
1494653|NCT00019760|adult solid tumor
1494654|NCT00019760|body system/site cancer
1494655|NCT00019760|cancer
1494656|NCT00019760|colon cancer
1494657|NCT00019760|colorectal cancer
1494658|NCT00019760|gastrointestinal cancer
1494659|NCT00019760|genetic condition
1494660|NCT00019760|liver and intrahepatic biliary tract cancer
1494661|NCT00019760|liver metastases
1494662|NCT00019760|metastatic cancer
1494663|NCT00019760|rectal cancer
1494664|NCT00019760|recurrent colon cancer
1494665|NCT00019760|recurrent rectal cancer
1494666|NCT00019760|site, metastatic cancer
1494667|NCT00019760|solid tumor
1494668|NCT00019760|stage IV colon cancer
1494669|NCT00019760|stage IV rectal cancer
1494670|NCT00019760|stage, colon cancer
1494671|NCT00019760|stage, rectal cancer
1494672|NCT00019760|unclassified/other cancer
1494673|NCT00019747|stage IV colon cancer
1494674|NCT00019747|stage IV rectal cancer
1494675|NCT00019747|recurrent colon cancer
1494677|NCT00019734|stage IV melanoma
1494678|NCT00019734|recurrent melanoma
1494679|NCT00019721|stage IV melanoma
1494680|NCT00019721|recurrent melanoma
1494681|NCT00019695|adenocarcinoma of the prostate
1494682|NCT00019695|adult solid tumor
1494683|NCT00019695|body system/site cancer
1494684|NCT00019695|bone metastases
1494685|NCT00019695|cancer
1494686|NCT00019695|cellular diagnosis, prostate cancer
1494687|NCT00019695|genetic condition
1494688|NCT00019695|male reproductive cancer
1494689|NCT00019695|metastatic cancer
1494690|NCT00019695|prostate cancer
1494691|NCT00019695|recurrent prostate cancer
1494692|NCT00019695|site, metastatic cancer
1494693|NCT00019695|solid tumor
1494694|NCT00019695|stage IV prostate cancer
1494695|NCT00019695|stage, prostate cancer
1494696|NCT00019695|unclassified/other cancer
1494697|NCT00019669|stage IV melanoma
1494698|NCT00019669|recurrent melanoma
1494699|NCT00019656|stage IV chronic lymphocytic leukemia
1494700|NCT00019656|refractory chronic lymphocytic leukemia
1494701|NCT00019656|unspecified adult solid tumor, protocol specific
1494702|NCT00019656|previously treated myelodysplastic syndromes
1494703|NCT00019656|de novo myelodysplastic syndromes
1494704|NCT00019656|recurrent adult diffuse large cell lymphoma
1494705|NCT00019656|recurrent adult diffuse mixed cell lymphoma
1494706|NCT00019656|recurrent adult diffuse small cleaved cell lymphoma
1494707|NCT00019656|recurrent adult Burkitt lymphoma
1494708|NCT00019656|recurrent adult Hodgkin lymphoma
1494709|NCT00019656|recurrent adult immunoblastic large cell lymphoma
1494710|NCT00019656|recurrent adult lymphoblastic lymphoma
1494711|NCT00019656|recurrent grade 1 follicular lymphoma
1494712|NCT00019656|recurrent grade 2 follicular lymphoma
1494713|NCT00019656|recurrent grade 3 follicular lymphoma
1494714|NCT00019656|recurrent mantle cell lymphoma
1494715|NCT00019656|secondary myelodysplastic syndromes
1494716|NCT00019656|stage IV adult diffuse large cell lymphoma
1494717|NCT00019656|stage IV adult diffuse mixed cell lymphoma
1494718|NCT00019656|stage IV adult diffuse small cleaved cell lymphoma
1494719|NCT00019656|stage IV adult Burkitt lymphoma
1494720|NCT00019656|stage IV adult Hodgkin lymphoma
1494721|NCT00019656|stage IV adult immunoblastic large cell lymphoma
1494722|NCT00019656|stage IV adult lymphoblastic lymphoma
1494723|NCT00019656|stage IV grade 1 follicular lymphoma
1494724|NCT00019656|stage IV grade 2 follicular lymphoma
1494725|NCT00019656|stage IV grade 3 follicular lymphoma
1494726|NCT00019656|stage IV mantle cell lymphoma
1494727|NCT00019656|chronic myelomonocytic leukemia
1494728|NCT00019656|atypical chronic myeloid leukemia, BCR-ABL1 negative
1494729|NCT00019656|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1494730|NCT00019656|recurrent marginal zone lymphoma
1494731|NCT00019656|recurrent small lymphocytic lymphoma
1494732|NCT00019656|stage IV small lymphocytic lymphoma
1494733|NCT00019656|stage IV marginal zone lymphoma
1494734|NCT00019656|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1494735|NCT00019656|nodal marginal zone B-cell lymphoma
1494736|NCT00019656|splenic marginal zone lymphoma
1494737|NCT00019643|adult solid tumor
1494738|NCT00019643|body system/site cancer
1494739|NCT00019643|breast cancer
1494740|NCT00019643|cancer
1494741|NCT00019643|cancer-related problem/condition
1494742|NCT00019643|depression
1494743|NCT00019643|depression and suicide
1494744|NCT00019643|nutrition
1494745|NCT00019643|psychosocial effects/treatment
1494746|NCT00019643|quality of life
1494747|NCT00019643|solid tumor
1494748|NCT00019643|stage I breast cancer
1494749|NCT00019643|stage I, II, and IIIA breast cancer
1494750|NCT00019643|stage II breast cancer
1494751|NCT00019643|stage III breast cancer
1494752|NCT00019643|stage IIIA breast cancer
1494753|NCT00019643|stage IIIB, IV, recurrent, and metastatic breast cancer
1494754|NCT00019643|stage, breast cancer
1494755|NCT00019630|Ewing's family of tumors
1494756|NCT00019630|Wilms' tumor
1494757|NCT00019630|adult solid tumor
1494758|NCT00019630|body system/site cancer
1494759|NCT00019630|bone cancer
1494760|NCT00019630|brain tumor
1494761|NCT00019630|cancer
1494762|NCT00019630|central nervous system cancer
1494763|NCT00019630|childhood brain stem glioma
1494764|NCT00019630|childhood brain tumor
1494765|NCT00019630|childhood cancer
1494766|NCT00019630|childhood central nervous system germ cell tumor
1494767|NCT00019630|childhood cerebellar astrocytoma
1494768|NCT00019630|childhood cerebral astrocytoma
1495779|NCT00018018|Immune Deficiency
1494769|NCT00019630|childhood choroid plexus tumor
1494770|NCT00019630|childhood craniopharyngioma
1494771|NCT00019630|childhood ependymoma
1494772|NCT00019630|childhood extracranial germ cell tumor
1494773|NCT00019630|childhood extragonadal malignant germ cell tumor
1494774|NCT00019630|childhood liver cancer
1494775|NCT00019630|childhood malignant ovarian germ cell tumor
1494776|NCT00019630|childhood malignant testicular germ cell tumor
1494777|NCT00019630|childhood mature and immature teratomas
1494778|NCT00019630|childhood medulloblastoma
1494779|NCT00019630|childhood meningioma
1494780|NCT00019630|childhood oligodendroglioma
1494781|NCT00019630|childhood rhabdomyosarcoma
1494782|NCT00019630|childhood soft tissue sarcoma
1494783|NCT00019630|childhood solid tumor
1494784|NCT00019630|childhood supratentorial primitive neuroectodermal and pineal tumors
1494785|NCT00019630|childhood visual pathway and hypothalamic glioma
1494786|NCT00019630|endocrine cancer
1494787|NCT00019630|gastrointestinal cancer
1494788|NCT00019630|genetic condition
1494789|NCT00019630|kidney tumor
1494790|NCT00019630|kidney/urinary cancer
1494791|NCT00019630|liver and intrahepatic biliary tract cancer
1494792|NCT00019630|muscle cancer
1494793|NCT00019630|musculoskeletal cancer
1494794|NCT00019630|neuroblastoma
1494795|NCT00019630|osteosarcoma
1494796|NCT00019630|osteosarcoma/malignant fibrous histiocytoma of bone
1494797|NCT00019630|pediatric germ cell tumor
1494798|NCT00019630|previously treated childhood rhabdomyosarcoma
1494799|NCT00019630|recurrent Wilms' tumor
1494800|NCT00019630|recurrent childhood brain stem glioma
1494801|NCT00019630|recurrent childhood brain tumor
1494802|NCT00019630|recurrent childhood cerebellar astrocytoma
1494803|NCT00019630|recurrent childhood cerebral astrocytoma
1494804|NCT00019630|recurrent childhood ependymoma
1494805|NCT00019630|recurrent childhood liver cancer
1494806|NCT00019630|recurrent childhood malignant germ cell tumor
1494807|NCT00019630|recurrent childhood medulloblastoma
1494808|NCT00019630|recurrent childhood rhabdomyosarcoma
1494809|NCT00019630|recurrent childhood soft tissue sarcoma
1494810|NCT00019630|recurrent childhood supratentorial primitive neuroectodermal and pineal tumors
1494811|NCT00019630|recurrent childhood visual pathway and hypothalamic glioma
1494812|NCT00019630|recurrent neuroblastoma
1494813|NCT00019630|recurrent osteosarcoma
1494814|NCT00019630|recurrent tumors of the Ewing's family
1494815|NCT00019630|solid tumor
1494816|NCT00019630|stage, Ewing's family of tumors
1494817|NCT00019630|stage, Wilms' tumor
1494818|NCT00019630|stage, childhood extracranial germ cell tumor
1494819|NCT00019630|stage, childhood liver cancer
1494820|NCT00019630|stage, childhood medulloblastoma
1494821|NCT00019630|stage, childhood rhabdomyosarcoma
1494822|NCT00019630|stage, childhood soft tissue sarcoma
1494823|NCT00019630|stage, neuroblastoma
1494824|NCT00019630|stage, osteosarcoma
1494825|NCT00019630|stage/type, childhood brain tumor
1494826|NCT00019630|unspecified childhood solid tumor, protocol specific
1494827|NCT00019604|localized unresectable adult primary liver cancer
1494828|NCT00019604|recurrent adult primary liver cancer
1494829|NCT00019604|liver metastases
1494830|NCT00019604|unspecified adult solid tumor, protocol specific
1494831|NCT00019591|stage III colon cancer
1494832|NCT00019591|stage IV colon cancer
1494833|NCT00019591|stage III rectal cancer
1494834|NCT00019591|stage IV rectal cancer
1494835|NCT00019591|recurrent colon cancer
1494836|NCT00019591|recurrent rectal cancer
1494837|NCT00019578|adult brain stem glioma
1494838|NCT00019578|adult brain tumor
1494839|NCT00019578|adult central nervous system germ cell tumor
1494840|NCT00019578|adult craniopharyngioma
1494841|NCT00019578|adult ependymoma
1494842|NCT00019578|adult infiltrating astrocytoma
1494843|NCT00019578|adult malignant meningioma
1494844|NCT00019578|adult medulloblastoma
1494845|NCT00019578|adult meningioma
1494846|NCT00019578|adult noninfiltrating astrocytoma
1494847|NCT00019578|adult oligodendroglioma
1494848|NCT00019578|adult pineal parenchymal tumor
1494849|NCT00019578|adult solid tumor
1494850|NCT00019578|body system/site cancer
1494851|NCT00019578|brain metastases
1494852|NCT00019578|brain tumor
1494853|NCT00019578|cancer
1494854|NCT00019578|central nervous system cancer
1494855|NCT00019578|genetic condition
1494856|NCT00019578|metastatic cancer
1494857|NCT00019578|mixed gliomas
1494858|NCT00019578|site, metastatic cancer
1494859|NCT00019578|solid tumor
1494860|NCT00019578|stage IV peripheral primitive neuroectodermal tumor
1494861|NCT00019578|stage/type, adult brain tumor
1494862|NCT00019578|unclassified/other cancer
1494863|NCT00019565|unspecified adult solid tumor, protocol specific
1494864|NCT00019552|recurrent ovarian epithelial cancer
1494865|NCT00019552|fallopian tube cancer
1494866|NCT00019552|primary peritoneal cavity cancer
1494867|NCT00019539|adult solid tumor
1494868|NCT00019539|body system/site cancer
1494869|NCT00019539|cancer
1494870|NCT00019539|kidney tumor
1494871|NCT00019539|kidney/urinary cancer
1494872|NCT00019539|recurrent renal cell cancer
1494873|NCT00019539|renal cell cancer
1494874|NCT00019539|solid tumor
1494875|NCT00019539|stage IV renal cell cancer
1494876|NCT00019539|stage, renal cell cancer
1494877|NCT00019513|stage IV adult Hodgkin lymphoma
1494878|NCT00019513|recurrent adult Hodgkin lymphoma
1494879|NCT00019513|stage IV cutaneous T-cell non-Hodgkin lymphoma
1494880|NCT00019513|recurrent cutaneous T-cell non-Hodgkin lymphoma
1494881|NCT00019513|small intestine lymphoma
1494882|NCT00019513|unspecified adult solid tumor, protocol specific
1494883|NCT00019513|stage IV grade 1 follicular lymphoma
1494884|NCT00019513|stage IV grade 2 follicular lymphoma
1494885|NCT00019513|stage IV grade 3 follicular lymphoma
1494886|NCT00019513|stage IV adult diffuse small cleaved cell lymphoma
1495182|NCT00019110|stage IV penile cancer
1494887|NCT00019513|stage IV adult diffuse mixed cell lymphoma
1494888|NCT00019513|stage IV adult diffuse large cell lymphoma
1494889|NCT00019513|stage IV adult immunoblastic large cell lymphoma
1494890|NCT00019513|stage IV adult lymphoblastic lymphoma
1494891|NCT00019513|stage IV adult Burkitt lymphoma
1494892|NCT00019513|recurrent grade 1 follicular lymphoma
1494893|NCT00019513|recurrent grade 2 follicular lymphoma
1494894|NCT00019513|recurrent grade 3 follicular lymphoma
1494895|NCT00019513|recurrent adult diffuse small cleaved cell lymphoma
1494896|NCT00019513|recurrent adult diffuse mixed cell lymphoma
1494897|NCT00019513|recurrent adult diffuse large cell lymphoma
1494898|NCT00019513|recurrent adult immunoblastic large cell lymphoma
1494899|NCT00019513|recurrent adult lymphoblastic lymphoma
1494900|NCT00019513|recurrent adult Burkitt lymphoma
1494901|NCT00019513|stage IV adult T-cell leukemia/lymphoma
1494902|NCT00019513|recurrent adult T-cell leukemia/lymphoma
1494903|NCT00019513|stage IV mantle cell lymphoma
1494904|NCT00019513|recurrent mantle cell lymphoma
1494905|NCT00019513|anaplastic large cell lymphoma
1494906|NCT00019513|stage IV mycosis fungoides/Sezary syndrome
1494907|NCT00019513|recurrent mycosis fungoides/Sezary syndrome
1494908|NCT00019513|recurrent adult primary liver cancer
1494909|NCT00019513|advanced adult primary liver cancer
1494910|NCT00019513|adult primary cholangiocellular carcinoma
1494911|NCT00019513|stage IV non-small cell lung cancer
1494912|NCT00019513|recurrent non-small cell lung cancer
1494913|NCT00019513|extensive stage small cell lung cancer
1494914|NCT00019513|recurrent small cell lung cancer
1494915|NCT00019513|recurrent pancreatic cancer
1494916|NCT00019513|stage IV esophageal cancer
1494917|NCT00019513|recurrent esophageal cancer
1494918|NCT00019513|recurrent colon cancer
1494919|NCT00019513|stage IV colon cancer
1494920|NCT00019513|recurrent gallbladder cancer
1494921|NCT00019513|unresectable gallbladder cancer
1494922|NCT00019513|cholangiocarcinoma of the gallbladder
1494923|NCT00019513|unresectable extrahepatic bile duct cancer
1494924|NCT00019513|recurrent extrahepatic bile duct cancer
1494925|NCT00019513|cholangiocarcinoma of the extrahepatic bile duct
1494926|NCT00019513|recurrent marginal zone lymphoma
1494927|NCT00019513|recurrent small lymphocytic lymphoma
1494928|NCT00019513|stage IV small lymphocytic lymphoma
1494929|NCT00019513|stage IV marginal zone lymphoma
1494930|NCT00019513|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1494931|NCT00019513|nodal marginal zone B-cell lymphoma
1494932|NCT00019513|splenic marginal zone lymphoma
1494933|NCT00019513|stage IV pancreatic cancer
1494934|NCT00019500|breast cancer
1494935|NCT00019487|stage IV melanoma
1494936|NCT00019487|recurrent melanoma
1494937|NCT00019474|stage III gastric cancer
1494938|NCT00019474|stage IV gastric cancer
1494939|NCT00019474|recurrent gastric cancer
1494940|NCT00019474|stage II pancreatic cancer
1494941|NCT00019474|stage III pancreatic cancer
1494942|NCT00019474|recurrent pancreatic cancer
1494943|NCT00019474|regional gastrointestinal carcinoid tumor
1494944|NCT00019474|metastatic gastrointestinal carcinoid tumor
1494945|NCT00019474|recurrent gastrointestinal carcinoid tumor
1494946|NCT00019474|localized unresectable adult primary liver cancer
1494947|NCT00019474|advanced adult primary liver cancer
1494948|NCT00019474|recurrent adult primary liver cancer
1494949|NCT00019474|small intestine adenocarcinoma
1494950|NCT00019474|unresectable extrahepatic bile duct cancer
1494951|NCT00019474|recurrent extrahepatic bile duct cancer
1494952|NCT00019474|recurrent small intestine cancer
1494953|NCT00019474|adult primary hepatocellular carcinoma
1494954|NCT00019474|stage IV pancreatic cancer
1494955|NCT00019461|recurrent ovarian epithelial cancer
1494956|NCT00019461|fallopian tube cancer
1494957|NCT00019461|primary peritoneal cavity cancer
1494958|NCT00019448|adult solid tumor
1494959|NCT00019448|body system/site cancer
1494960|NCT00019448|cancer
1494961|NCT00019448|melanoma
1494962|NCT00019448|recurrent melanoma
1494963|NCT00019448|skin tumor
1494964|NCT00019448|solid tumor
1494965|NCT00019448|stage IV melanoma
1494966|NCT00019448|stage, melanoma
1494967|NCT00019435|stage IV colon cancer
1494968|NCT00019435|stage IV breast cancer
1494969|NCT00019435|recurrent breast cancer
1494970|NCT00019435|stage IV gastric cancer
1494971|NCT00019435|recurrent gastric cancer
1494972|NCT00019435|recurrent non-small cell lung cancer
1494973|NCT00019435|recurrent pancreatic cancer
1494974|NCT00019435|recurrent colon cancer
1494975|NCT00019435|stage IV esophageal cancer
1494976|NCT00019435|recurrent esophageal cancer
1494977|NCT00019435|recurrent bladder cancer
1494978|NCT00019435|stage IV bladder cancer
1494979|NCT00019435|stage IV non-small cell lung cancer
1494980|NCT00019435|stage IV pancreatic cancer
1494981|NCT00019422|childhood low-grade cerebral astrocytoma
1494982|NCT00019422|recurrent childhood supratentorial primitive neuroectodermal tumor
1494983|NCT00019422|recurrent childhood cerebellar astrocytoma
1494984|NCT00019422|recurrent childhood cerebral astrocytoma
1494985|NCT00019422|recurrent childhood medulloblastoma
1494986|NCT00019422|untreated childhood visual pathway and hypothalamic glioma
1495183|NCT00019110|recurrent penile cancer
1494987|NCT00019422|recurrent childhood visual pathway and hypothalamic glioma
1494988|NCT00019422|recurrent childhood ependymoma
1494989|NCT00019409|untreated childhood acute lymphoblastic leukemia
1494990|NCT00019409|childhood acute lymphoblastic leukemia in remission
1494991|NCT00019409|L1 childhood acute lymphoblastic leukemia
1494992|NCT00019409|L2 childhood acute lymphoblastic leukemia
1494993|NCT00019396|adult solid tumor
1494994|NCT00019396|body system/site cancer
1494995|NCT00019396|cancer
1494996|NCT00019396|kidney tumor
1494997|NCT00019396|kidney/urinary cancer
1494998|NCT00019396|melanoma
1494999|NCT00019396|recurrent melanoma
1495000|NCT00019396|recurrent renal cell cancer
1495001|NCT00019396|renal cell cancer
1495002|NCT00019396|skin tumor
1495003|NCT00019396|solid tumor
1495004|NCT00019396|stage IV melanoma
1495005|NCT00019396|stage IV renal cell cancer
1495006|NCT00019396|stage, melanoma
1495007|NCT00019396|stage, renal cell cancer
1495008|NCT00019383|recurrent melanoma
1495009|NCT00019357|unspecified adult solid tumor, protocol specific
1495010|NCT00019344|stage IV adult Hodgkin lymphoma
1495011|NCT00019344|recurrent adult Hodgkin lymphoma
1495012|NCT00019344|stage IV cutaneous T-cell non-Hodgkin lymphoma
1495013|NCT00019344|recurrent cutaneous T-cell non-Hodgkin lymphoma
1495014|NCT00019344|small intestine lymphoma
1495015|NCT00019344|stage IV prostate cancer
1495016|NCT00019344|recurrent prostate cancer
1495017|NCT00019344|unspecified adult solid tumor, protocol specific
1495018|NCT00019344|stage IV grade 1 follicular lymphoma
1495019|NCT00019344|stage IV grade 2 follicular lymphoma
1495020|NCT00019344|stage IV grade 3 follicular lymphoma
1495021|NCT00019344|stage IV adult diffuse small cleaved cell lymphoma
1495022|NCT00019344|stage IV adult diffuse mixed cell lymphoma
1495023|NCT00019344|stage IV adult diffuse large cell lymphoma
1495024|NCT00019344|stage IV adult immunoblastic large cell lymphoma
1495025|NCT00019344|stage IV adult lymphoblastic lymphoma
1495026|NCT00019344|stage IV adult Burkitt lymphoma
1495027|NCT00019344|recurrent grade 1 follicular lymphoma
1495028|NCT00019344|recurrent grade 2 follicular lymphoma
1495029|NCT00019344|recurrent grade 3 follicular lymphoma
1495030|NCT00019344|recurrent adult diffuse small cleaved cell lymphoma
1495031|NCT00019344|recurrent adult diffuse mixed cell lymphoma
1495032|NCT00019344|recurrent adult diffuse large cell lymphoma
1495033|NCT00019344|recurrent adult immunoblastic large cell lymphoma
1495034|NCT00019344|recurrent adult lymphoblastic lymphoma
1495035|NCT00019344|recurrent adult Burkitt lymphoma
1495036|NCT00019344|stage IV adult T-cell leukemia/lymphoma
1495037|NCT00019344|recurrent adult T-cell leukemia/lymphoma
1495038|NCT00019344|intraocular lymphoma
1495039|NCT00019344|stage IV mantle cell lymphoma
1495040|NCT00019344|recurrent mantle cell lymphoma
1495041|NCT00019344|angioimmunoblastic T-cell lymphoma
1495042|NCT00019344|anaplastic large cell lymphoma
1495043|NCT00019344|stage IV mycosis fungoides/Sezary syndrome
1495044|NCT00019344|recurrent mycosis fungoides/Sezary syndrome
1495045|NCT00019344|recurrent marginal zone lymphoma
1495046|NCT00019344|recurrent small lymphocytic lymphoma
1495047|NCT00019344|stage IV small lymphocytic lymphoma
1495048|NCT00019344|stage IV marginal zone lymphoma
1495049|NCT00019344|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1495050|NCT00019344|nodal marginal zone B-cell lymphoma
1495051|NCT00019344|splenic marginal zone lymphoma
1495052|NCT00019331|stage IV colon cancer
1495053|NCT00019331|recurrent non-small cell lung cancer
1495054|NCT00019331|stage II pancreatic cancer
1495055|NCT00019331|stage III pancreatic cancer
1495056|NCT00019331|recurrent pancreatic cancer
1495057|NCT00019331|recurrent colon cancer
1495058|NCT00019331|extensive stage small cell lung cancer
1495059|NCT00019331|recurrent small cell lung cancer
1495060|NCT00019331|advanced adult primary liver cancer
1495061|NCT00019331|recurrent adult primary liver cancer
1495062|NCT00019331|stage IV endometrial carcinoma
1495063|NCT00019331|recurrent endometrial carcinoma
1495064|NCT00019331|stage III malignant testicular germ cell tumor
1495065|NCT00019331|recurrent malignant testicular germ cell tumor
1495066|NCT00019331|stage IV papillary thyroid cancer
1495067|NCT00019331|stage IV follicular thyroid cancer
1495068|NCT00019331|thyroid gland medullary carcinoma
1495069|NCT00019331|anaplastic thyroid cancer
1495070|NCT00019331|recurrent thyroid cancer
1495071|NCT00019331|stage IV melanoma
1495072|NCT00019331|recurrent melanoma
1495073|NCT00019331|stage IV non-small cell lung cancer
1495074|NCT00019331|unspecified adult solid tumor, protocol specific
1495075|NCT00019331|untreated metastatic squamous neck cancer with occult primary
1495076|NCT00019331|recurrent metastatic squamous neck cancer with occult primary
1495077|NCT00019331|adult primary hepatocellular carcinoma
1495078|NCT00019331|pulmonary carcinoid tumor
1495079|NCT00019331|stage IV squamous cell carcinoma of the lip and oral cavity
1495080|NCT00019331|stage IV basal cell carcinoma of the lip
1495081|NCT00019331|stage IV verrucous carcinoma of the oral cavity
1495082|NCT00019331|stage IV mucoepidermoid carcinoma of the oral cavity
1495083|NCT00019331|stage IV adenoid cystic carcinoma of the oral cavity
1495084|NCT00019331|recurrent squamous cell carcinoma of the lip and oral cavity
1495085|NCT00019331|recurrent basal cell carcinoma of the lip
1495086|NCT00019331|recurrent verrucous carcinoma of the oral cavity
1495087|NCT00019331|recurrent mucoepidermoid carcinoma of the oral cavity
1495088|NCT00019331|recurrent adenoid cystic carcinoma of the oral cavity
1495089|NCT00019331|stage IV squamous cell carcinoma of the oropharynx
1495090|NCT00019331|stage IV lymphoepithelioma of the oropharynx
1495091|NCT00019331|recurrent squamous cell carcinoma of the oropharynx
1495092|NCT00019331|recurrent lymphoepithelioma of the oropharynx
1495093|NCT00019331|stage IV squamous cell carcinoma of the nasopharynx
1495094|NCT00019331|stage IV lymphoepithelioma of the nasopharynx
1495095|NCT00019331|recurrent squamous cell carcinoma of the nasopharynx
1495096|NCT00019331|recurrent lymphoepithelioma of the nasopharynx
1495097|NCT00019331|stage IV squamous cell carcinoma of the hypopharynx
1495098|NCT00019331|recurrent squamous cell carcinoma of the hypopharynx
1495099|NCT00019331|stage IV squamous cell carcinoma of the larynx
1495100|NCT00019331|stage IV verrucous carcinoma of the larynx
1495101|NCT00019331|recurrent squamous cell carcinoma of the larynx
1495102|NCT00019331|recurrent verrucous carcinoma of the larynx
1495103|NCT00019331|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1495104|NCT00019331|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1495105|NCT00019331|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1495106|NCT00019331|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495107|NCT00019331|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1495108|NCT00019331|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1495109|NCT00019331|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1495110|NCT00019331|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495111|NCT00019331|insular thyroid cancer
1495112|NCT00019331|recurrent salivary gland cancer
1495113|NCT00019331|stage IV salivary gland cancer
1495114|NCT00019331|stage IV pancreatic cancer
1495115|NCT00019318|stage III cutaneous T-cell non-Hodgkin lymphoma
1495116|NCT00019318|stage IV cutaneous T-cell non-Hodgkin lymphoma
1495117|NCT00019318|recurrent cutaneous T-cell non-Hodgkin lymphoma
1495118|NCT00019318|stage III mycosis fungoides/Sezary syndrome
1495119|NCT00019318|stage IV mycosis fungoides/Sezary syndrome
1495120|NCT00019318|recurrent mycosis fungoides/Sezary syndrome
1495121|NCT00019240|classic Kaposi sarcoma
1495122|NCT00019240|AIDS-related Kaposi sarcoma
1495123|NCT00019240|recurrent Kaposi sarcoma
1495124|NCT00019227|stage I adult T-cell leukemia/lymphoma
1495125|NCT00019227|stage II adult T-cell leukemia/lymphoma
1495126|NCT00019227|stage III adult T-cell leukemia/lymphoma
1495127|NCT00019227|stage IV adult T-cell leukemia/lymphoma
1495128|NCT00019227|recurrent adult T-cell leukemia/lymphoma
1495129|NCT00019227|radiation toxicity
1495130|NCT00019214|recurrent melanoma
1495131|NCT00019201|stage I non-small cell lung cancer
1495132|NCT00019201|stage II non-small cell lung cancer
1495133|NCT00019201|stage III non-small cell lung cancer
1495134|NCT00019201|limited stage small cell lung cancer
1495135|NCT00019201|stage I nasopharyngeal cancer
1495136|NCT00019201|stage II nasopharyngeal cancer
1495137|NCT00019201|stage III nasopharyngeal cancer
1495138|NCT00019201|stage I lip and oral cavity cancer
1495139|NCT00019201|stage II lip and oral cavity cancer
1495140|NCT00019201|stage III lip and oral cavity cancer
1495141|NCT00019201|stage I hypopharyngeal cancer
1495142|NCT00019201|stage II hypopharyngeal cancer
1495143|NCT00019201|stage III hypopharyngeal cancer
1495144|NCT00019201|stage I laryngeal cancer
1495145|NCT00019201|stage II laryngeal cancer
1495146|NCT00019201|stage III laryngeal cancer
1495147|NCT00019201|stage I paranasal sinus and nasal cavity cancer
1495148|NCT00019201|stage II paranasal sinus and nasal cavity cancer
1495149|NCT00019201|stage III paranasal sinus and nasal cavity cancer
1495150|NCT00019201|stage I oropharyngeal cancer
1495151|NCT00019201|stage II oropharyngeal cancer
1495152|NCT00019201|stage III oropharyngeal cancer
1495153|NCT00019188|AIDS-related malignancies
1495154|NCT00019188|Kaposi's sarcoma
1495155|NCT00019188|adult solid tumor
1495156|NCT00019188|body system/site cancer
1495157|NCT00019188|cancer
1495158|NCT00019188|epidemic Kaposi's sarcoma
1495159|NCT00019188|recurrent Kaposi's sarcoma
1495160|NCT00019188|skin tumor
1495161|NCT00019188|solid tumor
1495162|NCT00019188|stage, Kaposi's sarcoma
1495163|NCT00019175|stage IV melanoma
1495164|NCT00019175|recurrent melanoma
1495780|NCT00018005|Heart Failure
1495165|NCT00019136|recurrent ovarian epithelial cancer
1495166|NCT00019123|AIDS-related Kaposi sarcoma
1495167|NCT00019110|stage IV anal cancer
1495168|NCT00019110|recurrent anal cancer
1495169|NCT00019110|stage II esophageal cancer
1495170|NCT00019110|stage III esophageal cancer
1495171|NCT00019110|stage IV esophageal cancer
1495172|NCT00019110|stage IIIA anal cancer
1495173|NCT00019110|stage IIIB anal cancer
1495174|NCT00019110|recurrent esophageal cancer
1495175|NCT00019110|stage III cervical cancer
1495176|NCT00019110|stage IV cervical cancer
1495177|NCT00019110|recurrent cervical cancer
1495178|NCT00019110|stage III vulvar cancer
1495179|NCT00019110|stage IVB vulvar cancer
1495180|NCT00019110|recurrent vulvar cancer
1495181|NCT00019110|stage III penile cancer
1495184|NCT00019110|recurrent metastatic squamous neck cancer with occult primary
1495185|NCT00019110|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1495186|NCT00019110|stage III squamous cell carcinoma of the lip and oral cavity
1495187|NCT00019110|stage III basal cell carcinoma of the lip
1495188|NCT00019110|stage III verrucous carcinoma of the oral cavity
1495189|NCT00019110|stage III mucoepidermoid carcinoma of the oral cavity
1495190|NCT00019110|stage III adenoid cystic carcinoma of the oral cavity
1495191|NCT00019110|stage IV squamous cell carcinoma of the lip and oral cavity
1495192|NCT00019110|stage IV basal cell carcinoma of the lip
1495193|NCT00019110|stage IV verrucous carcinoma of the oral cavity
1495194|NCT00019110|stage IV mucoepidermoid carcinoma of the oral cavity
1495195|NCT00019110|recurrent squamous cell carcinoma of the lip and oral cavity
1495196|NCT00019110|recurrent basal cell carcinoma of the lip
1495197|NCT00019110|recurrent verrucous carcinoma of the oral cavity
1495198|NCT00019110|recurrent mucoepidermoid carcinoma of the oral cavity
1495199|NCT00019110|recurrent adenoid cystic carcinoma of the oral cavity
1495200|NCT00019110|stage III squamous cell carcinoma of the oropharynx
1495201|NCT00019110|stage III lymphoepithelioma of the oropharynx
1495202|NCT00019110|stage IV squamous cell carcinoma of the oropharynx
1495203|NCT00019110|stage IV lymphoepithelioma of the oropharynx
1495204|NCT00019110|recurrent squamous cell carcinoma of the oropharynx
1495205|NCT00019110|recurrent lymphoepithelioma of the oropharynx
1495206|NCT00019110|stage III squamous cell carcinoma of the nasopharynx
1495207|NCT00019110|stage III lymphoepithelioma of the nasopharynx
1495208|NCT00019110|stage IV squamous cell carcinoma of the nasopharynx
1495209|NCT00019110|stage IV lymphoepithelioma of the nasopharynx
1495210|NCT00019110|recurrent squamous cell carcinoma of the nasopharynx
1495211|NCT00019110|recurrent lymphoepithelioma of the nasopharynx
1495212|NCT00019110|stage III squamous cell carcinoma of the hypopharynx
1495213|NCT00019110|stage IV squamous cell carcinoma of the hypopharynx
1495214|NCT00019110|recurrent squamous cell carcinoma of the hypopharynx
1495215|NCT00019110|stage III squamous cell carcinoma of the larynx
1495216|NCT00019110|stage III verrucous carcinoma of the larynx
1495217|NCT00019110|stage IV squamous cell carcinoma of the larynx
1495218|NCT00019110|stage IV verrucous carcinoma of the larynx
1495219|NCT00019110|recurrent squamous cell carcinoma of the larynx
1495220|NCT00019110|recurrent verrucous carcinoma of the larynx
1495221|NCT00019110|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1495222|NCT00019110|stage III inverted papilloma of the paranasal sinus and nasal cavity
1495223|NCT00019110|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1495224|NCT00019110|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495225|NCT00019110|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1495226|NCT00019110|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1495227|NCT00019110|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1495228|NCT00019110|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495229|NCT00019110|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1495230|NCT00019110|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1495231|NCT00019110|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1495232|NCT00019110|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495233|NCT00019110|recurrent salivary gland cancer
1495234|NCT00019110|stage IV salivary gland cancer
1495235|NCT00019110|stage III salivary gland cancer
1495236|NCT00019097|body system/site cancer
1495237|NCT00019097|cancer
1495238|NCT00019097|genetic condition
1495239|NCT00019097|hematopoietic/lymphoid cancer
1495240|NCT00019097|multiple myeloma
1495241|NCT00019097|multiple myeloma and other plasma cell neoplasms
1495242|NCT00019097|plasma cell neoplasm
1495243|NCT00019097|refractory plasma cell neoplasm
1495244|NCT00019097|stage II multiple myeloma
1495245|NCT00019097|stage III multiple myeloma
1495246|NCT00019097|stage, plasma cell neoplasm
1495247|NCT00019084|stage IV colon cancer
1495248|NCT00019084|stage IV breast cancer
1495249|NCT00019084|recurrent breast cancer
1495250|NCT00019084|recurrent non-small cell lung cancer
1495251|NCT00019084|stage II pancreatic cancer
1495252|NCT00019084|stage III pancreatic cancer
1495253|NCT00019084|recurrent pancreatic cancer
1495254|NCT00019084|recurrent colon cancer
1495255|NCT00019084|recurrent cervical cancer
1495256|NCT00019084|stage IVB cervical cancer
1495257|NCT00019084|stage IV ovarian epithelial cancer
1495258|NCT00019084|recurrent ovarian epithelial cancer
1495259|NCT00019084|extensive stage small cell lung cancer
1495260|NCT00019084|recurrent small cell lung cancer
1495261|NCT00019084|stage IV non-small cell lung cancer
1495262|NCT00019084|stage IV pancreatic cancer
1495263|NCT00019071|adult glioblastoma
1495264|NCT00019071|adult anaplastic astrocytoma
1495265|NCT00019071|adult giant cell glioblastoma
1495266|NCT00019071|adult gliosarcoma
1495267|NCT00019058|adult glioblastoma
1495268|NCT00019058|adult giant cell glioblastoma
1495269|NCT00019058|adult gliosarcoma
1495270|NCT00019032|refractory chronic lymphocytic leukemia
1495271|NCT00019032|T-cell large granular lymphocyte leukemia
1495272|NCT00019019|stage III adult Hodgkin lymphoma
1495273|NCT00019019|stage IV adult Hodgkin lymphoma
1495274|NCT00019019|stage IV breast cancer
1495275|NCT00019019|stage IIIA breast cancer
1495276|NCT00019019|recurrent breast cancer
1495277|NCT00019019|stage IIIB breast cancer
1495278|NCT00019019|recurrent non-small cell lung cancer
1495279|NCT00019019|recurrent adult Hodgkin lymphoma
1495280|NCT00019019|stage III cutaneous T-cell non-Hodgkin lymphoma
1495281|NCT00019019|stage IV cutaneous T-cell non-Hodgkin lymphoma
1495282|NCT00019019|recurrent cutaneous T-cell non-Hodgkin lymphoma
1495283|NCT00019019|stage III renal cell cancer
1495284|NCT00019019|stage IV renal cell cancer
1495285|NCT00019019|recurrent renal cell cancer
1495286|NCT00019019|stage III ovarian epithelial cancer
1495287|NCT00019019|stage IV ovarian epithelial cancer
1495288|NCT00019019|recurrent ovarian epithelial cancer
1495289|NCT00019019|recurrent adult brain tumor
1495290|NCT00019019|small intestine lymphoma
1495291|NCT00019019|adult brain stem glioma
1495292|NCT00019019|adult craniopharyngioma
1495293|NCT00019019|adult medulloblastoma
1495294|NCT00019019|adult meningioma
1495295|NCT00019019|adult glioblastoma
1495296|NCT00019019|stage III melanoma
1495297|NCT00019019|stage IV melanoma
1495298|NCT00019019|recurrent melanoma
1495299|NCT00019019|stage IIIA non-small cell lung cancer
1495300|NCT00019019|stage IIIB non-small cell lung cancer
1495301|NCT00019019|stage IIIC breast cancer
1495302|NCT00019019|stage IV non-small cell lung cancer
1495303|NCT00019019|unspecified adult solid tumor, protocol specific
1495304|NCT00019019|stage III grade 1 follicular lymphoma
1495305|NCT00019019|stage III grade 2 follicular lymphoma
1495306|NCT00019019|stage III grade 3 follicular lymphoma
1495307|NCT00019019|stage III adult diffuse small cleaved cell lymphoma
1495308|NCT00019019|stage III adult diffuse mixed cell lymphoma
1495309|NCT00019019|stage III adult diffuse large cell lymphoma
1495310|NCT00019019|stage III adult immunoblastic large cell lymphoma
1495311|NCT00019019|stage III adult lymphoblastic lymphoma
1495312|NCT00019019|stage III adult Burkitt lymphoma
1495313|NCT00019019|stage IV grade 1 follicular lymphoma
1495314|NCT00019019|stage IV grade 2 follicular lymphoma
1495315|NCT00019019|stage IV grade 3 follicular lymphoma
1495316|NCT00019019|stage IV adult diffuse small cleaved cell lymphoma
1495317|NCT00019019|stage IV adult diffuse mixed cell lymphoma
1495318|NCT00019019|stage IV adult diffuse large cell lymphoma
1495319|NCT00019019|stage IV adult immunoblastic large cell lymphoma
1495320|NCT00019019|stage IV adult lymphoblastic lymphoma
1495321|NCT00019019|stage IV adult Burkitt lymphoma
1495322|NCT00019019|recurrent grade 1 follicular lymphoma
1495323|NCT00019019|recurrent grade 2 follicular lymphoma
1495324|NCT00019019|recurrent grade 3 follicular lymphoma
1495325|NCT00019019|recurrent adult diffuse small cleaved cell lymphoma
1495326|NCT00019019|recurrent adult diffuse mixed cell lymphoma
1495327|NCT00019019|recurrent adult diffuse large cell lymphoma
1495328|NCT00019019|recurrent adult immunoblastic large cell lymphoma
1495329|NCT00019019|recurrent adult lymphoblastic lymphoma
1495330|NCT00019019|recurrent adult Burkitt lymphoma
1495331|NCT00019019|stage III adult T-cell leukemia/lymphoma
1495332|NCT00019019|stage IV adult T-cell leukemia/lymphoma
1495333|NCT00019019|recurrent adult T-cell leukemia/lymphoma
1495334|NCT00019019|adult anaplastic astrocytoma
1495335|NCT00019019|adult myxopapillary ependymoma
1495336|NCT00019019|adult anaplastic ependymoma
1495337|NCT00019019|adult anaplastic oligodendroglioma
1495338|NCT00019019|adult mixed glioma
1495339|NCT00019019|adult central nervous system germ cell tumor
1495340|NCT00019019|primary central nervous system non-Hodgkin lymphoma
1495341|NCT00019019|adult pilocytic astrocytoma
1495342|NCT00019019|adult subependymoma
1495343|NCT00019019|adult ependymoblastoma
1495344|NCT00019019|adult pineocytoma
1495345|NCT00019019|adult pineoblastoma
1495346|NCT00019019|adult meningeal hemangiopericytoma
1495347|NCT00019019|intraocular lymphoma
1495348|NCT00019019|stage III mantle cell lymphoma
1495349|NCT00019019|stage IV mantle cell lymphoma
1495350|NCT00019019|recurrent mantle cell lymphoma
1495351|NCT00019019|angioimmunoblastic T-cell lymphoma
1495352|NCT00019019|anaplastic large cell lymphoma
1495353|NCT00019019|adult choroid plexus tumor
1495354|NCT00019019|stage III mycosis fungoides/Sezary syndrome
1495355|NCT00019019|stage IV mycosis fungoides/Sezary syndrome
1495356|NCT00019019|recurrent mycosis fungoides/Sezary syndrome
1495357|NCT00019019|recurrent marginal zone lymphoma
1495358|NCT00019019|recurrent small lymphocytic lymphoma
1495359|NCT00019019|stage III small lymphocytic lymphoma
1495360|NCT00019019|stage III marginal zone lymphoma
1495361|NCT00019019|stage IV small lymphocytic lymphoma
1495362|NCT00019019|stage IV marginal zone lymphoma
1495363|NCT00019019|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1495364|NCT00019019|nodal marginal zone B-cell lymphoma
1495365|NCT00019019|splenic marginal zone lymphoma
1495366|NCT00019019|adult grade III meningioma
1495367|NCT00019019|adult oligodendroglioma
1495368|NCT00019019|adult giant cell glioblastoma
1495369|NCT00019019|adult gliosarcoma
1495370|NCT00019006|adult solid tumor
1495371|NCT00019006|body system/site cancer
1495372|NCT00019006|cancer
1495373|NCT00019006|colon cancer
1495374|NCT00019006|colorectal cancer
1495375|NCT00019006|extensive stage small cell lung cancer
1495376|NCT00019006|gastrointestinal cancer
1495377|NCT00019006|genetic condition
1495378|NCT00019006|limited stage small cell lung cancer
1495379|NCT00019006|lung cancer
1495380|NCT00019006|non-small cell lung cancer
1495381|NCT00019006|pancreatic cancer
1495382|NCT00019006|rectal cancer
1495383|NCT00019006|recurrent colon cancer
1495384|NCT00019006|recurrent pancreatic cancer
1495385|NCT00019006|recurrent rectal cancer
1495386|NCT00019006|small cell lung cancer
1495387|NCT00019006|solid tumor
1495388|NCT00019006|stage I pancreatic cancer
1495389|NCT00019006|stage II non-small cell lung cancer
1495390|NCT00019006|stage II pancreatic cancer
1495391|NCT00019006|stage III colon cancer
1495392|NCT00019006|stage III non-small cell lung cancer
1495393|NCT00019006|stage III pancreatic cancer
1495394|NCT00019006|stage III rectal cancer
1495395|NCT00019006|stage IV pancreatic cancer
1495396|NCT00019006|stage IVA pancreatic cancer
1495397|NCT00019006|stage IVB pancreatic cancer
1495398|NCT00019006|stage, colon cancer
1495399|NCT00019006|stage, non-small cell lung cancer
1495400|NCT00019006|stage, pancreatic cancer
1495401|NCT00019006|stage, rectal cancer
1495402|NCT00019006|stage, small cell lung cancer
1495403|NCT00019006|thorax/respiratory cancer
1495404|NCT00018967|unspecified childhood solid tumor, protocol specific
1495405|NCT00018967|unspecified adult solid tumor, protocol specific
1495406|NCT00018967|neurotoxicity
1495407|NCT00018954|stage I childhood lymphoblastic lymphoma
1495408|NCT00018954|stage II childhood lymphoblastic lymphoma
1495409|NCT00018954|stage III childhood lymphoblastic lymphoma
1495410|NCT00018954|stage IV childhood lymphoblastic lymphoma
1495411|NCT00018954|untreated adult acute lymphoblastic leukemia
1495412|NCT00018954|untreated childhood acute lymphoblastic leukemia
1495413|NCT00018954|stage I adult diffuse small cleaved cell lymphoma
1495414|NCT00018954|stage I adult diffuse mixed cell lymphoma
1495415|NCT00018954|stage I adult diffuse large cell lymphoma
1495416|NCT00018954|stage I adult immunoblastic large cell lymphoma
1495417|NCT00018954|stage I adult lymphoblastic lymphoma
1495418|NCT00018954|stage I adult Burkitt lymphoma
1495419|NCT00018954|stage III adult diffuse small cleaved cell lymphoma
1495420|NCT00018954|stage III adult diffuse mixed cell lymphoma
1495421|NCT00018954|stage III adult diffuse large cell lymphoma
1495422|NCT00018954|stage III adult immunoblastic large cell lymphoma
1495423|NCT00018954|stage III adult lymphoblastic lymphoma
1495424|NCT00018954|stage III adult Burkitt lymphoma
1495425|NCT00018954|stage IV adult diffuse small cleaved cell lymphoma
1495426|NCT00018954|stage IV adult diffuse mixed cell lymphoma
1495427|NCT00018954|stage IV adult diffuse large cell lymphoma
1495428|NCT00018954|stage IV adult immunoblastic large cell lymphoma
1495429|NCT00018954|stage IV adult lymphoblastic lymphoma
1495430|NCT00018954|stage IV adult Burkitt lymphoma
1495431|NCT00018954|stage I childhood small noncleaved cell lymphoma
1495432|NCT00018954|stage I childhood large cell lymphoma
1495433|NCT00018954|stage II childhood small noncleaved cell lymphoma
1495434|NCT00018954|stage II childhood large cell lymphoma
1495435|NCT00018954|stage III childhood small noncleaved cell lymphoma
1495436|NCT00018954|stage III childhood large cell lymphoma
1495437|NCT00018954|stage IV childhood small noncleaved cell lymphoma
1495438|NCT00018954|stage IV childhood large cell lymphoma
1495439|NCT00018954|stage I mantle cell lymphoma
1495440|NCT00018954|contiguous stage II adult diffuse small cleaved cell lymphoma
1495441|NCT00018954|contiguous stage II mantle cell lymphoma
1495442|NCT00018954|contiguous stage II adult diffuse mixed cell lymphoma
1495443|NCT00018954|contiguous stage II adult immunoblastic large cell lymphoma
1495444|NCT00018954|contiguous stage II adult diffuse large cell lymphoma
1495445|NCT00018954|contiguous stage II adult Burkitt lymphoma
1495446|NCT00018954|contiguous stage II adult lymphoblastic lymphoma
1495447|NCT00018954|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1495448|NCT00018954|noncontiguous stage II mantle cell lymphoma
1495449|NCT00018954|noncontiguous stage II adult diffuse mixed cell lymphoma
1495450|NCT00018954|noncontiguous stage II adult immunoblastic large cell lymphoma
1495451|NCT00018954|noncontiguous stage II adult diffuse large cell lymphoma
1495452|NCT00018954|noncontiguous stage II adult Burkitt lymphoma
1495453|NCT00018954|noncontiguous stage II adult lymphoblastic lymphoma
1495454|NCT00018954|stage III mantle cell lymphoma
1495455|NCT00018954|stage IV mantle cell lymphoma
1495456|NCT00018954|noncontiguous stage II small lymphocytic lymphoma
1495457|NCT00018954|noncontiguous stage II marginal zone lymphoma
1495458|NCT00018954|stage I marginal zone lymphoma
1495459|NCT00018954|stage I small lymphocytic lymphoma
1495460|NCT00018954|stage III small lymphocytic lymphoma
1495461|NCT00018954|stage III marginal zone lymphoma
1495462|NCT00018954|stage IV small lymphocytic lymphoma
1495463|NCT00018954|stage IV marginal zone lymphoma
1495464|NCT00018954|contiguous stage II marginal zone lymphoma
1495465|NCT00018954|contiguous stage II small lymphocytic lymphoma
1495466|NCT00018954|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1495467|NCT00018954|nodal marginal zone B-cell lymphoma
1495789|NCT00017992|Anti-HIV Agents
1495468|NCT00018954|splenic marginal zone lymphoma
1495469|NCT00018941|stage IV renal cell cancer
1495470|NCT00018941|recurrent renal cell cancer
1495471|NCT00018902|Depressive Disorder
1495472|NCT00018902|Adolescents
1495473|NCT00018902|Teenagers
1495474|NCT00018902|Teens
1495475|NCT00018902|Cognitive Behavior Therapy
1495476|NCT00018889|Clinical Evaluation
1495477|NCT00018889|Genetic Study
1495478|NCT00018889|Essential Tremor
1495479|NCT00018889|Familial Myoclonus
1495480|NCT00018889|Hereditary Ataxia
1495481|NCT00018889|Movement Disorder
1495482|NCT00018889|Inherited Movement Disorder
1495483|NCT00018876|Epidural fibrosis
1495484|NCT00018876|Failed back surgery syndrome
1495485|NCT00018876|Postlaminectomy syndrome
1495486|NCT00018876|Lumbar laminectomy
1495487|NCT00018876|Radiotherapy
1495488|NCT00018876|Radiation
1495489|NCT00018876|Perineural scar formation
1495490|NCT00018876|Peridural fibrosis
1495491|NCT00018876|Back surgery
1495492|NCT00018863|ADHD
1495493|NCT00018850|schizophrenia
1495494|NCT00018850|ondansetron
1495495|NCT00018850|nicotine
1495496|NCT00018850|haloperidol
1495497|NCT00018811|Relaxation Techniques
1495498|NCT00018811|Behavior Therapy Feedback
1495499|NCT00018811|Psychophysiology
1495500|NCT00018798|Combat-Related PTSD, Vietnam Veterans
1495501|NCT00018785|kidney transplantation
1495502|NCT00018785|immunosuppression
1495503|NCT00018785|bone marrow
1495504|NCT00018772|coagulation
1495505|NCT00018772|thrombosis genetic markers
1495506|NCT00018759|Serotonin, Hypertension, Depression
1495507|NCT00018733|Depression
1495508|NCT00018720|triglyceride
1495509|NCT00018720|bile acids
1495510|NCT00018720|cholelithias
1495511|NCT00018694|bile acid synthesis
1495512|NCT00018694|chenodeoxycholic acid
1495513|NCT00018694|sterol 27-hydroxylase
1495514|NCT00018668|Antipsychotics
1495515|NCT00018668|schizophrenia
1495516|NCT00018668|motor retardation
1495517|NCT00018668|bradykinesia
1495518|NCT00018655|Mood Disorders
1495519|NCT00018655|Substance-Related Disorders
1495520|NCT00018642|quetiapine
1495521|NCT00018642|haloperidol decanoate
1495522|NCT00018629|Aging
1495523|NCT00018629|Neuropsychology
1495524|NCT00018629|Psychotherapy
1495525|NCT00018629|Rehabilitation
1495526|NCT00018629|Schizophrenia
1495527|NCT00018616|compliance
1495528|NCT00018616|MEMS
1495529|NCT00018616|metformin
1495530|NCT00018603|PTSD
1495531|NCT00018590|Vascular Diseases
1495532|NCT00018538|vitamin D
1495533|NCT00018538|prostatic neoplasms
1495534|NCT00018538|neoplasm recurrence
1495535|NCT00018512|dental implant
1495536|NCT00018499|Traumatic Brain Injury
1495537|NCT00018330|Behavioral
1495538|NCT00018330|Weight Loss
1495539|NCT00018330|Genetics
1495540|NCT00018330|Lipoprotein lipase
1495541|NCT00018330|Visceral fat
1495542|NCT00018330|Lipoprotein
1495543|NCT00018317|Diet
1495544|NCT00018317|exercise
1495545|NCT00017550|refractory anemia
1495546|NCT00017550|refractory anemia with excess blasts
1495547|NCT00017550|de novo myelodysplastic syndromes
1495548|NCT00017550|previously treated myelodysplastic syndromes
1495549|NCT00017537|stage IV breast cancer
1495550|NCT00017537|recurrent breast cancer
1495551|NCT00017537|stage IV gastric cancer
1495552|NCT00017537|recurrent gastric cancer
1495553|NCT00017537|recurrent non-small cell lung cancer
1495554|NCT00017537|stage IV ovarian epithelial cancer
1495555|NCT00017537|recurrent ovarian epithelial cancer
1495556|NCT00017537|adenocarcinoma of the stomach
1495557|NCT00017537|stage IV non-small cell lung cancer
1495558|NCT00017537|unspecified adult solid tumor, protocol specific
1495559|NCT00017524|unspecified adult solid tumor, protocol specific
1495560|NCT00017511|stage I salivary gland cancer
1495561|NCT00017511|stage II salivary gland cancer
1495562|NCT00017511|stage III salivary gland cancer
1495563|NCT00017511|stage IV salivary gland cancer
1495564|NCT00017511|recurrent salivary gland cancer
1495565|NCT00017511|untreated metastatic squamous neck cancer with occult primary
1495566|NCT00017511|recurrent metastatic squamous neck cancer with occult primary
1495781|NCT00018005|Self-Management
1495567|NCT00017511|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1495568|NCT00017511|oral complications
1495569|NCT00017511|stage I squamous cell carcinoma of the lip and oral cavity
1495570|NCT00017511|stage I basal cell carcinoma of the lip
1495571|NCT00017511|stage I verrucous carcinoma of the oral cavity
1495572|NCT00017511|stage I mucoepidermoid carcinoma of the oral cavity
1495573|NCT00017511|stage I adenoid cystic carcinoma of the oral cavity
1495574|NCT00017511|stage II squamous cell carcinoma of the lip and oral cavity
1495575|NCT00017511|stage II basal cell carcinoma of the lip
1495576|NCT00017511|stage II verrucous carcinoma of the oral cavity
1495577|NCT00017511|stage II mucoepidermoid carcinoma of the oral cavity
1495578|NCT00017511|stage II adenoid cystic carcinoma of the oral cavity
1495579|NCT00017511|stage III squamous cell carcinoma of the lip and oral cavity
1495580|NCT00017511|stage III basal cell carcinoma of the lip
1495581|NCT00017511|stage III verrucous carcinoma of the oral cavity
1495582|NCT00017511|stage III mucoepidermoid carcinoma of the oral cavity
1495583|NCT00017511|stage III adenoid cystic carcinoma of the oral cavity
1495584|NCT00017511|stage IV squamous cell carcinoma of the lip and oral cavity
1495585|NCT00017511|stage IV basal cell carcinoma of the lip
1495586|NCT00017511|stage IV verrucous carcinoma of the oral cavity
1495587|NCT00017511|stage IV mucoepidermoid carcinoma of the oral cavity
1495588|NCT00017511|stage IV adenoid cystic carcinoma of the oral cavity
1495589|NCT00017511|recurrent squamous cell carcinoma of the lip and oral cavity
1495590|NCT00017511|recurrent basal cell carcinoma of the lip
1495591|NCT00017511|recurrent verrucous carcinoma of the oral cavity
1495592|NCT00017511|recurrent mucoepidermoid carcinoma of the oral cavity
1495593|NCT00017511|recurrent adenoid cystic carcinoma of the oral cavity
1495594|NCT00017511|stage I squamous cell carcinoma of the oropharynx
1495595|NCT00017511|stage I lymphoepithelioma of the oropharynx
1495596|NCT00017511|stage II squamous cell carcinoma of the oropharynx
1495597|NCT00017511|stage II lymphoepithelioma of the oropharynx
1495598|NCT00017511|stage III squamous cell carcinoma of the oropharynx
1495599|NCT00017511|stage III lymphoepithelioma of the oropharynx
1495600|NCT00017511|stage IV squamous cell carcinoma of the oropharynx
1495601|NCT00017511|stage IV lymphoepithelioma of the oropharynx
1495602|NCT00017511|recurrent squamous cell carcinoma of the oropharynx
1495603|NCT00017511|recurrent lymphoepithelioma of the oropharynx
1495604|NCT00017511|stage I squamous cell carcinoma of the nasopharynx
1495605|NCT00017511|stage I lymphoepithelioma of the nasopharynx
1495606|NCT00017511|stage II squamous cell carcinoma of the nasopharynx
1495607|NCT00017511|stage II lymphoepithelioma of the nasopharynx
1495608|NCT00017511|stage III squamous cell carcinoma of the nasopharynx
1495609|NCT00017511|stage III lymphoepithelioma of the nasopharynx
1495610|NCT00017511|stage IV squamous cell carcinoma of the nasopharynx
1495611|NCT00017511|stage IV lymphoepithelioma of the nasopharynx
1495612|NCT00017511|recurrent squamous cell carcinoma of the nasopharynx
1495613|NCT00017511|recurrent lymphoepithelioma of the nasopharynx
1495614|NCT00017511|stage I squamous cell carcinoma of the hypopharynx
1495615|NCT00017511|stage II squamous cell carcinoma of the hypopharynx
1495616|NCT00017511|stage III squamous cell carcinoma of the hypopharynx
1495617|NCT00017511|stage IV squamous cell carcinoma of the hypopharynx
1495618|NCT00017511|recurrent squamous cell carcinoma of the hypopharynx
1495619|NCT00017511|stage I squamous cell carcinoma of the larynx
1495620|NCT00017511|stage I verrucous carcinoma of the larynx
1495621|NCT00017511|stage II squamous cell carcinoma of the larynx
1495622|NCT00017511|stage II verrucous carcinoma of the larynx
1495623|NCT00017511|stage III squamous cell carcinoma of the larynx
1495624|NCT00017511|stage III verrucous carcinoma of the larynx
1495625|NCT00017511|stage IV squamous cell carcinoma of the larynx
1495626|NCT00017511|stage IV verrucous carcinoma of the larynx
1495627|NCT00017511|recurrent squamous cell carcinoma of the larynx
1495628|NCT00017511|recurrent verrucous carcinoma of the larynx
1495629|NCT00017511|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1495630|NCT00017511|stage I inverted papilloma of the paranasal sinus and nasal cavity
1495631|NCT00017511|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1495632|NCT00017511|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495633|NCT00017511|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1495634|NCT00017511|stage II inverted papilloma of the paranasal sinus and nasal cavity
1495635|NCT00017511|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1495636|NCT00017511|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495637|NCT00017511|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1495638|NCT00017511|stage III inverted papilloma of the paranasal sinus and nasal cavity
1495639|NCT00017511|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1495640|NCT00017511|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495641|NCT00017511|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1495642|NCT00017511|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1495643|NCT00017511|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1495644|NCT00017511|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495645|NCT00017511|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1495646|NCT00017511|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1495647|NCT00017511|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1495648|NCT00017511|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1495649|NCT00017511|radiation toxicity
1495650|NCT00017498|stage IV salivary gland cancer
1495651|NCT00017498|recurrent salivary gland cancer
1495652|NCT00017498|salivary gland adenoid cystic carcinoma
1495653|NCT00017498|stage IV adenoid cystic carcinoma of the oral cavity
1495654|NCT00017498|recurrent adenoid cystic carcinoma of the oral cavity
1495655|NCT00017485|basal cell carcinoma of the skin
1495656|NCT00017485|recurrent skin cancer
1495657|NCT00017459|recurrent non-small cell lung cancer
1495658|NCT00017459|stage IIIB non-small cell lung cancer
1495659|NCT00017459|stage IV non-small cell lung cancer
1495660|NCT00017446|stage III adult soft tissue sarcoma
1495661|NCT00017446|recurrent adult soft tissue sarcoma
1495790|NCT00017992|Pharmacokinetics
1495662|NCT00017446|stage IV adult soft tissue sarcoma
1495663|NCT00017433|refractory multiple myeloma
1495664|NCT00017433|stage II multiple myeloma
1495665|NCT00017433|stage III multiple myeloma
1495666|NCT00017407|recurrent non-small cell lung cancer
1495667|NCT00017407|stage IIIB non-small cell lung cancer
1495668|NCT00017407|stage IV non-small cell lung cancer
1495669|NCT00017368|regional neuroblastoma
1495670|NCT00017368|disseminated neuroblastoma
1495671|NCT00017368|localized unresectable neuroblastoma
1495672|NCT00017368|stage 4S neuroblastoma
1495673|NCT00017355|stage IV melanoma
1495674|NCT00017355|recurrent melanoma
1495675|NCT00018473|Risk Factors
1495676|NCT00018473|Genes
1495677|NCT00018473|Epidemiology
1495678|NCT00018473|Apolipoproteins E
1495679|NCT00018473|Alzheimer's Disease
1495680|NCT00018460|geriatrics
1495681|NCT00018460|vitamin B complex
1495682|NCT00018460|thrombomodulin
1495683|NCT00018460|anticoagulants
1495684|NCT00018447|osteoporosis
1495685|NCT00018434|Infection
1495686|NCT00018421|Cerebrovascular Disorders
1495687|NCT00018421|Exercise
1495688|NCT00018421|Rehabilitation
1495689|NCT00018408|COPD
1495690|NCT00018408|Smoking
1495691|NCT00018395|Calcium Metabolism
1495692|NCT00018369|Aging
1495693|NCT00018369|Hydrocortisone Corticotropin Feedback
1495694|NCT00018356|Aging
1495695|NCT00018356|nutrition
1495696|NCT00018356|rehabilitation
1495697|NCT00018304|blood pressure
1495698|NCT00018304|insulin sensitivity
1495699|NCT00018304|blood flow
1495700|NCT00018291|Dementia
1495701|NCT00018291|Agitated Behavior
1495702|NCT00018291|Behavioral disturbance
1495703|NCT00018265|Rehabilitation
1495704|NCT00018265|exercise test
1495705|NCT00018265|aging
1495706|NCT00018213|Naltrexone
1495707|NCT00018213|Nicotine patch
1495708|NCT00018213|Tobacco dependence
1495709|NCT00018200|analgesia
1495710|NCT00018200|Back pain
1495711|NCT00018200|sciatica
1495712|NCT00018187|smoking cessation
1495713|NCT00018187|bupropion
1495714|NCT00018187|mecamylamine
1495715|NCT00018187|nicotine
1495716|NCT00018174|Depression
1495717|NCT00018174|Fluoxetine
1495718|NCT00018174|Nicotine dependence
1495719|NCT00018161|Nicotine
1495720|NCT00018161|addiction
1495721|NCT00018161|cigarette smoking
1495722|NCT00018148|smoking cessation
1495723|NCT00018135|high iPTH levels
1495724|NCT00018122|Islet cell transplant
1495725|NCT00018096|Genetics
1495726|NCT00018096|Lipopolysaccharide
1495727|NCT00018070|Age-Related Macular Degeneration
1495728|NCT00018070|Choroid
1495729|NCT00018070|Blood Vessels
1495730|NCT00018070|Choroidal Neovascularization
1495731|NCT00018070|Laser
1495732|NCT00018070|Macular Degeneration
1495733|NCT00018070|AMD
1495734|NCT00018057|fMRI
1495735|NCT00018057|SSRI
1495736|NCT00018057|Neuropsychological
1495737|NCT00018057|Evaluative Learning
1495738|NCT00018057|Adolescent
1495739|NCT00018057|Normal Volunteers
1495740|NCT00018057|Magnetic Resonance Imaging
1495741|NCT00018057|CBT
1495742|NCT00018057|IPT
1495743|NCT00018057|Anxiety
1495744|NCT00018057|Anxiety Disorder
1495745|NCT00018057|Mood Disorder
1495746|NCT00018057|Depression
1495747|NCT00018057|Healthy Volunteer
1495748|NCT00018057|Normal Control
1495761|NCT00018031|Liver Disease
1495762|NCT00018031|Virologic Response
1495763|NCT00018031|Immune Mechanisms
1495764|NCT00018031|Cirrhosis
1495765|NCT00018031|Eradication
1495766|NCT00018031|HIV
1495767|NCT00018031|Hepatitis C
1495768|NCT00018018|Gene Therapy
1495769|NCT00018018|ADA-SCID
1495770|NCT00018018|Stem Cells
1495771|NCT00018018|Retroviruses
1495772|NCT00018018|Immune Deficiency Disease
1495773|NCT00018018|Adenosine Deaminase Deficiency
1495774|NCT00018018|ADA-Deficiency
1495775|NCT00018018|Retroviral Vectors
1495776|NCT00018018|Hematopoietic Progenitors
1495777|NCT00018018|Severe Combined Immunodeficiency
1495778|NCT00018018|SCID
1495782|NCT00018005|Behavioral Clinical Trial
1495783|NCT00017992|HIV-1
1495784|NCT00017992|Drug Administration Schedule
1495785|NCT00017992|Stavudine
1495786|NCT00017992|HIV Protease Inhibitors
1495787|NCT00017992|Ritonavir
1495788|NCT00017992|Reverse Transcriptase Inhibitors
1495791|NCT00017992|ABT 378
1495792|NCT00017992|emtricitabine
1495793|NCT00017979|Transcranial Magnetic Stimulation
1495794|NCT00017979|Motor Cortex
1495795|NCT00017979|Motor Imagery
1495796|NCT00017979|Reaction Time
1495797|NCT00017979|Cerebral Inhibition
1495798|NCT00017979|Healthy Volunteer
1495799|NCT00017979|Normal Control
1495800|NCT00017966|Transcranial Magnetic Stimulation
1495801|NCT00017966|Motor Cortex
1495802|NCT00017966|Cerebral Inhibition
1495803|NCT00017966|Corpus Callosum
1495804|NCT00017966|Evoked Potential
1495805|NCT00017966|Healthy Volunteer
1495806|NCT00017966|Normal Control
1495807|NCT00017953|Diabetes
1495808|NCT00017953|Weight loss
1495809|NCT00017953|Heart Attack
1495810|NCT00017953|Heart disease
1495811|NCT00017953|Lifestyle Intervention
1495812|NCT00017953|Physical Fitness/Physical Activity
1495813|NCT00017953|Psychosocial outcomes (e.g., depression, eating disorders)
1495814|NCT00017953|Bone Density
1495815|NCT00017940|Gene Therapy
1495816|NCT00017927|Acromegaly
1495817|NCT00017927|McCune-Albright Syndrome
1495818|NCT00017927|IGF-1
1495819|NCT00017927|Adenoma
1495820|NCT00017927|Hyperplasia
1495821|NCT00017927|MAS
1495822|NCT00017927|Polyostotic Fibrous Dysplasia
1495823|NCT00017927|PFD
1495824|NCT00017914|Adult and Pediatric Disease
1495825|NCT00017914|Idiopathic Inflammatory Myopathies
1495826|NCT00017914|Autoimmunity Pathogenesis
1495827|NCT00017914|Disease Assessment
1495828|NCT00017914|Genetic and Environmental Risk Factors
1495829|NCT00017914|Idiopathic Inflammatory Myopathy
1495830|NCT00017875|Transcranial Magnetic Stimulation
1495831|NCT00017875|Intracortical Inhibition
1495832|NCT00017875|Dystonia
1495833|NCT00017875|Focal Dystonia
1495834|NCT00017875|Dystonic Disorder
1495835|NCT00017875|DYTI Dystonia
1495836|NCT00017875|Movement Disorder
1495837|NCT00017875|Generalized Dystonia
1495838|NCT00017875|Healthy Control
1495839|NCT00017875|Normal Volunteer
1495840|NCT00017862|Eosinophils
1495841|NCT00017862|Monoclonal Antibody
1495842|NCT00017862|Hypereosinophilia
1495843|NCT00017862|Biologicals
1495844|NCT00017862|Hypereosinophilic Syndrome
1495845|NCT00017823|complementary therapies
1495846|NCT00017823|Acupressure
1495847|NCT00017823|HIV Infections
1495848|NCT00017823|Nausea
1495849|NCT00017823|Vomiting
1495850|NCT00017810|complementary therapies
1495851|NCT00017810|Behavior Therapy
1495852|NCT00017810|Diarrhea
1495853|NCT00017810|Diet Therapy
1495854|NCT00017810|Food
1495855|NCT00017810|HIV Seropositivity
1495856|NCT00017797|Pregnancy Complications, Infectious
1495857|NCT00017797|HIV-1
1495858|NCT00017797|HIV Protease Inhibitors
1495859|NCT00017797|Reverse Transcriptase Inhibitors
1495860|NCT00017797|Anti-HIV Agents
1495861|NCT00017797|Glucose Intolerance
1495862|NCT00017784|AIDS-Related Opportunistic Infections
1495863|NCT00017784|Infusions, Intravenous
1495864|NCT00017784|Antiviral Agents
1495865|NCT00017784|Cytomegalovirus Retinitis
1495866|NCT00017784|valganciclovir
1495867|NCT00017771|HIV-1
1495868|NCT00017771|CD4 Lymphocyte Count
1495869|NCT00017771|Risk Factors
1495870|NCT00017771|Hydroxyurea
1495871|NCT00017771|Disease Progression
1495872|NCT00017771|Alcohol Drinking
1495873|NCT00017771|Reverse Transcriptase Inhibitors
1495874|NCT00017771|Anti-HIV Agents
1495875|NCT00017771|Viral Load
1495876|NCT00017771|Polyneuropathies
1495877|NCT00017771|Treatment Experienced
1495878|NCT00017758|Drug Interactions
1495879|NCT00017758|Nelfinavir
1495880|NCT00017758|Reverse Transcriptase Inhibitors
1495881|NCT00017758|Anti-HIV Agents
1495882|NCT00017758|Pharmacokinetics
1495883|NCT00017758|Pravastatin
1495884|NCT00017758|efavirenz
1495885|NCT00017758|Simvastatin
1495886|NCT00017758|atorvastatin
1495887|NCT00017758|Hydroxymethylglutaryl-CoA Reductase Inhibitors
1495888|NCT00017745|DNA
1495889|NCT00017745|Hereditary Myopathies
1495890|NCT00017745|Intermediate Filaments
1495891|NCT00017745|Cardiomyopathies
1495892|NCT00017745|Genetic Testing
1495893|NCT00017745|Myopathy
1495894|NCT00017745|Inherited Neuromuscular Disorder
1495895|NCT00017732|Malformations
1495896|NCT00017732|Ethnicity
1495897|NCT00017732|Mutations
1495898|NCT00017732|Cholesterol
1495899|NCT00017732|Metabolism
1495900|NCT00017732|Smith-Lemli-Opitz Syndrome
1495901|NCT00017732|SLOS
1495902|NCT00017732|Cholesterol Metabolism
1495903|NCT00017719|Pregnancy Complications, Infectious
1495904|NCT00017719|HIV Protease Inhibitors
1495905|NCT00017719|Reverse Transcriptase Inhibitors
1495906|NCT00017719|Anti-HIV Agents
1495907|NCT00017719|Viral Load
1495908|NCT00017719|Combivir
1495909|NCT00017719|Treatment Naive
1495910|NCT00017706|physician education
1495911|NCT00017706|behavioral weight control
1495912|NCT00017706|physician intervention
1495913|NCT00017706|obesity counseling
1495914|NCT00017693|Recombinant Proteins
1495915|NCT00017693|Aerosols
1495916|NCT00017693|Asthma
1495917|NCT00017693|Receptors, Interleukin-4
1495918|NCT00017693|Forced Expiratory Volume
1495919|NCT00017680|amyloidosis
1495920|NCT00017680|arthritis & connective tissue diseases
1495921|NCT00017680|genetic diseases and dysmorphic syndromes
1495922|NCT00017680|hematopoietic/lymphoid cancer
1495923|NCT00017680|oncologic disorders
1495924|NCT00017680|plasma cell neoplasm
1495925|NCT00017680|primary systemic amyloidosis
1495926|NCT00017680|rare disease
1495927|NCT00017654|aplastic anemia
1495928|NCT00017654|disease-related problem/condition
1495929|NCT00017654|graft versus host disease
1495930|NCT00017654|hematologic disorders
1495931|NCT00017654|rare disease
1495932|NCT00017641|arthritis & connective tissue diseases
1495933|NCT00017641|immunologic disorders and infectious disorders
1495934|NCT00017641|rare disease
1495935|NCT00017641|systemic lupus erythematosus
1495936|NCT00017628|multiple sclerosis
1495937|NCT00017628|neurologic and psychiatric disorders
1495938|NCT00017628|rare disease
1495939|NCT00017602|refractory multiple myeloma
1495940|NCT00017602|stage I multiple myeloma
1495941|NCT00017602|stage II multiple myeloma
1495942|NCT00017602|stage III multiple myeloma
1495943|NCT00017589|recurrent adult acute myeloid leukemia
1495944|NCT00017576|adenocarcinoma of the prostate
1495945|NCT00017576|stage IV prostate cancer
1495946|NCT00017576|recurrent prostate cancer
1495947|NCT00017563|adenocarcinoma of the prostate
1495948|NCT00017563|stage II prostate cancer
1495949|NCT00017563|stage III prostate cancer
1495950|NCT00017342|recurrent adult acute myeloid leukemia
1495951|NCT00017342|adult acute myeloid leukemia with t(8;21)(q22;q22)
1495952|NCT00017342|adult acute myeloid leukemia with t(16;16)(p13;q22)
1495953|NCT00017342|adult acute myeloid leukemia with inv(16)(p13;q22)
1495954|NCT00017342|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1495955|NCT00017342|adult acute myeloid leukemia with t(15;17)(q22;q12)
1495956|NCT00017329|stage IV renal cell cancer
1495957|NCT00017316|stage IV melanoma
1495958|NCT00017316|recurrent melanoma
1495959|NCT00017303|stage III ovarian epithelial cancer
1495960|NCT00017303|ovarian undifferentiated adenocarcinoma
1495961|NCT00017303|ovarian mixed epithelial carcinoma
1495962|NCT00017303|ovarian serous cystadenocarcinoma
1495963|NCT00017303|ovarian mucinous cystadenocarcinoma
1495964|NCT00017303|ovarian endometrioid adenocarcinoma
1495965|NCT00017303|ovarian clear cell cystadenocarcinoma
1495966|NCT00017303|primary peritoneal cavity cancer
1495967|NCT00017303|Brenner tumor
1495968|NCT00017290|stage III grade 1 follicular lymphoma
1495969|NCT00017290|stage III grade 2 follicular lymphoma
1495970|NCT00017290|stage III grade 3 follicular lymphoma
1495971|NCT00017290|stage IV grade 1 follicular lymphoma
1495972|NCT00017290|stage IV grade 2 follicular lymphoma
1495973|NCT00017290|stage IV grade 3 follicular lymphoma
1495974|NCT00017277|stage I squamous cell carcinoma of the lip and oral cavity
1495975|NCT00017277|stage II squamous cell carcinoma of the lip and oral cavity
1495976|NCT00017277|stage III squamous cell carcinoma of the lip and oral cavity
1495977|NCT00017277|stage IV squamous cell carcinoma of the lip and oral cavity
1495978|NCT00017277|stage I squamous cell carcinoma of the oropharynx
1495979|NCT00017277|stage II squamous cell carcinoma of the oropharynx
1495980|NCT00017277|stage III squamous cell carcinoma of the oropharynx
1495981|NCT00017277|stage IV squamous cell carcinoma of the oropharynx
1495982|NCT00017277|stage I squamous cell carcinoma of the hypopharynx
1495983|NCT00017277|stage II squamous cell carcinoma of the hypopharynx
1495984|NCT00017277|stage III squamous cell carcinoma of the hypopharynx
1495985|NCT00017277|stage IV squamous cell carcinoma of the hypopharynx
1495986|NCT00017277|stage I squamous cell carcinoma of the larynx
1495987|NCT00017277|stage II squamous cell carcinoma of the larynx
1495988|NCT00017277|stage III squamous cell carcinoma of the larynx
1495989|NCT00017277|stage IV squamous cell carcinoma of the larynx
1495990|NCT00017264|recurrent adult brain tumor
1495991|NCT00017264|adult glioblastoma
1495992|NCT00017264|adult anaplastic astrocytoma
1495993|NCT00017264|adult anaplastic oligodendroglioma
1495994|NCT00017264|adult giant cell glioblastoma
1495995|NCT00017264|adult gliosarcoma
1495996|NCT00017225|localized resectable neuroblastoma
1495997|NCT00017225|regional neuroblastoma
1495998|NCT00017225|disseminated neuroblastoma
1495999|NCT00017225|stage 4S neuroblastoma
1496000|NCT00017225|recurrent neuroblastoma
1496001|NCT00017225|localized unresectable neuroblastoma
1496002|NCT00017212|stage III gastric cancer
1496003|NCT00017212|stage IV gastric cancer
1496004|NCT00017212|recurrent gastric cancer
1496005|NCT00017212|stage III esophageal cancer
1496006|NCT00017212|stage IV esophageal cancer
1496007|NCT00017212|recurrent esophageal cancer
1496008|NCT00017212|adenocarcinoma of the stomach
1496009|NCT00017212|adenocarcinoma of the esophagus
1496010|NCT00017199|metastatic gastrointestinal carcinoid tumor
1496011|NCT00017199|gastrinoma
1496012|NCT00017199|insulinoma
1496013|NCT00017199|somatostatinoma
1496014|NCT00017199|glucagonoma
1496122|NCT00016783|Anti-HIV Agents
1496015|NCT00017186|localized malignant mesothelioma
1496016|NCT00017186|advanced malignant mesothelioma
1496017|NCT00017186|recurrent malignant mesothelioma
1496018|NCT00017173|stage III squamous cell carcinoma of the lip and oral cavity
1496019|NCT00017173|stage IV squamous cell carcinoma of the lip and oral cavity
1496020|NCT00017173|stage III squamous cell carcinoma of the oropharynx
1496021|NCT00017173|stage IV squamous cell carcinoma of the oropharynx
1496022|NCT00017173|stage III squamous cell carcinoma of the hypopharynx
1496023|NCT00017173|stage III squamous cell carcinoma of the larynx
1496024|NCT00017173|stage IV squamous cell carcinoma of the hypopharynx
1496025|NCT00017173|stage IV verrucous carcinoma of the larynx
1496026|NCT00017147|adult glioblastoma
1496027|NCT00017147|adult giant cell glioblastoma
1496028|NCT00017147|adult gliosarcoma
1496029|NCT00017134|ovarian epithelial cancer
1496030|NCT00017121|stage IV melanoma
1496031|NCT00017121|recurrent melanoma
1496032|NCT00017121|lung metastases
1496033|NCT00017108|stage III chronic lymphocytic leukemia
1496034|NCT00017108|stage IV chronic lymphocytic leukemia
1496035|NCT00017108|B-cell chronic lymphocytic leukemia
1496036|NCT00017095|stage II breast cancer
1496037|NCT00017095|stage IIIA breast cancer
1496038|NCT00017095|stage IIIB breast cancer
1496039|NCT00017095|stage IIIC breast cancer
1496040|NCT00017095|inflammatory breast cancer
1496041|NCT00017082|stage IV colon cancer
1496042|NCT00017082|stage IV rectal cancer
1496043|NCT00017082|recurrent colon cancer
1496044|NCT00017082|recurrent rectal cancer
1496045|NCT00017082|adenocarcinoma of the colon
1496046|NCT00017082|adenocarcinoma of the rectum
1496047|NCT00017069|refractory multiple myeloma
1496048|NCT00017069|stage II multiple myeloma
1496049|NCT00017069|stage III multiple myeloma
1496050|NCT00017056|stage IV gastric cancer
1496051|NCT00017056|recurrent gastric cancer
1496052|NCT00017056|stage IV esophageal cancer
1496053|NCT00017056|recurrent esophageal cancer
1496054|NCT00017056|adenocarcinoma of the stomach
1496055|NCT00017056|adenocarcinoma of the esophagus
1496056|NCT00017043|stage IV gastric cancer
1496057|NCT00017043|recurrent gastric cancer
1496058|NCT00017043|stage IV esophageal cancer
1496059|NCT00017043|recurrent esophageal cancer
1496060|NCT00017043|adenocarcinoma of the stomach
1496061|NCT00017043|adenocarcinoma of the esophagus
1496062|NCT00017030|stage III adult soft tissue sarcoma
1496063|NCT00017030|recurrent adult soft tissue sarcoma
1496064|NCT00017030|stage IV adult soft tissue sarcoma
1496065|NCT00017017|recurrent ovarian epithelial cancer
1496066|NCT00017017|fallopian tube cancer
1496067|NCT00017017|primary peritoneal cavity cancer
1496068|NCT00016991|recurrent adult brain tumor
1496069|NCT00016991|adult glioblastoma
1496070|NCT00016991|adult giant cell glioblastoma
1496071|NCT00016991|adult gliosarcoma
1496072|NCT00016978|stage IV colon cancer
1496073|NCT00016978|stage IV rectal cancer
1496074|NCT00016978|recurrent colon cancer
1496075|NCT00016978|recurrent rectal cancer
1496076|NCT00016978|adenocarcinoma of the colon
1496077|NCT00016978|adenocarcinoma of the rectum
1496078|NCT00016965|stage II pancreatic cancer
1496079|NCT00016965|stage III pancreatic cancer
1496080|NCT00016965|recurrent pancreatic cancer
1496081|NCT00016965|adenocarcinoma of the pancreas
1496082|NCT00016965|stage IV pancreatic cancer
1496083|NCT00016952|stage IV colon cancer
1496084|NCT00016952|stage IV rectal cancer
1496085|NCT00016952|recurrent colon cancer
1496086|NCT00016952|recurrent rectal cancer
1496087|NCT00016952|adenocarcinoma of the colon
1496088|NCT00016952|adenocarcinoma of the rectum
1496089|NCT00016939|stage III renal cell cancer
1496090|NCT00016939|stage IV renal cell cancer
1496091|NCT00016939|recurrent renal cell cancer
1496092|NCT00016926|stage III cervical cancer
1496093|NCT00016926|recurrent cervical cancer
1496094|NCT00016926|stage IVB cervical cancer
1496095|NCT00016926|stage IVA cervical cancer
1496096|NCT00016926|cervical squamous cell carcinoma
1496097|NCT00016913|adenocarcinoma of the prostate
1496098|NCT00016913|stage III prostate cancer
1496099|NCT00016900|stage III esophageal cancer
1496100|NCT00016900|stage IV esophageal cancer
1496101|NCT00016900|recurrent esophageal cancer
1496102|NCT00016900|squamous cell carcinoma of the esophagus
1496103|NCT00016900|adenocarcinoma of the esophagus
1496104|NCT00016887|stage III mantle cell lymphoma
1496105|NCT00016887|stage IV mantle cell lymphoma
1496106|NCT00016874|unspecified adult solid tumor, protocol specific
1496107|NCT00016861|unspecified childhood solid tumor, protocol specific
1496108|NCT00016848|Obesity
1496109|NCT00016848|Endocrine
1496110|NCT00016848|Diet
1496111|NCT00016848|Metabolism
1496112|NCT00016848|Macronutrients
1496113|NCT00016835|Type 2 diabetes mellitus
1496114|NCT00016796|Reading
1496115|NCT00016796|Naming
1496116|NCT00016783|Drug Therapy, Combination
1496117|NCT00016783|Drug Administration Schedule
1496118|NCT00016783|HIV Protease Inhibitors
1496119|NCT00016783|CD4 Lymphocyte Count
1496120|NCT00016783|CD8-Positive T-Lymphocytes
1496121|NCT00016783|Reverse Transcriptase Inhibitors
1496123|NCT00016783|Viral Load
1496124|NCT00016783|Antiretroviral Therapy, Highly Active
1496125|NCT00016783|Treatment Experienced
1496126|NCT00016783|Treatment Interruption
1496127|NCT00016731|Depression
1496128|NCT00016731|Anxiety
1496129|NCT00016731|CAH
1496130|NCT00016731|Adults
1496131|NCT00016731|FMPP
1496132|NCT00016731|Emotion
1496133|NCT00016731|Cushing's Syndrome
1496134|NCT00016731|Adolescence
1496135|NCT00016731|Magnetic Resonance Imaging
1496136|NCT00016731|fMRI
1496137|NCT00016731|Healthy Volunteer
1496138|NCT00016731|HV
1496139|NCT00016731|MRI
1496140|NCT00016718|Didanosine
1496141|NCT00016718|Drug Therapy, Combination
1496142|NCT00016718|Drug Administration Schedule
1496143|NCT00016718|Reverse Transcriptase Inhibitors
1496144|NCT00016718|Anti-HIV Agents
1496145|NCT00016718|Pharmacokinetics
1496146|NCT00016718|Deoxycytidine
1496147|NCT00016718|Efavirenz
1496148|NCT00016718|Treatment Naive
1496149|NCT00016692|Drug tolerance
1496150|NCT00016692|Acute Infection
1496151|NCT00016679|Pharmacokinetics
1496152|NCT00016679|Metabolism
1496153|NCT00016679|Toxicity
1496154|NCT00016679|Side Effects
1496155|NCT00016679|Essential Tremor
1496156|NCT00016679|Tremor
1496157|NCT00016679|Movement Disorder
1496158|NCT00016666|Season
1496159|NCT00016666|Light
1496160|NCT00016666|Propranolol
1496161|NCT00016666|Photoperiod
1496162|NCT00016666|Pharmacokinetics
1496163|NCT00016666|Circadian Rhythm
1496164|NCT00016666|Seasonal Rhythm
1496165|NCT00016666|Seasonal Affective Disorder
1496166|NCT00016666|Pineal Gland
1496167|NCT00016666|Suprachiasmatic Nucleus
1496168|NCT00016666|Healthy Volunteer
1496169|NCT00016666|HV
1496170|NCT00016666|Winter Depression
1496171|NCT00016666|SAD
1496172|NCT00016653|Duchenne
1496173|NCT00016653|muscular
1496174|NCT00016653|dystrophy
1496175|NCT00016653|treatment
1496176|NCT00016601|Delayed-Action Preparations
1496177|NCT00016601|Drug Interactions
1496178|NCT00016601|Drug Therapy, Combination
1496179|NCT00016601|Nevirapine
1496180|NCT00016601|HIV Protease Inhibitors
1496181|NCT00016601|Ritonavir
1496182|NCT00016601|Indinavir
1496183|NCT00016601|Nelfinavir
1496184|NCT00016601|Reverse Transcriptase Inhibitors
1496185|NCT00016601|Anti-HIV Agents
1496186|NCT00016601|Pharmacokinetics
1496187|NCT00016601|Medroxyprogesterone 17-Acetate
1496188|NCT00016601|efavirenz
1496189|NCT00016588|HIV-1
1496190|NCT00016588|Adenine
1496191|NCT00016588|Anti-HIV Agents
1496192|NCT00016588|Viral Load
1496193|NCT00016588|Organophosphorus Compounds
1496194|NCT00016562|Genetic
1496195|NCT00016562|Degenerative
1496196|NCT00016562|Lysosomal
1496197|NCT00016562|Brain
1496198|NCT00016562|Mental Retardation
1496199|NCT00016562|Neurodegenerative Disorder
1496200|NCT00016562|Neurometabolic
1496201|NCT00016562|Metabolic Neurological Disorder
1496202|NCT00016562|Abnormal Metabolism
1496203|NCT00016549|Endothelial Proliferation
1496204|NCT00016549|Endothelial Apoptosis
1496205|NCT00016549|VEGF
1496206|NCT00016549|Magnetic Resonance Imaging
1496207|NCT00016549|Molecular Targets
1496208|NCT00016549|Breast Cancer
1496209|NCT00016549|Inflammatory Breast Cancer
1496210|NCT00016549|IBC
1496211|NCT00016536|Antiviral Agents
1496212|NCT00016536|Mucous Membrane
1496213|NCT00016536|Spermatocidal Agents
1496214|NCT00016536|Penis
1496215|NCT00016536|Epithelium
1496216|NCT00016536|PRO 2000
1496217|NCT00016536|Urethra
1496218|NCT00016536|HIV Seronegativity
1496219|NCT00016523|NICHD Neonatal Research Network
1496220|NCT00016523|Extremely Low Birth Weight (ELBW)
1496221|NCT00016523|Very Low Birth Weight (VLBW)
1496222|NCT00016523|Prematurity
1496223|NCT00016523|Inhaled nitric oxide
1496224|NCT00016523|Aspiration syndrome
1496225|NCT00016523|Idiopathic pulmonary hypertension
1496226|NCT00016523|Pulmonary hypoplasia
1496227|NCT00016510|Bilingualism
1496228|NCT00016510|Fluency
1496229|NCT00016510|Age at Acquisition
1496230|NCT00016510|Words and Sentences
1496231|NCT00016510|Cortical Area
1496232|NCT00016510|Healthy Volunteer
1496233|NCT00016510|HV
1496234|NCT00016510|Bilingual
1496235|NCT00016510|Second Language
1496236|NCT00016497|otitis media with effusion
1496237|NCT00016497|children
1496238|NCT00016497|tympanostomy tubes
1496239|NCT00016497|adenoidectomy
1496240|NCT00016458|arthritis & connective tissue diseases
1496241|NCT00016458|rare disease
1496242|NCT00016458|systemic sclerosis
1496243|NCT00016445|cardiovascular and respiratory diseases
1496244|NCT00016445|cystic fibrosis
1496245|NCT00016445|disease-related problem/condition
1496246|NCT00016445|genetic diseases and dysmorphic syndromes
1496247|NCT00016445|quality of life
1496248|NCT00016445|rare disease
1496249|NCT00016432|stage I breast cancer
1496250|NCT00016432|stage II breast cancer
1496251|NCT00016432|stage IIIA breast cancer
1496252|NCT00016419|refractory anemia
1496253|NCT00016419|refractory anemia with ringed sideroblasts
1496254|NCT00016419|refractory anemia with excess blasts
1496255|NCT00016419|de novo myelodysplastic syndromes
1496256|NCT00016419|secondary myelodysplastic syndromes
1496257|NCT00016419|childhood myelodysplastic syndromes
1496258|NCT00016406|stage II breast cancer
1496259|NCT00016406|stage IIIA breast cancer
1496260|NCT00016406|stage IIIB breast cancer
1496261|NCT00016406|stage IIIC breast cancer
1496262|NCT00016406|inflammatory breast cancer
1496263|NCT00016393|adenocarcinoma of the prostate
1496264|NCT00016393|stage IV prostate cancer
1496265|NCT00016393|recurrent prostate cancer
1496266|NCT00016380|nausea and vomiting
1496267|NCT00016380|stage I colon cancer
1496268|NCT00016380|stage II colon cancer
1496269|NCT00016380|stage III colon cancer
1496270|NCT00016380|stage IV colon cancer
1496271|NCT00016380|stage I gastric cancer
1496272|NCT00016380|stage II gastric cancer
1496273|NCT00016380|stage III gastric cancer
1496274|NCT00016380|stage IV gastric cancer
1496275|NCT00016380|recurrent gastric cancer
1496276|NCT00016380|stage I pancreatic cancer
1496277|NCT00016380|stage II pancreatic cancer
1496278|NCT00016380|stage III pancreatic cancer
1496279|NCT00016380|recurrent pancreatic cancer
1496280|NCT00016380|recurrent colon cancer
1496281|NCT00016380|recurrent cervical cancer
1496282|NCT00016380|stage IB cervical cancer
1496283|NCT00016380|stage IIB cervical cancer
1496284|NCT00016380|stage IVB cervical cancer
1496285|NCT00016380|stage IA cervical cancer
1496286|NCT00016380|stage IIA cervical cancer
1496287|NCT00016380|stage IVA cervical cancer
1496288|NCT00016380|stage I ovarian epithelial cancer
1496289|NCT00016380|stage II ovarian epithelial cancer
1496290|NCT00016380|stage III ovarian epithelial cancer
1496291|NCT00016380|stage IV ovarian epithelial cancer
1496292|NCT00016380|recurrent ovarian epithelial cancer
1496293|NCT00016380|localized gastrointestinal carcinoid tumor
1496294|NCT00016380|regional gastrointestinal carcinoid tumor
1496295|NCT00016380|metastatic gastrointestinal carcinoid tumor
1496296|NCT00016380|recurrent gastrointestinal carcinoid tumor
1496297|NCT00016380|localized resectable adult primary liver cancer
1496298|NCT00016380|localized unresectable adult primary liver cancer
1496299|NCT00016380|advanced adult primary liver cancer
1496300|NCT00016380|recurrent adult primary liver cancer
1496301|NCT00016380|small intestine adenocarcinoma
1496302|NCT00016380|small intestine lymphoma
1496303|NCT00016380|small intestine leiomyosarcoma
1496304|NCT00016380|localized gallbladder cancer
1496305|NCT00016380|unresectable gallbladder cancer
1496306|NCT00016380|recurrent gallbladder cancer
1496307|NCT00016380|localized extrahepatic bile duct cancer
1496308|NCT00016380|unresectable extrahepatic bile duct cancer
1496309|NCT00016380|recurrent extrahepatic bile duct cancer
1496310|NCT00016380|recurrent small intestine cancer
1496311|NCT00016380|testicular seminoma
1496312|NCT00016380|carcinoma of the appendix
1496313|NCT00016380|quality of life
1496314|NCT00016380|stage IV pancreatic cancer
1496315|NCT00016367|stage IIIB non-small cell lung cancer
1496316|NCT00016367|stage IV non-small cell lung cancer
1496317|NCT00016354|unspecified adult solid tumor, protocol specific
1496318|NCT00016341|stage III endometrial carcinoma
1496319|NCT00016341|stage IV endometrial carcinoma
1496320|NCT00016341|recurrent endometrial carcinoma
1496321|NCT00016315|stage IIIA non-small cell lung cancer
1496322|NCT00016315|stage IIIB non-small cell lung cancer
1496323|NCT00016263|stage III melanoma
1496324|NCT00016263|stage IV melanoma
1496325|NCT00016263|recurrent melanoma
1496326|NCT00016250|stage IV colon cancer
1496327|NCT00016250|stage IV rectal cancer
1496328|NCT00016250|recurrent colon cancer
1496329|NCT00016250|recurrent rectal cancer
1496330|NCT00016250|adenocarcinoma of the colon
1496331|NCT00016250|adenocarcinoma of the rectum
1496332|NCT00016237|recurrent non-small cell lung cancer
1496333|NCT00016237|squamous cell lung cancer
1496334|NCT00016237|stage IV renal cell cancer
1496335|NCT00016237|recurrent renal cell cancer
1496336|NCT00016237|extensive stage small cell lung cancer
1496337|NCT00016237|recurrent small cell lung cancer
1496338|NCT00016237|recurrent bladder cancer
1496339|NCT00016237|stage IV bladder cancer
1496340|NCT00016237|stage IV non-small cell lung cancer
1496341|NCT00016237|transitional cell carcinoma of the bladder
1496342|NCT00016237|squamous cell carcinoma of the bladder
1496343|NCT00016224|recurrent ovarian epithelial cancer
1496344|NCT00016211|extensive stage small cell lung cancer
1496345|NCT00016198|stage IV colon cancer
1496346|NCT00016198|stage IV rectal cancer
1496347|NCT00016198|recurrent colon cancer
1496348|NCT00016198|recurrent rectal cancer
1496349|NCT00016198|adenocarcinoma of the colon
1496350|NCT00016198|adenocarcinoma of the rectum
1496351|NCT00016185|unspecified adult solid tumor, protocol specific
1496352|NCT00016172|stage III adult Hodgkin lymphoma
1496353|NCT00016172|stage IV adult Hodgkin lymphoma
1496354|NCT00016172|recurrent adult Hodgkin lymphoma
1496355|NCT00016172|stage III cutaneous T-cell non-Hodgkin lymphoma
1496356|NCT00016172|stage IV cutaneous T-cell non-Hodgkin lymphoma
1496357|NCT00016172|recurrent cutaneous T-cell non-Hodgkin lymphoma
1496358|NCT00016172|small intestine lymphoma
1496359|NCT00016172|unspecified adult solid tumor, protocol specific
1496360|NCT00016172|stage III grade 1 follicular lymphoma
1496361|NCT00016172|stage III grade 2 follicular lymphoma
1496362|NCT00016172|stage III grade 3 follicular lymphoma
1496363|NCT00016172|stage III adult diffuse small cleaved cell lymphoma
1496364|NCT00016172|stage III adult diffuse mixed cell lymphoma
1496365|NCT00016172|stage III adult diffuse large cell lymphoma
1496366|NCT00016172|stage III adult immunoblastic large cell lymphoma
1496367|NCT00016172|stage III adult lymphoblastic lymphoma
1496368|NCT00016172|stage III adult Burkitt lymphoma
1496369|NCT00016172|stage IV grade 1 follicular lymphoma
1496370|NCT00016172|stage IV grade 2 follicular lymphoma
1496371|NCT00016172|stage IV grade 3 follicular lymphoma
1496372|NCT00016172|stage IV adult diffuse small cleaved cell lymphoma
1496373|NCT00016172|stage IV adult diffuse mixed cell lymphoma
1496374|NCT00016172|stage IV adult diffuse large cell lymphoma
1496375|NCT00016172|stage IV adult immunoblastic large cell lymphoma
1496376|NCT00016172|stage IV adult lymphoblastic lymphoma
1496377|NCT00016172|stage IV adult Burkitt lymphoma
1496378|NCT00016172|recurrent grade 1 follicular lymphoma
1496379|NCT00016172|recurrent grade 2 follicular lymphoma
1496380|NCT00016172|recurrent grade 3 follicular lymphoma
1496381|NCT00016172|recurrent adult diffuse small cleaved cell lymphoma
1496382|NCT00016172|recurrent adult diffuse mixed cell lymphoma
1496383|NCT00016172|recurrent adult diffuse large cell lymphoma
1496384|NCT00016172|recurrent adult immunoblastic large cell lymphoma
1496385|NCT00016172|recurrent adult lymphoblastic lymphoma
1496386|NCT00016172|recurrent adult Burkitt lymphoma
1496387|NCT00016172|stage III adult T-cell leukemia/lymphoma
1496388|NCT00016172|stage IV adult T-cell leukemia/lymphoma
1496389|NCT00016172|recurrent adult T-cell leukemia/lymphoma
1496390|NCT00016172|primary central nervous system non-Hodgkin lymphoma
1496391|NCT00016172|AIDS-related peripheral/systemic lymphoma
1496392|NCT00016172|AIDS-related primary CNS lymphoma
1496393|NCT00016172|intraocular lymphoma
1496394|NCT00016172|stage III mantle cell lymphoma
1496395|NCT00016172|stage IV mantle cell lymphoma
1496396|NCT00016172|recurrent mantle cell lymphoma
1496397|NCT00016172|angioimmunoblastic T-cell lymphoma
1496398|NCT00016172|anaplastic large cell lymphoma
1496399|NCT00016172|stage III mycosis fungoides/Sezary syndrome
1496400|NCT00016172|stage IV mycosis fungoides/Sezary syndrome
1496401|NCT00016172|recurrent mycosis fungoides/Sezary syndrome
1496402|NCT00016172|recurrent marginal zone lymphoma
1496403|NCT00016172|recurrent small lymphocytic lymphoma
1496404|NCT00016172|stage III small lymphocytic lymphoma
1496405|NCT00016172|stage III marginal zone lymphoma
1496406|NCT00016172|stage IV small lymphocytic lymphoma
1496407|NCT00016172|stage IV marginal zone lymphoma
1496408|NCT00016172|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1496409|NCT00016172|nodal marginal zone B-cell lymphoma
1496410|NCT00016172|splenic marginal zone lymphoma
1496411|NCT00016159|adult acute myeloid leukemia in remission
1496412|NCT00016159|childhood acute myeloid leukemia in remission
1496413|NCT00016159|adult acute promyelocytic leukemia (M3)
1496414|NCT00016159|childhood acute promyelocytic leukemia (M3)
1496415|NCT00016159|adult acute myeloid leukemia with t(15;17)(q22;q12)
1496416|NCT00016146|recurrent prostate cancer
1496417|NCT00016133|stage II colon cancer
1496418|NCT00016133|stage III colon cancer
1496419|NCT00016133|adenocarcinoma of the colon
1496420|NCT00016081|infection
1496421|NCT00016068|infection
1496422|NCT00016055|stage IV melanoma
1496423|NCT00016055|recurrent melanoma
1496424|NCT00016042|stage IV colon cancer
1496425|NCT00016042|stage IV rectal cancer
1496426|NCT00016042|recurrent colon cancer
1496427|NCT00016042|recurrent rectal cancer
1496428|NCT00016042|stage IV renal cell cancer
1496429|NCT00016042|recurrent renal cell cancer
1496430|NCT00016029|colon cancer
1496431|NCT00016029|rectal cancer
1496432|NCT00015977|adenocarcinoma of the prostate
1496433|NCT00015977|stage IV prostate cancer
1496434|NCT00015977|recurrent prostate cancer
1496435|NCT00015964|recurrent metastatic squamous neck cancer with occult primary
1496436|NCT00015964|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1496437|NCT00015964|stage IV squamous cell carcinoma of the lip and oral cavity
1496438|NCT00015964|recurrent squamous cell carcinoma of the lip and oral cavity
1496439|NCT00015964|stage IV squamous cell carcinoma of the oropharynx
1496440|NCT00015964|recurrent squamous cell carcinoma of the oropharynx
1496441|NCT00015964|stage IV squamous cell carcinoma of the nasopharynx
1496442|NCT00015964|recurrent squamous cell carcinoma of the nasopharynx
1496443|NCT00015964|stage IV squamous cell carcinoma of the hypopharynx
1496444|NCT00015964|recurrent squamous cell carcinoma of the hypopharynx
1496445|NCT00015964|stage IV squamous cell carcinoma of the larynx
1496446|NCT00015964|recurrent squamous cell carcinoma of the larynx
1496447|NCT00015964|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1496448|NCT00015964|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1496449|NCT00015951|recurrent adult acute myeloid leukemia
1496450|NCT00015951|relapsing chronic myelogenous leukemia
1496451|NCT00015951|blastic phase chronic myelogenous leukemia
1496452|NCT00015951|refractory anemia with excess blasts
1496453|NCT00015951|refractory anemia with excess blasts in transformation
1496454|NCT00015951|chronic myelomonocytic leukemia
1496455|NCT00015951|secondary acute myeloid leukemia
1496456|NCT00015951|previously treated myelodysplastic syndromes
1496457|NCT00015951|childhood myelodysplastic syndromes
1496458|NCT00015938|stage IV breast cancer
1496459|NCT00015938|recurrent breast cancer
1496460|NCT00015925|refractory multiple myeloma
1496461|NCT00015925|recurrent adult acute myeloid leukemia
1496462|NCT00015925|recurrent adult acute lymphoblastic leukemia
1496463|NCT00015925|relapsing chronic myelogenous leukemia
1496464|NCT00015925|chronic phase chronic myelogenous leukemia
1496465|NCT00015925|accelerated phase chronic myelogenous leukemia
1496466|NCT00015925|blastic phase chronic myelogenous leukemia
1496467|NCT00015925|untreated adult acute lymphoblastic leukemia
1496468|NCT00015925|untreated adult acute myeloid leukemia
1496469|NCT00015925|adult acute promyelocytic leukemia (M3)
1496470|NCT00015925|refractory anemia with excess blasts
1496471|NCT00015925|refractory anemia with excess blasts in transformation
1496472|NCT00015925|chronic myelomonocytic leukemia
1496473|NCT00015925|secondary acute myeloid leukemia
1496474|NCT00015925|de novo myelodysplastic syndromes
1496475|NCT00015925|previously treated myelodysplastic syndromes
1496476|NCT00015925|atypical chronic myeloid leukemia
1496477|NCT00015925|myelodysplastic/myeloproliferative disease, unclassifiable
1496478|NCT00015925|adult acute myeloid leukemia with t(8;21)(q22;q22)
1496479|NCT00015925|adult acute myeloid leukemia with t(16;16)(p13;q22)
1496480|NCT00015925|adult acute myeloid leukemia with inv(16)(p13;q22)
1496481|NCT00015925|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1496482|NCT00015925|adult acute myeloid leukemia with t(15;17)(q22;q12)
1496483|NCT00015899|childhood craniopharyngioma
1496484|NCT00015899|childhood central nervous system germ cell tumor
1496485|NCT00015899|childhood oligodendroglioma
1496486|NCT00015899|childhood choroid plexus tumor
1496487|NCT00015899|childhood grade I meningioma
1496488|NCT00015899|childhood grade II meningioma
1496489|NCT00015899|childhood grade III meningioma
1496490|NCT00015899|recurrent childhood cerebellar astrocytoma
1496491|NCT00015899|recurrent childhood cerebral astrocytoma
1496492|NCT00015899|recurrent childhood medulloblastoma
1496493|NCT00015899|recurrent childhood visual pathway and hypothalamic glioma
1496494|NCT00015899|recurrent childhood ependymoma
1496495|NCT00015899|childhood atypical teratoid/rhabdoid tumor
1496496|NCT00015899|childhood spinal cord neoplasm
1496497|NCT00015886|stage IV breast cancer
1496498|NCT00015886|recurrent breast cancer
1496499|NCT00015886|stage IIIB breast cancer
1496500|NCT00015873|untreated childhood acute lymphoblastic leukemia
1496501|NCT00015860|recurrent adult acute lymphoblastic leukemia
1496502|NCT00015860|relapsing chronic myelogenous leukemia
1496503|NCT00015860|blastic phase chronic myelogenous leukemia
1496504|NCT00015847|relapsing chronic myelogenous leukemia
1496505|NCT00015847|chronic phase chronic myelogenous leukemia
1496506|NCT00015847|Philadelphia chromosome positive chronic myelogenous leukemia
1496507|NCT00015808|Neurodegeneration
1496508|NCT00015808|Anti-Oxidant
1496509|NCT00015808|Neuropathy
1496510|NCT00015808|Hereditary
1496511|NCT00015808|Spinocerebellar
1496512|NCT00015808|Friedreich's Ataxia
1496513|NCT00015808|Friedreich Ataxia
1496514|NCT00015808|FRDA
1496515|NCT00015795|Pressure
1496516|NCT00015795|Botulinum Toxin
1496517|NCT00015795|Voice
1496518|NCT00015795|Dystonia
1496519|NCT00015795|Pathophysiology
1496520|NCT00015795|Healthy Volunteer
1496521|NCT00015795|HV
1496522|NCT00015795|ABSD
1496523|NCT00015795|Spasmodic Dysphonia
1496524|NCT00015795|Abductor Spasmodic Dysphonia
1496525|NCT00015782|Metabolic
1496526|NCT00015782|Genetic
1496527|NCT00015782|Storage
1496528|NCT00015782|Retinal Disease
1496529|NCT00015782|Degenerative
1496530|NCT00015782|Mucolipidosis Type IV
1496531|NCT00015782|ML-IV
1496532|NCT00015769|Mania
1496533|NCT00015769|Depression
1496534|NCT00015769|Anticonvulsants
1496535|NCT00015769|Mood Stabilizers
1496536|NCT00015769|Bipolar
1496537|NCT00015769|Mood Stabilizer
1496538|NCT00015756|Apheresis
1496539|NCT00015756|Transplantation
1496540|NCT00015756|Type III Secretion Pathway
1496541|NCT00015756|Exotoxins
1496542|NCT00015756|Pseudomonas Aeruginosa
1496543|NCT00015756|Cystic Fibrosis
1496544|NCT00015756|CF
1496545|NCT00015717|Imaging
1496546|NCT00015717|Complications
1496547|NCT00015717|Stenosis
1496548|NCT00015717|Treatment
1496549|NCT00015717|Strokes
1496550|NCT00015717|Cerebral Ischemia
1496551|NCT00015717|Cranial Cervical Angioplasty
1496552|NCT00015704|Treatment Experienced
1496553|NCT00015704|Treatment Interruption
1496554|NCT00015704|Drug Administration Schedule
1496555|NCT00015704|CD4 Lymphocyte Count
1496556|NCT00015704|Anti-HIV Agents
1496557|NCT00015704|Tetanus Toxoid
1496558|NCT00015704|Aldesleukin
1496559|NCT00015704|Diphtheria Toxoid
1496560|NCT00015691|Drug Therapy, Combination
1496561|NCT00015691|Adipose Tissue
1496562|NCT00015691|Area Under Curve
1496563|NCT00015691|Hypoglycemic Agents
1496564|NCT00015691|Anthropometry
1496565|NCT00015691|Hyperinsulinemia
1496566|NCT00015691|Metformin
1496567|NCT00015691|BRL 49653
1496568|NCT00015691|Insulin
1496569|NCT00015691|Glucose Tolerance Test
1496570|NCT00015678|Motor Cortex
1496571|NCT00015678|Drug
1496572|NCT00015678|GABA
1496573|NCT00015678|Cortical Modulation
1496574|NCT00015678|Magnetic Stimulation
1496575|NCT00015678|Healthy Volunteer
1496576|NCT00015665|Fungal
1496577|NCT00015665|Immunodeficiency
1496578|NCT00015665|Infection
1496579|NCT00015665|Refractory
1496580|NCT00015665|Severe
1496581|NCT00015665|Fungal Infections
1496582|NCT00015652|Ribavirin
1496583|NCT00015652|Polyethylene Glycols
1496584|NCT00015652|Interferon Alfa-2b
1496585|NCT00015652|Dose-Response Relationship, Drug
1496586|NCT00015652|Drug Therapy, Combination
1496587|NCT00015652|Antiviral Agents
1496588|NCT00015652|Hepatitis C
1496589|NCT00015652|Aldesleukin
1496590|NCT00015652|Peginterferon
1496591|NCT00015639|Blood Donors
1496592|NCT00015639|Employees
1496593|NCT00015639|Heparin
1496594|NCT00015639|Histidine-Rich Glycoprotein
1496595|NCT00015639|Membrane
1496596|NCT00015639|Healthy Volunteer
1496597|NCT00015613|Hispanics
1496598|NCT00015613|Acculturation
1496599|NCT00015613|Maternal Exposure
1496600|NCT00015613|Infant, Low Birth Weight
1496601|NCT00015613|Infant, Premature
1496602|NCT00015613|Organophosphates
1496603|NCT00015613|Pesticides
1496604|NCT00015613|Stress
1496605|NCT00015613|Nutrition
1496606|NCT00015600|Pesticide
1496607|NCT00015600|Farmworker
1496608|NCT00015600|Occupational health
1496609|NCT00015587|Molecular Epidemiology
1496610|NCT00015587|Case Control
1496611|NCT00015574|arrhythmia
1496612|NCT00015574|cardiac
1496613|NCT00015574|air pollution
1496614|NCT00015574|time series
1496615|NCT00015561|population studies
1496616|NCT00015561|laboratory evaluation
1496617|NCT00015561|hormone analysis
1496618|NCT00015561|semen analysis
1496619|NCT00015561|chromosome studies
1496620|NCT00015548|antipsychotic treatment
1496621|NCT00015548|Alzheimer's disease
1496622|NCT00015548|agitation
1496623|NCT00015548|dementia
1496624|NCT00015548|psychosis
1496625|NCT00015548|behavioral symptoms
1496626|NCT00015548|hallucinations
1496627|NCT00015548|delusions
1496628|NCT00015483|Hematotoxicity
1496629|NCT00015483|Benzene
1496630|NCT00015483|Bone Marrow
1496631|NCT00015470|Myopathy
1496632|NCT00015470|Dystrophy
1496633|NCT00015470|Neuropathy
1496634|NCT00015470|Muscle Weakness
1496635|NCT00015470|Muscle Cramps and Pains
1496636|NCT00015470|Neuromuscular Disorders
1496637|NCT00015457|Writer's Cramp
1496638|NCT00015457|Calcium Channel Antagonists
1496639|NCT00015457|Torticollis
1496640|NCT00015457|Chemodenervation
1496641|NCT00015444|Apparently Sporadic Spastic Paraplegia
1496642|NCT00015444|Spasticity
1496643|NCT00015444|Motor Neuron Disease
1496644|NCT00015444|Amyotrophic Lateral Sclerosis
1496645|NCT00015444|Primary Lateral Sclerosis
1496646|NCT00015444|Muscle Stiffness
1496647|NCT00015444|Involuntary Muscle Contraction
1496648|NCT00015444|Isaacs Syndrome
1496649|NCT00015431|Malabsorption
1496650|NCT00015431|Endoscopy
1496651|NCT00015431|Cytokine
1496652|NCT00015431|Immunophenotype
1496653|NCT00015431|Lymphocyte
1496654|NCT00015431|Common Variable Immunodeficiency
1496655|NCT00015431|Gastrointestinal
1496656|NCT00015340|Opioid Dependence
1496657|NCT00015249|cocaine dependence
1496658|NCT00015210|Cocaine Use Disorders Dependence Depression
1496659|NCT00015171|opioid dependence
1496660|NCT00015132|cocaine dependence
1496661|NCT00015106|cocaine dependence
1496662|NCT00015080|cocaine dependence
1496663|NCT00015054|cocaine dependence
1496664|NCT00015041|opiate dependence
1496665|NCT00015028|opioid dependence
1496666|NCT00015015|Dichloroacetate
1496667|NCT00015015|Chlorinated hydrocarbons
1496668|NCT00015015|Genetic disease
1496669|NCT00015015|Toxicology
1496670|NCT00015015|Biotransformation
1496671|NCT00015002|Antenatal corticosteroids
1496672|NCT00015002|Preterm delivery
1496673|NCT00014989|Preterm delivery
1496674|NCT00014989|Cerebral palsy
1496675|NCT00014989|Magnesium sulfate
1496676|NCT00014976|Pyramidal Tract
1496677|NCT00014976|Primary Lateral Sclerosis
1496678|NCT00014976|Spastic Paraparesis
1496679|NCT00014976|EMG
1496680|NCT00014976|Magnetic Stimulation
1496681|NCT00014976|Muscle Spasticity
1496682|NCT00014976|Healthy Volunteer
1496683|NCT00014963|benzene
1496684|NCT00014963|biomarkers
1496685|NCT00014963|air pollution
1496686|NCT00014963|muconic acid
1496687|NCT00014963|phenylmercapturic acid
1496688|NCT00014950|Cystic Fibrosis
1496689|NCT00014950|Immunoreactive trypsinogen
1496690|NCT00014950|deltaF508- CFTR gene
1496691|NCT00014950|newborn screening
1496692|NCT00014950|Pseudomonas aeruginosa infection
1496693|NCT00014950|nutrition
1496694|NCT00014950|pulmonary status
1496695|NCT00014950|meconium ileus
1496696|NCT00014950|growth
1496697|NCT00014950|Genetic counseling
1496698|NCT00014950|risk communication
1496699|NCT00014937|HIV-1
1496700|NCT00014937|Didanosine
1496701|NCT00014937|Drug Therapy, Combination
1496702|NCT00014937|Zidovudine
1496703|NCT00014937|Nevirapine
1496704|NCT00014937|Stavudine
1496705|NCT00014937|HIV Protease Inhibitors
1496706|NCT00014937|Ritonavir
1496707|NCT00014937|Lamivudine
1496708|NCT00014937|RNA, Viral
1496709|NCT00014937|Reverse Transcriptase Inhibitors
1496710|NCT00014937|Anti-HIV Agents
1496711|NCT00014937|Viral Load
1496712|NCT00014937|ABT 378
1496713|NCT00014937|Combivir
1496714|NCT00014937|Efavirenz
1496715|NCT00014937|Treatment Experienced
1496716|NCT00014898|Lead exposure
1496717|NCT00014898|Bone lead
1496718|NCT00014898|Attention deficit
1496719|NCT00014885|Lead exposure
1496720|NCT00014885|Bone lead
1496721|NCT00014885|Cognitive function
1496722|NCT00014885|Academic achievement
1496723|NCT00014885|Neurobehavior
1496724|NCT00014859|Pulmonary surfactant
1496725|NCT00014859|Surfactant protein B
1496726|NCT00014859|Surfactant protein C
1496727|NCT00014859|ABCA3
1496728|NCT00014859|NKX2-1
1496729|NCT00014807|Pesticide exposure
1496730|NCT00014807|Organophosphate
1496731|NCT00014807|Biomarkers of exposure
1496732|NCT00014807|Poisoning
1496733|NCT00014807|Occupational Health
1496734|NCT00014794|Arthritis
1496735|NCT00014794|Vascularity
1496736|NCT00014794|Angiogenesis
1496737|NCT00014794|Imaging
1496738|NCT00014794|MRI
1496739|NCT00014794|Rheumatoid Arthritis
1496740|NCT00014794|PET Scan
1496741|NCT00014794|Synovitis
1496742|NCT00014781|cardiovascular and respiratory diseases
1496743|NCT00014781|cystic fibrosis
1496744|NCT00014781|genetic diseases and dysmorphic syndromes
1496745|NCT00014781|rare disease
1496746|NCT00014768|cardiovascular and respiratory diseases
1496747|NCT00014768|cystic fibrosis
1496748|NCT00014768|genetic diseases and dysmorphic syndromes
1496749|NCT00014768|rare disease
1496750|NCT00014755|multiple sclerosis
1496751|NCT00014755|neurologic and psychiatric disorders
1496752|NCT00014755|rare disease
1496753|NCT00014742|Dupuytren's disease
1496754|NCT00014742|arthritis & connective tissue diseases
1496755|NCT00014742|rare disease
1496756|NCT00014729|dermatologic disorders
1496757|NCT00014729|epidermolysis bullosa
1496758|NCT00014729|genetic diseases and dysmorphic syndromes
1496759|NCT00014729|rare disease
1496760|NCT00014690|recurrent ovarian epithelial cancer
1496761|NCT00014690|fallopian tube cancer
1496762|NCT00014690|primary peritoneal cavity cancer
1496763|NCT00014677|recurrent adult brain tumor
1496764|NCT00014677|adult glioblastoma
1496765|NCT00014677|adult giant cell glioblastoma
1496766|NCT00014677|adult gliosarcoma
1496767|NCT00014664|recurrent grade 1 follicular lymphoma
1496768|NCT00014664|recurrent grade 2 follicular lymphoma
1496769|NCT00014664|recurrent grade 3 follicular lymphoma
1496770|NCT00014664|recurrent marginal zone lymphoma
1496771|NCT00014664|recurrent small lymphocytic lymphoma
1496772|NCT00014664|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1496773|NCT00014651|perioperative/postoperative complications
1496774|NCT00014651|stage I pancreatic cancer
1496775|NCT00014638|stage IV breast cancer
1496776|NCT00014638|recurrent breast cancer
1496777|NCT00014625|stage IV melanoma
1496778|NCT00014625|recurrent melanoma
1496779|NCT00014612|stage IA breast cancer
1496780|NCT00014612|stage IB breast cancer
1496781|NCT00014612|stage II breast cancer
1496782|NCT00014599|stage III vulvar cancer
1496783|NCT00014599|stage IV vulvar cancer
1496784|NCT00014599|recurrent vulvar cancer
1496785|NCT00014599|squamous cell carcinoma of the vulva
1496786|NCT00014586|stage I prostate cancer
1496787|NCT00014586|stage IIB prostate cancer
1496788|NCT00014586|stage IIA prostate cancer
1496789|NCT00014586|stage III prostate cancer
1496790|NCT00014573|childhood infratentorial ependymoma
1496791|NCT00014573|childhood supratentorial ependymoma
1496792|NCT00014573|childhood central nervous system germ cell tumor
1496793|NCT00014573|recurrent adult brain tumor
1496794|NCT00014573|adult brain stem glioma
1496795|NCT00014573|adult medulloblastoma
1496796|NCT00014573|adult glioblastoma
1496797|NCT00014573|childhood high-grade cerebral astrocytoma
1496798|NCT00014573|adult anaplastic astrocytoma
1496799|NCT00014573|childhood choroid plexus tumor
1496800|NCT00014573|childhood grade III meningioma
1496801|NCT00014573|adult anaplastic ependymoma
1496802|NCT00014573|adult mixed glioma
1496803|NCT00014573|adult central nervous system germ cell tumor
1496804|NCT00014573|adult ependymoblastoma
1496805|NCT00014573|recurrent childhood brain stem glioma
1496806|NCT00014573|recurrent childhood supratentorial primitive neuroectodermal tumor
1496807|NCT00014573|recurrent childhood cerebral astrocytoma
1496808|NCT00014573|recurrent childhood medulloblastoma
1496809|NCT00014573|adult choroid plexus tumor
1496810|NCT00014573|recurrent childhood ependymoma
1496811|NCT00014573|adult grade III meningioma
1496812|NCT00014573|adult giant cell glioblastoma
1496813|NCT00014573|adult gliosarcoma
1496814|NCT00014560|refractory chronic lymphocytic leukemia
1496815|NCT00014560|recurrent grade 1 follicular lymphoma
1496816|NCT00014560|recurrent grade 2 follicular lymphoma
1496817|NCT00014560|recurrent grade 3 follicular lymphoma
1496818|NCT00014560|recurrent adult diffuse small cleaved cell lymphoma
1496819|NCT00014560|recurrent adult diffuse mixed cell lymphoma
1496820|NCT00014560|recurrent adult diffuse large cell lymphoma
1496821|NCT00014560|recurrent adult immunoblastic large cell lymphoma
1496822|NCT00014560|recurrent adult lymphoblastic lymphoma
1496823|NCT00014560|recurrent adult Burkitt lymphoma
1496824|NCT00014560|recurrent mantle cell lymphoma
1496825|NCT00014560|recurrent small lymphocytic lymphoma
1496826|NCT00014547|extensive stage small cell lung cancer
1496827|NCT00014547|recurrent small cell lung cancer
1496828|NCT00014534|stage III bladder cancer
1496829|NCT00014534|stage IV bladder cancer
1496830|NCT00014534|transitional cell carcinoma of the bladder
1496831|NCT00014521|recurrent adult brain tumor
1496832|NCT00014521|adult glioblastoma
1496833|NCT00014521|adult anaplastic astrocytoma
1496834|NCT00014521|adult anaplastic oligodendroglioma
1496835|NCT00014521|adult giant cell glioblastoma
1496836|NCT00014521|adult gliosarcoma
1496837|NCT00014508|refractory multiple myeloma
1496838|NCT00014508|stage I multiple myeloma
1496839|NCT00014508|stage II multiple myeloma
1496840|NCT00014508|stage III multiple myeloma
1496841|NCT00014495|recurrent childhood acute myeloid leukemia
1496842|NCT00014495|recurrent adult acute myeloid leukemia
1496843|NCT00014495|accelerated phase chronic myelogenous leukemia
1496844|NCT00014495|blastic phase chronic myelogenous leukemia
1496845|NCT00014495|untreated adult acute myeloid leukemia
1496846|NCT00014495|untreated childhood acute myeloid leukemia and other myeloid malignancies
1496847|NCT00014495|refractory anemia with excess blasts
1496848|NCT00014495|refractory anemia with excess blasts in transformation
1496849|NCT00014495|chronic myelomonocytic leukemia
1496850|NCT00014495|previously treated myelodysplastic syndromes
1496851|NCT00014495|secondary myelodysplastic syndromes
1496852|NCT00014495|childhood chronic myelogenous leukemia
1496853|NCT00014495|atypical chronic myeloid leukemia, BCR-ABL1 negative
1496854|NCT00014495|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1496855|NCT00014495|adult acute myeloid leukemia with t(8;21)(q22;q22)
1496856|NCT00014495|adult acute myeloid leukemia with t(16;16)(p13;q22)
1496857|NCT00014495|adult acute myeloid leukemia with inv(16)(p13;q22)
1496858|NCT00014495|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1496859|NCT00014495|adult acute myeloid leukemia with t(15;17)(q22;q12)
1496860|NCT00014495|childhood myelodysplastic syndromes
1496861|NCT00014482|anxiety disorder
1496862|NCT00014482|depression
1496863|NCT00014482|pain
1496864|NCT00014482|recurrent adult Hodgkin lymphoma
1496865|NCT00014482|recurrent cutaneous T-cell non-Hodgkin lymphoma
1496866|NCT00014482|refractory multiple myeloma
1496867|NCT00014482|stage I multiple myeloma
1496868|NCT00014482|stage II multiple myeloma
1496869|NCT00014482|stage III multiple myeloma
1496870|NCT00014482|primary myelofibrosis
1496871|NCT00014482|stage III grade 1 follicular lymphoma
1496872|NCT00014482|stage III grade 2 follicular lymphoma
1496873|NCT00014482|stage III grade 3 follicular lymphoma
1496874|NCT00014482|stage III adult diffuse small cleaved cell lymphoma
1496875|NCT00014482|stage III adult diffuse mixed cell lymphoma
1496876|NCT00014482|stage III adult diffuse large cell lymphoma
1496877|NCT00014482|stage III adult immunoblastic large cell lymphoma
1496878|NCT00014482|stage III adult lymphoblastic lymphoma
1496879|NCT00014482|stage III adult Burkitt lymphoma
1496880|NCT00014482|stage IV grade 1 follicular lymphoma
1496881|NCT00014482|stage IV grade 2 follicular lymphoma
1496882|NCT00014482|stage IV grade 3 follicular lymphoma
1496883|NCT00014482|stage IV adult diffuse small cleaved cell lymphoma
1496884|NCT00014482|stage IV adult diffuse mixed cell lymphoma
1496885|NCT00014482|stage IV adult diffuse large cell lymphoma
1496886|NCT00014482|stage IV adult immunoblastic large cell lymphoma
1496887|NCT00014482|stage IV adult lymphoblastic lymphoma
1496888|NCT00014482|stage IV adult Burkitt lymphoma
1496889|NCT00014482|recurrent grade 1 follicular lymphoma
1496890|NCT00014482|recurrent grade 2 follicular lymphoma
1496891|NCT00014482|recurrent grade 3 follicular lymphoma
1496892|NCT00014482|recurrent adult diffuse small cleaved cell lymphoma
1496893|NCT00014482|recurrent adult diffuse mixed cell lymphoma
1496894|NCT00014482|recurrent adult diffuse large cell lymphoma
1496895|NCT00014482|recurrent adult immunoblastic large cell lymphoma
1496896|NCT00014482|recurrent adult lymphoblastic lymphoma
1496897|NCT00014482|recurrent adult Burkitt lymphoma
1496898|NCT00014482|de novo myelodysplastic syndromes
1496899|NCT00014482|previously treated myelodysplastic syndromes
1496900|NCT00014482|secondary myelodysplastic syndromes
1496901|NCT00014482|noncontiguous stage II grade 1 follicular lymphoma
1496902|NCT00014482|noncontiguous stage II grade 2 follicular lymphoma
1496903|NCT00014482|noncontiguous stage II grade 3 follicular lymphoma
1496904|NCT00014482|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1496905|NCT00014482|noncontiguous stage II mantle cell lymphoma
1496906|NCT00014482|noncontiguous stage II adult diffuse mixed cell lymphoma
1496907|NCT00014482|noncontiguous stage II adult immunoblastic large cell lymphoma
1496908|NCT00014482|noncontiguous stage II adult diffuse large cell lymphoma
1496909|NCT00014482|noncontiguous stage II adult Burkitt lymphoma
1496910|NCT00014482|noncontiguous stage II adult lymphoblastic lymphoma
1496911|NCT00014482|stage III mantle cell lymphoma
1496912|NCT00014482|stage IV mantle cell lymphoma
1496913|NCT00014482|recurrent mantle cell lymphoma
1496914|NCT00014482|recurrent mycosis fungoides/Sezary syndrome
1496915|NCT00014482|noncontiguous stage II small lymphocytic lymphoma
1496916|NCT00014482|noncontiguous stage II marginal zone lymphoma
1496917|NCT00014482|recurrent marginal zone lymphoma
1496918|NCT00014482|recurrent small lymphocytic lymphoma
1496919|NCT00014482|stage III small lymphocytic lymphoma
1496920|NCT00014482|stage III marginal zone lymphoma
1496921|NCT00014482|stage IV small lymphocytic lymphoma
1496922|NCT00014482|stage IV marginal zone lymphoma
1496923|NCT00014482|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1496924|NCT00014482|nodal marginal zone B-cell lymphoma
1496925|NCT00014482|splenic marginal zone lymphoma
1496926|NCT00014469|recurrent childhood acute lymphoblastic leukemia
1496927|NCT00014469|recurrent childhood acute myeloid leukemia
1496928|NCT00014469|recurrent adult acute myeloid leukemia
1496929|NCT00014469|recurrent adult acute lymphoblastic leukemia
1496930|NCT00014469|relapsing chronic myelogenous leukemia
1496931|NCT00014469|refractory chronic lymphocytic leukemia
1496932|NCT00014469|chronic phase chronic myelogenous leukemia
1496933|NCT00014469|accelerated phase chronic myelogenous leukemia
1496934|NCT00014469|blastic phase chronic myelogenous leukemia
1496935|NCT00014469|adult acute myeloid leukemia in remission
1496936|NCT00014469|adult acute lymphoblastic leukemia in remission
1496937|NCT00014469|childhood acute myeloid leukemia in remission
1496938|NCT00014469|childhood acute lymphoblastic leukemia in remission
1496939|NCT00014469|refractory anemia with excess blasts
1496940|NCT00014469|refractory anemia with excess blasts in transformation
1496941|NCT00014469|chronic myelomonocytic leukemia
1496942|NCT00014469|acute undifferentiated leukemia
1496943|NCT00014469|secondary acute myeloid leukemia
1496944|NCT00014469|de novo myelodysplastic syndromes
1496945|NCT00014469|previously treated myelodysplastic syndromes
1496946|NCT00014469|secondary myelodysplastic syndromes
1496947|NCT00014469|graft versus host disease
1496948|NCT00014469|refractory cytopenia with multilineage dysplasia
1496949|NCT00014469|juvenile myelomonocytic leukemia
1496950|NCT00014469|childhood chronic myelogenous leukemia
1496951|NCT00014469|atypical chronic myeloid leukemia, BCR-ABL1 negative
1496952|NCT00014469|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1496953|NCT00014469|adult acute myeloid leukemia with t(8;21)(q22;q22)
1496954|NCT00014469|adult acute myeloid leukemia with t(16;16)(p13;q22)
1496955|NCT00014469|adult acute myeloid leukemia with inv(16)(p13;q22)
1496956|NCT00014469|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1496957|NCT00014469|adult acute myeloid leukemia with t(15;17)(q22;q12)
1496958|NCT00014456|stage IV breast cancer
1496959|NCT00014456|recurrent breast cancer
1496960|NCT00014456|stage IV gastric cancer
1496961|NCT00014456|recurrent gastric cancer
1496962|NCT00014456|metastatic osteosarcoma
1496963|NCT00014456|recurrent non-small cell lung cancer
1496964|NCT00014456|stage II pancreatic cancer
1496965|NCT00014456|stage III pancreatic cancer
1496966|NCT00014456|recurrent pancreatic cancer
1496967|NCT00014456|stage II esophageal cancer
1496968|NCT00014456|stage III esophageal cancer
1496969|NCT00014456|stage IV esophageal cancer
1496970|NCT00014456|recurrent esophageal cancer
1496971|NCT00014456|chondrosarcoma
1496972|NCT00014456|recurrent adult soft tissue sarcoma
1496973|NCT00014456|stage IV ovarian epithelial cancer
1496974|NCT00014456|recurrent ovarian epithelial cancer
1496975|NCT00014456|extensive stage small cell lung cancer
1496976|NCT00014456|recurrent small cell lung cancer
1496977|NCT00014456|recurrent osteosarcoma
1496978|NCT00014456|recurrent bladder cancer
1496979|NCT00014456|stage IV bladder cancer
1496980|NCT00014456|stage IV prostate cancer
1496981|NCT00014456|recurrent prostate cancer
1496982|NCT00014456|stage IV melanoma
1496983|NCT00014456|recurrent melanoma
1496984|NCT00014456|stage IV non-small cell lung cancer
1496985|NCT00014456|stage IV salivary gland cancer
1496986|NCT00014456|recurrent salivary gland cancer
1496987|NCT00014456|classic Kaposi sarcoma
1496988|NCT00014456|AIDS-related Kaposi sarcoma
1497171|NCT00014352|thromboembolism
1496989|NCT00014456|recurrent Kaposi sarcoma
1496990|NCT00014456|recurrent metastatic squamous neck cancer with occult primary
1496991|NCT00014456|stage IV ovarian germ cell tumor
1496992|NCT00014456|recurrent ovarian germ cell tumor
1496993|NCT00014456|stage IV uterine sarcoma
1496994|NCT00014456|recurrent uterine sarcoma
1496995|NCT00014456|borderline ovarian surface epithelial-stromal tumor
1496996|NCT00014456|recurrent carcinoma of unknown primary
1496997|NCT00014456|ovarian sarcoma
1496998|NCT00014456|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1496999|NCT00014456|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1497000|NCT00014456|recurrent squamous cell carcinoma of the hypopharynx
1497001|NCT00014456|stage IV squamous cell carcinoma of the hypopharynx
1497002|NCT00014456|recurrent squamous cell carcinoma of the larynx
1497003|NCT00014456|recurrent verrucous carcinoma of the larynx
1497004|NCT00014456|stage IV squamous cell carcinoma of the larynx
1497005|NCT00014456|stage IV verrucous carcinoma of the larynx
1497006|NCT00014456|recurrent squamous cell carcinoma of the lip and oral cavity
1497007|NCT00014456|stage IV squamous cell carcinoma of the lip and oral cavity
1497008|NCT00014456|recurrent lymphoepithelioma of the nasopharynx
1497009|NCT00014456|recurrent squamous cell carcinoma of the nasopharynx
1497010|NCT00014456|stage IV lymphoepithelioma of the nasopharynx
1497011|NCT00014456|stage IV squamous cell carcinoma of the nasopharynx
1497012|NCT00014456|recurrent lymphoepithelioma of the oropharynx
1497013|NCT00014456|recurrent squamous cell carcinoma of the oropharynx
1497014|NCT00014456|stage IV lymphoepithelioma of the oropharynx
1497015|NCT00014456|stage IV squamous cell carcinoma of the oropharynx
1497016|NCT00014456|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1497017|NCT00014456|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1497018|NCT00014456|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1497019|NCT00014456|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1497020|NCT00014456|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1497021|NCT00014456|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1497022|NCT00014456|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1497023|NCT00014456|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1497024|NCT00014456|recurrent verrucous carcinoma of the oral cavity
1497025|NCT00014456|stage IV verrucous carcinoma of the oral cavity
1497026|NCT00014456|recurrent basal cell carcinoma of the lip
1497027|NCT00014456|stage IV basal cell carcinoma of the lip
1497028|NCT00014456|recurrent mucoepidermoid carcinoma of the oral cavity
1497029|NCT00014456|stage IV mucoepidermoid carcinoma of the oral cavity
1497030|NCT00014456|recurrent adenoid cystic carcinoma of the oral cavity
1497031|NCT00014456|stage IV adenoid cystic carcinoma of the oral cavity
1497032|NCT00014456|stage IV adult soft tissue sarcoma
1497033|NCT00014456|stage IV pancreatic cancer
1497034|NCT00014443|recurrent adult brain tumor
1497035|NCT00014443|adult glioblastoma
1497036|NCT00014443|adult anaplastic astrocytoma
1497037|NCT00014443|adult giant cell glioblastoma
1497038|NCT00014443|adult gliosarcoma
1497039|NCT00014430|stage IV breast cancer
1497040|NCT00014430|stage IIIA breast cancer
1497041|NCT00014430|recurrent breast cancer
1497042|NCT00014430|stage IIIB breast cancer
1497043|NCT00014404|lip and oral cavity cancer
1497044|NCT00014391|stage IV breast cancer
1497045|NCT00014391|stage IIIA breast cancer
1497046|NCT00014391|stage IIIB breast cancer
1497047|NCT00014391|recurrent childhood acute lymphoblastic leukemia
1497048|NCT00014391|recurrent adult Hodgkin lymphoma
1497049|NCT00014391|recurrent cutaneous T-cell non-Hodgkin lymphoma
1497050|NCT00014391|refractory multiple myeloma
1497051|NCT00014391|recurrent childhood rhabdomyosarcoma
1497052|NCT00014391|stage II ovarian epithelial cancer
1497053|NCT00014391|stage III ovarian epithelial cancer
1497054|NCT00014391|stage IV ovarian epithelial cancer
1497055|NCT00014391|recurrent ovarian epithelial cancer
1497056|NCT00014391|disseminated neuroblastoma
1497057|NCT00014391|recurrent neuroblastoma
1497058|NCT00014391|recurrent Wilms tumor and other childhood kidney tumors
1497059|NCT00014391|stage I multiple myeloma
1497060|NCT00014391|stage II multiple myeloma
1497061|NCT00014391|stage III multiple myeloma
1497062|NCT00014391|recurrent childhood lymphoblastic lymphoma
1497063|NCT00014391|stage III chronic lymphocytic leukemia
1497064|NCT00014391|stage IV chronic lymphocytic leukemia
1497065|NCT00014391|recurrent childhood acute myeloid leukemia
1497066|NCT00014391|recurrent adult acute myeloid leukemia
1497067|NCT00014391|recurrent adult acute lymphoblastic leukemia
1497068|NCT00014391|relapsing chronic myelogenous leukemia
1497069|NCT00014391|refractory chronic lymphocytic leukemia
1497070|NCT00014391|stage III malignant testicular germ cell tumor
1497071|NCT00014391|recurrent malignant testicular germ cell tumor
1497072|NCT00014391|chronic phase chronic myelogenous leukemia
1497073|NCT00014391|accelerated phase chronic myelogenous leukemia
1497074|NCT00014391|blastic phase chronic myelogenous leukemia
1497075|NCT00014391|meningeal chronic myelogenous leukemia
1497076|NCT00014391|chronic idiopathic myelofibrosis
1497077|NCT00014391|childhood acute promyelocytic leukemia (M3)
1497078|NCT00014391|testicular embryonal carcinoma
1497079|NCT00014391|testicular choriocarcinoma
1497080|NCT00014391|testicular teratoma
1497081|NCT00014391|testicular yolk sac tumor
1497082|NCT00014391|testicular embryonal carcinoma and teratoma
1497083|NCT00014391|testicular embryonal carcinoma and teratoma with seminoma
1497084|NCT00014391|testicular embryonal carcinoma and yolk sac tumor
1497085|NCT00014391|testicular embryonal carcinoma and yolk sac tumor with seminoma
1497086|NCT00014391|testicular embryonal carcinoma and seminoma
1497087|NCT00014391|testicular yolk sac tumor and teratoma
1497088|NCT00014391|testicular yolk sac tumor and teratoma with seminoma
1497089|NCT00014391|testicular choriocarcinoma and yolk sac tumor
1497090|NCT00014391|testicular choriocarcinoma and embryonal carcinoma
1497091|NCT00014391|testicular choriocarcinoma and teratoma
1497092|NCT00014391|testicular choriocarcinoma and seminoma
1497093|NCT00014391|refractory hairy cell leukemia
1497094|NCT00014391|recurrent/refractory childhood Hodgkin lymphoma
1497095|NCT00014391|recurrent ovarian germ cell tumor
1497096|NCT00014391|ovarian yolk sac tumor
1497097|NCT00014391|ovarian embryonal carcinoma
1497098|NCT00014391|ovarian polyembryoma
1497099|NCT00014391|ovarian choriocarcinoma
1497100|NCT00014391|ovarian immature teratoma
1497101|NCT00014391|ovarian mature teratoma
1497102|NCT00014391|ovarian monodermal and highly specialized teratoma
1497103|NCT00014391|ovarian mixed germ cell tumor
1497104|NCT00014391|stage III grade 1 follicular lymphoma
1497105|NCT00014391|stage III grade 2 follicular lymphoma
1497106|NCT00014391|stage III grade 3 follicular lymphoma
1497107|NCT00014391|stage III adult diffuse small cleaved cell lymphoma
1497108|NCT00014391|stage III adult diffuse mixed cell lymphoma
1497109|NCT00014391|stage III adult diffuse large cell lymphoma
1497110|NCT00014391|stage III adult immunoblastic large cell lymphoma
1497111|NCT00014391|stage III adult lymphoblastic lymphoma
1497112|NCT00014391|stage III adult Burkitt lymphoma
1497113|NCT00014391|stage IV grade 1 follicular lymphoma
1497114|NCT00014391|stage IV grade 2 follicular lymphoma
1497115|NCT00014391|stage IV grade 3 follicular lymphoma
1497116|NCT00014391|stage IV adult diffuse small cleaved cell lymphoma
1497117|NCT00014391|stage IV adult diffuse mixed cell lymphoma
1497118|NCT00014391|stage IV adult diffuse large cell lymphoma
1497119|NCT00014391|stage IV adult immunoblastic large cell lymphoma
1497120|NCT00014391|stage IV adult lymphoblastic lymphoma
1497121|NCT00014391|stage IV adult Burkitt lymphoma
1497122|NCT00014391|recurrent grade 1 follicular lymphoma
1497123|NCT00014391|recurrent grade 2 follicular lymphoma
1497124|NCT00014391|recurrent grade 3 follicular lymphoma
1497125|NCT00014391|recurrent adult diffuse small cleaved cell lymphoma
1497126|NCT00014391|recurrent adult diffuse mixed cell lymphoma
1497127|NCT00014391|recurrent adult diffuse large cell lymphoma
1497128|NCT00014391|recurrent adult immunoblastic large cell lymphoma
1497129|NCT00014391|recurrent adult lymphoblastic lymphoma
1497130|NCT00014391|recurrent adult Burkitt lymphoma
1497131|NCT00014391|secondary acute myeloid leukemia
1497132|NCT00014391|de novo myelodysplastic syndromes
1497133|NCT00014391|poor prognosis metastatic gestational trophoblastic tumor
1497134|NCT00014391|previously treated myelodysplastic syndromes
1497135|NCT00014391|secondary myelodysplastic syndromes
1497136|NCT00014391|infection
1497137|NCT00014391|pulmonary complications
1497138|NCT00014391|recurrent childhood small noncleaved cell lymphoma
1497139|NCT00014391|recurrent childhood large cell lymphoma
1497140|NCT00014391|noncontiguous stage II grade 1 follicular lymphoma
1497141|NCT00014391|noncontiguous stage II grade 2 follicular lymphoma
1497142|NCT00014391|noncontiguous stage II grade 3 follicular lymphoma
1497143|NCT00014391|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1497144|NCT00014391|noncontiguous stage II mantle cell lymphoma
1497145|NCT00014391|noncontiguous stage II adult diffuse mixed cell lymphoma
1497146|NCT00014391|noncontiguous stage II adult immunoblastic large cell lymphoma
1497147|NCT00014391|noncontiguous stage II adult diffuse large cell lymphoma
1497148|NCT00014391|noncontiguous stage II adult Burkitt lymphoma
1497149|NCT00014391|noncontiguous stage II adult lymphoblastic lymphoma
1497150|NCT00014391|stage III mantle cell lymphoma
1497151|NCT00014391|stage IV mantle cell lymphoma
1497152|NCT00014391|recurrent mantle cell lymphoma
1497153|NCT00014391|previously treated childhood rhabdomyosarcoma
1497154|NCT00014391|noncontiguous stage II small lymphocytic lymphoma
1497155|NCT00014391|noncontiguous stage II marginal zone lymphoma
1497156|NCT00014391|recurrent marginal zone lymphoma
1497157|NCT00014391|recurrent small lymphocytic lymphoma
1497158|NCT00014391|stage III small lymphocytic lymphoma
1497159|NCT00014391|stage III marginal zone lymphoma
1497160|NCT00014391|stage IV small lymphocytic lymphoma
1497161|NCT00014391|stage IV marginal zone lymphoma
1497162|NCT00014391|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1497163|NCT00014391|nodal marginal zone B-cell lymphoma
1497164|NCT00014391|splenic marginal zone lymphoma
1497165|NCT00014391|childhood myelodysplastic syndromes
1497166|NCT00014378|unspecified adult solid tumor, protocol specific
1497167|NCT00014365|unspecified adult solid tumor, protocol specific
1497168|NCT00014352|stage III prostate cancer
1497169|NCT00014352|stage IV prostate cancer
1497170|NCT00014352|recurrent prostate cancer
1497172|NCT00014339|stage II multiple myeloma
1497173|NCT00014339|stage III multiple myeloma
1497174|NCT00014326|stage I grade 1 follicular lymphoma
1497175|NCT00014326|stage I grade 2 follicular lymphoma
1497176|NCT00014326|stage I grade 3 follicular lymphoma
1497177|NCT00014326|contiguous stage II grade 1 follicular lymphoma
1497178|NCT00014326|contiguous stage II grade 2 follicular lymphoma
1497179|NCT00014326|contiguous stage II grade 3 follicular lymphoma
1497180|NCT00014326|noncontiguous stage II grade 1 follicular lymphoma
1497181|NCT00014326|noncontiguous stage II grade 2 follicular lymphoma
1497182|NCT00014326|noncontiguous stage II grade 3 follicular lymphoma
1497183|NCT00014326|contiguous stage II small lymphocytic lymphoma
1497184|NCT00014326|contiguous stage II marginal zone lymphoma
1497185|NCT00014326|noncontiguous stage II small lymphocytic lymphoma
1497186|NCT00014326|noncontiguous stage II marginal zone lymphoma
1497187|NCT00014326|nodal marginal zone B-cell lymphoma
1497188|NCT00014326|stage I marginal zone lymphoma
1497189|NCT00014326|stage I small lymphocytic lymphoma
1497190|NCT00014313|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1497191|NCT00014300|recurrent adult brain tumor
1497192|NCT00014300|adult glioblastoma
1497193|NCT00014300|adult giant cell glioblastoma
1497194|NCT00014300|adult gliosarcoma
1497195|NCT00014287|stage 0 bladder cancer
1497196|NCT00014287|stage I bladder cancer
1497197|NCT00014287|recurrent bladder cancer
1497198|NCT00014274|stage III bladder cancer
1497199|NCT00014274|stage IV bladder cancer
1497200|NCT00014274|transitional cell carcinoma of the bladder
1497201|NCT00014274|anterior urethral cancer
1497202|NCT00014274|posterior urethral cancer
1497203|NCT00014274|urethral cancer associated with invasive bladder cancer
1497204|NCT00014274|metastatic transitional cell cancer of the renal pelvis and ureter
1497205|NCT00014274|regional transitional cell cancer of the renal pelvis and ureter
1497206|NCT00014261|unspecified adult solid tumor, protocol specific
1497207|NCT00014248|unspecified adult solid tumor, protocol specific
1497208|NCT00014248|cachexia
1497209|NCT00014222|stage I breast cancer
1497210|NCT00014222|stage II breast cancer
1497211|NCT00014222|stage IIIA breast cancer
1497212|NCT00014222|stage IIIB breast cancer
1497213|NCT00014209|recurrent adult Hodgkin lymphoma
1497214|NCT00014209|recurrent adult diffuse mixed cell lymphoma
1497215|NCT00014209|recurrent adult diffuse large cell lymphoma
1497216|NCT00014209|recurrent adult immunoblastic large cell lymphoma
1497217|NCT00014209|anaplastic large cell lymphoma
1497218|NCT00014196|squamous cell lung cancer
1497219|NCT00014196|large cell lung cancer
1497220|NCT00014196|stage IIIB non-small cell lung cancer
1497221|NCT00014196|adenocarcinoma of the lung
1497222|NCT00014183|stage IV renal cell cancer
1497223|NCT00014183|recurrent renal cell cancer
1497224|NCT00014144|recurrent bladder cancer
1497225|NCT00014144|stage IV bladder cancer
1497226|NCT00014144|transitional cell carcinoma of the bladder
1497227|NCT00014144|recurrent urethral cancer
1497228|NCT00014144|urethral cancer associated with invasive bladder cancer
1497229|NCT00014144|metastatic transitional cell cancer of the renal pelvis and ureter
1497230|NCT00014144|recurrent transitional cell cancer of the renal pelvis and ureter
1497231|NCT00014144|anterior urethral cancer
1497232|NCT00014144|posterior urethral cancer
1497233|NCT00014131|stage III renal cell cancer
1497234|NCT00014131|stage IV renal cell cancer
1497235|NCT00014131|recurrent renal cell cancer
1497236|NCT00014118|stage III squamous cell carcinoma of the oropharynx
1497237|NCT00014118|stage IV squamous cell carcinoma of the oropharynx
1497238|NCT00014118|stage III squamous cell carcinoma of the larynx
1497239|NCT00014118|stage IV squamous cell carcinoma of the larynx
1497240|NCT00014105|recurrent adult brain tumor
1497241|NCT00014105|adult glioblastoma
1497242|NCT00014105|adult giant cell glioblastoma
1497243|NCT00014105|adult gliosarcoma
1497244|NCT00014092|stage IV melanoma
1497245|NCT00014092|recurrent melanoma
1497246|NCT00014079|colon cancer
1497247|NCT00014079|rectal cancer
1497248|NCT00014066|stage I non-small cell lung cancer
1497249|NCT00014066|recurrent non-small cell lung cancer
1497250|NCT00014066|limited stage small cell lung cancer
1497251|NCT00014066|recurrent small cell lung cancer
1497252|NCT00014066|stage 0 non-small cell lung cancer
1497253|NCT00014053|Reference Values
1497254|NCT00014053|HIV Seropositivity
1497255|NCT00014053|Immune System
1497256|NCT00014053|CD4-Positive T-Lymphocytes
1497257|NCT00014053|HIV Seronegativity
1497258|NCT00014053|Antigens, CD
1497259|NCT00014040|Angina Pectoris
1497260|NCT00014040|Endothelium
1497261|NCT00014040|Platelets
1497262|NCT00014040|Inflammation
1497263|NCT00014040|Atherosclerosis
1497264|NCT00014040|Coronary Artery Disease
1497265|NCT00014040|Chest Pain
1497266|NCT00014040|Nitrous Oxide Inhalation
1497267|NCT00014040|Treadmill Exercise
1497268|NCT00014027|Omega-3 Fatty Acids
1497269|NCT00014027|Cerebrospinal Fluid
1497270|NCT00014027|Neurotransmitters
1497271|NCT00014027|Cardiovascular
1497272|NCT00014027|Reactivity
1497273|NCT00014027|Healthy Volunteer
1497274|NCT00014027|Lumbar Puncture
1497275|NCT00014027|MRI
1497276|NCT00014014|Zidovudine
1497277|NCT00014014|Phosphorylation
1497278|NCT00014014|Drug Administration Schedule
1497279|NCT00014014|Lamivudine
1497280|NCT00014014|Reverse Transcriptase Inhibitors
1497281|NCT00014014|Anti-HIV Agents
1497282|NCT00014014|Pharmacokinetics
1497283|NCT00014014|Combivir
1497284|NCT00014001|Antipsychotic Treatment
1497285|NCT00014001|Effectiveness
1497286|NCT00013975|Framingham Risk Scoring
1497287|NCT00013975|Brachial Artery Reactivity
1497288|NCT00013975|EPC Colony Assay
1497289|NCT00013975|Healthy Volunteer
1497290|NCT00013975|Atherosclerosis Risk Factors
1497291|NCT00013975|Cholesterol
1497292|NCT00013975|Hypertension
1497293|NCT00013975|Smoking
1497294|NCT00013975|Diabetes
1497295|NCT00013975|Postmenopausal
1497296|NCT00013975|Heart Disease Risk Factors
1497297|NCT00013975|Risk Factors
1497298|NCT00013949|Holter monitoring
1497299|NCT00013949|ECG
1497300|NCT00013949|Cardiac
1497301|NCT00013949|particulate exposure
1497302|NCT00013936|Instrument Development
1497303|NCT00013936|Psychophysical Methods
1497304|NCT00013936|ETDRS
1497305|NCT00013936|Computer-Based Methods
1497306|NCT00013936|Validation Study
1497307|NCT00013936|Visual Acuity
1497308|NCT00013936|Vision Tests/Instrumentation
1497309|NCT00013936|Psychophysics
1497310|NCT00013936|Modified Binary Search
1497311|NCT00013936|Visual Acuity Test
1497312|NCT00013923|Nutritional Supplement
1497313|NCT00013910|glucagon-like peptide 1
1497314|NCT00013897|Placebos
1497315|NCT00013897|Drug Therapy, Combination
1497316|NCT00013897|Zidovudine
1497317|NCT00013897|HIV Protease Inhibitors
1497318|NCT00013897|Lamivudine
1497319|NCT00013897|RNA, Viral
1497320|NCT00013897|Reverse Transcriptase Inhibitors
1497321|NCT00013897|Anti-HIV Agents
1497322|NCT00013897|Viral Load
1497323|NCT00013897|BMS 232632
1497324|NCT00013897|efavirenz
1497325|NCT00013884|HIV
1497326|NCT00013884|T20
1497327|NCT00013884|HAART
1497328|NCT00013884|Interruption
1497329|NCT00013884|Therapy
1497330|NCT00013884|Fusion Inhibitor T20
1497331|NCT00013884|Treatment Interuption
1497332|NCT00013871|Measles-Mumps-Rubella Vaccine
1497333|NCT00013871|Antibodies, Viral
1497334|NCT00013871|Hepatitis B Vaccines
1497335|NCT00013871|Immunization, Secondary
1497336|NCT00013871|Pneumococcal Vaccines
1497337|NCT00013871|Antiretroviral Therapy, Highly Active
1497338|NCT00013871|Diphtheria-Tetanus-acellular Pertussis Vaccines
1497339|NCT00013858|methylmercury
1497340|NCT00013858|PCBs
1497341|NCT00013858|lead
1497342|NCT00013858|fish consumption
1497343|NCT00013858|breast-feeding
1497344|NCT00013845|Seizures
1497345|NCT00013845|Anti-Epileptic Drugs
1497346|NCT00013845|Pharmacotherapy
1497347|NCT00013845|Neuropsychology
1497348|NCT00013845|Temporal Lobe Epilepsy
1497349|NCT00013845|Frontal Lobe Epilepsy
1497350|NCT00013845|Complex Partial Seizures
1497351|NCT00013845|Grand Mal Seizures
1497352|NCT00013845|Generalized Seizures
1497353|NCT00013845|Epilepsy
1497354|NCT00013832|Pressure
1497355|NCT00013832|Swallowing
1497356|NCT00013832|Tongue
1497357|NCT00013832|Healthy Volunteer
1497358|NCT00013832|Dysphagia
1497359|NCT00013819|lead poisoning
1497360|NCT00013819|central nervous system
1497361|NCT00013819|peripheral nervous system
1497362|NCT00013819|occupational health
1497363|NCT00013819|genetic susceptibility
1497364|NCT00013026|Congestive Heart Failure
1497365|NCT00013806|Relapsed and refractory neuroblastoma
1497366|NCT00013780|ozone uptake
1497367|NCT00013780|inhalation toxicology
1497368|NCT00013780|nasal cavities
1497369|NCT00013780|antioxidants
1497370|NCT00013767|Pesticide
1497371|NCT00013767|Insecticide
1497372|NCT00013767|Organophosphate
1497373|NCT00013767|Child Health
1497374|NCT00013767|Exposure Prevention
1497375|NCT00013754|pesticide
1497376|NCT00013754|insecticide
1497377|NCT00013754|organophosphate
1497378|NCT00013754|exposure
1497379|NCT00013754|child health
1497380|NCT00013741|Acute Myocardial Infarction
1497381|NCT00013741|Diabetes Mellitus
1497382|NCT00013741|Renal Dialysis
1497383|NCT00013741|Heart Attack
1497384|NCT00013741|Coronary Heart Disease
1497385|NCT00013728|asthma
1497386|NCT00013728|particulate matter
1497387|NCT00013715|Asthma
1497388|NCT00013715|Rhinovirus
1497389|NCT00013715|Ozone
1497390|NCT00013702|Immunology
1497391|NCT00013702|Cirrhosis
1497392|NCT00013702|Ascites
1497393|NCT00013702|Open-Label
1497394|NCT00013702|Chronic
1497395|NCT00013702|HIV
1497396|NCT00013702|Hepatitis B
1497397|NCT00013689|Lymphadenopathy
1497398|NCT00013689|Splenomegaly
1497399|NCT00013689|Children
1497400|NCT00013689|Tomography
1497401|NCT00013689|Autoimmune Lymphoproliferative Syndrome (ALPS)
1497402|NCT00013663|Virus Replication
1497403|NCT00013663|HIV-1
1497404|NCT00013663|AIDS Vaccines
1497405|NCT00013663|RNA, Viral
1497406|NCT00013663|Avipoxvirus
1497407|NCT00013663|Genetic Vectors
1497408|NCT00013663|Viral Load
1497409|NCT00013663|aldesleukin
1497410|NCT00013663|Antiretroviral Therapy, Highly Active
1497411|NCT00013663|HIV Therapeutic Vaccine
1497412|NCT00013663|Treatment Interruption
1497413|NCT00013650|Alzheimer's Disease
1497414|NCT00013650|Immunomodulatory
1497415|NCT00013650|Antiinflammatory
1497416|NCT00013650|Cyclophosphamide
1497417|NCT00013650|Non-steroidal
1497418|NCT00013650|Complement
1497419|NCT00013650|Immune Function
1497420|NCT00013650|Immunotherapy
1497421|NCT00013637|Osteoporosis
1497422|NCT00013637|Lead
1497423|NCT00013624|Riluzole
1497424|NCT00013624|Dyskinesias
1497425|NCT00013624|L-Dopa Infusion
1497426|NCT00013624|Parkinson's Disease
1497427|NCT00013611|HIV
1497428|NCT00013611|Proleukin
1497429|NCT00013611|IL-2
1497430|NCT00013611|Adult
1497431|NCT00013611|HAART
1497432|NCT00013611|Treatment Experienced
1497433|NCT00013598|Insulin Resistance
1497434|NCT00013598|Obesity
1497435|NCT00013598|Diabetes
1497436|NCT00013598|Fatty Liver
1497437|NCT00013598|Cirrhosis
1497438|NCT00013598|Thiazolidinediones
1497439|NCT00013598|Peroxisome Proliferator-Activated Receptor Gamma
1497440|NCT00013598|PPARgamma
1497441|NCT00013598|Nonalcoholic Steatohepatitis
1497442|NCT00013598|Pioglitazone
1497443|NCT00013598|Non-Alcoholic Steatohepatitis
1497444|NCT00013598|Liver Biopsy
1497445|NCT00013598|Pharmacotherapy
1497446|NCT00013585|Cognitive Disorders
1497447|NCT00013585|AIDS Dementia Complex
1497448|NCT00013585|Selegiline
1497449|NCT00013585|Administration, Cutaneous
1497450|NCT00013585|Neuroprotective Agents
1497451|NCT00013572|Injections, Intramuscular
1497452|NCT00013572|Injections, Intradermal
1497453|NCT00013572|Injections, Subcutaneous
1497454|NCT00013572|HIV-1
1497455|NCT00013572|AIDS Vaccines
1497456|NCT00013572|Dendritic Cells
1497457|NCT00013572|HIV Seronegativity
1497458|NCT00013572|Genes, env
1497459|NCT00013572|Genes, pol
1497460|NCT00013572|Genes, gag
1497461|NCT00013572|Transfection
1497462|NCT00013572|HIV Preventive Vaccine
1497470|NCT00013546|Osteoporosis
1497471|NCT00013546|Body Composition
1497472|NCT00013546|Estrogen
1497473|NCT00013546|Androgen
1497474|NCT00013546|Ovarian Failure
1497475|NCT00013546|Turner's Syndrome
1497476|NCT00013546|Hormone Replacement
1497477|NCT00013546|Turners
1497478|NCT00013546|Turner's
1497479|NCT00013546|TS
1497480|NCT00013533|Leukemia
1497481|NCT00013533|Myelodysplastic Syndrome
1497482|NCT00013533|Bone Marrow Transplant
1497483|NCT00013533|Pediatric Oncology
1497484|NCT00013533|Lymphoma
1497485|NCT00013533|Efficacy
1497486|NCT00013533|Safety
1497487|NCT00013533|Childhood Cancer
1497488|NCT00013520|HIV-1
1497489|NCT00013520|Didanosine
1497490|NCT00013520|Drug Therapy, Combination
1497491|NCT00013520|Zidovudine
1497492|NCT00013520|Nevirapine
1497493|NCT00013520|Stavudine
1497494|NCT00013520|Lamivudine
1497495|NCT00013520|RNA, Viral
1497496|NCT00013520|Reverse Transcriptase Inhibitors
1497497|NCT00013520|Anti-HIV Agents
1497498|NCT00013520|Viral Load
1497499|NCT00013520|Combivir
1497500|NCT00013520|BMS 232632
1497501|NCT00013520|Efavirenz
1497502|NCT00013520|Treatment Naive
1497503|NCT00013507|Frail
1497504|NCT00013507|FIT
1497505|NCT00013507|transfer
1497506|NCT00013507|continence
1497507|NCT00013507|ambulation
1497508|NCT00013507|balance
1497509|NCT00013507|fall risk
1497510|NCT00013507|strength,endurance
1497511|NCT00013494|Hemiplegia
1497512|NCT00013494|elderly
1497513|NCT00013494|Video
1497514|NCT00013494|F-PAT,Functional Performance
1497515|NCT00013494|digitized videoclips
1497516|NCT00013481|stroke, hemiparesis, CNS, motor coordination
1497517|NCT00013468|Hearing loss, ear, steroids, auditory
1497518|NCT00013455|Hearing aid, hearing impaired
1497519|NCT00013442|Aphasia, auditory evoked, aging
1497520|NCT00013429|Vision, Opthalmology, blindness, aging
1497521|NCT00013416|Hearing loss, hearing aid, amplification
1497522|NCT00013403|Vision, quality of life
1497523|NCT00013390|Auditory, tinnitus
1497524|NCT00013377|Low vision, Driving rehabilitation
1497525|NCT00013364|Hearing loss, speech recognition
1497526|NCT00013351|Aging adult, attention, falls, vision
1497527|NCT00013338|Spinal cord injury, ambulation, treadmill
1497745|NCT00011856|Loci
1497528|NCT00013325|Spinal cord injury, heart disease, electrocardiography
1497529|NCT00013312|Spinal cord injury, gastrointestinal motility, gastrointestinal transit
1497530|NCT00013299|Foot ulcers, amputation prevention, diabetes, footwear, insoles
1497531|NCT00013286|Diabetes mellitus, foot ulcer, endothelium
1497532|NCT00013273|Venous insufficiency, plethysmography, hypertension
1497533|NCT00013260|Case management
1497534|NCT00013260|Nurse intervention
1497535|NCT00013195|Telephone
1497536|NCT00012844|Musculoskeletal Disorders
1497537|NCT00012844|Patient Lifting
1497538|NCT00012844|Occupational Accidents
1497539|NCT00012779|Health Care Education
1497540|NCT00012779|Health Care Cost
1497541|NCT00012558|Psychotic Disorders
1497542|NCT00012558|Mood Disorders
1497543|NCT00012558|Manic-Depressive Illness
1497544|NCT00012558|Hypomania
1497545|NCT00012558|Mania
1497546|NCT00012558|Mood Stabilizer
1497547|NCT00012545|Stem Cells
1497548|NCT00012545|Sickle Cell Disease
1497549|NCT00012545|Umbilical Cord Blood
1497550|NCT00012519|Dose-Response Relationship, Drug
1497551|NCT00012519|Drug Therapy, Combination
1497552|NCT00012519|HIV Protease Inhibitors
1497553|NCT00012519|Ritonavir
1497554|NCT00012519|Indinavir
1497555|NCT00012519|Anti-HIV Agents
1497556|NCT00012519|Viral Load
1497557|NCT00012519|Pharmacokinetics
1497558|NCT00012519|Treatment Experienced
1497559|NCT00012493|Cardiac event
1497560|NCT00012493|Heart disease
1497561|NCT00012493|Particulate Matter
1497562|NCT00012480|Lead
1497563|NCT00012480|Male infertility
1497564|NCT00012480|Gene expression
1497565|NCT00012480|Economics, Medical
1497566|NCT00012467|Interferon-gamma, Recombinant
1497567|NCT00012467|Injections, Subcutaneous
1497568|NCT00012467|Itraconazole
1497569|NCT00012467|Dose-Response Relationship, Drug
1497570|NCT00012467|Fluconazole
1497571|NCT00012467|Flucytosine
1497572|NCT00012467|Antifungal Agents
1497573|NCT00012467|Amphotericin B
1497574|NCT00012467|Meningitis, Cryptococcal
1497575|NCT00012454|Transforming Growth Factor-Beta
1497576|NCT00012454|Stroke
1497577|NCT00012454|Prevention
1497578|NCT00012454|Mucosal Tolerance
1497579|NCT00012454|E-selectin
1497580|NCT00012441|Renal Dialysis
1497581|NCT00012428|Cognitive development
1497582|NCT00012428|Prenatal exposure
1497583|NCT00012428|PCBs
1497584|NCT00012389|stage IV colon cancer
1497585|NCT00012389|stage IV rectal cancer
1497586|NCT00012389|recurrent colon cancer
1497587|NCT00012389|recurrent rectal cancer
1497588|NCT00012363|stage IV gastric cancer
1497589|NCT00012363|recurrent gastric cancer
1497590|NCT00012363|stage IV esophageal cancer
1497591|NCT00012363|recurrent esophageal cancer
1497592|NCT00012363|adenocarcinoma of the stomach
1497593|NCT00012363|squamous cell carcinoma of the esophagus
1497594|NCT00012363|adenocarcinoma of the esophagus
1497595|NCT00012350|refractory multiple myeloma
1497596|NCT00012350|stage II multiple myeloma
1497597|NCT00012350|stage III multiple myeloma
1497598|NCT00012350|plasma cell neoplasm
1497599|NCT00012337|stage IV renal cell cancer
1497600|NCT00012337|recurrent renal cell cancer
1497601|NCT00012324|localized unresectable adult primary liver cancer
1497602|NCT00012324|advanced adult primary liver cancer
1497603|NCT00012324|recurrent adult primary liver cancer
1497604|NCT00012324|adult primary hepatocellular carcinoma
1497605|NCT00012311|stage IV breast cancer
1497606|NCT00012311|recurrent breast cancer
1497607|NCT00012259|relapsing chronic myelogenous leukemia
1497608|NCT00012259|blastic phase chronic myelogenous leukemia
1497609|NCT00012259|chronic myelogenous leukemia, BCR-ABL1 positive
1497610|NCT00012246|stage II colon cancer
1497611|NCT00012246|stage III colon cancer
1497612|NCT00012246|stage IV colon cancer
1497613|NCT00012246|stage II gastric cancer
1497614|NCT00012246|stage III gastric cancer
1497615|NCT00012246|stage IV gastric cancer
1497616|NCT00012246|recurrent gastric cancer
1497617|NCT00012246|stage II pancreatic cancer
1497618|NCT00012246|stage III pancreatic cancer
1497619|NCT00012246|recurrent pancreatic cancer
1497620|NCT00012246|stage II rectal cancer
1497621|NCT00012246|stage III rectal cancer
1497622|NCT00012246|stage IV rectal cancer
1497623|NCT00012246|recurrent colon cancer
1497624|NCT00012246|recurrent rectal cancer
1497625|NCT00012246|stage II esophageal cancer
1497626|NCT00012246|stage III esophageal cancer
1497627|NCT00012246|stage IV esophageal cancer
1497628|NCT00012246|recurrent esophageal cancer
1497629|NCT00012246|adenocarcinoma of the stomach
1497630|NCT00012246|small intestine adenocarcinoma
1497631|NCT00012246|localized gallbladder cancer
1497632|NCT00012246|unresectable gallbladder cancer
1497633|NCT00012246|recurrent gallbladder cancer
1497634|NCT00012246|localized extrahepatic bile duct cancer
1497635|NCT00012246|unresectable extrahepatic bile duct cancer
1497636|NCT00012246|recurrent extrahepatic bile duct cancer
1497637|NCT00012246|recurrent small intestine cancer
1497638|NCT00012246|adenocarcinoma of the esophagus
1497639|NCT00012246|adenocarcinoma of the colon
1497744|NCT00011856|Cerebral
1497640|NCT00012246|adenocarcinoma of the rectum
1497641|NCT00012246|adenocarcinoma of the gallbladder
1497642|NCT00012246|adenocarcinoma of the extrahepatic bile duct
1497643|NCT00012246|adenocarcinoma of the pancreas
1497644|NCT00012246|stage IV pancreatic cancer
1497645|NCT00012220|adenocarcinoma of the pancreas
1497646|NCT00012220|stage IV pancreatic cancer
1497647|NCT00012207|recurrent grade 1 follicular lymphoma
1497648|NCT00012207|recurrent grade 2 follicular lymphoma
1497649|NCT00012207|recurrent grade 3 follicular lymphoma
1497650|NCT00012207|recurrent mantle cell lymphoma
1497651|NCT00012207|recurrent marginal zone lymphoma
1497652|NCT00012207|recurrent small lymphocytic lymphoma
1497653|NCT00012207|refractory chronic lymphocytic leukemia
1497654|NCT00012168|stage 0 oropharyngeal cancer
1497655|NCT00012168|stage 0 lip and oral cavity cancer
1497656|NCT00012168|stage I squamous cell carcinoma of the lip and oral cavity
1497657|NCT00012168|stage II squamous cell carcinoma of the lip and oral cavity
1497658|NCT00012168|stage III squamous cell carcinoma of the lip and oral cavity
1497659|NCT00012168|stage IV squamous cell carcinoma of the lip and oral cavity
1497660|NCT00012168|stage I squamous cell carcinoma of the oropharynx
1497661|NCT00012168|stage II squamous cell carcinoma of the oropharynx
1497662|NCT00012168|stage III squamous cell carcinoma of the oropharynx
1497663|NCT00012168|stage IV squamous cell carcinoma of the oropharynx
1497664|NCT00012155|stage IV colon cancer
1497665|NCT00012155|recurrent colon cancer
1497666|NCT00012155|adenocarcinoma of the colon
1497667|NCT00012155|liver metastases
1497668|NCT00012142|stage IV prostate cancer
1497669|NCT00012129|stage IV breast cancer
1497670|NCT00012129|stage IIIA breast cancer
1497671|NCT00012129|recurrent breast cancer
1497672|NCT00012129|stage IIIB breast cancer
1497673|NCT00012129|male breast cancer
1497674|NCT00012116|tumors metastatic to brain
1497675|NCT00012103|non-small cell lung cancer
1497676|NCT00012103|small cell lung cancer
1497677|NCT00012090|recurrent ovarian epithelial cancer
1497678|NCT00012090|fallopian tube cancer
1497679|NCT00012090|primary peritoneal cavity cancer
1497680|NCT00012064|stage IV melanoma
1497681|NCT00012064|recurrent melanoma
1497682|NCT00012051|recurrent grade 3 follicular lymphoma
1497683|NCT00012051|recurrent adult diffuse large cell lymphoma
1497684|NCT00012038|recurrent adult brain tumor
1497685|NCT00012038|adult glioblastoma
1497686|NCT00012038|adult anaplastic astrocytoma
1497687|NCT00012038|adult anaplastic oligodendroglioma
1497688|NCT00012038|adult giant cell glioblastoma
1497689|NCT00012038|adult gliosarcoma
1497690|NCT00012025|stage IV breast cancer
1497691|NCT00012025|recurrent breast cancer
1497692|NCT00012025|stage IIIB breast cancer
1497693|NCT00012025|stage IIIC breast cancer
1497694|NCT00012012|radiation toxicity
1497695|NCT00012012|stage III cervical cancer
1497696|NCT00012012|stage IVA cervical cancer
1497697|NCT00012012|cervical squamous cell carcinoma
1497698|NCT00012012|cervical adenocarcinoma
1497699|NCT00012012|cervical adenosquamous cell carcinoma
1497700|NCT00011999|stage III squamous cell carcinoma of the lip and oral cavity
1497701|NCT00011999|stage IV squamous cell carcinoma of the lip and oral cavity
1497702|NCT00011999|stage III squamous cell carcinoma of the oropharynx
1497703|NCT00011999|stage IV squamous cell carcinoma of the oropharynx
1497704|NCT00011999|stage III squamous cell carcinoma of the hypopharynx
1497705|NCT00011999|stage IV squamous cell carcinoma of the hypopharynx
1497706|NCT00011999|stage III squamous cell carcinoma of the larynx
1497707|NCT00011999|stage IV squamous cell carcinoma of the larynx
1497708|NCT00011973|stage III renal cell cancer
1497709|NCT00011973|stage IV renal cell cancer
1497710|NCT00011973|recurrent renal cell cancer
1497711|NCT00011960|stage I gastric cancer
1497712|NCT00011960|stage II gastric cancer
1497713|NCT00011960|stage III gastric cancer
1497714|NCT00011960|stage I esophageal cancer
1497715|NCT00011960|stage II esophageal cancer
1497716|NCT00011960|stage III esophageal cancer
1497717|NCT00011960|adenocarcinoma of the stomach
1497718|NCT00011960|adenocarcinoma of the esophagus
1497719|NCT00011934|relapsing chronic myelogenous leukemia
1497720|NCT00011934|chronic phase chronic myelogenous leukemia
1497721|NCT00011934|Philadelphia chromosome positive chronic myelogenous leukemia
1497722|NCT00011934|Philadelphia chromosome negative chronic myelogenous leukemia
1497723|NCT00011921|limited stage small cell lung cancer
1497724|NCT00011921|extensive stage small cell lung cancer
1497725|NCT00011908|Safety
1497726|NCT00011908|B-Lymphocyte Depletion
1497727|NCT00011908|Anti-CD22
1497728|NCT00011908|Response
1497729|NCT00011908|Efficacy
1497730|NCT00011908|Lupus
1497731|NCT00011908|Immunotherapy
1497732|NCT00011895|HIV-1
1497733|NCT00011895|Drug Therapy, Combination
1497734|NCT00011895|Zidovudine
1497735|NCT00011895|Lamivudine
1497736|NCT00011895|Drug Combinations
1497737|NCT00011895|RNA, Viral
1497738|NCT00011895|Reverse Transcriptase Inhibitors
1497739|NCT00011895|Anti-HIV Agents
1497740|NCT00011895|Viral Load
1497741|NCT00011895|abacavir
1497742|NCT00011895|efavirenz
1497743|NCT00011856|Intracranial Aneurysms
1497746|NCT00011856|Susceptibility Genes
1497747|NCT00011856|Cerebral Aneurysm
1497748|NCT00011856|Familial Cerebral Aneurysm
1497749|NCT00011856|Genetics
1497750|NCT00011843|X-Linked
1497751|NCT00011843|Heterogeneous
1497752|NCT00011843|Embryologic Development
1497753|NCT00011843|Mental Retardation
1497754|NCT00011843|Brain Development
1497755|NCT00011843|Microphthalmia
1497756|NCT00011843|Anophthalmia
1497757|NCT00011843|Malformations
1497758|NCT00011843|Lenz Dysplasia
1497759|NCT00011843|Microphthalmia/Anophthalmia
1497760|NCT00011843|Mutation Screening
1497761|NCT00011843|Gene Characterization
1497762|NCT00011830|Stem Cell Cryopreservation
1497763|NCT00011830|Leukapheresis
1497764|NCT00011817|Evaluation and Treatment
1497765|NCT00011817|Ophthalmic Genetic Diseases
1497766|NCT00011817|Genetic Testing
1497767|NCT00011817|Genetic Eye Diseases
1497768|NCT00011817|Evaluation
1497769|NCT00011804|Low Back Pain
1497770|NCT00011804|Lumbar Radiculopathy
1497771|NCT00011804|Anticonvulsants
1497772|NCT00011804|Neuropathic Pain
1497773|NCT00011804|Analgesia
1497774|NCT00011804|Sciatica
1497775|NCT00011791|CAH
1497776|NCT00011791|Catecholamines
1497777|NCT00011791|Adrenal Medulla
1497778|NCT00011791|Endocrine
1497779|NCT00011791|Congenital Adrenal Hyperplasia
1497780|NCT00011791|Exercise
1497781|NCT00011791|Healthy Volunteer
1497782|NCT00011778|Cell Cycle
1497783|NCT00011778|NFKB
1497784|NCT00011778|Combined Modality
1497785|NCT00011778|Radiosensitizer
1497786|NCT00011778|Ubiquitin
1497787|NCT00011778|Head and Neck Cancer
1497788|NCT00011778|Squamous Cell Carcinoma
1497789|NCT00011778|Radiation Therapy
1497790|NCT00011778|Protease Inhibitor
1497791|NCT00011765|Aggression
1497792|NCT00011765|Serotonin Reuptake Inhibitors (SSRI)
1497793|NCT00011765|Rage
1497794|NCT00011765|Fear
1497795|NCT00011765|Violence
1497796|NCT00011765|Domestic Violence
1497797|NCT00011765|Physical Aggression
1497798|NCT00011765|Serotonin Reuptake Inhibitor
1497799|NCT00011752|Serotonin Reuptake
1497800|NCT00011752|Large Neutral Amino Acids
1497801|NCT00011752|5-Hydroxyindoleacetic Acid
1497802|NCT00011752|Alcoholism
1497803|NCT00011752|PET
1497804|NCT00011752|TRP
1497805|NCT00011752|Tryptophan Depletion
1497806|NCT00011752|Healthy Volunteer
1497807|NCT00011739|Low back pain, Magnetic resonance imaging (MRI),
1497808|NCT00011726|Pregnancy
1497809|NCT00011726|Lead Exposure
1497810|NCT00011726|Lactation
1497811|NCT00011726|Bone Mineralization
1497812|NCT00011726|Maternal-Fetal Exchange
1497813|NCT00011713|Semen
1497814|NCT00011713|Infertility
1497815|NCT00011713|ART - Assisted Reproduction Technology
1497816|NCT00011713|Phthalates
1497817|NCT00011713|Bisphenol A
1497818|NCT00011700|idiopathic pulmonary hemorrhage in infants,
1497819|NCT00011700|toxigenic mold exposure
1497820|NCT00011687|Fertility
1497821|NCT00011687|Hormones
1497822|NCT00011687|Semen
1497823|NCT00011687|Reproductive Health
1497824|NCT00011674|Lead
1497825|NCT00011674|Prenatal
1497826|NCT00011674|Development
1497827|NCT00011674|Children
1497828|NCT00011674|Psychology
1497829|NCT00011674|Toxicology
1497830|NCT00011674|Teratology
1497831|NCT00011661|Lead poisoning
1497832|NCT00011661|Native Americans
1497833|NCT00011648|Echocardiogram
1497834|NCT00011648|Morbidity
1497835|NCT00011648|Mortality
1497836|NCT00011648|Sickle Cell Anemia
1497837|NCT00011648|Secondary Pulmonary Hypertension
1497838|NCT00011635|Caffeine
1497839|NCT00011635|Cytochrome P 450
1497840|NCT00011635|Dextromethorphan
1497841|NCT00011635|Drug Interaction
1497842|NCT00011635|Metabolism
1497843|NCT00011635|Drug Metabolism
1497844|NCT00011635|Healthy Volunteer
1497845|NCT00011635|Milk Thistle
1497846|NCT00011609|Robotics; Activities of Daily Living; Spinal Cord Injuries
1497847|NCT00011596|Hemiplegia, gait, electric stimulation
1497848|NCT00011583|Cerebrovascular
1497849|NCT00011583|Hemiplegia
1497850|NCT00011583|Robotics
1497851|NCT00011570|defecation
1497852|NCT00011570|electrical stimulation
1497853|NCT00011570|penile erection
1497854|NCT00011570|Spinal cord injury
1497855|NCT00011570|urology
1497856|NCT00011557|Bladder, electromagnetic fields, Spinal cord injury
1497857|NCT00011544|wheelchair, biomechanics, aging, functional outcome, disability
1497858|NCT00011531|Decubitus Ulcers
1497859|NCT00011531|dehiscence
1497860|NCT00011531|SCI
1497861|NCT00011531|wound healing
1497862|NCT00011518|Arsenic
1497863|NCT00011518|Bladder Cancer
1497864|NCT00011518|Drinking Water
1497865|NCT00011505|G-CSF
1497866|NCT00011505|Leukapheresis
1497867|NCT00011505|Stem Cell Cryopreservation
1497868|NCT00011505|Central Line Placement
1497869|NCT00011505|G-CSF Administration
1497870|NCT00011505|Stem Cell Preservation
1497871|NCT00011505|Diamond Blackfan Anemia
1497872|NCT00011505|Healthy Volunteer
1497873|NCT00011492|Oral Cancer
1497874|NCT00011492|Squamous Cell Cancer
1497875|NCT00011492|Head and Neck Cancer
1497876|NCT00011492|Laryngeal Cancer
1497877|NCT00011492|Pharnygeal Cancer
1497878|NCT00011492|Squamous Cell Carcinoma
1497879|NCT00011479|Administration, Oral
1497880|NCT00011479|Drug Administration Schedule
1497881|NCT00011479|Reverse Transcriptase Inhibitors
1497882|NCT00011479|Anti-HIV Agents
1497883|NCT00011479|Pharmacokinetics
1497884|NCT00011479|abacavir
1497885|NCT00011466|ADHD
1497886|NCT00011466|Attention Deficit Hyperactivity Disorder
1497887|NCT00011466|Carbohydrate Craving
1497888|NCT00011453|NQO1
1497889|NCT00011453|DT-diaphorase
1497890|NCT00011453|Benzene
1497891|NCT00011453|Leukemia
1497892|NCT00011453|Aplastic anemia
1497893|NCT00011440|Allergy
1497894|NCT00011440|Air pollution
1497895|NCT00011440|Lung function
1497896|NCT00011440|Inflammation
1497897|NCT00011414|Drug Resistance
1497898|NCT00011414|PEDIATRIC SOLID TUMORS
1497899|NCT00011414|Chemotherapy
1497900|NCT00011414|p-glycoprotien
1497901|NCT00011414|Brain Tumors
1497902|NCT00011414|Childhood Cancer
1497903|NCT00011414|Brain Tumor
1497904|NCT00011388|Organochlorine compounds
1497905|NCT00011388|Endocrine disruptors
1497906|NCT00011388|Sex Hormones
1497907|NCT00011388|Reproductive function
1497908|NCT00011388|Menstrual Disturbances
1497909|NCT00011375|Phosphodiesterase Inhibitor
1497910|NCT00011375|Immunology
1497911|NCT00011375|Immunomodulation
1497912|NCT00011375|Antidepressant
1497913|NCT00011375|Therapy
1497914|NCT00011375|Multiple Sclerosis
1497915|NCT00011375|Immunotherapy
1497916|NCT00011362|NICHD Neonatal Research Network
1497917|NCT00011362|Extremely Low Birth Weight (ELBW)
1497918|NCT00011362|Prematurity
1497919|NCT00011362|Dexamethasone
1497920|NCT00011362|Glucocorticoids
1497921|NCT00011362|Respiratory Distress Syndrome
1497922|NCT00011362|Respiratory insufficiency
1497923|NCT00011362|Steroids
1497924|NCT00011349|Prostate Cancer
1497925|NCT00011336|SCI
1497926|NCT00011336|chronic respiratory symptoms
1497927|NCT00011336|measures of pulmonary function
1497928|NCT00011336|respiratory illness
1497929|NCT00011323|osteoporosis,smoking, alcohol, caffeine
1497930|NCT00011310|Particulates
1497931|NCT00011310|Air Pollution
1497932|NCT00011310|Cardiopulmonary Disease
1497933|NCT00011310|Lung
1497934|NCT00011310|Inflammation
1497935|NCT00011284|Liver
1497936|NCT00011284|Inflammation
1497937|NCT00011284|Endotoxin
1497938|NCT00011284|Neutrophils
1497939|NCT00011284|Hepatocytes
1497940|NCT00011258|Atherosclerosis of the carotid arteries
1497941|NCT00011258|stroke
1497942|NCT00011258|lipoprotein metabolism
1497943|NCT00011258|paraoxonase
1497944|NCT00011245|Arachnoiditis
1497945|NCT00011245|Myelography
1497946|NCT00011245|Intraoperative Ultrasonography
1497947|NCT00011245|Magnetic Resonance
1497948|NCT00011245|CSF Pressure
1497949|NCT00011245|Trauma
1497950|NCT00011245|Meningitis
1497951|NCT00011245|Paralysis
1497952|NCT00011245|Spondylosis
1497953|NCT00011245|Spinal Syringomyelia
1497954|NCT00011245|Presyringomyelia
1497955|NCT00011245|Spinal Cord Edema
1497956|NCT00011245|Magnetic Resonance Imaging (MRI)
1497957|NCT00011245|Intraoperative Radiation
1497958|NCT00011245|Ultrasonography
1497959|NCT00011193|Cardiovascular Diseases
1497960|NCT00011193|Hypertension
1497961|NCT00011193|Postmenopausal
1497962|NCT00011193|Overweight or Obese
1497963|NCT00011193|Women
1497964|NCT00011193|Sedentary
1497965|NCT00011180|Venous thromboembolism (VTE)
1497966|NCT00011180|Deep vein thrombosis (DVT)
1497967|NCT00011180|Pulmonary embolism (PE)
1497968|NCT00011141|Immune-mediated diabetes mellitus
1497969|NCT00011128|HIV-1
1497970|NCT00011128|Drug Resistance, Microbial
1497971|NCT00011128|Microbial Sensitivity Tests
1497972|NCT00011128|Salvage Therapy
1497973|NCT00011128|Anti-HIV Agents
1497974|NCT00011128|Viral Load
1497975|NCT00011128|Treatment Experienced
1497976|NCT00011115|overweight
1497977|NCT00011102|weight gain
1497978|NCT00011089|HIV-1
1497979|NCT00011089|Disease Progression
1497980|NCT00011089|Reverse Transcriptase Inhibitors
1497981|NCT00011089|Anti-HIV Agents
1497982|NCT00011089|9-(2-phosphonylmethoxypropyl)adenine
1497983|NCT00011076|Deskar
1497984|NCT00011076|Fibrosis
1497985|NCT00011076|Myocardium
1497986|NCT00011076|Scarring
1497987|NCT00011076|Arrhythmia
1497988|NCT00011076|Hypertrophic Cardiomyopathy
1497989|NCT00011076|Left Ventricular Diastolic Dysfunction
1497990|NCT00011076|Myocardial Fibrosis
1497991|NCT00011063|Anti-Epileptic
1497992|NCT00011063|CYP2C9
1497993|NCT00011063|Herbal
1497994|NCT00011063|Interaction
1497995|NCT00011063|Metabolism
1497996|NCT00011063|Drug Interaction
1497997|NCT00011063|Drug Metabolism
1497998|NCT00011063|Ginko Biloba
1497999|NCT00011063|Healthy Volunteer
1498000|NCT00011050|Specimen Handling
1498001|NCT00011050|Blood
1498002|NCT00011050|Cryopreservation
1498003|NCT00011050|Lactic Acid
1498004|NCT00011050|Sodium Fluoride
1498005|NCT00011050|Oxalates
1498006|NCT00011037|HIV Antibodies
1498007|NCT00011037|HIV Antigens
1498008|NCT00011037|HIV Envelope Protein gp120
1498009|NCT00011037|AIDS Vaccines
1498010|NCT00011037|CD4-Positive T-Lymphocytes
1498011|NCT00011037|CD8-Positive T-Lymphocytes
1498012|NCT00011037|Neutralization Tests
1498013|NCT00011037|Haiti
1498014|NCT00011037|Brazil
1498015|NCT00011037|Cytotoxicity, Immunologic
1498016|NCT00011037|Epitopes
1498017|NCT00011037|Viral Proteins
1498018|NCT00011037|Trinidad and Tobago
1498019|NCT00011037|Peru
1498020|NCT00011037|HIV Preventive Vaccine
1498021|NCT00011037|HIV Seronegativity
1498022|NCT00011011|HIV-1
1498023|NCT00011011|Drug Administration Schedule
1498024|NCT00011011|AIDS Vaccines
1498025|NCT00011011|CD4 Lymphocyte Count
1498026|NCT00011011|RNA, Viral
1498027|NCT00011011|Anti-HIV Agents
1498028|NCT00011011|Viral Load
1498029|NCT00011011|HIV Therapeutic Vaccine
1498030|NCT00011011|Treatment Interruption
1498031|NCT00010998|Multiple Sclerosis
1498032|NCT00010998|Yoga
1498033|NCT00010985|Backpain
1498034|NCT00010985|Pain
1498035|NCT00010985|Alternative Medicine
1498036|NCT00010985|Acupuncture
1498037|NCT00010985|Chiropractic
1498038|NCT00010985|Massage Therapy
1498039|NCT00010959|menopause
1498040|NCT00010959|hot flashes
1498041|NCT00010959|botanicals
1498042|NCT00010946|acupuncture
1498043|NCT00010946|osteoarthritis
1498044|NCT00010946|elderly
1498045|NCT00010868|bipolar disorder
1498046|NCT00010868|omega-3 fatty acids
1498047|NCT00010868|eicosapentaenoic acid
1498048|NCT00010868|docosahexaenoic acid
1498049|NCT00010855|hypnosis
1498050|NCT00010855|relaxation
1498051|NCT00010855|invasive medical procedures
1498052|NCT00010855|interventional radiology
1498053|NCT00010855|conscious sedation
1498054|NCT00010855|anesthesia
1498055|NCT00010855|complications
1498056|NCT00010855|cost analysis
1498057|NCT00010855|Interventional procedures, complications
1498058|NCT00010855|Angiography
1498059|NCT00010855|Nephrostomy
1498060|NCT00010855|Hepatic chemoembolization
1498061|NCT00010855|Fibroid Embolization
1498062|NCT00010829|Cardiovascular Diseases
1498063|NCT00010829|Osteoporosis
1498064|NCT00010829|Breast Cancer
1498065|NCT00010829|Endometrial Cancer
1498066|NCT00010725|CVD
1498067|NCT00010712|Menopause
1498068|NCT00010712|Hot Flashes
1498069|NCT00010712|Osteoporosis
1498070|NCT00010712|Postmenopausal
1498071|NCT00010699|cvd
1498072|NCT00010608|CVD
1498073|NCT00010530|CVD
1498074|NCT00010504|acupuncture
1498075|NCT00010504|fibromyalgia
1498076|NCT00010504|pain
1498077|NCT00010504|analgesia
1498078|NCT00010491|Diarrhea
1498079|NCT00010491|complementary therapies
1498080|NCT00010452|cystic hygroma
1498081|NCT00010452|lymphangiomas
1498082|NCT00010452|lymphatic malformations
1498083|NCT00010439|arthritis & connective tissue diseases
1498084|NCT00010439|idiopathic juvenile osteoporosis
1498085|NCT00010439|rare disease
1498086|NCT00010426|cystinosis
1498087|NCT00010426|rare disease
1498088|NCT00010426|renal and genitourinary disorders
1498089|NCT00010413|immunologic disorders and infectious disorders
1498090|NCT00010413|pemphigus
1498091|NCT00010413|rare disease
1498092|NCT00010400|antiphospholipid antibody syndrome
1498093|NCT00010400|arthritis & connective tissue diseases
1498094|NCT00010400|immunologic disorders and infectious disorders
1498095|NCT00010400|rare disease
1498096|NCT00010400|systemic lupus erythematosus
1498097|NCT00010387|Felty syndrome
1498098|NCT00010387|autoimmune hemolytic anemia
1498099|NCT00010387|autoimmune neutropenia
1498100|NCT00010387|hematologic disorders
1498101|NCT00010387|immune thrombocytopenic purpura
1498102|NCT00010387|rare disease
1498103|NCT00010374|Diaphragm for Ventilatory Assist
1498104|NCT00010374|environmental/toxic disorders
1498105|NCT00010374|neurologic and psychiatric disorders
1498106|NCT00010374|rare disease
1498107|NCT00010374|spinal cord injury
1498108|NCT00010335|arthritis & connective tissue diseases
1498109|NCT00010335|dermatomyositis
1498110|NCT00010335|immunologic disorders and infectious disorders
1498111|NCT00010335|juvenile rheumatoid arthritis
1498112|NCT00010335|rare disease
1498113|NCT00010335|systemic lupus erythematosus
1498114|NCT00010335|systemic sclerosis
1498115|NCT00010322|stage IV breast cancer
1498116|NCT00010322|recurrent breast cancer
1498117|NCT00010309|stage II melanoma
1498118|NCT00010309|stage III melanoma
1498119|NCT00010309|stage IV melanoma
1498120|NCT00010283|stage III breast cancer
1498121|NCT00010283|stage IV breast cancer
1498122|NCT00010283|stage IIIA breast cancer
1498123|NCT00010283|stage IIIB breast cancer
1498124|NCT00010283|recurrent childhood acute lymphoblastic leukemia
1498125|NCT00010283|recurrent adult Hodgkin lymphoma
1498126|NCT00010283|stage IV cutaneous T-cell non-Hodgkin lymphoma
1498127|NCT00010283|recurrent cutaneous T-cell non-Hodgkin lymphoma
1498128|NCT00010283|Burkitt lymphoma
1498129|NCT00010283|extramedullary plasmacytoma
1498130|NCT00010283|refractory multiple myeloma
1498131|NCT00010283|stage II ovarian epithelial cancer
1498132|NCT00010283|stage III ovarian epithelial cancer
1498133|NCT00010283|stage IV ovarian epithelial cancer
1498134|NCT00010283|recurrent ovarian epithelial cancer
1498135|NCT00010283|disseminated neuroblastoma
1498136|NCT00010283|recurrent neuroblastoma
1498137|NCT00010283|recurrent Wilms tumor and other childhood kidney tumors
1498138|NCT00010283|stage I multiple myeloma
1498139|NCT00010283|stage II multiple myeloma
1498140|NCT00010283|stage III multiple myeloma
1498141|NCT00010283|recurrent childhood lymphoblastic lymphoma
1498142|NCT00010283|stage III chronic lymphocytic leukemia
1498143|NCT00010283|stage IV chronic lymphocytic leukemia
1498144|NCT00010283|recurrent childhood acute myeloid leukemia
1498145|NCT00010283|recurrent adult acute myeloid leukemia
1498146|NCT00010283|recurrent adult acute lymphoblastic leukemia
1498147|NCT00010283|relapsing chronic myelogenous leukemia
1498148|NCT00010283|refractory chronic lymphocytic leukemia
1498149|NCT00010283|stage III malignant testicular germ cell tumor
1498150|NCT00010283|childhood diffuse large cell lymphoma
1498151|NCT00010283|recurrent malignant testicular germ cell tumor
1498152|NCT00010283|childhood immunoblastic large cell lymphoma
1498153|NCT00010283|chronic phase chronic myelogenous leukemia
1498154|NCT00010283|accelerated phase chronic myelogenous leukemia
1498155|NCT00010283|blastic phase chronic myelogenous leukemia
1498156|NCT00010283|meningeal chronic myelogenous leukemia
1498157|NCT00010283|chronic idiopathic myelofibrosis
1498158|NCT00010283|essential thrombocythemia
1498159|NCT00010283|testicular embryonal carcinoma
1498160|NCT00010283|testicular choriocarcinoma
1498161|NCT00010283|testicular teratoma
1498162|NCT00010283|testicular yolk sac tumor
1498163|NCT00010283|testicular embryonal carcinoma and teratoma
1498164|NCT00010283|testicular embryonal carcinoma and teratoma with seminoma
1498165|NCT00010283|testicular embryonal carcinoma and yolk sac tumor
1498166|NCT00010283|testicular embryonal carcinoma and yolk sac tumor with seminoma
1498167|NCT00010283|testicular embryonal carcinoma and seminoma
1498168|NCT00010283|testicular yolk sac tumor and teratoma
1498169|NCT00010283|testicular yolk sac tumor and teratoma with seminoma
1498170|NCT00010283|testicular choriocarcinoma and yolk sac tumor
1498171|NCT00010283|testicular choriocarcinoma and embryonal carcinoma
1498172|NCT00010283|testicular choriocarcinoma and teratoma
1498173|NCT00010283|testicular choriocarcinoma and seminoma
1498174|NCT00010283|refractory hairy cell leukemia
1498175|NCT00010283|recurrent/refractory childhood Hodgkin lymphoma
1498176|NCT00010283|recurrent ovarian germ cell tumor
1498177|NCT00010283|chronic myelomonocytic leukemia
1498178|NCT00010283|ovarian yolk sac tumor
1498179|NCT00010283|ovarian embryonal carcinoma
1498180|NCT00010283|ovarian polyembryoma
1498181|NCT00010283|ovarian choriocarcinoma
1498182|NCT00010283|ovarian immature teratoma
1498183|NCT00010283|ovarian mature teratoma
1498184|NCT00010283|ovarian monodermal and highly specialized teratoma
1498185|NCT00010283|ovarian mixed germ cell tumor
1498186|NCT00010283|acute undifferentiated leukemia
1498187|NCT00010283|stage III grade 1 follicular lymphoma
1498188|NCT00010283|stage III grade 2 follicular lymphoma
1498189|NCT00010283|stage III grade 3 follicular lymphoma
1498190|NCT00010283|stage III adult diffuse small cleaved cell lymphoma
1498191|NCT00010283|stage III adult diffuse mixed cell lymphoma
1498192|NCT00010283|stage III adult diffuse large cell lymphoma
1498193|NCT00010283|stage III adult immunoblastic large cell lymphoma
1498194|NCT00010283|stage III adult lymphoblastic lymphoma
1498195|NCT00010283|stage III adult Burkitt lymphoma
1498196|NCT00010283|stage IV grade 1 follicular lymphoma
1498197|NCT00010283|stage IV grade 2 follicular lymphoma
1498198|NCT00010283|stage IV grade 3 follicular lymphoma
1498199|NCT00010283|stage IV adult diffuse small cleaved cell lymphoma
1498200|NCT00010283|stage IV adult diffuse mixed cell lymphoma
1498201|NCT00010283|stage IV adult diffuse large cell lymphoma
1498202|NCT00010283|stage IV adult immunoblastic large cell lymphoma
1498203|NCT00010283|stage IV adult lymphoblastic lymphoma
1498204|NCT00010283|stage IV adult Burkitt lymphoma
1498205|NCT00010283|recurrent grade 1 follicular lymphoma
1498206|NCT00010283|recurrent grade 2 follicular lymphoma
1498207|NCT00010283|recurrent grade 3 follicular lymphoma
1498208|NCT00010283|recurrent adult diffuse small cleaved cell lymphoma
1498209|NCT00010283|recurrent adult diffuse mixed cell lymphoma
1498210|NCT00010283|recurrent adult diffuse large cell lymphoma
1498211|NCT00010283|recurrent adult immunoblastic large cell lymphoma
1498212|NCT00010283|recurrent adult lymphoblastic lymphoma
1498213|NCT00010283|recurrent adult Burkitt lymphoma
1498214|NCT00010283|recurrent adult T-cell leukemia/lymphoma
1498622|NCT00009035|Antiangiogenesis
1498629|NCT00009009|Immune System
1498215|NCT00010283|secondary acute myeloid leukemia
1498216|NCT00010283|de novo myelodysplastic syndromes
1498217|NCT00010283|poor prognosis metastatic gestational trophoblastic tumor
1498218|NCT00010283|previously treated myelodysplastic syndromes
1498219|NCT00010283|secondary myelodysplastic syndromes
1498220|NCT00010283|graft versus host disease
1498221|NCT00010283|prolymphocytic leukemia
1498222|NCT00010283|primary systemic amyloidosis
1498223|NCT00010283|recurrent childhood small noncleaved cell lymphoma
1498224|NCT00010283|recurrent childhood large cell lymphoma
1498225|NCT00010283|noncontiguous stage II grade 1 follicular lymphoma
1498226|NCT00010283|noncontiguous stage II grade 2 follicular lymphoma
1498227|NCT00010283|noncontiguous stage II grade 3 follicular lymphoma
1498228|NCT00010283|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1498229|NCT00010283|noncontiguous stage II mantle cell lymphoma
1498230|NCT00010283|noncontiguous stage II adult diffuse mixed cell lymphoma
1498231|NCT00010283|noncontiguous stage II adult immunoblastic large cell lymphoma
1498232|NCT00010283|noncontiguous stage II adult diffuse large cell lymphoma
1498233|NCT00010283|noncontiguous stage II adult Burkitt lymphoma
1498234|NCT00010283|noncontiguous stage II adult lymphoblastic lymphoma
1498235|NCT00010283|stage III mantle cell lymphoma
1498236|NCT00010283|stage IV mantle cell lymphoma
1498237|NCT00010283|recurrent mantle cell lymphoma
1498238|NCT00010283|anaplastic large cell lymphoma
1498239|NCT00010283|stage IV mycosis fungoides/Sezary syndrome
1498240|NCT00010283|recurrent mycosis fungoides/Sezary syndrome
1498241|NCT00010283|noncontiguous stage II small lymphocytic lymphoma
1498242|NCT00010283|noncontiguous stage II marginal zone lymphoma
1498243|NCT00010283|recurrent marginal zone lymphoma
1498244|NCT00010283|recurrent small lymphocytic lymphoma
1498245|NCT00010283|stage III small lymphocytic lymphoma
1498246|NCT00010283|stage III marginal zone lymphoma
1498247|NCT00010283|stage IV small lymphocytic lymphoma
1498248|NCT00010283|stage IV marginal zone lymphoma
1498249|NCT00010283|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1498250|NCT00010283|nodal marginal zone B-cell lymphoma
1498251|NCT00010283|splenic marginal zone lymphoma
1498252|NCT00010283|childhood myelodysplastic syndromes
1498253|NCT00010270|stage IV colon cancer
1498254|NCT00010270|stage IV rectal cancer
1498255|NCT00010270|recurrent colon cancer
1498256|NCT00010270|recurrent rectal cancer
1498257|NCT00010270|adenocarcinoma of the colon
1498258|NCT00010270|stage III pancreatic cancer
1498259|NCT00010270|stage II pancreatic cancer
1498260|NCT00010270|recurrent pancreatic cancer
1498261|NCT00010270|adenocarcinoma of the pancreas
1498262|NCT00010270|stage IV gastric cancer
1498263|NCT00010270|adenocarcinoma of the stomach
1498264|NCT00010270|recurrent gastric cancer
1498265|NCT00010270|adenocarcinoma of the esophagus
1498266|NCT00010270|stage IV esophageal cancer
1498267|NCT00010270|stage III esophageal cancer
1498268|NCT00010270|recurrent esophageal cancer
1498269|NCT00010270|stage II esophageal cancer
1498270|NCT00010270|adenocarcinoma of the rectum
1498271|NCT00010270|stage III colon cancer
1498272|NCT00010270|stage III rectal cancer
1498273|NCT00010270|stage III gastric cancer
1498274|NCT00010270|stage IV pancreatic cancer
1498275|NCT00010257|thymoma
1498276|NCT00010257|thymic carcinoma
1498277|NCT00010244|stage IIB prostate cancer
1498278|NCT00010244|stage IIA prostate cancer
1498279|NCT00010244|stage III prostate cancer
1498280|NCT00010231|adenocarcinoma of the prostate
1498281|NCT00010231|stage III prostate cancer
1498282|NCT00010231|stage IV prostate cancer
1498283|NCT00010231|recurrent prostate cancer
1498284|NCT00010218|recurrent non-small cell lung cancer
1498285|NCT00010218|squamous cell lung cancer
1498286|NCT00010218|large cell lung cancer
1498287|NCT00010218|adenocarcinoma of the lung
1498288|NCT00010218|adenosquamous cell lung cancer
1498289|NCT00010218|bronchoalveolar cell lung cancer
1498290|NCT00010179|stage III ovarian epithelial cancer
1498291|NCT00010179|stage IV ovarian epithelial cancer
1498292|NCT00010179|recurrent ovarian epithelial cancer
1498293|NCT00010179|fallopian tube cancer
1498294|NCT00010179|peritoneal cavity cancer
1498295|NCT00010166|stage I pancreatic cancer
1498296|NCT00010166|adenocarcinoma of the pancreas
1498297|NCT00010153|stage I breast cancer
1498298|NCT00010153|stage II breast cancer
1498299|NCT00010140|stage II breast cancer
1498300|NCT00010140|stage IIIA breast cancer
1498301|NCT00010140|stage IIIB breast cancer
1498302|NCT00010140|stage IIIC breast cancer
1498303|NCT00010127|adenocarcinoma of the prostate
1498304|NCT00010127|stage IV prostate cancer
1498305|NCT00010114|childhood central nervous system germ cell tumor
1498306|NCT00010114|childhood choroid plexus tumor
1498307|NCT00010114|untreated childhood supratentorial primitive neuroectodermal tumor
1498308|NCT00010114|untreated childhood medulloblastoma
1498309|NCT00010114|newly diagnosed childhood ependymoma
1498310|NCT00010101|childhood choroid plexus tumor
1498311|NCT00010101|untreated childhood supratentorial primitive neuroectodermal tumor
1498312|NCT00010101|untreated childhood medulloblastoma
1498313|NCT00010101|childhood atypical teratoid/rhabdoid tumor
1498314|NCT00010088|stage II pancreatic cancer
1498315|NCT00010088|stage III pancreatic cancer
1498316|NCT00010088|unresectable extrahepatic bile duct cancer
1498317|NCT00010088|adenocarcinoma of the extrahepatic bile duct
1498318|NCT00010088|adenocarcinoma of the pancreas
1498319|NCT00010088|stage IV pancreatic cancer
1498320|NCT00010075|stage IV breast cancer
1498321|NCT00010075|recurrent breast cancer
1498322|NCT00010062|stage I pancreatic cancer
1498323|NCT00010062|stage II pancreatic cancer
1498324|NCT00010062|stage III pancreatic cancer
1498325|NCT00010062|adenocarcinoma of the pancreas
1498326|NCT00010062|stage IV pancreatic cancer
1498327|NCT00010049|recurrent adult brain tumor
1498328|NCT00010049|adult meningioma
1498329|NCT00010049|adult glioblastoma
1498330|NCT00010049|adult anaplastic astrocytoma
1498331|NCT00010049|adult anaplastic oligodendroglioma
1498332|NCT00010049|adult mixed glioma
1498333|NCT00010049|adult pilocytic astrocytoma
1498334|NCT00010049|adult subependymoma
1498335|NCT00010049|adult grade III meningioma
1498336|NCT00010049|adult giant cell glioblastoma
1498337|NCT00010049|adult gliosarcoma
1498338|NCT00010036|adult glioblastoma
1498339|NCT00010036|adult giant cell glioblastoma
1498340|NCT00010036|adult gliosarcoma
1498341|NCT00010023|stage IV breast cancer
1498342|NCT00010023|stage IIIA breast cancer
1498343|NCT00010023|recurrent breast cancer
1498344|NCT00010023|stage III gastric cancer
1498345|NCT00010023|stage IV gastric cancer
1498346|NCT00010023|recurrent gastric cancer
1498347|NCT00010023|stage IIIB breast cancer
1498348|NCT00010023|stage IIIC breast cancer
1498349|NCT00010023|recurrent non-small cell lung cancer
1498350|NCT00010023|stage III pancreatic cancer
1498351|NCT00010023|recurrent pancreatic cancer
1498352|NCT00010023|stage III esophageal cancer
1498353|NCT00010023|stage IV esophageal cancer
1498354|NCT00010023|recurrent esophageal cancer
1498355|NCT00010023|extensive stage small cell lung cancer
1498356|NCT00010023|recurrent small cell lung cancer
1498357|NCT00010023|metastatic gastrointestinal carcinoid tumor
1498358|NCT00010023|recurrent gastrointestinal carcinoid tumor
1498359|NCT00010023|localized unresectable adult primary liver cancer
1498360|NCT00010023|advanced adult primary liver cancer
1498361|NCT00010023|recurrent adult primary liver cancer
1498362|NCT00010023|small intestine adenocarcinoma
1498363|NCT00010023|unresectable gallbladder cancer
1498364|NCT00010023|recurrent gallbladder cancer
1498365|NCT00010023|unresectable extrahepatic bile duct cancer
1498366|NCT00010023|recurrent extrahepatic bile duct cancer
1498367|NCT00010023|recurrent small intestine cancer
1498368|NCT00010023|stage IIIA non-small cell lung cancer
1498369|NCT00010023|stage IIIB non-small cell lung cancer
1498370|NCT00010023|untreated metastatic squamous neck cancer with occult primary
1498371|NCT00010023|recurrent metastatic squamous neck cancer with occult primary
1498372|NCT00010023|pulmonary carcinoid tumor
1498373|NCT00010023|stage III squamous cell carcinoma of the lip and oral cavity
1498374|NCT00010023|stage III basal cell carcinoma of the lip
1498375|NCT00010023|stage III verrucous carcinoma of the oral cavity
1498376|NCT00010023|stage III mucoepidermoid carcinoma of the oral cavity
1498377|NCT00010023|stage III adenoid cystic carcinoma of the oral cavity
1498378|NCT00010023|stage IV squamous cell carcinoma of the lip and oral cavity
1498379|NCT00010023|stage IV basal cell carcinoma of the lip
1498380|NCT00010023|stage IV verrucous carcinoma of the oral cavity
1498381|NCT00010023|stage IV mucoepidermoid carcinoma of the oral cavity
1498382|NCT00010023|stage IV adenoid cystic carcinoma of the oral cavity
1498383|NCT00010023|recurrent squamous cell carcinoma of the lip and oral cavity
1498384|NCT00010023|recurrent basal cell carcinoma of the lip
1498385|NCT00010023|recurrent verrucous carcinoma of the oral cavity
1498386|NCT00010023|recurrent mucoepidermoid carcinoma of the oral cavity
1498387|NCT00010023|recurrent adenoid cystic carcinoma of the oral cavity
1498388|NCT00010023|stage III squamous cell carcinoma of the oropharynx
1498389|NCT00010023|stage III lymphoepithelioma of the oropharynx
1498390|NCT00010023|stage IV squamous cell carcinoma of the oropharynx
1498391|NCT00010023|stage IV lymphoepithelioma of the oropharynx
1498392|NCT00010023|recurrent squamous cell carcinoma of the oropharynx
1498393|NCT00010023|recurrent lymphoepithelioma of the oropharynx
1498394|NCT00010023|stage III squamous cell carcinoma of the nasopharynx
1498395|NCT00010023|stage III lymphoepithelioma of the nasopharynx
1498396|NCT00010023|stage IV squamous cell carcinoma of the nasopharynx
1498397|NCT00010023|stage IV lymphoepithelioma of the nasopharynx
1498398|NCT00010023|recurrent squamous cell carcinoma of the nasopharynx
1498399|NCT00010023|recurrent lymphoepithelioma of the nasopharynx
1498400|NCT00010023|stage III squamous cell carcinoma of the hypopharynx
1498401|NCT00010023|stage IV squamous cell carcinoma of the hypopharynx
1498402|NCT00010023|recurrent squamous cell carcinoma of the hypopharynx
1498403|NCT00010023|stage III squamous cell carcinoma of the larynx
1498404|NCT00010023|stage III verrucous carcinoma of the larynx
1498405|NCT00010023|stage IV squamous cell carcinoma of the larynx
1498406|NCT00010023|stage IV verrucous carcinoma of the larynx
1498407|NCT00010023|recurrent squamous cell carcinoma of the larynx
1498408|NCT00010023|recurrent verrucous carcinoma of the larynx
1498409|NCT00010023|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1498410|NCT00010023|stage III inverted papilloma of the paranasal sinus and nasal cavity
1498411|NCT00010023|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1498412|NCT00010023|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1498413|NCT00010023|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1498414|NCT00010023|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1498415|NCT00010023|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1498416|NCT00010023|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1498417|NCT00010023|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1498418|NCT00010023|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1498419|NCT00010023|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1498420|NCT00010023|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1498421|NCT00010023|newly diagnosed carcinoma of unknown primary
1498422|NCT00010023|carcinoma of the appendix
1498423|NCT00010023|recurrent carcinoma of unknown primary
1498424|NCT00010023|gastrointestinal stromal tumor
1498425|NCT00010023|recurrent salivary gland cancer
1498426|NCT00010023|stage III salivary gland cancer
1498427|NCT00010023|stage IV salivary gland cancer
1498428|NCT00010023|stage IV pancreatic cancer
1498429|NCT00010010|stage IV breast cancer
1498430|NCT00010010|recurrent breast cancer
1498431|NCT00009997|stage II breast cancer
1498432|NCT00009997|stage IIIA breast cancer
1498433|NCT00009997|stage IIIB breast cancer
1498434|NCT00009971|limited stage small cell lung cancer
1498435|NCT00009971|extensive stage small cell lung cancer
1498436|NCT00009971|recurrent small cell lung cancer
1498437|NCT00009945|stage I breast cancer
1498438|NCT00009945|stage II breast cancer
1498439|NCT00009932|unspecified adult solid tumor, protocol specific
1498440|NCT00009893|localized unresectable adult primary liver cancer
1498441|NCT00009893|advanced adult primary liver cancer
1498442|NCT00009893|recurrent adult primary liver cancer
1498443|NCT00009893|unresectable gallbladder cancer
1498444|NCT00009893|recurrent gallbladder cancer
1498445|NCT00009893|unresectable extrahepatic bile duct cancer
1498446|NCT00009893|recurrent extrahepatic bile duct cancer
1498447|NCT00009880|stage I gastric cancer
1498448|NCT00009880|stage II gastric cancer
1498449|NCT00009880|stage III gastric cancer
1498450|NCT00009880|stage I esophageal cancer
1498451|NCT00009880|stage II esophageal cancer
1498452|NCT00009880|stage III esophageal cancer
1498453|NCT00009880|adenocarcinoma of the stomach
1498454|NCT00009880|squamous cell carcinoma of the esophagus
1498455|NCT00009880|adenocarcinoma of the esophagus
1498456|NCT00009854|adult glioblastoma
1498457|NCT00009854|tumors metastatic to brain
1498458|NCT00009854|adult anaplastic astrocytoma
1498459|NCT00009854|adult anaplastic ependymoma
1498460|NCT00009854|adult anaplastic oligodendroglioma
1498461|NCT00009854|adult giant cell glioblastoma
1498462|NCT00009854|adult gliosarcoma
1498463|NCT00009841|untreated metastatic squamous neck cancer with occult primary
1498464|NCT00009841|recurrent metastatic squamous neck cancer with occult primary
1498465|NCT00009841|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1498466|NCT00009841|stage IV squamous cell carcinoma of the lip and oral cavity
1498467|NCT00009841|recurrent squamous cell carcinoma of the lip and oral cavity
1498468|NCT00009841|stage IV squamous cell carcinoma of the oropharynx
1498469|NCT00009841|recurrent squamous cell carcinoma of the oropharynx
1498470|NCT00009841|stage IV squamous cell carcinoma of the nasopharynx
1498471|NCT00009841|recurrent squamous cell carcinoma of the nasopharynx
1498472|NCT00009841|stage IV squamous cell carcinoma of the hypopharynx
1498473|NCT00009841|recurrent squamous cell carcinoma of the hypopharynx
1498474|NCT00009841|stage IV squamous cell carcinoma of the larynx
1498475|NCT00009841|recurrent squamous cell carcinoma of the larynx
1498476|NCT00009841|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1498477|NCT00009841|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1498478|NCT00009828|unspecified adult solid tumor, protocol specific
1498479|NCT00009815|unspecified adult solid tumor, protocol specific
1498480|NCT00009802|unspecified adult solid tumor, protocol specific
1498481|NCT00009789|stage I non-small cell lung cancer
1498482|NCT00009789|squamous cell lung cancer
1498483|NCT00009789|large cell lung cancer
1498484|NCT00009789|adenocarcinoma of the lung
1498485|NCT00009789|adenosquamous cell lung cancer
1498486|NCT00009789|bronchoalveolar cell lung cancer
1498487|NCT00009776|recurrent grade 1 follicular lymphoma
1498488|NCT00009776|recurrent grade 2 follicular lymphoma
1498489|NCT00009776|recurrent grade 3 follicular lymphoma
1498490|NCT00009776|recurrent adult diffuse small cleaved cell lymphoma
1498491|NCT00009776|recurrent adult diffuse mixed cell lymphoma
1498492|NCT00009776|recurrent adult diffuse large cell lymphoma
1498493|NCT00009776|recurrent adult immunoblastic large cell lymphoma
1498494|NCT00009776|recurrent adult lymphoblastic lymphoma
1498495|NCT00009776|recurrent adult Burkitt lymphoma
1498496|NCT00009776|recurrent mantle cell lymphoma
1498497|NCT00009776|recurrent marginal zone lymphoma
1498498|NCT00009776|recurrent small lymphocytic lymphoma
1498499|NCT00009776|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1498500|NCT00009776|nodal marginal zone B-cell lymphoma
1498501|NCT00009776|splenic marginal zone lymphoma
1498502|NCT00009763|stage IV breast cancer
1498503|NCT00009763|recurrent breast cancer
1498504|NCT00009750|stage IV prostate cancer
1498505|NCT00009750|recurrent prostate cancer
1498506|NCT00009711|long-term effects secondary to cancer therapy in children
1498507|NCT00009711|pulmonary complications
1498508|NCT00009698|recurrent childhood acute myeloid leukemia
1498509|NCT00009698|childhood acute myeloid leukemia in remission
1498510|NCT00009698|childhood acute myeloblastic leukemia without maturation (M1)
1498511|NCT00009698|childhood acute myeloblastic leukemia with maturation (M2)
1498512|NCT00009685|Vaccine
1498513|NCT00009685|HIV
1498514|NCT00009685|Codon-Optimized
1498515|NCT00009685|HIV Vaccine
1498516|NCT00009685|Healthy Volunteer
1498517|NCT00009685|HIV-1 DNA Vaccine
1498518|NCT00009685|HIV Seronegativity
1498519|NCT00009685|HIV Preventive Vaccine
1498520|NCT00009672|Low Back Pain
1498521|NCT00009672|Opioid
1498522|NCT00009672|Antidepressant
1498523|NCT00009672|Randomized Controlled Trial
1498524|NCT00009672|Analgesic
1498525|NCT00009672|Sciatica
1498526|NCT00009659|Endometrium
1498527|NCT00009659|Estrogen
1498528|NCT00009659|Antihormone
1498529|NCT00009659|Menopause
1498530|NCT00009659|Progesterone
1498531|NCT00009659|Postmenopausal Women
1498532|NCT00009659|Hormone Replacement
1498533|NCT00009646|Chronic lung disease
1498534|NCT00009646|Indocin
1498535|NCT00009646|Indomethacin
1498536|NCT00009646|Infants, very low birth weight
1498537|NCT00009646|Intraventricular hemorrhage
1498538|NCT00009646|Necrotizing enterocolitis
1498539|NCT00009646|Patent ductus arteriosus
1498540|NCT00009646|Pulmonary hemorrhage
1498546|NCT00009620|NICHD Neonatal Research Network
1498547|NCT00009620|Extremely Low Birth Weight (ELBW)
1498548|NCT00009620|Prematurity
1498549|NCT00009620|Cerebral hemorrhage
1498550|NCT00009620|Phenobarbital
1498551|NCT00009620|Pregnancy
1498552|NCT00009620|Prenatal care
1498553|NCT00009620|Intraventricular hemorrhage
1498554|NCT00009620|Periventricular leukomalacia
1498555|NCT00009620|Brain injury
1498556|NCT00009620|Brain hemorrhage
1498557|NCT00009581|Endothelial Function
1498558|NCT00009581|Hydroxyurea
1498559|NCT00009581|Leukocyte Gene Expression
1498560|NCT00009581|Nitrosylated Hemoglobin
1498561|NCT00009581|Sickle Cell Anemia
1498562|NCT00009581|Nitric Oxide
1498563|NCT00009568|Antidepressants
1498564|NCT00009568|Platelet Function
1498565|NCT00009568|SSRI
1498566|NCT00009568|Depression
1498567|NCT00009568|Bleeding Time
1498568|NCT00009555|Testosterone
1498569|NCT00009555|Anthropometry
1498570|NCT00009555|Obesity
1498571|NCT00009555|Abdomen
1498572|NCT00009542|Caffeine
1498573|NCT00009542|Cytochrome P 450
1498574|NCT00009542|Dextromethorphan
1498575|NCT00009542|Herbal
1498576|NCT00009542|Interactions
1498577|NCT00009542|Alternative Therapy
1498578|NCT00009542|Healthy Volunteer
1498579|NCT00009542|Kava
1498580|NCT00009256|Quasispecies Variation
1498581|NCT00009256|Genotyping
1498582|NCT00009256|Phenotyping
1498583|NCT00009256|Antiretroviral Therapy
1498584|NCT00009256|Drug Naive Patients
1498585|NCT00009256|HIV
1498586|NCT00009256|Treatment Naive
1498587|NCT00009243|Brain Scans
1498588|NCT00009243|Brain Imaging
1498589|NCT00009243|Brain
1498590|NCT00009243|Alteplase
1498591|NCT00009243|Acute Stroke
1498592|NCT00009243|Stroke
1498593|NCT00009243|TIA
1498594|NCT00009230|Age associated memory impairment
1498595|NCT00009230|Mild cognitive impairment
1498596|NCT00009217|Alzheimer's disease
1498597|NCT00009217|psychosis
1498598|NCT00009217|agitation
1498599|NCT00009217|haloperidol
1498600|NCT00009204|Behavioral problems
1498601|NCT00009204|Agitation
1498602|NCT00009178|Primary Care
1498603|NCT00009178|Fluoxetine
1498604|NCT00009061|HIV-1
1498605|NCT00009061|Drug Therapy, Combination
1498606|NCT00009061|HIV Protease Inhibitors
1498607|NCT00009061|Ritonavir
1498608|NCT00009061|Lamivudine
1498609|NCT00009061|Nelfinavir
1498610|NCT00009061|Reverse Transcriptase Inhibitors
1498611|NCT00009061|Anti-HIV Agents
1498612|NCT00009061|abacavir
1498613|NCT00009048|Dyskinesias
1498614|NCT00009048|L-Dopa Infusion
1498615|NCT00009048|Clinical Trial
1498616|NCT00009048|Motor Function
1498617|NCT00009048|Psychosis
1498618|NCT00009048|Parkinson's Disease
1498619|NCT00009035|Brain
1498620|NCT00009035|Tumor
1498621|NCT00009035|Chemotherapy
1498623|NCT00009035|Radiation
1498624|NCT00009035|CNS Tumor
1498625|NCT00009035|Glioma
1498626|NCT00009035|Medulloblastoma
1498627|NCT00009035|Astrocytoma
1498628|NCT00009035|Glioblastoma
1498630|NCT00009009|Biopsy
1498631|NCT00009009|AIDS
1498632|NCT00009009|HIV
1498633|NCT00009009|End Stage Renal Disease
1498634|NCT00009009|Kidney Transplant
1498635|NCT00008892|Magnetic Resonance Imaging
1498636|NCT00008892|Diffusion Tensor Imaging
1498637|NCT00008892|Twin Study
1498638|NCT00008892|Attention Deficit Hyperactivity Disorder
1498639|NCT00008892|Normal Volunteers
1498640|NCT00008866|HIV-1
1498641|NCT00008866|Didanosine
1498642|NCT00008866|Drug Therapy, Combination
1498643|NCT00008866|Drug Administration Schedule
1498644|NCT00008866|CD4-Positive T-Lymphocytes
1498645|NCT00008866|Hydroxyurea
1498646|NCT00008866|RNA, Viral
1498647|NCT00008866|Genotype
1498648|NCT00008866|Reverse Transcriptase Inhibitors
1498649|NCT00008866|Anti-HIV Agents
1498650|NCT00008866|Viral Load
1498651|NCT00008853|Clinical Evaluation
1498652|NCT00008827|Obesity
1498653|NCT00008827|Behavioral weight control
1498654|NCT00008827|Internet
1498655|NCT00008814|Cognition
1498656|NCT00008814|Infant Development
1498657|NCT00008814|MRI, Functional
1498658|NCT00008736|Feeding intolerance
1498659|NCT00008736|Infant, premature
1498660|NCT00008697|recurrent childhood acute myeloid leukemia
1498661|NCT00008697|recurrent adult acute myeloid leukemia
1498662|NCT00008697|adult acute promyelocytic leukemia (M3)
1498663|NCT00008697|childhood acute promyelocytic leukemia (M3)
1498664|NCT00008554|HIV-1
1498665|NCT00008554|Drug Therapy, Combination
1498666|NCT00008554|HIV Protease Inhibitors
1498667|NCT00008554|Lamivudine
1498668|NCT00008554|Nelfinavir
1498669|NCT00008554|Reverse Transcriptase Inhibitors
1498670|NCT00008554|Anti-HIV Agents
1498671|NCT00008554|abacavir
1498672|NCT00008541|Keratitis
1498673|NCT00008541|Conjunctivitis
1498674|NCT00008541|Meibomitis
1498675|NCT00008541|Corneal Infiltrates
1498676|NCT00008541|Dacryocystitis
1498677|NCT00008541|Blepharitis
1498678|NCT00008541|Dacryoadenitis
1498679|NCT00008541|Corneal Eye Disease
1498680|NCT00008528|HIV-1
1498681|NCT00008528|Drug Therapy, Combination
1498682|NCT00008528|Drug Resistance, Microbial
1498683|NCT00008528|RNA, Viral
1498684|NCT00008528|Membrane Fusion
1498685|NCT00008528|Anti-HIV Agents
1498686|NCT00008528|Viral Load
1498687|NCT00008515|Steroids
1498688|NCT00008515|Age-Related Macular Degeneration
1498689|NCT00008515|Implant
1498690|NCT00008515|Choroidal Neovascularization
1498691|NCT00008515|Sustained Release Implant
1498692|NCT00008502|Genetics
1498693|NCT00008502|African Americans
1498694|NCT00008502|Skin
1498695|NCT00008502|Keloids
1498696|NCT00008502|Familial Disposition
1498697|NCT00008489|Didanosine
1498698|NCT00008489|Gastrointestinal System
1498699|NCT00008489|Tablets
1498700|NCT00008489|Reverse Transcriptase Inhibitors
1498701|NCT00008489|Anti-HIV Agents
1498702|NCT00008489|Capsules
1498703|NCT00008476|Preemptive Analgesia
1498704|NCT00008476|Vanilloid
1498705|NCT00008476|Vanilloid Receptor (VR)
1498706|NCT00008476|Capsaicin
1498707|NCT00008476|Acute Pain
1498708|NCT00008476|Orofacial
1498709|NCT00008476|Visual Analog Scale (VAS)
1498710|NCT00008476|Resiniferatoxin
1498711|NCT00008476|Healthy Volunteer
1498712|NCT00008476|Wisdom Teeth
1498713|NCT00008476|Pain
1498714|NCT00008463|Ribavirin
1498715|NCT00008463|Polyethylene Glycols
1498716|NCT00008463|Interferon Alfa-2a
1498717|NCT00008463|HIV-1
1498718|NCT00008463|Antiviral Agents
1498719|NCT00008463|Hepatitis C, Chronic
1498720|NCT00008437|stage I breast cancer
1498721|NCT00008437|stage II breast cancer
1498722|NCT00008437|stage IIIA breast cancer
1498723|NCT00008424|unspecified childhood solid tumor, protocol specific
1498724|NCT00008411|stage IV breast cancer
1498725|NCT00008411|recurrent breast cancer
1498726|NCT00008398|stage I nasopharyngeal cancer
1498727|NCT00008398|stage II nasopharyngeal cancer
1498728|NCT00008398|stage III nasopharyngeal cancer
1498729|NCT00008398|stage IV nasopharyngeal cancer
1498730|NCT00008398|recurrent nasopharyngeal cancer
1498731|NCT00008398|stage 0 paranasal sinus and nasal cavity cancer
1498732|NCT00008398|stage 0 nasopharyngeal cancer
1498733|NCT00008398|stage 0 oropharyngeal cancer
1498734|NCT00008398|stage 0 laryngeal cancer
1498735|NCT00008398|stage 0 hypopharyngeal cancer
1498736|NCT00008398|untreated metastatic squamous neck cancer with occult primary
1498737|NCT00008398|recurrent metastatic squamous neck cancer with occult primary
1498738|NCT00008398|stage 0 lip and oral cavity cancer
1498739|NCT00008398|stage I lip and oral cavity cancer
1498740|NCT00008398|stage II lip and oral cavity cancer
1498741|NCT00008398|stage III lip and oral cavity cancer
1498742|NCT00008398|stage IV lip and oral cavity cancer
1498743|NCT00008398|recurrent lip and oral cavity cancer
1498744|NCT00008398|stage I hypopharyngeal cancer
1498745|NCT00008398|stage II hypopharyngeal cancer
1498746|NCT00008398|stage III hypopharyngeal cancer
1498747|NCT00008398|stage IV hypopharyngeal cancer
1498748|NCT00008398|recurrent hypopharyngeal cancer
1498749|NCT00008398|stage I paranasal sinus and nasal cavity cancer
1498750|NCT00008398|stage II paranasal sinus and nasal cavity cancer
1498751|NCT00008398|stage III paranasal sinus and nasal cavity cancer
1498752|NCT00008398|stage IV paranasal sinus and nasal cavity cancer
1498753|NCT00008398|recurrent paranasal sinus and nasal cavity cancer
1498754|NCT00008398|stage I oropharyngeal cancer
1498755|NCT00008398|stage II oropharyngeal cancer
1498756|NCT00008398|stage III oropharyngeal cancer
1498757|NCT00008398|stage IV oropharyngeal cancer
1498758|NCT00008398|recurrent oropharyngeal cancer
1498759|NCT00008398|oral complications
1498760|NCT00008398|radiation toxicity
1498761|NCT00008385|stage I non-small cell lung cancer
1498762|NCT00008372|extensive stage small cell lung cancer
1498763|NCT00008372|recurrent small cell lung cancer
1498764|NCT00008359|stage I adult Hodgkin lymphoma
1498765|NCT00008359|stage II adult Hodgkin lymphoma
1498766|NCT00008359|stage III adult Hodgkin lymphoma
1498767|NCT00008359|stage IV adult Hodgkin lymphoma
1498768|NCT00008359|stage IV breast cancer
1498769|NCT00008359|stage IIIA breast cancer
1498770|NCT00008359|monoclonal gammopathy of undetermined significance
1498771|NCT00008359|stage IIIB breast cancer
1498772|NCT00008359|recurrent adult Hodgkin lymphoma
1498773|NCT00008359|stage I cutaneous T-cell non-Hodgkin lymphoma
1498774|NCT00008359|stage II cutaneous T-cell non-Hodgkin lymphoma
1498775|NCT00008359|stage III cutaneous T-cell non-Hodgkin lymphoma
1498776|NCT00008359|stage IV cutaneous T-cell non-Hodgkin lymphoma
1498777|NCT00008359|recurrent cutaneous T-cell non-Hodgkin lymphoma
1498778|NCT00008359|isolated plasmacytoma of bone
1498779|NCT00008359|extramedullary plasmacytoma
1498780|NCT00008359|refractory multiple myeloma
1498781|NCT00008359|stage II ovarian epithelial cancer
1498782|NCT00008359|stage III ovarian epithelial cancer
1498783|NCT00008359|stage IV ovarian epithelial cancer
1498784|NCT00008359|recurrent ovarian epithelial cancer
1498785|NCT00008359|disseminated neuroblastoma
1498786|NCT00008359|recurrent neuroblastoma
1498787|NCT00008359|recurrent Wilms tumor and other childhood kidney tumors
1498788|NCT00008359|stage 0 chronic lymphocytic leukemia
1498789|NCT00008359|Waldenstrom macroglobulinemia
1498790|NCT00008359|stage I multiple myeloma
1498791|NCT00008359|stage II multiple myeloma
1498792|NCT00008359|stage III multiple myeloma
1498793|NCT00008359|stage I chronic lymphocytic leukemia
1498794|NCT00008359|stage II chronic lymphocytic leukemia
1498795|NCT00008359|stage III chronic lymphocytic leukemia
1498796|NCT00008359|stage IV chronic lymphocytic leukemia
1498797|NCT00008359|recurrent adult acute myeloid leukemia
1498798|NCT00008359|recurrent adult acute lymphoblastic leukemia
1498799|NCT00008359|relapsing chronic myelogenous leukemia
1498800|NCT00008359|refractory chronic lymphocytic leukemia
1498801|NCT00008359|small intestine lymphoma
1498802|NCT00008359|stage III malignant testicular germ cell tumor
1498803|NCT00008359|recurrent malignant testicular germ cell tumor
1498804|NCT00008359|unspecified adult solid tumor, protocol specific
1498805|NCT00008359|chronic phase chronic myelogenous leukemia
1498806|NCT00008359|accelerated phase chronic myelogenous leukemia
1498807|NCT00008359|blastic phase chronic myelogenous leukemia
1498808|NCT00008359|meningeal chronic myelogenous leukemia
1498809|NCT00008359|adult acute myeloid leukemia in remission
1498810|NCT00008359|adult acute lymphoblastic leukemia in remission
1498811|NCT00008359|polycythemia vera
1498812|NCT00008359|primary myelofibrosis
1498813|NCT00008359|essential thrombocythemia
1498814|NCT00008359|fever, sweats, and hot flashes
1498815|NCT00008359|testicular embryonal carcinoma
1498816|NCT00008359|testicular choriocarcinoma
1498817|NCT00008359|testicular teratoma
1498818|NCT00008359|testicular yolk sac tumor
1498819|NCT00008359|testicular embryonal carcinoma and teratoma
1498820|NCT00008359|testicular embryonal carcinoma and teratoma with seminoma
1498821|NCT00008359|testicular embryonal carcinoma and yolk sac tumor
1498822|NCT00008359|testicular embryonal carcinoma and yolk sac tumor with seminoma
1498823|NCT00008359|testicular embryonal carcinoma and seminoma
1498824|NCT00008359|testicular yolk sac tumor and teratoma
1498825|NCT00008359|testicular yolk sac tumor and teratoma with seminoma
1498826|NCT00008359|testicular choriocarcinoma and yolk sac tumor
1498827|NCT00008359|testicular choriocarcinoma and embryonal carcinoma
1498828|NCT00008359|testicular choriocarcinoma and teratoma
1498829|NCT00008359|testicular choriocarcinoma and seminoma
1498830|NCT00008359|progressive hairy cell leukemia, initial treatment
1498831|NCT00008359|refractory hairy cell leukemia
1498832|NCT00008359|stage I grade 1 follicular lymphoma
1498833|NCT00008359|stage I grade 2 follicular lymphoma
1498834|NCT00008359|stage I grade 3 follicular lymphoma
1498835|NCT00008359|stage I adult diffuse small cleaved cell lymphoma
1498836|NCT00008359|stage I adult diffuse mixed cell lymphoma
1498837|NCT00008359|stage I adult diffuse large cell lymphoma
1498838|NCT00008359|stage I adult immunoblastic large cell lymphoma
1498839|NCT00008359|stage I adult lymphoblastic lymphoma
1498840|NCT00008359|stage I adult Burkitt lymphoma
1498841|NCT00008359|recurrent ovarian germ cell tumor
1498842|NCT00008359|chronic myelomonocytic leukemia
1498843|NCT00008359|T-cell large granular lymphocyte leukemia
1498844|NCT00008359|ovarian yolk sac tumor
1498845|NCT00008359|ovarian embryonal carcinoma
1498846|NCT00008359|ovarian polyembryoma
1498847|NCT00008359|ovarian choriocarcinoma
1498848|NCT00008359|ovarian immature teratoma
1498849|NCT00008359|ovarian mature teratoma
1498850|NCT00008359|ovarian monodermal and highly specialized teratoma
1498851|NCT00008359|ovarian mixed germ cell tumor
1498852|NCT00008359|acute undifferentiated leukemia
1498853|NCT00008359|stage III grade 1 follicular lymphoma
1498854|NCT00008359|stage III grade 2 follicular lymphoma
1498855|NCT00008359|stage III grade 3 follicular lymphoma
1498856|NCT00008359|stage III adult diffuse small cleaved cell lymphoma
1498857|NCT00008359|stage III adult diffuse mixed cell lymphoma
1498858|NCT00008359|stage III adult diffuse large cell lymphoma
1498859|NCT00008359|stage III adult immunoblastic large cell lymphoma
1498860|NCT00008359|stage III adult lymphoblastic lymphoma
1498861|NCT00008359|stage III adult Burkitt lymphoma
1498862|NCT00008359|stage IV grade 1 follicular lymphoma
1498863|NCT00008359|stage IV grade 2 follicular lymphoma
1498864|NCT00008359|stage IV grade 3 follicular lymphoma
1498865|NCT00008359|stage IV adult diffuse small cleaved cell lymphoma
1498866|NCT00008359|stage IV adult diffuse mixed cell lymphoma
1498867|NCT00008359|stage IV adult diffuse large cell lymphoma
1498868|NCT00008359|stage IV adult immunoblastic large cell lymphoma
1498869|NCT00008359|stage IV adult lymphoblastic lymphoma
1498870|NCT00008359|stage IV adult Burkitt lymphoma
1498871|NCT00008359|recurrent grade 1 follicular lymphoma
1498872|NCT00008359|recurrent grade 2 follicular lymphoma
1498873|NCT00008359|recurrent grade 3 follicular lymphoma
1498874|NCT00008359|recurrent adult diffuse small cleaved cell lymphoma
1498875|NCT00008359|recurrent adult diffuse mixed cell lymphoma
1498876|NCT00008359|recurrent adult diffuse large cell lymphoma
1498877|NCT00008359|recurrent adult immunoblastic large cell lymphoma
1498878|NCT00008359|recurrent adult lymphoblastic lymphoma
1498879|NCT00008359|recurrent adult Burkitt lymphoma
1498880|NCT00008359|stage I adult T-cell leukemia/lymphoma
1498881|NCT00008359|stage II adult T-cell leukemia/lymphoma
1498882|NCT00008359|stage III adult T-cell leukemia/lymphoma
1498883|NCT00008359|stage IV adult T-cell leukemia/lymphoma
1498884|NCT00008359|recurrent adult T-cell leukemia/lymphoma
1498885|NCT00008359|secondary acute myeloid leukemia
1498886|NCT00008359|de novo myelodysplastic syndromes
1498887|NCT00008359|high risk metastatic gestational trophoblastic tumor
1498888|NCT00008359|previously treated myelodysplastic syndromes
1498889|NCT00008359|secondary myelodysplastic syndromes
1498890|NCT00008359|primary central nervous system non-Hodgkin lymphoma
1498891|NCT00008359|neutropenia
1498892|NCT00008359|infection
1498893|NCT00008359|prolymphocytic leukemia
1498894|NCT00008359|AIDS-related peripheral/systemic lymphoma
1498895|NCT00008359|AIDS-related primary CNS lymphoma
1498896|NCT00008359|primary systemic amyloidosis
1498897|NCT00008359|intraocular lymphoma
1498898|NCT00008359|stage I mantle cell lymphoma
1498899|NCT00008359|contiguous stage II grade 1 follicular lymphoma
1498900|NCT00008359|contiguous stage II grade 2 follicular lymphoma
1498901|NCT00008359|contiguous stage II grade 3 follicular lymphoma
1498902|NCT00008359|contiguous stage II adult diffuse small cleaved cell lymphoma
1498903|NCT00008359|contiguous stage II mantle cell lymphoma
1498904|NCT00008359|contiguous stage II adult diffuse mixed cell lymphoma
1498905|NCT00008359|contiguous stage II adult immunoblastic large cell lymphoma
1498906|NCT00008359|contiguous stage II adult diffuse large cell lymphoma
1498907|NCT00008359|contiguous stage II adult Burkitt lymphoma
1498908|NCT00008359|contiguous stage II adult lymphoblastic lymphoma
1498909|NCT00008359|noncontiguous stage II grade 1 follicular lymphoma
1498910|NCT00008359|noncontiguous stage II grade 2 follicular lymphoma
1498911|NCT00008359|noncontiguous stage II grade 3 follicular lymphoma
1498912|NCT00008359|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1498913|NCT00008359|noncontiguous stage II mantle cell lymphoma
1498914|NCT00008359|noncontiguous stage II adult diffuse mixed cell lymphoma
1498915|NCT00008359|noncontiguous stage II adult immunoblastic large cell lymphoma
1498916|NCT00008359|noncontiguous stage II adult diffuse large cell lymphoma
1498917|NCT00008359|noncontiguous stage II adult Burkitt lymphoma
1498918|NCT00008359|noncontiguous stage II adult lymphoblastic lymphoma
1498919|NCT00008359|stage III mantle cell lymphoma
1498920|NCT00008359|stage IV mantle cell lymphoma
1498921|NCT00008359|recurrent mantle cell lymphoma
1498922|NCT00008359|angioimmunoblastic T-cell lymphoma
1498923|NCT00008359|anaplastic large cell lymphoma
1498924|NCT00008359|stage I mycosis fungoides/Sezary syndrome
1498925|NCT00008359|stage II mycosis fungoides/Sezary syndrome
1498926|NCT00008359|stage III mycosis fungoides/Sezary syndrome
1498927|NCT00008359|stage IV mycosis fungoides/Sezary syndrome
1498928|NCT00008359|recurrent mycosis fungoides/Sezary syndrome
1498929|NCT00008359|noncontiguous stage II small lymphocytic lymphoma
1498930|NCT00008359|noncontiguous stage II marginal zone lymphoma
1499392|NCT00008086|adult subependymoma
1498931|NCT00008359|recurrent marginal zone lymphoma
1498932|NCT00008359|recurrent small lymphocytic lymphoma
1498933|NCT00008359|stage I marginal zone lymphoma
1498934|NCT00008359|stage I small lymphocytic lymphoma
1498935|NCT00008359|stage III small lymphocytic lymphoma
1498936|NCT00008359|stage III marginal zone lymphoma
1498937|NCT00008359|stage IV small lymphocytic lymphoma
1498938|NCT00008359|stage IV marginal zone lymphoma
1498939|NCT00008359|contiguous stage II marginal zone lymphoma
1498940|NCT00008359|contiguous stage II small lymphocytic lymphoma
1498941|NCT00008359|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1498942|NCT00008359|nodal marginal zone B-cell lymphoma
1498943|NCT00008359|splenic marginal zone lymphoma
1498944|NCT00008359|childhood myelodysplastic syndromes
1498945|NCT00008346|breast cancer
1498946|NCT00008333|stage IIIB non-small cell lung cancer
1498947|NCT00008333|stage IV non-small cell lung cancer
1498948|NCT00008320|stage IV breast cancer
1498949|NCT00008320|recurrent breast cancer
1498950|NCT00008307|stage I adult Hodgkin lymphoma
1498951|NCT00008307|stage II adult Hodgkin lymphoma
1498952|NCT00008307|stage III adult Hodgkin lymphoma
1498953|NCT00008307|stage IV adult Hodgkin lymphoma
1498954|NCT00008307|recurrent childhood acute lymphoblastic leukemia
1498955|NCT00008307|recurrent adult Hodgkin lymphoma
1498956|NCT00008307|stage I cutaneous T-cell non-Hodgkin lymphoma
1498957|NCT00008307|stage II cutaneous T-cell non-Hodgkin lymphoma
1498958|NCT00008307|stage III cutaneous T-cell non-Hodgkin lymphoma
1498959|NCT00008307|stage IV cutaneous T-cell non-Hodgkin lymphoma
1498960|NCT00008307|recurrent cutaneous T-cell non-Hodgkin lymphoma
1498961|NCT00008307|refractory multiple myeloma
1498962|NCT00008307|stage I multiple myeloma
1498963|NCT00008307|stage II multiple myeloma
1498964|NCT00008307|stage III multiple myeloma
1498965|NCT00008307|stage I childhood lymphoblastic lymphoma
1498966|NCT00008307|stage II childhood lymphoblastic lymphoma
1498967|NCT00008307|stage III childhood lymphoblastic lymphoma
1498968|NCT00008307|stage IV childhood lymphoblastic lymphoma
1498969|NCT00008307|recurrent childhood lymphoblastic lymphoma
1498970|NCT00008307|recurrent childhood acute myeloid leukemia
1498971|NCT00008307|recurrent adult acute myeloid leukemia
1498972|NCT00008307|recurrent adult acute lymphoblastic leukemia
1498973|NCT00008307|relapsing chronic myelogenous leukemia
1498974|NCT00008307|chronic phase chronic myelogenous leukemia
1498975|NCT00008307|accelerated phase chronic myelogenous leukemia
1498976|NCT00008307|blastic phase chronic myelogenous leukemia
1498977|NCT00008307|meningeal chronic myelogenous leukemia
1498978|NCT00008307|untreated adult acute lymphoblastic leukemia
1498979|NCT00008307|untreated adult acute myeloid leukemia
1498980|NCT00008307|untreated childhood acute myeloid leukemia and other myeloid malignancies
1498981|NCT00008307|untreated childhood acute lymphoblastic leukemia
1498982|NCT00008307|adult acute myeloid leukemia in remission
1498983|NCT00008307|adult acute lymphoblastic leukemia in remission
1498984|NCT00008307|childhood acute myeloid leukemia in remission
1498985|NCT00008307|childhood acute lymphoblastic leukemia in remission
1498986|NCT00008307|chronic myelogenous leukemia, BCR-ABL1 positive
1498987|NCT00008307|Philadelphia chromosome negative chronic myelogenous leukemia
1498988|NCT00008307|stage II childhood Hodgkin lymphoma
1498989|NCT00008307|stage I childhood Hodgkin lymphoma
1498990|NCT00008307|stage III childhood Hodgkin lymphoma
1498991|NCT00008307|stage IV childhood Hodgkin lymphoma
1498992|NCT00008307|recurrent/refractory childhood Hodgkin lymphoma
1498993|NCT00008307|stage I grade 1 follicular lymphoma
1498994|NCT00008307|stage I grade 2 follicular lymphoma
1498995|NCT00008307|stage I grade 3 follicular lymphoma
1498996|NCT00008307|stage I adult diffuse small cleaved cell lymphoma
1498997|NCT00008307|stage I adult diffuse mixed cell lymphoma
1498998|NCT00008307|stage I adult diffuse large cell lymphoma
1498999|NCT00008307|stage I adult immunoblastic large cell lymphoma
1499000|NCT00008307|stage I adult lymphoblastic lymphoma
1499001|NCT00008307|stage I adult Burkitt lymphoma
1499002|NCT00008307|stage III grade 1 follicular lymphoma
1499003|NCT00008307|stage III grade 2 follicular lymphoma
1499004|NCT00008307|stage III grade 3 follicular lymphoma
1499005|NCT00008307|stage III adult diffuse small cleaved cell lymphoma
1499006|NCT00008307|stage III adult diffuse mixed cell lymphoma
1499007|NCT00008307|stage III adult diffuse large cell lymphoma
1499008|NCT00008307|stage III adult immunoblastic large cell lymphoma
1499009|NCT00008307|stage III adult lymphoblastic lymphoma
1499010|NCT00008307|stage III adult Burkitt lymphoma
1499011|NCT00008307|stage IV grade 1 follicular lymphoma
1499012|NCT00008307|stage IV grade 2 follicular lymphoma
1499013|NCT00008307|stage IV grade 3 follicular lymphoma
1499014|NCT00008307|stage IV adult diffuse small cleaved cell lymphoma
1499015|NCT00008307|stage IV adult diffuse mixed cell lymphoma
1499016|NCT00008307|stage IV adult diffuse large cell lymphoma
1499017|NCT00008307|stage IV adult immunoblastic large cell lymphoma
1499018|NCT00008307|stage IV adult lymphoblastic lymphoma
1499019|NCT00008307|stage IV adult Burkitt lymphoma
1499020|NCT00008307|recurrent grade 1 follicular lymphoma
1499021|NCT00008307|recurrent grade 2 follicular lymphoma
1499022|NCT00008307|recurrent grade 3 follicular lymphoma
1499023|NCT00008307|recurrent adult diffuse small cleaved cell lymphoma
1499024|NCT00008307|recurrent adult diffuse mixed cell lymphoma
1499025|NCT00008307|recurrent adult diffuse large cell lymphoma
1499026|NCT00008307|recurrent adult immunoblastic large cell lymphoma
1499027|NCT00008307|recurrent adult lymphoblastic lymphoma
1499028|NCT00008307|recurrent adult Burkitt lymphoma
1499029|NCT00008307|stage I adult T-cell leukemia/lymphoma
1499030|NCT00008307|stage II adult T-cell leukemia/lymphoma
1499031|NCT00008307|stage III adult T-cell leukemia/lymphoma
1499032|NCT00008307|stage IV adult T-cell leukemia/lymphoma
1499033|NCT00008307|recurrent adult T-cell leukemia/lymphoma
1499034|NCT00008307|de novo myelodysplastic syndromes
1499035|NCT00008307|previously treated myelodysplastic syndromes
1499036|NCT00008307|secondary myelodysplastic syndromes
1499037|NCT00008307|intraocular lymphoma
1499038|NCT00008307|stage I childhood large cell lymphoma
1499039|NCT00008307|stage II childhood large cell lymphoma
1499040|NCT00008307|stage III childhood large cell lymphoma
1499041|NCT00008307|stage IV childhood large cell lymphoma
1499042|NCT00008307|recurrent childhood large cell lymphoma
1499043|NCT00008307|stage I mantle cell lymphoma
1499044|NCT00008307|contiguous stage II grade 1 follicular lymphoma
1499045|NCT00008307|contiguous stage II grade 2 follicular lymphoma
1499046|NCT00008307|contiguous stage II grade 3 follicular lymphoma
1499047|NCT00008307|contiguous stage II adult diffuse small cleaved cell lymphoma
1499048|NCT00008307|contiguous stage II mantle cell lymphoma
1499049|NCT00008307|contiguous stage II adult diffuse mixed cell lymphoma
1499050|NCT00008307|contiguous stage II adult immunoblastic large cell lymphoma
1499051|NCT00008307|contiguous stage II adult diffuse large cell lymphoma
1499052|NCT00008307|contiguous stage II adult Burkitt lymphoma
1499053|NCT00008307|contiguous stage II adult lymphoblastic lymphoma
1499054|NCT00008307|noncontiguous stage II grade 1 follicular lymphoma
1499055|NCT00008307|noncontiguous stage II grade 2 follicular lymphoma
1499056|NCT00008307|noncontiguous stage II grade 3 follicular lymphoma
1499057|NCT00008307|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1499058|NCT00008307|noncontiguous stage II mantle cell lymphoma
1499059|NCT00008307|noncontiguous stage II adult diffuse mixed cell lymphoma
1499060|NCT00008307|noncontiguous stage II adult immunoblastic large cell lymphoma
1499061|NCT00008307|noncontiguous stage II adult diffuse large cell lymphoma
1499062|NCT00008307|noncontiguous stage II adult Burkitt lymphoma
1499063|NCT00008307|noncontiguous stage II adult lymphoblastic lymphoma
1499064|NCT00008307|stage III mantle cell lymphoma
1499065|NCT00008307|stage IV mantle cell lymphoma
1499066|NCT00008307|recurrent mantle cell lymphoma
1499067|NCT00008307|angioimmunoblastic T-cell lymphoma
1499068|NCT00008307|anaplastic large cell lymphoma
1499069|NCT00008307|stage I mycosis fungoides/Sezary syndrome
1499070|NCT00008307|stage II mycosis fungoides/Sezary syndrome
1499071|NCT00008307|stage III mycosis fungoides/Sezary syndrome
1499072|NCT00008307|stage IV mycosis fungoides/Sezary syndrome
1499073|NCT00008307|recurrent mycosis fungoides/Sezary syndrome
1499074|NCT00008307|childhood chronic myelogenous leukemia
1499075|NCT00008307|contiguous stage II small lymphocytic lymphoma
1499076|NCT00008307|contiguous stage II marginal zone lymphoma
1499077|NCT00008307|noncontiguous stage II small lymphocytic lymphoma
1499078|NCT00008307|noncontiguous stage II marginal zone lymphoma
1499079|NCT00008307|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499080|NCT00008307|nodal marginal zone B-cell lymphoma
1499081|NCT00008307|splenic marginal zone lymphoma
1499082|NCT00008307|recurrent marginal zone lymphoma
1499083|NCT00008307|recurrent small lymphocytic lymphoma
1499084|NCT00008307|stage I marginal zone lymphoma
1499085|NCT00008307|stage I small lymphocytic lymphoma
1499086|NCT00008307|stage III small lymphocytic lymphoma
1499087|NCT00008307|stage III marginal zone lymphoma
1499088|NCT00008307|stage IV small lymphocytic lymphoma
1499089|NCT00008307|stage IV marginal zone lymphoma
1499090|NCT00008307|adult acute myeloid leukemia with t(8;21)(q22;q22)
1499091|NCT00008307|adult acute myeloid leukemia with t(16;16)(p13;q22)
1499092|NCT00008307|adult acute myeloid leukemia with inv(16)(p13;q22)
1499093|NCT00008307|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1499094|NCT00008307|adult acute myeloid leukemia with t(15;17)(q22;q12)
1499095|NCT00008307|childhood myelodysplastic syndromes
1499096|NCT00008294|stage IV colon cancer
1499097|NCT00008294|stage IV rectal cancer
1499098|NCT00008294|adenocarcinoma of the colon
1499099|NCT00008294|adenocarcinoma of the rectum
1499100|NCT00008294|liver metastases
1499101|NCT00008294|recurrent colon cancer
1499102|NCT00008294|recurrent rectal cancer
1499103|NCT00008281|stage IV colon cancer
1499104|NCT00008281|stage IV rectal cancer
1499105|NCT00008281|recurrent colon cancer
1499106|NCT00008281|recurrent rectal cancer
1499107|NCT00008281|adenocarcinoma of the colon
1499108|NCT00008281|adenocarcinoma of the rectum
1499109|NCT00008268|stage I multiple myeloma
1499110|NCT00008268|stage II multiple myeloma
1499111|NCT00008268|stage III multiple myeloma
1499112|NCT00008255|non-small cell lung cancer
1499113|NCT00008255|small cell lung cancer
1499114|NCT00008242|stage II multiple myeloma
1499115|NCT00008242|stage III multiple myeloma
1499116|NCT00008229|stage I multiple myeloma
1499117|NCT00008229|stage II multiple myeloma
1499118|NCT00008229|stage III multiple myeloma
1499119|NCT00008216|stage IV adult Hodgkin lymphoma
1499120|NCT00008216|recurrent childhood acute lymphoblastic leukemia
1499121|NCT00008216|recurrent adult Hodgkin lymphoma
1499122|NCT00008216|recurrent cutaneous T-cell non-Hodgkin lymphoma
1499123|NCT00008216|refractory multiple myeloma
1499124|NCT00008216|stage I multiple myeloma
1499125|NCT00008216|stage II multiple myeloma
1499126|NCT00008216|stage III multiple myeloma
1499127|NCT00008216|stage II childhood lymphoblastic lymphoma
1499128|NCT00008216|stage III childhood lymphoblastic lymphoma
1499129|NCT00008216|stage IV childhood lymphoblastic lymphoma
1499130|NCT00008216|recurrent childhood lymphoblastic lymphoma
1499131|NCT00008216|recurrent childhood acute myeloid leukemia
1499132|NCT00008216|recurrent adult acute myeloid leukemia
1499133|NCT00008216|recurrent adult acute lymphoblastic leukemia
1499134|NCT00008216|relapsing chronic myelogenous leukemia
1499135|NCT00008216|childhood Langerhans cell histiocytosis
1499136|NCT00008216|chronic phase chronic myelogenous leukemia
1499137|NCT00008216|accelerated phase chronic myelogenous leukemia
1499138|NCT00008216|blastic phase chronic myelogenous leukemia
1499139|NCT00008216|meningeal chronic myelogenous leukemia
1499140|NCT00008216|untreated adult acute lymphoblastic leukemia
1499141|NCT00008216|untreated adult acute myeloid leukemia
1499142|NCT00008216|untreated childhood acute myeloid leukemia and other myeloid malignancies
1499143|NCT00008216|untreated childhood acute lymphoblastic leukemia
1499144|NCT00008216|adult acute myeloid leukemia in remission
1499145|NCT00008216|adult acute lymphoblastic leukemia in remission
1499146|NCT00008216|childhood acute myeloid leukemia in remission
1499147|NCT00008216|childhood acute lymphoblastic leukemia in remission
1499148|NCT00008216|chronic myelogenous leukemia, BCR-ABL1 positive
1499149|NCT00008216|Philadelphia chromosome negative chronic myelogenous leukemia
1499150|NCT00008216|stage IV childhood Hodgkin lymphoma
1499151|NCT00008216|recurrent/refractory childhood Hodgkin lymphoma
1499152|NCT00008216|stage III grade 1 follicular lymphoma
1499153|NCT00008216|stage III grade 2 follicular lymphoma
1499154|NCT00008216|stage III grade 3 follicular lymphoma
1499155|NCT00008216|stage III adult diffuse small cleaved cell lymphoma
1499156|NCT00008216|stage III adult diffuse mixed cell lymphoma
1499157|NCT00008216|stage III adult diffuse large cell lymphoma
1499158|NCT00008216|stage III adult immunoblastic large cell lymphoma
1499159|NCT00008216|stage III adult lymphoblastic lymphoma
1499160|NCT00008216|stage III adult Burkitt lymphoma
1499161|NCT00008216|stage IV grade 1 follicular lymphoma
1499162|NCT00008216|stage IV grade 2 follicular lymphoma
1499163|NCT00008216|stage IV grade 3 follicular lymphoma
1499164|NCT00008216|stage IV adult diffuse small cleaved cell lymphoma
1499165|NCT00008216|stage IV adult diffuse mixed cell lymphoma
1499166|NCT00008216|stage IV adult diffuse large cell lymphoma
1499167|NCT00008216|stage IV adult immunoblastic large cell lymphoma
1499168|NCT00008216|stage IV adult lymphoblastic lymphoma
1499169|NCT00008216|stage IV adult Burkitt lymphoma
1499170|NCT00008216|recurrent grade 1 follicular lymphoma
1499171|NCT00008216|recurrent grade 2 follicular lymphoma
1499172|NCT00008216|recurrent grade 3 follicular lymphoma
1499173|NCT00008216|recurrent adult diffuse small cleaved cell lymphoma
1499174|NCT00008216|recurrent adult diffuse mixed cell lymphoma
1499175|NCT00008216|recurrent adult diffuse large cell lymphoma
1499176|NCT00008216|recurrent adult immunoblastic large cell lymphoma
1499177|NCT00008216|recurrent adult lymphoblastic lymphoma
1499178|NCT00008216|recurrent adult Burkitt lymphoma
1499179|NCT00008216|stage II adult T-cell leukemia/lymphoma
1499180|NCT00008216|stage III adult T-cell leukemia/lymphoma
1499181|NCT00008216|stage IV adult T-cell leukemia/lymphoma
1499182|NCT00008216|recurrent adult T-cell leukemia/lymphoma
1499183|NCT00008216|secondary acute myeloid leukemia
1499184|NCT00008216|de novo myelodysplastic syndromes
1499185|NCT00008216|previously treated myelodysplastic syndromes
1499186|NCT00008216|secondary myelodysplastic syndromes
1499187|NCT00008216|intraocular lymphoma
1499188|NCT00008216|stage II childhood small noncleaved cell lymphoma
1499189|NCT00008216|stage II childhood large cell lymphoma
1499190|NCT00008216|stage III childhood small noncleaved cell lymphoma
1499191|NCT00008216|stage III childhood large cell lymphoma
1499192|NCT00008216|stage IV childhood small noncleaved cell lymphoma
1499193|NCT00008216|stage IV childhood large cell lymphoma
1499194|NCT00008216|recurrent childhood small noncleaved cell lymphoma
1499195|NCT00008216|recurrent childhood large cell lymphoma
1499196|NCT00008216|contiguous stage II grade 1 follicular lymphoma
1499197|NCT00008216|contiguous stage II grade 2 follicular lymphoma
1499198|NCT00008216|contiguous stage II grade 3 follicular lymphoma
1499199|NCT00008216|contiguous stage II adult diffuse small cleaved cell lymphoma
1499200|NCT00008216|contiguous stage II mantle cell lymphoma
1499201|NCT00008216|contiguous stage II adult diffuse mixed cell lymphoma
1499202|NCT00008216|contiguous stage II adult immunoblastic large cell lymphoma
1499203|NCT00008216|contiguous stage II adult diffuse large cell lymphoma
1499204|NCT00008216|contiguous stage II adult Burkitt lymphoma
1499205|NCT00008216|contiguous stage II adult lymphoblastic lymphoma
1499206|NCT00008216|noncontiguous stage II grade 1 follicular lymphoma
1499207|NCT00008216|noncontiguous stage II grade 2 follicular lymphoma
1499208|NCT00008216|noncontiguous stage II grade 3 follicular lymphoma
1499209|NCT00008216|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1499210|NCT00008216|noncontiguous stage II mantle cell lymphoma
1499592|NCT00007800|obesity treatment
1499211|NCT00008216|noncontiguous stage II adult diffuse mixed cell lymphoma
1499212|NCT00008216|noncontiguous stage II adult immunoblastic large cell lymphoma
1499213|NCT00008216|noncontiguous stage II adult diffuse large cell lymphoma
1499214|NCT00008216|noncontiguous stage II adult Burkitt lymphoma
1499215|NCT00008216|noncontiguous stage II adult lymphoblastic lymphoma
1499216|NCT00008216|stage III mantle cell lymphoma
1499217|NCT00008216|stage IV mantle cell lymphoma
1499218|NCT00008216|recurrent mantle cell lymphoma
1499219|NCT00008216|angioimmunoblastic T-cell lymphoma
1499220|NCT00008216|anaplastic large cell lymphoma
1499221|NCT00008216|recurrent mycosis fungoides/Sezary syndrome
1499222|NCT00008216|juvenile myelomonocytic leukemia
1499223|NCT00008216|childhood chronic myelogenous leukemia
1499224|NCT00008216|atypical chronic myeloid leukemia, BCR-ABL1 negative
1499225|NCT00008216|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1499226|NCT00008216|chronic myelomonocytic leukemia
1499227|NCT00008216|contiguous stage II small lymphocytic lymphoma
1499228|NCT00008216|contiguous stage II marginal zone lymphoma
1499229|NCT00008216|noncontiguous stage II small lymphocytic lymphoma
1499230|NCT00008216|noncontiguous stage II marginal zone lymphoma
1499231|NCT00008216|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499232|NCT00008216|nodal marginal zone B-cell lymphoma
1499233|NCT00008216|splenic marginal zone lymphoma
1499234|NCT00008216|recurrent marginal zone lymphoma
1499235|NCT00008216|recurrent small lymphocytic lymphoma
1499236|NCT00008216|stage III small lymphocytic lymphoma
1499237|NCT00008216|stage III marginal zone lymphoma
1499238|NCT00008216|stage IV small lymphocytic lymphoma
1499239|NCT00008216|stage IV marginal zone lymphoma
1499240|NCT00008216|adult acute myeloid leukemia with t(8;21)(q22;q22)
1499241|NCT00008216|adult acute myeloid leukemia with t(16;16)(p13;q22)
1499242|NCT00008216|adult acute myeloid leukemia with inv(16)(p13;q22)
1499243|NCT00008216|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1499244|NCT00008216|adult acute myeloid leukemia with t(15;17)(q22;q12)
1499245|NCT00008216|childhood myelodysplastic syndromes
1499246|NCT00008216|adult Langerhans cell histiocytosis
1499247|NCT00008203|stage II breast cancer
1499248|NCT00008203|stage IIIA breast cancer
1499249|NCT00008203|stage IIIB breast cancer
1499250|NCT00008190|recurrent childhood acute lymphoblastic leukemia
1499251|NCT00008190|recurrent childhood acute myeloid leukemia
1499252|NCT00008190|recurrent adult acute myeloid leukemia
1499253|NCT00008190|recurrent adult acute lymphoblastic leukemia
1499254|NCT00008190|adult acute myeloid leukemia in remission
1499255|NCT00008190|adult acute lymphoblastic leukemia in remission
1499256|NCT00008190|childhood acute myeloid leukemia in remission
1499257|NCT00008190|childhood acute lymphoblastic leukemia in remission
1499258|NCT00008190|secondary acute myeloid leukemia
1499259|NCT00008164|recurrent childhood acute lymphoblastic leukemia
1499260|NCT00008164|recurrent adult Hodgkin lymphoma
1499261|NCT00008164|recurrent cutaneous T-cell non-Hodgkin lymphoma
1499262|NCT00008164|refractory multiple myeloma
1499263|NCT00008164|stage I multiple myeloma
1499264|NCT00008164|stage II multiple myeloma
1499265|NCT00008164|stage III multiple myeloma
1499266|NCT00008164|recurrent childhood lymphoblastic lymphoma
1499267|NCT00008164|recurrent childhood acute myeloid leukemia
1499268|NCT00008164|recurrent adult acute myeloid leukemia
1499269|NCT00008164|recurrent adult acute lymphoblastic leukemia
1499270|NCT00008164|relapsing chronic myelogenous leukemia
1499271|NCT00008164|childhood Langerhans cell histiocytosis
1499272|NCT00008164|chronic phase chronic myelogenous leukemia
1499273|NCT00008164|accelerated phase chronic myelogenous leukemia
1499274|NCT00008164|blastic phase chronic myelogenous leukemia
1499275|NCT00008164|meningeal chronic myelogenous leukemia
1499276|NCT00008164|untreated adult acute lymphoblastic leukemia
1499277|NCT00008164|untreated adult acute myeloid leukemia
1499278|NCT00008164|untreated childhood acute myeloid leukemia and other myeloid malignancies
1499279|NCT00008164|untreated childhood acute lymphoblastic leukemia
1499280|NCT00008164|recurrent/refractory childhood Hodgkin lymphoma
1499281|NCT00008164|stage I adult Burkitt lymphoma
1499282|NCT00008164|stage III grade 1 follicular lymphoma
1499283|NCT00008164|stage III grade 2 follicular lymphoma
1499284|NCT00008164|stage III grade 3 follicular lymphoma
1499285|NCT00008164|stage III adult diffuse small cleaved cell lymphoma
1499286|NCT00008164|stage III adult diffuse mixed cell lymphoma
1499287|NCT00008164|stage III adult diffuse large cell lymphoma
1499288|NCT00008164|stage III adult immunoblastic large cell lymphoma
1499289|NCT00008164|stage III adult lymphoblastic lymphoma
1499290|NCT00008164|stage III adult Burkitt lymphoma
1499291|NCT00008164|stage IV grade 1 follicular lymphoma
1499292|NCT00008164|stage IV grade 2 follicular lymphoma
1499293|NCT00008164|stage IV grade 3 follicular lymphoma
1499294|NCT00008164|stage IV adult diffuse small cleaved cell lymphoma
1499295|NCT00008164|stage IV adult diffuse mixed cell lymphoma
1499296|NCT00008164|stage IV adult diffuse large cell lymphoma
1499297|NCT00008164|stage IV adult immunoblastic large cell lymphoma
1499298|NCT00008164|stage IV adult lymphoblastic lymphoma
1499299|NCT00008164|stage IV adult Burkitt lymphoma
1499300|NCT00008164|recurrent grade 1 follicular lymphoma
1499301|NCT00008164|recurrent grade 2 follicular lymphoma
1499302|NCT00008164|recurrent grade 3 follicular lymphoma
1499303|NCT00008164|recurrent adult diffuse small cleaved cell lymphoma
1499304|NCT00008164|recurrent adult diffuse mixed cell lymphoma
1499305|NCT00008164|recurrent adult diffuse large cell lymphoma
1499306|NCT00008164|recurrent adult immunoblastic large cell lymphoma
1499307|NCT00008164|recurrent adult lymphoblastic lymphoma
1499308|NCT00008164|recurrent adult Burkitt lymphoma
1499309|NCT00008164|de novo myelodysplastic syndromes
1499310|NCT00008164|previously treated myelodysplastic syndromes
1499311|NCT00008164|secondary myelodysplastic syndromes
1499312|NCT00008164|recurrent childhood small noncleaved cell lymphoma
1499313|NCT00008164|recurrent childhood large cell lymphoma
1499314|NCT00008164|contiguous stage II adult Burkitt lymphoma
1499315|NCT00008164|contiguous stage II adult lymphoblastic lymphoma
1499316|NCT00008164|noncontiguous stage II grade 1 follicular lymphoma
1499317|NCT00008164|noncontiguous stage II grade 2 follicular lymphoma
1499318|NCT00008164|noncontiguous stage II grade 3 follicular lymphoma
1499319|NCT00008164|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1499320|NCT00008164|noncontiguous stage II mantle cell lymphoma
1499321|NCT00008164|noncontiguous stage II adult diffuse mixed cell lymphoma
1499322|NCT00008164|noncontiguous stage II adult immunoblastic large cell lymphoma
1499323|NCT00008164|noncontiguous stage II adult diffuse large cell lymphoma
1499324|NCT00008164|noncontiguous stage II adult Burkitt lymphoma
1499325|NCT00008164|noncontiguous stage II adult lymphoblastic lymphoma
1499326|NCT00008164|stage III mantle cell lymphoma
1499327|NCT00008164|stage IV mantle cell lymphoma
1499328|NCT00008164|recurrent mantle cell lymphoma
1499329|NCT00008164|recurrent mycosis fungoides/Sezary syndrome
1499330|NCT00008164|childhood chronic myelogenous leukemia
1499331|NCT00008164|atypical chronic myeloid leukemia, BCR-ABL1 negative
1499332|NCT00008164|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1499333|NCT00008164|noncontiguous stage II small lymphocytic lymphoma
1499334|NCT00008164|noncontiguous stage II marginal zone lymphoma
1499335|NCT00008164|recurrent marginal zone lymphoma
1499336|NCT00008164|recurrent small lymphocytic lymphoma
1499337|NCT00008164|stage III small lymphocytic lymphoma
1499338|NCT00008164|stage III marginal zone lymphoma
1499339|NCT00008164|stage IV small lymphocytic lymphoma
1499340|NCT00008164|stage IV marginal zone lymphoma
1499341|NCT00008164|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499342|NCT00008164|nodal marginal zone B-cell lymphoma
1499343|NCT00008164|splenic marginal zone lymphoma
1499344|NCT00008164|adult acute myeloid leukemia with t(8;21)(q22;q22)
1499345|NCT00008164|adult acute myeloid leukemia with t(16;16)(p13;q22)
1499346|NCT00008164|adult acute myeloid leukemia with inv(16)(p13;q22)
1499347|NCT00008164|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1499348|NCT00008164|adult acute myeloid leukemia with t(15;17)(q22;q12)
1499349|NCT00008164|childhood myelodysplastic syndromes
1499350|NCT00008151|recurrent childhood acute myeloid leukemia
1499351|NCT00008151|recurrent adult acute myeloid leukemia
1499352|NCT00008151|refractory anemia with excess blasts
1499353|NCT00008151|refractory anemia with excess blasts in transformation
1499354|NCT00008151|de novo myelodysplastic syndromes
1499355|NCT00008151|previously treated myelodysplastic syndromes
1499356|NCT00008151|secondary myelodysplastic syndromes
1499357|NCT00008151|childhood myelodysplastic syndromes
1499358|NCT00008138|stage III ovarian epithelial cancer
1499359|NCT00008138|stage IV ovarian epithelial cancer
1499360|NCT00008138|ovarian undifferentiated adenocarcinoma
1499361|NCT00008138|ovarian serous cystadenocarcinoma
1499362|NCT00008138|ovarian mucinous cystadenocarcinoma
1499363|NCT00008138|ovarian endometrioid adenocarcinoma
1499364|NCT00008138|ovarian clear cell cystadenocarcinoma
1499365|NCT00008138|fallopian tube cancer
1499366|NCT00008138|peritoneal cavity cancer
1499367|NCT00008125|unspecified adult solid tumor, protocol specific
1499368|NCT00008112|stage III cervical cancer
1499369|NCT00008112|stage IIB cervical cancer
1499370|NCT00008112|stage IVA cervical cancer
1499371|NCT00008112|cervical squamous cell carcinoma
1499372|NCT00008112|cervical adenocarcinoma
1499373|NCT00008112|cervical adenosquamous cell carcinoma
1499374|NCT00008099|stage I pancreatic cancer
1499375|NCT00008099|stage II pancreatic cancer
1499376|NCT00008099|stage III pancreatic cancer
1499377|NCT00008099|stage IV pancreatic cancer
1499378|NCT00008086|recurrent adult brain tumor
1499379|NCT00008086|adult brain stem glioma
1499380|NCT00008086|adult craniopharyngioma
1499381|NCT00008086|adult medulloblastoma
1499382|NCT00008086|adult meningioma
1499383|NCT00008086|adult glioblastoma
1499384|NCT00008086|unspecified adult solid tumor, protocol specific
1499385|NCT00008086|adult anaplastic astrocytoma
1499386|NCT00008086|adult myxopapillary ependymoma
1499387|NCT00008086|adult anaplastic ependymoma
1499388|NCT00008086|adult anaplastic oligodendroglioma
1499389|NCT00008086|adult mixed glioma
1499390|NCT00008086|adult central nervous system germ cell tumor
1499391|NCT00008086|adult pilocytic astrocytoma
1499393|NCT00008086|adult ependymoblastoma
1499394|NCT00008086|adult pineocytoma
1499395|NCT00008086|adult pineoblastoma
1499396|NCT00008086|adult meningeal hemangiopericytoma
1499397|NCT00008086|adult choroid plexus tumor
1499398|NCT00008086|adult grade III meningioma
1499399|NCT00008086|adult oligodendroglioma
1499400|NCT00008086|adult giant cell glioblastoma
1499401|NCT00008086|adult gliosarcoma
1499402|NCT00008073|unspecified adult solid tumor, protocol specific
1499403|NCT00008060|stage IV colon cancer
1499404|NCT00008060|stage IV rectal cancer
1499405|NCT00008060|recurrent colon cancer
1499406|NCT00008060|recurrent rectal cancer
1499407|NCT00008060|adenocarcinoma of the colon
1499408|NCT00008060|adenocarcinoma of the rectum
1499409|NCT00008047|stage II esophageal cancer
1499410|NCT00008047|stage III esophageal cancer
1499411|NCT00008034|stage II breast cancer
1499412|NCT00008034|stage IIIA breast cancer
1499413|NCT00008034|stage IIIB breast cancer
1499414|NCT00008034|inflammatory breast cancer
1499415|NCT00008021|recurrent grade 1 follicular lymphoma
1499416|NCT00008021|recurrent grade 2 follicular lymphoma
1499417|NCT00008021|recurrent grade 3 follicular lymphoma
1499418|NCT00008021|recurrent adult diffuse small cleaved cell lymphoma
1499419|NCT00008021|recurrent adult diffuse mixed cell lymphoma
1499420|NCT00008021|recurrent adult diffuse large cell lymphoma
1499421|NCT00008021|recurrent adult immunoblastic large cell lymphoma
1499422|NCT00008021|recurrent adult lymphoblastic lymphoma
1499423|NCT00008021|recurrent adult Burkitt lymphoma
1499424|NCT00008021|recurrent mantle cell lymphoma
1499425|NCT00008021|recurrent marginal zone lymphoma
1499426|NCT00008021|recurrent small lymphocytic lymphoma
1499427|NCT00008021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499428|NCT00008021|nodal marginal zone B-cell lymphoma
1499429|NCT00008021|splenic marginal zone lymphoma
1499430|NCT00008008|childhood infratentorial ependymoma
1499431|NCT00008008|childhood supratentorial ependymoma
1499432|NCT00008008|recurrent adult brain tumor
1499433|NCT00008008|adult medulloblastoma
1499434|NCT00008008|adult glioblastoma
1499435|NCT00008008|adult oligodendroglioma
1499436|NCT00008008|childhood high-grade cerebral astrocytoma
1499437|NCT00008008|childhood oligodendroglioma
1499438|NCT00008008|adult anaplastic astrocytoma
1499439|NCT00008008|adult anaplastic ependymoma
1499440|NCT00008008|adult mixed glioma
1499441|NCT00008008|recurrent childhood supratentorial primitive neuroectodermal tumor
1499442|NCT00008008|recurrent childhood cerebellar astrocytoma
1499443|NCT00008008|recurrent childhood cerebral astrocytoma
1499444|NCT00008008|recurrent childhood ependymoma
1499445|NCT00008008|adult giant cell glioblastoma
1499446|NCT00008008|adult gliosarcoma
1499447|NCT00008008|adult supratentorial primitive neuroectodermal tumor (PNET)
1499448|NCT00007995|refractory multiple myeloma
1499449|NCT00007995|stage I multiple myeloma
1499450|NCT00007995|stage II multiple myeloma
1499451|NCT00007995|stage III multiple myeloma
1499452|NCT00007995|primary systemic amyloidosis
1499453|NCT00007982|recurrent adult brain tumor
1499454|NCT00007982|adult medulloblastoma
1499455|NCT00007982|adult oligodendroglioma
1499456|NCT00007982|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1499457|NCT00007982|adult anaplastic astrocytoma
1499458|NCT00007982|adult central nervous system germ cell tumor
1499459|NCT00007982|primary central nervous system non-Hodgkin lymphoma
1499460|NCT00007982|adult anaplastic oligodendroglioma
1499461|NCT00007969|stage III melanoma
1499462|NCT00007969|stage IV melanoma
1499463|NCT00007969|recurrent melanoma
1499464|NCT00007956|recurrent grade 1 follicular lymphoma
1499465|NCT00007956|recurrent grade 2 follicular lymphoma
1499466|NCT00007956|recurrent grade 3 follicular lymphoma
1499467|NCT00007956|recurrent adult diffuse small cleaved cell lymphoma
1499468|NCT00007956|recurrent adult diffuse mixed cell lymphoma
1499469|NCT00007956|recurrent adult diffuse large cell lymphoma
1499470|NCT00007956|recurrent adult immunoblastic large cell lymphoma
1499471|NCT00007956|recurrent adult Burkitt lymphoma
1499472|NCT00007956|recurrent mantle cell lymphoma
1499473|NCT00007956|recurrent small lymphocytic lymphoma
1499474|NCT00007943|stage III colon cancer
1499475|NCT00007943|stage IV colon cancer
1499476|NCT00007943|stage III rectal cancer
1499477|NCT00007943|stage IV rectal cancer
1499478|NCT00007943|recurrent colon cancer
1499479|NCT00007943|recurrent rectal cancer
1499480|NCT00007930|stage I rectal cancer
1499481|NCT00007930|stage II rectal cancer
1499482|NCT00007930|stage III rectal cancer
1499483|NCT00007917|unspecified adult solid tumor, protocol specific
1499484|NCT00007904|stage II breast cancer
1499485|NCT00007904|stage IIIA breast cancer
1499486|NCT00007904|male breast cancer
1499487|NCT00007891|stage IV breast cancer
1499488|NCT00007891|recurrent breast cancer
1499489|NCT00007891|male breast cancer
1499490|NCT00007865|recurrent grade 1 follicular lymphoma
1499491|NCT00007865|recurrent grade 2 follicular lymphoma
1499492|NCT00007865|recurrent grade 3 follicular lymphoma
1499493|NCT00007865|recurrent adult diffuse small cleaved cell lymphoma
1499494|NCT00007865|recurrent adult diffuse mixed cell lymphoma
1499495|NCT00007865|recurrent adult diffuse large cell lymphoma
1499496|NCT00007865|recurrent adult immunoblastic large cell lymphoma
1499497|NCT00007865|recurrent adult Burkitt lymphoma
1499498|NCT00007865|recurrent mantle cell lymphoma
1499499|NCT00007865|recurrent marginal zone lymphoma
1499500|NCT00007865|recurrent small lymphocytic lymphoma
1499501|NCT00007865|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499502|NCT00007865|nodal marginal zone B-cell lymphoma
1499503|NCT00007865|splenic marginal zone lymphoma
1499504|NCT00007852|recurrent grade 1 follicular lymphoma
1499505|NCT00007852|recurrent grade 2 follicular lymphoma
1499506|NCT00007852|recurrent grade 3 follicular lymphoma
1499507|NCT00007852|recurrent adult diffuse small cleaved cell lymphoma
1499508|NCT00007852|recurrent adult diffuse mixed cell lymphoma
1499509|NCT00007852|recurrent adult diffuse large cell lymphoma
1499510|NCT00007852|recurrent adult immunoblastic large cell lymphoma
1499511|NCT00007852|recurrent adult Burkitt lymphoma
1499512|NCT00007852|recurrent mantle cell lymphoma
1499513|NCT00007852|recurrent marginal zone lymphoma
1499514|NCT00007852|recurrent small lymphocytic lymphoma
1499515|NCT00007852|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499516|NCT00007852|nodal marginal zone B-cell lymphoma
1499517|NCT00007852|splenic marginal zone lymphoma
1499518|NCT00007839|stage I grade 1 follicular lymphoma
1499519|NCT00007839|stage I grade 2 follicular lymphoma
1499520|NCT00007839|stage I adult diffuse small cleaved cell lymphoma
1499521|NCT00007839|stage III grade 1 follicular lymphoma
1499522|NCT00007839|stage III grade 2 follicular lymphoma
1499523|NCT00007839|stage III adult diffuse small cleaved cell lymphoma
1499524|NCT00007839|stage IV grade 1 follicular lymphoma
1499525|NCT00007839|stage IV grade 2 follicular lymphoma
1499526|NCT00007839|stage IV adult diffuse small cleaved cell lymphoma
1499527|NCT00007839|recurrent grade 1 follicular lymphoma
1499528|NCT00007839|recurrent grade 2 follicular lymphoma
1499529|NCT00007839|recurrent adult diffuse small cleaved cell lymphoma
1499530|NCT00007839|contiguous stage II grade 1 follicular lymphoma
1499531|NCT00007839|contiguous stage II grade 2 follicular lymphoma
1499532|NCT00007839|contiguous stage II adult diffuse small cleaved cell lymphoma
1499533|NCT00007839|noncontiguous stage II grade 1 follicular lymphoma
1499534|NCT00007839|noncontiguous stage II grade 2 follicular lymphoma
1499535|NCT00007839|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1499536|NCT00007839|noncontiguous stage II small lymphocytic lymphoma
1499537|NCT00007839|noncontiguous stage II marginal zone lymphoma
1499538|NCT00007839|recurrent marginal zone lymphoma
1499539|NCT00007839|recurrent small lymphocytic lymphoma
1499540|NCT00007839|stage I marginal zone lymphoma
1499541|NCT00007839|stage I small lymphocytic lymphoma
1499542|NCT00007839|stage III small lymphocytic lymphoma
1499543|NCT00007839|stage III marginal zone lymphoma
1499544|NCT00007839|stage IV small lymphocytic lymphoma
1499545|NCT00007839|stage IV marginal zone lymphoma
1499546|NCT00007839|contiguous stage II marginal zone lymphoma
1499547|NCT00007839|contiguous stage II small lymphocytic lymphoma
1499548|NCT00007839|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1499549|NCT00007839|nodal marginal zone B-cell lymphoma
1499550|NCT00007839|splenic marginal zone lymphoma
1499551|NCT00007826|stage II colon cancer
1499552|NCT00007826|stage III colon cancer
1499553|NCT00007826|stage IV colon cancer
1499554|NCT00007826|stage II rectal cancer
1499555|NCT00007826|stage III rectal cancer
1499556|NCT00007826|stage IV rectal cancer
1499557|NCT00007826|adenocarcinoma of the colon
1499558|NCT00007826|adenocarcinoma of the rectum
1499559|NCT00007813|recurrent childhood rhabdomyosarcoma
1499560|NCT00007813|childhood craniopharyngioma
1499561|NCT00007813|recurrent childhood brain tumor
1499562|NCT00007813|disseminated neuroblastoma
1499563|NCT00007813|stage 4S neuroblastoma
1499564|NCT00007813|recurrent neuroblastoma
1499565|NCT00007813|stage IV childhood liver cancer
1499566|NCT00007813|recurrent childhood liver cancer
1499567|NCT00007813|childhood hepatoblastoma
1499568|NCT00007813|childhood central nervous system germ cell tumor
1499569|NCT00007813|stage III malignant testicular germ cell tumor
1499570|NCT00007813|recurrent malignant testicular germ cell tumor
1499571|NCT00007813|childhood germ cell tumor
1499572|NCT00007813|stage IV ovarian germ cell tumor
1499573|NCT00007813|recurrent ovarian germ cell tumor
1499574|NCT00007813|extragonadal germ cell tumor
1499575|NCT00007813|childhood oligodendroglioma
1499576|NCT00007813|childhood choroid plexus tumor
1499577|NCT00007813|childhood grade III meningioma
1499578|NCT00007813|recurrent childhood cerebellar astrocytoma
1499579|NCT00007813|recurrent childhood cerebral astrocytoma
1499580|NCT00007813|recurrent childhood medulloblastoma
1499581|NCT00007813|recurrent childhood visual pathway and hypothalamic glioma
1499582|NCT00007813|previously treated childhood rhabdomyosarcoma
1499583|NCT00007813|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1499584|NCT00007813|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1499585|NCT00007813|recurrent childhood ependymoma
1499586|NCT00007813|childhood teratoma
1499587|NCT00007813|childhood malignant testicular germ cell tumor
1499588|NCT00007813|childhood malignant ovarian germ cell tumor
1499589|NCT00007813|childhood extragonadal germ cell tumor
1499590|NCT00007813|recurrent childhood malignant germ cell tumor
1499591|NCT00007813|childhood atypical teratoid/rhabdoid tumor
1499593|NCT00007800|non insulin dependent diabetes
1499594|NCT00007800|type 2 diabetes
1499595|NCT00007800|behavioral weight control
1499596|NCT00007800|motivational interviewing
1499597|NCT00007800|motivational enhancement
1499598|NCT00007774|Olanzapine, haloperidol, schizophrenia, schisoaffe
1499599|NCT00007761|Bipolar Disease Program intervention
1499600|NCT00007748|aerobic exercise
1499601|NCT00007748|cognitive behavioral therapy
1499602|NCT00007748|CBT
1499603|NCT00007748|Gulf War Illnesses
1499604|NCT00007748|GWI
1499605|NCT00007735|antibiotic treatment
1499606|NCT00007735|mycoplasma species
1499607|NCT00007735|Gulf War Veterans' Illnesses (GWI)
1499608|NCT00007735|mycoplasma positive
1499609|NCT00007735|Gulf War Syndrome
1499610|NCT00007722|ALS
1499611|NCT00007722|amyotrophic lateral sclerosis
1499612|NCT00007722|Gulf War Veterans
1499613|NCT00007709|Hepatitis C
1499614|NCT00007709|HIV
1499615|NCT00007709|severe mental illness (SMI)
1499616|NCT00007696|Diabetes Mellitus,DM,glycemic control
1499617|NCT00007683|aspirin
1499618|NCT00007683|clopidogrel
1499619|NCT00007683|embolic events
1499620|NCT00007683|Left ventricular ejection fraction less than or eq
1499621|NCT00007683|NYHA Class II, III or IV CHF
1499622|NCT00007683|symptomatic CHF
1499623|NCT00007683|warfarin
1499624|NCT00007670|gabapentin
1499625|NCT00007670|lamotrigine
1499626|NCT00007670|seizures in the elderly
1499627|NCT00007670|Carbamazepine
1499628|NCT00007657|PCI plus intensive medical therapy
1499629|NCT00007644|cancer of the prostate (CAP)
1499630|NCT00007644|cancer treatment
1499631|NCT00007644|chronic diseases
1499632|NCT00007644|expectant management
1499633|NCT00007644|genitourinary
1499634|NCT00007644|prostate
1499635|NCT00007644|prostate specific cancer mortality
1499636|NCT00007644|radical prostatectomy
1499637|NCT00007631|NMSC
1499638|NCT00007631|nonmelanoma skin cancer
1499639|NCT00007631|topical tretinoin cream
1499640|NCT00007618|colorectal cancer
1499641|NCT00007605|amiodarone
1499642|NCT00007605|atrial fibrillation converted to sinus rhythm
1499643|NCT00007605|cardiac mortality
1499644|NCT00007605|major and minor bleeds
1499645|NCT00007605|sinus rhythm
1499646|NCT00007605|sotalol
1499647|NCT00007592|Hypertension
1499648|NCT00007592|national data base on the treatment of hypertension
1499649|NCT00007592|cost of different antihypertensive regimens
1499650|NCT00007579|prostate cancer
1499651|NCT00007540|Prostate cancer
1499652|NCT00007540|CAG repeat sequence
1499653|NCT00007527|buprenorphine and naloxone
1499654|NCT00007527|opiate dependence
1499655|NCT00007527|narcotic treatment
1499656|NCT00007514|olfactory functioning
1499657|NCT00007514|neurotoxic exposure
1499658|NCT00007514|Gulf War-era veterans
1499659|NCT00007501|varicella-zoster vaccine
1499660|NCT00007488|HIV-1
1499661|NCT00007488|Lymphoid Tissue
1499662|NCT00007488|Viremia
1499663|NCT00007488|RNA, Viral
1499664|NCT00007488|Saliva
1499665|NCT00007488|Anti-HIV Agents
1499666|NCT00007488|Viral Load
1499667|NCT00007488|Genitalia, Female
1499668|NCT00007488|Genitalia, Male
1499669|NCT00007475|Plasma Exchange
1499670|NCT00007475|Cyclophosphamide
1499671|NCT00007475|Proteinuria
1499672|NCT00007475|Hemodialysis
1499673|NCT00007475|Expression Profiling
1499674|NCT00007449|HIV-1
1499675|NCT00007449|Drug Therapy, Combination
1499676|NCT00007449|RNA, Viral
1499677|NCT00007449|Reverse Transcriptase Inhibitors
1499678|NCT00007449|Anti-HIV Agents
1499679|NCT00007449|Viral Load
1499680|NCT00007436|HIV-1
1499681|NCT00007436|Drug Therapy, Combination
1499682|NCT00007436|Reverse Transcriptase Inhibitors
1499683|NCT00007436|Anti-HIV Agents
1499684|NCT00007436|9-(2-phosphonylmethoxypropyl)adenine
1499685|NCT00007423|HIV Antibodies
1499686|NCT00007423|HIV-1
1499687|NCT00007423|AIDS Vaccines
1499688|NCT00007423|HIV Seronegativity
1499689|NCT00007423|Uganda
1499690|NCT00007423|Cross Reactions
1499691|NCT00007423|HIV Preventive Vaccine
1499692|NCT00007358|Dexamethasone
1499693|NCT00007358|Anti-SSA/Ro antibodies
1499694|NCT00007358|Anti-SSB/La antibodies
1499695|NCT00007358|Ultrasound
1499696|NCT00007358|Atrioventricular (AV) nodal dysfunction
1499697|NCT00007358|Echocardiograms
1499698|NCT00007358|Mothers
1499699|NCT00007345|Histone Acetylase
1499700|NCT00007345|Differentiation
1499701|NCT00007345|Sezary Syndrome
1499702|NCT00007345|Mycosis Fungoides
1499703|NCT00007345|CD 30 Lymphoma
1499704|NCT00007332|Drug Therapy, Combination
1499705|NCT00007332|HIV Envelope Protein gp120
1499706|NCT00007332|AIDS Vaccines
1499707|NCT00007332|CD8-Positive T-Lymphocytes
1499708|NCT00007332|HIV Seronegativity
1499709|NCT00007332|AIDSVAX
1499710|NCT00007332|HIV Preventive Vaccine
1499711|NCT00007319|HIV Protease Inhibitors
1499712|NCT00007319|Risk Factors
1499713|NCT00007319|HIV Seronegativity
1499714|NCT00007319|Anti-HIV Agents
1499715|NCT00007319|Carotid Artery
1499716|NCT00007319|Tunica Intima
1499717|NCT00007319|Atherosclerosis
1499718|NCT00007306|Parathyroid hormone
1499719|NCT00007306|Psoriasis
1499720|NCT00007306|Lesions
1499721|NCT00007306|Topical medications
1499722|NCT00007306|Ointment
1499723|NCT00007306|Calcium metabolism
1499724|NCT00007306|Skin biopsy
1499725|NCT00007293|Phototherapy
1499726|NCT00007293|Psoriasis
1499727|NCT00007293|Scalp psoriasis
1499728|NCT00007293|Fiber optic
1499729|NCT00007293|Light comb
1499730|NCT00007293|UV source
1499731|NCT00007280|Bioengineered skin
1499732|NCT00007280|Venous leg ulcer
1499733|NCT00007267|Scleroderma
1499734|NCT00007267|Systemic sclerosis
1499735|NCT00007267|Depression
1499736|NCT00007267|Pain
1499737|NCT00007267|Disfigurement
1499738|NCT00007267|Body image dissatisfaction
1499739|NCT00007267|Cognitive-behavioral therapy
1499740|NCT00007267|Self-help
1499741|NCT00007267|Psychological intervention
1499742|NCT00007254|Analgesia
1499743|NCT00007254|Bedsore
1499744|NCT00007254|Morphine gel
1499745|NCT00007254|Pressure ulcer
1499746|NCT00007254|Pain
1499747|NCT00007254|Ulcer
1499748|NCT00007241|Osteoarthritis
1499749|NCT00007241|Knee
1499750|NCT00007241|OA
1499751|NCT00007241|Isometric
1499752|NCT00007241|Exercise
1499753|NCT00007241|Strengthening
1499754|NCT00007241|Joint-related pain
1499755|NCT00007228|Chorea
1499756|NCT00007228|DCM
1499757|NCT00007228|Hypertrophic Cardiomyopathy
1499758|NCT00007228|Sudden Death
1499759|NCT00007228|Neuroacanthocytosis
1499760|NCT00007215|Cataract
1499761|NCT00007215|Early Lens Changes
1499762|NCT00007215|Protein Aggregation
1499763|NCT00007215|Blindness
1499764|NCT00007215|Vision
1499765|NCT00007215|Dynamic Laser Scattering (DLS)
1499766|NCT00007215|Age-Related Changes
1499767|NCT00007215|Test Re-test Reproducibility
1499768|NCT00007215|Normal Volunteers
1499769|NCT00007215|Lens
1499770|NCT00007215|Healthy Volunteer
1499771|NCT00007202|Virus Replication
1499772|NCT00007202|HIV-1
1499773|NCT00007202|Didanosine
1499774|NCT00007202|Drug Therapy, Combination
1499775|NCT00007202|Stavudine
1499776|NCT00007202|HIV Protease Inhibitors
1499777|NCT00007202|Sensitivity and Specificity
1499778|NCT00007202|Reverse Transcriptase Inhibitors
1499779|NCT00007202|Anti-HIV Agents
1499780|NCT00007202|Viral Load
1499781|NCT00007202|Reverse Transcriptase Polymerase Chain Reaction
1499782|NCT00007202|Acute Infection
1499783|NCT00007189|Alzheimer disease
1499784|NCT00007189|Anti-inflammatory drugs
1499785|NCT00007163|Immunosuppression
1499786|NCT00007163|Recombinant IgG1
1499787|NCT00007163|Apoptosis
1499788|NCT00007163|Interferon Gamma
1499789|NCT00007163|Colonoscopy
1499790|NCT00007163|Crohn's Disease
1499791|NCT00007163|Immunotherapy
1499792|NCT00007163|IL-12
1499793|NCT00007150|Phlebotomy Therapy
1499794|NCT00007150|Hemochromatosis
1499795|NCT00007150|Iron Overload
1499796|NCT00007150|Hereditary Hemochromatosis
1499797|NCT00007150|Blood Donation
1499798|NCT00007137|3D MRI
1499799|NCT00007137|Diffusion Tensor
1499800|NCT00007137|Tongue
1499801|NCT00007137|Ultrasound
1499802|NCT00007137|Volume
1499803|NCT00007137|Healthy Volunteer
1499804|NCT00007137|Swallowing
1499805|NCT00007137|Tongue Weakness
1499806|NCT00007137|Tongue Movement Coordination Problem
1499807|NCT00007124|Myoclonus
1499808|NCT00007124|Epilepsy
1499809|NCT00007124|Dementia
1499810|NCT00007124|Polyglucosan
1499811|NCT00007124|Insulin
1499812|NCT00007124|Lafora Disease
1499813|NCT00007124|Restrictive Carbohydrate Diet
1499814|NCT00007059|disease-related problem/condition
1499815|NCT00007059|graft versus host disease
1499816|NCT00007059|rare disease
1499817|NCT00007046|arthritis & connective tissue diseases
1499818|NCT00007046|bone cancer
1499819|NCT00007046|diaphyseal medullary stenosis
1499820|NCT00007046|genetic diseases and dysmorphic syndromes
1499821|NCT00007046|malignant fibrous histiocytoma of bone
1499822|NCT00007046|musculoskeletal/mesodermal cancer
1499823|NCT00007046|oncologic disorders
1499824|NCT00007046|rare disease
1499825|NCT00007033|Alagille syndrome
1499826|NCT00007033|biliary atresia
1499827|NCT00007033|cholestasis
1499828|NCT00007033|gastrointestinal disorders
1499829|NCT00007033|rare disease
1499830|NCT00007007|tumors metastatic to brain
1499831|NCT00007007|radiation toxicity
1499832|NCT00007007|cognitive/functional effects
1499833|NCT00006994|oral complications of radiation therapy
1499834|NCT00006994|pain
1499835|NCT00006994|radiation toxicity
1499836|NCT00006994|stage I squamous cell carcinoma of the lip and oral cavity
1499837|NCT00006994|stage II squamous cell carcinoma of the lip and oral cavity
1499838|NCT00006994|stage III squamous cell carcinoma of the lip and oral cavity
1499839|NCT00006994|stage IV squamous cell carcinoma of the lip and oral cavity
1499840|NCT00006994|stage I squamous cell carcinoma of the oropharynx
1499841|NCT00006994|stage II squamous cell carcinoma of the oropharynx
1499842|NCT00006994|stage III squamous cell carcinoma of the oropharynx
1499843|NCT00006994|stage IV squamous cell carcinoma of the oropharynx
1499844|NCT00006981|recurrent non-small cell lung cancer
1499845|NCT00006981|stage III cervical cancer
1499846|NCT00006981|recurrent cervical cancer
1499847|NCT00006981|stage IVB cervical cancer
1499848|NCT00006981|stage IVA cervical cancer
1499849|NCT00006981|squamous cell lung cancer
1499850|NCT00006981|stage III ovarian epithelial cancer
1499851|NCT00006981|stage IV ovarian epithelial cancer
1499852|NCT00006981|recurrent ovarian epithelial cancer
1499853|NCT00006981|advanced malignant mesothelioma
1499854|NCT00006981|recurrent malignant mesothelioma
1499855|NCT00006981|stage IIIA non-small cell lung cancer
1499856|NCT00006981|stage IIIB non-small cell lung cancer
1499857|NCT00006981|stage IV non-small cell lung cancer
1499858|NCT00006981|recurrent metastatic squamous neck cancer with occult primary
1499859|NCT00006981|ovarian undifferentiated adenocarcinoma
1499860|NCT00006981|ovarian mixed epithelial carcinoma
1499861|NCT00006981|ovarian serous cystadenocarcinoma
1499862|NCT00006981|ovarian endometrioid adenocarcinoma
1499863|NCT00006981|ovarian clear cell cystadenocarcinoma
1499864|NCT00006981|cervical squamous cell carcinoma
1499865|NCT00006981|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1499866|NCT00006981|stage III squamous cell carcinoma of the lip and oral cavity
1499867|NCT00006981|stage IV squamous cell carcinoma of the lip and oral cavity
1499868|NCT00006981|recurrent squamous cell carcinoma of the lip and oral cavity
1499869|NCT00006981|stage III squamous cell carcinoma of the oropharynx
1499870|NCT00006981|stage IV squamous cell carcinoma of the oropharynx
1499871|NCT00006981|recurrent squamous cell carcinoma of the oropharynx
1499872|NCT00006981|stage III squamous cell carcinoma of the nasopharynx
1499873|NCT00006981|stage IV squamous cell carcinoma of the nasopharynx
1499874|NCT00006981|recurrent squamous cell carcinoma of the nasopharynx
1499875|NCT00006981|stage III squamous cell carcinoma of the hypopharynx
1499876|NCT00006981|stage IV squamous cell carcinoma of the hypopharynx
1499877|NCT00006981|recurrent squamous cell carcinoma of the hypopharynx
1499878|NCT00006981|stage III squamous cell carcinoma of the larynx
1499879|NCT00006981|stage IV squamous cell carcinoma of the larynx
1499880|NCT00006981|recurrent squamous cell carcinoma of the larynx
1499881|NCT00006981|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1499882|NCT00006981|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1499883|NCT00006981|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1499884|NCT00006981|fallopian tube cancer
1499885|NCT00006981|primary peritoneal cavity cancer
1499886|NCT00006981|ovarian carcinosarcoma
1499887|NCT00006981|Brenner tumor
1499888|NCT00006981|untreated metastatic squamous neck cancer with occult primary
1499889|NCT00006981|recurrent salivary gland cancer
1499890|NCT00006981|salivary gland squamous cell carcinoma
1499891|NCT00006981|stage III salivary gland cancer
1499892|NCT00006981|stage IV salivary gland cancer
1499893|NCT00006981|recurrent pancreatic cancer
1499894|NCT00006981|stage II pancreatic cancer
1499895|NCT00006981|stage III pancreatic cancer
1499896|NCT00006981|ovarian mucinous cystadenocarcinoma
1499897|NCT00006981|borderline ovarian surface epithelial-stromal tumor
1499898|NCT00006981|ovarian sarcoma
1499899|NCT00006981|ovarian stromal cancer
1499900|NCT00006981|stage IV pancreatic cancer
1499901|NCT00006968|stage III renal cell cancer
1499902|NCT00006968|stage IV renal cell cancer
1499903|NCT00006968|recurrent renal cell cancer
1499904|NCT00006916|adult glioblastoma
1499905|NCT00006916|adult giant cell glioblastoma
1499906|NCT00006916|adult gliosarcoma
1499907|NCT00006890|refractory multiple myeloma
1499908|NCT00006890|stage I multiple myeloma
1499909|NCT00006890|stage II multiple myeloma
1499910|NCT00006890|stage III multiple myeloma
1499911|NCT00006877|recurrent non-small cell lung cancer
1499912|NCT00006877|squamous cell lung cancer
1499913|NCT00006877|large cell lung cancer
1499914|NCT00006877|stage IV non-small cell lung cancer
1499915|NCT00006877|adenocarcinoma of the lung
1499916|NCT00006864|stage IV renal cell cancer
1499917|NCT00006864|recurrent renal cell cancer
1499918|NCT00006864|clear cell renal cell carcinoma
1499919|NCT00006825|stage IV breast cancer
1499920|NCT00006825|recurrent breast cancer
1499921|NCT00006812|recurrent ovarian epithelial cancer
1499922|NCT00006812|primary peritoneal cavity cancer
1499923|NCT00006799|untreated metastatic squamous neck cancer with occult primary
1499924|NCT00006799|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1499925|NCT00006799|stage I squamous cell carcinoma of the lip and oral cavity
1499926|NCT00006799|stage I basal cell carcinoma of the lip
1499927|NCT00006799|stage I verrucous carcinoma of the oral cavity
1499928|NCT00006799|stage I mucoepidermoid carcinoma of the oral cavity
1499929|NCT00006799|stage I adenoid cystic carcinoma of the oral cavity
1499930|NCT00006799|stage II squamous cell carcinoma of the lip and oral cavity
1499931|NCT00006799|stage II basal cell carcinoma of the lip
1499932|NCT00006799|stage II verrucous carcinoma of the oral cavity
1499933|NCT00006799|stage II mucoepidermoid carcinoma of the oral cavity
1499934|NCT00006799|stage II adenoid cystic carcinoma of the oral cavity
1499935|NCT00006799|stage III squamous cell carcinoma of the lip and oral cavity
1499936|NCT00006799|stage III basal cell carcinoma of the lip
1499937|NCT00006799|stage III verrucous carcinoma of the oral cavity
1499938|NCT00006799|stage III mucoepidermoid carcinoma of the oral cavity
1499939|NCT00006799|stage III adenoid cystic carcinoma of the oral cavity
1499940|NCT00006799|stage IV squamous cell carcinoma of the lip and oral cavity
1499941|NCT00006799|stage IV basal cell carcinoma of the lip
1499942|NCT00006799|stage IV verrucous carcinoma of the oral cavity
1499943|NCT00006799|stage IV mucoepidermoid carcinoma of the oral cavity
1499944|NCT00006799|stage IV adenoid cystic carcinoma of the oral cavity
1499945|NCT00006799|stage I squamous cell carcinoma of the oropharynx
1499946|NCT00006799|stage I lymphoepithelioma of the oropharynx
1499947|NCT00006799|stage II squamous cell carcinoma of the oropharynx
1499948|NCT00006799|stage II lymphoepithelioma of the oropharynx
1499949|NCT00006799|stage III squamous cell carcinoma of the oropharynx
1499950|NCT00006799|stage III lymphoepithelioma of the oropharynx
1499951|NCT00006799|stage IV squamous cell carcinoma of the oropharynx
1499952|NCT00006799|stage IV lymphoepithelioma of the oropharynx
1499953|NCT00006799|stage I squamous cell carcinoma of the nasopharynx
1499954|NCT00006799|stage I lymphoepithelioma of the nasopharynx
1499955|NCT00006799|stage II squamous cell carcinoma of the nasopharynx
1499956|NCT00006799|stage II lymphoepithelioma of the nasopharynx
1499957|NCT00006799|stage III squamous cell carcinoma of the nasopharynx
1499958|NCT00006799|stage III lymphoepithelioma of the nasopharynx
1499959|NCT00006799|stage IV squamous cell carcinoma of the nasopharynx
1499960|NCT00006799|stage IV lymphoepithelioma of the nasopharynx
1499961|NCT00006799|stage I squamous cell carcinoma of the hypopharynx
1499962|NCT00006799|stage II squamous cell carcinoma of the hypopharynx
1499963|NCT00006799|stage III squamous cell carcinoma of the hypopharynx
1499964|NCT00006799|stage IV squamous cell carcinoma of the hypopharynx
1499965|NCT00006799|stage I squamous cell carcinoma of the larynx
1499966|NCT00006799|stage I verrucous carcinoma of the larynx
1499967|NCT00006799|stage II squamous cell carcinoma of the larynx
1499968|NCT00006799|stage II verrucous carcinoma of the larynx
1499969|NCT00006799|stage III squamous cell carcinoma of the larynx
1499970|NCT00006799|stage III verrucous carcinoma of the larynx
1499971|NCT00006799|stage IV squamous cell carcinoma of the larynx
1499972|NCT00006799|stage IV verrucous carcinoma of the larynx
1499973|NCT00006799|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1499974|NCT00006799|stage I inverted papilloma of the paranasal sinus and nasal cavity
1499975|NCT00006799|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1499976|NCT00006799|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1499977|NCT00006799|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1499978|NCT00006799|stage II inverted papilloma of the paranasal sinus and nasal cavity
1499979|NCT00006799|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1499980|NCT00006799|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1499981|NCT00006799|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1499982|NCT00006799|stage III inverted papilloma of the paranasal sinus and nasal cavity
1499983|NCT00006799|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1499984|NCT00006799|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1499985|NCT00006799|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1499986|NCT00006799|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1499987|NCT00006799|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1499988|NCT00006799|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1499989|NCT00006799|anorexia
1499990|NCT00006799|cachexia
1499991|NCT00006799|quality of life
1499992|NCT00006786|stage IV colon cancer
1499993|NCT00006786|stage IV rectal cancer
1499994|NCT00006786|recurrent colon cancer
1499995|NCT00006786|recurrent rectal cancer
1499996|NCT00006786|adenocarcinoma of the colon
1499997|NCT00006786|adenocarcinoma of the rectum
1499998|NCT00006760|recurrent/refractory childhood Hodgkin lymphoma
1499999|NCT00006760|childhood lymphocyte predominant Hodgkin lymphoma
1500000|NCT00006760|childhood lymphocyte depletion Hodgkin lymphoma
1500001|NCT00006760|childhood nodular sclerosis Hodgkin lymphoma
1500002|NCT00006760|childhood mixed cellularity Hodgkin lymphoma
1500003|NCT00006747|graft versus host disease
1500004|NCT00006747|stage I mantle cell lymphoma
1500005|NCT00006747|contiguous stage II mantle cell lymphoma
1500006|NCT00006747|noncontiguous stage II mantle cell lymphoma
1500007|NCT00006747|stage III mantle cell lymphoma
1500008|NCT00006747|stage IV mantle cell lymphoma
1500009|NCT00006747|recurrent mantle cell lymphoma
1500010|NCT00006734|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1500011|NCT00006721|stage III grade 1 follicular lymphoma
1500012|NCT00006721|stage III grade 2 follicular lymphoma
1500130|NCT00006515|Pilot
1500013|NCT00006721|stage III grade 3 follicular lymphoma
1500014|NCT00006721|stage IV grade 1 follicular lymphoma
1500015|NCT00006721|stage IV grade 2 follicular lymphoma
1500135|NCT00006509|Treatment Experienced
1500016|NCT00006721|stage IV grade 3 follicular lymphoma
1500017|NCT00006721|contiguous stage II grade 1 follicular lymphoma
1500018|NCT00006721|contiguous stage II grade 2 follicular lymphoma
1500019|NCT00006721|contiguous stage II grade 3 follicular lymphoma
1500020|NCT00006721|noncontiguous stage II grade 1 follicular lymphoma
1500021|NCT00006721|noncontiguous stage II grade 2 follicular lymphoma
1500022|NCT00006721|noncontiguous stage II grade 3 follicular lymphoma
1500023|NCT00006708|recurrent adult diffuse large cell lymphoma
1500024|NCT00006708|recurrent adult Burkitt lymphoma
1500025|NCT00006695|recurrent adult diffuse mixed cell lymphoma
1500026|NCT00006695|recurrent adult diffuse large cell lymphoma
1500027|NCT00006695|recurrent adult immunoblastic large cell lymphoma
1500028|NCT00006682|stage IV breast cancer
1500029|NCT00006682|recurrent breast cancer
1500030|NCT00006669|recurrent grade 3 follicular lymphoma
1500031|NCT00006669|recurrent adult diffuse small cleaved cell lymphoma
1500032|NCT00006669|recurrent adult diffuse mixed cell lymphoma
1500033|NCT00006669|recurrent adult diffuse large cell lymphoma
1500034|NCT00006656|recurrent adult brain tumor
1500035|NCT00006656|adult glioblastoma
1500036|NCT00006656|adult giant cell glioblastoma
1500037|NCT00006656|adult gliosarcoma
1500038|NCT00006643|Liver
1500039|NCT00006643|Hepatitis C
1500040|NCT00006643|Biopsy
1500041|NCT00006643|Tomography, Emission-Computed, Single-Photon
1500042|NCT00006630|Smallpox Vaccine
1500043|NCT00006630|Injections, Intramuscular
1500044|NCT00006630|Immunoglobulins
1500045|NCT00006630|Orthopoxvirus
1500046|NCT00006617|HIV-1
1500047|NCT00006617|Drug Therapy, Combination
1500048|NCT00006617|Zidovudine
1500049|NCT00006617|Lymphoid Tissue
1500050|NCT00006617|Gastrointestinal System
1500051|NCT00006617|HIV Protease Inhibitors
1500052|NCT00006617|Lamivudine
1500053|NCT00006617|Lymphocyte Subsets
1500054|NCT00006617|VX 478
1500055|NCT00006617|Reverse Transcriptase Inhibitors
1500056|NCT00006617|Anti-HIV Agents
1500057|NCT00006617|Viral Load
1500058|NCT00006617|Cerebrospinal Fluid
1500059|NCT00006617|abacavir
1500060|NCT00006604|Dose-Response Relationship, Drug
1500061|NCT00006604|Drug Therapy, Combination
1500062|NCT00006604|Drug Administration Schedule
1500063|NCT00006604|HIV Protease Inhibitors
1500064|NCT00006604|Reverse Transcriptase Inhibitors
1500065|NCT00006604|Anti-HIV Agents
1500066|NCT00006604|Pharmacokinetics
1500067|NCT00006604|Treatment Experienced
1500068|NCT00006604|Treatment Naive
1500069|NCT00006591|Drug Therapy, Combination
1500070|NCT00006591|HIV Protease Inhibitors
1500071|NCT00006591|Ritonavir
1500072|NCT00006591|VX 478
1500073|NCT00006591|Salvage Therapy
1500074|NCT00006591|Anti-HIV Agents
1500075|NCT00006591|Drug Monitoring
1500076|NCT00006591|Nelfinavir
1500077|NCT00006591|Treatment Experienced
1500078|NCT00006578|Drug Therapy, Combination
1500079|NCT00006578|Granulocyte Colony-Stimulating Factor
1500080|NCT00006578|HIV Protease Inhibitors
1500081|NCT00006578|Ritonavir
1500082|NCT00006578|Lamivudine
1500083|NCT00006578|Stem Cells
1500084|NCT00006578|VX 478
1500085|NCT00006578|Reverse Transcriptase Inhibitors
1500086|NCT00006578|Anti-HIV Agents
1500087|NCT00006578|Antigens, CD34
1500088|NCT00006578|abacavir
1500089|NCT00006578|Treatment Naive
1500090|NCT00006565|asthma
1500091|NCT00006565|HEPA
1500092|NCT00006565|ETS
1500093|NCT00006519|Pharmacokinetic
1500094|NCT00006519|Pediatric AIDS
1500095|NCT00006519|Resistance Testing
1500096|NCT00006519|Combination Therapy
1500097|NCT00006519|Viral Drug Dynamics
1500098|NCT00006519|Treatment Experienced
1500099|NCT00006518|Tumor
1500100|NCT00006518|Viruses
1500101|NCT00006518|HIV
1500102|NCT00006518|KSHV
1500103|NCT00006518|AIDS
1500104|NCT00006517|Seasonal Affective Disorder (SAD)
1500105|NCT00006517|Winter Depression
1500106|NCT00006517|Mood disorders
1500107|NCT00006517|Bipolar I and II disorders
1500108|NCT00006517|Major Depressive Disorder, Recurrent
1500109|NCT00006517|Light therapy
1500110|NCT00006517|Phototherapy
1500111|NCT00006517|Dawn Simulation therapy
1500112|NCT00006517|Negative air ionization therapy
1500113|NCT00006517|Chronobiology
1500114|NCT00006517|Biological rhythms
1500115|NCT00006516|Neonatal brain injury
1500116|NCT00006516|Brain Hypoxia
1500117|NCT00006516|Cerebral Hypoxia
1500118|NCT00006516|Brain Hypoxia-Ischemia
1500119|NCT00006516|Brain Ischemia-Hypoxia
1500120|NCT00006516|Cerebral Hypoxia-Ischemia
1500121|NCT00006516|Cerebral Ischemia-Hypoxia
1500122|NCT00006516|Environmental enrichment
1500123|NCT00006516|Cognitive/sensorimotor stimulation
1500124|NCT00006516|Parent-infant interactions
1500125|NCT00006516|Prenatal hypoxia
1500126|NCT00006515|Pediatric
1500127|NCT00006515|Sarcoma
1500128|NCT00006515|Effects
1500129|NCT00006515|Survivors
1500131|NCT00006509|Recombinant Proteins
1500132|NCT00006509|HIV Envelope Protein gp160
1500133|NCT00006509|AIDS Vaccines
1500134|NCT00006509|Anti-HIV Agents
1500136|NCT00006509|HIV Therapeutic Vaccine
1500137|NCT00006507|Sensory integration
1500138|NCT00006507|Occupational therapy
1500139|NCT00006507|Sensory Modulation Dysfunction (SMD)
1500140|NCT00006506|Observational Studies
1500141|NCT00006506|Clinical Trials
1500142|NCT00006505|Islet Isolation
1500143|NCT00006505|Diabetes
1500144|NCT00006495|Placebos
1500145|NCT00006495|T-Lymphocytes, Helper-Inducer
1500146|NCT00006495|AIDS Vaccines
1500147|NCT00006495|RNA, Viral
1500148|NCT00006495|HIV Core Protein p24
1500149|NCT00006495|T-Lymphocytes, Cytotoxic
1500150|NCT00006495|Anti-HIV Agents
1500151|NCT00006495|HIV Therapeutic Vaccine
1500152|NCT00006494|AIDS
1500153|NCT00006494|Antiretroviral Therapy
1500154|NCT00006494|Drug Resistance
1500155|NCT00006494|Phenotype
1500156|NCT00006494|HIV
1500157|NCT00006494|Genotype
1500158|NCT00006494|Treatment Experienced
1500159|NCT00006493|HIV-associated hyperlipidemia
1500160|NCT00006492|Celiac Disease
1500161|NCT00006492|Cerebellar Ataxia
1500162|NCT00006492|Gluten-Free Diet
1500163|NCT00006490|HIV-1
1500164|NCT00006490|Drug Resistance, Microbial
1500165|NCT00006490|Sequence Analysis, DNA
1500166|NCT00006490|Microbial Sensitivity Tests
1500167|NCT00006490|Genotype
1500168|NCT00006490|Phenotype
1500169|NCT00006490|Anti-HIV Agents
1500170|NCT00006489|Alcoholism
1500171|NCT00006489|Alcohol Dependence
1500172|NCT00006489|Post-Traumatic Stress Disorder
1500173|NCT00006489|Naltrexone
1500174|NCT00006489|Cognitive Behavior Therapy
1500175|NCT00006487|limited stage small cell lung cancer
1500176|NCT00006485|unspecified adult solid tumor, protocol specific
1500177|NCT00006484|recurrent non-small cell lung cancer
1500178|NCT00006484|squamous cell lung cancer
1500179|NCT00006484|large cell lung cancer
1500180|NCT00006484|stage IIIB non-small cell lung cancer
1500181|NCT00006484|stage IV non-small cell lung cancer
1500182|NCT00006484|adenocarcinoma of the lung
1500183|NCT00006483|stage IV renal cell cancer
1500184|NCT00006483|recurrent renal cell cancer
1500185|NCT00006483|lung metastases
1500186|NCT00006482|recurrent cervical cancer
1500187|NCT00006482|stage IVB cervical cancer
1500188|NCT00006482|stage IVA cervical cancer
1500189|NCT00006482|cervical squamous cell carcinoma
1500190|NCT00006481|stage III squamous cell carcinoma of the lip and oral cavity
1500191|NCT00006481|stage IV squamous cell carcinoma of the lip and oral cavity
1500192|NCT00006481|stage III squamous cell carcinoma of the oropharynx
1500193|NCT00006481|stage IV squamous cell carcinoma of the oropharynx
1500194|NCT00006481|stage III squamous cell carcinoma of the hypopharynx
1500195|NCT00006481|stage IV squamous cell carcinoma of the hypopharynx
1500196|NCT00006481|stage III squamous cell carcinoma of the larynx
1500197|NCT00006481|stage IV squamous cell carcinoma of the larynx
1500198|NCT00006481|skin reactions secondary to radiation therapy
1500199|NCT00006480|disseminated neuroblastoma
1500200|NCT00006480|recurrent neuroblastoma
1500201|NCT00006479|stage IV colon cancer
1500202|NCT00006479|stage IV rectal cancer
1500203|NCT00006479|recurrent colon cancer
1500204|NCT00006479|recurrent rectal cancer
1500205|NCT00006479|liver metastases
1500206|NCT00006478|recurrent grade 1 follicular lymphoma
1500207|NCT00006478|recurrent grade 2 follicular lymphoma
1500208|NCT00006478|recurrent grade 3 follicular lymphoma
1500209|NCT00006477|unspecified adult solid tumor, protocol specific
1500210|NCT00006476|stage 0 bladder cancer
1500211|NCT00006476|stage I bladder cancer
1500212|NCT00006476|recurrent bladder cancer
1500213|NCT00006475|relapsing chronic myelogenous leukemia
1500214|NCT00006475|blastic phase chronic myelogenous leukemia
1500215|NCT00006475|chronic myelogenous leukemia, BCR-ABL1 positive
1500216|NCT00006475|Philadelphia chromosome negative chronic myelogenous leukemia
1500217|NCT00006474|recurrent adult brain tumor
1500218|NCT00006474|adult glioblastoma
1500219|NCT00006474|adult anaplastic astrocytoma
1500220|NCT00006474|adult anaplastic oligodendroglioma
1500221|NCT00006474|adult mixed glioma
1500222|NCT00006474|adult oligodendroglioma
1500223|NCT00006474|adult giant cell glioblastoma
1500224|NCT00006474|adult gliosarcoma
1500225|NCT00006472|stage I esophageal cancer
1500226|NCT00006472|stage II esophageal cancer
1500227|NCT00006472|stage III esophageal cancer
1500228|NCT00006472|squamous cell carcinoma of the esophagus
1500229|NCT00006472|adenocarcinoma of the esophagus
1500230|NCT00006471|untreated metastatic squamous neck cancer with occult primary
1500231|NCT00006471|recurrent metastatic squamous neck cancer with occult primary
1500232|NCT00006471|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1500233|NCT00006471|stage IV squamous cell carcinoma of the lip and oral cavity
1500234|NCT00006471|recurrent squamous cell carcinoma of the lip and oral cavity
1500235|NCT00006471|stage IV squamous cell carcinoma of the oropharynx
1500236|NCT00006471|recurrent squamous cell carcinoma of the oropharynx
1500237|NCT00006471|recurrent squamous cell carcinoma of the nasopharynx
1500238|NCT00006471|stage IV squamous cell carcinoma of the hypopharynx
1500239|NCT00006471|recurrent squamous cell carcinoma of the hypopharynx
1500344|NCT00006445|Down syndrome
1500240|NCT00006471|stage IV squamous cell carcinoma of the larynx
1500241|NCT00006471|recurrent squamous cell carcinoma of the larynx
1500242|NCT00006471|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1500243|NCT00006471|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1500244|NCT00006471|stage IV squamous cell carcinoma of the nasopharynx
1500245|NCT00006470|stage II non-small cell lung cancer
1500246|NCT00006470|stage IIIA non-small cell lung cancer
1500247|NCT00006469|stage II non-small cell lung cancer
1500248|NCT00006469|stage IIIA non-small cell lung cancer
1500249|NCT00006468|stage IV colon cancer
1500250|NCT00006468|stage IV rectal cancer
1500251|NCT00006468|recurrent colon cancer
1500252|NCT00006468|recurrent rectal cancer
1500253|NCT00006468|adenocarcinoma of the colon
1500254|NCT00006468|adenocarcinoma of the rectum
1500255|NCT00006467|stage III pancreatic cancer
1500256|NCT00006467|recurrent pancreatic cancer
1500257|NCT00006467|duct cell adenocarcinoma of the pancreas
1500258|NCT00006467|adenocarcinoma of the pancreas
1500259|NCT00006467|stage IV pancreatic cancer
1500260|NCT00006466|monoclonal gammopathy of undetermined significance
1500261|NCT00006466|isolated plasmacytoma of bone
1500262|NCT00006466|extramedullary plasmacytoma
1500263|NCT00006466|refractory multiple myeloma
1500264|NCT00006466|stage I multiple myeloma
1500265|NCT00006466|stage II multiple myeloma
1500266|NCT00006466|stage III multiple myeloma
1500267|NCT00006465|unspecified adult solid tumor, protocol specific
1500268|NCT00006464|unspecified adult solid tumor, protocol specific
1500269|NCT00006463|unspecified childhood solid tumor, protocol specific
1500270|NCT00006462|recurrent childhood acute lymphoblastic leukemia
1500271|NCT00006462|recurrent childhood acute myeloid leukemia
1500272|NCT00006460|adult glioblastoma
1500273|NCT00006460|adult giant cell glioblastoma
1500274|NCT00006460|adult gliosarcoma
1500275|NCT00006459|stage IV breast cancer
1500276|NCT00006459|stage IIIA breast cancer
1500277|NCT00006459|recurrent breast cancer
1500278|NCT00006459|stage IIIB breast cancer
1500279|NCT00006458|recurrent non-small cell lung cancer
1500280|NCT00006458|squamous cell lung cancer
1500281|NCT00006458|large cell lung cancer
1500282|NCT00006458|adenocarcinoma of the lung
1500283|NCT00006458|adenosquamous cell lung cancer
1500284|NCT00006457|non-small cell lung cancer
1500285|NCT00006457|small cell lung cancer
1500286|NCT00006456|unspecified adult solid tumor, protocol specific
1500287|NCT00006456|lung metastases
1500288|NCT00006456|liver metastases
1500289|NCT00006455|stage I childhood anaplastic large cell lymphoma
1500290|NCT00006455|stage II childhood anaplastic large cell lymphoma
1500291|NCT00006455|stage III childhood anaplastic large cell lymphoma
1500292|NCT00006455|stage IV childhood anaplastic large cell lymphoma
1500293|NCT00006455|recurrent childhood anaplastic large cell lymphoma
1500294|NCT00006454|stage II ovarian epithelial cancer
1500295|NCT00006454|stage III ovarian epithelial cancer
1500296|NCT00006454|stage IV ovarian epithelial cancer
1500297|NCT00006454|fallopian tube cancer
1500298|NCT00006453|recurrent ovarian epithelial cancer
1500299|NCT00006452|adult glioblastoma
1500300|NCT00006452|adult giant cell glioblastoma
1500301|NCT00006452|adult gliosarcoma
1500302|NCT00006451|recurrent childhood acute lymphoblastic leukemia
1500303|NCT00006451|stage IV childhood lymphoblastic lymphoma
1500304|NCT00006451|recurrent childhood acute myeloid leukemia
1500305|NCT00006451|recurrent adult acute myeloid leukemia
1500306|NCT00006451|recurrent adult acute lymphoblastic leukemia
1500307|NCT00006451|chronic phase chronic myelogenous leukemia
1500308|NCT00006451|accelerated phase chronic myelogenous leukemia
1500309|NCT00006451|adult acute lymphoblastic leukemia in remission
1500310|NCT00006451|childhood acute lymphoblastic leukemia in remission
1500311|NCT00006451|acute undifferentiated leukemia
1500312|NCT00006451|stage IV adult lymphoblastic lymphoma
1500313|NCT00006451|graft versus host disease
1500314|NCT00006450|Children
1500315|NCT00006450|Brain
1500316|NCT00006450|Maturation
1500317|NCT00006450|Phenylacetate
1500318|NCT00006450|Differentiation
1500319|NCT00006448|Spinal cord injury
1500320|NCT00006448|Amputation
1500321|NCT00006448|Pain management
1500322|NCT00006447|Brain Injuries
1500323|NCT00006447|Trauma
1500324|NCT00006447|Caregivers
1500325|NCT00006447|Burden and Dependency
1500326|NCT00006447|Rehabilitation
1500327|NCT00006447|Support, social
1500328|NCT00006447|Information System
1500329|NCT00006447|Information Resources (PT)
1500330|NCT00006447|Disability, persons with
1500331|NCT00006446|Behavioral disorders
1500332|NCT00006446|Parenting skills and communication
1500333|NCT00006446|Parent-child interactions
1500334|NCT00006446|At-risk preschooler
1500335|NCT00006446|Head Start
1500336|NCT00006445|Pregnancy
1500337|NCT00006445|Ultrasound
1500338|NCT00006445|Serum screen
1500339|NCT00006445|Pregnancy associated plasma protein-A (PAPP-A)
1500340|NCT00006445|Free-beta human chorionic gonadotropin (FbhCG)
1500341|NCT00006445|Alpha fetoprotein
1500342|NCT00006445|Unconjugated estriol
1500343|NCT00006445|Inhibin-A
1500345|NCT00006445|Aneuploidy
1500346|NCT00006444|Drug Therapy, Combination
1500347|NCT00006444|Papillomavirus, Human
1500348|NCT00006444|DNA, Viral
1500349|NCT00006444|Anti-HIV Agent
1500350|NCT00006444|Treatment Naive
1500351|NCT00006443|T-Lymphocytes
1500352|NCT00006443|HIV-1
1500353|NCT00006443|Lymphoid Tissue
1500354|NCT00006443|Stavudine
1500355|NCT00006443|HIV Protease Inhibitors
1500356|NCT00006443|Polymerase Chain Reaction
1500357|NCT00006443|Biological Markers
1500358|NCT00006443|Lamivudine
1500359|NCT00006443|Indinavir
1500360|NCT00006443|RNA, Viral
1500361|NCT00006443|Genotype
1500362|NCT00006443|Phenotype
1500363|NCT00006443|Cytokines
1500364|NCT00006443|Nelfinavir
1500365|NCT00006443|Macrophages
1500366|NCT00006443|Reverse Transcriptase Inhibitors
1500367|NCT00006443|In Situ Hybridization
1500368|NCT00006443|Anti-HIV Agents
1500369|NCT00006443|Viral Load
1500370|NCT00006443|Cell Membrane
1500371|NCT00006443|Acute Infection
1500372|NCT00006443|Treatment Naive
1500373|NCT00006442|Lymphocytes
1500374|NCT00006442|HIV-1
1500375|NCT00006442|Lymphoid Tissue
1500376|NCT00006442|Blood
1500377|NCT00006442|Anti-HIV Agents
1500378|NCT00006442|Viral Load
1500379|NCT00006441|Virus Replication
1500380|NCT00006441|HIV-1
1500381|NCT00006441|Interleukin-2
1500382|NCT00006441|Drug Therapy, Combination
1500383|NCT00006441|Zidovudine
1500384|NCT00006441|HIV Protease Inhibitors
1500385|NCT00006441|CD4-Positive T-Lymphocytes
1500386|NCT00006441|CD8-Positive T-Lymphocytes
1500387|NCT00006441|Biological Markers
1500388|NCT00006441|Lamivudine
1500389|NCT00006441|Reverse Transcriptase Inhibitors
1500390|NCT00006441|Anti-HIV Agents
1500391|NCT00006441|Nelfinavir
1500392|NCT00006441|Cytotoxicity, Immunologic
1500393|NCT00006441|Acute Infection
1500394|NCT00006440|Risk Factors
1500395|NCT00006440|Behavior Therapy
1500396|NCT00006440|Substance-Related Disorders
1500397|NCT00006440|Feasibility Studies
1500398|NCT00006439|HIV
1500399|NCT00006438|Rocker sole
1500400|NCT00006438|Plantar pressure
1500401|NCT00006438|Diabetic feet
1500402|NCT00006438|Insensate feet
1500403|NCT00006438|gait analysis
1500404|NCT00006438|Pedorthics
1500405|NCT00006438|Gait abnormalities
1500406|NCT00006437|MMP
1500407|NCT00006437|Proteases
1500408|NCT00006437|Adhesion
1500409|NCT00006437|Migration
1500410|NCT00006437|Extracellular Matrix
1500411|NCT00006436|AIDS
1500412|NCT00006436|Malignancy
1500413|NCT00006436|Antiretroviral
1500414|NCT00006436|Chemotherapy
1500415|NCT00006436|Monoclonal
1500419|NCT00006434|Dendritic cells
1500420|NCT00006429|Spinal Cord Injury
1500421|NCT00006429|Body Weight Supported Ambulation Training
1500422|NCT00006429|Treadmill Training
1500423|NCT00006429|Physical therapy
1500424|NCT00006429|Gait
1500425|NCT00006429|Assisted Ambulation
1500426|NCT00006428|Spinal Cord injury (SCI)
1500427|NCT00006428|Chronic Pain
1500428|NCT00006428|Amitriptyline
1500429|NCT00006427|Amputation
1500430|NCT00006427|Chronic Pain
1500431|NCT00006427|Amitriptyline
1500432|NCT00006426|Foot ulcers
1500433|NCT00006426|Diabetes
1500434|NCT00006426|Peripheral neuropathy
1500435|NCT00006426|Casting
1500436|NCT00006426|Achilles Lengthening
1500437|NCT00006426|Ambulatory surgery
1500438|NCT00006426|Foot deformity
1500444|NCT00006424|Plasticity
1500445|NCT00006424|Motor
1500446|NCT00006424|Stroke
1500447|NCT00006424|Amphetamine
1500448|NCT00006424|fMRI
1500449|NCT00006424|Cortical Reorganization
1500450|NCT00006424|Spectroscopy
1500451|NCT00006422|Lazy Eye
1500452|NCT00006422|Amblyopia
1500453|NCT00006422|Nystagmus
1500454|NCT00006422|Eye Movements
1500455|NCT00006422|Child Vision
1500460|NCT00006418|Schizophrenia
1500461|NCT00006418|Genetics
1500462|NCT00006417|Fludarabine
1500463|NCT00006417|Non-Myeloablative BMT
1500464|NCT00006417|Immunodeficiency
1500465|NCT00006417|Neutrophils
1500466|NCT00006417|Oxidase
1500467|NCT00006417|Engraftment
1500468|NCT00006417|Graft-versus-host Disease
1500469|NCT00006417|Cyclophosphamide
1500470|NCT00006417|Donor Apheresis
1500471|NCT00006417|Peripheral Blood Stem Cells
1500472|NCT00006417|Therapy
1500473|NCT00006415|Virus Replication
1500474|NCT00006415|HIV-1
1500475|NCT00006415|Polymerase Chain Reaction
1500476|NCT00006415|DNA, Viral
1500477|NCT00006415|RNA, Viral
1500478|NCT00006415|Sensitivity and Specificity
1500479|NCT00006415|Anti-HIV Agents
1500480|NCT00006415|Viral Load
1500481|NCT00006415|Proviruses
1500482|NCT00006415|Acute Infection
1500483|NCT00006414|Anesthesia
1500484|NCT00006414|Magnetic Stimulation
1500485|NCT00006414|Motor
1500486|NCT00006414|Neuroplasticity
1500487|NCT00006414|Practice
1500488|NCT00006414|Rehabilitation
1500489|NCT00006414|Stroke
1500490|NCT00006413|Peripheral Blood Stem Cells
1500491|NCT00006413|Non-Myeloablative Bone Marrow Transplantation
1500492|NCT00006413|Engraftment
1500493|NCT00006413|Graft-versus-host Disease
1500494|NCT00006413|Graft-Versus-Leukemia
1500495|NCT00006413|Graft-Versus-Mast Cell
1500496|NCT00006413|Cyclophosphamide
1500497|NCT00006413|Fludarabine
1500498|NCT00006413|Donor Apheresis
1500499|NCT00006413|Mast Cells
1500500|NCT00006412|Hyperlipidemia
1500501|NCT00006412|Procetofen
1500502|NCT00006412|Pravastatin
1500503|NCT00006412|Antilipemic Agents
1500504|NCT00006411|cornea transplant
1500505|NCT00006411|corneal endothelial cell density
1500506|NCT00006411|moderate risk corneal diseases requiring corneal transplantation
1500507|NCT00006411|corneal transplantation
1500508|NCT00006400|Blood Diseases
1500509|NCT00006400|Sickle Cell Anemia
1500510|NCT00006399|Alzheimer disease
1500511|NCT00006399|Estrogen therapy
1500512|NCT00006399|Post-menopausal women
1500513|NCT00006398|cirrhosis
1500514|NCT00006398|esophageal varices
1500515|NCT00006398|variceal hemorrhage
1500516|NCT00006398|beta-adrenergic blocker
1500517|NCT00006397|Didanosine
1500518|NCT00006397|Drug Therapy, Combination
1500519|NCT00006397|Stavudine
1500520|NCT00006397|HIV Protease Inhibitors
1500521|NCT00006397|Sex Factors
1500522|NCT00006397|Ritonavir
1500523|NCT00006397|Indinavir
1500524|NCT00006397|Dosage Forms
1500525|NCT00006397|Reverse Transcriptase Inhibitors
1500526|NCT00006397|Anti-HIV Agents
1500527|NCT00006396|Pregnancy Complications, Infectious
1500528|NCT00006396|HIV-1
1500529|NCT00006396|Administration, Oral
1500530|NCT00006396|Zidovudine
1500531|NCT00006396|Nevirapine
1500532|NCT00006396|RNA, Viral
1500533|NCT00006396|Disease Transmission, Vertical
1500534|NCT00006396|Enzyme-Linked Immunosorbent Assay
1500535|NCT00006396|Blotting, Western
1500536|NCT00006396|Reverse Transcriptase Inhibitors
1500537|NCT00006396|Anti-HIV Agents
1500538|NCT00006396|Viral Load
1500539|NCT00006396|HIV Seronegativity
1500540|NCT00006395|Antiepileptic
1500541|NCT00006395|CYP3A4
1500542|NCT00006395|Herbal
1500543|NCT00006395|Induction
1500544|NCT00006395|Interaction
1500545|NCT00006394|disease-related problem/condition
1500546|NCT00006394|endocrine disorders
1500547|NCT00006394|growth hormone deficiency
1500548|NCT00006394|osteoporosis
1500549|NCT00006394|quality of life
1500550|NCT00006394|rare disease
1500551|NCT00006393|arthritis & connective tissue diseases
1500552|NCT00006393|rare disease
1500553|NCT00006393|systemic sclerosis
1500554|NCT00006392|prostate cancer
1500555|NCT00006391|recurrent ovarian epithelial cancer
1500556|NCT00006391|fallopian tube cancer
1500557|NCT00006391|peritoneal cavity cancer
1500558|NCT00006390|stage III chronic lymphocytic leukemia
1500559|NCT00006390|stage IV chronic lymphocytic leukemia
1500560|NCT00006390|B-cell chronic lymphocytic leukemia
1500561|NCT00006390|stage I chronic lymphocytic leukemia
1500562|NCT00006390|stage II chronic lymphocytic leukemia
1500563|NCT00006388|adult glioblastoma
1500564|NCT00006388|adult giant cell glioblastoma
1500565|NCT00006388|adult gliosarcoma
1500566|NCT00006387|stage IV colon cancer
1500567|NCT00006387|recurrent pancreatic cancer
1500568|NCT00006387|stage IV rectal cancer
1500569|NCT00006387|recurrent colon cancer
1500570|NCT00006387|recurrent rectal cancer
1500571|NCT00006387|adenocarcinoma of the colon
1500572|NCT00006387|adenocarcinoma of the rectum
1500573|NCT00006387|adenocarcinoma of the pancreas
1500574|NCT00006387|stage IV pancreatic cancer
1500575|NCT00006386|adult glioblastoma
1500576|NCT00006386|adult giant cell glioblastoma
1500577|NCT00006386|adult gliosarcoma
1500578|NCT00006385|stage IV melanoma
1500579|NCT00006385|recurrent melanoma
1500580|NCT00006384|stage IV renal cell cancer
1500581|NCT00006384|recurrent renal cell cancer
1500582|NCT00006383|recurrent adult diffuse large cell lymphoma
1500583|NCT00006383|recurrent adult immunoblastic large cell lymphoma
1500584|NCT00006383|recurrent adult T-cell leukemia/lymphoma
1500585|NCT00006383|anaplastic large cell lymphoma
1500586|NCT00006382|non-small cell lung cancer
1500587|NCT00006382|small cell lung cancer
1500588|NCT00006381|stage IV breast cancer
1500589|NCT00006381|recurrent breast cancer
1500590|NCT00006380|stage III prostate cancer
1500591|NCT00006380|stage IV prostate cancer
1500592|NCT00006380|recurrent prostate cancer
1500593|NCT00006379|monoclonal gammopathy of undetermined significance
1500594|NCT00006379|recurrent childhood acute lymphoblastic leukemia
1500595|NCT00006379|recurrent adult Hodgkin lymphoma
1500596|NCT00006379|recurrent cutaneous T-cell non-Hodgkin lymphoma
1500597|NCT00006379|isolated plasmacytoma of bone
1500598|NCT00006379|extramedullary plasmacytoma
1500599|NCT00006379|refractory multiple myeloma
1500600|NCT00006379|Waldenstrom macroglobulinemia
1500796|NCT00006365|stage I prostate cancer
1500601|NCT00006379|recurrent childhood lymphoblastic lymphoma
1500602|NCT00006379|recurrent childhood acute myeloid leukemia
1500603|NCT00006379|recurrent adult acute myeloid leukemia
1500604|NCT00006379|recurrent adult acute lymphoblastic leukemia
1500605|NCT00006379|relapsing chronic myelogenous leukemia
1500606|NCT00006379|small intestine lymphoma
1500607|NCT00006379|chronic phase chronic myelogenous leukemia
1500608|NCT00006379|accelerated phase chronic myelogenous leukemia
1500609|NCT00006379|blastic phase chronic myelogenous leukemia
1500610|NCT00006379|adult acute myeloid leukemia in remission
1500611|NCT00006379|adult acute lymphoblastic leukemia in remission
1500612|NCT00006379|childhood acute myeloid leukemia in remission
1500613|NCT00006379|childhood acute lymphoblastic leukemia in remission
1500614|NCT00006379|polycythemia vera
1500615|NCT00006379|chronic idiopathic myelofibrosis
1500616|NCT00006379|essential thrombocythemia
1500617|NCT00006379|adult acute erythroid leukemia (M6)
1500618|NCT00006379|adult acute megakaryoblastic leukemia (M7)
1500619|NCT00006379|childhood acute erythroleukemia (M6)
1500620|NCT00006379|childhood acute megakaryocytic leukemia (M7)
1500621|NCT00006379|recurrent/refractory childhood Hodgkin lymphoma
1500622|NCT00006379|refractory anemia with excess blasts
1500623|NCT00006379|refractory anemia with excess blasts in transformation
1500624|NCT00006379|chronic myelomonocytic leukemia
1500625|NCT00006379|acute undifferentiated leukemia
1500626|NCT00006379|recurrent grade 1 follicular lymphoma
1500627|NCT00006379|recurrent grade 2 follicular lymphoma
1500628|NCT00006379|recurrent grade 3 follicular lymphoma
1500629|NCT00006379|recurrent adult diffuse small cleaved cell lymphoma
1500630|NCT00006379|recurrent adult diffuse mixed cell lymphoma
1500631|NCT00006379|recurrent adult diffuse large cell lymphoma
1500632|NCT00006379|recurrent adult immunoblastic large cell lymphoma
1500633|NCT00006379|recurrent adult lymphoblastic lymphoma
1500634|NCT00006379|recurrent adult Burkitt lymphoma
1500635|NCT00006379|recurrent adult T-cell leukemia/lymphoma
1500636|NCT00006379|secondary acute myeloid leukemia
1500637|NCT00006379|de novo myelodysplastic syndromes
1500638|NCT00006379|previously treated myelodysplastic syndromes
1500639|NCT00006379|secondary myelodysplastic syndromes
1500640|NCT00006379|prolymphocytic leukemia
1500641|NCT00006379|primary systemic amyloidosis
1500642|NCT00006379|adult acute minimally differentiated myeloid leukemia (M0)
1500643|NCT00006379|childhood acute minimally differentiated myeloid leukemia (M0)
1500644|NCT00006379|recurrent childhood small noncleaved cell lymphoma
1500645|NCT00006379|recurrent childhood large cell lymphoma
1500646|NCT00006379|recurrent mantle cell lymphoma
1500647|NCT00006379|angioimmunoblastic T-cell lymphoma
1500648|NCT00006379|anaplastic large cell lymphoma
1500649|NCT00006379|recurrent mycosis fungoides/Sezary syndrome
1500650|NCT00006379|childhood chronic myelogenous leukemia
1500651|NCT00006379|chronic eosinophilic leukemia
1500652|NCT00006379|chronic neutrophilic leukemia
1500653|NCT00006379|atypical chronic myeloid leukemia
1500654|NCT00006379|myelodysplastic/myeloproliferative disease, unclassifiable
1500655|NCT00006379|juvenile myelomonocytic leukemia
1500656|NCT00006379|recurrent marginal zone lymphoma
1500657|NCT00006379|recurrent small lymphocytic lymphoma
1500658|NCT00006379|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1500659|NCT00006379|nodal marginal zone B-cell lymphoma
1500660|NCT00006379|splenic marginal zone lymphoma
1500661|NCT00006379|adult acute myeloid leukemia with t(8;21)(q22;q22)
1500662|NCT00006379|adult acute myeloid leukemia with t(16;16)(p13;q22)
1500663|NCT00006379|adult acute myeloid leukemia with inv(16)(p13;q22)
1500664|NCT00006379|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1500665|NCT00006379|adult acute myeloid leukemia with t(15;17)(q22;q12)
1500666|NCT00006379|childhood myelodysplastic syndromes
1500667|NCT00006378|squamous cell lung cancer
1500668|NCT00006378|large cell lung cancer
1500669|NCT00006378|stage IIIA non-small cell lung cancer
1500670|NCT00006378|stage IIIB non-small cell lung cancer
1500671|NCT00006378|adenocarcinoma of the lung
1500672|NCT00006378|adenosquamous cell lung cancer
1500673|NCT00006378|bronchoalveolar cell lung cancer
1500674|NCT00006377|stage III endometrial carcinoma
1500675|NCT00006377|stage IV endometrial carcinoma
1500676|NCT00006377|recurrent endometrial carcinoma
1500677|NCT00006376|stage II bladder cancer
1500678|NCT00006376|stage III bladder cancer
1500679|NCT00006376|recurrent bladder cancer
1500680|NCT00006376|stage IV bladder cancer
1500681|NCT00006376|transitional cell carcinoma of the bladder
1500682|NCT00006376|metastatic transitional cell cancer of the renal pelvis and ureter
1500683|NCT00006376|regional transitional cell cancer of the renal pelvis and ureter
1500684|NCT00006376|recurrent transitional cell cancer of the renal pelvis and ureter
1500685|NCT00006375|unspecified adult solid tumor, protocol specific
1500686|NCT00006374|extensive stage small cell lung cancer
1500687|NCT00006374|recurrent small cell lung cancer
1500688|NCT00006373|stage III adult Hodgkin lymphoma
1500689|NCT00006373|stage IV adult Hodgkin lymphoma
1500690|NCT00006373|recurrent adult Hodgkin lymphoma
1500691|NCT00006373|recurrent grade 1 follicular lymphoma
1500692|NCT00006373|recurrent grade 2 follicular lymphoma
1500693|NCT00006373|recurrent grade 3 follicular lymphoma
1500694|NCT00006373|recurrent adult diffuse small cleaved cell lymphoma
1500695|NCT00006373|recurrent adult diffuse mixed cell lymphoma
1500696|NCT00006373|recurrent adult diffuse large cell lymphoma
1500697|NCT00006373|recurrent adult immunoblastic large cell lymphoma
1500698|NCT00006373|recurrent adult Burkitt lymphoma
1500699|NCT00006373|recurrent mantle cell lymphoma
1500700|NCT00006373|recurrent marginal zone lymphoma
1500701|NCT00006373|recurrent small lymphocytic lymphoma
1500702|NCT00006373|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1500703|NCT00006373|nodal marginal zone B-cell lymphoma
1500704|NCT00006373|splenic marginal zone lymphoma
1500705|NCT00006372|unspecified adult solid tumor, protocol specific
1500706|NCT00006371|adenocarcinoma of the prostate
1500707|NCT00006371|stage IV prostate cancer
1500708|NCT00006371|recurrent prostate cancer
1500709|NCT00006370|stage IV breast cancer
1500710|NCT00006370|recurrent breast cancer
1500711|NCT00006370|recurrent small cell lung cancer
1500712|NCT00006370|male breast cancer
1500713|NCT00006369|stage IV breast cancer
1500714|NCT00006369|recurrent breast cancer
1500715|NCT00006368|stage IV adult Hodgkin lymphoma
1500716|NCT00006368|stage IV breast cancer
1500717|NCT00006368|recurrent breast cancer
1500718|NCT00006368|recurrent non-small cell lung cancer
1500719|NCT00006368|recurrent adult Hodgkin lymphoma
1500720|NCT00006368|extensive stage small cell lung cancer
1500721|NCT00006368|recurrent small cell lung cancer
1500722|NCT00006368|metastatic gastrointestinal carcinoid tumor
1500723|NCT00006368|recurrent gastrointestinal carcinoid tumor
1500724|NCT00006368|gastrinoma
1500725|NCT00006368|recurrent adult brain tumor
1500726|NCT00006368|insulinoma
1500727|NCT00006368|recurrent islet cell carcinoma
1500728|NCT00006368|ACTH-producing pituitary tumor
1500729|NCT00006368|prolactin-producing pituitary tumor
1500730|NCT00006368|growth hormone-producing pituitary tumor
1500731|NCT00006368|recurrent pituitary tumor
1500732|NCT00006368|TSH producing pituitary tumor
1500733|NCT00006368|nonfunctioning pituitary tumor
1500734|NCT00006368|adult brain stem glioma
1500735|NCT00006368|adult craniopharyngioma
1500736|NCT00006368|adult medulloblastoma
1500737|NCT00006368|adult meningioma
1500738|NCT00006368|adult glioblastoma
1500739|NCT00006368|stage IV melanoma
1500740|NCT00006368|recurrent melanoma
1500741|NCT00006368|stage IV non-small cell lung cancer
1500742|NCT00006368|WDHA syndrome
1500743|NCT00006368|somatostatinoma
1500744|NCT00006368|pancreatic polypeptide tumor
1500745|NCT00006368|glucagonoma
1500746|NCT00006368|pulmonary carcinoid tumor
1500747|NCT00006368|stage IV grade 1 follicular lymphoma
1500748|NCT00006368|stage IV grade 2 follicular lymphoma
1500749|NCT00006368|stage IV grade 3 follicular lymphoma
1500750|NCT00006368|stage IV adult diffuse small cleaved cell lymphoma
1500751|NCT00006368|stage IV adult diffuse mixed cell lymphoma
1500752|NCT00006368|stage IV adult diffuse large cell lymphoma
1500753|NCT00006368|stage IV adult immunoblastic large cell lymphoma
1500754|NCT00006368|stage IV adult lymphoblastic lymphoma
1500755|NCT00006368|stage IV adult Burkitt lymphoma
1500756|NCT00006368|recurrent grade 1 follicular lymphoma
1500757|NCT00006368|recurrent grade 2 follicular lymphoma
1500758|NCT00006368|recurrent grade 3 follicular lymphoma
1500759|NCT00006368|recurrent adult diffuse small cleaved cell lymphoma
1500760|NCT00006368|recurrent adult diffuse mixed cell lymphoma
1500761|NCT00006368|recurrent adult diffuse large cell lymphoma
1500762|NCT00006368|recurrent adult immunoblastic large cell lymphoma
1500763|NCT00006368|recurrent adult lymphoblastic lymphoma
1500764|NCT00006368|recurrent adult Burkitt lymphoma
1500765|NCT00006368|adult anaplastic astrocytoma
1500766|NCT00006368|adult myxopapillary ependymoma
1500767|NCT00006368|adult anaplastic ependymoma
1500768|NCT00006368|adult anaplastic oligodendroglioma
1500769|NCT00006368|adult central nervous system germ cell tumor
1500770|NCT00006368|adult pilocytic astrocytoma
1500771|NCT00006368|adult subependymoma
1500772|NCT00006368|adult ependymoblastoma
1500773|NCT00006368|adult pineocytoma
1500774|NCT00006368|adult pineoblastoma
1500775|NCT00006368|adult meningeal hemangiopericytoma
1500776|NCT00006368|stage IV mantle cell lymphoma
1500777|NCT00006368|recurrent mantle cell lymphoma
1500778|NCT00006368|adult choroid plexus tumor
1500779|NCT00006368|recurrent marginal zone lymphoma
1500780|NCT00006368|recurrent small lymphocytic lymphoma
1500781|NCT00006368|stage IV small lymphocytic lymphoma
1500782|NCT00006368|stage IV marginal zone lymphoma
1500783|NCT00006368|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1500784|NCT00006368|nodal marginal zone B-cell lymphoma
1500785|NCT00006368|splenic marginal zone lymphoma
1500786|NCT00006368|adult grade III meningioma
1500787|NCT00006368|adult giant cell glioblastoma
1500788|NCT00006368|adult gliosarcoma
1500789|NCT00006367|polycythemia vera
1500790|NCT00006367|chronic idiopathic myelofibrosis
1500791|NCT00006367|essential thrombocythemia
1500792|NCT00006366|stage II rectal cancer
1500793|NCT00006366|stage III rectal cancer
1500794|NCT00006366|adenocarcinoma of the rectum
1500795|NCT00006365|adenocarcinoma of the prostate
1500797|NCT00006365|stage IIB prostate cancer
1500798|NCT00006365|stage IIA prostate cancer
1500799|NCT00006362|monoclonal gammopathy of undetermined significance
1500800|NCT00006362|isolated plasmacytoma of bone
1500801|NCT00006362|extramedullary plasmacytoma
1500802|NCT00006362|refractory multiple myeloma
1500803|NCT00006362|Waldenstrom macroglobulinemia
1500804|NCT00006362|stage III multiple myeloma
1500805|NCT00006362|stage IV chronic lymphocytic leukemia
1500806|NCT00006362|refractory chronic lymphocytic leukemia
1500807|NCT00006362|unspecified adult solid tumor, protocol specific
1500808|NCT00006362|B-cell chronic lymphocytic leukemia
1500809|NCT00006362|untreated hairy cell leukemia
1500810|NCT00006362|progressive hairy cell leukemia, initial treatment
1500811|NCT00006362|refractory hairy cell leukemia
1500812|NCT00006362|stage IV grade 1 follicular lymphoma
1500813|NCT00006362|stage IV grade 2 follicular lymphoma
1500814|NCT00006362|stage IV grade 3 follicular lymphoma
1500815|NCT00006362|stage IV adult diffuse small cleaved cell lymphoma
1500816|NCT00006362|stage IV adult diffuse mixed cell lymphoma
1500817|NCT00006362|stage IV adult diffuse large cell lymphoma
1500818|NCT00006362|stage IV adult immunoblastic large cell lymphoma
1500819|NCT00006362|stage IV adult lymphoblastic lymphoma
1500820|NCT00006362|stage IV adult Burkitt lymphoma
1500821|NCT00006362|recurrent grade 1 follicular lymphoma
1500822|NCT00006362|recurrent grade 2 follicular lymphoma
1500823|NCT00006362|recurrent grade 3 follicular lymphoma
1500824|NCT00006362|recurrent adult diffuse small cleaved cell lymphoma
1500825|NCT00006362|recurrent adult diffuse mixed cell lymphoma
1500826|NCT00006362|recurrent adult diffuse large cell lymphoma
1500827|NCT00006362|recurrent adult immunoblastic large cell lymphoma
1500828|NCT00006362|recurrent adult lymphoblastic lymphoma
1500829|NCT00006362|recurrent adult Burkitt lymphoma
1500830|NCT00006362|primary systemic amyloidosis
1500831|NCT00006362|stage IV mantle cell lymphoma
1500832|NCT00006362|recurrent mantle cell lymphoma
1500833|NCT00006362|recurrent marginal zone lymphoma
1500834|NCT00006362|recurrent small lymphocytic lymphoma
1500835|NCT00006362|stage IV small lymphocytic lymphoma
1500836|NCT00006362|stage IV marginal zone lymphoma
1500837|NCT00006362|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1500838|NCT00006362|nodal marginal zone B-cell lymphoma
1500839|NCT00006362|splenic marginal zone lymphoma
1500840|NCT00006361|squamous cell carcinoma of the skin
1500841|NCT00006361|recurrent skin cancer
1500842|NCT00006361|stage IV nasopharyngeal cancer
1500843|NCT00006361|recurrent metastatic squamous neck cancer with occult primary
1500844|NCT00006361|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1500845|NCT00006361|squamous cell carcinoma of unknown primary
1500846|NCT00006361|stage IV squamous cell carcinoma of the lip and oral cavity
1500847|NCT00006361|recurrent squamous cell carcinoma of the lip and oral cavity
1500848|NCT00006361|stage IV squamous cell carcinoma of the oropharynx
1500849|NCT00006361|recurrent squamous cell carcinoma of the oropharynx
1500850|NCT00006361|stage IV squamous cell carcinoma of the nasopharynx
1500851|NCT00006361|recurrent squamous cell carcinoma of the nasopharynx
1500852|NCT00006361|stage IV squamous cell carcinoma of the hypopharynx
1500853|NCT00006361|recurrent squamous cell carcinoma of the hypopharynx
1500854|NCT00006361|stage IV squamous cell carcinoma of the larynx
1500855|NCT00006361|recurrent squamous cell carcinoma of the larynx
1500856|NCT00006361|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1500857|NCT00006361|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1500858|NCT00006361|recurrent carcinoma of unknown primary
1500859|NCT00006360|stage II squamous cell carcinoma of the oropharynx
1500860|NCT00006360|stage III squamous cell carcinoma of the oropharynx
1500861|NCT00006360|radiation toxicity
1500862|NCT00006359|adenocarcinoma of the prostate
1500863|NCT00006359|stage I prostate cancer
1500864|NCT00006359|stage II prostate cancer
1500865|NCT00006359|stage III prostate cancer
1500866|NCT00006358|recurrent adult brain tumor
1500867|NCT00006358|adult glioblastoma
1500868|NCT00006358|adult giant cell glioblastoma
1500869|NCT00006358|adult gliosarcoma
1500870|NCT00006357|adult angiosarcoma
1500871|NCT00006357|adult fibrosarcoma
1500872|NCT00006357|adult leiomyosarcoma
1500873|NCT00006357|adult liposarcoma
1500874|NCT00006357|adult neurofibrosarcoma
1500875|NCT00006357|adult synovial sarcoma
1500876|NCT00006357|recurrent adult soft tissue sarcoma
1500877|NCT00006357|small intestine leiomyosarcoma
1500878|NCT00006357|adult alveolar soft-part sarcoma
1500879|NCT00006357|adult epithelioid sarcoma
1500880|NCT00006357|adult malignant fibrous histiocytoma
1500881|NCT00006357|adult malignant hemangiopericytoma
1500882|NCT00006357|adult malignant mesenchymoma
1500883|NCT00006357|adult rhabdomyosarcoma
1500884|NCT00006357|ovarian stromal cancer
1500885|NCT00006357|recurrent uterine sarcoma
1500886|NCT00006357|uterine carcinosarcoma
1500887|NCT00006357|uterine leiomyosarcoma
1500888|NCT00006357|endometrial stromal sarcoma
1500889|NCT00006357|ovarian sarcoma
1500890|NCT00006357|gastrointestinal stromal tumor
1500891|NCT00006356|recurrent ovarian epithelial cancer
1500892|NCT00006355|adult glioblastoma
1501270|NCT00006335|XSCID
1500893|NCT00006355|adult giant cell glioblastoma
1500894|NCT00006355|adult gliosarcoma
1500895|NCT00006354|unspecified adult solid tumor, protocol specific
1500896|NCT00006353|adult glioblastoma
1500897|NCT00006353|adult giant cell glioblastoma
1500898|NCT00006353|adult gliosarcoma
1500899|NCT00006352|limited stage small cell lung cancer
1500900|NCT00006351|recurrent bladder cancer
1500901|NCT00006351|stage IV bladder cancer
1500902|NCT00006351|transitional cell carcinoma of the bladder
1500903|NCT00006351|recurrent urethral cancer
1500904|NCT00006351|anterior urethral cancer
1500905|NCT00006351|posterior urethral cancer
1500906|NCT00006351|urethral cancer associated with invasive bladder cancer
1500907|NCT00006351|metastatic transitional cell cancer of the renal pelvis and ureter
1500908|NCT00006351|recurrent transitional cell cancer of the renal pelvis and ureter
1500909|NCT00006350|recurrent adult Hodgkin lymphoma
1500910|NCT00006350|refractory multiple myeloma
1500911|NCT00006350|stage I multiple myeloma
1500912|NCT00006350|stage II multiple myeloma
1500913|NCT00006350|stage III multiple myeloma
1500914|NCT00006350|stage III chronic lymphocytic leukemia
1500915|NCT00006350|stage IV chronic lymphocytic leukemia
1500916|NCT00006350|recurrent adult acute myeloid leukemia
1500917|NCT00006350|recurrent adult acute lymphoblastic leukemia
1500918|NCT00006350|relapsing chronic myelogenous leukemia
1500919|NCT00006350|refractory chronic lymphocytic leukemia
1500920|NCT00006350|chronic phase chronic myelogenous leukemia
1500921|NCT00006350|accelerated phase chronic myelogenous leukemia
1500922|NCT00006350|blastic phase chronic myelogenous leukemia
1500923|NCT00006350|meningeal chronic myelogenous leukemia
1500924|NCT00006350|adult acute myeloid leukemia in remission
1500925|NCT00006350|adult acute lymphoblastic leukemia in remission
1500926|NCT00006350|stage III grade 1 follicular lymphoma
1500927|NCT00006350|stage III grade 2 follicular lymphoma
1500928|NCT00006350|stage III grade 3 follicular lymphoma
1500929|NCT00006350|stage III adult diffuse small cleaved cell lymphoma
1500930|NCT00006350|stage III adult diffuse mixed cell lymphoma
1500931|NCT00006350|stage III adult diffuse large cell lymphoma
1500932|NCT00006350|stage III adult immunoblastic large cell lymphoma
1500933|NCT00006350|stage III adult lymphoblastic lymphoma
1500934|NCT00006350|stage III adult Burkitt lymphoma
1500935|NCT00006350|stage IV grade 1 follicular lymphoma
1500936|NCT00006350|stage IV grade 2 follicular lymphoma
1500937|NCT00006350|stage IV grade 3 follicular lymphoma
1500938|NCT00006350|stage IV adult diffuse small cleaved cell lymphoma
1500939|NCT00006350|stage IV adult diffuse mixed cell lymphoma
1500940|NCT00006350|stage IV adult diffuse large cell lymphoma
1500941|NCT00006350|stage IV adult lymphoblastic lymphoma
1500942|NCT00006350|stage IV adult Burkitt lymphoma
1500943|NCT00006350|recurrent grade 1 follicular lymphoma
1500944|NCT00006350|recurrent grade 2 follicular lymphoma
1500945|NCT00006350|recurrent grade 3 follicular lymphoma
1500946|NCT00006350|recurrent adult diffuse small cleaved cell lymphoma
1500947|NCT00006350|recurrent adult diffuse mixed cell lymphoma
1500948|NCT00006350|recurrent adult diffuse large cell lymphoma
1500949|NCT00006350|recurrent adult immunoblastic large cell lymphoma
1500950|NCT00006350|recurrent adult lymphoblastic lymphoma
1500951|NCT00006350|recurrent adult Burkitt lymphoma
1500952|NCT00006350|de novo myelodysplastic syndromes
1500953|NCT00006350|previously treated myelodysplastic syndromes
1500954|NCT00006350|secondary myelodysplastic syndromes
1500955|NCT00006350|contiguous stage II grade 1 follicular lymphoma
1500956|NCT00006350|contiguous stage II grade 2 follicular lymphoma
1500957|NCT00006350|contiguous stage II grade 3 follicular lymphoma
1500958|NCT00006350|contiguous stage II adult diffuse small cleaved cell lymphoma
1500959|NCT00006350|contiguous stage II adult diffuse mixed cell lymphoma
1500960|NCT00006350|contiguous stage II adult immunoblastic large cell lymphoma
1500961|NCT00006350|contiguous stage II adult diffuse large cell lymphoma
1500962|NCT00006350|contiguous stage II adult Burkitt lymphoma
1500963|NCT00006350|contiguous stage II adult lymphoblastic lymphoma
1500964|NCT00006350|noncontiguous stage II grade 1 follicular lymphoma
1500965|NCT00006350|noncontiguous stage II grade 2 follicular lymphoma
1500966|NCT00006350|noncontiguous stage II grade 3 follicular lymphoma
1500967|NCT00006350|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1500968|NCT00006350|noncontiguous stage II adult diffuse mixed cell lymphoma
1500969|NCT00006350|noncontiguous stage II adult immunoblastic large cell lymphoma
1500970|NCT00006350|noncontiguous stage II adult diffuse large cell lymphoma
1501381|NCT00006298|Neutralization Tests
1500971|NCT00006350|noncontiguous stage II adult Burkitt lymphoma
1500972|NCT00006350|noncontiguous stage II adult lymphoblastic lymphoma
1500973|NCT00006350|recurrent mantle cell lymphoma
1500974|NCT00006350|noncontiguous stage II small lymphocytic lymphoma
1500975|NCT00006350|noncontiguous stage II marginal zone lymphoma
1500976|NCT00006350|recurrent marginal zone lymphoma
1500977|NCT00006350|recurrent small lymphocytic lymphoma
1500978|NCT00006350|stage III small lymphocytic lymphoma
1500979|NCT00006350|stage III marginal zone lymphoma
1500980|NCT00006350|stage IV small lymphocytic lymphoma
1500981|NCT00006350|stage IV marginal zone lymphoma
1500982|NCT00006350|contiguous stage II marginal zone lymphoma
1501271|NCT00006335|Carrier Testing
1500983|NCT00006350|contiguous stage II small lymphocytic lymphoma
1500984|NCT00006350|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1500985|NCT00006350|nodal marginal zone B-cell lymphoma
1500986|NCT00006350|splenic marginal zone lymphoma
1500987|NCT00006349|depression
1500988|NCT00006349|delirium
1500989|NCT00006349|cognitive/functional effects
1500990|NCT00006349|radiation toxicity
1500991|NCT00006349|limited stage small cell lung cancer
1500992|NCT00006349|extensive stage small cell lung cancer
1500993|NCT00006349|recurrent small cell lung cancer
1500994|NCT00006348|stage IV adult Hodgkin lymphoma
1500995|NCT00006348|monoclonal gammopathy of undetermined significance
1500996|NCT00006348|recurrent childhood acute lymphoblastic leukemia
1500997|NCT00006348|recurrent adult Hodgkin lymphoma
1500998|NCT00006348|stage IV cutaneous T-cell non-Hodgkin lymphoma
1500999|NCT00006348|recurrent cutaneous T-cell non-Hodgkin lymphoma
1501000|NCT00006348|isolated plasmacytoma of bone
1501001|NCT00006348|extramedullary plasmacytoma
1501002|NCT00006348|refractory multiple myeloma
1501003|NCT00006348|Waldenström macroglobulinemia
1501004|NCT00006348|stage III multiple myeloma
1501005|NCT00006348|stage IV childhood lymphoblastic lymphoma
1501006|NCT00006348|recurrent childhood lymphoblastic lymphoma
1501007|NCT00006348|stage IV chronic lymphocytic leukemia
1501008|NCT00006348|recurrent childhood acute myeloid leukemia
1501009|NCT00006348|recurrent adult acute myeloid leukemia
1501010|NCT00006348|recurrent adult acute lymphoblastic leukemia
1501011|NCT00006348|relapsing chronic myelogenous leukemia
1501012|NCT00006348|refractory chronic lymphocytic leukemia
1501013|NCT00006348|small intestine lymphoma
1501014|NCT00006348|unspecified childhood solid tumor, protocol specific
1501015|NCT00006348|unspecified adult solid tumor, protocol specific
1501016|NCT00006348|chronic phase chronic myelogenous leukemia
1501017|NCT00006348|accelerated phase chronic myelogenous leukemia
1501018|NCT00006348|blastic phase chronic myelogenous leukemia
1501019|NCT00006348|meningeal chronic myelogenous leukemia
1501020|NCT00006348|untreated adult acute lymphoblastic leukemia
1501021|NCT00006348|untreated adult acute myeloid leukemia
1501022|NCT00006348|untreated childhood acute myeloid leukemia and other myeloid malignancies
1501023|NCT00006348|untreated childhood acute lymphoblastic leukemia
1501024|NCT00006348|polycythemia vera
1501025|NCT00006348|primary myelofibrosis
1501026|NCT00006348|essential thrombocythemia
1501027|NCT00006348|untreated hairy cell leukemia
1501028|NCT00006348|progressive hairy cell leukemia, initial treatment
1501029|NCT00006348|refractory hairy cell leukemia
1501030|NCT00006348|stage IV childhood Hodgkin lymphoma
1501031|NCT00006348|recurrent/refractory childhood Hodgkin lymphoma
1501032|NCT00006348|chronic myelomonocytic leukemia
1501033|NCT00006348|T-cell large granular lymphocyte leukemia
1501034|NCT00006348|acute undifferentiated leukemia
1501035|NCT00006348|stage IV grade 1 follicular lymphoma
1501036|NCT00006348|stage IV grade 2 follicular lymphoma
1501037|NCT00006348|stage IV grade 3 follicular lymphoma
1501038|NCT00006348|stage IV adult diffuse small cleaved cell lymphoma
1501039|NCT00006348|stage IV adult diffuse mixed cell lymphoma
1501040|NCT00006348|stage IV adult diffuse large cell lymphoma
1501041|NCT00006348|stage IV adult immunoblastic large cell lymphoma
1501042|NCT00006348|stage IV adult lymphoblastic lymphoma
1501043|NCT00006348|stage IV adult Burkitt lymphoma
1501044|NCT00006348|recurrent grade 1 follicular lymphoma
1501045|NCT00006348|recurrent grade 2 follicular lymphoma
1501046|NCT00006348|recurrent grade 3 follicular lymphoma
1501047|NCT00006348|recurrent adult diffuse small cleaved cell lymphoma
1501048|NCT00006348|recurrent adult diffuse mixed cell lymphoma
1501049|NCT00006348|recurrent adult diffuse large cell lymphoma
1501050|NCT00006348|recurrent adult immunoblastic large cell lymphoma
1501051|NCT00006348|recurrent adult lymphoblastic lymphoma
1501052|NCT00006348|recurrent adult Burkitt lymphoma
1501053|NCT00006348|stage IV adult T-cell leukemia/lymphoma
1501054|NCT00006348|recurrent adult T-cell leukemia/lymphoma
1501055|NCT00006348|secondary acute myeloid leukemia
1501056|NCT00006348|de novo myelodysplastic syndromes
1501057|NCT00006348|previously treated myelodysplastic syndromes
1501058|NCT00006348|secondary myelodysplastic syndromes
1501059|NCT00006348|primary central nervous system non-Hodgkin lymphoma
1501060|NCT00006348|nausea and vomiting
1501061|NCT00006348|prolymphocytic leukemia
1501062|NCT00006348|AIDS-related peripheral/systemic lymphoma
1501063|NCT00006348|AIDS-related primary CNS lymphoma
1501064|NCT00006348|primary systemic amyloidosis
1501065|NCT00006348|intraocular lymphoma
1501066|NCT00006348|stage IV childhood small noncleaved cell lymphoma
1501067|NCT00006348|stage IV childhood large cell lymphoma
1501068|NCT00006348|recurrent childhood small noncleaved cell lymphoma
1501069|NCT00006348|recurrent childhood large cell lymphoma
1501070|NCT00006348|stage IV mantle cell lymphoma
1501071|NCT00006348|recurrent mantle cell lymphoma
1501072|NCT00006348|angioimmunoblastic T-cell lymphoma
1501073|NCT00006348|anaplastic large cell lymphoma
1501074|NCT00006348|stage IV mycosis fungoides/Sezary syndrome
1501075|NCT00006348|recurrent mycosis fungoides/Sezary syndrome
1501076|NCT00006348|recurrent marginal zone lymphoma
1501077|NCT00006348|recurrent small lymphocytic lymphoma
1501078|NCT00006348|stage IV small lymphocytic lymphoma
1501079|NCT00006348|stage IV marginal zone lymphoma
1501080|NCT00006348|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1501081|NCT00006348|nodal marginal zone B-cell lymphoma
1501082|NCT00006348|splenic marginal zone lymphoma
1501083|NCT00006348|childhood myelodysplastic syndromes
1501084|NCT00006347|recurrent small cell lung cancer
1501085|NCT00006346|stage II breast cancer
1501086|NCT00006346|stage IV breast cancer
1501087|NCT00006346|stage IIIA breast cancer
1501088|NCT00006346|stage IIIB breast cancer
1501089|NCT00006346|psychosocial effects of cancer and its treatment
1501090|NCT00006345|recurrent cutaneous T-cell non-Hodgkin lymphoma
1501091|NCT00006345|drug/agent toxicity by tissue/organ
1501092|NCT00006345|recurrent mycosis fungoides/Sezary syndrome
1501093|NCT00006344|limited stage small cell lung cancer
1501094|NCT00006344|extensive stage small cell lung cancer
1501095|NCT00006343|chronic phase chronic myelogenous leukemia
1501096|NCT00006343|chronic myelogenous leukemia, BCR-ABL1 positive
1501097|NCT00006342|stage I adult Hodgkin lymphoma
1501098|NCT00006342|stage II adult Hodgkin lymphoma
1501099|NCT00006342|stage III adult Hodgkin lymphoma
1501100|NCT00006342|stage IV adult Hodgkin lymphoma
1501101|NCT00006342|recurrent adult Hodgkin lymphoma
1501102|NCT00006342|childhood infratentorial ependymoma
1501103|NCT00006342|childhood low-grade cerebral astrocytoma
1501104|NCT00006342|childhood supratentorial ependymoma
1501105|NCT00006342|stage II childhood Hodgkin lymphoma
1501106|NCT00006342|stage I childhood Hodgkin lymphoma
1501107|NCT00006342|stage III childhood Hodgkin lymphoma
1501108|NCT00006342|stage IV childhood Hodgkin lymphoma
1501109|NCT00006342|recurrent/refractory childhood Hodgkin lymphoma
1501110|NCT00006342|childhood high-grade cerebral astrocytoma
1501111|NCT00006342|untreated childhood brain stem glioma
1501112|NCT00006342|recurrent childhood brain stem glioma
1501113|NCT00006342|untreated childhood supratentorial primitive neuroectodermal tumor
1501114|NCT00006342|recurrent childhood supratentorial primitive neuroectodermal tumor
1501115|NCT00006342|untreated childhood cerebellar astrocytoma
1501116|NCT00006342|recurrent childhood cerebellar astrocytoma
1501117|NCT00006342|recurrent childhood cerebral astrocytoma
1501118|NCT00006342|untreated childhood medulloblastoma
1501119|NCT00006342|recurrent childhood medulloblastoma
1501120|NCT00006342|newly diagnosed childhood ependymoma
1501121|NCT00006342|recurrent childhood ependymoma
1501122|NCT00006341|stage I lip and oral cavity cancer
1501123|NCT00006341|stage II lip and oral cavity cancer
1501124|NCT00006341|stage III lip and oral cavity cancer
1501125|NCT00006340|stage I adult Hodgkin lymphoma
1501126|NCT00006340|stage II adult Hodgkin lymphoma
1501127|NCT00006340|stage III adult Hodgkin lymphoma
1501128|NCT00006340|stage IV adult Hodgkin lymphoma
1501129|NCT00006340|recurrent adult Hodgkin lymphoma
1501130|NCT00006340|stage I cutaneous T-cell non-Hodgkin lymphoma
1501131|NCT00006340|stage II cutaneous T-cell non-Hodgkin lymphoma
1501132|NCT00006340|stage III cutaneous T-cell non-Hodgkin lymphoma
1501133|NCT00006340|stage IV cutaneous T-cell non-Hodgkin lymphoma
1501134|NCT00006340|recurrent cutaneous T-cell non-Hodgkin lymphoma
1501135|NCT00006340|stage I childhood lymphoblastic lymphoma
1501136|NCT00006340|stage II childhood lymphoblastic lymphoma
1501137|NCT00006340|stage III childhood lymphoblastic lymphoma
1501138|NCT00006340|stage IV childhood lymphoblastic lymphoma
1501139|NCT00006340|recurrent childhood lymphoblastic lymphoma
1501140|NCT00006340|small intestine lymphoma
1501141|NCT00006340|childhood immunoblastic large cell lymphoma
1501142|NCT00006340|grade I lymphomatoid granulomatosis
1501143|NCT00006340|grade II lymphomatoid granulomatosis
1501144|NCT00006340|adult grade III lymphomatoid granulomatosis
1501145|NCT00006340|recurrent adult grade III lymphomatoid granulomatosis
1501146|NCT00006340|childhood grade III lymphomatoid granulomatosis
1501147|NCT00006340|recurrent childhood grade III lymphomatoid granulomatosis
1501148|NCT00006340|recurrent grade I lymphomatoid granulomatosis
1501149|NCT00006340|recurrent grade II lymphomatoid granulomatosis
1501150|NCT00006340|stage II childhood Hodgkin lymphoma
1501151|NCT00006340|stage I childhood Hodgkin lymphoma
1501152|NCT00006340|stage III childhood Hodgkin lymphoma
1501153|NCT00006340|stage IV childhood Hodgkin lymphoma
1501154|NCT00006340|recurrent/refractory childhood Hodgkin lymphoma
1501155|NCT00006340|stage I grade 1 follicular lymphoma
1501156|NCT00006340|stage I grade 2 follicular lymphoma
1501157|NCT00006340|stage I grade 3 follicular lymphoma
1501158|NCT00006340|stage I adult diffuse small cleaved cell lymphoma
1501382|NCT00006298|Viral Load
1501159|NCT00006340|stage I adult diffuse mixed cell lymphoma
1501160|NCT00006340|stage I adult diffuse large cell lymphoma
1501161|NCT00006340|stage I adult immunoblastic large cell lymphoma
1501162|NCT00006340|stage I adult lymphoblastic lymphoma
1501163|NCT00006340|stage I adult Burkitt lymphoma
1501164|NCT00006340|T-cell large granular lymphocyte leukemia
1501165|NCT00006340|stage II grade 1 follicular lymphoma
1501166|NCT00006340|stage II grade 2 follicular lymphoma
1501167|NCT00006340|stage II grade 3 follicular lymphoma
1501168|NCT00006340|stage II adult diffuse small cleaved cell lymphoma
1501169|NCT00006340|stage II adult diffuse mixed cell lymphoma
1501272|NCT00006335|X-Linked Disease
1501170|NCT00006340|stage II adult diffuse large cell lymphoma
1501171|NCT00006340|stage II adult immunoblastic large cell lymphoma
1501172|NCT00006340|stage II adult lymphoblastic lymphoma
1501173|NCT00006340|stage II adult Burkitt lymphoma
1501174|NCT00006340|stage III grade 1 follicular lymphoma
1501175|NCT00006340|stage III grade 2 follicular lymphoma
1501176|NCT00006340|stage III grade 3 follicular lymphoma
1501177|NCT00006340|stage III adult diffuse small cleaved cell lymphoma
1501178|NCT00006340|stage III adult diffuse mixed cell lymphoma
1501179|NCT00006340|stage III adult diffuse large cell lymphoma
1501180|NCT00006340|stage III adult immunoblastic large cell lymphoma
1501181|NCT00006340|stage III adult lymphoblastic lymphoma
1501182|NCT00006340|stage III adult Burkitt lymphoma
1501183|NCT00006340|stage IV grade 1 follicular lymphoma
1501184|NCT00006340|stage IV grade 2 follicular lymphoma
1501185|NCT00006340|stage IV grade 3 follicular lymphoma
1501186|NCT00006340|stage IV adult diffuse small cleaved cell lymphoma
1501187|NCT00006340|stage IV adult diffuse mixed cell lymphoma
1501188|NCT00006340|stage IV adult diffuse large cell lymphoma
1501189|NCT00006340|stage IV adult immunoblastic large cell lymphoma
1501190|NCT00006340|stage IV adult lymphoblastic lymphoma
1501191|NCT00006340|stage IV adult Burkitt lymphoma
1501192|NCT00006340|recurrent grade 1 follicular lymphoma
1501193|NCT00006340|recurrent grade 2 follicular lymphoma
1501194|NCT00006340|recurrent grade 3 follicular lymphoma
1501195|NCT00006340|recurrent adult diffuse small cleaved cell lymphoma
1501196|NCT00006340|recurrent adult diffuse mixed cell lymphoma
1501197|NCT00006340|recurrent adult diffuse large cell lymphoma
1501198|NCT00006340|recurrent adult immunoblastic large cell lymphoma
1501199|NCT00006340|recurrent adult lymphoblastic lymphoma
1501200|NCT00006340|recurrent adult Burkitt lymphoma
1501201|NCT00006340|stage I adult T-cell leukemia/lymphoma
1501202|NCT00006340|stage II adult T-cell leukemia/lymphoma
1501203|NCT00006340|stage III adult T-cell leukemia/lymphoma
1501204|NCT00006340|stage IV adult T-cell leukemia/lymphoma
1501205|NCT00006340|recurrent adult T-cell leukemia/lymphoma
1501206|NCT00006340|AIDS-related peripheral/systemic lymphoma
1501207|NCT00006340|AIDS-related primary CNS lymphoma
1501208|NCT00006340|stage I childhood small noncleaved cell lymphoma
1501209|NCT00006340|stage I childhood large cell lymphoma
1501210|NCT00006340|stage II childhood small noncleaved cell lymphoma
1501211|NCT00006340|stage II childhood large cell lymphoma
1501212|NCT00006340|stage III childhood small noncleaved cell lymphoma
1501213|NCT00006340|stage III childhood large cell lymphoma
1501214|NCT00006340|stage IV childhood small noncleaved cell lymphoma
1501215|NCT00006340|stage IV childhood large cell lymphoma
1501216|NCT00006340|recurrent childhood small noncleaved cell lymphoma
1501217|NCT00006340|recurrent childhood large cell lymphoma
1501218|NCT00006340|stage I mantle cell lymphoma
1501219|NCT00006340|stage III mantle cell lymphoma
1501220|NCT00006340|stage IV mantle cell lymphoma
1501221|NCT00006340|recurrent mantle cell lymphoma
1501222|NCT00006340|angioimmunoblastic T-cell lymphoma
1501223|NCT00006340|anaplastic large cell lymphoma
1501224|NCT00006340|stage II mantle cell lymphoma
1501225|NCT00006340|stage I mycosis fungoides/Sezary syndrome
1501226|NCT00006340|stage II mycosis fungoides/Sezary syndrome
1501227|NCT00006340|stage III mycosis fungoides/Sezary syndrome
1501228|NCT00006340|stage IV mycosis fungoides/Sezary syndrome
1501229|NCT00006340|recurrent mycosis fungoides/Sezary syndrome
1501230|NCT00006340|recurrent marginal zone lymphoma
1501231|NCT00006340|recurrent small lymphocytic lymphoma
1501232|NCT00006340|stage I marginal zone lymphoma
1501233|NCT00006340|stage I small lymphocytic lymphoma
1501234|NCT00006340|stage II small lymphocytic lymphoma
1501235|NCT00006340|stage II marginal zone lymphoma
1501236|NCT00006340|stage III small lymphocytic lymphoma
1501237|NCT00006340|stage III marginal zone lymphoma
1501238|NCT00006340|stage IV small lymphocytic lymphoma
1501239|NCT00006340|stage IV marginal zone lymphoma
1501240|NCT00006340|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1501241|NCT00006340|nodal marginal zone B-cell lymphoma
1501242|NCT00006340|splenic marginal zone lymphoma
1501243|NCT00006339|Prospective Studies
1501244|NCT00006339|HIV-1
1501245|NCT00006339|Didanosine
1501246|NCT00006339|Drug Therapy, Combination
1501247|NCT00006339|Stavudine
1501248|NCT00006339|HIV Protease Inhibitors
1501249|NCT00006339|Hydroxyurea
1501250|NCT00006339|Ritonavir
1501251|NCT00006339|Indinavir
1501252|NCT00006339|Reverse Transcriptase Inhibitors
1501253|NCT00006339|Anti-HIV Agents
1501254|NCT00006339|Viral Load
1501255|NCT00006339|Reverse Transcriptase Polymerase Chain Reaction
1501256|NCT00006337|Clinical Trial
1501257|NCT00006337|Dyskinesias
1501258|NCT00006337|Levodopa Infusion
1501259|NCT00006336|Gap Detection Test
1501260|NCT00006336|Fahn-Scale
1501261|NCT00006336|Visual Analog and Verbal Scale
1501262|NCT00006336|Writing Standard Paragraph
1501263|NCT00006336|Braille Reading Grade I
1501264|NCT00006335|Genetic
1501265|NCT00006335|Analysis
1501266|NCT00006335|Immune
1501267|NCT00006335|Teenage
1501268|NCT00006335|Girls
1501269|NCT00006335|Severe Combined Immune Deficiency (SCID)
1501273|NCT00006335|Adolescent
1501274|NCT00006334|Genes
1501275|NCT00006334|X-Chromosome
1501276|NCT00006334|Osteoporosis
1501277|NCT00006334|Ovarian Failure
1501278|NCT00006334|Imprinting
1501279|NCT00006334|Turner's
1501280|NCT00006334|Turner
1501281|NCT00006334|TS
1501282|NCT00006333|Rheumatoid Arthritis
1501283|NCT00006333|Inflammation
1501284|NCT00006333|Synovitis
1501285|NCT00006333|Genetics
1501286|NCT00006333|Synovial Biopsy
1501287|NCT00006333|Arthritis
1501288|NCT00006333|Juvenile Rheumatoid Arthritis
1501289|NCT00006333|JRA
1501290|NCT00006332|Molybdenum
1501291|NCT00006331|Kidney transplantation
1501292|NCT00006331|Immunology
1501293|NCT00006330|Digoxin
1501294|NCT00006330|Effect modifiers (Epidemiology)
1501295|NCT00006330|Rosales
1501296|NCT00006330|Drug Interaction
1501297|NCT00006329|Radionuclide imaging
1501298|NCT00006329|Surgery
1501299|NCT00006328|Chronic Allograft Nephropathy (CAN)
1501300|NCT00006328|Transplantation immunology
1501301|NCT00006328|Genetics
1501302|NCT00006328|Graft Rejection
1501303|NCT00006327|Recombinant Proteins
1501304|NCT00006327|HIV-1
1501305|NCT00006327|AIDS Serodiagnosis
1501306|NCT00006327|Substance Abuse, Intravenous
1501307|NCT00006327|Enzyme-Linked Immunosorbent Assay
1501308|NCT00006327|Blotting, Western
1501309|NCT00006327|HIV Envelope Protein gp120
1501310|NCT00006327|AIDSVAX
1501311|NCT00006326|Drug Therapy, Combination
1501312|NCT00006326|HIV Protease Inhibitors
1501313|NCT00006326|Ritonavir
1501314|NCT00006326|Indinavir
1501315|NCT00006326|Delavirdine
1501316|NCT00006326|Reverse Transcriptase Inhibitors
1501317|NCT00006326|Salvage Therapy
1501318|NCT00006326|Anti-HIV Agents
1501319|NCT00006326|Viral Load
1501320|NCT00006326|Nelfinavir
1501321|NCT00006325|Polyethylene Glycols
1501322|NCT00006325|Interferon Alfa-2b
1501323|NCT00006325|HIV-1
1501324|NCT00006325|Dose-Response Relationship, Drug
1501325|NCT00006325|Drug Therapy, Combination
1501326|NCT00006325|Virus Inhibitors
1501327|NCT00006325|Anti-HIV Agents
1501328|NCT00006325|Pharmacokinetics
1501329|NCT00006324|HIV Seronegativity
1501330|NCT00006324|Delayed-Action Preparations
1501331|NCT00006324|Risk Factors
1501332|NCT00006324|Prevalence
1501333|NCT00006324|Contraceptive Agents, Female
1501334|NCT00006324|Contraceptives, Oral, Combined
1501335|NCT00006324|Medroxyprogesterone 17-Acetate
1501336|NCT00006320|Reverse Transcriptase Inhibitor
1501337|NCT00006320|Protease Inhibitor
1501338|NCT00006319|X-Linked Agammagloblinemia
1501339|NCT00006319|Wiskott-Aldrich Syndrome
1501340|NCT00006319|Jak-3 SCID
1501341|NCT00006319|X-Linked SCID
1501342|NCT00006319|X-Linked Hyper-IgM Syndrome
1501343|NCT00006319|Primary Immunodeficiencies
1501344|NCT00006319|ADA-SCID
1501345|NCT00006319|CVID
1501346|NCT00006318|Cerebral Blood Flow
1501347|NCT00006318|CO2 Inhalation
1501348|NCT00006318|Imaging
1501349|NCT00006318|MRI
1501350|NCT00006318|Perfusion
1501351|NCT00006318|Functional Activation
1501352|NCT00006316|AIDS-Related Opportunistic Infections
1501353|NCT00006316|Histoplasmosis
1501354|NCT00006316|Antifungal Agents
1501355|NCT00006316|Recurrence
1501356|NCT00006316|Anti-HIV Agents
1501357|NCT00006304|Acquired Immunodeficiency Syndrome
1501358|NCT00006304|AIDS-Related Complex
1501359|NCT00006301|Hepatitis C
1501360|NCT00006301|Viral Sequence
1501361|NCT00006301|PCR
1501362|NCT00006301|T Cell
1501363|NCT00006301|Seroconversion
1501364|NCT00006301|Cytokines
1501365|NCT00006300|Immunosuppression
1501366|NCT00006300|Treatment Recommendations
1501367|NCT00006300|Pancytopenia
1501368|NCT00006300|Schizophrenia
1501369|NCT00006300|Inpatient Population
1501370|NCT00006299|Celecoxib
1501371|NCT00006299|Thromboxane B2
1501372|NCT00006299|Prostaglandin E2
1501373|NCT00006299|Microdialysis
1501374|NCT00006299|Ibuprofen
1501375|NCT00006298|HIV Antibodies
1501376|NCT00006298|HIV-1
1501377|NCT00006298|CD4 Lymphocyte Count
1501378|NCT00006298|T-Lymphocytes, Cytotoxic
1501379|NCT00006298|Genotype
1501380|NCT00006298|Species Specificity
1501383|NCT00006298|Alleles
1501384|NCT00006298|HLA Antigens
1501385|NCT00006298|Cross Reactions
1501386|NCT00006298|Immunodominant Epitopes
1501387|NCT00006298|Haplotypes
1501388|NCT00006292|Biologic Therapy
1501389|NCT00006292|Bone Erosion
1501390|NCT00006292|CT
1501391|NCT00006292|MRI
1501392|NCT00006292|Rheumatoid Arthritis
1501393|NCT00006292|RA
1501394|NCT00006291|Virus Replication
1501395|NCT00006291|T-Lymphocytes
1501396|NCT00006291|Lymphocyte Transformation
1501397|NCT00006291|AIDS Vaccines
1501398|NCT00006291|Anti-HIV Agents
1501399|NCT00006291|Viral Load
1501400|NCT00006291|Aldesleukin
1501401|NCT00006291|HIV Therapeutic Vaccine
1501402|NCT00006290|Drug Therapy, Combination
1501403|NCT00006290|Questionnaires
1501404|NCT00006290|Quality of Life
1501405|NCT00006290|Patient Compliance
1501406|NCT00006290|Body Composition
1501407|NCT00006290|Anti-HIV Agents
1501408|NCT00006290|Adipose Tissue
1501409|NCT00006290|Body Image
1501410|NCT00006289|Analgesia
1501411|NCT00006289|Causalgia
1501412|NCT00006289|CRPS
1501413|NCT00006289|Neuropathic Pain
1501414|NCT00006289|Oral Surgery
1501415|NCT00006289|Reflex Sympathetic Dystrophy
1501416|NCT00006289|Sympathetic Nervous System
1501417|NCT00006289|Chronic Regional Pain Syndrome
1501418|NCT00006286|Depression
1501419|NCT00006286|Major Depressive Disorder
1501420|NCT00006286|Fluoxetine
1501421|NCT00006286|Prozac
1501422|NCT00006286|SSRI
1501423|NCT00006286|Psychotherapy
1501424|NCT00006286|CBT
1501425|NCT00006286|Teenagers
1501426|NCT00006286|Adolescents
1501427|NCT00006286|Teens
1501428|NCT00006285|Transcranial Magnetic Stimulation
1501429|NCT00006285|Parietal Lobe
1501430|NCT00006285|fMRI
1501431|NCT00006285|Cognition
1501432|NCT00006285|Perception
1501433|NCT00006285|Cortical Stimulation
1501434|NCT00006285|Spatial Attention
1501435|NCT00006280|Cystic Fibrosis
1501436|NCT00006279|Pregnancy Complications, Infectious
1501437|NCT00006279|Dose-Response Relationship, Drug
1501438|NCT00006279|Drug Administration Schedule
1501439|NCT00006279|Nevirapine
1501440|NCT00006279|Disease Transmission, Vertical
1501441|NCT00006279|Reverse Transcriptase Inhibitors
1501442|NCT00006279|Anti-HIV Agents
1501443|NCT00006279|Breast Feeding
1501444|NCT00006278|Cushing's Syndrome
1501445|NCT00006278|Adrenal Glands
1501446|NCT00006278|Proteomics
1501447|NCT00006278|Cortisol
1501448|NCT00006276|Angiogenesis Inhibition
1501449|NCT00006276|Skin Disease
1501450|NCT00006276|Blood Vessels
1501451|NCT00006276|Cytokines
1501452|NCT00006276|Autoimmune Disease
1501453|NCT00006275|dermatologic disorders
1501454|NCT00006275|psoriasis
1501455|NCT00006275|rare disease
1501456|NCT00006274|cardiovascular and respiratory diseases
1501457|NCT00006274|neonatal disorders
1501458|NCT00006274|rare disease
1501459|NCT00006274|respiratory distress syndrome
1501460|NCT00006273|cardiovascular and respiratory diseases
1501461|NCT00006273|cystic fibrosis
1501462|NCT00006273|genetic diseases and dysmorphic syndromes
1501463|NCT00006273|rare disease
1501464|NCT00006272|cardiovascular and respiratory diseases
1501465|NCT00006272|heart defects
1501466|NCT00006272|rare disease
1501467|NCT00006271|brain injury
1501468|NCT00006271|neurologic and psychiatric disorders
1501469|NCT00006271|rare disease
1501470|NCT00006270|brain injury
1501471|NCT00006270|neurologic and psychiatric disorders
1501472|NCT00006270|rare disease
1501473|NCT00006269|stage IV colon cancer
1501474|NCT00006269|stage IV rectal cancer
1501475|NCT00006269|recurrent colon cancer
1501476|NCT00006269|recurrent rectal cancer
1501477|NCT00006269|diarrhea
1501478|NCT00006268|recurrent adult brain tumor
1501479|NCT00006268|adult glioblastoma
1501480|NCT00006268|adult anaplastic astrocytoma
1501481|NCT00006268|adult mixed glioma
1501482|NCT00006268|adult giant cell glioblastoma
1501483|NCT00006268|adult gliosarcoma
1501484|NCT00006267|stage IV ovarian epithelial cancer
1501485|NCT00006267|recurrent ovarian epithelial cancer
1501486|NCT00006267|primary peritoneal cavity cancer
1501487|NCT00006265|recurrent adult acute myeloid leukemia
1501488|NCT00006264|AIDS-related primary CNS lymphoma
1501489|NCT00006263|adult brain stem glioma
1501490|NCT00006263|adult glioblastoma
1501491|NCT00006263|childhood high-grade cerebral astrocytoma
1501492|NCT00006263|adult anaplastic astrocytoma
1501493|NCT00006263|adult anaplastic oligodendroglioma
1501494|NCT00006263|adult giant cell glioblastoma
1501495|NCT00006263|adult gliosarcoma
1501496|NCT00006262|stage III ovarian epithelial cancer
1501497|NCT00006262|stage IV ovarian epithelial cancer
1501498|NCT00006262|recurrent ovarian epithelial cancer
1501499|NCT00006261|stage IV breast cancer
1501500|NCT00006261|recurrent breast cancer
1501501|NCT00006260|stage IV breast cancer
1501502|NCT00006260|recurrent breast cancer
1501503|NCT00006259|tumors metastatic to brain
1501504|NCT00006258|childhood infratentorial ependymoma
1501505|NCT00006258|childhood supratentorial ependymoma
1501506|NCT00006258|adult medulloblastoma
1501507|NCT00006258|adult myxopapillary ependymoma
1501508|NCT00006258|adult anaplastic ependymoma
1501509|NCT00006258|adult ependymoblastoma
1501510|NCT00006258|untreated childhood supratentorial primitive neuroectodermal tumor
1501511|NCT00006258|untreated childhood medulloblastoma
1501512|NCT00006258|newly diagnosed childhood ependymoma
1501513|NCT00006258|adult supratentorial primitive neuroectodermal tumor (PNET)
1501514|NCT00006257|unspecified adult solid tumor, protocol specific
1501515|NCT00006256|stage II breast cancer
1501516|NCT00006256|stage IIIA breast cancer
1501517|NCT00006256|stage IIIB breast cancer
1501518|NCT00006256|stage IIIC breast cancer
1501519|NCT00006255|stage III renal cell cancer
1501520|NCT00006255|stage IV renal cell cancer
1501521|NCT00006255|recurrent renal cell cancer
1501522|NCT00006255|unspecified adult solid tumor, protocol specific
1501523|NCT00006255|liver metastases
1501524|NCT00006254|unspecified adult solid tumor, protocol specific
1501525|NCT00006253|symptom management
1501526|NCT00006253|cancer
1501527|NCT00006253|chemotherapy treatment
1501528|NCT00006253|Behavioral Research
1501529|NCT00006253|Physiological Effects of Drugs
1501530|NCT00006253|Clinical Trial, Phase II
1501531|NCT00006252|refractory chronic lymphocytic leukemia
1501532|NCT00006252|stage I grade 1 follicular lymphoma
1501533|NCT00006252|stage I grade 2 follicular lymphoma
1501534|NCT00006252|stage I adult diffuse small cleaved cell lymphoma
1501535|NCT00006252|stage III grade 1 follicular lymphoma
1501536|NCT00006252|stage III grade 2 follicular lymphoma
1501537|NCT00006252|stage III adult diffuse small cleaved cell lymphoma
1501538|NCT00006252|stage IV grade 1 follicular lymphoma
1501539|NCT00006252|stage IV grade 2 follicular lymphoma
1501540|NCT00006252|stage IV adult diffuse small cleaved cell lymphoma
1501541|NCT00006252|recurrent grade 1 follicular lymphoma
1501542|NCT00006252|recurrent grade 2 follicular lymphoma
1501543|NCT00006252|recurrent adult diffuse small cleaved cell lymphoma
1501544|NCT00006252|prolymphocytic leukemia
1501545|NCT00006252|stage I mantle cell lymphoma
1501546|NCT00006252|contiguous stage II grade 1 follicular lymphoma
1501547|NCT00006252|contiguous stage II grade 2 follicular lymphoma
1501548|NCT00006252|contiguous stage II adult diffuse small cleaved cell lymphoma
1501549|NCT00006252|contiguous stage II mantle cell lymphoma
1501550|NCT00006252|noncontiguous stage II grade 1 follicular lymphoma
1501551|NCT00006252|noncontiguous stage II grade 2 follicular lymphoma
1501552|NCT00006252|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1501553|NCT00006252|noncontiguous stage II mantle cell lymphoma
1501554|NCT00006252|stage III mantle cell lymphoma
1501555|NCT00006252|stage IV mantle cell lymphoma
1501556|NCT00006252|recurrent mantle cell lymphoma
1501557|NCT00006252|contiguous stage II small lymphocytic lymphoma
1501558|NCT00006252|contiguous stage II marginal zone lymphoma
1501559|NCT00006252|noncontiguous stage II small lymphocytic lymphoma
1501560|NCT00006252|noncontiguous stage II marginal zone lymphoma
1501561|NCT00006252|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1501562|NCT00006252|nodal marginal zone B-cell lymphoma
1501563|NCT00006252|splenic marginal zone lymphoma
1501564|NCT00006252|recurrent marginal zone lymphoma
1501565|NCT00006252|recurrent small lymphocytic lymphoma
1501566|NCT00006252|stage I marginal zone lymphoma
1501567|NCT00006252|stage I small lymphocytic lymphoma
1501568|NCT00006252|stage III small lymphocytic lymphoma
1501569|NCT00006252|stage III marginal zone lymphoma
1501570|NCT00006252|stage IV small lymphocytic lymphoma
1501571|NCT00006252|stage IV marginal zone lymphoma
1501572|NCT00006250|stage III grade 1 follicular lymphoma
1501573|NCT00006250|stage III grade 2 follicular lymphoma
1501574|NCT00006250|stage III grade 3 follicular lymphoma
1501575|NCT00006250|stage IV grade 1 follicular lymphoma
1501576|NCT00006250|stage IV grade 2 follicular lymphoma
1501577|NCT00006250|stage IV grade 3 follicular lymphoma
1501578|NCT00006249|stage III melanoma
1501579|NCT00006248|stage IV squamous cell carcinoma of the lip and oral cavity
1501580|NCT00006248|recurrent squamous cell carcinoma of the lip and oral cavity
1501581|NCT00006248|stage IV squamous cell carcinoma of the oropharynx
1501582|NCT00006248|recurrent squamous cell carcinoma of the oropharynx
1501583|NCT00006248|stage IV squamous cell carcinoma of the nasopharynx
1501584|NCT00006248|recurrent squamous cell carcinoma of the nasopharynx
1501585|NCT00006248|stage IV squamous cell carcinoma of the hypopharynx
1501586|NCT00006248|recurrent squamous cell carcinoma of the hypopharynx
1501587|NCT00006248|stage IV squamous cell carcinoma of the larynx
1501588|NCT00006248|recurrent squamous cell carcinoma of the larynx
1501589|NCT00006248|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1501590|NCT00006248|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1501591|NCT00006247|childhood craniopharyngioma
1501592|NCT00006247|childhood central nervous system germ cell tumor
1501593|NCT00006247|childhood oligodendroglioma
1501594|NCT00006247|childhood choroid plexus tumor
1501595|NCT00006247|childhood grade I meningioma
1501596|NCT00006247|childhood grade II meningioma
1501597|NCT00006247|childhood grade III meningioma
1501598|NCT00006247|recurrent childhood cerebellar astrocytoma
1501599|NCT00006247|recurrent childhood cerebral astrocytoma
1501600|NCT00006247|recurrent childhood medulloblastoma
1501601|NCT00006247|recurrent childhood visual pathway and hypothalamic glioma
1501602|NCT00006247|recurrent childhood ependymoma
1501603|NCT00006246|recurrent childhood acute lymphoblastic leukemia
1501604|NCT00006246|childhood infratentorial ependymoma
1501605|NCT00006246|recurrent childhood rhabdomyosarcoma
1501606|NCT00006246|recurrent childhood brain tumor
1501607|NCT00006246|recurrent retinoblastoma
1501608|NCT00006246|recurrent childhood lymphoblastic lymphoma
1501609|NCT00006246|childhood central nervous system germ cell tumor
1501610|NCT00006246|recurrent childhood acute myeloid leukemia
1501611|NCT00006246|recurrent/refractory childhood Hodgkin lymphoma
1501612|NCT00006246|leptomeningeal metastases
1501613|NCT00006246|childhood high-grade cerebral astrocytoma
1501614|NCT00006246|childhood oligodendroglioma
1501615|NCT00006246|childhood choroid plexus tumor
1501616|NCT00006246|childhood grade I meningioma
1501617|NCT00006246|childhood grade II meningioma
1501618|NCT00006246|childhood grade III meningioma
1501619|NCT00006246|recurrent childhood large cell lymphoma
1501620|NCT00006246|recurrent childhood brain stem glioma
1501621|NCT00006246|recurrent childhood supratentorial primitive neuroectodermal tumor
1501622|NCT00006246|recurrent childhood cerebellar astrocytoma
1501623|NCT00006246|recurrent childhood cerebral astrocytoma
1501624|NCT00006246|recurrent childhood medulloblastoma
1501625|NCT00006246|recurrent childhood visual pathway and hypothalamic glioma
1501626|NCT00006246|recurrent childhood ependymoma
1501627|NCT00006246|recurrent childhood malignant germ cell tumor
1501628|NCT00006245|stage III esophageal cancer
1501629|NCT00006245|stage IV esophageal cancer
1501630|NCT00006245|recurrent esophageal cancer
1501631|NCT00006245|squamous cell carcinoma of the esophagus
1501632|NCT00006245|adenocarcinoma of the esophagus
1501633|NCT00006241|recurrent grade 1 follicular lymphoma
1501634|NCT00006241|recurrent grade 2 follicular lymphoma
1501635|NCT00006241|recurrent grade 3 follicular lymphoma
1501636|NCT00006241|recurrent adult diffuse small cleaved cell lymphoma
1501637|NCT00006241|recurrent adult diffuse mixed cell lymphoma
1501638|NCT00006241|recurrent adult diffuse large cell lymphoma
1501639|NCT00006241|recurrent mantle cell lymphoma
1501640|NCT00006241|recurrent marginal zone lymphoma
1501641|NCT00006241|recurrent small lymphocytic lymphoma
1501642|NCT00006241|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1501643|NCT00006241|nodal marginal zone B-cell lymphoma
1501644|NCT00006241|splenic marginal zone lymphoma
1501645|NCT00006240|recurrent adult acute myeloid leukemia
1501646|NCT00006239|recurrent adult acute myeloid leukemia
1501647|NCT00006239|untreated adult acute myeloid leukemia
1501648|NCT00006239|refractory anemia
1501649|NCT00006239|refractory anemia with ringed sideroblasts
1501650|NCT00006239|refractory anemia with excess blasts
1501651|NCT00006239|refractory anemia with excess blasts in transformation
1501652|NCT00006239|chronic myelomonocytic leukemia
1501653|NCT00006239|previously treated myelodysplastic syndromes
1501654|NCT00006239|atypical chronic myeloid leukemia
1501655|NCT00006239|myelodysplastic/myeloproliferative disease, unclassifiable
1501656|NCT00006239|adult acute myeloid leukemia with t(8;21)(q22;q22)
1501657|NCT00006239|adult acute myeloid leukemia with t(16;16)(p13;q22)
1501658|NCT00006239|adult acute myeloid leukemia with inv(16)(p13;q22)
1501659|NCT00006239|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1501660|NCT00006239|adult acute myeloid leukemia with t(15;17)(q22;q12)
1501661|NCT00006237|stage III melanoma
1501662|NCT00006237|recurrent melanoma
1501663|NCT00006235|recurrent ovarian epithelial cancer
1501664|NCT00006235|ovarian undifferentiated adenocarcinoma
1501665|NCT00006235|ovarian mixed epithelial carcinoma
1501666|NCT00006235|ovarian serous cystadenocarcinoma
1501667|NCT00006235|ovarian mucinous cystadenocarcinoma
1501668|NCT00006235|ovarian endometrioid adenocarcinoma
1501669|NCT00006235|ovarian clear cell cystadenocarcinoma
1501670|NCT00006235|fallopian tube cancer
1501671|NCT00006235|primary peritoneal cavity cancer
1501672|NCT00006235|Brenner tumor
1501673|NCT00006234|recurrent childhood rhabdomyosarcoma
1501674|NCT00006234|recurrent adult soft tissue sarcoma
1501675|NCT00006234|adult rhabdomyosarcoma
1501676|NCT00006234|bone metastases
1501677|NCT00006234|previously treated childhood rhabdomyosarcoma
1501678|NCT00006234|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1501679|NCT00006234|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1501680|NCT00006234|stage IV adult soft tissue sarcoma
1501681|NCT00006233|stage IV melanoma
1501682|NCT00006233|recurrent melanoma
1501683|NCT00006232|stage II multiple myeloma
1501684|NCT00006232|stage III multiple myeloma
1501685|NCT00006231|localized malignant mesothelioma
1501686|NCT00006231|advanced malignant mesothelioma
1501687|NCT00006231|perioperative/postoperative complications
1501688|NCT00006230|stage III ovarian epithelial cancer
1501689|NCT00006230|stage IV ovarian epithelial cancer
1501690|NCT00006230|recurrent ovarian epithelial cancer
1501691|NCT00006229|stage IIIB non-small cell lung cancer
1501692|NCT00006229|stage IV non-small cell lung cancer
1501693|NCT00006225|stage IV adult Hodgkin lymphoma
1501694|NCT00006225|stage IV breast cancer
1501695|NCT00006225|stage IIIA breast cancer
1501696|NCT00006225|recurrent breast cancer
1501697|NCT00006225|stage IIIB breast cancer
1501698|NCT00006225|stage IIIC breast cancer
1501699|NCT00006225|recurrent adult Hodgkin lymphoma
1501700|NCT00006225|stage II cutaneous T-cell non-Hodgkin lymphoma
1501701|NCT00006225|stage III cutaneous T-cell non-Hodgkin lymphoma
1501702|NCT00006225|stage IV cutaneous T-cell non-Hodgkin lymphoma
1501703|NCT00006225|recurrent cutaneous T-cell non-Hodgkin lymphoma
1501704|NCT00006225|isolated plasmacytoma of bone
1501705|NCT00006225|extramedullary plasmacytoma
1501706|NCT00006225|refractory multiple myeloma
1501707|NCT00006225|Waldenstrom macroglobulinemia
1501708|NCT00006225|stage I multiple myeloma
1501709|NCT00006225|stage II multiple myeloma
1501710|NCT00006225|stage III multiple myeloma
1501711|NCT00006225|stage II chronic lymphocytic leukemia
1501712|NCT00006225|stage IV chronic lymphocytic leukemia
1501713|NCT00006225|recurrent adult acute lymphoblastic leukemia
1501714|NCT00006225|adult acute myeloid leukemia in remission
1501715|NCT00006225|adult acute lymphoblastic leukemia in remission
1501716|NCT00006225|T-cell large granular lymphocyte leukemia
1501717|NCT00006225|acute undifferentiated leukemia
1501718|NCT00006225|stage III grade 1 follicular lymphoma
1501719|NCT00006225|stage III grade 2 follicular lymphoma
1501720|NCT00006225|stage III grade 3 follicular lymphoma
1501721|NCT00006225|stage III adult diffuse small cleaved cell lymphoma
1501722|NCT00006225|stage III adult diffuse mixed cell lymphoma
1501723|NCT00006225|stage III adult diffuse large cell lymphoma
1501724|NCT00006225|stage III adult immunoblastic large cell lymphoma
1501725|NCT00006225|stage III adult lymphoblastic lymphoma
1501726|NCT00006225|stage III adult Burkitt lymphoma
1501727|NCT00006225|stage IV grade 1 follicular lymphoma
1501728|NCT00006225|stage IV grade 2 follicular lymphoma
1501729|NCT00006225|stage IV grade 3 follicular lymphoma
1501730|NCT00006225|stage IV adult diffuse small cleaved cell lymphoma
1501731|NCT00006225|stage IV adult diffuse mixed cell lymphoma
1501732|NCT00006225|stage IV adult diffuse large cell lymphoma
1501733|NCT00006225|stage IV adult immunoblastic large cell lymphoma
1501734|NCT00006225|stage IV adult lymphoblastic lymphoma
1501735|NCT00006225|stage IV adult Burkitt lymphoma
1501736|NCT00006225|recurrent grade 1 follicular lymphoma
1501737|NCT00006225|recurrent grade 2 follicular lymphoma
1501738|NCT00006225|recurrent grade 3 follicular lymphoma
1501739|NCT00006225|recurrent adult diffuse small cleaved cell lymphoma
1501740|NCT00006225|recurrent adult diffuse mixed cell lymphoma
1501741|NCT00006225|recurrent adult diffuse large cell lymphoma
1501742|NCT00006225|recurrent adult immunoblastic large cell lymphoma
1501743|NCT00006225|recurrent adult lymphoblastic lymphoma
1501744|NCT00006225|recurrent adult Burkitt lymphoma
1501745|NCT00006225|stage I adult T-cell leukemia/lymphoma
1501746|NCT00006225|stage II adult T-cell leukemia/lymphoma
1501747|NCT00006225|stage III adult T-cell leukemia/lymphoma
1501748|NCT00006225|stage IV adult T-cell leukemia/lymphoma
1501749|NCT00006225|recurrent adult T-cell leukemia/lymphoma
1501750|NCT00006225|primary central nervous system lymphoma
1501751|NCT00006225|male breast cancer
1501752|NCT00006225|intraocular lymphoma
1501753|NCT00006225|stage I mantle cell lymphoma
1501754|NCT00006225|contiguous stage II grade 1 follicular lymphoma
1501755|NCT00006225|contiguous stage II grade 2 follicular lymphoma
1501756|NCT00006225|contiguous stage II grade 3 follicular lymphoma
1501757|NCT00006225|contiguous stage II adult diffuse small cleaved cell lymphoma
1501758|NCT00006225|contiguous stage II mantle cell lymphoma
1501759|NCT00006225|contiguous stage II adult diffuse mixed cell lymphoma
1501760|NCT00006225|contiguous stage II adult immunoblastic large cell lymphoma
1501761|NCT00006225|contiguous stage II adult diffuse large cell lymphoma
1501762|NCT00006225|contiguous stage II adult Burkitt lymphoma
1501763|NCT00006225|contiguous stage II adult lymphoblastic lymphoma
1501764|NCT00006225|noncontiguous stage II grade 1 follicular lymphoma
1501765|NCT00006225|noncontiguous stage II grade 2 follicular lymphoma
1501766|NCT00006225|noncontiguous stage II grade 3 follicular lymphoma
1501767|NCT00006225|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1501768|NCT00006225|noncontiguous stage II mantle cell lymphoma
1501769|NCT00006225|noncontiguous stage II adult diffuse mixed cell lymphoma
1501770|NCT00006225|noncontiguous stage II adult immunoblastic large cell lymphoma
1501771|NCT00006225|noncontiguous stage II adult diffuse large cell lymphoma
1501772|NCT00006225|noncontiguous stage II adult Burkitt lymphoma
1501773|NCT00006225|noncontiguous stage II adult lymphoblastic lymphoma
1501774|NCT00006225|stage III mantle cell lymphoma
1501775|NCT00006225|stage IV mantle cell lymphoma
1501776|NCT00006225|recurrent mantle cell lymphoma
1501777|NCT00006225|angioimmunoblastic T-cell lymphoma
1501778|NCT00006225|anaplastic large cell lymphoma
1501779|NCT00006225|stage I mycosis fungoides/Sezary syndrome
1501780|NCT00006225|stage II mycosis fungoides/Sezary syndrome
1501781|NCT00006225|stage III mycosis fungoides/Sezary syndrome
1501782|NCT00006225|stage IV mycosis fungoides/Sezary syndrome
1501783|NCT00006225|recurrent mycosis fungoides/Sezary syndrome
1501784|NCT00006225|chronic myelomonocytic leukemia
1501994|NCT00006181|Health assessments
1501785|NCT00006225|atypical chronic myeloid leukemia
1501786|NCT00006225|myelodysplastic/myeloproliferative disease, unclassifiable
1501787|NCT00006225|noncontiguous stage II small lymphocytic lymphoma
1501788|NCT00006225|noncontiguous stage II marginal zone lymphoma
1501789|NCT00006225|recurrent marginal zone lymphoma
1501790|NCT00006225|recurrent small lymphocytic lymphoma
1501791|NCT00006225|stage III small lymphocytic lymphoma
1501792|NCT00006225|stage III marginal zone lymphoma
1501793|NCT00006225|stage IV small lymphocytic lymphoma
1501794|NCT00006225|stage IV marginal zone lymphoma
1501795|NCT00006225|contiguous stage II marginal zone lymphoma
1501796|NCT00006225|contiguous stage II small lymphocytic lymphoma
1501797|NCT00006225|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1501798|NCT00006225|nodal marginal zone B-cell lymphoma
1501799|NCT00006225|splenic marginal zone lymphoma
1501800|NCT00006224|recurrent cervical cancer
1501801|NCT00006224|cervical adenocarcinoma
1501802|NCT00006224|cervical adenosquamous cell carcinoma
1501803|NCT00006223|adult acute myeloid leukemia in remission
1501804|NCT00006223|adult acute erythroid leukemia (M6)
1501805|NCT00006223|adult acute myeloblastic leukemia without maturation (M1)
1501806|NCT00006223|adult acute myeloblastic leukemia with maturation (M2)
1501807|NCT00006223|adult acute promyelocytic leukemia (M3)
1501808|NCT00006223|adult acute myelomonocytic leukemia (M4)
1501809|NCT00006223|adult acute monoblastic leukemia (M5a)
1501810|NCT00006223|adult acute megakaryoblastic leukemia (M7)
1501811|NCT00006223|adult acute monocytic leukemia (M5b)
1501812|NCT00006223|adult acute minimally differentiated myeloid leukemia (M0)
1501813|NCT00006222|AIDS-related Kaposi sarcoma
1501814|NCT00006222|recurrent Kaposi sarcoma
1501815|NCT00006221|stage IV adult Hodgkin lymphoma
1501816|NCT00006221|recurrent adult Hodgkin lymphoma
1501817|NCT00006221|stage IV cutaneous T-cell non-Hodgkin lymphoma
1501818|NCT00006221|recurrent cutaneous T-cell non-Hodgkin lymphoma
1501819|NCT00006221|small intestine lymphoma
1501820|NCT00006221|unspecified adult solid tumor, protocol specific
1501821|NCT00006221|stage IV grade 1 follicular lymphoma
1501822|NCT00006221|stage IV grade 2 follicular lymphoma
1501823|NCT00006221|stage IV grade 3 follicular lymphoma
1501824|NCT00006221|stage IV adult diffuse small cleaved cell lymphoma
1501825|NCT00006221|stage IV adult diffuse mixed cell lymphoma
1501826|NCT00006221|stage IV adult diffuse large cell lymphoma
1501827|NCT00006221|stage IV adult immunoblastic large cell lymphoma
1501828|NCT00006221|stage IV adult lymphoblastic lymphoma
1501829|NCT00006221|stage IV adult Burkitt lymphoma
1501830|NCT00006221|recurrent grade 1 follicular lymphoma
1501831|NCT00006221|recurrent grade 2 follicular lymphoma
1501832|NCT00006221|recurrent grade 3 follicular lymphoma
1501833|NCT00006221|recurrent adult diffuse small cleaved cell lymphoma
1501834|NCT00006221|recurrent adult diffuse mixed cell lymphoma
1501835|NCT00006221|recurrent adult diffuse large cell lymphoma
1501836|NCT00006221|recurrent adult immunoblastic large cell lymphoma
1501837|NCT00006221|recurrent adult lymphoblastic lymphoma
1501838|NCT00006221|recurrent adult Burkitt lymphoma
1501839|NCT00006221|stage IV adult T-cell leukemia/lymphoma
1501840|NCT00006221|recurrent adult T-cell leukemia/lymphoma
1501841|NCT00006221|primary central nervous system non-Hodgkin lymphoma
1501842|NCT00006221|AIDS-related peripheral/systemic lymphoma
1501843|NCT00006221|AIDS-related primary CNS lymphoma
1501844|NCT00006221|intraocular lymphoma
1501845|NCT00006221|stage IV mantle cell lymphoma
1501846|NCT00006221|recurrent mantle cell lymphoma
1501847|NCT00006221|angioimmunoblastic T-cell lymphoma
1501848|NCT00006221|anaplastic large cell lymphoma
1501849|NCT00006221|stage IV mycosis fungoides/Sezary syndrome
1501850|NCT00006221|recurrent mycosis fungoides/Sezary syndrome
1501851|NCT00006221|recurrent marginal zone lymphoma
1501852|NCT00006221|recurrent small lymphocytic lymphoma
1501853|NCT00006221|stage IV small lymphocytic lymphoma
1501854|NCT00006221|stage IV marginal zone lymphoma
1501855|NCT00006221|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1501856|NCT00006221|nodal marginal zone B-cell lymphoma
1501857|NCT00006221|splenic marginal zone lymphoma
1501858|NCT00006220|stage III adult Hodgkin lymphoma
1501859|NCT00006220|stage IV adult Hodgkin lymphoma
1501860|NCT00006220|recurrent adult Hodgkin lymphoma
1501861|NCT00006220|refractory multiple myeloma
1501862|NCT00006220|recurrent adult acute myeloid leukemia
1501863|NCT00006220|recurrent adult acute lymphoblastic leukemia
1501864|NCT00006220|relapsing chronic myelogenous leukemia
1501865|NCT00006220|blastic phase chronic myelogenous leukemia
1501866|NCT00006220|refractory anemia with excess blasts
1501867|NCT00006220|refractory anemia with excess blasts in transformation
1501868|NCT00006220|stage III grade 3 follicular lymphoma
1501869|NCT00006220|stage III adult diffuse small cleaved cell lymphoma
1501870|NCT00006220|stage III adult diffuse mixed cell lymphoma
1501871|NCT00006220|stage III adult diffuse large cell lymphoma
1501872|NCT00006220|stage III adult immunoblastic large cell lymphoma
1501873|NCT00006220|stage III adult lymphoblastic lymphoma
1501874|NCT00006220|stage III adult Burkitt lymphoma
1501875|NCT00006220|stage IV grade 3 follicular lymphoma
1501876|NCT00006220|stage IV adult diffuse small cleaved cell lymphoma
1501995|NCT00006181|Strength
1501877|NCT00006220|stage IV adult diffuse mixed cell lymphoma
1501878|NCT00006220|stage IV adult diffuse large cell lymphoma
1501879|NCT00006220|stage IV adult immunoblastic large cell lymphoma
1501880|NCT00006220|stage IV adult lymphoblastic lymphoma
1501881|NCT00006220|stage IV adult Burkitt lymphoma
1501882|NCT00006220|recurrent grade 3 follicular lymphoma
1501883|NCT00006220|recurrent adult diffuse small cleaved cell lymphoma
1501884|NCT00006220|recurrent adult diffuse mixed cell lymphoma
1501885|NCT00006220|recurrent adult diffuse large cell lymphoma
1501886|NCT00006220|recurrent adult immunoblastic large cell lymphoma
1501887|NCT00006220|recurrent adult lymphoblastic lymphoma
1501888|NCT00006220|recurrent adult Burkitt lymphoma
1501889|NCT00006220|previously treated myelodysplastic syndromes
1501890|NCT00006220|stage III mantle cell lymphoma
1501891|NCT00006220|stage IV mantle cell lymphoma
1501892|NCT00006220|recurrent mantle cell lymphoma
1501893|NCT00006220|childhood myelodysplastic syndromes
1501894|NCT00006219|multiple myeloma
1501895|NCT00006218|unspecified adult solid tumor, protocol specific
1501896|NCT00006216|stage IA malignant mesothelioma
1501897|NCT00006216|stage IB malignant mesothelioma
1501898|NCT00006216|stage II malignant mesothelioma
1501899|NCT00006216|stage III malignant mesothelioma
1501900|NCT00006215|stage IIIB non-small cell lung cancer
1501901|NCT00006215|stage IV non-small cell lung cancer
1501902|NCT00006214|prostate cancer
1501903|NCT00006212|stage II non-small cell lung cancer
1501904|NCT00006212|stage IIIA non-small cell lung cancer
1501905|NCT00006212|stage IIIB non-small cell lung cancer
1501906|NCT00006211|Drug Therapy, Combination
1501907|NCT00006211|HIV Protease Inhibitors
1501908|NCT00006211|Reverse Transcriptase Inhibitors
1501909|NCT00006211|Anti-HIV Agents
1501910|NCT00006211|Viral Load
1501911|NCT00006211|Nelfinavir
1501912|NCT00006209|HIV-1
1501913|NCT00006209|Immunity, Cellular
1501914|NCT00006209|Drug Therapy, Combination
1501915|NCT00006209|CD4-Positive T-Lymphocytes
1501916|NCT00006209|Antigens
1501917|NCT00006209|Anti-HIV Agents
1501918|NCT00006209|Viral Load
1501919|NCT00006209|tucaresol
1501920|NCT00006208|HIV-1
1501921|NCT00006208|Didanosine
1501922|NCT00006208|Drug Therapy, Combination
1501923|NCT00006208|Reverse Transcriptase Inhibitors
1501924|NCT00006208|Anti-HIV Agents
1501925|NCT00006208|Deoxycytidine
1501926|NCT00006208|efavirenz
1501927|NCT00006207|HIV Seropositivity
1501928|NCT00006207|Dose-Response Relationship, Drug
1501929|NCT00006207|HIV Seronegativity
1501930|NCT00006207|Mucous Membrane
1501931|NCT00006207|Ulcer
1501932|NCT00006207|Vagina
1501933|NCT00006207|Anti-HIV Agents
1501934|NCT00006207|Sexual Abstinence
1501935|NCT00006207|Irritants
1501936|NCT00006207|PRO 2000
1501937|NCT00006205|alcoholism
1501938|NCT00006205|alcohol addiction
1501939|NCT00006204|Alcoholism
1501940|NCT00006204|Alcohol Dependence
1501941|NCT00006204|Depression
1501942|NCT00006204|Naltrexone
1501943|NCT00006204|Fluoxetine
1501944|NCT00006202|Serum levels of Lutein
1501945|NCT00006202|Age-Related Macular Degeneration
1501946|NCT00006202|Safety
1501947|NCT00006202|Toxicity
1501948|NCT00006199|solid tumor
1501949|NCT00006196|Vitamin D resistance
1501950|NCT00006194|sarcopenia
1501951|NCT00006191|Antiepileptic Drugs
1501952|NCT00006191|Motor Cortex
1501953|NCT00006191|Myoclonus
1501954|NCT00006191|Healthy Volunteer
1501955|NCT00006190|Lipoproteins
1501956|NCT00006190|Insulin resistance
1501957|NCT00006190|Adipose tissue
1501958|NCT00006188|Behcet's Disease
1501959|NCT00006188|Sarcoidosis
1501960|NCT00006188|Iritis
1501961|NCT00006188|Choroiditis
1501962|NCT00006188|Iridocyclitis
1501963|NCT00006188|Retinal Disease
1501964|NCT00006188|Cystoid Macular Edema
1501965|NCT00006188|Uveitis
1501966|NCT00006188|Intraocular Inflammation
1501967|NCT00006188|Inflammatory Eye DIsease
1501968|NCT00006187|Investigational Drug
1501969|NCT00006186|dilutional coagulopathy
1501970|NCT00006185|peripheral fat wasting
1501971|NCT00006185|truncal adiposity
1501972|NCT00006185|fat biopsy
1501973|NCT00006185|muscle biopsy
1501974|NCT00006185|intravenous lines
1501975|NCT00006185|blood draws
1501976|NCT00006185|insulin administration
1501977|NCT00006185|sugar water
1501978|NCT00006185|screening
1501979|NCT00006184|Immunoablative
1501980|NCT00006184|Mobilization
1501981|NCT00006184|Apheresis
1501982|NCT00006184|Multiple Myeloma
1501983|NCT00006184|IgG Multiple Myeloma
1501984|NCT00006184|IgA Multiple Myeloma
1501985|NCT00006181|Health behavior change
1501986|NCT00006181|Motivational interviewing
1501987|NCT00006181|Motivational enhancement
1501988|NCT00006181|Health counseling
1501989|NCT00006181|Team intervention
1501990|NCT00006181|One-on-one intervention
1501991|NCT00006181|Physical activity
1501992|NCT00006181|Exercise
1501993|NCT00006181|Nutrition
1501996|NCT00006181|Flexibility
1501997|NCT00006181|Percent body fat
1501998|NCT00006181|Social-learning theory
1501999|NCT00006181|PHLAME
1502000|NCT00006181|Fire fighters
1502001|NCT00006181|Fire stations
1502002|NCT00006181|Cancer
1502003|NCT00006181|Cardiovascular diseases
1502004|NCT00006180|Preventive Medicine
1502005|NCT00006180|Women's Health
1502006|NCT00006180|Bone Formation
1502007|NCT00006180|Mood Disorders
1502008|NCT00006180|Bone Resorption
1502009|NCT00006180|Major Depression
1502010|NCT00006180|Osteopenia
1502011|NCT00006180|Osteoporosis
1502012|NCT00006180|Bone Fracture
1502013|NCT00006180|Bisphosphonate
1502014|NCT00006180|Depression
1502015|NCT00006180|Bone Density
1502016|NCT00006180|Healthy Volunteer
1502017|NCT00006180|HV
1502018|NCT00006180|Normal Control
1502019|NCT00006178|Renal Failure
1502020|NCT00006178|Anti-rejection
1502021|NCT00006178|Apoptosis
1502022|NCT00006178|Polyclonal Antibody
1502023|NCT00006178|Kidney Transplant
1502024|NCT00006177|Emotion
1502025|NCT00006177|Children and Adolescents
1502026|NCT00006177|Affective Neuroscience
1502027|NCT00006177|Bipolar Disorder
1502028|NCT00006177|Child
1502029|NCT00006177|Child Bipolar
1502030|NCT00006177|BPD
1502031|NCT00006177|Adolescent Bipolar
1502032|NCT00006176|FENIB
1502033|NCT00006176|Presenile Dementia
1502034|NCT00006176|Progressive Myoclonic Epilepsy
1502035|NCT00006176|Dementia
1502036|NCT00006176|Early Onset Progressive Dementia
1502037|NCT00006176|Familial Presenile Dementia
1502038|NCT00006176|FDNIB
1502039|NCT00006176|familial encephalopathy with neuroserpin inclusion bodies
1502040|NCT00006176|Heredodegenerative Disorders, Nervous System
1502041|NCT00006175|Cyclooxygenase
1502042|NCT00006175|COX-1
1502043|NCT00006175|COX-2
1502044|NCT00006175|Prostanoids
1502045|NCT00006175|P.C.R.
1502046|NCT00006175|Healthy Volunteer
1502047|NCT00006174|Precocious Puberty
1502048|NCT00006174|Polyostotic
1502049|NCT00006174|Fibrous Dysplasia
1502050|NCT00006174|PFD
1502051|NCT00006174|McCune-Albright Syndrome (MAS)
1502052|NCT00006173|Atherosclerosis
1502053|NCT00006173|Hypertension
1502054|NCT00006173|Magnetic Resonance Angiography
1502055|NCT00006172|Antidepressive Agents
1502056|NCT00006172|Chronobiology
1502057|NCT00006172|Chronotherapy
1502058|NCT00006172|Circadian rhythms
1502059|NCT00006172|Depressive Disorder
1502060|NCT00006172|Ions
1502061|NCT00006172|Light
1502062|NCT00006172|Lighting
1502063|NCT00006172|Mood disorders
1502064|NCT00006172|Phototherapy.
1502065|NCT00006171|HHV-8
1502066|NCT00006171|Pathophysiology
1502067|NCT00006171|AIDS
1502068|NCT00006171|Cancer
1502069|NCT00006171|Anti-Retroviral
1502070|NCT00006171|Kaposi's Sarcoma
1502071|NCT00006171|HIV
1502072|NCT00006170|smoking cessation
1502073|NCT00006170|Women
1502074|NCT00006170|bupropion
1502075|NCT00006170|weight concerns
1502076|NCT00006170|weight
1502077|NCT00006169|Nutrition
1502078|NCT00006169|Behavior Therapy
1502079|NCT00006169|Cystic Fibrosis
1502080|NCT00006168|primary biliary cirrhosis
1502081|NCT00006168|Ursodeoxycholic acid
1502082|NCT00006168|UDCA
1502083|NCT00006168|MTX
1502084|NCT00006168|Hepatology
1502085|NCT00006168|methotrexate
1502086|NCT00006168|liver
1502087|NCT00006167|oxandrolone
1502088|NCT00006167|AIDS wasting
1502089|NCT00006167|strength training
1502090|NCT00006167|progressive resistance training
1502091|NCT00006167|exercise
1502092|NCT00006167|dietary intervention
1502093|NCT00006166|refractory ascites
1502094|NCT00006166|paracenteses
1502095|NCT00006165|Native Hawaiian
1502096|NCT00006165|Diabetes Mellitus
1502097|NCT00006165|Lifestyle Intervention
1502098|NCT00006165|Family Support
1502099|NCT00006165|Diabetes Mellitus, at-risk
1502100|NCT00006164|liver disease
1502101|NCT00006164|hepatitis c virus
1502102|NCT00006164|antiviral agent
1502103|NCT00006164|cirrhosis
1502104|NCT00006163|diabetes
1502105|NCT00006163|self-management
1502106|NCT00006163|randomized trial
1502107|NCT00006163|RE-AIM evaluation
1502108|NCT00006163|participation
1502109|NCT00006163|maintenance
1502110|NCT00006163|community resources
1502111|NCT00006163|dietary change
1502112|NCT00006162|low fat diet
1502113|NCT00006162|aerobic exercise
1502114|NCT00006162|impaired glucose tolerance
1502115|NCT00006162|Japanese Americans
1502116|NCT00006162|metabolic risk factors
1502117|NCT00006161|TIPS
1502118|NCT00006161|DSRS
1502119|NCT00006161|Varices
1502120|NCT00006161|Variceal bleeding
1502121|NCT00006161|Splenorenal Shunt
1502122|NCT00006161|Transjugular Intrahepatic Portosystemic Shunt
1502123|NCT00006161|Cirrhosis
1502124|NCT00006161|Portal hypertension
1502125|NCT00006161|Liver disease
1502126|NCT00006159|diabetes
1502127|NCT00006159|lifestyle intervention
1502128|NCT00006159|Native American
1502129|NCT00006159|community intervention
1502130|NCT00006159|diet
1502131|NCT00006159|exercise
1502132|NCT00006158|AIDS
1502133|NCT00006158|HIV
1502134|NCT00006158|weight loss
1502135|NCT00006158|Wasting Syndrome
1502136|NCT00006158|testosterone
1502137|NCT00006158|androgen levels
1502138|NCT00006158|hormones
1502139|NCT00006157|Functional bowel disorder
1502140|NCT00006157|Irritable bowel syndrome
1502141|NCT00006157|Painful constipation
1502142|NCT00006157|Unspecified functional bowel disorder
1502143|NCT00006157|Chronic functional abdominal pain
1502144|NCT00006157|Cognitive-behavioral psychological treatment
1502145|NCT00006157|IBS
1502146|NCT00006157|CFAP
1502147|NCT00006156|Ovarian Failure
1502148|NCT00006156|Ovary
1502149|NCT00006156|Aging
1502150|NCT00006156|Healthy Volunteer
1502151|NCT00006156|Primary Ovarian Insufficiency(POI)
1502152|NCT00006156|Premature Menopause
1502153|NCT00006156|Premature Ovarian Failure (POF)
1502154|NCT00006155|DNA Damage
1502155|NCT00006155|DNA Repair
1502156|NCT00006155|FLK-1
1502157|NCT00006155|Pharmacokinetics
1502158|NCT00006155|VEGF
1502159|NCT00006155|Fallopian Tube Cancer
1502160|NCT00006155|Ovarian Cancer
1502161|NCT00006155|Platinum-Refractory Disease
1502162|NCT00006154|Interleukin-2
1502163|NCT00006154|Didanosine
1502164|NCT00006154|Drug Therapy, Combination
1502165|NCT00006154|Stavudine
1502166|NCT00006154|HIV Protease Inhibitors
1502167|NCT00006154|Ritonavir
1502168|NCT00006154|Indinavir
1502169|NCT00006154|Virus Latency
1502170|NCT00006154|Reverse Transcriptase Inhibitors
1502171|NCT00006154|Anti-HIV Agents
1502172|NCT00006154|abacavir
1502173|NCT00006154|efavirenz
1502174|NCT00006154|Acute Infection
1502175|NCT00006153|HIV Antibodies
1502176|NCT00006153|Immunity, Cellular
1502177|NCT00006153|Drug Therapy, Combination
1502178|NCT00006153|Anti-HIV Agents
1502179|NCT00006153|remune
1502180|NCT00006153|HIV Therapeutic Vaccine
1502181|NCT00006152|Drug Therapy, Combination
1502182|NCT00006152|HIV Protease Inhibitors
1502183|NCT00006152|Ritonavir
1502184|NCT00006152|VX 478
1502185|NCT00006152|Reverse Transcriptase Inhibitors
1502186|NCT00006152|Anti-HIV Agents
1502187|NCT00006152|Viral Load
1502188|NCT00006152|abacavir
1502189|NCT00006151|nicotine fading
1502190|NCT00006151|Accu Drop
1502191|NCT00006151|cigarette tapering
1502192|NCT00006151|smoking cessation
1502193|NCT00006151|motivational interviewing
1502194|NCT00006150|IgE
1502195|NCT00006150|Fractures
1502196|NCT00006150|Pneumonia
1502197|NCT00006150|Scoliosis
1502198|NCT00006150|Eczema
1502199|NCT00006150|Job's Syndrome
1502200|NCT00006150|Hyperimmunologobulin E Syndrome
1502201|NCT00006150|HIE Syndrome
1502202|NCT00006148|Granulocyte Colony - Stimulation Factor
1502203|NCT00006148|Peripheral Blood Stem Cells
1502204|NCT00006148|Splenomegaly
1502205|NCT00006145|Ganciclovir
1502206|NCT00006145|Cytomegalovirus
1502207|NCT00006145|Cytomegalovirus Infections
1502208|NCT00006145|Administration, Oral
1502209|NCT00006145|Antiviral Agents
1502210|NCT00006145|Polymerase Chain Reaction
1502211|NCT00006145|Viremia
1502212|NCT00006145|DNA, Viral
1502213|NCT00006144|Drug Therapy, Combination
1502214|NCT00006144|Stavudine
1502215|NCT00006144|HIV Protease Inhibitors
1502216|NCT00006144|Cohort Studies
1502217|NCT00006144|Ritonavir
1502218|NCT00006144|Disease Progression
1502219|NCT00006144|Antigens, CD
1502220|NCT00006144|Reverse Transcriptase Inhibitors
1502221|NCT00006144|Anti-HIV Agents
1502222|NCT00006144|Immunophenotyping
1502223|NCT00006144|Deoxycytidine
1502224|NCT00006143|Treatment Outcome
1502225|NCT00006143|serostim
1502226|NCT00006143|Developmental Disabilities
1502227|NCT00006142|inborn errors of metabolism
1502228|NCT00006142|phenylketonuria
1502229|NCT00006142|rare disease
1502230|NCT00006138|disease-related problem/condition
1502231|NCT00006138|genetic diseases and dysmorphic syndromes
1502232|NCT00006138|hematologic disorders
1502233|NCT00006138|osteoporosis
1502234|NCT00006138|rare disease
1502235|NCT00006138|thalassemia major
1502236|NCT00006137|IgA glomerulonephritis
1502237|NCT00006137|rare disease
1502238|NCT00006137|renal and genitourinary disorders
1502239|NCT00006136|genetic diseases and dysmorphic syndromes
1502240|NCT00006136|hematologic disorders
1502241|NCT00006136|rare disease
1502242|NCT00006136|thalassemia intermedia
1502243|NCT00006135|herpes simplex virus infection
1502244|NCT00006135|herpesvirus infection
1502245|NCT00006135|immunologic disorders and infectious disorders
1502246|NCT00006135|rare disease
1502247|NCT00006135|viral infection
1502248|NCT00006134|arthritis & connective tissue diseases
1502732|NCT00006076|Tune Deafness
1502249|NCT00006134|immunologic disorders and infectious disorders
1502250|NCT00006134|rare disease
1502251|NCT00006134|systemic lupus erythematosus
1502252|NCT00006133|arthritis & connective tissue diseases
1502253|NCT00006133|immunologic disorders and infectious disorders
1502254|NCT00006133|rare disease
1502255|NCT00006133|systemic lupus erythematosus
1502256|NCT00006132|herpes simplex virus infection
1502257|NCT00006132|herpes virus infection
1502258|NCT00006132|immunologic disorders and infectious disorders
1502259|NCT00006132|rare disease
1502260|NCT00006132|viral infection
1502261|NCT00006130|arthritis & connective tissue diseases
1502262|NCT00006130|avascular necrosis
1502263|NCT00006130|disease-related problem/condition
1502264|NCT00006130|genetic diseases and dysmorphic syndromes
1502265|NCT00006130|hematologic disorders
1502266|NCT00006130|pain
1502267|NCT00006130|rare disease
1502268|NCT00006130|sickle cell anemia
1502269|NCT00006129|burns
1502270|NCT00006129|dermatologic disorders
1502271|NCT00006129|rare disease
1502272|NCT00006128|neurologic and psychiatric disorders
1502273|NCT00006128|rare disease
1502274|NCT00006127|Fanconi's anemia
1502275|NCT00006127|aplastic anemia
1502276|NCT00006127|hematologic disorders
1502277|NCT00006127|rare disease
1502278|NCT00006126|stage IV breast cancer
1502279|NCT00006126|recurrent breast cancer
1502280|NCT00006126|stage IV renal cell cancer
1502281|NCT00006126|recurrent renal cell cancer
1502282|NCT00006126|extensive stage small cell lung cancer
1502283|NCT00006126|recurrent small cell lung cancer
1502284|NCT00006126|stage II malignant testicular germ cell tumor
1502285|NCT00006126|stage III malignant testicular germ cell tumor
1502286|NCT00006126|recurrent malignant testicular germ cell tumor
1502287|NCT00006126|stage IV melanoma
1502288|NCT00006126|recurrent melanoma
1502289|NCT00006125|recurrent grade 3 follicular lymphoma
1502290|NCT00006125|recurrent adult diffuse large cell lymphoma
1502291|NCT00006125|recurrent adult Burkitt lymphoma
1502292|NCT00006125|anaplastic large cell lymphoma
1502293|NCT00006123|stage IV breast cancer
1502294|NCT00006122|untreated adult acute myeloid leukemia
1502295|NCT00006122|adult acute erythroid leukemia (M6)
1502296|NCT00006122|adult acute myeloblastic leukemia without maturation (M1)
1502297|NCT00006122|adult acute myeloblastic leukemia with maturation (M2)
1502298|NCT00006122|adult acute myelomonocytic leukemia (M4)
1502299|NCT00006122|adult acute monoblastic leukemia (M5a)
1502300|NCT00006122|adult acute megakaryoblastic leukemia (M7)
1502301|NCT00006122|secondary acute myeloid leukemia
1502302|NCT00006122|adult acute monocytic leukemia (M5b)
1502303|NCT00006122|adult acute minimally differentiated myeloid leukemia (M0)
1502304|NCT00006121|stage III breast cancer
1502305|NCT00006121|stage IV breast cancer
1502306|NCT00006121|recurrent breast cancer
1502307|NCT00006120|stage IV breast cancer
1502308|NCT00006120|stage IIIA breast cancer
1502309|NCT00006120|recurrent breast cancer
1502310|NCT00006120|stage IIIB breast cancer
1502311|NCT00006119|recurrent adult brain tumor
1502312|NCT00006119|adult grade III meningioma
1502313|NCT00006119|adult grade I meningioma
1502314|NCT00006119|adult grade II meningioma
1502315|NCT00006118|stage III bladder cancer
1502316|NCT00006118|stage IV bladder cancer
1502317|NCT00006118|transitional cell carcinoma of the bladder
1502318|NCT00006117|stage III pancreatic cancer
1502319|NCT00006117|stage IV pancreatic cancer
1502320|NCT00006117|adenocarcinoma of the pancreas
1502321|NCT00006116|recurrent non-small cell lung cancer
1502322|NCT00006116|squamous cell lung cancer
1502323|NCT00006116|large cell lung cancer
1502324|NCT00006116|stage IIIB non-small cell lung cancer
1502325|NCT00006116|stage IV non-small cell lung cancer
1502326|NCT00006116|adenocarcinoma of the lung
1502327|NCT00006115|stage IV colon cancer
1502328|NCT00006115|stage IV rectal cancer
1502329|NCT00006115|recurrent colon cancer
1502330|NCT00006115|recurrent rectal cancer
1502331|NCT00006115|adenocarcinoma of the colon
1502332|NCT00006115|adenocarcinoma of the rectum
1502333|NCT00006114|adenocarcinoma of the prostate
1502334|NCT00006114|stage IV prostate cancer
1502335|NCT00006114|recurrent prostate cancer
1502336|NCT00006113|stage III melanoma
1502337|NCT00006113|stage IV melanoma
1502338|NCT00006113|recurrent melanoma
1502339|NCT00006112|stage IV colon cancer
1502340|NCT00006112|stage IV rectal cancer
1502341|NCT00006112|adenocarcinoma of the colon
1502342|NCT00006112|adenocarcinoma of the rectum
1502343|NCT00006112|carcinoma of the appendix
1502344|NCT00006112|primary peritoneal cavity cancer
1502345|NCT00006111|stage II bladder cancer
1502346|NCT00006111|stage III bladder cancer
1502347|NCT00006111|stage IV bladder cancer
1502348|NCT00006111|anterior urethral cancer
1502349|NCT00006111|posterior urethral cancer
1502350|NCT00006111|urethral cancer associated with invasive bladder cancer
1502351|NCT00006111|metastatic transitional cell cancer of the renal pelvis and ureter
1502352|NCT00006111|regional transitional cell cancer of the renal pelvis and ureter
1502353|NCT00006110|stage II breast cancer
1502354|NCT00006110|stage IV breast cancer
1502355|NCT00006110|stage IIIA breast cancer
1502356|NCT00006110|stage IIIB breast cancer
1502357|NCT00006110|stage IIIC breast cancer
1502358|NCT00006110|inflammatory breast cancer
1502359|NCT00006108|stage IV breast cancer
1502360|NCT00006108|recurrent breast cancer
1502361|NCT00006107|recurrent metastatic squamous neck cancer with occult primary
1502362|NCT00006107|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1502363|NCT00006107|stage III squamous cell carcinoma of the lip and oral cavity
1502364|NCT00006107|stage IV squamous cell carcinoma of the lip and oral cavity
1502365|NCT00006107|recurrent squamous cell carcinoma of the lip and oral cavity
1502366|NCT00006107|stage III squamous cell carcinoma of the oropharynx
1502367|NCT00006107|stage IV squamous cell carcinoma of the oropharynx
1502368|NCT00006107|recurrent squamous cell carcinoma of the oropharynx
1502369|NCT00006107|stage III squamous cell carcinoma of the nasopharynx
1502370|NCT00006107|stage IV squamous cell carcinoma of the nasopharynx
1502371|NCT00006107|recurrent squamous cell carcinoma of the nasopharynx
1502372|NCT00006107|stage III squamous cell carcinoma of the hypopharynx
1502373|NCT00006107|stage IV squamous cell carcinoma of the hypopharynx
1502374|NCT00006107|recurrent squamous cell carcinoma of the hypopharynx
1502375|NCT00006107|stage III squamous cell carcinoma of the larynx
1502376|NCT00006107|stage IV squamous cell carcinoma of the larynx
1502377|NCT00006107|recurrent squamous cell carcinoma of the larynx
1502378|NCT00006107|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1502379|NCT00006107|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1502380|NCT00006107|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1502381|NCT00006107|recurrent salivary gland cancer
1502382|NCT00006107|stage III salivary gland cancer
1502383|NCT00006107|stage IV salivary gland cancer
1502384|NCT00006107|salivary gland squamous cell carcinoma
1502385|NCT00006107|recurrent lymphoepithelioma of the nasopharynx
1502386|NCT00006107|recurrent lymphoepithelioma of the oropharynx
1502387|NCT00006107|stage III lymphoepithelioma of the nasopharynx
1502388|NCT00006107|stage III lymphoepithelioma of the oropharynx
1502389|NCT00006107|stage IV lymphoepithelioma of the nasopharynx
1502390|NCT00006107|stage IV lymphoepithelioma of the oropharynx
1502391|NCT00006106|adult solid tumor
1502392|NCT00006106|body system/site cancer
1502393|NCT00006106|cancer
1502394|NCT00006106|cellular diagnosis, hypopharyngeal cancer
1502395|NCT00006106|cellular diagnosis, laryngeal cancer
1502396|NCT00006106|cellular diagnosis, lip and oral cavity cancer
1502397|NCT00006106|cellular diagnosis, nasopharyngeal cancer
1502398|NCT00006106|cellular diagnosis, oropharyngeal cancer
1502399|NCT00006106|cellular diagnosis, paranasal sinus and nasal cavity cancer
1502400|NCT00006106|head and neck cancer
1502401|NCT00006106|hypopharyngeal cancer
1502402|NCT00006106|hypopharyngeal squamous cell carcinoma
1502403|NCT00006106|laryngeal cancer
1502404|NCT00006106|laryngeal squamous cell carcinoma
1502405|NCT00006106|lip and oral cavity cancer
1502406|NCT00006106|lip and oral cavity squamous cell carcinoma
1502407|NCT00006106|metastatic squamous neck cancer with occult primary
1502408|NCT00006106|nasopharyngeal cancer
1502409|NCT00006106|nasopharyngeal squamous cell carcinoma
1502410|NCT00006106|oropharyngeal cancer
1502411|NCT00006106|oropharyngeal squamous cell carcinoma
1502412|NCT00006106|paranasal sinus and nasal cavity cancer
1502413|NCT00006106|paranasal sinus and nasal cavity squamous cell carcinoma
1502414|NCT00006106|recurrent hypopharyngeal cancer
1502415|NCT00006106|recurrent laryngeal cancer
1502416|NCT00006106|recurrent lip and oral cavity cancer
1502417|NCT00006106|recurrent metastatic squamous neck cancer with occult primary
1502418|NCT00006106|recurrent nasopharyngeal cancer
1502419|NCT00006106|recurrent oropharyngeal cancer
1502420|NCT00006106|recurrent paranasal sinus and nasal cavity cancer
1502421|NCT00006106|recurrent squamous cell carcinoma of the hypopharynx
1502422|NCT00006106|recurrent squamous cell carcinoma of the larynx
1502423|NCT00006106|recurrent squamous cell carcinoma of the lip and oral cavity
1502424|NCT00006106|recurrent squamous cell carcinoma of the nasopharynx
1502425|NCT00006106|recurrent squamous cell carcinoma of the oropharynx
1502426|NCT00006106|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1502427|NCT00006106|solid tumor
1502428|NCT00006106|stage III hypopharyngeal cancer
1502429|NCT00006106|stage III laryngeal cancer
1502430|NCT00006106|stage III lip and oral cavity cancer
1502431|NCT00006106|stage III nasopharyngeal cancer
1502432|NCT00006106|stage III oropharyngeal cancer
1502433|NCT00006106|stage III paranasal sinus and nasal cavity cancer
1502434|NCT00006106|stage III squamous cell carcinoma of the hypopharynx
1502435|NCT00006106|stage III squamous cell carcinoma of the larynx
1502436|NCT00006106|stage III squamous cell carcinoma of the lip and oral cavity
1502437|NCT00006106|stage III squamous cell carcinoma of the nasopharynx
1502438|NCT00006106|stage III squamous cell carcinoma of the oropharynx
1502439|NCT00006106|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1502440|NCT00006106|stage IV hypopharyngeal cancer
1502441|NCT00006106|stage IV laryngeal cancer
1502442|NCT00006106|stage IV lip and oral cavity cancer
1502443|NCT00006106|stage IV nasopharyngeal cancer
1502444|NCT00006106|stage IV oropharyngeal cancer
1502733|NCT00006076|HV
1502445|NCT00006106|stage IV paranasal sinus and nasal cavity cancer
1502446|NCT00006106|stage IV squamous cell carcinoma of the hypopharynx
1502447|NCT00006106|stage IV squamous cell carcinoma of the larynx
1502448|NCT00006106|stage IV squamous cell carcinoma of the lip and oral cavity
1502449|NCT00006106|stage IV squamous cell carcinoma of the nasopharynx
1502450|NCT00006106|stage IV squamous cell carcinoma of the oropharynx
1502451|NCT00006106|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1502452|NCT00006106|stage, hypopharyngeal cancer
1502453|NCT00006106|stage, laryngeal cancer
1502454|NCT00006106|stage, lip and oral cavity cancer
1502455|NCT00006106|stage, metastatic squamous neck cancer with occult primary
1502456|NCT00006106|stage, nasopharyngeal cancer
1502457|NCT00006106|stage, oropharyngeal cancer
1502458|NCT00006106|stage, paranasal sinus and nasal cavity cancer
1502459|NCT00006105|stage II bladder cancer
1502460|NCT00006105|stage III bladder cancer
1502461|NCT00006105|stage IV bladder cancer
1502462|NCT00006105|drug/agent toxicity by tissue/organ
1502463|NCT00006104|stage IV breast cancer
1502464|NCT00006104|recurrent breast cancer
1502465|NCT00006103|stage III colon cancer
1502466|NCT00006103|stage IV colon cancer
1502467|NCT00006103|stage III rectal cancer
1502468|NCT00006103|stage IV rectal cancer
1502469|NCT00006103|recurrent colon cancer
1502470|NCT00006103|recurrent rectal cancer
1502471|NCT00006103|adenocarcinoma of the colon
1502472|NCT00006103|adenocarcinoma of the rectum
1502473|NCT00006102|childhood infratentorial ependymoma
1502474|NCT00006102|recurrent childhood rhabdomyosarcoma
1502475|NCT00006102|childhood supratentorial ependymoma
1502476|NCT00006102|childhood craniopharyngioma
1502477|NCT00006102|disseminated neuroblastoma
1502478|NCT00006102|recurrent neuroblastoma
1502479|NCT00006102|intraocular retinoblastoma
1502480|NCT00006102|extraocular retinoblastoma
1502481|NCT00006102|stage III childhood lymphoblastic lymphoma
1502482|NCT00006102|stage IV childhood lymphoblastic lymphoma
1502483|NCT00006102|recurrent childhood lymphoblastic lymphoma
1502484|NCT00006102|childhood central nervous system germ cell tumor
1502485|NCT00006102|unspecified childhood solid tumor, protocol specific
1502486|NCT00006102|childhood high-grade cerebral astrocytoma
1502487|NCT00006102|childhood oligodendroglioma
1502488|NCT00006102|childhood choroid plexus tumor
1502489|NCT00006102|childhood grade I meningioma
1502490|NCT00006102|childhood grade II meningioma
1502491|NCT00006102|childhood grade III meningioma
1502492|NCT00006102|stage III childhood large cell lymphoma
1502493|NCT00006102|stage IV childhood small noncleaved cell lymphoma
1502494|NCT00006102|stage IV childhood large cell lymphoma
1502495|NCT00006102|recurrent childhood small noncleaved cell lymphoma
1502496|NCT00006102|recurrent childhood large cell lymphoma
1502497|NCT00006102|recurrent childhood brain stem glioma
1502498|NCT00006102|recurrent childhood supratentorial primitive neuroectodermal tumor
1502499|NCT00006102|recurrent childhood cerebellar astrocytoma
1502500|NCT00006102|recurrent childhood cerebral astrocytoma
1502501|NCT00006102|recurrent childhood medulloblastoma
1502502|NCT00006102|recurrent childhood visual pathway and hypothalamic glioma
1502503|NCT00006102|previously treated childhood rhabdomyosarcoma
1502504|NCT00006102|recurrent childhood ependymoma
1502505|NCT00006102|recurrent retinoblastoma
1502506|NCT00006101|stage I prostate cancer
1502507|NCT00006100|recurrent adult Hodgkin lymphoma
1502508|NCT00006099|ovarian epithelial cancer
1502509|NCT00006098|recurrent adult Hodgkin lymphoma
1502510|NCT00006098|refractory multiple myeloma
1502511|NCT00006098|recurrent adult acute myeloid leukemia
1502512|NCT00006098|recurrent adult acute lymphoblastic leukemia
1502513|NCT00006098|relapsing chronic myelogenous leukemia
1502514|NCT00006098|refractory chronic lymphocytic leukemia
1502515|NCT00006098|refractory anemia with excess blasts
1502516|NCT00006098|refractory anemia with excess blasts in transformation
1502517|NCT00006098|recurrent grade 1 follicular lymphoma
1502518|NCT00006098|recurrent grade 2 follicular lymphoma
1502519|NCT00006098|recurrent grade 3 follicular lymphoma
1502520|NCT00006098|recurrent adult diffuse small cleaved cell lymphoma
1502521|NCT00006098|recurrent adult diffuse mixed cell lymphoma
1502522|NCT00006098|recurrent adult diffuse large cell lymphoma
1502523|NCT00006098|recurrent adult immunoblastic large cell lymphoma
1502524|NCT00006098|recurrent adult lymphoblastic lymphoma
1502525|NCT00006098|recurrent adult Burkitt lymphoma
1502526|NCT00006098|previously treated myelodysplastic syndromes
1502527|NCT00006098|recurrent mantle cell lymphoma
1502528|NCT00006098|recurrent marginal zone lymphoma
1502529|NCT00006098|recurrent small lymphocytic lymphoma
1502530|NCT00006098|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1502531|NCT00006098|nodal marginal zone B-cell lymphoma
1502532|NCT00006098|splenic marginal zone lymphoma
1502533|NCT00006097|refractory chronic lymphocytic leukemia
1502534|NCT00006097|B-cell chronic lymphocytic leukemia
1502535|NCT00006096|stage I vulvar cancer
1502536|NCT00006096|stage II vulvar cancer
1502537|NCT00006096|stage III vulvar cancer
1502538|NCT00006096|stage IVB vulvar cancer
1502539|NCT00006096|squamous cell carcinoma of the vulva
1502540|NCT00006095|unspecified childhood solid tumor, protocol specific
1502541|NCT00006093|recurrent adult brain tumor
1502542|NCT00006093|adult glioblastoma
1502543|NCT00006093|adult anaplastic astrocytoma
1502544|NCT00006093|adult anaplastic oligodendroglioma
1502545|NCT00006093|adult giant cell glioblastoma
1502546|NCT00006093|adult gliosarcoma
1502547|NCT00006092|recurrent adult acute lymphoblastic leukemia
1502548|NCT00006092|relapsing chronic myelogenous leukemia
1502549|NCT00006092|blastic phase chronic myelogenous leukemia
1502550|NCT00006092|chronic myelogenous leukemia, BCR-ABL1 positive
1502551|NCT00006092|lymphoid leukemia
1502552|NCT00006092|myeloid and monocytic leukemia
1502553|NCT00006091|relapsing chronic myelogenous leukemia
1502554|NCT00006091|chronic phase chronic myelogenous leukemia
1502751|NCT00006073|Endocrine Disorder
1502555|NCT00006091|chronic myelogenous leukemia, BCR-ABL1 positive
1502556|NCT00006090|refractory chronic lymphocytic leukemia
1502557|NCT00006090|B-cell chronic lymphocytic leukemia
1502558|NCT00006088|unspecified adult solid tumor, protocol specific
1502559|NCT00006087|non-small cell lung cancer
1502560|NCT00006087|small cell lung cancer
1502561|NCT00006086|unspecified adult solid tumor, protocol specific
1502562|NCT00006085|unspecified adult solid tumor, protocol specific
1502563|NCT00006084|recurrent adult acute myeloid leukemia
1502564|NCT00006084|adult acute erythroid leukemia (M6)
1502565|NCT00006084|adult acute myeloblastic leukemia without maturation (M1)
1502566|NCT00006084|adult acute myeloblastic leukemia with maturation (M2)
1502567|NCT00006084|adult acute myelomonocytic leukemia (M4)
1502568|NCT00006084|adult acute monoblastic leukemia (M5a)
1502569|NCT00006084|adult acute megakaryoblastic leukemia (M7)
1502570|NCT00006084|secondary acute myeloid leukemia
1502571|NCT00006084|adult acute monocytic leukemia (M5b)
1502572|NCT00006084|adult acute minimally differentiated myeloid leukemia (M0)
1502573|NCT00006083|stage I adult Hodgkin lymphoma
1502574|NCT00006083|stage II adult Hodgkin lymphoma
1502575|NCT00006083|stage III adult Hodgkin lymphoma
1502576|NCT00006083|stage IV adult Hodgkin lymphoma
1502577|NCT00006083|monoclonal gammopathy of undetermined significance
1502578|NCT00006083|recurrent adult Hodgkin lymphoma
1502579|NCT00006083|stage I cutaneous T-cell non-Hodgkin lymphoma
1502580|NCT00006083|stage II cutaneous T-cell non-Hodgkin lymphoma
1502581|NCT00006083|stage III cutaneous T-cell non-Hodgkin lymphoma
1502582|NCT00006083|stage IV cutaneous T-cell non-Hodgkin lymphoma
1502583|NCT00006083|recurrent cutaneous T-cell non-Hodgkin lymphoma
1502584|NCT00006083|stage IB cervical cancer
1502585|NCT00006083|Burkitt lymphoma
1502586|NCT00006083|isolated plasmacytoma of bone
1502587|NCT00006083|extramedullary plasmacytoma
1502588|NCT00006083|refractory multiple myeloma
1502589|NCT00006083|stage 0 chronic lymphocytic leukemia
1502590|NCT00006083|stage I multiple myeloma
1502591|NCT00006083|stage II multiple myeloma
1502592|NCT00006083|stage III multiple myeloma
1502593|NCT00006083|stage I chronic lymphocytic leukemia
1502594|NCT00006083|stage II chronic lymphocytic leukemia
1502595|NCT00006083|stage IV chronic lymphocytic leukemia
1502596|NCT00006083|recurrent adult acute myeloid leukemia
1502597|NCT00006083|recurrent adult acute lymphoblastic leukemia
1502598|NCT00006083|relapsing chronic myelogenous leukemia
1502599|NCT00006083|refractory chronic lymphocytic leukemia
1502600|NCT00006083|unspecified adult solid tumor, protocol specific
1502601|NCT00006083|chronic phase chronic myelogenous leukemia
1502602|NCT00006083|accelerated phase chronic myelogenous leukemia
1502603|NCT00006083|blastic phase chronic myelogenous leukemia
1502604|NCT00006083|meningeal chronic myelogenous leukemia
1502605|NCT00006083|untreated adult acute lymphoblastic leukemia
1502606|NCT00006083|untreated adult acute myeloid leukemia
1502607|NCT00006083|adult acute myeloid leukemia in remission
1502608|NCT00006083|adult acute lymphoblastic leukemia in remission
1502609|NCT00006083|chronic idiopathic myelofibrosis
1502610|NCT00006083|essential thrombocythemia
1502611|NCT00006083|untreated hairy cell leukemia
1502612|NCT00006083|progressive hairy cell leukemia, initial treatment
1502613|NCT00006083|refractory hairy cell leukemia
1502614|NCT00006083|stage I grade 1 follicular lymphoma
1502615|NCT00006083|stage I grade 2 follicular lymphoma
1502616|NCT00006083|stage I grade 3 follicular lymphoma
1502617|NCT00006083|stage I adult diffuse small cleaved cell lymphoma
1502618|NCT00006083|stage I adult diffuse mixed cell lymphoma
1502619|NCT00006083|stage I adult diffuse large cell lymphoma
1502620|NCT00006083|stage I adult immunoblastic large cell lymphoma
1502621|NCT00006083|stage I adult lymphoblastic lymphoma
1502622|NCT00006083|stage I adult Burkitt lymphoma
1502623|NCT00006083|chronic myelomonocytic leukemia
1502624|NCT00006083|T-cell large granular lymphocyte leukemia
1502625|NCT00006083|acute undifferentiated leukemia
1502626|NCT00006083|stage III grade 1 follicular lymphoma
1502627|NCT00006083|stage III grade 2 follicular lymphoma
1502628|NCT00006083|stage III grade 3 follicular lymphoma
1502629|NCT00006083|stage III adult diffuse small cleaved cell lymphoma
1502630|NCT00006083|stage III adult diffuse mixed cell lymphoma
1502631|NCT00006083|stage III adult diffuse large cell lymphoma
1502632|NCT00006083|stage III adult immunoblastic large cell lymphoma
1502633|NCT00006083|stage III adult lymphoblastic lymphoma
1502634|NCT00006083|stage III adult Burkitt lymphoma
1502635|NCT00006083|stage IV grade 1 follicular lymphoma
1502636|NCT00006083|stage IV grade 2 follicular lymphoma
1502637|NCT00006083|stage IV grade 3 follicular lymphoma
1502638|NCT00006083|stage IV adult diffuse small cleaved cell lymphoma
1502639|NCT00006083|stage IV adult diffuse mixed cell lymphoma
1502640|NCT00006083|stage IV adult diffuse large cell lymphoma
1502641|NCT00006083|stage IV adult immunoblastic large cell lymphoma
1502642|NCT00006083|stage IV adult lymphoblastic lymphoma
1502643|NCT00006083|stage IV adult Burkitt lymphoma
1502644|NCT00006083|recurrent grade 1 follicular lymphoma
1502645|NCT00006083|recurrent grade 2 follicular lymphoma
1502646|NCT00006083|recurrent grade 3 follicular lymphoma
1502647|NCT00006083|recurrent adult diffuse small cleaved cell lymphoma
1502648|NCT00006083|recurrent adult diffuse mixed cell lymphoma
1502649|NCT00006083|recurrent adult diffuse large cell lymphoma
1502650|NCT00006083|recurrent adult immunoblastic large cell lymphoma
1502651|NCT00006083|recurrent adult lymphoblastic lymphoma
1502652|NCT00006083|recurrent adult Burkitt lymphoma
1502653|NCT00006083|stage I adult T-cell leukemia/lymphoma
1502654|NCT00006083|stage II adult T-cell leukemia/lymphoma
1502655|NCT00006083|stage III adult T-cell leukemia/lymphoma
1502656|NCT00006083|stage IV adult T-cell leukemia/lymphoma
1502657|NCT00006083|recurrent adult T-cell leukemia/lymphoma
1502658|NCT00006083|secondary acute myeloid leukemia
1502659|NCT00006083|de novo myelodysplastic syndromes
1502660|NCT00006083|previously treated myelodysplastic syndromes
1502661|NCT00006083|secondary myelodysplastic syndromes
1502662|NCT00006083|primary central nervous system lymphoma
1502663|NCT00006083|prolymphocytic leukemia
1502664|NCT00006083|primary systemic amyloidosis
1502665|NCT00006083|veno-occlusive disease
1502666|NCT00006083|stage I mantle cell lymphoma
1502667|NCT00006083|contiguous stage II grade 1 follicular lymphoma
1502668|NCT00006083|contiguous stage II grade 2 follicular lymphoma
1502669|NCT00006083|contiguous stage II grade 3 follicular lymphoma
1502670|NCT00006083|contiguous stage II adult diffuse small cleaved cell lymphoma
1502671|NCT00006083|contiguous stage II mantle cell lymphoma
1502672|NCT00006083|contiguous stage II adult diffuse mixed cell lymphoma
1502673|NCT00006083|contiguous stage II adult immunoblastic large cell lymphoma
1502674|NCT00006083|contiguous stage II adult diffuse large cell lymphoma
1502675|NCT00006083|contiguous stage II adult Burkitt lymphoma
1502676|NCT00006083|contiguous stage II adult lymphoblastic lymphoma
1502677|NCT00006083|noncontiguous stage II grade 1 follicular lymphoma
1502678|NCT00006083|noncontiguous stage II grade 2 follicular lymphoma
1502679|NCT00006083|noncontiguous stage II grade 3 follicular lymphoma
1502680|NCT00006083|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1502681|NCT00006083|noncontiguous stage II mantle cell lymphoma
1502682|NCT00006083|noncontiguous stage II adult diffuse mixed cell lymphoma
1502683|NCT00006083|noncontiguous stage II adult immunoblastic large cell lymphoma
1502684|NCT00006083|noncontiguous stage II adult diffuse large cell lymphoma
1502685|NCT00006083|noncontiguous stage II adult Burkitt lymphoma
1502686|NCT00006083|noncontiguous stage II adult lymphoblastic lymphoma
1502687|NCT00006083|stage III mantle cell lymphoma
1502688|NCT00006083|stage IV mantle cell lymphoma
1502689|NCT00006083|recurrent mantle cell lymphoma
1502690|NCT00006083|angioimmunoblastic T-cell lymphoma
1502691|NCT00006083|anaplastic large cell lymphoma
1502692|NCT00006083|noncontiguous stage II small lymphocytic lymphoma
1502693|NCT00006083|noncontiguous stage II marginal zone lymphoma
1502694|NCT00006083|recurrent marginal zone lymphoma
1502695|NCT00006083|recurrent small lymphocytic lymphoma
1502696|NCT00006083|stage I marginal zone lymphoma
1502697|NCT00006083|stage I small lymphocytic lymphoma
1502698|NCT00006083|stage III small lymphocytic lymphoma
1502699|NCT00006083|stage III marginal zone lymphoma
1502700|NCT00006083|stage IV small lymphocytic lymphoma
1502701|NCT00006083|stage IV marginal zone lymphoma
1502702|NCT00006083|contiguous stage II marginal zone lymphoma
1502703|NCT00006083|contiguous stage II small lymphocytic lymphoma
1502704|NCT00006083|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1502705|NCT00006083|nodal marginal zone B-cell lymphoma
1502706|NCT00006083|splenic marginal zone lymphoma
1502707|NCT00006082|extensive stage small cell lung cancer
1502708|NCT00006082|recurrent small cell lung cancer
1502709|NCT00006081|stage III gastric cancer
1502710|NCT00006081|stage IV gastric cancer
1502711|NCT00006081|stage III esophageal cancer
1502712|NCT00006081|stage IV esophageal cancer
1502713|NCT00006081|adenocarcinoma of the stomach
1502714|NCT00006081|adenocarcinoma of the esophagus
1502715|NCT00006080|recurrent adult brain tumor
1502716|NCT00006080|adult anaplastic astrocytoma
1502717|NCT00006080|adult anaplastic oligodendroglioma
1502718|NCT00006080|adult mixed glioma
1502719|NCT00006079|cervical cancer
1502720|NCT00006079|cervical intraepithelial neoplasia grade 2
1502721|NCT00006079|cervical intraepithelial neoplasia grade 3
1502722|NCT00006079|Eflornithine
1502723|NCT00006078|prostate cancer
1502724|NCT00006077|Clinical Trial
1502725|NCT00006077|Dyskinesias
1502726|NCT00006077|Levodopa Infusion
1502727|NCT00006077|Parkinson's Disease
1502728|NCT00006076|Hearing
1502729|NCT00006076|Auditory Processing
1502730|NCT00006076|Pitch Recognition
1502731|NCT00006076|Tone Deafness
1502734|NCT00006076|Deafness
1502735|NCT00006076|Congenital Amusia
1502736|NCT00006076|Healthy Volunteer
1502737|NCT00006075|Pregnancy Complications, Infectious
1502738|NCT00006075|Dose-Response Relationship, Drug
1502739|NCT00006075|Polymerase Chain Reaction
1502740|NCT00006075|Disease Transmission, Vertical
1502741|NCT00006075|Labor
1502742|NCT00006075|Disinfectants
1502743|NCT00006075|Vagina
1502744|NCT00006075|Chlorhexidine
1502745|NCT00006075|Irrigation
1502746|NCT00006073|Evaluation
1502747|NCT00006073|Endocrinology
1502748|NCT00006073|Hormones
1502749|NCT00006073|Metabolism
1502750|NCT00006073|Teaching
1502752|NCT00006071|Brachial Reactivity
1502753|NCT00006071|Endothelial Function
1502754|NCT00006071|Endothelial Markers
1502755|NCT00006071|Forearm Flow
1502756|NCT00006071|Insulin Resistance
1502757|NCT00006071|Elevated Cholesterol
1502758|NCT00006071|Hypertension
1502759|NCT00006070|Oral Surgery
1502760|NCT00006070|Swelling
1502761|NCT00006070|Pain
1502762|NCT00006070|TNF
1502763|NCT00006070|Etanercept
1502764|NCT00006066|Injections, Subcutaneous
1502765|NCT00006066|Interleukin-2
1502766|NCT00006066|Dose-Response Relationship, Drug
1502767|NCT00006066|Drug Therapy, Combination
1502768|NCT00006066|Immunocompromised Host
1502769|NCT00006066|CD4 Lymphocyte Count
1502770|NCT00006066|Anti-HIV Agents
1502771|NCT00006064|Tumor Necrosis Factor
1502772|NCT00006064|CD4 Lymphocyte Count
1502773|NCT00006064|Polymerase Chain Reaction
1502774|NCT00006064|Enzyme-Linked Immunosorbent Assay
1502775|NCT00006064|RNA, Messenger
1502776|NCT00006064|Interleukin-1
1502777|NCT00006064|Body Composition
1502778|NCT00006064|Anti-HIV Agents
1502779|NCT00006064|Viral Load
1502780|NCT00006064|Age Factors
1502781|NCT00006064|Anthropometry
1502782|NCT00006063|cardiovascular and respiratory diseases
1502783|NCT00006063|cystic fibrosis
1502784|NCT00006063|genetic diseases and dysmorphic syndromes
1502785|NCT00006063|rare disease
1502786|NCT00006062|Liver Impairment
1502787|NCT00006062|Pharmacokinetics
1502788|NCT00006062|Platinum Analogues
1502789|NCT00006061|genetic diseases and dysmorphic syndromes
1502790|NCT00006061|inborn errors of metabolism
1502791|NCT00006061|methionine adenosyltransferase deficiency
1502792|NCT00006061|rare disease
1502793|NCT00006060|multiple sclerosis
1502794|NCT00006060|neurologic and psychiatric disorders
1502795|NCT00006060|rare disease
1502796|NCT00006059|epilepsy
1502797|NCT00006059|neurologic and psychiatric disorders
1502798|NCT00006059|rare disease
1502799|NCT00006059|seizures
1502800|NCT00006058|bronchopulmonary dysplasia
1502801|NCT00006058|cardiovascular and respiratory diseases
1502802|NCT00006058|neonatal disorders
1502803|NCT00006058|rare disease
1502804|NCT00006058|respiratory distress syndrome
1502805|NCT00006056|Chediak-Higashi syndrome
1502806|NCT00006056|X-linked lymphoproliferative syndrome
1502807|NCT00006056|disease-related problem/condition
1502808|NCT00006056|familial erythrophagocytic lymphohistiocytosis
1502809|NCT00006056|genetic diseases and dysmorphic syndromes
1502810|NCT00006056|graft versus host disease
1502811|NCT00006056|hematologic disorders
1502812|NCT00006056|hemophagocytic lymphohistiocytosis
1502813|NCT00006056|histiocytosis
1502814|NCT00006056|immunologic disorders and infectious disorders
1502815|NCT00006056|primary immunodeficiency disease
1502816|NCT00006056|rare disease
1502817|NCT00006056|virus-associated hemophagocytic syndrome
1502818|NCT00006055|Churg-Strauss syndrome
1502819|NCT00006055|Schonlein-Henoch purpura
1502820|NCT00006055|Takayasu arteritis
1502821|NCT00006055|Wegener's granulomatosis
1502822|NCT00006055|arthritis & connective tissue diseases
1502823|NCT00006055|autoimmune hemolytic anemia
1502824|NCT00006055|cardiovascular and respiratory diseases
1502825|NCT00006055|disease-related problem/condition
1502826|NCT00006055|giant cell arteritis
1502827|NCT00006055|graft versus host disease
1502828|NCT00006055|hematologic disorders
1502829|NCT00006055|hypersensitivity vasculitis
1502830|NCT00006055|immune thrombocytopenic purpura
1502831|NCT00006055|immunologic disorders and infectious disorders
1502832|NCT00006055|juvenile rheumatoid arthritis
1502833|NCT00006055|polyarteritis nodosa
1502834|NCT00006055|pure red cell aplasia
1502835|NCT00006055|rare disease
1502836|NCT00006055|rheumatoid arthritis
1502837|NCT00006055|systemic lupus erythematosus
1502838|NCT00006055|vasculitis
1502839|NCT00006054|Chediak-Higashi syndrome
1502840|NCT00006054|Langerhans cell histiocytosis
1502841|NCT00006054|Wiskott-Aldrich syndrome
1502842|NCT00006054|X-linked agammaglobulinemia
1502843|NCT00006054|X-linked hyper IgM syndrome
1502844|NCT00006054|X-linked lymphoproliferative syndrome
1502845|NCT00006054|chronic granulomatous disease
1502846|NCT00006054|common variable immunodeficiency
1502847|NCT00006054|complement deficiency
1502848|NCT00006054|disease-related problem/condition
1502849|NCT00006054|familial erythrophagocytic lymphohistiocytosis
1502850|NCT00006054|genetic diseases and dysmorphic syndromes
1502851|NCT00006054|graft versus host disease
1502852|NCT00006054|hematologic disorders
1502853|NCT00006054|hemophagocytic lymphohistiocytosis
1502854|NCT00006054|histiocytosis
1502855|NCT00006054|immunologic disorders and infectious disorders
1502856|NCT00006054|leukocyte adhesion deficiency syndrome
1502857|NCT00006054|primary immunodeficiency disease
1502858|NCT00006054|rare disease
1502859|NCT00006054|severe combined immunodeficiency
1502860|NCT00006054|virus-associated hemophagocytic syndrome
1502861|NCT00006053|relapsing chronic myelogenous leukemia
1502862|NCT00006053|chronic phase chronic myelogenous leukemia
1502863|NCT00006053|chronic myelogenous leukemia, BCR-ABL1 positive
1502864|NCT00006053|Philadelphia chromosome negative chronic myelogenous leukemia
1502865|NCT00006052|accelerated phase chronic myelogenous leukemia
1502866|NCT00006052|chronic myelogenous leukemia, BCR-ABL1 positive
1502867|NCT00006052|Philadelphia chromosome negative chronic myelogenous leukemia
1502868|NCT00006051|stage I squamous cell carcinoma of the lip and oral cavity
1502869|NCT00006051|stage II squamous cell carcinoma of the lip and oral cavity
1502870|NCT00006051|stage III squamous cell carcinoma of the lip and oral cavity
1502871|NCT00006051|stage IV squamous cell carcinoma of the lip and oral cavity
1502872|NCT00006051|stage I squamous cell carcinoma of the oropharynx
1502873|NCT00006051|stage II squamous cell carcinoma of the oropharynx
1502874|NCT00006051|stage III squamous cell carcinoma of the oropharynx
1502875|NCT00006051|stage IV squamous cell carcinoma of the oropharynx
1502876|NCT00006051|stage I squamous cell carcinoma of the hypopharynx
1502877|NCT00006051|stage II squamous cell carcinoma of the hypopharynx
1502878|NCT00006051|stage III squamous cell carcinoma of the hypopharynx
1502879|NCT00006051|stage IV squamous cell carcinoma of the hypopharynx
1502880|NCT00006051|stage I squamous cell carcinoma of the larynx
1502881|NCT00006051|stage II squamous cell carcinoma of the larynx
1502882|NCT00006051|stage III squamous cell carcinoma of the larynx
1502883|NCT00006051|stage IV squamous cell carcinoma of the larynx
1502884|NCT00006050|stage IV colon cancer
1502885|NCT00006050|stage IV rectal cancer
1502886|NCT00006050|liver metastases
1502887|NCT00006049|recurrent non-small cell lung cancer
1502888|NCT00006049|stage IIIB non-small cell lung cancer
1502889|NCT00006049|stage IV non-small cell lung cancer
1502890|NCT00006048|recurrent non-small cell lung cancer
1502891|NCT00006048|stage IIIB non-small cell lung cancer
1502892|NCT00006048|stage IV non-small cell lung cancer
1502893|NCT00006047|unspecified adult solid tumor, protocol specific
1502894|NCT00006046|stage IV colon cancer
1502895|NCT00006046|stage IV rectal cancer
1502896|NCT00006046|recurrent colon cancer
1502897|NCT00006046|recurrent rectal cancer
1502898|NCT00006045|recurrent adult acute myeloid leukemia
1502899|NCT00006045|adult acute erythroid leukemia (M6)
1502900|NCT00006045|adult acute myeloblastic leukemia without maturation (M1)
1502901|NCT00006045|adult acute myeloblastic leukemia with maturation (M2)
1502902|NCT00006045|adult acute myelomonocytic leukemia (M4)
1502903|NCT00006045|adult acute monoblastic leukemia (M5a)
1502904|NCT00006045|adult acute megakaryoblastic leukemia (M7)
1502905|NCT00006045|secondary acute myeloid leukemia
1502906|NCT00006045|adult acute monocytic leukemia (M5b)
1502907|NCT00006045|adult acute minimally differentiated myeloid leukemia (M0)
1502908|NCT00006044|stage IV prostate cancer
1502909|NCT00006044|recurrent prostate cancer
1502910|NCT00006043|stage III malignant testicular germ cell tumor
1502911|NCT00006043|recurrent malignant testicular germ cell tumor
1502912|NCT00006043|stage IV ovarian germ cell tumor
1502913|NCT00006043|recurrent ovarian germ cell tumor
1502914|NCT00006042|recurrent adult Hodgkin lymphoma
1502915|NCT00006042|Burkitt lymphoma
1502916|NCT00006042|refractory multiple myeloma
1502917|NCT00006042|stage II multiple myeloma
1502918|NCT00006042|stage III multiple myeloma
1502919|NCT00006042|recurrent childhood lymphoblastic lymphoma
1502920|NCT00006042|stage III chronic lymphocytic leukemia
1502921|NCT00006042|stage IV chronic lymphocytic leukemia
1502922|NCT00006042|relapsing chronic myelogenous leukemia
1502923|NCT00006042|refractory chronic lymphocytic leukemia
1502924|NCT00006042|chronic phase chronic myelogenous leukemia
1502925|NCT00006042|adult acute myeloid leukemia in remission
1502926|NCT00006042|adult acute lymphoblastic leukemia in remission
1502927|NCT00006042|childhood acute myeloid leukemia in remission
1502928|NCT00006042|childhood acute lymphoblastic leukemia in remission
1502929|NCT00006042|recurrent/refractory childhood Hodgkin lymphoma
1502930|NCT00006042|stage II adult lymphoblastic lymphoma
1502931|NCT00006042|stage III grade 3 follicular lymphoma
1502932|NCT00006042|stage III adult diffuse mixed cell lymphoma
1502933|NCT00006042|stage III adult diffuse large cell lymphoma
1502934|NCT00006042|stage III adult immunoblastic large cell lymphoma
1502935|NCT00006042|stage III adult lymphoblastic lymphoma
1502936|NCT00006042|stage III adult Burkitt lymphoma
1502937|NCT00006042|stage IV grade 1 follicular lymphoma
1502938|NCT00006042|stage IV grade 2 follicular lymphoma
1502939|NCT00006042|stage IV grade 3 follicular lymphoma
1502940|NCT00006042|stage IV adult diffuse mixed cell lymphoma
1502941|NCT00006042|stage IV adult diffuse large cell lymphoma
1502942|NCT00006042|stage IV adult immunoblastic large cell lymphoma
1502943|NCT00006042|stage IV adult lymphoblastic lymphoma
1502944|NCT00006042|stage IV adult Burkitt lymphoma
1502945|NCT00006042|recurrent grade 1 follicular lymphoma
1502946|NCT00006042|recurrent grade 2 follicular lymphoma
1502947|NCT00006042|recurrent grade 3 follicular lymphoma
1502948|NCT00006042|recurrent adult diffuse small cleaved cell lymphoma
1502949|NCT00006042|recurrent adult diffuse mixed cell lymphoma
1502950|NCT00006042|recurrent adult diffuse large cell lymphoma
1502951|NCT00006042|recurrent adult immunoblastic large cell lymphoma
1502952|NCT00006042|recurrent adult lymphoblastic lymphoma
1502953|NCT00006042|recurrent adult Burkitt lymphoma
1502954|NCT00006042|de novo myelodysplastic syndromes
1502955|NCT00006042|previously treated myelodysplastic syndromes
1502956|NCT00006042|secondary myelodysplastic syndromes
1502957|NCT00006042|recurrent childhood small noncleaved cell lymphoma
1502958|NCT00006042|recurrent childhood large cell lymphoma
1502959|NCT00006042|noncontiguous stage II grade 3 follicular lymphoma
1502960|NCT00006042|noncontiguous stage II mantle cell lymphoma
1502961|NCT00006042|noncontiguous stage II adult diffuse mixed cell lymphoma
1502962|NCT00006042|noncontiguous stage II adult immunoblastic large cell lymphoma
1502963|NCT00006042|noncontiguous stage II adult diffuse large cell lymphoma
1502964|NCT00006042|noncontiguous stage II adult Burkitt lymphoma
1502965|NCT00006042|noncontiguous stage II adult lymphoblastic lymphoma
1502966|NCT00006042|stage III mantle cell lymphoma
1502967|NCT00006042|stage IV mantle cell lymphoma
1502968|NCT00006042|recurrent mantle cell lymphoma
1502969|NCT00006042|childhood chronic myelogenous leukemia
1502970|NCT00006042|atypical chronic myeloid leukemia
1502971|NCT00006042|myelodysplastic/myeloproliferative disease, unclassifiable
1502972|NCT00006042|recurrent marginal zone lymphoma
1502973|NCT00006042|recurrent small lymphocytic lymphoma
1502974|NCT00006042|stage III small lymphocytic lymphoma
1502975|NCT00006042|stage III marginal zone lymphoma
1502976|NCT00006042|stage IV small lymphocytic lymphoma
1502977|NCT00006042|stage IV marginal zone lymphoma
1502978|NCT00006042|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1502979|NCT00006042|nodal marginal zone B-cell lymphoma
1502980|NCT00006042|splenic marginal zone lymphoma
1502981|NCT00006042|adult acute myeloid leukemia with t(8;21)(q22;q22)
1502982|NCT00006042|adult acute myeloid leukemia with t(16;16)(p13;q22)
1502983|NCT00006042|adult acute myeloid leukemia with inv(16)(p13;q22)
1502984|NCT00006042|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1502985|NCT00006042|adult acute myeloid leukemia with t(15;17)(q22;q12)
1502986|NCT00006042|childhood myelodysplastic syndromes
1502987|NCT00006041|recurrent ovarian epithelial cancer
1502988|NCT00006041|fallopian tube cancer
1502989|NCT00006041|primary peritoneal cavity cancer
1502990|NCT00006040|recurrent adult acute myeloid leukemia
1502991|NCT00006040|recurrent adult acute lymphoblastic leukemia
1502992|NCT00006040|relapsing chronic myelogenous leukemia
1502993|NCT00006040|accelerated phase chronic myelogenous leukemia
1502994|NCT00006040|blastic phase chronic myelogenous leukemia
1502995|NCT00006040|previously treated myelodysplastic syndromes
1502996|NCT00006040|atypical chronic myeloid leukemia, BCR-ABL1 negative
1502997|NCT00006040|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1502998|NCT00006039|small intestine lymphoma
1502999|NCT00006039|stage III grade 1 follicular lymphoma
1503000|NCT00006039|stage III grade 2 follicular lymphoma
1503001|NCT00006039|stage IV grade 1 follicular lymphoma
1503002|NCT00006039|stage IV grade 2 follicular lymphoma
1503003|NCT00006039|recurrent grade 1 follicular lymphoma
1503004|NCT00006039|recurrent grade 2 follicular lymphoma
1503005|NCT00006039|contiguous stage II grade 1 follicular lymphoma
1503006|NCT00006039|contiguous stage II grade 2 follicular lymphoma
1503007|NCT00006039|noncontiguous stage II grade 1 follicular lymphoma
1503008|NCT00006039|noncontiguous stage II grade 2 follicular lymphoma
1503009|NCT00006039|noncontiguous stage II small lymphocytic lymphoma
1503010|NCT00006039|noncontiguous stage II marginal zone lymphoma
1503011|NCT00006039|recurrent marginal zone lymphoma
1503012|NCT00006039|recurrent small lymphocytic lymphoma
1503013|NCT00006039|stage III small lymphocytic lymphoma
1503014|NCT00006039|stage III marginal zone lymphoma
1503015|NCT00006039|stage IV small lymphocytic lymphoma
1503016|NCT00006039|stage IV marginal zone lymphoma
1503017|NCT00006039|contiguous stage II marginal zone lymphoma
1503018|NCT00006039|contiguous stage II small lymphocytic lymphoma
1503019|NCT00006039|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1503020|NCT00006039|nodal marginal zone B-cell lymphoma
1503021|NCT00006039|splenic marginal zone lymphoma
1503022|NCT00006038|stage II gastric cancer
1503023|NCT00006038|stage III gastric cancer
1503024|NCT00006038|stage IV gastric cancer
1503025|NCT00006038|stage II esophageal cancer
1503026|NCT00006038|stage III esophageal cancer
1503027|NCT00006038|adenocarcinoma of the stomach
1503028|NCT00006038|adenocarcinoma of the esophagus
1503029|NCT00006037|stage IV colon cancer
1503030|NCT00006037|stage IV rectal cancer
1503031|NCT00006037|recurrent colon cancer
1503032|NCT00006037|recurrent rectal cancer
1503033|NCT00006037|adenocarcinoma of the colon
1503034|NCT00006037|adenocarcinoma of the rectum
1503035|NCT00006036|recurrent non-small cell lung cancer
1503036|NCT00006036|stage III ovarian epithelial cancer
1503037|NCT00006036|stage IV ovarian epithelial cancer
1503038|NCT00006036|recurrent ovarian epithelial cancer
1503039|NCT00006036|extensive stage small cell lung cancer
1503040|NCT00006036|recurrent small cell lung cancer
1503041|NCT00006036|stage IV nasopharyngeal cancer
1503042|NCT00006036|stage IIIA non-small cell lung cancer
1503043|NCT00006036|stage IIIB non-small cell lung cancer
1503044|NCT00006036|stage IV non-small cell lung cancer
1503045|NCT00006036|unspecified adult solid tumor, protocol specific
1503046|NCT00006036|untreated metastatic squamous neck cancer with occult primary
1503047|NCT00006036|recurrent metastatic squamous neck cancer with occult primary
1503048|NCT00006036|ovarian stromal cancer
1503049|NCT00006036|stage III ovarian germ cell tumor
1503050|NCT00006036|stage IV ovarian germ cell tumor
1503051|NCT00006036|recurrent ovarian germ cell tumor
1503052|NCT00006036|stage III squamous cell carcinoma of the lip and oral cavity
1503053|NCT00006036|stage III basal cell carcinoma of the lip
1503054|NCT00006036|stage III verrucous carcinoma of the oral cavity
1503055|NCT00006036|stage III mucoepidermoid carcinoma of the oral cavity
1503056|NCT00006036|stage III adenoid cystic carcinoma of the oral cavity
1503057|NCT00006036|stage IV squamous cell carcinoma of the lip and oral cavity
1503058|NCT00006036|stage IV basal cell carcinoma of the lip
1503059|NCT00006036|stage IV verrucous carcinoma of the oral cavity
1503060|NCT00006036|stage IV mucoepidermoid carcinoma of the oral cavity
1503061|NCT00006036|stage IV adenoid cystic carcinoma of the oral cavity
1503062|NCT00006036|recurrent squamous cell carcinoma of the lip and oral cavity
1503063|NCT00006036|recurrent basal cell carcinoma of the lip
1503064|NCT00006036|recurrent verrucous carcinoma of the oral cavity
1503065|NCT00006036|recurrent mucoepidermoid carcinoma of the oral cavity
1503066|NCT00006036|recurrent adenoid cystic carcinoma of the oral cavity
1503067|NCT00006036|stage III squamous cell carcinoma of the oropharynx
1503068|NCT00006036|stage III lymphoepithelioma of the oropharynx
1503069|NCT00006036|stage IV squamous cell carcinoma of the oropharynx
1503070|NCT00006036|stage IV lymphoepithelioma of the oropharynx
1503071|NCT00006036|recurrent squamous cell carcinoma of the oropharynx
1503072|NCT00006036|recurrent lymphoepithelioma of the oropharynx
1503073|NCT00006036|stage III squamous cell carcinoma of the nasopharynx
1503074|NCT00006036|stage III lymphoepithelioma of the nasopharynx
1503075|NCT00006036|stage IV squamous cell carcinoma of the nasopharynx
1503076|NCT00006036|stage IV lymphoepithelioma of the nasopharynx
1503077|NCT00006036|recurrent squamous cell carcinoma of the nasopharynx
1503078|NCT00006036|recurrent lymphoepithelioma of the nasopharynx
1503079|NCT00006036|stage III squamous cell carcinoma of the hypopharynx
1503080|NCT00006036|stage IV squamous cell carcinoma of the hypopharynx
1503081|NCT00006036|recurrent squamous cell carcinoma of the hypopharynx
1503082|NCT00006036|stage III squamous cell carcinoma of the larynx
1503083|NCT00006036|stage III verrucous carcinoma of the larynx
1503084|NCT00006036|stage IV squamous cell carcinoma of the larynx
1503085|NCT00006036|stage IV verrucous carcinoma of the larynx
1503086|NCT00006036|recurrent squamous cell carcinoma of the larynx
1503087|NCT00006036|recurrent verrucous carcinoma of the larynx
1503088|NCT00006036|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1503089|NCT00006036|stage III inverted papilloma of the paranasal sinus and nasal cavity
1503090|NCT00006036|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1503091|NCT00006036|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1503092|NCT00006036|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1503093|NCT00006036|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1503094|NCT00006036|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1503095|NCT00006036|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1503096|NCT00006036|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1503097|NCT00006036|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1503098|NCT00006036|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1503099|NCT00006036|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1503100|NCT00006036|borderline ovarian surface epithelial-stromal tumor
1503101|NCT00006036|ovarian sarcoma
1503102|NCT00006035|stage III melanoma
1503103|NCT00006035|stage IV melanoma
1503104|NCT00006035|recurrent melanoma
1503105|NCT00006034|stage 0 bladder cancer
1503106|NCT00006034|recurrent bladder cancer
1503107|NCT00006033|recurrent metastatic squamous neck cancer with occult primary
1503108|NCT00006033|stage III squamous cell carcinoma of the lip and oral cavity
1503109|NCT00006033|stage IV squamous cell carcinoma of the lip and oral cavity
1503110|NCT00006033|recurrent squamous cell carcinoma of the lip and oral cavity
1503111|NCT00006033|stage III squamous cell carcinoma of the oropharynx
1503112|NCT00006033|stage IV squamous cell carcinoma of the oropharynx
1503113|NCT00006033|recurrent squamous cell carcinoma of the oropharynx
1503114|NCT00006033|stage III squamous cell carcinoma of the nasopharynx
1503115|NCT00006033|stage IV squamous cell carcinoma of the nasopharynx
1503116|NCT00006033|recurrent squamous cell carcinoma of the nasopharynx
1503117|NCT00006033|stage III squamous cell carcinoma of the hypopharynx
1503118|NCT00006033|stage IV squamous cell carcinoma of the hypopharynx
1503119|NCT00006033|recurrent squamous cell carcinoma of the hypopharynx
1503120|NCT00006033|stage III squamous cell carcinoma of the larynx
1503121|NCT00006033|stage IV squamous cell carcinoma of the larynx
1503122|NCT00006033|recurrent squamous cell carcinoma of the larynx
1503123|NCT00006033|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1503124|NCT00006033|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1503125|NCT00006033|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1503126|NCT00006032|stage IV breast cancer
1503127|NCT00006032|recurrent breast cancer
1503128|NCT00006031|biopsy
1503129|NCT00006031|radioactive seed
1503130|NCT00006031|nonpalpable lesions
1503131|NCT00006030|stage I breast cancer
1503132|NCT00006029|recurrent adult Hodgkin lymphoma
1503133|NCT00006029|recurrent/refractory childhood Hodgkin lymphoma
1503134|NCT00006028|recurrent ovarian epithelial cancer
1503135|NCT00006028|primary peritoneal cavity cancer
1503136|NCT00006027|stage I endometrial carcinoma
1503137|NCT00006027|stage II endometrial carcinoma
1503138|NCT00006027|endometrial adenocarcinoma
1503139|NCT00006027|endometrial adenosquamous cell carcinoma
1503140|NCT00006027|endometrial adenoacanthoma
1503141|NCT00006027|endometrial clear cell carcinoma
1503142|NCT00006027|endometrial papillary serous carcinoma
1503143|NCT00006026|recurrent bladder cancer
1503144|NCT00006026|stage IV bladder cancer
1503145|NCT00006026|transitional cell carcinoma of the bladder
1503146|NCT00006026|squamous cell carcinoma of the bladder
1503147|NCT00006026|adenocarcinoma of the bladder
1503148|NCT00006026|recurrent urethral cancer
1503149|NCT00006026|anterior urethral cancer
1503150|NCT00006026|posterior urethral cancer
1503151|NCT00006026|urethral cancer associated with invasive bladder cancer
1503152|NCT00006026|metastatic transitional cell cancer of the renal pelvis and ureter
1503153|NCT00006026|regional transitional cell cancer of the renal pelvis and ureter
1503154|NCT00006026|recurrent transitional cell cancer of the renal pelvis and ureter
1503155|NCT00006025|recurrent adult brain tumor
1503156|NCT00006025|adult glioblastoma
1503157|NCT00006025|adult anaplastic astrocytoma
1503158|NCT00006025|adult anaplastic oligodendroglioma
1503159|NCT00006025|adult mixed glioma
1503160|NCT00006025|adult giant cell glioblastoma
1503161|NCT00006025|adult gliosarcoma
1503162|NCT00006024|childhood high-grade cerebral astrocytoma
1503163|NCT00006023|stage IV prostate cancer
1503164|NCT00006023|recurrent prostate cancer
1503165|NCT00006022|stage III renal cell cancer
1503166|NCT00006022|stage IV renal cell cancer
1503167|NCT00006022|recurrent renal cell cancer
1503168|NCT00006022|stage III melanoma
1503169|NCT00006022|stage IV melanoma
1503170|NCT00006022|recurrent melanoma
1503171|NCT00006021|refractory multiple myeloma
1503172|NCT00006021|stage II multiple myeloma
1503173|NCT00006021|stage III multiple myeloma
1503174|NCT00006020|recurrent adult acute lymphoblastic leukemia
1503175|NCT00006020|L1 adult acute lymphoblastic leukemia
1503176|NCT00006020|L2 adult acute lymphoblastic leukemia
1503177|NCT00006020|B-cell adult acute lymphoblastic leukemia
1503178|NCT00006020|non-T, non-B adult acute lymphoblastic leukemia
1503179|NCT00006019|recurrent non-small cell lung cancer
1503180|NCT00006019|refractory multiple myeloma
1503181|NCT00006019|recurrent adult acute myeloid leukemia
1503182|NCT00006019|recurrent prostate cancer
1503183|NCT00006019|adult acute myeloblastic leukemia without maturation (M1)
1503184|NCT00006019|adult acute myeloblastic leukemia with maturation (M2)
1503185|NCT00006019|adult acute promyelocytic leukemia (M3)
1503186|NCT00006019|adult acute myelomonocytic leukemia (M4)
1503187|NCT00006019|adult acute monoblastic leukemia (M5a)
1503188|NCT00006019|recurrent grade 1 follicular lymphoma
1503189|NCT00006019|recurrent grade 2 follicular lymphoma
1503190|NCT00006019|recurrent grade 3 follicular lymphoma
1503191|NCT00006019|recurrent adult diffuse small cleaved cell lymphoma
1503192|NCT00006019|recurrent adult diffuse mixed cell lymphoma
1503193|NCT00006019|recurrent adult diffuse large cell lymphoma
1503194|NCT00006019|adult acute monocytic leukemia (M5b)
1503195|NCT00006019|previously treated myelodysplastic syndromes
1503196|NCT00006019|secondary myelodysplastic syndromes
1503197|NCT00006019|recurrent marginal zone lymphoma
1503198|NCT00006019|recurrent small lymphocytic lymphoma
1503199|NCT00006019|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1503200|NCT00006019|nodal marginal zone B-cell lymphoma
1503201|NCT00006019|splenic marginal zone lymphoma
1503202|NCT00006018|unspecified adult solid tumor, protocol specific
1503203|NCT00006017|recurrent non-small cell lung cancer
1503204|NCT00006017|stage IIIB non-small cell lung cancer
1503205|NCT00006017|stage IV non-small cell lung cancer
1503206|NCT00006015|stage IV colon cancer
1503207|NCT00006015|stage IV rectal cancer
1503208|NCT00006015|recurrent colon cancer
1503209|NCT00006015|recurrent rectal cancer
1503210|NCT00006015|adenocarcinoma of the colon
1503211|NCT00006015|adenocarcinoma of the rectum
1503212|NCT00006014|advanced malignant mesothelioma
1503213|NCT00006014|recurrent malignant mesothelioma
1503214|NCT00006014|epithelial mesothelioma
1503215|NCT00006014|sarcomatous mesothelioma
1503887|NCT00005931|Enzyme Inhibitors
1503216|NCT00006013|refractory multiple myeloma
1503217|NCT00006012|drug/agent toxicity by tissue/organ
1503218|NCT00006012|radiation toxicity
1503219|NCT00006012|limited stage small cell lung cancer
1503220|NCT00006010|localized unresectable adult primary liver cancer
1503221|NCT00006010|advanced adult primary liver cancer
1503222|NCT00006010|recurrent adult primary liver cancer
1503223|NCT00006010|adult primary hepatocellular carcinoma
1503224|NCT00006009|stage I cutaneous T-cell non-Hodgkin lymphoma
1503225|NCT00006009|stage II cutaneous T-cell non-Hodgkin lymphoma
1503226|NCT00006009|stage III cutaneous T-cell non-Hodgkin lymphoma
1503227|NCT00006009|stage IV cutaneous T-cell non-Hodgkin lymphoma
1503228|NCT00006009|recurrent cutaneous T-cell non-Hodgkin lymphoma
1503229|NCT00006009|small intestine lymphoma
1503230|NCT00006009|stage III adult T-cell leukemia/lymphoma
1503231|NCT00006009|stage IV adult T-cell leukemia/lymphoma
1503232|NCT00006009|recurrent adult T-cell leukemia/lymphoma
1503233|NCT00006009|angioimmunoblastic T-cell lymphoma
1503234|NCT00006009|anaplastic large cell lymphoma
1503235|NCT00006009|stage I mycosis fungoides/Sezary syndrome
1503236|NCT00006009|stage II mycosis fungoides/Sezary syndrome
1503237|NCT00006009|stage III mycosis fungoides/Sezary syndrome
1503238|NCT00006009|stage IV mycosis fungoides/Sezary syndrome
1503239|NCT00006009|recurrent mycosis fungoides/Sezary syndrome
1503240|NCT00006008|recurrent adult acute lymphoblastic leukemia
1503241|NCT00006008|L1 adult acute lymphoblastic leukemia
1503242|NCT00006008|L2 adult acute lymphoblastic leukemia
1503243|NCT00006008|L3 adult acute lymphoblastic leukemia
1503244|NCT00006007|stage IV breast cancer
1503245|NCT00006007|recurrent breast cancer
1503246|NCT00006006|localized unresectable adult primary liver cancer
1503247|NCT00006006|advanced adult primary liver cancer
1503248|NCT00006006|recurrent adult primary liver cancer
1503249|NCT00006006|adult primary hepatocellular carcinoma
1503250|NCT00006005|stage I uterine sarcoma
1503251|NCT00006005|stage II uterine sarcoma
1503252|NCT00006005|stage III uterine sarcoma
1503253|NCT00006005|stage IV uterine sarcoma
1503254|NCT00006005|recurrent uterine sarcoma
1503255|NCT00006005|uterine carcinosarcoma
1503256|NCT00006005|uterine leiomyosarcoma
1503257|NCT00006005|endometrial stromal sarcoma
1503258|NCT00006004|recurrent non-small cell lung cancer
1503259|NCT00006004|squamous cell lung cancer
1503260|NCT00006004|large cell lung cancer
1503261|NCT00006004|stage IIIB non-small cell lung cancer
1503262|NCT00006004|stage IV non-small cell lung cancer
1503263|NCT00006004|adenocarcinoma of the lung
1503264|NCT00006004|adenosquamous cell lung cancer
1503265|NCT00006004|bronchoalveolar cell lung cancer
1503266|NCT00006002|stage IV prostate cancer
1503267|NCT00006002|recurrent prostate cancer
1503268|NCT00006001|stage III colon cancer
1503269|NCT00006001|stage IV colon cancer
1503270|NCT00006001|stage III rectal cancer
1503271|NCT00006001|stage IV rectal cancer
1503272|NCT00006001|recurrent colon cancer
1503273|NCT00006001|recurrent rectal cancer
1503274|NCT00006001|adenocarcinoma of the colon
1503275|NCT00006001|adenocarcinoma of the rectum
1503276|NCT00006000|unspecified adult solid tumor, protocol specific
1503277|NCT00005999|recurrent cervical cancer
1503278|NCT00005999|stage IVB cervical cancer
1503279|NCT00005999|cervical squamous cell carcinoma
1503280|NCT00005999|cervical adenocarcinoma
1503281|NCT00005998|recurrent adult Hodgkin lymphoma
1503282|NCT00005998|recurrent grade 1 follicular lymphoma
1503283|NCT00005998|recurrent grade 2 follicular lymphoma
1503284|NCT00005998|recurrent grade 3 follicular lymphoma
1503285|NCT00005998|recurrent adult diffuse small cleaved cell lymphoma
1503286|NCT00005998|recurrent adult diffuse mixed cell lymphoma
1503287|NCT00005998|recurrent adult diffuse large cell lymphoma
1503288|NCT00005998|recurrent adult immunoblastic large cell lymphoma
1503289|NCT00005998|recurrent adult lymphoblastic lymphoma
1503290|NCT00005998|recurrent adult Burkitt lymphoma
1503291|NCT00005998|recurrent mantle cell lymphoma
1503292|NCT00005998|recurrent marginal zone lymphoma
1503293|NCT00005998|recurrent small lymphocytic lymphoma
1503294|NCT00005998|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1503295|NCT00005998|nodal marginal zone B-cell lymphoma
1503296|NCT00005998|splenic marginal zone lymphoma
1503297|NCT00005997|localized unresectable adult primary liver cancer
1503298|NCT00005997|advanced adult primary liver cancer
1503299|NCT00005997|unresectable gallbladder cancer
1503300|NCT00005997|unresectable extrahepatic bile duct cancer
1503301|NCT00005997|adult primary hepatocellular carcinoma
1503302|NCT00005997|cholangiocarcinoma of the gallbladder
1503303|NCT00005997|cholangiocarcinoma of the extrahepatic bile duct
1503304|NCT00005997|adult primary cholangiocellular carcinoma
1503305|NCT00005996|unspecified adult solid tumor, protocol specific
1503306|NCT00005995|stage IV renal cell cancer
1503307|NCT00005995|recurrent renal cell cancer
1503308|NCT00005994|nausea and vomiting
1503309|NCT00005994|unspecified adult solid tumor, protocol specific
1503310|NCT00005993|stage IV breast cancer
1503311|NCT00005993|stage IIIA breast cancer
1503312|NCT00005993|recurrent breast cancer
1503313|NCT00005993|stage IIIB breast cancer
1503888|NCT00005931|SU 5416
1503314|NCT00005993|recurrent adult Hodgkin lymphoma
1503315|NCT00005993|stage III grade 3 follicular lymphoma
1503316|NCT00005993|stage III adult diffuse mixed cell lymphoma
1503317|NCT00005993|stage III adult diffuse large cell lymphoma
1503318|NCT00005993|stage III adult immunoblastic large cell lymphoma
1503319|NCT00005993|stage III adult lymphoblastic lymphoma
1503320|NCT00005993|stage III adult Burkitt lymphoma
1503321|NCT00005993|stage IV grade 3 follicular lymphoma
1503322|NCT00005993|stage IV adult diffuse mixed cell lymphoma
1503323|NCT00005993|stage IV adult diffuse large cell lymphoma
1503324|NCT00005993|stage IV adult immunoblastic large cell lymphoma
1503325|NCT00005993|stage IV adult lymphoblastic lymphoma
1503326|NCT00005993|stage IV adult Burkitt lymphoma
1503327|NCT00005993|recurrent grade 1 follicular lymphoma
1503328|NCT00005993|recurrent grade 2 follicular lymphoma
1503329|NCT00005993|recurrent grade 3 follicular lymphoma
1503330|NCT00005993|recurrent adult diffuse small cleaved cell lymphoma
1503331|NCT00005993|recurrent adult diffuse mixed cell lymphoma
1503332|NCT00005993|recurrent adult diffuse large cell lymphoma
1503333|NCT00005993|recurrent adult immunoblastic large cell lymphoma
1503334|NCT00005993|recurrent adult lymphoblastic lymphoma
1503335|NCT00005993|recurrent adult Burkitt lymphoma
1503336|NCT00005993|noncontiguous stage II grade 3 follicular lymphoma
1503337|NCT00005993|noncontiguous stage II mantle cell lymphoma
1503338|NCT00005993|noncontiguous stage II adult diffuse mixed cell lymphoma
1503339|NCT00005993|noncontiguous stage II adult immunoblastic large cell lymphoma
1503340|NCT00005993|noncontiguous stage II adult diffuse large cell lymphoma
1503341|NCT00005993|noncontiguous stage II adult Burkitt lymphoma
1503342|NCT00005993|noncontiguous stage II adult lymphoblastic lymphoma
1503343|NCT00005993|stage III mantle cell lymphoma
1503344|NCT00005993|stage IV mantle cell lymphoma
1503345|NCT00005993|recurrent mantle cell lymphoma
1503346|NCT00005993|recurrent marginal zone lymphoma
1503347|NCT00005993|recurrent small lymphocytic lymphoma
1503348|NCT00005993|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1503349|NCT00005993|nodal marginal zone B-cell lymphoma
1503350|NCT00005993|splenic marginal zone lymphoma
1503351|NCT00005992|stage IV prostate cancer
1503352|NCT00005992|recurrent prostate cancer
1503353|NCT00005991|stage IV breast cancer
1503354|NCT00005991|recurrent breast cancer
1503355|NCT00005990|unspecified adult solid tumor, protocol specific
1503356|NCT00005989|recurrent non-small cell lung cancer
1503357|NCT00005989|stage IV non-small cell lung cancer
1503358|NCT00005988|recurrent childhood acute lymphoblastic leukemia
1503359|NCT00005988|recurrent adult Hodgkin lymphoma
1503360|NCT00005988|refractory multiple myeloma
1503361|NCT00005988|stage I multiple myeloma
1503362|NCT00005988|stage II multiple myeloma
1503363|NCT00005988|stage III multiple myeloma
1503364|NCT00005988|stage I childhood lymphoblastic lymphoma
1503365|NCT00005988|stage II childhood lymphoblastic lymphoma
1503366|NCT00005988|stage III childhood lymphoblastic lymphoma
1503367|NCT00005988|stage IV childhood lymphoblastic lymphoma
1503368|NCT00005988|recurrent childhood lymphoblastic lymphoma
1503369|NCT00005988|recurrent childhood acute myeloid leukemia
1503370|NCT00005988|recurrent adult acute myeloid leukemia
1503371|NCT00005988|recurrent adult acute lymphoblastic leukemia
1503372|NCT00005988|childhood diffuse large cell lymphoma
1503373|NCT00005988|childhood immunoblastic large cell lymphoma
1503374|NCT00005988|adult acute myeloid leukemia in remission
1503375|NCT00005988|adult acute lymphoblastic leukemia in remission
1503376|NCT00005988|childhood acute myeloid leukemia in remission
1503377|NCT00005988|childhood acute lymphoblastic leukemia in remission
1503378|NCT00005988|recurrent/refractory childhood Hodgkin lymphoma
1503379|NCT00005988|stage I grade 3 follicular lymphoma
1503380|NCT00005988|stage I adult diffuse small cleaved cell lymphoma
1503381|NCT00005988|stage I adult diffuse mixed cell lymphoma
1503382|NCT00005988|stage I adult diffuse large cell lymphoma
1503383|NCT00005988|stage I adult immunoblastic large cell lymphoma
1503384|NCT00005988|stage I adult lymphoblastic lymphoma
1503385|NCT00005988|stage I adult Burkitt lymphoma
1503386|NCT00005988|chronic myelomonocytic leukemia
1503387|NCT00005988|stage III grade 3 follicular lymphoma
1503388|NCT00005988|stage III adult diffuse small cleaved cell lymphoma
1503389|NCT00005988|stage III adult diffuse mixed cell lymphoma
1503390|NCT00005988|stage III adult diffuse large cell lymphoma
1503391|NCT00005988|stage III adult immunoblastic large cell lymphoma
1503392|NCT00005988|stage III adult lymphoblastic lymphoma
1503393|NCT00005988|stage III adult Burkitt lymphoma
1503394|NCT00005988|stage IV grade 3 follicular lymphoma
1503395|NCT00005988|stage IV adult diffuse mixed cell lymphoma
1503396|NCT00005988|stage IV adult diffuse large cell lymphoma
1503397|NCT00005988|stage IV adult immunoblastic large cell lymphoma
1503398|NCT00005988|stage IV adult lymphoblastic lymphoma
1503399|NCT00005988|stage IV adult Burkitt lymphoma
1503400|NCT00005988|recurrent grade 3 follicular lymphoma
1503401|NCT00005988|recurrent adult diffuse small cleaved cell lymphoma
1503402|NCT00005988|recurrent adult diffuse mixed cell lymphoma
1503403|NCT00005988|recurrent adult diffuse large cell lymphoma
1503404|NCT00005988|recurrent adult immunoblastic large cell lymphoma
1503405|NCT00005988|recurrent adult lymphoblastic lymphoma
1503406|NCT00005988|recurrent adult Burkitt lymphoma
1503407|NCT00005988|de novo myelodysplastic syndromes
1503408|NCT00005988|previously treated myelodysplastic syndromes
1503409|NCT00005988|secondary myelodysplastic syndromes
1503410|NCT00005988|graft versus host disease
1503411|NCT00005988|stage I childhood small noncleaved cell lymphoma
1503412|NCT00005988|stage I childhood large cell lymphoma
1503413|NCT00005988|stage II childhood small noncleaved cell lymphoma
1503414|NCT00005988|stage II childhood large cell lymphoma
1503415|NCT00005988|stage III childhood small noncleaved cell lymphoma
1503416|NCT00005988|stage III childhood large cell lymphoma
1503417|NCT00005988|stage IV childhood small noncleaved cell lymphoma
1503695|NCT00005957|stage I breast cancer
1503418|NCT00005988|stage IV childhood large cell lymphoma
1503419|NCT00005988|recurrent childhood small noncleaved cell lymphoma
1503420|NCT00005988|recurrent childhood large cell lymphoma
1503421|NCT00005988|contiguous stage II grade 3 follicular lymphoma
1503422|NCT00005988|contiguous stage II adult diffuse small cleaved cell lymphoma
1503423|NCT00005988|contiguous stage II adult diffuse mixed cell lymphoma
1503424|NCT00005988|contiguous stage II adult immunoblastic large cell lymphoma
1503425|NCT00005988|contiguous stage II adult diffuse large cell lymphoma
1503426|NCT00005988|contiguous stage II adult Burkitt lymphoma
1503427|NCT00005988|contiguous stage II adult lymphoblastic lymphoma
1503428|NCT00005988|noncontiguous stage II grade 3 follicular lymphoma
1503429|NCT00005988|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1503430|NCT00005988|noncontiguous stage II adult diffuse mixed cell lymphoma
1503431|NCT00005988|noncontiguous stage II adult immunoblastic large cell lymphoma
1503432|NCT00005988|noncontiguous stage II adult diffuse large cell lymphoma
1503433|NCT00005988|noncontiguous stage II adult Burkitt lymphoma
1503434|NCT00005988|noncontiguous stage II adult lymphoblastic lymphoma
1503435|NCT00005988|refractory cytopenia with multilineage dysplasia
1503436|NCT00005988|childhood myelodysplastic syndromes
1503437|NCT00005987|stage I multiple myeloma
1503438|NCT00005987|stage II multiple myeloma
1503439|NCT00005987|stage III multiple myeloma
1503440|NCT00005986|chronic phase chronic myelogenous leukemia
1503441|NCT00005986|accelerated phase chronic myelogenous leukemia
1503442|NCT00005986|Philadelphia chromosome positive chronic myelogenous leukemia
1503443|NCT00005985|stage I adult Hodgkin lymphoma
1503444|NCT00005985|stage II adult Hodgkin lymphoma
1503445|NCT00005985|stage III adult Hodgkin lymphoma
1503446|NCT00005985|stage IV adult Hodgkin lymphoma
1503447|NCT00005985|recurrent adult Hodgkin lymphoma
1503448|NCT00005985|stage I grade 1 follicular lymphoma
1503449|NCT00005985|stage I grade 2 follicular lymphoma
1503450|NCT00005985|stage I grade 3 follicular lymphoma
1503451|NCT00005985|stage I adult diffuse small cleaved cell lymphoma
1503452|NCT00005985|stage I adult diffuse mixed cell lymphoma
1503453|NCT00005985|stage I adult diffuse large cell lymphoma
1503454|NCT00005985|stage I adult immunoblastic large cell lymphoma
1503455|NCT00005985|stage I adult lymphoblastic lymphoma
1503456|NCT00005985|stage I adult Burkitt lymphoma
1503457|NCT00005985|stage III grade 1 follicular lymphoma
1503458|NCT00005985|stage III grade 2 follicular lymphoma
1503459|NCT00005985|stage III grade 3 follicular lymphoma
1503460|NCT00005985|stage III adult diffuse small cleaved cell lymphoma
1503461|NCT00005985|stage III adult diffuse mixed cell lymphoma
1503462|NCT00005985|stage III adult diffuse large cell lymphoma
1503463|NCT00005985|stage III adult immunoblastic large cell lymphoma
1503464|NCT00005985|stage III adult lymphoblastic lymphoma
1503465|NCT00005985|stage III adult Burkitt lymphoma
1503466|NCT00005985|stage IV grade 1 follicular lymphoma
1503467|NCT00005985|stage IV grade 2 follicular lymphoma
1503468|NCT00005985|stage IV grade 3 follicular lymphoma
1503469|NCT00005985|stage IV adult diffuse small cleaved cell lymphoma
1503470|NCT00005985|stage IV adult diffuse mixed cell lymphoma
1503471|NCT00005985|stage IV adult diffuse large cell lymphoma
1503472|NCT00005985|stage IV adult immunoblastic large cell lymphoma
1503473|NCT00005985|stage IV adult lymphoblastic lymphoma
1503474|NCT00005985|stage IV adult Burkitt lymphoma
1503475|NCT00005985|recurrent grade 1 follicular lymphoma
1503476|NCT00005985|recurrent grade 2 follicular lymphoma
1503477|NCT00005985|recurrent grade 3 follicular lymphoma
1503478|NCT00005985|recurrent adult diffuse small cleaved cell lymphoma
1503479|NCT00005985|recurrent adult diffuse mixed cell lymphoma
1503480|NCT00005985|recurrent adult diffuse large cell lymphoma
1503481|NCT00005985|recurrent adult immunoblastic large cell lymphoma
1503482|NCT00005985|recurrent adult lymphoblastic lymphoma
1503483|NCT00005985|recurrent adult Burkitt lymphoma
1503484|NCT00005985|stage I adult T-cell leukemia/lymphoma
1503485|NCT00005985|stage II adult T-cell leukemia/lymphoma
1503486|NCT00005985|stage III adult T-cell leukemia/lymphoma
1503487|NCT00005985|stage IV adult T-cell leukemia/lymphoma
1503488|NCT00005985|recurrent adult T-cell leukemia/lymphoma
1503489|NCT00005985|contiguous stage II grade 1 follicular lymphoma
1503490|NCT00005985|contiguous stage II grade 2 follicular lymphoma
1503491|NCT00005985|contiguous stage II grade 3 follicular lymphoma
1503492|NCT00005985|contiguous stage II adult diffuse small cleaved cell lymphoma
1503493|NCT00005985|contiguous stage II adult diffuse mixed cell lymphoma
1503494|NCT00005985|contiguous stage II adult immunoblastic large cell lymphoma
1503889|NCT00005931|Protein-Tyrosine Kinase
1503495|NCT00005985|contiguous stage II adult diffuse large cell lymphoma
1503496|NCT00005985|contiguous stage II adult Burkitt lymphoma
1503497|NCT00005985|contiguous stage II adult lymphoblastic lymphoma
1503498|NCT00005985|noncontiguous stage II grade 1 follicular lymphoma
1503499|NCT00005985|noncontiguous stage II grade 2 follicular lymphoma
1503500|NCT00005985|noncontiguous stage II grade 3 follicular lymphoma
1503501|NCT00005985|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1503502|NCT00005985|noncontiguous stage II adult diffuse mixed cell lymphoma
1503503|NCT00005985|noncontiguous stage II adult immunoblastic large cell lymphoma
1503504|NCT00005985|noncontiguous stage II adult diffuse large cell lymphoma
1503505|NCT00005985|noncontiguous stage II adult Burkitt lymphoma
1503506|NCT00005985|noncontiguous stage II adult lymphoblastic lymphoma
1503507|NCT00005985|contiguous stage II small lymphocytic lymphoma
1503508|NCT00005985|noncontiguous stage II small lymphocytic lymphoma
1503509|NCT00005985|recurrent small lymphocytic lymphoma
1503510|NCT00005985|stage I small lymphocytic lymphoma
1503511|NCT00005985|stage III small lymphocytic lymphoma
1503512|NCT00005985|stage IV small lymphocytic lymphoma
1503513|NCT00005984|chronic phase myelogenous leukemia
1503514|NCT00005984|accelerated phase myelogenous leukemia
1503515|NCT00005983|stage II breast cancer
1503516|NCT00005981|stage IV colon cancer
1503517|NCT00005981|stage IV rectal cancer
1503518|NCT00005981|recurrent colon cancer
1503519|NCT00005981|recurrent rectal cancer
1503520|NCT00005980|stage IV breast cancer
1503521|NCT00005980|recurrent breast cancer
1503522|NCT00005979|stage III colon cancer
1503523|NCT00005979|adenocarcinoma of the colon
1503524|NCT00005978|localized resectable neuroblastoma
1503525|NCT00005978|regional neuroblastoma
1503526|NCT00005978|disseminated neuroblastoma
1503527|NCT00005978|stage 4S neuroblastoma
1503528|NCT00005978|recurrent neuroblastoma
1503529|NCT00005978|localized unresectable neuroblastoma
1503530|NCT00005977|childhood Burkitt lymphoma
1503531|NCT00005977|L3 childhood acute lymphoblastic leukemia
1503532|NCT00005977|B-cell childhood acute lymphoblastic leukemia
1503533|NCT00005977|L3 adult acute lymphoblastic leukemia
1503534|NCT00005977|B-cell adult acute lymphoblastic leukemia
1503535|NCT00005977|stage III adult Burkitt lymphoma
1503536|NCT00005977|stage IV adult Burkitt lymphoma
1503537|NCT00005977|stage III childhood small noncleaved cell lymphoma
1503538|NCT00005977|stage IV childhood small noncleaved cell lymphoma
1503539|NCT00005976|recurrent adult brain tumor
1503540|NCT00005976|adult glioblastoma
1503541|NCT00005976|adult anaplastic astrocytoma
1503542|NCT00005976|adult anaplastic oligodendroglioma
1503543|NCT00005976|adult mixed glioma
1503544|NCT00005976|adult oligodendroglioma
1503545|NCT00005976|adult giant cell glioblastoma
1503546|NCT00005976|adult gliosarcoma
1503547|NCT00005975|stage I breast cancer
1503548|NCT00005975|stage II breast cancer
1503549|NCT00005975|hot flashes
1503550|NCT00005974|stage III adult soft tissue sarcoma
1503551|NCT00005974|stage IV adult soft tissue sarcoma
1503552|NCT00005972|recurrent small cell lung cancer
1503553|NCT00005971|stage IV melanoma
1503554|NCT00005969|recurrent adult Hodgkin lymphoma
1503555|NCT00005969|recurrent/refractory childhood Hodgkin lymphoma
1503556|NCT00005968|stage IV melanoma
1503557|NCT00005967|stage III adult Hodgkin lymphoma
1503558|NCT00005967|stage IV adult Hodgkin lymphoma
1503559|NCT00005967|recurrent adult Hodgkin lymphoma
1503560|NCT00005967|refractory multiple myeloma
1503561|NCT00005967|stage III multiple myeloma
1503562|NCT00005967|stage III chronic lymphocytic leukemia
1503563|NCT00005967|stage IV chronic lymphocytic leukemia
1503564|NCT00005967|recurrent adult acute myeloid leukemia
1503565|NCT00005967|recurrent adult acute lymphoblastic leukemia
1503566|NCT00005967|relapsing chronic myelogenous leukemia
1503567|NCT00005967|refractory chronic lymphocytic leukemia
1503568|NCT00005967|chronic phase chronic myelogenous leukemia
1503569|NCT00005967|accelerated phase chronic myelogenous leukemia
1503570|NCT00005967|blastic phase chronic myelogenous leukemia
1503571|NCT00005967|refractory anemia with excess blasts
1503572|NCT00005967|refractory anemia with excess blasts in transformation
1503573|NCT00005967|chronic myelomonocytic leukemia
1503574|NCT00005967|stage III grade 1 follicular lymphoma
1503575|NCT00005967|stage III grade 2 follicular lymphoma
1503576|NCT00005967|stage III grade 3 follicular lymphoma
1503577|NCT00005967|stage III adult diffuse small cleaved cell lymphoma
1503578|NCT00005967|stage III adult diffuse mixed cell lymphoma
1503579|NCT00005967|stage III adult diffuse large cell lymphoma
1503580|NCT00005967|stage III adult immunoblastic large cell lymphoma
1503581|NCT00005967|stage III adult lymphoblastic lymphoma
1503582|NCT00005967|stage III adult Burkitt lymphoma
1503583|NCT00005967|stage IV grade 1 follicular lymphoma
1503584|NCT00005967|stage IV grade 2 follicular lymphoma
1503585|NCT00005967|stage IV grade 3 follicular lymphoma
1503586|NCT00005967|stage IV adult diffuse small cleaved cell lymphoma
1503587|NCT00005967|stage IV adult diffuse mixed cell lymphoma
1503588|NCT00005967|stage IV adult diffuse large cell lymphoma
1503589|NCT00005967|stage IV adult immunoblastic large cell lymphoma
1503590|NCT00005967|stage IV adult lymphoblastic lymphoma
1503890|NCT00005928|ACE Inhibitor
1503591|NCT00005967|stage IV adult Burkitt lymphoma
1503592|NCT00005967|recurrent grade 1 follicular lymphoma
1503593|NCT00005967|recurrent grade 2 follicular lymphoma
1503594|NCT00005967|recurrent grade 3 follicular lymphoma
1503595|NCT00005967|recurrent adult diffuse small cleaved cell lymphoma
1503596|NCT00005967|recurrent adult diffuse mixed cell lymphoma
1503597|NCT00005967|recurrent adult diffuse large cell lymphoma
1503598|NCT00005967|recurrent adult immunoblastic large cell lymphoma
1503599|NCT00005967|recurrent adult lymphoblastic lymphoma
1503600|NCT00005967|recurrent adult Burkitt lymphoma
1503601|NCT00005967|previously treated myelodysplastic syndromes
1503696|NCT00005957|stage II breast cancer
1503602|NCT00005967|secondary myelodysplastic syndromes
1503603|NCT00005967|stage III mantle cell lymphoma
1503604|NCT00005967|stage IV mantle cell lymphoma
1503605|NCT00005967|recurrent mantle cell lymphoma
1503606|NCT00005967|polycythemia vera
1503607|NCT00005967|primary myelofibrosis
1503608|NCT00005967|essential thrombocythemia
1503609|NCT00005967|chronic eosinophilic leukemia
1503610|NCT00005967|chronic neutrophilic leukemia
1503611|NCT00005967|recurrent marginal zone lymphoma
1503612|NCT00005967|recurrent small lymphocytic lymphoma
1503613|NCT00005967|stage III small lymphocytic lymphoma
1503614|NCT00005967|stage III marginal zone lymphoma
1503615|NCT00005967|stage IV small lymphocytic lymphoma
1503616|NCT00005967|stage IV marginal zone lymphoma
1503617|NCT00005967|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1503618|NCT00005967|nodal marginal zone B-cell lymphoma
1503619|NCT00005967|splenic marginal zone lymphoma
1503620|NCT00005966|stage III renal cell cancer
1503621|NCT00005966|stage IV renal cell cancer
1503622|NCT00005965|stage III cervical cancer
1503623|NCT00005965|recurrent cervical cancer
1503624|NCT00005965|stage IVB cervical cancer
1503625|NCT00005965|stage IVA cervical cancer
1503626|NCT00005965|cervical squamous cell carcinoma
1503627|NCT00005965|cervical adenocarcinoma
1503628|NCT00005965|cervical adenosquamous cell carcinoma
1503629|NCT00005964|stage III adult diffuse large cell lymphoma
1503630|NCT00005964|stage III adult immunoblastic large cell lymphoma
1503631|NCT00005964|stage III adult lymphoblastic lymphoma
1503632|NCT00005964|stage IV adult diffuse large cell lymphoma
1503633|NCT00005964|stage IV adult immunoblastic large cell lymphoma
1503634|NCT00005964|stage IV adult lymphoblastic lymphoma
1503635|NCT00005964|contiguous stage II adult immunoblastic large cell lymphoma
1503636|NCT00005964|contiguous stage II adult diffuse large cell lymphoma
1503637|NCT00005964|contiguous stage II adult lymphoblastic lymphoma
1503638|NCT00005964|noncontiguous stage II adult immunoblastic large cell lymphoma
1503639|NCT00005964|noncontiguous stage II adult diffuse large cell lymphoma
1503640|NCT00005964|noncontiguous stage II adult lymphoblastic lymphoma
1503641|NCT00005963|stage IV breast cancer
1503642|NCT00005963|recurrent breast cancer
1503643|NCT00005962|recurrent adult acute myeloid leukemia
1503644|NCT00005962|adult acute erythroid leukemia (M6)
1503645|NCT00005962|adult acute myeloblastic leukemia without maturation (M1)
1503646|NCT00005962|adult acute myeloblastic leukemia with maturation (M2)
1503647|NCT00005962|adult acute promyelocytic leukemia (M3)
1503648|NCT00005962|adult acute myelomonocytic leukemia (M4)
1503649|NCT00005962|adult acute monoblastic leukemia (M5a)
1503650|NCT00005962|adult acute megakaryoblastic leukemia (M7)
1503651|NCT00005962|adult acute monocytic leukemia (M5b)
1503652|NCT00005962|adult acute minimally differentiated myeloid leukemia (M0)
1503653|NCT00005961|stage III melanoma
1503654|NCT00005961|stage IV melanoma
1503655|NCT00005961|recurrent melanoma
1503656|NCT00005960|adenocarcinoma of the prostate
1503657|NCT00005960|stage I prostate cancer
1503658|NCT00005960|stage IIB prostate cancer
1503659|NCT00005960|stage IIA prostate cancer
1503660|NCT00005960|stage III prostate cancer
1503661|NCT00005960|stage IV prostate cancer
1503662|NCT00005960|recurrent prostate cancer
1503663|NCT00005960|pain
1503664|NCT00005959|stage III grade 3 follicular lymphoma
1503665|NCT00005959|stage III adult diffuse small cleaved cell lymphoma
1503666|NCT00005959|stage III adult diffuse mixed cell lymphoma
1503667|NCT00005959|stage III adult diffuse large cell lymphoma
1503668|NCT00005959|stage III adult immunoblastic large cell lymphoma
1503669|NCT00005959|stage III adult Burkitt lymphoma
1503670|NCT00005959|stage IV grade 3 follicular lymphoma
1503671|NCT00005959|stage IV adult diffuse small cleaved cell lymphoma
1503672|NCT00005959|stage IV adult diffuse mixed cell lymphoma
1503673|NCT00005959|stage IV adult diffuse large cell lymphoma
1503674|NCT00005959|stage IV adult immunoblastic large cell lymphoma
1503675|NCT00005959|stage IV adult Burkitt lymphoma
1503676|NCT00005959|contiguous stage II grade 3 follicular lymphoma
1503677|NCT00005959|contiguous stage II adult diffuse small cleaved cell lymphoma
1503678|NCT00005959|contiguous stage II adult diffuse mixed cell lymphoma
1503679|NCT00005959|contiguous stage II adult immunoblastic large cell lymphoma
1503680|NCT00005959|contiguous stage II adult diffuse large cell lymphoma
1503681|NCT00005959|contiguous stage II adult Burkitt lymphoma
1503682|NCT00005959|noncontiguous stage II grade 3 follicular lymphoma
1503683|NCT00005959|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1503684|NCT00005959|noncontiguous stage II adult diffuse mixed cell lymphoma
1503685|NCT00005959|noncontiguous stage II adult immunoblastic large cell lymphoma
1503686|NCT00005959|noncontiguous stage II adult diffuse large cell lymphoma
1503687|NCT00005959|noncontiguous stage II adult Burkitt lymphoma
1503688|NCT00005958|stage III bladder cancer
1503689|NCT00005958|recurrent bladder cancer
1503690|NCT00005958|stage IV bladder cancer
1503691|NCT00005958|transitional cell carcinoma of the bladder
1503692|NCT00005958|metastatic transitional cell cancer of the renal pelvis and ureter
1503693|NCT00005958|regional transitional cell cancer of the renal pelvis and ureter
1503694|NCT00005958|recurrent transitional cell cancer of the renal pelvis and ureter
1503697|NCT00005956|stage II breast cancer
1503698|NCT00005956|stage IV breast cancer
1503699|NCT00005956|stage IIIA breast cancer
1503700|NCT00005956|stage II gastric cancer
1503701|NCT00005956|stage III gastric cancer
1503702|NCT00005956|stage IV gastric cancer
1503703|NCT00005956|stage IIIB breast cancer
1503704|NCT00005956|stage III ovarian epithelial cancer
1503705|NCT00005956|stage IV ovarian epithelial cancer
1503706|NCT00005955|childhood infratentorial ependymoma
1503707|NCT00005955|childhood low-grade cerebral astrocytoma
1503708|NCT00005955|childhood supratentorial ependymoma
1503709|NCT00005955|childhood craniopharyngioma
1503710|NCT00005955|localized resectable neuroblastoma
1503711|NCT00005955|regional neuroblastoma
1503712|NCT00005955|disseminated neuroblastoma
1503713|NCT00005955|stage 4S neuroblastoma
1503714|NCT00005955|childhood high-grade cerebral astrocytoma
1503715|NCT00005955|childhood oligodendroglioma
1503716|NCT00005955|childhood choroid plexus tumor
1503717|NCT00005955|childhood grade I meningioma
1503718|NCT00005955|childhood grade II meningioma
1503719|NCT00005955|childhood grade III meningioma
1503720|NCT00005955|untreated childhood supratentorial primitive neuroectodermal tumor
1503721|NCT00005955|untreated childhood cerebellar astrocytoma
1503722|NCT00005955|untreated childhood medulloblastoma
1503723|NCT00005955|untreated childhood visual pathway and hypothalamic glioma
1503724|NCT00005955|newly diagnosed childhood ependymoma
1503725|NCT00005955|childhood central nervous system choriocarcinoma
1503726|NCT00005955|childhood central nervous system embryonal tumor
1503727|NCT00005955|childhood central nervous system mixed germ cell tumor
1503728|NCT00005955|childhood central nervous system teratoma
1503729|NCT00005955|childhood central nervous system yolk sac tumor
1503730|NCT00005954|adult tumors metastatic to brain
1503731|NCT00005952|childhood low-grade cerebral astrocytoma
1503732|NCT00005952|recurrent childhood rhabdomyosarcoma
1503733|NCT00005952|childhood craniopharyngioma
1503734|NCT00005952|disseminated neuroblastoma
1503735|NCT00005952|stage 4S neuroblastoma
1503736|NCT00005952|recurrent neuroblastoma
1503737|NCT00005952|stage IV Wilms tumor
1503738|NCT00005952|stage V Wilms tumor
1503739|NCT00005952|recurrent Wilms tumor and other childhood kidney tumors
1503740|NCT00005952|childhood central nervous system germ cell tumor
1503741|NCT00005952|stage III malignant testicular germ cell tumor
1503742|NCT00005952|recurrent malignant testicular germ cell tumor
1503743|NCT00005952|stage IV nasopharyngeal cancer
1503744|NCT00005952|recurrent nasopharyngeal cancer
1503745|NCT00005952|childhood germ cell tumor
1503746|NCT00005952|metastatic childhood soft tissue sarcoma
1503747|NCT00005952|recurrent childhood soft tissue sarcoma
1503748|NCT00005952|stage IV ovarian germ cell tumor
1503749|NCT00005952|recurrent ovarian germ cell tumor
1503750|NCT00005952|childhood high-grade cerebral astrocytoma
1503751|NCT00005952|childhood oligodendroglioma
1503752|NCT00005952|childhood choroid plexus tumor
1503753|NCT00005952|untreated childhood brain stem glioma
1503754|NCT00005952|recurrent childhood brain stem glioma
1503755|NCT00005952|untreated childhood supratentorial primitive neuroectodermal tumor
1503756|NCT00005952|recurrent childhood supratentorial primitive neuroectodermal tumor
1503757|NCT00005952|untreated childhood cerebellar astrocytoma
1503758|NCT00005952|recurrent childhood cerebellar astrocytoma
1503759|NCT00005952|recurrent childhood cerebral astrocytoma
1503760|NCT00005952|untreated childhood medulloblastoma
1503761|NCT00005952|recurrent childhood medulloblastoma
1503762|NCT00005952|untreated childhood visual pathway and hypothalamic glioma
1503763|NCT00005952|recurrent childhood visual pathway and hypothalamic glioma
1503764|NCT00005952|previously treated childhood rhabdomyosarcoma
1503765|NCT00005952|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1503766|NCT00005952|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1503767|NCT00005952|newly diagnosed childhood ependymoma
1503768|NCT00005952|recurrent childhood ependymoma
1503769|NCT00005951|recurrent adult brain tumor
1503770|NCT00005951|adult glioblastoma
1503771|NCT00005951|adult anaplastic astrocytoma
1503772|NCT00005951|adult anaplastic oligodendroglioma
1503773|NCT00005951|adult mixed glioma
1503774|NCT00005951|adult giant cell glioblastoma
1503775|NCT00005951|adult gliosarcoma
1503776|NCT00005948|relapsing chronic myelogenous leukemia
1503777|NCT00005948|chronic phase chronic myelogenous leukemia
1503778|NCT00005948|accelerated phase chronic myelogenous leukemia
1503779|NCT00005947|adenocarcinoma of the prostate
1503780|NCT00005947|stage IV prostate cancer
1503781|NCT00005947|recurrent prostate cancer
1503782|NCT00005946|recurrent childhood acute lymphoblastic leukemia
1503783|NCT00005946|recurrent adult Hodgkin lymphoma
1503784|NCT00005946|refractory multiple myeloma
1503785|NCT00005946|recurrent childhood lymphoblastic lymphoma
1503786|NCT00005946|recurrent childhood acute myeloid leukemia
1503787|NCT00005946|recurrent adult acute myeloid leukemia
1503788|NCT00005946|recurrent adult acute lymphoblastic leukemia
1503789|NCT00005946|relapsing chronic myelogenous leukemia
1503790|NCT00005946|refractory chronic lymphocytic leukemia
1503791|NCT00005946|chronic phase chronic myelogenous leukemia
1503792|NCT00005946|accelerated phase chronic myelogenous leukemia
1503793|NCT00005946|blastic phase chronic myelogenous leukemia
1503794|NCT00005946|recurrent/refractory childhood Hodgkin lymphoma
1503795|NCT00005946|recurrent grade 1 follicular lymphoma
1503796|NCT00005946|recurrent grade 2 follicular lymphoma
1503797|NCT00005946|recurrent grade 3 follicular lymphoma
1503798|NCT00005946|recurrent adult diffuse small cleaved cell lymphoma
1503799|NCT00005946|recurrent adult diffuse mixed cell lymphoma
1503800|NCT00005946|recurrent adult diffuse large cell lymphoma
1503801|NCT00005946|recurrent adult immunoblastic large cell lymphoma
1503802|NCT00005946|recurrent adult lymphoblastic lymphoma
1503803|NCT00005946|recurrent adult Burkitt lymphoma
1503804|NCT00005946|previously treated myelodysplastic syndromes
1503805|NCT00005946|secondary myelodysplastic syndromes
1503806|NCT00005946|recurrent childhood small noncleaved cell lymphoma
1503807|NCT00005946|recurrent childhood large cell lymphoma
1503808|NCT00005946|recurrent mantle cell lymphoma
1503809|NCT00005946|recurrent marginal zone lymphoma
1503810|NCT00005946|recurrent small lymphocytic lymphoma
1503811|NCT00005946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1503812|NCT00005946|nodal marginal zone B-cell lymphoma
1503813|NCT00005946|splenic marginal zone lymphoma
1503814|NCT00005946|childhood myelodysplastic syndromes
1503815|NCT00005945|untreated childhood acute lymphoblastic leukemia
1503816|NCT00005945|L1 childhood acute lymphoblastic leukemia
1503817|NCT00005945|L2 childhood acute lymphoblastic leukemia
1503818|NCT00005945|L3 childhood acute lymphoblastic leukemia
1503819|NCT00005944|recurrent colon cancer
1503820|NCT00005944|recurrent rectal cancer
1503821|NCT00005944|adenocarcinoma of the colon
1503822|NCT00005944|adenocarcinoma of the rectum
1503823|NCT00005944|liver metastases
1503824|NCT00005944|primary peritoneal cavity cancer
1503825|NCT00005943|stage IV melanoma
1503826|NCT00005943|recurrent melanoma
1503827|NCT00005941|stage III cervical cancer
1503828|NCT00005941|recurrent cervical cancer
1503829|NCT00005941|stage IVB cervical cancer
1503830|NCT00005941|stage IVA cervical cancer
1503831|NCT00005941|stage III vaginal cancer
1503832|NCT00005941|stage IVA vaginal cancer
1503833|NCT00005941|stage IVB vaginal cancer
1503834|NCT00005941|recurrent vaginal cancer
1503835|NCT00005939|stage I prostate cancer
1503836|NCT00005939|stage IIB prostate cancer
1503837|NCT00005939|stage IIA prostate cancer
1503838|NCT00005939|stage III prostate cancer
1503839|NCT00005939|recurrent prostate cancer
1503840|NCT00005938|localized gallbladder cancer
1503841|NCT00005938|unresectable gallbladder cancer
1503842|NCT00005938|recurrent gallbladder cancer
1503843|NCT00005938|localized extrahepatic bile duct cancer
1503844|NCT00005938|unresectable extrahepatic bile duct cancer
1503845|NCT00005938|recurrent extrahepatic bile duct cancer
1503846|NCT00005938|liver and intrahepatic biliary tract cancer
1503847|NCT00005938|cholangiocarcinoma of the gallbladder
1503848|NCT00005938|cholangiocarcinoma of the extrahepatic bile duct
1503849|NCT00005938|adult primary cholangiocellular carcinoma
1503850|NCT00005937|MDS
1503851|NCT00005937|Immunosuppression
1503852|NCT00005937|ATG
1503853|NCT00005937|Cyclosporine
1503854|NCT00005937|Myelodysplastic Syndrome
1503855|NCT00005936|Fulminant Hepatitis
1503856|NCT00005936|Parvovirus
1503857|NCT00005936|Hepatitis
1503858|NCT00005936|Biopsy
1503859|NCT00005936|Control
1503860|NCT00005936|Liver Biopsy
1503861|NCT00005935|Immunosuppression
1503862|NCT00005935|T Cells
1503863|NCT00005935|Autoimmunity
1503864|NCT00005935|Bone Marrow Failure
1503865|NCT00005935|Hematopoiesis
1503866|NCT00005935|Relapsing Aplastic Anemia
1503867|NCT00005934|Fetal Hemoglobin
1503868|NCT00005934|5-Azacytidine
1503869|NCT00005934|Phenylbutyrate
1503870|NCT00005934|Thalassemia
1503871|NCT00005934|Hemoglobin
1503872|NCT00005934|Anemia
1503873|NCT00005934|Blood
1503874|NCT00005934|Thalassemia Major
1503875|NCT00005934|Beta Thalassemia
1503876|NCT00005933|Chronic Disease
1503877|NCT00005933|Pediatric
1503878|NCT00005933|Pulmonary
1503879|NCT00005933|Intelligence
1503880|NCT00005933|Coping
1503881|NCT00005933|Chronic Illness
1503882|NCT00005933|Learning
1503883|NCT00005931|Skin Neoplasms
1503884|NCT00005931|Sarcoma, Kaposi
1503885|NCT00005931|Acquired Immunodeficiency Syndrome
1503886|NCT00005931|Antineoplastic Agents
1503891|NCT00005928|Vascular Inflammation
1503892|NCT00005928|Vascular Compliance
1503893|NCT00005928|Cell Adhesion Molecules
1503894|NCT00005928|Coronary Artery Disease
1503895|NCT00005927|Adrenal Adenoma
1503896|NCT00005927|Adrenal Cancer
1503897|NCT00005927|Macronodular Adrenals
1503898|NCT00005927|Ectopic Receptors
1503899|NCT00005927|Gene Profiling
1503900|NCT00005927|Adrenocortical Carcinoma
1503901|NCT00005927|Cushing Syndrome
1503902|NCT00005927|Virilizing Adrenal Tumor
1503903|NCT00005927|Feminizing Adrenal Tumor
1503904|NCT00005927|Massive Macronodular Adrenocortical Disease
1503905|NCT00005927|Adrenal Gland Tumor
1503906|NCT00005926|Cancer
1503907|NCT00005926|Gemzar
1503908|NCT00005926|Her-2/Neu
1503909|NCT00005926|Pancreatic
1503910|NCT00005926|Radiotherapy
1503911|NCT00005926|Pancreatic Cancer
1503912|NCT00005925|Video-EEG
1503913|NCT00005925|Muscimol
1503914|NCT00005925|Depth Electrode
1503915|NCT00005925|Brain Catheter
1503916|NCT00005925|Pharmacology
1503917|NCT00005925|Epilepsy
1503918|NCT00005925|Infusion
1503919|NCT00005925|Magnetic Resonance Imaging
1503920|NCT00005924|B Cell
1503921|NCT00005924|Epstein-Barr Virus
1503922|NCT00005923|Joint Instability
1503923|NCT00005922|Conditioning
1503924|NCT00005922|Corticosteroid
1503925|NCT00005922|Lesions
1503926|NCT00005922|Pharmacotherapy
1503927|NCT00005922|Placebo effect
1503928|NCT00005922|Psoriasis
1503929|NCT00005922|Psychoneuroimmunology
1503930|NCT00005921|Dose-Response Relationship, Drug
1503931|NCT00005921|Antifungal Agents
1503932|NCT00005921|Candidiasis
1503933|NCT00005921|Esophageal Diseases
1503934|NCT00005921|MK 0991
1503935|NCT00005920|AIDS-Related Opportunistic Infections
1503936|NCT00005920|Dose-Response Relationship, Drug
1503937|NCT00005920|Fluconazole
1503938|NCT00005920|Antifungal Agents
1503939|NCT00005920|Candidiasis, Oral
1503940|NCT00005920|Pharyngeal Diseases
1503941|NCT00005920|MK 0991
1503942|NCT00005919|Pigment Dispersion
1503943|NCT00005919|Ocular Hypertension
1503944|NCT00005919|Glaucoma
1503945|NCT00005919|Pupil Reaction
1503946|NCT00005919|Natural History
1503947|NCT00005919|Pigment Dispersion Syndrome
1503948|NCT00005919|Gene Mutation
1503949|NCT00005918|Drug Therapy, Combination
1503950|NCT00005918|Stavudine
1503951|NCT00005918|Lamivudine
1503952|NCT00005918|RNA, Viral
1503953|NCT00005918|Dosage Forms
1503954|NCT00005918|Reverse Transcriptase Inhibitors
1503955|NCT00005918|Anti-HIV Agents
1503956|NCT00005918|Viral Load
1503957|NCT00005918|efavirenz
1503958|NCT00005917|Albinism
1503959|NCT00005917|Giant Granules
1503960|NCT00005917|Infection
1503961|NCT00005917|Melanosomes
1503962|NCT00005917|Platelet Storage Pool Defect
1503963|NCT00005916|Immunotherapy
1503964|NCT00005916|Radiation
1503965|NCT00005916|Immunology
1503966|NCT00005916|Prostvac
1503967|NCT00005916|Prostate Cancer
1503968|NCT00005915|HIV-1
1503969|NCT00005915|Drug Administration Schedule
1503970|NCT00005915|Drug Resistance, Microbial
1503971|NCT00005915|Disease Progression
1503972|NCT00005915|Genotype
1503973|NCT00005915|Phenotype
1503974|NCT00005915|Drug Resistance, Multiple
1503975|NCT00005915|Anti-HIV Agents
1503976|NCT00005915|Treatment Experienced
1503977|NCT00005914|Depression
1503978|NCT00005914|Depressive Disorder
1503979|NCT00005914|Family
1503980|NCT00005914|Genes
1503981|NCT00005914|Genetic Techniques
1503982|NCT00005914|Genetics
1503983|NCT00005914|Linkage (Genetics)
1503984|NCT00005914|Nuclear Family
1503985|NCT00005914|Recurrence
1503986|NCT00005914|Severity of Illness Index
1503987|NCT00005912|Aspergillosis
1503988|NCT00005912|Candidiasis
1503989|NCT00005912|Fungal Infections
1503990|NCT00005912|Fungemia
1503991|NCT00005912|Prophylactic Antifungal Therapy
1503992|NCT00005912|Pediatric Fungal Infection
1503993|NCT00005911|Magnetic Resonance Imaging
1503994|NCT00005911|Human Eye
1503995|NCT00005911|Lens
1503996|NCT00005911|Normal Volunteers
1503997|NCT00005911|Cataract
1503998|NCT00005911|Human Lens
1503999|NCT00005911|Healthy Volunteer
1504000|NCT00005910|Islet Cell Tumors
1504001|NCT00005910|Surgery
1504002|NCT00005910|Ultrasound
1504003|NCT00005910|Insulin
1504004|NCT00005910|Rapid Assay
1504005|NCT00005910|Arteriogram
1504006|NCT00005910|Pancreas
1504007|NCT00005910|Laparoscopy
1504008|NCT00005910|Insulinoma
1504009|NCT00005910|Localization
1504010|NCT00005910|Hypoglycemia
1504011|NCT00005909|Homogentisic Acid
1504012|NCT00005909|Ochronosis
1504013|NCT00005909|Inborn Error of Metabolism
1504014|NCT00005909|Arthritis
1504015|NCT00005909|Enzyme Defect
1504016|NCT00005909|Alkaptonuria
1504017|NCT00005909|Homogentisic Acid Oxidase
1504018|NCT00005908|cDNA Microarray
1504019|NCT00005908|Stage II and Stage III Breast Cancer
1504020|NCT00005908|Biological Response
1504021|NCT00005908|Molecular Profiling
1504022|NCT00005908|Fine Needle Aspirate
1504023|NCT00005908|Breast Cancer
1504024|NCT00005907|B Cell
1504025|NCT00005907|Reconstitution
1504026|NCT00005907|T Cell
1504027|NCT00005907|Transplant
1504028|NCT00005907|Vaccine
1504029|NCT00005906|Chylous Ascites
1504030|NCT00005906|Chylous Pleural Effusion
1504031|NCT00005906|Inhibitory Effects
1504032|NCT00005906|Lymphangioleiomyoma
1504033|NCT00005906|Somatostatin
1504034|NCT00005906|Lymphangioleiomyomatosis (LAM)
1504035|NCT00005905|Adipocyte - Development
1504036|NCT00005905|Insulin Resistance
1504037|NCT00005905|Dyslipidemia
1504038|NCT00005905|Diabetes Mellitus
1504039|NCT00005905|Non-Alcoholic Steatohepatitis
1504040|NCT00005905|Leptin Replacement
1504041|NCT00005903|Parkinsonism
1504042|NCT00005903|Trophic Factor
1504043|NCT00005903|Neurodegenerative Disorder
1504044|NCT00005903|Progressive Supranuclear Palsy
1504045|NCT00005902|Brain
1504046|NCT00005902|Brainstem
1504047|NCT00005902|Cyst
1504048|NCT00005902|Magnetic Resonance Imaging
1504049|NCT00005902|Spinal Cord
1504050|NCT00005902|von Hippel-Lindau
1504051|NCT00005901|Bisphosphonates
1504052|NCT00005901|Growth Hormone
1504053|NCT00005901|Bone Density
1504054|NCT00005901|Osteogenesis Imperfecta
1504055|NCT00005900|Gaucher's disease
1504056|NCT00005900|I cell disease
1504057|NCT00005900|Niemann-Pick disease
1504058|NCT00005900|Wolman disease
1504059|NCT00005900|adrenoleukodystrophy
1504060|NCT00005900|disease-related problem/condition
1504061|NCT00005900|fucosidosis
1504062|NCT00005900|genetic diseases and dysmorphic syndromes
1504063|NCT00005900|globoid cell leukodystrophy
1504064|NCT00005900|inborn errors of metabolism
1504065|NCT00005900|mannosidosis
1504066|NCT00005900|metachromatic leukodystrophy
1504067|NCT00005900|mucopolysaccharidosis
1504068|NCT00005900|mucopolysaccharidosis I
1504069|NCT00005900|mucopolysaccharidosis VI
1504070|NCT00005900|oncologic disorders
1504071|NCT00005900|pulmonary complications
1504072|NCT00005900|rare disease
1504073|NCT00005900|sphingolipidoses
1504074|NCT00005896|Fanconi's anemia
1504075|NCT00005896|aplastic anemia
1504076|NCT00005896|hematologic disorders
1504077|NCT00005896|rare disease
1504078|NCT00005893|chronic congenital neutropenia
1504079|NCT00005893|chronic neutropenia
1504080|NCT00005893|congenital pure red cell aplasia
1504081|NCT00005893|disease-related problem/condition
1504082|NCT00005893|genetic diseases and dysmorphic syndromes
1504083|NCT00005893|hematologic disorders
1504084|NCT00005893|neutropenia
1504085|NCT00005893|pure red cell aplasia
1504086|NCT00005893|rare disease
1504087|NCT00005893|sickle cell anemia
1504088|NCT00005893|thalassemia major
1504089|NCT00005892|Fanconi's anemia
1504090|NCT00005892|acute leukemia
1504091|NCT00005892|acute lymphocytic leukemia
1504092|NCT00005892|acute myeloid leukemia
1504093|NCT00005892|acute undifferentiated leukemia
1504094|NCT00005892|adult acute lymphoblastic leukemia
1504095|NCT00005892|adult acute lymphoblastic leukemia in remission
1504096|NCT00005892|adult acute myeloid leukemia
1504097|NCT00005892|adult acute myeloid leukemia in remission
1504098|NCT00005892|aplastic anemia
1504099|NCT00005892|childhood acute lymphoblastic leukemia
1504100|NCT00005892|childhood acute lymphoblastic leukemia in remission
1504101|NCT00005892|childhood acute myeloid leukemia
1504102|NCT00005892|childhood acute myeloid leukemia in remission
1504103|NCT00005892|de novo myelodysplastic syndrome
1504104|NCT00005892|hematologic disorders
1504105|NCT00005892|hematopoietic/lymphoid cancer
1504106|NCT00005892|leukemia
1504107|NCT00005892|myelodysplastic syndrome
1504108|NCT00005892|oncologic disorders
1504109|NCT00005892|previously treated myelodysplastic syndrome
1504110|NCT00005892|rare disease
1504111|NCT00005892|secondary myelodysplastic syndrome
1504112|NCT00005891|Fanconi's Anemia
1504113|NCT00005891|aplastic anemia
1504114|NCT00005891|hematologic disorders
1504115|NCT00005891|rare disease
1504116|NCT00005890|immunologic disorders and infectious disorders
1504117|NCT00005890|rare disease
1504118|NCT00005890|sepsis
1504119|NCT00005890|septic shock
1504120|NCT00005889|endocrine disorders
1504121|NCT00005889|hyperglycemia
1504122|NCT00005889|low birth weight
1504123|NCT00005889|neonatal disorders
1504124|NCT00005889|rare disease
1504125|NCT00005888|gastrointestinal disorders
1504126|NCT00005888|immunologic disorders and infectious disorders
1504127|NCT00005888|low birth weight
1504128|NCT00005888|necrotizing enterocolitis
1504129|NCT00005888|neonatal disorders
1504130|NCT00005888|rare disease
1504131|NCT00005888|sepsis
1504132|NCT00005887|tumors metastatic to brain
1504133|NCT00005886|stage I breast cancer
1504134|NCT00005886|stage II breast cancer
1504135|NCT00005886|ductal breast carcinoma in situ
1504136|NCT00005886|breast cancer in situ
1504137|NCT00005884|basal cell carcinoma of the skin
1504138|NCT00005884|squamous cell carcinoma of the skin
1504139|NCT00005883|non-small cell lung cancer
1504140|NCT00005883|small cell lung cancer
1504141|NCT00005881|recurrent childhood acute lymphoblastic leukemia
1504142|NCT00005881|childhood Burkitt lymphoma
1504143|NCT00005881|stage I childhood lymphoblastic lymphoma
1504144|NCT00005881|stage II childhood lymphoblastic lymphoma
1504145|NCT00005881|stage III childhood lymphoblastic lymphoma
1504146|NCT00005881|stage IV childhood lymphoblastic lymphoma
1504147|NCT00005881|recurrent childhood lymphoblastic lymphoma
1505357|NCT00005652|hematologic disorders
1504148|NCT00005881|recurrent childhood acute myeloid leukemia
1504149|NCT00005881|childhood diffuse large cell lymphoma
1504150|NCT00005881|childhood immunoblastic large cell lymphoma
1504151|NCT00005881|unspecified childhood solid tumor, protocol specific
1504152|NCT00005881|childhood acute myeloid leukemia in remission
1504153|NCT00005881|stage II childhood Hodgkin lymphoma
1504154|NCT00005881|stage I childhood Hodgkin lymphoma
1504155|NCT00005881|stage III childhood Hodgkin lymphoma
1504156|NCT00005881|stage IV childhood Hodgkin lymphoma
1504157|NCT00005881|recurrent/refractory childhood Hodgkin lymphoma
1504158|NCT00005881|stage I childhood small noncleaved cell lymphoma
1504159|NCT00005881|stage I childhood large cell lymphoma
1504160|NCT00005881|stage II childhood small noncleaved cell lymphoma
1504161|NCT00005881|stage II childhood large cell lymphoma
1504162|NCT00005881|stage III childhood small noncleaved cell lymphoma
1504163|NCT00005881|stage III childhood large cell lymphoma
1504164|NCT00005881|stage IV childhood small noncleaved cell lymphoma
1504165|NCT00005881|stage IV childhood large cell lymphoma
1504166|NCT00005881|recurrent childhood small noncleaved cell lymphoma
1504167|NCT00005881|recurrent childhood large cell lymphoma
1504168|NCT00005880|non-small cell lung cancer
1504169|NCT00005880|small cell lung cancer
1504170|NCT00005879|breast cancer
1504171|NCT00005878|esophageal cancer
1504172|NCT00005877|stage III colon cancer
1504173|NCT00005877|stage IV colon cancer
1504174|NCT00005877|stage III rectal cancer
1504175|NCT00005877|stage IV rectal cancer
1504176|NCT00005877|recurrent colon cancer
1504177|NCT00005877|recurrent rectal cancer
1504178|NCT00005876|stage III gastric cancer
1504179|NCT00005876|stage IV gastric cancer
1504180|NCT00005876|recurrent gastric cancer
1504181|NCT00005876|stage III esophageal cancer
1504182|NCT00005876|stage IV esophageal cancer
1504183|NCT00005876|recurrent esophageal cancer
1504184|NCT00005876|adenocarcinoma of the stomach
1504185|NCT00005876|adenocarcinoma of the esophagus
1504186|NCT00005875|stage IV melanoma
1504187|NCT00005875|recurrent melanoma
1504188|NCT00005874|adult leiomyosarcoma
1504189|NCT00005874|stage III adult soft tissue sarcoma
1504190|NCT00005874|recurrent adult soft tissue sarcoma
1504191|NCT00005874|small intestine leiomyosarcoma
1504192|NCT00005874|metastatic childhood soft tissue sarcoma
1504193|NCT00005874|recurrent childhood soft tissue sarcoma
1504194|NCT00005874|childhood leiomyosarcoma
1504195|NCT00005874|gastrointestinal stromal tumor
1504196|NCT00005874|stage IV adult soft tissue sarcoma
1504197|NCT00005873|stage IV breast cancer
1504198|NCT00005873|recurrent breast cancer
1504199|NCT00005872|recurrent non-small cell lung cancer
1504200|NCT00005871|recurrent pancreatic cancer
1504201|NCT00005871|adenocarcinoma of the pancreas
1504202|NCT00005870|recurrent pancreatic cancer
1504203|NCT00005870|adenocarcinoma of the pancreas
1504204|NCT00005869|stage II pancreatic cancer
1504205|NCT00005869|stage III pancreatic cancer
1504206|NCT00005869|recurrent pancreatic cancer
1504207|NCT00005869|adenocarcinoma of the pancreas
1504208|NCT00005869|stage IV pancreatic cancer
1504209|NCT00005868|stage IIIA non-small cell lung cancer
1504210|NCT00005867|stage I grade 3 follicular lymphoma
1504211|NCT00005867|stage I adult diffuse mixed cell lymphoma
1504212|NCT00005867|stage I adult diffuse large cell lymphoma
1504213|NCT00005867|stage I adult immunoblastic large cell lymphoma
1504214|NCT00005867|stage III grade 3 follicular lymphoma
1504215|NCT00005867|stage III adult diffuse mixed cell lymphoma
1504216|NCT00005867|stage III adult diffuse large cell lymphoma
1504217|NCT00005867|stage III adult immunoblastic large cell lymphoma
1504218|NCT00005867|stage IV grade 3 follicular lymphoma
1504219|NCT00005867|stage IV adult diffuse mixed cell lymphoma
1504220|NCT00005867|stage IV adult diffuse large cell lymphoma
1504221|NCT00005867|stage IV adult immunoblastic large cell lymphoma
1504222|NCT00005867|contiguous stage II grade 3 follicular lymphoma
1504223|NCT00005867|contiguous stage II adult diffuse mixed cell lymphoma
1504224|NCT00005867|contiguous stage II adult immunoblastic large cell lymphoma
1504225|NCT00005867|contiguous stage II adult diffuse large cell lymphoma
1504226|NCT00005867|noncontiguous stage II grade 3 follicular lymphoma
1504227|NCT00005867|noncontiguous stage II adult diffuse mixed cell lymphoma
1504228|NCT00005867|noncontiguous stage II adult immunoblastic large cell lymphoma
1504229|NCT00005867|noncontiguous stage II adult diffuse large cell lymphoma
1504230|NCT00005866|untreated adult acute myeloid leukemia
1504231|NCT00005866|refractory anemia with excess blasts
1504232|NCT00005866|refractory anemia with excess blasts in transformation
1504233|NCT00005866|chronic myelomonocytic leukemia
1504234|NCT00005866|secondary acute myeloid leukemia
1504235|NCT00005866|de novo myelodysplastic syndromes
1504236|NCT00005866|secondary myelodysplastic syndromes
1504237|NCT00005866|childhood myelodysplastic syndromes
1504238|NCT00005865|stage IIIB non-small cell lung cancer
1504239|NCT00005865|stage IV non-small cell lung cancer
1504240|NCT00005864|stage IV colon cancer
1504241|NCT00005864|stage IV rectal cancer
1504242|NCT00005864|recurrent colon cancer
1504243|NCT00005864|recurrent rectal cancer
1504244|NCT00005863|recurrent childhood acute myeloid leukemia
1504245|NCT00005863|recurrent adult acute myeloid leukemia
1504246|NCT00005863|adult acute myeloid leukemia in remission
1504247|NCT00005863|childhood acute myeloid leukemia in remission
1504248|NCT00005863|adult acute erythroid leukemia (M6)
1504249|NCT00005863|adult acute myeloblastic leukemia without maturation (M1)
1504250|NCT00005863|adult acute myeloblastic leukemia with maturation (M2)
1504251|NCT00005863|adult acute myelomonocytic leukemia (M4)
1504252|NCT00005863|adult acute monoblastic leukemia (M5a)
1504253|NCT00005863|adult acute megakaryoblastic leukemia (M7)
1504254|NCT00005863|childhood acute myeloblastic leukemia without maturation (M1)
1504255|NCT00005863|childhood acute myeloblastic leukemia with maturation (M2)
1504256|NCT00005863|childhood acute myelomonocytic leukemia (M4)
1504257|NCT00005863|childhood acute monoblastic leukemia (M5a)
1504258|NCT00005863|childhood acute monocytic leukemia (M5b)
1504259|NCT00005863|childhood acute erythroleukemia (M6)
1504260|NCT00005863|childhood acute megakaryocytic leukemia (M7)
1504261|NCT00005863|secondary acute myeloid leukemia
1504262|NCT00005863|de novo myelodysplastic syndromes
1504263|NCT00005863|adult acute monocytic leukemia (M5b)
1504264|NCT00005863|previously treated myelodysplastic syndromes
1504265|NCT00005863|secondary myelodysplastic syndromes
1504266|NCT00005863|adult acute minimally differentiated myeloid leukemia (M0)
1504267|NCT00005863|childhood acute minimally differentiated myeloid leukemia (M0)
1504268|NCT00005863|atypical chronic myeloid leukemia, BCR-ABL1 negative
1504269|NCT00005863|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1504270|NCT00005863|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1504271|NCT00005863|adult acute myeloid leukemia with inv(16)(p13;q22)
1504272|NCT00005863|adult acute myeloid leukemia with t(16;16)(p13;q22)
1504273|NCT00005863|adult acute myeloid leukemia with t(8;21)(q22;q22)
1504274|NCT00005863|childhood myelodysplastic syndromes
1504275|NCT00005862|stage III adult soft tissue sarcoma
1504276|NCT00005862|recurrent adult soft tissue sarcoma
1504277|NCT00005862|gastrointestinal stromal tumor
1504278|NCT00005862|stage IV adult soft tissue sarcoma
1504279|NCT00005861|stage III endometrial carcinoma
1504280|NCT00005861|stage IV endometrial carcinoma
1504281|NCT00005861|recurrent endometrial carcinoma
1504282|NCT00005860|stage IV colon cancer
1504283|NCT00005860|stage IV gastric cancer
1504284|NCT00005860|recurrent gastric cancer
1504285|NCT00005860|recurrent pancreatic cancer
1504286|NCT00005860|recurrent colon cancer
1504287|NCT00005860|regional neuroblastoma
1504288|NCT00005860|stage 4S neuroblastoma
1504289|NCT00005860|recurrent neuroblastoma
1504290|NCT00005860|regional gastrointestinal carcinoid tumor
1504291|NCT00005860|metastatic gastrointestinal carcinoid tumor
1504292|NCT00005860|recurrent gastrointestinal carcinoid tumor
1504293|NCT00005860|advanced adult primary liver cancer
1504294|NCT00005860|recurrent adult primary liver cancer
1504295|NCT00005860|gastrinoma
1504296|NCT00005860|small intestine adenocarcinoma
1504297|NCT00005860|small intestine lymphoma
1504298|NCT00005860|small intestine leiomyosarcoma
1504299|NCT00005860|unresectable gallbladder cancer
1504300|NCT00005860|recurrent gallbladder cancer
1504301|NCT00005860|unresectable extrahepatic bile duct cancer
1504302|NCT00005860|recurrent extrahepatic bile duct cancer
1504303|NCT00005860|recurrent small intestine cancer
1504304|NCT00005860|insulinoma
1504305|NCT00005860|recurrent islet cell carcinoma
1504306|NCT00005860|WDHA syndrome
1504307|NCT00005860|somatostatinoma
1504308|NCT00005860|pancreatic polypeptide tumor
1504309|NCT00005860|glucagonoma
1504310|NCT00005860|regional pheochromocytoma
1504311|NCT00005860|metastatic pheochromocytoma
1504312|NCT00005860|recurrent pheochromocytoma
1504313|NCT00005860|extragonadal germ cell tumor
1504314|NCT00005860|liver metastases
1504315|NCT00005860|malignant ascites
1504316|NCT00005860|newly diagnosed carcinoma of unknown primary
1504317|NCT00005860|carcinoma of the appendix
1504318|NCT00005860|pseudomyxoma peritonei
1504319|NCT00005860|fallopian tube cancer
1504320|NCT00005860|primary peritoneal cavity cancer
1504321|NCT00005860|recurrent carcinoma of unknown primary
1504322|NCT00005860|gastrointestinal stromal tumor
1504323|NCT00005860|stage IV pancreatic cancer
1504324|NCT00005859|recurrent adult brain tumor
1504325|NCT00005859|adult glioblastoma
1504326|NCT00005859|adult giant cell glioblastoma
1504327|NCT00005859|adult gliosarcoma
1504328|NCT00005858|stage III colon cancer
1504329|NCT00005858|stage IV colon cancer
1504330|NCT00005858|stage IV breast cancer
1504331|NCT00005858|stage IIIA breast cancer
1504332|NCT00005858|recurrent breast cancer
1504333|NCT00005858|stage IIIB breast cancer
1504334|NCT00005858|recurrent non-small cell lung cancer
1504335|NCT00005858|stage II pancreatic cancer
1504336|NCT00005858|stage III pancreatic cancer
1504337|NCT00005858|recurrent pancreatic cancer
1504338|NCT00005858|recurrent colon cancer
1504339|NCT00005858|stage III ovarian epithelial cancer
1504340|NCT00005858|stage IV ovarian epithelial cancer
1504341|NCT00005858|recurrent ovarian epithelial cancer
1504342|NCT00005858|stage III bladder cancer
1504343|NCT00005858|recurrent bladder cancer
1504344|NCT00005858|stage IV bladder cancer
1504345|NCT00005858|stage IIIA non-small cell lung cancer
1504346|NCT00005858|stage IIIB non-small cell lung cancer
1504347|NCT00005858|stage IV non-small cell lung cancer
1504348|NCT00005858|ovarian stromal cancer
1504349|NCT00005858|stage III ovarian germ cell tumor
1504350|NCT00005858|stage IV ovarian germ cell tumor
1504351|NCT00005858|recurrent ovarian germ cell tumor
1504352|NCT00005858|borderline ovarian surface epithelial-stromal tumor
1504353|NCT00005858|ovarian sarcoma
1504354|NCT00005858|male breast cancer
1504355|NCT00005858|stage IV pancreatic cancer
1504356|NCT00005857|stage IV prostate cancer
1504357|NCT00005857|recurrent prostate cancer
1504358|NCT00005855|adult glioblastoma
1504359|NCT00005855|adult anaplastic astrocytoma
1504360|NCT00005855|adult anaplastic oligodendroglioma
1504361|NCT00005855|recurrent adult brain tumor
1504362|NCT00005855|adult giant cell glioblastoma
1504363|NCT00005855|adult gliosarcoma
1504364|NCT00005854|recurrent childhood acute lymphoblastic leukemia
1504365|NCT00005854|refractory multiple myeloma
1504366|NCT00005854|stage I multiple myeloma
1504367|NCT00005854|stage II multiple myeloma
1504368|NCT00005854|stage III multiple myeloma
1504369|NCT00005854|recurrent childhood lymphoblastic lymphoma
1504370|NCT00005854|stage III chronic lymphocytic leukemia
1504371|NCT00005854|stage IV chronic lymphocytic leukemia
1504372|NCT00005854|recurrent childhood acute myeloid leukemia
1504373|NCT00005854|recurrent adult acute myeloid leukemia
1504374|NCT00005854|recurrent adult acute lymphoblastic leukemia
1504375|NCT00005854|relapsing chronic myelogenous leukemia
1504376|NCT00005854|refractory chronic lymphocytic leukemia
1504377|NCT00005854|accelerated phase chronic myelogenous leukemia
1504378|NCT00005854|blastic phase chronic myelogenous leukemia
1504379|NCT00005854|meningeal chronic myelogenous leukemia
1504380|NCT00005854|adult acute myeloid leukemia in remission
1504381|NCT00005854|adult acute lymphoblastic leukemia in remission
1504382|NCT00005854|childhood acute myeloid leukemia in remission
1504383|NCT00005854|childhood acute lymphoblastic leukemia in remission
1504384|NCT00005854|recurrent grade 1 follicular lymphoma
1504385|NCT00005854|recurrent grade 2 follicular lymphoma
1504386|NCT00005854|recurrent grade 3 follicular lymphoma
1504387|NCT00005854|recurrent adult diffuse small cleaved cell lymphoma
1504388|NCT00005854|recurrent adult diffuse mixed cell lymphoma
1504389|NCT00005854|recurrent adult diffuse large cell lymphoma
1504390|NCT00005854|recurrent adult immunoblastic large cell lymphoma
1504391|NCT00005854|recurrent adult lymphoblastic lymphoma
1504392|NCT00005854|recurrent adult Burkitt lymphoma
1504393|NCT00005854|secondary acute myeloid leukemia
1504394|NCT00005854|de novo myelodysplastic syndromes
1504395|NCT00005854|previously treated myelodysplastic syndromes
1504396|NCT00005854|secondary myelodysplastic syndromes
1504397|NCT00005854|recurrent childhood small noncleaved cell lymphoma
1504398|NCT00005854|recurrent childhood large cell lymphoma
1504399|NCT00005854|recurrent mantle cell lymphoma
1504400|NCT00005854|recurrent marginal zone lymphoma
1504401|NCT00005854|recurrent small lymphocytic lymphoma
1504402|NCT00005854|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1504403|NCT00005854|nodal marginal zone B-cell lymphoma
1504404|NCT00005854|splenic marginal zone lymphoma
1504405|NCT00005854|childhood myelodysplastic syndromes
1504406|NCT00005853|refractory anemia
1504407|NCT00005853|refractory anemia with ringed sideroblasts
1504408|NCT00005853|refractory anemia with excess blasts
1504409|NCT00005853|refractory anemia with excess blasts in transformation
1504410|NCT00005853|de novo myelodysplastic syndromes
1504411|NCT00005853|previously treated myelodysplastic syndromes
1504412|NCT00005853|secondary myelodysplastic syndromes
1504413|NCT00005853|refractory cytopenia with multilineage dysplasia
1504414|NCT00005853|childhood myelodysplastic syndromes
1504415|NCT00005852|recurrent childhood acute lymphoblastic leukemia
1504416|NCT00005852|recurrent adult Hodgkin lymphoma
1504417|NCT00005852|recurrent cutaneous T-cell non-Hodgkin lymphoma
1504418|NCT00005852|refractory multiple myeloma
1504419|NCT00005852|stage I multiple myeloma
1504420|NCT00005852|stage II multiple myeloma
1504421|NCT00005852|stage III multiple myeloma
1504422|NCT00005852|recurrent childhood lymphoblastic lymphoma
1504423|NCT00005852|recurrent childhood acute myeloid leukemia
1504424|NCT00005852|recurrent adult acute myeloid leukemia
1504425|NCT00005852|recurrent adult acute lymphoblastic leukemia
1504426|NCT00005852|relapsing chronic myelogenous leukemia
1504427|NCT00005852|refractory chronic lymphocytic leukemia
1504428|NCT00005852|primary myelofibrosis
1504429|NCT00005852|childhood acute promyelocytic leukemia (M3)
1504430|NCT00005852|refractory hairy cell leukemia
1504431|NCT00005852|recurrent/refractory childhood Hodgkin lymphoma
1504432|NCT00005852|recurrent grade 1 follicular lymphoma
1504433|NCT00005852|recurrent grade 2 follicular lymphoma
1504434|NCT00005852|recurrent grade 3 follicular lymphoma
1504435|NCT00005852|recurrent adult diffuse small cleaved cell lymphoma
1504436|NCT00005852|recurrent adult diffuse mixed cell lymphoma
1504437|NCT00005852|recurrent adult diffuse large cell lymphoma
1504438|NCT00005852|recurrent adult immunoblastic large cell lymphoma
1504439|NCT00005852|recurrent adult lymphoblastic lymphoma
1504440|NCT00005852|recurrent adult Burkitt lymphoma
1504441|NCT00005852|previously treated myelodysplastic syndromes
1504442|NCT00005852|secondary myelodysplastic syndromes
1504443|NCT00005852|graft versus host disease
1504444|NCT00005852|recurrent childhood small noncleaved cell lymphoma
1504445|NCT00005852|recurrent childhood large cell lymphoma
1504446|NCT00005852|recurrent mantle cell lymphoma
1504447|NCT00005852|recurrent marginal zone lymphoma
1504448|NCT00005852|recurrent small lymphocytic lymphoma
1504449|NCT00005852|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1504450|NCT00005852|nodal marginal zone B-cell lymphoma
1504451|NCT00005852|splenic marginal zone lymphoma
1504452|NCT00005852|childhood myelodysplastic syndromes
1504453|NCT00005850|stage I non-small cell lung cancer
1504454|NCT00005850|stage II non-small cell lung cancer
1504455|NCT00005850|recurrent non-small cell lung cancer
1504456|NCT00005850|squamous cell lung cancer
1504457|NCT00005850|large cell lung cancer
1504458|NCT00005850|stage IIIA non-small cell lung cancer
1504459|NCT00005850|stage IIIB non-small cell lung cancer
1504460|NCT00005850|stage IV non-small cell lung cancer
1504461|NCT00005850|adenocarcinoma of the lung
1504462|NCT00005850|adenosquamous cell lung cancer
1504463|NCT00005850|fatigue
1504464|NCT00005850|anxiety disorder
1504465|NCT00005850|depression
1504466|NCT00005849|recurrent non-small cell lung cancer
1504467|NCT00005849|stage IIIB non-small cell lung cancer
1504468|NCT00005849|stage IV non-small cell lung cancer
1504469|NCT00005848|adenocarcinoma of the prostate
1504470|NCT00005848|stage IV prostate cancer
1504471|NCT00005848|recurrent prostate cancer
1504472|NCT00005847|adenocarcinoma of the prostate
1504473|NCT00005847|stage IV prostate cancer
1504474|NCT00005847|recurrent prostate cancer
1504475|NCT00005846|relapsing chronic myelogenous leukemia
1504476|NCT00005846|chronic phase chronic myelogenous leukemia
1504477|NCT00005846|accelerated phase chronic myelogenous leukemia
1504478|NCT00005846|chronic myelogenous leukemia, BCR-ABL1 positive
1504479|NCT00005846|Philadelphia chromosome negative chronic myelogenous leukemia
1504480|NCT00005846|chronic myelomonocytic leukemia
1504481|NCT00005846|atypical chronic myeloid leukemia, BCR-ABL1 negative
1504482|NCT00005846|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1504483|NCT00005844|unspecified childhood solid tumor, protocol specific
1504484|NCT00005843|recurrent pancreatic cancer
1504485|NCT00005843|adenocarcinoma of the pancreas
1504486|NCT00005843|stage IV pancreatic cancer
1504487|NCT00005842|stage III colon cancer
1504488|NCT00005842|stage IV colon cancer
1504489|NCT00005842|stage IV breast cancer
1504490|NCT00005842|stage IIIA breast cancer
1504491|NCT00005842|recurrent breast cancer
1504492|NCT00005842|stage III gastric cancer
1504493|NCT00005842|stage IV gastric cancer
1504494|NCT00005842|recurrent gastric cancer
1504495|NCT00005842|occult non-small cell lung cancer
1504496|NCT00005842|stage IIIB breast cancer
1504497|NCT00005842|recurrent non-small cell lung cancer
1504498|NCT00005842|stage III pancreatic cancer
1504499|NCT00005842|recurrent pancreatic cancer
1504500|NCT00005842|stage III rectal cancer
1504501|NCT00005842|stage IV rectal cancer
1504502|NCT00005842|recurrent colon cancer
1504503|NCT00005842|recurrent rectal cancer
1504504|NCT00005842|stage IV anal cancer
1504505|NCT00005842|recurrent anal cancer
1504506|NCT00005842|stage III esophageal cancer
1504507|NCT00005842|stage IV esophageal cancer
1504508|NCT00005842|stage IIIA anal cancer
1504509|NCT00005842|stage IIIB anal cancer
1504510|NCT00005842|recurrent esophageal cancer
1504511|NCT00005842|stage III cervical cancer
1504512|NCT00005842|recurrent cervical cancer
1504513|NCT00005842|stage IVB cervical cancer
1504514|NCT00005842|stage IVA cervical cancer
1504515|NCT00005842|inflammatory breast cancer
1504516|NCT00005842|stage III renal cell cancer
1504517|NCT00005842|stage IV renal cell cancer
1504518|NCT00005842|recurrent renal cell cancer
1504519|NCT00005842|metastatic parathyroid cancer
1504520|NCT00005842|recurrent parathyroid cancer
1504521|NCT00005842|stage III vulvar cancer
1504522|NCT00005842|stage IVB vulvar cancer
1504523|NCT00005842|recurrent vulvar cancer
1504524|NCT00005842|stage III vaginal cancer
1504525|NCT00005842|stage IVA vaginal cancer
1504526|NCT00005842|stage IVB vaginal cancer
1504527|NCT00005842|recurrent vaginal cancer
1504528|NCT00005842|metastatic gastrointestinal carcinoid tumor
1504529|NCT00005842|recurrent gastrointestinal carcinoid tumor
1504530|NCT00005842|localized unresectable adult primary liver cancer
1504531|NCT00005842|advanced adult primary liver cancer
1504532|NCT00005842|recurrent adult primary liver cancer
1504533|NCT00005842|gastrinoma
1504534|NCT00005842|stage III endometrial carcinoma
1504535|NCT00005842|stage IV endometrial carcinoma
1504536|NCT00005842|recurrent endometrial carcinoma
1504537|NCT00005842|small intestine adenocarcinoma
1504538|NCT00005842|unresectable gallbladder cancer
1504539|NCT00005842|recurrent gallbladder cancer
1504540|NCT00005842|unresectable extrahepatic bile duct cancer
1504541|NCT00005842|recurrent extrahepatic bile duct cancer
1504542|NCT00005842|recurrent small intestine cancer
1504543|NCT00005842|stage III adrenocortical carcinoma
1504544|NCT00005842|stage IV adrenocortical carcinoma
1504545|NCT00005842|recurrent adrenocortical carcinoma
1504546|NCT00005842|stage III bladder cancer
1504547|NCT00005842|recurrent bladder cancer
1504548|NCT00005842|stage IV bladder cancer
1504549|NCT00005842|stage III malignant testicular germ cell tumor
1504550|NCT00005842|stage III prostate cancer
1504551|NCT00005842|stage IV prostate cancer
1504552|NCT00005842|recurrent prostate cancer
1504553|NCT00005842|recurrent malignant testicular germ cell tumor
1504554|NCT00005842|insulinoma
1504555|NCT00005842|recurrent islet cell carcinoma
1504556|NCT00005842|stage IV papillary thyroid cancer
1504557|NCT00005842|stage IV follicular thyroid cancer
1504558|NCT00005842|thyroid gland medullary carcinoma
1504559|NCT00005842|anaplastic thyroid cancer
1504560|NCT00005842|recurrent thyroid cancer
1504561|NCT00005842|stage IIIA non-small cell lung cancer
1504562|NCT00005842|stage IIIB non-small cell lung cancer
1504563|NCT00005842|stage IV non-small cell lung cancer
1504564|NCT00005842|stage III salivary gland cancer
1504565|NCT00005842|stage IV salivary gland cancer
1504566|NCT00005842|recurrent salivary gland cancer
1504567|NCT00005842|WDHA syndrome
1504568|NCT00005842|somatostatinoma
1504569|NCT00005842|pancreatic polypeptide tumor
1504570|NCT00005842|glucagonoma
1504571|NCT00005842|stage III follicular thyroid cancer
1504572|NCT00005842|stage III papillary thyroid cancer
1504573|NCT00005842|recurrent urethral cancer
1504574|NCT00005842|distal urethral cancer
1504575|NCT00005842|proximal urethral cancer
1504576|NCT00005842|urethral cancer associated with invasive bladder cancer
1504577|NCT00005842|metastatic transitional cell cancer of the renal pelvis and ureter
1504578|NCT00005842|pulmonary carcinoid tumor
1504579|NCT00005842|stage III mucoepidermoid carcinoma of the oral cavity
1504580|NCT00005842|stage III adenoid cystic carcinoma of the oral cavity
1504581|NCT00005842|stage IV mucoepidermoid carcinoma of the oral cavity
1504582|NCT00005842|stage IV adenoid cystic carcinoma of the oral cavity
1504583|NCT00005842|recurrent mucoepidermoid carcinoma of the oral cavity
1504584|NCT00005842|recurrent adenoid cystic carcinoma of the oral cavity
1504585|NCT00005842|tumors metastatic to brain
1504586|NCT00005842|lung metastases
1504587|NCT00005842|liver metastases
1504588|NCT00005842|bone metastases
1504589|NCT00005842|skin metastases
1504590|NCT00005842|leptomeningeal metastases
1504591|NCT00005842|malignant pericardial effusion
1504592|NCT00005842|malignant pleural effusion
1504593|NCT00005842|newly diagnosed carcinoma of unknown primary
1504594|NCT00005842|recurrent transitional cell cancer of the renal pelvis and ureter
1504595|NCT00005842|carcinoma of the appendix
1504596|NCT00005842|primary peritoneal cavity cancer
1504597|NCT00005842|recurrent carcinoma of unknown primary
1504598|NCT00005842|male breast cancer
1504599|NCT00005842|stage IV pancreatic cancer
1504600|NCT00005841|iris melanoma
1504601|NCT00005841|ciliary body and choroid melanoma, small size
1504602|NCT00005841|ciliary body and choroid melanoma, medium/large size
1504603|NCT00005841|extraocular extension melanoma
1504604|NCT00005841|recurrent intraocular melanoma
1504605|NCT00005841|stage III melanoma
1504606|NCT00005841|stage IV melanoma
1504607|NCT00005841|recurrent melanoma
1504608|NCT00005839|unspecified adult solid tumor, protocol specific
1504609|NCT00005837|recurrent cervical cancer
1504610|NCT00005837|cervical squamous cell carcinoma
1504611|NCT00005836|recurrent ovarian epithelial cancer
1504612|NCT00005836|primary peritoneal cavity cancer
1504613|NCT00005835|regional neuroblastoma
1504614|NCT00005835|disseminated neuroblastoma
1504615|NCT00005835|recurrent neuroblastoma
1504616|NCT00005835|localized unresectable neuroblastoma
1504617|NCT00005834|refractory multiple myeloma
1504618|NCT00005834|stage I multiple myeloma
1504619|NCT00005834|stage II multiple myeloma
1504620|NCT00005834|stage III multiple myeloma
1504621|NCT00005833|stage IV colon cancer
1504622|NCT00005833|stage IV rectal cancer
1504623|NCT00005833|recurrent colon cancer
1504624|NCT00005833|recurrent rectal cancer
1504625|NCT00005833|adenocarcinoma of the colon
1504626|NCT00005833|adenocarcinoma of the rectum
1504627|NCT00005832|stage II pancreatic cancer
1504628|NCT00005832|stage III pancreatic cancer
1504629|NCT00005832|duct cell adenocarcinoma of the pancreas
1504630|NCT00005832|adenocarcinoma of the pancreas
1504631|NCT00005832|stage IV pancreatic cancer
1504632|NCT00005829|refractory chronic lymphocytic leukemia
1504633|NCT00005829|B-cell chronic lymphocytic leukemia
1504634|NCT00005828|stage IV prostate cancer
1504635|NCT00005828|recurrent prostate cancer
1504636|NCT00005827|adenocarcinoma of the prostate
1504637|NCT00005827|stage II prostate cancer
1504638|NCT00005827|stage III prostate cancer
1504639|NCT00005827|stage IV prostate cancer
1504640|NCT00005827|recurrent prostate cancer
1504641|NCT00005826|adult glioblastoma
1504642|NCT00005826|adult giant cell glioblastoma
1504643|NCT00005826|adult gliosarcoma
1504644|NCT00005825|stage IIIB non-small cell lung cancer
1504645|NCT00005825|stage IV non-small cell lung cancer
1504646|NCT00005824|AIDS-related peripheral/systemic lymphoma
1504647|NCT00005824|AIDS-related diffuse large cell lymphoma
1504648|NCT00005824|AIDS-related immunoblastic large cell lymphoma
1504649|NCT00005824|AIDS-related small noncleaved cell lymphoma
1504650|NCT00005824|HIV-associated Hodgkin lymphoma
1504651|NCT00005824|AIDS-related diffuse mixed cell lymphoma
1504652|NCT00005824|AIDS-related diffuse small cleaved cell lymphoma
1504653|NCT00005824|AIDS-related lymphoblastic lymphoma
1504654|NCT00005823|untreated adult acute myeloid leukemia
1504655|NCT00005823|adult acute erythroid leukemia (M6)
1504656|NCT00005823|adult acute myeloblastic leukemia without maturation (M1)
1504657|NCT00005823|adult acute myeloblastic leukemia with maturation (M2)
1504658|NCT00005823|adult acute myelomonocytic leukemia (M4)
1504659|NCT00005823|adult acute monoblastic leukemia (M5a)
1504660|NCT00005823|adult acute megakaryoblastic leukemia (M7)
1504661|NCT00005823|refractory anemia with excess blasts
1504662|NCT00005823|refractory anemia with excess blasts in transformation
1504663|NCT00005823|chronic myelomonocytic leukemia
1504664|NCT00005823|secondary acute myeloid leukemia
1504665|NCT00005823|de novo myelodysplastic syndromes
1504666|NCT00005823|adult acute monocytic leukemia (M5b)
1504667|NCT00005823|secondary myelodysplastic syndromes
1504668|NCT00005823|adult acute minimally differentiated myeloid leukemia (M0)
1504669|NCT00005823|atypical chronic myeloid leukemia, BCR-ABL1 negative
1504670|NCT00005823|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1504671|NCT00005823|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1504672|NCT00005823|adult acute myeloid leukemia with inv(16)(p13;q22)
1504673|NCT00005823|adult acute myeloid leukemia with t(16;16)(p13;q22)
1504674|NCT00005823|adult acute myeloid leukemia with t(8;21)(q22;q22)
1504675|NCT00005822|stage IV breast cancer
1504676|NCT00005822|recurrent breast cancer
1504677|NCT00005822|stage IIIB breast cancer
1504678|NCT00005822|inflammatory breast cancer
1504679|NCT00005822|male breast cancer
1504680|NCT00005821|stage I breast cancer
1504681|NCT00005821|stage II breast cancer
1504682|NCT00005820|adenocarcinoma of the prostate
1504683|NCT00005820|stage IV prostate cancer
1504684|NCT00005820|recurrent prostate cancer
1504685|NCT00005819|unspecified adult solid tumor, protocol specific
1504686|NCT00005816|stage III renal cell cancer
1504687|NCT00005816|stage IV renal cell cancer
1504688|NCT00005815|iris melanoma
1504689|NCT00005815|ciliary body and choroid melanoma, small size
1504690|NCT00005815|ciliary body and choroid melanoma, medium/large size
1504691|NCT00005815|extraocular extension melanoma
1504692|NCT00005815|recurrent intraocular melanoma
1504693|NCT00005815|stage III melanoma
1504694|NCT00005815|stage IV melanoma
1504695|NCT00005815|recurrent melanoma
1504696|NCT00005814|stage III squamous cell carcinoma of the lip and oral cavity
1504697|NCT00005814|stage IV squamous cell carcinoma of the lip and oral cavity
1504698|NCT00005814|recurrent squamous cell carcinoma of the lip and oral cavity
1504699|NCT00005814|stage III squamous cell carcinoma of the oropharynx
1504700|NCT00005814|stage IV squamous cell carcinoma of the oropharynx
1504701|NCT00005814|recurrent squamous cell carcinoma of the oropharynx
1504702|NCT00005814|stage III squamous cell carcinoma of the hypopharynx
1504703|NCT00005814|stage IV squamous cell carcinoma of the hypopharynx
1504704|NCT00005814|recurrent squamous cell carcinoma of the hypopharynx
1504705|NCT00005814|stage III squamous cell carcinoma of the larynx
1504706|NCT00005814|stage IV squamous cell carcinoma of the larynx
1504707|NCT00005814|recurrent squamous cell carcinoma of the larynx
1504708|NCT00005814|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1504709|NCT00005814|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1504710|NCT00005814|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1504711|NCT00005813|adult glioblastoma
1504712|NCT00005813|adult giant cell glioblastoma
1504713|NCT00005813|adult gliosarcoma
1504714|NCT00005812|leptomeningeal metastases
1504715|NCT00005812|temozolomide
1504716|NCT00005810|adenocarcinoma of the prostate
1504717|NCT00005810|stage IV prostate cancer
1504718|NCT00005810|recurrent prostate cancer
1504719|NCT00005809|colon cancer
1504720|NCT00005809|rectal cancer
1504721|NCT00005807|stage IV breast cancer
1504722|NCT00005807|stage IIIA breast cancer
1504723|NCT00005807|recurrent breast cancer
1504724|NCT00005807|stage IIIB breast cancer
1504725|NCT00005807|stage III ovarian epithelial cancer
1504726|NCT00005807|stage IV ovarian epithelial cancer
1504727|NCT00005807|recurrent ovarian epithelial cancer
1504728|NCT00005807|unspecified adult solid tumor, protocol specific
1504729|NCT00005807|ovarian stromal cancer
1504730|NCT00005807|stage III ovarian germ cell tumor
1504731|NCT00005807|stage IV ovarian germ cell tumor
1504732|NCT00005807|recurrent ovarian germ cell tumor
1504733|NCT00005807|borderline ovarian surface epithelial-stromal tumor
1504734|NCT00005807|ovarian sarcoma
1504735|NCT00005807|male breast cancer
1504736|NCT00005806|recurrent non-small cell lung cancer
1504737|NCT00005806|stage IIIA non-small cell lung cancer
1504738|NCT00005806|stage IIIB non-small cell lung cancer
1504739|NCT00005806|stage IV non-small cell lung cancer
1504740|NCT00005805|stage I adult Hodgkin lymphoma
1504741|NCT00005805|stage II adult Hodgkin lymphoma
1504742|NCT00005805|stage III adult Hodgkin lymphoma
1504743|NCT00005805|stage IV adult Hodgkin lymphoma
1504744|NCT00005805|monoclonal gammopathy of undetermined significance
1504745|NCT00005805|recurrent adult Hodgkin lymphoma
1504746|NCT00005805|stage I cutaneous T-cell non-Hodgkin lymphoma
1504747|NCT00005805|stage II cutaneous T-cell non-Hodgkin lymphoma
1504748|NCT00005805|stage III cutaneous T-cell non-Hodgkin lymphoma
1504749|NCT00005805|stage IV cutaneous T-cell non-Hodgkin lymphoma
1504750|NCT00005805|recurrent cutaneous T-cell non-Hodgkin lymphoma
1504751|NCT00005805|childhood Burkitt lymphoma
1504752|NCT00005805|isolated plasmacytoma of bone
1504753|NCT00005805|extramedullary plasmacytoma
1504754|NCT00005805|refractory multiple myeloma
1504755|NCT00005805|stage 0 chronic lymphocytic leukemia
1504756|NCT00005805|Waldenström macroglobulinemia
1504757|NCT00005805|stage I multiple myeloma
1504758|NCT00005805|stage II multiple myeloma
1504759|NCT00005805|stage III multiple myeloma
1504760|NCT00005805|stage I chronic lymphocytic leukemia
1504761|NCT00005805|stage II chronic lymphocytic leukemia
1504762|NCT00005805|stage III chronic lymphocytic leukemia
1504763|NCT00005805|stage IV chronic lymphocytic leukemia
1504764|NCT00005805|recurrent childhood acute myeloid leukemia
1504765|NCT00005805|recurrent adult acute myeloid leukemia
1504766|NCT00005805|recurrent adult acute lymphoblastic leukemia
1504767|NCT00005805|relapsing chronic myelogenous leukemia
1504768|NCT00005805|refractory chronic lymphocytic leukemia
1504769|NCT00005805|unspecified adult solid tumor, protocol specific
1504770|NCT00005805|chronic phase chronic myelogenous leukemia
1504771|NCT00005805|accelerated phase chronic myelogenous leukemia
1504772|NCT00005805|blastic phase chronic myelogenous leukemia
1504773|NCT00005805|meningeal chronic myelogenous leukemia
1504774|NCT00005805|untreated adult acute lymphoblastic leukemia
1504775|NCT00005805|untreated adult acute myeloid leukemia
1504776|NCT00005805|untreated childhood acute myeloid leukemia and other myeloid malignancies
1504777|NCT00005805|adult acute lymphoblastic leukemia in remission
1504778|NCT00005805|childhood acute myeloid leukemia in remission
1504779|NCT00005805|polycythemia vera
1504780|NCT00005805|primary myelofibrosis
1504781|NCT00005805|essential thrombocythemia
1504782|NCT00005805|untreated hairy cell leukemia
1504783|NCT00005805|progressive hairy cell leukemia, initial treatment
1504784|NCT00005805|refractory hairy cell leukemia
1504785|NCT00005805|stage II childhood Hodgkin lymphoma
1504786|NCT00005805|stage I childhood Hodgkin lymphoma
1504787|NCT00005805|stage III childhood Hodgkin lymphoma
1504788|NCT00005805|stage IV childhood Hodgkin lymphoma
1504789|NCT00005805|recurrent/refractory childhood Hodgkin lymphoma
1504790|NCT00005805|stage I small lymphocytic lymphoma
1504791|NCT00005805|stage I grade 1 follicular lymphoma
1504792|NCT00005805|stage I grade 2 follicular lymphoma
1504793|NCT00005805|stage I grade 3 follicular lymphoma
1504794|NCT00005805|stage I adult diffuse small cleaved cell lymphoma
1504795|NCT00005805|stage I adult diffuse mixed cell lymphoma
1504796|NCT00005805|stage I adult diffuse large cell lymphoma
1504797|NCT00005805|stage I adult immunoblastic large cell lymphoma
1504798|NCT00005805|stage I adult lymphoblastic lymphoma
1504799|NCT00005805|stage I adult Burkitt lymphoma
1504800|NCT00005805|stage I adult non-Hodgkin lymphoma
1504801|NCT00005805|stage II adult non-Hodgkin lymphoma
1504802|NCT00005805|stage II small lymphocytic lymphoma
1504803|NCT00005805|stage II grade 1 follicular lymphoma
1504804|NCT00005805|stage II grade 2 follicular lymphoma
1504805|NCT00005805|stage II grade 3 follicular lymphoma
1504806|NCT00005805|stage II adult diffuse small cleaved cell lymphoma
1504807|NCT00005805|stage II adult diffuse mixed cell lymphoma
1504808|NCT00005805|stage II adult diffuse large cell lymphoma
1504809|NCT00005805|stage II adult immunoblastic large cell lymphoma
1504810|NCT00005805|stage II adult lymphoblastic lymphoma
1504811|NCT00005805|stage II adult Burkitt lymphoma
1504812|NCT00005805|stage III small lymphocytic lymphoma
1504813|NCT00005805|stage III grade 1 follicular lymphoma
1504814|NCT00005805|stage III grade 2 follicular lymphoma
1504815|NCT00005805|stage III grade 3 follicular lymphoma
1504816|NCT00005805|stage III adult diffuse small cleaved cell lymphoma
1504817|NCT00005805|stage III adult diffuse mixed cell lymphoma
1504818|NCT00005805|stage III adult diffuse large cell lymphoma
1504819|NCT00005805|stage III adult immunoblastic large cell lymphoma
1504820|NCT00005805|stage III adult lymphoblastic lymphoma
1504821|NCT00005805|stage III adult Burkitt lymphoma
1504822|NCT00005805|stage IV small lymphocytic lymphoma
1504823|NCT00005805|stage IV grade 1 follicular lymphoma
1504824|NCT00005805|stage IV grade 2 follicular lymphoma
1504825|NCT00005805|stage IV grade 3 follicular lymphoma
1504826|NCT00005805|stage IV adult diffuse small cleaved cell lymphoma
1504827|NCT00005805|stage IV adult diffuse mixed cell lymphoma
1504828|NCT00005805|stage IV adult diffuse large cell lymphoma
1504829|NCT00005805|stage IV adult immunoblastic large cell lymphoma
1504830|NCT00005805|stage IV adult lymphoblastic lymphoma
1504831|NCT00005805|stage IV adult Burkitt lymphoma
1504832|NCT00005805|recurrent small lymphocytic lymphoma
1504833|NCT00005805|recurrent grade 1 follicular lymphoma
1504834|NCT00005805|recurrent grade 2 follicular lymphoma
1504835|NCT00005805|recurrent grade 3 follicular lymphoma
1504836|NCT00005805|recurrent adult diffuse small cleaved cell lymphoma
1504837|NCT00005805|recurrent adult diffuse mixed cell lymphoma
1504838|NCT00005805|recurrent adult diffuse large cell lymphoma
1504839|NCT00005805|recurrent adult immunoblastic large cell lymphoma
1504840|NCT00005805|recurrent adult lymphoblastic lymphoma
1504841|NCT00005805|recurrent adult Burkitt lymphoma
1504842|NCT00005805|stage I adult T-cell leukemia/lymphoma
1504843|NCT00005805|stage II adult T-cell leukemia/lymphoma
1504844|NCT00005805|stage III adult T-cell leukemia/lymphoma
1504845|NCT00005805|stage IV adult T-cell leukemia/lymphoma
1504846|NCT00005805|recurrent adult T-cell leukemia/lymphoma
1504847|NCT00005805|de novo myelodysplastic syndromes
1504848|NCT00005805|previously treated myelodysplastic syndromes
1504849|NCT00005805|secondary myelodysplastic syndromes
1504850|NCT00005805|primary central nervous system non-Hodgkin lymphoma
1504851|NCT00005805|fatigue
1504852|NCT00005805|AIDS-related peripheral/systemic lymphoma
1504853|NCT00005805|AIDS-related primary CNS lymphoma
1504854|NCT00005805|primary systemic amyloidosis
1504855|NCT00005805|intraocular lymphoma
1504856|NCT00005805|stage I mantle cell lymphoma
1504857|NCT00005805|contiguous stage II adult non-Hodgkin lymphoma
1504858|NCT00005805|contiguous stage II grade 1 follicular lymphoma
1504859|NCT00005805|contiguous stage II grade 2 follicular lymphoma
1504860|NCT00005805|contiguous stage II grade 3 follicular lymphoma
1504861|NCT00005805|contiguous stage II adult diffuse small cleaved cell lymphoma
1504862|NCT00005805|contiguous stage II mantle cell lymphoma
1504863|NCT00005805|contiguous stage II adult diffuse mixed cell lymphoma
1504864|NCT00005805|contiguous stage II adult immunoblastic large cell lymphoma
1504865|NCT00005805|contiguous stage II adult diffuse large cell lymphoma
1504866|NCT00005805|contiguous stage II adult Burkitt lymphoma
1504867|NCT00005805|contiguous stage II adult lymphoblastic lymphoma
1504868|NCT00005805|noncontiguous stage II adult non-Hodgkin lymphoma
1504869|NCT00005805|noncontiguous stage II grade 1 follicular lymphoma
1504870|NCT00005805|noncontiguous stage II grade 2 follicular lymphoma
1504871|NCT00005805|noncontiguous stage II grade 3 follicular lymphoma
1504872|NCT00005805|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1504873|NCT00005805|noncontiguous stage II mantle cell lymphoma
1504874|NCT00005805|noncontiguous stage II adult diffuse mixed cell lymphoma
1504875|NCT00005805|noncontiguous stage II adult immunoblastic large cell lymphoma
1504876|NCT00005805|noncontiguous stage II adult diffuse large cell lymphoma
1504877|NCT00005805|noncontiguous stage II adult Burkitt lymphoma
1504878|NCT00005805|noncontiguous stage II adult lymphoblastic lymphoma
1504879|NCT00005805|stage III mantle cell lymphoma
1504880|NCT00005805|stage IV mantle cell lymphoma
1504881|NCT00005805|recurrent mantle cell lymphoma
1504882|NCT00005805|angioimmunoblastic T-cell lymphoma
1504883|NCT00005805|anaplastic large cell lymphoma
1504884|NCT00005805|stage II mantle cell lymphoma
1504885|NCT00005805|multiple myeloma
1504886|NCT00005805|noncontiguous stage II small lymphocytic lymphoma
1504887|NCT00005805|noncontiguous stage II marginal zone lymphoma
1504888|NCT00005805|recurrent marginal zone lymphoma
1504889|NCT00005805|stage I marginal zone lymphoma
1504890|NCT00005805|stage II marginal zone lymphoma
1504891|NCT00005805|stage III marginal zone lymphoma
1504892|NCT00005805|stage IV marginal zone lymphoma
1504893|NCT00005805|contiguous stage II marginal zone lymphoma
1504894|NCT00005805|contiguous stage II small lymphocytic lymphoma
1504895|NCT00005805|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1504896|NCT00005805|nodal marginal zone B-cell lymphoma
1504897|NCT00005805|splenic marginal zone lymphoma
1504898|NCT00005804|monoclonal gammopathy of undetermined significance
1504899|NCT00005804|recurrent childhood acute lymphoblastic leukemia
1504900|NCT00005804|recurrent adult Hodgkin lymphoma
1504901|NCT00005804|recurrent cutaneous T-cell non-Hodgkin lymphoma
1504902|NCT00005804|Burkitt lymphoma
1504903|NCT00005804|isolated plasmacytoma of bone
1504904|NCT00005804|extramedullary plasmacytoma
1504905|NCT00005804|refractory multiple myeloma
1504906|NCT00005804|Waldenstrom macroglobulinemia
1504907|NCT00005804|stage III multiple myeloma
1504908|NCT00005804|stage II childhood lymphoblastic lymphoma
1504909|NCT00005804|stage III childhood lymphoblastic lymphoma
1504910|NCT00005804|stage IV childhood lymphoblastic lymphoma
1504911|NCT00005804|recurrent childhood lymphoblastic lymphoma
1504912|NCT00005804|recurrent childhood acute myeloid leukemia
1504913|NCT00005804|recurrent adult acute myeloid leukemia
1504914|NCT00005804|recurrent adult acute lymphoblastic leukemia
1504915|NCT00005804|small intestine lymphoma
1504916|NCT00005804|childhood immunoblastic large cell lymphoma
1505011|NCT00005797|refractory anemia
1504917|NCT00005804|chronic phase chronic myelogenous leukemia
1504918|NCT00005804|accelerated phase chronic myelogenous leukemia
1504919|NCT00005804|blastic phase chronic myelogenous leukemia
1504920|NCT00005804|untreated adult acute lymphoblastic leukemia
1504921|NCT00005804|untreated adult acute myeloid leukemia
1504922|NCT00005804|untreated childhood acute myeloid leukemia and other myeloid malignancies
1504923|NCT00005804|untreated childhood acute lymphoblastic leukemia
1504924|NCT00005804|adult acute myeloid leukemia in remission
1504925|NCT00005804|adult acute lymphoblastic leukemia in remission
1504926|NCT00005804|childhood acute myeloid leukemia in remission
1504927|NCT00005804|childhood acute lymphoblastic leukemia in remission
1504928|NCT00005804|polycythemia vera
1504929|NCT00005804|chronic idiopathic myelofibrosis
1504930|NCT00005804|essential thrombocythemia
1504931|NCT00005804|progressive hairy cell leukemia, initial treatment
1504932|NCT00005804|refractory hairy cell leukemia
1504933|NCT00005804|recurrent/refractory childhood Hodgkin lymphoma
1504934|NCT00005804|chronic myelomonocytic leukemia
1504935|NCT00005804|T-cell large granular lymphocyte leukemia
1504936|NCT00005804|acute undifferentiated leukemia
1504937|NCT00005804|stage III adult lymphoblastic lymphoma
1504938|NCT00005804|stage IV adult lymphoblastic lymphoma
1504939|NCT00005804|recurrent grade 1 follicular lymphoma
1504940|NCT00005804|recurrent grade 2 follicular lymphoma
1504941|NCT00005804|recurrent grade 3 follicular lymphoma
1504942|NCT00005804|recurrent adult diffuse small cleaved cell lymphoma
1504943|NCT00005804|recurrent adult diffuse mixed cell lymphoma
1504944|NCT00005804|recurrent adult diffuse large cell lymphoma
1504945|NCT00005804|recurrent adult immunoblastic large cell lymphoma
1504946|NCT00005804|recurrent adult lymphoblastic lymphoma
1504947|NCT00005804|recurrent adult Burkitt lymphoma
1504948|NCT00005804|recurrent adult T-cell leukemia/lymphoma
1504949|NCT00005804|secondary acute myeloid leukemia
1504950|NCT00005804|de novo myelodysplastic syndromes
1504951|NCT00005804|previously treated myelodysplastic syndromes
1504952|NCT00005804|secondary myelodysplastic syndromes
1504953|NCT00005804|prolymphocytic leukemia
1504954|NCT00005804|primary systemic amyloidosis
1504955|NCT00005804|intraocular lymphoma
1504956|NCT00005804|recurrent childhood small noncleaved cell lymphoma
1504957|NCT00005804|recurrent childhood large cell lymphoma
1504958|NCT00005804|contiguous stage II adult lymphoblastic lymphoma
1504959|NCT00005804|noncontiguous stage II adult lymphoblastic lymphoma
1504960|NCT00005804|recurrent mantle cell lymphoma
1504961|NCT00005804|angioimmunoblastic T-cell lymphoma
1504962|NCT00005804|anaplastic large cell lymphoma
1504963|NCT00005804|recurrent mycosis fungoides/Sezary syndrome
1504964|NCT00005804|recurrent marginal zone lymphoma
1504965|NCT00005804|recurrent small lymphocytic lymphoma
1504966|NCT00005804|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1504967|NCT00005804|nodal marginal zone B-cell lymphoma
1504968|NCT00005804|splenic marginal zone lymphoma
1504969|NCT00005804|childhood myelodysplastic syndromes
1504970|NCT00005802|recurrent childhood acute lymphoblastic leukemia
1504971|NCT00005802|recurrent childhood acute myeloid leukemia
1504972|NCT00005802|recurrent adult acute myeloid leukemia
1504973|NCT00005802|recurrent adult acute lymphoblastic leukemia
1504974|NCT00005802|adult acute myeloid leukemia with t(8;21)(q22;q22)
1504975|NCT00005802|adult acute myeloid leukemia with t(16;16)(p13;q22)
1504976|NCT00005802|adult acute myeloid leukemia with inv(16)(p13;q22)
1504977|NCT00005802|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1504978|NCT00005802|adult acute myeloid leukemia with t(15;17)(q22;q12)
1504979|NCT00005801|adult acute myeloid leukemia in remission
1504980|NCT00005801|adult acute erythroid leukemia (M6)
1504981|NCT00005801|adult acute myeloblastic leukemia without maturation (M1)
1504982|NCT00005801|adult acute myeloblastic leukemia with maturation (M2)
1504983|NCT00005801|adult acute myelomonocytic leukemia (M4)
1504984|NCT00005801|adult acute monoblastic leukemia (M5a)
1504985|NCT00005801|adult acute megakaryoblastic leukemia (M7)
1504986|NCT00005801|adult acute monocytic leukemia (M5b)
1504987|NCT00005800|stage IIIA breast cancer
1504988|NCT00005800|stage IIIB breast cancer
1504989|NCT00005800|inflammatory breast cancer
1504990|NCT00005798|stage II breast cancer
1504991|NCT00005798|stage IV breast cancer
1504992|NCT00005798|stage IIIA breast cancer
1504993|NCT00005798|recurrent breast cancer
1504994|NCT00005798|stage IIIB breast cancer
1504995|NCT00005798|inflammatory breast cancer
1504996|NCT00005797|refractory multiple myeloma
1504997|NCT00005797|stage II multiple myeloma
1504998|NCT00005797|stage III multiple myeloma
1504999|NCT00005797|stage III chronic lymphocytic leukemia
1505000|NCT00005797|stage IV chronic lymphocytic leukemia
1505001|NCT00005797|recurrent adult acute myeloid leukemia
1505002|NCT00005797|recurrent adult acute lymphoblastic leukemia
1505003|NCT00005797|refractory chronic lymphocytic leukemia
1505004|NCT00005797|chronic phase chronic myelogenous leukemia
1505005|NCT00005797|accelerated phase chronic myelogenous leukemia
1505006|NCT00005797|adult acute myeloid leukemia in remission
1505007|NCT00005797|adult acute lymphoblastic leukemia in remission
1505008|NCT00005797|polycythemia vera
1505009|NCT00005797|primary myelofibrosis
1505010|NCT00005797|essential thrombocythemia
1505012|NCT00005797|refractory anemia with ringed sideroblasts
1505013|NCT00005797|refractory anemia with excess blasts
1505014|NCT00005797|refractory anemia with excess blasts in transformation
1505015|NCT00005797|chronic myelomonocytic leukemia
1505016|NCT00005797|previously treated myelodysplastic syndromes
1505017|NCT00005797|refractory cytopenia with multilineage dysplasia
1505018|NCT00005797|chronic eosinophilic leukemia
1505019|NCT00005797|chronic neutrophilic leukemia
1505020|NCT00005797|atypical chronic myeloid leukemia, BCR-ABL1 negative
1505021|NCT00005797|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1505022|NCT00005797|adult acute myeloid leukemia with t(8;21)(q22;q22)
1505023|NCT00005797|adult acute myeloid leukemia with t(16;16)(p13;q22)
1505024|NCT00005797|adult acute myeloid leukemia with inv(16)(p13;q22)
1505025|NCT00005797|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1505026|NCT00005797|adult acute myeloid leukemia with t(15;17)(q22;q12)
1505027|NCT00005797|childhood myelodysplastic syndromes
1505028|NCT00005796|recurrent adult brain tumor
1505029|NCT00005796|adult brain stem glioma
1505030|NCT00005796|adult ependymoma
1505031|NCT00005796|adult medulloblastoma
1505032|NCT00005796|adult glioblastoma
1505033|NCT00005796|childhood high-grade cerebral astrocytoma
1505034|NCT00005796|childhood oligodendroglioma
1505035|NCT00005796|adult anaplastic astrocytoma
1505036|NCT00005796|adult anaplastic oligodendroglioma
1505037|NCT00005796|adult mixed glioma
1505038|NCT00005796|drug/agent toxicity by tissue/organ
1505039|NCT00005796|bone marrow suppression
1505040|NCT00005796|untreated childhood brain stem glioma
1505041|NCT00005796|recurrent childhood brain stem glioma
1505042|NCT00005796|untreated childhood cerebellar astrocytoma
1505043|NCT00005796|recurrent childhood cerebellar astrocytoma
1505044|NCT00005796|recurrent childhood cerebral astrocytoma
1505045|NCT00005796|recurrent childhood medulloblastoma
1505046|NCT00005796|newly diagnosed childhood ependymoma
1505047|NCT00005796|recurrent childhood ependymoma
1505048|NCT00005796|adult giant cell glioblastoma
1505049|NCT00005796|adult gliosarcoma
1505050|NCT00005795|recurrent adult acute myeloid leukemia
1505051|NCT00005795|untreated adult acute myeloid leukemia
1505052|NCT00005795|adult acute erythroid leukemia (M6)
1505053|NCT00005795|adult acute myeloblastic leukemia without maturation (M1)
1505054|NCT00005795|adult acute myeloblastic leukemia with maturation (M2)
1505055|NCT00005795|adult acute myelomonocytic leukemia (M4)
1505056|NCT00005795|adult acute monoblastic leukemia (M5a)
1505057|NCT00005795|adult acute megakaryoblastic leukemia (M7)
1505058|NCT00005795|secondary acute myeloid leukemia
1505059|NCT00005795|adult acute monocytic leukemia (M5b)
1505060|NCT00005795|adult acute minimally differentiated myeloid leukemia (M0)
1505061|NCT00005794|unspecified adult solid tumor, protocol specific
1505062|NCT00005793|untreated adult acute myeloid leukemia
1505063|NCT00005793|adult acute erythroid leukemia (M6)
1505064|NCT00005793|adult acute myeloblastic leukemia without maturation (M1)
1505065|NCT00005793|adult acute myeloblastic leukemia with maturation (M2)
1505066|NCT00005793|adult acute myelomonocytic leukemia (M4)
1505067|NCT00005793|adult acute monoblastic leukemia (M5a)
1505068|NCT00005793|adult acute megakaryoblastic leukemia (M7)
1505069|NCT00005793|adult acute monocytic leukemia (M5b)
1505070|NCT00005793|adult acute minimally differentiated myeloid leukemia (M0)
1505071|NCT00005793|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1505072|NCT00005793|adult acute myeloid leukemia with inv(16)(p13;q22)
1505073|NCT00005793|adult acute myeloid leukemia with t(16;16)(p13;q22)
1505074|NCT00005793|adult acute myeloid leukemia with t(8;21)(q22;q22)
1505075|NCT00005792|refractory multiple myeloma
1505076|NCT00005792|stage I multiple myeloma
1505077|NCT00005792|stage II multiple myeloma
1505078|NCT00005792|stage III multiple myeloma
1505079|NCT00005791|unspecified adult solid tumor, protocol specific
1505080|NCT00005790|adult brain stem glioma
1505081|NCT00005790|adult ependymoma
1505082|NCT00005790|adult craniopharyngioma
1505083|NCT00005790|adult medulloblastoma
1505084|NCT00005790|adult meningioma
1505085|NCT00005790|adult glioblastoma
1505086|NCT00005790|adult oligodendroglioma
1505087|NCT00005790|adult anaplastic astrocytoma
1505088|NCT00005790|adult myxopapillary ependymoma
1505089|NCT00005790|adult anaplastic ependymoma
1505090|NCT00005790|adult anaplastic oligodendroglioma
1505091|NCT00005790|adult mixed glioma
1505092|NCT00005790|adult pineal parenchymal tumor
1505093|NCT00005790|adult central nervous system germ cell tumor
1505094|NCT00005790|adult pilocytic astrocytoma
1505095|NCT00005790|adult subependymoma
1505096|NCT00005790|adult diffuse astrocytoma
1505097|NCT00005790|adult ependymoblastoma
1505098|NCT00005790|adult pineocytoma
1505099|NCT00005790|adult pineoblastoma
1505100|NCT00005790|adult meningeal hemangiopericytoma
1505101|NCT00005790|adult choroid plexus tumor
1505102|NCT00005790|adult grade III meningioma
1505103|NCT00005790|adult giant cell glioblastoma
1505104|NCT00005790|adult gliosarcoma
1505105|NCT00005788|stage I cutaneous T-cell non-Hodgkin lymphoma
1505106|NCT00005788|stage II cutaneous T-cell non-Hodgkin lymphoma
1505107|NCT00005788|stage III cutaneous T-cell non-Hodgkin lymphoma
1505344|NCT00005657|Genetic Polymorphism
1505108|NCT00005788|stage IV cutaneous T-cell non-Hodgkin lymphoma
1505109|NCT00005788|recurrent cutaneous T-cell non-Hodgkin lymphoma
1505110|NCT00005788|stage I mycosis fungoides/Sezary syndrome
1505111|NCT00005788|stage II mycosis fungoides/Sezary syndrome
1505112|NCT00005788|stage III mycosis fungoides/Sezary syndrome
1505113|NCT00005788|stage IV mycosis fungoides/Sezary syndrome
1505114|NCT00005788|recurrent mycosis fungoides/Sezary syndrome
1505115|NCT00005787|neutropenia
1505116|NCT00005787|recurrent grade 1 follicular lymphoma
1505117|NCT00005787|recurrent grade 2 follicular lymphoma
1505118|NCT00005787|recurrent grade 3 follicular lymphoma
1505119|NCT00005787|recurrent adult diffuse small cleaved cell lymphoma
1505120|NCT00005787|recurrent adult diffuse mixed cell lymphoma
1505121|NCT00005787|recurrent adult diffuse large cell lymphoma
1505122|NCT00005787|recurrent adult immunoblastic large cell lymphoma
1505123|NCT00005787|recurrent adult lymphoblastic lymphoma
1505124|NCT00005787|recurrent adult Burkitt lymphoma
1505125|NCT00005787|recurrent mantle cell lymphoma
1505126|NCT00005787|recurrent marginal zone lymphoma
1505127|NCT00005787|recurrent small lymphocytic lymphoma
1505128|NCT00005787|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505129|NCT00005787|nodal marginal zone B-cell lymphoma
1505130|NCT00005787|splenic marginal zone lymphoma
1505131|NCT00005785|Peripheral Blood Stem Cells
1505132|NCT00005785|Engraftment
1505133|NCT00005785|Graft vs. Host Disease
1505134|NCT00005785|Graft-Versus-Leukemia
1505135|NCT00005785|Donor Apheresis
1505136|NCT00005785|Cyclophosphamide
1505137|NCT00005785|Fludarabine
1505138|NCT00005785|HIV
1505139|NCT00005785|AIDS
1505140|NCT00005785|Gene Therapy
1505141|NCT00005785|Chronic Myelogenous Leukemia
1505142|NCT00005785|Acute Lymphoblastic Leukemia
1505143|NCT00005785|Acute Myelogenous Leukemia
1505144|NCT00005785|Chronic Lymphocytic Leukemia
1505145|NCT00005784|Macular Degeneration
1505146|NCT00005784|Diabetic Retinopathy
1505147|NCT00005784|Vascular Occlusive Disease
1505148|NCT00005784|Central Serous Retinopathy
1505149|NCT00005784|Rare/Unknown Retinal Disease
1505150|NCT00005784|Retinal Disease
1505151|NCT00005784|Age-Related Macular Degeneration
1505152|NCT00005783|Fetal Hemoglobin
1505153|NCT00005783|Hematopoietic Growth Factor
1505154|NCT00005783|Peripheral Blood CD34 Cells
1505155|NCT00005783|Vasoocclusive Crisis
1505156|NCT00005783|Sickle Cell Anemia
1505157|NCT00005783|Sickle Cell Disease
1505158|NCT00005783|Sickle Cell Disorder
1505159|NCT00005782|Donor Apheresis
1505160|NCT00005782|Sickle Cell Trait
1505161|NCT00005782|Red Cell Alloimmunization
1505162|NCT00005781|Epidemiology
1505163|NCT00005781|NHANES
1505164|NCT00005781|Photography
1505165|NCT00005781|Prevalence
1505166|NCT00005781|Skin Disease
1505167|NCT00005781|Healthy Volunteer
1505168|NCT00005780|Lymphoma Vaccines
1505169|NCT00005780|Immune Response Against Lymphoma
1505170|NCT00005780|Molecular Complete Remissions
1505171|NCT00005780|Novel Treatment Approach
1505172|NCT00005780|Mantle Cell Lymphoma
1505173|NCT00005779|Virus Replication
1505174|NCT00005779|HIV-1
1505175|NCT00005779|AIDS Vaccines
1505176|NCT00005779|CD4 Lymphocyte Count
1505177|NCT00005779|Cohort Studies
1505178|NCT00005779|Interleukin-12
1505179|NCT00005779|HIV Therapeutic Vaccine
1505180|NCT00005778|Systemic Lupus Erythematosus (SLE)
1505181|NCT00005778|Cytoxan
1505182|NCT00005778|Cyclophosphamide
1505183|NCT00005778|High-dose immunoablative therapy
1505184|NCT00005777|NICHD Neonatal Research Network
1505185|NCT00005777|Extremely Low Birth Weight (ELBW)
1505186|NCT00005777|Prematurity
1505187|NCT00005777|Chronic Lung Disease (CLD)
1505188|NCT00005777|Dexamethasone
1505189|NCT00005777|Glucocorticoids
1505190|NCT00005777|Respiration, Artificial
1505191|NCT00005777|Mechanical ventilation
1505192|NCT00005777|Respiratory Insufficiency
1505193|NCT00005776|NICHD Neonatal Research Network
1505194|NCT00005776|Hypertension, pulmonary
1505195|NCT00005776|Hypoxic respiratory failure
1505196|NCT00005776|Meconium aspiration
1505197|NCT00005776|Methemoglobinemia
1505198|NCT00005776|Nitric oxide
1505199|NCT00005776|Oxygen inhalation therapy
1505200|NCT00005776|Persistent Fetal Circulation Syndrome
1505201|NCT00005776|Pneumonia, aspiration
1505202|NCT00005776|Respiratory distress syndrome
1505203|NCT00005776|Respiratory insufficiency
1505204|NCT00005776|Severe respiratory failure
1505205|NCT00005775|NICHD Neonatal Research Network
1505206|NCT00005775|Extremely Low Birth Weight (ELBW) infants
1505207|NCT00005775|Prematurity
1505208|NCT00005775|Glutamine
1505209|NCT00005775|Total parenteral nutrition
1505210|NCT00005775|Nutrition
1505211|NCT00005775|Very low birth weight (VLBW) infants
1505212|NCT00005774|NICHD Neonatal Research Network
1505213|NCT00005774|Pulmonary ventilation
1505214|NCT00005774|Respiratory distress syndrome
1505215|NCT00005774|Respiratory insufficiency
1505216|NCT00005774|Surfactant, pulmonary
1505217|NCT00005774|Mechanical Ventilation
1505218|NCT00005774|Survanta
1505219|NCT00005773|NICHD Neonatal Research Network
1505220|NCT00005773|Hypertension, pulmonary
1505221|NCT00005773|Hypoxic respiratory failure
1505222|NCT00005773|Meconium aspiration
1505223|NCT00005773|Methemoglobinemia
1505224|NCT00005773|Nitric oxide
1505225|NCT00005773|Oxygen inhalation therapy
1505226|NCT00005773|Persistent Fetal Circulation Syndrome
1505227|NCT00005773|Pneumonia, aspiration
1505228|NCT00005773|Respiratory distress syndrome
1505229|NCT00005773|Respiratory insufficiency
1505230|NCT00005773|Severe respiratory failure
1505231|NCT00005772|NICHD Neonatal Research Network
1505232|NCT00005772|Hypoxic-ischemic encephalopathy (HIE)
1505233|NCT00005772|Hypothermia
1505234|NCT00005772|Neonatal depression
1505235|NCT00005772|Perinatal asphyxia
1505236|NCT00005771|Abdominal Hollowing Exercises
1505237|NCT00005770|elastic property of skin
1505238|NCT00005767|Amino Acid Metabolism
1505239|NCT00005766|ALS
1505240|NCT00005764|HIV-1
1505241|NCT00005764|Zalcitabine
1505242|NCT00005764|Didanosine
1505243|NCT00005764|Drug Therapy, Combination
1505244|NCT00005764|Zidovudine
1505245|NCT00005764|Stavudine
1505246|NCT00005764|Lamivudine
1505247|NCT00005764|Blood
1505248|NCT00005764|Reverse Transcriptase Inhibitors
1505249|NCT00005764|Anti-HIV Agents
1505250|NCT00005764|Lipodystrophy
1505251|NCT00005764|Combivir
1505252|NCT00005764|Lactic Acid
1505253|NCT00005764|abacavir
1505254|NCT00005762|Drug Interactions
1505255|NCT00005762|Drug Therapy, Combination
1505256|NCT00005762|HIV Protease Inhibitors
1505257|NCT00005762|Ritonavir
1505258|NCT00005762|Dosage Forms
1505259|NCT00005762|Saquinavir
1505260|NCT00005762|VX 478
1505261|NCT00005762|Anti-HIV Agents
1505262|NCT00005762|Nelfinavir
1505263|NCT00005762|Pharmacokinetics
1505264|NCT00005762|efavirenz
1505265|NCT00005761|Types 1 & 2 Diabetes
1505266|NCT00005761|Cell Adhesion Molecules
1505267|NCT00005761|Chemokines
1505268|NCT00005761|Vascular Endothelial Growth Factor
1505269|NCT00005761|Cross-Sectional
1505270|NCT00005761|Serum Levels
1505271|NCT00005761|Diabetic Retinopathy
1505272|NCT00005760|Dyslipidemia
1505273|NCT00005760|Hypertension
1505274|NCT00005760|Metabolic Syndrome X
1505275|NCT00005760|Obesity
1505276|NCT00005760|Subcutaneous Adipose Tissue
1505277|NCT00005760|Visceral Abdominal Adipose Tissue
1505278|NCT00005758|T-Lymphocytes, Helper-Inducer
1505279|NCT00005758|Combined Modality Therapy
1505280|NCT00005758|HIV Envelope Protein gp120
1505281|NCT00005758|AIDS Vaccines
1505282|NCT00005758|RNA, Viral
1505283|NCT00005758|HIV Core Protein p24
1505284|NCT00005758|T-Lymphocytes, Cytotoxic
1505285|NCT00005758|Anti-HIV Agents
1505286|NCT00005758|Viral Load
1505287|NCT00005758|HIV Therapeutic Vaccine
1505288|NCT00005727|Nutrition
1505289|NCT00005727|Education
1505290|NCT00005675|Systemic Scleroderma (SSc)
1505291|NCT00005675|Bovine Type I Collagen (CI)
1505292|NCT00005675|Multicenter
1505293|NCT00005673|HIV
1505294|NCT00005673|Antiretroviral
1505295|NCT00005673|NNRTI
1505296|NCT00005671|Angina
1505297|NCT00005671|Condition Specific
1505298|NCT00005671|Heart Failure
1505299|NCT00005671|Symptom Distress
1505300|NCT00005671|Revascularization
1505301|NCT00005671|Coronary Artery Disease
1505302|NCT00005671|Ischemic Heart Disease
1505303|NCT00005669|Child
1505304|NCT00005669|Body Fat
1505305|NCT00005669|Food Intake
1505306|NCT00005669|Diabetes Mellitus
1505307|NCT00005669|Dyslipidemia
1505308|NCT00005669|Vitamin B12
1505309|NCT00005669|Childhood Obesity
1505310|NCT00005667|liver transplantation
1505311|NCT00005667|vancomycin resistance
1505312|NCT00005666|Diagnostic imaging
1505313|NCT00005664|Healthy Volunteers
1505314|NCT00005664|Endocrine Related Conditions
1505315|NCT00005664|Endocrine Dysfunction
1505316|NCT00005664|Early Pubertal Development
1505317|NCT00005663|Herpes Simplex
1505318|NCT00005663|Antiviral Agents
1505319|NCT00005663|Anus Diseases
1505320|NCT00005663|Herpes Genitalis
1505321|NCT00005663|Recurrence
1505322|NCT00005663|valacyclovir
1505323|NCT00005660|Hypertriglyceridemia
1505324|NCT00005660|Teratogenicity
1505325|NCT00005660|Ichthyosis
1505326|NCT00005660|Darier's Disease
1505327|NCT00005660|Retinoids
1505328|NCT00005660|Skin
1505329|NCT00005660|Psoriasis
1505330|NCT00005660|Basal cell carcinoma
1505331|NCT00005660|Skin Cancer
1505332|NCT00005658|Biochemical
1505333|NCT00005658|Schizophrenia
1505334|NCT00005658|NMDA
1505335|NCT00005658|Adolescence
1505336|NCT00005658|Psychosis
1505337|NCT00005658|Child Psychosis
1505338|NCT00005658|Biochemical Correlates
1505339|NCT00005658|Brain Imaging
1505340|NCT00005658|Glycine
1505341|NCT00005658|Adjunctive Glycine Therapy
1505342|NCT00005657|Cytokines
1505343|NCT00005657|Treatment
1505345|NCT00005657|Chronic Hepatitis C
1505346|NCT00005657|Mononuclear Cells
1505347|NCT00005655|Gene Expression
1505348|NCT00005655|Neovascularization
1505349|NCT00005655|antiangiogenic therapy
1505350|NCT00005655|immunomodulatory therapy
1505351|NCT00005655|Immunotherapy
1505352|NCT00005655|Tumor
1505353|NCT00005654|endocrine disorders
1505354|NCT00005654|hyperinsulinism
1505355|NCT00005654|polycystic ovarian syndrome
1505356|NCT00005654|rare disease
1505358|NCT00005652|immune thrombocytopenic purpura
1505359|NCT00005652|rare disease
1505360|NCT00005650|cardiovascular and respiratory diseases
1505361|NCT00005650|genetic diseases and dysmorphic syndromes
1505362|NCT00005650|primary ciliary dyskinesia
1505363|NCT00005650|rare disease
1505364|NCT00005649|stage IV breast cancer
1505365|NCT00005649|recurrent breast cancer
1505366|NCT00005648|Stage II pancreatic cancer
1505367|NCT00005648|Stage III pancreatic cancer
1505368|NCT00005648|Recurrent pancreatic cancer
1505369|NCT00005648|Adenocarcinoma of the pancreas
1505370|NCT00005648|Stage IV pancreatic cancer
1505371|NCT00005647|thyroid gland medullary carcinoma
1505372|NCT00005647|anaplastic thyroid cancer
1505373|NCT00005647|recurrent thyroid cancer
1505374|NCT00005647|recurrent salivary gland cancer
1505375|NCT00005647|recurrent metastatic squamous neck cancer with occult primary
1505376|NCT00005647|stage III follicular thyroid cancer
1505377|NCT00005647|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1505378|NCT00005647|recurrent hypopharyngeal cancer
1505379|NCT00005647|stage III adenoid cystic carcinoma of the oral cavity
1505380|NCT00005647|recurrent squamous cell carcinoma of the lip and oral cavity
1505381|NCT00005647|recurrent verrucous carcinoma of the oral cavity
1505382|NCT00005647|recurrent mucoepidermoid carcinoma of the oral cavity
1505383|NCT00005647|recurrent adenoid cystic carcinoma of the oral cavity
1505384|NCT00005647|recurrent squamous cell carcinoma of the oropharynx
1505385|NCT00005647|recurrent lymphoepithelioma of the oropharynx
1505386|NCT00005647|recurrent squamous cell carcinoma of the nasopharynx
1505387|NCT00005647|recurrent lymphoepithelioma of the nasopharynx
1505388|NCT00005647|recurrent squamous cell carcinoma of the hypopharynx
1505389|NCT00005647|recurrent squamous cell carcinoma of the larynx
1505390|NCT00005647|recurrent verrucous carcinoma of the larynx
1505391|NCT00005647|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1505392|NCT00005647|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1505393|NCT00005647|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1505394|NCT00005646|extensive stage small cell lung cancer
1505395|NCT00005645|stage III ovarian epithelial cancer
1505396|NCT00005645|stage IV ovarian epithelial cancer
1505397|NCT00005645|recurrent ovarian epithelial cancer
1505398|NCT00005645|liver metastases
1505399|NCT00005645|malignant pericardial effusion
1505400|NCT00005645|malignant pleural effusion
1505401|NCT00005645|malignant ascites
1505402|NCT00005645|fallopian tube cancer
1505403|NCT00005645|primary peritoneal cavity cancer
1505404|NCT00005644|stage III bladder cancer
1505405|NCT00005644|recurrent bladder cancer
1505406|NCT00005644|stage IV bladder cancer
1505407|NCT00005644|transitional cell carcinoma of the bladder
1505408|NCT00005644|recurrent urethral cancer
1505409|NCT00005644|distal urethral cancer
1505410|NCT00005644|proximal urethral cancer
1505411|NCT00005644|urethral cancer associated with invasive bladder cancer
1505412|NCT00005644|metastatic transitional cell cancer of the renal pelvis and ureter
1505413|NCT00005644|regional transitional cell cancer of the renal pelvis and ureter
1505414|NCT00005644|recurrent transitional cell cancer of the renal pelvis and ureter
1505415|NCT00005643|stage IV uterine sarcoma
1505416|NCT00005643|recurrent uterine sarcoma
1505417|NCT00005643|uterine carcinosarcoma
1505418|NCT00005643|uterine leiomyosarcoma
1505419|NCT00005643|endometrial stromal sarcoma
1505420|NCT00005642|unspecified adult solid tumor, protocol specific
1505421|NCT00005641|recurrent childhood acute lymphoblastic leukemia
1505422|NCT00005641|refractory multiple myeloma
1505423|NCT00005641|stage 0 chronic lymphocytic leukemia
1505424|NCT00005641|stage I multiple myeloma
1505425|NCT00005641|stage II multiple myeloma
1505426|NCT00005641|stage III multiple myeloma
1505427|NCT00005641|stage I chronic lymphocytic leukemia
1505428|NCT00005641|stage II chronic lymphocytic leukemia
1505429|NCT00005641|stage III chronic lymphocytic leukemia
1505430|NCT00005641|stage IV chronic lymphocytic leukemia
1505431|NCT00005641|recurrent childhood acute myeloid leukemia
1505432|NCT00005641|recurrent adult acute myeloid leukemia
1505433|NCT00005641|recurrent adult acute lymphoblastic leukemia
1505434|NCT00005641|relapsing chronic myelogenous leukemia
1505435|NCT00005641|refractory chronic lymphocytic leukemia
1505436|NCT00005641|chronic phase chronic myelogenous leukemia
1505437|NCT00005641|accelerated phase chronic myelogenous leukemia
1505438|NCT00005641|blastic phase chronic myelogenous leukemia
1505439|NCT00005641|adult acute myeloid leukemia in remission
1505440|NCT00005641|adult acute lymphoblastic leukemia in remission
1505441|NCT00005641|polycythemia vera
1505442|NCT00005641|primary myelofibrosis
1505443|NCT00005641|essential thrombocythemia
1505444|NCT00005641|refractory anemia
1505445|NCT00005641|refractory anemia with ringed sideroblasts
1505446|NCT00005641|refractory anemia with excess blasts
1505447|NCT00005641|refractory anemia with excess blasts in transformation
1505448|NCT00005641|chronic myelomonocytic leukemia
1505449|NCT00005641|de novo myelodysplastic syndromes
1505450|NCT00005641|previously treated myelodysplastic syndromes
1505451|NCT00005641|secondary myelodysplastic syndromes
1505452|NCT00005641|graft versus host disease
1505453|NCT00005641|refractory cytopenia with multilineage dysplasia
1505454|NCT00005641|childhood myelodysplastic syndromes
1505455|NCT00005640|stage I colon cancer
1505456|NCT00005640|stage II colon cancer
1505457|NCT00005640|stage III colon cancer
1505458|NCT00005640|stage I rectal cancer
1505459|NCT00005640|stage II rectal cancer
1505460|NCT00005640|stage III rectal cancer
1505461|NCT00005639|stage III adult Hodgkin lymphoma
1505462|NCT00005639|stage IV adult Hodgkin lymphoma
1505463|NCT00005639|recurrent adult Hodgkin lymphoma
1505464|NCT00005639|stage III cutaneous T-cell non-Hodgkin lymphoma
1505465|NCT00005639|stage IV cutaneous T-cell non-Hodgkin lymphoma
1505466|NCT00005639|recurrent cutaneous T-cell non-Hodgkin lymphoma
1505467|NCT00005639|small intestine lymphoma
1505468|NCT00005639|unspecified adult solid tumor, protocol specific
1505469|NCT00005639|stage III grade 1 follicular lymphoma
1505470|NCT00005639|stage III grade 2 follicular lymphoma
1505471|NCT00005639|stage III grade 3 follicular lymphoma
1505472|NCT00005639|stage III adult diffuse small cleaved cell lymphoma
1505473|NCT00005639|stage III adult diffuse mixed cell lymphoma
1505474|NCT00005639|stage III adult diffuse large cell lymphoma
1505475|NCT00005639|stage III adult immunoblastic large cell lymphoma
1505476|NCT00005639|stage III adult lymphoblastic lymphoma
1505477|NCT00005639|stage III adult Burkitt lymphoma
1505478|NCT00005639|stage IV grade 1 follicular lymphoma
1505479|NCT00005639|stage IV grade 2 follicular lymphoma
1505480|NCT00005639|stage IV grade 3 follicular lymphoma
1505481|NCT00005639|stage IV adult diffuse small cleaved cell lymphoma
1505482|NCT00005639|stage IV adult diffuse mixed cell lymphoma
1505483|NCT00005639|stage IV adult diffuse large cell lymphoma
1505484|NCT00005639|stage IV adult immunoblastic large cell lymphoma
1505485|NCT00005639|stage IV adult lymphoblastic lymphoma
1505486|NCT00005639|stage IV adult Burkitt lymphoma
1505487|NCT00005639|recurrent grade 1 follicular lymphoma
1505488|NCT00005639|recurrent grade 2 follicular lymphoma
1505489|NCT00005639|recurrent grade 3 follicular lymphoma
1505490|NCT00005639|recurrent adult diffuse small cleaved cell lymphoma
1505491|NCT00005639|recurrent adult diffuse mixed cell lymphoma
1505492|NCT00005639|recurrent adult diffuse large cell lymphoma
1505493|NCT00005639|recurrent adult immunoblastic large cell lymphoma
1505494|NCT00005639|recurrent adult lymphoblastic lymphoma
1505495|NCT00005639|recurrent adult Burkitt lymphoma
1505496|NCT00005639|stage III adult T-cell leukemia/lymphoma
1505497|NCT00005639|stage IV adult T-cell leukemia/lymphoma
1505498|NCT00005639|recurrent adult T-cell leukemia/lymphoma
1505499|NCT00005639|primary central nervous system non-Hodgkin lymphoma
1505500|NCT00005639|intraocular lymphoma
1505501|NCT00005639|stage III mantle cell lymphoma
1505502|NCT00005639|stage IV mantle cell lymphoma
1505503|NCT00005639|recurrent mantle cell lymphoma
1505504|NCT00005639|angioimmunoblastic T-cell lymphoma
1505505|NCT00005639|anaplastic large cell lymphoma
1505506|NCT00005639|stage III mycosis fungoides/Sezary syndrome
1505507|NCT00005639|stage IV mycosis fungoides/Sezary syndrome
1505508|NCT00005639|recurrent mycosis fungoides/Sezary syndrome
1505509|NCT00005639|recurrent marginal zone lymphoma
1505510|NCT00005639|recurrent small lymphocytic lymphoma
1505511|NCT00005639|stage III small lymphocytic lymphoma
1505512|NCT00005639|stage III marginal zone lymphoma
1505513|NCT00005639|stage IV small lymphocytic lymphoma
1505514|NCT00005639|stage IV marginal zone lymphoma
1505515|NCT00005639|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505516|NCT00005639|nodal marginal zone B-cell lymphoma
1505517|NCT00005639|splenic marginal zone lymphoma
1505518|NCT00005638|stage II gastric cancer
1505519|NCT00005638|stage III gastric cancer
1505520|NCT00005638|stage II esophageal cancer
1505521|NCT00005638|stage III esophageal cancer
1505522|NCT00005638|adenocarcinoma of the stomach
1505523|NCT00005638|squamous cell carcinoma of the esophagus
1505524|NCT00005638|adenocarcinoma of the esophagus
1505525|NCT00005637|adult glioblastoma
1505526|NCT00005637|adult anaplastic astrocytoma
1505527|NCT00005637|adult anaplastic oligodendroglioma
1505528|NCT00005637|adult mixed glioma
1505529|NCT00005637|adult giant cell glioblastoma
1505530|NCT00005637|adult gliosarcoma
1505531|NCT00005637|adult anaplastic ependymoma
1505532|NCT00005636|localized malignant mesothelioma
1505533|NCT00005636|advanced malignant mesothelioma
1505534|NCT00005636|recurrent malignant mesothelioma
1505535|NCT00005635|stage IV breast cancer
1505536|NCT00005635|recurrent breast cancer
1505537|NCT00005634|recurrent adult Hodgkin lymphoma
1505538|NCT00005634|recurrent cutaneous T-cell non-Hodgkin lymphoma
1505539|NCT00005634|isolated plasmacytoma of bone
1505540|NCT00005634|extramedullary plasmacytoma
1505541|NCT00005634|refractory multiple myeloma
1505542|NCT00005634|recurrent adult acute myeloid leukemia
1505543|NCT00005634|recurrent adult acute lymphoblastic leukemia
1505544|NCT00005634|relapsing chronic myelogenous leukemia
1505545|NCT00005634|refractory chronic lymphocytic leukemia
1505546|NCT00005634|small intestine lymphoma
1505547|NCT00005634|recurrent prostate cancer
1505548|NCT00005634|unspecified adult solid tumor, protocol specific
1505549|NCT00005634|chronic phase chronic myelogenous leukemia
1506136|NCT00005118|Ritonavir
1505550|NCT00005634|refractory hairy cell leukemia
1505551|NCT00005634|chronic myelomonocytic leukemia
1505552|NCT00005634|recurrent grade 1 follicular lymphoma
1505553|NCT00005634|recurrent grade 2 follicular lymphoma
1505554|NCT00005634|recurrent grade 3 follicular lymphoma
1505555|NCT00005634|recurrent adult diffuse small cleaved cell lymphoma
1505556|NCT00005634|recurrent adult diffuse mixed cell lymphoma
1505557|NCT00005634|recurrent adult diffuse large cell lymphoma
1505558|NCT00005634|recurrent adult immunoblastic large cell lymphoma
1505559|NCT00005634|recurrent adult lymphoblastic lymphoma
1505560|NCT00005634|recurrent adult Burkitt lymphoma
1505561|NCT00005634|recurrent adult T-cell leukemia/lymphoma
1505562|NCT00005634|secondary acute myeloid leukemia
1505563|NCT00005634|recurrent mantle cell lymphoma
1505564|NCT00005634|recurrent mycosis fungoides/Sezary syndrome
1505565|NCT00005634|recurrent marginal zone lymphoma
1505566|NCT00005634|recurrent small lymphocytic lymphoma
1505567|NCT00005634|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505568|NCT00005634|nodal marginal zone B-cell lymphoma
1505569|NCT00005634|splenic marginal zone lymphoma
1505570|NCT00005633|stage III melanoma
1505571|NCT00005633|stage IV melanoma
1505572|NCT00005633|recurrent melanoma
1505573|NCT00005632|recurrent prostate cancer
1505574|NCT00005631|recurrent adult diffuse large cell lymphoma
1505575|NCT00005631|recurrent adult immunoblastic large cell lymphoma
1505576|NCT00005631|anaplastic large cell lymphoma
1505577|NCT00005630|stage I non-small cell lung cancer
1505578|NCT00005630|stage II non-small cell lung cancer
1505579|NCT00005630|large cell lung cancer
1505580|NCT00005630|stage IIIA non-small cell lung cancer
1505581|NCT00005630|stage IIIB non-small cell lung cancer
1505582|NCT00005630|stage IV non-small cell lung cancer
1505583|NCT00005630|adenocarcinoma of the lung
1505584|NCT00005630|bronchoalveolar cell lung cancer
1505585|NCT00005629|localized resectable adult primary liver cancer
1505586|NCT00005629|localized unresectable adult primary liver cancer
1505587|NCT00005629|advanced adult primary liver cancer
1505588|NCT00005629|recurrent adult primary liver cancer
1505589|NCT00005629|adult primary hepatocellular carcinoma
1505590|NCT00005628|recurrent adult soft tissue sarcoma
1505591|NCT00005628|stage IV adult soft tissue sarcoma
1505592|NCT00005627|adenocarcinoma of the prostate
1505593|NCT00005627|recurrent prostate cancer
1505594|NCT00005626|stage III chronic lymphocytic leukemia
1505595|NCT00005626|stage IV chronic lymphocytic leukemia
1505596|NCT00005626|refractory chronic lymphocytic leukemia
1505597|NCT00005626|stage I grade 1 follicular lymphoma
1505598|NCT00005626|stage I grade 2 follicular lymphoma
1505599|NCT00005626|stage III grade 1 follicular lymphoma
1505600|NCT00005626|stage III grade 2 follicular lymphoma
1505601|NCT00005626|stage IV grade 1 follicular lymphoma
1505602|NCT00005626|stage IV grade 2 follicular lymphoma
1505603|NCT00005626|recurrent grade 1 follicular lymphoma
1505604|NCT00005626|recurrent grade 2 follicular lymphoma
1505605|NCT00005626|prolymphocytic leukemia
1505606|NCT00005626|stage I mantle cell lymphoma
1505607|NCT00005626|contiguous stage II grade 1 follicular lymphoma
1505608|NCT00005626|contiguous stage II grade 2 follicular lymphoma
1505609|NCT00005626|contiguous stage II mantle cell lymphoma
1505610|NCT00005626|noncontiguous stage II grade 1 follicular lymphoma
1505611|NCT00005626|noncontiguous stage II grade 2 follicular lymphoma
1505612|NCT00005626|noncontiguous stage II mantle cell lymphoma
1505613|NCT00005626|stage III mantle cell lymphoma
1505614|NCT00005626|stage IV mantle cell lymphoma
1505615|NCT00005626|recurrent mantle cell lymphoma
1505616|NCT00005626|noncontiguous stage II small lymphocytic lymphoma
1505617|NCT00005626|noncontiguous stage II marginal zone lymphoma
1505618|NCT00005626|recurrent marginal zone lymphoma
1505619|NCT00005626|recurrent small lymphocytic lymphoma
1505620|NCT00005626|stage I marginal zone lymphoma
1505621|NCT00005626|stage I small lymphocytic lymphoma
1505622|NCT00005626|stage III small lymphocytic lymphoma
1505623|NCT00005626|stage III marginal zone lymphoma
1505624|NCT00005626|stage IV small lymphocytic lymphoma
1505625|NCT00005626|stage IV marginal zone lymphoma
1505626|NCT00005626|contiguous stage II marginal zone lymphoma
1505627|NCT00005626|contiguous stage II small lymphocytic lymphoma
1505628|NCT00005626|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505629|NCT00005626|nodal marginal zone B-cell lymphoma
1505630|NCT00005626|splenic marginal zone lymphoma
1505631|NCT00005625|metastatic osteosarcoma
1505632|NCT00005625|recurrent osteosarcoma
1505633|NCT00005624|refractory multiple myeloma
1505634|NCT00005624|stage II multiple myeloma
1505635|NCT00005624|stage III multiple myeloma
1505636|NCT00005624|plasma cell neoplasm
1505637|NCT00005623|stage IV prostate cancer
1505638|NCT00005623|recurrent prostate cancer
1505639|NCT00005623|hot flashes
1505640|NCT00005622|recurrent childhood acute lymphoblastic leukemia
1505641|NCT00005622|refractory multiple myeloma
1505642|NCT00005622|stage I multiple myeloma
1505643|NCT00005622|stage II multiple myeloma
1505644|NCT00005622|stage III multiple myeloma
1505645|NCT00005622|stage I chronic lymphocytic leukemia
1505646|NCT00005622|stage II chronic lymphocytic leukemia
1505647|NCT00005622|stage III chronic lymphocytic leukemia
1505648|NCT00005622|stage IV chronic lymphocytic leukemia
1505649|NCT00005622|recurrent childhood acute myeloid leukemia
1505650|NCT00005622|recurrent adult acute myeloid leukemia
1505651|NCT00005622|recurrent adult acute lymphoblastic leukemia
1505652|NCT00005622|refractory chronic lymphocytic leukemia
1505653|NCT00005622|chronic phase chronic myelogenous leukemia
1505654|NCT00005622|accelerated phase chronic myelogenous leukemia
1505655|NCT00005622|blastic phase chronic myelogenous leukemia
1505656|NCT00005622|adult acute myeloid leukemia in remission
1505657|NCT00005622|adult acute lymphoblastic leukemia in remission
1505658|NCT00005622|childhood acute myeloid leukemia in remission
1505659|NCT00005622|childhood acute lymphoblastic leukemia in remission
1505660|NCT00005622|polycythemia vera
1505661|NCT00005622|primary myelofibrosis
1505662|NCT00005622|essential thrombocythemia
1505663|NCT00005622|refractory anemia
1505664|NCT00005622|refractory anemia with ringed sideroblasts
1505665|NCT00005622|refractory anemia with excess blasts
1505666|NCT00005622|refractory anemia with excess blasts in transformation
1505667|NCT00005622|chronic myelomonocytic leukemia
1505668|NCT00005622|de novo myelodysplastic syndromes
1505669|NCT00005622|previously treated myelodysplastic syndromes
1505670|NCT00005622|secondary myelodysplastic syndromes
1505671|NCT00005622|refractory cytopenia with multilineage dysplasia
1505672|NCT00005622|chronic eosinophilic leukemia
1505673|NCT00005622|chronic neutrophilic leukemia
1505674|NCT00005622|atypical chronic myeloid leukemia, BCR-ABL1 negative
1505675|NCT00005622|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1505676|NCT00005622|adult acute myeloid leukemia with t(8;21)(q22;q22)
1505677|NCT00005622|adult acute myeloid leukemia with t(16;16)(p13;q22)
1505678|NCT00005622|adult acute myeloid leukemia with inv(16)(p13;q22)
1505679|NCT00005622|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1505680|NCT00005622|adult acute myeloid leukemia with t(15;17)(q22;q12)
1505681|NCT00005622|childhood myelodysplastic syndromes
1505682|NCT00005619|progressive hairy cell leukemia, initial treatment
1505683|NCT00005619|refractory hairy cell leukemia
1505684|NCT00005618|relapsing chronic myelogenous leukemia
1505685|NCT00005618|chronic phase chronic myelogenous leukemia
1505686|NCT00005618|accelerated phase chronic myelogenous leukemia
1505687|NCT00005618|blastic phase chronic myelogenous leukemia
1505688|NCT00005617|stage IV melanoma
1505689|NCT00005617|recurrent melanoma
1505690|NCT00005616|stage I colon cancer
1505691|NCT00005616|stage II colon cancer
1505692|NCT00005616|stage III colon cancer
1505693|NCT00005616|stage IV colon cancer
1505694|NCT00005616|stage I rectal cancer
1505695|NCT00005616|stage II rectal cancer
1505696|NCT00005616|stage III rectal cancer
1505697|NCT00005616|stage IV rectal cancer
1505698|NCT00005616|recurrent colon cancer
1505699|NCT00005616|recurrent rectal cancer
1505700|NCT00005616|liver metastases
1505701|NCT00005615|stage III melanoma
1505702|NCT00005615|recurrent melanoma
1505703|NCT00005614|stage IV breast cancer
1505704|NCT00005614|recurrent breast cancer
1505705|NCT00005613|stage III adult Hodgkin lymphoma
1505706|NCT00005613|stage IV adult Hodgkin lymphoma
1505707|NCT00005613|recurrent adult Hodgkin lymphoma
1505708|NCT00005613|recurrent grade 1 follicular lymphoma
1505709|NCT00005613|recurrent grade 2 follicular lymphoma
1505710|NCT00005613|recurrent grade 3 follicular lymphoma
1505711|NCT00005613|recurrent adult diffuse small cleaved cell lymphoma
1505712|NCT00005613|recurrent adult diffuse mixed cell lymphoma
1505713|NCT00005613|recurrent adult diffuse large cell lymphoma
1505714|NCT00005613|recurrent adult immunoblastic large cell lymphoma
1505715|NCT00005613|recurrent adult Burkitt lymphoma
1505716|NCT00005613|recurrent mantle cell lymphoma
1505717|NCT00005613|recurrent marginal zone lymphoma
1505718|NCT00005613|recurrent small lymphocytic lymphoma
1505719|NCT00005613|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505720|NCT00005613|nodal marginal zone B-cell lymphoma
1505721|NCT00005613|splenic marginal zone lymphoma
1505722|NCT00005612|stage III ovarian epithelial cancer
1505723|NCT00005612|stage IV ovarian epithelial cancer
1505724|NCT00005612|recurrent ovarian epithelial cancer
1505725|NCT00005611|unspecified adult solid tumor, protocol specific
1505726|NCT00005610|stage IV melanoma
1505727|NCT00005610|recurrent melanoma
1505728|NCT00005610|lung metastases
1505729|NCT00005609|Waldenström macroglobulinemia
1505730|NCT00005608|stage IV breast cancer
1505731|NCT00005608|recurrent breast cancer
1505732|NCT00005607|stage IV gastric cancer
1505733|NCT00005607|recurrent gastric cancer
1505734|NCT00005607|stage IV esophageal cancer
1505735|NCT00005607|recurrent esophageal cancer
1505736|NCT00005607|adenocarcinoma of the stomach
1505737|NCT00005607|adenocarcinoma of the esophagus
1505738|NCT00005606|stage I adult Hodgkin lymphoma
1505739|NCT00005606|stage II adult Hodgkin lymphoma
1505740|NCT00005606|stage III adult Hodgkin lymphoma
1505741|NCT00005606|stage IV adult Hodgkin lymphoma
1505742|NCT00005606|recurrent childhood acute lymphoblastic leukemia
1505743|NCT00005606|recurrent adult Hodgkin lymphoma
1505744|NCT00005606|stage I cutaneous T-cell non-Hodgkin lymphoma
1506137|NCT00005118|Indinavir
1505745|NCT00005606|stage II cutaneous T-cell non-Hodgkin lymphoma
1505746|NCT00005606|stage III cutaneous T-cell non-Hodgkin lymphoma
1505747|NCT00005606|stage IV cutaneous T-cell non-Hodgkin lymphoma
1505748|NCT00005606|recurrent cutaneous T-cell non-Hodgkin lymphoma
1505749|NCT00005606|isolated plasmacytoma of bone
1505750|NCT00005606|extramedullary plasmacytoma
1505751|NCT00005606|stage 0 chronic lymphocytic leukemia
1505752|NCT00005606|stage I multiple myeloma
1505753|NCT00005606|stage II multiple myeloma
1505754|NCT00005606|stage III multiple myeloma
1505755|NCT00005606|stage I chronic lymphocytic leukemia
1505756|NCT00005606|stage II chronic lymphocytic leukemia
1505757|NCT00005606|stage III chronic lymphocytic leukemia
1505758|NCT00005606|stage IV chronic lymphocytic leukemia
1505759|NCT00005606|recurrent adult acute lymphoblastic leukemia
1505760|NCT00005606|refractory chronic lymphocytic leukemia
1505761|NCT00005606|untreated adult acute lymphoblastic leukemia
1505762|NCT00005606|untreated childhood acute lymphoblastic leukemia
1505763|NCT00005606|adult acute lymphoblastic leukemia in remission
1505764|NCT00005606|childhood acute lymphoblastic leukemia in remission
1505765|NCT00005606|untreated hairy cell leukemia
1505766|NCT00005606|progressive hairy cell leukemia, initial treatment
1505767|NCT00005606|refractory hairy cell leukemia
1505768|NCT00005606|stage II childhood Hodgkin lymphoma
1505769|NCT00005606|stage I childhood Hodgkin lymphoma
1505770|NCT00005606|stage III childhood Hodgkin lymphoma
1505771|NCT00005606|stage IV childhood Hodgkin lymphoma
1505772|NCT00005606|recurrent/refractory childhood Hodgkin lymphoma
1505773|NCT00005606|stage IV small lymphocytic lymphoma
1505774|NCT00005606|stage I adult T-cell leukemia/lymphoma
1505775|NCT00005606|stage II adult T-cell leukemia/lymphoma
1505776|NCT00005606|stage III adult T-cell leukemia/lymphoma
1505777|NCT00005606|stage IV adult T-cell leukemia/lymphoma
1505778|NCT00005606|recurrent adult T-cell leukemia/lymphoma
1505779|NCT00005606|stage I mycosis fungoides/Sezary syndrome
1505780|NCT00005606|stage II mycosis fungoides/Sezary syndrome
1505781|NCT00005606|stage III mycosis fungoides/Sezary syndrome
1505782|NCT00005606|stage IV mycosis fungoides/Sezary syndrome
1505783|NCT00005606|recurrent mycosis fungoides/Sezary syndrome
1505784|NCT00005606|noncontiguous stage II small lymphocytic lymphoma
1505785|NCT00005606|noncontiguous stage II marginal zone lymphoma
1505786|NCT00005606|recurrent marginal zone lymphoma
1505787|NCT00005606|recurrent small lymphocytic lymphoma
1505788|NCT00005606|stage I marginal zone lymphoma
1505789|NCT00005606|stage I small lymphocytic lymphoma
1505790|NCT00005606|stage II small lymphocytic lymphoma
1505791|NCT00005606|stage II marginal zone lymphoma
1505792|NCT00005606|stage III small lymphocytic lymphoma
1505793|NCT00005606|stage III marginal zone lymphoma
1505794|NCT00005606|stage IV marginal zone lymphoma
1505795|NCT00005606|contiguous stage II marginal zone lymphoma
1505796|NCT00005606|contiguous stage II small lymphocytic lymphoma
1505797|NCT00005606|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505798|NCT00005606|nodal marginal zone B-cell lymphoma
1505799|NCT00005606|splenic marginal zone lymphoma
1505800|NCT00005605|osteoporosis
1505801|NCT00005605|stage I breast cancer
1505802|NCT00005605|stage II breast cancer
1505803|NCT00005603|childhood acute lymphoblastic leukemia in remission
1505804|NCT00005603|B-cell childhood acute lymphoblastic leukemia
1505805|NCT00005602|untreated childhood brain stem glioma
1505806|NCT00005601|recurrent grade 1 follicular lymphoma
1505807|NCT00005601|recurrent grade 2 follicular lymphoma
1505808|NCT00005601|recurrent grade 3 follicular lymphoma
1505809|NCT00005601|recurrent adult diffuse small cleaved cell lymphoma
1505810|NCT00005601|recurrent adult diffuse mixed cell lymphoma
1505811|NCT00005601|recurrent adult diffuse large cell lymphoma
1505812|NCT00005601|recurrent adult immunoblastic large cell lymphoma
1505813|NCT00005601|recurrent adult lymphoblastic lymphoma
1505814|NCT00005601|recurrent adult Burkitt lymphoma
1505815|NCT00005601|recurrent mantle cell lymphoma
1505816|NCT00005601|recurrent marginal zone lymphoma
1505817|NCT00005601|recurrent small lymphocytic lymphoma
1505818|NCT00005601|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505819|NCT00005601|nodal marginal zone B-cell lymphoma
1505820|NCT00005601|splenic marginal zone lymphoma
1505821|NCT00005600|stage I breast cancer
1505822|NCT00005600|stage II breast cancer
1505823|NCT00005600|lymphedema
1505824|NCT00005600|perioperative/postoperative complications
1505825|NCT00005599|stage III gastric cancer
1505826|NCT00005599|stage IV gastric cancer
1505827|NCT00005599|recurrent gastric cancer
1505828|NCT00005599|stage III esophageal cancer
1505829|NCT00005599|stage IV esophageal cancer
1505830|NCT00005599|recurrent esophageal cancer
1505831|NCT00005599|squamous cell carcinoma of the esophagus
1505832|NCT00005599|adenocarcinoma of the esophagus
1505833|NCT00005598|refractory anemia
1505834|NCT00005598|de novo myelodysplastic syndromes
1505835|NCT00005598|previously treated myelodysplastic syndromes
1505836|NCT00005598|secondary myelodysplastic syndromes
1505837|NCT00005597|gastrointestinal stromal tumor
1505838|NCT00005596|untreated childhood acute lymphoblastic leukemia
1505839|NCT00005595|recurrent adult Hodgkin lymphoma
1505840|NCT00005594|stage III pancreatic cancer
1505841|NCT00005594|adenocarcinoma of the pancreas
1505842|NCT00005594|stage IV pancreatic cancer
1505843|NCT00005593|recurrent childhood acute lymphoblastic leukemia
1505844|NCT00005593|recurrent childhood acute myeloid leukemia
1505845|NCT00005593|recurrent adult acute myeloid leukemia
1505846|NCT00005593|recurrent adult acute lymphoblastic leukemia
1505847|NCT00005593|relapsing chronic myelogenous leukemia
1505848|NCT00005593|blastic phase chronic myelogenous leukemia
1505849|NCT00005593|L1 childhood acute lymphoblastic leukemia
1505850|NCT00005593|L2 childhood acute lymphoblastic leukemia
1505851|NCT00005593|L1 adult acute lymphoblastic leukemia
1505852|NCT00005593|L2 adult acute lymphoblastic leukemia
1505853|NCT00005593|adult acute erythroid leukemia (M6)
1505854|NCT00005593|adult acute myeloblastic leukemia without maturation (M1)
1505855|NCT00005593|adult acute myeloblastic leukemia with maturation (M2)
1505856|NCT00005593|adult acute promyelocytic leukemia (M3)
1505857|NCT00005593|adult acute myelomonocytic leukemia (M4)
1505858|NCT00005593|adult acute monoblastic leukemia (M5a)
1505859|NCT00005593|adult acute megakaryoblastic leukemia (M7)
1505860|NCT00005593|childhood acute myeloblastic leukemia without maturation (M1)
1505861|NCT00005593|childhood acute myeloblastic leukemia with maturation (M2)
1505862|NCT00005593|childhood acute promyelocytic leukemia (M3)
1505863|NCT00005593|childhood acute myelomonocytic leukemia (M4)
1505864|NCT00005593|childhood acute monoblastic leukemia (M5a)
1505865|NCT00005593|childhood acute monocytic leukemia (M5b)
1505866|NCT00005593|childhood acute erythroleukemia (M6)
1505867|NCT00005593|childhood acute megakaryocytic leukemia (M7)
1505868|NCT00005593|refractory anemia with excess blasts
1505869|NCT00005593|refractory anemia with excess blasts in transformation
1505870|NCT00005593|chronic myelomonocytic leukemia
1505871|NCT00005593|secondary acute myeloid leukemia
1505872|NCT00005593|adult acute monocytic leukemia (M5b)
1505873|NCT00005593|previously treated myelodysplastic syndromes
1505874|NCT00005593|secondary myelodysplastic syndromes
1505875|NCT00005593|adult acute minimally differentiated myeloid leukemia (M0)
1505876|NCT00005593|childhood acute minimally differentiated myeloid leukemia (M0)
1505877|NCT00005593|childhood myelodysplastic syndromes
1505878|NCT00005592|recurrent grade 1 follicular lymphoma
1505879|NCT00005592|recurrent grade 2 follicular lymphoma
1505880|NCT00005592|recurrent grade 3 follicular lymphoma
1505881|NCT00005592|recurrent adult diffuse small cleaved cell lymphoma
1505882|NCT00005592|recurrent marginal zone lymphoma
1505883|NCT00005592|recurrent small lymphocytic lymphoma
1505884|NCT00005592|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1505885|NCT00005592|nodal marginal zone B-cell lymphoma
1505886|NCT00005592|splenic marginal zone lymphoma
1505887|NCT00005591|stage III pancreatic cancer
1505888|NCT00005591|recurrent pancreatic cancer
1505889|NCT00005591|adenocarcinoma of the pancreas
1505890|NCT00005591|stage IV pancreatic cancer
1505891|NCT00005590|stage I adult Hodgkin lymphoma
1505892|NCT00005590|stage II adult Hodgkin lymphoma
1505893|NCT00005590|stage III adult Hodgkin lymphoma
1505894|NCT00005590|stage IV adult Hodgkin lymphoma
1505895|NCT00005590|recurrent breast cancer
1505896|NCT00005590|recurrent adult Hodgkin lymphoma
1505897|NCT00005590|stage I cutaneous T-cell non-Hodgkin lymphoma
1505898|NCT00005590|stage II cutaneous T-cell non-Hodgkin lymphoma
1505899|NCT00005590|stage III cutaneous T-cell non-Hodgkin lymphoma
1505900|NCT00005590|stage IV cutaneous T-cell non-Hodgkin lymphoma
1505901|NCT00005590|recurrent cutaneous T-cell non-Hodgkin lymphoma
1505902|NCT00005590|limited stage small cell lung cancer
1505903|NCT00005590|extensive stage small cell lung cancer
1505904|NCT00005590|recurrent small cell lung cancer
1505905|NCT00005590|small intestine lymphoma
1505906|NCT00005590|stage II malignant testicular germ cell tumor
1505907|NCT00005590|stage III malignant testicular germ cell tumor
1505908|NCT00005590|unspecified adult solid tumor, protocol specific
1505909|NCT00005590|stage I grade 2 follicular lymphoma
1505910|NCT00005590|stage I grade 3 follicular lymphoma
1505911|NCT00005590|stage I adult diffuse small cleaved cell lymphoma
1505912|NCT00005590|stage I adult diffuse mixed cell lymphoma
1505913|NCT00005590|stage I adult diffuse large cell lymphoma
1505914|NCT00005590|stage I adult immunoblastic large cell lymphoma
1505915|NCT00005590|stage I adult lymphoblastic lymphoma
1505916|NCT00005590|stage I adult Burkitt lymphoma
1505917|NCT00005590|stage II ovarian germ cell tumor
1505918|NCT00005590|stage III ovarian germ cell tumor
1505919|NCT00005590|stage IV ovarian germ cell tumor
1505920|NCT00005590|stage III grade 1 follicular lymphoma
1505921|NCT00005590|stage III grade 2 follicular lymphoma
1505922|NCT00005590|stage III grade 3 follicular lymphoma
1505923|NCT00005590|stage III adult diffuse small cleaved cell lymphoma
1505924|NCT00005590|stage III adult diffuse mixed cell lymphoma
1505925|NCT00005590|stage III adult diffuse large cell lymphoma
1505926|NCT00005590|stage III adult immunoblastic large cell lymphoma
1505927|NCT00005590|stage III adult lymphoblastic lymphoma
1505928|NCT00005590|stage III adult Burkitt lymphoma
1505929|NCT00005590|stage IV grade 1 follicular lymphoma
1505930|NCT00005590|stage IV grade 2 follicular lymphoma
1505931|NCT00005590|stage IV grade 3 follicular lymphoma
1505932|NCT00005590|stage IV adult diffuse small cleaved cell lymphoma
1505933|NCT00005590|stage IV adult diffuse mixed cell lymphoma
1505934|NCT00005590|stage IV adult diffuse large cell lymphoma
1505935|NCT00005590|stage IV adult immunoblastic large cell lymphoma
1505936|NCT00005590|stage IV adult lymphoblastic lymphoma
1505937|NCT00005590|stage IV adult Burkitt lymphoma
1505938|NCT00005590|recurrent grade 1 follicular lymphoma
1505939|NCT00005590|recurrent grade 2 follicular lymphoma
1505940|NCT00005590|recurrent grade 3 follicular lymphoma
1505941|NCT00005590|recurrent adult diffuse small cleaved cell lymphoma
1505942|NCT00005590|recurrent adult diffuse mixed cell lymphoma
1505943|NCT00005590|recurrent adult diffuse large cell lymphoma
1505944|NCT00005590|recurrent adult immunoblastic large cell lymphoma
1505945|NCT00005590|recurrent adult lymphoblastic lymphoma
1505946|NCT00005590|recurrent adult Burkitt lymphoma
1505947|NCT00005590|stage I adult T-cell leukemia/lymphoma
1505948|NCT00005590|stage II adult T-cell leukemia/lymphoma
1505949|NCT00005590|stage III adult T-cell leukemia/lymphoma
1505950|NCT00005590|stage IV adult T-cell leukemia/lymphoma
1505951|NCT00005590|recurrent adult T-cell leukemia/lymphoma
1505952|NCT00005590|extragonadal germ cell tumor
1505953|NCT00005590|adult central nervous system germ cell tumor
1505954|NCT00005590|primary central nervous system non-Hodgkin lymphoma
1505955|NCT00005590|infection
1505956|NCT00005590|intraocular lymphoma
1505957|NCT00005590|stage I mantle cell lymphoma
1505958|NCT00005590|contiguous stage II grade 1 follicular lymphoma
1505959|NCT00005590|contiguous stage II grade 2 follicular lymphoma
1505960|NCT00005590|contiguous stage II grade 3 follicular lymphoma
1505961|NCT00005590|contiguous stage II adult diffuse small cleaved cell lymphoma
1505962|NCT00005590|contiguous stage II mantle cell lymphoma
1505963|NCT00005590|contiguous stage II adult diffuse mixed cell lymphoma
1505964|NCT00005590|contiguous stage II adult immunoblastic large cell lymphoma
1505965|NCT00005590|contiguous stage II adult diffuse large cell lymphoma
1505966|NCT00005590|contiguous stage II adult Burkitt lymphoma
1505967|NCT00005590|contiguous stage II adult lymphoblastic lymphoma
1505968|NCT00005590|noncontiguous stage II grade 1 follicular lymphoma
1505969|NCT00005590|noncontiguous stage II grade 2 follicular lymphoma
1505970|NCT00005590|noncontiguous stage II grade 3 follicular lymphoma
1505971|NCT00005590|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1505972|NCT00005590|noncontiguous stage II mantle cell lymphoma
1505973|NCT00005590|noncontiguous stage II adult diffuse mixed cell lymphoma
1505974|NCT00005590|noncontiguous stage II adult immunoblastic large cell lymphoma
1505975|NCT00005590|noncontiguous stage II adult diffuse large cell lymphoma
1505976|NCT00005590|noncontiguous stage II adult Burkitt lymphoma
1505977|NCT00005590|noncontiguous stage II adult lymphoblastic lymphoma
1505978|NCT00005590|stage III mantle cell lymphoma
1505979|NCT00005590|stage IV mantle cell lymphoma
1505980|NCT00005590|recurrent mantle cell lymphoma
1505981|NCT00005590|angioimmunoblastic T-cell lymphoma
1505982|NCT00005590|anaplastic large cell lymphoma
1505983|NCT00005590|stage I mycosis fungoides/Sezary syndrome
1505984|NCT00005590|stage II mycosis fungoides/Sezary syndrome
1505985|NCT00005590|stage III mycosis fungoides/Sezary syndrome
1505986|NCT00005590|stage IV mycosis fungoides/Sezary syndrome
1505987|NCT00005590|recurrent mycosis fungoides/Sezary syndrome
1505988|NCT00005590|contiguous stage II marginal zone lymphoma
1505989|NCT00005590|contiguous stage II small lymphocytic lymphoma
1505990|NCT00005590|noncontiguous stage II small lymphocytic lymphoma
1505991|NCT00005590|noncontiguous stage II marginal zone lymphoma
1505992|NCT00005590|recurrent marginal zone lymphoma
1505993|NCT00005590|recurrent small lymphocytic lymphoma
1505994|NCT00005590|stage I marginal zone lymphoma
1505995|NCT00005590|stage I small lymphocytic lymphoma
1505996|NCT00005590|stage II small lymphocytic lymphoma
1505997|NCT00005590|stage II marginal zone lymphoma
1505998|NCT00005590|stage III small lymphocytic lymphoma
1505999|NCT00005590|stage III marginal zone lymphoma
1506000|NCT00005590|stage IV small lymphocytic lymphoma
1506001|NCT00005590|stage IV marginal zone lymphoma
1506002|NCT00005590|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1506003|NCT00005590|nodal marginal zone B-cell lymphoma
1506004|NCT00005590|splenic marginal zone lymphoma
1506005|NCT00005589|recurrent grade 1 follicular lymphoma
1506006|NCT00005589|recurrent grade 2 follicular lymphoma
1506007|NCT00005589|recurrent grade 3 follicular lymphoma
1506008|NCT00005588|stage I breast cancer
1506009|NCT00005588|stage II breast cancer
1506010|NCT00005588|stage IIIA breast cancer
1506011|NCT00005587|stage I breast cancer
1506012|NCT00005587|stage II breast cancer
1506013|NCT00005587|stage IIIA breast cancer
1506014|NCT00005586|stage II colon cancer
1506015|NCT00005586|stage III colon cancer
1506016|NCT00005586|stage II rectal cancer
1506017|NCT00005586|stage III rectal cancer
1506018|NCT00005585|childhood acute lymphoblastic leukemia in remission
1506019|NCT00005585|B-cell childhood acute lymphoblastic leukemia
1506020|NCT00005584|stage I adult Hodgkin lymphoma
1506021|NCT00005584|stage II adult Hodgkin lymphoma
1506022|NCT00005584|adult lymphocyte predominant Hodgkin lymphoma
1506023|NCT00005583|stage I endometrial carcinoma
1506024|NCT00005583|stage II endometrial carcinoma
1506025|NCT00005583|endometrial adenocarcinoma
1507561|NCT00004870|stage IV rectal cancer
1506026|NCT00005583|endometrial papillary serous carcinoma
1506027|NCT00005583|endometrial clear cell carcinoma
1506028|NCT00005581|stage II breast cancer
1506029|NCT00005581|stage IIIA breast cancer
1506030|NCT00005581|stage IIIB breast cancer
1506031|NCT00005580|recurrent cutaneous T-cell non-Hodgkin lymphoma
1506032|NCT00005580|Waldenstrom macroglobulinemia
1506033|NCT00005580|stage I chronic lymphocytic leukemia
1506034|NCT00005580|stage II chronic lymphocytic leukemia
1506035|NCT00005580|stage III chronic lymphocytic leukemia
1506036|NCT00005580|stage IV chronic lymphocytic leukemia
1506037|NCT00005580|refractory chronic lymphocytic leukemia
1506038|NCT00005580|T-cell large granular lymphocyte leukemia
1506039|NCT00005580|B-cell chronic lymphocytic leukemia
1506040|NCT00005580|refractory hairy cell leukemia
1506041|NCT00005580|recurrent grade 1 follicular lymphoma
1506042|NCT00005580|recurrent grade 2 follicular lymphoma
1506043|NCT00005580|recurrent adult diffuse small cleaved cell lymphoma
1506044|NCT00005580|recurrent adult T-cell leukemia/lymphoma
1506045|NCT00005580|prolymphocytic leukemia
1506046|NCT00005580|recurrent mantle cell lymphoma
1506047|NCT00005580|recurrent mycosis fungoides/Sezary syndrome
1506048|NCT00005580|recurrent marginal zone lymphoma
1506049|NCT00005580|recurrent small lymphocytic lymphoma
1506050|NCT00005580|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1506051|NCT00005580|nodal marginal zone B-cell lymphoma
1506052|NCT00005580|splenic marginal zone lymphoma
1506053|NCT00005579|Waldenström macroglobulinemia
1506054|NCT00005579|stage I chronic lymphocytic leukemia
1506055|NCT00005579|stage II chronic lymphocytic leukemia
1506056|NCT00005579|stage III chronic lymphocytic leukemia
1506057|NCT00005579|stage IV chronic lymphocytic leukemia
1506058|NCT00005579|refractory chronic lymphocytic leukemia
1506059|NCT00005579|stage III grade 1 follicular lymphoma
1506060|NCT00005579|stage III grade 2 follicular lymphoma
1506061|NCT00005579|stage III adult diffuse small cleaved cell lymphoma
1506062|NCT00005579|stage IV grade 1 follicular lymphoma
1506063|NCT00005579|stage IV grade 2 follicular lymphoma
1506064|NCT00005579|stage IV adult diffuse small cleaved cell lymphoma
1506065|NCT00005579|recurrent grade 1 follicular lymphoma
1506066|NCT00005579|recurrent grade 2 follicular lymphoma
1506067|NCT00005579|recurrent adult diffuse small cleaved cell lymphoma
1506068|NCT00005579|recurrent small lymphocytic lymphoma
1506069|NCT00005579|stage III small lymphocytic lymphoma
1506070|NCT00005579|stage IV small lymphocytic lymphoma
1506071|NCT00005578|stage II childhood Hodgkin lymphoma
1506072|NCT00005578|stage I childhood Hodgkin lymphoma
1506073|NCT00005578|stage III childhood Hodgkin lymphoma
1506074|NCT00005578|stage IV childhood Hodgkin lymphoma
1506075|NCT00005578|cardiac toxicity
1506076|NCT00005577|unspecified childhood solid tumor, protocol specific
1506077|NCT00005575|Imipramine
1506078|NCT00005575|Cognitive-Behavioral Therapy
1506079|NCT00005574|Becker Muscular Dystrophy
1506080|NCT00005574|Duchenne Muscular Dystrophy
1506081|NCT00005574|Muscle Disease
1506082|NCT00005574|Myopathy
1506083|NCT00005572|AIDS-Related Opportunistic Infections
1506084|NCT00005572|Pneumonia, Pneumocystis carinii
1506085|NCT00005572|Lymphocytes
1506086|NCT00005572|Histoplasmosis
1506087|NCT00005572|Recurrence
1506088|NCT00005572|Cytomegalovirus Retinitis
1506089|NCT00005572|Cell Division
1506090|NCT00005572|Immunocompetence
1506091|NCT00005572|Anti-HIV Agents
1506092|NCT00005571|Skin
1506093|NCT00005571|Humoral Immunity
1506094|NCT00005571|Myositis
1506095|NCT00005571|Complement
1506096|NCT00005571|Antibody
1506097|NCT00005571|Dermatomyositis
1506098|NCT00005570|Bleeding
1506099|NCT00005570|Cytokines
1506100|NCT00005570|Immune Response
1506101|NCT00005570|Pharmacogenomic
1506102|NCT00005570|Serum Antibodies
1506103|NCT00005570|ITP
1506104|NCT00005570|Immune Thrombocytopenia Purpura
1506105|NCT00005569|Elastase
1506106|NCT00005569|Inflammation
1506107|NCT00005569|Age
1506108|NCT00005569|Gender
1506109|NCT00005569|Cytokine
1506110|NCT00005569|Healthy Volunteer
1506111|NCT00005566|Suicide
1506112|NCT00005520|Hypertension
1506113|NCT00005520|Pharmacogenetics
1506114|NCT00005520|Hydrochlorothiazide
1506115|NCT00005520|Candesartan
1506116|NCT00005487|Coronary Arteriosclerosis
1506117|NCT00005487|Cerebrovascular Accident
1506118|NCT00005487|Heart Failure, Congestive
1506119|NCT00005487|Diabetes Mellitus, Non-Insulin Dependent
1506120|NCT00005120|CD4 Lymphocyte Count
1506121|NCT00005120|Biological Markers
1506122|NCT00005120|Anti-HIV Agents
1506123|NCT00005120|Viral Load
1506124|NCT00005120|Pharmacokinetics
1506125|NCT00005120|calanolide A
1506126|NCT00005119|Premenstrual Dysphoric Disorder
1506127|NCT00005119|Severe Premenstrual Syndrome
1506128|NCT00005119|Calcium metabolism
1506129|NCT00005119|Vitamin D
1506130|NCT00005119|Bone Markers
1506131|NCT00005119|Premenopausal
1506132|NCT00005119|Menstrual Cycle
1506133|NCT00005118|HIV-1
1506134|NCT00005118|Drug Therapy, Combination
1506135|NCT00005118|HIV Protease Inhibitors
1506138|NCT00005118|Reverse Transcriptase Inhibitors
1506139|NCT00005118|Anti-HIV Agents
1506140|NCT00005118|Viral Load
1506141|NCT00005118|Nelfinavir
1506142|NCT00005117|endothelial dysfunction
1506143|NCT00005116|depression
1506144|NCT00005111|Blood Flow
1506145|NCT00005111|Glucose
1506146|NCT00005111|Lysosomal Disease
1506147|NCT00005111|Metabolic
1506148|NCT00005111|Uptake
1506149|NCT00005111|Fabry Disease
1506150|NCT00005108|Menopause
1506151|NCT00005108|Atherosclerosis
1506152|NCT00005108|Estrogen
1506153|NCT00005108|MRI
1506154|NCT00005108|Ultrasound
1506155|NCT00005106|Drug Therapy, Combination
1506156|NCT00005106|Zidovudine
1506157|NCT00005106|Stavudine
1506158|NCT00005106|HIV Protease Inhibitors
1506159|NCT00005106|Lamivudine
1506160|NCT00005106|Nelfinavir
1506161|NCT00005106|Reverse Transcriptase Inhibitors
1506162|NCT00005106|Anti-HIV Agents
1506163|NCT00005106|Adipose Tissue
1506164|NCT00005106|Lipodystrophy
1506165|NCT00005106|abacavir
1506166|NCT00005105|endocrine disorders
1506167|NCT00005105|intrauterine growth retardation
1506168|NCT00005105|rare disease
1506169|NCT00005104|endocrine disorders
1506170|NCT00005104|hyperinsulinism
1506171|NCT00005104|polycystic ovarian syndrome
1506172|NCT00005104|rare disease
1506173|NCT00005103|inborn errors of metabolism
1506174|NCT00005103|porphyria
1506175|NCT00005103|porphyria cutanea tarda
1506176|NCT00005103|rare disease
1506177|NCT00005102|DiGeorge syndrome
1506178|NCT00005102|Shprintzen syndrome
1506179|NCT00005102|cardiovascular and respiratory diseases
1506180|NCT00005102|conotruncal cardiac defects
1506181|NCT00005102|genetic diseases and dysmorphic syndromes
1506182|NCT00005102|rare disease
1506183|NCT00005101|disease-related problem/condition
1506184|NCT00005101|osteoporosis
1506185|NCT00005101|rare disease
1506186|NCT00005100|acromegaly
1506187|NCT00005100|endocrine disorders
1506188|NCT00005100|rare disease
1506189|NCT00005021|stage III adult Hodgkin lymphoma
1506190|NCT00005021|stage IV adult Hodgkin lymphoma
1506191|NCT00005021|recurrent adult Hodgkin lymphoma
1506192|NCT00005021|stage III cutaneous T-cell non-Hodgkin lymphoma
1506193|NCT00005021|stage IV cutaneous T-cell non-Hodgkin lymphoma
1506194|NCT00005021|recurrent cutaneous T-cell non-Hodgkin lymphoma
1506195|NCT00005021|small intestine lymphoma
1506196|NCT00005021|unspecified adult solid tumor, protocol specific
1506197|NCT00005021|stage III grade 1 follicular lymphoma
1506198|NCT00005021|stage III grade 2 follicular lymphoma
1506199|NCT00005021|stage III grade 3 follicular lymphoma
1506200|NCT00005021|stage III adult diffuse small cleaved cell lymphoma
1506201|NCT00005021|stage III adult diffuse mixed cell lymphoma
1506202|NCT00005021|stage III adult diffuse large cell lymphoma
1506203|NCT00005021|stage III adult immunoblastic large cell lymphoma
1506204|NCT00005021|stage III adult lymphoblastic lymphoma
1506205|NCT00005021|stage III adult Burkitt lymphoma
1506206|NCT00005021|stage IV grade 1 follicular lymphoma
1506207|NCT00005021|stage IV grade 2 follicular lymphoma
1506208|NCT00005021|stage IV grade 3 follicular lymphoma
1506209|NCT00005021|stage IV adult diffuse small cleaved cell lymphoma
1506210|NCT00005021|stage IV adult diffuse mixed cell lymphoma
1506211|NCT00005021|stage IV adult diffuse large cell lymphoma
1506212|NCT00005021|stage IV adult immunoblastic large cell lymphoma
1506213|NCT00005021|stage IV adult lymphoblastic lymphoma
1506214|NCT00005021|stage IV adult Burkitt lymphoma
1506215|NCT00005021|recurrent grade 1 follicular lymphoma
1506216|NCT00005021|recurrent grade 2 follicular lymphoma
1506217|NCT00005021|recurrent grade 3 follicular lymphoma
1506218|NCT00005021|recurrent adult diffuse small cleaved cell lymphoma
1506219|NCT00005021|recurrent adult diffuse mixed cell lymphoma
1506220|NCT00005021|recurrent adult diffuse large cell lymphoma
1506221|NCT00005021|recurrent adult immunoblastic large cell lymphoma
1506222|NCT00005021|recurrent adult lymphoblastic lymphoma
1506223|NCT00005021|recurrent adult Burkitt lymphoma
1506224|NCT00005021|stage III adult T-cell leukemia/lymphoma
1506225|NCT00005021|stage IV adult T-cell leukemia/lymphoma
1506226|NCT00005021|recurrent adult T-cell leukemia/lymphoma
1506227|NCT00005021|primary central nervous system non-Hodgkin lymphoma
1506228|NCT00005021|AIDS-related peripheral/systemic lymphoma
1506229|NCT00005021|AIDS-related primary CNS lymphoma
1506230|NCT00005021|intraocular lymphoma
1506231|NCT00005021|stage III mantle cell lymphoma
1506232|NCT00005021|stage IV mantle cell lymphoma
1506233|NCT00005021|recurrent mantle cell lymphoma
1506234|NCT00005021|angioimmunoblastic T-cell lymphoma
1506235|NCT00005021|anaplastic large cell lymphoma
1506236|NCT00005021|stage III mycosis fungoides/Sezary syndrome
1506237|NCT00005021|stage IV mycosis fungoides/Sezary syndrome
1506238|NCT00005021|recurrent mycosis fungoides/Sezary syndrome
1506239|NCT00005021|recurrent marginal zone lymphoma
1506240|NCT00005021|recurrent small lymphocytic lymphoma
1506241|NCT00005021|stage III small lymphocytic lymphoma
1506242|NCT00005021|stage III marginal zone lymphoma
1506243|NCT00005021|stage IV small lymphocytic lymphoma
1506244|NCT00005021|stage IV marginal zone lymphoma
1506245|NCT00005021|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1506246|NCT00005021|nodal marginal zone B-cell lymphoma
1506247|NCT00005021|splenic marginal zone lymphoma
1506248|NCT00005020|CD4 Lymphocyte Count
1506249|NCT00005020|CD4-Positive T-Lymphocytes
1506250|NCT00005020|Phenotype
1506251|NCT00005020|Viral Load
1506252|NCT00005020|Acute Infection
1506253|NCT00005018|HIV-1
1506254|NCT00005018|Didanosine
1506255|NCT00005018|Drug Therapy, Combination
1506256|NCT00005018|Zidovudine
1506257|NCT00005018|Stavudine
1506258|NCT00005018|HIV Protease Inhibitors
1506259|NCT00005018|Hydroxyurea
1506260|NCT00005018|RNA, Viral
1506261|NCT00005018|Reverse Transcriptase Inhibitors
1506262|NCT00005018|Anti-HIV Agents
1506263|NCT00005018|Viral Load
1506264|NCT00005018|abacavir
1506265|NCT00005018|efavirenz
1506266|NCT00005098|alpha 1-antitrypsin deficiency
1506267|NCT00005098|genetic diseases and dysmorphic syndromes
1506268|NCT00005098|rare disease
1506269|NCT00005097|squamous cell carcinoma of the skin
1506270|NCT00005096|adenocarcinoma of the prostate
1506271|NCT00005096|stage II prostate cancer
1506272|NCT00005096|stage III prostate cancer
1506273|NCT00005095|ovarian epithelial cancer
1506274|NCT00005095|hereditary breast/ovarian cancer (BRCA1, BRCA2)
1506275|NCT00005095|fallopian tube cancer
1506276|NCT00005095|ovarian germ cell tumor
1506277|NCT00005095|ovarian sarcoma
1506278|NCT00005095|ovarian stromal cancer
1506279|NCT00005095|endometrial cancer
1506280|NCT00005095|uterine sarcoma
1506281|NCT00005095|vaginal cancer
1506282|NCT00005095|cervical cancer
1506283|NCT00005095|vulvar cancer
1506284|NCT00005095|uterine leiomyomata
1506285|NCT00005093|recurrent non-small cell lung cancer
1506286|NCT00005093|stage IIIA non-small cell lung cancer
1506287|NCT00005093|stage IIIB non-small cell lung cancer
1506288|NCT00005093|stage IV non-small cell lung cancer
1506289|NCT00005092|stage III adult Hodgkin lymphoma
1506290|NCT00005092|stage IV adult Hodgkin lymphoma
1506291|NCT00005092|recurrent childhood acute lymphoblastic leukemia
1506292|NCT00005092|recurrent adult Hodgkin lymphoma
1506293|NCT00005092|stage III cutaneous T-cell non-Hodgkin lymphoma
1506294|NCT00005092|stage IV cutaneous T-cell non-Hodgkin lymphoma
1506295|NCT00005092|recurrent cutaneous T-cell non-Hodgkin lymphoma
1506296|NCT00005092|refractory multiple myeloma
1506297|NCT00005092|stage III multiple myeloma
1506298|NCT00005092|stage III childhood lymphoblastic lymphoma
1506299|NCT00005092|stage IV childhood lymphoblastic lymphoma
1506300|NCT00005092|recurrent childhood lymphoblastic lymphoma
1506301|NCT00005092|stage III chronic lymphocytic leukemia
1506302|NCT00005092|stage IV chronic lymphocytic leukemia
1506303|NCT00005092|recurrent childhood acute myeloid leukemia
1506304|NCT00005092|recurrent adult acute myeloid leukemia
1506305|NCT00005092|recurrent adult acute lymphoblastic leukemia
1506306|NCT00005092|relapsing chronic myelogenous leukemia
1506307|NCT00005092|refractory chronic lymphocytic leukemia
1506308|NCT00005092|childhood diffuse large cell lymphoma
1506309|NCT00005092|childhood immunoblastic large cell lymphoma
1506310|NCT00005092|chronic phase chronic myelogenous leukemia
1506311|NCT00005092|accelerated phase chronic myelogenous leukemia
1506312|NCT00005092|blastic phase chronic myelogenous leukemia
1506313|NCT00005092|meningeal chronic myelogenous leukemia
1506314|NCT00005092|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
1506315|NCT00005092|childhood acute monoblastic leukemia and acute monocytic leukemia (M5)
1506316|NCT00005092|T-cell large granular lymphocyte leukemia
1506317|NCT00005092|B-cell chronic lymphocytic leukemia
1506318|NCT00005092|Philadelphia chromosome positive chronic myelogenous leukemia
1506319|NCT00005092|Philadelphia chromosome negative chronic myelogenous leukemia
1506320|NCT00005092|L1 childhood acute lymphoblastic leukemia
1506321|NCT00005092|L2 childhood acute lymphoblastic leukemia
1506322|NCT00005092|L3 childhood acute lymphoblastic leukemia
1506323|NCT00005092|T-cell childhood acute lymphoblastic leukemia
1506324|NCT00005092|B-cell childhood acute lymphoblastic leukemia
1506325|NCT00005092|non-T, non-B childhood acute lymphoblastic leukemia
1506326|NCT00005092|non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia
1506327|NCT00005092|non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia
1506328|NCT00005092|non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia
1506329|NCT00005092|L1 adult acute lymphoblastic leukemia
1506330|NCT00005092|L2 adult acute lymphoblastic leukemia
1506331|NCT00005092|L3 adult acute lymphoblastic leukemia
1506332|NCT00005092|T-cell adult acute lymphoblastic leukemia
1506333|NCT00005092|B-cell adult acute lymphoblastic leukemia
1506334|NCT00005092|non-T, non-B adult acute lymphoblastic leukemia
1506335|NCT00005092|non-T, non-B, cALLa positive adult acute lymphoblastic leukemia
1506336|NCT00005092|non-T, non-B, cALLa positive, pre-B adult acute lymphoblastic leukemia
1506337|NCT00005092|non-T, non-B, cALLa negative adult acute lymphoblastic leukemia
1506338|NCT00005092|TdT positive adult acute lymphoblastic leukemia
1506339|NCT00005092|TdT negative adult acute lymphoblastic leukemia
1506340|NCT00005092|TdT negative childhood acute lymphoblastic leukemia
1506341|NCT00005092|TdT positive childhood acute lymphoblastic leukemia
1506342|NCT00005092|adult acute erythroid leukemia (M6)
1506343|NCT00005092|adult acute myeloblastic leukemia without maturation (M1)
1506344|NCT00005092|adult acute myeloblastic leukemia with maturation (M2)
1506345|NCT00005092|adult acute promyelocytic leukemia (M3)
1506346|NCT00005092|adult acute myelomonocytic leukemia (M4)
1506347|NCT00005092|adult acute monoblastic leukemia (M5a)
1506348|NCT00005092|adult acute eosinophilic leukemia
1506349|NCT00005092|adult acute basophilic leukemia
1506350|NCT00005092|adult acute megakaryoblastic leukemia (M7)
1506351|NCT00005092|childhood acute myeloblastic leukemia without maturation (M1)
1506352|NCT00005092|childhood acute myeloblastic leukemia with maturation (M2)
1506353|NCT00005092|childhood acute promyelocytic leukemia (M3)
1506354|NCT00005092|childhood acute myelomonocytic leukemia (M4)
1506355|NCT00005092|childhood acute monoblastic leukemia (M5a)
1506356|NCT00005092|childhood acute monocytic leukemia (M5b)
1506357|NCT00005092|childhood acute erythroleukemia (M6)
1506358|NCT00005092|childhood acute eosinophilic leukemia
1506359|NCT00005092|childhood acute basophilic leukemia
1506360|NCT00005092|childhood acute megakaryocytic leukemia (M7)
1506361|NCT00005092|untreated hairy cell leukemia
1506362|NCT00005092|chronic myelomonocytic leukemia
1506363|NCT00005092|acute undifferentiated leukemia
1506364|NCT00005092|stage III grade 2 follicular lymphoma
1506365|NCT00005092|stage III grade 3 follicular lymphoma
1506366|NCT00005092|stage III adult diffuse small cleaved cell lymphoma
1506367|NCT00005092|stage III adult diffuse mixed cell lymphoma
1506368|NCT00005092|stage III adult diffuse large cell lymphoma
1506369|NCT00005092|stage III adult immunoblastic large cell lymphoma
1506370|NCT00005092|stage III adult lymphoblastic lymphoma
1506371|NCT00005092|stage III adult Burkitt lymphoma
1506372|NCT00005092|stage IV grade 2 follicular lymphoma
1506373|NCT00005092|stage IV grade 3 follicular lymphoma
1506374|NCT00005092|stage IV adult diffuse small cleaved cell lymphoma
1506375|NCT00005092|stage IV adult diffuse mixed cell lymphoma
1506376|NCT00005092|stage IV adult diffuse large cell lymphoma
1506377|NCT00005092|stage IV adult immunoblastic large cell lymphoma
1506378|NCT00005092|stage IV adult lymphoblastic lymphoma
1506379|NCT00005092|recurrent grade 2 follicular lymphoma
1506380|NCT00005092|recurrent grade 3 follicular lymphoma
1506381|NCT00005092|recurrent adult diffuse small cleaved cell lymphoma
1506382|NCT00005092|recurrent adult diffuse mixed cell lymphoma
1506383|NCT00005092|recurrent adult diffuse large cell lymphoma
1506384|NCT00005092|recurrent adult immunoblastic large cell lymphoma
1506385|NCT00005092|recurrent adult lymphoblastic lymphoma
1506386|NCT00005092|stage III adult T-cell leukemia/lymphoma
1506387|NCT00005092|stage IV adult T-cell leukemia/lymphoma
1506388|NCT00005092|recurrent adult T-cell leukemia/lymphoma
1506389|NCT00005092|secondary acute myeloid leukemia
1506390|NCT00005092|de novo myelodysplastic syndromes
1506391|NCT00005092|adult acute monocytic leukemia (M5b)
1506392|NCT00005092|previously treated myelodysplastic syndromes
1506393|NCT00005092|secondary myelodysplastic syndromes
1506394|NCT00005092|prolymphocytic leukemia
1506395|NCT00005092|adult acute minimally differentiated myeloid leukemia (M0)
1506396|NCT00005092|childhood acute minimally differentiated myeloid leukemia (M0)
1506397|NCT00005092|intraocular lymphoma
1506398|NCT00005092|stage III childhood large cell lymphoma
1506399|NCT00005092|stage IV childhood large cell lymphoma
1506400|NCT00005092|recurrent childhood large cell lymphoma
1506401|NCT00005092|childhood large cell lymphoma
1506402|NCT00005092|stage III mantle cell lymphoma
1506403|NCT00005092|stage IV mantle cell lymphoma
1506404|NCT00005092|recurrent mantle cell lymphoma
1506405|NCT00005092|angioimmunoblastic T-cell lymphoma
1506406|NCT00005092|anaplastic large cell lymphoma
1506407|NCT00005092|stage III mycosis fungoides/Sezary syndrome
1506408|NCT00005092|stage IV mycosis fungoides/Sezary syndrome
1506409|NCT00005092|recurrent mycosis fungoides/Sezary syndrome
1506410|NCT00005092|childhood myelodysplastic syndromes
1506411|NCT00005091|recurrent non-small cell lung cancer
1506412|NCT00005091|stage IIIB non-small cell lung cancer
1506413|NCT00005091|stage IV non-small cell lung cancer
1506414|NCT00005090|stage III adult Hodgkin lymphoma
1506415|NCT00005090|stage IV adult Hodgkin lymphoma
1506416|NCT00005089|stage I adult diffuse large cell lymphoma
1506417|NCT00005089|stage I adult Burkitt lymphoma
1506418|NCT00005089|stage I mantle cell lymphoma
1506419|NCT00005089|contiguous stage II mantle cell lymphoma
1506420|NCT00005089|contiguous stage II adult diffuse large cell lymphoma
1506421|NCT00005089|contiguous stage II adult Burkitt lymphoma
1506422|NCT00005089|noncontiguous stage II mantle cell lymphoma
1506423|NCT00005089|noncontiguous stage II adult diffuse large cell lymphoma
1506424|NCT00005089|noncontiguous stage II adult Burkitt lymphoma
1506425|NCT00005088|stage III squamous cell carcinoma of the lip and oral cavity
1506426|NCT00005088|stage IV squamous cell carcinoma of the lip and oral cavity
1506427|NCT00005088|stage III squamous cell carcinoma of the oropharynx
1506428|NCT00005088|stage IV squamous cell carcinoma of the oropharynx
1506429|NCT00005088|stage III squamous cell carcinoma of the hypopharynx
1506430|NCT00005088|stage IV squamous cell carcinoma of the hypopharynx
1506431|NCT00005088|stage III squamous cell carcinoma of the larynx
1506432|NCT00005088|stage IV squamous cell carcinoma of the larynx
1506433|NCT00005087|recurrent metastatic squamous neck cancer with occult primary
1506434|NCT00005087|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1506435|NCT00005087|stage I squamous cell carcinoma of the lip and oral cavity
1506436|NCT00005087|stage II squamous cell carcinoma of the lip and oral cavity
1506437|NCT00005087|stage III squamous cell carcinoma of the lip and oral cavity
1506438|NCT00005087|recurrent squamous cell carcinoma of the lip and oral cavity
1506439|NCT00005087|stage I squamous cell carcinoma of the oropharynx
1506440|NCT00005087|stage II squamous cell carcinoma of the oropharynx
1506441|NCT00005087|stage III squamous cell carcinoma of the oropharynx
1506442|NCT00005087|recurrent squamous cell carcinoma of the oropharynx
1506443|NCT00005087|stage I squamous cell carcinoma of the hypopharynx
1506444|NCT00005087|stage II squamous cell carcinoma of the hypopharynx
1506445|NCT00005087|stage III squamous cell carcinoma of the hypopharynx
1506446|NCT00005087|recurrent squamous cell carcinoma of the hypopharynx
1506447|NCT00005087|stage I squamous cell carcinoma of the larynx
1506448|NCT00005087|stage II squamous cell carcinoma of the larynx
1506449|NCT00005087|stage III squamous cell carcinoma of the larynx
1506450|NCT00005087|recurrent squamous cell carcinoma of the larynx
1506451|NCT00005087|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1506452|NCT00005087|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1506453|NCT00005087|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1506454|NCT00005087|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1506455|NCT00005086|stage IV bladder cancer
1506456|NCT00005086|transitional cell carcinoma of the bladder
1506457|NCT00005085|stage IV colon cancer
1506458|NCT00005085|stage IV rectal cancer
1506459|NCT00005085|recurrent colon cancer
1506460|NCT00005085|recurrent rectal cancer
1506461|NCT00005085|adenocarcinoma of the colon
1506462|NCT00005085|adenocarcinoma of the rectum
1506463|NCT00005084|childhood low-grade cerebral astrocytoma
1506464|NCT00005084|childhood low-grade cerebellar astrocytoma
1506465|NCT00005084|recurrent childhood cerebral astrocytoma
1506466|NCT00005083|adult glioblastoma
1506467|NCT00005083|adult anaplastic astrocytoma
1506468|NCT00005083|adult myxopapillary ependymoma
1506469|NCT00005083|adult anaplastic ependymoma
1506470|NCT00005083|adult anaplastic oligodendroglioma
1506471|NCT00005083|adult mixed glioma
1506472|NCT00005083|adult pilocytic astrocytoma
1506473|NCT00005083|adult subependymoma
1506474|NCT00005083|adult ependymoblastoma
1506475|NCT00005083|adult oligodendroglioma
1506476|NCT00005083|adult giant cell glioblastoma
1506477|NCT00005083|adult gliosarcoma
1506478|NCT00005082|adult medulloblastoma
1506479|NCT00005082|adult glioblastoma
1506480|NCT00005082|adult anaplastic astrocytoma
1506481|NCT00005082|adult myxopapillary ependymoma
1506482|NCT00005082|adult anaplastic ependymoma
1506483|NCT00005082|adult anaplastic oligodendroglioma
1506484|NCT00005082|adult mixed glioma
1506485|NCT00005082|adult pilocytic astrocytoma
1506486|NCT00005082|adult subependymoma
1506487|NCT00005082|adult ependymoblastoma
1506488|NCT00005082|adult oligodendroglioma
1506489|NCT00005082|adult giant cell glioblastoma
1506490|NCT00005082|adult gliosarcoma
1506491|NCT00005081|recurrent adult brain tumor
1506492|NCT00005081|adult glioblastoma
1506493|NCT00005081|adult anaplastic astrocytoma
1506494|NCT00005081|adult mixed glioma
1506495|NCT00005081|adult giant cell glioblastoma
1506496|NCT00005081|adult gliosarcoma
1506497|NCT00005079|stage I breast cancer
1506498|NCT00005079|stage II breast cancer
1506499|NCT00005079|stage IIIA breast cancer
1506500|NCT00005079|stage IIIB breast cancer
1506501|NCT00005078|unspecified adult solid tumor, protocol specific
1506502|NCT00005077|unspecified adult solid tumor, protocol specific
1506503|NCT00005076|stage III colon cancer
1506504|NCT00005076|stage IV colon cancer
1506505|NCT00005076|stage III rectal cancer
1506506|NCT00005076|stage IV rectal cancer
1506507|NCT00005076|recurrent colon cancer
1506508|NCT00005076|recurrent rectal cancer
1506509|NCT00005075|stage I prostate cancer
1506510|NCT00005075|stage II prostate cancer
1506511|NCT00005075|recurrent prostate cancer
1506512|NCT00005074|stage I mantle cell lymphoma
1506513|NCT00005074|stage III mantle cell lymphoma
1506514|NCT00005074|stage IV mantle cell lymphoma
1506515|NCT00005074|recurrent mantle cell lymphoma
1506516|NCT00005074|stage II mantle cell lymphoma
1506517|NCT00005073|stage I prostate cancer
1506518|NCT00005073|stage IIB prostate cancer
1506519|NCT00005073|stage IIA prostate cancer
1506520|NCT00005073|stage III prostate cancer
1506521|NCT00005073|recurrent prostate cancer
1506522|NCT00005072|stage I prostate cancer
1506523|NCT00005072|stage IIB prostate cancer
1506524|NCT00005072|stage IIA prostate cancer
1506525|NCT00005072|recurrent prostate cancer
1506526|NCT00005071|stage I non-small cell lung cancer
1506527|NCT00005071|stage II non-small cell lung cancer
1506528|NCT00005071|limited stage small cell lung cancer
1506529|NCT00005070|recurrent cervical cancer
1506530|NCT00005070|stage IVB cervical cancer
1506531|NCT00005070|cervical squamous cell carcinoma
1506532|NCT00005070|cervical adenocarcinoma
1506533|NCT00005070|cervical adenosquamous cell carcinoma
1506534|NCT00005069|stage IV renal cell cancer
1506535|NCT00005069|recurrent renal cell cancer
1506536|NCT00005068|unspecified adult solid tumor, protocol specific
1506537|NCT00005066|recurrent adult soft tissue sarcoma
1506538|NCT00005066|stage IV adult soft tissue sarcoma
1506539|NCT00005062|limited stage small cell lung cancer
1506540|NCT00005061|unspecified adult solid tumor, protocol specific
1506541|NCT00005060|stage II gastric cancer
1506542|NCT00005060|stage III gastric cancer
1506543|NCT00005059|recurrent non-small cell lung cancer
1506544|NCT00005059|stage IV non-small cell lung cancer
1506545|NCT00005058|stage I breast cancer
1506546|NCT00005058|stage II breast cancer
1506547|NCT00005058|stage IIIA breast cancer
1506548|NCT00005058|stage IIIB breast cancer
1506549|NCT00005058|inflammatory breast cancer
1506550|NCT00005057|stage IV melanoma
1506551|NCT00005057|recurrent melanoma
1506552|NCT00005057|lentigo maligna malignant melanoma
1506553|NCT00005057|superficial spreading malignant melanoma
1506554|NCT00005057|acral lentiginous malignant melanoma
1506555|NCT00005057|nodular malignant melanoma
1506556|NCT00005056|stage I renal cell cancer
1506557|NCT00005056|stage II renal cell cancer
1506558|NCT00005056|stage III renal cell cancer
1506559|NCT00005056|stage IV renal cell cancer
1506560|NCT00005056|recurrent renal cell cancer
1506561|NCT00005055|recurrent non-small cell lung cancer
1506562|NCT00005055|stage IIIA non-small cell lung cancer
1506563|NCT00005055|stage IIIB non-small cell lung cancer
1506564|NCT00005055|stage IV non-small cell lung cancer
1506565|NCT00005054|stage IV breast cancer
1506566|NCT00005054|stage IIIA breast cancer
1506567|NCT00005054|recurrent breast cancer
1506568|NCT00005054|stage IIIB breast cancer
1506569|NCT00005053|stage III pancreatic cancer
1506570|NCT00005053|recurrent pancreatic cancer
1506571|NCT00005053|adenocarcinoma of the pancreas
1506572|NCT00005053|stage IV pancreatic cancer
1506573|NCT00005052|stage II melanoma
1506574|NCT00005051|stage I ovarian epithelial cancer
1506575|NCT00005051|stage II ovarian epithelial cancer
1506576|NCT00005051|stage III ovarian epithelial cancer
1506577|NCT00005051|stage IV ovarian epithelial cancer
1506578|NCT00005050|stage III colon cancer
1506579|NCT00005050|stage IV colon cancer
1506580|NCT00005050|stage III rectal cancer
1506581|NCT00005050|stage IV rectal cancer
1506582|NCT00005050|recurrent colon cancer
1506583|NCT00005050|recurrent rectal cancer
1506584|NCT00005049|stage II colon cancer
1506585|NCT00005049|stage III colon cancer
1506586|NCT00005049|stage II gastric cancer
1506587|NCT00005049|stage III gastric cancer
1506588|NCT00005049|recurrent gastric cancer
1506589|NCT00005049|stage II rectal cancer
1506590|NCT00005049|stage III rectal cancer
1506591|NCT00005049|recurrent colon cancer
1506592|NCT00005049|stage III ovarian epithelial cancer
1506593|NCT00005049|recurrent ovarian epithelial cancer
1506594|NCT00005049|regional gastrointestinal carcinoid tumor
1506595|NCT00005049|small intestine adenocarcinoma
1506596|NCT00005049|small intestine lymphoma
1506597|NCT00005049|small intestine leiomyosarcoma
1506598|NCT00005049|recurrent small intestine cancer
1506599|NCT00005049|peritoneal cavity cancer
1506600|NCT00005049|gastrointestinal stromal tumor
1506601|NCT00005048|adenocarcinoma of the prostate
1506602|NCT00005048|recurrent prostate cancer
1506603|NCT00005047|stage I bladder cancer
1506604|NCT00005047|stage II bladder cancer
1506605|NCT00005047|transitional cell carcinoma of the bladder
1506606|NCT00005046|recurrent ovarian epithelial cancer
1506607|NCT00005046|primary peritoneal cavity cancer
1506608|NCT00005045|stage III renal cell cancer
1506609|NCT00005045|stage IV renal cell cancer
1506610|NCT00005045|recurrent renal cell cancer
1506611|NCT00005044|adenocarcinoma of the prostate
1506612|NCT00005044|stage IIB prostate cancer
1506613|NCT00005044|stage IIA prostate cancer
1506614|NCT00005044|stage III prostate cancer
1506615|NCT00005042|AIDS-related Kaposi sarcoma
1506616|NCT00005042|recurrent Kaposi sarcoma
1506617|NCT00005041|extensive stage small cell lung cancer
1506618|NCT00005041|recurrent small cell lung cancer
1506619|NCT00005040|recurrent adult grade III lymphomatoid granulomatosis
1506620|NCT00005040|recurrent grade 3 follicular lymphoma
1506621|NCT00005040|recurrent adult diffuse small cleaved cell lymphoma
1506622|NCT00005040|recurrent adult diffuse mixed cell lymphoma
1506623|NCT00005040|recurrent adult diffuse large cell lymphoma
1506624|NCT00005040|recurrent adult immunoblastic large cell lymphoma
1506625|NCT00005040|recurrent adult lymphoblastic lymphoma
1506626|NCT00005040|recurrent adult Burkitt lymphoma
1506731|NCT00005012|Viral Load
1506627|NCT00005040|recurrent adult T-cell leukemia/lymphoma
1506628|NCT00005040|recurrent mantle cell lymphoma
1506629|NCT00005040|angioimmunoblastic T-cell lymphoma
1506630|NCT00005040|anaplastic large cell lymphoma
1506631|NCT00005038|stage IV renal cell cancer
1506632|NCT00005038|recurrent renal cell cancer
1506633|NCT00005037|recurrent non-small cell lung cancer
1506634|NCT00005037|stage IIIB non-small cell lung cancer
1506635|NCT00005037|stage IV non-small cell lung cancer
1506636|NCT00005035|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1506637|NCT00005035|stage III squamous cell carcinoma of the lip and oral cavity
1506638|NCT00005035|stage IV squamous cell carcinoma of the lip and oral cavity
1506639|NCT00005035|recurrent squamous cell carcinoma of the lip and oral cavity
1506640|NCT00005035|stage III squamous cell carcinoma of the oropharynx
1506641|NCT00005035|stage IV squamous cell carcinoma of the oropharynx
1506642|NCT00005035|recurrent squamous cell carcinoma of the oropharynx
1506643|NCT00005035|stage III squamous cell carcinoma of the nasopharynx
1506644|NCT00005035|stage IV squamous cell carcinoma of the nasopharynx
1506645|NCT00005035|recurrent squamous cell carcinoma of the nasopharynx
1506646|NCT00005035|stage III squamous cell carcinoma of the hypopharynx
1506647|NCT00005035|stage IV squamous cell carcinoma of the hypopharynx
1506648|NCT00005035|recurrent squamous cell carcinoma of the hypopharynx
1506649|NCT00005035|stage III squamous cell carcinoma of the larynx
1506650|NCT00005035|stage IV squamous cell carcinoma of the larynx
1506651|NCT00005035|recurrent squamous cell carcinoma of the larynx
1506652|NCT00005035|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1506653|NCT00005035|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1506654|NCT00005035|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1506655|NCT00005033|recurrent osteosarcoma
1506656|NCT00005032|recurrent small cell lung cancer
1506657|NCT00005031|recurrent endometrial carcinoma
1506658|NCT00005030|stage IV colon cancer
1506659|NCT00005030|stage IV rectal cancer
1506660|NCT00005030|recurrent colon cancer
1506661|NCT00005030|recurrent rectal cancer
1506662|NCT00005030|liver metastases
1506663|NCT00005029|recurrent ovarian epithelial cancer
1506664|NCT00005029|primary peritoneal cavity cancer
1506665|NCT00005028|adenocarcinoma of the prostate
1506666|NCT00005028|stage IV prostate cancer
1506667|NCT00005028|recurrent prostate cancer
1506668|NCT00005027|stage III renal cell cancer
1506669|NCT00005027|stage IV renal cell cancer
1506670|NCT00005027|recurrent renal cell cancer
1506671|NCT00005026|stage III ovarian epithelial cancer
1506672|NCT00005026|stage IV ovarian epithelial cancer
1506673|NCT00005026|ovarian undifferentiated adenocarcinoma
1506674|NCT00005026|ovarian mixed epithelial carcinoma
1506675|NCT00005026|ovarian serous cystadenocarcinoma
1506676|NCT00005026|ovarian mucinous cystadenocarcinoma
1506677|NCT00005026|ovarian endometrioid adenocarcinoma
1506678|NCT00005026|ovarian clear cell cystadenocarcinoma
1506679|NCT00005026|primary peritoneal cavity cancer
1506680|NCT00005026|Brenner tumor
1506681|NCT00005025|recurrent ovarian epithelial cancer
1506682|NCT00005025|fallopian tube cancer
1506683|NCT00005025|primary peritoneal cavity cancer
1506684|NCT00005024|unspecified adult solid tumor, protocol specific
1506685|NCT00005023|stage IV breast cancer
1506686|NCT00005023|stage IIIA breast cancer
1506687|NCT00005023|stage III non-small cell lung cancer
1506688|NCT00005023|stage IIIB breast cancer
1506689|NCT00005023|stage III ovarian epithelial cancer
1506690|NCT00005023|stage IV ovarian epithelial cancer
1506691|NCT00005023|stage IV non-small cell lung cancer
1506692|NCT00005023|adenocarcinoma of the lung
1506693|NCT00005022|limited stage small cell lung cancer
1506694|NCT00005017|HIV-1
1506695|NCT00005017|Drug Therapy, Combination
1506696|NCT00005017|Stavudine
1506697|NCT00005017|HIV Protease Inhibitors
1506698|NCT00005017|Ritonavir
1506699|NCT00005017|Lamivudine
1506700|NCT00005017|VX 478
1506701|NCT00005017|Reverse Transcriptase Inhibitors
1506702|NCT00005017|Anti-HIV Agents
1506703|NCT00005017|abacavir
1506704|NCT00005017|efavirenz
1506705|NCT00005016|Fetal Anomaly
1506706|NCT00005016|Genetic Counseling
1506707|NCT00005016|Prenatal Diagnosis
1506708|NCT00005016|Psychosocial Issues
1506709|NCT00005016|Qualitative
1506710|NCT00005016|HPE
1506711|NCT00005016|Holoprosencephaly
1506712|NCT00005015|Bipolar Disorder
1506713|NCT00005015|Depression
1506714|NCT00005015|Fluoxetine
1506715|NCT00005014|Autistic Disorder
1506716|NCT00005014|Risperidone
1506717|NCT00005013|Antidepressive Agents
1506718|NCT00005013|Depression
1506719|NCT00005013|Depressive Disorder
1506720|NCT00005013|Herbs
1506721|NCT00005013|Hypericum
1506722|NCT00005013|Medicine, Herbal
1506723|NCT00005013|Plant Extracts
1506724|NCT00005013|Alternative Medicine
1506725|NCT00005012|Interferon Alfa-2b
1506726|NCT00005012|Lymphocyte Transformation
1506727|NCT00005012|CD4 Lymphocyte Count
1506728|NCT00005012|RNA, Viral
1506729|NCT00005012|Virus Inhibitors
1506730|NCT00005012|Anti-HIV Agents
1506732|NCT00005011|Depression
1506733|NCT00005011|Menstrual Cycle
1506734|NCT00005011|Gonadal Steroids
1506735|NCT00005011|GnRH Agonist
1506736|NCT00005011|PMS
1506737|NCT00005011|Estradiol
1506738|NCT00005011|Progesterone
1506739|NCT00005011|Mood
1506740|NCT00005011|MRMD
1506741|NCT00005011|PMDD
1506742|NCT00005011|Menstrually Related Mood Disorders
1506743|NCT00005009|pediatric renal transplant recipients
1506744|NCT00005009|varicella zoster virus (VZV) vaccine
1506745|NCT00005009|herpes zoster vaccine
1506746|NCT00005009|VZV susceptible
1506747|NCT00005009|safety
1506748|NCT00005009|immunogenicity
1506749|NCT00005007|Wegener's granulomatosis
1506750|NCT00005007|Vasculitis
1506751|NCT00005007|Etanercept
1506752|NCT00005007|Tumor necrosis factor
1506753|NCT00005006|Anabolic agent
1506754|NCT00005006|hPTH
1506755|NCT00005006|PTH
1506756|NCT00005006|Parathyroid hormone
1506757|NCT00005006|Bone mass
1506758|NCT00005006|Bone turnover
1506759|NCT00005006|Bone formation
1506760|NCT00005006|Alendronate
1506761|NCT00005006|Osteoporosis
1506762|NCT00005006|Cyclical therapy
1506763|NCT00005005|PTH
1506764|NCT00005005|Alendronate
1506765|NCT00005005|Parathyroid hormone
1506766|NCT00005005|Osteoporosis
1506767|NCT00005005|Postmenopausal
1506768|NCT00005004|Cognitive Processes
1506769|NCT00005004|Inferential Ambiguities
1506770|NCT00005004|Language Processes
1506771|NCT00005004|Lexical Ambiguities
1506772|NCT00005004|Suppression Mechanism
1506773|NCT00005004|Discourse Processes
1506774|NCT00005004|Discourse Production Analysis
1506775|NCT00005004|Magnetic Resonance Imaging
1506776|NCT00005004|Prefrontal Cortex Function
1506777|NCT00005004|Aging Effects
1506778|NCT00005004|Garden Path Phenomena
1506779|NCT00005004|Text Integration
1506780|NCT00005003|Handedness
1506781|NCT00005003|Laterality
1506782|NCT00005003|Linkage
1506783|NCT00005003|VNTR/Dinucleotide
1506784|NCT00005003|Dinucleotide
1506785|NCT00005003|High-Frequency-Trait Analysis
1506786|NCT00005002|HIV-1
1506787|NCT00005002|Drug Therapy, Combination
1506788|NCT00005002|HIV Protease Inhibitors
1506789|NCT00005002|CD4 Lymphocyte Count
1506790|NCT00005002|Nelfinavir
1506791|NCT00005002|Reverse Transcriptase Inhibitors
1506792|NCT00005002|Anti-HIV Agents
1506793|NCT00005002|Viral Load
1506794|NCT00005002|remune
1506795|NCT00005002|Combivir
1506796|NCT00005001|HIV-1
1506797|NCT00005001|Drug Therapy, Combination
1506798|NCT00005001|RNA, Viral
1506799|NCT00005001|Anti-HIV Agents
1506800|NCT00005001|Viral Load
1506801|NCT00005001|remune
1506802|NCT00005000|HIV-1
1506803|NCT00005000|Drug Therapy, Combination
1506804|NCT00005000|Lymphoid Tissue
1506805|NCT00005000|HIV Protease Inhibitors
1506806|NCT00005000|Genotype
1506807|NCT00005000|Phenotype
1506808|NCT00005000|Nelfinavir
1506809|NCT00005000|Reverse Transcriptase Inhibitors
1506810|NCT00005000|Anti-HIV Agents
1506811|NCT00005000|Viral Load
1506812|NCT00005000|Adipose Tissue
1506813|NCT00005000|Glucose
1506814|NCT00005000|Lipids
1506815|NCT00005000|Immunophenotyping
1506816|NCT00005000|efavirenz
1506817|NCT00004999|Drug Therapy, Combination
1506818|NCT00004999|Zidovudine
1506819|NCT00004999|HIV Protease Inhibitors
1506820|NCT00004999|Lamivudine
1506821|NCT00004999|Disease Progression
1506822|NCT00004999|Reverse Transcriptase Inhibitors
1506823|NCT00004999|Anti-HIV Agents
1506824|NCT00004999|Viral Load
1506825|NCT00004999|Nelfinavir
1506826|NCT00004999|Combivir
1506827|NCT00004998|Drug Therapy, Combination
1506828|NCT00004998|Zidovudine
1506829|NCT00004998|HIV Protease Inhibitors
1506830|NCT00004998|Lamivudine
1506831|NCT00004998|Reverse Transcriptase Inhibitors
1506832|NCT00004998|Anti-HIV Agents
1506833|NCT00004998|Nelfinavir
1506834|NCT00004998|Combivir
1506835|NCT00004997|Hematopoietic
1506836|NCT00004997|DHFR Enzyme
1506837|NCT00004997|Anemia
1506838|NCT00004997|Folic Acid
1506839|NCT00004997|MDS
1506840|NCT00004997|Myelodysplasia
1506841|NCT00004997|Myelodysplastic
1506842|NCT00004996|Antigen Presentation
1506843|NCT00004996|Cytokines
1506844|NCT00004996|Helminth
1506845|NCT00004996|Healthy Volunteer
1506846|NCT00004996|Cross-Over Study
1506847|NCT00004996|Helminth Infection
1506848|NCT00004994|Allogeneic Transplant
1506849|NCT00004994|Function
1506850|NCT00004994|Mini-Transplant
1506851|NCT00004994|Physical Symptoms
1506852|NCT00004994|Symptom Distress
1506853|NCT00004993|Parathyroid hormone (1-34)
1506854|NCT00004993|Glucocorticoid-induced osteoporosis
1506855|NCT00004993|Postmenopausal women
1506856|NCT00004993|osteoporotic fractures
1506857|NCT00004992|clinical trial
1506858|NCT00004992|multi-center
1506859|NCT00004992|NIDDM
1506860|NCT00004992|NIDDK
1506861|NCT00004992|DPP
1506862|NCT00004992|diabetes risk factors
1506863|NCT00004992|diabetes
1506864|NCT00004992|glycemia
1506865|NCT00004992|cardiovascular risk factors
1506866|NCT00004992|quality of life
1506867|NCT00004992|physical activity and nutrition
1506868|NCT00004992|occurrence of adverse events
1506869|NCT00004992|insulin secretion and sensitivity
1506870|NCT00004992|prevention
1506871|NCT00004992|abnormal glucose metabolism
1506872|NCT00004992|lifestyle intervention
1506873|NCT00004992|drug intervention
1506874|NCT00004991|Functional Magnetic Resonance Imaging
1506875|NCT00004991|Stuttering
1506876|NCT00004991|Speech Perception
1506877|NCT00004991|Speech Production
1506878|NCT00004991|Phonology
1506879|NCT00004991|Development
1506880|NCT00004991|Motor Control
1506881|NCT00004991|Neural Networks
1506882|NCT00004991|Phonological Disorders
1506883|NCT00004990|Nephrotic Syndrome
1506884|NCT00004990|Steroids
1506885|NCT00004990|Osteoporosis
1506886|NCT00004990|Adrenal Suppression
1506887|NCT00004990|Proteinuria
1506888|NCT00004990|Focal Segmental Glomerulosclerosis
1506889|NCT00004988|Anti-Tumor Effects
1506890|NCT00004988|Maximum Tolerated Dose (MTD)
1506891|NCT00004988|Metastatic Cancer
1506892|NCT00004988|Pharmacokinetics
1506893|NCT00004988|Solid Tumors
1506894|NCT00004988|Tumor
1506895|NCT00004987|Anti-HIV Agents
1506896|NCT00004987|Viral Load
1506897|NCT00004987|dextrin 2-sulfate
1506898|NCT00004987|Infusions, Parenteral
1506899|NCT00004986|AIDS-Related Opportunistic Infections
1506900|NCT00004986|Cryptosporidiosis
1506901|NCT00004986|Drug Evaluation
1506902|NCT00004986|Antiprotozoal Agents
1506903|NCT00004986|Treatment Failure
1506904|NCT00004986|nitazoxanide
1506905|NCT00004985|HIV-1
1506906|NCT00004985|Drug Therapy, Combination
1506907|NCT00004985|HIV Protease Inhibitors
1506908|NCT00004985|RNA, Viral
1506909|NCT00004985|Reverse Transcriptase Inhibitors
1506910|NCT00004985|Anti-HIV Agents
1506911|NCT00004985|Viral Load
1506912|NCT00004985|Nelfinavir
1506913|NCT00004984|diabetes
1506914|NCT00004984|insulin
1506915|NCT00004984|prediction
1506916|NCT00004984|prevention
1506917|NCT00004984|C-peptide levels
1506918|NCT00004984|insulin autoantibodies
1506919|NCT00004984|pancreatic beta cell autoantibodies
1506920|NCT00004984|cellular immune responses
1506921|NCT00004984|prediction of type 1 diabetes
1506922|NCT00004983|diabetes mellitus, type 2
1506923|NCT00004983|diabetes self-management education
1506924|NCT00004983|diabetes self-care
1506925|NCT00004983|blood glucose self-monitoring
1506926|NCT00004983|health education
1506927|NCT00004983|patient education
1506928|NCT00004982|chelation therapy
1506929|NCT00004982|combination chemotherapy
1506930|NCT00004982|iron poisoning
1506931|NCT00004982|thalassemia
1506932|NCT00004982|chelating agent
1506933|NCT00004982|deferoxamine
1506934|NCT00004982|drug screening /evaluation
1506935|NCT00004982|therapy evaluation
1506936|NCT00004981|Drug Therapy, Combination
1506937|NCT00004981|Zidovudine
1506938|NCT00004981|Drug Administration Schedule
1506939|NCT00004981|Lamivudine
1506940|NCT00004981|RNA, Viral
1506941|NCT00004981|Reverse Transcriptase Inhibitors
1506942|NCT00004981|Anti-HIV Agents
1506943|NCT00004981|Viral Load
1506944|NCT00004981|Combivir
1506945|NCT00004981|abacavir
1506946|NCT00004980|neurologic and psychiatric disorders
1506947|NCT00004980|rare disease
1506948|NCT00004980|schizophrenia
1506949|NCT00004979|unspecified adult solid tumor, protocol specific
1506950|NCT00004978|Recombinant Proteins
1506951|NCT00004978|Injections, Subcutaneous
1506952|NCT00004978|HIV-1
1506953|NCT00004978|Interleukin-2
1506954|NCT00004978|Drug Therapy, Combination
1506955|NCT00004978|CD4 Lymphocyte Count
1506956|NCT00004978|Disease Progression
1506957|NCT00004978|Follow-Up Studies
1506958|NCT00004978|Anti-HIV Agents
1506959|NCT00004941|Crohn's disease
1506960|NCT00004941|gastrointestinal disorders
1506961|NCT00004941|rare disease
1506962|NCT00004940|erythropoietic protoporphyria
1506963|NCT00004940|inborn errors of metabolism
1506964|NCT00004940|porphyria
1506965|NCT00004940|rare disease
1506966|NCT00004939|demyelinating neuropathy
1506967|NCT00004939|neurologic and psychiatric disorders
1506968|NCT00004939|rare disease
1506969|NCT00004938|fungal infection
1506970|NCT00004938|rare disease
1506971|NCT00004938|sporotrichosis
1506972|NCT00004937|recurrent adult brain tumor
1506973|NCT00004937|adult glioblastoma
1506974|NCT00004937|adult giant cell glioblastoma
1506975|NCT00004937|adult gliosarcoma
1506976|NCT00004936|stage III cervical cancer
1506977|NCT00004936|stage IB cervical cancer
1506978|NCT00004936|stage IIB cervical cancer
1506979|NCT00004936|stage IVB cervical cancer
1507653|NCT00004853|AMGEN
1506980|NCT00004936|stage IIA cervical cancer
1506981|NCT00004936|stage IVA cervical cancer
1506982|NCT00004936|cervical squamous cell carcinoma
1506983|NCT00004936|cervical adenocarcinoma
1506984|NCT00004936|cervical adenosquamous cell carcinoma
1506985|NCT00004935|stage IV breast cancer
1506986|NCT00004935|recurrent breast cancer
1506987|NCT00004934|stage II ovarian epithelial cancer
1506988|NCT00004934|stage III ovarian epithelial cancer
1506989|NCT00004934|stage IV ovarian epithelial cancer
1506990|NCT00004934|fallopian tube cancer
1506991|NCT00004934|primary peritoneal cavity cancer
1506992|NCT00004933|relapsing chronic myelogenous leukemia
1506993|NCT00004933|chronic phase chronic myelogenous leukemia
1506994|NCT00004933|Philadelphia chromosome positive chronic myelogenous leukemia
1506995|NCT00004932|recurrent childhood acute lymphoblastic leukemia
1506996|NCT00004932|recurrent childhood acute myeloid leukemia
1506997|NCT00004932|relapsing chronic myelogenous leukemia
1506998|NCT00004932|chronic myelogenous leukemia, BCR-ABL1 positive
1506999|NCT00004932|childhood chronic myelogenous leukemia
1507000|NCT00004930|recurrent non-small cell lung cancer
1507001|NCT00004930|extensive stage small cell lung cancer
1507002|NCT00004930|recurrent small cell lung cancer
1507003|NCT00004930|stage IIIB non-small cell lung cancer
1507004|NCT00004930|stage IV non-small cell lung cancer
1507005|NCT00004930|lung metastases
1507006|NCT00004930|bronchoalveolar cell lung cancer
1507007|NCT00004929|recurrent prostate cancer
1507008|NCT00004928|adenocarcinoma of the prostate
1507009|NCT00004928|stage I prostate cancer
1507010|NCT00004928|stage IIB prostate cancer
1507011|NCT00004928|stage IIA prostate cancer
1507012|NCT00004928|stage III prostate cancer
1507013|NCT00004928|stage IV prostate cancer
1507014|NCT00004928|recurrent prostate cancer
1507015|NCT00004927|unspecified adult solid tumor, protocol specific
1507016|NCT00004926|unspecified adult solid tumor, protocol specific
1507017|NCT00004925|stage IV breast cancer
1507018|NCT00004925|recurrent breast cancer
1507019|NCT00004925|stage IIIB breast cancer
1507020|NCT00004925|inflammatory breast cancer
1507021|NCT00004924|stage IIIB non-small cell lung cancer
1507022|NCT00004924|stage IV non-small cell lung cancer
1507023|NCT00004923|unspecified adult solid tumor, protocol specific
1507024|NCT00004922|newly diagnosed carcinoma of unknown primary
1507025|NCT00004922|recurrent carcinoma of unknown primary
1507026|NCT00004922|stage III neuroendocrine carcinoma of the skin
1507027|NCT00004922|recurrent neuroendocrine carcinoma of the skin
1507028|NCT00004922|neuroendocrine carcinoma
1507029|NCT00004921|stage III ovarian epithelial cancer
1507030|NCT00004921|stage IV ovarian epithelial cancer
1507031|NCT00004920|localized malignant mesothelioma
1507032|NCT00004920|advanced malignant mesothelioma
1507033|NCT00004920|recurrent malignant mesothelioma
1507034|NCT00004917|stage I squamous cell carcinoma of the lip and oral cavity
1507035|NCT00004917|stage II squamous cell carcinoma of the lip and oral cavity
1507036|NCT00004917|stage III squamous cell carcinoma of the lip and oral cavity
1507037|NCT00004917|stage IV squamous cell carcinoma of the lip and oral cavity
1507038|NCT00004917|stage I squamous cell carcinoma of the oropharynx
1507039|NCT00004917|stage II squamous cell carcinoma of the oropharynx
1507040|NCT00004917|stage III squamous cell carcinoma of the oropharynx
1507041|NCT00004917|stage IV squamous cell carcinoma of the oropharynx
1507042|NCT00004917|stage I squamous cell carcinoma of the hypopharynx
1507043|NCT00004917|stage II squamous cell carcinoma of the hypopharynx
1507044|NCT00004917|stage III squamous cell carcinoma of the hypopharynx
1507045|NCT00004917|stage IV squamous cell carcinoma of the hypopharynx
1507046|NCT00004917|stage I squamous cell carcinoma of the larynx
1507047|NCT00004917|stage II squamous cell carcinoma of the larynx
1507048|NCT00004917|stage III squamous cell carcinoma of the larynx
1507049|NCT00004917|stage IV squamous cell carcinoma of the larynx
1507050|NCT00004917|anemia
1507051|NCT00004916|recurrent grade 3 follicular lymphoma
1507052|NCT00004916|recurrent adult diffuse mixed cell lymphoma
1507053|NCT00004916|recurrent adult diffuse large cell lymphoma
1507054|NCT00004916|recurrent adult immunoblastic large cell lymphoma
1507055|NCT00004916|recurrent adult Burkitt lymphoma
1507056|NCT00004915|recurrent endometrial carcinoma
1507057|NCT00004914|unspecified adult solid tumor, protocol specific
1507058|NCT00004914|anemia
1507059|NCT00004914|fatigue
1507060|NCT00004913|unspecified adult solid tumor, protocol specific
1507061|NCT00004912|unspecified adult solid tumor, protocol specific
1507062|NCT00004912|fatigue
1507063|NCT00004912|cachexia
1507064|NCT00004911|stage I colon cancer
1507065|NCT00004911|stage II colon cancer
1507066|NCT00004911|stage III colon cancer
1507067|NCT00004911|stage IV colon cancer
1507068|NCT00004911|stage I gastric cancer
1507069|NCT00004911|stage II gastric cancer
1507070|NCT00004911|stage III gastric cancer
1507071|NCT00004911|stage IV gastric cancer
1507072|NCT00004911|recurrent gastric cancer
1507073|NCT00004911|stage I rectal cancer
1507074|NCT00004911|stage II rectal cancer
1507075|NCT00004911|stage III rectal cancer
1507076|NCT00004911|stage IV rectal cancer
1507077|NCT00004911|recurrent colon cancer
1507078|NCT00004911|recurrent rectal cancer
1507079|NCT00004911|localized gastrointestinal carcinoid tumor
1507080|NCT00004911|regional gastrointestinal carcinoid tumor
1507081|NCT00004911|metastatic gastrointestinal carcinoid tumor
1507082|NCT00004911|recurrent gastrointestinal carcinoid tumor
1507083|NCT00004911|small intestine adenocarcinoma
1507084|NCT00004911|small intestine lymphoma
1507085|NCT00004911|small intestine leiomyosarcoma
1507086|NCT00004911|recurrent small intestine cancer
1507087|NCT00004911|constipation, impaction, and bowel obstruction
1507088|NCT00004911|quality of life
1507089|NCT00004911|gastrointestinal stromal tumor
1507090|NCT00004910|stage I colon cancer
1507091|NCT00004910|stage II colon cancer
1507092|NCT00004910|stage III colon cancer
1507093|NCT00004910|stage IV colon cancer
1507094|NCT00004910|stage I gastric cancer
1507095|NCT00004910|stage II gastric cancer
1507096|NCT00004910|stage III gastric cancer
1507097|NCT00004910|stage IV gastric cancer
1507098|NCT00004910|recurrent gastric cancer
1507099|NCT00004910|stage I pancreatic cancer
1507100|NCT00004910|stage II pancreatic cancer
1507101|NCT00004910|stage III pancreatic cancer
1507102|NCT00004910|recurrent pancreatic cancer
1507103|NCT00004910|recurrent colon cancer
1507104|NCT00004910|localized gastrointestinal carcinoid tumor
1507105|NCT00004910|regional gastrointestinal carcinoid tumor
1507106|NCT00004910|metastatic gastrointestinal carcinoid tumor
1507107|NCT00004910|recurrent gastrointestinal carcinoid tumor
1507108|NCT00004910|small intestine adenocarcinoma
1507109|NCT00004910|small intestine lymphoma
1507110|NCT00004910|small intestine leiomyosarcoma
1507111|NCT00004910|localized extrahepatic bile duct cancer
1507112|NCT00004910|unresectable extrahepatic bile duct cancer
1507113|NCT00004910|recurrent extrahepatic bile duct cancer
1507114|NCT00004910|recurrent small intestine cancer
1507115|NCT00004910|constipation, impaction, and bowel obstruction
1507116|NCT00004910|quality of life
1507117|NCT00004910|gastrointestinal stromal tumor
1507118|NCT00004910|stage IV pancreatic cancer
1507119|NCT00004909|recurrent ovarian epithelial cancer
1507120|NCT00004909|peritoneal cavity cancer
1507121|NCT00004909|quality of life
1507122|NCT00004908|recurrent adult Hodgkin lymphoma
1507123|NCT00004908|recurrent/refractory childhood Hodgkin lymphoma
1507124|NCT00004908|recurrent grade 1 follicular lymphoma
1507125|NCT00004908|recurrent grade 2 follicular lymphoma
1507126|NCT00004908|recurrent grade 3 follicular lymphoma
1507127|NCT00004908|recurrent adult diffuse small cleaved cell lymphoma
1507128|NCT00004908|recurrent adult diffuse mixed cell lymphoma
1507129|NCT00004908|recurrent adult diffuse large cell lymphoma
1507130|NCT00004908|recurrent adult immunoblastic large cell lymphoma
1507131|NCT00004908|recurrent childhood large cell lymphoma
1507132|NCT00004908|recurrent marginal zone lymphoma
1507133|NCT00004908|recurrent small lymphocytic lymphoma
1507134|NCT00004908|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1507135|NCT00004908|nodal marginal zone B-cell lymphoma
1507136|NCT00004908|splenic marginal zone lymphoma
1507137|NCT00004907|recurrent adult Hodgkin lymphoma
1507138|NCT00004907|recurrent cutaneous T-cell non-Hodgkin lymphoma
1507139|NCT00004907|recurrent grade 1 follicular lymphoma
1507140|NCT00004907|recurrent grade 2 follicular lymphoma
1507141|NCT00004907|recurrent grade 3 follicular lymphoma
1507142|NCT00004907|recurrent adult diffuse small cleaved cell lymphoma
1507143|NCT00004907|recurrent adult diffuse mixed cell lymphoma
1507144|NCT00004907|recurrent adult diffuse large cell lymphoma
1507145|NCT00004907|recurrent adult immunoblastic large cell lymphoma
1507146|NCT00004907|recurrent mycosis fungoides/Sezary syndrome
1507147|NCT00004907|recurrent marginal zone lymphoma
1507148|NCT00004907|recurrent small lymphocytic lymphoma
1507149|NCT00004907|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1507150|NCT00004907|nodal marginal zone B-cell lymphoma
1507151|NCT00004907|splenic marginal zone lymphoma
1507152|NCT00004906|stage IV breast cancer
1507153|NCT00004906|recurrent breast cancer
1507154|NCT00004905|recurrent adult acute myeloid leukemia
1507155|NCT00004905|recurrent adult acute lymphoblastic leukemia
1507156|NCT00004905|relapsing chronic myelogenous leukemia
1507157|NCT00004905|chronic phase chronic myelogenous leukemia
1507158|NCT00004905|adult acute myeloid leukemia in remission
1507159|NCT00004905|adult acute lymphoblastic leukemia in remission
1507160|NCT00004904|monoclonal gammopathy of undetermined significance
1507161|NCT00004904|stage III cutaneous T-cell non-Hodgkin lymphoma
1507162|NCT00004904|stage IV cutaneous T-cell non-Hodgkin lymphoma
1507163|NCT00004904|recurrent cutaneous T-cell non-Hodgkin lymphoma
1507164|NCT00004904|isolated plasmacytoma of bone
1507165|NCT00004904|extramedullary plasmacytoma
1507166|NCT00004904|refractory multiple myeloma
1507167|NCT00004904|Waldenstrom macroglobulinemia
1507168|NCT00004904|stage III multiple myeloma
1507169|NCT00004904|recurrent childhood lymphoblastic lymphoma
1507170|NCT00004904|recurrent childhood acute myeloid leukemia
1507171|NCT00004904|recurrent adult acute myeloid leukemia
1507172|NCT00004904|recurrent adult acute lymphoblastic leukemia
1507173|NCT00004904|small intestine lymphoma
1507174|NCT00004904|chronic phase chronic myelogenous leukemia
1507175|NCT00004904|accelerated phase chronic myelogenous leukemia
1507176|NCT00004904|blastic phase chronic myelogenous leukemia
1507177|NCT00004904|adult acute myeloid leukemia in remission
1507178|NCT00004904|adult acute lymphoblastic leukemia in remission
1507179|NCT00004904|childhood acute myeloid leukemia in remission
1507180|NCT00004904|polycythemia vera
1507181|NCT00004904|chronic idiopathic myelofibrosis
1507182|NCT00004904|essential thrombocythemia
1507183|NCT00004904|refractory hairy cell leukemia
1507184|NCT00004904|T-cell large granular lymphocyte leukemia
1507185|NCT00004904|acute undifferentiated leukemia
1507186|NCT00004904|stage III grade 1 follicular lymphoma
1507187|NCT00004904|stage III grade 2 follicular lymphoma
1507188|NCT00004904|stage III grade 3 follicular lymphoma
1507189|NCT00004904|stage III adult diffuse small cleaved cell lymphoma
1507190|NCT00004904|stage III adult diffuse mixed cell lymphoma
1507191|NCT00004904|stage III adult diffuse large cell lymphoma
1507192|NCT00004904|stage III adult immunoblastic large cell lymphoma
1507193|NCT00004904|stage III adult lymphoblastic lymphoma
1507194|NCT00004904|stage III adult Burkitt lymphoma
1507195|NCT00004904|stage IV grade 1 follicular lymphoma
1507196|NCT00004904|stage IV grade 2 follicular lymphoma
1507197|NCT00004904|stage IV grade 3 follicular lymphoma
1507198|NCT00004904|stage IV adult diffuse small cleaved cell lymphoma
1507199|NCT00004904|stage IV adult diffuse mixed cell lymphoma
1507200|NCT00004904|stage IV adult diffuse large cell lymphoma
1507201|NCT00004904|stage IV adult immunoblastic large cell lymphoma
1507202|NCT00004904|stage IV adult lymphoblastic lymphoma
1507203|NCT00004904|stage IV adult Burkitt lymphoma
1507204|NCT00004904|recurrent grade 1 follicular lymphoma
1507205|NCT00004904|recurrent grade 2 follicular lymphoma
1507206|NCT00004904|recurrent grade 3 follicular lymphoma
1507207|NCT00004904|recurrent adult diffuse small cleaved cell lymphoma
1507208|NCT00004904|recurrent adult diffuse mixed cell lymphoma
1507209|NCT00004904|recurrent adult diffuse large cell lymphoma
1507210|NCT00004904|recurrent adult immunoblastic large cell lymphoma
1507211|NCT00004904|recurrent adult lymphoblastic lymphoma
1507212|NCT00004904|recurrent adult Burkitt lymphoma
1507213|NCT00004904|stage III adult T-cell leukemia/lymphoma
1507214|NCT00004904|stage IV adult T-cell leukemia/lymphoma
1507215|NCT00004904|recurrent adult T-cell leukemia/lymphoma
1507216|NCT00004904|secondary acute myeloid leukemia
1507217|NCT00004904|de novo myelodysplastic syndromes
1507218|NCT00004904|previously treated myelodysplastic syndromes
1507219|NCT00004904|secondary myelodysplastic syndromes
1507220|NCT00004904|graft versus host disease
1507221|NCT00004904|primary systemic amyloidosis
1507222|NCT00004904|intraocular lymphoma
1507223|NCT00004904|recurrent childhood small noncleaved cell lymphoma
1507224|NCT00004904|recurrent childhood large cell lymphoma
1507225|NCT00004904|stage III mantle cell lymphoma
1507226|NCT00004904|stage IV mantle cell lymphoma
1507227|NCT00004904|recurrent mantle cell lymphoma
1507228|NCT00004904|stage III mycosis fungoides/Sezary syndrome
1507229|NCT00004904|stage IV mycosis fungoides/Sezary syndrome
1507230|NCT00004904|recurrent mycosis fungoides/Sezary syndrome
1507231|NCT00004904|recurrent marginal zone lymphoma
1507232|NCT00004904|recurrent small lymphocytic lymphoma
1507233|NCT00004904|stage III small lymphocytic lymphoma
1507234|NCT00004904|stage III marginal zone lymphoma
1507235|NCT00004904|stage IV small lymphocytic lymphoma
1507236|NCT00004904|stage IV marginal zone lymphoma
1507237|NCT00004904|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1507238|NCT00004904|nodal marginal zone B-cell lymphoma
1507239|NCT00004904|splenic marginal zone lymphoma
1507240|NCT00004904|childhood myelodysplastic syndromes
1507241|NCT00004903|refractory multiple myeloma
1507242|NCT00004903|stage I multiple myeloma
1507243|NCT00004903|stage II multiple myeloma
1507244|NCT00004903|stage III multiple myeloma
1507245|NCT00004902|refractory multiple myeloma
1507246|NCT00004902|stage I multiple myeloma
1507247|NCT00004902|stage II multiple myeloma
1507248|NCT00004902|stage III multiple myeloma
1507249|NCT00004901|stage IV hypopharyngeal cancer
1507250|NCT00004901|recurrent hypopharyngeal cancer
1507251|NCT00004901|stage IV squamous cell carcinoma of the lip and oral cavity
1507252|NCT00004901|stage IV verrucous carcinoma of the oral cavity
1507253|NCT00004901|stage IV mucoepidermoid carcinoma of the oral cavity
1507254|NCT00004901|stage IV adenoid cystic carcinoma of the oral cavity
1507255|NCT00004901|recurrent squamous cell carcinoma of the lip and oral cavity
1507256|NCT00004901|recurrent verrucous carcinoma of the oral cavity
1507257|NCT00004901|recurrent mucoepidermoid carcinoma of the oral cavity
1507258|NCT00004901|recurrent adenoid cystic carcinoma of the oral cavity
1507259|NCT00004901|stage IV squamous cell carcinoma of the oropharynx
1507260|NCT00004901|stage IV lymphoepithelioma of the oropharynx
1507261|NCT00004901|recurrent squamous cell carcinoma of the oropharynx
1507262|NCT00004901|recurrent lymphoepithelioma of the oropharynx
1507263|NCT00004901|stage IV squamous cell carcinoma of the nasopharynx
1507264|NCT00004901|stage IV lymphoepithelioma of the nasopharynx
1507265|NCT00004901|recurrent squamous cell carcinoma of the nasopharynx
1507266|NCT00004901|recurrent lymphoepithelioma of the nasopharynx
1507267|NCT00004901|stage IV squamous cell carcinoma of the hypopharynx
1507268|NCT00004901|recurrent squamous cell carcinoma of the hypopharynx
1507269|NCT00004901|stage IV squamous cell carcinoma of the larynx
1507270|NCT00004901|stage IV verrucous carcinoma of the larynx
1507271|NCT00004901|recurrent squamous cell carcinoma of the larynx
1507272|NCT00004901|recurrent verrucous carcinoma of the larynx
1507273|NCT00004900|stage IV breast cancer
1507274|NCT00004900|recurrent breast cancer
1507275|NCT00004900|stage IIIB breast cancer
1507276|NCT00004899|recurrent childhood acute myeloid leukemia
1507277|NCT00004899|recurrent adult acute myeloid leukemia
1507278|NCT00004899|adult acute myeloid leukemia in remission
1507279|NCT00004899|childhood acute myeloid leukemia in remission
1507280|NCT00004899|adult acute erythroid leukemia (M6)
1507281|NCT00004899|adult acute myeloblastic leukemia without maturation (M1)
1507282|NCT00004899|adult acute myeloblastic leukemia with maturation (M2)
1507283|NCT00004899|adult acute promyelocytic leukemia (M3)
1507284|NCT00004899|adult acute myelomonocytic leukemia (M4)
1507285|NCT00004899|adult acute monoblastic leukemia (M5a)
1507286|NCT00004899|childhood acute myeloblastic leukemia without maturation (M1)
1507287|NCT00004899|childhood acute myeloblastic leukemia with maturation (M2)
1507288|NCT00004899|childhood acute promyelocytic leukemia (M3)
1507289|NCT00004899|childhood acute myelomonocytic leukemia (M4)
1507290|NCT00004899|childhood acute monoblastic leukemia (M5a)
1507291|NCT00004899|childhood acute monocytic leukemia (M5b)
1507292|NCT00004899|childhood acute erythroleukemia (M6)
1507293|NCT00004899|secondary acute myeloid leukemia
1507294|NCT00004899|adult acute monocytic leukemia (M5b)
1507295|NCT00004899|previously treated myelodysplastic syndromes
1507296|NCT00004899|myelodysplastic/myeloproliferative disease, unclassifiable
1507297|NCT00004899|atypical chronic myeloid leukemia
1507298|NCT00004899|adult acute myeloid leukemia with t(8;21)(q22;q22)
1507299|NCT00004899|adult acute myeloid leukemia with t(16;16)(p13;q22)
1507300|NCT00004899|adult acute myeloid leukemia with inv(16)(p13;q22)
1507301|NCT00004899|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1507302|NCT00004899|adult acute myeloid leukemia with t(15;17)(q22;q12)
1507303|NCT00004899|childhood myelodysplastic syndromes
1507304|NCT00004898|recurrent childhood acute lymphoblastic leukemia
1507305|NCT00004898|stage I childhood lymphoblastic lymphoma
1507306|NCT00004898|stage II childhood lymphoblastic lymphoma
1507307|NCT00004898|stage III childhood lymphoblastic lymphoma
1507308|NCT00004898|stage IV childhood lymphoblastic lymphoma
1507309|NCT00004898|recurrent childhood lymphoblastic lymphoma
1507310|NCT00004898|recurrent adult acute lymphoblastic leukemia
1507311|NCT00004898|adult acute lymphoblastic leukemia in remission
1507312|NCT00004898|childhood acute lymphoblastic leukemia in remission
1507313|NCT00004898|stage I adult immunoblastic large cell lymphoma
1507314|NCT00004898|stage I adult lymphoblastic lymphoma
1507315|NCT00004898|stage I adult Burkitt lymphoma
1507316|NCT00004898|stage II adult immunoblastic large cell lymphoma
1507317|NCT00004898|stage II adult lymphoblastic lymphoma
1507318|NCT00004898|stage II adult Burkitt lymphoma
1507319|NCT00004898|stage III adult immunoblastic large cell lymphoma
1507320|NCT00004898|stage III adult lymphoblastic lymphoma
1507321|NCT00004898|stage III adult Burkitt lymphoma
1507322|NCT00004898|stage IV adult immunoblastic large cell lymphoma
1507323|NCT00004898|stage IV adult lymphoblastic lymphoma
1507324|NCT00004898|stage IV adult Burkitt lymphoma
1507325|NCT00004898|recurrent adult immunoblastic large cell lymphoma
1507326|NCT00004898|recurrent adult lymphoblastic lymphoma
1507327|NCT00004898|recurrent adult Burkitt lymphoma
1507328|NCT00004898|stage I childhood small noncleaved cell lymphoma
1507329|NCT00004898|stage I childhood large cell lymphoma
1507330|NCT00004898|stage II childhood small noncleaved cell lymphoma
1507331|NCT00004898|stage II childhood large cell lymphoma
1507332|NCT00004898|stage III childhood small noncleaved cell lymphoma
1507333|NCT00004898|stage III childhood large cell lymphoma
1507334|NCT00004898|stage IV childhood small noncleaved cell lymphoma
1507335|NCT00004898|stage IV childhood large cell lymphoma
1507336|NCT00004898|recurrent childhood small noncleaved cell lymphoma
1507337|NCT00004898|recurrent childhood large cell lymphoma
1507338|NCT00004897|stage I esophageal cancer
1507339|NCT00004897|stage II esophageal cancer
1507340|NCT00004897|stage III esophageal cancer
1507341|NCT00004897|squamous cell carcinoma of the esophagus
1507342|NCT00004897|adenocarcinoma of the esophagus
1507343|NCT00004896|recurrent adult acute myeloid leukemia
1507344|NCT00004896|adult acute myeloid leukemia in remission
1507345|NCT00004896|adult acute erythroid leukemia (M6)
1507346|NCT00004896|adult acute myeloblastic leukemia without maturation (M1)
1507347|NCT00004896|adult acute myeloblastic leukemia with maturation (M2)
1507348|NCT00004896|adult acute promyelocytic leukemia (M3)
1507349|NCT00004896|adult acute myelomonocytic leukemia (M4)
1507350|NCT00004896|adult acute monoblastic leukemia (M5a)
1507351|NCT00004896|adult acute megakaryoblastic leukemia (M7)
1507352|NCT00004896|refractory anemia
1507353|NCT00004896|refractory anemia with ringed sideroblasts
1507354|NCT00004896|refractory anemia with excess blasts
1507355|NCT00004896|refractory anemia with excess blasts in transformation
1507356|NCT00004896|chronic myelomonocytic leukemia
1507357|NCT00004896|adult acute monocytic leukemia (M5b)
1507358|NCT00004896|previously treated myelodysplastic syndromes
1507890|NCT00004776|Lennox-Gastaut syndrome
1507359|NCT00004896|myelodysplastic/myeloproliferative disease, unclassifiable
1507360|NCT00004896|atypical chronic myeloid leukemia
1507361|NCT00004896|adult acute myeloid leukemia with t(8;21)(q22;q22)
1507362|NCT00004896|adult acute myeloid leukemia with t(16;16)(p13;q22)
1507363|NCT00004896|adult acute myeloid leukemia with inv(16)(p13;q22)
1507364|NCT00004896|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1507562|NCT00004870|recurrent colon cancer
1507365|NCT00004896|adult acute myeloid leukemia with t(15;17)(q22;q12)
1507366|NCT00004896|childhood myelodysplastic syndromes
1507367|NCT00004895|stage I colon cancer
1507368|NCT00004895|stage II colon cancer
1507369|NCT00004895|stage III colon cancer
1507370|NCT00004895|stage IV colon cancer
1507371|NCT00004895|stage I gastric cancer
1507372|NCT00004895|stage II gastric cancer
1507373|NCT00004895|stage III gastric cancer
1507374|NCT00004895|stage IV gastric cancer
1507375|NCT00004895|recurrent gastric cancer
1507376|NCT00004895|stage I pancreatic cancer
1507377|NCT00004895|stage II pancreatic cancer
1507378|NCT00004895|stage III pancreatic cancer
1507379|NCT00004895|stage IV pancreatic cancer
1507380|NCT00004895|recurrent pancreatic cancer
1507381|NCT00004895|stage I rectal cancer
1507382|NCT00004895|stage II rectal cancer
1507383|NCT00004895|stage III rectal cancer
1507384|NCT00004895|stage IV rectal cancer
1507385|NCT00004895|recurrent colon cancer
1507386|NCT00004895|recurrent rectal cancer
1507387|NCT00004895|stage I ovarian epithelial cancer
1507388|NCT00004895|stage II ovarian epithelial cancer
1507389|NCT00004895|stage III ovarian epithelial cancer
1507390|NCT00004895|stage IV ovarian epithelial cancer
1507391|NCT00004895|recurrent ovarian epithelial cancer
1507392|NCT00004895|small intestine adenocarcinoma
1507393|NCT00004895|small intestine lymphoma
1507394|NCT00004895|small intestine leiomyosarcoma
1507395|NCT00004895|localized extrahepatic bile duct cancer
1507396|NCT00004895|unresectable extrahepatic bile duct cancer
1507397|NCT00004895|recurrent extrahepatic bile duct cancer
1507398|NCT00004895|recurrent small intestine cancer
1507399|NCT00004895|constipation, impaction, and bowel obstruction
1507400|NCT00004895|peritoneal cavity cancer
1507401|NCT00004895|nausea and vomiting
1507402|NCT00004895|gastrointestinal stromal tumor
1507403|NCT00004893|stage IV breast cancer
1507404|NCT00004893|recurrent breast cancer
1507405|NCT00004892|recurrent adult brain tumor
1507406|NCT00004892|adult brain stem glioma
1507407|NCT00004892|adult ependymoma
1507408|NCT00004892|adult glioblastoma
1507409|NCT00004892|adult oligodendroglioma
1507410|NCT00004892|adult anaplastic astrocytoma
1507411|NCT00004892|adult mixed glioma
1507412|NCT00004892|adult giant cell glioblastoma
1507413|NCT00004892|adult gliosarcoma
1507414|NCT00004891|stage II rectal cancer
1507415|NCT00004891|stage III rectal cancer
1507416|NCT00004891|stage IV rectal cancer
1507417|NCT00004890|stage I renal cell cancer
1507418|NCT00004890|stage II renal cell cancer
1507419|NCT00004890|stage III renal cell cancer
1507420|NCT00004890|stage IV renal cell cancer
1507421|NCT00004890|recurrent renal cell cancer
1507422|NCT00004890|drug extravasation
1507423|NCT00004889|Waldenstrom macroglobulinemia
1507424|NCT00004887|stage IIIA non-small cell lung cancer
1507425|NCT00004887|stage IIIB non-small cell lung cancer
1507426|NCT00004887|stage IV non-small cell lung cancer
1507427|NCT00004886|unspecified adult solid tumor, protocol specific
1507428|NCT00004885|stage IV colon cancer
1507429|NCT00004885|stage IV rectal cancer
1507430|NCT00004885|recurrent colon cancer
1507431|NCT00004885|recurrent rectal cancer
1507432|NCT00004885|adenocarcinoma of the colon
1507433|NCT00004885|adenocarcinoma of the rectum
1507434|NCT00004884|stage III pancreatic cancer
1507435|NCT00004884|recurrent pancreatic cancer
1507436|NCT00004884|adenocarcinoma of the pancreas
1507437|NCT00004884|stage IV pancreatic cancer
1507438|NCT00004881|unspecified adult solid tumor, protocol specific
1507439|NCT00004880|stage IV renal cell cancer
1507440|NCT00004880|recurrent renal cell cancer
1507441|NCT00004879|recurrent renal cell cancer
1507442|NCT00004879|recurrent prostate cancer
1507443|NCT00004879|recurrent colon cancer
1507444|NCT00004879|recurrent rectal cancer
1507445|NCT00004879|recurrent non-small cell lung cancer
1507446|NCT00004879|recurrent pancreatic cancer
1507447|NCT00004879|recurrent esophageal cancer
1507448|NCT00004878|chronic phase chronic myelogenous leukemia
1507449|NCT00004878|accelerated phase chronic myelogenous leukemia
1507450|NCT00004878|Philadelphia chromosome positive chronic myelogenous leukemia
1507451|NCT00004878|graft versus host disease
1507452|NCT00004877|unspecified adult solid tumor, protocol specific
1507453|NCT00004876|stage IV ovarian epithelial cancer
1507454|NCT00004876|stage IC ovarian epithelial cancer
1507455|NCT00004876|stage IIA ovarian epithelial cancer
1507456|NCT00004876|stage IIB ovarian epithelial cancer
1507457|NCT00004876|stage IIC ovarian epithelial cancer
1507458|NCT00004876|stage IIIA ovarian epithelial cancer
1507459|NCT00004876|stage IIIB ovarian epithelial cancer
1507460|NCT00004876|stage IIIC ovarian epithelial cancer
1507461|NCT00004875|stage I adult Hodgkin lymphoma
1507462|NCT00004875|stage II adult Hodgkin lymphoma
1507463|NCT00004875|stage III adult Hodgkin lymphoma
1507464|NCT00004875|stage IV adult Hodgkin lymphoma
1507465|NCT00004875|recurrent adult Hodgkin lymphoma
1507466|NCT00004875|unspecified adult solid tumor, protocol specific
1507467|NCT00004875|stage I grade 1 follicular lymphoma
1507468|NCT00004875|stage I grade 2 follicular lymphoma
1507469|NCT00004875|stage I grade 3 follicular lymphoma
1507470|NCT00004875|stage I adult diffuse small cleaved cell lymphoma
1507471|NCT00004875|stage I adult diffuse mixed cell lymphoma
1507472|NCT00004875|stage I adult diffuse large cell lymphoma
1507473|NCT00004875|stage I adult immunoblastic large cell lymphoma
1507474|NCT00004875|stage I adult Burkitt lymphoma
1507475|NCT00004875|stage III grade 1 follicular lymphoma
1507476|NCT00004875|stage III grade 2 follicular lymphoma
1507477|NCT00004875|stage III grade 3 follicular lymphoma
1507478|NCT00004875|stage III adult diffuse small cleaved cell lymphoma
1507479|NCT00004875|stage III adult diffuse mixed cell lymphoma
1507480|NCT00004875|stage III adult diffuse large cell lymphoma
1507481|NCT00004875|stage III adult immunoblastic large cell lymphoma
1507482|NCT00004875|stage III adult Burkitt lymphoma
1507483|NCT00004875|stage IV grade 1 follicular lymphoma
1507484|NCT00004875|stage IV grade 2 follicular lymphoma
1507485|NCT00004875|stage IV grade 3 follicular lymphoma
1507486|NCT00004875|stage IV adult diffuse small cleaved cell lymphoma
1507487|NCT00004875|stage IV adult diffuse mixed cell lymphoma
1507488|NCT00004875|stage IV adult diffuse large cell lymphoma
1507489|NCT00004875|stage IV adult immunoblastic large cell lymphoma
1507490|NCT00004875|stage IV adult Burkitt lymphoma
1507491|NCT00004875|recurrent grade 1 follicular lymphoma
1507492|NCT00004875|recurrent grade 2 follicular lymphoma
1507493|NCT00004875|recurrent grade 3 follicular lymphoma
1507494|NCT00004875|recurrent adult diffuse small cleaved cell lymphoma
1507495|NCT00004875|recurrent adult diffuse mixed cell lymphoma
1507496|NCT00004875|recurrent adult diffuse large cell lymphoma
1507497|NCT00004875|recurrent adult immunoblastic large cell lymphoma
1507498|NCT00004875|recurrent adult Burkitt lymphoma
1507499|NCT00004875|AIDS-related peripheral/systemic lymphoma
1507500|NCT00004875|AIDS-related primary CNS lymphoma
1507501|NCT00004875|stage I mantle cell lymphoma
1507502|NCT00004875|contiguous stage II grade 1 follicular lymphoma
1507503|NCT00004875|contiguous stage II grade 2 follicular lymphoma
1507504|NCT00004875|contiguous stage II grade 3 follicular lymphoma
1507505|NCT00004875|contiguous stage II adult diffuse small cleaved cell lymphoma
1507506|NCT00004875|contiguous stage II mantle cell lymphoma
1507507|NCT00004875|contiguous stage II adult diffuse mixed cell lymphoma
1507508|NCT00004875|contiguous stage II adult immunoblastic large cell lymphoma
1507509|NCT00004875|contiguous stage II adult diffuse large cell lymphoma
1507510|NCT00004875|contiguous stage II adult Burkitt lymphoma
1507511|NCT00004875|noncontiguous stage II grade 1 follicular lymphoma
1507512|NCT00004875|noncontiguous stage II grade 2 follicular lymphoma
1507513|NCT00004875|noncontiguous stage II grade 3 follicular lymphoma
1507514|NCT00004875|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1507515|NCT00004875|noncontiguous stage II mantle cell lymphoma
1507516|NCT00004875|noncontiguous stage II adult diffuse mixed cell lymphoma
1507517|NCT00004875|noncontiguous stage II adult immunoblastic large cell lymphoma
1507518|NCT00004875|noncontiguous stage II adult diffuse large cell lymphoma
1507519|NCT00004875|noncontiguous stage II adult Burkitt lymphoma
1507520|NCT00004875|stage III mantle cell lymphoma
1507521|NCT00004875|stage IV mantle cell lymphoma
1507522|NCT00004875|recurrent mantle cell lymphoma
1507523|NCT00004875|angioimmunoblastic T-cell lymphoma
1507524|NCT00004875|anaplastic large cell lymphoma
1507525|NCT00004875|thromboembolism
1507526|NCT00004875|noncontiguous stage II small lymphocytic lymphoma
1507527|NCT00004875|noncontiguous stage II marginal zone lymphoma
1507528|NCT00004875|recurrent marginal zone lymphoma
1507529|NCT00004875|recurrent small lymphocytic lymphoma
1507530|NCT00004875|stage I marginal zone lymphoma
1507531|NCT00004875|stage I small lymphocytic lymphoma
1507532|NCT00004875|stage III small lymphocytic lymphoma
1507533|NCT00004875|stage III marginal zone lymphoma
1507534|NCT00004875|stage IV small lymphocytic lymphoma
1507535|NCT00004875|stage IV marginal zone lymphoma
1507536|NCT00004875|contiguous stage II marginal zone lymphoma
1507537|NCT00004875|contiguous stage II small lymphocytic lymphoma
1507538|NCT00004875|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1507539|NCT00004875|nodal marginal zone B-cell lymphoma
1507540|NCT00004875|splenic marginal zone lymphoma
1507541|NCT00004874|recurrent grade 1 follicular lymphoma
1507542|NCT00004874|recurrent grade 2 follicular lymphoma
1507543|NCT00004874|recurrent small lymphocytic lymphoma
1507544|NCT00004873|stage III gastric cancer
1507545|NCT00004873|stage IV gastric cancer
1507546|NCT00004873|recurrent gastric cancer
1507547|NCT00004872|unspecified adult solid tumor, protocol specific
1507548|NCT00004871|recurrent adult acute myeloid leukemia
1507549|NCT00004871|untreated adult acute myeloid leukemia
1507550|NCT00004871|refractory anemia
1507551|NCT00004871|refractory anemia with ringed sideroblasts
1507552|NCT00004871|refractory anemia with excess blasts
1507553|NCT00004871|refractory anemia with excess blasts in transformation
1507891|NCT00004776|epilepsy
1507554|NCT00004871|chronic myelomonocytic leukemia
1507555|NCT00004871|de novo myelodysplastic syndromes
1507556|NCT00004871|previously treated myelodysplastic syndromes
1507557|NCT00004871|secondary myelodysplastic syndromes
1507558|NCT00004871|atypical chronic myeloid leukemia
1507559|NCT00004871|myelodysplastic/myeloproliferative disease, unclassifiable
1507560|NCT00004870|stage IV colon cancer
1507563|NCT00004870|recurrent rectal cancer
1507564|NCT00004870|adenocarcinoma of the colon
1507565|NCT00004870|adenocarcinoma of the rectum
1507566|NCT00004868|recurrent adult brain tumor
1507567|NCT00004868|adult meningioma
1507568|NCT00004868|adult glioblastoma
1507569|NCT00004868|adult anaplastic astrocytoma
1507570|NCT00004868|adult anaplastic oligodendroglioma
1507571|NCT00004868|adult mixed glioma
1507572|NCT00004868|adult grade III meningioma
1507573|NCT00004868|adult giant cell glioblastoma
1507574|NCT00004868|adult gliosarcoma
1507575|NCT00004867|stage I esophageal cancer
1507576|NCT00004867|stage II esophageal cancer
1507577|NCT00004867|stage III esophageal cancer
1507578|NCT00004867|stage IV esophageal cancer
1507579|NCT00004867|squamous cell carcinoma of the esophagus
1507580|NCT00004867|adenocarcinoma of the esophagus
1507581|NCT00004866|stage III cervical cancer
1507582|NCT00004866|stage IV cervical cancer
1507583|NCT00004866|recurrent cervical cancer
1507584|NCT00004866|cervical squamous cell carcinoma
1507585|NCT00004865|recurrent metastatic squamous neck cancer with occult primary
1507586|NCT00004865|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1507587|NCT00004865|stage IV squamous cell carcinoma of the lip and oral cavity
1507588|NCT00004865|recurrent squamous cell carcinoma of the lip and oral cavity
1507589|NCT00004865|stage IV squamous cell carcinoma of the oropharynx
1507590|NCT00004865|recurrent squamous cell carcinoma of the oropharynx
1507591|NCT00004865|stage IV squamous cell carcinoma of the nasopharynx
1507592|NCT00004865|recurrent squamous cell carcinoma of the nasopharynx
1507593|NCT00004865|stage IV squamous cell carcinoma of the hypopharynx
1507594|NCT00004865|recurrent squamous cell carcinoma of the hypopharynx
1507595|NCT00004865|stage IV squamous cell carcinoma of the larynx
1507596|NCT00004865|recurrent squamous cell carcinoma of the larynx
1507597|NCT00004865|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1507598|NCT00004865|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1507599|NCT00004864|unspecified adult solid tumor, protocol specific
1507600|NCT00004863|unspecified adult solid tumor, protocol specific
1507601|NCT00004862|recurrent adult acute myeloid leukemia
1507602|NCT00004862|recurrent adult acute lymphoblastic leukemia
1507603|NCT00004861|stage II pancreatic cancer
1507604|NCT00004861|stage III pancreatic cancer
1507605|NCT00004861|adenocarcinoma of the pancreas
1507606|NCT00004861|stage IV pancreatic cancer
1507607|NCT00004860|stage III colon cancer
1507608|NCT00004860|stage IV colon cancer
1507609|NCT00004860|stage III rectal cancer
1507610|NCT00004860|stage IV rectal cancer
1507611|NCT00004860|recurrent colon cancer
1507612|NCT00004860|recurrent rectal cancer
1507613|NCT00004860|adenocarcinoma of the colon
1507614|NCT00004860|adenocarcinoma of the rectum
1507615|NCT00004859|squamous cell lung cancer
1507616|NCT00004859|large cell lung cancer
1507617|NCT00004859|stage IIIA non-small cell lung cancer
1507618|NCT00004859|stage IIIB non-small cell lung cancer
1507619|NCT00004859|adenocarcinoma of the lung
1507620|NCT00004859|adenosquamous cell lung cancer
1507621|NCT00004859|bronchoalveolar cell lung cancer
1507622|NCT00004858|recurrent childhood acute lymphoblastic leukemia
1507623|NCT00004858|recurrent childhood lymphoblastic lymphoma
1507624|NCT00004858|recurrent adult acute lymphoblastic leukemia
1507625|NCT00004858|recurrent grade 1 follicular lymphoma
1507626|NCT00004858|recurrent grade 2 follicular lymphoma
1507627|NCT00004858|recurrent grade 3 follicular lymphoma
1507628|NCT00004858|recurrent adult diffuse small cleaved cell lymphoma
1507629|NCT00004858|recurrent adult diffuse mixed cell lymphoma
1507630|NCT00004858|recurrent adult diffuse large cell lymphoma
1507631|NCT00004858|recurrent adult immunoblastic large cell lymphoma
1507632|NCT00004858|recurrent adult lymphoblastic lymphoma
1507633|NCT00004858|recurrent adult Burkitt lymphoma
1507634|NCT00004858|recurrent childhood small noncleaved cell lymphoma
1507635|NCT00004858|recurrent childhood large cell lymphoma
1507636|NCT00004858|recurrent small lymphocytic lymphoma
1507637|NCT00004857|stage I chronic lymphocytic leukemia
1507638|NCT00004857|stage II chronic lymphocytic leukemia
1507639|NCT00004857|stage III chronic lymphocytic leukemia
1507640|NCT00004857|stage IV chronic lymphocytic leukemia
1507641|NCT00004857|B-cell chronic lymphocytic leukemia
1507642|NCT00004855|Drug Therapy, Combination
1507643|NCT00004855|Nevirapine
1507644|NCT00004855|Stavudine
1507645|NCT00004855|HIV Protease Inhibitors
1507646|NCT00004855|Ritonavir
1507647|NCT00004855|Lamivudine
1507648|NCT00004855|Reverse Transcriptase Inhibitors
1507649|NCT00004855|Anti-HIV Agents
1507650|NCT00004855|ABT 378
1507651|NCT00004855|abacavir
1507652|NCT00004854|moderate heart failure
1507654|NCT00004853|Granulocyte Colony-Stimulating Factor
1507655|NCT00004853|MPNST
1507656|NCT00004853|Randomized
1507657|NCT00004853|Sarcoma
1507658|NCT00004853|Tumor
1507659|NCT00004852|HIV-1
1507660|NCT00004852|Drug Therapy, Combination
1507661|NCT00004852|Zidovudine
1507662|NCT00004852|Drug Administration Schedule
1507663|NCT00004852|Lamivudine
1507664|NCT00004852|Genotype
1507665|NCT00004852|Phenotype
1507666|NCT00004852|Reverse Transcriptase Inhibitors
1507667|NCT00004852|Anti-HIV Agents
1507668|NCT00004852|Viral Load
1507669|NCT00004852|efavirenz
1507670|NCT00004851|HCV Antibody Library
1507671|NCT00004850|Hepatitis C Virus
1507672|NCT00004850|Blood Donors
1507673|NCT00004850|Liver Biopsy
1507674|NCT00004850|ALT
1507675|NCT00004850|Natural History
1507676|NCT00004848|AIDS
1507677|NCT00004848|Autologous Blood
1507678|NCT00004848|Cardiac Surgery
1507679|NCT00004848|HIV
1507680|NCT00004848|Hepatocellular Inflammation
1507681|NCT00004848|Liver Biopsy
1507682|NCT00004848|Long Term Sera Storage
1507683|NCT00004848|Non-A Hepatitis
1507684|NCT00004848|Non-B Hepatitis
1507694|NCT00004846|Viral Gene Amplification
1507695|NCT00004846|Blood Transmitted Infections
1507696|NCT00004846|Transfusion Risks
1507697|NCT00004846|Transcription Mediated Analysis
1507698|NCT00004846|Viral Detection Assays
1507699|NCT00004846|HIV Seronegativity
1507700|NCT00004845|Anti-inflammatory
1507701|NCT00004844|Parkinson Disease
1507702|NCT00004844|neurologic and psychiatric disorders
1507703|NCT00004844|rare disease
1507704|NCT00004843|disease-related problem/condition
1507705|NCT00004843|endocrine disorders
1507706|NCT00004843|hyperparathyroidism
1507707|NCT00004843|quality of life
1507708|NCT00004843|rare disease
1507709|NCT00004842|cirrhosis
1507710|NCT00004842|gastrointestinal disorders
1507711|NCT00004842|primary biliary cirrhosis
1507712|NCT00004842|primary sclerosing cholangitis
1507713|NCT00004842|rare disease
1507714|NCT00004840|cardiovascular and respiratory diseases
1507715|NCT00004840|neonatal disorders
1507716|NCT00004840|rare disease
1507717|NCT00004840|respiratory distress syndrome
1507718|NCT00004838|environmental/toxic disorders
1507719|NCT00004838|lead poisoning
1507720|NCT00004838|rare disease
1507721|NCT00004834|anxiety disorder
1507722|NCT00004834|disease-related problem/condition
1507723|NCT00004834|neurologic and psychiatric disorders
1507724|NCT00004834|panic disorder
1507725|NCT00004834|rare disease
1507726|NCT00004833|Guillain-Barre syndrome
1507727|NCT00004833|demyelinating neuropathy
1507728|NCT00004833|neurologic and psychiatric disorders
1507729|NCT00004833|rare disease
1507730|NCT00004832|Lambert-Eaton myasthenic syndrome
1507731|NCT00004832|neurologic and psychiatric disorders
1507732|NCT00004832|rare disease
1507733|NCT00004831|erythropoietic protoporphyria
1507734|NCT00004831|inborn errors of metabolism
1507735|NCT00004831|porphyria
1507736|NCT00004831|rare disease
1507737|NCT00004829|bacterial infection
1507738|NCT00004829|cardiovascular and respiratory diseases
1507739|NCT00004829|cystic fibrosis
1507740|NCT00004829|genetic diseases and dysmorphic syndromes
1507741|NCT00004829|immunologic disorders and infectious disorders
1507742|NCT00004829|rare disease
1507743|NCT00004828|cardiovascular and respiratory diseases
1507744|NCT00004828|heart defects
1507745|NCT00004828|rare disease
1507746|NCT00004827|ophthalmologic disorders
1507747|NCT00004827|rare disease
1507748|NCT00004827|retinitis pigmentosa
1507749|NCT00004826|Parkinson disease
1507750|NCT00004826|neurologic and psychiatric disorders
1507751|NCT00004826|rare disease
1507752|NCT00004825|endocrine disorders
1507753|NCT00004825|hyperinsulinism
1507754|NCT00004825|rare disease
1507755|NCT00004817|neurologic and psychiatric disorders
1507756|NCT00004817|rare disease
1507757|NCT00004817|seizures
1507758|NCT00004816|multiple sclerosis
1507759|NCT00004816|neurologic and psychiatric disorders
1507760|NCT00004816|rare disease
1507761|NCT00004815|Werner's syndrome
1507762|NCT00004815|genetic diseases and dysmorphic syndromes
1507763|NCT00004815|rare disease
1507764|NCT00004814|multiple sclerosis
1507765|NCT00004814|neurologic and psychiatric disorders
1507766|NCT00004814|rare disease
1507767|NCT00004812|environmental/toxic disorders
1507768|NCT00004812|neurologic and psychiatric disorders
1507769|NCT00004812|rare disease
1507770|NCT00004812|spinal cord injury
1507771|NCT00004811|blastomycosis
1507772|NCT00004811|fungal infection
1507773|NCT00004811|histoplasmosis
1507774|NCT00004811|immunologic disorders and infectious disorders
1507775|NCT00004811|rare disease
1507776|NCT00004811|sporotrichosis
1507777|NCT00004810|gastrointestinal disorders
1507778|NCT00004810|rare disease
1507779|NCT00004810|ulcerative colitis
1507780|NCT00004809|familial hypercholesterolemia
1507781|NCT00004809|inborn errors of metabolism
1507782|NCT00004809|rare disease
1507783|NCT00004808|blastomycosis
1507784|NCT00004808|fungal infection
1507785|NCT00004808|histoplasmosis
1507786|NCT00004808|immunologic disorders and infectious disorders
1507787|NCT00004808|rare disease
1507788|NCT00004808|sporotrichosis
1507789|NCT00004807|Rett syndrome
1507790|NCT00004807|neurologic and psychiatric disorders
1507791|NCT00004807|rare disease
1507792|NCT00004806|cardiovascular and respiratory diseases
1507793|NCT00004806|cystic fibrosis
1507794|NCT00004806|genetic diseases and dysmorphic syndromes
1507795|NCT00004806|rare disease
1507796|NCT00004805|bronchopulmonary dysplasia
1507797|NCT00004805|cardiovascular and respiratory diseases
1507798|NCT00004805|disease-related problem/condition
1507799|NCT00004805|educational needs
1507800|NCT00004805|hypertensive disorder
1507801|NCT00004805|neonatal disorders
1507802|NCT00004805|primary pulmonary hypertension
1507803|NCT00004805|rare disease
1507804|NCT00004805|respiratory distress syndrome
1507805|NCT00004804|hepatitis C
1507806|NCT00004804|immunologic disorders and infectious disorders
1507807|NCT00004804|rare disease
1507808|NCT00004804|viral infection
1507809|NCT00004802|neurologic and psychiatric disorders
1507810|NCT00004802|periodic paralysis
1507811|NCT00004802|rare disease
1507812|NCT00004801|hematologic disorders
1507813|NCT00004801|rare disease
1507814|NCT00004800|bacterial infection
1507815|NCT00004800|immunologic disorders and infectious disorders
1507816|NCT00004800|pertussis
1507817|NCT00004800|rare disease
1507818|NCT00004799|bacterial infection
1507819|NCT00004799|immunologic disorders and infectious disorders
1507820|NCT00004799|pertussis
1507821|NCT00004799|rare disease
1507822|NCT00004797|disease-related problem/condition
1507823|NCT00004797|genetic diseases and dysmorphic syndromes
1507824|NCT00004797|hematologic disorders
1507825|NCT00004797|pain
1507826|NCT00004797|rare disease
1507827|NCT00004797|sickle cell anemia
1507828|NCT00004796|cardiovascular and respiratory diseases
1507829|NCT00004796|cirrhosis
1507830|NCT00004796|gastrointestinal disorders
1507831|NCT00004796|hypertensive disorder
1507832|NCT00004796|portal hypertension
1507833|NCT00004796|rare disease
1507834|NCT00004795|arthritis & connective tissue diseases
1507835|NCT00004795|immunologic disorders and infectious disorders
1507836|NCT00004795|rare disease
1507837|NCT00004795|systemic lupus erythematosus
1507838|NCT00004794|cytomegalovirus retinitis
1507839|NCT00004794|ophthalmologic disorders
1507840|NCT00004794|rare disease
1507841|NCT00004793|constitutional growth delay
1507842|NCT00004793|endocrine disorders
1507843|NCT00004793|rare disease
1507844|NCT00004791|dermatologic disorders
1507845|NCT00004791|epidermolysis bullosa
1507846|NCT00004791|genetic diseases and dysmorphic syndromes
1507847|NCT00004791|rare disease
1507848|NCT00004789|inborn errors of metabolism
1507849|NCT00004789|acute porphyria
1507850|NCT00004789|rare disease
1507851|NCT00004788|inborn errors of metabolism
1507852|NCT00004788|porphyria
1507853|NCT00004788|rare disease
1507854|NCT00004787|Fanconi's anemia
1507855|NCT00004787|Shwachman syndrome
1507856|NCT00004787|aplastic anemia
1507857|NCT00004787|dermatologic disorders
1507858|NCT00004787|dyskeratosis congenita
1507859|NCT00004787|hematologic disorders
1507860|NCT00004787|rare disease
1507861|NCT00004787|thrombocytopenia
1507862|NCT00004786|Raynaud's syndrome
1507863|NCT00004786|arthritis & connective tissue diseases
1507864|NCT00004786|cardiovascular and respiratory diseases
1507865|NCT00004786|rare disease
1507866|NCT00004786|systemic sclerosis
1507867|NCT00004785|bronchopulmonary dysplasia
1507868|NCT00004785|cardiovascular and respiratory diseases
1507869|NCT00004785|neonatal disorders
1507870|NCT00004785|rare disease
1507871|NCT00004784|cirrhosis
1507872|NCT00004784|gastrointestinal disorders
1507873|NCT00004784|primary biliary cirrhosis
1507874|NCT00004784|rare disease
1507875|NCT00004781|HIV-associated candidiasis
1507876|NCT00004781|candidiasis
1507877|NCT00004781|disease-related problem/condition
1507878|NCT00004781|fungal infection
1507879|NCT00004781|immunologic disorders and infectious disorders
1507880|NCT00004781|infection
1507881|NCT00004781|rare disease
1507882|NCT00004779|cardiovascular and respiratory diseases
1507883|NCT00004779|cystic fibrosis
1507884|NCT00004779|genetic diseases and dysmorphic syndromes
1507885|NCT00004779|rare disease
1507886|NCT00004778|cardiovascular and respiratory diseases
1507887|NCT00004778|neonatal disorders
1507888|NCT00004778|rare disease
1507889|NCT00004778|respiratory distress syndrome
1507892|NCT00004776|neurologic and psychiatric disorders
1507893|NCT00004776|rare disease
1507894|NCT00004776|seizures
1507895|NCT00004773|Rett syndrome
1507896|NCT00004773|neurologic and psychiatric disorders
1507897|NCT00004773|rare disease
1507898|NCT00004772|demyelinating neuropathy
1507899|NCT00004772|neurologic and psychiatric disorders
1507900|NCT00004772|rare disease
1507901|NCT00004771|amyotrophic lateral sclerosis
1507902|NCT00004771|motor neuron disease
1507903|NCT00004771|neurologic and psychiatric disorders
1507904|NCT00004771|rare disease
1507905|NCT00004771|spinal and bulbar muscular atrophy
1507906|NCT00004771|spinal muscular atrophy
1507907|NCT00004771|Kennedy's Syndrome
1507908|NCT00004770|inborn errors of metabolism
1507909|NCT00004770|mitochondrial myopathy
1507910|NCT00004770|rare disease
1507911|NCT00004769|Genetic diseases
1507912|NCT00004769|Myotonic muscular dystrophy
1507913|NCT00004769|Facioscapulohumeral muscular dystrophy
1507914|NCT00004769|CMT
1507915|NCT00004769|Rare disease
1507916|NCT00004767|inborn errors of metabolism
1507917|NCT00004767|rare disease
1507918|NCT00004767|urea cycle disorder
1507919|NCT00004763|endocrine disorders
1507920|NCT00004763|hyperandrogenism
1507921|NCT00004763|rare disease
1507922|NCT00004762|gastrointestinal disorders
1507923|NCT00004762|primary sclerosing cholangitis
1507924|NCT00004762|rare disease
1507925|NCT00004761|dermatologic disorders
1507926|NCT00004761|epidermolysis bullosa
1507927|NCT00004761|genetic diseases and dysmorphic syndromes
1507928|NCT00004761|rare disease
1507929|NCT00004760|Parkinson disease
1507930|NCT00004760|Neurologic and psychiatric disorders
1507931|NCT00004760|Rare disease
1507932|NCT00004759|environmental/toxic disorders
1507933|NCT00004759|neurologic and psychiatric disorders
1507934|NCT00004759|rare disease
1507935|NCT00004759|spinal cord injury
1507936|NCT00004758|infantile spasms
1507937|NCT00004758|epilepsy
1507938|NCT00004758|neurologic and psychiatric disorders
1507939|NCT00004758|rare disease
1507940|NCT00004758|seizures
1507941|NCT00004757|herpes simplex virus infection
1507942|NCT00004757|herpesvirus infection
1507943|NCT00004757|immunologic disorders and infectious disorders
1507944|NCT00004757|rare disease
1507945|NCT00004757|viral infection
1507946|NCT00004756|arthritis & connective tissue diseases
1507947|NCT00004756|disease-related problem/condition
1507948|NCT00004756|educational needs
1507949|NCT00004756|immunologic disorders and infectious disorders
1507950|NCT00004756|rare disease
1507951|NCT00004756|systemic lupus erythematosus
1507952|NCT00004755|dermatologic disorders
1507953|NCT00004755|environmental/toxic disorders
1507954|NCT00004755|immunologic disorders and infectious disorders
1507955|NCT00004755|leishmaniasis
1507956|NCT00004755|rare disease
1507957|NCT00004754|cardiovascular and respiratory diseases
1507958|NCT00004754|hypertensive disorder
1507959|NCT00004754|primary pulmonary hypertension
1507960|NCT00004754|rare disease
1507961|NCT00004753|Huntington's disease
1507962|NCT00004753|neurologic and psychiatric disorders
1507963|NCT00004753|rare disease
1507964|NCT00004751|cerebral palsy
1507965|NCT00004751|neurologic and psychiatric disorders
1507966|NCT00004751|rare disease
1507967|NCT00004751|spastic diplegia
1507968|NCT00004748|cirrhosis
1507969|NCT00004748|gastrointestinal disorders
1507970|NCT00004748|primary biliary cirrhosis
1507971|NCT00004748|rare disease
1507972|NCT00004747|bacterial infections
1507973|NCT00004747|cardiovascular and respiratory diseases
1507974|NCT00004747|cystic fibrosis
1507975|NCT00004747|genetic diseases and dysmorphic syndromes
1507976|NCT00004747|immunologic disorders and infectious disorders
1507977|NCT00004747|rare disease
1507978|NCT00004744|multiple sclerosis
1507979|NCT00004744|neurologic and psychiatric disorders
1507980|NCT00004744|rare disease
1507981|NCT00004740|cardiovascular and respiratory diseases
1507982|NCT00004740|rare disease
1507983|NCT00004740|tuberculosis
1507984|NCT00004739|Pediatric HIV infection
1507985|NCT00004738|Arnold Chiari Malformation
1507986|NCT00004738|Skeletal Dysplasia
1507987|NCT00004738|Syringomyelia
1507988|NCT00004738|Genetics
1507989|NCT00004738|Chiari I Malformation
1507990|NCT00004736|Tuberculosis
1507991|NCT00004736|Rifabutin
1507992|NCT00004736|AIDS-Related Opportunistic Infections
1507993|NCT00004736|Drug Therapy, Combination
1507994|NCT00004736|Antitubercular Agents
1507995|NCT00004736|Anti-HIV Agents
1507996|NCT00004735|Viral Vaccines
1507997|NCT00004735|Drug Therapy, Combination
1507998|NCT00004735|CD4-Positive T-Lymphocytes
1507999|NCT00004735|Immunologic Memory
1508000|NCT00004735|Antibody Formation
1508001|NCT00004735|Anti-HIV Agents
1508002|NCT00004735|Tetanus Toxoid
1508003|NCT00004735|Hepatitis A Virus, Human
1508004|NCT00004735|Enfuvirtide
1508005|NCT00004735|T-20
1508006|NCT00004735|Treatment Naive
1508007|NCT00004735|Treatment Experienced
1508008|NCT00004734|stroke
1508009|NCT00004734|cerebral infarction
1508010|NCT00004734|homocysteine
1508011|NCT00004734|vitamin
1508012|NCT00004734|folic acid
1508013|NCT00004734|pyridoxine
1508014|NCT00004734|vitamin B6
1508015|NCT00004734|cyanocobalamin
1508016|NCT00004734|vitamin B12
1508017|NCT00004734|multivitamin
1508018|NCT00004733|Parkinson's
1508019|NCT00004733|ELLDOPA
1508020|NCT00004733|L-dopa
1508021|NCT00004733|levodopa
1508022|NCT00004733|Sinemet
1508023|NCT00004733|tremor
1508024|NCT00004732|angioplasty
1508025|NCT00004732|asymptomatic
1508026|NCT00004732|atherosclerosis
1508027|NCT00004732|carotid endarterectomy
1508028|NCT00004732|carotid stenting
1508029|NCT00004732|CREST
1508030|NCT00004732|Cerebral Infarction
1508031|NCT00004732|device
1508032|NCT00004732|intervention
1508033|NCT00004732|restenosis
1508034|NCT00004732|revascularization
1508035|NCT00004732|stenosis
1508036|NCT00004732|stent
1508037|NCT00004732|stroke
1508038|NCT00004732|symptomatic
1508039|NCT00004732|surgery
1508040|NCT00004732|transient ischemic attack
1508041|NCT00004731|Parkinson's disease
1508042|NCT00004731|coenzyme Q10
1508043|NCT00004730|head injury
1508044|NCT00004730|traumatic brain injury
1508045|NCT00004730|concussion
1508046|NCT00004730|magnesium sulfate
1508047|NCT00004730|neuroprotection
1508048|NCT00004729|child
1508049|NCT00004729|children
1508050|NCT00004729|epilepsy
1508051|NCT00004729|seizure
1508052|NCT00004729|ketogenic
1508053|NCT00004729|diet
1508054|NCT00004729|Lennox-Gastaut Syndrome
1508055|NCT00004729|LGS
1508056|NCT00004728|stroke
1508057|NCT00004728|cerebral infarction
1508058|NCT00004728|warfarin
1508059|NCT00004728|coumadin
1508060|NCT00004728|aspirin
1508061|NCT00004728|ASA
1508062|NCT00004728|acetysalicylic acid
1508063|NCT00004728|atherosclerosis
1508064|NCT00004728|stenosis
1508065|NCT00004728|intracranial
1508066|NCT00004728|artery
1508067|NCT00004728|arteries
1508068|NCT00004728|transient ischemic attack
1508069|NCT00004728|TIA
1508070|NCT00004728|minorities
1508071|NCT00004727|African American
1508072|NCT00004727|antiplatelet
1508073|NCT00004727|aspirin
1508074|NCT00004727|ASA
1508075|NCT00004727|acetylsalicylic acid
1508076|NCT00004727|ticlopidine
1508077|NCT00004727|prevention
1508078|NCT00004727|stroke
1508079|NCT00004727|cerebral infarction
1508080|NCT00004727|Chicago
1508081|NCT00004727|non-cardioembolic ischemic stroke
1508082|NCT00004705|cardiovascular and respiratory diseases
1508083|NCT00004705|cystic fibrosis
1508084|NCT00004705|genetic diseases and dysmorphic syndromes
1508085|NCT00004705|rare disease
1508086|NCT00004700|endocrine disorders
1508087|NCT00004700|hyperinsulinism
1508088|NCT00004700|rare disease
1508089|NCT00004699|endocrine disorders
1508090|NCT00004699|hyperinsulinism
1508091|NCT00004699|rare disease
1508092|NCT00004697|gastrointestinal disorders
1508093|NCT00004697|hepatic steatosis
1508094|NCT00004697|rare disease
1508095|NCT00004696|disease-related problem/condition
1508096|NCT00004696|pain
1508097|NCT00004696|intraoperative/postoperative complications
1508098|NCT00004696|rare disease
1508099|NCT00004695|common variable immunodeficiency
1508100|NCT00004695|immunologic disorders and infectious disorders
1508101|NCT00004695|primary immunodeficiency disease
1508102|NCT00004695|rare disease
1508103|NCT00004694|genetic diseases and dysmorphic syndromes
1508104|NCT00004694|hereditary angioedema
1508105|NCT00004694|rare disease
1508106|NCT00004690|dermatologic disorders
1508107|NCT00004690|ichthyosis
1508108|NCT00004690|rare disease
1508109|NCT00004689|bacterial infection
1508110|NCT00004689|immunologic disorders and infectious disorders
1508111|NCT00004689|mycobacterium avium infection
1508112|NCT00004689|mycobacterium infection
1508113|NCT00004689|rare disease
1508114|NCT00004688|adult anaplastic astrocytoma
1508115|NCT00004688|adult anaplastic oligodendroglioma
1508116|NCT00004688|adult brain stem glioma
1508117|NCT00004688|adult brain tumor
1508118|NCT00004688|adult glioblastoma multiforme
1508119|NCT00004688|adult infiltrating astrocytoma
1508120|NCT00004688|brain tumor
1508121|NCT00004688|genetic condition
1508122|NCT00004688|miscellaneous sites/terms
1508123|NCT00004688|mixed gliomas
1508124|NCT00004688|nervous tissue tumors
1508125|NCT00004688|oncologic disorders
1508126|NCT00004688|rare disease
1508127|NCT00004688|recurrent adult brain tumor
1508128|NCT00004686|cardiovascular and respiratory diseases
1508129|NCT00004686|giant cell arteritis
1508130|NCT00004686|rare disease
1508131|NCT00004685|genetic diseases and dysmorphic syndromes
1508132|NCT00004685|muscular dystrophy
1508133|NCT00004685|neurologic and psychiatric disorders
1508134|NCT00004685|rare disease
1508135|NCT00004682|myasthenia gravis
1508136|NCT00004682|neurologic and psychiatric disorders
1508137|NCT00004682|rare disease
1508138|NCT00004670|Parkinson disease
1508139|NCT00004670|neurologic and psychiatric disorders
1508140|NCT00004670|rare disease
1508141|NCT00004669|bronchopulmonary dysplasia
1508142|NCT00004669|cardiovascular and respiratory diseases
1508143|NCT00004669|neonatal disorders
1508144|NCT00004669|rare disease
1508145|NCT00004667|hematologic disorders
1508146|NCT00004667|rare disease
1508147|NCT00004667|von Willebrand's disease
1508148|NCT00004665|arthritis & connective tissue diseases
1508149|NCT00004665|immunologic disorders and infectious disorders
1508150|NCT00004665|rare disease
1508151|NCT00004665|systemic lupus erythematosus
1508152|NCT00004664|disease-related problem/condition
1508153|NCT00004664|human immunodeficiency virus infection
1508154|NCT00004664|immunologic disorders and infectious disorders
1508155|NCT00004664|nutrition
1508156|NCT00004664|rare disease
1508157|NCT00004664|viral infection
1508158|NCT00004663|arthritis & connective tissue diseases
1508159|NCT00004663|immunologic disorders and infectious disorders
1508160|NCT00004663|rare disease
1508161|NCT00004663|systemic lupus erythematosus
1508162|NCT00004662|arthritis & connective tissue diseases
1508163|NCT00004662|immunologic disorders and infectious disorders
1508164|NCT00004662|rare disease
1508165|NCT00004662|systemic lupus erythematosus
1508166|NCT00004661|endocrine disorders
1508167|NCT00004661|pseudohypoparathyroidism
1508168|NCT00004661|rare disease
1508169|NCT00004660|Graves' disease
1508170|NCT00004660|thyroid disease
1508171|NCT00004660|endocrine disorders
1508172|NCT00004660|rare disease
1508173|NCT00004659|adult brain tumor
1508174|NCT00004659|brain tumor
1508175|NCT00004659|childhood brain tumor
1508176|NCT00004659|genetic condition
1508177|NCT00004659|nervous tissue tumors
1508178|NCT00004659|oncologic disorders
1508179|NCT00004659|rare disease
1508180|NCT00004658|5'-nucleotidase syndrome
1508181|NCT00004658|inborn errors of metabolism
1508182|NCT00004658|rare disease
1508183|NCT00004656|Rett syndrome
1508184|NCT00004656|neurologic and psychiatric disorders
1508185|NCT00004656|rare disease
1508186|NCT00004654|genetic diseases and dysmorphic syndromes
1508187|NCT00004654|hematologic disorders
1508188|NCT00004654|hereditary hemorrhagic telangiectasia
1508189|NCT00004654|rare disease
1508190|NCT00004652|Tourette syndrome
1508191|NCT00004652|neurologic and psychiatric disorders
1508192|NCT00004652|rare disease
1508193|NCT00004650|disease-related problem/condition
1508194|NCT00004650|osteoporosis
1508195|NCT00004650|rare disease
1508196|NCT00004649|genetic diseases and dysmorphic syndromes
1508197|NCT00004649|hematologic disorders
1508198|NCT00004649|hereditary hemorrhagic telangiectasia
1508199|NCT00004649|rare disease
1508200|NCT00004648|genetic diseases and dysmorphic syndromes
1508201|NCT00004648|hematologic disorders
1508202|NCT00004648|hereditary hemorrhagic telangiectasia
1508203|NCT00004648|rare disease
1508204|NCT00004648|Osler-Rendu-Weber disease
1508205|NCT00004647|diabetic neuropathy
1508206|NCT00004647|disease-related problem/condition
1508207|NCT00004647|neurologic and psychiatric disorders
1508208|NCT00004647|pain
1508209|NCT00004647|rare disease
1508210|NCT00004646|Duchenne muscular dystrophy
1508211|NCT00004646|genetic diseases and dysmorphic syndromes
1508212|NCT00004646|muscular dystrophy
1508213|NCT00004646|neurologic and psychiatric disorders
1508214|NCT00004646|rare disease
1508215|NCT00004645|Balo's concentric sclerosis
1508216|NCT00004645|Devic's syndrome
1508217|NCT00004645|Marburg's variant of multiple sclerosis
1508218|NCT00004645|acute disseminated encephalomyelitis
1508219|NCT00004645|acute transverse myelitis
1508220|NCT00004645|multiple sclerosis
1508221|NCT00004645|neurologic and psychiatric disorders
1508222|NCT00004645|rare disease
1508223|NCT00004644|herpes simplex virus infection
1508224|NCT00004644|herpesvirus infection
1508225|NCT00004644|immunologic disorders and infectious disorders
1508226|NCT00004644|rare disease
1508227|NCT00004644|viral infection
1508228|NCT00004643|arthritis & connective tissue diseases
1508229|NCT00004643|immunologic disorders and infectious disorders
1508230|NCT00004643|rare disease
1508231|NCT00004643|systemic lupus erythematosus
1508232|NCT00004642|congenital cytomegalovirus infection
1508233|NCT00004642|cytomegalovirus infection
1508234|NCT00004642|herpesvirus infection
1508235|NCT00004642|immunologic disorders and infectious disorders
1508236|NCT00004642|neonatal disorders
1508237|NCT00004642|rare disease
1508238|NCT00004642|viral infection
1508239|NCT00004640|Aging
1508240|NCT00004640|Elderly
1508241|NCT00004640|Periodontal Disease
1508242|NCT00004640|Dental Caries
1508243|NCT00004640|Fluoride
1508244|NCT00004640|Antibacterial rinse
1508245|NCT00004640|Chlorhexidine
1508246|NCT00004640|Tooth Mortality
1508247|NCT00004639|cleft lip and palate
1508248|NCT00004639|children
1508249|NCT00004639|speech
1508250|NCT00004639|velopharyngeal function
1508251|NCT00004639|congenital facial malformation
1508252|NCT00004639|von Langenbeck procedure
1508253|NCT00004639|Furlow procedure
1508254|NCT00004639|cleft lip and palate repair
1508255|NCT00004639|Unilateral cleft lip and palate
1508256|NCT00004638|chronic sinusitis
1508257|NCT00004635|Angiogenesis
1508258|NCT00004635|Cancer
1508259|NCT00004635|Hormonal Therapy
1508260|NCT00004635|Prostate
1508261|NCT00004635|Thalidomide
1508262|NCT00004635|Prostate Cancer
1508263|NCT00004604|stage IV colon cancer
1508264|NCT00004604|stage IV breast cancer
1508265|NCT00004604|recurrent breast cancer
1508266|NCT00004604|stage IV gastric cancer
1508267|NCT00004604|recurrent gastric cancer
1508268|NCT00004604|recurrent non-small cell lung cancer
1508269|NCT00004604|recurrent pancreatic cancer
1508270|NCT00004604|stage IV rectal cancer
1508271|NCT00004604|recurrent colon cancer
1508272|NCT00004604|recurrent rectal cancer
1508273|NCT00004604|inflammatory breast cancer
1508274|NCT00004604|stage IV ovarian epithelial cancer
1508275|NCT00004604|recurrent ovarian epithelial cancer
1508276|NCT00004604|extensive stage small cell lung cancer
1508277|NCT00004604|recurrent small cell lung cancer
1508278|NCT00004604|unresectable gallbladder cancer
1508279|NCT00004604|recurrent gallbladder cancer
1508280|NCT00004604|unresectable extrahepatic bile duct cancer
1508281|NCT00004604|recurrent extrahepatic bile duct cancer
1508282|NCT00004604|stage III malignant testicular germ cell tumor
1508283|NCT00004604|recurrent malignant testicular germ cell tumor
1508284|NCT00004604|thyroid gland medullary carcinoma
1508285|NCT00004604|stage IV non-small cell lung cancer
1508286|NCT00004604|stage IV salivary gland cancer
1508287|NCT00004604|recurrent salivary gland cancer
1508288|NCT00004604|Paget disease of the breast with invasive ductal carcinoma
1508289|NCT00004604|adult primary hepatocellular carcinoma
1508290|NCT00004604|testicular yolk sac tumor
1508291|NCT00004604|lung metastases
1508292|NCT00004604|liver metastases
1508293|NCT00004604|cholangiocarcinoma of the gallbladder
1508294|NCT00004604|cholangiocarcinoma of the extrahepatic bile duct
1508295|NCT00004604|male breast cancer
1508296|NCT00004604|stage IV pancreatic cancer
1508297|NCT00004585|Drug Therapy, Combination
1508298|NCT00004585|Zidovudine
1508299|NCT00004585|Lamivudine
1508300|NCT00004585|RNA, Viral
1508301|NCT00004585|Reverse Transcriptase Inhibitors
1508302|NCT00004585|Anti-HIV Agents
1508303|NCT00004585|Viral Load
1508304|NCT00004585|abacavir
1508305|NCT00004585|efavirenz
1508306|NCT00004584|Dose-Response Relationship, Drug
1508307|NCT00004584|Drug Therapy, Combination
1508308|NCT00004584|HIV Protease Inhibitors
1508309|NCT00004584|Ritonavir
1508310|NCT00004584|Saquinavir
1508311|NCT00004584|Reverse Transcriptase Inhibitors
1508312|NCT00004584|Anti-HIV Agents
1508313|NCT00004583|Drug Therapy, Combination
1508314|NCT00004583|Administration, Oral
1508315|NCT00004583|Stavudine
1508316|NCT00004583|HIV Protease Inhibitors
1508317|NCT00004583|Lamivudine
1508318|NCT00004583|Reverse Transcriptase Inhibitors
1508319|NCT00004583|Anti-HIV Agents
1508320|NCT00004583|Nelfinavir
1508321|NCT00004583|ABT 378
1508322|NCT00004582|HIV Protease Inhibitors
1508323|NCT00004582|Ritonavir
1508324|NCT00004582|Reverse Transcriptase Inhibitors
1508325|NCT00004582|Anti-HIV Agents
1508326|NCT00004582|Viral Load
1508327|NCT00004582|ABT 378
1508328|NCT00004582|efavirenz
1508329|NCT00004581|Drug Therapy, Combination
1508330|NCT00004581|Nevirapine
1508331|NCT00004581|HIV Protease Inhibitors
1508332|NCT00004581|Ritonavir
1508333|NCT00004581|Reverse Transcriptase Inhibitors
1508334|NCT00004581|Anti-HIV Agents
1508335|NCT00004581|ABT 378
1508336|NCT00004580|Drug Therapy, Combination
1508337|NCT00004580|Nevirapine
1508338|NCT00004580|HIV Protease Inhibitors
1508339|NCT00004580|Ritonavir
1508340|NCT00004580|Reverse Transcriptase Inhibitors
1508341|NCT00004579|Vaccines, Synthetic
1508342|NCT00004579|Viral Vaccines
1508343|NCT00004579|HIV-1
1508344|NCT00004579|Dose-Response Relationship, Drug
1508345|NCT00004579|HIV Envelope Protein gp160
1508346|NCT00004579|AIDS Vaccines
1508347|NCT00004579|HIV Seronegativity
1508348|NCT00004579|Avipoxvirus
1508349|NCT00004579|Immunization
1508350|NCT00004579|HIV Envelope Protein gp120
1508351|NCT00004579|Recombination, Genetic
1508352|NCT00004578|Stavudine
1508353|NCT00004578|HIV Protease Inhibitors
1508354|NCT00004578|Ritonavir
1508355|NCT00004578|Lamivudine
1508356|NCT00004578|Reverse Transcriptase Inhibitors
1508363|NCT00004576|Dyskinesias
1508364|NCT00004576|Glutamate
1508365|NCT00004576|Levodopa
1508366|NCT00004576|Parkinson's Disease
1508367|NCT00004575|Endothelium
1508368|NCT00004575|Vasodilation
1508369|NCT00004575|Vascular Biology
1508370|NCT00004575|Venous Occlusion Plethysmography
1508371|NCT00004574|Abetalipoproteinemia
1508372|NCT00004574|Ataxia
1508373|NCT00004574|Retinitis Pigmentosa
1508374|NCT00004574|Vitamin A
1508375|NCT00004574|Vitamin E
1508376|NCT00004573|cytomegalovirus viremia
1508377|NCT00004572|Type 2 Diabetes
1508378|NCT00004571|Magnetic Resonance Imaging
1508379|NCT00004571|Brain Metabolism
1508380|NCT00004571|Brain Physiology
1508381|NCT00004571|Neuropsychiatric Disorders
1508382|NCT00004571|Cognitition
1508383|NCT00004570|Temporal Processing
1508384|NCT00004570|Language Impairment
1508385|NCT00004570|Linkage Analysis
1508386|NCT00004570|Inheritance
1508387|NCT00004570|Language Delay
1508388|NCT00004570|Healthy
1508389|NCT00004570|Auditory Temporal Processing Disorder
1508390|NCT00004570|Speech Impediment
1508397|NCT00004567|Relapse
1508398|NCT00004567|Immunosuppressive
1508399|NCT00004567|Toxicity
1508400|NCT00004567|Purineantimetabolite
1508401|NCT00004567|Alternative Agents
1508402|NCT00004567|Wegener's Granulomatosis
1508403|NCT00004567|Wegener's Disease
1508404|NCT00004567|Blood Vessel Disorder
1508405|NCT00004567|Systemic Vasculitis
1508406|NCT00004566|3D Imaging
1508407|NCT00004566|Swallowing
1508408|NCT00004566|Fetal Development
1508409|NCT00004566|High-Risk Pregnancy
1508410|NCT00004566|Ultrasound
1508411|NCT00004565|Breast Cancer
1508412|NCT00004565|Genetics
1508413|NCT00004565|High Risk
1508414|NCT00004565|Polymorphisms
1508415|NCT00004565|Susceptibility
1508416|NCT00004565|Biomarkers
1508417|NCT00004565|Estrogen
1508418|NCT00004565|Genes
1508419|NCT00004564|Platelet Aggregation Inhibitors
1508420|NCT00004564|Cerebrovascular accident
1508421|NCT00004563|Lung Diseases
1508422|NCT00004563|Pulmonary Fibrosis
1508423|NCT00004563|Systemic Scleroderma
1508424|NCT00004563|Scleroderma, systemic
1508425|NCT00004557|Attention
1508426|NCT00004557|Cognition
1508427|NCT00004557|Dementia
1508428|NCT00004557|Memory
1508429|NCT00004557|Object Recognition
1508430|NCT00004557|Spatial Processes
1508431|NCT00004556|Stimulants
1508432|NCT00004556|Affect
1508433|NCT00004556|Cognition
1508434|NCT00004556|Brain Physiology
1508435|NCT00004556|Brain Metabolism
1508436|NCT00004556|Catecholamines
1508437|NCT00004556|Brain Imaging
1508438|NCT00004556|Cognitive Efficiency
1508439|NCT00004556|Dopamine Genes
1508440|NCT00004553|Single Fiber EMG
1508441|NCT00004553|Macro-EMG
1508442|NCT00004553|Myasthenia
1508443|NCT00004553|Post-Polio Syndrome
1508444|NCT00004553|Neuromuscular Transmission
1508445|NCT00004553|Motor Dysfunction
1508446|NCT00004553|Neuromuscular Disorder
1508447|NCT00004550|Screening
1508448|NCT00004550|Longitudinal
1508449|NCT00004550|Transition
1508450|NCT00004550|Treatment
1508451|NCT00004550|Comorbidity
1508452|NCT00004550|Obsessive Compulsive Disorder
1508453|NCT00004550|Evaluation
1508454|NCT00004550|Follow-Up
1508455|NCT00004550|OC Spectrum Disorders
1508456|NCT00004550|OCD
1508457|NCT00004549|Atherosclerosis
1508458|NCT00004549|Endothelium
1508459|NCT00004549|Peripheral Vascular Disease
1508460|NCT00004549|Markers of Inflammation
1508461|NCT00004549|Claudication
1508462|NCT00004547|Surgery
1508463|NCT00004547|Mesothelioma
1508464|NCT00004547|Pseudomyxoma
1508465|NCT00004547|Colon Cancer
1508466|NCT00004547|Chemotherapy
1508467|NCT00004533|cardiovascular and respiratory diseases
1508468|NCT00004533|cystic fibrosis
1508469|NCT00004533|genetic diseases and dysmorphic syndromes
1508470|NCT00004533|rare disease
1508471|NCT00004500|cardiovascular and respiratory diseases
1508472|NCT00004500|meconium aspiration syndrome
1508473|NCT00004500|rare disease
1508474|NCT00004498|genetic diseases and dysmorphic syndromes
1508475|NCT00004498|inborn errors of metabolism
1508476|NCT00004498|ornithine transcarbamylase deficiency
1508477|NCT00004498|rare disease
1508478|NCT00004498|urea cycle disorder
1508479|NCT00004497|cardiovascular and respiratory diseases
1508480|NCT00004497|hypertensive disorder
1508481|NCT00004497|primary pulmonary hypertension
1508482|NCT00004497|rare disease
1508483|NCT00004496|acute renal failure
1508484|NCT00004496|rare disease
1508485|NCT00004496|renal and genitourinary disorders
1508486|NCT00004495|cardiovascular and respiratory diseases
1508487|NCT00004495|end stage renal disease
1508488|NCT00004495|hyperhomocysteinemia
1508489|NCT00004495|rare disease
1508490|NCT00004495|renal and genitourinary disorders
1508491|NCT00004494|cardiovascular and respiratory diseases
1508492|NCT00004494|immunologic disorders and infectious disorders
1508493|NCT00004494|neonatal disorders
1508494|NCT00004494|rare disease
1508495|NCT00004494|respiratory distress syndrome
1508496|NCT00004494|sepsis
1508497|NCT00004493|inborn errors of metabolism
1508498|NCT00004493|lactic acidosis
1508499|NCT00004493|rare disease
1508500|NCT00004492|genetic diseases and dysmorphic syndromes
1508501|NCT00004492|hematologic disorders
1508502|NCT00004492|rare disease
1508503|NCT00004492|sickle cell anemia
1508504|NCT00004490|disease-related problem/condition
1508505|NCT00004490|inborn errors of metabolism
1508506|NCT00004490|lactic acidosis
1508507|NCT00004490|quality of life
1508508|NCT00004490|rare disease
1508509|NCT00004489|cardiovascular and respiratory diseases
1508510|NCT00004489|cystic fibrosis
1508511|NCT00004489|disease-related problem/condition
1508512|NCT00004489|genetic diseases and dysmorphic syndromes
1508513|NCT00004489|osteoporosis
1508514|NCT00004489|rare disease
1508515|NCT00004488|Gaucher's disease
1508516|NCT00004488|inborn errors of metabolism
1508517|NCT00004488|rare disease
1508518|NCT00004488|sphingolipidoses
1508519|NCT00004487|rare disease
1508520|NCT00004487|renal and genitourinary disorders
1508521|NCT00004487|vesicoureteral reflux
1508522|NCT00004486|autism
1508523|NCT00004486|neurologic and psychiatric disorders
1508524|NCT00004486|rare disease
1508525|NCT00004485|genetic diseases and dysmorphic syndromes
1508526|NCT00004485|hematologic disorders
1508527|NCT00004485|rare disease
1508528|NCT00004485|sickle cell anemia
1508529|NCT00004482|cardiovascular and respiratory diseases
1508530|NCT00004482|giant cell myocarditis
1508531|NCT00004482|rare disease
1508532|NCT00004481|endocrine disorders
1508533|NCT00004481|inborn errors of metabolism
1508534|NCT00004481|rare disease
1508535|NCT00004481|sitosterolemia
1508536|NCT00004480|dermatologic disorders
1508537|NCT00004480|hyperhidrosis
1508538|NCT00004480|rare disease
1508539|NCT00004479|neurologic and psychiatric disorders
1508540|NCT00004479|rare disease
1508541|NCT00004479|syncope
1508542|NCT00004478|Shy-Drager Syndrome
1508543|NCT00004478|cardiovascular and respiratory diseases
1508544|NCT00004478|neurologic and psychiatric disorders
1508545|NCT00004478|orthostatic hypotension
1508546|NCT00004478|rare disease
1508547|NCT00004474|Hematologic Disorders
1508548|NCT00004474|Rare Disease
1508549|NCT00004471|cardiovascular and respiratory diseases
1508550|NCT00004471|cystic fibrosis
1508551|NCT00004471|genetic diseases and dysmorphic syndromes
1508552|NCT00004471|rare disease
1508553|NCT00004468|dermatologic disorders
1508554|NCT00004468|psoriasis
1508555|NCT00004468|rare disease
1508556|NCT00004467|acute liver failure
1508557|NCT00004467|gastrointestinal disorders
1508558|NCT00004467|rare disease
1508559|NCT00004466|cardiovascular and respiratory diseases
1508560|NCT00004466|hyperlipidemia
1508561|NCT00004466|nephrotic syndrome
1508562|NCT00004466|rare disease
1508563|NCT00004466|renal and genitourinary disorders
1508564|NCT00004465|E. coli infection
1508565|NCT00004465|bacterial infection
1508566|NCT00004465|hemolytic uremic syndrome
1508567|NCT00004465|immunologic disorders and infectious disorders
1508568|NCT00004465|rare disease
1508569|NCT00004465|renal and genitourinary disorders
1508570|NCT00004464|aplastic anemia
1508571|NCT00004464|hematologic disorders
1508572|NCT00004464|paroxysmal nocturnal hemoglobinuria
1508573|NCT00004464|rare disease
1508574|NCT00004458|autism
1508575|NCT00004458|childhood disintegrative disorder
1508576|NCT00004458|neurologic and psychiatric disorders
1508577|NCT00004458|rare disease
1508578|NCT00004457|amyotrophic lateral sclerosis
1508579|NCT00004457|motor neuron disease
1508580|NCT00004457|neurologic and psychiatric disorders
1508581|NCT00004457|rare disease
1508582|NCT00004454|inborn errors of metabolism
1508583|NCT00004454|mucopolysaccharidosis
1508584|NCT00004454|mucopolysaccharidosis II
1508585|NCT00004454|rare disease
1508586|NCT00004451|Parkinson disease
1508587|NCT00004451|neurologic and psychiatric disorders
1508588|NCT00004451|rare disease
1508589|NCT00004450|adrenoleukodystrophy
1508590|NCT00004450|inborn errors of metabolism
1508591|NCT00004450|rare disease
1508592|NCT00004450|sphingolipidoses
1508593|NCT00004449|autism
1508594|NCT00004449|neurologic and psychiatric disorders
1508595|NCT00004449|rare disease
1508596|NCT00004448|IgA glomerulonephritis
1508597|NCT00004448|rare disease
1508598|NCT00004448|renal and genitourinary disorders
1508599|NCT00004446|depersonalization disorder
1508600|NCT00004446|neurologic and psychiatric disorders
1508601|NCT00004446|rare disease
1508602|NCT00004445|environmental/toxic disorders
1508603|NCT00004445|neurologic and psychiatric disorders
1508604|NCT00004445|rare disease
1508605|NCT00004445|spinal cord injury
1508606|NCT00004444|bacterial infection
1508607|NCT00004444|immunologic disorders and infectious disorders
1508608|NCT00004444|mycobacterium infection
1508609|NCT00004444|mycobacterium tuberculosis infection
1508610|NCT00004444|rare disease
1508611|NCT00004443|inborn errors of metabolism
1508612|NCT00004443|rare disease
1508613|NCT00004443|tyrosinemia I
1508614|NCT00004442|Zellweger syndrome
1508615|NCT00004442|adrenoleukodystrophy
1508616|NCT00004442|bifunctional enzyme deficiency
1508617|NCT00004442|inborn errors of metabolism
1508618|NCT00004442|infantile Refsum's disease
1508619|NCT00004442|peroxisomal disorders
1508620|NCT00004442|pseudo-Zellweger syndrome
1508621|NCT00004442|rare disease
1508622|NCT00004442|sphingolipidoses
1508623|NCT00004441|cardiovascular and respiratory diseases
1508624|NCT00004441|cystic fibrosis
1508625|NCT00004441|genetic diseases and dysmorphic syndromes
1508626|NCT00004441|rare disease
1508627|NCT00004440|cardiovascular and respiratory diseases
1508628|NCT00004440|cystic fibrosis
1508629|NCT00004440|genetic diseases and dysmorphic syndromes
1508630|NCT00004440|rare disease
1508631|NCT00004438|endocrine disorders
1508632|NCT00004438|hypogonadism
1508633|NCT00004438|rare disease
1508634|NCT00004437|acoustic neuroma
1508635|NCT00004437|genetic diseases and dysmorphic syndromes
1508636|NCT00004437|hearing loss
1508637|NCT00004437|neurofibromatosis
1508638|NCT00004437|neurologic and psychiatric disorders
1508639|NCT00004437|rare disease
1508640|NCT00004436|cardiovascular and respiratory diseases
1508641|NCT00004436|hemangioma
1508642|NCT00004436|rare disease
1508643|NCT00004433|Tourette syndrome
1508644|NCT00004433|neurologic and psychiatric disorders
1508645|NCT00004433|rare disease
1508646|NCT00004431|neurologic and psychiatric disorders
1508647|NCT00004431|rare disease
1508648|NCT00004431|trigeminal neuralgia
1508649|NCT00004430|cardiovascular and respiratory diseases
1508650|NCT00004430|corneal neovascularization
1508651|NCT00004430|rare disease
1508652|NCT00004429|end stage renal disease
1508653|NCT00004429|rare disease
1508654|NCT00004429|renal and genitourinary disorders
1508655|NCT00004428|cardiovascular and respiratory diseases
1508656|NCT00004428|cystic fibrosis
1508657|NCT00004428|genetic diseases and dysmorphic syndromes
1508658|NCT00004428|rare disease
1508659|NCT00004426|endocrine disorders
1508660|NCT00004426|hypogonadism
1508661|NCT00004426|rare disease
1508662|NCT00004424|disease-related problem/condition
1508663|NCT00004424|oncologic disorders
1508664|NCT00004424|pulmonary complications
1508665|NCT00004424|rare disease
1508666|NCT00004424|Respiration, Artificial
1508667|NCT00004423|Crohn's disease
1508668|NCT00004423|gastrointestinal disorders
1508669|NCT00004423|rare disease
1508670|NCT00004422|bacterial infection
1508671|NCT00004422|immunologic disorders and infectious disorders
1508672|NCT00004422|pertussis
1508673|NCT00004422|rare disease
1508674|NCT00004421|dystonia
1508675|NCT00004421|neurologic and psychiatric disorders
1508676|NCT00004421|rare disease
1508677|NCT00004420|arthritis & connective tissue diseases
1508678|NCT00004420|juvenile rheumatoid arthritis
1508679|NCT00004420|rare disease
1508680|NCT00004419|endocrine disorders
1508681|NCT00004419|insulin resistance
1508682|NCT00004419|rare disease
1508683|NCT00004418|adrenoleukodystrophy
1508684|NCT00004418|inborn errors of metabolism
1508685|NCT00004418|rare disease
1508686|NCT00004418|sphingolipidoses
1508687|NCT00004416|achalasia
1508688|NCT00004416|gastrointestinal disorders
1508689|NCT00004416|rare disease
1508690|NCT00004415|environmental/toxic disorders
1508691|NCT00004415|neurologic and psychiatric disorders
1508692|NCT00004415|rare disease
1508693|NCT00004415|spinal cord injury
1508694|NCT00004414|cholestasis
1508695|NCT00004414|gastrointestinal disorders
1508696|NCT00004414|rare disease
1508697|NCT00004412|dermatologic disorders
1508698|NCT00004412|genetic diseases and dysmorphic syndromes
1508699|NCT00004412|hematologic disorders
1508700|NCT00004412|rare disease
1508701|NCT00004412|sickle cell anemia
1508702|NCT00004412|skin ulcers
1508703|NCT00004412|thalassemia major
1508704|NCT00004410|cholestasis
1508705|NCT00004410|gastrointestinal disorders
1508706|NCT00004410|rare disease
1508707|NCT00004409|Dupuytren's disease
1508708|NCT00004409|arthritis & connective tissue diseases
1508709|NCT00004409|rare disease
1508710|NCT00004408|disease-related problem/condition
1508711|NCT00004408|genetic diseases and dysmorphic syndromes
1508712|NCT00004408|hematologic disorders
1508713|NCT00004408|pain
1508714|NCT00004408|rare disease
1508715|NCT00004408|sickle cell anemia
1508716|NCT00004407|diabetic amyotrophy
1508717|NCT00004407|diabetic lumbosacral radiculoplexus neuropathy
1508718|NCT00004407|diabetic neuropathy
1508719|NCT00004407|diabetic proximal neuropathy
1508720|NCT00004407|neurologic and psychiatric disorders
1508721|NCT00004407|rare disease
1508722|NCT00004406|disease-related problem/condition
1508723|NCT00004406|osteoporosis
1508724|NCT00004406|rare disease
1508725|NCT00004404|genetic diseases and dysmorphic syndromes
1508726|NCT00004404|hematologic disorders
1508727|NCT00004404|rare disease
1508728|NCT00004404|sickle cell anemia
1508729|NCT00004403|cysticercosis
1508730|NCT00004403|epilepsy
1508731|NCT00004403|immunologic disorders and infectious disorders
1508732|NCT00004403|neurologic and psychiatric disorders
1508733|NCT00004403|parasitic infection
1508734|NCT00004403|rare disease
1508735|NCT00004403|seizures
1508736|NCT00004402|genetic diseases and dysmorphic syndromes
1508737|NCT00004402|osteopetrosis
1508738|NCT00004402|rare disease
1508739|NCT00004401|bacterial infection
1508740|NCT00004401|clostridium infection
1508741|NCT00004401|immunologic disorders and infectious disorders
1508742|NCT00004401|infant botulism
1508743|NCT00004401|rare disease
1508744|NCT00004400|cachexia
1508745|NCT00004400|disease-related problem/condition
1508746|NCT00004400|human immunodeficiency virus infection
1508747|NCT00004400|immunologic disorders and infectious disorders
1508748|NCT00004400|nutrition
1508749|NCT00004400|quality of life
1508750|NCT00004400|rare disease
1508751|NCT00004400|viral infection
1508752|NCT00004399|cardiovascular and respiratory diseases
1508753|NCT00004399|hypertensive disorder
1508754|NCT00004399|pre-eclampsia
1508755|NCT00004399|rare disease
1508756|NCT00004398|inborn errors of metabolism
1508757|NCT00004398|porphyria
1508758|NCT00004398|rare disease
1508759|NCT00004397|inborn errors of metabolism
1508760|NCT00004397|porphyria
1508761|NCT00004397|rare disease
1508762|NCT00004396|inborn errors of metabolism
1508763|NCT00004396|porphyria
1508764|NCT00004396|rare disease
1508765|NCT00004393|Tourette syndrome
1508766|NCT00004393|neurologic and psychiatric disorders
1508767|NCT00004393|rare disease
1508768|NCT00004392|apnea
1508769|NCT00004392|cardiovascular and respiratory diseases
1508770|NCT00004392|neurologic and psychiatric disorders
1508771|NCT00004392|rare disease
1508772|NCT00004392|sudden infant death syndrome
1508773|NCT00004390|disease-related problem/condition
1508774|NCT00004390|herpes zoster infection
1508775|NCT00004390|herpesvirus infection
1508776|NCT00004390|immunologic disorders and infectious disorders
1508777|NCT00004390|pain
1508778|NCT00004390|rare disease
1508779|NCT00004390|viral infection
1508780|NCT00004387|Parkinson disease
1508781|NCT00004387|neurologic and psychiatric disorders
1508782|NCT00004387|rare disease
1508783|NCT00004386|inborn errors of metabolism
1508784|NCT00004386|rare disease
1508785|NCT00004386|urea cycle disorder
1508786|NCT00004382|hematologic disorders
1508787|NCT00004382|hyperbilirubinemia
1508788|NCT00004382|rare disease
1508789|NCT00004381|glucose-6-phosphate dehydrogenase deficiency
1508790|NCT00004381|hematologic disorders
1508791|NCT00004381|hemolytic disease
1508792|NCT00004381|hyperbilirubinemia
1508793|NCT00004381|neonatal disorders
1508794|NCT00004381|rare disease
1508795|NCT00004380|arthritis & connective tissue diseases
1508796|NCT00004380|rare disease
1508797|NCT00004380|systemic sclerosis
1508798|NCT00004378|Fanconi's anemia
1508799|NCT00004378|amegakaryocytic thrombocytopenia
1508800|NCT00004378|aplastic anemia
1508801|NCT00004378|congenital pure red cell aplasia
1508802|NCT00004378|genetic diseases and dysmorphic syndromes
1508803|NCT00004378|hematologic disorders
1508804|NCT00004378|inborn errors of metabolism
1508805|NCT00004378|metachromatic leukodystrophy
1508806|NCT00004378|pure red cell aplasia
1508807|NCT00004378|rare disease
1508808|NCT00004378|sphingolipidoses
1508809|NCT00004378|thalassemia major
1508810|NCT00004376|Tourette syndrome
1508811|NCT00004376|neurologic and psychiatric disorders
1508812|NCT00004376|rare disease
1508813|NCT00004375|arthritis & connective tissue diseases
1508814|NCT00004375|immunologic disorders and infectious disorders
1508815|NCT00004375|rare disease
1508816|NCT00004375|systemic lupus erythematosus
1508817|NCT00004374|amyloidosis
1508818|NCT00004374|arthritis & connective tissue diseases
1508819|NCT00004374|genetic diseases and dysmorphic syndromes
1508820|NCT00004374|rare disease
1508821|NCT00004373|anxiety disorder
1508822|NCT00004373|disease-related problem/condition
1508823|NCT00004373|neurologic and psychiatric disorders
1508824|NCT00004373|panic disorder
1508825|NCT00004373|rare disease
1508826|NCT00004368|hepatic cirrhosis
1508827|NCT00004368|gastrointestinal disorders
1508828|NCT00004368|rare disease
1508829|NCT00004367|anxiety disorder
1508830|NCT00004367|disease-related problem/condition
1508831|NCT00004367|neurologic and psychiatric disorders
1508832|NCT00004367|panic disorder
1508833|NCT00004367|rare disease
1508834|NCT00004366|agoraphobia
1508835|NCT00004366|anxiety disorder
1508836|NCT00004366|disease-related problem/condition
1508837|NCT00004366|neurologic and psychiatric disorders
1508838|NCT00004366|panic disorder
1508839|NCT00004366|rare disease
1508840|NCT00004366|vestibular diseases
1508841|NCT00004365|endocrine disorders
1508842|NCT00004365|growth hormone deficiency
1508843|NCT00004365|rare disease
1508844|NCT00004364|diabetes insipidus
1508845|NCT00004364|endocrine disorders
1508846|NCT00004364|rare disease
1508847|NCT00004363|diabetes insipidus
1508848|NCT00004363|endocrine disorders
1508849|NCT00004363|rare disease
1508850|NCT00004361|DiGeorge syndrome
1508851|NCT00004361|cardiovascular and respiratory diseases
1508852|NCT00004361|conotruncal cardiac defects
1508853|NCT00004361|endocrine disorders
1508854|NCT00004361|genetic diseases and dysmorphic syndromes
1508855|NCT00004361|hypoparathyroidism
1508856|NCT00004361|pulmonary valve stenosis
1508857|NCT00004361|rare disease
1508858|NCT00004361|tetralogy of Fallot
1508859|NCT00004360|diabetes insipidus
1508860|NCT00004360|endocrine disorders
1508861|NCT00004360|rare disease
1508862|NCT00004359|dermatologic disorders
1508863|NCT00004359|epidermolysis bullosa
1508864|NCT00004359|genetic diseases and dysmorphic syndromes
1508865|NCT00004359|rare disease
1508866|NCT00004358|arthritis & connective tissue diseases
1508867|NCT00004358|rare disease
1508868|NCT00004358|tumoral calcinosis
1508869|NCT00004357|Cardiovascular Disease
1508870|NCT00004357|Respiratory Disease
1508871|NCT00004357|Rare Diseases
1508872|NCT00004357|Vasculitis
1508873|NCT00004356|homocystinuria
1508874|NCT00004356|inborn errors of metabolism
1508875|NCT00004356|rare disease
1508876|NCT00004354|endocrine disorders
1508877|NCT00004354|genetic diseases and dysmorphic syndromes
1508878|NCT00004354|hyperaldosteronism
1508879|NCT00004354|rare disease
1508880|NCT00004353|MELAS syndrome
1508881|NCT00004353|inborn errors of metabolism
1508882|NCT00004353|lactic acidosis
1508883|NCT00004353|mitochondrial myopathy
1508884|NCT00004353|rare disease
1508885|NCT00004351|Angelman syndrome
1508886|NCT00004351|DiGeorge syndrome
1508887|NCT00004351|Prader-Willi syndrome
1508888|NCT00004351|Shprintzen syndrome
1508889|NCT00004351|Smith-Magenis syndrome
1508890|NCT00004351|Williams syndrome
1508891|NCT00004351|genetic diseases and dysmorphic syndromes
1508892|NCT00004351|neurologic and psychiatric disorders
1508893|NCT00004351|rare disease
1508894|NCT00004350|Fanconi syndrome
1508895|NCT00004350|cystinosis
1508896|NCT00004350|rare disease
1508897|NCT00004350|renal and genitourinary disorders
1508898|NCT00004348|beta-oxidation disorder
1508899|NCT00004348|inborn errors of metabolism
1508900|NCT00004348|rare disease
1508901|NCT00004347|Smith-Lemli-Opitz syndrome
1508902|NCT00004347|genetic diseases and dysmorphic syndromes
1508903|NCT00004347|rare disease
1508904|NCT00004346|cerebrotendinous xanthomatosis
1508905|NCT00004346|inborn errors of metabolism
1508906|NCT00004346|rare disease
1508907|NCT00004345|Usher syndrome
1508908|NCT00004345|ophthalmologic disorders
1508909|NCT00004345|rare disease
1508910|NCT00004345|retinitis pigmentosa
1508911|NCT00004344|endocrine disorders
1508912|NCT00004344|precocious puberty
1508913|NCT00004344|rare disease
1508914|NCT00004343|Cushing's syndrome
1508915|NCT00004343|endocrine disorders
1508916|NCT00004343|rare disease
1508917|NCT00004342|chronic neutropenia
1508918|NCT00004342|disease-related problem/condition
1508919|NCT00004342|hematologic disorders
1508920|NCT00004342|neutropenia
1508921|NCT00004342|rare disease
1508922|NCT00004342|severe chronic neutropenia
1508923|NCT00004341|Wiskott-Aldrich syndrome
1508924|NCT00004341|X-linked agammaglobulinemia
1508925|NCT00004341|X-linked hyper IgM syndrome
1508926|NCT00004341|genetic diseases and dysmorphic syndromes
1508927|NCT00004341|immunologic disorders and infectious disorders
1508928|NCT00004341|leukocyte adhesion deficiency syndrome
1508929|NCT00004341|primary immunodeficiency disease
1508930|NCT00004341|rare disease
1508931|NCT00004340|end stage renal disease
1508932|NCT00004340|rare disease
1508933|NCT00004340|renal and genitourinary disorders
1508934|NCT00004340|renal osteodystrophy
1508935|NCT00004339|Wilson disease
1508936|NCT00004339|inborn errors of metabolism
1508937|NCT00004339|rare disease
1508938|NCT00004338|Wilson disease
1508939|NCT00004338|inborn errors of metabolism
1508940|NCT00004338|rare disease
1508941|NCT00004229|unspecified adult solid tumor, protocol specific
1508942|NCT00004228|stage III childhood lymphoblastic lymphoma
1508943|NCT00004228|stage IV childhood lymphoblastic lymphoma
1508944|NCT00004227|stage III squamous cell carcinoma of the oropharynx
1508945|NCT00004227|stage IV squamous cell carcinoma of the oropharynx
1508946|NCT00004227|recurrent squamous cell carcinoma of the oropharynx
1508947|NCT00004227|stage III squamous cell carcinoma of the hypopharynx
1508948|NCT00004227|stage IV squamous cell carcinoma of the hypopharynx
1508949|NCT00004227|recurrent squamous cell carcinoma of the hypopharynx
1508950|NCT00004227|stage III squamous cell carcinoma of the larynx
1508951|NCT00004227|stage IV squamous cell carcinoma of the larynx
1508952|NCT00004227|recurrent squamous cell carcinoma of the larynx
1508953|NCT00004226|recurrent squamous cell carcinoma of the lip and oral cavity
1508954|NCT00004226|recurrent squamous cell carcinoma of the hypopharynx
1508955|NCT00004226|recurrent squamous cell carcinoma of the larynx
1508956|NCT00004226|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1508957|NCT00004226|recurrent squamous cell carcinoma of the oropharynx
1508958|NCT00004226|recurrent metastatic squamous neck cancer with occult primary
1508959|NCT00004225|recurrent non-small cell lung cancer
1508960|NCT00004224|childhood infratentorial ependymoma
1508961|NCT00004224|childhood supratentorial ependymoma
1508962|NCT00004224|newly diagnosed childhood ependymoma
1508963|NCT00004223|stage III bladder cancer
1508964|NCT00004223|recurrent bladder cancer
1508965|NCT00004223|stage IV bladder cancer
1508966|NCT00004223|transitional cell carcinoma of the bladder
1508967|NCT00004223|posterior urethral cancer
1508968|NCT00004223|metastatic transitional cell cancer of the renal pelvis and ureter
1508969|NCT00004223|regional transitional cell cancer of the renal pelvis and ureter
1508970|NCT00004220|unspecified adult solid tumor, protocol specific
1508971|NCT00004219|nausea and vomiting
1508972|NCT00004219|stage I malignant testicular germ cell tumor
1508973|NCT00004219|testicular seminoma
1508974|NCT00004218|stage I chronic lymphocytic leukemia
1509088|NCT00004300|rare disease
1508975|NCT00004218|stage II chronic lymphocytic leukemia
1508976|NCT00004218|stage III chronic lymphocytic leukemia
1508977|NCT00004218|B-cell chronic lymphocytic leukemia
1508978|NCT00004218|stage 0 chronic lymphocytic leukemia
1508979|NCT00004217|untreated adult acute myeloid leukemia
1508980|NCT00004217|adult acute erythroid leukemia (M6)
1508981|NCT00004217|adult acute myeloblastic leukemia without maturation (M1)
1508982|NCT00004217|adult acute myeloblastic leukemia with maturation (M2)
1508983|NCT00004217|adult acute myelomonocytic leukemia (M4)
1508984|NCT00004217|adult acute monoblastic leukemia (M5a)
1508985|NCT00004217|adult acute megakaryoblastic leukemia (M7)
1508986|NCT00004217|adult acute monocytic leukemia (M5b)
1508987|NCT00004217|adult acute minimally differentiated myeloid leukemia (M0)
1508988|NCT00004216|unspecified adult solid tumor, protocol specific
1508989|NCT00004336|Mondini dysplasia
1508990|NCT00004336|genetic diseases and dysmorphic syndromes
1508991|NCT00004336|rare disease
1508992|NCT00004335|endocrine disorders
1508993|NCT00004335|growth hormone deficiency
1508994|NCT00004335|hypogonadism
1508995|NCT00004335|precocious puberty
1508996|NCT00004335|rare disease
1508997|NCT00004334|Cushing's syndrome
1508998|NCT00004334|endocrine disorders
1508999|NCT00004334|rare disease
1509000|NCT00004333|inborn errors of metabolism
1509001|NCT00004333|rare disease
1509002|NCT00004333|tyrosinemia I
1509003|NCT00004332|acromegaly
1509004|NCT00004332|endocrine disorders
1509005|NCT00004332|rare disease
1509006|NCT00004331|inborn errors of metabolism
1509007|NCT00004331|porphyria
1509008|NCT00004331|rare disease
1509009|NCT00004330|inborn errors of metabolism
1509010|NCT00004330|porphyria
1509011|NCT00004330|rare disease
1509012|NCT00004329|endocrine disorders
1509013|NCT00004329|rare disease
1509014|NCT00004328|endocrine disorders
1509015|NCT00004328|pseudohypoaldosteronism
1509016|NCT00004328|rare disease
1509017|NCT00004327|genetic diseases and dysmorphic syndromes
1509018|NCT00004327|hematologic disorders
1509019|NCT00004327|hereditary hemorrhagic telangiectasia
1509020|NCT00004327|rare disease
1509021|NCT00004327|senile ectasia
1509022|NCT00004326|Cushing's syndrome
1509023|NCT00004326|endocrine disorders
1509024|NCT00004326|rare disease
1509025|NCT00004325|Tourette syndrome
1509026|NCT00004325|anxiety disorder
1509027|NCT00004325|disease-related problem/condition
1509028|NCT00004325|neurologic and psychiatric disorders
1509029|NCT00004325|obsessive compulsive disorder
1509030|NCT00004325|oncologic disorders
1509031|NCT00004325|rare disease
1509032|NCT00004324|Tourette syndrome
1509033|NCT00004324|anxiety disorder
1509034|NCT00004324|disease-related problem/condition
1509035|NCT00004324|neurologic and psychiatric disorders
1509036|NCT00004324|obsessive compulsive disorder
1509037|NCT00004324|oncologic disorders
1509038|NCT00004324|rare disease
1509039|NCT00004323|aplastic anemia
1509040|NCT00004323|hematologic disorders
1509041|NCT00004323|rare disease
1509042|NCT00004317|immunologic disorders and infectious disorders
1509043|NCT00004317|rare disease
1509044|NCT00004317|toxoplasmosis
1509045|NCT00004316|interstitial cystitis
1509046|NCT00004316|rare disease
1509047|NCT00004316|renal and genitourinary disorders
1509048|NCT00004316|vulvar vestibulitis
1509049|NCT00004315|cardiovascular and respiratory diseases
1509050|NCT00004315|cholestasis
1509051|NCT00004315|cystic fibrosis
1509052|NCT00004315|gastrointestinal disorders
1509053|NCT00004315|genetic diseases and dysmorphic syndromes
1509054|NCT00004315|rare disease
1509055|NCT00004314|Lesch-Nyhan syndrome
1509056|NCT00004314|inborn errors of metabolism
1509057|NCT00004314|neurologic and psychiatric disorders
1509058|NCT00004314|rare disease
1509059|NCT00004313|Addison's disease
1509060|NCT00004313|endocrine disorders
1509061|NCT00004313|rare disease
1509062|NCT00004313|primary adrenal insufficiency
1509063|NCT00004312|cystinosis
1509064|NCT00004312|rare disease
1509065|NCT00004312|renal and genitourinary disorders
1509066|NCT00004311|acanthosis nigricans
1509067|NCT00004311|dermatologic disorders
1509068|NCT00004311|endocrine disorders
1509069|NCT00004311|polycystic ovarian syndrome
1509070|NCT00004311|rare disease
1509071|NCT00004310|anxiety disorder
1509072|NCT00004310|disease-related problem/condition
1509073|NCT00004310|neurologic and psychiatric disorders
1509074|NCT00004310|obsessive compulsive disorder
1509075|NCT00004310|oncologic disorders
1509076|NCT00004310|rare disease
1509077|NCT00004307|inborn errors of metabolism
1509078|NCT00004307|rare disease
1509079|NCT00004307|urea cycle disorder
1509080|NCT00004306|hereditary ataxia
1509081|NCT00004306|neurologic and psychiatric disorders
1509082|NCT00004306|rare disease
1509083|NCT00004305|IgA glomerulonephritis
1509084|NCT00004305|rare disease
1509085|NCT00004305|renal and genitourinary disorders
1509086|NCT00004300|mental retardation
1509087|NCT00004300|neurologic and psychiatric disorders
1509089|NCT00004300|stereotyped behavior
1509090|NCT00004297|epilepsy
1509091|NCT00004297|neurologic and psychiatric disorders
1509092|NCT00004297|rare disease
1509093|NCT00004297|seizures
1509094|NCT00004297|status epilepticus
1509095|NCT00004296|atypical mycobacterium infection
1509096|NCT00004296|bacterial infection
1509097|NCT00004296|cardiovascular and respiratory diseases
1509098|NCT00004296|cystic fibrosis
1509099|NCT00004296|genetic diseases and dysmorphic syndromes
1509100|NCT00004296|immunologic disorders and infectious disorders
1509101|NCT00004296|mycobacterium infection
1509102|NCT00004296|rare disease
1509103|NCT00004294|Gaucher's disease
1509104|NCT00004294|inborn errors of metabolism
1509105|NCT00004294|rare disease
1509106|NCT00004294|sphingolipidoses
1509107|NCT00004293|Gaucher's disease
1509108|NCT00004293|inborn errors of metabolism
1509109|NCT00004293|rare disease
1509110|NCT00004293|sphingolipidoses
1509111|NCT00004288|ankylosing spondylitis
1509112|NCT00004288|genetic diseases and dysmorphic syndromes
1509113|NCT00004288|rare disease
1509114|NCT00004287|cardiovascular and respiratory diseases
1509115|NCT00004287|cystic fibrosis
1509116|NCT00004287|genetic diseases and dysmorphic syndromes
1509117|NCT00004287|rare disease
1509118|NCT00004286|demyelinating neuropathy
1509119|NCT00004286|neurologic and psychiatric disorders
1509120|NCT00004286|rare disease
1509121|NCT00004285|end stage renal disease
1509122|NCT00004285|rare disease
1509123|NCT00004285|renal and genitourinary disorders
1509124|NCT00004284|hypercalciuria
1509125|NCT00004284|nephrolithiasis
1509126|NCT00004284|rare disease
1509127|NCT00004284|renal and genitourinary disorders
1509128|NCT00004278|congenital cytomegalovirus infection
1509129|NCT00004278|cytomegalovirus infection
1509130|NCT00004278|herpesvirus infection
1509131|NCT00004278|immunologic disorders and infectious disorders
1509132|NCT00004278|neonatal disorders
1509133|NCT00004278|rare disease
1509134|NCT00004278|viral infection
1509135|NCT00004276|bacterial infection
1509136|NCT00004276|human immunodeficiency virus infection
1509137|NCT00004276|immunologic disorders and infectious disorders
1509138|NCT00004276|mycobacterium infection
1509139|NCT00004276|mycobacterium tuberculosis infection
1509140|NCT00004276|rare disease
1509141|NCT00004276|viral infection
1509142|NCT00004275|Turner's syndrome
1509143|NCT00004275|genetic diseases and dysmorphic syndromes
1509144|NCT00004275|rare disease
1509145|NCT00004274|Turner's syndrome
1509146|NCT00004274|genetic diseases and dysmorphic syndromes
1509147|NCT00004274|rare disease
1509148|NCT00004268|cardiovascular and respiratory diseases
1509149|NCT00004268|disease-related problem/condition
1509150|NCT00004268|orthostatic hypotension
1509151|NCT00004268|quality of life
1509152|NCT00004268|rare disease
1509153|NCT00004266|diabetic nephropathy
1509154|NCT00004266|rare disease
1509155|NCT00004266|renal and genitourinary disorders
1509156|NCT00004265|recurrent non-small cell lung cancer
1509157|NCT00004264|recurrent non-small cell lung cancer
1509158|NCT00004264|stage IV non-small cell lung cancer
1509159|NCT00004264|drug/agent toxicity by tissue/organ
1509160|NCT00004263|recurrent adult acute myeloid leukemia
1509161|NCT00004263|refractory anemia with excess blasts
1509162|NCT00004263|refractory anemia with excess blasts in transformation
1509163|NCT00004263|previously treated myelodysplastic syndromes
1509164|NCT00004263|childhood myelodysplastic syndromes
1509165|NCT00004263|Ara-C
1509166|NCT00004263|Cytosar
1509167|NCT00004263|DepoCyt
1509168|NCT00004263|Cytosine arabinosine hydrochloride
1509169|NCT00004263|cytarabine
1509170|NCT00004263|7-hydroxystaurosporine
1509171|NCT00004263|UCN-01
1509172|NCT00004261|stage I breast cancer
1509173|NCT00004261|stage II breast cancer
1509174|NCT00004261|stage IV breast cancer
1509175|NCT00004261|stage IIIA breast cancer
1509176|NCT00004261|breast cancer in situ
1509177|NCT00004261|recurrent breast cancer
1509178|NCT00004261|stage IIIB breast cancer
1509179|NCT00004261|stage 0 cervical cancer
1509180|NCT00004261|stage III cervical cancer
1509181|NCT00004261|recurrent cervical cancer
1509182|NCT00004261|stage IB cervical cancer
1509183|NCT00004261|stage IIB cervical cancer
1509184|NCT00004261|stage IVB cervical cancer
1509185|NCT00004261|stage IA cervical cancer
1509186|NCT00004261|stage IIA cervical cancer
1509187|NCT00004261|stage IVA cervical cancer
1509188|NCT00004261|inflammatory breast cancer
1509189|NCT00004261|stage III adult soft tissue sarcoma
1509190|NCT00004261|recurrent adult soft tissue sarcoma
1509191|NCT00004261|stage I prostate cancer
1509192|NCT00004261|stage IIB prostate cancer
1509193|NCT00004261|stage IIA prostate cancer
1509194|NCT00004261|stage III prostate cancer
1509195|NCT00004261|stage IV prostate cancer
1509196|NCT00004261|recurrent prostate cancer
1509197|NCT00004261|stage I nasopharyngeal cancer
1509198|NCT00004261|stage II nasopharyngeal cancer
1509199|NCT00004261|stage III nasopharyngeal cancer
1509200|NCT00004261|stage IV nasopharyngeal cancer
1509201|NCT00004261|recurrent nasopharyngeal cancer
1509202|NCT00004261|stage 0 paranasal sinus and nasal cavity cancer
1509203|NCT00004261|stage 0 nasopharyngeal cancer
1509204|NCT00004261|stage 0 oropharyngeal cancer
1509205|NCT00004261|stage 0 laryngeal cancer
1509206|NCT00004261|stage 0 hypopharyngeal cancer
1509207|NCT00004261|stage I salivary gland cancer
1509208|NCT00004261|stage II salivary gland cancer
1509209|NCT00004261|stage III salivary gland cancer
1509210|NCT00004261|stage IV salivary gland cancer
1509211|NCT00004261|recurrent salivary gland cancer
1509212|NCT00004261|untreated metastatic squamous neck cancer with occult primary
1509213|NCT00004261|recurrent metastatic squamous neck cancer with occult primary
1509214|NCT00004261|stage 0 lip and oral cavity cancer
1509215|NCT00004261|stage IV adult soft tissue sarcoma
1509216|NCT00004261|stage I lip and oral cavity cancer
1509217|NCT00004261|stage II lip and oral cavity cancer
1509218|NCT00004261|stage III lip and oral cavity cancer
1509219|NCT00004261|stage IV lip and oral cavity cancer
1509220|NCT00004261|recurrent lip and oral cavity cancer
1509221|NCT00004261|stage I hypopharyngeal cancer
1509222|NCT00004261|stage II hypopharyngeal cancer
1509223|NCT00004261|stage III hypopharyngeal cancer
1509224|NCT00004261|stage IV hypopharyngeal cancer
1509225|NCT00004261|recurrent hypopharyngeal cancer
1509226|NCT00004261|stage I laryngeal cancer
1509227|NCT00004261|stage II laryngeal cancer
1509228|NCT00004261|stage III laryngeal cancer
1509229|NCT00004261|stage IV laryngeal cancer
1509230|NCT00004261|recurrent laryngeal cancer
1509231|NCT00004261|stage I paranasal sinus and nasal cavity cancer
1509232|NCT00004261|stage II paranasal sinus and nasal cavity cancer
1509233|NCT00004261|stage III paranasal sinus and nasal cavity cancer
1509234|NCT00004261|stage IV paranasal sinus and nasal cavity cancer
1509235|NCT00004261|recurrent paranasal sinus and nasal cavity cancer
1509236|NCT00004261|stage I oropharyngeal cancer
1509237|NCT00004261|stage II oropharyngeal cancer
1509238|NCT00004261|stage III oropharyngeal cancer
1509239|NCT00004261|stage IV oropharyngeal cancer
1509240|NCT00004261|recurrent oropharyngeal cancer
1509241|NCT00004261|stage II adult soft tissue sarcoma
1509242|NCT00004261|stage I adult soft tissue sarcoma
1509243|NCT00004260|stage I grade 1 follicular lymphoma
1509244|NCT00004260|stage I grade 2 follicular lymphoma
1509245|NCT00004260|stage I grade 3 follicular lymphoma
1509246|NCT00004260|stage I adult diffuse small cleaved cell lymphoma
1509247|NCT00004260|stage I adult diffuse mixed cell lymphoma
1509248|NCT00004260|stage I adult diffuse large cell lymphoma
1509249|NCT00004260|stage I adult immunoblastic large cell lymphoma
1509250|NCT00004260|stage I adult lymphoblastic lymphoma
1509251|NCT00004260|stage I adult Burkitt lymphoma
1509252|NCT00004260|stage III grade 1 follicular lymphoma
1509253|NCT00004260|stage III grade 2 follicular lymphoma
1509254|NCT00004260|stage III grade 3 follicular lymphoma
1509255|NCT00004260|stage III adult diffuse small cleaved cell lymphoma
1509256|NCT00004260|stage III adult diffuse mixed cell lymphoma
1509257|NCT00004260|stage III adult diffuse large cell lymphoma
1509258|NCT00004260|stage III adult immunoblastic large cell lymphoma
1509259|NCT00004260|stage III adult lymphoblastic lymphoma
1509260|NCT00004260|stage III adult Burkitt lymphoma
1509261|NCT00004260|stage IV grade 1 follicular lymphoma
1509262|NCT00004260|stage IV grade 2 follicular lymphoma
1509263|NCT00004260|stage IV grade 3 follicular lymphoma
1509264|NCT00004260|stage IV adult diffuse small cleaved cell lymphoma
1509265|NCT00004260|stage IV adult diffuse mixed cell lymphoma
1509266|NCT00004260|stage IV adult diffuse large cell lymphoma
1509267|NCT00004260|stage IV adult immunoblastic large cell lymphoma
1509268|NCT00004260|stage IV adult lymphoblastic lymphoma
1509269|NCT00004260|stage IV adult Burkitt lymphoma
1509270|NCT00004260|recurrent grade 1 follicular lymphoma
1509271|NCT00004260|recurrent grade 2 follicular lymphoma
1509272|NCT00004260|recurrent grade 3 follicular lymphoma
1509273|NCT00004260|recurrent adult diffuse small cleaved cell lymphoma
1509274|NCT00004260|recurrent adult diffuse mixed cell lymphoma
1509275|NCT00004260|recurrent adult diffuse large cell lymphoma
1509276|NCT00004260|recurrent adult immunoblastic large cell lymphoma
1509277|NCT00004260|recurrent adult lymphoblastic lymphoma
1509278|NCT00004260|recurrent adult Burkitt lymphoma
1509279|NCT00004260|stage I mantle cell lymphoma
1509280|NCT00004260|contiguous stage II grade 1 follicular lymphoma
1509281|NCT00004260|contiguous stage II grade 2 follicular lymphoma
1509282|NCT00004260|contiguous stage II grade 3 follicular lymphoma
1509283|NCT00004260|contiguous stage II adult diffuse small cleaved cell lymphoma
1509284|NCT00004260|contiguous stage II mantle cell lymphoma
1509285|NCT00004260|contiguous stage II adult diffuse mixed cell lymphoma
1509286|NCT00004260|contiguous stage II adult immunoblastic large cell lymphoma
1509287|NCT00004260|contiguous stage II adult diffuse large cell lymphoma
1509288|NCT00004260|contiguous stage II adult Burkitt lymphoma
1509289|NCT00004260|contiguous stage II adult lymphoblastic lymphoma
1509290|NCT00004260|noncontiguous stage II grade 1 follicular lymphoma
1509291|NCT00004260|noncontiguous stage II grade 2 follicular lymphoma
1509292|NCT00004260|noncontiguous stage II grade 3 follicular lymphoma
1509293|NCT00004260|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1509294|NCT00004260|noncontiguous stage II mantle cell lymphoma
1509295|NCT00004260|noncontiguous stage II adult diffuse mixed cell lymphoma
1509296|NCT00004260|noncontiguous stage II adult immunoblastic large cell lymphoma
1509297|NCT00004260|noncontiguous stage II adult diffuse large cell lymphoma
1509298|NCT00004260|noncontiguous stage II adult Burkitt lymphoma
1509299|NCT00004260|noncontiguous stage II adult lymphoblastic lymphoma
1509300|NCT00004260|stage III mantle cell lymphoma
1509301|NCT00004260|stage IV mantle cell lymphoma
1509302|NCT00004260|recurrent mantle cell lymphoma
1509303|NCT00004260|noncontiguous stage II small lymphocytic lymphoma
1509304|NCT00004260|noncontiguous stage II marginal zone lymphoma
1509305|NCT00004260|recurrent marginal zone lymphoma
1509306|NCT00004260|recurrent small lymphocytic lymphoma
1509307|NCT00004260|stage I marginal zone lymphoma
1509308|NCT00004260|stage I small lymphocytic lymphoma
1509309|NCT00004260|stage III small lymphocytic lymphoma
1509310|NCT00004260|stage III marginal zone lymphoma
1509311|NCT00004260|stage IV small lymphocytic lymphoma
1509312|NCT00004260|stage IV marginal zone lymphoma
1509313|NCT00004260|contiguous stage II marginal zone lymphoma
1509314|NCT00004260|contiguous stage II small lymphocytic lymphoma
1509315|NCT00004260|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1509316|NCT00004260|nodal marginal zone B-cell lymphoma
1509317|NCT00004260|splenic marginal zone lymphoma
1509318|NCT00004259|adult anaplastic astrocytoma
1509319|NCT00004259|adult mixed glioma
1509320|NCT00004258|stage III adult Hodgkin lymphoma
1509321|NCT00004258|stage IV adult Hodgkin lymphoma
1509322|NCT00004258|monoclonal gammopathy of undetermined significance
1509323|NCT00004258|recurrent adult Hodgkin lymphoma
1509324|NCT00004258|stage I cutaneous T-cell non-Hodgkin lymphoma
1509325|NCT00004258|stage II cutaneous T-cell non-Hodgkin lymphoma
1509326|NCT00004258|stage III cutaneous T-cell non-Hodgkin lymphoma
1509327|NCT00004258|stage IV cutaneous T-cell non-Hodgkin lymphoma
1509328|NCT00004258|recurrent cutaneous T-cell non-Hodgkin lymphoma
1509329|NCT00004258|isolated plasmacytoma of bone
1509330|NCT00004258|extramedullary plasmacytoma
1509331|NCT00004258|refractory multiple myeloma
1509332|NCT00004258|Waldenstrom macroglobulinemia
1509333|NCT00004258|stage III multiple myeloma
1509334|NCT00004258|stage III chronic lymphocytic leukemia
1509335|NCT00004258|stage IV chronic lymphocytic leukemia
1509336|NCT00004258|recurrent adult acute myeloid leukemia
1509337|NCT00004258|recurrent adult acute lymphoblastic leukemia
1509338|NCT00004258|relapsing chronic myelogenous leukemia
1509339|NCT00004258|refractory chronic lymphocytic leukemia
1509340|NCT00004258|small intestine lymphoma
1509341|NCT00004258|unspecified adult solid tumor, protocol specific
1509342|NCT00004258|chronic phase chronic myelogenous leukemia
1509343|NCT00004258|blastic phase chronic myelogenous leukemia
1509344|NCT00004258|meningeal chronic myelogenous leukemia
1509345|NCT00004258|untreated adult acute lymphoblastic leukemia
1509346|NCT00004258|untreated adult acute myeloid leukemia
1509347|NCT00004258|polycythemia vera
1509348|NCT00004258|essential thrombocythemia
1509349|NCT00004258|untreated hairy cell leukemia
1509350|NCT00004258|progressive hairy cell leukemia, initial treatment
1509351|NCT00004258|refractory hairy cell leukemia
1509352|NCT00004258|chronic myelomonocytic leukemia
1509353|NCT00004258|T-cell large granular lymphocyte leukemia
1509354|NCT00004258|stage III grade 1 follicular lymphoma
1509355|NCT00004258|stage III grade 2 follicular lymphoma
1509356|NCT00004258|stage III grade 3 follicular lymphoma
1509357|NCT00004258|stage III adult diffuse small cleaved cell lymphoma
1509358|NCT00004258|stage III adult diffuse mixed cell lymphoma
1509359|NCT00004258|stage III adult diffuse large cell lymphoma
1509360|NCT00004258|stage III adult immunoblastic large cell lymphoma
1509361|NCT00004258|stage III adult lymphoblastic lymphoma
1509362|NCT00004258|stage III adult Burkitt lymphoma
1509363|NCT00004258|stage IV grade 1 follicular lymphoma
1509364|NCT00004258|stage IV grade 2 follicular lymphoma
1509365|NCT00004258|stage IV grade 3 follicular lymphoma
1509366|NCT00004258|stage IV adult diffuse small cleaved cell lymphoma
1509367|NCT00004258|stage IV adult diffuse mixed cell lymphoma
1509368|NCT00004258|stage IV adult diffuse large cell lymphoma
1509369|NCT00004258|stage IV adult immunoblastic large cell lymphoma
1509370|NCT00004258|stage IV adult lymphoblastic lymphoma
1509371|NCT00004258|stage IV adult Burkitt lymphoma
1509372|NCT00004258|recurrent grade 1 follicular lymphoma
1509373|NCT00004258|recurrent grade 2 follicular lymphoma
1509374|NCT00004258|recurrent grade 3 follicular lymphoma
1509375|NCT00004258|recurrent adult diffuse small cleaved cell lymphoma
1509376|NCT00004258|recurrent adult diffuse mixed cell lymphoma
1509377|NCT00004258|recurrent adult diffuse large cell lymphoma
1509378|NCT00004258|recurrent adult immunoblastic large cell lymphoma
1509379|NCT00004258|recurrent adult lymphoblastic lymphoma
1509380|NCT00004258|recurrent adult Burkitt lymphoma
1509381|NCT00004258|stage III adult T-cell leukemia/lymphoma
1509382|NCT00004258|stage IV adult T-cell leukemia/lymphoma
1509383|NCT00004258|recurrent adult T-cell leukemia/lymphoma
1509384|NCT00004258|secondary acute myeloid leukemia
1509385|NCT00004258|de novo myelodysplastic syndromes
1509386|NCT00004258|previously treated myelodysplastic syndromes
1509387|NCT00004258|secondary myelodysplastic syndromes
1509388|NCT00004258|prolymphocytic leukemia
1509389|NCT00004258|primary systemic amyloidosis
1509390|NCT00004258|stage III mantle cell lymphoma
1509391|NCT00004258|stage IV mantle cell lymphoma
1509392|NCT00004258|recurrent mantle cell lymphoma
1509393|NCT00004258|angioimmunoblastic T-cell lymphoma
1509394|NCT00004258|chronic idiopathic myelofibrosis
1509395|NCT00004258|recurrent marginal zone lymphoma
1509396|NCT00004258|recurrent small lymphocytic lymphoma
1509397|NCT00004258|stage III small lymphocytic lymphoma
1509398|NCT00004258|stage III marginal zone lymphoma
1509399|NCT00004258|stage IV small lymphocytic lymphoma
1509400|NCT00004258|stage IV marginal zone lymphoma
1509401|NCT00004258|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1509402|NCT00004258|nodal marginal zone B-cell lymphoma
1509403|NCT00004258|splenic marginal zone lymphoma
1509404|NCT00004257|stage I esophageal cancer
1509405|NCT00004257|stage II esophageal cancer
1509406|NCT00004257|stage III esophageal cancer
1509407|NCT00004257|squamous cell carcinoma of the esophagus
1509408|NCT00004257|adenocarcinoma of the esophagus
1509409|NCT00004256|stage I laryngeal cancer
1509410|NCT00004256|stage II laryngeal cancer
1509411|NCT00004256|recurrent laryngeal cancer
1509412|NCT00004256|oral complications
1509413|NCT00004256|radiation toxicity
1509414|NCT00004255|recurrent childhood acute lymphoblastic leukemia
1509415|NCT00004255|recurrent childhood acute myeloid leukemia
1509416|NCT00004255|recurrent adult acute myeloid leukemia
1509417|NCT00004255|recurrent adult acute lymphoblastic leukemia
1509418|NCT00004255|chronic phase chronic myelogenous leukemia
1509419|NCT00004255|accelerated phase chronic myelogenous leukemia
1509420|NCT00004255|adult acute myeloid leukemia in remission
1509421|NCT00004255|adult acute lymphoblastic leukemia in remission
1509422|NCT00004255|childhood acute myeloid leukemia in remission
1509423|NCT00004255|childhood acute lymphoblastic leukemia in remission
1509424|NCT00004255|refractory anemia with excess blasts
1509425|NCT00004255|refractory anemia with excess blasts in transformation
1509426|NCT00004255|secondary acute myeloid leukemia
1509427|NCT00004255|de novo myelodysplastic syndromes
1509428|NCT00004255|previously treated myelodysplastic syndromes
1509429|NCT00004255|secondary myelodysplastic syndromes
1509430|NCT00004255|graft versus host disease
1509431|NCT00004255|childhood myelodysplastic syndromes
1509432|NCT00004254|localized malignant mesothelioma
1509433|NCT00004254|advanced malignant mesothelioma
1509434|NCT00004254|recurrent malignant mesothelioma
1509435|NCT00004253|stage II non-small cell lung cancer
1509436|NCT00004253|stage IIIA non-small cell lung cancer
1509437|NCT00004253|stage IIIB non-small cell lung cancer
1509438|NCT00004252|stage IV colon cancer
1509439|NCT00004252|stage IV rectal cancer
1509440|NCT00004252|recurrent colon cancer
1509441|NCT00004252|recurrent rectal cancer
1509442|NCT00004252|adenocarcinoma of the colon
1509443|NCT00004251|stage IV endometrial carcinoma
1509444|NCT00004251|recurrent endometrial carcinoma
1509445|NCT00004251|endometrial adenocarcinoma
1509446|NCT00004251|endometrial adenosquamous cell carcinoma
1509447|NCT00004250|stage III adult soft tissue sarcoma
1509448|NCT00004250|recurrent adult soft tissue sarcoma
1509449|NCT00004250|stage III melanoma
1509450|NCT00004250|stage IV melanoma
1509451|NCT00004250|recurrent melanoma
1509452|NCT00004250|stage IV adult soft tissue sarcoma
1509453|NCT00004249|limited stage small cell lung cancer
1509454|NCT00004248|localized unresectable adult primary liver cancer
1509455|NCT00004248|recurrent adult primary liver cancer
1509456|NCT00004248|adult primary hepatocellular carcinoma
1509457|NCT00004246|Radiation Therapy
1509458|NCT00004246|RT
1509459|NCT00004246|Radiotherapy
1509460|NCT00004246|Fludarabine
1509461|NCT00004246|Fludara
1509462|NCT00004246|Fludarabine Phosphate
1509463|NCT00004246|stage III squamous cell carcinoma of the lip and oral cavity
1509464|NCT00004246|stage IV squamous cell carcinoma of the lip and oral cavity
1509465|NCT00004246|stage III squamous cell carcinoma of the oropharynx
1509466|NCT00004246|stage IV squamous cell carcinoma of the oropharynx
1509467|NCT00004246|stage III squamous cell carcinoma of the nasopharynx
1509468|NCT00004246|stage IV squamous cell carcinoma of the nasopharynx
1509469|NCT00004246|stage III squamous cell carcinoma of the hypopharynx
1509470|NCT00004246|stage IV squamous cell carcinoma of the hypopharynx
1509471|NCT00004246|stage III squamous cell carcinoma of the larynx
1509472|NCT00004246|stage IV squamous cell carcinoma of the larynx
1509473|NCT00004245|recurrent adult acute myeloid leukemia
1509474|NCT00004245|refractory chronic lymphocytic leukemia
1509475|NCT00004245|untreated adult acute myeloid leukemia
1509476|NCT00004245|refractory anemia with excess blasts
1509477|NCT00004245|refractory anemia with excess blasts in transformation
1509478|NCT00004245|chronic myelomonocytic leukemia
1509479|NCT00004245|previously treated myelodysplastic syndromes
1509480|NCT00004245|atypical chronic myeloid leukemia, BCR-ABL1 negative
1509481|NCT00004245|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1509482|NCT00004245|adult acute myeloid leukemia with t(8;21)(q22;q22)
1509483|NCT00004245|adult acute myeloid leukemia with t(16;16)(p13;q22)
1509484|NCT00004245|adult acute myeloid leukemia with inv(16)(p13;q22)
1509485|NCT00004245|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1509486|NCT00004245|adult acute myeloid leukemia with t(15;17)(q22;q12)
1509487|NCT00004244|stage IV renal cell cancer
1509488|NCT00004244|recurrent renal cell cancer
1509489|NCT00004244|stage IV melanoma
1509490|NCT00004244|recurrent melanoma
1509491|NCT00004243|unspecified adult solid tumor, protocol specific
1509492|NCT00004242|unspecified adult solid tumor, protocol specific
1509493|NCT00004239|recurrent adult Hodgkin lymphoma
1509494|NCT00004239|recurrent cutaneous T-cell non-Hodgkin lymphoma
1509495|NCT00004239|refractory multiple myeloma
1509496|NCT00004239|Waldenstrom macroglobulinemia
1509497|NCT00004239|stage III multiple myeloma
1509498|NCT00004239|recurrent adult acute myeloid leukemia
1509499|NCT00004239|recurrent adult acute lymphoblastic leukemia
1509500|NCT00004239|relapsing chronic myelogenous leukemia
1509501|NCT00004239|refractory chronic lymphocytic leukemia
1509502|NCT00004239|polycythemia vera
1509503|NCT00004239|primary myelofibrosis
1509504|NCT00004239|essential thrombocythemia
1509505|NCT00004239|refractory hairy cell leukemia
1509506|NCT00004239|chronic myelomonocytic leukemia
1509507|NCT00004239|recurrent grade 1 follicular lymphoma
1509508|NCT00004239|recurrent grade 2 follicular lymphoma
1509509|NCT00004239|recurrent grade 3 follicular lymphoma
1509510|NCT00004239|recurrent adult diffuse small cleaved cell lymphoma
1509511|NCT00004239|recurrent adult diffuse mixed cell lymphoma
1509512|NCT00004239|recurrent adult diffuse large cell lymphoma
1509513|NCT00004239|recurrent adult immunoblastic large cell lymphoma
1509514|NCT00004239|recurrent adult lymphoblastic lymphoma
1509515|NCT00004239|recurrent adult Burkitt lymphoma
1509516|NCT00004239|recurrent adult T-cell leukemia/lymphoma
1509517|NCT00004239|previously treated myelodysplastic syndromes
1509518|NCT00004239|prolymphocytic leukemia
1509519|NCT00004239|primary systemic amyloidosis
1509520|NCT00004239|recurrent mantle cell lymphoma
1509521|NCT00004239|anaplastic large cell lymphoma
1509522|NCT00004239|recurrent mycosis fungoides/Sezary syndrome
1509523|NCT00004239|recurrent marginal zone lymphoma
1509524|NCT00004239|recurrent small lymphocytic lymphoma
1509525|NCT00004239|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1509526|NCT00004239|nodal marginal zone B-cell lymphoma
1509527|NCT00004239|splenic marginal zone lymphoma
1509528|NCT00004238|recurrent non-small cell lung cancer
1509529|NCT00004238|stage IIIB non-small cell lung cancer
1509530|NCT00004238|stage IV non-small cell lung cancer
1509531|NCT00004237|stage I breast cancer
1509532|NCT00004237|stage II breast cancer
1509533|NCT00004236|stage III gastric cancer
1509534|NCT00004236|stage IV gastric cancer
1509535|NCT00004236|recurrent gastric cancer
1509536|NCT00004236|stage III esophageal cancer
1509537|NCT00004236|stage IV esophageal cancer
1509538|NCT00004236|recurrent esophageal cancer
1509539|NCT00004236|adenocarcinoma of the stomach
1509540|NCT00004236|adenocarcinoma of the esophagus
1509541|NCT00004235|stage IV gastric cancer
1509542|NCT00004235|recurrent gastric cancer
1509543|NCT00004235|stage II esophageal cancer
1509544|NCT00004235|stage III esophageal cancer
1509545|NCT00004235|stage IV esophageal cancer
1509546|NCT00004235|recurrent esophageal cancer
1509547|NCT00004235|adenocarcinoma of the stomach
1509548|NCT00004235|adenocarcinoma of the esophagus
1509549|NCT00004234|oral complications
1509550|NCT00004234|stage I squamous cell carcinoma of the lip and oral cavity
1509551|NCT00004234|stage II squamous cell carcinoma of the lip and oral cavity
1509552|NCT00004234|stage III squamous cell carcinoma of the lip and oral cavity
1509553|NCT00004234|stage IV squamous cell carcinoma of the lip and oral cavity
1509554|NCT00004234|recurrent squamous cell carcinoma of the lip and oral cavity
1509555|NCT00004234|stage I squamous cell carcinoma of the oropharynx
1509556|NCT00004234|stage II squamous cell carcinoma of the oropharynx
1509557|NCT00004234|stage III squamous cell carcinoma of the oropharynx
1509558|NCT00004234|stage IV squamous cell carcinoma of the oropharynx
1509559|NCT00004234|recurrent squamous cell carcinoma of the oropharynx
1509560|NCT00004234|stage I squamous cell carcinoma of the nasopharynx
1509561|NCT00004234|stage II squamous cell carcinoma of the nasopharynx
1509562|NCT00004234|stage III squamous cell carcinoma of the nasopharynx
1509563|NCT00004234|stage IV squamous cell carcinoma of the nasopharynx
1509564|NCT00004234|recurrent squamous cell carcinoma of the nasopharynx
1509565|NCT00004234|stage I squamous cell carcinoma of the hypopharynx
1509566|NCT00004234|stage II squamous cell carcinoma of the hypopharynx
1509567|NCT00004234|stage III squamous cell carcinoma of the hypopharynx
1509568|NCT00004234|stage IV squamous cell carcinoma of the hypopharynx
1509569|NCT00004234|recurrent squamous cell carcinoma of the hypopharynx
1509570|NCT00004234|stage I squamous cell carcinoma of the larynx
1509571|NCT00004234|stage II squamous cell carcinoma of the larynx
1509572|NCT00004234|stage III squamous cell carcinoma of the larynx
1509573|NCT00004234|stage IV squamous cell carcinoma of the larynx
1509574|NCT00004234|recurrent squamous cell carcinoma of the larynx
1509575|NCT00004233|stage III gastric cancer
1509576|NCT00004233|stage IV gastric cancer
1509577|NCT00004233|recurrent gastric cancer
1509578|NCT00004233|stage III esophageal cancer
1509579|NCT00004233|stage IV esophageal cancer
1509580|NCT00004233|recurrent esophageal cancer
1509581|NCT00004233|adenocarcinoma of the stomach
1509582|NCT00004233|adenocarcinoma of the esophagus
1509583|NCT00004232|stage I adult Hodgkin lymphoma
1509584|NCT00004232|stage II adult Hodgkin lymphoma
1509585|NCT00004232|stage III adult Hodgkin lymphoma
1509586|NCT00004232|stage IV adult Hodgkin lymphoma
1509587|NCT00004232|monoclonal gammopathy of undetermined significance
1509588|NCT00004232|recurrent childhood acute lymphoblastic leukemia
1509589|NCT00004232|recurrent adult Hodgkin lymphoma
1509590|NCT00004232|stage I cutaneous T-cell non-Hodgkin lymphoma
1509591|NCT00004232|stage II cutaneous T-cell non-Hodgkin lymphoma
1509592|NCT00004232|stage III cutaneous T-cell non-Hodgkin lymphoma
1509593|NCT00004232|stage IV cutaneous T-cell non-Hodgkin lymphoma
1509594|NCT00004232|recurrent cutaneous T-cell non-Hodgkin lymphoma
1509595|NCT00004232|Burkitt lymphoma
1509596|NCT00004232|isolated plasmacytoma of bone
1509597|NCT00004232|extramedullary plasmacytoma
1509598|NCT00004232|refractory multiple myeloma
1509599|NCT00004232|stage 0 chronic lymphocytic leukemia
1509600|NCT00004232|stage I multiple myeloma
1509601|NCT00004232|stage II multiple myeloma
1509602|NCT00004232|stage III multiple myeloma
1509603|NCT00004232|stage I childhood lymphoblastic lymphoma
1509604|NCT00004232|stage II childhood lymphoblastic lymphoma
1509605|NCT00004232|stage III childhood lymphoblastic lymphoma
1509606|NCT00004232|stage IV childhood lymphoblastic lymphoma
1509607|NCT00004232|recurrent childhood lymphoblastic lymphoma
1509608|NCT00004232|stage I chronic lymphocytic leukemia
1509609|NCT00004232|stage II chronic lymphocytic leukemia
1509610|NCT00004232|stage IV chronic lymphocytic leukemia
1509611|NCT00004232|recurrent childhood acute myeloid leukemia
1509612|NCT00004232|recurrent adult acute myeloid leukemia
1509613|NCT00004232|recurrent adult acute lymphoblastic leukemia
1509614|NCT00004232|relapsing chronic myelogenous leukemia
1509615|NCT00004232|refractory chronic lymphocytic leukemia
1509616|NCT00004232|childhood diffuse large cell lymphoma
1509617|NCT00004232|childhood immunoblastic large cell lymphoma
1509618|NCT00004232|chronic phase chronic myelogenous leukemia
1509619|NCT00004232|accelerated phase chronic myelogenous leukemia
1509620|NCT00004232|blastic phase chronic myelogenous leukemia
1509621|NCT00004232|meningeal chronic myelogenous leukemia
1509622|NCT00004232|untreated adult acute lymphoblastic leukemia
1509623|NCT00004232|untreated adult acute myeloid leukemia
1509624|NCT00004232|untreated childhood acute myeloid leukemia and other myeloid malignancies
1509625|NCT00004232|untreated childhood acute lymphoblastic leukemia
1509626|NCT00004232|adult acute myeloid leukemia in remission
1509627|NCT00004232|adult acute lymphoblastic leukemia in remission
1509628|NCT00004232|childhood acute myeloid leukemia in remission
1509629|NCT00004232|childhood acute lymphoblastic leukemia in remission
1509630|NCT00004232|chronic idiopathic myelofibrosis
1509631|NCT00004232|essential thrombocythemia
1509632|NCT00004232|untreated hairy cell leukemia
1509633|NCT00004232|progressive hairy cell leukemia, initial treatment
1509634|NCT00004232|refractory hairy cell leukemia
1509635|NCT00004232|stage II childhood Hodgkin lymphoma
1509636|NCT00004232|stage I childhood Hodgkin lymphoma
1509637|NCT00004232|stage III childhood Hodgkin lymphoma
1509638|NCT00004232|stage IV childhood Hodgkin lymphoma
1509639|NCT00004232|recurrent/refractory childhood Hodgkin lymphoma
1509640|NCT00004232|stage I grade 1 follicular lymphoma
1509641|NCT00004232|stage I grade 2 follicular lymphoma
1509642|NCT00004232|stage I grade 3 follicular lymphoma
1509643|NCT00004232|stage I adult diffuse small cleaved cell lymphoma
1509644|NCT00004232|stage I adult diffuse mixed cell lymphoma
1509645|NCT00004232|stage I adult diffuse large cell lymphoma
1509646|NCT00004232|stage I adult immunoblastic large cell lymphoma
1509647|NCT00004232|stage I adult lymphoblastic lymphoma
1509648|NCT00004232|stage I adult Burkitt lymphoma
1509649|NCT00004232|chronic myelomonocytic leukemia
1509650|NCT00004232|T-cell large granular lymphocyte leukemia
1509651|NCT00004232|acute undifferentiated leukemia
1509652|NCT00004232|stage III grade 1 follicular lymphoma
1509653|NCT00004232|stage III grade 2 follicular lymphoma
1509654|NCT00004232|stage III grade 3 follicular lymphoma
1509655|NCT00004232|stage III adult diffuse small cleaved cell lymphoma
1509656|NCT00004232|stage III adult diffuse mixed cell lymphoma
1509657|NCT00004232|stage III adult diffuse large cell lymphoma
1509658|NCT00004232|stage III adult immunoblastic large cell lymphoma
1509659|NCT00004232|stage III adult lymphoblastic lymphoma
1509660|NCT00004232|stage III adult Burkitt lymphoma
1509661|NCT00004232|stage IV grade 1 follicular lymphoma
1509662|NCT00004232|stage IV grade 2 follicular lymphoma
1509663|NCT00004232|stage IV grade 3 follicular lymphoma
1509664|NCT00004232|stage IV adult diffuse small cleaved cell lymphoma
1509665|NCT00004232|stage IV adult diffuse mixed cell lymphoma
1509666|NCT00004232|stage IV adult diffuse large cell lymphoma
1509667|NCT00004232|stage IV adult immunoblastic large cell lymphoma
1509668|NCT00004232|stage IV adult lymphoblastic lymphoma
1509669|NCT00004232|stage IV adult Burkitt lymphoma
1509670|NCT00004232|recurrent grade 1 follicular lymphoma
1509671|NCT00004232|recurrent grade 2 follicular lymphoma
1509672|NCT00004232|recurrent grade 3 follicular lymphoma
1509673|NCT00004232|recurrent adult diffuse small cleaved cell lymphoma
1509674|NCT00004232|recurrent adult diffuse mixed cell lymphoma
1509675|NCT00004232|recurrent adult diffuse large cell lymphoma
1509676|NCT00004232|recurrent adult immunoblastic large cell lymphoma
1509677|NCT00004232|recurrent adult lymphoblastic lymphoma
1509678|NCT00004232|recurrent adult Burkitt lymphoma
1509679|NCT00004232|stage I adult T-cell leukemia/lymphoma
1509680|NCT00004232|stage II adult T-cell leukemia/lymphoma
1509681|NCT00004232|stage III adult T-cell leukemia/lymphoma
1509682|NCT00004232|stage IV adult T-cell leukemia/lymphoma
1509683|NCT00004232|recurrent adult T-cell leukemia/lymphoma
1509684|NCT00004232|secondary acute myeloid leukemia
1509685|NCT00004232|de novo myelodysplastic syndromes
1509686|NCT00004232|previously treated myelodysplastic syndromes
1509687|NCT00004232|secondary myelodysplastic syndromes
1509688|NCT00004232|graft versus host disease
1509689|NCT00004232|prolymphocytic leukemia
1509690|NCT00004232|AIDS-related peripheral/systemic lymphoma
1509691|NCT00004232|primary systemic amyloidosis
1509692|NCT00004232|stage I childhood small noncleaved cell lymphoma
1509693|NCT00004232|stage I childhood large cell lymphoma
1509694|NCT00004232|stage II childhood small noncleaved cell lymphoma
1509695|NCT00004232|stage II childhood large cell lymphoma
1509696|NCT00004232|stage III childhood small noncleaved cell lymphoma
1509697|NCT00004232|stage III childhood large cell lymphoma
1509698|NCT00004232|stage IV childhood small noncleaved cell lymphoma
1509699|NCT00004232|stage IV childhood large cell lymphoma
1509700|NCT00004232|recurrent childhood small noncleaved cell lymphoma
1509701|NCT00004232|recurrent childhood large cell lymphoma
1509702|NCT00004232|stage I mantle cell lymphoma
1509703|NCT00004232|contiguous stage II grade 1 follicular lymphoma
1509704|NCT00004232|contiguous stage II grade 2 follicular lymphoma
1509705|NCT00004232|contiguous stage II grade 3 follicular lymphoma
1509706|NCT00004232|contiguous stage II adult diffuse small cleaved cell lymphoma
1509707|NCT00004232|contiguous stage II mantle cell lymphoma
1509708|NCT00004232|contiguous stage II adult diffuse mixed cell lymphoma
1509709|NCT00004232|contiguous stage II adult immunoblastic large cell lymphoma
1509710|NCT00004232|contiguous stage II adult diffuse large cell lymphoma
1509711|NCT00004232|contiguous stage II adult Burkitt lymphoma
1509712|NCT00004232|contiguous stage II adult lymphoblastic lymphoma
1509713|NCT00004232|noncontiguous stage II grade 1 follicular lymphoma
1509714|NCT00004232|noncontiguous stage II grade 2 follicular lymphoma
1509715|NCT00004232|noncontiguous stage II grade 3 follicular lymphoma
1509716|NCT00004232|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1509717|NCT00004232|noncontiguous stage II mantle cell lymphoma
1509718|NCT00004232|noncontiguous stage II adult diffuse mixed cell lymphoma
1509719|NCT00004232|noncontiguous stage II adult immunoblastic large cell lymphoma
1509720|NCT00004232|noncontiguous stage II adult diffuse large cell lymphoma
1509721|NCT00004232|noncontiguous stage II adult Burkitt lymphoma
1509722|NCT00004232|noncontiguous stage II adult lymphoblastic lymphoma
1509723|NCT00004232|stage III mantle cell lymphoma
1509724|NCT00004232|stage IV mantle cell lymphoma
1509725|NCT00004232|recurrent mantle cell lymphoma
1509726|NCT00004232|angioimmunoblastic T-cell lymphoma
1509727|NCT00004232|anaplastic large cell lymphoma
1509728|NCT00004232|stage I mycosis fungoides/Sezary syndrome
1509729|NCT00004232|stage II mycosis fungoides/Sezary syndrome
1509730|NCT00004232|stage III mycosis fungoides/Sezary syndrome
1509731|NCT00004232|stage IV mycosis fungoides/Sezary syndrome
1509732|NCT00004232|recurrent mycosis fungoides/Sezary syndrome
1509733|NCT00004232|noncontiguous stage II small lymphocytic lymphoma
1509734|NCT00004232|noncontiguous stage II marginal zone lymphoma
1509735|NCT00004232|recurrent marginal zone lymphoma
1509736|NCT00004232|recurrent small lymphocytic lymphoma
1509737|NCT00004232|stage I marginal zone lymphoma
1509738|NCT00004232|stage I small lymphocytic lymphoma
1509739|NCT00004232|stage III small lymphocytic lymphoma
1509740|NCT00004232|stage III marginal zone lymphoma
1509741|NCT00004232|stage IV small lymphocytic lymphoma
1509742|NCT00004232|stage IV marginal zone lymphoma
1509743|NCT00004232|contiguous stage II marginal zone lymphoma
1509744|NCT00004232|contiguous stage II small lymphocytic lymphoma
1509745|NCT00004232|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1509746|NCT00004232|nodal marginal zone B-cell lymphoma
1509747|NCT00004232|splenic marginal zone lymphoma
1509748|NCT00004232|childhood myelodysplastic syndromes
1509749|NCT00004231|stage III mantle cell lymphoma
1509750|NCT00004231|stage IV mantle cell lymphoma
1509751|NCT00004231|recurrent mantle cell lymphoma
1509752|NCT00004230|pulmonary complications
1509753|NCT00004230|stage IV breast cancer
1509754|NCT00004230|stage IIIA breast cancer
1509755|NCT00004230|stage IIIB breast cancer
1509756|NCT00004230|recurrent childhood acute lymphoblastic leukemia
1509757|NCT00004230|recurrent adult Hodgkin lymphoma
1509758|NCT00004230|recurrent cutaneous T-cell non-Hodgkin lymphoma
1509759|NCT00004230|refractory multiple myeloma
1509760|NCT00004230|recurrent childhood rhabdomyosarcoma
1509761|NCT00004230|stage II ovarian epithelial cancer
1509762|NCT00004230|stage III ovarian epithelial cancer
1510144|NCT00004178|recurrent rectal cancer
1509763|NCT00004230|stage IV ovarian epithelial cancer
1509764|NCT00004230|recurrent ovarian epithelial cancer
1509765|NCT00004230|disseminated neuroblastoma
1509766|NCT00004230|recurrent neuroblastoma
1509767|NCT00004230|recurrent Wilms tumor and other childhood kidney tumors
1509768|NCT00004230|stage I multiple myeloma
1509769|NCT00004230|stage II multiple myeloma
1509770|NCT00004230|stage III multiple myeloma
1509771|NCT00004230|recurrent childhood lymphoblastic lymphoma
1509772|NCT00004230|stage III chronic lymphocytic leukemia
1509773|NCT00004230|stage IV chronic lymphocytic leukemia
1509774|NCT00004230|recurrent childhood acute myeloid leukemia
1509775|NCT00004230|recurrent adult acute myeloid leukemia
1509776|NCT00004230|recurrent adult acute lymphoblastic leukemia
1509777|NCT00004230|relapsing chronic myelogenous leukemia
1509778|NCT00004230|refractory chronic lymphocytic leukemia
1509779|NCT00004230|stage III malignant testicular germ cell tumor
1509780|NCT00004230|recurrent malignant testicular germ cell tumor
1509781|NCT00004230|chronic phase chronic myelogenous leukemia
1509782|NCT00004230|accelerated phase chronic myelogenous leukemia
1509783|NCT00004230|blastic phase chronic myelogenous leukemia
1509784|NCT00004230|meningeal chronic myelogenous leukemia
1509785|NCT00004230|chronic idiopathic myelofibrosis
1509786|NCT00004230|childhood acute promyelocytic leukemia (M3)
1509787|NCT00004230|testicular embryonal carcinoma
1509788|NCT00004230|testicular choriocarcinoma
1509789|NCT00004230|testicular teratoma
1509790|NCT00004230|testicular yolk sac tumor
1509791|NCT00004230|testicular embryonal carcinoma and teratoma
1509792|NCT00004230|testicular embryonal carcinoma and teratoma with seminoma
1509793|NCT00004230|testicular embryonal carcinoma and yolk sac tumor
1509794|NCT00004230|testicular embryonal carcinoma and yolk sac tumor with seminoma
1509795|NCT00004230|testicular embryonal carcinoma and seminoma
1509796|NCT00004230|testicular yolk sac tumor and teratoma
1509797|NCT00004230|testicular yolk sac tumor and teratoma with seminoma
1509798|NCT00004230|testicular choriocarcinoma and yolk sac tumor
1509799|NCT00004230|testicular choriocarcinoma and embryonal carcinoma
1509800|NCT00004230|testicular choriocarcinoma and teratoma
1509801|NCT00004230|testicular choriocarcinoma and seminoma
1509802|NCT00004230|refractory hairy cell leukemia
1509803|NCT00004230|recurrent/refractory childhood Hodgkin lymphoma
1509804|NCT00004230|recurrent ovarian germ cell tumor
1509805|NCT00004230|ovarian yolk sac tumor
1509806|NCT00004230|ovarian embryonal carcinoma
1509807|NCT00004230|ovarian polyembryoma
1509808|NCT00004230|ovarian choriocarcinoma
1509809|NCT00004230|ovarian immature teratoma
1509810|NCT00004230|ovarian mature teratoma
1509811|NCT00004230|ovarian monodermal and highly specialized teratoma
1509812|NCT00004230|ovarian mixed germ cell tumor
1509813|NCT00004230|stage III grade 1 follicular lymphoma
1509814|NCT00004230|stage III grade 2 follicular lymphoma
1509815|NCT00004230|stage III grade 3 follicular lymphoma
1509816|NCT00004230|stage III adult diffuse small cleaved cell lymphoma
1509817|NCT00004230|stage III adult diffuse mixed cell lymphoma
1509818|NCT00004230|stage III adult diffuse large cell lymphoma
1509819|NCT00004230|stage III adult immunoblastic large cell lymphoma
1509820|NCT00004230|stage III adult lymphoblastic lymphoma
1509821|NCT00004230|stage III adult Burkitt lymphoma
1509822|NCT00004230|stage IV grade 1 follicular lymphoma
1509823|NCT00004230|stage IV grade 2 follicular lymphoma
1509824|NCT00004230|stage IV grade 3 follicular lymphoma
1509825|NCT00004230|stage IV adult diffuse small cleaved cell lymphoma
1509826|NCT00004230|stage IV adult diffuse mixed cell lymphoma
1509827|NCT00004230|stage IV adult diffuse large cell lymphoma
1509828|NCT00004230|stage IV adult immunoblastic large cell lymphoma
1509829|NCT00004230|stage IV adult lymphoblastic lymphoma
1509830|NCT00004230|stage IV adult Burkitt lymphoma
1509831|NCT00004230|recurrent grade 1 follicular lymphoma
1509922|NCT00004210|colon cancer
1509832|NCT00004230|recurrent grade 2 follicular lymphoma
1509833|NCT00004230|recurrent grade 3 follicular lymphoma
1509834|NCT00004230|recurrent adult diffuse small cleaved cell lymphoma
1509835|NCT00004230|recurrent adult diffuse mixed cell lymphoma
1509836|NCT00004230|recurrent adult diffuse large cell lymphoma
1509837|NCT00004230|recurrent adult immunoblastic large cell lymphoma
1509838|NCT00004230|recurrent adult lymphoblastic lymphoma
1509839|NCT00004230|recurrent adult Burkitt lymphoma
1509840|NCT00004230|secondary acute myeloid leukemia
1509841|NCT00004230|de novo myelodysplastic syndromes
1509842|NCT00004230|poor prognosis metastatic gestational trophoblastic tumor
1509843|NCT00004230|previously treated myelodysplastic syndromes
1509844|NCT00004230|secondary myelodysplastic syndromes
1509845|NCT00004230|recurrent childhood small noncleaved cell lymphoma
1509846|NCT00004230|recurrent childhood large cell lymphoma
1509847|NCT00004230|noncontiguous stage II grade 1 follicular lymphoma
1509848|NCT00004230|noncontiguous stage II grade 2 follicular lymphoma
1509849|NCT00004230|noncontiguous stage II grade 3 follicular lymphoma
1509850|NCT00004230|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1509851|NCT00004230|noncontiguous stage II mantle cell lymphoma
1509852|NCT00004230|noncontiguous stage II adult diffuse mixed cell lymphoma
1509853|NCT00004230|noncontiguous stage II adult immunoblastic large cell lymphoma
1510537|NCT00004132|oral complications
1509854|NCT00004230|noncontiguous stage II adult diffuse large cell lymphoma
1509855|NCT00004230|noncontiguous stage II adult Burkitt lymphoma
1509856|NCT00004230|noncontiguous stage II adult lymphoblastic lymphoma
1509857|NCT00004230|stage III mantle cell lymphoma
1509858|NCT00004230|stage IV mantle cell lymphoma
1509859|NCT00004230|recurrent mantle cell lymphoma
1509860|NCT00004230|previously treated childhood rhabdomyosarcoma
1509861|NCT00004230|recurrent mycosis fungoides/Sezary syndrome
1509862|NCT00004230|noncontiguous stage II small lymphocytic lymphoma
1509863|NCT00004230|noncontiguous stage II marginal zone lymphoma
1509864|NCT00004230|recurrent marginal zone lymphoma
1509865|NCT00004230|recurrent small lymphocytic lymphoma
1509866|NCT00004230|stage III small lymphocytic lymphoma
1509867|NCT00004230|stage III marginal zone lymphoma
1509868|NCT00004230|stage IV small lymphocytic lymphoma
1509869|NCT00004230|stage IV marginal zone lymphoma
1509870|NCT00004230|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1509871|NCT00004230|nodal marginal zone B-cell lymphoma
1509872|NCT00004230|splenic marginal zone lymphoma
1509873|NCT00004230|childhood myelodysplastic syndromes
1509874|NCT00004215|untreated adult acute myeloid leukemia
1509875|NCT00004215|adult acute erythroid leukemia (M6)
1509876|NCT00004215|adult acute myeloblastic leukemia without maturation (M1)
1509877|NCT00004215|adult acute myeloblastic leukemia with maturation (M2)
1509878|NCT00004215|adult acute myelomonocytic leukemia (M4)
1509879|NCT00004215|adult acute monoblastic leukemia (M5a)
1509880|NCT00004215|adult acute megakaryoblastic leukemia (M7)
1509881|NCT00004215|adult acute monocytic leukemia (M5b)
1509882|NCT00004215|anemia
1509883|NCT00004215|neutropenia
1509884|NCT00004215|thrombocytopenia
1509885|NCT00004215|adult acute minimally differentiated myeloid leukemia (M0)
1509886|NCT00004213|unspecified adult solid tumor, protocol specific
1509887|NCT00004212|childhood infratentorial ependymoma
1509888|NCT00004212|childhood supratentorial ependymoma
1509889|NCT00004212|childhood craniopharyngioma
1509890|NCT00004212|stage III childhood lymphoblastic lymphoma
1509891|NCT00004212|stage IV childhood lymphoblastic lymphoma
1509892|NCT00004212|recurrent childhood lymphoblastic lymphoma
1509893|NCT00004212|childhood central nervous system germ cell tumor
1509894|NCT00004212|unspecified childhood solid tumor, protocol specific
1509895|NCT00004212|stage III childhood Hodgkin lymphoma
1509896|NCT00004212|stage IV childhood Hodgkin lymphoma
1509897|NCT00004212|recurrent/refractory childhood Hodgkin lymphoma
1509898|NCT00004212|childhood high-grade cerebral astrocytoma
1509899|NCT00004212|childhood oligodendroglioma
1509900|NCT00004212|childhood choroid plexus tumor
1509901|NCT00004212|stage III childhood small noncleaved cell lymphoma
1509902|NCT00004212|stage III childhood large cell lymphoma
1509903|NCT00004212|stage IV childhood small noncleaved cell lymphoma
1509904|NCT00004212|stage IV childhood large cell lymphoma
1509905|NCT00004212|recurrent childhood small noncleaved cell lymphoma
1509906|NCT00004212|recurrent childhood large cell lymphoma
1509907|NCT00004212|untreated childhood brain stem glioma
1509908|NCT00004212|recurrent childhood brain stem glioma
1509909|NCT00004212|untreated childhood supratentorial primitive neuroectodermal tumor
1509910|NCT00004212|recurrent childhood supratentorial primitive neuroectodermal tumor
1509911|NCT00004212|untreated childhood cerebellar astrocytoma
1509912|NCT00004212|recurrent childhood cerebellar astrocytoma
1509913|NCT00004212|recurrent childhood cerebral astrocytoma
1509914|NCT00004212|untreated childhood medulloblastoma
1509915|NCT00004212|recurrent childhood medulloblastoma
1509916|NCT00004212|untreated childhood visual pathway and hypothalamic glioma
1509917|NCT00004212|recurrent childhood visual pathway and hypothalamic glioma
1509918|NCT00004212|newly diagnosed childhood ependymoma
1509919|NCT00004212|recurrent childhood ependymoma
1509920|NCT00004211|stage IV prostate cancer
1509921|NCT00004211|recurrent prostate cancer
1509923|NCT00004210|rectal cancer
1509924|NCT00004209|stage IIIB non-small cell lung cancer
1509925|NCT00004209|stage IV non-small cell lung cancer
1509926|NCT00004208|refractory anemia
1509927|NCT00004208|refractory anemia with ringed sideroblasts
1509928|NCT00004208|refractory anemia with excess blasts
1509929|NCT00004208|de novo myelodysplastic syndromes
1509930|NCT00004208|previously treated myelodysplastic syndromes
1509931|NCT00004208|secondary myelodysplastic syndromes
1509932|NCT00004207|stage IV breast cancer
1509933|NCT00004207|recurrent breast cancer
1509934|NCT00004206|recurrent ovarian epithelial cancer
1509935|NCT00004205|stage I breast cancer
1509936|NCT00004205|stage II breast cancer
1509937|NCT00004205|stage IIIA breast cancer
1509938|NCT00004205|breast cancer in situ
1509939|NCT00004205|recurrent breast cancer
1509940|NCT00004205|ductal breast carcinoma
1509941|NCT00004205|lobular breast carcinoma in situ
1509942|NCT00004204|recurrent adult brain tumor
1509943|NCT00004204|adult anaplastic astrocytoma
1509944|NCT00004204|adult anaplastic oligodendroglioma
1509945|NCT00004203|recurrent bladder cancer
1509946|NCT00004203|stage IV bladder cancer
1509947|NCT00004203|transitional cell carcinoma of the bladder
1509948|NCT00004203|metastatic transitional cell cancer of the renal pelvis and ureter
1510919|NCT00004087|stage IV rectal cancer
1509949|NCT00004203|recurrent transitional cell cancer of the renal pelvis and ureter
1509950|NCT00004202|recurrent non-small cell lung cancer
1509951|NCT00004202|stage IIIA non-small cell lung cancer
1509952|NCT00004202|stage IIIB non-small cell lung cancer
1509953|NCT00004201|recurrent non-small cell lung cancer
1509954|NCT00004201|stage IIIB non-small cell lung cancer
1509955|NCT00004201|stage IV non-small cell lung cancer
1509956|NCT00004200|adult glioblastoma
1509957|NCT00004200|adult giant cell glioblastoma
1509958|NCT00004200|adult gliosarcoma
1509959|NCT00004199|recurrent non-small cell lung cancer
1509960|NCT00004199|stage IV non-small cell lung cancer
1509961|NCT00004198|stage III grade 1 follicular lymphoma
1509962|NCT00004198|stage III grade 2 follicular lymphoma
1509963|NCT00004198|stage IV grade 1 follicular lymphoma
1509964|NCT00004198|stage IV grade 2 follicular lymphoma
1509965|NCT00004197|stage I grade 3 follicular lymphoma
1509966|NCT00004197|stage I adult diffuse mixed cell lymphoma
1509967|NCT00004197|stage I adult diffuse large cell lymphoma
1509968|NCT00004197|stage I adult immunoblastic large cell lymphoma
1509969|NCT00004197|stage III grade 3 follicular lymphoma
1509970|NCT00004197|stage III adult diffuse mixed cell lymphoma
1509971|NCT00004197|stage III adult diffuse large cell lymphoma
1509972|NCT00004197|stage III adult immunoblastic large cell lymphoma
1509973|NCT00004197|stage IV grade 3 follicular lymphoma
1509974|NCT00004197|stage IV adult diffuse mixed cell lymphoma
1509975|NCT00004197|stage IV adult diffuse large cell lymphoma
1509976|NCT00004197|stage IV adult immunoblastic large cell lymphoma
1509977|NCT00004197|stage I mantle cell lymphoma
1509978|NCT00004197|contiguous stage II grade 3 follicular lymphoma
1509979|NCT00004197|contiguous stage II mantle cell lymphoma
1509980|NCT00004197|contiguous stage II adult diffuse mixed cell lymphoma
1509981|NCT00004197|contiguous stage II adult immunoblastic large cell lymphoma
1509982|NCT00004197|contiguous stage II adult diffuse large cell lymphoma
1509983|NCT00004197|noncontiguous stage II grade 3 follicular lymphoma
1509984|NCT00004197|noncontiguous stage II mantle cell lymphoma
1509985|NCT00004197|noncontiguous stage II adult diffuse mixed cell lymphoma
1509986|NCT00004197|noncontiguous stage II adult immunoblastic large cell lymphoma
1509987|NCT00004197|noncontiguous stage II adult diffuse large cell lymphoma
1509988|NCT00004197|stage III mantle cell lymphoma
1509989|NCT00004197|stage IV mantle cell lymphoma
1509990|NCT00004196|stage I melanoma
1509991|NCT00004196|stage II melanoma
1509992|NCT00004196|stage III melanoma
1509993|NCT00004195|stage I colon cancer
1509994|NCT00004195|stage II colon cancer
1509995|NCT00004195|stage III colon cancer
1509996|NCT00004195|stage IV colon cancer
1509997|NCT00004195|stage I rectal cancer
1509998|NCT00004195|stage II rectal cancer
1509999|NCT00004195|stage III rectal cancer
1510000|NCT00004195|stage IV rectal cancer
1510001|NCT00004195|recurrent colon cancer
1510002|NCT00004195|recurrent rectal cancer
1510003|NCT00004194|graft versus host disease
1510004|NCT00004193|stage IV colon cancer
1510005|NCT00004193|stage IV rectal cancer
1510006|NCT00004193|recurrent colon cancer
1510007|NCT00004193|recurrent rectal cancer
1510008|NCT00004193|adenocarcinoma of the colon
1510009|NCT00004193|adenocarcinoma of the rectum
1510010|NCT00004192|neutropenia
1510011|NCT00004192|Waldenstrom macroglobulinemia
1510012|NCT00004192|recurrent grade 1 follicular lymphoma
1510013|NCT00004192|recurrent grade 2 follicular lymphoma
1510014|NCT00004192|recurrent grade 3 follicular lymphoma
1510015|NCT00004192|recurrent adult diffuse small cleaved cell lymphoma
1510016|NCT00004192|recurrent adult diffuse mixed cell lymphoma
1510017|NCT00004192|recurrent adult diffuse large cell lymphoma
1510018|NCT00004192|recurrent adult immunoblastic large cell lymphoma
1510019|NCT00004192|recurrent adult lymphoblastic lymphoma
1510020|NCT00004192|recurrent adult Burkitt lymphoma
1510021|NCT00004192|recurrent mantle cell lymphoma
1510022|NCT00004192|recurrent marginal zone lymphoma
1510023|NCT00004192|recurrent small lymphocytic lymphoma
1510024|NCT00004192|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510025|NCT00004192|nodal marginal zone B-cell lymphoma
1510026|NCT00004192|splenic marginal zone lymphoma
1510027|NCT00004190|stage III pancreatic cancer
1510028|NCT00004190|recurrent pancreatic cancer
1510029|NCT00004190|duct cell adenocarcinoma of the pancreas
1510030|NCT00004190|stage IV pancreatic cancer
1510031|NCT00004189|stage III adult Hodgkin lymphoma
1510032|NCT00004189|stage IV adult Hodgkin lymphoma
1510033|NCT00004189|recurrent adult Hodgkin lymphoma
1510034|NCT00004189|stage III cutaneous T-cell non-Hodgkin lymphoma
1510035|NCT00004189|stage IV cutaneous T-cell non-Hodgkin lymphoma
1510036|NCT00004189|recurrent cutaneous T-cell non-Hodgkin lymphoma
1510037|NCT00004189|small intestine lymphoma
1510038|NCT00004189|unspecified adult solid tumor, protocol specific
1510039|NCT00004189|stage III grade 1 follicular lymphoma
1510040|NCT00004189|stage III grade 2 follicular lymphoma
1510041|NCT00004189|stage III grade 3 follicular lymphoma
1510042|NCT00004189|stage III adult diffuse small cleaved cell lymphoma
1510043|NCT00004189|stage III adult diffuse mixed cell lymphoma
1510044|NCT00004189|stage III adult diffuse large cell lymphoma
1510920|NCT00004087|recurrent colon cancer
1510045|NCT00004189|stage III adult immunoblastic large cell lymphoma
1510046|NCT00004189|stage III adult lymphoblastic lymphoma
1510047|NCT00004189|stage III adult Burkitt lymphoma
1510048|NCT00004189|stage IV grade 1 follicular lymphoma
1510049|NCT00004189|stage IV grade 2 follicular lymphoma
1510050|NCT00004189|stage IV grade 3 follicular lymphoma
1510051|NCT00004189|stage IV adult diffuse small cleaved cell lymphoma
1510052|NCT00004189|stage IV adult diffuse mixed cell lymphoma
1510053|NCT00004189|stage IV adult diffuse large cell lymphoma
1510054|NCT00004189|stage IV adult immunoblastic large cell lymphoma
1510055|NCT00004189|stage IV adult lymphoblastic lymphoma
1510056|NCT00004189|stage IV adult Burkitt lymphoma
1510057|NCT00004189|recurrent grade 1 follicular lymphoma
1510058|NCT00004189|recurrent grade 2 follicular lymphoma
1510059|NCT00004189|recurrent grade 3 follicular lymphoma
1510060|NCT00004189|recurrent adult diffuse small cleaved cell lymphoma
1510061|NCT00004189|recurrent adult diffuse mixed cell lymphoma
1510062|NCT00004189|recurrent adult diffuse large cell lymphoma
1510063|NCT00004189|recurrent adult immunoblastic large cell lymphoma
1510064|NCT00004189|recurrent adult lymphoblastic lymphoma
1510065|NCT00004189|recurrent adult Burkitt lymphoma
1510066|NCT00004189|stage III adult T-cell leukemia/lymphoma
1510067|NCT00004189|stage IV adult T-cell leukemia/lymphoma
1510068|NCT00004189|recurrent adult T-cell leukemia/lymphoma
1510069|NCT00004189|primary central nervous system non-Hodgkin lymphoma
1510070|NCT00004189|AIDS-related peripheral/systemic lymphoma
1510071|NCT00004189|AIDS-related primary CNS lymphoma
1510072|NCT00004189|intraocular lymphoma
1510073|NCT00004189|stage III mantle cell lymphoma
1510074|NCT00004189|stage IV mantle cell lymphoma
1510075|NCT00004189|recurrent mantle cell lymphoma
1510076|NCT00004189|angioimmunoblastic T-cell lymphoma
1510077|NCT00004189|anaplastic large cell lymphoma
1510078|NCT00004189|stage III mycosis fungoides/Sezary syndrome
1510079|NCT00004189|stage IV mycosis fungoides/Sezary syndrome
1510080|NCT00004189|recurrent mycosis fungoides/Sezary syndrome
1510081|NCT00004189|recurrent marginal zone lymphoma
1510082|NCT00004189|recurrent small lymphocytic lymphoma
1510083|NCT00004189|stage III small lymphocytic lymphoma
1510084|NCT00004189|stage III marginal zone lymphoma
1510085|NCT00004189|stage IV small lymphocytic lymphoma
1510086|NCT00004189|stage IV marginal zone lymphoma
1510087|NCT00004189|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510088|NCT00004189|nodal marginal zone B-cell lymphoma
1510089|NCT00004189|splenic marginal zone lymphoma
1510090|NCT00004188|localized resectable neuroblastoma
1510091|NCT00004188|regional neuroblastoma
1510092|NCT00004188|disseminated neuroblastoma
1510093|NCT00004188|stage 4S neuroblastoma
1510094|NCT00004188|localized unresectable neuroblastoma
1510095|NCT00004187|stage III colon cancer
1510096|NCT00004187|stage IV colon cancer
1510097|NCT00004187|stage III rectal cancer
1510098|NCT00004187|stage IV rectal cancer
1510099|NCT00004187|recurrent colon cancer
1510100|NCT00004187|recurrent rectal cancer
1510101|NCT00004186|limited stage small cell lung cancer
1510102|NCT00004186|extensive stage small cell lung cancer
1510103|NCT00004186|recurrent small cell lung cancer
1510104|NCT00004184|stage III melanoma
1510105|NCT00004184|stage IV melanoma
1510106|NCT00004184|recurrent melanoma
1510107|NCT00004183|localized malignant mesothelioma
1510108|NCT00004183|advanced malignant mesothelioma
1510109|NCT00004183|recurrent malignant mesothelioma
1510110|NCT00004183|epithelial mesothelioma
1510111|NCT00004183|sarcomatous mesothelioma
1510112|NCT00004182|stage IV breast cancer
1510113|NCT00004182|recurrent breast cancer
1510114|NCT00004181|refractory multiple myeloma
1510115|NCT00004181|stage I multiple myeloma
1510116|NCT00004181|stage II multiple myeloma
1510117|NCT00004181|stage III multiple myeloma
1510118|NCT00004181|chronic phase chronic myelogenous leukemia
1510221|NCT00004176|radiation toxicity
1510119|NCT00004181|chronic idiopathic myelofibrosis
1510120|NCT00004181|Philadelphia chromosome positive chronic myelogenous leukemia
1510121|NCT00004180|adult liposarcoma
1510122|NCT00004180|recurrent adult soft tissue sarcoma
1510123|NCT00004179|stage III grade 1 follicular lymphoma
1510124|NCT00004179|stage III grade 2 follicular lymphoma
1510125|NCT00004179|stage III grade 3 follicular lymphoma
1510126|NCT00004179|stage IV grade 1 follicular lymphoma
1510127|NCT00004179|stage IV grade 2 follicular lymphoma
1510128|NCT00004179|stage IV grade 3 follicular lymphoma
1510129|NCT00004179|recurrent grade 1 follicular lymphoma
1510130|NCT00004179|recurrent grade 2 follicular lymphoma
1510131|NCT00004179|recurrent grade 3 follicular lymphoma
1510132|NCT00004178|stage III colon cancer
1510133|NCT00004178|stage IV colon cancer
1510134|NCT00004178|stage III gastric cancer
1510135|NCT00004178|stage IV gastric cancer
1510136|NCT00004178|recurrent gastric cancer
1510137|NCT00004178|recurrent non-small cell lung cancer
1510138|NCT00004178|stage II pancreatic cancer
1510139|NCT00004178|stage III pancreatic cancer
1510140|NCT00004178|recurrent pancreatic cancer
1510141|NCT00004178|stage III rectal cancer
1510142|NCT00004178|stage IV rectal cancer
1510143|NCT00004178|recurrent colon cancer
1510145|NCT00004178|stage II esophageal cancer
1510146|NCT00004178|stage III esophageal cancer
1510147|NCT00004178|stage IV esophageal cancer
1510148|NCT00004178|recurrent esophageal cancer
1510149|NCT00004178|stage III cervical cancer
1510150|NCT00004178|recurrent cervical cancer
1510151|NCT00004178|stage IVB cervical cancer
1510152|NCT00004178|stage IVA cervical cancer
1510153|NCT00004178|adenocarcinoma of the prostate
1510154|NCT00004178|stage III renal cell cancer
1510155|NCT00004178|stage IV renal cell cancer
1510156|NCT00004178|recurrent renal cell cancer
1510157|NCT00004178|stage III ovarian epithelial cancer
1510158|NCT00004178|stage IV ovarian epithelial cancer
1510159|NCT00004178|recurrent ovarian epithelial cancer
1510160|NCT00004178|adenocarcinoma of the stomach
1510161|NCT00004178|extensive stage small cell lung cancer
1510162|NCT00004178|recurrent small cell lung cancer
1510163|NCT00004178|stage III vaginal cancer
1510164|NCT00004178|stage IVA vaginal cancer
1510165|NCT00004178|stage IVB vaginal cancer
1510166|NCT00004178|recurrent vaginal cancer
1510167|NCT00004178|localized unresectable adult primary liver cancer
1510168|NCT00004178|advanced adult primary liver cancer
1510169|NCT00004178|recurrent adult primary liver cancer
1510170|NCT00004178|stage III endometrial carcinoma
1510171|NCT00004178|stage IV endometrial carcinoma
1510172|NCT00004178|recurrent endometrial carcinoma
1510173|NCT00004178|small intestine adenocarcinoma
1510174|NCT00004178|unresectable gallbladder cancer
1510175|NCT00004178|recurrent gallbladder cancer
1510176|NCT00004178|unresectable extrahepatic bile duct cancer
1510177|NCT00004178|recurrent extrahepatic bile duct cancer
1510178|NCT00004178|recurrent small intestine cancer
1510179|NCT00004178|stage III bladder cancer
1510180|NCT00004178|recurrent bladder cancer
1510181|NCT00004178|stage IV bladder cancer
1510182|NCT00004178|stage III prostate cancer
1510183|NCT00004178|stage IV prostate cancer
1510184|NCT00004178|recurrent prostate cancer
1510185|NCT00004178|stage IV non-small cell lung cancer
1510186|NCT00004178|stage III salivary gland cancer
1510187|NCT00004178|stage IV salivary gland cancer
1510188|NCT00004178|recurrent salivary gland cancer
1510189|NCT00004178|duct cell adenocarcinoma of the pancreas
1510190|NCT00004178|ovarian undifferentiated adenocarcinoma
1510191|NCT00004178|adenocarcinoma of the lung
1510192|NCT00004178|adenocarcinoma of the esophagus
1510193|NCT00004178|intestinal adenocarcinoma of the stomach
1510194|NCT00004178|adenocarcinoma of the colon
1510195|NCT00004178|diffuse adenocarcinoma of the stomach
1510196|NCT00004178|mixed adenocarcinoma of the stomach
1510197|NCT00004178|mucinous adenocarcinoma of the colon
1510198|NCT00004178|signet ring adenocarcinoma of the colon
1510199|NCT00004178|adenocarcinoma of the rectum
1510200|NCT00004178|adenocarcinoma of the gallbladder
1510201|NCT00004178|mucinous adenocarcinoma of the rectum
1510202|NCT00004178|signet ring adenocarcinoma of the rectum
1510203|NCT00004178|adenocarcinoma with squamous metaplasia of the gallbladder
1510204|NCT00004178|adenocarcinoma of the extrahepatic bile duct
1510205|NCT00004178|ovarian serous cystadenocarcinoma
1510206|NCT00004178|ovarian mucinous cystadenocarcinoma
1510207|NCT00004178|ovarian endometrioid adenocarcinoma
1510208|NCT00004178|ovarian clear cell cystadenocarcinoma
1510209|NCT00004178|vaginal adenocarcinoma
1510210|NCT00004178|vaginal clear cell adenocarcinoma
1510211|NCT00004178|endometrial adenocarcinoma
1510212|NCT00004178|cervical adenocarcinoma
1510213|NCT00004178|adenocarcinoma of the bladder
1510214|NCT00004178|salivary gland adenocarcinoma
1510215|NCT00004178|adenocarcinoma of unknown primary
1510216|NCT00004178|adenocarcinoma of the pancreas
1510217|NCT00004178|stage IV pancreatic cancer
1510218|NCT00004177|recurrent ovarian epithelial cancer
1510219|NCT00004176|limited stage small cell lung cancer
1510220|NCT00004176|drug/agent toxicity by tissue/organ
1510222|NCT00004175|stage IIIA breast cancer
1510223|NCT00004175|stage IIIB breast cancer
1510224|NCT00004174|stage IV breast cancer
1510225|NCT00004174|stage IIIA breast cancer
1510226|NCT00004174|recurrent breast cancer
1510227|NCT00004174|stage IIIB breast cancer
1510228|NCT00004173|unspecified adult solid tumor, protocol specific
1510229|NCT00004172|stage IV breast cancer
1510230|NCT00004172|stage IIIA breast cancer
1510231|NCT00004172|recurrent breast cancer
1510232|NCT00004172|stage IIIB breast cancer
1510233|NCT00004171|recurrent adult Hodgkin lymphoma
1510234|NCT00004171|childhood immunoblastic large cell lymphoma
1510235|NCT00004171|recurrent/refractory childhood Hodgkin lymphoma
1510236|NCT00004171|recurrent grade 3 follicular lymphoma
1510237|NCT00004171|recurrent adult diffuse small cleaved cell lymphoma
1510238|NCT00004171|recurrent adult diffuse mixed cell lymphoma
1510239|NCT00004171|recurrent adult diffuse large cell lymphoma
1510240|NCT00004171|recurrent adult immunoblastic large cell lymphoma
1510241|NCT00004169|recurrent adult Hodgkin lymphoma
1510242|NCT00004169|recurrent/refractory childhood Hodgkin lymphoma
1510243|NCT00004166|stage I ovarian epithelial cancer
1510244|NCT00004166|stage II ovarian epithelial cancer
1510245|NCT00004166|stage III ovarian epithelial cancer
1510921|NCT00004087|recurrent rectal cancer
1510246|NCT00004166|stage IV ovarian epithelial cancer
1510247|NCT00004166|quality of life
1510248|NCT00004165|refractory multiple myeloma
1510249|NCT00004165|stage I multiple myeloma
1510250|NCT00004165|stage II multiple myeloma
1510251|NCT00004165|stage III multiple myeloma
1510252|NCT00004165|primary systemic amyloidosis
1510253|NCT00004164|stage II nasopharyngeal cancer
1510254|NCT00004164|stage III nasopharyngeal cancer
1510255|NCT00004164|stage IV nasopharyngeal cancer
1510256|NCT00004163|stage III salivary gland cancer
1510257|NCT00004163|stage IV salivary gland cancer
1510258|NCT00004163|recurrent salivary gland cancer
1510259|NCT00004163|salivary gland squamous cell carcinoma
1510260|NCT00004163|salivary gland acinic cell tumor
1510261|NCT00004163|low-grade salivary gland mucoepidermoid carcinoma
1510262|NCT00004163|high-grade salivary gland mucoepidermoid carcinoma
1510263|NCT00004163|salivary gland adenocarcinoma
1510264|NCT00004163|salivary gland poorly differentiated carcinoma
1510265|NCT00004163|salivary gland malignant mixed cell type tumor
1510266|NCT00004163|salivary gland adenoid cystic carcinoma
1510267|NCT00004162|AIDS-related diffuse large cell lymphoma
1510268|NCT00004162|AIDS-related immunoblastic large cell lymphoma
1510269|NCT00004162|AIDS-related small noncleaved cell lymphoma
1510270|NCT00004162|AIDS-related diffuse mixed cell lymphoma
1510271|NCT00004162|AIDS-related diffuse small cleaved cell lymphoma
1510272|NCT00004162|AIDS-related lymphoblastic lymphoma
1510273|NCT00004161|lip and oral cavity cancer
1510274|NCT00004160|stage IIIA non-small cell lung cancer
1510275|NCT00004160|stage IIIB non-small cell lung cancer
1510276|NCT00004159|recurrent non-small cell lung cancer
1510277|NCT00004159|stage IV non-small cell lung cancer
1510278|NCT00004158|refractory multiple myeloma
1510279|NCT00004158|stage I multiple myeloma
1510280|NCT00004158|stage II multiple myeloma
1510281|NCT00004158|stage III multiple myeloma
1510282|NCT00004157|stage IV breast cancer
1510283|NCT00004157|stage IIIA breast cancer
1510284|NCT00004157|stage IIIB breast cancer
1510285|NCT00004157|recurrent adult Hodgkin lymphoma
1510286|NCT00004157|recurrent childhood rhabdomyosarcoma
1510287|NCT00004157|stage II ovarian epithelial cancer
1510288|NCT00004157|stage III ovarian epithelial cancer
1510289|NCT00004157|stage IV ovarian epithelial cancer
1510290|NCT00004157|recurrent ovarian epithelial cancer
1510291|NCT00004157|disseminated neuroblastoma
1510292|NCT00004157|recurrent neuroblastoma
1510293|NCT00004157|recurrent Wilms tumor and other childhood kidney tumors
1510294|NCT00004157|recurrent childhood lymphoblastic lymphoma
1510295|NCT00004157|stage III malignant testicular germ cell tumor
1510296|NCT00004157|recurrent malignant testicular germ cell tumor
1510297|NCT00004157|testicular embryonal carcinoma
1510298|NCT00004157|testicular choriocarcinoma
1510299|NCT00004157|testicular teratoma
1510300|NCT00004157|testicular yolk sac tumor
1510301|NCT00004157|testicular embryonal carcinoma and teratoma
1510302|NCT00004157|testicular embryonal carcinoma and teratoma with seminoma
1510303|NCT00004157|testicular embryonal carcinoma and yolk sac tumor
1510304|NCT00004157|testicular embryonal carcinoma and yolk sac tumor with seminoma
1510305|NCT00004157|testicular embryonal carcinoma and seminoma
1510306|NCT00004157|testicular yolk sac tumor and teratoma
1510307|NCT00004157|testicular yolk sac tumor and teratoma with seminoma
1510308|NCT00004157|testicular choriocarcinoma and yolk sac tumor
1510309|NCT00004157|testicular choriocarcinoma and embryonal carcinoma
1510310|NCT00004157|testicular choriocarcinoma and teratoma
1510311|NCT00004157|testicular choriocarcinoma and seminoma
1510312|NCT00004157|recurrent/refractory childhood Hodgkin lymphoma
1510313|NCT00004157|recurrent ovarian germ cell tumor
1510314|NCT00004157|ovarian yolk sac tumor
1510315|NCT00004157|ovarian embryonal carcinoma
1510316|NCT00004157|ovarian polyembryoma
1510317|NCT00004157|ovarian choriocarcinoma
1510318|NCT00004157|ovarian immature teratoma
1510319|NCT00004157|ovarian mature teratoma
1510320|NCT00004157|ovarian monodermal and highly specialized teratoma
1510321|NCT00004157|ovarian mixed germ cell tumor
1510322|NCT00004157|stage III grade 1 follicular lymphoma
1510323|NCT00004157|stage III grade 2 follicular lymphoma
1510324|NCT00004157|stage III grade 3 follicular lymphoma
1510325|NCT00004157|stage III adult diffuse small cleaved cell lymphoma
1510326|NCT00004157|stage III adult diffuse mixed cell lymphoma
1510327|NCT00004157|stage III adult diffuse large cell lymphoma
1510328|NCT00004157|stage III adult immunoblastic large cell lymphoma
1510329|NCT00004157|stage III adult lymphoblastic lymphoma
1510330|NCT00004157|stage III adult Burkitt lymphoma
1510331|NCT00004157|stage IV grade 1 follicular lymphoma
1510332|NCT00004157|stage IV grade 2 follicular lymphoma
1510333|NCT00004157|stage IV grade 3 follicular lymphoma
1510334|NCT00004157|stage IV adult diffuse small cleaved cell lymphoma
1510335|NCT00004157|stage IV adult diffuse mixed cell lymphoma
1510336|NCT00004157|stage IV adult diffuse large cell lymphoma
1510337|NCT00004157|stage IV adult immunoblastic large cell lymphoma
1510338|NCT00004157|stage IV adult lymphoblastic lymphoma
1510339|NCT00004157|stage IV adult Burkitt lymphoma
1510340|NCT00004157|recurrent grade 1 follicular lymphoma
1510341|NCT00004157|recurrent grade 2 follicular lymphoma
1513010|NCT00003824|stage 0 bladder cancer
1510342|NCT00004157|recurrent grade 3 follicular lymphoma
1510343|NCT00004157|recurrent adult diffuse small cleaved cell lymphoma
1510344|NCT00004157|recurrent adult diffuse mixed cell lymphoma
1510345|NCT00004157|recurrent adult diffuse large cell lymphoma
1510346|NCT00004157|recurrent adult immunoblastic large cell lymphoma
1510347|NCT00004157|recurrent adult lymphoblastic lymphoma
1510348|NCT00004157|recurrent adult Burkitt lymphoma
1510349|NCT00004157|poor prognosis metastatic gestational trophoblastic tumor
1510350|NCT00004157|recurrent childhood small noncleaved cell lymphoma
1510351|NCT00004157|recurrent childhood large cell lymphoma
1510352|NCT00004157|noncontiguous stage II grade 1 follicular lymphoma
1510353|NCT00004157|noncontiguous stage II grade 2 follicular lymphoma
1510354|NCT00004157|noncontiguous stage II grade 3 follicular lymphoma
1510355|NCT00004157|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1510356|NCT00004157|noncontiguous stage II mantle cell lymphoma
1510357|NCT00004157|noncontiguous stage II adult diffuse mixed cell lymphoma
1510358|NCT00004157|noncontiguous stage II adult immunoblastic large cell lymphoma
1510359|NCT00004157|noncontiguous stage II adult diffuse large cell lymphoma
1510360|NCT00004157|noncontiguous stage II adult Burkitt lymphoma
1510361|NCT00004157|noncontiguous stage II adult lymphoblastic lymphoma
1510362|NCT00004157|stage III mantle cell lymphoma
1510363|NCT00004157|stage IV mantle cell lymphoma
1510364|NCT00004157|recurrent mantle cell lymphoma
1510365|NCT00004157|previously treated childhood rhabdomyosarcoma
1510366|NCT00004157|noncontiguous stage II small lymphocytic lymphoma
1510367|NCT00004157|noncontiguous stage II marginal zone lymphoma
1510368|NCT00004157|recurrent marginal zone lymphoma
1510369|NCT00004157|recurrent small lymphocytic lymphoma
1510370|NCT00004157|stage III small lymphocytic lymphoma
1510371|NCT00004157|stage III marginal zone lymphoma
1510372|NCT00004157|stage IV small lymphocytic lymphoma
1510373|NCT00004157|stage IV marginal zone lymphoma
1510374|NCT00004157|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510375|NCT00004157|nodal marginal zone B-cell lymphoma
1510376|NCT00004157|splenic marginal zone lymphoma
1510377|NCT00004156|stage I breast cancer
1510378|NCT00004156|stage II breast cancer
1510379|NCT00004156|stage IV breast cancer
1510380|NCT00004156|stage IIIA breast cancer
1510381|NCT00004156|recurrent breast cancer
1510382|NCT00004156|stage IIIB breast cancer
1510383|NCT00004154|stage 0 bladder cancer
1510384|NCT00004154|stage I bladder cancer
1510385|NCT00004154|transitional cell carcinoma of the bladder
1510386|NCT00004153|stage I melanoma
1510387|NCT00004153|stage II melanoma
1510388|NCT00004153|stage III melanoma
1510389|NCT00004153|stage IV melanoma
1510390|NCT00004152|stage III melanoma
1510391|NCT00004152|stage IV melanoma
1510392|NCT00004152|recurrent melanoma
1510393|NCT00004151|recurrent non-small cell lung cancer
1510394|NCT00004151|stage IIIA non-small cell lung cancer
1510395|NCT00004151|stage IIIB non-small cell lung cancer
1510396|NCT00004151|stage IV non-small cell lung cancer
1510397|NCT00004150|stage III colon cancer
1510398|NCT00004150|adenocarcinoma of the colon
1510399|NCT00004150|mucinous adenocarcinoma of the colon
1510400|NCT00004149|stage IV prostate cancer
1510401|NCT00004149|recurrent prostate cancer
1510402|NCT00004148|stage III melanoma
1510403|NCT00004148|stage IV melanoma
1510404|NCT00004148|recurrent melanoma
1510405|NCT00004147|recurrent adult brain tumor
1510406|NCT00004147|adult glioblastoma
1510407|NCT00004147|adult anaplastic astrocytoma
1510408|NCT00004147|adult anaplastic oligodendroglioma
1510409|NCT00004147|adult giant cell glioblastoma
1510410|NCT00004147|adult gliosarcoma
1510411|NCT00004145|stage III adult Hodgkin lymphoma
1510412|NCT00004145|stage IV adult Hodgkin lymphoma
1510413|NCT00004145|recurrent adult Hodgkin lymphoma
1510414|NCT00004145|refractory multiple myeloma
1510415|NCT00004145|stage I multiple myeloma
1510416|NCT00004145|stage II multiple myeloma
1510417|NCT00004145|stage III multiple myeloma
1510418|NCT00004145|stage II chronic lymphocytic leukemia
1510419|NCT00004145|stage III chronic lymphocytic leukemia
1510420|NCT00004145|stage IV chronic lymphocytic leukemia
1510421|NCT00004145|recurrent adult acute myeloid leukemia
1510422|NCT00004145|recurrent adult acute lymphoblastic leukemia
1510423|NCT00004145|refractory chronic lymphocytic leukemia
1510424|NCT00004145|chronic phase chronic myelogenous leukemia
1510425|NCT00004145|accelerated phase chronic myelogenous leukemia
1510426|NCT00004145|adult acute myeloid leukemia in remission
1510427|NCT00004145|adult acute lymphoblastic leukemia in remission
1510428|NCT00004145|refractory anemia
1510429|NCT00004145|refractory anemia with ringed sideroblasts
1510430|NCT00004145|refractory anemia with excess blasts
1510431|NCT00004145|refractory anemia with excess blasts in transformation
1510432|NCT00004145|chronic myelomonocytic leukemia
1510433|NCT00004145|stage III grade 1 follicular lymphoma
1510434|NCT00004145|stage III grade 2 follicular lymphoma
1510435|NCT00004145|stage III grade 3 follicular lymphoma
1510436|NCT00004145|stage III adult diffuse small cleaved cell lymphoma
1510437|NCT00004145|stage III adult diffuse mixed cell lymphoma
1510438|NCT00004145|stage III adult diffuse large cell lymphoma
1510439|NCT00004145|stage III adult immunoblastic large cell lymphoma
1510440|NCT00004145|stage III adult lymphoblastic lymphoma
1510441|NCT00004145|stage III adult Burkitt lymphoma
1510442|NCT00004145|stage IV grade 1 follicular lymphoma
1510443|NCT00004145|stage IV grade 2 follicular lymphoma
1510444|NCT00004145|stage IV grade 3 follicular lymphoma
1510445|NCT00004145|stage IV adult diffuse small cleaved cell lymphoma
1510446|NCT00004145|stage IV adult diffuse mixed cell lymphoma
1510447|NCT00004145|stage IV adult diffuse large cell lymphoma
1510448|NCT00004145|stage IV adult immunoblastic large cell lymphoma
1510449|NCT00004145|stage IV adult lymphoblastic lymphoma
1510450|NCT00004145|stage IV adult Burkitt lymphoma
1510451|NCT00004145|recurrent grade 1 follicular lymphoma
1510452|NCT00004145|recurrent grade 2 follicular lymphoma
1510453|NCT00004145|recurrent grade 3 follicular lymphoma
1510454|NCT00004145|recurrent adult diffuse small cleaved cell lymphoma
1510455|NCT00004145|recurrent adult diffuse mixed cell lymphoma
1510456|NCT00004145|recurrent adult diffuse large cell lymphoma
1510457|NCT00004145|recurrent adult immunoblastic large cell lymphoma
1510458|NCT00004145|recurrent adult lymphoblastic lymphoma
1510459|NCT00004145|recurrent adult Burkitt lymphoma
1510460|NCT00004145|secondary acute myeloid leukemia
1510461|NCT00004145|de novo myelodysplastic syndromes
1510462|NCT00004145|previously treated myelodysplastic syndromes
1510463|NCT00004145|secondary myelodysplastic syndromes
1510464|NCT00004145|stage III mantle cell lymphoma
1510465|NCT00004145|stage IV mantle cell lymphoma
1510466|NCT00004145|recurrent mantle cell lymphoma
1510467|NCT00004145|recurrent marginal zone lymphoma
1510468|NCT00004145|recurrent small lymphocytic lymphoma
1510469|NCT00004145|stage III small lymphocytic lymphoma
1510470|NCT00004145|stage III marginal zone lymphoma
1510471|NCT00004145|stage IV small lymphocytic lymphoma
1510472|NCT00004145|stage IV marginal zone lymphoma
1510473|NCT00004145|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510474|NCT00004145|nodal marginal zone B-cell lymphoma
1510475|NCT00004145|splenic marginal zone lymphoma
1510476|NCT00004144|unspecified adult solid tumor, protocol specific
1510477|NCT00004143|sickle cell anemia
1510478|NCT00004143|severe aplastic anemia
1510479|NCT00004142|stage IV colon cancer
1510480|NCT00004142|stage IV rectal cancer
1510481|NCT00004142|recurrent colon cancer
1510482|NCT00004142|recurrent rectal cancer
1510483|NCT00004142|liver metastases
1510484|NCT00004141|stage III melanoma
1510485|NCT00004141|stage IV melanoma
1510486|NCT00004141|recurrent melanoma
1510487|NCT00004139|recurrent non-small cell lung cancer
1510488|NCT00004139|squamous cell lung cancer
1510489|NCT00004139|large cell lung cancer
1510490|NCT00004139|stage IIIB non-small cell lung cancer
1510491|NCT00004139|stage IV non-small cell lung cancer
1510492|NCT00004139|adenocarcinoma of the lung
1510493|NCT00004139|bronchoalveolar cell lung cancer
1510494|NCT00004138|stage I non-small cell lung cancer
1510495|NCT00004138|stage II non-small cell lung cancer
1510496|NCT00004138|squamous cell lung cancer
1510497|NCT00004138|large cell lung cancer
1510498|NCT00004138|stage IIIA non-small cell lung cancer
1510499|NCT00004138|adenocarcinoma of the lung
1510500|NCT00004138|bronchoalveolar cell lung cancer
1510501|NCT00004137|extensive stage small cell lung cancer
1510502|NCT00004136|stage III childhood liver cancer
1510503|NCT00004136|stage IV childhood liver cancer
1510504|NCT00004136|recurrent childhood liver cancer
1510505|NCT00004136|localized unresectable adult primary liver cancer
1510506|NCT00004136|advanced adult primary liver cancer
1510507|NCT00004136|recurrent adult primary liver cancer
1510508|NCT00004136|liver metastases
1510509|NCT00004135|stage IV renal cell cancer
1510510|NCT00004135|recurrent renal cell cancer
1510511|NCT00004135|stage IV melanoma
1510512|NCT00004135|recurrent melanoma
1510513|NCT00004132|stage I adult Hodgkin lymphoma
1510514|NCT00004132|stage II adult Hodgkin lymphoma
1510515|NCT00004132|stage III adult Hodgkin lymphoma
1510516|NCT00004132|stage IV adult Hodgkin lymphoma
1510517|NCT00004132|recurrent adult Hodgkin lymphoma
1510518|NCT00004132|childhood Burkitt lymphoma
1510519|NCT00004132|refractory multiple myeloma
1510520|NCT00004132|stage 0 chronic lymphocytic leukemia
1510521|NCT00004132|stage I multiple myeloma
1510522|NCT00004132|stage II multiple myeloma
1510523|NCT00004132|stage III multiple myeloma
1510524|NCT00004132|stage IV childhood lymphoblastic lymphoma
1510525|NCT00004132|stage I chronic lymphocytic leukemia
1510526|NCT00004132|stage II chronic lymphocytic leukemia
1510527|NCT00004132|stage III chronic lymphocytic leukemia
1510528|NCT00004132|stage IV chronic lymphocytic leukemia
1510529|NCT00004132|recurrent adult acute myeloid leukemia
1510530|NCT00004132|recurrent adult acute lymphoblastic leukemia
1510531|NCT00004132|refractory chronic lymphocytic leukemia
1510532|NCT00004132|blastic phase chronic myelogenous leukemia
1510533|NCT00004132|untreated adult acute lymphoblastic leukemia
1510534|NCT00004132|untreated adult acute myeloid leukemia
1510535|NCT00004132|untreated childhood acute myeloid leukemia and other myeloid malignancies
1510536|NCT00004132|untreated childhood acute lymphoblastic leukemia
1510538|NCT00004132|stage IV childhood Hodgkin lymphoma
1510539|NCT00004132|stage I grade 1 follicular lymphoma
1510540|NCT00004132|stage I grade 2 follicular lymphoma
1510541|NCT00004132|stage I grade 3 follicular lymphoma
1510542|NCT00004132|stage I adult diffuse small cleaved cell lymphoma
1510543|NCT00004132|stage I adult diffuse mixed cell lymphoma
1510544|NCT00004132|stage I adult diffuse large cell lymphoma
1510545|NCT00004132|stage I adult immunoblastic large cell lymphoma
1510546|NCT00004132|stage I adult lymphoblastic lymphoma
1510547|NCT00004132|stage I adult Burkitt lymphoma
1510548|NCT00004132|stage III grade 1 follicular lymphoma
1510549|NCT00004132|stage III grade 2 follicular lymphoma
1510550|NCT00004132|stage III grade 3 follicular lymphoma
1510551|NCT00004132|stage III adult diffuse small cleaved cell lymphoma
1510552|NCT00004132|stage III adult diffuse mixed cell lymphoma
1510553|NCT00004132|stage III adult diffuse large cell lymphoma
1510554|NCT00004132|stage III adult immunoblastic large cell lymphoma
1510555|NCT00004132|stage III adult lymphoblastic lymphoma
1510556|NCT00004132|stage III adult Burkitt lymphoma
1510557|NCT00004132|stage IV grade 1 follicular lymphoma
1510558|NCT00004132|stage IV grade 2 follicular lymphoma
1510559|NCT00004132|stage IV grade 3 follicular lymphoma
1510560|NCT00004132|stage IV adult diffuse small cleaved cell lymphoma
1510561|NCT00004132|stage IV adult diffuse mixed cell lymphoma
1510562|NCT00004132|stage IV adult diffuse large cell lymphoma
1510563|NCT00004132|stage IV adult immunoblastic large cell lymphoma
1510564|NCT00004132|stage IV adult lymphoblastic lymphoma
1510565|NCT00004132|stage IV adult Burkitt lymphoma
1510566|NCT00004132|recurrent grade 1 follicular lymphoma
1510567|NCT00004132|recurrent grade 2 follicular lymphoma
1510568|NCT00004132|recurrent grade 3 follicular lymphoma
1510569|NCT00004132|recurrent adult diffuse small cleaved cell lymphoma
1510570|NCT00004132|recurrent adult diffuse mixed cell lymphoma
1510571|NCT00004132|recurrent adult diffuse large cell lymphoma
1510572|NCT00004132|recurrent adult immunoblastic large cell lymphoma
1510573|NCT00004132|recurrent adult lymphoblastic lymphoma
1510574|NCT00004132|recurrent adult Burkitt lymphoma
1510575|NCT00004132|primary central nervous system non-Hodgkin lymphoma
1510576|NCT00004132|drug/agent toxicity by tissue/organ
1510577|NCT00004132|radiation toxicity
1510578|NCT00004132|stage IV childhood small noncleaved cell lymphoma
1510579|NCT00004132|stage IV childhood large cell lymphoma
1510580|NCT00004132|stage I mantle cell lymphoma
1510581|NCT00004132|contiguous stage II grade 1 follicular lymphoma
1510582|NCT00004132|contiguous stage II grade 2 follicular lymphoma
1510583|NCT00004132|contiguous stage II grade 3 follicular lymphoma
1510584|NCT00004132|contiguous stage II adult diffuse small cleaved cell lymphoma
1510585|NCT00004132|contiguous stage II mantle cell lymphoma
1510586|NCT00004132|contiguous stage II adult diffuse mixed cell lymphoma
1510587|NCT00004132|contiguous stage II adult immunoblastic large cell lymphoma
1510588|NCT00004132|contiguous stage II adult diffuse large cell lymphoma
1510589|NCT00004132|contiguous stage II adult Burkitt lymphoma
1510590|NCT00004132|contiguous stage II adult lymphoblastic lymphoma
1510591|NCT00004132|noncontiguous stage II grade 1 follicular lymphoma
1510592|NCT00004132|noncontiguous stage II grade 2 follicular lymphoma
1510593|NCT00004132|noncontiguous stage II grade 3 follicular lymphoma
1510594|NCT00004132|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1510595|NCT00004132|noncontiguous stage II mantle cell lymphoma
1510596|NCT00004132|noncontiguous stage II adult diffuse mixed cell lymphoma
1510597|NCT00004132|noncontiguous stage II adult immunoblastic large cell lymphoma
1510598|NCT00004132|noncontiguous stage II adult diffuse large cell lymphoma
1510599|NCT00004132|noncontiguous stage II adult Burkitt lymphoma
1510600|NCT00004132|noncontiguous stage II adult lymphoblastic lymphoma
1510601|NCT00004132|stage III mantle cell lymphoma
1510602|NCT00004132|stage IV mantle cell lymphoma
1510603|NCT00004132|recurrent mantle cell lymphoma
1510604|NCT00004132|anaplastic large cell lymphoma
1510605|NCT00004132|noncontiguous stage II small lymphocytic lymphoma
1510606|NCT00004132|noncontiguous stage II marginal zone lymphoma
1510607|NCT00004132|recurrent marginal zone lymphoma
1510608|NCT00004132|recurrent small lymphocytic lymphoma
1510609|NCT00004132|stage I marginal zone lymphoma
1510610|NCT00004132|stage I small lymphocytic lymphoma
1510611|NCT00004132|stage III small lymphocytic lymphoma
1510612|NCT00004132|stage III marginal zone lymphoma
1510613|NCT00004132|stage IV small lymphocytic lymphoma
1510614|NCT00004132|stage IV marginal zone lymphoma
1510615|NCT00004132|contiguous stage II marginal zone lymphoma
1510616|NCT00004132|contiguous stage II small lymphocytic lymphoma
1510617|NCT00004132|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510618|NCT00004132|nodal marginal zone B-cell lymphoma
1510619|NCT00004132|splenic marginal zone lymphoma
1510620|NCT00004129|recurrent adult brain tumor
1510621|NCT00004129|adult glioblastoma
1510622|NCT00004129|adult giant cell glioblastoma
1510623|NCT00004129|adult gliosarcoma
1510624|NCT00004128|untreated adult acute myeloid leukemia
1510625|NCT00004128|adult acute erythroid leukemia (M6)
1510626|NCT00004128|adult acute myeloblastic leukemia without maturation (M1)
1510627|NCT00004128|adult acute myeloblastic leukemia with maturation (M2)
1510628|NCT00004128|adult acute myelomonocytic leukemia (M4)
1510629|NCT00004128|adult acute monoblastic leukemia (M5a)
1510630|NCT00004128|adult acute megakaryoblastic leukemia (M7)
1510631|NCT00004128|adult acute monocytic leukemia (M5b)
1510632|NCT00004128|adult acute minimally differentiated myeloid leukemia (M0)
1510633|NCT00004128|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1510634|NCT00004128|adult acute myeloid leukemia with inv(16)(p13;q22)
1510635|NCT00004128|adult acute myeloid leukemia with t(16;16)(p13;q22)
1510636|NCT00004128|adult acute myeloid leukemia with t(8;21)(q22;q22)
1510637|NCT00004127|stage IV gastric cancer
1510638|NCT00004127|recurrent gastric cancer
1510639|NCT00004127|stage IV esophageal cancer
1510640|NCT00004127|recurrent esophageal cancer
1510641|NCT00004127|adenocarcinoma of the stomach
1510642|NCT00004127|adenocarcinoma of the esophagus
1510643|NCT00004126|recurrent non-small cell lung cancer
1510644|NCT00004126|stage IIIB non-small cell lung cancer
1510645|NCT00004126|stage IV non-small cell lung cancer
1510646|NCT00004125|stage II breast cancer
1510647|NCT00004125|stage IIIA breast cancer
1510648|NCT00004124|adenocarcinoma of the prostate
1510649|NCT00004124|stage I prostate cancer
1510650|NCT00004124|stage II prostate cancer
1510651|NCT00004124|stage III prostate cancer
1510652|NCT00004123|adult leiomyosarcoma
1510653|NCT00004123|adult liposarcoma
1510654|NCT00004123|stage III adult soft tissue sarcoma
1510655|NCT00004123|recurrent adult soft tissue sarcoma
1510656|NCT00004123|stage II adult soft tissue sarcoma
1510657|NCT00004122|stage I bladder cancer
1510658|NCT00004122|recurrent bladder cancer
1510659|NCT00004122|transitional cell carcinoma of the bladder
1510660|NCT00004115|stage I ovarian epithelial cancer
1510661|NCT00004115|stage II ovarian epithelial cancer
1510662|NCT00004115|stage III ovarian epithelial cancer
1510663|NCT00004115|stage IV ovarian epithelial cancer
1510664|NCT00004115|primary peritoneal cavity cancer
1510665|NCT00004114|recurrent adult Hodgkin lymphoma
1510666|NCT00004114|recurrent cutaneous T-cell non-Hodgkin lymphoma
1510667|NCT00004114|recurrent adult acute myeloid leukemia
1510668|NCT00004114|recurrent adult acute lymphoblastic leukemia
1510669|NCT00004114|relapsing chronic myelogenous leukemia
1510670|NCT00004114|refractory chronic lymphocytic leukemia
1510671|NCT00004114|chronic myelomonocytic leukemia
1510672|NCT00004114|recurrent grade 1 follicular lymphoma
1510673|NCT00004114|recurrent grade 2 follicular lymphoma
1510674|NCT00004114|recurrent grade 3 follicular lymphoma
1510675|NCT00004114|recurrent adult diffuse small cleaved cell lymphoma
1510676|NCT00004114|recurrent adult diffuse mixed cell lymphoma
1510677|NCT00004114|recurrent adult diffuse large cell lymphoma
1510678|NCT00004114|recurrent adult immunoblastic large cell lymphoma
1510679|NCT00004114|recurrent adult lymphoblastic lymphoma
1510680|NCT00004114|recurrent adult Burkitt lymphoma
1510681|NCT00004114|recurrent adult T-cell leukemia/lymphoma
1510682|NCT00004114|previously treated myelodysplastic syndromes
1510683|NCT00004114|AIDS-related peripheral/systemic lymphoma
1510684|NCT00004114|recurrent mantle cell lymphoma
1510685|NCT00004114|anaplastic large cell lymphoma
1510686|NCT00004114|refractory cytopenia with multilineage dysplasia
1510687|NCT00004114|recurrent mycosis fungoides/Sezary syndrome
1510688|NCT00004114|recurrent marginal zone lymphoma
1510689|NCT00004114|recurrent small lymphocytic lymphoma
1510690|NCT00004114|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510691|NCT00004114|nodal marginal zone B-cell lymphoma
1510692|NCT00004114|splenic marginal zone lymphoma
1510693|NCT00004113|recurrent adult brain tumor
1510694|NCT00004113|adult glioblastoma
1510695|NCT00004113|adult anaplastic astrocytoma
1510696|NCT00004113|adult anaplastic oligodendroglioma
1510697|NCT00004113|adult mixed glioma
1510698|NCT00004113|adult giant cell glioblastoma
1510699|NCT00004113|adult gliosarcoma
1510700|NCT00004112|stage II adult diffuse small cleaved cell lymphoma
1510701|NCT00004112|stage II adult diffuse mixed cell lymphoma
1510702|NCT00004112|stage II adult diffuse large cell lymphoma
1510703|NCT00004112|stage III adult diffuse small cleaved cell lymphoma
1510704|NCT00004112|stage III adult diffuse mixed cell lymphoma
1510705|NCT00004112|stage III adult diffuse large cell lymphoma
1510706|NCT00004112|stage IV adult diffuse small cleaved cell lymphoma
1510707|NCT00004112|stage IV adult diffuse mixed cell lymphoma
1510708|NCT00004112|stage IV adult diffuse large cell lymphoma
1510709|NCT00004112|stage III mantle cell lymphoma
1510710|NCT00004112|stage IV mantle cell lymphoma
1510711|NCT00004112|anaplastic large cell lymphoma
1510712|NCT00004112|stage II mantle cell lymphoma
1510713|NCT00004112|stage II small lymphocytic lymphoma
1510714|NCT00004112|stage II marginal zone lymphoma
1510715|NCT00004112|stage III small lymphocytic lymphoma
1510716|NCT00004112|stage III marginal zone lymphoma
1510717|NCT00004112|stage IV small lymphocytic lymphoma
1510718|NCT00004112|stage IV marginal zone lymphoma
1510719|NCT00004112|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510720|NCT00004112|nodal marginal zone B-cell lymphoma
1510721|NCT00004112|splenic marginal zone lymphoma
1510722|NCT00004110|regional neuroblastoma
1510723|NCT00004110|disseminated neuroblastoma
1510724|NCT00004110|recurrent neuroblastoma
1513383|NCT00003782|stage I breast cancer
1510725|NCT00004110|localized unresectable neuroblastoma
1510726|NCT00004109|stage III adult soft tissue sarcoma
1510727|NCT00004109|recurrent adult soft tissue sarcoma
1510728|NCT00004109|Doxorubicin
1510729|NCT00004109|External-Beam RT
1510730|NCT00004109|XRT
1510731|NCT00004109|cancer
1510732|NCT00004109|PREOPERATIVE CONCURRENT CHEMORADIATION
1510733|NCT00004109|EXTREMITY SOFT TISSUE SARCOMAS
1510734|NCT00004109|TRUNK SOFT TISSUE SARCOMAS
1510735|NCT00004109|Concurrent Chemoradiation
1510736|NCT00004109|Surgical Resection
1510737|NCT00004109|Localized Extremity Soft Tissue Sarcomas
1510738|NCT00004109|Body Wall Soft Tissue Sarcomas
1510739|NCT00004108|localized resectable adult primary liver cancer
1510740|NCT00004108|localized unresectable adult primary liver cancer
1510741|NCT00004108|advanced adult primary liver cancer
1510742|NCT00004108|recurrent adult primary liver cancer
1510743|NCT00004108|adult primary hepatocellular carcinoma
1510744|NCT00004107|Waldenstrom macroglobulinemia
1510745|NCT00004107|recurrent adult acute lymphoblastic leukemia
1510746|NCT00004107|refractory chronic lymphocytic leukemia
1510747|NCT00004107|B-cell chronic lymphocytic leukemia
1510748|NCT00004107|B-cell adult acute lymphoblastic leukemia
1510749|NCT00004107|recurrent grade 1 follicular lymphoma
1510750|NCT00004107|recurrent grade 2 follicular lymphoma
1510751|NCT00004107|recurrent grade 3 follicular lymphoma
1510752|NCT00004107|recurrent adult diffuse small cleaved cell lymphoma
1510753|NCT00004107|recurrent adult diffuse mixed cell lymphoma
1510754|NCT00004107|recurrent adult diffuse large cell lymphoma
1510755|NCT00004107|recurrent adult immunoblastic large cell lymphoma
1510756|NCT00004107|recurrent adult lymphoblastic lymphoma
1510757|NCT00004107|recurrent adult Burkitt lymphoma
1510758|NCT00004107|recurrent mantle cell lymphoma
1510759|NCT00004107|recurrent marginal zone lymphoma
1510760|NCT00004107|recurrent small lymphocytic lymphoma
1510761|NCT00004107|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510762|NCT00004107|nodal marginal zone B-cell lymphoma
1510763|NCT00004107|splenic marginal zone lymphoma
1510764|NCT00004106|stage I cutaneous T-cell non-Hodgkin lymphoma
1510765|NCT00004106|stage II cutaneous T-cell non-Hodgkin lymphoma
1510766|NCT00004106|stage III cutaneous T-cell non-Hodgkin lymphoma
1510767|NCT00004106|stage IV cutaneous T-cell non-Hodgkin lymphoma
1510768|NCT00004106|recurrent cutaneous T-cell non-Hodgkin lymphoma
1510769|NCT00004106|stage I mycosis fungoides/Sezary syndrome
1510770|NCT00004106|stage II mycosis fungoides/Sezary syndrome
1510771|NCT00004106|stage III mycosis fungoides/Sezary syndrome
1510772|NCT00004106|stage IV mycosis fungoides/Sezary syndrome
1510773|NCT00004106|recurrent mycosis fungoides/Sezary syndrome
1510774|NCT00004105|stage III adult Hodgkin lymphoma
1510775|NCT00004105|stage IV adult Hodgkin lymphoma
1510776|NCT00004105|recurrent adult Hodgkin lymphoma
1510777|NCT00004105|stage III chronic lymphocytic leukemia
1510778|NCT00004105|stage IV chronic lymphocytic leukemia
1510779|NCT00004105|recurrent adult acute myeloid leukemia
1510780|NCT00004105|unspecified adult solid tumor, protocol specific
1510781|NCT00004105|childhood fibrosarcoma
1510782|NCT00004105|stage III grade 1 follicular lymphoma
1510783|NCT00004105|stage III grade 2 follicular lymphoma
1510784|NCT00004105|stage III grade 3 follicular lymphoma
1510785|NCT00004105|stage III adult diffuse small cleaved cell lymphoma
1510786|NCT00004105|stage III adult diffuse mixed cell lymphoma
1510787|NCT00004105|stage III adult diffuse large cell lymphoma
1510788|NCT00004105|stage III adult immunoblastic large cell lymphoma
1510789|NCT00004105|stage III adult lymphoblastic lymphoma
1510790|NCT00004105|stage III adult Burkitt lymphoma
1510791|NCT00004105|stage IV grade 1 follicular lymphoma
1510792|NCT00004105|stage IV grade 2 follicular lymphoma
1510793|NCT00004105|stage IV grade 3 follicular lymphoma
1510794|NCT00004105|stage IV adult diffuse small cleaved cell lymphoma
1510795|NCT00004105|stage IV adult diffuse mixed cell lymphoma
1510796|NCT00004105|stage IV adult diffuse large cell lymphoma
1510797|NCT00004105|stage IV adult immunoblastic large cell lymphoma
1510798|NCT00004105|stage IV adult lymphoblastic lymphoma
1510799|NCT00004105|stage IV adult Burkitt lymphoma
1510800|NCT00004105|recurrent grade 1 follicular lymphoma
1510801|NCT00004105|recurrent grade 2 follicular lymphoma
1510802|NCT00004105|recurrent grade 3 follicular lymphoma
1510803|NCT00004105|recurrent adult diffuse small cleaved cell lymphoma
1510804|NCT00004105|recurrent adult diffuse mixed cell lymphoma
1510805|NCT00004105|recurrent adult diffuse large cell lymphoma
1510806|NCT00004105|recurrent adult immunoblastic large cell lymphoma
1510807|NCT00004105|recurrent adult lymphoblastic lymphoma
1510808|NCT00004105|recurrent adult Burkitt lymphoma
1510809|NCT00004105|stage III adult T-cell leukemia/lymphoma
1510810|NCT00004105|stage IV adult T-cell leukemia/lymphoma
1510811|NCT00004105|recurrent adult T-cell leukemia/lymphoma
1510812|NCT00004105|stage III mantle cell lymphoma
1510813|NCT00004105|stage IV mantle cell lymphoma
1510814|NCT00004105|recurrent mantle cell lymphoma
1510815|NCT00004105|recurrent marginal zone lymphoma
1510816|NCT00004105|recurrent small lymphocytic lymphoma
1510817|NCT00004105|stage III small lymphocytic lymphoma
1510818|NCT00004105|stage III marginal zone lymphoma
1510819|NCT00004105|stage IV small lymphocytic lymphoma
1510820|NCT00004105|stage IV marginal zone lymphoma
1510821|NCT00004105|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510822|NCT00004105|nodal marginal zone B-cell lymphoma
1510823|NCT00004105|splenic marginal zone lymphoma
1510824|NCT00004104|stage III melanoma
1510825|NCT00004103|stage I gastric cancer
1510826|NCT00004103|stage II gastric cancer
1510827|NCT00004103|stage III gastric cancer
1510828|NCT00004103|stage IV gastric cancer
1510829|NCT00004102|stage IV colon cancer
1510830|NCT00004102|stage IV rectal cancer
1510831|NCT00004102|recurrent colon cancer
1510832|NCT00004102|recurrent rectal cancer
1510833|NCT00004102|adenocarcinoma of the colon
1510834|NCT00004102|adenocarcinoma of the rectum
1510835|NCT00004101|recurrent grade 1 follicular lymphoma
1510836|NCT00004101|recurrent grade 2 follicular lymphoma
1510837|NCT00004101|recurrent grade 3 follicular lymphoma
1510838|NCT00004101|recurrent adult diffuse small cleaved cell lymphoma
1510839|NCT00004101|recurrent adult diffuse mixed cell lymphoma
1510840|NCT00004101|recurrent adult diffuse large cell lymphoma
1510841|NCT00004101|recurrent adult immunoblastic large cell lymphoma
1510842|NCT00004101|recurrent adult lymphoblastic lymphoma
1510843|NCT00004101|recurrent adult Burkitt lymphoma
1510844|NCT00004101|recurrent mantle cell lymphoma
1510845|NCT00004101|recurrent marginal zone lymphoma
1510846|NCT00004101|recurrent small lymphocytic lymphoma
1510847|NCT00004101|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510848|NCT00004101|nodal marginal zone B-cell lymphoma
1510849|NCT00004101|splenic marginal zone lymphoma
1510850|NCT00004100|stage IIIB non-small cell lung cancer
1510851|NCT00004100|stage IV non-small cell lung cancer
1510852|NCT00004099|stage II gastric cancer
1510853|NCT00004099|stage III gastric cancer
1510854|NCT00004099|stage IV gastric cancer
1510855|NCT00004099|intestinal adenocarcinoma of the stomach
1510856|NCT00004099|diffuse adenocarcinoma of the stomach
1510857|NCT00004099|mixed adenocarcinoma of the stomach
1510858|NCT00004097|stage III nasopharyngeal cancer
1510859|NCT00004097|stage IV nasopharyngeal cancer
1510860|NCT00004097|recurrent nasopharyngeal cancer
1510861|NCT00004097|untreated metastatic squamous neck cancer with occult primary
1510862|NCT00004097|recurrent metastatic squamous neck cancer with occult primary
1510863|NCT00004097|stage III lip and oral cavity cancer
1510864|NCT00004097|stage IV lip and oral cavity cancer
1510865|NCT00004097|recurrent lip and oral cavity cancer
1510866|NCT00004097|stage III hypopharyngeal cancer
1510867|NCT00004097|stage IV hypopharyngeal cancer
1510868|NCT00004097|recurrent hypopharyngeal cancer
1510869|NCT00004097|stage III laryngeal cancer
1510870|NCT00004097|stage IV laryngeal cancer
1510871|NCT00004097|recurrent laryngeal cancer
1510872|NCT00004097|stage III paranasal sinus and nasal cavity cancer
1510873|NCT00004097|stage IV paranasal sinus and nasal cavity cancer
1510874|NCT00004097|recurrent paranasal sinus and nasal cavity cancer
1510875|NCT00004097|stage III oropharyngeal cancer
1510876|NCT00004097|stage IV oropharyngeal cancer
1510877|NCT00004097|recurrent oropharyngeal cancer
1510878|NCT00004096|stage IIIB non-small cell lung cancer
1510879|NCT00004096|stage IV non-small cell lung cancer
1510880|NCT00004095|stage IV colon cancer
1510881|NCT00004095|stage IV breast cancer
1510882|NCT00004095|recurrent breast cancer
1510883|NCT00004095|recurrent non-small cell lung cancer
1510884|NCT00004095|recurrent pancreatic cancer
1510885|NCT00004095|stage IV rectal cancer
1510886|NCT00004095|recurrent colon cancer
1510887|NCT00004095|recurrent rectal cancer
1510888|NCT00004095|stage IV renal cell cancer
1510889|NCT00004095|recurrent renal cell cancer
1510890|NCT00004095|extensive stage small cell lung cancer
1510891|NCT00004095|recurrent small cell lung cancer
1510892|NCT00004095|recurrent bladder cancer
1510893|NCT00004095|stage IV bladder cancer
1510894|NCT00004095|stage IV non-small cell lung cancer
1510895|NCT00004095|stage IV pancreatic cancer
1510896|NCT00004094|stage III squamous cell carcinoma of the lip and oral cavity
1510897|NCT00004094|stage IV squamous cell carcinoma of the lip and oral cavity
1510898|NCT00004094|stage IV squamous cell carcinoma of the oropharynx
1510899|NCT00004094|stage IV lymphoepithelioma of the oropharynx
1510900|NCT00004094|stage IV squamous cell carcinoma of the nasopharynx
1510901|NCT00004094|stage IV lymphoepithelioma of the nasopharynx
1510902|NCT00004094|stage III squamous cell carcinoma of the hypopharynx
1510903|NCT00004094|stage IV squamous cell carcinoma of the hypopharynx
1510904|NCT00004094|stage IV squamous cell carcinoma of the larynx
1510905|NCT00004093|stage IIIA non-small cell lung cancer
1510906|NCT00004093|stage IIIB non-small cell lung cancer
1510907|NCT00004092|stage II breast cancer
1510908|NCT00004092|stage IIIA breast cancer
1510909|NCT00004092|stage IIIB breast cancer
1510910|NCT00004091|cervical cancer
1510911|NCT00004090|unspecified adult solid tumor, protocol specific
1510912|NCT00004089|anaplastic thyroid cancer
1510913|NCT00004088|stage I multiple myeloma
1510914|NCT00004088|stage II multiple myeloma
1510915|NCT00004088|stage III multiple myeloma
1510916|NCT00004087|stage IV colon cancer
1510917|NCT00004087|stage IV pancreatic cancer
1510918|NCT00004087|recurrent pancreatic cancer
1510922|NCT00004086|Waldenstrom macroglobulinemia
1510923|NCT00004086|refractory chronic lymphocytic leukemia
1510924|NCT00004086|B-cell chronic lymphocytic leukemia
1510925|NCT00004086|refractory hairy cell leukemia
1510926|NCT00004086|recurrent grade 1 follicular lymphoma
1510927|NCT00004086|recurrent grade 2 follicular lymphoma
1510928|NCT00004086|recurrent grade 3 follicular lymphoma
1510929|NCT00004086|recurrent adult diffuse small cleaved cell lymphoma
1510930|NCT00004086|recurrent adult diffuse mixed cell lymphoma
1510931|NCT00004086|recurrent adult diffuse large cell lymphoma
1510932|NCT00004086|recurrent adult immunoblastic large cell lymphoma
1510933|NCT00004086|recurrent adult lymphoblastic lymphoma
1510934|NCT00004086|recurrent adult Burkitt lymphoma
1510935|NCT00004086|recurrent mantle cell lymphoma
1510936|NCT00004086|recurrent marginal zone lymphoma
1510937|NCT00004086|recurrent small lymphocytic lymphoma
1510938|NCT00004086|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1510939|NCT00004086|nodal marginal zone B-cell lymphoma
1510940|NCT00004086|splenic marginal zone lymphoma
1510941|NCT00004085|stage IV breast cancer
1510942|NCT00004085|recurrent breast cancer
1510943|NCT00004084|stage I chronic lymphocytic leukemia
1510944|NCT00004084|stage II chronic lymphocytic leukemia
1510945|NCT00004084|stage III chronic lymphocytic leukemia
1510946|NCT00004084|stage IV chronic lymphocytic leukemia
1510947|NCT00004084|refractory chronic lymphocytic leukemia
1510948|NCT00004084|stage I grade 1 follicular lymphoma
1510949|NCT00004084|stage I grade 2 follicular lymphoma
1510950|NCT00004084|stage I grade 3 follicular lymphoma
1510951|NCT00004084|stage I adult diffuse mixed cell lymphoma
1510952|NCT00004084|stage I adult diffuse large cell lymphoma
1510953|NCT00004084|stage I adult immunoblastic large cell lymphoma
1510954|NCT00004084|stage I adult lymphoblastic lymphoma
1510955|NCT00004084|stage I adult Burkitt lymphoma
1510956|NCT00004084|stage III grade 1 follicular lymphoma
1510957|NCT00004084|stage III grade 2 follicular lymphoma
1510958|NCT00004084|stage III grade 3 follicular lymphoma
1510959|NCT00004084|stage III adult diffuse small cleaved cell lymphoma
1510960|NCT00004084|stage III adult diffuse mixed cell lymphoma
1510961|NCT00004084|stage III adult diffuse large cell lymphoma
1510962|NCT00004084|stage III adult immunoblastic large cell lymphoma
1510963|NCT00004084|stage III adult lymphoblastic lymphoma
1510964|NCT00004084|stage III adult Burkitt lymphoma
1510965|NCT00004084|stage IV grade 1 follicular lymphoma
1510966|NCT00004084|stage IV grade 2 follicular lymphoma
1510967|NCT00004084|stage IV grade 3 follicular lymphoma
1510968|NCT00004084|stage IV adult diffuse small cleaved cell lymphoma
1510969|NCT00004084|stage IV adult diffuse mixed cell lymphoma
1510970|NCT00004084|stage IV adult diffuse large cell lymphoma
1510971|NCT00004084|stage IV adult immunoblastic large cell lymphoma
1510972|NCT00004084|stage IV adult lymphoblastic lymphoma
1510973|NCT00004084|stage IV adult Burkitt lymphoma
1510974|NCT00004084|recurrent grade 1 follicular lymphoma
1510975|NCT00004084|recurrent grade 2 follicular lymphoma
1510976|NCT00004084|recurrent grade 3 follicular lymphoma
1510977|NCT00004084|recurrent adult diffuse small cleaved cell lymphoma
1510978|NCT00004084|recurrent adult diffuse mixed cell lymphoma
1510979|NCT00004084|recurrent adult diffuse large cell lymphoma
1510980|NCT00004084|recurrent adult immunoblastic large cell lymphoma
1510981|NCT00004084|recurrent adult lymphoblastic lymphoma
1510982|NCT00004084|recurrent adult Burkitt lymphoma
1510983|NCT00004084|contiguous stage II grade 1 follicular lymphoma
1510984|NCT00004084|contiguous stage II grade 2 follicular lymphoma
1510985|NCT00004084|contiguous stage II grade 3 follicular lymphoma
1510986|NCT00004084|contiguous stage II adult diffuse small cleaved cell lymphoma
1510987|NCT00004084|contiguous stage II mantle cell lymphoma
1510988|NCT00004084|contiguous stage II adult diffuse mixed cell lymphoma
1510989|NCT00004084|contiguous stage II adult immunoblastic large cell lymphoma
1510990|NCT00004084|contiguous stage II adult diffuse large cell lymphoma
1510991|NCT00004084|contiguous stage II adult Burkitt lymphoma
1510992|NCT00004084|contiguous stage II adult lymphoblastic lymphoma
1510993|NCT00004084|noncontiguous stage II grade 1 follicular lymphoma
1510994|NCT00004084|noncontiguous stage II grade 2 follicular lymphoma
1510995|NCT00004084|noncontiguous stage II grade 3 follicular lymphoma
1510996|NCT00004084|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1510997|NCT00004084|noncontiguous stage II mantle cell lymphoma
1510998|NCT00004084|noncontiguous stage II adult diffuse mixed cell lymphoma
1510999|NCT00004084|noncontiguous stage II adult immunoblastic large cell lymphoma
1511000|NCT00004084|noncontiguous stage II adult diffuse large cell lymphoma
1511001|NCT00004084|noncontiguous stage II adult Burkitt lymphoma
1511002|NCT00004084|noncontiguous stage II adult lymphoblastic lymphoma
1511003|NCT00004084|stage III mantle cell lymphoma
1511004|NCT00004084|stage IV mantle cell lymphoma
1511005|NCT00004084|recurrent mantle cell lymphoma
1511006|NCT00004084|contiguous stage II marginal zone lymphoma
1511007|NCT00004084|contiguous stage II small lymphocytic lymphoma
1511008|NCT00004084|noncontiguous stage II small lymphocytic lymphoma
1511009|NCT00004084|noncontiguous stage II marginal zone lymphoma
1511010|NCT00004084|recurrent marginal zone lymphoma
1511011|NCT00004084|recurrent small lymphocytic lymphoma
1511012|NCT00004084|stage I marginal zone lymphoma
1511013|NCT00004084|stage I small lymphocytic lymphoma
1511014|NCT00004084|stage III small lymphocytic lymphoma
1511015|NCT00004084|stage III marginal zone lymphoma
1511016|NCT00004084|stage IV small lymphocytic lymphoma
1511017|NCT00004084|stage IV marginal zone lymphoma
1511018|NCT00004084|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511019|NCT00004084|nodal marginal zone B-cell lymphoma
1511020|NCT00004084|splenic marginal zone lymphoma
1511021|NCT00004083|stage IV ovarian epithelial cancer
1511022|NCT00004083|recurrent ovarian epithelial cancer
1511023|NCT00004082|stage III ovarian epithelial cancer
1511024|NCT00004082|stage IV ovarian epithelial cancer
1511025|NCT00004082|stage III endometrial carcinoma
1511026|NCT00004082|stage IV endometrial carcinoma
1511027|NCT00004082|endometrial adenocarcinoma
1511028|NCT00004082|fallopian tube cancer
1511029|NCT00004082|primary peritoneal cavity cancer
1511030|NCT00004081|recurrent ovarian epithelial cancer
1511031|NCT00004081|peritoneal cavity cancer
1511032|NCT00004080|recurrent adult brain tumor
1511033|NCT00004080|adult glioblastoma
1511034|NCT00004080|adult anaplastic astrocytoma
1511035|NCT00004080|adult mixed glioma
1511036|NCT00004080|adult giant cell glioblastoma
1511037|NCT00004080|adult gliosarcoma
1511038|NCT00004077|stage III malignant testicular germ cell tumor
1511039|NCT00004077|recurrent malignant testicular germ cell tumor
1511040|NCT00004077|testicular embryonal carcinoma
1511041|NCT00004077|testicular choriocarcinoma
1511042|NCT00004077|testicular teratoma
1511043|NCT00004077|testicular yolk sac tumor
1511044|NCT00004077|testicular embryonal carcinoma and teratoma
1511045|NCT00004077|testicular embryonal carcinoma and yolk sac tumor
1511046|NCT00004077|testicular yolk sac tumor and teratoma
1511047|NCT00004077|testicular choriocarcinoma and yolk sac tumor
1511048|NCT00004077|testicular choriocarcinoma and embryonal carcinoma
1511049|NCT00004077|testicular choriocarcinoma and teratoma
1511050|NCT00004076|unspecified adult solid tumor, protocol specific
1511051|NCT00004075|unspecified adult solid tumor, protocol specific
1511052|NCT00004075|recurrent adult Burkitt lymphoma
1511053|NCT00004075|recurrent adult diffuse large cell lymphoma
1511054|NCT00004075|recurrent adult diffuse mixed cell lymphoma
1511055|NCT00004075|recurrent adult diffuse small cleaved cell lymphoma
1511056|NCT00004075|recurrent adult Hodgkin lymphoma
1511057|NCT00004075|recurrent adult immunoblastic large cell lymphoma
1511058|NCT00004075|recurrent adult lymphoblastic lymphoma
1511059|NCT00004075|recurrent grade 1 follicular lymphoma
1511060|NCT00004075|recurrent grade 2 follicular lymphoma
1511061|NCT00004075|recurrent grade 3 follicular lymphoma
1511062|NCT00004075|recurrent mantle cell lymphoma
1511063|NCT00004075|recurrent adult T-cell leukemia/lymphoma
1511064|NCT00004075|recurrent cutaneous T-cell non-Hodgkin lymphoma
1511065|NCT00004075|recurrent mycosis fungoides/Sezary syndrome
1511066|NCT00004075|recurrent adult grade III lymphomatoid granulomatosis
1511067|NCT00004075|recurrent marginal zone lymphoma
1511068|NCT00004075|recurrent small lymphocytic lymphoma
1511069|NCT00004075|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511070|NCT00004075|nodal marginal zone B-cell lymphoma
1511071|NCT00004075|splenic marginal zone lymphoma
1511072|NCT00004073|adult glioblastoma
1511073|NCT00004073|adult giant cell glioblastoma
1511074|NCT00004073|adult gliosarcoma
1511075|NCT00004072|refractory multiple myeloma
1511076|NCT00004072|stage I multiple myeloma
1511077|NCT00004072|stage II multiple myeloma
1511078|NCT00004072|stage III multiple myeloma
1511079|NCT00004071|stage IV prostate cancer
1511080|NCT00004071|recurrent prostate cancer
1511081|NCT00004070|recurrent metastatic squamous neck cancer with occult primary
1511082|NCT00004070|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1512510|NCT00003887|ovarian polyembryoma
1511083|NCT00004070|stage III squamous cell carcinoma of the lip and oral cavity
1511084|NCT00004070|stage IV squamous cell carcinoma of the lip and oral cavity
1511085|NCT00004070|recurrent squamous cell carcinoma of the lip and oral cavity
1511086|NCT00004070|stage III squamous cell carcinoma of the oropharynx
1511087|NCT00004070|stage IV squamous cell carcinoma of the oropharynx
1511088|NCT00004070|recurrent squamous cell carcinoma of the oropharynx
1511089|NCT00004070|stage III squamous cell carcinoma of the nasopharynx
1511090|NCT00004070|stage IV squamous cell carcinoma of the nasopharynx
1511091|NCT00004070|recurrent squamous cell carcinoma of the nasopharynx
1511092|NCT00004070|stage III squamous cell carcinoma of the hypopharynx
1511093|NCT00004070|stage IV squamous cell carcinoma of the hypopharynx
1511094|NCT00004070|recurrent squamous cell carcinoma of the hypopharynx
1511095|NCT00004070|stage III squamous cell carcinoma of the larynx
1511096|NCT00004070|stage IV squamous cell carcinoma of the larynx
1511097|NCT00004070|recurrent squamous cell carcinoma of the larynx
1511098|NCT00004070|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1511099|NCT00004070|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1511100|NCT00004070|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1511101|NCT00004068|childhood high-grade cerebral astrocytoma
1511102|NCT00004068|childhood high-grade cerebellar astrocytoma
1511103|NCT00004068|childhood oligodendroglioma
1511104|NCT00004068|untreated childhood brain stem glioma
1511105|NCT00004068|untreated childhood cerebellar astrocytoma
1511106|NCT00004067|stage II breast cancer
1511107|NCT00004067|stage IIIA breast cancer
1511108|NCT00004066|adult leiomyosarcoma
1511109|NCT00004066|recurrent adult soft tissue sarcoma
1511110|NCT00004066|small intestine leiomyosarcoma
1511111|NCT00004066|stage IV uterine sarcoma
1511112|NCT00004066|recurrent uterine sarcoma
1511113|NCT00004066|uterine leiomyosarcoma
1511114|NCT00004066|ovarian sarcoma
1511115|NCT00004066|recurrent small intestine cancer
1511116|NCT00004066|stage IV adult soft tissue sarcoma
1511117|NCT00004065|stage III colon cancer
1511118|NCT00004065|stage IV colon cancer
1511119|NCT00004065|stage IV breast cancer
1511120|NCT00004065|stage IIIA breast cancer
1511121|NCT00004065|recurrent breast cancer
1511122|NCT00004065|stage III gastric cancer
1511123|NCT00004065|stage IV gastric cancer
1511124|NCT00004065|recurrent gastric cancer
1511125|NCT00004065|stage IIIB breast cancer
1511126|NCT00004065|stage IIIC breast cancer
1511127|NCT00004065|recurrent non-small cell lung cancer
1511128|NCT00004065|recurrent colon cancer
1511129|NCT00004065|stage III renal cell cancer
1511130|NCT00004065|stage IV renal cell cancer
1511131|NCT00004065|recurrent renal cell cancer
1511132|NCT00004065|stage III ovarian epithelial cancer
1511133|NCT00004065|stage IV ovarian epithelial cancer
1511134|NCT00004065|recurrent ovarian epithelial cancer
1511135|NCT00004065|recurrent adult acute lymphoblastic leukemia
1511136|NCT00004065|relapsing chronic myelogenous leukemia
1511137|NCT00004065|stage III bladder cancer
1511138|NCT00004065|recurrent bladder cancer
1511139|NCT00004065|stage IV bladder cancer
1511140|NCT00004065|stage III prostate cancer
1511141|NCT00004065|stage IV prostate cancer
1511142|NCT00004065|recurrent prostate cancer
1511143|NCT00004065|stage III melanoma
1511144|NCT00004065|stage IV melanoma
1511145|NCT00004065|recurrent melanoma
1511146|NCT00004065|stage IIIA non-small cell lung cancer
1511147|NCT00004065|stage IIIB non-small cell lung cancer
1511148|NCT00004065|stage IV non-small cell lung cancer
1511149|NCT00004065|unspecified adult solid tumor, protocol specific
1511150|NCT00004065|chronic phase chronic myelogenous leukemia
1511151|NCT00004065|accelerated phase chronic myelogenous leukemia
1511152|NCT00004065|blastic phase chronic myelogenous leukemia
1511153|NCT00004065|untreated metastatic squamous neck cancer with occult primary
1511154|NCT00004065|recurrent metastatic squamous neck cancer with occult primary
1511155|NCT00004065|ovarian stromal cancer
1511156|NCT00004065|stage III ovarian germ cell tumor
1511157|NCT00004065|stage IV ovarian germ cell tumor
1511158|NCT00004065|recurrent ovarian germ cell tumor
1511159|NCT00004065|stage III squamous cell carcinoma of the lip and oral cavity
1511160|NCT00004065|stage III basal cell carcinoma of the lip
1511161|NCT00004065|stage III mucoepidermoid carcinoma of the oral cavity
1511162|NCT00004065|stage III adenoid cystic carcinoma of the oral cavity
1511163|NCT00004065|stage IV squamous cell carcinoma of the lip and oral cavity
1511164|NCT00004065|stage IV basal cell carcinoma of the lip
1511165|NCT00004065|stage IV verrucous carcinoma of the oral cavity
1511166|NCT00004065|stage IV mucoepidermoid carcinoma of the oral cavity
1511167|NCT00004065|stage IV adenoid cystic carcinoma of the oral cavity
1511168|NCT00004065|recurrent squamous cell carcinoma of the lip and oral cavity
1511169|NCT00004065|recurrent basal cell carcinoma of the lip
1511170|NCT00004065|recurrent verrucous carcinoma of the oral cavity
1511171|NCT00004065|recurrent mucoepidermoid carcinoma of the oral cavity
1511172|NCT00004065|recurrent adenoid cystic carcinoma of the oral cavity
1511173|NCT00004065|stage III squamous cell carcinoma of the oropharynx
1511174|NCT00004065|stage III lymphoepithelioma of the oropharynx
1511175|NCT00004065|stage IV squamous cell carcinoma of the oropharynx
1511176|NCT00004065|stage IV lymphoepithelioma of the oropharynx
1511177|NCT00004065|recurrent squamous cell carcinoma of the oropharynx
1511178|NCT00004065|recurrent lymphoepithelioma of the oropharynx
1511179|NCT00004065|stage III squamous cell carcinoma of the nasopharynx
1511180|NCT00004065|stage III lymphoepithelioma of the nasopharynx
1511181|NCT00004065|stage IV squamous cell carcinoma of the nasopharynx
1511182|NCT00004065|stage IV lymphoepithelioma of the nasopharynx
1511183|NCT00004065|recurrent squamous cell carcinoma of the nasopharynx
1511184|NCT00004065|recurrent lymphoepithelioma of the nasopharynx
1511185|NCT00004065|stage III squamous cell carcinoma of the hypopharynx
1511186|NCT00004065|stage IV squamous cell carcinoma of the hypopharynx
1511187|NCT00004065|recurrent squamous cell carcinoma of the hypopharynx
1511188|NCT00004065|stage III squamous cell carcinoma of the larynx
1511189|NCT00004065|stage III verrucous carcinoma of the larynx
1511190|NCT00004065|stage IV squamous cell carcinoma of the larynx
1511191|NCT00004065|stage IV verrucous carcinoma of the larynx
1511192|NCT00004065|recurrent squamous cell carcinoma of the larynx
1511193|NCT00004065|recurrent verrucous carcinoma of the larynx
1511194|NCT00004065|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1511195|NCT00004065|stage III inverted papilloma of the paranasal sinus and nasal cavity
1511196|NCT00004065|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1513384|NCT00003782|stage II breast cancer
1511197|NCT00004065|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1511198|NCT00004065|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1511199|NCT00004065|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1511200|NCT00004065|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1511201|NCT00004065|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1511202|NCT00004065|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1511203|NCT00004065|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1511204|NCT00004065|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1511205|NCT00004065|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1511206|NCT00004065|borderline ovarian surface epithelial-stromal tumor
1511207|NCT00004065|ovarian sarcoma
1511208|NCT00004065|stage III verrucous carcinoma of the oral cavity
1511209|NCT00004065|recurrent salivary gland cancer
1511210|NCT00004065|stage IV salivary gland cancer
1511211|NCT00004065|stage III salivary gland cancer
1511212|NCT00004064|stage I ovarian epithelial cancer
1511213|NCT00004064|stage II ovarian epithelial cancer
1511214|NCT00004064|stage III ovarian epithelial cancer
1511215|NCT00004064|stage IV ovarian epithelial cancer
1511216|NCT00004064|fallopian tube cancer
1511217|NCT00004064|primary peritoneal cavity cancer
1511218|NCT00004063|unspecified adult solid tumor, protocol specific
1511219|NCT00004062|stage IV papillary thyroid cancer
1511220|NCT00004062|stage IV follicular thyroid cancer
1511221|NCT00004062|recurrent thyroid cancer
1511222|NCT00004061|stage I adult Hodgkin lymphoma
1511223|NCT00004061|stage II adult Hodgkin lymphoma
1511224|NCT00004061|stage III adult Hodgkin lymphoma
1511225|NCT00004061|stage IV adult Hodgkin lymphoma
1511226|NCT00004061|recurrent adult Hodgkin lymphoma
1511227|NCT00004061|stage 0 chronic lymphocytic leukemia
1511228|NCT00004061|stage I chronic lymphocytic leukemia
1511229|NCT00004061|stage II chronic lymphocytic leukemia
1511230|NCT00004061|stage III chronic lymphocytic leukemia
1511231|NCT00004061|stage IV chronic lymphocytic leukemia
1511232|NCT00004061|recurrent adult acute myeloid leukemia
1511233|NCT00004061|recurrent adult acute lymphoblastic leukemia
1511234|NCT00004061|relapsing chronic myelogenous leukemia
1511235|NCT00004061|refractory chronic lymphocytic leukemia
1511236|NCT00004061|chronic phase chronic myelogenous leukemia
1511237|NCT00004061|accelerated phase chronic myelogenous leukemia
1511238|NCT00004061|blastic phase chronic myelogenous leukemia
1511239|NCT00004061|meningeal chronic myelogenous leukemia
1511240|NCT00004061|untreated adult acute lymphoblastic leukemia
1511241|NCT00004061|untreated adult acute myeloid leukemia
1511242|NCT00004061|adult acute myeloid leukemia in remission
1511243|NCT00004061|adult acute lymphoblastic leukemia in remission
1511244|NCT00004061|oral complications
1511245|NCT00004061|stage I grade 1 follicular lymphoma
1511246|NCT00004061|stage I grade 2 follicular lymphoma
1511247|NCT00004061|stage I grade 3 follicular lymphoma
1511248|NCT00004061|stage I adult diffuse small cleaved cell lymphoma
1511249|NCT00004061|stage I adult diffuse mixed cell lymphoma
1511250|NCT00004061|stage I adult diffuse large cell lymphoma
1511251|NCT00004061|stage I adult immunoblastic large cell lymphoma
1511252|NCT00004061|stage I adult lymphoblastic lymphoma
1511253|NCT00004061|stage I adult Burkitt lymphoma
1511254|NCT00004061|stage III grade 1 follicular lymphoma
1511255|NCT00004061|stage III grade 2 follicular lymphoma
1511256|NCT00004061|stage III grade 3 follicular lymphoma
1511257|NCT00004061|stage III adult diffuse small cleaved cell lymphoma
1511258|NCT00004061|stage III adult diffuse mixed cell lymphoma
1511259|NCT00004061|stage III adult diffuse large cell lymphoma
1511260|NCT00004061|stage III adult immunoblastic large cell lymphoma
1511261|NCT00004061|stage III adult lymphoblastic lymphoma
1511262|NCT00004061|stage III adult Burkitt lymphoma
1511263|NCT00004061|stage IV grade 1 follicular lymphoma
1512511|NCT00003887|ovarian choriocarcinoma
1511264|NCT00004061|stage IV grade 2 follicular lymphoma
1511265|NCT00004061|stage IV grade 3 follicular lymphoma
1511266|NCT00004061|stage IV adult diffuse small cleaved cell lymphoma
1511267|NCT00004061|stage IV adult diffuse mixed cell lymphoma
1511268|NCT00004061|stage IV adult diffuse large cell lymphoma
1511269|NCT00004061|stage IV adult immunoblastic large cell lymphoma
1511270|NCT00004061|stage IV adult lymphoblastic lymphoma
1511271|NCT00004061|stage IV adult Burkitt lymphoma
1511272|NCT00004061|recurrent grade 1 follicular lymphoma
1511273|NCT00004061|recurrent grade 2 follicular lymphoma
1511274|NCT00004061|recurrent grade 3 follicular lymphoma
1511275|NCT00004061|recurrent adult diffuse small cleaved cell lymphoma
1511276|NCT00004061|recurrent adult diffuse mixed cell lymphoma
1511277|NCT00004061|recurrent adult diffuse large cell lymphoma
1511278|NCT00004061|recurrent adult immunoblastic large cell lymphoma
1511279|NCT00004061|recurrent adult lymphoblastic lymphoma
1511280|NCT00004061|recurrent adult Burkitt lymphoma
1511281|NCT00004061|secondary acute myeloid leukemia
1511282|NCT00004061|stage I mantle cell lymphoma
1511283|NCT00004061|contiguous stage II grade 1 follicular lymphoma
1511284|NCT00004061|contiguous stage II grade 2 follicular lymphoma
1511285|NCT00004061|contiguous stage II grade 3 follicular lymphoma
1511286|NCT00004061|contiguous stage II adult diffuse small cleaved cell lymphoma
1511287|NCT00004061|contiguous stage II mantle cell lymphoma
1511288|NCT00004061|contiguous stage II adult diffuse mixed cell lymphoma
1511289|NCT00004061|contiguous stage II adult immunoblastic large cell lymphoma
1511290|NCT00004061|contiguous stage II adult diffuse large cell lymphoma
1511291|NCT00004061|contiguous stage II adult Burkitt lymphoma
1511292|NCT00004061|contiguous stage II adult lymphoblastic lymphoma
1511293|NCT00004061|noncontiguous stage II grade 1 follicular lymphoma
1511294|NCT00004061|noncontiguous stage II grade 2 follicular lymphoma
1511295|NCT00004061|noncontiguous stage II grade 3 follicular lymphoma
1511296|NCT00004061|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1511297|NCT00004061|noncontiguous stage II mantle cell lymphoma
1511298|NCT00004061|noncontiguous stage II adult diffuse mixed cell lymphoma
1511299|NCT00004061|noncontiguous stage II adult immunoblastic large cell lymphoma
1511300|NCT00004061|noncontiguous stage II adult diffuse large cell lymphoma
1511301|NCT00004061|noncontiguous stage II adult Burkitt lymphoma
1511302|NCT00004061|noncontiguous stage II adult lymphoblastic lymphoma
1511303|NCT00004061|stage III mantle cell lymphoma
1511304|NCT00004061|stage IV mantle cell lymphoma
1511305|NCT00004061|recurrent mantle cell lymphoma
1511306|NCT00004061|noncontiguous stage II small lymphocytic lymphoma
1511307|NCT00004061|noncontiguous stage II marginal zone lymphoma
1511308|NCT00004061|recurrent marginal zone lymphoma
1511309|NCT00004061|recurrent small lymphocytic lymphoma
1511310|NCT00004061|stage I marginal zone lymphoma
1511311|NCT00004061|stage I small lymphocytic lymphoma
1511312|NCT00004061|stage III small lymphocytic lymphoma
1511313|NCT00004061|stage III marginal zone lymphoma
1511314|NCT00004061|stage IV small lymphocytic lymphoma
1511315|NCT00004061|stage IV marginal zone lymphoma
1511316|NCT00004061|contiguous stage II marginal zone lymphoma
1511317|NCT00004061|contiguous stage II small lymphocytic lymphoma
1511318|NCT00004061|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511319|NCT00004061|nodal marginal zone B-cell lymphoma
1511320|NCT00004061|splenic marginal zone lymphoma
1511321|NCT00004060|stage III ovarian epithelial cancer
1511322|NCT00004060|stage IV ovarian epithelial cancer
1511323|NCT00004060|recurrent ovarian epithelial cancer
1511324|NCT00004060|fallopian tube cancer
1511325|NCT00004060|primary peritoneal cavity cancer
1511326|NCT00004059|unspecified adult solid tumor, protocol specific
1511327|NCT00004058|monoclonal gammopathy of undetermined significance
1511328|NCT00004058|recurrent adult Hodgkin lymphoma
1511329|NCT00004058|recurrent cutaneous T-cell non-Hodgkin lymphoma
1511330|NCT00004058|isolated plasmacytoma of bone
1511331|NCT00004058|extramedullary plasmacytoma
1511332|NCT00004058|refractory multiple myeloma
1511333|NCT00004058|Waldenstrom macroglobulinemia
1511334|NCT00004058|recurrent adult acute myeloid leukemia
1511335|NCT00004058|recurrent adult acute lymphoblastic leukemia
1511336|NCT00004058|relapsing chronic myelogenous leukemia
1511337|NCT00004058|refractory chronic lymphocytic leukemia
1511338|NCT00004058|polycythemia vera
1511339|NCT00004058|chronic idiopathic myelofibrosis
1511340|NCT00004058|essential thrombocythemia
1511341|NCT00004058|refractory hairy cell leukemia
1511342|NCT00004058|refractory anemia
1511343|NCT00004058|refractory anemia with ringed sideroblasts
1511344|NCT00004058|refractory anemia with excess blasts
1511345|NCT00004058|refractory anemia with excess blasts in transformation
1511346|NCT00004058|chronic myelomonocytic leukemia
1511347|NCT00004058|T-cell large granular lymphocyte leukemia
1511348|NCT00004058|acute undifferentiated leukemia
1511349|NCT00004058|recurrent grade 1 follicular lymphoma
1511350|NCT00004058|recurrent grade 2 follicular lymphoma
1511351|NCT00004058|recurrent grade 3 follicular lymphoma
1511352|NCT00004058|recurrent adult diffuse small cleaved cell lymphoma
1511353|NCT00004058|recurrent adult diffuse mixed cell lymphoma
1511354|NCT00004058|recurrent adult diffuse large cell lymphoma
1512986|NCT00003833|stage II colon cancer
1511355|NCT00004058|recurrent adult immunoblastic large cell lymphoma
1511356|NCT00004058|recurrent adult lymphoblastic lymphoma
1511357|NCT00004058|recurrent adult Burkitt lymphoma
1511358|NCT00004058|recurrent adult T-cell leukemia/lymphoma
1511359|NCT00004058|secondary acute myeloid leukemia
1511360|NCT00004058|previously treated myelodysplastic syndromes
1511361|NCT00004058|secondary myelodysplastic syndromes
1511362|NCT00004058|primary central nervous system lymphoma
1511363|NCT00004058|prolymphocytic leukemia
1511364|NCT00004058|primary systemic amyloidosis
1511365|NCT00004058|recurrent mantle cell lymphoma
1511366|NCT00004058|angioimmunoblastic T-cell lymphoma
1511367|NCT00004058|anaplastic large cell lymphoma
1511368|NCT00004058|refractory cytopenia with multilineage dysplasia
1511369|NCT00004058|recurrent mycosis fungoides/Sezary syndrome
1511370|NCT00004058|chronic eosinophilic leukemia
1511371|NCT00004058|chronic neutrophilic leukemia
1511372|NCT00004058|atypical chronic myeloid leukemia
1511373|NCT00004058|myelodysplastic/myeloproliferative disease, unclassifiable
1511374|NCT00004058|adult acute myeloid leukemia with t(8;21)(q22;q22)
1511375|NCT00004058|adult acute myeloid leukemia with t(16;16)(p13;q22)
1511376|NCT00004058|adult acute myeloid leukemia with inv(16)(p13;q22)
1511377|NCT00004058|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1511378|NCT00004058|adult acute myeloid leukemia with t(15;17)(q22;q12)
1511379|NCT00004057|recurrent adult Hodgkin lymphoma
1511380|NCT00004057|unspecified adult solid tumor, protocol specific
1511381|NCT00004057|recurrent grade 1 follicular lymphoma
1511382|NCT00004057|recurrent grade 2 follicular lymphoma
1511383|NCT00004057|recurrent grade 3 follicular lymphoma
1511384|NCT00004057|recurrent adult diffuse small cleaved cell lymphoma
1511385|NCT00004057|recurrent adult diffuse mixed cell lymphoma
1511386|NCT00004057|recurrent adult diffuse large cell lymphoma
1511387|NCT00004057|recurrent adult immunoblastic large cell lymphoma
1511388|NCT00004057|recurrent adult lymphoblastic lymphoma
1511389|NCT00004057|recurrent adult Burkitt lymphoma
1511390|NCT00004057|recurrent adult T-cell leukemia/lymphoma
1511391|NCT00004057|recurrent mantle cell lymphoma
1511392|NCT00004057|angioimmunoblastic T-cell lymphoma
1511393|NCT00004057|anaplastic large cell lymphoma
1511394|NCT00004057|recurrent marginal zone lymphoma
1511395|NCT00004057|recurrent small lymphocytic lymphoma
1511396|NCT00004057|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511397|NCT00004057|nodal marginal zone B-cell lymphoma
1511398|NCT00004057|splenic marginal zone lymphoma
1511399|NCT00004056|untreated childhood acute myeloid leukemia and other myeloid malignancies
1511400|NCT00004056|childhood acute monoblastic leukemia and acute monocytic leukemia (M5)
1511401|NCT00004056|childhood acute myeloblastic leukemia without maturation (M1)
1511402|NCT00004056|childhood acute myeloblastic leukemia with maturation (M2)
1511403|NCT00004056|childhood acute myelomonocytic leukemia (M4)
1511404|NCT00004056|childhood acute erythroleukemia (M6)
1511405|NCT00004056|childhood acute megakaryocytic leukemia (M7)
1511406|NCT00004056|childhood acute minimally differentiated myeloid leukemia (M0)
1511407|NCT00004055|extensive stage small cell lung cancer
1511408|NCT00004054|stage IIB prostate cancer
1511409|NCT00004054|stage IIA prostate cancer
1511410|NCT00004054|stage III prostate cancer
1511411|NCT00004054|stage IV prostate cancer
1511412|NCT00004052|relapsing chronic myelogenous leukemia
1511413|NCT00004052|chronic phase chronic myelogenous leukemia
1511414|NCT00004051|unspecified adult solid tumor, protocol specific
1511415|NCT00004050|stage IIB prostate cancer
1511416|NCT00004050|stage IIA prostate cancer
1511417|NCT00004050|stage III prostate cancer
1511418|NCT00004049|unspecified adult solid tumor, protocol specific
1511419|NCT00004048|thyroid gland medullary carcinoma
1511420|NCT00004047|recurrent childhood acute lymphoblastic leukemia
1511421|NCT00004047|recurrent childhood acute myeloid leukemia
1511422|NCT00004047|recurrent adult acute myeloid leukemia
1511423|NCT00004047|recurrent adult acute lymphoblastic leukemia
1511424|NCT00004047|relapsing chronic myelogenous leukemia
1511425|NCT00004047|refractory chronic lymphocytic leukemia
1511426|NCT00004047|blastic phase chronic myelogenous leukemia
1511427|NCT00004047|refractory anemia with excess blasts
1511428|NCT00004047|refractory anemia with excess blasts in transformation
1511429|NCT00004047|chronic myelomonocytic leukemia
1511430|NCT00004047|childhood myelodysplastic syndromes
1511431|NCT00004046|stage IV breast cancer
1511432|NCT00004046|recurrent breast cancer
1511433|NCT00004045|stage IV prostate cancer
1511434|NCT00004045|recurrent prostate cancer
1511435|NCT00004043|adenocarcinoma of the prostate
1511436|NCT00004043|recurrent prostate cancer
1511437|NCT00004042|stage III colon cancer
1511438|NCT00004042|stage IV colon cancer
1511439|NCT00004042|stage III rectal cancer
1511440|NCT00004042|stage IV rectal cancer
1511441|NCT00004042|recurrent colon cancer
1511442|NCT00004042|recurrent rectal cancer
1511443|NCT00004041|recurrent adult brain tumor
1511444|NCT00004041|adult glioblastoma
1511445|NCT00004041|adult anaplastic astrocytoma
1511446|NCT00004041|adult anaplastic oligodendroglioma
1511447|NCT00004041|adult mixed glioma
1511448|NCT00004041|adult giant cell glioblastoma
1511449|NCT00004041|adult gliosarcoma
1511450|NCT00004040|stage I multiple myeloma
1511451|NCT00004040|stage II multiple myeloma
1511452|NCT00004040|stage III multiple myeloma
1511453|NCT00004040|stage I chronic lymphocytic leukemia
1511454|NCT00004040|stage II chronic lymphocytic leukemia
1511455|NCT00004040|stage III chronic lymphocytic leukemia
1511456|NCT00004040|stage IV chronic lymphocytic leukemia
1511457|NCT00004040|B-cell chronic lymphocytic leukemia
1511458|NCT00004039|Waldenstrom macroglobulinemia
1511459|NCT00004039|stage II grade 3 follicular lymphoma
1511460|NCT00004039|stage II adult diffuse small cleaved cell lymphoma
1511461|NCT00004039|stage II adult diffuse mixed cell lymphoma
1511462|NCT00004039|stage II adult diffuse large cell lymphoma
1511463|NCT00004039|stage II adult immunoblastic large cell lymphoma
1511464|NCT00004039|stage II adult Burkitt lymphoma
1511465|NCT00004039|stage III grade 1 follicular lymphoma
1511466|NCT00004039|stage III grade 2 follicular lymphoma
1511467|NCT00004039|stage III grade 3 follicular lymphoma
1511468|NCT00004039|stage III adult diffuse small cleaved cell lymphoma
1511469|NCT00004039|stage III adult diffuse mixed cell lymphoma
1511470|NCT00004039|stage III adult diffuse large cell lymphoma
1511471|NCT00004039|stage III adult immunoblastic large cell lymphoma
1511472|NCT00004039|stage III adult Burkitt lymphoma
1513685|NCT00003704|stage III vulvar cancer
1511473|NCT00004039|stage IV grade 1 follicular lymphoma
1511474|NCT00004039|stage IV grade 2 follicular lymphoma
1511475|NCT00004039|stage IV grade 3 follicular lymphoma
1511476|NCT00004039|stage IV adult diffuse small cleaved cell lymphoma
1511477|NCT00004039|stage IV adult diffuse mixed cell lymphoma
1511478|NCT00004039|stage IV adult diffuse large cell lymphoma
1511479|NCT00004039|stage IV adult immunoblastic large cell lymphoma
1511480|NCT00004039|stage IV adult Burkitt lymphoma
1511481|NCT00004039|stage III mantle cell lymphoma
1511482|NCT00004039|stage IV mantle cell lymphoma
1511483|NCT00004038|stage I breast cancer
1511484|NCT00004038|stage II breast cancer
1511485|NCT00004038|stage IV breast cancer
1511486|NCT00004038|stage IIIA breast cancer
1511487|NCT00004038|recurrent breast cancer
1511488|NCT00004038|stage IIIB breast cancer
1511489|NCT00004037|stage IV ovarian epithelial cancer
1511490|NCT00004037|recurrent ovarian epithelial cancer
1511491|NCT00004037|primary peritoneal cavity cancer
1511492|NCT00004036|stage III adult Hodgkin lymphoma
1511493|NCT00004036|stage IV adult Hodgkin lymphoma
1511494|NCT00004036|monoclonal gammopathy of undetermined significance
1511495|NCT00004036|recurrent adult Hodgkin lymphoma
1511496|NCT00004036|isolated plasmacytoma of bone
1511497|NCT00004036|extramedullary plasmacytoma
1511498|NCT00004036|refractory multiple myeloma
1511499|NCT00004036|Waldenström macroglobulinemia
1511500|NCT00004036|stage III multiple myeloma
1511501|NCT00004036|stage III chronic lymphocytic leukemia
1511502|NCT00004036|stage IV chronic lymphocytic leukemia
1511503|NCT00004036|recurrent adult acute myeloid leukemia
1511504|NCT00004036|recurrent adult acute lymphoblastic leukemia
1511505|NCT00004036|relapsing chronic myelogenous leukemia
1511506|NCT00004036|refractory chronic lymphocytic leukemia
1511507|NCT00004036|unspecified adult solid tumor, protocol specific
1511508|NCT00004036|chronic phase chronic myelogenous leukemia
1511509|NCT00004036|accelerated phase chronic myelogenous leukemia
1511510|NCT00004036|blastic phase chronic myelogenous leukemia
1511511|NCT00004036|meningeal chronic myelogenous leukemia
1511512|NCT00004036|untreated adult acute lymphoblastic leukemia
1511513|NCT00004036|untreated adult acute myeloid leukemia
1511514|NCT00004036|adult acute myeloid leukemia in remission
1511515|NCT00004036|adult acute lymphoblastic leukemia in remission
1511516|NCT00004036|polycythemia vera
1511517|NCT00004036|primary myelofibrosis
1511518|NCT00004036|essential thrombocythemia
1511519|NCT00004036|untreated hairy cell leukemia
1511520|NCT00004036|progressive hairy cell leukemia, initial treatment
1511521|NCT00004036|refractory hairy cell leukemia
1511522|NCT00004036|chronic myelomonocytic leukemia
1511523|NCT00004036|T-cell large granular lymphocyte leukemia
1511524|NCT00004036|acute undifferentiated leukemia
1511525|NCT00004036|stage III grade 1 follicular lymphoma
1511526|NCT00004036|stage III grade 2 follicular lymphoma
1511527|NCT00004036|stage III grade 3 follicular lymphoma
1511528|NCT00004036|stage III adult diffuse small cleaved cell lymphoma
1511529|NCT00004036|stage III adult diffuse mixed cell lymphoma
1511530|NCT00004036|stage III adult diffuse large cell lymphoma
1511531|NCT00004036|stage III adult immunoblastic large cell lymphoma
1511532|NCT00004036|stage III adult lymphoblastic lymphoma
1511533|NCT00004036|stage III adult Burkitt lymphoma
1511534|NCT00004036|stage IV grade 1 follicular lymphoma
1511535|NCT00004036|stage IV grade 2 follicular lymphoma
1511536|NCT00004036|stage IV grade 3 follicular lymphoma
1511537|NCT00004036|stage IV adult diffuse small cleaved cell lymphoma
1511538|NCT00004036|stage IV adult diffuse mixed cell lymphoma
1511539|NCT00004036|stage IV adult diffuse large cell lymphoma
1511540|NCT00004036|stage IV adult immunoblastic large cell lymphoma
1511541|NCT00004036|stage IV adult lymphoblastic lymphoma
1511542|NCT00004036|stage IV adult Burkitt lymphoma
1511543|NCT00004036|recurrent grade 1 follicular lymphoma
1511544|NCT00004036|recurrent grade 2 follicular lymphoma
1511545|NCT00004036|recurrent grade 3 follicular lymphoma
1511546|NCT00004036|recurrent adult diffuse small cleaved cell lymphoma
1511547|NCT00004036|recurrent adult diffuse mixed cell lymphoma
1511548|NCT00004036|recurrent adult diffuse large cell lymphoma
1511549|NCT00004036|recurrent adult immunoblastic large cell lymphoma
1511550|NCT00004036|recurrent adult lymphoblastic lymphoma
1511551|NCT00004036|recurrent adult Burkitt lymphoma
1511552|NCT00004036|stage III adult T-cell leukemia/lymphoma
1511553|NCT00004036|stage IV adult T-cell leukemia/lymphoma
1511554|NCT00004036|recurrent adult T-cell leukemia/lymphoma
1511555|NCT00004036|secondary acute myeloid leukemia
1511556|NCT00004036|de novo myelodysplastic syndromes
1511557|NCT00004036|previously treated myelodysplastic syndromes
1511558|NCT00004036|secondary myelodysplastic syndromes
1511559|NCT00004036|drug/agent toxicity by tissue/organ
1511560|NCT00004036|prolymphocytic leukemia
1511561|NCT00004036|AIDS-related peripheral/systemic lymphoma
1511562|NCT00004036|AIDS-related primary CNS lymphoma
1511563|NCT00004036|primary systemic amyloidosis
1511564|NCT00004036|stage III mantle cell lymphoma
1511565|NCT00004036|stage IV mantle cell lymphoma
1511566|NCT00004036|recurrent mantle cell lymphoma
1511567|NCT00004036|angioimmunoblastic T-cell lymphoma
1511568|NCT00004036|anaplastic large cell lymphoma
1511569|NCT00004036|recurrent marginal zone lymphoma
1511570|NCT00004036|recurrent small lymphocytic lymphoma
1511571|NCT00004036|stage III small lymphocytic lymphoma
1511572|NCT00004036|stage III marginal zone lymphoma
1511573|NCT00004036|stage IV small lymphocytic lymphoma
1511574|NCT00004036|stage IV marginal zone lymphoma
1511575|NCT00004036|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511576|NCT00004036|nodal marginal zone B-cell lymphoma
1511577|NCT00004036|splenic marginal zone lymphoma
1511578|NCT00004033|localized malignant mesothelioma
1511579|NCT00004033|advanced malignant mesothelioma
1511580|NCT00004033|recurrent malignant mesothelioma
1511581|NCT00004031|stage III grade 3 follicular lymphoma
1511582|NCT00004031|stage III adult diffuse small cleaved cell lymphoma
1511583|NCT00004031|stage III adult diffuse mixed cell lymphoma
1511584|NCT00004031|stage III adult diffuse large cell lymphoma
1511585|NCT00004031|stage III adult immunoblastic large cell lymphoma
1511586|NCT00004031|stage III adult Burkitt lymphoma
1511587|NCT00004031|stage IV grade 3 follicular lymphoma
1511588|NCT00004031|stage IV adult diffuse small cleaved cell lymphoma
1511589|NCT00004031|stage IV adult diffuse mixed cell lymphoma
1511590|NCT00004031|stage IV adult diffuse large cell lymphoma
1511591|NCT00004031|stage IV adult immunoblastic large cell lymphoma
1511592|NCT00004031|stage IV adult Burkitt lymphoma
1511593|NCT00004031|contiguous stage II grade 3 follicular lymphoma
1511594|NCT00004031|contiguous stage II adult diffuse small cleaved cell lymphoma
1511595|NCT00004031|contiguous stage II adult diffuse mixed cell lymphoma
1511596|NCT00004031|contiguous stage II adult immunoblastic large cell lymphoma
1511597|NCT00004031|contiguous stage II adult diffuse large cell lymphoma
1511598|NCT00004031|contiguous stage II adult Burkitt lymphoma
1511599|NCT00004031|noncontiguous stage II grade 3 follicular lymphoma
1511600|NCT00004031|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1511601|NCT00004031|noncontiguous stage II adult diffuse mixed cell lymphoma
1511602|NCT00004031|noncontiguous stage II adult immunoblastic large cell lymphoma
1511603|NCT00004031|noncontiguous stage II adult diffuse large cell lymphoma
1511604|NCT00004031|noncontiguous stage II adult Burkitt lymphoma
1511605|NCT00004030|unspecified adult solid tumor, protocol specific
1511606|NCT00004029|adenocarcinoma of the prostate
1511607|NCT00004029|stage IV prostate cancer
1511608|NCT00004029|recurrent prostate cancer
1511609|NCT00004028|recurrent adult brain tumor
1511610|NCT00004028|adult glioblastoma
1511611|NCT00004028|adult anaplastic astrocytoma
1511612|NCT00004028|adult anaplastic ependymoma
1511613|NCT00004028|adult anaplastic oligodendroglioma
1511614|NCT00004028|adult mixed glioma
1511615|NCT00004028|adult ependymoblastoma
1511616|NCT00004028|adult giant cell glioblastoma
1511617|NCT00004028|adult gliosarcoma
1511618|NCT00004026|adenocarcinoma of the prostate
1511619|NCT00004026|stage IV prostate cancer
1511620|NCT00004026|recurrent prostate cancer
1511621|NCT00004025|stage III melanoma
1511622|NCT00004025|stage IV melanoma
1511623|NCT00004025|recurrent melanoma
1511624|NCT00004024|recurrent adult brain tumor
1511625|NCT00004024|adult glioblastoma
1511626|NCT00004024|adult anaplastic astrocytoma
1511627|NCT00004024|adult anaplastic oligodendroglioma
1511628|NCT00004024|adult subependymoma
1511629|NCT00004024|adult oligodendroglioma
1511630|NCT00004024|adult giant cell glioblastoma
1511631|NCT00004024|adult gliosarcoma
1511632|NCT00004024|adult diffuse astrocytoma
1511633|NCT00004022|stage III melanoma
1511634|NCT00004022|stage IV melanoma
1511635|NCT00004022|recurrent melanoma
1511636|NCT00004017|recurrent adult brain tumor
1511637|NCT00004017|adult glioblastoma
1511638|NCT00004017|adult anaplastic astrocytoma
1511639|NCT00004017|adult giant cell glioblastoma
1511640|NCT00004017|adult gliosarcoma
1511641|NCT00004016|stage III melanoma
1511642|NCT00004016|stage IV melanoma
1511643|NCT00004016|recurrent melanoma
1511644|NCT00004016|unspecified adult solid tumor, protocol specific
1511645|NCT00004015|adult glioblastoma
1511646|NCT00004015|adult giant cell glioblastoma
1511647|NCT00004015|adult gliosarcoma
1511648|NCT00004014|recurrent prostate cancer
1511649|NCT00004013|stage IV breast cancer
1511650|NCT00004013|recurrent breast cancer
1511651|NCT00004012|recurrent ovarian epithelial cancer
1511652|NCT00004012|fallopian tube cancer
1511653|NCT00004012|primary peritoneal cavity cancer
1511654|NCT00004011|stage I non-small cell lung cancer
1511655|NCT00004011|stage II non-small cell lung cancer
1511656|NCT00004011|stage IIIA non-small cell lung cancer
1511657|NCT00004010|stage II childhood Hodgkin lymphoma
1511658|NCT00004010|stage III childhood Hodgkin lymphoma
1511659|NCT00004010|stage IV childhood Hodgkin lymphoma
1511660|NCT00004010|childhood lymphocyte predominant Hodgkin lymphoma
1511661|NCT00004010|childhood lymphocyte depletion Hodgkin lymphoma
1511662|NCT00004010|childhood nodular sclerosis Hodgkin lymphoma
1511663|NCT00004010|childhood mixed cellularity Hodgkin lymphoma
1511664|NCT00004009|recurrent adult acute myeloid leukemia
1511665|NCT00004009|recurrent adult acute lymphoblastic leukemia
1511666|NCT00004009|accelerated phase chronic myelogenous leukemia
1511667|NCT00004009|blastic phase chronic myelogenous leukemia
1511668|NCT00004009|untreated adult acute lymphoblastic leukemia
1511669|NCT00004009|untreated adult acute myeloid leukemia
1511670|NCT00004009|adult acute promyelocytic leukemia (M3)
1511671|NCT00004009|secondary acute myeloid leukemia
1511672|NCT00004008|stage I ovarian epithelial cancer
1511673|NCT00004008|stage II ovarian epithelial cancer
1511674|NCT00004008|stage III ovarian epithelial cancer
1511675|NCT00004008|stage IV ovarian epithelial cancer
1511676|NCT00004008|recurrent ovarian epithelial cancer
1511677|NCT00004006|intraocular retinoblastoma
1511678|NCT00004006|extraocular retinoblastoma
1511679|NCT00004006|recurrent retinoblastoma
1511680|NCT00004005|stage III colon cancer
1511681|NCT00004005|stage IV colon cancer
1511682|NCT00004005|stage III rectal cancer
1511683|NCT00004005|stage IV rectal cancer
1511684|NCT00004005|unspecified childhood solid tumor, protocol specific
1511685|NCT00004005|unspecified adult solid tumor, protocol specific
1511686|NCT00004005|adenocarcinoma of unknown primary
1511687|NCT00004005|newly diagnosed carcinoma of unknown primary
1511688|NCT00004005|recurrent carcinoma of unknown primary
1511689|NCT00004004|recurrent adult brain tumor
1511690|NCT00004004|adult glioblastoma
1511691|NCT00004004|adult anaplastic astrocytoma
1511692|NCT00004004|adult anaplastic oligodendroglioma
1511693|NCT00004004|adult giant cell glioblastoma
1511694|NCT00004004|adult gliosarcoma
1511695|NCT00004003|stage III pancreatic cancer
1511696|NCT00004003|recurrent pancreatic cancer
1511697|NCT00004003|stage IV pancreatic cancer
1511698|NCT00004002|stage IV adult Hodgkin lymphoma
1511699|NCT00004002|recurrent adult Hodgkin lymphoma
1511700|NCT00004002|stage IV cutaneous T-cell non-Hodgkin lymphoma
1511701|NCT00004002|recurrent cutaneous T-cell non-Hodgkin lymphoma
1511702|NCT00004002|small intestine lymphoma
1511703|NCT00004002|unspecified adult solid tumor, protocol specific
1511704|NCT00004002|stage IV grade 1 follicular lymphoma
1511705|NCT00004002|stage IV grade 2 follicular lymphoma
1511706|NCT00004002|stage IV grade 3 follicular lymphoma
1511707|NCT00004002|stage IV adult diffuse small cleaved cell lymphoma
1511708|NCT00004002|stage IV adult diffuse mixed cell lymphoma
1511709|NCT00004002|stage IV adult diffuse large cell lymphoma
1511710|NCT00004002|stage IV adult immunoblastic large cell lymphoma
1511711|NCT00004002|stage IV adult lymphoblastic lymphoma
1511712|NCT00004002|stage IV adult Burkitt lymphoma
1511713|NCT00004002|recurrent grade 1 follicular lymphoma
1511714|NCT00004002|recurrent grade 2 follicular lymphoma
1511715|NCT00004002|recurrent grade 3 follicular lymphoma
1511716|NCT00004002|recurrent adult diffuse small cleaved cell lymphoma
1511717|NCT00004002|recurrent adult diffuse mixed cell lymphoma
1511718|NCT00004002|recurrent adult diffuse large cell lymphoma
1511719|NCT00004002|recurrent adult immunoblastic large cell lymphoma
1511720|NCT00004002|recurrent adult lymphoblastic lymphoma
1511721|NCT00004002|recurrent adult Burkitt lymphoma
1511722|NCT00004002|stage IV adult T-cell leukemia/lymphoma
1511723|NCT00004002|recurrent adult T-cell leukemia/lymphoma
1511724|NCT00004002|primary central nervous system non-Hodgkin lymphoma
1511725|NCT00004002|AIDS-related peripheral/systemic lymphoma
1511726|NCT00004002|AIDS-related primary CNS lymphoma
1511727|NCT00004002|intraocular lymphoma
1511728|NCT00004002|stage IV mantle cell lymphoma
1511729|NCT00004002|recurrent mantle cell lymphoma
1511730|NCT00004002|angioimmunoblastic T-cell lymphoma
1511731|NCT00004002|anaplastic large cell lymphoma
1511732|NCT00004002|stage IV mycosis fungoides/Sezary syndrome
1511733|NCT00004002|recurrent mycosis fungoides/Sezary syndrome
1511734|NCT00004002|recurrent marginal zone lymphoma
1511735|NCT00004002|recurrent small lymphocytic lymphoma
1511736|NCT00004002|stage IV small lymphocytic lymphoma
1511737|NCT00004002|stage IV marginal zone lymphoma
1511738|NCT00004002|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511739|NCT00004002|nodal marginal zone B-cell lymphoma
1511740|NCT00004002|splenic marginal zone lymphoma
1511741|NCT00004001|adenocarcinoma of the prostate
1511742|NCT00004001|stage IV prostate cancer
1511743|NCT00004001|recurrent prostate cancer
1511744|NCT00003998|stage I ovarian epithelial cancer
1511745|NCT00003998|stage II ovarian epithelial cancer
1511746|NCT00003998|stage III ovarian epithelial cancer
1511747|NCT00003998|stage IV ovarian epithelial cancer
1511748|NCT00003998|primary peritoneal cavity cancer
1511749|NCT00003997|recurrent adult acute myeloid leukemia
1511750|NCT00003997|recurrent adult acute lymphoblastic leukemia
1511751|NCT00003997|blastic phase chronic myelogenous leukemia
1511752|NCT00003997|previously treated myelodysplastic syndromes
1511753|NCT00003997|secondary myelodysplastic syndromes
1511754|NCT00003996|adult glioblastoma
1511755|NCT00003996|adult giant cell glioblastoma
1511756|NCT00003996|adult gliosarcoma
1511757|NCT00003995|stage IV colon cancer
1511758|NCT00003995|stage IV rectal cancer
1511759|NCT00003995|recurrent colon cancer
1511760|NCT00003995|recurrent rectal cancer
1511761|NCT00003993|stage IV adult Hodgkin lymphoma
1511762|NCT00003993|recurrent adult Hodgkin lymphoma
1511763|NCT00003993|stage IV cutaneous T-cell non-Hodgkin lymphoma
1511764|NCT00003993|recurrent cutaneous T-cell non-Hodgkin lymphoma
1511765|NCT00003993|small intestine lymphoma
1511766|NCT00003993|unspecified adult solid tumor, protocol specific
1511767|NCT00003993|stage IV grade 1 follicular lymphoma
1511768|NCT00003993|stage IV grade 2 follicular lymphoma
1511769|NCT00003993|stage IV grade 3 follicular lymphoma
1511770|NCT00003993|stage IV adult diffuse small cleaved cell lymphoma
1511771|NCT00003993|stage IV adult diffuse mixed cell lymphoma
1511772|NCT00003993|stage IV adult diffuse large cell lymphoma
1511773|NCT00003993|stage IV adult immunoblastic large cell lymphoma
1511774|NCT00003993|stage IV adult lymphoblastic lymphoma
1511775|NCT00003993|stage IV adult Burkitt lymphoma
1511776|NCT00003993|recurrent grade 1 follicular lymphoma
1511777|NCT00003993|recurrent grade 2 follicular lymphoma
1511778|NCT00003993|recurrent grade 3 follicular lymphoma
1511779|NCT00003993|recurrent adult diffuse small cleaved cell lymphoma
1511780|NCT00003993|recurrent adult diffuse mixed cell lymphoma
1511781|NCT00003993|recurrent adult diffuse large cell lymphoma
1511782|NCT00003993|recurrent adult immunoblastic large cell lymphoma
1511783|NCT00003993|recurrent adult lymphoblastic lymphoma
1511784|NCT00003993|recurrent adult Burkitt lymphoma
1511785|NCT00003993|stage IV adult T-cell leukemia/lymphoma
1511786|NCT00003993|recurrent adult T-cell leukemia/lymphoma
1511787|NCT00003993|primary central nervous system non-Hodgkin lymphoma
1511788|NCT00003993|intraocular lymphoma
1511789|NCT00003993|stage IV mantle cell lymphoma
1511790|NCT00003993|recurrent mantle cell lymphoma
1511791|NCT00003993|angioimmunoblastic T-cell lymphoma
1511792|NCT00003993|anaplastic large cell lymphoma
1511793|NCT00003993|stage IV mycosis fungoides/Sezary syndrome
1511794|NCT00003993|recurrent mycosis fungoides/Sezary syndrome
1511795|NCT00003993|recurrent marginal zone lymphoma
1511796|NCT00003993|recurrent small lymphocytic lymphoma
1511797|NCT00003993|stage IV small lymphocytic lymphoma
1511798|NCT00003993|stage IV marginal zone lymphoma
1511799|NCT00003993|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511800|NCT00003993|nodal marginal zone B-cell lymphoma
1511801|NCT00003993|splenic marginal zone lymphoma
1511802|NCT00003992|stage II breast cancer
1511803|NCT00003992|stage IIIA breast cancer
1511804|NCT00003991|adult acute myeloid leukemia in remission
1511805|NCT00003989|recurrent non-small cell lung cancer
1511806|NCT00003989|stage III melanoma
1511807|NCT00003989|stage IV melanoma
1511808|NCT00003989|recurrent melanoma
1511809|NCT00003989|stage IIIA non-small cell lung cancer
1511810|NCT00003989|stage IIIB non-small cell lung cancer
1511811|NCT00003989|stage IV non-small cell lung cancer
1511812|NCT00003985|non-small cell lung cancer
1511813|NCT00003985|unspecified adult solid tumor, protocol specific
1511814|NCT00003984|refractory anemia with excess blasts
1511815|NCT00003984|refractory anemia with excess blasts in transformation
1511816|NCT00003984|de novo myelodysplastic syndromes
1511817|NCT00003984|previously treated myelodysplastic syndromes
1511818|NCT00003984|secondary myelodysplastic syndromes
1511819|NCT00003982|unspecified adult solid tumor, protocol specific
1511820|NCT00003982|testicular embryonal carcinoma and yolk sac tumor
1511821|NCT00003981|unspecified adult solid tumor, protocol specific
1511822|NCT00003980|unspecified adult solid tumor, protocol specific
1511823|NCT00003979|unspecified adult solid tumor, protocol specific
1511824|NCT00003977|stage III cervical cancer
1511825|NCT00003977|recurrent cervical cancer
1511826|NCT00003977|stage IB cervical cancer
1511827|NCT00003977|stage IIB cervical cancer
1511828|NCT00003977|stage IVB cervical cancer
1511829|NCT00003977|stage IA cervical cancer
1511830|NCT00003977|stage IIA cervical cancer
1511831|NCT00003977|stage IVA cervical cancer
1511832|NCT00003976|unspecified adult solid tumor, protocol specific
1511833|NCT00003974|stage I non-small cell lung cancer
1511834|NCT00003974|stage II non-small cell lung cancer
1511835|NCT00003974|localized malignant mesothelioma
1511836|NCT00003974|stage IIIA non-small cell lung cancer
1511837|NCT00003972|stage II breast cancer
1511838|NCT00003972|stage IIIA breast cancer
1511839|NCT00003969|unspecified adult solid tumor, protocol specific
1511840|NCT00003968|stage IV renal cell cancer
1511841|NCT00003968|recurrent renal cell cancer
1511842|NCT00003967|recurrent ovarian epithelial cancer
1511843|NCT00003967|ovarian undifferentiated adenocarcinoma
1511844|NCT00003967|ovarian mixed epithelial carcinoma
1511845|NCT00003967|ovarian serous cystadenocarcinoma
1511846|NCT00003967|ovarian mucinous cystadenocarcinoma
1511847|NCT00003967|ovarian endometrioid adenocarcinoma
1511848|NCT00003967|ovarian clear cell cystadenocarcinoma
1511849|NCT00003967|fallopian tube cancer
1511850|NCT00003967|primary peritoneal cavity cancer
1511851|NCT00003967|Brenner tumor
1511852|NCT00003966|veno-occlusive disease
1511853|NCT00003963|Waldenstrom macroglobulinemia
1511854|NCT00003963|recurrent grade 1 follicular lymphoma
1511855|NCT00003963|recurrent grade 2 follicular lymphoma
1511856|NCT00003963|recurrent grade 3 follicular lymphoma
1511857|NCT00003963|recurrent adult diffuse small cleaved cell lymphoma
1511858|NCT00003963|recurrent adult diffuse mixed cell lymphoma
1511859|NCT00003963|recurrent adult diffuse large cell lymphoma
1511860|NCT00003963|recurrent adult immunoblastic large cell lymphoma
1511861|NCT00003963|recurrent adult lymphoblastic lymphoma
1511862|NCT00003963|recurrent adult Burkitt lymphoma
1511863|NCT00003963|recurrent mantle cell lymphoma
1511864|NCT00003963|recurrent marginal zone lymphoma
1511865|NCT00003963|recurrent small lymphocytic lymphoma
1511866|NCT00003963|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511867|NCT00003963|nodal marginal zone B-cell lymphoma
1511868|NCT00003963|splenic marginal zone lymphoma
1511869|NCT00003962|recurrent childhood acute lymphoblastic leukemia
1511870|NCT00003962|recurrent adult Hodgkin lymphoma
1511871|NCT00003962|refractory multiple myeloma
1511872|NCT00003962|stage I multiple myeloma
1511873|NCT00003962|stage II multiple myeloma
1511874|NCT00003962|stage III multiple myeloma
1511875|NCT00003962|recurrent childhood lymphoblastic lymphoma
1511876|NCT00003962|recurrent childhood acute myeloid leukemia
1511877|NCT00003962|recurrent adult acute myeloid leukemia
1511878|NCT00003962|recurrent adult acute lymphoblastic leukemia
1511879|NCT00003962|recurrent/refractory childhood Hodgkin lymphoma
1511880|NCT00003962|chronic myelomonocytic leukemia
1511881|NCT00003962|acute undifferentiated leukemia
1511882|NCT00003962|recurrent grade 1 follicular lymphoma
1511883|NCT00003962|recurrent grade 2 follicular lymphoma
1511884|NCT00003962|recurrent grade 3 follicular lymphoma
1511885|NCT00003962|recurrent adult diffuse small cleaved cell lymphoma
1511886|NCT00003962|recurrent adult diffuse mixed cell lymphoma
1511887|NCT00003962|recurrent adult diffuse large cell lymphoma
1511888|NCT00003962|recurrent adult immunoblastic large cell lymphoma
1511889|NCT00003962|recurrent adult lymphoblastic lymphoma
1511890|NCT00003962|recurrent adult T-cell leukemia/lymphoma
1511891|NCT00003962|secondary acute myeloid leukemia
1511892|NCT00003962|AIDS-related peripheral/systemic lymphoma
1511893|NCT00003962|recurrent childhood small noncleaved cell lymphoma
1511894|NCT00003962|recurrent childhood large cell lymphoma
1511895|NCT00003962|recurrent mantle cell lymphoma
1511896|NCT00003962|recurrent marginal zone lymphoma
1511897|NCT00003962|recurrent small lymphocytic lymphoma
1511898|NCT00003962|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511899|NCT00003962|nodal marginal zone B-cell lymphoma
1511900|NCT00003962|splenic marginal zone lymphoma
1511901|NCT00003961|refractory anemia with excess blasts
1511902|NCT00003961|refractory anemia with excess blasts in transformation
1511903|NCT00003961|chronic myelomonocytic leukemia
1511904|NCT00003961|de novo myelodysplastic syndromes
1511905|NCT00003961|previously treated myelodysplastic syndromes
1511906|NCT00003961|secondary myelodysplastic syndromes
1511907|NCT00003961|refractory cytopenia with multilineage dysplasia
1511908|NCT00003961|atypical chronic myeloid leukemia
1511909|NCT00003961|myelodysplastic/myeloproliferative disease, unclassifiable
1511910|NCT00003960|refractory multiple myeloma
1511911|NCT00003960|chronic phase chronic myelogenous leukemia
1511912|NCT00003960|adult acute myeloid leukemia in remission
1511913|NCT00003960|adult acute lymphoblastic leukemia in remission
1511914|NCT00003960|refractory anemia with excess blasts
1511915|NCT00003960|refractory anemia with excess blasts in transformation
1511916|NCT00003960|acute undifferentiated leukemia
1511917|NCT00003960|secondary acute myeloid leukemia
1511918|NCT00003960|de novo myelodysplastic syndromes
1511919|NCT00003960|previously treated myelodysplastic syndromes
1511920|NCT00003960|secondary myelodysplastic syndromes
1511921|NCT00003959|refractory anemia
1511922|NCT00003959|refractory anemia with ringed sideroblasts
1511923|NCT00003959|refractory anemia with excess blasts
1511924|NCT00003959|chronic myelomonocytic leukemia
1511925|NCT00003959|de novo myelodysplastic syndromes
1511926|NCT00003959|previously treated myelodysplastic syndromes
1511927|NCT00003959|secondary myelodysplastic syndromes
1511928|NCT00003957|recurrent grade 3 follicular lymphoma
1511929|NCT00003957|recurrent adult diffuse mixed cell lymphoma
1511930|NCT00003957|recurrent adult diffuse large cell lymphoma
1511931|NCT00003957|recurrent adult immunoblastic large cell lymphoma
1511932|NCT00003956|stage IV adult Hodgkin lymphoma
1511933|NCT00003956|recurrent adult Hodgkin lymphoma
1511934|NCT00003956|unspecified adult solid tumor, protocol specific
1511935|NCT00003956|stage IV grade 1 follicular lymphoma
1511936|NCT00003956|stage IV grade 2 follicular lymphoma
1511937|NCT00003956|stage IV grade 3 follicular lymphoma
1511938|NCT00003956|stage IV adult diffuse small cleaved cell lymphoma
1511939|NCT00003956|stage IV adult diffuse mixed cell lymphoma
1511940|NCT00003956|stage IV adult diffuse large cell lymphoma
1511941|NCT00003956|stage IV adult immunoblastic large cell lymphoma
1511942|NCT00003956|stage IV adult lymphoblastic lymphoma
1511943|NCT00003956|stage IV adult Burkitt lymphoma
1511944|NCT00003956|recurrent grade 1 follicular lymphoma
1511945|NCT00003956|recurrent grade 2 follicular lymphoma
1511946|NCT00003956|recurrent grade 3 follicular lymphoma
1511947|NCT00003956|recurrent adult diffuse small cleaved cell lymphoma
1511948|NCT00003956|recurrent adult diffuse mixed cell lymphoma
1511949|NCT00003956|recurrent adult diffuse large cell lymphoma
1511950|NCT00003956|recurrent adult immunoblastic large cell lymphoma
1511951|NCT00003956|recurrent adult lymphoblastic lymphoma
1511952|NCT00003956|recurrent adult Burkitt lymphoma
1511953|NCT00003956|stage IV adult T-cell leukemia/lymphoma
1511954|NCT00003956|recurrent adult T-cell leukemia/lymphoma
1511955|NCT00003956|AIDS-related peripheral/systemic lymphoma
1511956|NCT00003956|AIDS-related primary CNS lymphoma
1511957|NCT00003956|stage IV mantle cell lymphoma
1511958|NCT00003956|recurrent mantle cell lymphoma
1511959|NCT00003956|angioimmunoblastic T-cell lymphoma
1511960|NCT00003956|anaplastic large cell lymphoma
1511961|NCT00003956|recurrent marginal zone lymphoma
1511962|NCT00003956|recurrent small lymphocytic lymphoma
1511963|NCT00003956|stage IV small lymphocytic lymphoma
1511964|NCT00003956|stage IV marginal zone lymphoma
1511965|NCT00003956|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1511966|NCT00003956|nodal marginal zone B-cell lymphoma
1511967|NCT00003956|splenic marginal zone lymphoma
1511968|NCT00003955|embryonal childhood rhabdomyosarcoma
1511969|NCT00003955|alveolar childhood rhabdomyosarcoma
1511970|NCT00003955|metastatic childhood soft tissue sarcoma
1511971|NCT00003955|childhood malignant mesenchymoma
1511972|NCT00003955|previously untreated childhood rhabdomyosarcoma
1511973|NCT00003955|adult rhabdomyosarcoma
1511974|NCT00003955|adult malignant mesenchymoma
1511975|NCT00003955|stage IV adult soft tissue sarcoma
1511976|NCT00003953|stage II breast cancer
1511977|NCT00003953|stage IIIA breast cancer
1511978|NCT00003953|stage IIIB breast cancer
1511979|NCT00003951|recurrent pancreatic cancer
1511980|NCT00003951|duct cell adenocarcinoma of the pancreas
1511981|NCT00003951|stage IV pancreatic cancer
1511982|NCT00003950|stage IV colon cancer
1511983|NCT00003950|stage IV rectal cancer
1511984|NCT00003950|recurrent colon cancer
1511985|NCT00003950|recurrent rectal cancer
1511986|NCT00003950|adenocarcinoma of the colon
1511987|NCT00003950|adenocarcinoma of the rectum
1511988|NCT00003946|stage IV endometrial carcinoma
1511989|NCT00003946|recurrent endometrial carcinoma
1511990|NCT00003945|recurrent cervical cancer
1511991|NCT00003945|stage IVB cervical cancer
1511992|NCT00003945|cervical squamous cell carcinoma
1511993|NCT00003945|cervical adenocarcinoma
1511994|NCT00003945|cervical adenosquamous cell carcinoma
1511995|NCT00003944|stage III ovarian epithelial cancer
1511996|NCT00003944|stage IV ovarian epithelial cancer
1511997|NCT00003944|ovarian undifferentiated adenocarcinoma
1511998|NCT00003944|ovarian mixed epithelial carcinoma
1511999|NCT00003944|ovarian serous cystadenocarcinoma
1512000|NCT00003944|ovarian mucinous cystadenocarcinoma
1512001|NCT00003944|ovarian endometrioid adenocarcinoma
1512002|NCT00003944|ovarian clear cell cystadenocarcinoma
1512003|NCT00003944|fallopian tube cancer
1512004|NCT00003944|peritoneal cavity cancer
1512005|NCT00003943|extensive stage small cell lung cancer
1512006|NCT00003943|newly diagnosed carcinoma of unknown primary
1512007|NCT00003942|AIDS-related peripheral/systemic lymphoma
1512008|NCT00003942|AIDS-related diffuse large cell lymphoma
1512009|NCT00003942|AIDS-related immunoblastic large cell lymphoma
1512010|NCT00003942|AIDS-related small noncleaved cell lymphoma
1512011|NCT00003942|AIDS-related diffuse mixed cell lymphoma
1512012|NCT00003942|AIDS-related diffuse small cleaved cell lymphoma
1512013|NCT00003942|AIDS-related lymphoblastic lymphoma
1512014|NCT00003941|stage III malignant testicular germ cell tumor
1512015|NCT00003941|mediastinal cancer
1512016|NCT00003941|testicular embryonal carcinoma
1512017|NCT00003941|testicular choriocarcinoma
1512018|NCT00003941|testicular teratoma
1512019|NCT00003941|testicular yolk sac tumor
1512020|NCT00003941|testicular embryonal carcinoma and teratoma
1512021|NCT00003941|testicular embryonal carcinoma and teratoma with seminoma
1512022|NCT00003941|testicular embryonal carcinoma and yolk sac tumor
1512023|NCT00003941|testicular embryonal carcinoma and yolk sac tumor with seminoma
1512024|NCT00003941|testicular embryonal carcinoma and seminoma
1512025|NCT00003941|testicular yolk sac tumor and teratoma
1512026|NCT00003941|testicular yolk sac tumor and teratoma with seminoma
1512027|NCT00003941|testicular choriocarcinoma and yolk sac tumor
1512987|NCT00003833|stage III colon cancer
1512028|NCT00003941|testicular choriocarcinoma and embryonal carcinoma
1512029|NCT00003941|testicular choriocarcinoma and teratoma
1512030|NCT00003941|testicular choriocarcinoma and seminoma
1512031|NCT00003941|tumors metastatic to brain
1512032|NCT00003941|liver metastases
1512033|NCT00003941|bone metastases
1512034|NCT00003939|adult angiosarcoma
1512035|NCT00003939|adult fibrosarcoma
1512036|NCT00003939|adult leiomyosarcoma
1512037|NCT00003939|adult liposarcoma
1512038|NCT00003939|adult neurofibrosarcoma
1512039|NCT00003939|adult synovial sarcoma
1512040|NCT00003939|stage IV adult soft tissue sarcoma
1512041|NCT00003939|recurrent adult soft tissue sarcoma
1512042|NCT00003939|small intestine leiomyosarcoma
1512043|NCT00003939|adult alveolar soft-part sarcoma
1512044|NCT00003939|adult epithelioid sarcoma
1512045|NCT00003939|adult malignant fibrous histiocytoma
1512046|NCT00003939|adult malignant hemangiopericytoma
1512047|NCT00003939|adult malignant mesenchymoma
1512048|NCT00003939|adult rhabdomyosarcoma
1512049|NCT00003939|stage IV uterine sarcoma
1512050|NCT00003939|recurrent uterine sarcoma
1512051|NCT00003939|uterine carcinosarcoma
1512052|NCT00003939|uterine leiomyosarcoma
1512053|NCT00003939|endometrial stromal sarcoma
1512054|NCT00003939|ovarian sarcoma
1512055|NCT00003939|adult meningeal hemangiopericytoma
1512056|NCT00003939|gastrointestinal stromal tumor
1512057|NCT00003938|stage I adult Hodgkin lymphoma
1512058|NCT00003938|stage II adult Hodgkin lymphoma
1512059|NCT00003938|stage III adult Hodgkin lymphoma
1512060|NCT00003938|stage IV adult Hodgkin lymphoma
1512061|NCT00003938|stage IV breast cancer
1512062|NCT00003938|stage IIIA breast cancer
1512063|NCT00003938|monoclonal gammopathy of undetermined significance
1512064|NCT00003938|stage IIIB breast cancer
1512065|NCT00003938|recurrent childhood acute lymphoblastic leukemia
1512066|NCT00003938|recurrent adult Hodgkin lymphoma
1512067|NCT00003938|stage I cutaneous T-cell non-Hodgkin lymphoma
1512068|NCT00003938|stage II cutaneous T-cell non-Hodgkin lymphoma
1512069|NCT00003938|stage III cutaneous T-cell non-Hodgkin lymphoma
1512070|NCT00003938|stage IV cutaneous T-cell non-Hodgkin lymphoma
1512071|NCT00003938|recurrent cutaneous T-cell non-Hodgkin lymphoma
1512072|NCT00003938|isolated plasmacytoma of bone
1512073|NCT00003938|extramedullary plasmacytoma
1512074|NCT00003938|refractory multiple myeloma
1512075|NCT00003938|recurrent childhood rhabdomyosarcoma
1512076|NCT00003938|stage II ovarian epithelial cancer
1512077|NCT00003938|stage III ovarian epithelial cancer
1512078|NCT00003938|stage IV ovarian epithelial cancer
1512079|NCT00003938|recurrent ovarian epithelial cancer
1512080|NCT00003938|disseminated neuroblastoma
1512081|NCT00003938|recurrent neuroblastoma
1512082|NCT00003938|recurrent Wilms tumor and other childhood kidney tumors
1512083|NCT00003938|stage 0 chronic lymphocytic leukemia
1512084|NCT00003938|Waldenstrom macroglobulinemia
1512085|NCT00003938|stage I multiple myeloma
1512086|NCT00003938|stage II multiple myeloma
1512087|NCT00003938|stage III multiple myeloma
1512088|NCT00003938|stage I childhood lymphoblastic lymphoma
1512089|NCT00003938|stage II childhood lymphoblastic lymphoma
1512090|NCT00003938|stage III childhood lymphoblastic lymphoma
1512091|NCT00003938|stage IV childhood lymphoblastic lymphoma
1512092|NCT00003938|recurrent childhood lymphoblastic lymphoma
1512093|NCT00003938|stage I chronic lymphocytic leukemia
1512094|NCT00003938|stage II chronic lymphocytic leukemia
1512095|NCT00003938|stage III chronic lymphocytic leukemia
1512096|NCT00003938|stage IV chronic lymphocytic leukemia
1512097|NCT00003938|recurrent childhood acute myeloid leukemia
1512098|NCT00003938|recurrent adult acute myeloid leukemia
1512099|NCT00003938|recurrent adult acute lymphoblastic leukemia
1512100|NCT00003938|relapsing chronic myelogenous leukemia
1512101|NCT00003938|refractory chronic lymphocytic leukemia
1512102|NCT00003938|small intestine lymphoma
1512103|NCT00003938|stage III malignant testicular germ cell tumor
1512104|NCT00003938|recurrent malignant testicular germ cell tumor
1512105|NCT00003938|unspecified childhood solid tumor, protocol specific
1512106|NCT00003938|unspecified adult solid tumor, protocol specific
1512107|NCT00003938|chronic phase chronic myelogenous leukemia
1512108|NCT00003938|accelerated phase chronic myelogenous leukemia
1512109|NCT00003938|blastic phase chronic myelogenous leukemia
1512110|NCT00003938|meningeal chronic myelogenous leukemia
1512111|NCT00003938|adult acute myeloid leukemia in remission
1512112|NCT00003938|adult acute lymphoblastic leukemia in remission
1512113|NCT00003938|childhood acute myeloid leukemia in remission
1512114|NCT00003938|childhood acute lymphoblastic leukemia in remission
1512115|NCT00003938|polycythemia vera
1512116|NCT00003938|primary myelofibrosis
1512117|NCT00003938|essential thrombocythemia
1512118|NCT00003938|fever, sweats, and hot flashes
1512119|NCT00003938|childhood acute promyelocytic leukemia (M3)
1512120|NCT00003938|testicular embryonal carcinoma
1512121|NCT00003938|testicular choriocarcinoma
1512122|NCT00003938|testicular teratoma
1512123|NCT00003938|testicular yolk sac tumor
1512124|NCT00003938|testicular embryonal carcinoma and teratoma
1512125|NCT00003938|testicular embryonal carcinoma and teratoma with seminoma
1512126|NCT00003938|testicular embryonal carcinoma and yolk sac tumor
1512127|NCT00003938|testicular embryonal carcinoma and yolk sac tumor with seminoma
1512128|NCT00003938|testicular embryonal carcinoma and seminoma
1512129|NCT00003938|testicular yolk sac tumor and teratoma
1512130|NCT00003938|testicular yolk sac tumor and teratoma with seminoma
1512131|NCT00003938|testicular choriocarcinoma and yolk sac tumor
1512132|NCT00003938|testicular choriocarcinoma and embryonal carcinoma
1512133|NCT00003938|testicular choriocarcinoma and teratoma
1512134|NCT00003938|testicular choriocarcinoma and seminoma
1512135|NCT00003938|progressive hairy cell leukemia, initial treatment
1512136|NCT00003938|refractory hairy cell leukemia
1512137|NCT00003938|stage II childhood Hodgkin lymphoma
1512138|NCT00003938|stage I childhood Hodgkin lymphoma
1512139|NCT00003938|stage III childhood Hodgkin lymphoma
1512140|NCT00003938|stage IV childhood Hodgkin lymphoma
1512141|NCT00003938|recurrent/refractory childhood Hodgkin lymphoma
1512142|NCT00003938|stage I grade 1 follicular lymphoma
1512143|NCT00003938|stage I grade 2 follicular lymphoma
1512144|NCT00003938|stage I grade 3 follicular lymphoma
1512145|NCT00003938|stage I adult diffuse small cleaved cell lymphoma
1512146|NCT00003938|stage I adult diffuse mixed cell lymphoma
1512147|NCT00003938|stage I adult diffuse large cell lymphoma
1512148|NCT00003938|stage I adult immunoblastic large cell lymphoma
1512149|NCT00003938|stage I adult lymphoblastic lymphoma
1512150|NCT00003938|stage I adult Burkitt lymphoma
1512151|NCT00003938|recurrent ovarian germ cell tumor
1512152|NCT00003938|chronic myelomonocytic leukemia
1512153|NCT00003938|T-cell large granular lymphocyte leukemia
1512154|NCT00003938|ovarian yolk sac tumor
1512155|NCT00003938|ovarian embryonal carcinoma
1512156|NCT00003938|ovarian polyembryoma
1512157|NCT00003938|ovarian choriocarcinoma
1512158|NCT00003938|ovarian immature teratoma
1512159|NCT00003938|ovarian mature teratoma
1512160|NCT00003938|ovarian monodermal and highly specialized teratoma
1512161|NCT00003938|ovarian mixed germ cell tumor
1512162|NCT00003938|acute undifferentiated leukemia
1512163|NCT00003938|stage III grade 1 follicular lymphoma
1512164|NCT00003938|stage III grade 2 follicular lymphoma
1512165|NCT00003938|stage III grade 3 follicular lymphoma
1512166|NCT00003938|stage III adult diffuse small cleaved cell lymphoma
1512167|NCT00003938|stage III adult diffuse mixed cell lymphoma
1512168|NCT00003938|stage III adult diffuse large cell lymphoma
1512169|NCT00003938|stage III adult immunoblastic large cell lymphoma
1512170|NCT00003938|stage III adult lymphoblastic lymphoma
1512171|NCT00003938|stage III adult Burkitt lymphoma
1512172|NCT00003938|stage IV grade 1 follicular lymphoma
1512173|NCT00003938|stage IV grade 2 follicular lymphoma
1512174|NCT00003938|stage IV grade 3 follicular lymphoma
1512175|NCT00003938|stage IV adult diffuse small cleaved cell lymphoma
1512176|NCT00003938|stage IV adult diffuse mixed cell lymphoma
1512177|NCT00003938|stage IV adult diffuse large cell lymphoma
1512178|NCT00003938|stage IV adult immunoblastic large cell lymphoma
1512179|NCT00003938|stage IV adult lymphoblastic lymphoma
1512180|NCT00003938|stage IV adult Burkitt lymphoma
1512181|NCT00003938|recurrent grade 1 follicular lymphoma
1512182|NCT00003938|recurrent grade 2 follicular lymphoma
1512183|NCT00003938|recurrent grade 3 follicular lymphoma
1512184|NCT00003938|recurrent adult diffuse small cleaved cell lymphoma
1512185|NCT00003938|recurrent adult diffuse mixed cell lymphoma
1512186|NCT00003938|recurrent adult diffuse large cell lymphoma
1512187|NCT00003938|recurrent adult immunoblastic large cell lymphoma
1512188|NCT00003938|recurrent adult lymphoblastic lymphoma
1512189|NCT00003938|recurrent adult Burkitt lymphoma
1512190|NCT00003938|stage I adult T-cell leukemia/lymphoma
1512191|NCT00003938|stage II adult T-cell leukemia/lymphoma
1512192|NCT00003938|stage III adult T-cell leukemia/lymphoma
1512193|NCT00003938|stage IV adult T-cell leukemia/lymphoma
1512194|NCT00003938|recurrent adult T-cell leukemia/lymphoma
1512195|NCT00003938|de novo myelodysplastic syndromes
1512196|NCT00003938|high risk metastatic gestational trophoblastic tumor
1512197|NCT00003938|previously treated myelodysplastic syndromes
1512198|NCT00003938|secondary myelodysplastic syndromes
1512199|NCT00003938|primary central nervous system non-Hodgkin lymphoma
1512200|NCT00003938|neutropenia
1512201|NCT00003938|infection
1512202|NCT00003938|previously untreated childhood rhabdomyosarcoma
1512203|NCT00003938|prolymphocytic leukemia
1512204|NCT00003938|primary systemic amyloidosis
1512205|NCT00003938|intraocular lymphoma
1512206|NCT00003938|stage I childhood small noncleaved cell lymphoma
1512207|NCT00003938|stage I childhood large cell lymphoma
1512208|NCT00003938|stage II childhood small noncleaved cell lymphoma
1512209|NCT00003938|stage II childhood large cell lymphoma
1512210|NCT00003938|stage III childhood small noncleaved cell lymphoma
1512211|NCT00003938|stage III childhood large cell lymphoma
1512212|NCT00003938|stage IV childhood small noncleaved cell lymphoma
1512213|NCT00003938|stage IV childhood large cell lymphoma
1512214|NCT00003938|recurrent childhood small noncleaved cell lymphoma
1512215|NCT00003938|recurrent childhood large cell lymphoma
1512216|NCT00003938|stage I mantle cell lymphoma
1512217|NCT00003938|contiguous stage II grade 1 follicular lymphoma
1512218|NCT00003938|contiguous stage II grade 2 follicular lymphoma
1512219|NCT00003938|contiguous stage II grade 3 follicular lymphoma
1512220|NCT00003938|contiguous stage II adult diffuse small cleaved cell lymphoma
1512221|NCT00003938|contiguous stage II mantle cell lymphoma
1512222|NCT00003938|contiguous stage II adult diffuse mixed cell lymphoma
1512223|NCT00003938|contiguous stage II adult immunoblastic large cell lymphoma
1512224|NCT00003938|contiguous stage II adult diffuse large cell lymphoma
1512225|NCT00003938|contiguous stage II adult Burkitt lymphoma
1512226|NCT00003938|contiguous stage II adult lymphoblastic lymphoma
1512227|NCT00003938|noncontiguous stage II grade 1 follicular lymphoma
1512228|NCT00003938|noncontiguous stage II grade 2 follicular lymphoma
1512229|NCT00003938|noncontiguous stage II grade 3 follicular lymphoma
1512230|NCT00003938|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1512231|NCT00003938|noncontiguous stage II mantle cell lymphoma
1512232|NCT00003938|noncontiguous stage II adult diffuse mixed cell lymphoma
1512233|NCT00003938|noncontiguous stage II adult immunoblastic large cell lymphoma
1512234|NCT00003938|noncontiguous stage II adult diffuse large cell lymphoma
1512235|NCT00003938|noncontiguous stage II adult Burkitt lymphoma
1512236|NCT00003938|noncontiguous stage II adult lymphoblastic lymphoma
1512237|NCT00003938|stage III mantle cell lymphoma
1512238|NCT00003938|stage IV mantle cell lymphoma
1512239|NCT00003938|recurrent mantle cell lymphoma
1512240|NCT00003938|angioimmunoblastic T-cell lymphoma
1512241|NCT00003938|anaplastic large cell lymphoma
1512242|NCT00003938|previously treated childhood rhabdomyosarcoma
1512243|NCT00003938|stage I mycosis fungoides/Sezary syndrome
1512244|NCT00003938|stage II mycosis fungoides/Sezary syndrome
1512245|NCT00003938|stage III mycosis fungoides/Sezary syndrome
1512246|NCT00003938|stage IV mycosis fungoides/Sezary syndrome
1512247|NCT00003938|recurrent mycosis fungoides/Sezary syndrome
1512248|NCT00003938|childhood chronic myelogenous leukemia
1512249|NCT00003938|chronic eosinophilic leukemia
1512250|NCT00003938|chronic neutrophilic leukemia
1512251|NCT00003938|contiguous stage II marginal zone lymphoma
1512252|NCT00003938|contiguous stage II small lymphocytic lymphoma
1512253|NCT00003938|noncontiguous stage II small lymphocytic lymphoma
1512254|NCT00003938|noncontiguous stage II marginal zone lymphoma
1512255|NCT00003938|recurrent marginal zone lymphoma
1512256|NCT00003938|recurrent small lymphocytic lymphoma
1512257|NCT00003938|stage I marginal zone lymphoma
1512258|NCT00003938|stage I small lymphocytic lymphoma
1512259|NCT00003938|stage III small lymphocytic lymphoma
1512260|NCT00003938|stage III marginal zone lymphoma
1512261|NCT00003938|stage IV small lymphocytic lymphoma
1512262|NCT00003938|stage IV marginal zone lymphoma
1512263|NCT00003938|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1512264|NCT00003938|nodal marginal zone B-cell lymphoma
1512265|NCT00003938|splenic marginal zone lymphoma
1512266|NCT00003938|childhood myelodysplastic syndromes
1512267|NCT00003937|localized osteosarcoma
1512268|NCT00003937|cardiac toxicity
1512269|NCT00003936|recurrent adult Hodgkin lymphoma
1512270|NCT00003935|untreated childhood brain stem glioma
1512271|NCT00003933|recurrent childhood acute lymphoblastic leukemia
1512272|NCT00003931|recurrent adult acute myeloid leukemia
1512273|NCT00003931|adult acute myeloid leukemia in remission
1512274|NCT00003930|stage II bladder cancer
1512275|NCT00003930|stage III bladder cancer
1512276|NCT00003929|primary central nervous system lymphoma
1512277|NCT00003929|AIDS-related primary CNS lymphoma
1512278|NCT00003928|stage IV renal cell cancer
1512279|NCT00003928|recurrent renal cell cancer
1512280|NCT00003927|stage II breast cancer
1512281|NCT00003927|stage IV breast cancer
1512282|NCT00003927|stage IIIA breast cancer
1512283|NCT00003927|stage IIIB breast cancer
1512284|NCT00003926|soft tissue sarcoma
1512285|NCT00003926|regional neuroblastoma
1512286|NCT00003926|disseminated neuroblastoma
1512287|NCT00003926|recurrent Wilms tumor
1512288|NCT00003926|recurrent retinoblastoma
1512289|NCT00003926|recurrent adult brain tumor
1512290|NCT00003926|adult rhabdomyosarcoma
1512291|NCT00003926|ovarian germ cell tumor
1512292|NCT00003926|chordoma
1512293|NCT00003926|ovarian sarcoma
1512294|NCT00003926|unresectable neuroblastoma
1512295|NCT00003926|desmoplastic small round cell tumor
1512296|NCT00003926|rhabdomyosarcoma
1512297|NCT00003926|Ewing sarcoma
1512298|NCT00003926|neuroectodermal tumor
1512299|NCT00003926|teratoma
1512300|NCT00003926|malignant testicular germ cell tumor
1512301|NCT00003926|malignant ovarian germ cell tumor
1512302|NCT00003926|extragonadal germ cell tumor
1512303|NCT00003926|malignant germ cell tumor
1512304|NCT00003926|hepatoblastoma
1512305|NCT00003926|liver cancer
1512306|NCT00003926|medulloblastoma
1512307|NCT00003926|cerebellar astrocytoma
1512308|NCT00003926|brain stem glioma
1512309|NCT00003926|glioma
1512310|NCT00003926|cerebral astrocytoma
1512311|NCT00003926|ependymoma
1512312|NCT00003925|unspecified adult solid tumor, protocol specific
1512313|NCT00003924|recurrent adult Hodgkin lymphoma
1512314|NCT00003924|Waldenström macroglobulinemia
1512315|NCT00003924|recurrent grade 1 follicular lymphoma
1512316|NCT00003924|recurrent grade 2 follicular lymphoma
1512317|NCT00003924|recurrent grade 3 follicular lymphoma
1512318|NCT00003924|recurrent adult diffuse small cleaved cell lymphoma
1512319|NCT00003924|recurrent adult diffuse mixed cell lymphoma
1512320|NCT00003924|recurrent adult diffuse large cell lymphoma
1512321|NCT00003924|recurrent adult immunoblastic large cell lymphoma
1512322|NCT00003924|recurrent adult lymphoblastic lymphoma
1512323|NCT00003924|recurrent adult Burkitt lymphoma
1512324|NCT00003924|recurrent mantle cell lymphoma
1512325|NCT00003924|recurrent marginal zone lymphoma
1512326|NCT00003924|recurrent small lymphocytic lymphoma
1512327|NCT00003924|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1512328|NCT00003924|nodal marginal zone B-cell lymphoma
1512329|NCT00003924|splenic marginal zone lymphoma
1512330|NCT00003923|stage I pancreatic cancer
1512331|NCT00003923|stage II pancreatic cancer
1512332|NCT00003923|stage III pancreatic cancer
1512333|NCT00003923|stage IV pancreatic cancer
1512334|NCT00003923|recurrent pancreatic cancer
1512335|NCT00003923|unresectable gallbladder cancer
1512336|NCT00003923|recurrent gallbladder cancer
1512337|NCT00003923|unresectable extrahepatic bile duct cancer
1512338|NCT00003923|recurrent extrahepatic bile duct cancer
1512339|NCT00003923|cholangiocarcinoma of the gallbladder
1512340|NCT00003923|cholangiocarcinoma of the extrahepatic bile duct
1513686|NCT00003704|recurrent vulvar cancer
1512341|NCT00003923|adult primary cholangiocellular carcinoma
1512342|NCT00003920|stage IV breast cancer
1512343|NCT00003920|recurrent breast cancer
1512344|NCT00003917|limited stage small cell lung cancer
1512345|NCT00003917|extensive stage small cell lung cancer
1512346|NCT00003917|recurrent small cell lung cancer
1512347|NCT00003916|adult glioblastoma
1512348|NCT00003916|adult anaplastic astrocytoma
1512349|NCT00003916|adult giant cell glioblastoma
1512350|NCT00003916|adult gliosarcoma
1512351|NCT00003915|adenocarcinoma of the prostate
1512352|NCT00003915|stage I prostate cancer
1512353|NCT00003914|stage IV renal cell cancer
1512354|NCT00003914|recurrent renal cell cancer
1512355|NCT00003913|recurrent childhood acute lymphoblastic leukemia
1512356|NCT00003913|recurrent childhood lymphoblastic lymphoma
1512357|NCT00003913|recurrent childhood acute myeloid leukemia
1512358|NCT00003913|relapsing chronic myelogenous leukemia
1512359|NCT00003913|chronic phase chronic myelogenous leukemia
1512360|NCT00003913|accelerated phase chronic myelogenous leukemia
1512361|NCT00003913|childhood acute myeloid leukemia in remission
1512362|NCT00003913|childhood acute lymphoblastic leukemia in remission
1512363|NCT00003913|recurrent/refractory childhood Hodgkin lymphoma
1512364|NCT00003913|refractory anemia
1512365|NCT00003913|refractory anemia with ringed sideroblasts
1512366|NCT00003913|refractory anemia with excess blasts
1512367|NCT00003913|refractory anemia with excess blasts in transformation
1512368|NCT00003913|chronic myelomonocytic leukemia
1512369|NCT00003913|acute undifferentiated leukemia
1512370|NCT00003913|secondary acute myeloid leukemia
1512371|NCT00003913|de novo myelodysplastic syndromes
1512372|NCT00003913|previously treated myelodysplastic syndromes
1512373|NCT00003913|secondary myelodysplastic syndromes
1512374|NCT00003913|recurrent childhood small noncleaved cell lymphoma
1512375|NCT00003913|recurrent childhood large cell lymphoma
1512376|NCT00003913|juvenile myelomonocytic leukemia
1512377|NCT00003913|blastic phase chronic myelogenous leukemia
1512378|NCT00003913|childhood chronic myelogenous leukemia
1512379|NCT00003913|atypical chronic myeloid leukemia
1512380|NCT00003913|myelodysplastic/myeloproliferative disease, unclassifiable
1512381|NCT00003912|stage I childhood liver cancer
1512382|NCT00003912|stage II childhood liver cancer
1512383|NCT00003912|stage III childhood liver cancer
1512384|NCT00003912|stage IV childhood liver cancer
1512385|NCT00003912|recurrent childhood liver cancer
1512386|NCT00003912|childhood hepatoblastoma
1512387|NCT00003912|childhood hepatocellular carcinoma
1512388|NCT00003911|stage IV melanoma
1512389|NCT00003911|recurrent melanoma
1512390|NCT00003911|tumors metastatic to brain
1512391|NCT00003910|stage I chronic lymphocytic leukemia
1512392|NCT00003910|stage II chronic lymphocytic leukemia
1512393|NCT00003910|stage III chronic lymphocytic leukemia
1512394|NCT00003910|stage IV chronic lymphocytic leukemia
1512395|NCT00003910|T-cell large granular lymphocyte leukemia
1512396|NCT00003910|LGL clone
1512397|NCT00003908|recurrent metastatic squamous neck cancer with occult primary
1512398|NCT00003908|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1512399|NCT00003908|stage IV squamous cell carcinoma of the lip and oral cavity
1512400|NCT00003908|recurrent squamous cell carcinoma of the lip and oral cavity
1512401|NCT00003908|stage IV squamous cell carcinoma of the oropharynx
1512402|NCT00003908|recurrent squamous cell carcinoma of the oropharynx
1512403|NCT00003908|stage IV squamous cell carcinoma of the nasopharynx
1512404|NCT00003908|recurrent squamous cell carcinoma of the nasopharynx
1512405|NCT00003908|stage IV squamous cell carcinoma of the hypopharynx
1512406|NCT00003908|recurrent squamous cell carcinoma of the hypopharynx
1512407|NCT00003908|stage IV squamous cell carcinoma of the larynx
1512408|NCT00003908|recurrent squamous cell carcinoma of the larynx
1512409|NCT00003908|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1512410|NCT00003908|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1512411|NCT00003907|localized unresectable adult primary liver cancer
1512412|NCT00003907|advanced adult primary liver cancer
1512413|NCT00003907|recurrent adult primary liver cancer
1512414|NCT00003907|adult primary hepatocellular carcinoma
1512415|NCT00003907|liver metastases
1512416|NCT00003906|breast cancer
1512417|NCT00003903|stage I prostate cancer
1512418|NCT00003903|stage IIB prostate cancer
1512419|NCT00003903|stage IIA prostate cancer
1512420|NCT00003903|stage III prostate cancer
1512421|NCT00003903|stage IV prostate cancer
1512422|NCT00003903|osteoporosis
1512423|NCT00003902|stage IV breast cancer
1512424|NCT00003901|stage I non-small cell lung cancer
1512425|NCT00003901|stage II non-small cell lung cancer
1512426|NCT00003901|squamous cell lung cancer
1512427|NCT00003901|large cell lung cancer
1512428|NCT00003901|stage IIIA non-small cell lung cancer
1512429|NCT00003901|adenocarcinoma of the lung
1512430|NCT00003900|recurrent non-small cell lung cancer
1512431|NCT00003900|stage IV non-small cell lung cancer
1512432|NCT00003899|unspecified adult solid tumor, protocol specific
1512433|NCT00003898|unspecified childhood solid tumor, protocol specific
1512434|NCT00003898|oral complications
1512435|NCT00003897|stage IV melanoma
1512436|NCT00003897|recurrent melanoma
1512437|NCT00003896|stage III ovarian epithelial cancer
1512438|NCT00003896|peritoneal cavity cancer
1512439|NCT00003896|fallopian tube cancer
1512440|NCT00003894|unspecified childhood solid tumor, protocol specific
1512441|NCT00003894|unspecified adult solid tumor, protocol specific
1512442|NCT00003894|graft versus host disease
1512443|NCT00003893|stage I breast cancer
1512444|NCT00003892|stage IV ovarian epithelial cancer
1512445|NCT00003892|recurrent ovarian epithelial cancer
1512446|NCT00003891|unspecified adult solid tumor, protocol specific
1512447|NCT00003890|unspecified adult solid tumor, protocol specific
1512448|NCT00003888|stage III squamous cell carcinoma of the lip and oral cavity
1512449|NCT00003888|stage IV squamous cell carcinoma of the lip and oral cavity
1512450|NCT00003888|stage III squamous cell carcinoma of the oropharynx
1512451|NCT00003888|stage IV squamous cell carcinoma of the oropharynx
1512452|NCT00003888|stage III squamous cell carcinoma of the hypopharynx
1512453|NCT00003888|stage IV squamous cell carcinoma of the hypopharynx
1512454|NCT00003888|stage III squamous cell carcinoma of the larynx
1512455|NCT00003888|stage IV squamous cell carcinoma of the larynx
1512456|NCT00003887|stage IV breast cancer
1512457|NCT00003887|stage IIIA breast cancer
1512458|NCT00003887|stage IIIB breast cancer
1512459|NCT00003887|recurrent childhood acute lymphoblastic leukemia
1512460|NCT00003887|recurrent adult Hodgkin lymphoma
1512461|NCT00003887|recurrent cutaneous T-cell non-Hodgkin lymphoma
1512462|NCT00003887|refractory multiple myeloma
1512463|NCT00003887|recurrent childhood rhabdomyosarcoma
1512464|NCT00003887|stage II ovarian epithelial cancer
1512465|NCT00003887|stage III ovarian epithelial cancer
1512466|NCT00003887|stage IV ovarian epithelial cancer
1512467|NCT00003887|recurrent ovarian epithelial cancer
1512468|NCT00003887|disseminated neuroblastoma
1512469|NCT00003887|recurrent neuroblastoma
1512470|NCT00003887|recurrent Wilms tumor and other childhood kidney tumors
1512471|NCT00003887|stage I multiple myeloma
1512472|NCT00003887|stage II multiple myeloma
1512473|NCT00003887|stage III multiple myeloma
1512474|NCT00003887|recurrent childhood lymphoblastic lymphoma
1512475|NCT00003887|stage III chronic lymphocytic leukemia
1512476|NCT00003887|stage IV chronic lymphocytic leukemia
1512477|NCT00003887|recurrent childhood acute myeloid leukemia
1512478|NCT00003887|recurrent adult acute myeloid leukemia
1512479|NCT00003887|recurrent adult acute lymphoblastic leukemia
1512480|NCT00003887|relapsing chronic myelogenous leukemia
1512481|NCT00003887|refractory chronic lymphocytic leukemia
1512482|NCT00003887|stage III malignant testicular germ cell tumor
1512483|NCT00003887|recurrent malignant testicular germ cell tumor
1512484|NCT00003887|chronic phase chronic myelogenous leukemia
1512485|NCT00003887|accelerated phase chronic myelogenous leukemia
1512486|NCT00003887|blastic phase chronic myelogenous leukemia
1512487|NCT00003887|meningeal chronic myelogenous leukemia
1512488|NCT00003887|chronic idiopathic myelofibrosis
1512489|NCT00003887|childhood acute promyelocytic leukemia (M3)
1512490|NCT00003887|testicular embryonal carcinoma
1512491|NCT00003887|testicular choriocarcinoma
1512492|NCT00003887|testicular teratoma
1512493|NCT00003887|testicular yolk sac tumor
1512494|NCT00003887|testicular embryonal carcinoma and teratoma
1512495|NCT00003887|testicular embryonal carcinoma and teratoma with seminoma
1512496|NCT00003887|testicular embryonal carcinoma and yolk sac tumor
1512497|NCT00003887|testicular embryonal carcinoma and yolk sac tumor with seminoma
1512498|NCT00003887|testicular embryonal carcinoma and seminoma
1512499|NCT00003887|testicular yolk sac tumor and teratoma
1512500|NCT00003887|testicular yolk sac tumor and teratoma with seminoma
1512501|NCT00003887|testicular choriocarcinoma and yolk sac tumor
1512502|NCT00003887|testicular choriocarcinoma and embryonal carcinoma
1512503|NCT00003887|testicular choriocarcinoma and teratoma
1512504|NCT00003887|testicular choriocarcinoma and seminoma
1512505|NCT00003887|refractory hairy cell leukemia
1512506|NCT00003887|recurrent/refractory childhood Hodgkin lymphoma
1512507|NCT00003887|recurrent ovarian germ cell tumor
1512508|NCT00003887|ovarian yolk sac tumor
1512509|NCT00003887|ovarian embryonal carcinoma
1512512|NCT00003887|ovarian immature teratoma
1512513|NCT00003887|ovarian mature teratoma
1512514|NCT00003887|ovarian monodermal and highly specialized teratoma
1512515|NCT00003887|ovarian mixed germ cell tumor
1512516|NCT00003887|stage III grade 1 follicular lymphoma
1512517|NCT00003887|stage III grade 2 follicular lymphoma
1512518|NCT00003887|stage III grade 3 follicular lymphoma
1512519|NCT00003887|stage III adult diffuse small cleaved cell lymphoma
1512520|NCT00003887|stage III adult diffuse mixed cell lymphoma
1512521|NCT00003887|stage III adult diffuse large cell lymphoma
1512522|NCT00003887|stage III adult immunoblastic large cell lymphoma
1512523|NCT00003887|stage III adult lymphoblastic lymphoma
1512524|NCT00003887|stage III adult Burkitt lymphoma
1512525|NCT00003887|stage IV grade 1 follicular lymphoma
1512526|NCT00003887|stage IV grade 2 follicular lymphoma
1512527|NCT00003887|stage IV grade 3 follicular lymphoma
1512528|NCT00003887|stage IV adult diffuse small cleaved cell lymphoma
1512529|NCT00003887|stage IV adult diffuse mixed cell lymphoma
1512530|NCT00003887|stage IV adult diffuse large cell lymphoma
1512531|NCT00003887|stage IV adult immunoblastic large cell lymphoma
1512532|NCT00003887|stage IV adult lymphoblastic lymphoma
1512533|NCT00003887|stage IV adult Burkitt lymphoma
1512534|NCT00003887|recurrent grade 1 follicular lymphoma
1512535|NCT00003887|recurrent grade 2 follicular lymphoma
1512536|NCT00003887|recurrent grade 3 follicular lymphoma
1512537|NCT00003887|recurrent adult diffuse small cleaved cell lymphoma
1512538|NCT00003887|recurrent adult diffuse mixed cell lymphoma
1512539|NCT00003887|recurrent adult diffuse large cell lymphoma
1512540|NCT00003887|recurrent adult immunoblastic large cell lymphoma
1512541|NCT00003887|recurrent adult lymphoblastic lymphoma
1512542|NCT00003887|recurrent adult Burkitt lymphoma
1512543|NCT00003887|stage II adult T-cell leukemia/lymphoma
1512544|NCT00003887|secondary acute myeloid leukemia
1512545|NCT00003887|de novo myelodysplastic syndromes
1512546|NCT00003887|poor prognosis metastatic gestational trophoblastic tumor
1512547|NCT00003887|previously treated myelodysplastic syndromes
1512548|NCT00003887|secondary myelodysplastic syndromes
1512549|NCT00003887|recurrent childhood small noncleaved cell lymphoma
1512550|NCT00003887|recurrent childhood large cell lymphoma
1512551|NCT00003887|noncontiguous stage II grade 1 follicular lymphoma
1512552|NCT00003887|noncontiguous stage II grade 2 follicular lymphoma
1512553|NCT00003887|noncontiguous stage II grade 3 follicular lymphoma
1512554|NCT00003887|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1512555|NCT00003887|noncontiguous stage II mantle cell lymphoma
1512556|NCT00003887|noncontiguous stage II adult diffuse mixed cell lymphoma
1512557|NCT00003887|noncontiguous stage II adult immunoblastic large cell lymphoma
1512558|NCT00003887|noncontiguous stage II adult diffuse large cell lymphoma
1512559|NCT00003887|noncontiguous stage II adult Burkitt lymphoma
1512560|NCT00003887|noncontiguous stage II adult lymphoblastic lymphoma
1512561|NCT00003887|stage III mantle cell lymphoma
1512562|NCT00003887|stage IV mantle cell lymphoma
1512563|NCT00003887|recurrent mantle cell lymphoma
1512564|NCT00003887|previously treated childhood rhabdomyosarcoma
1512565|NCT00003887|recurrent mycosis fungoides/Sezary syndrome
1512566|NCT00003887|noncontiguous stage II small lymphocytic lymphoma
1512567|NCT00003887|noncontiguous stage II marginal zone lymphoma
1512568|NCT00003887|recurrent marginal zone lymphoma
1512569|NCT00003887|recurrent small lymphocytic lymphoma
1512570|NCT00003887|stage III small lymphocytic lymphoma
1512571|NCT00003887|stage III marginal zone lymphoma
1512572|NCT00003887|stage IV small lymphocytic lymphoma
1512573|NCT00003887|stage IV marginal zone lymphoma
1512574|NCT00003887|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1512575|NCT00003887|nodal marginal zone B-cell lymphoma
1512576|NCT00003887|splenic marginal zone lymphoma
1512577|NCT00003887|childhood myelodysplastic syndromes
1512578|NCT00003885|recurrent cutaneous T-cell non-Hodgkin lymphoma
1512579|NCT00003885|stage I multiple myeloma
1512580|NCT00003885|stage II multiple myeloma
1512581|NCT00003885|stage III multiple myeloma
1512582|NCT00003885|recurrent adult acute myeloid leukemia
1512583|NCT00003885|recurrent adult acute lymphoblastic leukemia
1512584|NCT00003885|blastic phase chronic myelogenous leukemia
1512585|NCT00003885|recurrent grade 1 follicular lymphoma
1512586|NCT00003885|recurrent grade 2 follicular lymphoma
1512587|NCT00003885|recurrent grade 3 follicular lymphoma
1512588|NCT00003885|recurrent adult diffuse small cleaved cell lymphoma
1512589|NCT00003885|recurrent adult diffuse mixed cell lymphoma
1512590|NCT00003885|recurrent adult diffuse large cell lymphoma
1512591|NCT00003885|recurrent adult immunoblastic large cell lymphoma
1512592|NCT00003885|recurrent adult lymphoblastic lymphoma
1512593|NCT00003885|recurrent adult Burkitt lymphoma
1512594|NCT00003885|recurrent adult T-cell leukemia/lymphoma
1512595|NCT00003885|previously treated myelodysplastic syndromes
1512596|NCT00003885|recurrent mantle cell lymphoma
1512597|NCT00003885|recurrent marginal zone lymphoma
1512598|NCT00003885|recurrent small lymphocytic lymphoma
1512599|NCT00003885|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1512600|NCT00003885|nodal marginal zone B-cell lymphoma
1512601|NCT00003885|splenic marginal zone lymphoma
1512602|NCT00003884|hypercalcemia of malignancy
1512603|NCT00003884|pain
1512604|NCT00003884|recurrent non-small cell lung cancer
1512605|NCT00003884|recurrent small cell lung cancer
1512606|NCT00003884|unspecified adult solid tumor, protocol specific
1512607|NCT00003884|bone metastases
1512608|NCT00003883|stage IV breast cancer
1512609|NCT00003883|stage IIIA breast cancer
1512610|NCT00003883|stage IIIB breast cancer
1512611|NCT00003883|recurrent childhood acute lymphoblastic leukemia
1512612|NCT00003883|recurrent adult Hodgkin lymphoma
1512613|NCT00003883|recurrent cutaneous T-cell non-Hodgkin lymphoma
1512614|NCT00003883|refractory multiple myeloma
1512615|NCT00003883|recurrent childhood rhabdomyosarcoma
1512616|NCT00003883|stage II ovarian epithelial cancer
1512617|NCT00003883|stage III ovarian epithelial cancer
1512618|NCT00003883|stage IV ovarian epithelial cancer
1512619|NCT00003883|recurrent ovarian epithelial cancer
1512620|NCT00003883|disseminated neuroblastoma
1512621|NCT00003883|recurrent neuroblastoma
1512622|NCT00003883|recurrent Wilms tumor and other childhood kidney tumors
1512623|NCT00003883|stage I multiple myeloma
1512624|NCT00003883|stage II multiple myeloma
1512625|NCT00003883|stage III multiple myeloma
1512626|NCT00003883|recurrent childhood lymphoblastic lymphoma
1512627|NCT00003883|stage III chronic lymphocytic leukemia
1512628|NCT00003883|stage IV chronic lymphocytic leukemia
1512629|NCT00003883|recurrent childhood acute myeloid leukemia
1512630|NCT00003883|recurrent adult acute myeloid leukemia
1512631|NCT00003883|recurrent adult acute lymphoblastic leukemia
1512632|NCT00003883|relapsing chronic myelogenous leukemia
1512633|NCT00003883|refractory chronic lymphocytic leukemia
1512634|NCT00003883|stage III malignant testicular germ cell tumor
1512635|NCT00003883|recurrent malignant testicular germ cell tumor
1512636|NCT00003883|chronic phase chronic myelogenous leukemia
1512637|NCT00003883|accelerated phase chronic myelogenous leukemia
1512638|NCT00003883|blastic phase chronic myelogenous leukemia
1512639|NCT00003883|meningeal chronic myelogenous leukemia
1512640|NCT00003883|chronic idiopathic myelofibrosis
1512641|NCT00003883|childhood acute promyelocytic leukemia (M3)
1512642|NCT00003883|testicular embryonal carcinoma
1512643|NCT00003883|testicular choriocarcinoma
1512644|NCT00003883|testicular teratoma
1512645|NCT00003883|testicular yolk sac tumor
1512646|NCT00003883|testicular embryonal carcinoma and teratoma
1512647|NCT00003883|testicular embryonal carcinoma and teratoma with seminoma
1512648|NCT00003883|testicular embryonal carcinoma and yolk sac tumor
1512649|NCT00003883|testicular embryonal carcinoma and yolk sac tumor with seminoma
1512650|NCT00003883|testicular embryonal carcinoma and seminoma
1512651|NCT00003883|testicular yolk sac tumor and teratoma
1512652|NCT00003883|testicular yolk sac tumor and teratoma with seminoma
1512653|NCT00003883|testicular choriocarcinoma and yolk sac tumor
1512654|NCT00003883|testicular choriocarcinoma and embryonal carcinoma
1512655|NCT00003883|testicular choriocarcinoma and teratoma
1512656|NCT00003883|testicular choriocarcinoma and seminoma
1512657|NCT00003883|refractory hairy cell leukemia
1512658|NCT00003883|recurrent/refractory childhood Hodgkin lymphoma
1512659|NCT00003883|recurrent ovarian germ cell tumor
1512660|NCT00003883|ovarian yolk sac tumor
1512661|NCT00003883|ovarian embryonal carcinoma
1512662|NCT00003883|ovarian polyembryoma
1512663|NCT00003883|ovarian choriocarcinoma
1512664|NCT00003883|ovarian immature teratoma
1512665|NCT00003883|ovarian mature teratoma
1512666|NCT00003883|ovarian monodermal and highly specialized teratoma
1512667|NCT00003883|ovarian mixed germ cell tumor
1512668|NCT00003883|stage III grade 1 follicular lymphoma
1512669|NCT00003883|stage III grade 2 follicular lymphoma
1512670|NCT00003883|stage III grade 3 follicular lymphoma
1512671|NCT00003883|stage III adult diffuse small cleaved cell lymphoma
1512672|NCT00003883|stage III adult diffuse mixed cell lymphoma
1512673|NCT00003883|stage III adult diffuse large cell lymphoma
1512674|NCT00003883|stage III adult immunoblastic large cell lymphoma
1512675|NCT00003883|stage III adult lymphoblastic lymphoma
1512676|NCT00003883|stage III adult Burkitt lymphoma
1512677|NCT00003883|stage IV grade 1 follicular lymphoma
1512678|NCT00003883|stage IV grade 2 follicular lymphoma
1512679|NCT00003883|stage IV grade 3 follicular lymphoma
1512680|NCT00003883|stage IV adult diffuse small cleaved cell lymphoma
1512681|NCT00003883|stage IV adult diffuse mixed cell lymphoma
1512682|NCT00003883|stage IV adult diffuse large cell lymphoma
1512683|NCT00003883|stage IV adult immunoblastic large cell lymphoma
1512684|NCT00003883|stage IV adult lymphoblastic lymphoma
1512685|NCT00003883|stage IV adult Burkitt lymphoma
1512686|NCT00003883|recurrent grade 1 follicular lymphoma
1512687|NCT00003883|recurrent grade 2 follicular lymphoma
1512688|NCT00003883|recurrent grade 3 follicular lymphoma
1512689|NCT00003883|recurrent adult diffuse small cleaved cell lymphoma
1512690|NCT00003883|recurrent adult diffuse mixed cell lymphoma
1512691|NCT00003883|recurrent adult diffuse large cell lymphoma
1512692|NCT00003883|recurrent adult immunoblastic large cell lymphoma
1512693|NCT00003883|recurrent adult lymphoblastic lymphoma
1512694|NCT00003883|recurrent adult Burkitt lymphoma
1512695|NCT00003883|secondary acute myeloid leukemia
1512696|NCT00003883|de novo myelodysplastic syndromes
1512697|NCT00003883|poor prognosis metastatic gestational trophoblastic tumor
1513362|NCT00003786|recurrent colon cancer
1512698|NCT00003883|previously treated myelodysplastic syndromes
1512699|NCT00003883|secondary myelodysplastic syndromes
1512700|NCT00003883|infection
1512701|NCT00003883|recurrent childhood small noncleaved cell lymphoma
1512702|NCT00003883|recurrent childhood large cell lymphoma
1512703|NCT00003883|noncontiguous stage II grade 1 follicular lymphoma
1512704|NCT00003883|noncontiguous stage II grade 2 follicular lymphoma
1512705|NCT00003883|noncontiguous stage II grade 3 follicular lymphoma
1512706|NCT00003883|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1512707|NCT00003883|noncontiguous stage II mantle cell lymphoma
1512708|NCT00003883|noncontiguous stage II adult diffuse mixed cell lymphoma
1512709|NCT00003883|noncontiguous stage II adult immunoblastic large cell lymphoma
1512710|NCT00003883|noncontiguous stage II adult diffuse large cell lymphoma
1512711|NCT00003883|noncontiguous stage II adult Burkitt lymphoma
1512712|NCT00003883|noncontiguous stage II adult lymphoblastic lymphoma
1512713|NCT00003883|stage III mantle cell lymphoma
1512714|NCT00003883|stage IV mantle cell lymphoma
1512715|NCT00003883|recurrent mantle cell lymphoma
1512716|NCT00003883|previously treated childhood rhabdomyosarcoma
1512717|NCT00003883|recurrent mycosis fungoides/Sezary syndrome
1512718|NCT00003883|noncontiguous stage II small lymphocytic lymphoma
1512719|NCT00003883|noncontiguous stage II marginal zone lymphoma
1512720|NCT00003883|recurrent marginal zone lymphoma
1512721|NCT00003883|recurrent small lymphocytic lymphoma
1512722|NCT00003883|stage III small lymphocytic lymphoma
1512723|NCT00003883|stage III marginal zone lymphoma
1512724|NCT00003883|stage IV small lymphocytic lymphoma
1512725|NCT00003883|stage IV marginal zone lymphoma
1512726|NCT00003883|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1512727|NCT00003883|nodal marginal zone B-cell lymphoma
1512728|NCT00003883|splenic marginal zone lymphoma
1512729|NCT00003883|childhood myelodysplastic syndromes
1512730|NCT00003882|unspecified adult solid tumor, protocol specific
1512731|NCT00003881|recurrent non-small cell lung cancer
1512732|NCT00003881|stage IIIB non-small cell lung cancer
1512733|NCT00003881|stage IV non-small cell lung cancer
1512734|NCT00003880|stage III ovarian epithelial cancer
1512735|NCT00003880|ovarian mixed epithelial carcinoma
1512736|NCT00003880|ovarian serous cystadenocarcinoma
1512737|NCT00003880|ovarian mucinous cystadenocarcinoma
1512738|NCT00003880|ovarian endometrioid adenocarcinoma
1512739|NCT00003880|ovarian clear cell cystadenocarcinoma
1512740|NCT00003880|primary peritoneal cavity cancer
1512741|NCT00003878|unspecified adult solid tumor, protocol specific
1512742|NCT00003878|tumors metastatic to brain
1512743|NCT00003877|stage IV breast cancer
1512744|NCT00003877|recurrent breast cancer
1512745|NCT00003876|recurrent adult brain tumor
1512746|NCT00003876|adult brain stem glioma
1512747|NCT00003876|adult glioblastoma
1512748|NCT00003876|adult anaplastic astrocytoma
1512749|NCT00003876|adult anaplastic oligodendroglioma
1512750|NCT00003876|adult mixed glioma
1512751|NCT00003876|adult giant cell glioblastoma
1512752|NCT00003876|adult gliosarcoma
1512753|NCT00003874|recurrent childhood acute lymphoblastic leukemia
1512754|NCT00003874|Waldenstrom macroglobulinemia
1512755|NCT00003874|recurrent childhood lymphoblastic lymphoma
1512756|NCT00003874|recurrent adult acute lymphoblastic leukemia
1512757|NCT00003874|refractory chronic lymphocytic leukemia
1512758|NCT00003874|B-cell chronic lymphocytic leukemia
1512759|NCT00003874|B-cell childhood acute lymphoblastic leukemia
1512760|NCT00003874|B-cell adult acute lymphoblastic leukemia
1512761|NCT00003874|recurrent grade 1 follicular lymphoma
1512762|NCT00003874|recurrent grade 2 follicular lymphoma
1512763|NCT00003874|recurrent grade 3 follicular lymphoma
1512764|NCT00003874|recurrent adult diffuse small cleaved cell lymphoma
1512765|NCT00003874|recurrent adult diffuse mixed cell lymphoma
1512766|NCT00003874|recurrent adult diffuse large cell lymphoma
1512767|NCT00003874|recurrent adult immunoblastic large cell lymphoma
1512768|NCT00003874|recurrent adult lymphoblastic lymphoma
1512769|NCT00003874|recurrent adult Burkitt lymphoma
1512770|NCT00003874|recurrent childhood small noncleaved cell lymphoma
1512771|NCT00003874|recurrent childhood large cell lymphoma
1512772|NCT00003874|recurrent mantle cell lymphoma
1512773|NCT00003874|recurrent marginal zone lymphoma
1512774|NCT00003874|recurrent small lymphocytic lymphoma
1512775|NCT00003874|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1512776|NCT00003874|nodal marginal zone B-cell lymphoma
1512777|NCT00003874|splenic marginal zone lymphoma
1512778|NCT00003871|stage IV prostate cancer
1512779|NCT00003871|recurrent prostate cancer
1512780|NCT00003870|recurrent childhood acute lymphoblastic leukemia
1512781|NCT00003870|recurrent adult acute lymphoblastic leukemia
1512782|NCT00003870|adult acute lymphoblastic leukemia in remission
1512783|NCT00003870|childhood acute lymphoblastic leukemia in remission
1512784|NCT00003868|recurrent childhood acute myeloid leukemia
1512785|NCT00003868|recurrent adult acute myeloid leukemia
1512786|NCT00003868|secondary acute myeloid leukemia
1512787|NCT00003868|adult acute myeloid leukemia with t(8;21)(q22;q22)
1512788|NCT00003868|adult acute myeloid leukemia with t(16;16)(p13;q22)
1512789|NCT00003868|adult acute myeloid leukemia with inv(16)(p13;q22)
1513363|NCT00003786|recurrent rectal cancer
1512790|NCT00003868|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1512791|NCT00003868|adult acute myeloid leukemia with t(15;17)(q22;q12)
1512792|NCT00003867|stage III colon cancer
1512793|NCT00003867|stage IV colon cancer
1512794|NCT00003867|stage IV breast cancer
1512795|NCT00003867|stage IIIA breast cancer
1512796|NCT00003867|recurrent breast cancer
1512797|NCT00003867|stage III gastric cancer
1512798|NCT00003867|stage IV gastric cancer
1512799|NCT00003867|recurrent gastric cancer
1512800|NCT00003867|stage IIIB breast cancer
1512801|NCT00003867|stage II pancreatic cancer
1512802|NCT00003867|stage III pancreatic cancer
1512803|NCT00003867|recurrent pancreatic cancer
1512804|NCT00003867|stage III rectal cancer
1512805|NCT00003867|stage IV rectal cancer
1512806|NCT00003867|recurrent colon cancer
1512807|NCT00003867|recurrent rectal cancer
1512808|NCT00003867|stage IV anal cancer
1512809|NCT00003867|recurrent anal cancer
1512810|NCT00003867|stage II esophageal cancer
1512811|NCT00003867|stage III esophageal cancer
1512812|NCT00003867|stage IV esophageal cancer
1512813|NCT00003867|stage IIIA anal cancer
1512814|NCT00003867|stage IIIB anal cancer
1512815|NCT00003867|recurrent esophageal cancer
1512816|NCT00003867|regional gastrointestinal carcinoid tumor
1512817|NCT00003867|metastatic gastrointestinal carcinoid tumor
1512818|NCT00003867|recurrent gastrointestinal carcinoid tumor
1512819|NCT00003867|localized unresectable adult primary liver cancer
1512820|NCT00003867|advanced adult primary liver cancer
1512821|NCT00003867|recurrent adult primary liver cancer
1512822|NCT00003867|small intestine adenocarcinoma
1512823|NCT00003867|small intestine lymphoma
1512824|NCT00003867|small intestine leiomyosarcoma
1512825|NCT00003867|unresectable gallbladder cancer
1512826|NCT00003867|recurrent gallbladder cancer
1512827|NCT00003867|unresectable extrahepatic bile duct cancer
1512828|NCT00003867|recurrent extrahepatic bile duct cancer
1512829|NCT00003867|recurrent small intestine cancer
1512830|NCT00003867|unspecified adult solid tumor, protocol specific
1512831|NCT00003867|newly diagnosed carcinoma of unknown primary
1512832|NCT00003867|carcinoma of the appendix
1512833|NCT00003867|recurrent carcinoma of unknown primary
1512834|NCT00003867|stage IV pancreatic cancer
1512835|NCT00003865|recurrent ovarian epithelial cancer
1512836|NCT00003865|ovarian serous cystadenocarcinoma
1512837|NCT00003864|stage III esophageal cancer
1512838|NCT00003864|stage IV esophageal cancer
1512839|NCT00003864|squamous cell carcinoma of the esophagus
1512840|NCT00003863|stage I adult diffuse small cleaved cell lymphoma
1512841|NCT00003863|stage I adult diffuse mixed cell lymphoma
1512842|NCT00003863|stage I adult diffuse large cell lymphoma
1512843|NCT00003863|stage I adult immunoblastic large cell lymphoma
1512844|NCT00003863|stage I adult Burkitt lymphoma
1512845|NCT00003863|stage III adult diffuse small cleaved cell lymphoma
1512846|NCT00003863|stage III adult diffuse mixed cell lymphoma
1512847|NCT00003863|stage III adult diffuse large cell lymphoma
1512848|NCT00003863|stage III adult immunoblastic large cell lymphoma
1512849|NCT00003863|stage III adult Burkitt lymphoma
1512850|NCT00003863|stage IV adult diffuse small cleaved cell lymphoma
1512851|NCT00003863|stage IV adult diffuse mixed cell lymphoma
1512852|NCT00003863|stage IV adult diffuse large cell lymphoma
1512853|NCT00003863|stage IV adult immunoblastic large cell lymphoma
1512854|NCT00003863|stage IV adult Burkitt lymphoma
1512855|NCT00003863|recurrent adult diffuse small cleaved cell lymphoma
1512856|NCT00003863|recurrent adult diffuse mixed cell lymphoma
1512857|NCT00003863|recurrent adult diffuse large cell lymphoma
1512858|NCT00003863|recurrent adult immunoblastic large cell lymphoma
1512859|NCT00003863|recurrent adult Burkitt lymphoma
1512860|NCT00003863|stage I mantle cell lymphoma
1512861|NCT00003863|contiguous stage II adult diffuse small cleaved cell lymphoma
1512862|NCT00003863|contiguous stage II mantle cell lymphoma
1512863|NCT00003863|contiguous stage II adult diffuse mixed cell lymphoma
1512864|NCT00003863|contiguous stage II adult immunoblastic large cell lymphoma
1512865|NCT00003863|contiguous stage II adult diffuse large cell lymphoma
1512866|NCT00003863|contiguous stage II adult Burkitt lymphoma
1512867|NCT00003863|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1512868|NCT00003863|noncontiguous stage II mantle cell lymphoma
1512869|NCT00003863|noncontiguous stage II adult diffuse mixed cell lymphoma
1512870|NCT00003863|noncontiguous stage II adult immunoblastic large cell lymphoma
1512871|NCT00003863|noncontiguous stage II adult diffuse large cell lymphoma
1512872|NCT00003863|noncontiguous stage II adult Burkitt lymphoma
1512873|NCT00003863|stage III mantle cell lymphoma
1512874|NCT00003863|stage IV mantle cell lymphoma
1512875|NCT00003863|recurrent mantle cell lymphoma
1512876|NCT00003862|stage I gastric cancer
1512877|NCT00003862|stage II gastric cancer
1512878|NCT00003862|stage III gastric cancer
1512879|NCT00003862|stage IV gastric cancer
1512880|NCT00003862|adenocarcinoma of the stomach
1512881|NCT00003860|extensive stage small cell lung cancer
1512882|NCT00003859|untreated childhood supratentorial primitive neuroectodermal tumor
1512883|NCT00003859|recurrent childhood supratentorial primitive neuroectodermal tumor
1512884|NCT00003858|adenocarcinoma of the prostate
1512885|NCT00003858|stage I prostate cancer
1512886|NCT00003858|stage IIB prostate cancer
1512887|NCT00003858|stage IIA prostate cancer
1512888|NCT00003858|stage III prostate cancer
1512889|NCT00003858|stage IV prostate cancer
1512890|NCT00003857|breast cancer in situ
1512891|NCT00003857|ductal breast carcinoma in situ
1512892|NCT00003856|recurrent salivary gland cancer
1512893|NCT00003856|recurrent metastatic squamous neck cancer with occult primary
1512894|NCT00003856|recurrent squamous cell carcinoma of the lip and oral cavity
1512895|NCT00003856|recurrent squamous cell carcinoma of the oropharynx
1512896|NCT00003856|recurrent squamous cell carcinoma of the nasopharynx
1512897|NCT00003856|recurrent squamous cell carcinoma of the hypopharynx
1512898|NCT00003856|recurrent squamous cell carcinoma of the larynx
1512899|NCT00003856|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1512900|NCT00003855|stage IA breast cancer
1512901|NCT00003855|stage IB breast cancer
1512902|NCT00003855|stage II breast cancer
1512903|NCT00003854|stage IA breast cancer
1512904|NCT00003854|stage IB breast cancer
1512905|NCT00003854|stage II breast cancer
1512906|NCT00003853|primary systemic amyloidosis
1512907|NCT00003852|recurrent malignant testicular germ cell tumor
1512908|NCT00003852|childhood germ cell tumor
1512909|NCT00003852|recurrent ovarian germ cell tumor
1512910|NCT00003852|extragonadal germ cell tumor
1512911|NCT00003851|malnutrition
1512912|NCT00003851|stage II pancreatic cancer
1512913|NCT00003851|stage III pancreatic cancer
1512914|NCT00003851|stage IV pancreatic cancer
1512915|NCT00003851|adenocarcinoma of the pancreas
1512916|NCT00003850|recurrent metastatic squamous neck cancer with occult primary
1512917|NCT00003850|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1512918|NCT00003850|stage IV squamous cell carcinoma of the lip and oral cavity
1512919|NCT00003850|recurrent squamous cell carcinoma of the lip and oral cavity
1512920|NCT00003850|stage IV squamous cell carcinoma of the oropharynx
1512921|NCT00003850|recurrent squamous cell carcinoma of the oropharynx
1512922|NCT00003850|stage IV squamous cell carcinoma of the nasopharynx
1512923|NCT00003850|recurrent squamous cell carcinoma of the nasopharynx
1512924|NCT00003850|stage IV squamous cell carcinoma of the hypopharynx
1512925|NCT00003850|recurrent squamous cell carcinoma of the hypopharynx
1512926|NCT00003850|stage IV squamous cell carcinoma of the larynx
1512927|NCT00003850|recurrent squamous cell carcinoma of the larynx
1512928|NCT00003850|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1512929|NCT00003850|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1512930|NCT00003849|recurrent adult Hodgkin lymphoma
1512931|NCT00003849|stage III grade 1 follicular lymphoma
1512932|NCT00003849|stage IV grade 1 follicular lymphoma
1512933|NCT00003847|recurrent small cell lung cancer
1512934|NCT00003847|intermediate type small cell lung cancer
1512935|NCT00003846|regional neuroblastoma
1512936|NCT00003846|disseminated neuroblastoma
1512937|NCT00003846|stage 4S neuroblastoma
1512938|NCT00003846|untreated childhood supratentorial primitive neuroectodermal tumor
1512939|NCT00003846|untreated childhood medulloblastoma
1512940|NCT00003846|newly diagnosed childhood ependymoma
1512941|NCT00003843|stage IV colon cancer
1512942|NCT00003843|stage IV rectal cancer
1512943|NCT00003843|recurrent colon cancer
1512944|NCT00003843|recurrent rectal cancer
1512945|NCT00003842|recurrent adult brain tumor
1512946|NCT00003842|adult glioblastoma
1512947|NCT00003842|adult anaplastic astrocytoma
1512948|NCT00003842|adult giant cell glioblastoma
1512949|NCT00003842|adult gliosarcoma
1512950|NCT00003840|recurrent adult acute myeloid leukemia
1512951|NCT00003840|secondary acute myeloid leukemia
1512952|NCT00003838|Graft-Versus-Leukemia
1512953|NCT00003838|Peripheral Blood Stem Cells
1512954|NCT00003838|Engraftment
1512955|NCT00003838|Cyclophosphamide
1512956|NCT00003838|Fludarabine
1512957|NCT00003838|Donor Apheresis
1512958|NCT00003838|Nonmyeloablative Bone Marrow Transplantation
1512959|NCT00003838|Graft-Versus-Tumor
1512960|NCT00003838|Graft-Versus-Host Disease
1512961|NCT00003838|Multiple Myeloma
1512962|NCT00003838|Extramedullary Plasmacytoma
1512963|NCT00003838|Chronic Disease
1512964|NCT00003838|Chronic Myelogenous Leukemia
1512965|NCT00003838|Acute Lymphoblastic Leukemia
1512966|NCT00003838|Acute Myelogenous Leukemia
1512967|NCT00003838|Myeloproliferative Disease
1512968|NCT00003838|Chronic Lymphocytic Leukemia
1512969|NCT00003838|Paroxysmal Nocturnal Hemoglobinuria
1512970|NCT00003838|Aplastic Anemia
1512971|NCT00003838|Myelodysplastic Syndrome (MDS)
1512972|NCT00003838|Chronic Myelomoncytic Leukemia
1512973|NCT00003838|Non-Hodgkin's Lymphoma (NHL)
1512974|NCT00003838|Hodgkin Disease
1512975|NCT00003838|Pure Red Cell Aplasia
1512976|NCT00003837|recurrent adult acute lymphoblastic leukemia
1512977|NCT00003837|T-cell adult acute lymphoblastic leukemia
1512978|NCT00003837|recurrent adult lymphoblastic lymphoma
1512979|NCT00003834|stage IV colon cancer
1512980|NCT00003834|stage IV rectal cancer
1512981|NCT00003834|recurrent colon cancer
1512982|NCT00003834|recurrent rectal cancer
1512983|NCT00003834|adenocarcinoma of the colon
1512984|NCT00003834|adenocarcinoma of the rectum
1512985|NCT00003834|liver metastases
1512988|NCT00003833|adenocarcinoma of the colon
1512989|NCT00003831|stage I non-small cell lung cancer
1512990|NCT00003831|stage II non-small cell lung cancer
1512991|NCT00003831|squamous cell lung cancer
1512992|NCT00003831|large cell lung cancer
1512993|NCT00003831|adenocarcinoma of the lung
1512994|NCT00003830|stage I breast cancer
1512995|NCT00003830|stage II breast cancer
1512996|NCT00003829|stage I chronic lymphocytic leukemia
1512997|NCT00003829|stage II chronic lymphocytic leukemia
1512998|NCT00003829|stage III chronic lymphocytic leukemia
1512999|NCT00003829|stage IV chronic lymphocytic leukemia
1513000|NCT00003829|B-cell chronic lymphocytic leukemia
1513001|NCT00003828|stage IV melanoma
1513002|NCT00003828|recurrent melanoma
1513003|NCT00003827|refractory anemia with excess blasts
1513004|NCT00003827|refractory anemia with excess blasts in transformation
1513005|NCT00003827|de novo myelodysplastic syndromes
1513006|NCT00003827|secondary myelodysplastic syndromes
1513007|NCT00003827|childhood myelodysplastic syndromes
1513008|NCT00003825|radiation enteritis
1513009|NCT00003825|diarrhea
1513011|NCT00003824|recurrent bladder cancer
1513012|NCT00003824|transitional cell carcinoma of the bladder
1513013|NCT00003822|unspecified adult solid tumor, protocol specific
1513014|NCT00003821|recurrent endometrial carcinoma
1513015|NCT00003819|stage I prostate cancer
1513016|NCT00003819|stage IIB prostate cancer
1513017|NCT00003819|stage IIA prostate cancer
1513018|NCT00003819|stage III prostate cancer
1513019|NCT00003819|recurrent prostate cancer
1513020|NCT00003817|unspecified adult solid tumor, protocol specific
1513021|NCT00003817|nausea and vomiting
1513022|NCT00003816|recurrent childhood acute lymphoblastic leukemia
1513023|NCT00003816|recurrent cutaneous T-cell non-Hodgkin lymphoma
1513024|NCT00003816|Burkitt lymphoma
1513025|NCT00003816|Waldenstrom macroglobulinemia
1513026|NCT00003816|recurrent childhood lymphoblastic lymphoma
1513027|NCT00003816|recurrent childhood acute myeloid leukemia
1513028|NCT00003816|recurrent adult acute myeloid leukemia
1513029|NCT00003816|recurrent adult acute lymphoblastic leukemia
1513030|NCT00003816|relapsing chronic myelogenous leukemia
1513031|NCT00003816|refractory chronic lymphocytic leukemia
1513032|NCT00003816|chronic phase chronic myelogenous leukemia
1513033|NCT00003816|accelerated phase chronic myelogenous leukemia
1513034|NCT00003816|blastic phase chronic myelogenous leukemia
1513035|NCT00003816|adult acute myeloid leukemia in remission
1513036|NCT00003816|adult acute lymphoblastic leukemia in remission
1513037|NCT00003816|childhood acute myeloid leukemia in remission
1513038|NCT00003816|childhood acute lymphoblastic leukemia in remission
1513039|NCT00003816|polycythemia vera
1513040|NCT00003816|essential thrombocythemia
1513041|NCT00003816|refractory anemia
1513042|NCT00003816|refractory anemia with excess blasts
1513043|NCT00003816|refractory anemia with excess blasts in transformation
1513044|NCT00003816|chronic myelomonocytic leukemia
1513045|NCT00003816|T-cell large granular lymphocyte leukemia
1513046|NCT00003816|acute undifferentiated leukemia
1513047|NCT00003816|recurrent grade 1 follicular lymphoma
1513048|NCT00003816|recurrent grade 2 follicular lymphoma
1513049|NCT00003816|recurrent grade 3 follicular lymphoma
1513050|NCT00003816|recurrent adult diffuse small cleaved cell lymphoma
1513051|NCT00003816|recurrent adult diffuse mixed cell lymphoma
1513052|NCT00003816|recurrent adult diffuse large cell lymphoma
1513053|NCT00003816|recurrent adult immunoblastic large cell lymphoma
1513054|NCT00003816|recurrent adult lymphoblastic lymphoma
1513055|NCT00003816|recurrent adult Burkitt lymphoma
1513056|NCT00003816|recurrent adult T-cell leukemia/lymphoma
1513057|NCT00003816|secondary acute myeloid leukemia
1513058|NCT00003816|de novo myelodysplastic syndromes
1513059|NCT00003816|previously treated myelodysplastic syndromes
1513060|NCT00003816|secondary myelodysplastic syndromes
1513061|NCT00003816|prolymphocytic leukemia
1513062|NCT00003816|intraocular lymphoma
1513063|NCT00003816|recurrent childhood small noncleaved cell lymphoma
1513064|NCT00003816|recurrent childhood large cell lymphoma
1513065|NCT00003816|recurrent mantle cell lymphoma
1513066|NCT00003816|angioimmunoblastic T-cell lymphoma
1513067|NCT00003816|anaplastic large cell lymphoma
1513068|NCT00003816|recurrent mycosis fungoides/Sezary syndrome
1513069|NCT00003816|primary myelofibrosis
1513070|NCT00003816|childhood chronic myelogenous leukemia
1513071|NCT00003816|atypical chronic myeloid leukemia
1513072|NCT00003816|myelodysplastic/myeloproliferative disease, unclassifiable
1513073|NCT00003816|recurrent marginal zone lymphoma
1513074|NCT00003816|recurrent small lymphocytic lymphoma
1513075|NCT00003816|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1513076|NCT00003816|nodal marginal zone B-cell lymphoma
1513077|NCT00003816|splenic marginal zone lymphoma
1513078|NCT00003816|adult acute myeloid leukemia with t(8;21)(q22;q22)
1513079|NCT00003816|adult acute myeloid leukemia with t(16;16)(p13;q22)
1513080|NCT00003816|adult acute myeloid leukemia with inv(16)(p13;q22)
1513081|NCT00003816|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1513082|NCT00003816|adult acute myeloid leukemia with t(15;17)(q22;q12)
1513083|NCT00003816|childhood myelodysplastic syndromes
1513084|NCT00003816|aplastic anemia
1513085|NCT00003816|unspecified adult solid tumor, protocol specific
1513086|NCT00003816|unspecified childhood solid tumor, protocol specific
1513087|NCT00003815|stage I adult diffuse mixed cell lymphoma
1513088|NCT00003815|stage I adult diffuse large cell lymphoma
1513089|NCT00003815|stage I adult immunoblastic large cell lymphoma
1513090|NCT00003815|stage I adult lymphoblastic lymphoma
1513091|NCT00003815|stage III adult diffuse mixed cell lymphoma
1513092|NCT00003815|stage III adult diffuse large cell lymphoma
1513093|NCT00003815|stage III adult immunoblastic large cell lymphoma
1513094|NCT00003815|stage III adult lymphoblastic lymphoma
1513095|NCT00003815|stage IV adult diffuse mixed cell lymphoma
1513096|NCT00003815|stage IV adult diffuse large cell lymphoma
1513097|NCT00003815|stage IV adult immunoblastic large cell lymphoma
1513098|NCT00003815|stage IV adult lymphoblastic lymphoma
1513099|NCT00003815|contiguous stage II adult diffuse mixed cell lymphoma
1513100|NCT00003815|contiguous stage II adult immunoblastic large cell lymphoma
1513101|NCT00003815|contiguous stage II adult diffuse large cell lymphoma
1513102|NCT00003815|contiguous stage II adult lymphoblastic lymphoma
1515116|NCT00003513|stage 4S neuroblastoma
1513103|NCT00003815|noncontiguous stage II adult diffuse mixed cell lymphoma
1513104|NCT00003815|noncontiguous stage II adult immunoblastic large cell lymphoma
1513105|NCT00003815|noncontiguous stage II adult diffuse large cell lymphoma
1513106|NCT00003815|noncontiguous stage II adult lymphoblastic lymphoma
1513107|NCT00003814|stage 0 bladder cancer
1513108|NCT00003814|stage I bladder cancer
1513109|NCT00003814|recurrent bladder cancer
1513110|NCT00003814|transitional cell carcinoma of the bladder
1513111|NCT00003812|limited stage small cell lung cancer
1513112|NCT00003811|drug/agent toxicity by tissue/organ
1513113|NCT00003811|childhood teratoma
1513114|NCT00003811|childhood malignant testicular germ cell tumor
1513115|NCT00003811|childhood malignant ovarian germ cell tumor
1513116|NCT00003811|childhood extragonadal germ cell tumor
1513117|NCT00003811|recurrent childhood malignant germ cell tumor
1513118|NCT00003810|stage III pancreatic cancer
1513119|NCT00003810|stage IV pancreatic cancer
1513120|NCT00003810|recurrent pancreatic cancer
1513121|NCT00003810|adenocarcinoma of the pancreas
1513122|NCT00003809|untreated metastatic squamous neck cancer with occult primary
1513123|NCT00003809|recurrent metastatic squamous neck cancer with occult primary
1513124|NCT00003809|stage III squamous cell carcinoma of the lip and oral cavity
1513125|NCT00003809|stage IV squamous cell carcinoma of the lip and oral cavity
1513126|NCT00003809|recurrent squamous cell carcinoma of the lip and oral cavity
1513127|NCT00003809|stage III squamous cell carcinoma of the oropharynx
1513128|NCT00003809|stage IV squamous cell carcinoma of the oropharynx
1513129|NCT00003809|recurrent squamous cell carcinoma of the oropharynx
1513130|NCT00003809|stage III squamous cell carcinoma of the hypopharynx
1513131|NCT00003809|stage IV squamous cell carcinoma of the hypopharynx
1513132|NCT00003809|recurrent squamous cell carcinoma of the hypopharynx
1513133|NCT00003809|stage III squamous cell carcinoma of the larynx
1513134|NCT00003809|stage IV squamous cell carcinoma of the larynx
1513135|NCT00003809|recurrent squamous cell carcinoma of the larynx
1513136|NCT00003809|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1513137|NCT00003809|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1513138|NCT00003809|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1513139|NCT00003808|stage 0 chronic lymphocytic leukemia
1513140|NCT00003808|stage I chronic lymphocytic leukemia
1513141|NCT00003808|stage II chronic lymphocytic leukemia
1513142|NCT00003808|B-cell chronic lymphocytic leukemia
1513143|NCT00003805|stage I adult Hodgkin lymphoma
1513144|NCT00003805|stage II adult Hodgkin lymphoma
1513145|NCT00003805|stage III adult Hodgkin lymphoma
1513146|NCT00003805|stage IV adult Hodgkin lymphoma
1513147|NCT00003805|recurrent childhood acute lymphoblastic leukemia
1513148|NCT00003805|recurrent adult Hodgkin lymphoma
1513149|NCT00003805|stage I cutaneous T-cell non-Hodgkin lymphoma
1513150|NCT00003805|stage II cutaneous T-cell non-Hodgkin lymphoma
1513151|NCT00003805|stage III cutaneous T-cell non-Hodgkin lymphoma
1513152|NCT00003805|stage IV cutaneous T-cell non-Hodgkin lymphoma
1513153|NCT00003805|recurrent cutaneous T-cell non-Hodgkin lymphoma
1513154|NCT00003805|Burkitt lymphoma
1513155|NCT00003805|stage 0 chronic lymphocytic leukemia
1513156|NCT00003805|Waldenstrom macroglobulinemia
1513157|NCT00003805|stage I multiple myeloma
1513158|NCT00003805|stage II multiple myeloma
1513159|NCT00003805|stage III multiple myeloma
1513160|NCT00003805|stage I childhood lymphoblastic lymphoma
1513161|NCT00003805|stage II childhood lymphoblastic lymphoma
1513162|NCT00003805|stage III childhood lymphoblastic lymphoma
1513163|NCT00003805|stage IV childhood lymphoblastic lymphoma
1513164|NCT00003805|recurrent childhood lymphoblastic lymphoma
1513165|NCT00003805|stage I chronic lymphocytic leukemia
1513166|NCT00003805|stage II chronic lymphocytic leukemia
1513167|NCT00003805|stage III chronic lymphocytic leukemia
1513168|NCT00003805|stage IV chronic lymphocytic leukemia
1513169|NCT00003805|recurrent childhood acute myeloid leukemia
1513170|NCT00003805|recurrent adult acute myeloid leukemia
1513171|NCT00003805|recurrent adult acute lymphoblastic leukemia
1513172|NCT00003805|relapsing chronic myelogenous leukemia
1513173|NCT00003805|refractory chronic lymphocytic leukemia
1513463|NCT00003763|ovarian sarcoma
1513174|NCT00003805|childhood diffuse large cell lymphoma
1513175|NCT00003805|childhood immunoblastic large cell lymphoma
1513176|NCT00003805|unspecified childhood solid tumor, protocol specific
1513177|NCT00003805|unspecified adult solid tumor, protocol specific
1513178|NCT00003805|chronic phase chronic myelogenous leukemia
1513179|NCT00003805|accelerated phase chronic myelogenous leukemia
1513180|NCT00003805|blastic phase chronic myelogenous leukemia
1513181|NCT00003805|meningeal chronic myelogenous leukemia
1513182|NCT00003805|adult acute myeloid leukemia in remission
1513183|NCT00003805|adult acute lymphoblastic leukemia in remission
1513184|NCT00003805|childhood acute myeloid leukemia in remission
1513185|NCT00003805|childhood acute lymphoblastic leukemia in remission
1513186|NCT00003805|fever, sweats, and hot flashes
1513187|NCT00003805|progressive hairy cell leukemia, initial treatment
1513188|NCT00003805|refractory hairy cell leukemia
1513189|NCT00003805|stage II childhood Hodgkin lymphoma
1513190|NCT00003805|stage I childhood Hodgkin lymphoma
1513191|NCT00003805|stage III childhood Hodgkin lymphoma
1513192|NCT00003805|stage IV childhood Hodgkin lymphoma
1513193|NCT00003805|recurrent/refractory childhood Hodgkin lymphoma
1513194|NCT00003805|stage I grade 2 follicular lymphoma
1513195|NCT00003805|stage I grade 3 follicular lymphoma
1513196|NCT00003805|stage I adult diffuse small cleaved cell lymphoma
1513197|NCT00003805|stage I adult diffuse mixed cell lymphoma
1513198|NCT00003805|stage I adult diffuse large cell lymphoma
1513199|NCT00003805|stage I adult immunoblastic large cell lymphoma
1513200|NCT00003805|stage I adult lymphoblastic lymphoma
1513201|NCT00003805|stage I adult Burkitt lymphoma
1513202|NCT00003805|stage III grade 1 follicular lymphoma
1513203|NCT00003805|stage III grade 2 follicular lymphoma
1513204|NCT00003805|stage III grade 3 follicular lymphoma
1513205|NCT00003805|stage III adult diffuse small cleaved cell lymphoma
1513206|NCT00003805|stage III adult diffuse mixed cell lymphoma
1513207|NCT00003805|stage III adult diffuse large cell lymphoma
1513208|NCT00003805|stage III adult immunoblastic large cell lymphoma
1513209|NCT00003805|stage III adult lymphoblastic lymphoma
1513210|NCT00003805|stage III adult Burkitt lymphoma
1513211|NCT00003805|stage IV grade 1 follicular lymphoma
1513212|NCT00003805|stage IV grade 2 follicular lymphoma
1513213|NCT00003805|stage IV grade 3 follicular lymphoma
1513214|NCT00003805|stage IV adult diffuse small cleaved cell lymphoma
1513215|NCT00003805|stage IV adult diffuse mixed cell lymphoma
1513216|NCT00003805|stage IV adult diffuse large cell lymphoma
1513217|NCT00003805|stage IV adult immunoblastic large cell lymphoma
1513218|NCT00003805|stage IV adult lymphoblastic lymphoma
1513219|NCT00003805|stage IV adult Burkitt lymphoma
1513220|NCT00003805|recurrent grade 1 follicular lymphoma
1513221|NCT00003805|recurrent grade 2 follicular lymphoma
1513222|NCT00003805|recurrent grade 3 follicular lymphoma
1513223|NCT00003805|recurrent adult diffuse small cleaved cell lymphoma
1513224|NCT00003805|recurrent adult diffuse mixed cell lymphoma
1513225|NCT00003805|recurrent adult diffuse large cell lymphoma
1513226|NCT00003805|recurrent adult immunoblastic large cell lymphoma
1513227|NCT00003805|recurrent adult lymphoblastic lymphoma
1513228|NCT00003805|recurrent adult Burkitt lymphoma
1513229|NCT00003805|stage I adult T-cell leukemia/lymphoma
1513230|NCT00003805|stage II adult T-cell leukemia/lymphoma
1513231|NCT00003805|stage III adult T-cell leukemia/lymphoma
1513232|NCT00003805|stage IV adult T-cell leukemia/lymphoma
1513233|NCT00003805|recurrent adult T-cell leukemia/lymphoma
1513234|NCT00003805|de novo myelodysplastic syndromes
1513235|NCT00003805|previously treated myelodysplastic syndromes
1513236|NCT00003805|secondary myelodysplastic syndromes
1513237|NCT00003805|infection
1513238|NCT00003805|bone marrow suppression
1513239|NCT00003805|stage I childhood small noncleaved cell lymphoma
1513240|NCT00003805|stage I childhood large cell lymphoma
1513241|NCT00003805|stage II childhood small noncleaved cell lymphoma
1513242|NCT00003805|stage II childhood large cell lymphoma
1513243|NCT00003805|stage III childhood small noncleaved cell lymphoma
1513244|NCT00003805|stage III childhood large cell lymphoma
1513245|NCT00003805|stage IV childhood small noncleaved cell lymphoma
1513246|NCT00003805|stage IV childhood large cell lymphoma
1513247|NCT00003805|recurrent childhood small noncleaved cell lymphoma
1513248|NCT00003805|recurrent childhood large cell lymphoma
1513249|NCT00003805|stage I mantle cell lymphoma
1513250|NCT00003805|contiguous stage II grade 1 follicular lymphoma
1513251|NCT00003805|contiguous stage II grade 2 follicular lymphoma
1513252|NCT00003805|contiguous stage II grade 3 follicular lymphoma
1513253|NCT00003805|contiguous stage II adult diffuse small cleaved cell lymphoma
1513254|NCT00003805|contiguous stage II mantle cell lymphoma
1513255|NCT00003805|contiguous stage II adult diffuse mixed cell lymphoma
1513256|NCT00003805|contiguous stage II adult immunoblastic large cell lymphoma
1513257|NCT00003805|contiguous stage II adult diffuse large cell lymphoma
1513258|NCT00003805|contiguous stage II adult Burkitt lymphoma
1513259|NCT00003805|contiguous stage II adult lymphoblastic lymphoma
1513260|NCT00003805|noncontiguous stage II grade 1 follicular lymphoma
1513261|NCT00003805|noncontiguous stage II grade 2 follicular lymphoma
1513262|NCT00003805|noncontiguous stage II grade 3 follicular lymphoma
1513263|NCT00003805|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1513264|NCT00003805|noncontiguous stage II mantle cell lymphoma
1513265|NCT00003805|noncontiguous stage II adult diffuse mixed cell lymphoma
1513266|NCT00003805|noncontiguous stage II adult immunoblastic large cell lymphoma
1513267|NCT00003805|noncontiguous stage II adult diffuse large cell lymphoma
1513268|NCT00003805|noncontiguous stage II adult Burkitt lymphoma
1513269|NCT00003805|noncontiguous stage II adult lymphoblastic lymphoma
1513270|NCT00003805|stage III mantle cell lymphoma
1513271|NCT00003805|stage IV mantle cell lymphoma
1513272|NCT00003805|recurrent mantle cell lymphoma
1513273|NCT00003805|contiguous stage II marginal zone lymphoma
1513274|NCT00003805|contiguous stage II small lymphocytic lymphoma
1513275|NCT00003805|noncontiguous stage II small lymphocytic lymphoma
1513276|NCT00003805|noncontiguous stage II marginal zone lymphoma
1513277|NCT00003805|recurrent marginal zone lymphoma
1513278|NCT00003805|recurrent small lymphocytic lymphoma
1513279|NCT00003805|stage I marginal zone lymphoma
1513280|NCT00003805|stage I small lymphocytic lymphoma
1513281|NCT00003805|stage III small lymphocytic lymphoma
1513282|NCT00003805|stage III marginal zone lymphoma
1513283|NCT00003805|stage IV small lymphocytic lymphoma
1513284|NCT00003805|stage IV marginal zone lymphoma
1513285|NCT00003805|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1513286|NCT00003805|nodal marginal zone B-cell lymphoma
1513287|NCT00003805|splenic marginal zone lymphoma
1513288|NCT00003805|childhood myelodysplastic syndromes
1513289|NCT00003804|stage I Wilms tumor
1513290|NCT00003803|stage I non-small cell lung cancer
1513291|NCT00003803|stage II non-small cell lung cancer
1513292|NCT00003803|stage III non-small cell lung cancer
1513293|NCT00003802|iris melanoma
1513294|NCT00003802|ciliary body and choroid melanoma, small size
1513295|NCT00003802|ciliary body and choroid melanoma, medium/large size
1513296|NCT00003802|extraocular extension melanoma
1513297|NCT00003802|recurrent intraocular melanoma
1513298|NCT00003802|stage IV melanoma
1513299|NCT00003802|recurrent melanoma
1513300|NCT00003801|long-term effects secondary to cancer therapy in children
1513301|NCT00003801|previously treated childhood rhabdomyosarcoma
1513302|NCT00003800|stage I malignant testicular germ cell tumor
1513303|NCT00003800|stage II malignant testicular germ cell tumor
1513304|NCT00003800|testicular embryonal carcinoma
1513305|NCT00003800|testicular choriocarcinoma
1513306|NCT00003800|testicular teratoma
1513307|NCT00003800|testicular yolk sac tumor
1513308|NCT00003800|testicular embryonal carcinoma and teratoma
1513309|NCT00003800|testicular embryonal carcinoma and yolk sac tumor
1513310|NCT00003800|testicular yolk sac tumor and teratoma
1513311|NCT00003800|testicular choriocarcinoma and yolk sac tumor
1513312|NCT00003800|testicular choriocarcinoma and embryonal carcinoma
1513313|NCT00003800|testicular choriocarcinoma and teratoma
1513314|NCT00003798|stage II pancreatic cancer
1513315|NCT00003798|stage III pancreatic cancer
1513316|NCT00003798|adenocarcinoma of the pancreas
1513317|NCT00003797|recurrent pancreatic cancer
1513318|NCT00003797|stage IV pancreatic cancer
1513319|NCT00003796|stage IV breast cancer
1513320|NCT00003796|recurrent breast cancer
1513321|NCT00003796|male breast cancer
1513322|NCT00003795|stage I ovarian epithelial cancer
1513323|NCT00003795|stage II ovarian epithelial cancer
1513324|NCT00003795|stage I endometrial carcinoma
1513325|NCT00003795|stage II endometrial carcinoma
1513326|NCT00003794|stage I ovarian germ cell tumor
1513327|NCT00003794|stage II ovarian germ cell tumor
1513328|NCT00003794|stage III ovarian germ cell tumor
1513329|NCT00003794|stage IV ovarian germ cell tumor
1513330|NCT00003794|recurrent ovarian germ cell tumor
1513331|NCT00003793|secondary acute myeloid leukemia
1513332|NCT00003793|secondary myelodysplastic syndromes
1513333|NCT00003793|localized osteosarcoma
1513334|NCT00003793|metastatic osteosarcoma
1513335|NCT00003793|childhood soft tissue sarcoma
1513336|NCT00003793|nonmetastatic childhood soft tissue sarcoma
1513337|NCT00003793|metastatic childhood soft tissue sarcoma
1513338|NCT00003793|childhood fibrosarcoma
1513339|NCT00003793|childhood synovial sarcoma
1513340|NCT00003793|childhood neurofibrosarcoma
1513341|NCT00003793|previously untreated childhood rhabdomyosarcoma
1513342|NCT00003793|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513343|NCT00003793|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513344|NCT00003792|stage IV melanoma
1513345|NCT00003792|recurrent melanoma
1513346|NCT00003790|recurrent childhood acute myeloid leukemia
1513347|NCT00003790|untreated childhood acute myeloid leukemia and other myeloid malignancies
1513348|NCT00003790|de novo myelodysplastic syndromes
1513349|NCT00003790|previously treated myelodysplastic syndromes
1513350|NCT00003790|secondary myelodysplastic syndromes
1513351|NCT00003788|recurrent adult brain tumor
1513352|NCT00003788|adult glioblastoma
1513353|NCT00003788|adult anaplastic astrocytoma
1513354|NCT00003788|adult giant cell glioblastoma
1513355|NCT00003788|adult gliosarcoma
1513356|NCT00003787|stage I breast cancer
1513357|NCT00003787|stage II breast cancer
1513358|NCT00003787|stage IIIA breast cancer
1513359|NCT00003787|recurrent breast cancer
1513360|NCT00003786|stage IV colon cancer
1513361|NCT00003786|stage IV rectal cancer
1513364|NCT00003786|adenocarcinoma of the colon
1513365|NCT00003786|adenocarcinoma of the rectum
1513366|NCT00003784|Waldenström macroglobulinemia
1513367|NCT00003784|stage III grade 1 follicular lymphoma
1513368|NCT00003784|stage III grade 2 follicular lymphoma
1513369|NCT00003784|stage III grade 3 follicular lymphoma
1513370|NCT00003784|stage IV grade 1 follicular lymphoma
1513371|NCT00003784|stage IV grade 2 follicular lymphoma
1513372|NCT00003784|stage IV grade 3 follicular lymphoma
1513373|NCT00003784|contiguous stage II grade 1 follicular lymphoma
1513374|NCT00003784|contiguous stage II grade 2 follicular lymphoma
1513375|NCT00003784|contiguous stage II grade 3 follicular lymphoma
1513376|NCT00003784|noncontiguous stage II grade 1 follicular lymphoma
1513377|NCT00003784|noncontiguous stage II grade 2 follicular lymphoma
1513378|NCT00003784|noncontiguous stage II grade 3 follicular lymphoma
1513379|NCT00003783|untreated childhood acute lymphoblastic leukemia
1513380|NCT00003783|L1 childhood acute lymphoblastic leukemia
1513381|NCT00003783|L2 childhood acute lymphoblastic leukemia
1513382|NCT00003783|B-cell childhood acute lymphoblastic leukemia
1513385|NCT00003782|stage IIIA breast cancer
1513386|NCT00003781|adenocarcinoma of the prostate
1513387|NCT00003781|stage IV prostate cancer
1513388|NCT00003781|recurrent prostate cancer
1513389|NCT00003781|pain
1513390|NCT00003780|stage II pancreatic cancer
1513391|NCT00003780|stage III pancreatic cancer
1513392|NCT00003780|stage IV pancreatic cancer
1513393|NCT00003779|stage 0 bladder cancer
1513394|NCT00003779|stage I bladder cancer
1513395|NCT00003778|recurrent adult soft tissue sarcoma
1513396|NCT00003778|stage IV uterine sarcoma
1513397|NCT00003778|recurrent uterine sarcoma
1513398|NCT00003778|ovarian sarcoma
1513399|NCT00003778|stage IV adult soft tissue sarcoma
1513400|NCT00003777|stage III lip and oral cavity cancer
1513401|NCT00003777|stage IV lip and oral cavity cancer
1513402|NCT00003777|recurrent lip and oral cavity cancer
1513403|NCT00003777|stage III hypopharyngeal cancer
1513404|NCT00003777|stage IV hypopharyngeal cancer
1513405|NCT00003777|recurrent hypopharyngeal cancer
1513406|NCT00003777|stage III laryngeal cancer
1513407|NCT00003777|stage IV laryngeal cancer
1513408|NCT00003777|recurrent laryngeal cancer
1513409|NCT00003777|stage III paranasal sinus and nasal cavity cancer
1513410|NCT00003777|stage IV paranasal sinus and nasal cavity cancer
1513411|NCT00003777|recurrent paranasal sinus and nasal cavity cancer
1513412|NCT00003777|stage III oropharyngeal cancer
1513413|NCT00003777|stage IV oropharyngeal cancer
1513414|NCT00003777|recurrent oropharyngeal cancer
1513415|NCT00003776|metastatic osteosarcoma
1513416|NCT00003775|recurrent adult brain tumor
1513417|NCT00003775|adult anaplastic astrocytoma
1513418|NCT00003775|adult mixed glioma
1513419|NCT00003773|recurrent ovarian epithelial cancer
1513420|NCT00003772|stage I ovarian epithelial cancer
1513421|NCT00003772|stage II ovarian epithelial cancer
1513422|NCT00003772|stage III ovarian epithelial cancer
1513423|NCT00003772|stage IV ovarian epithelial cancer
1513424|NCT00003772|recurrent ovarian epithelial cancer
1513425|NCT00003771|menopausal symptoms
1513426|NCT00003771|stage I breast cancer
1513427|NCT00003771|stage II breast cancer
1513428|NCT00003771|breast cancer in situ
1513429|NCT00003769|stage II pancreatic cancer
1513430|NCT00003769|stage III pancreatic cancer
1513431|NCT00003769|adenocarcinoma of the pancreas
1513432|NCT00003768|unspecified adult solid tumor, protocol specific
1513433|NCT00003766|unspecified adult solid tumor, protocol specific
1513434|NCT00003765|childhood craniopharyngioma
1513435|NCT00003765|childhood central nervous system germ cell tumor
1513436|NCT00003765|childhood oligodendroglioma
1513437|NCT00003765|childhood choroid plexus tumor
1513438|NCT00003765|recurrent childhood brain stem glioma
1513439|NCT00003765|recurrent childhood supratentorial primitive neuroectodermal tumor
1513440|NCT00003765|recurrent childhood visual pathway glioma
1513441|NCT00003765|recurrent childhood cerebellar astrocytoma
1513442|NCT00003765|recurrent childhood cerebral astrocytoma
1513443|NCT00003765|recurrent childhood medulloblastoma
1513444|NCT00003765|recurrent childhood ependymoma
1513445|NCT00003764|stage 0 chronic lymphocytic leukemia
1513446|NCT00003764|stage I chronic lymphocytic leukemia
1513447|NCT00003764|stage II chronic lymphocytic leukemia
1513448|NCT00003764|stage III chronic lymphocytic leukemia
1513449|NCT00003764|stage IV chronic lymphocytic leukemia
1513450|NCT00003764|B-cell chronic lymphocytic leukemia
1513451|NCT00003763|stage I ovarian epithelial cancer
1513452|NCT00003763|stage II ovarian epithelial cancer
1513453|NCT00003763|stage III ovarian epithelial cancer
1513454|NCT00003763|stage IV ovarian epithelial cancer
1513455|NCT00003763|recurrent ovarian epithelial cancer
1513456|NCT00003763|ovarian stromal cancer
1513457|NCT00003763|stage I ovarian germ cell tumor
1513458|NCT00003763|stage II ovarian germ cell tumor
1513459|NCT00003763|stage III ovarian germ cell tumor
1513460|NCT00003763|stage IV ovarian germ cell tumor
1513461|NCT00003763|recurrent ovarian germ cell tumor
1513462|NCT00003763|borderline ovarian surface epithelial-stromal tumor
1513464|NCT00003762|recurrent non-small cell lung cancer
1513465|NCT00003762|stage IIIB non-small cell lung cancer
1513466|NCT00003762|stage IV non-small cell lung cancer
1513467|NCT00003761|stage IV breast cancer
1513468|NCT00003761|recurrent breast cancer
1513469|NCT00003760|stage III pancreatic cancer
1513470|NCT00003760|stage IV pancreatic cancer
1513471|NCT00003760|recurrent pancreatic cancer
1513472|NCT00003760|adenocarcinoma of the pancreas
1513473|NCT00003759|stage 0 bladder cancer
1513474|NCT00003759|stage I bladder cancer
1513475|NCT00003759|recurrent bladder cancer
1513476|NCT00003758|recurrent childhood acute myeloid leukemia
1513477|NCT00003758|recurrent adult acute myeloid leukemia
1513478|NCT00003758|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
1513479|NCT00003758|childhood acute monoblastic leukemia and acute monocytic leukemia (M5)
1513480|NCT00003758|adult acute erythroid leukemia (M6)
1513481|NCT00003758|adult acute myeloblastic leukemia without maturation (M1)
1513482|NCT00003758|adult acute myeloblastic leukemia with maturation (M2)
1513483|NCT00003758|adult acute myelomonocytic leukemia (M4)
1513484|NCT00003758|adult acute eosinophilic leukemia
1513485|NCT00003758|adult acute basophilic leukemia
1513486|NCT00003758|adult acute megakaryoblastic leukemia (M7)
1513487|NCT00003758|childhood acute myeloblastic leukemia without maturation (M1)
1513488|NCT00003758|childhood acute myeloblastic leukemia with maturation (M2)
1513489|NCT00003758|childhood acute myelomonocytic leukemia (M4)
1513490|NCT00003758|childhood acute erythroleukemia (M6)
1513491|NCT00003758|childhood acute eosinophilic leukemia
1513492|NCT00003758|childhood acute basophilic leukemia
1513493|NCT00003758|childhood acute megakaryocytic leukemia (M7)
1513494|NCT00003758|adult acute minimally differentiated myeloid leukemia (M0)
1513495|NCT00003758|childhood acute minimally differentiated myeloid leukemia (M0)
1513496|NCT00003757|progressive hairy cell leukemia, initial treatment
1513497|NCT00003757|refractory hairy cell leukemia
1513498|NCT00003755|unspecified adult solid tumor, protocol specific
1513499|NCT00003754|unspecified childhood solid tumor, protocol specific
1513500|NCT00003753|stage IV colon cancer
1513501|NCT00003753|stage IV rectal cancer
1513502|NCT00003753|adenocarcinoma of the colon
1513503|NCT00003753|adenocarcinoma of the rectum
1513504|NCT00003753|liver metastases
1513505|NCT00003753|recurrent colon cancer
1513506|NCT00003753|recurrent rectal cancer
1513507|NCT00003752|stage IV breast cancer
1513508|NCT00003752|recurrent breast cancer
1513509|NCT00003751|adult glioblastoma
1513510|NCT00003751|adult giant cell glioblastoma
1513511|NCT00003751|adult gliosarcoma
1513512|NCT00003750|metastatic osteosarcoma
1513513|NCT00003750|recurrent neuroblastoma
1513514|NCT00003750|recurrent osteosarcoma
1513515|NCT00003750|recurrent melanoma
1513516|NCT00003750|unspecified childhood solid tumor, protocol specific
1513517|NCT00003750|metastatic childhood soft tissue sarcoma
1513518|NCT00003750|recurrent childhood soft tissue sarcoma
1513519|NCT00003749|stage I endometrial carcinoma
1513520|NCT00003749|stage II endometrial carcinoma
1513521|NCT00003749|endometrial clear cell carcinoma
1513522|NCT00003749|endometrial papillary serous carcinoma
1513523|NCT00003748|stage I gastric cancer
1513524|NCT00003748|stage II gastric cancer
1513525|NCT00003748|stage III gastric cancer
1513526|NCT00003748|stage IV gastric cancer
1513527|NCT00003748|recurrent gastric cancer
1513528|NCT00003748|stage I esophageal cancer
1513529|NCT00003748|stage II esophageal cancer
1513530|NCT00003748|stage III esophageal cancer
1513531|NCT00003748|stage IV esophageal cancer
1513532|NCT00003748|recurrent esophageal cancer
1513533|NCT00003748|adenocarcinoma of the stomach
1513534|NCT00003748|adenocarcinoma of the esophagus
1513535|NCT00003747|stage IV melanoma
1513536|NCT00003747|recurrent melanoma
1513537|NCT00003746|untreated hairy cell leukemia
1513538|NCT00003746|progressive hairy cell leukemia, initial treatment
1513539|NCT00003746|prolymphocytic leukemia
1513540|NCT00003745|recurrent childhood rhabdomyosarcoma
1513541|NCT00003745|recurrent osteosarcoma
1513542|NCT00003745|embryonal childhood rhabdomyosarcoma
1513543|NCT00003745|alveolar childhood rhabdomyosarcoma
1513544|NCT00003745|recurrent childhood soft tissue sarcoma
1513545|NCT00003745|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513546|NCT00003745|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513547|NCT00003744|stage III salivary gland cancer
1513548|NCT00003744|stage IV salivary gland cancer
1513549|NCT00003744|salivary gland squamous cell carcinoma
1513550|NCT00003744|salivary gland acinic cell tumor
1513551|NCT00003744|low-grade salivary gland mucoepidermoid carcinoma
1513552|NCT00003744|high-grade salivary gland mucoepidermoid carcinoma
1513553|NCT00003744|salivary gland adenocarcinoma
1513554|NCT00003744|salivary gland poorly differentiated carcinoma
1513555|NCT00003744|salivary gland anaplastic carcinoma
1513556|NCT00003744|salivary gland malignant mixed cell type tumor
1513557|NCT00003744|salivary gland adenoid cystic carcinoma
1513558|NCT00003743|disseminated neuroblastoma
1513559|NCT00003742|unspecified adult solid tumor, protocol specific
1513560|NCT00003741|recurrent adult Hodgkin lymphoma
1513561|NCT00003741|anaplastic large cell lymphoma
1513562|NCT00003740|stage IV prostate cancer
1513563|NCT00003740|recurrent prostate cancer
1513564|NCT00003739|unspecified childhood solid tumor, protocol specific
1513565|NCT00003739|fever, sweats, and hot flashes
1513566|NCT00003739|neutropenia
1513567|NCT00003737|recurrent neuroblastoma
1513568|NCT00003736|breast cancer
1513569|NCT00003735|recurrent childhood acute lymphoblastic leukemia
1513570|NCT00003735|recurrent childhood acute myeloid leukemia
1513571|NCT00003735|blastic phase chronic myelogenous leukemia
1513572|NCT00003734|adenocarcinoma of the prostate
1513573|NCT00003734|stage I prostate cancer
1513574|NCT00003734|stage IIB prostate cancer
1513575|NCT00003734|stage IIA prostate cancer
1513576|NCT00003734|stage III prostate cancer
1513577|NCT00003734|stage IV prostate cancer
1513578|NCT00003733|stage II ovarian epithelial cancer
1513579|NCT00003733|stage III ovarian epithelial cancer
1513580|NCT00003733|stage IV ovarian epithelial cancer
1513581|NCT00003732|stage IIB ovarian epithelial cancer
1513582|NCT00003732|stage IIC ovarian epithelial cancer
1513583|NCT00003732|stage IIIA ovarian epithelial cancer
1513584|NCT00003732|stage IIIB ovarian epithelial cancer
1513585|NCT00003732|stage IIIC ovarian epithelial cancer
1513586|NCT00003732|stage IV ovarian epithelial cancer
1513587|NCT00003731|adult oligodendroglioma
1513588|NCT00003731|adult mixed glioma
1513589|NCT00003730|stage IV breast cancer
1513590|NCT00003730|recurrent breast cancer
1513591|NCT00003729|recurrent childhood acute lymphoblastic leukemia
1513592|NCT00003729|L1 childhood acute lymphoblastic leukemia
1513593|NCT00003729|L2 childhood acute lymphoblastic leukemia
1513594|NCT00003728|stage I childhood lymphoblastic lymphoma
1513595|NCT00003728|stage II childhood lymphoblastic lymphoma
1513596|NCT00003728|stage III childhood lymphoblastic lymphoma
1513597|NCT00003728|stage IV childhood lymphoblastic lymphoma
1513598|NCT00003728|untreated childhood acute lymphoblastic leukemia
1513599|NCT00003728|L1 childhood acute lymphoblastic leukemia
1513600|NCT00003728|L2 childhood acute lymphoblastic leukemia
1513601|NCT00003728|T-cell childhood acute lymphoblastic leukemia
1513602|NCT00003728|B-cell childhood acute lymphoblastic leukemia
1513603|NCT00003728|acute undifferentiated leukemia
1513604|NCT00003727|relapsing chronic myelogenous leukemia
1513605|NCT00003727|chronic phase chronic myelogenous leukemia
1513606|NCT00003727|Philadelphia chromosome positive chronic myelogenous leukemia
1513607|NCT00003727|Philadelphia chromosome negative chronic myelogenous leukemia
1513608|NCT00003727|childhood chronic myelogenous leukemia
1513609|NCT00003726|extensive stage small cell lung cancer
1513610|NCT00003726|recurrent small cell lung cancer
1513611|NCT00003725|stage 0 bladder cancer
1513612|NCT00003725|stage I bladder cancer
1513613|NCT00003725|recurrent bladder cancer
1513614|NCT00003725|transitional cell carcinoma of the bladder
1513615|NCT00003724|lung metastases
1513616|NCT00003723|advanced malignant mesothelioma
1513617|NCT00003723|epithelial mesothelioma
1513618|NCT00003723|sarcomatous mesothelioma
1513619|NCT00003721|unspecified adult solid tumor, protocol specific
1513620|NCT00003720|AIDS-related Kaposi sarcoma
1513621|NCT00003720|recurrent Kaposi sarcoma
1513622|NCT00003719|stage IV adult soft tissue sarcoma
1513623|NCT00003719|recurrent adult soft tissue sarcoma
1513624|NCT00003718|adult angiosarcoma
1513625|NCT00003718|adult fibrosarcoma
1513626|NCT00003718|adult leiomyosarcoma
1513627|NCT00003718|adult liposarcoma
1513628|NCT00003718|adult neurofibrosarcoma
1513629|NCT00003718|adult synovial sarcoma
1513630|NCT00003718|recurrent adult soft tissue sarcoma
1513631|NCT00003718|adult extraskeletal chondrosarcoma
1513632|NCT00003718|adult alveolar soft-part sarcoma
1513633|NCT00003718|adult epithelioid sarcoma
1513634|NCT00003718|adult malignant fibrous histiocytoma
1513635|NCT00003718|adult malignant hemangiopericytoma
1513636|NCT00003718|adult malignant mesenchymoma
1513637|NCT00003718|adult rhabdomyosarcoma
1513638|NCT00003718|stage IV uterine sarcoma
1513639|NCT00003718|recurrent uterine sarcoma
1513640|NCT00003718|uterine carcinosarcoma
1513641|NCT00003718|uterine leiomyosarcoma
1513642|NCT00003718|endometrial stromal sarcoma
1513643|NCT00003718|ovarian sarcoma
1513644|NCT00003718|stage IV adult soft tissue sarcoma
1513645|NCT00003717|adenocarcinoma of the prostate
1513646|NCT00003717|stage IV prostate cancer
1513647|NCT00003717|recurrent prostate cancer
1513648|NCT00003716|childhood Burkitt lymphoma
1513649|NCT00003716|childhood immunoblastic large cell lymphoma
1513650|NCT00003716|stage IV adult immunoblastic large cell lymphoma
1513651|NCT00003716|stage IV adult Burkitt lymphoma
1513652|NCT00003716|recurrent adult immunoblastic large cell lymphoma
1513653|NCT00003716|recurrent adult Burkitt lymphoma
1513654|NCT00003716|stage IV childhood small noncleaved cell lymphoma
1513655|NCT00003716|stage IV childhood large cell lymphoma
1513656|NCT00003716|recurrent childhood small noncleaved cell lymphoma
1513657|NCT00003716|recurrent childhood large cell lymphoma
1513658|NCT00003715|stage III melanoma
1513659|NCT00003714|localized unresectable adult primary liver cancer
1513660|NCT00003714|advanced adult primary liver cancer
1513661|NCT00003714|adult primary hepatocellular carcinoma
1513662|NCT00003714|liver metastases
1513663|NCT00003713|unspecified adult solid tumor, protocol specific
1513664|NCT00003712|recurrent adult brain tumor
1513665|NCT00003712|unspecified adult solid tumor, protocol specific
1513666|NCT00003712|tumors metastatic to brain
1513667|NCT00003711|unspecified adult solid tumor, protocol specific
1513668|NCT00003710|unspecified adult solid tumor, protocol specific
1513669|NCT00003709|unspecified adult solid tumor, protocol specific
1513670|NCT00003708|unspecified adult solid tumor, protocol specific
1513671|NCT00003707|unspecified adult solid tumor, protocol specific
1513672|NCT00003706|unspecified adult solid tumor, protocol specific
1513673|NCT00003705|unspecified adult solid tumor, protocol specific
1513674|NCT00003704|stage III colon cancer
1513675|NCT00003704|stage III rectal cancer
1513676|NCT00003704|recurrent colon cancer
1513677|NCT00003704|recurrent rectal cancer
1513678|NCT00003704|recurrent anal cancer
1513679|NCT00003704|stage IIIA anal cancer
1513680|NCT00003704|stage IIIB anal cancer
1513681|NCT00003704|stage III cervical cancer
1513682|NCT00003704|recurrent cervical cancer
1513683|NCT00003704|stage III ovarian epithelial cancer
1513684|NCT00003704|recurrent ovarian epithelial cancer
1513687|NCT00003704|stage III vaginal cancer
1513688|NCT00003704|recurrent vaginal cancer
1513689|NCT00003704|stage III penile cancer
1513690|NCT00003704|recurrent penile cancer
1513691|NCT00003704|stage III endometrial carcinoma
1513692|NCT00003704|recurrent endometrial carcinoma
1513693|NCT00003704|stage III bladder cancer
1513694|NCT00003704|recurrent bladder cancer
1513695|NCT00003704|stage III malignant testicular germ cell tumor
1513696|NCT00003704|stage III prostate cancer
1513697|NCT00003704|recurrent prostate cancer
1513698|NCT00003704|recurrent malignant testicular germ cell tumor
1513699|NCT00003704|ovarian stromal cancer
1513700|NCT00003704|recurrent urethral cancer
1513701|NCT00003704|distal urethral cancer
1513702|NCT00003704|proximal urethral cancer
1513703|NCT00003704|stage III ovarian germ cell tumor
1513704|NCT00003704|recurrent ovarian germ cell tumor
1513705|NCT00003704|fallopian tube cancer
1513706|NCT00003704|primary peritoneal cavity cancer
1513707|NCT00003704|stage III uterine sarcoma
1513708|NCT00003704|recurrent uterine sarcoma
1513709|NCT00003704|borderline ovarian surface epithelial-stromal tumor
1513710|NCT00003704|ovarian sarcoma
1513711|NCT00003703|unspecified adult solid tumor, protocol specific
1513712|NCT00003701|stage III bladder cancer
1513713|NCT00003701|transitional cell carcinoma of the bladder
1513714|NCT00003701|urethral cancer associated with invasive bladder cancer
1513715|NCT00003700|untreated adult acute lymphoblastic leukemia
1513716|NCT00003700|L1 adult acute lymphoblastic leukemia
1513717|NCT00003700|L2 adult acute lymphoblastic leukemia
1513718|NCT00003698|unspecified adult solid tumor, protocol specific
1513719|NCT00003697|unspecified adult solid tumor, protocol specific
1513720|NCT00003696|extensive stage small cell lung cancer
1513721|NCT00003695|stage II ovarian epithelial cancer
1513722|NCT00003695|stage III ovarian epithelial cancer
1513723|NCT00003693|recurrent adult acute myeloid leukemia
1513724|NCT00003693|recurrent adult acute lymphoblastic leukemia
1513725|NCT00003693|relapsing chronic myelogenous leukemia
1513726|NCT00003693|blastic phase chronic myelogenous leukemia
1513727|NCT00003693|refractory anemia with excess blasts
1513728|NCT00003693|refractory anemia with excess blasts in transformation
1513729|NCT00003693|chronic myelomonocytic leukemia
1513730|NCT00003693|previously treated myelodysplastic syndromes
1513731|NCT00003693|childhood myelodysplastic syndromes
1513732|NCT00003692|occult non-small cell lung cancer
1513733|NCT00003692|stage I non-small cell lung cancer
1513734|NCT00003692|stage 0 non-small cell lung cancer
1513735|NCT00003691|stage III endometrial carcinoma
1513736|NCT00003691|stage IV endometrial carcinoma
1513737|NCT00003691|recurrent endometrial carcinoma
1513738|NCT00003690|stage IV breast cancer
1513739|NCT00003690|recurrent breast cancer
1513740|NCT00003690|stage IV prostate cancer
1513741|NCT00003690|recurrent prostate cancer
1513742|NCT00003690|stage IV melanoma
1513743|NCT00003690|recurrent melanoma
1513744|NCT00003690|unspecified adult solid tumor, protocol specific
1513745|NCT00003688|recurrent gestational trophoblastic tumor
1513746|NCT00003688|nonmetastatic gestational trophoblastic tumor
1513747|NCT00003688|low risk metastatic gestational trophoblastic tumor
1513748|NCT00003687|stage III adult Hodgkin lymphoma
1513749|NCT00003687|stage IV adult Hodgkin lymphoma
1513750|NCT00003687|monoclonal gammopathy of undetermined significance
1513751|NCT00003687|recurrent adult Hodgkin lymphoma
1513752|NCT00003687|stage III cutaneous T-cell non-Hodgkin lymphoma
1513753|NCT00003687|stage IV cutaneous T-cell non-Hodgkin lymphoma
1513754|NCT00003687|recurrent cutaneous T-cell non-Hodgkin lymphoma
1513755|NCT00003687|isolated plasmacytoma of bone
1513756|NCT00003687|extramedullary plasmacytoma
1513757|NCT00003687|refractory multiple myeloma
1513758|NCT00003687|Waldenstrom macroglobulinemia
1513759|NCT00003687|stage III multiple myeloma
1513760|NCT00003687|stage III chronic lymphocytic leukemia
1513761|NCT00003687|stage IV chronic lymphocytic leukemia
1513762|NCT00003687|recurrent adult acute myeloid leukemia
1513763|NCT00003687|recurrent adult acute lymphoblastic leukemia
1513764|NCT00003687|relapsing chronic myelogenous leukemia
1513765|NCT00003687|refractory chronic lymphocytic leukemia
1513766|NCT00003687|small intestine lymphoma
1513767|NCT00003687|unspecified adult solid tumor, protocol specific
1513768|NCT00003687|chronic phase chronic myelogenous leukemia
1513769|NCT00003687|accelerated phase chronic myelogenous leukemia
1513770|NCT00003687|blastic phase chronic myelogenous leukemia
1513771|NCT00003687|meningeal chronic myelogenous leukemia
1513772|NCT00003687|untreated adult acute lymphoblastic leukemia
1513773|NCT00003687|untreated adult acute myeloid leukemia
1513774|NCT00003687|adult acute myeloid leukemia in remission
1513775|NCT00003687|adult acute lymphoblastic leukemia in remission
1513776|NCT00003687|polycythemia vera
1513777|NCT00003687|chronic idiopathic myelofibrosis
1513778|NCT00003687|essential thrombocythemia
1513779|NCT00003687|untreated hairy cell leukemia
1513780|NCT00003687|progressive hairy cell leukemia, initial treatment
1513781|NCT00003687|refractory hairy cell leukemia
1513782|NCT00003687|chronic myelomonocytic leukemia
1513783|NCT00003687|T-cell large granular lymphocyte leukemia
1513784|NCT00003687|acute undifferentiated leukemia
1513785|NCT00003687|stage III grade 1 follicular lymphoma
1513786|NCT00003687|stage III grade 2 follicular lymphoma
1513787|NCT00003687|stage III grade 3 follicular lymphoma
1513788|NCT00003687|stage III adult diffuse small cleaved cell lymphoma
1513789|NCT00003687|stage III adult diffuse mixed cell lymphoma
1513790|NCT00003687|stage III adult diffuse large cell lymphoma
1513791|NCT00003687|stage III adult immunoblastic large cell lymphoma
1513792|NCT00003687|stage III adult lymphoblastic lymphoma
1513793|NCT00003687|stage III adult Burkitt lymphoma
1513794|NCT00003687|stage IV grade 1 follicular lymphoma
1513795|NCT00003687|stage IV grade 2 follicular lymphoma
1513796|NCT00003687|stage IV grade 3 follicular lymphoma
1513797|NCT00003687|stage IV adult diffuse small cleaved cell lymphoma
1513798|NCT00003687|stage IV adult diffuse mixed cell lymphoma
1513799|NCT00003687|stage IV adult diffuse large cell lymphoma
1513800|NCT00003687|stage IV adult immunoblastic large cell lymphoma
1513801|NCT00003687|stage IV adult lymphoblastic lymphoma
1513802|NCT00003687|stage IV adult Burkitt lymphoma
1513803|NCT00003687|recurrent grade 1 follicular lymphoma
1513804|NCT00003687|recurrent grade 2 follicular lymphoma
1513805|NCT00003687|recurrent grade 3 follicular lymphoma
1513806|NCT00003687|recurrent adult diffuse small cleaved cell lymphoma
1513807|NCT00003687|recurrent adult diffuse mixed cell lymphoma
1513808|NCT00003687|recurrent adult diffuse large cell lymphoma
1513809|NCT00003687|recurrent adult immunoblastic large cell lymphoma
1513810|NCT00003687|recurrent adult lymphoblastic lymphoma
1513811|NCT00003687|recurrent adult Burkitt lymphoma
1513812|NCT00003687|stage III adult T-cell leukemia/lymphoma
1513813|NCT00003687|stage IV adult T-cell leukemia/lymphoma
1513814|NCT00003687|recurrent adult T-cell leukemia/lymphoma
1513815|NCT00003687|secondary acute myeloid leukemia
1513816|NCT00003687|de novo myelodysplastic syndromes
1513817|NCT00003687|previously treated myelodysplastic syndromes
1513818|NCT00003687|secondary myelodysplastic syndromes
1513819|NCT00003687|pain
1513820|NCT00003687|prolymphocytic leukemia
1513821|NCT00003687|AIDS-related peripheral/systemic lymphoma
1513822|NCT00003687|AIDS-related primary CNS lymphoma
1513823|NCT00003687|primary systemic amyloidosis
1513824|NCT00003687|non-Hodgkin lymphoma during pregnancy
1513825|NCT00003687|stage III mantle cell lymphoma
1513826|NCT00003687|stage IV mantle cell lymphoma
1513827|NCT00003687|recurrent mantle cell lymphoma
1513828|NCT00003687|angioimmunoblastic T-cell lymphoma
1513829|NCT00003687|anaplastic large cell lymphoma
1513830|NCT00003687|stage III mycosis fungoides/Sezary syndrome
1513831|NCT00003687|stage IV mycosis fungoides/Sezary syndrome
1513832|NCT00003687|recurrent mycosis fungoides/Sezary syndrome
1513833|NCT00003687|chronic eosinophilic leukemia
1513834|NCT00003687|chronic neutrophilic leukemia
1513835|NCT00003687|recurrent marginal zone lymphoma
1513836|NCT00003687|recurrent small lymphocytic lymphoma
1513837|NCT00003687|stage III small lymphocytic lymphoma
1513838|NCT00003687|stage III marginal zone lymphoma
1513839|NCT00003687|stage IV small lymphocytic lymphoma
1513840|NCT00003687|stage IV marginal zone lymphoma
1513841|NCT00003687|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1513842|NCT00003687|nodal marginal zone B-cell lymphoma
1513843|NCT00003687|splenic marginal zone lymphoma
1513844|NCT00003687|childhood myelodysplastic syndromes
1513845|NCT00003686|oral complications
1513846|NCT00003686|quality of life
1513847|NCT00003685|stage III non-small cell lung cancer
1513848|NCT00003685|recurrent non-small cell lung cancer
1513849|NCT00003685|squamous cell lung cancer
1513850|NCT00003685|large cell lung cancer
1513851|NCT00003685|stage IV non-small cell lung cancer
1513852|NCT00003685|adenocarcinoma of the lung
1513853|NCT00003685|adenosquamous cell lung cancer
1513854|NCT00003685|fatigue
1513855|NCT00003685|nausea and vomiting
1513856|NCT00003685|pain
1513857|NCT00003685|pulmonary complications
1513858|NCT00003685|quality of life
1514142|NCT00003647|solid tumor
1513859|NCT00003684|unspecified adult solid tumor, protocol specific
1513860|NCT00003684|pulmonary complications
1513861|NCT00003684|quality of life
1513862|NCT00003683|stage IV renal cell cancer
1513863|NCT00003682|stage IV prostate cancer
1513864|NCT00003682|recurrent prostate cancer
1513865|NCT00003681|refractory anemia
1513866|NCT00003681|refractory anemia with ringed sideroblasts
1513867|NCT00003681|refractory anemia with excess blasts
1513868|NCT00003681|de novo myelodysplastic syndromes
1513869|NCT00003681|previously treated myelodysplastic syndromes
1513870|NCT00003681|secondary myelodysplastic syndromes
1513871|NCT00003681|anemia
1513872|NCT00003680|stage III breast cancer
1513873|NCT00003680|inflammatory breast cancer
1513874|NCT00003679|stage IIIA breast cancer
1513875|NCT00003679|stage IIIB breast cancer
1513876|NCT00003679|inflammatory breast cancer
1513877|NCT00003678|stage I breast cancer
1513878|NCT00003678|stage II breast cancer
1513879|NCT00003677|recurrent pancreatic cancer
1513880|NCT00003677|adenocarcinoma of the pancreas
1513881|NCT00003677|stage IV pancreatic cancer
1513882|NCT00003675|refractory anemia
1513883|NCT00003675|refractory anemia with ringed sideroblasts
1515117|NCT00003513|recurrent neuroblastoma
1513884|NCT00003675|refractory anemia with excess blasts
1513885|NCT00003675|refractory anemia with excess blasts in transformation
1513886|NCT00003675|chronic myelomonocytic leukemia
1513887|NCT00003675|de novo myelodysplastic syndromes
1513888|NCT00003675|secondary myelodysplastic syndromes
1513889|NCT00003675|refractory cytopenia with multilineage dysplasia
1513890|NCT00003675|childhood myelodysplastic syndromes
1513891|NCT00003674|stage IV colon cancer
1513892|NCT00003674|stage IV breast cancer
1513893|NCT00003674|recurrent breast cancer
1513894|NCT00003674|recurrent non-small cell lung cancer
1513895|NCT00003674|stage IV rectal cancer
1513896|NCT00003674|recurrent colon cancer
1513897|NCT00003674|recurrent rectal cancer
1513898|NCT00003674|extensive stage small cell lung cancer
1513899|NCT00003674|recurrent small cell lung cancer
1513900|NCT00003674|stage IV prostate cancer
1513901|NCT00003674|recurrent prostate cancer
1513902|NCT00003674|stage IV non-small cell lung cancer
1513903|NCT00003674|veno-occlusive disease
1513904|NCT00003673|recurrent adult acute myeloid leukemia
1513905|NCT00003671|untreated childhood acute lymphoblastic leukemia
1513906|NCT00003671|B-cell childhood acute lymphoblastic leukemia
1513907|NCT00003670|stage IV ovarian epithelial cancer
1513908|NCT00003670|recurrent ovarian epithelial cancer
1513909|NCT00003670|primary peritoneal cavity cancer
1513910|NCT00003669|stage IV endometrial carcinoma
1513911|NCT00003669|recurrent endometrial carcinoma
1513912|NCT00003667|nonmetastatic childhood soft tissue sarcoma
1513913|NCT00003667|metastatic childhood soft tissue sarcoma
1513914|NCT00003667|extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513915|NCT00003667|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513916|NCT00003667|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1513917|NCT00003666|recurrent non-small cell lung cancer
1513918|NCT00003666|squamous cell lung cancer
1513919|NCT00003666|large cell lung cancer
1513920|NCT00003666|adenocarcinoma of the lung
1513921|NCT00003666|bronchoalveolar cell lung cancer
1513922|NCT00003665|stage IV melanoma
1513923|NCT00003665|recurrent melanoma
1513924|NCT00003664|stage IV renal cell cancer
1513925|NCT00003664|recurrent renal cell cancer
1513926|NCT00003663|Waldenstrom macroglobulinemia
1513927|NCT00003663|stage III grade 1 follicular lymphoma
1513928|NCT00003663|stage III grade 2 follicular lymphoma
1513929|NCT00003663|stage III grade 3 follicular lymphoma
1513930|NCT00003663|stage IV grade 1 follicular lymphoma
1513931|NCT00003663|stage IV grade 2 follicular lymphoma
1513932|NCT00003663|stage IV grade 3 follicular lymphoma
1513933|NCT00003663|recurrent grade 1 follicular lymphoma
1513934|NCT00003663|recurrent grade 2 follicular lymphoma
1513935|NCT00003663|recurrent grade 3 follicular lymphoma
1513936|NCT00003663|recurrent marginal zone lymphoma
1513937|NCT00003663|recurrent small lymphocytic lymphoma
1513938|NCT00003663|stage III small lymphocytic lymphoma
1513939|NCT00003663|stage III marginal zone lymphoma
1513940|NCT00003663|stage IV small lymphocytic lymphoma
1513941|NCT00003663|stage IV marginal zone lymphoma
1513942|NCT00003663|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1513943|NCT00003663|nodal marginal zone B-cell lymphoma
1513944|NCT00003663|splenic marginal zone lymphoma
1513945|NCT00003662|noninvasive thymoma and thymic carcinoma
1513946|NCT00003662|recurrent thymoma and thymic carcinoma
1513947|NCT00003662|refractory anemia
1513948|NCT00003662|refractory anemia with ringed sideroblasts
1513949|NCT00003662|de novo myelodysplastic syndromes
1513950|NCT00003662|previously treated myelodysplastic syndromes
1513951|NCT00003662|secondary myelodysplastic syndromes
1513952|NCT00003662|graft versus host disease
1513953|NCT00003662|childhood myelodysplastic syndromes
1513954|NCT00003661|recurrent childhood acute lymphoblastic leukemia
1513955|NCT00003661|stage 4S neuroblastoma
1513956|NCT00003661|recurrent childhood lymphoblastic lymphoma
1513957|NCT00003661|recurrent adult acute lymphoblastic leukemia
1514143|NCT00003647|stage III melanoma
1513958|NCT00003661|chronic phase chronic myelogenous leukemia
1513959|NCT00003661|accelerated phase chronic myelogenous leukemia
1513960|NCT00003661|adult acute myeloid leukemia in remission
1513961|NCT00003661|adult acute lymphoblastic leukemia in remission
1513962|NCT00003661|childhood acute myeloid leukemia in remission
1513963|NCT00003661|childhood acute lymphoblastic leukemia in remission
1513964|NCT00003661|refractory anemia with excess blasts
1513965|NCT00003661|refractory anemia with excess blasts in transformation
1513966|NCT00003661|chronic myelomonocytic leukemia
1513967|NCT00003661|recurrent grade 1 follicular lymphoma
1513968|NCT00003661|recurrent grade 2 follicular lymphoma
1513969|NCT00003661|recurrent grade 3 follicular lymphoma
1513970|NCT00003661|recurrent adult diffuse small cleaved cell lymphoma
1513971|NCT00003661|recurrent adult diffuse mixed cell lymphoma
1513972|NCT00003661|recurrent adult diffuse large cell lymphoma
1513973|NCT00003661|recurrent adult immunoblastic large cell lymphoma
1513974|NCT00003661|recurrent adult lymphoblastic lymphoma
1513975|NCT00003661|recurrent adult Burkitt lymphoma
1513976|NCT00003661|de novo myelodysplastic syndromes
1513977|NCT00003661|previously treated myelodysplastic syndromes
1513978|NCT00003661|secondary myelodysplastic syndromes
1513979|NCT00003661|graft versus host disease
1513980|NCT00003661|adult acute minimally differentiated myeloid leukemia (M0)
1513981|NCT00003661|childhood acute minimally differentiated myeloid leukemia (M0)
1513982|NCT00003661|recurrent childhood small noncleaved cell lymphoma
1513983|NCT00003661|recurrent childhood large cell lymphoma
1513984|NCT00003661|recurrent mantle cell lymphoma
1513985|NCT00003661|recurrent marginal zone lymphoma
1513986|NCT00003661|recurrent small lymphocytic lymphoma
1513987|NCT00003661|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1513988|NCT00003661|nodal marginal zone B-cell lymphoma
1513989|NCT00003661|splenic marginal zone lymphoma
1513990|NCT00003661|childhood myelodysplastic syndromes
1513991|NCT00003659|stage II chronic lymphocytic leukemia
1513992|NCT00003659|stage III chronic lymphocytic leukemia
1513993|NCT00003659|stage IV chronic lymphocytic leukemia
1513994|NCT00003658|Waldenström macroglobulinemia
1513995|NCT00003658|stage II chronic lymphocytic leukemia
1513996|NCT00003658|stage III chronic lymphocytic leukemia
1513997|NCT00003658|stage IV chronic lymphocytic leukemia
1513998|NCT00003658|refractory chronic lymphocytic leukemia
1513999|NCT00003658|B-cell chronic lymphocytic leukemia
1514000|NCT00003658|stage I grade 1 follicular lymphoma
1514001|NCT00003658|stage I grade 2 follicular lymphoma
1514002|NCT00003658|stage III grade 1 follicular lymphoma
1514003|NCT00003658|stage III grade 2 follicular lymphoma
1514004|NCT00003658|stage IV grade 1 follicular lymphoma
1514005|NCT00003658|stage IV grade 2 follicular lymphoma
1514006|NCT00003658|recurrent grade 1 follicular lymphoma
1514007|NCT00003658|recurrent grade 2 follicular lymphoma
1514008|NCT00003658|contiguous stage II grade 1 follicular lymphoma
1514009|NCT00003658|contiguous stage II grade 2 follicular lymphoma
1514010|NCT00003658|noncontiguous stage II grade 1 follicular lymphoma
1514011|NCT00003658|noncontiguous stage II grade 2 follicular lymphoma
1514012|NCT00003658|contiguous stage II small lymphocytic lymphoma
1514013|NCT00003658|noncontiguous stage II small lymphocytic lymphoma
1514014|NCT00003658|recurrent small lymphocytic lymphoma
1514015|NCT00003658|stage I small lymphocytic lymphoma
1514016|NCT00003658|stage III small lymphocytic lymphoma
1514017|NCT00003658|stage IV small lymphocytic lymphoma
1514018|NCT00003657|metastatic osteosarcoma
1514019|NCT00003657|recurrent non-small cell lung cancer
1514020|NCT00003657|chondrosarcoma
1514021|NCT00003657|stage III adult soft tissue sarcoma
1514022|NCT00003657|recurrent adult soft tissue sarcoma
1514023|NCT00003657|stage III ovarian epithelial cancer
1514024|NCT00003657|stage IV ovarian epithelial cancer
1514025|NCT00003657|recurrent ovarian epithelial cancer
1514026|NCT00003657|extensive stage small cell lung cancer
1514027|NCT00003657|recurrent small cell lung cancer
1514028|NCT00003657|recurrent osteosarcoma
1514029|NCT00003657|stage III bladder cancer
1514030|NCT00003657|recurrent bladder cancer
1514031|NCT00003657|stage IV bladder cancer
1514032|NCT00003657|stage III malignant testicular germ cell tumor
1514033|NCT00003657|recurrent malignant testicular germ cell tumor
1514034|NCT00003657|stage IIIB non-small cell lung cancer
1514035|NCT00003657|unspecified adult solid tumor, protocol specific
1514036|NCT00003657|classic Kaposi sarcoma
1514037|NCT00003657|immunosuppressive treatment related Kaposi sarcoma
1514038|NCT00003657|AIDS-related Kaposi sarcoma
1514039|NCT00003657|recurrent Kaposi sarcoma
1514040|NCT00003657|untreated metastatic squamous neck cancer with occult primary
1514041|NCT00003657|recurrent metastatic squamous neck cancer with occult primary
1514042|NCT00003657|ovarian stromal cancer
1514043|NCT00003657|stage III ovarian germ cell tumor
1514044|NCT00003657|stage IV ovarian germ cell tumor
1514045|NCT00003657|recurrent ovarian germ cell tumor
1514046|NCT00003657|stage III squamous cell carcinoma of the lip and oral cavity
1514047|NCT00003657|stage III basal cell carcinoma of the lip
1514048|NCT00003657|stage III verrucous carcinoma of the oral cavity
1514049|NCT00003657|stage III mucoepidermoid carcinoma of the oral cavity
1514050|NCT00003657|stage III adenoid cystic carcinoma of the oral cavity
1514051|NCT00003657|stage IV squamous cell carcinoma of the lip and oral cavity
1514052|NCT00003657|stage IV basal cell carcinoma of the lip
1514053|NCT00003657|stage IV verrucous carcinoma of the oral cavity
1514054|NCT00003657|stage IV mucoepidermoid carcinoma of the oral cavity
1514055|NCT00003657|stage IV adenoid cystic carcinoma of the oral cavity
1514056|NCT00003657|recurrent squamous cell carcinoma of the lip and oral cavity
1514057|NCT00003657|recurrent basal cell carcinoma of the lip
1514058|NCT00003657|recurrent verrucous carcinoma of the oral cavity
1514059|NCT00003657|recurrent mucoepidermoid carcinoma of the oral cavity
1514060|NCT00003657|recurrent adenoid cystic carcinoma of the oral cavity
1514061|NCT00003657|stage III squamous cell carcinoma of the oropharynx
1514062|NCT00003657|stage III lymphoepithelioma of the oropharynx
1514063|NCT00003657|stage IV squamous cell carcinoma of the oropharynx
1514064|NCT00003657|stage IV lymphoepithelioma of the oropharynx
1514065|NCT00003657|recurrent squamous cell carcinoma of the oropharynx
1514066|NCT00003657|recurrent lymphoepithelioma of the oropharynx
1514067|NCT00003657|stage III squamous cell carcinoma of the nasopharynx
1514068|NCT00003657|stage III lymphoepithelioma of the nasopharynx
1514069|NCT00003657|stage IV squamous cell carcinoma of the nasopharynx
1520295|NCT00002764|adult leiomyosarcoma
1514070|NCT00003657|stage IV lymphoepithelioma of the nasopharynx
1514071|NCT00003657|recurrent squamous cell carcinoma of the nasopharynx
1514072|NCT00003657|recurrent lymphoepithelioma of the nasopharynx
1514073|NCT00003657|stage III squamous cell carcinoma of the hypopharynx
1514074|NCT00003657|stage IV squamous cell carcinoma of the hypopharynx
1514075|NCT00003657|recurrent squamous cell carcinoma of the hypopharynx
1514076|NCT00003657|stage III squamous cell carcinoma of the larynx
1514077|NCT00003657|stage III verrucous carcinoma of the larynx
1514078|NCT00003657|stage IV squamous cell carcinoma of the larynx
1514079|NCT00003657|stage IV verrucous carcinoma of the larynx
1514080|NCT00003657|recurrent squamous cell carcinoma of the larynx
1514081|NCT00003657|recurrent verrucous carcinoma of the larynx
1514082|NCT00003657|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1514083|NCT00003657|stage III inverted papilloma of the paranasal sinus and nasal cavity
1514084|NCT00003657|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1514085|NCT00003657|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1514086|NCT00003657|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1514087|NCT00003657|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1514088|NCT00003657|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1514089|NCT00003657|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1514090|NCT00003657|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1514091|NCT00003657|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1514092|NCT00003657|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1514093|NCT00003657|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1514094|NCT00003657|extragonadal germ cell tumor
1514095|NCT00003657|newly diagnosed carcinoma of unknown primary
1514096|NCT00003657|stage III uterine sarcoma
1514097|NCT00003657|stage IV uterine sarcoma
1514098|NCT00003657|recurrent uterine sarcoma
1514099|NCT00003657|borderline ovarian surface epithelial-stromal tumor
1514100|NCT00003657|recurrent carcinoma of unknown primary
1514101|NCT00003657|ovarian sarcoma
1514102|NCT00003657|adult central nervous system germ cell tumor
1514103|NCT00003657|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1514104|NCT00003657|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1514105|NCT00003657|clear cell sarcoma of the kidney
1514106|NCT00003657|stage IV adult soft tissue sarcoma
1514107|NCT00003656|stage IV renal cell cancer
1514108|NCT00003656|recurrent renal cell cancer
1514109|NCT00003654|stage I breast cancer
1514110|NCT00003654|stage II breast cancer
1514111|NCT00003653|adenocarcinoma of the prostate
1514112|NCT00003653|recurrent prostate cancer
1514113|NCT00003652|stage II anal cancer
1514114|NCT00003652|stage III anal cancer
1514115|NCT00003652|squamous cell carcinoma of the anus
1514116|NCT00003652|cloacogenic carcinoma of the anus
1514117|NCT00003652|basaloid carcinoma of the anus
1514118|NCT00003650|stage I childhood lymphoblastic lymphoma
1514119|NCT00003650|stage II childhood lymphoblastic lymphoma
1514120|NCT00003650|stage III childhood lymphoblastic lymphoma
1514121|NCT00003650|stage IV childhood lymphoblastic lymphoma
1514122|NCT00003649|recurrent non-small cell lung cancer
1514123|NCT00003649|stage IIIB non-small cell lung cancer
1514124|NCT00003649|stage IV non-small cell lung cancer
1514125|NCT00003649|bronchoalveolar cell lung cancer
1514126|NCT00003648|stage I colon cancer
1514127|NCT00003648|stage II colon cancer
1514128|NCT00003648|stage III colon cancer
1514129|NCT00003648|stage IV colon cancer
1514130|NCT00003648|stage I rectal cancer
1514131|NCT00003648|stage II rectal cancer
1514132|NCT00003648|stage III rectal cancer
1514133|NCT00003648|stage IV rectal cancer
1514134|NCT00003648|recurrent colon cancer
1514135|NCT00003648|recurrent rectal cancer
1514136|NCT00003647|adult solid tumor
1514137|NCT00003647|body system/site cancer
1514138|NCT00003647|cancer
1514139|NCT00003647|melanoma
1514140|NCT00003647|recurrent melanoma
1514141|NCT00003647|skin tumor
1514144|NCT00003647|stage IV melanoma
1514145|NCT00003647|stage, melanoma
1514146|NCT00003646|adult solid tumor
1514147|NCT00003646|body system/site cancer
1514148|NCT00003646|cancer
1514149|NCT00003646|melanoma
1514150|NCT00003646|recurrent melanoma
1514151|NCT00003646|skin tumor
1514152|NCT00003646|solid tumor
1514153|NCT00003646|stage III melanoma
1514154|NCT00003646|stage IV melanoma
1514155|NCT00003646|stage, melanoma
1514156|NCT00003645|stage I prostate cancer
1514157|NCT00003645|stage II prostate cancer
1514158|NCT00003644|stage I ovarian epithelial cancer
1514159|NCT00003644|stage II ovarian epithelial cancer
1514160|NCT00003644|ovarian undifferentiated adenocarcinoma
1514161|NCT00003644|ovarian mixed epithelial carcinoma
1514162|NCT00003644|ovarian serous cystadenocarcinoma
1514163|NCT00003644|ovarian mucinous cystadenocarcinoma
1514164|NCT00003644|ovarian endometrioid adenocarcinoma
1514165|NCT00003644|ovarian clear cell cystadenocarcinoma
1514166|NCT00003644|Brenner tumor
1514167|NCT00003643|stage III malignant testicular germ cell tumor
1514168|NCT00003643|testicular seminoma
1514169|NCT00003643|testicular embryonal carcinoma
1514170|NCT00003643|testicular choriocarcinoma
1514171|NCT00003643|testicular yolk sac tumor
1514172|NCT00003643|testicular embryonal carcinoma and teratoma
1514173|NCT00003643|testicular embryonal carcinoma and teratoma with seminoma
1514174|NCT00003643|testicular embryonal carcinoma and yolk sac tumor
1514175|NCT00003643|testicular embryonal carcinoma and yolk sac tumor with seminoma
1514176|NCT00003643|testicular embryonal carcinoma and seminoma
1514177|NCT00003643|testicular yolk sac tumor and teratoma
1514178|NCT00003643|testicular yolk sac tumor and teratoma with seminoma
1514179|NCT00003643|testicular choriocarcinoma and yolk sac tumor
1514180|NCT00003643|testicular choriocarcinoma and embryonal carcinoma
1514181|NCT00003643|testicular choriocarcinoma and teratoma
1514182|NCT00003643|testicular choriocarcinoma and seminoma
1514183|NCT00003643|stage IV extragonadal non-seminomatous germ cell tumor
1514184|NCT00003643|stage IV extragonadal seminoma
1514185|NCT00003643|testicular immature teratoma
1514186|NCT00003643|testicular mature teratoma
1514187|NCT00003643|adult teratoma
1514188|NCT00003642|stage II bladder cancer
1514189|NCT00003642|stage III bladder cancer
1514190|NCT00003642|transitional cell carcinoma of the bladder
1514191|NCT00003641|stage II melanoma
1514192|NCT00003641|stage III melanoma
1514193|NCT00003640|stage II bladder cancer
1514194|NCT00003640|stage III bladder cancer
1514195|NCT00003640|transitional cell carcinoma of the bladder
1514196|NCT00003639|stage III grade 1 follicular lymphoma
1514197|NCT00003639|stage III grade 2 follicular lymphoma
1514198|NCT00003639|stage IV grade 1 follicular lymphoma
1514199|NCT00003639|stage IV grade 2 follicular lymphoma
1514200|NCT00003639|contiguous stage II grade 1 follicular lymphoma
1514201|NCT00003639|contiguous stage II grade 2 follicular lymphoma
1514202|NCT00003639|noncontiguous stage II grade 1 follicular lymphoma
1514203|NCT00003639|noncontiguous stage II grade 2 follicular lymphoma
1514204|NCT00003639|noncontiguous stage II small lymphocytic lymphoma
1514205|NCT00003639|noncontiguous stage II marginal zone lymphoma
1514206|NCT00003639|stage III small lymphocytic lymphoma
1514207|NCT00003639|stage III marginal zone lymphoma
1514208|NCT00003639|stage IV small lymphocytic lymphoma
1514209|NCT00003639|stage IV marginal zone lymphoma
1514210|NCT00003639|contiguous stage II marginal zone lymphoma
1514211|NCT00003639|contiguous stage II small lymphocytic lymphoma
1514212|NCT00003639|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1514213|NCT00003639|nodal marginal zone B-cell lymphoma
1514214|NCT00003639|splenic marginal zone lymphoma
1514215|NCT00003638|stage IV breast cancer
1514216|NCT00003638|recurrent breast cancer
1514217|NCT00003637|stage III lymphoepithelioma of the nasopharynx
1514218|NCT00003637|stage IV squamous cell carcinoma of the nasopharynx
1514219|NCT00003637|stage III squamous cell carcinoma of the nasopharynx
1514220|NCT00003637|stage IV lymphoepithelioma of the nasopharynx
1514221|NCT00003636|stage III ovarian epithelial cancer
1514222|NCT00003636|stage IV ovarian epithelial cancer
1514223|NCT00003636|fallopian tube cancer
1514224|NCT00003636|primary peritoneal cavity cancer
1514225|NCT00003635|refractory chronic lymphocytic leukemia
1514226|NCT00003635|T-cell large granular lymphocyte leukemia
1514227|NCT00003635|B-cell chronic lymphocytic leukemia
1514228|NCT00003634|stage III ovarian epithelial cancer
1514229|NCT00003634|stage IV ovarian epithelial cancer
1514230|NCT00003634|fallopian tube cancer
1514231|NCT00003634|primary peritoneal cavity cancer
1514232|NCT00003633|adenocarcinoma of the prostate
1514233|NCT00003633|stage IV prostate cancer
1514234|NCT00003633|recurrent prostate cancer
1514235|NCT00003632|primary central nervous system non-Hodgkin lymphoma
1514236|NCT00003631|recurrent adult Hodgkin lymphoma
1514237|NCT00003631|recurrent/refractory childhood Hodgkin lymphoma
1514238|NCT00003630|unspecified childhood solid tumor, protocol specific
1514239|NCT00003630|unspecified adult solid tumor, protocol specific
1514240|NCT00003627|stage III squamous cell carcinoma of the oropharynx
1514241|NCT00003627|stage IV squamous cell carcinoma of the oropharynx
1514618|NCT00003571|stage III colon cancer
1514242|NCT00003627|stage III squamous cell carcinoma of the hypopharynx
1514243|NCT00003627|stage IV squamous cell carcinoma of the hypopharynx
1514244|NCT00003626|stage IV prostate cancer
1514245|NCT00003626|recurrent prostate cancer
1514246|NCT00003625|untreated childhood brain stem glioma
1514247|NCT00003624|stage I cervical cancer
1514248|NCT00003624|stage II cervical cancer
1514249|NCT00003624|stage III cervical cancer
1514250|NCT00003624|stage IV cervical cancer
1514251|NCT00003624|stage I ovarian epithelial cancer
1514252|NCT00003624|stage II ovarian epithelial cancer
1514253|NCT00003624|stage III ovarian epithelial cancer
1514254|NCT00003624|stage IV ovarian epithelial cancer
1514255|NCT00003624|stage I endometrial carcinoma
1514256|NCT00003624|stage II endometrial carcinoma
1514257|NCT00003624|stage III endometrial carcinoma
1514258|NCT00003624|stage IV endometrial carcinoma
1514259|NCT00003624|endometrial adenocarcinoma
1514260|NCT00003624|fallopian tube cancer
1514261|NCT00003624|primary peritoneal cavity cancer
1514262|NCT00003624|stage I uterine sarcoma
1514263|NCT00003624|stage II uterine sarcoma
1514264|NCT00003624|stage III uterine sarcoma
1514265|NCT00003624|stage IV uterine sarcoma
1514266|NCT00003624|neurotoxicity
1514267|NCT00003623|recurrent bladder cancer
1514268|NCT00003622|adenocarcinoma of the prostate
1514269|NCT00003622|stage IV prostate cancer
1514270|NCT00003622|recurrent prostate cancer
1514271|NCT00003621|adult anaplastic astrocytoma
1514272|NCT00003619|recurrent adult acute myeloid leukemia
1514273|NCT00003619|recurrent adult acute lymphoblastic leukemia
1514274|NCT00003619|relapsing chronic myelogenous leukemia
1514275|NCT00003619|blastic phase chronic myelogenous leukemia
1514276|NCT00003619|polycythemia vera
1514277|NCT00003619|primary myelofibrosis
1514278|NCT00003619|refractory anemia
1514279|NCT00003619|refractory anemia with ringed sideroblasts
1514280|NCT00003619|refractory anemia with excess blasts
1514281|NCT00003619|chronic myelomonocytic leukemia
1514282|NCT00003619|secondary acute myeloid leukemia
1514283|NCT00003619|previously treated myelodysplastic syndromes
1514284|NCT00003619|secondary myelodysplastic syndromes
1514285|NCT00003619|thrombocytopenia
1514286|NCT00003617|stage I gastric cancer
1514287|NCT00003616|recurrent adult brain tumor
1514288|NCT00003616|adult brain stem glioma
1514289|NCT00003616|adult oligodendroglioma
1514290|NCT00003616|adult mixed glioma
1514291|NCT00003616|adult diffuse astrocytoma
1514292|NCT00003615|Waldenstrom macroglobulinemia
1514293|NCT00003615|stage I grade 1 follicular lymphoma
1514294|NCT00003615|stage I grade 2 follicular lymphoma
1514295|NCT00003615|stage I grade 3 follicular lymphoma
1514296|NCT00003615|stage I adult diffuse large cell lymphoma
1514297|NCT00003615|stage III grade 1 follicular lymphoma
1514298|NCT00003615|stage III grade 2 follicular lymphoma
1514299|NCT00003615|stage III grade 3 follicular lymphoma
1514300|NCT00003615|stage III adult diffuse large cell lymphoma
1514301|NCT00003615|stage IV grade 1 follicular lymphoma
1514302|NCT00003615|stage IV grade 2 follicular lymphoma
1514303|NCT00003615|stage IV grade 3 follicular lymphoma
1514304|NCT00003615|stage IV adult diffuse large cell lymphoma
1514305|NCT00003615|recurrent grade 1 follicular lymphoma
1514306|NCT00003615|recurrent grade 2 follicular lymphoma
1514307|NCT00003615|recurrent grade 3 follicular lymphoma
1514308|NCT00003615|recurrent adult diffuse large cell lymphoma
1514309|NCT00003615|contiguous stage II grade 1 follicular lymphoma
1514310|NCT00003615|contiguous stage II grade 2 follicular lymphoma
1514311|NCT00003615|contiguous stage II grade 3 follicular lymphoma
1514312|NCT00003615|contiguous stage II adult diffuse large cell lymphoma
1514313|NCT00003615|noncontiguous stage II grade 1 follicular lymphoma
1514314|NCT00003615|noncontiguous stage II grade 2 follicular lymphoma
1514315|NCT00003615|noncontiguous stage II grade 3 follicular lymphoma
1514316|NCT00003615|noncontiguous stage II adult diffuse large cell lymphoma
1514317|NCT00003615|contiguous stage II marginal zone lymphoma
1514318|NCT00003615|contiguous stage II small lymphocytic lymphoma
1514319|NCT00003615|noncontiguous stage II small lymphocytic lymphoma
1514320|NCT00003615|noncontiguous stage II marginal zone lymphoma
1514321|NCT00003615|recurrent marginal zone lymphoma
1514322|NCT00003615|recurrent small lymphocytic lymphoma
1514323|NCT00003615|stage III small lymphocytic lymphoma
1514324|NCT00003615|stage III marginal zone lymphoma
1514325|NCT00003615|stage IV small lymphocytic lymphoma
1514326|NCT00003615|stage IV marginal zone lymphoma
1514327|NCT00003615|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1514328|NCT00003615|nodal marginal zone B-cell lymphoma
1514329|NCT00003615|splenic marginal zone lymphoma
1514330|NCT00003614|adenocarcinoma of the prostate
1514331|NCT00003614|stage IV prostate cancer
1514332|NCT00003614|recurrent prostate cancer
1514333|NCT00003612|stage IV breast cancer
1514334|NCT00003612|recurrent breast cancer
1514335|NCT00003611|basal cell carcinoma of the skin
1514336|NCT00003611|squamous cell carcinoma of the skin
1514337|NCT00003607|adenocarcinoma of the prostate
1514338|NCT00003607|stage I prostate cancer
1514339|NCT00003607|stage IIB prostate cancer
1514340|NCT00003607|stage IIA prostate cancer
1514341|NCT00003607|stage III prostate cancer
1514342|NCT00003606|extensive stage small cell lung cancer
1514343|NCT00003605|Waldenstrom macroglobulinemia
1514344|NCT00003605|stage III grade 1 follicular lymphoma
1514345|NCT00003605|stage III grade 2 follicular lymphoma
1514346|NCT00003605|stage III grade 3 follicular lymphoma
1514347|NCT00003605|stage III adult diffuse small cleaved cell lymphoma
1514348|NCT00003605|stage IV grade 1 follicular lymphoma
1514349|NCT00003605|stage IV grade 2 follicular lymphoma
1514350|NCT00003605|stage IV grade 3 follicular lymphoma
1514351|NCT00003605|stage IV adult diffuse small cleaved cell lymphoma
1514352|NCT00003605|stage III small lymphocytic lymphoma
1514353|NCT00003605|stage III marginal zone lymphoma
1514354|NCT00003605|stage IV small lymphocytic lymphoma
1514355|NCT00003605|stage IV marginal zone lymphoma
1514356|NCT00003605|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1514357|NCT00003605|nodal marginal zone B-cell lymphoma
1514358|NCT00003605|splenic marginal zone lymphoma
1514359|NCT00003604|stage III renal cell cancer
1514360|NCT00003604|stage IV renal cell cancer
1514361|NCT00003603|refractory multiple myeloma
1514362|NCT00003603|stage I multiple myeloma
1514363|NCT00003603|stage II multiple myeloma
1514364|NCT00003603|stage III multiple myeloma
1514365|NCT00003602|untreated adult acute myeloid leukemia
1514366|NCT00003602|refractory anemia with excess blasts
1514367|NCT00003602|refractory anemia with excess blasts in transformation
1514368|NCT00003602|secondary acute myeloid leukemia
1514369|NCT00003602|de novo myelodysplastic syndromes
1514370|NCT00003602|secondary myelodysplastic syndromes
1514371|NCT00003601|melanoma
1514372|NCT00003599|non-small cell lung cancer
1514373|NCT00003599|small cell lung cancer
1514374|NCT00003598|cervical cancer
1514375|NCT00003598|cervical intraepithelial neoplasia grade 2
1514376|NCT00003598|cervical intraepithelial neoplasia grade 3
1514377|NCT00003597|recurrent childhood rhabdomyosarcoma
1514378|NCT00003597|recurrent renal cell cancer
1514379|NCT00003597|recurrent neuroblastoma
1514380|NCT00003597|recurrent childhood liver cancer
1514381|NCT00003597|recurrent Wilms tumor and other childhood kidney tumors
1514382|NCT00003597|recurrent retinoblastoma
1514383|NCT00003597|childhood central nervous system germ cell tumor
1514384|NCT00003597|recurrent osteosarcoma
1514385|NCT00003597|recurrent gestational trophoblastic tumor
1514386|NCT00003597|recurrent malignant testicular germ cell tumor
1514387|NCT00003597|recurrent intraocular melanoma
1514388|NCT00003597|recurrent melanoma
1514389|NCT00003597|unspecified childhood solid tumor, protocol specific
1514390|NCT00003597|childhood germ cell tumor
1514391|NCT00003597|recurrent childhood soft tissue sarcoma
1514392|NCT00003597|recurrent ovarian germ cell tumor
1514393|NCT00003597|extragonadal germ cell tumor
1514394|NCT00003597|recurrent uterine sarcoma
1514395|NCT00003597|neutropenia
1514396|NCT00003597|thrombocytopenia
1514397|NCT00003597|recurrent childhood brain stem glioma
1514398|NCT00003597|recurrent childhood supratentorial primitive neuroectodermal tumor
1514399|NCT00003597|recurrent childhood visual pathway glioma
1514400|NCT00003597|recurrent childhood cerebellar astrocytoma
1514401|NCT00003597|recurrent childhood cerebral astrocytoma
1514402|NCT00003597|recurrent childhood medulloblastoma
1514403|NCT00003597|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1514404|NCT00003596|stage II anal cancer
1514405|NCT00003596|stage III anal cancer
1514406|NCT00003596|squamous cell carcinoma of the anus
1514407|NCT00003596|cloacogenic carcinoma of the anus
1514408|NCT00003596|basaloid carcinoma of the anus
1514409|NCT00003595|childhood Burkitt lymphoma
1514410|NCT00003595|AIDS-related peripheral/systemic lymphoma
1514411|NCT00003595|AIDS-related diffuse large cell lymphoma
1514412|NCT00003595|AIDS-related immunoblastic large cell lymphoma
1514413|NCT00003595|AIDS-related small noncleaved cell lymphoma
1514414|NCT00003594|stage III colon cancer
1514415|NCT00003594|stage IV colon cancer
1514416|NCT00003594|stage III rectal cancer
1514417|NCT00003594|stage IV rectal cancer
1514418|NCT00003594|recurrent colon cancer
1514419|NCT00003594|recurrent rectal cancer
1514420|NCT00003594|adenocarcinoma of the colon
1514421|NCT00003594|adenocarcinoma of the rectum
1514422|NCT00003593|childhood myelodysplastic syndromes
1514423|NCT00003593|untreated childhood acute myeloid leukemia and other myeloid malignancies
1514424|NCT00003593|childhood acute myeloblastic leukemia without maturation (M1)
1514425|NCT00003593|childhood acute myeloblastic leukemia with maturation (M2)
1514426|NCT00003593|childhood acute myelomonocytic leukemia (M4)
1514427|NCT00003593|childhood acute erythroleukemia (M6)
1514428|NCT00003593|childhood acute megakaryocytic leukemia (M7)
1514429|NCT00003593|refractory anemia
1514430|NCT00003593|refractory anemia with ringed sideroblasts
1514431|NCT00003593|refractory anemia with excess blasts
1514432|NCT00003593|refractory anemia with excess blasts in transformation
1514433|NCT00003593|de novo myelodysplastic syndromes
1514434|NCT00003593|childhood acute minimally differentiated myeloid leukemia (M0)
1514435|NCT00003593|childhood acute monocytic leukemia (M5b)
1514436|NCT00003593|childhood acute monoblastic leukemia (M5a)
1514437|NCT00003593|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1514438|NCT00003593|juvenile myelomonocytic leukemia
1514439|NCT00003593|chronic myelomonocytic leukemia
1514440|NCT00003593|secondary myelodysplastic syndromes
1514441|NCT00003592|stage IV salivary gland cancer
1514442|NCT00003592|recurrent salivary gland cancer
1514443|NCT00003592|salivary gland squamous cell carcinoma
1514444|NCT00003592|stage IV squamous cell carcinoma of the lip and oral cavity
1514445|NCT00003592|recurrent squamous cell carcinoma of the lip and oral cavity
1514446|NCT00003592|stage IV squamous cell carcinoma of the oropharynx
1514447|NCT00003592|recurrent squamous cell carcinoma of the oropharynx
1514448|NCT00003592|stage IV squamous cell carcinoma of the nasopharynx
1514449|NCT00003592|recurrent squamous cell carcinoma of the nasopharynx
1514450|NCT00003592|stage IV squamous cell carcinoma of the hypopharynx
1514451|NCT00003592|recurrent squamous cell carcinoma of the hypopharynx
1514452|NCT00003592|stage IV squamous cell carcinoma of the larynx
1514453|NCT00003592|recurrent squamous cell carcinoma of the larynx
1514454|NCT00003592|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1514455|NCT00003592|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1514456|NCT00003591|stage I pancreatic cancer
1514457|NCT00003591|stage II pancreatic cancer
1514458|NCT00003591|stage III pancreatic cancer
1514459|NCT00003591|recurrent pancreatic cancer
1514460|NCT00003591|adenocarcinoma of the pancreas
1514461|NCT00003590|recurrent adult brain tumor
1514462|NCT00003590|adult grade I meningioma
1514463|NCT00003589|recurrent small cell lung cancer
1514464|NCT00003589|stage IIIB non-small cell lung cancer
1514465|NCT00003589|stage IV non-small cell lung cancer
1514466|NCT00003588|stage IV ovarian epithelial cancer
1514467|NCT00003588|recurrent ovarian epithelial cancer
1514468|NCT00003587|recurrent non-small cell lung cancer
1514469|NCT00003587|squamous cell lung cancer
1514470|NCT00003587|large cell lung cancer
1514471|NCT00003587|stage IIIB non-small cell lung cancer
1514472|NCT00003587|stage IV non-small cell lung cancer
1514473|NCT00003587|adenocarcinoma of the lung
1514474|NCT00003585|stage IV renal cell cancer
1514475|NCT00003585|recurrent renal cell cancer
1514476|NCT00003584|stage IV renal cell cancer
1514477|NCT00003584|recurrent renal cell cancer
1514478|NCT00003583|limited stage small cell lung cancer
1514479|NCT00003583|drug/agent toxicity by tissue/organ
1514480|NCT00003583|radiation toxicity
1514481|NCT00003582|squamous cell carcinoma of unknown primary
1514482|NCT00003582|stage III squamous cell carcinoma of the lip and oral cavity
1514483|NCT00003582|stage IV squamous cell carcinoma of the lip and oral cavity
1514484|NCT00003582|stage III squamous cell carcinoma of the oropharynx
1514485|NCT00003582|stage IV squamous cell carcinoma of the oropharynx
1514486|NCT00003582|stage III squamous cell carcinoma of the nasopharynx
1514487|NCT00003582|stage IV squamous cell carcinoma of the nasopharynx
1514488|NCT00003582|stage III squamous cell carcinoma of the hypopharynx
1514489|NCT00003582|stage IV squamous cell carcinoma of the hypopharynx
1514490|NCT00003582|stage III squamous cell carcinoma of the larynx
1514491|NCT00003582|stage IV squamous cell carcinoma of the larynx
1514492|NCT00003582|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1514493|NCT00003582|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1514494|NCT00003580|oral complications
1514495|NCT00003580|stage III squamous cell carcinoma of the lip and oral cavity
1514496|NCT00003580|stage IV squamous cell carcinoma of the lip and oral cavity
1514497|NCT00003580|stage III squamous cell carcinoma of the oropharynx
1514498|NCT00003580|stage IV squamous cell carcinoma of the oropharynx
1514499|NCT00003580|stage III squamous cell carcinoma of the nasopharynx
1514500|NCT00003580|stage IV squamous cell carcinoma of the nasopharynx
1514501|NCT00003580|stage III squamous cell carcinoma of the hypopharynx
1514502|NCT00003580|stage IV squamous cell carcinoma of the hypopharynx
1514503|NCT00003580|stage III squamous cell carcinoma of the larynx
1514504|NCT00003580|stage IV squamous cell carcinoma of the larynx
1514505|NCT00003580|drug/agent toxicity by tissue/organ
1514506|NCT00003580|radiation toxicity
1514507|NCT00003578|stage III grade 3 follicular lymphoma
1514508|NCT00003578|stage III adult diffuse mixed cell lymphoma
1514509|NCT00003578|stage III adult diffuse large cell lymphoma
1514510|NCT00003578|stage III adult immunoblastic large cell lymphoma
1514511|NCT00003578|stage IV grade 3 follicular lymphoma
1514512|NCT00003578|stage IV adult diffuse mixed cell lymphoma
1514513|NCT00003578|stage IV adult diffuse large cell lymphoma
1514514|NCT00003578|stage IV adult immunoblastic large cell lymphoma
1514515|NCT00003577|stage I breast cancer
1514516|NCT00003577|stage II breast cancer
1514517|NCT00003576|stage III squamous cell carcinoma of the lip and oral cavity
1514518|NCT00003576|stage IV squamous cell carcinoma of the lip and oral cavity
1514519|NCT00003576|stage III squamous cell carcinoma of the oropharynx
1514520|NCT00003576|stage IV squamous cell carcinoma of the oropharynx
1514521|NCT00003576|stage III squamous cell carcinoma of the hypopharynx
1514522|NCT00003576|stage IV squamous cell carcinoma of the hypopharynx
1514523|NCT00003576|stage III squamous cell carcinoma of the larynx
1514524|NCT00003576|stage IV squamous cell carcinoma of the larynx
1514525|NCT00003576|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1514617|NCT00003572|splenic marginal zone lymphoma
1514526|NCT00003576|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1514527|NCT00003575|AIDS-related peripheral/systemic lymphoma
1514528|NCT00003575|AIDS-related diffuse large cell lymphoma
1514529|NCT00003575|AIDS-related immunoblastic large cell lymphoma
1514530|NCT00003575|AIDS-related small noncleaved cell lymphoma
1514531|NCT00003574|recurrent adult brain tumor
1514532|NCT00003574|adult glioblastoma
1514533|NCT00003574|adult anaplastic astrocytoma
1514534|NCT00003574|adult anaplastic oligodendroglioma
1514535|NCT00003574|adult giant cell glioblastoma
1514536|NCT00003574|adult gliosarcoma
1514537|NCT00003573|untreated childhood medulloblastoma
1514538|NCT00003572|stage I adult Hodgkin lymphoma
1514539|NCT00003572|stage II adult Hodgkin lymphoma
1514540|NCT00003572|stage III adult Hodgkin lymphoma
1514541|NCT00003572|stage IV adult Hodgkin lymphoma
1514542|NCT00003572|recurrent adult Hodgkin lymphoma
1514543|NCT00003572|Waldenstrom macroglobulinemia
1514544|NCT00003572|stage I multiple myeloma
1514545|NCT00003572|stage II multiple myeloma
1514546|NCT00003572|stage III multiple myeloma
1514547|NCT00003572|stage III chronic lymphocytic leukemia
1514548|NCT00003572|stage IV chronic lymphocytic leukemia
1514549|NCT00003572|chronic phase chronic myelogenous leukemia
1514550|NCT00003572|adult acute myeloid leukemia in remission
1514551|NCT00003572|adult acute lymphoblastic leukemia in remission
1514552|NCT00003572|stage I grade 1 follicular lymphoma
1514553|NCT00003572|stage I grade 2 follicular lymphoma
1514554|NCT00003572|stage I grade 3 follicular lymphoma
1514555|NCT00003572|stage I adult diffuse small cleaved cell lymphoma
1514556|NCT00003572|stage I adult diffuse mixed cell lymphoma
1514557|NCT00003572|stage I adult diffuse large cell lymphoma
1514558|NCT00003572|stage I adult immunoblastic large cell lymphoma
1514559|NCT00003572|stage I adult lymphoblastic lymphoma
1514560|NCT00003572|stage I adult Burkitt lymphoma
1514561|NCT00003572|stage III grade 1 follicular lymphoma
1514562|NCT00003572|stage III grade 2 follicular lymphoma
1514563|NCT00003572|stage III grade 3 follicular lymphoma
1514564|NCT00003572|stage III adult diffuse small cleaved cell lymphoma
1514565|NCT00003572|stage III adult diffuse mixed cell lymphoma
1514566|NCT00003572|stage III adult diffuse large cell lymphoma
1514567|NCT00003572|stage III adult immunoblastic large cell lymphoma
1514568|NCT00003572|stage III adult lymphoblastic lymphoma
1514569|NCT00003572|stage III adult Burkitt lymphoma
1514570|NCT00003572|stage IV grade 1 follicular lymphoma
1514571|NCT00003572|stage IV grade 2 follicular lymphoma
1514572|NCT00003572|stage IV grade 3 follicular lymphoma
1514573|NCT00003572|stage IV adult diffuse small cleaved cell lymphoma
1514574|NCT00003572|stage IV adult diffuse mixed cell lymphoma
1514575|NCT00003572|stage IV adult diffuse large cell lymphoma
1514576|NCT00003572|stage IV adult immunoblastic large cell lymphoma
1514577|NCT00003572|stage IV adult lymphoblastic lymphoma
1514578|NCT00003572|stage IV adult Burkitt lymphoma
1514579|NCT00003572|de novo myelodysplastic syndromes
1514580|NCT00003572|previously treated myelodysplastic syndromes
1514581|NCT00003572|secondary myelodysplastic syndromes
1514582|NCT00003572|stage I mantle cell lymphoma
1514583|NCT00003572|contiguous stage II grade 1 follicular lymphoma
1514584|NCT00003572|contiguous stage II grade 2 follicular lymphoma
1514585|NCT00003572|contiguous stage II grade 3 follicular lymphoma
1514586|NCT00003572|contiguous stage II adult diffuse small cleaved cell lymphoma
1514587|NCT00003572|contiguous stage II mantle cell lymphoma
1514588|NCT00003572|contiguous stage II adult diffuse mixed cell lymphoma
1514589|NCT00003572|contiguous stage II adult immunoblastic large cell lymphoma
1514590|NCT00003572|contiguous stage II adult diffuse large cell lymphoma
1514591|NCT00003572|contiguous stage II adult Burkitt lymphoma
1514592|NCT00003572|contiguous stage II adult lymphoblastic lymphoma
1514593|NCT00003572|noncontiguous stage II grade 1 follicular lymphoma
1514594|NCT00003572|noncontiguous stage II grade 2 follicular lymphoma
1514595|NCT00003572|noncontiguous stage II grade 3 follicular lymphoma
1514596|NCT00003572|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1514597|NCT00003572|noncontiguous stage II mantle cell lymphoma
1514598|NCT00003572|noncontiguous stage II adult diffuse mixed cell lymphoma
1514599|NCT00003572|noncontiguous stage II adult immunoblastic large cell lymphoma
1514600|NCT00003572|noncontiguous stage II adult diffuse large cell lymphoma
1514601|NCT00003572|noncontiguous stage II adult Burkitt lymphoma
1514602|NCT00003572|noncontiguous stage II adult lymphoblastic lymphoma
1514603|NCT00003572|stage III mantle cell lymphoma
1514604|NCT00003572|stage IV mantle cell lymphoma
1514605|NCT00003572|noncontiguous stage II small lymphocytic lymphoma
1514606|NCT00003572|noncontiguous stage II marginal zone lymphoma
1514607|NCT00003572|stage I marginal zone lymphoma
1514608|NCT00003572|stage I small lymphocytic lymphoma
1514609|NCT00003572|stage III small lymphocytic lymphoma
1514610|NCT00003572|stage III marginal zone lymphoma
1514611|NCT00003572|stage IV small lymphocytic lymphoma
1514612|NCT00003572|stage IV marginal zone lymphoma
1514613|NCT00003572|contiguous stage II marginal zone lymphoma
1514614|NCT00003572|contiguous stage II small lymphocytic lymphoma
1514615|NCT00003572|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1514616|NCT00003572|nodal marginal zone B-cell lymphoma
1514619|NCT00003571|adenocarcinoma of the colon
1514620|NCT00003569|stage III non-small cell lung cancer
1514621|NCT00003569|recurrent non-small cell lung cancer
1514622|NCT00003569|stage III ovarian epithelial cancer
1514623|NCT00003569|stage IV ovarian epithelial cancer
1514624|NCT00003569|recurrent ovarian epithelial cancer
1514625|NCT00003569|stage IV non-small cell lung cancer
1514626|NCT00003569|stage III squamous cell carcinoma of the lip and oral cavity
1514627|NCT00003569|stage IV squamous cell carcinoma of the lip and oral cavity
1514628|NCT00003569|recurrent squamous cell carcinoma of the lip and oral cavity
1514629|NCT00003569|stage III squamous cell carcinoma of the oropharynx
1514630|NCT00003569|stage IV squamous cell carcinoma of the oropharynx
1514631|NCT00003569|recurrent squamous cell carcinoma of the oropharynx
1514632|NCT00003569|stage III squamous cell carcinoma of the nasopharynx
1514633|NCT00003569|stage IV squamous cell carcinoma of the nasopharynx
1514634|NCT00003569|recurrent squamous cell carcinoma of the nasopharynx
1514635|NCT00003569|stage III squamous cell carcinoma of the hypopharynx
1514636|NCT00003569|stage IV squamous cell carcinoma of the hypopharynx
1514637|NCT00003569|recurrent squamous cell carcinoma of the hypopharynx
1514638|NCT00003569|stage III squamous cell carcinoma of the larynx
1514639|NCT00003569|stage IV squamous cell carcinoma of the larynx
1514640|NCT00003569|recurrent squamous cell carcinoma of the larynx
1514641|NCT00003569|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1514642|NCT00003569|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1514643|NCT00003569|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1514644|NCT00003569|neurotoxicity
1514645|NCT00003569|recurrent salivary gland cancer
1514646|NCT00003569|stage IV salivary gland cancer
1514647|NCT00003569|salivary gland squamous cell carcinoma
1514648|NCT00003569|stage III salivary gland cancer
1514649|NCT00003568|stage IV melanoma
1514650|NCT00003568|recurrent melanoma
1514651|NCT00003567|recurrent adult brain tumor
1514652|NCT00003567|adult brain stem glioma
1514653|NCT00003567|stage IV grade 1 follicular lymphoma
1514654|NCT00003567|stage IV grade 2 follicular lymphoma
1514655|NCT00003567|stage IV grade 3 follicular lymphoma
1514656|NCT00003567|stage IV adult diffuse small cleaved cell lymphoma
1514657|NCT00003567|stage IV adult diffuse mixed cell lymphoma
1514658|NCT00003567|stage IV adult diffuse large cell lymphoma
1514659|NCT00003567|stage IV adult immunoblastic large cell lymphoma
1514660|NCT00003567|stage IV adult lymphoblastic lymphoma
1514661|NCT00003567|stage IV adult Burkitt lymphoma
1514662|NCT00003567|recurrent grade 1 follicular lymphoma
1514663|NCT00003567|recurrent grade 2 follicular lymphoma
1514664|NCT00003567|recurrent grade 3 follicular lymphoma
1514665|NCT00003567|recurrent adult diffuse small cleaved cell lymphoma
1514666|NCT00003567|recurrent adult diffuse mixed cell lymphoma
1514667|NCT00003567|recurrent adult diffuse large cell lymphoma
1514668|NCT00003567|recurrent adult immunoblastic large cell lymphoma
1514669|NCT00003567|recurrent adult lymphoblastic lymphoma
1514670|NCT00003567|recurrent adult Burkitt lymphoma
1514671|NCT00003567|adult mixed glioma
1514672|NCT00003567|stage IV mantle cell lymphoma
1514673|NCT00003567|recurrent mantle cell lymphoma
1514674|NCT00003567|unspecified adult solid tumor, protocol specific
1514675|NCT00003567|adult anaplastic astrocytoma
1514676|NCT00003567|adult anaplastic oligodendroglioma
1514677|NCT00003567|adult glioblastoma
1514678|NCT00003567|adult pilocytic astrocytoma
1514679|NCT00003567|adult subependymoma
1514680|NCT00003567|adult anaplastic ependymoma
1514681|NCT00003567|adult myxopapillary ependymoma
1514682|NCT00003567|adult ependymoblastoma
1514683|NCT00003567|recurrent marginal zone lymphoma
1514684|NCT00003567|recurrent small lymphocytic lymphoma
1514685|NCT00003567|stage IV small lymphocytic lymphoma
1514686|NCT00003567|stage IV marginal zone lymphoma
1514687|NCT00003567|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1514688|NCT00003567|nodal marginal zone B-cell lymphoma
1514689|NCT00003567|splenic marginal zone lymphoma
1514690|NCT00003567|adult oligodendroglioma
1514691|NCT00003567|adult giant cell glioblastoma
1514692|NCT00003567|adult gliosarcoma
1514693|NCT00003567|adult diffuse astrocytoma
1514694|NCT00003566|stage IIIA non-small cell lung cancer
1514695|NCT00003565|stage IV breast cancer
1514696|NCT00003565|stage IIIA breast cancer
1514697|NCT00003565|recurrent breast cancer
1514698|NCT00003565|stage IIIB breast cancer
1514699|NCT00003565|stage IIIC breast cancer
1514700|NCT00003565|recurrent non-small cell lung cancer
1514701|NCT00003565|extensive stage small cell lung cancer
1514702|NCT00003565|recurrent small cell lung cancer
1514703|NCT00003565|stage III bladder cancer
1514704|NCT00003565|recurrent bladder cancer
1514705|NCT00003565|stage IV bladder cancer
1514706|NCT00003565|stage IV nasopharyngeal cancer
1514707|NCT00003565|stage IIIA non-small cell lung cancer
1514708|NCT00003565|stage IIIB non-small cell lung cancer
1514709|NCT00003565|stage IV non-small cell lung cancer
1514710|NCT00003565|unspecified adult solid tumor, protocol specific
1514711|NCT00003565|untreated metastatic squamous neck cancer with occult primary
1514712|NCT00003565|recurrent metastatic squamous neck cancer with occult primary
1514713|NCT00003565|pulmonary carcinoid tumor
1514714|NCT00003565|stage III squamous cell carcinoma of the lip and oral cavity
1514715|NCT00003565|stage III basal cell carcinoma of the lip
1514716|NCT00003565|stage III verrucous carcinoma of the oral cavity
1514717|NCT00003565|stage III mucoepidermoid carcinoma of the oral cavity
1514718|NCT00003565|stage III adenoid cystic carcinoma of the oral cavity
1514719|NCT00003565|stage IV squamous cell carcinoma of the lip and oral cavity
1514720|NCT00003565|stage IV basal cell carcinoma of the lip
1514721|NCT00003565|stage IV verrucous carcinoma of the oral cavity
1514722|NCT00003565|stage IV mucoepidermoid carcinoma of the oral cavity
1514723|NCT00003565|stage IV adenoid cystic carcinoma of the oral cavity
1514724|NCT00003565|recurrent squamous cell carcinoma of the lip and oral cavity
1514725|NCT00003565|recurrent basal cell carcinoma of the lip
1514726|NCT00003565|recurrent verrucous carcinoma of the oral cavity
1514727|NCT00003565|recurrent mucoepidermoid carcinoma of the oral cavity
1514728|NCT00003565|recurrent adenoid cystic carcinoma of the oral cavity
1514729|NCT00003565|stage III squamous cell carcinoma of the oropharynx
1514730|NCT00003565|stage III lymphoepithelioma of the oropharynx
1514731|NCT00003565|stage IV squamous cell carcinoma of the oropharynx
1514732|NCT00003565|stage IV lymphoepithelioma of the oropharynx
1514733|NCT00003565|recurrent squamous cell carcinoma of the oropharynx
1514734|NCT00003565|recurrent lymphoepithelioma of the oropharynx
1514735|NCT00003565|stage III squamous cell carcinoma of the nasopharynx
1514736|NCT00003565|stage III lymphoepithelioma of the nasopharynx
1514737|NCT00003565|stage IV squamous cell carcinoma of the nasopharynx
1514738|NCT00003565|stage IV lymphoepithelioma of the nasopharynx
1514739|NCT00003565|recurrent squamous cell carcinoma of the nasopharynx
1514740|NCT00003565|recurrent lymphoepithelioma of the nasopharynx
1514741|NCT00003565|stage III squamous cell carcinoma of the hypopharynx
1514742|NCT00003565|stage IV squamous cell carcinoma of the hypopharynx
1514743|NCT00003565|recurrent squamous cell carcinoma of the hypopharynx
1514744|NCT00003565|stage III squamous cell carcinoma of the larynx
1514745|NCT00003565|stage III verrucous carcinoma of the larynx
1514746|NCT00003565|stage IV squamous cell carcinoma of the larynx
1514747|NCT00003565|stage IV verrucous carcinoma of the larynx
1514748|NCT00003565|recurrent squamous cell carcinoma of the larynx
1514749|NCT00003565|recurrent verrucous carcinoma of the larynx
1514750|NCT00003565|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1514751|NCT00003565|stage III inverted papilloma of the paranasal sinus and nasal cavity
1514752|NCT00003565|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1514753|NCT00003565|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1514754|NCT00003565|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1514755|NCT00003565|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1514756|NCT00003565|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1514757|NCT00003565|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1514758|NCT00003565|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1514759|NCT00003565|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1514760|NCT00003565|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1514761|NCT00003565|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1514762|NCT00003565|recurrent salivary gland cancer
1514763|NCT00003565|stage III salivary gland cancer
1514764|NCT00003565|stage IV salivary gland cancer
1514765|NCT00003564|recurrent adult brain tumor
1514766|NCT00003564|adult glioblastoma
1514767|NCT00003564|adult anaplastic astrocytoma
1514768|NCT00003564|adult anaplastic oligodendroglioma
1514769|NCT00003564|adult mixed glioma
1514770|NCT00003564|adult giant cell glioblastoma
1514771|NCT00003564|adult gliosarcoma
1514772|NCT00003563|tumors metastatic to brain
1514773|NCT00003562|squamous cell lung cancer
1514774|NCT00003562|large cell lung cancer
1514775|NCT00003562|stage IIIB non-small cell lung cancer
1514776|NCT00003562|stage IV non-small cell lung cancer
1514777|NCT00003562|adenocarcinoma of the lung
1514778|NCT00003561|chronic phase chronic myelogenous leukemia
1514779|NCT00003561|Philadelphia chromosome positive chronic myelogenous leukemia
1514780|NCT00003561|Philadelphia chromosome negative chronic myelogenous leukemia
1514781|NCT00003560|stage III ovarian epithelial cancer
1514782|NCT00003560|stage IV ovarian epithelial cancer
1514783|NCT00003560|stage III endometrial carcinoma
1514784|NCT00003560|stage IV endometrial carcinoma
1514785|NCT00003560|endometrial papillary serous carcinoma
1514786|NCT00003560|fallopian tube cancer
1514787|NCT00003560|primary peritoneal cavity cancer
1514788|NCT00003558|adenocarcinoma of unknown primary
1514789|NCT00003558|newly diagnosed carcinoma of unknown primary
1514790|NCT00003557|advanced adult primary liver cancer
1514791|NCT00003557|recurrent adult primary liver cancer
1514792|NCT00003557|unresectable gallbladder cancer
1514793|NCT00003557|recurrent gallbladder cancer
1514794|NCT00003557|unresectable extrahepatic bile duct cancer
1514795|NCT00003557|recurrent extrahepatic bile duct cancer
1514796|NCT00003557|adult primary hepatocellular carcinoma
1514797|NCT00003557|cholangiocarcinoma of the gallbladder
1514798|NCT00003556|stage IV melanoma
1514799|NCT00003556|recurrent melanoma
1514800|NCT00003555|unspecified adult solid tumor, protocol specific
1514801|NCT00003554|stage I multiple myeloma
1514802|NCT00003554|stage II multiple myeloma
1514803|NCT00003554|stage III multiple myeloma
1514804|NCT00003553|stage IV renal cell cancer
1514805|NCT00003553|recurrent renal cell cancer
1514806|NCT00003552|adult solid tumor
1514807|NCT00003552|body system/site cancer
1514808|NCT00003552|cancer
1514809|NCT00003552|melanoma
1514810|NCT00003552|recurrent melanoma
1514811|NCT00003552|skin tumor
1514812|NCT00003552|solid tumor
1514813|NCT00003552|stage IV melanoma
1514814|NCT00003552|stage, melanoma
1514815|NCT00003551|stage III renal cell cancer
1514816|NCT00003551|stage IV renal cell cancer
1514817|NCT00003551|recurrent renal cell cancer
1514818|NCT00003549|stage II neuroendocrine carcinoma of the skin
1514819|NCT00003549|stage III neuroendocrine carcinoma of the skin
1514820|NCT00003549|recurrent neuroendocrine carcinoma of the skin
1514821|NCT00003548|stage IV colon cancer
1514822|NCT00003548|stage IV breast cancer
1514823|NCT00003548|recurrent breast cancer
1514824|NCT00003548|stage IV gastric cancer
1514825|NCT00003548|recurrent gastric cancer
1520296|NCT00002764|adult liposarcoma
1514826|NCT00003548|recurrent pancreatic cancer
1514827|NCT00003548|stage IV rectal cancer
1514828|NCT00003548|recurrent colon cancer
1514829|NCT00003548|recurrent rectal cancer
1514830|NCT00003548|stage IV anal cancer
1514831|NCT00003548|recurrent anal cancer
1514832|NCT00003548|stage IV esophageal cancer
1514833|NCT00003548|recurrent esophageal cancer
1514834|NCT00003548|stage IV cervical cancer
1514835|NCT00003548|recurrent cervical cancer
1514836|NCT00003548|stage IV ovarian epithelial cancer
1514837|NCT00003548|recurrent ovarian epithelial cancer
1514838|NCT00003548|stage IV vulvar cancer
1514839|NCT00003548|recurrent vulvar cancer
1514840|NCT00003548|stage IVA vaginal cancer
1514841|NCT00003548|stage IVB vaginal cancer
1514842|NCT00003548|recurrent vaginal cancer
1514843|NCT00003548|metastatic gastrointestinal carcinoid tumor
1514844|NCT00003548|recurrent gastrointestinal carcinoid tumor
1514845|NCT00003548|advanced adult primary liver cancer
1514846|NCT00003548|recurrent adult primary liver cancer
1514847|NCT00003548|recurrent gestational trophoblastic tumor
1514848|NCT00003548|stage IV endometrial carcinoma
1514849|NCT00003548|recurrent endometrial carcinoma
1514850|NCT00003548|unresectable gallbladder cancer
1514851|NCT00003548|recurrent gallbladder cancer
1514852|NCT00003548|unresectable extrahepatic bile duct cancer
1514853|NCT00003548|recurrent extrahepatic bile duct cancer
1514854|NCT00003548|recurrent small intestine cancer
1514855|NCT00003548|carcinoma of the appendix
1514856|NCT00003548|fallopian tube cancer
1514857|NCT00003548|stage IV uterine sarcoma
1514858|NCT00003548|recurrent uterine sarcoma
1514859|NCT00003548|recurrent carcinoma of unknown primary
1514860|NCT00003548|stage IV pancreatic cancer
1514861|NCT00003546|stage I pancreatic cancer
1514862|NCT00003546|stage II pancreatic cancer
1514863|NCT00003546|stage III pancreatic cancer
1514864|NCT00003546|adenocarcinoma of the pancreas
1514865|NCT00003545|recurrent childhood acute lymphoblastic leukemia
1514866|NCT00003545|recurrent childhood lymphoblastic lymphoma
1514867|NCT00003545|recurrent adult acute lymphoblastic leukemia
1514868|NCT00003545|T-cell childhood acute lymphoblastic leukemia
1514869|NCT00003545|T-cell adult acute lymphoblastic leukemia
1514870|NCT00003545|recurrent adult lymphoblastic lymphoma
1514871|NCT00003545|recurrent adult T-cell leukemia/lymphoma
1514872|NCT00003544|stage IV colon cancer
1514873|NCT00003544|stage IV rectal cancer
1514874|NCT00003544|recurrent colon cancer
1514875|NCT00003544|recurrent rectal cancer
1514876|NCT00003543|stage IV colon cancer
1514877|NCT00003543|stage IV rectal cancer
1514878|NCT00003543|recurrent colon cancer
1514879|NCT00003543|recurrent rectal cancer
1514880|NCT00003542|stage III renal cell cancer
1514881|NCT00003542|stage IV renal cell cancer
1514882|NCT00003541|stage III mantle cell lymphoma
1514883|NCT00003541|stage IV mantle cell lymphoma
1514884|NCT00003540|stage IV breast cancer
1514885|NCT00003540|recurrent breast cancer
1514886|NCT00003539|stage IV breast cancer
1514887|NCT00003539|recurrent breast cancer
1514888|NCT00003538|stage I adult Hodgkin lymphoma
1514889|NCT00003538|stage II adult Hodgkin lymphoma
1514890|NCT00003538|stage III adult Hodgkin lymphoma
1514891|NCT00003538|stage IV adult Hodgkin lymphoma
1514892|NCT00003538|stage IV breast cancer
1514893|NCT00003538|stage IIIA breast cancer
1514894|NCT00003538|stage IIIB breast cancer
1514895|NCT00003538|recurrent childhood acute lymphoblastic leukemia
1514896|NCT00003538|recurrent adult Hodgkin lymphoma
1514897|NCT00003538|recurrent childhood rhabdomyosarcoma
1514898|NCT00003538|stage II ovarian epithelial cancer
1514899|NCT00003538|stage III ovarian epithelial cancer
1514900|NCT00003538|stage IV ovarian epithelial cancer
1514901|NCT00003538|recurrent ovarian epithelial cancer
1514902|NCT00003538|disseminated neuroblastoma
1514903|NCT00003538|recurrent neuroblastoma
1514904|NCT00003538|recurrent Wilms tumor and other childhood kidney tumors
1514905|NCT00003538|Waldenstrom macroglobulinemia
1514906|NCT00003538|stage I multiple myeloma
1514907|NCT00003538|stage II multiple myeloma
1514908|NCT00003538|stage III multiple myeloma
1514909|NCT00003538|stage I childhood lymphoblastic lymphoma
1514910|NCT00003538|stage III childhood lymphoblastic lymphoma
1514911|NCT00003538|stage IV childhood lymphoblastic lymphoma
1514912|NCT00003538|recurrent childhood lymphoblastic lymphoma
1514913|NCT00003538|recurrent childhood acute myeloid leukemia
1514914|NCT00003538|recurrent adult acute myeloid leukemia
1514915|NCT00003538|recurrent adult acute lymphoblastic leukemia
1514916|NCT00003538|relapsing chronic myelogenous leukemia
1514917|NCT00003538|stage III malignant testicular germ cell tumor
1514918|NCT00003538|recurrent malignant testicular germ cell tumor
1514919|NCT00003538|chronic phase chronic myelogenous leukemia
1514920|NCT00003538|accelerated phase chronic myelogenous leukemia
1514921|NCT00003538|blastic phase chronic myelogenous leukemia
1514922|NCT00003538|meningeal chronic myelogenous leukemia
1514923|NCT00003538|untreated adult acute lymphoblastic leukemia
1514924|NCT00003538|untreated adult acute myeloid leukemia
1514925|NCT00003538|adult acute myeloid leukemia in remission
1514926|NCT00003538|adult acute lymphoblastic leukemia in remission
1520297|NCT00002764|adult neurofibrosarcoma
1514927|NCT00003538|childhood acute myeloid leukemia in remission
1514928|NCT00003538|childhood acute lymphoblastic leukemia in remission
1514929|NCT00003538|myelodysplastic syndromes
1514930|NCT00003538|Philadelphia chromosome positive chronic myelogenous leukemia
1514931|NCT00003538|Philadelphia chromosome negative chronic myelogenous leukemia
1514932|NCT00003538|untreated hairy cell leukemia
1514933|NCT00003538|progressive hairy cell leukemia, initial treatment
1514934|NCT00003538|refractory hairy cell leukemia
1514935|NCT00003538|stage II childhood Hodgkin lymphoma
1514936|NCT00003538|stage I childhood Hodgkin lymphoma
1514937|NCT00003538|stage III childhood Hodgkin lymphoma
1514938|NCT00003538|stage IV childhood Hodgkin lymphoma
1514939|NCT00003538|recurrent/refractory childhood Hodgkin lymphoma
1514940|NCT00003538|stage I grade 1 follicular lymphoma
1514941|NCT00003538|stage I grade 2 follicular lymphoma
1514942|NCT00003538|stage I grade 3 follicular lymphoma
1514943|NCT00003538|stage I adult diffuse small cleaved cell lymphoma
1514944|NCT00003538|stage I adult diffuse mixed cell lymphoma
1514945|NCT00003538|stage I adult diffuse large cell lymphoma
1514946|NCT00003538|stage I adult immunoblastic large cell lymphoma
1514947|NCT00003538|stage I adult lymphoblastic lymphoma
1514948|NCT00003538|stage I adult Burkitt lymphoma
1514949|NCT00003538|recurrent ovarian germ cell tumor
1514950|NCT00003538|chronic myelomonocytic leukemia
1514951|NCT00003538|acute undifferentiated leukemia
1514952|NCT00003538|stage III grade 1 follicular lymphoma
1514953|NCT00003538|stage III grade 2 follicular lymphoma
1514954|NCT00003538|stage III grade 3 follicular lymphoma
1514955|NCT00003538|stage III adult diffuse small cleaved cell lymphoma
1514956|NCT00003538|stage III adult diffuse mixed cell lymphoma
1514957|NCT00003538|stage III adult diffuse large cell lymphoma
1514958|NCT00003538|stage III adult immunoblastic large cell lymphoma
1514959|NCT00003538|stage III adult lymphoblastic lymphoma
1514960|NCT00003538|stage III adult Burkitt lymphoma
1514961|NCT00003538|stage IV small lymphocytic lymphoma
1514962|NCT00003538|stage IV grade 1 follicular lymphoma
1514963|NCT00003538|stage IV grade 2 follicular lymphoma
1514964|NCT00003538|stage IV grade 3 follicular lymphoma
1514965|NCT00003538|stage IV adult diffuse small cleaved cell lymphoma
1514966|NCT00003538|stage IV adult diffuse mixed cell lymphoma
1514967|NCT00003538|stage IV adult diffuse large cell lymphoma
1514968|NCT00003538|stage IV adult immunoblastic large cell lymphoma
1514969|NCT00003538|stage IV adult lymphoblastic lymphoma
1514970|NCT00003538|stage IV adult Burkitt lymphoma
1514971|NCT00003538|recurrent grade 1 follicular lymphoma
1514972|NCT00003538|recurrent grade 2 follicular lymphoma
1514973|NCT00003538|recurrent grade 3 follicular lymphoma
1514974|NCT00003538|recurrent adult diffuse small cleaved cell lymphoma
1514975|NCT00003538|recurrent adult diffuse mixed cell lymphoma
1514976|NCT00003538|recurrent adult diffuse large cell lymphoma
1514977|NCT00003538|recurrent adult immunoblastic large cell lymphoma
1514978|NCT00003538|recurrent adult lymphoblastic lymphoma
1514979|NCT00003538|recurrent adult Burkitt lymphoma
1514980|NCT00003538|stage III adult T-cell leukemia/lymphoma
1514981|NCT00003538|stage IV adult T-cell leukemia/lymphoma
1514982|NCT00003538|recurrent adult T-cell leukemia/lymphoma
1514983|NCT00003538|secondary acute myeloid leukemia
1514984|NCT00003538|de novo myelodysplastic syndromes
1514985|NCT00003538|poor prognosis metastatic gestational trophoblastic tumor
1514986|NCT00003538|previously treated myelodysplastic syndromes
1514987|NCT00003538|secondary myelodysplastic syndromes
1514988|NCT00003538|anemia
1514989|NCT00003538|graft versus host disease
1514990|NCT00003538|prolymphocytic leukemia
1514991|NCT00003538|AIDS-related peripheral/systemic lymphoma
1514992|NCT00003538|AIDS-related primary CNS lymphoma
1514993|NCT00003538|stage I childhood large cell lymphoma
1514994|NCT00003538|stage III childhood large cell lymphoma
1514995|NCT00003538|stage IV childhood small noncleaved cell lymphoma
1514996|NCT00003538|stage IV childhood large cell lymphoma
1514997|NCT00003538|recurrent childhood small noncleaved cell lymphoma
1514998|NCT00003538|recurrent childhood large cell lymphoma
1514999|NCT00003538|non-Hodgkin lymphoma during pregnancy
1515000|NCT00003538|stage I mantle cell lymphoma
1515001|NCT00003538|contiguous stage II grade 1 follicular lymphoma
1515002|NCT00003538|contiguous stage II grade 2 follicular lymphoma
1515003|NCT00003538|contiguous stage II grade 3 follicular lymphoma
1515004|NCT00003538|contiguous stage II adult diffuse small cleaved cell lymphoma
1515005|NCT00003538|contiguous stage II mantle cell lymphoma
1515006|NCT00003538|contiguous stage II adult diffuse mixed cell lymphoma
1515007|NCT00003538|contiguous stage II adult immunoblastic large cell lymphoma
1515008|NCT00003538|contiguous stage II adult diffuse large cell lymphoma
1515009|NCT00003538|contiguous stage II adult Burkitt lymphoma
1515010|NCT00003538|contiguous stage II adult lymphoblastic lymphoma
1515011|NCT00003538|noncontiguous stage II grade 1 follicular lymphoma
1515012|NCT00003538|noncontiguous stage II grade 2 follicular lymphoma
1515013|NCT00003538|noncontiguous stage II grade 3 follicular lymphoma
1515014|NCT00003538|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1515015|NCT00003538|noncontiguous stage II mantle cell lymphoma
1515016|NCT00003538|noncontiguous stage II adult diffuse mixed cell lymphoma
1515017|NCT00003538|noncontiguous stage II adult immunoblastic large cell lymphoma
1515018|NCT00003538|noncontiguous stage II adult diffuse large cell lymphoma
1515019|NCT00003538|noncontiguous stage II adult Burkitt lymphoma
1515020|NCT00003538|noncontiguous stage II adult lymphoblastic lymphoma
1515021|NCT00003538|stage III mantle cell lymphoma
1515022|NCT00003538|stage IV mantle cell lymphoma
1515023|NCT00003538|recurrent mantle cell lymphoma
1515024|NCT00003538|angioimmunoblastic T-cell lymphoma
1515025|NCT00003538|anaplastic large cell lymphoma
1515026|NCT00003538|childhood chronic myelogenous leukemia
1515027|NCT00003538|noncontiguous stage II small lymphocytic lymphoma
1515028|NCT00003538|noncontiguous stage II marginal zone lymphoma
1515029|NCT00003538|recurrent marginal zone lymphoma
1515030|NCT00003538|recurrent small lymphocytic lymphoma
1515031|NCT00003538|stage I marginal zone lymphoma
1515032|NCT00003538|stage I small lymphocytic lymphoma
1515033|NCT00003538|stage III small lymphocytic lymphoma
1515034|NCT00003538|stage III marginal zone lymphoma
1515035|NCT00003538|stage IV marginal zone lymphoma
1515036|NCT00003538|contiguous stage II marginal zone lymphoma
1515037|NCT00003538|contiguous stage II small lymphocytic lymphoma
1515038|NCT00003538|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515039|NCT00003538|nodal marginal zone B-cell lymphoma
1515040|NCT00003538|splenic marginal zone lymphoma
1515041|NCT00003538|childhood myelodysplastic syndromes
1515042|NCT00003537|adult anaplastic astrocytoma
1515043|NCT00003535|childhood high-grade cerebral astrocytoma
1515044|NCT00003535|recurrent childhood cerebral astrocytoma
1515045|NCT00003535|childhood cerebral astrocytoma/malignant glioma
1515046|NCT00003534|adenocarcinoma of the prostate
1515047|NCT00003534|stage IV prostate cancer
1515048|NCT00003534|recurrent prostate cancer
1515049|NCT00003533|adenocarcinoma of the prostate
1515050|NCT00003533|stage IV prostate cancer
1515051|NCT00003533|recurrent prostate cancer
1515052|NCT00003532|stage III ovarian epithelial cancer
1515053|NCT00003532|stage IV ovarian epithelial cancer
1515054|NCT00003532|recurrent ovarian epithelial cancer
1515055|NCT00003532|stage III ovarian germ cell tumor
1515056|NCT00003532|stage IV ovarian germ cell tumor
1515057|NCT00003532|recurrent ovarian germ cell tumor
1515058|NCT00003531|recurrent pancreatic cancer
1515059|NCT00003531|adenocarcinoma of the pancreas
1515060|NCT00003531|stage IV pancreatic cancer
1515061|NCT00003530|stage IV childhood liver cancer
1515062|NCT00003530|recurrent childhood liver cancer
1515063|NCT00003530|advanced adult primary liver cancer
1515064|NCT00003530|recurrent adult primary liver cancer
1515065|NCT00003526|adenocarcinoma of unknown primary
1515066|NCT00003526|recurrent carcinoma of unknown primary
1515067|NCT00003525|stage IV cervical cancer
1515068|NCT00003525|recurrent cervical cancer
1515069|NCT00003525|stage IV vulvar cancer
1515070|NCT00003525|recurrent vulvar cancer
1515071|NCT00003524|stage III gastric cancer
1515072|NCT00003524|stage IV gastric cancer
1515073|NCT00003524|recurrent gastric cancer
1515074|NCT00003524|adenocarcinoma of the stomach
1515075|NCT00003523|recurrent ovarian epithelial cancer
1515076|NCT00003523|primary peritoneal cavity cancer
1515077|NCT00003522|small intestine adenocarcinoma
1515078|NCT00003522|recurrent small intestine cancer
1515079|NCT00003521|stage III adult soft tissue sarcoma
1515080|NCT00003521|stage IV adult soft tissue sarcoma
1515081|NCT00003521|recurrent adult soft tissue sarcoma
1515082|NCT00003521|nonmetastatic childhood soft tissue sarcoma
1515083|NCT00003521|metastatic childhood soft tissue sarcoma
1515084|NCT00003521|recurrent childhood soft tissue sarcoma
1515085|NCT00003520|stage IV renal cell cancer
1515086|NCT00003520|recurrent renal cell cancer
1515087|NCT00003520|metastatic transitional cell cancer of the renal pelvis and ureter
1515088|NCT00003520|recurrent transitional cell cancer of the renal pelvis and ureter
1515089|NCT00003519|stage II breast cancer
1515090|NCT00003519|stage IIIA breast cancer
1515091|NCT00003519|stage IIIB breast cancer
1515092|NCT00003518|stage III malignant testicular germ cell tumor
1515093|NCT00003518|recurrent malignant testicular germ cell tumor
1515094|NCT00003518|stage IV ovarian germ cell tumor
1515095|NCT00003518|recurrent ovarian germ cell tumor
1515096|NCT00003516|adenocarcinoma of the prostate
1515097|NCT00003516|stage III prostate cancer
1515098|NCT00003516|stage IV prostate cancer
1515099|NCT00003516|recurrent prostate cancer
1515100|NCT00003515|metastatic childhood soft tissue sarcoma
1515101|NCT00003515|recurrent childhood soft tissue sarcoma
1515102|NCT00003515|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1515103|NCT00003515|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1515104|NCT00003514|ACTH-producing pituitary tumor
1515105|NCT00003514|prolactin-producing pituitary tumor
1515106|NCT00003514|growth hormone-producing pituitary tumor
1515107|NCT00003514|recurrent pituitary tumor
1515108|NCT00003514|TSH producing pituitary tumor
1515109|NCT00003514|nonfunctioning pituitary tumor
1515110|NCT00003514|somatostatinoma
1515111|NCT00003514|stage III Merkel cell carcinoma
1515112|NCT00003514|recurrent Merkel cell carcinoma
1515113|NCT00003514|neuroendocrine carcinoma
1515114|NCT00003513|regional neuroblastoma
1515115|NCT00003513|disseminated neuroblastoma
1515118|NCT00003513|localized unresectable neuroblastoma
1515119|NCT00003512|refractory multiple myeloma
1515120|NCT00003512|Waldenstrom macroglobulinemia
1515121|NCT00003511|refractory multiple myeloma
1515122|NCT00003511|stage I multiple myeloma
1515123|NCT00003511|stage II multiple myeloma
1515124|NCT00003511|stage III multiple myeloma
1515125|NCT00003509|stage IV melanoma
1515126|NCT00003509|recurrent melanoma
1515127|NCT00003508|advanced malignant mesothelioma
1515128|NCT00003508|recurrent malignant mesothelioma
1515129|NCT00003501|stage III adult immunoblastic large cell lymphoma
1515130|NCT00003501|stage III adult lymphoblastic lymphoma
1515131|NCT00003501|stage III adult Burkitt lymphoma
1515132|NCT00003501|stage IV adult immunoblastic large cell lymphoma
1515133|NCT00003501|stage IV adult lymphoblastic lymphoma
1515134|NCT00003501|stage IV adult Burkitt lymphoma
1515135|NCT00003501|recurrent adult immunoblastic large cell lymphoma
1515136|NCT00003501|recurrent adult lymphoblastic lymphoma
1515137|NCT00003501|recurrent adult Burkitt lymphoma
1515138|NCT00003501|contiguous stage II adult immunoblastic large cell lymphoma
1515139|NCT00003501|contiguous stage II adult Burkitt lymphoma
1515140|NCT00003501|contiguous stage II adult lymphoblastic lymphoma
1515141|NCT00003501|noncontiguous stage II adult immunoblastic large cell lymphoma
1515142|NCT00003501|noncontiguous stage II adult Burkitt lymphoma
1515143|NCT00003501|noncontiguous stage II adult lymphoblastic lymphoma
1515144|NCT00003500|stage III grade 3 follicular lymphoma
1515145|NCT00003500|stage III adult diffuse small cleaved cell lymphoma
1515146|NCT00003500|stage III adult diffuse mixed cell lymphoma
1515147|NCT00003500|stage III adult diffuse large cell lymphoma
1515148|NCT00003500|stage IV grade 3 follicular lymphoma
1515149|NCT00003500|stage IV adult diffuse small cleaved cell lymphoma
1515150|NCT00003500|stage IV adult diffuse mixed cell lymphoma
1515151|NCT00003500|stage IV adult diffuse large cell lymphoma
1515152|NCT00003500|recurrent grade 3 follicular lymphoma
1515153|NCT00003500|recurrent adult diffuse small cleaved cell lymphoma
1515154|NCT00003500|recurrent adult diffuse mixed cell lymphoma
1515155|NCT00003500|recurrent adult diffuse large cell lymphoma
1515156|NCT00003500|contiguous stage II grade 3 follicular lymphoma
1515157|NCT00003500|contiguous stage II adult diffuse small cleaved cell lymphoma
1515158|NCT00003500|contiguous stage II adult diffuse mixed cell lymphoma
1515159|NCT00003500|contiguous stage II adult diffuse large cell lymphoma
1515160|NCT00003500|noncontiguous stage II grade 3 follicular lymphoma
1515161|NCT00003500|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1515162|NCT00003500|noncontiguous stage II adult diffuse mixed cell lymphoma
1515163|NCT00003500|noncontiguous stage II adult diffuse large cell lymphoma
1515164|NCT00003499|stage III grade 1 follicular lymphoma
1515165|NCT00003499|stage III grade 2 follicular lymphoma
1515166|NCT00003499|stage IV grade 1 follicular lymphoma
1515167|NCT00003499|stage IV grade 2 follicular lymphoma
1515168|NCT00003499|contiguous stage II grade 1 follicular lymphoma
1515169|NCT00003499|contiguous stage II grade 2 follicular lymphoma
1515170|NCT00003499|noncontiguous stage II grade 1 follicular lymphoma
1515171|NCT00003499|noncontiguous stage II grade 2 follicular lymphoma
1515172|NCT00003499|contiguous stage II small lymphocytic lymphoma
1515173|NCT00003499|contiguous stage II marginal zone lymphoma
1515174|NCT00003499|noncontiguous stage II small lymphocytic lymphoma
1515175|NCT00003499|noncontiguous stage II marginal zone lymphoma
1515176|NCT00003499|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515177|NCT00003499|nodal marginal zone B-cell lymphoma
1515178|NCT00003499|splenic marginal zone lymphoma
1515179|NCT00003499|stage III small lymphocytic lymphoma
1515180|NCT00003499|stage III marginal zone lymphoma
1515181|NCT00003499|stage IV small lymphocytic lymphoma
1515182|NCT00003499|stage IV marginal zone lymphoma
1515183|NCT00003498|recurrent grade 1 follicular lymphoma
1515184|NCT00003498|recurrent grade 2 follicular lymphoma
1515185|NCT00003498|recurrent grade 3 follicular lymphoma
1515186|NCT00003498|recurrent adult diffuse small cleaved cell lymphoma
1515187|NCT00003498|recurrent adult diffuse mixed cell lymphoma
1515188|NCT00003498|recurrent adult diffuse large cell lymphoma
1515189|NCT00003498|recurrent adult immunoblastic large cell lymphoma
1515190|NCT00003498|recurrent adult lymphoblastic lymphoma
1515191|NCT00003498|recurrent adult Burkitt lymphoma
1515192|NCT00003498|recurrent mantle cell lymphoma
1515193|NCT00003498|recurrent marginal zone lymphoma
1515194|NCT00003498|recurrent small lymphocytic lymphoma
1515195|NCT00003498|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515196|NCT00003498|nodal marginal zone B-cell lymphoma
1515197|NCT00003498|splenic marginal zone lymphoma
1515198|NCT00003497|recurrent non-small cell lung cancer
1515199|NCT00003497|stage IV non-small cell lung cancer
1515200|NCT00003496|extensive stage small cell lung cancer
1515201|NCT00003496|recurrent small cell lung cancer
1515202|NCT00003495|recurrent non-small cell lung cancer
1515203|NCT00003495|squamous cell lung cancer
1515204|NCT00003495|stage IV non-small cell lung cancer
1515205|NCT00003494|recurrent non-small cell lung cancer
1515206|NCT00003494|stage IV non-small cell lung cancer
1515207|NCT00003494|bronchoalveolar cell lung cancer
1515208|NCT00003493|refractory multiple myeloma
1515209|NCT00003493|stage I multiple myeloma
1515210|NCT00003493|stage II multiple myeloma
1515211|NCT00003493|stage III multiple myeloma
1515212|NCT00003492|recurrent non-small cell lung cancer
1515213|NCT00003492|large cell lung cancer
1515214|NCT00003492|stage IV non-small cell lung cancer
1515215|NCT00003491|recurrent non-small cell lung cancer
1515216|NCT00003491|stage IV non-small cell lung cancer
1515217|NCT00003491|adenocarcinoma of the lung
1515218|NCT00003490|refractory multiple myeloma
1515219|NCT00003490|stage I multiple myeloma
1515220|NCT00003490|stage II multiple myeloma
1515221|NCT00003490|stage III multiple myeloma
1515222|NCT00003489|stage IV salivary gland cancer
1515223|NCT00003489|recurrent salivary gland cancer
1515224|NCT00003489|recurrent lymphoepithelioma of the nasopharynx
1515225|NCT00003489|recurrent squamous cell carcinoma of the nasopharynx
1515226|NCT00003489|stage IV lymphoepithelioma of the nasopharynx
1515227|NCT00003489|stage IV squamous cell carcinoma of the nasopharynx
1515228|NCT00003489|recurrent squamous cell carcinoma of the larynx
1515229|NCT00003489|recurrent verrucous carcinoma of the larynx
1515230|NCT00003489|stage IV squamous cell carcinoma of the larynx
1515231|NCT00003489|stage IV verrucous carcinoma of the larynx
1515232|NCT00003489|recurrent squamous cell carcinoma of the lip and oral cavity
1515233|NCT00003489|stage IV squamous cell carcinoma of the lip and oral cavity
1515234|NCT00003489|recurrent squamous cell carcinoma of the hypopharynx
1515235|NCT00003489|stage IV squamous cell carcinoma of the hypopharynx
1515236|NCT00003489|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1515237|NCT00003489|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1515238|NCT00003489|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1515239|NCT00003489|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1515240|NCT00003489|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1515241|NCT00003489|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1515242|NCT00003489|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1515243|NCT00003489|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1515244|NCT00003489|recurrent lymphoepithelioma of the oropharynx
1515245|NCT00003489|recurrent squamous cell carcinoma of the oropharynx
1515246|NCT00003489|stage IV lymphoepithelioma of the oropharynx
1515247|NCT00003489|stage IV squamous cell carcinoma of the oropharynx
1515248|NCT00003489|recurrent verrucous carcinoma of the oral cavity
1515249|NCT00003489|stage IV verrucous carcinoma of the oral cavity
1515250|NCT00003489|recurrent adenoid cystic carcinoma of the oral cavity
1515251|NCT00003489|stage IV adenoid cystic carcinoma of the oral cavity
1515252|NCT00003489|recurrent mucoepidermoid carcinoma of the oral cavity
1515253|NCT00003489|stage IV mucoepidermoid carcinoma of the oral cavity
1515254|NCT00003489|recurrent basal cell carcinoma of the lip
1515255|NCT00003489|stage IV basal cell carcinoma of the lip
1515256|NCT00003487|stage IV esophageal cancer
1515257|NCT00003487|recurrent esophageal cancer
1515258|NCT00003487|adenocarcinoma of the esophagus
1515259|NCT00003485|stage IV colon cancer
1515260|NCT00003485|recurrent colon cancer
1515261|NCT00003485|adenocarcinoma of the colon
1515262|NCT00003484|localized resectable neuroblastoma
1515263|NCT00003484|recurrent adult brain tumor
1515264|NCT00003484|adult craniopharyngioma
1515265|NCT00003484|adult medulloblastoma
1515266|NCT00003484|adult meningioma
1515267|NCT00003484|adult glioblastoma
1515268|NCT00003484|adult oligodendroglioma
1515269|NCT00003484|adult anaplastic astrocytoma
1515270|NCT00003484|adult mixed glioma
1515271|NCT00003484|adult pineal parenchymal tumor
1515272|NCT00003484|adult central nervous system germ cell tumor
1515273|NCT00003484|adult grade III meningioma
1515274|NCT00003484|adult pilocytic astrocytoma
1515275|NCT00003484|adult giant cell glioblastoma
1515276|NCT00003484|adult gliosarcoma
1515277|NCT00003483|adult meningioma
1515278|NCT00003483|recurrent adult meningioma
1515279|NCT00003479|Ependymoma
1515280|NCT00003479|Anaplastic Ependymoma
1515281|NCT00003478|recurrent adult brain tumor
1515282|NCT00003478|adult brain stem glioma
1515283|NCT00003478|adult medulloblastoma
1515284|NCT00003478|adult glioblastoma
1515285|NCT00003478|adult anaplastic astrocytoma
1515286|NCT00003478|adult anaplastic ependymoma
1515287|NCT00003478|adult anaplastic oligodendroglioma
1515288|NCT00003478|adult mixed glioma
1515289|NCT00003478|adult ependymoblastoma
1515290|NCT00003478|adult giant cell glioblastoma
1515291|NCT00003478|adult gliosarcoma
1515292|NCT00003477|visual pathway glioma not amenable to standard therapy
1515293|NCT00003477|visual pathway glioma not responding to standard therapy
1515294|NCT00003476|childhood anaplastic astrocytoma
1515295|NCT00003476|recurrent childhood anaplastic astrocytoma
1515296|NCT00003476|childhood glioblastoma multiforme
1515297|NCT00003476|recurrent childhood glioblastoma multiforme
1515298|NCT00003476|childhood brainstem glioma
1515299|NCT00003476|recurrent childhood brainstem glioma
1515300|NCT00003476|childhood primitive neuroectodermal tumor
1515301|NCT00003476|recurrent childhood primitive neuroectodermal tumor
1515302|NCT00003475|adult glioblastoma multiforme
1515303|NCT00003475|adult anaplastic astrocytoma
1515304|NCT00003475|adult anaplastic astrocytoma/Mixed
1515305|NCT00003473|recurrent adult mixed glioma
1515306|NCT00003473|refractoy adult mixed glioma
1515307|NCT00003472|recurrent adult brain tumor
1515308|NCT00003472|adult anaplastic oligodendroglioma
1515309|NCT00003472|adult oligodendroglioma
1515310|NCT00003471|recurrent adult brain tumor
1515311|NCT00003471|adult pilocytic astrocytoma
1515312|NCT00003471|adult diffuse astrocytoma
1515313|NCT00003470|persistent anaplastic astrocytoma
1515314|NCT00003470|recurrent anaplastic astrocytoma
1515315|NCT00003470|adult anaplastic astrocytoma
1515316|NCT00003469|childhood rhabdoid tumor
1515317|NCT00003468|childhood low-grade astrocytoma
1515318|NCT00003468|recurrent childhood astrocytoma
1515319|NCT00003468|persistent childhood astrocytoma
1515320|NCT00003467|recurrent adult brain tumor
1515321|NCT00003467|adult brain stem glioma
1515322|NCT00003467|adult mixed glioma
1515323|NCT00003467|adult anaplastic astrocytoma
1515324|NCT00003467|adult pilocytic astrocytoma
1515325|NCT00003467|adult oligodendroglioma
1515326|NCT00003466|recurrent adult brain tumor
1515327|NCT00003466|adult mixed glioma
1515328|NCT00003466|childhood mixed glioma
1515329|NCT00003466|adult pilocytic astrocytoma
1515330|NCT00003466|adult subependymoma
1515331|NCT00003466|recurrent childhood cerebral astrocytoma
1515332|NCT00003466|adult brain stem glioma
1515333|NCT00003466|recurrent childhood brain stem glioma
1515334|NCT00003466|untreated childhood brain stem glioma
1515335|NCT00003466|recurrent childhood visual pathway and hypothalamic glioma
1515336|NCT00003466|untreated childhood visual pathway and hypothalamic glioma
1515337|NCT00003466|adult oligodendroglioma
1515338|NCT00003466|adult diffuse astrocytoma
1515339|NCT00003465|recurrent adult brain tumor
1515340|NCT00003465|adult anaplastic oligodendroglioma
1515341|NCT00003464|adult glioblastoma
1515342|NCT00003464|adult giant cell glioblastoma
1515343|NCT00003464|adult gliosarcoma
1515344|NCT00003463|recurrent adult brain tumor
1515345|NCT00003463|adult brain stem glioma
1515346|NCT00003463|adult glioblastoma
1515347|NCT00003463|adult anaplastic astrocytoma
1515348|NCT00003463|adult mixed glioma
1515349|NCT00003463|adult giant cell glioblastoma
1515350|NCT00003463|adult gliosarcoma
1515351|NCT00003462|leptomeningeal metastases
1515352|NCT00003461|localized resectable neuroblastoma
1515353|NCT00003461|recurrent neuroblastoma
1515354|NCT00003461|recurrent adult brain tumor
1515355|NCT00003461|adult craniopharyngioma
1515356|NCT00003461|adult medulloblastoma
1515357|NCT00003461|adult meningioma
1515358|NCT00003461|adult glioblastoma
1515359|NCT00003461|adult oligodendroglioma
1515360|NCT00003461|tumors metastatic to brain
1515361|NCT00003461|adult anaplastic astrocytoma
1515362|NCT00003461|adult mixed glioma
1515363|NCT00003461|adult pineal parenchymal tumor
1515364|NCT00003461|adult central nervous system germ cell tumor
1515365|NCT00003461|adult grade III meningioma
1515366|NCT00003461|adult pilocytic astrocytoma
1515367|NCT00003461|adult giant cell glioblastoma
1515368|NCT00003461|adult gliosarcoma
1515369|NCT00003461|adult pineal gland astrocytoma
1515370|NCT00003460|Recurrent primitive neuroectodermal tumor
1515371|NCT00003459|recurrent adult brain stem glioma
1515372|NCT00003459|untreated adult brain stem glioma
1515373|NCT00003459|untreated childhood brain stem glioma
1515374|NCT00003459|recurrent childhood brain stem glioma
1515375|NCT00003458|Anaplastic astrocytoma
1515376|NCT00003458|Anaplastic glioma
1515377|NCT00003458|Anaplastic oligodendroglioma
1515378|NCT00003458|Astrocytoma
1515379|NCT00003458|Astrocytoma pilocytic
1515380|NCT00003458|Brain stem glioma
1515381|NCT00003458|Craniopharyngioma
1515382|NCT00003458|Ganglioglioma
1515383|NCT00003458|Glioblastoma multiforme
1515384|NCT00003458|Gliosarcoma
1515385|NCT00003458|Medulloepithelioma
1515386|NCT00003458|Neurocytoma
1515387|NCT00003458|Oligodendroglioma
1515388|NCT00003458|Oligodendroglioma-brainstem
1515389|NCT00003458|Primitive neuroectodermal tumor
1515390|NCT00003457|Anaplastic astrocytoma
1515391|NCT00003457|Anaplastic astrocytoma/Mixed
1515392|NCT00003457|Astrocytoma
1515393|NCT00003457|Astrocytoma/Pilocytic
1515394|NCT00003457|Brainstem glioma
1515395|NCT00003457|Glioblastoma multiforme
1515396|NCT00003457|Glioma
1515397|NCT00003457|Neurocytoma
1515398|NCT00003457|Primitive neuroectodermal tumor
1515399|NCT00003457|Tectal glioma
1515400|NCT00003456|adult glioblastoma
1515401|NCT00003456|adult giant cell glioblastoma
1515402|NCT00003456|adult gliosarcoma
1515403|NCT00003454|stage IV breast cancer
1515404|NCT00003454|recurrent breast cancer
1515405|NCT00003453|stage IV adrenocortical carcinoma
1515406|NCT00003453|recurrent adrenocortical carcinoma
1515407|NCT00003452|recurrent bladder cancer
1515408|NCT00003452|stage IV bladder cancer
1515409|NCT00003451|stage III adult Hodgkin lymphoma
1515410|NCT00003451|stage IV adult Hodgkin lymphoma
1515411|NCT00003451|monoclonal gammopathy of undetermined significance
1515412|NCT00003451|recurrent adult Hodgkin lymphoma
1520298|NCT00002764|adult synovial sarcoma
1515413|NCT00003451|isolated plasmacytoma of bone
1515414|NCT00003451|extramedullary plasmacytoma
1515415|NCT00003451|refractory multiple myeloma
1515416|NCT00003451|Waldenström macroglobulinemia
1515417|NCT00003451|stage III multiple myeloma
1515418|NCT00003451|stage IV chronic lymphocytic leukemia
1515419|NCT00003451|recurrent adult acute myeloid leukemia
1515420|NCT00003451|recurrent adult acute lymphoblastic leukemia
1515421|NCT00003451|relapsing chronic myelogenous leukemia
1515422|NCT00003451|refractory chronic lymphocytic leukemia
1515423|NCT00003451|unspecified adult solid tumor, protocol specific
1515424|NCT00003451|chronic phase chronic myelogenous leukemia
1515425|NCT00003451|accelerated phase chronic myelogenous leukemia
1515426|NCT00003451|blastic phase chronic myelogenous leukemia
1515427|NCT00003451|meningeal chronic myelogenous leukemia
1515428|NCT00003451|untreated adult acute lymphoblastic leukemia
1515429|NCT00003451|untreated adult acute myeloid leukemia
1515430|NCT00003451|adult acute myeloid leukemia in remission
1515431|NCT00003451|adult acute lymphoblastic leukemia in remission
1515432|NCT00003451|polycythemia vera
1515433|NCT00003451|primary myelofibrosis
1515434|NCT00003451|essential thrombocythemia
1515435|NCT00003451|untreated hairy cell leukemia
1515436|NCT00003451|progressive hairy cell leukemia, initial treatment
1515437|NCT00003451|refractory hairy cell leukemia
1515438|NCT00003451|chronic myelomonocytic leukemia
1515439|NCT00003451|T-cell large granular lymphocyte leukemia
1515440|NCT00003451|acute undifferentiated leukemia
1515441|NCT00003451|stage III grade 1 follicular lymphoma
1515442|NCT00003451|stage III grade 2 follicular lymphoma
1515443|NCT00003451|stage III grade 3 follicular lymphoma
1515444|NCT00003451|stage III adult diffuse small cleaved cell lymphoma
1515445|NCT00003451|stage III adult diffuse mixed cell lymphoma
1515446|NCT00003451|stage III adult diffuse large cell lymphoma
1515447|NCT00003451|stage III adult immunoblastic large cell lymphoma
1515448|NCT00003451|stage III adult lymphoblastic lymphoma
1515449|NCT00003451|stage III adult Burkitt lymphoma
1515450|NCT00003451|stage IV grade 1 follicular lymphoma
1515451|NCT00003451|stage IV grade 2 follicular lymphoma
1515452|NCT00003451|stage IV grade 3 follicular lymphoma
1515453|NCT00003451|stage IV adult diffuse small cleaved cell lymphoma
1515454|NCT00003451|stage IV adult diffuse mixed cell lymphoma
1515455|NCT00003451|stage IV adult diffuse large cell lymphoma
1515456|NCT00003451|stage IV adult immunoblastic large cell lymphoma
1515457|NCT00003451|stage IV adult lymphoblastic lymphoma
1515458|NCT00003451|stage IV adult Burkitt lymphoma
1515459|NCT00003451|recurrent grade 1 follicular lymphoma
1515460|NCT00003451|recurrent grade 2 follicular lymphoma
1515461|NCT00003451|recurrent grade 3 follicular lymphoma
1515462|NCT00003451|recurrent adult diffuse small cleaved cell lymphoma
1515463|NCT00003451|recurrent adult diffuse mixed cell lymphoma
1515464|NCT00003451|recurrent adult diffuse large cell lymphoma
1515465|NCT00003451|recurrent adult immunoblastic large cell lymphoma
1515466|NCT00003451|recurrent adult lymphoblastic lymphoma
1515467|NCT00003451|recurrent adult Burkitt lymphoma
1515468|NCT00003451|stage III adult T-cell leukemia/lymphoma
1515469|NCT00003451|stage IV adult T-cell leukemia/lymphoma
1515470|NCT00003451|recurrent adult T-cell leukemia/lymphoma
1515471|NCT00003451|secondary acute myeloid leukemia
1515472|NCT00003451|de novo myelodysplastic syndromes
1515473|NCT00003451|previously treated myelodysplastic syndromes
1515474|NCT00003451|secondary myelodysplastic syndromes
1515475|NCT00003451|prolymphocytic leukemia
1515476|NCT00003451|primary systemic amyloidosis
1515477|NCT00003451|stage III mantle cell lymphoma
1515478|NCT00003451|stage IV mantle cell lymphoma
1515479|NCT00003451|recurrent mantle cell lymphoma
1515480|NCT00003451|angioimmunoblastic T-cell lymphoma
1515481|NCT00003451|anaplastic large cell lymphoma
1515482|NCT00003451|recurrent marginal zone lymphoma
1515483|NCT00003451|recurrent small lymphocytic lymphoma
1515484|NCT00003451|stage III small lymphocytic lymphoma
1515485|NCT00003451|stage III marginal zone lymphoma
1515486|NCT00003451|stage IV small lymphocytic lymphoma
1515487|NCT00003451|stage IV marginal zone lymphoma
1515488|NCT00003451|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515489|NCT00003451|nodal marginal zone B-cell lymphoma
1515490|NCT00003451|splenic marginal zone lymphoma
1515491|NCT00003451|childhood myelodysplastic syndromes
1515492|NCT00003450|stage IV ovarian epithelial cancer
1515493|NCT00003450|recurrent ovarian epithelial cancer
1515494|NCT00003450|peritoneal cavity cancer
1515495|NCT00003449|recurrent ovarian epithelial cancer
1515496|NCT00003447|stage IIIB non-small cell lung cancer
1515497|NCT00003447|stage IV non-small cell lung cancer
1515498|NCT00003446|stage IV colon cancer
1515499|NCT00003446|stage IV rectal cancer
1515500|NCT00003446|recurrent colon cancer
1515501|NCT00003446|recurrent rectal cancer
1515502|NCT00003445|stage III cervical cancer
1515503|NCT00003445|stage IIB cervical cancer
1515504|NCT00003445|stage IVA cervical cancer
1515505|NCT00003445|cervical squamous cell carcinoma
1515506|NCT00003444|stage III melanoma
1515507|NCT00003444|stage IV melanoma
1515508|NCT00003444|recurrent melanoma
1515509|NCT00003443|stage IV squamous cell carcinoma of the lip and oral cavity
1515510|NCT00003443|recurrent squamous cell carcinoma of the lip and oral cavity
1515511|NCT00003443|stage IV squamous cell carcinoma of the oropharynx
1515512|NCT00003443|recurrent squamous cell carcinoma of the oropharynx
1515513|NCT00003443|stage IV squamous cell carcinoma of the nasopharynx
1515514|NCT00003443|recurrent squamous cell carcinoma of the nasopharynx
1515515|NCT00003443|stage IV squamous cell carcinoma of the hypopharynx
1515516|NCT00003443|recurrent squamous cell carcinoma of the hypopharynx
1515517|NCT00003443|stage IV squamous cell carcinoma of the larynx
1515518|NCT00003443|recurrent squamous cell carcinoma of the larynx
1515519|NCT00003443|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1515520|NCT00003443|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1515521|NCT00003441|stage IV colon cancer
1515522|NCT00003441|stage IV rectal cancer
1515523|NCT00003441|recurrent colon cancer
1515524|NCT00003441|recurrent rectal cancer
1515525|NCT00003441|adenocarcinoma of the colon
1515526|NCT00003441|adenocarcinoma of the rectum
1515527|NCT00003441|6-hydroxymethylacylfulvene
1515528|NCT00003441|MGI-114
1515529|NCT00003441|Irofulven
1515530|NCT00003439|stage IV colon cancer
1515531|NCT00003439|stage IV gastric cancer
1515532|NCT00003439|recurrent gastric cancer
1515533|NCT00003439|recurrent pancreatic cancer
1515534|NCT00003439|stage IV rectal cancer
1515535|NCT00003439|recurrent colon cancer
1515536|NCT00003439|recurrent rectal cancer
1515537|NCT00003439|stage IV anal cancer
1515538|NCT00003439|recurrent anal cancer
1515539|NCT00003439|stage IV ovarian epithelial cancer
1515540|NCT00003439|recurrent ovarian epithelial cancer
1515541|NCT00003439|metastatic gastrointestinal carcinoid tumor
1515542|NCT00003439|recurrent gastrointestinal carcinoid tumor
1515543|NCT00003439|advanced adult primary liver cancer
1515544|NCT00003439|recurrent adult primary liver cancer
1515545|NCT00003439|stage IV endometrial carcinoma
1515546|NCT00003439|recurrent endometrial carcinoma
1515547|NCT00003439|small intestine adenocarcinoma
1515548|NCT00003439|unresectable gallbladder cancer
1515549|NCT00003439|recurrent gallbladder cancer
1515550|NCT00003439|unresectable extrahepatic bile duct cancer
1515551|NCT00003439|recurrent extrahepatic bile duct cancer
1515552|NCT00003439|recurrent small intestine cancer
1515553|NCT00003439|stage IV prostate cancer
1515554|NCT00003439|recurrent prostate cancer
1515555|NCT00003439|fallopian tube cancer
1515556|NCT00003439|primary peritoneal cavity cancer
1515557|NCT00003439|stage IV pancreatic cancer
1515558|NCT00003437|recurrent childhood acute lymphoblastic leukemia
1515559|NCT00003437|untreated childhood acute lymphoblastic leukemia
1515560|NCT00003436|untreated childhood acute myeloid leukemia and other myeloid malignancies
1515561|NCT00003436|childhood acute promyelocytic leukemia (M3)
1515562|NCT00003436|refractory anemia with excess blasts
1515563|NCT00003436|refractory anemia with excess blasts in transformation
1515564|NCT00003436|secondary acute myeloid leukemia
1515565|NCT00003436|de novo myelodysplastic syndromes
1515566|NCT00003436|secondary myelodysplastic syndromes
1515567|NCT00003436|childhood myelodysplastic syndromes
1515568|NCT00003435|recurrent adult acute lymphoblastic leukemia
1515569|NCT00003435|secondary acute myeloid leukemia
1515570|NCT00003435|AIDS-related peripheral/systemic lymphoma
1515571|NCT00003435|HIV-associated Hodgkin lymphoma
1515572|NCT00003434|stage I pancreatic cancer
1515573|NCT00003434|stage II pancreatic cancer
1515574|NCT00003434|stage III pancreatic cancer
1515575|NCT00003434|adenocarcinoma of the pancreas
1515576|NCT00003433|stage IV colon cancer
1515577|NCT00003433|liver metastases
1515578|NCT00003432|stage IV breast cancer
1515579|NCT00003431|stage IV colon cancer
1515580|NCT00003431|lung metastases
1515581|NCT00003431|liver metastases
1515582|NCT00003430|recurrent nasopharyngeal cancer
1515583|NCT00003430|unspecified adult solid tumor, protocol specific
1515584|NCT00003430|recurrent lip and oral cavity cancer
1515585|NCT00003430|recurrent hypopharyngeal cancer
1515586|NCT00003430|recurrent laryngeal cancer
1517573|NCT00003239|DepotCyt
1515587|NCT00003430|recurrent paranasal sinus and nasal cavity cancer
1515588|NCT00003430|recurrent oropharyngeal cancer
1515589|NCT00003429|stage I cervical cancer
1515590|NCT00003429|stage II cervical cancer
1515591|NCT00003429|recurrent cervical cancer
1515592|NCT00003428|stage IV breast cancer
1515593|NCT00003428|recurrent breast cancer
1515594|NCT00003427|stage IV colon cancer
1515595|NCT00003427|stage IV gastric cancer
1515596|NCT00003427|recurrent gastric cancer
1515597|NCT00003427|recurrent pancreatic cancer
1515598|NCT00003427|stage IV rectal cancer
1515599|NCT00003427|recurrent colon cancer
1515600|NCT00003427|recurrent rectal cancer
1515601|NCT00003427|stage IV anal cancer
1515602|NCT00003427|recurrent anal cancer
1515603|NCT00003427|stage IV esophageal cancer
1515604|NCT00003427|recurrent esophageal cancer
1515605|NCT00003427|metastatic gastrointestinal carcinoid tumor
1515606|NCT00003427|recurrent gastrointestinal carcinoid tumor
1515607|NCT00003427|advanced adult primary liver cancer
1515608|NCT00003427|recurrent adult primary liver cancer
1515609|NCT00003427|unresectable gallbladder cancer
1515610|NCT00003427|recurrent gallbladder cancer
1515611|NCT00003427|unresectable extrahepatic bile duct cancer
1515612|NCT00003427|recurrent extrahepatic bile duct cancer
1515613|NCT00003427|recurrent small intestine cancer
1515614|NCT00003427|stage IV pancreatic cancer
1515615|NCT00003426|stage II pancreatic cancer
1515616|NCT00003426|stage III pancreatic cancer
1515617|NCT00003426|adenocarcinoma of the pancreas
1515618|NCT00003425|stage III adult Hodgkin lymphoma
1515619|NCT00003425|stage IV adult Hodgkin lymphoma
1515620|NCT00003425|stage IV breast cancer
1515621|NCT00003425|stage IIIA breast cancer
1515622|NCT00003425|recurrent breast cancer
1515623|NCT00003425|stage IIIB breast cancer
1515624|NCT00003425|recurrent adult Hodgkin lymphoma
1515625|NCT00003425|refractory multiple myeloma
1515626|NCT00003425|stage III ovarian epithelial cancer
1515627|NCT00003425|stage IV ovarian epithelial cancer
1515628|NCT00003425|recurrent ovarian epithelial cancer
1515629|NCT00003425|regional neuroblastoma
1515630|NCT00003425|disseminated neuroblastoma
1515631|NCT00003425|stage 4S neuroblastoma
1515632|NCT00003425|recurrent neuroblastoma
1515633|NCT00003425|stage III multiple myeloma
1515634|NCT00003425|recurrent adult acute myeloid leukemia
1515635|NCT00003425|recurrent adult acute lymphoblastic leukemia
1515636|NCT00003425|unspecified adult solid tumor, protocol specific
1515637|NCT00003425|untreated adult acute lymphoblastic leukemia
1515638|NCT00003425|untreated adult acute myeloid leukemia
1515639|NCT00003425|adult acute myeloid leukemia in remission
1515640|NCT00003425|adult acute lymphoblastic leukemia in remission
1515641|NCT00003425|ovarian stromal cancer
1515642|NCT00003425|stage III ovarian germ cell tumor
1515643|NCT00003425|stage IV ovarian germ cell tumor
1515644|NCT00003425|recurrent ovarian germ cell tumor
1515645|NCT00003425|acute undifferentiated leukemia
1515646|NCT00003425|stage III grade 1 follicular lymphoma
1515647|NCT00003425|stage III grade 2 follicular lymphoma
1515648|NCT00003425|stage III grade 3 follicular lymphoma
1515649|NCT00003425|stage III adult diffuse small cleaved cell lymphoma
1515650|NCT00003425|stage III adult diffuse mixed cell lymphoma
1515651|NCT00003425|stage III adult diffuse large cell lymphoma
1515652|NCT00003425|stage III adult immunoblastic large cell lymphoma
1515653|NCT00003425|stage III adult lymphoblastic lymphoma
1515654|NCT00003425|stage III adult Burkitt lymphoma
1515655|NCT00003425|stage IV grade 1 follicular lymphoma
1515656|NCT00003425|stage IV grade 2 follicular lymphoma
1515657|NCT00003425|stage IV grade 3 follicular lymphoma
1515658|NCT00003425|stage IV adult diffuse small cleaved cell lymphoma
1515659|NCT00003425|stage IV adult diffuse mixed cell lymphoma
1515660|NCT00003425|stage IV adult diffuse large cell lymphoma
1515661|NCT00003425|stage IV adult immunoblastic large cell lymphoma
1515662|NCT00003425|stage IV adult lymphoblastic lymphoma
1515663|NCT00003425|stage IV adult Burkitt lymphoma
1515664|NCT00003425|recurrent grade 1 follicular lymphoma
1515665|NCT00003425|recurrent grade 2 follicular lymphoma
1515666|NCT00003425|recurrent grade 3 follicular lymphoma
1515667|NCT00003425|recurrent adult diffuse small cleaved cell lymphoma
1515668|NCT00003425|recurrent adult diffuse mixed cell lymphoma
1515669|NCT00003425|recurrent adult diffuse large cell lymphoma
1515670|NCT00003425|recurrent adult immunoblastic large cell lymphoma
1515671|NCT00003425|recurrent adult lymphoblastic lymphoma
1515672|NCT00003425|recurrent adult Burkitt lymphoma
1515673|NCT00003425|secondary acute myeloid leukemia
1515674|NCT00003425|borderline ovarian surface epithelial-stromal tumor
1515675|NCT00003425|ovarian sarcoma
1515676|NCT00003425|localized unresectable neuroblastoma
1515677|NCT00003425|stage III mantle cell lymphoma
1515678|NCT00003425|stage IV mantle cell lymphoma
1515679|NCT00003425|recurrent mantle cell lymphoma
1515680|NCT00003425|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1515681|NCT00003425|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1515682|NCT00003425|recurrent marginal zone lymphoma
1515683|NCT00003425|recurrent small lymphocytic lymphoma
1515684|NCT00003425|stage III small lymphocytic lymphoma
1515685|NCT00003425|stage III marginal zone lymphoma
1515686|NCT00003425|stage IV small lymphocytic lymphoma
1515687|NCT00003425|stage IV marginal zone lymphoma
1515688|NCT00003425|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515689|NCT00003425|nodal marginal zone B-cell lymphoma
1515690|NCT00003425|splenic marginal zone lymphoma
1515691|NCT00003424|localized unresectable adult primary liver cancer
1515692|NCT00003424|advanced adult primary liver cancer
1515693|NCT00003424|adult primary hepatocellular carcinoma
1515694|NCT00003423|stage I childhood lymphoblastic lymphoma
1515695|NCT00003423|stage II childhood lymphoblastic lymphoma
1515696|NCT00003423|stage III childhood lymphoblastic lymphoma
1515697|NCT00003423|stage IV childhood lymphoblastic lymphoma
1515698|NCT00003423|stage I childhood large cell lymphoma
1515699|NCT00003423|stage II childhood large cell lymphoma
1515700|NCT00003423|stage III childhood large cell lymphoma
1515701|NCT00003423|stage IV childhood large cell lymphoma
1515702|NCT00003422|stage I rectal cancer
1515703|NCT00003422|stage II rectal cancer
1515704|NCT00003422|stage III rectal cancer
1515705|NCT00003422|adenocarcinoma of the rectum
1515706|NCT00003421|stage I adult Hodgkin lymphoma
1515707|NCT00003421|stage II adult Hodgkin lymphoma
1515708|NCT00003421|stage III adult Hodgkin lymphoma
1515709|NCT00003421|stage IV adult Hodgkin lymphoma
1515710|NCT00003420|stage I malignant testicular germ cell tumor
1515711|NCT00003420|testicular teratoma
1515712|NCT00003419|AIDS-related Kaposi sarcoma
1515713|NCT00003418|stage I breast cancer
1515714|NCT00003418|stage II breast cancer
1515715|NCT00003418|stage III breast cancer
1515716|NCT00003417|adult glioblastoma
1515717|NCT00003417|adult giant cell glioblastoma
1515718|NCT00003417|adult gliosarcoma
1515719|NCT00003416|Waldenström macroglobulinemia
1515720|NCT00003415|refractory anemia with excess blasts
1515721|NCT00003415|refractory anemia with excess blasts in transformation
1515722|NCT00003415|chronic myelomonocytic leukemia
1515723|NCT00003415|de novo myelodysplastic syndromes
1515724|NCT00003415|previously treated myelodysplastic syndromes
1515725|NCT00003414|recurrent adult Hodgkin lymphoma
1515726|NCT00003414|recurrent childhood lymphoblastic lymphoma
1515727|NCT00003414|recurrent/refractory childhood Hodgkin lymphoma
1515728|NCT00003414|recurrent grade 1 follicular lymphoma
1515729|NCT00003414|recurrent grade 2 follicular lymphoma
1515730|NCT00003414|recurrent grade 3 follicular lymphoma
1515731|NCT00003414|recurrent adult diffuse small cleaved cell lymphoma
1515732|NCT00003414|recurrent adult diffuse mixed cell lymphoma
1515733|NCT00003414|recurrent adult diffuse large cell lymphoma
1515734|NCT00003414|recurrent adult immunoblastic large cell lymphoma
1515735|NCT00003414|recurrent adult lymphoblastic lymphoma
1515736|NCT00003414|recurrent adult Burkitt lymphoma
1515737|NCT00003414|graft versus host disease
1515738|NCT00003414|recurrent childhood small noncleaved cell lymphoma
1515739|NCT00003414|recurrent childhood large cell lymphoma
1515740|NCT00003414|recurrent mantle cell lymphoma
1515741|NCT00003414|recurrent marginal zone lymphoma
1515742|NCT00003414|recurrent small lymphocytic lymphoma
1515743|NCT00003414|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515744|NCT00003414|nodal marginal zone B-cell lymphoma
1515745|NCT00003414|splenic marginal zone lymphoma
1515746|NCT00003413|stage III ovarian epithelial cancer
1515747|NCT00003413|stage IV ovarian epithelial cancer
1515748|NCT00003413|recurrent ovarian epithelial cancer
1515749|NCT00003412|stage IV breast cancer
1515750|NCT00003412|recurrent breast cancer
1515751|NCT00003411|stage II pancreatic cancer
1515752|NCT00003411|stage III pancreatic cancer
1515753|NCT00003411|unresectable gallbladder cancer
1515754|NCT00003411|unresectable extrahepatic bile duct cancer
1515755|NCT00003411|stage IV pancreatic cancer
1515756|NCT00003410|adult glioblastoma
1515757|NCT00003410|adult giant cell glioblastoma
1515758|NCT00003410|adult gliosarcoma
1515759|NCT00003409|adult glioblastoma
1515760|NCT00003409|adult giant cell glioblastoma
1515761|NCT00003409|adult gliosarcoma
1515762|NCT00003408|stage IV breast cancer
1515763|NCT00003408|recurrent childhood acute lymphoblastic leukemia
1515764|NCT00003408|recurrent adult Hodgkin lymphoma
1515765|NCT00003408|recurrent cutaneous T-cell non-Hodgkin lymphoma
1515766|NCT00003408|refractory multiple myeloma
1515767|NCT00003408|recurrent childhood rhabdomyosarcoma
1515768|NCT00003408|stage II ovarian epithelial cancer
1515769|NCT00003408|stage III ovarian epithelial cancer
1515770|NCT00003408|stage IV ovarian epithelial cancer
1515771|NCT00003408|recurrent ovarian epithelial cancer
1515772|NCT00003408|disseminated neuroblastoma
1515773|NCT00003408|recurrent neuroblastoma
1515774|NCT00003408|recurrent Wilms tumor and other childhood kidney tumors
1515775|NCT00003408|stage I multiple myeloma
1515776|NCT00003408|stage II multiple myeloma
1515777|NCT00003408|stage III multiple myeloma
1515778|NCT00003408|recurrent childhood lymphoblastic lymphoma
1515779|NCT00003408|stage III chronic lymphocytic leukemia
1515780|NCT00003408|stage IV chronic lymphocytic leukemia
1515781|NCT00003408|recurrent childhood acute myeloid leukemia
1515782|NCT00003408|recurrent adult acute myeloid leukemia
1515783|NCT00003408|recurrent adult acute lymphoblastic leukemia
1515784|NCT00003408|relapsing chronic myelogenous leukemia
1515785|NCT00003408|refractory chronic lymphocytic leukemia
1515786|NCT00003408|stage III malignant testicular germ cell tumor
1515787|NCT00003408|recurrent malignant testicular germ cell tumor
1515788|NCT00003408|chronic phase chronic myelogenous leukemia
1515789|NCT00003408|accelerated phase chronic myelogenous leukemia
1515790|NCT00003408|blastic phase chronic myelogenous leukemia
1515791|NCT00003408|meningeal chronic myelogenous leukemia
1515792|NCT00003408|chronic idiopathic myelofibrosis
1515793|NCT00003408|childhood acute promyelocytic leukemia (M3)
1515794|NCT00003408|testicular embryonal carcinoma
1515795|NCT00003408|testicular choriocarcinoma
1515796|NCT00003408|testicular teratoma
1515797|NCT00003408|testicular yolk sac tumor
1515798|NCT00003408|testicular embryonal carcinoma and teratoma
1515799|NCT00003408|testicular embryonal carcinoma and teratoma with seminoma
1515800|NCT00003408|testicular embryonal carcinoma and yolk sac tumor
1515801|NCT00003408|testicular embryonal carcinoma and yolk sac tumor with seminoma
1515802|NCT00003408|testicular embryonal carcinoma and seminoma
1515803|NCT00003408|testicular yolk sac tumor and teratoma
1515804|NCT00003408|testicular yolk sac tumor and teratoma with seminoma
1515805|NCT00003408|testicular choriocarcinoma and yolk sac tumor
1515806|NCT00003408|testicular choriocarcinoma and embryonal carcinoma
1515807|NCT00003408|testicular choriocarcinoma and teratoma
1515808|NCT00003408|testicular choriocarcinoma and seminoma
1515809|NCT00003408|refractory hairy cell leukemia
1515810|NCT00003408|recurrent/refractory childhood Hodgkin lymphoma
1515811|NCT00003408|recurrent ovarian germ cell tumor
1515812|NCT00003408|ovarian yolk sac tumor
1515813|NCT00003408|ovarian embryonal carcinoma
1515814|NCT00003408|ovarian polyembryoma
1515815|NCT00003408|ovarian choriocarcinoma
1515816|NCT00003408|ovarian immature teratoma
1515817|NCT00003408|ovarian mature teratoma
1515818|NCT00003408|ovarian monodermal and highly specialized teratoma
1515819|NCT00003408|ovarian mixed germ cell tumor
1515820|NCT00003408|stage III grade 1 follicular lymphoma
1515821|NCT00003408|stage III grade 2 follicular lymphoma
1515822|NCT00003408|stage III grade 3 follicular lymphoma
1515823|NCT00003408|stage III adult diffuse small cleaved cell lymphoma
1515824|NCT00003408|stage III adult diffuse mixed cell lymphoma
1515825|NCT00003408|stage III adult diffuse large cell lymphoma
1515826|NCT00003408|stage III adult immunoblastic large cell lymphoma
1515827|NCT00003408|stage III adult lymphoblastic lymphoma
1515828|NCT00003408|stage III adult Burkitt lymphoma
1515829|NCT00003408|stage IV grade 1 follicular lymphoma
1515830|NCT00003408|stage IV grade 2 follicular lymphoma
1515831|NCT00003408|stage IV grade 3 follicular lymphoma
1515832|NCT00003408|stage IV adult diffuse small cleaved cell lymphoma
1515833|NCT00003408|stage IV adult diffuse mixed cell lymphoma
1515834|NCT00003408|stage IV adult diffuse large cell lymphoma
1515835|NCT00003408|stage IV adult immunoblastic large cell lymphoma
1515836|NCT00003408|stage IV adult lymphoblastic lymphoma
1515837|NCT00003408|stage IV adult Burkitt lymphoma
1515838|NCT00003408|recurrent grade 1 follicular lymphoma
1515839|NCT00003408|recurrent grade 2 follicular lymphoma
1515840|NCT00003408|recurrent grade 3 follicular lymphoma
1515841|NCT00003408|recurrent adult diffuse small cleaved cell lymphoma
1515842|NCT00003408|recurrent adult diffuse mixed cell lymphoma
1515843|NCT00003408|recurrent adult diffuse large cell lymphoma
1515844|NCT00003408|recurrent adult immunoblastic large cell lymphoma
1515845|NCT00003408|recurrent adult lymphoblastic lymphoma
1515846|NCT00003408|recurrent adult Burkitt lymphoma
1515847|NCT00003408|secondary acute myeloid leukemia
1515848|NCT00003408|de novo myelodysplastic syndromes
1515849|NCT00003408|poor prognosis metastatic gestational trophoblastic tumor
1515850|NCT00003408|previously treated myelodysplastic syndromes
1515851|NCT00003408|secondary myelodysplastic syndromes
1515852|NCT00003408|recurrent childhood small noncleaved cell lymphoma
1515853|NCT00003408|recurrent childhood large cell lymphoma
1515854|NCT00003408|noncontiguous stage II grade 1 follicular lymphoma
1515855|NCT00003408|noncontiguous stage II grade 2 follicular lymphoma
1515856|NCT00003408|noncontiguous stage II grade 3 follicular lymphoma
1515857|NCT00003408|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1515858|NCT00003408|noncontiguous stage II mantle cell lymphoma
1515859|NCT00003408|noncontiguous stage II adult diffuse mixed cell lymphoma
1515860|NCT00003408|noncontiguous stage II adult immunoblastic large cell lymphoma
1515861|NCT00003408|noncontiguous stage II adult diffuse large cell lymphoma
1515862|NCT00003408|noncontiguous stage II adult Burkitt lymphoma
1515863|NCT00003408|noncontiguous stage II adult lymphoblastic lymphoma
1515864|NCT00003408|stage III mantle cell lymphoma
1515865|NCT00003408|stage IV mantle cell lymphoma
1515866|NCT00003408|recurrent mantle cell lymphoma
1515867|NCT00003408|previously treated childhood rhabdomyosarcoma
1515868|NCT00003408|recurrent mycosis fungoides/Sezary syndrome
1515869|NCT00003408|noncontiguous stage II small lymphocytic lymphoma
1515870|NCT00003408|noncontiguous stage II marginal zone lymphoma
1515871|NCT00003408|recurrent marginal zone lymphoma
1515872|NCT00003408|recurrent small lymphocytic lymphoma
1515873|NCT00003408|stage III small lymphocytic lymphoma
1515874|NCT00003408|stage III marginal zone lymphoma
1515875|NCT00003408|stage IV small lymphocytic lymphoma
1515876|NCT00003408|stage IV marginal zone lymphoma
1515877|NCT00003408|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515878|NCT00003408|nodal marginal zone B-cell lymphoma
1515879|NCT00003408|splenic marginal zone lymphoma
1515880|NCT00003408|childhood myelodysplastic syndromes
1515881|NCT00003407|recurrent adult acute myeloid leukemia
1515882|NCT00003407|blastic phase chronic myelogenous leukemia
1515883|NCT00003407|untreated adult acute myeloid leukemia
1515884|NCT00003407|refractory anemia with excess blasts in transformation
1515885|NCT00003407|secondary acute myeloid leukemia
1515886|NCT00003407|de novo myelodysplastic syndromes
1515887|NCT00003407|secondary myelodysplastic syndromes
1515888|NCT00003407|drug/agent toxicity by tissue/organ
1515889|NCT00003407|neutropenia
1515890|NCT00003406|stage III adult Hodgkin lymphoma
1515891|NCT00003406|stage IV adult Hodgkin lymphoma
1515892|NCT00003406|monoclonal gammopathy of undetermined significance
1515893|NCT00003406|recurrent adult Hodgkin lymphoma
1515894|NCT00003406|isolated plasmacytoma of bone
1515895|NCT00003406|extramedullary plasmacytoma
1521436|NCT00002608|childhood brain tumor
1515896|NCT00003406|refractory multiple myeloma
1515897|NCT00003406|Waldenstrom macroglobulinemia
1515898|NCT00003406|stage III multiple myeloma
1515899|NCT00003406|stage III chronic lymphocytic leukemia
1515900|NCT00003406|stage IV chronic lymphocytic leukemia
1515901|NCT00003406|recurrent adult acute myeloid leukemia
1515902|NCT00003406|recurrent adult acute lymphoblastic leukemia
1515903|NCT00003406|relapsing chronic myelogenous leukemia
1515904|NCT00003406|refractory chronic lymphocytic leukemia
1515905|NCT00003406|unspecified adult solid tumor, protocol specific
1515906|NCT00003406|chronic phase chronic myelogenous leukemia
1515907|NCT00003406|accelerated phase chronic myelogenous leukemia
1515908|NCT00003406|blastic phase chronic myelogenous leukemia
1515909|NCT00003406|meningeal chronic myelogenous leukemia
1515910|NCT00003406|adult acute myeloid leukemia in remission
1515911|NCT00003406|adult acute lymphoblastic leukemia in remission
1515912|NCT00003406|polycythemia vera
1515913|NCT00003406|chronic idiopathic myelofibrosis
1515914|NCT00003406|essential thrombocythemia
1515915|NCT00003406|progressive hairy cell leukemia, initial treatment
1515916|NCT00003406|refractory hairy cell leukemia
1515917|NCT00003406|chronic myelomonocytic leukemia
1515918|NCT00003406|T-cell large granular lymphocyte leukemia
1515919|NCT00003406|acute undifferentiated leukemia
1515920|NCT00003406|stage III grade 1 follicular lymphoma
1515921|NCT00003406|stage III grade 2 follicular lymphoma
1515922|NCT00003406|stage III grade 3 follicular lymphoma
1515923|NCT00003406|stage III adult diffuse small cleaved cell lymphoma
1515924|NCT00003406|stage III adult diffuse mixed cell lymphoma
1515925|NCT00003406|stage III adult diffuse large cell lymphoma
1515926|NCT00003406|stage III adult immunoblastic large cell lymphoma
1515927|NCT00003406|stage III adult lymphoblastic lymphoma
1515928|NCT00003406|stage III adult Burkitt lymphoma
1515929|NCT00003406|stage IV grade 1 follicular lymphoma
1515930|NCT00003406|stage IV grade 2 follicular lymphoma
1515931|NCT00003406|stage IV grade 3 follicular lymphoma
1515932|NCT00003406|stage IV adult diffuse small cleaved cell lymphoma
1515933|NCT00003406|stage IV adult diffuse mixed cell lymphoma
1515934|NCT00003406|stage IV adult diffuse large cell lymphoma
1515935|NCT00003406|stage IV adult immunoblastic large cell lymphoma
1515936|NCT00003406|stage IV adult lymphoblastic lymphoma
1515937|NCT00003406|stage IV adult Burkitt lymphoma
1515938|NCT00003406|recurrent grade 1 follicular lymphoma
1515939|NCT00003406|recurrent grade 2 follicular lymphoma
1515940|NCT00003406|recurrent grade 3 follicular lymphoma
1515941|NCT00003406|recurrent adult diffuse small cleaved cell lymphoma
1515942|NCT00003406|recurrent adult diffuse mixed cell lymphoma
1515943|NCT00003406|recurrent adult diffuse large cell lymphoma
1515944|NCT00003406|recurrent adult immunoblastic large cell lymphoma
1515945|NCT00003406|recurrent adult lymphoblastic lymphoma
1515946|NCT00003406|recurrent adult Burkitt lymphoma
1515947|NCT00003406|stage III adult T-cell leukemia/lymphoma
1515948|NCT00003406|stage IV adult T-cell leukemia/lymphoma
1515949|NCT00003406|recurrent adult T-cell leukemia/lymphoma
1515950|NCT00003406|secondary acute myeloid leukemia
1515951|NCT00003406|de novo myelodysplastic syndromes
1515952|NCT00003406|previously treated myelodysplastic syndromes
1515953|NCT00003406|secondary myelodysplastic syndromes
1515954|NCT00003406|prolymphocytic leukemia
1515955|NCT00003406|AIDS-related peripheral/systemic lymphoma
1515956|NCT00003406|AIDS-related primary CNS lymphoma
1515957|NCT00003406|primary systemic amyloidosis
1515958|NCT00003406|non-Hodgkin lymphoma during pregnancy
1515959|NCT00003406|stage III mantle cell lymphoma
1515960|NCT00003406|stage IV mantle cell lymphoma
1515961|NCT00003406|recurrent mantle cell lymphoma
1515962|NCT00003406|angioimmunoblastic T-cell lymphoma
1515963|NCT00003406|anaplastic large cell lymphoma
1515964|NCT00003406|recurrent marginal zone lymphoma
1515965|NCT00003406|recurrent small lymphocytic lymphoma
1515966|NCT00003406|stage III small lymphocytic lymphoma
1515967|NCT00003406|stage III marginal zone lymphoma
1515968|NCT00003406|stage IV small lymphocytic lymphoma
1515969|NCT00003406|stage IV marginal zone lymphoma
1515970|NCT00003406|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1515971|NCT00003406|nodal marginal zone B-cell lymphoma
1515972|NCT00003406|splenic marginal zone lymphoma
1515973|NCT00003406|childhood myelodysplastic syndromes
1515974|NCT00003405|untreated adult acute myeloid leukemia
1515975|NCT00003405|untreated childhood acute myeloid leukemia and other myeloid malignancies
1515976|NCT00003405|adult acute erythroid leukemia (M6)
1515977|NCT00003405|adult acute myeloblastic leukemia without maturation (M1)
1515978|NCT00003405|adult acute myeloblastic leukemia with maturation (M2)
1515979|NCT00003405|adult acute myelomonocytic leukemia (M4)
1515980|NCT00003405|adult acute monoblastic leukemia (M5a)
1515981|NCT00003405|adult acute megakaryoblastic leukemia (M7)
1515982|NCT00003405|childhood acute myeloblastic leukemia without maturation (M1)
1515983|NCT00003405|childhood acute myeloblastic leukemia with maturation (M2)
1515984|NCT00003405|childhood acute myelomonocytic leukemia (M4)
1515985|NCT00003405|childhood acute monoblastic leukemia (M5a)
1515986|NCT00003405|childhood acute monocytic leukemia (M5b)
1515987|NCT00003405|childhood acute erythroleukemia (M6)
1515988|NCT00003405|childhood acute megakaryocytic leukemia (M7)
1515989|NCT00003405|adult acute monocytic leukemia (M5b)
1515990|NCT00003404|recurrent breast cancer
1515991|NCT00003404|phyllodes tumor
1515992|NCT00003403|unspecified adult solid tumor, protocol specific
1515993|NCT00003402|Waldenstrom macroglobulinemia
1515994|NCT00003402|stage III chronic lymphocytic leukemia
1515995|NCT00003402|stage IV chronic lymphocytic leukemia
1515996|NCT00003402|refractory chronic lymphocytic leukemia
1515997|NCT00003402|stage III grade 1 follicular lymphoma
1515998|NCT00003402|stage III grade 2 follicular lymphoma
1515999|NCT00003402|stage IV grade 1 follicular lymphoma
1516000|NCT00003402|stage IV grade 2 follicular lymphoma
1516001|NCT00003402|recurrent grade 1 follicular lymphoma
1516002|NCT00003402|recurrent grade 2 follicular lymphoma
1516003|NCT00003402|stage III mantle cell lymphoma
1516004|NCT00003402|stage IV mantle cell lymphoma
1516005|NCT00003402|recurrent mantle cell lymphoma
1516006|NCT00003401|refractory multiple myeloma
1516007|NCT00003401|stage I multiple myeloma
1516008|NCT00003401|stage II multiple myeloma
1516009|NCT00003401|stage III multiple myeloma
1516010|NCT00003400|adenocarcinoma of the prostate
1516011|NCT00003400|stage IV prostate cancer
1516012|NCT00003400|recurrent prostate cancer
1516013|NCT00003399|refractory multiple myeloma
1516014|NCT00003399|stage I multiple myeloma
1516015|NCT00003399|stage II multiple myeloma
1516016|NCT00003399|stage III multiple myeloma
1516017|NCT00003398|stage III adult Hodgkin lymphoma
1516018|NCT00003398|stage IV adult Hodgkin lymphoma
1516019|NCT00003398|recurrent childhood acute lymphoblastic leukemia
1516020|NCT00003398|recurrent adult Hodgkin lymphoma
1516021|NCT00003398|Burkitt lymphoma
1516022|NCT00003398|refractory multiple myeloma
1516023|NCT00003398|Waldenstrom macroglobulinemia
1516024|NCT00003398|stage I multiple myeloma
1516025|NCT00003398|stage II multiple myeloma
1516026|NCT00003398|stage III multiple myeloma
1516027|NCT00003398|stage I childhood lymphoblastic lymphoma
1516028|NCT00003398|stage II childhood lymphoblastic lymphoma
1516029|NCT00003398|stage III childhood lymphoblastic lymphoma
1516030|NCT00003398|stage IV childhood lymphoblastic lymphoma
1516031|NCT00003398|recurrent childhood lymphoblastic lymphoma
1516032|NCT00003398|stage I chronic lymphocytic leukemia
1516033|NCT00003398|stage II chronic lymphocytic leukemia
1516034|NCT00003398|stage III chronic lymphocytic leukemia
1516035|NCT00003398|stage IV chronic lymphocytic leukemia
1516036|NCT00003398|recurrent childhood acute myeloid leukemia
1516037|NCT00003398|recurrent adult acute myeloid leukemia
1516038|NCT00003398|recurrent adult acute lymphoblastic leukemia
1516039|NCT00003398|refractory chronic lymphocytic leukemia
1516040|NCT00003398|childhood diffuse large cell lymphoma
1516041|NCT00003398|childhood immunoblastic large cell lymphoma
1516042|NCT00003398|chronic phase chronic myelogenous leukemia
1516043|NCT00003398|accelerated phase chronic myelogenous leukemia
1516044|NCT00003398|blastic phase chronic myelogenous leukemia
1516045|NCT00003398|meningeal chronic myelogenous leukemia
1516046|NCT00003398|adult acute myeloid leukemia in remission
1516047|NCT00003398|adult acute lymphoblastic leukemia in remission
1516048|NCT00003398|childhood acute myeloid leukemia in remission
1516049|NCT00003398|childhood acute lymphoblastic leukemia in remission
1516050|NCT00003398|adult acute myeloblastic leukemia without maturation (M1)
1516051|NCT00003398|adult acute myeloblastic leukemia with maturation (M2)
1516052|NCT00003398|adult acute promyelocytic leukemia (M3)
1516053|NCT00003398|adult acute myelomonocytic leukemia (M4)
1516054|NCT00003398|adult acute eosinophilic leukemia
1516055|NCT00003398|adult acute basophilic leukemia
1516056|NCT00003398|adult acute megakaryoblastic leukemia (M7)
1516057|NCT00003398|childhood acute myeloblastic leukemia with maturation (M2)
1516058|NCT00003398|childhood acute promyelocytic leukemia (M3)
1516059|NCT00003398|childhood acute myelomonocytic leukemia (M4)
1516060|NCT00003398|childhood acute eosinophilic leukemia
1516061|NCT00003398|childhood acute basophilic leukemia
1516062|NCT00003398|childhood acute megakaryocytic leukemia (M7)
1516063|NCT00003398|stage III childhood Hodgkin lymphoma
1516064|NCT00003398|stage IV childhood Hodgkin lymphoma
1516065|NCT00003398|recurrent/refractory childhood Hodgkin lymphoma
1516066|NCT00003398|stage I grade 1 follicular lymphoma
1516067|NCT00003398|stage I grade 2 follicular lymphoma
1516068|NCT00003398|stage I grade 3 follicular lymphoma
1516069|NCT00003398|stage I adult diffuse small cleaved cell lymphoma
1516070|NCT00003398|stage I adult diffuse mixed cell lymphoma
1516071|NCT00003398|stage I adult diffuse large cell lymphoma
1516072|NCT00003398|stage I adult immunoblastic large cell lymphoma
1516073|NCT00003398|stage I adult lymphoblastic lymphoma
1516074|NCT00003398|stage I adult Burkitt lymphoma
1516075|NCT00003398|stage III grade 1 follicular lymphoma
1516076|NCT00003398|stage III grade 2 follicular lymphoma
1516077|NCT00003398|stage III grade 3 follicular lymphoma
1516078|NCT00003398|stage III adult diffuse small cleaved cell lymphoma
1516079|NCT00003398|stage III adult diffuse mixed cell lymphoma
1516080|NCT00003398|stage III adult diffuse large cell lymphoma
1516081|NCT00003398|stage III adult immunoblastic large cell lymphoma
1516082|NCT00003398|stage III adult lymphoblastic lymphoma
1516083|NCT00003398|stage III adult Burkitt lymphoma
1522939|NCT00002438|Histoplasmosis
1516084|NCT00003398|stage IV grade 1 follicular lymphoma
1516085|NCT00003398|stage IV grade 2 follicular lymphoma
1516086|NCT00003398|stage IV grade 3 follicular lymphoma
1516087|NCT00003398|stage IV adult diffuse small cleaved cell lymphoma
1516088|NCT00003398|stage IV adult diffuse mixed cell lymphoma
1516089|NCT00003398|stage IV adult diffuse large cell lymphoma
1516090|NCT00003398|stage IV adult immunoblastic large cell lymphoma
1516091|NCT00003398|stage IV adult lymphoblastic lymphoma
1516092|NCT00003398|stage IV adult Burkitt lymphoma
1516093|NCT00003398|recurrent adult diffuse small cleaved cell lymphoma
1516094|NCT00003398|recurrent adult diffuse mixed cell lymphoma
1516095|NCT00003398|recurrent adult diffuse large cell lymphoma
1516096|NCT00003398|recurrent adult immunoblastic large cell lymphoma
1516097|NCT00003398|recurrent adult lymphoblastic lymphoma
1516098|NCT00003398|recurrent adult Burkitt lymphoma
1516099|NCT00003398|de novo myelodysplastic syndromes
1516100|NCT00003398|previously treated myelodysplastic syndromes
1516101|NCT00003398|secondary myelodysplastic syndromes
1516102|NCT00003398|anemia
1516103|NCT00003398|graft versus host disease
1516104|NCT00003398|adult acute minimally differentiated myeloid leukemia (M0)
1516105|NCT00003398|childhood acute minimally differentiated myeloid leukemia (M0)
1516106|NCT00003398|stage I childhood small noncleaved cell lymphoma
1516107|NCT00003398|stage I childhood large cell lymphoma
1516108|NCT00003398|stage II childhood small noncleaved cell lymphoma
1516109|NCT00003398|stage II childhood large cell lymphoma
1516110|NCT00003398|stage III childhood small noncleaved cell lymphoma
1516111|NCT00003398|stage III childhood large cell lymphoma
1516112|NCT00003398|stage IV childhood small noncleaved cell lymphoma
1516113|NCT00003398|stage IV childhood large cell lymphoma
1516114|NCT00003398|recurrent childhood small noncleaved cell lymphoma
1516115|NCT00003398|recurrent childhood large cell lymphoma
1516116|NCT00003398|stage I mantle cell lymphoma
1516117|NCT00003398|contiguous stage II grade 1 follicular lymphoma
1516118|NCT00003398|contiguous stage II grade 2 follicular lymphoma
1516119|NCT00003398|contiguous stage II grade 3 follicular lymphoma
1516120|NCT00003398|contiguous stage II adult diffuse small cleaved cell lymphoma
1516121|NCT00003398|contiguous stage II mantle cell lymphoma
1516122|NCT00003398|contiguous stage II adult diffuse mixed cell lymphoma
1516123|NCT00003398|contiguous stage II adult immunoblastic large cell lymphoma
1516124|NCT00003398|contiguous stage II adult diffuse large cell lymphoma
1516125|NCT00003398|contiguous stage II adult Burkitt lymphoma
1516126|NCT00003398|contiguous stage II adult lymphoblastic lymphoma
1516127|NCT00003398|noncontiguous stage II grade 1 follicular lymphoma
1516128|NCT00003398|noncontiguous stage II grade 2 follicular lymphoma
1516129|NCT00003398|noncontiguous stage II grade 3 follicular lymphoma
1516130|NCT00003398|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1516131|NCT00003398|noncontiguous stage II mantle cell lymphoma
1516132|NCT00003398|noncontiguous stage II adult diffuse mixed cell lymphoma
1516133|NCT00003398|noncontiguous stage II adult immunoblastic large cell lymphoma
1516134|NCT00003398|noncontiguous stage II adult diffuse large cell lymphoma
1516135|NCT00003398|noncontiguous stage II adult Burkitt lymphoma
1516136|NCT00003398|noncontiguous stage II adult lymphoblastic lymphoma
1516137|NCT00003398|stage III mantle cell lymphoma
1516138|NCT00003398|stage IV mantle cell lymphoma
1516139|NCT00003398|recurrent mantle cell lymphoma
1516140|NCT00003398|noncontiguous stage II small lymphocytic lymphoma
1516141|NCT00003398|noncontiguous stage II marginal zone lymphoma
1516142|NCT00003398|recurrent marginal zone lymphoma
1516143|NCT00003398|recurrent small lymphocytic lymphoma
1516144|NCT00003398|stage I marginal zone lymphoma
1516145|NCT00003398|stage I small lymphocytic lymphoma
1516146|NCT00003398|stage III small lymphocytic lymphoma
1516147|NCT00003398|stage III marginal zone lymphoma
1516148|NCT00003398|stage IV small lymphocytic lymphoma
1516149|NCT00003398|stage IV marginal zone lymphoma
1516150|NCT00003398|contiguous stage II marginal zone lymphoma
1516151|NCT00003398|contiguous stage II small lymphocytic lymphoma
1516152|NCT00003398|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516153|NCT00003398|nodal marginal zone B-cell lymphoma
1516154|NCT00003398|splenic marginal zone lymphoma
1516155|NCT00003398|childhood myelodysplastic syndromes
1516156|NCT00003397|stage I grade 3 follicular lymphoma
1516157|NCT00003397|stage I adult diffuse small cleaved cell lymphoma
1516158|NCT00003397|stage I adult diffuse mixed cell lymphoma
1516159|NCT00003397|stage I adult diffuse large cell lymphoma
1516160|NCT00003397|stage I adult immunoblastic large cell lymphoma
1516161|NCT00003397|stage I adult lymphoblastic lymphoma
1516162|NCT00003397|stage I adult Burkitt lymphoma
1516163|NCT00003397|stage III grade 3 follicular lymphoma
1516164|NCT00003397|stage III adult diffuse small cleaved cell lymphoma
1516165|NCT00003397|stage III adult diffuse mixed cell lymphoma
1516166|NCT00003397|stage III adult diffuse large cell lymphoma
1516167|NCT00003397|stage III adult immunoblastic large cell lymphoma
1516168|NCT00003397|stage III adult lymphoblastic lymphoma
1516169|NCT00003397|stage III adult Burkitt lymphoma
1516170|NCT00003397|stage IV grade 3 follicular lymphoma
1516171|NCT00003397|stage IV adult diffuse small cleaved cell lymphoma
1516172|NCT00003397|stage IV adult diffuse mixed cell lymphoma
1516173|NCT00003397|stage IV adult diffuse large cell lymphoma
1516174|NCT00003397|stage IV adult immunoblastic large cell lymphoma
1516175|NCT00003397|stage IV adult lymphoblastic lymphoma
1516176|NCT00003397|stage IV adult Burkitt lymphoma
1516177|NCT00003397|recurrent grade 3 follicular lymphoma
1516178|NCT00003397|recurrent adult diffuse small cleaved cell lymphoma
1516179|NCT00003397|recurrent adult diffuse mixed cell lymphoma
1516180|NCT00003397|recurrent adult diffuse large cell lymphoma
1516181|NCT00003397|recurrent adult immunoblastic large cell lymphoma
1516182|NCT00003397|recurrent adult lymphoblastic lymphoma
1516183|NCT00003397|recurrent adult Burkitt lymphoma
1516184|NCT00003397|stage I mantle cell lymphoma
1516185|NCT00003397|contiguous stage II grade 3 follicular lymphoma
1516186|NCT00003397|contiguous stage II adult diffuse small cleaved cell lymphoma
1516187|NCT00003397|contiguous stage II mantle cell lymphoma
1516188|NCT00003397|contiguous stage II adult diffuse mixed cell lymphoma
1516189|NCT00003397|contiguous stage II adult immunoblastic large cell lymphoma
1516190|NCT00003397|contiguous stage II adult diffuse large cell lymphoma
1516191|NCT00003397|contiguous stage II adult Burkitt lymphoma
1516192|NCT00003397|contiguous stage II adult lymphoblastic lymphoma
1516193|NCT00003397|noncontiguous stage II grade 3 follicular lymphoma
1516194|NCT00003397|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1516195|NCT00003397|noncontiguous stage II mantle cell lymphoma
1516196|NCT00003397|noncontiguous stage II adult diffuse mixed cell lymphoma
1516197|NCT00003397|noncontiguous stage II adult immunoblastic large cell lymphoma
1516198|NCT00003397|noncontiguous stage II adult diffuse large cell lymphoma
1516199|NCT00003397|noncontiguous stage II adult Burkitt lymphoma
1516200|NCT00003397|noncontiguous stage II adult lymphoblastic lymphoma
1516201|NCT00003397|stage III mantle cell lymphoma
1516202|NCT00003397|stage IV mantle cell lymphoma
1516203|NCT00003397|recurrent mantle cell lymphoma
1516204|NCT00003396|recurrent childhood acute lymphoblastic leukemia
1516205|NCT00003396|recurrent adult Hodgkin lymphoma
1516206|NCT00003396|refractory multiple myeloma
1516207|NCT00003396|Waldenstrom macroglobulinemia
1516208|NCT00003396|stage I multiple myeloma
1516209|NCT00003396|stage II multiple myeloma
1516210|NCT00003396|stage III multiple myeloma
1516211|NCT00003396|recurrent childhood lymphoblastic lymphoma
1516212|NCT00003396|recurrent childhood acute myeloid leukemia
1516213|NCT00003396|recurrent adult acute myeloid leukemia
1516214|NCT00003396|recurrent adult acute lymphoblastic leukemia
1516215|NCT00003396|relapsing chronic myelogenous leukemia
1516216|NCT00003396|refractory chronic lymphocytic leukemia
1516217|NCT00003396|accelerated phase chronic myelogenous leukemia
1516218|NCT00003396|blastic phase chronic myelogenous leukemia
1516219|NCT00003396|adult acute myeloid leukemia in remission
1516220|NCT00003396|adult acute lymphoblastic leukemia in remission
1516221|NCT00003396|childhood acute myeloid leukemia in remission
1516222|NCT00003396|childhood acute lymphoblastic leukemia in remission
1516223|NCT00003396|adult acute erythroid leukemia (M6)
1516224|NCT00003396|adult acute myeloblastic leukemia without maturation (M1)
1516225|NCT00003396|adult acute myeloblastic leukemia with maturation (M2)
1516226|NCT00003396|adult acute promyelocytic leukemia (M3)
1516227|NCT00003396|adult acute eosinophilic leukemia
1516228|NCT00003396|adult acute basophilic leukemia
1516229|NCT00003396|adult acute megakaryoblastic leukemia (M7)
1516230|NCT00003396|childhood acute myeloblastic leukemia without maturation (M1)
1516231|NCT00003396|childhood acute myeloblastic leukemia with maturation (M2)
1516232|NCT00003396|childhood acute promyelocytic leukemia (M3)
1516233|NCT00003396|childhood acute erythroleukemia (M6)
1516234|NCT00003396|childhood acute eosinophilic leukemia
1516235|NCT00003396|childhood acute basophilic leukemia
1516236|NCT00003396|childhood acute megakaryocytic leukemia (M7)
1516237|NCT00003396|recurrent/refractory childhood Hodgkin lymphoma
1516238|NCT00003396|recurrent grade 1 follicular lymphoma
1516239|NCT00003396|recurrent grade 2 follicular lymphoma
1516240|NCT00003396|recurrent grade 3 follicular lymphoma
1516241|NCT00003396|recurrent adult diffuse small cleaved cell lymphoma
1516242|NCT00003396|recurrent adult diffuse mixed cell lymphoma
1516243|NCT00003396|recurrent adult diffuse large cell lymphoma
1516244|NCT00003396|recurrent adult immunoblastic large cell lymphoma
1518929|NCT00003010|recurrent breast cancer
1516245|NCT00003396|recurrent adult lymphoblastic lymphoma
1516246|NCT00003396|recurrent adult Burkitt lymphoma
1516247|NCT00003396|previously treated myelodysplastic syndromes
1516248|NCT00003396|adult acute minimally differentiated myeloid leukemia (M0)
1516249|NCT00003396|childhood acute minimally differentiated myeloid leukemia (M0)
1516250|NCT00003396|recurrent childhood small noncleaved cell lymphoma
1516251|NCT00003396|recurrent childhood large cell lymphoma
1516252|NCT00003396|recurrent mantle cell lymphoma
1516253|NCT00003396|recurrent marginal zone lymphoma
1516254|NCT00003396|recurrent small lymphocytic lymphoma
1516255|NCT00003396|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516256|NCT00003396|nodal marginal zone B-cell lymphoma
1516257|NCT00003396|splenic marginal zone lymphoma
1516258|NCT00003396|childhood myelodysplastic syndromes
1516259|NCT00003395|stage IV adult Hodgkin lymphoma
1516260|NCT00003395|recurrent adult Hodgkin lymphoma
1516261|NCT00003395|stage IV cutaneous T-cell non-Hodgkin lymphoma
1516262|NCT00003395|recurrent cutaneous T-cell non-Hodgkin lymphoma
1516263|NCT00003395|refractory multiple myeloma
1516264|NCT00003395|Waldenström macroglobulinemia
1516265|NCT00003395|stage III multiple myeloma
1516266|NCT00003395|stage IV chronic lymphocytic leukemia
1516267|NCT00003395|recurrent adult acute myeloid leukemia
1516268|NCT00003395|recurrent adult acute lymphoblastic leukemia
1516269|NCT00003395|relapsing chronic myelogenous leukemia
1516270|NCT00003395|refractory chronic lymphocytic leukemia
1516271|NCT00003395|chronic phase chronic myelogenous leukemia
1516272|NCT00003395|accelerated phase chronic myelogenous leukemia
1516273|NCT00003395|blastic phase chronic myelogenous leukemia
1516274|NCT00003395|meningeal chronic myelogenous leukemia
1516275|NCT00003395|adult acute erythroid leukemia (M6)
1516276|NCT00003395|adult acute myeloblastic leukemia without maturation (M1)
1516277|NCT00003395|adult acute myeloblastic leukemia with maturation (M2)
1516278|NCT00003395|adult acute myelomonocytic leukemia (M4)
1516279|NCT00003395|adult acute monoblastic leukemia (M5a)
1516280|NCT00003395|adult acute eosinophilic leukemia
1516281|NCT00003395|adult acute basophilic leukemia
1516282|NCT00003395|adult acute megakaryoblastic leukemia (M7)
1516283|NCT00003395|progressive hairy cell leukemia, initial treatment
1516284|NCT00003395|refractory hairy cell leukemia
1516285|NCT00003395|acute undifferentiated leukemia
1516286|NCT00003395|stage IV grade 1 follicular lymphoma
1516287|NCT00003395|stage IV grade 2 follicular lymphoma
1516288|NCT00003395|stage IV grade 3 follicular lymphoma
1516289|NCT00003395|stage IV adult diffuse small cleaved cell lymphoma
1516290|NCT00003395|stage IV adult diffuse mixed cell lymphoma
1516291|NCT00003395|stage IV adult diffuse large cell lymphoma
1516292|NCT00003395|stage IV adult immunoblastic large cell lymphoma
1516293|NCT00003395|stage IV adult lymphoblastic lymphoma
1516294|NCT00003395|stage IV adult Burkitt lymphoma
1516295|NCT00003395|recurrent grade 1 follicular lymphoma
1516296|NCT00003395|recurrent grade 2 follicular lymphoma
1516297|NCT00003395|recurrent grade 3 follicular lymphoma
1516298|NCT00003395|recurrent adult diffuse small cleaved cell lymphoma
1516299|NCT00003395|recurrent adult diffuse mixed cell lymphoma
1516300|NCT00003395|recurrent adult diffuse large cell lymphoma
1516301|NCT00003395|recurrent adult immunoblastic large cell lymphoma
1516302|NCT00003395|recurrent adult lymphoblastic lymphoma
1516303|NCT00003395|recurrent adult Burkitt lymphoma
1516304|NCT00003395|stage IV adult T-cell leukemia/lymphoma
1516305|NCT00003395|recurrent adult T-cell leukemia/lymphoma
1516306|NCT00003395|secondary acute myeloid leukemia
1516307|NCT00003395|adult acute monocytic leukemia (M5b)
1516308|NCT00003395|primary central nervous system non-Hodgkin lymphoma
1516309|NCT00003395|AIDS-related peripheral/systemic lymphoma
1516310|NCT00003395|AIDS-related primary CNS lymphoma
1516311|NCT00003395|adult acute minimally differentiated myeloid leukemia (M0)
1516312|NCT00003395|intraocular lymphoma
1516313|NCT00003395|stage IV mantle cell lymphoma
1516314|NCT00003395|recurrent mantle cell lymphoma
1516315|NCT00003395|anaplastic large cell lymphoma
1516316|NCT00003395|stage IV mycosis fungoides/Sezary syndrome
1516317|NCT00003395|recurrent mycosis fungoides/Sezary syndrome
1516318|NCT00003395|juvenile myelomonocytic leukemia
1516319|NCT00003395|recurrent marginal zone lymphoma
1516320|NCT00003395|recurrent small lymphocytic lymphoma
1516321|NCT00003395|stage IV small lymphocytic lymphoma
1516322|NCT00003395|stage IV marginal zone lymphoma
1516323|NCT00003395|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516324|NCT00003395|nodal marginal zone B-cell lymphoma
1516325|NCT00003395|splenic marginal zone lymphoma
1516326|NCT00003394|adenocarcinoma of the prostate
1516327|NCT00003394|stage I prostate cancer
1516328|NCT00003394|stage IIB prostate cancer
1516329|NCT00003394|stage IIA prostate cancer
1516330|NCT00003394|stage III prostate cancer
1516331|NCT00003394|stage IV prostate cancer
1516332|NCT00003394|recurrent prostate cancer
1516333|NCT00003392|stage IV breast cancer
1516334|NCT00003392|recurrent breast cancer
1516335|NCT00003391|adenocarcinoma of the prostate
1516336|NCT00003391|stage IV prostate cancer
1516337|NCT00003391|recurrent prostate cancer
1516338|NCT00003390|stage IV renal cell cancer
1516339|NCT00003390|recurrent renal cell cancer
1516340|NCT00003389|stage I adult Hodgkin lymphoma
1516341|NCT00003389|stage II adult Hodgkin lymphoma
1516342|NCT00003389|stage III adult Hodgkin lymphoma
1516343|NCT00003389|stage IV adult Hodgkin lymphoma
1516344|NCT00003389|adult lymphocyte depletion Hodgkin lymphoma
1516345|NCT00003389|adult nodular sclerosis Hodgkin lymphoma
1516346|NCT00003389|adult mixed cellularity Hodgkin lymphoma
1516347|NCT00003388|AIDS-related peripheral/systemic lymphoma
1516348|NCT00003388|AIDS-related diffuse large cell lymphoma
1516349|NCT00003388|AIDS-related immunoblastic large cell lymphoma
1516350|NCT00003388|AIDS-related small noncleaved cell lymphoma
1516351|NCT00003388|AIDS-related diffuse mixed cell lymphoma
1516352|NCT00003388|AIDS-related diffuse small cleaved cell lymphoma
1516353|NCT00003388|AIDS-related lymphoblastic lymphoma
1516354|NCT00003388|anaplastic large cell lymphoma
1516355|NCT00003387|stage III non-small cell lung cancer
1516356|NCT00003387|squamous cell lung cancer
1516357|NCT00003387|large cell lung cancer
1516358|NCT00003387|adenocarcinoma of the lung
1516359|NCT00003386|stage III ovarian epithelial cancer
1516360|NCT00003386|stage IV ovarian epithelial cancer
1516361|NCT00003385|stage I ovarian epithelial cancer
1516362|NCT00003385|stage II ovarian epithelial cancer
1516363|NCT00003385|stage III ovarian epithelial cancer
1516364|NCT00003385|stage IV ovarian epithelial cancer
1516365|NCT00003385|ovarian undifferentiated adenocarcinoma
1516366|NCT00003385|ovarian mixed epithelial carcinoma
1516367|NCT00003385|ovarian serous cystadenocarcinoma
1516368|NCT00003385|ovarian mucinous cystadenocarcinoma
1516369|NCT00003385|ovarian endometrioid adenocarcinoma
1516370|NCT00003385|ovarian clear cell cystadenocarcinoma
1516371|NCT00003385|fallopian tube cancer
1516372|NCT00003385|primary peritoneal cavity cancer
1516373|NCT00003385|Brenner tumor
1516374|NCT00003382|stage I ovarian epithelial cancer
1516375|NCT00003382|stage II ovarian epithelial cancer
1516376|NCT00003382|stage III ovarian epithelial cancer
1516377|NCT00003382|stage IV ovarian epithelial cancer
1516378|NCT00003382|recurrent ovarian epithelial cancer
1516379|NCT00003382|fallopian tube cancer
1516380|NCT00003382|primary peritoneal cavity cancer
1516381|NCT00003380|recurrent ovarian epithelial cancer
1516382|NCT00003380|ovarian undifferentiated adenocarcinoma
1516383|NCT00003380|ovarian mixed epithelial carcinoma
1516384|NCT00003380|ovarian serous cystadenocarcinoma
1516385|NCT00003380|ovarian mucinous cystadenocarcinoma
1516386|NCT00003380|ovarian endometrioid adenocarcinoma
1516387|NCT00003380|ovarian clear cell cystadenocarcinoma
1516388|NCT00003380|fallopian tube cancer
1516389|NCT00003380|primary peritoneal cavity cancer
1516390|NCT00003380|Brenner tumor
1516391|NCT00003379|stage III cervical cancer
1516392|NCT00003379|stage IB cervical cancer
1516393|NCT00003379|stage IIB cervical cancer
1516394|NCT00003379|stage IIA cervical cancer
1516395|NCT00003379|stage IVA cervical cancer
1516396|NCT00003379|cervical squamous cell carcinoma
1516397|NCT00003379|cervical adenocarcinoma
1516398|NCT00003379|cervical adenosquamous cell carcinoma
1516399|NCT00003379|cervical small cell carcinoma
1516400|NCT00003378|stage III ovarian epithelial cancer
1516401|NCT00003378|stage IV ovarian epithelial cancer
1516402|NCT00003378|primary peritoneal cavity cancer
1516403|NCT00003377|stage III cervical cancer
1516404|NCT00003377|stage IVA cervical cancer
1516405|NCT00003377|cervical squamous cell carcinoma
1516406|NCT00003377|cervical adenocarcinoma
1516407|NCT00003377|cervical adenosquamous cell carcinoma
1516408|NCT00003376|stage III bladder cancer
1516409|NCT00003376|stage IV bladder cancer
1516410|NCT00003376|transitional cell carcinoma of the bladder
1516411|NCT00003376|anterior urethral cancer
1516412|NCT00003376|posterior urethral cancer
1516413|NCT00003376|urethral cancer associated with invasive bladder cancer
1516414|NCT00003376|metastatic transitional cell cancer of the renal pelvis and ureter
1516415|NCT00003376|regional transitional cell cancer of the renal pelvis and ureter
1516416|NCT00003375|adult oligodendroglioma
1516417|NCT00003375|adult diffuse astrocytoma
1516418|NCT00003375|adult pilocytic astrocytoma
1516419|NCT00003372|recurrent adult brain tumor
1516420|NCT00003372|adult anaplastic oligodendroglioma
1516421|NCT00003372|adult mixed glioma
1516422|NCT00003370|unspecified childhood solid tumor, protocol specific
1516423|NCT00003369|stage IV cervical cancer
1516424|NCT00003369|recurrent cervical cancer
1516425|NCT00003369|cervical squamous cell carcinoma
1516426|NCT00003369|cervical adenosquamous cell carcinoma
1516427|NCT00003368|stage III adult Hodgkin lymphoma
1516428|NCT00003368|stage IV adult Hodgkin lymphoma
1516429|NCT00003368|recurrent adult Hodgkin lymphoma
1516430|NCT00003368|stage III cutaneous T-cell non-Hodgkin lymphoma
1516431|NCT00003368|stage IV cutaneous T-cell non-Hodgkin lymphoma
1516432|NCT00003368|recurrent cutaneous T-cell non-Hodgkin lymphoma
1516433|NCT00003368|small intestine lymphoma
1516434|NCT00003368|unspecified adult solid tumor, protocol specific
1516435|NCT00003368|stage III grade 1 follicular lymphoma
1516436|NCT00003368|stage III grade 2 follicular lymphoma
1516437|NCT00003368|stage III grade 3 follicular lymphoma
1519882|NCT00002854|recurrent anal cancer
1516438|NCT00003368|stage III adult diffuse small cleaved cell lymphoma
1516439|NCT00003368|stage III adult diffuse mixed cell lymphoma
1516440|NCT00003368|stage III adult diffuse large cell lymphoma
1516441|NCT00003368|stage III adult immunoblastic large cell lymphoma
1516442|NCT00003368|stage III adult lymphoblastic lymphoma
1516443|NCT00003368|stage III adult Burkitt lymphoma
1516444|NCT00003368|stage IV grade 1 follicular lymphoma
1516445|NCT00003368|stage IV grade 2 follicular lymphoma
1516446|NCT00003368|stage IV grade 3 follicular lymphoma
1516447|NCT00003368|stage IV adult diffuse small cleaved cell lymphoma
1516448|NCT00003368|stage IV adult diffuse mixed cell lymphoma
1516449|NCT00003368|stage IV adult diffuse large cell lymphoma
1516450|NCT00003368|stage IV adult immunoblastic large cell lymphoma
1516451|NCT00003368|stage IV adult lymphoblastic lymphoma
1516452|NCT00003368|stage IV adult Burkitt lymphoma
1516453|NCT00003368|recurrent grade 1 follicular lymphoma
1516454|NCT00003368|recurrent grade 2 follicular lymphoma
1516455|NCT00003368|recurrent grade 3 follicular lymphoma
1516456|NCT00003368|recurrent adult diffuse small cleaved cell lymphoma
1516457|NCT00003368|recurrent adult diffuse mixed cell lymphoma
1516458|NCT00003368|recurrent adult diffuse large cell lymphoma
1516459|NCT00003368|recurrent adult immunoblastic large cell lymphoma
1516460|NCT00003368|recurrent adult lymphoblastic lymphoma
1516461|NCT00003368|recurrent adult Burkitt lymphoma
1516462|NCT00003368|stage III adult T-cell leukemia/lymphoma
1516463|NCT00003368|stage IV adult T-cell leukemia/lymphoma
1516464|NCT00003368|recurrent adult T-cell leukemia/lymphoma
1516465|NCT00003368|primary central nervous system non-Hodgkin lymphoma
1516466|NCT00003368|AIDS-related peripheral/systemic lymphoma
1516467|NCT00003368|AIDS-related primary CNS lymphoma
1516468|NCT00003368|intraocular lymphoma
1516469|NCT00003368|stage III mantle cell lymphoma
1516470|NCT00003368|stage IV mantle cell lymphoma
1516471|NCT00003368|recurrent mantle cell lymphoma
1516472|NCT00003368|angioimmunoblastic T-cell lymphoma
1516473|NCT00003368|anaplastic large cell lymphoma
1516474|NCT00003368|stage III mycosis fungoides/Sezary syndrome
1516475|NCT00003368|stage IV mycosis fungoides/Sezary syndrome
1516476|NCT00003368|recurrent mycosis fungoides/Sezary syndrome
1516477|NCT00003368|recurrent marginal zone lymphoma
1516478|NCT00003368|recurrent small lymphocytic lymphoma
1516479|NCT00003368|stage III small lymphocytic lymphoma
1516480|NCT00003368|stage III marginal zone lymphoma
1516481|NCT00003368|stage IV small lymphocytic lymphoma
1516482|NCT00003368|stage IV marginal zone lymphoma
1516483|NCT00003368|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516484|NCT00003368|nodal marginal zone B-cell lymphoma
1516485|NCT00003368|splenic marginal zone lymphoma
1516486|NCT00003367|adenocarcinoma of the prostate
1516487|NCT00003367|stage I prostate cancer
1516488|NCT00003367|stage IIB prostate cancer
1516489|NCT00003367|stage IIA prostate cancer
1516490|NCT00003367|stage III prostate cancer
1516491|NCT00003367|stage IV prostate cancer
1516492|NCT00003367|recurrent prostate cancer
1516493|NCT00003365|colon cancer
1516494|NCT00003364|limited stage small cell lung cancer
1516495|NCT00003362|stage III melanoma
1516496|NCT00003362|stage IV melanoma
1516497|NCT00003362|recurrent melanoma
1516498|NCT00003361|refractory anemia
1516499|NCT00003361|refractory anemia with ringed sideroblasts
1516500|NCT00003361|refractory anemia with excess blasts
1516501|NCT00003361|refractory anemia with excess blasts in transformation
1516502|NCT00003361|chronic myelomonocytic leukemia
1516503|NCT00003361|de novo myelodysplastic syndromes
1516504|NCT00003361|previously treated myelodysplastic syndromes
1516505|NCT00003361|secondary myelodysplastic syndromes
1516506|NCT00003361|childhood myelodysplastic syndromes
1516507|NCT00003360|stage IV colon cancer
1516508|NCT00003360|stage IV rectal cancer
1516509|NCT00003360|recurrent colon cancer
1516510|NCT00003360|recurrent rectal cancer
1516511|NCT00003359|unspecified adult solid tumor, protocol specific
1516512|NCT00003358|stage I ovarian epithelial cancer
1516513|NCT00003358|stage II ovarian epithelial cancer
1516514|NCT00003358|stage III ovarian epithelial cancer
1516515|NCT00003358|stage IV ovarian epithelial cancer
1516516|NCT00003358|recurrent ovarian epithelial cancer
1516517|NCT00003358|fallopian tube cancer
1516518|NCT00003358|primary peritoneal cavity cancer
1516519|NCT00003357|stage I breast cancer
1516520|NCT00003357|stage II breast cancer
1516521|NCT00003357|stage III breast cancer
1516522|NCT00003356|stage I grade 1 follicular lymphoma
1516523|NCT00003356|stage I grade 2 follicular lymphoma
1516524|NCT00003356|stage III grade 1 follicular lymphoma
1516525|NCT00003356|stage III grade 2 follicular lymphoma
1516526|NCT00003356|stage IV grade 1 follicular lymphoma
1516527|NCT00003356|stage IV grade 2 follicular lymphoma
1516528|NCT00003356|recurrent grade 1 follicular lymphoma
1516529|NCT00003356|recurrent grade 2 follicular lymphoma
1516530|NCT00003356|stage I mantle cell lymphoma
1516531|NCT00003356|contiguous stage II grade 1 follicular lymphoma
1516532|NCT00003356|contiguous stage II grade 2 follicular lymphoma
1516533|NCT00003356|contiguous stage II mantle cell lymphoma
1516534|NCT00003356|noncontiguous stage II grade 1 follicular lymphoma
1516535|NCT00003356|noncontiguous stage II grade 2 follicular lymphoma
1516536|NCT00003356|noncontiguous stage II mantle cell lymphoma
1516537|NCT00003356|stage III mantle cell lymphoma
1516538|NCT00003356|stage IV mantle cell lymphoma
1516539|NCT00003356|recurrent mantle cell lymphoma
1516540|NCT00003356|noncontiguous stage II small lymphocytic lymphoma
1516541|NCT00003356|noncontiguous stage II marginal zone lymphoma
1516542|NCT00003356|recurrent marginal zone lymphoma
1516543|NCT00003356|recurrent small lymphocytic lymphoma
1516544|NCT00003356|stage I marginal zone lymphoma
1516545|NCT00003356|stage I small lymphocytic lymphoma
1516546|NCT00003356|stage III small lymphocytic lymphoma
1516547|NCT00003356|stage III marginal zone lymphoma
1516548|NCT00003356|stage IV small lymphocytic lymphoma
1516549|NCT00003356|stage IV marginal zone lymphoma
1516550|NCT00003356|contiguous stage II marginal zone lymphoma
1516551|NCT00003356|contiguous stage II small lymphocytic lymphoma
1516648|NCT00003341|stage III mantle cell lymphoma
1516552|NCT00003356|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516553|NCT00003356|nodal marginal zone B-cell lymphoma
1516554|NCT00003356|splenic marginal zone lymphoma
1516555|NCT00003354|stage I colon cancer
1516556|NCT00003354|stage II colon cancer
1516557|NCT00003354|stage III colon cancer
1516558|NCT00003354|stage IV colon cancer
1516559|NCT00003354|stage 0 colon cancer
1516560|NCT00003354|stage 0 rectal cancer
1516561|NCT00003354|stage I rectal cancer
1516562|NCT00003354|stage II rectal cancer
1516563|NCT00003354|stage III rectal cancer
1516564|NCT00003354|stage IV rectal cancer
1516565|NCT00003353|primary systemic amyloidosis
1516566|NCT00003352|stage IV breast cancer
1516567|NCT00003352|recurrent breast cancer
1516568|NCT00003352|stage IIIB breast cancer
1516569|NCT00003351|stage IV breast cancer
1516570|NCT00003348|recurrent adult brain tumor
1516571|NCT00003348|adult glioblastoma
1516572|NCT00003348|adult anaplastic astrocytoma
1516573|NCT00003348|adult giant cell glioblastoma
1516574|NCT00003348|adult gliosarcoma
1516575|NCT00003346|stage III melanoma
1516576|NCT00003346|stage IV melanoma
1516577|NCT00003346|recurrent melanoma
1516578|NCT00003345|stage I ovarian epithelial cancer
1516579|NCT00003345|stage II ovarian epithelial cancer
1516580|NCT00003345|stage III ovarian epithelial cancer
1516581|NCT00003345|stage IV ovarian epithelial cancer
1516582|NCT00003345|recurrent ovarian epithelial cancer
1516583|NCT00003345|fallopian tube cancer
1516584|NCT00003345|primary peritoneal cavity cancer
1516585|NCT00003344|stage II colon cancer
1516586|NCT00003344|stage III colon cancer
1516587|NCT00003344|stage II rectal cancer
1516588|NCT00003344|stage III rectal cancer
1516589|NCT00003344|recurrent colon cancer
1516590|NCT00003344|recurrent rectal cancer
1516591|NCT00003343|stage IV prostate cancer
1516592|NCT00003342|stage III bladder cancer
1516593|NCT00003342|stage IV bladder cancer
1516594|NCT00003342|transitional cell carcinoma of the bladder
1516595|NCT00003342|metastatic transitional cell cancer of the renal pelvis and ureter
1516596|NCT00003342|localized transitional cell cancer of the renal pelvis and ureter
1516597|NCT00003342|regional transitional cell cancer of the renal pelvis and ureter
1516598|NCT00003341|stage II adult Hodgkin lymphoma
1516599|NCT00003341|stage III adult Hodgkin lymphoma
1516600|NCT00003341|stage IV adult Hodgkin lymphoma
1516601|NCT00003341|recurrent adult Hodgkin lymphoma
1516602|NCT00003341|refractory multiple myeloma
1516603|NCT00003341|Waldenström macroglobulinemia
1516604|NCT00003341|stage II multiple myeloma
1516605|NCT00003341|stage III multiple myeloma
1516606|NCT00003341|stage II chronic lymphocytic leukemia
1516607|NCT00003341|stage III chronic lymphocytic leukemia
1516608|NCT00003341|stage IV chronic lymphocytic leukemia
1516609|NCT00003341|refractory chronic lymphocytic leukemia
1516610|NCT00003341|stage III grade 1 follicular lymphoma
1516611|NCT00003341|stage III grade 2 follicular lymphoma
1516612|NCT00003341|stage III grade 3 follicular lymphoma
1516613|NCT00003341|stage III adult diffuse small cleaved cell lymphoma
1516614|NCT00003341|stage III adult diffuse mixed cell lymphoma
1516615|NCT00003341|stage III adult diffuse large cell lymphoma
1516616|NCT00003341|stage III adult immunoblastic large cell lymphoma
1516617|NCT00003341|stage IV grade 1 follicular lymphoma
1516618|NCT00003341|stage IV grade 2 follicular lymphoma
1516619|NCT00003341|stage IV grade 3 follicular lymphoma
1516620|NCT00003341|stage IV adult diffuse small cleaved cell lymphoma
1516621|NCT00003341|stage IV adult diffuse mixed cell lymphoma
1516622|NCT00003341|stage IV adult diffuse large cell lymphoma
1516623|NCT00003341|stage IV adult immunoblastic large cell lymphoma
1516624|NCT00003341|recurrent grade 1 follicular lymphoma
1516625|NCT00003341|recurrent grade 2 follicular lymphoma
1516626|NCT00003341|recurrent grade 3 follicular lymphoma
1516627|NCT00003341|recurrent adult diffuse small cleaved cell lymphoma
1516628|NCT00003341|recurrent adult diffuse mixed cell lymphoma
1516629|NCT00003341|recurrent adult diffuse large cell lymphoma
1516630|NCT00003341|recurrent adult immunoblastic large cell lymphoma
1516631|NCT00003341|anemia
1516632|NCT00003341|contiguous stage II grade 1 follicular lymphoma
1516633|NCT00003341|contiguous stage II grade 2 follicular lymphoma
1520755|NCT00002680|recurrent breast cancer
1516634|NCT00003341|contiguous stage II grade 3 follicular lymphoma
1516635|NCT00003341|contiguous stage II adult diffuse small cleaved cell lymphoma
1516636|NCT00003341|contiguous stage II mantle cell lymphoma
1516637|NCT00003341|contiguous stage II adult diffuse mixed cell lymphoma
1516638|NCT00003341|contiguous stage II adult immunoblastic large cell lymphoma
1516639|NCT00003341|contiguous stage II adult diffuse large cell lymphoma
1516640|NCT00003341|noncontiguous stage II grade 1 follicular lymphoma
1516641|NCT00003341|noncontiguous stage II grade 2 follicular lymphoma
1516642|NCT00003341|noncontiguous stage II grade 3 follicular lymphoma
1516643|NCT00003341|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1516644|NCT00003341|noncontiguous stage II mantle cell lymphoma
1516645|NCT00003341|noncontiguous stage II adult diffuse mixed cell lymphoma
1516646|NCT00003341|noncontiguous stage II adult immunoblastic large cell lymphoma
1516647|NCT00003341|noncontiguous stage II adult diffuse large cell lymphoma
1516649|NCT00003341|stage IV mantle cell lymphoma
1516650|NCT00003341|recurrent mantle cell lymphoma
1516651|NCT00003341|noncontiguous stage II small lymphocytic lymphoma
1516652|NCT00003341|noncontiguous stage II marginal zone lymphoma
1516653|NCT00003341|recurrent marginal zone lymphoma
1516654|NCT00003341|recurrent small lymphocytic lymphoma
1516655|NCT00003341|stage III small lymphocytic lymphoma
1516656|NCT00003341|stage III marginal zone lymphoma
1516657|NCT00003341|stage IV small lymphocytic lymphoma
1516658|NCT00003341|stage IV marginal zone lymphoma
1516659|NCT00003341|contiguous stage II marginal zone lymphoma
1516660|NCT00003341|contiguous stage II small lymphocytic lymphoma
1516661|NCT00003341|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516662|NCT00003341|nodal marginal zone B-cell lymphoma
1516663|NCT00003341|splenic marginal zone lymphoma
1516664|NCT00003340|recurrent adult acute myeloid leukemia
1516665|NCT00003339|recurrent intraocular melanoma
1516666|NCT00003339|stage III melanoma
1516667|NCT00003339|stage IV melanoma
1516668|NCT00003339|recurrent melanoma
1516669|NCT00003338|stage I grade 1 follicular lymphoma
1516670|NCT00003338|stage I grade 2 follicular lymphoma
1516671|NCT00003338|stage I grade 3 follicular lymphoma
1516672|NCT00003338|stage I adult diffuse small cleaved cell lymphoma
1516673|NCT00003338|stage I adult diffuse mixed cell lymphoma
1516674|NCT00003338|stage I adult diffuse large cell lymphoma
1516675|NCT00003338|stage I adult immunoblastic large cell lymphoma
1516676|NCT00003338|stage I adult lymphoblastic lymphoma
1516677|NCT00003338|stage I adult Burkitt lymphoma
1516678|NCT00003338|stage III grade 1 follicular lymphoma
1516679|NCT00003338|stage III grade 2 follicular lymphoma
1516680|NCT00003338|stage III grade 3 follicular lymphoma
1516681|NCT00003338|stage III adult diffuse small cleaved cell lymphoma
1516682|NCT00003338|stage III adult diffuse mixed cell lymphoma
1516683|NCT00003338|stage III adult diffuse large cell lymphoma
1516684|NCT00003338|stage III adult immunoblastic large cell lymphoma
1516685|NCT00003338|stage III adult lymphoblastic lymphoma
1516686|NCT00003338|stage III adult Burkitt lymphoma
1516687|NCT00003338|stage IV grade 1 follicular lymphoma
1516688|NCT00003338|stage IV grade 2 follicular lymphoma
1516689|NCT00003338|stage IV grade 3 follicular lymphoma
1516690|NCT00003338|stage IV adult diffuse small cleaved cell lymphoma
1516691|NCT00003338|stage IV adult diffuse mixed cell lymphoma
1516692|NCT00003338|stage IV adult diffuse large cell lymphoma
1516693|NCT00003338|stage IV adult immunoblastic large cell lymphoma
1516694|NCT00003338|stage IV adult lymphoblastic lymphoma
1516695|NCT00003338|stage IV adult Burkitt lymphoma
1516696|NCT00003338|recurrent grade 1 follicular lymphoma
1516697|NCT00003338|recurrent grade 2 follicular lymphoma
1516698|NCT00003338|recurrent grade 3 follicular lymphoma
1516699|NCT00003338|recurrent adult diffuse small cleaved cell lymphoma
1516700|NCT00003338|recurrent adult diffuse mixed cell lymphoma
1516701|NCT00003338|recurrent adult diffuse large cell lymphoma
1516702|NCT00003338|recurrent adult immunoblastic large cell lymphoma
1516703|NCT00003338|recurrent adult lymphoblastic lymphoma
1516704|NCT00003338|recurrent adult Burkitt lymphoma
1516705|NCT00003338|stage I mantle cell lymphoma
1516706|NCT00003338|contiguous stage II grade 1 follicular lymphoma
1516707|NCT00003338|contiguous stage II grade 2 follicular lymphoma
1516708|NCT00003338|contiguous stage II grade 3 follicular lymphoma
1516709|NCT00003338|contiguous stage II adult diffuse small cleaved cell lymphoma
1516710|NCT00003338|contiguous stage II mantle cell lymphoma
1516711|NCT00003338|contiguous stage II adult diffuse mixed cell lymphoma
1516712|NCT00003338|contiguous stage II adult immunoblastic large cell lymphoma
1516713|NCT00003338|contiguous stage II adult diffuse large cell lymphoma
1516714|NCT00003338|contiguous stage II adult Burkitt lymphoma
1516715|NCT00003338|contiguous stage II adult lymphoblastic lymphoma
1516716|NCT00003338|noncontiguous stage II grade 1 follicular lymphoma
1516717|NCT00003338|noncontiguous stage II grade 2 follicular lymphoma
1516718|NCT00003338|noncontiguous stage II grade 3 follicular lymphoma
1516719|NCT00003338|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1516720|NCT00003338|noncontiguous stage II mantle cell lymphoma
1516721|NCT00003338|noncontiguous stage II adult diffuse mixed cell lymphoma
1516722|NCT00003338|noncontiguous stage II adult immunoblastic large cell lymphoma
1516723|NCT00003338|noncontiguous stage II adult diffuse large cell lymphoma
1516724|NCT00003338|noncontiguous stage II adult Burkitt lymphoma
1516725|NCT00003338|noncontiguous stage II adult lymphoblastic lymphoma
1516726|NCT00003338|stage III mantle cell lymphoma
1516727|NCT00003338|stage IV mantle cell lymphoma
1516728|NCT00003338|recurrent mantle cell lymphoma
1516729|NCT00003338|noncontiguous stage II small lymphocytic lymphoma
1516730|NCT00003338|noncontiguous stage II marginal zone lymphoma
1516731|NCT00003338|recurrent marginal zone lymphoma
1516732|NCT00003338|recurrent small lymphocytic lymphoma
1516733|NCT00003338|stage I marginal zone lymphoma
1516734|NCT00003338|stage I small lymphocytic lymphoma
1516735|NCT00003338|stage III small lymphocytic lymphoma
1516736|NCT00003338|stage III marginal zone lymphoma
1516737|NCT00003338|stage IV small lymphocytic lymphoma
1516738|NCT00003338|stage IV marginal zone lymphoma
1516739|NCT00003338|contiguous stage II marginal zone lymphoma
1516740|NCT00003338|contiguous stage II small lymphocytic lymphoma
1516741|NCT00003338|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516742|NCT00003338|nodal marginal zone B-cell lymphoma
1516743|NCT00003338|splenic marginal zone lymphoma
1516744|NCT00003337|stage I grade 1 follicular lymphoma
1516745|NCT00003337|stage I grade 2 follicular lymphoma
1516746|NCT00003337|stage I grade 3 follicular lymphoma
1516747|NCT00003337|stage I adult diffuse small cleaved cell lymphoma
1516748|NCT00003337|stage I adult diffuse mixed cell lymphoma
1516749|NCT00003337|stage I adult diffuse large cell lymphoma
1516750|NCT00003337|stage I adult immunoblastic large cell lymphoma
1516751|NCT00003337|stage I adult lymphoblastic lymphoma
1516752|NCT00003337|stage I adult Burkitt lymphoma
1516753|NCT00003337|stage III grade 1 follicular lymphoma
1516754|NCT00003337|stage III grade 2 follicular lymphoma
1516755|NCT00003337|stage III grade 3 follicular lymphoma
1516756|NCT00003337|stage III adult diffuse small cleaved cell lymphoma
1516757|NCT00003337|stage III adult diffuse mixed cell lymphoma
1516758|NCT00003337|stage III adult diffuse large cell lymphoma
1516759|NCT00003337|stage III adult immunoblastic large cell lymphoma
1516760|NCT00003337|stage III adult lymphoblastic lymphoma
1516761|NCT00003337|stage III adult Burkitt lymphoma
1516762|NCT00003337|stage IV grade 1 follicular lymphoma
1516763|NCT00003337|stage IV grade 2 follicular lymphoma
1516764|NCT00003337|stage IV grade 3 follicular lymphoma
1516765|NCT00003337|stage IV adult diffuse small cleaved cell lymphoma
1516766|NCT00003337|stage IV adult diffuse mixed cell lymphoma
1516767|NCT00003337|stage IV adult diffuse large cell lymphoma
1516768|NCT00003337|stage IV adult immunoblastic large cell lymphoma
1516769|NCT00003337|stage IV adult lymphoblastic lymphoma
1516770|NCT00003337|stage IV adult Burkitt lymphoma
1516771|NCT00003337|recurrent grade 1 follicular lymphoma
1516772|NCT00003337|recurrent grade 2 follicular lymphoma
1516773|NCT00003337|recurrent grade 3 follicular lymphoma
1516774|NCT00003337|recurrent adult diffuse small cleaved cell lymphoma
1516775|NCT00003337|recurrent adult diffuse mixed cell lymphoma
1516776|NCT00003337|recurrent adult diffuse large cell lymphoma
1516777|NCT00003337|recurrent adult immunoblastic large cell lymphoma
1516778|NCT00003337|recurrent adult lymphoblastic lymphoma
1516779|NCT00003337|recurrent adult Burkitt lymphoma
1516780|NCT00003337|stage I mantle cell lymphoma
1516781|NCT00003337|contiguous stage II grade 1 follicular lymphoma
1516782|NCT00003337|contiguous stage II grade 2 follicular lymphoma
1516783|NCT00003337|contiguous stage II grade 3 follicular lymphoma
1516784|NCT00003337|contiguous stage II adult diffuse small cleaved cell lymphoma
1516785|NCT00003337|contiguous stage II mantle cell lymphoma
1516786|NCT00003337|contiguous stage II adult diffuse mixed cell lymphoma
1516787|NCT00003337|contiguous stage II adult immunoblastic large cell lymphoma
1516788|NCT00003337|contiguous stage II adult diffuse large cell lymphoma
1516789|NCT00003337|contiguous stage II adult Burkitt lymphoma
1516790|NCT00003337|contiguous stage II adult lymphoblastic lymphoma
1516791|NCT00003337|noncontiguous stage II grade 1 follicular lymphoma
1516792|NCT00003337|noncontiguous stage II grade 2 follicular lymphoma
1516793|NCT00003337|noncontiguous stage II grade 3 follicular lymphoma
1516794|NCT00003337|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1516795|NCT00003337|noncontiguous stage II mantle cell lymphoma
1516796|NCT00003337|noncontiguous stage II adult diffuse mixed cell lymphoma
1516797|NCT00003337|noncontiguous stage II adult immunoblastic large cell lymphoma
1516798|NCT00003337|noncontiguous stage II adult diffuse large cell lymphoma
1516799|NCT00003337|noncontiguous stage II adult Burkitt lymphoma
1516800|NCT00003337|noncontiguous stage II adult lymphoblastic lymphoma
1516801|NCT00003337|stage III mantle cell lymphoma
1516802|NCT00003337|stage IV mantle cell lymphoma
1516803|NCT00003337|recurrent mantle cell lymphoma
1516804|NCT00003337|noncontiguous stage II small lymphocytic lymphoma
1516805|NCT00003337|noncontiguous stage II marginal zone lymphoma
1516806|NCT00003337|recurrent marginal zone lymphoma
1516807|NCT00003337|recurrent small lymphocytic lymphoma
1516808|NCT00003337|stage I marginal zone lymphoma
1516809|NCT00003337|stage I small lymphocytic lymphoma
1516810|NCT00003337|stage III small lymphocytic lymphoma
1516811|NCT00003337|stage III marginal zone lymphoma
1516812|NCT00003337|stage IV small lymphocytic lymphoma
1516813|NCT00003337|stage IV marginal zone lymphoma
1516814|NCT00003337|contiguous stage II marginal zone lymphoma
1516815|NCT00003337|contiguous stage II small lymphocytic lymphoma
1516816|NCT00003337|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516817|NCT00003337|nodal marginal zone B-cell lymphoma
1516818|NCT00003337|splenic marginal zone lymphoma
1516819|NCT00003336|refractory anemia
1516820|NCT00003336|refractory anemia with ringed sideroblasts
1516821|NCT00003336|de novo myelodysplastic syndromes
1516822|NCT00003336|previously treated myelodysplastic syndromes
1516823|NCT00003336|secondary myelodysplastic syndromes
1516824|NCT00003336|atypical chronic myeloid leukemia
1516825|NCT00003336|myelodysplastic/myeloproliferative disease, unclassifiable
1516826|NCT00003336|childhood myelodysplastic syndromes
1516827|NCT00003335|recurrent childhood acute lymphoblastic leukemia
1516828|NCT00003335|recurrent childhood lymphoblastic lymphoma
1516829|NCT00003335|recurrent adult acute lymphoblastic leukemia
1516830|NCT00003335|chronic phase chronic myelogenous leukemia
1516831|NCT00003335|accelerated phase chronic myelogenous leukemia
1516832|NCT00003335|blastic phase chronic myelogenous leukemia
1516833|NCT00003335|untreated childhood acute lymphoblastic leukemia
1516834|NCT00003335|adult acute myeloid leukemia in remission
1516835|NCT00003335|adult acute lymphoblastic leukemia in remission
1516836|NCT00003335|childhood acute myeloid leukemia in remission
1516837|NCT00003335|childhood acute lymphoblastic leukemia in remission
1516838|NCT00003335|adult acute erythroid leukemia (M6)
1516839|NCT00003335|adult acute megakaryoblastic leukemia (M7)
1516840|NCT00003335|childhood acute erythroleukemia (M6)
1516841|NCT00003335|childhood acute megakaryocytic leukemia (M7)
1516842|NCT00003335|refractory anemia with excess blasts
1516843|NCT00003335|refractory anemia with excess blasts in transformation
1516844|NCT00003335|recurrent grade 1 follicular lymphoma
1516845|NCT00003335|recurrent grade 2 follicular lymphoma
1516846|NCT00003335|recurrent grade 3 follicular lymphoma
1516847|NCT00003335|recurrent adult diffuse small cleaved cell lymphoma
1516848|NCT00003335|recurrent adult diffuse mixed cell lymphoma
1516849|NCT00003335|recurrent adult diffuse large cell lymphoma
1516850|NCT00003335|recurrent adult immunoblastic large cell lymphoma
1516851|NCT00003335|recurrent adult lymphoblastic lymphoma
1516852|NCT00003335|recurrent adult Burkitt lymphoma
1516853|NCT00003335|de novo myelodysplastic syndromes
1516854|NCT00003335|previously treated myelodysplastic syndromes
1516855|NCT00003335|secondary myelodysplastic syndromes
1516856|NCT00003335|graft versus host disease
1516857|NCT00003335|adult acute minimally differentiated myeloid leukemia (M0)
1516858|NCT00003335|childhood acute minimally differentiated myeloid leukemia (M0)
1516859|NCT00003335|recurrent childhood small noncleaved cell lymphoma
1516860|NCT00003335|recurrent childhood large cell lymphoma
1516861|NCT00003335|recurrent mantle cell lymphoma
1516862|NCT00003335|childhood chronic myelogenous leukemia
1516863|NCT00003335|atypical chronic myeloid leukemia
1516864|NCT00003335|myelodysplastic/myeloproliferative disease, unclassifiable
1516865|NCT00003335|recurrent marginal zone lymphoma
1516866|NCT00003335|recurrent small lymphocytic lymphoma
1516867|NCT00003335|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516868|NCT00003335|nodal marginal zone B-cell lymphoma
1516869|NCT00003335|splenic marginal zone lymphoma
1516870|NCT00003335|adult acute myeloid leukemia with t(8;21)(q22;q22)
1516871|NCT00003335|adult acute myeloid leukemia with t(16;16)(p13;q22)
1516872|NCT00003335|adult acute myeloid leukemia with inv(16)(p13;q22)
1516873|NCT00003335|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1516874|NCT00003335|adult acute myeloid leukemia with t(15;17)(q22;q12)
1516875|NCT00003335|childhood myelodysplastic syndromes
1516876|NCT00003334|stage IV endometrial carcinoma
1516877|NCT00003334|recurrent endometrial carcinoma
1516878|NCT00003334|fallopian tube cancer
1516879|NCT00003334|stage IV uterine sarcoma
1516880|NCT00003334|recurrent uterine sarcoma
1516881|NCT00003334|uterine carcinosarcoma
1516882|NCT00003334|uterine leiomyosarcoma
1516883|NCT00003334|endometrial stromal sarcoma
1516884|NCT00003334|ovarian sarcoma
1516885|NCT00003334|ovarian carcinosarcoma
1516886|NCT00003332|stage I pancreatic cancer
1516887|NCT00003332|stage II pancreatic cancer
1516888|NCT00003332|stage III pancreatic cancer
1516889|NCT00003332|adenocarcinoma of the pancreas
1516890|NCT00003331|stage III adult Hodgkin lymphoma
1516891|NCT00003331|stage IV adult Hodgkin lymphoma
1516892|NCT00003331|monoclonal gammopathy of undetermined significance
1516893|NCT00003331|recurrent adult Hodgkin lymphoma
1516894|NCT00003331|isolated plasmacytoma of bone
1516895|NCT00003331|extramedullary plasmacytoma
1516896|NCT00003331|refractory multiple myeloma
1516897|NCT00003331|Waldenstrom macroglobulinemia
1516898|NCT00003331|stage III multiple myeloma
1516899|NCT00003331|stage IV chronic lymphocytic leukemia
1516900|NCT00003331|recurrent adult acute myeloid leukemia
1516901|NCT00003331|recurrent adult acute lymphoblastic leukemia
1516902|NCT00003331|relapsing chronic myelogenous leukemia
1516903|NCT00003331|refractory chronic lymphocytic leukemia
1516904|NCT00003331|unspecified adult solid tumor, protocol specific
1516905|NCT00003331|chronic phase chronic myelogenous leukemia
1516906|NCT00003331|accelerated phase chronic myelogenous leukemia
1516907|NCT00003331|blastic phase chronic myelogenous leukemia
1516908|NCT00003331|meningeal chronic myelogenous leukemia
1516909|NCT00003331|untreated adult acute lymphoblastic leukemia
1516910|NCT00003331|untreated adult acute myeloid leukemia
1516911|NCT00003331|adult acute myeloid leukemia in remission
1516912|NCT00003331|adult acute lymphoblastic leukemia in remission
1516913|NCT00003331|polycythemia vera
1516914|NCT00003331|primary myelofibrosis
1516915|NCT00003331|essential thrombocythemia
1516916|NCT00003331|untreated hairy cell leukemia
1516917|NCT00003331|progressive hairy cell leukemia, initial treatment
1516918|NCT00003331|refractory hairy cell leukemia
1516919|NCT00003331|chronic myelomonocytic leukemia
1516920|NCT00003331|T-cell large granular lymphocyte leukemia
1516921|NCT00003331|acute undifferentiated leukemia
1516922|NCT00003331|stage III grade 1 follicular lymphoma
1516923|NCT00003331|stage III grade 2 follicular lymphoma
1517020|NCT00003325|stage II vulvar cancer
1516924|NCT00003331|stage III grade 3 follicular lymphoma
1516925|NCT00003331|stage III adult diffuse small cleaved cell lymphoma
1516926|NCT00003331|stage III adult diffuse mixed cell lymphoma
1516927|NCT00003331|stage III adult diffuse large cell lymphoma
1516928|NCT00003331|stage III adult immunoblastic large cell lymphoma
1516929|NCT00003331|stage III adult lymphoblastic lymphoma
1516930|NCT00003331|stage III adult Burkitt lymphoma
1516931|NCT00003331|stage IV grade 1 follicular lymphoma
1516932|NCT00003331|stage IV grade 2 follicular lymphoma
1516933|NCT00003331|stage IV grade 3 follicular lymphoma
1516934|NCT00003331|stage IV adult diffuse small cleaved cell lymphoma
1516935|NCT00003331|stage IV adult diffuse mixed cell lymphoma
1516936|NCT00003331|stage IV adult diffuse large cell lymphoma
1516937|NCT00003331|stage IV adult immunoblastic large cell lymphoma
1516938|NCT00003331|stage IV adult lymphoblastic lymphoma
1516939|NCT00003331|stage IV adult Burkitt lymphoma
1516940|NCT00003331|recurrent grade 1 follicular lymphoma
1516941|NCT00003331|recurrent grade 2 follicular lymphoma
1516942|NCT00003331|recurrent grade 3 follicular lymphoma
1516943|NCT00003331|recurrent adult diffuse small cleaved cell lymphoma
1516944|NCT00003331|recurrent adult diffuse mixed cell lymphoma
1516945|NCT00003331|recurrent adult diffuse large cell lymphoma
1516946|NCT00003331|recurrent adult immunoblastic large cell lymphoma
1516947|NCT00003331|recurrent adult lymphoblastic lymphoma
1516948|NCT00003331|recurrent adult Burkitt lymphoma
1516949|NCT00003331|stage III adult T-cell leukemia/lymphoma
1516950|NCT00003331|stage IV adult T-cell leukemia/lymphoma
1516951|NCT00003331|recurrent adult T-cell leukemia/lymphoma
1516952|NCT00003331|secondary acute myeloid leukemia
1516953|NCT00003331|de novo myelodysplastic syndromes
1516954|NCT00003331|previously treated myelodysplastic syndromes
1516955|NCT00003331|secondary myelodysplastic syndromes
1516956|NCT00003331|prolymphocytic leukemia
1516957|NCT00003331|AIDS-related peripheral/systemic lymphoma
1516958|NCT00003331|AIDS-related primary CNS lymphoma
1516959|NCT00003331|primary systemic amyloidosis
1516960|NCT00003331|stage III mantle cell lymphoma
1516961|NCT00003331|stage IV mantle cell lymphoma
1516962|NCT00003331|recurrent mantle cell lymphoma
1516963|NCT00003331|angioimmunoblastic T-cell lymphoma
1516964|NCT00003331|anaplastic large cell lymphoma
1516965|NCT00003331|recurrent marginal zone lymphoma
1516966|NCT00003331|recurrent small lymphocytic lymphoma
1516967|NCT00003331|stage III small lymphocytic lymphoma
1516968|NCT00003331|stage III marginal zone lymphoma
1516969|NCT00003331|stage IV small lymphocytic lymphoma
1516970|NCT00003331|stage IV marginal zone lymphoma
1516971|NCT00003331|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1516972|NCT00003331|nodal marginal zone B-cell lymphoma
1516973|NCT00003331|splenic marginal zone lymphoma
1516974|NCT00003330|unspecified adult solid tumor, protocol specific
1516975|NCT00003329|stage I colon cancer
1516976|NCT00003329|stage II colon cancer
1516977|NCT00003329|stage III colon cancer
1516978|NCT00003329|stage IV colon cancer
1516979|NCT00003329|stage I breast cancer
1516980|NCT00003329|stage II breast cancer
1516981|NCT00003329|stage IIIA breast cancer
1516982|NCT00003329|stage IIIB breast cancer
1516983|NCT00003329|stage IIIC breast cancer
1516984|NCT00003329|stage IV breast cancer
1516985|NCT00003329|stage I non-small cell lung cancer
1516986|NCT00003329|stage II non-small cell lung cancer
1516987|NCT00003329|stage III non-small cell lung cancer
1516988|NCT00003329|limited stage small cell lung cancer
1516989|NCT00003329|extensive stage small cell lung cancer
1516990|NCT00003329|stage I prostate cancer
1516991|NCT00003329|stage II prostate cancer
1516992|NCT00003329|stage III prostate cancer
1516993|NCT00003329|stage IV prostate cancer
1516994|NCT00003329|stage IV non-small cell lung cancer
1516995|NCT00003328|stage III squamous cell carcinoma of the lip and oral cavity
1516996|NCT00003328|stage IV squamous cell carcinoma of the lip and oral cavity
1516997|NCT00003328|stage III squamous cell carcinoma of the oropharynx
1516998|NCT00003328|stage IV squamous cell carcinoma of the oropharynx
1516999|NCT00003328|stage III squamous cell carcinoma of the hypopharynx
1517000|NCT00003328|stage IV squamous cell carcinoma of the hypopharynx
1517001|NCT00003328|stage III squamous cell carcinoma of the larynx
1517002|NCT00003328|stage IV squamous cell carcinoma of the larynx
1517003|NCT00003327|stage IV nasopharyngeal cancer
1517004|NCT00003327|recurrent nasopharyngeal cancer
1517005|NCT00003327|stage IV lip and oral cavity cancer
1517006|NCT00003327|recurrent lip and oral cavity cancer
1517007|NCT00003327|stage IV hypopharyngeal cancer
1517008|NCT00003327|recurrent hypopharyngeal cancer
1517009|NCT00003327|stage IV laryngeal cancer
1517010|NCT00003327|recurrent laryngeal cancer
1517011|NCT00003327|stage IV paranasal sinus and nasal cavity cancer
1517012|NCT00003327|recurrent paranasal sinus and nasal cavity cancer
1517013|NCT00003327|stage IV oropharyngeal cancer
1517014|NCT00003327|recurrent oropharyngeal cancer
1517015|NCT00003326|stage IV esophageal cancer
1517016|NCT00003326|recurrent esophageal cancer
1517017|NCT00003326|squamous cell carcinoma of the esophagus
1517018|NCT00003326|adenocarcinoma of the esophagus
1517019|NCT00003325|stage I vulvar cancer
1517021|NCT00003325|squamous cell carcinoma of the vulva
1517022|NCT00003324|tumors metastatic to brain
1517023|NCT00003323|adenocarcinoma of the prostate
1517024|NCT00003323|recurrent prostate cancer
1517025|NCT00003323|sexual dysfunction and infertility
1517026|NCT00003322|stage III ovarian epithelial cancer
1517027|NCT00003322|recurrent ovarian epithelial cancer
1517028|NCT00003322|ovarian undifferentiated adenocarcinoma
1517029|NCT00003322|ovarian mixed epithelial carcinoma
1517030|NCT00003322|ovarian serous cystadenocarcinoma
1517031|NCT00003322|ovarian mucinous cystadenocarcinoma
1517032|NCT00003322|ovarian endometrioid adenocarcinoma
1517033|NCT00003322|ovarian clear cell cystadenocarcinoma
1517034|NCT00003322|primary peritoneal cavity cancer
1517035|NCT00003322|Brenner tumor
1517036|NCT00003321|stage I esophageal cancer
1517037|NCT00003321|stage II esophageal cancer
1517038|NCT00003321|stage III esophageal cancer
1517039|NCT00003321|stage IV esophageal cancer
1517040|NCT00003321|recurrent esophageal cancer
1517041|NCT00003320|tumors metastatic to brain
1517042|NCT00003317|stage IIIA non-small cell lung cancer
1517043|NCT00003316|recurrent uterine sarcoma
1517044|NCT00003316|uterine leiomyosarcoma
1517045|NCT00003315|infection
1517046|NCT00003313|stage II non-small cell lung cancer
1517047|NCT00003313|stage IIIA non-small cell lung cancer
1517048|NCT00003313|stage IIIB non-small cell lung cancer
1517049|NCT00003313|oral complications
1517050|NCT00003313|drug/agent toxicity by tissue/organ
1517051|NCT00003313|radiation toxicity
1517052|NCT00003312|stage I prostate cancer
1517053|NCT00003312|stage IIB prostate cancer
1517054|NCT00003312|stage IIA prostate cancer
1517055|NCT00003311|stage I mantle cell lymphoma
1517056|NCT00003311|contiguous stage II mantle cell lymphoma
1517057|NCT00003311|noncontiguous stage II mantle cell lymphoma
1517058|NCT00003311|stage III mantle cell lymphoma
1517059|NCT00003311|stage IV mantle cell lymphoma
1517060|NCT00003309|adult medulloblastoma
1517061|NCT00003309|adult anaplastic ependymoma
1517062|NCT00003309|adult ependymoma
1517063|NCT00003309|adult supratentorial primitive neuroectodermal tumor (PNET)
1517064|NCT00003308|metastatic osteosarcoma
1517065|NCT00003308|chondrosarcoma
1517066|NCT00003308|stage IV renal cell cancer
1517067|NCT00003308|stage IV melanoma
1517068|NCT00003308|tumors metastatic to brain
1517069|NCT00003308|stage IV uterine sarcoma
1517070|NCT00003308|ovarian sarcoma
1517071|NCT00003308|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1517072|NCT00003308|stage IV adult soft tissue sarcoma
1517073|NCT00003307|adenocarcinoma of the prostate
1517074|NCT00003307|stage I prostate cancer
1517075|NCT00003307|stage II prostate cancer
1517076|NCT00003307|stage III prostate cancer
1517077|NCT00003307|radiation toxicity
1517078|NCT00003305|recurrent childhood acute lymphoblastic leukemia
1517079|NCT00003305|recurrent childhood acute myeloid leukemia
1517080|NCT00003305|recurrent adult acute myeloid leukemia
1517081|NCT00003305|recurrent adult acute lymphoblastic leukemia
1517082|NCT00003304|adult oligodendroglioma
1517083|NCT00003302|breast cancer
1517084|NCT00003301|recurrent adult brain tumor
1517085|NCT00003301|adult glioblastoma
1517086|NCT00003301|adult anaplastic astrocytoma
1517087|NCT00003301|adult giant cell glioblastoma
1517088|NCT00003301|adult gliosarcoma
1517089|NCT00003299|extensive stage small cell lung cancer
1517090|NCT00003298|stage II gastric cancer
1517091|NCT00003298|stage III gastric cancer
1517092|NCT00003298|stage IV gastric cancer
1517093|NCT00003298|adenocarcinoma of the stomach
1517094|NCT00003297|stage III ovarian epithelial cancer
1517095|NCT00003297|stage IV ovarian epithelial cancer
1517096|NCT00003297|recurrent ovarian epithelial cancer
1517097|NCT00003296|localized resectable adult primary liver cancer
1517098|NCT00003296|localized unresectable adult primary liver cancer
1517099|NCT00003296|advanced adult primary liver cancer
1517100|NCT00003296|recurrent adult primary liver cancer
1517101|NCT00003296|localized gallbladder cancer
1517102|NCT00003296|unresectable gallbladder cancer
1517103|NCT00003296|recurrent gallbladder cancer
1517104|NCT00003296|localized extrahepatic bile duct cancer
1517105|NCT00003296|unresectable extrahepatic bile duct cancer
1517106|NCT00003296|recurrent extrahepatic bile duct cancer
1517107|NCT00003296|adult primary hepatocellular carcinoma
1517108|NCT00003296|cholangiocarcinoma of the gallbladder
1517109|NCT00003296|cholangiocarcinoma of the extrahepatic bile duct
1517110|NCT00003296|adult primary cholangiocellular carcinoma
1517111|NCT00003294|stage III adult Hodgkin lymphoma
1517112|NCT00003294|stage IV adult Hodgkin lymphoma
1517113|NCT00003294|recurrent adult Hodgkin lymphoma
1517114|NCT00003294|stage III chronic lymphocytic leukemia
1517115|NCT00003294|stage IV chronic lymphocytic leukemia
1517116|NCT00003294|recurrent adult acute myeloid leukemia
1517117|NCT00003294|recurrent adult acute lymphoblastic leukemia
1517118|NCT00003294|relapsing chronic myelogenous leukemia
1517119|NCT00003294|refractory chronic lymphocytic leukemia
1517120|NCT00003294|unspecified adult solid tumor, protocol specific
1517121|NCT00003294|chronic phase chronic myelogenous leukemia
1517122|NCT00003294|accelerated phase chronic myelogenous leukemia
1517123|NCT00003294|blastic phase chronic myelogenous leukemia
1517124|NCT00003294|meningeal chronic myelogenous leukemia
1517125|NCT00003294|untreated adult acute lymphoblastic leukemia
1517126|NCT00003294|untreated adult acute myeloid leukemia
1517127|NCT00003294|untreated hairy cell leukemia
1517128|NCT00003294|progressive hairy cell leukemia, initial treatment
1517129|NCT00003294|refractory hairy cell leukemia
1517130|NCT00003294|chronic myelomonocytic leukemia
1517131|NCT00003294|stage IV grade 1 follicular lymphoma
1517132|NCT00003294|stage IV grade 2 follicular lymphoma
1517133|NCT00003294|stage IV grade 3 follicular lymphoma
1517134|NCT00003294|stage IV adult diffuse small cleaved cell lymphoma
1517135|NCT00003294|stage IV adult diffuse mixed cell lymphoma
1517136|NCT00003294|stage IV adult diffuse large cell lymphoma
1517137|NCT00003294|stage IV adult immunoblastic large cell lymphoma
1517138|NCT00003294|stage IV adult lymphoblastic lymphoma
1517139|NCT00003294|stage IV adult Burkitt lymphoma
1517140|NCT00003294|recurrent grade 1 follicular lymphoma
1517141|NCT00003294|recurrent grade 2 follicular lymphoma
1517142|NCT00003294|recurrent grade 3 follicular lymphoma
1517143|NCT00003294|recurrent adult diffuse small cleaved cell lymphoma
1517144|NCT00003294|recurrent adult diffuse mixed cell lymphoma
1517145|NCT00003294|recurrent adult diffuse large cell lymphoma
1517146|NCT00003294|recurrent adult immunoblastic large cell lymphoma
1517147|NCT00003294|recurrent adult lymphoblastic lymphoma
1517148|NCT00003294|recurrent adult Burkitt lymphoma
1517149|NCT00003294|stage III adult T-cell leukemia/lymphoma
1517150|NCT00003294|stage IV adult T-cell leukemia/lymphoma
1517151|NCT00003294|recurrent adult T-cell leukemia/lymphoma
1517152|NCT00003294|prolymphocytic leukemia
1517153|NCT00003294|AIDS-related peripheral/systemic lymphoma
1517154|NCT00003294|AIDS-related primary CNS lymphoma
1517155|NCT00003294|stage IV mantle cell lymphoma
1517156|NCT00003294|recurrent mantle cell lymphoma
1517157|NCT00003294|angioimmunoblastic T-cell lymphoma
1517158|NCT00003294|anaplastic large cell lymphoma
1517159|NCT00003294|recurrent marginal zone lymphoma
1517160|NCT00003294|recurrent small lymphocytic lymphoma
1517161|NCT00003294|stage IV small lymphocytic lymphoma
1517162|NCT00003294|stage IV marginal zone lymphoma
1517163|NCT00003294|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1517164|NCT00003294|nodal marginal zone B-cell lymphoma
1517165|NCT00003294|splenic marginal zone lymphoma
1517166|NCT00003293|recurrent adult brain tumor
1517167|NCT00003293|adult glioblastoma
1517168|NCT00003293|adult giant cell glioblastoma
1517169|NCT00003293|adult gliosarcoma
1517170|NCT00003291|untreated childhood acute lymphoblastic leukemia
1517171|NCT00003290|stage IIB prostate cancer
1517172|NCT00003290|stage IIA prostate cancer
1517173|NCT00003290|stage III prostate cancer
1517174|NCT00003289|Waldenstrom macroglobulinemia
1517175|NCT00003289|stage III chronic lymphocytic leukemia
1517176|NCT00003289|stage IV chronic lymphocytic leukemia
1517177|NCT00003289|refractory chronic lymphocytic leukemia
1517178|NCT00003289|unspecified adult solid tumor, protocol specific
1517179|NCT00003289|refractory hairy cell leukemia
1517180|NCT00003289|stage III grade 1 follicular lymphoma
1517181|NCT00003289|stage III grade 2 follicular lymphoma
1517182|NCT00003289|stage III grade 3 follicular lymphoma
1517183|NCT00003289|stage III adult diffuse small cleaved cell lymphoma
1517184|NCT00003289|stage III adult diffuse mixed cell lymphoma
1517185|NCT00003289|stage IV grade 1 follicular lymphoma
1517186|NCT00003289|stage IV grade 2 follicular lymphoma
1517187|NCT00003289|stage IV adult diffuse small cleaved cell lymphoma
1517188|NCT00003289|stage IV adult diffuse mixed cell lymphoma
1517189|NCT00003289|recurrent grade 1 follicular lymphoma
1517190|NCT00003289|recurrent grade 2 follicular lymphoma
1517191|NCT00003289|recurrent grade 3 follicular lymphoma
1517192|NCT00003289|recurrent adult diffuse small cleaved cell lymphoma
1517193|NCT00003289|recurrent adult diffuse mixed cell lymphoma
1517194|NCT00003289|prolymphocytic leukemia
1517195|NCT00003289|stage III mantle cell lymphoma
1517196|NCT00003289|stage IV mantle cell lymphoma
1517197|NCT00003289|recurrent mantle cell lymphoma
1517198|NCT00003289|recurrent marginal zone lymphoma
1517199|NCT00003289|recurrent small lymphocytic lymphoma
1517200|NCT00003289|stage III small lymphocytic lymphoma
1517201|NCT00003289|stage III marginal zone lymphoma
1517202|NCT00003289|stage IV small lymphocytic lymphoma
1517203|NCT00003289|stage IV marginal zone lymphoma
1517204|NCT00003289|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1517205|NCT00003289|nodal marginal zone B-cell lymphoma
1517206|NCT00003289|splenic marginal zone lymphoma
1517207|NCT00003288|unspecified childhood solid tumor, protocol specific
1517208|NCT00003287|stage IV colon cancer
1517209|NCT00003287|stage IV rectal cancer
1517210|NCT00003287|recurrent colon cancer
1517211|NCT00003287|recurrent rectal cancer
1517212|NCT00003287|adenocarcinoma of the colon
1517213|NCT00003287|adenocarcinoma of the rectum
1517214|NCT00003284|stage II non-small cell lung cancer
1517215|NCT00003284|limited stage small cell lung cancer
1517216|NCT00003284|extensive stage small cell lung cancer
1517217|NCT00003284|recurrent small cell lung cancer
1517218|NCT00003284|stage IIIA non-small cell lung cancer
1517219|NCT00003284|stage IIIB non-small cell lung cancer
1517220|NCT00003284|stage IV non-small cell lung cancer
1517221|NCT00003283|invasive thymoma and thymic carcinoma
1517222|NCT00003283|recurrent thymoma and thymic carcinoma
1517223|NCT00003281|recurrent small cell lung cancer
1517224|NCT00003280|stage I mantle cell lymphoma
1517225|NCT00003280|contiguous stage II mantle cell lymphoma
1517226|NCT00003280|noncontiguous stage II mantle cell lymphoma
1517227|NCT00003280|stage III mantle cell lymphoma
1517228|NCT00003280|stage IV mantle cell lymphoma
1517229|NCT00003280|recurrent mantle cell lymphoma
1517230|NCT00003279|limited stage small cell lung cancer
1517231|NCT00003278|primary central nervous system non-Hodgkin lymphoma
1517232|NCT00003278|intraocular lymphoma
1517233|NCT00003276|unresectable gallbladder cancer
1517234|NCT00003276|recurrent gallbladder cancer
1517235|NCT00003274|stage II melanoma
1517236|NCT00003273|childhood infratentorial ependymoma
1517237|NCT00003273|childhood supratentorial ependymoma
1517238|NCT00003273|localized resectable neuroblastoma
1517239|NCT00003273|regional neuroblastoma
1517240|NCT00003273|disseminated neuroblastoma
1517241|NCT00003273|stage 4S neuroblastoma
1517242|NCT00003273|extraocular retinoblastoma
1517243|NCT00003273|childhood choroid plexus tumor
1517244|NCT00003273|localized unresectable neuroblastoma
1517245|NCT00003273|previously untreated childhood rhabdomyosarcoma
1517246|NCT00003273|untreated childhood supratentorial primitive neuroectodermal tumor
1517247|NCT00003273|untreated childhood medulloblastoma
1517248|NCT00003273|newly diagnosed childhood ependymoma
1517249|NCT00003270|recurrent childhood acute lymphoblastic leukemia
1517250|NCT00003270|recurrent adult Hodgkin lymphoma
1517251|NCT00003270|Burkitt lymphoma
1517252|NCT00003270|refractory multiple myeloma
1517253|NCT00003270|stage I multiple myeloma
1517254|NCT00003270|stage II multiple myeloma
1517255|NCT00003270|stage III multiple myeloma
1517256|NCT00003270|recurrent childhood lymphoblastic lymphoma
1517257|NCT00003270|recurrent childhood acute myeloid leukemia
1517258|NCT00003270|recurrent adult acute myeloid leukemia
1517259|NCT00003270|recurrent adult acute lymphoblastic leukemia
1517260|NCT00003270|relapsing chronic myelogenous leukemia
1517261|NCT00003270|childhood diffuse large cell lymphoma
1517262|NCT00003270|childhood immunoblastic large cell lymphoma
1517263|NCT00003270|chronic phase chronic myelogenous leukemia
1517264|NCT00003270|accelerated phase chronic myelogenous leukemia
1517265|NCT00003270|blastic phase chronic myelogenous leukemia
1517266|NCT00003270|meningeal chronic myelogenous leukemia
1517267|NCT00003270|adult acute myeloid leukemia in remission
1517268|NCT00003270|adult acute lymphoblastic leukemia in remission
1517269|NCT00003270|childhood acute myeloid leukemia in remission
1517270|NCT00003270|childhood acute lymphoblastic leukemia in remission
1517271|NCT00003270|recurrent/refractory childhood Hodgkin lymphoma
1517272|NCT00003270|recurrent grade 1 follicular lymphoma
1517273|NCT00003270|recurrent grade 2 follicular lymphoma
1517274|NCT00003270|recurrent grade 3 follicular lymphoma
1517275|NCT00003270|recurrent adult diffuse small cleaved cell lymphoma
1517276|NCT00003270|recurrent adult diffuse mixed cell lymphoma
1517277|NCT00003270|recurrent adult diffuse large cell lymphoma
1517278|NCT00003270|recurrent adult immunoblastic large cell lymphoma
1517279|NCT00003270|recurrent adult lymphoblastic lymphoma
1517280|NCT00003270|recurrent adult Burkitt lymphoma
1517281|NCT00003270|secondary acute myeloid leukemia
1517282|NCT00003270|de novo myelodysplastic syndromes
1517283|NCT00003270|previously treated myelodysplastic syndromes
1517284|NCT00003270|secondary myelodysplastic syndromes
1517285|NCT00003270|graft versus host disease
1517286|NCT00003270|recurrent childhood small noncleaved cell lymphoma
1517287|NCT00003270|recurrent childhood large cell lymphoma
1517288|NCT00003270|recurrent mantle cell lymphoma
1517289|NCT00003270|recurrent marginal zone lymphoma
1517290|NCT00003270|recurrent small lymphocytic lymphoma
1517291|NCT00003270|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1517292|NCT00003270|nodal marginal zone B-cell lymphoma
1517293|NCT00003270|splenic marginal zone lymphoma
1517294|NCT00003270|childhood myelodysplastic syndromes
1517295|NCT00003269|stage I adult Hodgkin lymphoma
1517296|NCT00003269|stage II adult Hodgkin lymphoma
1517297|NCT00003269|stage III adult Hodgkin lymphoma
1517298|NCT00003269|stage IV adult Hodgkin lymphoma
1517299|NCT00003269|stage I breast cancer
1517300|NCT00003269|stage II breast cancer
1517301|NCT00003269|stage IV breast cancer
1517302|NCT00003269|stage IIIA breast cancer
1517303|NCT00003269|stage I non-small cell lung cancer
1517304|NCT00003269|stage II non-small cell lung cancer
1517305|NCT00003269|stage IIIB breast cancer
1517306|NCT00003269|stage I cutaneous T-cell non-Hodgkin lymphoma
1517307|NCT00003269|stage II cutaneous T-cell non-Hodgkin lymphoma
1517308|NCT00003269|stage III cutaneous T-cell non-Hodgkin lymphoma
1517309|NCT00003269|stage IV cutaneous T-cell non-Hodgkin lymphoma
1517310|NCT00003269|stage I ovarian epithelial cancer
1517311|NCT00003269|stage II ovarian epithelial cancer
1517312|NCT00003269|stage III ovarian epithelial cancer
1517313|NCT00003269|stage IV ovarian epithelial cancer
1517314|NCT00003269|Waldenstrom macroglobulinemia
1518842|NCT00003023|metastatic osteosarcoma
1517315|NCT00003269|limited stage small cell lung cancer
1517316|NCT00003269|extensive stage small cell lung cancer
1517317|NCT00003269|stage IIIA non-small cell lung cancer
1517318|NCT00003269|stage IIIB non-small cell lung cancer
1517319|NCT00003269|stage IV non-small cell lung cancer
1517320|NCT00003269|unspecified adult solid tumor, protocol specific
1517321|NCT00003269|stage I grade 1 follicular lymphoma
1517322|NCT00003269|stage I grade 2 follicular lymphoma
1517323|NCT00003269|stage I grade 3 follicular lymphoma
1517324|NCT00003269|stage I adult diffuse small cleaved cell lymphoma
1517325|NCT00003269|stage I adult diffuse mixed cell lymphoma
1517326|NCT00003269|stage I adult diffuse large cell lymphoma
1517327|NCT00003269|stage I adult immunoblastic large cell lymphoma
1517328|NCT00003269|stage I adult lymphoblastic lymphoma
1517329|NCT00003269|stage I adult Burkitt lymphoma
1517330|NCT00003269|stage III grade 1 follicular lymphoma
1517331|NCT00003269|stage III grade 2 follicular lymphoma
1517332|NCT00003269|stage III grade 3 follicular lymphoma
1517333|NCT00003269|stage III adult diffuse small cleaved cell lymphoma
1517334|NCT00003269|stage III adult diffuse mixed cell lymphoma
1517335|NCT00003269|stage III adult diffuse large cell lymphoma
1517336|NCT00003269|stage III adult immunoblastic large cell lymphoma
1517337|NCT00003269|stage III adult lymphoblastic lymphoma
1517338|NCT00003269|stage III adult Burkitt lymphoma
1517339|NCT00003269|stage IV grade 1 follicular lymphoma
1517340|NCT00003269|stage IV grade 2 follicular lymphoma
1517341|NCT00003269|stage IV grade 3 follicular lymphoma
1517342|NCT00003269|stage IV adult diffuse small cleaved cell lymphoma
1517343|NCT00003269|stage IV adult diffuse mixed cell lymphoma
1517344|NCT00003269|stage IV adult diffuse large cell lymphoma
1517345|NCT00003269|stage IV adult immunoblastic large cell lymphoma
1517346|NCT00003269|stage IV adult lymphoblastic lymphoma
1517347|NCT00003269|stage IV adult Burkitt lymphoma
1517348|NCT00003269|stage I adult T-cell leukemia/lymphoma
1517349|NCT00003269|stage II adult T-cell leukemia/lymphoma
1517350|NCT00003269|stage III adult T-cell leukemia/lymphoma
1517351|NCT00003269|stage IV adult T-cell leukemia/lymphoma
1517352|NCT00003269|drug/agent toxicity by tissue/organ
1517353|NCT00003269|stage I mantle cell lymphoma
1517354|NCT00003269|contiguous stage II grade 1 follicular lymphoma
1517355|NCT00003269|contiguous stage II grade 2 follicular lymphoma
1517356|NCT00003269|contiguous stage II grade 3 follicular lymphoma
1517357|NCT00003269|contiguous stage II adult diffuse small cleaved cell lymphoma
1517358|NCT00003269|contiguous stage II mantle cell lymphoma
1517359|NCT00003269|contiguous stage II adult diffuse mixed cell lymphoma
1517360|NCT00003269|contiguous stage II adult immunoblastic large cell lymphoma
1517361|NCT00003269|contiguous stage II adult diffuse large cell lymphoma
1517362|NCT00003269|contiguous stage II adult Burkitt lymphoma
1517363|NCT00003269|contiguous stage II adult lymphoblastic lymphoma
1517364|NCT00003269|noncontiguous stage II grade 1 follicular lymphoma
1517365|NCT00003269|noncontiguous stage II grade 2 follicular lymphoma
1517366|NCT00003269|noncontiguous stage II grade 3 follicular lymphoma
1517367|NCT00003269|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1517368|NCT00003269|noncontiguous stage II mantle cell lymphoma
1517369|NCT00003269|noncontiguous stage II adult diffuse mixed cell lymphoma
1517370|NCT00003269|noncontiguous stage II adult immunoblastic large cell lymphoma
1517371|NCT00003269|noncontiguous stage II adult diffuse large cell lymphoma
1517372|NCT00003269|noncontiguous stage II adult Burkitt lymphoma
1517373|NCT00003269|noncontiguous stage II adult lymphoblastic lymphoma
1517374|NCT00003269|stage III mantle cell lymphoma
1517375|NCT00003269|stage IV mantle cell lymphoma
1517376|NCT00003269|noncontiguous stage II small lymphocytic lymphoma
1517377|NCT00003269|noncontiguous stage II marginal zone lymphoma
1517378|NCT00003269|stage I marginal zone lymphoma
1517379|NCT00003269|stage I small lymphocytic lymphoma
1517380|NCT00003269|stage III small lymphocytic lymphoma
1517381|NCT00003269|stage III marginal zone lymphoma
1517382|NCT00003269|stage IV small lymphocytic lymphoma
1517383|NCT00003269|stage IV marginal zone lymphoma
1517384|NCT00003269|contiguous stage II marginal zone lymphoma
1517385|NCT00003269|contiguous stage II small lymphocytic lymphoma
1517386|NCT00003269|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520756|NCT00002679|stage II breast cancer
1517387|NCT00003269|nodal marginal zone B-cell lymphoma
1517388|NCT00003269|splenic marginal zone lymphoma
1517389|NCT00003268|untreated adult acute myeloid leukemia
1517390|NCT00003268|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
1517391|NCT00003268|adult acute erythroid leukemia (M6)
1517392|NCT00003268|adult acute myeloblastic leukemia without maturation (M1)
1517393|NCT00003268|adult acute myeloblastic leukemia with maturation (M2)
1517394|NCT00003268|adult acute myelomonocytic leukemia (M4)
1517395|NCT00003268|adult acute megakaryoblastic leukemia (M7)
1517396|NCT00003268|drug/agent toxicity by tissue/organ
1517397|NCT00003268|adult acute minimally differentiated myeloid leukemia (M0)
1517398|NCT00003267|stage I cervical cancer
1517399|NCT00003267|stage II cervical cancer
1517400|NCT00003267|stage I vaginal cancer
1517401|NCT00003267|stage II vaginal cancer
1517402|NCT00003267|stage I endometrial carcinoma
1517403|NCT00003267|stage II endometrial carcinoma
1517404|NCT00003267|infection
1517405|NCT00003267|perioperative/postoperative complications
1517406|NCT00003266|unspecified adult solid tumor, protocol specific
1517407|NCT00003266|fatigue
1517408|NCT00003264|stage IV salivary gland cancer
1517409|NCT00003264|recurrent salivary gland cancer
1517410|NCT00003264|recurrent metastatic squamous neck cancer with occult primary
1517411|NCT00003264|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1517412|NCT00003264|salivary gland squamous cell carcinoma
1517413|NCT00003264|stage IV squamous cell carcinoma of the lip and oral cavity
1517414|NCT00003264|recurrent squamous cell carcinoma of the lip and oral cavity
1517415|NCT00003264|stage IV squamous cell carcinoma of the oropharynx
1517416|NCT00003264|recurrent squamous cell carcinoma of the oropharynx
1517417|NCT00003264|stage IV squamous cell carcinoma of the nasopharynx
1517418|NCT00003264|recurrent squamous cell carcinoma of the nasopharynx
1517419|NCT00003264|stage IV squamous cell carcinoma of the hypopharynx
1517420|NCT00003264|recurrent squamous cell carcinoma of the hypopharynx
1517421|NCT00003264|stage IV squamous cell carcinoma of the larynx
1517422|NCT00003264|recurrent squamous cell carcinoma of the larynx
1517423|NCT00003264|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1517424|NCT00003264|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1517425|NCT00003263|localized malignant mesothelioma
1517426|NCT00003262|stage I adult Hodgkin lymphoma
1517427|NCT00003262|stage II adult Hodgkin lymphoma
1517428|NCT00003262|stage III adult Hodgkin lymphoma
1517429|NCT00003262|stage IV adult Hodgkin lymphoma
1517430|NCT00003262|AIDS-related peripheral/systemic lymphoma
1517431|NCT00003262|HIV-associated Hodgkin lymphoma
1517432|NCT00003261|AIDS-related primary CNS lymphoma
1517433|NCT00003260|stage IV colon cancer
1517434|NCT00003260|stage IV rectal cancer
1517435|NCT00003260|recurrent colon cancer
1517436|NCT00003260|recurrent rectal cancer
1517437|NCT00003260|adenocarcinoma of the colon
1517438|NCT00003260|adenocarcinoma of the rectum
1517439|NCT00003259|stage IV prostate cancer
1517440|NCT00003257|recurrent metastatic squamous neck cancer with occult primary
1517441|NCT00003257|recurrent squamous cell carcinoma of the lip and oral cavity
1517442|NCT00003257|recurrent squamous cell carcinoma of the oropharynx
1517443|NCT00003257|recurrent squamous cell carcinoma of the nasopharynx
1517444|NCT00003257|recurrent squamous cell carcinoma of the hypopharynx
1517445|NCT00003257|recurrent squamous cell carcinoma of the larynx
1517446|NCT00003257|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1517447|NCT00003256|adenocarcinoma of the prostate
1517448|NCT00003256|stage IV prostate cancer
1517449|NCT00003255|recurrent adult acute myeloid leukemia
1517450|NCT00003255|secondary acute myeloid leukemia
1517451|NCT00003254|stage IV colon cancer
1517452|NCT00003254|stage IV rectal cancer
1517453|NCT00003254|recurrent colon cancer
1517454|NCT00003254|recurrent rectal cancer
1517455|NCT00003253|stage IV breast cancer
1517456|NCT00003253|recurrent breast cancer
1517457|NCT00003253|male breast cancer
1517458|NCT00003252|unspecified adult solid tumor, protocol specific
1517459|NCT00003252|drug/agent toxicity by tissue/organ
1517460|NCT00003251|stage III nasopharyngeal cancer
1517461|NCT00003251|stage IV nasopharyngeal cancer
1517462|NCT00003251|recurrent nasopharyngeal cancer
1517463|NCT00003251|stage III salivary gland cancer
1517464|NCT00003251|stage IV salivary gland cancer
1517465|NCT00003251|recurrent salivary gland cancer
1517466|NCT00003251|salivary gland squamous cell carcinoma
1517467|NCT00003251|high-grade salivary gland mucoepidermoid carcinoma
1517468|NCT00003251|stage III lip and oral cavity cancer
1517469|NCT00003251|stage IV lip and oral cavity cancer
1517470|NCT00003251|recurrent lip and oral cavity cancer
1517471|NCT00003251|stage III hypopharyngeal cancer
1517472|NCT00003251|stage IV hypopharyngeal cancer
1517473|NCT00003251|recurrent hypopharyngeal cancer
1517474|NCT00003251|stage III laryngeal cancer
1517475|NCT00003251|stage IV laryngeal cancer
1517476|NCT00003251|recurrent laryngeal cancer
1517477|NCT00003251|stage III paranasal sinus and nasal cavity cancer
1517478|NCT00003251|stage IV paranasal sinus and nasal cavity cancer
1517479|NCT00003251|recurrent paranasal sinus and nasal cavity cancer
1517480|NCT00003251|stage III oropharyngeal cancer
1517481|NCT00003251|stage IV oropharyngeal cancer
1517482|NCT00003251|recurrent oropharyngeal cancer
1517483|NCT00003251|stage III squamous cell carcinoma of the lip and oral cavity
1517484|NCT00003251|stage III mucoepidermoid carcinoma of the oral cavity
1517485|NCT00003251|stage IV squamous cell carcinoma of the lip and oral cavity
1517486|NCT00003251|stage IV mucoepidermoid carcinoma of the oral cavity
1517487|NCT00003251|recurrent squamous cell carcinoma of the lip and oral cavity
1517488|NCT00003251|recurrent mucoepidermoid carcinoma of the oral cavity
1517489|NCT00003251|stage III squamous cell carcinoma of the oropharynx
1517490|NCT00003251|stage IV squamous cell carcinoma of the oropharynx
1517491|NCT00003251|recurrent squamous cell carcinoma of the oropharynx
1517492|NCT00003251|stage III squamous cell carcinoma of the nasopharynx
1517493|NCT00003251|stage IV squamous cell carcinoma of the nasopharynx
1517494|NCT00003251|recurrent squamous cell carcinoma of the nasopharynx
1517495|NCT00003251|stage III squamous cell carcinoma of the hypopharynx
1517496|NCT00003251|stage IV squamous cell carcinoma of the hypopharynx
1517497|NCT00003251|recurrent squamous cell carcinoma of the hypopharynx
1517498|NCT00003251|stage III squamous cell carcinoma of the larynx
1517499|NCT00003251|stage IV squamous cell carcinoma of the larynx
1517500|NCT00003251|recurrent squamous cell carcinoma of the larynx
1517501|NCT00003251|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1517502|NCT00003251|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1517503|NCT00003251|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1517504|NCT00003251|drug/agent toxicity by tissue/organ
1517505|NCT00003251|radiation toxicity
1517506|NCT00003250|unspecified adult solid tumor, protocol specific
1517507|NCT00003249|unspecified adult solid tumor, protocol specific
1517508|NCT00003248|stage I chronic lymphocytic leukemia
1517509|NCT00003248|stage II chronic lymphocytic leukemia
1517510|NCT00003248|stage III chronic lymphocytic leukemia
1517511|NCT00003248|stage IV chronic lymphocytic leukemia
1517512|NCT00003248|B-cell chronic lymphocytic leukemia
1517513|NCT00003245|Waldenström macroglobulinemia
1517514|NCT00003245|recurrent grade 1 follicular lymphoma
1517515|NCT00003245|recurrent grade 2 follicular lymphoma
1517516|NCT00003245|recurrent grade 3 follicular lymphoma
1517517|NCT00003245|recurrent adult diffuse small cleaved cell lymphoma
1517518|NCT00003245|recurrent adult diffuse mixed cell lymphoma
1517519|NCT00003245|recurrent adult diffuse large cell lymphoma
1517520|NCT00003245|recurrent adult immunoblastic large cell lymphoma
1517521|NCT00003245|recurrent adult Burkitt lymphoma
1517522|NCT00003245|recurrent mantle cell lymphoma
1517523|NCT00003245|recurrent marginal zone lymphoma
1517524|NCT00003245|recurrent small lymphocytic lymphoma
1517525|NCT00003245|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1517526|NCT00003245|nodal marginal zone B-cell lymphoma
1517527|NCT00003245|splenic marginal zone lymphoma
1517528|NCT00003243|recurrent childhood acute lymphoblastic leukemia
1517529|NCT00003243|recurrent childhood lymphoblastic lymphoma
1517530|NCT00003243|recurrent childhood acute myeloid leukemia
1517531|NCT00003243|recurrent adult acute myeloid leukemia
1517532|NCT00003243|recurrent adult acute lymphoblastic leukemia
1517533|NCT00003243|relapsing chronic myelogenous leukemia
1517534|NCT00003243|accelerated phase chronic myelogenous leukemia
1517535|NCT00003243|blastic phase chronic myelogenous leukemia
1517536|NCT00003243|acute undifferentiated leukemia
1517537|NCT00003243|recurrent adult diffuse mixed cell lymphoma
1517538|NCT00003243|recurrent adult diffuse large cell lymphoma
1517539|NCT00003243|recurrent adult lymphoblastic lymphoma
1517540|NCT00003243|recurrent adult Burkitt lymphoma
1517541|NCT00003243|secondary acute myeloid leukemia
1517542|NCT00003243|previously treated myelodysplastic syndromes
1517543|NCT00003243|recurrent childhood small noncleaved cell lymphoma
1517544|NCT00003243|recurrent childhood large cell lymphoma
1517545|NCT00003243|childhood chronic myelogenous leukemia
1517546|NCT00003243|atypical chronic myeloid leukemia
1517547|NCT00003243|myelodysplastic/myeloproliferative disease, unclassifiable
1517548|NCT00003243|childhood myelodysplastic syndromes
1517549|NCT00003242|unspecified adult solid tumor, protocol specific
1517550|NCT00003241|recurrent childhood brain tumor
1517551|NCT00003241|childhood high-grade cerebral astrocytoma
1517552|NCT00003241|untreated childhood brain stem glioma
1517553|NCT00003241|recurrent childhood brain stem glioma
1517554|NCT00003241|recurrent childhood supratentorial primitive neuroectodermal tumor
1517555|NCT00003241|recurrent childhood cerebellar astrocytoma
1517556|NCT00003241|recurrent childhood cerebral astrocytoma
1517557|NCT00003241|recurrent childhood medulloblastoma
1517558|NCT00003241|recurrent childhood ependymoma
1517559|NCT00003240|stage I non-small cell lung cancer
1517560|NCT00003240|stage II non-small cell lung cancer
1517561|NCT00003240|stage IIIA non-small cell lung cancer
1517562|NCT00003240|stage IIIB non-small cell lung cancer
1517563|NCT00003240|stage IV non-small cell lung cancer
1517564|NCT00003239|chronic phase chronic myelogenous leukemia
1517565|NCT00003239|Philadelphia chromosome positive chronic myelogenous leukemia
1517566|NCT00003239|Homoharringtonine
1517567|NCT00003239|HHT
1517568|NCT00003239|cephalotaxus alkaloid
1517569|NCT00003239|cytarabine
1517570|NCT00003239|Interferon Alpha 2-A
1517571|NCT00003239|Roferon-A
1517572|NCT00003239|Ara-C
1517574|NCT00003239|Cytosine Arabinosine Hydrochloride
1517575|NCT00003238|recurrent prostate cancer
1517576|NCT00003237|stage II gastric cancer
1517577|NCT00003237|stage III gastric cancer
1517578|NCT00003237|stage II esophageal cancer
1517579|NCT00003237|stage III esophageal cancer
1517580|NCT00003237|adenocarcinoma of the stomach
1517581|NCT00003237|adenocarcinoma of the esophagus
1517582|NCT00003236|recurrent breast cancer
1517583|NCT00003235|squamous cell lung cancer
1517584|NCT00003235|large cell lung cancer
1517585|NCT00003235|stage IIIA non-small cell lung cancer
1517586|NCT00003235|stage IIIB non-small cell lung cancer
1517587|NCT00003235|adenocarcinoma of the lung
1517588|NCT00003234|recurrent childhood rhabdomyosarcoma
1517589|NCT00003234|recurrent neuroblastoma
1517590|NCT00003234|recurrent childhood soft tissue sarcoma
1517591|NCT00003234|recurrent childhood supratentorial primitive neuroectodermal tumor
1519423|NCT00002933|stage IV colon cancer
1517592|NCT00003234|recurrent childhood cerebellar astrocytoma
1517593|NCT00003234|recurrent childhood cerebral astrocytoma
1517594|NCT00003234|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1517595|NCT00003234|recurrent childhood ependymoma
1517596|NCT00003232|adenocarcinoma of the prostate
1517597|NCT00003232|recurrent prostate cancer
1517598|NCT00003232|pain
1517599|NCT00003232|quality of life
1517600|NCT00003231|squamous cell lung cancer
1517601|NCT00003231|large cell lung cancer
1517602|NCT00003231|stage IIIA non-small cell lung cancer
1517603|NCT00003231|adenocarcinoma of the lung
1517604|NCT00003230|recurrent adult acute myeloid leukemia
1517605|NCT00003230|recurrent adult acute lymphoblastic leukemia
1517606|NCT00003230|blastic phase chronic myelogenous leukemia
1517607|NCT00003230|untreated adult acute lymphoblastic leukemia
1517608|NCT00003230|untreated adult acute myeloid leukemia
1517609|NCT00003229|stage IV melanoma
1517610|NCT00003229|recurrent melanoma
1517611|NCT00003225|stage IV colon cancer
1517612|NCT00003225|stage IV rectal cancer
1517613|NCT00003225|recurrent colon cancer
1517614|NCT00003225|recurrent rectal cancer
1517615|NCT00003224|stage II melanoma
1517616|NCT00003224|stage III melanoma
1517617|NCT00003224|stage IV melanoma
1517618|NCT00003224|recurrent melanoma
1517619|NCT00003223|lip and oral cavity cancer
1517620|NCT00003222|stage III melanoma
1517621|NCT00003222|stage IV melanoma
1517622|NCT00003222|recurrent melanoma
1517623|NCT00003220|stage IV colon cancer
1517624|NCT00003220|stage IV rectal cancer
1517625|NCT00003220|recurrent colon cancer
1517626|NCT00003220|recurrent rectal cancer
1517627|NCT00003220|adenocarcinoma of the colon
1517628|NCT00003220|adenocarcinoma of the rectum
1517629|NCT00003219|stage IV breast cancer
1517630|NCT00003219|recurrent breast cancer
1517631|NCT00003217|childhood Burkitt lymphoma
1517632|NCT00003217|untreated childhood acute lymphoblastic leukemia
1517633|NCT00003217|B-cell childhood acute lymphoblastic leukemia
1517634|NCT00003217|stage III childhood small noncleaved cell lymphoma
1517635|NCT00003217|stage IV childhood small noncleaved cell lymphoma
1517636|NCT00003216|stage I pancreatic cancer
1517637|NCT00003216|stage II pancreatic cancer
1517638|NCT00003216|stage III pancreatic cancer
1517639|NCT00003216|adenocarcinoma of the pancreas
1517640|NCT00003216|stage IV pancreatic cancer
1517641|NCT00003215|stage I adult diffuse mixed cell lymphoma
1517642|NCT00003215|stage I adult diffuse large cell lymphoma
1517643|NCT00003215|stage I adult immunoblastic large cell lymphoma
1517644|NCT00003215|stage III adult diffuse mixed cell lymphoma
1517645|NCT00003215|stage III adult diffuse large cell lymphoma
1517646|NCT00003215|stage III adult immunoblastic large cell lymphoma
1517647|NCT00003215|stage IV adult diffuse mixed cell lymphoma
1517648|NCT00003215|stage IV adult diffuse large cell lymphoma
1517649|NCT00003215|stage IV adult immunoblastic large cell lymphoma
1517650|NCT00003215|contiguous stage II adult diffuse mixed cell lymphoma
1517651|NCT00003215|contiguous stage II adult immunoblastic large cell lymphoma
1517652|NCT00003215|contiguous stage II adult diffuse large cell lymphoma
1517653|NCT00003215|noncontiguous stage II adult diffuse mixed cell lymphoma
1517654|NCT00003215|noncontiguous stage II adult immunoblastic large cell lymphoma
1517655|NCT00003215|noncontiguous stage II adult diffuse large cell lymphoma
1517656|NCT00003215|anaplastic large cell lymphoma
1517657|NCT00003214|stage III ovarian epithelial cancer
1517658|NCT00003214|stage IV ovarian epithelial cancer
1517659|NCT00003213|unspecified adult solid tumor, protocol specific
1517660|NCT00003213|nausea and vomiting
1517661|NCT00003212|adult angiosarcoma
1517662|NCT00003212|adult fibrosarcoma
1517663|NCT00003212|adult leiomyosarcoma
1517664|NCT00003212|adult liposarcoma
1517665|NCT00003212|adult neurofibrosarcoma
1517666|NCT00003212|adult synovial sarcoma
1517667|NCT00003212|recurrent adult soft tissue sarcoma
1517668|NCT00003212|adult malignant fibrous histiocytoma
1517669|NCT00003212|adult malignant hemangiopericytoma
1517670|NCT00003212|adult rhabdomyosarcoma
1517671|NCT00003212|stage IV uterine sarcoma
1517672|NCT00003212|recurrent uterine sarcoma
1517673|NCT00003212|stage IV adult soft tissue sarcoma
1517674|NCT00003211|untreated childhood supratentorial primitive neuroectodermal tumor
1517675|NCT00003211|untreated childhood medulloblastoma
1517676|NCT00003209|stage IB cervical cancer
1517677|NCT00003209|stage IIA cervical cancer
1517678|NCT00003209|cervical squamous cell carcinoma
1517679|NCT00003209|cervical adenocarcinoma
1517680|NCT00003209|cervical adenosquamous cell carcinoma
1517681|NCT00003207|unspecified adult solid tumor, protocol specific
1517682|NCT00003207|AIDS-related Kaposi sarcoma
1517683|NCT00003207|recurrent Kaposi sarcoma
1517684|NCT00003206|stage IV nasopharyngeal cancer
1517685|NCT00003206|recurrent nasopharyngeal cancer
1517686|NCT00003205|stage IV breast cancer
1517687|NCT00003205|recurrent breast cancer
1517688|NCT00003203|untreated childhood supratentorial primitive neuroectodermal tumor
1517689|NCT00003203|untreated childhood medulloblastoma
1517690|NCT00003203|localized unresectable neuroblastoma
1517691|NCT00003203|regional neuroblastoma
1517692|NCT00003203|stage 4S neuroblastoma
1517693|NCT00003202|squamous cell lung cancer
1517694|NCT00003202|large cell lung cancer
1517695|NCT00003202|stage IIIA non-small cell lung cancer
1517696|NCT00003202|stage IIIB non-small cell lung cancer
1517697|NCT00003202|adenocarcinoma of the lung
1517698|NCT00003202|adenosquamous cell lung cancer
1517699|NCT00003200|stage III squamous cell carcinoma of the lip and oral cavity
1517700|NCT00003200|stage IV squamous cell carcinoma of the lip and oral cavity
1517701|NCT00003200|stage III squamous cell carcinoma of the oropharynx
1517702|NCT00003200|stage III lymphoepithelioma of the oropharynx
1517703|NCT00003200|stage IV squamous cell carcinoma of the oropharynx
1517704|NCT00003200|stage IV lymphoepithelioma of the oropharynx
1517705|NCT00003200|stage III squamous cell carcinoma of the nasopharynx
1517706|NCT00003200|stage III lymphoepithelioma of the nasopharynx
1517707|NCT00003200|stage IV squamous cell carcinoma of the nasopharynx
1517708|NCT00003200|stage IV lymphoepithelioma of the nasopharynx
1517709|NCT00003200|stage III squamous cell carcinoma of the hypopharynx
1517710|NCT00003200|stage IV squamous cell carcinoma of the hypopharynx
1517711|NCT00003200|stage III squamous cell carcinoma of the larynx
1517712|NCT00003200|stage IV squamous cell carcinoma of the larynx
1517713|NCT00003200|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1517714|NCT00003200|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1517715|NCT00003198|unspecified adult solid tumor, protocol specific
1517716|NCT00003197|unspecified adult solid tumor, protocol specific
1517717|NCT00003195|refractory multiple myeloma
1517718|NCT00003195|stage II multiple myeloma
1517719|NCT00003195|stage III multiple myeloma
1517720|NCT00003194|unspecified childhood solid tumor, protocol specific
1517721|NCT00003193|oral complications
1517722|NCT00003193|stage III squamous cell carcinoma of the lip and oral cavity
1517723|NCT00003193|stage IV squamous cell carcinoma of the lip and oral cavity
1517724|NCT00003193|stage III squamous cell carcinoma of the oropharynx
1517725|NCT00003193|stage IV squamous cell carcinoma of the oropharynx
1517726|NCT00003193|stage III squamous cell carcinoma of the nasopharynx
1517727|NCT00003193|stage IV squamous cell carcinoma of the nasopharynx
1517728|NCT00003193|stage III squamous cell carcinoma of the hypopharynx
1517729|NCT00003193|stage IV squamous cell carcinoma of the hypopharynx
1517730|NCT00003193|stage III squamous cell carcinoma of the larynx
1517731|NCT00003193|stage IV squamous cell carcinoma of the larynx
1517732|NCT00003193|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1517733|NCT00003193|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1517734|NCT00003192|stage III gastric cancer
1517735|NCT00003192|stage IV gastric cancer
1517736|NCT00003192|recurrent gastric cancer
1517737|NCT00003192|stage III esophageal cancer
1517738|NCT00003192|stage IV esophageal cancer
1517739|NCT00003192|recurrent esophageal cancer
1517740|NCT00003192|adenocarcinoma of the stomach
1517741|NCT00003191|recurrent neuroblastoma
1517742|NCT00003191|unspecified childhood solid tumor, protocol specific
1517743|NCT00003187|recurrent childhood acute lymphoblastic leukemia
1517744|NCT00003187|stage IV childhood lymphoblastic lymphoma
1517745|NCT00003187|recurrent childhood acute myeloid leukemia
1517746|NCT00003187|recurrent adult acute myeloid leukemia
1517747|NCT00003187|recurrent adult acute lymphoblastic leukemia
1517748|NCT00003187|relapsing chronic myelogenous leukemia
1517749|NCT00003187|chronic phase chronic myelogenous leukemia
1517750|NCT00003187|accelerated phase chronic myelogenous leukemia
1517751|NCT00003187|untreated adult acute lymphoblastic leukemia
1517752|NCT00003187|untreated adult acute myeloid leukemia
1517753|NCT00003187|untreated childhood acute myeloid leukemia and other myeloid malignancies
1517754|NCT00003187|untreated childhood acute lymphoblastic leukemia
1517755|NCT00003187|adult acute myeloid leukemia in remission
1517756|NCT00003187|adult acute lymphoblastic leukemia in remission
1517757|NCT00003187|childhood acute myeloid leukemia in remission
1517758|NCT00003187|childhood acute lymphoblastic leukemia in remission
1517759|NCT00003187|refractory anemia
1517760|NCT00003187|refractory anemia with ringed sideroblasts
1517761|NCT00003187|refractory anemia with excess blasts
1517762|NCT00003187|refractory anemia with excess blasts in transformation
1517763|NCT00003187|chronic myelomonocytic leukemia
1517764|NCT00003187|acute undifferentiated leukemia
1517765|NCT00003187|stage IV adult lymphoblastic lymphoma
1517766|NCT00003187|de novo myelodysplastic syndromes
1517767|NCT00003187|previously treated myelodysplastic syndromes
1517768|NCT00003187|secondary myelodysplastic syndromes
1517769|NCT00003187|childhood myelodysplastic syndromes
1517770|NCT00003186|stage I colon cancer
1517771|NCT00003186|stage II colon cancer
1517772|NCT00003186|stage III colon cancer
1517773|NCT00003186|stage IV colon cancer
1517774|NCT00003186|stage I rectal cancer
1517775|NCT00003186|stage II rectal cancer
1517776|NCT00003186|stage III rectal cancer
1517777|NCT00003186|stage IV rectal cancer
1517778|NCT00003186|adenocarcinoma of the colon
1517779|NCT00003186|liver metastases
1517780|NCT00003185|adult glioblastoma
1517781|NCT00003185|adult anaplastic astrocytoma
1517782|NCT00003185|adult giant cell glioblastoma
1517783|NCT00003185|adult gliosarcoma
1517784|NCT00003184|stage IV breast cancer
1517785|NCT00003184|recurrent breast cancer
1517786|NCT00003183|adenocarcinoma of the prostate
1517787|NCT00003183|stage IV prostate cancer
1517788|NCT00003183|recurrent prostate cancer
1517789|NCT00003182|stage III nasopharyngeal cancer
1517790|NCT00003182|stage IV nasopharyngeal cancer
1517791|NCT00003182|recurrent nasopharyngeal cancer
1517792|NCT00003182|stage III salivary gland cancer
1517793|NCT00003182|stage IV salivary gland cancer
1517794|NCT00003182|recurrent salivary gland cancer
1517795|NCT00003182|salivary gland squamous cell carcinoma
1517796|NCT00003182|stage III lip and oral cavity cancer
1517797|NCT00003182|stage IV lip and oral cavity cancer
1517798|NCT00003182|recurrent lip and oral cavity cancer
1517799|NCT00003182|stage III hypopharyngeal cancer
1517800|NCT00003182|stage IV hypopharyngeal cancer
1517801|NCT00003182|recurrent hypopharyngeal cancer
1517802|NCT00003182|stage III laryngeal cancer
1517803|NCT00003182|stage IV laryngeal cancer
1517804|NCT00003182|recurrent laryngeal cancer
1517805|NCT00003182|stage III paranasal sinus and nasal cavity cancer
1517806|NCT00003182|stage IV paranasal sinus and nasal cavity cancer
1517807|NCT00003182|recurrent paranasal sinus and nasal cavity cancer
1517808|NCT00003182|stage III oropharyngeal cancer
1517809|NCT00003182|stage IV oropharyngeal cancer
1517810|NCT00003182|recurrent oropharyngeal cancer
1517811|NCT00003182|stage III squamous cell carcinoma of the lip and oral cavity
1517812|NCT00003182|stage IV squamous cell carcinoma of the lip and oral cavity
1517813|NCT00003182|recurrent squamous cell carcinoma of the lip and oral cavity
1517814|NCT00003182|stage III squamous cell carcinoma of the oropharynx
1517815|NCT00003182|stage IV squamous cell carcinoma of the oropharynx
1517816|NCT00003182|recurrent squamous cell carcinoma of the oropharynx
1517817|NCT00003182|stage III squamous cell carcinoma of the nasopharynx
1517818|NCT00003182|stage IV squamous cell carcinoma of the nasopharynx
1517819|NCT00003182|recurrent squamous cell carcinoma of the nasopharynx
1517820|NCT00003182|stage III squamous cell carcinoma of the hypopharynx
1517821|NCT00003182|stage IV squamous cell carcinoma of the hypopharynx
1517822|NCT00003182|recurrent squamous cell carcinoma of the hypopharynx
1517823|NCT00003182|stage III squamous cell carcinoma of the larynx
1517824|NCT00003182|stage IV squamous cell carcinoma of the larynx
1517825|NCT00003182|recurrent squamous cell carcinoma of the larynx
1517826|NCT00003182|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1517827|NCT00003182|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1517828|NCT00003182|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1517829|NCT00003181|stage IV renal cell cancer
1517830|NCT00003181|recurrent renal cell cancer
1517831|NCT00003179|endometrial cancer
1517832|NCT00003178|recurrent childhood acute myeloid leukemia
1517833|NCT00003178|childhood acute myeloblastic leukemia without maturation (M1)
1517834|NCT00003178|childhood acute myeloblastic leukemia with maturation (M2)
1517835|NCT00003178|childhood acute promyelocytic leukemia (M3)
1517836|NCT00003178|childhood acute myelomonocytic leukemia (M4)
1517837|NCT00003178|childhood acute monoblastic leukemia (M5a)
1517838|NCT00003178|childhood acute monocytic leukemia (M5b)
1517839|NCT00003178|childhood acute erythroleukemia (M6)
1517840|NCT00003178|childhood acute megakaryocytic leukemia (M7)
1517841|NCT00003178|childhood acute minimally differentiated myeloid leukemia (M0)
1517842|NCT00003176|recurrent adult brain tumor
1517843|NCT00003176|adult glioblastoma
1517844|NCT00003176|adult anaplastic astrocytoma
1517845|NCT00003176|adult mixed glioma
1517846|NCT00003176|adult giant cell glioblastoma
1517847|NCT00003176|adult gliosarcoma
1517848|NCT00003175|recurrent bladder cancer
1517849|NCT00003175|transitional cell carcinoma of the bladder
1517850|NCT00003175|recurrent urethral cancer
1517851|NCT00003175|recurrent transitional cell cancer of the renal pelvis and ureter
1517852|NCT00003174|stage I chronic lymphocytic leukemia
1517853|NCT00003174|stage II chronic lymphocytic leukemia
1517854|NCT00003174|stage III chronic lymphocytic leukemia
1517855|NCT00003174|stage IV chronic lymphocytic leukemia
1517856|NCT00003174|refractory chronic lymphocytic leukemia
1517857|NCT00003173|intraocular retinoblastoma
1517858|NCT00003173|recurrent retinoblastoma
1517859|NCT00003173|childhood central nervous system germ cell tumor
1517860|NCT00003173|stage III malignant testicular germ cell tumor
1517861|NCT00003173|recurrent malignant testicular germ cell tumor
1517862|NCT00003173|unspecified childhood solid tumor, protocol specific
1517863|NCT00003173|unspecified adult solid tumor, protocol specific
1517864|NCT00003173|childhood germ cell tumor
1517865|NCT00003173|stage III ovarian germ cell tumor
1517866|NCT00003173|stage IV ovarian germ cell tumor
1517867|NCT00003173|recurrent ovarian germ cell tumor
1517868|NCT00003173|extragonadal germ cell tumor
1517869|NCT00003173|adult central nervous system germ cell tumor
1517870|NCT00003173|childhood teratoma
1517871|NCT00003173|childhood malignant testicular germ cell tumor
1517872|NCT00003173|childhood malignant ovarian germ cell tumor
1517873|NCT00003173|childhood extragonadal germ cell tumor
1517874|NCT00003173|recurrent childhood malignant germ cell tumor
1517875|NCT00003172|stage III gastric cancer
1517876|NCT00003172|stage IV gastric cancer
1517877|NCT00003172|recurrent gastric cancer
1517878|NCT00003171|refractory anemia
1517879|NCT00003171|refractory anemia with ringed sideroblasts
1517880|NCT00003171|refractory anemia with excess blasts
1517881|NCT00003171|refractory anemia with excess blasts in transformation
1517882|NCT00003171|chronic myelomonocytic leukemia
1517883|NCT00003171|de novo myelodysplastic syndromes
1517884|NCT00003171|previously treated myelodysplastic syndromes
1517885|NCT00003171|secondary myelodysplastic syndromes
1517886|NCT00003165|stage IV breast cancer
1517887|NCT00003165|recurrent breast cancer
1517888|NCT00003163|refractory multiple myeloma
1517889|NCT00003163|Waldenström macroglobulinemia
1517890|NCT00003163|stage I multiple myeloma
1517891|NCT00003163|stage II multiple myeloma
1517892|NCT00003163|stage III multiple myeloma
1517893|NCT00003163|stage III grade 1 follicular lymphoma
1517894|NCT00003163|stage III grade 2 follicular lymphoma
1517895|NCT00003163|stage III grade 3 follicular lymphoma
1517896|NCT00003163|stage III adult diffuse small cleaved cell lymphoma
1517897|NCT00003163|stage III adult diffuse mixed cell lymphoma
1517898|NCT00003163|stage III adult diffuse large cell lymphoma
1517899|NCT00003163|stage III adult immunoblastic large cell lymphoma
1517900|NCT00003163|stage III adult lymphoblastic lymphoma
1517901|NCT00003163|stage III adult Burkitt lymphoma
1517902|NCT00003163|stage IV grade 1 follicular lymphoma
1517903|NCT00003163|stage IV grade 2 follicular lymphoma
1517904|NCT00003163|stage IV grade 3 follicular lymphoma
1517905|NCT00003163|stage IV adult diffuse small cleaved cell lymphoma
1517906|NCT00003163|stage IV adult diffuse mixed cell lymphoma
1517907|NCT00003163|stage IV adult diffuse large cell lymphoma
1517908|NCT00003163|stage IV adult immunoblastic large cell lymphoma
1517909|NCT00003163|stage IV adult lymphoblastic lymphoma
1517910|NCT00003163|stage IV adult Burkitt lymphoma
1517911|NCT00003163|recurrent grade 1 follicular lymphoma
1517912|NCT00003163|recurrent grade 2 follicular lymphoma
1517913|NCT00003163|recurrent grade 3 follicular lymphoma
1517914|NCT00003163|recurrent adult diffuse small cleaved cell lymphoma
1517915|NCT00003163|recurrent adult diffuse mixed cell lymphoma
1517916|NCT00003163|recurrent adult diffuse large cell lymphoma
1517917|NCT00003163|recurrent adult immunoblastic large cell lymphoma
1517918|NCT00003163|recurrent adult lymphoblastic lymphoma
1517919|NCT00003163|recurrent adult Burkitt lymphoma
1517920|NCT00003163|primary systemic amyloidosis
1517921|NCT00003163|contiguous stage II grade 1 follicular lymphoma
1517922|NCT00003163|contiguous stage II grade 2 follicular lymphoma
1517923|NCT00003163|contiguous stage II grade 3 follicular lymphoma
1517924|NCT00003163|contiguous stage II adult diffuse small cleaved cell lymphoma
1517925|NCT00003163|contiguous stage II mantle cell lymphoma
1517926|NCT00003163|contiguous stage II adult diffuse mixed cell lymphoma
1517927|NCT00003163|contiguous stage II adult immunoblastic large cell lymphoma
1517928|NCT00003163|contiguous stage II adult diffuse large cell lymphoma
1517929|NCT00003163|contiguous stage II adult Burkitt lymphoma
1517930|NCT00003163|contiguous stage II adult lymphoblastic lymphoma
1517931|NCT00003163|noncontiguous stage II grade 1 follicular lymphoma
1517932|NCT00003163|noncontiguous stage II grade 2 follicular lymphoma
1517933|NCT00003163|noncontiguous stage II grade 3 follicular lymphoma
1517934|NCT00003163|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1517935|NCT00003163|noncontiguous stage II mantle cell lymphoma
1517936|NCT00003163|noncontiguous stage II adult diffuse mixed cell lymphoma
1517937|NCT00003163|noncontiguous stage II adult immunoblastic large cell lymphoma
1517938|NCT00003163|noncontiguous stage II adult diffuse large cell lymphoma
1517939|NCT00003163|noncontiguous stage II adult Burkitt lymphoma
1517940|NCT00003163|noncontiguous stage II adult lymphoblastic lymphoma
1517941|NCT00003163|stage III mantle cell lymphoma
1517942|NCT00003163|stage IV mantle cell lymphoma
1517943|NCT00003163|recurrent mantle cell lymphoma
1517944|NCT00003163|noncontiguous stage II small lymphocytic lymphoma
1517945|NCT00003163|noncontiguous stage II marginal zone lymphoma
1517946|NCT00003163|recurrent marginal zone lymphoma
1517947|NCT00003163|recurrent small lymphocytic lymphoma
1517948|NCT00003163|stage III small lymphocytic lymphoma
1517949|NCT00003163|stage III marginal zone lymphoma
1517950|NCT00003163|stage IV small lymphocytic lymphoma
1517951|NCT00003163|stage IV marginal zone lymphoma
1517952|NCT00003163|contiguous stage II marginal zone lymphoma
1517953|NCT00003163|contiguous stage II small lymphocytic lymphoma
1517954|NCT00003163|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1517955|NCT00003163|nodal marginal zone B-cell lymphoma
1517956|NCT00003163|splenic marginal zone lymphoma
1517957|NCT00003162|stage IV breast cancer
1517958|NCT00003162|recurrent breast cancer
1517959|NCT00003162|stage IV prostate cancer
1517960|NCT00003162|recurrent prostate cancer
1517961|NCT00003162|bone metastases
1517962|NCT00003162|pain
1517963|NCT00003160|stage III ovarian epithelial cancer
1517964|NCT00003160|stage IV ovarian epithelial cancer
1517965|NCT00003160|recurrent ovarian epithelial cancer
1517966|NCT00003160|fallopian tube cancer
1517967|NCT00003160|primary peritoneal cavity cancer
1517968|NCT00003159|stage I non-small cell lung cancer
1517969|NCT00003159|stage II non-small cell lung cancer
1517970|NCT00003159|stage IIIA non-small cell lung cancer
1517971|NCT00003159|stage IIIB non-small cell lung cancer
1517972|NCT00003159|stage 0 non-small cell lung cancer
1517973|NCT00003158|stage IIIA non-small cell lung cancer
1517974|NCT00003158|stage IIIB non-small cell lung cancer
1517975|NCT00003157|stage IV gastric cancer
1517976|NCT00003157|recurrent gastric cancer
1517977|NCT00003157|recurrent pancreatic cancer
1517978|NCT00003157|stage IV pancreatic cancer
1517979|NCT00003156|recurrent uterine sarcoma
1517980|NCT00003156|uterine carcinosarcoma
1517981|NCT00003154|stage IIIB non-small cell lung cancer
1517982|NCT00003154|stage IV non-small cell lung cancer
1517983|NCT00003153|refractory multiple myeloma
1517984|NCT00003152|stage III grade 1 follicular lymphoma
1517985|NCT00003152|stage III grade 2 follicular lymphoma
1517986|NCT00003152|stage III grade 3 follicular lymphoma
1517987|NCT00003152|stage IV grade 1 follicular lymphoma
1517988|NCT00003152|stage IV grade 2 follicular lymphoma
1517989|NCT00003152|stage IV grade 3 follicular lymphoma
1517990|NCT00003151|contiguous stage II marginal zone lymphoma
1517991|NCT00003151|contiguous stage II small lymphocytic lymphoma
1517992|NCT00003151|stage I marginal zone lymphoma
1517993|NCT00003151|stage I small lymphocytic lymphoma
1517994|NCT00003151|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1517995|NCT00003150|stage I adult diffuse mixed cell lymphoma
1517996|NCT00003150|stage I adult diffuse large cell lymphoma
1517997|NCT00003150|stage I adult immunoblastic large cell lymphoma
1517998|NCT00003150|stage III adult diffuse mixed cell lymphoma
1517999|NCT00003150|stage III adult diffuse large cell lymphoma
1518000|NCT00003150|stage III adult immunoblastic large cell lymphoma
1518001|NCT00003150|stage IV adult diffuse mixed cell lymphoma
1518002|NCT00003150|stage IV adult diffuse large cell lymphoma
1518003|NCT00003150|stage IV adult immunoblastic large cell lymphoma
1518004|NCT00003150|contiguous stage II adult diffuse mixed cell lymphoma
1518005|NCT00003150|contiguous stage II adult immunoblastic large cell lymphoma
1518006|NCT00003150|contiguous stage II adult diffuse large cell lymphoma
1518007|NCT00003150|noncontiguous stage II adult diffuse mixed cell lymphoma
1518008|NCT00003150|noncontiguous stage II adult immunoblastic large cell lymphoma
1518009|NCT00003150|noncontiguous stage II adult diffuse large cell lymphoma
1518010|NCT00003149|stage I multiple myeloma
1518011|NCT00003149|stage II multiple myeloma
1518012|NCT00003149|stage III multiple myeloma
1518013|NCT00003148|recurrent adult acute myeloid leukemia
1518014|NCT00003147|localized unresectable adult primary liver cancer
1518015|NCT00003147|adult primary hepatocellular carcinoma
1518016|NCT00003146|stage I multiple myeloma
1518017|NCT00003146|stage II multiple myeloma
1518018|NCT00003146|stage III multiple myeloma
1518019|NCT00003144|unspecified adult solid tumor, protocol specific
1518020|NCT00003144|drug/agent toxicity by tissue/organ
1518021|NCT00003143|recurrent adult Hodgkin lymphoma
1518022|NCT00003143|Waldenström macroglobulinemia
1518023|NCT00003143|recurrent grade 1 follicular lymphoma
1518024|NCT00003143|recurrent grade 2 follicular lymphoma
1518025|NCT00003143|recurrent grade 3 follicular lymphoma
1518026|NCT00003143|recurrent adult diffuse small cleaved cell lymphoma
1518027|NCT00003143|recurrent adult diffuse mixed cell lymphoma
1518028|NCT00003143|recurrent adult diffuse large cell lymphoma
1518029|NCT00003143|recurrent adult immunoblastic large cell lymphoma
1518030|NCT00003143|recurrent adult lymphoblastic lymphoma
1518031|NCT00003143|recurrent adult Burkitt lymphoma
1518032|NCT00003143|recurrent mantle cell lymphoma
1518033|NCT00003143|recurrent marginal zone lymphoma
1518034|NCT00003143|recurrent small lymphocytic lymphoma
1518035|NCT00003143|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1518036|NCT00003143|nodal marginal zone B-cell lymphoma
1518037|NCT00003143|splenic marginal zone lymphoma
1518038|NCT00003141|childhood infratentorial ependymoma
1518039|NCT00003141|childhood supratentorial ependymoma
1518040|NCT00003141|disseminated neuroblastoma
1518041|NCT00003141|stage 4S neuroblastoma
1518042|NCT00003141|embryonal childhood rhabdomyosarcoma
1518043|NCT00003141|childhood high-grade cerebral astrocytoma
1518044|NCT00003141|childhood choroid plexus tumor
1518045|NCT00003141|previously untreated childhood rhabdomyosarcoma
1518046|NCT00003141|untreated childhood brain stem glioma
1518047|NCT00003141|untreated childhood supratentorial primitive neuroectodermal tumor
1518048|NCT00003141|untreated childhood cerebellar astrocytoma
1518049|NCT00003141|untreated childhood medulloblastoma
1518050|NCT00003141|newly diagnosed childhood ependymoma
1518051|NCT00003141|localized resectable neuroblastoma
1518052|NCT00003141|localized unresectable neuroblastoma
1518053|NCT00003141|regional neuroblastoma
1518054|NCT00003141|childhood spinal cord neoplasm
1518055|NCT00003141|childhood atypical teratoid/rhabdoid tumor
1518056|NCT00003141|childhood low-grade cerebral astrocytoma
1518057|NCT00003141|childhood central nervous system choriocarcinoma
1518058|NCT00003141|childhood central nervous system embryonal tumor
1518059|NCT00003141|childhood central nervous system germinoma
1518060|NCT00003141|childhood central nervous system mixed germ cell tumor
1518061|NCT00003141|childhood central nervous system teratoma
1518062|NCT00003141|childhood central nervous system yolk sac tumor
1518063|NCT00003140|stage I breast cancer
1518064|NCT00003140|stage II breast cancer
1518065|NCT00003140|stage IIIA breast cancer
1518066|NCT00003139|oral complications
1518067|NCT00003139|lip and oral cavity squamous cell carcinoma
1518068|NCT00003139|oropharyngeal squamous cell carcinoma
1518069|NCT00003138|anemia
1518070|NCT00003138|refractory anemia
1518071|NCT00003138|myelodysplastic syndromes
1518072|NCT00003138|erythropoietin
1518073|NCT00003138|filgrastim
1518074|NCT00003137|stage IV gastric cancer
1518075|NCT00003137|stage IV esophageal cancer
1518076|NCT00003137|adenocarcinoma of the esophagus
1518077|NCT00003137|intestinal adenocarcinoma of the stomach
1518078|NCT00003137|diffuse adenocarcinoma of the stomach
1518079|NCT00003137|mixed adenocarcinoma of the stomach
1518080|NCT00003136|recurrent ovarian epithelial cancer
1518081|NCT00003136|primary peritoneal cavity cancer
1518082|NCT00003135|stage IV breast cancer
1518083|NCT00003135|recurrent breast cancer
1518084|NCT00003135|recurrent cervical cancer
1518085|NCT00003135|stage IVB cervical cancer
1518086|NCT00003135|stage IVA cervical cancer
1518087|NCT00003135|stage IV ovarian epithelial cancer
1518088|NCT00003135|recurrent ovarian epithelial cancer
1518089|NCT00003135|stage IV endometrial carcinoma
1518090|NCT00003135|recurrent endometrial carcinoma
1518091|NCT00003135|stage IV ovarian germ cell tumor
1518092|NCT00003135|recurrent ovarian germ cell tumor
1518093|NCT00003135|male breast cancer
1518094|NCT00003134|recurrent adult brain tumor
1518095|NCT00003134|adult brain stem glioma
1518096|NCT00003134|adult oligodendroglioma
1518097|NCT00003134|adult mixed glioma
1518098|NCT00003134|adult diffuse astrocytoma
1518099|NCT00003133|stage III bladder cancer
1518100|NCT00003133|stage IV bladder cancer
1518101|NCT00003133|transitional cell carcinoma of the bladder
1518102|NCT00003133|metastatic transitional cell cancer of the renal pelvis and ureter
1518103|NCT00003133|regional transitional cell cancer of the renal pelvis and ureter
1518104|NCT00003132|unspecified adult solid tumor, protocol specific
1518105|NCT00003131|recurrent adult acute myeloid leukemia
1518106|NCT00003130|unspecified adult solid tumor, protocol specific
1518107|NCT00003129|stage 0 bladder cancer
1518108|NCT00003129|stage I bladder cancer
1518109|NCT00003129|transitional cell carcinoma of the bladder
1518110|NCT00003128|stage III uterine sarcoma
1518111|NCT00003128|stage IV uterine sarcoma
1518112|NCT00003128|recurrent uterine sarcoma
1518113|NCT00003128|uterine carcinosarcoma
1518114|NCT00003127|stage IV endometrial carcinoma
1518115|NCT00003127|recurrent endometrial carcinoma
1518116|NCT00003127|endometrial adenocarcinoma
1518117|NCT00003127|endometrial adenosquamous cell carcinoma
1518118|NCT00003127|endometrial clear cell carcinoma
1518119|NCT00003126|renal cell cancer
1518120|NCT00003126|renal cell carcinoma
1518121|NCT00003126|interleukin-2
1518122|NCT00003125|stage IV breast cancer
1518123|NCT00003125|stage IIIA breast cancer
1518124|NCT00003125|stage III gastric cancer
1518125|NCT00003125|stage IV gastric cancer
1518126|NCT00003125|stage IIIB breast cancer
1518127|NCT00003125|stage II pancreatic cancer
1518128|NCT00003125|stage III pancreatic cancer
1518129|NCT00003125|stage II esophageal cancer
1518130|NCT00003125|stage III esophageal cancer
1518131|NCT00003125|stage IIIA non-small cell lung cancer
1518132|NCT00003125|stage IIIB non-small cell lung cancer
1518133|NCT00003125|unspecified adult solid tumor, protocol specific
1518134|NCT00003125|stage IV pancreatic cancer
1518135|NCT00003124|adenocarcinoma of the prostate
1518136|NCT00003124|stage I prostate cancer
1518137|NCT00003124|stage IIB prostate cancer
1518138|NCT00003124|stage IIA prostate cancer
1518139|NCT00003124|stage III prostate cancer
1518140|NCT00003123|refractory anemia
1518141|NCT00003123|refractory anemia with ringed sideroblasts
1518142|NCT00003123|refractory anemia with excess blasts
1518143|NCT00003123|refractory anemia with excess blasts in transformation
1518144|NCT00003122|localized resectable neuroblastoma
1518145|NCT00003122|localized unresectable neuroblastoma
1518146|NCT00003120|stage III ovarian epithelial cancer
1518147|NCT00003120|stage IV ovarian epithelial cancer
1518148|NCT00003120|recurrent ovarian epithelial cancer
1518149|NCT00003120|fallopian tube cancer
1518150|NCT00003120|peritoneal cavity cancer
1518151|NCT00003119|localized resectable neuroblastoma
1518152|NCT00003119|stage 4S neuroblastoma
1518153|NCT00003118|stage I esophageal cancer
1518154|NCT00003118|stage II esophageal cancer
1518155|NCT00003118|stage III esophageal cancer
1518156|NCT00003118|squamous cell carcinoma of the esophagus
1518157|NCT00003118|adenocarcinoma of the esophagus
1518158|NCT00003117|recurrent non-small cell lung cancer
1518159|NCT00003117|squamous cell lung cancer
1518160|NCT00003117|large cell lung cancer
1518161|NCT00003117|stage IIIB non-small cell lung cancer
1518162|NCT00003117|stage IV non-small cell lung cancer
1518163|NCT00003117|adenocarcinoma of the lung
1518164|NCT00003117|adenosquamous cell lung cancer
1518165|NCT00003116|recurrent childhood acute lymphoblastic leukemia
1518166|NCT00003116|recurrent adult Hodgkin lymphoma
1518167|NCT00003116|refractory multiple myeloma
1519424|NCT00002933|stage IV rectal cancer
1518168|NCT00003116|recurrent childhood lymphoblastic lymphoma
1518169|NCT00003116|recurrent childhood acute myeloid leukemia
1518170|NCT00003116|recurrent adult acute myeloid leukemia
1518171|NCT00003116|recurrent adult acute lymphoblastic leukemia
1518172|NCT00003116|adult acute myeloid leukemia in remission
1518173|NCT00003116|adult acute lymphoblastic leukemia in remission
1518174|NCT00003116|childhood acute myeloid leukemia in remission
1518175|NCT00003116|childhood acute lymphoblastic leukemia in remission
1518176|NCT00003116|recurrent/refractory childhood Hodgkin lymphoma
1518177|NCT00003116|recurrent grade 1 follicular lymphoma
1518178|NCT00003116|recurrent grade 2 follicular lymphoma
1518179|NCT00003116|recurrent grade 3 follicular lymphoma
1518180|NCT00003116|recurrent adult diffuse small cleaved cell lymphoma
1518181|NCT00003116|recurrent adult diffuse mixed cell lymphoma
1518182|NCT00003116|recurrent adult diffuse large cell lymphoma
1518183|NCT00003116|recurrent adult immunoblastic large cell lymphoma
1518184|NCT00003116|recurrent adult lymphoblastic lymphoma
1518185|NCT00003116|recurrent adult Burkitt lymphoma
1518186|NCT00003116|de novo myelodysplastic syndromes
1518187|NCT00003116|previously treated myelodysplastic syndromes
1518188|NCT00003116|secondary myelodysplastic syndromes
1518189|NCT00003116|recurrent childhood small noncleaved cell lymphoma
1518190|NCT00003116|recurrent childhood large cell lymphoma
1518191|NCT00003116|recurrent mantle cell lymphoma
1518192|NCT00003116|atypical chronic myeloid leukemia
1518193|NCT00003116|myelodysplastic/myeloproliferative disease, unclassifiable
1518194|NCT00003116|recurrent marginal zone lymphoma
1518195|NCT00003116|recurrent small lymphocytic lymphoma
1518196|NCT00003116|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1518197|NCT00003116|nodal marginal zone B-cell lymphoma
1518198|NCT00003116|splenic marginal zone lymphoma
1518199|NCT00003116|adult acute myeloid leukemia with t(8;21)(q22;q22)
1518200|NCT00003116|adult acute myeloid leukemia with t(16;16)(p13;q22)
1518201|NCT00003116|adult acute myeloid leukemia with inv(16)(p13;q22)
1518202|NCT00003116|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1518203|NCT00003116|adult acute myeloid leukemia with t(15;17)(q22;q12)
1518204|NCT00003116|childhood myelodysplastic syndromes
1518205|NCT00003115|prostate cancer
1518206|NCT00003115|pain
1518207|NCT00003114|AIDS-related lymphoma
1518208|NCT00003114|HIV-associated Hodgkin lymphoma
1518209|NCT00003113|stage I grade 3 follicular lymphoma
1518210|NCT00003113|stage I adult diffuse small cleaved cell lymphoma
1518211|NCT00003113|stage I adult diffuse mixed cell lymphoma
1518212|NCT00003113|stage I adult diffuse large cell lymphoma
1518213|NCT00003113|stage I adult immunoblastic large cell lymphoma
1518214|NCT00003113|stage I adult lymphoblastic lymphoma
1518215|NCT00003113|stage I adult Burkitt lymphoma
1518216|NCT00003113|stage III grade 3 follicular lymphoma
1518217|NCT00003113|stage III adult diffuse small cleaved cell lymphoma
1518218|NCT00003113|stage III adult diffuse mixed cell lymphoma
1518219|NCT00003113|stage III adult diffuse large cell lymphoma
1518220|NCT00003113|stage III adult immunoblastic large cell lymphoma
1518221|NCT00003113|stage III adult lymphoblastic lymphoma
1518222|NCT00003113|stage III adult Burkitt lymphoma
1518223|NCT00003113|stage IV grade 3 follicular lymphoma
1518224|NCT00003113|stage IV adult diffuse small cleaved cell lymphoma
1518225|NCT00003113|stage IV adult diffuse mixed cell lymphoma
1518226|NCT00003113|stage IV adult diffuse large cell lymphoma
1518227|NCT00003113|stage IV adult immunoblastic large cell lymphoma
1518228|NCT00003113|stage IV adult lymphoblastic lymphoma
1518229|NCT00003113|stage IV adult Burkitt lymphoma
1518230|NCT00003113|stage I mantle cell lymphoma
1518231|NCT00003113|contiguous stage II grade 3 follicular lymphoma
1518232|NCT00003113|contiguous stage II adult diffuse small cleaved cell lymphoma
1518233|NCT00003113|contiguous stage II mantle cell lymphoma
1518234|NCT00003113|contiguous stage II adult diffuse mixed cell lymphoma
1518235|NCT00003113|contiguous stage II adult immunoblastic large cell lymphoma
1518236|NCT00003113|contiguous stage II adult diffuse large cell lymphoma
1518237|NCT00003113|contiguous stage II adult Burkitt lymphoma
1518238|NCT00003113|contiguous stage II adult lymphoblastic lymphoma
1518239|NCT00003113|noncontiguous stage II grade 3 follicular lymphoma
1518240|NCT00003113|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1518241|NCT00003113|noncontiguous stage II mantle cell lymphoma
1518242|NCT00003113|noncontiguous stage II adult diffuse mixed cell lymphoma
1518243|NCT00003113|noncontiguous stage II adult immunoblastic large cell lymphoma
1518244|NCT00003113|noncontiguous stage II adult diffuse large cell lymphoma
1518245|NCT00003113|noncontiguous stage II adult Burkitt lymphoma
1518246|NCT00003113|noncontiguous stage II adult lymphoblastic lymphoma
1518247|NCT00003113|stage III mantle cell lymphoma
1518248|NCT00003113|stage IV mantle cell lymphoma
1518249|NCT00003113|stage II mantle cell lymphoma
1518250|NCT00003111|stage IIIA non-small cell lung cancer
1518251|NCT00003110|recurrent childhood lymphoblastic lymphoma
1518252|NCT00003110|recurrent grade 3 follicular lymphoma
1518253|NCT00003110|recurrent adult diffuse small cleaved cell lymphoma
1518254|NCT00003110|recurrent adult diffuse mixed cell lymphoma
1518255|NCT00003110|recurrent adult diffuse large cell lymphoma
1518256|NCT00003110|recurrent adult immunoblastic large cell lymphoma
1519425|NCT00002933|recurrent colon cancer
1518257|NCT00003110|recurrent adult lymphoblastic lymphoma
1518258|NCT00003110|recurrent adult Burkitt lymphoma
1518259|NCT00003110|AIDS-related peripheral/systemic lymphoma
1518260|NCT00003110|AIDS-related diffuse large cell lymphoma
1518261|NCT00003110|AIDS-related immunoblastic large cell lymphoma
1518262|NCT00003110|AIDS-related small noncleaved cell lymphoma
1518263|NCT00003110|AIDS-related diffuse mixed cell lymphoma
1518264|NCT00003110|AIDS-related diffuse small cleaved cell lymphoma
1518265|NCT00003110|AIDS-related lymphoblastic lymphoma
1518266|NCT00003110|recurrent childhood small noncleaved cell lymphoma
1518267|NCT00003110|recurrent childhood large cell lymphoma
1518268|NCT00003110|recurrent mantle cell lymphoma
1518269|NCT00003109|unspecified adult solid tumor, protocol specific
1518270|NCT00003108|unspecified adult solid tumor, protocol specific
1518271|NCT00003107|stage IV breast cancer
1518272|NCT00003107|stage IIIA breast cancer
1518273|NCT00003107|stage IIIB breast cancer
1518274|NCT00003107|recurrent adult Hodgkin lymphoma
1518275|NCT00003107|recurrent cutaneous T-cell non-Hodgkin lymphoma
1518276|NCT00003107|refractory multiple myeloma
1518277|NCT00003107|stage II ovarian epithelial cancer
1518278|NCT00003107|stage III ovarian epithelial cancer
1518279|NCT00003107|stage IV ovarian epithelial cancer
1518280|NCT00003107|recurrent ovarian epithelial cancer
1518281|NCT00003107|disseminated neuroblastoma
1518282|NCT00003107|recurrent neuroblastoma
1518283|NCT00003107|recurrent Wilms tumor and other childhood kidney tumors
1518284|NCT00003107|stage I multiple myeloma
1518285|NCT00003107|stage II multiple myeloma
1518286|NCT00003107|stage III multiple myeloma
1518287|NCT00003107|stage III chronic lymphocytic leukemia
1518288|NCT00003107|stage IV chronic lymphocytic leukemia
1518289|NCT00003107|recurrent adult acute myeloid leukemia
1518290|NCT00003107|recurrent adult acute lymphoblastic leukemia
1518291|NCT00003107|relapsing chronic myelogenous leukemia
1518292|NCT00003107|refractory chronic lymphocytic leukemia
1518293|NCT00003107|stage III malignant testicular germ cell tumor
1518294|NCT00003107|recurrent malignant testicular germ cell tumor
1518295|NCT00003107|chronic phase chronic myelogenous leukemia
1518296|NCT00003107|accelerated phase chronic myelogenous leukemia
1518297|NCT00003107|blastic phase chronic myelogenous leukemia
1518298|NCT00003107|meningeal chronic myelogenous leukemia
1518299|NCT00003107|chronic idiopathic myelofibrosis
1518300|NCT00003107|testicular embryonal carcinoma
1518301|NCT00003107|testicular choriocarcinoma
1518302|NCT00003107|testicular teratoma
1518303|NCT00003107|testicular yolk sac tumor
1518304|NCT00003107|testicular embryonal carcinoma and teratoma
1518305|NCT00003107|testicular embryonal carcinoma and teratoma with seminoma
1518306|NCT00003107|testicular embryonal carcinoma and yolk sac tumor
1518307|NCT00003107|testicular embryonal carcinoma and yolk sac tumor with seminoma
1518308|NCT00003107|testicular embryonal carcinoma and seminoma
1518309|NCT00003107|testicular yolk sac tumor and teratoma
1518310|NCT00003107|testicular yolk sac tumor and teratoma with seminoma
1518311|NCT00003107|testicular choriocarcinoma and yolk sac tumor
1518312|NCT00003107|testicular choriocarcinoma and embryonal carcinoma
1518313|NCT00003107|testicular choriocarcinoma and teratoma
1518314|NCT00003107|testicular choriocarcinoma and seminoma
1518315|NCT00003107|refractory hairy cell leukemia
1518316|NCT00003107|recurrent ovarian germ cell tumor
1518317|NCT00003107|ovarian yolk sac tumor
1518318|NCT00003107|ovarian embryonal carcinoma
1518319|NCT00003107|ovarian polyembryoma
1518320|NCT00003107|ovarian choriocarcinoma
1518321|NCT00003107|ovarian immature teratoma
1518322|NCT00003107|ovarian mature teratoma
1518323|NCT00003107|ovarian monodermal and highly specialized teratoma
1518324|NCT00003107|ovarian mixed germ cell tumor
1518325|NCT00003107|stage III grade 1 follicular lymphoma
1518326|NCT00003107|stage III grade 2 follicular lymphoma
1518327|NCT00003107|stage III grade 3 follicular lymphoma
1518328|NCT00003107|stage III adult diffuse small cleaved cell lymphoma
1518329|NCT00003107|stage III adult diffuse mixed cell lymphoma
1518330|NCT00003107|stage III adult diffuse large cell lymphoma
1518331|NCT00003107|stage III adult immunoblastic large cell lymphoma
1518332|NCT00003107|stage III adult lymphoblastic lymphoma
1518333|NCT00003107|stage III adult Burkitt lymphoma
1518334|NCT00003107|stage IV grade 1 follicular lymphoma
1518335|NCT00003107|stage IV grade 2 follicular lymphoma
1518336|NCT00003107|stage IV grade 3 follicular lymphoma
1518337|NCT00003107|stage IV adult diffuse small cleaved cell lymphoma
1518338|NCT00003107|stage IV adult diffuse mixed cell lymphoma
1518339|NCT00003107|stage IV adult diffuse large cell lymphoma
1518340|NCT00003107|stage IV adult immunoblastic large cell lymphoma
1518341|NCT00003107|stage IV adult lymphoblastic lymphoma
1518342|NCT00003107|stage IV adult Burkitt lymphoma
1518343|NCT00003107|recurrent grade 1 follicular lymphoma
1518344|NCT00003107|recurrent grade 2 follicular lymphoma
1518345|NCT00003107|recurrent grade 3 follicular lymphoma
1518346|NCT00003107|recurrent adult diffuse small cleaved cell lymphoma
1518347|NCT00003107|recurrent adult diffuse mixed cell lymphoma
1518348|NCT00003107|recurrent adult diffuse large cell lymphoma
1518349|NCT00003107|recurrent adult immunoblastic large cell lymphoma
1518350|NCT00003107|recurrent adult lymphoblastic lymphoma
1518351|NCT00003107|recurrent adult Burkitt lymphoma
1518352|NCT00003107|secondary acute myeloid leukemia
1518353|NCT00003107|de novo myelodysplastic syndromes
1518354|NCT00003107|poor prognosis metastatic gestational trophoblastic tumor
1518355|NCT00003107|previously treated myelodysplastic syndromes
1518356|NCT00003107|secondary myelodysplastic syndromes
1518357|NCT00003107|noncontiguous stage II grade 1 follicular lymphoma
1518358|NCT00003107|noncontiguous stage II grade 2 follicular lymphoma
1518359|NCT00003107|noncontiguous stage II grade 3 follicular lymphoma
1518360|NCT00003107|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1518361|NCT00003107|noncontiguous stage II mantle cell lymphoma
1518362|NCT00003107|noncontiguous stage II adult diffuse mixed cell lymphoma
1518363|NCT00003107|noncontiguous stage II adult immunoblastic large cell lymphoma
1518364|NCT00003107|noncontiguous stage II adult diffuse large cell lymphoma
1518365|NCT00003107|noncontiguous stage II adult Burkitt lymphoma
1518366|NCT00003107|noncontiguous stage II adult lymphoblastic lymphoma
1518367|NCT00003107|stage III mantle cell lymphoma
1518368|NCT00003107|stage IV mantle cell lymphoma
1518369|NCT00003107|recurrent mantle cell lymphoma
1518370|NCT00003107|recurrent mycosis fungoides/Sezary syndrome
1518371|NCT00003107|noncontiguous stage II small lymphocytic lymphoma
1518372|NCT00003107|noncontiguous stage II marginal zone lymphoma
1518373|NCT00003107|recurrent marginal zone lymphoma
1518374|NCT00003107|recurrent small lymphocytic lymphoma
1518375|NCT00003107|stage III small lymphocytic lymphoma
1518376|NCT00003107|stage III marginal zone lymphoma
1518377|NCT00003107|stage IV small lymphocytic lymphoma
1518378|NCT00003107|stage IV marginal zone lymphoma
1518379|NCT00003107|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1518380|NCT00003107|nodal marginal zone B-cell lymphoma
1518381|NCT00003107|splenic marginal zone lymphoma
1518382|NCT00003105|stage III bladder cancer
1518383|NCT00003105|recurrent bladder cancer
1518384|NCT00003105|stage IV bladder cancer
1518385|NCT00003105|transitional cell carcinoma of the bladder
1518386|NCT00003105|metastatic transitional cell cancer of the renal pelvis and ureter
1518387|NCT00003105|regional transitional cell cancer of the renal pelvis and ureter
1518388|NCT00003105|recurrent transitional cell cancer of the renal pelvis and ureter
1518389|NCT00003104|adenocarcinoma of the prostate
1518390|NCT00003104|stage IIB prostate cancer
1518391|NCT00003104|stage IIA prostate cancer
1518392|NCT00003103|stage III colon cancer
1518393|NCT00003103|stage IV colon cancer
1518394|NCT00003103|stage IV breast cancer
1518395|NCT00003103|stage IIIA breast cancer
1518396|NCT00003103|recurrent breast cancer
1518397|NCT00003103|stage IIIB breast cancer
1518398|NCT00003103|recurrent non-small cell lung cancer
1518399|NCT00003103|stage III rectal cancer
1518400|NCT00003103|stage IV rectal cancer
1518401|NCT00003103|recurrent colon cancer
1518402|NCT00003103|recurrent rectal cancer
1518403|NCT00003103|stage II esophageal cancer
1518404|NCT00003103|stage III esophageal cancer
1518405|NCT00003103|stage IV esophageal cancer
1518406|NCT00003103|recurrent esophageal cancer
1518407|NCT00003103|stage III renal cell cancer
1518408|NCT00003103|stage IV renal cell cancer
1518409|NCT00003103|recurrent renal cell cancer
1518410|NCT00003103|stage III ovarian epithelial cancer
1518411|NCT00003103|stage IV ovarian epithelial cancer
1518412|NCT00003103|recurrent ovarian epithelial cancer
1518413|NCT00003103|stage III Wilms tumor
1518414|NCT00003103|stage IV Wilms tumor
1518415|NCT00003103|stage V Wilms tumor
1518416|NCT00003103|recurrent Wilms tumor and other childhood kidney tumors
1518417|NCT00003103|stage III bladder cancer
1518418|NCT00003103|recurrent bladder cancer
1518419|NCT00003103|stage IV bladder cancer
1518420|NCT00003103|stage III prostate cancer
1518421|NCT00003103|stage IV prostate cancer
1518422|NCT00003103|recurrent prostate cancer
1518423|NCT00003103|stage IIIA non-small cell lung cancer
1518424|NCT00003103|stage IIIB non-small cell lung cancer
1518425|NCT00003103|stage IV non-small cell lung cancer
1518426|NCT00003103|unspecified adult solid tumor, protocol specific
1518427|NCT00003103|untreated metastatic squamous neck cancer with occult primary
1518428|NCT00003103|recurrent metastatic squamous neck cancer with occult primary
1518429|NCT00003103|ovarian stromal cancer
1518430|NCT00003103|stage III ovarian germ cell tumor
1518431|NCT00003103|stage IV ovarian germ cell tumor
1518432|NCT00003103|recurrent ovarian germ cell tumor
1518433|NCT00003103|stage III squamous cell carcinoma of the lip and oral cavity
1518434|NCT00003103|stage III basal cell carcinoma of the lip
1518435|NCT00003103|stage III verrucous carcinoma of the oral cavity
1518436|NCT00003103|stage III mucoepidermoid carcinoma of the oral cavity
1518437|NCT00003103|stage III adenoid cystic carcinoma of the oral cavity
1518438|NCT00003103|stage IV squamous cell carcinoma of the lip and oral cavity
1518439|NCT00003103|stage IV basal cell carcinoma of the lip
1518440|NCT00003103|stage IV verrucous carcinoma of the oral cavity
1518441|NCT00003103|stage IV mucoepidermoid carcinoma of the oral cavity
1518442|NCT00003103|stage IV adenoid cystic carcinoma of the oral cavity
1518443|NCT00003103|recurrent squamous cell carcinoma of the lip and oral cavity
1518444|NCT00003103|recurrent basal cell carcinoma of the lip
1518445|NCT00003103|recurrent verrucous carcinoma of the oral cavity
1518446|NCT00003103|recurrent mucoepidermoid carcinoma of the oral cavity
1518447|NCT00003103|recurrent adenoid cystic carcinoma of the oral cavity
1518448|NCT00003103|stage III squamous cell carcinoma of the oropharynx
1518449|NCT00003103|stage III lymphoepithelioma of the oropharynx
1518450|NCT00003103|stage IV squamous cell carcinoma of the oropharynx
1518451|NCT00003103|stage IV lymphoepithelioma of the oropharynx
1518452|NCT00003103|recurrent squamous cell carcinoma of the oropharynx
1518453|NCT00003103|recurrent lymphoepithelioma of the oropharynx
1518454|NCT00003103|stage III squamous cell carcinoma of the nasopharynx
1518455|NCT00003103|stage III lymphoepithelioma of the nasopharynx
1518456|NCT00003103|stage IV squamous cell carcinoma of the nasopharynx
1518457|NCT00003103|stage IV lymphoepithelioma of the nasopharynx
1518458|NCT00003103|recurrent squamous cell carcinoma of the nasopharynx
1518459|NCT00003103|recurrent lymphoepithelioma of the nasopharynx
1518460|NCT00003103|stage III squamous cell carcinoma of the hypopharynx
1518461|NCT00003103|stage IV squamous cell carcinoma of the hypopharynx
1518462|NCT00003103|recurrent squamous cell carcinoma of the hypopharynx
1518463|NCT00003103|stage III squamous cell carcinoma of the larynx
1518464|NCT00003103|stage III verrucous carcinoma of the larynx
1518465|NCT00003103|stage IV squamous cell carcinoma of the larynx
1518466|NCT00003103|stage IV verrucous carcinoma of the larynx
1518467|NCT00003103|recurrent squamous cell carcinoma of the larynx
1518468|NCT00003103|recurrent verrucous carcinoma of the larynx
1518469|NCT00003103|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1518470|NCT00003103|stage III inverted papilloma of the paranasal sinus and nasal cavity
1518471|NCT00003103|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1518472|NCT00003103|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1518473|NCT00003103|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1518474|NCT00003103|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1518475|NCT00003103|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1518476|NCT00003103|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1518477|NCT00003103|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1518478|NCT00003103|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1518479|NCT00003103|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1518480|NCT00003103|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1518481|NCT00003103|borderline ovarian surface epithelial-stromal tumor
1518482|NCT00003103|ovarian sarcoma
1518483|NCT00003103|clear cell sarcoma of the kidney
1518484|NCT00003103|rhabdoid tumor of the kidney
1518485|NCT00003102|stage IV renal cell cancer
1518486|NCT00003102|recurrent renal cell cancer
1518487|NCT00003101|adult oligodendroglioma
1518488|NCT00003101|adult anaplastic oligodendroglioma
1518489|NCT00003100|unspecified adult solid tumor, protocol specific
1518490|NCT00003099|breast cancer
1518491|NCT00003099|Tamoxifen
1518492|NCT00003099|Fenretinide
1518493|NCT00003099|Chemoprevention Therapy
1518494|NCT00003099|N-(4-hydroxyphenyl) Retinamide
1518495|NCT00003099|4-HPR
1518496|NCT00003099|Breast Neoplasia
1518497|NCT00003099|Diagnostic Core Biopsy
1518498|NCT00003099|Surgery
1518499|NCT00003098|breast cancer
1518500|NCT00003097|basal cell carcinoma of the skin
1518501|NCT00003097|squamous cell carcinoma of the skin
1518502|NCT00003096|untreated childhood supratentorial primitive neuroectodermal tumor
1518503|NCT00003096|untreated childhood medulloblastoma
1518504|NCT00003095|stage II breast cancer
1518505|NCT00003095|stage III breast cancer
1518506|NCT00003094|cervical cancer
1518507|NCT00003093|regional neuroblastoma
1518508|NCT00003093|disseminated neuroblastoma
1518509|NCT00003093|stage 4S neuroblastoma
1518510|NCT00003093|localized unresectable neuroblastoma
1518511|NCT00003092|unspecified adult solid tumor, protocol specific
1518512|NCT00003091|stage IV renal cell cancer
1518513|NCT00003091|recurrent renal cell cancer
1518514|NCT00003091|stage IV melanoma
1518515|NCT00003091|recurrent melanoma
1518516|NCT00003090|recurrent non-small cell lung cancer
1518517|NCT00003089|stage II non-small cell lung cancer
1518518|NCT00003089|squamous cell lung cancer
1518519|NCT00003089|large cell lung cancer
1518520|NCT00003089|stage IIIA non-small cell lung cancer
1518521|NCT00003089|stage IIIB non-small cell lung cancer
1522247|NCT00002511|stage I prostate cancer
1518522|NCT00003089|adenocarcinoma of the lung
1518523|NCT00003089|drug/agent toxicity by tissue/organ
1518524|NCT00003088|stage II breast cancer
1518525|NCT00003088|stage IIIA breast cancer
1518526|NCT00003087|stage II esophageal cancer
1518527|NCT00003087|stage III esophageal cancer
1518528|NCT00003087|squamous cell carcinoma of the esophagus
1518529|NCT00003087|adenocarcinoma of the esophagus
1518530|NCT00003086|stage IV breast cancer
1518531|NCT00003085|stage I pancreatic cancer
1518532|NCT00003085|stage II pancreatic cancer
1518533|NCT00003084|adenocarcinoma of the prostate
1518534|NCT00003084|stage I prostate cancer
1518535|NCT00003084|stage II prostate cancer
1518536|NCT00003084|stage III prostate cancer
1518537|NCT00003084|stage IV prostate cancer
1518538|NCT00003084|recurrent prostate cancer
1518539|NCT00003084|Chemotherapy
1518540|NCT00003084|Ketoconazole
1518541|NCT00003084|Estramustine
1518542|NCT00003084|Etoposide
1518543|NCT00003084|Paclitaxel
1518544|NCT00003084|Doxorubicin
1518545|NCT00003084|Vinblastine
1518546|NCT00003082|stage III adult Hodgkin lymphoma
1518547|NCT00003082|stage IV adult Hodgkin lymphoma
1518548|NCT00003082|monoclonal gammopathy of undetermined significance
1518549|NCT00003082|recurrent adult Hodgkin lymphoma
1518550|NCT00003082|isolated plasmacytoma of bone
1518551|NCT00003082|extramedullary plasmacytoma
1518552|NCT00003082|refractory multiple myeloma
1518553|NCT00003082|Waldenstrom macroglobulinemia
1518554|NCT00003082|stage III multiple myeloma
1518555|NCT00003082|stage III chronic lymphocytic leukemia
1518556|NCT00003082|stage IV chronic lymphocytic leukemia
1518557|NCT00003082|recurrent adult acute myeloid leukemia
1518558|NCT00003082|recurrent adult acute lymphoblastic leukemia
1518559|NCT00003082|relapsing chronic myelogenous leukemia
1518560|NCT00003082|refractory chronic lymphocytic leukemia
1518561|NCT00003082|unspecified adult solid tumor, protocol specific
1518562|NCT00003082|chronic phase chronic myelogenous leukemia
1518563|NCT00003082|accelerated phase chronic myelogenous leukemia
1518564|NCT00003082|blastic phase chronic myelogenous leukemia
1518565|NCT00003082|meningeal chronic myelogenous leukemia
1518566|NCT00003082|untreated adult acute lymphoblastic leukemia
1518567|NCT00003082|untreated adult acute myeloid leukemia
1518568|NCT00003082|adult acute myeloid leukemia in remission
1518569|NCT00003082|adult acute lymphoblastic leukemia in remission
1518570|NCT00003082|polycythemia vera
1518571|NCT00003082|chronic idiopathic myelofibrosis
1518572|NCT00003082|essential thrombocythemia
1518573|NCT00003082|untreated hairy cell leukemia
1518574|NCT00003082|progressive hairy cell leukemia, initial treatment
1518575|NCT00003082|refractory hairy cell leukemia
1518576|NCT00003082|chronic myelomonocytic leukemia
1518577|NCT00003082|T-cell large granular lymphocyte leukemia
1518578|NCT00003082|acute undifferentiated leukemia
1518579|NCT00003082|stage III grade 1 follicular lymphoma
1518580|NCT00003082|stage III grade 2 follicular lymphoma
1518581|NCT00003082|stage III grade 3 follicular lymphoma
1518582|NCT00003082|stage III adult diffuse small cleaved cell lymphoma
1518583|NCT00003082|stage III adult diffuse mixed cell lymphoma
1518584|NCT00003082|stage III adult diffuse large cell lymphoma
1518585|NCT00003082|stage III adult immunoblastic large cell lymphoma
1518586|NCT00003082|stage III adult lymphoblastic lymphoma
1518587|NCT00003082|stage III adult Burkitt lymphoma
1518588|NCT00003082|stage IV grade 1 follicular lymphoma
1518589|NCT00003082|stage IV grade 2 follicular lymphoma
1518590|NCT00003082|stage IV grade 3 follicular lymphoma
1518591|NCT00003082|stage IV adult diffuse small cleaved cell lymphoma
1518592|NCT00003082|stage IV adult diffuse mixed cell lymphoma
1518593|NCT00003082|stage IV adult diffuse large cell lymphoma
1518594|NCT00003082|stage IV adult immunoblastic large cell lymphoma
1518595|NCT00003082|stage IV adult lymphoblastic lymphoma
1518596|NCT00003082|stage IV adult Burkitt lymphoma
1518597|NCT00003082|recurrent grade 1 follicular lymphoma
1518598|NCT00003082|recurrent grade 2 follicular lymphoma
1518599|NCT00003082|recurrent grade 3 follicular lymphoma
1518600|NCT00003082|recurrent adult diffuse small cleaved cell lymphoma
1518601|NCT00003082|recurrent adult diffuse mixed cell lymphoma
1518602|NCT00003082|recurrent adult diffuse large cell lymphoma
1518603|NCT00003082|recurrent adult immunoblastic large cell lymphoma
1518604|NCT00003082|recurrent adult lymphoblastic lymphoma
1518605|NCT00003082|recurrent adult Burkitt lymphoma
1518606|NCT00003082|stage III adult T-cell leukemia/lymphoma
1518607|NCT00003082|stage IV adult T-cell leukemia/lymphoma
1518608|NCT00003082|recurrent adult T-cell leukemia/lymphoma
1518609|NCT00003082|secondary acute myeloid leukemia
1518610|NCT00003082|de novo myelodysplastic syndromes
1518611|NCT00003082|previously treated myelodysplastic syndromes
1518612|NCT00003082|secondary myelodysplastic syndromes
1518613|NCT00003082|prolymphocytic leukemia
1518614|NCT00003082|AIDS-related peripheral/systemic lymphoma
1518615|NCT00003082|AIDS-related primary CNS lymphoma
1518616|NCT00003082|primary systemic amyloidosis
1518617|NCT00003082|stage III mantle cell lymphoma
1518618|NCT00003082|stage IV mantle cell lymphoma
1518619|NCT00003082|recurrent mantle cell lymphoma
1518620|NCT00003082|angioimmunoblastic T-cell lymphoma
1518621|NCT00003082|anaplastic large cell lymphoma
1518622|NCT00003082|recurrent marginal zone lymphoma
1518623|NCT00003082|recurrent small lymphocytic lymphoma
1518624|NCT00003082|stage III small lymphocytic lymphoma
1518625|NCT00003082|stage III marginal zone lymphoma
1518626|NCT00003082|stage IV small lymphocytic lymphoma
1518627|NCT00003082|stage IV marginal zone lymphoma
1518628|NCT00003082|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1518629|NCT00003082|nodal marginal zone B-cell lymphoma
1518630|NCT00003082|splenic marginal zone lymphoma
1518631|NCT00003081|recurrent childhood rhabdomyosarcoma
1518632|NCT00003081|recurrent adult soft tissue sarcoma
1518633|NCT00003081|adult rhabdomyosarcoma
1518634|NCT00003081|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1518635|NCT00003080|stage III ovarian epithelial cancer
1518636|NCT00003080|stage IV ovarian epithelial cancer
1518637|NCT00003080|recurrent ovarian epithelial cancer
1518638|NCT00003079|recurrent adult acute myeloid leukemia
1518639|NCT00003079|recurrent adult acute lymphoblastic leukemia
1518640|NCT00003079|blastic phase chronic myelogenous leukemia
1518641|NCT00003079|recurrent adult lymphoblastic lymphoma
1518642|NCT00003078|stage III cervical cancer
1518643|NCT00003078|stage IIB cervical cancer
1518644|NCT00003078|stage IVA cervical cancer
1518645|NCT00003078|cervical squamous cell carcinoma
1518646|NCT00003078|cervical adenocarcinoma
1518647|NCT00003078|cervical adenosquamous cell carcinoma
1518648|NCT00003076|esophageal cancer
1518649|NCT00003075|cervical cancer
1518650|NCT00003075|cervical intraepithelial neoplasia grade 2
1518651|NCT00003075|cervical intraepithelial neoplasia grade 3
1518652|NCT00003073|recurrent childhood acute lymphoblastic leukemia
1518653|NCT00003073|recurrent childhood lymphoblastic lymphoma
1518654|NCT00003073|recurrent childhood acute myeloid leukemia
1518655|NCT00003073|childhood diffuse large cell lymphoma
1518656|NCT00003073|childhood immunoblastic large cell lymphoma
1518657|NCT00003073|unspecified childhood solid tumor, protocol specific
1518658|NCT00003073|recurrent/refractory childhood Hodgkin lymphoma
1518659|NCT00003073|leptomeningeal metastases
1518660|NCT00003073|recurrent childhood small noncleaved cell lymphoma
1518661|NCT00003073|recurrent childhood large cell lymphoma
1518662|NCT00003072|stage III non-small cell lung cancer
1518663|NCT00003072|stage III ovarian epithelial cancer
1518664|NCT00003072|stage IV ovarian epithelial cancer
1518665|NCT00003072|stage IV non-small cell lung cancer
1518666|NCT00003072|neurotoxicity
1518667|NCT00003070|unspecified childhood solid tumor, protocol specific
1518668|NCT00003070|cardiac toxicity
1518669|NCT00003068|stage IV breast cancer
1518670|NCT00003068|stage IIIA breast cancer
1518671|NCT00003068|recurrent breast cancer
1518672|NCT00003068|stage IIIB breast cancer
1518673|NCT00003068|drug/agent toxicity by tissue/organ
1518674|NCT00003067|recurrent adult brain tumor
1518675|NCT00003067|adult glioblastoma
1518676|NCT00003067|adult anaplastic astrocytoma
1518677|NCT00003067|adult mixed glioma
1518678|NCT00003067|adult giant cell glioblastoma
1518679|NCT00003067|adult gliosarcoma
1518680|NCT00003066|stage IV breast cancer
1518681|NCT00003066|recurrent breast cancer
1518682|NCT00003065|recurrent cervical cancer
1518683|NCT00003065|stage IVB cervical cancer
1518684|NCT00003065|stage IVA cervical cancer
1518685|NCT00003065|cervical squamous cell carcinoma
1518686|NCT00003065|cervical adenocarcinoma
1518687|NCT00003064|recurrent ovarian epithelial cancer
1518688|NCT00003064|fallopian tube cancer
1518689|NCT00003064|primary peritoneal cavity cancer
1518690|NCT00003063|stage II colon cancer
1518691|NCT00003063|stage III colon cancer
1518692|NCT00003063|stage II rectal cancer
1518693|NCT00003063|stage III rectal cancer
1518694|NCT00003062|recurrent non-small cell lung cancer
1518695|NCT00003062|stage IV non-small cell lung cancer
1518696|NCT00003061|primary central nervous system non-Hodgkin lymphoma
1518697|NCT00003060|recurrent melanoma
1518698|NCT00003058|adult liposarcoma
1518699|NCT00003058|recurrent adult soft tissue sarcoma
1518700|NCT00003057|colon cancer
1518701|NCT00003057|rectal cancer
1518702|NCT00003057|diarrhea
1518703|NCT00003056|recurrent adult Hodgkin lymphoma
1518704|NCT00003056|recurrent adult acute myeloid leukemia
1518705|NCT00003056|recurrent adult acute lymphoblastic leukemia
1518706|NCT00003056|chronic phase chronic myelogenous leukemia
1518707|NCT00003056|accelerated phase chronic myelogenous leukemia
1518708|NCT00003056|adult acute myeloid leukemia in remission
1518709|NCT00003056|adult acute lymphoblastic leukemia in remission
1518710|NCT00003056|recurrent grade 1 follicular lymphoma
1518711|NCT00003056|recurrent grade 2 follicular lymphoma
1518712|NCT00003056|recurrent grade 3 follicular lymphoma
1518713|NCT00003056|recurrent adult diffuse small cleaved cell lymphoma
1518714|NCT00003056|recurrent adult diffuse mixed cell lymphoma
1518715|NCT00003056|recurrent adult diffuse large cell lymphoma
1518716|NCT00003056|recurrent adult immunoblastic large cell lymphoma
1518717|NCT00003056|recurrent adult lymphoblastic lymphoma
1518718|NCT00003056|recurrent adult Burkitt lymphoma
1518719|NCT00003056|graft versus host disease
1518720|NCT00003056|recurrent mantle cell lymphoma
1518721|NCT00003056|recurrent marginal zone lymphoma
1518722|NCT00003056|recurrent small lymphocytic lymphoma
1518723|NCT00003056|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1518724|NCT00003056|nodal marginal zone B-cell lymphoma
1518725|NCT00003056|splenic marginal zone lymphoma
1518726|NCT00003055|stage III gastric cancer
1518727|NCT00003055|stage IV gastric cancer
1518728|NCT00003055|recurrent gastric cancer
1518729|NCT00003055|stage III esophageal cancer
1518730|NCT00003055|stage IV esophageal cancer
1518731|NCT00003055|recurrent esophageal cancer
1518732|NCT00003055|squamous cell carcinoma of the esophagus
1518733|NCT00003054|recurrent uterine sarcoma
1518734|NCT00003054|uterine leiomyosarcoma
1518735|NCT00003053|stage I non-small cell lung cancer
1518736|NCT00003053|stage II non-small cell lung cancer
1518737|NCT00003053|stage IIIA non-small cell lung cancer
1518738|NCT00003052|adult angiosarcoma
1518739|NCT00003052|adult fibrosarcoma
1518740|NCT00003052|adult leiomyosarcoma
1518741|NCT00003052|adult liposarcoma
1518742|NCT00003052|adult neurofibrosarcoma
1518743|NCT00003052|adult synovial sarcoma
1518744|NCT00003052|stage III adult soft tissue sarcoma
1518745|NCT00003052|recurrent adult soft tissue sarcoma
1518746|NCT00003052|adult extraskeletal osteosarcoma
1518747|NCT00003052|adult malignant fibrous histiocytoma
1518748|NCT00003052|adult rhabdomyosarcoma
1518749|NCT00003052|stage I adult soft tissue sarcoma
1518750|NCT00003052|stage II adult soft tissue sarcoma
1518751|NCT00003050|stage II breast cancer
1518752|NCT00003050|stage IIIA breast cancer
1518753|NCT00003050|stage IIIB breast cancer
1518754|NCT00003049|stage I pancreatic cancer
1518755|NCT00003049|stage II pancreatic cancer
1518756|NCT00003049|stage III pancreatic cancer
1518757|NCT00003049|adenocarcinoma of the pancreas
1518758|NCT00003048|de novo myelodysplastic syndromes
1518759|NCT00003048|previously treated myelodysplastic syndromes
1518760|NCT00003048|secondary myelodysplastic syndromes
1518761|NCT00003048|Amifostine
1518762|NCT00003048|Ethyol
1518763|NCT00003048|Ethiofos
1518764|NCT00003048|Gammaphos
1518765|NCT00003046|anal cancer
1518766|NCT00003046|carcinoma of the appendix
1518767|NCT00003046|colorectal cancer
1518768|NCT00003046|extrahepatic bile duct cancer
1518769|NCT00003046|gallbladder cancer
1518770|NCT00003046|gastric cancer
1518771|NCT00003046|gastrointestinal carcinoid tumor
1518772|NCT00003046|malignant mesothelioma
1518773|NCT00003046|pancreatic cancer
1518774|NCT00003046|small intestine cancer
1518775|NCT00003046|stage IV colon cancer
1518776|NCT00003046|stage IV gastric cancer
1518777|NCT00003046|recurrent gastric cancer
1518778|NCT00003046|recurrent pancreatic cancer
1518779|NCT00003046|stage IV rectal cancer
1518780|NCT00003046|recurrent colon cancer
1518781|NCT00003046|recurrent rectal cancer
1518782|NCT00003046|stage IV anal cancer
1518783|NCT00003046|recurrent anal cancer
1518784|NCT00003046|metastatic gastrointestinal carcinoid tumor
1518785|NCT00003046|recurrent gastrointestinal carcinoid tumor
1518786|NCT00003046|advanced malignant mesothelioma
1518787|NCT00003046|recurrent malignant mesothelioma
1518788|NCT00003046|small intestine adenocarcinoma
1518789|NCT00003046|unresectable gallbladder cancer
1518790|NCT00003046|recurrent gallbladder cancer
1518791|NCT00003046|unresectable extrahepatic bile duct cancer
1518792|NCT00003046|recurrent extrahepatic bile duct cancer
1518793|NCT00003046|recurrent small intestine cancer
1518794|NCT00003046|stage IV pancreatic cancer
1518795|NCT00003045|adenocarcinoma of the prostate
1518796|NCT00003045|stage II prostate cancer
1518797|NCT00003045|stage III prostate cancer
1518798|NCT00003044|localized unresectable adult primary liver cancer
1518799|NCT00003042|stage IIIB breast cancer
1518800|NCT00003042|inflammatory breast cancer
1518801|NCT00003041|recurrent breast cancer
1518802|NCT00003040|stage I squamous cell carcinoma of the larynx
1518803|NCT00003040|stage II squamous cell carcinoma of the larynx
1518804|NCT00003040|stage III squamous cell carcinoma of the larynx
1518805|NCT00003039|recurrent grade 3 follicular lymphoma
1518806|NCT00003039|recurrent adult diffuse small cleaved cell lymphoma
1518807|NCT00003039|recurrent adult diffuse mixed cell lymphoma
1518808|NCT00003039|recurrent adult diffuse large cell lymphoma
1518809|NCT00003039|recurrent adult immunoblastic large cell lymphoma
1518810|NCT00003039|recurrent adult lymphoblastic lymphoma
1518811|NCT00003039|recurrent adult Burkitt lymphoma
1518812|NCT00003039|recurrent mantle cell lymphoma
1518813|NCT00003038|stage IV colon cancer
1518814|NCT00003038|stage IV breast cancer
1518815|NCT00003038|recurrent breast cancer
1518816|NCT00003038|recurrent colon cancer
1518817|NCT00003038|stage IV adrenocortical carcinoma
1518818|NCT00003038|recurrent adrenocortical carcinoma
1518819|NCT00003038|stage IV prostate cancer
1518820|NCT00003038|recurrent prostate cancer
1518821|NCT00003038|unspecified adult solid tumor, protocol specific
1518822|NCT00003037|stage IIIA non-small cell lung cancer
1518823|NCT00003037|stage IIIB non-small cell lung cancer
1518824|NCT00003035|stage IIIA breast cancer
1518825|NCT00003035|stage IIIB breast cancer
1518826|NCT00003034|localized malignant mesothelioma
1518827|NCT00003034|advanced malignant mesothelioma
1518828|NCT00003034|recurrent malignant mesothelioma
1518829|NCT00003032|stage IV breast cancer
1518830|NCT00003032|recurrent breast cancer
1518831|NCT00003031|infection
1518832|NCT00003031|pulmonary complications
1518833|NCT00003029|stage III pancreatic cancer
1518834|NCT00003029|adenocarcinoma of the pancreas
1518835|NCT00003029|stage IV pancreatic cancer
1518836|NCT00003028|unspecified adult solid tumor, protocol specific
1518837|NCT00003027|stage IV melanoma
1518838|NCT00003026|adenocarcinoma of the prostate
1518839|NCT00003025|stage I pancreatic cancer
1518840|NCT00003025|stage II pancreatic cancer
1518841|NCT00003025|adenocarcinoma of the pancreas
1518843|NCT00003023|recurrent adult soft tissue sarcoma
1518844|NCT00003023|disseminated neuroblastoma
1518845|NCT00003023|stage 4S neuroblastoma
1518846|NCT00003023|recurrent neuroblastoma
1518847|NCT00003023|recurrent osteosarcoma
1518848|NCT00003023|metastatic childhood soft tissue sarcoma
1518849|NCT00003023|recurrent childhood soft tissue sarcoma
1518850|NCT00003023|stage IV adult soft tissue sarcoma
1518851|NCT00003022|metastatic osteosarcoma
1518852|NCT00003022|childhood infratentorial ependymoma
1518853|NCT00003022|recurrent childhood rhabdomyosarcoma
1518854|NCT00003022|childhood supratentorial ependymoma
1518855|NCT00003022|regional neuroblastoma
1518856|NCT00003022|disseminated neuroblastoma
1518857|NCT00003022|stage 4S neuroblastoma
1518858|NCT00003022|recurrent neuroblastoma
1518859|NCT00003022|retinoblastoma
1518860|NCT00003022|intraocular retinoblastoma
1518861|NCT00003022|extraocular retinoblastoma
1518862|NCT00003022|recurrent retinoblastoma
1518863|NCT00003022|extensive stage small cell lung cancer
1518864|NCT00003022|recurrent small cell lung cancer
1518865|NCT00003022|recurrent osteosarcoma
1518866|NCT00003022|recurrent adult brain tumor
1518867|NCT00003022|iris melanoma
1518868|NCT00003022|ciliary body and choroid melanoma, small size
1518869|NCT00003022|ciliary body and choroid melanoma, medium/large size
1518870|NCT00003022|extraocular extension melanoma
1518871|NCT00003022|recurrent intraocular melanoma
1518872|NCT00003022|adult brain stem glioma
1518873|NCT00003022|adult medulloblastoma
1518874|NCT00003022|stage IV melanoma
1518875|NCT00003022|recurrent melanoma
1518876|NCT00003022|metastatic childhood soft tissue sarcoma
1518877|NCT00003022|recurrent childhood soft tissue sarcoma
1518878|NCT00003022|adult myxopapillary ependymoma
1518879|NCT00003022|adult anaplastic ependymoma
1518880|NCT00003022|adult anaplastic oligodendroglioma
1518881|NCT00003022|adult mixed glioma
1518882|NCT00003022|localized unresectable neuroblastoma
1518883|NCT00003022|adult ependymoblastoma
1518884|NCT00003022|recurrent childhood brain stem glioma
1518885|NCT00003022|recurrent childhood supratentorial primitive neuroectodermal tumor
1518886|NCT00003022|recurrent childhood visual pathway glioma
1518887|NCT00003022|recurrent childhood medulloblastoma
1518888|NCT00003022|recurrent childhood visual pathway and hypothalamic glioma
1518889|NCT00003022|previously treated childhood rhabdomyosarcoma
1518890|NCT00003022|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1518891|NCT00003022|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1518892|NCT00003022|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1518893|NCT00003022|recurrent childhood ependymoma
1518894|NCT00003022|adult oligodendroglioma
1518895|NCT00003022|adult anaplastic astrocytoma
1518896|NCT00003022|adult supratentorial primitive neuroectodermal tumor (PNET)
1518897|NCT00003022|adult diffuse astrocytoma
1518898|NCT00003022|adult pilocytic astrocytoma
1518899|NCT00003022|adult giant cell glioblastoma
1518900|NCT00003022|adult glioblastoma
1518901|NCT00003022|adult gliosarcoma
1518902|NCT00003021|unspecified adult solid tumor, protocol specific
1518903|NCT00003020|leptomeningeal metastases
1518904|NCT00003019|desmoid tumor
1518905|NCT00003018|stage II pancreatic cancer
1518906|NCT00003018|stage III pancreatic cancer
1518907|NCT00003018|duct cell adenocarcinoma of the pancreas
1518908|NCT00003017|stage IV cervical cancer
1518909|NCT00003017|recurrent cervical cancer
1518910|NCT00003017|cervical squamous cell carcinoma
1518911|NCT00003017|cervical adenocarcinoma
1518912|NCT00003017|cervical adenosquamous cell carcinoma
1518913|NCT00003016|stage I breast cancer
1518914|NCT00003016|stage II breast cancer
1518915|NCT00003016|stage IIIA breast cancer
1518916|NCT00003016|stage IIIB breast cancer
1518917|NCT00003016|stage IIIC breast cancer
1518918|NCT00003015|childhood low-grade cerebral astrocytoma
1518919|NCT00003015|childhood oligodendroglioma
1518920|NCT00003015|untreated childhood visual pathway glioma
1518921|NCT00003015|untreated childhood cerebellar astrocytoma
1518922|NCT00003014|stage I malignant testicular germ cell tumor
1518923|NCT00003014|testicular seminoma
1518924|NCT00003013|stage II breast cancer
1518925|NCT00003013|stage IIIA breast cancer
1518926|NCT00003012|stage II breast cancer
1518927|NCT00003012|stage IIIA breast cancer
1518928|NCT00003011|recurrent small cell lung cancer
1518930|NCT00003009|unspecified adult solid tumor, protocol specific
1518931|NCT00003008|AIDS-related Kaposi sarcoma
1518932|NCT00003008|recurrent Kaposi sarcoma
1518933|NCT00003007|refractory multiple myeloma
1518934|NCT00003007|stage III multiple myeloma
1518935|NCT00003006|stage I non-small cell lung cancer
1518936|NCT00003005|recurrent adult acute lymphoblastic leukemia
1518937|NCT00003005|blastic phase chronic myelogenous leukemia
1518938|NCT00003005|TdT positive adult acute lymphoblastic leukemia
1518939|NCT00003004|unspecified adult solid tumor, protocol specific
1518940|NCT00003003|recurrent adult acute myeloid leukemia
1518941|NCT00003003|secondary acute myeloid leukemia
1518942|NCT00003002|stage III breast cancer
1518943|NCT00003002|stage IV breast cancer
1518944|NCT00003002|stage III non-small cell lung cancer
1518945|NCT00003002|stage III ovarian epithelial cancer
1518946|NCT00003002|stage IV ovarian epithelial cancer
1518947|NCT00003002|stage IV non-small cell lung cancer
1518948|NCT00003002|adenocarcinoma of the lung
1518949|NCT00003001|stage IV colon cancer
1518950|NCT00003001|stage IV rectal cancer
1518951|NCT00003001|recurrent colon cancer
1518952|NCT00003001|recurrent rectal cancer
1518953|NCT00003000|pain
1518954|NCT00002999|stage III nasopharyngeal cancer
1518955|NCT00002999|stage IV nasopharyngeal cancer
1518956|NCT00002998|stage IV breast cancer
1518957|NCT00002998|recurrent breast cancer
1518958|NCT00002997|stage IV colon cancer
1518959|NCT00002997|stage IV rectal cancer
1518960|NCT00002997|recurrent colon cancer
1518961|NCT00002997|recurrent rectal cancer
1518962|NCT00002997|adenocarcinoma of the colon
1518963|NCT00002997|adenocarcinoma of the rectum
1518964|NCT00002997|liver metastases
1518965|NCT00002996|pain
1518966|NCT00002995|embryonal childhood rhabdomyosarcoma
1518967|NCT00002995|embryonal-botryoid childhood rhabdomyosarcoma
1518968|NCT00002995|previously untreated childhood rhabdomyosarcoma
1518969|NCT00002995|adult rhabdomyosarcoma
1518970|NCT00002995|adult malignant mesenchymoma
1518971|NCT00002995|childhood malignant mesenchymoma
1518972|NCT00002995|nonmetastatic childhood soft tissue sarcoma
1518973|NCT00002995|stage II adult soft tissue sarcoma
1518974|NCT00002995|stage III adult soft tissue sarcoma
1518975|NCT00002995|stage I adult soft tissue sarcoma
1518976|NCT00002994|unspecified adult solid tumor, protocol specific
1518977|NCT00002993|stage III uterine sarcoma
1518978|NCT00002993|stage IV uterine sarcoma
1518979|NCT00002993|recurrent uterine sarcoma
1518980|NCT00002990|stage 0 bladder cancer
1518981|NCT00002990|stage I bladder cancer
1518982|NCT00002990|transitional cell carcinoma of the bladder
1518983|NCT00002989|stage I multiple myeloma
1518984|NCT00002989|stage II multiple myeloma
1518985|NCT00002989|stage III multiple myeloma
1518986|NCT00002989|recurrent adult acute myeloid leukemia
1518987|NCT00002989|recurrent adult acute lymphoblastic leukemia
1518988|NCT00002989|relapsing chronic myelogenous leukemia
1518989|NCT00002989|refractory chronic lymphocytic leukemia
1518990|NCT00002989|adult acute myeloid leukemia in remission
1518991|NCT00002989|adult acute lymphoblastic leukemia in remission
1518992|NCT00002989|stage I grade 1 follicular lymphoma
1518993|NCT00002989|stage I grade 2 follicular lymphoma
1518994|NCT00002989|stage I grade 3 follicular lymphoma
1518995|NCT00002989|stage I adult diffuse small cleaved cell lymphoma
1518996|NCT00002989|stage I adult diffuse mixed cell lymphoma
1518997|NCT00002989|stage I adult diffuse large cell lymphoma
1518998|NCT00002989|stage I adult immunoblastic large cell lymphoma
1518999|NCT00002989|stage I adult lymphoblastic lymphoma
1519000|NCT00002989|stage I adult Burkitt lymphoma
1519001|NCT00002989|stage III grade 2 follicular lymphoma
1519002|NCT00002989|stage III grade 3 follicular lymphoma
1519003|NCT00002989|stage III adult diffuse small cleaved cell lymphoma
1519004|NCT00002989|stage III adult diffuse mixed cell lymphoma
1519005|NCT00002989|stage III adult diffuse large cell lymphoma
1519006|NCT00002989|stage III adult immunoblastic large cell lymphoma
1519007|NCT00002989|stage III adult lymphoblastic lymphoma
1519008|NCT00002989|stage III adult Burkitt lymphoma
1519009|NCT00002989|stage IV grade 1 follicular lymphoma
1519010|NCT00002989|stage IV grade 2 follicular lymphoma
1519011|NCT00002989|stage IV grade 3 follicular lymphoma
1519012|NCT00002989|stage IV adult diffuse small cleaved cell lymphoma
1519013|NCT00002989|stage IV adult diffuse mixed cell lymphoma
1519014|NCT00002989|stage IV adult diffuse large cell lymphoma
1519015|NCT00002989|stage IV adult immunoblastic large cell lymphoma
1519016|NCT00002989|stage IV adult lymphoblastic lymphoma
1519017|NCT00002989|stage IV adult Burkitt lymphoma
1519018|NCT00002989|recurrent grade 1 follicular lymphoma
1519019|NCT00002989|recurrent grade 2 follicular lymphoma
1519020|NCT00002989|recurrent grade 3 follicular lymphoma
1519021|NCT00002989|recurrent adult diffuse small cleaved cell lymphoma
1519022|NCT00002989|recurrent adult diffuse mixed cell lymphoma
1519023|NCT00002989|recurrent adult diffuse large cell lymphoma
1519024|NCT00002989|recurrent adult immunoblastic large cell lymphoma
1519025|NCT00002989|recurrent adult lymphoblastic lymphoma
1519026|NCT00002989|recurrent adult Burkitt lymphoma
1519027|NCT00002989|previously treated myelodysplastic syndromes
1519028|NCT00002989|stage I mantle cell lymphoma
1519029|NCT00002989|contiguous stage II grade 1 follicular lymphoma
1519030|NCT00002989|contiguous stage II grade 2 follicular lymphoma
1519031|NCT00002989|contiguous stage II grade 3 follicular lymphoma
1519032|NCT00002989|contiguous stage II adult diffuse small cleaved cell lymphoma
1519033|NCT00002989|contiguous stage II mantle cell lymphoma
1519034|NCT00002989|contiguous stage II adult diffuse mixed cell lymphoma
1519035|NCT00002989|contiguous stage II adult immunoblastic large cell lymphoma
1519036|NCT00002989|contiguous stage II adult diffuse large cell lymphoma
1519037|NCT00002989|contiguous stage II adult Burkitt lymphoma
1519038|NCT00002989|contiguous stage II adult lymphoblastic lymphoma
1519039|NCT00002989|noncontiguous stage II grade 1 follicular lymphoma
1519040|NCT00002989|noncontiguous stage II grade 2 follicular lymphoma
1519426|NCT00002933|recurrent rectal cancer
1519041|NCT00002989|noncontiguous stage II grade 3 follicular lymphoma
1519042|NCT00002989|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1519043|NCT00002989|noncontiguous stage II mantle cell lymphoma
1519044|NCT00002989|noncontiguous stage II adult diffuse mixed cell lymphoma
1519045|NCT00002989|noncontiguous stage II adult immunoblastic large cell lymphoma
1519046|NCT00002989|noncontiguous stage II adult diffuse large cell lymphoma
1519047|NCT00002989|noncontiguous stage II adult Burkitt lymphoma
1519048|NCT00002989|noncontiguous stage II adult lymphoblastic lymphoma
1519049|NCT00002989|stage III mantle cell lymphoma
1519050|NCT00002989|stage IV mantle cell lymphoma
1519051|NCT00002989|recurrent mantle cell lymphoma
1519052|NCT00002989|contiguous stage II marginal zone lymphoma
1519053|NCT00002989|contiguous stage II small lymphocytic lymphoma
1519054|NCT00002989|noncontiguous stage II small lymphocytic lymphoma
1519055|NCT00002989|noncontiguous stage II marginal zone lymphoma
1519056|NCT00002989|recurrent marginal zone lymphoma
1519057|NCT00002989|recurrent small lymphocytic lymphoma
1519058|NCT00002989|stage I marginal zone lymphoma
1519059|NCT00002989|stage I small lymphocytic lymphoma
1519060|NCT00002989|stage III small lymphocytic lymphoma
1519061|NCT00002989|stage III marginal zone lymphoma
1519062|NCT00002989|stage IV small lymphocytic lymphoma
1519063|NCT00002989|stage IV marginal zone lymphoma
1519064|NCT00002989|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519065|NCT00002989|nodal marginal zone B-cell lymphoma
1519066|NCT00002989|splenic marginal zone lymphoma
1519067|NCT00002989|childhood myelodysplastic syndromes
1519068|NCT00002988|recurrent adult brain tumor
1519069|NCT00002987|stage I adult Hodgkin lymphoma
1519070|NCT00002987|stage II adult Hodgkin lymphoma
1519071|NCT00002986|recurrent adult brain tumor
1519072|NCT00002985|AIDS-related Kaposi sarcoma
1519073|NCT00002984|stage II esophageal cancer
1519074|NCT00002984|stage III esophageal cancer
1519075|NCT00002984|stage IV esophageal cancer
1519076|NCT00002984|squamous cell carcinoma of the esophagus
1519077|NCT00002984|adenocarcinoma of the esophagus
1519078|NCT00002982|recurrent grade 3 follicular lymphoma
1519079|NCT00002982|recurrent adult diffuse small cleaved cell lymphoma
1519080|NCT00002982|recurrent adult diffuse mixed cell lymphoma
1519081|NCT00002982|recurrent adult diffuse large cell lymphoma
1519082|NCT00002982|recurrent adult immunoblastic large cell lymphoma
1519083|NCT00002982|anaplastic large cell lymphoma
1519084|NCT00002981|adenocarcinoma of the prostate
1519085|NCT00002981|stage IV prostate cancer
1519086|NCT00002981|recurrent prostate cancer
1519087|NCT00002980|stage IV adult Hodgkin lymphoma
1519088|NCT00002980|monoclonal gammopathy of undetermined significance
1519089|NCT00002980|recurrent adult Hodgkin lymphoma
1519090|NCT00002980|isolated plasmacytoma of bone
1519091|NCT00002980|extramedullary plasmacytoma
1519092|NCT00002980|refractory multiple myeloma
1519093|NCT00002980|Waldenström macroglobulinemia
1519094|NCT00002980|stage IV chronic lymphocytic leukemia
1519095|NCT00002980|recurrent adult acute myeloid leukemia
1519096|NCT00002980|recurrent adult acute lymphoblastic leukemia
1519097|NCT00002980|relapsing chronic myelogenous leukemia
1519098|NCT00002980|refractory chronic lymphocytic leukemia
1519099|NCT00002980|unspecified adult solid tumor, protocol specific
1519100|NCT00002980|chronic phase chronic myelogenous leukemia
1519101|NCT00002980|accelerated phase chronic myelogenous leukemia
1519102|NCT00002980|blastic phase chronic myelogenous leukemia
1519103|NCT00002980|untreated adult acute lymphoblastic leukemia
1519104|NCT00002980|untreated adult acute myeloid leukemia
1519105|NCT00002980|adult acute myeloid leukemia in remission
1519106|NCT00002980|adult acute lymphoblastic leukemia in remission
1519107|NCT00002980|polycythemia vera
1519108|NCT00002980|primary myelofibrosis
1519109|NCT00002980|essential thrombocythemia
1519110|NCT00002980|untreated hairy cell leukemia
1519111|NCT00002980|progressive hairy cell leukemia, initial treatment
1519112|NCT00002980|refractory hairy cell leukemia
1519113|NCT00002980|chronic myelomonocytic leukemia
1519114|NCT00002980|T-cell large granular lymphocyte leukemia
1519115|NCT00002980|acute undifferentiated leukemia
1519116|NCT00002980|stage IV grade 1 follicular lymphoma
1519117|NCT00002980|stage IV grade 2 follicular lymphoma
1519118|NCT00002980|stage IV grade 3 follicular lymphoma
1519119|NCT00002980|stage IV adult diffuse small cleaved cell lymphoma
1519120|NCT00002980|stage IV adult diffuse mixed cell lymphoma
1519121|NCT00002980|stage IV adult diffuse large cell lymphoma
1519122|NCT00002980|stage IV adult immunoblastic large cell lymphoma
1519123|NCT00002980|stage IV adult lymphoblastic lymphoma
1519124|NCT00002980|stage IV adult Burkitt lymphoma
1519125|NCT00002980|recurrent grade 1 follicular lymphoma
1519126|NCT00002980|recurrent grade 2 follicular lymphoma
1519127|NCT00002980|recurrent grade 3 follicular lymphoma
1519128|NCT00002980|recurrent adult diffuse small cleaved cell lymphoma
1519129|NCT00002980|recurrent adult diffuse mixed cell lymphoma
1519130|NCT00002980|recurrent adult diffuse large cell lymphoma
1519131|NCT00002980|recurrent adult immunoblastic large cell lymphoma
1519132|NCT00002980|recurrent adult lymphoblastic lymphoma
1519133|NCT00002980|recurrent adult Burkitt lymphoma
1519134|NCT00002980|stage IV adult T-cell leukemia/lymphoma
1519135|NCT00002980|recurrent adult T-cell leukemia/lymphoma
1519136|NCT00002980|secondary acute myeloid leukemia
1519137|NCT00002980|de novo myelodysplastic syndromes
1519138|NCT00002980|previously treated myelodysplastic syndromes
1519139|NCT00002980|secondary myelodysplastic syndromes
1519140|NCT00002980|prolymphocytic leukemia
1519141|NCT00002980|primary systemic amyloidosis
1519142|NCT00002980|stage IV mantle cell lymphoma
1519143|NCT00002980|recurrent mantle cell lymphoma
1519144|NCT00002980|angioimmunoblastic T-cell lymphoma
1519145|NCT00002980|anaplastic large cell lymphoma
1519146|NCT00002980|recurrent marginal zone lymphoma
1519147|NCT00002980|recurrent small lymphocytic lymphoma
1519148|NCT00002980|stage IV small lymphocytic lymphoma
1519149|NCT00002980|stage IV marginal zone lymphoma
1519150|NCT00002980|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519151|NCT00002980|nodal marginal zone B-cell lymphoma
1519152|NCT00002980|splenic marginal zone lymphoma
1519153|NCT00002977|stage III ovarian epithelial cancer
1519154|NCT00002977|stage IV ovarian epithelial cancer
1519155|NCT00002977|recurrent ovarian epithelial cancer
1519156|NCT00002977|ovarian undifferentiated adenocarcinoma
1519157|NCT00002977|ovarian mixed epithelial carcinoma
1519158|NCT00002977|ovarian serous cystadenocarcinoma
1519159|NCT00002977|ovarian mucinous cystadenocarcinoma
1519160|NCT00002977|ovarian endometrioid adenocarcinoma
1519161|NCT00002977|ovarian clear cell cystadenocarcinoma
1519162|NCT00002977|Brenner tumor
1519163|NCT00002976|stage I endometrial carcinoma
1519164|NCT00002976|stage II endometrial carcinoma
1519165|NCT00002976|endometrial adenocarcinoma
1519166|NCT00002975|basal cell carcinoma of the skin
1519167|NCT00002975|squamous cell carcinoma of the skin
1519168|NCT00002975|actinic keratosis
1519169|NCT00002974|recurrent adult soft tissue sarcoma
1519170|NCT00002974|stage IV adult soft tissue sarcoma
1519171|NCT00002973|stage III melanoma
1519172|NCT00002973|stage IV melanoma
1519173|NCT00002973|recurrent melanoma
1519174|NCT00002972|recurrent non-small cell lung cancer
1519175|NCT00002972|stage IIIB non-small cell lung cancer
1519176|NCT00002972|stage IV non-small cell lung cancer
1519177|NCT00002972|adenocarcinoma of the lung
1519178|NCT00002971|recurrent adult brain tumor
1519179|NCT00002971|adult glioblastoma
1519180|NCT00002971|adult anaplastic astrocytoma
1519181|NCT00002971|adult giant cell glioblastoma
1519182|NCT00002971|adult gliosarcoma
1519183|NCT00002969|recurrent non-small cell lung cancer
1519184|NCT00002969|stage IIIB non-small cell lung cancer
1519185|NCT00002969|stage IV non-small cell lung cancer
1519186|NCT00002967|stage I breast cancer
1519187|NCT00002967|stage II breast cancer
1519188|NCT00002967|invasive ductal breast carcinoma
1519189|NCT00002965|recurrent adult brain tumor
1519190|NCT00002964|stage 0 oropharyngeal cancer
1519191|NCT00002964|stage 0 laryngeal cancer
1519192|NCT00002964|stage 0 hypopharyngeal cancer
1519193|NCT00002964|stage 0 lip and oral cavity cancer
1519194|NCT00002964|stage I lip and oral cavity cancer
1519195|NCT00002964|stage I hypopharyngeal cancer
1519196|NCT00002964|stage I laryngeal cancer
1519197|NCT00002964|stage I oropharyngeal cancer
1519198|NCT00002963|basal cell carcinoma of the skin
1519199|NCT00002963|squamous cell carcinoma of the skin
1519200|NCT00002961|recurrent childhood acute lymphoblastic leukemia
1519201|NCT00002961|childhood acute lymphoblastic leukemia in remission
1519202|NCT00002960|recurrent ovarian epithelial cancer
1519203|NCT00002960|malignant ascites
1519204|NCT00002960|fallopian tube cancer
1519205|NCT00002960|primary peritoneal cavity cancer
1519206|NCT00002956|recurrent adult Hodgkin lymphoma
1519207|NCT00002956|recurrent childhood lymphoblastic lymphoma
1519208|NCT00002956|childhood diffuse large cell lymphoma
1519209|NCT00002956|childhood immunoblastic large cell lymphoma
1519210|NCT00002956|recurrent/refractory childhood Hodgkin lymphoma
1519211|NCT00002956|T-cell large granular lymphocyte leukemia
1519212|NCT00002956|recurrent grade 1 follicular lymphoma
1519213|NCT00002956|recurrent grade 2 follicular lymphoma
1519214|NCT00002956|recurrent grade 3 follicular lymphoma
1519215|NCT00002956|recurrent adult diffuse small cleaved cell lymphoma
1519216|NCT00002956|recurrent adult diffuse mixed cell lymphoma
1519217|NCT00002956|recurrent adult diffuse large cell lymphoma
1519218|NCT00002956|recurrent adult immunoblastic large cell lymphoma
1519219|NCT00002956|recurrent adult lymphoblastic lymphoma
1523038|NCT00002422|Anti-HIV Agents
1519220|NCT00002956|recurrent adult Burkitt lymphoma
1519221|NCT00002956|recurrent childhood small noncleaved cell lymphoma
1519222|NCT00002956|recurrent childhood large cell lymphoma
1519223|NCT00002956|recurrent mantle cell lymphoma
1519224|NCT00002956|recurrent marginal zone lymphoma
1519225|NCT00002956|recurrent small lymphocytic lymphoma
1519226|NCT00002956|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519227|NCT00002956|nodal marginal zone B-cell lymphoma
1519228|NCT00002956|splenic marginal zone lymphoma
1519229|NCT00002955|stage IV pancreatic cancer
1519230|NCT00002953|stage IV breast cancer
1519231|NCT00002952|stage IV melanoma
1519232|NCT00002952|recurrent melanoma
1519233|NCT00002951|stage II esophageal cancer
1519234|NCT00002951|stage III esophageal cancer
1519235|NCT00002951|stage II nasopharyngeal cancer
1519236|NCT00002951|stage III nasopharyngeal cancer
1519237|NCT00002951|stage II lip and oral cavity cancer
1519238|NCT00002951|stage III lip and oral cavity cancer
1519239|NCT00002951|stage II hypopharyngeal cancer
1519240|NCT00002951|stage III hypopharyngeal cancer
1519241|NCT00002951|stage II laryngeal cancer
1519242|NCT00002951|stage III laryngeal cancer
1519243|NCT00002951|stage II paranasal sinus and nasal cavity cancer
1519244|NCT00002951|stage III paranasal sinus and nasal cavity cancer
1519245|NCT00002951|stage II oropharyngeal cancer
1519246|NCT00002951|stage III oropharyngeal cancer
1519247|NCT00002950|unspecified adult solid tumor, protocol specific
1519248|NCT00002949|stage II cervical cancer
1519249|NCT00002949|stage III cervical cancer
1519250|NCT00002949|stage IV cervical cancer
1519251|NCT00002949|stage II vaginal cancer
1519252|NCT00002949|stage III vaginal cancer
1519253|NCT00002949|stage IVA vaginal cancer
1519254|NCT00002949|stage IVB vaginal cancer
1519255|NCT00002949|stage II endometrial carcinoma
1519256|NCT00002949|stage III endometrial carcinoma
1519257|NCT00002949|stage IV endometrial carcinoma
1519258|NCT00002949|stage II bladder cancer
1519259|NCT00002949|stage III bladder cancer
1519260|NCT00002949|stage IV bladder cancer
1519261|NCT00002948|unspecified adult solid tumor, protocol specific
1519262|NCT00002947|stage IV renal cell cancer
1519263|NCT00002947|recurrent renal cell cancer
1519264|NCT00002947|extensive stage small cell lung cancer
1519265|NCT00002947|recurrent small cell lung cancer
1519266|NCT00002947|metastatic gastrointestinal carcinoid tumor
1519267|NCT00002947|recurrent gastrointestinal carcinoid tumor
1519268|NCT00002947|gastrinoma
1519269|NCT00002947|insulinoma
1519270|NCT00002947|recurrent islet cell carcinoma
1519271|NCT00002947|thyroid gland medullary carcinoma
1519272|NCT00002947|prolactin-producing pituitary tumor
1519273|NCT00002947|iris melanoma
1519274|NCT00002947|ciliary body and choroid melanoma, medium/large size
1519275|NCT00002947|extraocular extension melanoma
1519276|NCT00002947|recurrent intraocular melanoma
1519277|NCT00002947|stage IV melanoma
1519278|NCT00002947|recurrent melanoma
1519279|NCT00002947|WDHA syndrome
1519280|NCT00002947|somatostatinoma
1519281|NCT00002947|pancreatic polypeptide tumor
1519282|NCT00002947|glucagonoma
1519283|NCT00002947|childhood Langerhans cell histiocytosis
1519284|NCT00002947|metastatic pheochromocytoma
1519285|NCT00002947|recurrent pheochromocytoma
1519286|NCT00002947|pulmonary carcinoid tumor
1519287|NCT00002947|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1519288|NCT00002947|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1519289|NCT00002947|stage III neuroendocrine carcinoma of the skin
1519290|NCT00002947|recurrent neuroendocrine carcinoma of the skin
1519291|NCT00002946|stage I adult Hodgkin lymphoma
1519292|NCT00002946|stage II adult Hodgkin lymphoma
1519293|NCT00002946|stage III adult Hodgkin lymphoma
1519294|NCT00002946|stage IV adult Hodgkin lymphoma
1519295|NCT00002946|recurrent adult Hodgkin lymphoma
1519296|NCT00002946|unspecified adult solid tumor, protocol specific
1519297|NCT00002946|stage I grade 1 follicular lymphoma
1519298|NCT00002946|stage I grade 2 follicular lymphoma
1519299|NCT00002946|stage I grade 3 follicular lymphoma
1519300|NCT00002946|stage I adult diffuse small cleaved cell lymphoma
1519301|NCT00002946|stage I adult diffuse mixed cell lymphoma
1519302|NCT00002946|stage I adult diffuse large cell lymphoma
1519303|NCT00002946|stage I adult immunoblastic large cell lymphoma
1519304|NCT00002946|stage I adult lymphoblastic lymphoma
1519305|NCT00002946|stage I adult Burkitt lymphoma
1519306|NCT00002946|stage III grade 1 follicular lymphoma
1519307|NCT00002946|stage III grade 2 follicular lymphoma
1519308|NCT00002946|stage III grade 3 follicular lymphoma
1519309|NCT00002946|stage III adult diffuse small cleaved cell lymphoma
1519310|NCT00002946|stage III adult diffuse mixed cell lymphoma
1519311|NCT00002946|stage III adult diffuse large cell lymphoma
1519312|NCT00002946|stage III adult immunoblastic large cell lymphoma
1519313|NCT00002946|stage III adult lymphoblastic lymphoma
1519314|NCT00002946|stage III adult Burkitt lymphoma
1519315|NCT00002946|stage IV grade 1 follicular lymphoma
1519316|NCT00002946|stage IV grade 2 follicular lymphoma
1519317|NCT00002946|stage IV grade 3 follicular lymphoma
1519318|NCT00002946|stage IV adult diffuse small cleaved cell lymphoma
1519319|NCT00002946|stage IV adult diffuse mixed cell lymphoma
1519320|NCT00002946|stage IV adult diffuse large cell lymphoma
1519321|NCT00002946|stage IV adult immunoblastic large cell lymphoma
1519322|NCT00002946|stage IV adult lymphoblastic lymphoma
1519323|NCT00002946|stage IV adult Burkitt lymphoma
1519324|NCT00002946|recurrent grade 1 follicular lymphoma
1519325|NCT00002946|recurrent grade 2 follicular lymphoma
1519326|NCT00002946|recurrent grade 3 follicular lymphoma
1519327|NCT00002946|recurrent adult diffuse small cleaved cell lymphoma
1519328|NCT00002946|recurrent adult diffuse mixed cell lymphoma
1519329|NCT00002946|recurrent adult diffuse large cell lymphoma
1519330|NCT00002946|recurrent adult immunoblastic large cell lymphoma
1519331|NCT00002946|recurrent adult lymphoblastic lymphoma
1519332|NCT00002946|recurrent adult Burkitt lymphoma
1519333|NCT00002946|stage I adult T-cell leukemia/lymphoma
1519334|NCT00002946|stage II adult T-cell leukemia/lymphoma
1519335|NCT00002946|stage III adult T-cell leukemia/lymphoma
1519336|NCT00002946|stage IV adult T-cell leukemia/lymphoma
1519337|NCT00002946|recurrent adult T-cell leukemia/lymphoma
1519338|NCT00002946|AIDS-related peripheral/systemic lymphoma
1519339|NCT00002946|AIDS-related primary CNS lymphoma
1519340|NCT00002946|stage I mantle cell lymphoma
1519341|NCT00002946|contiguous stage II grade 1 follicular lymphoma
1519342|NCT00002946|contiguous stage II grade 2 follicular lymphoma
1519343|NCT00002946|contiguous stage II grade 3 follicular lymphoma
1519344|NCT00002946|contiguous stage II adult diffuse small cleaved cell lymphoma
1519345|NCT00002946|contiguous stage II mantle cell lymphoma
1519346|NCT00002946|contiguous stage II adult diffuse mixed cell lymphoma
1519347|NCT00002946|contiguous stage II adult immunoblastic large cell lymphoma
1519348|NCT00002946|contiguous stage II adult diffuse large cell lymphoma
1519349|NCT00002946|contiguous stage II adult Burkitt lymphoma
1519350|NCT00002946|contiguous stage II adult lymphoblastic lymphoma
1519351|NCT00002946|noncontiguous stage II grade 1 follicular lymphoma
1519352|NCT00002946|noncontiguous stage II grade 2 follicular lymphoma
1519353|NCT00002946|noncontiguous stage II grade 3 follicular lymphoma
1519354|NCT00002946|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1519355|NCT00002946|noncontiguous stage II mantle cell lymphoma
1519356|NCT00002946|noncontiguous stage II adult diffuse mixed cell lymphoma
1519357|NCT00002946|noncontiguous stage II adult immunoblastic large cell lymphoma
1519358|NCT00002946|noncontiguous stage II adult diffuse large cell lymphoma
1519359|NCT00002946|noncontiguous stage II adult Burkitt lymphoma
1519360|NCT00002946|noncontiguous stage II adult lymphoblastic lymphoma
1519361|NCT00002946|stage III mantle cell lymphoma
1519362|NCT00002946|stage IV mantle cell lymphoma
1519363|NCT00002946|recurrent mantle cell lymphoma
1519364|NCT00002946|angioimmunoblastic T-cell lymphoma
1519365|NCT00002946|anaplastic large cell lymphoma
1519366|NCT00002946|noncontiguous stage II small lymphocytic lymphoma
1519367|NCT00002946|noncontiguous stage II marginal zone lymphoma
1519368|NCT00002946|recurrent marginal zone lymphoma
1519369|NCT00002946|recurrent small lymphocytic lymphoma
1519370|NCT00002946|stage I marginal zone lymphoma
1519371|NCT00002946|stage I small lymphocytic lymphoma
1519372|NCT00002946|stage III small lymphocytic lymphoma
1519373|NCT00002946|stage III marginal zone lymphoma
1519374|NCT00002946|stage IV small lymphocytic lymphoma
1519375|NCT00002946|stage IV marginal zone lymphoma
1519376|NCT00002946|contiguous stage II marginal zone lymphoma
1519377|NCT00002946|contiguous stage II small lymphocytic lymphoma
1519378|NCT00002946|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519379|NCT00002946|nodal marginal zone B-cell lymphoma
1519380|NCT00002946|splenic marginal zone lymphoma
1519381|NCT00002945|untreated adult acute myeloid leukemia
1519382|NCT00002945|adult acute monoblastic leukemia and acute monocytic leukemia (M5)
1519383|NCT00002945|adult acute erythroid leukemia (M6)
1519384|NCT00002945|adult acute myeloblastic leukemia without maturation (M1)
1519385|NCT00002945|adult acute myeloblastic leukemia with maturation (M2)
1519386|NCT00002945|adult acute myelomonocytic leukemia (M4)
1519387|NCT00002945|adult acute megakaryoblastic leukemia (M7)
1519388|NCT00002945|secondary acute myeloid leukemia
1519389|NCT00002945|adult acute minimally differentiated myeloid leukemia (M0)
1519390|NCT00002944|recurrent childhood brain stem glioma
1519391|NCT00002944|recurrent childhood visual pathway glioma
1519392|NCT00002944|recurrent childhood cerebellar astrocytoma
1519393|NCT00002944|recurrent childhood cerebral astrocytoma
1519394|NCT00002944|childhood low-grade cerebellar astrocytoma
1519395|NCT00002944|childhood low-grade cerebral astrocytoma
1519396|NCT00002943|stage III malignant testicular germ cell tumor
1519397|NCT00002943|recurrent malignant testicular germ cell tumor
1519398|NCT00002943|unspecified adult solid tumor, protocol specific
1519399|NCT00002943|stage III ovarian germ cell tumor
1519400|NCT00002943|stage IV ovarian germ cell tumor
1519401|NCT00002943|recurrent ovarian germ cell tumor
1519402|NCT00002943|extragonadal germ cell tumor
1519403|NCT00002942|stage II breast cancer
1519404|NCT00002942|stage IV breast cancer
1519405|NCT00002942|stage IIIA breast cancer
1519406|NCT00002942|stage IIIB breast cancer
1519407|NCT00002941|recurrent childhood lymphoblastic lymphoma
1519408|NCT00002941|childhood diffuse large cell lymphoma
1519409|NCT00002941|childhood immunoblastic large cell lymphoma
1519410|NCT00002941|recurrent/refractory childhood Hodgkin lymphoma
1519411|NCT00002941|recurrent childhood small noncleaved cell lymphoma
1519412|NCT00002941|recurrent childhood large cell lymphoma
1519413|NCT00002940|AIDS-related primary CNS lymphoma
1519414|NCT00002939|unspecified adult solid tumor, protocol specific
1519415|NCT00002938|recurrent prostate cancer
1519416|NCT00002937|recurrent breast cancer
1519417|NCT00002936|AIDS-related Kaposi sarcoma
1519418|NCT00002936|recurrent Kaposi sarcoma
1519419|NCT00002936|AIDS-related peripheral/systemic lymphoma
1519420|NCT00002935|stage 0 esophageal cancer
1519421|NCT00002934|breast cancer in situ
1519422|NCT00002934|ductal breast carcinoma
1519427|NCT00002933|adenocarcinoma of the colon
1519428|NCT00002933|adenocarcinoma of the rectum
1519429|NCT00002932|stage IV squamous cell carcinoma of the lip and oral cavity
1519430|NCT00002932|stage IV squamous cell carcinoma of the oropharynx
1519431|NCT00002932|stage IV squamous cell carcinoma of the hypopharynx
1519432|NCT00002932|stage IV squamous cell carcinoma of the larynx
1519433|NCT00002931|recurrent malignant testicular germ cell tumor
1519434|NCT00002931|testicular seminoma
1519435|NCT00002931|testicular embryonal carcinoma
1519436|NCT00002931|testicular choriocarcinoma
1519437|NCT00002931|testicular yolk sac tumor
1519438|NCT00002931|testicular embryonal carcinoma and teratoma
1519439|NCT00002931|testicular embryonal carcinoma and teratoma with seminoma
1519440|NCT00002931|testicular embryonal carcinoma and yolk sac tumor
1519441|NCT00002931|testicular embryonal carcinoma and yolk sac tumor with seminoma
1519442|NCT00002931|testicular embryonal carcinoma and seminoma
1519443|NCT00002931|testicular yolk sac tumor and teratoma
1519444|NCT00002931|testicular yolk sac tumor and teratoma with seminoma
1519445|NCT00002931|testicular choriocarcinoma and yolk sac tumor
1519446|NCT00002931|testicular choriocarcinoma and embryonal carcinoma
1519447|NCT00002931|testicular choriocarcinoma and teratoma
1519448|NCT00002931|testicular choriocarcinoma and seminoma
1519449|NCT00002931|recurrent ovarian germ cell tumor
1519450|NCT00002931|recurrent extragonadal non-seminomatous germ cell tumor
1519451|NCT00002931|recurrent extragonadal seminoma
1519452|NCT00002931|recurrent extragonadal germ cell tumor
1519453|NCT00002931|adult teratoma
1519454|NCT00002931|testicular immature teratoma
1519455|NCT00002931|testicular mature teratoma
1519456|NCT00002931|ovarian immature teratoma
1519457|NCT00002931|ovarian mature teratoma
1519458|NCT00002931|ovarian monodermal and highly specialized teratoma
1519459|NCT00002931|stage III malignant testicular germ cell tumor
1519460|NCT00002931|stage IV ovarian germ cell tumor
1519461|NCT00002931|stage IV extragonadal non-seminomatous germ cell tumor
1519462|NCT00002931|stage IV extragonadal seminoma
1519463|NCT00002931|adult central nervous system germ cell tumor
1519464|NCT00002930|stage I non-small cell lung cancer
1519465|NCT00002930|stage II non-small cell lung cancer
1519466|NCT00002930|stage I esophageal cancer
1519467|NCT00002930|stage II esophageal cancer
1519468|NCT00002930|stage III esophageal cancer
1519469|NCT00002930|stage IIIA non-small cell lung cancer
1519470|NCT00002930|stage IIIB non-small cell lung cancer
1519471|NCT00002928|recurrent ovarian epithelial cancer
1519472|NCT00002926|secondary acute myeloid leukemia
1519473|NCT00002926|refractory anemia
1519474|NCT00002926|refractory anemia with ringed sideroblasts
1519475|NCT00002926|refractory anemia with excess blasts
1519476|NCT00002926|refractory anemia with excess blasts in transformation
1519477|NCT00002926|chronic myelomonocytic leukemia
1519478|NCT00002926|de novo myelodysplastic syndromes
1519479|NCT00002926|previously treated myelodysplastic syndromes
1519480|NCT00002926|secondary myelodysplastic syndromes
1519481|NCT00002926|refractory cytopenia with multilineage dysplasia
1519482|NCT00002926|childhood myelodysplastic syndromes
1519483|NCT00002925|untreated adult acute myeloid leukemia
1519484|NCT00002925|adult acute erythroid leukemia (M6)
1519485|NCT00002925|adult acute myeloblastic leukemia without maturation (M1)
1519486|NCT00002925|adult acute myeloblastic leukemia with maturation (M2)
1519487|NCT00002925|adult acute myelomonocytic leukemia (M4)
1519488|NCT00002925|adult acute monoblastic leukemia (M5a)
1519489|NCT00002925|adult acute megakaryoblastic leukemia (M7)
1519490|NCT00002925|adult acute monocytic leukemia (M5b)
1519491|NCT00002925|adult acute minimally differentiated myeloid leukemia (M0)
1519492|NCT00002924|adenocarcinoma of the prostate
1519493|NCT00002924|recurrent prostate cancer
1519494|NCT00002923|unspecified adult solid tumor, protocol specific
1519495|NCT00002922|stage IV squamous cell carcinoma of the lip and oral cavity
1519496|NCT00002922|recurrent squamous cell carcinoma of the lip and oral cavity
1519497|NCT00002922|stage IV squamous cell carcinoma of the oropharynx
1519498|NCT00002922|recurrent squamous cell carcinoma of the oropharynx
1519499|NCT00002922|stage IV squamous cell carcinoma of the nasopharynx
1519500|NCT00002922|recurrent squamous cell carcinoma of the nasopharynx
1519501|NCT00002922|stage IV squamous cell carcinoma of the hypopharynx
1519502|NCT00002922|recurrent squamous cell carcinoma of the hypopharynx
1519503|NCT00002922|stage IV squamous cell carcinoma of the larynx
1519504|NCT00002922|recurrent squamous cell carcinoma of the larynx
1519505|NCT00002922|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1519506|NCT00002922|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1519507|NCT00002921|stage III adrenocortical carcinoma
1519508|NCT00002921|stage IV adrenocortical carcinoma
1519509|NCT00002920|endometrial cancer
1519510|NCT00002920|stage I breast cancer
1519511|NCT00002920|stage II breast cancer
1519512|NCT00002920|ductal breast carcinoma in situ
1519513|NCT00002920|lobular breast carcinoma in situ
1519514|NCT00002920|Paget disease of the breast
1519515|NCT00002919|stage II bladder cancer
1519516|NCT00002919|transitional cell carcinoma of the bladder
1519517|NCT00002917|stage 0 bladder cancer
1519518|NCT00002917|stage I bladder cancer
1519519|NCT00002917|transitional cell carcinoma of the bladder
1519520|NCT00002916|stage IB cervical cancer
1519521|NCT00002916|stage IIA cervical cancer
1519522|NCT00002916|cervical squamous cell carcinoma
1519523|NCT00002916|cervical adenocarcinoma
1519524|NCT00002916|cervical adenosquamous cell carcinoma
1519525|NCT00002915|unspecified adult solid tumor, protocol specific
1519526|NCT00002914|recurrent bladder cancer
1519527|NCT00002914|transitional cell carcinoma of the bladder
1519528|NCT00002914|squamous cell carcinoma of the bladder
1519529|NCT00002914|adenocarcinoma of the bladder
1519530|NCT00002914|recurrent urethral cancer
1519531|NCT00002914|recurrent transitional cell cancer of the renal pelvis and ureter
1519532|NCT00002912|recurrent childhood acute lymphoblastic leukemia
1519533|NCT00002912|recurrent childhood acute myeloid leukemia
1519534|NCT00002912|secondary acute myeloid leukemia
1519535|NCT00002911|stage IIIA non-small cell lung cancer
1519536|NCT00002911|stage IIIB non-small cell lung cancer
1519537|NCT00002909|stage III adult Hodgkin lymphoma
1519538|NCT00002909|stage IV adult Hodgkin lymphoma
1519539|NCT00002909|recurrent adult Hodgkin lymphoma
1519540|NCT00002909|unspecified adult solid tumor, protocol specific
1519541|NCT00002909|stage III grade 1 follicular lymphoma
1519542|NCT00002909|stage III grade 2 follicular lymphoma
1519543|NCT00002909|stage III grade 3 follicular lymphoma
1519544|NCT00002909|stage III adult diffuse small cleaved cell lymphoma
1519545|NCT00002909|stage III adult diffuse mixed cell lymphoma
1519546|NCT00002909|stage III adult diffuse large cell lymphoma
1519547|NCT00002909|stage III adult immunoblastic large cell lymphoma
1519548|NCT00002909|stage III adult lymphoblastic lymphoma
1519549|NCT00002909|stage III adult Burkitt lymphoma
1519550|NCT00002909|stage IV grade 1 follicular lymphoma
1519551|NCT00002909|stage IV grade 2 follicular lymphoma
1519552|NCT00002909|stage IV grade 3 follicular lymphoma
1519553|NCT00002909|stage IV adult diffuse small cleaved cell lymphoma
1519554|NCT00002909|stage IV adult diffuse mixed cell lymphoma
1519555|NCT00002909|stage IV adult diffuse large cell lymphoma
1519556|NCT00002909|stage IV adult immunoblastic large cell lymphoma
1519557|NCT00002909|stage IV adult lymphoblastic lymphoma
1519558|NCT00002909|stage IV adult Burkitt lymphoma
1519559|NCT00002909|recurrent grade 1 follicular lymphoma
1519560|NCT00002909|recurrent grade 2 follicular lymphoma
1519561|NCT00002909|recurrent grade 3 follicular lymphoma
1519562|NCT00002909|recurrent adult diffuse small cleaved cell lymphoma
1519563|NCT00002909|recurrent adult diffuse mixed cell lymphoma
1519564|NCT00002909|recurrent adult diffuse large cell lymphoma
1519565|NCT00002909|recurrent adult immunoblastic large cell lymphoma
1519566|NCT00002909|recurrent adult lymphoblastic lymphoma
1519567|NCT00002909|recurrent adult Burkitt lymphoma
1519568|NCT00002909|stage III adult T-cell leukemia/lymphoma
1519569|NCT00002909|stage IV adult T-cell leukemia/lymphoma
1519570|NCT00002909|stage III mantle cell lymphoma
1519571|NCT00002909|stage IV mantle cell lymphoma
1519572|NCT00002909|recurrent mantle cell lymphoma
1519573|NCT00002909|angioimmunoblastic T-cell lymphoma
1519574|NCT00002909|anaplastic large cell lymphoma
1519575|NCT00002909|recurrent marginal zone lymphoma
1519576|NCT00002909|recurrent small lymphocytic lymphoma
1519577|NCT00002909|stage III small lymphocytic lymphoma
1519578|NCT00002909|stage III marginal zone lymphoma
1519579|NCT00002909|stage IV small lymphocytic lymphoma
1519580|NCT00002909|stage IV marginal zone lymphoma
1519581|NCT00002909|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519582|NCT00002909|nodal marginal zone B-cell lymphoma
1519583|NCT00002909|splenic marginal zone lymphoma
1519584|NCT00002908|refractory chronic lymphocytic leukemia
1519585|NCT00002908|recurrent small lymphocytic lymphoma
1519586|NCT00002908|recurrent grade 1 follicular lymphoma
1519587|NCT00002908|recurrent grade 2 follicular lymphoma
1519588|NCT00002908|recurrent grade 3 follicular lymphoma
1519589|NCT00002908|recurrent adult diffuse small cleaved cell lymphoma
1519590|NCT00002908|recurrent adult diffuse mixed cell lymphoma
1519591|NCT00002908|recurrent adult diffuse large cell lymphoma
1519592|NCT00002908|recurrent adult immunoblastic large cell lymphoma
1519593|NCT00002908|recurrent adult lymphoblastic lymphoma
1519594|NCT00002908|recurrent adult Burkitt lymphoma
1519595|NCT00002908|recurrent mantle cell lymphoma
1519596|NCT00002908|recurrent marginal zone lymphoma
1519597|NCT00002908|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519598|NCT00002908|nodal marginal zone B-cell lymphoma
1519599|NCT00002908|splenic marginal zone lymphoma
1519600|NCT00002907|refractory multiple myeloma
1519601|NCT00002905|AIDS-related peripheral/systemic lymphoma
1519602|NCT00002904|unspecified adult solid tumor, protocol specific
1519603|NCT00002903|recurrent malignant testicular germ cell tumor
1519604|NCT00002903|testicular seminoma
1519605|NCT00002903|recurrent ovarian germ cell tumor
1519606|NCT00002903|extragonadal germ cell tumor
1519607|NCT00002902|unspecified adult solid tumor, protocol specific
1519608|NCT00002901|stage IV breast cancer
1519609|NCT00002901|stage IIIA breast cancer
1519610|NCT00002901|recurrent breast cancer
1519611|NCT00002901|stage IIIB breast cancer
1519612|NCT00002901|recurrent non-small cell lung cancer
1519613|NCT00002901|stage III ovarian epithelial cancer
1519614|NCT00002901|stage IV ovarian epithelial cancer
1519615|NCT00002901|recurrent ovarian epithelial cancer
1519616|NCT00002901|stage IV nasopharyngeal cancer
1519617|NCT00002901|stage IIIA non-small cell lung cancer
1519618|NCT00002901|stage IIIB non-small cell lung cancer
1519619|NCT00002901|stage IV non-small cell lung cancer
1519620|NCT00002901|unspecified adult solid tumor, protocol specific
1519621|NCT00002901|recurrent metastatic squamous neck cancer with occult primary
1519622|NCT00002901|ovarian stromal cancer
1519623|NCT00002901|stage III ovarian germ cell tumor
1519624|NCT00002901|stage IV ovarian germ cell tumor
1519625|NCT00002901|recurrent ovarian germ cell tumor
1519626|NCT00002901|stage III squamous cell carcinoma of the lip and oral cavity
1519627|NCT00002901|stage III basal cell carcinoma of the lip
1519628|NCT00002901|stage III verrucous carcinoma of the oral cavity
1519629|NCT00002901|stage III mucoepidermoid carcinoma of the oral cavity
1519630|NCT00002901|stage III adenoid cystic carcinoma of the oral cavity
1519631|NCT00002901|stage IV squamous cell carcinoma of the lip and oral cavity
1519632|NCT00002901|stage IV basal cell carcinoma of the lip
1519633|NCT00002901|stage IV verrucous carcinoma of the oral cavity
1519634|NCT00002901|stage IV mucoepidermoid carcinoma of the oral cavity
1519635|NCT00002901|stage IV adenoid cystic carcinoma of the oral cavity
1519636|NCT00002901|recurrent squamous cell carcinoma of the lip and oral cavity
1519637|NCT00002901|recurrent basal cell carcinoma of the lip
1519638|NCT00002901|recurrent verrucous carcinoma of the oral cavity
1519639|NCT00002901|recurrent mucoepidermoid carcinoma of the oral cavity
1519640|NCT00002901|recurrent adenoid cystic carcinoma of the oral cavity
1519641|NCT00002901|stage III squamous cell carcinoma of the oropharynx
1519642|NCT00002901|stage III lymphoepithelioma of the oropharynx
1519643|NCT00002901|stage IV squamous cell carcinoma of the oropharynx
1519644|NCT00002901|stage IV lymphoepithelioma of the oropharynx
1519645|NCT00002901|recurrent squamous cell carcinoma of the oropharynx
1519646|NCT00002901|recurrent lymphoepithelioma of the oropharynx
1519647|NCT00002901|stage III squamous cell carcinoma of the nasopharynx
1519648|NCT00002901|stage III lymphoepithelioma of the nasopharynx
1519649|NCT00002901|stage IV squamous cell carcinoma of the nasopharynx
1519650|NCT00002901|stage IV lymphoepithelioma of the nasopharynx
1519651|NCT00002901|recurrent squamous cell carcinoma of the nasopharynx
1519652|NCT00002901|recurrent lymphoepithelioma of the nasopharynx
1519653|NCT00002901|stage III squamous cell carcinoma of the hypopharynx
1519654|NCT00002901|stage IV squamous cell carcinoma of the hypopharynx
1519655|NCT00002901|recurrent squamous cell carcinoma of the hypopharynx
1519656|NCT00002901|stage III squamous cell carcinoma of the larynx
1519657|NCT00002901|stage III verrucous carcinoma of the larynx
1519658|NCT00002901|stage IV squamous cell carcinoma of the larynx
1519659|NCT00002901|stage IV verrucous carcinoma of the larynx
1519660|NCT00002901|recurrent squamous cell carcinoma of the larynx
1519661|NCT00002901|recurrent verrucous carcinoma of the larynx
1519662|NCT00002901|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1519663|NCT00002901|stage III inverted papilloma of the paranasal sinus and nasal cavity
1519664|NCT00002901|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1519665|NCT00002901|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1519666|NCT00002901|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1519667|NCT00002901|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1519668|NCT00002901|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1519669|NCT00002901|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1519670|NCT00002901|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1519671|NCT00002901|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1519672|NCT00002901|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1519673|NCT00002901|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1519674|NCT00002901|borderline ovarian surface epithelial-stromal tumor
1519675|NCT00002901|ovarian sarcoma
1519676|NCT00002900|stage I breast cancer
1519677|NCT00002900|stage II breast cancer
1519678|NCT00002900|ductal breast carcinoma
1519679|NCT00002900|cardiac toxicity
1519680|NCT00002899|tumors metastatic to brain
1519681|NCT00002898|embryonal childhood rhabdomyosarcoma
1519682|NCT00002898|alveolar childhood rhabdomyosarcoma
1519683|NCT00002898|pleomorphic childhood rhabdomyosarcoma
1519684|NCT00002898|mixed childhood rhabdomyosarcoma
1519685|NCT00002898|embryonal-botryoid childhood rhabdomyosarcoma
1519686|NCT00002898|nonmetastatic childhood soft tissue sarcoma
1519687|NCT00002898|childhood fibrosarcoma
1519688|NCT00002898|childhood synovial sarcoma
1519689|NCT00002898|childhood malignant hemangiopericytoma
1519690|NCT00002898|childhood liposarcoma
1519691|NCT00002898|childhood alveolar soft-part sarcoma
1519692|NCT00002898|childhood leiomyosarcoma
1519693|NCT00002898|childhood neurofibrosarcoma
1519694|NCT00002898|childhood angiosarcoma
1519695|NCT00002898|childhood epithelioid sarcoma
1519696|NCT00002898|childhood malignant fibrous histiocytoma of bone
1519697|NCT00002898|childhood malignant mesenchymoma
1519698|NCT00002898|previously untreated childhood rhabdomyosarcoma
1519699|NCT00002898|childhood desmoplastic small round cell tumor
1519700|NCT00002898|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1519701|NCT00002897|stage II esophageal cancer
1519702|NCT00002897|stage III esophageal cancer
1519703|NCT00002897|squamous cell carcinoma of the esophagus
1519704|NCT00002896|stage II rectal cancer
1519705|NCT00002896|stage III rectal cancer
1519706|NCT00002896|recurrent rectal cancer
1519707|NCT00002896|adenocarcinoma of the rectum
1519708|NCT00002896|mucinous adenocarcinoma of the rectum
1519709|NCT00002895|recurrent ovarian epithelial cancer
1519710|NCT00002895|primary peritoneal cavity cancer
1519711|NCT00002895|fallopian tube cancer
1519712|NCT00002894|recurrent ovarian epithelial cancer
1519713|NCT00002894|primary peritoneal cavity cancer
1519714|NCT00002893|stage III colon cancer
1519715|NCT00002893|stage IV colon cancer
1519716|NCT00002893|stage III rectal cancer
1519717|NCT00002893|stage IV rectal cancer
1519718|NCT00002893|recurrent colon cancer
1519719|NCT00002893|recurrent rectal cancer
1519720|NCT00002893|adenocarcinoma of the colon
1519721|NCT00002893|adenocarcinoma of the rectum
1519722|NCT00002892|stage II melanoma
1519723|NCT00002892|stage III melanoma
1519724|NCT00002892|recurrent melanoma
1519725|NCT00002890|recurrent adult acute myeloid leukemia
1519726|NCT00002890|relapsing chronic myelogenous leukemia
1519727|NCT00002890|accelerated phase chronic myelogenous leukemia
1519728|NCT00002890|blastic phase chronic myelogenous leukemia
1519729|NCT00002890|refractory anemia with excess blasts
1519730|NCT00002890|refractory anemia with excess blasts in transformation
1519731|NCT00002890|chronic myelomonocytic leukemia
1519732|NCT00002890|de novo myelodysplastic syndromes
1519733|NCT00002890|previously treated myelodysplastic syndromes
1519734|NCT00002890|childhood myelodysplastic syndromes
1519735|NCT00002889|adenocarcinoma of the prostate
1519736|NCT00002889|stage I prostate cancer
1519737|NCT00002889|stage II prostate cancer
1519738|NCT00002889|stage III prostate cancer
1519739|NCT00002889|stage IV prostate cancer
1519740|NCT00002888|stage III squamous cell carcinoma of the lip and oral cavity
1519741|NCT00002888|stage IV squamous cell carcinoma of the lip and oral cavity
1519742|NCT00002888|recurrent squamous cell carcinoma of the lip and oral cavity
1519743|NCT00002888|stage III squamous cell carcinoma of the oropharynx
1519744|NCT00002888|stage IV squamous cell carcinoma of the oropharynx
1519745|NCT00002888|recurrent squamous cell carcinoma of the oropharynx
1519746|NCT00002888|stage III squamous cell carcinoma of the hypopharynx
1519747|NCT00002888|stage IV squamous cell carcinoma of the hypopharynx
1519748|NCT00002888|recurrent squamous cell carcinoma of the hypopharynx
1519749|NCT00002888|stage III squamous cell carcinoma of the larynx
1519750|NCT00002888|stage IV squamous cell carcinoma of the larynx
1519751|NCT00002888|recurrent squamous cell carcinoma of the larynx
1519752|NCT00002888|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1519753|NCT00002888|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1519754|NCT00002888|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1519755|NCT00002887|recurrent non-small cell lung cancer
1519756|NCT00002884|stage I esophageal cancer
1519757|NCT00002884|stage II esophageal cancer
1519758|NCT00002884|stage III esophageal cancer
1519759|NCT00002884|squamous cell carcinoma of the esophagus
1519760|NCT00002884|adenocarcinoma of the esophagus
1519761|NCT00002883|stage I gastric cancer
1519762|NCT00002883|stage II gastric cancer
1519763|NCT00002883|stage I esophageal cancer
1519764|NCT00002883|stage II esophageal cancer
1519765|NCT00002883|adenocarcinoma of the stomach
1519766|NCT00002883|adenocarcinoma of the esophagus
1519767|NCT00002882|stage III melanoma
1519768|NCT00002881|adenocarcinoma of the prostate
1519769|NCT00002881|stage IV prostate cancer
1519770|NCT00002881|recurrent prostate cancer
1519771|NCT00002880|Waldenstrom macroglobulinemia
1519772|NCT00002880|recurrent small lymphocytic lymphoma
1519773|NCT00002880|recurrent grade 1 follicular lymphoma
1519774|NCT00002880|recurrent grade 2 follicular lymphoma
1519775|NCT00002880|recurrent grade 3 follicular lymphoma
1519776|NCT00002880|recurrent adult diffuse small cleaved cell lymphoma
1519777|NCT00002880|recurrent adult diffuse mixed cell lymphoma
1519778|NCT00002880|recurrent adult diffuse large cell lymphoma
1519779|NCT00002880|recurrent adult immunoblastic large cell lymphoma
1519780|NCT00002879|mantle cell lymphoma
1523164|NCT00002398|HIV-1
1519781|NCT00002879|stage I mantle cell lymphoma
1519782|NCT00002879|contiguous stage II mantle cell lymphoma
1519783|NCT00002879|noncontiguous stage II mantle cell lymphoma
1519784|NCT00002879|stage III mantle cell lymphoma
1519785|NCT00002879|stage IV mantle cell lymphoma
1519786|NCT00002879|recurrent mantle cell lymphoma
1519787|NCT00002878|refractory multiple myeloma
1519788|NCT00002876|recurrent adult brain tumor
1519789|NCT00002876|adult myxopapillary ependymoma
1519790|NCT00002876|adult anaplastic ependymoma
1519791|NCT00002875|untreated childhood medulloblastoma
1519792|NCT00002874|stage IIB prostate cancer
1519793|NCT00002874|stage IIA prostate cancer
1519794|NCT00002874|stage III prostate cancer
1519795|NCT00002874|recurrent prostate cancer
1519796|NCT00002873|stage I breast cancer
1519797|NCT00002873|stage II breast cancer
1519798|NCT00002873|medullary ductal breast carcinoma with lymphocytic infiltrate
1519799|NCT00002873|mucinous ductal breast carcinoma
1519800|NCT00002873|invasive ductal breast carcinoma
1519801|NCT00002873|papillary ductal breast carcinoma
1519802|NCT00002873|tubular ductal breast carcinoma
1519803|NCT00002872|malignant pleural effusion
1519804|NCT00002870|stage IV breast cancer
1519805|NCT00002870|recurrent breast cancer
1519806|NCT00002869|chronic phase chronic myelogenous leukemia
1519807|NCT00002869|chronic myelogenous leukemia, BCR-ABL1 positive
1519808|NCT00002869|Philadelphia chromosome negative chronic myelogenous leukemia
1519809|NCT00002868|chronic phase chronic myelogenous leukemia
1519810|NCT00002866|stage IV breast cancer
1519811|NCT00002866|recurrent breast cancer
1519812|NCT00002866|neutropenia
1519813|NCT00002865|recurrent adult acute lymphoblastic leukemia
1519814|NCT00002864|stage I breast cancer
1519815|NCT00002864|stage II breast cancer
1519816|NCT00002864|stage III breast cancer
1519817|NCT00002863|recurrent childhood rhabdomyosarcoma
1519818|NCT00002863|stage I adult soft tissue sarcoma
1519819|NCT00002863|stage II adult soft tissue sarcoma
1519820|NCT00002863|stage III adult soft tissue sarcoma
1519821|NCT00002863|recurrent adult soft tissue sarcoma
1519822|NCT00002863|nonmetastatic childhood soft tissue sarcoma
1519823|NCT00002863|recurrent childhood soft tissue sarcoma
1519824|NCT00002863|previously untreated childhood rhabdomyosarcoma
1519825|NCT00002863|stage IV adult soft tissue sarcoma
1519826|NCT00002862|stage IV adult Hodgkin lymphoma
1519827|NCT00002862|recurrent adult Hodgkin lymphoma
1519828|NCT00002862|unspecified adult solid tumor, protocol specific
1519829|NCT00002862|stage IV grade 1 follicular lymphoma
1519830|NCT00002862|stage IV grade 2 follicular lymphoma
1519831|NCT00002862|stage IV grade 3 follicular lymphoma
1519832|NCT00002862|stage IV adult diffuse small cleaved cell lymphoma
1519833|NCT00002862|stage IV adult diffuse mixed cell lymphoma
1519834|NCT00002862|stage IV adult diffuse large cell lymphoma
1519835|NCT00002862|stage IV adult immunoblastic large cell lymphoma
1519836|NCT00002862|stage IV adult lymphoblastic lymphoma
1519837|NCT00002862|stage IV adult Burkitt lymphoma
1519838|NCT00002862|recurrent grade 1 follicular lymphoma
1519839|NCT00002862|recurrent grade 2 follicular lymphoma
1519840|NCT00002862|recurrent grade 3 follicular lymphoma
1519841|NCT00002862|recurrent adult diffuse small cleaved cell lymphoma
1519842|NCT00002862|recurrent adult diffuse mixed cell lymphoma
1519843|NCT00002862|recurrent adult diffuse large cell lymphoma
1519844|NCT00002862|recurrent adult immunoblastic large cell lymphoma
1519845|NCT00002862|recurrent adult lymphoblastic lymphoma
1519846|NCT00002862|recurrent adult Burkitt lymphoma
1519847|NCT00002862|stage IV adult T-cell leukemia/lymphoma
1519848|NCT00002862|recurrent adult T-cell leukemia/lymphoma
1519849|NCT00002862|stage IV mantle cell lymphoma
1519850|NCT00002862|recurrent mantle cell lymphoma
1519851|NCT00002862|angioimmunoblastic T-cell lymphoma
1519852|NCT00002862|anaplastic large cell lymphoma
1519853|NCT00002862|recurrent marginal zone lymphoma
1519854|NCT00002862|recurrent small lymphocytic lymphoma
1519855|NCT00002862|stage IV small lymphocytic lymphoma
1519856|NCT00002862|stage IV marginal zone lymphoma
1519857|NCT00002862|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1519858|NCT00002862|nodal marginal zone B-cell lymphoma
1519859|NCT00002862|splenic marginal zone lymphoma
1519860|NCT00002860|stage IV melanoma
1519861|NCT00002860|recurrent melanoma
1519862|NCT00002858|limited stage small cell lung cancer
1519863|NCT00002855|adenocarcinoma of the prostate
1519864|NCT00002855|stage III prostate cancer
1519865|NCT00002855|stage IV prostate cancer
1519866|NCT00002855|recurrent prostate cancer
1519867|NCT00002854|stage IV colon cancer
1519868|NCT00002854|stage II breast cancer
1519869|NCT00002854|stage IV breast cancer
1519870|NCT00002854|stage IIIA breast cancer
1519871|NCT00002854|recurrent breast cancer
1519872|NCT00002854|stage IV gastric cancer
1519873|NCT00002854|recurrent gastric cancer
1519874|NCT00002854|localized osteosarcoma
1519875|NCT00002854|metastatic osteosarcoma
1519876|NCT00002854|stage IIIB breast cancer
1519877|NCT00002854|recurrent pancreatic cancer
1519878|NCT00002854|stage IV rectal cancer
1519879|NCT00002854|recurrent colon cancer
1519880|NCT00002854|recurrent rectal cancer
1519881|NCT00002854|stage IV anal cancer
1519883|NCT00002854|stage IV esophageal cancer
1519884|NCT00002854|recurrent esophageal cancer
1519885|NCT00002854|stage III adult soft tissue sarcoma
1519886|NCT00002854|recurrent adult soft tissue sarcoma
1519887|NCT00002854|stage III ovarian epithelial cancer
1519888|NCT00002854|stage IV ovarian epithelial cancer
1519889|NCT00002854|recurrent ovarian epithelial cancer
1519890|NCT00002854|recurrent Wilms tumor and other childhood kidney tumors
1519891|NCT00002854|advanced adult primary liver cancer
1519892|NCT00002854|recurrent adult primary liver cancer
1519893|NCT00002854|recurrent osteosarcoma
1519894|NCT00002854|recurrent gallbladder cancer
1519895|NCT00002854|recurrent extrahepatic bile duct cancer
1519896|NCT00002854|recurrent small intestine cancer
1519897|NCT00002854|stage II melanoma
1519898|NCT00002854|stage III melanoma
1519899|NCT00002854|stage IV melanoma
1519900|NCT00002854|recurrent melanoma
1519901|NCT00002854|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1519902|NCT00002854|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1519903|NCT00002854|stage IV adult soft tissue sarcoma
1519904|NCT00002854|stage IV pancreatic cancer
1519905|NCT00002851|stage I breast cancer
1519906|NCT00002851|stage II breast cancer
1519907|NCT00002851|stage IIIA breast cancer
1519908|NCT00002850|stage I multiple myeloma
1519909|NCT00002850|stage II multiple myeloma
1519910|NCT00002850|stage III multiple myeloma
1519911|NCT00002850|infection
1519912|NCT00002849|primary systemic amyloidosis
1519913|NCT00002848|stage I prostate cancer
1519914|NCT00002848|stage IIB prostate cancer
1519915|NCT00002848|stage IIA prostate cancer
1519916|NCT00002848|psychosocial effects of cancer and its treatment
1519917|NCT00002847|stage IV renal cell cancer
1519918|NCT00002847|recurrent renal cell cancer
1519919|NCT00002846|stage IV renal cell cancer
1519920|NCT00002846|recurrent renal cell cancer
1519921|NCT00002845|stage IV melanoma
1519922|NCT00002845|recurrent melanoma
1519923|NCT00002844|refractory chronic lymphocytic leukemia
1519924|NCT00002844|Cyclophosphamide
1519925|NCT00002844|Cytoxan
1519926|NCT00002844|Neosar
1519927|NCT00002844|Bone Marrow Transplantation
1519928|NCT00002844|total body irradiation
1519929|NCT00002844|chronic lymphocytic leukemia
1519930|NCT00002844|allogeneic
1519931|NCT00002844|autologous
1519932|NCT00002842|stage IV colon cancer
1519933|NCT00002842|stage IV rectal cancer
1519934|NCT00002842|recurrent colon cancer
1519935|NCT00002842|recurrent rectal cancer
1519936|NCT00002842|liver metastases
1519937|NCT00002840|recurrent adult brain tumor
1519938|NCT00002840|adult anaplastic oligodendroglioma
1519939|NCT00002840|adult mixed glioma
1519940|NCT00002839|stage II squamous cell carcinoma of the hypopharynx
1519941|NCT00002839|stage III squamous cell carcinoma of the hypopharynx
1519942|NCT00002839|stage IV squamous cell carcinoma of the hypopharynx
1519943|NCT00002839|stage III squamous cell carcinoma of the larynx
1519944|NCT00002839|stage IV squamous cell carcinoma of the larynx
1519945|NCT00002838|stage III chronic lymphocytic leukemia
1519946|NCT00002838|stage IV chronic lymphocytic leukemia
1519947|NCT00002838|refractory chronic lymphocytic leukemia
1519948|NCT00002837|stage IV breast cancer
1519949|NCT00002837|recurrent breast cancer
1519950|NCT00002836|recurrent breast cancer
1519951|NCT00002835|stage I grade 3 follicular lymphoma
1519952|NCT00002835|stage I adult diffuse small cleaved cell lymphoma
1519953|NCT00002835|stage I adult diffuse mixed cell lymphoma
1519954|NCT00002835|stage I adult diffuse large cell lymphoma
1519955|NCT00002835|stage I adult immunoblastic large cell lymphoma
1519956|NCT00002835|stage III grade 3 follicular lymphoma
1519957|NCT00002835|stage III adult diffuse small cleaved cell lymphoma
1519958|NCT00002835|stage III adult diffuse mixed cell lymphoma
1519959|NCT00002835|stage III adult diffuse large cell lymphoma
1519960|NCT00002835|stage III adult immunoblastic large cell lymphoma
1519961|NCT00002835|stage IV grade 3 follicular lymphoma
1519962|NCT00002835|stage IV adult diffuse small cleaved cell lymphoma
1519963|NCT00002835|stage IV adult diffuse mixed cell lymphoma
1519964|NCT00002835|stage IV adult diffuse large cell lymphoma
1519965|NCT00002835|stage IV adult immunoblastic large cell lymphoma
1519966|NCT00002835|contiguous stage II grade 3 follicular lymphoma
1519967|NCT00002835|contiguous stage II adult diffuse small cleaved cell lymphoma
1519968|NCT00002835|contiguous stage II adult diffuse mixed cell lymphoma
1519969|NCT00002835|contiguous stage II adult immunoblastic large cell lymphoma
1519970|NCT00002835|contiguous stage II adult diffuse large cell lymphoma
1519971|NCT00002835|noncontiguous stage II grade 3 follicular lymphoma
1519972|NCT00002835|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1519973|NCT00002835|noncontiguous stage II adult diffuse mixed cell lymphoma
1519974|NCT00002835|noncontiguous stage II adult immunoblastic large cell lymphoma
1519975|NCT00002835|noncontiguous stage II adult diffuse large cell lymphoma
1519976|NCT00002833|recurrent adult acute myeloid leukemia
1519977|NCT00002833|relapsing chronic myelogenous leukemia
1519978|NCT00002833|chronic phase chronic myelogenous leukemia
1519979|NCT00002833|accelerated phase chronic myelogenous leukemia
1519980|NCT00002833|blastic phase chronic myelogenous leukemia
1519981|NCT00002833|adult acute myeloid leukemia in remission
1519982|NCT00002833|Philadelphia chromosome positive chronic myelogenous leukemia
1519983|NCT00002833|refractory anemia with excess blasts
1519984|NCT00002833|refractory anemia with excess blasts in transformation
1519985|NCT00002833|chronic myelomonocytic leukemia
1519986|NCT00002833|graft versus host disease
1519987|NCT00002832|Decitabine
1519988|NCT00002832|Dacogen
1519989|NCT00002832|Filgrastim
1519990|NCT00002832|G-CSF
1519991|NCT00002832|Neupogen
1519992|NCT00002832|Cyclosporine
1519993|NCT00002832|Sandimmune
1519994|NCT00002832|CYA
1519995|NCT00002832|Cyclosporin A
1519996|NCT00002832|Peripheral blood stem cells
1519997|NCT00002832|PBSC
1519998|NCT00002832|Allogeneic bone marrow transplantation
1519999|NCT00002832|recurrent childhood acute lymphoblastic leukemia
1520198|NCT00002783|stage IV gastric cancer
1520000|NCT00002832|recurrent childhood acute myeloid leukemia
1520001|NCT00002832|recurrent adult acute myeloid leukemia
1520002|NCT00002832|recurrent adult acute lymphoblastic leukemia
1520003|NCT00002832|accelerated phase chronic myelogenous leukemia
1520004|NCT00002832|blastic phase chronic myelogenous leukemia
1520005|NCT00002832|previously treated myelodysplastic syndromes
1520006|NCT00002832|childhood myelodysplastic syndromes
1520007|NCT00002831|recurrent adult acute myeloid leukemia
1520008|NCT00002831|accelerated phase chronic myelogenous leukemia
1520009|NCT00002831|blastic phase chronic myelogenous leukemia
1520010|NCT00002829|Waldenstrom macroglobulinemia
1520011|NCT00002829|recurrent grade 1 follicular lymphoma
1520012|NCT00002829|recurrent grade 2 follicular lymphoma
1520013|NCT00002829|recurrent marginal zone lymphoma
1520014|NCT00002829|recurrent small lymphocytic lymphoma
1520015|NCT00002829|extranodal marginal zone B-cell lymphoma
1520016|NCT00002829|mucosa-associated lymphoid tissue
1520017|NCT00002829|nodal marginal zone B-cell lymphoma
1520018|NCT00002829|splenic marginal zone lymphoma
1520019|NCT00002828|stage III colon cancer
1520020|NCT00002828|stage IV colon cancer
1520021|NCT00002828|stage III rectal cancer
1520022|NCT00002828|stage IV rectal cancer
1520023|NCT00002828|recurrent colon cancer
1520024|NCT00002828|recurrent rectal cancer
1520025|NCT00002827|stage II childhood Hodgkin lymphoma
1520026|NCT00002827|stage I childhood Hodgkin lymphoma
1520027|NCT00002827|stage III childhood Hodgkin lymphoma
1520028|NCT00002827|cardiac toxicity
1520029|NCT00002826|stage IV breast cancer
1520030|NCT00002826|recurrent breast cancer
1520031|NCT00002825|recurrent childhood rhabdomyosarcoma
1520032|NCT00002825|recurrent neuroblastoma
1520033|NCT00002825|recurrent osteosarcoma
1520034|NCT00002825|recurrent childhood soft tissue sarcoma
1520035|NCT00002825|recurrent childhood brain stem glioma
1520036|NCT00002825|recurrent childhood supratentorial primitive neuroectodermal tumor
1520037|NCT00002825|recurrent childhood cerebellar astrocytoma
1520038|NCT00002825|recurrent childhood cerebral astrocytoma
1520039|NCT00002825|recurrent childhood medulloblastoma
1520040|NCT00002825|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1520041|NCT00002825|recurrent childhood ependymoma
1520042|NCT00002824|recurrent adult brain tumor
1520043|NCT00002824|adult glioblastoma
1520044|NCT00002824|adult anaplastic astrocytoma
1520045|NCT00002824|adult giant cell glioblastoma
1520046|NCT00002824|adult gliosarcoma
1520047|NCT00002823|stage I non-small cell lung cancer
1520048|NCT00002823|stage II non-small cell lung cancer
1520049|NCT00002823|stage III non-small cell lung cancer
1520050|NCT00002823|squamous cell lung cancer
1520051|NCT00002823|large cell lung cancer
1520052|NCT00002823|adenocarcinoma of the lung
1520053|NCT00002823|adenosquamous cell lung cancer
1520054|NCT00002822|limited stage small cell lung cancer
1520055|NCT00002822|extensive stage small cell lung cancer
1520056|NCT00002819|stage III ovarian epithelial cancer
1520057|NCT00002819|recurrent ovarian epithelial cancer
1520058|NCT00002819|ovarian undifferentiated adenocarcinoma
1520059|NCT00002819|ovarian mixed epithelial carcinoma
1520060|NCT00002819|ovarian serous cystadenocarcinoma
1520061|NCT00002819|ovarian mucinous cystadenocarcinoma
1520062|NCT00002819|ovarian endometrioid adenocarcinoma
1520063|NCT00002819|ovarian clear cell cystadenocarcinoma
1520064|NCT00002819|Brenner tumor
1520065|NCT00002818|recurrent adult Hodgkin lymphoma
1520066|NCT00002818|refractory multiple myeloma
1520067|NCT00002818|recurrent adult acute myeloid leukemia
1520068|NCT00002818|recurrent adult acute lymphoblastic leukemia
1520069|NCT00002818|relapsing chronic myelogenous leukemia
1520070|NCT00002818|blastic phase chronic myelogenous leukemia
1520071|NCT00002818|recurrent grade 1 follicular lymphoma
1520072|NCT00002818|recurrent grade 2 follicular lymphoma
1520073|NCT00002818|recurrent grade 3 follicular lymphoma
1520074|NCT00002818|recurrent adult diffuse small cleaved cell lymphoma
1520075|NCT00002818|recurrent adult diffuse mixed cell lymphoma
1520076|NCT00002818|recurrent adult diffuse large cell lymphoma
1520077|NCT00002818|recurrent adult immunoblastic large cell lymphoma
1520078|NCT00002818|recurrent adult lymphoblastic lymphoma
1520079|NCT00002818|recurrent adult Burkitt lymphoma
1520080|NCT00002818|drug/agent toxicity by tissue/organ
1520081|NCT00002818|recurrent mantle cell lymphoma
1520082|NCT00002818|recurrent marginal zone lymphoma
1520083|NCT00002818|recurrent small lymphocytic lymphoma
1520084|NCT00002818|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520085|NCT00002818|nodal marginal zone B-cell lymphoma
1520086|NCT00002818|splenic marginal zone lymphoma
1520087|NCT00002817|stage III melanoma
1520088|NCT00002817|stage IV melanoma
1520089|NCT00002817|recurrent melanoma
1520090|NCT00002816|recurrent childhood acute lymphoblastic leukemia
1520091|NCT00002814|recurrent adult brain tumor
1520092|NCT00002814|adult glioblastoma
1520093|NCT00002814|adult anaplastic astrocytoma
1520094|NCT00002814|adult giant cell glioblastoma
1520095|NCT00002814|adult gliosarcoma
1520096|NCT00002813|recurrent cervical cancer
1520097|NCT00002813|stage IVB cervical cancer
1520098|NCT00002813|cervical squamous cell carcinoma
1520099|NCT00002812|untreated childhood acute lymphoblastic leukemia
1520100|NCT00002812|L1 childhood acute lymphoblastic leukemia
1520101|NCT00002812|L2 childhood acute lymphoblastic leukemia
1520102|NCT00002811|actinic keratosis
1520103|NCT00002810|refractory multiple myeloma
1520104|NCT00002810|stage I multiple myeloma
1520105|NCT00002810|stage II multiple myeloma
1520106|NCT00002810|stage III multiple myeloma
1520107|NCT00002810|primary systemic amyloidosis
1520108|NCT00002809|recurrent adult acute myeloid leukemia
1520109|NCT00002809|recurrent adult acute lymphoblastic leukemia
1520110|NCT00002809|refractory chronic lymphocytic leukemia
1520111|NCT00002809|chronic phase chronic myelogenous leukemia
1520112|NCT00002809|accelerated phase chronic myelogenous leukemia
1520113|NCT00002809|adult acute myeloid leukemia in remission
1520114|NCT00002809|adult acute lymphoblastic leukemia in remission
1520115|NCT00002809|refractory anemia
1520116|NCT00002809|refractory anemia with excess blasts
1520117|NCT00002809|refractory anemia with excess blasts in transformation
1520118|NCT00002809|secondary acute myeloid leukemia
1520119|NCT00002809|previously treated myelodysplastic syndromes
1520120|NCT00002809|atypical chronic myeloid leukemia
1520121|NCT00002809|myelodysplastic/myeloproliferative disease, unclassifiable
1520122|NCT00002809|adult acute myeloid leukemia with t(8;21)(q22;q22)
1520123|NCT00002809|adult acute myeloid leukemia with t(16;16)(p13;q22)
1520124|NCT00002809|adult acute myeloid leukemia with inv(16)(p13;q22)
1520125|NCT00002809|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1520126|NCT00002809|adult acute myeloid leukemia with t(15;17)(q22;q12)
1520127|NCT00002807|stage I endometrial carcinoma
1520128|NCT00002807|stage II endometrial carcinoma
1520129|NCT00002807|endometrial adenocarcinoma
1520130|NCT00002807|endometrial adenosquamous cell carcinoma
1520131|NCT00002807|endometrial papillary carcinoma
1520132|NCT00002807|endometrial clear cell carcinoma
1520133|NCT00002806|adult diffuse astrocytoma
1520134|NCT00002805|recurrent childhood acute myeloid leukemia
1520135|NCT00002805|secondary acute myeloid leukemia
1520136|NCT00002805|childhood myelodysplastic syndromes
1520137|NCT00002804|nonmetastatic childhood soft tissue sarcoma
1520138|NCT00002804|metastatic childhood soft tissue sarcoma
1520139|NCT00002803|localized resectable neuroblastoma
1520140|NCT00002803|regional neuroblastoma
1520141|NCT00002803|stage 4S neuroblastoma
1520142|NCT00002803|localized unresectable neuroblastoma
1520143|NCT00002802|localized resectable neuroblastoma
1520144|NCT00002802|regional neuroblastoma
1520145|NCT00002802|disseminated neuroblastoma
1520146|NCT00002802|stage 4S neuroblastoma
1520147|NCT00002802|localized unresectable neuroblastoma
1520148|NCT00002801|stage II colon cancer
1520149|NCT00002801|stage III colon cancer
1520150|NCT00002801|stage I rectal cancer
1520151|NCT00002801|stage II rectal cancer
1520152|NCT00002801|stage III rectal cancer
1520153|NCT00002800|accelerated phase chronic myelogenous leukemia
1520154|NCT00002800|blastic phase chronic myelogenous leukemia
1520155|NCT00002800|untreated adult acute myeloid leukemia
1520156|NCT00002800|refractory anemia with excess blasts
1520157|NCT00002800|refractory anemia with excess blasts in transformation
1520158|NCT00002800|chronic myelomonocytic leukemia
1520159|NCT00002800|de novo myelodysplastic syndromes
1520160|NCT00002800|neutropenia
1520161|NCT00002794|intraocular retinoblastoma
1520162|NCT00002793|stage IV colon cancer
1520163|NCT00002793|stage IV rectal cancer
1520164|NCT00002793|recurrent colon cancer
1520165|NCT00002793|recurrent rectal cancer
1520166|NCT00002793|liver metastases
1520167|NCT00002792|polycythemia vera
1520168|NCT00002792|chronic idiopathic myelofibrosis
1520169|NCT00002792|essential thrombocythemia
1520170|NCT00002792|atypical chronic myeloid leukemia
1520171|NCT00002792|myelodysplastic/myeloproliferative disease, unclassifiable
1520172|NCT00002791|stage II adult soft tissue sarcoma
1520173|NCT00002791|stage III adult soft tissue sarcoma
1520174|NCT00002791|recurrent adult soft tissue sarcoma
1520175|NCT00002790|childhood acute lymphoblastic leukemia
1520176|NCT00002790|chronic lymphocytic leukemia
1520177|NCT00002790|adult acute lymphoblastic leukemia
1520178|NCT00002790|adult acute myeloid leukemia
1520179|NCT00002790|chronic myelogenous leukemia
1520180|NCT00002790|childhood acute myeloid leukemia/other myeloid malignancies
1520181|NCT00002790|myelodysplastic syndromes
1520182|NCT00002790|graft versus host disease
1520183|NCT00002790|childhood myelodysplastic syndromes
1520184|NCT00002789|chronic phase chronic myelogenous leukemia
1520185|NCT00002789|accelerated phase chronic myelogenous leukemia
1520186|NCT00002789|Philadelphia chromosome positive chronic myelogenous leukemia
1520187|NCT00002788|stage III chronic lymphocytic leukemia
1520188|NCT00002788|stage IV chronic lymphocytic leukemia
1520189|NCT00002788|refractory chronic lymphocytic leukemia
1520190|NCT00002788|B-cell chronic lymphocytic leukemia
1520191|NCT00002786|stage IV melanoma
1520192|NCT00002786|recurrent melanoma
1520193|NCT00002785|untreated childhood acute lymphoblastic leukemia
1520194|NCT00002784|stage II breast cancer
1520195|NCT00002784|stage IIIA breast cancer
1520196|NCT00002783|stage II gastric cancer
1520197|NCT00002783|stage III gastric cancer
1520199|NCT00002783|adenocarcinoma of the stomach
1520200|NCT00002781|stage III melanoma
1520201|NCT00002781|recurrent melanoma
1520202|NCT00002780|stage IV breast cancer
1520203|NCT00002780|recurrent breast cancer
1520204|NCT00002780|stage IIIB breast cancer
1520205|NCT00002779|Waldenström macroglobulinemia
1520206|NCT00002779|recurrent small lymphocytic lymphoma
1520207|NCT00002779|recurrent grade 1 follicular lymphoma
1520208|NCT00002779|recurrent grade 2 follicular lymphoma
1520209|NCT00002779|recurrent mantle cell lymphoma
1520210|NCT00002779|recurrent marginal zone lymphoma
1520211|NCT00002779|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520212|NCT00002779|nodal marginal zone B-cell lymphoma
1520213|NCT00002778|relapsing chronic myelogenous leukemia
1520214|NCT00002778|chronic phase chronic myelogenous leukemia
1520215|NCT00002778|accelerated phase chronic myelogenous leukemia
1520216|NCT00002778|Philadelphia chromosome positive chronic myelogenous leukemia
1520217|NCT00002778|Philadelphia chromosome negative chronic myelogenous leukemia
1520218|NCT00002778|atypical chronic myeloid leukemia
1520219|NCT00002777|stage IV breast cancer
1520220|NCT00002777|recurrent breast cancer
1520221|NCT00002775|adenocarcinoma of the prostate
1520222|NCT00002775|stage IV prostate cancer
1520223|NCT00002775|recurrent prostate cancer
1520224|NCT00002774|stage III
1520225|NCT00002774|stage IV
1520226|NCT00002774|recurrent
1520227|NCT00002773|stage II pancreatic cancer
1520228|NCT00002773|stage III pancreatic cancer
1520229|NCT00002773|recurrent pancreatic cancer
1520230|NCT00002773|adenocarcinoma of the pancreas
1520231|NCT00002773|stage IV pancreatic cancer
1520232|NCT00002772|stage II breast cancer
1520233|NCT00002772|stage IIIA breast cancer
1520234|NCT00002771|chronic phase chronic myelogenous leukemia
1520235|NCT00002771|chronic myelogenous leukemia, BCR-ABL1 positive
1520236|NCT00002771|Philadelphia chromosome negative chronic myelogenous leukemia
1520237|NCT00002771|childhood chronic myelogenous leukemia
1520238|NCT00002768|adult acute myeloid leukemia in remission
1520239|NCT00002768|adult acute erythroid leukemia (M6)
1520240|NCT00002768|adult acute myeloblastic leukemia without maturation (M1)
1520241|NCT00002768|adult acute myeloblastic leukemia with maturation (M2)
1520242|NCT00002768|adult acute promyelocytic leukemia (M3)
1520243|NCT00002768|adult acute myelomonocytic leukemia (M4)
1520244|NCT00002768|adult acute monoblastic leukemia (M5a)
1520245|NCT00002768|adult acute megakaryoblastic leukemia (M7)
1520246|NCT00002768|adult acute monocytic leukemia (M5b)
1520247|NCT00002768|adult acute minimally differentiated myeloid leukemia (M0)
1520248|NCT00002767|stage IV melanoma
1520249|NCT00002767|recurrent melanoma
1520250|NCT00002766|blastic phase chronic myelogenous leukemia
1520251|NCT00002766|untreated adult acute lymphoblastic leukemia
1520252|NCT00002766|chronic myelogenous leukemia, BCR-ABL1 positive
1520253|NCT00002766|T-cell adult acute lymphoblastic leukemia
1520254|NCT00002766|B-cell adult acute lymphoblastic leukemia
1520255|NCT00002766|stage I adult lymphoblastic lymphoma
1520256|NCT00002766|stage II adult lymphoblastic lymphoma
1520257|NCT00002766|stage III adult lymphoblastic lymphoma
1520258|NCT00002766|stage IV adult lymphoblastic lymphoma
1520259|NCT00002766|contiguous stage II adult lymphoblastic lymphoma
1520260|NCT00002766|noncontiguous stage II adult lymphoblastic lymphoma
1520261|NCT00002765|recurrent adult Hodgkin lymphoma
1520262|NCT00002765|stage IV cutaneous T-cell non-Hodgkin lymphoma
1520263|NCT00002765|recurrent cutaneous T-cell non-Hodgkin lymphoma
1520264|NCT00002765|Waldenström macroglobulinemia
1520265|NCT00002765|recurrent adult acute myeloid leukemia
1520266|NCT00002765|recurrent adult acute lymphoblastic leukemia
1520267|NCT00002765|relapsing chronic myelogenous leukemia
1520268|NCT00002765|refractory chronic lymphocytic leukemia
1520269|NCT00002765|refractory hairy cell leukemia
1520270|NCT00002765|recurrent small lymphocytic lymphoma
1520271|NCT00002765|recurrent grade 1 follicular lymphoma
1520272|NCT00002765|recurrent grade 2 follicular lymphoma
1520273|NCT00002765|recurrent grade 3 follicular lymphoma
1520274|NCT00002765|recurrent adult diffuse small cleaved cell lymphoma
1520275|NCT00002765|recurrent adult diffuse mixed cell lymphoma
1520276|NCT00002765|recurrent adult diffuse large cell lymphoma
1520277|NCT00002765|recurrent adult immunoblastic large cell lymphoma
1520278|NCT00002765|recurrent adult lymphoblastic lymphoma
1520279|NCT00002765|recurrent adult Burkitt lymphoma
1520280|NCT00002765|stage I adult T-cell leukemia/lymphoma
1520281|NCT00002765|stage II adult T-cell leukemia/lymphoma
1520282|NCT00002765|stage III adult T-cell leukemia/lymphoma
1520283|NCT00002765|stage IV adult T-cell leukemia/lymphoma
1520284|NCT00002765|recurrent adult T-cell leukemia/lymphoma
1520285|NCT00002765|prolymphocytic leukemia
1520286|NCT00002765|recurrent mantle cell lymphoma
1520287|NCT00002765|stage IV mycosis fungoides/Sezary syndrome
1520288|NCT00002765|recurrent mycosis fungoides/Sezary syndrome
1520289|NCT00002765|recurrent marginal zone lymphoma
1520290|NCT00002765|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520291|NCT00002765|nodal marginal zone B-cell lymphoma
1520292|NCT00002765|splenic marginal zone lymphoma
1520293|NCT00002764|adult angiosarcoma
1520294|NCT00002764|adult fibrosarcoma
1520299|NCT00002764|recurrent adult soft tissue sarcoma
1520300|NCT00002764|adult malignant fibrous histiocytoma
1520301|NCT00002764|adult malignant hemangiopericytoma
1520302|NCT00002764|adult malignant mesenchymoma
1520303|NCT00002764|localized benign pheochromocytoma
1520304|NCT00002764|regional pheochromocytoma
1520305|NCT00002764|lung metastases
1520306|NCT00002764|stage IV uterine sarcoma
1520307|NCT00002764|recurrent uterine sarcoma
1520308|NCT00002764|uterine leiomyosarcoma
1520309|NCT00002764|endometrial stromal sarcoma
1520310|NCT00002764|ovarian sarcoma
1520311|NCT00002764|clear cell sarcoma of the kidney
1520312|NCT00002764|stage IV adult soft tissue sarcoma
1520313|NCT00002763|stage III melanoma
1520314|NCT00002763|recurrent melanoma
1520315|NCT00002762|stage I breast cancer
1520316|NCT00002762|stage II breast cancer
1520317|NCT00002762|perioperative/postoperative complications
1520318|NCT00002761|relapsing chronic myelogenous leukemia
1520319|NCT00002761|chronic phase chronic myelogenous leukemia
1520320|NCT00002761|chronic myelogenous leukemia, BCR-ABL1 positive
1520321|NCT00002760|adenocarcinoma of the prostate
1520322|NCT00002760|recurrent prostate cancer
1520323|NCT00002759|stage III adult Hodgkin lymphoma
1520324|NCT00002759|stage IV adult Hodgkin lymphoma
1520325|NCT00002759|recurrent adult Hodgkin lymphoma
1520326|NCT00002759|stage III cutaneous T-cell non-Hodgkin lymphoma
1520327|NCT00002759|stage IV cutaneous T-cell non-Hodgkin lymphoma
1520328|NCT00002759|recurrent cutaneous T-cell non-Hodgkin lymphoma
1520329|NCT00002759|small intestine lymphoma
1520330|NCT00002759|unspecified adult solid tumor, protocol specific
1520331|NCT00002759|stage III grade 1 follicular lymphoma
1520332|NCT00002759|stage III grade 2 follicular lymphoma
1520333|NCT00002759|stage III grade 3 follicular lymphoma
1520334|NCT00002759|stage III adult diffuse small cleaved cell lymphoma
1520335|NCT00002759|stage III adult diffuse mixed cell lymphoma
1520336|NCT00002759|stage III adult diffuse large cell lymphoma
1520337|NCT00002759|stage III adult immunoblastic large cell lymphoma
1520338|NCT00002759|stage III adult lymphoblastic lymphoma
1520339|NCT00002759|stage III adult Burkitt lymphoma
1520340|NCT00002759|stage IV grade 1 follicular lymphoma
1520341|NCT00002759|stage IV grade 2 follicular lymphoma
1520342|NCT00002759|stage IV grade 3 follicular lymphoma
1520343|NCT00002759|stage IV adult diffuse small cleaved cell lymphoma
1520344|NCT00002759|stage IV adult diffuse mixed cell lymphoma
1520345|NCT00002759|stage IV adult diffuse large cell lymphoma
1520346|NCT00002759|stage IV adult immunoblastic large cell lymphoma
1520347|NCT00002759|stage IV adult lymphoblastic lymphoma
1520348|NCT00002759|stage IV adult Burkitt lymphoma
1520349|NCT00002759|recurrent grade 1 follicular lymphoma
1520350|NCT00002759|recurrent grade 2 follicular lymphoma
1520351|NCT00002759|recurrent grade 3 follicular lymphoma
1520352|NCT00002759|recurrent adult diffuse small cleaved cell lymphoma
1520353|NCT00002759|recurrent adult diffuse mixed cell lymphoma
1520354|NCT00002759|recurrent adult diffuse large cell lymphoma
1520355|NCT00002759|recurrent adult immunoblastic large cell lymphoma
1520356|NCT00002759|recurrent adult lymphoblastic lymphoma
1520357|NCT00002759|recurrent adult Burkitt lymphoma
1520358|NCT00002759|stage III adult T-cell leukemia/lymphoma
1520359|NCT00002759|stage IV adult T-cell leukemia/lymphoma
1520360|NCT00002759|recurrent adult T-cell leukemia/lymphoma
1520361|NCT00002759|primary central nervous system non-Hodgkin lymphoma
1520362|NCT00002759|drug/agent toxicity by tissue/organ
1520363|NCT00002759|neutropenia
1520364|NCT00002759|AIDS-related peripheral/systemic lymphoma
1520365|NCT00002759|AIDS-related primary CNS lymphoma
1520366|NCT00002759|intraocular lymphoma
1520367|NCT00002759|stage III mantle cell lymphoma
1520368|NCT00002759|stage IV mantle cell lymphoma
1520369|NCT00002759|recurrent mantle cell lymphoma
1520370|NCT00002759|angioimmunoblastic T-cell lymphoma
1520371|NCT00002759|anaplastic large cell lymphoma
1520372|NCT00002759|stage III mycosis fungoides/Sezary syndrome
1520373|NCT00002759|stage IV mycosis fungoides/Sezary syndrome
1520374|NCT00002759|recurrent mycosis fungoides/Sezary syndrome
1520375|NCT00002759|recurrent marginal zone lymphoma
1520376|NCT00002759|recurrent small lymphocytic lymphoma
1520377|NCT00002759|stage III small lymphocytic lymphoma
1520378|NCT00002759|stage III marginal zone lymphoma
1520379|NCT00002759|stage IV small lymphocytic lymphoma
1520380|NCT00002759|stage IV marginal zone lymphoma
1520381|NCT00002759|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520382|NCT00002759|nodal marginal zone B-cell lymphoma
1520383|NCT00002759|splenic marginal zone lymphoma
1520384|NCT00002757|childhood Burkitt lymphoma
1520385|NCT00002757|untreated childhood acute lymphoblastic leukemia
1520386|NCT00002757|L3 childhood acute lymphoblastic leukemia
1520387|NCT00002757|stage I childhood small noncleaved cell lymphoma
1520388|NCT00002757|stage I childhood large cell lymphoma
1520389|NCT00002757|stage II childhood small noncleaved cell lymphoma
1520390|NCT00002757|stage II childhood large cell lymphoma
1520391|NCT00002757|stage III childhood small noncleaved cell lymphoma
1520392|NCT00002757|stage III childhood large cell lymphoma
1520393|NCT00002757|stage IV childhood small noncleaved cell lymphoma
1520394|NCT00002757|stage IV childhood large cell lymphoma
1520395|NCT00002756|untreated childhood acute lymphoblastic leukemia
1520396|NCT00002756|acute undifferentiated leukemia
1520397|NCT00002755|stage II breast cancer
1520398|NCT00002755|stage IIIA breast cancer
1520399|NCT00002754|recurrent adult brain tumor
1520400|NCT00002754|adult glioblastoma
1520401|NCT00002754|stage IV melanoma
1520402|NCT00002754|tumors metastatic to brain
1520403|NCT00002754|childhood high-grade cerebral astrocytoma
1520404|NCT00002754|adult anaplastic astrocytoma
1520405|NCT00002754|adult anaplastic oligodendroglioma
1520406|NCT00002754|adult mixed glioma
1520407|NCT00002754|recurrent childhood cerebral astrocytoma
1520408|NCT00002754|adult giant cell glioblastoma
1520409|NCT00002754|adult gliosarcoma
1520410|NCT00002753|childhood supratentorial ependymoma
1520411|NCT00002753|recurrent childhood brain tumor
1520412|NCT00002753|recurrent adult brain tumor
1520413|NCT00002753|adult glioblastoma
1520414|NCT00002753|adult anaplastic astrocytoma
1520415|NCT00002753|adult myxopapillary ependymoma
1520416|NCT00002753|adult anaplastic ependymoma
1520417|NCT00002753|adult anaplastic oligodendroglioma
1520418|NCT00002753|adult mixed glioma
1520419|NCT00002753|adult ependymoblastoma
1520420|NCT00002753|recurrent childhood cerebral astrocytoma
1520421|NCT00002753|recurrent childhood ependymoma
1520422|NCT00002753|adult giant cell glioblastoma
1520423|NCT00002753|adult gliosarcoma
1520424|NCT00002752|childhood supratentorial ependymoma
1520425|NCT00002752|recurrent childhood brain tumor
1520426|NCT00002752|recurrent adult brain tumor
1520427|NCT00002752|adult medulloblastoma
1520428|NCT00002752|adult glioblastoma
1520429|NCT00002752|tumors metastatic to brain
1520430|NCT00002752|childhood high-grade cerebral astrocytoma
1520431|NCT00002752|adult anaplastic astrocytoma
1520432|NCT00002752|adult myxopapillary ependymoma
1520433|NCT00002752|adult anaplastic ependymoma
1520434|NCT00002752|adult anaplastic oligodendroglioma
1520435|NCT00002752|adult mixed glioma
1520436|NCT00002752|adult pilocytic astrocytoma
1520437|NCT00002752|adult subependymoma
1520438|NCT00002752|adult ependymoblastoma
1520439|NCT00002752|recurrent childhood supratentorial primitive neuroectodermal tumor
1520440|NCT00002752|recurrent childhood cerebellar astrocytoma
1520441|NCT00002752|recurrent childhood cerebral astrocytoma
1520442|NCT00002752|recurrent childhood medulloblastoma
1520443|NCT00002752|newly diagnosed childhood ependymoma
1520444|NCT00002752|recurrent childhood ependymoma
1520445|NCT00002752|adult oligodendroglioma
1520446|NCT00002752|adult giant cell glioblastoma
1520447|NCT00002752|adult gliosarcoma
1520448|NCT00002751|leptomeningeal metastases
1520449|NCT00002750|recurrent childhood acute lymphoblastic leukemia
1520450|NCT00002750|recurrent adult Hodgkin lymphoma
1520451|NCT00002750|Waldenström macroglobulinemia
1520452|NCT00002750|recurrent childhood lymphoblastic lymphoma
1520453|NCT00002750|childhood central nervous system germ cell tumor
1520454|NCT00002750|recurrent childhood acute myeloid leukemia
1520455|NCT00002750|recurrent adult acute myeloid leukemia
1520456|NCT00002750|recurrent adult acute lymphoblastic leukemia
1520457|NCT00002750|recurrent/refractory childhood Hodgkin lymphoma
1520458|NCT00002750|recurrent ovarian germ cell tumor
1520459|NCT00002750|recurrent adult non-Hodgkin lymphoma
1520460|NCT00002750|recurrent grade 1 follicular lymphoma
1520461|NCT00002750|recurrent grade 2 follicular lymphoma
1520462|NCT00002750|recurrent grade 3 follicular lymphoma
1520463|NCT00002750|recurrent adult diffuse small cleaved cell lymphoma
1520464|NCT00002750|recurrent adult diffuse mixed cell lymphoma
1520465|NCT00002750|recurrent adult diffuse large cell lymphoma
1520466|NCT00002750|recurrent adult immunoblastic large cell lymphoma
1520467|NCT00002750|recurrent adult lymphoblastic lymphoma
1520468|NCT00002750|recurrent adult Burkitt lymphoma
1520469|NCT00002750|extragonadal germ cell tumor
1520470|NCT00002750|leptomeningeal metastases
1520471|NCT00002750|recurrent childhood small noncleaved cell lymphoma
1520472|NCT00002750|recurrent childhood large cell lymphoma
1520473|NCT00002750|recurrent mantle cell lymphoma
1523411|NCT00002360|Tablets
1520474|NCT00002750|recurrent marginal zone lymphoma
1520475|NCT00002750|recurrent small lymphocytic lymphoma
1520476|NCT00002750|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520477|NCT00002750|nodal marginal zone B-cell lymphoma
1520478|NCT00002750|splenic marginal zone lymphoma
1520479|NCT00002749|childhood low-grade cerebral astrocytoma
1520480|NCT00002749|recurrent adult brain tumor
1520481|NCT00002749|adult brain stem glioma
1520482|NCT00002749|childhood oligodendroglioma
1520483|NCT00002749|untreated childhood brain stem glioma
1520484|NCT00002749|recurrent childhood brain stem glioma
1520485|NCT00002749|untreated childhood visual pathway glioma
1520486|NCT00002749|recurrent childhood visual pathway glioma
1520487|NCT00002749|untreated childhood cerebellar astrocytoma
1520488|NCT00002749|recurrent childhood cerebellar astrocytoma
1520489|NCT00002749|recurrent childhood cerebral astrocytoma
1520490|NCT00002749|adult anaplastic astrocytoma
1520491|NCT00002749|adult oligodendroglioma
1520492|NCT00002748|recurrent neuroblastoma
1520493|NCT00002747|stage II squamous cell carcinoma of the lip and oral cavity
1520494|NCT00002747|stage III squamous cell carcinoma of the lip and oral cavity
1520495|NCT00002747|stage IV squamous cell carcinoma of the lip and oral cavity
1520496|NCT00002746|refractory anemia
1520497|NCT00002746|refractory anemia with ringed sideroblasts
1520498|NCT00002746|refractory anemia with excess blasts
1520499|NCT00002746|chronic myelomonocytic leukemia
1520500|NCT00002746|de novo myelodysplastic syndromes
1520501|NCT00002746|previously treated myelodysplastic syndromes
1520502|NCT00002746|secondary myelodysplastic syndromes
1520503|NCT00002746|atypical chronic myeloid leukemia, BCR-ABL1 negative
1520504|NCT00002746|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1520505|NCT00002746|childhood myelodysplastic syndromes
1520506|NCT00002745|Waldenstrom macroglobulinemia
1520507|NCT00002745|recurrent grade 1 follicular lymphoma
1520508|NCT00002745|recurrent grade 2 follicular lymphoma
1520509|NCT00002745|recurrent small lymphocytic lymphoma
1520510|NCT00002744|untreated childhood acute lymphoblastic leukemia
1520511|NCT00002744|L1 childhood acute lymphoblastic leukemia
1520512|NCT00002744|L2 childhood acute lymphoblastic leukemia
1520513|NCT00002742|adult Hodgkin lymphoma
1520514|NCT00002742|adult non-Hodgkin lymphoma
1520515|NCT00002742|leukemia
1520516|NCT00002742|childhood non-Hodgkin lymphoma
1520517|NCT00002742|chronic myeloproliferative disorders
1520518|NCT00002742|myelodysplastic syndromes
1520519|NCT00002742|childhood Hodgkin lymphoma
1520520|NCT00002742|recurrent adult non-Hodgkin lymphoma
1520521|NCT00002742|infection
1520522|NCT00002742|multiple myeloma and other plasma cell neoplasms
1520523|NCT00002742|childhood myelodysplastic syndromes
1520524|NCT00002740|disseminated neuroblastoma
1520525|NCT00002738|recurrent childhood acute lymphoblastic leukemia
1520526|NCT00002738|recurrent childhood lymphoblastic lymphoma
1520527|NCT00002738|recurrent osteosarcoma
1520528|NCT00002738|recurrent childhood small noncleaved cell lymphoma
1520529|NCT00002738|recurrent childhood large cell lymphoma
1520530|NCT00002737|stage IV renal cell cancer
1520531|NCT00002737|recurrent renal cell cancer
1520532|NCT00002735|stage III squamous cell carcinoma of the oropharynx
1520533|NCT00002735|stage IV squamous cell carcinoma of the oropharynx
1520534|NCT00002735|stage III squamous cell carcinoma of the hypopharynx
1520535|NCT00002735|stage IV squamous cell carcinoma of the hypopharynx
1520536|NCT00002734|recurrent ovarian epithelial cancer
1520537|NCT00002734|primary peritoneal cavity cancer
1520538|NCT00002733|stage IV renal cell cancer
1520539|NCT00002733|stage IV melanoma
1520540|NCT00002733|unspecified adult solid tumor, protocol specific
1520541|NCT00002730|recurrent neuroblastoma
1520542|NCT00002727|stage II squamous cell carcinoma of the larynx
1520543|NCT00002725|recurrent small lymphocytic lymphoma
1520544|NCT00002725|recurrent grade 1 follicular lymphoma
1520545|NCT00002725|recurrent grade 2 follicular lymphoma
1520546|NCT00002725|recurrent grade 3 follicular lymphoma
1520547|NCT00002725|recurrent adult diffuse small cleaved cell lymphoma
1520548|NCT00002725|recurrent adult diffuse mixed cell lymphoma
1520549|NCT00002725|recurrent adult diffuse large cell lymphoma
1520550|NCT00002725|recurrent adult immunoblastic large cell lymphoma
1520551|NCT00002725|recurrent adult lymphoblastic lymphoma
1520552|NCT00002725|recurrent adult Burkitt lymphoma
1520553|NCT00002725|recurrent mantle cell lymphoma
1520554|NCT00002725|recurrent marginal zone lymphoma
1520555|NCT00002725|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520556|NCT00002725|nodal marginal zone B-cell lymphoma
1520557|NCT00002725|splenic marginal zone lymphoma
1520558|NCT00002723|adenocarcinoma of the prostate
1520559|NCT00002723|stage III prostate cancer
1520560|NCT00002723|stage IV prostate cancer
1520561|NCT00002723|recurrent prostate cancer
1520562|NCT00002722|stage III gastric cancer
1520563|NCT00002722|stage IV gastric cancer
1520564|NCT00002721|recurrent prostate cancer
1520565|NCT00002720|stage I breast cancer
1520566|NCT00002719|untreated adult acute myeloid leukemia
1520567|NCT00002719|adult acute erythroid leukemia (M6)
1520568|NCT00002719|adult acute myeloblastic leukemia without maturation (M1)
1523530|NCT00002332|AIDS-Related Complex
1520569|NCT00002719|adult acute myeloblastic leukemia with maturation (M2)
1520570|NCT00002719|adult acute myelomonocytic leukemia (M4)
1520571|NCT00002719|adult acute monoblastic leukemia (M5a)
1520572|NCT00002719|adult acute megakaryoblastic leukemia (M7)
1520573|NCT00002719|secondary acute myeloid leukemia
1520574|NCT00002719|adult acute monocytic leukemia (M5b)
1520575|NCT00002719|neutropenia
1520576|NCT00002719|adult acute minimally differentiated myeloid leukemia (M0)
1520577|NCT00002718|recurrent childhood acute lymphoblastic leukemia
1520578|NCT00002718|stage IV childhood lymphoblastic lymphoma
1520579|NCT00002718|recurrent childhood lymphoblastic lymphoma
1520580|NCT00002718|recurrent childhood acute myeloid leukemia
1520581|NCT00002718|recurrent adult acute myeloid leukemia
1520582|NCT00002718|recurrent adult acute lymphoblastic leukemia
1520583|NCT00002718|relapsing chronic myelogenous leukemia
1520584|NCT00002718|chronic phase chronic myelogenous leukemia
1520585|NCT00002718|accelerated phase chronic myelogenous leukemia
1520586|NCT00002718|adult acute myeloid leukemia in remission
1520587|NCT00002718|adult acute lymphoblastic leukemia in remission
1520588|NCT00002718|childhood acute myeloid leukemia in remission
1520589|NCT00002718|childhood acute lymphoblastic leukemia in remission
1520590|NCT00002718|stage IV adult lymphoblastic lymphoma
1520591|NCT00002718|recurrent adult lymphoblastic lymphoma
1520592|NCT00002718|secondary acute myeloid leukemia
1520593|NCT00002718|de novo myelodysplastic syndromes
1520594|NCT00002718|previously treated myelodysplastic syndromes
1520595|NCT00002718|secondary myelodysplastic syndromes
1520596|NCT00002718|juvenile myelomonocytic leukemia
1520597|NCT00002718|childhood chronic myelogenous leukemia
1520598|NCT00002718|atypical chronic myeloid leukemia, BCR-ABL1 negative
1520599|NCT00002718|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1520600|NCT00002718|chronic myelomonocytic leukemia
1520601|NCT00002718|childhood myelodysplastic syndromes
1520602|NCT00002717|stage III ovarian epithelial cancer
1520603|NCT00002717|stage IV ovarian epithelial cancer
1520604|NCT00002717|ovarian undifferentiated adenocarcinoma
1520605|NCT00002717|ovarian mixed epithelial carcinoma
1520606|NCT00002717|ovarian serous cystadenocarcinoma
1520607|NCT00002717|ovarian mucinous cystadenocarcinoma
1520608|NCT00002717|ovarian endometrioid adenocarcinoma
1520609|NCT00002717|ovarian clear cell cystadenocarcinoma
1520610|NCT00002717|primary peritoneal cavity cancer
1520611|NCT00002717|Brenner tumor
1520612|NCT00002716|stage IV colon cancer
1520613|NCT00002716|stage IV rectal cancer
1520614|NCT00002716|recurrent colon cancer
1520615|NCT00002716|recurrent rectal cancer
1520616|NCT00002716|adenocarcinoma of the colon
1520617|NCT00002716|adenocarcinoma of the rectum
1520618|NCT00002716|liver metastases
1520619|NCT00002715|stage I adult Hodgkin lymphoma
1520620|NCT00002715|stage II adult Hodgkin lymphoma
1520621|NCT00002715|stage III adult Hodgkin lymphoma
1520622|NCT00002715|stage IV adult Hodgkin lymphoma
1520623|NCT00002715|adult lymphocyte predominant Hodgkin lymphoma
1520624|NCT00002715|adult lymphocyte depletion Hodgkin lymphoma
1520625|NCT00002715|adult nodular sclerosis Hodgkin lymphoma
1520626|NCT00002715|adult mixed cellularity Hodgkin lymphoma
1520627|NCT00002714|stage I adult Hodgkin lymphoma
1520628|NCT00002714|stage II adult Hodgkin lymphoma
1520629|NCT00002711|stage I esophageal cancer
1520630|NCT00002711|stage II esophageal cancer
1520631|NCT00002711|stage III esophageal cancer
1520632|NCT00002711|recurrent esophageal cancer
1520633|NCT00002711|squamous cell carcinoma of the esophagus
1520634|NCT00002711|adenocarcinoma of the esophagus
1520635|NCT00002708|tumors metastatic to brain
1520636|NCT00002707|stage I breast cancer
1520637|NCT00002707|stage II breast cancer
1520638|NCT00002707|stage IIIA breast cancer
1520639|NCT00002705|recurrent childhood acute lymphoblastic leukemia
1520640|NCT00002705|recurrent childhood acute myeloid leukemia
1520641|NCT00002705|relapsing chronic myelogenous leukemia
1520642|NCT00002704|recurrent childhood acute lymphoblastic leukemia
1520643|NCT00002704|T-cell childhood acute lymphoblastic leukemia
1520644|NCT00002704|B-cell childhood acute lymphoblastic leukemia
1520645|NCT00002704|TdT positive childhood acute lymphoblastic leukemia
1520646|NCT00002703|adenocarcinoma of the prostate
1520647|NCT00002703|stage I prostate cancer
1520648|NCT00002703|stage IIB prostate cancer
1520649|NCT00002703|stage IIA prostate cancer
1520650|NCT00002702|stage II squamous cell carcinoma of the lip and oral cavity
1520651|NCT00002702|stage III squamous cell carcinoma of the lip and oral cavity
1520652|NCT00002702|stage IV squamous cell carcinoma of the lip and oral cavity
1520653|NCT00002702|stage II squamous cell carcinoma of the oropharynx
1520654|NCT00002702|stage III squamous cell carcinoma of the oropharynx
1520655|NCT00002702|stage IV squamous cell carcinoma of the oropharynx
1520656|NCT00002702|tongue cancer
1520657|NCT00002701|untreated adult acute myeloid leukemia
1520658|NCT00002701|adult acute promyelocytic leukemia (M3)
1520659|NCT00002700|untreated adult acute lymphoblastic leukemia
1520660|NCT00002700|stage I adult lymphoblastic lymphoma
1520661|NCT00002700|stage III adult lymphoblastic lymphoma
1520662|NCT00002700|stage IV adult lymphoblastic lymphoma
1520663|NCT00002700|contiguous stage II adult lymphoblastic lymphoma
1523885|NCT00002258|Recombinant Proteins
1520664|NCT00002700|noncontiguous stage II adult lymphoblastic lymphoma
1520665|NCT00002697|recurrent grade 1 follicular lymphoma
1520666|NCT00002697|recurrent grade 2 follicular lymphoma
1520667|NCT00002697|recurrent grade 3 follicular lymphoma
1520668|NCT00002697|recurrent adult diffuse small cleaved cell lymphoma
1520669|NCT00002697|recurrent adult diffuse mixed cell lymphoma
1520670|NCT00002697|recurrent adult diffuse large cell lymphoma
1520671|NCT00002697|recurrent adult immunoblastic large cell lymphoma
1520672|NCT00002697|recurrent marginal zone lymphoma
1520673|NCT00002697|recurrent small lymphocytic lymphoma
1520674|NCT00002697|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520675|NCT00002697|nodal marginal zone B-cell lymphoma
1520676|NCT00002697|splenic marginal zone lymphoma
1520677|NCT00002696|stage IIIA breast cancer
1520678|NCT00002696|stage IIIB breast cancer
1520679|NCT00002696|stage IIIC breast cancer
1520680|NCT00002695|stage I squamous cell carcinoma of the lip and oral cavity
1520681|NCT00002695|stage II squamous cell carcinoma of the lip and oral cavity
1523061|NCT00002416|RNA, Viral
1520682|NCT00002695|stage III squamous cell carcinoma of the lip and oral cavity
1520683|NCT00002695|stage IV squamous cell carcinoma of the lip and oral cavity
1520684|NCT00002695|recurrent squamous cell carcinoma of the lip and oral cavity
1520685|NCT00002695|stage I squamous cell carcinoma of the oropharynx
1520686|NCT00002695|stage II squamous cell carcinoma of the oropharynx
1520687|NCT00002695|stage III squamous cell carcinoma of the oropharynx
1520688|NCT00002695|stage IV squamous cell carcinoma of the oropharynx
1520689|NCT00002695|recurrent squamous cell carcinoma of the oropharynx
1520690|NCT00002695|stage I squamous cell carcinoma of the hypopharynx
1520691|NCT00002695|stage II squamous cell carcinoma of the hypopharynx
1520692|NCT00002695|stage III squamous cell carcinoma of the hypopharynx
1520693|NCT00002695|stage IV squamous cell carcinoma of the hypopharynx
1520694|NCT00002695|recurrent squamous cell carcinoma of the hypopharynx
1520695|NCT00002695|stage I squamous cell carcinoma of the larynx
1520696|NCT00002695|stage II squamous cell carcinoma of the larynx
1520697|NCT00002695|stage III squamous cell carcinoma of the larynx
1520698|NCT00002695|stage IV squamous cell carcinoma of the larynx
1520699|NCT00002695|recurrent squamous cell carcinoma of the larynx
1520700|NCT00002695|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1520701|NCT00002695|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1520702|NCT00002695|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1520703|NCT00002695|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1520704|NCT00002695|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1520705|NCT00002693|recurrent adult acute myeloid leukemia
1520706|NCT00002693|recurrent adult acute lymphoblastic leukemia
1520707|NCT00002693|relapsing chronic myelogenous leukemia
1520708|NCT00002693|accelerated phase chronic myelogenous leukemia
1520709|NCT00002693|blastic phase chronic myelogenous leukemia
1520710|NCT00002693|neutropenia
1520711|NCT00002692|stage IV colon cancer
1520712|NCT00002692|stage IV rectal cancer
1520713|NCT00002692|recurrent colon cancer
1520714|NCT00002692|recurrent rectal cancer
1520715|NCT00002692|adenocarcinoma of the colon
1520716|NCT00002692|adenocarcinoma of the rectum
1520717|NCT00002692|liver metastases
1520718|NCT00002691|stage III childhood lymphoblastic lymphoma
1520719|NCT00002691|stage IV childhood lymphoblastic lymphoma
1520720|NCT00002691|stage III childhood small noncleaved cell lymphoma
1520721|NCT00002691|stage III childhood large cell lymphoma
1520722|NCT00002691|stage IV childhood large cell lymphoma
1520723|NCT00002689|stage I pancreatic cancer
1520724|NCT00002689|stage II pancreatic cancer
1520725|NCT00002689|stage III pancreatic cancer
1520726|NCT00002689|adenocarcinoma of the pancreas
1520727|NCT00002688|recurrent adult acute myeloid leukemia
1520728|NCT00002687|stage II cutaneous T-cell non-Hodgkin lymphoma
1520729|NCT00002687|stage III cutaneous T-cell non-Hodgkin lymphoma
1520730|NCT00002687|stage IV cutaneous T-cell non-Hodgkin lymphoma
1520731|NCT00002687|recurrent cutaneous T-cell non-Hodgkin lymphoma
1520732|NCT00002687|stage II mycosis fungoides/Sezary syndrome
1520733|NCT00002687|stage III mycosis fungoides/Sezary syndrome
1520734|NCT00002687|stage IV mycosis fungoides/Sezary syndrome
1520735|NCT00002687|recurrent mycosis fungoides/Sezary syndrome
1520736|NCT00002684|stage III bladder cancer
1520737|NCT00002684|recurrent bladder cancer
1520738|NCT00002684|stage IV bladder cancer
1520739|NCT00002684|squamous cell carcinoma of the bladder
1520740|NCT00002684|adenocarcinoma of the bladder
1520741|NCT00002684|recurrent urethral cancer
1520742|NCT00002684|distal urethral cancer
1520743|NCT00002684|proximal urethral cancer
1520744|NCT00002684|urethral cancer associated with invasive bladder cancer
1520745|NCT00002682|Antibiotic Treatment
1520746|NCT00002682|Gastric Malt Lymphoma
1520747|NCT00002682|stage I marginal zone lymphoma
1520748|NCT00002682|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520749|NCT00002681|recurrent adult Hodgkin lymphoma
1520750|NCT00002681|recurrent adult acute myeloid leukemia
1520751|NCT00002681|relapsing chronic myelogenous leukemia
1520752|NCT00002681|chronic phase chronic myelogenous leukemia
1520753|NCT00002681|atypical chronic myeloid leukemia, BCR-ABL negative
1520754|NCT00002680|stage IV breast cancer
1520757|NCT00002679|stage IIIA breast cancer
1520758|NCT00002679|male breast cancer
1520759|NCT00002678|stage I multiple myeloma
1520760|NCT00002678|stage II multiple myeloma
1520761|NCT00002678|stage III multiple myeloma
1520762|NCT00002677|stage IV prostate cancer
1520763|NCT00002677|recurrent prostate cancer
1520764|NCT00002677|unspecified adult solid tumor, protocol specific
1520765|NCT00002676|primary central nervous system non-Hodgkin lymphoma
1520766|NCT00002675|intraocular retinoblastoma
1520767|NCT00002674|relapsing chronic myelogenous leukemia
1520768|NCT00002674|chronic phase chronic myelogenous leukemia
1520769|NCT00002674|accelerated phase chronic myelogenous leukemia
1520770|NCT00002674|Philadelphia chromosome positive chronic myelogenous leukemia
1520771|NCT00002673|stage IV breast cancer
1520772|NCT00002673|stage IIIA breast cancer
1520773|NCT00002673|stage IIIB breast cancer
1520774|NCT00002673|recurrent childhood acute lymphoblastic leukemia
1520775|NCT00002673|recurrent adult Hodgkin lymphoma
1523311|NCT00002378|Nelfinavir
1520776|NCT00002673|recurrent cutaneous T-cell non-Hodgkin lymphoma
1520777|NCT00002673|recurrent childhood rhabdomyosarcoma
1520778|NCT00002673|stage II ovarian epithelial cancer
1520779|NCT00002673|stage III ovarian epithelial cancer
1520780|NCT00002673|stage IV ovarian epithelial cancer
1520781|NCT00002673|recurrent ovarian epithelial cancer
1520782|NCT00002673|disseminated neuroblastoma
1520783|NCT00002673|recurrent neuroblastoma
1520784|NCT00002673|recurrent Wilms tumor and other childhood kidney tumors
1520785|NCT00002673|stage I multiple myeloma
1520786|NCT00002673|stage II multiple myeloma
1520787|NCT00002673|stage III multiple myeloma
1520788|NCT00002673|recurrent childhood lymphoblastic lymphoma
1520789|NCT00002673|stage III chronic lymphocytic leukemia
1520790|NCT00002673|stage IV chronic lymphocytic leukemia
1520791|NCT00002673|recurrent childhood acute myeloid leukemia
1520792|NCT00002673|recurrent adult acute myeloid leukemia
1520793|NCT00002673|recurrent adult acute lymphoblastic leukemia
1520794|NCT00002673|refractory chronic lymphocytic leukemia
1520795|NCT00002673|stage III malignant testicular germ cell tumor
1520796|NCT00002673|recurrent malignant testicular germ cell tumor
1520797|NCT00002673|chronic phase chronic myelogenous leukemia
1520798|NCT00002673|accelerated phase chronic myelogenous leukemia
1520799|NCT00002673|blastic phase chronic myelogenous leukemia
1520800|NCT00002673|adult acute myeloid leukemia in remission
1520801|NCT00002673|adult acute lymphoblastic leukemia in remission
1520802|NCT00002673|childhood acute myeloid leukemia in remission
1520803|NCT00002673|childhood acute lymphoblastic leukemia in remission
1520804|NCT00002673|chronic idiopathic myelofibrosis
1520805|NCT00002673|childhood acute promyelocytic leukemia (M3)
1520806|NCT00002673|testicular embryonal carcinoma
1520807|NCT00002673|testicular choriocarcinoma
1520808|NCT00002673|testicular teratoma
1520809|NCT00002673|testicular yolk sac tumor
1520810|NCT00002673|testicular embryonal carcinoma and teratoma
1520811|NCT00002673|testicular embryonal carcinoma and teratoma with seminoma
1520812|NCT00002673|testicular embryonal carcinoma and yolk sac tumor
1520813|NCT00002673|testicular embryonal carcinoma and yolk sac tumor with seminoma
1520814|NCT00002673|testicular embryonal carcinoma and seminoma
1520815|NCT00002673|testicular yolk sac tumor and teratoma
1520816|NCT00002673|testicular yolk sac tumor and teratoma with seminoma
1520817|NCT00002673|testicular choriocarcinoma and yolk sac tumor
1520818|NCT00002673|testicular choriocarcinoma and embryonal carcinoma
1520819|NCT00002673|testicular choriocarcinoma and teratoma
1520820|NCT00002673|testicular choriocarcinoma and seminoma
1520821|NCT00002673|refractory hairy cell leukemia
1520822|NCT00002673|recurrent/refractory childhood Hodgkin lymphoma
1520823|NCT00002673|ovarian germ cell tumor
1520824|NCT00002673|recurrent ovarian germ cell tumor
1520825|NCT00002673|ovarian yolk sac tumor
1520826|NCT00002673|ovarian embryonal carcinoma
1520827|NCT00002673|ovarian polyembryoma
1520828|NCT00002673|ovarian choriocarcinoma
1520829|NCT00002673|ovarian teratoma
1520830|NCT00002673|ovarian immature teratoma
1520831|NCT00002673|ovarian mature teratoma
1520832|NCT00002673|ovarian monodermal and highly specialized teratoma
1520833|NCT00002673|stage II adult lymphoblastic lymphoma
1520834|NCT00002673|stage II adult Burkitt lymphoma
1520835|NCT00002673|stage III grade 1 follicular lymphoma
1520836|NCT00002673|stage III grade 2 follicular lymphoma
1520837|NCT00002673|stage III grade 3 follicular lymphoma
1520838|NCT00002673|stage III adult diffuse small cleaved cell lymphoma
1520839|NCT00002673|stage III adult diffuse mixed cell lymphoma
1520840|NCT00002673|stage III adult diffuse large cell lymphoma
1520841|NCT00002673|stage III adult immunoblastic large cell lymphoma
1520842|NCT00002673|stage III adult lymphoblastic lymphoma
1520843|NCT00002673|stage III adult Burkitt lymphoma
1520844|NCT00002673|stage IV grade 1 follicular lymphoma
1520845|NCT00002673|stage IV grade 2 follicular lymphoma
1520846|NCT00002673|stage IV grade 3 follicular lymphoma
1520847|NCT00002673|stage IV adult diffuse small cleaved cell lymphoma
1520848|NCT00002673|stage IV adult diffuse mixed cell lymphoma
1520849|NCT00002673|stage IV adult diffuse large cell lymphoma
1520850|NCT00002673|stage IV adult immunoblastic large cell lymphoma
1520851|NCT00002673|stage IV adult lymphoblastic lymphoma
1520852|NCT00002673|stage IV adult Burkitt lymphoma
1520853|NCT00002673|recurrent grade 1 follicular lymphoma
1520854|NCT00002673|recurrent grade 2 follicular lymphoma
1520855|NCT00002673|recurrent grade 3 follicular lymphoma
1520856|NCT00002673|recurrent adult diffuse small cleaved cell lymphoma
1520857|NCT00002673|recurrent adult diffuse mixed cell lymphoma
1520858|NCT00002673|recurrent adult diffuse large cell lymphoma
1520859|NCT00002673|recurrent adult immunoblastic large cell lymphoma
1520860|NCT00002673|recurrent adult lymphoblastic lymphoma
1520861|NCT00002673|recurrent adult Burkitt lymphoma
1520862|NCT00002673|poor prognosis metastatic gestational trophoblastic tumor
1520863|NCT00002673|previously treated myelodysplastic syndromes
1520864|NCT00002673|secondary myelodysplastic syndromes
1520865|NCT00002673|infection
1520866|NCT00002673|recurrent childhood small noncleaved cell lymphoma
1520867|NCT00002673|recurrent childhood large cell lymphoma
1520868|NCT00002673|noncontiguous stage II grade 1 follicular lymphoma
1520869|NCT00002673|noncontiguous stage II grade 2 follicular lymphoma
1520870|NCT00002673|noncontiguous stage II grade 3 follicular lymphoma
1520871|NCT00002673|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1520872|NCT00002673|noncontiguous stage II mantle cell lymphoma
1520873|NCT00002673|noncontiguous stage II adult diffuse mixed cell lymphoma
1520874|NCT00002673|noncontiguous stage II adult immunoblastic large cell lymphoma
1520875|NCT00002673|noncontiguous stage II adult diffuse large cell lymphoma
1520876|NCT00002673|noncontiguous stage II adult Burkitt lymphoma
1520877|NCT00002673|noncontiguous stage II adult lymphoblastic lymphoma
1520878|NCT00002673|stage III mantle cell lymphoma
1520879|NCT00002673|stage IV mantle cell lymphoma
1520880|NCT00002673|previously treated childhood rhabdomyosarcoma
1520881|NCT00002673|noncontiguous stage II small lymphocytic lymphoma
1520882|NCT00002673|noncontiguous stage II marginal zone lymphoma
1520883|NCT00002673|recurrent marginal zone lymphoma
1520884|NCT00002673|recurrent small lymphocytic lymphoma
1520885|NCT00002673|stage III small lymphocytic lymphoma
1520886|NCT00002673|stage III marginal zone lymphoma
1520887|NCT00002673|stage IV small lymphocytic lymphoma
1520888|NCT00002673|stage IV marginal zone lymphoma
1520889|NCT00002673|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1520890|NCT00002673|nodal marginal zone B-cell lymphoma
1520891|NCT00002673|splenic marginal zone lymphoma
1520892|NCT00002673|childhood myelodysplastic syndromes
1520893|NCT00002671|stage III ovarian epithelial cancer
1520894|NCT00002671|stage IV ovarian epithelial cancer
1520895|NCT00002671|recurrent ovarian epithelial cancer
1520896|NCT00002670|stage II squamous cell carcinoma of the lip and oral cavity
1520897|NCT00002670|stage III squamous cell carcinoma of the lip and oral cavity
1520898|NCT00002670|stage IV squamous cell carcinoma of the lip and oral cavity
1520899|NCT00002670|stage II squamous cell carcinoma of the oropharynx
1520900|NCT00002670|stage III squamous cell carcinoma of the oropharynx
1520901|NCT00002670|stage IV squamous cell carcinoma of the oropharynx
1520902|NCT00002670|stage II squamous cell carcinoma of the hypopharynx
1520903|NCT00002670|stage III squamous cell carcinoma of the hypopharynx
1520904|NCT00002670|stage IV squamous cell carcinoma of the hypopharynx
1520905|NCT00002670|stage II squamous cell carcinoma of the larynx
1520906|NCT00002670|stage III squamous cell carcinoma of the larynx
1520907|NCT00002670|stage IV squamous cell carcinoma of the larynx
1520908|NCT00002669|stage IV melanoma
1520909|NCT00002669|recurrent melanoma
1520910|NCT00002668|stage IV breast cancer
1520911|NCT00002668|recurrent breast cancer
1520912|NCT00002668|stage IV prostate cancer
1520913|NCT00002668|recurrent prostate cancer
1520914|NCT00002668|pain
1520915|NCT00002667|stage I non-small cell lung cancer
1520916|NCT00002665|untreated adult acute lymphoblastic leukemia
1520917|NCT00002665|L1 adult acute lymphoblastic leukemia
1520918|NCT00002665|L2 adult acute lymphoblastic leukemia
1520919|NCT00002665|L3 adult acute lymphoblastic leukemia
1520920|NCT00002665|neutropenia
1520921|NCT00002665|thrombocytopenia
1520922|NCT00002664|recurrent colon cancer
1520923|NCT00002664|recurrent rectal cancer
1520924|NCT00002663|stage I adult Hodgkin lymphoma
1520925|NCT00002663|stage II adult Hodgkin lymphoma
1520926|NCT00002663|stage III adult Hodgkin lymphoma
1520927|NCT00002663|stage IV adult Hodgkin lymphoma
1520928|NCT00002663|recurrent adult Hodgkin lymphoma
1520929|NCT00002663|stage I cutaneous T-cell non-Hodgkin lymphoma
1520930|NCT00002663|stage II cutaneous T-cell non-Hodgkin lymphoma
1520931|NCT00002663|stage III cutaneous T-cell non-Hodgkin lymphoma
1520932|NCT00002663|stage IV cutaneous T-cell non-Hodgkin lymphoma
1520933|NCT00002663|recurrent cutaneous T-cell non-Hodgkin lymphoma
1520934|NCT00002663|childhood Burkitt lymphoma
1520935|NCT00002663|stage I childhood lymphoblastic lymphoma
1520936|NCT00002663|stage II childhood lymphoblastic lymphoma
1520937|NCT00002663|stage III childhood lymphoblastic lymphoma
1520938|NCT00002663|stage IV childhood lymphoblastic lymphoma
1520939|NCT00002663|recurrent childhood lymphoblastic lymphoma
1520940|NCT00002663|childhood diffuse large cell lymphoma
1520941|NCT00002663|childhood immunoblastic large cell lymphoma
1520942|NCT00002663|stage II childhood Hodgkin lymphoma
1520943|NCT00002663|stage I childhood Hodgkin lymphoma
1523886|NCT00002258|Leukopenia
1520944|NCT00002663|stage III childhood Hodgkin lymphoma
1520945|NCT00002663|stage IV childhood Hodgkin lymphoma
1520946|NCT00002663|recurrent/refractory childhood Hodgkin lymphoma
1520947|NCT00002663|stage I grade 1 follicular lymphoma
1520948|NCT00002663|stage I grade 2 follicular lymphoma
1520949|NCT00002663|stage I grade 3 follicular lymphoma
1520950|NCT00002663|stage I adult diffuse small cleaved cell lymphoma
1520951|NCT00002663|stage I adult diffuse mixed cell lymphoma
1520952|NCT00002663|stage I adult diffuse large cell lymphoma
1520953|NCT00002663|stage I adult immunoblastic large cell lymphoma
1520954|NCT00002663|stage I adult lymphoblastic lymphoma
1520955|NCT00002663|stage I adult Burkitt lymphoma
1520956|NCT00002663|T-cell large granular lymphocyte leukemia
1520957|NCT00002663|stage III grade 1 follicular lymphoma
1520958|NCT00002663|stage III grade 2 follicular lymphoma
1520959|NCT00002663|stage III grade 3 follicular lymphoma
1520960|NCT00002663|stage III adult diffuse small cleaved cell lymphoma
1520961|NCT00002663|stage III adult diffuse mixed cell lymphoma
1520962|NCT00002663|stage III adult diffuse large cell lymphoma
1520963|NCT00002663|stage III adult immunoblastic large cell lymphoma
1520964|NCT00002663|stage III adult lymphoblastic lymphoma
1520965|NCT00002663|stage III adult Burkitt lymphoma
1520966|NCT00002663|stage IV grade 1 follicular lymphoma
1520967|NCT00002663|stage IV grade 2 follicular lymphoma
1520968|NCT00002663|stage IV grade 3 follicular lymphoma
1520969|NCT00002663|stage IV adult diffuse small cleaved cell lymphoma
1520970|NCT00002663|stage IV adult diffuse mixed cell lymphoma
1520971|NCT00002663|stage IV adult diffuse large cell lymphoma
1520972|NCT00002663|stage IV adult immunoblastic large cell lymphoma
1520973|NCT00002663|stage IV adult lymphoblastic lymphoma
1520974|NCT00002663|stage IV adult Burkitt lymphoma
1520975|NCT00002663|recurrent grade 1 follicular lymphoma
1520976|NCT00002663|recurrent grade 2 follicular lymphoma
1520977|NCT00002663|recurrent grade 3 follicular lymphoma
1520978|NCT00002663|recurrent adult diffuse small cleaved cell lymphoma
1520979|NCT00002663|recurrent adult diffuse mixed cell lymphoma
1520980|NCT00002663|recurrent adult diffuse large cell lymphoma
1520981|NCT00002663|recurrent adult immunoblastic large cell lymphoma
1520982|NCT00002663|recurrent adult lymphoblastic lymphoma
1520983|NCT00002663|recurrent adult Burkitt lymphoma
1520984|NCT00002663|stage I adult T-cell leukemia/lymphoma
1520985|NCT00002663|stage II adult T-cell leukemia/lymphoma
1520986|NCT00002663|stage III adult T-cell leukemia/lymphoma
1520987|NCT00002663|stage IV adult T-cell leukemia/lymphoma
1520988|NCT00002663|recurrent adult T-cell leukemia/lymphoma
1520989|NCT00002663|AIDS-related peripheral/systemic lymphoma
1520990|NCT00002663|HIV-associated Hodgkin lymphoma
1520991|NCT00002663|stage I childhood small noncleaved cell lymphoma
1520992|NCT00002663|stage I childhood large cell lymphoma
1520993|NCT00002663|stage II childhood small noncleaved cell lymphoma
1520994|NCT00002663|stage II childhood large cell lymphoma
1520995|NCT00002663|stage III childhood small noncleaved cell lymphoma
1520996|NCT00002663|stage III childhood large cell lymphoma
1520997|NCT00002663|stage IV childhood small noncleaved cell lymphoma
1520998|NCT00002663|stage IV childhood large cell lymphoma
1520999|NCT00002663|recurrent childhood small noncleaved cell lymphoma
1521000|NCT00002663|recurrent childhood large cell lymphoma
1521001|NCT00002663|stage I mantle cell lymphoma
1521002|NCT00002663|contiguous stage II grade 1 follicular lymphoma
1521003|NCT00002663|contiguous stage II grade 2 follicular lymphoma
1521004|NCT00002663|contiguous stage II grade 3 follicular lymphoma
1521005|NCT00002663|contiguous stage II adult diffuse small cleaved cell lymphoma
1521006|NCT00002663|contiguous stage II mantle cell lymphoma
1521007|NCT00002663|contiguous stage II adult diffuse mixed cell lymphoma
1521008|NCT00002663|contiguous stage II adult immunoblastic large cell lymphoma
1521009|NCT00002663|contiguous stage II adult diffuse large cell lymphoma
1521010|NCT00002663|contiguous stage II adult Burkitt lymphoma
1521011|NCT00002663|contiguous stage II adult lymphoblastic lymphoma
1521012|NCT00002663|noncontiguous stage II grade 1 follicular lymphoma
1521013|NCT00002663|noncontiguous stage II grade 2 follicular lymphoma
1521014|NCT00002663|noncontiguous stage II grade 3 follicular lymphoma
1521015|NCT00002663|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1521016|NCT00002663|noncontiguous stage II mantle cell lymphoma
1521017|NCT00002663|noncontiguous stage II adult diffuse mixed cell lymphoma
1521018|NCT00002663|noncontiguous stage II adult immunoblastic large cell lymphoma
1521019|NCT00002663|noncontiguous stage II adult diffuse large cell lymphoma
1521020|NCT00002663|noncontiguous stage II adult Burkitt lymphoma
1521021|NCT00002663|noncontiguous stage II adult lymphoblastic lymphoma
1521022|NCT00002663|stage III mantle cell lymphoma
1521023|NCT00002663|stage IV mantle cell lymphoma
1521024|NCT00002663|recurrent mantle cell lymphoma
1521025|NCT00002663|stage I mycosis fungoides/Sezary syndrome
1521026|NCT00002663|stage II mycosis fungoides/Sezary syndrome
1521027|NCT00002663|stage III mycosis fungoides/Sezary syndrome
1521028|NCT00002663|stage IV mycosis fungoides/Sezary syndrome
1521029|NCT00002663|recurrent mycosis fungoides/Sezary syndrome
1521030|NCT00002663|contiguous stage II small lymphocytic lymphoma
1521031|NCT00002663|contiguous stage II marginal zone lymphoma
1521032|NCT00002663|noncontiguous stage II small lymphocytic lymphoma
1521033|NCT00002663|noncontiguous stage II marginal zone lymphoma
1521034|NCT00002663|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1521035|NCT00002663|nodal marginal zone B-cell lymphoma
1521036|NCT00002663|splenic marginal zone lymphoma
1521037|NCT00002663|recurrent marginal zone lymphoma
1521038|NCT00002663|recurrent small lymphocytic lymphoma
1521039|NCT00002663|stage I marginal zone lymphoma
1521040|NCT00002663|stage I small lymphocytic lymphoma
1521041|NCT00002663|stage III small lymphocytic lymphoma
1521042|NCT00002663|stage III marginal zone lymphoma
1521043|NCT00002663|stage IV small lymphocytic lymphoma
1521044|NCT00002663|stage IV marginal zone lymphoma
1521045|NCT00002663|unspecified adult solid tumor, protocol specific
1521046|NCT00002663|unspecified childhood solid tumor, protocol specific
1521047|NCT00002662|stage IV breast cancer
1521048|NCT00002662|stage IIIA breast cancer
1521049|NCT00002662|recurrent breast cancer
1521050|NCT00002662|stage IIIB breast cancer
1521051|NCT00002662|stage IIIC breast cancer
1521052|NCT00002659|recurrent squamous cell carcinoma of the lip and oral cavity
1521053|NCT00002659|recurrent squamous cell carcinoma of the oropharynx
1521054|NCT00002659|recurrent squamous cell carcinoma of the nasopharynx
1521055|NCT00002659|recurrent squamous cell carcinoma of the hypopharynx
1521056|NCT00002659|recurrent squamous cell carcinoma of the larynx
1521057|NCT00002659|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1521058|NCT00002658|untreated adult acute myeloid leukemia
1521059|NCT00002658|adult acute erythroid leukemia (M6)
1521060|NCT00002658|adult acute myeloblastic leukemia without maturation (M1)
1521061|NCT00002658|adult acute myeloblastic leukemia with maturation (M2)
1521062|NCT00002658|adult acute promyelocytic leukemia (M3)
1521063|NCT00002658|adult acute myelomonocytic leukemia (M4)
1521064|NCT00002658|adult acute monoblastic leukemia (M5a)
1521065|NCT00002658|adult acute megakaryoblastic leukemia (M7)
1521066|NCT00002658|secondary acute myeloid leukemia
1521067|NCT00002658|adult acute monocytic leukemia (M5b)
1521068|NCT00002658|neutropenia
1521069|NCT00002658|adult acute minimally differentiated myeloid leukemia (M0)
1521070|NCT00002657|isolated plasmacytoma of bone
1521071|NCT00002657|extramedullary plasmacytoma
1521072|NCT00002657|refractory multiple myeloma
1521073|NCT00002657|Waldenstrom macroglobulinemia
1521074|NCT00002657|stage I multiple myeloma
1521075|NCT00002657|stage II multiple myeloma
1521076|NCT00002657|stage III multiple myeloma
1521077|NCT00002657|stage I small lymphocytic lymphoma
1521078|NCT00002657|stage I grade 1 follicular lymphoma
1521079|NCT00002657|stage I grade 2 follicular lymphoma
1521080|NCT00002657|stage I grade 3 follicular lymphoma
1521081|NCT00002657|stage I adult diffuse small cleaved cell lymphoma
1521082|NCT00002657|stage I adult diffuse mixed cell lymphoma
1521083|NCT00002657|stage I adult diffuse large cell lymphoma
1521084|NCT00002657|stage I adult immunoblastic large cell lymphoma
1521085|NCT00002657|stage I adult Burkitt lymphoma
1521086|NCT00002657|stage II small lymphocytic lymphoma
1521087|NCT00002657|stage II grade 1 follicular lymphoma
1521088|NCT00002657|stage II grade 2 follicular lymphoma
1521089|NCT00002657|stage II grade 3 follicular lymphoma
1521090|NCT00002657|stage II adult diffuse small cleaved cell lymphoma
1521091|NCT00002657|stage II adult diffuse mixed cell lymphoma
1521092|NCT00002657|stage II adult diffuse large cell lymphoma
1521093|NCT00002657|stage II adult immunoblastic large cell lymphoma
1521094|NCT00002657|stage II adult Burkitt lymphoma
1521095|NCT00002657|stage III small lymphocytic lymphoma
1521096|NCT00002657|stage III grade 1 follicular lymphoma
1521097|NCT00002657|stage III grade 2 follicular lymphoma
1521098|NCT00002657|stage III grade 3 follicular lymphoma
1521099|NCT00002657|stage III adult diffuse small cleaved cell lymphoma
1521100|NCT00002657|stage III adult diffuse mixed cell lymphoma
1521101|NCT00002657|stage III adult diffuse large cell lymphoma
1521102|NCT00002657|stage III adult immunoblastic large cell lymphoma
1521103|NCT00002657|stage III adult Burkitt lymphoma
1521104|NCT00002657|stage IV small lymphocytic lymphoma
1521105|NCT00002657|stage IV grade 1 follicular lymphoma
1521106|NCT00002657|stage IV grade 2 follicular lymphoma
1521107|NCT00002657|stage IV grade 3 follicular lymphoma
1521108|NCT00002657|stage IV adult diffuse small cleaved cell lymphoma
1521109|NCT00002657|stage IV adult diffuse mixed cell lymphoma
1521110|NCT00002657|stage IV adult diffuse large cell lymphoma
1521111|NCT00002657|stage IV adult immunoblastic large cell lymphoma
1521112|NCT00002657|stage IV adult Burkitt lymphoma
1521113|NCT00002657|recurrent small lymphocytic lymphoma
1521114|NCT00002657|recurrent grade 1 follicular lymphoma
1521115|NCT00002657|recurrent grade 2 follicular lymphoma
1521116|NCT00002657|recurrent grade 3 follicular lymphoma
1521117|NCT00002657|recurrent adult diffuse small cleaved cell lymphoma
1521118|NCT00002657|recurrent adult diffuse mixed cell lymphoma
1521119|NCT00002657|recurrent adult diffuse large cell lymphoma
1521120|NCT00002657|recurrent adult immunoblastic large cell lymphoma
1521121|NCT00002657|recurrent adult Burkitt lymphoma
1521122|NCT00002657|contiguous stage II grade 1 follicular lymphoma
1521123|NCT00002657|contiguous stage II grade 2 follicular lymphoma
1521124|NCT00002657|contiguous stage II grade 3 follicular lymphoma
1524130|NCT00002213|Antiviral Agents
1521125|NCT00002657|contiguous stage II adult diffuse small cleaved cell lymphoma
1521126|NCT00002657|contiguous stage II adult diffuse mixed cell lymphoma
1521127|NCT00002657|contiguous stage II adult immunoblastic large cell lymphoma
1521128|NCT00002657|contiguous stage II adult diffuse large cell lymphoma
1521129|NCT00002657|contiguous stage II adult Burkitt lymphoma
1521130|NCT00002657|noncontiguous stage II grade 1 follicular lymphoma
1521131|NCT00002657|noncontiguous stage II grade 2 follicular lymphoma
1521132|NCT00002657|noncontiguous stage II grade 3 follicular lymphoma
1521133|NCT00002657|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1521134|NCT00002657|noncontiguous stage II adult diffuse mixed cell lymphoma
1521135|NCT00002657|noncontiguous stage II adult immunoblastic large cell lymphoma
1521136|NCT00002657|noncontiguous stage II adult diffuse large cell lymphoma
1521137|NCT00002657|noncontiguous stage II adult Burkitt lymphoma
1521138|NCT00002657|noncontiguous stage II small lymphocytic lymphoma
1521139|NCT00002657|noncontiguous stage II marginal zone lymphoma
1521140|NCT00002657|recurrent marginal zone lymphoma
1521141|NCT00002657|stage I marginal zone lymphoma
1521142|NCT00002657|stage III marginal zone lymphoma
1521143|NCT00002657|stage IV marginal zone lymphoma
1521144|NCT00002657|contiguous stage II marginal zone lymphoma
1521145|NCT00002657|contiguous stage II small lymphocytic lymphoma
1521146|NCT00002657|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1521147|NCT00002657|nodal marginal zone B-cell lymphoma
1521148|NCT00002657|splenic marginal zone lymphoma
1521149|NCT00002656|recurrent non-small cell lung cancer
1521150|NCT00002656|stage IIIB non-small cell lung cancer
1521151|NCT00002656|stage IV non-small cell lung cancer
1521152|NCT00002655|localized unresectable adult primary liver cancer
1521153|NCT00002655|recurrent adult primary liver cancer
1521154|NCT00002655|liver metastases
1521155|NCT00002654|stage III squamous cell carcinoma of the lip and oral cavity
1521156|NCT00002654|stage IV squamous cell carcinoma of the lip and oral cavity
1521157|NCT00002654|stage III squamous cell carcinoma of the oropharynx
1521158|NCT00002654|stage IV squamous cell carcinoma of the oropharynx
1521159|NCT00002654|stage III squamous cell carcinoma of the hypopharynx
1521160|NCT00002654|stage IV squamous cell carcinoma of the hypopharynx
1521161|NCT00002654|stage III squamous cell carcinoma of the larynx
1521162|NCT00002654|stage IV squamous cell carcinoma of the larynx
1521163|NCT00002653|stage I multiple myeloma
1521164|NCT00002653|stage II multiple myeloma
1521165|NCT00002653|stage III multiple myeloma
1521166|NCT00002652|refractory multiple myeloma
1521167|NCT00002651|adenocarcinoma of the prostate
1521168|NCT00002651|stage IV prostate cancer
1521169|NCT00002651|recurrent prostate cancer
1521170|NCT00002650|colon cancer
1521171|NCT00002650|rectal cancer
1521172|NCT00002647|recurrent adult brain tumor
1521173|NCT00002647|tumors metastatic to brain
1521174|NCT00002647|recurrent childhood brain stem glioma
1521175|NCT00002647|recurrent childhood anaplastic astrocytoma
1521176|NCT00002647|recurrent childhood anaplastic oligoastrocytoma
1521177|NCT00002647|recurrent childhood anaplastic oligodendroglioma
1521178|NCT00002647|recurrent childhood cerebellar astrocytoma
1521179|NCT00002647|recurrent childhood cerebral astrocytoma
1521180|NCT00002647|recurrent childhood diffuse astrocytoma
1521181|NCT00002647|recurrent childhood fibrillary astrocytoma
1521182|NCT00002647|recurrent childhood gemistocytic astrocytoma
1521183|NCT00002647|recurrent childhood giant cell glioblastoma
1521184|NCT00002647|recurrent childhood glioblastoma
1521185|NCT00002647|recurrent childhood gliomatosis cerebri
1521186|NCT00002647|recurrent childhood gliosarcoma
1521187|NCT00002647|recurrent childhood oligodendroglioma
1521188|NCT00002647|recurrent childhood pilocytic astrocytoma
1521189|NCT00002647|recurrent childhood pilomyxoid astrocytoma
1521190|NCT00002647|recurrent childhood pleomorphic xanthoastrocytoma
1521191|NCT00002647|recurrent childhood protoplasmic astrocytoma
1521192|NCT00002647|recurrent childhood subependymal giant cell astrocytoma
1521193|NCT00002647|recurrent childhood visual pathway and hypothalamic glioma
1521194|NCT00002647|recurrent childhood visual pathway glioma
1521195|NCT00002647|recurrent childhood pineoblastoma
1521196|NCT00002647|recurrent childhood supratentorial primitive neuroectodermal tumor
1521197|NCT00002647|recurrent childhood medulloblastoma
1521198|NCT00002647|recurrent childhood ependymoma
1521199|NCT00002647|recurrent childhood brain tumor
1521200|NCT00002647|adult anaplastic astrocytoma
1521201|NCT00002647|adult anaplastic ependymoma
1521202|NCT00002647|adult anaplastic meningioma
1521203|NCT00002647|adult anaplastic oligodendroglioma
1521204|NCT00002647|adult brain stem glioma
1521205|NCT00002647|adult central nervous system germ cell tumor
1521206|NCT00002647|adult choroid plexus tumor
1521207|NCT00002647|adult craniopharyngioma
1521208|NCT00002647|adult diffuse astrocytoma
1521209|NCT00002647|adult ependymoblastoma
1521210|NCT00002647|adult ependymoma
1521211|NCT00002647|adult giant cell glioblastoma
1521212|NCT00002647|adult glioblastoma
1521213|NCT00002647|adult gliosarcoma
1521214|NCT00002647|adult medulloblastoma
1521215|NCT00002647|meningeal melanocytoma
1521216|NCT00002647|adult meningeal hemangiopericytoma
1521217|NCT00002647|adult oligodendroglioma
1521218|NCT00002647|adult papillary meningioma
1521219|NCT00002647|adult pilocytic astrocytoma
1521220|NCT00002647|adult pineal gland astrocytoma
1521221|NCT00002647|adult pineoblastoma
1521222|NCT00002647|adult pineocytoma
1521223|NCT00002647|adult subependymal giant cell astrocytoma
1521224|NCT00002647|adult subependymoma
1521225|NCT00002647|adult supratentorial primitive neuroectodermal tumor (PNET)
1521226|NCT00002647|childhood grade I meningioma
1521227|NCT00002647|childhood grade II meningioma
1521228|NCT00002647|childhood grade III meningioma
1521229|NCT00002647|adult grade III meningioma
1521230|NCT00002647|childhood central nervous system germ cell tumor
1521231|NCT00002647|childhood choroid plexus tumor
1521232|NCT00002647|childhood craniopharyngioma
1521233|NCT00002647|childhood infratentorial ependymoma
1521234|NCT00002647|childhood supratentorial ependymoma
1521235|NCT00002647|childhood low-grade cerebral astrocytoma
1521236|NCT00002647|childhood high-grade cerebral astrocytoma
1521237|NCT00002646|stage II breast cancer
1523312|NCT00002376|HIV-1
1521238|NCT00002646|stage IIIA breast cancer
1521239|NCT00002644|breast cancer
1521240|NCT00002643|neutropenia
1521241|NCT00002643|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1521242|NCT00002642|squamous cell lung cancer
1521243|NCT00002642|large cell lung cancer
1521244|NCT00002642|stage IIIA non-small cell lung cancer
1521245|NCT00002642|stage IIIB non-small cell lung cancer
1521246|NCT00002642|adenocarcinoma of the lung
1521247|NCT00002642|adenosquamous cell lung cancer
1521248|NCT00002641|adult angiosarcoma
1521249|NCT00002641|adult fibrosarcoma
1521250|NCT00002641|adult leiomyosarcoma
1521251|NCT00002641|adult liposarcoma
1521252|NCT00002641|adult neurofibrosarcoma
1521253|NCT00002641|adult synovial sarcoma
1521254|NCT00002641|stage III adult soft tissue sarcoma
1521255|NCT00002641|recurrent adult soft tissue sarcoma
1521256|NCT00002641|adult alveolar soft-part sarcoma
1521257|NCT00002641|adult epithelioid sarcoma
1521258|NCT00002641|adult malignant fibrous histiocytoma
1521259|NCT00002641|adult malignant hemangiopericytoma
1521260|NCT00002641|adult malignant mesenchymoma
1521261|NCT00002641|adult rhabdomyosarcoma
1521262|NCT00002641|localized benign pheochromocytoma
1521263|NCT00002641|regional pheochromocytoma
1521264|NCT00002641|recurrent pheochromocytoma
1521265|NCT00002641|stage II uterine sarcoma
1521266|NCT00002641|stage III uterine sarcoma
1521267|NCT00002641|recurrent uterine sarcoma
1521268|NCT00002641|uterine carcinosarcoma
1521269|NCT00002641|uterine leiomyosarcoma
1521270|NCT00002641|endometrial stromal sarcoma
1521271|NCT00002641|ovarian sarcoma
1521272|NCT00002641|clear cell sarcoma of the kidney
1521273|NCT00002641|stage II adult soft tissue sarcoma
1521274|NCT00002639|recurrent adult brain tumor
1521275|NCT00002639|adult glioblastoma
1521276|NCT00002639|adult anaplastic astrocytoma
1521277|NCT00002639|adult anaplastic oligodendroglioma
1521278|NCT00002639|adult mixed glioma
1521279|NCT00002639|adult giant cell glioblastoma
1521280|NCT00002639|adult gliosarcoma
1521281|NCT00002638|recurrent childhood acute lymphoblastic leukemia
1521282|NCT00002637|recurrent prostate cancer
1521283|NCT00002635|stage II cutaneous T-cell non-Hodgkin lymphoma
1521284|NCT00002635|stage III cutaneous T-cell non-Hodgkin lymphoma
1521285|NCT00002635|stage IV cutaneous T-cell non-Hodgkin lymphoma
1521286|NCT00002635|recurrent cutaneous T-cell non-Hodgkin lymphoma
1521287|NCT00002634|localized resectable neuroblastoma
1521288|NCT00002634|regional neuroblastoma
1521289|NCT00002634|disseminated neuroblastoma
1521290|NCT00002634|recurrent neuroblastoma
1521291|NCT00002634|localized unresectable neuroblastoma
1521292|NCT00002633|adenocarcinoma of the prostate
1521293|NCT00002633|stage II prostate cancer
1521294|NCT00002633|stage III prostate cancer
1521295|NCT00002633|stage IV prostate cancer
1521296|NCT00002632|stage IV salivary gland cancer
1521297|NCT00002632|recurrent salivary gland cancer
1521298|NCT00002632|high-grade salivary gland mucoepidermoid carcinoma
1521299|NCT00002632|salivary gland adenocarcinoma
1521300|NCT00002631|stage I esophageal cancer
1521301|NCT00002631|stage II esophageal cancer
1521302|NCT00002631|stage III esophageal cancer
1521303|NCT00002631|squamous cell carcinoma of the esophagus
1521304|NCT00002631|adenocarcinoma of the esophagus
1521305|NCT00002630|refractory multiple myeloma
1521306|NCT00002630|stage II multiple myeloma
1521307|NCT00002630|stage III multiple myeloma
1521308|NCT00002628|stage IV breast cancer
1521309|NCT00002628|recurrent breast cancer
1521310|NCT00002627|stage II breast cancer
1521311|NCT00002627|stage IIIA breast cancer
1521312|NCT00002627|stage IIIB breast cancer
1521313|NCT00002627|inflammatory breast cancer
1521314|NCT00002625|stage III adult Hodgkin lymphoma
1521315|NCT00002625|stage IV adult Hodgkin lymphoma
1521316|NCT00002625|recurrent non-small cell lung cancer
1521317|NCT00002625|recurrent adult Hodgkin lymphoma
1521318|NCT00002625|recurrent esophageal cancer
1521319|NCT00002625|stage III cutaneous T-cell non-Hodgkin lymphoma
1521320|NCT00002625|stage IV cutaneous T-cell non-Hodgkin lymphoma
1521321|NCT00002625|recurrent cutaneous T-cell non-Hodgkin lymphoma
1521322|NCT00002625|recurrent small cell lung cancer
1521323|NCT00002625|stage III grade 1 follicular lymphoma
1521324|NCT00002625|stage III grade 2 follicular lymphoma
1521325|NCT00002625|stage III grade 3 follicular lymphoma
1521326|NCT00002625|stage III adult diffuse small cleaved cell lymphoma
1521327|NCT00002625|stage III adult diffuse mixed cell lymphoma
1521328|NCT00002625|stage III adult diffuse large cell lymphoma
1521329|NCT00002625|stage III adult immunoblastic large cell lymphoma
1521330|NCT00002625|stage III adult lymphoblastic lymphoma
1521331|NCT00002625|stage III adult Burkitt lymphoma
1521332|NCT00002625|stage IV grade 1 follicular lymphoma
1521333|NCT00002625|stage IV grade 2 follicular lymphoma
1521334|NCT00002625|stage IV grade 3 follicular lymphoma
1521335|NCT00002625|stage IV adult diffuse small cleaved cell lymphoma
1521336|NCT00002625|stage IV adult diffuse mixed cell lymphoma
1521337|NCT00002625|stage IV adult diffuse large cell lymphoma
1521338|NCT00002625|stage IV adult immunoblastic large cell lymphoma
1521339|NCT00002625|stage IV adult lymphoblastic lymphoma
1521340|NCT00002625|stage IV adult Burkitt lymphoma
1521341|NCT00002625|recurrent grade 1 follicular lymphoma
1521342|NCT00002625|recurrent grade 2 follicular lymphoma
1521343|NCT00002625|recurrent grade 3 follicular lymphoma
1521344|NCT00002625|recurrent adult diffuse small cleaved cell lymphoma
1521345|NCT00002625|recurrent adult diffuse mixed cell lymphoma
1521346|NCT00002625|recurrent adult diffuse large cell lymphoma
1521347|NCT00002625|recurrent adult immunoblastic large cell lymphoma
1521348|NCT00002625|recurrent adult lymphoblastic lymphoma
1521349|NCT00002625|recurrent adult Burkitt lymphoma
1521350|NCT00002625|stage III adult T-cell leukemia/lymphoma
1521351|NCT00002625|stage IV adult T-cell leukemia/lymphoma
1521352|NCT00002625|recurrent adult T-cell leukemia/lymphoma
1521353|NCT00002625|stage III mantle cell lymphoma
1521354|NCT00002625|stage IV mantle cell lymphoma
1521355|NCT00002625|recurrent mantle cell lymphoma
1521356|NCT00002625|recurrent marginal zone lymphoma
1521357|NCT00002625|recurrent small lymphocytic lymphoma
1521358|NCT00002625|stage III small lymphocytic lymphoma
1521359|NCT00002625|stage III marginal zone lymphoma
1521360|NCT00002625|stage IV small lymphocytic lymphoma
1521361|NCT00002625|stage IV marginal zone lymphoma
1521362|NCT00002625|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1521363|NCT00002625|nodal marginal zone B-cell lymphoma
1521364|NCT00002625|splenic marginal zone lymphoma
1521365|NCT00002624|stage I non-small cell lung cancer
1521366|NCT00002624|squamous cell lung cancer
1521367|NCT00002624|large cell lung cancer
1521368|NCT00002624|adenocarcinoma of the lung
1521369|NCT00002624|bronchoalveolar cell lung cancer
1521370|NCT00002623|squamous cell lung cancer
1521371|NCT00002623|large cell lung cancer
1521372|NCT00002623|stage IIIA non-small cell lung cancer
1521373|NCT00002623|adenocarcinoma of the lung
1521374|NCT00002623|adenosquamous cell lung cancer
1521375|NCT00002623|bronchoalveolar cell lung cancer
1521376|NCT00002622|malignant pleural effusion
1521377|NCT00002621|recurrent childhood acute lymphoblastic leukemia
1521378|NCT00002621|stage I childhood lymphoblastic lymphoma
1521379|NCT00002621|stage II childhood lymphoblastic lymphoma
1521380|NCT00002621|stage III childhood lymphoblastic lymphoma
1521381|NCT00002621|stage IV childhood lymphoblastic lymphoma
1521382|NCT00002621|recurrent childhood lymphoblastic lymphoma
1521383|NCT00002621|recurrent childhood acute myeloid leukemia
1521384|NCT00002621|unspecified childhood solid tumor, protocol specific
1521385|NCT00002621|untreated childhood acute myeloid leukemia and other myeloid malignancies
1521386|NCT00002621|untreated childhood acute lymphoblastic leukemia
1521387|NCT00002621|childhood acute myeloid leukemia in remission
1521388|NCT00002621|childhood acute lymphoblastic leukemia in remission
1521389|NCT00002621|AIDS-related peripheral/systemic lymphoma
1521390|NCT00002621|AIDS-related primary CNS lymphoma
1521391|NCT00002621|stage I childhood small noncleaved cell lymphoma
1521392|NCT00002621|stage I childhood large cell lymphoma
1521393|NCT00002621|stage II childhood small noncleaved cell lymphoma
1521394|NCT00002621|stage II childhood large cell lymphoma
1521395|NCT00002621|stage III childhood small noncleaved cell lymphoma
1521396|NCT00002621|stage III childhood large cell lymphoma
1521397|NCT00002621|stage IV childhood small noncleaved cell lymphoma
1521398|NCT00002621|stage IV childhood large cell lymphoma
1521399|NCT00002621|recurrent childhood small noncleaved cell lymphoma
1521400|NCT00002621|recurrent childhood large cell lymphoma
1521401|NCT00002620|adult anaplastic astrocytoma
1521402|NCT00002619|adult brain stem glioma
1521403|NCT00002619|adult glioblastoma
1521404|NCT00002619|childhood high-grade cerebral astrocytoma
1521405|NCT00002619|untreated childhood brain stem glioma
1521406|NCT00002619|adult giant cell glioblastoma
1521407|NCT00002619|adult gliosarcoma
1521408|NCT00002618|childhood diffuse large cell lymphoma
1521409|NCT00002618|childhood immunoblastic large cell lymphoma
1521410|NCT00002618|AIDS-related peripheral/systemic lymphoma
1521411|NCT00002618|AIDS-related diffuse large cell lymphoma
1521412|NCT00002618|AIDS-related immunoblastic large cell lymphoma
1521413|NCT00002618|AIDS-related diffuse mixed cell lymphoma
1521414|NCT00002618|stage III childhood large cell lymphoma
1521415|NCT00002618|stage IV childhood large cell lymphoma
1521416|NCT00002616|stage IV breast cancer
1521417|NCT00002616|recurrent breast cancer
1521418|NCT00002616|stage IIIB breast cancer
1521419|NCT00002616|inflammatory breast cancer
1521420|NCT00002615|stage II gastric cancer
1521421|NCT00002615|stage III gastric cancer
1521422|NCT00002615|adenocarcinoma of the stomach
1521423|NCT00002611|stage I Wilms tumor
1521424|NCT00002611|stage II Wilms tumor
1521425|NCT00002611|stage III Wilms tumor
1521426|NCT00002611|stage IV Wilms tumor
1521427|NCT00002611|stage V Wilms tumor
1521428|NCT00002611|clear cell sarcoma of the kidney
1521429|NCT00002610|recurrent Wilms tumor and other childhood kidney tumors
1521430|NCT00002610|clear cell sarcoma of the kidney
1521431|NCT00002610|rhabdoid tumor of the kidney
1521432|NCT00002609|adult acute myeloid leukemia in remission
1521433|NCT00002609|childhood acute myeloid leukemia in remission
1521434|NCT00002609|adult acute promyelocytic leukemia (M3)
1521435|NCT00002609|childhood acute promyelocytic leukemia (M3)
1521437|NCT00002608|childhood infratentorial ependymoma
1521438|NCT00002608|childhood supratentorial ependymoma
1521439|NCT00002608|recurrent adult soft tissue sarcoma
1521440|NCT00002608|recurrent childhood brain tumor
1521441|NCT00002608|childhood liver cancer
1521442|NCT00002608|stage IV childhood liver cancer
1521443|NCT00002608|recurrent childhood liver cancer
1521444|NCT00002608|advanced malignant mesothelioma
1521445|NCT00002608|recurrent malignant mesothelioma
1521446|NCT00002608|localized unresectable adult primary liver cancer
1521447|NCT00002608|advanced adult primary liver cancer
1521448|NCT00002608|recurrent adult primary liver cancer
1521449|NCT00002608|recurrent adult brain tumor
1521450|NCT00002608|stage IV adrenocortical carcinoma
1521451|NCT00002608|recurrent adrenocortical carcinoma
1521452|NCT00002608|stage IV papillary thyroid cancer
1521453|NCT00002608|stage IV follicular thyroid cancer
1521454|NCT00002608|thyroid gland medullary carcinoma
1521455|NCT00002608|anaplastic thyroid cancer
1521456|NCT00002608|recurrent thyroid cancer
1521457|NCT00002608|adult brain stem glioma
1521458|NCT00002608|adult medulloblastoma
1521459|NCT00002608|adult glioblastoma
1521460|NCT00002608|metastatic pheochromocytoma
1521461|NCT00002608|recurrent pheochromocytoma
1521462|NCT00002608|childhood soft tissue sarcoma
1521463|NCT00002608|metastatic childhood soft tissue sarcoma
1521464|NCT00002608|recurrent childhood soft tissue sarcoma
1521465|NCT00002608|childhood high-grade cerebral astrocytoma
1521466|NCT00002608|childhood oligodendroglioma
1521467|NCT00002608|adult anaplastic astrocytoma
1521468|NCT00002608|adult myxopapillary ependymoma
1521469|NCT00002608|adult anaplastic ependymoma
1521470|NCT00002608|adult anaplastic oligodendroglioma
1521471|NCT00002608|adult mixed glioma
1521472|NCT00002608|adult pilocytic astrocytoma
1521473|NCT00002608|adult subependymoma
1521474|NCT00002608|recurrent childhood brain stem glioma
1521475|NCT00002608|recurrent childhood cerebellar astrocytoma
1521476|NCT00002608|recurrent childhood cerebral astrocytoma
1521477|NCT00002608|recurrent childhood medulloblastoma
1521478|NCT00002608|recurrent childhood visual pathway and hypothalamic glioma
1521479|NCT00002608|recurrent childhood ependymoma
1521480|NCT00002608|stage IV adult soft tissue sarcoma
1521481|NCT00002608|adult oligodendroglioma
1521482|NCT00002608|adult giant cell glioblastoma
1521483|NCT00002608|adult gliosarcoma
1521484|NCT00002608|adult diffuse astrocytoma
1521485|NCT00002604|unspecified adult solid tumor, protocol specific
1521486|NCT00002602|adenocarcinoma of the prostate
1521487|NCT00002602|stage IIB prostate cancer
1521488|NCT00002602|stage IIA prostate cancer
1521489|NCT00002602|stage III prostate cancer
1521490|NCT00002601|metastatic osteosarcoma
1521491|NCT00002601|recurrent childhood rhabdomyosarcoma
1521492|NCT00002601|recurrent adult soft tissue sarcoma
1521493|NCT00002601|recurrent osteosarcoma
1521494|NCT00002601|adult rhabdomyosarcoma
1521495|NCT00002601|metastatic childhood soft tissue sarcoma
1521496|NCT00002601|recurrent childhood soft tissue sarcoma
1521497|NCT00002601|previously treated childhood rhabdomyosarcoma
1521498|NCT00002601|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1521499|NCT00002601|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1521500|NCT00002601|stage IV adult soft tissue sarcoma
1521501|NCT00002600|recurrent ovarian epithelial cancer
1521502|NCT00002600|ovarian undifferentiated adenocarcinoma
1521503|NCT00002600|ovarian mixed epithelial carcinoma
1521504|NCT00002600|ovarian serous cystadenocarcinoma
1521505|NCT00002600|ovarian mucinous cystadenocarcinoma
1521506|NCT00002600|ovarian endometrioid adenocarcinoma
1521507|NCT00002600|ovarian clear cell cystadenocarcinoma
1521508|NCT00002600|fallopian tube cancer
1521509|NCT00002600|primary peritoneal cavity cancer
1521510|NCT00002599|stage I multiple myeloma
1521511|NCT00002599|stage II multiple myeloma
1521512|NCT00002599|stage III multiple myeloma
1521513|NCT00002598|relapsing chronic myelogenous leukemia
1521514|NCT00002598|blastic phase chronic myelogenous leukemia
1521515|NCT00002598|atypical chronic myeloid leukemia, BCR-ABL1 negative
1521516|NCT00002597|adenocarcinoma of the prostate
1521517|NCT00002597|stage I prostate cancer
1521518|NCT00002597|stage IIB prostate cancer
1521519|NCT00002597|stage IIA prostate cancer
1521520|NCT00002596|stage II malignant testicular germ cell tumor
1521521|NCT00002596|stage III malignant testicular germ cell tumor
1521522|NCT00002596|testicular seminoma
1521523|NCT00002596|testicular embryonal carcinoma
1521524|NCT00002596|testicular choriocarcinoma
1521525|NCT00002596|testicular teratoma
1521526|NCT00002596|testicular yolk sac tumor
1521527|NCT00002596|testicular embryonal carcinoma and teratoma
1521528|NCT00002596|testicular embryonal carcinoma and teratoma with seminoma
1521529|NCT00002596|testicular embryonal carcinoma and yolk sac tumor
1521530|NCT00002596|testicular embryonal carcinoma and yolk sac tumor with seminoma
1521531|NCT00002596|testicular embryonal carcinoma and seminoma
1521532|NCT00002596|testicular yolk sac tumor and teratoma
1521533|NCT00002596|testicular yolk sac tumor and teratoma with seminoma
1521534|NCT00002596|testicular choriocarcinoma and yolk sac tumor
1521535|NCT00002596|testicular choriocarcinoma and embryonal carcinoma
1521536|NCT00002596|testicular choriocarcinoma and teratoma
1521537|NCT00002596|testicular choriocarcinoma and seminoma
1521538|NCT00002596|extragonadal germ cell tumor
1521539|NCT00002596|childhood teratoma
1521540|NCT00002596|childhood malignant testicular germ cell tumor
1521541|NCT00002596|childhood extragonadal germ cell tumor
1521542|NCT00002595|desmoid tumor
1521543|NCT00002594|recurrent childhood brain tumor
1521544|NCT00002594|childhood central nervous system germ cell tumor
1521545|NCT00002594|recurrent childhood medulloblastoma
1521546|NCT00002593|stage II colon cancer
1521547|NCT00002593|stage III colon cancer
1521548|NCT00002592|relapsing chronic myelogenous leukemia
1521549|NCT00002592|chronic phase chronic myelogenous leukemia
1521550|NCT00002592|accelerated phase chronic myelogenous leukemia
1521551|NCT00002590|stage IV childhood lymphoblastic lymphoma
1521552|NCT00002590|stage IV childhood large cell lymphoma
1521553|NCT00002589|stage III renal cell cancer
1521554|NCT00002589|stage IV renal cell cancer
1521555|NCT00002589|recurrent renal cell cancer
1521556|NCT00002588|recurrent adult acute myeloid leukemia
1521557|NCT00002588|recurrent adult acute lymphoblastic leukemia
1521558|NCT00002588|relapsing chronic myelogenous leukemia
1521559|NCT00002588|blastic phase chronic myelogenous leukemia
1521560|NCT00002588|L1 adult acute lymphoblastic leukemia
1521561|NCT00002588|L2 adult acute lymphoblastic leukemia
1521562|NCT00002588|adult acute erythroid leukemia (M6)
1521563|NCT00002588|adult acute myeloblastic leukemia without maturation (M1)
1521564|NCT00002588|adult acute myeloblastic leukemia with maturation (M2)
1521565|NCT00002588|adult acute promyelocytic leukemia (M3)
1521566|NCT00002588|adult acute myelomonocytic leukemia (M4)
1521567|NCT00002588|adult acute monoblastic leukemia (M5a)
1521568|NCT00002588|adult acute megakaryoblastic leukemia (M7)
1521569|NCT00002588|secondary acute myeloid leukemia
1521570|NCT00002588|adult acute monocytic leukemia (M5b)
1521571|NCT00002588|adult acute minimally differentiated myeloid leukemia (M0)
1521572|NCT00002587|unspecified adult solid tumor, protocol specific
1521573|NCT00002586|non-small cell lung cancer
1521574|NCT00002586|small cell lung cancer
1521575|NCT00002586|drug/agent toxicity by tissue/organ
1521576|NCT00002585|stage IV breast cancer
1521577|NCT00002585|recurrent breast cancer
1521578|NCT00002583|stage I non-small cell lung cancer
1521579|NCT00002583|stage II non-small cell lung cancer
1521580|NCT00002582|stage I breast cancer
1521581|NCT00002582|stage II breast cancer
1521582|NCT00002582|stage IIIA breast cancer
1521583|NCT00002581|stage I breast cancer
1521584|NCT00002581|stage II breast cancer
1521585|NCT00002581|stage IIIA breast cancer
1521586|NCT00002580|stage I breast cancer
1521587|NCT00002580|stage II breast cancer
1521588|NCT00002580|stage IIIA breast cancer
1521589|NCT00002579|stage I breast cancer
1521590|NCT00002579|stage II breast cancer
1521591|NCT00002579|stage IIIA breast cancer
1521592|NCT00002578|AIDS-related peripheral/systemic lymphoma
1521593|NCT00002578|AIDS-related diffuse large cell lymphoma
1521594|NCT00002578|AIDS-related immunoblastic large cell lymphoma
1521595|NCT00002578|AIDS-related small noncleaved cell lymphoma
1521596|NCT00002578|AIDS-related diffuse mixed cell lymphoma
1521597|NCT00002578|AIDS-related diffuse small cleaved cell lymphoma
1521598|NCT00002578|AIDS-related lymphoblastic lymphoma
1521599|NCT00002577|stage I non-small cell lung cancer
1521600|NCT00002577|stage II non-small cell lung cancer
1521601|NCT00002577|recurrent non-small cell lung cancer
1521602|NCT00002577|squamous cell lung cancer
1521603|NCT00002577|large cell lung cancer
1521604|NCT00002577|stage IIIA non-small cell lung cancer
1521605|NCT00002577|stage IIIB non-small cell lung cancer
1521606|NCT00002577|adenocarcinoma of the lung
1521607|NCT00002576|stage I adult diffuse mixed cell lymphoma
1521608|NCT00002576|stage I adult diffuse large cell lymphoma
1521609|NCT00002576|stage I adult immunoblastic large cell lymphoma
1521610|NCT00002576|stage I adult lymphoblastic lymphoma
1521611|NCT00002576|stage I adult Burkitt lymphoma
1521612|NCT00002576|stage II adult diffuse mixed cell lymphoma
1521613|NCT00002576|stage II adult diffuse large cell lymphoma
1521614|NCT00002576|stage II adult immunoblastic large cell lymphoma
1521615|NCT00002576|stage II adult lymphoblastic lymphoma
1521616|NCT00002576|stage II adult Burkitt lymphoma
1521617|NCT00002576|stage III adult diffuse mixed cell lymphoma
1521618|NCT00002576|stage III adult diffuse large cell lymphoma
1521619|NCT00002576|stage III adult immunoblastic large cell lymphoma
1521620|NCT00002576|stage III adult lymphoblastic lymphoma
1521621|NCT00002576|stage III adult Burkitt lymphoma
1521622|NCT00002576|stage IV adult diffuse mixed cell lymphoma
1521623|NCT00002576|stage IV adult diffuse large cell lymphoma
1521624|NCT00002576|stage IV adult immunoblastic large cell lymphoma
1521625|NCT00002576|stage IV adult lymphoblastic lymphoma
1521626|NCT00002576|stage IV adult Burkitt lymphoma
1521627|NCT00002576|contiguous stage II adult diffuse mixed cell lymphoma
1521628|NCT00002576|contiguous stage II adult immunoblastic large cell lymphoma
1521629|NCT00002576|contiguous stage II adult diffuse large cell lymphoma
1521630|NCT00002576|contiguous stage II adult Burkitt lymphoma
1521631|NCT00002576|contiguous stage II adult lymphoblastic lymphoma
1523313|NCT00002376|CD4 Lymphocyte Count
1521632|NCT00002576|noncontiguous stage II adult diffuse mixed cell lymphoma
1521633|NCT00002576|noncontiguous stage II adult immunoblastic large cell lymphoma
1521634|NCT00002576|noncontiguous stage II adult diffuse large cell lymphoma
1521635|NCT00002576|noncontiguous stage II adult Burkitt lymphoma
1521636|NCT00002576|noncontiguous stage II adult lymphoblastic lymphoma
1521637|NCT00002575|stage I colon cancer
1521638|NCT00002575|stage II colon cancer
1521639|NCT00002575|stage III colon cancer
1521640|NCT00002575|adenocarcinoma of the colon
1521641|NCT00002574|relapsing chronic myelogenous leukemia
1521642|NCT00002574|chronic phase chronic myelogenous leukemia
1521643|NCT00002572|recurrent adult brain tumor
1521644|NCT00002572|adult glioblastoma
1521645|NCT00002572|adult anaplastic astrocytoma
1521646|NCT00002572|adult anaplastic oligodendroglioma
1521647|NCT00002572|adult mixed glioma
1521648|NCT00002572|adult giant cell glioblastoma
1521649|NCT00002572|adult gliosarcoma
1521650|NCT00002571|AIDS-related peripheral/systemic lymphoma
1521651|NCT00002571|AIDS-related diffuse large cell lymphoma
1521652|NCT00002571|AIDS-related immunoblastic large cell lymphoma
1521653|NCT00002571|AIDS-related small noncleaved cell lymphoma
1521654|NCT00002571|AIDS-related diffuse mixed cell lymphoma
1521655|NCT00002571|AIDS-related diffuse small cleaved cell lymphoma
1521656|NCT00002570|stage III colon cancer
1521657|NCT00002570|stage IV colon cancer
1521658|NCT00002570|stage III rectal cancer
1521659|NCT00002570|stage IV rectal cancer
1521660|NCT00002570|recurrent colon cancer
1521661|NCT00002570|recurrent rectal cancer
1521662|NCT00002569|adult anaplastic oligodendroglioma
1521663|NCT00002569|adult mixed glioma
1521664|NCT00002568|stage III ovarian epithelial cancer
1521665|NCT00002568|ovarian undifferentiated adenocarcinoma
1521666|NCT00002568|ovarian mixed epithelial carcinoma
1521667|NCT00002568|ovarian serous cystadenocarcinoma
1521668|NCT00002568|ovarian mucinous cystadenocarcinoma
1521669|NCT00002568|ovarian endometrioid adenocarcinoma
1521670|NCT00002568|ovarian clear cell cystadenocarcinoma
1521671|NCT00002568|Brenner tumor
1521672|NCT00002567|adult acute myeloid leukemia in remission
1521673|NCT00002567|adult acute lymphoblastic leukemia in remission
1521674|NCT00002567|adult acute erythroid leukemia (M6)
1521675|NCT00002567|adult acute myeloblastic leukemia without maturation (M1)
1521676|NCT00002567|adult acute myeloblastic leukemia with maturation (M2)
1521677|NCT00002567|adult acute promyelocytic leukemia (M3)
1521678|NCT00002567|adult acute myelomonocytic leukemia (M4)
1521679|NCT00002567|adult acute monoblastic leukemia (M5a)
1521680|NCT00002567|adult acute megakaryoblastic leukemia (M7)
1521681|NCT00002567|adult acute monocytic leukemia (M5b)
1521682|NCT00002567|bone marrow ablation
1521683|NCT00002567|adult acute minimally differentiated myeloid leukemia (M0)
1521684|NCT00002566|recurrent malignant testicular germ cell tumor
1521685|NCT00002566|extragonadal germ cell tumor
1521686|NCT00002565|stage I grade 3 follicular lymphoma
1521687|NCT00002565|stage I adult diffuse mixed cell lymphoma
1521688|NCT00002565|stage I adult diffuse large cell lymphoma
1521689|NCT00002565|stage I adult immunoblastic large cell lymphoma
1521690|NCT00002565|stage II grade 3 follicular lymphoma
1521691|NCT00002565|stage II adult diffuse mixed cell lymphoma
1521692|NCT00002565|stage II adult diffuse large cell lymphoma
1521693|NCT00002565|stage II adult immunoblastic large cell lymphoma
1521694|NCT00002565|stage III grade 3 follicular lymphoma
1521695|NCT00002565|stage III adult diffuse mixed cell lymphoma
1521696|NCT00002565|stage III adult diffuse large cell lymphoma
1521697|NCT00002565|stage III adult immunoblastic large cell lymphoma
1521698|NCT00002565|stage IV grade 3 follicular lymphoma
1521699|NCT00002565|stage IV adult diffuse mixed cell lymphoma
1521700|NCT00002565|stage IV adult diffuse large cell lymphoma
1521701|NCT00002565|stage IV adult immunoblastic large cell lymphoma
1521702|NCT00002565|contiguous stage II grade 3 follicular lymphoma
1521703|NCT00002565|contiguous stage II adult diffuse mixed cell lymphoma
1521704|NCT00002565|contiguous stage II adult immunoblastic large cell lymphoma
1521705|NCT00002565|contiguous stage II adult diffuse large cell lymphoma
1521706|NCT00002565|noncontiguous stage II grade 3 follicular lymphoma
1521707|NCT00002565|noncontiguous stage II adult diffuse mixed cell lymphoma
1521708|NCT00002565|noncontiguous stage II adult immunoblastic large cell lymphoma
1521709|NCT00002565|noncontiguous stage II adult diffuse large cell lymphoma
1521710|NCT00002564|recurrent breast cancer
1521711|NCT00002563|stage I adult Hodgkin lymphoma
1521712|NCT00002563|stage II adult Hodgkin lymphoma
1521713|NCT00002563|psychosocial effects of cancer and its treatment
1521714|NCT00002562|recurrent cervical cancer
1521715|NCT00002562|recurrent vaginal cancer
1521716|NCT00002562|vaginal clear cell adenocarcinoma
1521717|NCT00002562|cervical adenocarcinoma
1521718|NCT00002561|stage I adult Hodgkin lymphoma
1521719|NCT00002561|stage II adult Hodgkin lymphoma
1521720|NCT00002561|adult lymphocyte predominant Hodgkin lymphoma
1521721|NCT00002561|adult lymphocyte depletion Hodgkin lymphoma
1521722|NCT00002561|adult nodular sclerosis Hodgkin lymphoma
1521723|NCT00002561|adult mixed cellularity Hodgkin lymphoma
1521724|NCT00002560|recurrent neuroblastoma
1521725|NCT00002559|recurrent malignant testicular germ cell tumor
1521726|NCT00002559|recurrent ovarian germ cell tumor
1521727|NCT00002558|recurrent malignant testicular germ cell tumor
1521728|NCT00002558|recurrent ovarian germ cell tumor
1521729|NCT00002558|extragonadal germ cell tumor
1521730|NCT00002557|stage III cutaneous T-cell non-Hodgkin lymphoma
1521731|NCT00002557|stage IV cutaneous T-cell non-Hodgkin lymphoma
1521732|NCT00002557|recurrent cutaneous T-cell non-Hodgkin lymphoma
1521733|NCT00002555|stage III squamous cell carcinoma of the lip and oral cavity
1521734|NCT00002555|stage IV squamous cell carcinoma of the lip and oral cavity
1521735|NCT00002555|stage III squamous cell carcinoma of the oropharynx
1521736|NCT00002555|stage IV squamous cell carcinoma of the oropharynx
1521737|NCT00002555|stage III squamous cell carcinoma of the hypopharynx
1521738|NCT00002555|stage IV squamous cell carcinoma of the hypopharynx
1521739|NCT00002555|stage III squamous cell carcinoma of the larynx
1521740|NCT00002555|stage IV squamous cell carcinoma of the larynx
1521741|NCT00002554|recurrent adult acute myeloid leukemia
1521742|NCT00002554|adult acute myeloid leukemia in remission
1521743|NCT00002553|stage IV adult Hodgkin lymphoma
1521744|NCT00002553|recurrent childhood acute lymphoblastic leukemia
1521745|NCT00002553|recurrent adult Hodgkin lymphoma
1521746|NCT00002553|Waldenstrom macroglobulinemia
1521747|NCT00002553|stage IV childhood lymphoblastic lymphoma
1521748|NCT00002553|recurrent childhood lymphoblastic lymphoma
1521749|NCT00002553|recurrent childhood acute myeloid leukemia
1521750|NCT00002553|recurrent adult acute myeloid leukemia
1521751|NCT00002553|recurrent adult acute lymphoblastic leukemia
1521752|NCT00002553|relapsing chronic myelogenous leukemia
1521753|NCT00002553|chronic phase chronic myelogenous leukemia
1521754|NCT00002553|accelerated phase chronic myelogenous leukemia
1521755|NCT00002553|blastic phase chronic myelogenous leukemia
1521756|NCT00002553|untreated adult acute lymphoblastic leukemia
1521757|NCT00002553|untreated adult acute myeloid leukemia
1521758|NCT00002553|untreated childhood acute myeloid leukemia and other myeloid malignancies
1521759|NCT00002553|untreated childhood acute lymphoblastic leukemia
1521760|NCT00002553|adult acute myeloid leukemia in remission
1521761|NCT00002553|adult acute lymphoblastic leukemia in remission
1521762|NCT00002553|childhood acute myeloid leukemia in remission
1521763|NCT00002553|childhood acute lymphoblastic leukemia in remission
1521764|NCT00002553|stage IV childhood Hodgkin lymphoma
1521765|NCT00002553|recurrent/refractory childhood Hodgkin lymphoma
1521766|NCT00002553|recurrent adult non-Hodgkin lymphoma
1521767|NCT00002553|recurrent grade 1 follicular lymphoma
1521768|NCT00002553|recurrent grade 2 follicular lymphoma
1521769|NCT00002553|recurrent grade 3 follicular lymphoma
1521770|NCT00002553|recurrent adult diffuse small cleaved cell lymphoma
1521771|NCT00002553|recurrent adult diffuse mixed cell lymphoma
1521772|NCT00002553|recurrent adult diffuse large cell lymphoma
1521773|NCT00002553|recurrent adult immunoblastic large cell lymphoma
1521774|NCT00002553|recurrent adult lymphoblastic lymphoma
1521775|NCT00002553|recurrent adult Burkitt lymphoma
1521776|NCT00002553|stage IV childhood small noncleaved cell lymphoma
1521777|NCT00002553|stage IV childhood large cell lymphoma
1521778|NCT00002553|recurrent childhood small noncleaved cell lymphoma
1521779|NCT00002553|recurrent childhood large cell lymphoma
1521780|NCT00002553|recurrent mantle cell lymphoma
1521781|NCT00002553|recurrent marginal zone lymphoma
1521782|NCT00002553|recurrent small lymphocytic lymphoma
1521783|NCT00002553|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1521784|NCT00002553|nodal marginal zone B-cell lymphoma
1521785|NCT00002553|splenic marginal zone lymphoma
1521786|NCT00002552|recurrent adult Hodgkin lymphoma
1521787|NCT00002552|refractory multiple myeloma
1521788|NCT00002552|recurrent small lymphocytic lymphoma
1521789|NCT00002552|recurrent grade 1 follicular lymphoma
1521790|NCT00002552|recurrent grade 2 follicular lymphoma
1521791|NCT00002552|recurrent grade 3 follicular lymphoma
1521792|NCT00002552|recurrent adult diffuse small cleaved cell lymphoma
1521793|NCT00002552|recurrent adult diffuse mixed cell lymphoma
1521794|NCT00002552|recurrent adult diffuse large cell lymphoma
1521795|NCT00002552|recurrent adult immunoblastic large cell lymphoma
1521796|NCT00002552|recurrent adult lymphoblastic lymphoma
1521797|NCT00002552|recurrent adult Burkitt lymphoma
1521798|NCT00002552|recurrent mantle cell lymphoma
1521799|NCT00002552|recurrent marginal zone lymphoma
1521800|NCT00002552|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1521801|NCT00002552|nodal marginal zone B-cell lymphoma
1521802|NCT00002552|splenic marginal zone lymphoma
1521803|NCT00002552|adult unfavorable prognosis Hodgkin lymphoma
1521804|NCT00002552|childhood unfavorable prognosis Hodgkin lymphoma
1521805|NCT00002551|stage II rectal cancer
1521806|NCT00002551|stage III rectal cancer
1521807|NCT00002551|adenocarcinoma of the rectum
1521808|NCT00002550|squamous cell lung cancer
1521809|NCT00002550|large cell lung cancer
1521810|NCT00002550|stage IIIA non-small cell lung cancer
1521811|NCT00002550|adenocarcinoma of the lung
1521812|NCT00002550|bronchoalveolar cell lung cancer
1521813|NCT00002549|untreated adult acute myeloid leukemia
1521814|NCT00002549|adult acute erythroid leukemia (M6)
1521815|NCT00002549|adult acute myeloblastic leukemia without maturation (M1)
1521816|NCT00002549|adult acute myeloblastic leukemia with maturation (M2)
1521817|NCT00002549|adult acute myelomonocytic leukemia (M4)
1521818|NCT00002549|adult acute monoblastic leukemia (M5a)
1521819|NCT00002549|adult acute megakaryoblastic leukemia (M7)
1521820|NCT00002549|secondary acute myeloid leukemia
1521821|NCT00002549|adult acute monocytic leukemia (M5b)
1521822|NCT00002548|stage I multiple myeloma
1521823|NCT00002548|stage II multiple myeloma
1521824|NCT00002548|stage III multiple myeloma
1521825|NCT00002547|recurrent childhood acute myeloid leukemia
1521826|NCT00002547|recurrent adult acute myeloid leukemia
1521827|NCT00002547|untreated adult acute myeloid leukemia
1521828|NCT00002547|untreated childhood acute myeloid leukemia and other myeloid malignancies
1521829|NCT00002547|adult acute myeloid leukemia in remission
1521830|NCT00002547|childhood acute myeloid leukemia in remission
1521831|NCT00002547|adult acute erythroid leukemia (M6)
1521832|NCT00002547|adult acute myeloblastic leukemia without maturation (M1)
1521833|NCT00002547|adult acute myeloblastic leukemia with maturation (M2)
1521834|NCT00002547|adult acute promyelocytic leukemia (M3)
1521835|NCT00002547|adult acute myelomonocytic leukemia (M4)
1521836|NCT00002547|adult acute monoblastic leukemia (M5a)
1521837|NCT00002547|adult acute megakaryoblastic leukemia (M7)
1521838|NCT00002547|childhood acute myeloblastic leukemia without maturation (M1)
1521839|NCT00002547|childhood acute myeloblastic leukemia with maturation (M2)
1521840|NCT00002547|childhood acute promyelocytic leukemia (M3)
1521841|NCT00002547|childhood acute myelomonocytic leukemia (M4)
1521842|NCT00002547|childhood acute monoblastic leukemia (M5a)
1521843|NCT00002547|childhood acute monocytic leukemia (M5b)
1521844|NCT00002547|childhood acute erythroleukemia (M6)
1521845|NCT00002547|childhood acute megakaryocytic leukemia (M7)
1521846|NCT00002547|refractory anemia with excess blasts
1521847|NCT00002547|refractory anemia with excess blasts in transformation
1521848|NCT00002547|chronic myelomonocytic leukemia
1521849|NCT00002547|secondary acute myeloid leukemia
1521850|NCT00002547|adult acute monocytic leukemia (M5b)
1521851|NCT00002547|previously treated myelodysplastic syndromes
1521852|NCT00002547|childhood myelodysplastic syndromes
1521853|NCT00002546|stage I uterine sarcoma
1521854|NCT00002546|stage II uterine sarcoma
1521855|NCT00002546|stage III uterine sarcoma
1521856|NCT00002546|stage IV uterine sarcoma
1521857|NCT00002546|uterine carcinosarcoma
1521858|NCT00002545|adult glioblastoma
1521859|NCT00002545|adult giant cell glioblastoma
1521860|NCT00002545|adult gliosarcoma
1521861|NCT00002544|stage IV breast cancer
1521862|NCT00002544|recurrent breast cancer
1521863|NCT00002543|recurrent childhood rhabdomyosarcoma
1521864|NCT00002543|recurrent childhood brain tumor
1521865|NCT00002543|recurrent neuroblastoma
1521866|NCT00002543|recurrent childhood lymphoblastic lymphoma
1521867|NCT00002543|unspecified childhood solid tumor, protocol specific
1521868|NCT00002543|recurrent childhood small noncleaved cell lymphoma
1521869|NCT00002543|recurrent childhood large cell lymphoma
1521870|NCT00002542|stage I breast cancer
1521871|NCT00002542|stage II breast cancer
1521872|NCT00002542|stage IIIA breast cancer
1521873|NCT00002539|localized osteosarcoma
1521874|NCT00002538|stage I ovarian epithelial cancer
1521875|NCT00002538|stage II ovarian epithelial cancer
1521876|NCT00002538|stage III ovarian epithelial cancer
1521877|NCT00002538|ovarian undifferentiated adenocarcinoma
1521878|NCT00002538|ovarian mixed epithelial carcinoma
1521879|NCT00002538|ovarian serous cystadenocarcinoma
1521880|NCT00002538|ovarian mucinous cystadenocarcinoma
1521881|NCT00002538|ovarian endometrioid adenocarcinoma
1521882|NCT00002538|ovarian clear cell cystadenocarcinoma
1521883|NCT00002538|fallopian tube cancer
1521884|NCT00002538|primary peritoneal cavity cancer
1521885|NCT00002537|recurrent non-small cell lung cancer
1521886|NCT00002537|stage IIIA non-small cell lung cancer
1521887|NCT00002537|stage IIIB non-small cell lung cancer
1521888|NCT00002537|stage IV non-small cell lung cancer
1521889|NCT00002536|stage IB cervical cancer
1521890|NCT00002535|stage III melanoma
1521891|NCT00002535|stage IV melanoma
1521892|NCT00002535|recurrent melanoma
1521893|NCT00002534|recurrent childhood acute lymphoblastic leukemia
1521894|NCT00002534|recurrent childhood acute myeloid leukemia
1521895|NCT00002534|recurrent adult acute myeloid leukemia
1521896|NCT00002534|recurrent adult acute lymphoblastic leukemia
1521897|NCT00002534|adult acute myeloid leukemia in remission
1521898|NCT00002534|adult acute lymphoblastic leukemia in remission
1521899|NCT00002534|childhood acute myeloid leukemia in remission
1521900|NCT00002534|childhood acute lymphoblastic leukemia in remission
1521901|NCT00002534|acute undifferentiated leukemia
1521902|NCT00002533|untreated metastatic squamous neck cancer with occult primary
1521903|NCT00002533|recurrent metastatic squamous neck cancer with occult primary
1521904|NCT00002533|metastatic squamous neck cancer with occult primary squamous cell carcinoma
1521905|NCT00002533|oral complications
1521906|NCT00002533|stage I squamous cell carcinoma of the lip and oral cavity
1521907|NCT00002533|stage I basal cell carcinoma of the lip
1521908|NCT00002533|stage I verrucous carcinoma of the oral cavity
1521909|NCT00002533|stage I mucoepidermoid carcinoma of the oral cavity
1521910|NCT00002533|stage I adenoid cystic carcinoma of the oral cavity
1523314|NCT00002376|RNA, Viral
1521911|NCT00002533|stage II squamous cell carcinoma of the lip and oral cavity
1521912|NCT00002533|stage II basal cell carcinoma of the lip
1521913|NCT00002533|stage II verrucous carcinoma of the oral cavity
1521914|NCT00002533|stage II mucoepidermoid carcinoma of the oral cavity
1521915|NCT00002533|stage II adenoid cystic carcinoma of the oral cavity
1521916|NCT00002533|stage III squamous cell carcinoma of the lip and oral cavity
1521917|NCT00002533|stage III basal cell carcinoma of the lip
1521918|NCT00002533|stage III verrucous carcinoma of the oral cavity
1521919|NCT00002533|stage III mucoepidermoid carcinoma of the oral cavity
1521920|NCT00002533|stage III adenoid cystic carcinoma of the oral cavity
1521921|NCT00002533|stage IV squamous cell carcinoma of the lip and oral cavity
1521922|NCT00002533|stage IV basal cell carcinoma of the lip
1521923|NCT00002533|stage IV verrucous carcinoma of the oral cavity
1521924|NCT00002533|stage IV mucoepidermoid carcinoma of the oral cavity
1521925|NCT00002533|stage IV adenoid cystic carcinoma of the oral cavity
1521926|NCT00002533|recurrent squamous cell carcinoma of the lip and oral cavity
1521927|NCT00002533|recurrent basal cell carcinoma of the lip
1521928|NCT00002533|recurrent verrucous carcinoma of the oral cavity
1521929|NCT00002533|recurrent mucoepidermoid carcinoma of the oral cavity
1521930|NCT00002533|recurrent adenoid cystic carcinoma of the oral cavity
1521931|NCT00002533|stage I squamous cell carcinoma of the oropharynx
1521932|NCT00002533|stage I lymphoepithelioma of the oropharynx
1521933|NCT00002533|stage II squamous cell carcinoma of the oropharynx
1521934|NCT00002533|stage II lymphoepithelioma of the oropharynx
1521935|NCT00002533|stage III squamous cell carcinoma of the oropharynx
1521936|NCT00002533|stage III lymphoepithelioma of the oropharynx
1521937|NCT00002533|stage IV squamous cell carcinoma of the oropharynx
1521938|NCT00002533|stage IV lymphoepithelioma of the oropharynx
1521939|NCT00002533|recurrent squamous cell carcinoma of the oropharynx
1521940|NCT00002533|recurrent lymphoepithelioma of the oropharynx
1521941|NCT00002533|stage I squamous cell carcinoma of the nasopharynx
1521942|NCT00002533|stage I lymphoepithelioma of the nasopharynx
1521943|NCT00002533|stage II squamous cell carcinoma of the nasopharynx
1521944|NCT00002533|stage II lymphoepithelioma of the nasopharynx
1521945|NCT00002533|stage III squamous cell carcinoma of the nasopharynx
1521946|NCT00002533|stage III lymphoepithelioma of the nasopharynx
1521947|NCT00002533|stage IV squamous cell carcinoma of the nasopharynx
1521948|NCT00002533|stage IV lymphoepithelioma of the nasopharynx
1521949|NCT00002533|recurrent squamous cell carcinoma of the nasopharynx
1521950|NCT00002533|recurrent lymphoepithelioma of the nasopharynx
1521951|NCT00002533|stage I squamous cell carcinoma of the hypopharynx
1521952|NCT00002533|stage II squamous cell carcinoma of the hypopharynx
1521953|NCT00002533|stage III squamous cell carcinoma of the hypopharynx
1521954|NCT00002533|stage IV squamous cell carcinoma of the hypopharynx
1521955|NCT00002533|recurrent squamous cell carcinoma of the hypopharynx
1521956|NCT00002533|stage I squamous cell carcinoma of the larynx
1521957|NCT00002533|stage I verrucous carcinoma of the larynx
1521958|NCT00002533|stage II squamous cell carcinoma of the larynx
1521959|NCT00002533|stage II verrucous carcinoma of the larynx
1521960|NCT00002533|stage III squamous cell carcinoma of the larynx
1521961|NCT00002533|stage III verrucous carcinoma of the larynx
1521962|NCT00002533|stage IV squamous cell carcinoma of the larynx
1521963|NCT00002533|stage IV verrucous carcinoma of the larynx
1521964|NCT00002533|recurrent squamous cell carcinoma of the larynx
1521965|NCT00002533|recurrent verrucous carcinoma of the larynx
1521966|NCT00002533|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1521967|NCT00002533|stage I inverted papilloma of the paranasal sinus and nasal cavity
1521968|NCT00002533|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1521969|NCT00002533|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1521970|NCT00002533|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1521971|NCT00002533|stage II inverted papilloma of the paranasal sinus and nasal cavity
1521972|NCT00002533|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1521973|NCT00002533|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1521974|NCT00002533|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1521975|NCT00002533|stage III inverted papilloma of the paranasal sinus and nasal cavity
1521976|NCT00002533|stage III midline lethal granuloma of the paranasal sinus and nasal cavity
1521977|NCT00002533|stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
1521978|NCT00002533|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1521979|NCT00002533|stage IV inverted papilloma of the paranasal sinus and nasal cavity
1521980|NCT00002533|stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
1521981|NCT00002533|stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
1521982|NCT00002533|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1521983|NCT00002533|recurrent inverted papilloma of the paranasal sinus and nasal cavity
1521984|NCT00002533|recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
1521985|NCT00002533|recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
1521986|NCT00002533|infection
1521987|NCT00002532|recurrent adult acute lymphoblastic leukemia
1521988|NCT00002531|untreated adult acute lymphoblastic leukemia
1521989|NCT00002531|T-cell adult acute lymphoblastic leukemia
1521990|NCT00002531|B-cell adult acute lymphoblastic leukemia
1521991|NCT00002531|non-T, non-B adult acute lymphoblastic leukemia
1521992|NCT00002529|stage II breast cancer
1521993|NCT00002529|stage IIIA breast cancer
1521994|NCT00002528|stage I breast cancer
1521995|NCT00002528|stage II breast cancer
1521996|NCT00002527|colon cancer
1521997|NCT00002527|rectal cancer
1521998|NCT00002526|stage III adult soft tissue sarcoma
1521999|NCT00002526|recurrent adult soft tissue sarcoma
1522000|NCT00002526|stage III uterine sarcoma
1522001|NCT00002526|stage IV uterine sarcoma
1522002|NCT00002526|recurrent uterine sarcoma
1522003|NCT00002526|ovarian sarcoma
1522004|NCT00002526|stage IV adult soft tissue sarcoma
1522005|NCT00002525|stage II colon cancer
1522006|NCT00002525|stage III colon cancer
1522007|NCT00002524|AIDS-related peripheral/systemic lymphoma
1522008|NCT00002524|AIDS-related primary CNS lymphoma
1522009|NCT00002524|AIDS-related diffuse large cell lymphoma
1522010|NCT00002524|AIDS-related immunoblastic large cell lymphoma
1522011|NCT00002524|AIDS-related small noncleaved cell lymphoma
1522012|NCT00002524|AIDS-related diffuse mixed cell lymphoma
1522013|NCT00002524|AIDS-related diffuse small cleaved cell lymphoma
1522014|NCT00002523|stage II rectal cancer
1522015|NCT00002523|stage III rectal cancer
1522016|NCT00002523|adenocarcinoma of the rectum
1522017|NCT00002522|stage I adult Hodgkin lymphoma
1522018|NCT00002522|stage II adult Hodgkin lymphoma
1522019|NCT00002522|stage III adult Hodgkin lymphoma
1522020|NCT00002522|stage IV adult Hodgkin lymphoma
1522021|NCT00002522|recurrent adult Hodgkin lymphoma
1522022|NCT00002521|stage I adult diffuse small cleaved cell lymphoma
1522023|NCT00002521|stage I adult diffuse mixed cell lymphoma
1522024|NCT00002521|stage I adult diffuse large cell lymphoma
1522025|NCT00002521|stage I adult immunoblastic large cell lymphoma
1522026|NCT00002521|stage I adult lymphoblastic lymphoma
1522027|NCT00002521|stage I adult Burkitt lymphoma
1522028|NCT00002521|stage III adult diffuse small cleaved cell lymphoma
1522029|NCT00002521|stage III adult diffuse mixed cell lymphoma
1522030|NCT00002521|stage III adult diffuse large cell lymphoma
1522031|NCT00002521|stage III adult immunoblastic large cell lymphoma
1522032|NCT00002521|stage III adult lymphoblastic lymphoma
1522033|NCT00002521|stage III adult Burkitt lymphoma
1522034|NCT00002521|stage IV adult diffuse small cleaved cell lymphoma
1522035|NCT00002521|stage IV adult diffuse mixed cell lymphoma
1522036|NCT00002521|stage IV adult diffuse large cell lymphoma
1522037|NCT00002521|stage IV adult immunoblastic large cell lymphoma
1522038|NCT00002521|stage IV adult lymphoblastic lymphoma
1522039|NCT00002521|stage IV adult Burkitt lymphoma
1522040|NCT00002521|recurrent adult diffuse small cleaved cell lymphoma
1522041|NCT00002521|recurrent adult diffuse mixed cell lymphoma
1522042|NCT00002521|recurrent adult diffuse large cell lymphoma
1522043|NCT00002521|recurrent adult immunoblastic large cell lymphoma
1522044|NCT00002521|recurrent adult lymphoblastic lymphoma
1522045|NCT00002521|recurrent adult Burkitt lymphoma
1522046|NCT00002521|contiguous stage II adult diffuse small cleaved cell lymphoma
1522047|NCT00002521|contiguous stage II adult diffuse mixed cell lymphoma
1522048|NCT00002521|contiguous stage II adult immunoblastic large cell lymphoma
1522049|NCT00002521|contiguous stage II adult diffuse large cell lymphoma
1522050|NCT00002521|contiguous stage II adult Burkitt lymphoma
1522051|NCT00002521|contiguous stage II adult lymphoblastic lymphoma
1522052|NCT00002521|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1522053|NCT00002521|noncontiguous stage II adult diffuse mixed cell lymphoma
1522054|NCT00002521|noncontiguous stage II adult immunoblastic large cell lymphoma
1522055|NCT00002521|noncontiguous stage II adult diffuse large cell lymphoma
1522056|NCT00002521|noncontiguous stage II adult Burkitt lymphoma
1522057|NCT00002521|noncontiguous stage II adult lymphoblastic lymphoma
1522058|NCT00002520|stage I adult Hodgkin lymphoma
1522059|NCT00002520|angioimmunoblastic T-cell lymphoma
1522060|NCT00002520|stage II adult Hodgkin lymphoma
1522061|NCT00002520|stage III adult Hodgkin lymphoma
1522062|NCT00002520|stage IV adult Hodgkin lymphoma
1522063|NCT00002520|stage I colon cancer
1522064|NCT00002520|stage II colon cancer
1522065|NCT00002520|stage I breast cancer
1522066|NCT00002520|AIDS-related peripheral/systemic lymphoma
1522067|NCT00002520|AIDS-related primary CNS lymphoma
1522068|NCT00002520|anaplastic large cell lymphoma
1522069|NCT00002520|contiguous stage II adult diffuse large cell lymphoma
1522070|NCT00002520|contiguous stage II adult diffuse mixed cell lymphoma
1522071|NCT00002520|contiguous stage II adult diffuse small cleaved cell lymphoma
1522072|NCT00002520|contiguous stage II adult Burkitt lymphoma
1522073|NCT00002520|contiguous stage II adult immunoblastic large cell lymphoma
1522074|NCT00002520|contiguous stage II adult lymphoblastic lymphoma
1522075|NCT00002520|contiguous stage II grade 1 follicular lymphoma
1522076|NCT00002520|contiguous stage II grade 2 follicular lymphoma
1522077|NCT00002520|contiguous stage II grade 3 follicular lymphoma
1522078|NCT00002520|contiguous stage II mantle cell lymphoma
1522079|NCT00002520|intraocular lymphoma
1522080|NCT00002520|limited stage small cell lung cancer
1522081|NCT00002520|noncontiguous stage II adult diffuse large cell lymphoma
1522082|NCT00002520|noncontiguous stage II adult diffuse mixed cell lymphoma
1522083|NCT00002520|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1522084|NCT00002520|noncontiguous stage II adult Burkitt lymphoma
1522085|NCT00002520|noncontiguous stage II adult immunoblastic large cell lymphoma
1522086|NCT00002520|noncontiguous stage II adult lymphoblastic lymphoma
1522087|NCT00002520|noncontiguous stage II grade 1 follicular lymphoma
1522088|NCT00002520|noncontiguous stage II grade 2 follicular lymphoma
1522089|NCT00002520|noncontiguous stage II grade 3 follicular lymphoma
1522090|NCT00002520|noncontiguous stage II mantle cell lymphoma
1522091|NCT00002520|primary central nervous system lymphoma
1522092|NCT00002520|tobacco use disorder
1522093|NCT00002520|stage I adenoid cystic carcinoma of the oral cavity
1522094|NCT00002520|stage I adult T-cell leukemia/lymphoma
1522095|NCT00002520|stage I adult diffuse large cell lymphoma
1522096|NCT00002520|stage I adult diffuse mixed cell lymphoma
1522097|NCT00002520|stage I adult diffuse small cleaved cell lymphoma
1522098|NCT00002520|stage I adult Burkitt lymphoma
1522099|NCT00002520|stage I adult immunoblastic large cell lymphoma
1522100|NCT00002520|stage I adult lymphoblastic lymphoma
1522101|NCT00002520|stage I basal cell carcinoma of the lip
1522102|NCT00002520|stage I cutaneous T-cell non-Hodgkin lymphoma
1522103|NCT00002520|stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
1522104|NCT00002520|stage I grade 1 follicular lymphoma
1522105|NCT00002520|stage I grade 2 follicular lymphoma
1522106|NCT00002520|stage I grade 3 follicular lymphoma
1522107|NCT00002520|stage I inverted papilloma of the paranasal sinus and nasal cavity
1522108|NCT00002520|stage I lymphoepithelioma of the nasopharynx
1522109|NCT00002520|stage I lymphoepithelioma of the oropharynx
1522110|NCT00002520|stage I mantle cell lymphoma
1522111|NCT00002520|stage I midline lethal granuloma of the paranasal sinus and nasal cavity
1522112|NCT00002520|stage I mucoepidermoid carcinoma of the oral cavity
1522113|NCT00002520|stage I mycosis fungoides/Sezary syndrome
1522114|NCT00002520|stage I non-small cell lung cancer
1522115|NCT00002520|stage I prostate cancer
1522116|NCT00002520|stage I rectal cancer
1522117|NCT00002520|stage I squamous cell carcinoma of the hypopharynx
1522118|NCT00002520|stage I squamous cell carcinoma of the larynx
1522119|NCT00002520|stage I squamous cell carcinoma of the lip and oral cavity
1522120|NCT00002520|stage I squamous cell carcinoma of the nasopharynx
1522121|NCT00002520|stage I squamous cell carcinoma of the oropharynx
1522122|NCT00002520|stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
1522123|NCT00002520|stage I malignant testicular germ cell tumor
1522124|NCT00002520|stage I verrucous carcinoma of the larynx
1522125|NCT00002520|stage I verrucous carcinoma of the oral cavity
1522126|NCT00002520|stage II adult T-cell leukemia/lymphoma
1522127|NCT00002520|stage II adenoid cystic carcinoma of the oral cavity
1522128|NCT00002520|stage II basal cell carcinoma of the lip
1522129|NCT00002520|stage II bladder cancer
1522130|NCT00002520|stage II breast cancer
1522131|NCT00002520|stage II cutaneous T-cell non-Hodgkin lymphoma
1522132|NCT00002520|stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
1522133|NCT00002520|stage II inverted papilloma of the paranasal sinus and nasal cavity
1522134|NCT00002520|stage II lymphoepithelioma of the nasopharynx
1522135|NCT00002520|stage II lymphoepithelioma of the oropharynx
1522136|NCT00002520|stage II midline lethal granuloma of the paranasal sinus and nasal cavity
1522137|NCT00002520|stage II mucoepidermoid carcinoma of the oral cavity
1522138|NCT00002520|stage II mycosis fungoides/Sezary syndrome
1522139|NCT00002520|stage I bladder cancer
1522140|NCT00002520|stage II non-small cell lung cancer
1522141|NCT00002520|stage II prostate cancer
1522142|NCT00002520|stage II rectal cancer
1522143|NCT00002520|stage II squamous cell carcinoma of the hypopharynx
1522144|NCT00002520|stage II squamous cell carcinoma of the larynx
1522145|NCT00002520|stage II squamous cell carcinoma of the lip and oral cavity
1522146|NCT00002520|stage II squamous cell carcinoma of the nasopharynx
1522147|NCT00002520|stage II squamous cell carcinoma of the oropharynx
1522148|NCT00002520|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1522149|NCT00002520|stage II malignant testicular germ cell tumor
1522150|NCT00002520|stage II verrucous carcinoma of the larynx
1522151|NCT00002520|stage II verrucous carcinoma of the oral cavity
1522152|NCT00002520|stage III adult T-cell leukemia/lymphoma
1522153|NCT00002520|stage III adult diffuse large cell lymphoma
1522154|NCT00002520|stage III adult diffuse mixed cell lymphoma
1522155|NCT00002520|stage III adult diffuse small cleaved cell lymphoma
1522156|NCT00002520|stage III adult Burkitt lymphoma
1522157|NCT00002520|stage III adult immunoblastic large cell lymphoma
1522158|NCT00002520|stage III adult lymphoblastic lymphoma
1522159|NCT00002520|stage III cutaneous T-cell non-Hodgkin lymphoma
1522160|NCT00002520|stage III grade 1 follicular lymphoma
1522161|NCT00002520|stage III grade 2 follicular lymphoma
1522162|NCT00002520|stage III grade 3 follicular lymphoma
1522163|NCT00002520|stage III mantle cell lymphoma
1522164|NCT00002520|stage III mycosis fungoides/Sezary syndrome
1522165|NCT00002520|stage III prostate cancer
1522166|NCT00002520|stage III malignant testicular germ cell tumor
1522167|NCT00002520|stage IIIA breast cancer
1522168|NCT00002520|stage IIIB breast cancer
1522169|NCT00002520|stage IV adult T-cell leukemia/lymphoma
1522170|NCT00002520|stage IV adult diffuse large cell lymphoma
1522171|NCT00002520|stage IV adult diffuse mixed cell lymphoma
1523315|NCT00002376|Anti-HIV Agents
1522172|NCT00002520|stage IV adult diffuse small cleaved cell lymphoma
1522173|NCT00002520|stage IV adult Burkitt lymphoma
1522174|NCT00002520|stage IV adult immunoblastic large cell lymphoma
1522175|NCT00002520|stage IV adult lymphoblastic lymphoma
1522176|NCT00002520|stage IV breast cancer
1522177|NCT00002520|stage IV cutaneous T-cell non-Hodgkin lymphoma
1522178|NCT00002520|stage IV grade 1 follicular lymphoma
1522179|NCT00002520|stage IV grade 2 follicular lymphoma
1522180|NCT00002520|stage IV grade 3 follicular lymphoma
1522181|NCT00002520|stage IV mantle cell lymphoma
1522182|NCT00002520|stage IV mycosis fungoides/Sezary syndrome
1522183|NCT00002520|stage IV prostate cancer
1522184|NCT00002520|unspecified adult solid tumor, protocol specific
1522185|NCT00002520|contiguous stage II marginal zone lymphoma
1522186|NCT00002520|contiguous stage II small lymphocytic lymphoma
1522187|NCT00002520|noncontiguous stage II small lymphocytic lymphoma
1522188|NCT00002520|noncontiguous stage II marginal zone lymphoma
1522189|NCT00002520|stage I marginal zone lymphoma
1522190|NCT00002520|stage I small lymphocytic lymphoma
1522191|NCT00002520|stage III small lymphocytic lymphoma
1522192|NCT00002520|stage III marginal zone lymphoma
1522193|NCT00002520|stage IV small lymphocytic lymphoma
1522194|NCT00002520|stage IV marginal zone lymphoma
1522195|NCT00002520|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1522196|NCT00002520|nodal marginal zone B-cell lymphoma
1522197|NCT00002520|splenic marginal zone lymphoma
1522198|NCT00002519|stage IIIA non-small cell lung cancer
1522199|NCT00002519|stage IIIB non-small cell lung cancer
1522200|NCT00002517|childhood myelodysplastic syndromes
1522201|NCT00002517|untreated childhood acute myeloid leukemia and other myeloid malignancies
1522202|NCT00002517|childhood acute myeloblastic leukemia without maturation (M1)
1522203|NCT00002517|childhood acute myeloblastic leukemia with maturation (M2)
1522204|NCT00002517|childhood acute myelomonocytic leukemia (M4)
1522205|NCT00002517|childhood acute monoblastic leukemia (M5a)
1522206|NCT00002517|childhood acute monocytic leukemia (M5b)
1522207|NCT00002517|childhood acute erythroleukemia (M6)
1522208|NCT00002517|childhood acute megakaryocytic leukemia (M7)
1522209|NCT00002517|refractory anemia with excess blasts
1522210|NCT00002517|refractory anemia with excess blasts in transformation
1522211|NCT00002517|chronic myelomonocytic leukemia
1522212|NCT00002517|de novo myelodysplastic syndromes
1522213|NCT00002517|childhood acute minimally differentiated myeloid leukemia (M0)
1522214|NCT00002516|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1522215|NCT00002516|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1522216|NCT00002515|chondrosarcoma
1522217|NCT00002515|recurrent childhood rhabdomyosarcoma
1522218|NCT00002515|stage IV childhood liver cancer
1522219|NCT00002515|recurrent neuroblastoma
1522220|NCT00002515|recurrent childhood liver cancer
1522221|NCT00002515|recurrent Wilms tumor and other childhood kidney tumors
1522222|NCT00002515|stage IV Wilms tumor
1522223|NCT00002515|recurrent retinoblastoma
1522224|NCT00002515|stage IV childhood lymphoblastic lymphoma
1522225|NCT00002515|recurrent childhood lymphoblastic lymphoma
1522226|NCT00002515|recurrent osteosarcoma
1522227|NCT00002515|stage IV ovarian germ cell tumor
1522228|NCT00002515|recurrent malignant testicular germ cell tumor
1522229|NCT00002515|childhood germ cell tumor
1522230|NCT00002515|alveolar childhood rhabdomyosarcoma
1522231|NCT00002515|recurrent childhood soft tissue sarcoma
1522232|NCT00002515|recurrent ovarian germ cell tumor
1522233|NCT00002515|childhood fibrosarcoma
1522234|NCT00002515|extragonadal germ cell tumor
1522235|NCT00002515|childhood desmoplastic small round cell tumor
1522236|NCT00002515|recurrent childhood small noncleaved cell lymphoma
1522237|NCT00002515|stage IV childhood small noncleaved cell lymphoma
1522238|NCT00002515|recurrent childhood large cell lymphoma
1522239|NCT00002515|stage IV childhood large cell lymphoma
1522240|NCT00002515|recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
1522241|NCT00002515|stage IV lymphoepithelioma of the nasopharynx
1522242|NCT00002515|stage IV squamous cell carcinoma of the nasopharynx
1522243|NCT00002515|recurrent squamous cell carcinoma of the nasopharynx
1522244|NCT00002515|recurrent lymphoepithelioma of the nasopharynx
1522245|NCT00002514|adult acute lymphoblastic leukemia in remission
1522246|NCT00002511|adenocarcinoma of the prostate
1522248|NCT00002511|stage IIB prostate cancer
1522249|NCT00002511|stage IIA prostate cancer
1522250|NCT00002511|stage III prostate cancer
1522251|NCT00002510|Waldenstrom macroglobulinemia
1522252|NCT00002510|recurrent small lymphocytic lymphoma
1522253|NCT00002510|recurrent grade 1 follicular lymphoma
1522254|NCT00002510|recurrent grade 2 follicular lymphoma
1522255|NCT00002510|recurrent grade 3 follicular lymphoma
1522256|NCT00002509|stage II breast cancer
1522257|NCT00002509|stage IV breast cancer
1522258|NCT00002509|stage IIIA breast cancer
1522259|NCT00002509|recurrent breast cancer
1522260|NCT00002509|stage IIIB breast cancer
1522261|NCT00002508|recurrent malignant testicular germ cell tumor
1522262|NCT00002508|recurrent ovarian germ cell tumor
1522263|NCT00002508|extragonadal germ cell tumor
1522264|NCT00002507|stage I squamous cell carcinoma of the lip and oral cavity
1522265|NCT00002507|stage I adenoid cystic carcinoma of the oral cavity
1523316|NCT00002376|Viral Load
1522266|NCT00002507|stage II squamous cell carcinoma of the lip and oral cavity
1522267|NCT00002507|stage II adenoid cystic carcinoma of the oral cavity
1522268|NCT00002507|stage III squamous cell carcinoma of the lip and oral cavity
1522269|NCT00002507|stage III adenoid cystic carcinoma of the oral cavity
1522270|NCT00002507|stage IV squamous cell carcinoma of the lip and oral cavity
1522271|NCT00002507|stage IV adenoid cystic carcinoma of the oral cavity
1522272|NCT00002507|recurrent squamous cell carcinoma of the lip and oral cavity
1522273|NCT00002507|recurrent adenoid cystic carcinoma of the oral cavity
1522274|NCT00002507|stage I squamous cell carcinoma of the oropharynx
1522275|NCT00002507|stage I lymphoepithelioma of the oropharynx
1522276|NCT00002507|stage II squamous cell carcinoma of the oropharynx
1522277|NCT00002507|stage II lymphoepithelioma of the oropharynx
1522278|NCT00002507|stage III squamous cell carcinoma of the oropharynx
1522279|NCT00002507|stage III lymphoepithelioma of the oropharynx
1522280|NCT00002507|stage IV squamous cell carcinoma of the oropharynx
1522281|NCT00002507|stage IV lymphoepithelioma of the oropharynx
1522282|NCT00002507|recurrent squamous cell carcinoma of the oropharynx
1522283|NCT00002507|recurrent lymphoepithelioma of the oropharynx
1522284|NCT00002507|stage I squamous cell carcinoma of the nasopharynx
1522285|NCT00002507|stage I lymphoepithelioma of the nasopharynx
1522286|NCT00002507|stage II squamous cell carcinoma of the nasopharynx
1522287|NCT00002507|stage II lymphoepithelioma of the nasopharynx
1522288|NCT00002507|stage III squamous cell carcinoma of the nasopharynx
1522289|NCT00002507|stage III lymphoepithelioma of the nasopharynx
1522290|NCT00002507|stage IV squamous cell carcinoma of the nasopharynx
1522291|NCT00002507|stage IV lymphoepithelioma of the nasopharynx
1522292|NCT00002507|recurrent squamous cell carcinoma of the nasopharynx
1522293|NCT00002507|recurrent lymphoepithelioma of the nasopharynx
1522294|NCT00002507|stage I squamous cell carcinoma of the hypopharynx
1522295|NCT00002507|stage II squamous cell carcinoma of the hypopharynx
1522296|NCT00002507|stage III squamous cell carcinoma of the hypopharynx
1522297|NCT00002507|stage IV squamous cell carcinoma of the hypopharynx
1522298|NCT00002507|recurrent squamous cell carcinoma of the hypopharynx
1522299|NCT00002507|stage I squamous cell carcinoma of the larynx
1522300|NCT00002507|stage II squamous cell carcinoma of the larynx
1522301|NCT00002507|stage III squamous cell carcinoma of the larynx
1522302|NCT00002507|stage IV squamous cell carcinoma of the larynx
1522303|NCT00002507|recurrent squamous cell carcinoma of the larynx
1522304|NCT00002507|newly diagnosed carcinoma of unknown primary
1522305|NCT00002507|recurrent carcinoma of unknown primary
1522306|NCT00002506|recurrent non-small cell lung cancer
1522307|NCT00002506|recurrent esophageal cancer
1522308|NCT00002506|recurrent cervical cancer
1522309|NCT00002506|squamous cell lung cancer
1522310|NCT00002506|squamous cell carcinoma of the skin
1522311|NCT00002506|recurrent penile cancer
1522312|NCT00002506|recurrent skin cancer
1522313|NCT00002506|squamous cell carcinoma of the esophagus
1522314|NCT00002506|cervical squamous cell carcinoma
1522315|NCT00002506|penile squamous cell carcinoma
1522316|NCT00002506|recurrent squamous cell carcinoma of the lip and oral cavity
1522317|NCT00002506|recurrent squamous cell carcinoma of the oropharynx
1522318|NCT00002506|recurrent squamous cell carcinoma of the nasopharynx
1522319|NCT00002506|recurrent squamous cell carcinoma of the hypopharynx
1522320|NCT00002506|recurrent squamous cell carcinoma of the larynx
1522321|NCT00002506|recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
1522322|NCT00002505|unspecified adult solid tumor, protocol specific
1522323|NCT00002504|stage IV adult Hodgkin lymphoma
1522324|NCT00002504|monoclonal gammopathy of undetermined significance
1522325|NCT00002504|recurrent adult Hodgkin lymphoma
1522326|NCT00002504|isolated plasmacytoma of bone
1522327|NCT00002504|extramedullary plasmacytoma
1522328|NCT00002504|refractory multiple myeloma
1522329|NCT00002504|Waldenstrom macroglobulinemia
1522330|NCT00002504|stage IV chronic lymphocytic leukemia
1522331|NCT00002504|recurrent adult acute myeloid leukemia
1522332|NCT00002504|recurrent adult acute lymphoblastic leukemia
1522333|NCT00002504|relapsing chronic myelogenous leukemia
1522334|NCT00002504|refractory chronic lymphocytic leukemia
1522335|NCT00002504|unspecified adult solid tumor, protocol specific
1522336|NCT00002504|chronic phase chronic myelogenous leukemia
1522337|NCT00002504|accelerated phase chronic myelogenous leukemia
1522338|NCT00002504|blastic phase chronic myelogenous leukemia
1522339|NCT00002504|meningeal chronic myelogenous leukemia
1522340|NCT00002504|untreated adult acute lymphoblastic leukemia
1522341|NCT00002504|untreated adult acute myeloid leukemia
1522342|NCT00002504|adult acute myeloid leukemia in remission
1522343|NCT00002504|adult acute lymphoblastic leukemia in remission
1522344|NCT00002504|polycythemia vera
1522345|NCT00002504|chronic idiopathic myelofibrosis
1522346|NCT00002504|essential thrombocythemia
1522347|NCT00002504|untreated hairy cell leukemia
1522348|NCT00002504|progressive hairy cell leukemia, initial treatment
1522349|NCT00002504|refractory hairy cell leukemia
1522350|NCT00002504|chronic myelomonocytic leukemia
1522351|NCT00002504|T-cell large granular lymphocyte leukemia
1522352|NCT00002504|acute undifferentiated leukemia
1522353|NCT00002504|stage IV grade 1 follicular lymphoma
1522354|NCT00002504|stage IV grade 2 follicular lymphoma
1523556|NCT00002326|Antiviral Agents
1522355|NCT00002504|stage IV grade 3 follicular lymphoma
1522356|NCT00002504|stage IV adult diffuse small cleaved cell lymphoma
1522357|NCT00002504|stage IV adult diffuse mixed cell lymphoma
1522358|NCT00002504|stage IV adult diffuse large cell lymphoma
1522359|NCT00002504|stage IV adult immunoblastic large cell lymphoma
1522360|NCT00002504|stage IV adult lymphoblastic lymphoma
1522361|NCT00002504|stage IV adult Burkitt lymphoma
1522362|NCT00002504|recurrent grade 1 follicular lymphoma
1522363|NCT00002504|recurrent grade 2 follicular lymphoma
1522364|NCT00002504|recurrent grade 3 follicular lymphoma
1522365|NCT00002504|recurrent adult diffuse small cleaved cell lymphoma
1522366|NCT00002504|recurrent adult diffuse mixed cell lymphoma
1522367|NCT00002504|recurrent adult diffuse large cell lymphoma
1522368|NCT00002504|recurrent adult immunoblastic large cell lymphoma
1522369|NCT00002504|recurrent adult lymphoblastic lymphoma
1522370|NCT00002504|recurrent adult Burkitt lymphoma
1522371|NCT00002504|stage IV adult T-cell leukemia/lymphoma
1522372|NCT00002504|recurrent adult T-cell leukemia/lymphoma
1522373|NCT00002504|secondary acute myeloid leukemia
1522374|NCT00002504|de novo myelodysplastic syndromes
1522375|NCT00002504|previously treated myelodysplastic syndromes
1522376|NCT00002504|secondary myelodysplastic syndromes
1522377|NCT00002504|prolymphocytic leukemia
1522378|NCT00002504|primary systemic amyloidosis
1522379|NCT00002504|stage IV mantle cell lymphoma
1522380|NCT00002504|recurrent mantle cell lymphoma
1522381|NCT00002504|angioimmunoblastic T-cell lymphoma
1522382|NCT00002504|anaplastic large cell lymphoma
1522383|NCT00002504|recurrent marginal zone lymphoma
1522384|NCT00002504|recurrent small lymphocytic lymphoma
1522385|NCT00002504|stage IV small lymphocytic lymphoma
1522386|NCT00002504|stage IV marginal zone lymphoma
1522387|NCT00002504|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1522388|NCT00002504|nodal marginal zone B-cell lymphoma
1522389|NCT00002504|splenic marginal zone lymphoma
1522390|NCT00002503|recurrent prostate cancer
1522391|NCT00002503|bone metastases
1522392|NCT00002502|stage I adult Hodgkin lymphoma
1522393|NCT00002502|stage II adult Hodgkin lymphoma
1522394|NCT00002502|stage III adult Hodgkin lymphoma
1522395|NCT00002502|stage IV adult Hodgkin lymphoma
1522396|NCT00002502|recurrent childhood acute lymphoblastic leukemia
1522397|NCT00002502|recurrent adult Hodgkin lymphoma
1522398|NCT00002502|stage I cutaneous T-cell non-Hodgkin lymphoma
1522399|NCT00002502|stage II cutaneous T-cell non-Hodgkin lymphoma
1522400|NCT00002502|stage III cutaneous T-cell non-Hodgkin lymphoma
1522401|NCT00002502|stage IV cutaneous T-cell non-Hodgkin lymphoma
1522402|NCT00002502|recurrent cutaneous T-cell non-Hodgkin lymphoma
1522403|NCT00002502|childhood Burkitt lymphoma
1522404|NCT00002502|refractory multiple myeloma
1522405|NCT00002502|Waldenström macroglobulinemia
1522406|NCT00002502|stage I multiple myeloma
1522407|NCT00002502|stage II multiple myeloma
1522408|NCT00002502|stage III multiple myeloma
1522409|NCT00002502|stage I childhood lymphoblastic lymphoma
1522410|NCT00002502|stage II childhood lymphoblastic lymphoma
1522411|NCT00002502|stage III childhood lymphoblastic lymphoma
1522412|NCT00002502|stage IV childhood lymphoblastic lymphoma
1522413|NCT00002502|recurrent childhood lymphoblastic lymphoma
1522414|NCT00002502|recurrent childhood acute myeloid leukemia
1522415|NCT00002502|recurrent adult acute myeloid leukemia
1522416|NCT00002502|recurrent adult acute lymphoblastic leukemia
1522417|NCT00002502|childhood diffuse large cell lymphoma
1522418|NCT00002502|childhood immunoblastic large cell lymphoma
1522419|NCT00002502|chronic phase chronic myelogenous leukemia
1522420|NCT00002502|accelerated phase chronic myelogenous leukemia
1522421|NCT00002502|blastic phase chronic myelogenous leukemia
1522422|NCT00002502|adult acute myeloid leukemia in remission
1522423|NCT00002502|adult acute lymphoblastic leukemia in remission
1522424|NCT00002502|childhood acute myeloid leukemia in remission
1522425|NCT00002502|childhood acute lymphoblastic leukemia in remission
1522426|NCT00002502|stage II childhood Hodgkin lymphoma
1522427|NCT00002502|stage I childhood Hodgkin lymphoma
1522428|NCT00002502|stage III childhood Hodgkin lymphoma
1522429|NCT00002502|stage IV childhood Hodgkin lymphoma
1522430|NCT00002502|recurrent/refractory childhood Hodgkin lymphoma
1522431|NCT00002502|stage I grade 1 follicular lymphoma
1522432|NCT00002502|stage I grade 2 follicular lymphoma
1522433|NCT00002502|stage I grade 3 follicular lymphoma
1522434|NCT00002502|stage I adult diffuse small cleaved cell lymphoma
1522435|NCT00002502|stage I adult diffuse mixed cell lymphoma
1522436|NCT00002502|stage I adult diffuse large cell lymphoma
1522437|NCT00002502|stage I adult immunoblastic large cell lymphoma
1522438|NCT00002502|stage I adult lymphoblastic lymphoma
1522439|NCT00002502|stage I adult Burkitt lymphoma
1522440|NCT00002502|refractory anemia
1522441|NCT00002502|refractory anemia with ringed sideroblasts
1522442|NCT00002502|refractory anemia with excess blasts
1522443|NCT00002502|chronic myelomonocytic leukemia
1522444|NCT00002502|stage III grade 1 follicular lymphoma
1522445|NCT00002502|stage III grade 2 follicular lymphoma
1522446|NCT00002502|stage III grade 3 follicular lymphoma
1522447|NCT00002502|stage III adult diffuse small cleaved cell lymphoma
1522448|NCT00002502|stage III adult diffuse mixed cell lymphoma
1522449|NCT00002502|stage III adult diffuse large cell lymphoma
1522450|NCT00002502|stage III adult immunoblastic large cell lymphoma
1522451|NCT00002502|stage III adult lymphoblastic lymphoma
1522452|NCT00002502|stage III adult Burkitt lymphoma
1522453|NCT00002502|stage IV grade 1 follicular lymphoma
1522454|NCT00002502|stage IV grade 2 follicular lymphoma
1522455|NCT00002502|stage IV grade 3 follicular lymphoma
1522456|NCT00002502|stage IV adult diffuse small cleaved cell lymphoma
1522457|NCT00002502|stage IV adult diffuse mixed cell lymphoma
1522458|NCT00002502|stage IV adult diffuse large cell lymphoma
1522459|NCT00002502|stage IV adult immunoblastic large cell lymphoma
1522460|NCT00002502|stage IV adult lymphoblastic lymphoma
1522461|NCT00002502|stage IV adult Burkitt lymphoma
1522462|NCT00002502|recurrent grade 1 follicular lymphoma
1522463|NCT00002502|recurrent grade 2 follicular lymphoma
1522464|NCT00002502|recurrent grade 3 follicular lymphoma
1522465|NCT00002502|recurrent adult diffuse small cleaved cell lymphoma
1522466|NCT00002502|recurrent adult diffuse mixed cell lymphoma
1522467|NCT00002502|recurrent adult diffuse large cell lymphoma
1522468|NCT00002502|recurrent adult immunoblastic large cell lymphoma
1522469|NCT00002502|recurrent adult lymphoblastic lymphoma
1522470|NCT00002502|recurrent adult Burkitt lymphoma
1522471|NCT00002502|secondary acute myeloid leukemia
1522472|NCT00002502|de novo myelodysplastic syndromes
1522473|NCT00002502|previously treated myelodysplastic syndromes
1522474|NCT00002502|secondary myelodysplastic syndromes
1522475|NCT00002502|intraocular lymphoma
1522476|NCT00002502|stage I childhood small noncleaved cell lymphoma
1522477|NCT00002502|stage I childhood large cell lymphoma
1522478|NCT00002502|stage II childhood small noncleaved cell lymphoma
1522479|NCT00002502|stage II childhood large cell lymphoma
1522480|NCT00002502|stage III childhood small noncleaved cell lymphoma
1522481|NCT00002502|stage III childhood large cell lymphoma
1522482|NCT00002502|stage IV childhood small noncleaved cell lymphoma
1522483|NCT00002502|stage IV childhood large cell lymphoma
1522484|NCT00002502|recurrent childhood small noncleaved cell lymphoma
1522485|NCT00002502|recurrent childhood large cell lymphoma
1522486|NCT00002502|stage I mantle cell lymphoma
1522487|NCT00002502|contiguous stage II grade 1 follicular lymphoma
1522488|NCT00002502|contiguous stage II grade 2 follicular lymphoma
1522489|NCT00002502|contiguous stage II grade 3 follicular lymphoma
1522490|NCT00002502|contiguous stage II adult diffuse small cleaved cell lymphoma
1522491|NCT00002502|contiguous stage II mantle cell lymphoma
1522492|NCT00002502|contiguous stage II adult diffuse mixed cell lymphoma
1522493|NCT00002502|contiguous stage II adult immunoblastic large cell lymphoma
1522494|NCT00002502|contiguous stage II adult diffuse large cell lymphoma
1522495|NCT00002502|contiguous stage II adult Burkitt lymphoma
1522496|NCT00002502|contiguous stage II adult lymphoblastic lymphoma
1522497|NCT00002502|noncontiguous stage II grade 1 follicular lymphoma
1522498|NCT00002502|noncontiguous stage II grade 2 follicular lymphoma
1522499|NCT00002502|noncontiguous stage II grade 3 follicular lymphoma
1522500|NCT00002502|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1522501|NCT00002502|noncontiguous stage II mantle cell lymphoma
1522502|NCT00002502|noncontiguous stage II adult diffuse mixed cell lymphoma
1522503|NCT00002502|noncontiguous stage II adult immunoblastic large cell lymphoma
1522504|NCT00002502|noncontiguous stage II adult diffuse large cell lymphoma
1522505|NCT00002502|noncontiguous stage II adult Burkitt lymphoma
1522506|NCT00002502|noncontiguous stage II adult lymphoblastic lymphoma
1522507|NCT00002502|stage III mantle cell lymphoma
1522508|NCT00002502|stage IV mantle cell lymphoma
1522509|NCT00002502|recurrent mantle cell lymphoma
1522510|NCT00002502|angioimmunoblastic T-cell lymphoma
1522511|NCT00002502|anaplastic large cell lymphoma
1522512|NCT00002502|noncontiguous stage II small lymphocytic lymphoma
1522513|NCT00002502|noncontiguous stage II marginal zone lymphoma
1522514|NCT00002502|recurrent marginal zone lymphoma
1522515|NCT00002502|recurrent small lymphocytic lymphoma
1522516|NCT00002502|stage I marginal zone lymphoma
1522517|NCT00002502|stage I small lymphocytic lymphoma
1522518|NCT00002502|stage III small lymphocytic lymphoma
1522519|NCT00002502|stage III marginal zone lymphoma
1522520|NCT00002502|stage IV small lymphocytic lymphoma
1522521|NCT00002502|stage IV marginal zone lymphoma
1522522|NCT00002502|contiguous stage II marginal zone lymphoma
1524131|NCT00002213|HIV Protease Inhibitors
1522523|NCT00002502|contiguous stage II small lymphocytic lymphoma
1522524|NCT00002502|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1522525|NCT00002502|nodal marginal zone B-cell lymphoma
1522526|NCT00002502|splenic marginal zone lymphoma
1522527|NCT00002502|childhood myelodysplastic syndromes
1522528|NCT00002501|stage IV grade 1 follicular lymphoma
1522529|NCT00002501|stage IV grade 2 follicular lymphoma
1522530|NCT00002501|recurrent grade 1 follicular lymphoma
1522531|NCT00002501|recurrent grade 2 follicular lymphoma
1522532|NCT00002499|recurrent childhood acute lymphoblastic leukemia
1522533|NCT00002498|stage IV breast cancer
1522534|NCT00002498|recurrent breast cancer
1522535|NCT00002496|stage III squamous cell carcinoma of the larynx
1522536|NCT00002496|stage IV squamous cell carcinoma of the larynx
1522537|NCT00002495|stage I adult Hodgkin lymphoma
1522538|NCT00002495|stage II adult Hodgkin lymphoma
1522539|NCT00002494|untreated adult acute lymphoblastic leukemia
1522540|NCT00002494|L3 adult acute lymphoblastic leukemia
1522541|NCT00002494|stage I adult Burkitt lymphoma
1522542|NCT00002494|stage II adult Burkitt lymphoma
1522543|NCT00002494|stage III adult Burkitt lymphoma
1522544|NCT00002494|stage IV adult Burkitt lymphoma
1522545|NCT00002494|contiguous stage II adult Burkitt lymphoma
1522546|NCT00002494|noncontiguous stage II adult Burkitt lymphoma
1522547|NCT00002493|stage III endometrial carcinoma
1522548|NCT00002493|stage IV endometrial carcinoma
1522549|NCT00002493|endometrial adenocarcinoma
1522550|NCT00002493|endometrial adenosquamous cell carcinoma
1522551|NCT00002493|endometrial adenoacanthoma
1522552|NCT00002493|endometrial papillary serous carcinoma
1522553|NCT00002493|endometrial clear cell carcinoma
1522554|NCT00002493|psychosocial effects of cancer and its treatment
1522555|NCT00002492|stage I adult soft tissue sarcoma
1522556|NCT00002492|stage II adult soft tissue sarcoma
1522557|NCT00002492|stage III adult soft tissue sarcoma
1522558|NCT00002490|stage I bladder cancer
1522559|NCT00002490|transitional cell carcinoma of the bladder
1522560|NCT00002489|stage II ovarian germ cell tumor
1522561|NCT00002489|stage III ovarian germ cell tumor
1522562|NCT00002489|stage IV ovarian germ cell tumor
1522563|NCT00002489|ovarian teratoma
1522564|NCT00002489|extragonadal germ cell tumor
1522565|NCT00002488|recurrent grade 3 follicular lymphoma
1522566|NCT00002488|recurrent adult diffuse small cleaved cell lymphoma
1522567|NCT00002488|recurrent adult diffuse mixed cell lymphoma
1522568|NCT00002488|recurrent adult diffuse large cell lymphoma
1522569|NCT00002488|recurrent adult immunoblastic large cell lymphoma
1522570|NCT00002488|recurrent adult lymphoblastic lymphoma
1522571|NCT00002488|recurrent adult Burkitt lymphoma
1522572|NCT00002487|recurrent ovarian epithelial cancer
1522573|NCT00002485|localized osteosarcoma
1522574|NCT00002485|metastatic osteosarcoma
1522575|NCT00002485|recurrent childhood acute lymphoblastic leukemia
1522576|NCT00002485|childhood infratentorial ependymoma
1522577|NCT00002485|childhood low-grade cerebral astrocytoma
1522578|NCT00002485|childhood supratentorial ependymoma
1522579|NCT00002485|childhood craniopharyngioma
1522580|NCT00002485|localized resectable neuroblastoma
1522581|NCT00002485|regional neuroblastoma
1522582|NCT00002485|disseminated neuroblastoma
1522583|NCT00002485|stage 4S neuroblastoma
1522584|NCT00002485|recurrent neuroblastoma
1522585|NCT00002485|stage I childhood liver cancer
1522586|NCT00002485|stage II childhood liver cancer
1522587|NCT00002485|stage III childhood liver cancer
1522588|NCT00002485|stage IV childhood liver cancer
1522589|NCT00002485|recurrent childhood liver cancer
1522590|NCT00002485|childhood hepatoblastoma
1522591|NCT00002485|stage I childhood lymphoblastic lymphoma
1522592|NCT00002485|stage II childhood lymphoblastic lymphoma
1522593|NCT00002485|stage III childhood lymphoblastic lymphoma
1522594|NCT00002485|stage IV childhood lymphoblastic lymphoma
1522595|NCT00002485|recurrent childhood lymphoblastic lymphoma
1522596|NCT00002485|childhood central nervous system germ cell tumor
1522597|NCT00002485|recurrent childhood acute myeloid leukemia
1522598|NCT00002485|recurrent osteosarcoma
1522599|NCT00002485|unspecified childhood solid tumor, protocol specific
1522600|NCT00002485|childhood germ cell tumor
1522601|NCT00002485|untreated childhood acute myeloid leukemia and other myeloid malignancies
1522602|NCT00002485|untreated childhood acute lymphoblastic leukemia
1522603|NCT00002485|childhood acute myeloid leukemia in remission
1522604|NCT00002485|childhood acute lymphoblastic leukemia in remission
1522605|NCT00002485|stage II childhood Hodgkin lymphoma
1522606|NCT00002485|stage I childhood Hodgkin lymphoma
1522607|NCT00002485|stage III childhood Hodgkin lymphoma
1522608|NCT00002485|stage IV childhood Hodgkin lymphoma
1522609|NCT00002485|recurrent/refractory childhood Hodgkin lymphoma
1522610|NCT00002485|nonmetastatic childhood soft tissue sarcoma
1522611|NCT00002485|metastatic childhood soft tissue sarcoma
1522612|NCT00002485|recurrent childhood soft tissue sarcoma
1522613|NCT00002485|extragonadal germ cell tumor
1522614|NCT00002485|childhood high-grade cerebral astrocytoma
1522615|NCT00002485|childhood oligodendroglioma
1522616|NCT00002485|childhood choroid plexus tumor
1522617|NCT00002485|childhood meningioma
1522618|NCT00002485|localized unresectable neuroblastoma
1522619|NCT00002485|psychosocial effects of cancer and its treatment
1522620|NCT00002485|stage I childhood small noncleaved cell lymphoma
1522621|NCT00002485|stage I childhood large cell lymphoma
1522622|NCT00002485|stage II childhood small noncleaved cell lymphoma
1522623|NCT00002485|stage II childhood large cell lymphoma
1522624|NCT00002485|stage III childhood small noncleaved cell lymphoma
1522625|NCT00002485|stage III childhood large cell lymphoma
1522626|NCT00002485|stage IV childhood small noncleaved cell lymphoma
1522627|NCT00002485|stage IV childhood large cell lymphoma
1522628|NCT00002485|recurrent childhood small noncleaved cell lymphoma
1522629|NCT00002485|recurrent childhood large cell lymphoma
1522630|NCT00002485|untreated childhood brain stem glioma
1522631|NCT00002485|recurrent childhood brain stem glioma
1522632|NCT00002485|untreated childhood supratentorial primitive neuroectodermal tumor
1522724|NCT00002475|stage IV non-small cell lung cancer
1522633|NCT00002485|recurrent childhood supratentorial primitive neuroectodermal tumor
1522634|NCT00002485|untreated childhood cerebellar astrocytoma
1522635|NCT00002485|recurrent childhood cerebellar astrocytoma
1522636|NCT00002485|recurrent childhood cerebral astrocytoma
1522637|NCT00002485|untreated childhood medulloblastoma
1522638|NCT00002485|recurrent childhood medulloblastoma
1522639|NCT00002485|untreated childhood visual pathway and hypothalamic glioma
1522640|NCT00002485|recurrent childhood visual pathway and hypothalamic glioma
1522641|NCT00002485|newly diagnosed childhood ependymoma
1522642|NCT00002485|recurrent childhood ependymoma
1522643|NCT00002485|childhood teratoma
1522644|NCT00002485|childhood malignant testicular germ cell tumor
1522645|NCT00002485|childhood malignant ovarian germ cell tumor
1522646|NCT00002485|childhood extragonadal germ cell tumor
1522647|NCT00002485|recurrent childhood malignant germ cell tumor
1522648|NCT00002485|childhood atypical teratoid/rhabdoid tumor
1522649|NCT00002484|stage I non-small cell lung cancer
1522650|NCT00002484|stage II non-small cell lung cancer
1522651|NCT00002484|stage IIIA non-small cell lung cancer
1522652|NCT00002484|stage IIIB non-small cell lung cancer
1522653|NCT00002482|unspecified adult solid tumor, protocol specific
1522654|NCT00002481|recurrent grade 1 follicular lymphoma
1522655|NCT00002481|recurrent grade 2 follicular lymphoma
1522656|NCT00002481|recurrent grade 3 follicular lymphoma
1522657|NCT00002481|recurrent adult diffuse small cleaved cell lymphoma
1522658|NCT00002481|recurrent adult diffuse mixed cell lymphoma
1522659|NCT00002481|recurrent adult diffuse large cell lymphoma
1522660|NCT00002481|recurrent adult immunoblastic large cell lymphoma
1522661|NCT00002481|recurrent adult lymphoblastic lymphoma
1522662|NCT00002481|recurrent adult Burkitt lymphoma
1522663|NCT00002481|recurrent mantle cell lymphoma
1522664|NCT00002481|recurrent marginal zone lymphoma
1522665|NCT00002481|recurrent small lymphocytic lymphoma
1522666|NCT00002481|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1522667|NCT00002481|nodal marginal zone B-cell lymphoma
1522668|NCT00002481|splenic marginal zone lymphoma
1522669|NCT00002480|adenocarcinoma of the prostate
1522670|NCT00002480|stage IIB prostate cancer
1522671|NCT00002480|stage IIA prostate cancer
1522672|NCT00002480|stage III prostate cancer
1522673|NCT00002479|stage I cutaneous T-cell non-Hodgkin lymphoma
1522674|NCT00002479|stage II cutaneous T-cell non-Hodgkin lymphoma
1522675|NCT00002479|stage III cutaneous T-cell non-Hodgkin lymphoma
1522676|NCT00002479|stage IV cutaneous T-cell non-Hodgkin lymphoma
1522677|NCT00002478|recurrent cervical cancer
1522678|NCT00002478|recurrent ovarian epithelial cancer
1522679|NCT00002477|stage I ovarian epithelial cancer
1522680|NCT00002477|stage II ovarian epithelial cancer
1522681|NCT00002476|stage II squamous cell carcinoma of the lip and oral cavity
1522682|NCT00002476|stage II verrucous carcinoma of the oral cavity
1522683|NCT00002476|stage III squamous cell carcinoma of the lip and oral cavity
1522684|NCT00002476|stage III verrucous carcinoma of the oral cavity
1522685|NCT00002476|stage IV squamous cell carcinoma of the lip and oral cavity
1522686|NCT00002476|stage IV verrucous carcinoma of the oral cavity
1522687|NCT00002476|stage II squamous cell carcinoma of the oropharynx
1522688|NCT00002476|stage III squamous cell carcinoma of the oropharynx
1522689|NCT00002476|stage IV squamous cell carcinoma of the oropharynx
1522690|NCT00002476|stage II squamous cell carcinoma of the nasopharynx
1522691|NCT00002476|stage III squamous cell carcinoma of the nasopharynx
1522692|NCT00002476|stage IV squamous cell carcinoma of the nasopharynx
1522693|NCT00002476|stage II squamous cell carcinoma of the hypopharynx
1522694|NCT00002476|stage III squamous cell carcinoma of the hypopharynx
1522695|NCT00002476|stage IV squamous cell carcinoma of the hypopharynx
1522696|NCT00002476|stage II squamous cell carcinoma of the larynx
1522697|NCT00002476|stage II verrucous carcinoma of the larynx
1522698|NCT00002476|stage III squamous cell carcinoma of the larynx
1522699|NCT00002476|stage III verrucous carcinoma of the larynx
1522700|NCT00002476|stage IV squamous cell carcinoma of the larynx
1522701|NCT00002476|stage IV verrucous carcinoma of the larynx
1522702|NCT00002476|stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
1522703|NCT00002476|stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
1522704|NCT00002476|stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
1522705|NCT00002475|stage III colon cancer
1522706|NCT00002475|stage IV colon cancer
1522707|NCT00002475|stage IV breast cancer
1522708|NCT00002475|stage IIIA breast cancer
1522709|NCT00002475|recurrent breast cancer
1522710|NCT00002475|stage IIIB breast cancer
1522711|NCT00002475|recurrent non-small cell lung cancer
1522712|NCT00002475|stage II pancreatic cancer
1522713|NCT00002475|stage III pancreatic cancer
1522714|NCT00002475|recurrent pancreatic cancer
1522715|NCT00002475|recurrent colon cancer
1522716|NCT00002475|stage III renal cell cancer
1522717|NCT00002475|stage IV renal cell cancer
1522718|NCT00002475|recurrent renal cell cancer
1522719|NCT00002475|extensive stage small cell lung cancer
1522720|NCT00002475|recurrent small cell lung cancer
1522721|NCT00002475|stage IIIA non-small cell lung cancer
1522722|NCT00002475|stage IIIB non-small cell lung cancer
1522723|NCT00002475|stage IIIC breast cancer
1522938|NCT00002438|Itraconazole
1522725|NCT00002475|pulmonary carcinoid tumor
1522726|NCT00002475|recurrent malignant mesothelioma
1522727|NCT00002475|stage IV pancreatic cancer
1522728|NCT00002474|recurrent ovarian epithelial cancer
1522729|NCT00002473|stage I renal cell cancer
1522730|NCT00002473|stage II renal cell cancer
1522731|NCT00002472|childhood central nervous system germ cell tumor
1522732|NCT00002472|extragonadal germ cell tumor
1522733|NCT00002472|adult central nervous system germ cell tumor
1522734|NCT00002472|childhood teratoma
1522735|NCT00002472|childhood central nervous system choriocarcinoma
1522736|NCT00002472|childhood central nervous system embryonal tumor
1522737|NCT00002472|childhood central nervous system germinoma
1522738|NCT00002472|childhood central nervous system mixed germ cell tumor
1522739|NCT00002472|childhood central nervous system teratoma
1522740|NCT00002472|childhood central nervous system yolk sac tumor
1522741|NCT00002471|childhood Burkitt lymphoma
1522742|NCT00002471|L3 childhood acute lymphoblastic leukemia
1522743|NCT00002471|B-cell childhood acute lymphoblastic leukemia
1522744|NCT00002471|L3 adult acute lymphoblastic leukemia
1522745|NCT00002471|B-cell adult acute lymphoblastic leukemia
1522746|NCT00002471|recurrent adult non-Hodgkin lymphoma
1522747|NCT00002471|stage III adult diffuse large cell lymphoma
1522748|NCT00002471|stage III adult immunoblastic large cell lymphoma
1522749|NCT00002471|stage III adult Burkitt lymphoma
1522750|NCT00002471|stage IV grade 3 follicular lymphoma
1522751|NCT00002471|stage IV adult diffuse large cell lymphoma
1522752|NCT00002471|stage IV adult immunoblastic large cell lymphoma
1522753|NCT00002471|stage IV adult Burkitt lymphoma
1522754|NCT00002471|recurrent grade 3 follicular lymphoma
1522755|NCT00002471|recurrent adult diffuse large cell lymphoma
1522756|NCT00002471|recurrent adult immunoblastic large cell lymphoma
1522757|NCT00002471|recurrent adult Burkitt lymphoma
1522758|NCT00002471|stage III childhood small noncleaved cell lymphoma
1522759|NCT00002471|stage IV childhood small noncleaved cell lymphoma
1522760|NCT00002471|stage IV childhood large cell lymphoma
1522761|NCT00002471|recurrent childhood small noncleaved cell lymphoma
1522762|NCT00002471|recurrent childhood large cell lymphoma
1522763|NCT00002470|metastatic gastrointestinal carcinoid tumor
1522764|NCT00002470|recurrent gastrointestinal carcinoid tumor
1522765|NCT00002470|pulmonary carcinoid tumor
1522766|NCT00002466|localized osteosarcoma
1522767|NCT00002466|metastatic osteosarcoma
1522768|NCT00002466|stage III adult soft tissue sarcoma
1522769|NCT00002466|stage III Wilms tumor
1522770|NCT00002466|stage IV Wilms tumor
1522771|NCT00002466|nonmetastatic childhood soft tissue sarcoma
1522772|NCT00002466|metastatic childhood soft tissue sarcoma
1522773|NCT00002466|childhood desmoplastic small round cell tumor
1522774|NCT00002466|localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
1522775|NCT00002466|metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
1522776|NCT00002466|stage IV adult soft tissue sarcoma
1522777|NCT00002466|Askin tumor
1522778|NCT00002466|peripheral primitive neuroectodermal tumor
1522779|NCT00002465|stage IV breast cancer
1522780|NCT00002465|recurrent breast cancer
1522781|NCT00002465|advanced malignant mesothelioma
1522782|NCT00002465|recurrent malignant mesothelioma
1522783|NCT00002465|stage IV endometrial carcinoma
1522784|NCT00002465|recurrent endometrial carcinoma
1522785|NCT00002463|childhood infratentorial ependymoma
1522786|NCT00002463|childhood low-grade cerebral astrocytoma
1522787|NCT00002463|childhood low-grade cerebellar astrocytoma
1522788|NCT00002463|childhood supratentorial ependymoma
1522789|NCT00002463|childhood high-grade cerebral astrocytoma
1522790|NCT00002463|untreated childhood supratentorial primitive neuroectodermal tumor
1522791|NCT00002463|untreated childhood cerebellar astrocytoma
1522792|NCT00002463|untreated childhood medulloblastoma
1522793|NCT00002463|untreated childhood visual pathway and hypothalamic glioma
1522794|NCT00002463|newly diagnosed childhood ependymoma
1522795|NCT00002462|stage III adult Hodgkin lymphoma
1522796|NCT00002462|stage IV adult Hodgkin lymphoma
1522797|NCT00002461|recurrent adult Hodgkin lymphoma
1522798|NCT00002461|adult lymphocyte predominant Hodgkin lymphoma
1522799|NCT00002461|adult lymphocyte depletion Hodgkin lymphoma
1522800|NCT00002461|adult nodular sclerosis Hodgkin lymphoma
1522801|NCT00002461|adult mixed cellularity Hodgkin lymphoma
1522802|NCT00002461|recurrent grade 1 follicular lymphoma
1522803|NCT00002461|recurrent grade 2 follicular lymphoma
1522804|NCT00002461|recurrent grade 3 follicular lymphoma
1522805|NCT00002461|recurrent adult diffuse small cleaved cell lymphoma
1522806|NCT00002461|recurrent adult diffuse mixed cell lymphoma
1522807|NCT00002461|recurrent adult diffuse large cell lymphoma
1522808|NCT00002461|recurrent adult immunoblastic large cell lymphoma
1522809|NCT00002461|recurrent adult lymphoblastic lymphoma
1522810|NCT00002461|recurrent adult Burkitt lymphoma
1522811|NCT00002461|recurrent mantle cell lymphoma
1522812|NCT00002461|recurrent small lymphocytic lymphoma
1522813|NCT00002460|stage I breast cancer
1522814|NCT00002460|stage II breast cancer
1522815|NCT00002460|stage IIIA breast cancer
1522816|NCT00002459|stage I uterine sarcoma
1522817|NCT00002459|stage II uterine sarcoma
1522818|NCT00002459|uterine carcinosarcoma
1522819|NCT00002459|uterine leiomyosarcoma
1522820|NCT00002459|endometrial stromal sarcoma
1522821|NCT00002458|disseminated neuroblastoma
1522822|NCT00002458|recurrent neuroblastoma
1522823|NCT00002456|recurrent childhood acute lymphoblastic leukemia
1522824|NCT00002456|childhood non-Hodgkin lymphoma
1522825|NCT00002456|recurrent childhood lymphoblastic lymphoma
1522826|NCT00002456|recurrent childhood acute myeloid leukemia
1522827|NCT00002456|recurrent adult acute myeloid leukemia
1522828|NCT00002456|recurrent adult acute lymphoblastic leukemia
1522829|NCT00002456|relapsing chronic myelogenous leukemia
1522830|NCT00002456|refractory chronic lymphocytic leukemia
1522831|NCT00002456|recurrent adult non-Hodgkin lymphoma
1522832|NCT00002456|graft versus host disease
1522833|NCT00002455|stage I colon cancer
1522834|NCT00002455|stage II colon cancer
1522835|NCT00002455|stage III colon cancer
1522836|NCT00002455|stage I breast cancer
1522837|NCT00002455|stage II breast cancer
1522838|NCT00002455|stage IIIA breast cancer
1522839|NCT00002455|recurrent breast cancer
1522840|NCT00002455|recurrent colon cancer
1522841|NCT00002455|stage I melanoma
1522842|NCT00002455|stage II melanoma
1522843|NCT00002455|stage III melanoma
1522844|NCT00002455|recurrent melanoma
1522845|NCT00002454|lung papilloma
1522846|NCT00002453|HIV-1
1522847|NCT00002453|Drug Therapy, Combination
1522848|NCT00002453|Disease Progression
1522849|NCT00002453|Anti-HIV Agents
1522850|NCT00002452|Drug Therapy, Combination
1522851|NCT00002452|HIV Protease Inhibitors
1522852|NCT00002452|Indinavir
1522853|NCT00002452|Reverse Transcriptase Inhibitors
1522854|NCT00002452|Anti-HIV Agents
1522855|NCT00002452|Viral Load
1522856|NCT00002451|Drug Therapy, Combination
1522857|NCT00002451|Stavudine
1522858|NCT00002451|HIV Protease Inhibitors
1522859|NCT00002451|CD4 Lymphocyte Count
1522860|NCT00002451|Ritonavir
1522861|NCT00002451|Lamivudine
1522862|NCT00002451|Indinavir
1522863|NCT00002451|Reverse Transcriptase Inhibitors
1522864|NCT00002451|Anti-HIV Agents
1522865|NCT00002451|Viral Load
1522866|NCT00002450|HIV-1
1522867|NCT00002450|Drug Therapy, Combination
1522868|NCT00002450|Drug Administration Schedule
1522869|NCT00002450|RNA, Viral
1522870|NCT00002450|Anti-HIV Agents
1522871|NCT00002450|Viral Load
1522872|NCT00002449|Recombinant Proteins
1522873|NCT00002449|Injections, Subcutaneous
1522874|NCT00002449|Interleukin-2
1522875|NCT00002449|Dose-Response Relationship, Drug
1522876|NCT00002449|CD4 Lymphocyte Count
1522877|NCT00002449|Anti-HIV Agents
1522878|NCT00002449|Viral Load
1522879|NCT00002449|Pharmacokinetics
1522880|NCT00002448|Drug Therapy, Combination
1522881|NCT00002448|HIV Protease Inhibitors
1522882|NCT00002448|Ritonavir
1522883|NCT00002448|Dosage Forms
1522884|NCT00002448|Saquinavir
1522885|NCT00002448|Reverse Transcriptase Inhibitors
1522886|NCT00002448|Anti-HIV Agents
1522887|NCT00002448|efavirenz
1522888|NCT00002447|Drug Therapy, Combination
1522889|NCT00002447|Saquinavir
1522890|NCT00002447|HIV Protease Inhibitors
1522891|NCT00002447|Ritonavir
1522892|NCT00002447|Dosage Forms
1522893|NCT00002447|Reverse Transcriptase Inhibitors
1522894|NCT00002447|Anti-HIV Agents
1522895|NCT00002447|efavirenz
1522896|NCT00002446|AIDS-Related Opportunistic Infections
1522897|NCT00002446|Fluconazole
1522898|NCT00002446|Administration, Oral
1522899|NCT00002446|Antifungal Agents
1522900|NCT00002446|Candidiasis, Oral
1522901|NCT00002446|Pharyngeal Diseases
1522902|NCT00002446|posaconazole
1522903|NCT00002445|AIDS-Related Opportunistic Infections
1522904|NCT00002445|Placebos
1522905|NCT00002445|Sarcoma, Kaposi
1522906|NCT00002445|Antineoplastic Agents
1522907|NCT00002445|Treatment Outcome
1522908|NCT00002445|Quality of Life
1522909|NCT00002442|Drug Therapy, Combination
1522910|NCT00002442|Zidovudine
1522911|NCT00002442|Drug Administration Schedule
1522912|NCT00002442|Stavudine
1522913|NCT00002442|HIV Protease Inhibitors
1522914|NCT00002442|Lamivudine
1522915|NCT00002442|Indinavir
1522916|NCT00002442|Dosage Forms
1522917|NCT00002442|Nelfinavir
1524132|NCT00002213|RNA, Viral
1522918|NCT00002442|Reverse Transcriptase Inhibitors
1522919|NCT00002442|Anti-HIV Agents
1522920|NCT00002441|HIV-1
1522921|NCT00002441|Dose-Response Relationship, Drug
1522922|NCT00002441|Acquired Immunodeficiency Syndrome
1522923|NCT00002441|AIDS Vaccines
1522924|NCT00002441|Sexually Transmitted Diseases
1522925|NCT00002441|Risk Factors
1522926|NCT00002441|HIV Seronegativity
1522927|NCT00002441|Antigens, Viral
1522928|NCT00002441|Alum Compounds
1522929|NCT00002440|HIV-1
1522930|NCT00002440|Drug Therapy, Combination
1522931|NCT00002440|HIV Protease Inhibitors
1522932|NCT00002440|Mutation
1522933|NCT00002440|HIV-1 Reverse Transcriptase
1522934|NCT00002440|HIV Protease
1522935|NCT00002440|Reverse Transcriptase Inhibitors
1522936|NCT00002440|Anti-HIV Agents
1522937|NCT00002440|abacavir
1522940|NCT00002438|Acquired Immunodeficiency Syndrome
1522941|NCT00002437|Retinitis
1522942|NCT00002437|Probenecid
1522943|NCT00002437|Drug Therapy, Combination
1522944|NCT00002437|Cytomegalovirus Infections
1522945|NCT00002437|Acquired Immunodeficiency Syndrome
1522946|NCT00002437|Antiviral Agents
1522947|NCT00002437|cidofovir
1522948|NCT00002436|Zalcitabine
1522949|NCT00002436|Drug Therapy, Combination
1522950|NCT00002436|Acquired Immunodeficiency Syndrome
1522951|NCT00002436|AIDS-Related Complex
1522952|NCT00002436|Antiviral Agents
1522953|NCT00002436|Zidovudine
1522954|NCT00002435|Drug Therapy, Combination
1522955|NCT00002435|Antiviral Agents
1522956|NCT00002435|Zidovudine
1522957|NCT00002435|thymic humoral factor gamma 2
1522958|NCT00002434|Trimetrexate
1522959|NCT00002434|Pneumonia, Pneumocystis carinii
1522960|NCT00002434|Leucovorin
1522961|NCT00002434|Drug Therapy, Combination
1522962|NCT00002434|Acquired Immunodeficiency Syndrome
1522963|NCT00002433|Pulmonary Alveoli
1522964|NCT00002433|Macrophage Activation
1522965|NCT00002433|Interferon-gamma, Recombinant
1522966|NCT00002433|Injections, Subcutaneous
1522967|NCT00002433|Aerosols
1522968|NCT00002433|Acquired Immunodeficiency Syndrome
1522969|NCT00002432|Retinitis
1522970|NCT00002432|AIDS-Related Opportunistic Infections
1522971|NCT00002432|Foscarnet
1522972|NCT00002432|Cytomegalovirus Infections
1522973|NCT00002432|Acquired Immunodeficiency Syndrome
1522974|NCT00002431|AIDS-Related Opportunistic Infections
1522975|NCT00002431|chlorhexidine gluconate
1522976|NCT00002431|Acquired Immunodeficiency Syndrome
1522977|NCT00002431|Anti-Infective Agents, Local
1522978|NCT00002431|AIDS-Related Complex
1522979|NCT00002431|Candidiasis, Oral
1522980|NCT00002430|Drug Therapy, Combination
1522981|NCT00002430|HIV Protease Inhibitors
1522982|NCT00002430|Lamivudine
1522983|NCT00002430|Indinavir
1522984|NCT00002430|Reverse Transcriptase Inhibitors
1522985|NCT00002430|Anti-HIV Agents
1522986|NCT00002430|Nelfinavir
1522987|NCT00002429|Didanosine
1522988|NCT00002429|Drug Therapy, Combination
1522989|NCT00002429|Stavudine
1522990|NCT00002429|RNA, Viral
1522991|NCT00002429|Nelfinavir
1522992|NCT00002429|Reverse Transcriptase Inhibitors
1522993|NCT00002429|Anti-HIV Agents
1522994|NCT00002428|Vaccines, Synthetic
1522995|NCT00002428|HIV-1
1522996|NCT00002428|HIV Envelope Protein gp120
1522997|NCT00002428|AIDS Vaccines
1522998|NCT00002428|HIV Seronegativity
1522999|NCT00002427|Didanosine
1523000|NCT00002427|Dose-Response Relationship, Drug
1523001|NCT00002427|Drug Therapy, Combination
1523002|NCT00002427|Stavudine
1523003|NCT00002427|Hydroxyurea
1523004|NCT00002427|Reverse Transcriptase Inhibitors
1523005|NCT00002427|Anti-HIV Agents
1523006|NCT00002426|HIV-1
1523007|NCT00002426|RNA, Viral
1523008|NCT00002426|VX 478
1523009|NCT00002426|Reverse Transcriptase Inhibitors
1523010|NCT00002426|Anti-HIV Agents
1523011|NCT00002426|Viral Load
1523012|NCT00002425|Drug Therapy, Combination
1523013|NCT00002425|Saquinavir
1523014|NCT00002425|HIV Protease Inhibitors
1523015|NCT00002425|Dosage Forms
1523016|NCT00002425|Anti-HIV Agents
1523017|NCT00002424|Drug Therapy, Combination
1523018|NCT00002424|Drug Administration Schedule
1523019|NCT00002424|Stavudine
1523020|NCT00002424|HIV Protease Inhibitors
1523021|NCT00002424|Lamivudine
1523022|NCT00002424|Indinavir
1523023|NCT00002424|Reverse Transcriptase Inhibitors
1523024|NCT00002424|Anti-HIV Agents
1523025|NCT00002423|Drug Therapy, Combination
1523026|NCT00002423|HIV Protease Inhibitors
1523027|NCT00002423|Lamivudine
1523028|NCT00002423|Indinavir
1523029|NCT00002423|Nelfinavir
1523030|NCT00002423|VX 478
1523031|NCT00002423|Reverse Transcriptase Inhibitors
1523032|NCT00002423|Anti-HIV Agents
1523033|NCT00002423|Viral Load
1523034|NCT00002423|abacavir
1523035|NCT00002422|Injections, Intramuscular
1523036|NCT00002422|Drug Interactions
1523037|NCT00002422|Salvage Therapy
1523039|NCT00002420|Drug Therapy, Combination
1523040|NCT00002420|Reverse Transcriptase Inhibitors
1523041|NCT00002420|Anti-HIV Agents
1523042|NCT00002419|Drug Therapy, Combination
1523043|NCT00002419|HIV Protease Inhibitors
1523044|NCT00002419|Reverse Transcriptase Inhibitors
1523045|NCT00002419|Anti-HIV Agents
1523046|NCT00002418|Drug Therapy, Combination
1523047|NCT00002418|Reverse Transcriptase Inhibitors
1523048|NCT00002418|Anti-HIV Agents
1523049|NCT00002418|Viral Load
1523050|NCT00002417|Drug Therapy, Combination
1523051|NCT00002417|HIV Protease Inhibitors
1523052|NCT00002417|VX 478
1523053|NCT00002417|Lipodystrophy
1523054|NCT00002417|Hyperlipidemia
1523055|NCT00002416|HIV-1
1523056|NCT00002416|Zalcitabine
1523057|NCT00002416|Zidovudine
1523058|NCT00002416|Stavudine
1523059|NCT00002416|HIV Protease Inhibitors
1523060|NCT00002416|Lamivudine
1523062|NCT00002416|Reverse Transcriptase Inhibitors
1523063|NCT00002416|Anti-HIV Agents
1523064|NCT00002415|Drug Therapy, Combination
1523065|NCT00002415|Prodrugs
1523066|NCT00002415|Anti-HIV Agents
1523067|NCT00002414|AIDS Dementia Complex
1523068|NCT00002414|Anti-HIV Agents
1523069|NCT00002413|Anti-HIV Agents
1523070|NCT00002413|Viral Load
1523071|NCT00002413|MKC 442
1523072|NCT00002412|Didanosine
1523073|NCT00002412|Drug Therapy, Combination
1523074|NCT00002412|Stavudine
1523075|NCT00002412|Hydroxyurea
1523076|NCT00002412|Reverse Transcriptase Inhibitors
1523077|NCT00002412|Anti-HIV Agents
1523078|NCT00002412|Viral Load
1523079|NCT00002412|MKC 442
1523080|NCT00002411|HIV-1
1523081|NCT00002411|Didanosine
1523082|NCT00002411|Drug Therapy, Combination
1523083|NCT00002411|Zidovudine
1523084|NCT00002411|Stavudine
1523085|NCT00002411|Lamivudine
1523086|NCT00002411|RNA, Viral
1523087|NCT00002411|Nelfinavir
1523088|NCT00002411|Anti-HIV Agents
1523089|NCT00002411|Viral Load
1523090|NCT00002410|HIV-1
1523091|NCT00002410|Drug Therapy, Combination
1523092|NCT00002410|Zidovudine
1523093|NCT00002410|Drug Resistance, Microbial
1523094|NCT00002410|HIV Protease Inhibitors
1523095|NCT00002410|Lamivudine
1523096|NCT00002410|Indinavir
1523097|NCT00002410|Genotype
1523098|NCT00002410|Reverse Transcriptase Inhibitors
1523099|NCT00002410|efavirenz
1523100|NCT00002409|Drug Therapy, Combination
1523101|NCT00002409|Zidovudine
1523102|NCT00002409|HIV Protease Inhibitors
1523103|NCT00002409|Lamivudine
1523104|NCT00002409|Patient Education
1523105|NCT00002409|Patient Compliance
1523106|NCT00002409|Reverse Transcriptase Inhibitors
1523107|NCT00002409|Anti-HIV Agents
1523108|NCT00002409|Viral Load
1523109|NCT00002409|abacavir
1523110|NCT00002408|Diarrhea
1523111|NCT00002408|Acquired Immunodeficiency Syndrome
1523112|NCT00002406|HIV-1
1523113|NCT00002406|Dose-Response Relationship, Drug
1523114|NCT00002406|HIV Protease Inhibitors
1523115|NCT00002406|Indinavir
1523116|NCT00002406|RNA, Viral
1523117|NCT00002406|Reverse Transcriptase Inhibitors
1523118|NCT00002405|Drug Therapy, Combination
1523119|NCT00002405|HIV Protease Inhibitors
1523120|NCT00002405|VX 478
1523121|NCT00002405|Anti-HIV Agents
1523122|NCT00002404|HIV-1
1523123|NCT00002404|Antiviral Agents
1523124|NCT00002404|Herpes Genitalis
1523125|NCT00002404|Recurrence
1523126|NCT00002404|DNA, Viral
1523127|NCT00002404|RNA, Viral
1523128|NCT00002404|valacyclovir
1523129|NCT00002404|Herpesvirus 2, Human
1523130|NCT00002403|HIV-1
1523131|NCT00002403|Dose-Response Relationship, Drug
1523132|NCT00002403|HIV Integrase Inhibitors
1523133|NCT00002403|HIV Integrase
1523134|NCT00002402|HIV-1
1523135|NCT00002402|Dose-Response Relationship, Drug
1523136|NCT00002402|Acquired Immunodeficiency Syndrome
1523137|NCT00002402|AIDS Vaccines
1523138|NCT00002402|HIV Seronegativity
1523139|NCT00002402|Antigens, Viral
1523140|NCT00002402|Alum Compounds
1523141|NCT00002401|HIV-1
1523142|NCT00002401|Zidovudine
1523143|NCT00002401|HIV Protease Inhibitors
1523144|NCT00002401|Lamivudine
1523145|NCT00002401|Indinavir
1523146|NCT00002401|RNA, Viral
1523147|NCT00002401|Delavirdine
1523148|NCT00002401|Reverse Transcriptase Inhibitors
1523149|NCT00002401|Viral Load
1523150|NCT00002400|HIV-1
1523151|NCT00002400|Drug Therapy, Combination
1523152|NCT00002400|Zidovudine
1523153|NCT00002400|HIV Protease Inhibitors
1523154|NCT00002400|Lamivudine
1523155|NCT00002400|Indinavir
1523156|NCT00002400|RNA, Viral
1523157|NCT00002400|Delavirdine
1523158|NCT00002400|Reverse Transcriptase Inhibitors
1523159|NCT00002399|AIDS-Related Opportunistic Infections
1523160|NCT00002399|Fluconazole
1523161|NCT00002399|Antifungal Agents
1523162|NCT00002399|Candidiasis
1523163|NCT00002399|Triazoles
1523165|NCT00002398|Acquired Immunodeficiency Syndrome
1523166|NCT00002398|Adenine
1523167|NCT00002398|Anti-HIV Agents
1523168|NCT00002397|Kidney Failure, Chronic
1523169|NCT00002397|HIV-1
1523170|NCT00002397|Drug Therapy, Combination
1523171|NCT00002397|Stavudine
1523172|NCT00002397|HIV Protease Inhibitors
1523173|NCT00002397|Lamivudine
1523174|NCT00002397|Saquinavir
1523175|NCT00002397|AIDS-Associated Nephropathy
1523176|NCT00002397|Reverse Transcriptase Inhibitors
1523177|NCT00002397|Viral Load
1523178|NCT00002397|Nelfinavir
1523179|NCT00002396|Dose-Response Relationship, Drug
1523180|NCT00002396|Adenine
1523181|NCT00002396|Anti-HIV Agents
1523182|NCT00002395|AIDS-Related Opportunistic Infections
1523183|NCT00002395|Leukoencephalopathy, Progressive Multifocal
1523184|NCT00002395|Infusions, Intravenous
1523185|NCT00002395|Drug Administration Schedule
1523186|NCT00002395|Topotecan
1523557|NCT00002326|Zidovudine
1523187|NCT00002394|AIDS-Related Opportunistic Infections
1523188|NCT00002394|Dose-Response Relationship, Drug
1523189|NCT00002394|Fluconazole
1523190|NCT00002394|Antifungal Agents
1523191|NCT00002394|Candidiasis, Oral
1523192|NCT00002394|Drug Administration Schedule
1523193|NCT00002394|terbinafine
1523194|NCT00002393|Placebos
1523195|NCT00002393|Drug Therapy, Combination
1523196|NCT00002393|HIV Protease Inhibitors
1523197|NCT00002393|Indinavir
1523198|NCT00002393|Reverse Transcriptase Inhibitors
1523199|NCT00002393|efavirenz
1523200|NCT00002392|Lymphocyte Transformation
1523201|NCT00002392|Immunity, Cellular
1523202|NCT00002392|Drug Therapy, Combination
1523203|NCT00002392|Adjuvants, Immunologic
1523204|NCT00002392|Thalidomide
1523205|NCT00002392|Immunologic Memory
1523206|NCT00002392|Streptococcus pneumoniae
1523207|NCT00002392|Tetanus Toxoid
1523208|NCT00002392|Pneumococcal Vaccines
1523209|NCT00002391|HIV-1
1523210|NCT00002391|Drug Therapy, Combination
1523211|NCT00002391|Zidovudine
1523212|NCT00002391|Lamivudine
1523213|NCT00002391|Reverse Transcriptase Inhibitors
1523214|NCT00002391|Anti-HIV Agents
1523215|NCT00002391|Viral Load
1523216|NCT00002391|Child Development
1523217|NCT00002391|abacavir
1523218|NCT00002389|HIV-1
1523219|NCT00002389|Drug Therapy, Combination
1523220|NCT00002389|Antiviral Agents
1523221|NCT00002389|Zidovudine
1523222|NCT00002389|CD4 Lymphocyte Count
1523223|NCT00002389|Lamivudine
1523224|NCT00002389|RNA, Viral
1523225|NCT00002389|Reverse Transcriptase Inhibitors
1523226|NCT00002389|Anti-HIV Agents
1523227|NCT00002389|Viral Load
1523228|NCT00002389|abacavir
1523229|NCT00002388|HIV-1
1523230|NCT00002388|Reverse Transcriptase Inhibitors
1523231|NCT00002388|Anti-HIV Agents
1523232|NCT00002387|Acquired Immunodeficiency Syndrome
1523233|NCT00002387|Drug Administration Schedule
1523234|NCT00002387|HIV Protease Inhibitors
1523235|NCT00002387|Indinavir
1523236|NCT00002387|Reverse Transcriptase Inhibitors
1523237|NCT00002387|Anti-HIV Agents
1523238|NCT00002387|efavirenz
1523239|NCT00002386|Drug Therapy, Combination
1523240|NCT00002386|HIV Protease Inhibitors
1523241|NCT00002386|Indinavir
1523242|NCT00002386|Factor VIII
1523243|NCT00002386|Factor IX
1523244|NCT00002386|Half-Life
1523245|NCT00002386|Reverse Transcriptase Inhibitors
1523246|NCT00002386|Anti-HIV Agents
1523247|NCT00002386|Platelet Aggregation
1523248|NCT00002386|Hemophilia A
1523249|NCT00002386|Hemophilia B
1523250|NCT00002385|Dose-Response Relationship, Drug
1523251|NCT00002385|Cohort Studies
1523252|NCT00002385|Anti-HIV Agents
1523253|NCT00002308|Acquired Immunodeficiency Syndrome
1523254|NCT00002308|AIDS-Related Complex
1523255|NCT00002308|Stavudine
1523256|NCT00002307|Zidovudine
1523257|NCT00002307|Stavudine
1523258|NCT00002383|Drug Administration Schedule
1523259|NCT00002383|HIV Protease Inhibitors
1523260|NCT00002383|Dosage Forms
1523261|NCT00002383|Saquinavir
1523262|NCT00002383|Anti-HIV Agents
1523263|NCT00002382|Zalcitabine
1523264|NCT00002382|Didanosine
1523265|NCT00002382|Drug Therapy, Combination
1523266|NCT00002382|Zidovudine
1523267|NCT00002382|HIV Protease Inhibitors
1523268|NCT00002382|Saquinavir
1523269|NCT00002382|Patient Selection
1523270|NCT00002382|Anti-HIV Agents
1523271|NCT00002381|HIV-1
1523272|NCT00002381|Drug Therapy, Combination
1523273|NCT00002381|Nevirapine
1523274|NCT00002381|Stavudine
1523275|NCT00002381|RNA, Viral
1523276|NCT00002381|Nelfinavir
1523277|NCT00002381|Anti-HIV Agents
1523278|NCT00002381|Viral Load
1523279|NCT00002380|Drug Therapy, Combination
1523280|NCT00002380|HIV Protease Inhibitors
1523281|NCT00002380|Dosage Forms
1523282|NCT00002380|Saquinavir
1523283|NCT00002380|Nelfinavir
1523284|NCT00002380|Anti-HIV Agents
1523285|NCT00002379|HIV-1
1523286|NCT00002379|Drug Therapy, Combination
1523287|NCT00002379|Administration, Oral
1523288|NCT00002379|Acquired Immunodeficiency Syndrome
1523289|NCT00002379|Zidovudine
1523290|NCT00002379|Stavudine
1523291|NCT00002379|HIV Protease Inhibitors
1523292|NCT00002379|CD4 Lymphocyte Count
1523293|NCT00002379|Lamivudine
1523294|NCT00002379|Indinavir
1523295|NCT00002379|RNA, Viral
1523296|NCT00002379|Adenine
1523297|NCT00002379|Anti-HIV Agents
1523298|NCT00002379|Viral Load
1523299|NCT00002378|HIV-1
1523300|NCT00002378|Drug Therapy, Combination
1523301|NCT00002378|Zidovudine
1523302|NCT00002378|Stavudine
1523303|NCT00002378|HIV Protease Inhibitors
1523304|NCT00002378|Lamivudine
1523305|NCT00002378|RNA, Viral
1523306|NCT00002378|Dosage Forms
1523307|NCT00002378|Saquinavir
1523308|NCT00002378|Reverse Transcriptase Inhibitors
1523309|NCT00002378|Anti-HIV Agents
1523310|NCT00002378|Viral Load
1523317|NCT00002375|Drug Therapy, Combination
1523318|NCT00002375|HIV Protease Inhibitors
1523319|NCT00002375|Indinavir
1523320|NCT00002375|Nelfinavir
1523321|NCT00002375|Anti-HIV Agents
1523322|NCT00002374|HIV-1
1523323|NCT00002374|Drug Therapy, Combination
1523324|NCT00002374|Acquired Immunodeficiency Syndrome
1523325|NCT00002374|HIV Protease Inhibitors
1523326|NCT00002374|RNA, Viral
1523327|NCT00002374|Saquinavir
1523328|NCT00002374|Anti-HIV Agents
1523329|NCT00002374|Viral Load
1523330|NCT00002373|Cytomegalovirus
1523331|NCT00002373|Cytomegalovirus Infections
1523332|NCT00002373|Administration, Oral
1523333|NCT00002373|Acquired Immunodeficiency Syndrome
1523334|NCT00002373|Antiviral Agents
1523335|NCT00002373|Virus Shedding
1523336|NCT00002373|Viral Load
1523337|NCT00002372|Drug Therapy, Combination
1523338|NCT00002372|Administration, Oral
1523339|NCT00002372|HIV Protease Inhibitors
1523340|NCT00002372|Indinavir
1523341|NCT00002372|Saquinavir
1523342|NCT00002372|Nelfinavir
1523343|NCT00002372|VX 478
1523344|NCT00002371|HIV-1
1523345|NCT00002371|Drug Therapy, Combination
1523346|NCT00002371|Stavudine
1523347|NCT00002371|Lamivudine
1523348|NCT00002371|RNA, Viral
1523349|NCT00002371|Anti-HIV Agents
1523350|NCT00002371|Viral Load
1523351|NCT00002370|Itraconazole
1523352|NCT00002370|Administration, Oral
1523353|NCT00002370|Antifungal Agents
1523354|NCT00002370|Acquired Immunodeficiency Syndrome
1523355|NCT00002370|Drug Administration Schedule
1523356|NCT00002369|Drug Therapy, Combination
1523357|NCT00002369|Zidovudine
1523358|NCT00002369|Stavudine
1523359|NCT00002369|HIV Protease Inhibitors
1523360|NCT00002369|CD4 Lymphocyte Count
1523361|NCT00002369|Lamivudine
1523362|NCT00002369|Indinavir
1523363|NCT00002369|Reverse Transcriptase Inhibitors
1523364|NCT00002369|Anti-HIV Agents
1523365|NCT00002369|Viral Load
1523366|NCT00002368|Drug Therapy, Combination
1523367|NCT00002368|Acquired Immunodeficiency Syndrome
1523368|NCT00002368|Nevirapine
1523369|NCT00002368|Lamivudine
1523370|NCT00002368|Disease Progression
1523371|NCT00002368|Reverse Transcriptase Inhibitors
1523372|NCT00002368|Anti-HIV Agents
1523373|NCT00002367|Drug Therapy, Combination
1523374|NCT00002367|Acquired Immunodeficiency Syndrome
1523375|NCT00002367|Zidovudine
1523376|NCT00002367|HIV Protease Inhibitors
1523377|NCT00002367|Lamivudine
1523378|NCT00002367|Saquinavir
1523379|NCT00002367|Reverse Transcriptase Inhibitors
1523380|NCT00002367|Anti-HIV Agents
1523381|NCT00002366|Skin Neoplasms
1523382|NCT00002366|Sarcoma, Kaposi
1523383|NCT00002366|Acquired Immunodeficiency Syndrome
1523384|NCT00002366|HIV Protease Inhibitors
1523385|NCT00002366|Ritonavir
1523386|NCT00002365|Dose-Response Relationship, Drug
1523387|NCT00002365|Administration, Oral
1523388|NCT00002365|Acquired Immunodeficiency Syndrome
1523389|NCT00002365|Anti-HIV Agents
1523390|NCT00002364|Drug Therapy, Combination
1523391|NCT00002364|Acquired Immunodeficiency Syndrome
1523392|NCT00002364|AIDS-Related Complex
1523393|NCT00002364|Antiviral Agents
1523394|NCT00002363|Acquired Immunodeficiency Syndrome
1523395|NCT00002363|AIDS-Related Complex
1523396|NCT00002363|Antiviral Agents
1523397|NCT00002362|Dideoxynucleosides
1523398|NCT00002362|Drug Therapy, Combination
1523399|NCT00002362|Stavudine
1523400|NCT00002362|Reverse Transcriptase Inhibitors
1523401|NCT00002362|abacavir
1523402|NCT00002362|efavirenz
1523403|NCT00002361|Drug Therapy, Combination
1523404|NCT00002361|HIV Protease Inhibitors
1523405|NCT00002361|Ritonavir
1523406|NCT00002361|Indinavir
1523407|NCT00002361|Reverse Transcriptase Inhibitors
1523408|NCT00002361|Anti-HIV Agents
1523409|NCT00002361|Viral Load
1523410|NCT00002360|Didanosine
1523412|NCT00002360|Reverse Transcriptase Inhibitors
1523413|NCT00002360|Anti-HIV Agents
1523414|NCT00002360|Therapeutic Equivalency
1523415|NCT00002359|Vaccines, Synthetic
1523416|NCT00002359|Viral Vaccines
1523417|NCT00002359|HIV-1
1523418|NCT00002359|AIDS-Related Complex
1523419|NCT00002359|AIDS Vaccines
1523420|NCT00002359|Salk HIV Immunogen
1523421|NCT00002358|Herpes Zoster
1523422|NCT00002358|Acquired Immunodeficiency Syndrome
1523423|NCT00002358|AIDS-Related Complex
1523424|NCT00002358|Antiviral Agents
1523425|NCT00002358|sorivudine
1523426|NCT00002358|Chickenpox
1523427|NCT00002357|Drug Therapy, Combination
1523428|NCT00002357|AIDS-Related Complex
1523429|NCT00002357|Antiviral Agents
1523430|NCT00002357|Zidovudine
1523431|NCT00002356|Acquired Immunodeficiency Syndrome
1523432|NCT00002356|Antiviral Agents
1523433|NCT00002356|Cytomegalovirus Retinitis
1523434|NCT00002355|AIDS-Related Opportunistic Infections
1523435|NCT00002355|Acquired Immunodeficiency Syndrome
1523436|NCT00002355|Antiviral Agents
1523437|NCT00002355|Cytomegalovirus Retinitis
1523438|NCT00002354|Drug Therapy, Combination
1523439|NCT00002354|Acquired Immunodeficiency Syndrome
1523440|NCT00002354|AIDS-Related Complex
1523441|NCT00002354|Stavudine
1523442|NCT00002354|HIV Protease Inhibitors
1523443|NCT00002354|Indinavir
1523444|NCT00002353|Vaccines, Synthetic
1523445|NCT00002353|AIDS Vaccines
1523446|NCT00002352|Cytomegalovirus Infections
1523447|NCT00002352|Acquired Immunodeficiency Syndrome
1523448|NCT00002352|Antiviral Agents
1523449|NCT00002351|Acquired Immunodeficiency Syndrome
1523450|NCT00002351|AIDS-Related Complex
1523451|NCT00002351|HIV Protease Inhibitors
1523452|NCT00002351|Indinavir
1523453|NCT00002350|Vaccines, Synthetic
1523454|NCT00002350|AIDS Vaccines
1523455|NCT00002350|DNA, Viral
1523456|NCT00002349|AIDS-Related Complex
1523457|NCT00002349|Stavudine
1523458|NCT00002348|Lymphoma, Non-Hodgkin
1523459|NCT00002348|Acquired Immunodeficiency Syndrome
1523460|NCT00002348|Lymphoma, AIDS-Related
1523461|NCT00002348|Mitoguazone
1523462|NCT00002347|Zalcitabine
1523463|NCT00002347|Drug Therapy, Combination
1523464|NCT00002347|Acquired Immunodeficiency Syndrome
1523465|NCT00002347|AIDS-Related Complex
1523466|NCT00002347|Zidovudine
1523467|NCT00002347|Nevirapine
1523468|NCT00002347|Saquinavir
1523469|NCT00002346|Acquired Immunodeficiency Syndrome
1523470|NCT00002346|AIDS-Related Complex
1523471|NCT00002346|Antiviral Agents
1523472|NCT00002346|Adenine
1523473|NCT00002345|Megestrol
1523474|NCT00002345|Acquired Immunodeficiency Syndrome
1523475|NCT00002345|Anorexia
1523476|NCT00002345|Cachexia
1523477|NCT00002345|Suspensions
1523478|NCT00002344|Azithromycin
1523479|NCT00002344|Bacterial Infections
1523480|NCT00002343|Rifabutin
1523481|NCT00002343|Mycobacterium avium-intracellulare Infection
1523482|NCT00002343|Drug Therapy, Combination
1523483|NCT00002343|Ethambutol
1523484|NCT00002343|Acquired Immunodeficiency Syndrome
1523485|NCT00002342|Neoplasms
1523486|NCT00002342|Sarcoma, Kaposi
1523487|NCT00002342|Acquired Immunodeficiency Syndrome
1523488|NCT00002342|Antineoplastic Agents
1523489|NCT00002342|tecogalan
1523490|NCT00002341|Itraconazole
1523491|NCT00002341|Acquired Immunodeficiency Syndrome
1523492|NCT00002341|AIDS-Related Complex
1523493|NCT00002341|Candidiasis, Oral
1523494|NCT00002340|Pneumonia, Pneumocystis carinii
1523495|NCT00002340|Pentamidine
1523496|NCT00002340|Antifungal Agents
1523497|NCT00002340|Acquired Immunodeficiency Syndrome
1523498|NCT00002340|AIDS-Related Complex
1523499|NCT00002340|atovaquone
1523500|NCT00002339|Esophagitis
1523501|NCT00002339|Fluconazole
1523502|NCT00002339|Acquired Immunodeficiency Syndrome
1523503|NCT00002339|Candidiasis
1523504|NCT00002339|Immunocompromised Host
1523505|NCT00002338|Acquired Immunodeficiency Syndrome
1523506|NCT00002338|AIDS-Related Complex
1523507|NCT00002338|Antiviral Agents
1523508|NCT00002337|Acquired Immunodeficiency Syndrome
1523509|NCT00002337|Antiviral Agents
1523510|NCT00002337|vesnarinone
1523511|NCT00002336|Mycobacterium avium-intracellular Infection
1523512|NCT00002336|Acquired Immunodeficiency Syndrome
1523513|NCT00002336|Clarithromycin
1523514|NCT00002335|Acquired Immunodeficiency Syndrome
1523515|NCT00002335|AIDS-Related Complex
1523516|NCT00002335|Antiviral Agents
1523517|NCT00002334|Drug Therapy, Combination
1523518|NCT00002334|Acquired Immunodeficiency Syndrome
1523519|NCT00002334|AIDS-Related Complex
1523520|NCT00002334|Zidovudine
1523521|NCT00002334|Saquinavir
1523522|NCT00002334|HIV Protease Inhibitors
1523523|NCT00002333|Zalcitabine
1523524|NCT00002333|Drug Therapy, Combination
1523525|NCT00002333|Acquired Immunodeficiency Syndrome
1523526|NCT00002333|AIDS-Related Complex
1523527|NCT00002333|Saquinavir
1523528|NCT00002333|HIV Protease Inhibitors
1523529|NCT00002332|Thymopentin
1523531|NCT00002331|Mycobacterium avium-intracellular Infection
1523532|NCT00002331|Drug Therapy, Combination
1523533|NCT00002331|Ethambutol
1523534|NCT00002331|Clofazimine
1523535|NCT00002331|Acquired Immunodeficiency Syndrome
1523536|NCT00002331|Clarithromycin
1523537|NCT00002330|Retinitis
1523538|NCT00002330|Ganciclovir
1523539|NCT00002330|Cytomegalovirus Infections
1523540|NCT00002330|Acquired Immunodeficiency Syndrome
1523541|NCT00002329|MDL 28574
1523542|NCT00002328|Antidiarrheals
1523543|NCT00002328|Cryptosporidiosis
1523544|NCT00002328|Diarrhea
1523545|NCT00002328|Acquired Immunodeficiency Syndrome
1523546|NCT00002328|Azithromycin
1523547|NCT00002327|AIDS-Related Opportunistic Infections
1523548|NCT00002327|Acquired Immunodeficiency Syndrome
1523549|NCT00002327|AIDS-Related Complex
1523550|NCT00002327|Antiviral Agents
1523551|NCT00002327|Condylomata Acuminata
1523552|NCT00002327|cidofovir
1523553|NCT00002326|Drug Therapy, Combination
1523554|NCT00002326|Acquired Immunodeficiency Syndrome
1523555|NCT00002326|AIDS-Related Complex
1523558|NCT00002326|Adenine
1523559|NCT00002325|Mycoses
1523560|NCT00002325|Fluconazole
1523561|NCT00002325|Acquired Immunodeficiency Syndrome
1523562|NCT00002325|AIDS-Related Complex
1523563|NCT00002325|Coccidioidomycosis
1523564|NCT00002324|Drug Therapy, Combination
1523565|NCT00002324|AIDS-Related Complex
1523566|NCT00002324|Zidovudine
1523567|NCT00002324|Nevirapine
1523568|NCT00002323|Drug Therapy, Combination
1523569|NCT00002323|Zidovudine
1523570|NCT00002323|Nevirapine
1523571|NCT00002322|Drug Therapy, Combination
1523572|NCT00002322|Acquired Immunodeficiency Syndrome
1523573|NCT00002322|AIDS-Related Complex
1523574|NCT00002322|Antiviral Agents
1523575|NCT00002321|Retinitis
1523576|NCT00002321|Interleukin-2
1523577|NCT00002321|Ganciclovir
1523578|NCT00002321|Drug Therapy, Combination
1523579|NCT00002321|Acquired Immunodeficiency Syndrome
1523580|NCT00002321|Antiviral Agents
1523581|NCT00002320|Drug Therapy, Combination
1523582|NCT00002320|Acquired Immunodeficiency Syndrome
1523583|NCT00002320|AIDS-Related Complex
1523584|NCT00002320|Antiviral Agents
1523585|NCT00002320|Zidovudine
1523586|NCT00002319|Sarcoma, Kaposi
1523587|NCT00002319|Liposomes
1523588|NCT00002319|Doxorubicin
1523589|NCT00002319|Acquired Immunodeficiency Syndrome
1523590|NCT00002319|Drug Carriers
1523591|NCT00002318|Vincristine
1523592|NCT00002318|Sarcoma, Kaposi
1523593|NCT00002318|Liposomes
1523594|NCT00002318|Doxorubicin
1523595|NCT00002318|Drug Therapy, Combination
1523596|NCT00002318|Acquired Immunodeficiency Syndrome
1523597|NCT00002318|Bleomycin
1523598|NCT00002318|Drug Carriers
1523599|NCT00002317|Trimetrexate
1523600|NCT00002317|Pneumonia, Pneumocystis carinii
1523601|NCT00002317|Leucovorin
1523602|NCT00002317|Drug Therapy, Combination
1523603|NCT00002317|Acquired Immunodeficiency Syndrome
1523604|NCT00002316|AIDS-Related Opportunistic Infections
1523605|NCT00002316|Meningitis
1523606|NCT00002316|Drug Therapy, Combination
1523607|NCT00002316|Antifungal Agents
1523608|NCT00002316|Acquired Immunodeficiency Syndrome
1523609|NCT00002316|Amphotericin B
1523610|NCT00002315|Herpes Zoster
1523611|NCT00002315|Acyclovir
1523612|NCT00002315|Acquired Immunodeficiency Syndrome
1523613|NCT00002315|AIDS-Related Complex
1523614|NCT00002315|Antiviral Agents
1523615|NCT00002314|Sarcoma, Kaposi
1523616|NCT00002314|Acquired Immunodeficiency Syndrome
1523617|NCT00002314|Antineoplastic Agents
1523618|NCT00002314|Gene Products, tat
1523619|NCT00002313|Nystatin
1523620|NCT00002313|Didanosine
1523621|NCT00002313|Drug Therapy, Combination
1523622|NCT00002313|Acquired Immunodeficiency Syndrome
1523623|NCT00002313|AIDS-Related Complex
1523624|NCT00002312|Drug Interactions
1523625|NCT00002312|Antiviral Agents
1523626|NCT00002312|Zidovudine
1523627|NCT00002311|Acquired Immunodeficiency Syndrome
1523628|NCT00002311|AIDS-Related Complex
1523629|NCT00002311|Wobenzym
1523630|NCT00002311|Hydrolases
1523631|NCT00002310|Herpes Simplex
1523632|NCT00002310|HIV-1
1523633|NCT00002310|Acquired Immunodeficiency Syndrome
1523634|NCT00002310|Antiviral Agents
1523635|NCT00002310|Administration, Topical
1523636|NCT00002309|Mycobacterium avium-intracellulare Infection
1523637|NCT00002309|Acquired Immunodeficiency Syndrome
1523638|NCT00002309|AIDS-Related Complex
1523639|NCT00002309|Azithromycin
1523640|NCT00002306|AIDS-Related Opportunistic Infections
1523641|NCT00002306|Meningitis
1523642|NCT00002306|Cryptococcosis
1523643|NCT00002306|Fluconazole
1523644|NCT00002306|Acquired Immunodeficiency Syndrome
1523645|NCT00002306|Amphotericin B
1523646|NCT00002305|AIDS-Related Opportunistic Infections
1523647|NCT00002305|Meningitis
1523648|NCT00002305|Cryptococcosis
1523649|NCT00002305|Drug Therapy, Combination
1523650|NCT00002305|Fluconazole
1523651|NCT00002305|Flucytosine
1523652|NCT00002305|Acquired Immunodeficiency Syndrome
1523653|NCT00002305|Amphotericin B
1523654|NCT00002304|AIDS-Related Opportunistic Infections
1523655|NCT00002304|Immune Tolerance
1523656|NCT00002304|Ketoconazole
1523657|NCT00002304|Esophagitis
1523658|NCT00002304|Fluconazole
1523659|NCT00002304|Acquired Immunodeficiency Syndrome
1523660|NCT00002304|Candidiasis, Oral
1523661|NCT00002303|Recombinant Proteins
1523662|NCT00002303|Erythropoietin
1523663|NCT00002303|Acquired Immunodeficiency Syndrome
1523664|NCT00002303|Anemia
1523665|NCT00002303|AIDS-Related Complex
1523666|NCT00002303|Zidovudine
1523667|NCT00002302|Recombinant Proteins
1523668|NCT00002302|Injections, Subcutaneous
1523669|NCT00002302|Erythropoietin
1523670|NCT00002302|Acquired Immunodeficiency Syndrome
1523671|NCT00002302|Anemia
1523672|NCT00002302|Zidovudine
1523673|NCT00002301|Retinitis
1523674|NCT00002301|AIDS-Related Opportunistic Infections
1523675|NCT00002301|Ganciclovir
1523676|NCT00002301|Foscarnet
1523913|NCT00002251|Ganciclovir
1523677|NCT00002301|Cytomegalovirus Infections
1523678|NCT00002301|Acquired Immunodeficiency Syndrome
1523679|NCT00002301|Antiviral Agents
1523680|NCT00002300|T-Lymphocytes
1523681|NCT00002300|Megestrol
1523682|NCT00002300|Dose-Response Relationship, Drug
1523683|NCT00002300|Acquired Immunodeficiency Syndrome
1523684|NCT00002300|Anorexia
1523685|NCT00002300|Cachexia
1523686|NCT00002299|Retinitis
1523687|NCT00002299|AIDS-Related Opportunistic Infections
1523688|NCT00002299|Ganciclovir
1523689|NCT00002299|Drug Therapy, Combination
1523690|NCT00002299|Cytomegalovirus Infections
1523691|NCT00002299|Acquired Immunodeficiency Syndrome
1523692|NCT00002299|Interferon Type I
1523693|NCT00002298|Ribavirin
1523694|NCT00002298|AIDS-Related Complex
1523695|NCT00002297|Inosine Pranobex
1523696|NCT00002297|AIDS-Related Complex
1523697|NCT00002296|T-Lymphocytes
1523698|NCT00002296|Immune Tolerance
1523699|NCT00002296|Inosine Pranobex
1523700|NCT00002296|Killer Cells
1523701|NCT00002296|T-Lymphocytes, Helper-Inducer
1523702|NCT00002296|Acquired Immunodeficiency Syndrome
1523703|NCT00002296|AIDS-Related Complex
1523704|NCT00002295|Infusions, Intravenous
1523705|NCT00002295|Drug Evaluation
1523706|NCT00002295|Administration, Oral
1523707|NCT00002295|Acquired Immunodeficiency Syndrome
1523708|NCT00002295|AIDS-Related Complex
1523709|NCT00002295|Zidovudine
1523710|NCT00002295|Biological Availability
1523711|NCT00002294|AIDS-Related Opportunistic Infections
1523712|NCT00002294|Meningitis
1523713|NCT00002294|Cryptococcosis
1523714|NCT00002294|Fluconazole
1523715|NCT00002294|Acquired Immunodeficiency Syndrome
1523716|NCT00002293|Nystatin
1523717|NCT00002293|AIDS-Related Opportunistic Infections
1523718|NCT00002293|Acquired Immunodeficiency Syndrome
1523719|NCT00002293|AIDS-Related Complex
1523720|NCT00002293|Candidiasis, Oral
1523721|NCT00002292|AIDS-Related Opportunistic Infections
1523722|NCT00002292|Pneumonia, Pneumocystis carinii
1523723|NCT00002292|Pentamidine
1523724|NCT00002292|Injections, Intravenous
1523725|NCT00002292|Administration, Inhalation
1523726|NCT00002292|Aerosols
1523727|NCT00002292|Acquired Immunodeficiency Syndrome
1523728|NCT00002291|AIDS-Related Opportunistic Infections
1523729|NCT00002291|Pneumonia, Pneumocystis carinii
1523730|NCT00002291|Pentamidine
1523731|NCT00002291|Dose-Response Relationship, Drug
1523732|NCT00002291|Aerosols
1523733|NCT00002291|Acquired Immunodeficiency Syndrome
1523734|NCT00002290|AIDS-Related Opportunistic Infections
1523735|NCT00002290|Drug Therapy, Combination
1523736|NCT00002290|Acyclovir
1523737|NCT00002290|AIDS-Related Complex
1523738|NCT00002290|Zidovudine
1523739|NCT00002289|Semen
1523740|NCT00002289|Thymopentin
1523741|NCT00002289|Leukocytes, Mononuclear
1523742|NCT00002289|HIV Seropositivity
1523743|NCT00002289|AIDS-Related Complex
1523744|NCT00002288|Neuropsychological Tests
1523745|NCT00002288|AIDS-Related Complex
1523746|NCT00002288|Zidovudine
1523747|NCT00002287|Health Manpower
1523748|NCT00002287|Accidents, Occupational
1523749|NCT00002287|Zidovudine
1523750|NCT00002286|Pilot Projects
1523751|NCT00002286|Psoriasis
1523752|NCT00002286|Acquired Immunodeficiency Syndrome
1523753|NCT00002286|Zidovudine
1523754|NCT00002285|Virus Replication
1523755|NCT00002285|Pilot Projects
1523756|NCT00002285|Immune Tolerance
1523757|NCT00002285|Lymphocytes
1523758|NCT00002285|Drug Evaluation
1523759|NCT00002285|Combined Modality Therapy
1523760|NCT00002285|Acquired Immunodeficiency Syndrome
1523761|NCT00002285|Transplantation, Homologous
1523762|NCT00002285|Zidovudine
1523763|NCT00002284|Lymphoma, Large-Cell
1523764|NCT00002284|Acquired Immunodeficiency Syndrome
1523765|NCT00002284|AIDS-Related Complex
1523766|NCT00002284|Zidovudine
1523767|NCT00002284|Bone Marrow Transplantation
1523768|NCT00002283|Trimethoprim-Sulfamethoxazole Combination
1523769|NCT00002283|AIDS-Related Opportunistic Infections
1523770|NCT00002283|Pneumonia, Pneumocystis carinii
1523771|NCT00002283|Dapsone
1523772|NCT00002283|Acquired Immunodeficiency Syndrome
1523773|NCT00002282|AIDS-Related Opportunistic Infections
1523774|NCT00002282|Fluconazole
1523775|NCT00002282|Clotrimazole
1523776|NCT00002282|Acquired Immunodeficiency Syndrome
1523777|NCT00002282|Candidiasis, Oral
1523778|NCT00002281|Injections, Subcutaneous
1523779|NCT00002281|Erythropoietin
1523780|NCT00002281|Acquired Immunodeficiency Syndrome
1523781|NCT00002281|AIDS-Related Complex
1523782|NCT00002281|Zidovudine
1523783|NCT00002280|Didanosine
1523784|NCT00002280|Drugs, Investigational
1523785|NCT00002280|Acquired Immunodeficiency Syndrome
1523786|NCT00002280|Zidovudine
1523787|NCT00002279|Zalcitabine
1523788|NCT00002279|Didanosine
1523789|NCT00002279|Drugs, Investigational
1523790|NCT00002279|Acquired Immunodeficiency Syndrome
1523791|NCT00002279|AIDS-Related Complex
1523792|NCT00002279|Zidovudine
1524036|NCT00002230|Anti-HIV Agents
1523793|NCT00002278|AIDS-Related Opportunistic Infections
1523794|NCT00002278|Cryptosporidiosis
1523795|NCT00002278|Diarrhea
1523796|NCT00002278|diclazuril
1523797|NCT00002278|Coccidiostats
1523798|NCT00002278|Acquired Immunodeficiency Syndrome
1523799|NCT00002277|Mycoses
1523800|NCT00002277|Neoplasms
1523801|NCT00002277|Neutropenia
1523802|NCT00002277|Fluconazole
1523803|NCT00002277|Amphotericin B
1523804|NCT00002276|Blood Platelets
1523805|NCT00002276|Ibuprofen
1523806|NCT00002276|Drug Interactions
1523807|NCT00002276|Zidovudine
1523808|NCT00002276|Hemophilia A
1523809|NCT00002275|Weight Loss
1523810|NCT00002275|Pneumonia, Pneumocystis carinii
1523811|NCT00002275|Parenteral Nutrition
1523812|NCT00002275|Liposyn
1523813|NCT00002275|Acquired Immunodeficiency Syndrome
1523814|NCT00002274|Didanosine
1523815|NCT00002274|Drugs, Investigational
1523816|NCT00002274|Acquired Immunodeficiency Syndrome
1523817|NCT00002274|Zidovudine
1523818|NCT00002273|AIDS-Related Opportunistic Infections
1523819|NCT00002273|Ganciclovir
1523820|NCT00002273|Cytomegalovirus Infections
1523821|NCT00002273|Colitis
1523822|NCT00002273|Acquired Immunodeficiency Syndrome
1523823|NCT00002272|AIDS-Related Opportunistic Infections
1523824|NCT00002272|Immune Tolerance
1523825|NCT00002272|Injections, Intravenous
1523826|NCT00002272|Herpes Simplex
1523827|NCT00002272|Immunity, Cellular
1523828|NCT00002272|Drug Resistance
1523829|NCT00002272|Foscarnet
1523830|NCT00002272|Acyclovir
1523831|NCT00002272|Acquired Immunodeficiency Syndrome
1523832|NCT00002272|Antiviral Agents
1523833|NCT00002271|Thymidine
1523834|NCT00002271|Nucleosides
1523835|NCT00002271|Antiviral Agents
1523836|NCT00002270|Leukoencephalopathy, Progressive Multifocal
1523837|NCT00002270|Interferon Alfa-2b
1523838|NCT00002270|Drug Evaluation
1523839|NCT00002270|Acquired Immunodeficiency Syndrome
1523840|NCT00002270|Zidovudine
1523841|NCT00002269|Acquired Immunodeficiency Syndrome
1523842|NCT00002269|ampligen
1523843|NCT00002269|AIDS-Related Complex
1523844|NCT00002269|Zidovudine
1523845|NCT00002268|AIDS-Related Opportunistic Infections
1523846|NCT00002268|Immunotherapy
1523847|NCT00002268|Drug Evaluation
1523848|NCT00002268|Cytomegalovirus Infections
1523849|NCT00002268|Antibodies, Monoclonal
1523850|NCT00002267|Rifabutin
1523851|NCT00002267|AIDS-Related Opportunistic Infections
1523852|NCT00002267|Mycobacterium avium-intracellulare Infection
1523853|NCT00002267|Acquired Immunodeficiency Syndrome
1523854|NCT00002267|Antitubercular Agents
1523855|NCT00002266|Drug Therapy, Combination
1523856|NCT00002266|Acquired Immunodeficiency Syndrome
1523857|NCT00002266|AIDS-Related Complex
1523858|NCT00002266|ammonium trichloro(dioxoethylene-O,O'-)tellurute
1523859|NCT00002265|Zalcitabine
1523860|NCT00002265|Drug Evaluation
1523861|NCT00002265|Acquired Immunodeficiency Syndrome
1523862|NCT00002265|AIDS-Related Complex
1523863|NCT00002265|Zidovudine
1523864|NCT00002263|Pilot Projects
1523865|NCT00002263|Neutropenia
1523866|NCT00002263|Granulocyte-Macrophage Colony-Stimulating Factor
1523867|NCT00002263|Acquired Immunodeficiency Syndrome
1523868|NCT00002263|Zidovudine
1523869|NCT00002262|Skin Neoplasms
1523870|NCT00002262|Tumor Necrosis Factor
1523871|NCT00002262|Acquired Immunodeficiency Syndrome
1523872|NCT00002261|Vaccines, Synthetic
1523873|NCT00002261|Vaccinia Virus
1523874|NCT00002261|Viral Vaccines
1523875|NCT00002261|Smallpox Vaccine
1523876|NCT00002261|HIV-1
1523877|NCT00002261|AIDS Vaccines
1523878|NCT00002261|HIV Seronegativity
1523879|NCT00002260|Biological Availability
1523880|NCT00002260|alovudine
1523881|NCT00002260|Food
1523882|NCT00002259|Mitoxantrone
1523883|NCT00002259|Acquired Immunodeficiency Syndrome
1523884|NCT00002258|Interleukin-3
1523887|NCT00002258|Acquired Immunodeficiency Syndrome
1523888|NCT00002258|AIDS-Related Complex
1523889|NCT00002258|Thrombocytopenia
1523890|NCT00002257|Retinitis
1523891|NCT00002257|Ganciclovir
1523892|NCT00002257|Cytomegalovirus Infections
1523893|NCT00002257|Acquired Immunodeficiency Syndrome
1523894|NCT00002256|Zalcitabine
1523895|NCT00002256|Acquired Immunodeficiency Syndrome
1523896|NCT00002256|AIDS-Related Complex
1523897|NCT00002256|Zidovudine
1523898|NCT00002255|Erythropoietin
1523899|NCT00002255|Granulocyte Colony-Stimulating Factor
1523900|NCT00002255|Acquired Immunodeficiency Syndrome
1523901|NCT00002255|AIDS-Related Complex
1523902|NCT00002255|Zidovudine
1523903|NCT00002254|Acquired Immunodeficiency Syndrome
1523904|NCT00002253|Octreotide
1523905|NCT00002253|Diarrhea
1523906|NCT00002253|Acquired Immunodeficiency Syndrome
1523907|NCT00002253|AIDS-Related Complex
1523908|NCT00002252|Octreotide
1523909|NCT00002252|Diarrhea
1523910|NCT00002252|Acquired Immunodeficiency Syndrome
1523911|NCT00002252|AIDS-Related Complex
1523912|NCT00002251|AIDS-Related Opportunistic Infections
1523914|NCT00002251|Cytomegalovirus Infections
1523915|NCT00002251|Acquired Immunodeficiency Syndrome
1523916|NCT00002251|Biological Availability
1523917|NCT00002250|Recombinant Proteins
1523918|NCT00002250|IgG
1523919|NCT00002250|Drug Evaluation
1523920|NCT00002250|Antigens, CD4
1523921|NCT00002249|Anti-Infective Agents, Quinolone
1523922|NCT00002249|Ofloxacin
1523923|NCT00002249|Acquired Immunodeficiency Syndrome
1523924|NCT00002248|Antidiarrheals
1523925|NCT00002248|Cryptosporidiosis
1523926|NCT00002248|Diarrhea
1523927|NCT00002248|Acquired Immunodeficiency Syndrome
1523928|NCT00002248|Cryptosporidium
1523929|NCT00002248|Immunization, Passive
1523930|NCT00002247|Retinitis
1523931|NCT00002247|Ganciclovir
1523932|NCT00002247|Cytomegalovirus Infections
1523933|NCT00002247|Administration, Oral
1523934|NCT00002247|Acquired Immunodeficiency Syndrome
1523935|NCT00002246|AIDS Dementia Complex
1523936|NCT00002246|Zidovudine
1523937|NCT00002246|Stavudine
1523938|NCT00002246|Reverse Transcriptase Inhibitors
1523939|NCT00002245|Drug Therapy, Combination
1523940|NCT00002245|HIV Protease Inhibitors
1523941|NCT00002245|Lamivudine
1523942|NCT00002245|Carbohydrates
1523943|NCT00002245|VX 478
1523944|NCT00002245|Reverse Transcriptase Inhibitors
1523945|NCT00002245|Anti-HIV Agents
1523946|NCT00002245|Lipids
1523947|NCT00002245|Insulin Resistance
1523948|NCT00002245|abacavir
1523949|NCT00002244|Placebos
1523950|NCT00002244|Infusions, Intravenous
1523951|NCT00002244|Quality of Life
1523952|NCT00002244|Anti-HIV Agents
1523953|NCT00002244|tetrachlorodecaoxide
1523954|NCT00002243|Anti-HIV Agents
1523955|NCT00002241|Drug Therapy, Combination
1523956|NCT00002241|Stavudine
1523957|NCT00002241|HIV Protease Inhibitors
1523958|NCT00002241|Ritonavir
1523959|NCT00002241|Lamivudine
1523960|NCT00002241|Indinavir
1523961|NCT00002241|Reverse Transcriptase Inhibitors
1523962|NCT00002241|Anti-HIV Agents
1523963|NCT00002241|Viral Load
1523964|NCT00002240|Didanosine
1523965|NCT00002240|Dose-Response Relationship, Drug
1523966|NCT00002240|Drug Therapy, Combination
1523967|NCT00002240|Stavudine
1523968|NCT00002240|HIV Protease Inhibitors
1523969|NCT00002240|Reverse Transcriptase Inhibitors
1523970|NCT00002240|Anti-HIV Agents
1523971|NCT00002240|Nelfinavir
1523972|NCT00002239|HIV-1
1523973|NCT00002239|Dose-Response Relationship, Drug
1523974|NCT00002239|Drug Therapy, Combination
1523975|NCT00002239|VX 478
1523976|NCT00002239|Anti-HIV Agents
1523977|NCT00002239|pentafuside
1523978|NCT00002239|abacavir
1523979|NCT00002239|efavirenz
1523980|NCT00002238|Drug Therapy, Combination
1523981|NCT00002238|Acquired Immunodeficiency Syndrome
1523982|NCT00002238|AIDS-Related Complex
1523983|NCT00002238|Zidovudine
1523984|NCT00002238|Interferon Type I
1523985|NCT00002237|Placebos
1523986|NCT00002237|Administration, Oral
1523987|NCT00002237|Anti-HIV Agents
1523988|NCT00002237|Viral Load
1523989|NCT00002237|peldesine
1523990|NCT00002236|Drug Therapy, Combination
1523991|NCT00002236|Zidovudine
1523992|NCT00002236|Drug Administration Schedule
1523993|NCT00002236|HIV Protease Inhibitors
1523994|NCT00002236|CD4 Lymphocyte Count
1523995|NCT00002236|Indinavir
1523996|NCT00002236|Delavirdine
1523997|NCT00002236|Reverse Transcriptase Inhibitors
1523998|NCT00002236|Anti-HIV Agents
1523999|NCT00002236|Viral Load
1524000|NCT00002235|Drug Therapy, Combination
1524001|NCT00002235|HIV Protease Inhibitors
1524002|NCT00002235|Indinavir
1524003|NCT00002235|Nelfinavir
1524004|NCT00002235|Reverse Transcriptase Inhibitors
1524005|NCT00002235|Anti-HIV Agents
1524006|NCT00002235|efavirenz
1524007|NCT00002234|Drug Therapy, Combination
1524008|NCT00002234|Reverse Transcriptase Inhibitors
1524009|NCT00002234|Anti-HIV Agents
1524010|NCT00002233|Drug Therapy, Combination
1524011|NCT00002233|HIV Protease Inhibitors
1524012|NCT00002233|CD4 Lymphocyte Count
1524013|NCT00002233|Reverse Transcriptase Inhibitors
1524014|NCT00002233|Anti-HIV Agents
1524015|NCT00002233|Viral Load
1524016|NCT00002232|Injections, Intradermal
1524017|NCT00002232|Injections, Intramuscular
1524018|NCT00002232|HIV Antibodies
1524019|NCT00002232|Immunity, Cellular
1524020|NCT00002232|AIDS Vaccines
1524021|NCT00002232|HIV Seronegativity
1524022|NCT00002232|Dose-Response Relationship, Immunologic
1524023|NCT00002232|Vaccines, DNA
1524024|NCT00002232|Immunity, Mucosal
1524025|NCT00002231|Injections, Intramuscular
1524026|NCT00002231|HIV Antibodies
1524027|NCT00002231|Immunity, Cellular
1524028|NCT00002231|AIDS Vaccines
1524029|NCT00002231|HIV Seronegativity
1524030|NCT00002231|Dose-Response Relationship, Immunologic
1524031|NCT00002231|Vaccines, DNA
1524032|NCT00002230|Didanosine
1524033|NCT00002230|Drug Therapy, Combination
1524034|NCT00002230|Stavudine
1524035|NCT00002230|Hydroxyurea
1524037|NCT00002229|Drug Therapy, Combination
1524038|NCT00002229|HIV Protease Inhibitors
1524039|NCT00002229|Dosage Forms
1524040|NCT00002229|Saquinavir
1524041|NCT00002229|Reverse Transcriptase Inhibitors
1524042|NCT00002229|Anti-HIV Agents
1524043|NCT00002228|Injections, Subcutaneous
1524044|NCT00002228|HIV-1
1524045|NCT00002228|Anti-HIV Agents
1524046|NCT00002228|peptide T20
1524047|NCT00002227|Drug Therapy, Combination
1524048|NCT00002227|Stavudine
1524049|NCT00002227|Lamivudine
1524050|NCT00002227|Reverse Transcriptase Inhibitors
1524051|NCT00002227|efavirenz
1524052|NCT00002226|Skin Neoplasms
1524053|NCT00002226|Sarcoma, Kaposi
1524054|NCT00002226|Antineoplastic Agents
1524055|NCT00002225|Didanosine
1524056|NCT00002225|Drug Therapy, Combination
1524057|NCT00002225|Stavudine
1524058|NCT00002225|Reverse Transcriptase Inhibitors
1524059|NCT00002225|efavirenz
1524060|NCT00002224|Didanosine
1524061|NCT00002224|Drug Therapy, Combination
1524062|NCT00002224|Drug Administration Schedule
1524063|NCT00002224|Stavudine
1524064|NCT00002224|HIV Protease Inhibitors
1524065|NCT00002224|Nelfinavir
1524066|NCT00002224|Reverse Transcriptase Inhibitors
1524067|NCT00002224|Anti-HIV Agents
1524068|NCT00002224|Viral Load
1524069|NCT00002223|Drug Therapy, Combination
1524070|NCT00002223|Adolescent Behavior
1524071|NCT00002223|HIV Protease Inhibitors
1524072|NCT00002223|Ritonavir
1524073|NCT00002223|Indinavir
1524074|NCT00002222|AIDS-Related Opportunistic Infections
1524075|NCT00002222|Ganciclovir
1524076|NCT00002222|Antiviral Agents
1524077|NCT00002222|Drug Administration Schedule
1524078|NCT00002222|Cytomegalovirus Retinitis
1524079|NCT00002222|Prodrugs
1524080|NCT00002221|Lymphoma, Non-Hodgkin
1524081|NCT00002221|Bone Marrow
1524082|NCT00002221|Lymphocyte Transformation
1524083|NCT00002221|HIV-1
1524084|NCT00002221|Retroviridae
1524085|NCT00002221|Lymphoma, AIDS-Related
1524086|NCT00002221|Genetic Vectors
1524087|NCT00002221|Transduction, Genetic
1524088|NCT00002221|Gene Transfer Techniques
1524089|NCT00002220|Drug Resistance
1524090|NCT00002220|Drug Therapy, Combination
1524091|NCT00002220|Antiviral Agents
1524092|NCT00002220|HIV Protease Inhibitors
1524093|NCT00002220|Indinavir
1524094|NCT00002220|RNA, Viral
1524095|NCT00002220|Adenine
1524096|NCT00002220|efavirenz
1524097|NCT00002219|Dose-Response Relationship, Drug
1524098|NCT00002219|Antiviral Agents
1524099|NCT00002219|HIV Protease Inhibitors
1524100|NCT00002219|Disease Progression
1524101|NCT00002219|RNA, Viral
1524102|NCT00002219|Adenine
1524103|NCT00002219|Viral Load
1524104|NCT00002219|Age Factors
1524105|NCT00002219|Nelfinavir
1524106|NCT00002218|HIV-1
1524107|NCT00002218|Dose-Response Relationship, Drug
1524108|NCT00002218|Anti-HIV Agents
1524109|NCT00002217|Drug Therapy, Combination
1524110|NCT00002217|Patient Compliance
1524111|NCT00002217|Anti-HIV Agents
1524112|NCT00002217|abacavir
1524113|NCT00002216|Drug Therapy, Combination
1524114|NCT00002216|HIV Protease Inhibitors
1524115|NCT00002216|VX 478
1524116|NCT00002216|Reverse Transcriptase Inhibitors
1524117|NCT00002216|Anti-HIV Agents
1524118|NCT00002216|abacavir
1524119|NCT00002215|Drug Therapy, Combination
1524120|NCT00002215|HIV Protease Inhibitors
1524121|NCT00002215|RNA, Viral
1524122|NCT00002215|Reverse Transcriptase Inhibitors
1524123|NCT00002215|Viral Load
1524124|NCT00002215|Nelfinavir
1524125|NCT00002215|Uracil
1524126|NCT00002214|Dose-Response Relationship, Drug
1524127|NCT00002214|Reverse Transcriptase Inhibitors
1524128|NCT00002213|HIV-1
1524129|NCT00002213|Drug Therapy, Combination
1524133|NCT00002213|VX 478
1524134|NCT00002213|Anti-HIV Agents
1524135|NCT00002213|abacavir
1524136|NCT00002213|efavirenz
1524137|NCT00002212|Sarcoma, Kaposi
1524138|NCT00002212|Acquired Immunodeficiency Syndrome
1524139|NCT00002212|Anticarcinogenic Agents
1524140|NCT00002211|HIV-1
1524141|NCT00002211|Didanosine
1524142|NCT00002211|Stavudine
1524143|NCT00002211|HIV Protease Inhibitors
1524144|NCT00002211|RNA, Viral
1524145|NCT00002211|Delavirdine
1524146|NCT00002211|Reverse Transcriptase Inhibitors
1524147|NCT00002211|Viral Load
1524148|NCT00002211|Nelfinavir
1524149|NCT00002210|HIV-1
1524150|NCT00002210|Drug Therapy, Combination
1524151|NCT00002210|Delavirdine
1524152|NCT00002210|Reverse Transcriptase Inhibitors
1524153|NCT00002209|Dose-Response Relationship, Drug
1524154|NCT00002209|Drug Therapy, Combination
1524155|NCT00002209|AIDS Dementia Complex
1524156|NCT00002209|Zidovudine
1524157|NCT00002209|Lamivudine
1524158|NCT00002209|Indinavir
1524159|NCT00002209|Reverse Transcriptase Inhibitors
1524160|NCT00002208|HIV-1
1524161|NCT00002208|Drug Therapy, Combination
1524162|NCT00002208|Zidovudine
1524163|NCT00002208|HIV Protease Inhibitors
1524164|NCT00002208|Lamivudine
1524165|NCT00002208|Indinavir
1524166|NCT00002208|Reverse Transcriptase Inhibitors
1524167|NCT00002207|Didanosine
1524168|NCT00002207|Drug Therapy, Combination
1524169|NCT00002207|Stavudine
1524170|NCT00002207|Reverse Transcriptase Inhibitors
1524171|NCT00002206|HIV-1
1524172|NCT00002206|Adenine
1524173|NCT00002206|Anti-HIV Agents
1524174|NCT00002205|HIV Protease Inhibitors
1524175|NCT00002205|VX 478
1524176|NCT00002205|Anti-HIV Agents
1524177|NCT00002205|abacavir
1524178|NCT00002204|Reference Values
1524179|NCT00002204|Placebos
1524180|NCT00002204|AIDS Vaccines
1524181|NCT00002204|HIV Core Protein p24
1524182|NCT00002204|HIV Seronegativity
1524183|NCT00002204|MF59 oil emulsion
1524184|NCT00002203|Drug Therapy, Combination
1524185|NCT00002203|Zidovudine
1524186|NCT00002203|HIV Protease Inhibitors
1524187|NCT00002203|CD4 Lymphocyte Count
1524188|NCT00002203|CD4-CD8 Ratio
1524189|NCT00002203|Lamivudine
1524190|NCT00002203|Patient Compliance
1524191|NCT00002203|Reverse Transcriptase Inhibitors
1524192|NCT00002203|Anti-HIV Agents
1524193|NCT00002203|Viral Load
1524194|NCT00002202|HIV-1
1524195|NCT00002202|Drug Therapy, Combination
1524196|NCT00002202|HIV Protease Inhibitors
1524197|NCT00002202|Indinavir
1524198|NCT00002202|RNA, Viral
1524199|NCT00002202|VX 478
1524200|NCT00002202|Reverse Transcriptase Inhibitors
1524201|NCT00002202|Anti-HIV Agents
1524202|NCT00002202|Viral Load
1524203|NCT00002201|Drug Therapy, Combination
1524204|NCT00002201|HIV Protease Inhibitors
1524205|NCT00002201|Ritonavir
1524206|NCT00002201|Nelfinavir
1524207|NCT00002201|Anti-HIV Agents
1524208|NCT00002200|HIV-1
1524209|NCT00002200|Administration, Oral
1524210|NCT00002200|CD4 Lymphocyte Count
1524211|NCT00002200|RNA, Viral
1524212|NCT00002200|Reverse Transcriptase Inhibitors
1524213|NCT00002200|Anti-HIV Agents
1524214|NCT00002200|Viral Load
1524215|NCT00002200|abacavir
1524216|NCT00002199|HIV-1
1524217|NCT00002199|Drug Therapy, Combination
1524218|NCT00002199|Zidovudine
1524219|NCT00002199|Drug Resistance, Microbial
1524220|NCT00002199|HIV Protease Inhibitors
1524221|NCT00002199|Lamivudine
1524222|NCT00002199|Indinavir
1524223|NCT00002199|Genotype
1524224|NCT00002199|Phenotype
1524225|NCT00002199|Reverse Transcriptase Inhibitors
1524226|NCT00002199|Anti-HIV Agents
1524227|NCT00002199|abacavir
1524228|NCT00002198|Drug Interactions
1524229|NCT00002198|Antiviral Agents
1524230|NCT00002198|Ethanol
1524231|NCT00002198|abacavir
1524232|NCT00002197|HIV-1
1524233|NCT00002197|CD4 Lymphocyte Count
1524234|NCT00002197|Reverse Transcriptase Inhibitors
1524235|NCT00002197|Anti-HIV Agents
1524236|NCT00002197|Viral Load
1524237|NCT00002197|abacavir
1524238|NCT00002196|Dose-Response Relationship, Drug
1524239|NCT00002196|Administration, Oral
1524240|NCT00002196|Drug Administration Schedule
1524241|NCT00002196|CD4 Lymphocyte Count
1524242|NCT00002196|Anti-HIV Agents
1524243|NCT00002195|Drug Therapy, Combination
1524244|NCT00002195|Zidovudine
1524245|NCT00002195|HIV Protease Inhibitors
1524246|NCT00002195|Lamivudine
1524247|NCT00002195|VX 478
1524248|NCT00002195|Reverse Transcriptase Inhibitors
1524249|NCT00002195|Anti-HIV Agents
1524250|NCT00002195|Viral Load
1524251|NCT00002194|Antibiotics, Macrolide
1524252|NCT00002194|Clarithromycin
1524253|NCT00002194|Nevirapine
1524254|NCT00002194|Reverse Transcriptase Inhibitors
1524255|NCT00002194|Cytochrome P-450
1524256|NCT00002194|Anti-HIV Agents
1524257|NCT00002193|HIV-1
1524258|NCT00002193|Drug Therapy, Combination
1524259|NCT00002193|HIV Protease Inhibitors
1524260|NCT00002193|RNA, Viral
1524261|NCT00002193|VX 478
1524262|NCT00002193|Reverse Transcriptase Inhibitors
1524263|NCT00002193|Anti-HIV Agents
1524264|NCT00002193|Viral Load
1524265|NCT00002192|AIDS-Related Opportunistic Infections
1524266|NCT00002192|Mycobacterium avium-intracellulare Infection
1524267|NCT00002192|Drug Therapy, Combination
1524268|NCT00002192|Antitubercular Agents
1524269|NCT00002192|Azithromycin
1524270|NCT00002192|Clarithromycin
1524271|NCT00002192|Bacteremia
1524272|NCT00002192|rifapentine
1524273|NCT00002191|AIDS-Related Opportunistic Infections
1524274|NCT00002191|Placebos
1524275|NCT00002191|Protozoan Infections
1524276|NCT00002191|Intestinal Diseases
1524277|NCT00002191|Albendazole
1524278|NCT00002191|Microsporida
1524279|NCT00002191|Anthelmintics
1524280|NCT00002190|Drug Therapy, Combination
1524281|NCT00002190|Zidovudine
1524282|NCT00002190|HIV Protease Inhibitors
1524283|NCT00002190|Lamivudine
1524284|NCT00002190|Saquinavir
1524285|NCT00002190|Reverse Transcriptase Inhibitors
1524286|NCT00002190|Anti-HIV Agents
1524287|NCT00002189|Sarcoma, Kaposi
1524288|NCT00002189|Acquired Immunodeficiency Syndrome
1524289|NCT00002189|Paclitaxel
1524290|NCT00002189|Treatment Outcome
1524291|NCT00002189|Antineoplastic Agents, Phytogenic
1524292|NCT00002188|AIDS-Related Opportunistic Infections
1524293|NCT00002188|Sarcoma, Kaposi
1524294|NCT00002188|Antineoplastic Agents
1524295|NCT00002187|AIDS-Related Opportunistic Infections
1524296|NCT00002187|Antiviral Agents
1524297|NCT00002187|Drug Administration Schedule
1524298|NCT00002187|Cytomegalovirus Retinitis
1524299|NCT00002187|fomivirsen
1524300|NCT00002187|Vitreous Body
1524301|NCT00002186|AIDS-Related Opportunistic Infections
1524302|NCT00002186|Herpes Simplex
1524303|NCT00002186|Drug Therapy, Combination
1524304|NCT00002186|Acyclovir
1524305|NCT00002186|Antiviral Agents
1524306|NCT00002186|Gels
1524307|NCT00002186|SP 303
1524308|NCT00002185|Skin Neoplasms
1524309|NCT00002185|AIDS-Related Opportunistic Infections
1524310|NCT00002185|Sarcoma, Kaposi
1524311|NCT00002185|Drug Therapy, Combination
1524312|NCT00002185|HIV Protease Inhibitors
1524313|NCT00002185|Mucous Membrane
1524314|NCT00002185|Nelfinavir
1524315|NCT00002185|Anti-HIV Agents
1524316|NCT00002184|HIV-1
1524317|NCT00002184|Dose-Response Relationship, Drug
1524318|NCT00002184|Drug Therapy, Combination
1524319|NCT00002184|Acquired Immunodeficiency Syndrome
1524320|NCT00002184|Zidovudine
1524321|NCT00002184|Stavudine
1524322|NCT00002184|HIV Protease Inhibitors
1524323|NCT00002184|CD4 Lymphocyte Count
1524324|NCT00002184|Lamivudine
1524325|NCT00002184|RNA, Viral
1524326|NCT00002184|Saquinavir
1524327|NCT00002184|Nelfinavir
1524328|NCT00002184|Reverse Transcriptase Inhibitors
1524329|NCT00002184|Adenine
1524330|NCT00002184|Anti-HIV Agents
1524331|NCT00002184|Viral Load
1524332|NCT00002183|Drug Therapy, Combination
1524333|NCT00002183|Drug Administration Schedule
1524334|NCT00002183|HIV Protease Inhibitors
1524335|NCT00002183|VX 478
1524336|NCT00002183|Anti-HIV Agents
1524337|NCT00002182|Placebos
1524338|NCT00002182|Appetite Stimulants
1524339|NCT00002182|Megestrol Acetate
1524340|NCT00002182|Failure to Thrive
1524341|NCT00002181|AIDS-Related Opportunistic Infections
1524342|NCT00002181|Herpes Simplex
1524343|NCT00002181|Acyclovir
1524344|NCT00002181|Antiviral Agents
1524345|NCT00002181|Gels
1524346|NCT00002181|cidofovir
1524347|NCT00002180|Placebos
1524348|NCT00002180|Anti-HIV Agents
1524349|NCT00002180|Adenine
1524350|NCT00002179|Semen
1524351|NCT00002179|Monocytes
1524352|NCT00002179|HIV-1
1524353|NCT00002179|Drug Therapy, Combination
1524354|NCT00002179|Zidovudine
1524355|NCT00002179|Lymph Nodes
1524356|NCT00002179|HIV Protease Inhibitors
1524357|NCT00002179|Lamivudine
1524358|NCT00002179|Indinavir
1524359|NCT00002179|RNA, Viral
1524360|NCT00002179|Reverse Transcriptase Inhibitors
1524361|NCT00002179|Anti-HIV Agents
1524362|NCT00002179|Viral Load
1524363|NCT00002178|HIV-1
1524364|NCT00002178|Drug Therapy, Combination
1524365|NCT00002178|HIV Protease Inhibitors
1524366|NCT00002178|RNA, Viral
1524367|NCT00002178|Dosage Forms
1524368|NCT00002178|Saquinavir
1524369|NCT00002178|Reverse Transcriptase Inhibitors
1524370|NCT00002178|Anti-HIV Agents
1524371|NCT00002178|Viral Load
1524372|NCT00002177|Pilot Projects
1524373|NCT00002177|HIV-1
1524374|NCT00002177|Didanosine
1524375|NCT00002177|Drug Therapy, Combination
1524376|NCT00002177|Stavudine
1524377|NCT00002177|Hydroxyurea
1524378|NCT00002177|RNA, Viral
1524379|NCT00002177|Nelfinavir
1524380|NCT00002177|Anti-HIV Agents
1524381|NCT00002177|Viral Load
1524382|NCT00002176|Pilot Projects
1524383|NCT00002176|Didanosine
1524384|NCT00002176|Drug Therapy, Combination
1524385|NCT00002176|Stavudine
1524386|NCT00002176|Hydroxyurea
1524387|NCT00002176|Nelfinavir
1524388|NCT00002176|Anti-HIV Agents
1524389|NCT00002176|Viral Load
1524390|NCT00002175|Cohort Studies
1524391|NCT00002175|RNA, Viral
1524392|NCT00002175|Administration, Cutaneous
1524393|NCT00002175|Anti-HIV Agents
1524394|NCT00002175|Dinitrobenzenes
1524395|NCT00002174|Adjuvants, Immunologic
1524396|NCT00002174|Thalidomide
1524397|NCT00002174|Cytokines
1524398|NCT00002174|Viral Load
1524399|NCT00002173|Acquired Immunodeficiency Syndrome
1524400|NCT00002173|AIDS Vaccines
1524401|NCT00002173|CD4 Lymphocyte Count
1524402|NCT00002173|Salk HIV Immunogen
1524403|NCT00002172|Acquired Immunodeficiency Syndrome
1524404|NCT00002172|AIDS Vaccines
1524405|NCT00002172|CD4 Lymphocyte Count
1524406|NCT00002172|Salk HIV Immunogen
1524407|NCT00002171|Placebos
1524408|NCT00002171|Drug Therapy, Combination
1524409|NCT00002171|Stavudine
1524410|NCT00002171|HIV Protease Inhibitors
1524411|NCT00002171|Lamivudine
1524412|NCT00002171|Nelfinavir
1524413|NCT00002171|Anti-HIV Agents
1524414|NCT00002170|AIDS-Related Opportunistic Infections
1524415|NCT00002170|Placebos
1524416|NCT00002170|Mycobacterium avium-intracellulare Infection
1524417|NCT00002170|Acquired Immunodeficiency Syndrome
1524418|NCT00002170|HIV Protease Inhibitors
1524419|NCT00002170|Nelfinavir
1524420|NCT00002170|Anti-Infective Agents
1524421|NCT00002170|Anti-HIV Agents
1524422|NCT00002169|AIDS-Related Opportunistic Infections
1524423|NCT00002169|Placebos
1524424|NCT00002169|Antiviral Agents
1524425|NCT00002169|Cytomegalovirus Retinitis
1524426|NCT00002169|Treatment Outcome
1524427|NCT00002169|Nelfinavir
1524428|NCT00002168|Didanosine
1524429|NCT00002168|Drug Therapy, Combination
1524430|NCT00002168|Zidovudine
1524431|NCT00002168|Stavudine
1524432|NCT00002168|HIV Protease Inhibitors
1524433|NCT00002168|CD4 Lymphocyte Count
1524434|NCT00002168|Lamivudine
1524435|NCT00002168|Indinavir
1524436|NCT00002168|Reverse Transcriptase Inhibitors
1524437|NCT00002168|Anti-HIV Agents
1524438|NCT00002168|Viral Load
1524439|NCT00002167|Skin Neoplasms
1524440|NCT00002167|Sarcoma, Kaposi
1524441|NCT00002167|Acquired Immunodeficiency Syndrome
1524442|NCT00002167|Photochemotherapy
1524443|NCT00002167|tin etiopurpurin
1524444|NCT00002167|Radiation-Sensitizing Agents
1524445|NCT00002166|Nevirapine
1524446|NCT00002166|Reverse Transcriptase Inhibitors
1524447|NCT00002166|Anti-HIV Agents
1524448|NCT00002165|Acquired Immunodeficiency Syndrome
1524449|NCT00002165|HIV Protease Inhibitors
1524450|NCT00002165|CD4 Lymphocyte Count
1524451|NCT00002165|Nelfinavir
1524452|NCT00002165|Anti-HIV Agents
1524453|NCT00002164|Biological Availability
1524454|NCT00002164|HIV Protease Inhibitors
1524455|NCT00002164|Dosage Forms
1524456|NCT00002164|Nelfinavir
1524457|NCT00002163|Acquired Immunodeficiency Syndrome
1524458|NCT00002163|AIDS Dementia Complex
1524459|NCT00002163|Antiviral Agents
1524460|NCT00002163|abacavir
1524461|NCT00002162|Drug Therapy, Combination
1524462|NCT00002162|Acquired Immunodeficiency Syndrome
1524463|NCT00002162|AIDS-Related Complex
1524464|NCT00002162|Antiviral Agents
1524465|NCT00002162|Saquinavir
1524466|NCT00002161|Drug Therapy, Combination
1524467|NCT00002161|Acquired Immunodeficiency Syndrome
1524468|NCT00002161|AIDS-Related Complex
1524469|NCT00002161|Antiviral Agents
1524470|NCT00002161|Adenine
1524471|NCT00002160|Acquired Immunodeficiency Syndrome
1524472|NCT00002160|AIDS-Related Complex
1524473|NCT00002160|Pain
1524474|NCT00002160|Palliative Care
1524475|NCT00002160|omega-conopeptide MVIIA
1524476|NCT00002160|Calcium Channel Blockers
1524477|NCT00002159|Itraconazole
1524478|NCT00002159|Histoplasmosis
1524479|NCT00002159|Antifungal Agents
1524480|NCT00002159|Acquired Immunodeficiency Syndrome
1524481|NCT00002159|Amphotericin B
1524482|NCT00002159|AIDS-Related Complex
1524483|NCT00002159|Blastomycosis
1524484|NCT00002159|Antibiotics, Antifungal
1524485|NCT00002158|Cryptosporidiosis
1524486|NCT00002158|Diarrhea
1524487|NCT00002158|Acquired Immunodeficiency Syndrome
1524488|NCT00002158|nitazoxanide
1524489|NCT00002158|Antiparasitic Agents
1524490|NCT00002157|Acquired Immunodeficiency Syndrome
1524491|NCT00002157|Cachexia
1524492|NCT00002157|Thalidomide
1524493|NCT00002156|AIDS-Related Opportunistic Infections
1524494|NCT00002156|Ganciclovir
1524495|NCT00002156|Drug Therapy, Combination
1524496|NCT00002156|Acquired Immunodeficiency Syndrome
1524497|NCT00002156|Antiviral Agents
1524498|NCT00002156|Cytomegalovirus Retinitis
1524499|NCT00002156|Injections
1524500|NCT00002155|Drug Therapy, Combination
1524501|NCT00002155|Acquired Immunodeficiency Syndrome
1524502|NCT00002155|Antiviral Agents
1524503|NCT00002155|Zidovudine
1524504|NCT00002155|HIV Protease Inhibitors
1524505|NCT00002155|Lamivudine
1524506|NCT00002155|Indinavir
1524507|NCT00002154|Drug Therapy, Combination
1524508|NCT00002154|Cognition Disorders
1524509|NCT00002154|Acquired Immunodeficiency Syndrome
1524510|NCT00002154|AIDS-Related Complex
1524511|NCT00002154|Thioctic Acid
1524512|NCT00002154|Selegiline
1524513|NCT00002153|Skin Neoplasms
1524514|NCT00002153|Sarcoma, Kaposi
1524515|NCT00002153|Acquired Immunodeficiency Syndrome
1524516|NCT00002153|Antineoplastic Agents
1524517|NCT00002152|Acquired Immunodeficiency Syndrome
1524518|NCT00002152|Antiviral Agents
1524519|NCT00002151|Drug Therapy, Combination
1524520|NCT00002151|AIDS-Related Complex
1524521|NCT00002151|Zidovudine
1524522|NCT00002151|MDL 28574
1524523|NCT00002150|Drug Therapy, Combination
1524524|NCT00002150|Acquired Immunodeficiency Syndrome
1524525|NCT00002150|AIDS-Related Complex
1524526|NCT00002150|Zidovudine
1524527|NCT00002150|MDL 28574
1524528|NCT00002149|AIDS-Related Opportunistic Infections
1524529|NCT00002149|Drug Therapy, Combination
1524530|NCT00002149|Acquired Immunodeficiency Syndrome
1524531|NCT00002149|AIDS-Related Complex
1524532|NCT00002149|Sinusitis
1524533|NCT00002149|Ephedrine
1524534|NCT00002149|Acupuncture Therapy
1524535|NCT00002149|Drugs, Chinese Herbal
1524536|NCT00002149|Medicine, Chinese Traditional
1524537|NCT00002149|Drug Combinations
1524538|NCT00002149|Antibiotics, Combined
1524539|NCT00002149|Amoxicillin-Potassium Clavulanate Combination
1524540|NCT00002148|Cognition Disorders
1524541|NCT00002148|Acquired Immunodeficiency Syndrome
1524542|NCT00002148|AIDS-Related Complex
1524543|NCT00002148|Free Radical Scavengers
1524544|NCT00002148|Antioxidants
1524545|NCT00002148|OPC 14117
1524546|NCT00002147|Sarcoma, Kaposi
1524547|NCT00002147|Liposomes
1524548|NCT00002147|Doxorubicin
1524549|NCT00002147|Acquired Immunodeficiency Syndrome
1524550|NCT00002147|Drug Carriers
1524551|NCT00002146|Infusions, Intravenous
1524552|NCT00002146|Foscarnet
1524553|NCT00002146|Cytomegalovirus Infections
1524554|NCT00002146|Acquired Immunodeficiency Syndrome
1524555|NCT00002146|Magnesium Sulfate
1524556|NCT00002146|Magnesium Deficiency
1524557|NCT00002146|Hypocalcemia
1524558|NCT00002145|Foscarnet
1524559|NCT00002145|Cytomegalovirus Infections
1524560|NCT00002145|Acquired Immunodeficiency Syndrome
1524561|NCT00002144|Herpes Simplex
1524562|NCT00002144|Foscarnet
1524563|NCT00002144|Acquired Immunodeficiency Syndrome
1524564|NCT00002143|Psoriasis
1524565|NCT00002143|Acquired Immunodeficiency Syndrome
1524566|NCT00002143|AIDS-Related Complex
1524567|NCT00002143|Acitretin
1524568|NCT00002142|Retinitis
1524569|NCT00002142|Probenecid
1524570|NCT00002142|Drug Therapy, Combination
1524571|NCT00002142|Cytomegalovirus Infections
1524572|NCT00002142|Acquired Immunodeficiency Syndrome
1524573|NCT00002142|Antiviral Agents
1524574|NCT00002142|cidofovir
1524575|NCT00002141|Biological Availability
1524576|NCT00002141|Reverse Transcriptase Inhibitors
1524577|NCT00002141|Food-Drug Interactions
1524578|NCT00002141|abacavir
1524579|NCT00002140|Mycobacterium avium-intracellulare Infection
1524580|NCT00002140|Drug Therapy, Combination
1524581|NCT00002140|Ethambutol
1524582|NCT00002140|Acquired Immunodeficiency Syndrome
1524583|NCT00002140|Azithromycin
1524584|NCT00002140|Clarithromycin
1524585|NCT00002139|Acquired Immunodeficiency Syndrome
1524586|NCT00002139|Azithromycin
1524587|NCT00002139|Bacterial Infections
1524588|NCT00002138|Neoplasms
1524589|NCT00002138|Sarcoma, Kaposi
1524590|NCT00002138|Acquired Immunodeficiency Syndrome
1524591|NCT00002138|Antineoplastic Agents
1524592|NCT00002138|tecogalan
1524593|NCT00002137|Neoplasms
1524594|NCT00002137|Sarcoma, Kaposi
1524595|NCT00002137|Acquired Immunodeficiency Syndrome
1524596|NCT00002137|Antineoplastic Agents
1524597|NCT00002137|tecogalan
1524598|NCT00002136|Neoplasms
1524599|NCT00002136|Sarcoma, Kaposi
1524600|NCT00002136|Acquired Immunodeficiency Syndrome
1524601|NCT00002136|Antineoplastic Agents
1524602|NCT00002136|tecogalan
1524603|NCT00002135|Retinitis
1524604|NCT00002135|Ganciclovir
1524605|NCT00002135|Administration, Oral
1524606|NCT00002135|Acquired Immunodeficiency Syndrome
1524607|NCT00002134|Retinitis
1524608|NCT00002134|Ganciclovir
1524609|NCT00002134|Administration, Oral
1524610|NCT00002134|Acquired Immunodeficiency Syndrome
1524611|NCT00002133|Itraconazole
1524612|NCT00002133|Acquired Immunodeficiency Syndrome
1524613|NCT00002133|AIDS-Related Complex
1524614|NCT00002133|Candidiasis, Oral
1524615|NCT00002132|Itraconazole
1524616|NCT00002132|Fluconazole
1524617|NCT00002132|Acquired Immunodeficiency Syndrome
1524618|NCT00002132|Candidiasis
1524619|NCT00002132|Immunocompromised Host
1524620|NCT00002131|Sarcoma, Kaposi
1524621|NCT00002131|Acquired Immunodeficiency Syndrome
1524622|NCT00002131|Antiviral Agents
1524623|NCT00002131|vesnarinone
1524624|NCT00002130|Acquired Immunodeficiency Syndrome
1524625|NCT00002130|Antiviral Agents
1524626|NCT00002130|vesnarinone
1524627|NCT00002129|vesnarinone
1524628|NCT00002128|Acquired Immunodeficiency Syndrome
1524629|NCT00002128|AIDS-Related Complex
1524630|NCT00002128|Antiviral Agents
1524631|NCT00002128|Adenine
1524632|NCT00002127|Acquired Immunodeficiency Syndrome
1524633|NCT00002127|Cachexia
1524634|NCT00002127|Thalidomide
1524635|NCT00002126|Neutropenia
1524636|NCT00002126|Granulocyte Colony-Stimulating Factor
1524637|NCT00002126|Acquired Immunodeficiency Syndrome
1524638|NCT00002125|Retinitis
1524639|NCT00002125|Infusions, Intravenous
1524640|NCT00002125|Foscarnet
1524641|NCT00002125|Cytomegalovirus Infections
1524642|NCT00002125|Administration, Oral
1524643|NCT00002125|Acquired Immunodeficiency Syndrome
1524644|NCT00002125|Fluid Therapy
1524645|NCT00002124|Drug Therapy, Combination
1524646|NCT00002124|Acquired Immunodeficiency Syndrome
1524647|NCT00002124|AIDS-Related Complex
1524648|NCT00002124|Antiviral Agents
1524649|NCT00002124|Zidovudine
1524650|NCT00002123|Didanosine
1524651|NCT00002123|Drug Therapy, Combination
1524652|NCT00002123|Acquired Immunodeficiency Syndrome
1524653|NCT00002123|AIDS-Related Complex
1524654|NCT00002123|Antiviral Agents
1524655|NCT00002122|Rifabutin
1524656|NCT00002122|Mycobacterium avium-intracellulare Infection
1524657|NCT00002122|Mycoses
1524658|NCT00002122|Drug Therapy, Combination
1524659|NCT00002122|Fluconazole
1524660|NCT00002122|Acquired Immunodeficiency Syndrome
1524661|NCT00002122|Azithromycin
1524662|NCT00002121|Antidiarrheals
1524663|NCT00002121|Diarrhea
1524664|NCT00002121|Acquired Immunodeficiency Syndrome
1524665|NCT00002121|AIDS-Related Complex
1524666|NCT00002121|N(1),N(14)-bis(ethyl)homospermine
1524667|NCT00002120|Trimethoprim-Sulfamethoxazole Combination
1524668|NCT00002120|Trimetrexate
1524669|NCT00002120|Pneumonia, Pneumocystis carinii
1524670|NCT00002120|Leucovorin
1524671|NCT00002120|Dapsone
1524672|NCT00002120|Drug Therapy, Combination
1524673|NCT00002120|Acquired Immunodeficiency Syndrome
1524674|NCT00002119|Acquired Immunodeficiency Syndrome
1524675|NCT00002119|AIDS-Related Complex
1524676|NCT00002119|Antiviral Agents
1524677|NCT00002118|Zalcitabine
1524678|NCT00002118|Acquired Immunodeficiency Syndrome
1524679|NCT00002118|AIDS-Related Complex
1524680|NCT00002117|Zalcitabine
1524681|NCT00002117|Drug Therapy, Combination
1524682|NCT00002117|Acquired Immunodeficiency Syndrome
1524683|NCT00002117|AIDS-Related Complex
1524684|NCT00002117|Zidovudine
1524685|NCT00002116|Herpes Simplex
1524686|NCT00002116|Acquired Immunodeficiency Syndrome
1524687|NCT00002116|Antiviral Agents
1524688|NCT00002116|cidofovir
1524689|NCT00002115|Acquired Immunodeficiency Syndrome
1524690|NCT00002115|Antiviral Agents
1524691|NCT00002115|Adenine
1524692|NCT00002113|Meningitis
1524693|NCT00002113|Cryptococcosis
1524694|NCT00002113|Drug Therapy, Combination
1524695|NCT00002113|Fluconazole
1524696|NCT00002113|Flucytosine
1524697|NCT00002113|Acquired Immunodeficiency Syndrome
1524698|NCT00002112|Nystatin
1524699|NCT00002112|Fluconazole
1524700|NCT00002112|Acquired Immunodeficiency Syndrome
1524701|NCT00002112|AIDS-Related Complex
1524702|NCT00002112|Candidiasis, Oral
1524703|NCT00002111|AIDS-Related Complex
1524704|NCT00002111|Saquinavir
1524705|NCT00002111|HIV Protease Inhibitors
1524706|NCT00002110|Drug Therapy, Combination
1524707|NCT00002110|AIDS-Related Complex
1524708|NCT00002110|Zidovudine
1524709|NCT00002110|Cysteamine
1524710|NCT00002109|Thymopentin
1524711|NCT00002109|Zalcitabine
1524712|NCT00002109|Didanosine
1524713|NCT00002109|Drug Therapy, Combination
1524714|NCT00002109|Zidovudine
1524715|NCT00002109|Stavudine
1524716|NCT00002108|Drug Therapy, Combination
1524717|NCT00002108|Acquired Immunodeficiency Syndrome
1524718|NCT00002108|AIDS-Related Complex
1524719|NCT00002108|Antiviral Agents
1524720|NCT00002108|Zidovudine
1524721|NCT00002107|Interleukin-2
1524722|NCT00002107|Acquired Immunodeficiency Syndrome
1524723|NCT00002107|AIDS-Related Complex
1524724|NCT00002106|Ranitidine
1524725|NCT00002105|Vincristine
1524726|NCT00002105|Sarcoma, Kaposi
1524727|NCT00002105|Liposomes
1524728|NCT00002105|Doxorubicin
1524729|NCT00002105|Drug Therapy, Combination
1524730|NCT00002105|Acquired Immunodeficiency Syndrome
1524731|NCT00002105|Bleomycin
1524732|NCT00002105|Drug Carriers
1524733|NCT00002104|Mycobacterium tuberculosis
1524734|NCT00002104|Mycobacterium Infections
1524735|NCT00002104|AIDS-Related Opportunistic Infections
1524736|NCT00002104|Mycobacterium avium-intracellulare Infection
1524737|NCT00002104|Acquired Immunodeficiency Syndrome
1524738|NCT00002104|AIDS-Related Complex
1524739|NCT00002104|Mycobacterium Infections, Atypical
1524740|NCT00002104|Thalidomide
1524741|NCT00002103|Trimetrexate
1524742|NCT00002103|Pneumonia, Pneumocystis carinii
1524743|NCT00002103|Leucovorin
1524744|NCT00002103|Drug Therapy, Combination
1524745|NCT00002103|Acquired Immunodeficiency Syndrome
1524746|NCT00002102|Trimetrexate
1524747|NCT00002102|Pneumonia, Pneumocystis carinii
1524748|NCT00002102|Leucovorin
1524749|NCT00002102|Drug Therapy, Combination
1524750|NCT00002102|Acquired Immunodeficiency Syndrome
1524751|NCT00002101|Rifabutin
1524752|NCT00002101|Mycobacterium avium-intracellulare Infection
1524753|NCT00002101|Drug Therapy, Combination
1524754|NCT00002101|Ethambutol
1524755|NCT00002101|Acquired Immunodeficiency Syndrome
1524756|NCT00002101|Clarithromycin
1524757|NCT00002100|Acquired Immunodeficiency Syndrome
1524758|NCT00002100|AIDS-Related Complex
1524759|NCT00002100|curdlan sulfate
1524760|NCT00002099|Didanosine
1524761|NCT00002099|Drug Therapy, Combination
1524762|NCT00002099|Acquired Immunodeficiency Syndrome
1524763|NCT00002099|AIDS-Related Complex
1524764|NCT00002099|Lentinan
1524765|NCT00002098|Didanosine
1524766|NCT00002098|Drug Therapy, Combination
1524767|NCT00002098|Acquired Immunodeficiency Syndrome
1524768|NCT00002098|AIDS-Related Complex
1524769|NCT00002098|Lentinan
1524770|NCT00002097|Nystatin
1524771|NCT00002097|Acquired Immunodeficiency Syndrome
1524772|NCT00002097|AIDS-Related Complex
1524773|NCT00002096|Didanosine
1524774|NCT00002096|Ganciclovir
1524775|NCT00002096|Drug Interactions
1524776|NCT00002096|Cytomegalovirus Infections
1524777|NCT00002096|Acquired Immunodeficiency Syndrome
1524778|NCT00002096|Zidovudine
1524779|NCT00002095|Ganciclovir
1524780|NCT00002095|Cytomegalovirus Infections
1524781|NCT00002095|Acquired Immunodeficiency Syndrome
1524782|NCT00002094|Virus Replication
1524783|NCT00002094|Acquired Immunodeficiency Syndrome
1524784|NCT00002094|Antiviral Agents
1524785|NCT00002093|Vincristine
1524786|NCT00002093|Sarcoma, Kaposi
1524787|NCT00002093|Liposomes
1524788|NCT00002093|Doxorubicin
1524789|NCT00002093|Acquired Immunodeficiency Syndrome
1524790|NCT00002093|Bleomycin
1524791|NCT00002093|Daunorubicin
1524792|NCT00002093|Drug Carriers
1524793|NCT00002092|Acquired Immunodeficiency Syndrome
1524794|NCT00002092|AIDS-Related Complex
1524795|NCT00002092|Cimetidine
1524796|NCT00002091|Pentoxifylline
1524797|NCT00002091|Acquired Immunodeficiency Syndrome
1524798|NCT00002091|AIDS-Related Complex
1524799|NCT00002090|Mycobacterium avium-intracellulare Infection
1524800|NCT00002090|Acquired Immunodeficiency Syndrome
1524801|NCT00002090|Azithromycin
1524802|NCT00002089|Mycobacterium avium-intracellulare Infection
1524803|NCT00002089|Acquired Immunodeficiency Syndrome
1524804|NCT00002089|Azithromycin
1524805|NCT00002088|Diarrhea
1524806|NCT00002088|Acquired Immunodeficiency Syndrome
1524807|NCT00002088|AIDS-Related Complex
1524808|NCT00002088|Saccharomyces
1524809|NCT00002087|Recombinant Proteins
1524810|NCT00002087|Acquired Immunodeficiency Syndrome
1524811|NCT00002087|Antigens, CD4
1524812|NCT00002087|AIDS-Related Complex
1524813|NCT00002086|Zalcitabine
1524814|NCT00002086|Drug Therapy, Combination
1524815|NCT00002086|AIDS-Related Complex
1524816|NCT00002086|Zidovudine
1524817|NCT00002086|Interferon-alpha
1524818|NCT00002085|Mycobacterium avium-intracellulare Infection
1524819|NCT00002085|Acquired Immunodeficiency Syndrome
1524820|NCT00002085|Azithromycin
1524821|NCT00002085|Mycobacterium Infections, Atypical
1524822|NCT00002084|Acyclovir
1524823|NCT00002084|Acquired Immunodeficiency Syndrome
1524824|NCT00002084|AIDS-Related Complex
1524825|NCT00002084|Antiviral Agents
1524826|NCT00002084|Anus Diseases
1524827|NCT00002084|Herpes Genitalis
1524828|NCT00002083|Peptide T
1524829|NCT00002083|HIV-1
1524830|NCT00002083|Administration, Intranasal
1524831|NCT00002083|Acquired Immunodeficiency Syndrome
1524832|NCT00002083|Peripheral Nervous System Diseases
1524833|NCT00002082|Cryptosporidiosis
1524834|NCT00002082|Acquired Immunodeficiency Syndrome
1524835|NCT00002082|Azithromycin
1524836|NCT00002081|Zalcitabine
1524837|NCT00002081|Acquired Immunodeficiency Syndrome
1524838|NCT00002081|AIDS-Related Complex
1524839|NCT00002081|Zidovudine
1524840|NCT00002080|Rifabutin
1524841|NCT00002080|Acquired Immunodeficiency Syndrome
1524842|NCT00002080|AIDS-Related Complex
1524843|NCT00002080|Mycobacterium avium Complex
1524844|NCT00002080|Bacteremia
1524845|NCT00002079|Zidovudine
1524846|NCT00002079|1-Deoxynojirimycin
1524847|NCT00002078|Drug Evaluation
1524848|NCT00002078|Interferon-alpha
1524849|NCT00002077|AIDS-Related Opportunistic Infections
1524850|NCT00002077|Meningitis
1524851|NCT00002077|Injections, Intravenous
1524852|NCT00002077|Cryptococcosis
1524853|NCT00002077|Fluconazole
1524854|NCT00002077|Administration, Oral
1524855|NCT00002077|Acquired Immunodeficiency Syndrome
1524856|NCT00002076|AIDS-Related Opportunistic Infections
1524857|NCT00002076|Meningitis
1524858|NCT00002076|Cryptococcosis
1524859|NCT00002076|Fluconazole
1524860|NCT00002076|Administration, Oral
1524861|NCT00002076|Acquired Immunodeficiency Syndrome
1524862|NCT00002075|AIDS-Related Opportunistic Infections
1524863|NCT00002075|Meningitis
1524864|NCT00002075|Cryptococcosis
1524865|NCT00002075|Drug Therapy, Combination
1524866|NCT00002075|Fluconazole
1524867|NCT00002075|Flucytosine
1524868|NCT00002075|Acquired Immunodeficiency Syndrome
1524869|NCT00002075|Amphotericin B
1524870|NCT00002074|AIDS-Related Opportunistic Infections
1524871|NCT00002074|Meningitis
1524872|NCT00002074|Cryptococcosis
1524873|NCT00002074|Fluconazole
1524874|NCT00002074|Acquired Immunodeficiency Syndrome
1524875|NCT00002074|Amphotericin B
1524876|NCT00002073|Recombinant Proteins
1524877|NCT00002073|Injections, Subcutaneous
1524878|NCT00002073|Erythropoietin
1524879|NCT00002073|Acquired Immunodeficiency Syndrome
1524880|NCT00002073|Anemia
1524881|NCT00002073|Zidovudine
1524882|NCT00002072|Recombinant Proteins
1524883|NCT00002072|Erythropoietin
1524884|NCT00002072|Acquired Immunodeficiency Syndrome
1524885|NCT00002072|Anemia
1524886|NCT00002072|Zidovudine
1524887|NCT00002071|Recombinant Proteins
1524888|NCT00002071|Erythropoietin
1524889|NCT00002071|Acquired Immunodeficiency Syndrome
1524890|NCT00002071|Anemia
1524891|NCT00002071|Zidovudine
1524892|NCT00002070|Recombinant Proteins
1524893|NCT00002070|Retinitis
1524894|NCT00002070|AIDS-Related Opportunistic Infections
1524895|NCT00002070|Neutropenia
1524896|NCT00002070|Ganciclovir
1524897|NCT00002070|Drug Therapy, Combination
1524898|NCT00002070|Granulocyte-Macrophage Colony-Stimulating Factor
1524899|NCT00002070|Cytomegalovirus Infections
1524900|NCT00002070|Acquired Immunodeficiency Syndrome
1524901|NCT00002069|Ditiocarb
1524902|NCT00002069|Acquired Immunodeficiency Syndrome
1524903|NCT00002069|AIDS-Related Complex
1524904|NCT00002068|AIDS-Related Opportunistic Infections
1524905|NCT00002068|Meningitis
1524906|NCT00002068|Cryptococcosis
1524907|NCT00002068|Drug Therapy, Combination
1524908|NCT00002068|Fluconazole
1524909|NCT00002068|Flucytosine
1524910|NCT00002068|Acquired Immunodeficiency Syndrome
1524911|NCT00002068|Amphotericin B
1524912|NCT00002067|Body Weight
1524913|NCT00002067|T-Lymphocytes
1524914|NCT00002067|Nutritional Status
1524915|NCT00002067|Megestrol
1524916|NCT00002067|Acquired Immunodeficiency Syndrome
1524917|NCT00002067|Anorexia
1524918|NCT00002067|Cachexia
1524919|NCT00002067|Energy Intake
1524920|NCT00002066|Thymopentin
1524921|NCT00002066|Acquired Immunodeficiency Syndrome
1524922|NCT00002065|Delayed-Action Preparations
1524923|NCT00002065|Disulfiram
1524924|NCT00002065|Acquired Immunodeficiency Syndrome
1524925|NCT00002065|AIDS-Related Complex
1524926|NCT00002064|Sulfonamides
1524927|NCT00002064|Toxoplasmosis
1524928|NCT00002064|AIDS-Related Opportunistic Infections
1524929|NCT00002064|Pyrimethamine
1524930|NCT00002064|Drug Therapy, Combination
1524931|NCT00002064|Encephalitis
1524932|NCT00002064|Acquired Immunodeficiency Syndrome
1524933|NCT00002064|Clindamycin
1524934|NCT00002063|Immune Tolerance
1524935|NCT00002063|AIDS-Related Complex
1524936|NCT00002063|Zidovudine
1524937|NCT00002062|Spiramycin
1524938|NCT00002062|AIDS-Related Opportunistic Infections
1524939|NCT00002062|Immune Tolerance
1524940|NCT00002062|Cryptosporidiosis
1524941|NCT00002062|Diarrhea
1524942|NCT00002062|Drugs, Investigational
1524943|NCT00002062|Acquired Immunodeficiency Syndrome
1524944|NCT00002061|T-Lymphocytes
1524945|NCT00002061|Immune Tolerance
1524946|NCT00002061|Inosine Pranobex
1524947|NCT00002061|Killer Cells
1524948|NCT00002061|T-Lymphocytes, Helper-Inducer
1524949|NCT00002061|Acquired Immunodeficiency Syndrome
1524950|NCT00002061|AIDS-Related Complex
1524951|NCT00002060|AIDS-Related Opportunistic Infections
1524952|NCT00002060|Inosine Pranobex
1524953|NCT00002060|Homosexuality
1524954|NCT00002060|Acquired Immunodeficiency Syndrome
1524955|NCT00002060|AIDS-Related Complex
1524956|NCT00002059|T-Lymphocytes, Suppressor-Effector
1524957|NCT00002059|Neoplasms
1524958|NCT00002059|Inosine Pranobex
1524959|NCT00002059|Killer Cells
1524960|NCT00002059|T-Lymphocytes, Helper-Inducer
1524961|NCT00002059|Acquired Immunodeficiency Syndrome
1524962|NCT00002059|AIDS-Related Complex
1524963|NCT00002058|AIDS-Related Opportunistic Infections
1524964|NCT00002058|Mycobacterium avium-intracellulare Infection
1524965|NCT00002058|Clofazimine
1524966|NCT00002058|Acquired Immunodeficiency Syndrome
1524967|NCT00002057|Nystatin
1524968|NCT00002057|AIDS-Related Opportunistic Infections
1524969|NCT00002057|Acquired Immunodeficiency Syndrome
1524970|NCT00002057|AIDS-Related Complex
1524971|NCT00002057|Candidiasis, Oral
1524972|NCT00002056|Trimethoprim-Sulfamethoxazole Combination
1524973|NCT00002056|AIDS-Related Opportunistic Infections
1524974|NCT00002056|Pneumonia, Pneumocystis carinii
1524975|NCT00002056|Pentamidine
1524976|NCT00002056|Injections, Intravenous
1524977|NCT00002056|Administration, Oral
1524978|NCT00002056|Aerosols
1524979|NCT00002056|Acquired Immunodeficiency Syndrome
1524980|NCT00002055|AIDS-Related Opportunistic Infections
1524981|NCT00002055|Pneumonia, Pneumocystis carinii
1524982|NCT00002055|Pentamidine
1524983|NCT00002055|Dose-Response Relationship, Drug
1524984|NCT00002055|Aerosols
1524985|NCT00002055|Acquired Immunodeficiency Syndrome
1524986|NCT00002054|AIDS-Related Opportunistic Infections
1524987|NCT00002054|Pneumonia, Pneumocystis carinii
1524988|NCT00002054|Pentamidine
1524989|NCT00002054|Dose-Response Relationship, Drug
1524990|NCT00002054|Acquired Immunodeficiency Syndrome
1524991|NCT00002053|AIDS-Related Opportunistic Infections
1524992|NCT00002053|Pneumonia, Pneumocystis carinii
1524993|NCT00002053|Pentamidine
1524994|NCT00002053|Acquired Immunodeficiency Syndrome
1524995|NCT00002052|Salmonella Infections
1524996|NCT00002052|AIDS-Related Opportunistic Infections
1525113|NCT00002027|Diarrhea
1524997|NCT00002052|Acquired Immunodeficiency Syndrome
1524998|NCT00002052|Amoxicillin
1524999|NCT00002052|Ceftriaxone
1525000|NCT00002051|Thymopentin
1525001|NCT00002051|Acquired Immunodeficiency Syndrome
1525002|NCT00002050|Semen
1525003|NCT00002050|Thymopentin
1525004|NCT00002050|Leukocytes, Mononuclear
1525005|NCT00002050|AIDS-Related Complex
1525006|NCT00002049|Semen
1525007|NCT00002049|Thymopentin
1525008|NCT00002049|Leukocytes, Mononuclear
1525009|NCT00002049|HIV Seropositivity
1525010|NCT00002049|AIDS-Related Complex
1525011|NCT00002048|Acquired Immunodeficiency Syndrome
1525012|NCT00002048|Zidovudine
1525013|NCT00002047|Kidney Failure, Chronic
1525014|NCT00002047|Acquired Immunodeficiency Syndrome
1525015|NCT00002047|AIDS-Related Complex
1525016|NCT00002047|Zidovudine
1525017|NCT00002047|Renal Dialysis
1525018|NCT00002046|Acquired Immunodeficiency Syndrome
1525019|NCT00002046|AIDS-Related Complex
1525020|NCT00002046|Zidovudine
1525021|NCT00002045|Prospective Studies
1525022|NCT00002045|Zidovudine
1525023|NCT00002044|Pilot Projects
1525024|NCT00002044|Neuromuscular Diseases
1525025|NCT00002044|Drug Evaluation
1525026|NCT00002044|Acquired Immunodeficiency Syndrome
1525027|NCT00002044|AIDS Dementia Complex
1525028|NCT00002044|AIDS-Related Complex
1525029|NCT00002044|Zidovudine
1525030|NCT00002043|AIDS-Related Opportunistic Infections
1525031|NCT00002043|Pneumonia, Pneumocystis carinii
1525032|NCT00002043|Leukoplakia, Oral
1525033|NCT00002043|Dapsone
1525034|NCT00002043|AIDS-Related Complex
1525035|NCT00002043|Candidiasis, Oral
1525036|NCT00002042|Recombinant Proteins
1525037|NCT00002042|Erythropoietin
1525038|NCT00002042|Acquired Immunodeficiency Syndrome
1525039|NCT00002042|Anemia
1525040|NCT00002042|AIDS-Related Complex
1525041|NCT00002042|Zidovudine
1525042|NCT00002041|AIDS-Related Opportunistic Infections
1525043|NCT00002041|Esophagitis
1525044|NCT00002041|Acquired Immunodeficiency Syndrome
1525045|NCT00002041|Amphotericin B
1525046|NCT00002041|Candidiasis, Oral
1525047|NCT00002040|AIDS-Related Opportunistic Infections
1525048|NCT00002040|Meningitis
1525049|NCT00002040|Injections, Intravenous
1525050|NCT00002040|Cryptococcosis
1525051|NCT00002040|Fluconazole
1525052|NCT00002040|Administration, Oral
1525053|NCT00002040|Acquired Immunodeficiency Syndrome
1525054|NCT00002039|Retinitis
1525055|NCT00002039|AIDS-Related Opportunistic Infections
1525056|NCT00002039|Drug Therapy, Combination
1525057|NCT00002039|Foscarnet
1525058|NCT00002039|Cytomegalovirus Infections
1525059|NCT00002039|Acquired Immunodeficiency Syndrome
1525060|NCT00002039|Antiviral Agents
1525061|NCT00002039|Zidovudine
1525062|NCT00002038|Mycoses
1525063|NCT00002038|Drugs, Investigational
1525064|NCT00002038|Fluconazole
1525065|NCT00002037|AIDS-Related Opportunistic Infections
1525066|NCT00002037|Mycobacterium avium-intracellulare Infection
1525067|NCT00002037|Interferon-gamma, Recombinant
1525068|NCT00002037|Acquired Immunodeficiency Syndrome
1525069|NCT00002036|Acquired Immunodeficiency Syndrome
1525070|NCT00002036|AIDS-Related Complex
1525071|NCT00002036|Immunization, Passive
1525072|NCT00002035|Didanosine
1525073|NCT00002035|Acquired Immunodeficiency Syndrome
1525074|NCT00002035|AIDS-Related Complex
1525075|NCT00002035|Zidovudine
1525076|NCT00002034|Retinitis
1525077|NCT00002034|AIDS-Related Opportunistic Infections
1525078|NCT00002034|Ganciclovir
1525079|NCT00002034|Drug Interactions
1525080|NCT00002034|Cytomegalovirus Infections
1525081|NCT00002034|Acquired Immunodeficiency Syndrome
1525082|NCT00002034|Zidovudine
1525083|NCT00002033|Acquired Immunodeficiency Syndrome
1525084|NCT00002033|AIDS-Related Complex
1525085|NCT00002033|ammonium trichloro(dioxoethylene-O,O'-)tellurute
1525086|NCT00002033|Zidovudine
1525087|NCT00002032|Rifabutin
1525088|NCT00002032|AIDS-Related Opportunistic Infections
1525089|NCT00002032|Mycobacterium avium-intracellulare Infection
1525090|NCT00002032|Acquired Immunodeficiency Syndrome
1525091|NCT00002032|Antitubercular Agents
1525092|NCT00002031|Langerhans Cells
1525093|NCT00002031|Dinitrochlorobenzene
1525094|NCT00002031|Acquired Immunodeficiency Syndrome
1525095|NCT00002031|AIDS-Related Complex
1525096|NCT00002030|AIDS-Related Opportunistic Infections
1525097|NCT00002030|Pneumonia, Pneumocystis carinii
1525098|NCT00002030|Pentamidine
1525099|NCT00002030|Aerosols
1525100|NCT00002030|Acquired Immunodeficiency Syndrome
1525101|NCT00002029|Weight Loss
1525102|NCT00002029|Parenteral Nutrition, Total
1525103|NCT00002029|AIDS-Related Opportunistic Infections
1525104|NCT00002029|Liposyn
1525105|NCT00002029|Acquired Immunodeficiency Syndrome
1525106|NCT00002028|Didanosine
1525107|NCT00002028|Drugs, Investigational
1525108|NCT00002028|Acquired Immunodeficiency Syndrome
1525109|NCT00002028|AIDS-Related Complex
1525110|NCT00002028|Zidovudine
1525111|NCT00002027|AIDS-Related Opportunistic Infections
1525112|NCT00002027|Cryptosporidiosis
1525114|NCT00002027|diclazuril
1525115|NCT00002027|Coccidiostats
1525116|NCT00002027|Acquired Immunodeficiency Syndrome
1525117|NCT00002026|AIDS-Related Opportunistic Infections
1525118|NCT00002026|Leukoplakia, Oral
1525119|NCT00002026|Herpesvirus 4, Human
1525120|NCT00002026|Acyclovir
1525121|NCT00002026|AIDS-Related Complex
1525122|NCT00002025|Retinitis
1525123|NCT00002025|AIDS-Related Opportunistic Infections
1525124|NCT00002025|Immune Tolerance
1525125|NCT00002025|Injections, Intravenous
1525126|NCT00002025|Ganciclovir
1525127|NCT00002025|Cytomegalovirus Infections
1525128|NCT00002025|Acquired Immunodeficiency Syndrome
1525129|NCT00002024|AIDS-Related Opportunistic Infections
1525130|NCT00002024|Immune Tolerance
1525131|NCT00002024|Ganciclovir
1525132|NCT00002024|Drugs, Investigational
1525133|NCT00002024|Cytomegalovirus Infections
1525134|NCT00002024|Acquired Immunodeficiency Syndrome
1525135|NCT00002023|Dose-Response Relationship, Drug
1525136|NCT00002023|Acquired Immunodeficiency Syndrome
1525137|NCT00002023|AIDS-Related Complex
1525138|NCT00002023|Zidovudine
1525139|NCT00002022|Recombinant Proteins
1525140|NCT00002022|Drugs, Investigational
1525141|NCT00002022|Erythropoietin
1525142|NCT00002022|Acquired Immunodeficiency Syndrome
1525143|NCT00002022|Anemia
1525144|NCT00002022|Zidovudine
1525145|NCT00002021|AIDS-Related Opportunistic Infections
1525146|NCT00002021|Immune Tolerance
1525147|NCT00002021|Injections, Intravenous
1525148|NCT00002021|Herpes Simplex
1525149|NCT00002021|Immunity, Cellular
1525150|NCT00002021|Foscarnet
1525151|NCT00002021|Acquired Immunodeficiency Syndrome
1525152|NCT00002021|Antiviral Agents
1525153|NCT00002020|Acquired Immunodeficiency Syndrome
1525154|NCT00002020|AIDS-Related Complex
1525155|NCT00002020|Zidovudine
1525156|NCT00002019|Meningitis
1525157|NCT00002019|Liposomes
1525158|NCT00002019|Cryptococcosis
1525159|NCT00002019|Acquired Immunodeficiency Syndrome
1525160|NCT00002019|Amphotericin B
1525161|NCT00002019|Chemistry, Pharmaceutical
1525162|NCT00002018|Interferon Type I
1525163|NCT00002017|Polyethylene Glycols
1525164|NCT00002017|Interleukin-2
1525165|NCT00002016|Retinitis
1525166|NCT00002016|Ganciclovir
1525167|NCT00002016|Cytomegalovirus
1525168|NCT00002016|Cytomegalovirus Infections
1525169|NCT00002016|Acquired Immunodeficiency Syndrome
1525170|NCT00002016|Antibodies, Monoclonal
1525171|NCT00002015|Retinitis
1525172|NCT00002015|Ganciclovir
1525173|NCT00002015|Cytomegalovirus Infections
1525174|NCT00002015|Acquired Immunodeficiency Syndrome
1525175|NCT00002015|Immunocompromised Host
1525176|NCT00002014|Didanosine
1525177|NCT00002014|Drug Evaluation
1525178|NCT00002014|Zidovudine
1525179|NCT00002013|Drug Therapy, Combination
1525180|NCT00002013|Acquired Immunodeficiency Syndrome
1525181|NCT00002013|AIDS-Related Complex
1525182|NCT00002013|ammonium trichloro(dioxoethylene-O,O'-)tellurute
1525183|NCT00002013|Zidovudine
1525184|NCT00002012|Acquired Immunodeficiency Syndrome
1525185|NCT00002012|AIDS-Related Complex
1525186|NCT00002012|Interferon Type I, Recombinant
1525187|NCT00002011|PUVA Therapy
1525188|NCT00002011|Methoxsalen
1525189|NCT00002011|AIDS-Related Complex
1525190|NCT00002010|AIDS-Related Opportunistic Infections
1525191|NCT00002010|Meningitis
1525192|NCT00002010|Fluconazole
1525193|NCT00002010|Coccidioidin
1525194|NCT00002010|Acquired Immunodeficiency Syndrome
1525195|NCT00002010|Coccidioidomycosis
1525196|NCT00002009|Leukopenia
1525197|NCT00002009|Drug Evaluation
1525198|NCT00002009|Granulocyte-Macrophage Colony-Stimulating Factor
1525199|NCT00002008|Leukopenia
1525200|NCT00002008|Drug Evaluation
1525201|NCT00002008|Granulocyte-Macrophage Colony-Stimulating Factor
1525202|NCT00002007|Leukopenia
1525203|NCT00002007|Granulocyte-Macrophage Colony-Stimulating Factor
1525204|NCT00002007|Acquired Immunodeficiency Syndrome
1525205|NCT00002007|Zidovudine
1525206|NCT00002006|Neutropenia
1525207|NCT00002006|Drug Interactions
1525208|NCT00002006|Granulocyte-Macrophage Colony-Stimulating Factor
1525209|NCT00002006|Acquired Immunodeficiency Syndrome
1525210|NCT00002006|Zidovudine
1525211|NCT00002005|Acquired Immunodeficiency Syndrome
1525212|NCT00002005|Antigens, CD4
1525213|NCT00002005|AIDS-Related Complex
1525214|NCT00002004|Recombinant Proteins
1525215|NCT00002004|Acquired Immunodeficiency Syndrome
1525216|NCT00002004|Antigens, CD4
1525217|NCT00002004|AIDS-Related Complex
1525218|NCT00002003|Mitoxantrone
1525219|NCT00002003|Lymphoma, Large-Cell
1525220|NCT00002003|Etoposide
1525221|NCT00002003|Acquired Immunodeficiency Syndrome
1525222|NCT00002002|Trimethoprim-Sulfamethoxazole Combination
1525223|NCT00002002|AIDS-Related Opportunistic Infections
1525224|NCT00002002|Pneumonia, Pneumocystis carinii
1525225|NCT00002002|Acquired Immunodeficiency Syndrome
1525226|NCT00002001|Zalcitabine
1525227|NCT00002001|Didanosine
1525228|NCT00002001|Drug Therapy, Combination
1525229|NCT00002001|Acquired Immunodeficiency Syndrome
1525230|NCT00002001|Zidovudine
1525231|NCT00002000|Acyclovir
1525232|NCT00002000|Acquired Immunodeficiency Syndrome
1525233|NCT00002000|AIDS-Related Complex
1525234|NCT00002000|Antiviral Agents
1525235|NCT00002000|Anus Diseases
1525236|NCT00002000|Herpes Genitalis
1525237|NCT00001999|Retinitis
1525238|NCT00001999|Gamma-Globulins
1525239|NCT00001999|Ganciclovir
1525240|NCT00001999|Drug Therapy, Combination
1525241|NCT00001999|Cytomegalovirus Infections
1525242|NCT00001999|Acquired Immunodeficiency Syndrome
1525243|NCT00001999|Immunization, Passive
1525244|NCT00001998|Nystatin
1525245|NCT00001998|Acquired Immunodeficiency Syndrome
1525246|NCT00001998|AIDS-Related Complex
1525247|NCT00001997|Recombinant Proteins
1525248|NCT00001997|Polyethylene Glycols
1525249|NCT00001997|Interleukin-2
1525250|NCT00001997|Didanosine
1525251|NCT00001997|Zidovudine
1525252|NCT00001996|Trimethoprim-Sulfamethoxazole Combination
1525253|NCT00001996|Pneumonia, Pneumocystis carinii
1525254|NCT00001996|Pentamidine
1525255|NCT00001996|Acquired Immunodeficiency Syndrome
1525256|NCT00001996|atovaquone
1525257|NCT00001995|Rifabutin
1525258|NCT00001995|Mycobacterium avium-intracellulare Infection
1525259|NCT00001995|Acquired Immunodeficiency Syndrome
1525260|NCT00001994|Toxoplasmosis
1525261|NCT00001994|AIDS-Related Opportunistic Infections
1525262|NCT00001994|Naphthoquinones
1525263|NCT00001994|Encephalitis
1525264|NCT00001994|Acquired Immunodeficiency Syndrome
1525265|NCT00001993|Drug Therapy, Combination
1525266|NCT00001993|Zidovudine
1525267|NCT00001992|Vaccines, Synthetic
1525268|NCT00001992|Drug Evaluation
1525269|NCT00001992|Acquired Immunodeficiency Syndrome
1525270|NCT00001992|AIDS Vaccines
1525271|NCT00001991|Trimethoprim-Sulfamethoxazole Combination
1525272|NCT00001991|Pneumonia, Pneumocystis carinii
1525273|NCT00001991|Antifungal Agents
1525274|NCT00001991|Acquired Immunodeficiency Syndrome
1525275|NCT00001991|atovaquone
1525276|NCT00001990|Trimethoprim-Sulfamethoxazole Combination
1525277|NCT00001990|Pneumonia, Pneumocystis carinii
1525278|NCT00001990|Pentamidine
1525279|NCT00001990|Antifungal Agents
1525280|NCT00001990|Acquired Immunodeficiency Syndrome
1525281|NCT00001990|atovaquone
1525282|NCT00001989|Trichosanthin
1525283|NCT00001989|Drug Evaluation
1525284|NCT00001989|Drug Therapy, Combination
1525285|NCT00001989|Acquired Immunodeficiency Syndrome
1525286|NCT00001989|AIDS-Related Complex
1525287|NCT00001989|Antiviral Agents
1525288|NCT00001989|Zidovudine
1525289|NCT00001987|Diabetes Mellitus
1525290|NCT00001987|Severe Insulin Resistance
1525291|NCT00001987|Type B Insulin Resistance
1525292|NCT00001986|Alcohol
1525293|NCT00001986|Octanol
1525294|NCT00001986|Treatment
1525295|NCT00001986|Tremor
1525296|NCT00001985|Diabetes
1525297|NCT00001985|Gene
1525298|NCT00001984|Immunosuppression
1525299|NCT00001984|Tolerance
1525300|NCT00001984|DSG
1525301|NCT00001984|Alemtuzumab
1525302|NCT00001983|Questionnaires
1525303|NCT00001983|Eligibility
1525304|NCT00001983|History
1525305|NCT00001983|Physical Examination
1525306|NCT00001983|Tests
1525307|NCT00001983|Fibromyalgia
1525308|NCT00001982|Aminotransferases
1525309|NCT00001982|Anti-HCV
1525310|NCT00001982|Blood Donors
1525311|NCT00001982|HCV RNA
1525312|NCT00001982|Hepatitis C
1525313|NCT00001982|Liver Biopsy
1525314|NCT00001982|Serum Aminotransferases
1525315|NCT00001982|Transfusion
1525316|NCT00001981|Somatostatin Analogue
1525317|NCT00001981|Acromegaly
1525318|NCT00001981|TSH Producing Tumor
1525319|NCT00001981|Islet Cell Tumor
1525320|NCT00001981|Ursodeoxycholate
1525321|NCT00001981|Pituitary
1525322|NCT00001981|Irradiation
1525323|NCT00001981|Treatment
1525324|NCT00001979|Kidney Disease
1525325|NCT00001979|Autoimmune Diseases
1525326|NCT00001979|Nephrotic Syndrome
1525327|NCT00001978|Kidney Disease
1525328|NCT00001978|Kidney Function Tests
1525329|NCT00001978|Proteinuria
1525330|NCT00001977|Alzheimer's Disease
1525331|NCT00001977|Attention
1525332|NCT00001977|Brain
1525333|NCT00001977|Functional Magnetic Resonance Imaging
1525334|NCT00001977|Physostigmine
1525335|NCT00001977|Positron Emission Tomography
1525336|NCT00001977|Working Memory
1525337|NCT00001976|CMV
1525338|NCT00001976|Infection
1525339|NCT00001976|Comparison
1525340|NCT00001976|Observational
1525341|NCT00001976|Cytomegalovirus
1525342|NCT00001976|RT-PCR
1525343|NCT00001975|Skin Biopsy
1525344|NCT00001975|Familial Tumor Syndrome
1525345|NCT00001975|Cell Growth
1525346|NCT00001975|Loss of Heterozygosity
1525347|NCT00001975|Cytokines
1525348|NCT00001975|Tuberous Sclerosis
1525349|NCT00001973|G Protein Mutation
1525350|NCT00001973|McCune-Albright Syndrome
1525351|NCT00001973|Fibrous Dysplasia
1525352|NCT00001973|Mutation
1525353|NCT00001973|Pathology
1525354|NCT00001973|Immunohistochemistry
1525355|NCT00001973|PCR
1525356|NCT00001973|In Situ Hybridization
1525357|NCT00001973|Juvenile Dermatomyositis
1525358|NCT00001973|Calcinosis
1525359|NCT00001972|Alzheimer's Disease
1525360|NCT00001972|Positron Emission Tomography
1525361|NCT00001972|Brain Phospholipid
1525362|NCT00001972|Fatty Acids
1525363|NCT00001972|11C Arachidonate
1525364|NCT00001972|Signal Transduction
1525365|NCT00001972|Brain
1525366|NCT00001971|Hepatitis B
1525367|NCT00001971|Hepatitis C
1525368|NCT00001971|Hepatitis D
1525369|NCT00001971|Chronic Cholestatic Syndromes
1525370|NCT00001971|Primary Biliary Cirrhosis
1525371|NCT00001971|Primary Sclerosing Cholangitis
1525372|NCT00001971|Non-Alcoholic Steatohepatitis
1525373|NCT00001971|Wilson's Disease
1525374|NCT00001971|Hemochromatosis
1525375|NCT00001971|Liver Biopsy
1525376|NCT00001971|Noncirrhotic Portal Hypertension
1525377|NCT00001971|Liver Disease
1525378|NCT00001969|Cardiovascular Disease
1525379|NCT00001969|Glucose Clamp
1525380|NCT00001969|Hypercortisolism
1525381|NCT00001969|Insulin Sensitivity
1525382|NCT00001969|Major Depression Disorder
1525383|NCT00001969|Inflammation
1525384|NCT00001969|Coagulation
1525385|NCT00001969|Metabolic
1525386|NCT00001969|Insulin
1525387|NCT00001969|Cytokine
1525388|NCT00001969|Depression
1525389|NCT00001969|Volunteer
1525390|NCT00001969|Healthy Volunteer
1525391|NCT00001968|AIDS
1525392|NCT00001968|Anti-Retroviral Therapy
1525393|NCT00001968|Drug Interactions
1525394|NCT00001968|HIV
1525395|NCT00001968|Protease Inhibitor
1525396|NCT00001967|HIV
1525397|NCT00001967|HAART
1525398|NCT00001967|Immunity
1525399|NCT00001967|Toxicity
1525400|NCT00001967|Resistance
1525401|NCT00001967|Treatment Interruption
1525402|NCT00001966|Adjustment
1525403|NCT00001966|Alternative
1525404|NCT00001966|Anxiety
1525405|NCT00001966|Guided-Imagery
1525406|NCT00001966|Meditation
1525407|NCT00001966|Ehlers-Danlos Syndrome
1525408|NCT00001965|Calcineurin
1525409|NCT00001965|Cardiac Hypertrophy
1525410|NCT00001965|Hypertrophic Cardiomyopathy
1525411|NCT00001964|Hematopoiesis
1525412|NCT00001964|Bone Marrow Failure
1525413|NCT00001964|Aplastic Anemia
1525414|NCT00001963|Blood Flow
1525415|NCT00001963|Exercise
1525416|NCT00001963|Microcirculation
1525417|NCT00001963|S-nitrosohemoglobin
1525418|NCT00001963|Vasodilation
1525419|NCT00001963|Healthy Volunteer
1525420|NCT00001962|Immunosuppression
1525421|NCT00001962|T-cells
1525422|NCT00001962|Hematopoiesis
1525423|NCT00001962|Monoclonal Antibody Therapy
1525424|NCT00001962|Immunosuppressive Therapy
1525425|NCT00001962|Aplastic Anemia
1525426|NCT00001961|Myocardial Infarction
1525427|NCT00001961|Coronary Artery Disease
1525428|NCT00001961|Adenosine
1525429|NCT00001961|Stress Testing
1525430|NCT00001961|Perfusion
1525431|NCT00001960|HCM
1525432|NCT00001960|Pediatric
1525433|NCT00001960|Pacemaker
1525434|NCT00001960|Treatment
1525435|NCT00001960|Symptoms
1525436|NCT00001959|Fibrosis
1525437|NCT00001959|Nephrotic Syndrome
1525438|NCT00001959|Proteinuria
1525439|NCT00001959|Renal Failure
1525440|NCT00001959|TGF-Beta
1525441|NCT00001959|Focal Segmental Glomerulosclerosis
1525442|NCT00001959|FSGS
1525443|NCT00001958|Gamma Gene
1525444|NCT00001958|Hemoglobin Switching
1525445|NCT00001958|Erythropoiesis
1525446|NCT00001958|HbE Hemoglobin Chain Synthesis Imbalance
1525447|NCT00001958|Cooley's Anemia
1525448|NCT00001958|Beta-Thalassemia Intermedia
1525449|NCT00001957|Ostoacoustic Emission
1525450|NCT00001957|Central Auditory Processing
1525451|NCT00001957|CAPD
1525452|NCT00001957|Medial Olivocochlear Bundle
1525453|NCT00001957|Speech Impediment
1525454|NCT00001956|Genetic Markers
1525455|NCT00001956|Thermal Pain
1525456|NCT00001956|Hyperalgesia
1525457|NCT00001956|Oral Surgery
1525458|NCT00001956|Cold Pain
1525459|NCT00001956|Peripheral Nerve
1525460|NCT00001956|Allodynia
1525461|NCT00001956|Spinal Cord
1525462|NCT00001956|Personality Traits
1525463|NCT00001956|Pain Ratings
1525464|NCT00001955|Clinical Trial
1525465|NCT00001955|Temporomandibular Joints
1525466|NCT00001955|Celecoxib
1525467|NCT00001955|Etanercept
1525468|NCT00001955|Tumor Necrosis Factor
1525469|NCT00001955|TMJ
1525470|NCT00001955|TMD
1525471|NCT00001954|Clinical Trial
1525472|NCT00001954|Autoimmune
1525473|NCT00001954|Disease Activity
1525474|NCT00001954|Cytokine
1525475|NCT00001954|Saliva
1525476|NCT00001954|Xerostomia
1525477|NCT00001954|Salivary Glands
1525478|NCT00001954|Sjogren's Syndrome
1525479|NCT00001953|Endocrine System
1525480|NCT00001953|Autoimmunity
1525481|NCT00001953|Salivary Glands
1525482|NCT00001953|Glucose Tolerance Test
1525483|NCT00001953|Growth Hormone
1525484|NCT00001953|Somatostatin
1525485|NCT00001953|Sjogren's Syndrome
1525486|NCT00001952|Fentanyl
1525487|NCT00001952|Intraosseous-Anesthesia
1525488|NCT00001952|Endodontics
1525489|NCT00001952|Denti Patch
1525490|NCT00001952|Pain
1525491|NCT00001952|Chronic Inflammation
1525492|NCT00001951|Bone
1525493|NCT00001951|Cognition
1525494|NCT00001951|Estrogen
1525495|NCT00001951|Mood
1525496|NCT00001951|Testosterone
1525497|NCT00001951|Osteoporosis
1525498|NCT00001951|Ovarian Failure
1525499|NCT00001951|Hormone Replacement Therapy
1525500|NCT00001951|POF
1525501|NCT00001951|Premature Ovarian Failure
1525502|NCT00001950|Cognition
1525503|NCT00001950|Infancy
1525504|NCT00001950|Perception
1525505|NCT00001948|Human Immunodeficiency Virus
1525506|NCT00001948|Symptom Distress
1525507|NCT00001948|Immune Function
1525508|NCT00001948|Medication Trial
1525509|NCT00001948|Physical Symptoms
1525510|NCT00001946|Magnetic Resonance Angiography
1525511|NCT00001946|Gadolinium
1525512|NCT00001946|Suburban Hospital
1525513|NCT00001946|Atherosclerosis
1525514|NCT00001944|Drug Resistance
1525515|NCT00001944|MDR-1
1525516|NCT00001944|P-Glycoprotein Blocker
1525517|NCT00001944|Pgp
1525518|NCT00001944|Resistance Reversal
1525519|NCT00001941|Interleukin-2 Receptor alpha chain
1525520|NCT00001941|Interleukin-2
1525521|NCT00001941|HTLV-I
1525522|NCT00001941|Adult T-Cell Leukemia (ATL)
1525523|NCT00001941|Monoclonal Antibody (Daclizumab, Zenapax)
1525524|NCT00001940|Antifungal Agent
1525525|NCT00001940|Aspergillosis
1525526|NCT00001940|Candidemia
1525527|NCT00001940|Fungemia
1525528|NCT00001938|Ovarian Cancer
1525529|NCT00001938|Proteomics
1525530|NCT00001937|Aspergillosis
1525531|NCT00001937|Candidiasis
1525532|NCT00001937|Fungal Infections
1525533|NCT00001937|Fungemia
1525534|NCT00001937|Prophylactic Antifungal Therapy
1525535|NCT00001936|Neuromuscular Stimulation
1525536|NCT00001936|Laryngeal Elevation
1525537|NCT00001936|Dysphagia
1525538|NCT00001936|Stroke
1525539|NCT00001936|Neuroprosthesis
1525540|NCT00001936|Dysphonia
1525541|NCT00001936|Aspiration
1525542|NCT00001936|Motor Control
1525543|NCT00001936|Videofluoroscopy
1525544|NCT00001936|Upper Esophageal Sphincter
1525545|NCT00001936|Healthy Volunteer
1525546|NCT00001936|Swallowing Disorders
1525547|NCT00001934|Multiple Sclerosis
1525548|NCT00001934|Immunotherapy
1525549|NCT00001934|MRI
1525550|NCT00001933|Acetylcholine
1525551|NCT00001933|Clinical Trial
1525552|NCT00001933|GABA
1525553|NCT00001933|Cognition
1525554|NCT00001933|Nicotine
1525555|NCT00001932|Epilepsy
1525556|NCT00001932|Temporal Lobe
1525557|NCT00001932|Blood Flow
1525558|NCT00001932|Metabolism
1525559|NCT00001932|Localization
1525560|NCT00001931|Continuous Stimulation
1525561|NCT00001931|Dose Finding
1525562|NCT00001931|Skin Patch
1525563|NCT00001930|Amantadine
1525564|NCT00001930|Chorea
1525565|NCT00001930|Glutamate Antagonist
1525566|NCT00001929|Dyskinesias
1525567|NCT00001929|Glutamate Antagonist
1525568|NCT00001929|Levodopa
1525569|NCT00001928|Diagnosis
1525570|NCT00001928|Infusion
1525571|NCT00001928|Parkinsonism
1525572|NCT00001927|Factor V Leiden
1525573|NCT00001927|Prothrombin Mutation
1525574|NCT00001927|Antiphospholipids
1525575|NCT00001927|Cerebral Infarction
1525576|NCT00001927|Thrombophilia
1525577|NCT00001927|Porencephaly
1525578|NCT00001927|Perinatal Stroke
1525579|NCT00001927|Healthy Mothers
1525580|NCT00001927|Healthy Children
1525581|NCT00001926|Plasticity
1525582|NCT00001926|Magnetic Stimulation
1525583|NCT00001926|PET
1525584|NCT00001926|Blind
1525585|NCT00001926|Braille
1525586|NCT00001926|Transcranial Magnetic Stimulation
1525587|NCT00001925|Inferior Olives
1525588|NCT00001925|Calcium Channels
1525589|NCT00001925|Accelerometry
1525590|NCT00001925|Electromyography
1525591|NCT00001925|Palatal Tremor
1525592|NCT00001923|Pain
1525593|NCT00001923|Amputee
1525594|NCT00001923|Phantom Limb
1525595|NCT00001923|Amputation
1525596|NCT00001923|Magnetic Stimulation
1525597|NCT00001923|Phantom
1525598|NCT00001922|Evoked Response
1525599|NCT00001922|Spasmodic Dysphonia
1525600|NCT00001922|Aerodynamic
1525601|NCT00001922|Vibration
1525602|NCT00001922|Laryngeal
1525603|NCT00001922|Voice Disorders
1525604|NCT00001922|Laryngeal Brainstem Evoked Responses
1525605|NCT00001922|Long-latency Responses
1525606|NCT00001922|Muscular Tension Dysphonia
1525607|NCT00001921|Functional Connectivity
1525608|NCT00001921|Frontotemporal Interaction
1525609|NCT00001921|Electrophysiology
1525610|NCT00001921|Functional Magnetic Resonance Imaging
1525611|NCT00001921|Healthy Subjects
1525612|NCT00001921|Schizophrenia
1525613|NCT00001921|MEG
1525614|NCT00001921|Neuroimaging
1525615|NCT00001921|EEG
1525616|NCT00001921|MRI
1525617|NCT00001920|Schizophrenia
1525618|NCT00001920|Eyeblink
1525619|NCT00001920|Evoked Potentials
1525620|NCT00001920|Learning
1525621|NCT00001920|Normal Volunteer
1525622|NCT00001920|Healthy Volunteer
1525623|NCT00001919|Mechanism of Action
1525624|NCT00001919|BCIT-SPECT
1525625|NCT00001919|St. John's Wort
1525626|NCT00001919|Hypericum Perforatum
1525627|NCT00001919|Depression
1525628|NCT00001919|Serotonin
1525629|NCT00001919|Dopamine Transporter
1525630|NCT00001919|SPECT
1525631|NCT00001919|Brain Disorders
1525632|NCT00001918|Cognitive Function
1525633|NCT00001918|Depression
1525634|NCT00001918|EMG
1525635|NCT00001918|Eosinophilia Myalgia Syndrome
1525636|NCT00001918|Impurities
1525637|NCT00001918|L-5-HTP
1525638|NCT00001918|Memory Impairment
1525639|NCT00001918|Nerve-Muscle Biopsy
1525640|NCT00001918|Sleep Disorders
1525641|NCT00001917|Positron Emission Tomography
1525642|NCT00001917|Physostigmine
1525643|NCT00001917|Visual Stimulation
1525644|NCT00001917|Cholinergic Stimulation
1525645|NCT00001917|[F-18] FP-TZIP
1525646|NCT00001917|Aging
1525647|NCT00001917|Alzheimer's Disease
1525648|NCT00001917|Visual Activation
1525649|NCT00001916|Bone Remodeling
1525650|NCT00001916|Corticosteroids
1525651|NCT00001916|Cytokine
1525652|NCT00001916|Depression
1525653|NCT00001916|Glucocorticoids
1525654|NCT00001916|Osteopenia
1525655|NCT00001916|Osteoporosis
1525656|NCT00001916|Primary Affective Disorder
1525657|NCT00001915|Cortical Stimulation
1525658|NCT00001915|Motor Control
1525659|NCT00001915|Neuromotor Maturation
1525660|NCT00001915|Magnetic Stimulation
1525661|NCT00001915|Attention Deficit Hyperactivity Disorder
1525662|NCT00001915|Hearing Loss
1525663|NCT00001915|Hearing Conservation
1525664|NCT00001915|Hearing Protective Devices
1525665|NCT00001915|Safety Study
1525666|NCT00001915|Noise Induced Hearing Loss
1525667|NCT00001915|Normal Volunteer
1525668|NCT00001913|Visual Processing
1525669|NCT00001913|Functional Magnetic Resonance Imaging
1525670|NCT00001913|Maternal Behavior
1525671|NCT00001913|Attachment
1525672|NCT00001913|Bereavement
1525673|NCT00001912|Cysticercosis
1525674|NCT00001912|T. Solium
1525675|NCT00001912|MRI
1525676|NCT00001912|Seizures
1525677|NCT00001912|Calcified Cysts
1525678|NCT00001912|Taenia
1525679|NCT00001911|Cytokine
1525680|NCT00001911|Interferon Gamma
1525681|NCT00001911|Pulmonary
1525682|NCT00001911|Disseminated
1525683|NCT00001911|Refractory
1525684|NCT00001911|Mycobacterial Infection
1525685|NCT00001911|Nontuberculosis Mycobacterial Infection
1525686|NCT00001911|Pulmonary Nontuberculous Mycobacterial Infection
1525687|NCT00001910|T Cells
1525688|NCT00001910|Allergy
1525689|NCT00001910|Asthma
1525690|NCT00001910|Cytokine
1525691|NCT00001910|Vaccine
1525692|NCT00001909|Allergy
1525693|NCT00001909|Immunomodulator
1525694|NCT00001909|Inflammation
1525695|NCT00001909|Interleukin
1525696|NCT00001909|Th2
1525697|NCT00001909|Asthma
1525698|NCT00001908|Allergy
1525699|NCT00001908|Interleukin
1525700|NCT00001908|Immunomodulator
1525701|NCT00001908|Th2
1525702|NCT00001908|Inflammation
1525703|NCT00001908|Asthma
1525704|NCT00001906|Alum
1525705|NCT00001906|Antigen
1525706|NCT00001906|Cytokine
1525707|NCT00001906|Parasitic Infection
1525708|NCT00001906|Phase I
1525709|NCT00001906|Cutaneous Leishmaniasis
1525710|NCT00001905|Neutrophil
1525711|NCT00001905|Immunodeficiency
1525712|NCT00001905|Cytokine
1525713|NCT00001905|Treatment
1525714|NCT00001905|Trafficking
1525715|NCT00001905|Leukocyte Adhesion Deficiency Type I
1525716|NCT00001905|LAD I
1525717|NCT00001904|Atherosclerosis
1525718|NCT00001904|Cardiovascular Disease
1525719|NCT00001904|Computerized Edge Reader
1525720|NCT00001904|Myocardial Infarction
1525721|NCT00001904|Risk Factor
1525722|NCT00001903|Immunization
1525723|NCT00001903|Immunocompromised
1525724|NCT00001903|Immunoglobulin
1525725|NCT00001903|Prophylaxis
1525726|NCT00001903|Respiratory Virus
1525727|NCT00001903|Bone Marrow Transplantation
1525728|NCT00001903|Mini-Transplantation
1525729|NCT00001903|Peripheral Stem Cell Transplantation
1525730|NCT00001901|Vasculitis
1525731|NCT00001901|Prednisone-sparing
1525732|NCT00001901|Methotrexate
1525733|NCT00001901|Tumor Necrosis Factor
1525734|NCT00001901|Remission
1525735|NCT00001901|Wegener's Granulomatosis
1525736|NCT00001899|Viral Suppression
1525737|NCT00001899|Latency
1525738|NCT00001899|AIDS Therapy
1525739|NCT00001899|Viral Relapse
1525740|NCT00001899|Immunodeficiency
1525741|NCT00001899|HIV
1525742|NCT00001899|Treatment Interruption
1525743|NCT00001898|Melanoma
1525744|NCT00001898|Breast Cancer
1525745|NCT00001898|Gene Expression
1525746|NCT00001898|DNA Chip Technology
1525747|NCT00001898|Expressed Sequence Tags
1525748|NCT00001895|Electromechanical Mapping
1525749|NCT00001895|Myocardial Viability
1525750|NCT00001895|Myocardial Ischemia
1525751|NCT00001895|Positron Emission Tomography
1525752|NCT00001895|Magnetic Resonance Imaging
1525753|NCT00001894|HCM
1525754|NCT00001894|Alcohol
1525755|NCT00001894|Septal Ablation
1525756|NCT00001894|Pacemaker
1525757|NCT00001893|Bronchoprovocation
1525758|NCT00001893|Airway Inflammation
1525759|NCT00001893|Tumor Necrosis Factor
1525760|NCT00001893|Bronchoalveolar Lavage
1525761|NCT00001893|Pulmonary Function Test
1525762|NCT00001893|Asthma
1525763|NCT00001891|CABG
1525764|NCT00001891|Hibernation
1525765|NCT00001891|LV Function
1525766|NCT00001891|Microbubbles
1525767|NCT00001891|Revascularization
1525768|NCT00001891|Coronary Artery Disease
1525769|NCT00001890|Cellular Immunity
1525770|NCT00001890|Cytokines
1525771|NCT00001890|Estrogen
1525772|NCT00001890|Humoral Immunity
1525773|NCT00001890|Progesterone
1525774|NCT00001890|Chlamydia Pneumoniae
1525775|NCT00001890|Human Cytomegalovirus
1525776|NCT00001890|Postmenopause
1525777|NCT00001889|Microbubbles
1525778|NCT00001889|Myocardial Blood Flow
1525779|NCT00001889|Myocardial Ischemia
1525780|NCT00001889|Second Harmonics
1525781|NCT00001889|Ultrasound
1525782|NCT00001889|Coronary Artery Disease
1525790|NCT00001887|Airway Inflammation
1525791|NCT00001887|Allergen Challenge
1525792|NCT00001887|Bronchoscopy
1525793|NCT00001887|Cytokines
1525794|NCT00001887|Receptors
1525795|NCT00001887|Asthma
1525796|NCT00001887|Normal Volunteer
1525797|NCT00001886|Coronary Artery Disease
1525798|NCT00001886|Ischemia
1525799|NCT00001886|Ultrasound
1525800|NCT00001886|Ventricular Function
1525801|NCT00001886|Wall Motion
1525802|NCT00001885|Interstitial Lung Disease
1525803|NCT00001885|Inherited Disease
1525804|NCT00001885|Genetic Markers
1525805|NCT00001885|Alpha 1 Protease Inhibitor
1525806|NCT00001885|DNA Mutations
1525807|NCT00001885|Rheumatoid Arthritis
1525808|NCT00001885|Pulmonary Fibrosis
1525809|NCT00001885|Normal Volunteer
1525810|NCT00001884|Bronchoscopy
1525811|NCT00001884|Idiopathic Pulmonary Fibrosis
1525812|NCT00001884|Proteases
1525813|NCT00001884|Fibroblast Proliferation
1525814|NCT00001884|Reactive Proteins
1525815|NCT00001884|Rheumatoid Arthritis
1525816|NCT00001884|Pulmonary Fibrosis
1525817|NCT00001883|Treadmill
1525818|NCT00001883|Bicycle
1525819|NCT00001883|Lung Function
1525820|NCT00001883|Physiology
1525821|NCT00001883|Quality Control
1525822|NCT00001883|Normal Volunteers
1525823|NCT00001881|Cardiac Hypertrophy
1525824|NCT00001881|Genetics
1525825|NCT00001881|Phenotypes
1525826|NCT00001881|Hypertrophic Cardiomyopathy
1525827|NCT00001880|Graft-Versus-Tumor
1525828|NCT00001880|Peripheral Blood Stem Cells
1525829|NCT00001880|Non-Myeloablative Bone Marrow Transplantation
1525830|NCT00001880|Metastatic Solid Tumors
1525831|NCT00001880|Engraftment
1525832|NCT00001880|Cyclophosphamide
1525833|NCT00001880|Fludarabine
1525834|NCT00001880|Donor Apheresis
1525835|NCT00001880|Graft-Versus-Host Disease
1525836|NCT00001880|Cancer
1525837|NCT00001880|Tumor
1525838|NCT00001879|Liver Disease
1525839|NCT00001879|Novel Agents
1525840|NCT00001879|Serum
1525841|NCT00001879|Viruses
1525842|NCT00001879|non-A,G Hepatitis
1525843|NCT00001879|Seronegative Acute Hepatitis
1525844|NCT00001878|Growth Hormone
1525845|NCT00001878|Cardiac Hypertrophy
1525846|NCT00001878|Hypertrophic Cardiomyopathy
1525847|NCT00001878|Sarcomeric Gene Mutations
1525848|NCT00001877|Tumor Necrosis Factor
1525849|NCT00001877|Corticosteroids
1525850|NCT00001877|Macrophages
1525851|NCT00001877|Phosphodiesterase
1525852|NCT00001877|Autoimmune
1525853|NCT00001877|Pulmonary Sarcoidosis
1525854|NCT00001876|Interstitial Lung Disease
1525855|NCT00001876|Collagen Vascular Disease
1525856|NCT00001876|Extracellular Matrix
1525857|NCT00001876|Pulmonary Function
1525858|NCT00001876|DTPA Lung Clearance Scan
1525859|NCT00001876|Rheumatoid Arthritis
1525860|NCT00001876|Pulmonary Fibrosis
1525861|NCT00001876|Idiopathic Pulmonary Fibrosis
1525862|NCT00001874|Imaging
1525863|NCT00001874|Spectroscopy
1525864|NCT00001874|MRI
1525865|NCT00001874|Cardiovascular
1525866|NCT00001874|Technical Development
1525867|NCT00001874|Safety
1525868|NCT00001874|Gadolinium
1525869|NCT00001874|Heart
1525870|NCT00001874|Toxicity
1525871|NCT00001874|Adverse Events
1525872|NCT00001874|Normal Volunteer
1525873|NCT00001873|Peripheral Blood Stem Cells
1525874|NCT00001873|Cyclosporine
1525875|NCT00001873|Cyclosphosphamide
1525876|NCT00001873|Whole Body Irradiation
1525877|NCT00001873|Donor Apheresis
1525878|NCT00001873|Leukemic Relapse
1525879|NCT00001873|Graft vs. Host Disease
1525880|NCT00001873|Graft-Versus-Leukemia
1525881|NCT00001873|Graft-Versus-Myeloma
1525882|NCT00001873|Chronic Myelogenous Leukemia
1525883|NCT00001873|Acute Lymphoblastic Leukemia
1525884|NCT00001873|Acute Myelogenous Leukemia
1525885|NCT00001873|Myelodysplastic Syndromes
1525886|NCT00001873|Multiple Myeloma
1525887|NCT00001873|Chronic Lymphocytic Leukemia
1525888|NCT00001873|Non-Hodgkin's Lymphoma
1525889|NCT00001872|Volunteer
1525890|NCT00001872|Leukocyte Donors
1525891|NCT00001872|Family Members
1525892|NCT00001872|Leukocyte Collection
1525893|NCT00001872|No Reimbursement
1525894|NCT00001871|Genetic Mutations
1525895|NCT00001871|Hypertrophic Cardiomyopathy
1525896|NCT00001871|Oculopharyngeal Muscular Dystrophy
1525897|NCT00001870|Insulin Resistance
1525898|NCT00001870|Oxidative Stress
1525899|NCT00001870|Antioxidant
1525900|NCT00001870|Endothelial Function
1525901|NCT00001870|Glucose Clamp
1525902|NCT00001870|Type 2 Diabetes
1525903|NCT00001870|Vitamin C Deficiency
1525904|NCT00001869|Progesterone
1525905|NCT00001869|Pulmonary Function Tests
1525906|NCT00001869|Pneumothorax
1525907|NCT00001869|Oopherectomy
1525908|NCT00001869|High Resolution CT
1525909|NCT00001869|Tuberous Sclerosis Complex
1525910|NCT00001869|Lymphangioleiomyomatosis (LAM)
1525911|NCT00001867|Cytokine
1525912|NCT00001867|Gestation
1525913|NCT00001867|Postpartum
1525914|NCT00001867|Pregnancy
1525915|NCT00001867|Th 1 Lymphocyte
1525916|NCT00001867|Th 2 Lymphocyte
1525917|NCT00001867|Uveitis
1525918|NCT00001866|Eye Movements
1525919|NCT00001866|Eye Oscillations
1525920|NCT00001866|Extraocular Muscles
1525921|NCT00001866|Eye Development
1525922|NCT00001866|Pediatric Ophthalmology
1525923|NCT00001866|Congenital Nystagmus
1525924|NCT00001865|Behcet's
1525925|NCT00001865|Monoclonal Antibody
1525926|NCT00001865|Uveitis
1525927|NCT00001865|Interleukin 2
1525928|NCT00001865|Retinal Vasculitis
1525929|NCT00001865|Hyopyon
1525930|NCT00001865|Interleukin 2 Receptor
1525931|NCT00001865|Bechet's Disease
1525932|NCT00001865|Ocular Disease
1525933|NCT00001864|Lazy Eye
1525934|NCT00001864|Atropine Penalization
1525935|NCT00001864|Patching
1525936|NCT00001864|Vision Loss
1525937|NCT00001864|Amblyopia
1525938|NCT00001863|Immunosuppression
1525939|NCT00001863|Inflammation
1525940|NCT00001863|Eye
1525941|NCT00001863|Vision
1525942|NCT00001863|Medication
1525943|NCT00001863|Uveitis
1525944|NCT00001863|Leflunomide
1525945|NCT00001863|Vitritis
1525946|NCT00001862|Ocular Inflammation
1525947|NCT00001862|Children
1525948|NCT00001862|Immunotherapy
1525949|NCT00001862|Cytokine
1525950|NCT00001862|Clinical Trial
1525951|NCT00001862|Uveitis
1525952|NCT00001862|Immunosuppression
1525953|NCT00001862|Joint
1525954|NCT00001862|Inflammation
1525955|NCT00001861|Eye Movements
1525956|NCT00001861|Amblyopia
1525957|NCT00001861|Orthoptics
1525958|NCT00001861|Lazy Eye
1525959|NCT00001861|Eye Development
1525960|NCT00001861|Nystagmus
1525961|NCT00001861|Strabismus
1525962|NCT00001861|Screening Protocol
1525963|NCT00001861|Eye Movement Disorders
1525964|NCT00001860|Growth Hormone
1525965|NCT00001860|Somatostatin
1525966|NCT00001860|Insulin-like Growth Factor-One
1525967|NCT00001860|Acromegaly
1525968|NCT00001860|Macroadenoma
1525969|NCT00001859|Evaluation
1525970|NCT00001859|Diabetes
1525971|NCT00001859|Renal Failure
1525972|NCT00001858|Biopsy
1525973|NCT00001858|Immune System
1525974|NCT00001858|Renal
1525975|NCT00001857|Costimulation
1525976|NCT00001857|Immunosuppression
1525977|NCT00001857|Tolerance
1525978|NCT00001856|Living Donor
1525979|NCT00001856|Transplantation
1525980|NCT00001856|Nephrectomy
1525981|NCT00001854|Ribavirin
1525982|NCT00001854|Liver Disease
1525983|NCT00001854|Antiviral Agent
1525984|NCT00001854|Cirrhosis
1525985|NCT00001854|Chronic Hepatitis
1525986|NCT00001854|Iron
1525987|NCT00001854|Viral Hepatitis
1525988|NCT00001854|Hepatitis C Virus
1525989|NCT00001854|Hemolytic Anemia
1525990|NCT00001854|Hemolysis
1525991|NCT00001853|Healthy Volunteers
1525992|NCT00001853|Health Disparities
1525993|NCT00001853|Diabetes
1525994|NCT00001853|Cardiovascular Disease
1525995|NCT00001852|Xerostomia
1525996|NCT00001852|Oral Dryness
1525997|NCT00001852|Salivary Function
1525998|NCT00001851|Marrow
1525999|NCT00001851|Grafting
1526000|NCT00001851|Imaging
1526001|NCT00001851|Injection
1526002|NCT00001851|Aspiration
1526003|NCT00001851|Bone Marrow Stromal Cells
1526004|NCT00001851|Bone Grafting
1526005|NCT00001851|Bone Graft Substitutes
1526006|NCT00001851|Bio and Pharmacological Regulators of Bone Turnover
1526007|NCT00001850|Training
1526008|NCT00001850|Reproduction
1526009|NCT00001850|Infertility
1526010|NCT00001850|Women's Health
1526011|NCT00001850|Hormone
1526012|NCT00001849|PET
1526013|NCT00001849|(18F)-DOPA
1526014|NCT00001849|Pentetreotide
1526015|NCT00001849|ACTH
1526016|NCT00001849|Octreotide
1526017|NCT00001849|Cushing's Syndrome
1526018|NCT00001849|Ectopic Cushing Syndrome
1526019|NCT00001848|Estrogen Receptor
1526020|NCT00001848|Laparoscopy
1526021|NCT00001848|Surgical Excision
1526022|NCT00001848|Raloxifene
1526023|NCT00001848|Selective Estrogen Receptor Modulator
1526024|NCT00001848|Estrogen
1526025|NCT00001848|Endometriosis
1526026|NCT00001848|Pelvic Pain
1526027|NCT00001846|Volunteer Donor
1526028|NCT00001846|Research Samples
1526029|NCT00001846|Leukapheresis
1526030|NCT00001846|Plateletpheresis
1526031|NCT00001846|Plasmapheresis
1526032|NCT00001846|Healthy Volunteer
1526033|NCT00001846|Normal Volunteer
1526034|NCT00001845|MRI
1526035|NCT00001845|Cerebral Blood Flow
1526036|NCT00001845|CO2 Inhalation
1526037|NCT00001845|Acetazolamide
1526038|NCT00001845|Perfusion
1526039|NCT00001845|Healthy Volunteer
1526040|NCT00001844|MRI/MRS
1526041|NCT00001844|Functional MRI
1526042|NCT00001844|Metabolic Imaging
1526043|NCT00001844|Brain
1526044|NCT00001844|Healthy Volunteer
1526045|NCT00001842|Granulocytes
1526046|NCT00001842|Granulocyte Colony Stimulating Factor
1526047|NCT00001842|Granulocyte Transfusion Factor
1526048|NCT00001842|Apheresis
1526049|NCT00001842|Blood Donors
1526050|NCT00001842|Healthy Volunteer
1526051|NCT00001841|Arteriosclerosis
1526052|NCT00001841|Imaging
1526053|NCT00001841|MRA
1526054|NCT00001841|Narrowing of Vessels
1526055|NCT00001841|Hardening of Arteries
1526056|NCT00001840|Infarct
1526057|NCT00001840|Ischemia
1526058|NCT00001840|MRI
1526059|NCT00001840|Natural History
1526060|NCT00001840|Stroke
1526061|NCT00001840|Treatment
1526062|NCT00001840|Brain Stroke
1526063|NCT00001839|Anemia
1526064|NCT00001839|Immunosuppressive
1526065|NCT00001839|Phase II Trial
1526066|NCT00001839|Pre-Leukemia
1526067|NCT00001839|Therapy
1526068|NCT00001839|Myelodysplastic Syndrome
1526069|NCT00001837|Sonohysterography
1526070|NCT00001837|Color Doppler Sonography
1526071|NCT00001837|Endometrium
1526072|NCT00001837|Gynecologic
1526073|NCT00001837|Menstrual Cycle
1526074|NCT00001837|Premenopause
1526075|NCT00001836|Coronary Artery Disease
1526076|NCT00001836|EBCT
1526077|NCT00001836|Volumetric Scan
1526078|NCT00001836|Coronary Artery Calcium
1526079|NCT00001836|Prospective Gating
1526080|NCT00001835|Renal Dysfunction
1526081|NCT00001835|Pharmacokinetics
1526082|NCT00001835|Platinum Analogues
1526083|NCT00001835|Renal Cancer
1526084|NCT00001835|Kidney Cancer
1526085|NCT00001832|Immunotherapy
1526086|NCT00001832|Adoptive Transfer
1526087|NCT00001832|IL-2
1526088|NCT00001832|Toxicity
1526089|NCT00001832|Clinical Response
1526090|NCT00001832|Breast Cancer
1526091|NCT00001830|Bone Marrow Transplantation
1526092|NCT00001830|Chronic Lymphocytic Leukemia
1526093|NCT00001830|Immunotherapy
1526094|NCT00001830|Lymphoma
1526095|NCT00001830|Multiple Myeloma
1526096|NCT00001830|Graft vs. Host Disease
1526097|NCT00001830|Lymphoid Malignancy
1526098|NCT00001830|Leukemia
1526099|NCT00001827|Immunotherapy
1526100|NCT00001827|Cancer
1526101|NCT00001827|Oncogenes
1526102|NCT00001827|T-cells
1526103|NCT00001827|Vaccine Therapy
1526104|NCT00001827|p53 Peptide
1526105|NCT00001827|Ovarian Cancer
1526106|NCT00001826|CD-4-Naive T Cells
1526107|NCT00001826|CD-4-Memory T Cells
1526108|NCT00001826|Antiviral Activity
1526109|NCT00001826|VB Repertoire
1526110|NCT00001826|Immunizations
1526111|NCT00001826|HIV
1526112|NCT00001826|Treatment Experienced
1526118|NCT00001818|Antiretrovirals
1526119|NCT00001818|Resistant Virus
1526120|NCT00001818|T-cell activation
1526121|NCT00001818|Immune Suppression
1526122|NCT00001818|Cytotoxic Agent
1526123|NCT00001816|Anger
1526124|NCT00001816|Loneliness
1526125|NCT00001816|Mood
1526126|NCT00001816|Psychosocial
1526127|NCT00001816|Virtual Network
1526128|NCT00001814|Hereditary
1526129|NCT00001814|Kidney
1526130|NCT00001814|MET
1526131|NCT00001814|Oncocytoma
1526132|NCT00001814|VHL
1526133|NCT00001813|Xeroderma Pigmentosum
1526134|NCT00001813|Trichothiodystrophy
1526135|NCT00001813|Cockayne Syndrome
1526136|NCT00001813|Skin Cancer
1526137|NCT00001813|DNA Repair
1526138|NCT00001812|Mucositis
1526139|NCT00001812|Oral Candidiasis
1526140|NCT00001812|Prophylaxis
1526141|NCT00001812|Stomatitis
1526142|NCT00001812|Swish and Swallow
1526143|NCT00001810|Antifungal Agent
1526144|NCT00001810|Aspergillosis
1526145|NCT00001810|Candidiasis
1526146|NCT00001810|Fungemia
1526147|NCT00001807|CNS directed therapy
1526148|NCT00001807|Neurotoxicity
1526149|NCT00001807|H-NMRS
1526150|NCT00001807|MRI
1526151|NCT00001806|Genetic Testing
1526152|NCT00001806|Genetic Counseling
1526153|NCT00001806|BRCA1/BRCA2
1526154|NCT00001806|Genetic Education
1526155|NCT00001806|Informed Consent
1526156|NCT00001806|Breast Cancer
1526157|NCT00001806|Ovarian Cancer
1526158|NCT00001806|Known Family Mutation
1526159|NCT00001805|Breast Cancer
1526160|NCT00001805|Colon Cancer
1526161|NCT00001805|Gastric Cancer
1526162|NCT00001805|Lung Cancer
1526163|NCT00001805|Pancreatic Cancer
1526164|NCT00001803|Gene-Environment Interaction
1526165|NCT00001803|Kidney Cancer
1526166|NCT00001803|VHL
1526167|NCT00001803|Genetic Epidemiology
1526168|NCT00001797|Cytokines
1526169|NCT00001797|Immunomodulation
1526170|NCT00001797|Inflammation
1526171|NCT00001797|Skin
1526172|NCT00001797|Therapy
1526173|NCT00001790|Aspergillosis
1526174|NCT00001790|Candidiasis
1526175|NCT00001790|Empiric Therapy
1526176|NCT00001790|Fungal Infection
1526177|NCT00001790|Fungemia
1526178|NCT00001789|Autoantibody
1526179|NCT00001789|Autoimmunity
1526180|NCT00001789|Inflammation
1526181|NCT00001789|Kidney
1526182|NCT00001789|Lymphocyte
1526183|NCT00001789|Proliferative Lupus Glomerulonephritis
1526184|NCT00001789|SLE-GN
1526185|NCT00001788|Cytokine
1526186|NCT00001788|Stat
1526187|NCT00001788|Jak
1526188|NCT00001788|IL-12
1526189|NCT00001788|Mutation
1526190|NCT00001788|Immunodeficiency
1526191|NCT00001785|HTLV-1-Associated Myelopathy
1526192|NCT00001785|Virus
1526193|NCT00001785|Spontaneous Proliferation
1526194|NCT00001784|Blepharospasm
1526195|NCT00001784|Writer's Cramp
1526196|NCT00001784|Muscle Spindle Afferents
1526197|NCT00001784|Sodium Channels
1526198|NCT00001784|Sensorimotor Integration
1526199|NCT00001784|Focal Dystonia
1526200|NCT00001783|Rehabilitation
1526201|NCT00001783|Plasticity
1526202|NCT00001783|Stroke
1526203|NCT00001783|Amphetamine
1526204|NCT00001783|Motor
1526205|NCT00001783|Hemiparetic
1526206|NCT00001783|Thromboembolic Non-Hemorrhagic Infarction
1526207|NCT00001782|Deafness
1526208|NCT00001782|Hemisphere Dominance
1526209|NCT00001782|Language
1526210|NCT00001782|Plasticity
1526211|NCT00001782|Speech
1526212|NCT00001782|rTMS
1526213|NCT00001781|Multiple Sclerosis
1526214|NCT00001781|Immunology
1526215|NCT00001781|Treatment
1526216|NCT00001780|Myelopathy
1526217|NCT00001780|Demyelination
1526218|NCT00001780|Leukodystrophy
1526219|NCT00001780|Motor Neuron Disease
1526220|NCT00001780|Movement Disorders
1526221|NCT00001780|Normal Volunteer
1526229|NCT00001777|Frontal Lobe Dementia
1526230|NCT00001777|Serotonergic Transmission
1526231|NCT00001776|Magnetic Stimulation
1526232|NCT00001776|Plasticity
1526233|NCT00001776|SRTT
1526234|NCT00001776|Sequence
1526235|NCT00001776|Implicit Memory
1526236|NCT00001776|Explicit Memory
1526237|NCT00001776|Memory
1526238|NCT00001776|Parkinson's Disease
1526239|NCT00001776|Cerebellar Deficit
1526240|NCT00001776|Frontal Lobe Lesions
1526241|NCT00001776|Frontal Lobe Dementia
1526242|NCT00001776|Normal Volunteer
1526243|NCT00001774|Acetylcholine
1526244|NCT00001774|Blood Flow
1526245|NCT00001774|Blood vessel
1526246|NCT00001774|Resistance
1526247|NCT00001774|Sodium Nitroprusside
1526248|NCT00001774|Fabry Disease
1526249|NCT00001774|Normal Volunteer
1526250|NCT00001772|Bipolar Disorder
1526251|NCT00001772|Rapid Cycling
1526252|NCT00001772|Screening
1526253|NCT00001771|Receptors
1526254|NCT00001771|Re-Uptake
1526255|NCT00001771|Neurotransmitters
1526256|NCT00001771|Neuroimaging
1526257|NCT00001771|Drug Abuse
1526258|NCT00001771|Serotonin
1526259|NCT00001771|Brain Scan
1526260|NCT00001771|Tourette's Syndrome
1526261|NCT00001771|Obsessive Compulsive Disorder
1526262|NCT00001771|Schizophrenia
1526263|NCT00001771|Normal Volunteer
1526264|NCT00001770|Depression
1526265|NCT00001770|Estrogen
1526266|NCT00001770|Hormone Replacement Therapy
1526267|NCT00001770|Mood
1526268|NCT00001770|Progestin
1526269|NCT00001770|Progesterone
1526270|NCT00001770|Anxiety
1526271|NCT00001768|Autoimmunity
1526272|NCT00001768|Childhood Onset Schizophrenia
1526273|NCT00001768|Intravenous Gammaglobulin
1526274|NCT00001766|Abacavir
1526275|NCT00001766|Salvage
1526276|NCT00001766|Drug Interaction
1526277|NCT00001766|Drug Levels
1526278|NCT00001766|Anti-Viral
1526279|NCT00001766|HIV
1526280|NCT00001765|Engraftment
1526281|NCT00001765|Minitransplant
1526282|NCT00001765|Fludarabine
1526283|NCT00001765|Neutrophil
1526284|NCT00001765|Allogenic
1526285|NCT00001765|Donor Apheresis
1526286|NCT00001765|Anti-Thymocyte Globin
1526287|NCT00001765|Cyclophosphamide
1526288|NCT00001765|Nonmyeloablative Bone Marrow Transplantation
1526289|NCT00001765|Graft-versus-host Disease
1526290|NCT00001765|Chronic Granulomatous Disease
1526291|NCT00001764|Alternative agent
1526292|NCT00001764|Purine Antimetabolite
1526293|NCT00001764|Immunosuppressive
1526294|NCT00001764|Previous relapse
1526295|NCT00001764|Drug Intolerance
1526296|NCT00001764|Wegener's Granulomatosis
1526297|NCT00001763|AIDS
1526298|NCT00001763|Cell Mediated Immunity
1526299|NCT00001763|Cytokine
1526300|NCT00001763|MAC
1526301|NCT00001763|Thl Response
1526302|NCT00001762|Protease Inhibitor
1526303|NCT00001762|HIV Infection
1526304|NCT00001762|Appearance
1526305|NCT00001762|Subcutaneous Fat
1526306|NCT00001762|Facial Wasting
1526307|NCT00001761|Autoimmunity
1526308|NCT00001761|Cytokine
1526309|NCT00001761|Inflammation
1526310|NCT00001761|Interleukin
1526311|NCT00001761|Vasculitis
1526312|NCT00001761|Wegener's Granulomatosis
1526313|NCT00001760|Stem Cell Factor
1526314|NCT00001760|Cytokine
1526315|NCT00001760|Chemokines
1526316|NCT00001760|Chemotaxis
1526317|NCT00001760|Mast Cells
1526318|NCT00001760|Normal Volunteer
1526319|NCT00001760|Systemic Mastocytosis
1526320|NCT00001760|Atopic Dermatitis
1526321|NCT00001759|Allergy
1526322|NCT00001759|Fluorodeoxyglucose
1526323|NCT00001759|Imaging
1526324|NCT00001759|PET
1526325|NCT00001759|Wegener's Granulomatosis
1526326|NCT00001759|Asthma
1526327|NCT00001758|Antiretroviral
1526328|NCT00001758|HIV-1
1526329|NCT00001758|1592U89
1526330|NCT00001758|141W94
1526331|NCT00001758|DMP 266
1526332|NCT00001757|Azole
1526333|NCT00001757|Immunocompromised
1526334|NCT00001757|Mycosis
1526335|NCT00001757|Invasive Fungal Infection
1526336|NCT00001757|Systemic Fungal Infection
1526337|NCT00001756|Leukapheresis
1526338|NCT00001756|Mastocytosis
1526339|NCT00001756|G-CSF
1526340|NCT00001756|Mast Cells
1526341|NCT00001756|Normal Volunteer
1526342|NCT00001756|Systemic Mastocytosis
1526343|NCT00001754|Dwarfism
1526344|NCT00001754|Gene Mapping
1526345|NCT00001754|Linkage
1526346|NCT00001754|Mutation Analysis
1526347|NCT00001754|Skeletal Biology
1526348|NCT00001754|Brachydactyly Types C & E
1526349|NCT00001754|Cartilage-Hair Hypoplasia
1526350|NCT00001754|Ellis Van Crevald
1526351|NCT00001754|FgFR-3
1526352|NCT00001754|Proximal Symphalangism
1526353|NCT00001754|Pyknodysotosis
1526354|NCT00001754|Schmid Metaphyseal
1526355|NCT00001754|Short Stature
1526356|NCT00001754|Skeletal Dysplasia
1526357|NCT00001754|Type II Collagen Disorder
1526358|NCT00001753|Exercise
1526359|NCT00001753|MRI
1526360|NCT00001753|MRS
1526361|NCT00001753|Normal Volunteer
1526362|NCT00001753|Tibialix Anterior
1526363|NCT00001752|Adhesion Molecules
1526364|NCT00001752|Endothelial Function
1526365|NCT00001752|Inflammation
1526366|NCT00001752|Lipoproteins
1526367|NCT00001752|Nitric Oxide
1526368|NCT00001752|Hormone Therapy
1526369|NCT00001752|Postmenopausal Women
1526370|NCT00001750|G-CSF
1526371|NCT00001750|Cell-Cycle
1526372|NCT00001750|Stem Cell
1526373|NCT00001750|Apheresis
1526374|NCT00001750|Melphalan
1526375|NCT00001750|Gene Transfer
1526376|NCT00001750|Retroviral Receptor
1526377|NCT00001750|Stem Cell Expansion
1526378|NCT00001750|Multiple Myeloma
1526379|NCT00001749|Immune Suppression
1526380|NCT00001749|Erythroid Hypoplasia
1526381|NCT00001749|Congenital Anemia
1526382|NCT00001749|Reticulocytopenia
1526383|NCT00001749|Diamond Blackfan Anemia
1526384|NCT00001748|Cyclophosphamide
1526385|NCT00001748|Donor Apheresis
1526386|NCT00001748|Graft vs. Host Disease
1526387|NCT00001748|Graft-Versus-Leukemia
1526388|NCT00001748|Leukemic Relapse
1526389|NCT00001748|Myeloma
1526390|NCT00001748|Peripheral Blood Stem Cells
1526391|NCT00001748|Whole Body Irradiation
1526392|NCT00001748|Acute Lymphoblastic Leukemia (ALL)
1526393|NCT00001748|Chronic Lymphocytic Leukemia (CLL)
1526394|NCT00001748|Chronic Myelogenous Leukemia (CML)
1526395|NCT00001748|Hematological Malignancies
1526396|NCT00001748|Myelodysplastic Syndrome
1526397|NCT00001748|Myeloproliferative Disorders
1526398|NCT00001747|Brachial Artery
1526399|NCT00001747|Doppler
1526400|NCT00001747|Endothelium
1526401|NCT00001747|Nitric Oxide
1526402|NCT00001747|Nitroglycerin
1526403|NCT00001747|Normal Volunteer
1526404|NCT00001746|Hypertrophic Cardiomyopathy
1526405|NCT00001746|HCM
1526406|NCT00001746|Evaluation for Research
1526407|NCT00001746|Medical Advice
1526408|NCT00001742|Acetylcholine
1526409|NCT00001742|Aspirin
1526410|NCT00001742|Nitric Oxide
1526411|NCT00001742|Sodium Nitroprusside
1526412|NCT00001742|Hypercholesterolemia
1526413|NCT00001742|Hypertension
1526414|NCT00001741|Angiotensin II Receptor
1526415|NCT00001741|Polymorphism, Genetic
1526416|NCT00001741|Vascular Tone
1526417|NCT00001741|Angiotensin II
1526418|NCT00001741|Losartan
1526419|NCT00001740|Cardiac
1526420|NCT00001740|Function
1526421|NCT00001740|MRI
1526422|NCT00001740|Reconstruction
1526423|NCT00001740|Ultrasound
1526424|NCT00001740|Heart Disease (Cardiovascular Disease)
1526425|NCT00001738|Intermediate Uveitis
1526426|NCT00001738|Pars Planitis
1526427|NCT00001738|Retinal Vasculature
1526428|NCT00001738|Uveitis
1526429|NCT00001738|Vascular Permeability
1526430|NCT00001738|Vitreous
1526431|NCT00001737|Eye
1526432|NCT00001737|Immunosuppression
1526433|NCT00001737|Inflammation
1526434|NCT00001737|Therapy
1526435|NCT00001737|Vitreous
1526436|NCT00001737|Uveitis
1526437|NCT00001736|Corneal Crystals
1526438|NCT00001736|Cysteamine
1526439|NCT00001736|Cystinosis
1526440|NCT00001736|Eye
1526441|NCT00001735|Gene Therapy
1526442|NCT00001735|Graft
1526443|NCT00001735|Ornithine
1526444|NCT00001735|Retina
1526445|NCT00001735|Retinovirus
1526446|NCT00001735|Retrovirus
1526447|NCT00001735|Skin
1526448|NCT00001735|Gyrate Atrophy
1526449|NCT00001734|Uveitis
1526450|NCT00001734|Conjunctivitis
1526451|NCT00001734|Iritis
1526452|NCT00001734|Retinitis
1526453|NCT00001734|Keratitis
1526454|NCT00001734|Screening Protocol
1526455|NCT00001734|Ocular Immunology
1526456|NCT00001734|Inflammation
1526457|NCT00001734|Eye Inflammation
1526458|NCT00001733|Diabetic Retinopathy
1526459|NCT00001733|Age-Related Macular Degeneration
1526460|NCT00001733|Neovascularization
1526461|NCT00001733|Macular Degeneration
1526462|NCT00001733|Retinal Disease
1526463|NCT00001733|Diabetes
1526464|NCT00001732|Genetics
1526465|NCT00001732|Diagnosis
1526466|NCT00001732|Screening Protocol
1526467|NCT00001732|Ophthalmic Genetic Diseases
1526468|NCT00001732|Genetic Testing
1526469|NCT00001732|Family Studies
1526470|NCT00001731|Conjunctiva
1526471|NCT00001731|Dry Eyes
1526472|NCT00001731|Inflammation
1526473|NCT00001731|Lacrimal Gland
1526474|NCT00001731|T Lymphocyte
1526475|NCT00001731|Keratoconjunctivitis Sicca
1526476|NCT00001730|Ablation
1526477|NCT00001730|Activity-Time Curves
1526478|NCT00001730|Iodine Biokinetics
1526479|NCT00001730|Thyroid Carcinoma
1526480|NCT00001730|Thyroid Remnant
1526481|NCT00001729|Cirrhosis
1526482|NCT00001729|Liver Disease
1526483|NCT00001729|Hemolytic Anemia
1526484|NCT00001729|Liver Biopsy
1526485|NCT00001729|Ribavirin
1526486|NCT00001729|Alpha Interferon
1526487|NCT00001729|Viral Hepatitis
1526488|NCT00001729|Hepatitis C Virus
1526489|NCT00001729|Chronic Hepatitis
1526490|NCT00001729|Antiviral Agents
1526491|NCT00001728|Bone Marrow Stromal Cells
1526492|NCT00001728|Bone Turnover
1526493|NCT00001728|Fibrous Dysplastic Lesion
1526494|NCT00001728|Polyostotic Fibrous Dysplasia
1526495|NCT00001728|McCune-Albright Syndrome
1526496|NCT00001727|Fibrous Dysplasia (FD)
1526497|NCT00001727|McCune-Albright Syndrome
1526498|NCT00001727|Polyostotic Fibrous Dysplasia
1526499|NCT00001726|Bacterial Colonization
1526500|NCT00001726|Plaque
1526501|NCT00001726|Mouth
1526502|NCT00001726|Saliva
1526503|NCT00001726|Adhesion
1526504|NCT00001726|Dental Plaque Formation
1526505|NCT00001726|Dental Caries
1526506|NCT00001725|Trigeminal Neuralgia
1526507|NCT00001725|Dextromethorphan
1526508|NCT00001725|Topiramate
1526509|NCT00001725|Orofacial Pain
1526510|NCT00001725|Neuropathic Pain
1526511|NCT00001725|Facial Neuralgia
1526512|NCT00001724|Pain
1526513|NCT00001724|Microencapsulated Drug
1526514|NCT00001724|NSAID
1526515|NCT00001724|Acute Inflammation
1526516|NCT00001724|Peripheral Administration
1526517|NCT00001724|Dose-Response
1526518|NCT00001724|Relative Potency Assay
1526519|NCT00001724|Pharmacokinetics
1526520|NCT00001723|Dyslipidemia
1526521|NCT00001723|Race
1526522|NCT00001723|Body Fat
1526523|NCT00001723|Visceral Fat
1526524|NCT00001723|Sleep Apnea
1526525|NCT00001723|Fat-Soluble Vitamins
1526526|NCT00001723|Type 2 Diabetes
1526527|NCT00001723|Obesity
1526528|NCT00001723|Childhood Obesity
1526529|NCT00001722|Obesity
1526530|NCT00001722|Sympathetic Nervous System
1526531|NCT00001722|Fat Tissue
1526532|NCT00001722|Metabolism
1526533|NCT00001722|Adipose Tissue
1526534|NCT00001722|Microdialysis
1526535|NCT00001722|Leptin
1526536|NCT00001722|Lipolysis
1526537|NCT00001722|Normal Volunteer
1526544|NCT00001720|Glucocorticoids
1526545|NCT00001720|Bone Mineral Density
1526546|NCT00001720|Bisphosphonates
1526547|NCT00001720|Vertebral Fracture
1526548|NCT00001720|Childhood Osteoporosis
1526549|NCT00001719|Blood Flow
1526550|NCT00001719|Hepatic Disease
1526551|NCT00001719|Liver
1526552|NCT00001719|Modeling
1526553|NCT00001719|Rheology
1526554|NCT00001719|Normal Volunteer
1526555|NCT00001718|Biofeedback
1526556|NCT00001718|Swallowing
1526557|NCT00001718|Swallowing Therapy
1526558|NCT00001718|Tongue/Palate
1526559|NCT00001718|Ultrasound
1526560|NCT00001718|Dysphagia
1526561|NCT00001717|Compensation
1526562|NCT00001717|Motivations
1526563|NCT00001717|Volunteers
1526564|NCT00001717|HIV
1526565|NCT00001716|Hemoglobin
1526566|NCT00001716|P50
1526567|NCT00001716|Microvascular
1526568|NCT00001716|Perfusion
1526569|NCT00001716|Magnetic Resonance Imaging
1526570|NCT00001716|Sickle Cell Anemia
1526571|NCT00001715|Consultation
1526572|NCT00001715|Training
1526573|NCT00001715|Referral
1526574|NCT00001715|Fellowship Program
1526575|NCT00001715|Outpatient
1526576|NCT00001715|Blood Disorder
1526577|NCT00001714|MRI
1526578|NCT00001714|Macromolecules
1526579|NCT00001714|Magnetization Transfer
1526580|NCT00001714|Metabolites
1526581|NCT00001714|Tissue Characterization
1526582|NCT00001714|Normal Volunteer
1526583|NCT00001713|rtPA
1526584|NCT00001713|Catheter Directed
1526585|NCT00001713|Thrombolysis
1526586|NCT00001713|Anticoagulation
1526587|NCT00001713|Emboli
1526588|NCT00001713|Acute Deep Venous Thrombosis
1526589|NCT00001713|TPA
1526590|NCT00001713|DVT
1526591|NCT00001712|Healthcare Worker
1526592|NCT00001712|Bloodborne Diseases
1526593|NCT00001712|Hepatitis B
1526594|NCT00001712|Hepatitis C
1526595|NCT00001712|Human Immunodeficiency Virus
1526596|NCT00001712|Parenteral Exposure
1526597|NCT00001712|Non-Parenteral Exposure
1526598|NCT00001712|Blood and Body Substances
1526599|NCT00001712|Universal Precautions
1526600|NCT00001712|HIV Seronegativity
1526605|NCT00001705|Antigen
1526606|NCT00001705|Cancer
1526607|NCT00001705|Immunotherapy
1526608|NCT00001703|Immunotherapy
1526609|NCT00001703|Kidney
1526610|NCT00001703|Genes
1526611|NCT00001703|Vaccine Therapy
1526612|NCT00001703|Renal Cell Carcinoma
1526613|NCT00001702|Genetic
1526614|NCT00001702|Variant Alleles
1526615|NCT00001702|Risk Factor
1526616|NCT00001702|Cancer
1526617|NCT00001702|Transplantation
1526618|NCT00001701|Risk Factor
1526619|NCT00001701|Genetic
1526620|NCT00001701|Variant Alleles
1526621|NCT00001701|Cancer
1526622|NCT00001701|Transplantation
1526623|NCT00001699|AIDS
1526624|NCT00001699|Compliance
1526625|NCT00001699|HIV
1526626|NCT00001699|Medication
1526627|NCT00001699|Perceived Threat
1526628|NCT00001699|Teenagers
1526629|NCT00001698|Chemoprevention
1526630|NCT00001698|Direct Epithelial Delivery
1526631|NCT00001698|Tobacco-induced Cancer
1526632|NCT00001698|Field Cancerization
1526633|NCT00001696|Anti-metastatic
1526634|NCT00001696|Chemoprevention
1526635|NCT00001696|Isoflavinoid
1526636|NCT00001696|Prostate Cancer
1526637|NCT00001696|Signal Transduction
1526638|NCT00001695|Complementary Medicine
1526639|NCT00001695|Unproven Treatments
1526640|NCT00001695|Herbal
1526641|NCT00001693|Chemoprevention
1526642|NCT00001693|Biomarkers
1526643|NCT00001693|Endoscopy
1526644|NCT00001693|Colorectal
1526645|NCT00001693|Celecoxib
1526646|NCT00001689|Neurotoxicity
1526647|NCT00001689|A.L.L.
1526648|NCT00001689|Limited Sampling
1526649|NCT00001689|Dose Individualization
1526650|NCT00001689|Vinca Alkaloids
1526651|NCT00001688|CD4 Cells
1526652|NCT00001688|Cytokines
1526653|NCT00001688|Anti-Retroviral Activity
1526654|NCT00001688|V Beta Repertoire
1526655|NCT00001688|CD-4-Naive T Cells
1526656|NCT00001688|CD-4-Memory T Cells
1526657|NCT00001686|Leukemia
1526658|NCT00001686|Ewing's Sarcoma
1526659|NCT00001686|Neuroectodermal Tumors
1526660|NCT00001686|Osteosarcoma Lymphoma
1526661|NCT00001686|Rhabdomyosarcoma Brain Tumors
1526662|NCT00001686|Lymphoma
1526663|NCT00001686|Neoplasm
1526664|NCT00001686|Sarcoma
1526665|NCT00001685|Cancer
1526666|NCT00001685|IL-12
1526667|NCT00001685|IL-2
1526668|NCT00001685|Immunotherapy
1526669|NCT00001685|Vaccine
1526670|NCT00001683|Collagen Breakdown
1526671|NCT00001683|Pharmacokinetics
1526672|NCT00001683|Rapid Escalation Phase I
1526673|NCT00001683|Angiogenesis
1526674|NCT00001683|Tissue Inhibitors of Metalloproteinase
1526675|NCT00001681|Cytokines
1526676|NCT00001681|Gene Regulation
1526677|NCT00001681|Immunization
1526678|NCT00001681|Influenza
1526679|NCT00001681|Pathogenesis
1526680|NCT00001680|Double-masked
1526681|NCT00001680|Neuropathy
1526682|NCT00001680|Occlusive Dressing
1526683|NCT00001680|Pilot
1526684|NCT00001680|Placebo
1526685|NCT00001679|Immunogenetics
1526686|NCT00001679|Joint Damage
1526687|NCT00001679|Reactive Arthritis
1526688|NCT00001679|Rheumatoid Arthritis
1526689|NCT00001679|Synovium
1526690|NCT00001679|Synovitis
1526691|NCT00001678|Autoimmunity
1526692|NCT00001678|Sibling Pairs
1526693|NCT00001678|Genes
1526694|NCT00001678|Rheumatoid Arthritis
1526695|NCT00001678|Bone Erosion
1526696|NCT00001677|Immunosuppression
1526697|NCT00001677|Lymphocytes
1526698|NCT00001677|Magnetic Resonance
1526699|NCT00001677|Synovial Biopsy
1526700|NCT00001677|Synovitis
1526701|NCT00001677|Rheumatoid Arthritis
1526702|NCT00001676|Remission
1526703|NCT00001676|Renal Function
1526704|NCT00001676|Infection
1526705|NCT00001676|Germinal Center
1526706|NCT00001676|Immunoglobulin
1526707|NCT00001676|Glomerulonephritis
1526708|NCT00001676|Systemic Lupus Erythematosus
1526709|NCT00001676|Lupus Nephritis
1526710|NCT00001675|Brain Imaging
1526711|NCT00001675|Affect
1526712|NCT00001675|Limbic System
1526713|NCT00001675|Cerebral Blood Volume
1526714|NCT00001675|Alcoholism
1526715|NCT00001675|Emotion
1526716|NCT00001675|Brain
1526717|NCT00001675|Operant
1526718|NCT00001675|Autonomic
1526719|NCT00001675|Relapse
1526720|NCT00001675|Normal Volunteer
1526721|NCT00001673|Alcoholics
1526722|NCT00001673|Screening
1526723|NCT00001673|Healthy Volunteers
1526724|NCT00001673|Violent Abusers
1526725|NCT00001673|Illicit Drug Testing
1526726|NCT00001673|Blood Tests
1526727|NCT00001673|Normal Volunteer
1526728|NCT00001672|Brain Mapping
1526729|NCT00001672|Cognition
1526730|NCT00001672|Noninvasive
1526731|NCT00001672|Temporal Lobe
1526732|NCT00001672|Visual Naming
1526733|NCT00001671|White Matter
1526734|NCT00001671|Myelin
1526735|NCT00001671|Degenerative Diseases
1526736|NCT00001671|Genetic
1526737|NCT00001671|Oligodendrocytes
1526738|NCT00001671|Leukodystrophy
1526739|NCT00001669|EAE
1526740|NCT00001669|EDSS
1526741|NCT00001669|MRI
1526742|NCT00001669|SNRS
1526743|NCT00001669|Multiple Sclerosis
1526744|NCT00001668|Deafness
1526745|NCT00001668|Hemangioblastoma
1526746|NCT00001668|Papillary Carcinoma
1526747|NCT00001668|VHL Gene
1526748|NCT00001668|Vestibular Function
1526749|NCT00001668|von Hippel-Lindau Disease
1526750|NCT00001667|Family Studies
1526751|NCT00001667|Genetic
1526752|NCT00001667|Myoclonus
1526753|NCT00001667|Tics
1526754|NCT00001667|Tremor
1526755|NCT00001667|Movement Disorders
1526756|NCT00001667|Neurological Disease
1526757|NCT00001666|Seizures
1526758|NCT00001666|Partial Epilepsy
1526759|NCT00001666|Intractable
1526760|NCT00001666|TMS
1526761|NCT00001665|Magnetic Stimulation
1526762|NCT00001665|Motor Skills
1526763|NCT00001665|Parkinson's Disease
1526764|NCT00001665|rTMS
1526765|NCT00001664|Narcolepsy
1526766|NCT00001664|Polysomnography
1526767|NCT00001664|Multiple Sleep Latency Test
1526768|NCT00001664|Sleep Disorders
1526769|NCT00001664|Hypersomnia
1526770|NCT00001664|Periodic Leg Movements
1526771|NCT00001663|Neurological Disorders
1526772|NCT00001663|Movement Disorders
1526773|NCT00001663|Physiology
1526774|NCT00001663|Noninvasive
1526775|NCT00001663|Brain Stimulation
1526776|NCT00001663|Cortical Myoclonus
1526777|NCT00001662|Dementia
1526778|NCT00001662|Glutamate
1526779|NCT00001662|Clinical Trial
1526780|NCT00001662|Neurotransmitter
1526781|NCT00001662|Alzheimer's Disease
1526782|NCT00001661|Plasticity
1526783|NCT00001661|Use
1526784|NCT00001661|Stroke
1526785|NCT00001661|Spinal Cord Injury
1526786|NCT00001661|Amputation
1526787|NCT00001661|Intracortical Inhibition
1526788|NCT00001659|Bereavement
1526789|NCT00001659|Depression
1526790|NCT00001659|Suicide
1526791|NCT00001659|Activity of Daily Living
1526792|NCT00001659|Immune Function
1526793|NCT00001659|Occupational Performance
1526794|NCT00001659|Sleep Disorders
1526795|NCT00001659|Mood Changes
1526796|NCT00001658|Amoxicillin
1526797|NCT00001658|Antibiotics
1526798|NCT00001658|Cytokines
1526799|NCT00001658|Group A beta-Hemolytic Strep Infections
1526800|NCT00001658|Obsessive Compulsive Disorder
1526801|NCT00001658|Streptococcal Infection
1526802|NCT00001658|Tic Disorders
1526803|NCT00001657|15 O PET Scanning
1526804|NCT00001657|Anxiety
1526805|NCT00001657|Cerebral Blood Flow
1526806|NCT00001657|Depression
1526807|NCT00001657|Domestic Abuse
1526808|NCT00001657|Neuroendocrine
1526809|NCT00001657|PET Scanning
1526810|NCT00001657|Police Officers
1526811|NCT00001657|Post Traumatic Stress Disorder
1526812|NCT00001657|Repetitive Transcranial Magnetic Stimulation
1526813|NCT00001656|Clozapine
1526814|NCT00001656|Olanzapine
1526815|NCT00001656|Drug Response
1526816|NCT00001656|Safety
1526817|NCT00001656|Childhood Onset Schizophrenia
1526818|NCT00001656|Schizoaffective Disorder
1526819|NCT00001656|Multidimensionally Impaired Syndrome
1526820|NCT00001656|Phenomenology
1526821|NCT00001656|Biochemical Correlates
1526822|NCT00001656|Brain Imaging
1526823|NCT00001656|Schizophrenia
1526824|NCT00001656|Childhood Schizophrenia
1526825|NCT00001656|Psychosis
1526826|NCT00001654|Adolescence
1526827|NCT00001654|Comorbid Disorders
1526828|NCT00001654|Physiology
1526829|NCT00001654|Socialization
1526830|NCT00001654|Gender
1526831|NCT00001654|Conduct Problems
1526832|NCT00001654|Anxiety
1526833|NCT00001654|Sadness
1526834|NCT00001654|Emotion
1526835|NCT00001654|Psychophysiology
1526836|NCT00001652|Life-Charting
1526837|NCT00001652|Cerebrospinal Fluid
1526838|NCT00001652|Diagnostic Tests
1526839|NCT00001652|Cognitive Testing
1526840|NCT00001652|Course of Illness
1526841|NCT00001652|Bipolar Disorder
1526842|NCT00001651|Deuterium
1526843|NCT00001651|HIV
1526844|NCT00001651|Labeling
1526845|NCT00001651|CD4 Cells
1526846|NCT00001651|Immunodeficiency
1526847|NCT00001650|BrDU
1526848|NCT00001650|HIV
1526849|NCT00001650|Labeling
1526850|NCT00001650|CD4 Cells
1526851|NCT00001650|Immunodeficiency
1526852|NCT00001649|Clinical Trial
1526853|NCT00001649|Sexual Transmitted Disease
1526854|NCT00001649|Phase III
1526855|NCT00001649|HSV
1526856|NCT00001649|Valtrex
1526857|NCT00001649|Valaciclovir
1526858|NCT00001649|HS2A/B3009
1526859|NCT00001649|Herpes Simplex Virus Transmission
1526860|NCT00001649|Heterosexual Couples
1526861|NCT00001648|HVEM Gene
1526862|NCT00001648|HSV
1526863|NCT00001648|Herpes Simplex Virus
1526864|NCT00001647|AIDS
1526865|NCT00001647|Immunotherapy
1526866|NCT00001647|Adoptive Cell Transfers
1526867|NCT00001647|T Cell Repertoire
1526868|NCT00001647|Identical Twins
1526869|NCT00001646|Aspergillus
1526870|NCT00001646|Azole
1526871|NCT00001646|Immunocompromise
1526872|NCT00001645|Chagas' Disease
1526873|NCT00001645|Trypanosomiasis
1526874|NCT00001645|Malaria
1526875|NCT00001645|Parasitic Infection
1526876|NCT00001644|Immunodeficiency
1526877|NCT00001644|Latency
1526878|NCT00001644|T Cell Turnover
1526879|NCT00001644|Infected Cell Turnover
1526880|NCT00001644|Follicular Dendritic Cells
1526881|NCT00001643|Lewy Body
1526882|NCT00001643|Mutation
1526883|NCT00001643|Hereditary
1526884|NCT00001643|Dominant
1526885|NCT00001643|Sporadic
1526886|NCT00001643|Parkinson's Disease
1526887|NCT00001642|Chromosomal Deletion
1526888|NCT00001642|Mutations
1526889|NCT00001642|Paucity of Bile Ducts
1526890|NCT00001642|Physical Map
1526891|NCT00001642|Transcript Identification
1526892|NCT00001642|Alagille Syndrome
1526893|NCT00001642|Syndromic Bile Duct Paucity
1526894|NCT00001641|Fibrillin
1526895|NCT00001641|Collagen
1526896|NCT00001641|Marfan Syndrome
1526897|NCT00001641|Stickler Syndrome
1526898|NCT00001641|Aortic Dissection
1526899|NCT00001641|Ehlers-Danlos
1526900|NCT00001641|Connective Tissue Disorders
1526901|NCT00001641|Ehlers-Danlos Syndrome
1526902|NCT00001641|Nail-Patella Syndrome
1526903|NCT00001640|Parkinson's Disease
1526904|NCT00001639|Gene Dosage
1526905|NCT00001639|Haploinsufficiency
1526906|NCT00001639|Karyotype
1526907|NCT00001639|Malformations
1526908|NCT00001639|Mental Retardation
1526909|NCT00001638|Echocardiography
1526910|NCT00001638|Heart
1526911|NCT00001638|Gadolinium
1526912|NCT00001638|Dobutamine
1526913|NCT00001638|Toxicity
1526914|NCT00001638|Adverse Events
1526915|NCT00001638|Myocardial Infarction
1526916|NCT00001638|Myocardial Viability
1526917|NCT00001638|Myocardial Perfusion
1526918|NCT00001638|Myocardial Function
1526919|NCT00001638|Cardiovascular Disease
1526920|NCT00001637|Peripheral Blood Stem Cells
1526921|NCT00001637|Engraftment
1526922|NCT00001637|Fludarabine
1526923|NCT00001637|Nonmyeloablative
1526924|NCT00001637|Graft-Versus-Leukemia
1526925|NCT00001637|Graft vs. Host Disease
1526926|NCT00001637|Cyclophosphamide
1526927|NCT00001637|Donor Apheresis
1526928|NCT00001637|Nonmyeloablative Bone Marrow Transplantation
1526929|NCT00001637|Chronic Myelogenous Leukemia (CML)
1526930|NCT00001637|Acute Lymphoblastic Leukemia (ALL)
1526931|NCT00001637|Acute Myelogenous Leukemia (AML)
1526932|NCT00001637|Myelodysplastic Syndromes
1526933|NCT00001637|Chronic Lymphocytic Leukemia (CLL)
1526934|NCT00001637|Prolymphocytic Leukemia
1526935|NCT00001633|Contrast Media
1526936|NCT00001633|Coronary Artery Disease
1526937|NCT00001633|Coronary Vessels
1526938|NCT00001633|Magnetic Resonance Angiography
1526939|NCT00001633|Magnetic Resonance Imaging
1526940|NCT00001632|Hypertrophy
1526941|NCT00001632|Integrated
1526942|NCT00001632|Backscatter
1526943|NCT00001632|Cyclic
1526944|NCT00001632|Echocardiography
1526945|NCT00001632|Hypertrophic Cardiomyopathy
1526946|NCT00001631|Gadolinium
1526947|NCT00001631|Ischemia
1526948|NCT00001631|Coronary Artery Disease
1526949|NCT00001631|Hypertrophic Cardiomyopathy
1526950|NCT00001631|Dipyridamole
1526951|NCT00001630|Immunosuppression
1526952|NCT00001630|Thrombocytopenia
1526953|NCT00001630|Autoimmune Disease
1526954|NCT00001630|Evan's Syndrome
1526955|NCT00001630|Autoimmune Hemolytic Anemia
1526956|NCT00001630|Episodic Bleeding
1526957|NCT00001629|Angiotensin AT-1 Receptor
1526958|NCT00001629|Angiotensin Receptor Antagonist
1526959|NCT00001629|Atherosclerosis
1526960|NCT00001629|Blood Flow
1526961|NCT00001629|Cold Pressor Test
1526962|NCT00001629|Endothelium
1526963|NCT00001629|Exercise
1526964|NCT00001629|Coronary Artery Disease
1526965|NCT00001629|Heart Failure
1526966|NCT00001628|Angiotensin Receptor Antagonist
1526967|NCT00001628|Atherosclerosis
1526968|NCT00001628|Blood Flow
1526969|NCT00001628|Endothelium
1526970|NCT00001628|Endothelial Dysfunction
1526971|NCT00001627|Bone Marrow
1526972|NCT00001627|Hematopoiesis
1526973|NCT00001627|DNA
1526974|NCT00001627|RNA
1526975|NCT00001627|Viruses
1526976|NCT00001627|Normal Volunteer
1526977|NCT00001627|Aplastic Anemia
1526978|NCT00001627|Myelodysplasia
1526979|NCT00001627|Fanconi's Anemia
1526980|NCT00001627|Single Lineage Cytopenia
1526981|NCT00001626|Cytopenia
1526982|NCT00001626|Randomized
1526983|NCT00001626|Immunosuppression
1526984|NCT00001626|Severe Aplastic Anemia
1526985|NCT00001625|Insulin Resistance
1526986|NCT00001625|Obesity
1526987|NCT00001625|Hypertension
1526988|NCT00001625|Diabetes
1526989|NCT00001625|Mathematical Modeling
1526990|NCT00001625|Normal Volunteer
1526991|NCT00001624|BQ-123
1526992|NCT00001624|Endothelin
1526993|NCT00001624|Insulin
1526994|NCT00001624|Plethysmography
1526995|NCT00001624|Vasoconstriction
1526996|NCT00001624|Healthy Volunteer
1526997|NCT00001623|Peripheral Blood Stem Cells
1526998|NCT00001623|Graft-Versus-Leukemia
1526999|NCT00001623|Graft vs. Host Disease
1527000|NCT00001623|Whole Body Irradiation
1527001|NCT00001623|Donor Apheresis
1527002|NCT00001623|Cyclophosphamide
1527003|NCT00001623|Graft-Versus-Myeloma
1527004|NCT00001623|Leukemic Relapse
1527005|NCT00001623|Multiple Myeloma
1527006|NCT00001623|Acute Myelogenous Leukemia (AML)
1527007|NCT00001623|Chronic Myelogenous Leukemia (CML)
1527008|NCT00001623|Acute Lymphoblastic Leukemia (ALL)
1527009|NCT00001623|Myelodysplastic Syndromes
1527010|NCT00001623|Chronic Lymphocytic Leukemia (CLL)
1527011|NCT00001622|Endothelium
1527012|NCT00001622|Hypercholesterolemia
1527013|NCT00001622|Hypertension
1527014|NCT00001622|Microvessels
1527015|NCT00001622|Vasodilation
1527016|NCT00001622|Normal Volunteer
1527017|NCT00001621|Teaching
1527018|NCT00001621|Pulmonary Disease
1527019|NCT00001621|Routine Testing
1527020|NCT00001621|Medically Indicated
1527021|NCT00001621|Pulmonary Function Test
1527022|NCT00001620|Thrombocytopenia
1527023|NCT00001620|Anemia
1527024|NCT00001620|Neutropenia
1527025|NCT00001620|Dysplasia
1527026|NCT00001620|Cytopenia
1527027|NCT00001620|Hematologic Malignancy
1527028|NCT00001619|Imaging
1527029|NCT00001619|Spectroscopy
1527030|NCT00001619|MRI
1527031|NCT00001619|Cardiovascular
1527032|NCT00001619|Technical Development
1527033|NCT00001619|Heart
1527034|NCT00001619|Safety
1527035|NCT00001619|Toxicity
1527036|NCT00001619|Gadolinium
1527037|NCT00001619|Adverse Events
1527038|NCT00001619|Normal Volunteer
1527039|NCT00001618|Cystic Fibrosis
1527040|NCT00001618|Healthy Volunteers
1527041|NCT00001618|Asthma
1527042|NCT00001618|Normal Volunteer
1527043|NCT00001618|Chronic Lung Disease
1527044|NCT00001617|Aging
1527045|NCT00001617|Cataract
1527046|NCT00001617|Eye
1527047|NCT00001617|Human Lens
1527048|NCT00001617|Normal Volunteer
1527049|NCT00001615|Age-Related Macular Degeneration
1527050|NCT00001615|Choroidal Neovascularization
1527051|NCT00001615|Disciform
1527052|NCT00001615|Drusen
1527053|NCT00001615|Natural History
1527054|NCT00001615|Periocular
1527055|NCT00001615|Quality of Life
1527056|NCT00001615|Steroids
1527057|NCT00001615|Corticosteroid
1527058|NCT00001614|Eye
1527059|NCT00001614|Immunosuppression
1527060|NCT00001614|Inflammation
1527061|NCT00001614|Iritis
1527062|NCT00001614|Joint
1527063|NCT00001614|Oral Tolerance
1527064|NCT00001614|Juvenile Rheumatoid Arthritis
1527065|NCT00001614|Uveitis
1527066|NCT00001613|Cataract Surgery
1527067|NCT00001613|Human Lens
1527068|NCT00001613|Crystallins
1527069|NCT00001613|Post-Translational
1527070|NCT00001613|Protein Modification
1527071|NCT00001613|Nuclear Cataract
1527072|NCT00001613|Cataract Extraction
1527073|NCT00001612|Diabetic Retinopathy
1527074|NCT00001612|Long-Term Visual Outcome
1527075|NCT00001612|Photocoagulation
1527076|NCT00001612|J. H. Wilmer Eye Institute
1527077|NCT00001611|AIDS
1527078|NCT00001611|Eye
1527079|NCT00001611|Treatment
1527080|NCT00001611|Opportunistic Infection
1527081|NCT00001611|Immunology
1527082|NCT00001611|Retinitis
1527083|NCT00001610|Standing Potential
1527084|NCT00001610|Fast Oscillation
1527085|NCT00001610|Slow Oscillation
1527086|NCT00001610|Retinal Pigment
1527087|NCT00001610|Epithelium
1527088|NCT00001610|Electro-oculogram
1527089|NCT00001610|Cellular Immune Response
1527090|NCT00001610|Retinal Antigens
1527091|NCT00001610|IRBP
1527092|NCT00001610|S-Antigen
1527093|NCT00001610|Normal Volunteer
1527094|NCT00001609|Linkage
1527095|NCT00001609|Genetic Analysis
1527096|NCT00001609|Lens
1527097|NCT00001609|Opacity
1527098|NCT00001609|Inherited
1527099|NCT00001609|Linkage Analysis
1527100|NCT00001609|Genomic DNA
1527101|NCT00001609|Risk Prediction
1527102|NCT00001609|Pedigree Analysis
1527103|NCT00001609|Congenital Cataracts
1527104|NCT00001609|Hereditary Cataracts
1527105|NCT00001606|Linkage Analysis
1527106|NCT00001606|Positional Cloning
1527107|NCT00001606|Mutation Screening
1527108|NCT00001606|Syndromic Hearing Impairment
1527109|NCT00001606|Non-Syndromic Hearing Impairment
1527110|NCT00001605|Conjugate Vaccine
1527111|NCT00001605|Detoxified Lipooligosaccharide
1527112|NCT00001605|Tetanus Toxoid
1527113|NCT00001605|Normal Volunteers
1527114|NCT00001604|DNA Samples
1527115|NCT00001604|Buccal Swab
1527116|NCT00001604|Genotyping
1527117|NCT00001604|Statistical Analysis
1527118|NCT00001604|Computers
1527119|NCT00001604|Stuttering
1527120|NCT00001603|Cytokines
1527121|NCT00001603|Squamous Cell Carcinoma
1527122|NCT00001603|Papilloma
1527123|NCT00001603|Communication
1527124|NCT00001603|Immunity
1527125|NCT00001603|Head
1527126|NCT00001603|Neck
1527127|NCT00001603|Head and Neck Cancer
1527128|NCT00001602|Dysfluency
1527129|NCT00001602|Polymorphism
1527130|NCT00001602|Stuttering
1527131|NCT00001602|Dopamine
1527132|NCT00001602|Family Studies
1527133|NCT00001602|Receptors
1527134|NCT00001602|Serotonin
1527135|NCT00001602|Enzymes
1527136|NCT00001602|Genetics
1527137|NCT00001602|Linkage Analysis
1527138|NCT00001601|Oral Medicine
1527139|NCT00001601|Clinical Experience
1527140|NCT00001601|Therapy
1527141|NCT00001601|Educational Training
1527142|NCT00001601|Pathogenesis
1527143|NCT00001601|Oral Lesions
1527144|NCT00001601|Aphthous Ulcers
1527145|NCT00001601|Lichen Planus
1527146|NCT00001601|Burning Mouth
1527147|NCT00001601|Temporomandibular Dysfunction (TMD)
1527148|NCT00001601|Oral Disease
1527149|NCT00001601|Oral Manifestations
1527150|NCT00001600|Screening Protocol
1527151|NCT00001600|Temporomandibular Disorders
1527152|NCT00001600|Oral Surgery
1527153|NCT00001600|Chronic Orofacial Pain
1527154|NCT00001599|Xerostomia
1527155|NCT00001599|Autoimmunity
1527156|NCT00001599|Salivary Glands
1527157|NCT00001599|Lacrimal Function
1527158|NCT00001599|Immunomodulator
1527159|NCT00001599|Sjogren's Syndrome
1527160|NCT00001599|Dry Mouth
1527161|NCT00001598|Xerostomia
1527162|NCT00001598|Autoimmunity
1527163|NCT00001598|Salivary Glands
1527164|NCT00001598|Androgen Therapy
1527165|NCT00001598|Lacrimal Function
1527166|NCT00001598|DHEA
1527167|NCT00001598|Sjogren's Syndrome
1527168|NCT00001598|Dehydroepiandrosterone
1527169|NCT00001597|Psychophysics
1527170|NCT00001597|Validation
1527171|NCT00001597|Fentanyl
1527172|NCT00001597|Normal Volunteer
1527173|NCT00001597|Pain
1527174|NCT00001596|Albinism
1527175|NCT00001596|Platelet Storage Pool Deficiency
1527176|NCT00001596|Pulmonary Fibrosis
1527177|NCT00001596|Hermansky-Pudlak Syndrome
1527178|NCT00001595|Oncogenesis
1527179|NCT00001595|Adenoma
1527180|NCT00001595|Craniopharyngioma
1527181|NCT00001595|Cushing Syndrome
1527182|NCT00001595|Homeobox-Containing Genes
1527183|NCT00001595|Developmental Defect
1527184|NCT00001595|Pituitary Gland
1527185|NCT00001594|Osteogenesis Imperfecta
1527186|NCT00001594|Basilar Invagination
1527187|NCT00001591|Central Nervous System
1527188|NCT00001591|Technical Development
1527189|NCT00001591|Activation Studies
1527190|NCT00001591|Pulse Sequences
1527191|NCT00001591|Metabolites
1527192|NCT00001591|Normal Volunteer
1527193|NCT00001589|Ferritin
1527194|NCT00001589|Atherosclerosis
1527195|NCT00001589|Myocardial Infarction
1527196|NCT00001589|Blood Donors
1527197|NCT00001589|Low Density Lipoprotein
1527198|NCT00001589|Asymptomatic Carotid Atherosclerosis
1527199|NCT00001587|Hyperthermia
1527200|NCT00001587|Metastases
1527201|NCT00001587|Organ Perfusion
1527202|NCT00001587|Regional Therapy
1527203|NCT00001586|Genetics
1527204|NCT00001586|Bone Marrow Transplantation
1527205|NCT00001586|Immunosuppression
1527206|NCT00001586|T Lymphocytes
1527207|NCT00001586|Marrow Purging
1527208|NCT00001584|Pathogenesis
1527209|NCT00001584|Resistance
1527210|NCT00001584|Sanctuary Sites
1527211|NCT00001584|Semen
1527212|NCT00001584|Sexual Transmission
1527213|NCT00001582|Autoimmune Disorder
1527214|NCT00001582|Immune System Evaluation
1527215|NCT00001582|Human Response Investigation
1527216|NCT00001582|Tissue Acquisition
1527217|NCT00001580|Molecular Diagnostics
1527218|NCT00001580|Ovary
1527219|NCT00001580|Tissue Acquisition
1527220|NCT00001580|cDNA Library
1527221|NCT00001580|CGAP
1527222|NCT00001579|Biochemical Modulation
1527223|NCT00001579|Dihydropyrimidine Dehydrogenase
1527224|NCT00001579|Oral Administration
1527225|NCT00001579|Pharmacokinetics
1527226|NCT00001577|Chemotherapy
1527227|NCT00001577|Hyperthermia
1527228|NCT00001577|Isolation perfusion
1527229|NCT00001577|Regional Therapy
1527230|NCT00001576|Regional Therapy
1527231|NCT00001576|Organ Perfusion
1527232|NCT00001576|Metastases
1527233|NCT00001576|Hyperthermia
1527234|NCT00001575|Yttrium 90
1527235|NCT00001575|Radiolabeled
1527236|NCT00001575|Anti -Tac
1527237|NCT00001575|Calcium DTPA
1527238|NCT00001574|Metabolites
1527239|NCT00001574|Proton Nuclear Magnetic Resonance Spectroscopic Imaging
1527240|NCT00001574|Scans
1527241|NCT00001573|Glioma
1527242|NCT00001573|PDGF
1527243|NCT00001573|Pharmacokinetics
1527244|NCT00001573|Sarcoma
1527245|NCT00001573|Toxicity
1527246|NCT00001572|B-Cell Lymphoma
1527247|NCT00001572|BCL- 2 Positive Tumor
1527248|NCT00001572|Immunization
1527249|NCT00001572|Induction Chemotherapy
1527250|NCT00001572|Lymphoma Vaccine
1527251|NCT00001572|Follicular Lymphoma
1527252|NCT00001572|Tumor-Derived Immunoglobulin Idiotype
1527253|NCT00001571|Cancer
1527254|NCT00001571|DDT, PCB
1527255|NCT00001571|Epidemiology
1527256|NCT00001571|Pesticides
1527257|NCT00001571|Serum
1527258|NCT00001570|Cytochrome P 450
1527259|NCT00001570|Multi-Drug Resistance
1527260|NCT00001570|P-Glycoprotein
1527261|NCT00001570|Pharmacokinetics
1527262|NCT00001569|Gastrointestinal
1527263|NCT00001569|Adenocarcinoma
1527264|NCT00001569|Taxol
1527265|NCT00001568|Tumors
1527266|NCT00001568|Detection
1527267|NCT00001568|Follow-Up
1527268|NCT00001568|Markers
1527269|NCT00001568|Radiolabeled
1527270|NCT00001567|Follow-Up Study
1527271|NCT00001567|Relapse-Free Survival
1527272|NCT00001567|Serum Soluble IL-2 Receptor
1527273|NCT00001567|Hematologic Malignancy
1527274|NCT00001567|Chronic Therapy
1527275|NCT00001566|Rhabdomyosarcoma
1527276|NCT00001566|Ewing's Sarcoma
1527277|NCT00001566|Immunotherapy
1527278|NCT00001566|Tumor Vaccine
1527279|NCT00001566|Interleukin-2
1527280|NCT00001565|Brain Tumors
1527281|NCT00001565|Differentiation
1527282|NCT00001565|Maximally Tolerated Dose
1527283|NCT00001565|Neuroblastoma
1527284|NCT00001565|Phenylacetate
1527290|NCT00001563|Lymphomagenesis
1527291|NCT00001563|Molecular markers of drug resistance
1527292|NCT00001563|Refractory, progressive, or relapsed HIV + NHL
1527293|NCT00001563|AIDS-related NHL
1527294|NCT00001561|Multiple Myeloma
1527295|NCT00001561|Vaccine
1527296|NCT00001561|Idiotype-Specific Immunity
1527297|NCT00001561|Immune Transfer
1527298|NCT00001561|Myeloma Immunoglobulin
1527299|NCT00001560|AIDS
1527300|NCT00001560|Multidisciplinary
1527301|NCT00001560|Leukemia
1527302|NCT00001560|Lymphoma
1527303|NCT00001560|Kaposi's Sarcoma
1527304|NCT00001554|Cortical Localization
1527305|NCT00001554|Optical Imaging
1527306|NCT00001554|Thermal Imaging
1527307|NCT00001553|Plasticity
1527308|NCT00001553|Recovery
1527309|NCT00001553|Stroke
1527310|NCT00001553|Use
1527311|NCT00001553|Cortico-subcortical Stroke
1527312|NCT00001552|Spasmodic Dysphonia
1527313|NCT00001552|Pedigree
1527314|NCT00001552|Vocal Fold Paralysis
1527315|NCT00001552|Voice Disorder
1527316|NCT00001551|Stuttering
1527317|NCT00001551|Linkage
1527318|NCT00001551|Pedigree
1527319|NCT00001551|Speech Articulation
1527320|NCT00001551|Phonological Processing Disorders
1527321|NCT00001551|Speech Disorder
1527322|NCT00001550|Immunotherapy
1527323|NCT00001550|Muscle Stiffness
1527324|NCT00001550|Rigidity
1527325|NCT00001550|Anti-GAD Antibodies
1527326|NCT00001550|Episodic Spasms
1527327|NCT00001550|Intravenous High-Dose Immunoglobulin
1527328|NCT00001550|Stiff-man Syndrome
1527329|NCT00001549|Movement Disorders
1527330|NCT00001549|Parkinson's
1527331|NCT00001549|Alzheimer's
1527332|NCT00001549|Screening
1527333|NCT00001549|Diagnostic Puzzles
1527334|NCT00001549|Alzheimer Disease
1527335|NCT00001549|Progressive Supranuclear Palsy
1527336|NCT00001549|PSP
1527337|NCT00001549|Restless Leg Syndrome
1527338|NCT00001549|RLS
1527339|NCT00001549|Parkinsonism
1527340|NCT00001549|PD
1527341|NCT00001548|Genetic
1527342|NCT00001548|Psychiatric Disorder
1527343|NCT00001548|Affected Sib Pairs
1527344|NCT00001548|Obsessions
1527345|NCT00001548|Compulsions
1527346|NCT00001548|Family Study
1527347|NCT00001548|OCD Spectrum Disorders
1527348|NCT00001548|Trichotillomania
1527349|NCT00001548|Tourette's Syndrome
1527350|NCT00001547|Drug
1527351|NCT00001547|Imaging
1527352|NCT00001547|Brain
1527353|NCT00001547|Metabolism
1527354|NCT00001547|Organic Mental Syndrome
1527355|NCT00001547|Magnetic Resonance Imaging
1527356|NCT00001547|Spectroscopy
1527357|NCT00001547|Neuropsychiatric Disorders
1527358|NCT00001547|Drug Effects
1527359|NCT00001547|Interferon-alpha
1527360|NCT00001546|Biochemical Screening
1527361|NCT00001546|Body Temperature
1527362|NCT00001546|Consent Form
1527363|NCT00001546|EEG
1527364|NCT00001546|EKG
1527365|NCT00001546|Melatonin
1527366|NCT00001546|Mood
1527367|NCT00001546|Physical Examination
1527368|NCT00001546|Psychiatric Examination
1527369|NCT00001546|Sleep Duration
1527370|NCT00001546|Sleep Disorders
1527371|NCT00001545|Affective Disorders
1527372|NCT00001545|Repetitive Transcranial Magnetic Stimulation
1527373|NCT00001545|Mania
1527374|NCT00001545|Bipolar Disorder
1527375|NCT00001545|Depression
1527376|NCT00001545|Unipolar Disorder
1527377|NCT00001545|Unipolar Depression
1527378|NCT00001544|DNA Probes
1527379|NCT00001544|Trinucleotide Repeats
1527380|NCT00001544|Family Studies
1527381|NCT00001544|Lymphoblast Cell Lines
1527382|NCT00001544|Genotyping
1527383|NCT00001544|Bipolar Affective Disorders
1527384|NCT00001544|Schizophrenia
1527385|NCT00001544|Mental Retardation
1527386|NCT00001544|Neuropsychiatric Disorders
1527387|NCT00001543|Major Depression
1527388|NCT00001543|Metabolic Clearance Rate
1527389|NCT00001543|Pulsatility
1527390|NCT00001543|Adrenocorticotropic Hormone
1527391|NCT00001543|Cortisol
1527392|NCT00001543|Corticotropin Releasing Hormone Binding Protein
1527393|NCT00001543|Pharmacokinetics
1527394|NCT00001543|Half-Life
1527395|NCT00001543|Bioavailability
1527396|NCT00001543|Cushing's Syndrome
1527397|NCT00001542|Candidiasis
1527398|NCT00001542|Azole
1527399|NCT00001542|Resistance
1527400|NCT00001542|Candida Albicans
1527401|NCT00001542|Oropharynx
1527402|NCT00001541|Vasculitis
1527403|NCT00001541|Inflammation
1527404|NCT00001541|Bronchoscopy
1527405|NCT00001541|Cytokines
1527406|NCT00001541|Inflammatory Mediators
1527407|NCT00001541|Wegener's Granulomatosis
1527408|NCT00001540|Diagnostic
1527409|NCT00001540|Immune Function
1527410|NCT00001540|Immunization
1527411|NCT00001540|Immunodeficiency
1527412|NCT00001540|Quantitative
1527413|NCT00001539|Central Nervous System
1527414|NCT00001539|Lyme Disease
1527415|NCT00001539|Borrelia Burgdorferi
1527416|NCT00001539|Neuroborreliosis
1527417|NCT00001539|Chronic Symptoms
1527418|NCT00001538|AIDS
1527419|NCT00001538|DNA Vaccine
1527420|NCT00001538|Naked DNA
1527421|NCT00001538|Plasmid
1527422|NCT00001538|gp 160
1527423|NCT00001536|Disability
1527424|NCT00001536|Dwarfism
1527425|NCT00001536|Ethics in Genetic Counseling
1527426|NCT00001536|Quality of Life
1527427|NCT00001536|Reproductive Issues
1527428|NCT00001536|Support Groups
1527429|NCT00001536|Achondroplasia
1527430|NCT00001535|Intracellular Immunization
1527431|NCT00001535|Immune Based Therapy
1527432|NCT00001535|Ex Vivo Cell Processing
1527433|NCT00001535|Identical Twins
1527434|NCT00001535|HIV/AIDS
1527435|NCT00001535|Kaposi's Sarcoma
1527436|NCT00001534|Genetics
1527437|NCT00001534|Myocardial Ischemia
1527438|NCT00001534|Diastolic Dysfunction
1527439|NCT00001534|Renin-Angiotensin System
1527440|NCT00001534|Hypertrophic Cardiomyopathy
1527441|NCT00001534|Left Ventricular (LV) Hypertrophy
1527442|NCT00001533|Anemia
1527582|NCT00001502|Bradykinin
1527443|NCT00001533|Chronic T Cell Lymphocytosis with Neutropenia
1527444|NCT00001533|Immunosuppression
1527445|NCT00001533|Neutropenia
1527446|NCT00001533|T-LGL Leukemia
1527447|NCT00001532|Genetic Polymorphism
1527448|NCT00001532|Nitric Oxide Synthase
1527449|NCT00001532|Alpha 1-Antitrypsin
1527450|NCT00001532|Candidate Genes
1527451|NCT00001532|Lung Pathology
1527452|NCT00001532|Asthma
1527453|NCT00001532|Lung Disease
1527454|NCT00001532|Cystic Fibrosis
1527455|NCT00001531|Atherogenesis
1527456|NCT00001531|Cell Mediated Immunity
1527457|NCT00001531|Coronary Artery Disease
1527458|NCT00001530|Cardiac Hypertrophy
1527459|NCT00001530|Drug-Refractory
1527460|NCT00001530|Hemodynamic Benefits
1527461|NCT00001530|Obstruction
1527462|NCT00001530|Pacemaker Therapy
1527463|NCT00001530|Hypertrophic Cardiomyopathy
1527464|NCT00001529|G-CSF
1527465|NCT00001529|Donor Apheresis
1527466|NCT00001529|Graft vs. Host Disease
1527467|NCT00001529|Graft-Versus-Leukemia
1527468|NCT00001529|Dexamethasone
1527469|NCT00001529|Transient Lymphopenia
1527470|NCT00001529|Improved T-Cell Depletion
1527471|NCT00001529|Normal Volunteer
1527472|NCT00001528|Coronary Artery Disease
1527473|NCT00001528|Gated Blood Pool Tomography
1527474|NCT00001528|Myocardial Blood Flow
1527475|NCT00001528|Myocardial Stunning
1527476|NCT00001528|Positron Emission Tomography
1527477|NCT00001527|BQ-123
1527478|NCT00001527|BQ-788
1527479|NCT00001527|Endothelin
1527480|NCT00001527|Endothelium
1527481|NCT00001527|Plethysmography
1527482|NCT00001527|Essential Hypertension
1527483|NCT00001526|Uveitis
1527484|NCT00001526|Interleukin 2 Receptor
1527485|NCT00001526|Daclizumab
1527486|NCT00001526|HAT
1527487|NCT00001526|Zenapax
1527488|NCT00001526|Interleukin 2
1527489|NCT00001524|Thalidomide
1527490|NCT00001524|Clinical Trial
1527491|NCT00001524|Tumor Necrosis Factor
1527492|NCT00001524|Delayed Healing
1527493|NCT00001524|Painful Oral Lesions
1527494|NCT00001524|HIV/AIDS
1527495|NCT00001524|Mouth Ulcers
1527496|NCT00001524|Aphthous Ulcers
1527497|NCT00001524|Healing
1527498|NCT00001524|Cytokines
1527499|NCT00001523|Cytology
1527500|NCT00001523|Diagnostic Imaging
1527501|NCT00001523|Radiation Damage
1527502|NCT00001523|Saliva
1527503|NCT00001523|Serostomia
1527504|NCT00001523|Xerostomia
1527505|NCT00001523|Head Cancer
1527506|NCT00001523|Neck Cancer
1527518|NCT00001520|Endotracheal Intubation
1527519|NCT00001520|Neuromuscular Blockade
1527520|NCT00001520|Neuromuscular Blocking Agents
1527521|NCT00001520|Paralysis
1527522|NCT00001520|Reversal Agents
1527523|NCT00001519|Exercise
1527524|NCT00001519|Exercise Intensity
1527525|NCT00001519|Non-Linear Regression
1527526|NCT00001519|Oxygen Uptake
1527527|NCT00001519|Recovery
1527528|NCT00001519|Subject Comparison
1527529|NCT00001519|Time Constant
1527530|NCT00001519|VO2
1527531|NCT00001518|Groshong Catheter
1527532|NCT00001518|Heparinized Flush Solution
1527533|NCT00001518|Intraluminal Clot
1527534|NCT00001518|Urokinase
1527535|NCT00001518|Venous Access Device
1527536|NCT00001518|Withdrawal Occlusion
1527537|NCT00001516|Case Study Design
1527538|NCT00001516|Rehabilitation
1527539|NCT00001516|Treatment Efficacy
1527540|NCT00001516|Occupational Therapy Process
1527541|NCT00001516|Reflection
1527542|NCT00001516|Occupational Therapy
1527543|NCT00001515|Wegener's Granulomatosis
1527544|NCT00001515|Computer Assisted Visualization
1527545|NCT00001515|Lung Cavities
1527546|NCT00001515|Endobronchial Lesions
1527547|NCT00001515|Computed Tomography (CT)
1527548|NCT00001515|Bronchogenic Carcinoma
1527549|NCT00001512|ProMace Chemotherapy
1527550|NCT00001512|Indolent Lymphoma
1527551|NCT00001512|Anti-Idiotype Antibody
1527552|NCT00001512|GM-CSF
1527553|NCT00001512|B-Cell Lymphoma
1527554|NCT00001509|Differentiation
1527555|NCT00001509|N-myc Expression
1527556|NCT00001509|Retinoid
1527557|NCT00001509|Solid Tumor
1527558|NCT00001509|Trk Expression
1527559|NCT00001507|T-cells
1527560|NCT00001507|CD34+ Selection
1527561|NCT00001507|T-Cell Depletion
1527562|NCT00001507|Apheresis
1527563|NCT00001507|Mobilization
1527564|NCT00001506|Training Protocol
1527565|NCT00001506|Natural History
1527566|NCT00001506|Consultation
1527567|NCT00001506|Standard Therapy
1527568|NCT00001506|Standard Tests
1527569|NCT00001506|Training
1527570|NCT00001505|Biopsy
1527571|NCT00001505|Research
1527572|NCT00001505|Autoimmune
1527573|NCT00001505|Blistering
1527574|NCT00001505|Compensation
1527575|NCT00001504|Retinoids
1527576|NCT00001504|Biomarkers
1527577|NCT00001503|Cancer
1527578|NCT00001503|Late Effects
1527579|NCT00001503|Survival
1527580|NCT00001503|Follow-Up
1527581|NCT00001502|Blood-Brain Barrier
1527583|NCT00001502|Children
1527584|NCT00001502|Glioma
1527585|NCT00001502|Medulloblastoma
1527586|NCT00001500|Smoking
1527587|NCT00001500|Alcohol
1527588|NCT00001500|HIV
1527589|NCT00001500|AIDS
1527590|NCT00001500|DNA Markers
1527591|NCT00001500|Personality
1527592|NCT00001500|Healthy Volunteers
1527593|NCT00001500|Normal Volunteer
1527594|NCT00001499|Carcinoma
1527595|NCT00001499|Combination Chemotherapy
1527596|NCT00001499|Combined Modality Therapy
1527597|NCT00001499|Infusion
1527598|NCT00001499|Intravenous
1527599|NCT00001499|Lung Neoplasm
1527600|NCT00001499|Non-Small Cell Lung Cancer
1527601|NCT00001498|5-Fluorouracil
1527602|NCT00001498|Cyclophosphamide
1527603|NCT00001498|Methotrexate
1527604|NCT00001498|Thiotepa
1527605|NCT00001497|Brain Imaging
1527606|NCT00001497|Encephalopathy
1527607|NCT00001497|Hyperactivity
1527608|NCT00001497|Neuroimmunology
1527609|NCT00001497|Reaction Time Tasks
1527610|NCT00001496|BRCA-1
1527611|NCT00001496|Familial Breast Cancer
1527612|NCT00001496|Breast Cell Culture
1527613|NCT00001496|High Risk
1527614|NCT00001495|Camptothecin
1527615|NCT00001495|Cancer
1527616|NCT00001495|Chemotherapy
1527617|NCT00001495|Natural Products
1527618|NCT00001495|Neoplasms
1527619|NCT00001493|Dose Intensity
1527620|NCT00001493|Gene Therapy
1527621|NCT00001493|Multidrug Resistance
1527622|NCT00001491|Ceramidetrihexosidase Deficiency
1527623|NCT00001491|Sural Nerve Biopsy
1527624|NCT00001491|Nerve Conduction Studies
1527625|NCT00001491|Quantitative Sensory Testing
1527626|NCT00001491|PGP 9.5 Levels (Skin, Serum and CSF)
1527627|NCT00001491|Fabry Disease
1527628|NCT00001491|Fabrys
1527629|NCT00001491|Fabry's
1527630|NCT00001489|Cerebral Metabolism
1527631|NCT00001489|Complex Partial Seizures
1527632|NCT00001489|Epilepsy
1527633|NCT00001487|Menopause
1527634|NCT00001487|Andropause
1527635|NCT00001487|Depression
1527636|NCT00001487|DHEA
1527637|NCT00001487|Steroids
1527638|NCT00001487|Mid-Life Depression
1527639|NCT00001487|Mid Life
1527640|NCT00001487|Perimenopause
1527641|NCT00001487|Climecteric-Related Mood Disorder
1527642|NCT00001486|Paranoia
1527643|NCT00001486|Schizophrenic Research
1527644|NCT00001486|Hallucinations
1527645|NCT00001486|Delusions
1527646|NCT00001486|Brain Scans
1527647|NCT00001486|Negative Symptoms
1527648|NCT00001486|Symptoms of Schizophrenia
1527649|NCT00001486|Causes of Schizophrenia
1527650|NCT00001486|Psychosis and Schizophrenia
1527651|NCT00001486|Compensation
1527652|NCT00001486|Schizophrenia
1527653|NCT00001486|Schizoaffective Disorder
1527654|NCT00001486|Psychosis
1527655|NCT00001486|Manic-Depression
1527656|NCT00001485|Chemical Mediators
1527657|NCT00001485|Circadian Rhythms
1527658|NCT00001485|Gender Differences
1527659|NCT00001485|Melatonin
1527660|NCT00001485|Photoperiodism
1527661|NCT00001485|Seasonal Changes
1527662|NCT00001483|Manic-Depressive Disorder
1527663|NCT00001483|Antidepressants
1527664|NCT00001483|Re-Randomization
1527665|NCT00001483|Continuation
1527666|NCT00001483|Ratings
1527667|NCT00001483|Bipolar Illness
1527668|NCT00001483|Depression
1527669|NCT00001483|Bupropion
1527670|NCT00001483|Sertraline
1527671|NCT00001482|Anticonvulsants
1527672|NCT00001482|Bipolar Disorder
1527673|NCT00001482|Depression
1527674|NCT00001482|Gabapentin
1527675|NCT00001482|Lamotrigine
1527676|NCT00001482|Mania
1527677|NCT00001482|Mood Disorders
1527678|NCT00001481|Postpartum Disorders
1527679|NCT00001481|Depression
1527680|NCT00001481|Mood
1527681|NCT00001481|Postpartum Depression
1527682|NCT00001481|Hormones
1527683|NCT00001481|Pregnancy
1527684|NCT00001481|Estrogen
1527685|NCT00001481|Progesterone
1527686|NCT00001481|Gonadal Steroids
1527687|NCT00001481|GnRH Agonist
1527688|NCT00001481|Postpartum
1527689|NCT00001481|Mood Disorder
1527690|NCT00001480|Dementia
1527691|NCT00001480|Alzheimer's Disease
1527692|NCT00001480|Cerebrospinal Fluid
1527693|NCT00001480|Diagnostic Test
1527694|NCT00001480|Cognitive Testing
1527695|NCT00001480|Memory Disorder
1527696|NCT00001480|Normal Volunteer
1527697|NCT00001479|ACTH
1527698|NCT00001479|Adrenocorticotropic Hormone
1527699|NCT00001479|Antidepressant Treatment
1527700|NCT00001479|Chaos Theory
1527701|NCT00001479|Chronic Fatigue Syndrome
1527702|NCT00001479|Major Depression
1527703|NCT00001479|Normal Volunteer
1527704|NCT00001479|Primary Affective Disorder
1527705|NCT00001478|Bupropion
1527706|NCT00001478|Carbamazepine
1527707|NCT00001478|Cerebral Blood Flow
1527708|NCT00001478|Gabapentin
1527709|NCT00001478|Lamotrigine
1527710|NCT00001478|Mood Disorders
1527711|NCT00001478|Nimodipine
1527712|NCT00001478|Oxygen-15
1527713|NCT00001478|Positron Emission Tomography
1527714|NCT00001478|Venlafaxine
1527715|NCT00001477|Communicable Infection
1527716|NCT00001477|Monitoring
1527717|NCT00001477|Non-Invasive Tests
1527718|NCT00001477|Opportunistic Infection
1527719|NCT00001476|CD34+ Progenitor
1527720|NCT00001476|Retrovirus
1527721|NCT00001476|Leukapheresis
1527722|NCT00001476|Transduction
1527723|NCT00001476|Granulocytes
1527724|NCT00001476|Chronic Granulomatous Disease
1527725|NCT00001475|AIDS
1527726|NCT00001475|Cytokines
1527727|NCT00001475|Thalidomide
1527728|NCT00001475|Monoclonal Antibody
1527729|NCT00001475|Immunomodulator
1527730|NCT00001474|Cytokines
1527731|NCT00001474|Immunoregulation
1527732|NCT00001474|Infusion Duration
1527733|NCT00001474|CD4 Cells
1527734|NCT00001473|Vasculitis
1527735|NCT00001473|Remission
1527736|NCT00001473|Relapse
1527737|NCT00001473|Toxicity
1527738|NCT00001473|ANCA
1527739|NCT00001473|Wegener's Granulomatosis
1527740|NCT00001471|AIDS
1527741|NCT00001471|HIV
1527742|NCT00001471|Retrovirus
1527743|NCT00001471|Therapy
1527744|NCT00001471|Response
1527745|NCT00001469|Cancer Susceptibility Alleles
1527746|NCT00001469|Prostate Cancer
1527747|NCT00001469|Cancer Genetics
1527748|NCT00001469|Cancer
1527749|NCT00001469|Prostate Cancer (hereditary)
1527750|NCT00001468|Behavioral and Attitudinal Changes
1527751|NCT00001468|Breast Cancer
1527752|NCT00001468|High Risk Families
1527753|NCT00001468|Inherited Susceptibility
1527754|NCT00001468|Psychological Responses to Risk
1527757|NCT00001466|Clinical Genetics
1527758|NCT00001466|Etiology
1527759|NCT00001466|Medical Screening
1527760|NCT00001466|Prognosis
1527761|NCT00001466|Genetic Disorders
1527762|NCT00001465|Smooth Muscle Proliferation
1527763|NCT00001465|Bronchoscopy
1527764|NCT00001465|Female
1527765|NCT00001465|Pneumothorax
1527766|NCT00001465|Tuberous Sclerosis
1527767|NCT00001465|Lymphangioleiomyomatosis (LAM)
1527768|NCT00001464|Oxygen
1527769|NCT00001464|Bronchoalveolar Lavage
1527770|NCT00001464|DNA Repair
1527771|NCT00001464|Carbonyl Groups
1527772|NCT00001464|Serum
1527773|NCT00001464|ADP-ribosylation
1527774|NCT00001464|Defensin
1527775|NCT00001464|Protein Oxidation
1527776|NCT00001464|Human Volunteers
1527777|NCT00001462|Alpha 1-Antitrypsin Deficiency
1527778|NCT00001462|Emphysema
1527779|NCT00001462|Genetic Diseases
1527780|NCT00001462|Inflammation
1527781|NCT00001462|Nitric Oxide
1527782|NCT00001462|Protease
1527783|NCT00001461|Angiotensin Converting Enzyme
1527784|NCT00001461|Angiotensin Converting Enzyme Inhibitors
1527785|NCT00001461|Bradykinin
1527786|NCT00001461|Endothelial Function
1527787|NCT00001461|Nitric Oxide
1527788|NCT00001461|Coronary Artery Disease
1527789|NCT00001460|Training Protocol
1527790|NCT00001460|Cardiac Diagnosis
1527791|NCT00001460|Congenital Heart Disease
1527792|NCT00001460|Acquired Heart Disease
1527793|NCT00001460|Arrhythmias
1527794|NCT00001459|Gated Blood Pool
1527795|NCT00001459|SPECT Scan
1527796|NCT00001459|Coronary Artery Disease
1527797|NCT00001459|Hypertrophic Cardiomyopathy
1527798|NCT00001459|Microvascular Angina
1527799|NCT00001458|Exercise Testing
1527800|NCT00001458|Echocardiography
1527801|NCT00001458|Cardiac Catheterization
1527802|NCT00001458|Radionuclide Stress Testing
1527803|NCT00001458|Holter Monitoring
1527804|NCT00001458|Heart Disease
1527805|NCT00001458|Muscle Leg Pain
1527806|NCT00001458|Leg Pain
1527807|NCT00001458|Circulation
1527808|NCT00001458|Peripheral Arterial Disease
1527809|NCT00001458|Intermittent Claudication
1527810|NCT00001458|Renal Vascular Disease
1527811|NCT00001458|Uncontrolled Hypertension
1527812|NCT00001457|Nucleoside Analogues
1527813|NCT00001457|Delta Hepatitis
1527814|NCT00001457|Glomerulonephritis
1527815|NCT00001457|Polyarteritis Nodosa
1527816|NCT00001457|Hepatitis Mutants
1527817|NCT00001457|3TC
1527818|NCT00001457|Chronic Hepatitis B
1527819|NCT00001457|Chronic Hepatitis D
1527820|NCT00001457|Cirrhosis
1527821|NCT00001457|Lamivudine
1527822|NCT00001456|Albinism
1527823|NCT00001456|Platelet Storage Pool Deficiency
1527824|NCT00001456|Metabolic Disease
1527825|NCT00001456|Hermansky-Pudlak Syndrome
1527826|NCT00001455|Genetics
1527827|NCT00001455|Hemochromatosis
1527828|NCT00001455|Iron Metabolism
1527829|NCT00001455|Iron Storage Disorder
1527830|NCT00001455|Pedigree
1527831|NCT00001455|Iron Overload
1527832|NCT00001454|Estrogen
1527833|NCT00001454|Progesterone
1527834|NCT00001454|Menses
1527835|NCT00001454|Endometrium
1527836|NCT00001454|Normal Volunteer
1527837|NCT00001453|Petrosal Sinus Sampling
1527838|NCT00001453|Corticotropin Releasing Hormone
1527839|NCT00001453|Cushing Syndrome
1527840|NCT00001453|Internal Jugular Vein Sampling
1527841|NCT00001453|Corticotropin Releasing Hormone Stimulation
1527842|NCT00001452|Cushing Syndrome
1527843|NCT00001452|Gene Mapping
1527844|NCT00001452|Linkage
1527845|NCT00001452|Oncogene
1527846|NCT00001452|Linkage Analysis
1527847|NCT00001452|Gene Identification
1527848|NCT00001452|Tumors
1527849|NCT00001452|Familial Neoplasia
1527850|NCT00001452|Adrenal Gland
1527851|NCT00001452|Lentigines
1527852|NCT00001452|Carney Complex
1527853|NCT00001451|Bone Marrow Transplantation
1527854|NCT00001451|Bone Marrow Donor
1527855|NCT00001451|Marrow Transplant
1527856|NCT00001451|National Marrow Donor Program (NMDP)
1527857|NCT00001451|Unrelated Marrow Donor
1527858|NCT00001451|Healthy Volunteer
1527859|NCT00001450|Chemotherapy
1527860|NCT00001450|In Vitro Testing
1527861|NCT00001450|Infusional
1527862|NCT00001450|Lung Neoplasm
1527863|NCT00001450|Pharmacokinetics
1527864|NCT00001449|Anti-Cancer Agents
1527865|NCT00001449|Antimetabolite
1527866|NCT00001449|Palliation
1527867|NCT00001449|Pharmacodynamics
1527868|NCT00001449|Pharmacokinetics
1527869|NCT00001448|Antifungal Therapy
1527870|NCT00001448|Articulation
1527871|NCT00001448|Behavior
1527872|NCT00001448|Expressive Language
1527873|NCT00001448|Thrush
1527874|NCT00001446|Angiogenesis
1527875|NCT00001446|Malignancy
1527876|NCT00001446|Neuropathy
1527877|NCT00001446|Pharmacokinetics
1527878|NCT00001446|Sedation
1527879|NCT00001445|Adjuvant-Controlled Study
1527880|NCT00001445|Double Blind Randomization
1527881|NCT00001445|Env-Deleted Inactivated HIV-1
1527882|NCT00001445|Therapeutic HIV Vaccine
1527883|NCT00001444|Pharmacokinetics
1527884|NCT00001444|Natural Products
1527885|NCT00001444|Salvage Therapy
1527886|NCT00001444|Protein Kinase Antagonist
1527887|NCT00001443|AIDS
1527888|NCT00001443|Bioavailability
1527889|NCT00001443|Immunologic Evaluations
1527890|NCT00001443|Pharmacokinetics
1527891|NCT00001443|Toxicity
1527892|NCT00001442|Taxol
1527893|NCT00001442|Squamous Cell Carcinoma
1527894|NCT00001442|Radiosensitizer
1527895|NCT00001442|Radiotherapy
1527896|NCT00001442|Tumor Potential Doubling Time (Tpot)
1527897|NCT00001440|p53
1527898|NCT00001440|Interleukin-2
1527899|NCT00001440|T-Cell Repopulation
1527900|NCT00001440|Apheresis
1527901|NCT00001440|RAS
1527902|NCT00001439|Cancer
1527903|NCT00001439|Immunotherapy
1527904|NCT00001438|HIV Infection
1527905|NCT00001438|Immune Response
1527906|NCT00001438|Pediatric
1527907|NCT00001438|Pharmacokinetics
1527908|NCT00001438|Toxicity
1527909|NCT00001437|Cytokines
1527910|NCT00001437|Fibrosis Intensity
1527911|NCT00001437|Post-Radiation Fibrosis
1527912|NCT00001437|Radiation Injury
1527913|NCT00001437|Trental
1527914|NCT00001436|Hormone Interactions
1527915|NCT00001436|IGF-I
1527916|NCT00001436|Metastatic
1527917|NCT00001436|Pediatric
1527918|NCT00001436|Recurrent
1527919|NCT00001435|Anxiety
1527920|NCT00001435|Depression
1527921|NCT00001435|Family Functioning
1527922|NCT00001435|Psychosocial Adjustment
1527923|NCT00001435|Social Support
1527924|NCT00001432|Purging
1527925|NCT00001432|Apheresis
1527926|NCT00001432|Long Term Culture
1527927|NCT00001432|T Cells
1527928|NCT00001432|Stem Cell
1527929|NCT00001431|Combined Modality
1527930|NCT00001431|GI Cancer
1527931|NCT00001431|Pancreatic Cancer
1527932|NCT00001431|Radiotherapy
1527933|NCT00001430|IL-2
1527934|NCT00001430|Drug Resistance
1527935|NCT00001430|Continuous Infusion
1527936|NCT00001430|Peripheral Stem Cells
1527937|NCT00001430|MDR
1527938|NCT00001428|Chemotherapy
1527939|NCT00001428|Cytokine
1527940|NCT00001428|Efficacy
1527941|NCT00001428|Palliation
1527942|NCT00001428|Solid Tumor
1527943|NCT00001427|Pharmacodynamic Studies
1527944|NCT00001427|Pharmacokinetics
1527945|NCT00001426|Ovarian Cancer
1527946|NCT00001426|Initial Therapy
1527947|NCT00001426|Paclitaxel
1527948|NCT00001426|Cisplatin
1527949|NCT00001426|Cyclophosphamide
1527950|NCT00001424|AIDS
1527951|NCT00001424|Children
1527952|NCT00001424|Human Immunodeficiency Virus
1527953|NCT00001422|Adenine Analogue
1527954|NCT00001422|Apoptosis
1527955|NCT00001422|Cytokines
1527956|NCT00001422|Psoriasis
1527957|NCT00001422|Synovium
1527958|NCT00001422|Psoriatic Arthritis
1527959|NCT00001421|Cytotoxicity
1527960|NCT00001421|HLA Class I
1527961|NCT00001421|Lymphocytes
1527962|NCT00001421|Muscle
1527963|NCT00001421|Myositis
1527964|NCT00001421|Thionamides
1527965|NCT00001421|Dermatomyositis
1527966|NCT00001421|Polymyositis
1527967|NCT00001420|Lymphocytes
1527968|NCT00001420|Cytokines
1527969|NCT00001420|Apoptosis
1527970|NCT00001420|Psoriasis
1527971|NCT00001420|Genetics
1527972|NCT00001420|Psoriatic Arthritis
1527973|NCT00001418|Sympathetic Nervous System
1527974|NCT00001418|Dysautonomias
1527975|NCT00001418|Postural Tachycardia Syndrome
1527976|NCT00001418|Neurocardiogenic Syncope
1527977|NCT00001418|Hypernoradrenergic Hypertension
1527978|NCT00001418|Sympathectomy
1527979|NCT00001418|Fluorodopamine
1527980|NCT00001418|Positron Emission Tomography
1527981|NCT00001418|Norepinephrine
1527982|NCT00001418|Dopamine
1527983|NCT00001418|Neurocardiologic Disorder
1527984|NCT00001417|Needle Biopsy
1527985|NCT00001417|Computed Tomography
1527986|NCT00001417|Magnetic Resonance Imaging
1527987|NCT00001417|Spinal Angiography
1527988|NCT00001417|Intratumoral Pressure
1527989|NCT00001417|Vertebral Hemangioma
1527990|NCT00001417|Spinal Metastasis
1527991|NCT00001417|Absolute Ethanol
1527992|NCT00001417|Spinal Tumor
1527993|NCT00001417|Vertebral Tumor
1527994|NCT00001416|Bone Disease
1527995|NCT00001416|Calcitriol
1527996|NCT00001416|Enzyme Replacement Therapy
1527997|NCT00001416|Gaucher's Disease
1527998|NCT00001416|Vitamin D
1527999|NCT00001415|IL-1
1528000|NCT00001415|IL-6
1528001|NCT00001415|Immune Response
1528002|NCT00001415|Inflammation
1528003|NCT00001415|Steroids
1528004|NCT00001415|Chronic Fatigue Syndrome
1528005|NCT00001415|Depression
1528006|NCT00001415|Fibromyalgia
1528007|NCT00001415|Normal Volunteer
1528008|NCT00001414|Behavior Genetics
1528009|NCT00001414|Normal Personality
1528010|NCT00001414|Intelligence
1528011|NCT00001414|Siblings
1528012|NCT00001414|Sixteen Personality Factor Questionnaire
1528013|NCT00001414|NEO-Personality Inventory (Revised)
1528014|NCT00001414|X-Chromosome
1528015|NCT00001413|Corticosteroids
1528016|NCT00001413|Osteoporosis
1528017|NCT00001413|Depression
1528018|NCT00001413|DEXA Scan
1528019|NCT00001413|Body Mass
1528020|NCT00001413|Dual X-Ray
1528021|NCT00001413|Energy Absorptiometry
1528022|NCT00001413|Normal Volunteer
1528023|NCT00001412|Gonadal Steroids
1528024|NCT00001412|Central Nervous System Function
1528025|NCT00001412|GnRH Agonist
1528026|NCT00001412|Testosterone
1528027|NCT00001412|Leuprolide Acetate
1528028|NCT00001412|Mood
1528029|NCT00001412|Behavior
1528030|NCT00001412|Cognitive Function
1528031|NCT00001410|Recombinant Production
1528032|NCT00001410|Inherited Disease
1528033|NCT00001410|Lysosomal Disorder
1528034|NCT00001410|Inborn Error of Metabolism
1528035|NCT00001410|Enzyme Replacement Therapy
1528036|NCT00001410|Glucocerebrosidase
1528037|NCT00001410|Polyethylene Glycol
1528038|NCT00001410|Gaucher Disease
1528039|NCT00001410|Recombinant Enzyme
1528040|NCT00001409|AIDS
1528041|NCT00001409|Gene Therapy
1528042|NCT00001409|T Cell Universal Receptor
1528043|NCT00001409|Ex Vivo Activation
1528044|NCT00001408|Lymphocytes
1528045|NCT00001408|Asthma
1528046|NCT00001408|Cytokines
1528047|NCT00001408|Interleukin-5
1528048|NCT00001408|Late Phase Response
1528049|NCT00001407|Cytokines
1528050|NCT00001407|Mycobacteria
1528051|NCT00001407|Pneumonia
1528052|NCT00001407|Multiple Drug Resistant Tuberculosis
1528053|NCT00001406|Eosinophils
1528054|NCT00001406|Helminth Parasites
1528055|NCT00001406|Hypereosinophilia
1528056|NCT00001406|Allergy
1528057|NCT00001406|Asthma
1528058|NCT00001405|Chronic Granulomatous Disease
1528059|NCT00001405|Apheresis
1528060|NCT00001405|CD34 Cells
1528061|NCT00001405|Infection
1528062|NCT00001405|Nadph Oxidase
1528063|NCT00001405|Normal Volunteer
1528064|NCT00001404|Abnormalities, Multiple
1528065|NCT00001404|Hypothalamic Hamartoma
1528066|NCT00001404|Polysyndactyly
1528067|NCT00001404|Autosomal Dominant
1528068|NCT00001404|Mutation
1528069|NCT00001404|Gelastic
1528070|NCT00001404|Gelastic Seizure
1528071|NCT00001404|Hypothalamic
1528072|NCT00001404|Malformations
1528073|NCT00001404|Polydactyly
1528074|NCT00001404|Pallister-Hall Syndrome
1528077|NCT00001402|Dilated Cardiomyopathy
1528078|NCT00001402|Hibernating Myocardium
1528079|NCT00001402|Ischemic Cardiomyopathy
1528080|NCT00001402|Metoprolol
1528081|NCT00001402|Stress Thallium Scintigraphy
1528082|NCT00001402|Congestive Cardiomyopathy
1528083|NCT00001402|Congestive Heart Failure
1528084|NCT00001402|Heart Failure
1528085|NCT00001400|Heart Disease
1528086|NCT00001400|Screening
1528087|NCT00001400|Follow-Up
1528088|NCT00001399|Gene Therapy
1528089|NCT00001399|Stem Cell Rescue
1528090|NCT00001399|Bone Marrow Failure
1528091|NCT00001399|Fanconi Anemia
1528092|NCT00001398|Hematopoiesis
1528093|NCT00001398|Stem Cell Cycling
1528094|NCT00001398|Bone Marrow Failure
1528095|NCT00001398|Acquired Aplastic Anemia
1528096|NCT00001397|Hematologic Malignancies
1528097|NCT00001396|Pacemaker
1528098|NCT00001396|Pediatric
1528099|NCT00001396|Obstructive HCM
1528100|NCT00001395|Cataracts
1528101|NCT00001395|Complications
1528102|NCT00001395|Rates of Progression
1528103|NCT00001395|Diabetic Retinopathy
1528104|NCT00001394|Hyperparathyroidism
1528105|NCT00001394|Arterial Stimulation
1528106|NCT00001394|Venous Sampling
1528107|NCT00001394|Parathyroid Adenoma
1528108|NCT00001394|Parathyroid Hyperplasia
1528109|NCT00001393|Collapsing Glomerulopathy
1528110|NCT00001393|Renal Disease
1528111|NCT00001393|HIV Associated Nephropathy
1528112|NCT00001392|Retrovirus
1528113|NCT00001392|PCR
1528114|NCT00001392|Renal Failure
1528115|NCT00001392|HIV
1528116|NCT00001392|Rituximab
1528117|NCT00001391|Augmentation
1528118|NCT00001391|Osteogenesis
1528119|NCT00001391|Stem Cells
1528120|NCT00001391|Bone Formation
1528121|NCT00001391|Bone Induction
1528122|NCT00001390|Saliva
1528123|NCT00001390|Parotid
1528124|NCT00001390|Lip Biopsy
1528125|NCT00001390|Health
1528126|NCT00001390|Exocrine
1528127|NCT00001390|Normal Volunteer
1528128|NCT00001387|Paclitaxel
1528129|NCT00001387|Pediatric
1528130|NCT00001387|Pharmacokinetics
1528131|NCT00001387|Phase I
1528132|NCT00001387|Toxicity
1528133|NCT00001386|AIDS
1528134|NCT00001386|Retrovirus
1528135|NCT00001386|Therapeutic Vaccine
1528136|NCT00001386|Vaccine
1528137|NCT00001386|Helper T Cells
1528138|NCT00001385|Cancer Diagnosis
1528139|NCT00001385|Cancer Metabolism
1528140|NCT00001385|FDG
1528141|NCT00001385|FDG Breast Imaging
1528142|NCT00001385|PET
1528143|NCT00001385|Positron Emission Mammography
1528144|NCT00001385|Radiopharmaceutical
1528145|NCT00001385|Scintimammography
1528146|NCT00001384|14-Day Cycle
1528147|NCT00001384|Dose Intensity
1528148|NCT00001384|Filgrastim
1528149|NCT00001384|Lymph Node Positive
1528150|NCT00001384|Non-Cross Resistant
1528151|NCT00001383|Cyclosporine Analogue
1528152|NCT00001383|Multidrug Resistance
1528153|NCT00001383|Pgp Blocker
1528154|NCT00001383|Pump Blocker
1528155|NCT00001383|Taxol Over 90 Hours
1528156|NCT00001382|Immunotherapy
1528157|NCT00001382|Vaccine
1528158|NCT00001381|Adult
1528159|NCT00001381|Intravesical Chemotherapy
1528160|NCT00001379|Epstein-Barr Virus
1528161|NCT00001379|Lymphoproliferative Disorder
1528162|NCT00001379|Viral
1528163|NCT00001379|Immunosuppression
1528164|NCT00001379|Lymphoma
1528165|NCT00001378|4-Quadrant Fine Needle Aspiration
1528166|NCT00001378|Biomarkers
1528167|NCT00001378|Chemoprevention
1528168|NCT00001378|Nipple Suction Aspirates
1528169|NCT00001378|TGF Beta
1528170|NCT00001377|Familial
1528171|NCT00001377|Inherited Prostate Cancer
1528172|NCT00001377|Linkage
1528173|NCT00001377|Prostate Cancer
1528174|NCT00001376|Androgens
1528175|NCT00001376|Female
1528176|NCT00001376|Immunology
1528177|NCT00001376|Neuroendocrine Axis
1528178|NCT00001376|Rheumatoid Arthritis
1528179|NCT00001376|Postpartum
1528180|NCT00001376|Pregnancy
1528181|NCT00001375|Infection
1528182|NCT00001375|Reactive Arthritis
1528183|NCT00001375|Rheumatoid Arthritis
1528184|NCT00001375|Synovial Biopsy
1528185|NCT00001375|Synovial Fluid
1528186|NCT00001375|Synovitis
1528187|NCT00001373|Auto-Inflammation
1528188|NCT00001373|Familial Mediterranean Fever
1528189|NCT00001373|Genetics
1528190|NCT00001373|Periodic Fever
1528191|NCT00001372|Systemic Lupus Erythematosus
1528192|NCT00001372|Natural History
1528193|NCT00001372|Lupus Nephritis
1528194|NCT00001372|Lupus
1528195|NCT00001372|Systemic Lupus
1528196|NCT00001372|SLE
1528197|NCT00001371|Inflammation
1528198|NCT00001371|Lipocortin
1528199|NCT00001371|Phospholipase A-2
1528200|NCT00001371|Skin
1528201|NCT00001371|Uteroglobin
1528202|NCT00001371|Psoriasis
1528203|NCT00001368|Cerebral Ischemia
1528204|NCT00001368|Hypertension
1528205|NCT00001368|Immune Response
1528206|NCT00001368|Carotid Stenosis
1528207|NCT00001368|Atherosclerosis
1528208|NCT00001367|Human
1528209|NCT00001367|Movement
1528210|NCT00001367|Non-Investigational to Diagnostic Puzzle
1528211|NCT00001367|Parkinson's
1528212|NCT00001367|Dystonia
1528213|NCT00001367|Cerebellar
1528214|NCT00001367|Puzzles
1528215|NCT00001367|Neurological Disorders
1528216|NCT00001367|Movement Disorders
1528217|NCT00001366|Neuroimaging
1528218|NCT00001366|Seizures
1528219|NCT00001366|Cerebral Localization
1528220|NCT00001366|Partial Epilepsy
1528221|NCT00001366|Epilepsy
1528222|NCT00001365|Dextromethorphan
1528223|NCT00001365|Dextrorphan
1528224|NCT00001365|Glutamate Antagonist
1528225|NCT00001365|Parkinson's Disease
1528226|NCT00001364|Spinal Arteriovenous Malformations
1528227|NCT00001364|Spinal Dural Arteriovenous Fistulas
1528228|NCT00001364|Surgery
1528229|NCT00001364|Embolization
1528230|NCT00001364|Spinal Arteriography
1528231|NCT00001363|Blood Flow
1528232|NCT00001363|Chess Play
1528233|NCT00001363|Frontal Lobe
1528234|NCT00001363|Neurobehavioral Deficits
1528235|NCT00001363|Neuropsychology
1528236|NCT00001363|Positron Emission Tomography
1528237|NCT00001363|Prefrontal Cortex
1528238|NCT00001362|Magnetic Resonance Imaging
1528239|NCT00001362|Contrast Enhancement
1528240|NCT00001362|Neuroanatomic Morphometry
1528241|NCT00001362|Neurobehavioral Deficits
1528242|NCT00001362|Neurological Disorders
1528243|NCT00001362|Blood Flow
1528244|NCT00001362|Blood Volume
1528245|NCT00001362|Normal Volunteer
1528246|NCT00001361|Movement Disorders
1528247|NCT00001361|Sensory Processing
1528248|NCT00001361|Stroke
1528249|NCT00001361|Spinal Cord Injury
1528250|NCT00001361|Blood Flow
1528251|NCT00001361|Blood Volume
1528252|NCT00001361|Cognitive Function
1528253|NCT00001361|Neurobehavioral Deficits
1528254|NCT00001361|Neurological Disorders
1528255|NCT00001361|Magnetic Resonance Imaging
1528256|NCT00001361|Plasticity
1528257|NCT00001361|Normal Volunteer
1528258|NCT00001360|Cognition
1528259|NCT00001360|Vision
1528260|NCT00001360|Cortex
1528261|NCT00001360|Visual Processing
1528262|NCT00001360|Magnetic Resonance Imaging
1528263|NCT00001359|Obsessive Compulsive Disorder
1528264|NCT00001359|PANDAS Associated with Streptococcal Infections
1528265|NCT00001359|Adolescents
1528266|NCT00001359|Autoimmune Illness
1528267|NCT00001359|Children
1528268|NCT00001359|Tic Disorders
1528269|NCT00001359|Streptococcal Infections
1528270|NCT00001359|Childhood Onset Neuropsychiatric Disorder
1528271|NCT00001357|Cytokines
1528272|NCT00001357|Immunoregulation
1528273|NCT00001357|CD4 Cells
1528274|NCT00001356|IL-3
1528275|NCT00001356|Stem Cell Factor
1528276|NCT00001356|Cytokines
1528277|NCT00001356|Cell Differentiation
1528278|NCT00001356|Receptors
1528279|NCT00001356|Bone Marrow
1528280|NCT00001356|Mastocytosis
1528286|NCT00001354|AIDS
1528287|NCT00001354|Immunotherapy
1528288|NCT00001354|CD4 Cells
1528289|NCT00001354|Immunomodulator
1528290|NCT00001354|Cytokines
1528291|NCT00001353|AIDS
1528292|NCT00001353|Immune Based Therapy
1528293|NCT00001353|Adoptive Immunotherapy
1528294|NCT00001353|Lymphapheresis
1528295|NCT00001353|Ex Vivo Activation
1528296|NCT00001353|HIV
1528297|NCT00001353|Gene Therapy
1528298|NCT00001353|Protease Inhibitor
1528299|NCT00001353|Interleukin-2
1528300|NCT00001353|Indinavir
1528304|NCT00001351|Chronic Infection
1528305|NCT00001351|Infectious Diseases
1528306|NCT00001351|Host Response
1528307|NCT00001351|Immunologic Disorders
1528308|NCT00001351|Acute Infection
1528309|NCT00001350|Immunoregulation
1528310|NCT00001350|T Cell Receptor Alpha/Beta
1528311|NCT00001350|Lymphadenopathy
1528312|NCT00001350|ALPS
1528313|NCT00001350|Autoimmune Lymphoproliferative Syndrome
1528314|NCT00001349|Plasmapheresis
1528315|NCT00001349|Lymphocytes
1528316|NCT00001349|Eosinophils
1528317|NCT00001349|Neutrophils
1528318|NCT00001347|Linkage Analysis
1528319|NCT00001347|Genomic DNA
1528320|NCT00001347|Pedigree Analysis
1528321|NCT00001347|Usher Syndrome
1528322|NCT00001347|Usher Syndrome Type 1
1528323|NCT00001347|Usher Syndrome Type 2
1528324|NCT00001346|Diabetic Macular Edema
1528325|NCT00001346|Diabetic Retinopathy
1528326|NCT00001346|Macular Edema
1528327|NCT00001346|Photocoagulation
1528328|NCT00001346|Psychophysical Testing
1528329|NCT00001346|Stiles-Crawford Effect
1528330|NCT00001345|Hypercalcemia
1528331|NCT00001345|Multiple Endocrine Neoplasia (MEN)
1528332|NCT00001345|Familial Hypocalciuric Hypercalcemia
1528333|NCT00001345|Hyperparathyroidism
1528334|NCT00001345|Linkage Analysis
1528335|NCT00001344|Diabetes Mellitus
1528336|NCT00001344|Diabetic Neuropathy
1528337|NCT00001344|Memantine
1528338|NCT00001344|NMDA Receptor Antagonists
1528339|NCT00001344|Neuropathic Pain
1528340|NCT00001344|Neuropathy
1528341|NCT00001344|Post-Herpetic Neuralgia
1528342|NCT00001344|Shingles
1528343|NCT00001343|Turner's Syndrome
1528344|NCT00001343|Short Stature
1528345|NCT00001343|Cognitive Function
1528346|NCT00001343|Sex Steroids
1528347|NCT00001343|Turner Syndrome
1528348|NCT00001343|TS
1528349|NCT00001342|Electrooculography
1528350|NCT00001342|Electroretinogram
1528351|NCT00001342|Fluorescein Angiogram
1528352|NCT00001342|Glycogen Storage Disease
1528353|NCT00001341|Antifolate
1528354|NCT00001341|Inhibitor
1528355|NCT00001341|Pharmacokinetics
1528356|NCT00001341|Thymidylate Synthetase
1528357|NCT00001341|Toxicity
1528358|NCT00001339|Multidrug Resistance
1528359|NCT00001339|Reversal of Drug Resistance
1528360|NCT00001339|P-Glycoprotein
1528361|NCT00001339|MDR-1
1528362|NCT00001338|Fusion Protein
1528363|NCT00001337|Primary Mediastinal B-Cell Lymphoma
1528364|NCT00001337|CD20 +
1528365|NCT00001337|Diffuse Large B-Cell Lymphoma
1528366|NCT00001337|Anaplastic Large Cell Lymphoma
1528367|NCT00001337|De Novo
1528368|NCT00001336|Transplantation
1528369|NCT00001336|Cancer
1528370|NCT00001336|Cellular Immunity
1528371|NCT00001336|Stem Cell Function
1528372|NCT00001336|Immunodeficiency
1528373|NCT00001335|Peripheral Stem Cell Transfusion
1528374|NCT00001335|Up-Front Phase II Window
1528375|NCT00001335|Dose-Intensive Vincristine
1528376|NCT00001335|Dose-Intensive Doxorubicin
1528377|NCT00001335|Dose-Intensive Cyclophosphamide
1528378|NCT00001335|ADR-529 for Cardioprotection
1528379|NCT00001335|BID Radiation Therapy for Local Control
1528380|NCT00001333|Intraventricular
1528381|NCT00001333|Meningeal Malignancy
1528382|NCT00001333|NSC 609699
1528383|NCT00001333|SKF 104864
1528384|NCT00001333|Topoisomerase 1
1528385|NCT00001332|Cancer Treatment
1528386|NCT00001332|Chemotherapy
1528387|NCT00001332|Regional Therapy
1528388|NCT00001332|Surgery
1528389|NCT00001331|Myopathy
1528390|NCT00001331|Phosphofructokinase
1528391|NCT00001331|Acid Maltase
1528392|NCT00001331|Pompe
1528393|NCT00001331|Muscle Diseases
1528394|NCT00001331|Genetic Muscle Diseases
1528395|NCT00001330|Autoimmune Diseases
1528396|NCT00001330|Connective Tissue Disease
1528397|NCT00001330|Scleroderma
1528398|NCT00001330|Silicone Device Implants
1528399|NCT00001330|Silicone Injection
1528400|NCT00001330|Idiopathic Scleroderma
1528401|NCT00001330|Myositis
1528402|NCT00001330|Systemic Sclerosis
1528403|NCT00001329|Yohimbine
1528404|NCT00001329|Catecholamines
1528405|NCT00001329|Sympathoadrenal Response
1528406|NCT00001329|Sympathetic Nervous System
1528407|NCT00001329|Stress
1528408|NCT00001329|Hypertension
1528409|NCT00001329|Autonomic Failure
1528410|NCT00001328|Cancer
1528411|NCT00001328|Gene Transfer
1528412|NCT00001328|Recurrent Tumors
1528413|NCT00001328|Primary Tumors
1528414|NCT00001328|Metastases
1528415|NCT00001328|Anti-Viral Drugs
1528416|NCT00001328|Chemosensitization
1528417|NCT00001328|Brain Tumors
1528418|NCT00001328|Gene Therapy
1528419|NCT00001328|Ganciclovir
1528420|NCT00001327|Syringomyelia
1528421|NCT00001327|Chiari Malformation
1528422|NCT00001327|Magnetic Resonance Imaging
1528423|NCT00001327|Intraoperative Ultrasonography
1528424|NCT00001327|Hydrocephalus
1528425|NCT00001327|Spinal Cord
1528426|NCT00001327|Ventriculostomy
1528427|NCT00001327|Lumbar Puncture
1528428|NCT00001327|Pressure Measurement
1528429|NCT00001325|Positron
1528430|NCT00001325|Tomography
1528431|NCT00001325|Seizures
1528432|NCT00001325|Epileptic Focus
1528433|NCT00001325|Electroencephalography
1528434|NCT00001325|Metabolism
1528435|NCT00001325|Glucose
1528436|NCT00001325|Cerebral
1528437|NCT00001325|Positron Emission Tomography
1528438|NCT00001325|Lennox Gastaut Syndrome
1528439|NCT00001324|Ataxia
1528440|NCT00001324|Brain
1528441|NCT00001324|Motor Learning
1528442|NCT00001324|Parkinson's Disease
1528443|NCT00001324|Physiology
1528444|NCT00001324|Positron Emission Tomography
1528445|NCT00001324|Stroke
1528446|NCT00001324|Tremor
1528447|NCT00001324|Voluntary and Involuntary Movement Physiology
1528448|NCT00001324|Movement Disorders
1528449|NCT00001324|Normal Volunteer
1528450|NCT00001323|Cognition
1528451|NCT00001323|Neuropsychology
1528452|NCT00001323|Neuropsychological Tests
1528453|NCT00001323|Neurological Exam
1528454|NCT00001323|Psychiatric
1528455|NCT00001323|Attention
1528456|NCT00001323|Schizophrenic
1528457|NCT00001323|Schizoaffective
1528458|NCT00001323|Working Memory
1528459|NCT00001323|Memory
1528460|NCT00001322|Gonadal Steroids
1528461|NCT00001322|Mood
1528462|NCT00001322|Menstrual Cycle
1528463|NCT00001322|Neuropsychological Testing
1528464|NCT00001322|Estrogen
1528465|NCT00001322|Dexamethasone
1528466|NCT00001322|Progesterone
1528467|NCT00001322|Central Nervous System Function
1528468|NCT00001322|Estradiol
1528469|NCT00001322|GnRH Agonist
1528470|NCT00001320|Parkinson's Disease
1528471|NCT00001320|Schizophrenia
1528472|NCT00001320|Dopamine D2/D3 receptors
1528473|NCT00001320|Brain Imaging
1528474|NCT00001320|SPECT
1528475|NCT00001320|Equilibrium
1528476|NCT00001320|Brain Scan
1528477|NCT00001320|Brain Research
1528478|NCT00001320|Brain Disorders
1528479|NCT00001320|Schizoaffective Disorder
1528480|NCT00001320|Normal Volunteer
1528481|NCT00001319|HIV Negative
1528482|NCT00001319|CD4 Deficiency
1528483|NCT00001319|Retrovirus
1528484|NCT00001318|Immune Adjuvant
1528485|NCT00001318|Phagocytes
1528486|NCT00001318|Non-tuberculous Mycobacterial Infection
1528487|NCT00001317|Children
1528488|NCT00001317|Gamma Interferon
1528489|NCT00001317|Hospitalizations
1528490|NCT00001317|Infection
1528491|NCT00001317|Chronic Granulomatous Disease
1528497|NCT00001314|Aortic Regurgitation
1528498|NCT00001314|Dobutamine Stress
1528499|NCT00001314|Left Ventricular Function
1528500|NCT00001314|Mitral Regurgitation
1528501|NCT00001314|Myocardial Contractile Reserve
1528502|NCT00001314|Transesophageal Echocardiography
1528503|NCT00001313|Cardiac Diagnosis
1528504|NCT00001313|Chest Pain
1528505|NCT00001313|Hypertrophic Cardiomyopathy
1528506|NCT00001313|Coronary Artery Disease
1528507|NCT00001313|Microvascular Angina
1528508|NCT00001313|Cardiac Investigation
1528509|NCT00001313|Follow-up
1528510|NCT00001313|Heart Disease
1528511|NCT00001311|Cell/Flare Meter
1528512|NCT00001311|Heparin Coating
1528513|NCT00001311|Inflammation
1528514|NCT00001311|Laser Cell Flare Photometry
1528515|NCT00001311|Multicentric
1528516|NCT00001311|Polymethylmetacrylate
1528517|NCT00001311|Specular Micrography
1528518|NCT00001311|Specular Microscopy
1528519|NCT00001310|Retinal Disease
1528520|NCT00001310|Diabetic Retinopathy
1528521|NCT00001310|Uveitis
1528522|NCT00001310|Age-Related Macular Degeneration
1528523|NCT00001310|Corneal Disease
1528524|NCT00001310|Ocular Disease
1528525|NCT00001309|Pharmacokinetics
1528526|NCT00001309|Biodistribution
1528527|NCT00001309|Ascorbic Acid
1528528|NCT00001308|Stuttering
1528529|NCT00001308|Tourette's Syndrome
1528530|NCT00001308|Spasmodic Dysphonia
1528531|NCT00001308|Dysarthria
1528532|NCT00001308|Parkinson's Disease
1528533|NCT00001308|Verbal Dyspraxia
1528534|NCT00001308|Aphasia
1528535|NCT00001308|Speech
1528536|NCT00001308|Motor Control
1528537|NCT00001307|Analgesia
1528538|NCT00001307|PET
1528539|NCT00001307|Positron Emission
1528540|NCT00001307|Functional Brain Imaging
1528541|NCT00001307|Allodynia
1528542|NCT00001307|Thalamus
1528543|NCT00001307|Somatosensory Cortex
1528544|NCT00001307|Reflex Sympathetic Dystrophy
1528545|NCT00001307|Normal Volunteer
1528546|NCT00001307|Chronic Pain
1528547|NCT00001306|Infertility
1528548|NCT00001306|Ovulation
1528549|NCT00001306|Autoimmune
1528550|NCT00001306|Follicle
1528551|NCT00001306|Menopause
1528552|NCT00001306|Biopsy
1528553|NCT00001306|Glucocorticoids
1528554|NCT00001306|Premature Ovarian Failure
1528555|NCT00001306|Amenorrhea
1528556|NCT00001306|Ovarian Failure
1528557|NCT00001306|POF
1528558|NCT00001305|Osteogenesis Imperfecta
1528559|NCT00001304|Hypoparathyroidism
1528560|NCT00001304|Parathyroid Hormone
1528561|NCT00001304|Vitamin D
1528562|NCT00001304|Calcium Metabolism
1528563|NCT00001304|PTH 1-34
1528564|NCT00001304|Bone
1528565|NCT00001303|Hemodynamics
1528566|NCT00001303|Lung Permeability
1528567|NCT00001303|Endotoxin Tolerance
1528568|NCT00001303|Bronchoscopy
1528569|NCT00001303|Human Recombinant Interleukin-1 Receptor
1528570|NCT00001303|Normal Volunteer
1528571|NCT00001302|Vinblastine
1528572|NCT00001302|Multidrug Resistance
1528573|NCT00001302|Resistance Reversal
1528574|NCT00001302|Pgp Blocker
1528575|NCT00001302|Pharmacokinetics
1528576|NCT00001302|Cyclosporine
1528577|NCT00001302|Drug Interactions
1528578|NCT00001301|Adverse Effects
1528579|NCT00001301|Burkitt's Lymphoma
1528580|NCT00001301|Diffuse Large Cell Lymphoma
1528581|NCT00001301|Extended Remission
1528582|NCT00001301|Health Status
1528583|NCT00001301|Lymphoblastic Lymphoma
1528584|NCT00001301|Molecular Studies
1528585|NCT00001300|Adjuvant Chemotherapy
1528586|NCT00001300|Ifosfamide
1528587|NCT00001300|Randomized Study
1528588|NCT00001300|Soft Tissue Sarcoma
1528589|NCT00001298|Antibody
1528590|NCT00001298|DAMPA
1528591|NCT00001298|Enzyme
1528592|NCT00001298|Kidney
1528593|NCT00001298|Pharmacokinetics
1528594|NCT00001298|Thymidine
1528595|NCT00001298|Toxicity
1528596|NCT00001296|Interferon-Gamma
1528597|NCT00001296|Isolated Limb Perfusion
1528598|NCT00001296|Melanoma
1528599|NCT00001296|Melphalan
1528600|NCT00001296|TNF
1528601|NCT00001295|Follow-Up
1528602|NCT00001295|Treatment
1528603|NCT00001294|Genetic Linkage
1528604|NCT00001294|Sex Behavior
1528605|NCT00001294|AIDS
1528606|NCT00001294|Alcohol Dependence
1528607|NCT00001294|HLA System
1528608|NCT00001294|Cancer
1528609|NCT00001292|DNA Markers
1528610|NCT00001292|Family Studies
1528611|NCT00001292|Gene Mapping
1528612|NCT00001292|Ichthyosis
1528613|NCT00001292|Keratin
1528614|NCT00001292|Linkage Analysis
1528615|NCT00001292|Scaling Disorders
1528616|NCT00001292|Skin
1528617|NCT00001291|Osteoarthritis
1528618|NCT00001291|Psoriatic Arthritis
1528619|NCT00001291|Rheumatoid Arthritis
1528620|NCT00001291|Synovial Biopsy
1528621|NCT00001291|Synovitis
1528622|NCT00001291|Synovium
1528623|NCT00001289|Enzyme Replacement
1528624|NCT00001289|Type 3 Gaucher's Disease
1528625|NCT00001289|Lysosomal Storage
1528626|NCT00001289|Supranuclear Gaze Palsy
1528627|NCT00001289|Seizures
1528628|NCT00001289|Mental Retardation
1528629|NCT00001289|Gaucher Disease
1528630|NCT00001288|Positron Emission Tomography
1528631|NCT00001288|Epilepsy
1528632|NCT00001288|Stroke
1528633|NCT00001287|Intravenous High-Dose Immunoglobulin
1528634|NCT00001287|Monoclonal Gammopathies
1528635|NCT00001287|Peripheral Nerve Demyelination
1528636|NCT00001287|CIDP
1528637|NCT00001287|Chronic Inflammatory Demyelinating Polyneuropathy
1528638|NCT00001285|Circadian Rhythms
1528639|NCT00001285|Environmental Light
1528640|NCT00001285|Estrogen
1528641|NCT00001285|Melatonin
1528642|NCT00001285|Progesterone
1528643|NCT00001285|Rapid Cycling Bipolar Disorder
1528644|NCT00001285|Sleep
1528645|NCT00001285|Testosterone
1528646|NCT00001285|Depression
1528647|NCT00001285|Hypomania
1528648|NCT00001285|Mania
1528649|NCT00001284|Cognition
1528650|NCT00001284|Schizophrenia
1528651|NCT00001284|Magnetic Resonance Imaging
1528652|NCT00001284|Magnetic Resonance Spectroscopy
1528653|NCT00001284|Dopaminergic Mechanisms
1528654|NCT00001282|HIV
1528655|NCT00001282|Immunomodulator
1528656|NCT00001282|Anti-Viral
1528660|NCT00001280|Aspergillosis
1528661|NCT00001280|Phagocyte Defect
1528662|NCT00001280|Torulopsis
1528663|NCT00001280|Chronic Granulomatous Disease
1528664|NCT00001278|Conjunctival Biopsy
1528665|NCT00001278|Lacrimal Gland Biopsy
1528666|NCT00001278|Sarcoid Uveitis
1528667|NCT00001278|Sarcoidosis
1528668|NCT00001278|Conjunctiva
1528669|NCT00001278|Inflammatory Eye Disease
1528673|NCT00001276|Hypoglycemia
1528674|NCT00001276|Insulinoma
1528675|NCT00001275|Menopause
1528676|NCT00001275|Estrogen
1528677|NCT00001275|Infertility
1528678|NCT00001275|Ovulation
1528679|NCT00001275|Amenorrhea
1528680|NCT00001275|Hypergonadotropic Hypogonadism
1528681|NCT00001275|Young Women
1528682|NCT00001275|Gonadal Steroid Deficiency
1528683|NCT00001275|Mineralocorticoid Deficiency
1528684|NCT00001275|Premature Ovarian Failure
1528685|NCT00001275|POF
1528686|NCT00001272|Adult
1528687|NCT00001272|Cytotoxic Chemotherapy
1528688|NCT00001272|Hematopoietic Growth Factor
1528689|NCT00001271|Antigen Modulation
1528690|NCT00001271|Pharmacokinetics
1528691|NCT00001271|Ricin A Chain
1528692|NCT00001270|Chemotherapy
1528693|NCT00001270|High Dose
1528694|NCT00001270|Protection
1528695|NCT00001269|Dose-Intensive Chemotherapy
1528696|NCT00001269|Hematopoietic Growth Factor
1528697|NCT00001269|Peripheral Blood Progenitor Cell
1528698|NCT00001267|Anti-Viral
1528699|NCT00001267|Dideoxynucleosides
1528700|NCT00001267|HIV
1528701|NCT00001267|Retrovirus
1528702|NCT00001266|Bayesian
1528703|NCT00001266|Hydroxy-Flutamide
1528704|NCT00001266|Combined Androgen Ablation
1528705|NCT00001266|Prostate Specific Antigen
1528706|NCT00001265|Autoimmune Diseases
1528707|NCT00001265|Idiopathic Inflammatory Myopathies
1528708|NCT00001265|Polymyositis
1528709|NCT00001265|Dermatomyositis
1528710|NCT00001265|Inclusion Body Myositis
1528711|NCT00001265|Pathogenesis
1528712|NCT00001265|Connective Tissue Diseases
1528713|NCT00001262|Menkes
1528714|NCT00001262|Copper
1528715|NCT00001262|X-Linked
1528716|NCT00001262|Neurodegeneration
1528717|NCT00001262|ATP7A
1528718|NCT00001261|Polymyositis/Dermatomyositis
1528719|NCT00001261|Muscle Immunopathology
1528720|NCT00001261|Intravenous High-Dose Immunoglobulin
1528721|NCT00001261|Inclusion Body Myositis
1528722|NCT00001260|Schizophrenia
1528723|NCT00001260|Neuropathology
1528724|NCT00001260|Neurochemistry
1528725|NCT00001260|Substance Abuse
1528726|NCT00001260|Bipolar Disorder
1528727|NCT00001260|Aging
1528728|NCT00001260|Normal Development
1528729|NCT00001260|Depression
1528730|NCT00001260|Anxiety Disorders
1528731|NCT00001260|Suicide
1528732|NCT00001260|Dementia
1528733|NCT00001260|Neuropsychiatric Disorders
1528734|NCT00001260|Tourette's Syndrome
1528735|NCT00001260|Normal Controls
1528736|NCT00001259|Depression
1528737|NCT00001259|Menstrual Cycle
1528738|NCT00001259|Gonadal Steroids
1528739|NCT00001259|GnRH Agonist
1528740|NCT00001259|Mood Disorders
1528741|NCT00001258|Neuropsychology
1528742|NCT00001258|Cerebral Blood Flow
1528743|NCT00001258|Cognitive Disorders
1528744|NCT00001258|Prefrontal Cortex
1528745|NCT00001258|Hormones
1528746|NCT00001258|Psychosis
1528747|NCT00001258|Neuroimaging
1528748|NCT00001258|Brain Scan
1528749|NCT00001258|Healthy Volunteers
1528750|NCT00001258|Schizophrenia
1528751|NCT00001257|Lymphokines
1528752|NCT00001257|LTB4
1528753|NCT00001257|Inflammation
1528754|NCT00001257|Normal Volunteer
1528755|NCT00001257|Abnormal Phagocyte Function
1528756|NCT00001256|Vasculitis
1528757|NCT00001256|Cytotoxic Therapy
1528758|NCT00001256|Inflammation
1528759|NCT00001256|Glomerulonephritis
1528760|NCT00001256|Inflammatory Sinusitis
1528761|NCT00001255|Retroviral Vector
1528762|NCT00001255|Gene Therapy
1528763|NCT00001255|PEG-ADA
1528764|NCT00001255|Severe Combined Immunodeficiency (SCID)
1528765|NCT00001255|Adenosine Deaminase Deficiency (ADA)
1528766|NCT00001254|Islet Cell Tumors
1528767|NCT00001253|Turner's Syndrome
1528768|NCT00001253|Estrogen
1528769|NCT00001253|Ethinyl estradiol
1528770|NCT00001253|Learning
1528771|NCT00001253|Ovarian dysgenesis
1528772|NCT00001252|Biomechanics
1528773|NCT00001252|Kinesiology
1528774|NCT00001252|Walking
1528775|NCT00001252|ACL
1528776|NCT00001252|Stroke
1528777|NCT00001252|Leg Weakness
1528778|NCT00001252|Paralysis
1528779|NCT00001252|Anterior Cruciate Ligament
1528780|NCT00001252|Gait Degicit
1528781|NCT00001251|Meningeal Malignancy
1528782|NCT00001251|Pediatric
1528783|NCT00001251|Alkylating Agents
1528784|NCT00001250|Neoadjuvant Chemotherapy
1528785|NCT00001250|Dose Intense Chemotherapy
1528786|NCT00001250|Stage II Breast Cancer
1528787|NCT00001250|Early Stage Breast Cancer
1528788|NCT00001249|Interleukin-2 Receptor
1528789|NCT00001248|Multiple Sclerosis
1528790|NCT00001248|MRI (Magnetic Resonance Imaging)
1528791|NCT00001247|Schizophrenia
1528792|NCT00001247|Psychosis
1528793|NCT00001247|Neuroleptics
1528794|NCT00001247|Schizoaffective Disorder
1528795|NCT00001246|Cognitive
1528796|NCT00001246|Genetics
1528797|NCT00001246|Development
1528798|NCT00001246|Klinefelter Syndrome
1528799|NCT00001246|Jacob Syndrome
1528800|NCT00001246|Trisomy X
1528801|NCT00001246|Healthy Volunteer
1528802|NCT00001246|XXY
1528803|NCT00001246|XXXY
1528804|NCT00001246|XXXXY
1528805|NCT00001246|XYY
1528806|NCT00001246|XXYY
1528807|NCT00001246|XO
1528808|NCT00001246|XXXX
1528809|NCT00001246|XXX
1528810|NCT00001246|XXXXX
1528811|NCT00001246|Triple X
1528812|NCT00001246|Congenital Adrenal Hyperplasia
1528813|NCT00001246|Twin
1528814|NCT00001245|Strongyloidiasis
1528815|NCT00001245|Immediate Hypersensitivity Skin Test
1528816|NCT00001245|IgE
1528817|NCT00001245|Nematode
1528818|NCT00001245|Immunosuppression
1528819|NCT00001245|Skin Test
1528820|NCT00001245|Diagnosis
1528821|NCT00001245|Intestinal Helminth
1528822|NCT00001245|Immediate Hypersensitivity
1528823|NCT00001244|Agammaglobulinemia
1528824|NCT00001244|Primary Immune Deficiency
1528825|NCT00001244|Immune Response
1528826|NCT00001243|AIDS
1528827|NCT00001243|Myeloid Progenitors
1528828|NCT00001243|Monocytes
1528829|NCT00001243|Plasmid Libraries
1528830|NCT00001243|Cytokines
1528831|NCT00001242|Calcium
1528832|NCT00001242|Vitamin D
1528833|NCT00001242|Calcitriol
1528834|NCT00001242|Parathyroid
1528835|NCT00001242|Cyclic AMP
1528836|NCT00001242|Rickets
1528837|NCT00001241|Gastric Acid Secretion
1528838|NCT00001241|Histamine H2-Receptor Antagonists
1528839|NCT00001240|Stomach
1528840|NCT00001240|Hypersecretion
1528841|NCT00001240|Hyposecretion
1528842|NCT00001240|Gastrinoma
1528843|NCT00001240|Zollinger-Ellison Syndrome
1528844|NCT00001239|5-Fluorouracil
1528845|NCT00001239|Adriamycin
1528846|NCT00001239|Breast Carcinoma
1528847|NCT00001239|Leucovorin
1528848|NCT00001239|Phase II
1528849|NCT00001238|Urologic Malignant Disorders
1528850|NCT00001238|Birt Hogg Dube
1528851|NCT00001238|Von Hippel Lindau
1528852|NCT00001238|Hereditary Papillary Renal Cancer/Renal Cell Acarcinoma
1528853|NCT00001237|Burkitt's Lymphoma
1528854|NCT00001237|GM-CSF
1528855|NCT00001237|High-Grade
1528856|NCT00001235|Primary Neuronal Degeneration
1528857|NCT00001235|Genetics
1528858|NCT00001235|Neurotransmitters
1528859|NCT00001235|DNA
1528860|NCT00001235|Lymphoblasts
1528861|NCT00001235|Skin Fibroblast
1528862|NCT00001235|Alzheimer's Disease
1528863|NCT00001234|Bone Marrow
1528864|NCT00001234|Retroviral-Mediated Gene Transfer
1528865|NCT00001234|Hematopoietic Progenitor Cell
1528866|NCT00001233|Adolescence
1528867|NCT00001233|Aggressivity
1528868|NCT00001233|Anger
1528869|NCT00001233|Developmental Psychopathology
1528870|NCT00001233|Disruptive Behavior Disorders
1528871|NCT00001233|Early Onset Aggression
1528872|NCT00001233|Emotion Regulation
1528873|NCT00001233|Family Violence
1528874|NCT00001233|Preschool Conduct Problems
1528875|NCT00001232|Depression
1528876|NCT00001232|FSH
1528877|NCT00001232|GnRH
1528878|NCT00001232|LH
1528879|NCT00001232|Menopause
1528880|NCT00001232|Menstrual Cycle
1528881|NCT00001231|Mood
1528882|NCT00001231|Behavior
1528883|NCT00001231|Cognition
1528884|NCT00001231|Climacteric
1528885|NCT00001231|Menopause
1528886|NCT00001231|Perimenopause
1528887|NCT00001231|Midlife
1528888|NCT00001231|Depression
1528889|NCT00001230|Wuchereria Bancrofti
1528890|NCT00001230|Loa Loa
1528891|NCT00001230|Brugia Malayi
1528892|NCT00001230|Brugia Timori
1528893|NCT00001230|Onchocerca Volvulus
1528894|NCT00001230|Mansonella Perstans
1528895|NCT00001230|Mansonella Ozzardi
1528896|NCT00001230|Diethylcarbamazine (DEC)
1528897|NCT00001230|Suramin
1528898|NCT00001230|Ivermectin
1528899|NCT00001230|Filarial Infection
1528900|NCT00001229|Calcium-Pentagastrin
1528901|NCT00001229|Clonidine
1528902|NCT00001229|Glucagon
1528903|NCT00001229|Pheochromocytoma
1528904|NCT00001228|Interferon
1528905|NCT00001228|Zollinger-Ellison Syndrome
1528906|NCT00001226|Nonradioactive Isotopes
1528907|NCT00001226|Lipoprotein Kinetics
1528908|NCT00001226|Apolipoproteins
1528909|NCT00001226|Dyslipoproteinemia
1528910|NCT00001226|Healthy Volunteers
1528911|NCT00001225|DNA Polymorphisms
1528912|NCT00001225|Echocardiography
1528913|NCT00001225|Gene Mapping
1528914|NCT00001225|Linkage Analysis
1528915|NCT00001225|Hypertrophic Cardiomyopathy
1528916|NCT00001224|Ocular Inflammatory Disease
1528917|NCT00001224|Cataracts
1528918|NCT00001224|Vitrectomy
1528919|NCT00001224|Extracapsular
1528920|NCT00001224|Cataract Surgery
1528921|NCT00001224|Uveitis
1528922|NCT00001224|Lenticular Opacity
1528923|NCT00001224|Vitreal Opacity
1528924|NCT00001223|Cystic Fibrosis
1528925|NCT00001223|Pancreatic Insufficiency
1528926|NCT00001223|Bronchiectasis
1528927|NCT00001221|Growth
1528928|NCT00001221|Gonadal Dysgenesis
1528929|NCT00001221|Estrogen
1528930|NCT00001221|Somatotropin
1528931|NCT00001221|Turner's Syndrome
1528932|NCT00001221|Growth Hormone
1528933|NCT00001220|Swallowing Disorders
1528934|NCT00001220|Neuromotor Dysfunction
1528935|NCT00001220|Aspiration
1528936|NCT00001220|Imaging
1528937|NCT00001219|Magnetic Resonance Imaging
1528938|NCT00001219|Pulse Sequences
1528939|NCT00001218|Baseline Data
1528940|NCT00001218|Curve Averaging
1528941|NCT00001218|Curve Fitting
1528942|NCT00001218|Movement Patterns
1528943|NCT00001218|Normative Data
1528944|NCT00001218|Polar Distribution
1528945|NCT00001218|Tongue
1528946|NCT00001218|Tongue Shape
1528947|NCT00001218|Ultrasound
1528948|NCT00001217|Non-Metastatic Osteosarcoma
1528949|NCT00001217|Presurgical Chemotherapy
1528950|NCT00001216|Amputations
1528951|NCT00001216|Brainstem Stimulation
1528952|NCT00001216|Cerebellar Stimulation
1528953|NCT00001216|Cortical Motor Physiology
1528954|NCT00001216|Electrical Stimulation
1528955|NCT00001216|Motor Cortex
1528956|NCT00001216|Plasticity
1528957|NCT00001216|Spinal Cord Injury
1528958|NCT00001216|Stroke
1528959|NCT00001215|Lysosomal Storage Disorders
1528960|NCT00001215|Variants
1528961|NCT00001215|Chemical Phenotype
1528962|NCT00001215|Proteins
1528963|NCT00001215|Genes
1528964|NCT00001215|Phenotype
1528965|NCT00001215|Mutations
1528966|NCT00001215|Parkinsonism
1528967|NCT00001214|Bone Marrow Failure
1528968|NCT00001214|Lymphocytapheresis
1528969|NCT00001214|Pancytopenia
1528970|NCT00001214|Aplastic Anemia
1528971|NCT00001214|Hematosuppressive Disease
1528972|NCT00001213|Cysteamine Eye Drops
1528973|NCT00001213|Nephropathic Cystinosis
1528974|NCT00001213|Corneal Crystals
1528975|NCT00001213|Benzalkonium
1528976|NCT00001213|Toxicity
1528977|NCT00001213|Efficacy
1528978|NCT00001213|Cystinosis
1528979|NCT00001212|Systemic Lupus Erythematosus
1528980|NCT00001212|Nephrotic Syndrome
1528981|NCT00001212|Immunosuppressive Drugs
1528982|NCT00001212|Prednisone
1528983|NCT00001212|Methylprednisolone
1528984|NCT00001212|Cyclophosphamide
1528985|NCT00001212|Cyclosporine
1528986|NCT00001212|Cyclosporin A
1528987|NCT00001211|Ectodermal Dysplasia
1528988|NCT00001211|Edentulous
1528989|NCT00001211|Endosseous
1528990|NCT00001211|Implants
1528991|NCT00001211|Mandibular Atrophy
1528992|NCT00001211|Oral
1528993|NCT00001211|Titanium
1528994|NCT00001210|Blood Donors
1528995|NCT00001210|Epitopes
1528996|NCT00001210|HIV
1528997|NCT00001209|Combined Chemotherapy
1528998|NCT00001209|Irradiation
1528999|NCT00001209|Unresectable
1529000|NCT00001208|Spasmodic Torticollis
1529001|NCT00001208|Writer's Cramp
1529002|NCT00001208|Spasmodic Dysphonia
1529003|NCT00001208|Stuttering
1529004|NCT00001208|Oromandibular Dystonia
1529005|NCT00001208|Palatal Myoclonus
1529006|NCT00001208|Dystonia
1529007|NCT00001208|Essential Tremor
1529008|NCT00001208|Movement Disorders
1529009|NCT00001206|Attention Deficit Hyperactivity Disorder
1529010|NCT00001206|Disruptive Behavior Disorders
1529011|NCT00001206|Cerebrospinal Fluid
1529012|NCT00001206|Lumbar Puncture
1529013|NCT00001206|CSF
1529014|NCT00001206|Longitudinal Prospective Follow-Up
1529015|NCT00001206|Psychosocial Functioning
1529016|NCT00001206|Risk Factors
1529017|NCT00001206|Genetics
1529018|NCT00001205|Taenia Solium
1529019|NCT00001205|Cysticercosis
1529020|NCT00001205|Praziquantel
1529021|NCT00001204|Dyslipoprotein
1529022|NCT00001204|Hypercholesterolemia
1529023|NCT00001204|Atherosclerosis
1529024|NCT00001203|Desferal
1529025|NCT00001203|Thalassemia
1529026|NCT00001203|Liver Iron Concentration
1529027|NCT00001203|Endocrine Evaluation
1529028|NCT00001203|Diabetes Mellitus
1529029|NCT00001203|Cardiac Disease
1529030|NCT00001203|Acquired Anemia
1529031|NCT00001202|Luteinizing Hormone
1529032|NCT00001202|High Serum Testosterone Levels
1529033|NCT00001202|Low Baseline Gonadotropin
1529034|NCT00001202|LHRH
1529035|NCT00001202|Precocious Puberty
1529036|NCT00001202|Familial Isosexual Precocious Puberty
1529037|NCT00001201|Nerve Conduction Studies
1529038|NCT00001201|EMG
1529039|NCT00001201|Normal Volunteer
1529040|NCT00001201|Electrophysiology
1529041|NCT00001201|Peripheral Neuropathies
1529042|NCT00001201|Myopathies
1529043|NCT00001198|Schizophrenia
1529044|NCT00001198|Observational
1529045|NCT00001197|Gene Expression Therapy
1529046|NCT00001197|Gamma Globin Gene
1529047|NCT00001197|Hemoglobin Switching
1529048|NCT00001197|Bone Marrow
1529049|NCT00001197|Sickle Cell Anemia
1529050|NCT00001196|Salivary Function
1529051|NCT00001196|Salivary Gland
1529052|NCT00001196|Sjogren's Syndrome
1529053|NCT00001196|Dry Mouth
1529054|NCT00001195|Development
1529055|NCT00001195|Hormones
1529056|NCT00001195|Growth
1529057|NCT00001195|Metabolism
1529058|NCT00001195|Eating Behavior
1529059|NCT00001195|Body Composition
1529060|NCT00001195|Normal Volunteer
1529061|NCT00001194|Helium Cryogen
1529062|NCT00001194|Magnetic Field
1529063|NCT00001194|Multi-Institute
1529064|NCT00001194|Nitrogen Cryogen
1529065|NCT00001194|Radiofrequency
1529066|NCT00001193|Autologous
1529067|NCT00001193|Melphalan
1529068|NCT00001193|Stage III
1529069|NCT00001193|Transplantation
1529070|NCT00001192|Executive Functions
1529071|NCT00001192|Language
1529072|NCT00001192|Attention
1529073|NCT00001192|Visual-Spatial Ability
1529074|NCT00001192|Memory
1529075|NCT00001192|Motor Behavior
1529076|NCT00001192|Intelligence
1529077|NCT00001192|Personality
1529078|NCT00001192|Visual and Auditory Functioning
1529079|NCT00001192|Hand and Eye Dominance
1529080|NCT00001192|Normal Volunteer
1529081|NCT00001192|Neuropsychiatric Disorders
1529082|NCT00001191|Zollinger-Ellison Syndrome
1529083|NCT00001191|Gastrinoma
1529084|NCT00001191|Acid Hypersecretion
1529085|NCT00001191|H+-K+ ATPase Inhibitor
1529086|NCT00001190|Growth
1529087|NCT00001190|Adolescence
1529088|NCT00001190|Children
1529089|NCT00001189|Adjuvant Radiotherapy
1529090|NCT00001189|Low-Grade Sarcoma
1529091|NCT00001189|Radiotherapy
1529092|NCT00001189|Randomized Study
1529093|NCT00001189|Sarcoma
1529094|NCT00001189|Surgery
1529095|NCT00001188|Chemotherapy
1529096|NCT00001188|Radiation Therapy
1529097|NCT00001188|Sarcoma
1529098|NCT00001188|Surgery
1529099|NCT00001186|Psychosocial
1529100|NCT00001186|Self Esteem
1529101|NCT00001186|Oncology
1529102|NCT00001186|Well-Being
1529103|NCT00001186|Pediatrics
1529104|NCT00001185|Poliomyelitis
1529105|NCT00001185|Amyotrophic Lateral Sclerosis
1529106|NCT00001185|Motor Neurons
1529107|NCT00001185|Late Viral Infection
1529108|NCT00001185|Motor Neuron Firing
1529109|NCT00001185|Immune Defects
1529110|NCT00001185|Post-polio Syndrome
1529111|NCT00001185|Post-polio Motor Neuron Disease
1529117|NCT00001183|Computed Tomography
1529118|NCT00001183|Fiberoptic Bronchoscopy
1529119|NCT00001183|Pulmonary Function Testing
1529120|NCT00001183|Cardiopulmonary Exercise Testing
1529121|NCT00001183|Allergen Skin Testing
1529122|NCT00001183|Chronic Lung Disease
1529123|NCT00001182|General Dental
1529124|NCT00001182|Diagnostic
1529125|NCT00001182|Therapeutic
1529126|NCT00001181|McCune-Albright Syndrome
1529127|NCT00001181|Aromatase Inhibitor
1529128|NCT00001181|Teslac
1529129|NCT00001180|Corticotropin Releasing Hormone
1529130|NCT00001180|Cushing Syndrome
1529131|NCT00001180|Psychiatric Hypercortisolism
1529132|NCT00001180|Adrenal Insufficiency
1529133|NCT00001180|Normal Volunteer
1529134|NCT00001178|Alzheimer's Disease
1529135|NCT00001178|Cerebral Metabolism
1529136|NCT00001178|Cerebrospinal Fluid
1529137|NCT00001178|Dementia of the Alzheimer Type
1529138|NCT00001178|18-F-Fluoro-2-Deoxy-D-Glucose (FDG)
1529139|NCT00001178|Magnetic Resonance Imaging
1529140|NCT00001178|Positron Emission Tomography
1529141|NCT00001178|X-Ray Computed Tomography (CT)
1529142|NCT00001178|Senile Dementia
1529143|NCT00001178|Down Syndrome
1529144|NCT00001178|Trisomy 21
1529145|NCT00001177|Mood
1529146|NCT00001177|Depression
1529147|NCT00001177|Cognition
1529148|NCT00001177|Menstrual
1529149|NCT00001177|Neuroendocrine
1529150|NCT00001177|Genetics
1529151|NCT00001177|PMDD
1529152|NCT00001177|PMS Premenstrual Syndrome
1529153|NCT00001177|MRMD Menstrually Related Mood Disorder
1529154|NCT00001176|Adrenergic Nervous System
1529155|NCT00001176|Dopaminergic Nervous System
1529156|NCT00001176|Salt-Sensitive Hypertension
1529157|NCT00001176|Hypertension
1529158|NCT00001176|Primary Aldosteronism
1529159|NCT00001174|Bipolar Manic-Depressive Illness
1529160|NCT00001174|Affective Disorder
1529161|NCT00001174|Depression
1529162|NCT00001174|Genetic
1529163|NCT00001174|DNA
1529164|NCT00001174|Mania
1529165|NCT00001174|Affected Sibling Pairs
1529166|NCT00001174|Family Study
1529167|NCT00001174|Genome-Wide Scan
1529168|NCT00001174|Lymphoblastoid Cell Lines
1529169|NCT00001174|Diagnostic Interview for Genetic Studies (DIGS)
1529170|NCT00001174|Panic Disorder
1529171|NCT00001174|Bipolar Disorder
1529172|NCT00001173|B Cells
1529173|NCT00001173|Humoral Immunity
1529174|NCT00001173|Lymphocytes
1529175|NCT00001173|Tetanus Toxoid
1529176|NCT00001172|Vision
1529177|NCT00001172|Eye Movement
1529178|NCT00001172|Perception
1529179|NCT00001172|Healthy Volunteer
1529180|NCT00001171|Brain Tumors
1529181|NCT00001171|Glioma
1529182|NCT00001171|Glioblastoma Multiforme
1529183|NCT00001171|Pituitary Adenoma
1529184|NCT00001170|Parental Psychopathology
1529185|NCT00001170|Child Rearing
1529186|NCT00001170|Depression
1529187|NCT00001170|Bipolar Affective Disorders
1529188|NCT00001170|Manic-Depression
1529189|NCT00001170|Social-Emotional Development
1529190|NCT00001170|Cognitive Development
1529191|NCT00001170|Child Psychopathology
1529192|NCT00001170|Affective Disorder
1529193|NCT00001170|Children at Risk
1529194|NCT00001169|Chemotherapy
1529195|NCT00001169|Cytokines
1529196|NCT00001169|Immunology
1529197|NCT00001169|Kala-Azar
1529198|NCT00001169|Leishmaniasis
1529199|NCT00001168|Dyslipoproteinemia
1529200|NCT00001168|Hypercholesterolemia
1529201|NCT00001168|Hypertriglyceridemia
1529202|NCT00001168|hypoalphalipoproteinemia
1529203|NCT00001168|Atherosclerosis
1529204|NCT00001168|Type III Hyperlipoproteinemia
1529205|NCT00001168|Plasma Lipoproteins
1529206|NCT00001167|Dysphagia
1529207|NCT00001167|Dysarthria
1529208|NCT00001167|Tongue Motion
1529209|NCT00001167|Xerostomia
1529210|NCT00001167|Swallowing
1529211|NCT00001167|Speech
1529212|NCT00001167|Polymyositis
1529213|NCT00001167|Speech Disorders
1529214|NCT00001167|Oral-Facial Paralysis
1529215|NCT00001167|Ultrasound
1529216|NCT00001166|Hyperornithinemia
1529217|NCT00001166|Ornithine-Aminotransferase (OAT)
1529218|NCT00001166|Tissue Culture
1529219|NCT00001166|Pyridoxine Hydrochloride
1529220|NCT00001166|Pyridoxal Phosphate
1529221|NCT00001166|Arginine
1529222|NCT00001166|Skin Fibroblast
1529223|NCT00001166|Gyrate Atrophy
1529224|NCT00001166|Autosomal Recessive Retinitis Pigmentosa
1529225|NCT00001166|Bietti's Crystalline Retinopathy
1529226|NCT00001166|Chorioretinal Degeneration
1529227|NCT00001165|Gastrinoma
1529228|NCT00001165|Acid Secretion
1529229|NCT00001165|Toxicity
1529230|NCT00001164|Genetic Evaluation
1529231|NCT00001164|Immunologic Evaluations
1529232|NCT00001164|Inflammatory Skin Disease
1529233|NCT00001164|Muscular Dystrophies
1529234|NCT00001164|Neoplastic Skin Diseases
1529235|NCT00001164|Neuronal Degenerations
1529236|NCT00001164|Retinal Degenerations
1529237|NCT00001164|Viral Diseases
1529238|NCT00001163|Cancer
1529239|NCT00001163|Genes/Genetics
1529240|NCT00001163|Hereditary Neoplasms
1529241|NCT00001163|Environment
1529242|NCT00001162|Giardia
1529243|NCT00001162|Helminth
1529244|NCT00001162|Cryptosporidium
1529245|NCT00001162|Hookworms
1529246|NCT00001162|Trichuris
1529247|NCT00001162|Strongyloides
1529248|NCT00001162|Protozoa
1529249|NCT00001162|Small Bowel Biopsy
1529250|NCT00001162|E. Histolytica
1529251|NCT00001162|Duodenal Aspiration
1529252|NCT00001162|Coccidiosis
1529253|NCT00001162|Clonorchis
1529254|NCT00001162|Amebiasis
1529255|NCT00001162|Parasitic Disease
1529256|NCT00001162|Tapeworm
1529257|NCT00001162|Trichinosis
1529258|NCT00001162|Gastrointestinal Trematodes
1529259|NCT00001162|Opisthorchis
1529260|NCT00001162|Paragonimiasis
1529261|NCT00001162|Echinococcus
1529262|NCT00001161|Irido Corneal Angle
1529263|NCT00001161|Mesothelium
1529264|NCT00001161|Congenital Anomalies
1529265|NCT00001161|Neural Crest
1529266|NCT00001161|Increased Intraocular Pressure
1529267|NCT00001161|Glaucoma
1529268|NCT00001161|Axenfeld's Syndrome
1529269|NCT00001161|Rieger's Anomaly
1529270|NCT00001161|Peter's Anomaly
1529271|NCT00001161|Iridocorneal Endothelial Syndrome
1529272|NCT00001161|Aniridia
1529273|NCT00001161|Pigment Dispersion Syndrome
1529274|NCT00001161|Megalocornea
1529275|NCT00001160|Thyroid Fine Needle Biopsy
1529276|NCT00001160|Radioiodine
1529277|NCT00001160|Dosimetry
1529278|NCT00001159|Hyperthyroidism
1529279|NCT00001159|Hypothyroidism
1529280|NCT00001159|Thyroid-Stimulating Hormone Secreting Pituitary Adenomas
1529281|NCT00001158|Cellular Immunity
1529282|NCT00001158|Humoral Immunity
1529283|NCT00001158|Immunodeficiency Disease
1529284|NCT00001156|Immunogenetics
1529285|NCT00001156|Tropical Spastic Paraplegia
1529286|NCT00001156|Twins
1529287|NCT00001156|Epstein-Barr Virus
1529288|NCT00001156|HTLV-I
1529289|NCT00001156|Vasculitis
1529290|NCT00001156|Cerebrospinal Fluid
1529291|NCT00001156|Immunity to Viruses
1529292|NCT00001156|Multiple Sclerosis
1529293|NCT00001156|Magnetic Resonance Imaging
1529294|NCT00001155|Vasculitis
1529295|NCT00001155|Prednisone
1529296|NCT00001155|Granuloma
1529297|NCT00001155|Wegener's Granulomatosis
1529298|NCT00001155|Cyclophosphamide
1529299|NCT00001155|Renal Biopsy
1529300|NCT00001154|Cholesterol
1529301|NCT00001154|Apolipoproteins
1529302|NCT00001154|Kinetics
1529303|NCT00001153|Albinism
1529304|NCT00001153|Ocular Albinism
1529305|NCT00001153|Oculocutaneous Albinism
1529306|NCT00001153|Tyrosinase Negative
1529307|NCT00001153|Tyrosinase Positive
1529308|NCT00001152|Aqueous Humor Dynamics
1529309|NCT00001152|Glaucoma
1529310|NCT00001152|Ocular Hypertension
1529311|NCT00001152|Pigment Dispersion Syndrome
1529312|NCT00001152|Primary Open Angle Glaucoma
1529313|NCT00001152|Pseudo-Exfoliation of the Lens Capsule
1529314|NCT00001151|Calciferol
1529315|NCT00001151|Hypocalcemia
1529316|NCT00001151|Rickets
1529317|NCT00001150|Blister Formation
1529318|NCT00001150|Inflammatory Mediator Assay
1529319|NCT00001150|Ultraviolet Radiation
1529320|NCT00001149|Anticonvulsants
1529321|NCT00001149|Intensive Monitoring
1529322|NCT00001149|Epilepsy
1529323|NCT00001148|Metastasis
1529324|NCT00001148|Glioma
1529325|NCT00001148|Venous
1529326|NCT00001148|Sampling
1529327|NCT00001148|p53 Mutation
1529328|NCT00001148|Glioblastoma Multiforme
1529329|NCT00001148|Circulating Tumor Cells
1529330|NCT00001148|Mutation
1529331|NCT00001148|Anaplastic Astrocytoma
1529332|NCT00001147|Dopamine
1529333|NCT00001147|Metanephrine
1529334|NCT00001147|Norepinephrine
1529335|NCT00001147|Epinephrine
1529336|NCT00001147|Catecholamines
1529337|NCT00001147|Tyrosine Hydroxylase
1529338|NCT00001147|Monoamine Oxidase
1529339|NCT00001147|Phenosulfotransferase
1529340|NCT00001147|Sympathetic Nervous System
1529341|NCT00001147|Normetanephrine
1529342|NCT00001146|Bipolar Disorder
1529343|NCT00001146|Clinical Trial
1529344|NCT00001146|Eicosapentaenoic Ethyl Ester
1529345|NCT00001146|Life Chart Methodology
1529346|NCT00001146|Mood Disorders
1529347|NCT00001146|Omega-3 Fatty Acid
1529348|NCT00001146|Rapid Cycling
1529349|NCT00001146|Treatment
1529350|NCT00001145|Primary Immunodeficiency
1529351|NCT00001145|Gamma Globulin (IgG) Immunization
1529352|NCT00001145|KLH
1529353|NCT00001145|Phi-X 174
1529354|NCT00001145|X-linked HyperIgM Syndrome
1529355|NCT00001144|Peripheral Blood Stem Cells
1529356|NCT00001144|Engraftment
1529357|NCT00001144|Graft vs. Host Disease
1529358|NCT00001144|Graft-Versus-Leukemia
1529359|NCT00001144|Graft-Versus-Tumor/Melanoma
1529360|NCT00001144|Chronic Myelogenous Leukemia
1529361|NCT00001143|Eye Movements
1529362|NCT00001143|Strabismus
1529363|NCT00001143|Infants
1529364|NCT00001143|Development
1529365|NCT00001143|Ocular Motor System
1529366|NCT00001142|Body Fat
1529367|NCT00001142|DXA
1529368|NCT00001142|HAART
1529369|NCT00001142|Hyperlipidemia
1529370|NCT00001142|Insulin Resistance
1529371|NCT00001142|Lipodystrophy
1529372|NCT00001142|MRI
1529373|NCT00001142|Protease Inhibitor
1529374|NCT00001142|Side-Effects
1529375|NCT00001142|Visceral Fat
1529376|NCT00001142|Chronic Infection
1529377|NCT00001142|HIV
1529378|NCT00001142|Healthy Volunteer
1529379|NCT00001137|Treatment Experienced
1529380|NCT00001137|Treatment Naive
1529381|NCT00001137|Virus Replication
1529382|NCT00001137|AIDS-Related Opportunistic Infections
1529383|NCT00001137|HIV-1
1529384|NCT00001137|Risk Factors
1529385|NCT00001137|Incidence
1529386|NCT00001137|RNA, Viral
1529387|NCT00001137|Anti-HIV Agents
1529388|NCT00001137|Viral Load
1529389|NCT00001137|Lipodystrophy
1529390|NCT00001137|Nervous System
1529391|NCT00001137|Cardiovascular System
1529392|NCT00001137|Neurologic Symptoms
1529393|NCT00001136|Injections, Intramuscular
1529394|NCT00001136|HIV-1
1529395|NCT00001136|AIDS Vaccines
1529396|NCT00001136|CD4-Positive T-Lymphocytes
1529397|NCT00001136|CD8-Positive T-Lymphocytes
1529398|NCT00001136|T-Lymphocytes, Cytotoxic
1529399|NCT00001136|Gene Products, gag
1529400|NCT00001136|HIV Seronegativity
1529401|NCT00001136|Immunologic Memory
1529402|NCT00001136|Antibodies, Viral
1529403|NCT00001136|Genetic Vectors
1529404|NCT00001136|Gene Products, env
1529405|NCT00001136|Poxviridae
1529406|NCT00001136|HIV Preventive Vaccine
1529407|NCT00001135|Placebos
1529408|NCT00001135|Pregnancy
1529409|NCT00001135|Pregnancy Complications, Infectious
1529410|NCT00001135|Nevirapine
1529411|NCT00001135|Disease Transmission, Vertical
1529412|NCT00001135|Labor
1529413|NCT00001135|Anti-HIV Agents
1529414|NCT00001133|Dose-Response Relationship, Drug
1529415|NCT00001133|Drug Therapy, Combination
1529416|NCT00001133|HIV Protease Inhibitors
1529417|NCT00001133|Ritonavir
1529418|NCT00001133|Indinavir
1529419|NCT00001133|Anti-HIV Agents
1529420|NCT00001133|Pharmacokinetics
1529421|NCT00001133|Treatment Experienced
1529422|NCT00001132|Placebos
1529423|NCT00001132|HIV-1
1529424|NCT00001132|Drug Therapy, Combination
1529425|NCT00001132|RNA, Viral
1529426|NCT00001132|Reverse Transcriptase Inhibitors
1529427|NCT00001132|Anti-HIV Agents
1529428|NCT00001132|Viral Load
1529429|NCT00001132|abacavir
1529430|NCT00001131|Interleukin-2
1529431|NCT00001131|Drug Therapy, Combination
1529432|NCT00001131|Drug Administration Schedule
1529433|NCT00001131|Viremia
1529434|NCT00001131|T-Lymphocytes, Cytotoxic
1529435|NCT00001131|Anti-HIV Agents
1529436|NCT00001131|Treatment Experienced
1529437|NCT00001130|Questionnaires
1529438|NCT00001130|Antibodies, Viral
1529439|NCT00001130|Emergency Service, Hospital
1529440|NCT00001129|Drug Therapy, Combination
1529441|NCT00001129|RNA, Viral
1529442|NCT00001129|Patient Compliance
1529443|NCT00001129|Anti-HIV Agents
1529444|NCT00001129|Viral Load
1529445|NCT00001129|Reminder Systems
1529446|NCT00001129|Treatment Experienced
1529447|NCT00001129|Treatment Naive
1529448|NCT00001128|AIDS-Related Opportunistic Infections
1529449|NCT00001128|Cryptosporidiosis
1529450|NCT00001128|Acquired Immunodeficiency Syndrome
1529451|NCT00001128|Azithromycin
1529452|NCT00001128|Paromomycin
1529453|NCT00001128|Interleukin-12
1529454|NCT00001125|Antibodies, Viral
1529455|NCT00001125|Chickenpox
1529456|NCT00001125|Chickenpox Vaccine
1529457|NCT00001122|Didanosine
1529458|NCT00001122|Drug Therapy, Combination
1529459|NCT00001122|Stavudine
1529460|NCT00001122|HIV Protease Inhibitors
1529461|NCT00001122|CD4 Lymphocyte Count
1529462|NCT00001122|Nelfinavir
1529463|NCT00001122|Reverse Transcriptase Inhibitors
1529464|NCT00001122|Self Care
1529465|NCT00001122|Anti-HIV Agents
1529466|NCT00001122|Viral Load
1529467|NCT00001122|efavirenz
1529468|NCT00001122|Treatment Naive
1529469|NCT00001121|Placebos
1529470|NCT00001121|AIDS Vaccines
1529471|NCT00001121|Follow-Up Studies
1529472|NCT00001121|HIV Therapeutic Vaccine
1529473|NCT00001120|Prospective Studies
1529474|NCT00001120|Sarcoma, Kaposi
1529475|NCT00001120|Herpesvirus 4, Human
1529476|NCT00001120|Acquired Immunodeficiency Syndrome
1529477|NCT00001120|Cohort Studies
1529478|NCT00001120|Risk Factors
1529479|NCT00001120|Lymphoma, AIDS-Related
1529480|NCT00001120|Antibodies, Viral
1529481|NCT00001120|Lymphoproliferative Disorders
1529482|NCT00001120|Viral Load
1529483|NCT00001120|Herpesvirus, Kaposi Sarcoma-Associated
1529484|NCT00001120|Translocation (Genetics)
1529485|NCT00001119|Immunity, Cellular
1529486|NCT00001119|Drug Therapy, Combination
1529487|NCT00001119|HIV Protease Inhibitors
1529488|NCT00001119|Antibody Formation
1529489|NCT00001119|Reverse Transcriptase Inhibitors
1529490|NCT00001119|Anti-HIV Agents
1529491|NCT00001119|Viral Load
1529492|NCT00001119|Tetanus Toxoid
1529493|NCT00001119|Case-Control Studies
1529494|NCT00001119|Hepatitis B Surface Antigens
1529495|NCT00001119|Acute Infection
1529496|NCT00001118|Injections, Intravenous
1529497|NCT00001118|Injections, Subcutaneous
1529498|NCT00001118|Drug Therapy, Combination
1529499|NCT00001118|HIV Protease Inhibitors
1529500|NCT00001118|Membrane Fusion
1529501|NCT00001118|Reverse Transcriptase Inhibitors
1529502|NCT00001118|Anti-HIV Agents
1529503|NCT00001118|Viral Load
1529504|NCT00001118|peptide T20
1529505|NCT00001117|HIV-1
1529506|NCT00001117|Drug Therapy, Combination
1529507|NCT00001117|Hepatitis C
1529508|NCT00001117|RNA, Viral
1529509|NCT00001117|Anti-HIV Agents
1529510|NCT00001116|Tumor Necrosis Factor
1529511|NCT00001116|Interleukin-2
1529512|NCT00001116|Immunity, Cellular
1529513|NCT00001116|Antiviral Agents
1529514|NCT00001116|Interleukin-6
1529515|NCT00001116|Receptors, Tumor Necrosis Factor
1529516|NCT00001115|Herpes Simplex
1529517|NCT00001115|Acyclovir
1529518|NCT00001115|Acquired Immunodeficiency Syndrome
1529519|NCT00001114|Sarcoma, Kaposi
1529520|NCT00001114|Didanosine
1529521|NCT00001114|Drug Interactions
1529522|NCT00001114|Acquired Immunodeficiency Syndrome
1529523|NCT00001114|Interferon-alpha
1529524|NCT00001113|Interferon Alfa-2a
1529525|NCT00001113|Sarcoma, Kaposi
1529526|NCT00001113|Dose-Response Relationship, Drug
1529527|NCT00001113|Drug Evaluation
1529528|NCT00001113|Drug Therapy, Combination
1529529|NCT00001113|Acquired Immunodeficiency Syndrome
1529530|NCT00001113|Zidovudine
1529531|NCT00001113|Interferon Type I
1529532|NCT00001112|Monocytes
1529533|NCT00001112|Interferon-gamma, Recombinant
1529534|NCT00001112|Injections, Subcutaneous
1529535|NCT00001112|Immune System
1529536|NCT00001112|Drug Evaluation
1529537|NCT00001112|Drug Therapy, Combination
1529538|NCT00001112|Acquired Immunodeficiency Syndrome
1529539|NCT00001112|Zidovudine
1529540|NCT00001112|Blood Bactericidal Activity
1529541|NCT00001111|Drug Therapy, Combination
1529542|NCT00001111|Acquired Immunodeficiency Syndrome
1529543|NCT00001111|AIDS-Related Complex
1529544|NCT00001111|Antiviral Agents
1529545|NCT00001111|Zidovudine
1529546|NCT00001111|Nevirapine
1529547|NCT00001110|Lung
1529548|NCT00001110|HIV-1
1529549|NCT00001110|Viremia
1529550|NCT00001110|Anti-HIV Agents
1529551|NCT00001110|Viral Load
1529552|NCT00001110|Bronchoalveolar Lavage Fluid
1529553|NCT00001109|Monocytes
1529554|NCT00001109|Flow Cytometry
1529555|NCT00001109|HIV Seronegativity
1529556|NCT00001109|Phenotype
1529557|NCT00001109|Lymphocyte Subsets
1529558|NCT00001108|Dose-Response Relationship, Drug
1529559|NCT00001108|Drug Therapy, Combination
1529560|NCT00001108|HIV Protease Inhibitors
1529561|NCT00001108|Reverse Transcriptase Inhibitors
1529562|NCT00001108|Salvage Therapy
1529563|NCT00001108|Anti-HIV Agents
1529564|NCT00001106|Pregnancy
1529565|NCT00001106|Pregnancy Complications, Infectious
1529566|NCT00001106|Prenatal Exposure Delayed Effects
1529567|NCT00001106|Drug Evaluation
1529568|NCT00001106|Acquired Immunodeficiency Syndrome
1529569|NCT00001106|Zidovudine
1529570|NCT00001105|Antibodies, Monoclonal
1529571|NCT00001105|AIDS-Related Complex
1529572|NCT00001105|Immunization, Passive
1529573|NCT00001104|Sex Behavior
1529574|NCT00001104|T-Lymphocytes
1529575|NCT00001104|HIV Antibodies
1529576|NCT00001104|Acquired Immunodeficiency Syndrome
1529577|NCT00001104|AIDS-Related Complex
1529578|NCT00001104|Zidovudine
1529579|NCT00001104|Hemophilia A
1529580|NCT00001103|Neuropsychological Tests
1529581|NCT00001103|HIV-1
1529582|NCT00001103|RNA, Viral
1529583|NCT00001103|Anti-HIV Agents
1529584|NCT00001103|Viral Load
1529585|NCT00001102|Drug Therapy, Combination
1529586|NCT00001102|HIV Protease Inhibitors
1529587|NCT00001102|Reverse Transcriptase Inhibitors
1529588|NCT00001102|Body Composition
1529589|NCT00001102|Anti-HIV Agents
1529590|NCT00001102|Cholesterol
1529591|NCT00001102|Triglycerides
1529592|NCT00001097|Drug Therapy, Combination
1529593|NCT00001097|HIV Protease Inhibitors
1529594|NCT00001097|Reverse Transcriptase Inhibitors
1529595|NCT00001097|Anti-HIV Agents
1529596|NCT00001096|Vaccines, Synthetic
1529597|NCT00001096|HIV Antibodies
1529598|NCT00001096|HIV Antigens
1529599|NCT00001096|HIV-1
1529600|NCT00001096|Adjuvants, Immunologic
1529601|NCT00001096|AIDS Vaccines
1529602|NCT00001096|T-Lymphocytes, Cytotoxic
1529603|NCT00001096|HIV Seronegativity
1529604|NCT00001096|HIV Envelope Protein gp120
1529605|NCT00001096|Alum Compounds
1529606|NCT00001096|HIV Preventive Vaccine
1529607|NCT00001095|Drug Therapy, Combination
1529608|NCT00001095|Zidovudine
1529609|NCT00001095|Nevirapine
1529610|NCT00001095|Stavudine
1529611|NCT00001095|HIV Protease Inhibitors
1529612|NCT00001095|Lamivudine
1529613|NCT00001095|VX 478
1529614|NCT00001095|Reverse Transcriptase Inhibitors
1529615|NCT00001095|Anti-HIV Agents
1529616|NCT00001095|Viral Load
1529617|NCT00001094|HIV-1
1529618|NCT00001094|Drug Therapy, Combination
1529619|NCT00001094|Zidovudine
1529620|NCT00001094|Lamivudine
1529621|NCT00001094|RNA, Viral
1529622|NCT00001094|Saquinavir
1529623|NCT00001094|Delavirdine
1529624|NCT00001094|Anti-HIV Agents
1529625|NCT00001094|Nelfinavir
1529626|NCT00001093|Immunity, Cellular
1529627|NCT00001093|Sexual Partners
1529628|NCT00001093|Treatment Outcome
1529629|NCT00001093|Anti-HIV Agents
1529630|NCT00001093|Viral Load
1529631|NCT00001093|Acute Infection
1529632|NCT00001092|Semen
1529633|NCT00001092|HIV-1
1529634|NCT00001092|Sexual Partners
1529635|NCT00001092|Drug Resistance, Microbial
1529636|NCT00001092|CD8-Positive T-Lymphocytes
1529637|NCT00001092|Saliva
1529638|NCT00001092|Blood
1529639|NCT00001092|Cervix Uteri
1529640|NCT00001092|Vagina
1529641|NCT00001092|Acute Infection
1529642|NCT00001091|Drug Therapy, Combination
1529643|NCT00001091|Nevirapine
1529644|NCT00001091|Stavudine
1529645|NCT00001091|HIV Protease Inhibitors
1529646|NCT00001091|Ritonavir
1529647|NCT00001091|Lamivudine
1529648|NCT00001091|Nelfinavir
1529649|NCT00001091|Reverse Transcriptase Inhibitors
1529650|NCT00001090|Reference Values
1529651|NCT00001090|Granulocyte-Macrophage Colony-Stimulating Factor
1529652|NCT00001090|AIDS Vaccines
1529653|NCT00001090|HIV Seronegativity
1529654|NCT00001090|Dose-Response Relationship, Immunologic
1529655|NCT00001090|HIV Preventive Vaccine
1529656|NCT00001089|Prospective Studies
1529657|NCT00001089|HIV-1
1529658|NCT00001089|Cytomegalovirus
1529659|NCT00001089|Cytomegalovirus Infections
1529660|NCT00001089|Acquired Immunodeficiency Syndrome
1529661|NCT00001089|Anti-HIV Agents
1529662|NCT00001089|Viral Load
1529663|NCT00001089|Multiple Organ Failure
1529664|NCT00001088|Injections, Intramuscular
1529665|NCT00001088|AIDS Vaccines
1529666|NCT00001088|HIV Seronegativity
1529667|NCT00001088|Dose-Response Relationship, Immunologic
1529668|NCT00001088|Fusion Proteins, gag-pol
1529669|NCT00001088|Vaccines, DNA
1529670|NCT00001088|HIV Preventive Vaccine
1529671|NCT00001087|Drug Therapy, Combination
1529672|NCT00001087|Antiviral Agents
1529673|NCT00001087|HIV Protease Inhibitors
1529674|NCT00001087|Ritonavir
1529675|NCT00001087|Saquinavir
1529676|NCT00001087|Nelfinavir
1529677|NCT00001087|Reverse Transcriptase Inhibitors
1529678|NCT00001087|Adenine
1529679|NCT00001087|Anti-HIV Agents
1529680|NCT00001087|efavirenz
1529681|NCT00001086|Placebos
1529682|NCT00001086|HIV-1
1529683|NCT00001086|Drug Therapy, Combination
1529684|NCT00001086|HIV Protease Inhibitors
1529685|NCT00001086|Indinavir
1529686|NCT00001086|RNA, Viral
1529687|NCT00001086|Reverse Transcriptase Inhibitors
1529688|NCT00001086|Anti-HIV Agents
1529689|NCT00001086|Viral Load
1529690|NCT00001086|efavirenz
1529691|NCT00001085|HIV-1
1529692|NCT00001085|Drug Therapy, Combination
1529693|NCT00001085|Acquired Immunodeficiency Syndrome
1529694|NCT00001085|Zidovudine
1529695|NCT00001085|HIV Protease Inhibitors
1529696|NCT00001085|Lamivudine
1529697|NCT00001085|RNA, Viral
1529698|NCT00001085|VX 478
1529699|NCT00001085|Reverse Transcriptase Inhibitors
1529700|NCT00001085|Anti-HIV Agents
1529701|NCT00001085|Viral Load
1529702|NCT00001084|Prospective Studies
1529703|NCT00001084|Drug Therapy, Combination
1529704|NCT00001084|Zidovudine
1529705|NCT00001084|HIV Protease Inhibitors
1529706|NCT00001084|Lamivudine
1529707|NCT00001084|Indinavir
1529708|NCT00001084|RNA, Viral
1529709|NCT00001084|Reverse Transcriptase Inhibitors
1529710|NCT00001084|Anti-HIV Agents
1529711|NCT00001084|Viral Load
1529712|NCT00001083|HIV-1
1529713|NCT00001083|Drug Therapy, Combination
1529714|NCT00001083|Zidovudine
1529715|NCT00001083|Nevirapine
1529716|NCT00001083|Stavudine
1529717|NCT00001083|HIV Protease Inhibitors
1529718|NCT00001083|Ritonavir
1529719|NCT00001083|Lamivudine
1529720|NCT00001083|Indinavir
1529721|NCT00001083|RNA, Viral
1529722|NCT00001083|Reverse Transcriptase Inhibitors
1529723|NCT00001083|Anti-HIV Agents
1529724|NCT00001082|Cytomegalovirus Infections
1529725|NCT00001082|Antiviral Agents
1529726|NCT00001082|CD4 Lymphocyte Count
1529727|NCT00001082|Prodrugs
1529728|NCT00001082|Survival
1529729|NCT00001082|Adenine
1529730|NCT00001081|AIDS-Related Opportunistic Infections
1529731|NCT00001081|Cryptosporidiosis
1529732|NCT00001081|Antiprotozoal Agents
1529733|NCT00001081|nitazoxanide
1529734|NCT00001080|Lymphocyte Transformation
1529735|NCT00001080|HIV-1
1529736|NCT00001080|Drug Resistance, Microbial
1529737|NCT00001080|CD4-Positive T-Lymphocytes
1529738|NCT00001080|Lamivudine
1529739|NCT00001080|Influenza Vaccine
1529740|NCT00001080|RNA, Viral
1529741|NCT00001080|Bacterial Vaccines
1529742|NCT00001080|Anti-HIV Agents
1529743|NCT00001080|Pneumonia, Pneumococcal
1529744|NCT00001080|Viral Load
1529745|NCT00001079|Placebos
1529746|NCT00001079|Drug Therapy, Combination
1529747|NCT00001079|Acquired Immunodeficiency Syndrome
1529748|NCT00001079|AIDS-Related Complex
1529749|NCT00001079|HIV Wasting Syndrome
1529750|NCT00001079|Megestrol Acetate
1529751|NCT00001079|dihydrotestosterone heptanoate
1529752|NCT00001078|Viral Vaccines
1529753|NCT00001078|AIDS-Related Opportunistic Infections
1529754|NCT00001078|Anti-HIV Agents
1529755|NCT00001078|Hepatitis A Virus, Human
1529756|NCT00001077|Weight Loss
1529757|NCT00001077|Acquired Immunodeficiency Syndrome
1529758|NCT00001077|Nutritional Support
1529759|NCT00001076|Vaccines, Synthetic
1529760|NCT00001076|HIV Envelope Protein gp120
1529761|NCT00001076|AIDS Vaccines
1529762|NCT00001076|HIV Seronegativity
1529763|NCT00001076|Avipoxvirus
1529764|NCT00001076|HIV Preventive Vaccine
1529765|NCT00001075|Drug Therapy, Combination
1529766|NCT00001075|Acquired Immunodeficiency Syndrome
1529767|NCT00001075|AIDS-Related Complex
1529768|NCT00001075|Antiviral Agents
1529769|NCT00001075|Zidovudine
1529770|NCT00001075|HIV Protease Inhibitors
1529771|NCT00001075|Ritonavir
1529772|NCT00001075|Lamivudine
1529773|NCT00001074|Didanosine
1529774|NCT00001074|Drug Therapy, Combination
1529775|NCT00001074|Antiviral Agents
1529776|NCT00001074|Hydroxyurea
1529898|NCT00001053|HIV Seronegativity
1529777|NCT00001073|Acquired Immunodeficiency Syndrome
1529778|NCT00001073|AIDS-Related Complex
1529779|NCT00001073|Cervix Dysplasia
1529780|NCT00001073|Cervix Diseases
1529781|NCT00001073|Isotretinoin
1529782|NCT00001073|Cervical Intraepithelial Neoplasia
1529783|NCT00001073|Cervix Neoplasms
1529784|NCT00001073|Keratolytic Agents
1529785|NCT00001072|Vaccines, Synthetic
1529786|NCT00001072|HIV Envelope Protein gp120
1529787|NCT00001072|AIDS Vaccines
1529788|NCT00001072|HIV Seronegativity
1529789|NCT00001072|Avipoxvirus
1529790|NCT00001072|HIV Preventive Vaccine
1529791|NCT00001071|Granulocyte Colony-Stimulating Factor
1529792|NCT00001071|Acquired Immunodeficiency Syndrome
1529793|NCT00001071|AIDS-Related Complex
1529794|NCT00001071|Stem Cells
1529795|NCT00001069|Acquired Immunodeficiency Syndrome
1529796|NCT00001069|AIDS-Related Complex
1529797|NCT00001069|Antiviral Agents
1529798|NCT00001069|Decision Making
1529799|NCT00001069|Physician's Practice Patterns
1529800|NCT00001068|Zalcitabine
1529801|NCT00001068|Didanosine
1529802|NCT00001068|Drug Therapy, Combination
1529803|NCT00001068|AIDS-Related Complex
1529804|NCT00001068|Antiviral Agents
1529805|NCT00001068|Zidovudine
1529806|NCT00001068|Lamivudine
1529807|NCT00001067|Drug Therapy, Combination
1529808|NCT00001067|AIDS-Related Complex
1529809|NCT00001067|Zidovudine
1529810|NCT00001067|Stavudine
1529811|NCT00001067|Lamivudine
1529812|NCT00001066|Didanosine
1529813|NCT00001066|Drug Therapy, Combination
1529814|NCT00001066|Acquired Immunodeficiency Syndrome
1529815|NCT00001066|AIDS-Related Complex
1529816|NCT00001066|Zidovudine
1529817|NCT00001066|Lamivudine
1529818|NCT00001065|Administration, Oral
1529819|NCT00001065|Acquired Immunodeficiency Syndrome
1529820|NCT00001065|Amphotericin B
1529821|NCT00001065|AIDS-Related Complex
1529822|NCT00001065|Candidiasis, Oral
1529823|NCT00001065|Suspensions
1529824|NCT00001064|HIV Antigens
1529825|NCT00001064|Immunotherapy, Adoptive
1529826|NCT00001064|Dendritic Cells
1529827|NCT00001063|Didanosine
1529828|NCT00001063|Drug Therapy, Combination
1529829|NCT00001063|AIDS-Related Complex
1529830|NCT00001063|Zidovudine
1529831|NCT00001063|Stavudine
1529832|NCT00001062|Infusions, Intravenous
1529833|NCT00001062|Ganciclovir
1529834|NCT00001062|Administration, Oral
1529835|NCT00001062|Acquired Immunodeficiency Syndrome
1529836|NCT00001062|Antiviral Agents
1529837|NCT00001062|Cytomegalovirus Retinitis
1529838|NCT00001061|AIDS-Related Opportunistic Infections
1529839|NCT00001061|Ganciclovir
1529840|NCT00001061|Foscarnet
1529841|NCT00001061|Acquired Immunodeficiency Syndrome
1529842|NCT00001061|Antibodies, Monoclonal
1529843|NCT00001061|Cytomegalovirus Retinitis
1529844|NCT00001060|Vaccines, Synthetic
1529845|NCT00001060|HIV-1
1529846|NCT00001060|Acquired Immunodeficiency Syndrome
1529847|NCT00001060|AIDS-Related Complex
1529848|NCT00001060|AIDS Vaccines
1529849|NCT00001060|HIV Therapeutic Vaccine
1529850|NCT00001059|Vincristine
1529851|NCT00001059|Sarcoma, Kaposi
1529852|NCT00001059|Liposomes
1529853|NCT00001059|Doxorubicin
1529854|NCT00001059|Drug Therapy, Combination
1529855|NCT00001059|Granulocyte Colony-Stimulating Factor
1529856|NCT00001059|Acquired Immunodeficiency Syndrome
1529857|NCT00001059|Bleomycin
1529858|NCT00001059|Drug Carriers
1529859|NCT00001058|Rifabutin
1529860|NCT00001058|Mycobacterium avium-intracellulare Infection
1529861|NCT00001058|Drug Therapy, Combination
1529862|NCT00001058|Ethambutol
1529863|NCT00001058|Clofazimine
1529864|NCT00001058|Acquired Immunodeficiency Syndrome
1529865|NCT00001058|Ciprofloxacin
1529866|NCT00001058|Clarithromycin
1529867|NCT00001057|Didanosine
1529868|NCT00001057|Drug Therapy, Combination
1529869|NCT00001057|Zidovudine
1529870|NCT00001056|Vaccines, Synthetic
1529871|NCT00001056|Vaccinia Virus
1529872|NCT00001056|Viral Vaccines
1529873|NCT00001056|HIV-1
1529874|NCT00001056|HIV Envelope Protein gp160
1529875|NCT00001056|AIDS Vaccines
1529876|NCT00001056|HIV Seronegativity
1529877|NCT00001056|HIV Preventive Vaccine
1529878|NCT00001055|Vaccines, Synthetic
1529879|NCT00001055|HIV Envelope Protein gp120
1529880|NCT00001055|AIDS Vaccines
1529881|NCT00001055|HIV Seronegativity
1529882|NCT00001055|Avipoxvirus
1529883|NCT00001055|HIV Preventive Vaccine
1529884|NCT00001054|Herpes Zoster
1529885|NCT00001054|AIDS-Related Opportunistic Infections
1529886|NCT00001054|Herpes Simplex
1529887|NCT00001054|Acquired Immunodeficiency Syndrome
1529888|NCT00001054|AIDS-Related Complex
1529889|NCT00001054|valacyclovir
1529890|NCT00001054|Chickenpox
1529891|NCT00001053|Vaccines, Synthetic
1529892|NCT00001053|Recombinant Proteins
1529893|NCT00001053|HIV-1
1529894|NCT00001053|AIDS Vaccines
1529895|NCT00001053|HIV Core Protein p24
1529896|NCT00001053|p24-VLP vaccine
1529897|NCT00001053|Gene Products, gag
1529899|NCT00001053|HIV Preventive Vaccine
1529900|NCT00001052|Vaccines, Synthetic
1529901|NCT00001052|Drug Therapy, Combination
1529902|NCT00001052|Adjuvants, Immunologic
1529903|NCT00001052|HIV Envelope Protein gp120
1529904|NCT00001052|AIDS Vaccines
1529905|NCT00001052|HIV Seronegativity
1529906|NCT00001052|HIV Preventive Vaccine
1529907|NCT00001049|Didanosine
1529908|NCT00001049|Drug Therapy, Combination
1529909|NCT00001049|Acquired Immunodeficiency Syndrome
1529910|NCT00001049|AIDS-Related Complex
1529911|NCT00001049|Zidovudine
1529912|NCT00001048|Leukoencephalopathy, Progressive Multifocal
1529913|NCT00001048|Infusions, Intravenous
1529914|NCT00001048|Cytarabine
1529915|NCT00001048|Zalcitabine
1529916|NCT00001048|Didanosine
1529917|NCT00001048|Drug Therapy, Combination
1529918|NCT00001048|Granulocyte Colony-Stimulating Factor
1529919|NCT00001048|Acquired Immunodeficiency Syndrome
1529920|NCT00001048|Zidovudine
1529921|NCT00001048|Injections, Spinal
1529922|NCT00001047|Rifabutin
1529923|NCT00001047|Mycobacterium avium-intracellulare Infection
1529924|NCT00001047|Drug Therapy, Combination
1529925|NCT00001047|Ethambutol
1529926|NCT00001047|Clofazimine
1529927|NCT00001047|Acquired Immunodeficiency Syndrome
1529928|NCT00001047|Clarithromycin
1529929|NCT00001046|Vaccines, Synthetic
1529930|NCT00001046|Pregnancy
1529931|NCT00001046|Pregnancy Complications, Infectious
1529932|NCT00001046|AIDS-Related Complex
1529933|NCT00001046|HIV Envelope Protein gp120
1529934|NCT00001046|HIV Preventive Vaccine
1529935|NCT00001046|HIV Therapeutic Vaccine
1529936|NCT00001045|Didanosine
1529937|NCT00001045|Drug Therapy, Combination
1529938|NCT00001045|Zidovudine
1529939|NCT00001045|Nevirapine
1529940|NCT00001044|Vaccines, Synthetic
1529941|NCT00001044|Drug Therapy, Combination
1529942|NCT00001044|Adjuvants, Immunologic
1529943|NCT00001044|HIV Envelope Protein gp120
1529944|NCT00001044|AIDS Vaccines
1529945|NCT00001044|HIV Seronegativity
1529946|NCT00001044|HIV Preventive Vaccine
1529947|NCT00001043|Vaccines, Synthetic
1529948|NCT00001043|Vaccinia Virus
1529949|NCT00001043|Viral Vaccines
1529950|NCT00001043|Smallpox Vaccine
1529951|NCT00001043|HIV-1
1529952|NCT00001043|HIV Envelope Protein gp160
1529953|NCT00001043|AIDS Vaccines
1529954|NCT00001043|HIV Seronegativity
1529955|NCT00001043|HIV Preventive Vaccine
1529956|NCT00001042|Vaccines, Synthetic
1529957|NCT00001042|Drug Therapy, Combination
1529958|NCT00001042|Adjuvants, Immunologic
1529959|NCT00001042|HIV Envelope Protein gp120
1529960|NCT00001042|Acetylmuramyl-Alanyl-Isoglutamine
1529961|NCT00001042|monophosphoryl lipid A
1529962|NCT00001042|AIDS Vaccines
1529963|NCT00001042|HIV Seronegativity
1529964|NCT00001042|HIV Preventive Vaccine
1529965|NCT00001041|Vaccines, Synthetic
1529966|NCT00001041|Pregnancy
1529967|NCT00001041|Pregnancy Complications, Infectious
1529968|NCT00001041|HIV Envelope Protein gp120
1529969|NCT00001041|AIDS Vaccines
1529970|NCT00001041|HIV Therapeutic Vaccine
1529971|NCT00001040|Zalcitabine
1529972|NCT00001040|Drug Therapy, Combination
1529973|NCT00001040|Acquired Immunodeficiency Syndrome
1529974|NCT00001040|AIDS-Related Complex
1529975|NCT00001040|Zidovudine
1529976|NCT00001040|Saquinavir
1529977|NCT00001040|HIV Protease Inhibitors
1529978|NCT00001039|Mycobacterium avium-intracellulare Infection
1529979|NCT00001039|Drug Therapy, Combination
1529980|NCT00001039|Ethambutol
1529981|NCT00001039|Acquired Immunodeficiency Syndrome
1529982|NCT00001039|Clarithromycin
1529983|NCT00001038|Cytomegalovirus Infections
1529984|NCT00001038|Acquired Immunodeficiency Syndrome
1529985|NCT00001038|Antiviral Agents
1529986|NCT00001037|Vaccines, Synthetic
1529987|NCT00001037|HIV-1
1529988|NCT00001037|HIV Envelope Protein gp160
1529989|NCT00001037|AIDS Vaccines
1529990|NCT00001037|HIV Seronegativity
1529991|NCT00001037|HIV Preventive Vaccine
1529992|NCT00001036|T-Lymphocytes
1529993|NCT00001036|Polyethylene Glycols
1529994|NCT00001036|Interleukin-2
1529995|NCT00001036|Drug Therapy, Combination
1529996|NCT00001036|Adjuvants, Immunologic
1529997|NCT00001036|Acquired Immunodeficiency Syndrome
1529998|NCT00001036|Zidovudine
1529999|NCT00001036|thymosin alpha(1)
1530000|NCT00001035|AIDS-Related Opportunistic Infections
1530001|NCT00001035|Interferon Alfa-2b
1530002|NCT00001035|Zalcitabine
1530003|NCT00001035|Didanosine
1530004|NCT00001035|Drug Therapy, Combination
1530005|NCT00001035|Acquired Immunodeficiency Syndrome
1530006|NCT00001035|Zidovudine
1530007|NCT00001035|Hepatitis C
1530008|NCT00001034|Retinitis
1530009|NCT00001034|Ganciclovir
1530010|NCT00001034|Cytomegalovirus Infections
1530011|NCT00001034|Administration, Oral
1530012|NCT00001034|Acquired Immunodeficiency Syndrome
1530013|NCT00001034|Gastrointestinal System
1530014|NCT00001033|Isoniazid
1530015|NCT00001033|Tuberculosis, Pulmonary
1530016|NCT00001033|Pyrazinamide
1530017|NCT00001033|Pyridoxine
1530018|NCT00001033|Ofloxacin
1530019|NCT00001033|Rifampin
1530020|NCT00001033|AIDS-Related Opportunistic Infections
1530021|NCT00001033|Ethambutol
1530022|NCT00001033|Acquired Immunodeficiency Syndrome
1530023|NCT00001032|Zalcitabine
1530024|NCT00001032|Drug Therapy, Combination
1530025|NCT00001032|Acquired Immunodeficiency Syndrome
1530026|NCT00001032|AIDS-Related Complex
1530027|NCT00001032|Zidovudine
1530028|NCT00001031|Vaccines, Synthetic
1530029|NCT00001031|HIV-1
1530030|NCT00001031|HIV Envelope Protein gp120
1530031|NCT00001031|AIDS Vaccines
1530032|NCT00001031|HIV Seronegativity
1530033|NCT00001031|HIV Preventive Vaccine
1530034|NCT00001030|Rifabutin
1530035|NCT00001030|Mycobacterium avium-intracellulare Infection
1530036|NCT00001030|Acquired Immunodeficiency Syndrome
1530037|NCT00001030|Clarithromycin
1530038|NCT00001029|Zalcitabine
1530039|NCT00001029|Didanosine
1530040|NCT00001029|Drug Therapy, Combination
1530041|NCT00001029|Acquired Immunodeficiency Syndrome
1530042|NCT00001029|Zidovudine
1530043|NCT00001028|Pneumonia, Pneumocystis carinii
1530044|NCT00001028|Pentamidine
1530045|NCT00001028|Dapsone
1530046|NCT00001028|Acquired Immunodeficiency Syndrome
1530047|NCT00001028|AIDS-Related Complex
1530048|NCT00001027|Pneumonia, Pneumocystis carinii
1530049|NCT00001027|Pentamidine
1530050|NCT00001027|Acquired Immunodeficiency Syndrome
1530051|NCT00001027|AIDS-Related Complex
1530052|NCT00001026|Vaccines, Synthetic
1530053|NCT00001026|Vaccinia Virus
1530054|NCT00001026|Viral Vaccines
1530055|NCT00001026|HIV Envelope Protein gp160
1530056|NCT00001026|HIV Envelope Protein gp120
1530057|NCT00001026|AIDS Vaccines
1530058|NCT00001026|HIV Seronegativity
1530059|NCT00001026|HIV Preventive Vaccine
1530060|NCT00001025|Virus Replication
1530061|NCT00001025|Didanosine
1530062|NCT00001025|Acquired Immunodeficiency Syndrome
1530063|NCT00001025|AIDS-Related Complex
1530064|NCT00001025|Zidovudine
1530065|NCT00001024|Didanosine
1530066|NCT00001024|AIDS-Related Complex
1530067|NCT00001024|Zidovudine
1530068|NCT00001024|Lymph Nodes
1530069|NCT00001024|Lymphoid Tissue
1530070|NCT00001023|Rifabutin
1530071|NCT00001023|Mycobacterium avium-intracellulare Infection
1530072|NCT00001023|Drug Interactions
1530073|NCT00001023|Azithromycin
1530074|NCT00001023|Clarithromycin
1530075|NCT00001022|Zalcitabine
1530076|NCT00001022|Didanosine
1530077|NCT00001022|Drug Therapy, Combination
1530078|NCT00001022|Acquired Immunodeficiency Syndrome
1530079|NCT00001022|AIDS-Related Complex
1530080|NCT00001022|Zidovudine
1530081|NCT00001021|Vaccines, Synthetic
1530082|NCT00001021|HIV-1
1530083|NCT00001021|HIV Envelope Protein gp120
1530084|NCT00001021|AIDS Vaccines
1530085|NCT00001021|HIV Seronegativity
1530086|NCT00001021|HIV Preventive Vaccine
1530087|NCT00001020|Vaccines, Synthetic
1530088|NCT00001020|Viral Vaccines
1530089|NCT00001020|HIV-1
1530090|NCT00001020|HIV Envelope Protein gp120
1530091|NCT00001020|AIDS Vaccines
1530092|NCT00001020|HIV Seronegativity
1530093|NCT00001020|HIV Preventive Vaccine
1530094|NCT00001019|Vaccines, Synthetic
1530095|NCT00001019|Adjuvants, Immunologic
1530096|NCT00001019|HIV Envelope Protein gp120
1530097|NCT00001019|AIDS Vaccines
1530098|NCT00001019|HIV Seronegativity
1530099|NCT00001019|HIV Preventive Vaccine
1530100|NCT00001018|Cryptosporidiosis
1530101|NCT00001018|Diarrhea
1530102|NCT00001018|Acquired Immunodeficiency Syndrome
1530103|NCT00001018|Antiprotozoal Agents
1530104|NCT00001018|Triazines
1530105|NCT00001017|AIDS-Related Opportunistic Infections
1530106|NCT00001017|Meningitis
1530107|NCT00001017|Injections, Intravenous
1530108|NCT00001017|Cryptococcosis
1530109|NCT00001017|Fluconazole
1530110|NCT00001017|Administration, Oral
1530111|NCT00001017|Acquired Immunodeficiency Syndrome
1530112|NCT00001017|Amphotericin B
1530113|NCT00001016|Trimetrexate
1530114|NCT00001016|Pneumonia, Pneumocystis carinii
1530115|NCT00001016|Quinazolines
1530116|NCT00001016|Infusions, Intravenous
1530117|NCT00001016|Injections, Intravenous
1530118|NCT00001016|Leucovorin
1530119|NCT00001016|Drug Evaluation
1530120|NCT00001016|Drug Therapy, Combination
1530121|NCT00001016|Administration, Oral
1530122|NCT00001016|Acquired Immunodeficiency Syndrome
1530123|NCT00001016|Antiprotozoal Agents
1530124|NCT00001016|AIDS-Related Complex
1530125|NCT00001015|Ribavirin
1530126|NCT00001015|T-Lymphocytes
1530127|NCT00001015|Acquired Immunodeficiency Syndrome
1530128|NCT00001015|AIDS-Related Complex
1530129|NCT00001014|Trimethoprim-Sulfamethoxazole Combination
1530130|NCT00001014|Trimetrexate
1530131|NCT00001014|AIDS-Related Opportunistic Infections
1530132|NCT00001014|Pneumonia, Pneumocystis carinii
1530133|NCT00001014|Infusions, Intravenous
1530134|NCT00001014|Leucovorin
1530135|NCT00001014|Drug Therapy, Combination
1530136|NCT00001014|Administration, Oral
1530137|NCT00001014|Acquired Immunodeficiency Syndrome
1530138|NCT00001014|Antiprotozoal Agents
1530139|NCT00001014|AIDS-Related Complex
1530140|NCT00001014|Sulfamethoxazole-Trimethoprim
1530141|NCT00001013|Trimethoprim-Sulfamethoxazole Combination
1530142|NCT00001013|Trimetrexate
1530143|NCT00001013|AIDS-Related Opportunistic Infections
1530144|NCT00001013|Pneumonia, Pneumocystis carinii
1530145|NCT00001013|Pentamidine
1530146|NCT00001013|Infusions, Intravenous
1530147|NCT00001013|Leucovorin
1530148|NCT00001013|Drug Therapy, Combination
1530149|NCT00001013|Folic Acid Antagonists
1530150|NCT00001013|Aerosols
1530151|NCT00001013|Acquired Immunodeficiency Syndrome
1530152|NCT00001013|Antiprotozoal Agents
1530153|NCT00001013|AIDS-Related Complex
1530154|NCT00001013|Sulfamethoxazole-Trimethoprim
1530155|NCT00001012|Virus Replication
1530156|NCT00001012|T-Lymphocytes
1530157|NCT00001012|Dose-Response Relationship, Drug
1530158|NCT00001012|Drug Evaluation
1530159|NCT00001012|Acquired Immunodeficiency Syndrome
1530160|NCT00001012|AL 721
1530161|NCT00001012|AIDS-Related Complex
1530162|NCT00001012|Antiviral Agents
1530163|NCT00001011|Virus Replication
1530164|NCT00001011|AIDS-Related Complex
1530165|NCT00001011|Zidovudine
1530166|NCT00001010|Immune Tolerance
1530167|NCT00001010|Dose-Response Relationship, Drug
1530168|NCT00001010|Drug Evaluation
1530169|NCT00001010|Drug Therapy, Combination
1530170|NCT00001010|Acyclovir
1530171|NCT00001010|Acquired Immunodeficiency Syndrome
1530172|NCT00001010|AIDS-Related Complex
1530173|NCT00001010|Zidovudine
1530174|NCT00001009|T-Lymphocytes
1530175|NCT00001009|HIV Antigens
1530176|NCT00001009|Dextran Sulfate
1530177|NCT00001009|Dose-Response Relationship, Drug
1530178|NCT00001009|Drug Evaluation
1530179|NCT00001009|Drug Therapy, Combination
1530180|NCT00001009|Acquired Immunodeficiency Syndrome
1530181|NCT00001009|AIDS-Related Complex
1530182|NCT00001008|Substance Withdrawal Syndrome
1530183|NCT00001008|Methadone
1530184|NCT00001008|Opioid-Related Disorders
1530185|NCT00001008|Drug Evaluation
1530186|NCT00001008|Drug Interactions
1530187|NCT00001008|Drug Therapy, Combination
1530188|NCT00001008|Administration, Oral
1530189|NCT00001008|Acquired Immunodeficiency Syndrome
1530190|NCT00001008|AIDS-Related Complex
1530191|NCT00001008|Zidovudine
1530192|NCT00001007|Pregnancy
1530193|NCT00001007|Pregnancy Complications, Infectious
1530194|NCT00001007|Infant, Newborn, Diseases
1530195|NCT00001007|Infusions, Intravenous
1530196|NCT00001007|Drug Evaluation
1530197|NCT00001007|Administration, Oral
1530198|NCT00001007|Acquired Immunodeficiency Syndrome
1530199|NCT00001007|Zidovudine
1530200|NCT00001006|Infusions, Intravenous
1530201|NCT00001006|Immunologic Surveillance
1530202|NCT00001006|Drug Evaluation
1530203|NCT00001006|Adjuvants, Immunologic
1530204|NCT00001006|Acquired Immunodeficiency Syndrome
1530205|NCT00001006|AIDS-Related Complex
1530206|NCT00001006|ammonium trichloro(dioxoethylene-O,O'-)tellurute
1530207|NCT00001005|Recombinant Proteins
1530208|NCT00001005|HIV Seropositivity
1530209|NCT00001005|Interleukin-2
1530210|NCT00001005|Drug Evaluation
1530211|NCT00001005|Drug Therapy, Combination
1530212|NCT00001005|Acquired Immunodeficiency Syndrome
1530213|NCT00001005|AIDS-Related Complex
1530214|NCT00001005|Zidovudine
1530215|NCT00001004|Tumor Necrosis Factor
1530216|NCT00001004|Interferon-gamma, Recombinant
1530217|NCT00001004|HIV Antigens
1530218|NCT00001004|Immunologic Surveillance
1530219|NCT00001004|Drug Therapy, Combination
1530220|NCT00001004|Acquired Immunodeficiency Syndrome
1530221|NCT00001004|AIDS-Related Complex
1530222|NCT00001003|AIDS-Related Opportunistic Infections
1530223|NCT00001003|Pneumonia, Pneumocystis carinii
1530224|NCT00001003|Pentamidine
1530225|NCT00001003|Nebulizers and Vaporizers
1530226|NCT00001003|Lung
1530227|NCT00001003|Administration, Inhalation
1530228|NCT00001003|Acquired Immunodeficiency Syndrome
1530229|NCT00001003|Zidovudine
1530230|NCT00001002|Drug Therapy, Combination
1530231|NCT00001002|Foscarnet
1530232|NCT00001002|Acquired Immunodeficiency Syndrome
1530233|NCT00001002|AIDS-Related Complex
1530234|NCT00001002|Antiviral Agents
1530235|NCT00001002|Zidovudine
1530236|NCT00001001|Liver
1530237|NCT00001001|Liver Diseases
1530238|NCT00001001|Liver Function Tests
1530239|NCT00001001|HIV Seropositivity
1530240|NCT00001001|Acquired Immunodeficiency Syndrome
1530241|NCT00001001|Zidovudine
1530242|NCT00001001|Biological Availability
1530243|NCT00001000|Macrophage Activation
1530244|NCT00001000|Lymphocyte Transformation
1530245|NCT00001000|Immunologic Surveillance
1530246|NCT00001000|ampligen
1530247|NCT00001000|Antiviral Agents
1530248|NCT00000999|Acquired Immunodeficiency Syndrome
1530249|NCT00000999|AIDS-Related Complex
1530250|NCT00000999|Zidovudine
1530251|NCT00000998|Trimetrexate
1530252|NCT00000998|AIDS-Related Opportunistic Infections
1530253|NCT00000998|Pneumonia, Pneumocystis carinii
1530254|NCT00000998|Injections, Intravenous
1530255|NCT00000998|Leucovorin
1530256|NCT00000998|Dose-Response Relationship, Drug
1530257|NCT00000998|Drug Therapy, Combination
1530258|NCT00000998|Folic Acid Antagonists
1530259|NCT00000998|Administration, Oral
1530260|NCT00000998|Acquired Immunodeficiency Syndrome
1530261|NCT00000998|Antineoplastic Agents
1530262|NCT00000997|Zalcitabine
1530263|NCT00000997|Drug Evaluation
1530264|NCT00000997|Acquired Immunodeficiency Syndrome
1530265|NCT00000997|AIDS-Related Complex
1530266|NCT00000997|Biological Availability
1530267|NCT00000996|Doxorubicin
1530268|NCT00000996|Drug Evaluation
1530269|NCT00000996|Acquired Immunodeficiency Syndrome
1530270|NCT00000995|AIDS-Related Opportunistic Infections
1530271|NCT00000995|Ganciclovir
1530272|NCT00000995|Drug Evaluation
1530273|NCT00000995|Drug Therapy, Combination
1530274|NCT00000995|Cytomegalovirus Infections
1530275|NCT00000995|Acquired Immunodeficiency Syndrome
1530276|NCT00000995|Zidovudine
1530277|NCT00000994|AIDS-Related Opportunistic Infections
1530278|NCT00000994|Sarcoma, Kaposi
1530279|NCT00000994|Acquired Immunodeficiency Syndrome
1530280|NCT00000994|Zidovudine
1530281|NCT00000993|HIV-1
1530282|NCT00000993|Drug Evaluation
1530283|NCT00000993|Accidents
1530284|NCT00000993|Acquired Immunodeficiency Syndrome
1530285|NCT00000993|AIDS Serodiagnosis
1530286|NCT00000993|Zidovudine
1530287|NCT00000992|AIDS-Related Opportunistic Infections
1530288|NCT00000992|Ketoconazole
1530289|NCT00000992|Histoplasmosis
1530290|NCT00000992|Drug Evaluation
1530291|NCT00000992|Antifungal Agents
1530292|NCT00000992|Acquired Immunodeficiency Syndrome
1530293|NCT00000991|Trimethoprim-Sulfamethoxazole Combination
1530294|NCT00000991|Toxoplasmosis
1530295|NCT00000991|AIDS-Related Opportunistic Infections
1530296|NCT00000991|Pneumonia, Pneumocystis carinii
1530297|NCT00000991|Pentamidine
1530298|NCT00000991|Dapsone
1530299|NCT00000991|Drug Evaluation
1530300|NCT00000991|Drug Therapy, Combination
1530301|NCT00000991|Acquired Immunodeficiency Syndrome
1530302|NCT00000991|Zidovudine
1530303|NCT00000991|Sulfamethoxazole-Trimethoprim
1530304|NCT00000990|AIDS-Related Opportunistic Infections
1530305|NCT00000990|Pulmonary Fibrosis
1530306|NCT00000990|Zidovudine
1530307|NCT00000989|Retinitis
1530308|NCT00000989|Ganciclovir
1530309|NCT00000989|Drug Evaluation
1530310|NCT00000989|Drug Therapy, Combination
1530311|NCT00000989|Cytomegalovirus Infections
1530312|NCT00000989|Acquired Immunodeficiency Syndrome
1530313|NCT00000989|Zidovudine
1530314|NCT00000988|Injections, Intravenous
1530315|NCT00000988|Drug Evaluation
1530316|NCT00000988|Administration, Oral
1530317|NCT00000988|Acquired Immunodeficiency Syndrome
1530318|NCT00000988|AIDS-Related Complex
1530319|NCT00000988|Antiviral Agents
1530320|NCT00000987|Vincristine
1530321|NCT00000987|Doxorubicin
1530322|NCT00000987|Drug Therapy, Combination
1530323|NCT00000987|Acquired Immunodeficiency Syndrome
1530324|NCT00000987|Zidovudine
1530325|NCT00000987|Bleomycin
1530326|NCT00000986|Recombinant Proteins
1530327|NCT00000986|Interleukin-2
1530328|NCT00000986|Drug Interactions
1530329|NCT00000986|Drug Therapy, Combination
1530330|NCT00000986|Acquired Immunodeficiency Syndrome
1530331|NCT00000986|AIDS-Related Complex
1530332|NCT00000986|Zidovudine
1530333|NCT00000985|Vidarabine
1530334|NCT00000985|Phosphonoacetic Acid
1530335|NCT00000985|Herpes Simplex
1530336|NCT00000985|Foscarnet
1530337|NCT00000985|Acyclovir
1530338|NCT00000985|Acquired Immunodeficiency Syndrome
1530339|NCT00000984|Recombinant Proteins
1530340|NCT00000984|Acquired Immunodeficiency Syndrome
1530341|NCT00000984|Antigens, CD4
1530342|NCT00000984|Antiviral Agents
1530343|NCT00000983|Acquired Immunodeficiency Syndrome
1530344|NCT00000983|Zidovudine
1530345|NCT00000982|Central Nervous System Diseases
1530346|NCT00000982|Acquired Immunodeficiency Syndrome
1530347|NCT00000982|Zidovudine
1530348|NCT00000981|Retinitis
1530349|NCT00000981|AIDS-Related Opportunistic Infections
1530350|NCT00000981|Pyrimidine Nucleosides
1530351|NCT00000981|Drug Evaluation
1530352|NCT00000981|fiacitabine
1530353|NCT00000981|Cytomegalovirus Infections
1530354|NCT00000981|Acquired Immunodeficiency Syndrome
1530355|NCT00000981|Antiviral Agents
1530356|NCT00000980|Single-Blind Method
1530357|NCT00000980|Spiramycin
1530358|NCT00000980|AIDS-Related Opportunistic Infections
1530359|NCT00000980|Injections, Intravenous
1530360|NCT00000980|Cryptosporidiosis
1530361|NCT00000980|Diarrhea
1530362|NCT00000980|Drug Evaluation
1530363|NCT00000980|Acquired Immunodeficiency Syndrome
1530364|NCT00000979|Didanosine
1530365|NCT00000979|Zidovudine
1530366|NCT00000978|Zalcitabine
1530367|NCT00000978|Drug Therapy, Combination
1530368|NCT00000978|Acquired Immunodeficiency Syndrome
1530369|NCT00000978|AIDS-Related Complex
1530370|NCT00000978|Zidovudine
1530371|NCT00000977|Vaccines, Synthetic
1530372|NCT00000977|HIV Seropositivity
1530373|NCT00000977|HIV-1
1530374|NCT00000977|Drug Evaluation
1530375|NCT00000977|AIDS Vaccines
1530376|NCT00000977|HIV Therapeutic Vaccine
1530377|NCT00000976|Recombinant Proteins
1530378|NCT00000976|Injections, Intravenous
1530379|NCT00000976|IgG
1530380|NCT00000976|Drug Evaluation
1530381|NCT00000976|Administration, Oral
1530382|NCT00000976|Acquired Immunodeficiency Syndrome
1530383|NCT00000976|Antigens, CD4
1530384|NCT00000976|Zidovudine
1530385|NCT00000976|Carrier Proteins
1530386|NCT00000975|AIDS-Related Opportunistic Infections
1530387|NCT00000975|Histoplasmosis
1530388|NCT00000975|Drug Evaluation
1530389|NCT00000975|Antifungal Agents
1530390|NCT00000975|Acquired Immunodeficiency Syndrome
1530391|NCT00000974|AIDS-Related Opportunistic Infections
1530392|NCT00000974|Pneumonia, Pneumocystis carinii
1530393|NCT00000974|Pentamidine
1530394|NCT00000974|Injections, Intravenous
1530395|NCT00000974|Drug Evaluation
1530396|NCT00000974|Aerosols
1530397|NCT00000974|Acquired Immunodeficiency Syndrome
1530398|NCT00000973|Toxoplasmosis
1530399|NCT00000973|Toxoplasma
1530400|NCT00000973|Pyrimethamine
1530401|NCT00000973|Leucovorin
1530402|NCT00000973|Drug Evaluation
1530403|NCT00000973|Encephalitis
1530404|NCT00000973|Zidovudine
1530405|NCT00000972|Vaccines, Synthetic
1530406|NCT00000972|Drug Evaluation
1530407|NCT00000972|Adjuvants, Immunologic
1530408|NCT00000972|AIDS Vaccines
1530409|NCT00000972|HIV Preventive Vaccine
1530410|NCT00000971|AIDS-Related Opportunistic Infections
1530411|NCT00000971|Mycobacterium avium-intracellulare Infection
1530412|NCT00000971|Didanosine
1530413|NCT00000971|Drug Evaluation
1530414|NCT00000971|Drug Interactions
1530415|NCT00000971|Drug Therapy, Combination
1530416|NCT00000971|Acquired Immunodeficiency Syndrome
1530417|NCT00000971|Zidovudine
1530418|NCT00000970|Retinitis
1530419|NCT00000970|AIDS-Related Opportunistic Infections
1530420|NCT00000970|Ganciclovir
1530421|NCT00000970|Drug Evaluation
1530422|NCT00000970|Drug Therapy, Combination
1530423|NCT00000970|Foscarnet
1530424|NCT00000970|Cytomegalovirus Infections
1530425|NCT00000970|Acquired Immunodeficiency Syndrome
1530426|NCT00000969|Zalcitabine
1530427|NCT00000969|Didanosine
1530428|NCT00000969|Drug Evaluation
1530429|NCT00000969|Zidovudine
1530430|NCT00000968|Vaccines, Synthetic
1530431|NCT00000968|Drug Evaluation
1530432|NCT00000968|HIV Envelope Protein gp160
1530433|NCT00000968|AIDS Vaccines
1530434|NCT00000968|HIV Seronegativity
1530435|NCT00000968|HIV Preventive Vaccine
1530436|NCT00000967|Drug Therapy, Combination
1530437|NCT00000967|AIDS-Related Complex
1530438|NCT00000967|Zidovudine
1530439|NCT00000967|Interferon Type I
1530440|NCT00000966|Toxoplasmosis
1530441|NCT00000966|Toxoplasma
1530442|NCT00000966|Pyrimethamine
1530443|NCT00000966|Leucovorin
1530444|NCT00000966|Drug Evaluation
1530445|NCT00000966|Drug Therapy, Combination
1530446|NCT00000966|Encephalitis
1530447|NCT00000966|Administration, Oral
1530448|NCT00000966|Acquired Immunodeficiency Syndrome
1530449|NCT00000966|Azithromycin
1530450|NCT00000965|Leukocytes, Mononuclear
1530451|NCT00000965|Drug Evaluation
1530452|NCT00000965|Acquired Immunodeficiency Syndrome
1530453|NCT00000965|AIDS-Related Complex
1530454|NCT00000965|Zidovudine
1530455|NCT00000965|Phosphorylation
1530456|NCT00000964|Ranitidine
1530457|NCT00000964|Phosphorus Acids
1530458|NCT00000964|Drug Evaluation
1530459|NCT00000964|Acquired Immunodeficiency Syndrome
1530460|NCT00000963|Didanosine
1530461|NCT00000963|Drug Evaluation
1530462|NCT00000963|Acquired Immunodeficiency Syndrome
1530463|NCT00000963|AIDS-Related Complex
1530464|NCT00000963|Zidovudine
1530465|NCT00000962|Drug Evaluation
1530466|NCT00000962|Acquired Immunodeficiency Syndrome
1530467|NCT00000962|AIDS-Related Complex
1530468|NCT00000962|Nevirapine
1530469|NCT00000961|Drug Therapy, Combination
1530470|NCT00000961|Zidovudine
1530471|NCT00000960|Pregnancy
1530472|NCT00000960|Pregnancy Complications, Infectious
1530473|NCT00000960|Prenatal Exposure Delayed Effects
1530474|NCT00000960|Administration, Oral
1530475|NCT00000960|AIDS-Related Complex
1530476|NCT00000960|Zidovudine
1530477|NCT00000959|Tuberculosis
1530478|NCT00000959|Isoniazid
1530479|NCT00000959|Pyridoxine
1530480|NCT00000959|AIDS-Related Opportunistic Infections
1530481|NCT00000959|Drug Evaluation
1530482|NCT00000959|Acquired Immunodeficiency Syndrome
1530483|NCT00000959|Antitubercular Agents
1530484|NCT00000958|Vaccines, Synthetic
1530485|NCT00000958|Recombinant Proteins
1530486|NCT00000958|Adjuvants, Immunologic
1530487|NCT00000958|Acquired Immunodeficiency Syndrome
1530488|NCT00000958|HIV Envelope Protein gp120
1530489|NCT00000958|AIDS Vaccines
1530490|NCT00000958|HIV Therapeutic Vaccine
1530491|NCT00000957|Vaccines, Synthetic
1530492|NCT00000957|Vaccinia Virus
1530493|NCT00000957|Viral Vaccines
1530494|NCT00000957|HIV-1
1530495|NCT00000957|Drug Evaluation
1530496|NCT00000957|HIV Envelope Protein gp160
1530497|NCT00000957|Drug Administration Schedule
1530498|NCT00000957|AIDS Vaccines
1530499|NCT00000957|HIV Seronegativity
1530500|NCT00000957|HIV Preventive Vaccine
1530501|NCT00000956|Vaccines, Synthetic
1530502|NCT00000956|Vaccinia Virus
1530503|NCT00000956|HIV-1
1530504|NCT00000956|HIV Envelope Protein gp160
1530505|NCT00000956|AIDS Vaccines
1530506|NCT00000956|HIV Seronegativity
1530507|NCT00000956|HIV Preventive Vaccine
1530508|NCT00000955|Tuberculosis
1530509|NCT00000955|Immunologic Tests
1530510|NCT00000955|Tuberculin
1530511|NCT00000955|Tuberculin Test
1530512|NCT00000955|AIDS-Related Opportunistic Infections
1530513|NCT00000955|Injections, Intradermal
1530514|NCT00000955|Acquired Immunodeficiency Syndrome
1530515|NCT00000955|AIDS-Related Complex
1530516|NCT00000955|Hypersensitivity, Delayed
1530517|NCT00000954|Vincristine
1530518|NCT00000954|Sarcoma, Kaposi
1530519|NCT00000954|Zalcitabine
1530520|NCT00000954|Didanosine
1530521|NCT00000954|Doxorubicin
1530522|NCT00000954|Drug Evaluation
1530523|NCT00000954|Drug Interactions
1530524|NCT00000954|Drug Therapy, Combination
1530525|NCT00000954|Combined Modality Therapy
1530526|NCT00000954|Acquired Immunodeficiency Syndrome
1530527|NCT00000954|Antineoplastic Agents
1530528|NCT00000954|Antineoplastic Agents, Combined
1530529|NCT00000954|Antiviral Agents
1530530|NCT00000954|Bleomycin
1530531|NCT00000953|Herpes Zoster
1530532|NCT00000953|Acyclovir
1530533|NCT00000953|Acquired Immunodeficiency Syndrome
1530534|NCT00000953|AIDS-Related Complex
1530535|NCT00000953|Antiviral Agents
1530536|NCT00000953|sorivudine
1530537|NCT00000952|Dose-Response Relationship, Drug
1530538|NCT00000952|Drug Therapy, Combination
1530539|NCT00000952|Zidovudine
1530540|NCT00000952|HIV Protease Inhibitors
1530541|NCT00000952|Ritonavir
1530542|NCT00000952|Lamivudine
1530543|NCT00000952|Anti-HIV Agents
1530544|NCT00000951|AIDS-Related Opportunistic Infections
1530545|NCT00000951|Fluconazole
1530546|NCT00000951|Antifungal Agents
1530547|NCT00000951|Candidiasis, Oral
1530548|NCT00000951|Drug Administration Schedule
1530549|NCT00000951|Pharyngeal Diseases
1530550|NCT00000950|Tuberculosis
1530551|NCT00000950|Isoniazid
1530552|NCT00000950|Pyrazinamide
1530553|NCT00000950|Pyridoxine
1530554|NCT00000950|Rifampin
1530555|NCT00000950|AIDS-Related Opportunistic Infections
1530556|NCT00000950|Drug Therapy, Combination
1530557|NCT00000950|Ethambutol
1530558|NCT00000950|Acquired Immunodeficiency Syndrome
1530559|NCT00000950|Antitubercular Agents
1530560|NCT00000949|AIDS-Related Opportunistic Infections
1530561|NCT00000949|Interleukin-2
1530562|NCT00000949|Dose-Response Relationship, Drug
1530563|NCT00000949|Adolescent Behavior
1530564|NCT00000949|CD4 Lymphocyte Count
1530565|NCT00000949|RNA, Viral
1530566|NCT00000949|Quality of Life
1530567|NCT00000949|Anti-HIV Agents
1530568|NCT00000949|Viral Load
1530569|NCT00000948|Injections, Subcutaneous
1530570|NCT00000948|Interleukin-2
1530571|NCT00000948|Dose-Response Relationship, Drug
1530572|NCT00000948|Drug Therapy, Combination
1530573|NCT00000948|CD4 Lymphocyte Count
1530574|NCT00000948|Anti-HIV Agents
1530575|NCT00000947|AIDS-Related Opportunistic Infections
1530576|NCT00000947|Placebos
1530577|NCT00000947|Mycobacterium avium-intracellulare Infection
1530578|NCT00000947|Acquired Immunodeficiency Syndrome
1530579|NCT00000947|Antitubercular Agents
1530580|NCT00000947|Azithromycin
1530581|NCT00000947|Drug Resistance, Microbial
1530582|NCT00000947|CD4 Lymphocyte Count
1530583|NCT00000947|Antibiotics
1530584|NCT00000947|Time Factors
1530585|NCT00000947|Anti-HIV Agents
1530586|NCT00000947|Pneumonia, Bacterial
1530587|NCT00000947|Streptococcus pneumoniae
1530588|NCT00000946|Drug Evaluation
1530589|NCT00000946|Drug Therapy, Combination
1530590|NCT00000946|AIDS Vaccines
1530591|NCT00000946|HIV Seronegativity
1530592|NCT00000946|HIV Preventive Vaccine
1530593|NCT00000945|Leukoencephalopathy, Progressive Multifocal
1530594|NCT00000945|Probenecid
1530595|NCT00000945|HIV-1
1530596|NCT00000945|Central Nervous System Diseases
1530597|NCT00000945|Acquired Immunodeficiency Syndrome
1530598|NCT00000945|DNA, Viral
1530599|NCT00000945|cidofovir
1530600|NCT00000945|Anti-HIV Agents
1530601|NCT00000945|Neurologic Examination
1530602|NCT00000945|Renal Agents
1530603|NCT00000944|Pregnancy
1530604|NCT00000944|Pregnancy Complications, Infectious
1530605|NCT00000944|Drug Therapy, Combination
1530606|NCT00000944|Zidovudine
1530607|NCT00000944|HIV Protease Inhibitors
1530608|NCT00000944|Lamivudine
1530609|NCT00000944|Indinavir
1530610|NCT00000944|Disease Transmission, Vertical
1530611|NCT00000944|Anti-HIV Agents
1530612|NCT00000943|Lymphocytes
1530613|NCT00000943|Interleukin-2
1530614|NCT00000943|Drug Therapy, Combination
1530615|NCT00000943|AIDS Vaccines
1530616|NCT00000943|CD4 Lymphocyte Count
1530617|NCT00000943|Cell Division
1530618|NCT00000943|HIV Core Protein p24
1530619|NCT00000943|Anti-HIV Agents
1530620|NCT00000943|HIV Therapeutic Vaccine
1530621|NCT00000942|Placebos
1530622|NCT00000942|Pregnancy
1530623|NCT00000942|Pregnancy Complications, Infectious
1530624|NCT00000942|Nevirapine
1530625|NCT00000942|Disease Transmission, Vertical
1530626|NCT00000942|Labor
1530627|NCT00000942|Anti-HIV Agents
1530628|NCT00000941|Drug Interactions
1530629|NCT00000941|HIV Protease Inhibitors
1530630|NCT00000941|Ritonavir
1530631|NCT00000941|HIV Seronegativity
1530632|NCT00000941|Saquinavir
1530633|NCT00000941|Nelfinavir
1530634|NCT00000941|Anticholesteremic Agents
1530635|NCT00000940|Drug Therapy, Combination
1530636|NCT00000940|Stavudine
1530637|NCT00000940|Amprenavir/Ritonavir
1530638|NCT00000940|Protease Inhibitors
1530639|NCT00000940|Lamivudine
1530640|NCT00000940|VX 478
1530641|NCT00000940|Reverse Transcriptase Inhibitors
1530642|NCT00000940|Anti-HIV Agents
1530643|NCT00000940|Viral Load
1530644|NCT00000940|Abacavir Sulfate
1530645|NCT00000940|Acute Infection
1530646|NCT00000940|Treatment Interruption
1530647|NCT00000939|Didanosine
1530648|NCT00000939|Drug Therapy, Combination
1530649|NCT00000939|Stavudine
1530650|NCT00000939|HIV Protease Inhibitors
1530651|NCT00000939|Hydroxyurea
1530652|NCT00000939|RNA, Viral
1530653|NCT00000939|Reverse Transcriptase Inhibitors
1530654|NCT00000939|Anti-HIV Agents
1530655|NCT00000939|Viral Load
1530656|NCT00000939|efavirenz
1530657|NCT00000933|AIDS-Related Opportunistic Infections
1530658|NCT00000933|Mycobacterium avium-intracellulare Infection
1530659|NCT00000933|Antibiotics, Macrolide
1530660|NCT00000933|Azithromycin
1530661|NCT00000933|Drug Administration Schedule
1530662|NCT00000933|Drug Resistance, Microbial
1530663|NCT00000933|Carrier State
1530664|NCT00000933|Streptococcus pneumoniae
1530665|NCT00000932|Prospective Studies
1530666|NCT00000932|HIV-1
1530667|NCT00000932|Drug Therapy, Combination
1530668|NCT00000932|Drug Resistance, Microbial
1530669|NCT00000932|CD4 Lymphocyte Count
1530670|NCT00000932|Disease Progression
1530671|NCT00000932|Treatment Outcome
1530672|NCT00000932|Genotype
1530673|NCT00000932|Anti-HIV Agents
1530674|NCT00000932|Viral Load
1530675|NCT00000931|Homosexuality, Male
1530676|NCT00000931|Risk-Taking
1530677|NCT00000931|Behavior Therapy
1530678|NCT00000931|HIV Seronegativity
1530679|NCT00000930|Sexual Partners
1530680|NCT00000930|Drug Resistance, Microbial
1530681|NCT00000930|Cohort Studies
1530682|NCT00000930|Risk Factors
1530683|NCT00000930|Substance Abuse, Intravenous
1530684|NCT00000930|Disease Progression
1530685|NCT00000930|Homosexuality, Male
1530686|NCT00000930|Genotype
1530687|NCT00000930|Phenotype
1530688|NCT00000929|Sexual Partners
1530689|NCT00000929|Homosexuality, Male
1530690|NCT00000929|Anti-Infective Agents
1530691|NCT00000929|Patient Compliance
1530692|NCT00000929|Nonoxynol
1530693|NCT00000929|Rectum
1530694|NCT00000928|Sexual Partners
1530695|NCT00000928|Condoms
1530696|NCT00000928|Counseling
1530697|NCT00000927|Administration, Topical
1530698|NCT00000927|Mucous Membrane
1530699|NCT00000927|Anti-Infective Agents
1530700|NCT00000927|Cervix Uteri
1530701|NCT00000927|Vagina
1530702|NCT00000927|Vulva
1530703|NCT00000927|Buffers
1530704|NCT00000926|Nonoxynol
1530705|NCT00000925|Dietary Proteins
1530706|NCT00000925|HIV Wasting Syndrome
1530707|NCT00000924|Drug Therapy, Combination
1530708|NCT00000924|HIV Protease Inhibitors
1530709|NCT00000924|Reverse Transcriptase Inhibitors
1530710|NCT00000924|Anti-HIV Agents
1530711|NCT00000923|Interleukin-2
1530712|NCT00000923|Drug Therapy, Combination
1530713|NCT00000923|CD4 Lymphocyte Count
1530714|NCT00000923|Anti-HIV Agents
1530715|NCT00000923|Viral Load
1530716|NCT00000922|Drug Therapy, Combination
1530717|NCT00000922|HIV Protease Inhibitors
1530718|NCT00000922|Reverse Transcriptase Inhibitors
1530719|NCT00000922|Anti-HIV Agents
1530720|NCT00000922|Treatment Naive
1530721|NCT00000921|Drug Therapy, Combination
1530722|NCT00000921|Prednisone
1530723|NCT00000921|Anti-HIV Agents
1530724|NCT00000920|Pregnancy
1530725|NCT00000920|Drug Therapy, Combination
1530726|NCT00000920|Zidovudine
1530727|NCT00000920|Pregnancy Complications
1530728|NCT00000920|Ritonavir
1530729|NCT00000920|Lamivudine
1530730|NCT00000920|Saquinavir
1530731|NCT00000920|Anti-HIV Agents
1530732|NCT00000919|HIV Protease Inhibitors
1530733|NCT00000919|Reverse Transcriptase Inhibitors
1530734|NCT00000919|Anti-HIV Agents
1530735|NCT00000919|Viral Load
1530736|NCT00000918|Drug Therapy, Combination
1530737|NCT00000918|HIV Protease Inhibitors
1530738|NCT00000918|Reverse Transcriptase Inhibitors
1530739|NCT00000918|Salvage Therapy
1530740|NCT00000918|Anti-HIV Agents
1530741|NCT00000918|Viral Load
1530742|NCT00000917|Gene Therapy
1530743|NCT00000917|Specimen Handling
1530744|NCT00000917|Blood Banks
1530745|NCT00000917|Fetal Blood
1530746|NCT00000916|Drug Therapy, Combination
1530747|NCT00000916|HIV Protease Inhibitors
1530748|NCT00000916|Hydroxyurea
1530749|NCT00000916|Reverse Transcriptase Inhibitors
1530750|NCT00000916|Anti-HIV Agents
1530751|NCT00000916|Viral Load
1530752|NCT00000915|AIDS Vaccines
1530753|NCT00000915|Incidence
1530754|NCT00000915|Knowledge, Attitudes, Practice
1530755|NCT00000915|Risk-Taking
1530756|NCT00000914|Drug Therapy, Combination
1530757|NCT00000914|HIV Protease Inhibitors
1530758|NCT00000914|Ritonavir
1530759|NCT00000914|Indinavir
1530760|NCT00000914|Saquinavir
1530761|NCT00000914|Reverse Transcriptase Inhibitors
1530762|NCT00000914|Viral Load
1530763|NCT00000914|Nelfinavir
1530764|NCT00000913|Saquinavir
1530765|NCT00000913|Reverse Transcriptase Inhibitors
1530766|NCT00000913|Anti-HIV Agents
1530767|NCT00000913|Viral Load
1530768|NCT00000912|Placebos
1530769|NCT00000912|Drug Therapy, Combination
1530770|NCT00000912|HIV Protease Inhibitors
1530771|NCT00000912|VX 478
1530772|NCT00000912|Anti-HIV Agents
1530773|NCT00000912|Viral Load
1530774|NCT00000912|efavirenz
1530775|NCT00000911|Semen
1530776|NCT00000911|HIV-1
1530777|NCT00000911|Immunity, Cellular
1530778|NCT00000911|Lymph Nodes
1530779|NCT00000911|Viremia
1530780|NCT00000911|Antibodies, Viral
1530781|NCT00000911|Vagina
1530782|NCT00000911|Viral Load
1530783|NCT00000911|Acute Infection
1530784|NCT00000910|Pregnancy
1530785|NCT00000910|Anti-HIV Agents
1530786|NCT00000909|Interleukin-2
1530787|NCT00000909|Dose-Response Relationship, Drug
1530788|NCT00000909|CD4 Lymphocyte Count
1530789|NCT00000909|RNA, Viral
1530790|NCT00000908|AIDS-Related Opportunistic Infections
1530791|NCT00000908|Pneumonia, Pneumocystis carinii
1530792|NCT00000908|Antiviral Agents
1530793|NCT00000908|CD4 Lymphocyte Count
1530794|NCT00000908|RNA, Viral
1530795|NCT00000907|AIDS-Related Opportunistic Infections
1530796|NCT00000907|Mycobacterium avium-intracellulare Infection
1530797|NCT00000907|Immunity, Cellular
1530798|NCT00000907|Antibiotics, Macrolide
1530799|NCT00000907|Mycobacterium avium Complex
1530800|NCT00000907|CD4 Lymphocyte Count
1530801|NCT00000907|Disease Progression
1530802|NCT00000907|Anti-HIV Agents
1530803|NCT00000906|Methadone
1530804|NCT00000906|HIV-1
1530805|NCT00000906|Dose-Response Relationship, Drug
1530806|NCT00000906|Drug Interactions
1530807|NCT00000906|Drug Therapy, Combination
1530808|NCT00000906|Saquinavir
1530809|NCT00000906|Adolescent Behavior
1530810|NCT00000906|HIV Protease Inhibitors
1530811|NCT00000906|Ritonavir
1530812|NCT00000906|Narcotics
1530813|NCT00000906|Substance-Related Disorders
1530814|NCT00000905|Immunity, Cellular
1530815|NCT00000905|Disease Progression
1530816|NCT00000905|Cytomegalovirus Retinitis
1530817|NCT00000905|DNA, Viral
1530818|NCT00000905|Prognosis
1530819|NCT00000904|Vaccines, Synthetic
1530820|NCT00000904|Viral Vaccines
1530821|NCT00000904|HIV Antibodies
1530822|NCT00000904|HIV Envelope Protein gp160
1530823|NCT00000904|AIDS Vaccines
1530824|NCT00000904|T-Lymphocytes, Cytotoxic
1530825|NCT00000904|HIV Seronegativity
1530826|NCT00000904|Antibody Formation
1530827|NCT00000904|Risk-Taking
1530828|NCT00000904|Avipoxvirus
1530829|NCT00000904|Genetic Vectors
1530830|NCT00000904|Immunization
1530831|NCT00000904|HIV Preventive Vaccine
1530832|NCT00000903|Drug Therapy, Combination
1530833|NCT00000903|Zidovudine
1530834|NCT00000903|HIV Protease Inhibitors
1530835|NCT00000903|Lamivudine
1530836|NCT00000903|Indinavir
1530837|NCT00000903|RNA, Viral
1530838|NCT00000903|Reverse Transcriptase Inhibitors
1530839|NCT00000903|Nelfinavir
1530840|NCT00000903|efavirenz
1530841|NCT00000902|Zalcitabine
1530842|NCT00000902|Didanosine
1530843|NCT00000902|Drug Therapy, Combination
1530844|NCT00000902|Zidovudine
1530845|NCT00000902|Nevirapine
1530846|NCT00000902|Stavudine
1530847|NCT00000902|Ritonavir
1530848|NCT00000902|Lamivudine
1530849|NCT00000902|RNA, Viral
1530850|NCT00000902|Anti-HIV Agents
1530851|NCT00000902|Nelfinavir
1530852|NCT00000901|Dose-Response Relationship, Drug
1530853|NCT00000901|Drug Therapy, Combination
1530854|NCT00000901|Stavudine
1530855|NCT00000901|HIV Protease Inhibitors
1530856|NCT00000901|Lamivudine
1530857|NCT00000901|Indinavir
1530858|NCT00000901|RNA, Viral
1530859|NCT00000901|Reverse Transcriptase Inhibitors
1530860|NCT00000901|Viral Load
1530861|NCT00000900|AIDS-Related Opportunistic Infections
1530862|NCT00000900|HIV-1
1530863|NCT00000900|Antiviral Agents
1530864|NCT00000900|CD4 Lymphocyte Count
1530865|NCT00000900|Polymerase Chain Reaction
1530866|NCT00000900|RNA, Viral
1530867|NCT00000900|Fever
1530868|NCT00000900|Viral Load
1530869|NCT00000899|Cyclophosphamide
1530870|NCT00000899|Dose-Response Relationship, Drug
1530871|NCT00000899|Drug Therapy, Combination
1530872|NCT00000899|Granulocyte Colony-Stimulating Factor
1530873|NCT00000899|Combined Modality Therapy
1530874|NCT00000899|Antineoplastic Agents
1530875|NCT00000899|Lymph Nodes
1530876|NCT00000899|Stavudine
1530877|NCT00000899|HIV Protease Inhibitors
1530878|NCT00000899|Lamivudine
1530879|NCT00000899|DNA, Viral
1530880|NCT00000899|RNA, Viral
1530881|NCT00000899|Reverse Transcriptase Inhibitors
1530882|NCT00000899|Anti-HIV Agents
1530883|NCT00000899|Nelfinavir
1530884|NCT00000899|Antineoplastic Agents, Alkylating
1530885|NCT00000898|Drug Interactions
1530886|NCT00000898|Drug Therapy, Combination
1530887|NCT00000898|Saquinavir
1530888|NCT00000898|HIV Protease Inhibitors
1530889|NCT00000898|Ritonavir
1530890|NCT00000898|Nelfinavir
1530891|NCT00000897|Drug Interactions
1530892|NCT00000897|Zidovudine
1530893|NCT00000897|Sex Factors
1530894|NCT00000897|Reverse Transcriptase Inhibitors
1530895|NCT00000897|Contraceptives, Oral
1530896|NCT00000897|Progestational Hormones, Synthetic
1530897|NCT00000897|Anti-HIV Agents
1530898|NCT00000897|Viral Load
1530899|NCT00000897|Estrogens
1530900|NCT00000896|HIV-1
1530901|NCT00000896|Drug Therapy, Combination
1530902|NCT00000896|Granulocyte Colony-Stimulating Factor
1530903|NCT00000896|Acquired Immunodeficiency Syndrome
1530904|NCT00000896|Zidovudine
1530905|NCT00000896|Nevirapine
1530906|NCT00000896|Stavudine
1530907|NCT00000896|HIV Protease Inhibitors
1530908|NCT00000896|Lamivudine
1530909|NCT00000896|Indinavir
1530910|NCT00000896|Interleukin-12
1530911|NCT00000896|Reverse Transcriptase Inhibitors
1530912|NCT00000895|AIDS-Related Opportunistic Infections
1530913|NCT00000895|Mycobacterium avium-intracellulare Infection
1530914|NCT00000895|HIV-1
1530915|NCT00000895|Drug Therapy, Combination
1530916|NCT00000895|Acquired Immunodeficiency Syndrome
1530917|NCT00000895|Mycobacterium avium Complex
1530918|NCT00000895|Bacteremia
1530919|NCT00000895|Nevirapine
1530920|NCT00000895|HIV Protease Inhibitors
1530921|NCT00000895|Risk Factors
1530922|NCT00000895|RNA, Viral
1530923|NCT00000895|Reverse Transcriptase Inhibitors
1530924|NCT00000895|Nelfinavir
1530925|NCT00000894|Infusions, Intravenous
1530926|NCT00000894|Ganciclovir
1530927|NCT00000894|Drug Therapy, Combination
1530928|NCT00000894|Administration, Oral
1530929|NCT00000894|Antiviral Agents
1530930|NCT00000894|Drug Implants
1530931|NCT00000894|Cytomegalovirus Retinitis
1530932|NCT00000894|Eye
1530933|NCT00000894|cidofovir
1530934|NCT00000893|Dose-Response Relationship, Drug
1530935|NCT00000893|Drug Therapy, Combination
1530936|NCT00000893|HIV Protease Inhibitors
1530937|NCT00000893|Nelfinavir
1530938|NCT00000893|Reverse Transcriptase Inhibitors
1530939|NCT00000893|Area Under Curve
1530940|NCT00000893|efavirenz
1530941|NCT00000892|HIV-1
1530942|NCT00000892|Drug Therapy, Combination
1530943|NCT00000892|HIV Protease Inhibitors
1530944|NCT00000892|Ritonavir
1530945|NCT00000892|Indinavir
1530946|NCT00000892|RNA, Viral
1530947|NCT00000892|Saquinavir
1530948|NCT00000892|Delavirdine
1530949|NCT00000892|Nelfinavir
1530950|NCT00000892|Adenine
1530951|NCT00000892|Anti-HIV Agents
1530952|NCT00000892|Viral Load
1530953|NCT00000891|Drug Therapy, Combination
1530954|NCT00000891|Hypersensitivity, Delayed
1530955|NCT00000891|Follow-Up Studies
1530956|NCT00000891|Anti-HIV Agents
1530957|NCT00000891|Viral Load
1530958|NCT00000890|HIV-1
1530959|NCT00000890|Muscles
1530960|NCT00000890|RNA, Viral
1530961|NCT00000890|Body Composition
1530962|NCT00000890|Anti-HIV Agents
1530963|NCT00000890|Viral Load
1530964|NCT00000889|Interleukin-2
1530965|NCT00000889|CD4 Lymphocyte Count
1530966|NCT00000889|Anti-HIV Agents
1530967|NCT00000888|Pregnancy
1530968|NCT00000888|Pregnancy Complications, Infectious
1530969|NCT00000888|Drug Therapy, Combination
1530970|NCT00000888|Administration, Oral
1530971|NCT00000888|Zidovudine
1530972|NCT00000888|HIV Protease Inhibitors
1530973|NCT00000888|Ritonavir
1530974|NCT00000888|Disease Transmission, Vertical
1530975|NCT00000888|Anti-HIV Agents
1530976|NCT00000888|Fetal Blood
1530977|NCT00000887|Pregnancy
1530978|NCT00000887|Pregnancy Complications, Infectious
1530979|NCT00000887|Drug Therapy, Combination
1530980|NCT00000887|Zidovudine
1530981|NCT00000887|HIV Protease Inhibitors
1530982|NCT00000887|Lamivudine
1530983|NCT00000887|Disease Transmission, Vertical
1530984|NCT00000887|Nelfinavir
1530985|NCT00000887|Anti-HIV Agents
1530986|NCT00000886|HIV Antibodies
1530987|NCT00000886|HIV Envelope Protein gp120
1530988|NCT00000886|Drug Carriers
1530989|NCT00000886|Hypersensitivity, Delayed
1530990|NCT00000886|AIDS Vaccines
1530991|NCT00000886|CD4-Positive T-Lymphocytes
1530992|NCT00000886|CD8-Positive T-Lymphocytes
1530993|NCT00000886|HIV Seronegativity
1530994|NCT00000886|Neutralization Tests
1530995|NCT00000886|Mineral Oil
1530996|NCT00000886|Oleic Acids
1530997|NCT00000886|Mannose
1530998|NCT00000886|HLA-B7 Antigen
1530999|NCT00000886|HLA-A2 Antigen
1531000|NCT00000886|HIV Preventive Vaccine
1531001|NCT00000885|HIV-1
1531002|NCT00000885|Drug Therapy, Combination
1531003|NCT00000885|Zidovudine
1531004|NCT00000885|HIV Protease Inhibitors
1531005|NCT00000885|Lamivudine
1531006|NCT00000885|Indinavir
1531007|NCT00000885|RNA, Viral
1531008|NCT00000885|Treatment Failure
1531009|NCT00000885|Reverse Transcriptase Inhibitors
1531010|NCT00000885|Anti-HIV Agents
1531011|NCT00000885|Viral Load
1531012|NCT00000884|Vaccines, Synthetic
1531013|NCT00000884|Injections, Intramuscular
1531014|NCT00000884|HIV-1
1531015|NCT00000884|Immunity, Cellular
1531016|NCT00000884|AIDS Vaccines
1531017|NCT00000884|HIV Seronegativity
1531018|NCT00000884|Mucous Membrane
1531019|NCT00000884|Antibodies, Viral
1531020|NCT00000884|Avipoxvirus
1531021|NCT00000884|Genetic Vectors
1531022|NCT00000884|HIV Envelope Protein gp120
1531023|NCT00000884|Immunity, Mucosal
1531024|NCT00000884|Rabies Vaccines
1531025|NCT00000884|HIV Preventive Vaccine
1531026|NCT00000883|AIDS-Related Opportunistic Infections
1531027|NCT00000883|Mycobacterium avium-intracellulare Infection
1531028|NCT00000883|Antibiotics, Macrolide
1531029|NCT00000883|Acquired Immunodeficiency Syndrome
1531030|NCT00000883|Azithromycin
1531031|NCT00000883|CD4 Lymphocyte Count
1531032|NCT00000883|Anti-HIV Agents
1531033|NCT00000882|HIV-1
1531034|NCT00000882|Drug Therapy, Combination
1531035|NCT00000882|Stavudine
1531036|NCT00000882|HIV Protease Inhibitors
1531037|NCT00000882|Lamivudine
1531038|NCT00000882|Indinavir
1531039|NCT00000882|RNA, Viral
1531040|NCT00000882|Delavirdine
1531041|NCT00000882|Reverse Transcriptase Inhibitors
1531042|NCT00000882|Anti-HIV Agents
1531043|NCT00000882|Viral Load
1531044|NCT00000881|AIDS-Related Opportunistic Infections
1531045|NCT00000881|Cytomegalovirus Infections
1531046|NCT00000881|Antiviral Agents
1531047|NCT00000881|cidofovir
1531048|NCT00000880|T-Lymphocytes
1531049|NCT00000880|Lymphocyte Transformation
1531050|NCT00000880|HIV-1
1531051|NCT00000880|Drug Therapy, Combination
1531052|NCT00000880|Immunosuppressive Agents
1531053|NCT00000880|Apoptosis
1531054|NCT00000880|Cyclosporine
1531055|NCT00000880|Anti-HIV Agents
1531056|NCT00000879|Pregnancy
1531057|NCT00000879|Pregnancy Complications, Infectious
1531058|NCT00000879|AIDS Vaccines
1531059|NCT00000879|Disease Transmission, Vertical
1531060|NCT00000879|Avipoxvirus
1531061|NCT00000879|HIV Preventive Vaccine
1531062|NCT00000879|HIV Therapeutic Vaccine
1531063|NCT00000878|Pregnancy
1531064|NCT00000878|Pregnancy Complications, Infectious
1531065|NCT00000878|Drug Therapy, Combination
1531066|NCT00000878|Stavudine
1531067|NCT00000878|Lamivudine
1531068|NCT00000878|Disease Transmission, Vertical
1531069|NCT00000878|Reverse Transcriptase Inhibitors
1531070|NCT00000878|Anti-HIV Agents
1531071|NCT00000878|Viral Load
1531072|NCT00000877|Rifabutin
1531073|NCT00000877|Drug Therapy, Combination
1531074|NCT00000877|HIV Protease Inhibitors
1531075|NCT00000877|Indinavir
1531076|NCT00000877|HIV Seronegativity
1531077|NCT00000877|Anti-HIV Agents
1531078|NCT00000876|Antiviral Agents
1531079|NCT00000876|CD4-IgG(2)
1531080|NCT00000876|PRO 542
1531081|NCT00000875|Drug Therapy, Combination
1531082|NCT00000875|Immunotherapy, Adoptive
1531083|NCT00000875|T-Lymphocytes, Cytotoxic
1531084|NCT00000875|Anti-HIV Agents
1531085|NCT00000875|Viral Load
1531086|NCT00000874|HIV-1
1531087|NCT00000874|Drug Therapy, Combination
1531088|NCT00000874|Zidovudine
1531089|NCT00000874|Stavudine
1531090|NCT00000874|Drug Resistance, Microbial
1531091|NCT00000874|HIV Protease Inhibitors
1531092|NCT00000874|CD4 Lymphocyte Count
1531093|NCT00000874|Ritonavir
1531094|NCT00000874|Lamivudine
1531095|NCT00000874|Indinavir
1531096|NCT00000874|RNA, Viral
1531097|NCT00000874|Genotype
1531098|NCT00000874|Reverse Transcriptase Inhibitors
1531099|NCT00000874|Anti-HIV Agents
1531100|NCT00000874|Viral Load
1531101|NCT00000873|Nutritional Status
1531102|NCT00000873|HIV Seronegativity
1531103|NCT00000873|Infant Food
1531104|NCT00000872|Virus Replication
1531105|NCT00000872|HIV-1
1531106|NCT00000872|Drug Therapy, Combination
1531107|NCT00000872|Zidovudine
1531108|NCT00000872|Nevirapine
1531109|NCT00000872|Stavudine
1531110|NCT00000872|HIV Protease Inhibitors
1531111|NCT00000872|CD4 Lymphocyte Count
1531112|NCT00000872|Lamivudine
1531113|NCT00000872|RNA, Viral
1531114|NCT00000872|Reverse Transcriptase Inhibitors
1531115|NCT00000872|Anti-HIV Agents
1531116|NCT00000872|Viral Load
1531117|NCT00000872|Nelfinavir
1531118|NCT00000871|Vaccines, Synthetic
1531119|NCT00000871|AIDS Vaccines
1531120|NCT00000871|HIV Seronegativity
1531121|NCT00000871|Avipoxvirus
1531122|NCT00000871|HIV Preventive Vaccine
1531123|NCT00000870|Recombinant Proteins
1531124|NCT00000870|Infusions, Intravenous
1531125|NCT00000870|Injections, Intravenous
1531126|NCT00000870|Injections, Subcutaneous
1531127|NCT00000870|Interleukin-2
1531128|NCT00000870|Drug Administration Schedule
1531129|NCT00000870|CD4 Lymphocyte Count
1531130|NCT00000870|Quality of Life
1531131|NCT00000870|Anti-HIV Agents
1531132|NCT00000869|Pregnancy Trimester, Third
1531133|NCT00000869|Placebos
1531134|NCT00000869|Pregnancy
1531135|NCT00000869|Pregnancy Complications, Infectious
1531136|NCT00000869|Administration, Oral
1531137|NCT00000869|Nevirapine
1531138|NCT00000869|Disease Transmission, Vertical
1531139|NCT00000869|Reverse Transcriptase Inhibitors
1531140|NCT00000869|Anti-HIV Agents
1531141|NCT00000868|Vaccines, Synthetic
1531142|NCT00000868|HIV-1
1531143|NCT00000868|Administration, Oral
1531144|NCT00000868|AIDS Vaccines
1531145|NCT00000868|HIV Seronegativity
1531146|NCT00000868|HIV Envelope Protein gp120
1531147|NCT00000868|Recombination, Genetic
1531148|NCT00000868|Salmonella typhi
1531149|NCT00000868|HIV Preventive Vaccine
1531150|NCT00000867|Drug Therapy, Combination
1531151|NCT00000867|Administration, Oral
1531152|NCT00000867|AIDS Dementia Complex
1531153|NCT00000867|Zidovudine
1531154|NCT00000867|Anti-HIV Agents
1531155|NCT00000867|Memantine
1531156|NCT00000866|Vaccines, Synthetic
1531157|NCT00000866|Vaccinia Virus
1531158|NCT00000866|Placebos
1531159|NCT00000866|HIV-1
1531160|NCT00000866|AIDS Vaccines
1531161|NCT00000866|HIV Seronegativity
1531162|NCT00000866|Genes, env
1531163|NCT00000866|Genes, pol
1531164|NCT00000866|Genes, gag
1531165|NCT00000866|HIV Preventive Vaccine
1531166|NCT00000865|Drug Therapy, Combination
1531167|NCT00000865|Reverse Transcriptase Inhibitors
1531168|NCT00000865|Anti-HIV Agents
1531169|NCT00000864|Pregnancy
1531170|NCT00000864|Pregnancy Complications, Infectious
1531171|NCT00000864|HIV-1
1531172|NCT00000864|Drug Therapy, Combination
1531173|NCT00000864|Zidovudine
1531174|NCT00000864|Drug Administration Schedule
1531175|NCT00000864|Disease Transmission, Vertical
1531176|NCT00000864|Reverse Transcriptase Inhibitors
1531177|NCT00000864|Anti-HIV Agents
1531178|NCT00000863|AIDS-Related Opportunistic Infections
1531179|NCT00000863|Pneumonia, Pneumocystis carinii
1531180|NCT00000863|Administration, Oral
1531181|NCT00000863|WR 6026
1531182|NCT00000862|Pregnancy
1531183|NCT00000862|Pregnancy Complications, Infectious
1531184|NCT00000862|Administration, Oral
1531185|NCT00000862|Zidovudine
1531186|NCT00000862|Delivery
1531187|NCT00000862|Labor
1531188|NCT00000862|Anti-HIV Agents
1531189|NCT00000861|Drug Administration Schedule
1531190|NCT00000861|HIV Protease Inhibitors
1531191|NCT00000861|CD4 Lymphocyte Count
1531192|NCT00000861|Indinavir
1531193|NCT00000861|RNA, Viral
1531194|NCT00000861|Anti-HIV Agents
1531195|NCT00000861|Viral Load
1531196|NCT00000860|Tumor Necrosis Factor
1531197|NCT00000860|AIDS-Related Opportunistic Infections
1531198|NCT00000860|Mycobacterium avium-intracellulare Infection
1531199|NCT00000860|Drug Therapy, Combination
1531200|NCT00000860|Anti-HIV Agents
1531201|NCT00000859|HIV-1
1531202|NCT00000859|Drug Resistance
1531203|NCT00000859|Drug Therapy, Combination
1531204|NCT00000859|HIV Protease Inhibitors
1531205|NCT00000859|CD4 Lymphocyte Count
1531206|NCT00000859|Ritonavir
1531207|NCT00000859|Indinavir
1531208|NCT00000859|Disease Progression
1531209|NCT00000859|RNA, Viral
1531210|NCT00000859|Genotype
1531211|NCT00000859|Nelfinavir
1531212|NCT00000859|Anti-HIV Agents
1531213|NCT00000859|Viral Load
1531214|NCT00000858|HIV-1
1531215|NCT00000858|Vagina
1531216|NCT00000857|Recombinant Proteins
1531217|NCT00000857|T-Lymphocytes
1531218|NCT00000857|Dose-Response Relationship, Drug
1531219|NCT00000857|Mycobacterium avium Complex
1531220|NCT00000857|CD4 Lymphocyte Count
1531221|NCT00000857|Interleukin-12
1531222|NCT00000857|Killer Cells, Natural
1531223|NCT00000857|Th1 Cells
1531224|NCT00000857|Interferon Type II
1531225|NCT00000856|AIDS-Related Opportunistic Infections
1531226|NCT00000856|Ganciclovir
1531227|NCT00000856|Drug Therapy, Combination
1531228|NCT00000856|Encephalitis
1531229|NCT00000856|Foscarnet
1531230|NCT00000856|Cytomegalovirus Infections
1531231|NCT00000856|Antiviral Agents
1531232|NCT00000856|Radiculopathy
1531233|NCT00000855|Zidovudine
1531234|NCT00000855|Anti-HIV Agents
1531235|NCT00000854|Placebos
1531236|NCT00000854|Acquired Immunodeficiency Syndrome
1531237|NCT00000854|AIDS-Related Complex
1531238|NCT00000854|Anabolic Steroids
1531239|NCT00000854|HIV Wasting Syndrome
1531240|NCT00000854|nandrolone decanoate
1531241|NCT00000853|Vaccines, Synthetic
1531242|NCT00000853|HIV-1
1531243|NCT00000853|HIV Envelope Protein gp120
1531244|NCT00000853|AIDS Vaccines
1531245|NCT00000853|HIV Seronegativity
1531246|NCT00000853|HIV Preventive Vaccine
1531247|NCT00000852|T-Lymphocytes
1531248|NCT00000852|Acquired Immunodeficiency Syndrome
1531249|NCT00000852|Transplantation, Homologous
1531250|NCT00000852|Immunotherapy, Adoptive
1531251|NCT00000851|Didanosine
1531252|NCT00000851|Drug Therapy, Combination
1531253|NCT00000851|Antiviral Agents
1531254|NCT00000851|Stavudine
1531255|NCT00000850|HIV-1
1531256|NCT00000850|Granulocyte-Macrophage Colony-Stimulating Factor
1531257|NCT00000850|RNA, Viral
1531258|NCT00000850|Anti-HIV Agents
1531259|NCT00000850|Viral Load
1531260|NCT00000850|Receptors, Chemokine
1531261|NCT00000849|Interleukin-2
1531262|NCT00000849|Immunity, Cellular
1531263|NCT00000849|Dose-Response Relationship, Drug
1531264|NCT00000849|Acquired Immunodeficiency Syndrome
1531265|NCT00000849|AIDS-Related Complex
1531266|NCT00000849|Viral Load
1531267|NCT00000848|Administration, Oral
1531268|NCT00000848|Acquired Immunodeficiency Syndrome
1531269|NCT00000848|AIDS-Related Complex
1531270|NCT00000848|Antiviral Agents
1531271|NCT00000848|HIV Protease Inhibitors
1531272|NCT00000848|Biological Markers
1531273|NCT00000848|Indinavir
1531274|NCT00000848|Viremia
1531275|NCT00000848|RNA, Viral
1531276|NCT00000848|Saquinavir
1531277|NCT00000847|Vaccines, Synthetic
1531278|NCT00000847|HIV Envelope Protein gp120
1531279|NCT00000847|AIDS Vaccines
1531280|NCT00000847|HIV Seronegativity
1531281|NCT00000847|Avipoxvirus
1531282|NCT00000847|HIV Preventive Vaccine
1531283|NCT00000846|Vaccines, Synthetic
1531284|NCT00000846|HIV-1
1531285|NCT00000846|AIDS Vaccines
1531286|NCT00000846|HIV Seronegativity
1531287|NCT00000846|HIV Preventive Vaccine
1531288|NCT00000845|Vaccines, Synthetic
1531289|NCT00000845|AIDS Vaccines
1531290|NCT00000845|HIV Seronegativity
1531291|NCT00000845|HIV Preventive Vaccine
1531292|NCT00000844|Drug Therapy, Combination
1531293|NCT00000844|Adjuvants, Immunologic
1531294|NCT00000844|Administration, Oral
1531295|NCT00000844|Acquired Immunodeficiency Syndrome
1531296|NCT00000844|AIDS-Related Complex
1531297|NCT00000844|Interferon-alpha
1531298|NCT00000843|Antiviral Agents
1531299|NCT00000843|Adenine
1531300|NCT00000842|Acquired Immunodeficiency Syndrome
1531301|NCT00000842|AIDS-Related Complex
1531302|NCT00000842|Peripheral Nervous System Diseases
1531303|NCT00000842|Nerve Growth Factors
1531304|NCT00000842|Growth Substances
1531305|NCT00000841|Drug Therapy, Combination
1531306|NCT00000841|Acquired Immunodeficiency Syndrome
1531307|NCT00000841|Antiviral Agents
1531308|NCT00000841|Zidovudine
1531309|NCT00000841|Stavudine
1531310|NCT00000841|HIV Protease Inhibitors
1531311|NCT00000841|Lamivudine
1531312|NCT00000841|Indinavir
1531313|NCT00000840|Acquired Immunodeficiency Syndrome
1531314|NCT00000840|AIDS-Related Complex
1531315|NCT00000840|Antiviral Agents
1531316|NCT00000840|Zidovudine
1531317|NCT00000840|Biological Markers
1531318|NCT00000840|Viremia
1531319|NCT00000840|RNA, Viral
1531320|NCT00000839|Pregnancy Trimester, Third
1531321|NCT00000839|Pregnancy
1531322|NCT00000839|Pregnancy Complications, Infectious
1531323|NCT00000839|Didanosine
1531324|NCT00000839|Acquired Immunodeficiency Syndrome
1531325|NCT00000839|AIDS-Related Complex
1531326|NCT00000838|Didanosine
1531917|NCT00000732|Zidovudine
1531327|NCT00000838|Drug Therapy, Combination
1531328|NCT00000838|Acquired Immunodeficiency Syndrome
1531329|NCT00000838|AIDS-Related Complex
1531330|NCT00000838|Antiviral Agents
1531331|NCT00000838|Zidovudine
1531332|NCT00000838|Stavudine
1531333|NCT00000838|Lamivudine
1531334|NCT00000837|Herpesvirus 3, Human
1531335|NCT00000837|Viral Vaccines
1531336|NCT00000837|AIDS-Related Complex
1531337|NCT00000837|Vaccines, Attenuated
1531338|NCT00000837|Chickenpox
1531339|NCT00000837|Chickenpox Vaccine
1531340|NCT00000836|AIDS-Related Opportunistic Infections
1531341|NCT00000836|Acquired Immunodeficiency Syndrome
1531342|NCT00000836|Antibodies, Monoclonal
1531343|NCT00000836|Cytomegalovirus Retinitis
1531344|NCT00000834|Methotrexate
1531345|NCT00000834|Acquired Immunodeficiency Syndrome
1531346|NCT00000834|AIDS-Related Complex
1531347|NCT00000834|Zidovudine
1531348|NCT00000834|Lamivudine
1531349|NCT00000834|Disease Progression
1531350|NCT00000834|Anti-Inflammatory Agents
1531351|NCT00000834|Anti-HIV Agents
1531352|NCT00000833|Ribavirin
1531353|NCT00000833|Didanosine
1531354|NCT00000833|Drug Therapy, Combination
1531355|NCT00000833|Acquired Immunodeficiency Syndrome
1531356|NCT00000833|AIDS-Related Complex
1531357|NCT00000833|Antiviral Agents
1531358|NCT00000832|Vaccines, Synthetic
1531359|NCT00000832|HIV-1
1531360|NCT00000832|Adjuvants, Immunologic
1531361|NCT00000832|HIV Envelope Protein gp120
1531362|NCT00000832|AIDS Vaccines
1531363|NCT00000832|HIV Seronegativity
1531364|NCT00000832|HIV Preventive Vaccine
1531365|NCT00000831|Didanosine
1531366|NCT00000831|Drug Therapy, Combination
1531367|NCT00000831|AIDS-Related Complex
1531368|NCT00000831|Antiviral Agents
1531369|NCT00000831|Zidovudine
1531370|NCT00000831|Stavudine
1531371|NCT00000831|Lamivudine
1531372|NCT00000831|Drug Combinations
1531373|NCT00000829|Vaccines, Synthetic
1531374|NCT00000829|Acquired Immunodeficiency Syndrome
1531375|NCT00000829|AIDS-Related Complex
1531376|NCT00000829|Pneumococcal Infections
1531377|NCT00000829|Bacterial Vaccines
1531378|NCT00000828|Pregnancy
1531379|NCT00000828|Pregnancy Complications, Infectious
1531380|NCT00000828|Acquired Immunodeficiency Syndrome
1531381|NCT00000828|AIDS-Related Complex
1531382|NCT00000828|Zidovudine
1531383|NCT00000828|Drug Resistance, Microbial
1531384|NCT00000828|Disease Transmission, Vertical
1531385|NCT00000827|Acquired Immunodeficiency Syndrome
1531386|NCT00000827|AIDS-Related Complex
1531387|NCT00000827|Immunoglobulins, Intravenous
1531388|NCT00000827|Immunization, Passive
1531389|NCT00000826|Rifabutin
1531390|NCT00000826|Trimethoprim-Sulfamethoxazole Combination
1531391|NCT00000826|AIDS-Related Opportunistic Infections
1531392|NCT00000826|Dapsone
1531393|NCT00000826|Drug Interactions
1531394|NCT00000826|Fluconazole
1531395|NCT00000826|Acquired Immunodeficiency Syndrome
1531396|NCT00000826|AIDS-Related Complex
1531397|NCT00000826|Clarithromycin
1531398|NCT00000826|Sulfamethoxazole-Trimethoprim
1531399|NCT00000825|HIV-1
1531400|NCT00000825|Interleukin-2
1531401|NCT00000825|Dose-Response Relationship, Drug
1531402|NCT00000825|Antiviral Agents
1531403|NCT00000825|CD4 Lymphocyte Count
1531404|NCT00000825|DNA, Viral
1531405|NCT00000824|Immunotherapy, Adoptive
1531406|NCT00000824|T-Lymphocyte Subsets
1531407|NCT00000824|T-Lymphocytes, Cytotoxic
1531408|NCT00000824|Dendritic Cells
1531409|NCT00000823|Didanosine
1531410|NCT00000823|Drug Therapy, Combination
1531411|NCT00000823|Zidovudine
1531412|NCT00000823|Drug Administration Schedule
1531413|NCT00000822|Vaccines, Synthetic
1531414|NCT00000822|Didanosine
1531415|NCT00000822|Drug Therapy, Combination
1531416|NCT00000822|HIV Envelope Protein gp160
1531417|NCT00000822|Acquired Immunodeficiency Syndrome
1531418|NCT00000822|AIDS-Related Complex
1531419|NCT00000822|Stavudine
1531420|NCT00000822|HIV Protease Inhibitors
1531421|NCT00000822|AIDS Vaccines
1531422|NCT00000822|Ritonavir
1531423|NCT00000822|Reverse Transcriptase Inhibitors
1531424|NCT00000822|HIV Therapeutic Vaccine
1531425|NCT00000821|Interleukin-2
1531426|NCT00000821|AIDS-Related Complex
1531427|NCT00000820|Interleukin-2
1531428|NCT00000820|Drug Therapy, Combination
1531429|NCT00000820|AIDS-Related Complex
1531430|NCT00000820|Antiviral Agents
1531431|NCT00000819|AIDS-Related Complex
1531432|NCT00000819|Prednisone
1531433|NCT00000819|AIDS-Associated Nephropathy
1531434|NCT00000818|Acquired Immunodeficiency Syndrome
1531435|NCT00000818|AIDS-Related Complex
1531436|NCT00000818|Zidovudine
1531437|NCT00000818|Lymph Nodes
1531438|NCT00000818|Lymphoid Tissue
1531439|NCT00000817|Acquired Immunodeficiency Syndrome
1531440|NCT00000817|AIDS-Related Complex
1531441|NCT00000817|Peripheral Nervous System Diseases
1531442|NCT00000817|Amitriptyline
1531443|NCT00000817|Pain
1531444|NCT00000817|Acupuncture Therapy
1532267|NCT00000681|Zidovudine
1531445|NCT00000816|Trimethoprim-Sulfamethoxazole Combination
1531446|NCT00000816|Pneumonia, Pneumocystis carinii
1531447|NCT00000816|Acquired Immunodeficiency Syndrome
1531448|NCT00000816|AIDS-Related Complex
1531449|NCT00000816|Sulfamethoxazole-Trimethoprim
1531450|NCT00000815|Acquired Immunodeficiency Syndrome
1531451|NCT00000815|AIDS-Related Complex
1531452|NCT00000815|Measles-Mumps-Rubella Vaccine
1531453|NCT00000815|Vaccines, Attenuated
1531454|NCT00000815|Measles Vaccine
1531455|NCT00000815|Immunization Schedule
1531456|NCT00000815|Measles Virus
1531457|NCT00000815|Measles
1531458|NCT00000814|Didanosine
1531459|NCT00000814|Drug Therapy, Combination
1531460|NCT00000814|Acquired Immunodeficiency Syndrome
1531461|NCT00000814|AIDS-Related Complex
1531462|NCT00000814|Zidovudine
1531463|NCT00000814|Nevirapine
1531464|NCT00000813|Vaccines, Synthetic
1531465|NCT00000813|HIV Envelope Protein gp160
1531466|NCT00000813|HIV Envelope Protein gp120
1531467|NCT00000813|AIDS Vaccines
1531468|NCT00000813|HIV Seronegativity
1531469|NCT00000813|Avipoxvirus
1531470|NCT00000813|HIV Preventive Vaccine
1531471|NCT00000812|Acquired Immunodeficiency Syndrome
1531472|NCT00000812|AIDS-Related Complex
1531473|NCT00000812|Thalidomide
1531474|NCT00000811|Trimethoprim-Sulfamethoxazole Combination
1531475|NCT00000811|Pneumonia, Pneumocystis carinii
1531476|NCT00000811|Drug Therapy, Combination
1531477|NCT00000811|Acquired Immunodeficiency Syndrome
1531478|NCT00000811|Antiprotozoal Agents
1531479|NCT00000811|AIDS-Related Complex
1531480|NCT00000811|Azithromycin
1531481|NCT00000811|Bacterial Infections
1531482|NCT00000811|atovaquone
1531483|NCT00000810|Didanosine
1531484|NCT00000810|Acquired Immunodeficiency Syndrome
1531485|NCT00000810|AIDS-Related Complex
1531486|NCT00000810|Antiviral Agents
1531487|NCT00000810|Zidovudine
1531488|NCT00000750|Acquired Immunodeficiency Syndrome
1531489|NCT00000750|AIDS-Related Complex
1531490|NCT00000750|Zidovudine
1531491|NCT00000749|Vaccines, Synthetic
1531492|NCT00000749|HIV Envelope Protein gp120
1531493|NCT00000749|AIDS Vaccines
1531494|NCT00000749|HIV Seronegativity
1531495|NCT00000749|HIV Preventive Vaccine
1531496|NCT00000809|HIV Preventive Vaccine
1531497|NCT00000809|HIV Therapeutic Vaccine
1531498|NCT00000808|Pregnancy
1531499|NCT00000808|Pregnancy Complications, Infectious
1531500|NCT00000808|Acquired Immunodeficiency Syndrome
1531501|NCT00000808|AIDS-Related Complex
1531502|NCT00000808|Nevirapine
1531503|NCT00000807|Sarcoma, Kaposi
1531504|NCT00000807|Etoposide
1531505|NCT00000807|Acquired Immunodeficiency Syndrome
1531506|NCT00000806|Acquired Immunodeficiency Syndrome
1531507|NCT00000806|AIDS-Related Complex
1531508|NCT00000806|HIV Protease Inhibitors
1531509|NCT00000805|Ganciclovir
1531510|NCT00000805|Cytomegalovirus Infections
1531511|NCT00000805|Acquired Immunodeficiency Syndrome
1531512|NCT00000803|Didanosine
1531513|NCT00000803|Drug Therapy, Combination
1531514|NCT00000803|Acquired Immunodeficiency Syndrome
1531515|NCT00000803|AIDS-Related Complex
1531516|NCT00000803|Antiviral Agents
1531517|NCT00000803|Zidovudine
1531518|NCT00000802|Pneumonia, Pneumocystis carinii
1531519|NCT00000802|Dapsone
1531520|NCT00000802|Antifungal Agents
1531521|NCT00000802|Acquired Immunodeficiency Syndrome
1531522|NCT00000802|atovaquone
1531523|NCT00000801|Vincristine
1531524|NCT00000801|Cyclophosphamide
1531525|NCT00000801|Cytarabine
1531526|NCT00000801|Dexamethasone
1531527|NCT00000801|Doxorubicin
1531528|NCT00000801|Granulocyte Colony-Stimulating Factor
1531529|NCT00000801|Combined Modality Therapy
1531530|NCT00000801|Acquired Immunodeficiency Syndrome
1531531|NCT00000801|Antineoplastic Agents, Combined
1531532|NCT00000801|Brain Neoplasms
1531533|NCT00000801|Lymphoma, High-Grade
1531534|NCT00000801|Lymphoma, Intermediate-Grade
1531535|NCT00000800|Methadone
1531536|NCT00000800|Drug Interactions
1531537|NCT00000800|Drug Therapy, Combination
1531538|NCT00000800|Acquired Immunodeficiency Syndrome
1531539|NCT00000800|AIDS-Related Complex
1531540|NCT00000800|Zidovudine
1531541|NCT00000799|Retinitis
1531542|NCT00000799|Cytomegalovirus Infections
1531543|NCT00000799|Acquired Immunodeficiency Syndrome
1531544|NCT00000799|Antiviral Agents
1531545|NCT00000799|cidofovir
1531546|NCT00000798|Vaccines, Synthetic
1531547|NCT00000798|HIV-1
1531548|NCT00000798|Administration, Oral
1531549|NCT00000798|AIDS Vaccines
1531550|NCT00000798|HIV Seronegativity
1531551|NCT00000798|HIV Preventive Vaccine
1531552|NCT00000796|Isoniazid
1531553|NCT00000796|Tuberculosis, Pulmonary
1531554|NCT00000796|Pyrazinamide
1531555|NCT00000796|Pyridoxine
1531556|NCT00000796|Ofloxacin
1531557|NCT00000796|Rifampin
1531558|NCT00000796|AIDS-Related Opportunistic Infections
1531559|NCT00000796|Drug Therapy, Combination
1531560|NCT00000796|Ethambutol
1531561|NCT00000796|Clofazimine
1532268|NCT00000681|Bleomycin
1531562|NCT00000796|Acquired Immunodeficiency Syndrome
1531563|NCT00000796|Amikacin
1531564|NCT00000796|Drug Resistance, Microbial
1531565|NCT00000796|Cycloserine
1531566|NCT00000796|Capreomycin Sulfate
1531567|NCT00000796|Ethionamide
1531568|NCT00000796|Aminosalicylic Acids
1531569|NCT00000796|Streptomycin
1531570|NCT00000796|p-Aminosalicylic Acid
1531571|NCT00000795|Vaccines, Synthetic
1531572|NCT00000795|HIV-1
1531573|NCT00000795|AIDS Vaccines
1531574|NCT00000795|HIV Seronegativity
1531575|NCT00000795|HIV Preventive Vaccine
1531576|NCT00000794|Pyrimethamine
1531577|NCT00000794|Leucovorin
1531578|NCT00000794|Drug Therapy, Combination
1531579|NCT00000794|Encephalitis
1531580|NCT00000794|Acquired Immunodeficiency Syndrome
1531581|NCT00000794|Antiprotozoal Agents
1531582|NCT00000794|Clarithromycin
1531583|NCT00000794|atovaquone
1531584|NCT00000794|Toxoplasmosis, Cerebral
1531585|NCT00000794|Sulfadiazine
1531586|NCT00000793|Acquired Immunodeficiency Syndrome
1531587|NCT00000793|AIDS-Related Complex
1531588|NCT00000793|Peripheral Nervous System Diseases
1531589|NCT00000793|Amitriptyline
1531590|NCT00000793|Pain
1531591|NCT00000793|Mexiletine
1531592|NCT00000793|benzatropine methanesulfonate
1531593|NCT00000793|Parasympatholytics
1531594|NCT00000792|Administration, Oral
1531595|NCT00000792|Acquired Immunodeficiency Syndrome
1531596|NCT00000792|AIDS-Related Complex
1531597|NCT00000792|Antiviral Agents
1531598|NCT00000791|Drug Therapy, Combination
1531599|NCT00000791|Acquired Immunodeficiency Syndrome
1531600|NCT00000791|AIDS-Related Complex
1531601|NCT00000791|Antiviral Agents
1531602|NCT00000791|Zidovudine
1531603|NCT00000790|Acquired Immunodeficiency Syndrome
1531604|NCT00000790|AIDS-Related Complex
1531605|NCT00000790|Thalidomide
1531606|NCT00000790|Stomatitis, Aphthous
1531607|NCT00000789|Acquired Immunodeficiency Syndrome
1531608|NCT00000789|AIDS-Related Complex
1531609|NCT00000789|Zidovudine
1531610|NCT00000789|Stavudine
1531611|NCT00000788|Methadone
1531612|NCT00000788|Drug Interactions
1531613|NCT00000788|Drug Therapy, Combination
1531614|NCT00000788|Fluconazole
1531615|NCT00000788|Antifungal Agents
1531616|NCT00000788|Acquired Immunodeficiency Syndrome
1531617|NCT00000788|AIDS-Related Complex
1531618|NCT00000787|Sex Behavior
1531619|NCT00000785|Tuberculosis
1531620|NCT00000785|Mycobacterium tuberculosis
1531621|NCT00000785|AIDS-Related Opportunistic Infections
1531622|NCT00000785|Acquired Immunodeficiency Syndrome
1531623|NCT00000785|Drug Resistance, Microbial
1531624|NCT00000784|Acquired Immunodeficiency Syndrome
1531625|NCT00000784|AIDS-Related Complex
1531626|NCT00000783|Sex Behavior
1531627|NCT00000783|Sexual Partners
1531628|NCT00000782|Vaccines, Synthetic
1531629|NCT00000782|Injections, Intradermal
1531630|NCT00000782|HIV Antigens
1531631|NCT00000782|HIV-1
1531632|NCT00000782|HIV Envelope Protein gp160
1531633|NCT00000782|Acquired Immunodeficiency Syndrome
1531634|NCT00000782|AIDS-Related Complex
1531635|NCT00000782|Hypersensitivity, Delayed
1531636|NCT00000782|AIDS Vaccines
1531637|NCT00000782|HIV Therapeutic Vaccine
1531638|NCT00000781|Zalcitabine
1531639|NCT00000781|Didanosine
1531640|NCT00000781|Drug Therapy, Combination
1531641|NCT00000781|Acquired Immunodeficiency Syndrome
1531642|NCT00000781|Zidovudine
1531643|NCT00000781|Nevirapine
1531644|NCT00000780|Acquired Immunodeficiency Syndrome
1531645|NCT00000780|AIDS-Related Complex
1531646|NCT00000780|Adolescent Behavior
1531647|NCT00000779|Vaccines, Synthetic
1531648|NCT00000779|HIV-1
1531649|NCT00000779|Adjuvants, Immunologic
1531650|NCT00000779|AIDS-Related Complex
1531651|NCT00000779|HIV Envelope Protein gp120
1531652|NCT00000779|AIDS Vaccines
1531653|NCT00000779|HIV Therapeutic Vaccine
1531654|NCT00000778|Isoniazid
1531655|NCT00000778|Tuberculosis, Pulmonary
1531656|NCT00000778|Pyridoxine
1531657|NCT00000778|Ofloxacin
1531658|NCT00000778|AIDS-Related Opportunistic Infections
1531659|NCT00000778|Drug Evaluation
1531660|NCT00000778|Acquired Immunodeficiency Syndrome
1531661|NCT00000778|Sputum
1531662|NCT00000778|Colony Count, Microbial
1531663|NCT00000777|Vaccines, Synthetic
1531664|NCT00000777|Pregnancy
1531665|NCT00000777|Pregnancy Complications, Infectious
1531666|NCT00000777|HIV Envelope Protein gp160
1531667|NCT00000777|AIDS Vaccines
1531668|NCT00000777|HIV Preventive Vaccine
1531669|NCT00000777|HIV Therapeutic Vaccine
1531670|NCT00000776|AIDS-Related Opportunistic Infections
1531671|NCT00000776|Meningitis
1531672|NCT00000776|Cryptococcosis
1531673|NCT00000776|Dexamethasone
1531674|NCT00000776|Drug Therapy, Combination
1531675|NCT00000776|Fluconazole
1531676|NCT00000776|Flucytosine
1531677|NCT00000776|Acquired Immunodeficiency Syndrome
1531678|NCT00000776|Amphotericin B
1531679|NCT00000776|Brain Diseases
1531680|NCT00000775|Vaccines, Synthetic
1531681|NCT00000775|HIV-1
1531682|NCT00000775|HIV Envelope Protein gp120
1531683|NCT00000775|AIDS Vaccines
1531684|NCT00000775|HIV Seronegativity
1531685|NCT00000775|HIV Preventive Vaccine
1531686|NCT00000774|Vaccines, Synthetic
1531687|NCT00000774|Virus Replication
1531688|NCT00000774|HIV Envelope Protein gp120
1531689|NCT00000774|AIDS Vaccines
1531690|NCT00000774|HIV Preventive Vaccine
1531691|NCT00000774|HIV Therapeutic Vaccine
1531692|NCT00000773|Pneumonia, Pneumocystis carinii
1531693|NCT00000773|Antifungal Agents
1531694|NCT00000773|Acquired Immunodeficiency Syndrome
1531695|NCT00000773|AIDS-Related Complex
1531696|NCT00000773|Biological Availability
1531697|NCT00000773|atovaquone
1531698|NCT00000772|Ribavirin
1531699|NCT00000772|Didanosine
1531700|NCT00000772|Drug Therapy, Combination
1531701|NCT00000772|Acquired Immunodeficiency Syndrome
1531702|NCT00000772|AIDS-Related Complex
1531703|NCT00000771|Cryptosporidiosis
1532054|NCT00000714|Drug Evaluation
1531704|NCT00000771|Acquired Immunodeficiency Syndrome
1531705|NCT00000771|Paromomycin
1531706|NCT00000770|Didanosine
1531707|NCT00000770|Drug Therapy, Combination
1531708|NCT00000770|Acquired Immunodeficiency Syndrome
1531709|NCT00000770|AIDS-Related Complex
1531710|NCT00000770|Zidovudine
1531711|NCT00000770|Nevirapine
1531712|NCT00000769|Sarcoma, Kaposi
1531713|NCT00000769|Acquired Immunodeficiency Syndrome
1531714|NCT00000769|Interleukin-4
1531715|NCT00000768|Intestinal Absorption
1531716|NCT00000768|Ganciclovir
1531717|NCT00000768|Drug Therapy, Combination
1531718|NCT00000768|Cytomegalovirus Infections
1531719|NCT00000768|Colitis
1531720|NCT00000768|Administration, Oral
1531721|NCT00000768|Acquired Immunodeficiency Syndrome
1531722|NCT00000768|Biological Availability
1531723|NCT00000768|Glutamic Acid
1531724|NCT00000767|Vaccines, Synthetic
1531725|NCT00000767|Vaccinia Virus
1531726|NCT00000767|Viral Vaccines
1531727|NCT00000767|Smallpox Vaccine
1531728|NCT00000767|HIV-1
1531729|NCT00000767|AIDS Vaccines
1531730|NCT00000767|HIV Seronegativity
1531731|NCT00000767|HIV Preventive Vaccine
1531732|NCT00000766|Retinitis
1531733|NCT00000766|Ganciclovir
1531734|NCT00000766|Foscarnet
1531735|NCT00000766|Cytomegalovirus Infections
1531736|NCT00000766|Acquired Immunodeficiency Syndrome
1531737|NCT00000765|Zidovudine
1531738|NCT00000764|Interferon Alfa-2a
1531739|NCT00000764|Acquired Immunodeficiency Syndrome
1531740|NCT00000764|AIDS-Related Complex
1531741|NCT00000764|Anus Neoplasms
1531742|NCT00000764|Papillomavirus, Human
1531743|NCT00000764|Papovaviridae Infections
1531744|NCT00000764|Tumor Virus Infections
1531745|NCT00000764|Isotretinoin
1531746|NCT00000763|Sarcoma, Kaposi
1531747|NCT00000763|Acquired Immunodeficiency Syndrome
1531748|NCT00000763|Antineoplastic Agents
1531749|NCT00000762|Vaccines, Synthetic
1531750|NCT00000762|HIV Envelope Protein gp160
1531751|NCT00000762|HIV Envelope Protein gp120
1531752|NCT00000762|AIDS Vaccines
1531753|NCT00000762|HIV Therapeutic Vaccine
1531754|NCT00000761|Interferon-gamma, Recombinant
1531755|NCT00000761|Acquired Immunodeficiency Syndrome
1531756|NCT00000761|AIDS-Related Complex
1531757|NCT00000760|Didanosine
1531758|NCT00000760|Acquired Immunodeficiency Syndrome
1531759|NCT00000760|AIDS-Related Complex
1531760|NCT00000760|Antiviral Agents
1531761|NCT00000760|Zidovudine
1531762|NCT00000760|Gene Products, tat
1531763|NCT00000759|Central Nervous System Diseases
1531764|NCT00000759|Acquired Immunodeficiency Syndrome
1531765|NCT00000759|AIDS-Related Complex
1531766|NCT00000759|Peripheral Nervous System Diseases
1531767|NCT00000758|Acquired Immunodeficiency Syndrome
1531768|NCT00000758|AIDS-Related Complex
1531769|NCT00000758|Fluorouracil
1531770|NCT00000758|Cervix Dysplasia
1531771|NCT00000758|Cervix Diseases
1531772|NCT00000757|Vaccines, Synthetic
1531773|NCT00000757|Vaccinia Virus
1531774|NCT00000757|HIV-1
1531775|NCT00000757|HIV Envelope Protein gp160
1531776|NCT00000757|AIDS Vaccines
1531777|NCT00000757|HIV Seronegativity
1531778|NCT00000757|HIV Preventive Vaccine
1531779|NCT00000756|T-Lymphocytes
1531780|NCT00000756|Acquired Immunodeficiency Syndrome
1531781|NCT00000756|AIDS-Related Complex
1531782|NCT00000756|Immunotherapy, Adoptive
1531783|NCT00000756|Transplantation, Autologous
1531784|NCT00000755|Vaccines, Synthetic
1531785|NCT00000755|HIV-1
1531786|NCT00000755|Acquired Immunodeficiency Syndrome
1531787|NCT00000755|AIDS-Related Complex
1531788|NCT00000755|Zidovudine
1531789|NCT00000755|HIV Envelope Protein gp120
1531790|NCT00000755|AIDS Vaccines
1531791|NCT00000755|HIV Therapeutic Vaccine
1531792|NCT00000754|Zalcitabine
1531793|NCT00000754|Acquired Immunodeficiency Syndrome
1531794|NCT00000754|AIDS-Related Complex
1531795|NCT00000754|Zidovudine
1531796|NCT00000754|Interferon-alpha
1531797|NCT00000753|Zalcitabine
1531798|NCT00000753|Didanosine
1531799|NCT00000753|Drug Therapy, Combination
1531800|NCT00000753|Acquired Immunodeficiency Syndrome
1531801|NCT00000753|AIDS-Related Complex
1531802|NCT00000753|Antiviral Agents
1531803|NCT00000753|Zidovudine
1531804|NCT00000752|Drug Therapy, Combination
1531805|NCT00000752|Acquired Immunodeficiency Syndrome
1531806|NCT00000752|AIDS-Related Complex
1531807|NCT00000752|cefuroxime axetil
1531808|NCT00000752|Beclomethasone
1531809|NCT00000752|Guaiacol Glyceryl Ether
1531810|NCT00000752|Sinusitis
1531811|NCT00000752|Ephedrine
1531812|NCT00000751|Pregnancy
1531813|NCT00000751|Pregnancy Complications, Infectious
1531814|NCT00000751|Drug Therapy, Combination
1531815|NCT00000751|Acquired Immunodeficiency Syndrome
1531816|NCT00000751|AIDS-Related Complex
1531817|NCT00000751|Zidovudine
1531818|NCT00000751|Immunoglobulins, Intravenous
1531819|NCT00000751|Immunization, Passive
1531820|NCT00000748|Trimethoprim-Sulfamethoxazole Combination
1531821|NCT00000748|Pneumonia, Pneumocystis carinii
1531822|NCT00000748|Acquired Immunodeficiency Syndrome
1531823|NCT00000748|AIDS-Related Complex
1531824|NCT00000748|Sulfamethoxazole-Trimethoprim
1531825|NCT00000747|Drug Resistance
1531826|NCT00000747|AIDS-Related Complex
1531827|NCT00000747|Antiviral Agents
1531828|NCT00000747|Nevirapine
1531829|NCT00000746|Vaccines, Synthetic
1531830|NCT00000746|Vaccinia Virus
1531831|NCT00000746|Viral Vaccines
1531832|NCT00000746|HIV-1
1531833|NCT00000746|HIV Envelope Protein gp160
1531834|NCT00000746|HIV Envelope Protein gp120
1531835|NCT00000746|AIDS Vaccines
1531836|NCT00000746|HIV Seronegativity
1531837|NCT00000746|HIV Preventive Vaccine
1531838|NCT00000745|Vaccines, Synthetic
1531839|NCT00000745|Vaccinia Virus
1531840|NCT00000745|Viral Vaccines
1531841|NCT00000745|HIV-1
1531842|NCT00000745|HIV Envelope Protein gp160
1531843|NCT00000745|AIDS Vaccines
1531844|NCT00000745|HIV Seronegativity
1531845|NCT00000745|HIV Preventive Vaccine
1531846|NCT00000744|Fluconazole
1531847|NCT00000744|Acquired Immunodeficiency Syndrome
1531848|NCT00000744|AIDS-Related Complex
1531849|NCT00000744|Candidiasis
1531850|NCT00000743|Recombinant Proteins
1531851|NCT00000743|Acquired Immunodeficiency Syndrome
1531852|NCT00000743|Antigens, CD4
1531853|NCT00000743|AIDS-Related Complex
1531854|NCT00000743|Zidovudine
1531855|NCT00000742|Didanosine
1531856|NCT00000742|Drug Therapy, Combination
1531857|NCT00000742|Acquired Immunodeficiency Syndrome
1531858|NCT00000742|AIDS-Related Complex
1531859|NCT00000742|Antiviral Agents
1531860|NCT00000742|Zidovudine
1531861|NCT00000741|Pneumonia, Pneumocystis carinii
1531862|NCT00000741|Acquired Immunodeficiency Syndrome
1531863|NCT00000741|Methylprednisolone
1531864|NCT00000740|Pneumonia, Pneumocystis carinii
1531865|NCT00000740|Acquired Immunodeficiency Syndrome
1531866|NCT00000740|AIDS-Related Complex
1531867|NCT00000740|WR 6026
1531868|NCT00000739|Pneumonia, Pneumocystis carinii
1531869|NCT00000739|Dapsone
1531870|NCT00000739|Acquired Immunodeficiency Syndrome
1531871|NCT00000739|AIDS-Related Complex
1531872|NCT00000739|Drug Administration Schedule
1531873|NCT00000738|Central Nervous System Diseases
1531874|NCT00000738|Acquired Immunodeficiency Syndrome
1531875|NCT00000738|AIDS Dementia Complex
1531876|NCT00000738|AIDS-Related Complex
1531877|NCT00000738|Zidovudine
1531878|NCT00000738|Nimodipine
1531879|NCT00000737|Weight Loss
1531880|NCT00000737|Megestrol
1531881|NCT00000737|Cachexia
1531882|NCT00000737|Eating Disorders
1531883|NCT00000737|Tetrahydrocannabinol
1531884|NCT00000737|Appetite
1531885|NCT00000736|Acquired Immunodeficiency Syndrome
1531886|NCT00000736|AIDS-Related Complex
1531887|NCT00000736|Zidovudine
1531888|NCT00000735|Virus Replication
1531889|NCT00000735|T-Lymphocytes
1531890|NCT00000735|Infusions, Intravenous
1531891|NCT00000735|Immunologic Surveillance
1531892|NCT00000735|Acquired Immunodeficiency Syndrome
1531893|NCT00000735|ampligen
1531894|NCT00000735|AIDS-Related Complex
1531895|NCT00000735|Antiviral Agents
1531896|NCT00000734|Trimethoprim-Sulfamethoxazole Combination
1531897|NCT00000734|AIDS-Related Opportunistic Infections
1531898|NCT00000734|Pneumonia, Pneumocystis carinii
1531899|NCT00000734|Drug Interactions
1531900|NCT00000734|Drug Therapy, Combination
1531901|NCT00000734|Acquired Immunodeficiency Syndrome
1531902|NCT00000734|AIDS-Related Complex
1531903|NCT00000734|Zidovudine
1531904|NCT00000734|Sulfamethoxazole-Trimethoprim
1531905|NCT00000733|Ribavirin
1531906|NCT00000733|T-Lymphocytes
1531907|NCT00000733|Infusions, Intravenous
1531908|NCT00000733|Immunologic Surveillance
1531909|NCT00000733|Administration, Oral
1531910|NCT00000733|Acquired Immunodeficiency Syndrome
1531911|NCT00000732|Trimethoprim-Sulfamethoxazole Combination
1531912|NCT00000732|Pneumonia, Pneumocystis carinii
1531913|NCT00000732|Drug Interactions
1531914|NCT00000732|Drug Therapy, Combination
1531915|NCT00000732|Acquired Immunodeficiency Syndrome
1531916|NCT00000732|AIDS-Related Complex
1531918|NCT00000732|Sulfamethoxazole-Trimethoprim
1531919|NCT00000731|Acetaminophen
1531920|NCT00000731|Drug Interactions
1531921|NCT00000731|Drug Therapy, Combination
1531922|NCT00000731|Acquired Immunodeficiency Syndrome
1531923|NCT00000731|AIDS-Related Complex
1531924|NCT00000731|Zidovudine
1531925|NCT00000730|Trimethoprim-Sulfamethoxazole Combination
1531926|NCT00000730|Trimetrexate
1531927|NCT00000730|AIDS-Related Opportunistic Infections
1531928|NCT00000730|Pneumonia, Pneumocystis carinii
1531929|NCT00000730|Leucovorin
1531930|NCT00000730|Folic Acid Antagonists
1531931|NCT00000730|Acquired Immunodeficiency Syndrome
1531932|NCT00000730|Antiprotozoal Agents
1531933|NCT00000730|Sulfamethoxazole-Trimethoprim
1531934|NCT00000729|Virus Replication
1531935|NCT00000729|Infusions, Intravenous
1531936|NCT00000729|Dose-Response Relationship, Drug
1531937|NCT00000729|Foscarnet
1532172|NCT00000696|Interferon Alfa-2a
1531938|NCT00000729|Acquired Immunodeficiency Syndrome
1531939|NCT00000729|AIDS-Related Complex
1531940|NCT00000729|Antiviral Agents
1531941|NCT00000729|CD4-Positive T-Lymphocytes
1531942|NCT00000728|Immune Tolerance
1531943|NCT00000728|Interleukin-2
1531944|NCT00000728|Drug Therapy, Combination
1531945|NCT00000728|AIDS-Related Complex
1531946|NCT00000728|Zidovudine
1531947|NCT00000728|CD4-Positive T-Lymphocytes
1531948|NCT00000727|Sulfadoxine
1531949|NCT00000727|Trimethoprim-Sulfamethoxazole Combination
1531950|NCT00000727|AIDS-Related Opportunistic Infections
1531951|NCT00000727|Pneumonia, Pneumocystis carinii
1531952|NCT00000727|Pentamidine
1531953|NCT00000727|Pyrimethamine
1531954|NCT00000727|Drug Evaluation
1531955|NCT00000727|Administration, Inhalation
1531956|NCT00000727|Administration, Oral
1531957|NCT00000727|Aerosols
1531958|NCT00000727|Acquired Immunodeficiency Syndrome
1531959|NCT00000727|Zidovudine
1531960|NCT00000726|Retinitis
1531961|NCT00000726|AIDS-Related Opportunistic Infections
1531962|NCT00000726|Foscarnet
1531963|NCT00000726|Cytomegalovirus Infections
1531964|NCT00000726|Acquired Immunodeficiency Syndrome
1531965|NCT00000726|Antiviral Agents
1531966|NCT00000725|Interferon Alfa-2a
1531967|NCT00000725|Sarcoma, Kaposi
1531968|NCT00000725|Dose-Response Relationship, Drug
1531969|NCT00000725|Drug Therapy, Combination
1531970|NCT00000725|Acquired Immunodeficiency Syndrome
1531971|NCT00000725|Zidovudine
1531972|NCT00000725|Interferon Type I
1531973|NCT00000724|Trimetrexate
1531974|NCT00000724|Pneumonia, Pneumocystis carinii
1531975|NCT00000724|Injections, Intravenous
1531976|NCT00000724|Leucovorin
1531977|NCT00000724|Drug Evaluation
1531978|NCT00000724|Drug Therapy, Combination
1531979|NCT00000724|Folic Acid Antagonists
1531980|NCT00000724|Acquired Immunodeficiency Syndrome
1531981|NCT00000724|Antiprotozoal Agents
1531982|NCT00000723|AIDS-Related Opportunistic Infections
1531983|NCT00000723|Lymphoma
1531984|NCT00000723|Methotrexate
1531985|NCT00000723|Leucovorin
1531986|NCT00000723|Dexamethasone
1531987|NCT00000723|Drug Evaluation
1531988|NCT00000723|Drug Therapy, Combination
1531989|NCT00000723|Combined Modality Therapy
1531990|NCT00000723|Acquired Immunodeficiency Syndrome
1531991|NCT00000723|Zidovudine
1531992|NCT00000723|Brain Neoplasms
1531993|NCT00000722|AIDS-Related Opportunistic Infections
1531994|NCT00000722|Pneumonia, Pneumocystis carinii
1531995|NCT00000722|Pentamidine
1531996|NCT00000722|Injections, Intravenous
1531997|NCT00000722|Lung
1531998|NCT00000722|Administration, Inhalation
1531999|NCT00000722|Aerosols
1532000|NCT00000722|Acquired Immunodeficiency Syndrome
1532001|NCT00000721|Recombinant Proteins
1532002|NCT00000721|Infusions, Intravenous
1532003|NCT00000721|Injections, Intramuscular
1532004|NCT00000721|Injections, Intravenous
1532005|NCT00000721|Injections, Subcutaneous
1532006|NCT00000721|Dose-Response Relationship, Drug
1532007|NCT00000721|Drug Evaluation
1532008|NCT00000721|Acquired Immunodeficiency Syndrome
1532009|NCT00000721|Antigens, CD4
1532010|NCT00000721|AIDS-Related Complex
1532011|NCT00000720|AIDS-Related Opportunistic Infections
1532012|NCT00000720|Placebos
1532013|NCT00000720|Infusions, Intravenous
1532014|NCT00000720|Gamma-Globulins
1532015|NCT00000720|Combined Modality Therapy
1532016|NCT00000720|Acquired Immunodeficiency Syndrome
1532017|NCT00000720|Zidovudine
1532018|NCT00000720|Bacterial Infections
1532019|NCT00000720|Immunization, Passive
1532020|NCT00000719|Zalcitabine
1532021|NCT00000719|Acquired Immunodeficiency Syndrome
1532022|NCT00000719|Zidovudine
1532023|NCT00000718|Zalcitabine
1532024|NCT00000718|Dose-Response Relationship, Drug
1532025|NCT00000718|Acquired Immunodeficiency Syndrome
1532026|NCT00000718|AIDS-Related Complex
1532027|NCT00000718|Zidovudine
1532028|NCT00000717|AIDS-Related Opportunistic Infections
1532029|NCT00000717|Pneumonia, Pneumocystis carinii
1532030|NCT00000717|Primaquine
1532031|NCT00000717|Infusions, Intravenous
1532032|NCT00000717|Drug Evaluation
1532033|NCT00000717|Drug Therapy, Combination
1532034|NCT00000717|Administration, Oral
1532035|NCT00000717|Acquired Immunodeficiency Syndrome
1532036|NCT00000717|Clindamycin
1532037|NCT00000716|Drug Evaluation
1532038|NCT00000716|Administration, Oral
1532039|NCT00000716|Acquired Immunodeficiency Syndrome
1532040|NCT00000716|Zidovudine
1532041|NCT00000715|Trimethoprim-Sulfamethoxazole Combination
1532042|NCT00000715|AIDS-Related Opportunistic Infections
1532043|NCT00000715|Pneumonia, Pneumocystis carinii
1532044|NCT00000715|Pentamidine
1532045|NCT00000715|Infusions, Intravenous
1532046|NCT00000715|Administration, Inhalation
1532047|NCT00000715|Aerosols
1532048|NCT00000715|Acquired Immunodeficiency Syndrome
1532049|NCT00000715|Sulfamethoxazole-Trimethoprim
1532050|NCT00000714|Trimetrexate
1532051|NCT00000714|AIDS-Related Opportunistic Infections
1532052|NCT00000714|Pneumonia, Pneumocystis carinii
1532053|NCT00000714|Leucovorin
1532055|NCT00000714|Drug Therapy, Combination
1532056|NCT00000714|Acquired Immunodeficiency Syndrome
1532057|NCT00000714|Antiprotozoal Agents
1532058|NCT00000713|Polyribonucleotides
1532059|NCT00000713|HIV Seropositivity
1532060|NCT00000713|Dose-Response Relationship, Drug
1532061|NCT00000713|Drug Evaluation
1532062|NCT00000713|Acquired Immunodeficiency Syndrome
1532063|NCT00000713|ampligen
1532064|NCT00000713|AIDS-Related Complex
1532065|NCT00000713|Antiviral Agents
1532066|NCT00000712|AIDS-Related Opportunistic Infections
1532067|NCT00000712|Herpesviridae Infections
1532068|NCT00000712|Drug Evaluation
1532069|NCT00000712|Drug Therapy, Combination
1532070|NCT00000712|Herpesvirus 4, Human
1532071|NCT00000712|Cytomegalovirus Infections
1532072|NCT00000712|Acyclovir
1532073|NCT00000712|Acquired Immunodeficiency Syndrome
1532074|NCT00000712|Antiviral Agents
1532075|NCT00000712|Zidovudine
1532076|NCT00000711|Neutropenia
1532077|NCT00000711|Drug Evaluation
1532078|NCT00000711|Drug Therapy, Combination
1532079|NCT00000711|Granulocyte-Macrophage Colony-Stimulating Factor
1532080|NCT00000711|Acquired Immunodeficiency Syndrome
1532081|NCT00000711|AIDS-Related Complex
1532082|NCT00000711|Zidovudine
1532083|NCT00000710|Injections, Intravenous
1532084|NCT00000710|Didanosine
1532085|NCT00000710|Dose-Response Relationship, Drug
1532086|NCT00000710|Drug Evaluation
1532087|NCT00000710|Acquired Immunodeficiency Syndrome
1532088|NCT00000710|AIDS-Related Complex
1532089|NCT00000709|Neuropsychological Tests
1532090|NCT00000709|AIDS Dementia Complex
1532091|NCT00000709|Zidovudine
1532092|NCT00000709|CD4-Positive T-Lymphocytes
1532093|NCT00000708|AIDS-Related Opportunistic Infections
1532094|NCT00000708|Meningitis
1532095|NCT00000708|Injections, Intravenous
1532096|NCT00000708|Cryptococcus neoformans
1532097|NCT00000708|Cryptococcosis
1532098|NCT00000708|Drug Therapy, Combination
1532099|NCT00000708|Fluconazole
1532100|NCT00000708|Administration, Oral
1532101|NCT00000708|Acquired Immunodeficiency Syndrome
1532102|NCT00000708|Amphotericin B
1532103|NCT00000707|Respiratory Function Tests
1532104|NCT00000707|AIDS-Related Opportunistic Infections
1532105|NCT00000707|Pneumonia, Pneumocystis carinii
1532106|NCT00000707|Pentamidine
1532107|NCT00000707|Lung
1532108|NCT00000707|HIV Seropositivity
1532109|NCT00000707|Drug Evaluation
1532110|NCT00000707|Administration, Inhalation
1532111|NCT00000707|Aerosols
1532112|NCT00000707|Acquired Immunodeficiency Syndrome
1532113|NCT00000706|Quinine
1532114|NCT00000706|Probenecid
1532115|NCT00000706|Drug Therapy, Combination
1532116|NCT00000706|Acquired Immunodeficiency Syndrome
1532117|NCT00000706|AIDS-Related Complex
1532118|NCT00000706|Zidovudine
1532119|NCT00000705|Drug Evaluation
1532120|NCT00000705|Zidovudine
1532121|NCT00000705|Hemophilia A
1532122|NCT00000704|HIV Antigens
1532123|NCT00000704|Immunologic Surveillance
1532124|NCT00000704|Zalcitabine
1532125|NCT00000704|Dose-Response Relationship, Drug
1532126|NCT00000704|Acquired Immunodeficiency Syndrome
1532127|NCT00000704|AIDS-Related Complex
1532128|NCT00000704|CD4-Positive T-Lymphocytes
1532129|NCT00000703|Vincristine
1532130|NCT00000703|Lymphoma
1532131|NCT00000703|Methotrexate
1532132|NCT00000703|Cyclophosphamide
1532133|NCT00000703|Cytarabine
1532134|NCT00000703|Dexamethasone
1532135|NCT00000703|Doxorubicin
1532136|NCT00000703|Drug Therapy, Combination
1532137|NCT00000703|Combined Modality Therapy
1532138|NCT00000703|Acquired Immunodeficiency Syndrome
1532139|NCT00000703|Antineoplastic Agents, Combined
1532140|NCT00000703|Zidovudine
1532141|NCT00000703|Bleomycin
1532142|NCT00000702|AIDS Dementia Complex
1532143|NCT00000702|Zidovudine
1532144|NCT00000701|Drug Evaluation
1532145|NCT00000701|Acquired Immunodeficiency Syndrome
1532146|NCT00000701|AIDS-Related Complex
1532147|NCT00000701|Zidovudine
1532148|NCT00000700|United States
1532149|NCT00000700|AIDS-Related Opportunistic Infections
1532150|NCT00000700|Pneumonia, Pneumocystis carinii
1532151|NCT00000700|Acquired Immunodeficiency Syndrome
1532152|NCT00000700|Zidovudine
1532153|NCT00000699|Ribavirin
1532154|NCT00000699|Inosine Pranobex
1532155|NCT00000699|Dose-Response Relationship, Drug
1532156|NCT00000699|Drug Evaluation
1532157|NCT00000699|Drug Therapy, Combination
1532158|NCT00000699|AIDS-Related Complex
1532159|NCT00000698|Retinitis
1532160|NCT00000698|AIDS-Related Opportunistic Infections
1532161|NCT00000698|Ganciclovir
1532162|NCT00000698|Cytomegalovirus Infections
1532163|NCT00000698|Acquired Immunodeficiency Syndrome
1532164|NCT00000697|Retinitis
1532165|NCT00000697|AIDS-Related Opportunistic Infections
1532166|NCT00000697|Bone Marrow
1532167|NCT00000697|Ganciclovir
1532168|NCT00000697|Foscarnet
1532169|NCT00000697|Cytomegalovirus Infections
1532170|NCT00000697|Acquired Immunodeficiency Syndrome
1532171|NCT00000697|Antiviral Agents
1532173|NCT00000696|Drug Therapy, Combination
1532174|NCT00000696|AIDS-Related Complex
1532175|NCT00000696|Zidovudine
1532176|NCT00000695|Drug Evaluation
1532177|NCT00000695|Drug Therapy, Combination
1532178|NCT00000695|Acquired Immunodeficiency Syndrome
1532179|NCT00000695|Zidovudine
1532180|NCT00000695|Interferon Type I
1532181|NCT00000694|Interferon Alfa-2b
1532182|NCT00000694|Immune System
1532183|NCT00000694|Drug Evaluation
1532184|NCT00000694|Drug Therapy, Combination
1532185|NCT00000694|Granulocyte-Macrophage Colony-Stimulating Factor
1532186|NCT00000694|Acquired Immunodeficiency Syndrome
1532187|NCT00000694|Zidovudine
1532188|NCT00000693|Retinitis
1532189|NCT00000693|Drug Evaluation
1532190|NCT00000693|Drug Therapy, Combination
1532191|NCT00000693|Cytomegalovirus Infections
1532192|NCT00000693|Acyclovir
1532193|NCT00000693|Acquired Immunodeficiency Syndrome
1532194|NCT00000693|Zidovudine
1532195|NCT00000692|Acquired Immunodeficiency Syndrome
1532196|NCT00000692|AIDS-Related Complex
1532197|NCT00000692|Antiviral Agents
1532198|NCT00000692|Biological Availability
1532199|NCT00000692|1-Deoxynojirimycin
1532200|NCT00000691|Retinitis
1532201|NCT00000691|AIDS-Related Opportunistic Infections
1532202|NCT00000691|Ganciclovir
1532203|NCT00000691|Drug Evaluation
1532204|NCT00000691|Foscarnet
1532205|NCT00000691|Cytomegalovirus Infections
1532206|NCT00000691|Acquired Immunodeficiency Syndrome
1532207|NCT00000691|Antiviral Agents
1532208|NCT00000690|Reference Values
1532209|NCT00000690|Infusions, Intravenous
1532210|NCT00000690|Intestinal Absorption
1532211|NCT00000690|Dextran Sulfate
1532212|NCT00000690|Administration, Oral
1532213|NCT00000690|Blood Coagulation
1532214|NCT00000689|M-BACOD protocol
1532215|NCT00000689|Nervous System Neoplasms
1532216|NCT00000689|Infusions, Intravenous
1532217|NCT00000689|Injections, Intravenous
1532218|NCT00000689|Leucovorin
1532219|NCT00000689|Cytarabine
1532220|NCT00000689|Drug Evaluation
1532221|NCT00000689|Drug Therapy, Combination
1532222|NCT00000689|Granulocyte-Macrophage Colony-Stimulating Factor
1532223|NCT00000689|Administration, Oral
1532224|NCT00000689|Acquired Immunodeficiency Syndrome
1532225|NCT00000689|Antineoplastic Agents, Combined
1532226|NCT00000688|Retinitis
1532227|NCT00000688|Injections, Intravenous
1532228|NCT00000688|Ganciclovir
1532229|NCT00000688|Cytomegalovirus Infections
1532230|NCT00000688|Acquired Immunodeficiency Syndrome
1532231|NCT00000687|Interferon Alfa-2a
1532232|NCT00000687|Drug Evaluation
1532233|NCT00000687|Drug Therapy, Combination
1532234|NCT00000687|Acquired Immunodeficiency Syndrome
1532235|NCT00000687|Zidovudine
1532236|NCT00000686|Drug Evaluation
1532237|NCT00000686|Acquired Immunodeficiency Syndrome
1532238|NCT00000686|AIDS-Related Complex
1532239|NCT00000686|Antiviral Agents
1532240|NCT00000686|Zidovudine
1532241|NCT00000685|Kidney Diseases
1532242|NCT00000685|Drug Evaluation
1532243|NCT00000685|Acquired Immunodeficiency Syndrome
1532244|NCT00000685|Zidovudine
1532245|NCT00000685|Renal Dialysis
1532246|NCT00000684|Infusions, Intravenous
1532247|NCT00000684|Dextran Sulfate
1532248|NCT00000684|Acquired Immunodeficiency Syndrome
1532249|NCT00000683|Vaccines, Synthetic
1532250|NCT00000683|Vaccinia Virus
1532251|NCT00000683|Viral Envelope Proteins
1532252|NCT00000683|Acquired Immunodeficiency Syndrome
1532253|NCT00000683|AIDS Vaccines
1532254|NCT00000683|HIV Seronegativity
1532255|NCT00000683|HIV Preventive Vaccine
1532256|NCT00000682|AIDS-Related Opportunistic Infections
1532257|NCT00000682|Pneumonia, Pneumocystis carinii
1532258|NCT00000682|Zalcitabine
1532259|NCT00000682|Acquired Immunodeficiency Syndrome
1532260|NCT00000682|Zidovudine
1532261|NCT00000681|Vincristine
1532262|NCT00000681|Doxorubicin
1532263|NCT00000681|Drug Evaluation
1532264|NCT00000681|Drug Therapy, Combination
1532265|NCT00000681|Granulocyte-Macrophage Colony-Stimulating Factor
1532266|NCT00000681|Acquired Immunodeficiency Syndrome
1532269|NCT00000680|T-Lymphocytes, Suppressor-Effector
1532270|NCT00000680|Indium Radioisotopes
1532271|NCT00000680|Leukapheresis
1532272|NCT00000680|Interleukin-2
1532273|NCT00000680|Acquired Immunodeficiency Syndrome
1532274|NCT00000680|AIDS-Related Complex
1532275|NCT00000680|Zidovudine
1532276|NCT00000680|Immunization, Passive
1532277|NCT00000679|Zalcitabine
1532278|NCT00000679|Acquired Immunodeficiency Syndrome
1532279|NCT00000679|AIDS-Related Complex
1532280|NCT00000679|Zidovudine
1532281|NCT00000678|Zalcitabine
1532282|NCT00000678|Drug Evaluation
1532283|NCT00000678|Acquired Immunodeficiency Syndrome
1532284|NCT00000678|AIDS-Related Complex
1532285|NCT00000678|Zidovudine
1532286|NCT00000677|Sch 39304
1532287|NCT00000677|AIDS-Related Opportunistic Infections
1532288|NCT00000677|Meningitis
1532289|NCT00000677|Cryptococcosis
1532290|NCT00000677|Drug Evaluation
1532291|NCT00000677|Antifungal Agents
1532292|NCT00000677|Acquired Immunodeficiency Syndrome
1532293|NCT00000676|Mycoses
1532294|NCT00000676|Fluconazole
1532295|NCT00000676|Clotrimazole
1532296|NCT00000676|Antifungal Agents
1532297|NCT00000676|Acquired Immunodeficiency Syndrome
1532298|NCT00000676|AIDS-Related Complex
1532299|NCT00000675|Recombinant Proteins
1532300|NCT00000675|IgG
1532301|NCT00000675|Drug Evaluation
1532302|NCT00000675|Acquired Immunodeficiency Syndrome
1532303|NCT00000675|Antigens, CD4
1532304|NCT00000675|AIDS-Related Complex
1532305|NCT00000675|Carrier Proteins
1532306|NCT00000674|Toxoplasmosis
1532307|NCT00000674|AIDS-Related Opportunistic Infections
1532308|NCT00000674|Pyrimethamine
1532309|NCT00000674|Leucovorin
1532310|NCT00000674|Drug Evaluation
1532311|NCT00000674|Drug Therapy, Combination
1532312|NCT00000674|Encephalitis
1532313|NCT00000674|Acquired Immunodeficiency Syndrome
1532314|NCT00000674|Clindamycin
1532315|NCT00000673|Retinitis
1532316|NCT00000673|AIDS-Related Opportunistic Infections
1532317|NCT00000673|Ganciclovir
1532318|NCT00000673|Cytomegalovirus Infections
1532319|NCT00000673|Acquired Immunodeficiency Syndrome
1532320|NCT00000672|Didanosine
1532321|NCT00000672|Zidovudine
1532322|NCT00000671|Didanosine
1532323|NCT00000671|Zidovudine
1532324|NCT00000670|Probenecid
1532325|NCT00000670|Drug Evaluation
1532326|NCT00000670|Drug Interactions
1532327|NCT00000670|Acquired Immunodeficiency Syndrome
1532328|NCT00000670|Zidovudine
1532329|NCT00000669|Didanosine
1532330|NCT00000669|Drug Evaluation
1532331|NCT00000669|Acquired Immunodeficiency Syndrome
1532332|NCT00000669|AIDS-Related Complex
1532333|NCT00000668|Retinitis
1532334|NCT00000668|AIDS-Related Opportunistic Infections
1532335|NCT00000668|Ganciclovir
1532336|NCT00000668|Cytomegalovirus Infections
1532337|NCT00000668|Acquired Immunodeficiency Syndrome
1532338|NCT00000667|Vaccines, Synthetic
1532339|NCT00000667|Injections, Intradermal
1532340|NCT00000667|HIV Antigens
1532341|NCT00000667|HIV Seropositivity
1532342|NCT00000667|HIV-1
1532343|NCT00000667|Drug Evaluation
1532344|NCT00000667|Hypersensitivity, Delayed
1532345|NCT00000667|AIDS Vaccines
1532346|NCT00000667|HIV Therapeutic Vaccine
1532347|NCT00000666|Toxoplasmosis
1532348|NCT00000666|AIDS-Related Opportunistic Infections
1532349|NCT00000666|Pyrimethamine
1532350|NCT00000666|Drug Evaluation
1532351|NCT00000666|Encephalitis
1532352|NCT00000666|Acquired Immunodeficiency Syndrome
1532353|NCT00000665|Retinitis
1532354|NCT00000665|AIDS-Related Opportunistic Infections
1532355|NCT00000665|Ganciclovir
1532356|NCT00000665|Foscarnet
1532357|NCT00000665|Cytomegalovirus Infections
1532358|NCT00000665|Acquired Immunodeficiency Syndrome
1532359|NCT00000665|Antiviral Agents
1532360|NCT00000664|Polyethylene Glycols
1532361|NCT00000664|Interleukin-2
1532362|NCT00000664|Drug Evaluation
1532363|NCT00000664|Zidovudine
1532364|NCT00000663|Recombinant Proteins
1532365|NCT00000663|Injections, Intravenous
1532366|NCT00000663|IgG
1532367|NCT00000663|Drug Evaluation
1532368|NCT00000663|Acquired Immunodeficiency Syndrome
1532369|NCT00000663|Antigens, CD4
1532370|NCT00000663|Carrier Proteins
1532371|NCT00000662|Drugs, Investigational
1532372|NCT00000662|Acquired Immunodeficiency Syndrome
1532373|NCT00000662|AIDS-Related Complex
1532374|NCT00000662|Zidovudine
1532375|NCT00000661|Oxazepam
1532376|NCT00000661|Drug Evaluation
1532377|NCT00000661|Drug Interactions
1532378|NCT00000661|Zidovudine
1532379|NCT00000660|Sarcoma, Kaposi
1532380|NCT00000660|Drug Evaluation
1532381|NCT00000660|Etoposide
1532382|NCT00000660|Acquired Immunodeficiency Syndrome
1532383|NCT00000659|Acquired Immunodeficiency Syndrome
1532384|NCT00000659|Antigens, CD4
1532385|NCT00000659|AIDS-Related Complex
1532386|NCT00000659|Zidovudine
1532387|NCT00000658|M-BACOD protocol
1532388|NCT00000658|Granulocyte-Macrophage Colony-Stimulating Factor
1532389|NCT00000658|Acquired Immunodeficiency Syndrome
1532390|NCT00000658|Allopurinol
1532391|NCT00000658|Antineoplastic Agents, Combined
1532392|NCT00000657|Didanosine
1532393|NCT00000657|Drug Evaluation
1532394|NCT00000657|Drugs, Investigational
1532395|NCT00000657|AIDS Dementia Complex
1532396|NCT00000657|Zidovudine
1532397|NCT00000656|Didanosine
1532398|NCT00000656|Drug Therapy, Combination
1532399|NCT00000656|Zidovudine
1532400|NCT00000655|Trimethoprim-Sulfamethoxazole Combination
1532401|NCT00000655|AIDS-Related Opportunistic Infections
1532402|NCT00000655|Pneumonia, Pneumocystis carinii
1532403|NCT00000655|Naphthoquinones
1532404|NCT00000655|Antifungal Agents
1532405|NCT00000655|Acquired Immunodeficiency Syndrome
1532406|NCT00000655|Sulfamethoxazole-Trimethoprim
1532407|NCT00000654|AIDS-Related Opportunistic Infections
1532408|NCT00000654|Pyrimidine Nucleosides
1532409|NCT00000654|Herpesviridae Infections
1532410|NCT00000654|Drug Evaluation
1532411|NCT00000654|Antiviral Agents
1532412|NCT00000654|Hepatitis B
1532413|NCT00000653|Zalcitabine
1532414|NCT00000653|Drug Evaluation
1532415|NCT00000653|Acquired Immunodeficiency Syndrome
1532416|NCT00000653|AIDS-Related Complex
1532417|NCT00000652|Didanosine
1532418|NCT00000652|Drug Evaluation
1532419|NCT00000652|Drug Therapy, Combination
1532420|NCT00000652|Zidovudine
1532421|NCT00000651|Zalcitabine
1532422|NCT00000651|Antiviral Agents
1532423|NCT00000651|Zidovudine
1532424|NCT00000650|Drug Evaluation
1532425|NCT00000650|Ditiocarb
1532426|NCT00000650|Acquired Immunodeficiency Syndrome
1532427|NCT00000649|Drug Therapy, Combination
1532428|NCT00000649|Acquired Immunodeficiency Syndrome
1532429|NCT00000649|AIDS-Related Complex
1532430|NCT00000649|Zidovudine
1532431|NCT00000649|Nevirapine
1532432|NCT00000648|Penicillin G
1532433|NCT00000648|Neurosyphilis
1532434|NCT00000648|Drug Evaluation
1532435|NCT00000648|Acquired Immunodeficiency Syndrome
1532436|NCT00000648|AIDS-Related Complex
1532437|NCT00000648|Ceftriaxone
1532438|NCT00000647|Recombinant Proteins
1532439|NCT00000647|IgG
1532440|NCT00000647|Drug Evaluation
1532441|NCT00000647|Drug Therapy, Combination
1532442|NCT00000647|Acquired Immunodeficiency Syndrome
1532443|NCT00000647|Antigens, CD4
1532444|NCT00000647|Zidovudine
1532445|NCT00000647|Carrier Proteins
1532446|NCT00000647|Interferon Type I
1532447|NCT00000646|Pentoxifylline
1532448|NCT00000646|Virus Replication
1532449|NCT00000646|Tumor Necrosis Factor
1532450|NCT00000646|Drug Evaluation
1532451|NCT00000646|Acquired Immunodeficiency Syndrome
1532452|NCT00000646|Cachexia
1532453|NCT00000646|Drug Synergism
1532454|NCT00000645|Drug Evaluation
1532455|NCT00000645|Acquired Immunodeficiency Syndrome
1532456|NCT00000645|AIDS-Related Complex
1532457|NCT00000645|Antiviral Agents
1532458|NCT00000644|AIDS-Related Opportunistic Infections
1532459|NCT00000644|Mycobacterium avium-intracellulare Infection
1532460|NCT00000644|Acquired Immunodeficiency Syndrome
1532461|NCT00000644|Clarithromycin
1532462|NCT00000643|Toxoplasmosis
1532463|NCT00000643|Pyrimethamine
1532464|NCT00000643|Leucovorin
1532465|NCT00000643|Drug Evaluation
1532466|NCT00000643|Acquired Immunodeficiency Syndrome
1532467|NCT00000643|AIDS-Related Complex
1532468|NCT00000643|Brain Diseases
1532469|NCT00000642|Recombinant Proteins
1532470|NCT00000642|Pregnancy Trimester, Third
1532471|NCT00000642|Pregnancy
1532472|NCT00000642|Pregnancy Complications, Infectious
1532473|NCT00000642|IgG
1532474|NCT00000642|Drug Evaluation
1532475|NCT00000642|Antigens, CD4
1532476|NCT00000642|AIDS-Related Complex
1532477|NCT00000642|Immunization, Passive
1532478|NCT00000641|Rifampin
1532479|NCT00000641|Mycobacterium avium-intracellulare Infection
1532480|NCT00000641|Drug Evaluation
1532481|NCT00000641|Drug Therapy, Combination
1532482|NCT00000641|Ethambutol
1532483|NCT00000641|Clofazimine
1532484|NCT00000641|Acquired Immunodeficiency Syndrome
1532485|NCT00000641|Amikacin
1532486|NCT00000641|Azithromycin
1532487|NCT00000641|Ciprofloxacin
1532488|NCT00000640|Trimethoprim-Sulfamethoxazole Combination
1532489|NCT00000640|Pneumonia, Pneumocystis carinii
1532490|NCT00000640|Primaquine
1532491|NCT00000640|Dapsone
1532492|NCT00000640|Drug Therapy, Combination
1532493|NCT00000640|Acquired Immunodeficiency Syndrome
1532494|NCT00000640|Clindamycin
1532495|NCT00000640|Sulfamethoxazole-Trimethoprim
1532496|NCT00000639|AIDS-Related Opportunistic Infections
1532497|NCT00000639|Meningitis
1532498|NCT00000639|Cryptococcosis
1532499|NCT00000639|Drug Evaluation
1532500|NCT00000639|Drug Therapy, Combination
1532501|NCT00000639|Fluconazole
1532502|NCT00000639|Flucytosine
1532503|NCT00000639|Acquired Immunodeficiency Syndrome
1532504|NCT00000639|Amphotericin B
1532505|NCT00000639|Brain Diseases
1532506|NCT00000638|Tuberculosis
1532507|NCT00000638|Isoniazid
1532508|NCT00000638|Mycobacterium tuberculosis
1532509|NCT00000638|Pyrazinamide
1532510|NCT00000638|Pyridoxine
1532511|NCT00000638|Rifampin
1532512|NCT00000638|AIDS-Related Opportunistic Infections
1532513|NCT00000638|Drug Therapy, Combination
1532514|NCT00000638|Acquired Immunodeficiency Syndrome
1532515|NCT00000638|Antitubercular Agents
1532516|NCT00000638|AIDS-Related Complex
1532517|NCT00000637|Didanosine
1532518|NCT00000637|Drug Evaluation
1532519|NCT00000637|Drug Therapy, Combination
1532520|NCT00000637|Acquired Immunodeficiency Syndrome
1532521|NCT00000637|AIDS-Related Complex
1532522|NCT00000637|Zidovudine
1532523|NCT00000636|Tuberculosis
1532524|NCT00000636|Isoniazid
1532525|NCT00000636|Pyrazinamide
1532526|NCT00000636|Pyridoxine
1532527|NCT00000636|Rifampin
1532528|NCT00000636|AIDS-Related Opportunistic Infections
1532529|NCT00000636|Drug Therapy, Combination
1532530|NCT00000636|Acquired Immunodeficiency Syndrome
1532531|NCT00000636|Antitubercular Agents
1532532|NCT00000636|AIDS-Related Complex
1532533|NCT00000635|Bacitracin
1532534|NCT00000635|Polymyxin B
1532535|NCT00000635|Trifluridine
1532536|NCT00000635|AIDS-Related Opportunistic Infections
1532537|NCT00000635|Herpesviridae Infections
1532538|NCT00000635|Drug Evaluation
1532539|NCT00000635|Acquired Immunodeficiency Syndrome
1532540|NCT00000635|Anti-Infective Agents, Local
1532541|NCT00000635|Antiviral Agents
1532542|NCT00000634|Benzodiazepines
1532543|NCT00000634|Drug Evaluation
1532544|NCT00000634|Drugs, Investigational
1532545|NCT00000634|Acquired Immunodeficiency Syndrome
1532546|NCT00000634|Antiviral Agents
1532547|NCT00000633|Vaccines, Synthetic
1532548|NCT00000633|Vaccinia Virus
1532549|NCT00000633|Viral Vaccines
1532550|NCT00000633|HIV-1
1532551|NCT00000633|HIV Envelope Protein gp160
1532552|NCT00000633|Acquired Immunodeficiency Syndrome
1532553|NCT00000633|AIDS-Related Complex
1532554|NCT00000633|AIDS Vaccines
1532555|NCT00000633|HIV Therapeutic Vaccine
1532556|NCT00000632|Vaccines, Synthetic
1532557|NCT00000632|Drug Evaluation
1532558|NCT00000632|Adjuvants, Immunologic
1532559|NCT00000632|AIDS Vaccines
1532560|NCT00000632|HIV Preventive Vaccine
1532561|NCT00000631|Vaccines, Synthetic
1532562|NCT00000631|Vaccinia Virus
1532563|NCT00000631|Viral Envelope Proteins
1532564|NCT00000631|Viral Vaccines
1532565|NCT00000631|AIDS Vaccines
1532566|NCT00000631|HIV Seronegativity
1532567|NCT00000631|HIV Preventive Vaccine
1532568|NCT00000630|Vaccines, Synthetic
1532569|NCT00000630|Vaccinia Virus
1532570|NCT00000630|Viral Envelope Proteins
1532571|NCT00000630|Acquired Immunodeficiency Syndrome
1532572|NCT00000630|AIDS Vaccines
1532573|NCT00000630|HIV Seronegativity
1532574|NCT00000630|HIV Preventive Vaccine
1532575|NCT00000629|Valproic Acid
1532576|NCT00000629|Zidovudine
1532577|NCT00000628|Drug Evaluation
1532578|NCT00000628|Drugs, Investigational
1532579|NCT00000628|Drug Therapy, Combination
1532580|NCT00000628|Acquired Immunodeficiency Syndrome
1532581|NCT00000628|AIDS-Related Complex
1532582|NCT00000628|Antiviral Agents
1532583|NCT00000627|Pilot Projects
1532584|NCT00000627|Histoplasmosis
1532585|NCT00000627|Drug Evaluation
1532586|NCT00000627|Fluconazole
1532587|NCT00000627|Acquired Immunodeficiency Syndrome
1532588|NCT00000627|Recurrence
1532589|NCT00000626|Granulocyte Colony-Stimulating Factor
1532590|NCT00000626|Acquired Immunodeficiency Syndrome
1532591|NCT00000626|Antineoplastic Agents, Combined
1532592|NCT00000626|AIDS-Related Complex
1532593|NCT00000626|Hodgkin Disease
1532594|NCT00000626|ABVD protocol
1532595|NCT00000625|Zalcitabine
1532596|NCT00000625|Didanosine
1532597|NCT00000625|Drug Therapy, Combination
1532598|NCT00000625|AIDS-Related Complex
1532599|NCT00000625|Antiviral Agents
1532600|NCT00000625|Zidovudine
1532601|NCT00000623|chelator
1532602|NCT00000623|iron
1532603|NCT00000623|transfusion
1532604|NCT00000623|anemia
1532605|NCT00000623|thalassemia
1532606|NCT00000620|Diabetes Mellitus, Non-Insulin-Dependent
1532607|NCT00000456|Alcoholism
1532608|NCT00000456|Alcohol Dependence
1532609|NCT00000456|Naltrexone
1532610|NCT00000456|Cognitive Behavioral Therapy
1532611|NCT00000451|Alcoholism
1532612|NCT00000451|Alcohol Dependence
1532613|NCT00000436|Hip fracture
1532614|NCT00000436|Self-efficacy
1532615|NCT00000436|Strength training
1532616|NCT00000436|Rehabilitation
1532617|NCT00000436|Postoperative
1532618|NCT00000435|RA
1532619|NCT00000435|Immune Modulation
1532620|NCT00000435|Oral Tolerance
1532621|NCT00000435|Peptide
1532622|NCT00000435|dnaJ
1532623|NCT00000434|Osteoarthritis
1532624|NCT00000434|Health education
1532625|NCT00000434|Aerobic exercise
1532626|NCT00000434|Self-efficacy
1532627|NCT00000434|Muscle strength
1532628|NCT00000434|Outcomes research
1532629|NCT00000434|Longitudinal study
1532630|NCT00000433|Spondylitis
1532631|NCT00000433|Etanercept
1532632|NCT00000433|ENBREL
1532633|NCT00000433|Tumor necrosis factor-alpha
1532634|NCT00000432|Lyme disease
1532635|NCT00000432|Education evaluation
1532636|NCT00000432|Communicable disease control
1532637|NCT00000432|Outcomes research
1532638|NCT00000432|Tick-transmitted diseases
1532639|NCT00000431|Venous leg ulcer
1532640|NCT00000431|Wound healing
1532641|NCT00000431|Somatic gene therapy
1532642|NCT00000431|PDGF-B
1532643|NCT00000430|Osteoporosis
1532644|NCT00000430|Osteopenia
1532645|NCT00000430|Postmenopausal women
1532646|NCT00000430|Hormone replacement therapy
1532647|NCT00000430|Alendronate
1532648|NCT00000429|JRA
1532649|NCT00000429|Osteopenia
1532650|NCT00000429|Dietary calcium
1532651|NCT00000429|Diet therapy
1532652|NCT00000429|Bone density
1532653|NCT00000429|Ossification
1532654|NCT00000429|Biomarker
1532655|NCT00000429|Dietary supplement
1532656|NCT00000428|Fibromyalgia Syndrome (FMS)
1532657|NCT00000428|Amitriptyline
1532658|NCT00000428|Fluoxetine
1532659|NCT00000427|Parathyroid Hormone (PTH)
1532660|NCT00000427|Alendronate
1532661|NCT00000427|Bone metabolism
1532662|NCT00000427|Bone mineral density (BMD)
1532663|NCT00000427|Bone loss
1532664|NCT00000427|Postmenopausal osteoporosis
1532665|NCT00000427|Osteoporosis in men
1532666|NCT00000426|Calcium deficiency
1532667|NCT00000426|Dietary calcium
1532668|NCT00000426|Dietary protein
1532669|NCT00000426|Osteoporosis
1532670|NCT00000426|Calcium supplement
1532671|NCT00000426|Bone density
1532672|NCT00000426|Bone mass
1532673|NCT00000426|Bone mass accumulation
1532674|NCT00000425|Osteoarthritis
1532675|NCT00000425|Skeletal disorder
1532676|NCT00000425|Chemotherapy
1532677|NCT00000425|Nonsteroidal anti-inflammatory drugs (NSAIDs)
1532678|NCT00000425|Arthroplasty
1532679|NCT00000425|Cartilage metabolism
1532680|NCT00000425|Hip
1532681|NCT00000425|Knee
1532682|NCT00000425|Outcomes research
1532683|NCT00000424|Osteoarthritis (OA)
1532684|NCT00000424|Knee
1532685|NCT00000424|Sham lavage
1532686|NCT00000424|Tidal lavage
1532687|NCT00000424|Lavage therapy
1532688|NCT00000424|Nonsteroidal anti-inflammatory drug (NSAID)
1532689|NCT00000424|Placebo
1532690|NCT00000424|Radiography
1532691|NCT00000424|Human therapy evaluation
1532692|NCT00000424|WOMAC
1532693|NCT00000423|Fibromyalgia
1532694|NCT00000423|Health education
1532695|NCT00000423|Program evaluation
1532696|NCT00000423|Social support
1532697|NCT00000423|Managed care
1532698|NCT00000423|Quality of well-being
1532699|NCT00000422|Fibromyalgia Syndrome (FMS)
1532700|NCT00000422|Physical therapy
1532701|NCT00000422|Psychotherapy
1532702|NCT00000422|Group counseling
1532703|NCT00000422|Human therapy relations
1532704|NCT00000422|Interpersonal relations
1532705|NCT00000422|Chronic pain
1532706|NCT00000422|Cognition
1532707|NCT00000422|Emotion
1532708|NCT00000422|Memory
1532709|NCT00000422|Musculoskeletal disorder
1532710|NCT00000422|Psychological stressor
1532711|NCT00000422|Psychological adaptation
1532712|NCT00000422|Outcomes research
1532713|NCT00000421|SLE
1532714|NCT00000421|Lupus
1532715|NCT00000421|Anti-double-stranded DNA antibody
1532716|NCT00000421|Corticosteroid treatment
1532717|NCT00000421|Hormone therapy
1532718|NCT00000421|Complement
1532719|NCT00000421|Hypertension
1532720|NCT00000421|Estrogen
1532721|NCT00000421|SELENA
1532722|NCT00000420|SLE
1532723|NCT00000420|SELENA
1532724|NCT00000420|Oral contraceptives
1532725|NCT00000420|The pill
1532726|NCT00000420|Birth control
1532727|NCT00000420|Condom
1532728|NCT00000420|Diaphragm
1532729|NCT00000420|Estrogen
1532730|NCT00000420|Lupus
1532731|NCT00000420|Placebo
1532732|NCT00000419|SLE
1532733|NCT00000419|SELENA
1532734|NCT00000419|Estrogen Replacement Therapy (ERT)
1532735|NCT00000419|Postmenopause
1532736|NCT00000419|Osteoporosis
1532737|NCT00000419|Estrogens
1532738|NCT00000419|Steroids
1532739|NCT00000419|Progestin
1532740|NCT00000419|Placebo
1532741|NCT00000418|OA
1532742|NCT00000418|Patient education
1532743|NCT00000418|Acute low back pain (ALBP)
1532744|NCT00000418|Social support systems
1532745|NCT00000417|SLE
1532746|NCT00000417|Lupus
1532747|NCT00000417|Educational intervention
1532748|NCT00000417|Health education
1532749|NCT00000417|Social support network
1532750|NCT00000417|Outcomes research
1532751|NCT00000417|Self-help
1532752|NCT00000416|Arthritis
1532753|NCT00000416|Rheumatic disorders
1532754|NCT00000416|Work-related disability
1532755|NCT00000416|Vocational rehabilitation (VR)
1532756|NCT00000416|Job retention services
1532757|NCT00000416|Work limitations
1532758|NCT00000416|Work instability
1532759|NCT00000415|Calcium
1532760|NCT00000415|Physical activity
1532761|NCT00000415|Children
1532762|NCT00000415|Bone mass accretion
1532763|NCT00000415|Bone mineral density (BMD)
1532764|NCT00000415|Bone response to activity and calcium supplements
1532765|NCT00000415|Placebo
1532766|NCT00000415|Bone growth
1532767|NCT00000414|Rheumatoid arthritis (RA)
1532768|NCT00000414|Osteoarthritis (OA)
1532769|NCT00000414|Arthritis education
1532770|NCT00000414|Health care service evaluation
1532771|NCT00000414|Outcomes research
1532772|NCT00000414|Arthritis Self-Management Program (ASMP)
1532773|NCT00000414|Self-Managed Arthritis Relief Therapy (SMART) Program
1532774|NCT00000413|Osteoporosis prevention
1532775|NCT00000413|Behavioral/educational intervention
1532776|NCT00000413|Preadolescent
1532777|NCT00000413|Calcium
1532778|NCT00000413|Exercise
1532779|NCT00000413|Peak bone mass
1532780|NCT00000413|Bone density
1532781|NCT00000412|Osteoporosis
1532782|NCT00000412|Osteopenia
1532783|NCT00000412|Heart transplant
1532784|NCT00000412|Bone fracture
1532785|NCT00000412|Bone density
1532786|NCT00000412|Dual energy x-ray absorptiometry
1532787|NCT00000411|Spinal stenosis (SpS)
1532788|NCT00000411|Intervertebral disc herniation (IDH)
1532789|NCT00000411|Degenerative spondylolisthesis (DS)
1532790|NCT00000411|Low back pain (LBP)
1532791|NCT00000411|Surgical therapy
1532792|NCT00000411|Nonsurgical therapy
1532793|NCT00000411|Randomized study
1532794|NCT00000411|Multicenter
1532795|NCT00000411|MRI
1532796|NCT00000410|Intervertebral disc herniation (IDH)
1532797|NCT00000410|Stenosis with degenerative spondylolisthesis (DS)
1532798|NCT00000410|Spinal stenosis (SpS)
1532799|NCT00000410|Low back pain (LBP)
1532800|NCT00000410|Leg pain
1532801|NCT00000410|Surgical therapy
1532802|NCT00000410|Non-surgical therapy
1532803|NCT00000410|Randomized study
1532804|NCT00000410|Multicenter
1532805|NCT00000410|MRI
1532806|NCT00000409|Intervertebral disc herniation (IDH)
1532807|NCT00000409|Degenerative spondylolisthesis (DS)
1532808|NCT00000409|Spinal stenosis (SpS)
1532809|NCT00000409|Low back pain (LBP)
1532810|NCT00000409|Leg pain
1532811|NCT00000409|Surgical therapy
1532812|NCT00000409|Randomized study
1532813|NCT00000409|Multicenter
1532814|NCT00000409|MRI
1532815|NCT00000409|Nonsurgical therapy
1532816|NCT00000408|Health education
1532817|NCT00000408|Back injury
1532818|NCT00000408|Chronic pain
1532819|NCT00000408|Education/evaluation planning
1532820|NCT00000408|Outcomes research
1532821|NCT00000407|Arthritis and related musculoskeletal disorders (ARMD)
1532822|NCT00000407|Vocational rehabilitation (VR)
1532823|NCT00000407|Agency enhancement intervention
1532824|NCT00000407|Health care service evaluation
1532825|NCT00000407|Musculoskeletal disability
1532826|NCT00000407|Return to work
1532827|NCT00000407|Outcomes research
1532828|NCT00000407|Unemployment
1532829|NCT00000407|Work disability
1532830|NCT00000406|Osteoarthritis (OA)
1532831|NCT00000406|Knee
1532832|NCT00000406|Radiographic OA
1532833|NCT00000406|Strength training
1532834|NCT00000406|Physical therapy
1532835|NCT00000406|Exercise
1532836|NCT00000406|Body composition
1532837|NCT00000406|Striated muscle
1532838|NCT00000406|Depression
1532839|NCT00000406|Radiographic OA with knee pain
1532840|NCT00000406|Radiographic OA without knee pain
1532841|NCT00000406|Knee pain without radiographic OA
1532842|NCT00000406|Normal elderly (no radiographic OA, no knee pain)
1532843|NCT00000405|Osteoporosis
1532844|NCT00000405|Bone fractures
1532845|NCT00000405|Bone mass
1532846|NCT00000405|Bone mineral density (BMD)
1532847|NCT00000405|Ossification
1532848|NCT00000405|Biomechanics
1532849|NCT00000405|Exercise
1532850|NCT00000405|Diet
1532851|NCT00000405|Spine
1532852|NCT00000405|Middle childhood (6-11)
1532853|NCT00000404|Osteoarthritis (OA)
1532854|NCT00000404|Knee
1532855|NCT00000404|HMO
1532856|NCT00000404|Comprehensive care
1532857|NCT00000403|Osteoarthritis (OA)
1532858|NCT00000403|Knee
1532859|NCT00000403|Doxycycline
1532860|NCT00000403|Skeletal disorder
1532861|NCT00000403|Placebo
1532862|NCT00000403|Urinalysis
1532863|NCT00000403|NSAIDs
1532864|NCT00000403|Joint space narrowing (JSN)
1532865|NCT00000403|WOMAC
1532866|NCT00000402|Osteoporosis
1532867|NCT00000402|Dietary calcium
1532868|NCT00000402|Puberty
1532869|NCT00000402|Bone density
1532870|NCT00000402|Bone mass
1532871|NCT00000402|Primary prevention of osteoporosis
1532872|NCT00000401|NSAIDs
1532873|NCT00000401|Oral Tolerance
1532874|NCT00000401|Drug Interaction
1532875|NCT00000401|Oral Administration
1532876|NCT00000401|Interleukin 10
1532877|NCT00000401|Collagen
1532878|NCT00000401|Chemotherapy
1532879|NCT00000401|Human Therapy Evaluation
1532880|NCT00000401|DMARDs
1532881|NCT00000401|RA
1532882|NCT00000401|IL-10
1532883|NCT00000400|Osteoporosis
1532884|NCT00000400|Bone formation
1532885|NCT00000400|Bone resorption
1532886|NCT00000400|Parathyroid hormone (PTH)
1532887|NCT00000400|Postmenopause
1532888|NCT00000399|Estrogen
1532889|NCT00000399|Hormone therapy
1532890|NCT00000399|Strength training
1532891|NCT00000399|Exercise
1532892|NCT00000399|Postmenopause
1532893|NCT00000399|Disorder prevention
1532894|NCT00000399|Osteoporosis
1532895|NCT00000399|Bone mineral density
1532896|NCT00000399|Bone mass
1532897|NCT00000399|Cholesterol
1532898|NCT00000399|Body composition
1532899|NCT00000398|Fibromyalgia
1532900|NCT00000398|Pain
1532901|NCT00000398|Coping skills training
1532902|NCT00000398|Physical exercise training
1532903|NCT00000398|Combined coping skills training and exercise training
1532904|NCT00000397|Fibromyalgia
1532905|NCT00000397|Insomnia
1532906|NCT00000397|Cognitive-behavioral therapy (CBT)
1532907|NCT00000397|Behavioral insomnia therapy
1532908|NCT00000396|Arthritis
1532909|NCT00000396|Arthritis education
1532910|NCT00000396|African Americans
1532911|NCT00000396|Self-help
1532912|NCT00000396|Self-management
1532913|NCT00000396|Cultural beliefs
1532914|NCT00000395|Rheumatoid arthritis
1532915|NCT00000395|Lewis rat adjuvant arthritis
1532916|NCT00000395|Antifolate efficacy
1532917|NCT00000395|Autoimmunity
1532918|NCT00000395|Adenosine metabolism
1532919|NCT00000395|Methotrexate therapy
1532920|NCT00000395|Skeletal disorder
1532921|NCT00000395|Dietary supplement
1532922|NCT00000395|Antiarthritic agent
1532923|NCT00000395|Folic acid
1532924|NCT00000394|Carpal tunnel syndrome
1532925|NCT00000394|Acupuncture
1532926|NCT00000394|Median nerve
1532927|NCT00000394|Single-blind mute methodology
1532928|NCT00000393|Acquired Immunodeficiency Syndrome
1532929|NCT00000392|Acquired Immunodeficiency Syndrome
1532930|NCT00000392|AIDS-Related Complex
1532931|NCT00000391|Acquired Immunodeficiency Syndrome
1532932|NCT00000391|AIDS-Related Complex
1532933|NCT00000390|Adult
1532934|NCT00000390|Acquired Immunodeficiency Syndrome
1532935|NCT00000390|Depression
1532936|NCT00000390|Female
1532937|NCT00000390|Human
1532938|NCT00000390|Imipramine
1532939|NCT00000390|Male
1532940|NCT00000390|Middle Age
1532941|NCT00000390|Acquired Immunodeficiency Syndrome -- *complications
1532942|NCT00000390|Depression -- *drug therapy
1532943|NCT00000390|Depression -- etiology
1532944|NCT00000390|Imipramine -- *therapeutic use
1532945|NCT00000389|Adolescence
1532946|NCT00000389|Anxiety Disorders
1532947|NCT00000389|Child
1532948|NCT00000389|Female
1532949|NCT00000389|Fluvoxamine
1532950|NCT00000389|Human
1532951|NCT00000389|Male
1532952|NCT00000389|Serotonin Uptake Inhibitors
1532953|NCT00000389|Anxiety Disorders -- *drug therapy
1532954|NCT00000389|Fluvoxamine -- *therapeutic use
1532955|NCT00000389|Serotonin Uptake Inhibitors -- *therapeutic use
1532956|NCT00000388|Attention Deficit Disorder with Hyperactivity
1532957|NCT00000388|Adolescence
1532958|NCT00000388|Child
1532959|NCT00000388|Cognition
1532960|NCT00000388|Combined Modality Therapy
1532961|NCT00000388|Female
1532962|NCT00000388|Human
1532963|NCT00000388|Male
1532964|NCT00000388|Peer Group
1532965|NCT00000388|Risk Factors
1532966|NCT00000388|Treatment Outcome
1532967|NCT00000388|Attention Deficit Disorder with Hyperactivity -- *therapy
1532968|NCT00000388|Attention Deficit Disorder with Hyperactivity -- drug therapy
1532969|NCT00000388|Attention Deficit Disorder with Hyperactivity -- psychology
1532970|NCT00000387|Adolescence
1532971|NCT00000387|Family
1532972|NCT00000387|Female
1532973|NCT00000387|Human
1532974|NCT00000387|Male
1532975|NCT00000387|Schizophrenia
1532976|NCT00000387|Self Care
1532977|NCT00000387|Community Health Services
1532978|NCT00000386|Adolescence
1532979|NCT00000386|Child
1532980|NCT00000386|Comparative Study
1532981|NCT00000386|Family
1532982|NCT00000386|Female
1532983|NCT00000386|Human
1532984|NCT00000386|Male
1532985|NCT00000386|Obsessive-Compulsive Disorder
1532986|NCT00000386|Relaxation Techniques
1532987|NCT00000386|Obsessive-Compulsive Disorder -- *therapy
1532988|NCT00000385|Aggressive conduct disorder
1532989|NCT00000385|Adolescence
1532990|NCT00000385|Child
1532991|NCT00000385|Conduct Disorder
1532992|NCT00000385|Female
1532993|NCT00000385|Lithium
1532994|NCT00000385|Male
1532995|NCT00000385|Placebos
1532996|NCT00000385|Conduct Disorder -- *drug therapy
1532997|NCT00000385|Lithium -- *therapeutic use
1532998|NCT00000384|Adolescence
1532999|NCT00000384|Child
1533000|NCT00000384|Cognitive Therapy
1533001|NCT00000384|Combined Modality Therapy
1533002|NCT00000384|Obsessive-Compulsive Disorder
1533003|NCT00000384|Placebos
1533004|NCT00000384|Sertraline
1533005|NCT00000384|Patient Education
1533006|NCT00000384|Psychotherapy
1533007|NCT00000383|Adolescence
1533008|NCT00000383|Child
1533009|NCT00000383|Cognitive Therapy
1533010|NCT00000383|Comparative Study
1533011|NCT00000383|Female
1533012|NCT00000383|Human
1533013|NCT00000383|Male
1533014|NCT00000383|Stress Disorders, Post-Traumatic
1533015|NCT00000383|Child Abuse, Sexual
1533016|NCT00000383|Stress Disorders, Post-Traumatic -- *therapy
1533017|NCT00000383|Child Abuse, Sexual -- *psychology
1533018|NCT00000382|Child Abuse
1533019|NCT00000382|Female
1533020|NCT00000382|Human
1533021|NCT00000382|Infant
1533022|NCT00000382|Male
1533023|NCT00000382|Caregivers
1533024|NCT00000382|Patient Education
1533025|NCT00000382|Psychotherapy
1533026|NCT00000382|Child Abuse -- *prevention & control
1533027|NCT00000381|Adolescence
1533028|NCT00000381|Anxiety Disorders
1533029|NCT00000381|Child
1533030|NCT00000381|Female
1533031|NCT00000381|Fluoxetine
1533032|NCT00000381|Male
1533033|NCT00000381|Placebos
1533034|NCT00000381|Serotonin Uptake Inhibitors
1533035|NCT00000381|Anxiety Disorders -- *drug therapy
1533036|NCT00000381|Fluoxetine -- *therapeutic use
1533037|NCT00000381|Serotonin Uptake Inhibitors -- *therapeutic use
1533038|NCT00000380|Adult
1533039|NCT00000380|Estrogen Replacement Therapy
1533040|NCT00000380|Female
1533041|NCT00000380|Hormone Replacement Therapy
1533042|NCT00000380|Human
1533043|NCT00000380|Insulin-Like Growth Factor I
1533044|NCT00000380|Male
1533045|NCT00000380|Placebos
1533046|NCT00000380|Sleep Disorders
1533047|NCT00000380|Somatotropin-Releasing Hormone
1533048|NCT00000380|Somatotropin
1533049|NCT00000380|Insulin-Like Growth Factor I -- secretion
1533050|NCT00000380|Sleep Disorders -- *drug therapy
1533051|NCT00000380|Somatotropin-Releasing Hormone -- *therapeutic use
1533052|NCT00000380|Somatotropin -- secretion
1533053|NCT00000379|Adult
1533054|NCT00000379|Comparative Study
1533055|NCT00000379|Desensitization, Psychologic
1533056|NCT00000379|Eye Movements
1533057|NCT00000379|Female
1533058|NCT00000379|Fluoxetine
1533059|NCT00000379|Human
1533060|NCT00000379|Male
1533061|NCT00000379|Placebos
1533062|NCT00000379|Stress Disorders, Post-Traumatic
1533063|NCT00000379|Treatment Outcome
1533064|NCT00000379|Desensitization, Psychologic -- *methods
1533065|NCT00000379|Fluoxetine -- *therapeutic use
1533066|NCT00000379|Stress Disorders, Post-Traumatic -- *therapy
1533067|NCT00000379|Stress Disorders, Post-Traumatic -- drug therapy
1533068|NCT00000378|Aged
1533069|NCT00000378|Antidepressive Agents, Tricyclic
1533070|NCT00000378|Depression
1533071|NCT00000378|Female
1533072|NCT00000378|Human
1533073|NCT00000378|Male
1533074|NCT00000378|Middle Age
1533075|NCT00000378|Nortriptyline
1533076|NCT00000378|Sertraline
1533077|NCT00000378|Serotonin Uptake Inhibitors
1533078|NCT00000378|Antidepressive Agents, Tricyclic -- *therapeutic use
1533079|NCT00000378|Antidepressive Agents, Tricyclic -- adverse effects
1533080|NCT00000378|Depression -- *drug therapy
1533081|NCT00000378|Nortriptyline -- *therapeutic use
1533082|NCT00000378|Nortriptyline -- adverse effects
1533083|NCT00000378|Sertraline -- *therapeutic use
1533084|NCT00000378|Sertraline -- adverse effects
1533085|NCT00000378|Serotonin Uptake Inhibitors -- *therapeutic use
1533086|NCT00000378|Serotonin Uptake Inhibitors -- adverse effects
1533087|NCT00000377|Aged
1533088|NCT00000377|Antidepressive Agents
1533089|NCT00000377|Depression
1533090|NCT00000377|Dose-Response Relationship, Drug
1533091|NCT00000377|Female
1533092|NCT00000377|Human
1533093|NCT00000377|Male
1533094|NCT00000377|Middle Age
1533095|NCT00000377|Nortriptyline
1533096|NCT00000377|Placebos
1533097|NCT00000377|Recurrence
1533098|NCT00000377|Aged, 80 and over
1533099|NCT00000377|Antidepressive Agents -- *therapeutic use
1533100|NCT00000377|Antidepressive Agents -- administration & dosage
1533101|NCT00000377|Depression -- *drug therapy
1533102|NCT00000377|Nortriptyline -- *therapeutic use
1533103|NCT00000377|Nortriptyline -- administration & dosage
1533104|NCT00000376|Adult
1533105|NCT00000376|Antidepressive Agents, Tricyclic
1533106|NCT00000376|Anxiety Disorders
1533107|NCT00000376|Cognitive Therapy
1533108|NCT00000376|Combined Modality Therapy
1533109|NCT00000376|Depression
1533110|NCT00000376|Desipramine
1533111|NCT00000376|Female
1533112|NCT00000376|Human
1533113|NCT00000376|Male
1533114|NCT00000376|Personality Disorders
1533115|NCT00000376|Pilot Projects
1533116|NCT00000376|Patient Care Team
1533117|NCT00000376|Antidepressive Agents, Tricyclic -- *therapeutic use
1533118|NCT00000376|Depression -- *therapy
1533119|NCT00000376|Depression -- drug therapy
1533120|NCT00000376|Desipramine -- *therapeutic use
1533121|NCT00000375|Adult
1533122|NCT00000375|Antidepressive Agents
1533123|NCT00000375|Depressive Disorder
1533124|NCT00000375|Electroconvulsive Therapy
1533125|NCT00000375|Female
1533126|NCT00000375|Human
1533127|NCT00000375|Lithium
1533128|NCT00000375|Male
1533129|NCT00000375|Nortriptyline
1533130|NCT00000375|Serotonin Uptake Inhibitors
1533131|NCT00000375|Antidepressive Agents -- *therapeutic use
1533132|NCT00000375|Antidepressive Agents -- adverse effects
1533133|NCT00000375|Lithium -- *therapeutic use
1533134|NCT00000375|Lithium -- adverse effects
1533135|NCT00000375|Nortriptyline -- *therapeutic use
1533136|NCT00000375|Nortriptyline -- adverse effects
1533137|NCT00000374|Adolescence
1533138|NCT00000374|Adult
1533139|NCT00000374|Antipsychotic Agents
1533140|NCT00000374|Female
1533141|NCT00000374|Human
1533142|NCT00000374|Male
1533143|NCT00000374|olanzapine
1533144|NCT00000374|Risperidone
1533145|NCT00000374|Schizophrenia
1533146|NCT00000374|Antipsychotic Agents -- *therapeutic use
1533147|NCT00000374|olanzapine -- *therapeutic use
1533148|NCT00000374|Risperidone -- *therapeutic use
1533149|NCT00000374|Schizophrenia -- *drug therapy
1533150|NCT00000373|Adolescence
1533151|NCT00000373|Adult
1533152|NCT00000373|Antipsychotic Agents
1533153|NCT00000373|Dopamine Antagonists
1533154|NCT00000373|Female
1533155|NCT00000373|Fluvoxamine
1533156|NCT00000373|Haloperidol
1533157|NCT00000373|Human
1533158|NCT00000373|Male
1533159|NCT00000373|Middle Age
1533160|NCT00000373|Obsessive-Compulsive Disorder
1533161|NCT00000373|Placebos
1533162|NCT00000373|Serotonin Uptake Inhibitors
1533163|NCT00000373|Tourette Syndrome
1533164|NCT00000373|Tryptophan
1533165|NCT00000373|Drug Combinations
1533166|NCT00000373|Antipsychotic Agents -- *therapeutic use
1533167|NCT00000373|Fluvoxamine -- *therapeutic use
1533168|NCT00000373|Haloperidol -- *therapeutic use
1533169|NCT00000373|Obsessive-Compulsive Disorder -- *drug therapy
1533170|NCT00000373|Obsessive-Compulsive Disorder -- physiopathology
1533171|NCT00000373|Serotonin Uptake Inhibitors -- *therapeutic use
1533172|NCT00000372|Adult
1533173|NCT00000372|Amino Acids
1533174|NCT00000372|Cycloserine
1533175|NCT00000372|Female
1533176|NCT00000372|Glycine
1533177|NCT00000372|Human
1533178|NCT00000372|Male
1533179|NCT00000372|N-Methylaspartate
1533180|NCT00000372|Placebos
1533181|NCT00000372|Schizophrenia
1533182|NCT00000372|Amino Acids -- blood
1533183|NCT00000372|Cycloserine -- *therapeutic use
1533184|NCT00000372|Glycine -- *therapeutic use
1533185|NCT00000372|Schizophrenia -- *drug therapy
1533186|NCT00000372|Schizophrenia -- physiopathology
1533187|NCT00000371|Adult
1533188|NCT00000371|Cognition
1533189|NCT00000371|Cycloserine
1533190|NCT00000371|Dopamine
1533191|NCT00000371|Female
1533192|NCT00000371|Glutamic Acid
1533193|NCT00000371|Human
1533194|NCT00000371|Male
1533195|NCT00000371|Receptors, N-Methyl-D-Aspartate
1533196|NCT00000371|Schizophrenia
1533197|NCT00000371|Serotonin
1533198|NCT00000371|Quality of Life
1533199|NCT00000371|Cycloserine -- *therapeutic use
1533200|NCT00000371|Dopamine -- blood
1533201|NCT00000371|Dopamine -- cerebrospinal fluid
1533202|NCT00000371|Glutamic Acid -- blood
1533203|NCT00000371|Glutamic Acid -- cerebrospinal fluid
1533204|NCT00000371|Serotonin -- blood
1533205|NCT00000371|Serotonin -- cerebrospinal fluid
1533206|NCT00000370|Cognitive Therapy
1533207|NCT00000370|Cost of Illness
1533208|NCT00000370|Female
1533209|NCT00000370|Human
1533210|NCT00000370|Male
1533211|NCT00000370|Phobic Disorders
1533212|NCT00000370|Phobic Disorders -- *therapy
1533213|NCT00000370|Phobic Disorders -- pathology
1533214|NCT00000369|Adult
1533215|NCT00000369|Antidepressive Agents
1533216|NCT00000369|Bipolar Disorder
1533217|NCT00000369|Combined Modality Therapy
1533218|NCT00000369|Female
1533219|NCT00000369|Human
1533220|NCT00000369|Lithium Carbonate
1533221|NCT00000369|Male
1533222|NCT00000369|Psychotherapy
1533223|NCT00000369|Antidepressive Agents -- *therapeutic use
1533224|NCT00000369|Bipolar Disorder -- *therapy
1533225|NCT00000369|Bipolar Disorder -- drug therapy
1533226|NCT00000369|Lithium Carbonate -- *therapeutic use
1533227|NCT00000368|Adult
1533228|NCT00000368|Cognitive Behavioral Therapy
1533229|NCT00000368|Pharmacotherapy
1533230|NCT00000368|Long term treatment
1533231|NCT00000368|Remission and relapse
1533232|NCT00000368|Male
1533233|NCT00000368|Panic Disorder
1533234|NCT00000368|Paroxetine
1533235|NCT00000368|Serotonin Uptake Inhibitors
1533236|NCT00000368|Panic Disorder -- *therapy
1533237|NCT00000368|Panic Disorder -- drug therapy
1533238|NCT00000368|Paroxetine -- *therapeutic use
1533239|NCT00000368|Serotonin Uptake Inhibitors -- *therapeutic use
1533240|NCT00000367|Depression
1533241|NCT00000367|Family
1533242|NCT00000367|Female
1533243|NCT00000367|Human
1533244|NCT00000367|Male
1533245|NCT00000367|Practice Guidelines
1533246|NCT00000367|Education, Medical, Continuing
1533247|NCT00000367|Patient Education
1533248|NCT00000367|Suicide
1533249|NCT00000363|Antibiotics
1533250|NCT00000363|Adrenal Cortex Hormones
1533251|NCT00000363|Histamine H1 Antagonists
1533252|NCT00000363|Infant
1533253|NCT00000363|Otitis Media
1533254|NCT00000362|Deglutition Disorders
1533255|NCT00000362|Dementia
1533256|NCT00000362|Parkinson Disease
1533257|NCT00000362|Pneumonia, Aspiration
1533258|NCT00000361|Autoimmune Diseases
1533259|NCT00000361|Cyclophosphamide
1533260|NCT00000361|Hearing
1533261|NCT00000361|Labyrinth Diseases
1533262|NCT00000361|Methotrexate
1533263|NCT00000361|Prednisone
1533264|NCT00000359|Physical Therapy
1533265|NCT00000359|Vertigo
1533266|NCT00000359|rehabilitation
1533267|NCT00000359|occupational therapy
1533268|NCT00000161|Age-Related Macular Degeneration
1533269|NCT00000160|Vision Loss
1533270|NCT00000158|photocoagulation
1533271|NCT00000158|argon blue-green laser
1533272|NCT00000158|krypton red laser
1533273|NCT00000357|opiate dependence
1533274|NCT00000356|opiate dependence
1533275|NCT00000355|opiate dependence
1533276|NCT00000153|Diabetic Disc Neovascularization
1533277|NCT00000153|Optic Disk
1533278|NCT00000354|opiate dependence
1533279|NCT00000353|opiate dependence
1533280|NCT00000352|opiate dependence
1533281|NCT00000350|amphetamine dependence
1533282|NCT00000349|cocaine dependence
1533283|NCT00000348|cocaine dependence
1533284|NCT00000347|cocaine dependence
1533285|NCT00000152|Age-Related Macular Degeneration
1533286|NCT00000150|Ocular Histoplasmosis Syndrome
1533287|NCT00000150|Idiopathic Choroidal Neovascularization
1533288|NCT00000145|Age-Related Macular Degeneration
1533289|NCT00000139|Herpes Simplex Stromal Keratitis
1533290|NCT00000138|Herpes Simplex Stromal Keratitis
1533291|NCT00000131|Central Vein Occlusion
1533292|NCT00000131|Ischemic Retina
1533293|NCT00000130|Bacterial Endophthalmitis
1533294|NCT00000346|amphetamine dependence
1533295|NCT00000345|opioid dependence
1533296|NCT00000344|opioid dependence
1533297|NCT00000343|stimulant dependence
1533298|NCT00000342|cocaine dependence
1533299|NCT00000341|opioid dependence
1533300|NCT00000340|cocaine dependence
1533301|NCT00000339|cocaine dependence
1533302|NCT00000338|cocaine dependence
1533303|NCT00000337|cocaine dependence
1533304|NCT00000336|cocaine dependence
1533305|NCT00000335|opioid dependence
1533306|NCT00000331|Heroin Dependence
1533307|NCT00000330|Heroin Dependence
1533308|NCT00000329|drug dependence
1533309|NCT00000328|drug dependence
1533310|NCT00000327|drug dependence
1533311|NCT00000326|Heroin Dependence
1533312|NCT00000128|Near-point Esophoria
1533313|NCT00000127|Non-arteritic Ischemic Optic Neuropathy
1533314|NCT00000126|Non-arteritic Ischemic Optic Neuropathy
1533315|NCT00000124|Choroidal Melanoma
1533316|NCT00000124|Ocular Melanoma
1533317|NCT00000121|strabismus
1533318|NCT00000325|cocaine dependence
1533319|NCT00000323|cocaine dependence
1533320|NCT00000322|amphetamine dependence
1533321|NCT00000321|methamphetamine dependence
1533322|NCT00000320|opioid dependence
1533323|NCT00000318|opioid dependence
1533324|NCT00000316|cocaine dependence
1533325|NCT00000315|cocaine dependence
1533326|NCT00000314|cocaine dependence
1533327|NCT00000313|cocaine dependence
1533328|NCT00000310|cocaine dependence
1533329|NCT00000309|cocaine abuse, cocaine addiction
1533330|NCT00000308|cocaine dependence
1533331|NCT00000307|alcohol dependence
1533332|NCT00000306|cocaine dependence
1533333|NCT00000120|Neonatal Conjunctivitis
1533334|NCT00000114|retinitis pigmentosa
1533335|NCT00000114|vitamin supplements
1533336|NCT00000113|myopia
1533337|NCT00000113|nearsightedness
1533338|NCT00000111|mouth mucosa
1533339|NCT00000111|transplants
1533340|NCT00000110|exercise
1533341|NCT00000110|exertion
1533342|NCT00000110|physical fitness
1533343|NCT00000110|lipids
1533344|NCT00000110|nutrition
1533345|NCT00000304|cocaine dependence
1533346|NCT00000303|Cocaine dependence
1533347|NCT00000301|Amantadine
1533348|NCT00000301|Cocaine
1533349|NCT00000301|Pharmacotherapy
1533350|NCT00000301|Outpatient
1533351|NCT00000299|Opioid-Related Disorders
1533352|NCT00000296|nicotine dependence
1533353|NCT00000293|cocaine dependence
1533354|NCT00000291|cocaine dependence
1533355|NCT00000290|cocaine dependence
1533356|NCT00000288|nicotine dependence
1533357|NCT00000287|Cocaine-Related Disorders
1533358|NCT00000286|cocaine dependence
1533359|NCT00000285|cocaine dependence
1533360|NCT00000284|nicotine dependence
1533361|NCT00000282|pemoline
1533362|NCT00000281|anti psychotic agents
1533363|NCT00000280|cocaine
1533364|NCT00000108|exercise
1533365|NCT00000107|Cyanotic Congenital Heart Disease
1533366|NCT00000106|Rheumatoid Diseases
1533367|NCT00000275|cocaine dependence
1533368|NCT00000274|cocaine dependence
1533369|NCT00000269|cocaine dependence
1533370|NCT00000268|cocaine dependence
1533371|NCT00000267|cocaine dependence
1533372|NCT00000104|lead overburden
1533373|NCT00000266|cocaine dependence
1533374|NCT00000265|nitrous oxide
1533375|NCT00000265|anxiety
1533376|NCT00000265|subjective effects
1533377|NCT00000265|dental
1533378|NCT00000265|patients
1533379|NCT00000264|nitrous oxide
1533380|NCT00000264|inhalant
1533381|NCT00000264|ethanol
1533382|NCT00000264|subjective effects
1533383|NCT00000264|psychomotor effects
1533384|NCT00000264|healthy volunteer
1533385|NCT00000263|nitrous oxide
1533386|NCT00000263|ethanol
1533387|NCT00000263|drug interaction
1533388|NCT00000263|subjective effects
1533389|NCT00000263|healthy volunteer
1533390|NCT00000262|nitrous oxide
1533391|NCT00000262|sevoflurane
1533392|NCT00000262|drug interaction
1533393|NCT00000262|subjective effects
1533394|NCT00000262|analgesia
1533395|NCT00000262|healthy volunteers
1533396|NCT00000261|nitrous oxide
1533397|NCT00000261|sevoflurane
1533398|NCT00000261|ethanol
1533399|NCT00000261|subjective effects
1533400|NCT00000261|healthy volunteer
1533401|NCT00000260|nitrous oxide
1533402|NCT00000260|subjective effects
1533403|NCT00000260|reinforcer
1533404|NCT00000260|inhalant
1533405|NCT00000260|healthy volunteer
1533406|NCT00000259|sevoflurane
1533407|NCT00000259|nitrous oxide
1533408|NCT00000259|subjective effects
1533409|NCT00000259|healthy volunteer
1533410|NCT00000258|nitrous oxide
1533411|NCT00000258|instruction
1533412|NCT00000258|subjective effects
1533413|NCT00000258|reinforcer
1533414|NCT00000258|healthy volunteer
1533415|NCT00000257|nitrous oxide
1533416|NCT00000257|subjective effects
1533417|NCT00000257|ethanol
1533418|NCT00000257|healthy volunteer
1533419|NCT00000256|nitrous oxide
1533420|NCT00000256|reinforcer
1533421|NCT00000256|subjective effects
1533422|NCT00000256|healthy volunteer
1533423|NCT00000255|nitrous oxide
1533424|NCT00000255|acute tolerance
1533425|NCT00000255|subjective effects
1533426|NCT00000255|analgesia
1533427|NCT00000255|psychomotor
1533428|NCT00000255|healthy volunteer
1533429|NCT00000254|isoflurane
1533430|NCT00000254|general anesthetic
1533431|NCT00000254|inhalant
1533432|NCT00000254|subjective effects
1533433|NCT00000254|healthy volunteer
1533434|NCT00000253|nitrous oxide
1533435|NCT00000253|inhalant
1533436|NCT00000253|subjective effects
1533437|NCT00000253|healthy volunteer
1533438|NCT00000252|nitrous oxide
1533439|NCT00000252|acute tolerance
1533440|NCT00000252|subjective effects
1533441|NCT00000252|psychomotor
1533442|NCT00000252|analgesia
1533443|NCT00000252|healthy volunteer
1533444|NCT00000251|nitrous oxide
1533445|NCT00000251|isoflurane
1533446|NCT00000251|subjective effects
1533447|NCT00000251|psychomotor
1533448|NCT00000251|healthy volunteer
1533449|NCT00000251|drug interaction
1533450|NCT00000250|nitrous oxide
1533451|NCT00000250|choice
1533452|NCT00000250|subjective effects
1533453|NCT00000250|pain
1533454|NCT00000250|analgesia
1533455|NCT00000250|reinforcer
1533456|NCT00000250|healthy volunteer
1533457|NCT00000249|nitrous oxide
1533458|NCT00000249|subjective effects
1533459|NCT00000249|healthy volunteer
1533460|NCT00000246|Substance-Related Disorders
1533461|NCT00000245|cocaine dependence
1533462|NCT00000244|addiction
1533463|NCT00000244|opiate
1533464|NCT00000244|heroin
1533465|NCT00000244|dynorphin
1533466|NCT00000243|opioid dependence
1533467|NCT00000242|Cocaine
1533468|NCT00000242|Substance Abuse
1533469|NCT00000241|methamphetamine dependence
1533470|NCT00000218|cocaine dependence
1533471|NCT00000217|drug abuse
1533472|NCT00000215|cocaine dependence
1533473|NCT00000214|intravenous abuse
1533474|NCT00000213|intravenous abuse
1533475|NCT00000212|crack cocaine
1533476|NCT00000210|opioid addiction
1533477|NCT00000210|cocaine addiction
1533478|NCT00000207|Buprenorphine
1533479|NCT00000207|Opioid
1533480|NCT00000206|Opioid
1533481|NCT00000201|cocaine dependence
1533482|NCT00000200|self-administration
1533483|NCT00000199|cocaine
1533484|NCT00000198|cocaine
1533485|NCT00000197|cocaine
1533486|NCT00000195|opioid disorders
1533487|NCT00000194|opioid disorders
1533488|NCT00000193|Opioid disorders
1533489|NCT00000192|opioid disorders
1533490|NCT00000191|Cocaine Dependence
1533491|NCT00000191|Carbamazepine
1533492|NCT00000190|Cocaine Detection
1533493|NCT00000190|Parotid Saliva
1533494|NCT00000189|Cocaine Dependence
1533495|NCT00000189|Gepirone
1533496|NCT00000188|Cocaine Dependence
1533497|NCT00000188|Selegiline
1533498|NCT00000187|Cocaine Dependence
1533499|NCT00000187|ritanserin
1533500|NCT00000180|Memory
1533501|NCT00000180|Mild cognitive impairment
1533502|NCT00000180|Nerve growth factors
1533503|NCT00000179|Alzheimer's disease
1533504|NCT00000179|Psychomotor agitation
1533505|NCT00000179|Behavioral symptoms
1533506|NCT00000179|Haloperidol
1533507|NCT00000179|Trazodone
1533508|NCT00000179|Anti-psychotic agents
1533509|NCT00000179|Anti-depressant agents
1533510|NCT00000178|Alzheimer's disease
1533511|NCT00000178|Prednisone
1533512|NCT00000178|Anti-inflammatory agents
1533513|NCT00000177|Alzheimer's disease
1533514|NCT00000177|Estrogen
1533515|NCT00000176|Alzheimer's disease
1533516|NCT00000176|memory loss
1533517|NCT00000176|Estrogen
1533518|NCT00000175|Emotions
1533519|NCT00000175|Cognition
1533520|NCT00000175|Aging
1533521|NCT00000175|Memory
1533522|NCT00000174|Mild cognitive impairment
1533523|NCT00000174|Alzheimer's disease
1533524|NCT00000174|Memory
1533525|NCT00000174|Cholinergic agents
1533526|NCT00000174|Cholinesterase inhibitors
1533527|NCT00000173|Mild cognitive impairment
1533528|NCT00000173|Alzheimer's disease
1533529|NCT00000173|Memory
1533530|NCT00000173|Donepezil
1533531|NCT00000173|Vitamin E
1533532|NCT00000173|Antioxidants
1533533|NCT00000173|Cholinergic agents
1533534|NCT00000173|Cholinesterase inhibitors
1533535|NCT00000172|Alzheimer's disease
1533536|NCT00000172|Cholinergic agents
1533537|NCT00000172|Cholinergic agonists
1533538|NCT00000172|Cholinesterase inhibitors
1533539|NCT00000171|Alzheimer's disease
1533540|NCT00000171|Sleep disorders
1533541|NCT00000171|Melatonin
1533542|NCT00000170|Amblyopia
1533543|NCT00000170|patching
1533544|NCT00000170|atropine
1533545|NCT00000167|Age-Related Macular Degeneration
1533546|NCT00000163|Congenital Esotropia
1533585|NCT03192631|financial incentive
1533586|NCT03190811|advanced solid tumor
1533587|NCT03190811|DC-CIK
1533588|NCT03190811|anti-PD-1 antibody
1533589|NCT03190811|immunotherapy
1533590|NCT03192722|Filters
1533591|NCT03192722|Illumination
1533592|NCT03192722|Low vision
1533593|NCT03192722|Reading
1533594|NCT03191123|Hepatocellular Carcinoma
1533595|NCT03191123|Hepatic Resection
1533596|NCT03191123|TACE
1533597|NCT03191123|Solitary Huge Tumor
1533598|NCT03191123|Overall Survival
1533601|NCT03192800|clinical outcome
1533602|NCT03192800|prognositic factor
1533603|NCT03192800|spinal dural arteriovenous fistula
1533619|NCT03185793|SHR4640, Phase II, monotherapy, dose-finding
1533628|NCT03184857|maxillary sinus
1533629|NCT03184857|augmentation
1533630|NCT03184857|bovine bone
1533631|NCT03184857|Nano hydroxy appatite
1533641|NCT03178799|Fractures
1533642|NCT03178799|Osteoporosis
1533643|NCT03178799|Care management
1533644|NCT03178799|cost-effeciveness
1533645|NCT03178799|Randomized controlled trial
1533650|NCT03192917|Shock wave therapy
1533651|NCT03192917|erectile dysfunction
1533669|NCT03189004|mHealth, health services, technology, smartphones, Bangladesh
1533687|NCT03157726|benign prostatic hyperplasia
1533688|NCT03157726|multicenter randomized control clinical trial
1533689|NCT03157726|transurethral plasmakinetic enucleation of prostate
1533690|NCT03157726|transurethral resection of prostate
1533704|NCT03192709|Sildenafil IVF ICI failure
1533711|NCT03134352|subacute
1533718|NCT03127228|Laser
1533757|NCT03093428|Prostate Cancer
1533839|NCT02974725|NSCLC
1533840|NCT02974725|KRAS
1533841|NCT02974725|BRAF
1533842|NCT02974725|LXH254
1533843|NCT02974725|LTT462
1533844|NCT02974725|Non-small cell lung carcinoma (NSCLC)
1533845|NCT02974725|treatment of lung cancer after first metastasis
1533846|NCT02974725|lung cancer
1533847|NCT02974725|lung adenocarcinoma
1533848|NCT02974725|Large-cell lung carcinoma
1533849|NCT02974725|Non small cell lung carcinoma
1533850|NCT02974725|Non small cell lung cancer
1533851|NCT02974725|Large cell lung carcinoma
1533852|NCT02974725|Large cell lung cancer
1533853|NCT02974725|squamous cell lung carcinoma
1533901|NCT02876952|Cardio-respiratory fitness
1533902|NCT02876952|high intensity exercise training
1533913|NCT02845505|intravascular ultrasonography
1533914|NCT02845505|Computed Tomography
1533940|NCT03191409|cognitive impairment
1533941|NCT03191409|ESRD
1533942|NCT03191409|functional MRI
1533950|NCT02814578|OCT
1533951|NCT02814578|IVUS
1533952|NCT02814578|BVS
1533970|NCT02890069|PDR001
1533971|NCT02890069|CRC
1533972|NCT02890069|TNBC
1533973|NCT02890069|NSCLC
1533974|NCT02890069|Immunomodulation
1533975|NCT02890069|Biomarkers
1533976|NCT02890069|Bayesian logistic regression model
1533985|NCT02752360|intestinal reconstruction
1533986|NCT02752360|end to end anastomosis
1534029|NCT02648334|Drug-Coated Balloon
1534030|NCT02648334|Superficial Femoral artery
1534031|NCT02648334|popliteal peripheral Artery
1534032|NCT02646150|Magnetic Resonance perfusion imaging
1534033|NCT02646150|distal perfusion
1534034|NCT02646150|Critical Limb Ischemia
1534035|NCT02646150|endovascular revascularization
1534036|NCT02897206|Acute pancreatitis
1534037|NCT02897206|Antibiotic prophylaxis
1534038|NCT02897206|Imipenem-cilastatin
1534039|NCT02897206|Infected pancreatic necrosis
1534040|NCT02897206|Infection
1534041|NCT02897206|Organ failure
1534068|NCT02622100|Bioresorbable Vascular Scaffold
1534069|NCT02622100|Routine Clinical Practice
1534070|NCT02622100|Angioplasty, Transluminal, Percutaneous Coronary
1534071|NCT02622100|Coronary Artery Disease
1534072|NCT02622100|drug eluting stent
1534088|NCT02586454|Transmuscular quadratus lumborum block, total abdominal hysterectomy
1534185|NCT02394184|transcatheter aortic valve replacement
1534234|NCT02308150|transcatheter aortic valve replacement
1534235|NCT02308150|asian pacific
1534236|NCT02308150|asian
1534300|NCT02208388|Computed tomography perfusion
1534301|NCT02208388|Fractional flow reserve
1534344|NCT02143479|France
1534345|NCT02143479|Prograf
1534346|NCT02143479|Pharmaco-epidemiology
1534347|NCT02143479|Tacrolimus
1534348|NCT02143479|Observational
1534382|NCT02038660|Coronary Artery Disease
1534383|NCT02038660|Angioplasty, Balloon
1534384|NCT02042300|XIENCE Xpedition
1534385|NCT02042300|Routine Clinical Practice
1534386|NCT02042300|Alpine
1534387|NCT02039752|Multivessel
1534486|NCT01869569|Radiation
1534487|NCT01869569|Neuropathic Pain
1534488|NCT01869569|Pregabalin
1534550|NCT01645202|Aortic stenosis
1534551|NCT01645202|TAVI
1534552|NCT01645202|Device success
1534553|NCT01645202|Aortic regurgitation
1534779|NCT03194906|Pediatric oncology
1534780|NCT03194906|Brain tumor
1534781|NCT03194906|Low grade glioma
1534782|NCT03194906|Cognitive late effects
1534783|NCT03194906|Radiation therapy
1534784|NCT03194906|Neuroprotection
1534785|NCT03194906|Memantine
1534786|NCT03194854|Well-Being
1534787|NCT03194854|e-Health
1534788|NCT03194854|Randomized Controlled Trial
1534789|NCT03194854|Self-Efficacy
1534790|NCT03194854|Interpersonal well-being
1534791|NCT03194854|Community well-being
1534792|NCT03194854|Occupational well-being
1534793|NCT03194854|Physical well-being
1534794|NCT03194854|Psychological well-being
1534795|NCT03194854|Economic well-being
1534796|NCT03194308|HIV risk reduction
1534797|NCT03194308|Safer Conception
1534798|NCT03194308|Pre-exposure prophylaxis
1534799|NCT03194308|South Africa
1534800|NCT03194308|Women
1534801|NCT03194308|Reproductive Health
1534802|NCT03194945|Type 2 diabetes mellitus
1534803|NCT03194945|Continuous subcutaneous insulin infusion
1534804|NCT03194945|Metformin
1534805|NCT03194945|Linagliptin
1534821|NCT03194711|Percutaneous Coronary Revascularization
1534822|NCT03194711|Optical Coherence Tomography
1534823|NCT03194711|Stents, Drug-Eluting
1534829|NCT03194620|Flavanols
1534830|NCT03194620|Cocoa Flavanols
1534831|NCT03194620|Epicatechins
1534832|NCT03194620|Polyphenols
1534833|NCT03194620|Procyanidins
1534834|NCT03194620|EGCG
1534835|NCT03194620|EGC
1534836|NCT03194620|ECG
1534837|NCT03194620|Theaflavins
1534838|NCT03194620|Thearubigins
1534861|NCT03193437|Thymus
1534862|NCT03193437|Selinexor
1534863|NCT03193437|KPT-330
1534864|NCT03193398|Major Depressive Disorder
1534865|NCT03193398|Anhedonia
1534866|NCT03193398|antidepressant
1534867|NCT03193398|Nociceptin
1534868|NCT03193398|NOPR
1534869|NCT03193801|SAPIEN 3
1534870|NCT03193801|PARTNER 3
1534871|NCT03193801|cardiovascular disease
1534872|NCT03193801|TMVR
1534873|NCT03193801|failing valve
1534874|NCT03193801|failing bioprosthetic valve
1534875|NCT03193034|Arthroplasty
1534876|NCT03193034|replacement
1534877|NCT03193034|Knee
1534878|NCT03193034|function
1534879|NCT03193034|radiographic
1534880|NCT03193034|survivorship
1534881|NCT03193333|glaucoma
1534882|NCT03193333|primary open-angle glaucoma
1534883|NCT03193333|Ophthalmic antihypertensives
1534884|NCT03193333|Krytantek Ofteno®.
1534885|NCT03193333|timolol
1534886|NCT03193333|brimonidine
1534887|NCT03193333|dorzolamide
1534888|NCT03193047|Cholesterol
1534889|NCT03193047|PCSK9
1534890|NCT03193047|Repatha
1534891|NCT03193047|evolocumab
1534892|NCT03193047|LDL-C
1534893|NCT03192826|Nd-YAG capsulotomy
1534894|NCT03192826|ocular hypertension
1534895|NCT03192826|brimonidine
1534896|NCT03192826|brinzolamide
1534919|NCT03192241|reading
1534930|NCT03193970|Bladder Cancer
1534931|NCT03193970|Registry
1534932|NCT03193970|Post‐surgical outcomes
1534933|NCT03193970|Radical cystectomy
1534934|NCT03193970|MD Anderson Symptom inventory
1534935|NCT03193970|MDASI
1534947|NCT03193112|Agomelatine
1534948|NCT03193112|Depression
1534949|NCT03193112|Intraocular pressure
1534960|NCT03193281|Dasatinib
1534961|NCT03193281|Imatinib
1534987|NCT03191812|Falls
1534988|NCT03191812|transcranial Direct Current Stimulation
1534989|NCT03191812|Mobility
1534990|NCT03191812|Dual Task
1535001|NCT03192527|KN015
1535002|NCT03192527|Long-acting FSH
1535006|NCT03191825|online intervention
1535007|NCT03191825|mHealth m-Health
1535008|NCT03191825|eHealth e-Health
1535009|NCT03191825|smoking cessation
1535010|NCT03191825|lapse management
1535011|NCT03191825|relapse prevention
1535016|NCT03194048|drooling
1535017|NCT03194048|tongue thrust
1535018|NCT03192423|Stress
1535019|NCT03192423|Performance of procedures
1535020|NCT03192423|Lumbar Puncture
1535021|NCT03187704|air filtration, HEPA, In-home,
1535022|NCT03192514|Polypharmacy
1535023|NCT03192514|Benzodiazepine use
1535028|NCT03188692|Haemophilus influenza type b
1535029|NCT03188692|Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivate
1535030|NCT03188692|poliovirus combined vaccine
1535031|NCT03188692|Hib
1535032|NCT03188692|DPT-IPV
1535033|NCT03188692|Intramuscular
1535034|NCT03194659|Nutrition
1535035|NCT03194659|choline
1535036|NCT03194659|pregnancy
1535037|NCT03194659|docosahexaenoic acid
1535038|NCT03194659|DHA
1535039|NCT03194659|fatty acids
1535045|NCT03194230|Cervical dilators
1535046|NCT03194230|induction of labor
1535047|NCT03194230|cervical ripening
1535048|NCT03194230|medical termination of pregnancy
1535049|NCT03194230|second-trimester of pregnancy.
1535050|NCT03194971|glioblastoma
1535051|NCT03194971|brain tumor autopsy
1535052|NCT03194971|autopsy
1535053|NCT03194971|Optune therapy
1535054|NCT03194971|tumor treatment fields
1535055|NCT03194971|TTFields
1535056|NCT03194971|Recurrent glioblastoma
1535057|NCT03194971|grade IV
1535058|NCT03194971|brain tumor
1535059|NCT03194971|newly diagnosed glioblastoma
1535060|NCT03192995|HIV
1535061|NCT03192995|sexual behavior
1535073|NCT03194568|Scoliosis
1535074|NCT03194568|Idiopathic Scoliosis
1535075|NCT03194568|Adolescent Idiopathic Scoliosis
1535076|NCT03186352|photodynamic therapy
1535077|NCT03186352|photoactivated disinfection
1535078|NCT03186352|primary root caries lesion
1535079|NCT03186352|cavity disinfection
1535080|NCT03186352|lasers
1535081|NCT03186352|root caries
1535082|NCT03185585|Nutritional screenings
1535102|NCT03194256|Smoking
1535103|NCT03194256|Cigarettes
1535104|NCT03194256|E-Cigarettes
1535105|NCT03182491|Platelet activating factor
1535106|NCT03182491|Basophil activation test
1535107|NCT03182491|Anaphylatoxins
1535122|NCT03194009|diabetes
1535123|NCT03194009|prevention
1535124|NCT03194009|metformin
1535125|NCT03194009|Mexico City
1535126|NCT03191032|Peripheral nerves/lesions; hands; rehabilitation; fMRI
1535130|NCT03193268|sensorimotor training
1535131|NCT03193268|quality of life
1535132|NCT03193268|posture
1535160|NCT03190226|L-PRF
1535161|NCT03190226|keratinised tissues
1535162|NCT03190226|implant
1535163|NCT03190226|free gingival graft
1535164|NCT03192059|Immunotherapy
1535165|NCT03192059|Radiotherapy
1535166|NCT03192059|Immune-modulatory cocktail
1535179|NCT03193983|occlusive dressing
1535212|NCT03168243|nutrition support, home enteral feeding
1535216|NCT03191071|pneumonia
1535217|NCT03191071|procalcitonin
1535218|NCT03191071|lung ultrassound
1535219|NCT03191071|point of care testing
1535220|NCT03191071|antibiotic prescription
1535221|NCT03191071|respiratory pathogens
1535222|NCT03191071|host biomarkers
1535223|NCT03186209|Asthma,
1535224|NCT03186209|Bronchial Diseases,
1535225|NCT03186209|Respiratory Tract Diseases,
1535226|NCT03186209|Lung Diseases,
1535227|NCT03186209|Obstructive Lung Diseases
1535228|NCT03164057|DNA methyltransferase inhibitors
1535229|NCT03164057|Acute myeloid leukemia
1535236|NCT03152188|Hepatic Encephalopathy
1535237|NCT03152188|Cirrhosis
1535238|NCT03152188|Liver
1535239|NCT03152188|Openbiome
1535240|NCT03152188|FMT Capsule
1535241|NCT03152188|Placebo
1535245|NCT03155841|Prevention
1535246|NCT03155841|Internet
1535247|NCT03155841|Adolescence
1535248|NCT03155841|LGBT
1535249|NCT03155841|Sexuality
1535250|NCT03159078|Acinetobacter
1535251|NCT03159078|Polymyxins
1535252|NCT03159078|Imipenem
1535253|NCT03194828|Adherence
1535254|NCT03194828|Mobile health
1535255|NCT03194828|Real-time data
1535256|NCT03193242|Asthma
1535257|NCT03193242|Asthma Action Plan
1535266|NCT03194503|Intubation
1535267|NCT03194503|Video Laryngoscope
1535268|NCT03194503|Coaching/training
1535275|NCT03138889|NKTR-214
1535276|NCT03138889|Atezolizumab
1535277|NCT03138889|Tecentriq
1535278|NCT03138889|Metastatic Urothelial Bladder Cancer
1535279|NCT03138889|Metastatic Non-Small Cell Lung Cancer
1535280|NCT03138187|spontaneous physical activity
1535281|NCT03138187|caloric intake
1535283|NCT03193008|Breast Cancer
1535284|NCT03193008|Axillary ultrasound
1535285|NCT03193008|Sentinel lymph node biopsy
1535286|NCT03193008|Axillary management
1535290|NCT03137121|nausea
1535291|NCT03137121|vomiting
1535292|NCT03137121|olanzapine
1535295|NCT03137368|ovarian function suppression/ablation
1535296|NCT03137368|breast cancer
1535297|NCT03137368|Exemestane
1535298|NCT03137368|Tamoxifen
1535299|NCT03137368|CYP2D6*10 mutations
1535300|NCT03194516|prostate cancer
1535301|NCT03194516|ketogenic diet
1535302|NCT03194516|overweight, obese
1535303|NCT03128723|Acne
1535312|NCT03178695|Infertility
1535313|NCT03178695|Pregnancy
1535314|NCT03178695|Menopause
1535315|NCT03178695|Perimenopause
1535316|NCT03178695|Premature Ovarian Failure
1535318|NCT03141008|Ketosis
1535319|NCT03141008|NAFLD
1535320|NCT03141008|Obesity
1535321|NCT03122899|SI-BONE
1535322|NCT03122899|sacroiliac joint
1535323|NCT03122899|degenerative sacroiliitis
1535324|NCT03122899|sacroiliac joint disruption
1535325|NCT03122899|iFuse
1535326|NCT03118362|Burns
1535327|NCT03118362|Critically ill
1535328|NCT03118362|Acid-Base status
1535330|NCT03188900|Preeclampsia
1535331|NCT03188900|apheresis
1535332|NCT03188900|sflt-1
1535333|NCT03127514|Randomized
1535334|NCT03127514|Double-blind
1535335|NCT03127514|Placebo-controlled
1535336|NCT03127514|Amyotrophic Lateral Sclerosis
1535337|NCT03127514|Sodium Phenylbutyrate
1535338|NCT03127514|Tauroursodeoxycholic Acid
1535355|NCT03118193|depression
1535356|NCT03118193|antidepressant
1535357|NCT03118193|resistance
1535364|NCT03110588|metastatic prostate cancer
1535365|NCT03110588|castration-resistant prostate cancer
1535366|NCT03110588|PACE (Prednisone, Abiraterone, Cabazitaxel, and Enzalutamide)
1535367|NCT03121664|Drug drug interaction, CYP3A4, itraconazole
1535392|NCT03102320|cholangiocarcinoma
1535393|NCT03102320|pancreatic cancer
1535394|NCT03102320|triple-negative breast cancer
1535395|NCT03102320|non-small cell lung cancer
1535396|NCT03102320|thymic carcinoma
1535397|NCT03102320|gastric including gastroesophageal junction cancer
1535403|NCT03120130|Phase I,
1535404|NCT03130179|Bioequivalence
1535408|NCT03107013|Mass Balance
1535409|NCT03107013|Phase 1
1535415|NCT03112356|infectious endocarditis
1535416|NCT03112356|prosthetic valve infection
1535417|NCT03112356|implantable cardiac device infection
1535418|NCT03112356|99mTc-Leukoscan® scintigraphy
1535452|NCT03126136|Fetal heart rate abnormalities
1535453|NCT03126136|Pregnancy
1535454|NCT03126136|Epidural analgesia
1535455|NCT03126136|Pulse pressure
1535456|NCT03089476|Prevention
1535457|NCT03089476|Predictors
1535458|NCT03093259|ABX464
1535459|NCT03093259|Ulcerative Colitis
1535460|NCT03093259|Refractory
1535461|NCT03093272|Prostate Cancer
1535468|NCT03084107|Elder care
1535469|NCT03084107|Active aging
1535470|NCT03084107|Intelligent Care Facilities for Elders
1535471|NCT03087019|adenoid cystic carcinoma
1535495|NCT03071809|Solid tumor
1535496|NCT03071809|carcinoma
1535497|NCT03071809|sarcoma
1535498|NCT03071809|stage I
1535499|NCT03071809|stage II
1535500|NCT03071809|stage III
1535502|NCT03069352|Treatment naïve
1535503|NCT03069352|Leukemia
1535504|NCT03069352|Venetoclax
1535505|NCT03069352|Acute Myeloid Leukemia
1535506|NCT03069352|Cytarabine
1535519|NCT03083600|protein hydrolysates
1535520|NCT03083600|HbA1c
1535521|NCT03083600|prediabetes
1535522|NCT03076879|Cervical Cancer
1535523|NCT03076879|Pap smear
1535524|NCT03076879|Screening
1535525|NCT03076879|Beliefs
1535526|NCT03076879|Attitude
1535527|NCT03076879|Nursing
1535528|NCT03194295|Drug-free community support
1535529|NCT03194295|Methadone maintenance
1535530|NCT03194295|Social networks
1535531|NCT03080909|Satiety
1535532|NCT03080909|Nutrient
1535533|NCT03080909|Appetite
1535534|NCT03080909|Encapsulation
1535535|NCT03080909|Lipid
1535536|NCT03080909|Amino acid
1535537|NCT03080909|Probiotic bacteria
1535538|NCT03079908|Laparoscopy
1535539|NCT03079908|Surgery
1535540|NCT03079908|Training
1535541|NCT03079908|Virtual reality
1535542|NCT03079908|Simulation
1535543|NCT03079908|Robotic Surgery
1535544|NCT03079908|Da Vinci
1535569|NCT03058848|Phenylketonuria
1535570|NCT03058848|PKU
1535571|NCT03058848|Metabolism
1535572|NCT03058848|Metabolic
1535573|NCT03058848|Control
1535574|NCT03058848|Acceptability
1535582|NCT03049111|Der F (House Dust Mite)
1535583|NCT03058952|pain management
1535584|NCT03058952|fatigue
1535585|NCT03058952|mindfulness
1535586|NCT03058952|Gulf War
1535587|NCT03194815|Psychosis
1535588|NCT03194815|Immunotherapy
1535589|NCT03194815|Autoantibodies
1535604|NCT03042663|stellate ganglion block
1535605|NCT03042663|arterial cannula
1535606|NCT03042663|ischemia
1535607|NCT03042663|septic shock
1535608|NCT03048344|acute promyelocytic leukemia
1535609|NCT03048344|APL
1535610|NCT03048344|arsenic trioxide
1535617|NCT03072303|Brittle Bone
1535618|NCT03072303|Osteogenesis Imperfecta
1535619|NCT03072303|BBD
1535620|NCT03072303|OI
1535621|NCT03072303|Congenital Abnormalities
1535622|NCT03072303|Congenital Bone Disorder
1535623|NCT03072303|Lobstein Syndrome
1535646|NCT03033914|Nivolumab
1535647|NCT03033914|adriamycin
1535648|NCT03033914|bleomycin
1535649|NCT03033914|vinblastine
1535650|NCT03033914|dacarbazine
1535651|NCT03033914|16-1536
1535652|NCT03031119|nonalcoholic steatohepatitis
1535659|NCT03028870|Osteoarthritis
1535660|NCT03028870|Pain
1535661|NCT03028870|Osteoarthritis Knee
1535664|NCT03036007|Spine, Disc, Neck pain, Rehabilitation, Exercise Therapy, Internet
1535665|NCT03033901|Veterans
1535666|NCT03033901|Comparative Effectiveness Research
1535667|NCT03033901|Diagnosis
1535693|NCT03010423|Non-obstructive coronary artery disease
1535694|NCT03010423|Nicorandil
1535699|NCT03011151|pediatric
1535700|NCT03011151|critical illness
1535701|NCT03011151|surgery
1535702|NCT03011151|gastrointestinal dysfunction
1535703|NCT03011151|gastric emptying
1535704|NCT03011151|epithelial barrier
1535705|NCT03011151|nutrition
1535706|NCT03008889|Repetitive Self-Injurious Behavior
1535707|NCT03008889|N-acetylcysteine (NAC)
1535711|NCT03000686|GSK2586881, Acute hypoxia, Exercise
1535719|NCT03000270|Infarct Size
1535720|NCT03000270|Impella
1535721|NCT03000270|Unloading
1535722|NCT03000270|Left Ventricle
1535723|NCT03000270|PPCI
1535724|NCT03000270|STEMI
1535728|NCT02990325|ABX464, HIV infection
1535730|NCT02982187|HANDIHALER
1535731|NCT02982187|ELLIPTA
1535732|NCT02982187|TURBUHALER
1535733|NCT02982187|DISKUS
1535734|NCT02982187|COPD
1535735|NCT02982187|critical error
1535736|NCT02982187|inhaler preference
1535755|NCT02994680|Air Pollution
1535756|NCT02994680|Liquefied Petroleum Gas
1535757|NCT02994680|Cookstove
1535758|NCT02994680|Behavioral Intervention
1535759|NCT02994680|Propane Stove
1535769|NCT02994667|Electrophysiology
1535770|NCT02987803|Patient Engagement
1535771|NCT02987803|Public Reporting
1535772|NCT02987803|Quality Measurement
1535797|NCT02965040|ASP1517
1535798|NCT02965040|Normal renal function
1535799|NCT02965040|Dialysis
1535800|NCT02965040|Roxadustat
1535801|NCT02965040|Metabolites
1535802|NCT02965040|Pharmacokinetics
1535803|NCT02965040|Impaired renal function
1535804|NCT02960022|prostate cancer
1535805|NCT02960022|prednisone
1535806|NCT02960022|MDV3100
1535807|NCT02960022|enzalutamide
1535808|NCT02960022|Xtandi
1535809|NCT02960022|abiraterone acetate
1535810|NCT02966678|Glaucoma, Dychromatopsia
1535811|NCT02958865|Mayo score
1535828|NCT02978677|brain tumors
1535829|NCT02978677|proton radiotherapy
1535830|NCT02978677|photon radiotherapy
1535831|NCT02940145|inflammatory biomarkers
1535832|NCT02940145|Interleukines
1535833|NCT02940145|resistance training
1535834|NCT02940145|phase angle
1535835|NCT02940145|oxidative stress
1535848|NCT02926196|ER-Negative
1535849|NCT02926196|PR-Negative
1535850|NCT02926196|HER2-Negative
1535851|NCT02927431|Anti-inflammatory
1535852|NCT02927431|Danirixin
1535853|NCT02927431|Influenza
1535854|NCT02927431|Hospitalized patients
1535857|NCT02902978|E6130
1535858|NCT02902978|Japanese healthy adult male participants
1535859|NCT02902978|Phase 1
1535860|NCT02902978|Pharmacokinetics
1535861|NCT02903966|Tolerability
1535862|NCT02903966|GSK2982772
1535863|NCT02903966|Safety
1535864|NCT02903966|Pharmacokinetics
1535865|NCT02903966|RIP1 kinase inhibitor
1535866|NCT02903966|Ulcerative colitis
1535867|NCT02903966|Pharmacodynamics
1535868|NCT02913105|Non-alcoholic Steatohepatitis
1535869|NCT02913105|NASH
1535870|NCT02913105|Fatty liver disease
1535879|NCT02908074|Hypogonadotropic
1535880|NCT02908074|hypogonadism
1535881|NCT02908074|testosterone
1535882|NCT02903771|Cantrixil
1535883|NCT02903771|Intraperitoneal
1535884|NCT02893033|Dysphagia
1535885|NCT02893033|Repetitive Transcranial Magnetic Stimulation
1535886|NCT02893033|Stroke
1535892|NCT02894398|HR+
1535893|NCT02894398|HER2-
1535894|NCT02894398|Locally advanced (inoperable or metastatic) Breast Cancer
1535895|NCT02894398|Palbociclib
1535896|NCT02894398|Aromatase inhibitor or fulvestrant
1535897|NCT02894398|Pre-/perimenopausal receiving LHRH agonist / ovarian ablation
1535898|NCT02894398|Postmenopausal
1535906|NCT02881177|oxytocin
1535907|NCT02881177|tolerability
1535908|NCT02881177|HIV
1535909|NCT02881177|men who have sex with men (MSM)
1535910|NCT02881177|addiction
1535981|NCT02868281|Cluster Randomization
1535982|NCT02868281|Peak Expiratory Flow
1535983|NCT02868281|Forced Expiratory Volume
1535984|NCT02868281|Standardized Asthma Quality of Life Questionnaire
1535985|NCT02868281|Asthma Control Test
1535986|NCT02865811|Ovarian Cancer
1535987|NCT02863575|third molar extraction
1535988|NCT02863575|ibuprofen
1535989|NCT02863575|ibuprofen/caffeine
1535990|NCT02863575|post-surgical dental pain
1535991|NCT02861573|Metastatic Castration-Resistant Prostate Cancer
1535992|NCT02861573|mCRPC
1535993|NCT02861573|PD1
1535994|NCT02861573|PD-1
1535995|NCT02861573|PDL1
1535996|NCT02861573|PD-L1
1535997|NCT02880371|Advanced Solid Tumors
1535998|NCT02880371|Pembrolizumab
1535999|NCT02880371|ARRY-382
1536017|NCT02856776|Vitamin D
1536018|NCT02856776|Metabolomics
1536019|NCT02856776|Microbiota
1536020|NCT02856776|Gene Expression
1536037|NCT02836496|Safety
1536038|NCT02836496|Mepolizumab
1536039|NCT02836496|Hypereosinophilic syndrome
1536040|NCT02836496|HES flare
1536041|NCT02836496|Efficacy
1536042|NCT02841241|esmolol
1536043|NCT02841241|adrenergic storm
1536044|NCT02841241|septic shock
1536045|NCT02824718|Hypoparathyroidism
1536046|NCT02824718|PTH(1-34)
1536047|NCT02824718|Thiazides
1536048|NCT02824718|Hypercalciuria
1536049|NCT02824718|Calcium sensing receptor
1536050|NCT02823834|osteoarthritis
1536051|NCT02823834|avascular necrosis
1536052|NCT02823834|ankylosis
1536053|NCT02823834|protrusio acetabuli
1536054|NCT02823834|painful hip dysplasia
1536055|NCT02823834|rheumatoid arthritis
1536056|NCT02823834|correction of functional deformity
1536057|NCT02823600|retinal screening
1536058|NCT02823600|outpatient dialysis
1536063|NCT02834637|HPV
1536064|NCT02834637|cervical cancer
1536065|NCT02834637|vaccines
1536066|NCT02834637|HPV vaccine
1536067|NCT02834637|dose reduction
1536068|NCT02834637|Human papilloma virus vaccine schedules
1536074|NCT02825758|Micronutrients
1536075|NCT02825758|restricted
1536076|NCT02825758|ketogenic
1536077|NCT02825758|diet
1536078|NCT02825758|acceptability
1536079|NCT02814825|ViviGen
1536080|NCT02814825|ACDF
1536081|NCT02814825|Cervical
1536082|NCT02819882|Unresectable
1536083|NCT02819882|locally
1536084|NCT02819882|advanced
1536085|NCT02819882|metastatic disease
1536087|NCT02810951|RDEB
1536088|NCT02798315|Paritaprevir/r - Ombitasvir, ± Dasabuvir
1536089|NCT02798315|Sustained Virological Response
1536090|NCT02798315|Chronic Hepatitis C genotype 4
1536091|NCT02798315|Observational Study
1536092|NCT02798315|Chronic Hepatitis C genotype 1
1536093|NCT02798315|Chronic Hepatitis C
1536095|NCT02791230|amyloidosis
1536096|NCT02791230|amyloid
1536097|NCT02791230|transthyretin
1536098|NCT02791230|TTR
1536106|NCT02787668|childhood obesity
1536107|NCT02787668|Non-alcoholic fatty liver disease
1536108|NCT02787668|insulin resistance
1536109|NCT02787668|carbohydrate-restriction
1536113|NCT02812147|L-dihydoxyphenylserine
1536114|NCT02812147|L-DOPS
1536115|NCT02812147|Northera
1536116|NCT02784587|stellate ganglion block
1536117|NCT02784587|cardiac surgery
1536118|NCT02780180|Aminopeptidase A inhibitor
1536119|NCT02780180|Heart Failure
1536120|NCT02780180|Up-titration
1536121|NCT02780180|Dose-Response Relationship, Drug
1536122|NCT02780180|Pharmacokinetics
1536123|NCT02780180|Patient Safety
1536124|NCT02780180|Treatment Efficacy
1536125|NCT02772432|resiliency training
1536126|NCT02772432|parenting
1536127|NCT02772432|special learning disability
1536128|NCT02766543|prostate cancer
1536129|NCT02766543|high intensity transurethral ultrasound ablation
1536130|NCT02766543|MRI-guided
1536131|NCT02766543|minimally invasive
1536132|NCT02766543|real-time temperature feedback control
1536133|NCT02765412|decision support
1536134|NCT02765412|patient preferences
1536135|NCT02765412|risk adjustment
1536164|NCT02753842|Sexually Transmitted Infections
1536165|NCT02753842|Condoms
1536166|NCT02753842|Contraceptive Devices
1536167|NCT02753842|HIV
1536171|NCT02746874|Total Knee Replacement, Replacement of the knee joint,
1536172|NCT02743871|FIH, Pharmacokinetics
1536173|NCT02763644|transplant associated microangiopathy
1536174|NCT02741609|Borrelia
1536175|NCT02741609|spirochetes
1536176|NCT02741609|culture
1536177|NCT02741609|immunostaining
1536212|NCT02739451|immunocompromized patients
1536213|NCT02739451|critically ill patients
1536231|NCT02720445|Alzheimer's Disease
1536232|NCT02720445|Nicotine
1536233|NCT02720445|Transdermal Patch
1536237|NCT02720094|Pre-Exposure Prophylaxis
1536238|NCT02720094|PrEP
1536249|NCT02708654|Remote monitoring
1536250|NCT02708654|Incentives
1536255|NCT02713529|Solid Tumor
1536256|NCT02713529|Pancreatic Cancer
1536257|NCT02713529|Colorectal Cancer
1536258|NCT02713529|Non-Small Cell Lung Cancer
1536259|NCT02704273|MTM
1536260|NCT02704273|XLMTM
1536267|NCT02699515|MSB0011359C
1536294|NCT02699242|Fiberoptic intubation Training Simulation Performance
1536303|NCT02689960|addison disease
1536304|NCT02689960|adrenal crisis
1536305|NCT02689960|prednisone
1536306|NCT02682927|seizure
1536307|NCT02682927|tonic-atonic
1536308|NCT02682927|clonic
1536309|NCT02682927|epilepsy
1536310|NCT02682927|myoclonic
1536311|NCT02682927|encephalopathy
1536312|NCT02675985|Physical Therapy, early intervention
1536313|NCT02674633|ADHD
1536315|NCT02670408|Heart transplant
1536316|NCT02670408|global gene expression
1536317|NCT02670408|molecular diagnostics
1536321|NCT02662621|personalized care
1536322|NCT02662621|early diagnosis
1536323|NCT02662621|ovarian cancer
1536324|NCT02662621|breast cancer
1536325|NCT02662621|lung cancer
1536326|NCT02662621|Early Detection
1536327|NCT02662621|Cancer [E01.390.500]
1536328|NCT02664740|Phage Therapy
1536329|NCT02657382|Biofeedback
1536330|NCT02657382|Myocardial Imaging
1536331|NCT02654015|intracranial hemorrhage
1536332|NCT02654015|neurosurgery
1536333|NCT02660411|Sevoflurane
1536334|NCT02660411|Propofol
1536335|NCT02660411|Aged
1536336|NCT02660411|Neoplasm
1536337|NCT02660411|Surgical Procedure, Operative
1536338|NCT02660411|Long-term survival
1536339|NCT02651116|cough, acute cough, pediatric, Dextromethorphan Hydrobromide, antitussive, ambulatory cough recording device
1536340|NCT02648100|Muscle invasive bladder cancer
1536341|NCT02648100|Basal subtype
1536342|NCT02648100|Anti-EGFR treatment
1536343|NCT02648100|Nanostring
1536344|NCT02662257|Sevoflurane
1536345|NCT02662257|Propofol
1536346|NCT02662257|Aged
1536347|NCT02662257|Neoplasm
1536348|NCT02662257|Surgical Procedure, Operative
1536349|NCT02662257|Delirium
1536350|NCT02662257|Postoperative Complications
1536362|NCT02654990|multiple myeloma
1536363|NCT02654990|relapsed or relapsed/refractory
1536364|NCT02654990|LBH589
1536365|NCT02654990|panobinostat
1536366|NCT02654990|bortezomib
1536367|NCT02654990|dexamethasone
1536368|NCT02630316|Treprostinil
1536369|NCT02630316|PH
1536370|NCT02630316|ILD
1536371|NCT02630316|CPFE
1536372|NCT02630316|6 Minute Walk Test
1536373|NCT02633293|Treprostinil
1536374|NCT02633293|PH
1536375|NCT02633293|ILD
1536376|NCT02633293|CPFE
1536377|NCT02633293|6 Minute Walk Test
1536415|NCT02647866|4083-002
1536416|NCT02647866|Intestinal Diseases
1536417|NCT02647866|Ulcerative Colitis
1536418|NCT02647866|UC
1536419|NCT02647866|Mayo Clinic Scoring
1536420|NCT02647866|Gastrointestinal Tract
1536429|NCT02637869|Health Expenditures
1536430|NCT02637869|Prospective Payment System
1536431|NCT02637869|Health Care Utilization
1536432|NCT02637869|Health Care Quality, Access, and Evaluation
1536433|NCT02620813|acne
1536434|NCT02620813|sebaceous gland
1536435|NCT02620813|lipid
1536436|NCT02620813|sebum
1536439|NCT02630732|Back School
1536440|NCT02630732|Brain School
1536441|NCT02630732|Lumbar surgery
1536442|NCT02630732|Education
1536443|NCT02614235|Cardiac Arrhythmia
1536444|NCT02614235|Syncope
1536445|NCT02614235|Ambulatory Electrocardiography Monitoring
1536454|NCT02643459|Triage
1536455|NCT02643459|Risk stratification
1536456|NCT02643459|Acute care
1536457|NCT02643459|suPAR
1536470|NCT02602457|Atrial Fibrillation
1536485|NCT02588261|erlotinib
1536486|NCT02588261|EGFR mutation
1536487|NCT02588261|Non-small cell lung cancer (NSCLC)
1536488|NCT02588261|ASP8273
1536489|NCT02588261|gefitinib
1536490|NCT02606201|stress urinary incontinence
1536491|NCT02606201|intrinsic sphincter deficiency
1536492|NCT02606201|myofiber
1536493|NCT02606201|autologous
1536494|NCT02606201|skeletal muscle precursor cells
1536495|NCT02606201|autologous serum
1536496|NCT02569541|fusidic acid
1536497|NCT02569541|prosthetic joint infections
1536498|NCT02569541|bone infections
1536499|NCT02569541|osteomyelitis
1536502|NCT02574312|Mechanical Axis Alignment
1536503|NCT02574312|Knee Arthroplasty, Total
1536504|NCT02576236|Naïve patient
1536505|NCT02576236|Suspicion of H pylori infection
1536506|NCT02576236|Endoscopy
1536507|NCT02576236|Antibiotics therapeutic strategies
1536508|NCT02576236|Urea breath test
1536527|NCT02565511|Randomization, Placebo controlled, Parallel-group, APOE4 Homozygotes, Preclinical Alzheimer's Disease (AD), Aβ lowering
1536528|NCT02561221|primary care
1536529|NCT02561221|pragmatic trial
1536530|NCT02561221|weight loss
1536531|NCT02561221|overweight
1536532|NCT02561221|diet
1536533|NCT02561221|physical activity
1536534|NCT02561221|PCORI
1536535|NCT02546999|Botulinum Toxins, Type A
1536536|NCT02546999|Walking
1536537|NCT02572297|epilepsy
1536538|NCT02572297|SUDEP
1536539|NCT02572297|SpO2
1536540|NCT02541903|Epidermal growth factor receptor (EGFR),
1536541|NCT02541903|Human Papillomavirus (HPV)
1536542|NCT02541903|Penile squamous cell carcinoma (PSCC)
1536543|NCT02541903|Gilotrif
1536576|NCT02572674|Bipolar disorder
1536577|NCT02572674|relapse risk factors
1536578|NCT02572674|prospective follow up
1536601|NCT02539771|vaso-occlusive crisis
1536602|NCT02539771|obstructive sleep apnea
1536603|NCT02539771|priapism
1536609|NCT02507258|osteoarthritis
1536610|NCT02507258|avascular necrosis
1536611|NCT02507258|correction of functional deformity
1536612|NCT02507258|painful hip dysplasia
1536613|NCT02507258|protrusio acetabuli
1536614|NCT02507258|rheumatoid arthritis
1536615|NCT02507258|ankylosis
1536626|NCT02505269|limited stage
1536627|NCT02505269|Hodgkin's disease
1536628|NCT02505269|non-bulky
1536670|NCT02478294|Atrial Fibrillation
1536671|NCT02478294|Stroke
1536672|NCT02478294|Systemic embolism
1536673|NCT02478294|Left atrial appendage excision
1536674|NCT02478294|Warfarin
1536679|NCT02465515|cardiovascular events /outcomes
1536680|NCT02465515|Type 2 diabetes mellitus
1536681|NCT02465515|albiglutide
1536682|NCT02465515|glucagon-like peptide-1 receptor agonist
1536683|NCT02471976|Leonetti law
1536684|NCT02471976|palliative care
1536685|NCT02459119|urothelial cancer
1536686|NCT02459119|Regorafenib
1536690|NCT02509689|mTBI
1536691|NCT02509689|cognition disorders
1536692|NCT02509689|post-concussive syndrome
1536693|NCT02509689|neuroplasticity
1536694|NCT02509689|EEG
1536695|NCT02509689|biofeedback
1536696|NCT02509689|stress disorder/post-traumatic
1536697|NCT02509689|depression
1536698|NCT02454855|quality of life
1536699|NCT02454855|melatonin
1536700|NCT02454855|Elderly patient
1536710|NCT02424435|Friedreich Ataxia
1536711|NCT02424435|FRDA
1536760|NCT02434224|Music therapy
1536761|NCT02434224|premature infant
1536762|NCT02434224|brain development
1536763|NCT02397746|osteoarthritis
1536764|NCT02397746|avascular necrosis
1536765|NCT02397746|ankylosis
1536766|NCT02397746|protrusio acetabuli
1536767|NCT02397746|rheumatoid arthritis
1536768|NCT02397746|correction of functional deformity
1536769|NCT02397746|revision procedures
1536770|NCT02403739|Growth
1536771|NCT02399228|radiation therapy
1536772|NCT02399228|chemotherapy
1536773|NCT02399228|head and neck cancer
1536780|NCT02466165|cardiometabolic risk
1536781|NCT02466165|physical exercise
1536782|NCT02383641|Lipid Metabolism
1536783|NCT02383641|Inborn Errors
1536784|NCT02383641|Cholesterol Ester Storage Disease
1536785|NCT02435173|APDS PASLI PI3Kdelta
1536786|NCT02393625|NSCLC, ALK-positive
1536790|NCT02400476|HER2 +
1536791|NCT02400476|Breast Cancer
1536792|NCT02400476|Neratinib
1536796|NCT02367378|Minimally invasive surgery
1536797|NCT02428647|growth
1536798|NCT02428647|plasma zinc concentration
1536799|NCT02434250|Open angle glaucoma
1536800|NCT02434250|Ocular hypertension
1536801|NCT02434250|Cataract
1536802|NCT02434250|Selective Laser Trabeculoplasty
1536803|NCT02434250|Eximer Laser Trabeculectomy
1536804|NCT02434250|Phacoemulsification Cataract Extraction
1536823|NCT02322021|E2609
1536824|NCT02322021|Mild Cognitive Impairment
1536825|NCT02322021|Mild to Moderate Dementia
1536826|NCT02322021|Alzheimer's Disease
1536827|NCT02322021|Prodromal Alzheimer's Disease
1536828|NCT02328547|fecal microbiota transplantation
1536829|NCT02328547|diarrhea-predominant
1536830|NCT02401035|candidate for acid suppression therapy
1536831|NCT02401035|presumptive diagnosis of GERD
1536832|NCT02401035|clinical diagnosis of suspected GERD
1536833|NCT02401035|symptomatic GERD
1536834|NCT02401035|endoscopically proven GERD
1536835|NCT02314611|osteoarthritis
1536836|NCT02314611|avascular necrosis
1536837|NCT02314611|ankylosis
1536838|NCT02314611|protrusio acetabuli
1536839|NCT02314611|painful hip dysplasia
1536840|NCT02314611|rheumatoid arthritis
1536841|NCT02314611|correction of functional deformity
1536842|NCT02314611|revision procedures
1536843|NCT02322905|informal caregivers
1536844|NCT02322905|caregiving
1536845|NCT02322905|psychotherapy for caregivers
1536846|NCT02322905|cancer
1536847|NCT02322905|emotion regulation
1536848|NCT02322905|distress
1536849|NCT02322905|inflammation
1536850|NCT02309593|osteoarthritis
1536851|NCT02309593|avascular necrosis
1536852|NCT02309593|ankylosis
1536853|NCT02309593|protrusio acetabuli
1536854|NCT02309593|painful hip dysplasia
1536855|NCT02309593|rheumatoid arthritis
1536856|NCT02309593|correction of functional deformity
1536857|NCT02309593|revision procedures
1536858|NCT02314702|Osteoarthritis
1536859|NCT02314702|Avascular necrosis
1536860|NCT02314702|Ankylosis
1536861|NCT02314702|Protrusio acetabuli
1536862|NCT02314702|Painful hip dysplasia
1536863|NCT02314702|Rheumatoid arthritis
1536864|NCT02314702|Correction of functional deformity
1536865|NCT02314702|Revision procedures
1536867|NCT02444143|Kidney
1536868|NCT02444143|Immunosuppression
1536869|NCT02444143|Transplant
1536881|NCT02302664|Achilles
1536882|NCT02302664|Platelet Rich Plasma
1536883|NCT02302664|Patient reported outcome measure
1536884|NCT02302664|Orthopaedic trauma
1536885|NCT02302664|Musculoskeletal
1536886|NCT02302664|Tendon
1536887|NCT02302664|Sports Injury
1536888|NCT02302664|Heel-Rise Endurance Test
1536889|NCT02308111|Primary Biliary Cirrhosis
1536890|NCT02308111|PBC
1536891|NCT02308111|Cirrhosis
1536892|NCT02308111|Liver
1536893|NCT02290028|CRT-D therapy
1536894|NCT02290028|quadripolar left ventricular lead
1536895|NCT02285842|osteoarthritis
1536896|NCT02285842|avascular necrosis
1536897|NCT02285842|ankylosis
1536898|NCT02285842|protrusio acetabuli
1536899|NCT02285842|painful hip dysplasia
1536900|NCT02285842|rheumatoid arthritis
1536901|NCT02285842|correction of functional deformity
1536902|NCT02285842|revision procedures
1536903|NCT02310763|Duchenne Muscular Dystrophy, myostatin
1536917|NCT02281357|Asthma
1536918|NCT02281357|Reactive Airways
1536919|NCT02281357|Repiratory Tract Disease
1536920|NCT02281357|Obstructive Lung Disease
1536921|NCT02281357|Lung Diseases
1536933|NCT02279693|Raypilot dosimetry
1536934|NCT02279693|CBCT (cone beam computed tomography)
1536935|NCT02281214|lung cancer, mutations
1536936|NCT02281214|patients
1536937|NCT02281214|mutations
1536943|NCT02261220|advanced solid tumors
1536944|NCT02261220|durvalumab
1536945|NCT02261220|tremelimumab
1536947|NCT02248922|Cystic Fibrosis, Pseudomonas aeruginosa, Lung Clearance Index, Multiple Breath Washout, Inhaled Tobramycin, Inhaled Antibiotics.
1536960|NCT02239783|osteoarthritis
1536961|NCT02239783|avascular necrosis
1536962|NCT02239783|ankylosis
1536963|NCT02239783|protrusio acetabuli
1536964|NCT02239783|painful hip dysplasia
1536965|NCT02239783|rheumatoid arthritis
1536966|NCT02239783|correction of functional deformity
1536967|NCT02239783|revision procedures
1536968|NCT02240875|Ebola
1536969|NCT02240875|Zaire
1536975|NCT02478502|testicular cancer
1536976|NCT02478502|cisplatin resistancy
1536980|NCT02225366|Melanoma
1536981|NCT02225366|Metastatic
1536982|NCT02225366|Antimicrobial peptide
1536983|NCT02225366|LL37
1536984|NCT02225366|Photographs
1536985|NCT02221700|Gastrointestinal cancer
1536986|NCT02221700|Chemotherapy Induced Peripheral Neuropathy
1536987|NCT02221700|CIPN
1536988|NCT02221700|Symptom reduction
1536989|NCT02221700|Massage
1536990|NCT02221700|Symptom questionnaires
1536991|NCT02221700|Surveys
1536992|NCT02221700|Leg function and balance tests
1536993|NCT02221960|Recurrent or metastatic solid tumors, MEDI6383, OX40
1537008|NCT02207634|High cholesterol
1537009|NCT02207634|Treatment for high cholesterol
1537010|NCT02207634|Lowering cholesterol
1537011|NCT02207634|Lowering high cholesterol
1537012|NCT02207634|Hypercholesterolemia
1537013|NCT02225041|intensive care
1537014|NCT02225041|critical care
1537015|NCT02225041|child
1537016|NCT02225041|family
1537017|NCT02225041|survivors
1537018|NCT02202954|Stroke
1537019|NCT02202954|Muscle Spasticity
1537020|NCT02202954|Rehabilitation
1537021|NCT02200666|Type 2 diabetes mellitus
1537022|NCT02200666|Diabetes
1537023|NCT02200666|Forxiga
1537024|NCT02200666|Long-term use
1537029|NCT02201771|CABG
1537030|NCT02201771|Antiplatelet
1537031|NCT02201771|Ticagrelor
1537032|NCT02197897|Tamoxifen citrate
1537033|NCT02197897|Bladder Cancer
1537034|NCT02201732|Incomplete miscarriage
1537035|NCT02201732|Hysteroscopy
1537036|NCT02201732|curettage, pregnancy
1537037|NCT02201732|RCT
1537038|NCT02196454|HPV vaccine
1537039|NCT02196454|vaccination
1537040|NCT02196454|immunization
1537041|NCT02196454|video
1537042|NCT02196454|health education
1537043|NCT02196454|communication
1537052|NCT02184611|lung function
1537053|NCT02184611|Umeclidinium
1537054|NCT02184611|GSK573719
1537055|NCT02184611|anticholinergic
1537056|NCT02184611|novel dry powder inhaler
1537057|NCT02184611|long-acting muscarinic receptor antagonist
1537058|NCT02184611|Chronic Obstructive Pulmonary Disease
1537068|NCT02159716|Subjects
1537081|NCT02173522|Prostate cancer
1537082|NCT02173522|Prostate artery embolization
1537083|NCT02173522|Robot-assisted laparoscopic radical prostatectomy
1537084|NCT02149667|osteoarthritis
1537085|NCT02149667|avascular necrosis
1537086|NCT02149667|ankylosis
1537087|NCT02149667|protrusio acetabuli
1537088|NCT02149667|painful hip dysplasia
1537089|NCT02149667|rheumatoid arthritis
1537090|NCT02149667|correction of functional deformity
1537091|NCT02149667|revision procedures
1537092|NCT02142530|NHL
1537093|NCT02142530|DLBCL
1537094|NCT02142530|PTCL
1537095|NCT02142530|Marginal zone lymphoma
1537096|NCT02142530|lymphoplasmacytic lymphoma
1537097|NCT02142530|Waldenstrom's macroglobulinemia
1537098|NCT02148159|anorexia
1537099|NCT02148159|cachexia
1537100|NCT02148159|cancer
1537101|NCT02148159|unintentional weigh loss
1537102|NCT02148159|gastrointestinal tract
1537103|NCT02148159|adults
1537111|NCT02096211|Total hip replacement
1537112|NCT02096211|Total hip arthroplasty
1537113|NCT02096211|Hip joint replacement
1537114|NCT02096211|Hip prosthesis replacement
1537115|NCT02091960|Enzalutamide
1537116|NCT02091960|Trastuzumab
1537117|NCT02091960|Breast cancer
1537118|NCT02091960|HER2
1537119|NCT02091960|Androgen receptor positive
1537120|NCT02091960|Xtandi
1537121|NCT02094963|acute coronary syndrome
1537122|NCT02094963|coronary disease
1537123|NCT02094963|coronary artery disease
1537124|NCT02083653|Metastatic Colorectal Cancer
1537125|NCT02083653|Sym004
1537126|NCT02083653|Best Supportive Care
1537127|NCT02083653|Capecitabine
1537128|NCT02083653|Fluorouracil (5-FU)
1537132|NCT02080923|Adolescent
1537133|NCT02080923|Adolescent Behavior
1537134|NCT02080923|Age Factors
1537135|NCT02080923|Courtship
1537136|NCT02080923|Randomized Control Trial
1537137|NCT02080923|Female
1537138|NCT02080923|Male
1537139|NCT02080923|Minority Groups/statistics & numerical data
1537140|NCT02080923|Risk-Taking
1537141|NCT02080923|Sex Factors
1537142|NCT02080923|Sexual Behavior/statistics & numerical data
1537143|NCT02080923|Substance-Related Disorders/epidemiology
1537144|NCT02080923|Urban Population/statistics & numerical data
1537145|NCT02080923|Violence/statistics & numerical data
1537146|NCT02080923|Dating Violence
1537147|NCT02080923|Dating Aggression
1537148|NCT02080923|Perpetration
1537149|NCT02102204|Secondary Hyperparathyroidism (SHPT), chrominc kidney disease (CKD), hemodialysis
1537150|NCT02078882|Primary Biliary Cirrhosis
1537151|NCT02078882|Ursodeoxycholic acid
1537152|NCT02078882|Abatacept
1537153|NCT02078882|Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)
1537154|NCT02075047|Bipolar I Disorder (current or most recent episode manic). Children and adolescents aged 10 to 17 years.
1537164|NCT02060487|pulmonary arterial hypertension
1537165|NCT02060487|pulmonary hypertension
1537166|NCT02060487|PAH
1537167|NCT02060487|sildenafil
1537168|NCT02060487|revatio
1537169|NCT03059745|Cholecystitis
1537170|NCT03059745|Cholelithiasis
1537171|NCT02064036|Prostate Cancer
1537172|NCT02064036|Radiotherapy
1537173|NCT02064036|Androgen Deprivation
1537180|NCT02053064|Neurodegenerative diseases
1537181|NCT02053064|Nervous systems diseases
1537182|NCT02053064|Genetic diseases, Inborn
1537183|NCT02053064|Metabolic diseases
1537184|NCT02053064|Gene therapy
1537185|NCT02053064|Adeno Associated Virus (AAV)
1537204|NCT02033655|weight loss
1537205|NCT02033655|older adults
1537206|NCT02033655|obesity
1537213|NCT02031822|Primary Headache
1537214|NCT02031822|Greater Occipital Nerve
1537215|NCT02031822|Ultrasound
1537216|NCT02031822|Chronic Pain
1537217|NCT02031822|Cervicogenic
1537218|NCT02031822|Occipital Neuralgia
1537219|NCT02031822|Migraine
1537220|NCT02031822|Tension type headache
1537221|NCT02031822|Cluster headache
1537260|NCT02000817|Beta Cell
1537261|NCT02000817|Monoclonal Antibody
1537262|NCT02000817|Otelixizumab
1537263|NCT02000817|Cytokine Release Syndrome
1537264|NCT02000817|Epstein-Barr Virus
1537265|NCT02000817|Diabetes Mellitus
1537266|NCT01984346|Atrial Fibrillation
1537267|NCT01984346|Convergent Procedure
1537268|NCT01984346|Combined Epicardial/ Endocardial Ablation
1537269|NCT01984346|Hybrid Procedure
1537270|NCT01984346|Radiofrequency Ablation
1537271|NCT01984346|Arrhythmia
1537272|NCT01984346|RF Ablation
1537273|NCT01983969|Advanced Cancers
1537274|NCT01983969|Lymphoma
1537275|NCT01983969|Recurrent Hodgkin's
1537276|NCT01983969|non-Hodgkin's lymphoma
1537277|NCT01983969|Stem cell transplant
1537278|NCT01983969|Azacitidine
1537279|NCT01983969|5-azacytidine
1537280|NCT01983969|5-aza
1537281|NCT01983969|Vidaza
1537282|NCT01983969|5-AZC
1537283|NCT01983969|AZA-CR
1537284|NCT01983969|Ladakamycin
1537285|NCT01983969|NSC-102816
1537286|NCT01983969|Azacytidine
1537287|NCT01983969|Vorinostat
1537288|NCT01983969|SAHA
1537289|NCT01983969|Suberoylanilide Hydroxamic Acid
1537290|NCT01983969|MSK-390
1537291|NCT01983969|Zolinza
1537292|NCT01983969|Gemcitabine
1537293|NCT01983969|Gemcitabine Hydrochloride
1537294|NCT01983969|Gemzar
1537295|NCT01983969|Busulfan
1537296|NCT01983969|Busulfex
1537297|NCT01983969|Myleran
1537298|NCT01983969|Melphalan
1537299|NCT01983969|Alkeran
1537300|NCT01983969|Dexamethasone
1537301|NCT01983969|Decadron
1537302|NCT01983969|Caphosol
1537303|NCT01983969|Glutamine
1537304|NCT01983969|Enterex
1537305|NCT01983969|Glutapak-10
1537306|NCT01983969|NutreStore
1537307|NCT01983969|Resource
1537308|NCT01983969|GlutaSolve
1537309|NCT01983969|Sympt-X G.I.
1537310|NCT01983969|Sympt-X
1537311|NCT01983969|Pyridoxine
1537312|NCT01983969|Rituximab
1537313|NCT01983969|Rituxan
1537335|NCT02011802|Sorbact TM
1537336|NCT02011802|Alginates
1537337|NCT02011802|Dressing
1537338|NCT02011802|Wound healing
1537339|NCT01961479|Premenstrual syndrome (PMS)
1537340|NCT01961479|Premenstrual Dysphoric Disorder (PMDD)
1537341|NCT01961479|Internet-based Therapy
1537342|NCT01961479|Cognitive Behavioural Therapy (CBT)
1537343|NCT01958112|Cervical Cancer
1537344|NCT01958112|Cervical
1537345|NCT01958112|Cervix
1537346|NCT01962103|Neuroblastoma
1537347|NCT01962103|Rhabdomyosarcoma
1537348|NCT01962103|Soft Tissue
1537349|NCT01962103|Pediatric Oncology
1537350|NCT01962103|Abraxane
1537351|NCT01962103|albumin-bound paclitaxel
1537352|NCT01962103|nab-paclitaxel
1537353|NCT01962103|ABI-007
1537354|NCT01962103|taxane
1537355|NCT01962103|solid tumors
1537356|NCT01954082|Retinopathy
1537357|NCT01954082|Prematurity
1537358|NCT01954082|Infant, Newborn, Diseases
1537359|NCT01951326|Crohn's Disease
1537360|NCT01951326|moderate to severe
1537361|NCT01951326|remission
1537362|NCT01951326|MAP
1537363|NCT01951326|antibiotic
1537364|NCT01943461|Solid Tumors
1537365|NCT01943461|MSB0010718C
1537366|NCT01943461|anti PD-L1
1537367|NCT01943461|avelumab
1537368|NCT01943461|Phase 1
1537371|NCT01931462|Cancer of the Kidney
1537372|NCT01931462|Renal Cancer
1537373|NCT01931462|Renal Neoplasms
1537374|NCT01931462|Neoplasms, Kidney
1537375|NCT01932372|Rheumatoid Arthritis
1537376|NCT01932372|Good Post Marketing Study Practice
1537377|NCT01932372|Tofacitinib
1537378|NCT01932372|Xeljanz
1537379|NCT01932372|Regulatory Post Marketing Commitment Plan
1537380|NCT01909609|male
1537388|NCT01904032|Vitamin D
1537389|NCT01904032|Diabetes
1537390|NCT01904032|Self-Management
1537391|NCT01904032|Depression
1537392|NCT01904032|Women
1537414|NCT03185754|lung cancer
1537415|NCT03185754|surgery
1537416|NCT03185754|lobectomy
1537417|NCT03185754|sublobar resection
1537418|NCT01873469|glioblastoma multiforme
1537419|NCT01873469|radiotherapy
1537420|NCT01866371|Retina
1537421|NCT01866371|imaging
1537422|NCT01866371|retinal degeneration
1537430|NCT01855412|PAD
1537431|NCT01855412|LIBERTY
1537432|NCT01855412|Observational
1537442|NCT01896102|Adrenoleukodystrophy
1537443|NCT01896102|X-linked adrenoleukodystrophy
1537444|NCT01896102|Gene therapy
1537445|NCT01896102|Hematopoietic stem cell
1537446|NCT01813422|Cholesterol
1537447|NCT01813422|High Cholesterol
1537448|NCT01813422|Elevated Cholesterol
1537449|NCT01813422|Raised Cholesterol
1537473|NCT01793129|NICHD Neonatal Research Network
1537474|NCT01793129|Hypoxic-ischemic encephalopathy (HIE)
1537475|NCT01793129|Hypothermia
1537476|NCT01793129|Neonatal depression
1537477|NCT01793129|Perinatal asphyxia
1537495|NCT01783795|Dent
1537496|NCT01783795|Dents
1537497|NCT01783795|Dent Disease
1537498|NCT01783795|Dent genetic testing
1537499|NCT01783795|CLCN5
1537500|NCT01783795|OCRL1
1537501|NCT01783795|Genetic testing for Dent Disease
1537502|NCT01783795|Hereditary study for Dent Disease
1537503|NCT01770418|Non Small Cell Lung Cancer
1537504|NCT01770418|Cancer
1537505|NCT01770418|Lung
1537506|NCT01770418|Proton
1537507|NCT01770418|Radiation
1537508|NCT01764633|High cholesterol
1537509|NCT01764633|Treatment for high cholesterol
1537510|NCT01764633|Lowering cholesterol
1537511|NCT01764633|Lowering high cholesterol
1537512|NCT01764633|Hypercholesterolemia
1537513|NCT01827098|Immature teeth
1537514|NCT01827098|Calcium Hydroxide
1537515|NCT01827098|Blood clot
1537516|NCT01827098|Revascularization
1537517|NCT01827098|Revitalization
1537518|NCT01765218|Hypoxic ischemic encephalopathy
1537519|NCT01765218|HIE
1537520|NCT01765218|Perinatal depression
1537521|NCT01765218|Whole body cooling
1537522|NCT01765218|Therapeutic hypothermia
1537532|NCT01758445|Breast
1537533|NCT01758445|Cancer
1537534|NCT01758445|Radiation
1537535|NCT01758445|Proton
1537541|NCT01745575|Bioequivalence
1537542|NCT01745575|Alprazolam
1537543|NCT01745575|Anxiety disorders
1537544|NCT01745575|Mexico
1537548|NCT01741454|Tolterodine
1537549|NCT01741454|Tamsulosin
1537550|NCT01741454|Ureteral Obstruction
1537551|NCT01738893|Gabapentin
1537552|NCT01738893|Bioequivalence
1537553|NCT01738893|Pharmacokinetics
1537554|NCT01738893|Mexico
1537558|NCT01730534|Phase IIIb
1537559|NCT01730534|T2DM
1537560|NCT01730534|cardiovascular events
1537585|NCT01715753|Function
1537586|NCT01715753|Muscle mass
1537587|NCT01709201|Alcohol abuse
1537588|NCT01709201|Drug abuse
1537589|NCT01709201|Diabetes Mellitus
1537590|NCT01709201|Persistent Asthma
1537591|NCT01709201|Juvenile Arthritis
1537592|NCT01709201|Ulcerative Colitis
1537593|NCT01702636|Intracerebral Hemorrhage
1537594|NCT01702636|ICH
1537595|NCT01702636|Stroke
1537596|NCT01702636|Cerebrovascular Disorders
1537597|NCT01702636|Brain Diseases
1537598|NCT01702636|Central Nervous System Diseases
1537599|NCT01702636|Nervous System Diseases
1537600|NCT01702636|Vascular Diseases
1537601|NCT01702636|Cardiovascular Diseases
1537602|NCT01702636|Tranexamic Acid
1537603|NCT01702636|Antifibrinolytic Agents
1537604|NCT01702636|Fibrin Modulating Agents
1537605|NCT01702636|Pharmacologic Actions
1537606|NCT01702636|Cardiovascular Agents
1537607|NCT01702636|Therapeutic Uses
1537608|NCT01702636|Hematologic Agents
1537609|NCT01702636|Hemostatics
1537610|NCT01702636|Contrast Media
1537611|NCT01702636|Angiography
1537612|NCT01702636|Cerebral Angiography
1537613|NCT01702636|Tomography, X-Ray Computed
1537617|NCT01720524|persistent pulmonary hypertension
1537618|NCT01720524|newborn
1537619|NCT01720524|neonates
1537620|NCT01720524|iv sildenafil
1537621|NCT01720524|hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn
1537635|NCT01702805|NICHD Neonatal Research Network
1537636|NCT01702805|Very Low Birth Weight (VLBW)
1537637|NCT01702805|Extremely Low Birth Weight (ELBW)
1537638|NCT01702805|Transfusions
1537641|NCT01670097|Advanced Cancers
1537642|NCT01670097|Hematologic Disorder
1537643|NCT01670097|Solid Tumors
1537644|NCT01670097|Dyspnea
1537645|NCT01670097|Difficulty breathing
1537646|NCT01670097|Shortness of breath
1537647|NCT01670097|Dexamethasone
1537648|NCT01670097|Decadron
1537649|NCT01670097|Placebo
1537650|NCT01670097|Sugar pill
1537651|NCT01670097|Questionnaires
1537652|NCT01670097|Surveys
1537653|NCT01670097|Spirometer
1537654|NCT01670097|Phone calls
1537655|NCT01657435|Total hip replacement
1537656|NCT01657435|Total hip arthroplasty
1537657|NCT01657435|Hip joint replacement
1537658|NCT01657435|Hip prosthesis replacement
1537662|NCT01632241|Systemic Lupus Erythematosus
1537663|NCT01632241|African Continental Ancestry Group
1537664|NCT01632241|Autoimmune Disease
1537665|NCT01632241|Antibodies
1537666|NCT01632241|Minority Groups
1537667|NCT01632241|Black Race
1537668|NCT01632241|African Americans
1537669|NCT01632241|SLE
1537670|NCT01632241|Belimumab
1537671|NCT01632241|Lupus
1537705|NCT01563042|immunogenicity
1537706|NCT01563042|GSK2434735
1537707|NCT01563042|pharmacokinetics (PK)
1537708|NCT01563042|PK
1537709|NCT01563042|biospecific antibody
1537726|NCT01544218|Alcohol related disorders
1537727|NCT01534481|NICHD Neonatal Research Network
1537728|NCT01534481|Extremely Low Birth Weight (ELBW)
1537729|NCT01534481|Prematurity
1537730|NCT01534481|Neurodevelopmental Impairment
1537731|NCT01534481|Donor Breast Milk
1537732|NCT01534481|Preterm Formula
1537740|NCT01540318|ultrasonography
1537741|NCT01540318|Abdominal Injuries
1537742|NCT01540318|Trauma
1537750|NCT01503775|intracranial
1537751|NCT01503775|ruptured
1537752|NCT01503775|non-ruptured
1537753|NCT01503775|aneurysms
1537754|NCT01503775|Intracranial ruptured or non-ruptured aneurysms
1537776|NCT01494636|Capsaicin Challenge
1537777|NCT01494636|Pharmacodynamics
1537778|NCT01494636|Safety
1537779|NCT01494636|Pharmacokinetics
1537780|NCT01494636|Oral GSK2339345
1537781|NCT01494636|Tolerability
1537782|NCT01494636|FTIH
1537783|NCT01494636|Chronic Cough
1537795|NCT01435993|Multiple Sclerosis, Secondary-Progressive with relapses
1537796|NCT01420393|Heart Failure
1537797|NCT01420393|Atrial Fibrillation
1537798|NCT01420393|Catheter Ablation
1537799|NCT01420393|Anti-arrhythmic Medications
1537800|NCT01420393|Cardiovascular Mortality
1537801|NCT01416194|Osteoporosis
1537808|NCT01388777|Breast Cancer
1537809|NCT01388777|Breast Carcinoma
1537810|NCT01388777|Cryoablation
1537811|NCT01388777|The Visica 2™ Treatment System
1537812|NCT01388777|Unifocal primary invasive ductal breast carcinoma
1537813|NCT01388777|Cryoprobe
1537819|NCT01416324|pharmacodynamics
1537820|NCT01416324|first time in human
1537821|NCT01416324|pharmacokinetics
1537831|NCT01348412|non resectable metastases
1537832|NCT01348412|liver of colic or rectal origin
1537833|NCT01348412|after failure of the conventional treatments
1537834|NCT01353313|NICHD Neonatal Research Network
1537835|NCT01353313|Extremely Low Birth Weight (ELBW)
1537836|NCT01353313|Very Low Birth Weight (VLBW)
1537837|NCT01353313|Prematurity
1537838|NCT01353313|Mechanical ventilation
1537839|NCT01353313|Intubation
1537840|NCT01353313|Neurodevelopmental impairment
1537841|NCT01424462|healthy volunteers
1537842|NCT01424462|firategrast
1537843|NCT01424462|Pharmacokinetics
1537844|NCT01424462|modified release
1537845|NCT01400685|CLL
1537846|NCT01400685|Leukemia
1537847|NCT01400685|Untreated
1537848|NCT01400685|B-CLL
1537849|NCT01400685|SLL
1537859|NCT01420237|Noninflammatory joint disease of the hip.
1537860|NCT01299168|global gene expression
1537861|NCT01299168|molecular diagnostic classifiers
1537862|NCT01302080|prospective
1537863|NCT01302080|cohort
1537864|NCT01302080|sertraline
1537865|NCT01302080|long-term impact
1537866|NCT01302080|cognition
1537867|NCT01302080|emotional and physical development
1537868|NCT01302080|pubertal maturation
1537882|NCT01265901|Metastatic Renal Cell Carcinoma
1537883|NCT01265901|First line
1537884|NCT01265901|Eligible for sunitinib
1537892|NCT01255748|cancer, proton, radiation
1537893|NCT01248390|traumatic brain injury
1537894|NCT01248390|post-concussion
1537896|NCT01208558|Blood pressure
1537897|NCT01208558|Cereals
1537898|NCT01208558|Diet Therapy
1537899|NCT01208558|Dietary carbohydrates
1537900|NCT01208558|Dietary fiber
1537901|NCT01208558|Exercise Therapy
1537902|NCT01208558|Food
1537903|NCT01208558|Glucose intolerance
1537904|NCT01208558|Lifestyle
1537905|NCT01208558|Physiotherapy
1537906|NCT01208558|Stroke
1537907|NCT01208558|TIA
1537908|NCT01208558|Waist circumference
1537909|NCT01208558|Weight loss
1537910|NCT01209039|Schizophrenia
1537911|NCT01209039|PET
1537912|NCT01187641|cancer, colon, MRI scan
1537913|NCT01179295|MEK inhibitor
1537914|NCT01179295|BAY86-9766
1537915|NCT01179295|RDEA 119
1537916|NCT01179295|Solid tumor
1537922|NCT01308515|knee
1537923|NCT01308515|osteoarthritis
1537924|NCT01308515|joint
1537925|NCT01308515|replacement
1537926|NCT01308515|knee surgery
1537935|NCT01115322|Healthy volunteer study
1537936|NCT01115322|phototoxicity
1537937|NCT01113476|Advanced Malignancies
1537938|NCT01113476|Nab-paclitaxel
1537939|NCT01113476|Gemcitabine
1537940|NCT01113476|Bevacizumab
1537941|NCT01112787|Healthy Volunteer Subjects
1537942|NCT01111019|Hypochondroplasia
1537943|NCT01111019|Skeletal dysplasia
1537944|NCT01111019|Growth
1537945|NCT01111019|Growth Hormone
1537946|NCT01111019|Recombinant-human Growth Hormone
1537947|NCT01110694|Idiopathic pulmonary fibrosis
1537948|NCT01110694|Interstitial lung disease
1537949|NCT01110694|Prognosis
1537950|NCT01110694|Biomarkers
1537951|NCT01110694|Mortality
1537952|NCT01110694|Acute exacerbations
1537963|NCT01102088|Cancer
1537964|NCT01102088|Gastroesophageal
1537965|NCT01102088|Simultaneous Integrated Boost
1537966|NCT01102088|SIB
1537967|NCT01102088|5-Fluorouracil
1537968|NCT01102088|5-FU
1537969|NCT01102088|Adrucil
1537970|NCT01102088|Efudex
1537971|NCT01102088|Docetaxel
1537972|NCT01102088|Taxotere
1537973|NCT01102088|Radiation
1537974|NCT01102088|chemoradiation
1537975|NCT01097395|ribavirin
1537976|NCT01097395|pharmacokinetics
1537977|NCT01097395|Hepatitis C virus
1537978|NCT01094353|Urodynamic Stress urinary incontinence
1537979|NCT01094353|Minisling
1537980|NCT01094353|Ophira™
1537981|NCT01094353|Unitape™
1538004|NCT01058239|bortezomib
1538005|NCT01058239|rituximab
1538006|NCT01058239|PTLD
1538007|NCT01058239|EBV
1538008|NCT01058239|transplantation
1538016|NCT01039974|ketoconazole
1538017|NCT01039974|GSK962040
1538018|NCT01039974|Drug-Drug Interaction
1538019|NCT01039974|Phase I
1538026|NCT01014962|Pharmacokinetic
1538027|NCT01014962|tolerability
1538028|NCT01014962|multiple escalating doses
1538030|NCT01030939|Healthy volunteers
1538031|NCT01030939|Men and women
1538032|NCT01030939|adults and elderly
1538033|NCT01030939|repeat dose
1538034|NCT01013766|GSK1362885
1538035|NCT01013766|Pharmacodynamics
1538036|NCT01013766|Safety
1538037|NCT01013766|Pharmacokinetics
1538038|NCT01013766|T2DM
1538039|NCT01013766|Tolerability
1538051|NCT00976105|Pharmacokinetics
1538052|NCT00976105|Pharmacodynamics
1538053|NCT00976105|Safety and tolerability
1538054|NCT00976105|Repeat dose
1538055|NCT00976105|Personality traits
1538056|NCT00976105|Fat mass
1538057|NCT00976105|Healthy volunteers
1538058|NCT00976066|Obesity
1538059|NCT00976066|Naltrexone
1538060|NCT00976066|Carfentanil
1538061|NCT00976066|Receptor Occupancy
1538062|NCT00976066|mu-opioid Receptor
1538063|NCT00976066|PET (Positron Emission Tomography)
1538064|NCT00976066|BOLD-fMRI
1538065|NCT00974987|adult giant cell glioblastoma
1538066|NCT00974987|adult glioblastoma
1538067|NCT00974987|adult gliosarcoma
1538068|NCT00983593|Mind Body Bridging
1538069|NCT00983593|Domestic Violence Offender Treatment
1538070|NCT00983593|Batterer Treatment
1538072|NCT00964106|inducer
1538073|NCT00964106|midazolam
1538074|NCT00964106|inhibitor
1538075|NCT00964106|rosiglitazone
1538076|NCT00964106|dextromethorphan
1538077|NCT00964106|caffeine
1538078|NCT00964106|cocktail
1538079|NCT00964106|pioglitazone
1538080|NCT00964106|omeprazole
1538081|NCT00964106|CYP
1538082|NCT00964106|rosuvastatin
1538083|NCT00964106|probe drug
1538084|NCT00964106|drug interaction
1538085|NCT00964106|flurbiprofen
1538186|NCT00858598|Total Knee Arthroplasty
1538187|NCT00858598|Revision
1538188|NCT00858598|Tibial
1538189|NCT00858598|Void
1538190|NCT00858598|Bone Filler
1538191|NCT00859157|perioperative/postoperative complications
1538192|NCT00859157|pain
1538193|NCT00859157|ductal breast carcinoma in situ
1538194|NCT00859157|invasive ductal breast carcinoma
1538195|NCT00859157|invasive lobular breast carcinoma
1538196|NCT00859157|stage IA breast cancer
1538197|NCT00859157|stage IB breast cancer
1538198|NCT00859157|stage II breast cancer
1538199|NCT00859157|stage IIIA breast cancer
1538200|NCT00859157|stage IIIB breast cancer
1538213|NCT00828867|healthy subjects
1538214|NCT00828867|FTIH, single dose, food effect, healthy subjects, double-blind
1538239|NCT00754637|Joint
1538240|NCT00754637|Osteoarthritis
1538241|NCT00754637|Avascular Necrosis
1538257|NCT00716573|Cardiac transplantation
1538258|NCT00716573|Chronic renal insufficiency
1538259|NCT00716573|Everolimus
1538260|NCT00699088|Total Hip Arthroplasty
1538261|NCT00699088|Total Hip Replacement
1538262|NCT00699088|Minimally Invasive
1538263|NCT00699088|Microplasty
1538264|NCT00699257|Partial Knee Arthroplasty
1538265|NCT00699257|Partial Knee Replacement
1538266|NCT00699257|Arthritis of Medial Compartment of the Knee
1538267|NCT00699257|Oxford Knee
1538268|NCT00699309|Total Hip Replacement
1538269|NCT00699309|Total Hip Arthroplasty
1538270|NCT00699309|Minimally Invasive
1538271|NCT00699309|Microplasty
1538272|NCT00699309|Hip Arthritis
1538273|NCT00698750|Fractured Humeral Head
1538274|NCT00698750|Traumatic Arthritis
1538275|NCT00698750|Resurfacing Shoulder
1538276|NCT00698750|Shoulder Replacement
1538277|NCT00698750|Shoulder Arthritis
1538278|NCT00698633|Hip arthroplasty
1538279|NCT00698503|Metal on Metal
1538280|NCT00698503|Total Hip Arthroplasty
1538281|NCT00698503|Total Hip Replacement
1538282|NCT00698347|Total Knee Replacement
1538283|NCT00698347|Total Knee Arthroplasty
1538284|NCT00698347|Hip Arthritis
1538285|NCT00699270|Total Shoulder Arthroplasty
1538286|NCT00699270|Total Shoulder Replacement
1538287|NCT00699270|Shoulder Arthritis
1538298|NCT00622219|Alcohol abuse
1538299|NCT00622219|Drug abuse
1538301|NCT00584272|cleft palate
1538302|NCT00584272|suture materials
1538303|NCT00586170|nonunion
1538304|NCT00586170|fracture
1538305|NCT00580255|CHF
1538306|NCT00580255|CRT
1538307|NCT00580255|Atrial Arrhythmias
1538308|NCT00580255|Ventricular Arrhythmias
1538309|NCT00580255|BioZ
1538310|NCT00580255|Optivol
1538311|NCT00578851|Hip Arthroplasty
1538312|NCT00578851|Hip Arthritis
1538313|NCT00575198|Chest tubes
1538314|NCT00575198|Trauma
1538317|NCT00533234|Elbow fracture
1538318|NCT00533234|Elbow dislocation
1538319|NCT00533234|Radial head fracture
1538320|NCT00533234|Radial neck fracture
1538321|NCT00519272|Cervical Cancer
1538322|NCT00519272|Cervix
1538323|NCT00519272|Precancerous Lesions
1538324|NCT00519272|Cervical carcinoma in situ
1538325|NCT00519272|CIS
1538326|NCT00519272|Early cervical cancer detection and treatment
1538327|NCT00519272|Barriers to Care
1538328|NCT00519272|Harris County
1538329|NCT00519272|Questionnaire
1538330|NCT00504790|GSK923295,
1538331|NCT00504790|First Time in Human,
1538332|NCT00504790|pharmacodynamics
1538333|NCT00504790|cancer,
1538334|NCT00504790|maximally tolerated dose, pharmacokinetics,
1538335|NCT00504790|Refractory Cancer
1538336|NCT00504790|CENPE,
1538337|NCT00504790|Phase I,
1538338|NCT00500734|Cardiomyopathy
1538339|NCT00500734|Tissue Bank
1538340|NCT00500734|Heart Disease
1538341|NCT00500734|Heart Failure
1538342|NCT00500734|Congestive Heart Failure
1538367|NCT00438113|blood pressure
1538368|NCT00438113|atrial fibrillation
1538369|NCT00438113|catheter ablation
1538370|NCT00412477|HIV
1538371|NCT00412477|Lfn-p24
1538372|NCT00412477|Anthrax
1538373|NCT00412477|IM
1538374|NCT00412477|HIV-1
1538375|NCT00412477|HIV Preventive Vaccine
1538376|NCT00411801|bleeding disorder
1538377|NCT00411801|universal plasma
1538378|NCT00411801|plasma
1538379|NCT00411801|plasma exchange
1538391|NCT00349726|NICHD Neonatal Research Network
1538392|NCT00349726|Pharmacokinetics
1538393|NCT00349726|Inositol
1538394|NCT00349726|Very Low Birth Weight (VLBW)
1538395|NCT00349726|Extremely Low Birth Weight (ELBW)
1538396|NCT00349726|Prematurity
1538405|NCT00306605|Emotional experiences
1538406|NCT00306605|fathers
1538407|NCT00306605|stress
1538408|NCT00306605|depressive symptomatology
1538409|NCT00306605|NICU
1538410|NCT00306605|preterm birth
1538413|NCT00214617|hypercholesterolemia
1538414|NCT00214617|HMG CoA Reductase Inhibtors
1538415|NCT00214617|tracer kinetics
1538416|NCT00214617|Apolipoproteins
1538417|NCT00130533|TNBC Triple-Negative Early Breast Cancer
1538418|NCT00130533|Maintenance Adjuvant Chemotherapy
1538419|NCT00130533|Capecitabine
1538420|NCT00130533|Basal-like genotype
1538496|NCT00020670|recurrent childhood acute lymphoblastic leukemia
1538497|NCT00020670|recurrent adult acute lymphoblastic leukemia
1538498|NCT00020670|B-cell childhood acute lymphoblastic leukemia
1538499|NCT00020670|B-cell adult acute lymphoblastic leukemia
1538507|NCT00009633|NICHD Neonatal Research Network
1538508|NCT00009633|Extremely Low Birth Weight (ELBW)
1538509|NCT00009633|Prematurity
1538510|NCT00009633|Neurodevelopmental Outcome
1538511|NCT00009633|Follow up studies
1538589|NCT03196427|Drug therapy
1538590|NCT03194646|Uterine Fibroid
1538594|NCT03196388|ENZALUTAMIDE
1538595|NCT03196388|External Beam Hypofractionated Radiotherapy Intermediate Risk Prostate Cancer
1538596|NCT03196375|Motor Neuron Disease
1538597|NCT03196375|Neurodegenerative Diseases
1538598|NCT03196375|Nervous System Diseases
1538599|NCT03196375|Neuromuscular Diseases
1538600|NCT03196375|Amyotrophic Lateral Sclerosis
1538601|NCT03196375|Primary Lateral Sclerosis
1538602|NCT03196375|Progressive Muscular Atrophy
1538603|NCT03196375|Muscle cramps
1538604|NCT03196375|Muscle cramping
1538605|NCT03196375|ALS
1538606|NCT03196375|MND
1538607|NCT03196375|PMA
1538608|NCT03196375|PLS
1538609|NCT03196375|FLX-787
1538610|NCT03196362|short-term intensive insulin therapy
1538611|NCT03196362|pioglitazone
1538612|NCT03196362|metformin
1538613|NCT03196362|remission
1538614|NCT03196362|sequential therapy
1538615|NCT03194893|Non−small cell lung cancer (NSCLC)
1538616|NCT03194893|Anaplastic lymphoma kinase (ALK)
1538617|NCT03194893|Rearranged during transfection (RET)
1538618|NCT03194893|Alectinib
1538619|NCT03194893|Crizotinib
1538620|NCT03196466|antiepileptics
1538621|NCT03196466|pharmacokinetics
1538622|NCT03196466|children
1538632|NCT03195231|Parkinson`s disease
1538633|NCT03195231|Depression
1538634|NCT03195231|Wuling Powder
1538641|NCT03196102|tobacco prevention; tobacco intervention; military; brief intervention
1538642|NCT03196063|Exercise Therapy
1538643|NCT03196063|Heavy Slow Resistance Program
1538644|NCT03196063|Rehabilitation
1538645|NCT03196024|Diabetes; CVD; Lifestyle; Hispanic; Promotora
1538646|NCT03196024|Diabetes Mellitus, Type 2
1538647|NCT03196024|Cardiovascular Diseases
1538648|NCT03196024|Risk Reduction Behavior
1538649|NCT03196024|Hispanic Americans; Latinos
1538650|NCT03196024|Community Health Workers
1538660|NCT03196440|eldery
1538661|NCT03196440|taste
1538662|NCT03196440|thresholds
1538663|NCT03195660|adaptive servo-ventilation
1538664|NCT03195660|ASV
1538665|NCT03195660|HFpEF
1538666|NCT03195673|Carotid artery stenting
1538667|NCT03195673|Silent embolism
1538668|NCT03195673|Terazosin
1538670|NCT03194919|online intervention
1538671|NCT03194919|e-Health
1538672|NCT03194919|negotiating quit date
1538673|NCT03194529|Crohn's Disease
1538674|NCT03194529|PCDAI
1538675|NCT03194529|16s rRNA
1538676|NCT03194529|Fecal Microbiota Transplantation
1538677|NCT03194529|Gut Microbiome
1538678|NCT03194529|FMT
1538679|NCT03194477|HIV young Black men who have sex with men substance use
1538680|NCT03193671|HE4, CA125, RMI, ROMA
1538687|NCT03193658|spine surgery
1538688|NCT03193658|Thoracolumbar Interfascial Plane block
1538689|NCT03193658|regional anesthesia
1538690|NCT03193658|postoperative analgesia
1538691|NCT03193658|opioid consumption
1538692|NCT03194776|PAD
1538693|NCT03194776|peripheral artery/arterial disease
1538694|NCT03194776|peripheral vascular disease
1538695|NCT03194776|leg pain
1538696|NCT03194776|claudication
1538697|NCT03194776|leg pain with exercise
1538698|NCT03194776|exercise test
1538699|NCT03194776|walk test
1538700|NCT03196154|Homeostasis Model Assessment
1538701|NCT03196154|Insulin Resistance
1538702|NCT03196154|Beta Cell Function
1538703|NCT03196154|Liquid Chromatography Tandem Mass Spectrometry
1538708|NCT03193749|Chagas disease, cardiomyopathy, amiodarone, clinical trial
1538709|NCT03194139|Healthy Adult
1538710|NCT03194139|Superoxide Dismutase
1538711|NCT03194139|First in Human
1538712|NCT03194139|Free Radical Dismutase
1538713|NCT03195270|Positron emission tomography
1538714|NCT03195270|Magnetic Resonance Imaging
1538715|NCT03195270|PET/MRI
1538716|NCT03195270|Fluorodeoxyglucose
1538717|NCT03195270|FDG
1538718|NCT03195270|Pain
1538719|NCT03195270|Chronic Pain
1538720|NCT03195270|Neuropathic Pain
1538721|NCT03195270|Inflammatory Pain
1538722|NCT03195270|Nociceptive Pain
1538723|NCT03193723|Hernia
1538724|NCT03193723|Local anesthesia
1538725|NCT03193723|ultrasound
1538726|NCT03193762|pain
1538727|NCT03193762|pain management
1538728|NCT03193762|anxiety
1538729|NCT03193632|lean body mass
1538730|NCT03193632|resting energy expenditure
1538731|NCT03193632|oxygen consumption
1538732|NCT03193632|Indirect calorimetry
1538733|NCT03193632|carbon dioxide excretion
1538734|NCT03193632|respiratory quotient
1538735|NCT03195413|Hand blast injury
1538736|NCT03195413|Nerve block
1538737|NCT03195413|Hand injury
1538738|NCT03195413|Forearm nerve block
1538739|NCT03195413|Ultrasound guided nerve block
1538740|NCT03195413|Ultrasound nerve block
1538741|NCT03195413|Emergency department
1538742|NCT03195413|Emergency physician
1538743|NCT03195413|Emergency room
1538744|NCT03194412|Frail Elderly
1538745|NCT03194412|Geriatric Assessment
1538746|NCT03194412|Humans
1538747|NCT03194412|Aged
1538748|NCT03194698|Intense Pulsed Light
1538749|NCT03194074|Laser Laryngeal Surgery
1538750|NCT03194074|Desflurane
1538751|NCT03194074|Propofol
1538752|NCT03194997|Breast Cancer
1538753|NCT03194997|Quality of life
1538754|NCT03194997|Lymphedema
1538755|NCT03194997|Fatigue
1538756|NCT03194997|Depressive symptoms
1538757|NCT03194997|Body image
1538758|NCT03194997|Self Esteem
1538759|NCT03194997|Optimism
1538760|NCT03194997|Sexual function
1538761|NCT03194997|Stress
1538762|NCT03194997|Sleep quality
1538763|NCT03194997|Pain
1538764|NCT03194997|Muscular strength
1538765|NCT03194997|Postural
1538766|NCT03194997|Balance
1538767|NCT03194997|Range of motion
1538768|NCT03194997|Cardiorespiratory fitness
1538779|NCT03191695|Participation
1538780|NCT03191695|Activity
1538781|NCT03191695|Cerebral Palsy
1538782|NCT03191695|LIFE Habits (life-H)
1538783|NCT03191695|Gross Motor Function
1538784|NCT03191695|Health-related Quality of Life
1538785|NCT03191695|Family
1538795|NCT03195127|Physical Therapy Modalities
1538796|NCT03195127|Rehabilitation
1538797|NCT03195127|Exercise Therapy
1538798|NCT03195127|Critical Illness
1538799|NCT03195127|Respiration, Artificial
1538800|NCT03195127|Chronic Disease
1538801|NCT03194035|inflammation
1538802|NCT03194035|exercise
1538803|NCT03194035|ultra endurance
1538804|NCT03193216|Barrett's
1538805|NCT03193216|GERD
1538806|NCT03193216|reflux
1538807|NCT03193216|alginate solution
1538808|NCT03193216|proton pump inhibitor
1538820|NCT03195036|HIV-exposed
1538821|NCT03195036|Early Childhood Development
1538822|NCT03195036|Cameroon
1538823|NCT03194542|Luspatercept
1538824|NCT03194542|ACE-536
1538825|NCT03194542|Myeloproliferative Neoplasm-Associated Myelofibrosis
1538826|NCT03194542|Primary Myelofibrosis
1538827|NCT03194542|Post-Polycythemia Vera Myelofibrosis
1538828|NCT03194542|Post-Essential Thrombocythemia
1538829|NCT03194542|Anemia
1538830|NCT03194542|Red Blood Cell (RBC) Transfusion
1538831|NCT03194542|Ruxolitinib
1538832|NCT03192176|Menopause
1538833|NCT03192176|Hot flashes
1538834|NCT03192176|Perimenopause
1538835|NCT03192176|Vasomotor symptoms
1538841|NCT03194438|Pulmonary Hypertension
1538842|NCT03194438|Symptom Management
1538843|NCT03194438|Behavioral Intervention
1538844|NCT03194438|Integrative Therapy
1538845|NCT03194438|Quality of Life
1538846|NCT03191383|Maternal immunization
1538847|NCT03191383|Immunogenicity
1538848|NCT03191383|Vaccines
1538849|NCT03191383|Safety
1538850|NCT03191383|Reactogenicity
1538851|NCT03191383|Respiratory Syncytial Virus
1538854|NCT03194334|vegetarianism
1538855|NCT03194334|creatine
1538856|NCT03194334|carnosine
1538857|NCT03194334|carnitine
1538861|NCT03189420|glioma
1538862|NCT03189420|glioblastoma
1538863|NCT03189420|low grade tumor
1538877|NCT03191942|Myopia control
1538878|NCT03191942|Orthokeratology
1538879|NCT03191942|Children
1538880|NCT03191942|Treatment zone
1538883|NCT03195816|Mild Cognitive Impairment
1538884|NCT03195816|white matter hyperintensities
1538885|NCT03195816|computerized cognitive training
1538886|NCT03195816|brain plasticity
1538887|NCT03194165|antiretroviral
1538888|NCT03194165|children
1538889|NCT03194165|pharmacokinetics
1538891|NCT03196258|fracture
1538892|NCT03196258|persistent pain
1538893|NCT03196258|cognitive behavioural therapy
1538894|NCT03196258|post surgical pain
1538895|NCT03196258|health-related quality of life
1538907|NCT03195244|aquatic therapy, hydrotherapy
1538908|NCT03195829|Mild Cognitive Impairment
1538909|NCT03195829|Computerized Cognitive Stimulation
1538910|NCT03195829|Cognition
1538911|NCT03195829|Psychosocial factors
1538912|NCT03188744|Cervical cancer
1538913|NCT03188744|Pelvic floor muscles
1538914|NCT03188744|Physiotherapy
1538915|NCT03188744|Quality of life
1538916|NCT03191747|Masculine Norms
1538917|NCT03191747|Skin Care
1538918|NCT03191747|Gender
1538923|NCT03191578|NMIBC
1538924|NCT03191578|Immunotherapy
1538925|NCT03191578|RUTI
1538926|NCT03191578|Non-muscle invasive bladder cancer
1538927|NCT03195972|Adherence, Patient, oncology, oral therapy
1538928|NCT03185013|Cervical intraepithelial neoplasia (CIN)
1538929|NCT03185013|Human papillomavirus (HPV)
1538930|NCT03185013|High grade squamous intraepithelial lesion (HSIL)
1538931|NCT03185013|CIN 2
1538932|NCT03185013|CIN 3
1538933|NCT03185013|papillomavirus
1538934|NCT03183401|childhood cancer survivor
1538939|NCT03182725|POTS
1538940|NCT03182725|tachycardia
1538941|NCT03182725|ivabradine
1538946|NCT03182790|Smoking Cessation
1538947|NCT03182790|Quit to Win
1538948|NCT03182790|Brief intervention
1538949|NCT03182790|Semi-personalized Instant messaging
1538950|NCT03182790|Incentives
1538951|NCT03182790|AWARD model
1538952|NCT03182790|Smoking Cessation Intervention
1538953|NCT03182790|Regular messages
1538986|NCT03193164|Electric Stimulation Therapy; Endothelial Progenitor Cells.
1539001|NCT03173937|Haploidentical
1539002|NCT03173937|Nonmyeloablative
1539020|NCT03177616|Migraine
1539021|NCT03177616|Women
1539022|NCT03177616|Adult
1539023|NCT03177616|Feasibility
1539024|NCT03177616|Safety
1539025|NCT03177616|Pilot Randomized Trial
1539026|NCT03177616|Randomized Control Trial
1539027|NCT03177616|Chiropractic
1539028|NCT03194087|Secondary Hyperparathyroidism
1539029|NCT03194087|Low parathyroid hormone
1539030|NCT03194087|Hemodialysis
1539031|NCT03174002|Oxygenation
1539032|NCT03174002|Acute Respiratory Distress Syndrome
1539033|NCT03174002|Mechanical ventilation
1539034|NCT03174002|Critical illness
1539035|NCT03174002|Critical care
1539036|NCT03184337|Weight loss
1539037|NCT03184337|Women
1539038|NCT03184337|Sleep
1539039|NCT03184337|Intervention
1539040|NCT03184337|Diet
1539041|NCT03184337|Physical activity
1539042|NCT03184337|Fitbit
1539048|NCT03194243|acute dyspnea
1539049|NCT03194243|acute heart failure
1539050|NCT03194243|emergency
1539056|NCT03193775|HBV vaccine
1539057|NCT03193775|persistent
1539058|NCT03193775|HBsAg
1539059|NCT03193775|IP-10
1539060|NCT03169153|contact lenses
1539061|NCT03169153|lipids
1539062|NCT03169153|deposits
1539063|NCT03171987|lidocaine patch
1539064|NCT03171987|flurbiprofen patch
1539065|NCT03171987|acute back pain
1539073|NCT03166215|Drug therapy
1539079|NCT03164395|atrial fibrillation
1539080|NCT03164395|implantable cardiac defibrillator
1539081|NCT03164395|cardioversion
1539109|NCT03194425|Sacral neuromodulation
1539110|NCT03194425|Electromyography
1539111|NCT03194425|Pelvic floor
1539112|NCT03144778|Malignant Neoplasms of Oropharynx
1539113|NCT03144778|CD8+ tumor infiltrating lymphocytes
1539114|NCT03144778|Biomarkers
1539115|NCT03144778|Durvalumab
1539116|NCT03144778|MEDI4736
1539117|NCT03144778|Tremelimumab
1539118|NCT03144778|Ticilimumab
1539119|NCT03144778|CP-675,206
1539120|NCT03148626|mindfulness curriculum
1539121|NCT03194685|Acute Myeloid Leukemia
1539122|NCT03156946|breastfeeding
1539123|NCT03156946|mother-to-mother support
1539124|NCT03156946|lactation consultant
1539125|NCT03156946|stepped wedge cluster randomized trial
1539126|NCT03156946|peer counseling
1539134|NCT03140072|Asthma, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), AZD9898
1539135|NCT03135509|Healthy Subjects
1539136|NCT03135509|CC-220 Capsules
1539137|NCT03135509|Relative Bioavailability
1539138|NCT03135509|Phase 1
1539140|NCT03134573|Relapsing Remitting Multiple Sclerosis (RRMS),
1539141|NCT03134573|Clinically isolated Syndrome (CIS),
1539142|NCT03134573|Secondary Progressive Multiple Sclerosis (SPMS)
1539146|NCT03138369|Obesity
1539147|NCT03138369|Metabolic Syndrome
1539148|NCT03138369|Prediabetes
1539149|NCT03138369|Glycemic control
1539150|NCT03138369|Hypercholesterolemia
1539151|NCT03138369|Abdominal obesity
1539152|NCT03138369|Weight Loss
1539153|NCT03194061|chemotherapy
1539154|NCT03194061|complication
1539160|NCT03126695|Abnormal hemoglobin (called hemoglobin S or sickle hemoglobin) in the red blood cells
1539161|NCT03126695|Thrombotic cardiovascular events
1539162|NCT03126695|Acute coronary syndrome
1539163|NCT03126695|P2Y12 platelet inhibitor
1539164|NCT03126695|Brilinta
1539165|NCT03153917|shift work
1539166|NCT03153917|melatonin
1539167|NCT03153917|sleep
1539168|NCT03138655|Drug therapy
1539196|NCT03119077|PCOS
1539207|NCT03114969|Overall error
1539208|NCT03114969|Error rate
1539209|NCT03114969|Critical error
1539210|NCT03114969|COPD
1539211|NCT03114969|ELLIPTA
1539212|NCT03114969|Dry powder inhaler
1539213|NCT03168802|Focused ultrasound Ablation
1539214|NCT03168802|Radiofrequency Ablation
1539215|NCT03168802|Facet joint syndrome
1539216|NCT03168802|Chronic low back pain
1539223|NCT03119402|Reading
1539224|NCT03119402|Developmental Dyslexia
1539225|NCT03119402|Music
1539226|NCT03119402|Rhythm
1539227|NCT03119402|transcranial electrical stimulation
1539228|NCT03119402|transcranial direct current stimulation
1539233|NCT03122548|stomach cancer
1539234|NCT03122548|gastric cancer
1539235|NCT03122548|esophageal cancer
1539236|NCT03122548|digestive system diseases
1539237|NCT03122548|gastrointestinal diseases
1539238|NCT03122548|stomach diseases
1539239|NCT03133728|EID HIV
1539240|NCT03133728|Early Infant Diagnosis
1539241|NCT03133728|Point of Care
1539242|NCT03133728|Infant
1539243|NCT03133728|HIV
1539244|NCT03113890|pharmacogenetic testing
1539245|NCT03113890|genomic
1539246|NCT03113890|assay
1539247|NCT03113890|PTSD
1539248|NCT03113890|pharmacodynamic
1539249|NCT03113890|pharmacokinetic
1539250|NCT03113890|psychiatric disorders
1539252|NCT03105115|fentanyl
1539253|NCT03105115|dexmedetomidine
1539265|NCT03194386|Post-Traumatic Syndrome
1539266|NCT03194386|Eye-Movement Desensitization and Reprocessing
1539270|NCT03099759|Vitamin D Dosing Regimens
1539271|NCT03099759|Blood Serum 25(OH)D3 Levels
1539272|NCT03104387|Air pollution
1539273|NCT03104387|Diesel exhaust
1539274|NCT03104387|Ultrafine particles
1539275|NCT03104387|Vascular function
1539276|NCT03104387|Endothelium function
1539277|NCT03104387|Heart rate variability
1539278|NCT03104387|DNA damage
1539285|NCT03092518|Surgical Resection
1539286|NCT03092518|Progression Free Survival
1539287|NCT03092518|Gastroesophageal Junction (Siewert III) Adenocarcinoma
1539292|NCT03089879|Immunogenicity, Vaccine
1539293|NCT03089879|Immunologic Memory
1539294|NCT03089879|GMMA
1539295|NCT03089879|Shigella Vaccines
1539296|NCT03089879|Shigellosis
1539297|NCT03089879|Dysentery, Bacillary
1539298|NCT03089879|Healthy Volunteers
1539299|NCT03089879|Safety
1539300|NCT03089879|Bacteria
1539301|NCT03089879|Clinical Trials, Phase 1
1539302|NCT03089879|Shigella sonnei
1539324|NCT03081494|PDR001
1539325|NCT03081494|immunotherapy
1539326|NCT03081494|regorafenib
1539327|NCT03081494|CRC
1539328|NCT03081494|MMS
1539329|NCT03081494|CMS4
1539330|NCT03081494|ElevatION:CRC-102
1539331|NCT03082131|Gut Microbiota
1539332|NCT03082131|Glycemic Response
1539333|NCT03082131|Resistant Starch
1539334|NCT03082131|Fiber
1539335|NCT03089593|Thermic Effect of Food
1539336|NCT03089593|Energy Expenditure
1539337|NCT03089593|Ginger
1539338|NCT03097380|Healthy volunteer study
1539339|NCT03072160|Anti-PD1/PDL1
1539340|NCT03072160|Vaccine Therapy
1539341|NCT03072160|TKI-Naive
1539342|NCT03078075|Methamphetamine
1539343|NCT03078075|Methamphetamine Use Disorder
1539344|NCT03078075|Naltrexone
1539345|NCT03078075|Bupropion
1539346|NCT03078075|Vivitrol®
1539353|NCT03069989|Tolerability
1539354|NCT03069989|IPF
1539355|NCT03069989|PET imaging
1539356|NCT03069989|Idiopathic Pulmonary Fibrosis
1539357|NCT03069989|Safety
1539358|NCT03069989|Pharmacokinetics
1539359|NCT03069989|Double-blind
1539367|NCT03066778|Extensive stage small cell lung cancer (ES-SCLC)
1539368|NCT03066778|Programmed cell death protein-1 (PD-1)
1539369|NCT03066778|Programmed cell death-ligand 1 (PD-L1)
1539370|NCT03066778|PD1
1539371|NCT03066778|PDL1
1539372|NCT03066492|Tertiary Care Center
1539373|NCT03066492|Patient Readmission
1539374|NCT03066492|Health Services Research
1539375|NCT03066492|Hospital Readmissions
1539378|NCT03062358|Programmed Cell Death Receptor 1 (PD-1)
1539379|NCT03062358|Programmed Cell Death Receptor Ligand 1 (PD-L1)
1539380|NCT03062358|Programmed Cell Death Receptor Ligand 2 (PD-L2)
1539381|NCT03062358|PD1
1539382|NCT03062358|PD-1
1539383|NCT03062358|PDL1
1539384|NCT03062358|PD-L1
1539385|NCT03062358|PDL2
1539386|NCT03070899|Uterine Fibroid
1539387|NCT03070899|Leiomyomata
1539388|NCT03070899|Heavy Menstrual Bleeding
1539389|NCT03070899|HMB
1539390|NCT03070899|Heavy Uterine Bleeding
1539391|NCT03070899|Menorrhagia
1539392|NCT03070899|OBE2109 + Add-back
1539424|NCT03052894|anesthesiology
1539425|NCT03052894|neuromuscular blockade
1539426|NCT03052894|monitoring device
1539427|NCT03050346|Magnetic Resonance Imaging
1539428|NCT03050346|Coronary Artery Disease
1539429|NCT03050346|Apnea
1539430|NCT03050346|Hyperventilation
1539431|NCT03050346|BOLD
1539432|NCT03050346|Breathing Maneuvers
1539433|NCT03050346|Myocardial Oxygenation
1539434|NCT03048435|Cervical Cancer
1539435|NCT03048435|Patient Reported Outcomes
1539436|NCT03048435|Radiation Therapy
1539437|NCT03048435|EORTC QLQ-CX24
1539438|NCT03048435|Quality of Life
1539444|NCT03043222|prostate artery embolization
1539445|NCT03043222|Prostatic Urethral Lift, Urolift
1539446|NCT03043222|Minimally invasive
1539447|NCT03043222|non-surgical
1539448|NCT03043222|maintenance of sexual function
1539449|NCT03043222|complications of TURP , surgery
1539450|NCT03040999|Head and Neck Squamous Cell Carcinoma
1539451|NCT03040999|Programmed Cell Death Receptor 1 (PD-1)
1539452|NCT03040999|Programmed Cell Death Receptor Ligand 1 (PD-L1)
1539453|NCT03040999|Programmed Cell Death Receptor Ligand 2 (PD-L2)
1539454|NCT03040999|PD1
1539455|NCT03040999|PD-1
1539456|NCT03040999|PDL1
1539457|NCT03040999|PD-L1
1539458|NCT03040999|PDL2
1539467|NCT03039673|interleukin-2
1539468|NCT03039673|low-dose interleukin-2
1539473|NCT03036488|PD1
1539474|NCT03036488|PD-1
1539475|NCT03036488|PDL1
1539476|NCT03036488|PD-L1
1539489|NCT03037645|CLL
1539490|NCT03037645|Hematological diseases
1539491|NCT03037645|Relapsed
1539492|NCT03037645|cancer
1539493|NCT03037645|malignancy
1539494|NCT03037645|SNS-062
1539495|NCT03037645|B-lymphoid
1539496|NCT03037645|Chronic lymphocytic leukemia
1539497|NCT03037645|Small lymphocytic lymphoma
1539498|NCT03037645|Lymphoplasmacytoid lymphoma
1539499|NCT03037645|Waldenström's macrogloulinemia
1539500|NCT03037645|Mantle cell lymphoma
1539501|NCT03037645|SLL
1539502|NCT03037645|LPL
1539503|NCT03037645|WM
1539504|NCT03037645|MCL
1539505|NCT03037645|Refractory
1539507|NCT03186963|distal radius fracture
1539508|NCT03186963|volar plate
1539509|NCT03186963|immobilization
1539515|NCT03029728|Hereditary and acquired C1-inhibitor deficiency
1539516|NCT03029728|C1 esterase inhibitor, hereditary angioedema,
1539517|NCT03039855|Mitral
1539518|NCT03039855|Regurgitation
1539519|NCT03039855|Heart valve
1539520|NCT03039855|Transcatheter
1539521|NCT03039855|Transapical
1539522|NCT03039855|Functional
1539523|NCT03039855|Degenerative
1539524|NCT03039855|TMVR
1539528|NCT03021928|Stroke
1539529|NCT03021928|Atrial Fibrillation
1539530|NCT03021928|Anticoagulation
1539531|NCT03021928|NOAC
1539532|NCT03019588|PD1
1539533|NCT03019588|PD-1
1539534|NCT03019588|PDL1
1539535|NCT03019588|PD-L1
1539536|NCT03010163|pedometer
1539537|NCT03010163|walking
1539538|NCT03010163|taxi driver
1539539|NCT03010163|16-1659
1539541|NCT03004053|Reflectance Confocal Microscopy
1539542|NCT03004053|Normal Oral Tissue
1539543|NCT03004053|16-1652
1539545|NCT02999113|non-technical skills
1539546|NCT02999113|patient safety
1539547|NCT02999113|medical education
1539575|NCT02991430|migraine headache, episodic
1539588|NCT02982941|Neuroblastoma
1539589|NCT02982941|Rhabdomyosarcoma
1539590|NCT02982941|Osteosarcoma
1539591|NCT02982941|Ewing Sarcoma
1539592|NCT02982941|Wilms Tumor
1539593|NCT02982941|Desmoplastic Small Round Cell Tumor
1539594|NCT02982941|pediatric
1539595|NCT02980874|RVO
1539596|NCT02980874|ME
1539597|NCT02980874|Central Subfield Thickness
1539598|NCT02980874|OCT
1539599|NCT02980874|Optical Coherence Tomography
1539600|NCT02980874|Cystoid Macular Edema
1539601|NCT02980874|Subretinal Fluid
1539602|NCT02980874|Eylea
1539603|NCT02980874|Aflibercept
1539604|NCT02980874|Anti-VEGF
1539605|NCT02980874|Suprachoroidal
1539626|NCT02974582|Marketing
1539627|NCT02974582|Smoking
1539628|NCT02974582|Cigarette
1539629|NCT02974582|Young Adult
1539630|NCT02974582|Socioeconomic Status
1539631|NCT02972359|Neridronic Acid
1539632|NCT02972359|Neridronate
1539633|NCT02972359|CRPS
1539634|NCT02972359|RSD (reflex sympathetic dystrophy)
1539636|NCT02967692|PDR001
1539637|NCT02967692|dabrafenib
1539638|NCT02967692|trametinib
1539639|NCT02967692|melanoma
1539640|NCT02967692|immunotherapy
1539641|NCT02967692|PD 1 inhibitor
1539642|NCT02967692|anti PD1
1539643|NCT02967692|PD-1
1539644|NCT02967692|anti-PD-1
1539645|NCT02967692|combination treatment
1539646|NCT02967692|malignant skin cancer
1539647|NCT02967692|skin cancer
1539648|NCT02967692|BRAF V600
1539649|NCT02967692|unresectable BRAF V600 mutated melanoma
1539650|NCT02967692|metastatic BRAF V600 mutated melanoma
1539651|NCT02982317|Neuraxial anesthesia
1539652|NCT02982317|Obstetrics
1539653|NCT02982317|Ultrasound
1539654|NCT02966028|CAC
1539655|NCT02966028|calcium
1539656|NCT02966028|ESRD
1539657|NCT02966028|calcification
1539658|NCT02966028|cardiovascular
1539659|NCT02966028|heart
1539660|NCT02966028|kidney
1539661|NCT02966028|hemodialysis
1539662|NCT02966028|Agatston
1539664|NCT02971228|glucagon
1539665|NCT02971228|T1DM
1539666|NCT02971228|Bionic Pancreas
1539667|NCT02971228|diabetes
1539668|NCT02971228|iLet
1539669|NCT02971228|iPhone
1539670|NCT02971228|Beta Bionics
1539671|NCT02971228|Anti-hypoglycemia
1539672|NCT02971228|Glucagon Analog
1539677|NCT02978781|Tremor
1539678|NCT02942966|Angioplasty
1539679|NCT02942966|Below the Knee
1539680|NCT02942966|PAD
1539681|NCT02942966|Critical Limb Ischemia
1539682|NCT02942966|Lesion
1539683|NCT02942966|Claudication
1539685|NCT02949622|Metabolic syndrome
1539686|NCT02949622|Mediterranean diet
1539687|NCT02949622|Stress
1539688|NCT02949622|quality of life
1539689|NCT02949622|psychological factors
1539690|NCT03194464|hemiparesis
1539691|NCT02941081|iron supplement
1539707|NCT02922153|CryoAnalgesia
1539708|NCT02922153|Thoracotomy
1539709|NCT02922153|FEV1
1539710|NCT02922153|VAS
1539711|NCT02911077|Bacteria
1539712|NCT02933021|MGUS
1539718|NCT02909777|Lymphoma
1539719|NCT02909777|Neuroblastoma
1539720|NCT02909777|Brain Tumor
1539721|NCT02909777|Solid Tumor
1539722|NCT02891070|Cranial Surgery
1539723|NCT02891070|Cerebrospinal Fluid Leak
1539724|NCT02891070|Tisseel
1539725|NCT02910063|Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma
1539726|NCT02910063|Blinatumomab
1539727|NCT02910063|Leukemia
1539728|NCT02910063|Standard of Care
1539729|NCT02910063|SOC
1539730|NCT02910063|Cancer
1539731|NCT02910063|Chemotherapy
1539732|NCT02885272|Malignant neoplasms of eye brain and other parts of central nervous system
1539733|NCT02885272|Glioblastoma
1539734|NCT02885272|FDG PET
1539735|NCT02885272|CT
1539736|NCT02885272|MRI
1539737|NCT02877303|Leukemia
1539738|NCT02877303|Acute lymphoblastic leukemia
1539739|NCT02877303|ALL
1539740|NCT02877303|Newly diagnosed B-Cell Lineage Acute lymphoblastic leukemia
1539741|NCT02877303|Blinatumomab
1539742|NCT02877303|Blincyto
1539743|NCT02877303|G-CSF
1539744|NCT02877303|Filgrastim
1539745|NCT02877303|Neupogen
1539746|NCT02877303|Pegfilgrastim
1539747|NCT02877303|Neulasta
1539748|NCT02877303|PEG-G-CSF
1539749|NCT02877303|Cyclophosphamide
1539750|NCT02877303|Cytoxan
1539751|NCT02877303|Neosar
1539752|NCT02877303|Revimmune
1539753|NCT02877303|Clafen
1539754|NCT02877303|Mesna
1539755|NCT02877303|Mesnex
1539756|NCT02877303|Dexamethasone
1539757|NCT02877303|Decadron
1539758|NCT02877303|Ofatumumab
1539759|NCT02877303|Arzerra
1539760|NCT02877303|Methotrexate
1539761|NCT02877303|MTX
1539762|NCT02877303|Doxorubicin
1539763|NCT02877303|Doxorubicin Hydrochloride
1539764|NCT02877303|Adriamycin PFS
1539765|NCT02877303|Adriamycin RDF
1539766|NCT02877303|Adriamycin
1539767|NCT02877303|Rubex
1539768|NCT02877303|Vincristine
1539769|NCT02877303|Oncovin
1539770|NCT02877303|Vincasar PFS
1539771|NCT02877303|Vincristine Sulfate
1539772|NCT02877303|LCR
1539773|NCT02877303|VCR
1539774|NCT02877303|Cytarabine
1539775|NCT02877303|ARA-C
1539776|NCT02877303|Cytosar
1539777|NCT02877303|DepoCyt
1539778|NCT02877303|Cytosine Arabinosine Hydrochloride
1539779|NCT02877303|Arabino Sylcytosine
1539780|NCT02877303|Cytosine Arabinoside
1539781|NCT02877303|Rituximab
1539782|NCT02877303|Rituxan
1539783|NCT02877303|Leucovorin
1539784|NCT02877303|Citrovorum
1539785|NCT02877303|Wellcovorin
1539786|NCT02877303|6-Mercaptopurine
1539787|NCT02877303|Mercaptopurine
1539788|NCT02877303|Purinethol
1539789|NCT02877303|6-MP
1539790|NCT02877303|Prednisone
1539791|NCT02877303|Deltasone
1539792|NCT02877303|Orasone
1539793|NCT02877303|Prednicen-M
1539800|NCT02869438|Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
1539803|NCT02898662|inhaled
1539804|NCT02898662|TLR9 agonist
1539805|NCT02898662|withdrawal design
1539806|NCT02898662|loss of control
1539807|NCT02871713|quadratus lumborum block
1539821|NCT02853305|PD1
1539822|NCT02853305|PD-1
1539823|NCT02853305|PDL1
1539824|NCT02853305|PD-L1
1539825|NCT02858895|High grade glioma
1539826|NCT02858895|malignant glioma
1539827|NCT02858895|recurrent glioblastoma
1539828|NCT02858895|recurrent GBM
1539829|NCT02858895|recurrent GB
1539830|NCT02858895|glioblastoma (GB)
1539831|NCT02858895|glioblastoma multiforme (GBM)
1539832|NCT02858895|progressive glioblastoma
1539833|NCT02858895|Brain tumor
1539834|NCT02858895|Brain cancer
1539835|NCT02858895|immunotherapy
1539836|NCT02858895|targeted
1539837|NCT02858895|IL4R
1539842|NCT02840448|Williams Syndrome
1539843|NCT02840448|Blood Flow
1539844|NCT02840448|Brain
1539845|NCT02840448|Arterial Stiffness
1539846|NCT02839733|Brain Imaging
1539847|NCT02839733|Adult
1539848|NCT02839733|DNA Testing
1539849|NCT02839733|Children
1539850|NCT02840487|Zika Infection
1539851|NCT02840487|Flavivirus
1539852|NCT02840487|Vaccine-Mediated Protection
1539853|NCT02840487|Immune Response
1539854|NCT02840487|Arthropod-Borne Virus
1539863|NCT02821832|Tuberculosis
1539864|NCT02821832|PET/CT Scanning
1539865|NCT02821832|Immunological Markers
1539866|NCT02821832|4-Month Treatment Completion
1539867|NCT02828657|ORBERA
1539868|NCT02819518|PD1
1539869|NCT02819518|PD-1
1539870|NCT02819518|PDL1
1539871|NCT02819518|PD-L1
1539872|NCT02821416|asthma
1539873|NCT02794285|Lupus Erythematosus, Systemic Autoimmune Diseases, Connective Tissue Diseases,Immune System Diseases
1539886|NCT02845245|Comminuted intra-articular distal tibia fractures
1539887|NCT02845245|3D printing
1539888|NCT02845245|pre-operative planning
1539889|NCT02784444|NASH
1539902|NCT02765490|Hepatitis C, Chronic
1539903|NCT02765490|AL-335
1539904|NCT02765490|Odalasvir
1539905|NCT02765490|Simeprevir
1539906|NCT02765490|ODV
1539907|NCT02765490|SMV
1539908|NCT02765490|ACH-3102
1539909|NCT02765490|ACH-0143102
1539910|NCT02765490|TMC435
1539911|NCT02760615|Drug therapy
1539918|NCT02761330|Anesthesia
1539919|NCT02761330|Electroconvulsive therapy
1539920|NCT02761330|Delirium
1539921|NCT02761330|Electroencephalography
1539922|NCT02761330|Seizures
1539923|NCT02761330|Depression
1539924|NCT02761330|Ketamine
1539925|NCT02761330|Etomidate
1539926|NCT02761330|Physiological Effects of Drugs
1539927|NCT02761330|Pharmacologic Actions
1539928|NCT02761330|Confusion
1539929|NCT02761330|Mental Disorders
1539930|NCT02761330|Neurobehavioral Manifestations
1539931|NCT02761330|Signs and Symptoms
1539932|NCT02761330|Neurologic Manifestations
1539933|NCT02761330|Cognitive Disorders
1539934|NCT02755584|Aging
1539935|NCT02755584|Senescent Cells
1539936|NCT02754752|Malignant neoplasm of breast
1539937|NCT02754752|Post-Mastectomy Pain Syndrome
1539938|NCT02754752|PMPS
1539939|NCT02754752|Electro-acupuncture
1539940|NCT02754752|Questionnaires
1539941|NCT02754752|Surveys
1539942|NCT02754752|Standard of care
1539943|NCT02750319|Amiodarone
1539944|NCT02750319|N-Acetylcysteine
1539945|NCT02750319|16-307
1539955|NCT02739880|Vaginal discomfort
1539956|NCT02739880|Vaginal dryness
1539957|NCT02778464|Inflammatory Bowel Disease
1539958|NCT02778464|Pregnancy
1539959|NCT02778464|Stool markers
1539960|NCT02778464|Calprotectin
1539961|NCT02778464|Faecal S100A12 (f-SA12)
1539962|NCT02778464|Faecal calprotectin (f-Cp)
1539963|NCT02733536|endotracheal intubation
1539964|NCT02733536|trauma
1539965|NCT02733536|paramedic
1539966|NCT02760329|asthma
1539967|NCT02760329|COPD
1539968|NCT02760329|chronic obstructive pulmonary disease
1539969|NCT02760329|lung disease
1539970|NCT02760329|chronic airways disease
1539971|NCT02760329|obstructive lung disease
1539978|NCT02770599|IBD
1539979|NCT02770599|HRQoL
1539980|NCT02770599|QoC
1539981|NCT02770599|Adherence
1539982|NCT02770599|IBD nurse
1539983|NCT02770599|MDT
1539984|NCT02807506|elders
1539985|NCT02807506|robotics
1539986|NCT02807506|low income population
1539987|NCT02807506|activities of daily living
1539988|NCT02807506|instrumental activities of daily living
1539989|NCT02807506|social robotics
1539990|NCT02807506|stroke
1539991|NCT02807506|aged
1539992|NCT02807506|Retirement
1539993|NCT02807506|Housing for elderly
1539994|NCT02807506|Homes for the aged
1540004|NCT02721732|Advanced Cancers
1540005|NCT02721732|Rare tumors
1540006|NCT02721732|Squamous cell carcinoma of the skin
1540007|NCT02721732|Anaplastic thyroid cancer
1540008|NCT02721732|Adrenocortical carcinoma
1540009|NCT02721732|Medullary renal cell carcinoma
1540010|NCT02721732|Carcinoma of unknown primary
1540011|NCT02721732|Penile carcinoma
1540012|NCT02721732|Thymoma
1540013|NCT02721732|Testicular carcinoma
1540014|NCT02721732|Paraganglioma-pheochromocytoma
1540015|NCT02721732|Pembrolizumab
1540016|NCT02721732|Keytruda
1540017|NCT02721732|MK-3475
1540018|NCT02721732|SCH-900475
1540019|NCT02720263|Schizophrenia
1540020|NCT02720263|ASP4345
1540021|NCT02719106|real world data
1540022|NCT02719106|percutaneous coronary intervention
1540023|NCT02719106|drug eluting stent
1540024|NCT02730169|Hypogonadotropic
1540025|NCT02730169|hypogonadism
1540026|NCT02730169|testosterone
1540027|NCT02709226|Brain Tumor
1540028|NCT02709226|Astrocytoma
1540029|NCT02709226|GBM
1540030|NCT02709226|Radiation Therapy
1540031|NCT02731872|COPD
1540032|NCT02731872|oxygen treatment
1540033|NCT02731872|quality of life
1540039|NCT02702401|PD1
1540040|NCT02702401|PD-1
1540041|NCT02702401|PDL1
1540042|NCT02702401|PD-L1
1540046|NCT02699671|Bioresorbable Vascular Scaffold
1540047|NCT02699671|Routine Clinical Practice
1540048|NCT02699671|Angioplasty, Transluminal, Percutaneous Coronary
1540049|NCT02699671|Coronary Artery Disease
1540050|NCT02699671|drug eluting stent
1540051|NCT02699671|acute myocardial infarction
1540056|NCT02740985|AZD4635
1540057|NCT02740985|durvalumab
1540058|NCT02740985|non-small cell lung cancer
1540059|NCT02740985|advanced solid malignancies
1540066|NCT02703636|Alzheimer's disease
1540078|NCT02691702|Multiple Ascending Dose Study
1540079|NCT02691702|Safety and Tolerability
1540080|NCT02691702|Pharmacokinetics
1540081|NCT02691702|Pharmacodynamics
1540082|NCT02691702|Melatonin
1540083|NCT02691702|Plasma
1540084|NCT02691702|Dim Light Melatonin Onset
1540085|NCT02689453|T-cell Lymphoproliferative Disorder
1540086|NCT02689453|CD4/CD25 Expressing T-cells in Blood and Lymphoid Tissues
1540087|NCT02689453|Anti-CD52 Monoclonal Antibody
1540088|NCT02689453|Antibody Dependent Cellular Cytotoxicity
1540089|NCT02695329|navigation system
1540090|NCT02695329|palm-sized
1540091|NCT02695329|total knee arthroplasty
1540092|NCT02685020|Healthy
1540093|NCT02685020|Human Immunodeficiency Virus
1540094|NCT02685020|adenovirus serotype 26
1540095|NCT02685020|Ad26.Mos.HIV
1540096|NCT02685020|Vaccine
1540097|NCT02685020|Placebo
1540098|NCT02685020|Glycoprotein
1540099|NCT02685020|IPCAVD010
1540104|NCT02669069|Bi-modal neuromodulation
1540115|NCT02680847|Pediatric
1540116|NCT02680847|pain indication
1540117|NCT02680847|controlled release oxycodone
1540118|NCT02656173|Tamsulosin
1540119|NCT02656173|Overactive bladder
1540120|NCT02656173|Benign prostatic hypertrophy
1540121|NCT02656173|Mirabegron
1540122|NCT02653625|Primary Sclerosing Cholangitis
1540126|NCT02650193|HSP-130 Phase 1-2 Study in patients with Breast cancer
1540130|NCT02647385|serratus anterior plane block
1540131|NCT02647385|pectoral nerve block
1540132|NCT02647385|breast surgery
1540133|NCT02647385|cancer
1540134|NCT02647385|analgesia
1540135|NCT02647385|inflammatory cytokines
1540136|NCT02643875|myopia control
1540137|NCT02643875|orthokeratology
1540138|NCT02643342|myopia control
1540139|NCT02643342|orthokeratology
1540140|NCT02637414|Stress
1540141|NCT02637414|Well-being
1540142|NCT02637414|Positive psychology
1540152|NCT02625961|PD1
1540153|NCT02625961|PDL1
1540154|NCT02625961|PD-L1
1540155|NCT02625961|PD-1
1540157|NCT02624427|Glaucoma
1540158|NCT02624427|Intraocular Pressure
1540159|NCT02612545|Plasmodium Falciparum
1540160|NCT02612545|Artemisinin Combination Therapy
1540161|NCT02612545|Triple Artemisinin Combination Therapy
1540162|NCT02612545|Piperaquine
1540163|NCT02612545|Mefloquine
1540164|NCT02610075|AZD1775
1540165|NCT02610075|Metastatic solid tumors
1540166|NCT02610075|Ovarian cancer
1540167|NCT02615704|Brilique treatment adherence via electronic device application (APP)
1540168|NCT02598388|Healthy
1540169|NCT02598388|Vaccine
1540170|NCT02598388|Ebola viruses
1540171|NCT02598388|Ebola virus disease (EVD)
1540172|NCT02598388|Filoviruses
1540173|NCT02598388|Hemorrhagic fever
1540174|NCT02598388|Monovalent vaccine
1540175|NCT02598388|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
1540176|NCT02598388|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
1540177|NCT02598388|Safety
1540178|NCT02598388|Immunogenicity
1540185|NCT02665572|renal transplantation
1540186|NCT02665572|defunctionalized bladder
1540187|NCT02665572|bladder recycling
1540188|NCT02590458|Breast Cancer
1540189|NCT02590458|Short Breast MRI Scan
1540190|NCT02590458|SBMRI
1540191|NCT02590458|Routine MRI
1540192|NCT02590458|High risk for breast cancer
1540193|NCT02590458|Screening
1540194|NCT02624388|Genistein
1540195|NCT02624388|Soy
1540196|NCT02624388|Chemotherapy side-effects
1540197|NCT02624388|Pediatric Cancer
1540198|NCT02624388|Isoflavone
1540206|NCT02566161|Genetics
1540207|NCT02566161|Genomics
1540208|NCT02564523|Healthy
1540209|NCT02564523|Vaccine
1540210|NCT02564523|Ebola viruses
1540211|NCT02564523|Ebola virus disease (EVD)
1540212|NCT02564523|Filoviruses
1540213|NCT02564523|Hemorrhagic fever
1540214|NCT02564523|Monovalent vaccine
1540215|NCT02564523|Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
1540216|NCT02564523|Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
1540217|NCT02564523|Safety
1540218|NCT02564523|Immunogenicity
1540223|NCT02565745|Prevention
1540224|NCT02565745|Pressure ulcers
1540225|NCT02565745|Clinical trial
1540226|NCT02565745|Nursing
1540227|NCT02563002|PD1
1540228|NCT02563002|PDL1
1540229|NCT02563002|PD-L1
1540230|NCT02561247|Acute Kidney Injury
1540231|NCT02561247|Continuous Renal Replacement Therapy
1540232|NCT02561247|Blood Urea Nitrogen (BUN)
1540233|NCT02561247|Prismaflex
1540234|NCT02561247|Pediatric
1540240|NCT02582879|Chronic Lymphocytic Leukemia
1540241|NCT02582879|CLL
1540242|NCT02582879|Small Lymphocytic Leukemia
1540243|NCT02582879|SLL
1540244|NCT02575248|dienogest
1540245|NCT02575248|infertility
1540246|NCT02575248|endometriosis
1540250|NCT02544607|Ketamine
1540251|NCT02544607|Depression
1540252|NCT02544607|Anxious Depression
1540253|NCT02544607|MRI
1540254|NCT02532257|Lymphoma
1540255|NCT02532257|Follicular Lymphoma
1540256|NCT02532257|FL
1540257|NCT02532257|Previously untreated
1540258|NCT02532257|Lenalidomide
1540259|NCT02532257|CC-5013
1540260|NCT02532257|Revlimid
1540261|NCT02532257|Rituximab
1540262|NCT02532257|Rituxan
1540263|NCT02532257|Ibrutinib
1540264|NCT02532257|PCI-32765
1540265|NCT02532257|Imbruvica
1540291|NCT02530918|DS-7080a Monoclonal Antibody
1540294|NCT02529943|Spinal Stenosis
1540295|NCT02529943|Motor Evoked Potential
1540299|NCT02520154|Ovarian Cancer
1540300|NCT02520154|Metastatic Ovarian Cancer
1540301|NCT02520154|High-grade epithelial non-mucinous ovarian cancer
1540302|NCT02520154|Advanced stage ovarian cancer
1540303|NCT02520154|Carboplatin
1540304|NCT02520154|Paraplatin
1540305|NCT02520154|Paclitaxel
1540306|NCT02520154|Taxol
1540307|NCT02520154|Pembrolizumab
1540308|NCT02520154|Keytruda
1540309|NCT02520154|MK-3475
1540310|NCT02520154|SCH-900475
1540323|NCT02504840|Multiple Sclerosis
1540324|NCT02504840|Clinically Isolated Syndrome
1540325|NCT02504840|CNS Inflammatory Demyellnation
1540326|NCT02504840|Radiologically Isolated Syndrome
1540327|NCT02509026|non-radiographic axial spondyloarthritis
1540328|NCT02504905|Parietal Lobe
1540329|NCT02504905|Plasticity
1540330|NCT02504905|Cerebellum
1540331|NCT02504905|Dystonia
1540332|NCT02504905|Transcranial Magnetic Stimulation (TMS)
1540333|NCT02504918|Plasmodium Falciparum
1540334|NCT02504918|Regulatory
1540335|NCT02504918|Chemoprevention
1540336|NCT02504918|Coartem
1540337|NCT02504918|Parasitemia
1540341|NCT02506244|Atrial Fibrillation
1540342|NCT02506244|Wearable device
1540343|NCT02506244|Wristband
1540344|NCT02506244|ECG Patch
1540345|NCT02506244|Strokes
1540346|NCT02506244|Asymptomatic
1540347|NCT02506244|Heart Rhythm
1540348|NCT02506244|Home Monitoring
1540349|NCT02513732|Drug Eluting Stent
1540350|NCT02513732|Coronary Stent
1540351|NCT02513732|Everolimus
1540352|NCT02513732|Stent Thrombosis
1540355|NCT02486900|Craving
1540356|NCT02486900|Cue Reactivity
1540357|NCT02486900|Neurofeedback
1540362|NCT02486536|capsule endoscopy
1540363|NCT02486536|polyethylene glycol
1540364|NCT02486536|bowel preparation solutions
1540365|NCT02481297|Leukemia
1540366|NCT02481297|Chronic Lymphocytic Leukemia
1540367|NCT02481297|CLL
1540368|NCT02481297|Refractory/Relapsed
1540369|NCT02481297|Untreated with high-risk molecular features
1540370|NCT02481297|Small lymphocytic leukemia
1540371|NCT02481297|SLL
1540372|NCT02481297|Lirilumab
1540373|NCT02481297|Rituximab
1540374|NCT02481297|Rituxan
1540375|NCT02496923|prophylactic NHFO
1540376|NCT02496923|risk of developing postoperative pulmonary complications
1540377|NCT02496923|reduces hospital length of stay
1540378|NCT02479698|Stem cell transplant
1540379|NCT02479698|Human Leukocyte Antigen
1540380|NCT02479698|HLA
1540381|NCT02479698|BK specific CTL lines
1540382|NCT02479698|BK-CTLs
1540383|NCT02479698|Hematopoietic stem cell transplantation
1540384|NCT02479698|HSCT
1540385|NCT02479698|BK Infection
1540386|NCT02479698|Cytotoxic T lymphocytes
1540387|NCT02479698|CTLs
1540388|NCT02479698|Myeloablative
1540389|NCT02479698|Non-myeloablative
1540390|NCT02479698|Graft Versus Host Disease
1540391|NCT02479698|GVHD
1540392|NCT02477475|reflux esophagitis
1540393|NCT02477475|Nexium
1540394|NCT02472067|Musculoskeletal Injury
1540395|NCT02472067|physical therapy
1540396|NCT02472067|psychological intervention
1540397|NCT02472067|risk factors
1540398|NCT02497261|Food Allergy
1540399|NCT02497261|Peanut
1540400|NCT02497261|Sensitization
1540401|NCT02497261|Child
1540402|NCT02497261|Double-blind placebo-controlled challenge
1540403|NCT02497261|Prospective cohort
1540404|NCT02466529|type 1 spinal muscular atrophy (SMA)
1540413|NCT02450552|Amyotrophic Lateral Sclerosis
1540414|NCT02450552|ALS
1540415|NCT02450552|Lou Gehrig
1540417|NCT02446834|PCOS
1540418|NCT02446834|intensive lifestyle intervention
1540419|NCT02446834|IGT
1540420|NCT02446834|drugs treatment
1540421|NCT02433158|Rivipansel
1540422|NCT02433158|GMI-1070
1540423|NCT02433158|Selectin Inhibitor
1540424|NCT02433158|SCD
1540425|NCT02433158|VOC
1540439|NCT02419495|Advanced cancers
1540440|NCT02419495|Malignant neoplasms
1540441|NCT02419495|Paclitaxel
1540442|NCT02419495|Taxol
1540443|NCT02419495|Eribulin
1540444|NCT02419495|E7389
1540445|NCT02419495|Doxorubicin
1540446|NCT02419495|Doxorubicin Hydrochloride
1540447|NCT02419495|Adriamycin PFS
1540448|NCT02419495|Adriamycin RDF
1540449|NCT02419495|Adriamycin
1540450|NCT02419495|Rubex
1540451|NCT02419495|Cyclophosphamide
1540452|NCT02419495|Cytoxan
1540453|NCT02419495|Neosar
1540454|NCT02419495|Pemetrexed
1540455|NCT02419495|LY231514
1540456|NCT02419495|Alimta
1540457|NCT02419495|MTA
1540458|NCT02419495|Multitargeted Antifolate
1540459|NCT02419495|NSC-698037
1540460|NCT02419495|Topotecan
1540461|NCT02419495|Hycamtin
1540462|NCT02419495|Selinexor
1540463|NCT02419495|KPT-330
1540464|NCT02419495|Carboplatin
1540465|NCT02419495|Paraplatin
1540466|NCT02419495|Irinotecan
1540467|NCT02419495|CPT-11
1540468|NCT02419495|Camptosar
1540469|NCT02419495|5-FU
1540470|NCT02419495|Fluorouracil
1540471|NCT02419495|5-Fluorouracil
1540472|NCT02419495|Adrucil
1540473|NCT02419495|Efudex
1540474|NCT02419495|Capecitabine
1540475|NCT02419495|Xeloda
1540476|NCT02419495|Oxaliplatin
1540477|NCT02419495|Eloxatin
1540478|NCT02419495|Olaparib
1540479|NCT02419495|Lynparza
1540480|NCT02419495|Pembrolizumab
1540481|NCT02419495|Keytruda
1540482|NCT02419495|MK-3475
1540483|NCT02419495|SCH-900475
1540484|NCT02419495|Nivolumab
1540485|NCT02419495|BMS-936558
1540486|NCT02419495|Opdivo
1540516|NCT02394730|HIV, d-dimer, hs-CRP, activated T-lymphocytes
1540517|NCT02400736|Individual Placement and Support
1540518|NCT02400736|Supported Employment
1540519|NCT02400736|Employment
1540520|NCT02400736|Vocational Rehabilitation
1540521|NCT02400736|Veterans
1540522|NCT02400736|Patient Aligned Care Team
1540523|NCT02388191|Contraception
1540524|NCT02388191|Naproxen
1540525|NCT02388191|Intrauterine devices
1540526|NCT02388191|Pain Control
1540527|NCT02398617|Heart Failure
1540528|NCT02398617|End of Life Care
1540529|NCT02398617|Decision Making
1540530|NCT02363322|Medical Countermeasures
1540531|NCT02363322|VHF
1540532|NCT02363322|EVD
1540536|NCT02399475|Levothyroxine
1540537|NCT02399475|Liothyronine
1540538|NCT02399475|Thyrotropin Releasing Hormone
1540539|NCT02399475|Aging
1540540|NCT02399475|Hypothyroidism
1540541|NCT02399475|Thyroid diseases
1540542|NCT02354014|Multidrug-Resistant Tuberculosis
1540543|NCT02354014|Bedaquiline
1540544|NCT02354014|TMC207
1540549|NCT02350283|Acute Ischemic Stroke
1540550|NCT02350283|Endovascular therapy
1540551|NCT02350283|Solitaire
1540552|NCT02350283|Standard Medical Management
1540559|NCT02349152|Cardiopulmonary bypass
1540560|NCT02349152|Heart surgery
1540561|NCT02327884|Genetics
1540562|NCT02327884|Dry Mouth
1540563|NCT02327884|Sjogren's Syndrome
1540564|NCT02327884|Gland Dysfuntion
1540565|NCT02327884|Induced Pluripotent Stem Cell (iPS) Cell Lines
1540566|NCT02324647|Urinary steroid profiling
1540567|NCT02324647|Adrenal incidentaloma
1540568|NCT02324647|Adrenocortical carcinoma
1540569|NCT02324647|cost-effectiveness
1540587|NCT02767479|eradication rates
1540588|NCT02767479|rabeprazole
1540589|NCT02767479|esomeprazole
1540590|NCT02312219|HIV
1540591|NCT02312219|Inflammation
1540592|NCT02312219|Atherosclerosis
1540593|NCT02312219|Positron-Emission Tomography
1540594|NCT02312219|Imaging
1540595|NCT02312219|fluorodeoxyglucose
1540596|NCT02321046|Non-Small Cell Lung Cancer, NSCLC, Epidermal growth factor receptor, EGFR
1540598|NCT02302339|Advanced melanoma
1540599|NCT02302339|Unresectable melanoma
1540600|NCT02302339|Metastatic melanoma
1540601|NCT02302339|Targeted Treatment for melanoma
1540602|NCT02302339|GPNMB
1540603|NCT02302339|CDX-011
1540604|NCT02302339|Glembatumumab vedotin
1540605|NCT02302339|Antibody-drug-conjugate
1540606|NCT02302339|Skin neoplasm
1540607|NCT02302339|Varlilumab
1540608|NCT02302339|CDX-1127
1540609|NCT02306746|Enteral nutrition
1540610|NCT02306746|randomised control trial
1540611|NCT02306746|Critical care
1540612|NCT02306746|Outcome
1540613|NCT02285114|HIV
1540614|NCT02285114|emtricitabine
1540615|NCT02285114|FTC
1540616|NCT02285114|tenofovir
1540617|NCT02285114|TDF
1540618|NCT02285114|TAF
1540619|NCT02285114|antiretroviral
1540620|NCT02285114|pharmacokinetic
1540621|NCT02285114|PK
1540622|NCT02285114|adolescents
1540623|NCT02285114|children
1540624|NCT02285114|pediatric
1540625|NCT02285114|Gilead
1540626|NCT02262819|Skin Blister
1540627|NCT02262819|Immune Response
1540628|NCT02262819|Suction Device
1540629|NCT02262819|Anti-Microbial
1540630|NCT02262819|Killed Microbe
1540631|NCT02251275|Autosomal Dominant Polycystic Kidney Disease
1540640|NCT02239900|Liver Cancer
1540641|NCT02239900|Lung Cancer
1540642|NCT02239900|Adrenal Gland
1540643|NCT02239900|Metastasis
1540644|NCT02239900|Advanced Solid Malignancies
1540645|NCT02239900|Ipilimumab
1540646|NCT02239900|Yervoy
1540647|NCT02239900|BMS-734016
1540648|NCT02239900|MDX010
1540649|NCT02239900|Stereotactic Body Radiation Therapy
1540650|NCT02239900|SBRT
1540651|NCT02239900|XRT
1540662|NCT02232022|Stroke
1540663|NCT02232022|Ischemic stroke
1540664|NCT02232022|Atrial fibrillation
1540665|NCT02232022|Insertable cardiac monitor
1540666|NCT02232022|Non-cryptogenic
1540667|NCT02225132|Hydroxyurea
1540668|NCT02225132|Sickle Cell Disease
1540669|NCT02225132|Fetal Hemoglobin Induction
1540676|NCT02252172|Multiple Myeloma
1540677|NCT02252172|Daratumumab
1540678|NCT02252172|JNJ-54767414
1540679|NCT02252172|Lenalidomide
1540680|NCT02252172|Dexamethasone
1540681|NCT02213042|biomarker
1540682|NCT02213042|Lapatinib
1540683|NCT02213042|Prosigna
1540684|NCT02213042|ErbB2
1540685|NCT02213042|PAM50
1540686|NCT02213042|HER2
1540687|NCT02213042|HER2-overexpressing metastatic breast cancer
1540688|NCT02213042|HER2-enriched
1540689|NCT02213042|Trastuzumab
1540700|NCT02201563|Adverse radiation effects (ARE)
1540701|NCT02201563|Radiosurgery
1540702|NCT02201563|Brain metastases
1540703|NCT02201563|Minocycline
1540704|NCT02200445|Ulcerative colitis
1540705|NCT02200445|Inflammatory bowel disease
1540706|NCT02200445|Interleukin 2
1540707|NCT02200445|Interleukin-2
1540708|NCT02200445|IL-2
1540709|NCT02200445|Regulatory T Cells
1540710|NCT02200445|Tregs
1540711|NCT02200445|T-Lymphocytes, Regulatory
1540712|NCT02202109|Screen
1540713|NCT02202109|self-sampler
1540714|NCT02202109|cervical, cancer
1540715|NCT02202109|women
1540716|NCT02202109|community health workers
1540717|NCT02202109|Hispanic/ Latinas
1540718|NCT02202109|Haitian
1540719|NCT02202109|Focus of study is cervical cancer
1540735|NCT02181283|alcohol
1540736|NCT02181283|prescribed drugs
1540737|NCT02181283|National Guard
1540744|NCT02170298|ADHD
1540745|NCT02170298|Attention Deficit Hyperactivity Disorder
1540746|NCT02170298|Vyvanse
1540747|NCT02170298|Lisdexamfetamine
1540748|NCT02158702|Relapsed Myeloma Patients
1540749|NCT02158702|Relapsed after use of Bortezomib and Lenalidomide
1540750|NCT02158702|Pomalidomide and Dexamethasone
1540751|NCT02158702|Efficacy and Safety
1540752|NCT02154009|Autonomic Nervous System
1540753|NCT02154009|Catecholamines
1540754|NCT02154009|Dysautonomia
1540755|NCT02154009|Parasympathetic Cholinergic System
1540756|NCT02154009|Sympathetic Adrenergic System
1540758|NCT02164422|Alcohol
1540759|NCT02164422|Drinkers
1540760|NCT02164422|Guanfacine
1540787|NCT02108028|Advance Care Planning Guide
1540788|NCT02108028|End-of-Life
1540794|NCT02105766|Sickle Cell Disease
1540795|NCT02105766|Allogeneic Hematopoietic Stem Cell Transplant
1540796|NCT02105766|Pentostatin (Nipent)
1540797|NCT02105766|Cyclophosphamide
1540798|NCT02105766|Alemtuzumab (Campath)
1540799|NCT02083198|hyperchloremic acidosis
1540800|NCT02083198|balanced fluids
1540801|NCT02083198|plasmalyte
1540802|NCT02081196|Lipolysis
1540803|NCT02081196|Cryolipolysis
1540804|NCT02081196|Fat Reduction
1540805|NCT02081209|Lipolysis
1540806|NCT02081209|Cryolipolysis
1540807|NCT02081209|Fat Reduction
1540825|NCT02060630|Surgical revascularization
1540826|NCT02060630|Endovascular revascularization
1540827|NCT02060630|Amputation
1540828|NCT02060630|Peripheral artery disease
1540829|NCT02060630|Critical limb ischemia
1540830|NCT02060630|claudication
1540831|NCT02060630|leg pain
1540832|NCT02060630|leg ulcer
1540833|NCT02060630|gangrene
1540843|NCT02053207|Cognitive training
1540844|NCT02053207|Brain training
1540845|NCT02053207|Plasticity-based training
1540846|NCT02053207|Cardiac surgery
1540847|NCT02053207|Preoperative
1540848|NCT02053207|Cognitive function
1540849|NCT02051309|Smokers
1540850|NCT02051309|Quit Smoking
1540851|NCT02051309|Treatment
1540852|NCT02051309|Guanfacine
1540853|NCT02037295|Gut Microbiota
1540854|NCT02037295|Obesity
1540855|NCT02037295|Absorption
1540856|NCT02037295|Overfeeding
1540857|NCT02120287|Border Zone Stereotactic Radiosurgery
1540858|NCT02120287|Bevacizumab
1540859|NCT02120287|Recurrent Glioblastoma Multiforme
1540860|NCT02120287|Progressive Glioblastoma Multiforme
1540861|NCT02120287|Magnetic Resonance Spectroscopy
1540862|NCT02120287|Glioblastoma
1540863|NCT02120287|Brain Cancer
1540864|NCT02120287|Brain Tumor
1540865|NCT02120287|Radiosurgery
1540866|NCT02043210|substance use, Spanish speaking, CBT4CBT
1540867|NCT02034058|Wingspan Stent System
1540868|NCT02034058|Wingspan Stent
1540869|NCT02034058|Intracranial Stent
1540870|NCT02034058|Ischemic Stroke
1540871|NCT02034058|Intracranial Atherosclerotic Disease
1540872|NCT02034058|Intracranial Stenosis
1540873|NCT02043574|Aerobic Exercise
1540874|NCT02043574|Treadmill Test
1540875|NCT02043574|Sedentary Lifestyle
1540877|NCT02015104|Urothelial Cancinoma
1540878|NCT02015104|Vaccines
1540879|NCT02015104|Immunotherapy
1540880|NCT02015104|TICE BCG
1540881|NCT02015104|Intravesical Treatment
1540885|NCT02024477|endothelial cells
1540886|NCT02024477|cellular biomarker
1540887|NCT02024477|endothelial dysfunction
1540888|NCT02015013|Leukapheresis
1540889|NCT02015013|Progenitor Cells
1540890|NCT02007447|autism, oxytocin, autism spectrum disorder, social skills.
1540897|NCT01993719|Metastatic
1540898|NCT01993719|Melanoma
1540899|NCT01993719|Adoptive Cell Therapy
1540900|NCT01998529|Lung Cancer
1540901|NCT01998529|Unilateral Pleural Malignancy
1540902|NCT01998529|Metastatic active pleural malignancy
1540903|NCT01998529|Lung tumors
1540904|NCT01998529|Sarcomas
1540905|NCT01998529|Cytoreductive Surgery
1540906|NCT01998529|Hyperthermic Intrathoracic Pleural Chemotherapy
1540907|NCT01998529|HITC
1540908|NCT01998529|Cisplatin
1540909|NCT01998529|Platinol-AQ
1540910|NCT01998529|Platinol
1540911|NCT01998529|CDDP
1540912|NCT01998529|Amifostine
1540913|NCT01998529|Ethyol
1540914|NCT01998529|Ethiofos
1540915|NCT01998529|Gammaphos
1540916|NCT01989546|DNA Damage
1540917|NCT01989546|Advanced Solid Tumors
1540918|NCT01989546|BRCA Mutations
1540919|NCT01989546|PARP Inhibitor
1540920|NCT01989546|Pharmacodynamics
1540921|NCT01976715|HIV
1540922|NCT01976715|Treatment Failure
1540923|NCT01976715|Drug Resistance
1540942|NCT01977534|Bioabsorbable
1540943|NCT01977534|Coronary Stent
1540944|NCT01977534|Everolimus
1540945|NCT01977534|drug eluting stents
1540946|NCT01977534|stents
1540947|NCT01977534|angioplasty
1540948|NCT01977534|coronary artery disease
1540949|NCT01977534|total coronary occlusion
1540950|NCT01977534|coronary artery restenosis
1540951|NCT01977534|stent thrombosis
1540952|NCT01977534|vascular disease
1540953|NCT01977534|myocardial ischemia
1540954|NCT01977534|coronary artery stenosis
1540955|NCT01977534|CAD
1540956|NCT01977534|CAOD
1540957|NCT01961557|EEG
1540958|NCT01961557|Cerebral Palsy
1540959|NCT01961557|Knee
1540967|NCT01942980|Breast cancer
1540968|NCT01942980|one brain metastasis
1540993|NCT02467231|new diagnosis of cancer
1540994|NCT02467231|chemotherapy
1540995|NCT02467231|oncofertility
1540996|NCT02467231|alkylating agent
1540997|NCT02467231|fertility preservation
1540998|NCT02467231|fertility after cancer
1540999|NCT02467231|late effects
1541000|NCT01902472|HIV-1
1541001|NCT01902472|Truvada
1541002|NCT01902472|FTC/TDF
1541003|NCT01902472|Pre-exposure prophylaxy
1541004|NCT01902472|PrEP
1541005|NCT01902472|Resistance
1541006|NCT01906255|HIV-1
1541007|NCT01906255|Truvada
1541008|NCT01906255|FTC/TDF
1541009|NCT01906255|Pre-exposure prophylaxy
1541010|NCT01906255|PrEP
1541011|NCT01906255|Adherence
1541012|NCT01906255|Resistance
1541016|NCT01892215|Uterine incision.
1541017|NCT01892215|Blunt transversal expansion.
1541018|NCT01892215|Blunt cephalad-caudad expansion.
1541019|NCT01893359|hyperopia
1541020|NCT01893359|hyperopic astigmatism
1541021|NCT01893359|cross-linking
1541022|NCT01893983|Mental Health
1541023|NCT01893983|Veterans Health
1541024|NCT01893983|Rural
1541025|NCT01893983|Motivational Interviewing
1541026|NCT01881789|multiple myeloma
1541027|NCT01881789|proteasome inhibitor
1541028|NCT01881789|oprozomib
1541029|NCT01881789|orpozomib tablets
1541033|NCT01861106|Allogeneic Donors
1541034|NCT01861106|Peripheral Blood Stem Cell
1541035|NCT01861106|Immunodeficiency
1541036|NCT01861106|Myelodysplasia
1541037|NCT01861106|Haploidentical
1541047|NCT01864928|Acute Ischemic stroke
1541048|NCT01864928|ePRISM
1541049|NCT01853618|Liver Cancer
1541050|NCT01853618|Monoclonal Antibody
1541051|NCT01853618|CTLA-4
1541052|NCT01853618|Ablative Therapy
1541102|NCT01822561|Central Serous Chorioretinopathy
1541103|NCT01822561|Eplerenone
1541104|NCT01822561|Optical Coherence Tomography
1541105|NCT01822561|Enhanced Depth Imaging
1541106|NCT01822561|Subretinal Fluid
1541111|NCT01814007|Lipolysis
1541112|NCT01814007|Cryolipolysis
1541113|NCT01814007|Fat Reduction
1541117|NCT01800006|Atrial Fibrillation
1541118|NCT01800006|Observation
1541119|NCT01800006|Stroke
1541120|NCT01800006|Embolism
1541121|NCT01797523|Endometrial cancer
1541122|NCT01797523|Advanced or Recurrent Endometrial Carcinoma
1541123|NCT01797523|Metformin
1541124|NCT01797523|Letrozole
1541125|NCT01797523|Femara
1541126|NCT01797523|Everolimus
1541127|NCT01797523|Afinitor
1541128|NCT01797523|Zortress
1541129|NCT01797523|RAD001
1541130|NCT01794104|Topoisomerase Inhibitor
1541131|NCT01794104|Advanced Malignancies
1541132|NCT01794104|Pharmacodynamics
1541133|NCT01794104|DNA Damage
1541134|NCT01794104|Pharmacokinetics
1541135|NCT01792336|Repetitive TMS (rTMS)
1541136|NCT01792336|Transcranial Magnetic Stimulation (TMS)
1541137|NCT01792336|Motor Cortex
1541138|NCT01792336|Focal Hand Dystonia
1541139|NCT01792336|Facilitation
1541140|NCT01787500|Advanced Cancers
1541141|NCT01787500|Advanced Solid Cancers
1541325|NCT01573442|stage IA breast cancer
1541142|NCT01787500|BRAF V600 Mutant Advanced Solid Malignancies
1541143|NCT01787500|Metastatic
1541144|NCT01787500|Unresectable
1541145|NCT01787500|BRAF mutant, KRAS wild type colorectal cancer
1541146|NCT01787500|BRAF mutant, KRAS wild type solid tumor cancers
1541147|NCT01787500|Vemurafenib
1541148|NCT01787500|PLX4032
1541149|NCT01787500|RO5185426
1541150|NCT01787500|Cetuximab
1541151|NCT01787500|C225
1541152|NCT01787500|Erbitux
1541153|NCT01787500|IMC-C225
1541154|NCT01787500|Irinotecan
1541155|NCT01787500|CPT-11
1541156|NCT01787500|Camptosar
1541157|NCT01883492|Only Female
1541158|NCT01883492|Age between 20 - 75 at the time of operation
1541176|NCT01767142|Lipolysis
1541177|NCT01767142|Cryolipolysis
1541178|NCT01767142|Fat Reduction
1541179|NCT01766297|Breast Cancer
1541180|NCT01766297|Proton
1541181|NCT01766297|Radiation
1541182|NCT01758523|neuroactive steroids
1541183|NCT01762761|eltrombopag
1541184|NCT01762761|TPO-R agonist
1541185|NCT01762761|Chronic ITP
1541190|NCT01755195|Dual Inhibitor of MET and VEGFR
1541191|NCT01755195|XL184
1541192|NCT01755195|Metastatic Refractory
1541193|NCT01755195|Soft Tissue Sarcoma
1541194|NCT01755195|Rare Heterogeneous Tumor
1541197|NCT01747148|Antisense
1541198|NCT01747148|Influenza
1541199|NCT01747148|IV Injection
1541200|NCT01747148|RNA Based Therapeutic
1541201|NCT01747148|RNA Interference
1541211|NCT01757067|ablations
1541212|NCT01757067|CHF
1541213|NCT01757067|PVC
1541226|NCT01736631|social phobia
1541227|NCT01736631|bipolar disorder
1541228|NCT01736631|cognitive behavioural therapy
1541229|NCT01729182|Low dose Aspirin(LDA)
1541230|NCT01729182|Gastric ulcer or duodenal ulcer
1541231|NCT01729182|Nexium
1541232|NCT01728857|Lipolysis
1541233|NCT01728857|Cryolipolysis
1541234|NCT01728857|Fat Reduction
1541235|NCT01729091|Myeloma
1541236|NCT01729091|Multiple myeloma
1541237|NCT01729091|MM
1541238|NCT01729091|Umbilical cord blood
1541239|NCT01729091|UCB
1541240|NCT01729091|Natural killer cells
1541241|NCT01729091|NK
1541242|NCT01729091|Autologous stem cell transplant
1541243|NCT01729091|Stem cell infusion
1541244|NCT01729091|High dose chemotherapy
1541245|NCT01729091|Lenalidomide
1541246|NCT01729091|CC-5013
1541247|NCT01729091|Revlimid
1541248|NCT01729091|Melphalan
1541249|NCT01729091|Alkeran
1541250|NCT01729091|G-CSF
1541251|NCT01729091|Filgrastim
1541252|NCT01729091|Neupogen
1541253|NCT01729091|Elotuzumab
1541254|NCT01729091|Dexamethasone
1541255|NCT01729091|Decadron
1541260|NCT01704547|Breast cancer
1541261|NCT01704547|Lumpectomy
1541262|NCT01704547|Breast Irradiation
1541263|NCT01705054|Angina
1541264|NCT01705054|Stable ischemic heart disease
1541265|NCT01705054|Quality of Life
1541266|NCT01705054|Seattle Angina Questionnaire (SAQ)
1541267|NCT01692873|pancreatic tumor
1541268|NCT01686841|Lipolysis
1541269|NCT01686841|Cryolipolysis
1541270|NCT01686841|Fat Reduction
1541271|NCT01687673|Advanced HCC
1541272|NCT01687673|Temsirolimus
1541273|NCT01687673|TORISEL
1541274|NCT01687673|Sorafenib
1541275|NCT01682226|CYCLOPHOSPHAMIDE (CYTOXAN)
1541276|NCT01682226|CYCLOSPORINE
1541277|NCT01682226|FLUDARABINE
1541278|NCT01682226|G-CSF
1541279|NCT01682226|MYCOPHENOLATE MOFETIL (MMF)
1541280|NCT01682226|Cord Blood Transplantation
1541281|NCT01682226|CliniMACS
1541282|NCT01682226|12-153
1541283|NCT01670175|Histologic verification of solid tumor, including lymphomas
1541284|NCT01670175|Original diagnosis or relapse
1541288|NCT01643252|Corneal Ectasia
1541289|NCT01643252|Refractive surgery
1541290|NCT01643252|Cross-Linking
1541291|NCT01628029|Advanced Cancers
1541292|NCT01628029|Metastatic
1541293|NCT01628029|Locally advanced
1541294|NCT01628029|Sleep disturbance
1541295|NCT01628029|Sleep problems
1541296|NCT01628029|Litebook
1541297|NCT01628029|Melatonin
1541298|NCT01628029|Methylphenidate
1541299|NCT01628029|Methylphenidate hydrochloride
1541300|NCT01628029|Ritalin
1541301|NCT01628029|Concerta
1541302|NCT01628029|Placebo
1541303|NCT01628029|Supportive counseling
1541304|NCT01628029|Questionnaires
1541305|NCT01628029|Study Diaries
1541306|NCT01623037|Lipolysis
1541307|NCT01623037|Cryolipolysis
1541308|NCT01623037|Fat Reduction
1541313|NCT01581086|HIV
1541314|NCT01581086|COPD
1541315|NCT01581086|Pulmonary disease
1541316|NCT01600638|Lipolysis
1541317|NCT01600638|Cryolipolysis
1541318|NCT01600638|Fat Reduction
1541319|NCT01573442|hot flashes
1541320|NCT01573442|musculoskeletal complications
1541321|NCT01573442|sexual dysfunction
1541322|NCT01573442|estrogen receptor-positive breast cancer
1541323|NCT01573442|progesterone receptor-positive breast cancer
1541324|NCT01573442|arthralgia
1541326|NCT01573442|stage IB breast cancer
1541327|NCT01573442|stage II breast cancer
1541328|NCT01573442|stage IIIA breast cancer
1541329|NCT01573442|stage IIIB breast cancer
1541330|NCT01573442|stage IIIC breast cancer
1541335|NCT01562600|NSAIDs
1541336|NCT01562600|Gastric ulcer or duodenal ulcer
1541337|NCT01562600|Nexium
1541341|NCT01557244|neurogenic detrusor overactivity
1541342|NCT01557244|neurogenic bladder
1541343|NCT01557244|neuropathic bladder
1541344|NCT01557244|neurologic disease
1541345|NCT01557244|fesoterodine
1541346|NCT01579487|Lipolysis
1541347|NCT01579487|Cryolipolysis
1541348|NCT01579487|Fat Reduction
1541349|NCT01555619|Left heart pacing lead
1541350|NCT01555619|Cardiac resynchronization therapy (CRT)
1541351|NCT01555619|Heart Failure
1541352|NCT01555619|Quadripolar pacing
1541353|NCT01553461|Transplant
1541354|NCT01553461|Umbilical Cord Blood
1541355|NCT01553461|Graft Rejection
1541356|NCT01553461|Graft Versus Host Disease
1541357|NCT01547767|Metabolism
1541358|NCT01547767|Muscle
1541359|NCT01547767|Mutation
1541360|NCT01547767|ISCU Myopathy
1541361|NCT01547767|Myopathy
1541366|NCT01524549|Cardiovascular
1541367|NCT01524549|P450s
1541368|NCT01524549|Flow-Mediated Dilatation
1541369|NCT01524549|Brachial Artery Ultrasound
1541370|NCT01524549|Endothelial Cell Function
1541371|NCT01524549|Healthy Volunteer
1541372|NCT01524549|HV
1541373|NCT01515787|stage IIA rectal cancer
1541374|NCT01515787|stage IIIA rectal cancer
1541375|NCT01515787|stage IIIB rectal cancer
1541376|NCT01517659|Lipolysis
1541377|NCT01517659|Cryolipolysis
1541378|NCT01517659|Fat Reduction
1541379|NCT01513408|breast cancer
1541380|NCT01513408|CD8+
1541381|NCT01513408|Foxp3
1541382|NCT01513408|neoadjuvant chemotherapy
1541383|NCT01517646|Lipolysis
1541384|NCT01517646|Cryolipolysis
1541385|NCT01517646|Fat Reduction
1541395|NCT01500447|Hypogonadotropic Hypogonadism
1541396|NCT01500447|Kallmann Syndrome
1541397|NCT01500447|Delayed Puberty
1541398|NCT01500447|Infertility
1541399|NCT01500447|Hypothalamic Amenorrhea
1541400|NCT01500447|Early Puberty
1541401|NCT01500447|Late Puberty
1541402|NCT01500447|Hypogonadism
1541403|NCT01500447|Amenorrhea
1541404|NCT01500447|Endocrine Diseases
1541405|NCT01496599|Brain Imaging
1541406|NCT01496599|Parkinson's Disease
1541407|NCT01496599|Parkinsonism
1541408|NCT01496599|Parkinson Disease
1541409|NCT01496599|PD
1541410|NCT01496599|Healthy Volunteer
1541411|NCT01496599|HV
1541412|NCT01492972|Prostate
1541413|NCT01492972|proton
1541414|NCT01492972|radiation
1541415|NCT01492972|intermediate risk
1541416|NCT01483079|donor human milk products
1541417|NCT01483079|post-discharge
1541418|NCT01483079|growth
1541419|NCT01483079|development
1541422|NCT01443936|Influenza Vaccine
1541423|NCT01443936|H5N1 Influenza
1541424|NCT01443936|Normal Volunteer
1541425|NCT01443936|Adenovirus
1541426|NCT01443936|Live Virus Vaccine
1541427|NCT01443936|Healthy Volunteer
1541428|NCT01443936|HV
1541432|NCT01412853|localized
1541433|NCT01409044|Patient-Controlled Analgesia (PCA)
1541434|NCT01409044|Music Listening
1541435|NCT01409044|Opioids
1541436|NCT01409044|Post Surgical Intensive Care Patient
1541437|NCT01409044|Patient-Controlled Analgesia
1541438|NCT01391923|Lipolysis
1541439|NCT01391923|Cryolipolysis
1541440|NCT01391923|Fat Reduction
1541441|NCT01392222|focus group
1541442|NCT01392222|11-108
1541443|NCT01377740|Lipolysis
1541444|NCT01377740|Cryolipolysis
1541445|NCT01377740|Fat Reduction
1541446|NCT01375543|Gene Identification
1541447|NCT01375543|Genetics
1541448|NCT01375543|Genetic Disorders
1541449|NCT01369901|Exercise
1541450|NCT01369901|Spinal Bulbar Muscular Atrophy
1541451|NCT01369901|Spinal and Bulbar Muscular Atrophy
1541452|NCT01369901|SBMA
1541453|NCT01369901|Motor Neuron Disease
1541454|NCT01365169|Cyberinfrastructure
1541455|NCT01365169|CI
1541456|NCT01365169|CYCORE
1541457|NCT01365169|Quality of Life
1541458|NCT01365169|QOL
1541459|NCT01365169|Head and Neck
1541460|NCT01365169|H&N
1541461|NCT01365169|Carbon Monoxide
1541462|NCT01365169|CO
1541463|NCT01365169|Colorectal Cancer
1541464|NCT01365169|Oropharyngeal Cancer
1541465|NCT01365169|Laryngeal Cancer
1541466|NCT01365169|Hypopharyngeal Cancer
1541467|NCT01365169|Nasopharyngeal Cancer
1541468|NCT01365169|Smoker
1541469|NCT01365169|Recent Smoking Cessation
1541470|NCT01348958|Patello femoral
1541471|NCT01348958|osteoarthritis
1541472|NCT01348958|arthroplasty
1541473|NCT01348217|unoperated cancers
1541474|NCT01348217|oesophagus
1541475|NCT01348217|radiochemotherapy
1541476|NCT01348217|with and without increased doses
1541477|NCT01326715|Multiple Sclerosis
1541478|NCT01326715|MRI
1541479|NCT01326715|Manganese Enhanced MRI
1541480|NCT01326715|Optic Neuritis
1541481|NCT01326715|Healthy Volunteer
1541482|NCT01323322|Health Disparities
1541483|NCT01323322|Diversity
1541484|NCT01323322|Socioeconomic Status
1541485|NCT01323322|Epidemiology
1541494|NCT01287143|Fever
1541495|NCT01287143|Signs and Symptoms
1541496|NCT01287143|Febrile Assessment Tool (FAST)
1541497|NCT01282502|rectal cancer
1541498|NCT01282502|chemotherapy
1541499|NCT01282502|chemoradiation
1541505|NCT01266902|HIV-1 Infection
1541506|NCT01266902|HIV-1
1541507|NCT01266902|HIV
1541508|NCT01266902|TMC278-TiDP6-C222
1541509|NCT01266902|TMC278-C222
1541510|NCT01266902|TMC278
1541511|NCT01266902|Rilpivirine
1541512|NCT01264055|Rare Diseases of Airways
1541513|NCT01264055|Bronchiectasis
1541514|NCT01264055|Idiopathic Bronchiectasis
1541515|NCT01264055|Chronic Cough
1541516|NCT01264055|Nontuberculous Mycobacteriam Infection
1541517|NCT01263574|Catheter related infections prevention/control
1541518|NCT01263574|Anti infective agents
1541519|NCT01263574|Catheter related infections prevention
1541520|NCT01260831|BedsidePEWS
1541521|NCT01260831|Intensive Care
1541522|NCT01253317|Rett Syndrome
1541523|NCT01253317|IGF-1
1541524|NCT01253317|Increlex
1541525|NCT01253317|Mecasermin
1541526|NCT01253317|IGF1
1541527|NCT01253317|MECP2
1541528|NCT01253317|RTT
1541529|NCT01233687|Recurrent
1541530|NCT01233687|progressive
1541531|NCT01233687|advanced
1541532|NCT01230866|Proton Radiation Prostate Cancer
1541537|NCT01191177|oral fish oil
1541538|NCT01191177|Lovaza
1541539|NCT01191177|Omega-3-acid supplementation
1541540|NCT01168271|Observational
1541541|NCT01168271|Newborns
1541542|NCT01168271|Hospitalized
1541543|NCT01168271|Febrile
1541544|NCT01168271|Resistance
1541563|NCT01118026|stage I adult Hodgkin lymphoma
1541564|NCT01118026|stage II adult Hodgkin lymphoma
1541565|NCT01118026|adult favorable prognosis Hodgkin lymphoma
1541566|NCT01118026|adult lymphocyte depletion Hodgkin lymphoma
1541567|NCT01118026|adult lymphocyte predominant Hodgkin lymphoma
1541568|NCT01118026|adult mixed cellularity Hodgkin lymphoma
1541569|NCT01118026|adult nodular sclerosis Hodgkin lymphoma
1541570|NCT01118026|adult unfavorable prognosis Hodgkin lymphoma
1541585|NCT01092195|Women's Health
1541586|NCT01092195|Genital Precancer
1541587|NCT01092195|Stem Cell Donor
1541588|NCT01092195|Cervical Cytology
1541589|NCT01092195|Healthy Volunteers
1541590|NCT01092195|Stem Cell Transplant
1541591|NCT01092195|Healthy Volunteer
1541592|NCT01092195|HV
1541593|NCT01087346|Parents
1541594|NCT01087346|Obesity
1541595|NCT01087346|Family History
1541596|NCT01087346|Healthy Volunteer
1541597|NCT01087346|HV
1541604|NCT01369433|tivozanib
1541605|NCT01074151|Pregnancy
1541606|NCT01074151|pregnant
1541607|NCT01074151|Cymbalta
1541608|NCT01074151|Pregnancy Outcomes
1541609|NCT01071642|Change in eGFR from baseline to 72 hours following the exposure to the contrast.
1541610|NCT01071642|Rate of eGFR decrease>25% from the baseline
1541611|NCT01071642|Length of hospitalization.
1541612|NCT01071642|Requirement of unplanned therapy for elevated blood pressure
1541613|NCT01057745|woman
1541614|NCT01057745|chemotherapy
1541615|NCT01057745|radiation
1541616|NCT01057745|fertility preservation
1541617|NCT01057745|cryobank
1541618|NCT01044160|cancer as trauma in children
1541619|NCT01044160|PTG/PTSS/ PTSD in children with cancer vs healthy children
1541623|NCT01030575|NICHD Neonatal Research Network
1541624|NCT01030575|Pharmacokinetics
1541625|NCT01030575|Inositol
1541626|NCT01030575|Very Low Birth Weight (VLBW)
1541627|NCT01030575|Extremely Low Birth Weight (ELBW)
1541628|NCT01030575|Prematurity
1541629|NCT01014715|Breast Cancer
1541640|NCT00980538|TMC125-TiDP35-C239
1541641|NCT00980538|TMC125-C239
1541642|NCT00980538|TMC125
1541643|NCT00980538|HIV
1541644|NCT00980538|Etravirine
1541645|NCT00980538|Intelence
1541646|NCT00980538|IntelenceTM
1541647|NCT00977067|GDC0152
1541648|NCT00977067|IAP
1541649|NCT00977067|IAP Antagonist
1541650|NCT00976898|proton beam radiation
1541651|NCT00956085|OCD
1541652|NCT00943514|Primary Ciliary Dyskinesia
1541653|NCT00943514|Variant Cystic Fibrosis
1541654|NCT00943514|Bronchopulmonary Mycosis
1541655|NCT00943514|Airway Infection Susceptibility
1541656|NCT00943514|Chronic Respiratory Infection
1541657|NCT00943514|Bronchiectasis
1541658|NCT00942877|VEGF
1541659|NCT00942877|Antiangiogenesis
1541660|NCT00942877|Tyrosine Kinase Inhibitor
1541661|NCT00942877|Advanced Cancer
1541662|NCT00942877|Alveolar Soft Part Sarcoma
1541663|NCT00942877|Sarcoma
1541672|NCT00939770|unspecified childhood solid tumor, protocol specific
1541673|NCT00939770|recurrent neuroblastoma
1541674|NCT00939770|recurrent childhood anaplastic large cell lymphoma
1541675|NCT00939770|recurrent childhood brain stem glioma
1541676|NCT00939770|recurrent childhood cerebellar astrocytoma
1541677|NCT00939770|recurrent childhood cerebral astrocytoma
1541678|NCT00939770|recurrent childhood anaplastic astrocytoma
1541679|NCT00939770|recurrent childhood anaplastic oligoastrocytoma
1541680|NCT00939770|recurrent childhood anaplastic oligodendroglioma
1541681|NCT00939770|recurrent childhood fibrillary astrocytoma
1541682|NCT00939770|recurrent childhood gemistocytic astrocytoma
1541683|NCT00939770|recurrent childhood giant cell glioblastoma
1541684|NCT00939770|recurrent childhood glioblastoma
1541685|NCT00939770|recurrent childhood gliomatosis cerebri
1541686|NCT00939770|recurrent childhood gliosarcoma
1541687|NCT00939770|recurrent childhood oligoastrocytoma
1541688|NCT00939770|recurrent childhood oligodendroglioma
1541689|NCT00939770|recurrent childhood pilocytic astrocytoma
1541690|NCT00939770|recurrent childhood pilomyxoid astrocytoma
1541691|NCT00939770|recurrent childhood pleomorphic xanthoastrocytoma
1541692|NCT00939770|recurrent childhood protoplasmic astrocytoma
1541693|NCT00939770|recurrent childhood subependymal giant cell astrocytoma
1541694|NCT00939770|recurrent childhood visual pathway and hypothalamic glioma
1541695|NCT00939770|recurrent childhood visual pathway glioma
1541696|NCT00939770|recurrent childhood medulloblastoma
1541697|NCT00939770|recurrent childhood ependymoma
1541698|NCT00939770|recurrent childhood pineoblastoma
1541699|NCT00939770|recurrent childhood supratentorial primitive neuroectodermal tumor
1541700|NCT00939770|childhood choroid plexus tumor
1541701|NCT00939770|childhood craniopharyngioma
1541702|NCT00939770|childhood ependymoblastoma
1541703|NCT00939770|childhood medulloepithelioma
1541704|NCT00939770|childhood grade I meningioma
1541705|NCT00939770|childhood grade II meningioma
1541706|NCT00939770|childhood grade III meningioma
1541707|NCT00939770|childhood central nervous system germ cell tumor
1541708|NCT00939770|recurrent childhood spinal cord neoplasm
1541709|NCT00939770|childhood infratentorial ependymoma
1541710|NCT00939770|childhood supratentorial ependymoma
1541711|NCT00939770|childhood high-grade cerebellar astrocytoma
1541712|NCT00939770|childhood high-grade cerebral astrocytoma
1541713|NCT00939770|childhood low-grade cerebellar astrocytoma
1541714|NCT00939770|childhood low-grade cerebral astrocytoma
1541715|NCT00939770|childhood atypical teratoid/rhabdoid tumor
1541716|NCT00926640|Solid Tumors
1541717|NCT00926640|Histone deacetylase inhibitors
1541718|NCT00926640|EP &amp; Belinostat
1541719|NCT00926640|Phase I
1541720|NCT00926640|SCLC
1541721|NCT00926640|Small Cell Lung Cancer
1541722|NCT00924027|Radiation
1541723|NCT00924027|Cancer
1541724|NCT00924027|HDR
1541725|NCT00924027|Brachytherapy
1541726|NCT00924027|Training
1541727|NCT00924326|B Cell Malignancies
1541728|NCT00924326|T Cell Persistence
1541729|NCT00924326|Immunotherapy
1541730|NCT00924326|Cell Transfer
1541731|NCT00924326|Leukemia
1541732|NCT00924326|Chronic Lymphocytic Leukemia
1541733|NCT00924326|CLL
1541734|NCT00924326|Lymphoma
1541736|NCT00895271|Primary Immunodeficiency
1541737|NCT00895271|Immunodysregulation
1541738|NCT00895271|Skin Biopsy
1541739|NCT00895271|Induced Pluripotent Stem Cell (iPS)
1541740|NCT00895271|Lymphocyte
1541741|NCT00895271|Common Variable Immunodeficiency
1541742|NCT00895271|Severe Combined Immunodeficiency
1541743|NCT00895271|Healthy Volunteer
1541744|NCT00895271|HV
1541745|NCT00890162|Omalizumab
1541746|NCT00890162|Idiopathic Anaphylaxis
1541747|NCT00890162|Serum Tryptase
1541748|NCT00890162|Placebo-Controlled
1541749|NCT00890162|Adult
1541750|NCT00890162|Anaphylaxis
1541751|NCT00890162|Allergic Reaction
1541755|NCT00867269|Idiopathic Lymphocytopenia
1541756|NCT00867269|Opportunistic Infection
1541757|NCT00867269|Immunodeficiency Syndrome
1541758|NCT00867269|Autoimmune Disease
1541759|NCT00867269|CD4+ Lymphocytes
1541760|NCT00867269|Idiopathic CD4 Lymphocytopenia
1541761|NCT00857207|Cognitive Therapy
1541762|NCT00857207|Outcomes Assessment
1541765|NCT00843973|Iliac Crest Bone Graft
1541766|NCT00843973|Reamer Irrigator Aspirator
1541767|NCT00824278|Pediatrics
1541768|NCT00824278|Distresss Screening
1541769|NCT00824278|Cancer
1541770|NCT00824278|Neurofibromatosis
1541771|NCT00824278|HIV
1541772|NCT00824278|Pediatric Cancer
1541773|NCT00824278|Distress Screening
1541774|NCT00810264|Long-term safety and reliability of a bipolar left ventricular lead on congestive heart failure patients
1541775|NCT00799864|HIV Infection
1541776|NCT00799864|Antiretroviral
1541777|NCT00799864|HIV-1
1541778|NCT00799864|AIDS
1541779|NCT00799864|Children
1541780|NCT00799864|Rilpivirine (TMC278)
1541781|NCT00799864|Pediatric
1541791|NCT00773357|smoking lapse behavior
1541792|NCT00773357|smoking cessation
1541793|NCT00773357|guanfacine
1541794|NCT00773357|carvedilol
1541795|NCT00773357|medication effect on smoking lapse behavior
1541796|NCT00773357|medication effect on smoking cessation
1541797|NCT00773357|stress
1541798|NCT00773357|gender differences
1541799|NCT00738894|cryptogenic
1541800|NCT00738894|stroke
1541801|NCT00738894|transient ischemic attack
1541802|NCT00738894|TIA
1541803|NCT00738894|PFO
1541804|NCT00738894|Patent foramen ovale
1541805|NCT00738894|HELEX
1541806|NCT00738894|Septal Occluder
1541807|NCT00738894|PFO Occluder
1541820|NCT00694330|vaccine
1541821|NCT00694330|GM-K562
1541822|NCT00694330|malignant glioma
1541828|NCT00632853|limited stage small cell lung cancer
1541834|NCT00592293|proton beam radiation
1541842|NCT00556842|Hemi-Arthroplasty
1541843|NCT00556842|Total Hip Arthroplasty
1541844|NCT00532233|Idiopathic Pulmonary Fibrosis
1541845|NCT00500994|Conversion Disorder
1541846|NCT00500994|Psychogenic Movement Disorders
1541847|NCT00500994|Non-Epileptic Seizure
1541848|NCT00500994|Functional Magnetic Resonance Imaging (fMRI)
1541849|NCT00500994|Genetic Polymorphisms
1541850|NCT00500994|Psychogenic Movement Disorder
1541851|NCT00500994|PMD
1541852|NCT00500994|NES
1541853|NCT00500994|Healthy Volunteer
1541854|NCT00500994|HV
1541855|NCT00495170|Non-Small Cell Lung Cancer
1541856|NCT00495170|Lung Cancer
1541857|NCT00495170|Proton Radiotherapy
1541858|NCT00495170|Proton Beam
1541859|NCT00495170|Paclitaxel
1541860|NCT00495170|Taxol
1541861|NCT00495170|Carboplatin
1541862|NCT00495170|Paraplatin
1541863|NCT00495170|NSCLC
1541864|NCT00495040|Non-Small Cell Lung Cancer
1541865|NCT00495040|Lung Cancer
1541866|NCT00495040|Proton Radiotherapy
1541867|NCT00495040|Proton Beam
1541868|NCT00495040|NSCLC
1541869|NCT00483327|Well
1541870|NCT00483327|Moderately
1541871|NCT00483327|Differentiated
1541889|NCT00369421|Dietary Therapy
1541890|NCT00369421|Biochemical Defects
1541891|NCT00369421|Enzyme Defects
1541892|NCT00369421|Transport
1541893|NCT00369421|Rare Diseases
1541894|NCT00369421|Varied Disorders
1541895|NCT00369421|Screening
1541896|NCT00369421|Relatives
1541897|NCT00352924|Cancer
1541898|NCT00352924|Pesticides
1541899|NCT00352924|Agriculture
1541900|NCT00342771|Tobacco Use
1541901|NCT00342771|Tumor Biology
1541902|NCT00342771|Biomarker
1541903|NCT00342771|Risk Factor
1541904|NCT00342771|Health Disparity
1541905|NCT00314119|Tumor Imaging
1541906|NCT00314119|NF1
1541907|NCT00314119|Neurofibromatosis
1541908|NCT00233272|Frailty
1541909|NCT00233272|Disease Processes
1541920|NCT00092235|cGVHD-associated graft-versus-tumor effects (GVT)
1541921|NCT00092235|Allo-HSCT controls
1541922|NCT00092235|Leukapheresis
1541923|NCT00092235|Chronic Graft-Versus-Host Disease
1541924|NCT00092235|cGVHD
1541925|NCT00090662|Normal Volunteer
1541926|NCT00090662|Eosinophilopoiesis
1541927|NCT00090662|Healthy Volunteer
1541928|NCT00090662|HV
1541934|NCT00061581|Chronic Myelogenous Leukemia
1541935|NCT00061581|Acute Lymphoblastic Leukemia
1541936|NCT00061581|Acute Myelogenous Leukemia (AML)
1541937|NCT00061581|Chronic Lymphocytic Leukemia
1541938|NCT00061581|Myelodysplastic Syndrome
1541939|NCT00061581|Non-Hodgkin's Lymphoma
1541940|NCT00061581|Graft-Versus Leukemia/Myeloma
1541941|NCT00061581|Graft-Versus-Host Disease
1541942|NCT00061581|Cyclosporine
1541943|NCT00061581|Fludarabine
1541944|NCT00061581|Myelodysplasia Syndrome
1541945|NCT00060606|Maternal fetal surgery
1541946|NCT00060606|Fetal diagnosis
1541947|NCT00060606|Myelomeningocele
1541948|NCT00060606|Meningomyelocele
1541949|NCT00060606|Open neural tube defect
1541950|NCT00060606|ONTD
1541951|NCT00060606|Spina bifida
1541964|NCT00039676|Genetics
1541965|NCT00039676|Risk Factors
1541966|NCT00039676|Natural History
1541967|NCT00039676|Lymphoma
1541968|NCT00039676|Leukemia
1541969|NCT00039676|Lymph Node Cancer
1541970|NCT00028340|Breast Cancer
1541971|NCT00028340|Post Menopausal
1541972|NCT00028340|Breast Duct
1541973|NCT00028340|Healthy Volunteer
1541974|NCT00028340|HV
1541975|NCT00028340|Normal Control
1541976|NCT00027170|Myocardial Infarction
1541977|NCT00027170|Myocardial Viability
1541978|NCT00027170|Myocardial Perfusion
1541979|NCT00027170|Myocardial Ischemia
1541980|NCT00027170|Atherosclerosis
1541981|NCT00027170|Cardiovascular Disease
1541982|NCT00027170|Coronary Artery Disease
1541983|NCT00026754|Screening
1541984|NCT00026754|Cancer
1541985|NCT00026754|HIV Infection
1541986|NCT00026754|Scans
1541987|NCT00026754|Laboratory Tests
1541988|NCT00026754|HIV
1541989|NCT00026754|Skin Disorders
1541990|NCT00024804|SKELETAL DISEASE
1541991|NCT00024804|Osteoporosis
1541992|NCT00024804|Dysplasia
1541993|NCT00024804|Osteomalacia
1541994|NCT00024804|Bone Diseases
1541995|NCT00013559|Sleep Disturbance
1541996|NCT00013559|Developmental Delay/ MR
1541997|NCT00013559|Deletion 17p11.2
1541998|NCT00013559|Chromosomal Abnormalities
1541999|NCT00013559|Behavioral Phenotype
1542000|NCT00013559|Smith-Magenis Syndrome
1542001|NCT00013559|Genetics
1542002|NCT00006425|Breast MRI
1542003|NCT00006425|Ductal lavage
1542004|NCT00006425|Nipple Aspirate Fluid
1542005|NCT00006425|Transvaginal ultrasound
1542006|NCT00006425|Healthy Volunteer
1542011|NCT00004577|BOLD Effect
1542012|NCT00004577|Cerebral Blood Flow
1542013|NCT00004577|Cerebral Blood Volume
1542014|NCT00004577|Functional Imaging
1542015|NCT00004577|Magnetic Resonance Imaging
1542016|NCT00004577|Technical Developments
1542017|NCT00004568|Peripheral Neuropathies
1542018|NCT00004568|Myopathy
1542019|NCT00004568|Muscular Dystrophy
1542020|NCT00004568|Motor Neuron Disease
1542021|NCT00004568|Spinocerebellar Degeneration
1542022|NCT00004568|Neurological Disorders
1542023|NCT00001352|Cryptococcus Neoformans
1542024|NCT00001352|Cryptococcosis
1542025|NCT00001352|CD4
1542026|NCT00001888|Induced Sputum
1542027|NCT00001888|Exhaled Breath Condensate
1542028|NCT00001888|Fiberoptic Bronchoscopy
1542029|NCT00001888|Bronchoscopy
1542030|NCT00001888|mRNA
1542031|NCT00001888|Asthma
1542032|NCT00001888|Normal Volunteer
1542038|NCT00001778|Immune Response
1542039|NCT00001778|Sero-Indeterminant
1542040|NCT00001778|Transmission
1542041|NCT00001778|Tropical Spastic Paraparesis
1542042|NCT00001778|Viral Load
1542043|NCT00001778|HTLV-I
1542044|NCT00001778|HAM/TSP
1542050|NCT00001521|21-Hydroxylase Deficiency
1542051|NCT00001521|11-Hydroxylase Deficiency
1542052|NCT00001521|Antiandrogen
1542053|NCT00001521|Aromatase Inhibitor
1542054|NCT00001521|Growth Disorder
1542055|NCT00001521|Congenital Adrenal Hyperplasia (CAH)
1542056|NCT00001403|Proteus Syndrome
1542057|NCT00001403|Overgrowth
1542063|NCT00001823|Cancer
1542064|NCT00001823|Gene Therapy
1542065|NCT00001823|Immunotherapy
1542066|NCT00001823|Melanoma
1542067|NCT00001823|Clinical Trial
1542106|NCT03196869|NPC peripheral blood dendritic cell chronic-chemotherap
1542114|NCT03196622|Sarcopenia
1542115|NCT03196622|Elderly people
1542116|NCT03196622|Hospitalization
1542118|NCT03196401|Durvalumb
1542119|NCT03196401|Radiation Therapy
1542120|NCT03196401|Clonal Bone Marrow Plasmacytosis
1542121|NCT03196401|MEDI4736
1542122|NCT03196401|17-269
1542123|NCT03196518|PET Imaging
1542124|NCT03196518|18F-TFB
1542125|NCT03196518|17-315
1542132|NCT03195634|Cirrhosis
1542133|NCT03195634|Portal Hypertension
1542134|NCT03195621|Coronary Artery Disease
1542135|NCT03195621|Critical lesion
1542138|NCT03197909|COPD (Chronic Obstructive Pulmonary Patients)
1542139|NCT03197909|Atrophy
1542140|NCT03197909|cell cultur
1542141|NCT03197909|systemic inflammation
1542142|NCT03197909|Catabolism
1542143|NCT03195101|orbital tumors
1542144|NCT03195101|transconjunctival approach
1542145|NCT03195907|Stroke
1542146|NCT03195907|Mortality
1542147|NCT03195907|Intensive care unit
1542148|NCT03195907|Pulmonary rehabilitation
1542149|NCT03195218|Cancer prevention
1542150|NCT03195218|Diagnosis
1542151|NCT03195218|Microendoscope
1542152|NCT03195218|High Resolution Microendoscope
1542156|NCT03196505|Anesthetics, Local
1542157|NCT03196505|Liposomal Bupivacaine
1542158|NCT03196505|Bupivacaine
1542159|NCT03196505|Postoperative Complications
1542160|NCT03196505|Roux-en-Y Gastric Bypass
1542161|NCT03196505|Sleeve Gastrectomy
1542162|NCT03196505|Laparoscopic Bariatric Surgery
1542166|NCT03198078|Brexpiprazole
1542167|NCT03198078|Schizophrenia
1542168|NCT03198078|Adolescent
1542176|NCT03196700|palliative care
1542177|NCT03196700|head and neck cancer
1542178|NCT03196700|radiotherapy
1542179|NCT03196700|pain
1542180|NCT03196700|quality of life
1542181|NCT03196713|Allegiance
1542182|NCT03196713|Knowledge
1542183|NCT03196713|Supervision
1542184|NCT03196713|Early intervention
1542185|NCT03196713|Autism
1542186|NCT03195569|QL1101 Avastin® Non Small Cell Lung Cancer
1542189|NCT03196726|cognitive-behavioral therapy
1542193|NCT03196830|Relapse/refractory non-Hodgkin lymphoma
1542194|NCT03196830|CAR - T CD19/CD20/CD22/CD30
1542205|NCT03196908|ECG
1542206|NCT03196908|Blood Pressure
1542207|NCT03196908|Energy Drinks
1542208|NCT03197012|neuroendocrine tumor (NET)
1542209|NCT03197012|Peptide Receptor Radionuclide Therapy (PRRT)
1542210|NCT03197012|somatostatin receptor (SSTR)
1542211|NCT03194789|FGBMM
1542212|NCT03194789|LPSE
1542213|NCT03194789|UDI - 6
1542214|NCT03194789|UIQ - 7
1542217|NCT03195933|Depression
1542218|NCT03195933|Childhood Adversity
1542219|NCT03195933|Childhood Abuse
1542220|NCT03195933|Cortisol
1542221|NCT03195933|Emotional Memory
1542222|NCT03195933|Magnetic Resonance Imaging (MRI)
1542223|NCT03198104|Multiparametric MR Imaging
1542224|NCT03198104|Paediatric
1542225|NCT03197662|Prader-Willi Syndrome
1542226|NCT03197662|Hyperphagia
1542229|NCT03198065|Laparoscopic appendectomy
1542230|NCT03198065|Single-incision laparoscopic appendectomy
1542231|NCT03198065|Single-incision laparoscopic surgery setting
1542232|NCT03198065|Simple appendicitis
1542233|NCT03198065|Complicated appendicitis
1542234|NCT03197142|cardiac arrest
1542235|NCT03197142|resuscitation
1542236|NCT03197142|Out-Of-Hospital Cardiac Arrest
1542237|NCT03197142|CPR
1542243|NCT03195335|Cerebral Palsy
1542244|NCT03195335|Participation
1542245|NCT03195335|LIFE Habits (life-H)
1542246|NCT03195335|Validity
1542247|NCT03195335|Reliability
1542253|NCT03192852|Tooth bleaching color
1542254|NCT03192852|dental esthetic
1542255|NCT03192852|Clinical Trial
1542256|NCT03192852|Violet LED light
1542257|NCT03192852|Violet LED
1542258|NCT03192852|color
1542259|NCT03192852|sensibility
1542260|NCT03192852|dental aesthetic
1542271|NCT03192319|Herpes zoster vaccine
1542272|NCT03192319|Cell-mediated immunity
1542273|NCT03192319|allogenic hematopoietic stem cell transplantation
1542279|NCT03195049|hyperbilirubinemia
1542280|NCT03195049|kernicterus
1542286|NCT03191318|ERAS
1542287|NCT03191318|Enhanced recovery after sugery in bariatric surgery
1542288|NCT03191318|sleeve gastrectomy
1542308|NCT03195140|Diabetes Mellitus
1542309|NCT03195140|Diabetes
1542310|NCT03195140|Sensor Augmented Pump
1542311|NCT03195140|Hypoglycemia
1542312|NCT03191019|Cell phones
1542313|NCT03191019|Women
1542314|NCT03196856|Greek Yogurt
1542315|NCT03196856|Muscle Size
1542316|NCT03196856|Bone Health
1542317|NCT03196856|Body Composition
1542318|NCT03196856|Exercise
1542322|NCT03187938|Alkaline Phosphatase
1542323|NCT03187938|Pregnancy
1542324|NCT03187938|Suboptimal fetal growth
1542325|NCT03187938|Placental insufficiency
1542326|NCT03187938|Low birth weight
1542327|NCT03187938|IUGR
1542328|NCT03197714|Myeloid Leukemia
1542342|NCT03189641|Drug eluting stents
1542343|NCT03189641|Coronary artery disease
1542344|NCT03189641|Coronary artery stenosis
1542345|NCT03189641|Myocardial ischemia
1542346|NCT03189641|Angioplasty
1542352|NCT03195374|Analgesic opioids
1542353|NCT03195374|Misuse
1542354|NCT03195374|Use disorder
1542355|NCT03195374|Pain
1542356|NCT03186430|Vaccine
1542357|NCT03186430|Vaccination
1542358|NCT03186430|Behavioral Research
1542359|NCT03186430|Adolescent
1542360|NCT03186430|Health Promotion
1542361|NCT03186430|Public Health
1542370|NCT03197090|Screening
1542371|NCT03197090|Zenicor
1542374|NCT03184480|Drug Use Investigation
1542375|NCT03184480|GW685698
1542376|NCT03184480|asthma
1542377|NCT03184480|Post-marketing surveillance
1542378|NCT03184480|ARNUITY ELLIPTA
1542379|NCT03197038|Cognitive function
1542380|NCT03197038|Kidney Disease
1542381|NCT03197038|Exercise
1542382|NCT03197038|Older adults
1542391|NCT03181100|Malignant neoplasms of thyroid and other endocrine glands
1542392|NCT03181100|Anaplastic thyroid carcinoma
1542393|NCT03181100|ATC
1542394|NCT03181100|Poorly differentiated thyroid cancer
1542395|NCT03181100|PDTC
1542396|NCT03181100|Nab-paclitaxel
1542397|NCT03181100|Paclitaxel (protein bound)
1542398|NCT03181100|Abraxane
1542399|NCT03181100|ABI-007
1542400|NCT03181100|Paclitaxel
1542401|NCT03181100|Taxol
1542402|NCT03181100|Vemurafenib
1542403|NCT03181100|PLX4032
1542404|NCT03181100|R05185426
1542405|NCT03181100|Cobimetinib
1542406|NCT03181100|Atezolizumab
1542407|NCT03181100|MPDL3280A
1542408|NCT03181100|Bevacizumab
1542409|NCT03181100|Avastin
1542410|NCT03181100|Anti-VEGF monoclonal antibody
1542411|NCT03181100|rhuMAb-VEGF
1542412|NCT03181100|BRAF
1542413|NCT03181100|BRAF inhibitor
1542414|NCT03181100|MEK
1542415|NCT03181100|MEK inhibitor
1542416|NCT03181100|Immunotherapy
1542417|NCT03181100|Targeted therapy
1542423|NCT03197480|Anti-Vascular Endothelial Growth Factor
1542424|NCT03197480|Aflibercept
1542425|NCT03197480|Intravitreal injection
1542426|NCT03197480|Diabetic Macular Edema
1542437|NCT03195283|meal service
1542438|NCT03195283|protein intake
1542439|NCT03195283|satisfaction
1542440|NCT03195283|hospitalized patients
1542441|NCT03186820|Endometriosis
1542442|NCT03186820|Magnetic resonance imaging (MRI)
1542443|NCT03186820|Susceptibility-weighted imaging (SWI)
1542445|NCT03195868|chemotherapy
1542446|NCT03195868|chemo-induced
1542447|NCT03195868|CIPN
1542448|NCT03188263|diabetes
1542449|NCT03188263|sleep
1542450|NCT03188263|circadian rhythm
1542451|NCT03188263|light treatment
1542452|NCT03174197|Malignant neoplasms of eye brain and other parts of central nervous system
1542453|NCT03174197|Glioblastoma (GBM)
1542454|NCT03174197|GBM
1542455|NCT03174197|Gliosarcoma
1542456|NCT03174197|Temozolomide
1542457|NCT03174197|Temodar
1542458|NCT03174197|TMZ
1542459|NCT03174197|Atezolizumab
1542460|NCT03174197|MPDL3280A
1542461|NCT03174197|Radiation therapy
1542462|NCT03174197|External beam
1542463|NCT03174197|XRT
1542484|NCT03198091|stable angina pectoris
1542485|NCT03198091|Dun Ye Guan Xin Ning
1542493|NCT03197766|Achondroplasia
1542494|NCT03197766|Dwarfism
1542495|NCT03197766|Bone Diseases
1542496|NCT03197766|Bone Diseases, Developmental
1542497|NCT03197766|ACH
1542498|NCT03197766|Natriuretic Peptide, C-Type
1542499|NCT03197766|Musculoskeletal Diseases
1542500|NCT03197766|Natriuretic Agents
1542501|NCT03197766|Physiological Effects of Drugs
1542502|NCT03197766|Skeletal Dysplasias
1542503|NCT03197766|Genetic Diseases, Inborn
1542504|NCT03197766|Osteochondrodysplasias
1542523|NCT03165747|Probiotics
1542524|NCT03165747|Menopausal Osteoporosis
1542534|NCT03161912|Diabetes
1542535|NCT03161912|Retinal Diseases
1542536|NCT03161912|Diabetic Retinopathy
1542537|NCT03161912|Diabetic macular edema
1542538|NCT03161912|Retinal vein occlusion
1542539|NCT03161912|Macular edema secondary to retinal vein occlusion
1542540|NCT03161912|Intravitreal anti-VEGF (vascular endothelial growth factor)
1542541|NCT03161912|VEGF inhibitor
1542542|NCT03161912|aflibercept
1542543|NCT03161912|real world data
1542544|NCT03161912|treatment pattern
1542545|NCT03197259|CLL, del(17p)
1542546|NCT03164278|Wheelchair
1542547|NCT03164278|Biomechanics
1542548|NCT03164278|Transfer
1542549|NCT03164278|Participation
1542550|NCT03164278|Training
1542554|NCT03156998|CARE
1542555|NCT03156998|Paediatric asthma
1542556|NCT03156998|Compliance
1542557|NCT03156998|Home nebulizer
1542564|NCT03195894|Alcohol abuse, Alcoholometer, Medical Device, App
1542573|NCT03197857|Bariatric surgery
1542574|NCT03197857|Morbid obesity
1542575|NCT03197857|Physical condition
1542576|NCT03197857|Muscle
1542577|NCT03197857|6-minute walking test
1542578|NCT03197857|Protein supplementation
1542579|NCT03197857|Physical activity program
1542587|NCT03138564|Nursing
1542588|NCT03138564|Nephrology
1542589|NCT03138564|Behavioral Research
1542590|NCT03138564|Social Research
1542591|NCT03138811|asthma
1542592|NCT03138811|Thymic stromal lymphopoietin
1542593|NCT03138811|allergen bronchoprovocation
1542594|NCT03138811|pharmacodynamics
1542595|NCT03138811|pharmacokinetics
1542596|NCT03138811|safety
1542597|NCT03138811|tolerability
1542598|NCT03144583|CART19
1542599|NCT03135652|Radiotherapy
1542600|NCT03135652|Colorectal Cancer
1542601|NCT03135652|Liver Metastases
1542611|NCT03126773|non-interventional
1542612|NCT03126773|cohort
1542613|NCT03126773|Angeliq Micro
1542614|NCT03126773|menopause
1542615|NCT03126773|Russia
1542616|NCT03197623|Glucocorticoids
1542617|NCT03195309|Cesarean Delivery
1542618|NCT03195309|Ropivacaine
1542619|NCT03195309|Fentanyl
1542620|NCT03195309|Patient-controlled Epidural Analgesia
1542622|NCT03122522|unresectable
1542623|NCT03122522|III or stage IV
1542624|NCT03122522|Ipilimumab
1542625|NCT03122522|Nivolumab
1542626|NCT03122522|17-162
1542627|NCT03197415|Platelet-rich plasma
1542628|NCT03197415|Intervertebral Disc Degeneration
1542629|NCT03197415|Low Back Pain
1542630|NCT03197441|Platelet-rich plasma
1542631|NCT03197441|Osteoarthritis Knee
1542632|NCT03118648|upper limb
1542633|NCT03118648|functional recovery
1542634|NCT03118648|activities of daily living
1542635|NCT03197428|Platelet-Rich Plasma
1542636|NCT03197428|Ankle Injuries
1542637|NCT03197428|Lateral Ligament, Ankle
1542638|NCT03118778|Stress Ulcer Prevention
1542646|NCT03116529|Neoadjuvant
1542647|NCT03116529|Soft Tissue Sarcoma
1542648|NCT03116529|Immunotherapy
1542649|NCT03116529|Checkpoint Inhibitor
1542650|NCT03116529|PD-1 (Programmed Cell Death Protein 1)
1542651|NCT03116529|PD-L1 (Programmed Death Ligand 1)
1542652|NCT03116529|CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4)
1542653|NCT03116529|Radiotherapy
1542654|NCT03116529|Durvalumab
1542655|NCT03116529|Tremelimumab
1542656|NCT03116529|Surgery
1542657|NCT03116529|Radiation
1542658|NCT03116529|Combined
1542659|NCT03116529|Preoperative
1542669|NCT03127735|Phase 1
1542670|NCT03127735|mIDH1
1542671|NCT03127735|IDH1 mutation
1542672|NCT03127735|mIDH1 inhibitor
1542694|NCT03161067|Tetraplegia
1542734|NCT03098030|Dinutuximab
1542735|NCT03098030|Irinotecan
1542736|NCT03098030|Topotecan
1542737|NCT03099824|Healthy Adult
1542738|NCT03099824|Oral Capsule
1542739|NCT03099824|Superoxide Dismutase
1542740|NCT03099824|Free Radical Oxygen
1542741|NCT03099824|Single Ascending Dose
1542742|NCT03099824|GC4702 Oral Form Capsule
1542743|NCT03099824|Food Effect Cohort
1542744|NCT03096093|Pancreatic
1542745|NCT03096093|Late stage cancer
1542746|NCT03096093|Immunotherapy
1542747|NCT03096093|Phase I
1542748|NCT03096093|Vaccination
1542749|NCT03096834|Migraine
1542750|NCT03096834|attack
1542751|NCT03096834|headache
1542752|NCT03096834|episodic
1542753|NCT03096834|aura
1542754|NCT03096834|AMG 334
1542755|NCT03096834|CGRP receptor agonist
1542756|NCT03096834|erenumab
1542757|NCT03092960|Latino
1542758|NCT03092960|Male
1542759|NCT03195114|post TAVR quantification
1542760|NCT03195114|cardiac MRI
1542761|NCT03195114|echocardiography
1542762|NCT03195114|biomarkers
1542772|NCT03067506|Drug Therapy
1542773|NCT03067571|Hematopoietic/Lymphoid Cancer
1542774|NCT03067571|Acute Myelogenous Leukemia
1542775|NCT03067571|AML
1542776|NCT03067571|High-Risk Myelodysplastic Syndrome
1542777|NCT03067571|MDA
1542778|NCT03067571|Daratumumab
1542787|NCT03076983|Ventilation Monitoring
1542788|NCT03076983|Electrical Impedance Tomography
1542789|NCT03079089|Allogenic cell stem transplant
1542790|NCT03079089|Sequential chemotherapy
1542791|NCT03079089|Haploidentical transplant
1542792|NCT03056755|advanced breast cancer
1542793|NCT03056755|PIK3CA
1542794|NCT03056755|CDK 4/6 inhibitor
1542795|NCT03056755|fulvestrant
1542796|NCT03056755|letrozole
1542797|NCT03056755|HR+
1542798|NCT03056755|HER-negative
1542799|NCT03056755|post menopausal
1542800|NCT03056339|B-Lymphoid Malignancies
1542801|NCT03056339|Relapsed/Refractory
1542802|NCT03056339|Acute lymphocytic leukemia
1542803|NCT03056339|ALL
1542804|NCT03056339|Chronic lymphocytic leukemia
1542805|NCT03056339|CLL
1542806|NCT03056339|Non-Hodgkin lymphoma
1542807|NCT03056339|NHL
1542808|NCT03056339|(CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer cells
1542809|NCT03056339|CB-NK cells
1542810|NCT03056339|Fludarabine
1542811|NCT03056339|Fludarabine phosphate
1542812|NCT03056339|Fludara
1542813|NCT03056339|Cyclophosphamide
1542814|NCT03056339|Cytoxan
1542815|NCT03056339|Neosar
1542816|NCT03056339|AP1903
1542817|NCT03056339|Mesna
1542818|NCT03056339|Mesnex
1542819|NCT03080311|Bcl-2/Bcl-xL dual inhibitor
1542865|NCT03041493|Electronic Cigarettes
1542866|NCT03041493|17-071
1542867|NCT03078335|Late onset sepsis
1542868|NCT03078335|glove based care
1542869|NCT03078335|NICU
1542870|NCT03078335|Non sterile gloves
1542871|NCT03078335|infection control
1542872|NCT03042325|Drug therapy
1542873|NCT03043651|Pulmonary Hypertension
1542874|NCT03043651|HFpEF
1542875|NCT03043651|6-Minute Walk Test
1542876|NCT03043651|Oral Treprostinil
1542877|NCT03037580|Pulmonary Hypertension
1542878|NCT03037580|6-Minute Walk Test
1542879|NCT03037580|HFpEF
1542880|NCT03037580|Oral Treprostinil
1542881|NCT03046459|cytokines
1542882|NCT03046459|interleukin-2
1542883|NCT03046459|Safety Issues
1542887|NCT03030924|suicide
1542891|NCT03043872|Carcinoma, Small Cell Lung
1542892|NCT03043872|Oat Cell Carcinoma of Lung
1542893|NCT03043872|Oat Cell Lung Cancer
1542894|NCT03043872|Small Cell Cancer Of The Lung
1542895|NCT03043872|Small Cell Lung Cancer
1542896|NCT03028012|Trigger Point Injections
1542897|NCT03028012|steroid
1542898|NCT03028012|nsaid
1542917|NCT03004300|maxillary expansion
1542918|NCT03004300|adenotonsillar hypertrophy
1542919|NCT03004300|airway volume
1542920|NCT03053934|Online counselling
1542921|NCT03007394|Cocaine Use Disorder
1542925|NCT03015519|GSK716155
1542926|NCT03015519|Type 2 diabetes mellitus
1542927|NCT03015519|albiglutide
1542928|NCT03015519|safety
1542929|NCT03015519|pediatric
1542930|NCT03015519|efficacy
1542931|NCT03003663|Fall Prevention
1542932|NCT03003663|Interrupted Time-Series Study
1542933|NCT03003663|Patient Safety
1542934|NCT03003663|Patient-Centered Care
1542935|NCT03003663|Patient Monitoring
1542936|NCT03003663|Health Care Technology
1542937|NCT03003663|Mobile Applications
1542938|NCT03003663|Bedside Monitor
1542939|NCT03003663|Mechanical Fall
1542940|NCT03014050|physical activity
1542941|NCT03014050|fitness
1542942|NCT03014050|cognition
1542943|NCT03014050|mood
1542944|NCT03014050|depression
1542945|NCT03014050|anxiety
1542946|NCT03014050|sleep quality
1542947|NCT03014050|tremor
1542948|NCT03014050|gait
1542949|NCT02989857|IDH1
1542950|NCT02983604|Exemestane
1542951|NCT02983604|Aromasin
1542952|NCT02983604|Fulvestrant
1542953|NCT02983604|Faslodex
1542954|NCT02983604|Breast Cancer,
1542955|NCT02983604|HER 2-
1542956|NCT02983604|Estrogen receptor positive
1542957|NCT02982720|cholangiocarcinoma
1542958|NCT02982720|Pembrolizumab
1542959|NCT02982720|MK-3475
1542960|NCT02982720|Sylatron
1542961|NCT02982720|peginterferon alfa-2b
1542966|NCT02985047|Brief admission
1542967|NCT02985047|admission
1542968|NCT02985047|deliberate self-harm
1542969|NCT02985047|self-harm
1542970|NCT02975362|Acupuncture Treatment; Motor Dysfunction; Stroke Patients
1542971|NCT02975336|Systemic Lupus Erythematosus
1542972|NCT02975336|M2951
1542973|NCT02975336|Placebo
1542974|NCT02975336|Dose response
1542975|NCT02975336|Oral Corticosteroids
1542976|NCT02975336|Safety
1542977|NCT02975336|Efficacy
1542978|NCT02975336|Autoimmune And Inflammatory Disorders
1542979|NCT02974816|Glooko
1542980|NCT02974816|Mobile health application
1542981|NCT02974816|Insulin treated
1542982|NCT02974816|Type 2 Diabetes
1542983|NCT02974816|Remote patient monitoring
1542984|NCT02974816|Certified diabetes educator
1542985|NCT02974816|mHealth Advantage
1542986|NCT02974816|Population health
1542991|NCT02969863|bionic pancreas
1542998|NCT02963766|Pediatrics
1543013|NCT02999100|oxytocin
1543014|NCT02999100|non-pregnant
1543015|NCT02999100|pregnant
1543016|NCT02999100|Postpartum Hemorrhage
1543030|NCT03196895|Diabetes Mellitus, Type 2
1543031|NCT03196895|Continuous Glucose Monitoring
1543032|NCT03196895|Lifestyle Modification
1543033|NCT02951364|observational
1543050|NCT02940652|Laryngeal mask,MRI
1543051|NCT02937454|Acute Heart Failure
1543052|NCT02937454|Iron Deficiency
1543053|NCT02941029|Radiation
1543054|NCT02941029|Chemotherapy
1543055|NCT02959827|Hypothyroidism,
1543056|NCT02959827|children,
1543057|NCT02959827|iodinated contrast agents,
1543058|NCT02959827|retrospective cohort,
1543059|NCT02959827|database
1543060|NCT02939859|Multiple Sclerosis
1543061|NCT02939859|Demyelinating Diseases
1543062|NCT02939859|Nervous System Diseases
1543063|NCT02939859|Autoimmune Disorders
1543064|NCT02923726|Antitachycardia Pacing Therapy
1543065|NCT02923726|Shock Therapy
1543066|NCT02923726|Primary Prevention
1543075|NCT02908945|Ketamine
1543076|NCT02908945|Anesthesia
1543077|NCT02908945|EEG
1543078|NCT02908945|NeuroSENSE
1543079|NCT02908945|Pain
1543089|NCT02874274|Corticobasal syndrome
1543090|NCT02874274|Dementia with Lewy Bodies
1543091|NCT02874274|Home Visit Program (HVP)
1543092|NCT02874274|Multidimensional Caregiver Strain Index
1543093|NCT02874274|Parkinson's Disease Dementia
1543094|NCT02874274|Progressive Supranuclear Palsy
1543097|NCT02876185|Glaucoma surveillance
1543098|NCT02876185|Orthoptist
1543099|NCT02865915|Acne
1543100|NCT02865915|Hirsutism
1543101|NCT02865915|Menstrual Irregularity
1543102|NCT02865915|Alopecia
1543112|NCT02906124|hypercholesterolaemia
1543113|NCT02906124|Lipid lowering therapies
1543114|NCT02906124|Pregnancy
1543115|NCT02854631|Cirrhosis
1543116|NCT02854631|Prednisone
1543117|NCT02854631|Jaundice
1543118|NCT02852655|Brain Tumor
1543119|NCT02897219|SGLT2 inhibitor
1543120|NCT02897219|ASP1941
1543121|NCT02897219|type 1 diabetes mellitus
1543130|NCT02840019|Fetal MRI
1543131|NCT02840019|Pregnancy
1543132|NCT02840019|Pregnant Women
1543133|NCT02840019|MRI Coil
1543134|NCT02840019|MRI Sequence Development/Testing
1543135|NCT02840019|Abnormal Fetuses
1543136|NCT02840019|Typically Developing Fetuses
1543137|NCT02840019|Fetal MRI Technology Development
1543148|NCT02805283|Diabetes Mellitus, Type 2
1543149|NCT02804178|ATR-101
1543150|NCT02804178|classic congenital adrenal hyperplasia
1543151|NCT02804178|21-hydroxylase deficiency
1543152|NCT02804178|CAH
1543172|NCT02801578|Chronic Lymphocytic Leukemia
1543173|NCT02801578|CLL
1543174|NCT02801578|Malignant neoplasms stated as primary lymphoid haematopoietic
1543175|NCT02801578|Ibrutinib
1543176|NCT02801578|PCI-32765
1543177|NCT02801578|Imbruvica
1543178|NCT02801578|Pharmacodynamics
1543179|NCT02789176|Phenobarbital
1543180|NCT02789176|EEG
1543181|NCT02789176|family impact
1543182|NCT02789176|neurodevelopment
1543183|NCT02775903|MEDI4736
1543184|NCT02775903|Durvalumab
1543185|NCT02775903|Myelodysplastic Syndromes
1543186|NCT02775903|Acute Myeloid Leukemia
1543187|NCT02775903|Hematopoietic Stem Cell Transplantation
1543188|NCT02775903|Azacitidine
1543189|NCT02775903|Safety
1543190|NCT02775903|Efficacy
1543191|NCT02775903|PD-L1
1543195|NCT02775760|brain
1543196|NCT02775760|brain mapping
1543197|NCT02775760|cognition
1543198|NCT02775760|exercise
1543199|NCT02775760|physical activity
1543200|NCT02775760|hippocampus
1543201|NCT02775760|entorhinal cortex
1543202|NCT02775760|spatial navigation
1543203|NCT02775760|learning
1543204|NCT02775760|memory
1543205|NCT02775760|magnetic resonance imaging
1543206|NCT02775760|functional neuroimaging
1543207|NCT02775760|physical endurance
1543208|NCT02775760|physical fitness
1543209|NCT02775760|resistance training
1543210|NCT02775760|walking
1543211|NCT02775760|muscle stretching exercises
1543212|NCT02775760|exercise test
1543213|NCT02775760|neuropsychological tests
1543214|NCT02775760|executive function
1543215|NCT02775760|attention
1543216|NCT02775760|body composition
1543217|NCT02813629|transcranial Direct Current Stimulation
1543218|NCT02813629|Peripheral Electrical Stimulation
1543219|NCT02813629|Sickle Cell Disease
1543220|NCT02813629|Transcutaneous Electrical Nerve Stimulation
1543221|NCT02813629|quantitative Electroencephalography
1543222|NCT02966275|glucagon
1543223|NCT02966275|continuous glucose monitorering (CGM)
1543224|NCT02966275|artificial pancreas
1543225|NCT02966275|hypoglycemia
1543226|NCT02966275|post-bariatric hypoglycemia
1543227|NCT02966275|bionic pancreas
1543228|NCT02966275|bariatric surgery
1543234|NCT02771002|critically ill patients
1543235|NCT02771002|septic shock
1543236|NCT02771002|peripheral perfusion index
1543237|NCT02771002|capillary refill time
1543238|NCT02771002|mottling score
1543239|NCT02771002|microcirculation
1543240|NCT02770131|hypercholesterolaemia
1543241|NCT02770131|lipid-lowering therapies
1543242|NCT02780882|Pasireotide
1543243|NCT02780882|Ectopic ACTH
1543244|NCT02780882|SOM230
1543245|NCT02780882|ectopic ACTH-dependent Cushing's syndrome
1543249|NCT02746081|BAY1436032
1543250|NCT02746081|Solid tumors
1543251|NCT02746081|IDH1-R132X Mutation
1543252|NCT02746081|Cancer
1543253|NCT02746081|Safety
1543254|NCT02746081|Tolerability
1543255|NCT02746081|Pharmacokinetics
1543256|NCT02746081|Pharmacodynamics
1543257|NCT02746081|Efficacy
1543258|NCT02740179|Eplerenone
1543259|NCT02740179|Cardiovascular Disease
1543260|NCT02740179|Mineralocorticoid Receptor Antagonist
1543261|NCT02740179|Coronary Vasculature
1543262|NCT02740179|Myocardial Inflammation
1543263|NCT02740179|Myocardial Fibrosis
1543264|NCT02740179|Atherosclerosis
1543265|NCT02740179|Aldosterone
1543266|NCT02732600|Veterans
1543267|NCT02732600|Veterans Health
1543268|NCT02732600|Patient Compliance
1543269|NCT02732600|Primary Health Care
1543270|NCT02732600|Health Care Providers
1543271|NCT02732600|Health Promotion
1543272|NCT02723331|Stereotactic Body Radiation Therapy
1543273|NCT02723331|Perioperative Therapy
1543274|NCT02723331|Resectable Pancreas Ductal Adenocarcinoma
1543275|NCT02723331|Borderline Resectable Pancreas Ductal Adenocarcinoma
1543276|NCT02723331|Nab-paclitaxel
1543277|NCT02723331|Abraxane
1543278|NCT02723331|Gemcitabine
1543279|NCT02723331|Neoadjuvant Therapy
1543280|NCT02723331|Adjuvant Therapy
1543282|NCT02811939|Cannabis
1543283|NCT02811939|Marijuana
1543284|NCT02811939|THC
1543285|NCT02811939|Dronabinol
1543286|NCT02811939|Pregnenolone
1543287|NCT02811939|PREG
1543288|NCT02811939|Psychotic Disorders
1543289|NCT02710708|birth control,
1543290|NCT02710708|contraceptives safety,
1543291|NCT02710708|contraceptives efficacy,
1543292|NCT02710708|moderate acne vulgaris
1543300|NCT02707003|Post-operative respiratory distress
1543301|NCT02722421|efavirenz
1543302|NCT02722421|levonorgestrel
1543303|NCT02722421|contraceptive implant
1543304|NCT02714647|motor learning
1543305|NCT02714647|attention
1543306|NCT02714647|priming
1543307|NCT02714647|rehabilitation
1543308|NCT02701257|Bionic Pancreas
1543309|NCT02701257|Insulin
1543310|NCT02701257|Glucagon
1543311|NCT02701257|Continuous Glucose Monitor
1543312|NCT02799745|Therapeutic Cancer Progression
1543313|NCT02799745|Pathological Cancer Progression
1543314|NCT02799745|Enzalutamide
1543315|NCT02799745|Prostate Cancer
1543316|NCT02799745|Active surveillance
1543317|NCT02696798|Ankylosing Spondylitis
1543318|NCT02696785|Ankylosing Spondylitis
1543319|NCT02696291|Dengue
1543320|NCT02696291|Arbovirus Infections
1543321|NCT02696291|Flaviviridae Infections
1543322|NCT02696291|Flavivirus Infections
1543323|NCT02696291|Hemorrhagic Fevers, Viral
1543324|NCT02696291|RNA Virus Infections
1543325|NCT02696291|Virus Diseases
1543326|NCT02696291|Pharmaceutical Solutions
1543327|NCT02696291|Pharmacologic Actions
1543328|NCT02696291|Therapeutic Uses
1543329|NCT02791880|acute kidney injury
1543330|NCT02791880|transcatheter aortic valve replacement
1543331|NCT02791880|genomics
1543332|NCT02791880|biomarker
1543338|NCT02684747|Healthy Volunteers
1543339|NCT02684747|Sports Medicine
1543340|NCT02684747|Athletes
1543341|NCT02684747|Anti-doping
1543345|NCT02665793|Peanut allergy
1543346|NCT02665793|Food allergy
1543347|NCT02665793|Thresholds
1543348|NCT02665793|Anaphylaxis
1543349|NCT02665065|Acute Myeloid Leukemia
1543350|NCT02665065|Leukemia, Acute Myeloid
1543351|NCT02665065|Myeloid Leukemia, Acute
1543352|NCT02665065|Bone Marrow Cell Transplantation
1543353|NCT02665065|Transplantation, Bone Marrow
1543354|NCT02665065|HCT
1543355|NCT02665065|HSCT
1543356|NCT02665065|Refractory AML
1543357|NCT02665065|Relapsed AML
1543358|NCT02665065|BC8
1543359|NCT02665065|I-131
1543360|NCT02665065|Iomab
1543361|NCT02665065|Iomab-B
1543362|NCT02665065|CD45
1543363|NCT02665065|Iodine
1543364|NCT02665065|Iodine-131
1543365|NCT02665065|131-I
1543366|NCT02665065|AML
1543367|NCT02665065|BMT
1543368|NCT02665065|radioimmunotherapy
1543369|NCT02683785|Pain intensity
1543370|NCT02683785|Hand Osteoarthritis
1543371|NCT02683785|GSK3196165
1543372|NCT02683785|AUSCAN
1543373|NCT02683785|GM-CSF
1543374|NCT02683785|Numerical Rating Scale
1543375|NCT02646930|chronic endometritis
1543376|NCT02646930|invitro fertilization
1543377|NCT02646930|spontaneous abortion
1543378|NCT02775877|PCOS
1543379|NCT02775877|letrozole
1543380|NCT02775877|clomiphene
1543381|NCT02642913|Enzalutamide
1543382|NCT02642913|Sorafenib
1543383|NCT02642913|15-279
1543384|NCT02643043|Next Generation Sequencing
1543385|NCT02643043|Genomic Analysis
1543386|NCT02627768|STELARA
1543387|NCT02627768|Psoriatic Arthritis
1543388|NCT02627768|Ustekinumab
1543395|NCT02622763|Tolerogenic Dendritic Cells
1543397|NCT02624895|"metastatic colorectal cancer gene RAS not mutated WILD TYPE"
1543398|NCT02633319|Parenting
1543399|NCT02633319|Child maltreatment
1543400|NCT02633319|Economic strengthening
1543401|NCT02633319|Early childhood development
1543402|NCT02633319|Cluster randomized controlled trial
1543403|NCT02633319|Pilot evaluation
1543404|NCT02605733|Premature infant
1543405|NCT02605733|Amplitude integrated EEG
1543406|NCT02605733|Near-infrared spectroscopy
1543407|NCT02578641|Nasopharyngeal Carcinoma
1543408|NCT02578641|Epstein-Barr Virus
1543409|NCT02578641|Cell therapy
1543410|NCT02578641|Cytotoxic T Lymphocytes
1543411|NCT02576171|cognitive behavioral therapy;
1543412|NCT02576171|guided self-help
1543413|NCT02576171|adolescent
1543414|NCT02564263|PD1
1543415|NCT02564263|PD-L1
1543416|NCT02564263|PDL1
1543417|NCT02564263|Gene expression profiling (GEP)
1543418|NCT02563574|Alcohol and brain function
1543419|NCT02563574|HIV and brain function
1543420|NCT02563574|Motivational Interviewing
1543421|NCT02560246|Microbiome
1543422|NCT02561143|cachexia
1543423|NCT02561143|nutrition supplementation
1543424|NCT02561143|IAtta
1543425|NCT02561143|palliative care
1543426|NCT02561143|quality of life
1543438|NCT02553577|prenatal
1543439|NCT02553577|cytokines
1543440|NCT02543632|heart failure
1543441|NCT02543632|parachute
1543442|NCT02543632|partitioning device
1543446|NCT02530047|Ovarian cancer
1543447|NCT02530047|Epithelial ovarian cancer
1543448|NCT02530047|Mesenchymal Stem Cells Secreting Interferon Beta
1543449|NCT02530047|MSC-INFb
1543450|NCT02530047|Questionnaires
1543451|NCT02530047|Surveys
1543458|NCT02607852|Patient Reported Outcomes Measure
1543459|NCT02607852|Burns
1543462|NCT02521909|Root Canal length
1543463|NCT02521909|Electronic apex locator
1543464|NCT02521909|Endodontics
1543469|NCT02520141|Biliary cancer
1543470|NCT02520141|Advanced biliary cancers
1543471|NCT02520141|Intrahepatic cholangiocarcinoma
1543472|NCT02520141|Extrahepatic cholangiocarcinoma
1543473|NCT02520141|Gallbladder cancer
1543474|NCT02520141|Received prior chemotherapy
1543475|NCT02520141|Ramucirumab
1543476|NCT02520141|IMC-1121B
1543477|NCT02514083|Ibrutinib
1543478|NCT02514083|Fludarabine
1543479|NCT02514083|BTK Inhibitor
1543480|NCT02514083|T-Cell Modulation
1543483|NCT02504190|Lymphoma
1543484|NCT02504190|TEAM conditioning
1543485|NCT02504190|autologous stem cells transplantation
1543496|NCT02490904|Kidney transplantation
1543497|NCT02490904|Eplerenon
1543498|NCT02487472|France
1543499|NCT02487472|Post-herpetic neuralgia
1543500|NCT02487472|Herpes zoster
1543501|NCT02487472|Economic burden of disease
1543502|NCT02491281|Primary Osteoarthritis, Total Knee Replacement, cartilage
1543507|NCT02453997|lupus nephritis
1543508|NCT02453997|mycophenolic acid
1543509|NCT02453997|pharmacokinetics
1543510|NCT02453997|pharmacogenomics
1543511|NCT02453737|Proton
1543512|NCT02453737|Brachytherapy
1543513|NCT02453737|Partial Breast Irradiation
1543514|NCT02453737|3D Conformal Photon
1543515|NCT02446899|Active Systemic Lupus Erythematosus
1543528|NCT02440672|Osteoarthritis
1543529|NCT02440672|TKA
1543530|NCT02440672|Degenerative Knee Disease
1543531|NCT02439476|Multiple myeloma
1543532|NCT02439476|ASCT
1543533|NCT02439476|plerixafor
1543534|NCT02439476|stem cell mobilization
1543535|NCT02439476|Salvage ASCT using plerixafor-based stem cell mobilization in relapsed multiple myeloma
1543536|NCT02437071|Radiotherapy
1543537|NCT02437071|Ablation
1543538|NCT02437071|Pembrolizumab
1543539|NCT02437071|15-069
1543540|NCT02437071|Metastatic Colorectal Cancer Patients
1543546|NCT02415075|Return to work, state of subjective health, medical rehabilitation, motivational interviewing
1543547|NCT02407548|cholesterol efflux
1543548|NCT02407548|dyslipidemia
1543549|NCT02411084|Graft vs Host Disease
1543550|NCT02411084|Immune System Diseases
1543551|NCT02411084|Dipeptidyl Peptidase 4
1543552|NCT02411084|CD4-Positive T-Lymphocytes
1543553|NCT02411084|Hematopoietic Stem Cell Transplantation
1543554|NCT02576912|Cannabis
1543555|NCT02576912|Marijuana
1543556|NCT02576912|THC
1543557|NCT02576912|Pregnenolone
1543558|NCT02576912|Psychotic Disorders
1543559|NCT02576912|PREG
1543576|NCT02404792|Frail Elderly
1543577|NCT02404792|IGF-1
1543578|NCT02432586|T1DM
1543579|NCT02432586|Diabetes
1543580|NCT02432586|Child
1543581|NCT02432586|Toddler
1543582|NCT02367183|Crohn's Disease
1543583|NCT02367183|Active Crohn's Disease
1543584|NCT02367183|GED-0301
1543585|NCT02367183|Endoscopic
1543586|NCT02367183|Double-Blind
1543587|NCT02367183|IBD
1543588|NCT02367183|Mongersen
1543596|NCT02452697|Nonmyeloablative
1543597|NCT02452697|Stem Cell
1543598|NCT02452697|Transplant
1543604|NCT02368236|Early Detection of Cancer
1543605|NCT02368236|Intervention Studies
1543606|NCT02368236|Randomized Controlled Trial
1543607|NCT02368236|Colorectal Neoplasms
1543608|NCT02368236|Colonic Neoplasms
1543609|NCT02349672|HIE
1543610|NCT02349672|Neonates
1543611|NCT02346162|Pre-pregnancy
1543612|NCT02346162|Weight management
1543613|NCT02342665|Non Hodgkin's Lymphomas
1543624|NCT02336282|Adult survivor of acute lymphoblastic leukemia
1543625|NCT02336282|Executive dysfunction
1543626|NCT02336282|Transcranial direct current stimulation
1543627|NCT02336282|Cancer prevention and control
1543628|NCT02368756|dme
1543629|NCT02316197|DNA-PK Inhibitor
1543630|NCT02316197|advanced solid tumors
1543631|NCT02316197|Chronic lymphocytic Leukemia
1543632|NCT02316197|Phase I, first-in-human
1543633|NCT02316197|dose escalation
1543634|NCT02316197|dose expansion
1543635|NCT02316197|safety profile
1543636|NCT02316197|tolerability
1543637|NCT02316197|PK
1543638|NCT02316197|antitumor activity
1543639|NCT02316197|maximum tolerated dose
1543640|NCT02316197|M3814
1543647|NCT02310867|hand transplantation, amputation
1543648|NCT02302040|Adolescent
1543649|NCT02292355|Temporomandibular Joint Disorders
1543650|NCT02292355|posture
1543651|NCT02292355|pain
1543652|NCT02292355|clinical trial
1543653|NCT02292355|Pilates
1543669|NCT02241837|heart failure
1543670|NCT02241837|percutaneous
1543671|NCT02241837|interventional cardiology
1543672|NCT02241837|apical remodeling
1543673|NCT02241837|LV dilatation
1543674|NCT02241837|akinesis
1543675|NCT02241837|dyskinesis
1543676|NCT02241837|myocardial infarction
1543677|NCT02240940|Heart Failure
1543678|NCT02240940|Volume Reduction
1543679|NCT02240940|Pressure Reduction
1543680|NCT02240940|Ischemic Heart Failure
1543681|NCT02240940|LAD Infarct
1543682|NCT02232893|Gastrointestinal Quality of Life Index (GIQLI)
1543683|NCT02232893|Abdominal Discomfort
1543684|NCT02232893|Abdominal Bloating
1543685|NCT02232893|Laparoscopic colectomy
1543686|NCT02232893|Postoperative ileus (POI)
1543692|NCT02220790|IPFN
1543693|NCT02220790|Pediatric
1543694|NCT02220790|Fungal
1543695|NCT02220790|Biomarker Assays
1543696|NCT02220790|Candida
1543697|NCT02220790|Pediatric ICU patient
1543701|NCT02207816|Infants
1543702|NCT02207816|Efficacy
1543703|NCT02207816|Children
1543704|NCT02207816|Malaria
1543705|NCT02207816|Plasmodium falciparum
1543706|NCT02207816|Safety
1543707|NCT02207816|Surveillance
1543708|NCT02207816|Immunogenicity
1543709|NCT02207816|RTS,S/AS01E
1543710|NCT02207816|Africa
1543724|NCT02185560|Sorafenib
1543725|NCT02185560|Differentiated Thyroid Carcinoma,
1543726|NCT02185560|Japan
1543727|NCT02185560|Post Marketing Surveillance
1543728|NCT02185560|Drug Use Investigation
1543729|NCT02186652|obese
1543730|NCT02186652|children
1543731|NCT02186652|adolescents
1543732|NCT02186652|GERD
1543733|NCT02186652|pharmacokinetic
1543739|NCT02174731|Renal,
1543740|NCT02174731|CKD,
1543741|NCT02174731|Epoetin alfa,
1543742|NCT02174731|Roxadustat,
1543743|NCT02174731|dialysis,
1543744|NCT02174731|anemia
1543746|NCT02161354|Dental Pain
1543747|NCT02161354|Acute Pain
1543748|NCT02161354|Mild Pain
1543749|NCT02161354|Moderate Pain
1543751|NCT02162771|Advanced Follicular Lymphoma
1543752|NCT02141438|Radium-223
1543753|NCT02141438|Metastatic castration-resistant prostate cancer
1543754|NCT02141438|CRPC
1543755|NCT02141438|Phase IV
1543756|NCT02141438|Safety study
1543764|NCT02117492|hysterectomy
1543765|NCT02117492|vaginal cuff
1543785|NCT02117908|prevention
1543786|NCT02117908|radiofrequency treatment
1543787|NCT02117908|lung cancer ablation
1543788|NCT02112656|Carcinoma
1543789|NCT02112656|Carcinoma, Hepatocellular
1543790|NCT02112656|Neoplasms, Glandular and Epithelial
1543791|NCT02112656|Neoplasms by Histologic Type
1543792|NCT02112656|Neoplasms
1543793|NCT02112656|Adenocarcinoma
1543794|NCT02112656|Liver Neoplasms
1543795|NCT02112656|Digestive System Neoplasms
1543796|NCT02112656|Neoplasms by Site
1543797|NCT02112656|Digestive System Diseases
1543798|NCT02112656|Liver Diseases
1543799|NCT02112656|Doxorubicin
1543800|NCT02112656|Antibiotics, Antineoplastic
1543801|NCT02112656|Antineoplastic Agents
1543802|NCT02112656|Therapeutic Uses
1543803|NCT02112656|Pharmacologic Actions
1543804|NCT02106936|Focal Hand Dystonia
1543805|NCT02106936|Depotentiation
1543806|NCT02106936|Transcranial Magnetic Stimulation (TMS)
1543807|NCT02106936|Rapid Paired Associative Stimulation
1543808|NCT02106936|Healthy Volunteer
1543811|NCT02108912|stroke
1543812|NCT02108912|gait
1543813|NCT02108912|cardiovascular
1543817|NCT02086175|relapsed/refractory indolent B cell non-Hodgkin lymphomas
1543818|NCT02085486|dialysis
1543819|NCT02085486|av shunt
1543820|NCT02085486|cannulation
1543821|NCT02085486|ultrasound
1543822|NCT02085486|outcome
1543823|NCT02079077|HIV, Immune quiescence, ASA, Hydroxychloroquin
1543838|NCT02068456|Drug therapy
1543839|NCT02064491|Non-small cell lung cancer
1543840|NCT02064491|EGFR mutant
1543841|NCT02064491|Erlotinib
1543842|NCT02064491|Treatment Beyond Progression
1543844|NCT02058225|Infant Nutrition
1543845|NCT02058225|Magnetic resonance spectroscopy
1543846|NCT02058225|Infant Brain Development
1543847|NCT02058225|Diffusion weighted Imaging
1543848|NCT02058225|Diffusion tensor tractography
1543849|NCT02056223|Patent ductus arteriosus
1543850|NCT02056223|Preterm infant
1543851|NCT02056223|Paracetamol
1543852|NCT02056223|Ibuprofen
1543853|NCT02053350|Clostridium difficile
1543854|NCT02053350|glutamine
1543855|NCT02053350|diarrhea
1543856|NCT02053350|alanyl-glutamine
1543862|NCT02060721|Chronic thromboembolic pulmonary hypertension (CTEPH)
1543863|NCT02027428|Nab-paclitaxel
1543864|NCT02027428|Albumin bound paclitaxel
1543865|NCT02027428|Taxanes
1543866|NCT02027428|Maintenance trials
1543867|NCT02027428|Celgene
1543868|NCT02027428|Abraxane
1543869|NCT02027428|ABI-007
1543870|NCT02027428|NSCLC
1543871|NCT02027428|Non-Small Cell Lung Cancer
1543872|NCT02027428|Cancer of the Lung
1543873|NCT02027428|Carcinoma, Squamous Cell
1543874|NCT02027428|Lung Neoplasms
1543875|NCT02027428|Abound.sqm
1543880|NCT02019420|Pneumonia
1543881|NCT02019420|Tedizolid Phosphate
1543882|NCT02019420|TR-701
1543888|NCT02015767|Drug therapy
1543889|NCT02002884|Upper limb spasticity
1543890|NCT02002884|lower limb spasticity
1543891|NCT02002884|combined upper and lower limb spasticity
1543895|NCT02001142|Insulin Sensitivity
1543896|NCT02001142|Exercise
1543897|NCT02001142|Metabolism
1543909|NCT01976741|Phase I
1543910|NCT01976741|Dose escalation
1543911|NCT01976741|refractory, locally advanced or metastatic solid tumor
1543912|NCT01976741|Bladder cancer
1543913|NCT01976741|squamous non-small cell lung cancer
1543914|NCT01976741|pan-FGFR inhibitor
1543915|NCT01976741|lung adenocarcinoma
1543916|NCT01976741|head and neck cancer
1543917|NCT01970657|Venous Stasis Ulcer
1543918|NCT01970657|VLU
1543919|NCT01975727|PONV
1543920|NCT01975727|Dexamethasone
1543921|NCT01975727|Treatment
1543927|NCT01955239|Head and Neck Cancer
1543928|NCT01955239|Radiotherapy
1543929|NCT01955239|IMRT
1543930|NCT01955239|Stem cell
1543931|NCT01955239|Parotid gland
1543934|NCT01954576|bevacizumab-naïve recurrent GBM
1543935|NCT01954576|bevacizumab-refractory GBM
1543936|NCT01946282|neoplasm
1543937|NCT01946282|colorectal
1543938|NCT01946282|cancer
1543939|NCT01946282|uninsured
1543940|NCT01946282|FIT
1543941|NCT01946282|Fecal Immunochemical Test
1543942|NCT01935063|Vulvodynia
1543943|NCT01935063|Provoked vestibulodynia
1543944|NCT01935063|Vulvar pain
1543945|NCT01935063|Dyspareunia
1543946|NCT01935063|Couples therapy
1543947|NCT01935063|Lidocaine
1543948|NCT01935063|Cognitive behavioral couple therapy
1543949|NCT01935063|Cognitive behavioral therapy
1543950|NCT01935063|Pain
1543951|NCT01935063|Pain during sexual intercourse
1543952|NCT01930864|metformin
1543953|NCT01930864|colorectal cancer
1543954|NCT01930864|chemotherapy
1543955|NCT01931033|Autism Spectrum Disorders
1543956|NCT01931033|Pervasive Developmental Disorders
1543957|NCT01931033|ASD
1543958|NCT01931033|PDD
1543959|NCT01931033|Oxytocin
1543960|NCT01931033|Syntocinon
1543961|NCT01931033|treatment
1543969|NCT01924689|Phase 1
1543970|NCT01924689|Metastatic Disease
1543971|NCT01924689|Solid Tumor
1543972|NCT01924689|Malignancy
1543973|NCT01924689|Metastases
1543974|NCT01924689|Clinical Trial
1543975|NCT01924689|Hypoxia
1543976|NCT01924689|Necrosis
1543977|NCT01924689|Intratumoral
1543978|NCT01924689|Locally advanced cancer
1543979|NCT01924689|Immunotherapy
1543980|NCT01924689|Sarcoma
1543981|NCT01924689|Chordoma
1543982|NCT01924689|Bacteriolytic
1543988|NCT01916135|[18F]-SKI-249380
1543989|NCT01916135|PET Imaging
1543990|NCT01916135|CT Imaging
1543991|NCT01916135|12-182
1544004|NCT01898507|low nicotine
1544005|NCT01898507|cigarettes
1544006|NCT01898507|NMR
1544007|NCT01894230|high cholesterol
1544008|NCT01894230|genetic testing
1544009|NCT01894230|medication adherence
1544010|NCT01894230|statins
1544011|NCT01894230|Adverse Effects
1544012|NCT01894230|pharmacogenetics
1544015|NCT01890421|Myocardial Perfusion Imaging
1544016|NCT01869829|Candida
1544017|NCT01869829|Pediatric
1544018|NCT01869829|Antifungal
1544019|NCT01862315|Hepatic Arterial Infusion (HAI)
1544020|NCT01862315|Floxuridine (FUDR)
1544021|NCT01862315|Dexamethasone (DEX)
1544022|NCT01862315|Gemcitabine
1544023|NCT01862315|Oxaliplatin
1544024|NCT01862315|13-066
1544031|NCT01848249|deceased donors
1544032|NCT01848249|kidney donor
1544033|NCT01848249|transplant recipients
1544034|NCT01848249|kidney transplant
1544035|NCT01848249|delayed graft function
1544036|NCT01848249|biomarkers
1544037|NCT01848249|end stage renal disease
1544038|NCT01848249|graft failure
1544039|NCT01852370|Lung transplantation
1544040|NCT01852370|Bone Marrow Transplantation
1544041|NCT01852370|Unrelated Donor
1544042|NCT01852370|Cadaveric Donor
1544043|NCT01852370|Deceased Donor
1544044|NCT01852370|HLA-mismatch
1544045|NCT01852370|BOLT
1544046|NCT01852370|BMT
1544047|NCT01852370|HSCT
1544051|NCT01830582|MRI
1544052|NCT01830582|rectum
1544053|NCT01830582|13-019
1544083|NCT01817166|cholecalciferol
1544084|NCT01817166|vitamin D
1544085|NCT01817166|immune disease
1544086|NCT01817166|clinically isolated syndrome
1544094|NCT01802359|Erectile dysfunction
1544095|NCT01802359|Mirodenafil
1544096|NCT01802359|Bravonto
1544100|NCT01772212|Mexico
1544101|NCT01772212|terbinafine
1544102|NCT01772212|mycoses
1544103|NCT01772212|pharmacokinetics
1544104|NCT01772160|Adults
1544105|NCT01772160|Italy
1544106|NCT01772160|Herpes Zoster
1544107|NCT01772160|Complications
1544108|NCT01772160|Quality of life
1544109|NCT01772160|Surveillance
1544110|NCT01772160|Burden
1544111|NCT01772160|Cost
1544112|NCT01772160|Incidence
1544113|NCT01767532|Cephalexin
1544114|NCT01767532|Respiratory infections
1544115|NCT01767532|Mexico
1544116|NCT01767532|Bioequivalence
1544117|NCT01755611|Minocycline
1544118|NCT01755611|Mexico
1544119|NCT01755611|Acne
1544120|NCT01755611|bioequivalence
1544121|NCT01748123|Pragmatic
1544122|NCT01748123|Comparative Effectiveness
1544123|NCT01746836|Leukemia
1544124|NCT01746836|Chronic Myeloid Leukemia
1544125|NCT01746836|CML
1544126|NCT01746836|Imatinib-resistant or intolerant
1544127|NCT01746836|Imatinib failure
1544128|NCT01746836|Ph-positive (by cytogenetics or FISH)
1544129|NCT01746836|BCR-ABL-positive (by PCR) CML in chronic phase
1544130|NCT01746836|Ponatinib
1544131|NCT01746836|AP24534
1544132|NCT01738204|endometriosis
1544133|NCT01738204|dysmenorrhea
1544134|NCT01738204|pelvic pain
1544135|NCT01738204|women's health
1544136|NCT01738204|adolescence
1544137|NCT01738204|biorepository
1544138|NCT01738204|observational
1544139|NCT01738204|women
1544140|NCT01738204|female
1544141|NCT01738204|gynecology
1544142|NCT01738204|fertility
1544143|NCT01738204|infertility
1544144|NCT01712659|JAK 1/2
1544145|NCT01712659|Human T-Cell Lymphotropic Virus 1
1544146|NCT01712659|HTLV-1
1544147|NCT01712659|Janus Kinase Inhibitor
1544148|NCT01694485|Ulcerative Colitis, IBD
1544155|NCT01652976|Metastatic
1544156|NCT01652976|Pancreatic Cancer
1544157|NCT01652976|Adenocarcinoma
1544176|NCT01730781|Cannabis dependence
1544177|NCT01730781|Brain Imaging
1544178|NCT01730781|Schizophrenia
1544179|NCT01618890|Prevention
1544180|NCT01618890|Esophageal variceal bleeding
1544181|NCT01618890|Hepatic Venous Pressure Gradient
1544182|NCT01618890|Betablocker therapy
1544183|NCT01614652|Congestive Heart Failure Due to LV Systolic Dysfunction
1544184|NCT01595620|Cannabis
1544185|NCT01595620|THC
1544186|NCT01595620|Pain
1544187|NCT01591629|Cannabis
1544188|NCT01591629|Marijuana
1544189|NCT01591629|Naloxone
1544190|NCT01591629|THC
1544191|NCT01591629|Psychotic Disorders
1544196|NCT01569022|post traumatic stress disorder
1544197|NCT01569022|continuous positive airway pressure
1544198|NCT01569022|oral appliance
1544205|NCT01536275|critical illness
1544206|NCT01536275|children
1544207|NCT01536275|nutrition
1544208|NCT01536275|metabolism
1544214|NCT01500733|Treatment
1544215|NCT01500733|CLL (Chronic Lymphocytic Leukemia)
1544216|NCT01500733|SLL (Small Lymphocytic Lymphoma)
1544217|NCT01500733|Leukemia
1544218|NCT01500733|Lymphocytic Leukemia
1544219|NCT01500733|Chronic Lymphocytic Leukemia
1544220|NCT01500733|CLL
1544221|NCT01500733|Small Lymphocytic Leukemia
1544222|NCT01500733|SLL
1544223|NCT01452048|insulin sensitivity
1544224|NCT01452048|fatty acid metabolism
1544225|NCT01443728|sickle cell disease
1544226|NCT01443728|acute chest syndrome
1544227|NCT01443728|respiratory complications
1544228|NCT01443728|vitamin D
1544229|NCT01577693|dutasteride
1544230|NCT01577693|cross over study
1544231|NCT01577693|bioavailability
1544232|NCT01354093|MacTel
1544233|NCT01354093|Macular telangiectasia type 2
1544243|NCT01297296|heart failure
1544244|NCT01297296|percutaneous
1544245|NCT01297296|interventional cardiology
1544246|NCT01297296|apical remodeling
1544247|NCT01297296|LV dilatation
1544248|NCT01297296|akinesis
1544249|NCT01297296|dyskinesis
1544250|NCT01297296|myocardial infarction
1544251|NCT01286116|heart failure
1544252|NCT01286116|percutaneous
1544253|NCT01286116|interventional cardiology
1544254|NCT01286116|apical remodeling
1544255|NCT01286116|LV dilatation
1544256|NCT01286116|akinesis
1544257|NCT01286116|dyskinesis
1544258|NCT01286116|myocardial infarction
1544259|NCT01277809|Long term care
1544260|NCT01277809|Aging
1544261|NCT01277809|Accidental Falls
1544262|NCT01277809|Muscle Weakness
1544263|NCT01277809|Gait
1544264|NCT01277809|Physical Fitness
1544265|NCT01277809|Muscle Strength
1544266|NCT01277809|Postural Balance
1544267|NCT01277809|Activities of Daily Living
1544268|NCT01277809|Body Weight
1544269|NCT01277809|Blood Pressure
1544270|NCT01277809|Depression
1544271|NCT01277809|Behavior
1544272|NCT01277809|Dementia
1544273|NCT01276483|GIST
1544274|NCT01276483|Response Monitoring
1544275|NCT01276483|Functional Magnetic Imaging
1544276|NCT01276483|Positron Emission Tomography
1544277|NCT01276483|Computer Tomography
1544278|NCT01276587|sickle cell disease
1544279|NCT01276587|children
1544280|NCT01276587|vitamin D
1544281|NCT01276587|safety
1544282|NCT01260675|phase 1 study
1544283|NCT01260675|volunteers
1544288|NCT01345266|Pharyngometry
1544289|NCT01345266|Novel Dry Powder Inhaler
1544290|NCT01345266|HRCT
1544291|NCT01345266|Inhalation Profiles
1544300|NCT01145209|Arzerra
1544301|NCT01145209|Chemoimmunotherapy
1544302|NCT01145209|CLL (Chronic Lymphocytic Leukemia)
1544303|NCT01145209|SLL
1544304|NCT01145209|Small Lymphocytic Lymphoma (SLL)
1544305|NCT01134601|Rectal Cancer
1544306|NCT01134601|Radiation Therapy
1544307|NCT01134601|Capecitabine
1544308|NCT01134601|AZD6244
1544321|NCT01147731|pharmacokinetics
1544322|NCT01147731|albiglutide
1544323|NCT01147731|warfarin
1544324|NCT01147731|Healthy volunteers
1544335|NCT01090440|schizophrenia
1544336|NCT01090440|GSK1144814
1544337|NCT01090440|effect of food
1544338|NCT01090440|healthy subjects
1544339|NCT01090440|depressive disorder
1544340|NCT01090440|pharmacokinetics
1544348|NCT01039883|Healthy Volunteers
1544349|NCT01036061|compulsive discorders
1544350|NCT01036061|addiction
1544352|NCT01016483|MEK inhibitor
1544353|NCT01016483|cancer
1544354|NCT01016483|pancreatic Adenocarcinoma
1544355|NCT01016483|metastatic
1544356|NCT01016483|chemo-naive
1544357|NCT01016483|phase II
1544358|NCT01012999|acute pain, intranasal, sufentanil,
1544359|NCT01012999|Acute pain control with an intranasal opiate
1544360|NCT01000597|pharmacokinetics
1544361|NCT01000597|serum cortisol
1544362|NCT01000597|pharmacodynamics
1544363|NCT01000597|fluticasone furoate
1544364|NCT01000597|healthy Caucasian, Japanese, Korean and Chinese subjects
1544365|NCT00996268|hypertriglyceridemia
1544366|NCT00996268|GSK2212836
1544367|NCT00996268|relative bioavailability
1544368|NCT00982982|Schizophrenia
1544369|NCT00982982|Mental Disorders
1544370|NCT00982982|Psychotic Disorders
1544371|NCT00982982|Schizophrenia and Disorders with Psychotic Features
1544372|NCT00982982|Cannabis
1544373|NCT00941395|Cancer Prevention
1544374|NCT00941395|College students
1544375|NCT00941395|Prevention intervention
1544376|NCT00941395|Smoking
1544377|NCT00941395|Tobacco
1544378|NCT00941395|Internet-based
1544379|NCT00941395|Cognitive Behavioral Therapy
1544380|NCT00941395|Nicotine lozenges
1544387|NCT00896558|GSK1322322, repeat dose, healthy subjects, elderly, drug-drug interaction, probe, midazolam, double-blind
1544388|NCT00880841|healthy normals, phase 1
1544389|NCT00880841|phase 1a study for healthy normals
1544411|NCT00840320|Safety
1544412|NCT00840320|tolerability
1544413|NCT00729768|Renal transplant
1544414|NCT00729768|Raptiva
1544426|NCT00700076|ORG 25935
1544427|NCT00700076|Ketamine
1544428|NCT00700076|healthy subjects
1544432|NCT00697684|Reduced Intensity Allogeneic Stem Cell Transplant
1544433|NCT00697684|Clofarabine
1544434|NCT00697684|Rabbit Antithymocyte Globulin
1544435|NCT00697684|Total Lymphoid Radiation
1544436|NCT00692939|Stem cell transplantation
1544437|NCT00692939|Crohn's Disease
1544438|NCT00678730|THC
1544439|NCT00678730|COMT gene polymorphism
1544440|NCT00678730|schizophrenia
1544441|NCT00678730|cannabis use
1544442|NCT00646503|Hepatitis B, Chronic
1544443|NCT00646503|Telbivudine
1544444|NCT00646503|Polymerase Chain reaction
1544445|NCT00633295|GIST
1544446|NCT00633295|TKI
1544447|NCT00633295|IMATINIB
1544448|NCT00633295|NILOTINIB
1544449|NCT00633295|AMN107
1544450|NCT00573560|Heart failure
1544451|NCT00573560|percutaneous
1544452|NCT00573560|interventional cardiology
1544453|NCT00573560|apical remodeling
1544454|NCT00573560|LV dilatation
1544455|NCT00573560|akinesis
1544456|NCT00573560|dyskinesis
1544580|NCT03197350|heart failure with preserved ejection fraction
1544457|NCT00537537|Hepatitis B, Chronic, Hepatitis B e Antigen positive, Adults, Telbivudine, Adefovir
1544458|NCT00471471|recurrent melanoma
1544459|NCT00471471|stage IV melanoma
1544460|NCT00471471|ciliary body and choroid melanoma, medium/large size
1544461|NCT00471471|extraocular extension melanoma
1544462|NCT00471471|iris melanoma
1544463|NCT00471471|recurrent intraocular melanoma
1544464|NCT00471471|metastatic intraocular melanoma
1544465|NCT00471471|conjunctival melanoma
1544466|NCT00471471|stage IIIA melanoma
1544467|NCT00471471|stage IIIB melanoma
1544468|NCT00471471|stage IIIC melanoma
1544469|NCT00467545|HBeAg-positive
1544470|NCT00467545|chronic hepatitis B
1544471|NCT00467545|telbivudine
1544472|NCT00460512|Schizophrenia
1544473|NCT00460512|Flexible dosing
1544474|NCT00460512|Non-acute patients
1544475|NCT00460512|Antipsychotic
1544476|NCT00460512|Atypical
1544477|NCT00460512|INVEGA
1544484|NCT00214916|Tight glycemic control with
1544485|NCT00214916|intensive insulin treatment
1544486|NCT00214916|versus conventional glycemic control
1544487|NCT00214916|in infant or child in ICU
1544491|NCT00141921|Immunex
1544492|NCT00141921|Amgen
1544493|NCT00141921|Pediatric,
1544494|NCT00141921|plaque psoriasis
1544495|NCT00141921|clinical trial
1544496|NCT00135512|MDD
1544497|NCT00125658|biomechanics
1544498|NCT00125658|Cerebrovascular Accident
1544499|NCT00125658|electromyography
1544500|NCT00125658|muscular weakness
1544501|NCT00125658|recovery of function
1544502|NCT00125658|reflex variability stroke
1544503|NCT00125658|upper-extremity kinematics
1544511|NCT00044122|Mastocytosis
1544512|NCT00044122|Urticaria Pigmentosa
1544513|NCT00044122|Classification
1544514|NCT00044122|Tryptase
1544515|NCT00044122|Mutations
1544528|NCT00001355|Immunodeficiency
1544529|NCT00001355|Infections
1544530|NCT00001355|Phagocytes
1544531|NCT00001355|Cytokines
1544532|NCT00001355|Genetics
1544538|NCT03197753|laryngeal mask airway
1544539|NCT03197753|nasotracheal intubation
1544540|NCT03197753|dental treatment
1544541|NCT03198052|Lung Cancer
1544542|NCT03198052|Immunotherapy
1544543|NCT03198052|CAR-T Cell Therapy
1544544|NCT03198052|PSCA
1544545|NCT03198052|MUC1
1544546|NCT03198052|Cancer with PSCA/MUC1
1544547|NCT03197701|Lung function
1544548|NCT03197701|Inspiratory flow rates
1544549|NCT03198000|Eye Redness
1544550|NCT03198000|Eye Comfort
1544551|NCT03198000|Red Eyes
1544552|NCT03197987|adenoma detection rate
1544553|NCT03197987|cap-assisted colonoscopy
1544554|NCT03197987|endocuff
1544558|NCT03197727|Tooth wear, risk factors, saliva, diet, oral hygiene
1544559|NCT03197337|Vulvodynia
1544560|NCT03197337|Localized Provoked Vulvodynia (LPV)
1544561|NCT03197337|Referred pain
1544562|NCT03197337|Utero-Sacral ligaments laxity
1544563|NCT03197311|Oral surgery
1544564|NCT03197311|Medication adherence
1544565|NCT03196752|cricothyroid membrane
1544566|NCT03196960|Mobilization Therapy
1544567|NCT03196960|Critical Illness
1544568|NCT03196960|Muscle Strength
1544569|NCT03196960|Functional Mobility
1544570|NCT03196960|Outcome
1544571|NCT03196960|Intensive Care Unit
1544572|NCT03196960|Quality of Life
1544573|NCT03196609|Intestinal microbiota, microbial genes, oncology
1544574|NCT03196453|overweight
1544575|NCT03196453|probiotic
1544576|NCT03196453|weight management
1544577|NCT03197402|Leucine
1544578|NCT03197402|Protein
1544579|NCT03197402|Supplementation
1544581|NCT03197350|Imaging
1544582|NCT03197350|Prognosis
1544583|NCT03195959|Pulmonary arterial hypertension
1544584|NCT03195959|Chronic thromboembolic pulmonary hypertension
1544585|NCT03195959|Hypoxia
1544586|NCT03195959|Hyperoxia
1544592|NCT03195751|telemonitoring
1544593|NCT03197272|Myopia
1544594|NCT03197272|corneal Crosslinking
1544595|NCT03198039|Meditation
1544596|NCT03198039|Cognitive Dysfunction
1544597|NCT03198039|Postoperative Period
1544598|NCT03198039|Cardiac Surgery
1544599|NCT03197805|Equivocal Her 2
1544600|NCT03197805|Genomic test
1544611|NCT03194451|bone tissue engineering, dental stem cell differentiation
1544626|NCT03196882|pregnancy
1544627|NCT03196882|iron
1544628|NCT03196882|hemoglobin
1544629|NCT03196882|supplementation
1544630|NCT03196882|neurodevelopment
1544631|NCT03196882|newborn
1544632|NCT03196882|anemia
1544633|NCT03196882|clinical trial
1544634|NCT03197246|PICC line
1544635|NCT03197246|ECG
1544636|NCT03197246|chest x-ray
1544637|NCT03197246|IVECG
1544638|NCT03197246|ICECG
1544639|NCT03195517|Osteopenia
1544640|NCT03195517|Physical activity
1544641|NCT03195517|Bone turnover markers
1544642|NCT03195517|Osteoprogenitor cells
1544643|NCT03195517|Quality of life
1544650|NCT03195738|pediatrics
1544651|NCT03195738|case series
1544652|NCT03195738|feasibility
1544654|NCT03187613|Retinal shift
1544655|NCT03187613|Aniseikonia
1544656|NCT03187613|Metamorphopsia
1544657|NCT03187613|Autofluorescence
1544663|NCT03197597|B. pertussis
1544664|NCT03197597|Acellular vaccination
1544665|NCT03197597|Strain variation
1544666|NCT03186092|Respiratory muscle strength
1544667|NCT03186092|Pulmonary hypertension
1544668|NCT03186092|Respiratory muscle training
1544669|NCT03197285|neck pain
1544670|NCT03197285|eye
1544671|NCT03197285|propioception
1544672|NCT03197285|range of motion
1544673|NCT03197285|pain
1544674|NCT03193840|old acetabular fracture; posterior wall osteotomy
1544675|NCT03185468|CAR T
1544676|NCT03185468|Bladder
1544685|NCT03178669|Colitis, Ulcerative
1544686|NCT03178669|Gastrointestinal Diseases
1544687|NCT03178669|Inflammatory Bowel Disease
1544688|NCT03178669|Immunomodulator Therapy
1544689|NCT03178669|Glucocorticoids
1544690|NCT03178669|Anti-Inflammatory Agents
1544691|NCT03178669|Therapeutic uses
1544692|NCT03178669|Kappaproct
1544693|NCT03178669|IDX0150
1544694|NCT03178669|DIMS0150
1544695|NCT03197389|Biomarker
1544701|NCT03173248|Acute Myeloid Leukemia
1544702|NCT03173248|Leukemia
1544703|NCT03173248|Azacitidine
1544704|NCT03173248|AG-120
1544705|NCT03173248|ivosidenib
1544706|NCT03191331|dietary intervention
1544707|NCT03191331|gestational weight gain
1544708|NCT03191331|gestational diabetes
1544709|NCT03191331|overweight
1544710|NCT03191331|obesity
1544723|NCT03197298|Acute Coronary Syndrome
1544724|NCT03197298|Percutaneous Coronary Intervention
1544725|NCT03197298|Drug-Eluting Stents
1544726|NCT03197298|Platelet Aggregation Inhibitors
1544727|NCT03197298|Ticagrelor
1544728|NCT03197298|clopidogrel
1544729|NCT03197298|Purinergic P2Y Receptor Antagonists
1544735|NCT03166878|CAR-T
1544736|NCT03166878|Cancer treatment
1544737|NCT03166878|Immunotherapy
1544738|NCT03166878|Adoptive cell therapy
1544739|NCT03166878|Chimeric antigen receptor
1544740|NCT03166878|Universal CAR-T
1544741|NCT03197792|Transesophageal ultrasound
1544742|NCT03197792|TEE
1544743|NCT03197792|Portal vein pulsatility
1544744|NCT03197792|Splenic vein pulsatility
1544745|NCT03197792|Venous congestion
1544746|NCT03197792|Strain
1544747|NCT03197792|Right ventricular dysfunction
1544748|NCT03197792|Pulmonary hypertension
1544749|NCT03197792|Venous hypertension
1544750|NCT03160833|HMPL453
1544751|NCT03160833|solid tumor
1544752|NCT03160833|dose escalation
1544759|NCT03156959|Eating disorders
1544760|NCT03156959|Cognitive Behavioral Therapy
1544761|NCT03156959|Eye Movement Desensitization and Processing
1544762|NCT03196687|diastolic dysfunction
1544763|NCT03143426|3D laparoscopic cholecystectomy
1544764|NCT03143426|Junior surgeons
1544765|NCT03143426|Complication
1544766|NCT03143426|Conversion
1544767|NCT03157427|Solar Lentigo, Cryotherapy, Difluoroethane
1544768|NCT03140514|Urine chemokine monitoring
1544769|NCT03139604|Acute graft-versus-host disease
1544770|NCT03139604|Janus kinase (JAK) inhibitor
1544771|NCT03139604|itacitinib
1544772|NCT03139604|corticosteroids
1544773|NCT03139604|allogeneic hematopoietic stem cell transplant (allo-HSCT)
1544774|NCT03126786|Diabetes Mellitus
1544775|NCT03126786|Diabetic Retinopathy
1544776|NCT03126786|Microneedle
1544777|NCT03126786|Mircoinjection
1544778|NCT03126786|Triamcinolone
1544779|NCT03126786|Choroid
1544780|NCT03126786|Choroid Injection
1544781|NCT03126786|Aflibercept
1544782|NCT03126786|Suprachoroidal
1544787|NCT03118323|willingness topay
1544788|NCT03118323|WTP
1544789|NCT03118323|health economic
1544790|NCT03118323|preference-based measures
1544800|NCT03148821|pressure ulcer
1544801|NCT03148821|pressure sore
1544802|NCT03148821|patient positioning
1544807|NCT03118570|Osteogenesis Imperfecta
1544808|NCT03118570|Brittle Bone Disease
1544823|NCT03107728|orthotics
1544824|NCT03107728|high-energy lower extremity trauma
1544825|NCT03107728|physical therapy
1544826|NCT03107728|bracing
1544827|NCT03107728|functional performance
1544828|NCT03107728|performance assessment
1544829|NCT03110458|Acute unilateral vestibulopathy, AUV
1544830|NCT03097315|Uveitis
1544831|NCT03097315|UME
1544832|NCT03097315|Posterior Uveitis
1544833|NCT03097315|Anterior Uveitis
1544834|NCT03097315|Intermediate Uveitis
1544835|NCT03097315|Panuveitis
1544836|NCT03097315|Non-infectious Uveitis
1544837|NCT03097315|Triamcinolone
1544838|NCT03097315|Choroid
1544839|NCT03097315|Choroidal Injection
1544840|NCT03097315|Suprachoroidal
1544841|NCT03097315|Microneedle
1544842|NCT03097315|Microinjection
1544843|NCT03105362|Oral Rehydration Solutions
1544859|NCT03073200|children
1544860|NCT03073200|psoriasis treatment
1544861|NCT03073200|adolescents
1544863|NCT03197636|Vitamin D
1544864|NCT03197636|Soluble PD-1
1544865|NCT03052751|UCB7665
1544866|NCT03052751|Myasthenia Gravis
1544867|NCT03063450|anti PD-L1
1544868|NCT03063450|nivolumab
1544869|NCT03063450|immunotherapy
1544870|NCT03063450|RECIST
1544871|NCT03063450|quality of life
1544872|NCT03063450|survival
1544873|NCT03063450|immune checkpoint inhibition
1544874|NCT03053297|EGFR
1544875|NCT03053297|EGFR mutation
1544876|NCT03053297|EGFRm
1544877|NCT03053297|EGFR-TKI
1544878|NCT03053297|Health care resource utilization
1544879|NCT03053297|Health-Related Quality of Life
1544880|NCT03053297|Locally advanced or metastatic lung cancer
1544881|NCT03053297|NSCLC
1544882|NCT03053297|Non-Small Cell Lung Cancer
1544883|NCT03053297|Observational study
1544884|NCT03053297|Osimertinib
1544885|NCT03053297|Personalized medicine
1544886|NCT03053297|PRO
1544887|NCT03053297|Patient Reported Outcome
1544888|NCT03053297|Resistance
1544889|NCT03053297|T790M
1544890|NCT03053297|Carcinoma, Non-Small-Cell Lung
1544891|NCT03053297|Carcinoma, Bronchogenic
1544892|NCT03053297|Bronchial Neoplasms
1544893|NCT03053297|Lung Neoplasms
1544894|NCT03053297|Respiratory Tract Neoplasms
1544895|NCT03053297|Thoracic neoplasms, Neoplasms by site
1544896|NCT03053297|Lung diseases
1544897|NCT03053297|Respiratory Tract diseases
1544898|NCT03053297|Cancer Chemotherapy
1544899|NCT03053297|Combination Chemotherapy
1544900|NCT03053297|Immunotherapy
1544901|NCT03053297|Radiation
1544907|NCT03197818|COPD
1544908|NCT03197818|Anticholinergics
1544909|NCT03197818|Triple Combination
1544910|NCT03036241|drug-eluting balloon,
1544911|NCT03036241|target lesion revascularization (TLR)
1544912|NCT03036241|restenosis
1544913|NCT03026868|acetabular
1544914|NCT03026868|quadrilateral surface plate
1544915|NCT03035474|Heart Failure
1544916|NCT03035474|Quality Improvement
1544917|NCT03010527|Chronic plaque psoriasis
1544918|NCT03010527|Psoriasis
1544919|NCT03010527|Bimekizumab
1544920|NCT03010150|Malignant neoplasms of lip oral cavity and pharynx
1544921|NCT03010150|Head and Neck Cancer
1544922|NCT03010150|Nasopharyngeal cancer
1544923|NCT03010150|Oropharyngeal cancer
1544924|NCT03010150|Hypopharyngeal cancer
1544925|NCT03010150|Laryngeal cancer
1544926|NCT03010150|Unknown primary cancer with cervical metastases
1544927|NCT03010150|Questionnaire
1544928|NCT03010150|Survey
1544929|NCT03010150|Blood draw
1544930|NCT03010150|Cytokines
1544934|NCT02997202|Gilteritinib
1544935|NCT02997202|ASP2215
1544936|NCT02997202|Safety and Efficacy
1544937|NCT02997202|Acute Myeloid Leukemia
1544938|NCT02963506|AS
1544939|NCT02963506|Ankylosing Spondylitis
1544940|NCT02963506|Bimekizumab
1544941|NCT02969525|Psoriatic Arthritis
1544942|NCT02969525|PsA
1544943|NCT02969525|Bimekizumab
1544944|NCT02956330|RVO
1544945|NCT02956330|ME
1544946|NCT02956330|Central Subfield Thickness
1544947|NCT02956330|OCT
1544948|NCT02956330|Optical Coherence Tomography
1544949|NCT02956330|Cystoid Macular Edema
1544950|NCT02956330|Subretinal Fluid
1544951|NCT02956330|Eylea
1544952|NCT02956330|Aflibercept
1544953|NCT02956330|Anti-VEGF
1544954|NCT02956343|Atrial fibrillation
1544955|NCT02956343|cardiovascular App
1544956|NCT02956343|Rhythm monitoring
1544957|NCT02956343|Stroke prevention
1544958|NCT02952001|Uveitis
1544959|NCT02952001|UME
1544960|NCT02952001|Posterior Uveitis
1544961|NCT02952001|Anterior Uveitis
1544962|NCT02952001|Intermediate Uveitis
1544963|NCT02952001|Panuveitis
1544964|NCT02952001|Non-infectious Uveitis
1544965|NCT02952001|Triamcinolone
1544966|NCT02952001|Choroid
1544967|NCT02952001|Choroidal Injection
1544968|NCT02952001|Suprachoroidal
1544969|NCT02952001|Microneedle
1544970|NCT02952001|Microinjection
1544971|NCT02949180|Atrial fibrillation
1544972|NCT02949180|Rhythm monitoring
1544973|NCT02949180|Cardiovascular App
1544974|NCT02949180|m-health
1544975|NCT03196817|Random Allocation
1544976|NCT03196817|Injections
1544977|NCT03196817|Orthotic Devices
1544978|NCT02942095|Advanced Solid Tumors
1544979|NCT02942095|Metastatic cancer
1544980|NCT02942095|Ixazomib
1544981|NCT02942095|MLN9708
1544982|NCT02942095|Erlotinib
1544983|NCT02942095|Erlotinib hydrochloride
1544984|NCT02942095|OSI-774
1544985|NCT02942095|CP358774
1544986|NCT02942095|Tarceva
1544987|NCT02911038|Complete denture
1544988|NCT02911038|PMMA
1544989|NCT02911038|Stereolithography
1544990|NCT03036462|intravenous iron
1544991|NCT03036462|systolic heart failure
1544992|NCT03036462|iron deficiency
1544993|NCT03036462|morbidity
1544994|NCT03036462|mortality
1544995|NCT02905006|Psoriasis
1544996|NCT02905006|Chronic Plaque Psoriasis
1544997|NCT02905006|Bimekizumab
1544998|NCT03197168|stigma
1544999|NCT03197168|psychosocial intervention
1545000|NCT03197168|low-and-middle income countries
1545001|NCT02895841|oncology
1545002|NCT02895841|bone marrow transplant
1545003|NCT02895841|sickle cell disease
1545004|NCT02874573|Inflammation
1545005|NCT02874573|Schizophrenia
1545006|NCT02858323|Alloimmunization
1545007|NCT02858323|Refractoriness
1545008|NCT02858323|Corrected Count Increment
1545009|NCT02858323|HLA-Compatible
1545014|NCT02839681|Lung Adenocarcinoma
1545015|NCT02839681|Immunotoxin
1545016|NCT02839681|Immunotherapy
1545018|NCT02829034|pulmonary hypertension
1545019|NCT02829034|right ventricular function
1545020|NCT02829034|ranolazine
1545021|NCT02837042|penile cancer
1545022|NCT02837042|Pembrolizumab
1545023|NCT02837042|penile squamous cell carcinoma
1545024|NCT02837042|squamous cell cancer
1545025|NCT02832323|hemodialysis
1545026|NCT02832323|EPO
1545027|NCT02832323|MIRCERA
1545028|NCT02789345|T790M
1545029|NCT02789345|epidermal growth factor receptor (EGFR)
1545047|NCT02780856|Caries Activity Demineralisation
1545048|NCT02780856|Demineralisation
1545049|NCT02771522|Caries, Acitivity, Demineralsiation
1545050|NCT02763566|Hormone Receptor-Positive
1545051|NCT02763566|HER2-Negative
1545052|NCT02763566|CDK4
1545053|NCT02763566|CDK6
1545054|NCT02780635|family, caregiving, ptsd, couples
1545055|NCT02758743|smoking
1545056|NCT02758743|tobacco
1545057|NCT02758743|smoking cessation
1545058|NCT02734862|mycoses
1545059|NCT02710890|Epilepsy
1545060|NCT02710890|pediatric
1545061|NCT02710890|intravenous
1545062|NCT02710890|children
1545063|NCT02710890|Lacosamide
1545064|NCT02710890|VIMPAT®
1545065|NCT02710890|seizure
1545066|NCT02673905|nasal chondrocytes
1545067|NCT02673905|articular chondral lesions
1545068|NCT02673905|tissue engineering
1545069|NCT02673905|femoral condyle
1545070|NCT02673905|trochlea
1545071|NCT02668848|Stroke
1545072|NCT02668848|Dehydration
1545073|NCT02668848|Fluid therapy
1545074|NCT02625922|Serelaxin,
1545075|NCT02625922|Chronic heart failure,
1545076|NCT02625922|Spiroergometry,
1545077|NCT02625922|Troponin,
1545078|NCT02625922|New York Heart Association (NYHA) functional Class II/III,
1545079|NCT02625922|Left ventricular ejection fraction,
1545080|NCT02610543|Primary Sjogren's Syndrome
1545081|NCT02552212|Axial Spondyloarthritis
1545082|NCT02552212|axSpA
1545083|NCT02552212|Ankylosing Spondylitis
1545084|NCT02552212|Anti TNF-alpha
1545085|NCT02552212|Certolizumab Pegol
1545086|NCT02552212|Nr-axSpA
1545087|NCT02552212|Non-radiographic
1545088|NCT02552212|Spondylarthropathies
1545089|NCT02552212|Arthritis
1545090|NCT02552212|Spinal Diseases
1545091|NCT02552212|Immunosuppressive Agents
1545095|NCT02572310|total knee arthroplasty
1545096|NCT02528643|MDV3100
1545097|NCT02528643|advanced hepatocellular carcinoma
1545098|NCT02528643|enzalutamide
1545099|NCT02528643|Xtandi
1545100|NCT02528643|ASP9785
1545101|NCT02532062|lung cancer risk
1545102|NCT02532062|cigarette smokers
1545103|NCT02520011|Refractory AML
1545104|NCT02520011|Relapsed AML
1545105|NCT02520011|AML
1545106|NCT02520011|Newly diagnosed high-risk AML
1545107|NCT02521844|solid tumors
1545108|NCT02521844|responsive to Wnt signalling regulation
1545109|NCT02505542|Axial Spondyloarthritis
1545110|NCT02505542|axSpA
1545111|NCT02505542|Ankylosing Spondylitis
1545112|NCT02505542|Anti TNF-alpha
1545113|NCT02505542|Certolizumab Pegol
1545114|NCT02505542|Remission
1545115|NCT02505542|Spondylarthropathies
1545116|NCT02505542|Arthritis
1545117|NCT02505542|Spinal Diseases
1545118|NCT02505542|Immunosuppressive Agents
1545119|NCT02464787|antioxidants
1545120|NCT02464787|carotenoids
1545121|NCT02464787|diet
1545122|NCT02482428|human papilloma virus (HPV), Genital Warts, Sexually transmitted disease (STD), viral disease
1545123|NCT02451358|Influenza
1545124|NCT02451358|Quadrivalent Inactivated Influenza Vaccine (QIV)
1545125|NCT02477839|epilepsy, children, partial-onset seizures, Lacosamide, LCM, pediatric
1545126|NCT02443324|immuno-oncology
1545259|NCT02075034|Intermediate-2 risk
1545127|NCT02443324|Vascular Endothelial Growth Factor (VEGF)
1545128|NCT02443324|angiogenesis
1545129|NCT02443324|PD-1
1545130|NCT02443324|carcinoma of the bladder
1545131|NCT02443324|carcinoma of the urethra
1545132|NCT02443324|carcinoma of the ureter
1545133|NCT02443324|carcinoma of the renal pelvis
1545134|NCT02443324|carcinoma of the biliary tract
1545135|NCT02408887|Thyroidectomy
1545136|NCT02408887|pCND
1545137|NCT02408887|QOL
1545138|NCT02408887|Outcomes
1545139|NCT02408887|Screening
1545140|NCT02397720|Leukemia
1545141|NCT02397720|Acute myeloid leukemia
1545142|NCT02397720|AML
1545143|NCT02397720|Refractory/ relapsed
1545144|NCT02397720|5-azacytidine
1545145|NCT02397720|Azacitidine
1545146|NCT02397720|5-aza
1545147|NCT02397720|Vidaza
1545148|NCT02397720|5-AZC
1545149|NCT02397720|AZA-CR
1545150|NCT02397720|Ladakamycin
1545151|NCT02397720|NSC-102816
1545152|NCT02397720|Azacytidine
1545153|NCT02397720|Nivolumab
1545154|NCT02397720|BMS-936558
1545155|NCT02397720|Phone calls
1545156|NCT02371928|Shoulder
1545157|NCT02371928|Instability
1545158|NCT02371928|Neuromuscular
1545159|NCT02371928|Physiotherapy
1545160|NCT02371928|Exercise
1545161|NCT02371928|Dislocation
1545162|NCT02371928|Recurrence
1545163|NCT02361762|Executive Function
1545164|NCT02361762|Theory of Mind
1545165|NCT02361762|Individual Differences
1545166|NCT02361762|Social Skills
1545167|NCT02361762|Executive Control
1545168|NCT02330926|Combined modality treatment
1545169|NCT02330926|Diet therapy
1545170|NCT02330926|Exercise therapy
1545171|NCT02330926|Ibuprofen
1545172|NCT02330926|Dietary supplements
1545173|NCT02315833|Migraine
1545174|NCT02315833|Aura
1545175|NCT02310828|Cluster headache
1545176|NCT02310828|Migrainous neuralgia
1545177|NCT02310828|Horton's headache
1545178|NCT02310828|Histaminic cephalalgia
1545179|NCT02283047|cardiovascular risk, obesity, interval training, diet
1545180|NCT02261857|Obstructive Sleep Apnea
1545181|NCT02261857|Craniofacial Abnormalities
1545182|NCT02261857|Pediatrics
1545183|NCT02261857|Computer-Aided Design
1545184|NCT02261857|Continuous Positive Airway Pressure
1545185|NCT02261857|Three-Dimensional Printing
1545186|NCT02261857|Additive Manufacturing
1545187|NCT02256124|Neurofibromatosis type 1
1545188|NCT02256124|NF1
1545189|NCT02256124|Cognition
1545190|NCT02256124|Learning problems
1545191|NCT02256124|Lamotrigine
1545192|NCT02256124|Transcranial magnetic stimulation
1545193|NCT02256124|TMS
1545199|NCT02225522|Intensive Care Units, Neonatal
1545200|NCT02225522|Infant, Newborn
1545201|NCT02225522|Genetic Diseases, Inborn
1545202|NCT02209532|Lymph node mapping
1545203|NCT02209532|Endometrial cancer
1545204|NCT02209532|Uterine cancer
1545205|NCT02209532|Cervical cancer
1545206|NCT02205307|Rectal cancer
1545207|NCT02205307|Rectal neoplasm
1545208|NCT02205307|Colorectal surgery
1545209|NCT02205307|Anastomosis
1545210|NCT02203019|Dexmedetomidine
1545211|NCT02203019|Propofol
1545212|NCT02203019|Sepsis
1545213|NCT02203019|Mechanical Ventilation
1545214|NCT02203019|Respiratory Failure
1545215|NCT02173743|plasma, calcific tendinitis, rotator cuff, PRP
1545216|NCT02154477|hypogonadotropic hypogonadism
1545217|NCT02125461|Locally advanced
1545218|NCT02125461|Unresectable Non-Small Cell Lung Cancer
1545219|NCT02125461|MEDI4736
1545220|NCT02125461|PD-L1
1545221|NCT02125461|Stage III Non-Small Cell Lung Cancer
1545222|NCT02125461|Chemoradiation
1545223|NCT02125461|Immune-mediated cancer therapy
1545224|NCT02115295|Leukemia
1545225|NCT02115295|Acute Myeloid Leukemia
1545226|NCT02115295|AML
1545227|NCT02115295|High Risk Myelodysplastic Syndrome
1545228|NCT02115295|HR MDS
1545229|NCT02115295|Myeloid Blast Phase of Chronic Myeloid Leukemia
1545230|NCT02115295|CML
1545231|NCT02115295|Acute Biphenotypic Leukemia
1545232|NCT02115295|Cladribine
1545233|NCT02115295|Leustatin
1545234|NCT02115295|2-CdA
1545235|NCT02115295|Cytarabine
1545236|NCT02115295|Ara-C
1545237|NCT02115295|Cytosar
1545238|NCT02115295|DepoCyt
1545239|NCT02115295|Cytosine Arabinosine Hydrochloride
1545240|NCT02115295|Idarubicin
1545241|NCT02115295|Idamycin
1545242|NCT02115295|Phone calls
1545243|NCT02107235|Chemoradiotherapy
1545244|NCT02107235|cisplatin
1545245|NCT02099383|Stroke
1545246|NCT02099383|Dehydration
1545247|NCT02099383|Fluid Therapy
1545248|NCT02077868|CRC
1545249|NCT02077868|mCRC
1545250|NCT02077868|maintenance treatment
1545251|NCT02077868|immune modulation
1545252|NCT02077868|colorectal cancer
1545253|NCT02077868|immunotherapy
1545254|NCT02077868|metastatic
1545255|NCT02075034|Myelodysplastic syndrome
1545256|NCT02075034|MDS
1545257|NCT02075034|Low risk
1545258|NCT02075034|Intermediate-1 risk
1545260|NCT02075034|International Prognostic Scoring System
1545261|NCT02075034|IPSS
1545262|NCT02061774|acetaminophen in transforaminal lumbar interbody fusion
1545263|NCT02047253|carfilzomib
1545264|NCT02047253|prostate cancer
1545265|NCT02047253|PSA (prostate-specific antigen)
1545266|NCT02047253|CRPC (castration-resistant prostate cancer)
1545267|NCT02029768|outcome
1545268|NCT02069899|Hemophagocytic lymphohistiocytosis (HLH) previously treated with NI-0501
1545269|NCT02019641|Exercise
1545270|NCT02019641|Interstitial Lung Disease
1545271|NCT02019641|Pulmonary Rehabilitation
1545272|NCT02016924|Pediatrics
1545273|NCT02016924|Adolescents
1545274|NCT02016924|HIV
1545275|NCT02016924|HIV-1
1545276|NCT02016924|Treatment experienced
1545277|NCT02008552|Genetic factor
1545278|NCT02008552|Valvulopathy
1545279|NCT02008552|Mediator
1545280|NCT01996241|adolescent girls
1545281|NCT01996241|female sex work
1545282|NCT01996241|age at marriage
1545283|NCT01996241|retention in school
1545284|NCT01996241|sexual debut
1545285|NCT01996241|India
1545286|NCT01996241|Karnataka
1545291|NCT01955343|Immune response
1545292|NCT01955343|Cancer
1545293|NCT01927731|Blood And Marrow Transplantation
1545294|NCT01927731|Cord blood transplantation
1545295|NCT01927731|CBT
1545296|NCT01927731|Platelet count
1545297|NCT01927731|Haploidentical donor stem cell transplant
1545298|NCT01927731|Eltrombopag
1545299|NCT01927731|Promacta
1545300|NCT01917136|pulmonary hypertension
1545301|NCT01917136|right ventricular function
1545302|NCT01917136|11C acetate
1545303|NCT01917136|FDG
1545304|NCT01917136|ranolazine
1545305|NCT03197532|fertility
1545306|NCT03197532|hormones
1545307|NCT03197532|healthy
1545308|NCT03197532|chemotherapy
1545309|NCT03197532|oncofertility
1545310|NCT03197532|alkylating agent
1545311|NCT03197532|fertility after cancer
1545312|NCT03197532|late effects
1545313|NCT03197532|survivorship
1545314|NCT03197532|healthy volunteers
1545315|NCT03197532|perimenopause
1545316|NCT03197532|middle age
1545317|NCT01894204|HTTPE
1545318|NCT01894204|Idiopathic Pulmonary embolism
1545319|NCT01857349|Efficacy
1545320|NCT01857349|surgical scrubs
1545321|NCT01857349|Total Knee Arthroplasty
1545322|NCT01839110|pulmonary hypertension
1545323|NCT01839110|right ventricular function
1545324|NCT01839110|ranolazine
1545325|NCT01823198|Leukemia
1545326|NCT01823198|Acute myeloid leukemia
1545327|NCT01823198|AML
1545328|NCT01823198|Myelodysplastic syndromes
1545329|NCT01823198|MDS
1545330|NCT01823198|Blood And Marrow Transplantation
1545331|NCT01823198|Myeloproliferative Diseases
1545332|NCT01823198|High Risk Myeloid Malignancies
1545333|NCT01823198|Allogeneic stem cell transplant
1545334|NCT01823198|Natural Killer Cells
1545335|NCT01823198|NK
1545336|NCT01823198|Immune cells
1545337|NCT01823198|Stem cell transplant
1545338|NCT01823198|Busulfan
1545339|NCT01823198|Busulfex
1545340|NCT01823198|Myleran
1545341|NCT01823198|Interleukin-2
1545342|NCT01823198|IL-2
1545343|NCT01823198|Aldesleukin
1545344|NCT01823198|Proleukin
1545345|NCT01823198|Thymoglobulin
1545346|NCT01823198|Antithymocyte globulin
1545347|NCT01823198|ATG
1545348|NCT01823198|G-CSF
1545349|NCT01823198|Filgrastim
1545350|NCT01823198|Neupogen
1545351|NCT01823198|Tacrolimus
1545352|NCT01823198|Prograf
1545353|NCT01823198|Methotrexate
1545354|NCT01814475|myelofibrosis
1545355|NCT01814475|unfavourable prognostic factors
1545356|NCT01814475|Allogeneic stem cell transplantation
1545357|NCT01814475|Progression Free Survival
1545358|NCT01814475|thrombocythemia vera
1545359|NCT01814475|polycythemia vera
1545360|NCT01814475|Reduced-intensity conditioning
1545361|NCT01792271|COPD
1545362|NCT01792271|Chronic Bronchitis
1545363|NCT01792271|Hypertonic Saline
1545364|NCT01676662|Urinary Incontinence
1545365|NCT01676662|Urinary Incontinence, Stress
1545366|NCT01676662|Urination Disorders
1545367|NCT01676662|Urologic Diseases
1545368|NCT01676662|Urological Manifestations
1545369|NCT01676662|Signs and Symptoms
1545374|NCT01639469|Parkinson Disease
1545375|NCT01639469|Quality of Life
1545376|NCT01639469|Exercise Therapy
1545377|NCT01656278|Arthritis, Rheumatoid/drug therapy
1545378|NCT01656278|Arthritis, Rheumatoid/pathology
1545379|NCT01656278|Disease Progression
1545380|NCT01656278|Longitudinal Studies
1545381|NCT01656278|Prospective Studies
1545382|NCT01656278|Imaging, Magnetic Resonance
1545383|NCT01656278|Remission Induction
1545384|NCT01656278|Synovitis/immunology
1545385|NCT01656278|Synovitis/pathology
1545386|NCT01656278|Wrist Joint/pathology
1545387|NCT01656278|Wrist Joint/physiopathology
1545388|NCT01538563|ON 01910.Na
1545389|NCT01538563|rigosertib sodium
1545390|NCT01538563|rogosertib
1545391|NCT01538537|ON 01910.Na
1545392|NCT01538537|rigosertib Sodium
1545393|NCT01538537|rigosertib
1545394|NCT01572519|Relapsed Hodgkin lymphoma
1545395|NCT01572519|Refractory Hodgkin lymphoma
1545396|NCT01572519|JNJ-40346527
1545397|NCT01572519|Dose-escalation
1545398|NCT01572519|Pharmacokinetics
1545408|NCT01261325|Epilepsy
1545409|NCT01261325|Brivaracetam
1545410|NCT01261325|Partial Onset Seizures
1545411|NCT01261325|Adjunctive treatment
1545412|NCT01165905|cancer
1545413|NCT01165905|solid malignancy
1545414|NCT01165905|tumor
1545415|NCT01165905|malignant neoplasm
1545416|NCT01165905|histologically confirmed solid malignancy
1545417|NCT01161121|Fractional flow reserve
1545418|NCT01161121|adenosine
1545419|NCT01161121|regadenoson
1545420|NCT01125891|gemcitabine hydrochloride
1545421|NCT01125891|Gemzar
1545422|NCT01125891|ON 01910.Na
1545423|NCT01089478|Back pain
1545424|NCT01089478|Low back pain
1545425|NCT01089478|Cytology
1545426|NCT01089478|Epiduroscopy
1545427|NCT01089478|Pain
1545428|NCT01089478|Radiculopathy
1545429|NCT01084889|polypropylene mesh
1545430|NCT01084889|Prolapse
1545431|NCT01084889|Cystocele
1545432|NCT01084889|Surgical Mesh
1545438|NCT01048619|Myelodysplastic Syndrome
1545439|NCT01048619|MDS
1545440|NCT01019603|Acne
1545441|NCT00938912|Lacosamide (VIMPAT)
1545442|NCT00909714|stroke
1545443|NCT00909714|non-invasive cortical stimulation
1545444|NCT00909714|motor recovery
1545445|NCT00909714|cortical plasticity
1545446|NCT00909714|TDCS
1545447|NCT00867061|Myelodysplastic
1545448|NCT00867061|IPSS Intermediate 1
1545449|NCT00867061|IPSS Intermediate 2
1545450|NCT00867061|IPSS High risk
1545451|NCT00861783|oxaliplatin
1545452|NCT00861783|diaminocyclohexane oxalatoplatinum
1545453|NCT00861783|oxalatoplatin
1545454|NCT00861783|oxalatoplatinum
1545455|NCT00861783|Eloxatin
1545456|NCT00861328|Phase 1
1545457|NCT00861328|maximum tolerated dose
1545458|NCT00861328|oxaliplatin
1545459|NCT00861328|irinotecan
1545460|NCT00861328|ON 01910.Na
1545461|NCT00859963|Press fit tibial tray
1545462|NCT00850291|Partial duodenopancreatectomy using electrosurgical vessel sealing device
1545463|NCT00854646|ON 01910.Na
1545464|NCT00854646|refractory
1545465|NCT00854646|leukemia
1545466|NCT00854646|myelodysplastic
1545467|NCT00854646|cell cycle
1545474|NCT00702988|Neonatal outcome
1545475|NCT00702988|Congenital malformations
1545476|NCT00702988|In-Vitro Fertilization
1545477|NCT00702988|Controlled ovarian stimulation
1545478|NCT00702988|Follow-up
1545479|NCT00698854|Total Knee Arthroplasty
1545480|NCT00698854|Total Knee Replacement
1545481|NCT00698854|Knee Arthritis
1545482|NCT00341406|Obesity
1545483|NCT00341406|Type 2 Diabetes Mellitus
1545484|NCT00341406|Adipose Cell Turn Over
1545485|NCT00280748|recurrent non-small cell lung cancer
1545486|NCT00280748|stage IV non-small cell lung cancer
1545487|NCT00280748|tumors metastatic to brain
1545488|NCT00144794|Hurler's Syndrome
1545489|NCT00144794|Hurler-Scheie Syndrome
1545490|NCT00144794|Scheie Syndrome
1545498|NCT00018044|Morphotype
1545499|NCT00018044|Pulmonary
1545500|NCT00018044|Infection
1545501|NCT00018044|Mycobacterium
1545502|NCT00018044|Nontuberculous
1545503|NCT00018044|Mycobacterial Infection
1545504|NCT00018044|Nontuberculous Mycobacterial Infection
1545505|NCT00018044|NTM
1545506|NCT00018044|Job's Syndrome
1545507|NCT00018044|Job Syndrome
1545508|NCT00018044|Cystic Fibrosis
1545509|NCT00018044|CF
1545521|NCT03200600|Carcinoma, Non-Small-Cell Lung
1545522|NCT03200600|Surgery
1545523|NCT03200600|Dexamethasone
1545524|NCT03200600|Flubiprofen Axetil
1545525|NCT03200600|Delirium
1545564|NCT03200197|Chewing gum
1545565|NCT03200197|Artificial saliva
1545566|NCT03200197|Saliva
1545567|NCT03200197|Mastication
1545568|NCT03200197|Salivary glands
1545569|NCT03200197|Xerostomia
1545570|NCT03197974|stage
1545571|NCT03197974|online
1545572|NCT03197974|self-help
1545573|NCT03197974|coaching support
1545574|NCT03197974|quality of life
1545575|NCT03197974|mindfulness
1545576|NCT03197974|psychoeducation
1545577|NCT03197974|persuasive systems design
1545578|NCT03197974|psychosocial
1545660|NCT03192020|Hand dysfunction
1545661|NCT03192020|Xiapex
1545662|NCT03192020|Xiaflex
1545663|NCT03192020|Aponeurectomy
1545664|NCT03192020|Aponeurotomy
1545665|NCT03192020|Dupuytren disease
1545666|NCT03192020|Joint contracture
1545667|NCT03192020|Surgery
1545687|NCT03199989|colon cancer
1545688|NCT03199989|adjuvant chemotherapy
1545689|NCT03199989|high risk
1545698|NCT03172988|Carcinoma, Non-Small-Cell Lung
1545699|NCT03172988|Surgery
1545700|NCT03172988|Dexamethasone
1545701|NCT03172988|Flurbiprofen axetil
1545702|NCT03172988|Long-term survival
1545703|NCT03200184|Hepatitis C
1545704|NCT03200184|sofosbuvir
1545705|NCT03200184|daclatasvir
1545715|NCT03172442|Class III treatment
1545716|NCT03172442|orthodontic removable traction appliance
1545717|NCT03172442|RCT
1545731|NCT03158025|Recreational sedatives
1545732|NCT03158025|Healthy participants
1545733|NCT03158025|Lemborexant
1545734|NCT03158025|E2006
1545735|NCT03158025|Zolpidem
1545736|NCT03158025|Suvorexant
1545740|NCT03200158|Stress related mucosal disease (SRMD)
1545741|NCT03200158|APACHEII score
1545742|NCT03200158|C-reactive protein
1545743|NCT03200158|Malondialdehyde (MDA)
1545744|NCT03200158|transforming growth factor (TGF)
1545745|NCT03200158|interleukin (IL)
1545746|NCT03200938|pulpotomy
1545747|NCT03200938|Biological cement
1545748|NCT03200938|Deciduous tooth
1545827|NCT03129178|Nitrate
1545828|NCT03129178|Nitric oxide
1545829|NCT03129178|Microvascular
1545851|NCT03177174|locally advanced nasopharyngeal carcinoma
1545852|NCT03177174|Concurrent chemoradiotherapy
1545853|NCT03177174|Toxic reaction
1545922|NCT02993874|Ergonemic resources
1545923|NCT02993874|Walking capacity
1545924|NCT02993874|Peripheral artery disease
1545925|NCT02987790|Intensive care
1545926|NCT02987790|Sepsis
1545927|NCT02987790|Biomarkers
1545928|NCT02987790|C-reactive Protein
1545929|NCT02987790|Antimicrobial
1545930|NCT02987790|Systemic infection
1546044|NCT02886754|Clinical Communication
1546045|NCT02886754|ISBAR
1546046|NCT02886754|Simulation
1546047|NCT02886754|Performance
1546048|NCT02886754|Non technical skills
1546049|NCT02886754|Proficiency
1546071|NCT02843633|Acute Coronary Syndrome
1546072|NCT02843633|Percutaneous Coronary Intervention
1546073|NCT02843633|Drug Coated Stent
1546074|NCT02843633|Drug Eluting Stent
1546089|NCT02908490|Arthritis, Rheumatoid
1546090|NCT02908490|Atherosclerosis
1546091|NCT02819336|urinary incontinence
1546092|NCT02819336|electroacupuncture
1546093|NCT02819336|stroke
1546094|NCT02819336|complications
1546095|NCT02819336|randomized controlled trial
1546096|NCT02819336|pilot projects
1546135|NCT02797951|cluster headache
1546136|NCT02797951|headache
1546137|NCT02797951|brain diseases
1546138|NCT02797951|central nervous system diseases
1546139|NCT02797951|headache disorders
1546140|NCT02797951|headache disorders, primary
1546141|NCT02797951|nervous system diseases
1546142|NCT02797951|neurologic manifestations
1546143|NCT02797951|pain
1546144|NCT02797951|trigeminal autonomic cephalalgias
1546200|NCT02777216|RDN
1546384|NCT02589665|IL-23 antibody
1546452|NCT02563717|Resuscitation
1546453|NCT02563717|Positive-Pressure Respiration
1546454|NCT02563717|Infant, Extremely Premature
1546455|NCT02563717|Continuous Positive Airway Pressure
1546456|NCT02563717|Intubation
1546537|NCT02435433|liver cancer
1546585|NCT02410265|guided self-help
1546586|NCT02410265|student mental health
1546587|NCT02410265|task shifting
1546588|NCT02410265|prevention
1546613|NCT02361814|flexor tendon
1546614|NCT02361814|finger
1546615|NCT02361814|amniotic membrane
1546616|NCT02361814|allograft
1546617|NCT02361814|tendon injury
1546654|NCT02320929|irrigation
1546655|NCT02320929|tenosynovitis
1546656|NCT02320929|purulent
1546657|NCT02320929|closed-catheter
1546658|NCT02320929|flexor tendon
1546769|NCT02151877|Ischemia/reperfusion injury
1546788|NCT02043717|Cystic Fibrosis
1546789|NCT02043717|Vitamin D
1546790|NCT02043717|Lung function
1546814|NCT02261883|PPHN
1546838|NCT01890213|alphavirus
1546839|NCT01890213|colon cancer
1546840|NCT01890213|immune response
1546841|NCT01890213|CEA
1546865|NCT01851044|Platelet Rich Plasma
1546866|NCT01851044|Whole Blood Injection
1546867|NCT01851044|Lateral Epicondylitis
1546868|NCT01851044|Tennis Elbow
1546907|NCT01710397|Antiretroviral therapy
1546908|NCT01710397|South Africa
1546924|NCT01655225|Advanced Breast Cancer
1546925|NCT01655225|Advanced Lung Cancer
1546926|NCT01655225|Mesothelioma
1546927|NCT01655225|Lymphoma
1546935|NCT01623076|Neuromyelitis Optica
1546936|NCT01623076|Neuromyelitis Optica Spectrum Disorder
1546937|NCT01623076|Transverse Myelitis
1546938|NCT01623076|Optic Neuritis
1546939|NCT01623076|Biorepository
1547019|NCT01155635|Myocardial infarction
1547020|NCT01155635|Adrenergic beta-Antagonists
1547021|NCT01155635|Percutaneous coronary intervention
1547233|NCT03201601|Polycystic ovarian syndrome
1547234|NCT03201601|D-chiro-inositol
1547235|NCT03201601|Fertility
1547240|NCT03202667|SGLT2-inhibitor
1547241|NCT03202667|Treatment
1547242|NCT03201718|Hepatitis C
1547243|NCT03201718|Paritaprevir
1547244|NCT03201718|Ritonavir
1547245|NCT03201718|Ombitasvir
1547246|NCT03201718|Dasabuvir
1547247|NCT03201848|Huaiqihuang granule
1547248|NCT03201848|immune thrombocytopenia
1547249|NCT03201848|randomized
1547250|NCT03201848|double-blind
1547251|NCT03201848|placebo-controlled,
1547252|NCT03201900|perampanel
1547253|NCT03202004|PGA
1547254|NCT03202004|efficacy
1547255|NCT03202004|PASI
1547256|NCT03202004|GSK2894512
1547257|NCT03202004|NRS
1547258|NCT03202004|Topical
1547259|NCT03202004|psoriasis
1547263|NCT03202160|Goiter
1547264|NCT03202173|Probe-based confocal laser endomicroscopy
1547265|NCT03202173|Optical biopsy
1547266|NCT03202199|Adenocarcinoma, pancreas, PET/MRI
1547267|NCT03202303|Autism
1547268|NCT03202303|Irritability
1547269|NCT03202303|cannabinoids
1547270|NCT03202316|Malignant neoplasm of breast
1547271|NCT03202316|Metastatic inflammatory breast cancer
1547272|NCT03202316|mIBC
1547273|NCT03202316|Cobimetinib
1547274|NCT03202316|Atezolizumab
1547275|NCT03202316|MPDL3280A
1547276|NCT03202316|Eribulin
1547277|NCT03202316|E7389
1547278|NCT03201978|Healthy adults
1547279|NCT03201978|GSK2894512
1547280|NCT03201978|Topical
1547281|NCT03201978|Psoriasis
1547282|NCT03201978|Pharmacokinetics
1547283|NCT03201185|Cardiovascular events
1547284|NCT03201185|Ventricular remodeling
1547285|NCT03201406|Renal biopsy, Chronic kidney disease,Diabetic nephropathy,Lupus Nephritis
1547286|NCT03201575|Intensive care
1547287|NCT03201575|septic shock
1547288|NCT03201575|multiple organ failure
1547289|NCT03201575|Ischemia-reperfusion
1547290|NCT03201575|ischemic conditioning
1547291|NCT03201575|remote conditioning
1547292|NCT03201575|SOFA score
1547293|NCT03199976|wheeze
1547294|NCT03199976|shortness of breath
1547295|NCT03202147|Ischemic stroke, post-stroke cognitive impairment, PSCI
1547296|NCT03202108|Ketogenic
1547297|NCT03202108|Diet
1547298|NCT03202108|Epilepsy
1547299|NCT03202108|Glut-1 DS
1547300|NCT03202108|Krio
1547301|NCT03202095|Depression
1547302|NCT03202095|Type 2 Diabetes
1547303|NCT03202095|Creatine
1547304|NCT03202095|Diabetes
1547305|NCT03202069|Protein
1547306|NCT03202069|Weight Loss
1547307|NCT03202030|immediate dentoalveolar restoration
1547308|NCT03202030|bio-oss
1547309|NCT03202030|immediate dental implant
1547310|NCT03202030|bovine bone
1547311|NCT03201991|ALS
1547315|NCT03202641|ARDS
1547316|NCT03202641|PEEP titration
1547317|NCT03202641|Open Lung Strategy
1547318|NCT03202641|Right heart function
1547319|NCT03202641|Lung recruitment maneuver
1547320|NCT03202641|Esophageal Pressure
1547321|NCT03202641|Respiratory system compliance
1547322|NCT03200925|video
1547323|NCT03200925|skin-to-skin
1547324|NCT03200925|kangaroo care
1547325|NCT03200925|prenatal education
1547326|NCT03200808|Nonneoplastic Epithelial Disorders
1547327|NCT03200808|methylene blue
1547328|NCT03200808|treatment
1547329|NCT03200210|Continuous Ambulatory Peritoneal Dialysis (CAPD)
1547330|NCT03200210|Hyperuricemia
1547331|NCT03200210|Cardiovascular events
1547332|NCT03200210|Treatment
1547333|NCT03200730|Family Dignity Intervention
1547334|NCT03200730|Multicentre Randomized Control Trial
1547335|NCT03200730|Palliative Care
1547336|NCT03200730|End-of-Life Care
1547337|NCT03200275|Legionella urine antigen test
1547338|NCT03200860|heart failure
1547339|NCT03200860|diuretic response
1547340|NCT03200860|empagliflozin
1547341|NCT03199313|tuberculosis
1547342|NCT03199313|TB
1547343|NCT03199313|Sutezolid
1547344|NCT03199313|pulmonary tuberculosis
1547345|NCT03200093|Clostridium difficile
1547346|NCT03200093|C diff
1547347|NCT03200093|Oral Vancomycin
1547348|NCT03200093|Prophylaxis
1547349|NCT03200483|Autonomic Nervous System
1547350|NCT03200483|Aerobic exercise
1547351|NCT03200483|Recuperation
1547352|NCT03200483|Music
1547353|NCT03199950|Delirium
1547354|NCT03199950|Haloperidol
1547355|NCT03199950|Prophylactic
1547356|NCT03199950|High-risk
1547357|NCT03201276|glucosamine sulfate
1547358|NCT03201276|individual differences
1547359|NCT03201276|gene polymorphism
1547360|NCT03200847|Pembrolizumab
1547361|NCT03200847|All-Trans Retinoic Acid
1547362|NCT03199599|PET/CT
1547363|NCT03199599|image processing
1547364|NCT03199599|outcome
1547365|NCT03202277|physical activity, sleep, sedentary behavior, dietary intake, smartphone
1547366|NCT03199573|sunscreen
1547367|NCT03202459|Anesthesia
1547368|NCT03202459|Complications
1547369|NCT03202459|Nausea
1547370|NCT03202459|Vomiting
1547371|NCT03201783|frozen-thawed embryo transfer
1547372|NCT03201783|time interval
1547373|NCT03201796|Bacterial prostatitis
1547374|NCT03201796|CBP
1547375|NCT03201796|Levofloxacin
1547376|NCT03201796|Prulifloxacin
1547377|NCT03199339|tuberculosis
1547378|NCT03199339|TBA7371
1547379|NCT03199339|TBA-7371
1547380|NCT03199339|TB Alliance
1547381|NCT03199339|TB
1547382|NCT03199339|Pulmonary Tuberculosis
1547383|NCT03198923|Non-small Cell Lung Cancer
1547384|NCT03202485|astigmatism
1547385|NCT03202485|high myopia
1547386|NCT03202485|phakic intraocular lens
1547387|NCT03202485|astigmatic keratotomy
1547388|NCT03202485|toric
1547392|NCT03200509|nonspecific low back pain
1547393|NCT03200509|chronic pain
1547394|NCT03199755|therapeutic
1547395|NCT03199755|ACT
1547396|NCT03199755|gametocyte
1547397|NCT03201952|Glucose
1547398|NCT03201952|Ileostomy
1547399|NCT03201939|HIV/AIDS
1547400|NCT03201939|sub-Saharan Africa
1547401|NCT03201939|Kidney disease
1547402|NCT03201939|Albuminuria
1547403|NCT03201939|Genetic risk
1547404|NCT03200457|Liver iron
1547405|NCT03200457|Liver steatosis
1547406|NCT03200457|MRI
1547407|NCT03201003|AR101
1547408|NCT03201003|Characterized Peanut Allergen
1547409|NCT03201003|CPNA (Characterized Peanut Allergen)
1547410|NCT03201003|OIT (oral immunotherapy)
1547411|NCT03201003|Peanut Allergy
1547412|NCT03201003|Peanut-Allergic Children
1547413|NCT03201003|Desensitization
1547414|NCT03201003|ARTEMIS
1547415|NCT03201003|Allergy
1547416|NCT03201029|center for ethnic skin
1547417|NCT03201029|skin of color clinic
1547418|NCT03201029|ethnic skin center
1547419|NCT03200691|Esophageal Squamous Cell Carcinoma
1547420|NCT03200691|PD-1
1547421|NCT03200691|Neoadjuvant treatment
1547422|NCT03201770|Uncomplicated Malaria
1547423|NCT03201770|Pyramax
1547424|NCT03201770|Pyronaridine artesunate
1547425|NCT03197831|Medicaid Expansion, Affordable Care Act, Health Care Reform
1547426|NCT03197103|Autologous fat grafting
1547427|NCT03197103|Breast
1547428|NCT03197103|Deformity
1547429|NCT03197103|Asymmetry
1547430|NCT03197103|Tuberous breast
1547431|NCT03197103|Acetylcysteine
1547432|NCT03200899|cognitive rehabilitation
1547433|NCT03199937|Autism Spectrum Disorder
1547434|NCT03199937|Executive Functioning
1547435|NCT03199937|Intervention
1547436|NCT03199937|Flexible
1547437|NCT03199937|Unstuck
1547438|NCT03199937|Transition
1547439|NCT03199937|Behavior
1547440|NCT03199937|High school
1547441|NCT03199937|Problem Solving
1547442|NCT03199937|Self-Control
1547443|NCT03199937|Coping
1547444|NCT03200756|sedentary behavior
1547445|NCT03197922|Autism Spectrum Disorder
1547446|NCT03197922|Constipation
1547447|NCT03202589|Preoperative assessement for geriatric patients
1547448|NCT03202589|FOCUS Echocardiography
1547449|NCT03202589|Orthopedic
1547450|NCT03202589|Surgery
1547451|NCT03202589|Geriatric
1547452|NCT03202394|intubation
1547453|NCT03202394|aerosol
1547454|NCT03202394|sepsis
1547455|NCT03202394|edema
1547456|NCT03197363|Civilization diseases
1547457|NCT03197363|Cardiovascular Risk Factor
1547458|NCT03197363|Population study
1547459|NCT03197363|Intestinal microbiome
1547460|NCT03197363|Oral microbiome
1547461|NCT03200249|dose escalation, chemo-radiation, rectum cancer, phase 2
1547462|NCT03200002|Lupus Nephritis, cyclophosphamide, Mycophenolate mofetil
1547463|NCT03196115|Autosomal Recessive Disorder
1547464|NCT03196115|Gingival Hypertrophy
1547465|NCT03196115|Skin and Connective Tissue Diseases
1547466|NCT03200392|Er,Cr:YSGG laser
1547467|NCT03200392|connective tissue graft
1547468|NCT03200392|root coverage
1547469|NCT03200392|mucogingival surgery
1547470|NCT03200392|gingival recession
1547471|NCT03196167|sugammadex
1547472|NCT03196167|extubation
1547473|NCT03196167|CABG
1547474|NCT03201237|Cerebral palsy
1547475|NCT03200795|Diabetes
1547476|NCT03200795|Musculoskelatal pain
1547477|NCT03200795|Rebound exercises
1547478|NCT03200795|Depression
1547479|NCT03200795|Glucose
1547480|NCT03200795|Quality of life
1547481|NCT03200743|Hypertension
1547482|NCT03200743|Pregnancy
1547483|NCT03200743|Catestatin
1547485|NCT03197675|Chronic pain
1547486|NCT03197675|Acupuncture
1547487|NCT03201822|flavanol
1547488|NCT03201822|ADME
1547489|NCT03201822|cocoa flavanols
1547490|NCT03201822|polyphenols
1547491|NCT03202355|Alignment phase
1547492|NCT03202355|Photobiomodulation
1547493|NCT03202355|Orthodontic treatment
1547494|NCT03202355|Malocclusion
1547495|NCT03202355|OrthoPulse™
1547496|NCT03201211|Safety
1547497|NCT03201211|Immunogenicity
1547498|NCT03199508|Nocturnal Enuresis
1547499|NCT03199508|Voiding Diary
1547500|NCT03201081|elderly
1547501|NCT03201081|motivation
1547502|NCT03201081|adherence
1547503|NCT03201081|resistance-training
1547504|NCT03201081|health
1547505|NCT03200236|Lung Cancer Screening
1547506|NCT03200236|Smoking Cessation
1547507|NCT03200236|Tobacco Use
1547508|NCT03202433|Virtual Reality
1547509|NCT03202433|Stress Reduction
1547510|NCT03202433|Needle Aspiration
1547511|NCT03202433|Blood Donors
1547512|NCT03202433|Intervention
1547537|NCT03201757|Alkermes
1547538|NCT03201757|ALKS 3831
1547539|NCT03201757|Olanzapine
1547540|NCT03201757|Samidorphan
1547541|NCT03201757|Schizophrenia
1547542|NCT03201757|Schizophreniform
1547543|NCT03201757|Bipolar I
1547544|NCT03193879|Pulmonary function
1547545|NCT03193879|Particulate matter
1547546|NCT03193879|COPD
1547547|NCT03193879|Asthma
1547552|NCT03189589|Pharmacokinetics
1547553|NCT03189589|Healthy
1547554|NCT03189589|ELLIPTA
1547555|NCT03189589|Safety
1547556|NCT03189589|GSK2269557
1547557|NCT03189589|Inhalation
1547558|NCT03189589|Tolerability
1547561|NCT03200886|hyaluronic acid
1547562|NCT03200886|intra-articular injections
1547563|NCT03200886|triamcinolone
1547564|NCT03200886|osteoarthritis of the thumb
1547572|NCT03200873|transcranial magnetic stimulation
1547573|NCT03200873|theta burst stimulation
1547574|NCT03200873|impulsivity
1547575|NCT03187977|Cognitive intervention
1547576|NCT03187977|Survivors
1547577|NCT03187977|Childhood ALL
1547578|NCT03189706|Hu3F8
1547579|NCT03189706|Irinotecan
1547580|NCT03189706|Temozolomide
1547581|NCT03189706|Sargramostim
1547582|NCT03189706|Chemoimmunotherapy
1547583|NCT03189706|17-251
1547589|NCT03193177|fasting-like diet
1547590|NCT03193177|chronic diseases
1547591|NCT03193177|autoimmune diseases
1547592|NCT03193177|metabolic disorder
1547593|NCT03202576|nasogastric tube
1547594|NCT03202576|microbridle
1547595|NCT03202381|Androgen deprivation therapy
1547596|NCT03202381|GnRH antagonist
1547597|NCT03200769|CPAP
1547598|NCT03200769|Sleep Apnea Syndrome
1547599|NCT03200769|Pharmacoresistant Epilepsy
1547600|NCT03200769|Apnea Hypopnea-Index
1547601|NCT03196843|raltitrexed
1547602|NCT03196843|radiotherapy
1547603|NCT03196843|older patient
1547604|NCT03196843|head and neck squamous cell carcinoma
1547605|NCT03184987|fluticasone furoate
1547606|NCT03184987|fixed dose combination
1547607|NCT03184987|Japanese subjects
1547608|NCT03184987|vilanterol
1547609|NCT03184987|asthma
1547610|NCT03184987|umeclidinium bromide
1547611|NCT03184987|closed triple therapy
1547612|NCT03200574|Perceval
1547613|NCT03200574|Mitroflow
1547614|NCT03200574|CROWN PRT
1547615|NCT03200574|Freedom Solo
1547616|NCT03200574|Solo Smart
1547621|NCT03202524|Paracentesis
1547622|NCT03202524|Albumin
1547623|NCT03202524|Plasma
1547624|NCT03199235|iron intake
1547625|NCT03199235|iron bioavailability
1547626|NCT03184636|ACLF
1547627|NCT03184636|SOFA
1547628|NCT03184636|Zagazig university
1547629|NCT03181737|diabetes mellitus typ 2, adherence, psychological online-intervention, randomized controlled study
1547630|NCT03187301|Parkinson's Disease
1547631|NCT03187301|Off episodes
1547636|NCT03181789|HIV vaccine
1547637|NCT03181789|DNA vaccine
1547638|NCT03181789|IL-12
1547639|NCT03181789|Electroporation
1547640|NCT03181789|p24
1547641|NCT03181789|Gag
1547642|NCT03181789|Adjuvant
1547643|NCT03181789|Healthy
1547644|NCT03182686|osteoarthritis
1547645|NCT03182686|osteoarthritis of the knee
1547646|NCT03182686|OA
1547647|NCT03182686|OAK
1547648|NCT03182686|Kellgren Lawrence (KL)
1547649|NCT03195166|elderly spinal anesthesia
1547650|NCT03202693|Tuberculosis, PA-824
1547656|NCT03200782|postprandial hypoglycemia
1547657|NCT03200782|bariatric surgery
1547658|NCT03200782|late dumping syndrome
1547659|NCT03200782|anakinra
1547660|NCT03200782|empagliflozin
1547661|NCT03200782|SGLT2 inhibitor
1547662|NCT03200782|IL-1Beta
1547663|NCT03200782|IL1
1547664|NCT03173092|Drug therapy
1547670|NCT03201367|Portal vein
1547671|NCT03201367|thrombosis
1547672|NCT03201367|acute
1547673|NCT03201367|rivaroxaban
1547676|NCT03168438|Cell Therapy
1547677|NCT03168438|Multiple Myeloma
1547678|NCT03168438|Immuno-oncology
1547679|NCT03168438|T Cell Therapy
1547680|NCT03168438|Metastatic
1547681|NCT03168438|SPEAR T Cell
1547682|NCT03168438|T Cell Receptor
1547683|NCT03168438|Previously Treated
1547684|NCT03168438|NY-ESO-1
1547690|NCT03200678|knee muscle
1547691|NCT03200678|strength
1547692|NCT03200678|fatigue
1547693|NCT03200678|MRI
1547694|NCT03200678|ACL
1547695|NCT03194191|Insomnia
1547696|NCT03194191|Pregnancy
1547697|NCT03194191|Acupuncture
1547698|NCT03194191|Insomnia severity index
1547699|NCT03194191|Pittsburgh Sleep Quality Index
1547700|NCT03194191|Anxiety
1547701|NCT03194191|Depression
1547707|NCT03168425|safe opioid prescribing
1547708|NCT03161587|FEV1
1547709|NCT03161587|COPD
1547710|NCT03161587|CAT
1547711|NCT03161587|treatment modality
1547712|NCT03161587|FVC
1547713|NCT03161587|GOLD 2016
1547714|NCT03161587|mMRC
1547715|NCT03163732|Solid tumor
1547716|NCT03163732|Advanced tumor
1547717|NCT03163732|Profiling panel
1547718|NCT03169933|adjuvant
1547719|NCT03169933|androgen suppressive therapy
1547720|NCT03169933|literature review
1547721|NCT03169933|phase II
1547722|NCT03169933|prostate neoplasms
1547723|NCT03169933|radiotherapy
1547724|NCT03201315|Fentanyl, opioids
1547725|NCT03160456|upper airway
1547726|NCT03160456|genioglossus
1547727|NCT03160456|CPAP
1547728|NCT03160456|electrical stimulation
1547729|NCT03160456|sleep
1547730|NCT03160456|sleep disordered breathing
1547731|NCT03157154|Haemophilia
1547732|NCT03157154|Atherosclerosis
1547733|NCT03157154|Atrial fibrillation
1547734|NCT03157154|Antiplatelets
1547735|NCT03157154|Anticoagulant
1547736|NCT03156244|PROMIS
1547737|NCT03157908|South Africa
1547738|NCT03157908|Retention in care
1547739|NCT03157908|Pregnancy
1547740|NCT03157908|Mobile health
1547741|NCT03163446|Staphylococcus aureus
1547742|NCT03163446|bacteremia
1547743|NCT03163446|staphylococcal endocarditis
1547744|NCT03202602|Obstructive sleep apnea
1547745|NCT03202602|Continuous positive airway pressure
1547746|NCT03202602|Telemoedicine
1547747|NCT03160859|unsedated colonoscopy
1547748|NCT03160859|water exchange colonoscopy
1547749|NCT03160859|cap
1547750|NCT03160859|colonoscopy pain
1547757|NCT03199443|Sacral neuromodulation
1547758|NCT03199443|Electromyography
1547759|NCT03199443|Pelvic floor
1547760|NCT03201016|cirrhosis
1547761|NCT03149575|Glioma
1547762|NCT03149575|Glioblastoma
1547763|NCT03149575|Glioblastoma multiforme
1547764|NCT03149575|GBM
1547765|NCT03149575|brain tumor
1547766|NCT03149575|brain cancer
1547767|NCT03149575|recurrent brain tumor
1547768|NCT03149575|recurrent brain cancer
1547769|NCT03149575|refractory brain tumor
1547770|NCT03149575|refractory brain cancer
1547771|NCT03149575|recurrent GBM
1547772|NCT03149575|refractory GBM
1547773|NCT03149575|recurrent glioma
1547774|NCT03149575|refractory glioma
1547775|NCT03149575|recurrent glioblastoma
1547776|NCT03149575|refractory glioblastoma
1547777|NCT03149575|recurrent glioblastoma multiforme
1547778|NCT03149575|refractory glioblastoma multiforme
1547779|NCT03149575|failed temodar
1547780|NCT03149575|failed temozolomide
1547781|NCT03149575|temodar refractory
1547782|NCT03149575|temozolomide refractory
1547783|NCT03149575|failed avastin
1547784|NCT03149575|avastin refractory
1547785|NCT03149575|failed bevacizumab
1547786|NCT03149575|bevacizumab refractory
1547787|NCT03149575|avastin failure
1547788|NCT03149575|bevacizumab failure
1547789|NCT03149575|STAR-3
1547790|NCT03152045|communication between adolescent patients and their clinician
1547791|NCT03142815|Coronary Artery Bypass Graft (CABG), Arterial stiffness
1547792|NCT03138174|Blood Glucose Monitor System Accuracy
1547793|NCT03136120|Ipratropium bromide
1547794|NCT03136120|Cryobiopsy
1547795|NCT03136120|TBCB
1547796|NCT03136120|IPF
1547797|NCT03136120|Transbronchial cryobiopsy
1547798|NCT03136120|Interstitial lung disease
1547799|NCT03156283|smartphone
1547800|NCT03156283|obstructive sleep apnea
1547801|NCT03156283|adherence
1547802|NCT03133650|Vascular-Targeted Photodynamic Therapy (VTP)
1547803|NCT03133650|15-319
1547804|NCT03132922|Cell Therapy
1547805|NCT03132922|T Cell Therapy
1547806|NCT03132922|SPEAR T Cell
1547807|NCT03132922|MAGE-A4
1547808|NCT03132922|Immuno-oncology
1547809|NCT03132922|Metastatic
1547810|NCT03132922|Urothelial Cancer
1547811|NCT03132922|Previously Treated
1547812|NCT03132922|T Cell Receptor
1547813|NCT03132922|Squamous, adenosquamous, or large cell NSCLC
1547814|NCT03132922|Squamous or adenocarcinoma esophageal cancer
1547815|NCT03134183|D&E
1547816|NCT03134183|dilation and evacuation
1547817|NCT03134183|abortion
1547818|NCT03134183|second trimester
1547819|NCT03134183|mifepristone
1547820|NCT03134183|misoprostol
1547821|NCT03130517|hemolysis,newborn
1547822|NCT03130257|blood pressure measurement
1547823|NCT03176940|Dementia
1547824|NCT03132571|Schizophrenia
1547825|NCT03132571|Diabetes
1547826|NCT03132571|Obesity
1547827|NCT03125655|cytokines
1547828|NCT03155191|Acute lymphoblastic leukemia
1547829|NCT03155191|Leukemia
1547830|NCT03155191|Lymphoblastic
1547831|NCT03155191|TBI-1501
1547832|NCT03155191|Anti-CD19 CAR Expressing T cells Therapy
1547833|NCT03155191|CD19 CAR Gene-Transduced Lymphocyte
1547834|NCT03155191|Adoptive Immunotherapy
1547835|NCT03155191|Genetically Engineered Lymphocyte Therapy
1547836|NCT03155191|Retroviral Vector
1547837|NCT03155191|Neoplasms by Histologic Type
1547838|NCT03155191|Neoplasms
1547839|NCT03155191|Neoplasms, Experimental
1547840|NCT03155191|Immune System Diseases
1547841|NCT03155191|Chimeric antigen receptor
1547842|NCT03138161|cancer immunotherapy, combination chemo-/immunotherapy
1547843|NCT03120871|Beta cell failure
1547844|NCT03120871|Puberty
1547845|NCT03120871|Microbiome
1547846|NCT03120871|Insulin Sensitivity
1547847|NCT03118544|Chronic Total Occlusion
1547848|NCT03118544|Coronary Artery Disease
1547849|NCT03118544|Percutaneous Coronary Intervention
1547850|NCT03118544|CTO
1547851|NCT03118544|PCI
1547852|NCT03157999|Older Adults
1547853|NCT03157999|Transitional Care
1547854|NCT03157999|Caregiver
1547855|NCT03157999|Intervention
1547866|NCT03113643|Acute Myeloid Leukemia
1547867|NCT03113643|Myelodysplastic Syndrome
1547868|NCT03139851|Solid tumor
1547869|NCT03139851|Breast cancer
1547870|NCT03139851|Metastatic cancer
1547871|NCT03139851|Pembrolizumab
1547872|NCT03139851|Metronomic cyclophosphamide
1547873|NCT03114839|Lactobacillus casei strain Shirota
1547874|NCT03114839|Yakult
1547875|NCT03114839|IntelliCap
1547878|NCT03110978|Malignant neoplasms of respiratory and intrathoracic organs
1547879|NCT03110978|Non-small Cell Lung Cancer
1547880|NCT03110978|NSCLC
1547881|NCT03110978|Squamous cell carcinoma
1547882|NCT03110978|Adenocarcinoma
1547883|NCT03110978|Large cell carcinoma
1547884|NCT03110978|Bronchioloalveolar cell carcinoma
1547885|NCT03110978|Stereotactic ablative radiotherapy
1547886|NCT03110978|SABR
1547887|NCT03110978|Nivolumab
1547888|NCT03110978|BMS-936558
1547889|NCT03110978|Opdivo
1547890|NCT03110978|Immunotherapy
1547891|NCT03202498|Cirrhosis, Liver
1547892|NCT03202498|Fibrosis, Liver
1547893|NCT03202498|Hepatic Cirrhosis
1547894|NCT03202498|Liver Fibrosis
1547899|NCT03114891|depression
1547900|NCT03114891|post-traumatic stress
1547901|NCT03104205|frail elderly
1547902|NCT03104205|telemedicine
1547903|NCT03104205|obesity
1547904|NCT03104205|rural health
1547905|NCT03104205|health promotion
1547906|NCT03104205|weight loss
1547907|NCT03104192|frail elderly
1547908|NCT03104192|telemedicine
1547909|NCT03104192|obesity
1547910|NCT03104192|rural health
1547911|NCT03104192|health promotion
1547912|NCT03104192|weight loss
1547913|NCT03110133|Clostridium Difficile Infection
1547914|NCT03110133|CP101
1547915|NCT03110133|Crestovo
1547916|NCT03110133|FMT
1547917|NCT03110133|CDI
1547918|NCT03110133|C. difficile
1547919|NCT03099161|Advanced Solid Tumor
1547920|NCT03099161|Programmed Cell Death Receptor 1 (PD-1)
1547921|NCT03099161|Programmed Cell Death Receptor Ligand 1 (PD-L1)
1547922|NCT03099161|PD1
1547923|NCT03099161|PD-1
1547924|NCT03099161|PDL1
1547925|NCT03099161|PD-L1
1547931|NCT03103750|Vitamin D
1547932|NCT03201341|Stroke
1547933|NCT03201341|Multisensory
1547934|NCT03201341|Plasticity
1547935|NCT03201341|Body
1547936|NCT03201341|Space
1547937|NCT03201341|MRI
1547941|NCT03099109|TIM-3
1547942|NCT03099109|PD-L1
1547943|NCT03110770|Flavivirus
1547944|NCT03110770|Zika
1547945|NCT03110770|Vaccine
1547946|NCT03110770|Physiological Effects of Drugs
1547947|NCT03110770|Immunologic Factors
1547948|NCT03110770|Virus-like Particles
1547949|NCT03103932|biomarkers
1547950|NCT03103932|heart failure
1547951|NCT03103932|hospital admission
1547952|NCT03123861|Pelvic Organ Prolapse
1547953|NCT03123861|postoperative gluteal pain
1547954|NCT03123861|opioid use
1547955|NCT03200834|Right colon cancer
1547956|NCT03200834|D3 dissection
1547957|NCT03200834|complete mesocolic excision
1547958|NCT03200834|Hemicolectomy
1547959|NCT03095287|Factor VIII
1547960|NCT03095287|von Willebrand Factor
1547961|NCT03095287|Plasma-derived
1547962|NCT03095287|Inhibitors
1547963|NCT03095287|Immune tolerance induction
1547964|NCT03095287|ITI
1547965|NCT03095287|Antibodies
1547966|NCT03095287|Hemophilia A
1547977|NCT03093090|furosemide
1547978|NCT03131362|COPD
1547979|NCT03100565|colposcopy
1547980|NCT03100565|pain
1547981|NCT03100565|coughing
1547982|NCT03100565|anesthetic spray
1547983|NCT03086707|nasal mucociliary clearance
1547984|NCT03086707|saccharine transit time
1547985|NCT03085797|SB240563
1547986|NCT03085797|Nasal Polyps
1547987|NCT03085797|Mepolizumab
1547988|NCT03085797|Phase 3
1547989|NCT03085797|Parallel group
1547990|NCT03085797|Efficacy
1547991|NCT03087864|esophageal cancer
1547992|NCT03087864|PD-L1 inhibition
1547993|NCT03087864|chemoradiation
1547994|NCT03109093|ALL
1547995|NCT03109093|acute lymphoblastic leukemia
1547996|NCT03109093|MRD positive
1547997|NCT03109093|minimal residual disease
1547998|NCT03109093|blinatumomab
1547999|NCT03084211|emergency department
1548000|NCT03084211|concussion
1548001|NCT03084211|head injury
1548002|NCT03094312|SEEG
1548003|NCT03094312|ISD
1548004|NCT03094312|cognitive disorder
1548005|NCT03094312|epilepsy surgery
1548006|NCT03096080|ARPKD
1548007|NCT03096080|Autosomal Recessive Polycystic Kidney Disease
1548008|NCT03096080|Pediatric Polycystic Kidney
1548009|NCT03096080|Tesevatinib
1548010|NCT03096080|Polycystic Kidney Disease
1548013|NCT03085589|elderly
1548014|NCT03085589|telemedicine
1548015|NCT03085589|obesity
1548016|NCT03085589|rural health
1548017|NCT03085589|health promotion
1548018|NCT03076710|spine surgery
1548019|NCT03076710|post-operative pain
1548020|NCT03076710|patient controlled analgesia
1548021|NCT03076710|Exparel®
1548022|NCT03076710|bupivacaine
1548023|NCT03202264|Polypharmacy
1548024|NCT03202264|Mobility
1548025|NCT03202264|Multimorbidity
1548026|NCT03202264|Drug Discontinuation
1548027|NCT03202264|Patient Preference
1548028|NCT03202264|eHealth
1548029|NCT03066427|Clear Cell Renal Carcinoma
1548030|NCT03066427|Sunitinib
1548031|NCT03064451|persistent atrial fibrillation - ablation procedure
1548032|NCT03063645|Healthy volunteer
1548033|NCT03063645|AC-1202
1548034|NCT03063645|AC-SD-01
1548035|NCT03063645|Pharacokinetic
1548036|NCT03063645|ketone body
1548037|NCT03072030|Ebola Virus Disease
1548038|NCT03072030|Hemorrhagic Fever, Ebola
1548039|NCT03072030|Vaccines
1548040|NCT03072030|GP protein, Ebola virus
1548041|NCT03072030|Ebola Virus Vaccines
1548042|NCT03058406|Sarcoma, Soft Tissue
1548043|NCT03058406|Halaven Injection
1548044|NCT03058406|E7389
1548045|NCT03058042|Urinary Incontinence, Stress
1548046|NCT03058042|Pelvic Floor; Exercise
1548047|NCT03058042|Physical Therapy Modalities
1548048|NCT03062046|Atrial Fibrillation
1548049|NCT03055000|Mosquito-Borne Diseases
1548050|NCT03055000|Universal Mosquito Vaccine
1548051|NCT03055000|Mosquito Transmission
1548052|NCT03055000|Vector Borne Viruses
1548053|NCT03055000|Vaccine
1548054|NCT03059043|Phakic Intraocular Lenses
1548055|NCT03059043|viscoelastic
1548056|NCT03055195|subcutaneous
1548057|NCT03055195|safety
1548058|NCT03055195|mepolizumab
1548059|NCT03055195|efficacy
1548060|NCT03055195|atopic dermatitis
1548061|NCT03049449|Gene Therapy
1548062|NCT03049449|Adoptive T Cell Therapy
1548063|NCT03049449|T-cell infusion
1548064|NCT03049449|Allogeneic Stem Cell Transplantation
1548065|NCT03049449|Immunohistochemistry
1548066|NCT03053193|breast cancer
1548067|NCT03053193|stage I
1548068|NCT03053193|stage II
1548069|NCT03053193|stage III
1548073|NCT03148249|Randomized control trial
1548074|NCT03148249|Charles Bonnet syndrome
1548075|NCT03148249|visual hallucinations
1548076|NCT03148249|age related macular degeneration
1548077|NCT03148249|patient education
1548078|NCT03064763|Unresectable Stage IIIB-IV Malignant Melanoma
1548079|NCT03051620|Bone turnover markers
1548080|NCT03051620|Alendronate
1548081|NCT03051620|Drug Holiday
1548082|NCT03070145|Prostate Cancer
1548083|NCT03061890|children's environmental health
1548084|NCT03061890|prematurity
1548085|NCT03061890|preterm birth
1548086|NCT03061890|phthalates
1548087|NCT03061890|NICU
1548088|NCT03061890|stress
1548089|NCT03061890|lung health
1548090|NCT03061890|neurodevelopment
1548091|NCT03061890|growth
1548092|NCT03047317|pharmacokinetics
1548093|NCT03047629|non-motor symptoms
1548099|NCT03080701|Behavioral: Automated Mailing
1548100|NCT03088202|cancer
1548101|NCT03088202|palliative care
1548102|NCT03088202|PROMs
1548103|NCT03088202|survival
1548104|NCT03088202|QoL
1548105|NCT03088202|referral
1548106|NCT03049800|Recent onset psychotic illness
1548107|NCT03049800|Healthy controls
1548108|NCT03049800|Cognitive training
1548109|NCT03049800|7T Magnetic Resonance Imaging
1548110|NCT03034915|Vilanterol
1548111|NCT03034915|COPD
1548112|NCT03034915|HRQoL
1548113|NCT03034915|Salmeterol
1548114|NCT03034915|Umeclidinium
1548115|NCT03029247|Anemia
1548116|NCT03029247|Daprodustat
1548117|NCT03029247|Blood pressure
1548118|NCT03029247|ESA
1548119|NCT03029247|CKD
1548120|NCT03029208|Daprodustat, recombinant human erythropoietin, darbepoetin, anemia, chronic kidney disease, dialysis, ESRD
1548121|NCT03034265|hypertension; exosome; angiotensin; sodium channel; kidney; aldosterone; renin; urine
1548122|NCT03027960|cardio-renal
1548123|NCT03027557|Primary Hyperparathyroidism
1548124|NCT03027557|Parathyroid Adenoma
1548125|NCT03027557|Parathyroid Hyperplasia
1548126|NCT03027557|Cinacalcet
1548127|NCT03027557|Denosumab
1548128|NCT03027557|Drug Therapy
1548129|NCT03027557|Bone Mineral Density
1548130|NCT03027557|Calcium
1548131|NCT03069443|Isometric handgrip training
1548132|NCT03069443|home training
1548133|NCT03069443|older adults
1548134|NCT03069443|Hypertension
1548135|NCT03023657|arousal
1548136|NCT03023657|Consciousness Disorders
1548137|NCT03023657|vegetative state
1548138|NCT03023657|minimally conscious state
1548139|NCT03028467|GSK3196165
1548140|NCT03028467|Active Rheumatoid Arthritis
1548141|NCT03028467|Methotrexate
1548142|NCT03028467|Monoclonal Antibody
1548143|NCT03028467|Efficacy
1548144|NCT03028467|Electrocardiogram
1548145|NCT03028467|Tolerability
1548146|NCT03028467|Pharmacokinetics
1548147|NCT03028467|Japanese Subjects
1548148|NCT03019458|prospective randomized trial
1548149|NCT03051074|Anxiety
1548150|NCT03051074|Floating
1548151|NCT03019042|Hou Gu Mi Xi
1548152|NCT03019042|Shen Ling Bai Zhu San
1548153|NCT03019042|mild gastrointestinal disorders
1548154|NCT03019042|traditional Chinese medicine
1548155|NCT03019042|randomized controlled trial
1548156|NCT03009461|Hepatocellular carcinoma
1548157|NCT03009461|Portal vein tumor thrombosis
1548158|NCT03009461|Hepatic arterial infusion chemotherapy
1548159|NCT03009461|Sorafenib
1548160|NCT03201302|bone
1548161|NCT03201302|childhood
1548162|NCT03201302|pre-adolescence
1548163|NCT03201302|bone turnover markers
1548164|NCT03201302|sclerostin
1548165|NCT03201302|sports
1548166|NCT03201302|physical activity
1548167|NCT03201302|nutrition
1548168|NCT03003520|Lymphoma
1548169|NCT03003520|Diffuse-large B-Cell Lymphoma
1548170|NCT03003520|Durvalumab
1548171|NCT03003520|Anti-PD-L1 Antibody
1548172|NCT03003520|MEDI4736
1548173|NCT03003520|Immune Checkpoint
1548174|NCT03003520|Rituximab
1548175|NCT03003520|Cyclophosphamide
1548176|NCT03003520|Doxorubicin
1548177|NCT03003520|Vincristine
1548178|NCT03003520|Prednisone/Prednisolone
1548179|NCT03003520|Lenalidomide
1548180|NCT03004534|Breast Cancer
1548181|NCT03004534|Breast Carcinoma
1548182|NCT03004534|Breast Tumours
1548183|NCT03004534|Early Breast Cancer
1548184|NCT03017768|Acute tryptophan depletion, esophageal sensitivity,
1548185|NCT02999646|head and neck squamous cell carcinoma
1548186|NCT02999646|cancer
1548187|NCT02999646|HNSCC
1548188|NCT02999646|immunotherapy
1548189|NCT02999646|MVX-ONCO-1
1548190|NCT02996474|Pembrolizumab
1548191|NCT02996474|Decitabine
1548192|NCT02996474|AML (Acute Myelogenous Leukemia)
1548193|NCT02992197|Rotavirus
1548194|NCT02992197|Oral vaccines
1548195|NCT02992197|Vaccine underperformance
1548196|NCT02992197|Vaccine shedding
1548197|NCT02994342|vaginal dryness
1548198|NCT02994342|vaginal gel
1548199|NCT02994342|colostrum
1548200|NCT02994342|vaginal atrophy
1548201|NCT03041831|frail elderly
1548202|NCT03041831|telemedicine
1548203|NCT03041831|obesity
1548204|NCT03041831|rural health
1548205|NCT03041831|health promotion
1548206|NCT02976597|Abdominal surgery, pain, local, transversus abdominus block.
1548207|NCT02998840|elevated blood pressure
1548208|NCT02983825|CPAP
1548209|NCT02983825|Bronchopulmonary Dysplasia
1548210|NCT02983825|Ventilator Induced Lung Injury
1548211|NCT02983825|V/Q mismatch
1548212|NCT02972983|Staphylococcus aureus
1548213|NCT02972983|Bacteremia
1548214|NCT02972983|Daptomycin
1548215|NCT02977052|Melanoma
1548216|NCT02977052|Ipilimumab
1548217|NCT02977052|Nivolumab
1548218|NCT02977052|Neo-adjuvant
1548219|NCT02972658|Alzheimer's Disease
1548220|NCT02972658|Dementia
1548221|NCT02972658|Brain Diseases
1548222|NCT02972658|Neurodegenerative Diseases
1548223|NCT02972658|Central Nervous System Diseases
1548224|NCT02972658|Nervous System Diseases
1548225|NCT02972658|Mental Disorders
1548226|NCT02972658|Delirium, Dementia, Amnestic, Cognitive Disorders
1548227|NCT02972658|Tauopathies
1548228|NCT02972658|Memory
1548229|NCT02972658|Amyloid
1548230|NCT02975921|Pleural Effusion
1548231|NCT02975921|Thoracentesis
1548232|NCT02975921|Pleural Cavity
1548233|NCT02975921|Pleurodesis
1548234|NCT02975921|Tunneled Pleural Catheter
1548235|NCT02968186|Mass Screening
1548236|NCT02968186|Counseling
1548237|NCT02968186|Primary Health Care
1548238|NCT02966457|hematological infection, decolonization
1548239|NCT02966834|PBC
1548240|NCT02966834|itch
1548241|NCT02966834|GSK2330672
1548242|NCT02966834|GLIMMER
1548243|NCT02966834|primary biliary cholangitis
1548244|NCT02966834|pruritus
1548245|NCT02978963|Excessive worry
1548246|NCT02978963|Worry
1548247|NCT02978963|Adolescents
1548248|NCT02978963|Intolerance of uncertainty
1548249|NCT02964507|GSK525762
1548250|NCT02964507|ER+ breast cancer
1548251|NCT02964507|mTPI
1548252|NCT02973893|Chronic Venous Leg Ulcer
1548253|NCT02989064|Cell Therapy
1548254|NCT02989064|T Cell Therapy
1548255|NCT02989064|SPEAR T Cell
1548256|NCT02989064|MAGE-A10
1548257|NCT02989064|Immuno-oncology
1548258|NCT02989064|Metastatic
1548259|NCT02989064|Urothelial Cancer
1548260|NCT02989064|Previously Treated
1548261|NCT02989064|T Cell Receptor
1548262|NCT02960490|E6011
1548263|NCT02960490|rheumatoid arthritis
1548264|NCT02960438|E6011
1548265|NCT02960438|rheumatoid arthritis
1548266|NCT02955537|Hypertension
1548267|NCT02955537|mHealth
1548268|NCT02961933|hypoxemia
1548269|NCT02961933|intubation
1548270|NCT02961933|apneic oxygenation
1548271|NCT02960542|lifestyle intervention
1548272|NCT02960542|weight-loss
1548273|NCT02962297|Vitamin E, Non Diabetic
1548274|NCT02948413|Traumatic Stress
1548275|NCT02948413|Oncology
1548276|NCT02948413|Lymphoma
1548277|NCT02945878|radiotherapy, oral mucositis,oral mucosa protection
1548278|NCT02943473|Smoldering multiple myeloma
1548279|NCT02943473|myeloma
1548280|NCT02943473|smoldering
1548281|NCT02943473|ibrutinib
1548282|NCT02944968|Interventional
1548283|NCT02944968|Radiofrequency Ablation
1548284|NCT02944968|Paroxysmal Atrial Fibrillation
1548285|NCT02937272|TGF Beta
1548286|NCT02934789|submucosal fibroids
1548287|NCT02934789|heavy menstrual bleeding
1548288|NCT02934789|quality of life
1548289|NCT02935517|Color vision deficiency
1548290|NCT02935517|Color vision defects
1548291|NCT02935517|Vision disorders
1548292|NCT02935517|Sensation disorders
1548293|NCT02935517|Neurologic manifestations
1548294|NCT02935517|Nervous system diseases
1548295|NCT02935517|Eye diseases
1548296|NCT02935517|Signs and symptoms
1548297|NCT02959762|G01 [Biological Sciences]
1548298|NCT02959762|G02.513 [Nutrition]
1548299|NCT02959762|G06.696.259 [Child Nutrition]
1548300|NCT02959762|G07.553.481.398.571 [Obesity]
1548301|NCT02959762|G06 [Biochemical Phenomena, Metabolism, and Nutrition]
1548302|NCT02959762|G12.392.617 [Insulin Resistance]
1548303|NCT02959762|G06.696.259.500 [Adolescent Nutrition]
1548304|NCT02959762|A06 [Endocrine System]
1548305|NCT02959762|A07 [Cardiovascular System]
1548306|NCT02959762|C18.452.297.681 [Obesity in Diabetes]
1548307|NCT02959762|C18.452.555 [Insulin Resistance]
1548308|NCT02959762|C18 [Nutritional and Metabolic Diseases]
1548309|NCT02959762|C18.452.494 [Hyperlipidemia]
1548310|NCT02959762|C18.452.460 [Hyperglycemia]
1548311|NCT02959762|C14 [Cardiovascular Diseases]
1548312|NCT02959762|D11.786.875.844 [Vitamin K 2]
1548313|NCT02959762|D02.806.550.750 [Vitamin K 2]
1548314|NCT02959762|E02.293 [Diet Therapy]
1548315|NCT02959762|E02 [Therapeutics]
1548316|NCT02959762|F04.096.544.215.508.428 [Primary Prevention]
1548317|NCT02959762|N01.224.425.525 [Nutritional Status]
1548318|NCT02981940|Brain Tumor
1548319|NCT02927665|Weight Loss
1548320|NCT02927262|Acute myeloid leukemia
1548321|NCT02927262|First Complete Remission
1548322|NCT02927262|FLT3/ITD
1548323|NCT02927262|AML
1548324|NCT02927262|ASP2215
1548325|NCT02925533|Bladder Cancer
1548326|NCT02925533|Urothelial Cancer
1548327|NCT02920008|AML, acute myeloid leukemia, guadecitabine, SGI-110, Phase 3
1548328|NCT02943746|Standard Protein Diet
1548329|NCT02943746|High Protein Diet
1548330|NCT02943746|Growth
1548331|NCT02943746|Body Composition
1548332|NCT02943746|Extremely Low Birth Weight
1548333|NCT02943746|Human Milk Derived Fortifier
1548334|NCT02943746|Protein
1548335|NCT02943746|Targeted Fortification
1548336|NCT02943746|Human Milk Diet
1548337|NCT02943746|Prematurity
1548338|NCT02916745|Non-small cell lung cancer
1548339|NCT02916745|NSCLC
1548340|NCT02916745|lung cancer
1548341|NCT02916745|lung carcinoma
1548342|NCT02916745|lung metastasis
1548343|NCT02913703|Ghrelin
1548344|NCT02911064|Questionnaires
1548345|NCT02911064|Surveys
1548346|NCT02911064|Benign neoplasms
1548347|NCT02911064|Malignant neoplasms of independent (primary) multiple sites
1548348|NCT02911064|Inpatient rehabilitation therapy
1548349|NCT02932150|CHB
1548350|NCT02932150|HBV
1548351|NCT02902809|open-label study
1548352|NCT02902809|tralokinumab
1548353|NCT02902809|subcutaneous
1548354|NCT02902809|inadequately controlled asthma
1548355|NCT02902809|asthma
1548356|NCT02902809|medium to high-dose of inhaled corticosteroid
1548357|NCT02902809|long-acting β2-agonist
1548358|NCT02924688|umeclidinium bromide
1548359|NCT02924688|fluticasone furoate
1548360|NCT02924688|vilanterol
1548361|NCT02924688|fixed dose combination
1548362|NCT02924688|lung function
1548363|NCT02924688|albuterol/salbutamol
1548364|NCT02924688|asthma
1548365|NCT02924688|closed triple therapy
1548366|NCT02947152|HKT288
1548367|NCT02947152|CDH6
1548368|NCT02947152|ADC
1548369|NCT02947152|maytansine
1548370|NCT02947152|epithelial ovarian cancer
1548371|NCT02947152|renal cell carcinoma
1548372|NCT02947152|RCC
1548373|NCT02891226|inflammatory bowel disease
1548374|NCT02891226|IL-23
1548375|NCT02891226|biologic
1548376|NCT02901483|Head and Neck
1548377|NCT02927457|Cutaneous Lupus Erythematosus-CLE
1548378|NCT02927457|Spleen Tyrosine Kinase-SYK
1548379|NCT02927457|Photoprovocation-PV
1548380|NCT02927457|GSK2646264
1548381|NCT02879305|erythropoiesis stimulating agents
1548382|NCT02879305|GSK1278863
1548383|NCT02879305|daprodustat
1548384|NCT02879305|anemia
1548385|NCT02879305|chronic kidney disease
1548386|NCT02879305|hemoglobin
1548387|NCT02879305|recombinant human erythropoietin
1548388|NCT02883023|Bleomycin
1548389|NCT02883023|Electroporation
1548390|NCT02876835|hemoglobin
1548391|NCT02876835|anemia
1548392|NCT02876835|non-dialysis
1548393|NCT02876835|GSK1278863
1548394|NCT02876835|erythropoiesis stimulating agents
1548395|NCT02876835|daprodustat
1548396|NCT02876835|chronic kidney disease
1548397|NCT02888080|pulmonary sarcoidosis
1548398|NCT02888080|sarcoidosis
1548399|NCT02888080|canakinumab
1548400|NCT02888080|autoimmune diseases
1548401|NCT02888080|granulomas
1548402|NCT02888080|inflammation
1548403|NCT02888080|lung function testing
1548404|NCT02888080|immunosuppressive agents
1548405|NCT02888080|interleukin
1548406|NCT02888080|interleukin-1Beta
1548407|NCT02888080|[F-18]FDG-PET/CT
1548408|NCT02888080|respiratory
1548409|NCT02888080|pulmonary
1548410|NCT02888080|steroids
1548411|NCT02888080|corticosteroids
1548412|NCT02888080|lung diseases
1548413|NCT02881762|hepatitis C virus (HCV)
1548414|NCT02881762|Maraviroc
1548415|NCT02881762|Human immunodeficiency virus (HCV)
1548416|NCT02858336|Luteinizing Hormone (LH)
1548417|NCT02858336|Functional Hypothalamic Amenorrhea (HA)
1548418|NCT02858336|Energy Deficiency
1548419|NCT02858336|Gonadotropin-Releasing Hormone
1548420|NCT02858336|Leptin
1548421|NCT02865538|Hot flashes
1548422|NCT02865538|Post-menopausal
1548423|NCT02967484|Acupuncture
1548424|NCT02967484|Hypertension
1548425|NCT02967484|Second prevention of Stroke
1548426|NCT02967484|Efficacy
1548427|NCT02967484|RCT
1548428|NCT02967484|Study protocol
1548429|NCT02931500|machine learning
1548430|NCT02931500|cohort study
1548431|NCT02892864|Bell's Palsy
1548432|NCT02892864|Peripheral facial palsy
1548433|NCT02840474|HIV Viral Load
1548434|NCT02840474|Antiviral
1548435|NCT02840474|CD4 Count
1548436|NCT02840474|HIV-1 Infection
1548437|NCT02840500|Breakthrough Cancer Pain
1548438|NCT02840500|Quality of life
1548439|NCT02840500|Palliative Care Units
1548440|NCT02843425|Cancer Prevention
1548441|NCT02843425|Precancerous colorectal polyps
1548442|NCT02843425|Canned beans
1548443|NCT02843425|Questionnaires
1548444|NCT02843425|Surveys
1548445|NCT02843425|Stool samples
1548446|NCT02853968|Unlock the Cell
1548447|NCT02853968|Castleman's Disease
1548448|NCT02853968|CD
1548449|NCT02853968|Castleman Disease
1548450|NCT02853968|MCD
1548451|NCT02853968|iMCD
1548452|NCT02853968|Angiofollicular Lymph Hyperplasia
1548453|NCT02853968|multicentric Castleman's disease
1548454|NCT02853968|multicentric Castleman disease
1548455|NCT02853968|idiopathic multicentric Castleman disease
1548456|NCT02836041|assess sleep
1548457|NCT02836041|Sleep Deprivation
1548458|NCT02836041|16-866
1548459|NCT02836197|Uncertainty;hope;cancer;communication skills training;physicians
1548460|NCT02836379|Breakthrough Cancer Pain
1548461|NCT02836379|Quality of life
1548462|NCT02836379|Radiotherapy
1548463|NCT02840201|biomarkers
1548464|NCT02831049|Reconsolidation
1548465|NCT02831764|tolerability
1548466|NCT02831764|HIV 1
1548467|NCT02831764|efficacy
1548468|NCT02831764|treatment naïve
1548469|NCT02831764|two-drug regimen
1548470|NCT02831764|safety
1548471|NCT02831764|non inferiority
1548472|NCT02821767|Pathogenesis
1548473|NCT02821767|Ocular Disorders
1548474|NCT02821767|Eye
1548475|NCT02821767|Eye Diseases
1548476|NCT02818582|Liberia
1548477|NCT02818582|EBV
1548478|NCT02818582|Semen
1548479|NCT02817776|Interventional
1548480|NCT02817776|Radiofrequency Ablation
1548481|NCT02817776|Persistent Atrial Fibrillation
1548482|NCT02835300|Asthma
1548483|NCT02835300|Adolescents
1548484|NCT02835300|e-Health
1548485|NCT02835300|Intervention
1548488|NCT02817997|patient registry
1548489|NCT02817997|ACCELERATE study
1548490|NCT02817997|CD
1548491|NCT02817997|MCD
1548492|NCT02817997|iMCD
1548493|NCT02817997|Castleman
1548494|NCT02817997|Castleman's Disease
1548495|NCT02817997|Angiofollicular Lymph Hyperplasia
1548496|NCT02817997|multicentric Castleman's disease
1548497|NCT02817997|multicentric Castleman disease
1548498|NCT02807844|Triple negative breast cancer
1548499|NCT02807844|Pancreatic carcinoma
1548500|NCT02807844|Melanoma
1548501|NCT02807844|Endometrial Carcinoma
1548502|NCT02807844|Immuno oncology
1548503|NCT02807844|Monoclonal antibody
1548504|NCT02807844|PDR001
1548505|NCT02807844|MCS110
1548506|NCT02816021|Melanoma and other malignant neoplasms of skin
1548507|NCT02816021|Metastatic melanoma
1548508|NCT02816021|Advanced melanoma
1548509|NCT02816021|Azacitidine
1548510|NCT02816021|5-azacytidine
1548511|NCT02816021|5-aza
1548512|NCT02816021|Vidaza
1548513|NCT02816021|5-AZC
1548514|NCT02816021|Ladakamycin
1548515|NCT02816021|NSC-102816
1548516|NCT02816021|Azacytidine
1548517|NCT02816021|Pembrolizumab
1548518|NCT02816021|Keytruda
1548519|NCT02816021|MK-3475
1548520|NCT02816021|SCH-900475
1548521|NCT02800941|Pulmonary Arterial hypertension
1548522|NCT02800941|Oral anticoagulants
1548523|NCT02800941|Major bleedings
1548524|NCT02831972|Healthy Volunteers
1548525|NCT02802189|Chronic Mechanical Neck Pain
1548526|NCT02802189|exercise
1548527|NCT02802189|Integrated Neuromuscular Inhibition Technique
1548528|NCT02809508|Omega-3
1548529|NCT02809508|Child nutrition
1548530|NCT02809508|Dietary recommendations
1548531|NCT02809508|Cardiovascular risk markers
1548532|NCT02809508|Cognitive function
1548533|NCT02809508|Mental health
1548534|NCT02842814|Systemic Lupus Erythematosus
1548535|NCT02842814|Stable
1548536|NCT02842814|Relapse Risk
1548537|NCT02842814|Glucocorticoid Withdrawal
1548538|NCT02796391|nicotine
1548539|NCT02796391|cigarettes
1548540|NCT02796391|very low nicotine content (VLNC)
1548541|NCT02791516|Osteoporosis.
1548542|NCT02791516|Osteoporosis-Postmenopausal.
1548543|NCT02791516|Bone Diseases-Metabolic.
1548544|NCT02791516|Bone Diseases.
1548545|NCT02791516|Musculoskeletal Diseases.
1548546|NCT02791334|PDL1
1548547|NCT02791334|PD-L1
1548548|NCT02836340|neuroprotection
1548549|NCT02791191|BACE inhibitor
1548550|NCT02797054|HPV vaccination
1548551|NCT02797054|Vaccination decision-making
1548552|NCT02797054|Tailored health messaging
1548553|NCT02797054|Barriers to vaccination
1548554|NCT02797054|Attitudes
1548555|NCT02788279|Locally advanced or Metastatic colorectal adenocarcinoma
1548556|NCT02796859|Inflammation
1548557|NCT02796859|Psychosis
1548558|NCT02796859|Schizophrenia
1548559|NCT02802085|Total Knee Arthroplasty
1548560|NCT02802085|Total Knee Replacement
1548561|NCT02802085|TKA
1548562|NCT02802085|TKR
1548563|NCT02802085|Stiffness of Knee
1548564|NCT02802085|Deformity
1548565|NCT02802085|Knee Joint
1548566|NCT02802085|Instability
1548567|NCT02802085|Post-traumatic
1548568|NCT02802085|Arthrosis
1548569|NCT02788084|Next Generation Sequencing
1548570|NCT02788084|Cell free DNA
1548571|NCT02783755|pain
1548572|NCT02783755|coping
1548573|NCT02783755|mhealth
1548574|NCT02783755|Breast cancer
1548575|NCT02783573|dementia
1548576|NCT02783573|brain diseases
1548577|NCT02783573|neurodegenerative diseases
1548578|NCT02783573|central nervous system diseases
1548579|NCT02783573|nervous system diseases
1548580|NCT02783573|mental disorders
1548581|NCT02783573|delirium, dementia, amnestic, cognitive
1548582|NCT02783573|tauopathies
1548583|NCT02783573|memory
1548584|NCT02783573|amyloid
1548585|NCT02789332|carboplatin
1548586|NCT02789332|olaparib
1548587|NCT02789332|pCR
1548588|NCT02789332|neoadjuvant
1548589|NCT02789332|triple-negative
1548590|NCT02789332|hormonreceptor-positive
1548591|NCT02789332|BRCA1/2
1548592|NCT02789332|HRD, homologous recominant deficient
1548593|NCT02789332|breast cancer
1548594|NCT02789332|genetic testing (somatic and germline mutations)
1548595|NCT02783495|glioma
1548596|NCT02783495|neurocognitive
1548597|NCT02783495|quality of life
1548598|NCT02780609|autologous hematopoietic cell transplantation (HCT)
1548599|NCT02780609|high-dose melphalan
1548600|NCT02780609|selinexor
1548601|NCT02900664|CRC
1548602|NCT02900664|TNBC
1548603|NCT02900664|NSCLC (adenocarcinoma)
1548604|NCT02900664|Immunomodulation
1548605|NCT02900664|Biomarkers
1548606|NCT02900664|Bayesian logistic regression model
1548607|NCT02900664|PDR001
1548608|NCT02900664|Immunotherapy
1548609|NCT02763319|Diffuse Large B-cell Lymphoma
1548610|NCT02763319|bendamustine
1548611|NCT02763319|rituximab
1548612|NCT02763319|combination therapy
1548613|NCT02763319|CD19 monoclonal antibody
1548614|NCT02763319|transplant ineligible
1548615|NCT02760316|Healthy Volunteers
1548616|NCT02760316|Obese
1548617|NCT02760316|Insulin Resistant Subjects
1548618|NCT02760316|Rheumatoid Arthritis
1548619|NCT02828384|fodmap diet
1548620|NCT02744079|diet
1548621|NCT02744079|dietary intervention
1548622|NCT02744079|carbohydrate restriction
1548623|NCT02744079|low carbohydrate
1548624|NCT02744079|fat restriction
1548625|NCT02744079|low fat
1548626|NCT02744079|cancer
1548627|NCT02744079|breast cancer
1548628|NCT02744079|pre-surgical window
1548629|NCT02744079|biomarker
1548630|NCT02753920|voiding trial
1548631|NCT02753920|prolapse
1548632|NCT02741115|Fontan
1548633|NCT02741115|Maximal Oxygen Consumption
1548634|NCT02741115|Vascular Function
1548635|NCT02741115|EndoPAT
1548636|NCT02741115|Myocardial Performance
1548637|NCT02728843|Parkinson's disease
1548638|NCT02728843|Deferiprone
1548639|NCT02771210|Active psoriatic arthritis
1548640|NCT02771210|Axial spondyloarthritides
1548641|NCT02771210|Subcutaneous
1548642|NCT02771210|Secukinumab in prefilled syringe
1548643|NCT02771210|Enthesitis
1548644|NCT02771210|Achilles tendon
1548645|NCT02734615|LSZ102
1548646|NCT02734615|ER+ breast cancer
1548647|NCT02734615|advanced ER+ breast cancer
1548648|NCT02734615|metastatic ER+ breast cancer
1548649|NCT02734615|SERD
1548650|NCT02734615|SERM
1548651|NCT02734615|fulvestrant
1548652|NCT02734615|tamoxifen
1548653|NCT02734615|aromatase inhibitor
1548654|NCT02734615|ESR1
1548655|NCT02734615|estrogen receptor
1548656|NCT02734615|endocrine therapy
1548657|NCT02718157|Polymerase Chain Reaction (PCR)
1548658|NCT02718157|GBS
1548659|NCT02718157|Streptococcus agalactiae
1548660|NCT02718157|Antepartum women
1548661|NCT02713334|Decision Making
1548662|NCT02713334|Communication
1548663|NCT02713334|16-080
1548664|NCT02727764|Rheumatoid Arthritis
1548665|NCT02727764|Gene therapy
1548666|NCT02727764|Phase Ib
1548667|NCT02727764|Intra-articular
1548668|NCT02707042|Microbiome
1548669|NCT02707042|Amoxicillin
1548670|NCT02707042|Azithromycin
1548671|NCT02707042|Metagenome
1548672|NCT02707042|Metabolic
1548673|NCT02707029|Screening Protocol
1548674|NCT02707029|Pain
1548675|NCT02707029|Phenotypes
1548676|NCT02714374|GL-ONC1
1548677|NCT02714374|Solid Organ Cancer
1548678|NCT02714374|Cancer
1548679|NCT02714374|Surgery
1548680|NCT02714374|Oncolytic Virus
1548681|NCT02714374|Soliris
1548682|NCT02714374|Metastatic melanoma
1548683|NCT02714374|Esophageal and gastric adenocarcinoma (Stage III/IV)
1548684|NCT02714374|Cholangiocarcinoma
1548685|NCT02714374|Pancreatic adenocarcinoma
1548686|NCT02714374|Gallbladder cancer
1548687|NCT02714374|Colorectal cancer (Stage IV)
1548688|NCT02714374|High-grade mucinous appendix cancer
1548689|NCT02714374|High-grade gastrointestinal neuroendocrine cancer
1548690|NCT02714374|Mesothelioma
1548691|NCT02714374|High-grade soft tissue sarcoma
1548692|NCT02714374|Stage III or IV
1548693|NCT02694783|JC VIRUS
1548694|NCT02694783|Progressive Multifocal Encephalopathy (PML)
1548695|NCT02697734|Cushing's disease
1548696|NCT02697734|LCI699
1548697|NCT02697734|osilodrostat
1548698|NCT02697734|Pituitary Gland
1548699|NCT02697734|Adrenocorticotropic
1548700|NCT02697734|Hormone
1548701|NCT02697734|ACTH
1548702|NCT02697734|UFC
1548703|NCT02700035|Intervention
1548704|NCT02700035|Prevention
1548705|NCT02700035|Randomized Controlled Trial
1548706|NCT02700035|Bii-Zin-Da-De-Dah
1548707|NCT03064308|Frailty
1548708|NCT03064308|Surgery
1548709|NCT03064308|Physical function
1548710|NCT03064308|Cognitive function
1548711|NCT03064308|Quality of life
1548712|NCT03064308|Exercise
1548713|NCT03064308|Rehabilitation
1548714|NCT03064308|Delirium
1548715|NCT03064308|Morbidity
1548716|NCT03064308|Mortality
1548717|NCT03064308|Length of stay
1548718|NCT03064308|Well-being
1548719|NCT03064308|Elderly
1548720|NCT03064308|Older surgical patient
1548721|NCT03064308|Radical prostatectomy
1548722|NCT03064308|Radical cystectomy
1548723|NCT03064308|Radical cystoprostatectomy
1548724|NCT03064308|Aortic Aneurysm Repair
1548725|NCT03064308|Major Cavity Surgery
1548726|NCT03064308|Abdominal Surgery
1548727|NCT03064308|Recovery
1548728|NCT03064308|Nephrectomy
1548729|NCT02696564|COPD
1548730|NCT02696564|emphysema
1548731|NCT02696564|HRCT
1548732|NCT02696564|losartan
1548733|NCT02692742|Chemotherapy
1548734|NCT02692742|Chemotherapy-induced Neutropenia
1548735|NCT02692742|Supportive Care
1548736|NCT02692742|Myelosuppression
1548737|NCT02692742|CIN
1548738|NCT02699099|Children
1548739|NCT02699099|Infants
1548740|NCT02699099|SB257049
1548741|NCT02699099|Malaria
1548742|NCT02699099|Immunogenicity
1548743|NCT02699099|Surveillance
1548744|NCT02699099|Efficacy
1548745|NCT02699099|Safety
1548746|NCT02699099|Africa
1548747|NCT02699099|Plasmodium falciparum
1548748|NCT02685358|Stress Disorders, Post-traumatic
1548749|NCT02685358|Primary Health Care
1548750|NCT02685358|Mobile Applications
1548751|NCT02685358|Veterans
1548752|NCT02685982|Unipolar
1548753|NCT02685982|Depression
1548754|NCT02685982|Depressive Disorder
1548755|NCT02685982|Behavioural Symptoms
1548756|NCT02685982|Mood Disorder
1548757|NCT02685982|Adjunctive Therapy
1548758|NCT02685982|Music Therapy
1548759|NCT02685982|Brain Stimulation
1548760|NCT02693535|cancer
1548761|NCT02693535|off-label
1548762|NCT02693535|precision medicine
1548763|NCT02693535|targeted therapy
1548764|NCT02691468|one lung ventilation
1548765|NCT02691468|double lumen endobronchial tube
1548766|NCT02691468|displacement
1548767|NCT02691468|Fiberoptic bronchoscope
1548768|NCT02680886|Rapid Absorbable Suture Material
1548769|NCT02680886|Children / Adults
1548770|NCT02680886|Novosyn Quick
1548771|NCT02704520|Rectal Cancer
1548772|NCT02704520|Magnetic Resonance Imaging
1548773|NCT02704520|Chemoradiotherapy
1548774|NCT02704520|Chemotherapy
1548775|NCT02704520|Diagnostic Imaging
1548776|NCT02676778|Peripheral T-cell lymphoma
1548777|NCT02676778|Cutaneous T-cell lymphoma
1548778|NCT02676778|E7777
1548779|NCT02676778|Phase 2
1548780|NCT02668354|Childhood Cancer
1548781|NCT02668354|Pediatric Oncology
1548782|NCT02668354|Infant tumors
1548783|NCT02670577|stage I
1548784|NCT02670577|stage II
1548785|NCT02670577|HER2 positive
1548786|NCT02670577|Triple Negative
1548787|NCT02675465|Pompe, rhGAA
1548788|NCT02672189|Climacteric symptoms
1548789|NCT02672189|Menopause
1548790|NCT02672189|Breast Cancer Survivors
1548791|NCT02672189|Internet-based
1548792|NCT02672189|Cognitive behavioral therapy
1548793|NCT02672189|Psychosocial intervention
1548794|NCT02665975|Tinnitus treatment
1548795|NCT02665975|Internet-intervention
1548796|NCT02665975|CBT
1548797|NCT02649855|PSA
1548798|NCT02649855|Vaccine
1548799|NCT02649855|Immunotherapy
1548800|NCT02649855|Immune Response
1548801|NCT02649855|Androgen Deprivation Therapy
1548802|NCT02729532|Extra-pulmonary tuberculosis
1548803|NCT02729532|multiple drug resistant tuberculosis
1548804|NCT02729532|mycobacterium tuberculosis
1548805|NCT02729532|human immunodeficiency virus
1548806|NCT02656017|kidney disease
1548807|NCT02656017|polycystic kidney disease
1548808|NCT02656017|autosomal dominant kidney disease
1548809|NCT02656017|kidney cysts
1548810|NCT02656017|PKD
1548811|NCT02639273|Nalmefene
1548812|NCT02639273|fMRI
1548813|NCT02639273|Incentive Salience
1548814|NCT02639273|Reward Processing
1548815|NCT02639273|Aversive Event Processing
1548816|NCT02639312|Cranofacial
1548817|NCT02639312|Microsomia
1548818|NCT02639312|Mandibular
1548819|NCT02639312|Facial Defects
1548820|NCT02639312|Hasburg Jaw
1548821|NCT02642393|SURE-PD3
1548822|NCT02642393|Parkinson's disease
1548823|NCT02642393|PD
1548824|NCT02642393|Inosine
1548825|NCT02642393|Urate
1548826|NCT02642393|Parkinson Study Group (PSG)
1548827|NCT02685072|Smoking Cessation
1548828|NCT02685072|Nicotine Cessation
1548829|NCT02635841|Pantothenate Kinase-Associated Neurodegeneration
1548830|NCT02635841|PKAN
1548831|NCT02635841|Neurodegeneration with Brain Iron Accumulation
1548832|NCT02635841|NBIA
1548833|NCT02635841|Deferiprone
1548834|NCT02635841|Ferriprox
1548835|NCT02637687|Pediatric
1548836|NCT02637687|NTRK1
1548837|NCT02637687|NTRK2
1548838|NCT02637687|NTRK3
1548839|NCT02637687|Fusion
1548840|NCT02637687|Tumors
1548841|NCT02637687|Solid Tumors
1548842|NCT02637687|CNS Tumors
1548843|NCT02637687|Central Nervous System Tumors
1548844|NCT02637687|NTRK Fusion Positive
1548845|NCT02637687|TRKA
1548846|NCT02637687|TRKB
1548847|NCT02637687|TRKC
1548848|NCT02637687|Infantile Fibrosarcoma
1548849|NCT02637687|NTRK Gene Rearrangements
1548850|NCT02637687|TRK Fusion
1548851|NCT02637687|NTRK1 fusion
1548852|NCT02637687|NTRK2 fusion
1548853|NCT02637687|NTRK3 fusion
1548854|NCT02637687|NTRK1 gene rearrangement
1548855|NCT02637687|NTRK2 gene rearrangement
1548856|NCT02637687|NTRK3 gene rearrangement
1548857|NCT02637687|ETV6-NTRK3
1548858|NCT02637687|ETV6
1548859|NCT02637687|ETV6 fusion
1548860|NCT02637687|ETV6 gene rearrangement
1548861|NCT02637687|Solid CNS tumor
1548862|NCT02637687|Primary CNS tumor
1548863|NCT02637687|Advanced CNS tumor
1548864|NCT02637687|Metastatic CNS tumor
1548865|NCT02637687|Metastatic infantile fibrosarcoma
1548866|NCT02637687|Advanced infantile fibrosarcoma
1548867|NCT02637687|Fibrosarcoma
1548868|NCT02637687|Congenital mesoblastic nephroma
1548869|NCT02637687|Congenital nephroma
1548870|NCT02637687|Thyroid
1548871|NCT02637687|Larotrectinib
1548872|NCT02627196|Heart Failure
1548873|NCT02627196|BAROSTIM NEO®
1548874|NCT02627196|Baroreceptor
1548875|NCT02627196|Baroreflex
1548876|NCT02627196|Baroreflex Activation Therapy™
1548877|NCT02627196|New York Heart Associate Class III Heart Failure
1548878|NCT02625896|Aviation
1548879|NCT02625896|Parachuting
1548880|NCT02625857|Prostatic Neoplasms, Castration-Resistant
1548881|NCT02625857|JNJ-64041809
1548882|NCT02625857|Listeria monocytogenes
1548883|NCT03202615|lactoferrin
1548884|NCT03202615|iron deficiency anemia in pregnancy
1548885|NCT02633202|Nasopharyngeal carcinoma
1548886|NCT02633202|Concurrent chemoradiotherapy
1548887|NCT02633202|intermediate risk
1548888|NCT02633202|intensity-modulated radiotherapy
1548889|NCT02620384|Metolazone
1548890|NCT02620384|Heart Failure
1548891|NCT02621047|Healthy volunteer
1548892|NCT02621047|Alectinib
1548893|NCT02621047|Hepatic impairment
1548894|NCT02760589|ACL tear
1548895|NCT02760589|ACL lesion
1548896|NCT02760589|ACL reconstruction
1548897|NCT02760589|InternalBrace
1548898|NCT02760589|functional performance test
1548899|NCT02760589|anterior cruciate ligament
1548900|NCT02636855|Solid and Hematological Malignancies
1548901|NCT02636855|Screening
1548902|NCT02636855|Metastatic
1548903|NCT02636855|Previously Treated
1548904|NCT02636855|NY-ESO-1
1548905|NCT02636855|MAGE A10
1548906|NCT02636855|MAGE-A4
1548907|NCT02612155|Hypoxic-ischemic encephalopathy
1548908|NCT02612155|autologous cord blood cells
1548909|NCT02612155|newborn infants
1548910|NCT02610283|AKI
1548911|NCT02607475|telesonography
1548912|NCT02607475|ultrasound
1548913|NCT02607475|robotic telesonography
1548914|NCT02605083|Cancer
1548915|NCT02605083|Neoplasm
1548916|NCT02605083|Solid Tumor
1548917|NCT02605083|Breast
1548918|NCT02605083|Head and Neck
1548919|NCT02605083|Lung
1548920|NCT02605083|Pancreatic
1548921|NCT02605083|Hepatic
1548922|NCT02605083|Melanoma
1548923|NCT02605083|Colon
1548924|NCT02605083|Renal
1548925|NCT02605083|Thyroid
1548926|NCT02605083|Prostate
1548927|NCT02605083|Ovarian
1548928|NCT02605083|MNK1
1548929|NCT02605083|MNK2
1548930|NCT02605083|eIF4E
1548931|NCT02599896|Dose Escalation
1548932|NCT02599896|HIV Prevention
1548933|NCT02599896|Broadly HIV-1 Neutralizing Activity
1548934|NCT02599896|Open-Label
1548935|NCT02599896|Half-Life
1548936|NCT02595125|intrauterine device
1548937|NCT02595125|contraceptive method
1548938|NCT02595125|direct technique
1548939|NCT02595125|torpedo technique
1548940|NCT02595125|verbal numeric scale
1548941|NCT02588612|Previously Treated
1548942|NCT02588612|Cell Therapy
1548943|NCT02588612|T Cell Therapy
1548944|NCT02588612|NY-ESO-1
1548945|NCT02588612|Immuno-oncology
1548946|NCT02588612|T Cell Receptor
1548947|NCT02591030|Bile Duct Cancer
1548948|NCT02591030|phase II/III
1548949|NCT02591030|Modified folfirinox
1548950|NCT02591030|Gemcis
1548951|NCT02592577|Previously Treated
1548952|NCT02592577|Cell Therapy
1548953|NCT02592577|T Cell Therapy
1548954|NCT02592577|MAGE-A10
1548955|NCT02592577|Immuno-oncology
1548956|NCT02592577|T Cell Receptor
1548957|NCT02592577|Metastatic
1548958|NCT02608268|Solid tumors
1548959|NCT02608268|Melanoma
1548960|NCT02608268|Non small cell lung cancer
1548961|NCT02608268|NSCLC
1548962|NCT02608268|Renal cell carcinoma
1548963|NCT02608268|RCC
1548964|NCT02608268|Phase I-Ib/II
1548965|NCT02608268|MBG453
1548966|NCT02608268|PDR001
1548967|NCT02608268|Checkpoint inhibitor
1548968|NCT02608268|PD-1
1548969|NCT02608268|TIM-3
1548970|NCT02669303|Subacromial injection
1548971|NCT02669303|methylprednisolone
1548972|NCT02669303|treatment
1548973|NCT02669303|Platelet-rich plasma
1548974|NCT02576990|PD1
1548975|NCT02576990|PD-1
1548976|NCT02576990|PDL1
1548977|NCT02576990|PD-L1
1548978|NCT02592512|Hypoxia
1548979|NCT02592512|hypercapnia
1548986|NCT02568267|Entrectinib
1548987|NCT02568267|RXDX-101
1548988|NCT02568267|TrkA
1548989|NCT02568267|TrkB
1548990|NCT02568267|TrkC
1548991|NCT02568267|NTRK1
1548992|NCT02568267|NTRK2
1548993|NCT02568267|NTRK3
1548994|NCT02568267|ROS1
1548995|NCT02568267|ALK
1548996|NCT02568267|Trk Fusions
1548997|NCT02568267|NTRK Gene Rearrangements
1548998|NCT02568267|ROS1 Fusions
1548999|NCT02568267|ROS1 Gene Rearrangements
1549000|NCT02568267|ALK Fusions
1549001|NCT02568267|ALK Gene Rearrangements
1549002|NCT02568267|Basket study
1549003|NCT02568267|Non-small cell lung cancer
1549004|NCT02568267|Colorectal cancer
1549005|NCT02568267|Salivary gland cancers
1549006|NCT02568267|Primary brain tumors
1549007|NCT02568267|Melanoma
1549008|NCT02568267|Sarcomas
1549009|NCT02568267|Papillary thyroid cancer
1549010|NCT02568267|Renal cell cancer
1549011|NCT02568267|Pancreatic cancer
1549012|NCT02568267|Breast cancer
1549013|NCT02568267|Cholangiocarcinoma
1549014|NCT02568267|Head & Neck cancers
1549015|NCT02568267|Ovarian cancer
1549016|NCT02568267|Neuroendocrine tumors
1549017|NCT02568267|Anaplastic Large Cell Lymphoma
1549018|NCT02572557|Spray Cryotherapy
1549019|NCT02564055|Vehicle-Controlled
1549020|NCT02564055|GSK2894512
1549021|NCT02564055|Double blind
1549022|NCT02564055|Dose-finding
1549023|NCT02564055|Atopic Dermatitis
1549024|NCT02563145|Real-time fMRI feedback
1549025|NCT02562755|Hepatocellular Carcinoma (HCC)
1549026|NCT02562755|Pexastimogene Devacirepvec (Pexa-Vec)
1549027|NCT02562755|Sorafenib
1549028|NCT02562755|GM-CSF therapy
1549029|NCT02562755|Thymidine Kinase-Deactivated Vaccinia Virus
1549030|NCT02562755|Oncology
1549031|NCT02562755|Recombinant Vaccinia Virus
1549032|NCT02562755|Oncolytic Virus Therapy
1549033|NCT02562755|Oncolytic virotherapy
1549034|NCT02557750|Childhood Cancer
1549035|NCT02557750|Pediatric Oncology
1549036|NCT02557243|Childhood Cancer
1549037|NCT02557243|Soft Tissue Tumors
1549038|NCT02557243|Bone Tumors
1549039|NCT02557243|Extremity Tumor
1549040|NCT02557243|Pediatric Oncology
1549041|NCT02556229|Aflibercept
1549042|NCT02556229|inflammatory choroidal neovascularization
1549043|NCT02556229|young patient
1549044|NCT02550522|without associated head injury
1549045|NCT02546817|Treatment
1549046|NCT02546817|Tx
1549047|NCT02546817|Prevent
1549048|NCT02550548|Incretins
1549049|NCT02550548|GLP-1
1549050|NCT02550548|GIP
1549051|NCT02550548|hyperglycemic clamp
1549052|NCT02531880|MRI
1549053|NCT02531880|Manganese Enhanced MRI
1549054|NCT02531880|Seizure Disorder
1549055|NCT02531880|Seizures
1549056|NCT02531880|Epileptic Focus
1549057|NCT02562352|polypharmacy
1549058|NCT02562352|multimorbidity
1549059|NCT02562352|randomized controlled trial
1549060|NCT02562352|drug discontinuation
1549061|NCT02562352|patient preference
1549062|NCT02562352|eHealth
1549063|NCT02532283|Influenza A virus
1549064|NCT02532283|JNJ-63623872
1549065|NCT02532283|Oseltamivir
1549066|NCT02531061|Rheumatoid Arthritis
1549067|NCT02531061|bDMARDs
1549068|NCT02531061|biotherapy
1549069|NCT02531061|remission
1549070|NCT02531061|erosion
1549071|NCT02519322|Melanoma
1549072|NCT02519322|Oligometastatic melanoma
1549073|NCT02519322|Resectable
1549074|NCT02519322|Nivolumab
1549075|NCT02519322|BMS-936558
1549076|NCT02519322|Opdivo
1549077|NCT02519322|Ipilimumab
1549078|NCT02519322|Yervoy
1549079|NCT02519322|BMS-734016
1549080|NCT02519322|MDX010
1549081|NCT02516150|Type 1 Diabetes
1549082|NCT02516150|Bionic Pancreas
1549083|NCT02516150|Artificial Pancreas
1549084|NCT02516150|Insulin
1549085|NCT02516150|Glucagon
1549086|NCT02516150|Alcohol
1549087|NCT02516150|Alcohol Clamp
1549091|NCT02509507|Liver tumours
1549092|NCT02503436|Ovarian Cancer, Fallopian Tube Cancer, primary peritoneal cancer, BRCA1 Gene, BRCA2 Gene
1549093|NCT02483637|spray cryotherapy
1549094|NCT02483637|cryotherapy
1549095|NCT02483637|chronic bronchitis
1549096|NCT02483637|airflow restrictions
1549097|NCT02487238|Microbiome
1549098|NCT02487238|Microbiota
1549099|NCT02487238|Fecal Microbial Transplant
1549100|NCT02487238|FMT
1549101|NCT02487238|Pediatrics
1549102|NCT02487238|Gastroenterology
1549103|NCT02487238|IBD
1549104|NCT02487238|Inflammatory Bowel Disease
1549105|NCT02487238|Ulcerative Colitis
1549106|NCT02487238|UC
1549107|NCT02487238|Inflammatory Bowel Disease Unclassified
1549108|NCT02487238|IBD-U
1549109|NCT02487238|Rebiotix
1549110|NCT02487238|RBX2660
1549111|NCT02485925|Interventional
1549112|NCT02485925|Radiofrequency ablation
1549113|NCT02485925|Paroxysmal Atrial Fibrillation
1549114|NCT02485925|Catheter ablation
1549115|NCT02512237|HER2
1549116|NCT02512237|breast cancer
1549117|NCT02512237|ADC
1549118|NCT02512237|antibody drug conjugate
1549119|NCT02512237|elevated HER2 expression
1549120|NCT02485587|Arousal Biofeedback
1549121|NCT02485587|Electrodermal activity
1549122|NCT02485132|Type 2 diabetes
1549123|NCT02485132|Sulfonylurea
1549124|NCT02485132|Hypoglycemia
1549125|NCT02485132|Quality of life
1549126|NCT02484716|Hemorrhagic Hereditary Telangiectasia (HHT)
1549127|NCT02484716|Antiangiogenic therapy
1549128|NCT02484716|Timolol
1549129|NCT02466568|advanced
1549130|NCT02466568|metastatic
1549131|NCT02466568|lung disease
1549132|NCT02466568|adenocarcinoma
1549133|NCT02466568|non-small cell lung cancer (NSCLC)
1549134|NCT02472600|extended spectrum beta-lactamase producing enterobacteriaceae
1549135|NCT02472600|carbapenemase producing enterobacteriaceae
1549136|NCT02472600|multidrug resistant bacteria
1549137|NCT02460172|bi lateral
1549138|NCT02460172|knee surgery
1549139|NCT02460172|arthroplasty
1549140|NCT02460172|orthopedics
1549141|NCT02457546|Fibrin sealant
1549142|NCT02457546|CSF leak
1549143|NCT02474355|NSCLC
1549144|NCT02474355|EGFRm
1549145|NCT02474355|T790M
1549146|NCT02460276|Mantle cell lymphoma
1549147|NCT02460276|Relapsed mantle cell lymphoma
1549148|NCT02460276|Lenalidomide
1549149|NCT02460276|Rituximab
1549150|NCT02460276|Ibrutinib
1549151|NCT02460276|Response duration
1549152|NCT02460276|Complete remission rate
1549153|NCT02460276|Quality of life
1549154|NCT02460276|Overall survival
1549155|NCT02460276|Safety
1549156|NCT02475733|Complicated intra-abdominal infections (cIAIs)
1549157|NCT02446262|Pain
1549158|NCT02446262|Visual Analogue Pain Scale
1549159|NCT02446262|Placebo
1549160|NCT02446262|Affective Neuroscience
1549161|NCT02446262|Functional Magnetic Resonance Imaging (fMRI)
1549162|NCT02455336|tetraplegia
1549163|NCT02455336|paraplegia
1549164|NCT02455336|hypertriglyceridemia
1549165|NCT02455336|hyperlipidemia
1549166|NCT02455336|peroxisome proliferator-activated receptor alpha
1549167|NCT02451267|neck pain
1549168|NCT02451267|aerobic exercise
1549169|NCT02451267|cervical pain
1549170|NCT02460224|Non-small cell lung cancer
1549171|NCT02460224|Melanoma
1549172|NCT02460224|Renal cancer
1549173|NCT02476708|schizophrenia
1549174|NCT02476708|schizoaffective disorder
1549175|NCT02476708|cognition
1549176|NCT02476708|curcumin
1549177|NCT02433535|severe asthma
1549178|NCT02433535|simvastatin
1549179|NCT02433535|allergic airway inflammation
1549180|NCT02439749|Uncontrolled hypertension
1549181|NCT02439749|Renal denervation
1549182|NCT02433015|Electronic Cigarette
1549183|NCT02427464|diabetic
1549184|NCT02427464|neuropathy
1549185|NCT02427464|shooting pain
1549186|NCT02427464|burning pain
1549187|NCT02427464|pins and needles pain
1549188|NCT02427464|foot pain
1549189|NCT02427464|ViroMed
1549190|NCT02419469|Leukemia
1549191|NCT02419469|Precursor-B acute lymphoblastic leukemia
1549192|NCT02419469|ALL
1549193|NCT02419469|Lymphoblastic lymphoma
1549194|NCT02419469|LL
1549195|NCT02419469|Lymphoma
1549196|NCT02419469|Cytarabine
1549197|NCT02419469|Ara-C
1549198|NCT02419469|Cytosar
1549199|NCT02419469|DepoCyt
1549200|NCT02419469|Cytosine Arabinosine Hydrochloride
1549201|NCT02419469|Daunorubicin
1549202|NCT02419469|Daunorubicin Hydrochloride
1549203|NCT02419469|Cerubidine
1549204|NCT02419469|Daunomycin
1549205|NCT02419469|DNR
1549206|NCT02419469|Vincristine
1549207|NCT02419469|Prednisone
1549208|NCT02419469|PEG asparaginase
1549209|NCT02419469|Pegaspargase
1549210|NCT02419469|Oncaspar
1549211|NCT02419469|Polyethylene glycol conjugated lasparaginase-H
1549212|NCT02419469|Ofatumumab
1549213|NCT02419469|Arzerra
1549214|NCT02419469|Rituximab
1549215|NCT02419469|Rituxan
1549216|NCT02419469|Methotrexate
1549217|NCT02419469|Cyclophosphamide
1549218|NCT02419469|Cytoxan
1549219|NCT02419469|Neosar
1549220|NCT02419469|Mercaptopurine
1549221|NCT02419469|6-mercaptopurine
1549222|NCT02419469|Purinethol
1549223|NCT02419469|6-MP
1549224|NCT02419469|Doxorubicin
1549225|NCT02419469|Doxorubicin hydrochloride
1549226|NCT02419469|Adriamycin PFS
1549227|NCT02419469|Adriamycin RDF
1549228|NCT02419469|Adriamycin
1549229|NCT02419469|Rubex
1549230|NCT02419469|Dexamethasone
1549231|NCT02419469|Decadron
1549232|NCT02419469|Thioguanine
1549233|NCT02419469|6-thioguanine
1549234|NCT02416622|XLRS
1549235|NCT02416622|maculoschisis
1549236|NCT02416622|retinal degeneration
1549237|NCT02416622|RS1
1549238|NCT02416622|adeno-associated virus
1549239|NCT02416622|gene therapy
1549240|NCT02416622|AAV
1549241|NCT02414139|Non Small Cell Lung
1549242|NCT02414139|cMET
1549243|NCT02408224|ACS
1549244|NCT02412462|Phase I
1549245|NCT02412462|Clusterin
1549246|NCT02412462|Epithelial-to-Mesenchymal Transition (EMT)
1549247|NCT02412462|Circulating Tumor Cells (CTC)
1549248|NCT02412462|EMT and Stem Cell Biomarkers
1549249|NCT02412462|Pharmacokinetics
1549250|NCT02404545|Hernia
1549251|NCT02404545|Mesh
1549252|NCT02404545|Ileal conduit
1549253|NCT02395614|tissue expander
1549254|NCT02395614|breast reconstruction
1549255|NCT02395003|Obesity
1549256|NCT02395003|Pediatric
1549257|NCT02412306|Amgen
1549258|NCT02394626|Recurrent glioblastoma
1549259|NCT02394626|Surgery
1549260|NCT02394626|Complete resection of enhancing tumor
1549261|NCT02394626|Survival
1549262|NCT02394626|Quality of life
1549263|NCT02387099|Stage IIIB
1549264|NCT02387099|Stage IV
1549265|NCT02387099|Recurrent
1549266|NCT02387099|Metastatic
1549267|NCT02380274|Prostate Cancer
1549268|NCT02380274|Castration-resistant Prostate Cancer
1549269|NCT02380274|Metastatic Prostate Cancer
1549270|NCT02381054|Patient reported outcomes
1549271|NCT02376777|Anticoagulants
1549272|NCT02376777|Antithrombins
1549273|NCT02376777|Atrial Fibrillation
1549274|NCT02376777|Intracranial haemorrhage
1549275|NCT02376777|Gastrointestinal haemorrhage
1549276|NCT02376777|Myocardial infarction
1549277|NCT02376777|Stroke
1549278|NCT02376777|Venous thrombosis
1549279|NCT02376777|Primary care
1549280|NCT02432287|aging
1549281|NCT02432287|metformin
1549282|NCT02432287|prediabetes
1549283|NCT02534935|Phase 2 Immunogenicity
1549284|NCT02534935|Safety
1549285|NCT02534935|Tolerability Study
1549286|NCT02534935|rLP2086 Vaccine
1549287|NCT02534935|Healthy Toddlers
1549288|NCT02534935|Neisseria meningitidis
1549289|NCT02534935|Duration of Immunogenicity
1549290|NCT02387736|BPD
1549291|NCT02387736|DBT
1549292|NCT02387736|Dialectical Behaviour Therapy
1549293|NCT02387736|Borderline Personality Disorder
1549294|NCT02387736|Suicide
1549295|NCT02387736|Non-suicidal self injury
1549296|NCT02387736|NSSI
1549297|NCT02387736|Randomized Control trials
1549298|NCT02387736|treatment
1549299|NCT02386540|Community Health Workers
1549300|NCT02386540|Community Health Workers: utilization
1549301|NCT02386540|Emergency Service
1549302|NCT02386540|Primary Health Care/utilization
1549303|NCT02386540|Health Services Accessibility
1549304|NCT02366481|Vitamin K
1549305|NCT02366481|Vitamin K2
1549306|NCT02366481|Menaquinone-7
1549307|NCT02366481|Osteocalcin
1549308|NCT02366481|Adults
1549309|NCT02366481|Obesity
1549310|NCT02366481|Insulin resistance
1549311|NCT02366481|Insulin sensitivity
1549312|NCT02366481|Beta-cell function
1549313|NCT02366481|Prediabetes
1549314|NCT02368977|Colonoscopy
1549315|NCT02368977|Polyps
1549316|NCT02368977|Adenomas
1549317|NCT02367521|TBI Depression
1549318|NCT02367521|co-morbid psychiatric symptoms
1549319|NCT02370810|tinnitus treatment, internet-intervention, CBT
1549320|NCT02355717|children, bone
1549321|NCT02355717|Simple obesity
1549322|NCT02355717|cardiovascular disease
1549323|NCT02355717|osteoporosis
1549324|NCT02355717|diabetes
1549325|NCT02347722|biomarkers
1549326|NCT02347722|diagnosis
1549327|NCT02347722|etiology of heart failure
1549328|NCT02369653|Anticoagulation
1549329|NCT02421744|rehabilitation
1549330|NCT02421744|Multiple Sclerosis
1549331|NCT02421744|mobility
1549332|NCT02421744|gait
1549333|NCT02421744|task-oriented training
1549334|NCT02339012|Genome Wide Association
1549335|NCT02339012|Biomarkers
1549336|NCT02339012|Methylation
1549337|NCT02339012|Phenotype
1549338|NCT02339012|Cytometry
1549339|NCT02352428|Skin Cancer
1549340|NCT02352428|Secondary Prevention
1549341|NCT02352428|Population Screening
1549342|NCT02332291|Depression
1549343|NCT02332291|Geriatrics
1549344|NCT02332291|Elderly
1549345|NCT02332291|MRI
1549346|NCT02332291|Antidepressants
1549347|NCT02383173|end of life
1549348|NCT02383173|palliative care
1549349|NCT02383173|implementation
1549350|NCT02322307|Inflammatory Bowel Disease
1549351|NCT02322307|Crohn's Disease
1549352|NCT02322307|Ulcerative Colitis
1549353|NCT02322307|Colitis
1549354|NCT02322307|PRO
1549355|NCT02322307|Patient-centric
1549356|NCT02322307|HealthPROMISE
1549357|NCT02321501|Head and Neck Cancer
1549358|NCT02321501|Lung Cancer
1549359|NCT02321501|Non small cell lung
1549360|NCT02321501|NSCLC
1549361|NCT02321501|Metastatic
1549362|NCT02321501|Locally advanced
1549363|NCT02321501|Metastatic solid tumors
1549364|NCT02321501|Anaplastic lymphoma kinase
1549365|NCT02321501|ALK
1549366|NCT02321501|Ceritinib
1549367|NCT02321501|LDK378
1549368|NCT02321501|Zykadia
1549369|NCT02321501|Everolimus
1549370|NCT02321501|Afinitor
1549371|NCT02321501|Zortress
1549372|NCT02321501|RAD001
1549373|NCT02321501|Pharmacokinetic
1549374|NCT02321501|PK
1549375|NCT02321501|Biomarker testing
1549376|NCT02317887|Gene Transfer
1549377|NCT02317887|X-Linked
1549378|NCT02317887|Retinoschisis
1549379|NCT02317887|AAV Vector
1549380|NCT02318888|Small bowel obstruction, Surgery, Colorectal cancer
1549381|NCT02433977|Asthma
1549382|NCT02433977|Obesity
1549383|NCT02433977|conjugated linolenic acid
1549384|NCT02433977|nitrate
1549385|NCT02433977|nitrite
1549386|NCT02433977|nutritional supplements
1549387|NCT02324582|Urinary Bladder Neoplasms
1549388|NCT02324582|Mycobacterium bovis
1549389|NCT02324582|Programmed Cell Death 1 Receptor
1549390|NCT02324582|pembrolizumab
1549391|NCT02328859|Gait
1549392|NCT02328859|Rehabilitation
1549393|NCT02328859|Virtual Reality
1549394|NCT02331173|XLRS
1549395|NCT02331173|RS1
1549396|NCT02331173|maculoschisis
1549397|NCT02311998|Leukemia
1549398|NCT02311998|CD22-positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
1549399|NCT02311998|ALL
1549400|NCT02311998|Chronic Myeloid Leukemia Lymphoid Blast Phase
1549401|NCT02311998|CML
1549402|NCT02311998|Bosutinib
1549403|NCT02311998|SKI-606
1549404|NCT02311998|Inotuzumab Ozogamicin
1549405|NCT02311998|CMC-544
1549406|NCT02311998|Phone Call
1549407|NCT02312869|Mechanical Ventilation
1549408|NCT02312869|Burn patients
1549409|NCT02310152|Child
1549410|NCT02310152|Adolescent
1549411|NCT02310152|Parents
1549412|NCT02310152|Cognitive Therapy
1549413|NCT02310152|Cognitive Behavior Therapy
1549414|NCT02310152|Anxiety
1549415|NCT02316457|TNBC
1549416|NCT02316457|Breast Cancer
1549417|NCT02316457|Warehouse
1549418|NCT02316457|Mutanome
1549419|NCT02316457|RNA
1549420|NCT02316457|Vaccine
1549421|NCT02300090|COPD, Exacerbation, respiratory disease, lung disease, breathlessness, dyspnoea, sputum, wheezing, cough
1549422|NCT02293824|Infant, Premature
1549423|NCT02293824|Caffeine
1549424|NCT02293824|Pharmacokinetics
1549425|NCT02293824|Metabolism
1549426|NCT02292550|Non-small cell lung cancer,
1549427|NCT02292550|ALK translocation,
1549428|NCT02292550|ALK-positive,
1549429|NCT02292550|NSCLC,
1549430|NCT02292550|LEE011,
1549431|NCT02292550|CDK4/6 inhibitor,
1549432|NCT02292550|EML4-ALK
1549433|NCT02278341|ASP1517
1549434|NCT02278341|FG-4592
1549435|NCT02278341|Anemia
1549436|NCT02278341|End Stage Renal Disease (ESRD)
1549437|NCT02278341|Erythropoetin Stimulating Agents (ESAs)
1549438|NCT02278341|Chronic Kidney Disease
1549439|NCT02278341|Hematopoetic Agents
1549440|NCT02278341|HIF-PH inhibitor
1549441|NCT02278341|Hemoglobin
1549442|NCT02278341|Dialysis
1549443|NCT02278341|roxadustat
1549444|NCT02288936|Hormone-refractory prostate cancer
1549445|NCT02288936|Enzalutamide
1549446|NCT02288936|TMPRSS2-ETS fusion gene
1549447|NCT02277925|Pelvic Organ Prolapse
1549448|NCT02277925|Vaginal mesh exposure rates
1549449|NCT02277925|Vaginal suture exposure rates
1549450|NCT02279108|sentinel lymph node
1549451|NCT02279108|indocyanine green
1549452|NCT02279108|fluorescence method
1549453|NCT02279108|radioisotope conventional method
1549454|NCT02279108|breast cancer
1549455|NCT02277587|Plenadren
1549456|NCT02277587|Addison's disease
1549457|NCT02277587|Hydrocortisone
1549458|NCT02277587|Cortisone Acetate
1549459|NCT02277587|Monocytes
1549460|NCT02277587|Natural Killer cells
1549461|NCT02277587|Immunological profile
1549462|NCT02277587|Inflammation
1549463|NCT02275910|Solid Tumors
1549464|NCT02275910|E7090
1549465|NCT02309645|fibrin sealant
1549466|NCT02309645|CSF leak
1549467|NCT02256371|Neuropathic pain
1549468|NCT02256371|Hypnosis
1549469|NCT02256371|Relaxation
1549475|NCT02254577|Infertility
1549476|NCT02254577|Progesterone
1549477|NCT02254577|ART
1549478|NCT02254577|IVF
1549479|NCT02254577|FET
1549480|NCT02254577|FBT
1549481|NCT02254577|Frozen Embryo Transfer
1549482|NCT02263508|Talimogene Laherparepvec
1549483|NCT02263508|pembrolizumab
1549484|NCT02263508|KEYNOTE-034
1549485|NCT02263508|MASTERKEY-265
1549486|NCT02253316|Multiple Myeloma
1549487|NCT02253316|Autologous Stem Cell Transplantation
1549488|NCT02253316|Ixazomib
1549489|NCT02253316|Lenalidomide
1549490|NCT02253316|Dexamethasone
1549491|NCT02246972|PTSD
1549492|NCT02246972|Military sexual trauma
1549493|NCT02246972|Veterans
1549494|NCT02246972|Women in the military
1549495|NCT02246972|Sexual assault
1549496|NCT02245737|Alzheimer's disease
1549497|NCT02245737|Dementia
1549498|NCT02245737|Brain Diseases
1549499|NCT02245737|Neurogenerative Diseases
1549500|NCT02245737|Central Nervous System Diseases
1549501|NCT02245737|Nervous System Diseases
1549502|NCT02245737|Mental Disorders
1549503|NCT02245737|Delirium, Dementia, Amnestic, Cognitive Disorders
1549504|NCT02245737|Tauopathies
1549505|NCT02243332|Knee
1549506|NCT02243332|Pain
1549507|NCT02243332|Joint
1549508|NCT02243332|Rehabilitation
1549509|NCT02243332|Patellofemoral Pain Syndrome
1549510|NCT02243332|Anterior Knee Pain Syndrome
1549511|NCT02243332|Knee Pain
1549512|NCT02243332|Quadriceps
1549513|NCT02237248|Adolescent Idiopathic Scoliosis
1549514|NCT02237248|Functional Movement Screen
1549515|NCT02237248|Y Balance Test
1549516|NCT02268461|Post-Stroke Spasticity
1549517|NCT02231853|BK Virus
1549518|NCT02231853|Cytotoxic T Cells
1549519|NCT02231853|EBV
1549520|NCT02231853|Adenovirus
1549521|NCT02231853|CMV
1549522|NCT02227706|Fibrin Sealant
1549523|NCT02227706|Hemostatics
1549524|NCT02227706|Coagulants
1549525|NCT02225106|Dopamine Receptors
1549526|NCT02225106|Methylphenidate
1549527|NCT02225106|Traumatic Brain Injury
1549528|NCT02225106|C-11 Raclopride
1549529|NCT02225106|Dopamine Release
1549530|NCT02225093|Safety
1549531|NCT02225093|Dextromethorphan
1549532|NCT02225093|CYP2D6
1549533|NCT02225093|Phase 1
1549534|NCT02225093|Prostate cancer
1549535|NCT02225093|CYP1A2
1549536|NCT02225093|Pharmacokinetics
1549537|NCT02225093|Drug-drug interactions
1549538|NCT02225093|Caffeine
1549539|NCT02225093|Enzalutamide
1549540|NCT02222493|Phase 3
1549541|NCT02222493|infliximab
1549542|NCT02222493|rheumatoid arthritis
1549543|NCT02226432|Barthel Scale
1549544|NCT02226432|Disability
1549545|NCT02226432|Modified Ashworth Scale
1549546|NCT02226432|Right Arm
1549547|NCT02226432|Neuromodulation
1549548|NCT02226432|Spasticity
1549549|NCT02226432|Stroke
1549550|NCT02203513|p53 Dysfunction
1549551|NCT02203513|Cell Cycle Arrest
1549552|NCT02203513|Checkpoint Kinases
1549553|NCT02203513|DNA Damage Repair Pathways
1549554|NCT02203513|Hereditary Breast and Ovarian Cancer Syndrome
1549555|NCT02227992|Fibrin Sealant
1549556|NCT02227992|Hemostatics
1549557|NCT02227992|Coagulants
1549558|NCT02199496|Malabsorption
1549559|NCT02199496|Enteropathy
1549560|NCT02199496|Diarrhea
1549561|NCT02199496|IL-23
1549562|NCT02199496|IL-12
1549563|NCT02185417|Hypertension
1549564|NCT02185417|Diuretic
1549565|NCT02185417|Comparative Effectiveness Research
1549566|NCT02185417|Point of Care Research
1549567|NCT02179125|COPD
1549568|NCT02179125|Endobronchial treatment
1549569|NCT02180217|LCI699
1549570|NCT02180217|Cushing's disease
1549571|NCT02166658|Patients with breast or lung cancer and recurrent or progressive brain
1549572|NCT02166658|metastases
1549573|NCT02166294|Foot
1549574|NCT02166294|Ulcer
1549575|NCT02166294|Diabetes
1549576|NCT02166294|Amputation
1549577|NCT02166294|Limb salvage
1549578|NCT02165683|Cancer
1549579|NCT02165683|Pediatric
1549580|NCT02165683|PET Scan
1549581|NCT02164734|surfactant
1549582|NCT02167659|Lymphedema
1549583|NCT02167659|Breast cancer
1549584|NCT02167659|Bioimpedance Spectroscopy
1549585|NCT02167659|L-Dex
1549586|NCT02164513|COPD
1549587|NCT02164513|umeclidinium
1549588|NCT02164513|fluticasone furoate
1549589|NCT02164513|vilanterol
1549590|NCT02164513|triple therapy
1549591|NCT02164513|exacerbation
1549592|NCT02162849|Tobacco Use Cessation
1549593|NCT02162849|Smoking Cessation
1549594|NCT02162849|Cancer Prevention
1549595|NCT02162849|Behavioral Counseling
1549596|NCT02162849|Nicotine Replacement Therapy
1549597|NCT02162849|NRT
1549598|NCT02162849|Nicotine patch
1549599|NCT02162849|Placebo patch
1549600|NCT02162849|Placebo pill
1549601|NCT02162849|Sugar pill
1549602|NCT02162849|Varenicline
1549603|NCT02162849|Chantix
1549604|NCT02162849|Questionnaires
1549605|NCT02162849|Surveys
1549606|NCT02162849|Saliva test
1549607|NCT02266758|Gestational Diabetes
1549608|NCT02266758|Obesity
1549609|NCT02266758|Pregnancy
1549610|NCT02138422|colorectal cancer
1549611|NCT02124772|v600-mutation
1549612|NCT02124772|neuroblastoma
1549613|NCT02124772|Trametinib
1549614|NCT02124772|pediatrics
1549615|NCT02124772|Langerhans Cell Histiocytosis
1549616|NCT02124772|low grade glioma plexiform neurofibromas
1549617|NCT02120404|septic shock, hemodynamic tolerance, esmolol
1549618|NCT02106455|Pharmacological theapy
1549619|NCT02105610|volatile anesthetics
1549620|NCT02105610|desflurane
1549621|NCT02105610|isoflurane
1549622|NCT02105610|sevoflurane
1549623|NCT02105610|TIVA
1549624|NCT02105610|cardiac surgery
1549625|NCT02105610|mortality
1549626|NCT02105610|anesthesia
1549627|NCT02105610|intensive care
1549628|NCT02096549|cerebral palsy
1549629|NCT02096549|Botulinum toxin
1549630|NCT02096549|Propofol
1549631|NCT02096549|Deep sedation
1549632|NCT02096549|Bispectral index monitor
1549633|NCT02102711|VITAMIN A
1549634|NCT02102711|BLOOD CONCENTRATION
1549635|NCT02102711|retinopathy of prematurity
1549636|NCT02081638|Immune Activation
1549637|NCT02077894|Whole Genome Sequencing
1549638|NCT02077894|Genetic Eye Disease
1549639|NCT02072369|stroke
1549640|NCT02072369|hand
1549641|NCT02072369|fingers
1549642|NCT02072369|rehabilitation
1549643|NCT02072369|training
1549644|NCT02065336|HBV
1549645|NCT02065336|Hepatitis
1549646|NCT02076152|Recurrent Glioblastoma
1549647|NCT02050867|Youth Suicide
1549648|NCT02050867|Suicide
1549649|NCT02075385|Dysphagia
1549650|NCT02075385|speech language therapy
1549651|NCT02075385|quality of life
1549652|NCT02075385|induction chemotherapy
1549653|NCT02075385|concurrent chemoradiotherapy
1549654|NCT02043678|Phase III
1549655|NCT02043678|Radium-223 dichloride
1549656|NCT02043678|Abiraterone acetate
1549657|NCT02043678|Combination therapy
1549658|NCT02043678|Chemotherapy-naive
1549659|NCT02043678|Bone metastasis
1549660|NCT02043678|Castration-resistant prostate cancer (CRPC)
1549661|NCT02043886|Type 2 Diabetes, Postprandial Hypotension, Acarbose
1549662|NCT02066623|coronary artery stenosis, vascular scaffold, ABSORB
1549663|NCT02037113|IVUS
1549664|NCT02037113|PAD
1549665|NCT02037113|Femoro-popliteal disease
1549666|NCT02037113|Intravascular ultrasound
1549667|NCT02036060|Metastatic prostate cancer
1549668|NCT02036060|Abiraterone acetate
1549669|NCT02078323|Irritable Bowel Syndrome with Constipation (IBS-C)
1549670|NCT02078323|Linaclotide
1549671|NCT02022579|Breast Cancer
1549672|NCT02022579|Diagnosis
1549673|NCT02022579|Malignant
1549674|NCT02022579|Benign
1549675|NCT02022579|Biopsy
1549676|NCT01996540|gastric neoplasm
1549677|NCT01996540|pancreatic neoplasm
1549678|NCT01996540|advanced
1549679|NCT01996540|palliative care
1549680|NCT01996865|Lymphoma, Mantle cell Lymphoma, Follicular Lymphoma, Marginal zone Lymphoma, Lenalidomide treatment, rituximab treatment, Non Hodgkins Lymphoma
1549681|NCT01995097|smoking cessation
1549682|NCT01995097|smoking reduction
1549683|NCT01995097|scheduled gradual reduction
1549684|NCT01995097|pregnancy
1549685|NCT01995097|text message intervention
1549702|NCT01987830|Recurrent glioblastoma
1549703|NCT01981551|Desmoid Tumor
1549704|NCT01981551|Aggressive Fibromatosis
1549705|NCT01981551|Gamma-secretase Inhibitor
1549706|NCT01981551|Notch Pathway
1549712|NCT01976364|Tofacitinib
1549713|NCT01976364|Psoriatic Arthritis
1549714|NCT01976364|Xeljanz
1549715|NCT01976364|CP-690550
1549716|NCT01976364|Jak-inhibitor
1549717|NCT01976364|oral treatment
1549718|NCT01976364|psoriasis
1549719|NCT01976364|OPAL BALANCE
1549720|NCT01976364|methotrexate
1549721|NCT01976364|pruritus
1549722|NCT01976364|itch
1549723|NCT01976364|DLQI
1549724|NCT01976520|Cancer vaccine
1549725|NCT01976520|Chronic lymphocytic leukemia
1549726|NCT01976520|CLL
1549727|NCT01976520|Autologous vaccine
1549728|NCT01976520|B cell leukemia
1549729|NCT01982448|TRIPLE NEGATIVE BREAST CANCER WITHOUT GERMLINE BRCA MUTATIONS
1549730|NCT01982448|CISPLATIN
1549731|NCT01982448|PACLITAXEL
1549732|NCT01974427|Magnetic Resonance Imaging (MRI)
1549733|NCT01974427|Functional Imaging
1549734|NCT01974427|BOLD Effect
1549735|NCT01974427|EEG
1549736|NCT01974427|MEG
1549737|NCT01973790|Z-338
1549738|NCT01973790|Functional Dyspepsia
1549739|NCT01973790|Postprandial Distress Syndrome
1549740|NCT01973543|PD
1549741|NCT01973543|Parkinson's disease
1549742|NCT01973543|Aromatic Amino Acid Decarboxylase
1549743|NCT01973543|AADC
1549744|NCT01973543|AAV2-AADC
1549745|NCT01973543|AAV2
1549746|NCT01973543|Viral Vector
1549747|NCT01973543|Gene Therapy
1549748|NCT01973543|Gene Transfer
1549749|NCT01973543|MRI
1549750|NCT01973543|PET
1549751|NCT01973543|VY-AADC01
1549752|NCT01972217|Olaparib
1549753|NCT01972217|castration-resistant, metastatic prostate cancer
1549754|NCT01972217|Prior Docetaxel Chemotherapy
1549755|NCT01972113|Vitamin K
1549756|NCT01972113|Vitamin K2
1549757|NCT01972113|Menaquinone-7
1549758|NCT01972113|Osteocalcin
1549759|NCT01972113|Children
1549760|NCT01972113|Obesity
1549761|NCT01972113|Insulin resistance
1549762|NCT01972113|Insulin sensitivity
1549763|NCT01972113|Beta-cell function
1549764|NCT01972113|Prediabetes
1549765|NCT01972113|Matrix Gla protein
1549766|NCT01972113|Arterial stiffness
1549767|NCT01972113|Endothelial function
1549768|NCT01967576|Mutation in SDHB gene
1549769|NCT01967576|Mutation in SDHV gene
1549770|NCT01967576|Mutation in VHL gene
1549771|NCT01967576|Pharmacogenomics analyses
1549772|NCT01967576|Germline DNA examination
1549773|NCT01967823|Metastatic Cancer
1549774|NCT01967823|Gene Therapy
1549775|NCT01967823|Immunotherapy
1549776|NCT01967823|Tumor Regression
1549777|NCT01965366|Dexamethasone
1549778|NCT01965366|Virtual Reality
1549779|NCT01965366|Military
1549780|NCT01965366|PTSD
1549781|NCT01959425|Anticoagulation
1549782|NCT01959425|Oral
1549783|NCT01959425|Paroxysmal atrial fibrillation
1549784|NCT01959425|Patients post successful cardiac ablation
1549785|NCT01959425|Symptomatic high-burden paroxysmal AF
1549786|NCT01959425|3 months post procedure
1549787|NCT01959425|Remain free from AF recurrence
1549788|NCT01952171|Genomics
1549789|NCT01952171|Congenital Malformations
1549790|NCT01952171|Birth Defects
1549791|NCT01952171|Heart Disease
1549792|NCT01949324|MacTel
1549793|NCT02012673|COPD
1549794|NCT02012673|Emphysema
1549795|NCT02012673|Bronchoscopy
1549796|NCT02012673|Lung Volume Reduction
1549797|NCT01914146|Diabetes
1549798|NCT01914146|Insulin
1549799|NCT01914146|Orthostatic Hypotension
1549800|NCT01914146|Falls
1549801|NCT01914146|Syncope
1549802|NCT01905826|Hematopoiesis
1549803|NCT01905826|Immunodeficiency
1549804|NCT01905826|Myelodysplasia/Leukemia
1549805|NCT01905826|Lymphedema
1549806|NCT01905826|Pulmonary Alveolar Proteinosis
1549807|NCT01883921|Primary Immunodeficiency
1549808|NCT01883921|Immunodeficiencies
1549809|NCT01883921|Primary Immunodeficiency Diseases
1549810|NCT01883921|PIDD
1549811|NCT01883921|CVID
1549812|NCT01883921|PI
1549813|NCT01883921|Common Variable Immunodeficiency
1549814|NCT01883921|Hypogammaglobulinemia
1549815|NCT01883921|Acquired Hypogammaglobulinemia
1549816|NCT01883921|Immunology
1549817|NCT01883921|Autoimmune Deficiency
1549818|NCT01883921|Intravenous Immunoglobulin
1549819|NCT01883921|Subcutaneous Immunoglobulin
1549820|NCT01883921|IVIg
1549821|NCT01883921|SCIg
1549822|NCT01883921|Immune Globulin
1549823|NCT01883921|Outcomes Research
1549824|NCT01883921|Immunodeficiency
1549825|NCT01875588|Healthy Controls
1549826|NCT01875588|HIV-positive
1549827|NCT01875588|Neurophyschological Testing
1549828|NCT01875588|PET/CT Scan
1549829|NCT01875588|Lumbar Drain/Puncture
1549830|NCT01869205|COPD
1549831|NCT01869205|Emphysema
1549832|NCT01869205|Bronchoscopic lung volume reduction
1549833|NCT01869205|Endobronchial valve
1549834|NCT01863446|Pregnancy
1549835|NCT01863446|Melatonin
1549836|NCT01863446|Contractions
1549837|NCT01863446|Light
1549838|NCT01893775|Anti CD 122
1549839|NCT01893775|Monoclonal Antibody Therapy
1549840|NCT01893775|Autoimmune Inflammatory Enteropathy
1549841|NCT01859299|Oral Tolerance
1549842|NCT01859299|Uveitis
1549843|NCT01859299|AMD
1549844|NCT01853124|Diarrhea
1549845|NCT01858649|metastatic
1549846|NCT01858649|colorectal
1549847|NCT01858649|cancer
1549848|NCT01858649|liver
1549849|NCT01858649|Bevacizumab
1549850|NCT01858649|Pathological response
1549851|NCT01846052|achromatopsia, CNGB3
1549852|NCT01854736|Allergy
1549853|NCT01854736|Phleum pratense
1549854|NCT01854736|Rhinoconjunctivitis
1549855|NCT01854736|asthma
1549856|NCT01854736|positive SPT to Phleum pratense
1549857|NCT01843686|Acute 2nd and 3rd Degree Burns
1549858|NCT01843686|Autologous Platelet Rich Plasma (PRP)
1549859|NCT01843686|Skin Grafting
1549860|NCT01843686|Magellan® System
1549861|NCT01843686|Wounds
1549862|NCT01837602|refractory to at least one standard therapy
1549863|NCT01837602|newly diagnosed
1549864|NCT01837602|with operable triple negative breast cancer
1549865|NCT01819675|Neuronal plasticity
1549866|NCT01819675|Neurotransmitter agents
1549867|NCT01819675|Receptors, neurotransmitter
1549868|NCT01819675|Transcranial magnetic stimulation
1549869|NCT01819675|Stroke
1549870|NCT01819675|gamma-Aminobutyric Acid
1549871|NCT01810861|serotype distribution
1549872|NCT01810861|streptococcus pneumoniae
1549873|NCT01810861|pneumonia
1549874|NCT01806909|Flu Vaccine
1549875|NCT01806909|Healthy Volunteer
1549876|NCT01791829|Luminal A
1549877|NCT01791829|Ipsilateral Breast Tumour Recurrence
1549878|NCT01786967|overactive bladder
1549879|NCT01786967|urge urinary incontinence
1549880|NCT01786967|pharmacogenetics
1549881|NCT01787305|microbiome
1549882|NCT01787305|commensals
1549883|NCT01787305|autoantibodies
1549884|NCT01787305|autoreactive T cells
1549885|NCT01784068|Ph+ CML-CP
1549886|NCT01784068|chronic phase
1549887|NCT01784068|nilotinib treatment
1549888|NCT01784068|2 years treatment
1549889|NCT01784068|MR 4.5
1549890|NCT01784068|Loss of MR 4
1549891|NCT01784068|Loss of MMR
1549892|NCT01778543|Coloboma
1549893|NCT01767857|Pivotal
1549894|NCT01767857|Colorectal
1549895|NCT01767857|Survival
1549896|NCT01767857|Phase 3
1549897|NCT01736293|Retinal Degeneration
1549898|NCT01730131|Immune Reconstitution Syndrome
1549899|NCT01730131|Human Immunodeficiency Virus
1549900|NCT01730131|Multiple Sclerosis
1549901|NCT01726673|Stroke
1549902|NCT01726673|Cerebrovascular Accident
1549903|NCT01726673|Cerebral Stroke
1549904|NCT01726673|CVA
1549905|NCT01726673|Robotic therapy
1549906|NCT01726673|Upper extremity recovery
1549907|NCT01726673|tDCS
1549908|NCT01726673|Non-invasive brain stimulation
1549909|NCT01889368|Insulin resistance
1549910|NCT01889368|Central adiposity
1549911|NCT01889368|Elevated blood pressure
1549912|NCT01889368|Vascular reactivity
1549913|NCT01889368|Elevated triglycerides
1549914|NCT01889368|Low high-density lipoprotein (HDL)
1549915|NCT01699542|Refractory Anastomotic esophageal strictures
1549916|NCT01695993|Nausea
1549917|NCT01695993|Quality of life
1549918|NCT01695993|Chemotherapy
1549919|NCT01695993|Expectancy
1549920|NCT01703520|Males breast cancer
1549921|NCT01703520|Finasteride
1549922|NCT01703520|PROSCAR®
1549923|NCT01703520|PROPECIA®
1549924|NCT01702350|Healthy Subjects
1549925|NCT01702350|Relative Bioavailability
1549926|NCT01702350|Pharmacokinetics
1549927|NCT01702350|Elderly Subjects
1549928|NCT01691859|extension study
1549929|NCT01691859|Severe refractory asthma
1549930|NCT01691859|safety
1549931|NCT01691859|SB-240563
1549932|NCT01691859|mepolizumab
1549933|NCT01691859|eosinophils
1549934|NCT01681849|PTSD
1549935|NCT01681849|childhood abuse
1549936|NCT01682473|PI3K inhibitor
1549937|NCT01682473|clinical trial
1549938|NCT01666496|Adolescent
1549939|NCT01666496|risk
1549940|NCT01666496|HIV
1549941|NCT01666496|video games
1549942|NCT01656252|Acute Leukemia
1549943|NCT01656252|Complete Remission
1549944|NCT01656252|Consolidation
1549945|NCT01656252|Consolidation Chemotherapy
1549946|NCT01656252|Cytarabine
1549947|NCT01656252|Eltrombopag
1549948|NCT01656252|Leukemia
1549949|NCT01656252|Thrombocytopenia
1549950|NCT01656252|Thrombopoietin
1549951|NCT01709292|Thyroid Cancer
1549952|NCT01709292|ERK
1549953|NCT01709292|Extracellular-signal-regulated kinase
1549954|NCT01709292|Biomarkers
1549955|NCT01709292|Papillary thyroid cancer
1549956|NCT01709292|PTC
1549957|NCT01709292|BRAF mutated
1549958|NCT01709292|Vemurafenib
1549959|NCT01709292|PLX4032
1549960|NCT01709292|RO5185426
1549961|NCT01709292|Zelboraf™
1549962|NCT01656941|neonate
1549963|NCT01656941|congenital heart disease
1549964|NCT01656941|single ventricle cardiac disease
1549965|NCT01656941|hypoplastic left heart syndrome
1549966|NCT01656941|hypoplastic right heart syndrome
1549967|NCT01656941|d-Transposition of the Great Arteries
1549968|NCT01642056|Fibroblasts
1549969|NCT01642056|Mitochondria
1549970|NCT01642056|Energy
1549971|NCT01642056|Redox
1549972|NCT01642056|Metabolic Disease
1549973|NCT01626495|Biological: CART19
1549974|NCT03201536|ZipLine3 device vs. conventional sutures
1549975|NCT01884259|local advanced squamous cell carcinoma
1549976|NCT01884259|Larynx
1549977|NCT01884259|Hypopharynx
1549978|NCT01884259|Oropharynx
1549979|NCT01884259|Cavum oris
1549980|NCT01884259|docetaxel
1549981|NCT01884259|cisplatin
1549982|NCT01884259|5-fluorouracil
1549983|NCT01884259|Cetuximab
1549984|NCT01599754|renal cell carcinoma
1549985|NCT01599754|axitinib
1549986|NCT01599754|tyrosine kinase inhibitor
1549987|NCT01572493|Pharmacokinetics of lL-15
1549988|NCT01572493|Cytokine Therapy
1549989|NCT01572493|Effects of rhlL-15 on T-cells and NK cells
1549990|NCT01572493|Immunotherapy
1549991|NCT01573429|Biologic Sample Collection
1549992|NCT01573429|Metabolism
1549993|NCT01573429|Healthy Volunteer
1549994|NCT01573429|HV
1549995|NCT01570361|Atrial Fibrillation
1549996|NCT01570361|Arrhythmias, Cardiac
1549997|NCT01570361|Heart Diseases
1549998|NCT01570361|Cardiovascular Diseases
1549999|NCT01570361|Pathologic Processes
1550000|NCT01563874|Antibodies
1550001|NCT01563874|Reverse Phase Microarrays
1550002|NCT01563874|Epigenetics
1550003|NCT01563874|Acetylation
1550004|NCT01563874|Methylation
1550005|NCT01563874|Lymphoma
1550006|NCT01564992|Parkinson's disease
1550007|NCT01564992|Pharmacogenetics
1550008|NCT01564992|Genetics
1550009|NCT01540708|Asthma
1550010|NCT01540708|Respiratory
1550011|NCT01540708|COPD
1550012|NCT01534598|DNA Methylation
1550013|NCT01534598|Advanced Cancer
1550014|NCT01534598|Methyltransferase Inhibitor
1550015|NCT01534598|Epigenetics
1550016|NCT01534598|Gene Re-Expression
1550017|NCT01534598|Cancer
1550018|NCT01534598|Solid Tumor
1550019|NCT01543256|benign biliary strictures secondary to chronic pancreatitis
1550020|NCT01531114|Diabetes mellitus
1550021|NCT01531114|antiplatelet effect
1550022|NCT01531114|prasugrel
1550023|NCT01531114|ticagrelor
1550024|NCT01531114|STEMI
1550025|NCT01531114|Insulin
1550026|NCT01520675|chronic pancreatitis
1550027|NCT01520675|randomized controlled trial
1550028|NCT01520675|endoscopic therapy
1550029|NCT01520675|surgery
1550030|NCT01520675|ESWL
1550031|NCT02207452|Hyperpolarised helium-3
1550032|NCT02207452|Lung Imaging
1550033|NCT02207452|Magnetic Resonance Imaging
1550034|NCT01503619|small cell lung cancer
1550035|NCT01498263|Family Systems
1550036|NCT01498263|Caregiving
1550037|NCT01498263|Alzheimer Disease
1550038|NCT01498263|Family History
1550039|NCT01498263|Alzheimer's Disease
1550040|NCT01498263|AD
1550041|NCT03201354|Glaucoma
1550042|NCT03201354|Ocular hypertension
1550043|NCT03201354|Filtration surgery
1550044|NCT03201354|Trabeculectomy with Ex-PRESS
1550045|NCT03201354|Non penetrating deep sclerectomy
1550046|NCT03201354|Phacoemulsification
1550047|NCT03201354|Combined surgery
1550048|NCT01497444|recurrent adult primary liver cancer
1550049|NCT01497444|recurrent renal cell cancer
1550050|NCT01497444|advanced adult primary liver cancer
1550051|NCT01497444|localized unresectable adult primary liver cancer
1550052|NCT01497444|adult primary hepatocellular carcinoma
1550053|NCT01486602|stage IIIA non-small cell lung cancer
1550054|NCT01486602|stage IIIB non-small cell lung cancer
1550055|NCT01482546|colonoscopy
1550056|NCT01482546|trainees
1550057|NCT01482546|water
1550058|NCT01482546|adenoma detection rate
1550059|NCT01482546|cecal intubation rate
1550060|NCT01480271|Allergic Rhinitis
1550061|NCT01480271|Healthy Volunteers
1550062|NCT01480271|Single Dose Escalation
1550063|NCT01480271|TLR7 agonist
1550064|NCT01480271|First Time in Human Study
1550065|NCT01475695|Mass balance
1550066|NCT01475695|intravenous
1550067|NCT01475695|GSK2251052
1550068|NCT01475695|Healthy volunteer
1550069|NCT01475695|Antimicrobial
1550070|NCT01475695|Radiolabel
1550071|NCT01459393|Actinic keratosis
1550072|NCT01459393|Photodynamic therapy
1550073|NCT01459393|5-aminolevulinic acid
1550074|NCT01459393|Cryotherapy
1550075|NCT01446822|urinary bladder neoplasm
1550076|NCT01446822|bipolar transurethral resection
1550077|NCT01446822|monopolar transurethral resection
1550078|NCT01446822|obturator nerve
1550079|NCT01414595|adenocarcinoma of the lung
1550080|NCT01414595|adenosquamous cell lung cancer
1550081|NCT01414595|non-small cell lung cancer
1550082|NCT01414595|squamous cell lung cancer
1550083|NCT01413061|Other Hindfoot Conditions requiring Subtalar Arthrodesis
1550084|NCT01413061|Post-traumatic Arthritis
1550085|NCT01426542|brain injury
1550086|NCT01426542|stroke
1550087|NCT01426542|cerebral palsy
1550088|NCT01426542|seizures
1550089|NCT01409200|Prostate cancer
1550090|NCT01409200|Adenocarcinoma of the prostate
1550091|NCT01409200|Ductal adenocarcinoma
1550092|NCT01409200|Androgen deprivation therapy
1550093|NCT01409200|ADT
1550094|NCT01409200|Hormonal therapy
1550095|NCT01409200|Suspected lymph node metastasis
1550096|NCT01409200|TxN1M0 or TxNxM1a
1550097|NCT01409200|Progression-free
1550098|NCT01409200|Pathologic complete response
1550099|NCT01409200|pCR
1550100|NCT01409200|Systemic therapy
1550101|NCT01409200|Radical prostatectomy
1550102|NCT01409200|Pelvic lymph node dissection
1550103|NCT01409200|Axitinib
1550104|NCT01409200|AG-013736
1550105|NCT01415440|ADHD
1550106|NCT01415440|Vyvanse
1550107|NCT01415440|stimulant medication
1550108|NCT01415440|ADD
1550109|NCT01390584|stage I adult Hodgkin lymphoma
1550110|NCT01390584|stage II adult Hodgkin lymphoma
1550111|NCT01390584|adult favorable prognosis Hodgkin lymphoma
1550112|NCT01390584|adult mixed cellularity Hodgkin lymphoma
1550113|NCT01390584|adult nodular sclerosis Hodgkin lymphoma
1550114|NCT01390584|adult lymphocyte depletion Hodgkin lymphoma
1550115|NCT01390584|adult unfavorable prognosis Hodgkin lymphoma
1550116|NCT01375140|Myeloproliferative Diseases
1550117|NCT01375140|Myelofibrosis
1550118|NCT01375140|Post essential thrombocythemia/polycythemia vera
1550119|NCT01375140|Ruxolitinib
1550120|NCT01375140|INCB018424
1550121|NCT01375140|Lenalidomide
1550122|NCT01375140|CC-5013
1550123|NCT01375140|Revlimid
1550124|NCT01375140|Prednisone
1550125|NCT01375140|Interactive Voice Response System
1550126|NCT01375140|IVR
1550132|NCT01317901|follicular lymphoma
1550133|NCT01317901|small lymphocytic lymphoma
1550134|NCT01317901|marginal zone lymphoma
1550135|NCT01317901|non-Hodgkin's lymphoma
1550136|NCT01317901|indolent lymphoma
1550137|NCT01306045|AZD6244
1550138|NCT01306045|MK-2206
1550139|NCT01306045|Lepatinib
1550140|NCT01306045|Erlotinib
1550141|NCT01306045|Sunitinib
1550142|NCT01306045|Lung Cancer
1550143|NCT01306045|Thymic Cancer
1550144|NCT01306045|Small Cell Lung Cancer
1550145|NCT01306045|Non-Small Cell Lung Cancer
1550146|NCT01309789|Antibodies, Monoclonal
1550147|NCT01309789|Antibody-Drug Conjugate
1550148|NCT01309789|Antigens, CD30
1550149|NCT01309789|Drug Therapy
1550150|NCT01309789|Hematologic Diseases
1550151|NCT01309789|Lymphoma
1550152|NCT01309789|monomethyl auristatin E
1550153|NCT01309789|Lymphoma, Large-Cell, Anaplastic
1550154|NCT01309789|Lymphoma, T-cell
1550155|NCT01309789|Lymphoma, NK-cell
1550156|NCT01305941|everolimus
1550157|NCT01305941|trastuzumab
1550158|NCT01305941|vinorelbine
1550159|NCT01305941|RAD001
1550160|NCT01305941|Breast Cancer
1550161|NCT01305941|Herceptin
1550162|NCT01305941|Navelbine
1550163|NCT01305941|Lineberger Comprehensive Cancer Center
1550164|NCT01305941|Brain Metastases
1550165|NCT01294566|safety
1550166|NCT01294566|motilin agonist
1550167|NCT01294566|single dose
1550168|NCT01294566|ascending dose
1550169|NCT01294566|GSK1322888
1550170|NCT01294566|migrating motor complex
1550171|NCT01294566|tolerability
1550172|NCT01294566|FTIH
1550173|NCT01294566|gastric emptying
1550174|NCT01285622|Surgery; gynecological
1550175|NCT01285622|Stroke volume
1550176|NCT01280578|Migraine
1550177|NCT01277692|First administration to human, safety, pharmacokinetics, healthy subjects, antiviral activity, hepatitis C patients
1550178|NCT01274013|Hepatitis C
1550179|NCT01274013|Chronic Hepatitis C
1550180|NCT01274013|Vitamin D
1550181|NCT01274013|Vitamin D deficiency
1550182|NCT01271868|Recombinant Factor IX
1550183|NCT01262885|pharmacokinetics
1550184|NCT01262885|tolerability
1550185|NCT01262885|single dose
1550186|NCT01262885|antibiotics
1550187|NCT01262885|repeat dose
1550188|NCT01262885|GSK2251052
1550189|NCT01262885|safety
1550190|NCT01257269|Thrombotic thrombocytopenic purpura
1550191|NCT01257269|ADAMTS13
1550192|NCT01257269|Von Willebrand factor
1550193|NCT01257269|Von Willebrand factor cleaving protease
1550194|NCT01257269|Thrombocytopenia
1550195|NCT01257269|Hemolytic anemia
1550196|NCT01197040|Minimal Change Nephrotic Syndrome
1550197|NCT01197040|Complete remission
1550198|NCT01197040|Myfortic
1550199|NCT01197040|Minimal Change Disease
1550200|NCT01188681|CLL
1550201|NCT01188681|TRU-016
1550202|NCT01188681|chronic lymphocytic leukemia
1550203|NCT01188681|relapsed CLL
1550204|NCT01188681|bendamustine
1550205|NCT01153802|Positron Emission Tomography
1550206|NCT01153802|serotonin
1550207|NCT01153802|inhibitor of the neurotransmitters
1550208|NCT01153802|safety of single oral doses
1550209|NCT01153802|norepinephrine
1550210|NCT01153802|dopamine
1550211|NCT01153776|Arterial switch operation
1550212|NCT01153776|Transposition of the great arteries
1550213|NCT01153776|Congenital heart diseases
1550214|NCT01153776|CT coronary angiography
1550215|NCT01150045|adenocarcinoma of the colon
1550216|NCT01150045|stage III colon cancer
1550217|NCT01153815|efficacy
1550218|NCT01153815|Spasticity, Post-Stroke
1550219|NCT01153815|safety
1550220|NCT01153815|Botulinum toxin type A
1550221|NCT01153815|placebo
1550222|NCT01153815|spasticity
1550223|NCT01130519|Advanced HLRCC
1550224|NCT01130519|Sporadic Papillary Renal Cell Cancer
1550225|NCT01130519|Papillary Kidney Cancer
1550226|NCT01130519|Bevacizumab
1550227|NCT01130519|Erlotinib
1550228|NCT01130519|Kidney Cancer
1550229|NCT01130519|Renal Cell Cancer
1550230|NCT01130519|Hereditary Leiomyomatosis and Renal Cell Cancer
1550231|NCT01130519|HLRCC
1550232|NCT01110018|Tolerability
1550233|NCT01110018|COPD
1550234|NCT01110018|Safety
1550235|NCT01110018|Muscarinic receptor (mAChR) antagonist
1550236|NCT01110018|GSK573719
1550237|NCT01110018|Healthy subjects
1550238|NCT01110018|Pharmacokinetics
1550239|NCT01110018|IV study
1550240|NCT01099488|Immunological assays
1550241|NCT01476059|Treatment compliance
1550242|NCT01476059|Pediatric
1550243|NCT01476059|Asthma
1550244|NCT01057459|Stage II Grade 1 Contiguous Follicular Lymphoma
1550245|NCT01057459|Stage II Grade 1 Non-Contiguous Follicular Lymphoma
1550246|NCT01057459|Stage II Grade 2 Contiguous Follicular Lymphoma
1550247|NCT01057459|Stage II Grade 2 Non-Contiguous Follicular Lymphoma
1550248|NCT01057459|Stage II Grade 3 Contiguous Follicular Lymphoma
1550249|NCT01057459|Stage II Grade 3 Non-Contiguous Follicular Lymphoma
1550250|NCT01057459|stage III grade 1 follicular lymphoma
1550251|NCT01057459|stage III grade 2 follicular lymphoma
1550252|NCT01057459|stage III grade 3 follicular lymphoma
1550253|NCT01057459|stage IV grade 1 follicular lymphoma
1550254|NCT01057459|stage IV grade 2 follicular lymphoma
1550255|NCT01057459|stage IV grade 3 follicular lymphoma
1550256|NCT01052922|Colorectal Neoplasms
1550257|NCT01052922|Mass Screening
1550258|NCT01052922|Population Surveillance
1550259|NCT01052922|Randomized controlled trial
1550260|NCT01052922|Occult Blood
1550261|NCT01052922|Colonoscopy
1550262|NCT01052922|Sigmoidoscopy
1550263|NCT01052922|Health Behavior
1550264|NCT01051635|DNA Repair
1550265|NCT01051635|DNA Damage
1550266|NCT01051635|Advanced Cancer
1550267|NCT01051635|Advanced Malignancies
1550268|NCT01051635|Topoisomerase Inhibitor
1550269|NCT01181908|alcohol
1550270|NCT01181908|drug interaction
1550271|NCT01181908|pharmacodynamic
1550272|NCT00975936|Microdose
1550273|NCT00975936|Drug-Drug Interaction
1550274|NCT00975936|Ketoconazole
1550275|NCT00975936|Phase 0
1550276|NCT00976144|safety
1550277|NCT00976144|LAMA
1550278|NCT00976144|pharmacodynamics
1550279|NCT00976144|tolerability
1550280|NCT00976144|Muscarinic receptor antagonist,
1550281|NCT00976144|anticholinergic,
1550282|NCT00976144|beta-2 agonist
1550283|NCT00976144|healthy Japanese subjects
1550284|NCT00976144|LABA
1550285|NCT00976144|Chronic Obstructive Pulmonary Disease (COPD)
1550286|NCT00976144|pharmacokinetics
1550287|NCT00963534|Mantle cell lymphoma
1550288|NCT00963534|Lenalidomide
1550289|NCT00963534|Bendamustine
1550290|NCT00963534|Rituximab
1550291|NCT00963534|Nordic Lymphoma Group
1550292|NCT00963534|MTD for lenalidomide
1550293|NCT00963534|Untreated patients
1550294|NCT00963534|Patients with mantle cell lymphoma, age over 65 years
1550295|NCT00951366|For clinicians and researchers to better understand BPD
1550296|NCT00951366|To improve care of individuals with BPD
1550297|NCT00951366|To examine quality improvement initiatives
1550298|NCT00951366|To examine changing health care issues
1550299|NCT00951366|To determine eligibility of clinical research studies
1550300|NCT00950248|Idebenone
1550301|NCT00950248|Magnetic Resonance Imaging (MRI)
1550302|NCT00950248|Magnetic Resonance Spectroscopy
1550303|NCT00950248|Mitochondrial Enhancer
1550304|NCT00950248|Multiple Sclerosis
1550305|NCT00950248|MS
1550306|NCT00950248|Primary Progressive Multiple Sclerosis
1550307|NCT00944307|HIV
1550308|NCT00944307|antiretroviral
1550309|NCT00944307|drug interaction
1550310|NCT00944307|human immunodeficiency virus
1550311|NCT00936325|SCLS
1550312|NCT00936325|Systemic Capillary Leak Syndrome
1550313|NCT00937846|Cognitive impairment
1550314|NCT00937846|Schizophrenia
1550315|NCT00937846|Alzheimer's Disease
1550316|NCT00937846|PET
1550317|NCT00923884|NSCLC
1550318|NCT00923884|Genotype
1550319|NCT00923884|SCLC
1550320|NCT00923884|Lung Cancer
1550321|NCT00923884|Non-Small Cell Lung Cancer
1550322|NCT00923884|Small Cell Lung Cancer
1550323|NCT00923026|Gene Therapy
1550324|NCT00923026|Follow-Up
1550325|NCT00923026|Delayed Toxicity
1550326|NCT00923026|Adenocarcinoma
1550327|NCT00923026|Melanoma
1550328|NCT00923026|Neuroendocrine Tumors
1550329|NCT00923026|Carcinoma
1550330|NCT00903565|genomic profiling
1550331|NCT00903565|gene expression
1550332|NCT00903565|ColoPrint
1550333|NCT00903565|adenocarcinoma colon
1550334|NCT00903565|recurrence risk assessment
1550335|NCT00903565|prospective
1550336|NCT00900198|Tissue Collection
1550337|NCT00900198|Biospecimen
1550338|NCT00900198|Assay Development
1550339|NCT00900198|Tissue Acquisition
1550340|NCT00900198|Tissue Biopsies
1550341|NCT00887419|chronic back pain
1550342|NCT00887419|spinal cord stimulator implant
1550343|NCT00887146|adult anaplastic astrocytoma
1550344|NCT00887146|adult anaplastic oligodendroglioma
1550345|NCT00887146|adult mixed glioma
1550346|NCT00811785|Copper Deficiency
1550347|NCT00811785|Menkes Disease
1550348|NCT00811785|Neurodevelopment
1550349|NCT00811785|Occipital Horn Syndrome
1550350|NCT00776412|Immunologic Non-Responder
1550351|NCT00776412|Cardiovascular Disease
1550352|NCT00776412|D-dimer
1550353|NCT00776412|Antiretroviral
1550354|NCT00776412|Mortality
1550355|NCT00776412|HIV Positive
1550356|NCT00776412|HIV Negative
1550357|NCT00776412|Healthy Volunteer
1550358|NCT00776412|HV
1550359|NCT00719719|Mast Cell
1550360|NCT00719719|Tryptase
1550361|NCT00719719|Bone Marrow
1550362|NCT00719719|Hives
1550363|NCT00719719|Adult
1550364|NCT00719719|Anaphylaxis
1550365|NCT00715936|Integrated early child development, growth and health
1550366|NCT00715936|Psychosocial stimulation
1550367|NCT00715936|Care for child development
1550368|NCT00698997|autism
1550369|NCT00698997|autism spectrum disorder
1550370|NCT00698997|intensive intervention for toddlers with autism
1550371|NCT00698997|PDD NOS
1550372|NCT00698997|early steps study
1550373|NCT00698997|early start denver model
1550374|NCT00698997|early intervention for infants and toddlers with autism
1550375|NCT00698997|toddler treatment
1550376|NCT00698997|Sally Rogers
1550377|NCT00698997|University of California, Davis
1550378|NCT00698997|University of Michigan
1550379|NCT00698997|MIND Institute
1550380|NCT00697047|Colorectal Neoplasms
1550381|NCT00697047|Mass Screening
1550382|NCT00697047|Population Surveillance
1550383|NCT00697047|Randomized controlled trial
1550384|NCT00697047|Occult Blood
1550385|NCT00697047|Colonoscopy
1550386|NCT00697047|Sigmoidoscopy
1550387|NCT00697047|Health Behavior
1550388|NCT00697047|Colorectal Screening
1550389|NCT00651716|stage III adult Burkitt lymphoma
1550390|NCT00651716|stage III adult diffuse large cell lymphoma
1550391|NCT00651716|stage III adult diffuse mixed cell lymphoma
1550392|NCT00651716|stage III adult diffuse small cleaved cell lymphoma
1550393|NCT00651716|stage III adult Hodgkin lymphoma
1550394|NCT00651716|stage III adult immunoblastic large cell lymphoma
1550395|NCT00651716|stage III adult lymphoblastic lymphoma
1550396|NCT00651716|stage III grade 1 follicular lymphoma
1550397|NCT00651716|stage III grade 2 follicular lymphoma
1550398|NCT00651716|stage III grade 3 follicular lymphoma
1550399|NCT00651716|stage III mantle cell lymphoma
1550400|NCT00651716|stage III marginal zone lymphoma
1550401|NCT00651716|stage III small lymphocytic lymphoma
1550402|NCT00651716|stage IV adult Burkitt lymphoma
1550403|NCT00651716|stage IV adult diffuse large cell lymphoma
1550404|NCT00651716|stage IV adult diffuse mixed cell lymphoma
1550405|NCT00651716|stage IV adult diffuse small cleaved cell lymphoma
1550406|NCT00651716|stage IV adult Hodgkin lymphoma
1550407|NCT00651716|stage IV adult immunoblastic large cell lymphoma
1550408|NCT00651716|stage IV adult lymphoblastic lymphoma
1550409|NCT00651716|stage IV grade 1 follicular lymphoma
1550410|NCT00651716|stage IV grade 2 follicular lymphoma
1550411|NCT00651716|stage IV grade 3 follicular lymphoma
1550412|NCT00651716|stage IV mantle cell lymphoma
1550413|NCT00651716|stage IV marginal zone lymphoma
1550414|NCT00651716|stage IV small lymphocytic lymphoma
1550415|NCT00651716|recurrent adult Burkitt lymphoma
1550416|NCT00651716|recurrent adult diffuse large cell lymphoma
1550417|NCT00651716|recurrent adult diffuse mixed cell lymphoma
1550418|NCT00651716|recurrent adult diffuse small cleaved cell lymphoma
1550419|NCT00651716|recurrent adult Hodgkin lymphoma
1550420|NCT00651716|recurrent adult immunoblastic large cell lymphoma
1550421|NCT00651716|recurrent adult lymphoblastic lymphoma
1550422|NCT00651716|recurrent cutaneous T-cell non-Hodgkin lymphoma
1550423|NCT00651716|recurrent grade 1 follicular lymphoma
1550424|NCT00651716|recurrent grade 2 follicular lymphoma
1550425|NCT00651716|recurrent grade 3 follicular lymphoma
1550426|NCT00651716|recurrent mantle cell lymphoma
1550427|NCT00651716|recurrent marginal zone lymphoma
1550428|NCT00651716|recurrent small lymphocytic lymphoma
1550429|NCT00651716|recurrent mycosis fungoides/Sezary syndrome
1550430|NCT00651716|extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
1550431|NCT00651716|nodal marginal zone B-cell lymphoma
1550432|NCT00651716|splenic marginal zone lymphoma
1550433|NCT00651716|noncontiguous stage II adult Burkitt lymphoma
1550434|NCT00651716|noncontiguous stage II adult diffuse large cell lymphoma
1550435|NCT00651716|noncontiguous stage II adult diffuse mixed cell lymphoma
1550436|NCT00651716|noncontiguous stage II adult diffuse small cleaved cell lymphoma
1550437|NCT00651716|noncontiguous stage II adult immunoblastic large cell lymphoma
1550438|NCT00651716|noncontiguous stage II adult lymphoblastic lymphoma
1550439|NCT00651716|noncontiguous stage II grade 1 follicular lymphoma
1550440|NCT00651716|noncontiguous stage II grade 2 follicular lymphoma
1550441|NCT00651716|noncontiguous stage II grade 3 follicular lymphoma
1550442|NCT00651716|noncontiguous stage II mantle cell lymphoma
1550443|NCT00651716|noncontiguous stage II marginal zone lymphoma
1550444|NCT00651716|noncontiguous stage II small lymphocytic lymphoma
1550445|NCT00651716|accelerated phase chronic myelogenous leukemia
1550446|NCT00651716|adult acute lymphoblastic leukemia in remission
1550447|NCT00651716|adult acute myeloid leukemia in remission
1550448|NCT00651716|adult acute myeloid leukemia with 11q23 (MLL) abnormalities
1550449|NCT00651716|adult acute myeloid leukemia with inv(16)(p13;q22)
1550450|NCT00651716|adult acute myeloid leukemia with t(15;17)(q22;q12)
1550451|NCT00651716|adult acute myeloid leukemia with t(16;16)(p13;q22)
1550452|NCT00651716|adult acute myeloid leukemia with t(8;21)(q22;q22)
1550453|NCT00651716|atypical chronic myeloid leukemia, BCR-ABL negative
1550454|NCT00651716|blastic phase chronic myelogenous leukemia
1550455|NCT00651716|chronic myelomonocytic leukemia
1550456|NCT00651716|chronic phase chronic myelogenous leukemia
1550457|NCT00651716|recurrent adult acute lymphoblastic leukemia
1550458|NCT00651716|recurrent adult acute myeloid leukemia
1550459|NCT00651716|refractory chronic lymphocytic leukemia
1550460|NCT00651716|refractory hairy cell leukemia
1550461|NCT00651716|relapsing chronic myelogenous leukemia
1550462|NCT00651716|secondary acute myeloid leukemia
1550463|NCT00651716|stage III chronic lymphocytic leukemia
1550464|NCT00651716|stage IV chronic lymphocytic leukemia
1550465|NCT00651716|chronic eosinophilic leukemia
1550466|NCT00651716|primary myelofibrosis
1550467|NCT00651716|chronic neutrophilic leukemia
1550468|NCT00651716|de novo myelodysplastic syndromes
1550469|NCT00651716|disseminated neuroblastoma
1550470|NCT00651716|myelodysplastic/myeloproliferative neoplasm, unclassifiable
1550471|NCT00651716|poor prognosis metastatic gestational trophoblastic tumor
1550472|NCT00651716|previously treated myelodysplastic syndromes
1550473|NCT00651716|recurrent neuroblastoma
1550474|NCT00651716|recurrent ovarian epithelial cancer
1550475|NCT00651716|recurrent ovarian germ cell tumor
1550476|NCT00651716|recurrent malignant testicular germ cell tumor
1550477|NCT00651716|secondary myelodysplastic syndromes
1550478|NCT00651716|stage I multiple myeloma
1550479|NCT00651716|stage II multiple myeloma
1550480|NCT00651716|stage III multiple myeloma
1550481|NCT00651716|stage II ovarian epithelial cancer
1550482|NCT00651716|stage III ovarian epithelial cancer
1550483|NCT00651716|stage IV ovarian epithelial cancer
1550484|NCT00651716|stage III malignant testicular germ cell tumor
1550485|NCT00651716|stage IIIA breast cancer
1550486|NCT00651716|stage IIIB breast cancer
1550487|NCT00651716|stage IIIC breast cancer
1550488|NCT00651716|stage IV breast cancer
1550489|NCT00651716|refractory multiple myeloma
1550490|NCT00643318|lung cancer
1550491|NCT00643318|lung tumor
1550492|NCT00643318|non-small cell lung cancer
1550493|NCT00643318|NSCLC
1550494|NCT00643318|CyberKnife
1550495|NCT00643318|radiosurgery
1550496|NCT00643318|lung surgery
1550497|NCT00631852|Breast Cancer, Biomarkers, Ginseng Root
1550498|NCT00622583|Herniorrhaphy
1550499|NCT00614042|CLL
1550500|NCT00614042|NHL
1550501|NCT00614042|TRU-016
1550502|NCT00614042|chronic lymphocytic leukemia
1550503|NCT00614042|non-Hodgkin's lymphoma
1550504|NCT00598923|tbi
1550505|NCT00598923|traumatic brain injury
1550506|NCT00598923|epilepsy
1550507|NCT00575679|Automobile driving
1550508|NCT00575679|Driving under the influence
1550509|NCT00575679|Interview, psychological
1550510|NCT00575679|Brief intervention
1550511|NCT00575679|Brief motivational interview
1550512|NCT00524758|ologen
1550513|NCT00524758|oculusgen
1550514|NCT00524758|collagen matrix
1550515|NCT00524758|trabeculectomy
1550516|NCT00524758|filtering surgery
1550517|NCT00524758|mitomycin-C
1550518|NCT00524758|MMC
1550519|NCT00524758|Aeon Astron
1550520|NCT00453505|Transcranial Direct Current Stimulation (TDCS)
1550521|NCT00453505|Transcranial Magnetic Stimulation (TMS)
1550522|NCT00453505|Peripheral Nerve Stimulation
1550523|NCT00453505|Primary Motor Cortex
1550524|NCT00453505|Corticomotor Excitability
1550525|NCT00453505|Healthy Volunteer
1550526|NCT00453505|HV
1550527|NCT00448929|Glaucoma
1550528|NCT00448929|Collagen matrix
1550529|NCT00448929|ologen
1550530|NCT00448929|OculusGen
1550531|NCT00448929|Trabeculectomy
1550532|NCT00432471|Skin Cancer
1550533|NCT00432471|Non-Melanoma Skin Cancer
1550534|NCT00432471|Optical Imaging
1550535|NCT00432471|Multispectral Digital Microscope System
1550536|NCT00432471|MDM
1550537|NCT00430183|stage I prostate cancer
1550538|NCT00430183|stage IIB prostate cancer
1550539|NCT00430183|stage IIA prostate cancer
1550540|NCT00430183|stage III prostate cancer
1550541|NCT00430183|adenocarcinoma of the prostate
1550542|NCT00424138|stage IIIB non-small cell lung cancer
1550543|NCT00424138|stage IV non-small cell lung cancer
1550544|NCT00424138|recurrent non-small cell lung cancer
1550672|NCT03204266|Bladder cancer
1550545|NCT00424138|stage IIIA non-small cell lung cancer
1550546|NCT00417040|adenocarcinoma of the prostate
1550547|NCT00417040|recurrent prostate cancer
1550548|NCT00417040|stage IV prostate cancer
1550549|NCT00214422|Prostate
1550550|NCT00214422|Radiation
1550551|NCT00214422|Cancer
1550552|NCT00214422|Prostate Cancer
1550553|NCT00341237|Polymorphism
1550554|NCT00341237|Genotype
1550555|NCT00341237|Phenotype
1550556|NCT00341237|Environmental Factor
1550557|NCT00341237|Single Nucleotide Polymorphism
1550558|NCT00331058|Severe Asthma bronchoscopy
1550559|NCT00310869|Preterm Birth
1550560|NCT00310869|Prematurity
1550561|NCT00310869|NIDCAP
1550562|NCT00310869|Adolescence
1550563|NCT00310869|Developmental Care
1550564|NCT00310869|Follow-up
1550565|NCT00310869|Neurobehavior
1550566|NCT00301457|Hormone Sensitive Primary Breast Cancer
1550567|NCT00301457|Adjuvant Treatment
1550568|NCT00301457|Aromatase Inhibitor
1550569|NCT00283257|Problem solving
1550570|NCT00283257|psychosocial support
1550571|NCT00208429|Hip
1550572|NCT00208429|Cementless
1550573|NCT00170378|Enoxaparin
1550574|NCT00170378|Safety
1550575|NCT00102544|CT-Guided
1550576|NCT00102544|Electromagnetic Tracking
1550577|NCT00102544|Ultrasound-Guided Biopsy
1550578|NCT00102544|Ablation
1550579|NCT00102544|Surgical Navigation
1550580|NCT00088426|Holoprosencephaly
1550581|NCT00088426|HPE
1550582|NCT00082147|MRI
1550583|NCT00082147|Biopsy
1550584|NCT00082147|Fiducial Marker
1550585|NCT00082147|Prostate Cancer
1550586|NCT00081354|Esophageal Adenocarcinoma
1550587|NCT00081354|Dysplasia
1550588|NCT00081354|Surveillance
1550589|NCT00081354|Proteomics
1550590|NCT00081354|SNP's
1550591|NCT00081354|Barrett Esophagus
1550592|NCT00081354|Gastroesophageal Reflux Disease
1550593|NCT00081354|GERD
1550594|NCT00081354|Dysphagia
1550595|NCT00081354|Swallowing Difficulty
1550596|NCT00071045|Tissue Procurement
1550597|NCT00071045|Sample Collection
1550598|NCT00071045|Laboratory Research
1550599|NCT00071045|Tissue Sample
1550600|NCT00071045|Solid Tumor
1550601|NCT00071045|Blood Disorder
1550602|NCT00071045|HLA Donor
1550610|NCT00023036|Genetics
1550611|NCT00023036|Deafness
1550612|NCT00023036|EVA
1550613|NCT00023036|Pendred
1550614|NCT00023036|Hearing
1550615|NCT00023036|Hearing Impairment
1550616|NCT00023036|Nonsyndromic Hereditary Hearing Impairment
1550617|NCT00023036|SNHL
1550618|NCT00023036|Inner Ear
1550619|NCT00023036|Enlarged Vestibular Aqueducts
1550620|NCT00006435|Tissue Repository
1550621|NCT00006435|Growth Rate
1550622|NCT00006435|Volumetric MRI
1550623|NCT00006421|Breast MRI
1550624|NCT00006421|Nipple Aspirate Fluid
1550625|NCT00006421|Transvaginal ultrasound
1550626|NCT00006421|Ductal lavage
1550627|NCT00004847|Neurofibromatosis
1550628|NCT00004847|Multiple Endocrine Neoplasia (MEN)
1550629|NCT00004847|Von Hippel-Lindau Disease
1550630|NCT00004847|Norepinephrine
1550631|NCT00004847|Epinephrine
1550632|NCT00004847|Metanephrines
1550633|NCT00004847|PET
1550634|NCT00004847|Paraganglioma
1550635|NCT00004847|Pheochromocytoma
1550636|NCT00001184|Inflammatory Bowel Disease
1550637|NCT00001184|Regional Enteritis
1550638|NCT00001184|Crohn's Disease
1550639|NCT00001184|Ulcerative Colitis
1550640|NCT00001184|IBD
1550641|NCT00001281|Lymphocytes
1550642|NCT00001281|Venipuncture
1550643|NCT00001281|Mononuclear Cells
1550644|NCT00001711|Magnetic Resonance Imaging
1550645|NCT00001711|Gadolinium
1550646|NCT00001711|Magnetic Resonance Angiography
1550647|NCT00001711|Normal Volunteer
1550653|NCT00001522|Insulin Resistance
1550654|NCT00001522|Race
1550655|NCT00001522|Body Fat
1550656|NCT00001522|Body Composition
1550657|NCT00001522|Obesity
1550658|NCT00001467|Primary Immunodeficiency Disorders
1550659|NCT00001467|Immunologic Disorders
1550660|NCT00001316|Lymph Node
1550661|NCT00001316|Polymerase Chain Reaction (PCR)
1550662|NCT00001316|In Situ Hybridization
1550663|NCT00001316|AIDS
1550664|NCT00001316|Excisional Biopsy
1550665|NCT00001721|Dysmorphology
1550666|NCT00001721|Cholesterol
1550667|NCT00001721|Endocrine
1550668|NCT00001721|MRI
1550669|NCT00001721|Demyelination
1550670|NCT00001721|Smith-Lemli-Opitz Syndrome (SLO)
1550671|NCT03204266|Malignant neoplasms of urinary tract
1550673|NCT03204266|Radical cystectomy
1550674|NCT03204266|RC
1550675|NCT03204266|Pro Stat Sugar Free AWC
1550676|NCT03204266|Omega-3 Fatty Acids
1550677|NCT03203447|RVO
1550678|NCT03203447|ME
1550679|NCT03203447|Microneedle
1550680|NCT03203447|Microinjection
1550681|NCT03203447|Triamcinolone
1550682|NCT03203447|Choroid
1550683|NCT03203447|Choroid injection
1550684|NCT03203447|Aflibercept
1550685|NCT03203447|Suprachoroidal
1550686|NCT03203447|Anti-VEGF
1550687|NCT03203447|Eylea
1550688|NCT03203447|Subretinal Fluid
1550689|NCT03203447|Cystoid Macular Edema
1550690|NCT03203447|Optical Coherence Tomography
1550691|NCT03203447|OCT
1550692|NCT03203447|Central Subfield Thickness
1550693|NCT03203655|Mobile text
1550694|NCT03203655|Obesity
1550695|NCT03203655|Hispanic
1550696|NCT03203655|Women
1550697|NCT03204214|binge drinking
1550698|NCT03204201|Fluorescence
1550699|NCT03204188|BTK Inhibitor
1550700|NCT03204188|Checkpoint Inhibitor
1550701|NCT03203902|Therapeutic touch
1550702|NCT03203902|Post-traumatic Stress Disorder
1550703|NCT03203902|Homeless
1550704|NCT03203928|ADHD
1550705|NCT03203928|Occupational Therapy
1550706|NCT03204032|Tegafur
1550707|NCT03204032|Temozolomide
1550708|NCT03204032|Thalidomide
1550709|NCT03204032|Extrapancreatic Neuroendocrine Tumor
1550710|NCT03204019|Tegafur
1550711|NCT03204019|Temozolomide
1550712|NCT03204019|Thalidomide
1550713|NCT03204019|Pancreatic Neuroendocrine Tumor
1550714|NCT03203499|Substance abuse disorder
1550715|NCT03202550|Oral Sedation
1550716|NCT03202550|Lorazepam
1550717|NCT03202550|Oxycodone
1550718|NCT03204123|prostate cancer
1550719|NCT03204123|prostatectomy
1550720|NCT03204123|biochemical recurrence
1550721|NCT03204123|Ga-HBED-iPSMA
1550722|NCT03204123|16-306
1550723|NCT03203525|Liver Cancer
1550724|NCT03203525|Hepatic metastases
1550725|NCT03203525|Advanced liver cancer
1550726|NCT03203525|Eloxatin
1550727|NCT03203525|Oxaliplatin
1550728|NCT03203525|Leucovorin
1550729|NCT03203525|Citrovorum
1550730|NCT03203525|Wellcovorin
1550731|NCT03203525|5-fluorouracil
1550732|NCT03203525|Fluorouracil
1550733|NCT03203525|5-FU
1550734|NCT03203525|Adrucil
1550735|NCT03203525|Efudex
1550736|NCT03203525|Bevacizumab
1550737|NCT03203525|Avastin
1550738|NCT03203525|Anti-VEGF monoclonal antibody
1550739|NCT03203525|rhuMab-VEGF
1550740|NCT03203525|Liposomal Doxorubicin
1550741|NCT03203525|Doxil
1550742|NCT03203525|Doxorubicin Hydrochloride (Liposomal)
1550743|NCT03203525|Temsirolimus
1550744|NCT03203525|CCI-779
1550745|NCT03203525|Torisel
1550746|NCT03203525|NovoTTF-100L System
1550747|NCT03204227|Japanese Encephalitis
1550748|NCT03204227|JECEVAX
1550749|NCT03204227|Vietnam
1550750|NCT03201679|SIRS, systemic inflammatory response syndrome
1550751|NCT03201679|Hip Fracture Surgery
1550752|NCT03201679|Sepsis
1550753|NCT03201679|Mortality
1550754|NCT03201666|prenatal diagnosis
1550755|NCT03201666|non-invasive prenatal tests
1550756|NCT03201666|chromosome microarray analysis
1550757|NCT03203642|ADPKD
1550758|NCT03203642|Autosomal Dominant Polycystic Kidney Disease
1550759|NCT03203642|Polycystic Kidney
1550760|NCT03203642|Tesevatinib
1550761|NCT03203642|Polycystic Kidney Disease
1550762|NCT03203642|PKD
1550763|NCT03203889|American Indians
1550764|NCT03203889|Native Americans
1550765|NCT03203889|Community Reinforcement Approach and Family Training
1550766|NCT03203889|Nar-Anonymous Facilitation
1550767|NCT03203889|Treatment Entry
1550768|NCT03203889|Cultural adaptations
1550769|NCT03203889|Spirituality
1550770|NCT03203018|Cardiovascular Diseases (CVD)
1550771|NCT03203018|Community-based intervention
1550772|NCT03203018|Socio-economic status (SES)
1550773|NCT03203018|Health literacy (HL)
1550774|NCT03203746|Lycopene
1550775|NCT03203746|Chronic periodontitis
1550776|NCT03203746|Protein carbonyl
1550777|NCT03203291|stroke
1550778|NCT03203291|robotic training
1550779|NCT03203291|gait
1550780|NCT03200171|Carcinoma, Hepatocellular
1550781|NCT03200171|Hepatitis C
1550782|NCT03199365|Cancer Prevention
1550783|NCT03199365|Latino Families
1550784|NCT03199365|Healthy eating
1550785|NCT03199365|Physical activity
1550786|NCT03199365|PA
1550787|NCT03199365|Food inventory
1550788|NCT03199365|Questionnaires
1550789|NCT03199365|Surveys
1550790|NCT03199365|Interviews
1550791|NCT03199365|Accelerometer
1550792|NCT03198221|Golytely, Prepopik, bowel prep
1550793|NCT03197025|HPV-16
1550794|NCT03197025|premalignancy
1550795|NCT03197025|T Cell Therapy
1550796|NCT03203850|hereditary hemochromatosis
1550797|NCT03203850|ICL670
1550798|NCT03203850|deferasirox FCT
1550799|NCT03203850|iron overload
1550800|NCT03203083|Reproducibility of Results
1550801|NCT03203083|Clinical Assessment
1550802|NCT03203460|Prostate Cancer
1550803|NCT03203460|Active Surveillance
1550804|NCT03203460|Exercise
1550805|NCT03203460|High-Intensity Interval Training
1550806|NCT03203460|Randomized Controlled Trial
1550807|NCT03197194|Central retinal artery occlusion
1550808|NCT03197194|visual acuity
1550809|NCT03197194|visual field
1550810|NCT03197194|mRs
1550811|NCT03197194|NEI-VFQ-25
1550812|NCT03203837|Radioembolization
1550813|NCT03203837|Y90
1550814|NCT03203837|TheraSphere
1550815|NCT03203837|HCC
1550816|NCT03203837|Biomarker
1550817|NCT03203837|Prognostic factor
1550818|NCT03203837|Angiogenesis
1550819|NCT03203837|Inflammatory
1550820|NCT03203837|Liver
1550821|NCT03201588|Retinopathy of Prematurity
1550822|NCT03203031|pain
1550823|NCT03203031|neonate
1550824|NCT03203031|regional anesthesia
1550825|NCT03203031|postoperative
1550826|NCT03190967|Ado-trastuzumab Emtansine
1550827|NCT03190967|Systemic Control of Disease
1550828|NCT03190967|Maximum Tolerated Dose
1550829|NCT03190967|Preventing the Formation of a Metastasis
1550830|NCT03190941|KRAS
1550831|NCT03190941|HRAS
1550832|NCT03190941|NRAS
1550833|NCT03190941|Cell Therapy
1550834|NCT03190941|Immunotherapy
1550835|NCT03190928|Disease Monitoring
1550836|NCT03190928|Molecular Monitoring
1550837|NCT03190928|Novel Biomarker Identification
1550838|NCT03190928|Gene Expression Analyses
1550839|NCT03190928|Watchful-Waiting
1550840|NCT03194555|Innate Immune System
1550841|NCT03194555|Cytokines
1550842|NCT03194555|Cox-2
1550843|NCT03194555|Headache
1550844|NCT03194555|Migraine
1550845|NCT03194555|Migraine Prevention
1550846|NCT03190954|C-11 Raclopride
1550847|NCT03190954|[11C] NNC-112
1550848|NCT03190954|Functional Magnetic Resonance Imaging (fMRI)
1550849|NCT03190954|Dopamine D1 Receptor
1550850|NCT03190954|D2 Receptors
1550851|NCT03201393|Back pain
1550852|NCT03201393|Neuropathic Pain
1550853|NCT03201393|Radiculopathy
1550854|NCT03201393|Allodynia
1550855|NCT03189121|Metabolism
1550856|NCT03189121|Macronutrients
1550857|NCT03189121|Obesity
1550858|NCT03189121|Energy Expenditure
1550859|NCT03189121|Glucose
1550860|NCT03188406|Intestinal Metaplasia
1550861|NCT03188406|Epidemiology
1550862|NCT03188406|Risk Stratification
1550863|NCT03188406|Helicobacter Pylori
1550864|NCT03188419|Prospective Donors
1550865|NCT03188419|Immunodeficiency
1550866|NCT03190278|Acute Myeloid Leukemia
1550867|NCT03190278|Relapsed/Refractory Acute Myeloid Leukemia
1550868|NCT03190278|Newly diagnosed AML
1550869|NCT03190278|ELN adverse genetic risk group
1550870|NCT03190278|Chimeric Antigen Receptor T-Cell (CAR-T) therapy
1550871|NCT03190278|Allogeneic
1550872|NCT03204240|Spinal Cord Injury
1550873|NCT03204240|Skeletal Muscle
1550874|NCT03204240|Functional Electrical Stimulation
1550875|NCT03204240|Diabetes
1550876|NCT03203369|Blastic plasmacytoid dendritic cell neoplasm
1550877|NCT03203369|Natural Killer (NK) cell blastic lymphoma
1550878|NCT03203369|Hematologic malignancies
1550879|NCT03203369|Cluster of differentiation (CD) CD4+CD56+ hematodermic tumor
1550880|NCT03203369|Acute leukemia and myeloid neoplasms
1550881|NCT03203369|Chimeric Antigen Receptor T-cell (CAR-T) therapy
1550882|NCT03203369|Allogeneic
1550883|NCT03203369|Cluster of differentiation 4 (CD4)
1550884|NCT03203369|Cluster of differentiation 56 (CD56)
1550885|NCT03186781|Flu Virus
1550886|NCT03186781|Flu Shot
1550887|NCT03186781|H2N2
1550888|NCT03186781|Protein
1550889|NCT03186781|Immune Response
1550890|NCT03203148|Cardiopulmonary Bypass
1550891|NCT03203148|Blood Coagulation Testing
1550892|NCT03203148|Point-of-Care Testing
1550893|NCT03186794|Fatigue
1550894|NCT03186118|pediatric
1550895|NCT03186118|young adult
1550896|NCT03186118|acute lymphoblastic leukemia
1550897|NCT03186118|CD 19
1550898|NCT03186118|leukemia
1550899|NCT03186118|chimeric antigen receptor
1550900|NCT03186118|T cell
1550901|NCT03203811|Healthy Subjects
1550902|NCT03181867|PET/ CT
1550903|NCT03181867|Endorectal MRI
1550904|NCT03181867|Imaging
1550905|NCT03181867|PSMA
1550906|NCT03180034|Human Papillomavirus
1550907|NCT03180034|Cervical Cancer
1550908|NCT03180034|Costa Rica
1550909|NCT03180034|Fewer Doses
1550910|NCT03173950|Immunotherapy
1550911|NCT03173950|Anti-PD-1 Antibody
1550912|NCT03173950|Brain Tumors
1550913|NCT03173950|MDASI-BT
1550914|NCT03173950|Spinal Cord Tumors
1550915|NCT03203967|Adults
1550916|NCT03203967|Unilateral TKA
1550917|NCT03203967|Single femoral nerve block
1550918|NCT03203967|Low-dose epidural morphine
1550919|NCT03203967|Effect of postoperative analgesia
1550920|NCT03203967|Quality of life
1550921|NCT03173963|Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
1550922|NCT03173963|Kidney Biopsy
1550923|NCT03173963|Morphometry
1550924|NCT03173963|American Indians
1550925|NCT03173963|Glomerular Filtration Rate
1550926|NCT03203473|Renal Cancer
1550927|NCT03167450|CRISPR
1550928|NCT03167450|Gene Editing
1550929|NCT03167450|Qualitative
1550930|NCT03167450|Participation Clinical Trials
1550931|NCT03167450|Genetic Literacy
1550932|NCT03167437|Reduce Symptoms of Crohn's Disease
1550933|NCT03167437|HDAC Inhibitors
1550934|NCT03186027|chronic fatigue
1550935|NCT03186027|Sleep problems
1550936|NCT03186027|Autonomic dysfunction
1550937|NCT03186027|Health-Related Quality of Life
1550938|NCT03186027|Coenzyme Q10
1550939|NCT03186027|NADH
1550940|NCT03165721|Renal Cancer
1550941|NCT03165721|DNA Hypermethylation
1550942|NCT03165721|Gastrointestinal Stromal Tumors
1550943|NCT03165721|DNA Methyltransferase (DNMT) Inhibitor
1550944|NCT03165721|Succinate Dehydrogenase (SDH) Deficiency
1550945|NCT03159442|Chronic obstructive pulmonary disease (COPD)
1550946|NCT03159442|Asthma
1550947|NCT03159442|AZD8871
1550948|NCT03159442|muscarinic receptor antagonist and β2 adrenoceptor agonist (MABA)
1550949|NCT03159442|Phase I
1550950|NCT03159442|Safety
1550951|NCT03159442|Tolerability
1550952|NCT03159442|Pharmacokinetics
1550953|NCT03159442|long-acting muscarinic antagonist (LAMA)
1550954|NCT03159442|long-acting β2-agonist (LABA)
1550955|NCT03159442|Japanese
1550956|NCT03158480|DC-CIK
1550957|NCT03158480|interferon
1550958|NCT03162536|ARQ 531
1550959|NCT03162536|Hematologic Malignancies
1550960|NCT03162536|SLL
1550961|NCT03162536|CLL
1550962|NCT03162536|B-cell NHL
1550963|NCT03162536|WM
1550964|NCT03162536|BTK
1550965|NCT03162536|cancer
1550966|NCT03162536|refractory
1550967|NCT03162536|relapsed
1550968|NCT03152760|Alcoholism
1550969|NCT03152760|Healthy Volunteers
1550970|NCT03152760|Craving
1550971|NCT03152760|Gut
1550972|NCT03152773|MRI Catheterization
1550973|NCT03152773|Real-time MRI
1550974|NCT03147898|Whooping cough
1550975|NCT03147898|Pertussis
1550976|NCT03145948|Tolerability
1550977|NCT03145948|Psoriasis
1550978|NCT03145948|Pharmacokinetics
1550979|NCT03145948|Healthy Volunteers
1550980|NCT03145948|Safety
1550981|NCT03145766|Rabies virus
1550982|NCT03203109|lateropulsion
1550983|NCT03203109|pusher syndrome
1550984|NCT03203109|posture
1550985|NCT03203109|balance
1550986|NCT03203109|PASS
1550987|NCT03203109|verticality perception
1550988|NCT03203109|gait
1550989|NCT03144921|Early-stage Dementia
1550990|NCT03144921|Early-stage Alzheimer's disease
1550991|NCT03144921|Care partner
1550992|NCT03144921|Caregivers
1550993|NCT03144921|Caregiving
1550994|NCT03132584|Non Hodgkin Lymphoma
1550995|NCT03131635|Developmental
1550996|NCT03127059|Dysfunctional Breathing
1550997|NCT03127059|Uncontrolled Asthma
1550998|NCT03127059|Breathing Exercises
1550999|NCT03127059|Adults
1551000|NCT03122912|fish oil
1551001|NCT03125733|Endoscopy, Digestive system
1551002|NCT03125733|Natural orifice transluminal endoscopic surgery
1551003|NCT03125733|Therapeutic
1551004|NCT03125733|Complications
1551005|NCT03111745|Reactivation or Proliferation of Latent Viral Infections.
1551006|NCT03111745|Viral Infections
1551007|NCT03111745|Lymphoproliferation
1551008|NCT03109288|Targeted Therapy
1551009|NCT03109288|Multiple Sclerosis
1551010|NCT03109288|Biomarkers
1551011|NCT03109288|Combination Therapy
1551012|NCT03109301|Mesenchymal Neoplasm
1551013|NCT03109301|Neurofibromatosis 1
1551014|NCT03109301|Plexiform Neurofibromas
1551015|NCT03118934|contact lenses
1551016|NCT03118934|presbyopia
1551017|NCT03118934|multifocal
1551018|NCT03105492|Prenatal Testing
1551019|NCT03105492|Whole Genome Sequencing
1551020|NCT03112603|Graft-versus-host disease (GvHD)
1551021|NCT03112603|Chronic GvHD (cGvHD)
1551022|NCT03112603|steroid-refractory
1551023|NCT03112603|ruxolitinib
1551024|NCT03112603|Janus kinase inhibitor
1551025|NCT03106077|Malignant neoplasm of breast
1551026|NCT03106077|Triple-Negative Breast Cancer
1551027|NCT03106077|TNBC
1551028|NCT03106077|Metastatic Triple-Negative Breast Cancer
1551029|NCT03106077|Newly Diagnosed Triple-Negative Breast Cancer
1551030|NCT03106077|Mirvetuximab Soravtansine
1551031|NCT03106077|IMGN853
1551032|NCT03104725|5-S-Cysteinyldopamine
1551033|NCT03104725|Cerebrospinal Fluid
1551034|NCT03104725|PARKINSONS DISEASE
1551035|NCT03104725|MONOAMINE OXIDASE INHIBITOR
1551036|NCT03104400|Psoriasis
1551037|NCT03104400|Anti-Rheumatic
1551038|NCT03104400|Anti-inflammatory
1551039|NCT03104400|Musculoskeletal disease
1551040|NCT03104400|Joint disease
1551041|NCT03104400|Arthritis
1551042|NCT03104374|Musculoskeletal disease
1551043|NCT03104374|Anti-Rheumatic
1551044|NCT03104374|Joint disease
1551045|NCT03104374|Psoriasis
1551046|NCT03104374|Anti-inflammatory
1551047|NCT03104374|Arthritis
1551048|NCT03108664|SYL1001
1551049|NCT03108664|siRNA
1551050|NCT03101748|Malignant neoplasm of breast
1551051|NCT03101748|Metastatic breast cancer
1551052|NCT03101748|Locally advanced breast cancer
1551053|NCT03101748|HER2-positive
1551054|NCT03101748|HER2+
1551055|NCT03101748|HER2-negative/ER-positive
1551056|NCT03101748|HER2-/ER+
1551057|NCT03101748|Locally advanced inflammatory breast cancer
1551058|NCT03101748|IBC
1551059|NCT03101748|Neratinib
1551060|NCT03101748|Paclitaxel
1551061|NCT03101748|Taxol
1551062|NCT03101748|Doxorubicin
1551063|NCT03101748|Doxorubicin Hydrochloride
1551064|NCT03101748|Adriamycin PFS
1551065|NCT03101748|Adriamycin RDF
1551066|NCT03101748|Adriamycin
1551067|NCT03101748|Rubex
1551068|NCT03101748|Pertuzumab
1551069|NCT03101748|Perjeta
1551070|NCT03101748|Trastuzumab
1551071|NCT03101748|Herceptin
1551072|NCT03101748|Cyclophosphamide
1551073|NCT03101748|Cytoxan
1551074|NCT03101748|Neosar
1551075|NCT03098862|Ebola Virus
1551076|NCT03098862|Genome-Wide Association Study
1551077|NCT03098862|Liberia
1551078|NCT03098862|Ebola Survivors
1551079|NCT03098862|Ebola Contacts
1551080|NCT03096353|NALOXONE
1551081|NCT03096353|fMRI
1551082|NCT03096353|Functional Magnetic Resonance Imaging (fMRI)
1551083|NCT03108729|epilepsy
1551084|NCT03108729|partial on-set seizures
1551085|NCT03109821|Exercise Therapy
1551086|NCT03109821|Rehabilitation
1551087|NCT03106987|polymerisation inhibitor (PARPi)
1551088|NCT03106987|PARPi re-treatment
1551089|NCT03106987|BRCA1/2 (+ve)
1551090|NCT03106987|BRCA1/2 (-ve)
1551091|NCT03106987|Olaparib
1551092|NCT03106987|ovarian cancer
1551093|NCT03106987|progression free survival (PFS)
1551094|NCT03092687|Mental Illness
1551095|NCT03092687|Aging
1551096|NCT03092687|Normal Development
1551097|NCT03092505|Herpes
1551098|NCT03092505|Uganda
1551099|NCT03092505|HSV
1551100|NCT03092505|Sample
1551101|NCT03092492|Age Related Macular Degeneration
1551102|NCT03092492|Age Related Macular Degeneration (AMD)
1551103|NCT03092492|Reticular Pseudodrusen
1551104|NCT03089944|Genotype (GT) 1, 2, 4, 5 or 6
1551105|NCT03089944|Glecaprevir
1551106|NCT03089944|Pibrentasvir
1551107|NCT03089944|Pangenotypic
1551108|NCT03089944|Hepatitis C Virus (HCV)
1551109|NCT03089944|Treatment Naïve
1551110|NCT03089944|Compensated Cirrhosis
1551111|NCT03089944|Cirrhosis
1551112|NCT03086343|Arthritis
1551113|NCT03086343|Anti-inflammatory agents
1551114|NCT03086343|Joint Disease
1551115|NCT03086343|Musculoskeletal Disease
1551116|NCT03086343|Antirheumatic agents
1551117|NCT03086239|Rovalpituzumab tesirine
1551118|NCT03086239|Small Cell Lung Cancer
1551119|NCT03086239|Cancer
1551120|NCT03086239|Advanced, Recurrent Small Cell Lung Cancer
1551121|NCT03090269|cocaine
1551122|NCT03090269|methylphenidate
1551123|NCT03090269|psychostimulant
1551124|NCT03090269|ADHD
1551125|NCT03090269|effective dose
1551126|NCT03090269|pharmacokinetics
1551127|NCT03090269|crack
1551128|NCT03082209|non-Hodgkin lymphoma
1551129|NCT03082209|Solid Tumors
1551130|NCT03082209|acute myeloid leukemia (AML)
1551131|NCT03082209|Cancer
1551132|NCT03082209|Hematologic Malignancies
1551133|NCT03082209|colorectal cancer (CRC)
1551134|NCT03077438|Meningitis
1551135|NCT03077438|Meningococcal Meningitis
1551136|NCT03077438|MenACYW conjugate vaccine
1551137|NCT03077438|MENVEO®
1551138|NCT03078374|Reduced anti-coagulation, mechanical circulatory support.
1551139|NCT03071757|Cholangiocarcinoma
1551140|NCT03071757|Merkel cell carcinoma
1551141|NCT03071757|Mesothelioma
1551142|NCT03071757|Metastatic Solid Tumors
1551143|NCT03071757|Non-small cell lung cancer (NSCLC)
1551144|NCT03071757|Small cell lung cancer (SCLC)
1551145|NCT03071757|Triple negative breast cancer
1551146|NCT03071757|Hepatocellular carcinoma (HCC)
1551147|NCT03071757|Ovarian cancer
1551148|NCT03071757|Cancer
1551149|NCT03071757|Gastric cancer
1551150|NCT03071757|Solid Tumors
1551151|NCT03071757|Melanoma
1551152|NCT03071757|Advanced Solid Tumors
1551153|NCT03068546|Oral Microbiota
1551154|NCT03069365|non-cirrhotic
1551155|NCT03069365|Chronic Kidney Disease
1551156|NCT03069365|compensated cirrhosis
1551157|NCT03069365|sofosbuvir (SOF)
1551158|NCT03069365|ribavirin (RBV)
1551159|NCT03069365|treatment naïve
1551160|NCT03069365|interferon (IFN)
1551161|NCT03069365|Hepatitis C Virus Genotype
1551162|NCT03069365|Chronic Hepatitis C Virus
1551163|NCT03069365|pegylated interferon (pegIFN)
1551164|NCT03069365|Glecaprevir
1551165|NCT03069365|Pibrentasvir
1551166|NCT03070093|Acute myeloid leukemia (AML)
1551167|NCT03070093|FMS-like Tyrosine kinase-3 (FLT3) mutations
1551168|NCT03070093|gilteritinib
1551169|NCT03070093|Expanded access
1551170|NCT03070093|ASP2215
1551171|NCT03078751|Hormone receptor-positive
1551172|NCT03078751|Estrogen and/or progesterone receptor-positive
1551173|NCT03078751|HER2-negative
1551174|NCT03078751|High risk early breast cancer
1551175|NCT03078751|Adjuvant
1551176|NCT03078751|Ribociclib
1551177|NCT03078751|LEE011
1551178|NCT03078751|CDK4/6 inhibitor
1551179|NCT03078751|Endocrine therapy
1551180|NCT03078751|Phase III
1551181|NCT03078751|Breast carcinoma
1551182|NCT03078751|Breast cancer
1551183|NCT03067129|Compensated (Child-Pugh A) cirrhosis
1551184|NCT03067129|Treatment naïve
1551185|NCT03067129|pegylated interferon (pegIFN)
1551186|NCT03067129|Ribavirin (RBV)
1551187|NCT03067129|Chronic Hepatitis C Virus
1551188|NCT03067129|Treatment experienced
1551189|NCT03067129|Interferon (IFN)
1551190|NCT03067129|Pharmacokinetic
1551191|NCT03067129|Non-cirrhotic cirrhosis
1551192|NCT03067129|Glecaprevir
1551193|NCT03067129|sofosbuvir
1551194|NCT03067129|Pibrentasvir
1551195|NCT03073525|Stage IIIb
1551196|NCT03073525|Stage IV
1551197|NCT03073525|Ovarian Cancer
1551198|NCT03073525|Cervical Cancer
1551199|NCT03073525|Uterine Cancer
1551200|NCT03073525|Immunotherapy
1551201|NCT03061812|metastatic
1551202|NCT03061812|Delta-like protein 3 (DLL3)
1551203|NCT03061812|Small cell lung cancer (SCLC)
1551204|NCT03061812|topotecan
1551205|NCT03061812|rovalpituzumab tesirine
1551206|NCT03060772|Pulmonary Medicine
1551207|NCT03060772|Oxidative Stress
1551208|NCT03060772|Pioglitazone
1551209|NCT03060772|Immunology
1551210|NCT03060772|Addictive/Compulsive Behavior
1551211|NCT03061734|Migraine Disorders
1551212|NCT03061734|Headache Disorders
1551213|NCT03061734|Migraine with Aura
1551214|NCT03061734|Migraine without Aura
1551215|NCT03066908|Chronic Rhinosinusitis
1551216|NCT03056690|ASP0819
1551217|NCT03056690|Fibromyalgia
1551218|NCT03124160|Healthy Women
1551219|NCT03124160|Female Contraception
1551220|NCT03124160|IUD
1551221|NCT03047395|ABBV-066
1551222|NCT03047395|BI 655066
1551223|NCT03054740|Vapocoolant applied prior to IV access
1551224|NCT03041701|ERMS
1551225|NCT03041701|ARMS
1551226|NCT03041701|Monoclonal Antibody
1551227|NCT03041701|YES
1551228|NCT03041701|RMS
1551229|NCT03041311|Small Cell Lung Cancer
1551230|NCT03041311|CDK 4/6 Inhibitor
1551231|NCT03041311|Immune Checkpoint Inhibitor
1551232|NCT03041129|hepatic de novo lipogenesis
1551233|NCT03040193|Lignocaine
1551234|NCT03033511|Cancer
1551235|NCT03033511|Platinum-Based Chemotherapy
1551236|NCT03033511|Extensive-Stage Small Cell Lung Cancer (ED SCLC)
1551237|NCT03033511|Rovalpituzumab tesirine
1551238|NCT03033511|first-line chemotherapy
1551239|NCT03035279|Advanced colorectal cancer
1551240|NCT03035279|Unresectable colorectal cancer
1551241|NCT03035279|Maximum tolerated dose
1551242|NCT03035279|Metastatic colorectal cancer
1551243|NCT03035279|Cancer
1551244|NCT03035279|Pharmacokinetics
1551245|NCT03026166|Nivolumab
1551246|NCT03026166|Ipilimumab
1551247|NCT03026166|Rovalpituzumab tesirine
1551248|NCT03026166|Cancer
1551249|NCT03026166|Extensive-Stage Small Cell Lung Cancer
1551250|NCT03035721|Full term healthy infants
1551251|NCT03035721|Low protein content formula
1551252|NCT03035721|Safety
1551253|NCT03035721|Growth
1551254|NCT03035721|Body composition
1551255|NCT03026829|Sound therapy
1551256|NCT03026829|Tinnitus relief
1551257|NCT03022045|risankizumab
1551258|NCT03022045|Erythrodermic Psoriasis
1551259|NCT03022045|Japanese
1551260|NCT03022045|Generalized Pustular Psoriasis
1551261|NCT03021434|Water Supply/standards
1551262|NCT03021434|Water microbiology
1551263|NCT03021434|India
1551264|NCT03021434|Hand disinfection
1551265|NCT03021434|Escherichia coli Infections/prevention & control
1551266|NCT03021434|Hygiene
1551267|NCT03021434|Health behavior
1551268|NCT03021434|Drinking water
1551269|NCT03021434|Informational intervention
1551270|NCT03115086|Bile Acid Synthesis Disorder
1551271|NCT03115086|Zellweger Spectrum Disorder
1551272|NCT03115086|Peroxisomal Disorder
1551273|NCT03115086|Cholic Acid
1551274|NCT03115086|Cholbam
1551275|NCT03115086|Kolbam
1551276|NCT03115086|The Replace Registry
1551277|NCT03015662|Quality of Life
1551278|NCT03015662|Fatigue
1551279|NCT03015662|Anxiety
1551280|NCT03015662|Physical Therapy Modalities
1551281|NCT03015662|Pain
1551282|NCT03026413|atrial fibrillation
1551283|NCT03026413|pulmonary vein isolation
1551284|NCT03026413|Contact Force
1551285|NCT03026413|antrum
1551286|NCT03004703|Interleukin 6
1551287|NCT03004703|Tocilizumab
1551288|NCT03004703|Acute coronary syndrome
1551289|NCT03004703|STEMI
1551290|NCT03004703|Inflammation
1551291|NCT03002805|Phase I
1551292|NCT03002805|CBT-1®
1551293|NCT03002805|Doxorubicin
1551294|NCT03002805|Sarcoma
1551295|NCT02993523|Azacitidine
1551296|NCT02993523|Acute Myeloid Leukemia
1551297|NCT02993523|Venetoclax
1551298|NCT02993523|Treatment Naïve
1551299|NCT02993757|Dengue Fever
1551300|NCT02993757|Dengue Hemorrhagic Fever
1551301|NCT02993757|Human Papillomavirus Disease
1551302|NCT02993757|CYD Dengue Vaccine
1551303|NCT02993757|Dengvaxia®
1551304|NCT02993757|Gardasil®
1551305|NCT02992418|Dengue Fever
1551306|NCT02992418|Dengue Hemorrhagic Fever
1551307|NCT02992418|CYD Dengue Vaccine
1551308|NCT02992418|Degavaxia®
1551309|NCT02991144|Gene Transfer
1551310|NCT02991144|OTC Deficiency
1551311|NCT02991144|Urea Cycle Disorder
1551312|NCT02991274|T790M
1551313|NCT02991274|EGFR (Epidermal Growth Factor Receptor) mutation
1551314|NCT02991274|NSCLC
1551315|NCT02988960|Non-small cell lung cancer (NSCLC)
1551316|NCT02988960|Pancreatic adenocarcinoma
1551317|NCT02988960|Squamous cell carcinoma of the head and neck (SCCHN)
1551318|NCT02988960|Nivolumab
1551319|NCT02988960|Cutaneous melanoma
1551320|NCT02988960|Advanced solid tumor
1551321|NCT02988960|Cancer
1551322|NCT02991794|prostatectomy
1551323|NCT02991794|laparoscopy
1551324|NCT02991794|3D visualization
1551325|NCT02991794|learning curve
1551326|NCT02991794|anastomosis
1551327|NCT02991690|Hypothermia
1551328|NCT02991690|Cervical Spinal Cord Injury
1551329|NCT02991690|Trauma
1551330|NCT02990364|Circumcision
1551331|NCT02990364|Analgesia
1551332|NCT02990364|Controlled Clinical Trial
1551333|NCT02979535|Dengue Fever
1551334|NCT02979535|Dengue Hemorrhagic Fever
1551335|NCT02979535|Human Papillomavirus Disease
1551336|NCT02979535|CYD Dengue Vaccine
1551337|NCT02979535|Dengvaxia®
1551338|NCT02979535|Cervarix®
1551339|NCT02975349|M2951
1551340|NCT02975349|Relapsing Multiple Sclerosis
1551341|NCT02975349|Bruton's Tyrosine Kinase inhibitor
1551342|NCT02966795|sofosbuvir (SOF)
1551343|NCT02966795|ribavirin (RBV)
1551344|NCT02966795|pegylated interferon (pegIFN)
1551345|NCT02966795|interferon (IFN)
1551346|NCT02966795|pegylated-interferon (pegIFN)
1551347|NCT02966795|non-cirrhotic
1551348|NCT02966795|glecaprevir
1551349|NCT02966795|compensated cirrhosis
1551350|NCT02966795|pibrentasvir
1551351|NCT02966795|Sustained Virologic Response 12 weeks post dosing (SVR12)
1551352|NCT02966782|Azacitidine
1551353|NCT02966782|Venetoclax
1551354|NCT02966782|Higher-Risk (HR) Myelodysplastic Syndromes (MDS)
1551355|NCT02966782|International Prognostic Scoring System (IPSS)
1551356|NCT02966782|Hypomethylating Agent-Failure (HMA)
1551357|NCT02966314|Angioedema
1551358|NCT02966314|Idiopathic Angioedema
1551359|NCT02966314|IAE
1551360|NCT02965846|EDE
1551361|NCT02965846|evaporative dry eye
1551362|NCT02960659|Metformin
1551363|NCT02960659|Glucose
1551364|NCT02960555|Myeloma
1551365|NCT02960555|Smoldering Multiple Myeloma
1551366|NCT02960555|SMM
1551367|NCT02960555|Intermediate or high risk
1551368|NCT02960555|SAR650984
1551369|NCT02960555|Diphenhydramine
1551370|NCT02960555|Benadryl
1551371|NCT02960555|Ranitidine
1551372|NCT02960555|Ranitidine Hydrochloride
1551373|NCT02960555|Zantac
1551374|NCT02960555|Methylprednisolone
1551375|NCT02960555|Depo-Medrol
1551376|NCT02960555|Medrol
1551377|NCT02960555|Solu-Medrol
1551378|NCT02955797|Meningitis
1551379|NCT02955797|Meningococcal Meningitis
1551380|NCT02955797|MenACYW conjugate vaccine
1551381|NCT02955797|Nimenrix®
1551382|NCT02955797|Menjugate®
1551383|NCT02948933|Dengue Fever
1551384|NCT02948933|Dengue Hemorrhagic Fever
1551385|NCT02948933|Dengvaxia®
1551386|NCT02950909|Therapeutic exercise
1551387|NCT02950909|Chronic pain
1551388|NCT02950909|Neck extensors
1551389|NCT02949427|Microbiome
1551390|NCT02949427|Mycobiome
1551391|NCT02949427|Virome
1551392|NCT02949427|Pediatric leukemia
1551393|NCT02949427|Pediatric bone marrow transplantation
1551394|NCT02935582|Topical
1551395|NCT02935582|Real-world
1551396|NCT02935582|Local standard of care
1551397|NCT02935582|Non-interventional
1551398|NCT02935582|Calcipotriol
1551399|NCT02958527|Effexor
1551400|NCT02958527|Depression
1551401|NCT02958527|Depressed state
1551402|NCT02936323|SCLC small cell lung cancer neuroendocrine NET
1551403|NCT02943980|Intraoperative nerve monitoring, airway management
1551404|NCT02933710|Japanese encephalitis
1551405|NCT02933710|IMOJEV®
1551406|NCT02933710|Japanese encephalitis chimeric virus vaccine
1551407|NCT02925117|ABT-494
1551408|NCT02925117|Atopic Dermatitis
1551409|NCT02933112|Oral appliance therapy
1551410|NCT02921789|Bleselumab
1551411|NCT02921789|ASKP1240
1551412|NCT02921789|Efficacy and Safety
1551413|NCT02908269|Influenza
1551414|NCT02908269|Fluzone® Quadrivalent, Influenza Vaccine (2016-2017 formulation)
1551415|NCT02908269|Fluzone® High Dose, Influenza Vaccine (2016-2017 formulation)
1551416|NCT03000829|Code blue
1551417|NCT03000829|Code team
1551418|NCT03000829|Crisis team leadership
1551419|NCT03000829|Cardiopulmonary resuscitation
1551420|NCT03000829|Telemedicine
1551421|NCT03000829|Simulation
1551422|NCT03000829|Mock code
1551423|NCT03000829|In-hospital cardiac arrest
1551424|NCT02896101|Mild to moderate
1551425|NCT02899052|Refractory myeloma
1551426|NCT02899052|Multiple Myeloma
1551427|NCT02899052|Relapsed myeloma
1551428|NCT02889562|apixaban
1551429|NCT02889562|anticoagulant
1551430|NCT02889562|CABG
1551431|NCT02889562|thrombosis
1551432|NCT02889562|fibrillation
1551433|NCT02880293|transplant conditioning
1551434|NCT02880293|KIR/HLA based haploidentical donor selection
1551435|NCT02880293|allogeneic hematopoietic cell transplantation
1551436|NCT02876107|Malignant neoplasm of breast
1551437|NCT02876107|Breast cancer
1551438|NCT02876107|Newly diagnosed primary triple-negative inflammatory breast cancer
1551439|NCT02876107|Inflammatory breast cancer
1551440|NCT02876107|IBC
1551441|NCT02876107|TN-IBC
1551442|NCT02876107|Breast biopsy
1551443|NCT02876107|Mammogram
1551444|NCT02876107|Ultrasound
1551445|NCT02876107|Paclitaxel
1551446|NCT02876107|Taxol
1551447|NCT02876107|Carboplatin
1551448|NCT02876107|Paraplatin
1551449|NCT02876107|Panitumumab
1551450|NCT02876107|Vectibix
1551451|NCT02876107|Doxorubicin
1551452|NCT02876107|Doxorubicin Hydrochloride
1551453|NCT02876107|Adriamycin PFS
1551454|NCT02876107|Adriamycin RDF
1551455|NCT02876107|Adriamycin
1551456|NCT02876107|Rubex
1551457|NCT02876107|Cyclophosphamide
1551458|NCT02876107|Cytoxan
1551459|NCT02876107|Neosar
1551460|NCT02864524|Physical Therapy Modalities
1551461|NCT02864524|Exercises
1551462|NCT02864524|Musculoskeletal Manipulations
1551463|NCT02864927|Meningitis
1551464|NCT02864927|Meningococcal Meningitis
1551465|NCT02864927|Meningococcal Infections
1551466|NCT02864927|Menactra®
1551467|NCT02864927|Meningococcal Vaccine
1551468|NCT02859467|Physical Therapy Modalities
1551469|NCT02859467|Exercise
1551470|NCT02859467|Electrical Stimulation Therapy
1551471|NCT02859467|Bandages
1551472|NCT02868489|Microbiota
1551473|NCT02847650|Early Parkinson Disease
1551474|NCT02847650|Phase 2
1551475|NCT02848248|Acute Myeloid Leukemia
1551476|NCT02848248|Antibody-Drug Conjugate
1551477|NCT02848248|CD123 Antigen
1551478|NCT02848248|Drug Therapy
1551479|NCT02848248|AML
1551480|NCT02848248|Leukemia, Myeloid, Acute
1551481|NCT02842853|Meningitis
1551482|NCT02842853|Meningococcal Meningitis
1551483|NCT02842853|Meningococcal Infections
1551484|NCT02842853|MenACYW conjugate vaccine
1551485|NCT02842853|Licensed MCV4 vaccine
1551486|NCT02836535|complications
1551487|NCT02836535|surgery
1551488|NCT02827162|Dengue Fever
1551489|NCT02827162|Dengue Haemorrhagic Fever
1551490|NCT02827162|Tetravalent Dengue Vaccine
1551491|NCT02817451|Diphtheria
1551492|NCT02817451|Tetanus
1551493|NCT02817451|Pertussis
1551494|NCT02817451|Hepatitis B
1551495|NCT02817451|DTaP IPV HB PRP-T Combined Vaccine
1551496|NCT02817451|Human Immunodeficiency Virus
1551497|NCT02824042|Phase 1
1551498|NCT02824042|Solid tumors
1551499|NCT02824042|Mesothelin
1551500|NCT02824042|Itraconazole
1551501|NCT02824042|PK DDI
1551502|NCT02824042|ECG thorough QTC
1551503|NCT02815293|EDE
1551504|NCT02815293|evaporative dry eye
1551505|NCT02817061|no keywords for disease type and/or category
1551506|NCT02808429|Atacicept
1551507|NCT02808429|IgA Nephropathy
1551508|NCT02808429|Berger´s disease
1551509|NCT02808429|Glomerulonephritis
1551510|NCT02808429|Proteinuria
1551511|NCT02799381|efficacy
1551512|NCT02799381|carbidopa
1551513|NCT02799381|levodopa
1551514|NCT02799381|levodopa-carbidopa intestinal gel
1551515|NCT02793271|Depression
1551516|NCT02793271|Primary Health Care
1551517|NCT02793271|Social Stigma
1551518|NCT02793271|Stereotyping
1551519|NCT02793271|Health Care Quality
1551520|NCT02793271|Access
1551521|NCT02793271|Evaluation
1551522|NCT02793128|TC-3
1551523|NCT02793128|Mitogel
1551524|NCT02793128|UTUC
1551525|NCT02793128|Ureteral
1551526|NCT02793128|Upper Tract
1551527|NCT02793128|Carcinoma
1551528|NCT02793128|Kidney
1551529|NCT02793128|Renal
1551530|NCT02793128|Gel
1551531|NCT02793128|Local
1551532|NCT02793128|Mitomycin C
1551533|NCT02793128|Prolonged Release
1551534|NCT02793128|Slow Release
1551535|NCT02793128|Kidney Sparing
1551536|NCT02793128|T1
1551537|NCT02793128|T0
1551538|NCT02793128|Low Grade
1551539|NCT02777658|Epidermal Growth Factor Receptor (EGFR), non-small cell lung cancer (NSCLC), EGFR T790M, EGFR Mutation-Positive Locally Advanced or Advanced NSCLC
1551540|NCT02781181|Stenting
1551541|NCT02781181|Protection device
1551542|NCT02781181|EPD usage
1551543|NCT02775045|EoE
1551544|NCT02765750|Emergence agitation
1551545|NCT02752906|Meningitis
1551546|NCT02752906|Meningococcal Meningitis
1551547|NCT02752906|Meningococcal Infections
1551671|NCT02592876|Rituximab
1551548|NCT02752906|MenACYW conjugate vaccine
1551549|NCT02752906|Licensed Meningococcal Conjugate Vaccine (MCV4)
1551550|NCT02751918|Mesothelin-expressing platinum-resistant cancer
1551551|NCT02753309|BCG
1551552|NCT02753309|Rapamycin
1551553|NCT02741128|Dengue Fever
1551554|NCT02741128|Dengue Hemorrhagic Fever
1551555|NCT02741128|Human Immunodeficiency Virus
1551556|NCT02741128|CYD Dengue Vaccine
1551557|NCT02725593|Diabetes Mellitus
1551558|NCT02725593|Dapagliflozin
1551559|NCT02725593|Placebo
1551560|NCT02725593|Insulin resistance
1551561|NCT02725593|Metabolic Diseases
1551562|NCT02722720|Carotid atherosclerosis
1551563|NCT02722720|Carotid stenosis
1551564|NCT02722720|Ischemic attack
1551565|NCT02722720|Stroke
1551566|NCT02722720|Carotid stenting
1551567|NCT02722720|Transradial approach
1551568|NCT02722720|Transfemoral approach
1551569|NCT02722720|Bleeding
1551570|NCT02722720|Thromboembolism
1551571|NCT02722720|Embolism
1551572|NCT02722720|Neurocognitive disorders
1551573|NCT02709486|Osteoarthritis, pain, tanezumab.
1551574|NCT02702141|Non-hodgkin lymphoma
1551575|NCT02702141|Antibody-drug conjugate
1551576|NCT02702141|CD19
1551577|NCT02702141|Diffuse large B-cell lymphoma
1551578|NCT02702141|DLBCL
1551579|NCT02702141|Grade 3 follicular lymphoma
1551580|NCT02697929|Rocuronium
1551581|NCT02693743|suicidality
1551582|NCT02693743|rTMS
1551583|NCT02693743|suicide ideation
1551584|NCT02698657|Rheumatoid arthritis (RA)
1551585|NCT02698657|Methotrexate
1551586|NCT02698657|ASP5094
1551587|NCT02679326|Therapeutic ultrasound, Treatment, Plantar fasciitis
1551588|NCT02701036|sporadic ataxia
1551589|NCT02701036|MSAc
1551590|NCT02701036|SAOA
1551591|NCT02701036|multiple system atrophy of cerebellar type
1551592|NCT02701036|natural history
1551593|NCT02725411|Chronic low back pain
1551594|NCT02725411|Chronic pain
1551595|NCT02655796|Accidental Falls
1551596|NCT02655796|Risk Assessment
1551597|NCT02655796|Frail Elderly
1551598|NCT02647632|HCV genotype 1 or 4
1551599|NCT02647632|failure to DAA
1551600|NCT02670148|Chiropractic Manipulative Therapy
1551601|NCT02670148|Low back pain
1551602|NCT02670148|Trunk muscle strength
1551603|NCT02670148|Balance
1551604|NCT02670148|Active military personnel
1551605|NCT02633072|Multifocal Intraocular Lens
1551606|NCT02633072|Binocular Trifocality
1551607|NCT02633072|Cataract Surgery
1551608|NCT02633072|Spectacle Independence
1551609|NCT02633072|Intermediate Vision
1551610|NCT02633072|Photopic Vision
1551611|NCT02633072|Mesopic Vision
1551612|NCT02633072|Scotopic Vision
1551613|NCT02633072|Binocular Vision
1551614|NCT02633228|Multifocal Intraocular Lens
1551615|NCT02633228|Binocular Trifocality
1551616|NCT02633228|Cataract Surgery
1551617|NCT02633228|Spectacle Independence
1551618|NCT02633228|Intermediate Vision
1551619|NCT02633228|Photopic Vision
1551620|NCT02633228|Mesopic Vision
1551621|NCT02633228|Scotopic Vision
1551622|NCT02633228|Binocular Vision
1551623|NCT02628444|Dengue Fever
1551624|NCT02628444|Dengue virus
1551625|NCT02628444|Dengue Hemorrhagic Fever
1551626|NCT02628444|CYD Dengue Vaccine
1551627|NCT02626130|Kidney Cancer
1551628|NCT02626130|Tremelimumab
1551629|NCT02626130|Cryoablation
1551630|NCT02626130|Cryoprobe
1551631|NCT02623725|Dengue Fever
1551632|NCT02623725|Dengue virus
1551633|NCT02623725|Dengue Hemorrhagic Fever
1551634|NCT02623725|CYD Dengue Vaccine
1551635|NCT02638220|Cerebrotendinous Xanthomatosis
1551636|NCT02638220|CTX Prevalence Study
1551637|NCT02638220|CTX
1551638|NCT02638220|Idiopathic Bilateral Cataracts
1551639|NCT02638220|Cataracts
1551640|NCT02638220|Bilateral Cataracts
1551641|NCT02638220|Early-Onset Idiopathic Bilateral Cataracts
1551642|NCT02638220|Observational Study
1551643|NCT02638220|Ophthalmology
1551644|NCT02610777|Drug Therapy
1551645|NCT02612857|dermatomyositis
1551646|NCT02612857|IMO-8400
1551647|NCT02612857|Pioneer
1551648|NCT02605486|palbociclib
1551649|NCT02605486|bicalutamide
1551650|NCT02605486|AR(+)
1551651|NCT02605486|15-207
1551652|NCT02592876|Antibodies, Monoclonal
1551653|NCT02592876|Antibody-Drug Conjugate
1551654|NCT02592876|Antigens, CD19
1551655|NCT02592876|Autologous Stem Cell Transplant
1551656|NCT02592876|Drug Therapy
1551657|NCT02592876|Follicular Lymphoma Grade 3b
1551658|NCT02592876|Hematologic Diseases
1551659|NCT02592876|Immune System Diseases
1551660|NCT02592876|Immunoproliferative Disorders
1551661|NCT02592876|Immunotherapy
1551662|NCT02592876|Lymphatic Diseases
1551663|NCT02592876|Lymphoma
1551664|NCT02592876|Lymphoma, B-Cell
1551665|NCT02592876|Lymphoma, Large B-Cell, Diffuse
1551666|NCT02592876|Lymphoma, Non-Hodgkin
1551667|NCT02592876|Monomethylauristatin F
1551668|NCT02592876|Neoplasms
1551669|NCT02592876|Neoplasms by Histologic Type
1551670|NCT02592876|Transformed Lymphoma / DLBCL
1551672|NCT02592876|Ifosfamide
1551673|NCT02592876|Carboplatin
1551674|NCT02592876|Etoposide
1551675|NCT02587520|Tetanus
1551676|NCT02587520|Diphtheria
1551677|NCT02587520|Pertussis
1551678|NCT02587520|SP0173
1551679|NCT02587520|Tdap vaccine
1551680|NCT02588105|Phase I, open label study; safety and efficacy of AZD0156; ATM inhibitor
1551681|NCT02580448|Breast Cancer
1551682|NCT02580448|Breast
1551683|NCT02580448|Advanced Breast Cancer
1551684|NCT02580448|Metastatic Breast Cancer
1551685|NCT02580448|CYP17
1551686|NCT02580448|Male Breast Cancer
1551687|NCT02580448|Triple Negative Cancer
1551688|NCT02580448|ER+ Breast Cancer
1551689|NCT02572167|Monomethyl auristatin E
1551690|NCT02572167|Antigens, CD30
1551691|NCT02572167|Antibody-Drug Conjugate
1551692|NCT02572167|Antibodies, Monoclonal
1551693|NCT02572167|Immunotherapy
1551694|NCT02572167|Autologous stem cell transplant
1551695|NCT02712346|Sickle Cell Anemia
1551696|NCT02712346|Sickle Cell Thalassemia
1551697|NCT02712346|Sickle Beta Thalassemia
1551698|NCT02712346|Proteinuria
1551699|NCT02712346|Sickle nephropathy
1551700|NCT02554409|Fluzone Quadrivalent Intradermal Influenza Vaccine
1551701|NCT02554409|Pregnancy Registry
1551702|NCT02554409|Influenza
1551703|NCT02642978|minimally invasive surgery
1551704|NCT02642978|colorectal liver metastasis
1551705|NCT02642978|robotic surgery
1551706|NCT02642978|Patients with resectable colorectal liver metastasis
1551707|NCT02544633|Mirati
1551708|NCT02544633|MGCD265
1551709|NCT02544633|MET
1551710|NCT02544633|NSCLC
1551711|NCT02536105|Attention Deficit Hyperactivity Disorder
1551712|NCT02536105|ADHD
1551713|NCT02529813|Leukemia
1551714|NCT02529813|Lymphoma
1551715|NCT02529813|Advanced Lymphoid Malignancies
1551716|NCT02529813|CD19+ lymphoid malignancy
1551717|NCT02529813|Multiple myeloma
1551718|NCT02529813|MM
1551719|NCT02529813|CD19-specific T cells
1551720|NCT02529813|Chimeric Antigen Receptor T cells
1551721|NCT02529813|CAR T cells
1551722|NCT02529813|Autologous
1551723|NCT02529813|Allogeneic
1551724|NCT02529813|Fludarabine
1551725|NCT02529813|Fludarabine phosphate
1551726|NCT02529813|Cyclophosphamide
1551727|NCT02529813|Cytoxan
1551728|NCT02529813|Neosar
1551729|NCT02529813|nonviral
1551730|NCT02529813|non-viral
1551731|NCT02529813|DNA plasmids
1551732|NCT02681666|FODMAP Diet
1551733|NCT02681666|Bowel Habit
1551734|NCT02681666|Rome IV Criteria
1551735|NCT02681666|Mindfulness
1551736|NCT02681666|Abdominal pain
1551737|NCT02681666|Irritable Bowel Syndrome
1551738|NCT02596217|ABBV-066
1551739|NCT02596217|BI 655066
1551740|NCT02596217|risankizumab
1551741|NCT02540369|Diabetic macular edema
1551742|NCT02540369|Wet Age-related macular degeneration
1551743|NCT02510885|neovascular age-related macular degeneration
1551744|NCT02510885|age-related macular degeneration
1551745|NCT02510885|diabetic retinopathy
1551746|NCT02510885|SD-OCT
1551747|NCT02510885|Angiography
1551748|NCT02510885|diabetic macular edema
1551749|NCT02523183|Epilepsy
1551750|NCT02523183|Marijuana
1551751|NCT02509611|Yoga
1551752|NCT02509611|Parkinson's disease
1551753|NCT02509611|redox status
1551754|NCT02509611|motor function
1551755|NCT02498600|Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian
1551756|NCT02498600|Primary Peritoneal or Fallopian
1551757|NCT02498600|Tube Cancer
1551758|NCT02573467|sporadic inclusion body myositis,
1551759|NCT02573467|muscle wasting,
1551760|NCT02573467|extension study,
1551761|NCT02573467|BYM338,
1551762|NCT02573467|bimagrumab,
1551763|NCT02500199|HER2 positive
1551764|NCT02489721|peripherally inserted central venous catheter
1551765|NCT02489721|depp vein thrombosis
1551766|NCT02489721|related blood stream infections
1551767|NCT02489721|midline
1551768|NCT02490826|Speech Sound Disorders
1551769|NCT02490826|Tabletop
1551770|NCT02490826|Digital
1551771|NCT02463201|Sleep Apnea, Obstructive
1551772|NCT02463201|Pediatric Obesity
1551773|NCT02501928|neurogenic detrusor overactivity
1551774|NCT02501928|fesoterodine
1551775|NCT02501928|Japan
1551776|NCT02468661|Non-Small Cell Lung Cancer
1551777|NCT02459886|alpha synuclein
1551778|NCT02459886|PD
1551779|NCT02446418|dry powder inahler
1551780|NCT02446418|vilanerol
1551781|NCT02446418|efficacy
1551782|NCT02446418|safety
1551783|NCT02446418|fluticasone furoate
1551784|NCT02446418|quality of life
1551785|NCT02443558|Robotics
1551786|NCT02443558|Cerebral cortex
1551787|NCT02443558|Brain waves
1551788|NCT02443558|Electroencephalography
1551789|NCT02443558|Rehabilitation
1551790|NCT02443558|Brain-Computer Interfaces
1551791|NCT02442596|Abdominal sepsis
1551792|NCT02442596|Sepsis
1551793|NCT02442596|Septic shock
1551794|NCT02442596|Epidemiology
1551795|NCT02442596|Etiology
1551796|NCT02442596|Microbiology
1551797|NCT02442596|Abdomen
1551798|NCT02442596|Intra-abdominal
1551799|NCT02442596|Infection
1551800|NCT02442596|Gastrointestinal tract
1551801|NCT02442596|Perforation
1551802|NCT02442596|Peritonitis
1551803|NCT02442596|Pancreas
1551804|NCT02442596|Biliary tract
1551805|NCT02442596|Megacolon
1551806|NCT02440763|Natural History
1551807|NCT02428491|Diphtheria
1551808|NCT02428491|Tetanus
1551809|NCT02428491|Pertussis
1551810|NCT02428491|Poliomyelitis
1551811|NCT02428491|Hepatitis B
1551812|NCT02428491|DTaP-IPV-Hep B-PRP-T Combined Vaccine (Hexaxim™)
1551813|NCT02423915|Leukemia
1551814|NCT02423915|Lymphoma
1551815|NCT02423915|Advanced hematologic malignancies
1551816|NCT02423915|Graft versus host disease
1551817|NCT02423915|GVHD
1551818|NCT02423915|Fucosylated umbilical cord blood Regulatory T cells
1551819|NCT02423915|CB
1551820|NCT02423915|Tregs
1551821|NCT02423915|T cells
1551822|NCT02423915|Cord blood transplant
1551823|NCT02423915|Total body radiation
1551824|NCT02423915|TBI
1551825|NCT02423915|Radiation therapy
1551826|NCT02423915|XRT
1551827|NCT02423915|Rituximab
1551828|NCT02423915|Rituxan
1551829|NCT02423915|Fludarabine
1551830|NCT02423915|Fludarabine phosphate
1551831|NCT02423915|Fludara
1551832|NCT02423915|Cyclophosphamide
1551833|NCT02423915|Cytoxan
1551834|NCT02423915|Neosar
1551835|NCT02423915|Mycophenolate
1551836|NCT02423915|Mycophenolate mofetil
1551837|NCT02423915|MMF
1551838|NCT02423915|CellCept
1551839|NCT02423915|Sirolimus
1551840|NCT02423915|Rapamune
1551841|NCT02423915|G-CSF
1551842|NCT02423915|Filgrastim
1551843|NCT02423915|Neupogen
1551844|NCT02424916|Onco-dermatology
1551845|NCT02424916|Adoptive transfer
1551846|NCT02424916|Immunotherapy
1551847|NCT02384226|mobile application
1551848|NCT02384226|postpartum
1551849|NCT02384226|weight loss
1551850|NCT02389660|Depression, Blended Cognitive Behavioural Therapy, Internet intervention
1551851|NCT02376699|CD40 Antigen
1551852|NCT02376699|Drug Therapy
1551853|NCT02376699|Follicular Lymphoma
1551854|NCT02376699|Hodgkin Disease
1551855|NCT02376699|Immunotherapy
1551856|NCT02376699|Indolent Lymphoma
1551857|NCT02376699|Lymphoma
1551858|NCT02376699|Lymphoma, B-Cell
1551859|NCT02376699|Lymphoma, Large B-Cell, Diffuse
1551860|NCT02376699|Lymphoma, Non-Hodgkin
1551861|NCT02376699|Monoclonal Antibody
1551862|NCT02376699|Neoplasms
1551863|NCT02376699|Neoplasm Metastasis
1551864|NCT02376699|Solid tumor
1551865|NCT02357290|mania
1551866|NCT02357290|temper tantrum
1551867|NCT02357290|irritability
1551868|NCT02357290|mood
1551869|NCT02357290|bipolar
1551870|NCT02366468|Diabetic macular edema
1551871|NCT02366468|Visual impairment
1551872|NCT02333370|Advanced breast cancer
1551873|NCT02333370|Hormone receptor positive
1551874|NCT02333370|HER2-negative
1551875|NCT02333370|LEE011,
1551876|NCT02333370|Letrozole
1551877|NCT02333370|Tamoxifen
1551878|NCT02333370|Fulvestrant
1551879|NCT02333370|Postmenopausal Asian women
1551880|NCT02333370|Pre and Postmenopausal Japanese women
1551881|NCT02285062|R-CHOP chemotherapy
1551882|NCT02285062|DLBCL front line therapy
1551883|NCT02285062|gene expression profiling (GEP) activated B-cell (ABC) type DLBCL biomarkers
1551884|NCT02285062|Activated B-Cell (ABC) type
1551885|NCT02285062|Diffuse Large B-Cell Lymphoma, not otherwise specified
1551886|NCT02285062|Diffuse Large B-Cell Lymphoma, associated with chronic inflammation
1551887|NCT02285062|Diffuse Large B-Cell Lymphoma, Epstein-Barr virus positive (EBS+) of the elderly
1551888|NCT02285062|Diffuse Large B-Cell Lymphoma, T-cell / histiocyte-rich
1551889|NCT02278120|HR-positive
1551890|NCT02278120|HER2-negative
1551891|NCT02278120|Advanced breast cancer
1551892|NCT02278120|Letrozole
1551893|NCT02278120|Anastrozole
1551894|NCT02278120|Tamoxifen
1551895|NCT02278120|Goserelin
1551896|NCT02278120|CDK
1551897|NCT02278120|CDK4
1551898|NCT02278120|CDK6
1551899|NCT02278120|CDK4/6
1551900|NCT02278120|Phase III
1551901|NCT02278120|ER-positive
1551902|NCT02278120|PR-positive
1551903|NCT02278120|Premenopausal
1551904|NCT02274285|Tetanus
1551905|NCT02274285|Diphtheria
1551906|NCT02274285|Pertussis
1551907|NCT02274285|Poliomyelitis
1551908|NCT02274285|Bacterial meningitis
1551909|NCT02274285|DTaP-IPV/Hib Combination vaccine
1551910|NCT02255435|RTA 408
1551911|NCT02255435|RTA 408 Capsules
1551912|NCT02255435|Oxidative Stress
1551913|NCT02255435|Mitochondrial dysfunction
1551914|NCT02255435|omaveloxolone
1551915|NCT02261389|breast cancer
1551916|NCT02261389|follow-up
1551917|NCT02261389|tumor markers
1551918|NCT02252588|COPD
1551919|NCT02252588|Bacteria
1551920|NCT02223052|CC-486
1551921|NCT02223052|Oral Azacitidine
1551922|NCT02223052|Soli Tumor Malignancy
1551923|NCT02223052|Hematological Malignancy
1551924|NCT02223052|Leukemia
1551925|NCT02223052|Lymphoma
1551926|NCT02223052|Multiple Myeloma
1551927|NCT02223052|Acute Myeloid Leukemia
1551928|NCT02223052|Myelodysplastic Syndromes
1551929|NCT02223052|Neoplasms
1551930|NCT02223052|Melanoma
1551931|NCT02223052|Breast Cancer
1551932|NCT02223052|Metastatic Breast Cancer
1551933|NCT02223052|Non-Small Cell Lung Cancer
1551934|NCT02223052|Small Cell Lung Cancer
1551935|NCT02223052|Renal Cell Carcinoma
1551936|NCT02223052|Glioblastoma Multiforme
1551937|NCT02223052|Brain Cancer
1551938|NCT02223052|Kidney Cancer
1551939|NCT02223052|Lung cancer
1551940|NCT02223052|Blood Cancer
1551941|NCT02223052|Thyroid Cancer
1551942|NCT02223052|Bone Cancer
1551943|NCT02223052|Bone Metastasis
1551944|NCT02223052|Testicular Cancer
1551945|NCT02223052|Prostate Cancer
1551946|NCT02223052|Bladder Cancer
1551947|NCT02223052|Ovarian Cancer
1551948|NCT02223052|Skin Cancer
1551949|NCT02223052|Cancer general
1551950|NCT02223052|Survival
1551951|NCT02223052|Chemotherapy
1551952|NCT02223052|Targeted Therapy
1551953|NCT02223052|Genitourinary
1551954|NCT02223052|MM
1551955|NCT02223052|MDS
1551956|NCT02223052|AML
1551957|NCT02223052|NHL
1551958|NCT02223052|HL
1551959|NCT02223052|MBC
1551960|NCT02223052|NSCLC
1551961|NCT02223052|SCLC
1551962|NCT02223052|GBM
1551963|NCT02216214|Urinary Incontinence
1551964|NCT02216214|Mirabegron
1551965|NCT02216214|Overactive Bladder
1551966|NCT02182440|SA-AKI
1551967|NCT02182440|Sepsis
1551968|NCT02182440|AKI
1551969|NCT02182440|Recombinant Alkaline Phosphatase
1551970|NCT02182440|recAP
1551971|NCT02187003|Sickle Cell Anemia
1551972|NCT02187003|Sickle Cell Disease
1551973|NCT02187003|Sickle Cell Disorders
1551974|NCT02187003|pain crisis
1551975|NCT02187003|vaso-occlusive crisis
1551976|NCT02187003|rivipansel
1551977|NCT02187003|GMI-1070
1551978|NCT02187003|selectin inhibitor
1551979|NCT02187003|SCD
1551980|NCT02187003|VOC
1551981|NCT02164006|Hodgkin's
1551982|NCT02145988|DLBS1033
1551983|NCT02145988|Peripheral arterial disease
1551984|NCT02145988|Ankle-brachial index
1551985|NCT02137005|walking
1551986|NCT02137005|gait disorders, neurologic
1551987|NCT02137005|health status
1551988|NCT02137005|cognition
1551989|NCT02137005|quality of life
1551990|NCT02137005|Transition to Adult Care
1551991|NCT02125500|HCV/HIV coinfection
1551992|NCT02125500|HCV genotype 1
1551993|NCT02125149|pregnancy
1551994|NCT02125149|obese
1551995|NCT02100982|Multimorbidity
1551996|NCT02100982|Communication
1551997|NCT02100982|Primary Care
1551998|NCT02100982|Mental Health
1551999|NCT02091999|Metastatic Urothelial Cancer
1552000|NCT02091999|Safety
1552001|NCT02091999|AGS-22C3E
1552002|NCT02091999|Nectin 4 protein, humans
1552003|NCT02091999|Clinical Trial, Phase 1
1552004|NCT02091999|ASG-22CE
1552005|NCT02091999|ASG-22ME
1552006|NCT02091999|Pharmacokinetics of ASG-22CE
1552007|NCT02101554|Pediatric
1552008|NCT02101554|pain indication
1552009|NCT02101554|controlled release morphine
1552010|NCT02065492|Thalassemia
1552011|NCT02065492|Amlodipine
1552012|NCT02065492|Chelation
1552013|NCT02065492|T2*
1552014|NCT02065492|MRI
1552015|NCT02065492|Myocardial Iron
1552016|NCT02058654|Creatine
1552017|NCT02058654|Functional magnetic resonance imaging (fMRI)
1552018|NCT02058654|Phosphorus-31 magnetic resonance spectroscopy (31P-MRS)
1552019|NCT02036970|Pulmonary Arterial Hypertension
1552020|NCT02036970|PAH
1552021|NCT02036970|Bardoxolone methyl
1552022|NCT02036970|6-minute walk distance
1552023|NCT02036970|CDDO-me
1552024|NCT02036970|RTA 402
1552025|NCT02036970|Pulmonary Hypertension
1552026|NCT02036970|Interstitial Lung Disease
1552027|NCT02036970|Idiopathic Interstitial Pneumonia
1552028|NCT02036970|Idiopathic Pulmonary Fibrosis
1552029|NCT02036970|Sarcoidosis
1552030|NCT02036970|Respiratory Bronchiolitis Associated ILD
1552031|NCT02036970|Desquamative Interstitial Pneumonia
1552032|NCT02036970|Cryptogenic Organizing Pneumonia
1552033|NCT02036970|Acute Interstitial Pneumonitis
1552034|NCT02036970|Idiopathic Lymphoid Interstitial Pneumonia
1552035|NCT02036970|Idiopathic Pleuroparenchymal Fibroelastosis
1552036|NCT02021006|antibiotic prophylaxis
1552037|NCT02021006|vesicoureteral reflux
1552038|NCT02021006|congenital abnormalities of kidney
1552039|NCT02021006|renal hypodysplasia
1552040|NCT02021006|chronic kidney disease
1552041|NCT01997333|Metastatic Breast Cancer
1552042|NCT01997333|Locally advanced breast cancer
1552043|NCT01997333|Breast cancer
1552044|NCT01997333|Triple negative
1552045|NCT01997333|Estrogen
1552046|NCT01997333|Progesterone
1552047|NCT01997333|HER2 receptors
1552048|NCT01997333|Targeted treatment for breast cancer
1552049|NCT01997333|Antibody-drug-conjugate
1552050|NCT01997333|Breast Neoplasms
1552051|NCT01997333|CDX-011
1552052|NCT01997333|gpNMB
1552053|NCT01997333|METRIC
1552054|NCT01997333|Glembatumumab vedotin
1552055|NCT01997333|Triple Negative Breast Cancer
1552056|NCT01997333|TNBC
1552057|NCT02019225|dialysis
1552058|NCT02019225|hemodialysis
1552059|NCT02019225|pragmatic trial
1552060|NCT02019225|end stage renal disease
1552061|NCT02019225|randomized clinical trial
1552062|NCT01971515|MSC2363318A
1552063|NCT01971515|Maximum tolerated dose
1552064|NCT01971515|Dose limiting toxicities
1552065|NCT01971515|Recommended phase 2 dose
1552066|NCT01971515|M2698
1552067|NCT01971515|Metastatic Breast Cancer
1552068|NCT01971515|HER2+ Metastatic Breast Cancer
1552069|NCT01971515|Hormone refractory ER/PR+ breast cancer
1552070|NCT01971515|Tamoxifen
1552071|NCT01971515|PAM Pathway Alteration(s)
1552072|NCT01971515|PAM Pathway
1552073|NCT01971515|Targeted Therapy
1552074|NCT01971515|P70S6K
1552075|NCT01971515|AKT Inhibition
1552076|NCT01971515|PI3K Pathway
1552077|NCT01971515|HER2+ Trastuzumab Resistance
1552078|NCT01969643|Breast cancer
1552079|NCT01969643|Monomethyl auristatin E
1552080|NCT01969643|Antibody-drug conjugate
1552081|NCT01969643|Drug therapy
1552082|NCT01969643|Metastatic
1552083|NCT01969643|LIV-1 protein, human
1552084|NCT01969643|Trastuzumab
1552085|NCT01959451|Prasugrel
1552086|NCT01959451|Clopidogrel
1552087|NCT01953926|Neratinib
1552088|NCT01953926|Fulvestrant
1552089|NCT01953926|Breast
1552090|NCT01953926|Gastroesophageal
1552091|NCT01953926|Endometrial Ovarian Cancer
1552092|NCT01953926|Biliary Tract
1552093|NCT01953926|Solid tumors
1552094|NCT01953926|HER2
1552095|NCT01953926|Paclitaxel
1552096|NCT01953926|Bladder/Urinary Tract
1552097|NCT01950351|Prostate Cancer
1552098|NCT01950351|Localized prostate cancer
1552099|NCT01950351|Adenocarcinoma of the prostate
1552100|NCT01950351|Proton therapy
1552101|NCT01950351|Radiation therapy
1552102|NCT01950351|XRT
1552103|NCT01950351|Gray
1552104|NCT01950351|Gy
1552105|NCT01950351|Questionnaire
1552106|NCT01950351|Survey
1552107|NCT01945424|Quadrivalent Influenza Vaccine
1552108|NCT01945424|Pregnancy Registry
1552109|NCT01945424|Influenza
1552110|NCT01942122|DLBS1442
1552111|NCT01942122|Endometriosis
1552112|NCT01942122|Pain
1552113|NCT01942122|Visual Analogue Scale
1552114|NCT01942122|Endometriosis Health Profile (EHP-30TM)
1552115|NCT01942837|Enzalutamid
1552116|NCT01942837|Prostate Cancer
1552117|NCT01944852|icodextrin
1552118|NCT01944852|double dose
1552119|NCT01944852|elderly incident CAPD patients
1552120|NCT01944852|DIDo study
1552121|NCT01933620|Microbiome
1552122|NCT01933620|Nosocomial Infection
1552123|NCT01933620|Multidrug Resistance
1552124|NCT01932541|Bipolar Disorder
1552125|NCT01932541|Mania
1552126|NCT01932541|Bipolar I
1552127|NCT01932541|Bipolar II
1552128|NCT01932541|Bipolar Spectrum Disorder
1552129|NCT01932541|Pediatric
1552130|NCT01898767|mild
1552131|NCT01898767|asthma
1552132|NCT01898767|allergic
1552133|NCT01892293|Multiple Myeloma
1552134|NCT01892293|Autologous stem cell transplantation
1552135|NCT01892293|Received initial treatment previously
1552136|NCT01886742|Perioperative antibiotic prophylaxis
1552137|NCT01886742|Morbidly Obese
1552138|NCT01811225|Women
1552139|NCT01811225|Pregnancy
1552140|NCT01811225|Smoking
1552141|NCT01800760|healthy
1552142|NCT01800760|obese
1552143|NCT01800760|women
1552144|NCT01773993|Lyrica
1552145|NCT01773993|pregabalin
1552146|NCT01773993|Good post marketing practice
1552147|NCT01773993|Post Marketing Surveillance
1552148|NCT01773993|Regulatory Post Marketing Commitment Plan
1552149|NCT01773993|Fibromyalgia
1552150|NCT01772004|Solid Tumors
1552151|NCT01772004|MSB0010718C
1552152|NCT01772004|Phase 1
1552153|NCT01772004|Pharmacokinetic
1552154|NCT01772004|anti PD-L1
1552155|NCT01772004|Non-small cell lung cancer (NSCLC)
1552156|NCT01772004|Metastatic breast cancer (MBC)
1552157|NCT01772004|Gastric and gastroesophageal junction (GEJ) cancer
1552158|NCT01772004|Ovarian cancer
1552159|NCT01772004|Colorectal cancer (CRC)
1552160|NCT01772004|Castrate-resistant prostate cancer (CRPC)
1552161|NCT01772004|Melanoma
1552162|NCT01772004|Urothelial carcinoma
1552163|NCT01772004|Bladder cancer
1552164|NCT01772004|Head and neck squamous cell carcinoma (HNSCC)
1552165|NCT01772004|Renal cell carcinoma (RCC)
1552166|NCT01772004|Adrenocortical carcinoma (ACC)
1552167|NCT01760915|asthma
1552168|NCT01760915|severe
1552169|NCT01757535|Maintenance therapy
1552170|NCT01757535|AML
1552171|NCT01757535|Acute Myeloid Leukemia
1552172|NCT01757535|oral Azacitidine
1552173|NCT01757535|best supportive care
1552174|NCT01757535|complete remission
1552175|NCT01730118|Metastatic Solid Tumors
1552176|NCT01730118|Human Epidermal Growth Factor Receptor 2 Expression (HER2/neu)
1552177|NCT01730118|Trastuzumab Exposure
1552178|NCT01730118|Dendritic Cell Vaccine
1552179|NCT01730118|Breast Cancer
1552180|NCT01716806|Antibody-Drug Conjugate
1552181|NCT01716806|Antibodies, Monoclonal
1552182|NCT01716806|Hematologic Diseases
1552183|NCT01716806|Hodgkin Disease
1552184|NCT01716806|Antigens, CD30
1552185|NCT01716806|Lymphoma
1552186|NCT01716806|monomethylauristatin E
1552187|NCT01716806|Drug Therapy
1552188|NCT01622062|Rabies
1552189|NCT01622062|Verorab®
1552190|NCT01622062|Favirab®
1552191|NCT01595230|Internal Hernias
1552192|NCT01595230|Clips
1552193|NCT01595230|Gastric Bypass
1552194|NCT01595230|Avoid
1552195|NCT01572506|Anemia
1552196|NCT01572506|Elderly
1552197|NCT01572506|Mechanisms
1552198|NCT01572506|Red Cell Survival
1552199|NCT01580202|malignancy
1552200|NCT01580202|hepatitis B
1552201|NCT01580202|lamivudine
1552202|NCT01580202|entecavir
1552203|NCT01580202|prophylaxis
1552204|NCT01585831|Klinefelter syndrome
1552205|NCT01585831|XXY syndrome
1552206|NCT01585831|Sex Chromosome Abnormality
1552207|NCT01585831|Testosterone replacement therapy
1552208|NCT01703481|Tumor
1552209|NCT01703481|Fibroblast Growth Factor Receptor (FGFR)
1552210|NCT01703481|Non-Small Cell Lung Cancer (NSCLC)
1552211|NCT01703481|Small Cell Lung Cancer (SCLC)
1552212|NCT01703481|JNJ-42756493
1552213|NCT01546753|Walnut hypersensitivity
1552214|NCT01546753|Tree nut hypersensitivity
1552215|NCT01546753|Oral immunotherapy
1552216|NCT01546753|Food allergy
1552217|NCT01546753|Walnut allergy
1552218|NCT01546753|tree nut allergy
1552219|NCT01550588|PFO
1552220|NCT01550588|Stroke
1552221|NCT01480024|healthy women
1552222|NCT01480024|oocytes
1552223|NCT01480024|in vitro fertilization
1552224|NCT01480024|pregnancy
1552225|NCT01480024|childbearing-age
1552226|NCT01421524|Neoplasm
1552227|NCT01421524|Malignancy
1552228|NCT01421524|Carcinoma
1552229|NCT01421524|Lymphoma
1552230|NCT01421524|Multiple Myeloma
1552231|NCT01421524|DNA-PK inhibitor
1552232|NCT01421524|Advanced Solid Tumors
1552233|NCT01421524|Glioblastoma multiforme
1552234|NCT01421524|Hepatocellular Carcinoma
1552235|NCT01421524|Diffuse large B-cell lymphoma
1552236|NCT01421524|Mantel Cell Lymphoma
1552237|NCT01421524|Advanced unresectable Solid Tumors
1552238|NCT01421524|Primary CNS Lymphoma
1552239|NCT01396486|Omega-3 Fatty Acids
1552240|NCT01396486|Fish Oil
1552241|NCT01396486|Inositol
1552242|NCT01396486|Natural supplements
1552243|NCT01396486|Bipolar Spectrum Disorders
1552244|NCT01396486|Mania
1552245|NCT01396486|Depression
1552246|NCT01396486|Children
1552247|NCT01395082|Myocarditis
1552248|NCT01395082|Pericarditis
1552249|NCT01395082|Vaccinia virus
1552250|NCT01395082|ACAM2000®
1552251|NCT01395082|Smallpox vaccine
1552252|NCT01319565|Young TIL
1552253|NCT01319565|Metastatic Melanoma
1552254|NCT01319565|Immunotherapy
1552255|NCT01319565|Adoptive Cell Therapy
1552256|NCT01319565|Skin Cancer
1552257|NCT01279850|Lyrica
1552258|NCT01279850|Regulatory Post Marketing Commitment Plan
1552259|NCT01279850|Safety
1552260|NCT01279850|Neuropathic Pain
1552261|NCT01279850|Post Marketing Surveillance
1552262|NCT01384266|Intraocular Inflammation following routine Cataract Surgery
1552263|NCT01265277|sudden infant death syndrome
1552264|NCT01265277|SIDS
1552265|NCT01265277|infant
1552266|NCT01265277|licensed day care
1552267|NCT01265277|sleep patterns
1552268|NCT01265277|stress levels
1552269|NCT01256593|Lyrica
1552270|NCT01256593|Regulatory Post Marketing Commitment Plan
1552271|NCT01256593|Safety
1552272|NCT01256593|Neuropathic Pain
1552273|NCT01256593|Post Marketing Surveillance
1552274|NCT01131117|healthy
1552275|NCT01131117|women
1552276|NCT01131117|pregnancy
1552277|NCT01129362|Pertussis
1552278|NCT01129362|Whooping Cough
1552279|NCT01129362|Pertussis Vaccine
1552280|NCT01109394|Genomics
1552281|NCT01109394|Proteomics
1552282|NCT01109394|Tissue Repository
1552283|NCT01109394|Omics
1552284|NCT01109394|Cell Lines
1552285|NCT01109394|Pediatric Cancer
1552286|NCT01109394|Solid Tumor
1552287|NCT01109394|Sarcoma
1552288|NCT01109394|Kidney Cancer
1552289|NCT01109394|Neuroblastoma
1552290|NCT01104454|healthy pregnant women
1552291|NCT01077518|Refractory
1552292|NCT01077518|Safety
1552293|NCT01077518|Efficacy
1552294|NCT01077518|Rituximab refractory
1552295|NCT01077518|Oncology
1552296|NCT01069458|Dietary intervention
1552297|NCT01069458|Smoking cessation
1552298|NCT01069458|Body weight
1552299|NCT01028846|Type 2 Diabetes
1552300|NCT01026298|asthma
1552301|NCT01026298|obstructive sleep apnea
1552302|NCT01026298|severe asthma
1552303|NCT01026298|OSA
1552304|NCT00948363|Kiwi fruits
1552305|NCT00948363|Blood pressure
1552306|NCT00948363|Endothelial function
1552307|NCT00948363|Antioxidant capacity
1552308|NCT00927719|Smallpox
1552309|NCT00927719|Smallpox Vaccine
1552310|NCT00927719|Vaccinia virus
1552311|NCT00927719|Military
1552312|NCT00855855|Diphtheria
1552313|NCT00855855|Tetanus
1552314|NCT00855855|Pertussis
1552315|NCT00855855|Poliovirus types 1-3
1552316|NCT00855855|Haemophilus influenzae type b
1552317|NCT00855855|Pentacel®
1552318|NCT00827359|everolimus
1552319|NCT00802438|asthma
1552320|NCT00802438|allergic inflammation
1552321|NCT00802438|interleukin-5
1552322|NCT00735423|Healthy children
1552323|NCT00735423|Brain Function
1552324|NCT00735423|Diet
1552325|NCT00735423|Nutrition
1552326|NCT00735423|Language
1552327|NCT00735423|fMRI
1552328|NCT00735423|ERP
1552329|NCT00735423|Behavior
1552330|NCT00665561|Maraviroc
1552331|NCT00665561|HIV-1
1552332|NCT00665561|Safety
1552333|NCT00665561|Non-interventional
1552334|NCT00774176|Chronic Obstructive Pulmonary Disease
1552335|NCT00774176|COPD
1552336|NCT00774176|COPD Exacerbation
1552337|NCT00774176|Genetic markers COPD
1552338|NCT00774176|Gene expression in COPD exacerbations
1552339|NCT00774176|COPD Exacerbation Symptom Reporting
1552340|NCT00774176|COPD Exacerbation Disease Management
1552341|NCT00774176|COPD Treatment
1552342|NCT00774176|Breathing disorders
1552343|NCT00774176|Emphysema
1552344|NCT00774176|COPD with Healthy Control comparators for genetic association studies.
1552345|NCT00616395|Infant Nutrition
1552346|NCT00616395|Soy Phytochemicals
1552347|NCT00616395|Infant Body Composition
1552348|NCT00616395|Brain Function
1552349|NCT00616395|Cognition and Development
1552350|NCT00616395|Healthy Infants
1552351|NCT00514046|Multiple Endocrine Neoplasia (MEN)
1552352|NCT00514046|Medullary Thyroid Carcinoma
1552353|NCT00514046|Molecularly-Targeted Therapy
1552354|NCT00514046|Pediatric
1552355|NCT00514046|Pharmacokinetics
1552356|NCT00514046|MTC
1552357|NCT00514046|Multiple Endocrine Neoplasia
1552358|NCT00514046|MEN
1552359|NCT00477100|Inflammatory Breast Cancer
1552360|NCT00477100|Cancer Registry
1552361|NCT00477100|Core Biopsy
1552362|NCT00477100|Skin Biopsy
1552363|NCT00477100|IBC
1552364|NCT00445627|Type 2 Diabetes
1552365|NCT00445627|Obesity
1552366|NCT00445627|Overweight
1552367|NCT00068003|Adoptive Cell Therapy
1552368|NCT00068003|Screening
1552369|NCT00068003|Cell Harvest
1552370|NCT00068003|Blood
1552371|NCT00068003|Tumor Tissue
1552372|NCT00059033|6-[18F]Fluorodopamine
1552373|NCT00059033|Autonomic Failure
1552374|NCT00059033|Parkinson's Disease
1552375|NCT00059033|Multiple System Atrophy
1552376|NCT00059033|Pure Autonomic Failure
1552377|NCT00059033|Primary Chronic Autonomic Failure
1552378|NCT00059033|CAF
1552379|NCT00001277|Hypoglycemia
1552380|NCT00001277|Genetics
1552381|NCT00001277|Hyperparathyroidism
1552382|NCT00001564|Rhabdomyosarcoma
1552383|NCT00001564|Ewing's Sarcoma
1552384|NCT00001564|Immunotherapy
1552385|NCT00001564|Tumor Vaccine
1552386|NCT00001564|Fusion Protein
